<SEC-DOCUMENT>0001193125-23-007234.txt : 20230112
<SEC-HEADER>0001193125-23-007234.hdr.sgml : 20230112
<ACCEPTANCE-DATETIME>20230112164552
ACCESSION NUMBER:		0001193125-23-007234
CONFORMED SUBMISSION TYPE:	S-1
PUBLIC DOCUMENT COUNT:		118
FILED AS OF DATE:		20230112
DATE AS OF CHANGE:		20230112

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Scilex Holding Co
		CENTRAL INDEX KEY:			0001820190
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-269205
		FILM NUMBER:		23526364

	BUSINESS ADDRESS:	
		STREET 1:		960 SAN ANTONIO ROAD
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94303
		BUSINESS PHONE:		(650) 516-4310

	MAIL ADDRESS:	
		STREET 1:		960 SAN ANTONIO ROAD
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94303

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Scilex Holding Company/DE
		DATE OF NAME CHANGE:	20221117

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Vickers Vantage Corp. I
		DATE OF NAME CHANGE:	20200804
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1
<SEQUENCE>1
<FILENAME>d428534ds1.htm
<DESCRIPTION>S-1
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:sclx="http://www.vickersvantagecorp.com/20220930" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>S-1</title>
<meta content="text/html; charset=UTF-8" http-equiv="Content-Type"/>
</head>
<body style="">
<h5><a href="#toc">Table of Contents</a></h5>
<div style='display: none'><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" contextRef="P01_01_2022To09_30_2022">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityRegistrantName" id="hidden63195201" contextRef="P01_01_2022To09_30_2022">Scilex Holding Company/DE</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="P01_01_2022To09_30_2022">0001820190</ix:nonNumeric><ix:footnote id="FN_220028" xml:lang="en-US">At December 31, 2020, includes an aggregate of up to 450,000 ordinary shares that are subject to forfeiture depending on the extent to which the underwriters&#8217; over-allotment option is exercised (see Note 6). On January 6, 2021, the Company effected a share capitalization of 0.2 shares for each share outstanding, resulting in 3,450,000 ordinary shares issued and outstanding (see Note 6). All share and per share amounts have been retroactively restated to reflect the share capitalization. As a result of the underwriters&#8217; full exercise of their overallotment option on January 11, 2021, no shares were forfeited.</ix:footnote ><ix:footnote id="FN_220029" xml:lang="en-US">At December 31, 2020, excludes an aggregate of up to 450,000 ordinary shares that were subject to forfeiture.</ix:footnote ><ix:footnote id="FN_220030" xml:lang="en-US">Inclusive of variable lease costs, sublease income, and impairment, which were immaterial for the periods presented.</ix:footnote ></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="sclx-20220930.xsd" /><link:linkbaseRef xlink:type="simple" xlink:href="sclx-20220930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="sclx-20220930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="sclx-20220930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="sclx-20220930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /></ix:references><ix:resources><xbrli:context id="PAsOn12_31_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To09_30_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_01_2019To02_28_2019" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-02-01</xbrli:startDate> <xbrli:endDate>2019-02-28</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_31_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-07-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_31_2019" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-05-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2019" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_17_2019" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-03-17</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P03_01_2019To03_31_2019" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-03-01</xbrli:startDate> <xbrli:endDate>2019-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_02_2018" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-10-02</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_17_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-10-17</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:PrivatePlacementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis_WarrantMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:WarrantMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_MinimumMembersrtRangeAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_MaximumMembersrtRangeAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_PrivatePlacementWarrantMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >sclx:PrivatePlacementWarrantMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_VantageMergerSubIncMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >sclx:VantageMergerSubIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_ScilexCommonStockMemberusgaapRelatedPartyTransactionAxis_SeriesAPreferredStockMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >sclx:ScilexCommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_FounderSharesMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" >sclx:FounderSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMemberusgaapBusinessAcquisitionAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_LicensingAgreementsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:LicensingAgreementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_AssembledWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >sclx:AssembledWorkforceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:PatentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_TwoThousandNineteenStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >sclx:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_ScilexPharmaTwoThousandSeventeenPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >sclx:ScilexPharmaTwoThousandSeventeenPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_SenmurMemberusgaapAssetAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis" >sclx:SenmurMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_RomegLicenseAgreementMemberusgaapAssetAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis" >sclx:RomegLicenseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_AardvarkMemberusgaapAssetAcquisitionAxis_ApprovalBasedMilestoneMemberSCLXMilestoneAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis" >sclx:AardvarkMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:MilestoneAxis" >sclx:ApprovalBasedMilestoneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_AardvarkMemberusgaapAssetAcquisitionAxis_ReveueBasedMilestoneMemberSCLXMilestoneAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis" >sclx:AardvarkMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:MilestoneAxis" >sclx:ReveueBasedMilestoneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_AardvarkMemberusgaapAssetAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis" >sclx:AardvarkMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >sclx:SorrentoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >sclx:PromissoryNoteRelatedPartyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_MinimumMembersrtRangeAxis_ProjectAgreementMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >sclx:ProjectAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_MaximumMembersrtRangeAxis_ProjectAgreementMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >sclx:ProjectAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:ScilexPharmaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >sclx:PromissoryNoteRelatedPartyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:ScilexPharmaNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_ScilexPharmaMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:ScilexPharmaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_TwoThousandAndTwentyTwoPromissoryNoteMemberusgaapLongtermDebtTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis" >sclx:TwoThousandAndTwentyTwoPromissoryNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_SorrentoMemberSCLXInvesteeAxis_TwoThousandTwentyTwoPromissoryNoteMemberusgaapLongtermDebtTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis" >sclx:TwoThousandTwentyTwoPromissoryNoteMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:InvesteeAxis" >sclx:SorrentoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_DecemberOptionalRepurchaseMemberSCLXStatementAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:StatementAxis" >sclx:DecemberOptionalRepurchaseMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:ScilexPharmaNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_FebruaryOptionalRepurchaseMemberSCLXStatementAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:StatementAxis" >sclx:FebruaryOptionalRepurchaseMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:ScilexPharmaNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_AprilOptionalRepurchaseMemberSCLXStatementAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:StatementAxis" >sclx:AprilOptionalRepurchaseMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:ScilexPharmaNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:ScilexPharmaNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_LetterOfCreditMemberusgaapCreditFacilityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:LetterOfCreditMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_AccountsReceivableRevolvingLoanFacilityMemberusgaapCreditFacilityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >sclx:AccountsReceivableRevolvingLoanFacilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_DebtExchangeAgreementMemberSCLXAgreementAxis_SorrentoMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:AgreementAxis" >sclx:DebtExchangeAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >sclx:SorrentoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:PrivatePlacementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis_WarrantMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:WarrantMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_PrivatePlacementWarrantMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >sclx:PrivatePlacementWarrantMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_VantageMergerSubIncMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >sclx:VantageMergerSubIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FounderSharesMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" >sclx:FounderSharesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_SponsorMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >sclx:SponsorMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CumulativeSalesRelatedContingencyMemberSCLXEventAxis_ScilexPharmaMemberdeiLegalEntityAxis_SeniorSecuredNotesDueTwoThousandAndTwentySixMemberusgaapLongtermDebtTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:ScilexPharmaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis" >sclx:SeniorSecuredNotesDueTwoThousandAndTwentySixMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:EventAxis" >sclx:CumulativeSalesRelatedContingencyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:PatentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AssembledWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >sclx:AssembledWorkforceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ScilexPharmaTwoThousandSeventeenPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >sclx:ScilexPharmaTwoThousandSeventeenPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_TwoThousandNineteenStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >sclx:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_SenmurMemberusgaapAssetAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis" >sclx:SenmurMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ConstructionInProgressMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:ConstructionInProgressMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:ComputerEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >sclx:SorrentoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >sclx:PromissoryNoteRelatedPartyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:ScilexPharmaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >sclx:PromissoryNoteRelatedPartyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_MinimumMembersrtRangeAxis_ProjectAgreementMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >sclx:ProjectAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_MaximumMembersrtRangeAxis_ProjectAgreementMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >sclx:ProjectAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:DomesticCountryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_IndefiniteCarryforwardPeriodMemberusgaapTaxPeriodAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:DomesticCountryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis" >sclx:IndefiniteCarryforwardPeriodMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_ResearchMemberusgaapTaxCreditCarryforwardAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:DomesticCountryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis" >us-gaap:ResearchMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ScilexPharmaMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:ScilexPharmaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:ScilexPharmaNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:ScilexPharmaNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:ScilexPharmaNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:PrivatePlacementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_FounderSharesMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >sclx:FounderSharesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMemberusgaapBusinessAcquisitionAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_ConvertiblePromisoryNoteMemberusgaapShortTermDebtTypeAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis" >sclx:ConvertiblePromisoryNoteMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_WeightedAverageMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:WeightedAverageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_TwoThousandNineteenStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >sclx:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_DerivativeFinancialInstrumentsLiabilitiesMemberusgaapFairValueByLiabilityClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" >us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_OperatingExpensesMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >sclx:OperatingExpensesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >sclx:SorrentoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_MaximumMembersrtRangeAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >sclx:ProductDevelopmentAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_MinimumMembersrtRangeAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >sclx:ProductDevelopmentAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >sclx:ProductDevelopmentAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_ExclusiveDistributionAgreementMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >sclx:ExclusiveDistributionAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_ExclusiveDistributionAgreementMemberusgaapTypeOfArrangementAxis_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >sclx:ExclusiveDistributionAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_ExclusiveDistributionAgreementMemberusgaapTypeOfArrangementAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >sclx:ExclusiveDistributionAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_ProjectAgreementMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >sclx:ProjectAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:ScilexPharmaNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_SorrentoMemberSCLXInvesteeAxis_TwoThousandTwentyTwoPromissoryNoteMemberusgaapLongtermDebtTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis" >sclx:TwoThousandTwentyTwoPromissoryNoteMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:InvesteeAxis" >sclx:SorrentoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_TwoThousandAndEighteenPurchaseAgreementsAndIndentureMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:ScilexPharmaNoteMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >sclx:TwoThousandAndEighteenPurchaseAgreementsAndIndentureMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_RomegLicenseAgreementMemberusgaapAssetAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis" >sclx:RomegLicenseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:ScilexPharmaNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis_YorkvilleMemberSCLXInvesteeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:InvesteeAxis" >sclx:YorkvilleMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To09_30_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_10_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-10-10</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To09_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To09_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To09_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To09_30_2021_OperatingExpensesMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >sclx:OperatingExpensesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To09_30_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >sclx:SorrentoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To09_30_2021_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_TwoThousandAndEighteenPurchaseAgreementsAndIndentureMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:ScilexPharmaNoteMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >sclx:TwoThousandAndEighteenPurchaseAgreementsAndIndentureMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To09_30_2021_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:ScilexPharmaNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To09_30_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_17_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-10-17</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_17_2022_FundingCommitmentLetterMemberusgaapCreditFacilityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >sclx:FundingCommitmentLetterMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-10-17</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_17_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-10-17</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_17_2022_FundingCommitmentLetterMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >sclx:FundingCommitmentLetterMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-10-17</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P10_17_2022To10_17_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-10-17</xbrli:startDate> <xbrli:endDate>2022-10-17</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To09_30_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:PrivatePlacementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To09_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To09_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2022To09_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2021To09_30_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:PrivatePlacementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2021To09_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2021To09_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2021To09_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ConversionOptionLiabilityMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >sclx:ConversionOptionLiabilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:PrivatePlacementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_FounderSharesMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >sclx:FounderSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ConvertiblePromisoryNoteMemberusgaapShortTermDebtTypeAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis" >sclx:ConvertiblePromisoryNoteMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ConvertibleNotesPayableMemberusgaapShortTermDebtTypeAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis" >us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_PrivatePlacementWarrantMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >sclx:PrivatePlacementWarrantMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:PatentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_AssembledWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >sclx:AssembledWorkforceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_WeightedAverageMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:WeightedAverageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_TwoThousandNineteenStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >sclx:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_DerivativeFinancialInstrumentsLiabilitiesMemberusgaapFairValueByLiabilityClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" >us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_OperatingExpensesMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >sclx:OperatingExpensesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_SoleDistributorMembersrtMajorCustomersAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >sclx:SoleDistributorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >us-gaap:SalesRevenueNetMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >sclx:SorrentoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:DomesticCountryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_FourHundredAndOneKPlanMemberusgaapRetirementPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis" >sclx:FourHundredAndOneKPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_IndebentureMemberSCLXAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:AgreementAxis" >sclx:IndebentureMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:ScilexPharmaNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CoronavirusAidReliefAndEconomicSecurityActMemberSCLXEventTypeAxis_NonPayrollCostsMemberSCLXClassificationOfCostAxis_PaycheckProtectionProgramMemberusgaapLongtermDebtTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis" >sclx:PaycheckProtectionProgramMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:EventTypeAxis" >sclx:CoronavirusAidReliefAndEconomicSecurityActMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:ClassificationOfCostAxis" >sclx:NonPayrollCostsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CoronavirusAidReliefAndEconomicSecurityActMemberSCLXEventTypeAxis_PaycheckProtectionProgramMemberusgaapLongtermDebtTypeAxis_PayrollCostsBasisMemberSCLXClassificationOfCostAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis" >sclx:PaycheckProtectionProgramMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:EventTypeAxis" >sclx:CoronavirusAidReliefAndEconomicSecurityActMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:ClassificationOfCostAxis" >sclx:PayrollCostsBasisMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_ConversionOptionLiabilityMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >sclx:ConversionOptionLiabilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:PrivatePlacementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:PrivatePlacementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To06_30_2022_AmendmentNoFourMemberSCLXAmendmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:AmendmentAxis" >sclx:AmendmentNoFourMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To03_31_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:PrivatePlacementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To03_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To03_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To03_31_2021_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:PrivatePlacementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_01_2021To12_31_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:PrivatePlacementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-10-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To09_30_2022_ConversionOptionLiabilityMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >sclx:ConversionOptionLiabilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_11_2022_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-11</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_17_2022_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-17</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_12_2022_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-12</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_12_2022_DebtExchangeAgreementMemberSCLXAgreementAxis_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:AgreementAxis" >sclx:DebtExchangeAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >sclx:SorrentoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-12</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_12_2022_DebtExchangeAgreementMemberSCLXAgreementAxis_SorrentoMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:AgreementAxis" >sclx:DebtExchangeAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >sclx:SorrentoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-12</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P03_17_2022To03_17_2022_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-03-17</xbrli:startDate> <xbrli:endDate>2022-03-17</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_10_2022To09_11_2022_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-08-10</xbrli:startDate> <xbrli:endDate>2022-09-11</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_11_2022To07_11_2022_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-11</xbrli:startDate> <xbrli:endDate>2022-07-11</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_04_2021To01_11_2021_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-04</xbrli:startDate> <xbrli:endDate>2021-01-11</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_04_2021To01_11_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-04</xbrli:startDate> <xbrli:endDate>2021-01-11</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_04_2021To01_11_2021_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-04</xbrli:startDate> <xbrli:endDate>2021-01-11</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_11_2021_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-01-11</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_11_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-01-11</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_11_2021_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-01-11</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_11_2021_AsRestatedMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RestatementAxis" >sclx:AsRestatedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-01-11</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_11_2021_AdjustmentsRestatement2MembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis" >sclx:AdjustmentsRestatement2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-01-11</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_11_2021_RestatementAdjustmentMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis" >srt:RestatementAdjustmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-01-11</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_11_2021_ScenarioPreviouslyReportedMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis" >srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-01-11</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2022To04_01_2022_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-01</xbrli:startDate> <xbrli:endDate>2022-04-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_18_2022_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-04-18</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_11_2022_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-04-11</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To01_27_2022_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-01-27</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To01_27_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-01-27</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_10_2022_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-01-10</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_10_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-01-10</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_20_2021_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-20</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_20_2021_ScilexPharmaMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:ScilexPharmaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-20</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_20_2021_MeasurementInputEffectiveDebtYieldMemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >sclx:MeasurementInputEffectiveDebtYieldMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-20</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_20_2021_MeasurementInputRiskadjustedNetSalesForecastMemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >sclx:MeasurementInputRiskadjustedNetSalesForecastMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-20</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_20_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >sclx:SorrentoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-20</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_05_2021To01_14_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-05</xbrli:startDate> <xbrli:endDate>2021-01-14</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_16_2020_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >sclx:PromissoryNoteRelatedPartyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-07-16</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2020To12_31_2020_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-12-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2020To12_31_2020_TwoThousandNineteenStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >sclx:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-12-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_02_2020To07_16_2020_FounderSharesMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >sclx:FounderSharesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-02</xbrli:startDate> <xbrli:endDate>2020-07-16</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_01_2020To10_08_2020_FounderSharesMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >sclx:FounderSharesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-10-01</xbrli:startDate> <xbrli:endDate>2020-10-08</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2020To12_07_2020_FounderSharesMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >sclx:FounderSharesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-12-01</xbrli:startDate> <xbrli:endDate>2020-12-07</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_03_2021To01_06_2021_FounderSharesMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >sclx:FounderSharesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-03</xbrli:startDate> <xbrli:endDate>2021-01-06</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2021To12_20_2021_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-01</xbrli:startDate> <xbrli:endDate>2021-12-20</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_01_2022To08_11_2022_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-08-01</xbrli:startDate> <xbrli:endDate>2022-08-11</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_10_2022To10_10_2022_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-10-10</xbrli:startDate> <xbrli:endDate>2022-10-10</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_09_2022To09_09_2022_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-09-09</xbrli:startDate> <xbrli:endDate>2022-09-09</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To01_10_2022_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-01-10</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To01_10_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-01-10</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-02-21</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_21_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-02-21</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_21_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-02-21</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_21_2020To12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-02-21</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis_WarrantMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:WarrantMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:PrivatePlacementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_CommonClassAMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:PatentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_AssembledWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >sclx:AssembledWorkforceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_TwoThousandNineteenStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >sclx:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_AmendmentToTwoThousandNineteenStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >sclx:AmendmentToTwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_SenmurMemberusgaapAssetAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis" >sclx:SenmurMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_SenmurMemberusgaapAssetAcquisitionAxis_SorrentoMemberSCLXInvesteeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis" >sclx:SenmurMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:InvesteeAxis" >sclx:SorrentoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_ConstructionInProgressMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:ConstructionInProgressMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:ComputerEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_SenmurMemberusgaapAssetAcquisitionAxis_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis" >sclx:SenmurMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >sclx:SorrentoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_ItochuMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >sclx:ItochuMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >sclx:SorrentoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >sclx:PromissoryNoteRelatedPartyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:ScilexPharmaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_ScilexPharmaMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:ScilexPharmaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeMarch312021MemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >sclx:MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeMarch312021Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_MeasurementInputEffectiveDebtYieldMemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >sclx:MeasurementInputEffectiveDebtYieldMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_MeasurementInputRiskadjustedNetSalesForecastMemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >sclx:MeasurementInputRiskadjustedNetSalesForecastMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:ScilexPharmaNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:ScilexPharmaNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:ScilexPharmaNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_TwoThousandNineteenStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >sclx:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_DerivativeFinancialInstrumentsLiabilitiesMemberusgaapFairValueByLiabilityClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" >us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_OperatingExpensesMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >sclx:OperatingExpensesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_SoleDistributorMembersrtMajorCustomersAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >us-gaap:SalesRevenueNetMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >sclx:SoleDistributorMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >sclx:SorrentoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_FourHundredAndOneKPlanMemberusgaapRetirementPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis" >sclx:FourHundredAndOneKPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:ScilexPharmaNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_DerivativeFinancialInstrumentsLiabilitiesMemberusgaapFairValueByLiabilityClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" >us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_OperatingExpensesMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >sclx:OperatingExpensesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_SoleDistributorMembersrtMajorCustomersAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis" >us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis" >us-gaap:SalesRevenueNetMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:MajorCustomersAxis" >sclx:SoleDistributorMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_SenmurMemberusgaapAssetAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis" >sclx:SenmurMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >sclx:SorrentoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_FourHundredAndOneKPlanMemberusgaapRetirementPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis" >sclx:FourHundredAndOneKPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2019To12_31_2019_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:ScilexPharmaNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_18_2019_ReorganizationMemberSCLXEventAxis_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >sclx:SorrentoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:EventAxis" >sclx:ReorganizationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-03-18</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_18_2019_ContributionAndLoanAgreementMemberSCLXAgreementAxis_ReorganizationMemberSCLXEventAxis_ScilexPharmaMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:EventAxis" >sclx:ReorganizationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >sclx:ScilexPharmaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:AgreementAxis" >sclx:ContributionAndLoanAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-03-18</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis" >sclx:SenmurMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-03-18</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheTwoMemberSCLXTrancheAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis" >sclx:SenmurMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:MilestoneAxis" >sclx:ReveueBasedMilestoneMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:TrancheAxis" >sclx:TrancheTwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-03-18</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_18_2019_RegulatoryBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis" >sclx:SenmurMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:MilestoneAxis" >sclx:RegulatoryBasedMilestoneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-03-18</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheOneMemberSCLXTrancheAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis" >sclx:SenmurMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:MilestoneAxis" >sclx:ReveueBasedMilestoneMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:TrancheAxis" >sclx:TrancheOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-03-18</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheThreeMemberSCLXTrancheAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis" >sclx:SenmurMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:MilestoneAxis" >sclx:ReveueBasedMilestoneMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:TrancheAxis" >sclx:TrancheThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-03-18</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheFourMemberSCLXTrancheAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis" >sclx:SenmurMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:MilestoneAxis" >sclx:ReveueBasedMilestoneMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:TrancheAxis" >sclx:TrancheFourMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-03-18</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_18_2019_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >sclx:SorrentoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-03-18</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_14_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_SubordinatedDebtMemberusgaapLongtermDebtTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis" >us-gaap:SubordinatedDebtMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:ScilexPharmaNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-02-14</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_14_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_SubordinatedDebtMemberusgaapLongtermDebtTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:ScilexPharmaNoteMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis" >us-gaap:SubordinatedDebtMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-02-14</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_28_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_SubordinatedDebtMemberusgaapLongtermDebtTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:ScilexPharmaNoteMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis" >us-gaap:SubordinatedDebtMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-02-28</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_28_2022_LetterOfCreditDrawnDownMemberSCLXEventAxis_ScilexPharmaMemberdeiLegalEntityAxis_SeniorSecuredNotesDueTwoThousandAndTwentySixMemberusgaapLongtermDebtTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:ScilexPharmaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis" >sclx:SeniorSecuredNotesDueTwoThousandAndTwentySixMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:EventAxis" >sclx:LetterOfCreditDrawnDownMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-02-28</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_28_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_SubordinatedDebtMemberusgaapLongtermDebtTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:ScilexPharmaNoteMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis" >us-gaap:SubordinatedDebtMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-02-28</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_15_2022_MaximumMembersrtRangeAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_SubordinatedDebtMemberusgaapLongtermDebtTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:ScilexPharmaNoteMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis" >us-gaap:SubordinatedDebtMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-02-15</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_15_2022_MaximumMembersrtRangeAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:TwoThousandAndEighteenPurchaseAgreementsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-02-15</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P02_15_2022To02_15_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_SubordinatedDebtMemberusgaapLongtermDebtTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis" >us-gaap:SubordinatedDebtMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:ScilexPharmaNoteMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-02-15</xbrli:startDate> <xbrli:endDate>2022-02-15</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_15_2022To02_15_2022_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:TwoThousandAndEighteenPurchaseAgreementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-02-15</xbrli:startDate> <xbrli:endDate>2022-02-15</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_30_2022_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >sclx:SorrentoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2018_ScilexPharmaMemberdeiLegalEntityAxis_SeniorSecuredNotesDueTwoThousandAndTwentySixMemberusgaapLongtermDebtTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:ScilexPharmaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis" >sclx:SeniorSecuredNotesDueTwoThousandAndTwentySixMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P09_01_2018To09_30_2018_ScilexPharmaMemberdeiLegalEntityAxis_SeniorSecuredNotesDueTwoThousandAndTwentySixMemberusgaapLongtermDebtTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:ScilexPharmaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis" >sclx:SeniorSecuredNotesDueTwoThousandAndTwentySixMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-09-01</xbrli:startDate> <xbrli:endDate>2018-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_30_2021_ScilexPharmaMemberdeiLegalEntityAxis_SeniorSecuredNotesDueTwoThousandAndTwentySixMemberusgaapLongtermDebtTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis" >sclx:SeniorSecuredNotesDueTwoThousandAndTwentySixMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:ScilexPharmaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-04-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2020_ScilexPharmaMemberdeiLegalEntityAxis_SeniorSecuredNotesDueTwoThousandAndTwentySixMemberusgaapLongtermDebtTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:ScilexPharmaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis" >sclx:SeniorSecuredNotesDueTwoThousandAndTwentySixMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2017_ScilexPharmaTwoThousandSeventeenPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >sclx:ScilexPharmaTwoThousandSeventeenPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2017-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P06_30_2017To06_30_2017_ScilexPharmaTwoThousandSeventeenPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >sclx:ScilexPharmaTwoThousandSeventeenPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2017-06-30</xbrli:startDate> <xbrli:endDate>2017-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_TwoThousandNineteenStockOptionPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >sclx:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeJuly12023MemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >sclx:MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeJuly12023Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeMarch312021MemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >sclx:MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeMarch312021Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_MeasurementInputEffectiveDebtYieldMemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >sclx:MeasurementInputEffectiveDebtYieldMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_MeasurementInputRiskadjustedNetSalesForecastMemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >sclx:MeasurementInputRiskadjustedNetSalesForecastMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P03_18_2019To03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis" >sclx:SenmurMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-03-18</xbrli:startDate> <xbrli:endDate>2019-03-18</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_18_2019To03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheFourMemberSCLXTrancheAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:TrancheAxis" >sclx:TrancheFourMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:MilestoneAxis" >sclx:ReveueBasedMilestoneMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis" >sclx:SenmurMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-03-18</xbrli:startDate> <xbrli:endDate>2019-03-18</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_18_2019To03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheThreeMemberSCLXTrancheAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:TrancheAxis" >sclx:TrancheThreeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:MilestoneAxis" >sclx:ReveueBasedMilestoneMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis" >sclx:SenmurMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-03-18</xbrli:startDate> <xbrli:endDate>2019-03-18</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_18_2019To03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheTwoMemberSCLXTrancheAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis" >sclx:SenmurMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:MilestoneAxis" >sclx:ReveueBasedMilestoneMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:TrancheAxis" >sclx:TrancheTwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-03-18</xbrli:startDate> <xbrli:endDate>2019-03-18</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_18_2019To03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheOneMemberSCLXTrancheAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis" >sclx:SenmurMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:TrancheAxis" >sclx:TrancheOneMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:MilestoneAxis" >sclx:ReveueBasedMilestoneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-03-18</xbrli:startDate> <xbrli:endDate>2019-03-18</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To06_30_2022_DerivativeFinancialInstrumentsLiabilitiesMemberusgaapFairValueByLiabilityClassAxis_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:ScilexPharmaNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" >us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_01_2019_SenmurMemberusgaapAssetAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis" >sclx:SenmurMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-03-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P03_01_2019To03_31_2019_SenmurMemberusgaapAssetAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis" >sclx:SenmurMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-03-01</xbrli:startDate> <xbrli:endDate>2019-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_01_2019To03_31_2019_SenmurMemberusgaapAssetAcquisitionAxis_SorrentoMemberSCLXInvesteeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis" >sclx:SenmurMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:InvesteeAxis" >sclx:SorrentoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-03-01</xbrli:startDate> <xbrli:endDate>2019-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_29_2021_SenmurMemberusgaapAssetAcquisitionAxis_SorrentoMemberSCLXInvesteeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis" >sclx:SenmurMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:InvesteeAxis" >sclx:SorrentoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-01-29</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_29_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >sclx:SorrentoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-01-29</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_13_2021_ItochuMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >sclx:ItochuMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-01-13</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_07_2019_SenmurMemberusgaapAssetAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis" >sclx:SenmurMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-08-07</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_07_2019_AsRestatedMembersrtRestatementAxis_SenmurMemberusgaapAssetAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis" >sclx:SenmurMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RestatementAxis" >sclx:AsRestatedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-08-07</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_07_2019_AsRestatedMembersrtRestatementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RestatementAxis" >sclx:AsRestatedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-08-07</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P08_07_2019To08_07_2019_SenmurMemberusgaapAssetAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis" >sclx:SenmurMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-08-07</xbrli:startDate> <xbrli:endDate>2019-08-07</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P11_10_2020To11_10_2020_VantageMergerSubIncMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >sclx:VantageMergerSubIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-11-10</xbrli:startDate> <xbrli:endDate>2020-11-10</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P11_10_2020To11_10_2020_DebtExchangeAgreementMemberSCLXAgreementAxis_VantageMergerSubIncMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >sclx:VantageMergerSubIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:AgreementAxis" >sclx:DebtExchangeAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-11-10</xbrli:startDate> <xbrli:endDate>2020-11-10</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To01_06_2021_FounderSharesMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >sclx:FounderSharesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-01-06</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2021_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >sclx:PromissoryNoteRelatedPartyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:ScilexPharmaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P12_31_2021To12_31_2021_MaximumMembersrtRangeAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >sclx:ProductDevelopmentAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-31</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_31_2021To12_31_2021_MinimumMembersrtRangeAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >sclx:ProductDevelopmentAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-31</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_31_2021To12_31_2021_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >sclx:ProductDevelopmentAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-31</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_31_2021To12_31_2021_ExclusiveDistributionAgreementMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >sclx:ExclusiveDistributionAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-31</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_31_2021To12_31_2021_ExclusiveDistributionAgreementMemberusgaapTypeOfArrangementAxis_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >sclx:ExclusiveDistributionAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-31</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_31_2021To12_31_2021_ExclusiveDistributionAgreementMemberusgaapTypeOfArrangementAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >sclx:ExclusiveDistributionAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-31</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_31_2021To12_31_2021_ProjectAgreementMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >sclx:ProjectAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-12-31</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_01_2021To02_26_2021_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-01</xbrli:startDate> <xbrli:endDate>2021-02-26</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_05_2018_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:ScilexPharmaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >sclx:PromissoryNoteRelatedPartyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-10-05</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_05_2018_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >sclx:PromissoryNoteRelatedPartyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-10-05</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_05_2018_AmendmentNoFourMemberSCLXAmendmentAxis_PromissoryNoteMemberusgaapRelatedPartyTransactionAxis_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:AmendmentAxis" >sclx:AmendmentNoFourMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >sclx:PromissoryNoteMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >sclx:SorrentoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-10-05</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_22_2018_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >sclx:PromissoryNoteRelatedPartyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:ScilexPharmaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-10-22</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P10_22_2018To10_22_2018_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:ScilexPharmaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >sclx:PromissoryNoteRelatedPartyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-10-22</xbrli:startDate> <xbrli:endDate>2018-10-22</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_01_2022To09_30_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:ScilexPharmaNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-08-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_28_2022_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:ScilexPharmaNotesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-28</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P06_14_2022To06_14_2022_LicensingAgreementsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >us-gaap:LicensingAgreementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-06-14</xbrli:startDate> <xbrli:endDate>2022-06-14</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P05_12_2022To05_12_2022_SorrentoMemberusgaapBusinessAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_TwoThousandAndTwentyTwoPromissoryNoteMemberusgaapLongtermDebtTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis" >sclx:TwoThousandAndTwentyTwoPromissoryNoteMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >sclx:SorrentoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-05-12</xbrli:startDate> <xbrli:endDate>2022-05-12</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P05_12_2022To05_12_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-05-12</xbrli:startDate> <xbrli:endDate>2022-05-12</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P05_12_2022To05_12_2022_AardvarkMemberusgaapAssetAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis" >sclx:AardvarkMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-05-12</xbrli:startDate> <xbrli:endDate>2022-05-12</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P05_12_2022To05_12_2022_SorrentoMemberusgaapBusinessAcquisitionAxis_TwoThousandAndTwentyTwoPromissoryNoteMemberusgaapLongtermDebtTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis" >sclx:TwoThousandAndTwentyTwoPromissoryNoteMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >sclx:SorrentoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-05-12</xbrli:startDate> <xbrli:endDate>2022-05-12</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_12_2022_SorrentoMemberusgaapBusinessAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_TwoThousandAndTwentyTwoPromissoryNoteMemberusgaapLongtermDebtTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis" >sclx:TwoThousandAndTwentyTwoPromissoryNoteMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >sclx:SorrentoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-05-12</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_12_2022_SorrentoMemberusgaapBusinessAcquisitionAxis_TwoThousandAndTwentyTwoPromissoryNoteMemberusgaapLongtermDebtTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis" >sclx:TwoThousandAndTwentyTwoPromissoryNoteMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >sclx:SorrentoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-05-12</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_12_2022_PromissoryNoteMemberusgaapRelatedPartyTransactionAxis_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >sclx:SorrentoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >sclx:PromissoryNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-05-12</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_07_2018_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:TwoThousandAndEighteenPurchaseAgreementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-09-07</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P10_02_2018To10_02_2018_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >sclx:PromissoryNoteRelatedPartyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:ScilexPharmaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-10-02</xbrli:startDate> <xbrli:endDate>2018-10-02</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_07_2018To09_07_2018_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:TwoThousandAndEighteenPurchaseAgreementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-09-07</xbrli:startDate> <xbrli:endDate>2018-09-07</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_28_2021To02_28_2021_SorrentoMemberSCLXInvesteeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:InvesteeAxis" >sclx:SorrentoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-28</xbrli:startDate> <xbrli:endDate>2021-02-28</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_28_2021To02_28_2021_ScilexPharmaMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:ScilexPharmaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-28</xbrli:startDate> <xbrli:endDate>2021-02-28</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_MeasurementInputRiskadjustedNetSalesForecastMemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >sclx:MeasurementInputRiskadjustedNetSalesForecastMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_MeasurementInputEffectiveDebtYieldMemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >sclx:MeasurementInputEffectiveDebtYieldMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_01_2022_PaloAltoAadministrativeFacilityMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >sclx:PaloAltoAadministrativeFacilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P09_30_2022To09_30_2022_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >sclx:SorrentoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-09-30</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_30_2022To09_30_2022_LetterOfCreditMemberusgaapCreditFacilityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:LetterOfCreditMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-09-30</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_30_2022To09_30_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:ScilexPharmaNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-09-30</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_15_2019To02_15_2019_MinimumMembersrtRangeAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:TwoThousandAndEighteenPurchaseAgreementsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-02-15</xbrli:startDate> <xbrli:endDate>2019-02-15</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_15_2019To02_15_2019_MaximumMembersrtRangeAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:TwoThousandAndEighteenPurchaseAgreementsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-02-15</xbrli:startDate> <xbrli:endDate>2019-02-15</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_15_2019To02_15_2019_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:ScilexPharmaNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-02-15</xbrli:startDate> <xbrli:endDate>2019-02-15</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_15_2019To02_15_2019_MinimumMembersrtRangeAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:ScilexPharmaNoteMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-02-15</xbrli:startDate> <xbrli:endDate>2019-02-15</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_15_2019To02_15_2019_MaximumMembersrtRangeAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:ScilexPharmaNoteMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-02-15</xbrli:startDate> <xbrli:endDate>2019-02-15</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_15_2019To02_15_2019_IndebentureMemberSCLXAgreementAxis_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:AgreementAxis" >sclx:IndebentureMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-02-15</xbrli:startDate> <xbrli:endDate>2019-02-15</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_15_2019To02_15_2019_IndebentureMemberSCLXAgreementAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:AgreementAxis" >sclx:IndebentureMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-02-15</xbrli:startDate> <xbrli:endDate>2019-02-15</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_01_2022To09_30_2023_DebtInstrumentRedemptionPeriodOneMemberusgaapDebtInstrumentRedemptionPeriodAxis_ScenarioAdjustmentMembersrtStatementScenarioAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:TwoThousandAndEighteenPurchaseAgreementsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis" >us-gaap:ScenarioAdjustmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis" >us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-10-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_01_2022To09_30_2023_DebtInstrumentRedemptionPeriodThreeMemberusgaapDebtInstrumentRedemptionPeriodAxis_ScenarioAdjustmentMembersrtStatementScenarioAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis" >us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis" >us-gaap:ScenarioAdjustmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:TwoThousandAndEighteenPurchaseAgreementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-10-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_01_2022To09_30_2023_DebtInstrumentRedemptionPeriodOneMemberusgaapDebtInstrumentRedemptionPeriodAxis_MinimumMembersrtRangeAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis" >us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:TwoThousandAndEighteenPurchaseAgreementsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-10-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_01_2022To09_30_2023_DebtInstrumentRedemptionPeriodOneMemberusgaapDebtInstrumentRedemptionPeriodAxis_MaximumMembersrtRangeAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis" >us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:TwoThousandAndEighteenPurchaseAgreementsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-10-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_01_2022To09_30_2023_DebtInstrumentRedemptionPeriodThreeMemberusgaapDebtInstrumentRedemptionPeriodAxis_MinimumMembersrtRangeAxis_ScenarioAdjustmentMembersrtStatementScenarioAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis" >us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis" >us-gaap:ScenarioAdjustmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:TwoThousandAndEighteenPurchaseAgreementsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-10-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_01_2022To09_30_2023_DebtInstrumentRedemptionPeriodThreeMemberusgaapDebtInstrumentRedemptionPeriodAxis_MaximumMembersrtRangeAxis_ScenarioAdjustmentMembersrtStatementScenarioAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis" >us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis" >us-gaap:ScenarioAdjustmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:TwoThousandAndEighteenPurchaseAgreementsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-10-01</xbrli:startDate> <xbrli:endDate>2023-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_07_2018To12_31_2021_DebtInstrumentRedemptionPeriodTwoMemberusgaapDebtInstrumentRedemptionPeriodAxis_ScenarioAdjustmentMembersrtStatementScenarioAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis" >us-gaap:ScenarioAdjustmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis" >us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:TwoThousandAndEighteenPurchaseAgreementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-09-07</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_07_2018To12_31_2021_LetterOfCreditMemberusgaapCreditFacilityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:LetterOfCreditMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-09-07</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_14_2020_IndebentureMemberSCLXAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:AgreementAxis" >sclx:IndebentureMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-14</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_14_2020_IfLetterOfCreditIsDrawnMembersrtStatementScenarioAxis_IndebentureMemberSCLXAgreementAxis_LetterOfCreditMemberusgaapCreditFacilityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:LetterOfCreditMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:AgreementAxis" >sclx:IndebentureMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis" >sclx:IfLetterOfCreditIsDrawnMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-14</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_14_2020_IndebentureMemberSCLXAgreementAxis_LetterOfCreditMemberusgaapCreditFacilityAxis_MarketingApprovalLetterMembersrtStatementScenarioAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:LetterOfCreditMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:AgreementAxis" >sclx:IndebentureMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis" >sclx:MarketingApprovalLetterMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-14</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_14_2020_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:ScilexPharmaNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-14</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_14_2020_PrimeRateMemberusgaapVariableRateAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis" >us-gaap:PrimeRateMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:ScilexPharmaNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-14</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P12_14_2020To12_14_2020_IndebentureMemberSCLXAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:AgreementAxis" >sclx:IndebentureMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-12-14</xbrli:startDate> <xbrli:endDate>2020-12-14</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_30_2021To04_30_2021_SorrentoMemberSCLXInvesteeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:InvesteeAxis" >sclx:SorrentoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-30</xbrli:startDate> <xbrli:endDate>2021-04-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_30_2021To04_30_2021_LetterOfCreditMemberusgaapCreditFacilityAxis_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:LetterOfCreditMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-30</xbrli:startDate> <xbrli:endDate>2021-04-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_30_2021To04_30_2021_LetterOfCreditMemberusgaapCreditFacilityAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:LetterOfCreditMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-30</xbrli:startDate> <xbrli:endDate>2021-04-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_12_2022To09_12_2022_DebtExchangeAgreementMemberSCLXAgreementAxis_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >sclx:PromissoryNoteRelatedPartyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:ScilexPharmaMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:AgreementAxis" >sclx:DebtExchangeAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-09-12</xbrli:startDate> <xbrli:endDate>2022-09-12</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_10_2022_MinimumMembersrtRangeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-10</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_10_2022_MaximumMembersrtRangeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-10</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_10_2022_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-10</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_10_2022_DebtExchangeAgreementMemberSCLXAgreementAxis_SorrentoMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:AgreementAxis" >sclx:DebtExchangeAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >sclx:SorrentoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-10</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P11_10_2022To11_10_2022_DebtExchangeAgreementMemberSCLXAgreementAxis_PreferredStockMemberusgaapStatementEquityComponentsAxis_SorrentoMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:AgreementAxis" >sclx:DebtExchangeAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >sclx:SorrentoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:PreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-11-10</xbrli:startDate> <xbrli:endDate>2022-11-10</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P11_10_2022To11_10_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_DebtExchangeAgreementMemberSCLXAgreementAxis_SorrentoMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:AgreementAxis" >sclx:DebtExchangeAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >sclx:SorrentoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-11-10</xbrli:startDate> <xbrli:endDate>2022-11-10</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_16_2022To02_16_2022_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:ScilexPharmaNoteMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis" >us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-02-16</xbrli:startDate> <xbrli:endDate>2022-02-16</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P05_01_2020To05_31_2020_PaycheckProtectionProgramMemberusgaapLongtermDebtTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis" >sclx:PaycheckProtectionProgramMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-05-01</xbrli:startDate> <xbrli:endDate>2020-05-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_31_2020_PaycheckProtectionProgramMemberusgaapLongtermDebtTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis" >sclx:PaycheckProtectionProgramMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-05-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_02_2022_AmendmentNoFourMemberSCLXAmendmentAxis_PromissoryNoteMemberusgaapRelatedPartyTransactionAxis_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:AmendmentAxis" >sclx:AmendmentNoFourMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >sclx:PromissoryNoteMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >sclx:SorrentoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-02</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_02_2022_AmendmentNoFourMemberSCLXAmendmentAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:AmendmentAxis" >sclx:AmendmentNoFourMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:ScilexPharmaNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-02</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_02_2022_AmendmentNoFourMemberSCLXAmendmentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:AmendmentAxis" >sclx:AmendmentNoFourMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-02</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_03_2022_AmendmentNoFourMemberSCLXAmendmentAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:AmendmentAxis" >sclx:AmendmentNoFourMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:ScilexPharmaNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-03</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P06_02_2022To06_02_2022_AmendmentNoFourMemberSCLXAmendmentAxis_MaximumMembersrtRangeAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:AmendmentAxis" >sclx:AmendmentNoFourMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:ScilexPharmaNoteMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-06-02</xbrli:startDate> <xbrli:endDate>2022-06-02</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P06_02_2022To06_02_2022_AmendmentNoFourMemberSCLXAmendmentAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:ScilexPharmaNoteMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:AmendmentAxis" >sclx:AmendmentNoFourMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-06-02</xbrli:startDate> <xbrli:endDate>2022-06-02</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P06_02_2022To06_02_2022_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >sclx:SorrentoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-06-02</xbrli:startDate> <xbrli:endDate>2022-06-02</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P06_02_2022To06_02_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:ScilexPharmaNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-06-02</xbrli:startDate> <xbrli:endDate>2022-06-02</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_01_2022To09_30_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >sclx:ScilexPharmaNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-09-01</xbrli:startDate> <xbrli:endDate>2022-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_01_2022To11_30_2022_AgreementWithCertainOfTheThirdPartyProfessionalServiceProvidersMemberSCLXAgreementAxis_SorrentoMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:AgreementAxis" >sclx:AgreementWithCertainOfTheThirdPartyProfessionalServiceProvidersMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:SorrentoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-10-01</xbrli:startDate> <xbrli:endDate>2022-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_01_2022To11_30_2022_AccountsPayableMemberusgaapBalanceSheetLocationAxis_AgreementWithCertainOfTheThirdPartyProfessionalServiceProvidersMemberSCLXAgreementAxis_SorrentoMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis" >us-gaap:AccountsPayableMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:AgreementAxis" >sclx:AgreementWithCertainOfTheThirdPartyProfessionalServiceProvidersMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:SorrentoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-10-01</xbrli:startDate> <xbrli:endDate>2022-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_01_2022To11_30_2022_AccruedLiabilitiesMemberusgaapBalanceSheetLocationAxis_AgreementWithCertainOfTheThirdPartyProfessionalServiceProvidersMemberSCLXAgreementAxis_SorrentoMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis" >us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:AgreementAxis" >sclx:AgreementWithCertainOfTheThirdPartyProfessionalServiceProvidersMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:SorrentoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-10-01</xbrli:startDate> <xbrli:endDate>2022-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P11_17_2022To11_17_2022_StandbyEquityPurchaseAgreementMemberSCLXAgreementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_YorkvilleMemberSCLXInvesteeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:InvesteeAxis" >sclx:YorkvilleMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:AgreementAxis" >sclx:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-11-17</xbrli:startDate> <xbrli:endDate>2022-11-17</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_01_2022To02_28_2022_ScilexPharmaMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:ScilexPharmaMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-02-01</xbrli:startDate> <xbrli:endDate>2022-02-28</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_01_2022To02_28_2022_DueOnOrAfterFebruaryTwoThousandAndThirtyMemberSCLXPeriodAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:PeriodAxis" >sclx:DueOnOrAfterFebruaryTwoThousandAndThirtyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-02-01</xbrli:startDate> <xbrli:endDate>2022-02-28</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_06_2021_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-01-06</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_11_2021To01_11_2021_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-11</xbrli:startDate> <xbrli:endDate>2021-01-11</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_28_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >sclx:SorrentoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-02-28</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P12_21_2020To12_20_2021_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-12-21</xbrli:startDate> <xbrli:endDate>2021-12-20</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_11_2022To07_11_2022_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-07-11</xbrli:startDate> <xbrli:endDate>2022-07-11</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_10_2022To01_10_2022_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-10</xbrli:startDate> <xbrli:endDate>2022-01-10</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_31_2023_B.RileyMemberSCLXInvesteeAxis_PurchasetypeAMembersrtProductOrServiceAxis_ScilexCommonStockMemberusgaapRelatedPartyTransactionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:InvesteeAxis" >sclx:B.RileyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >sclx:ScilexCommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >sclx:PurchasetypeAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-01-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_31_2023_B.RileyMemberSCLXInvesteeAxis_PurchasetypeBMembersrtProductOrServiceAxis_ScilexCommonStockMemberusgaapRelatedPartyTransactionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:InvesteeAxis" >sclx:B.RileyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >sclx:ScilexCommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >sclx:PurchasetypeBMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-01-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_31_2023To01_31_2023_B.RileyMemberSCLXInvesteeAxis_StandbyEquityPurchaseAgreementMemberSCLXAgreementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:InvesteeAxis" >sclx:B.RileyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:AgreementAxis" >sclx:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-31</xbrli:startDate> <xbrli:endDate>2023-01-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_31_2023To01_31_2023_B.RileyMemberSCLXInvesteeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:InvesteeAxis" >sclx:B.RileyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-31</xbrli:startDate> <xbrli:endDate>2023-01-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_31_2023To01_31_2023_B.RileyMemberSCLXInvesteeAxis_PurchasetypeAMembersrtProductOrServiceAxis_ScilexCommonStockMemberusgaapRelatedPartyTransactionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:InvesteeAxis" >sclx:B.RileyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >sclx:ScilexCommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >sclx:PurchasetypeAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-31</xbrli:startDate> <xbrli:endDate>2023-01-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_31_2023To01_31_2023_B.RileyMemberSCLXInvesteeAxis_PurchasetypeBMembersrtProductOrServiceAxis_ScilexCommonStockMemberusgaapRelatedPartyTransactionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:InvesteeAxis" >sclx:B.RileyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >sclx:ScilexCommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis" >sclx:PurchasetypeBMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-31</xbrli:startDate> <xbrli:endDate>2023-01-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_17_2022_StandbyEquityPurchaseAgreementMemberSCLXAgreementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_YorkvilleMemberSCLXInvesteeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="sclx:InvesteeAxis" >sclx:YorkvilleMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:AgreementAxis" >sclx:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-11-17</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_08_2023To01_08_2023_B.RileyMemberSCLXInvesteeAxis_StandbyEquityPurchaseAgreementMemberSCLXAgreementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:AgreementAxis" >sclx:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:InvesteeAxis" >sclx:B.RileyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-08</xbrli:startDate> <xbrli:endDate>2023-01-08</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_08_2023_B.RileyMemberSCLXInvesteeAxis_StandbyEquityPurchaseAgreementMemberSCLXAgreementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:AgreementAxis" >sclx:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="sclx:InvesteeAxis" >sclx:B.RileyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-01-08</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_DerivativeFinancialInstrumentsLiabilitiesMemberusgaapFairValueByLiabilityClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" >us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2021_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:PrivatePlacementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_ConversionOptionLiabilityMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >sclx:ConversionOptionLiabilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ConversionOptionLiabilityMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >sclx:ConversionOptionLiabilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:PrivatePlacementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_ConversionOptionLiabilityMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >sclx:ConversionOptionLiabilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:PrivatePlacementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:PrivatePlacementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:PrivatePlacementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2022_ConversionOptionLiabilityMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >sclx:ConversionOptionLiabilityMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_20_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-02-20</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_20_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-02-20</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_20_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-02-20</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_20_2020_VickersVantageMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >sclx:VickersVantageMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-02-20</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_DerivativeFinancialInstrumentsLiabilitiesMemberusgaapFairValueByLiabilityClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" >us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_DerivativeFinancialInstrumentsLiabilitiesMemberusgaapFairValueByLiabilityClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis" >us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001820190</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:unit id="Unit_shares" > <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_USD" > <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Year" > <xbrli:measure>utr:Year</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_pure" > <xbrli:measure>xbrli:pure</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Day" > <xbrli:measure>utr:Day</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Month" > <xbrli:measure>utr:Month</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_USD_per_Share" > <xbrli:divide> <xbrli:unitNumerator> <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unitNumerator> <xbrli:unitDenominator> <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unitDenominator> </xbrli:divide> </xbrli:unit><ix:relationship fromRefs="Fact_63193284" toRefs="FN_220028"/><ix:relationship fromRefs="Fact_63193285" toRefs="FN_220028"/><ix:relationship fromRefs="Fact_63193636" toRefs="FN_220029"/><ix:relationship fromRefs="Fact_63193637" toRefs="FN_220029"/><ix:relationship fromRefs="Fact_63195334" toRefs="FN_220030"/><ix:relationship fromRefs="Fact_63195335" toRefs="FN_220030"/><ix:relationship fromRefs="Fact_63195336" toRefs="FN_220030"/></ix:resources></ix:header></div><div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: Times New Roman; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As filed with the U.S. Securities and Exchange Commission </div></div></div> <div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 12.6667px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 700; letter-spacing: normal; orphans: 2; text-align: center; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;">on January&#160;12, 20</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">23 </div></div></div></div> <div style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Registration <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;333-&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div> </div></div></div> <div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="line-height: 1pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="line-height: 3pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 18pt; margin-top: 4pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">UNITED STATES </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">SECURITIES AND EXCHANGE COMMISSION </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">Washington, D.C. 20549 </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center;;text-indent: 0px;"> <div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 12pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:DocumentType" contextRef="P01_01_2022To09_30_2022">S-1</ix:nonNumeric></div> </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">REGISTRATION STATEMENT </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 12pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">UNDER </div></div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">THE SECURITIES ACT OF 1933 </div></div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center;;text-indent: 0px;"> <div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 24pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 24pt; letter-spacing: 0px; top: 0px;;display:inline;"><span style="-sec-ix-hidden:hidden63195201">Scilex Holding Company</span> </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">(Exact name of Registrant as specified in its charter) </div></div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center;;text-indent: 0px;"> <div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 34%;"></td>
<td style="vertical-align: bottom;"></td>
<td style="width: 32%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 32%;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Delaware</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2836</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">92-1062542</div></div></div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(State or other jurisdiction of<br/>incorporation or organization)</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Primary Standard Industrial<br/>Classification Code Number)</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(I.R.S. Employer<br/>Identification Number)</div></div></div></td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Scilex Holding Company </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">960 San Antonio Road </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Palo Alto, CA 94303 </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">(Address, including zip code, and telephone number, including area code, of Registrant&#8217;s principal executive offices) </div></div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center;;text-indent: 0px;"> <div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Jaisim Shah </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Chief Executive Officer&#160;&amp; President </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">960 San Antonio Road </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Palo Alto, CA 94303 </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(650) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">516-4310</div> </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 7.5pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7.5pt; letter-spacing: 0px; top: 0px;;display:inline;">(Name, address, including zip code, and telephone number, including area code, of agent for service) </div></div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center;;text-indent: 0px;"> <div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Copies to: </div></div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Jeffrey T. Hartlin, Esq. </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Elizabeth A. Razzano, Esq. </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Paul Hastings LLP </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">1117 S. California Avenue </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Palo Alto, CA 94304 </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(650) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">320-1800</div> </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center;;text-indent: 0px;"> <div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 9.5pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Approximate date of commencement of proposed sale to the public: </div></div>As soon as practicable after this registration statement becomes effective. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 9.5pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box.&#160;&#160;&#9746; </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 9.5pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#160;&#160;&#9744; </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 9.5pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#160;&#160;&#9744; </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 9.5pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#160;&#160;&#9744; </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 9.5pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-accelerated</div> filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12b-2</div> of the Exchange Act. </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 16%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 60%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 19%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 2%;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Large&#160;accelerated&#160;filer</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#9744;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Accelerated&#160;filer</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#9744;</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="2" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="2" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="2" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"></div><ix:nonNumeric name="dei:EntityFilerCategory" contextRef="P01_01_2022To09_30_2022" format="ixt-sec:entityfilercategoryen"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-accelerated</div> filer</ix:nonNumeric></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#9746;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Smaller&#160;reporting&#160;company</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntitySmallBusiness" contextRef="P01_01_2022To09_30_2022" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="2" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="2" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="2" style="height: 6pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Emerging&#160;growth&#160;company</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="P01_01_2022To09_30_2022" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></div></td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-family: Times New Roman; font-size: 9.5pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;7(a)(2)(B) of the Securities Act.&#160;&#160;<ix:nonNumeric name="dei:EntityExTransitionPeriod" contextRef="P01_01_2022To09_30_2022" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric> </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">The Registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section&#160;8(a) of the Securities Act of 1933, as amended, or until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section&#160;8(a), may determine. </div></div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="line-height: 1pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="line-height: 3pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </div> </div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow"><span style="color:#eb0029"><span style="font-weight:bold">The information in this preliminary prospectus is not complete and may be changed. These securities may not be sold until the registration statement filed with the U.S. Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted. </span></span></p> <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="color:#eb0029"><span style="font-weight:bold">PRELIMINARY &#8212; SUBJECT TO COMPLETION, DATED JANUARY&#160;12, 2023 </span></span></p> <p style="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">PRELIMINARY PROSPECTUS </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center">SCILEX HOLDING COMPANY </p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman;font-weight:bold;text-align:center">Up to 28,128,422 Shares of Common Stock </p> <p style="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:9.5pt; font-family:Times New Roman">This prospectus relates to the resale from time to time of up to 28,128,422 shares of common stock, par value $0.0001 per share (the &#8220;Common Stock&#8221;), of Scilex Holding Company, a Delaware corporation (&#8220;Scilex&#8221;), by B. Riley Principal Capital II, LLC, a Delaware limited liability company (the &#8220;Selling Securityholder&#8221;). The shares included in this prospectus consist of shares of Common Stock that we have issued or that we may, in our discretion, elect to issue and sell to the Selling Securityholder, from time to time after the date of this prospectus, pursuant to a standby equity purchase agreement we entered into with the Selling Securityholder on January 8, 2023 (the &#8220;B. Riley Purchase Agreement&#8221;), in which the Selling Securityholder has committed to purchase from us, at our direction, up to $500,000,000 of our Common Stock, subject to terms and conditions specified in the B. Riley Purchase Agreement. As consideration for the Selling Securityholder&#8217;s irrevocable commitment to purchase shares of our Common Stock at our election and in our discretion from time to time after the date of this prospectus and prior to the first day of the month next following <span style="white-space:nowrap">the&#160;36-month&#160;anniversary</span> of the date on which this registration statement has been declared effective by the Securities and Exchange Commission, upon the terms and subject to the satisfaction of the conditions set forth in the B. Riley Purchase Agreement, we have agreed to issue to the Selling Securityholder 250,000 shares of Common Stock pursuant to the terms of the B. Riley Purchase Agreement (the &#8220;Commitment Shares&#8221;). See the section of this prospectus titled &#8220;<span style="font-style:italic">Committed Equity Financing</span>&#8221; for a description of the B. Riley Purchase Agreement and the section titled &#8220;<span style="font-style:italic">Selling Securityholder</span>&#8221; for additional information regarding the Selling Securityholder. </p> <p style="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:9.5pt; font-family:Times New Roman">Our registration of the securities covered by this prospectus does not mean that the Selling Securityholder will offer or sell any of the shares of Common Stock. The Selling Securityholder may offer, sell, or distribute all or a portion of its shares of Common Stock publicly or through private transactions at prevailing market prices or at negotiated prices. We will not receive any proceeds from the sale of shares of Common Stock by the Selling Securityholder pursuant to this prospectus. However, we may receive up to $500,000,000 in aggregate gross proceeds from sales of our Common Stock to the Selling Securityholder that we may, in our discretion, elect to make, from time to time after the date of this prospectus, pursuant to the B. Riley Purchase Agreement. We provide more information about how the Selling Securityholder may sell or otherwise dispose of the shares of our Common Stock in the section titled &#8220;<span style="font-style:italic">Plan of Distribution</span>.&#8221; We will bear all costs, expenses and fees in connection with the registration of the shares of Common Stock offered hereby. The Selling Securityholder will bear all commissions and discounts, if any, attributable to its sales of the shares of Common Stock offered hereby. </p> <p style="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:9.5pt; font-family:Times New Roman">The Selling Securityholder is an &#8220;underwriter&#8221; within the meaning of Section&#160;2(a)(11) of the U.S. Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and any profits on the sales of shares of our Common Stock by the Selling Securityholder and any discounts, commissions or concessions received by the Selling Securityholder are deemed to be underwriting discounts and commissions under the Securities Act. </p> <p style="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:9.5pt; font-family:Times New Roman">Our Common Stock is listed on the Nasdaq Capital Market under the symbol &#8220;SCLX&#8221;. On January&#160;11, 2023, the last reported sales price per share of our Common Stock was $7.47. </p> <p style="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:9.5pt; font-family:Times New Roman">We are an &#8220;emerging growth company&#8221; as that term is used in the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;) and, as such, we have elected to comply with certain reduced public company reporting requirements for this prospectus and future filings with the Securities and Exchange Commission. </p> <p style="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:9.5pt; font-family:Times New Roman">We may amend or supplement this prospectus from time to time by filing amendments or supplements as required. You should read this prospectus, together with additional information described under the heading &#8220;<span style="font-style:italic">Where You Can Find More Information</span>&#8221;, and any amendments or supplements carefully before you invest in any of our securities. </p> <p style="margin-top:4pt; margin-bottom:0pt; text-indent:5%; font-size:10.5pt; font-family:Times New Roman;font-weight:bold">INVESTING IN OUR COMMON STOCK INVOLVES SUBSTANTIAL RISKS. YOU SHOULD REVIEW CAREFULLY THE RISKS AND UNCERTAINTIES DESCRIBED UNDER THE HEADING &#8220;<a href="#rom428534_11">RISK FACTORS</a>&#8221; BEGINNING ON PAGE 13 OF THIS PROSPECTUS. </p> <p style="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:9.5pt; font-family:Times New Roman">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense. </p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">The date of this prospectus is &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2023 </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc">TABLE OF CONTENTS </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:94%"></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">PAGE</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_1">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">v</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_2">CERTAIN DEFINED TERMS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">vii</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_3">PROSPECTUS SUMMARY</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_4">The Company</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_5">Business Combination</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_5a">Recent Developments </a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_6">Committed Equity Financing</a>s</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_7">Emerging Growth Company</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_8">Summary Risk Factors</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_9">Corporate Information</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_10">THE OFFERING</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_11">RISK FACTORS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_12">Risks Related to our Limited Operating History, Financial Condition and Capital Requirements</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_13">Risks Related to our Commercial Operations and Product Development</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_14">Risks Related to our Business and Operations</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">34</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_15">Risks Related to Scilex&#8217;s Intellectual Property</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">40</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_16">Risks Related to Government Regulations</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">57</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_17">Risks Related to our Relationship with Sorrento</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">72</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_18">Risks Related to this Offering</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">76</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_19">Risks Related to Ownership of our Common Stock</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">78</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_20">COMMITTED EQUITY FINANCING</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">89</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_201">Advances of Common Stock Under B. Riley Purchase Agreement</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">90</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_202">Additional Advances of Common Stock under B. Riley Purchase Agreement</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">91</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_203">Conditions to Each Advance and Additional Advance</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">91</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_204">Termination of the B. Riley Purchase Agreement</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">91</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_205">No Short-Selling by Securityholder</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">92</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_206">Effect of Sales of our Common Stock under the B. Riley Purchase Agreement on our Stockholders</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">92</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_21">MARKET AND INDUSTRY DATA</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">95</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_22">USE OF PROCEEDS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">96</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_23">DETERMINATION OF OFFERING PRICE</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">97</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_24">MARKET INFORMATION FOR SECURITIES AND DIVIDEND POLICY</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">98</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_25">Market Information</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">98</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_26">Dividend Policy</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">98</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_27">Securities Authorized for Issuance under Equity Compensation Plans</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">98</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_28">UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">99</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_29">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">114</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_30">Overview</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">114</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_31">Business Combination</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">115</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_32">Recent Developments</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">116</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_33">Impact of <span style="white-space:nowrap">COVID-19</span> on Our Business</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">118</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_34">Comparability of Our Results and Our Relationship with Sorrento</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">118</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_35">Components of Our Results of Operations</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">118</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_36">Operating Costs and Expenses</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">119</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_37">Results of Operations</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">121</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_38">Comparison of Nine Months Ended September&#160;30, 2022 and 2021</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">122</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_39">Comparison of Years Ended December&#160;31, 2021 and 2020</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">124</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_40">Comparison of Years Ended December&#160;31, 2020 and 2019</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">126</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">i </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:94%"></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">PAGE</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_41">Liquidity and Capital Resources</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">127</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_42">Debt Financings</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">128</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_43">Critical Accounting Policies and Estimates</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">133</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_44">Recent Accounting Pronouncements</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">140</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_45">Quantitative and Qualitative Disclosures About Market Risk</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">140</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_46">Emerging Growth Company</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">141</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_47">Smaller Reporting Company</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">142</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_48">BUSINESS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">143</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_49">The Company</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">143</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_50">Our Marketed Product and Pipeline</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">144</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_51">Our Strategy</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">145</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_52">Our Management Team</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">146</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_53">Our Product Portfolio</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">147</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_54">Commercialization and Market Access</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">159</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_55">Clinical Development Overview</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">161</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_56">Medical Affairs</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">172</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_57">Manufacturing and Supply Chain</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">172</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_58">Competition</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">173</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_59">Material Agreements</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">175</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_60">Intellectual Property</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">183</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_61">Government Regulation and Product Approval</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">184</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_62">Employees and Human Capital Resources</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">202</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_63">Facilities and Properties</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">202</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_64">Legal Proceedings</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">202</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_65">Our Corporate History</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">203</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_66">Website</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">204</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_67">MANAGEMENT</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">205</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_68">Executive Officers and Directors</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">205</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_69">Family Relationships</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">208</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_70">Board Composition</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">208</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_71">Controlled Company Exemption</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">209</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_72">Director Independence</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">210</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_73">Role of Board in Risk Oversight Process</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">210</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_74">Board Leadership Structure</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">210</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_75">Board Diversity</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">211</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_76">Committees of our Board</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">211</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_77">Code of Business Conduct and Ethics</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">214</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_78">Compensation Committee Interlocks and Insider Participation</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">215</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_79">Limitation of Liability and Indemnification of Directors and Officers</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">215</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_80">EXECUTIVE AND DIRECTOR COMPENSATION</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">217</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_81">Executive Compensation</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">217</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_82">Summary Compensation Table</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">217</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_83">Narrative Disclosure to Summary Compensation Table</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">218</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_84">Potential Payments upon Termination or Change in Control</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">220</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_85">Perquisites, Health, Welfare and Retirement Benefits</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">220</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_86">Pension Benefits and Nonqualified Deferred Compensation</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">220</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_87">Outstanding Equity Awards at Fiscal <span style="white-space:nowrap">Year-End</span> 2022</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">220</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_88">Equity-Based Incentive Plans</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">221</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_89">Emerging Growth Company Status</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">235</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_90">Director Compensation</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">235</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_91">Director Compensation Policy</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">236</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">ii </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:94%"></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">PAGE</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_92">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">237</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_93">Certain Relationships of Vickers</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">237</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_94">Certain Relationships of Legacy Scilex</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">240</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_95">PRINCIPAL SECURITYHOLDERS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">248</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_96">SELLING SECURITYHOLDER</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">249</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_97">PLAN OF DISTRIBUTION</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">251</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_98">MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">253</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_207">U.S. Holders</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">254</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_208">Non-U.S. Holders</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">255</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_209">Foreign Account Tax Compliance Act</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">256</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_99">DESCRIPTION OF OUR SECURITIES</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">258</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_100">General</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">258</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_101">Authorized and Outstanding Stock</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">258</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_210">Our Common Stock </a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">258</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_102">Our Preferred Stock</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">259</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_103">Registration Rights</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">261</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_104">Anti-Takeover Matters in our Governing Documents and Under Delaware Law</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">261</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_105">Conflicts of Interest</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">266</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_106">Rights of Appraisal and Payment</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">266</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_107">Stockholders&#8217; Derivative Actions</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">267</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_108">Warrants</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">267</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_109">Transfer Agent and Registrar</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">269</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_110">Listing</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">269</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_111">LEGAL MATTERS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">269</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_112">EXPERTS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">270</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_113">CHANGE IN AUDITORS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">270</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_114">WHERE YOU CAN FIND MORE INFORMATION</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">271</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#rom428534_115">INDEX TO FINANCIAL STATEMENTS</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"><span style="white-space:nowrap">F-1</span></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should rely only on the information we have provided in this prospectus, any applicable prospectus supplement and any related free writing prospectus. Neither we nor the Selling Securityholder have authorized anyone to provide you with information different from that contained in this prospectus, any applicable prospectus supplement or any related free writing prospectus. No dealer, salesperson or other person is authorized to give any information or to represent anything not contained in this prospectus, any applicable prospectus supplement or any related free writing prospectus. You must not rely on any unauthorized information or representation. This prospectus is an offer to sell only the securities offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. You should assume that the information in this prospectus, any applicable prospectus supplement or any related free writing prospectus is accurate only as of the date on the front of the document, regardless of the time of delivery of this prospectus or any sale of a security. Since the date of this prospectus and the documents incorporated by reference into this prospectus, our business, financial condition, results of operations and prospects may have changed. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">For Investors Outside the United States</span>: The Selling Securityholder is offering to sell, and seeking offers to buy, the securities offered by this prospectus only in jurisdictions where offers and sales are permitted. Neither we nor the Selling Securityholder have done anything that would permit this offering or the possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the securities offered by this prospectus and the distribution of this prospectus outside the United States. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">iii </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">ABOUT THIS PROSPECTUS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement on <span style="white-space:nowrap">Form&#160;S-1</span> that we filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) using the &#8220;shelf&#8221; registration process. Under this shelf registration process, the Selling Securityholder may, from time to time, sell the securities offered by it described in this prospectus. We will not receive any proceeds from the sale by such Selling Securityholder of the securities offered by it described in this prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither we nor the Selling Securityholder have authorized anyone to provide you with any information or to make any representations other than those contained in this prospectus or any applicable prospectus supplement or any free writing prospectuses prepared by or on behalf of us or to which we have referred you. Neither we nor the Selling Securityholder take responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. Neither we nor the Selling Securityholder will make an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may also provide a prospectus supplement or post-effective amendment to the registration statement to add information to, or update or change information contained in, this prospectus. You should read both this prospectus and any applicable prospectus supplement or post-effective amendment to the registration statement together with the additional information to which we refer you in the section of this prospectus titled &#8220;<span style="font-style:italic">Where You Can Find More Information</span>.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&#160;10, 2022, we consummated the previously-announced business combination (the &#8220;Business Combination&#8221;) pursuant to that certain Agreement and Plan of Merger, dated as of March&#160;17, 2022 (as amended, restated or supplemented from time to time, including by Amendment No.&#160;1 to Agreement and Plan of Merger, dated as of September&#160;12, 2022) (the &#8220;Merger Agreement&#8221;), by and among us, Vantage Merger Sub Inc., our then-wholly owned subsidiary (the &#8220;Merger Sub&#8221;), and the <span style="white-space:nowrap">pre-Business</span> Combination Scilex Holding Company (&#8220;Legacy Scilex&#8221;). Pursuant to the terms of the Merger Agreement, we effected a deregistration under the Cayman Islands Companies Act (as revised) and a domestication under Section&#160;388 of the Delaware General Corporation Law, as amended (the &#8220;DGCL&#8221;), pursuant to which our jurisdiction of incorporation was changed from the Cayman Islands to the State of Delaware (the &#8220;Domestication&#8221;), and, on the terms and subject to the conditions set forth in the Merger Agreement and in accordance with the DGCL, Merger Sub merged with and into Legacy Scilex (the &#8220;Merger&#8221; or the &#8220;Business Combination&#8221;), with Legacy Scilex surviving as our wholly owned subsidiary. In connection with the Business Combination, we changed our name from Vickers Vantage Corp. I to Scilex Holding Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the context indicates otherwise, references in this prospectus to the &#8220;Company,&#8221; &#8220;Scilex,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; and similar terms refer to Scilex Holding Company, a Delaware corporation formerly known as Vickers Vantage Corp. I, and its consolidated subsidiaries. References to &#8220;Legacy Scilex&#8221; refer to the private Delaware corporation that is now our wholly owned subsidiary, named Scilex, Inc. (formerly known as Scilex Holding Company). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus is a part, and you may obtain copies of those documents as described below under &#8220;<span style="font-style:italic">Where You Can Find More Information</span>.&#8221; </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">iv </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom428534_1">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain statements contained in this prospectus may constitute &#8220;forward-looking statements&#8221; for purposes of federal securities laws. Such statements can be identified by the fact that they do not relate strictly to historical or current facts. Forward-looking statements appear in a number of places in this prospectus including, without limitation, in the sections titled &#8220;<span style="font-style:italic">Business</span>&#8221; and &#8220;<span style="font-style:italic">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span>.&#8221; In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. Forward-looking statements are typically identified by words such as &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;contemplate,&#8221; &#8220;intend,&#8221; &#8220;outlook,&#8221; &#8220;estimate,&#8221; &#8220;forecast,&#8221; &#8220;project,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;possible,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and other similar words and expressions (including the negative of any of the foregoing), but the absence of these words does not mean that a statement is not forward-looking. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These forward-looking statements are based on information available as of the date of this prospectus and our managements&#8217; current expectations, forecasts and assumptions, and involve a number of judgments, known and unknown risks and uncertainties and other factors, many of which are outside the control of the Company and our directors, officers and affiliates. There can be no assurance that future developments will be those that have been anticipated. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These forward-looking statements involve a number of risks, uncertainties or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described in &#8220;<span style="font-style:italic">Risk Factors,</span>&#8221; our periodic filings with the SEC and the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to maintain the listing of our Common Stock on the Nasdaq Capital Market; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our public securities&#8217; liquidity and trading; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to raise financing in the future; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the outcome of any legal proceedings that may be instituted against us; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to attract and retain qualified directors, officers, employees and key personnel; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to compete effectively in a highly competitive market; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the competition from larger pharmaceutical companies that have greater resources, technology, relationships and/or expertise; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the ability to protect and enhance our corporate reputation and brand; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the impact from future regulatory, judicial and legislative changes in our industry; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to obtain and maintain regulatory approval of any of our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to research, discover and develop additional product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to grow and manage growth profitably; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to obtain and maintain intellectual property protection and not infringe on the rights of others; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to execute our business plans and strategy; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the impact of the <span style="white-space:nowrap">COVID-19</span> pandemic and other similar disruptions in the future; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">other factors detailed under the section of this prospectus titled &#8220;<span style="font-style:italic">Risk Factors</span>.&#8221; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">v </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Should one or more of these risks or uncertainties materialize or should any of the assumptions made by our management prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Some of these risks and uncertainties may in the future be amplified by the continuing <span style="white-space:nowrap">COVID-19</span> pandemic, and there may be additional risks that we consider immaterial or which are unknown. It is not possible to predict or identify all such risks. We do not undertake any obligation to update, add or to otherwise correct any forward-looking statements contained herein to reflect events or circumstances after the date they were made, whether as a result of new information, future events, inaccuracies that become apparent after the date hereof or otherwise, except as may be required under applicable securities laws. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">vi </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom428534_2">CERTAIN DEFINED TERMS </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Board</span>&#8221; means the board of directors of the Company. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Business Combination</span>&#8221; means the merger contemplated by the Merger Agreement. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Bylaws</span>&#8221; means the Bylaws of Scilex Holding Company, effective as of November&#160;10, 2022. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Certificate of Designations</span>&#8221; means the Certificate of Designations of the Company, designating the series of preferred stock, par value $0.0001 per share, of the Company as &#8220;Series A Preferred Stock&#8221;. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Certificate of Incorporation</span>&#8221; means the Restated Certificate of Incorporation of Scilex Holding Company, filed with Secretary of State of the State of Delaware on November&#160;10, 2022. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Closing</span>&#8221; means the closing of the Business Combination. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Closing Date</span>&#8221; means date of the Closing. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Code</span>&#8221; means the Internal Revenue Code of 1986, as amended. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Common Stock</span>&#8221; means the common stock, par value $0.0001 per share, of Scilex. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Continental</span>&#8221; means Continental Stock Transfer&#160;&amp; Trust Company, our transfer agent. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Debt Exchange Agreement</span>&#8221; means the Contribution and Satisfaction of Indebtedness Agreement, dated as of September&#160;12, 2022, by and among Sorrento, Legacy Scilex and Scilex Pharmaceuticals, Inc. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">DGCL</span>&#8221; means the General Corporation Law of the State of Delaware, as amended. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Domestication</span>&#8221; means the change of our domicile pursuant to a transfer by way of continuation of an exempted company out of the Cayman Islands and a domestication into the State of Delaware as a corporation, and our <span style="white-space:nowrap">de-registration</span> in the Cayman Islands. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Effective Time</span>&#8221; means the time at which the Business Combination became effective. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Equity Incentive Plan</span>&#8221; means the Scilex Holding Company 2022 Equity Incentive Plan. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">ESPP</span>&#8221; means the Scilex Holding Company 2022 Employee Stock Purchase Plan. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Exchange Act</span>&#8221; means the Securities Exchange Act of 1934, as amended. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">founder shares</span>&#8221; means the 3,450,000 outstanding Vickers Ordinary Shares held by the Sponsors and the following directors of Vickers: Pei Wei Woo, Suneel Kaji and Steve Myint, which were converted into 3,450,000 shares of Common Stock in connection with the Domestication. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Funding Commitment Letter</span>&#8221; means that certain letter agreement, dated as of October&#160;17, 2022, between Sorrento and Legacy Scilex. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">GAAP</span>&#8221; means accounting principles generally accepted in the United States of America. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Initial Shareholders</span>&#8221; means the Sponsors, Pei Wei Woo, Suneel Kaji and Steve Myint, each as the holders of founder shares. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">IPO</span>&#8221; refers to the initial public offering of 13,800,000 Units of Vickers consummated on January&#160;11, 2021. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">IRS</span>&#8221; means the United States Internal Revenue Service. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Legacy Scilex Board</span>&#8221; means the board of directors of Legacy Scilex. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Legacy Scilex Common Stock</span>&#8221; means the common stock of Legacy Scilex, par value $0.0001 per share, prior to the Effective Time. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">vii </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Legacy Scilex Preferred Stock</span>&#8221; means the Series A Preferred Stock, par value $0.0001 per share, of Legacy Scilex issued to Sorrento prior to the Effective Time pursuant to the Debt Exchange Agreement. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Maxim</span>&#8221; means Maxim Group LLC, the representative of the underwriters in the IPO. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Merger Agreement</span>&#8221; means that certain Agreement and Plan of Merger, dated as of March&#160;17, 2022, by and among us, Merger Sub and Legacy Scilex, as it may be amended or restated from time to time, including by the Merger Agreement Amendment. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Merger Agreement Amendment</span>&#8221; means that Amendment No.&#160;1 to Agreement and Plan of Merger, dated as of September&#160;12, 2022, by and among us, Merger Sub and Legacy Scilex. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Merger Sub</span>&#8221; means Vantage Merger Sub Inc., a Delaware corporation that was a wholly owned subsidiary of Vickers prior to the Closing and that, pursuant to the Business Combination, was merged with and into Legacy Scilex, with Legacy Scilex continuing as our wholly owned subsidiary. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Nasdaq</span>&#8221; means The Nasdaq Stock Market LLC. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Nasdaq Listing Rules</span>&#8221; means the rules and listing standards of Nasdaq. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Private Placement Warrants</span>&#8221; means the 6,840,000 warrants sold in a private placement to Vickers Venture Fund VI Pte Ltd and Vickers Venture Fund VI (Plan) Pte Ltd consummated on January&#160;11, 2021 (of which 2,736,000 were forfeited pursuant to the Sponsor Support Agreement and 3,104,000 were transferred to Sorrento pursuant to the Warrant Transfer Agreement, in each case in connection with the Business Combination). </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">public shareholders</span>&#8221; means the holders of the public shares. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">public shares</span>&#8221; means the Vickers Ordinary Shares which were sold as part of the IPO, whether they were purchased in the IPO or in the aftermarket, including any of our Initial Shareholders to the extent that they purchase such public shares (except that our Initial Shareholders will not have conversion or tender rights with respect to any public shares they own). </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Public Warrants</span>&#8221; means the redeemable warrants that were included in the Units that entitle the holder of each whole warrant to purchase one Vickers Ordinary Share at a price of $11.50 per share. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">SEC</span>&#8221; means the U.S. Securities and Exchange Commission. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Securities Act</span>&#8221; means the Securities Act of 1933, as amended. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Series A Preferred Stock</span>&#8221; means the preferred stock, par value $0.0001 per share, of the Company, designated as Series A Preferred Stock pursuant to the Certificate of Designations. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Sorrento</span>&#8221; means Sorrento Therapeutics, Inc. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Sorrento Group</span>&#8221; means Sorrento together with its affiliates, subsidiaries, successors and assigns (other than us and our subsidiaries). </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Sorrento Trigger Event</span>&#8221; means the time that the Sorrento Group first ceases to beneficially own more than 50% in voting power of the then-outstanding shares of our stock entitled to vote generally in the election of directors. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Sponsors</span>&#8221; means Vickers Venture Fund VI Pte Ltd and Vickers Venture Fund VI (Plan) Pte Ltd. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Sponsor Support Agreement</span>&#8221; means that certain Sponsor Support Agreement, dated March&#160;17, 2022, by and among the Initial Shareholders and with Scilex, Inc. (f/k/a Scilex Holding Company). </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Stockholder Agreement</span>&#8221; means the Stockholder Agreement, dated as of September&#160;12, 2022, between Vickers and Sorrento. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">viii </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Trust Account</span>&#8221; means the Trust Account of Vickers that held the proceeds from Vickers&#8217;s IPO and the private placement of the Private Placement Warrants. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Units</span>&#8221; means the units of Vickers, each of which consisted of one Vickers Ordinary Share and <span style="white-space:nowrap">one-half</span> of one redeemable warrant upon the consummation of an initial business combination, which units, if not separated into its component securities as of immediately prior to the Effective Time were, without any action on the part of the holder, separated automatically into its component securities, comprised of one share of Common Stock and <span style="white-space:nowrap">one-half</span> of one warrant to purchase one share of Common Stock. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Vickers</span>&#8221; means Vickers Vantage Corp. I, our predecessor company. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Vickers Debt Agreement</span>&#8221; means that certain Debt Contribution Agreement, dated as of October&#160;17, 2022, by and among Vickers and the Sponsors. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Vickers Ordinary Shares</span>&#8221; means (i)&#160;the ordinary shares, par value $0.0001 per share, of Vickers prior to the Domestication and (ii)&#160;the Common Stock following the Domestication. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;<span style="font-style:italic">Warrant Transfer Agreement</span>&#8221; means that certain Warrant Transfer Agreement, dated as of October&#160;17, 2022, by and among Sorrento, the Sponsors, Vickers and Maxim. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">ix </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom428534_3">PROSPECTUS SUMMARY </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">This summary highlights selected information that is presented in greater detail elsewhere in this prospectus. Because it is only a summary, it does not contain all of the information you should consider before investing in our securities and it is qualified in its entirety by, and should be read in conjunction with, the more detailed information included elsewhere in this prospectus. Before you decide whether to purchase our securities, you should read this entire prospectus carefully, including the section of this prospectus titled &#8220;Risk Factors&#8221;. You should also carefully read the information in this prospectus, including our financial statements, and the exhibits to the registration statement of which this prospectus is a part. </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_4">The Company </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an innovative revenue-generating company focused on acquiring, developing and commercializing <span style="white-space:nowrap">non-opioid</span> pain management products for the treatment of acute and chronic pain. We believe that our innovative <span style="white-space:nowrap">non-opioid</span> product portfolio has the potential to provide effective pain management therapies that can have a transformative impact on patients&#8217; lives. We target indications with high unmet needs and large market opportunities with <span style="white-space:nowrap">non-opioid</span> therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. We launched our first commercial product in October 2018 and are developing our late-stage pipeline, which includes a pivotal Phase 3 candidate, a Phase 2 candidate and a Phase 1 candidate that is expected to enter into Phase 2 studies in the first half of 2023. Our commercial product, ZTlido (lidocaine topical system) 1.8% (&#8220;ZTlido&#8221;) is a prescription lidocaine topical product approved by the U.S. Food and Drug Administration, for the relief of neuropathic pain associated with postherpetic neuralgia (&#8220;PHN&#8221;) which is a form of post-shingles nerve pain. ZTlido possesses novel delivery and adhesion technology designed to address many of the limitations of current prescription lidocaine patches by providing significantly improved adhesion and continuous pain relief throughout the <span style="white-space:nowrap">12-hour</span> administration period. Scilex licenses the rights to ZTlido from and relies exclusively on Oishi Koseido Co., Ltd. (&#8220;Oishi&#8221;) and Itochu Chemical Frontier Corporation (&#8220;Itochu,&#8221; and together with Oishi, the &#8220;Developers&#8221;) pursuant to the Product Development Agreement and Commercial Supply Agreement (both as defined below). The Developers have the right to terminate the Product Development Agreement and the Commercial Supply Agreement under certain circumstances as more fully described in the sections titled &#8220;<span style="font-style:italic">Business &#8212; Material Agreements &#8212; Itochu and Oishi Product Development Agreement&#8221; and &#8220;Business &#8212; Material Agreements &#8212; Itochu and Oishi Commercial Supply Agreement,</span>&#8221; including, among other things, if our total net profits for ZTlido and <span style="white-space:nowrap">SP-103</span> are equal to or less than five percent of its net sales of ZTlido and <span style="white-space:nowrap">SP-103</span> for a period of four or more consecutive quarters. As of the date of this prospectus, our net profits for ZTlido and <span style="white-space:nowrap">SP-103</span> have not exceeded five percent of net sales. Accordingly, Oishi and Itochu have the right to terminate the Product Development Agreement and Commercial Supply Agreement. As of the date of this prospectus, neither Oishi nor Itochu has exercised its right of termination. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our three product candidates are <span style="white-space:nowrap">(i)&#160;SP-102</span> (10 mg, dexamethasone sodium phosphate viscous gel) (&#8220;SEMDEXA&#8221;), a Phase 3, novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, <span style="white-space:nowrap">(ii)&#160;SP-103</span> (lidocaine topical system) 5.4%, <span style="white-space:nowrap">(&#8220;SP-103&#8221;),</span> a Phase 2, next-generation, triple-strength formulation of ZTlido, for the treatment of low back pain (&#8220;LBP&#8221;), and <span style="white-space:nowrap">(iii)&#160;SP-104</span> (4.5 mg, <span style="white-space:nowrap">low-dose</span> naltrexone hydrochloride delayed-release capsules) <span style="white-space:nowrap">(&#8220;SP-104&#8221;),</span> a novel <span style="white-space:nowrap">low-dose</span> delayed-release naltrexone hydrochloride formulation for treatment of fibromyalgia, for which Phase 1 trials were completed in the second quarter of 2022 and a Phase 2 clinical trial is expected to commence in the first half of 2023. If these product candidates are approved by the FDA, we believe each of them could become the treatment option for their respective indications in the United States. In addition, on June&#160;14, 2022, we entered into a License and Commercialization Agreement (the &#8220;Romeg Agreement&#8221;) with RxOmeg Therapeutics, LLC (a/k/a Romeg Therapeutics, Inc.) (&#8220;Romeg&#8221;). Pursuant to the Romeg Agreement, among other things, Romeg granted us (1)&#160;the right to manufacture, promote, market, distribute and sell pharmaceutical products comprising </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">1 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
liquid formulations of colchicine for the prophylactic treatment of gout (a painful arthritic disorder) in adult humans in the United States and (2)&#160;an exclusive, transferable license to use the trademark &#8220;GLOPERBA&#8221;. GLOPERBA is an <span style="white-space:nowrap">FDA-approved,</span> oral medication for the treatment of gout in adults and we are planning to commercialize GLOPERBA in 2023 and believe we are well-positioned to market and distribute the product. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Our Marketed Product and Innovative <span style="white-space:nowrap">Non-Opioid</span> Pipeline </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are focused on developing and commercializing innovative <span style="white-space:nowrap">non-opioid</span> therapies that will provide safe, substantial and localized pain relief for large market opportunities. The following chart illustrates our current commercial product and novel product candidates, for which we have worldwide commercialization rights, except with respect to Japan for ZTlido and <span style="white-space:nowrap">SP-103.</span> </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt">


<img src="g428534g56j49.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our principal executive offices are located at 960 San Antonio Road, Palo Alto, California 94303, and our telephone number is (650) <span style="white-space:nowrap">516-4310.</span> For additional information about us, please see the sections of this prospectus titled &#8220;<span style="font-style:italic">Business</span>&#8221; and &#8220;<span style="font-style:italic">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span>.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See the section titled &#8220;<span style="font-style:italic">Risk Factors</span>&#8221; in this prospectus for a discussion of some of the risks related to the execution of our business strategy. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_5">Business Combination </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&#160;10, 2022 (the &#8220;Closing Date&#8221;), Vickers consummated the previously announced Business Combination pursuant to the terms of the Merger Agreement, by and among Vickers, Merger Sub and Legacy Scilex. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Merger Agreement, (i)&#160;prior to the Closing, Vickers changed its jurisdiction of incorporation by deregistrating as a Cayman Islands exempted company and continuing and domesticating as a corporation incorporated under the laws of the State of Delaware (the &#8220;Domestication&#8221;) and (ii)&#160;at the Closing, and following the Domestication, Merger Sub merged with and into Legacy Scilex (the &#8220;Merger&#8221;), with Legacy Scilex as the surviving company in the Merger, and, after giving effect to such Merger, Legacy Scilex became a wholly owned subsidiary of Vickers. The Merger was approved by Vickers&#8217;s shareholders at a meeting held on November&#160;9, 2022. In connection with the Business Combination, Vickers changed its name to &#8220;Scilex Holding Company.&#8221; </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">2 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with the terms and subject to the conditions of the Merger Agreement, at the Effective Time, (i)&#160;each outstanding share of Legacy Scilex Common Stock outstanding immediately prior to the Effective Time was automatically cancelled in exchange for the right to receive 0.673498 shares of our Common Stock, (ii)&#160;each share of Legacy Scilex Preferred Stock outstanding immediately prior to the Effective Time was cancelled in exchange for the right to receive (a)&#160;one share of Series A Preferred Stock and <span style="white-space:nowrap">(b)&#160;one-tenth</span> of one share of our Common Stock, and (iii)&#160;each option to purchase shares of Legacy Scilex Common Stock outstanding as of immediately prior to the Effective Time was converted into the right to receive a comparable option to purchase shares of our Common Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Common Stock and Public Warrants are currently listed on the Nasdaq Capital Market under the symbols &#8220;SCLX&#8221; and &#8220;SCLXW,&#8221; respectively. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The rights of holders of our Common Stock and Warrants are governed by the Certificate of Incorporation, the Bylaws and the DGCL, and, in the case of the Warrants, the Warrant Agreement, dated January&#160;6, 2021, between Vickers and Continental (the &#8220;Warrant Agreement&#8221;). See sections of this prospectus titled &#8220;<span style="font-style:italic">Description of Our Securities</span>&#8221; and &#8220;<span style="font-style:italic">Certain Relationships and Related Party Transactions</span>.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_5a">Recent Developments </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&#160;3, 2023, we filed a Current Report on Form <span style="white-space:nowrap">8-K</span> providing certain preliminary unaudited financial results for the one and twelve months ended December&#160;31, 2022, and as of December&#160;31, 2022, based on then-currently available information. Our independent auditor has not reviewed or audited these preliminary estimated financial results. Our actual results may differ materially from these preliminary financial results, and may be outside the estimated ranges. This preliminary financial data has been prepared by and is the responsibility of the Company. We have not fully completed our review of these preliminary financial results for the one and twelve months ended December&#160;31, 2022, and as of December&#160;31, 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In such Current Report on Form <span style="white-space:nowrap">8-K,</span> we estimated that: ZTlido gross sales for December 2022 were in the range of $10.0&#160;million to $12.0&#160;million; the gross sales for ZTlido in 2022 were in the range of $93.0&#160;million to $98.0&#160;million, compared to $63.9&#160;million in 2021, representing growth in the range of 45% to 53%; net sales for 2022 were in the range of $37.0&#160;million to $42.0&#160;million, compared to net sales of $31.3&#160;million in 2021, representing growth in the range of 18% to 34%; and, as of December&#160;31, 2022, our cash and cash equivalents were in the range of $1.8&#160;million to $2.5&#160;million, and our accounts receivables were in the range of $18.0&#160;million to $22.0&#160;million. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_6">Committed Equity Financings </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">B. Riley Purchase Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January 8, 2023, we entered into the B. Riley Purchase Agreement with the Selling Securityholder. Pursuant to the B. Riley Purchase Agreement, we have the right to sell to the Selling Securityholder up to $500,000,000 of shares of our Common Stock, subject to certain limitations and conditions set forth in the B. Riley Purchase Agreement, from time to time during the term of the B. Riley Purchase Agreement. Sales of Common Stock to the Selling Securityholder under the B. Riley Purchase Agreement, and the timing of any such sales, are at our option, and we are under no obligation to sell any securities to the Selling Securityholder under the B. Riley Purchase Agreement. In accordance with our obligations under the B. Riley Purchase Agreement, we have filed the registration statement of which this prospectus forms a part with the SEC to register under the Securities Act the resale by the Selling Securityholder of up to 28,128,422 shares of Common Stock, consisting of an aggregate amount of 250,000 Commitment Shares and up to 27,878,422 shares of Common Stock that we may elect, in our sole discretion, to issue and sell to the Selling Securityholder, from time to time under the B. Riley Purchase Agreement. </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">3 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the satisfaction of the conditions to the Selling Securityholder&#8217;s purchase obligation set forth in the B. Riley Purchase Agreement, including that the registration statement of which this prospectus forms a part be declared effective by the SEC and the final form of this prospectus is filed with the SEC, we will have the right, but not the obligation, from time to time at our discretion until the first day of the month next following the <span style="white-space:nowrap">36-month</span> anniversary of the date on which this registration statement has been declared effective by the SEC, to direct the Selling Securityholder to purchase a specified amount of shares of Common Stock (each such sale, an &#8220;Advance&#8221;) by delivering an irrevocable written notice to the Selling Securityholder (each, an &#8220;Advance Notice&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares of Common Stock, if any, that we elect to sell to the Selling Securityholder pursuant to an Advance will be purchased at a price equal to 98% of the VWAP (as defined below) during the period (such period, the &#8220;Pricing Period&#8221;) beginning at 9:30:01 a.m., New York City time, on the date of purchase of shares of Common Stock issued and sold to the Selling Stockholder pursuant to an Advance Notice (such shares, the &#8220;Advance Shares&#8221;) or such later time publicly announced as the official open of the primary (or &#8220;regular&#8221;) trading session on the Nasdaq Capital Market on such purchase date (the &#8220;Purchase Commencement Time&#8221;) and ending at the earliest of (i) 3:59 p.m., New York City Time, on the purchase date or such earlier time publicly announced as the official close of the primary (or &#8220;regular&#8221;) trading session on the Nasdaq Capital Market on such purchase date, (ii)&#160;immediately at such time following the Purchase Commencement Time for such purchase that the total number (or volume) of shares of Common Stock traded on the Nasdaq Capital Market during such period has exceeded the Advance Share Volume Maximum (as defined below) for such purchase and (iii)&#160;if we so elect in the applicable Advance Notice for such Advance (such election, a &#8220;Limit Order Discontinue Election&#8221;), such time the sale price of the shares of Common Stock traded on the Nasdaq Capital Market during such Pricing Period is less than the applicable minimum price threshold determined in accordance with the B. Riley Purchase Agreement. &#8220;VWAP&#8221; means, for the Common Stock for a specified period, the dollar volume-weighted average price of the Common Stock on the Nasdaq Capital Market for such period as reported by Bloomberg through its &#8220;AOR&#8221; function, subject to certain exceptions, qualifications and limitations. &#8220;Advance Share Volume Maximum&#8221; means, with respect to an Advance, if such Advance is designated in the Advance Notice as a (i)&#160;purchase-Type A, a number of shares of Common Stock that is equal to the quotient obtained by dividing (a)&#160;the Advance Share amount to be purchased by the Selling Securityholder, by (b) 0.10, or (ii)&#160;purchase-Type B, a number of shares of Common Stock that is equal to the quotient obtained by dividing (a)&#160;the Advance Share amount to be purchased by the Selling Securityholder, by (b) 0.25 (in each case, subject to certain adjustments). We may also specify a certain minimum acceptable price per share in each Advance. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While there is no mandatory minimum amount for any Advance, subject to the terms and conditions of the B. Riley Purchase Agreement, an Advance may be for a number of shares of Common Stock not to exceed (i)&#160;with respect to an Advance, purchase-Type A, such number of shares of Common Stock that is equal to the lesser of: (a) 1,000,000, and (b)&#160;the product of (1) 0.10, multiplied by (2)&#160;the total number (or volume) of shares of Common Stock traded on the Nasdaq Capital Market during the Pricing Period for such purchase-Type A, and (ii)&#160;with respect to an Advance, purchase-Type B, such number of shares of Common Stock that is equal to the lesser of: (a) 1,000,000 and (b)&#160;the product of (1) 0.25, multiplied by (2)&#160;the total number (or volume) of shares of Common Stock traded on the Nasdaq Capital Market during the Pricing Period for such purchase-Type B. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The B. Riley Purchase Agreement also provides that we have the right, but not the obligation, to sell to the Selling Securityholder, from time to time subject to certain limitations, at our sole and absolute discretion an additional number of shares of Common Stock (each such additional sale, an &#8220;Additional Advance&#8221;) at a purchase price per share equal to 98% of the VWAP during the Additional Pricing Period (as defined in the B. Riley Purchase Agreement) by delivering an irrevocable written notice to the Selling Securityholder (each, an &#8220;Additional Advance Notice&#8221;). The purpose of the Additional Advance is to allow us to execute more than one advance request on a purchase date with the Selling Stockholder as each prior advance has been completed under the terms of the B. Riley Purchase Agreement. Each Additional Advance is generally subject to terms and </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">4 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
conditions consistent with those of an Advance, except for, among other things, the time period of the pricing period for such Additional Advance. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is no upper limit on the price per share that the Selling Securityholder could be obligated to pay for the Common Stock we may elect to sell to the Selling Securityholder in any Advance or Additional Advance. We will control the timing and amount of any sales of Common Stock to the Selling Securityholder. Actual sales of shares of our Common Stock to the Selling Securityholder under the B. Riley Purchase Agreement will depend on a variety of factors to be determined by us from time to time, which may include, among other things, market conditions, the trading price of our Common Stock, and determinations by us as to the appropriate sources of funding for our company and its operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the B. Riley Purchase Agreement, we may not sell any shares of Common Stock thereunder and the Selling Securityholder shall not have the obligation to purchase shares of Common Stock thereunder to the extent (but only to the extent) that after giving effect to such purchase and sale, the aggregate number of shares of Common Stock issued thereunder would exceed 28,128,422 shares of Common Stock, which number of shares is equal to 19.9% of the aggregate amount of Common Stock issued and outstanding as of the date of the B. Riley Purchase Agreement (the &#8220;Exchange Cap&#8221;), unless (i)&#160;we obtain stockholder approval to issue shares of Common Stock in excess of the Exchange Cap in accordance with the applicable Nasdaq Listing Rules or (ii)&#160;the average price of all applicable sales of shares of Common Stock under the B. Riley Purchase Agreement equals or exceeds $4.87, which represents the &#8220;Minimum Price&#8221; (as such term is defined in Rule 5635 of the Nasdaq Listing Rules). Moreover, we may not issue or sell any shares of Common Stock to the Selling Securityholder under the B. Riley Purchase Agreement which, when aggregated with all other shares of Common Stock then beneficially owned by the Selling Securityholder and its affiliates (as calculated pursuant to Section&#160;13(d) of the U.S. Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and Rule <span style="white-space:nowrap">13d-3</span> promulgated thereunder), would result in the Selling Securityholder beneficially owning more than 4.99% of the outstanding voting power or number of shares of Common Stock (the &#8220;Beneficial Ownership Limitation&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The net proceeds under the B. Riley Purchase Agreement to us will depend on the frequency and prices at which we sell shares of our Common Stock to the Selling Securityholder. We expect that any proceeds received by us from such sales to the Selling Securityholder will be used for working capital and general corporate purposes, which may include capital expenditures, research and development expenditures, regulatory affairs expenditures, clinical trial expenditures, acquisitions of new technologies and investments, business combinations and the repayment, refinancing, redemption or repurchase of indebtedness or capital stock. The Selling Securityholder has agreed that it and its affiliates will not engage in any short sales of the Common Stock nor enter into any transaction that establishes a net short position in the Common Stock during the term of the B. Riley Purchase Agreement. The B. Riley Purchase Agreement will automatically terminate on the earliest to occur of (i)&#160;the first day of the month next following the <span style="white-space:nowrap">36-month</span> anniversary of the date on which this registration statement has been declared effective by the SEC or (ii)&#160;the date on which the Selling Securityholder shall have purchased from us under the B. Riley Purchase Agreement shares of our Common Stock for an aggregate gross purchase price of $500,000,000. We have the right to terminate the B. Riley Purchase Agreement at no cost or penalty upon five trading days&#8217; prior written notice to the Selling Securityholder; provided that there are no outstanding Advance Notices or Additional Advance Notices and all outstanding amounts owed to the Selling Securityholder have been paid. We and the Selling Securityholder may also agree to terminate the B. Riley Purchase Agreement by mutual written consent. Neither we nor the Selling Securityholder may assign or transfer our respective rights and obligations under the B. Riley Purchase Agreement, and no provision of the B. Riley Purchase Agreement may be modified or waived by us or the Selling Securityholder other than by an instrument in writing signed by both parties. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As consideration for the Selling Securityholder&#8217;s commitment to purchase shares of Common Stock at our direction upon the terms and subject to the conditions set forth in the B. Riley Purchase Agreement, we issued </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">5 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
250,000 Commitment Shares to the Selling Securityholder. The B. Riley Purchase Agreement contains customary representations, warranties, conditions, and indemnification obligations of the parties. The representations, warranties, and covenants contained in such agreements were made only for purposes of such agreements and as of specific dates, were solely for the benefit of the parties to such agreements, and may be subject to limitations agreed upon by the contracting parties. We do not know what the purchase price for our Common Stock will be and therefore cannot be certain as to the number of shares we might issue to the Selling Securityholder under the B. Riley Purchase Agreement. Although the B. Riley Purchase Agreement provides that we may sell up to $500,000,000 of our Common Stock to the Selling Securityholder, only 28,128,422 shares of our Common Stock are being registered for resale by the Selling Securityholder under the registration statement of which this prospectus forms a part, which represents (i)&#160;the 250,000 Commitment Shares that we issued to the Selling Securityholder under the B. Riley Purchase Agreement in consideration of its commitment to purchase shares of Common Stock at our election under the B. Riley Purchase Agreement and (ii)&#160;up to 27,878,422 shares of Common Stock that may be issued to the Selling Securityholder from time to time, if and when we elect to sell shares to the Selling Securityholder under the B. Riley Purchase Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If and when we elect to issue and sell shares to the Selling Securityholder under the B. Riley Purchase Agreement, we may need to register for resale under the Securities Act additional shares of our Common Stock in order to receive aggregate gross proceeds equal to the $500,000,000 available to us under the B. Riley Purchase Agreement, depending on market prices for our Common Stock. If all of the 28,128,422 shares offered by the Selling Securityholder for resale under the registration statement of which this prospectus forms a part were issued and outstanding as of the date hereof (without taking into account the 4.99% Beneficial Ownership Limitation or the 19.9% Exchange Cap limitation), such shares would represent approximately 16.6% of the total number of shares of our Common Stock outstanding and approximately 82.7% of the total number of outstanding shares held by <span style="white-space:nowrap">non-affiliates,</span> in each case as of January&#160;11, 2023 (and assuming we have not otherwise issued any shares to YA II pursuant to the Yorkville Purchase Agreement which is more fully described elsewhere in this prospectus). If we elect to issue and sell more than the 28,128,422 shares offered under this prospectus to the Selling Securityholder, which we have the right, but not the obligation, to do, we must first register for resale under the Securities Act any such additional shares, which could cause substantial additional dilution to our stockholders. The number of shares ultimately offered for resale by the Selling Securityholder is dependent upon the number of shares we may elect to sell to the Selling Securityholder under the B. Riley Purchase Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are substantial risks to our stockholders as a result of the sale and issuance of Common Stock to the Selling Securityholder under the B. Riley Purchase Agreement. These risks include the potential for substantial dilution and significant declines in our stock price. See the section titled &#8220;<span style="font-style:italic">Risk Factors</span>&#8221; for details. Issuances of our Common Stock in this offering will not affect the rights or privileges of our existing stockholders, except that the economic and voting interests of each of our existing stockholders will be diluted as a result of any such issuance. Although the number of shares of Common Stock that our existing stockholders own will not decrease as a result of sales, if any, under the B. Riley Purchase Agreement, the shares owned by our existing stockholders will represent a smaller percentage of our total outstanding shares after any such issuance to the Selling Securityholder. For more detailed information regarding the B. Riley Purchase Agreement, see the section titled &#8220;<span style="font-style:italic">Committed Equity Financing</span>.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Yorkville Purchase Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&#160;17, 2022, we entered into a standby equity purchase agreement (the &#8220;Yorkville Purchase Agreement&#8221;) with YA II PN, Ltd., a Cayman Islands exempt limited partnership (&#8220;YA II&#8221;), pursuant to which we will have the right, but not the obligation, to sell to YA II up to $500,000,000 of our Common Stock. YA II is a fund managed by Yorkville Advisors Global, LP, headquartered in Mountainside, New Jersey. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the satisfaction of the conditions to YA II&#8217;s purchase obligations set forth in the Yorkville Purchase Agreement, we will have the right, but not the obligation, from time to time at our discretion until the first day of </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">6 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the month following <span style="white-space:nowrap">the&#160;36-month&#160;anniversary</span> of the date on which the initial registration statement filed with respect to the Yorkville Purchase Agreement has been declared effective by the SEC, to direct YA II to purchase a specified amount of shares of Common Stock (each such sale, a &#8220;Yorkville Advance&#8221;) by delivering written notice to YA II (each, a &#8220;Yorkville Advance Notice&#8221;). The registration statement on Form <span style="white-space:nowrap">S-1</span> (File <span style="white-space:nowrap">No.&#160;333-268607)</span> related to the Yorkville Purchase Agreement was filed with the SEC on November&#160;30, 2022, was declared effective by the SEC on December&#160;9, 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While there is no mandatory minimum amount for any Yorkville Advance, a Yorkville Advance may be for a number of shares of Common Stock not to exceed 200% of the average of the daily trading volume of the Common Stock on the Nasdaq Capital Market during regular trading hours as reported by Bloomberg L.P. during the five trading days immediately preceding the date of the Yorkville Advance Notice. The shares of Common Stock, if any, that we elect to sell to YA II pursuant to a Yorkville Advance will be purchased at a price equal to 98% of the lowest daily VWAP (as defined below) during the two consecutive trading days commencing on the date of delivery of a Yorkville Advance Notice. &#8220;VWAP&#8221; means, for any trading day, the daily volume weighted average price of the Common Stock for such trading day on the Nasdaq Capital Market as reported by Bloomberg L.P. during regular trading hours. See the section of this prospectus titled &#8220;<span style="font-style:italic">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations &#8212; Recent Developments</span>&#8221; for addition information regarding the Yorkville Purchase Agreement. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_7">Emerging Growth Company </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an &#8220;emerging growth company,&#8221; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;). As an emerging growth company, we are eligible to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including, but not limited to, not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act of 2002, as amended (the &#8220;Sarbanes-Oxley Act&#8221;), reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, Section&#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to <span style="white-space:nowrap">non-emerging</span> growth companies but any such election to opt out is irrevocable. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. As a result, changes in rules of U.S. generally accepted accounting principles or their interpretation, the adoption of new guidance or the application of existing guidance to changes in our business could significantly affect our business, financial condition and results of operations. In addition, we are in the process of evaluating the benefits of relying on the other exemptions and reduced reporting requirements provided by the JOBS Act, as more fully described in the section of this prospectus titled &#8220;<span style="font-style:italic">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations &#8212; Emerging Growth Company</span>.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will remain an emerging growth company until the earlier of: (i)&#160;the last day of the fiscal year (a)&#160;following the fifth anniversary of the closing of the IPO, (b)&#160;in which we have total annual gross revenue of at least $1.235&#160;billion, or (c)&#160;in which we are deemed to be a large accelerated filer, which means the market value of our common equity that is held by <span style="white-space:nowrap">non-affiliates</span> equals or exceeds $700&#160;million as of the last business day of our most recently completed second fiscal quarter; and (ii)&#160;the date on which we have issued more than </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">7 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
$1.0&#160;billion in <span style="white-space:nowrap">non-convertible</span> debt securities during the prior three-year period. References herein to &#8220;emerging growth company&#8221; have the meaning associated with it in the JOBS Act. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_8">Summary Risk Factors </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Risks Related to our Limited Operating History, Financial Condition and Capital Requirements </span></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We are currently a single commercial product company that is heavily dependent on the commercial success of ZTlido and we may be unable to generate sufficient revenue to support our operations. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We have a limited operating history and have incurred significant losses since our inception. We anticipate that we will incur continued losses for the foreseeable future. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We will require substantial additional funding, which may not be available to us on acceptable terms, or at all. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our recurring losses from operations, negative cash flows and substantial cumulative net losses raise substantial doubt about our ability to continue as a going concern. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Risks Related to our Commercial Operations and Product Development </span></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We obtain our commercial supply of ZTlido, clinical supply of our product candidates and certain of the raw materials used in our product candidates from sole or single source suppliers and manufacturers. In the event of a loss of one of these suppliers or manufacturers, or a failure by any such supplier or manufacturer to comply with FDA regulations, we may not be able to find an alternative source on commercially reasonable terms, or at all. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We rely on third parties to conduct our clinical trials and intend to rely on third parties to conduct all of our future clinical trials. If these third parties do not successfully carry out their contractual duties, fail to comply with applicable regulatory requirements or meet expected deadlines, we may be unable to obtain regulatory approval for our product candidates. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Interim <span style="white-space:nowrap">&#8220;top-line&#8221;</span> and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">ZTlido and GLOPERBA may have undesirable properties that could result in significant negative consequences, and our product candidates may cause undesirable side effects that could delay or prevent their regulatory approval. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Risks Related to our Business and Operations </span></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">If we are unable to retain our key executives, it may delay our development efforts and harm our business, financial condition and results of operations. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Any disruption in our research and development facilities could adversely affect our business, financial condition and results of operations. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Risks Related to our Intellectual Property </span></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We are substantially dependent on the intellectual property we <span style="white-space:nowrap">in-license</span> from Oishi and Itochu, and if we lose the right to license such intellectual property or if the Product Development Agreement is terminated for any reason, our ability to commercialize ZTlido and develop and commercialize <span style="white-space:nowrap">SP-103</span> would be harmed. </p></td></tr></table>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">8 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We recently entered into the Romeg Agreement for the <span style="white-space:nowrap">in-licensing</span> of certain intellectual property rights from Romeg with respect to the commercialization of GLOPERBA, and if we lose the right to license such intellectual property or if the Romeg Agreement is terminated for any reason, our ability to commercialize GLOPERBA would be harmed. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">If we are unable to maintain patent protection for ZTlido, GLOPERBA and our product candidates, or if the scope of the patent protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Risks Related to Government Regulations </span></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The regulatory approval processes of the FDA are lengthy, time-consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business, financial condition and results of operations will be substantially harmed. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Any approved product candidate will be subject to ongoing and continued regulatory review, which may result in significant expense and limit our ability to commercialize such products. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Risks Related to our Relationship with Sorrento </span></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Certain of our directors and officers may have actual or potential conflicts of interest because of their positions with Sorrento. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We are controlled by Sorrento, whose interests may differ from those of our public shareholders. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Risks Related to this Offering and Ownership of our Common Stock </span></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">It is not possible to predict the actual number of shares we will sell under the B. Riley Purchase Agreement to the Selling Securityholder, or the actual gross proceeds resulting from those sales. Further, we may not have access to the full amount available under the B. Riley Purchase Agreement with the Selling Securityholder. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The sale and issuance of our Common Stock to the Selling Securityholder will cause dilution to our existing stockholders, and the sale of the shares of Common Stock acquired by the Selling Securityholder, or the perception that such sales may occur, could cause the price of our Common Stock to fall. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Investors who buy shares of Common Stock at different times will likely pay different prices. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our management team will have broad discretion over the use of the net proceeds from our sale of shares of Common Stock to the Selling Securityholder, if any, and you may not agree with how we use the proceeds and the proceeds may not be invested successfully. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">If our operations and performance do not meet the expectations of investors or securities analysts, the market price of our securities may decline. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We are an emerging growth company, and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies will make our Common Stock less attractive to investors. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We are a controlled company within the meaning of the Nasdaq Listing Rules and, as a result, will qualify for, and may rely on, exemptions from certain corporate governance requirements. Our stockholders may not have the same protection afforded to stockholders of companies that are subject to such governance requirements. </p></td></tr></table>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">9 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_9">Corporate Information </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were incorporated under the name &#8220;Vickers Vantage Corp. I&#8221; on February&#160;21, 2020 as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. On November&#160;9, 2022, we changed our jurisdiction of incorporation by deregistering as a Cayman Islands exempted company and continuing and domesticating as a corporation incorporated under the laws of the State of Delaware. On November&#160;9, 2022, we changed our name to &#8220;Scilex Holding Company&#8221;. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our principal executive offices are located at 960 San Antonio Road, Palo Alto, California 94303, and our telephone number is (650) <span style="white-space:nowrap">516-4310.</span> Our website address is <span style="font-style:italic">www.scilexholding.com</span>. Any information contained on, or that can be accessed through, our website is not incorporated by reference into, nor is it in any way part of this prospectus and should not be relied upon in connection with making any decision with respect to an investment in our securities. We are required to file annual, quarterly and current reports, proxy statements and other information with the SEC. You may obtain any of the documents filed by us with the SEC at no cost from the SEC&#8217;s website at <span style="font-style:italic">http://www.sec.gov.</span> </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">10 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom428534_10">THE OFFERING </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Issuer </p></td>
<td>Scilex Holding Company </td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Shares of Common Stock Offered by the Selling Securityholder </p></td>
<td>28,128,422 shares of Common Stock, consisting of (i) 250,000 Commitment Shares and (ii)&#160;up to 27,878,422 shares of Common Stock we may elect, in our discretion, to issue and sell to the Selling Securityholder under the B. Riley Purchase Agreement from time to time. </td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Terms of the Offering </p></td>
<td>The Selling Securityholder will determine when and how it will dispose of any shares of Common Stock registered under this prospectus for resale. </td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; padding-bottom:3pt; margin-top:-2pt; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common Stock Outstanding Before this Offering<sup style="font-size:75%; vertical-align:top">(1)</sup> </p></td>
<td>141,598,856 shares of Common Stock. </td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common Stock Outstanding After this Offering </p></td>
<td>169,727,278 shares of Common Stock. </td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of Proceeds </p></td>
<td>We will not receive any proceeds from the resale of shares of Common Stock included in this prospectus by the Selling Securityholder. However, we may receive up to $500,000,000 in aggregate gross proceeds under the B. Riley Purchase Agreement from sales of Common Stock that we may elect to make to the Selling Securityholder pursuant to the B. Riley Purchase Agreement, if any, from time to time in our discretion. We expect to use the net proceeds that we receive under the B. Riley Purchase Agreement for working capital and general corporate purposes, which may include capital expenditures, research and development expenditures, regulatory affairs expenditures, clinical trial expenditures, acquisitions of new technologies and investments, business combinations and the repayment, refinancing, redemption or repurchase of indebtedness or capital stock. However, we have not designated any specific uses and have no current agreement with respect to any acquisition or strategic transaction. See &#8220;<span style="font-style:italic">Use of Proceeds</span>.&#8221; </td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Market for our Common Stock </p></td>
<td>Our Common Stock is listed on the Nasdaq Capital Market under the symbol &#8220;SCLX&#8221;. </td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk factors </p></td>
<td>See &#8220;<span style="font-style:italic">Risk Factors</span>&#8221; beginning on page&#160;13 and other information included in this prospectus for a discussion of factors you should carefully consider before deciding to invest in the securities being offered by this prospectus. </td></tr></table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The number of shares of Common Stock outstanding is based on an aggregate of 141,598,856 shares outstanding as of January&#160;11, 2023, assumes that we have not otherwise issued any shares of Common Stock to YA&#160;II pursuant to the Yorkville Purchase Agreement (other than the 250,000 shares of Common </p></td></tr></table>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">11 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td align="left" style="vertical-align:top">
Stock issued to YA II in connection with the signing of such agreement) which is more fully described elsewhere in this prospectus, and excludes: </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">744,201 shares of Common Stock issuable upon the exercise of stock options outstanding under the Scilex Pharma 2017 Plan; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">16,195,178 shares of Common Stock issuable upon the exercise of stock options outstanding under the 2019 Stock Option Plan; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">11,003,988 shares of Common Stock issuable upon the exercise of the Warrants, with an exercise price of $11.50 per share; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">up to 20,276,666 shares of Common Stock available for future issuance under the Equity Incentive Plan (which number includes the annual increase on January&#160;1, 2023 (but does not include a possible increase in any subsequent year) pursuant to the provisions of such plan which provides for a possible annual increase on January&#160;1 of each year beginning on January&#160;1, 2023 and ending on (and including) January&#160;1, 2032, in an amount equal to up to 4% of the total number of shares of our Common Stock outstanding on December&#160;31 of the immediately preceding year); and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">up to 2,875,759 shares of Common Stock available for future issuance under the ESPP (which number includes the annual increase on January&#160;1, 2023 (but does not include a possible increase in any subsequent year) pursuant to the provisions of such plan which provides for a possible annual increase on January&#160;1 of each year beginning on January&#160;1, 2023 and ending on (and including) January&#160;1, 2032, in an amount equal to up to 1% of the total number of shares of our Common Stock outstanding on December&#160;31 of the immediately preceding year). </p></td></tr></table>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">12 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom428534_11">RISK FACTORS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Investing in our securities involves a high degree of risk. Before making an investment decision, you should consider carefully the following risk factors, as well as the other information set forth in this prospectus, including matters addressed in the section titled &#8220;Cautionary Note Regarding Forward-Looking Statements&#8221;. If any of these risks actually occur, it may materially harm our business, financial condition, liquidity and results of operations. As a result, the market price of our securities could decline, and you could lose all or part of your investment. Additionally, the risks and uncertainties described in this prospectus, any prospectus supplement, any post-effective amendment or in any document incorporated by reference herein or therein are not the only risks and uncertainties that we face. We may face additional risks and uncertainties that are not presently known to us, or that we currently deem immaterial. The following discussions should be read in conjunction with our financial statements and the notes to the financial statements included therein. </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_12">Risks Related to our Limited Operating History, Financial Condition and Capital Requirements </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We are currently a single commercial product company that is heavily dependent on the commercial success of ZTlido and we may be unable to generate sufficient revenue to support our operations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ZTlido is our only product approved for commercial sale and we are entirely dependent upon its sales to generate revenue. In February 2018, we obtained regulatory approval for ZTlido for the relief of neuropathic pain associated with PHN, which is a form of post-shingles nerve pain, and we began commercializing ZTlido in the United States in October 2018. As a result, it is difficult to evaluate our current business and predict our future prospects. We cannot assure that ZTlido will gain market acceptance among physicians, health care payors, patients and the medical community, which is critical to our commercial success. We have limited experience engaging in commercial activities and limited relationships with physicians, hospitals and payors. Market acceptance of ZTlido depends on a number of factors, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">acceptance by physicians, major operators of clinics and patients of the drug as a safe and effective treatment for the relief of neuropathic pain associated with PHN; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the availability, cost and potential advantages of alternative treatments, including less expensive generic products; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the effectiveness of our sales and marketing efforts; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the availability of coverage, adequacy of reimbursement and favorability of pricing policies by third-party payors and government authorities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the timing of market introduction of other competitive products; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the product labeling or any product inserts required by the U.S. Food and Drug Administration (the &#8220;FDA&#8221;); and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the prevalence and severity of adverse side effects. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to successfully commercialize ZTlido, we will need to expand our marketing efforts to develop new relationships and expand existing relationships. Physicians may decide not to prescribe ZTlido for a variety of reasons, including changes in available offerings, adverse publicity, perceived safety issues, inadequate coverage or reimbursement for ZTlido or the utilization of products developed by other parties, all of which are circumstances outside of our control. Demand for ZTlido may not increase as quickly as we predict, and we may be unable to increase our revenue to the level that we currently expect. Even if we succeed in increasing market acceptance of ZTlido, maintaining and creating relationships with physicians, we may be unable to reach or sustain a level of profitability. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to effectively promote ZTlido will also depend on pricing and cost-effectiveness, including our ability to produce at a competitive price. In addition, our efforts to educate the medical community and third-party payors on the benefits of ZTlido may require significant resources, may be constrained by FDA rules and policies on product promotion and may never be successful. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">13 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We have a limited operating history and have incurred significant losses since our inception. We anticipate that we will incur continued losses for the foreseeable future. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have a limited operating history. Prior to March 2019, our operations were conducted through Scilex Pharmaceuticals Inc. (&#8220;Scilex Pharma&#8221;), which was formed in September 2012 and is now our wholly owned subsidiary. In March 2019, we effected a corporate reorganization and acquired Semnur Pharmaceuticals, Inc. (&#8220;Semnur&#8221;), which was formed in June 2013. Since our inception, we have focused on organizing and staffing our company, business planning, raising capital, identifying potential <span style="white-space:nowrap">non-opioid</span> pain therapy candidates, undertaking preclinical studies and clinical trials of our product candidates and establishing research and development and manufacturing collaborations. All of our revenue to date is attributable to sales of ZTlido, and we expect that sales of ZTlido will account for all of our revenue for at least the near term. Our relatively short operating history as a company makes any assessment of our future success and viability subject to significant uncertainty. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investment in biopharmaceutical product development is highly speculative because it entails substantial upfront capital expenditures and significant risk that any potential product candidate will fail to demonstrate adequate effect or an acceptable safety profile, gain regulatory approval and become commercially viable. We will encounter risks and difficulties frequently experienced by early-stage biopharmaceutical companies in rapidly evolving fields, and we have not yet demonstrated an ability to overcome such risks and difficulties successfully. Our ability to execute on our business model and generate revenues depends on a number of factors including our ability to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">successfully complete ongoing <span style="white-space:nowrap">pre-clinical</span> studies and clinical trials and obtain regulatory approvals for our current and future product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">identify new acquisition or <span style="white-space:nowrap">in-licensing</span> opportunities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">successfully identify new product candidates and advance those product candidates into <span style="white-space:nowrap">pre-clinical</span> studies and clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">raise additional funds when needed and on terms acceptable to us; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">attract and retain experienced management and advisory teams; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">add operational, financial and management information systems and personnel, including personnel to support clinical, <span style="white-space:nowrap">pre-clinical</span> manufacturing and planned future commercialization efforts and operations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">launch commercial sales of our product candidates, whether alone or in collaboration with others; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">initiate and continue relationships with third-party suppliers and manufacturers and have commercial quantities of product candidates manufactured at acceptable cost and quality levels and in compliance with the FDA, and other regulatory requirements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">set acceptable prices for product candidates and obtain coverage and adequate reimbursement from third-party payors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">achieve market acceptance of product candidates in the medical community and with third-party payors and consumers; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">maintain, expand and protect our intellectual property portfolio. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we cannot successfully execute any one of the foregoing, our business may not succeed or become profitable. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our inception, we have incurred significant net losses, with net losses of $88.4&#160;million, $47.5&#160;million, and $178.6&#160;million for the years ended December&#160;31, 2021, 2020, and 2019, respectively. As of December&#160;31, 2021, we had an accumulated deficit of approximately $352.6&#160;million. For the foreseeable future, we expect to </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">14 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
continue to incur significant expenses related to the commercialization of ZTlido and GLOPERBA and the research and development of our product candidates, <span style="white-space:nowrap">SP-102</span> (10 mg dexamethasone sodium phosphate viscous gel) (&#8220;SEMDEXA&#8221;), <span style="white-space:nowrap">SP-103</span> (lidocaine topical system) 5.4% <span style="white-space:nowrap">(&#8220;SP-103&#8221;),</span> and <span style="white-space:nowrap">SP-104</span> (4.5mg, <span style="white-space:nowrap">low-dose</span> naltrexone hydrochloride delayed-release capsules) <span style="white-space:nowrap">(&#8220;SP-104&#8221;).</span> We anticipate that our expenses will increase substantially due to the completion of the pivotal Phase 3 trial for SEMDEXA, commencement of the Phase 2 clinical trial for <span style="white-space:nowrap">SP-103</span> and multiple Phase 1 trials for <span style="white-space:nowrap">SP-104.</span> Consequently, we expect to incur substantial losses for the foreseeable future and may never become profitable. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to risks incidental to the development of new biopharmaceutical products, and we may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may be required to make milestone payments to the former stockholders of Semnur in connection with our development and commercialization of SEMDEXA, which could adversely affect the overall profitability of SEMDEXA, if approved. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of the Agreement and Plan of Merger we entered into with Semnur, Sigma Merger Sub, Inc., our prior wholly owned subsidiary, Fortis Advisors LLC, solely as representative of the holders of Semnur equity, or the Semnur Equityholders, and Sorrento, for limited purposes, we are obligated to pay the Semnur Equityholders up to an aggregate of $280.0&#160;million in contingent cash consideration based on the achievement of certain milestones. A $40.0&#160;million payment will be due upon obtaining the first approval of a new drug application by the FDA (&#8220;NDA&#8221;) of any Semnur product, which includes SEMDEXA. Additional payments will be due upon the achievement of certain cumulative net sales of Semnur products, as follows: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a $20.0&#160;million payment upon the achievement of $100.0&#160;million in cumulative net sales of a Semnur product; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a $20.0&#160;million payment upon the achievement of $250.0&#160;million in cumulative net sales of a Semnur product; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a $50.0&#160;million payment upon the achievement of $500.0&#160;million in cumulative net sales of a Semnur product; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a $150.0&#160;million payment upon the achievement of $750.0&#160;million in cumulative net sales of a Semnur product. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These milestone obligations could impose substantial additional costs on us, divert resources from other aspects of our business, and adversely affect the overall profitability of SEMDEXA, if approved. We may need to obtain additional financing to satisfy these milestone payments, and cannot be sure that any additional funding, if needed, will be available on terms favorable to us, or at all. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We will require substantial additional funding, which may not be available to us on acceptable terms, or at all. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our operations have consumed substantial amounts of cash since inception. We expect to significantly increase our spending to continue our commercialization efforts for ZTlido and GLOPERBA, advance development of our current product candidates and launch and commercialize any product candidates for which we receive regulatory approval. Furthermore, we expect to incur additional costs associated with operating as a public company. We will also require additional capital to fund our other operating expenses and capital expenditures. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">15 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September&#160;30, 2022, our cash and cash equivalents were approximately $2.5&#160;million and we had an accumulated deficit of approximately $358.0&#160;million. The amount and timing of our future funding requirements will depend on many factors, some of which are outside of our control, including but not limited to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs and expenses associated with our ongoing commercialization efforts for ZTlido and GLOPERBA; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the degree of success we experience in commercializing ZTlido and GLOPERBA; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the revenue generated by sales of ZTlido, GLOPERBA and other products that may be approved, if any; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the scope, progress, results and costs of conducting studies and clinical trials for our product candidates, SEMDEXA, <span style="white-space:nowrap">SP-103</span> and <span style="white-space:nowrap">SP-104;</span> </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the timing of, and the costs involved in, obtaining regulatory approvals for our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs of manufacturing ZTlido, GLOPERBA and our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the timing and amount of any milestone, royalty or other payments we are required to make pursuant to any current or future collaboration or license agreements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to maintain existing, and establish new, strategic collaborations, licensing or other arrangements and the financial terms of any such agreements, including the timing and amount of any future milestone, royalty or other payments due under any such agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the extent to which ZTlido, GLOPERBA or any of our product candidates, if approved for commercialization, is adopted by the physician community; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our need to expand our research and development activities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs of acquiring, licensing or investing in businesses, product candidates and technologies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the effect of competing products and product candidates and other market developments; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the number and types of future products we develop and commercialize; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any product liability or other lawsuits related to our products; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the expenses needed to attract, hire and retain skilled personnel; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs associated with being a public company; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our need to implement additional internal systems and infrastructure, including financial and reporting systems; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the number of public shares that are redeemed by our public shareholders; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs of preparing, filing and prosecuting patent applications and maintaining, enforcing and defending intellectual property-related claims; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the extent and scope of our general and administrative expenses. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until we are able to generate significant revenue, if ever, we expect to finance our operations through a combination of equity offerings, debt financings, collaborations, government contracts or other strategic transactions. We cannot be sure that any additional funding, if needed, will be available on terms favorable to us, or at all. Any additional fundraising efforts may divert our management from their <span style="white-space:nowrap"><span style="white-space:nowrap">day-to-day</span></span> activities, which may adversely affect our ability to develop and commercialize our product candidates. Furthermore, any additional equity or equity-related financing may be dilutive to our stockholders, and debt or equity financing, if available, may subject us to restrictive covenants and significant interest costs. If we raise additional funds through collaborations or strategic alliances with third parties, we may have to relinquish valuable rights to our product candidates, future revenue streams, research programs or technologies, or grant licenses on terms that may not be favorable to us. If we are unsuccessful in our efforts to raise additional financing on acceptable terms, we may be required to significantly reduce or cease our operations. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">16 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our recurring losses from operations, negative cash flows and substantial cumulative net losses raise substantial doubt about our ability to continue as a going concern. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In Note 2 titled &#8220;<span style="font-style:italic">Liquidity and Going Concern</span>&#8221; of our consolidated financial statements included elsewhere in this prospectus, we disclose that there is substantial doubt about our ability to continue as a going concern. In addition, our independent registered public accounting firm included an explanatory paragraph in its report on our consolidated financial statements as of and for the year ended December&#160;31, 2021, which stated that substantial doubt existed about our ability to continue as a going concern. We have negative working capital and have incurred significant operating losses and negative cash flows from operations and expect to continue incurring losses for the foreseeable future. Further, we had an accumulated deficit of approximately $352.6&#160;million as of December&#160;31, 2021 and approximately $264.1&#160;million as of December&#160;31, 2020. These conditions raise substantial doubt about our ability to continue as a going concern. Our consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to become a profitable operating company is dependent upon our ability to generate revenue and obtain financing adequate to fulfill our development and commercialization activities, and achieving a level of revenue adequate to support our cost structure. We have plans to obtain additional resources to fund our currently planned operations and expenditures through additional debt and equity financing. Our plans are substantially dependent upon the success of future sales of ZTlido, which is still in the early stages of commercialization, and are dependent upon, among other things, the success of our marketing of ZTlido and our ability to secure additional payor contracts with terms that are consistent with our business plan. If we are unable to obtain sufficient funding, our financial condition and results of operations will be materially and adversely affected and we may be unable to continue as a going concern. Future financial statements may disclose substantial doubt about our ability to continue as a going concern. If we seek additional financing to fund our business activities in the future and there remains substantial doubt about our ability to continue as a going concern, investors or other financing sources may be unwilling to provide additional funding to us on commercially reasonable terms or at all. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We have identified a material weakness in our internal control over financial reporting. Any material weakness may cause us to fail to timely and accurately report our financial results or result in a material misstatement of our financial statements. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the audit of our consolidated financial statements for the years ended December&#160;31, 2021 and 2020, we identified control deficiencies in the design and operation of our internal control over financial reporting that constituted a material weakness. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our financial statements will not be prevented or detected on a timely basis. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the years ended December&#160;31, 2021 and 2020, the material weakness identified in our internal control over financial reporting related to ineffective control activities in the areas of revenue, debt, derivative liabilities, cash flows and leases caused by a lack of sufficient accounting resources. As a result of the material weakness, we hired additional accounting personnel and are implementing remediation measures including, but not limited to, performing a comprehensive assessment of accounting and finance resource requirements and hiring other personnel with sufficient accounting expertise at Sorrento to improve the operating effectiveness of our review controls and monitoring activities, and utilizing external accounting experts as appropriate. Any potential material misstatements were identified and corrected as audit adjustments in the applicable periods and are properly reflected in our financial statements included in this prospectus. We hired a new Chief Financial Officer in May 2022 at Legacy Scilex and she became Chief Financial Officer of the Company in connection with the closing of the Business Combination. In addition, we expect to hire additional personnel with accounting expertise and utilize external accounting experts. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the future, in order to properly manage our internal control over financial reporting, we may need to take additional measures to further augment our finance resources, and we cannot be certain that the measures we </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">17 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
have taken, and expect to take, to improve our internal controls will be sufficient to ensure that our internal controls will remain effective and eliminate the possibility that other material weaknesses or deficiencies may develop or be identified in the future. If we experience future material weaknesses or deficiencies in internal controls and we are unable to correct them in a timely manner, our ability to record, process, summarize and report financial information accurately and within the time periods specified in the rules and forms of the SEC, will be adversely affected. Any such failure could negatively affect the market price and trading liquidity of our Common Stock, lead to delisting, cause investors to lose confidence in our reported financial information, subject us to civil and criminal investigations and penalties, and generally materially and adversely impact our business and financial condition. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we identify future material weaknesses in our internal controls over financial reporting or fail to meet the demands that will be placed upon us as a public company, including the requirements of the Sarbanes-Oxley Act as, we may be unable to accurately report our financial results or report them within the timeframes required by law or stock exchange regulations. Failure to comply with Section&#160;404 of the Sarbanes-Oxley Act could also potentially subject us to sanctions or investigations by the SEC or other regulatory authorities. If additional material weaknesses exist or are discovered in the future, and we are unable to remediate any such material weakness, our business, financial condition and results of operations could suffer. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_13">Risks Related to our Commercial Operations and Product Development </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We obtain our commercial supply of ZTlido, clinical supply of our product candidates and certain of the raw materials used in our product candidates from sole or single source suppliers and manufacturers. In the event of a loss of one of these suppliers or manufacturers, or a failure by any such supplier or manufacturer to comply with FDA regulations, we may not be able to find an alternative source on commercially reasonable terms, or at all. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely on a number of sole or single source suppliers and manufacturers, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the manufacturer and supplier for the commercial supply of ZTlido; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the manufacturer and supplier for the clinical supply of <span style="white-space:nowrap">SP-103;</span> </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the manufacturer and supplier for the clinical supply of <span style="white-space:nowrap">SP-104;</span> </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the supplier of sodium hyaluronate, one of the excipients for SEMDEXA; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the manufacturer for the clinical supply of SEMDEXA. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Product Development Agreement, dated as of May&#160;11, 2011, by and among Scilex Pharmaceuticals, Inc. (as successor to Stason Pharmaceuticals, Inc.), Oishi Koseido Co., Ltd. (&#8220;Oishi&#8221;) and Itochu Chemical Frontier Corporation (&#8220;Itochu&#8221;) (as amended, the &#8220;Product Development Agreement&#8221;), and the Commercial Supply Agreement, dated as of February&#160;16, 2017, by and among Scilex Pharma and Oishi and Itochu (as amended, the &#8220;Commercial Supply Agreement&#8221;), we license the rights to ZTlido from and rely exclusively on Oishi and Itochu for the manufacturing and supply of ZTlido and <span style="white-space:nowrap">SP-103</span> (collectively, the &#8220;Products&#8221;). Oishi and Itochu have the right to terminate the Product Development Agreement and the Commercial Supply Agreement under certain circumstances, including, among other things: (1)&#160;if we are in material breach of the agreement and the breach is not curable or if the breach is curable and we fail to cure such material breach within 180 days after notice requesting to cure; (2)&#160;if, at any time during the term of the Product Development Agreement and the Commercial Supply Agreement, the market conditions are such that (a)&#160;our total net profits for ZTlido and <span style="white-space:nowrap">SP-103</span> are equal to or less than five percent of our net sales of ZTlido and <span style="white-space:nowrap">SP-103</span> for a period of four or more consecutive quarters, or (b)&#160;the economic viability of ZTlido and <span style="white-space:nowrap">SP-103</span> is affected significantly as evidenced by documentation and substantial information by any external circumstances deemed detrimental to all parties as agreed to by us, on the one hand, and Oishi and Itochu, on the other hand, and the parties are unable to resolve the concerns under the foregoing clauses (a)&#160;and (b)&#160;after 30&#160;days of good-faith discussion; and (3)&#160;in the event of our bankruptcy or assignment for the benefit of creditors. As of the date of this </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">18 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
prospectus, our net profits for ZTlido and <span style="white-space:nowrap">SP-103</span> have not exceeded five percent of net sales. Accordingly, Oishi and Itochu have the right to terminate the Product Development Agreement and Commercial Supply Agreement. As of the date of this prospectus, neither Oishi nor Itochu has exercised its right of termination. If the Product Development Agreement and the Commercial Supply Agreement are terminated, we would lose access to the intellectual property and proprietary manufacturing process upon which ZTlido and <span style="white-space:nowrap">SP-103</span> depend. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under our exclusive Supply Agreement, dated December&#160;17, 2015 (the &#8220;Genzyme Supply Agreement&#8221;), with Genzyme Corporation (&#8220;Genzyme&#8221;), we depend on Genzyme to fulfill our clinical and commercial supply requirements for sodium hyaluronate, one of the excipients for SEMDEXA. Genzyme has the right to terminate the Supply Agreement under certain circumstances, including, but not limited to: (1)&#160;if we are in material breach of the agreement and fail to cure such breach within 30 days of written notice of such breach, (2)&#160;if our development of SEMDEXA is ceased or we do not file for regulatory approval for SEMDEXA by January&#160;1, 2020, or (3)&#160;if Genzyme decides to discontinue manufacturing the product at its facility for economic or strategic reasons and provides us with 24 months&#8217; notice. We did not file for regulatory approval for SEMDEXA by January&#160;1, 2020 and we are only aware of a limited number of suppliers of the excipient. In accordance with the preceding clause&#160;(3), Genzyme has notified us of its intention to terminate the Genzyme Supply Agreement, effective as of May&#160;31, 2024. Although we are currently in the process of identifying and certifying new suppliers to fulfill our clinical and commercial supply requirements for sodium hyaluronate we may not be able to find an alternative supplier of sodium hyaluronate on commercially reasonable terms. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under our Master Services Agreement, dated January&#160;27, 2017 (as amended, the &#8220;Lifecore Master Services Agreement&#8221;), with Lifecore Biomedical, LLC (&#8220;Lifecore&#8221;), we depend on Lifecore to manufacture clinical supplies of SEMDEXA. Lifecore has the right to terminate the Lifecore Master Services Agreement under certain circumstances, including, but not limited to: (1)&#160;if we are in material breach of the agreement and fail to cure such breach within 30 days of written notice; (2)&#160;if we (a)&#160;become insolvent, (b)&#160;cease to function as a going concern, (c)&#160;become convicted of or plead guilty to a charge of violating any law relating to either party&#8217;s business, or (d)&#160;engage in any act which materially impairs goodwill associated with SEMDEXA or materially impairs the terminating party&#8217;s trademark or trade name; (3)&#160;if we fail to pay past due invoices upon 30 days&#8217; written notice, or (4)&#160;if we reject or fail to respond to a major change proposed by Lifecore that does not change Semnur&#8217;s written and approved acceptance criteria in its product specifications. In the event that Lifecore decides to terminate the Lifecore Master Services Agreement, finding an alternative manufacturer may be difficult. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Master Services Agreement (the &#8220;Tulex Master Services Agreement&#8221;) and statement of work with Tulex Pharmaceuticals Inc. (&#8220;Tulex&#8221;), we depend on Tulex to develop, test and manufacture clinical supplies of <span style="white-space:nowrap">SP-104.</span> Tulex has the right to terminate the Tulex Master Services Agreement under certain circumstances, including, but not limited to: (1)&#160;if we are in material breach of the agreement or a statement of work and fail to cure such breach within 15 days after receipt of notice of such breach (or such other time period expressly stated in the applicable statement of work) or (2)&#160;in the event of our insolvency, bankruptcy, reorganization, liquidation or receivership, or a failure to remove any insolvency, bankruptcy, reorganization, liquidation or receivership proceedings within ten days from the date of institution of such proceedings. In addition, we may terminate the agreement or any statement of work (a)&#160;without cause upon 30 days prior written notice to Tulex or (b)&#160;immediately upon written notice in the event Tulex is dissolved or undergoes a change in control. In the event that the Tulex Master Services Agreement or a statement of work is terminated, we may not be able to find an alternative manufacturer and supplier on commercially reasonable terms. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, the manufacturing facilities used by our third-party suppliers and manufacturers must continue to comply with FDA regulations and are subject to periodic announced or unannounced inspections. We have limited control over the ability of our third-party suppliers and manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If our third-party suppliers and manufacturers fail to comply with FDA regulations, the FDA may not authorize the manufacture of our products and product candidates at these facilities, and we may be unable to find alternative manufacturing facilities in a timely manner or at all. The failure by such third parties to comply with applicable regulations could result in sanctions being imposed on us, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">19 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
including clinical holds, fines, injunctions, import detention, civil penalties, delays, suspension or withdrawal of approvals, seizures or recalls of our product, operating restrictions and criminal prosecutions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, our product candidates may compete with other product candidates and products for access to manufacturing facilities and other supplies. There are a limited number of manufacturers that operate under current Good Manufacturing Practices (&#8220;cGMP&#8221;) regulations and that might be capable of manufacturing for us. Also, prior to the approval of our product candidates, we would need to identify a contract manufacturer that could produce our products at a commercial scale and that could successfully complete FDA <span style="white-space:nowrap">pre-approval</span> inspection and inspections by other health authorities. Agreements with such manufacturers or suppliers may not be available to us at the time we would need to have that capability and capacity. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our commercial supply of ZTlido, clinical supply of our product candidates and certain of the raw materials used in our product candidates are disrupted or delayed, there can be no assurance that alternative sources can serve as adequate replacements or that supplies will be available on terms that are favorable to us, if at all. Any disruption in supply could affect the profitability of ZTlido and the development of SEMDEXA, <span style="white-space:nowrap">SP-103</span> and <span style="white-space:nowrap">SP-104.</span> </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We rely on a single third-party logistics distribution provider, Cardinal Health 105, which until recently had also been our only customer. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently rely on Cardinal Health 105, LLC (&#8220;Cardinal Health 105&#8221;) as our third-party logistics distribution provider for ZTlido in the United States. Cardinal Health 105 also performs the following services on our behalf: customer service, credit checks, invoicing, chargebacks, distributor fee for service, government reporting, customer returns, accounts receivable, inventory control, product security (DSCSA serialization) inquiries and recall assistance. In the years ended December&#160;31, 2019, 2020 and 2021, and in the first quarter of 2022, Cardinal Health 105 was our only customer and sales to Cardinal Health 105 represented all of our net revenue for such periods. Beginning on April&#160;1, 2022, we began selling ZTlido directly to three large distributors, McKesson Corporation (&#8220;McKesson&#8221;), Cardinal Health 110, LLC (&#8220;Cardinal Health 110&#8221;) and AmerisourceBergen Corporation (&#8220;AmerisourceBergen&#8221;), as well as to numerous pharmacies. If we are unable to maintain a favorable relationship with Cardinal Health 105 (or with any of our other two distributors), we expect that our revenue would decline and our business would be harmed as a result. We may be unable to control the timing of the delivery of ZTlido to distributors, and any financial uncertainty or loss of key logistic employees of Cardinal Health 105, as our only third-party logistics provider, may negatively impact our sales. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As we continue to expand the commercialization of ZTlido, we expanded our direct distribution network to national and regional distributors and pharmacies in the second quarter of 2022. We currently hold wholesaler licenses and commenced selling directly to our main distributor customers as well as pharmacies. We discontinued our use of &#8220;title model&#8221; services provided by Cardinal Health 105, but expect that Cardinal Health 105 will continue to perform other third-party logistics services for us. Any disruption in the abovementioned distribution channel would adversely affect our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we fail to achieve certain milestones in our Product Development Agreement with Itochu and Oishi, we could lose rights that are important to our business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of our existing license and supply agreements impose various milestone and other obligations on us. For example, under our Product Development Agreement with Itochu and Oishi, if our total net profits for ZTlido and <span style="white-space:nowrap">SP-103</span> are equal to or less than five percent of our net sales of ZTlido and <span style="white-space:nowrap">SP-103</span> for a period of four or more consecutive quarters, Itochu and Oishi have the right to terminate the Product Development Agreement if the parties are unable to resolve the concerns after 30 days of good-faith negotiation. As of the date of this prospectus, our net profits for ZTlido and <span style="white-space:nowrap">SP-103</span> have not exceeded five percent of net sales. Accordingly, Oishi and Itochu have the right to terminate the Product Development Agreement and Commercial Supply Agreement. As of the date of this prospectus, neither Oishi nor Itochu has exercised its right of termination. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">20 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we fail to achieve the milestones under the Product Development Agreement, we may lose our exclusivity rights or the counterparty may have the right to terminate the agreement, any of which could adversely affect our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We rely on third parties to conduct our clinical trials and intend to rely on third parties to conduct all of our future clinical trials. If these third parties do not successfully carry out their contractual duties, fail to comply with applicable regulatory requirements or meet expected deadlines, we may be unable to obtain regulatory approval for our product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently do not have the ability to independently conduct any clinical trials. The FDA and regulatory authorities in other jurisdictions require us to comply with regulations and standards, commonly referred to as good clinical practice (&#8220;GCP&#8221;) requirements for conducting, monitoring, recording and reporting the results of clinical trials, in order to ensure that the data and results are scientifically credible and accurate and that the trial subjects are adequately informed of the potential risks of participating in clinical trials. We rely on medical institutions, clinical investigators, contract laboratories and other third parties, such as contract research organizations (&#8220;CROs&#8221;), to conduct <span style="white-space:nowrap">GCP-compliant</span> clinical trials of our product candidates properly and on time. While we have agreements governing their activities, we control only certain aspects of their activities and have limited influence over their actual performance. The third parties with whom we contract for execution of our <span style="white-space:nowrap">GCP-compliant</span> clinical trials play a significant role in the conduct of these studies and trials and the subsequent collection and analysis of data. These third parties are not our employees and, except for restrictions imposed by our contracts with such third parties, we have limited ability to control the amount and timing of resources that they devote to our programs. Although we rely on these third parties to conduct our <span style="white-space:nowrap">GCP-compliant</span> clinical trials, we remain responsible for ensuring that each of our clinical trials is conducted in accordance with our investigational plan and protocol and applicable laws and regulations, and our reliance on the CROs does not relieve us of our regulatory responsibilities. For any violations of laws and regulations in the conduct of our preclinical studies and clinical trials, we could be subject to warning letters or enforcement actions that may include civil penalties up to and including criminal prosecution. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of the third parties with whom we contract may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other drug development activities that could harm our competitive position. We face the risk of potential unauthorized disclosure or infringement, misappropriation or other violation of our intellectual property by CROs, which may reduce our trade secret and intellectual property protection and allow our potential competitors to access and exploit our proprietary technology. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, any of these third parties may terminate their engagements with us or be unable to fulfill their contractual obligations. If the third parties conducting our clinical trials do not adequately perform their contractual duties or obligations, experience significant business challenges, disruptions or failures, do not meet expected deadlines, terminate their agreements with us or need to be replaced, or if the quality or accuracy of the data they obtain is compromised due to their failure to adhere to our protocols or to GCPs, or for any other reason, we may need to enter into new arrangements with alternative third parties. This could be difficult, costly or impossible, and our clinical trials may need to be extended, delayed, terminated or repeated. As a result, we may not be able to obtain regulatory approval or successful commercialization in a timely fashion, or at all, for the applicable product candidate. Our financial results and the commercial prospects for our product candidates would be harmed, our costs could increase, and our ability to generate revenue could be delayed. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may in the future enter into collaborations, <span style="white-space:nowrap">in-licensing</span> arrangements, joint ventures, or strategic alliances with third-parties that may not result in the development of commercially viable products or the generation of significant future revenues. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business is substantially dependent upon the intellectual property licensed from Oishi and Itochu. In the ordinary course of our business, we may enter into collaborations, additional <span style="white-space:nowrap">in-licensing</span> arrangements (such as, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">21 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
for example, the Romeg Agreement), joint ventures, or strategic alliances to develop proposed products and to pursue new markets. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Proposing, negotiating and implementing collaborations, <span style="white-space:nowrap">in-licensing</span> arrangements, joint ventures, strategic alliances or partnerships may be a lengthy and complex process. Other companies, including those with substantially greater financial, marketing, sales, technology or other business resources, may compete with us for these opportunities or arrangements. We may not identify, secure or complete any such transactions or arrangements in a timely manner, on a cost-effective basis, on acceptable terms, or at all, and may not realize the anticipated benefits of any such transactions or arrangements. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, with respect to current and future collaborations, we may not be in a position to exercise sole decision-making authority regarding the transaction or arrangement, which could create the potential risk of creating impasses on decisions, and our collaborators may have economic or business interests or goals that are, or that may become, inconsistent with our business interests or goals. It is possible that conflicts may arise with our collaborators, such as conflicts concerning the achievement of performance milestones, or the interpretation of significant terms under any agreement, such as those related to financial obligations or the ownership or control of intellectual property developed during the collaboration. If any conflicts arise with our current or future collaborators, they may act in their self-interest, which may be adverse to our best interest, and they may breach their obligations to us. In addition, we have limited control over the amount and timing of resources that our current collaborators or any future collaborators devote to our collaborators&#8217; or our future products. Disputes between us and our collaborators may result in litigation or arbitration which would increase our expenses and divert the attention of our management. Further, these transactions and arrangements are contractual in nature and may be terminated or dissolved under the terms of the applicable agreements and, in such event, we may not continue to have rights to the products relating to such transaction or arrangement or may need to purchase such rights at a premium. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Delays in clinical trials could result in increased costs to us and delay our ability to obtain commercial approval and generate additional revenue. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before obtaining marketing approval for the sale of our product candidates, we must conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates for their intended indications. Clinical testing is expensive, time-consuming and uncertain as to outcome. We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, if at all. A failure of one or more clinical trials can occur at any stage of testing. Events that may prevent successful or timely completion of clinical development include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays in obtaining regulatory authorizations to commence a clinical trial or reaching a consensus with regulatory authorities on trial design; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays in identifying prospective clinical investigators or clinical trial sites that have necessary qualifications, interest and capacity to perform a requested protocol; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays in reaching agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays in obtaining approval from one or more institutional review boards (&#8220;IRBs&#8221;); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">IRBs refusing to approve, suspending or terminating the trial at the investigational site, precluding enrollment of additional subjects, or withdrawing their approval of the trial; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes to the clinical trial protocol; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays in recruiting suitable subjects to participate in our clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">failure by us, any CROs we engage or any other third parties to adhere to clinical trial requirements; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">22 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">failure to perform in accordance with GCPs; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays in the testing, validation, manufacturing and delivery of our product candidates to the clinical sites, including delays by third parties with whom we have contracted to perform certain of those functions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays in subjects completing participation in a trial or returning for post-treatment <span style="white-space:nowrap">follow-up,</span> including, for example, as a result of reluctance to visit medical facilities as a result of the <span style="white-space:nowrap">COVID-19</span> pandemic; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">clinical trial sites or subjects dropping out of a trial; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">lack of adequate funding to continue the trial; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">selection of clinical endpoints that require prolonged periods of clinical observation or analysis of the resulting data; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">subjects experiencing severe or unexpected drug-related adverse effects; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">imposition of a clinical hold by regulatory authorities as a result of a serious adverse event, after an inspection of our clinical trial operations, trial sites or manufacturing facilities, or for other reasons; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">occurrence of serious adverse events in our trials or in trials of the same class of agents conducted by other sponsors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes in regulatory requirements or guidance that require amending or submitting new clinical protocols; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a facility manufacturing our product candidates or any of their components being ordered by the FDA to temporarily or permanently shut down due to violations of cGMP regulations or other applicable requirements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any changes to our manufacturing process that may be necessary or desired; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">third-party clinical investigators losing the licenses or permits necessary to perform our clinical trials, not performing our clinical trials on our anticipated schedule or consistent with the clinical trial protocol, GCP, or other regulatory requirements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">third-party contractors not performing data collection or analysis in a timely or accurate manner; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">third-party contractors becoming debarred or suspended or otherwise penalized by the FDA or other government or regulatory authorities for violations of regulatory requirements, in which case we may need to find a substitute contractor, and we may not be able to use some or all of the data produced by subcontractors in support of our marketing applications. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We could also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such trials are being conducted, by a Data Safety Monitoring Board for such trial or by the FDA. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, participants being exposed to unacceptable health risks, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. In addition, changes in regulatory requirements and policies may occur, and we may need to amend clinical trial protocols to comply with these changes. Amendments may require us to resubmit our clinical trial protocols to IRBs for reexamination, which may impact the costs, timing or successful completion of a clinical trial. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our product development costs will increase if we experience delays in testing or marketing approvals. The FDA and other regulatory agencies may impose new or refined testing expectations based on experience and </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">23 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
increased knowledge over time. In addition, if we make manufacturing or other changes to our product candidates, we may need to conduct additional studies to bridge our modified product candidates to earlier versions. We do not know whether any of our clinical trials, including our planned clinical trials of <span style="white-space:nowrap">SP-103,</span> <span style="white-space:nowrap">SP-104</span> and SEMDEXA, will begin or continue as planned, will need to be restructured or will be completed on schedule, or at all. We may not have the necessary capabilities, including adequate staffing, to successfully manage the execution and completion of any clinical trials we initiate in a way that leads to our obtaining marketing approval for our product candidates in a timely manner, or at all. Significant clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do and impair our ability to successfully commercialize our product candidates. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We face potential business disruptions and related risks resulting from the <span style="white-space:nowrap">COVID-19</span> pandemic, which could have a material adverse effect on our business, financial condition and results of operations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2019, a novel strain of coronavirus, or <span style="white-space:nowrap"><span style="white-space:nowrap">SARS-CoV-2,</span></span> was reported to have surfaced in Wuhan, China. <span style="white-space:nowrap"><span style="white-space:nowrap">SARS-CoV-2</span></span> is the virus that causes <span style="white-space:nowrap">COVID-19.</span> The <span style="white-space:nowrap">COVID-19</span> outbreak has grown into a global pandemic that has impacted countries throughout the world. Financial markets have been experiencing extreme fluctuations that may cause a contraction in available liquidity globally as important segments of the credit markets react to the development. The pandemic may lead to a decline in business and consumer confidence. The global outbreak of <span style="white-space:nowrap">COVID-19</span> continues to rapidly evolve. As a result, businesses have closed or limited operations and limits have been placed on travel. The extent to which <span style="white-space:nowrap">COVID-19</span> may impact our business, clinical trials and sales of ZTlido will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease and variants, the duration of the outbreak, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the disease. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are monitoring the potential impact of the <span style="white-space:nowrap">COVID-19</span> outbreak, and if <span style="white-space:nowrap">COVID-19</span> or variants of concern continue to spread globally, including in the United States, we may experience disruptions that could severely impact the development of our product candidates, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays or difficulties in enrolling patients in our clinical trials as patients may be reluctant, or unable, to visit clinical sites; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators, clinical site staff and potential closure of clinical facilities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">decreases in patients seeking treatment for chronic pain; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays in receiving approval from local regulatory authorities to initiate our planned clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays in clinical sites receiving the supplies and materials needed to conduct our clinical trials, including interruption in global shipping that may affect the transport of clinical trial materials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes in local regulations as part of a response to the <span style="white-space:nowrap">COVID-19</span> outbreak, which may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, or cause us to discontinue the clinical trials altogether; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">risk that participants enrolled in our clinical trials will acquire <span style="white-space:nowrap">COVID-19</span> while the clinical trial is ongoing, which could impact the results of the clinical trial, including by increasing the number of observed adverse events; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays in necessary interactions with local regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or forced furlough of government employees; and </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">24 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Quarantines, <span style="white-space:nowrap"><span style="white-space:nowrap">shelter-in-place</span></span> and similar government orders, or the perception that such orders, shutdowns or other restrictions on the conduct of business operations could occur, related to <span style="white-space:nowrap">COVID-19</span> or other infectious diseases could impact personnel at third-party suppliers in the United States and other countries, or the availability or cost of materials, which would disrupt our supply chain. Any manufacturing supply interruption of materials could adversely affect our ability to conduct ongoing and future research and testing activities. For example, we obtain our commercial supply of ZTlido and our clinical supply of <span style="white-space:nowrap">SP-103</span> exclusively from Oishi and Itochu in Japan. The <span style="white-space:nowrap">COVID-19</span> pandemic may result in delays in the procurement and shipping of ZTlido, which may have an adverse impact on our operating results. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&#160;24, 2021, the Safer Federal Workforce Task Force issued written guidance to implement Executive Order 14042, which was signed by President Biden on September&#160;9, 2021. A number of federal courts have issued orders enjoining enforcement of the Executive Order, including one on a nationwide basis. As a result, the government stated that it will take no action to enforce the requirements of the Executive Order at this time. As a federal contractor, we have mandated that all of our employees and, in addition, contractors that enter our U.S. buildings and certain other locations, be fully vaccinated against <span style="white-space:nowrap">COVID-19,</span> subject to disability and religious exemptions, by December&#160;8, 2021. Despite the government&#8217;s <span style="white-space:nowrap">no-action</span> position, we continue to comply with the Executive Order. We may experience workforce constraints due to shortages of vaccinated personnel, strains on the labor market, limitations on hiring new employees and difficulty retaining and securing employees who are vaccinated, all of which could negatively affect our business and operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The spread of <span style="white-space:nowrap">COVID-19,</span> which has caused a broad impact globally, may materially affect the Company economically. While the potential economic impact brought by, and the duration of, <span style="white-space:nowrap">COVID-19</span> may be difficult to assess or predict, a widespread pandemic could result in significant disruption of global financial markets, which could in the future negatively affect our liquidity. In addition, a recession or market correction resulting from the spread of <span style="white-space:nowrap">COVID-19</span> could materially affect our business and the value of our Common Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the continued spread of <span style="white-space:nowrap">COVID-19</span> globally could materially and adversely impact our operations, including without limitation, our manufacturing and supply chain, sales and marketing efforts, sales of ZTlido, travel and employee health and availability, which may have a material and adverse effect on our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Even if we complete the necessary clinical trials, we cannot predict when, or if, we will obtain regulatory approval for our product candidates and the approval may be for a more narrow indication than we seek. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot commercialize our product candidates until the appropriate regulatory authorities have reviewed and approved the product candidates. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state and local statutes and regulations require the expenditure of substantial time and financial resources and we may not be able to obtain the required regulatory approvals. Even if our product candidates meet the safety and efficacy endpoints in clinical trials, the regulatory authorities may not complete their review processes in a timely manner, or we may not be able to obtain regulatory approval. Additional delays may result if an FDA advisory committee, if convened, recommends <span style="white-space:nowrap">non-approval</span> or restrictions on approval. In addition, we may experience delays or rejections based upon additional government regulation from future legislation or administrative action or changes in regulatory authority policy or data requirements during the period of product development, clinical trials and the regulatory review process. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we receive regulatory approval, the FDA may approve a product candidate for more limited indications than requested or they may impose significant limitations in the form of narrow indications, warnings or a Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;). The FDA may require labeling that includes precautions or contra-indications with respect to conditions of use, or may grant approval subject to the performance of costly </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">25 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
post-marketing clinical trials. In addition, the FDA may not approve the labeling claims that are necessary or desirable for the successful commercialization of our product candidates. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, if the results of any clinical trials are inconclusive or if there are safety concerns or serious adverse events associated with our product candidates, we may: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">be delayed or fail in obtaining marketing approval for our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">obtain approval for indications or patient populations that are not as broad as we intended or desired; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">be subject to changes in the way the products are administered; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">be required to perform additional clinical trials to support approval or be subject to additional post-marketing testing requirements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">have regulatory authorities withdraw, or suspend, their approval of the product or impose restrictions on its distribution in the form of a modified REMS; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">be sued and held liable for harm caused to patients; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">experience damage to our reputation. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may find it difficult to enroll or maintain patients in our clinical trials, which could delay or prevent us from proceeding with clinical trials of our product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Identifying and qualifying patients to participate in any clinical trials of our product candidates is critical to our success. The timing of any clinical trials depends on our ability to recruit patients and to complete required <span style="white-space:nowrap">follow-up</span> periods. If patients are unwilling to participate in our clinical trials due to negative publicity from adverse events, competitive clinical trials for similar patient populations, or for other reasons, the timeline for recruiting patients, conducting trials and potentially obtaining regulatory approval may be delayed. We may also experience delays if patients withdraw from a clinical trial or do not complete the required monitoring period. These delays could result in increased costs, delays in advancing our product candidates, delays in testing the effectiveness of our product candidates or termination of clinical trials altogether. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patient enrollment is affected by many factors, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the size and nature of the patient population; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the proximity of patients to clinical sites; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the eligibility and exclusion criteria for the trial; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the design of the clinical trial; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">competing clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the risk that enrolled patients will not complete a clinical trial; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">ability to monitor patients adequately during and after treatment; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">potential disruptions caused by the <span style="white-space:nowrap">COVID-19</span> pandemic, including difficulties in initiating clinical sites, enrolling and retaining participants, diversion of healthcare resources away from clinical trials, travel or quarantine policies that may be implemented and other factors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to recruit clinical trial investigators with the appropriate competencies and experience; and </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">26 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the product candidate in relation to other available products. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The conditions for which we currently plan to evaluate our product candidates are common but the eligibility criteria of our clinical trials limit the pool of available trial participants. For example, we experienced a delay in the enrollment of our now completed SEMDEXA Phase 3 clinical trial in sciatica due to the selective eligibility criteria in place to reduce the placebo effect and the impacts of <span style="white-space:nowrap">COVID-19,</span> and may experience similar issues with enrollment of our other planned clinical trials. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, our clinical trials will compete with other clinical trials for product candidates that are in the same therapeutic areas as our product candidates, and this competition will reduce the number and types of patients available to it, because some patients who have opted to enroll in our trials may instead opt to enroll in a trial being conducted by a competitor. We may conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials at such clinical trial sites. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The incidence and prevalence for target patient populations of our product candidates are based on estimates and third-party sources. If the market opportunities for our product candidates are smaller than we estimate or if any approval that we obtain is based on a narrower definition of the patient population, our revenue and ability to achieve profitability might be materially and adversely affected. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Periodically, we make estimates regarding the incidence and prevalence of target patient populations of our product candidates based on various third-party sources and internally generated analyses and use such estimates in making decisions regarding our product development strategy, including acquiring or <span style="white-space:nowrap">in-licensing</span> product candidates and determining indications on which to focus in preclinical studies or clinical trials. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These estimates may be inaccurate or based on imprecise data. For example, the total addressable market opportunities will depend on, among other things, acceptance by the medical community and patient access, drug pricing and reimbursement. The number of patients in the addressable markets may turn out to be lower than expected, patients may not be otherwise amenable to treatment with our product candidates, or new patients may become increasingly difficult to identify or gain access to, all of which may significantly harm our business, financial condition, results of operations and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We face significant competition and our competitors may discover, develop or commercialize products faster or more successfully than us. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The biotechnology and pharmaceutical industries are characterized by intense competition and rapid technological advances. In addition, the competition in the pain management market, and other relevant markets, is intense. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ZTlido and our product candidate, <span style="white-space:nowrap">SP-103,</span> face and will likely face competition from prescription and generic topical lidocaine patches, including Lidoderm<sup style="font-size:75%; vertical-align:top">&#174;</sup> (a branded, prescription 5% lidocaine patch product) (&#8220;Lidoderm&#8221;) and generic lidocaine patches manufactured by Mylan N.V., Teva Pharmaceutical Industries Limited (&#8220;Teva&#8221;) and Par Pharmaceutical, Inc. Additionally, <span style="white-space:nowrap">SP-103,</span> if approved, will likely compete with various opioid pain medications, nonsteroidal anti-inflammatory drugs (&#8220;NSAIDs&#8221;), muscle relaxants, antidepressants and anticonvulsants particularly as we seek approval for the treatment of acute LBP. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SEMDEXA, if approved, has the potential to become the first <span style="white-space:nowrap">FDA-approved</span> epidural steroid product for the treatment of sciatica. While there are currently no FDA approved epidural steroid injections indicated for the treatment of sciatica, we are aware of certain <span style="white-space:nowrap">non-steroid</span> product candidates in development. SEMDEXA, if approved, also will compete with various opioid pain medications, NSAIDs, muscle relaxants, antidepressants, anticonvulsants and surgical procedures. Procedures may include nerve blocks and transcutaneous electrical nerve stimulations. We may also face indirect competition from the <span style="white-space:nowrap">off-label</span> and unapproved use of branded and generic injectable steroids. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">27 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While there are currently no formulations containing naltrexone in clinical development for the treatment of fibromyalgia, we are aware of certain <span style="white-space:nowrap">non-opioid</span> therapeutics currently in a late-stage phase 3 pipeline containing two 505(b)(2) development programs. Our product candidate, <span style="white-space:nowrap">SP-104,</span> will likely face direct competition from these candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that the market will become increasingly competitive in the future. Many of our competitors, either alone or together with their collaborative partners, operate larger research and development programs and have substantially greater financial resources than we do, as well as significantly greater experience in developing product candidates and technologies, undertaking preclinical studies and clinical trials, obtaining FDA and other regulatory approvals of product candidates, formulating and manufacturing product candidates, and launching, marketing and selling product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additional mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in our competitors. As a result, these companies may obtain regulatory approval more rapidly than we are able to and may be more effective in selling and marketing their products as well. Smaller or early-stage companies or generic or biosimilar pharmaceutical manufacturers may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these industries. Our commercial opportunity could be reduced or eliminated if our competitors succeed in developing, acquiring or licensing on an exclusive basis, products that are more effective or less costly than any product candidate that we are currently developing or that we may develop. If approved, our product candidates will face competition from commercially available drugs as well as drugs that are in the development pipelines of our competitors and later enter the market. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Established pharmaceutical companies may invest heavily to accelerate discovery and development of novel compounds or to <span style="white-space:nowrap">in-license</span> novel compounds that could make our product candidates less competitive. Accordingly, our competitors may succeed in obtaining patent protection, receiving FDA approval or discovering, developing and commercializing medicines before we do, which would have a material adverse impact on our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The third-party payor coverage and reimbursement status of newly approved products is uncertain. Failure to obtain or maintain coverage and adequate reimbursement for ZTlido, GLOPERBA or our product candidates, if approved, could decrease our ability to generate product revenue. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is significant uncertainty related to the third-party coverage and reimbursement of existing and newly approved products. Market acceptance and sales of ZTlido, GLOPERBA and our product candidates, if approved, in domestic markets will depend significantly on the availability of coverage and adequacy of reimbursement from third-party payors, including government programs (such as Medicare and Medicaid) and private payor healthcare and insurance programs. In the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors. Coverage and reimbursement for ZTlido can differ significantly from payor to payor, and we may not be able to maintain adequate coverage and reimbursement in the future. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, obtaining coverage and reimbursement approval for a product from a government or other third-party payor is a time-consuming and costly process that could require us to provide supporting scientific, clinical and cost-effectiveness data for the use of our products to each third-party payor separately, with no assurance that coverage and adequate reimbursement will be obtained or applied consistently. We may not be able to provide data sufficient to gain acceptance with respect to coverage and reimbursement. Additionally, coverage may be more limited than the purposes for which the product is approved by the FDA or similar regulatory authorities </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">28 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
outside of the United States. Assuming that coverage is obtained for a given product, the resulting reimbursement rates might not be adequate or may require <span style="white-space:nowrap">co-payments</span> or <span style="white-space:nowrap">co-insurance</span> that patients find unacceptably high. Patients, physicians, and other healthcare providers may be less likely to prescribe, dispense or use, as applicable, any approved product unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The market for our products will depend significantly on access to third-party payors&#8217; drug formularies for which third-party payors provide coverage and reimbursement. The industry competition to be included in such formularies often leads to downward pricing pressures on pharmaceutical companies. Also, third-party payors may refuse to include a particular branded product in their formularies or otherwise restrict patient access to a branded product when a less costly generic equivalent or other alternative is available. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, even if we obtain adequate levels of reimbursement, third-party payors carefully review and increasingly question the coverage of, and challenge the prices charged for, products. A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Increasingly, third-party payors are requiring that pharmaceutical companies provide them with predetermined discounts from list prices and are challenging the prices for products. We cannot be sure that coverage and reimbursement will be available for any product candidate that we commercialize and, if reimbursement is available, what the level of reimbursement will be. If coverage and reimbursement of our product candidates are unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, we may be unable to achieve or sustain profitability. Furthermore, the requirements governing medical product pricing vary widely from country to country. In some foreign countries, the proposed pricing for a prescription device must be approved before it may be lawfully marketed. Historically, products launched in the European Union do not follow price structures of the United States and generally prices tend to be significantly lower. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our product candidate SEMDEXA is expected to be a physician-administered injectable viscous gel and as such, separate reimbursement for the product itself may not be available. Instead, if SEMDEXA receives regulatory approval, the administering physician may be reimbursed only for providing the treatment or procedure in which SEMDEXA is used. To the extent separate coverage and reimbursement should become available for SEMDEXA, we anticipate that it will be sold to physicians on a &#8220;buy and bill&#8221; basis. Buy and bill products must be purchased by healthcare providers before they can be administered to patients. Healthcare providers subsequently must seek reimbursement for the product from the applicable third-party payor, such as Medicare or a health insurance company. Healthcare providers may be reluctant to administer our product candidates, if approved, because they would have to fund the purchase of the product and then seek reimbursement, which may be lower than their purchase price, or because they do not want the additional administrative burden required to obtain reimbursement for the product. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, the codes used by providers to bill for SEMDEXA, if approved, could also affect reimbursement. <span style="white-space:nowrap">J-Codes</span> are codes maintained by the Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;), which are a component of the Healthcare Common Procedure Coding System and are typically used to report injectable drugs that ordinarily cannot be self-administered. We do not have a specific <span style="white-space:nowrap">J-Code</span> for any of our product candidates. If our product candidates are approved, we may apply for one but cannot guarantee that a <span style="white-space:nowrap">J-Code</span> will be granted. To the extent separate coverage or reimbursement is available for any product candidate, if approved, and a specific <span style="white-space:nowrap">J-Code</span> is not available, physicians would need to use a <span style="white-space:nowrap">non-specific</span> miscellaneous <span style="white-space:nowrap">J-Code</span> to bill third-party payors for these physician-administered drugs. Because miscellaneous <span style="white-space:nowrap">J-Codes</span> may be used for a wide variety of products, health plans may have more difficulties determining the actual product used and billed for the patient. These claims must often be submitted with additional information and manually processed, which can create delays in claims processing times as well as increasing the likelihood for claim denials and claim errors. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">29 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Because we have multiple programs and product candidates in our development pipeline and are pursuing a variety of target indications and treatment approaches, we may expend our limited resources to pursue a particular product candidate and fail to capitalize on development opportunities or product candidates that may be more profitable or for which there is a greater likelihood of success. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Apart from our <span style="white-space:nowrap">FDA-approved</span> product, ZTlido, we currently have several product candidates that are at various stages of development. We have limited financial and management resources. As a result, we may forego or delay pursuit of opportunities with potential target indications or product candidates that later prove to have greater commercial potential than our current and planned development programs and product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We strive to progress product candidates that can address unmet or underserved medical needs and favor those candidates with large market opportunities. However, our resource allocation decisions may cause us to fail to capitalize on viable commercial product candidates or profitable market opportunities. Our spending on current and future research and development programs and other future product candidates for specific indications may not yield any commercially viable future product candidates. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may be required to relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such future product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, we may pursue additional <span style="white-space:nowrap">in-licenses</span> or acquisitions of product candidates or programs, which entails additional risk to us. Identifying, selecting and acquiring promising product candidates requires substantial technical, financial and human resources expertise. Efforts to do so may not result in the actual acquisition or license of a successful product candidate, potentially resulting in a diversion of our management&#8217;s time and the expenditure of our resources with no resulting benefit. For example, if we are unable to identify programs that ultimately result in approved products, we may spend material amounts of our capital and other resources evaluating, acquiring and developing products that ultimately do not provide a return on our investment. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Drug development involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical testing is expensive, difficult to design and implement, and can take many years to complete, in part because it is subject to rigorous regulatory requirements. The FDA or other regulatory authorities may not agree with the proposed analysis plans or trial design for the clinical trials of our product candidates. They may also not agree with the scope of our proposed investigational plan. In addition, the outcome of our clinical trials is risky and uncertain. Failure can occur at any time during the clinical trial process. The results of preclinical studies and early clinical trials may not be predictive of the results of later-stage clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical trials. It is not uncommon for companies in the pharmaceutical industry to suffer significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials. Our future clinical trial results may not be successful. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This product candidate development risk is heightened by any changes in the planned clinical trials compared to the completed clinical trials. As product candidates are developed through preclinical to early and late stage clinical trials towards approval and commercialization, it is customary that various aspects of the development program, such as manufacturing and methods of administration, are altered along the way in an effort to optimize processes and results. While these types of changes are common and are intended to optimize the product candidates for late stage clinical trials, approval and commercialization, such changes carry the risk that they will not achieve their intended objectives. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A Phase 3 trial was completed for SEMDEXA for the treatment of sciatica, a Phase 2 trial commenced in the second quarter of 2022 for <span style="white-space:nowrap">SP-103,</span> and multiple Phase 1 trials were initiated in the first quarter of 2022 for </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">30 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<span style="white-space:nowrap">SP-104.</span> We may not have the necessary capabilities, including adequate staffing, to successfully manage the execution and completion of such clinical trials in a way that leads to our obtaining marketing approval for our product candidates in a timely manner, or at all. Our clinical trials may produce negative or inconclusive results, and, in the future, we may decide, or regulators may require us, to conduct additional clinical trials and preclinical studies in addition to those we have planned. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2022, we announced final results from our Phase 3 trial for SEMDEXA, which results reflect achievement of primary and secondary endpoints, and we intend to use the results to support an NDA submission seeking approval for the treatment of sciatica. However, the FDA may disagree with our assumptions and require us to conduct an additional Phase 3 trial before submitting an NDA. Our failure to adequately demonstrate the safety and effectiveness of our product candidates would prevent receipt of regulatory clearance or approval and, ultimately, the commercialization of that product or indication for use. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Interim <span style="white-space:nowrap">&#8220;top-line&#8221;</span> and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, we may publish interim <span style="white-space:nowrap">&#8220;top-line&#8221;</span> or preliminary data from our clinical trials, which are based on a preliminary analysis of then-available data. Preliminary or interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Preliminary or interim data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. In some instances, there can be significant variability in safety or efficacy results between different clinical trials or clinical trial sites for the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the dosing regimen and other clinical trial procedures and the rate of dropout among clinical trial participants. As a result, interim and preliminary data should be viewed with caution until the final data are available. Adverse differences between preliminary or interim data and final data could significantly harm our business, financial condition and results of operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. Data disclosures must be carefully managed to conform to limitations on preapproval promotion and laws related to clinical trial registration and posting of results. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and stockholders may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular drug, product, product candidate or our business. If the <span style="white-space:nowrap">&#8220;top-line&#8221;</span> data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our clinical trials may fail to demonstrate substantial evidence of the safety and efficacy of product candidates that we may identify and pursue for their intended uses, which would prevent, delay or limit the scope of regulatory approval and commercialization. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before obtaining regulatory approvals for the commercial sale of any of our product candidates, we must demonstrate through lengthy, complex and expensive <span style="white-space:nowrap">non-clinical</span> studies, <span style="white-space:nowrap">pre-clinical</span> studies and clinical trials that the applicable product candidate is both safe and effective for use in each target indication. Each product candidate must demonstrate an adequate risk versus benefit profile in its intended patient population and for its intended use. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">31 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical development process. Most product candidates that begin clinical trials are never approved by regulatory authorities for commercialization. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot be certain that our current clinical trials or any other future clinical trials will be successful. Additionally, any safety concerns observed in any one of our clinical trials in our targeted indications could limit the prospects for regulatory approval of our product candidates in those and other indications, which could have a material adverse effect on our business, financial condition and results of operations. In addition, even if such clinical trials are successfully completed, we cannot guarantee that the FDA or comparable <span style="white-space:nowrap">non-U.S.</span> regulatory authorities will interpret the results as we do, and more trials could be required before we submit our product candidates for approval. To the extent that the results of the trials are not satisfactory to the FDA or comparable <span style="white-space:nowrap">non-U.S.</span> regulatory authorities for support of a marketing approval, we may be required to expend significant resources, which may not be available to us, to conduct additional trials in support of potential approval of our product candidates. Even if regulatory approval is secured for a product candidate, the terms of such approval may limit the scope and use of the specific product candidate, which may also limit its commercial potential. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Even if we obtain FDA approval for any of our product candidates in the United States, we may never obtain approval for or commercialize any of them in any other jurisdiction, which would limit our ability to realize their full market potential. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to market any products in any particular jurisdiction, we must establish and comply with numerous and varying regulatory requirements on a <span style="white-space:nowrap"><span style="white-space:nowrap">country-by-country</span></span> basis regarding safety and efficacy. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Approval by the FDA in the United States does not ensure approval by regulatory authorities in other countries or jurisdictions. However, the failure to obtain approval in one jurisdiction may negatively impact our ability to obtain approval elsewhere. In addition, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not guarantee regulatory approval in any other country. In cases where data from United States clinical trials are intended to serve as the basis for marketing approval in the foreign countries, the standards for clinical trials and approval may be different. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Approval processes vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking foreign regulatory approval could result in difficulties and increased costs for us and require additional preclinical studies or clinical trials, which could be costly and time-consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if regulatory approvals in international markets are delayed, our target market will be reduced and our ability to realize the full market potential of any product we develop will be impeded. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our business may suffer reputational harm due to failures of our product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The failure of any of our product candidates could have a lasting negative impact on our reputation, which could, in turn, impact our ability to successfully enter into future licensing arrangements or other transactions with potential counterparties, raise future capital or attract key personnel to join us. As a result, our business and prospects would be materially harmed and our results of operations and financial condition would likely suffer materially. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">ZTlido and GLOPERBA may have undesirable properties that could result in significant negative consequences, and our product candidates may cause undesirable side effects that could delay or prevent their regulatory approval. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As is the case with pharmaceuticals generally, it is likely that there may be side effects and adverse events associated with ZTlido, GLOPERBA and our product candidates. In the event that ZTlido or GLOPERBA is </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">32 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
identified to have undesirable side effects, a number of potentially significant negative consequences could occur. Regulatory authorities may withdraw their approval of the product or seize the product. Restrictions may be imposed on the manufacturing or marketing of ZTlido or GLOPERBA or any component thereof, including the imposition of a REMS plan that may require creation of a Medication Guide outlining the risks of such side effects for distribution to patients, as well as elements to assure safe use of the product, such as a patient registry and training and certification of prescribers. Any of these events could damage our reputation and prevent us from achieving or maintaining market acceptance of ZTlido or GLOPERBA. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the clinical trials we conduct with our product candidates, patients may experience changes in their health, including illnesses, injuries, discomforts or a fatal outcome. Often, it is not possible to determine whether the product candidate being studied caused or was associated with these conditions. In addition, it is possible that as we test our clinical products in larger, longer and more extensive clinical programs, or as use of these product candidates becomes more widespread if they receive regulatory approval, illnesses, injuries, discomforts and other adverse events that were observed in earlier clinical trials, as well as conditions that did not occur or went undetected in previous clinical trials, will be reported by subjects. Many times, side effects are only detectable after investigational products are tested in large-scale, Phase 3 clinical trial. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that our product candidates reveal an unacceptable severity and prevalence of these or other side effects, the clinical trials could be suspended or terminated and the FDA could order us to cease further development of or deny approval of our product candidates, for any or all targeted indications. The drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may harm our business, financial condition and results of operations significantly. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">ZTlido, GLOPERBA and our product candidates are complex and difficult to manufacture. We could experience delays in satisfying regulatory authorities or manufacturing problems that result in delays in our development or commercialization programs, limit the supply of our product candidates, or otherwise harm our business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently depend on contract manufacturers to conduct the manufacturing and supply activities for ZTlido, GLOPERBA and our product candidates. Manufacturing these product candidates require facilities specifically designed for and validated for this purpose and sophisticated quality assurance and quality control procedures are necessary. Several factors could cause production interruptions, including equipment malfunctions, facility contamination, raw material shortages or contamination, natural disasters, disruption in utility services, human error or disruptions in the operations of our suppliers. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If contaminations are discovered in our supply of ZTlido, GLOPERBA or our product candidates or in the manufacturing facilities, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. We may not be successful in securing additional sources at all or on a timely basis, which could materially harm our development timelines. Any delay or interruption in the supply of clinical trial supplies could delay the completion of clinical trials, increase the costs associated with maintaining clinical trial programs and, depending upon the period of delay, require us to begin new clinical trials at additional expense or terminate clinical trials completely. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, there are risks associated with large scale manufacturing for clinical trials or commercial scale including, among others, cost overruns, potential problems with process <span style="white-space:nowrap">scale-up,</span> process reproducibility, stability issues, compliance with cGMP, lot consistency and timely availability of raw materials. Slight deviations in the manufacturing process, including those affecting quality attributes and stability, may result in unacceptable changes in the product that could result in lot failures or product recalls. Lot failures or product recalls could cause us to delay clinical trials or product launches, which could be costly to us and otherwise harm our business, financial condition and results of operations. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">33 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, our manufacturers may encounter problems hiring and retaining the experienced scientific, quality assurance, quality-control and manufacturing personnel needed to operate our complex manufacturing processes, which could result in delays in production or difficulties in maintaining compliance with applicable regulatory requirements. Any problems in our manufacturing process or facilities could make us a less attractive collaborator for potential partners, including larger biotechnology companies and academic research institutions, which could limit our access to additional attractive development programs. Problems in our manufacturing process could restrict our ability to meet potential future market demand for products, which could harm our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_14">Risks Related to our Business and Operations </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we are unable to retain our key executives, it may delay our development efforts and harm our business, financial condition and results of operations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our industry has experienced a high rate of turnover of management personnel in recent years. If we are not able to attract, retain and motivate key executives to accomplish our business objectives, we may experience constraints that will significantly impede our ability to raise additional capital and our ability to implement our overall business strategy. In particular, we are highly dependent upon our executive officers, including Jaisim Shah, our President and Chief Executive Officer, Henry Ji, Ph.D., our Executive Chairperson, and Elizabeth Czerepak, our Executive Vice President, Chief Financial Officer and Chief Business Officer. The loss of services of these executive officers could delay or prevent the successful development of our product pipeline, completion of our planned clinical trials and the successful commercialization of ZTlido and GLOPERBA. We do not carry &#8220;key person&#8221; insurance on any of our executive officers or other employees. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Competition for key executives in the biotechnology and pharmaceuticals field is intense, due to the limited number of individuals who possess the skills and experience required by our industry. Many of the pharmaceutical companies against which we compete for qualified personnel have greater financial and other resources, different risk profiles and a longer history in the industry than we do. They may also provide more diverse opportunities and better chances for career advancement. Some of these characteristics may be more appealing to qualified candidates than what we have to offer. In addition, we may experience employee turnover as a result of the ongoing &#8220;great resignation&#8221; occurring throughout the U.S. economy, which has impacted job market dynamics. New hires require training and take time before they achieve full productivity. New employees may not become as productive as we expect, and we may be unable to hire or retain sufficient numbers of qualified individuals. Moreover, we conduct our operations in the San Francisco Bay Area, a region that is home to many other biopharmaceutical companies as well as many academic and research institutions, resulting in fierce competition for qualified personnel. As such, we could have difficulty attracting and retaining experienced executives and may be required to expend significant financial resources in our recruitment and retention efforts. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may need to increase the size of our company and may not effectively manage our growth. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September&#160;30, 2022, we had approximately 85 full-time employees. We may need to continue to expand our managerial, operational, sales and marketing, finance and other resources in order to manage our operations, clinical trials, research and development activities, regulatory filings, manufacturing and supply activities, and any marketing and commercialization activities, including <span style="white-space:nowrap">co-promotion</span> activities. Future growth would impose significant added responsibilities on members of management, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">identifying, recruiting, integrating, maintaining and motivating additional employees; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">managing our internal development efforts effectively, including the clinical, FDA and internal regulatory review process for our product candidates, while complying with our contractual obligations to contractors and other third parties; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">improving our operational, financial and management controls, reporting systems and procedures. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">34 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our future financial performance and our ability to commercialize our product candidates will depend, in part, on our ability to effectively manage any future growth, if any, which may cause a significant strain on our management, and our operational, financial and other resources. Our ability to manage our growth effectively will require us to implement and improve our operational, financial and management systems and to expand, train, manage and motivate our employees. These demands may require the hiring of additional management personnel and the development of additional expertise by management. Any increase in resources devoted to research and product development without a corresponding increase in our operational, financial and management systems could have a material adverse effect on our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our insurance policies are expensive and protect us only from some business risks, which leaves us exposed to significant uninsured liabilities. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we endeavor to obtain appropriate insurance coverage for insurable risks that we identify, we do not carry insurance for all categories of risk that our business may encounter. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Insurance coverage is becoming increasingly expensive. We have observed rapidly changing conditions in the insurance markets relating to nearly all areas of traditional corporate insurance. Such conditions have resulted in higher premium costs, higher policy deductibles and lower coverage limits. We may not be able to maintain insurance coverage at a reasonable cost, or in sufficient amounts to protect us against losses due to liability. While we maintain property, casualty and general liability coverage, we do not carry specific biological or hazardous waste insurance coverage and our insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. Accordingly, in the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not know if we will be able to maintain existing insurance with adequate levels of coverage. Any significant uninsured liability may require us to pay substantial amounts, which would adversely affect our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Manufacturing and marketing of ZTlido and clinical testing of our product candidates may expose us to individual product liability claims, class action lawsuits or actions, and other individual or mass tort claims. For example, we may be sued if any product we develop allegedly causes injury or is found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. In addition, physicians may misuse our products with their patients if they are not adequately trained, potentially leading to injury and increased risk of product liability. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of risks inherent in the product, negligence, strict liability and a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our product candidates, if approved. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">loss of revenue from product sales; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">decreased demand for our product candidates or products that we develop; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">injury to our reputation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">withdrawal of clinical trial participants; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">initiation of investigations by regulators; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">35 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">restrictions on labeling, the marketing or manufacturing of the product, withdrawal of the product from the market or voluntary or mandatory product recalls; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">costs to defend the related litigation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a diversion of management&#8217;s time and our resources; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">substantial monetary awards to trial participants or patients; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the inability to commercialize our product candidates. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our inability to obtain and maintain sufficient product liability insurance at an acceptable cost and scope of coverage to protect against potential product liability claims could prevent or inhibit the commercialization of any products we develop. We currently carry product liability insurance covering use in our clinical trials in the amount of $10.0&#160;million in the aggregate. Although we maintain such insurance, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. Our insurance policies also have various exclusions and deductibles, and we may be subject to a product liability claim for which we have no coverage. We will have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Moreover, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Any disruption in our research and development facilities could adversely affect our business, financial condition and results of operations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our principal executive offices are in the San Francisco Bay Area, California. Our facilities may be affected by natural or <span style="white-space:nowrap">man-made</span> disasters. Earthquakes are of particular significance since our facilities are located in an earthquake-prone area. We are also vulnerable to damage from other types of disasters, including power loss, attacks from extremist organizations, fires, floods and similar events. If our facilities are affected by a natural or <span style="white-space:nowrap">man-made</span> disaster, we may be forced to curtail our operations and/or rely on third-parties to perform some or all of our research and development activities. Although we believe we possess adequate insurance for damage to our property and the disruption of our business from casualties, such insurance may not be sufficient to cover all of our potential losses and may not continue to be available to us on acceptable terms, or at all. In the future, we may choose to expand our operations in either our existing facilities or in new facilities. If we expand our worldwide manufacturing locations, there can be no assurance that this expansion will occur without implementation difficulties, or at all. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may seek to grow our business through acquisitions and may fail to realize the anticipated benefits of any acquisition, and acquisitions can be costly and dilutive. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success depends on our ability to continually enhance and broaden our product offerings in response to changing customer demands, competitive pressures, technologies and market pressures. Accordingly, from time to time we may expand our business and intellectual property portfolio through the acquisition of new businesses and technologies. We cannot assure that we will achieve anticipated benefits from any acquisition to justify the transaction. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Competition within our industry for acquisitions of businesses, technologies and assets may become intense. Even if we are able to identify an acquisition that we would like to consummate, we may not be able to complete the acquisition on commercially reasonable terms or the target may be acquired by another company. We may enter into negotiations for acquisitions that are not ultimately consummated. Those negotiations could result in diversion of management time and significant <span style="white-space:nowrap"><span style="white-space:nowrap">out-of-pocket</span></span> costs. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The success of any acquisition depends on, among other things, our ability to combine our business with an acquired business in a manner that does not materially disrupt existing relationships and that allows us to achieve </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">36 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
development and operational synergies. If we are unable to achieve these objectives, the anticipated benefits of an acquisition may not be realized fully, or at all, or may take longer to realize than expected. In particular, if we undertake such a transaction, we may issue dilutive securities, assume or incur debt obligations, incur large <span style="white-space:nowrap">one-time</span> expenses or acquire intangible assets that could result in significant future amortization expenses. As a result, an acquisition may not be accretive to our stock value or development pipeline in the near or long term. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to incur higher development and regulatory costs, and additional costs integrating the operations and personnel of any companies we acquire, which cannot be estimated accurately at this time. If the total costs of the integration of our companies and advancement of acquired product candidates and technologies exceed the anticipated benefits of the acquisition, our business, financial condition and results of operations could be adversely affected. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">International components of our business expose us to business, legal, regulatory, political, operational, financial and economic risks associated with conducting business outside of the United States. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently collaborate with international manufacturing partners and may potentially expand our business internationally in the future. The purchase and shipment of components from international sources subjects us to U.S. and foreign governmental trade, import and export, and customs regulations and laws. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Compliance with these regulations and laws is costly and exposes us to penalties for <span style="white-space:nowrap">non-compliance.</span> Other laws and regulations that can significantly impact us include various anti-bribery laws, including the U.S. Foreign Corrupt Practices Act (the &#8220;FCPA&#8221;), as well as export controls laws. Any failure to comply with applicable legal and regulatory obligations could impact us in a variety of ways that include, but are not limited to, significant criminal, civil and administrative penalties, including imprisonment of individuals, fines and penalties, denial of export privileges, seizure of shipments, restrictions on certain business activities and exclusion or debarment from government contracting. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Conducting business internationally involves a number of risks, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">multiple, sometimes conflicting and changing laws and regulations such as tax laws, export and import restrictions, employment laws, anti-bribery and anti-corruption laws, regulatory requirements and other governmental approvals, permits and licenses; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">difficulties in enforcing our intellectual property rights and in defending against third-party threats and intellectual property enforcement actions against us, our distributors or any of our third-party suppliers; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">failure by us or our distributors to obtain appropriate licenses or regulatory approvals for the sale or use of our product candidates, if approved, in various countries; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">difficulties in managing foreign operations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">foreign currency exchange rate fluctuations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes in duties and tariffs, license obligations and other <span style="white-space:nowrap">non-tariff</span> barriers to trade; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the imposition of new trade restrictions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">difficulties in enforcing agreements and collecting receivables through certain foreign legal systems; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">complexities associated with managing multiple payor-reimbursement regimes or <span style="white-space:nowrap">self-pay</span> systems; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">natural disasters, political and economic instability, including wars, terrorism and political unrest, outbreak of disease, boycotts, curtailment of trade and other business restrictions; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">failure to comply with the FCPA, including its books and records provisions and its anti-bribery provisions, and similar anti-bribery and anti-corruption laws in other jurisdictions, for example by failing to maintain accurate information and control over sales or distributors&#8217; activities. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">37 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of these risks, if encountered, could significantly harm our future international expansion and operations and, consequently, negatively impact our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The increasing use of social media platforms presents new risks and challenges. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Social media is increasingly being used to communicate about our research, product candidates, investigational medicines and the diseases our product candidates and investigational medicines are being developed to treat. Social media practices in the biopharmaceutical industry continue to evolve and regulations relating to such use are not always clear. This evolution creates uncertainty and risk of <span style="white-space:nowrap">non-compliance</span> with regulations applicable to our business, resulting in potential regulatory actions against us. For example, patients may use social media channels to comment on their experience in an ongoing blinded clinical study or to report an alleged adverse event. When such disclosures occur, there is a risk that we may fail to monitor and comply with applicable adverse event reporting obligations or we may not be able to defend our business or the public&#8217;s legitimate interests in the face of the political and market pressures generated by social media due to restrictions on what we may say about our product candidates. There is also a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us on any social networking website. Furthermore, our employees, affiliates and/or business partners may use social media for their personal use, and their activities on social media or in other forums could result in adverse publicity for us. Any negative publicity as a result of social media posts, whether or not such claims are accurate, could adversely impact us. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face regulatory actions, or incur other harm to our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our business and operations would suffer in the event of system failures. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Despite the implementation of security measures, our internal computer systems and those of our CROs and other contractors and consultants are vulnerable to damage from computer viruses, unauthorized access, cybersecurity attacks or hacking, natural disasters, terrorism, war and telecommunication and electrical failures. While we have not experienced any such system failure, accident or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our product development programs or a loss of our trade secrets or other proprietary information. For example, the loss of clinical trial data from completed or ongoing or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur material legal claims and liability, damage to our reputation, suffer loss or harm to our intellectual property rights and the further research, development and commercial efforts of ZTlido, GLOPERBA and our product candidates, if approved, could be delayed. If we are held liable for a claim against which we are not insured or for damages exceeding the limits of our insurance coverage, whether arising out of cybersecurity matters, or from some other matter, that claim could have a material adverse effect on our business, financial condition and results of operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, a cybersecurity attack, data breach or privacy violation that leads to disclosure or modification of, or prevents access to, patient information, including personally identifiable information or protected health information, could harm our reputation, compel us to comply with federal and/or state breach notification laws and foreign law equivalents, subject us to mandatory corrective action, require us to verify the correctness of database contents and otherwise subject us to liability under laws and regulations that protect personal data, resulting in increased costs or loss of revenue. Our ability to effectively manage and maintain our internal business information, and to ship products to customers and invoice them on a timely basis, depends significantly on our enterprise resource planning system and other information systems. Portions of our information technology systems may experience interruptions, delays or cessations of service or produce errors in connection with ongoing systems implementation work. Cybersecurity attacks in particular are evolving and include, but are not limited to, threats, malicious software, ransom ware, attempts to gain unauthorized access to data and other electronic security breaches that could lead to disruptions in systems, misappropriation of confidential or </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">38 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
otherwise protected information and corruption of data. If we are unable to prevent such cybersecurity attacks, data security breaches or privacy violations or implement satisfactory remedial measures, our operations could be disrupted, and we may suffer loss of reputation, governmental investigations, claims or litigation that may not be covered by insurance, financial loss and other regulatory penalties because of lost or misappropriated information, including sensitive patient data. In addition, these breaches and other inappropriate access can be difficult to detect, and any delay in identifying them may lead to increased harm of the type described above. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and results of operations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As widely reported, global credit and financial markets have experienced volatility and disruptions in the past several years and especially in 2020 and 2021 due to the impacts of the <span style="white-space:nowrap">COVID-19</span> pandemic, including severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. For example, an overall decrease in or loss of insurance coverage among individuals in the United States as a result of unemployment, underemployment or the repeal of certain provisions of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (the &#8220;ACA&#8221;), may decrease the demand for healthcare services and pharmaceuticals. If fewer patients seek medical care because they do not have insurance coverage, we may experience difficulties in any eventual commercialization of our product candidates and our business, results of operations, financial condition and cash flows could be adversely affected. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There can be no assurances that further deterioration in credit and financial markets and confidence in economic conditions will not occur. Our general business strategy may be adversely affected by any such economic downturn, volatile business environment or continued unpredictable and unstable market conditions. If the current equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult, more costly and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our growth strategy, financial performance and price of our Common Stock, and could require us to delay or abandon clinical development plans. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our ability to effectively monitor and respond to the rapid and ongoing developments and expectations relating to the environmental, social and governance matters, including related social expectations and concerns, may impose unexpected costs or results in reputational or other harm that could have a material adverse effect on our business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is an increasing focus from certain investors, employees, regulators, listing exchanges and other stakeholders concerning corporate responsibility and sustainability matters, specifically related to environmental, social and governance (&#8220;ESG&#8221;) factors. Some investors and investor advocacy groups may use these factors to guide investment strategies and, in some cases, investors may choose not to invest in us if they believe our policies relating to corporate responsibility are inadequate. Third-party providers of corporate responsibility ratings and reports on companies have increased to meet growing investor demand for measurement of corporate responsibility performance, and a variety of organizations currently measure the performance of companies on such ESG topics, and the results of these assessments are widely publicized. Investors, particularly institutional investors, use these ratings to benchmark companies against their peers, and major institutional investors have publicly emphasized the importance of ESG measures to their investment decisions. Topics taken into account in such assessments include, among others, companies&#8217; efforts and impacts on climate change and human rights, ethics and compliance with law, diversity and the role of companies&#8217; board of directors in supervising various sustainability issues. In light of investors&#8217; increased focus on ESG matters, if we are perceived as lagging with respect to ESG initiatives, these investors may engage with us to improve ESG disclosures or performance and may also make voting decisions, or take other actions, to hold us and our Board accountable. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, there are rapid and ongoing developments and changing expectations relating to ESG matters, and the criteria by which our corporate responsibility practices are assessed may change, which could result in </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">39 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
greater expectations of us and cause us to undertake costly initiatives to satisfy such new criteria. If we elect not to or are unable to adequately recognize and respond to such developments and governmental, societal, investor and consumer expectations relating to such ESG matters, we may miss corporate opportunities, become subject to additional scrutiny or incur unexpected costs. We may face risk of litigation or reputational damage in the event that our corporate responsibility procedures or standards do not meet the standards set by various constituencies. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may also face reputational damage if we are unable to achieve an acceptable ESG or sustainability rating from third-party rating services. A low ESG or sustainability rating by a third-party rating service could also result in the exclusion of our Common Stock from consideration by certain investors who may elect to invest with our competitors instead. Ongoing focus on corporate responsibility matters by investors and other parties as described above may impose additional costs or expose us to new risks. Any failure or perceived failure by us in this regard could have a material adverse effect on our reputation and on our business, financial condition or results of operations, including the sustainability of our business over time, and could cause the market value of our Common Stock to decline. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, our emphasis on ESG issues may not maximize short-term financial results and may yield financial results that conflict with the market&#8217;s expectations. We may in the future make business decisions that may reduce our short-term financial results if we believe that the decisions are consistent with our ESG goals, which we believe will improve our financial results over the long-term. These decisions may not be consistent with the short-term expectations of our stockholders and may not produce the long-term benefits that we expect, in which case our business, financial condition and results of operations could be harmed. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_15">Risks Related to Scilex&#8217;s Intellectual Property </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We are substantially dependent on the intellectual property we <span style="white-space:nowrap">in-license</span> from Oishi and Itochu, and if we lose the right to license such intellectual property or if the Product Development Agreement is terminated for any reason, our ability to commercialize ZTlido and develop and commercialize <span style="white-space:nowrap">SP-103</span> would be harmed. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business is substantially dependent upon the intellectual property licensed from Oishi and Itochu. Pursuant to the Product Development Agreement, we have been granted an exclusive, worldwide license (except with respect to Japan) under current and future intellectual property rights relating to ZTlido and <span style="white-space:nowrap">SP-103</span> lidocaine tape products and the lidocaine in such products, including, among other things: (1)&#160;any patent applications, continuation applications, any issued or issuing patents, as well as any foreign patent applications, (2)&#160;all <span style="white-space:nowrap">know-how,</span> work product, trade secrets, invents, data, processes, techniques, procedures, compositions, devices, methods, formulas, protocols and information, whether patentable or not, (3)&#160;copyrightable works, copyrights and applications, registrations and renewals, (4)&#160;logos, trademarks, service marks, and all applications and registrations relating thereto, (5)&#160;other proprietary rights, (6)&#160;abbreviated new drug applications or other applications to market, and (7)&#160;any regulatory exclusivities or supplemental protection certificates. Our ability to commercialize ZTlido and develop <span style="white-space:nowrap">SP-103</span> depends on the effectiveness and continuation of the Product Development Agreement. If we lose the right to license the intellectual property rights granted by the Product Development Agreement, our ability to develop ZTlido and <span style="white-space:nowrap">SP-103</span> as well as new product candidates based on the licensed intellectual property would be harmed. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Product Development Agreement imposes various development, regulatory and/or commercial diligence obligations, payments and other obligations. Oishi and Itochu have the right to terminate the Product Development Agreement under certain circumstances, including, among other things: (1)&#160;if we are in material breach of the agreement and the breach is not curable or if the breach is curable and we fail to cure such material breach within 180 days after notice requesting to cure; (2)&#160;if, at any time during the term of the Product Development Agreement, the market conditions are such that (a)&#160;our total net profits for ZTlido and <span style="white-space:nowrap">SP-103</span> are equal to or less than five percent of our net sales of ZTlido and <span style="white-space:nowrap">SP-103</span> for a period of four or more consecutive quarters, or (b)&#160;the economic viability of ZTlido and <span style="white-space:nowrap">SP-103</span> is affected significantly as evidenced by </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">40 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
documentation and substantial information by any external circumstances deemed detrimental to all parties as agreed to by us, on the one hand, and Oishi and Itochu, on the other hand, and the parties are unable to resolve the concerns under the foregoing clauses (a)&#160;and (b)&#160;after 30 days of good-faith discussion; and (3)&#160;in the event of our bankruptcy or assignment for the benefit of creditors. As of the date of this prospectus, Scilex&#8217;s net profits for ZTlido and <span style="white-space:nowrap">SP-103</span> have not exceeded five percent of net sales. Accordingly, Oishi and Itochu have the right to terminate the Product Development Agreement and Commercial Supply Agreement. As of the date of this prospectus, neither Oishi nor Itochu has exercised its right of termination. If the Product Development Agreement is terminated for certain reasons, such as our material breach of the agreement, our bankruptcy, or lack of economic viability, we will be required to transfer all licensed intellectual property rights, including those relating to ZTlido and <span style="white-space:nowrap">SP-103,</span> to Oishi and Itochu or their designee, at our own cost and expense. The loss of such licenses could materially harm our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We recently entered into the Romeg Agreement for the <span style="white-space:nowrap">in-licensing</span> of certain intellectual property rights from Romeg with respect to the commercialization of GLOPERBA, and if we lose the right to license such intellectual property or if the Romeg Agreement is terminated for any reason, our ability to commercialize GLOPERBA would be harmed. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recently entered into the Romeg Agreement for the <span style="white-space:nowrap">in-licensing</span> of certain intellectual property rights from Romeg with respect to the commercialization of GLOPERBA. Pursuant to the Romeg Agreement, we have been granted (1)&#160;the right to manufacture, promote, market, distribute and sell pharmaceutical products comprising liquid formulations of colchicine for the prophylactic treatment of gout in adult humans in the United States and (2)&#160;an exclusive, transferable license to use the trademark &#8220;GLOPERBA.&#8221; Under the Romeg Agreement, among other things, Romeg granted us (1)&#160;a transferable license, with the right to sublicense, under the patents and <span style="white-space:nowrap">know-how</span> specified therein to (a)&#160;commercialize the pharmaceutical product comprising liquid formulations of colchicine for the prophylactic treatment of gout in adult humans (the &#8220;Initial Licensed Product&#8221;) in the United States (including its territories) (the &#8220;Territory&#8221;), (b) develop other products comprising the Initial Licensed Product as an active pharmaceutical ingredient (together with the Initial Licensed Product, the &#8220;Licensed Products&#8221;) and commercialize any such products and (c)&#160;manufacture Licensed Products anywhere in the world, solely for commercialization in the Territory; and (2)&#160;an exclusive, transferable license, with right to sublicense, to use the trademark &#8220;GLOPERBA&#8221; and logos, designs, translations, and modifications thereof in connection with the commercialization of the Initial Licensed Product solely in the Territory. The license to <span style="white-space:nowrap">know-how</span> is exclusive for purposes of developing and commercializing Licensed Products in the Territory during the royalty term, but is otherwise <span style="white-space:nowrap">non-exclusive.</span> The license to patents is exclusive for purposes of developing and commercializing Licensed Products in the Territory until July&#160;1, 2027 and, thereafter, is <span style="white-space:nowrap">co-exclusive</span> with Granules Pharmaceuticals, Inc. for the royalty term for such purposes. The royalty term begins on the date of the agreement and ends on the later of (i)&#160;expiration of the last to expire of the patents that covers the manufacture or commercialization of the Licensed Products in the Territory or (ii)&#160;the tenth anniversary of the date of the Romeg Agreement. Our ability to commercialize GLOPERBA and develop Licensed Products depends on the effectiveness and continuation of the Romeg Agreement. If we lose the right to license the intellectual property rights granted by the Romeg Agreement, our ability to develop GLOPERBA as well as new product candidates based on the licensed intellectual property would be harmed. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Romeg Agreement imposes various development, regulatory and/or commercial diligence obligations, payments and other obligations. Romeg has the right to terminate the Romeg Agreement under certain circumstances, including, among other things: (a)&#160;in the event we are in material breach of the Romeg Agreement, unless we have cured any such breach within 60 days after any notice thereof was provided; (b)&#160;upon notice to us, if we fail to timely pay any milestone payment, percentage royalties or minimum quarterly royalties or fail to timely deliver the requisite quarterly report, which termination will be effective 30 days after the date of such notice, unless we have made such payment in full or delivered such quarterly report within such 30 day period; (c)&#160;immediately, if we challenge the licensed patents under any court action or proceeding or before any patent office or assist any third party to conduct any of these activities; (d)&#160;by written notice to us if sales of Licensed Products do not commence or continue within specified periods agreed to by the parties; or (e)&#160;in the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">41 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
event of our bankruptcy or assignment for the benefit of creditors. If the Romeg Agreement is terminated for certain reasons, such as our material breach of the agreement, our bankruptcy, or our failure to timely pay milestone payments, we will be required upon Romeg&#8217;s request to transfer all licensed intellectual property rights, including those relating to the GLOPERBA and the Licensed Products, to Romeg or their designee, within thirty days after the termination of the Romeg Agreement at a price to be agreed upon by the parties. The loss of such licenses could materially harm our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Potential disputes over intellectual property rights that we have licensed may prevent or impair our ability to maintain our current licensing arrangements on acceptable terms. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Licensing of intellectual property rights is of high importance to our business and involves complex legal, business and scientific issues. Disputes may arise between us and our licensors regarding intellectual property rights subject to a license agreement, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the scope of rights granted under the license agreement and other interpretation-related issues; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our financial or other obligations under the license agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">whether and the extent to which our technology and processes infringe on intellectual property rights of the licensor that are not subject to the licensing agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our right to sublicense intellectual property rights to third parties under collaborative development relationships; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our product candidates, and what activities satisfy those diligence obligations; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the ownership of inventions and <span style="white-space:nowrap">know-how</span> resulting from the joint creation or use of intellectual property by our licensors and us and our partners. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If disputes over intellectual property rights that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, our business, financial condition and results of operations may be adversely affected. We may enter into additional licenses in the future and if we fail to comply with obligations under those agreements, we could suffer adverse consequences. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, if our licenses are terminated, or if the underlying patents fail to provide the intended exclusivity, competitors or other third parties would have the freedom to seek regulatory approval of, and to market, products identical or competitive to ours and we may be required to cease our development and commercialization of certain of our product candidates, if approved. Moreover, if disputes over intellectual property that we license prevent or impair our ability to maintain other licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates. Any of the foregoing could have a material adverse effect on our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we are unable to maintain patent protection for ZTlido, GLOPERBA and our product candidates, or if the scope of the patent protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely upon a combination of patents, trademarks, trade secret protection, and confidentiality agreements to protect the intellectual property related to ZTlido, GLOPERBA and our product candidates. Our success depends in part on our ability to obtain and maintain patent protection in the United States, for GLOPERBA, and in the United States and other countries with respect to ZTlido and our product candidates. We seek to protect our proprietary position by filing and/or <span style="white-space:nowrap">in-licensing</span> patent applications in the United States and abroad related to our development programs and product candidates. The patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">42 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patents and patent applications that we own or <span style="white-space:nowrap">in-license</span> may fail to result in issued patents with claims that protect ZTlido, GLOPERBA and our product candidates in the United States or in other foreign countries. There is no assurance that all of the potentially relevant prior art relating to our patents and patent applications has been found, which can prevent a patent from issuing from a pending patent application, or be used to invalidate a patent. Even if patents do successfully issue and even if such patents cover ZTlido, GLOPERBA and our product candidates, third parties may challenge their validity, enforceability or scope, which may result in such patents being narrowed, invalidated or held unenforceable. Any successful opposition to these patents or any other patents owned by or licensed to us could deprive us of rights necessary for the successful commercialization of any product candidates that we may develop. Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product candidate under patent protection could be reduced. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or any of our potential future collaborators will be successful in protecting our product candidates by obtaining and defending patents. These risks and uncertainties include the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the U.S. Patent and Trademark Office (&#8220;PTO&#8221;) and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent process, the <span style="white-space:nowrap">non-compliance</span> with which can result in abandonment or lapse of a patent or patent application, and partial or complete loss of patent rights in the relevant jurisdiction; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">patent applications may not result in any patents being issued; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">patents may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable or otherwise may not provide any competitive advantage; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our competitors, many of whom have substantially greater resources than we do and many of whom have made significant investments in competing technologies, may seek or may have already obtained patents that will limit, interfere with or block our ability to make, use and sell our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">there may be significant pressure on the U.S. government and international governmental bodies to limit the scope of patent protection both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">countries other than the United States may have patent laws less favorable to patentees than those upheld by U.S. courts, allowing foreign competitors a better opportunity to create, develop and market competing products; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">other parties may have designed around our claims or developed technologies that may be related or competitive to our platform, may have filed or may file patent applications and may have received or may receive patents that overlap or conflict with our patent applications, either by claiming the same methods or devices or by claiming subject matter that could dominate our patent position; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any successful opposition to any patents owned by or licensed to us could deprive us of rights necessary for the practice of our technologies or the successful commercialization of any products or product candidates that we may develop; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">because patent applications in the United States and most other countries are confidential for a period of time after filing, we cannot be certain that we or our licensors were the first to file any patent application related to our product candidates, proprietary technologies and their uses; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an interference proceeding can be provoked by a third party or instituted by the PTO to determine who was the first to invent any of the subject matter covered by the patent claims of our applications for any application with an effective filing date before March&#160;16, 2013. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent prosecution process is also expensive and time-consuming, and we and our licensors may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">43 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or in all jurisdictions where protection may be commercially advantageous. It is also possible that we and our licensors will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the patent applications we hold or <span style="white-space:nowrap">in-license</span> with respect to our development programs and product candidates fail to issue, if their breadth or strength of protection is threatened, or if they fail to provide meaningful exclusivity for ZTlido, GLOPERBA and our product candidates, it could dissuade other companies from collaborating with us to develop product candidates, and threaten our ability to commercialize ZTlido, GLOPERBA and our product candidates. Any such outcome could have a materially adverse effect on our business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may not be successful in obtaining or maintaining necessary rights to product components and processes and brands for our development pipeline through acquisitions and <span style="white-space:nowrap">in-licenses.</span> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Presently we have intellectual property rights, through licenses from third parties related to ZTlido, <span style="white-space:nowrap">SP-103,</span> and GLOPERBA. Because our programs for ZTlido, GLOPERBA, <span style="white-space:nowrap">SP-103</span> and <span style="white-space:nowrap">SP-104</span> may require the use of additional proprietary rights held by third parties, the growth of our business will likely depend in part on our ability to acquire, <span style="white-space:nowrap">in-license</span> or use these proprietary rights. In addition, our product candidates may require specific formulations to work effectively and efficiently and these rights may be held by others. It may also be commercially advantageous to use trademarks held by others. We may be unable to acquire or <span style="white-space:nowrap">in-license</span> proprietary rights related to any compositions, formulations, methods of use, processes or other intellectual property rights from third parties that we identify as being necessary for our product candidates. Even if we are able to obtain a license to such proprietary rights, it may be <span style="white-space:nowrap">non-exclusive,</span> thereby giving our competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement technology. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Where we obtain licenses from or collaborate with third parties, we may not have the right to control the preparation, filing and prosecution of patent and trademark applications, or to maintain the patents covering technology that we license from third parties and associated trademark registrations, or such activities, if controlled by us, may require the input of such third parties. We may also require the cooperation of our licensors and collaborators to enforce any licensed patent rights, and such cooperation may not be provided. Therefore, these patents, trademarks and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business, in compliance with applicable laws and regulations, which may affect the validity and enforceability of such patents and trademarks, or any patents and trademark registrations that may issue from such applications. Moreover, if we do obtain necessary licenses, we will likely have obligations under those licenses, including making royalty and milestone payments, and any failure to satisfy those obligations could give our licensor the right to terminate the license. Termination of a necessary license, or expiration of licensed patents or patent applications, or loss of trademark rights, could have a material adverse impact on our business. Our business would suffer if any such licenses terminate, if the licensors fail to abide by the terms of the license, if the licensors fail to enforce licensed patents or trademarks against infringing third parties, if the licensed patents or other rights are found to be invalid or unenforceable, or if we are unable to enter into necessary licenses on acceptable terms. Furthermore, if any licenses terminate, or if the underlying patents fail to provide the intended exclusivity, competitors or other third parties may gain the freedom to seek regulatory approval of, and to market, products identical to ours. Moreover, our licensors may own or control intellectual property that has not been licensed to us and, as a result, we may be subject to claims, regardless of their merit, that we are infringing or otherwise violating the licensor&#8217;s rights. In addition, while we cannot currently determine the amount of the royalty obligations we would be required to pay on sales of future products, if any, the amounts may be significant. The amount of our future royalty obligations will depend on the technology and intellectual property we use in products that we successfully develop and commercialize, if any. Therefore, even if we successfully develop and commercialize products, we may be unable to achieve or maintain profitability. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The licensing and acquisition of third-party proprietary rights is a competitive area, and companies, which may be more established, or have greater resources than we do, may also be pursuing strategies to license or </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">44 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
acquire third-party proprietary rights that we may consider necessary or attractive in order to commercialize our product candidates. More established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. We may be unable to negotiate a license within the specified time frame or under terms that are acceptable to us. If we are unable to do so, the third-party may offer, on an exclusive basis, their proprietary rights to other parties, potentially blocking our ability to pursue our program. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us, either on reasonable terms, or at all. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment, or at all. If we are unable to successfully obtain rights to required third-party intellectual property rights on commercially reasonable terms, our ability to commercialize our products, and our business, financial condition and results of operations could suffer. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may become subject to claims challenging the inventorship or ownership of our patents and other intellectual property. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may be subject to claims that former employees (including former employees of our licensors), collaborators or other third parties have an interest in our patents or other intellectual property as an inventor or <span style="white-space:nowrap">co-inventor.</span> The failure to name the proper inventors on a patent application can result in the patents issuing thereon being unenforceable. Inventorship disputes may arise from conflicting views regarding the contributions of different individuals named as inventors, the effects of foreign laws where foreign nationals are involved in the development of the subject matter of the patent, conflicting obligations of third parties involved in developing our product candidates or as a result of questions regarding <span style="white-space:nowrap">co-ownership</span> of potential joint inventions. Litigation may be necessary to resolve these and other claims challenging inventorship and/or ownership. Alternatively, or additionally, we may enter into agreements to clarify the scope of our rights in such intellectual property. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Claims that we infringe, misappropriate, or violate the intellectual property rights of third parties may give rise to costly and lengthy litigation, and we could be prevented from selling products, forced to pay damages, and defend against litigation. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third parties may assert patent or other intellectual property infringement or misappropriation claims against us or our strategic partners, licensors or licensees with respect to ZTlido, GLOPERBA and our product candidates. If ZTlido, GLOPERBA or any of our product candidates, methods, processes and other technologies are alleged to infringe on or be improperly based on the proprietary rights of other parties, we could face adverse consequences. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The pharmaceutical and biotechnology industries have produced a proliferation of patents, and it is not always clear to industry participants, including us, which patents cover various types of products or methods of use. The coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform. We cannot assure that any of our current or future product candidates will not infringe existing or future patents. We may not be aware of patents that have already issued that a third party might assert are infringed by one of our current or future product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There may be third-party patents of which we are currently unaware with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. Because patent applications can take many years to issue and may be confidential for 18 months or more after filing, there may be currently pending third-party patent applications which may later result in issued patents that </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">45 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
our product candidates or our technologies may infringe, or which such third parties claim are infringed by the use of our technologies. Parties making claims against us for infringement or misappropriation of their intellectual property rights may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates. Defense of these claims, regardless of their merit, could involve substantial expenses and could be a substantial diversion of our valuable management and employee resources from our business. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we collaborate with third parties in the development of technology in the future, our collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to litigation or potential liability. Further, collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability. In the future, we may agree to indemnify our commercial collaborators against certain intellectual property infringement claims brought by third parties. Any claims of patent infringement asserted by third parties would be time-consuming and could: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">result in costly litigation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">divert the time and attention of our technical personnel and management; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">cause development delays; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">prevent us from commercializing our product candidates until the asserted patent expires or is held finally invalid or not infringed in a court of law; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">require us to develop <span style="white-space:nowrap">non-infringing</span> technology, which may not be possible on a cost-effective basis; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">require us to pay damages to the party whose intellectual property rights we may be found to be infringing, which may include treble damages if we are found to have been willfully infringing such intellectual property; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">require us to pay the attorney&#8217;s fees and costs of litigation to the party whose intellectual property rights we may be found to be infringing; and/or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">require us to enter into royalty or licensing agreements, which may not be available on commercially reasonable terms, or at all. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are sued for patent infringement, we would need to demonstrate that our products or methods either do not infringe the patent claims of the relevant patent or that the patent claims are invalid, and we may not be able to do either. Proving invalidity is difficult. For example, in the United States, proving invalidity requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. Even if we are successful in these proceedings, we may incur substantial costs and divert management&#8217;s time and attention in pursuing these proceedings, which could have a material adverse effect on us. If we are unable to avoid infringing the patent rights of others, we may be required to seek a license, which may not be available, defend an infringement action or challenge the validity of the patents in court. Patent litigation is costly and time-consuming. We may not have sufficient resources to bring these actions to a successful conclusion. In addition, if we do not obtain a license, develop or obtain <span style="white-space:nowrap">non-infringing</span> technology, fail to defend an infringement action successfully or have infringed patents declared invalid, we may incur substantial monetary damages, encounter significant delays in bringing our product candidates to market and be precluded from manufacturing or selling our product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot be certain that others have not filed patent applications for technology covered by our pending applications, or that we were the first to invent the technology, because: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">some patent applications in the United States may be maintained in secrecy until the patents are issued; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">patent applications in the United States and elsewhere can be pending for many years before issuance, or unintentionally abandoned patents or applications can be revived; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">46 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our technologies, our product candidates or the use of our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">identification of third-party patent rights that may be relevant to our technology is difficult because patent searching is imperfect due to differences in terminology among patents, incomplete databases and the difficulty in assessing the meaning of patent claims; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">patent applications in the United States are typically not published until 18 months after the priority date; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">publications in the scientific literature often lag behind actual discoveries. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, the scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#8217;s prosecution history and can involve other factors such as expert opinion. Our interpretation of the relevance or the scope of claims in a patent or a pending application may be incorrect, which may negatively impact our ability to market our products. Further, we may incorrectly determine that our technologies, products, or product candidates are not covered by a third-party patent or may incorrectly predict whether a third party&#8217;s pending patent application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the United States or internationally that we consider relevant may be incorrect, which may negatively impact our ability to develop and market our products or product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our competitors may have filed, and may in the future file, patent applications covering technology similar to ours, and others may have or obtain patents or proprietary rights that could limit our ability to make, use, sell, offer for sale or import our product candidates and future approved products or impair our competitive position. Numerous third-party U.S. and foreign issued patents and pending patent applications exist in the fields in which we are developing product candidates. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. Any such patent application may have priority over our patent applications, which could further require us to obtain rights to issued patents covering such technologies. If another party has filed a U.S. patent application on inventions similar to ours, we may have to participate in an interference proceeding declared by the PTO to determine priority of invention in the United States. The costs of these proceedings could be substantial, and it is possible that such efforts would be unsuccessful if, unbeknownst to us, the other party had independently arrived at the same or similar invention prior to our own invention, resulting in a loss of our U.S. patent position with respect to such inventions. Other countries have similar laws that permit secrecy of patent applications, and may be entitled to priority over our applications in such jurisdictions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we were to prevail, any litigation or administrative proceeding could be costly and time-consuming and would divert the attention of our management and key personnel from our business operations. Furthermore, as a result of a patent infringement suit brought against us or our strategic partners or licensees, we or our strategic partners or licensees may be forced to stop or delay developing, manufacturing or selling technologies, product candidates or potential products that are claimed to infringe a third party&#8217;s intellectual property unless that party grants us or our strategic partners&#8217; or licensees&#8217; rights to use its intellectual property. Ultimately, we may be unable to develop some of our product candidates or may have to discontinue development of a product candidate or cease some of our business operations as a result of patent infringement claims, which could severely harm our business, financial condition and results of operations. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">47 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time-consuming and unsuccessful. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Competitors may infringe our patents, trademarks, copyrights or other intellectual property. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming and divert the time and attention of our management and key personnel. For example, on June&#160;22, 2022, we filed a complaint against Aveva Drug Delivery Systems, Inc., Apotex Corp. and Apotex, Inc. (together, &#8220;Aveva&#8221;) in the U.S. District Court for the Southern District of Florida alleging infringement of certain Orange Book patents covering ZTlido. See the section titled &#8220;<span style="font-style:italic">Business &#8212; Legal Proceedings</span>&#8221; for additional information regarding such proceedings. Any claims we assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe their patents, in addition to counterclaims asserting that our patents are invalid or unenforceable, or both. In any patent infringement proceeding, there is a risk that a court will decide that a patent of ours is invalid or unenforceable, in whole or in part, and that we do not have the right to stop the other party from using the invention at issue. There is also a risk that, even if the validity of such patents is upheld, the court will construe the patent&#8217;s claims narrowly or decide that we do not have the right to stop the other party from using the invention at issue on the grounds that our patent claims do not cover the invention. An adverse outcome in a litigation or proceeding involving our patents could limit our ability to assert our patents against those parties or other competitors, and may curtail or preclude our ability to exclude third parties from making and selling similar or competitive products. Any of these occurrences could adversely affect our business, financial condition and results of operations. Similarly, if we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we establish infringement, the court may decide not to grant an injunction against further infringing activity and instead award only monetary damages, which may not be an adequate remedy. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, there can be no assurance that we will have sufficient financial or other resources to file and pursue such infringement claims, which typically last for years before they are concluded. Even if we ultimately prevail in such claims, the monetary cost of such litigation and the diversion of the attention of our management and scientific personnel could outweigh any benefit we receive as a result of the proceedings. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of the expense and uncertainty of litigation, we may conclude that even if a third party is infringing our issued patent, any patents that may be issued as a result of our pending or future patent applications or other intellectual property rights, the risk-adjusted cost of bringing and enforcing such a claim or action may be too high or not in the best interest of our company or our stockholders. In such cases, we may decide that the more prudent course of action is to simply monitor the situation or initiate or seek some other <span style="white-space:nowrap">non-litigious</span> action or solution. Any of the foregoing may have a material adverse effect on our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If our intellectual property rights are invalidated or circumvented, our business, financial condition and results of operations will be adversely affected. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our long-term success depends on our ability to continually discover, develop and commercialize innovative new pharmaceutical products. Without strong intellectual property protection, we would be unable to generate the returns necessary to support the enormous investments in research and development and capital as well as other expenditures required to bring new product candidates to the market and for commercialization. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Intellectual property protection varies throughout the world and is subject to change over time. In the United States, for small molecule drug products, such as ZTlido and GLOPERBA, the Hatch-Waxman Act provides </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">48 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
generic companies powerful incentives to seek to invalidate our pharmaceutical patents. As a result, we expect that our U.S. patents on major pharmaceutical products will be routinely challenged, and there can be no assurance that our patents will be upheld. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a distraction to management and other employees. We face generic manufacturer challenges to our patents outside the United States as well. In addition, competitors or other third parties may claim that our activities infringe patents or other intellectual property rights held by them. If successful, such claims could result in our being unable to market a product in a particular territory or being required to pay damages for past infringement or royalties on future sales. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition and our business, financial condition and results of operations may be adversely affected. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have registered trademarks with the PTO for the mark &#8220;ZTlido,&#8221; &#8220;SCILEX&#8221; and &#8220;RESPONSIBLE BY DESIGN,&#8221; and we have filed trademark applications for the marks &#8220;SEMNUR PHARMACEUTICALS&#8221; and &#8220;SEMDEXA&#8221; in the United States. We also have trademark registrations for ZTlido in the UK and Greece, we have a pending trademark application for ZTlido in China and we are appealing a decision refusing to register a trademark application for ZTlido in China. In China, we detected a third-party trademark registration for ZTlido and filed an invalidation proceeding &#8212; Invalidation of TM Registration No.&#160;36299669 &#8220;ZTlido&#8221; in Class&#160;5 in the name of


<img src="g428534g73e11.jpg" alt="LOGO" />
 (Qinhuangdao Hengjun Trading Co., Ltd.) (the &#8220;China ZTlido Trademark Invalidation Proceeding&#8221;). The China ZTlido Trademark Invalidation Proceeding is pending. Our trademarks or trade names may be challenged, infringed, diluted, tarnished, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors or other third parties may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement, dilution or tarnishment claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business, financial condition and results of operations may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Changes in patent laws or patent jurisprudence could diminish the value of patents in general, thereby impairing our ability to protect our product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As is the case with other biotechnology and pharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biotechnology and pharmaceutical industries involve both technological and legal complexity. Therefore, obtaining and enforcing biotechnology and pharmaceutical patents is costly, time-consuming and inherently uncertain. In addition, the America Invents Act (the &#8220;AIA&#8221;), which was passed in September 2011, resulted in significant changes to the U.S. patent system. An important change introduced by the AIA is that, as of March&#160;16, 2013, the United States transitioned from a <span style="white-space:nowrap"><span style="white-space:nowrap">&#8220;first-to-invent&#8221;</span></span> to a <span style="white-space:nowrap"><span style="white-space:nowrap">&#8220;first-to-file&#8221;</span></span> system for deciding which party should be granted a patent when two or more patent applications are filed by different parties claiming the same invention. Under a <span style="white-space:nowrap"><span style="white-space:nowrap">&#8220;first-to-file&#8221;</span></span> system, assuming the other requirements for patentability are met, the first inventor to file a patent application generally will be entitled to a patent on the invention regardless of whether another inventor had made the invention earlier. A third party that files a patent application in the PTO after that date but before us could therefore be awarded a patent covering an invention of ours even if we made the invention before it was made by the third party. This will require us to be cognizant going forward of the time from invention to filing of a patent application and diligent in filing patent applications, but circumstances could prevent us from promptly filing patent applications on our inventions. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">49 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Among some of the other changes introduced by the AIA are changes that limit where a patentee may file a patent infringement suit and providing opportunities for third parties to challenge any issued patent in the PTO. This applies to all of our U.S. patents, even those issued before March&#160;16, 2013. Because of a lower evidentiary standard in PTO proceedings compared to the evidentiary standard in U.S. federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a PTO proceeding sufficient for the PTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accordingly, a third party may attempt to use the PTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. It is not clear what, if any, impact the AIA will have on the operation of our business. However, the AIA and its implementation could increase the uncertainties and costs surrounding the prosecution of our or our licensors&#8217; patent applications and the enforcement or defense of our or our licensors&#8217; issued patents. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may become involved in opposition, interference, derivation, <span style="font-style:italic">inter partes </span>review or other proceedings challenging our or our licensors&#8217; patent rights, and the outcome of any proceedings are highly uncertain. An adverse determination in any such proceeding could reduce the scope of, or invalidate, our owned or <span style="white-space:nowrap">in-licensed</span> patent rights, allow third parties to commercialize ZTlido, GLOPERBA and our product candidates and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, the U.S. Supreme Court has ruled on several patent cases in recent years either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations, and there are other open questions under patent law that courts have yet to decisively address. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by Congress, the federal courts and the PTO, the laws and regulations governing patents could change in unpredictable ways and could weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. For example, the Biden administration recently indicated its support for a proposal at the World Trade Organization to waive patent rights with respect to <span style="white-space:nowrap">COVID-19</span> vaccines. Any waiver of our patent or other intellectual property protection by the U.S. and other foreign governments could have a material adverse effect on our competitive position, business, financial condition and results of operations. In addition, the European patent system is relatively stringent in the type of amendments that are allowed during prosecution, but, the complexity and uncertainty of European patent laws has also increased in recent years. Complying with these laws and regulations could limit our ability to obtain new patents in the future that may be important for our business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for <span style="white-space:nowrap">non-compliance</span> with these requirements. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The PTO and various foreign patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions to maintain patent applications and issued patents. For example, periodic maintenance fees on any issued patent are due to be paid to the PTO and other foreign patent agencies in several stages over the lifetime of the patent. The PTO and various foreign national or international patent agencies require compliance with a number of procedural, documentary, fee payment, and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which <span style="white-space:nowrap">non-compliance</span> can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. <span style="white-space:nowrap">Non-compliance</span> events that could result in abandonment or lapse of patent rights include, but are not limited to, failure to timely file national and regional stage patent applications based on our international patent application, failure to respond to official actions within </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">50 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
prescribed time limits, <span style="white-space:nowrap">non-payment</span> of fees, and failure to properly legalize and submit formal documents. If we or any of our licensors fail to maintain the patents or patent applications covering ZTlido, GLOPERBA and our product candidates, our competitors may be able to enter the market, which would have an adverse effect on our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Confidentiality agreements with employees may not adequately prevent disclosure of our trade secrets and other proprietary information and may not adequately protect our intellectual property, which could limit our ability to compete. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To help protect our proprietary <span style="white-space:nowrap">know-how</span> and our inventions for which patents may be unobtainable or difficult to obtain, or prior to seeking patent protection, we rely on trade secret protection and confidentiality agreements. To this end, we require all our employees to enter into agreements that prohibit the disclosure of confidential information and, where applicable, require disclosure and assignment to us of the ideas, developments, discoveries and inventions important to our business. These agreements typically limit the rights of the third parties to use or disclose our confidential information. We also typically obtain agreements from these parties that provide that inventions conceived by the party in the course of rendering services to us will be our exclusive property. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, current or former employees may unintentionally or willfully disclose our confidential information to competitors, and confidentiality agreements may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. The need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our competitive position is based, in part, on our <span style="white-space:nowrap">know-how</span> and trade secrets, a competitor&#8217;s discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have an adverse effect on our business, financial condition and results of operations. Enforcing a claim that a third party obtained illegally, and is using, trade secrets and/or confidential <span style="white-space:nowrap">know-how</span> is expensive, time-consuming and unpredictable, and the enforceability of confidentiality agreements may vary from jurisdiction to jurisdiction. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of our trade secrets, <span style="white-space:nowrap">know-how</span> or other proprietary information is disclosed, the value of our trade secrets, <span style="white-space:nowrap">know-how</span> and other proprietary rights would be significantly impaired and our business and competitive position would suffer. Moreover, our third-party licensing partners may retain rights in some of our proprietary or joint trade secrets, <span style="white-space:nowrap">know-how,</span> patented inventions or other proprietary information, including rights to sublicense and rights of publication, which may adversely impact our ability to obtain patents and protect trade secrets, <span style="white-space:nowrap">know-how</span> or other proprietary information. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may be subject to claims asserting that our employees, consultants or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of our employees, consultants or advisors are currently, or were previously, employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors, as well as our academic partners. Although we try to ensure that our employees, consultants and advisors do not use the proprietary information or <span style="white-space:nowrap">know-how</span> of others in their work for us, we may be subject to claims that these individuals or we have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#8217;s current or former employer. We may also be subject to claims that patents and applications that we may file to protect inventions of our employees or consultants are rightfully owned by their former employers or other third parties. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. An inability to incorporate such technologies or features would have a material adverse effect on our business, financial condition and results of operations and may prevent us from successfully commercializing ZTlido, GLOPERBA and our product candidates, if approved. Moreover, any such </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">51 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
litigation or the threat of such litigation may adversely affect our ability to hire employees or contract with independent contractors. A loss of key personnel or their work product could hamper or prevent our ability to commercialize ZTlido, GLOPERBA and our product candidates, if approved. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. Moreover, even when we obtain agreements assigning intellectual property to us, the assignment of intellectual property rights may not be self-executing or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. In addition, individuals executing agreements with us may have preexisting or competing obligations to a third party. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our position as a relatively small company may cause us to be at a significant disadvantage in defending our intellectual property rights and in defending against infringement claims by third parties. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Litigation relating to the ownership and use of intellectual property is expensive, and our position as a relatively small company in an industry dominated by very large companies may cause us to be at a significant disadvantage in defending our intellectual property rights and in defending against claims that ZTlido, GLOPERBA or any of our product candidates infringes or misappropriates third-party intellectual property rights. However, we may seek to use various post-grant administrative proceedings, including new procedures created under the AIA, to invalidate potentially overly-broad third-party rights. Even if we can defend our position, the cost of doing so may adversely affect our ability to grow, generate revenue or become profitable. In the course of the ongoing litigation or any future additional litigation to which we may be subject, we may not be able to protect our intellectual property at a reasonable cost, or at all. The outcome of litigation is always uncertain, and in some cases could include judgments against us that require us to pay damages, enjoin us from certain activities or otherwise affect our legal, contractual or intellectual property rights, which could have a significant adverse effect on our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Third-party claims of intellectual property infringement may prevent or delay our drug discovery and development efforts. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is a substantial amount of litigation involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including PTO administrative proceedings, such as <span style="font-style:italic">inter partes </span>reviews, and reexamination proceedings before the PTO or oppositions and revocations and other comparable proceedings in foreign jurisdictions. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that ZTlido, GLOPERBA or our product candidates may give rise to claims of infringement of the patent rights of others. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Despite safe harbor provisions, third parties may assert that we are employing their proprietary technology without authorization. There may be third-party patents, of which we are currently unaware, with claims to materials, formulations, methods of doing research, methods of manufacture or methods for treatment related to the use or manufacture of ZTlido, GLOPERBA or our product candidates. Because patent applications can take many years to issue, there may be currently pending unpublished patent applications which may later result in issued patents that ZTlido, GLOPERBA or our product candidates may infringe. In addition, third parties may obtain patents in the future and claim that the use of our technologies infringes these patents. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of ZTlido, GLOPERBA or any of our product candidates, any molecules formed during the manufacturing process or any final product itself, the holders of any such patents may be able to block our ability to commercialize such </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">52 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
product candidate unless we obtain a license under the applicable patents, or until such patents expire or they are finally determined to be held invalid or unenforceable. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Similarly, if any third-party patent were held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture or methods of use, including combination therapy or patient selection methods, the holders of any such patent may be able to block our ability to develop and commercialize the applicable product candidate unless we obtain a license, limit our uses, or until such patent expires or is finally determined to be held invalid or unenforceable. In either case, such a license may not be available on commercially reasonable terms, or at all. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further commercialize ZTlido and GLOPERBA, or develop and commercialize one or more of our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties, cease marketing ZTlido or GLOPERBA, or developing our product candidates, limit our uses, pay royalties or redesign our infringing product candidates, which may be impossible or require substantial time and monetary expenditure. We cannot predict whether any such license would be available at all or whether it would be available on commercially reasonable terms. Furthermore, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research or allow commercialization of ZTlido, GLOPERBA or our product candidates, if approved. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further commercialize ZTlido or GLOPERBA, or develop and commercialize one or more of our product candidates, which could harm our business, financial condition and results of operations significantly. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may be subject to claims that we have wrongfully hired an employee from a competitor or that we or our employees have wrongfully used or disclosed alleged confidential information or trade secrets of their former employers. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As is common in the biotechnology and pharmaceutical industries, in addition to our employees, we engage the services of consultants to assist us in the development of our product candidates. Many of these consultants, and many of our employees, were previously employed at, or may have previously provided or may be currently providing consulting services to, other pharmaceutical companies including our competitors or potential competitors. We may become subject to claims that we, our employees or a consultant inadvertently or otherwise used or disclosed trade secrets or other information proprietary to their former employers or their former or current clients. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely affect our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to our management team and other employees. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may not be able to protect our intellectual property rights throughout the world. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The requirements for patentability and the patent enforcement differ in many countries. Filing, prosecuting and defending patents on ZTlido and all of our product candidates throughout the world would be prohibitively expensive. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but enforcement in some countries is not as strong as that in the United States. These products may compete with ZTlido and our </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">53 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
product candidates, if approved, in jurisdictions where we do not have any issued patents and our patent claims or other intellectual property rights may not be effective or sufficient to prevent them from so competing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ongoing conflict in Ukraine and related sanctions could significantly devalue our Ukrainian and Russian, patent applications. Recent Russian decrees may significantly limit our ability to enforce Russian patents. We cannot predict when or how this situation will change. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many companies have encountered significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biopharmaceuticals and methods of treatment of the human body, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, many countries have compulsory licensing laws under which a patent owner may be compelled under specified circumstances to grant licenses to third parties. Furthermore, many countries limit the enforceability of patents against government agencies or government contractors. In those countries, we may have limited remedies if patents are infringed or if we are compelled to grant a license to a third party, which could materially diminish the value of those patents and limit our potential revenue opportunities. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license, which could adversely affect our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely on trade secrets to protect our proprietary technologies, especially where we do not believe patent protection is appropriate or obtainable. However, trade secrets are difficult to protect. We rely in part on confidentiality agreements with our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors, and inventions agreements with employees, consultants and advisors, to protect our trade secrets and other proprietary information. In addition to contractual measures, we try to protect the confidential nature of our proprietary information using commonly accepted physical and technological security measures. Despite these efforts, we cannot provide any assurances that all such agreements have been duly executed, and these agreements may not effectively prevent disclosure of confidential information and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. In addition, others may independently discover our trade secrets and proprietary information. For example, in 2010, the FDA, as part of its Transparency Initiative, recommended steps that the FDA could take to increase transparency, including with respect to making additional information publicly available on a routine basis, which may include information that we may consider to be trade secrets or other proprietary information, and it is not clear at the present time how the FDA&#8217;s disclosure policies may change in the future, if at all. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and failure to obtain or maintain trade secret protection could adversely affect our competitive business position. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, such security measures may not provide adequate protection for our proprietary information, for example, in the case of misappropriation of a trade secret by an employee, consultant, customer or third party with authorized access. Our security measures may not prevent an employee, consultant or customer from misappropriating our trade secrets and providing them to a competitor, and any recourse we take against such misconduct may not provide an adequate remedy to protect our interests fully. Monitoring unauthorized uses and </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">54 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
disclosures is difficult, and we do not know whether the steps we have taken to protect our proprietary technologies will be effective. Unauthorized parties may also attempt to copy or reverse engineer certain aspects of our products that we consider proprietary. Competitors and other third parties could attempt to replicate some or all of the competitive advantages we derive from our development efforts, willfully infringe our intellectual property rights, design around our protected technology or develop their own competitive technologies that fall outside of our intellectual property rights. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Enforcing a claim that a party illegally disclosed or misappropriated a trade secret can be difficult, expensive and time-consuming, and the outcome is unpredictable. Even though we use commonly accepted security measures, the criteria for protection of trade secrets can vary among different jurisdictions. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. Moreover, trade secrets will over time be disseminated within the industry through independent development, the publication of journal articles and the movement of personnel skilled in the art from company to company or academic to industry scientific positions. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent such competitor from using that technology or information to compete with us, which could harm our competitive position. If any of these events occurs or if we otherwise lose protection for our trade secrets, the value of this information may be greatly reduced and our competitive position would be harmed. If we do not apply for patent protection prior to such publication or if we cannot otherwise maintain the confidentiality of our proprietary technology and other confidential information, then our ability to obtain patent protection or to protect our trade secret information may be jeopardized. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our reliance on third parties may require us to share our trade secrets, which increases the possibility that our trade secrets will be misappropriated or disclosed. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because we rely on third parties to help manufacture and supply our products and product candidates, and we expect to collaborate with third parties on the continuing development of future product candidates, we must, at times, share trade secrets with them. We also expect to conduct research and development programs that may require us to share trade secrets under the terms of our partnerships or agreements with CROs. We seek to protect our proprietary technology in part by entering into agreements containing confidentiality and use restrictions and obligations, including, material transfer agreements, consulting agreements, confidentiality agreements or other similar agreements with our advisors, contractors, service providers and consultants prior to disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our <span style="white-space:nowrap">know-how</span> and trade secrets, a competitor&#8217;s discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have an adverse effect on our business, financial condition and results of operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, these agreements typically restrict the ability of our advisors, third-party contractors and consultants to publish data potentially relating to our trade secrets, although our agreements may contain certain limited publication rights. Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach of our agreements with third parties, independent development or publication of information by any of our third-party collaborators. A competitor&#8217;s discovery of our trade secrets would impair our competitive position and have an adverse impact on our business, financial condition and results of operations. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">55 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Intellectual property rights and regulatory exclusivity rights do not necessarily address all potential threats to our competitive advantage. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The degree of future protection for our proprietary rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage. If we do not adequately protect our intellectual property and proprietary technology, competitors may be able to use our product candidates and proprietary technologies and erode or negate any competitive advantage we may have, which could have a material adverse effect on our financial condition and results of operations. For example: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Others may be able to make products that are similar to ZTlido, GLOPERBA or our product candidates but that are not covered by the claims of the patents that we own or have exclusively licensed; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We or our licensors or strategic partners might not have been the first to make the inventions covered by the issued patent or pending patent application that we own or have exclusively licensed; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We or our licensors or strategic partners might not have been the first to file patent applications covering certain of our inventions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our pending patent applications may not lead to issued patents; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Issued patents that we own or have exclusively licensed may not provide us with any competitive advantage, or may be held invalid or unenforceable, as a result of legal challenges by our competitors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We may not develop additional proprietary technologies that are patentable; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The patents of others may have an adverse effect on our business. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Should any of these events occur, they could significantly harm our business, financial condition and results of operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is possible that defects of form in the preparation or filing of our patents or patent applications may exist, or may arise in the future, for example with respect to proper priority claims, inventorship, claim scope or requests for patent term adjustments. If we or our partners, collaborators, licensees or licensors, whether current or future, fail to establish, maintain or protect such patents and other intellectual property rights, such rights may be reduced or eliminated. If our partners, collaborators, licensees or licensors, are not fully cooperative or disagree with us as to the prosecution, maintenance or enforcement of any patent rights, such patent rights could be compromised. If there are material defects in the form, preparation, prosecution or enforcement of our patents or patent applications, such patents may be invalid and/or unenforceable, and such applications may never result in valid, enforceable patents. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business, financial condition and results of operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions, and has been and will continue to be the subject of litigation and new legislation. Publications in scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in our own patents or pending patent applications, or that we were the first to file for patent protection of such inventions. As a result of these and other factors, the issuance, scope, validity, enforceability, and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">56 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
patents being issued that protect ZTlido, GLOPERBA and our product candidates, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection. If these changes were to occur, they could have a material adverse effect on our ability to generate revenue. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, we may be subject to a third-party <span style="white-space:nowrap">pre-issuance</span> submission of prior art to the PTO or become involved in opposition, derivation, reexamination, <span style="font-style:italic">inter partes </span>review, post-grant review or interference proceedings challenging our patent rights or the patent rights of others. The costs of defending our patents or enforcing our proprietary rights in post-issuance administrative proceedings and litigation can be substantial and the outcome can be uncertain. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize ZTlido, GLOPERBA and our product candidates and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and potentially licensed patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of ZTlido, GLOPERBA or our product candidates. Generally, patents are granted a term of 20 years from the earliest claimed <span style="white-space:nowrap">non-provisional</span> filing date. In certain instances, patent term can be adjusted and increased to recapture a portion of delay incurred by the PTO in examining the patent application. The scope of patent protection may also be limited. Without patent protection for our current or future product candidates, we may be open to competition from generic versions of such products. Given the amount of time required for the development, testing, and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_16">Risks Related to Government Regulations </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The regulatory approval processes of the FDA are lengthy, time-consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business, financial condition and results of operations will be substantially harmed. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The time required to obtain approval from the FDA is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities, and its outcome is inherently uncertain. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions. For example, we believe that the data from our Phase 3 CLEAR trial will be sufficient to support a 505(b)(2) NDA submission for SEMDEXA. However, the FDA may disagree and may require us to conduct additional clinical studies before we are able to submit the NDA, even though we believe the data from the CLEAR trial are adequate. Our future success depends on our ability to develop, receive regulatory approval for, and introduce new products or product enhancements that will be accepted by the market in a timely manner. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA can delay, limit or deny approval of a product candidate for many reasons, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">it may disagree with the design or implementation of our clinical trials; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">57 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we may be unable to demonstrate to such authorities&#8217; satisfaction that a product candidate is safe and effective for its proposed indication; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">negative or ambiguous results from our clinical trials may not meet the level of statistical significance required for approval by the FDA; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">it may disagree with our interpretation of data from preclinical studies or clinical trials; </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">it may not agree that the data collected from clinical trials of our product candidates are acceptable or sufficient to support the submission of an NDA or other submission or to obtain regulatory approval in the United States, and such authorities may impose requirements for additional preclinical studies or clinical trials; </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">it may disagree regarding the formulation, labeling and/or the specifications of our product candidates; </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">such authorities may decline to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the approval policies or regulations of the FDA may significantly change in a manner rendering our clinical data insufficient for approval. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Of the large number of drugs in development, only a small percentage successfully complete the FDA regulatory approval processes and are commercialized. This lengthy approval process, as well as the unpredictability of future clinical trial results, may result in our failing to obtain regulatory approval to market our product candidates, which would significantly harm our business, financial condition and results of operations. In addition, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, may not approve the price we intend to charge for our product candidates, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other than an NDA submitted for ZTlido in the United States, which was approved by the FDA in February 2018, we have not previously submitted an NDA to the FDA for any product candidate, and we cannot be certain that any of our product candidates will be successful in clinical trials or receive regulatory approval. Further, our product candidates may not receive regulatory approval even if our clinical trials are successful. If we do not receive regulatory approvals for our product candidates, our business, financial condition and results of operations will be substantially harmed. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If the FDA does not conclude that certain of our product candidates satisfy the requirements for the Section&#160;505(b)(2) regulatory approval pathway, or if the requirements for such product candidates under Section&#160;505(b)(2) are not as we expect, the approval pathway for those product candidates will likely take significantly longer, cost significantly more and entail significantly greater complications and risks than anticipated, and in either case may not be successful. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For our product candidates SEMDEXA, <span style="white-space:nowrap">SP-103</span> and <span style="white-space:nowrap">SP-104,</span> we may seek FDA approval through the Section&#160;505(b)(2) regulatory pathway. The Hatch-Waxman Act added Section&#160;505(b)(2) to the Federal Food, Drug and Cosmetic Act (the &#8220;FDCA&#8221;). Section&#160;505(b)(2) permits the filing of an NDA where at least some of the information required for approval comes from trials that were not conducted by or for the applicant and for which the applicant has not obtained a right of reference. Section&#160;505(b)(2) allows an NDA we submit to the FDA to rely in part on data in the public domain or the FDA&#8217;s prior conclusions regarding the safety and effectiveness of approved compounds, which could expedite the development program for our product candidates by potentially </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">58 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
decreasing the amount of data that we would need to generate in order to obtain FDA approval. If the FDA does not agree that the Section&#160;505(b)(2) regulatory pathway is acceptable as we anticipated, we may need to conduct additional clinical trials, provide additional data and information and meet additional standards for regulatory approval. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if FDA accepts our plan to pursue the Section&#160;505(b)(2) regulatory pathway, we cannot assure that our product candidates will receive the requisite approvals for commercialization. In addition, the pharmaceutical industry is highly competitive, and Section&#160;505(b)(2) NDAs are subject to special requirements designed to protect the patent and market exclusivity rights of sponsors of previously approved drugs that are referenced in a Section&#160;505(b)(2) NDA. These requirements may give rise to patent litigation against us and mandatory delays in approval of our NDAs for up to 30 months or longer depending on the outcome of any litigation. Further, a manufacturer of an approved product may file a citizen petition with the FDA seeking to delay approval of, or impose additional approval requirements for, pending competing products. FDA imposes strict requirements on such petitions in part to dissuade companies from improperly using these petitions to delay approval of competing drug products. Nonetheless, if successful, such petitions can significantly delay, or even prevent, the approval of the new product. However, even if the FDA ultimately denies such a petition, the FDA may delay approval while it considers and responds to the petition. In addition, even if we are able to utilize the Section&#160;505(b)(2) regulatory pathway, there is no guarantee this would ultimately lead to accelerated product development or earlier approval. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Any approved product candidate will be subject to ongoing and continued regulatory review, which may result in significant expense and limit our ability to commercialize such products. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even after a product is approved, we will remain subject to ongoing FDA and other regulatory requirements governing the manufacturing, testing, labeling, packaging, storage, distribution, safety surveillance, advertising, promotion, import, export, record-keeping and reporting of safety and other post-market information. The holder of an approved NDA is obligated to monitor and report adverse events and, among other things, any failure of a distributed product to meet the specifications in the NDA. The holder of an approved NDA must also submit new or supplemental applications and obtain FDA approval for certain changes to the approved product, product labeling or manufacturing process. Advertising and promotional materials must comply with FDA rules and are subject to FDA review, in addition to other potentially applicable federal and state laws. In addition, the FDA may impose significant restrictions on the approved indicated uses for which the product may be marketed. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These requirements include submissions of safety and other post-marketing information and reports, registration and listing, as well as continued compliance with cGMPs and GCPs for any clinical trials that we conduct post-approval. The future discovery of previously unknown problems with a product, including adverse events of unanticipated type, severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">investigation or additional study obligations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">communications to prescribers or patients about specific information or issues; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">restrictions on the marketing or manufacturing of the product, withdrawal of the product from the market, or voluntary or mandatory product recalls; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">fines, warning or untitled letters or holds on clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">refusal by the FDA to approve pending applications or supplements to approved applications filed by us, or suspension or revocation of product license approvals; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">product seizure or detention, or refusal to permit the import or export of products; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">injunctions or the imposition of civil or criminal penalties. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The occurrence of any event or penalty described above may inhibit our ability to successfully commercialize our product candidates and generate revenue and could require us to expend significant time and </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">59 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
resources in response and could generate negative publicity. We may not be able to regain compliance, or we may only be able to regain compliance after a lengthy delay, significant expense, lost revenues and damage to our reputation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA&#8217;s and other regulatory authorities&#8217; policies may change, and additional laws or government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, which would adversely affect our ability to generate revenue and achieve or sustain profitability. Changes in law or government regulations may also alter the competitive landscape, potentially to our disadvantage. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain manufacturers in the market in which we compete distribute certain products without completing the FDA approval process. For example, we believe certain lidocaine topical patches, plaster or poultice products marketed <span style="white-space:nowrap"><span style="white-space:nowrap">over-the-counter</span></span> (&#8220;OTC&#8221;) and without FDA approval, require approval and compete inappropriately with ZTlido. In December 2018, we filed a citizen&#8217;s petition asking the FDA to clarify its requirements and take enforcement action against such products. The FDA has not responded with a decision or action. The FDA has generally held the position that requests for enforcement action via citizen petition are not allowed, which may reduce the likelihood of the FDA taking action explicitly in response to our December 2018 petition. Furthermore, we believe the labeling and marketing of certain OTC lidocaine patches products are false and deceptive, which could cause significant damages to our business and a diminution of goodwill in our intellectual property. In February 2021, we filed a complaint against such manufacturers to seek an award of damages and the entry of injective relief enjoining further dissemination of such false and deceptive advertisement. In addition, on March&#160;7, 2020, the Coronavirus Aid, Relief, and Economic Security Act (the &#8220;CARES Act&#8221;) was signed into law, which included statutory provisions reforming FDA&#8217;s mechanisms for regulating OTC drugs. Under the CARES Act, the FDA considers a drug to be generally recognized as safe and effective (&#8220;GRASE&#8221;) if it meets certain requirements, including items such as the active ingredient, indication for use, dosage, route of administration, and labeling set forth in the OTC monograph and related rulemakings. Historically, the FDA was required to establish, revise, and amend an OTC monograph by <span style="white-space:nowrap"><span style="white-space:nowrap">notice-and-comment</span></span> rulemaking, which was lengthy and resource-intensive. The CARES Act replaces the rulemaking process with a final administrative order process. Administrative orders may be initiated by the FDA or at the request of a drug manufacturer or any other person. After a period for public comment on the administrative order, the FDA is able to issue a final administrative order, rather than a regulation, permitting the drug to be marketed over the counter. As this process is much more streamlined and less burdensome, this may benefit the manufacturers of lidocaine topical patches to obtain GRASE status from the FDA and thereby legally market these products <span style="white-space:nowrap"><span style="white-space:nowrap">over-the-counter</span></span> and compete with ZTlido. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. For example, certain policies of the current U.S. administration may impact our business and industry. Namely, recent U.S. administrations have taken several executive actions, including the issuance of a number of Executive Orders, that could impose significant burdens on, or otherwise materially delay, the FDA&#8217;s ability to engage in routine regulatory and oversight activities such as implementing statutes through rulemaking, issuance of guidance, and review and approval of marketing applications. It is difficult to predict how these executive actions, including the Executive Orders, will be implemented, and the extent to which they will impact the FDA&#8217;s ability to exercise its regulatory authority. If these executive actions impose constraints on FDA&#8217;s ability to engage in oversight and implementation activities in the normal course, our business, financial condition and results of operations may be negatively affected. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">60 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">A fast track product designation, breakthrough therapy designation or other designation to facilitate product candidate development may not lead to faster development or regulatory review or approval process, and it does not increase the likelihood that our product candidates will receive marketing approval. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A product sponsor may apply for fast track designation from the FDA if a product is intended for the treatment of a serious or life-threatening condition and preclinical or clinical data demonstrate the potential to address an unmet medical need for this condition. The FDA has broad discretion whether or not to grant this designation. We have received fast track designation for SEMDEXA for the treatment of sciatica and <span style="white-space:nowrap">SP-103</span> for the treatment of acute LBP. Even though SEMDEXA and <span style="white-space:nowrap">SP-103</span> have received fast track designation, we may not experience a faster process, review or approval compared to conventional FDA procedures. A fast track designation does not expedite clinical trials, or mean that regulatory requirements are less stringent or provide assurance of ultimate marketing approval by the FDA. Instead, fast track designation provides opportunities for frequent interactions with FDA review staff, as well as eligibility for priority review, if relevant criteria are met, and rolling review of individual sections of an NDA submitted to the FDA as they become finalized. The FDA may rescind the fast track designation if it believes that the designation is no longer supported by data from our clinical development program. The FDA may also withdraw any fast track designation at any time. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have applied for breakthrough therapy designation and expect to seek priority review for SEMDEXA for the treatment of sciatica. A breakthrough therapy is defined as a therapy that is intended, alone or in combination with one or more other therapies, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the therapy may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For therapies that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in potentially less efficacious control regimens. Therapies designated as breakthrough therapies by the FDA may also be eligible for priority review and accelerated approval. Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe a product candidate meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to provide such designation. In any event, the receipt of a breakthrough therapy designation may not result in a faster development process, review or approval compared to therapies considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if SEMDEXA qualifies as a breakthrough therapy for sciatica, the FDA may later decide that SEMDEXA no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If approved, our products candidates regulated as biologics may face competition from biosimilars approved through an abbreviated regulatory pathway. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ACA includes a subtitle called the Biologics Price Competition and Innovation Act of 2009 (the &#8220;BPCIA&#8221;), which created an abbreviated approval pathway under section 351(k) of the Public Health Service Act (the &#8220;PHSA&#8221;) for biological products that are biosimilar to or interchangeable with an <span style="white-space:nowrap">FDA-licensed</span> reference biological product. Under the BPCIA, a section 351(k) application for a biosimilar or interchangeable product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar or interchangeable product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this <span style="white-space:nowrap">12-year</span> period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full Biologics License Application (&#8220;BLA&#8221;) for the competing product submitted under section 351(a) of the PHSA containing the competing sponsor&#8217;s own <span style="white-space:nowrap">pre-clinical</span> data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity, and potency of the other company&#8217;s biological product. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">61 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whether approval of a biological product qualifies for reference product exclusivity turns on whether FDA consider the approval a &#8220;first licensure&#8221;. Not every licensure of a biological product is considered a &#8220;first licensure&#8221; that gives rise to its own exclusivity period. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. Moreover, the extent to which a biosimilar, once licensed, will be substituted for any one of our product candidates in a way that is similar to traditional generic substitution for <span style="white-space:nowrap">non-biological</span> products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing. If competitors are able to obtain marketing approval for biosimilars referencing our product candidates, our product candidates may become subject to competition from such biosimilars, with the attendant competitive pressure and consequences. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Changes in funding for the FDA could hinder its ability to hire and retain key leadership and other personnel, or otherwise prevent new products and services from being developed or commercialized in a timely manner, which could negatively impact our business, financial condition and results of operations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Disruptions at the FDA and other regulatory authorities may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business, financial condition and results of operations. For example, over the last several years, including for 35 days beginning on December&#160;22, 2018, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business, financial condition and results of operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Separately, in response to the <span style="white-space:nowrap">COVID-19</span> pandemic, on March&#160;10, 2020, the FDA announced its intention to postpone most inspections of foreign manufacturing facilities, and on March&#160;18, 2020, the FDA temporarily postponed routine surveillance inspections of domestic manufacturing facilities. Subsequently, on July&#160;10, 2020, the FDA announced its intention to resume certain <span style="white-space:nowrap">on-site</span> inspections of domestic manufacturing facilities subject to a risk-based prioritization system. Increased cases associated with a <span style="white-space:nowrap">COVID-19</span> variant led the FDA to again pause inspections, although the FDA announced in February 2022 that it would resume routine domestic surveillance inspections and that it would proceed with certain foreign surveillance inspections where country conditions permit. Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the <span style="white-space:nowrap">COVID-19</span> pandemic. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Failure to comply with health and data protection laws and regulations could lead to government enforcement actions and civil or criminal penalties, private litigation or adverse publicity and could negatively affect our operating results and business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and our collaborators are subject to federal, state and foreign data protection laws and regulations which address privacy and data security. In the United States, such laws may include, but are not limited to, numerous federal and state laws and regulations, including the U.S. federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;) and its implementing regulations, state data breach notification laws, state health information privacy laws and federal and state consumer protection laws, including Section&#160;5 of the Federal </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">62 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Trade Commission Act, which govern the collection, use, disclosure and protection of health-related and other personal information. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we are not subject to HIPAA, as we are neither a Covered Entity nor Business Associate (as defined in HIPAA), we may have access to very sensitive data regarding patients who participate, or whose tissue samples or other biospecimens are used, in our clinical trials. The maintenance of this data imposes upon us administrative and financial burdens, and litigation risks. In addition, we may obtain health information from third parties, including research institutions from which we obtain clinical trial data that are subject to privacy and security requirements under HIPAA and other privacy and data security and consumer protection laws. Depending on the facts and circumstances, we could be subject to criminal penalties if we knowingly receive individually identifiable health information maintained by a HIPAA-Covered Entity in a manner that is not authorized or permitted by HIPAA, and subject to other civil and/or criminal penalties if we obtain, use, or disclose information in a manner not permitted by other privacy and data security and consumer protection laws. Our ability to use or disclose information may be limited by the scope of an authorization signed by clinical trial subjects or the terms of the contract that we enter into with providers or other data sources. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, states are constantly adopting new laws or amending existing laws relating to the data privacy and security and consumer protection, requiring attention to frequently changing regulatory requirements. For example, California enacted the California Consumer Privacy Act (the &#8220;CCPA&#8221;), which creates new individual privacy rights for California consumers and places increased privacy and security obligations on entities handling personal data of consumers or households. The CCPA requires covered companies to provide new disclosure to consumers about such companies&#8217; data collection, use and sharing practices, provide such consumers new ways to <span style="white-space:nowrap">opt-out</span> of certain sales or transfers of personal information, and provide consumers with a private right of action in connection with certain types of incidents. The CCPA has been amended several times, and will be significantly updated from the California Privacy Rights Act (the &#8220;CPRA&#8221;), a ballot initiative that passed in November 2020 and which will go into effect on January&#160;1, 2023. The CPRA introduced significant amendments to the CCPA and also created a new state agency vested with authority to implement and enforce the CCPA and the CPRA, the California Privacy Protection Agency (the &#8220;CPPA&#8221;). New implementing regulations are expected to be introduced by the CPPA. Virginia also recently enacted a CCPA/CPRA-like law, the Virginia Consumer Data Privacy Act (the &#8220;VDCPA&#8221;), to provide its residents with similar rights, and Colorado, Connecticut and Utah have passed similar laws. New legislation enacted in various other states will continue to shape the data privacy environment nationally. Certain state laws may be more stringent or broader in scope, or offer greater individual rights, with respect to confidential, sensitive and personal information than federal, international or other state laws, and such laws may differ from each other, which may complicate compliance efforts. The effects on our business of the CCPA, CPRA, VDCPA and other similar state laws and general consumer protection authorities are potentially significant, and may require us to modify our data processing practices and policies and to incur substantial costs and expenses in an effort to comply. Privacy laws and regulations are constantly evolving and there are a number of legislative proposals at both the state and federal level that could impose new obligations or limitations in areas affecting our business. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Federal Trade Commission (the &#8220;FTC&#8221;) also sets expectations for failing to take appropriate steps to keep consumers&#8217; personal information secure, or failing to provide a level of security commensurate to promises made to individual about the security of their personal information (such as in a privacy notice) may constitute unfair or deceptive acts or practices in violation of Section&#160;5(a) of the Federal Trade Commission Act (the &#8220;FTC Act&#8221;). The FTC expects a company&#8217;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. Individually identifiable health information is considered sensitive data that merits stronger safeguards. With respect to privacy, the FTC also sets expectations that companies honor the privacy promises made to individuals about how the company handles consumers&#8217; personal information. Any failure to honor promises, such as the statements made in a privacy policy or on a website, may also constitute unfair or deceptive acts or practices in violation of the FTC Act. While we do not intend to engage in unfair or deceptive acts or practices, the FTC has the power to enforce promises as it </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">63 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
interprets them, and events that we cannot fully control, such as data breaches, may be result in FTC enforcement. Enforcement by the FTC under the FTC Act can result in civil penalties or enforcement actions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">International data protection laws, including Regulation 2016/679, known as the General Data Protection Regulation (the &#8220;GDPR&#8221;), may also apply to health-related and other personal information obtained outside of the United States. The GDPR imposes several data protection requirements in the European Union, as well as imposes potential fines for noncompliant companies of up to the greater of &#8364;20&#160;million or 4% of annual global revenue. The regulation imposes numerous requirements for the collection, use, storage and disclosure of personal information, including more stringent requirements relating to consent and the information that must be shared with data subjects about how their personal information is used, the obligation to notify regulators and affected individuals of personal data breaches, extensive new internal privacy governance obligations and obligations to honor expanded rights of individuals in relation to their personal information, including the right to access, correct and delete their data. In addition, the GDPR includes restrictions on cross-border data transfers. The GDPR increased our responsibility and liability in relation to personal data that we process where such processing is subject to the GDPR, and we may be required to put in place additional mechanisms to ensure compliance with the GDPR, including as implemented by individual European Union countries. Further, the United Kingdom&#8217;s decision to leave the European Union, often referred to as Brexit, has led and could also lead to legislative and regulatory changes and may increase our compliance costs. As of January&#160;1, 2021 and the expiry of transitional arrangements agreed to between the United Kingdom and the European Union, data processing in the United Kingdom is governed by a United Kingdom version of the GDPR (combining the GDPR and the Data Protection Act 2018), exposing us to two parallel regimes, each of which authorizes similar fines and other potentially divergent enforcement actions for certain violations. On June&#160;28, 2021, the European Commission adopted an Adequacy Decision for the United Kingdom, allowing for the relatively free exchange of personal information between the European Union and the United Kingdom, however, the European Commission may suspend the Adequacy Decision if it considers that the United Kingdom no longer provides for an adequate level of data protection. Other jurisdictions outside the European Union are similarly introducing or enhancing privacy and data security laws, rules and regulations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Compliance with U.S. and international data protection laws and regulations could require us to take on more onerous obligations in our contracts, increase our compliance costs, restrict our ability to collect, use and disclose data, or in some cases, impact our ability to operate in certain jurisdictions. We cannot guarantee that we are, or will be, in compliance with all applicable international regulations as they are enforced now or as they evolve. Claims that we have violated individuals&#8217; privacy rights, failed to comply with data protection laws or breached our contractual obligations, even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our business involves the use of hazardous materials and we and third-parties with whom we contract must comply with environmental laws and regulations, which can be expensive and restrict how we do business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our research and development activities involve the controlled storage, use and disposal of hazardous materials, including the components of our product candidates and other hazardous compounds. We and manufacturers and suppliers with whom we may contract are subject to laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials. In some cases, these hazardous materials and various wastes resulting from their use are stored at our manufacturers&#8217; facilities pending their use and disposal. We cannot eliminate the risk of contamination, which could cause an interruption of our commercialization efforts, research and development efforts and business operations, environmental damage resulting in costly <span style="white-space:nowrap">clean-up</span> and liabilities under applicable laws and regulations governing the use, storage, handling and disposal of these materials and specified waste products. We cannot guarantee that the safety procedures utilized by third-party manufacturers and suppliers with whom we may contract will comply with the standards prescribed by laws and regulations or will eliminate the risk of accidental contamination or injury from these materials. We do not carry specific biological or hazardous waste insurance coverage, and our property, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">64 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
casualty and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. Accordingly, in the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources and state or federal or other applicable authorities may curtail our use of certain materials and/or interrupt our business operations. We may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Furthermore, environmental laws and regulations are complex, change frequently and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our employees, independent contractors, consultants, commercial partners, and vendors may engage in misconduct or other improper activities, including <span style="white-space:nowrap">non-compliance</span> with regulatory standards and requirements, which could have a material adverse effect on our business, financial condition and results of operations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are exposed to the risk of fraud, illegal activity or other misconduct by our employees, independent contractors, consultants, commercial partners and vendors. Misconduct by employees could include intentional, reckless and/or negligent conduct that fails to comply with the laws and regulations of the FDA, EU Member States, EMA and other similar foreign regulatory bodies, provide true, complete and accurate information to the FDA, EMA and other similar foreign regulatory bodies, comply with manufacturing standards we have established, comply with federal and state health-care fraud and abuse laws and regulations, comply with laws and regulations, including, but not limited to the FCPA and internal policies restricting payments to government agencies and representatives, report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Misconduct by employees, independent contractors, consultants, commercial partners and vendors could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter misconduct by our employees, independent contractors, consultants, commercial partners and vendors, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or FDA debarment or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, financial condition and results of operations, including the imposition of significant fines or other sanctions and serious harm to our reputation. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, transparency and disclosure, or sunshine, laws, government price reporting, and health information privacy and security laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our current and future arrangements with healthcare professionals, clinical sites and clinical investigators, consultants, customers, patient organizations and third-party payors may subject us to various federal and state fraud and abuse laws, including, without limitation, the federal Anti-Kickback Statute and the federal False Claims Act. These laws may impact, among other things, our current activities with clinical study investigators and research subjects, as well as our current and future sales, marketing, patient assistance and education programs. In addition, we may be subject to physician payment transparency laws and patient privacy regulation </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">65 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
by both the federal government and the states and foreign jurisdictions in which we conduct our business. The laws that may affect our ability to operate include, but are not limited to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, to induce, or in return for, either the referral of an individual, or the furnishing, recommending, or arranging for an item or service for which payment may be made under a federal healthcare program, such as the Medicare and Medicaid programs &#8212; a person or entity does not need to have actual knowledge of the federal Anti-Kickback Statute or special intent to violate the law in order to have committed a violation; in addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">federal civil and criminal false claims laws, including the False Claims Act, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, a false or fraudulent claim for payment of government funds, or knowingly making, using, or causing to be made or used a false statement material to a false or fraudulent claim, or knowingly concealing or knowingly and improperly avoiding or decreasing an obligation to pay money to the federal government. The False Claims Act has been used to assert liability on the basis of kickbacks and other improper referrals, improperly reported government pricing metrics such as Best Price or Average Manufacturer Price, and improper promotion of <span style="white-space:nowrap">off-label</span> uses (i.e., uses not expressly approved by the FDA in a drug&#8217;s label); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">HIPAA, which imposes criminal liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third party payors, or falsifying or covering up a material fact or making any materially false or fraudulent statement in connection with the delivery of or payment for health care benefits, items or services &#8212; similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">HIPAA and its implementing regulations, which imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the federal Physician Payment Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) to report annually to CMS information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), teaching hospitals and, beginning in 2022, certain other healthcare professionals, as well as ownership and investment interests held by the physicians described above and their immediate family members; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the FDCA, which prohibits, among other things, the adulteration or misbranding of drugs, biologics and medical devices; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">federal government price reporting laws, which require drug manufacturers to calculate and report complex pricing metrics to government agencies, including CMS and Department of Veterans Affairs (&#8220;VA&#8221;), where such reported prices may be used in the calculation of reimbursement and/or discounts on marketed products paid by government healthcare programs. Participation in these programs and compliance with the applicable requirements may result in potentially significant discounts on products subject to reimbursement under federal healthcare programs and increased infrastructure costs, and may potentially limit a drug manufacturer&#8217;s ability to offer certain marketplace discounts; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">66 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the Prescription Drug Marketing Act, which restricts the manner in which manufacturers may disseminate complimentary drug samples to healthcare practitioners, requires physical and accounting controls, and establishes penalties for improper sample distribution; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">state law equivalents of each of the above federal laws, such as licensing, anti-kickback, false claims, consumer protection and unfair competition laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers, state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government that otherwise restricts payments that may be made to healthcare providers and other potential referral sources; state laws that require drug manufacturers to file reports with states regarding pricing information and marketing expenditures, such as the tracking and reporting of gifts, compensations and other remuneration and items of value provided to healthcare professionals and entities, and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, any future research and development of our product candidates outside the United States, and any future sales of our product or product candidates once commercialized outside the United States will also likely subject us to foreign equivalents of the healthcare laws mentioned above, among other foreign laws. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws. The risk of our being found in violation of these laws is increased by the fact that many of them have not been fully interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of interpretations. Efforts to ensure that our business practices and arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to, without limitation, civil, criminal, and administrative penalties, damages, monetary fines, disgorgement, exclusion from government-funded healthcare programs, such as Medicare and Medicaid or similar programs in other countries or jurisdictions, integrity oversight and reporting obligations to resolve allegations of <span style="white-space:nowrap">non-compliance,</span> imprisonment, contractual damages, reputational harm, diminished profits and future earnings and curtailment or restructuring of our operations, any of which could adversely affect our business, financial condition and results of operations. If any of the physicians or other healthcare providers or entities with whom we expect to do business is found not to be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from participation in government healthcare programs, which could also materially affect our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of <span style="white-space:nowrap">off-label</span> uses. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are found to have improperly promoted <span style="white-space:nowrap">off-label</span> uses of ZTlido, GLOPERBA or our product candidates, if approved, or if we are found to have improperly engaged in <span style="white-space:nowrap">pre-approval</span> promotion prior to the approval of such product candidates, we may become subject to significant liability. Such enforcement has become more common in the industry. The FDA and other regulatory agencies strictly regulate the promotional claims that may be made about prescription products, such as ZTlido, GLOPERBA and our product candidates, if approved. In particular, a product may not be promoted for uses that are not approved by the FDA or such other regulatory agencies as reflected in the product&#8217;s approved labeling. If we receive marketing approval for our product candidates for our proposed indications, physicians may nevertheless use our product for their patients in </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">67 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
a manner that is inconsistent with the approved label, if the physicians believe in their professional medical judgment it could be used in such manner. However, if we are found to have promoted our product for any <span style="white-space:nowrap">off-label</span> uses, the federal government could levy civil, criminal and/or administrative penalties, and seek fines against us. The FDA, Department of Justice or other regulatory authorities could also request that we enter into a consent decree or a corporate integrity agreement, or seek a permanent injunction against us under which specified promotional conduct is monitored, changed or curtailed. If we cannot successfully manage the promotion of ZTlido, GLOPERBA or our product candidates, if approved, we could become subject to significant liability, which would materially adversely affect our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Healthcare reform measures could hinder or prevent our product candidates&#8217; commercial success. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There have been, and we expect there will continue to be, a number of legislative and regulatory changes to health care systems in the United States and abroad that could impact our ability to sell our products profitably. The United States government and other governments have shown significant interest in pursuing healthcare reform. For example, in 2010, the ACA was enacted, which substantially changed the way healthcare is financed by both governmental and private insurers in the United States. Healthcare reform measures like the ACA may adversely impact the pricing of healthcare products and services in the United States or internationally and the amount of reimbursement available from governmental agencies or other third-party payors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since its enactment, there have been ongoing efforts to modify the ACA and its implementing regulations. For example, tax legislation enacted at the end of 2017 includes provisions that, effective January&#160;1, 2019, eliminated the tax penalty for individuals who do not maintain sufficient health insurance coverage, or the <span style="white-space:nowrap">so-called</span> &#8220;individual mandate.&#8221; It is unclear how healthcare reform measures enacted by Congress or implemented by the Biden administration or efforts, if any, to modify the ACA or its implementing regulations, or portions thereof, will impact our business. Litigation and legislation over the ACA and other healthcare reform measures are likely to continue, with unpredictable and uncertain results. Further, additional legislative changes to and regulatory changes under or related to the ACA remain possible. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, led to aggregate reductions of Medicare payments to providers of, on average, 2% per fiscal year. These reductions went into effect in April 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2030, with the exception of a temporary suspension from May&#160;1, 2020, through May&#160;31, 2022, due to the <span style="white-space:nowrap">COVID-19</span> pandemic. The law provides for 1% Medicare sequestration in the second quarter of 2022 and allows the full 2% sequestration thereafter until 2030. To offset the temporary suspension during the <span style="white-space:nowrap">COVID-19</span> pandemic, in 2030, the sequestration will be 2.25% for the first half of the year, and 3% in the second half of the year. The American Taxpayer Relief Act of 2012 further reduced Medicare payments to several providers, including hospitals and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. For example, CMS may develop new payment and delivery models, such as bundled payment models. In addition, recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under government payor programs, and review the relationship between pricing and manufacturer patient programs, as addressed further in the risk factor below titled &#8220;<span style="font-style:italic">If we fail to comply with our reporting and payment obligations under the Medicaid Drug Rebate Program or other governmental pricing programs once our products come to market, we could be subject to additional reimbursement requirements, penalties, sanctions, and fines, which could have a material adverse effect on our business, financial condition, results of operations, and future prospects</span>.&#8221; While any proposed measures may </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">68 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
require authorization through additional legislation to become effective, Congress and the Biden administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. We expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal health care programs and commercial payers will pay for healthcare products and services, which could result in reduced demand for ZTlido, GLOPERBA and our product candidates, if approved, or additional pricing pressures. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Individual states in the United States have also increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Legally-mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, financial condition and results of operations. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. Furthermore, there has been increased interest by third-party payors and governmental authorities in reference pricing systems and publication of discounts and list prices. These or other reforms could reduce the ultimate demand for ZTlido, GLOPERBA and our product candidates, if approved, or put pressure on our product pricing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action in the United States. If we or any third parties we may engage are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, ZTlido may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we fail to comply with our reporting and payment obligations under the Medicaid Drug Rebate Program or other governmental pricing programs applicable to our product or product candidates, if approved, we could be subject to additional reimbursement requirements, penalties, sanctions and fines, which could have a material adverse effect on our business, financial condition, results of operations and future prospects. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pricing and rebate calculations vary across products and programs, are complex, and are often subject to interpretation by manufacturers, governmental or regulatory agencies and the courts. Such interpretation can change and evolve over time. In the case of Medicaid pricing data, if a manufacturer becomes aware that its reporting for a prior quarter was incorrect, or has changed as a result of recalculation of the pricing data, the manufacturer is obligated to resubmit the corrected data for up to three years after those data originally were due. Such restatements and recalculations increase costs for complying with the laws and regulations governing the Medicaid Drug Rebate Program and could result in an overage or underage in rebate liability for past quarters. Price recalculations also may affect the ceiling price at which a manufacturer is required to offer its products under the 340B program. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A failure to comply with reporting and payment obligations under the Medicaid Drug Rebate program and other governmental programs could negatively affect financial results. CMS issued a final regulation, which became effective on April&#160;1, 2016, to implement the changes under the ACA to the Medicaid Drug Rebate Program. The final regulation has increased and will continue to increase costs and the complexity of compliance, has been and will continue to be time-consuming to implement, and could have a material adverse effect on the results of operations, particularly if CMS challenges the approach a manufacturer has taken in the implementation of the final regulation. Other regulations and coverage expansion by various governmental agencies relating to the Medicaid Drug Rebate Program may have a similar impact. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Manufacturers have obligations to report the average sales price for certain of drugs to the Medicare program as a part of the agreement to participate in the Medicaid Drug Rebate program. For calendar quarters beginning January&#160;1, 2022, manufacturers are required to report the average sales price for certain drugs under </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">69 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Medicare program regardless of whether they participate in the Medicaid Drug Rebate program. Statutory or regulatory changes or CMS guidance could affect the average sales price calculations for products and the resulting Medicare payment rate, and could negatively affect results of operations. Starting in 2023, manufacturers must pay refunds to Medicare for single source drugs or biologics, or biosimilar biological products, reimbursed under Medicare Part B and packaged in single-dose containers or <span style="white-space:nowrap">single-use</span> packages, for units of discarded drug reimbursed by Medicare Part B in excess of 10% of total allowed charges under Medicare Part B for that drug. Manufacturers that fail to pay refunds could be subject to civil monetary penalties of 125&#160;percent of the refund amount. Congress further could enact a Medicare Part B inflation rebate, under which manufacturers would owe additional rebates if the average sales price of a drug were to increase faster than the pace of inflation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Health Resources and Services Administration (&#8220;HRSA&#8221;) issued a final regulation regarding the calculation of the 340B ceiling price and the imposition of civil monetary penalties on manufacturers that knowingly and intentionally overcharge covered entities, which became effective on January&#160;1, 2019. Implementation of this regulation has affected manufacturer obligations and potential liability under the 340B program. Manufacturers are also required to report the 340B ceiling prices for covered outpatient drugs to HRSA, which then publishes them to 340B covered entities. Any charge by HRSA that a manufacturer has violated the requirements of the program or the regulation could negatively affect financial results. Moreover, under a final regulation effective January&#160;13, 2021, HRSA newly established an administrative dispute resolution (&#8220;ADR&#8221;) process for claims by covered entities that a manufacturer has engaged in overcharging, and by manufacturers that a covered entity violated the prohibitions against diversion or duplicate discounts. Such claims are to be resolved through an ADR panel of government officials rendering a decision that can be appealed to a federal court. An ADR proceeding could subject a manufacturer to onerous procedural requirements and could result in additional liability. Further, any additional future changes to the definition of average manufacturer price and the Medicaid rebate amount under the ACA or otherwise could affect our 340B ceiling price calculations and negatively affect results of operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Civil monetary penalties can be applied if a manufacturer (i)&#160;is found to have knowingly submitted any false price or product information to the government, (ii)&#160;is found to have made a misrepresentation in the reporting of its average sales price, (iii)&#160;fails to submit the required price data on a timely basis, or (iv)&#160;is found to have knowingly and intentionally charged 340B covered entities more than the statutorily mandated ceiling price. CMS could also decide to terminate the Medicaid Drug Rebate Agreement, or HRSA, or to terminate the 340B program participation agreement, in which case federal payments may not be available under Medicaid or Medicare Part B for the manufacturer&#8217;s covered outpatient drugs. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, manufacturers are required to provide to CMS a 70% discount on brand name prescription drugs utilized by Medicare Part D beneficiaries when those beneficiaries are in the coverage gap phase of the Part D benefit design. Congress could enact legislation that sunsets this discount program and replaces it with a new manufacturer discount program. Under either program, civil monetary penalties could be applied if a manufacturer fails to provide these discounts in the amount of 125&#160;percent of the discount that was due. Furthermore, Congress could enact a Medicare Part D inflation rebate, under which manufacturers would owe additional rebates if the average manufacturer price of a drug were to increase faster than the pace of inflation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Congress could also enact additional changes that affect our overall rebate liability and the information we report to the government as part of price reporting calculations. In addition, Congress could enact a drug price negotiation program under which the prices for certain high Medicare spend single source drugs would be capped by reference to the <span style="white-space:nowrap">non-federal</span> average manufacturer price. This or any other legislative change could impact the market conditions for our products. We expect continued scrutiny on government price reporting and pricing more generally from Congress, agencies, and other bodies and are seeing an increase in state interest in price reporting, transparency and other policies to address drug pricing concerns. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">70 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to applicable law, knowing provision of false information in connection with price reporting or contract-based requirements under the VA Federal Supply Schedule and/or Tricare programs can subject a manufacturer to civil monetary penalties. These programs and contract-based obligations also contain extensive disclosure and certification requirements. If a manufacturer overcharges the government in connection with its arrangements with Federal Supply Schedule or Tricare, the manufacturer may be required to refund the difference to the government. Failure to make necessary disclosures or to identify contract overcharges can result in allegations against us under the False Claims Act and other laws and regulations. Unexpected refunds to the government, and/or response to a government investigation or enforcement action, would be expensive and time-consuming, and could have a material adverse effect on our business, financial condition, results of operations and future prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We will need to obtain prior FDA authorization for any proposed product brand names, and any failure or delay associated with such approval may adversely impact our business, financial condition and results of operations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any brand names we intend to use for our product candidates will require authorization from the FDA regardless of whether we have secured a formal trademark registration from the PTO. The FDA typically conducts a review of proposed product brand names, including an evaluation of potential for confusion with other product names. The FDA may also object to a product brand name if it believes the name inappropriately implies medical claims. If the FDA objects to any of our proposed product brand names, we may be required to adopt an alternative brand name for our product candidates. If we adopt an alternative brand name, we would lose the benefit of our existing trademark applications for such product candidate and may be required to expend significant additional resources in an effort to identify a suitable product brand name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA. We may be unable to build a successful brand identity for a new trademark in a timely manner, or at all, which would limit our ability to successfully commercialize our product candidates. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We are subject to the U.S. Foreign Corrupt Practices Act and other anti-corruption laws, as well as export control laws, customs laws, sanctions laws and other laws governing our operations. If we fail to comply with these laws, we could be subject to civil or criminal penalties, other remedial measures, and legal expenses, which could adversely affect our business, financial condition and results of operations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our operations are subject to certain anti-corruption laws, including the FCPA, and other anti-corruption laws that apply in countries where we conduct business, including performing clinical trials. The FCPA and other anti-corruption laws generally prohibit us and our employees and intermediaries from bribing, being bribed or making other prohibited payments to government officials or other persons to obtain or retain business or gain some other business advantage. We, our commercial partners and our affiliates operate in a number of jurisdictions that pose a risk of potential FCPA violations and we participate in collaborations and relationships with third parties whose actions could potentially subject us to liability under the FCPA or local anti-corruption laws. In addition, we cannot predict the nature, scope or effect of future regulatory requirements to which our international operations might be subject or the manner in which existing laws might be administered or interpreted. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There can be no assurance that we will be completely effective in ensuring our compliance with all applicable anti-corruption laws, including the FCPA or other legal requirements, such as trade control laws. Any investigation of potential violations of the FCPA, other anti-corruption laws or trade control laws by U.S., European Union or other authorities could have an adverse impact on our reputation, our business, financial condition and results of operations. Furthermore, should we be found not to be in compliance with the FCPA, other anti-corruption laws or trade control laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures, as well as the accompanying legal expenses, any of which could have a material adverse effect on our reputation and liquidity, as well as on our business, financial condition and results of operations. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">71 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_17">Risks Related to our Relationship with Sorrento </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Certain of our directors and officers may have actual or potential conflicts of interest because of their positions with Sorrento. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mr.&#160;Jaisim Shah, Dr.&#160;Henry Ji, Mr.&#160;Dorman Followwill, Ms.&#160;Laura&#160;J. Hamill, <span style="white-space:nowrap">Dr.&#160;Tien-Li</span> Lee, Mr.&#160;David Lemus and Mr.&#160;Tommy Thompson serve on our Board. Mr.&#160;Jaisim Shah and Dr.&#160;Henry Ji, who are our executive officers, are also members of the board of directors of Sorrento (and in the case of Dr.&#160;Henry Ji, the positions of President, Chief Executive Officer and Chairman of the board of directors of Sorrento). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While our Board has determined that Mr.&#160;Dorman Followwill, Ms.&#160;Laura&#160;J. Hamill, <span style="white-space:nowrap">Dr.&#160;Tien-Li</span> Lee, Mr.&#160;David Lemus and Mr.&#160;Tommy Thompson are &#8220;independent directors&#8221; within the meaning of applicable regulatory and stock exchange requirements in the United States, both Mr.&#160;David Lemus and Mr.&#160;Dorman Followwill have served, and continue to serve, as directors of Sorrento (and in the case of Mr.&#160;Dorman Followwill, the Lead Independent Director of Sorrento) and Tommy Thompson has served, and continues to serve, as special consultant to the Chief Executive Officer of Sorrento, Dr.&#160;Henry Ji. Further, <span style="white-space:nowrap">Dr.&#160;Tien-Li</span> Lee is the founder, the Chief Executive Officer and a director of Aardvark, which has been involved in an asset purchase transaction with Sorrento in connection with Sorrento&#8217;s acquisition of Aardvark&#8217;s delayed burst release low dose naltrexone formulation asset and intellectual property rights. As part of Sorrento&#8217;s investment in Aardvark relating to such asset purchase transaction, Sorrento paid cash for shares of Aardvark&#8217;s Series B Preferred Stock, resulting in Sorrento holding approximately 8% of Aardvark&#8217;s ownership interest as of December&#160;31, 2021. Also as part of such investment, Dr.&#160;Henry Ji joined the board of directors of Aardvark in May 2021. Sorrento and Aardvark may enter into more commercial arrangements in the future. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, such directors and officers may own shares of Sorrento common stock, options to purchase shares of Sorrento common stock or other Sorrento equity awards. These individuals&#8217; holdings of Sorrento common stock, options to purchase shares of Sorrento common stock or other equity awards of Sorrento may be significant for some of these persons compared to these persons&#8217; total assets. Their position at Sorrento and the ownership of any Sorrento equity or equity awards creates, or may create the appearance of, conflicts of interest when these directors and officers are faced with decisions that could have different implications for Sorrento than the decisions have for us. For example, potential conflicts of interest could arise in connection with the resolution of any dispute that may arise between Sorrento and us regarding the terms of the agreements governing the transition services and the relationship thereafter between the companies. Potential conflicts of interest may also arise if we enter into commercial arrangements with Sorrento in the future. As a result of these actual or apparent conflicts, we may be precluded from pursuing certain growth initiatives. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Sorrento currently performs or supports many of our important corporate functions. Our financial statements may not necessarily be indicative of the conditions that would have existed or our results of operations if we had been operated as an unaffiliated company of Sorrento, and we will incur incremental costs as a stand-alone public company. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are in the process of replicating and replacing certain functions, systems and infrastructure to which we no longer have the same access after the Business Combination. We are also making investments and hiring additional employees to operate without the same access to Sorrento&#8217;s existing operational and administrative infrastructure. These initiatives are costly to implement. Due to the scope and complexity of the underlying projects relative to these efforts, the amount of total costs could be materially higher than our estimate, and the timing of the incurrence of these costs is subject to change. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sorrento currently performs or supports many important corporate functions for our company. Our financial statements reflect charges for these services on an allocation basis. As a result, our historical financial statements may not be reflective of conditions that would have existed or what our results of operations would have been had we been a stand-alone public company and no longer a majority-owned subsidiary of Sorrento. Pursuant to agreements we expect to enter into with Sorrento, we expect that Sorrento will continue to provide us with some </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">72 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of the services related to these functions on a transitional basis in exchange for agreed-upon fees, and we expect to incur other costs to replace the services and resources that will not be provided by Sorrento. We are also incurring additional costs as a stand-alone public company. As a stand-alone public company, our total costs related to certain support functions may differ from the costs that were historically allocated to us from Sorrento. In addition, in the future, we expect to incur internal costs to implement certain new systems, including infrastructure and an enterprise resource planning system, while our legacy systems are currently being fully supported by Sorrento. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not be able to replace these services or enter into appropriate third-party agreements on terms and conditions, including costs, comparable to those that we will receive from Sorrento under our agreements with Sorrento. Additionally, after the agreements terminate, we may be unable to sustain the services at the same levels or obtain the same benefits as when we were receiving such services and benefits from Sorrento. When we begin to operate these functions separately, if we do not have our own adequate systems and business functions in place, or are unable to obtain them from other providers, we may not be able to operate our business effectively or at comparable costs, and our profitability may decline. In addition, we have historically received informal support from Sorrento, which may not be addressed in our agreements with Sorrento. The level of this informal support will diminish or cease following the Business Combination. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We are controlled by Sorrento, whose interests may differ from those of our public shareholders. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the date of this prospectus, Sorrento controls approximately 96.6% of our voting power, which means that, based on its percentage voting power, Sorrento controls the vote of all matters submitted to a vote of our stockholders. This control will enable Sorrento to control the election of the members of our Board and all other corporate decisions. In particular, for so long as Sorrento continues to own a majority of our Common Stock, Sorrento will be able to cause or prevent a change of control of the Company or a change in the composition of our Board and could preclude any unsolicited acquisition of the Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Registration Rights Agreement and the Certificate of Incorporation, Sorrento has certain rights, and the ability to take certain actions, that are not otherwise available to all of our stockholders. For example, the Registration Rights Agreement provides Sorrento the right, subject to certain conditions, to demand that we file a registration statement or request that their shares of our Common Stock be covered by a registration statement that we are otherwise filing. See the section titled &#8220;<span style="font-style:italic">Description of Our Securities &#8212; Registration Rights</span>&#8221; for additional information regarding these rights. We have filed the registration statement of which this prospectus forms a part in order to satisfy these obligations. In addition, until such time as Sorrento first ceases to own greater than 50% of the outstanding voting power of our Common Stock, the Certificate of Incorporation effectively provides Sorrento with the ability to fill vacancies on our Board, remove directors (with or without cause), call a special meeting of our stockholders, amend the Certificate of Incorporation (subject to approval of our Board) and amend the Bylaws. The directors so elected will have the authority, subject to the terms of our indebtedness and applicable rules and regulations, to issue additional stock, implement stock repurchase programs, declare dividends and make other decisions. See the section titled &#8220;<span style="font-style:italic">Description of Our Securities &#8212; Anti-Takeover Matters in our Governing Documents and Under Delaware Law</span>&#8221; for additional information regarding Sorrento&#8217;s ability to take such actions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even when Sorrento ceases to control a majority of the total voting power of Scilex, for so long as Sorrento continues to own a significant percentage of our Common Stock and for so long as the Sorrento Group owns any shares of Series A Preferred Stock, Sorrento will still be able to significantly influence the composition of our Board and the approval of actions requiring stockholder approval. Accordingly, for such period of time, Sorrento will have significant influence with respect to our management, business plans and policies. Because of the significant ownership position held by Sorrento, our classified board structure and the rights granted to Sorrento under the Stockholder Agreement, new investors may not be able to effect a change in our business or management. The concentration of ownership and availability of the foregoing rights could deprive our stockholders of an opportunity to receive a premium for their shares of common stock as part of a sale of the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">73 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company and ultimately might affect the market price of our Common Stock. See the risk factor below titled &#8220;<span style="font-style:italic">Sorrento, as the holder of Series A Preferred Stock, will have rights, preferences and privileges that are not held by, and are preferential to, the rights of holders of our Common Stock.</span>&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, the interests of Sorrento may not be aligned with those of our other stockholders and this could lead to actions that may not be in the best interests of our other stockholders. For example, Sorrento may have different tax positions or strategic plans for the Company, which could influence its decisions regarding whether and when we should dispose of assets or incur new or refinance existing indebtedness. Additionally, Sorrento&#8217;s significant ownership in the Company may discourage someone from making a significant equity investment in the Company, or could discourage transactions involving a change in control. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, Sorrento and its affiliates engage in a broad spectrum of activities, including investments in our industry generally. In the ordinary course of their business activities, Sorrento and its affiliates may engage in activities where their interests conflict with our interests or those of our other stockholders, such as investing in or advising businesses that directly or indirectly compete with certain portions of our business or those businesses that are suppliers or customers of ours. The Certificate of Incorporation provides that, to the fullest extent permitted by law, none of Sorrento and its affiliates and any person or entity who, while a stockholder, director, officer or agent of us or any of our affiliates, is a director, officer, principal, partner, member, manager, employee, agent and/or other representative of Sorrento and its affiliates (each an &#8220;Identified Person&#8221;) will have any duty to refrain from (i)&#160;engaging in a corporate opportunity in the same or similar business activities or lines of business in which we or our affiliates are engaged or that are deemed to be competing with us or any of our affiliates or (ii)&#160;otherwise investing in or providing services to any person that competes with us or our affiliates engaging, directly or indirectly, in the same or similar business activities or lines of business in which we operate. In addition, to the fullest extent permitted by law, no Identified Person will have any obligation to offer us or our subsidiaries or affiliates the right to participate in any corporate opportunity in the same or similar business activities or lines of business in which we or our affiliates are engaged or that are deemed to be competing with us or any of our affiliates. This means that Sorrento may pursue acquisition opportunities that may be complementary to our business and, as a result, those acquisition opportunities may not be available to us. In addition, Sorrento may have an interest in pursuing acquisitions, divestitures and other transactions that, in its judgment, could enhance its investment, even though such transactions might involve risks to our stockholders or may not prove beneficial. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, on December&#160;30, 2022, Sorrento announced that its board of directors has authorized Sorrento to dividend to Sorrento equityholders of record as of January&#160;9, 2023 an aggregate of 76,000,000 shares of our Common Stock that are currently held by Sorrento. Provided that the board of directors of Sorrento does not revoke the dividend prior to January&#160;19, 2023, the scheduled payment date therefor, following such dividend Sorrento will still continue to hold approximately 53.3% of our voting power, including shares of our Series A Preferred Stock and shares issuable upon exercise of warrants to purchase shares of our Common Stock, which shares have the rights, preferences and privileges described below, and Sorrento would still have significant rights that are not otherwise available to holders of our Common Stock.&#160;&#160;&#160;&#160; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Sorrento, as the holder of Series A Preferred Stock, has rights, preferences and privileges that are not held by, and are preferential to, the rights of holders of our Common Stock. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Series A Preferred Stock is issued only to Sorrento and is not convertible into shares of our Common Stock. The holders of Series A Preferred Stock have rights, preferences and privileges that are senior, or in addition, to the rights, preferences and privileges of the holders of our Common Stock, including the right to receive, in the event of a change of control, liquidation dissolution or winding up of the Company, a preference amount out of the assets available for distribution to stockholders before any distribution can be made to holders of our Common Stock. The preference amount is $10.00 per share (subject to adjustment as set forth in the Certificate of Designations). If our Board declares or pays a dividend on our Common Stock, the holders of Series A Preferred Stock will participate, on a deemed <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">as-converted-to-common</span></span></span> stock basis, in such dividend with the holders of our Common Stock. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">74 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of Series A Preferred Stock will have certain voting rights over our corporate actions (including, among others, any change to the shares of Series A Preferred Stock into cash or other property, the issuance of equity securities that rank on a parity with or senior to Series A Preferred Stock with respect to dividend rights or rights upon liquidation, dissolution or <span style="white-space:nowrap">winding-up</span> of the Company and the amendment of the Certificate of Incorporation in a manner that adversely affects the holders of shares of Series A Preferred Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the Stockholder Agreement, from and after the Effective Time, and for so long as the Sorrento Group beneficially owns any shares of Series A Preferred Stock, among other things, (i)&#160;Sorrento shall have the right, but not the obligation, to designate each director to be nominated, elected or appointed to our Board (each, a &#8220;Stockholder Designee&#8221; and collectively, the &#8220;Stockholder Designees&#8221;), regardless of whether such Stockholder Designee is to be elected to our Board at a meeting of stockholders called for the purpose of electing directors (or by consent in lieu of meeting) or appointed by our Board in order to fill any vacancy created by the departure of any director or increase in the authorized number of members of our Board, or the size of our Board and (ii)&#160;we are required to take all actions reasonably necessary, and not otherwise prohibited by applicable law, to cause each Stockholder Designee to be so nominated, elected or appointed to our Board as more fully described in the Stockholder Agreement. Sorrento shall also have the right to designate a replacement director for any Stockholder Designee that has been removed from our Board and the right to appoint a representative of Sorrento to attend all meetings of the committees of our Board. Notwithstanding the foregoing, the parties have agreed to ensure that our Board complies with all applicable requirements of the stock exchange, including independence requirements. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Stockholder Agreement also provides that we are prohibited from taking certain actions without the consent of Sorrento. Such actions include, among other things, amendments to the Certificate of Designations, increases or decreases in the size of our Board, the incurrence of certain amounts of indebtedness and the payment of dividends on our Common Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For more information on the terms of Series A Preferred Stock, see the section titled &#8220;<span style="font-style:italic">Description of Our Securities &#8212; Our Preferred Stock</span>&#8221; and the section titled &#8220;<span style="font-style:italic">Certain Relationships and Related Party Transactions &#8212; Certain Relationships of Vickers &#8212; Stockholder Agreement with Sorrento.</span>&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We are subject to recently enacted state laws in California that require gender and diversity quotas for boards of directors of public companies headquartered in California. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2018, California enacted Senator Bill 826 (&#8220;SB 826&#8221;), which generally requires public companies with principal executive offices in California to have at least two female directors on its board of directors if the company has at least five directors, and at least three female directors on its board of directors if the company has at least six directors. SB 826 has been challenged in legal proceedings and on May&#160;13, 2022, the Superior Court of California for the County of Los Angeles entered an order striking down SB 826, holding that the statute violates the Equal Protection Clause of the California Constitution. The California Secretary of State has appealed the order and such appeal is currently pending. On September&#160;16, 2022, the appellate court ruled to temporarily stay enforcement of the trial court&#8217;s order, which prevented the California Secretary of State from collecting diversity data on corporate disclosure forms pursuant to SB&#160;826, pending a further order of the appellate court. To the extent that this ruling of the appellate court permits the Secretary of State of California to collect and report diversity data, we may be required to comply with additional disclosure requirements. However, ultimate enforceability of SB 826 remains uncertain. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, on September&#160;30, 2020, California enacted Assembly Bill 979 (&#8220;AB 979&#8221;), which generally requires public companies with principal executive offices in California to include specified numbers of directors from &#8220;underrepresented communities&#8221;. A director from an &#8220;underrepresented community&#8221; means a director who self-identifies as Black, African American, Hispanic, Latino, Asian, Pacific Islander, Native American, Native Hawaiian, Alaska Native, gay, lesbian, bisexual or transgender. By December&#160;31, 2021, each public company with principal executive offices in California was required to have at least one director from an underrepresented </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">75 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
community. By December&#160;31, 2022, a public company with more than four but fewer than nine directors will be required to have a minimum of two directors from underrepresented communities, and a public company with nine or more directors will need to have a minimum of three directors from underrepresented communities. On April&#160;1, 2022, the Superior Court of California for the County of Los Angeles entered an order striking down AB 979, holding that the statute violates the Equal Protection Clause of the California Constitution. On June&#160;6, 2022, a notice of appeal was filed. On September&#160;16, 2022, the appellate court ruled to temporarily stay enforcement of the trial court&#8217;s order, which prevented the California Secretary of State from collecting diversity data on corporate disclosure forms pursuant to AB&#160;979, pending a further order of the appellate court. To the extent that this ruling of the appellate court permits the Secretary of State of California to collect and report diversity data, we may be required to comply with additional disclosure requirements. Litigation regarding AB&#160;979 will continue. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot assure that we can recruit, attract and/or retain qualified members of our Board and meet gender and diversity quotas under Nasdaq Listing Rules or any California law that may become applicable to the Company, which may expose us to financial penalties and adversely affect our reputation. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_18">Risks Related to this Offering </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">It is not possible to predict the actual number of shares we will sell under the B. Riley Purchase Agreement to the Selling Securityholder, or the actual gross proceeds resulting from those sales. Further, we may not have access to the full amount available under the B. Riley Purchase Agreement with the Selling Securityholder. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January 8, 2023, we entered into the B. Riley Purchase Agreement with the Selling Securityholder, pursuant to which the Selling Securityholder has committed to purchase up to $500,000,000 of our Common Stock, subject to certain limitations and conditions set forth in the B. Riley Purchase Agreement. The shares of our Common Stock that may be issued under the B. Riley Purchase Agreement may be sold by us to the Selling Securityholder at our discretion from time to time. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We generally have the right to control the timing and amount of any sales of our shares of Common Stock to the Selling Securityholder under the B. Riley Purchase Agreement. Sales of our Common Stock, if any, to the Selling Securityholder under the B. Riley Purchase Agreement will depend upon market conditions and other factors to be determined by us. We may ultimately decide to sell to the Selling Securityholder all, some or none of the shares of our Common Stock that may be available for us to sell to the Selling Securityholder pursuant to the B. Riley Purchase Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because the purchase price per share to be paid by the Selling Securityholder for the shares of Common Stock that we may elect to sell to the Selling Securityholder under the B. Riley Purchase Agreement, if any, will fluctuate based on the market prices of our Common Stock prior to each Advance or Additional Advance made pursuant to the B. Riley Purchase Agreement, if any, it is not possible for us to predict, as of the date of this prospectus and prior to any such sales or additional sales, the number of shares of Common Stock that we will sell to the Selling Securityholder under the B. Riley Purchase Agreement, the purchase price per share that the Selling Securityholder will pay for shares purchased from us under the B. Riley Purchase Agreement, or the aggregate gross proceeds that we will receive from those purchases by the Selling Securityholder under the B. Riley Purchase Agreement, if any. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, although the B. Riley Purchase Agreement provides that we may sell up to an aggregate of $500,000,000 of our Common Stock to the Selling Securityholder, only 28,128,422 shares of our Common Stock (including the aggregate amount of 250,000 Commitment Shares issued to the Selling Securityholder pursuant to the B. Riley Purchase Agreement) are being registered for resale under the registration statement of which this prospectus forms a part. If we elect to sell to the Selling Securityholder all of the 28,128,422 shares of Common Stock being registered for resale under this prospectus, depending on the market price of our Common Stock prior to each Advance or Additional Advance made pursuant to the B. Riley Purchase Agreement, the actual </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">76 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
gross proceeds from the sale of all such shares may be substantially less than the $500,000,000 available to us under the B. Riley Purchase Agreement, which could materially adversely affect our liquidity. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If it becomes necessary for us to issue and sell to the Selling Securityholder under the B. Riley Purchase Agreement more than the 28,128,422 shares being registered for resale under this prospectus in order to receive aggregate gross proceeds equal to $500,000,000 under the B. Riley Purchase Agreement, we must file with the SEC one or more additional registration statements to register under the Securities Act the resale by the Selling Securityholder of any such additional shares of our Common Stock we wish to sell from time to time under the B. Riley Purchase Agreement, which the SEC must declare effective. Additionally, we would need to obtain stockholder approval to issue shares of Common Stock in excess of the Exchange Cap under the B. Riley Purchase Agreement in accordance with applicable Nasdaq Listing Rules, unless the average price of all applicable sales of shares of Common Stock under the B. Riley Purchase Agreement equals or exceeds the &#8220;Minimum Price&#8221; (as such term is defined in Rule 5635 of the Nasdaq Listing Rules), in which case the Exchange Cap limitation would not apply to issuances and sales of Common Stock under the B. Riley Purchase Agreement. Any issuance and sale by us under the B. Riley Purchase Agreement of shares of Common Stock in addition to the 28,128,422 shares of Common Stock being registered for resale by the Selling Securityholder under the registration statement of which this prospectus forms a part could cause additional dilution to our stockholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are not required or permitted to issue any shares of Common Stock under the B. Riley Purchase Agreement if such issuance would breach our obligations under the rules or regulations of Nasdaq. In addition, the Selling Securityholder will not be required to purchase any shares of our Common Stock if such sale or additional sale would result in the Selling Securityholder&#8217;s beneficial ownership exceeding 4.99% of the then outstanding voting power or number of Common Stock. Our inability to access a part or all of the amount available under the B. Riley Purchase Agreement, in the absence of any other financing sources, could have a material adverse effect on our business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The sale and issuance of our Common Stock to the Selling Securityholder will cause dilution to our existing stockholders, and the sale of the shares of Common Stock acquired by the Selling Securityholder, or the perception that such sales may occur, could cause the price of our Common Stock to fall. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purchase price for the shares that we may sell to the Selling Securityholder under the B. Riley Purchase Agreement will fluctuate based on the price of our Common Stock. Depending on a number of factors, including market liquidity, sales of such shares may cause the trading price of our Common Stock to fall. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If and when we do sell shares to the Selling Securityholder, the Selling Securityholder may resell all, some, or none of those shares at its discretion, subject to the terms of the B. Riley Purchase Agreement. Therefore, sales to the Selling Securityholder by us could result in substantial dilution to the interests of other holders of our Common Stock. Additionally, the sale of a substantial number of shares of our Common Stock to the Selling Securityholder, or the anticipation of such sales, could make it more difficult for us to sell equity or equity-related securities in the future at a desirable time and price. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Investors who buy shares of Common Stock at different times will likely pay different prices. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the B. Riley Purchase Agreement, we control the timing and amount of any sales of Common Stock to the Selling Securityholder. If and when we do elect to sell shares of our Common Stock to the Selling Securityholder pursuant to the B. Riley Purchase Agreement, the Selling Securityholder may resell all, some, or none of such shares in its discretion and at different prices, subject to the terms of the B. Riley Purchase Agreement. As a result, investors who purchase shares from the Selling Securityholder in this offering at different times will likely pay different prices for those shares, and so may experience different levels of dilution and, in some cases, substantial dilution and different outcomes in their investment results. Investors may experience a decline in the value of the shares they purchase from the Selling Securityholder in this offering as a </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">77 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
result of future sales made by us to the Selling Securityholder at prices lower than the prices such investors paid for their shares in this offering. In addition, if we sell a substantial number of shares to the Selling Securityholder under the B. Riley Purchase Agreement, or if investors expect that we will do so, the actual sales of shares or the mere existence of our arrangement with the Selling Securityholder may make it more difficult for us to sell equity or equity-related securities in the future at a desirable time and price. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our management team will have broad discretion over the use of the net proceeds from our sale of shares of Common Stock to the Selling Securityholder, if any, and you may not agree with how we use the proceeds and the proceeds may not be invested successfully. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management team will have broad discretion as to the use of the net proceeds from our sale of shares of Common Stock to the Selling Securityholder, if any, and we could use such proceeds for purposes other than those contemplated at the time of commencement of this offering. Accordingly, you will be relying on the judgment of our management team with regard to the use of those net proceeds, and you will not have the opportunity, as part of your investment decision, to assess whether the proceeds are being used appropriately. It is possible that, pending their use, we may invest those net proceeds in a way that does not yield a favorable, or any, return for us. The failure of our management team to use such funds effectively could have a material adverse effect on our business, financial condition, operating results and cash flows. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_19">Risks Related to Ownership of our Common Stock </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If our operations and performance do not meet the expectations of investors or securities analysts, the market price of our securities may decline. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of the factors listed below could have a negative impact on your investment in our securities, and our securities may trade at prices significantly below the price you paid for them. In such circumstances, the trading price of our securities may not recover and may experience a further decline. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Factors affecting the trading price of our securities may include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to commercialize ZTlido, GLOPERBA or our product candidates, if approved; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the status and cost of our marketing commitments for ZTlido, GLOPERBA and our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">announcements regarding results of any clinical trials relating to our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">unanticipated serious safety concerns related to the use of ZTlido, GLOPERBA or any of our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">adverse regulatory decisions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes in laws or regulations applicable to ZTlido, GLOPERBA or our product candidates, including but not limited to clinical trial requirements for approvals; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">legal disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for ZTlido, GLOPERBA or our product candidates, government investigations and the results of any proceedings or lawsuits, including, but not limited to, patent or stockholder litigation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our decision to initiate a clinical trial, not initiate a clinical trial or to terminate an existing clinical trial; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our dependence on third parties; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">announcements of the introduction of new products by our competitors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">market conditions and trends in the pharmaceutical and biotechnology sectors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">announcements concerning product development results or intellectual property rights of others; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">78 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">future issuances of common stock or other securities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the recruitment or departure of key personnel; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">failure to meet or exceed any financial guidance or expectations regarding product development milestones that we may provide to the public; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">actual or anticipated variations in quarterly operating results; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our failure to meet or exceed the estimates and projections of the investment community; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">overall performance of the equity markets and other factors that may be unrelated to our operating performance or the operating performance of our competitors, including changes in market valuations of similar companies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us or our competitors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes in financial estimates by the Company or by any securities analysts who might cover our stock; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">fluctuation of the market values of any of our potential strategic investments; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">issuances of debt or equity securities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">compliance with our contractual obligations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">sales of our Common Stock by us or our stockholders in the future; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">trading volume of our Common Stock; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">ineffectiveness of our internal controls; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">publication of research reports about the Company or its industry or positive or negative recommendations or withdrawal of research coverage by securities analysts; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">failure to effectively integrate the operations of Semnur; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">general political and economic conditions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">effects of natural or <span style="white-space:nowrap">man-made</span> catastrophic events; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">effects of public health crises, pandemics and epidemics, such as the <span style="white-space:nowrap">COVID-19</span> pandemic; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">other events or factors, many of which are beyond our control. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, the equity markets in general have recently experienced extreme price and volume fluctuations. Continued market fluctuations could result in extreme volatility in the price of our Common Stock, which could cause a decline in the value of our Common Stock. Price volatility of our Common Stock might worsen if the trading volume of our Common Stock is low. In the past, stockholders have initiated class action lawsuits against pharmaceutical and biotechnology companies following periods of volatility in the market prices of these companies&#8217; stock. Such litigation, if instituted against the Company, could cause us to incur substantial costs and divert management&#8217;s attention and resources from our business. The realization of any of the above risks or any of a broad range of other risks, including those described in these &#8220;<span style="font-style:italic">Risk Factors</span>&#8221;, could have a dramatic and material adverse impact on the market price of our Common Stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Legacy Scilex has not paid cash dividends in the past and we do not expect to pay cash dividends in the foreseeable future. Any return on investment may be limited to the capital appreciation, if any, of our Common Stock. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Legacy Scilex has not paid cash dividends on its common stock and we do not anticipate paying cash dividends on our Common Stock in the foreseeable future. Should we decide in the future to do so, as a holding </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">79 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
company, our ability to pay dividends on our capital stock and meet other obligations depends upon the receipt of dividends or other payments from our operating subsidiaries, including Legacy Scilex. In addition, our ability to pay dividends may be limited by covenants in future outstanding indebtedness that we or our subsidiaries may incur. Since we do not intend to pay dividends, a stockholder&#8217;s ability to receive a return on such stockholder&#8217;s investment will depend on any future appreciation in the market value of our Common Stock. There is no guarantee that our Common Stock will appreciate or even maintain the price at which our stockholders have purchased it. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Future sales of a substantial number of shares of our Common Stock may cause the price of our Common Stock to decline. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our existing stockholders sell, or indicate an intention to sell, substantial amounts of our Common Stock, the trading price of our Common Stock could decline and it could impair our ability to raise capital through the sale of additional equity securities. Unless otherwise waived by the Company and the applicable parties to the Registration Rights Agreement, Sorrento and certain directors and equityholders of Vickers, including the Sponsors, are subject to <span style="white-space:nowrap">lock-up</span> provisions that restrict their ability to transfer certain of their shares of our Common Stock or any security convertible into or exercisable or exchanged for our Common Stock until 180 days from the Effective Time, subject to certain exceptions. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our operating results may fluctuate significantly. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect our operating results to be subject to quarterly, and possibly annual, fluctuations. Our net loss and other operating results will be affected by numerous factors, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">variations in the level of expenses related to our development programs; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the addition or termination of clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any intellectual property infringement lawsuit in which we may become involved; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">regulatory developments affecting ZTlido, GLOPERBA or our product candidates, regulatory approvals of our product candidates, and the level of underlying demand for such products and purchasing patterns; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our execution of any collaborative, licensing or similar arrangements, and the timing of payments we may make or receive under these arrangements. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our quarterly or annual operating results fall below the expectations of investors or securities analysts, the price of our Common Stock could decline substantially. Furthermore, any quarterly or annual fluctuations in our operating results may, in turn, cause the price of our Common Stock to fluctuate substantially. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse opinion regarding our stock, our stock price and trading volume could decline. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trading market for our Common Stock will be influenced by the research and reports that industry or securities analysts publish about the Company or our business. We do not currently have and may never obtain research coverage by securities and industry analysts. Since we became public through a merger, securities analysts of major brokerage firms may not provide coverage of the Company since there is no incentive to brokerage firms to recommend the purchase of our Common Stock. If no or few securities or industry analysts commence coverage of the Company, the trading price for our stock would be negatively impacted. In the event we obtain securities or industry analyst coverage, if any of the analysts who cover it issues an adverse opinion regarding the Company, our business model, our intellectual property or our stock performance, or if our clinical trials and operating results fail to meet the expectations of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of the Company or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">80 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to ZTlido or our product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue additional equity securities to fund future expansion and pursuant to equity incentive or employee benefit plans. We may also issue additional equity for other purposes. These securities may have the same rights as our Common Stock or, alternatively, may have dividend, liquidation or other preferences to our Common Stock. The issuance of additional equity securities, whether pursuant to the B. Riley Purchase Agreement, the Yorkville Purchase Agreement (pursuant to which may also sell up to $500,000,000 of shares of our Common Stock, as more fully described elsewhere in this prospectus) or otherwise, will dilute the holdings of existing stockholders and may reduce the share price of our Common Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Equity Incentive Plan, which became effective on November&#160;9, 2022, we are authorized to grant equity awards to our employees, directors and consultants. In addition, pursuant to the ESPP, which became effective on November&#160;9, 2022, we are authorized to sell shares to our employees. A total of 20,276,666 and 2,875,759 shares of our Common Stock have been reserved for future issuance under the Equity Incentive Plan and the ESPP, respectively. In addition, the Equity Incentive Plan and ESPP provide for annual automatic increases in the number of shares reserved thereunder, in each case, beginning on January&#160;1, 2023. As a result of such annual increases, our stockholders may experience additional dilution, which could cause the price of our Common Stock to fall. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Registration Rights Agreement entered into in connection with the Business Combination, certain stockholders of Vickers and Legacy Scilex can each demand that we register their registrable securities under certain circumstances and will each also have piggyback registration rights for these securities. In addition, we are required to file and maintain an effective registration statement under the Securities Act covering such securities and certain of our other securities. We have filed the registration statement of which this prospectus forms a part in order to satisfy the foregoing obligations. The registration of these securities will permit the public sale of such securities, subject to certain contractual restrictions imposed by the Registration Rights Agreement and the Merger Agreement. The presence of these additional shares of our Common Stock trading in the public market may have an adverse effect on the market price of our securities. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we raise additional funds through collaboration, licensing or other similar arrangements, we may have to relinquish valuable rights to ZTlido or our product candidates, or grant licenses on terms unfavorable to the Company. If adequate funds are not available, our ability to achieve profitability or to respond to competitive pressures would be significantly limited and we may be required to delay, significantly curtail or eliminate the development of our product candidates. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our principal stockholders, directors and executive officers will own a significant percentage of our capital stock, and have significant influence over our management. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our directors, executive officers, holders of 5% or more of our capital stock and their respective beneficially own, in the aggregate, approximately 97% of our outstanding voting stock (and following the dividend of 76,000,000 shares of our Common Stock by Sorrento to certain of its equityholders, approximately 60% of our outstanding voting stock). This concentration of voting power may make it less likely that any other holder of our Common Stock will be able to affect the way we are managed and could delay or prevent an acquisition of the Company on terms that other stockholders may desire. This could prevent transactions in which stockholders might otherwise recover a premium for their shares over current market prices. See &#8220;<span style="font-style:italic">Risk Factors &#8212; We are</span> <span style="font-style:italic">controlled by Sorrento, whose interests may differ from those of our public shareholders</span>&#8221; above for additional information regarding Sorrento&#8217;s influence and control in the Company. See &#8220;<span style="font-style:italic">Security Ownership of Certain Beneficial Owners and Management</span>&#8221; for information regarding the ownership of our outstanding Common Stock by our directors, executive officers, and current beneficial owners of 5% or more of our voting securities and their respective affiliates. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">81 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our ability to use our net operating loss and tax credit carryforwards may be subject to limitation. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, a change of more than 50% in the ownership of a company&#8217;s stock, by value, over a three-year period constitutes an ownership change for U.S. federal income tax purposes. An ownership change may limit our ability to use our net operating loss carryforwards attributable to the period prior to the change. We have experienced a corporate reorganization in the past, some ownership changes as a result of the Business Combination and/or some subsequent changes in the future in our stock ownership (some of which shifts are outside our control). As a result, if we earn net taxable income, our ability to use our <span style="white-space:nowrap">pre-change</span> net operating loss carryforwards to offset U.S. federal taxable income may become subject to limitations, which could potentially result in increased future tax liability for the Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Tax Cuts and Jobs Act of 2017 (the &#8220;TCJA&#8221;), as amended by the CARES Act, includes changes to U.S. federal tax rates and the rules governing net operating loss (&#8220;NOL&#8221;) carryforwards. Under the TCJA, as modified by the CARES Act, limits a taxpayer&#8217;s ability to utilize NOL carryforwards to 80% of taxable income (as calculated before taking the NOLs, and certain other tax attributes, into account) for taxable years beginning after December&#160;31, 2020. In addition, NOLs arising in tax years ending after December&#160;31, 2017 and before January&#160;1, 2021 may be carried back to each of the five taxable years preceding the tax year of such loss, but NOLs arising in taxable years beginning after December&#160;31, 2020 and before January&#160;1, 2026 may not be carried back. NOLs arising in tax years beginning after December&#160;31, 2017 can be carried forward indefinitely. NOLs generated in tax years beginning before January&#160;1, 2021 will not be subject to the taxable income limitation, and NOLs generated in tax years ending before January&#160;1, 2018 will continue to have a <span style="white-space:nowrap">two-year</span> carryback and <span style="white-space:nowrap">20-year</span> carryforward period. Deferred tax assets for NOLs will need to be measured at the applicable tax rate in effect when the NOL is expected to be utilized. The changes in the carryforward/carryback periods, as well as the new limitation on use of NOLs may significantly impact our ability to utilize our NOLs to offset taxable income in the future. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If our estimates or judgments relating to our critical accounting policies are based on assumptions that change or prove to be incorrect, our operating results could fall below our publicly announced guidance or the expectations of securities analysts and investors, resulting in a decline in the market price of our Common Stock. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in our combined consolidated financial statements and accompanying notes. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets, liabilities, equity, revenue and expenses that are not readily apparent from other sources. If our assumptions change or if actual circumstances differ from our assumptions, our operating results may be adversely affected and could fall below our publicly announced guidance or the expectations of securities analysts and investors, resulting in a decline in the market price of our Common Stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Anti-takeover provisions in the Certificate of Incorporation and the Bylaws and under Delaware law could make an acquisition of our Company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation and the Bylaws and the DGCL contains provisions that could make it more difficult for a third party to acquire the Company, even if doing so might be beneficial to our stockholders. Among other things, these provisions include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">allow our Board to authorize the issuance of undesignated preferred stock, the terms of which may be established and the shares of which may be issued without stockholder approval, and which may include supermajority voting, special approval, dividend, or other rights or preferences superior to the rights of other stockholders; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">82 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">provide for a classified board of directors with staggered three-year terms; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">provide that, at any time after the Sorrento Group first ceases to beneficially own more than 50% in voting power of the then-outstanding shares of our Common Stock entitled to vote generally in the election of directors (the &#8220;Sorrento Trigger Event&#8221;), directors may only be removed for cause, and only by the affirmative vote of holders of at least 66 2/3% in voting power of all the then-outstanding shares of our Common Stock entitled to vote thereon, voting together as a single class; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">prohibit stockholder action by written consent from and after the Sorrento Trigger Event; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">provide that, at any time after the Sorrento Trigger Event, special meetings may only be called by or at the direction of the Chairperson of the Board, the Board or the Chief Executive Officer; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">provide that, at any time after the Sorrento Trigger Event, any alteration, amendment or repeal, in whole or in part, of any provision of the Bylaws by our stockholders will require the affirmative vote of the holders of at least 66 2/3% in voting power of all the then-outstanding shares of our Common Stock entitled to vote thereon, voting together as a single class; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">establish advance notice requirements for nominations for elections to the Board and for proposing matters that can be acted upon by stockholders at stockholder meetings. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&#160;203 of the DGCL generally prohibits a Delaware corporation from engaging in any of a broad range of business combinations with any interested stockholder for a period of three years following the date on which the stockholder became an interested stockholder. We have expressly elected not to be governed by Section&#160;203 of the DGCL until the occurrence of a Sorrento Trigger Event. At that time, such election shall be automatically withdrawn and we will thereafter be governed by Section&#160;203 of the DGCL, except that the restrictions on business combinations of Section&#160;203 of the DGCL will not apply to Sorrento or its current or future Affiliates (as defined in the Certificate of Incorporation) regardless of its percentage ownership of our Common Stock. These provisions could discourage, delay or prevent a transaction involving a change in control of the Company. These provisions could also discourage proxy contests and make it more difficult for our stockholders to elect directors of their choosing and cause us to take other corporate actions they desire, including actions that our stockholders may deem advantageous. In addition, because our Board is responsible for appointing the members of our management team, these provisions could in turn affect any attempt by our stockholders to replace current members of our management team. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These anti-takeover provisions and other provisions in the Certificate of Incorporation, the Bylaws and Delaware law could make it more difficult for stockholders or potential acquirors to obtain control of the Board or initiate actions that are opposed by our then-current board of directors and could also delay or impede a merger, tender offer or proxy contest involving the Company. The existence of these provisions could negatively affect the price of our Common Stock and limit opportunities for a stockholder to realize value in a corporate transaction. For information regarding these and other provisions, see the section titled &#8220;<span style="font-style:italic">Description of Our Securities.</span>&#8221; In addition, if prospective takeovers are not consummated for any reason, we may experience negative reactions from the financial markets, including negative impacts on the price of our Common Stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The Certificate of Incorporation designates the Court of Chancery of the State of Delaware as the exclusive forum for certain litigation that may be initiated by our stockholders and the federal district courts of the United States as the exclusive forum for litigation arising under the Securities Act, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with the Company. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Certificate of Incorporation, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if and only if the Court of Chancery of the State of Delaware lacks subject matter jurisdiction, any state court located within the State of Delaware or, if and only if all such state courts lack subject matter jurisdiction, the federal district court for the District of Delaware) and any appellate court therefrom, will, to the fullest extent permitted by law, be the sole and exclusive forum for </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">83 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(i)&#160;any derivative action or proceeding brought on our behalf; (ii)&#160;any action asserting a claim of breach of a fiduciary duty owed by any of our current or former directors, officers, employees or stockholders to us or our stockholders; (iii)&#160;any action asserting a claim against us or any of our current or former directors, officers, employees or stockholders arising pursuant to any provision of the DGCL, the Certificate of Incorporation or the Bylaws; (iv)&#160;any claim or cause of action seeking to interpret, apply, enforce or determine the validity of the Certificate of Incorporation or the Bylaws; (v)&#160;any action or proceeding asserting a claim against us or any of our current or former directors, officers, employees or stockholders as to which the DGCL confers jurisdiction to the Court of Chancery of the State of Delaware and (vi)&#160;any action asserting an &#8220;internal corporate claim,&#8221; as that term is defined in Section&#160;115 of the DGCL; <span style="font-style:italic">provided that</span>, for the avoidance of doubt, the foregoing forum selection provision will not apply to claims arising under the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation also provides that, unless we consent in writing to the selection of an alternative forum, to the fullest extent permitted by law, the federal district courts of the United States shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. The Certificate of Incorporation further provides that any person or entity purchasing or otherwise acquiring any interest in shares of our Common Stock is deemed to have notice of and consented to the provisions of the Certificate of Incorporation described above. See the section titled &#8220;<span style="font-style:italic">Description of Our Securities &#8212; Anti-Takeover Measures in our Governing Documents and Under Delaware Law &#8212; Exclusive Forum</span>.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The forum selection provisions in the Certificate of Incorporation may have the effect of discouraging lawsuits against our directors and officers. The enforceability of similar choice of forum provisions in other companies&#8217; certificates of incorporation has been challenged in legal proceedings and there is uncertainty as to whether a court would enforce such provisions. In addition, investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder. If the enforceability of our forum selection provisions were to be challenged, it may incur additional costs associated with resolving such challenge. While we currently have no basis to expect any such challenge would be successful, if a court were to find its forum selection provisions to be inapplicable or unenforceable with respect to one or more of these specified types of actions or proceedings, we may incur additional costs associated with having to litigate in other jurisdictions, which could result in a diversion of the time and resources of our employees, management and board of directors, and could have an adverse effect on our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We are an emerging growth company, and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies will make our Common Stock less attractive to investors. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an emerging growth company, as defined in the JOBS Act. For as long as we continue to be an emerging growth company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements and exemptions from the requirements of holding nonbinding advisory stockholder votes on executive compensation and stockholder approval of any golden parachute payments not previously approved. We cannot predict if investors will find our Common Stock less attractive because we may rely on these exemptions. If some investors find our Common Stock less attractive as a result, there may be a less active trading market for our Common Stock and our stock price may be more volatile. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will remain an emerging growth company until the earlier of (1)&#160;the last day of the fiscal year (a)&#160;following the fifth anniversary of the closing of the IPO, (b)&#160;in which we have total annual gross revenue of at least $1.235&#160;billion, or (c)&#160;in which we are deemed to be a large accelerated filer, which requires the market value of our Common Stock that is held by <span style="white-space:nowrap">non-affiliates</span> to equal or exceed $700&#160;million as of the last business day of the second fiscal quarter of such year, and (2)&#160;the date on which we have issued more than $1&#160;billion in <span style="white-space:nowrap">non-convertible</span> debt during the prior three-year period. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">84 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the JOBS Act, emerging growth companies can also delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. As a result, changes in rules of U.S. generally accepted accounting principles or their interpretation, the adoption of new guidance or the application of existing guidance to changes in our business could significantly affect our business, financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We are a controlled company within the meaning of the Nasdaq Listing Rules and, as a result, will qualify for, and may rely on, exemptions from certain corporate governance requirements. Our stockholders may not have the same protection afforded to stockholders of companies that are subject to such governance requirements. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sorrento controls a majority of the voting power of our outstanding shares of Common Stock. As a result, we are a &#8220;controlled company&#8221; within the meaning of the corporate governance standards of Nasdaq. Under these corporate governance standards, a company of which more than 50% of the voting power for the election of directors is held by an individual, group or another company is a &#8220;controlled company&#8221; and may elect not to comply with certain corporate governance requirements. For example, controlled companies, within one year of the date of the listing of their common stock: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">are not required to have a board that is composed of a majority of &#8220;independent directors&#8221; as defined under the Nasdaq Listing Rules; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">are not required to have a compensation committee that is composed entirely of independent directors or have a written charter addressing the committee&#8217;s purpose and responsibilities; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">are not required to have director nominations be made, or recommended to the full board of directors, by its independent directors or by a nominating and corporate governance committee that is composed entirely of independent directors, and to adopt a written charter or a board resolution addressing the nominations process. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While we do not presently intend to rely on these exemptions, we may opt to utilize these exemptions in the future as long as we remain a controlled company. Accordingly, our stockholders may not have the same protections afforded to stockholders of companies that are subject to all of the corporate governance requirements of Nasdaq. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we cease to be a &#8220;controlled company&#8221; in the future, we will be required to comply with the Nasdaq listing standards, which may require replacing a number of our directors and will require development of certain other governance-related policies and practices. These and any other actions necessary to achieve compliance with such rules may increase our legal and administrative costs, will make some activities more difficult, time-consuming and costly and may also place additional strain on our personnel, systems and resources. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We will incur increased costs as a result of operating as a public company, and our management will devote substantial time to related compliance initiatives. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We incur significant legal, accounting and other expenses that Legacy Scilex did not incur as a private company, and these expenses may increase even more after we are no longer an &#8220;emerging growth company.&#8221; We are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act (the &#8220;Dodd-Frank Act&#8221;), as well as rules and regulations adopted, and to be adopted, by the SEC and Nasdaq. Our management and other personnel need to devote a substantial amount of time to these compliance initiatives. Moreover, we expect these rules and regulations to substantially increase our legal and financial compliance costs and to make some activities more time-consuming and costly, which will increase our operating expenses. For example, we expect these rules and regulations to make it more difficult and more expensive for the Company to obtain directors&#8217; and officers&#8217; liability insurance and we may be </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">85 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
required to incur substantial costs to maintain sufficient coverage. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on the Board, our board committees or as executive officers. Advocacy efforts by stockholders and third parties may also prompt additional changes in governance and reporting requirements, which could further increase costs. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we expect that we will need to implement an enterprise resource planning (&#8220;ERP&#8221;) system. An ERP system is intended to combine and streamline the management of our financial, accounting, human resources, sales and marketing and other functions, enabling it to manage operations and track performance more effectively. However, an ERP system would likely require us to complete many processes and procedures for the effective use of the system or to run our business using the system, which may result in substantial costs. Any disruptions or difficulties in implementing or using an ERP system could adversely affect our controls and harm our business, financial condition and results of operations, including our ability to forecast or make sales and collect our receivables. Moreover, such disruption or difficulties could result in unanticipated costs and diversion of management attention. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a public company, we are required to incur additional costs and obligations in order to comply with SEC rules that implement Section&#160;404 of the Sarbanes-Oxley Act. Under these rules, we are required to make a formal assessment of the effectiveness of our internal control over financial reporting, and once we cease to be an emerging growth company, we will be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with Section&#160;404 within the prescribed period, we will be engaging in a process to document and evaluate its internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of our internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are designed and operating effectively, and implement a continuous reporting and improvement process for internal control over financial reporting. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The rules governing the standards that must be met for management to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation to meet the detailed standards under the rules. During the course of our testing, our management may identify material weaknesses or deficiencies which may not be remedied in time to meet the deadline imposed by the Sarbanes-Oxley Act. See &#8220;<span style="font-style:italic">Risk Factors &#8212; We have identified a material weakness in our internal control over financial reporting. Any material weakness may cause us to fail to timely and accurately report our financial results or</span> <span style="font-style:italic">result in a material misstatement of our financial statements.</span>&#8221; above for additional information regarding a previously identified material weakness. These reporting and other obligations place significant demands on our management and administrative and operational resources, including accounting resources. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, changing laws, regulations and standards relating to corporate governance and public disclosure are creating uncertainty for public companies, increasing legal and financial compliance costs and making some activities more time-consuming. These laws, regulations and standards are subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. We intend to invest resources to comply with evolving laws, regulations and standards, and this investment may result in increased general and administrative expenses and a diversion of our management&#8217;s time and attention from revenue-generating activities to compliance activities. If our efforts to comply with new laws, regulations and standards differ from the activities intended by regulatory or governing bodies due to ambiguities related to their application and practice, regulatory authorities may initiate legal proceedings against us and there could be a material adverse effect on our business, financial condition and results of operations. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">86 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our failure to meet Nasdaq&#8217;s continued listing requirements could result in a delisting of our Common Stock. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we fail to satisfy Nasdaq&#8217;s continued listing requirements, such as the corporate governance requirements or the minimum closing bid price requirement, Nasdaq may take steps to delist our Common Stock. Such a delisting would likely have a negative effect on the price of our Common Stock and would impair a stockholder&#8217;s ability to sell or purchase our Common Stock when a stockholder wishes to do so. In the event of a delisting, we can provide no assurance that any action taken by us to restore compliance with listing requirements would allow our Common Stock to become listed again, stabilize the market price or improve the liquidity of our Common Stock, prevent our Common Stock from dropping below the Nasdaq minimum bid price requirement or prevent future <span style="white-space:nowrap">non-compliance</span> with Nasdaq&#8217;s listing requirements. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Comprehensive U.S. federal income tax reform could adversely affect the Company. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Changes to tax laws, which changes may have retroactive application, could adversely affect the Company or holders of our Common Stock. In recent years, many changes have been made to applicable tax laws and changes are likely to continue to occur in the future. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The TCJA, which was enacted in 2017, included changes to U.S. federal tax rates, imposed significant additional limitations on the deductibility of interest, allowed for the expensing of capital expenditures, and put into effect the migration from a &#8220;worldwide&#8221; system of taxation to a modified territorial system. On March&#160;27, 2020, President Trump signed into law the CARES Act, which included certain changes in tax law (including to the TCJA) intended to stimulate the U.S. economy in light of the <span style="white-space:nowrap">COVID-19</span> pandemic, including temporary beneficial changes to the treatment of net operating losses, interest deductibility limitations and payroll tax matters. On August&#160;16, 2022, President Biden signed into law the Inflation Reduction Act of 2022, which contained certain tax measures, including a corporate alternative minimum tax of 15% on some large corporations, an excise tax of 1% on certain corporate stock <span style="white-space:nowrap">buy-backs,</span> and an excise tax with respect to certain drug sales for failing to offer a price that is not equal to or less than the negotiated &#8220;maximum fair price&#8221; under the law or for taking price increases that exceed inflation. Future changes in tax laws could have a material adverse effect on our business, cash flow, financial condition or results of operations. The impact of these tax reforms on holders of our Common Stock is uncertain and could be adverse. We urge our stockholders to consult with their legal and tax advisors with respect to such legislation and the potential tax consequences of investing in our Common Stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The Warrants will become exercisable for our Common Stock, which would increase the number of shares eligible for future resale in the public market and result in dilution to our stockholders. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Outstanding warrants to purchase an aggregate of 11,003,988 shares of our Common Stock are exercisable in accordance with the terms of the Warrant Agreement governing those securities. The exercise price of these Warrants is $11.50 per share. To the extent such Warrants are exercised, additional shares of our Common Stock will be issued, which will result in dilution to the holders of our Common Stock and increase the number of shares eligible for resale in the public market. Sales of substantial numbers of such shares in the public market, or the fact that such Warrants may be exercised, could adversely affect the prevailing market prices of our Common Stock. However, there is no guarantee that the Warrants will ever be in the money prior to their expiration, and as such, the Warrants may expire worthless. See below risk factor, &#8220;<span style="font-style:italic">The Warrants may never be in the money, and they may expire worthless and the terms of the Warrants may be amended in a manner adverse to a holder if holders of a majority of the then-outstanding Warrants approve of such amendment</span>.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The Warrants may never be in the money, they may expire worthless and the terms of the Warrants may be amended in a manner adverse to a holder if holders of a majority of the then-outstanding Warrants approve of such amendment. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Warrants were issued in registered form under the Warrant Agreement between Continental, as warrant agent, and Vickers. The Warrant Agreement provides that the terms of the Warrants may be amended without the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">87 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
consent of any holder to cure any ambiguity or correct any defective provision or correct any mistake, but requires the approval by the holders of a majority of the then-outstanding Warrants to make any change that adversely affects the interests of the registered holders of Warrants. Accordingly, we may amend the terms of the Warrants in a manner adverse to a holder if holders of a majority of the then-outstanding Warrants approve of such amendment. Although our ability to amend the terms of the Warrants with the consent of majority of the then-outstanding Warrants is unlimited, examples of such amendments could be amendments to, among other things, increase the exercise price of the Warrants, convert the Warrants into cash, shorten the exercise period, or decrease the number of shares of our Common Stock purchasable upon exercise of a Warrant. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may redeem any unexpired Warrants prior to their exercise at a time that is disadvantageous to you, thereby making the Warrants worthless. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have the ability to redeem outstanding Warrants at any time after they become exercisable and prior to their expiration, at a price of $0.01 per Warrant, provided that the closing price of our Common Stock equals or exceeds $18.00 per share (as adjusted for share subdivisions, share dividends, rights issuances, subdivisions, reorganizations, recapitalizations and the like) on each of the 20 trading days within any <span style="white-space:nowrap"><span style="white-space:nowrap">30-trading-day</span></span> period commencing after the Warrants become exercisable and ending on the third trading day prior to the date on which notice of redemption is given. If and when the Warrants become redeemable by us, we may exercise our redemption right even if we are unable to register or qualify the underlying securities for sale under all applicable state securities laws. Redemption of the outstanding Warrants could force the holders thereof to: (i)&#160;exercise such Warrants and pay the exercise price therefor at a time when it may be disadvantageous for a holder to do so; (ii)&#160;sell such Warrants at the then-current market price when a holder might otherwise wish to hold such Warrants; or (iii)&#160;accept the nominal redemption price that, at the time the outstanding Warrants are called for redemption, is likely to be substantially less than the market value of such Warrants. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we may redeem the Warrants at any time after they become exercisable and prior to their expiration for a number of shares of our Common Stock determined based on the fair market value of our Common Stock. The value received upon exercise of the Warrants (1)&#160;may be less than the value the holders would have received if they had exercised their Warrants at a later time where the underlying share price is higher and (2)&#160;may not compensate the holders for the value of the Warrants. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">88 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom428534_20">COMMITTED EQUITY FINANCING </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January 8, 2023, we entered into the B. Riley Purchase Agreement with the Selling Securityholder. Pursuant to the B. Riley Purchase Agreement, we have the right to sell to the Selling Securityholder up to $500,000,000 of shares of our Common Stock, subject to certain limitations and conditions set forth in the B. Riley Purchase Agreement, from time to time during the term of the B. Riley Purchase Agreement. Sales of Common Stock to the Selling Securityholder under the B. Riley Purchase Agreement, and the timing of any such sales, are at our option, and we are under no obligation to sell any securities to the Selling Securityholder under the B. Riley Purchase Agreement. In accordance with our obligations under the B. Riley Purchase Agreement, we have filed the registration statement of which this prospectus forms a part with the SEC to register under the Securities Act the resale by the Selling Securityholder of up to 28,128,422 shares of Common Stock, consisting of an aggregate amount of 250,000 Commitment Shares and up to 27,878,422 shares of Common Stock that we may elect, in our sole discretion, to issue and sell to the Selling Securityholder, from time to time under the B. Riley Purchase Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not have the right to commence any sales of our Common Stock to the Selling Securityholder under the B. Riley Purchase Agreement until the date on which all of the conditions to the Selling Securityholder&#8217;s purchase obligation set forth in the B. Riley Purchase Agreement have been satisfied, including that the registration statement of which this prospectus forms a part be declared effective by the SEC and the final form of this prospectus is filed with the SEC. From and after such date, we will have the right, but not the obligation, from time to time at our discretion until the first day of the month next following <span style="white-space:nowrap">the&#160;36-month&#160;anniversary</span> of the date on which this registration statement has been declared effective by the SEC, to purchase a number of shares of Common Stock not to exceed the Maximum Advance Amount as described further below under the heading &#8220;&#8212;<span style="font-style:italic">Advances and Payments of Common Stock Under the B. Riley Purchase Agreement</span>.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will control the timing and amount of any sales of Common Stock to the Selling Securityholder. Actual sales of shares of our Common Stock to the Selling Securityholder under the B. Riley Purchase Agreement will depend on a variety of factors to be determined by us from time to time, which may include, among other things, market conditions, the trading price of our Common Stock, and determinations by us as to the appropriate sources of funding for our company and its operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the B. Riley Purchase Agreement, we may not sell any shares of Common Stock thereunder and the Selling Securityholder shall not have the obligation to purchase shares of Common Stock thereunder to the extent (but only to the extent) that after giving effect to such purchase and sale, the aggregate number of shares of Common Stock issued thereunder would exceed 28,128,422 shares of Common Stock, which number of shares is equal to 19.9% of the aggregate amount of Common Stock issued and outstanding as of the date of the B. Riley Purchase Agreement, unless (i)&#160;we obtain stockholder approval to issue shares of Common Stock in excess of the Exchange Cap in accordance with the applicable Nasdaq Listing Rules or (ii)&#160;the average price of all applicable sales of shares of Common Stock under the B. Riley Purchase Agreement equals or exceeds $4.87 which represents the &#8220;Minimum Price&#8221; (as such term is defined in Rule 5635 of the Nasdaq Listing Rules). Moreover, we may not issue or sell any shares of Common Stock to the Selling Securityholder under the B. Riley Purchase Agreement which, when aggregated with all other shares of Common Stock then beneficially owned by the Selling Securityholder and its affiliates (as calculated pursuant to Section&#160;13(d) of the Exchange Act and Rule <span style="white-space:nowrap">13d-3</span> promulgated thereunder), would result in the Selling Securityholder beneficially owning shares of Common Stock in excess of the 4.99% Beneficial Ownership Limitation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither we nor the Selling Securityholder may assign or transfer any of our respective rights and obligations under the B. Riley Purchase Agreement, and no provision of the B. Riley Purchase Agreement may be modified or waived by the parties other than by an instrument in writing signed by both parties. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The net proceeds from sales, if any, under the B. Riley Purchase Agreement, will depend on the frequency and prices at which we sell shares of Common Stock to the Selling Securityholder. To the extent we sell shares </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">89 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
under the B. Riley Purchase Agreement, we currently plan to use any proceeds therefrom for working capital and general corporate purposes, which may include capital expenditures, research and development expenditures, regulatory affairs expenditures, clinical trial expenditures, acquisitions of new technologies and investments, business combinations and the repayment, refinancing, redemption or repurchase of indebtedness or capital stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As consideration for the Selling Securityholder&#8217;s commitment to purchase shares of Common Stock at our direction upon the terms and subject to the conditions set forth in the B. Riley Purchase Agreement, we issued 250,000 Commitment Shares to the Selling Securityholder and paid $10,000 to B. Riley Principal Investments, LLC, a subsidiary of the Selling Securityholder. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The B. Riley Purchase Agreement contains customary representations, warranties, conditions and indemnification obligations of the parties. The representations, warranties and covenants contained in such agreements were made only for purposes of such agreements and as of specific dates, were solely for the benefit of the parties to such agreements and may be subject to limitations agreed upon by the contracting parties. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_201">Advances of Common Stock Under the B. Riley Purchase Agreement </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will have the right, but not the obligation, from time to time at our discretion, until the first day of the month next following <span style="white-space:nowrap">the&#160;36-month&#160;anniversary</span> of the date on which this registration statement has been declared effective by the SEC, to direct the Selling Securityholder to purchase up to a specified maximum amount of shares of Common Stock as set forth in the B. Riley Purchase Agreement by delivering an irrevocable written notice to the Selling Securityholder (each, an &#8220;Advance Notice&#8221;) on any trading day (each, an &#8220;Advance Notice Date&#8221;), so long as: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the number of shares be issued under any single Advance does not exceed (i)&#160;with respect to an Advance, purchase-Type A, such number of shares of Common Stock that is equal to the lesser of: (a) 1,000,000, and (b)&#160;the product of (1) 0.10, multiplied by (2)&#160;the total number (or volume) of shares of Common Stock traded on Nasdaq during the Pricing Period (as defined below) for such purchase-Type A, and (ii)&#160;with respect to an Advance, purchase-Type B, such number of shares of Common Stock that is equal to the lesser of: (a) 1,000,000 and (b)&#160;the product of (1) 0.25, multiplied by (2)&#160;the total number (or volume) of shares of Common Stock traded on Nasdaq during the Pricing Period for such purchase-Type B (such amount in clause (i)&#160;and (ii), the &#8220;Maximum Advance Amount&#8221;), unless otherwise agreed by the parties. &#8220;Pricing Period&#8221; means the period beginning at 9:30:01 a.m., New York City time, on the date of purchase of Advance Shares or such later time publicly announced as the official open of the primary (or &#8220;regular&#8221;) trading session on Nasdaq on such purchase date (the &#8220;Purchase Commencement Time&#8221;) and ending at the earliest of (i) 3:59 p.m., New York City Time, on the purchase date or such earlier time publicly announced as the official close of the primary (or &#8220;regular&#8221;) trading session on Nasdaq on such purchase date, (ii)&#160;immediately at such time following the Purchase Commencement Time for such purchase that the total number (or volume) of shares of Common Stock traded on Nasdaq during such period has exceeded the Advance Share Volume Maximum for such purchase and (iii)&#160;if we so elect in the applicable Advance Notice for such Advance (such election, a &#8220;Limit Order Discontinue Election&#8221;), such time the sale price of the shares of Common Stock traded on Nasdaq during such Pricing Period is less than the applicable minium price threshold determined in accordance with the B. Riley Purchase Agreement. &#8220;Advance Share Volume Maximum&#8221; means, with respect to an Advance, if such Advance is designated in the Advance Notice as a (i)&#160;purchase-Type A, a number of shares of Common Stock that is equal to the quotient obtained by dividing (a)&#160;the Advance Share amount to be purchased by the Selling Securityholder, by (b) 0.10, and (ii)&#160;purchase-Type B, a number of shares of Common Stock that is equal to the quotient obtained by dividing (a)&#160;the Advance Share amount to be purchased by the Selling Securityholder, by (b) 0.25 (in each case, subject to certain adjustments); and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the applicable Pricing Period for all prior Advances has been completed and all shares of Common Stock subject to all prior Advances have been received by the Selling Securityholder. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">90 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_202">Additional Advances of Common Stock Under the B. Riley Purchase Agreement </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The B. Riley Purchase Agreement also provides that we have the right, but not the obligation, to sell to the Selling Securityholder, from time to time subject to certain limitations, at our sole and absolute discretion an additional number of shares of Common Stock (each such additional sale, an &#8220;Additional Advance&#8221;) by delivering an irrevocable written notice to the Selling Securityholder (each, an &#8220;Additional Advance Notice&#8221;) on any trading day (each, an &#8220;Additional Advance Notice Day&#8221;). The purpose of the Additional Advance is to allow us to execute more than one advance request on a purchase date with the Selling Stockholder as each prior advance has been completed under the terms of the B. Riley Purchase Agreement. Each Additional Advance is generally subject to terms and conditions consistent with those of an Advance, except for, among other things, the time period of the pricing period for such Additional Advance. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_203">Conditions to Each Advance and Additional Advance </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Selling Securityholder&#8217;s obligation to accept Advance Notices and Additional Advance Notices that are timely delivered by us under the B. Riley Purchase Agreement and to purchase shares of our Common Stock in Advances and Additional Advances under the B. Riley Purchase Agreement are subject to the satisfaction, at the applicable Advance Notice Date or Additional Advance Notice Date, of the conditions precedent thereto set forth in the B. Riley Purchase Agreement, all of which are entirely outside of the Selling Securityholder&#8217;s control, which conditions include the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the accuracy in all material respects of our representations and warranties included in the B. Riley Purchase Agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">there being an effective registration statement pursuant to which the Selling Securityholder is permitted to utilize the prospectus thereunder to resell all of the Common Stock that we shall issue and sell to the Selling Securityholder (the &#8220;Advance Shares&#8221; or &#8220;Additional Advance Shares&#8221;, as the case may be) pursuant to such Advance Notice or Additional Advance Notice; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the sale and issuance of such Advance Shares or Additional Advance Shares being legally permitted by all laws and regulations to which we are subject; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">no Material Outside Event (as such term is defined in the B. Riley Purchase Agreement) shall have occurred and be continuing; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">us having performed, satisfied, and complied in all material respects with all covenants, agreements, and conditions required by the B. Riley Purchase Agreement to be performed, satisfied, or complied with by us; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">no statute, rule, regulation, executive order, decree, ruling, or injunction having been enacted, entered, promulgated, or endorsed by any court or governmental authority of competent jurisdiction that prohibits or directly, materially, and adversely affects any of the transactions contemplated by the B. Riley Purchase Agreement; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the Common Stock being quoted for trading on Nasdaq and us having not received any written notice that is then still pending threatening the continued quotation of the Common Stock on Nasdaq. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_204">Termination of the B. Riley Purchase Agreement </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless earlier terminated as provided in the B. Riley Purchase Agreement, the B. Riley Purchase Agreement will terminate automatically on the earliest to occur of: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the first day of the month next following <span style="white-space:nowrap">the&#160;36-month&#160;anniversary</span> of the date on which this registration statement has been declared effective by the SEC; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the date on which the Selling Securityholder shall have purchased shares of Common Stock under the B. Riley Purchase Agreement for an aggregate gross purchase price equal to $500,000,000. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">91 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also have the right to terminate the B. Riley Purchase Agreement at any time, at no cost or penalty, upon five trading days&#8217; prior written notice to the Selling Securityholder; <span style="font-style:italic">provided</span> that there are no outstanding Advance Notices or Additional Advance Notices under which we are yet to issue Common Stock. We and the Selling Securityholder may also terminate the B. Riley Purchase Agreement at any time by mutual written consent.<span style="font-style:italic"></span><span style="font-style:italic">&#160;</span> </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_205">No Short-Selling by the Selling Securityholder </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Selling Securityholder has agreed that it and its affiliates will not engage in any short sales during the term of the B. Riley Purchase Agreement and will not enter into any transaction that establishes a net short position with respect to the Common Stock, provided that nothing shall restrict the Selling Securityholder from selling a number of shares of Common Stock that it is obligated to purchase under a pending Advance Notice or Additional Advance Notice but has not yet received from us. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_206">Effect of Sales of our Common Stock under the B. Riley Purchase Agreement on our Stockholders </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All shares of Common Stock that may be issued or sold by us to the Selling Securityholder under the B. Riley Purchase Agreement that are being registered under the Securities Act for resale by the Selling Securityholder in this offering are expected to be freely tradable. The shares of Common Stock being registered for resale in this offering may be issued and sold by us to the Selling Securityholder from time to time at our discretion over the term of the B. Riley Purchase Agreement. The resale by the Selling Securityholder of a significant amount of shares registered for resale in this offering at any given time, or the perception that these sales may occur, could cause the market price of our Common Stock to decline and to be highly volatile. Sales of our Common Stock, if any, to the Selling Securityholder under the B. Riley Purchase Agreement will depend upon market conditions and other factors to be determined by us. We may ultimately decide to sell to the Selling Securityholder all, some, or none of the shares of our Common Stock that may be available for us to sell to the Selling Securityholder pursuant to the B. Riley Purchase Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If and when we do elect to sell shares of our Common Stock to the Selling Securityholder pursuant to the B. Riley Purchase Agreement, the Selling Securityholder may resell all, some, or none of such shares in its discretion and at different prices subject to the terms of the B. Riley Purchase Agreement. As a result, investors who purchase shares from the Selling Securityholder in this offering at different times will likely pay different prices for those shares, and so may experience different levels of dilution and, in some cases, substantial dilution and different outcomes in their investment results. Investors may experience a decline in the value of the shares they purchase from the Selling Securityholder in this offering as a result of future sales made by us to the Selling Securityholder at prices lower than the prices such investors paid for their shares in this offering. In addition, if we sell a substantial number of shares to the Selling Securityholder under the B. Riley Purchase Agreement, or if investors expect that we will do so, the actual sales of shares or the mere existence of our arrangement with the Selling Securityholder may make it more difficult for us to sell equity or equity-related securities in the future at a desirable time and price. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because the purchase price per share to be paid by the Selling Securityholder for the shares of Common Stock that we may elect to sell to the Selling Securityholder under the B. Riley Purchase Agreement, if any, will fluctuate based on the market prices of our Common Stock during the applicable Pricing Period, as of the date of this prospectus we cannot reliably predict the number of shares of Common Stock that we will sell to the Selling Securityholder under the B. Riley Purchase Agreement, the actual purchase price per share to be paid by the Selling Securityholder for those shares, or the actual gross proceeds to be raised by us from those sales, if any. As of January&#160;11, 2023, there were 141,598,856 shares of our Common Stock outstanding, of which 5,872,266 shares were held by <span style="white-space:nowrap">non-affiliates.</span> If all of the 28,128,422 shares offered for resale by the Selling Securityholder under the registration statement that includes this prospectus were issued and outstanding as of January&#160;11, 2023, such shares would represent approximately 16.6% of the total number of shares of our Common Stock outstanding and approximately 82.7% of the total number of outstanding shares held by <span style="white-space:nowrap">non-affiliates.</span> </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">92 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although the B. Riley Purchase Agreement provides that we may, in our discretion, from time to time after the date of this prospectus and during the term of the B. Riley Purchase Agreement, direct the Selling Securityholder to purchase shares of our Common Stock from us in one or more Advances or Additional Advances under the B. Riley Purchase Agreement, for a maximum aggregate purchase price of up to $500,000,000, only 28,128,422 shares of Common Stock (250,000 of which represent the aggregate amount of Commitment Shares we issued to the Selling Securityholder pursuant to the B. Riley Purchase Agreement as payment for the Selling Securityholder&#8217;s commitment to purchase shares of our Common Stock under the B. Riley Purchase Agreement) are being registered for resale under the registration statement that includes this prospectus. Assuming all of such 28,128,422 shares were sold to the Selling Securityholder at the maximum 98% discount to the per share price of $4.87 (which represents the lower of the official closing price of our Common Stock on Nasdaq on January 6, 2023, the trading day immediately preceding the date of the B. Riley Purchase Agreement, and the average official closing price of our Common Stock on Nasdaq for the five consecutive trading days ending on January 6, 2023, the trading day immediately preceding the date of the B. Riley Purchase Agreement), such number of shares would be insufficient to enable us to receive aggregate gross proceeds from the sale of such shares to the Selling Securityholder equal to the Selling Securityholder&#8217;s $500,000,000 total aggregate purchase commitment under the B. Riley Purchase Agreement. While the market price of our Common Stock may fluctuate from time to time after the date of this prospectus and, as a result, the actual purchase price to be paid by the Selling Securityholder under the B. Riley Purchase Agreement for shares of our Common Stock, if any, may also fluctuate, in order for us to receive the full amount of the Selling Securityholder&#8217;s commitment under the B. Riley Purchase Agreement, it is possible that we may need to issue and sell more than the number of shares being registered for resale under the registration statement that includes this prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If it becomes necessary for us to issue and sell to the Selling Securityholder more shares than are being registered for resale under this prospectus in order to receive aggregate gross proceeds equal to $500,000,000 under the B. Riley Purchase Agreement, we must first (i)&#160;to the extent necessary, obtain stockholder approval prior to issuing shares of the Common Stock in excess of the Exchange Cap in accordance with applicable Nasdaq Listing Rules, and (ii)&#160;file with the SEC one or more additional registration statements to register under the Securities Act the resale by the Selling Securityholder of any such additional shares of our Common Stock, which the SEC must declare effective, in each case, before we may elect to sell any additional shares of our Common Stock to the Selling Securityholder under the B. Riley Purchase Agreement. The number of shares of our Common Stock ultimately offered for resale by the Selling Securityholder depends upon the number of shares of Common Stock, if any, we ultimately sell to the Selling Securityholder under the B. Riley Purchase Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The issuance, if any, of shares of our Common Stock to the Selling Securityholder pursuant to the B. Riley Purchase Agreement would not affect the rights or privileges of our existing stockholders, except that the economic and voting interests of each of our existing stockholders would be diluted. Although the number of shares of our Common Stock that our existing stockholders own would not decrease as a result of sales, if any, under the B. Riley Purchase Agreement, the shares of our Common Stock owned by our existing stockholders would represent a smaller percentage of our total outstanding shares of our Common Stock after any such issuance. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">93 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the amount of gross proceeds we would receive from the Selling Securityholder from our sale of shares of Common Stock to the Selling Securityholder under the B. Riley Purchase Agreement at varying purchase prices: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">


<tr>

<td style="width:40%"></td>

<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Assumed<br />Average<br />Purchase<br />Price<br />Per<br />Share</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number of<br />Registered<br />Shares to be<br />Issued if<br />Full Purchase<sup style="font-size:75%; vertical-align:top">(1)</sup></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Percentage of<br />Outstanding<br />Shares<br />After Giving<br />Effect to<br />the Issuance to<br />the<br />Selling<br />Securityholder<sup style="font-size:75%; vertical-align:top">(2)</sup></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Gross Proceeds<br />from the<br />Sale of Shares to the<br />Selling<br />Securityholder<br />Under&#160;the&#160;B.&#160;Riley&#160;Purchase<br />Agreement</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$2.00</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">250,000,000.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">63.80</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">500,000,000.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$3.00</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">166,666,666.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">54.02</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">499,999,998.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$4.00</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">125,000,000.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">46.84</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">500,000,000.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$4.87<sup style="font-size:75%; vertical-align:top">(3)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">102,669,404.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">41.99</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">499,999,997.48</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$5.00</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">100,000,000.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">41.35</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">500,000,000.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$6.00</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">83,333,333.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">37.01</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">499,999,998.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$7.00</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">71,428,571.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">33.49</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">499,999,997.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$7.87<sup style="font-size:75%; vertical-align:top">(4)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">66,934,404.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">32.06</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">499,999,997.88</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$8.00</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">62,500,000.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">30.58</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">500,000,000.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Does not include the aggregate amount of 250,000 Commitment Shares that we issued to the Selling Securityholder as consideration for its commitment to purchase shares of Common Stock under the B. Riley Purchase Agreement. The number of shares of Common Stock offered by this prospectus may not cover all the shares we ultimately sell to the Selling Securityholder under the B. Riley Purchase Agreement, depending on the purchase price per share. We have included in this column only those shares being offered for resale by the Selling Securityholder under this prospectus (excluding the 250,000 Commitment Shares), without regard for the Beneficial Ownership Limitation. The assumed average purchase prices are solely for illustration and are not intended to be estimates or predictions of future stock performance. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The denominator is based on 141,598,856 shares outstanding as of January&#160;11, 2023 (which includes the aggregate amount of 250,000 Commitment Shares we issued to the Selling Securityholder), adjusted to include the issuance of the number of shares set forth in the second column that we would have sold to the Selling Securityholder, assuming the average purchase price in the first column. The numerator is based on the number of shares of Common Stock set forth in the second column. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents the average Nasdaq Official Closing Price for the five trading days immediately preceding the date of the B. Riley Purchase Agreement) on January&#160;6, 2023, the trading day prior to execution of the B. Riley Purchase Agreement. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents the closing price of the Common Stock on Nasdaq on January&#160;11, 2023, the trading day prior to the filing of the registration statement of which this prospectus forms a part. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">94 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom428534_21">MARKET AND INDUSTRY DATA </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain information contained in this prospectus relates to or is based on studies, publications, surveys and other data obtained from third-party sources and our own internal estimates and research. While we believe these third-party sources to be reliable as of the date of this prospectus, we have not independently verified the market and industry data contained in this prospectus or the underlying assumptions relied on therein. Finally, while we believe our own internal research is reliable, such research has not been verified by any independent source. Notwithstanding the foregoing, we are liable for the information provided in this prospectus. The industry in which we operate is subject to a high degree of uncertainty and risk due to a variety of factors, including those described in the section of this prospectus titled &#8220;<span style="font-style:italic">Risk Factors</span>&#8221;. These and other factors could cause results to differ materially from those expressed in the estimates made by the independent parties and by us. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">95 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom428534_22">USE OF PROCEEDS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of the shares of our Common Stock offered by the Selling Securityholder pursuant to this prospectus will be sold by the Selling Securityholder for its own account. We will not receive any of the direct proceeds from these sales. However, we may receive up to $500,000,000 aggregate gross proceeds from any sales we make to the Selling Securityholder pursuant to the B. Riley Purchase Agreement. The net proceeds from sales, if any, under the B. Riley Purchase Agreement, will depend on the frequency and prices at which we sell shares of Common Stock to the Selling Securityholder after the date of this prospectus. See the section titled &#8220;<span style="font-style:italic">Plan of Distribution</span>&#8221; elsewhere in this prospectus for more information. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to use the net proceeds that we receive under the B. Riley Purchase Agreement for working capital and general corporate purposes, which may include capital expenditures, research and development expenditures, regulatory affairs expenditures, clinical trial expenditures, acquisitions of new technologies and investments, business combinations and the repayment, refinancing, redemption or repurchase of indebtedness or capital stock. However, we have not designated any specific uses and have no current agreement with respect to any acquisition or strategic transaction. As of the date of this prospectus, we cannot specify with certainty all of the particular uses, and the respective amounts we may allocate to those uses, for any net proceeds we receive. Accordingly, we will retain broad discretion over the use of these proceeds. Pending our use of the net proceeds as described above, we intend to invest the net proceeds pursuant to the B. Riley Purchase Agreement in interest-bearing instruments. Our expected use of the net proceeds from this offering represents our current intentions based upon our present plans and business condition. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although it is difficult to predict our liquidity requirements, we anticipate that we will continue to incur net losses into the foreseeable future as we support our clinical development to expand approved indications, continue our development of, and seek regulatory approvals for, our product candidates, and expand our corporate infrastructure. As a result, we have concluded that there is substantial doubt about our ability to continue as a going concern within one year after the date that the consolidated financial statements are issued. See Note 2 titled &#8220;Liquidity and Going Concern&#8221; to our consolidated financial statements included elsewhere in this prospectus for additional information. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the date of this prospectus, we cannot specify with certainty all of the particular uses, and the respective amounts we may allocate to those uses, for any net proceeds we receive. The costs and timing of development activities, particularly conducting clinical trials and preclinical studies, are highly uncertain, subject to substantial risks and can often change. Due to the many variables inherent to the development of our drug candidates, we cannot currently predict the stage of development we expect the net proceeds of this offering to achieve for our clinical trials, preclinical studies and drug candidates. Accordingly, we will retain broad discretion over the use of these proceeds. For example, if we identify opportunities that we believe are in the best interests of our stockholders, we may use a portion of the net proceeds from this offering to acquire, invest in or license complementary products, technologies or businesses, although we have no current understandings, agreements or commitments to do so. In addition, the amounts and timing of our actual expenditures will depend upon numerous factors, including the results of our research and development efforts, the timing and success of preclinical studies, our ongoing clinical trials or clinical trials we may commence in the future and the timing of regulatory submissions. Depending on the outcome of these activities and other unforeseen events, our plans and priorities may change and we may apply the net proceeds of this offering toward different uses and in different proportions than we currently anticipate. Pending our use of the net proceeds as described above, we intend to invest the net proceeds from this offering in interest-bearing instruments. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">96 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom428534_23">DETERMINATION OF OFFERING PRICE </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot currently determine the price or prices at which shares of our Common Stock may be sold by the Selling Securityholder under this prospectus. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">97 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom428534_24">MARKET INFORMATION FOR SECURITIES AND DIVIDEND POLICY </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_25">Market Information </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Common Stock and Public Warrants are currently listed on Nasdaq under the symbols &#8220;SCLX&#8221; and &#8220;SCLXW,&#8221; respectively. Prior to the consummation of the Business Combination, Vickers&#8217;s Ordinary Shares, units and warrants were each listed on Nasdaq under the symbols &#8220;VCKA,&#8221; &#8220;VCKAU&#8221; and &#8220;VCKAW,&#8221; respectively. At the Effective Time, without any action on the part of the holder, each Unit then outstanding separated automatically into its component securities, comprised of one share of Common Stock and <span style="white-space:nowrap">one-half</span> of one warrant to purchase one share of Common Stock. As of November&#160;10, 2022, there were eleven holders of record of our Common Stock and four holders of record of our Warrants, which amount does not include participants of The Depository Trust Company or beneficial owners holding shares through nominee names. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_26">Dividend Policy </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never declared or paid any dividend on shares of our Common Stock. We anticipate that we will retain all of our future earnings, if any, to fund the development and growth of our business. Any future determination to pay dividends on our capital stock will be at the discretion of our Board. It is the present intention of our Board to retain all earnings, if any, for use in our business operations and, accordingly, our Board does not anticipate declaring any dividend in the foreseeable future. Should we decide in the future to do so, as a holding company, our ability to pay dividends on our capital stock and meet other obligations depends upon the receipt of dividends or other payments from our operating subsidiaries, including Legacy Scilex. Further, our ability to pay dividends may be limited by covenants of any existing and future outstanding indebtedness we or our subsidiaries incur. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_27">Securities Authorized for Issuance under Equity Compensation Plans </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of January 1, 2023, there were up to 20,276,666 shares of Common Stock authorized for future issuance under our Equity Incentive Plan and 2,875,759 shares of Common Stock authorized for future issuance under our ESPP. Our stockholders approved the Equity Incentive Plan and the ESPP on November&#160;9, 2022 in connection with the Business Combination and became effective upon the Closing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to file one or more registration statements on Form <span style="white-space:nowrap">S-8</span> under the Securities Act to register the shares of Common Stock issued or issuable under the Equity Incentive Plan, the ESPP and the assumed Legacy Scilex options and other awards outstanding under the Scilex Pharma 2017 Plan and the 2019 Stock Option Plan. Any such Form <span style="white-space:nowrap">S-8</span> registration statement will become effective automatically upon filing. Once these shares are registered, they can be sold in the public market upon issuance, subject to applicable restrictions. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">98 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom428534_28">UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following unaudited pro forma condensed combined balance sheet as of September&#160;30, 2022 and the unaudited pro forma condensed combined statements of operations for the year ended December&#160;31, 2021 and nine months ended September&#160;30, 2022 present the combined financial information of Vickers and Legacy Scilex after giving effect to the Business Combination and related adjustments described in the accompanying notes. Vickers and Legacy Scilex are collectively referred to herein as the &#8220;Companies,&#8221; and the Companies, subsequent to the Business Combination, are referred to herein as &#8220;New Scilex.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial information has been prepared in accordance with Article 11 of Regulation <span style="white-space:nowrap">S-X,</span> Pro Forma Financial Information, as amended by the final rule, Release 33 10786. The following unaudited pro forma condensed combined statements of operations for the year ended December&#160;31, 2021 and nine months ended September&#160;30, 2022 give pro forma effect to the Business Combination as if it had occurred on January&#160;1, 2021. The unaudited pro forma condensed combined balance sheet as of September&#160;30, 2022 gives pro forma effect to the Business Combination as if it was completed on September&#160;30, 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial information are based on and should be read in conjunction with: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the accompanying notes to the unaudited pro forma condensed combined financial information; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the audited historical financial statements and the unaudited historical financial statements of each of Vickers and Legacy Scilex as of and for the year ended December&#160;31, 2021, and as of and for the nine months ended September&#160;30, 2022, respectively, and the related notes thereto, and; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">other information relating to Vickers and Legacy Scilex contained in this prospectus, including the Merger Agreement, which is filed as an exhibit to the registration statement of which this prospectus forms a part, and the disclosures contained in the section of this prospectus titled &#8220;<span style="font-style:italic">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span>&#8221;. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial statements have been presented for illustrative purposes only and do not necessarily reflect what the combined company&#8217;s financial condition or results of operations would have been had the Business Combination occurred on the dates indicated. Further, the unaudited pro forma condensed combined financial information also may not be useful in predicting the future financial condition and results of operations of the combined company. The actual financial position and results of operations may differ significantly from the pro forma amounts reflected herein due to a variety of factors. The unaudited pro forma adjustments represent management&#8217;s estimates based on information available as of the date of these unaudited pro forma condensed combined financial statements and are subject to change as additional information becomes available and analyses are performed. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&#160;17, 2022, Vickers Vantage Corp. I (&#8220;Vickers&#8221;) entered into the Agreement and Plan of Merger (as amended on September&#160;12, 2022, the &#8220;Merger Agreement&#8221;) with Vantage Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Vickers (&#8220;Merger Sub&#8221;), and Scilex Holding Company, a Delaware corporation (&#8220;Legacy Scilex&#8221;) under which Merger Sub was merged with and into Legacy Scilex with Legacy Scilex continuing as the surviving corporation and a wholly owned subsidiary of Vickers. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The closing of the Business Combination occurred on November&#160;10, 2022 (the &#8220;Closing&#8221;), in which Vickers was renamed &#8220;Scilex Holding Company&#8221; (&#8220;New Scilex&#8221;). At the Closing, each outstanding share of Legacy Scilex Common Stock as of immediately prior to the time in which the Business Combination became effective as stated in the Merger Agreement (&#8220;Effective Time&#8221;) was exchanged for shares of Common Stock and each outstanding share of Legacy Scilex Preferred Stock as of immediately prior to the Effective Time was exchanged for the right to receive (a)&#160;one share of Series A Preferred Stock and <span style="white-space:nowrap">(b)&#160;one-tenth</span> of one share of Common </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">99 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Stock. Each Legacy Scilex stock option outstanding immediately prior to the Effective Time was converted into a stock option to acquire a share of Common Stock upon substantially the same terms and conditions with respect to existing vesting and termination-related provisions. On November&#160;11, 2022, shares of Common Stock and Public Warrants started trading on the Nasdaq Capital Market under the ticker symbols &#8220;SCLX&#8221; and &#8220;SCLXW,&#8221; respectively. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate consideration paid to the equityholders of Legacy Scilex upon the Closing of the Business Combination was 133,060,532 shares of Common Stock. The unaudited pro forma condensed combined financial information contained herein incorporates the results of Vickers&#8217;s public shareholders having elected to redeem 8,576,838 shares of their public shares for $89,884,677 in cash based upon actual redemptions as of the Closing. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">100 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNAUDITED PRO FORMA CONDENSED COMBINED BALANCE SHEET </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">As of September&#160;30, 2022 </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(in thousands, except share and per share amounts) </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:58%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="18" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">As of September&#160;30, 2022</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">(Note 2)<br />Vickers<br />Vantage<br />Corp. I<br />(Adjusted)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Scilex<br />Holding<br />Company<br />(Historical)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Pro Forma<br />Adjustments</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Pro&#160;Forma<br />Combined</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assets</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">35</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,483</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12,047</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3(B)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,643</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(5,190</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3(C)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(2,533</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3(E)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,199</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3(K)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable, net</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">17,474</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">17,474</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Inventory</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">933</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">933</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">131</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10,583</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(7,270</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3(E)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,444</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">166</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">31,473</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(4,145</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">27,494</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Non-current</span> assets</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">782</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">782</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease <span style="white-space:nowrap"><span style="white-space:nowrap">right-of-use</span></span> asset</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,271</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,271</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangibles, net</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">41,617</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">41,617</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goodwill</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13,481</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13,481</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term deposit</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">153</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">153</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and securities held in Trust Account</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">101,293</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(89,246</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3(A)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(12,047</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3(B)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">101,459</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">88,777</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(105,438</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">84,798</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liabilities and Stockholders&#8217; Equitv</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11,684</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(6,862</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3(G)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,822</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued payroll</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,426</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,426</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">809</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">23,862</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,637</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3(E)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">24,833</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,475</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3(G)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current portion of debt</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">133</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">133</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Related party payable</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">166,145</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8,337</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3(G)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(174,482</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3(H)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Related party note payable</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">47,108</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(47,108</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3(H)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current portion of operating lease liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">717</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">717</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">809</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">251,075</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(219,953</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">31,931</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Non current liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term debt, net of discount</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,517</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,517</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Related party note payable</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,007</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">62,717</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(62,717</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3(H)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(5,007</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3(1)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derivative liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,163</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(465</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3(J)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">698</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">863</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">863</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred underwriting fee payable</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,190</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(5,190</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3(C)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12,169</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">318,172</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(293,332</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">37,009</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">101 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:60%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="18" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">As of September&#160;30, 2022</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">(Note 2)<br />Vickers<br />Vantage<br />Corp. I<br />(Adjusted)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Scilex<br />Holding<br />Company<br />(Historical)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Pro Forma<br />Adjustments</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Pro&#160;Forma<br />Combined</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and contingencies</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ordinary shares subject to possible redemption 9,726,395 and 13,800,000 as of September&#160;30, 2022 and December&#160;31, 2021 at redemption value of approximately $10.41 and $10.00, respectively per share</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">101,293</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(101,293</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3(A)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#8217; deficit</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preference shares $0.0001 par value; 1,000,000 shares authorized; none issued or outstanding</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ordinary shares, $0.0001 par value; 200,000,000 shares authorized; 3,450,000 <span style="white-space:nowrap">non-redeemable</span> shares issued and outstanding at September&#160;30, 2022 and December&#160;31, 2021</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New Scilex Preferred stock, $0.0001 par value; 45,000,000 shares authorized</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3(H)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New Scilex Common stock, $0.0001 par value; 740,000,000 shares authorized</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3(A)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3(D)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock, $0.0001 par value, 20,000,000 shares authorized; none issued or outstanding at September&#160;30, 2022 and December&#160;31, 2021</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.0001 par value, 350,000,000 shares authorized 197,566,338 and 197,266,338 shares issued and outstanding at September&#160;30, 2022 and December&#160;31, 2021 respectively</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(20</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3(D)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <span style="white-space:nowrap">paid-in</span> capital</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">128,615</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12,047</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3(A)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">407,237</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3(D)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(10,415</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3(E)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(12,793</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3(F)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">284,304</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3(H)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,007</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3(1)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">465</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3(J)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(12,003</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(358,030</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,025</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3(E)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(359,464</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,199</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3(K)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12,793</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3(F)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#8217; deficit</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(12,003</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(229,395</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">289,187</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">47,789</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities and stockholders&#8217; deficit</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">101,459</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">88,777</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(105,438</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">84,798</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">102 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">For the Nine Months Ended September&#160;30, 2022 </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(in thousands, except share and per share amounts) </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:48%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="18" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">For the Nine Months Ended September&#160;30, 2022</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">(Note 2)<br />Vickers<br />Vantage<br />Corp. I<br />(Adjusted)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Scilex Holding<br />Company<br />(Historical)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Pro Forma<br />Adjustments</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Pro Forma<br />Combined</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net revenue</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">26,115</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">26,115</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating costs and expenses:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of revenue</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,284</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,284</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,457</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,457</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and administrative</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">41,371</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">41,371</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible amortization</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,896</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,896</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating and formation costs</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,412</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(690</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4(BB)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,722</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating costs and expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,412</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">57,008</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(690</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">58,730</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(2,412</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(30,893</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">690</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(32,615</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense (income):</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on derivative liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(2,196</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(5,300</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(878</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4(CC)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(8,374</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on debt extinguishment, net</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(28,634</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(28,634</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Scilex Pharma Notes principal increase</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8,596</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8,613</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on foreign currency exchange</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(39</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(39</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income on mandatorily redeemable ordinary shares liability</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(192</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">192</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4(FF)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest earned on investments held in Trust Account</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(665</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">665</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4(AA)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other expense</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(3,036</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(25,377</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(21</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(28,434</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before income taxes</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">624</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(5,516</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">711</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(4,181</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(36</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(36</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">624</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(5,480</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">711</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(4,145</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares used to compute net loss per share attributable to Vickers ordinary shares, basic</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">15,862,288</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic net loss per share of Vickers ordinary shares</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.04</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares used to compute net loss per share attributable to Vickers ordinary shares, diluted</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">15,862,288</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted net loss per share of Vickers ordinary shares</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.04</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares used to compute net loss per share attributable to Scilex common stock, basic and diluted</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">197,549,794</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share of Scilex common stock</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(0.03</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares used to compute net loss per share attributable to New Scilex common stockholders, basic and diluted</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">141,098,856</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share of New Scilex common stock</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(0.03</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">103 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">For the Year Ended December&#160;31, 2021 </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(in thousands, except share and per share amounts) </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:51%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="18" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">For the Year Ended December&#160;31, 2021</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">(Note 2)<br />Vickers<br />Vantage<br />Corp. I<br />(Adjusted)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Scilex Holding<br />Company<br />(Historical)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Pro Forma<br />Adjustments</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Pro Forma<br />Combined</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net revenue</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">31,317</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">31,317</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating costs and expenses:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of revenue</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,634</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,634</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,201</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,201</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and administrative</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">50,582</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(235</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4(BB)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">51,697</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">151</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4(DD)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,199</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4(EE)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible amortization</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,738</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,738</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating and formation costs</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,005</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(100</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4(BB)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">905</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating costs and expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,005</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">67,155</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,015</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">69,175</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,005</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(35,838</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,015</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(37,858</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other (income) expense:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Gain) loss on derivative liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,791</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">300</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">716</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4(CC)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(775</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on debt extinguishment, net</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12,463</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12,463</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Scilex Pharma Notes principal increase</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">28,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">28,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">32</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11,764</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11,796</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on foreign currency exchange</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">54</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">54</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest earned on investments held in Trust Account</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(31</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">31</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4(AA)</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other (income) expense</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,790</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">52,581</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">747</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">51,538</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain (loss) before income taxes</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">785</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(88,419</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,762</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(89,396</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">785</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(88,424</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,762</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(89,401</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares used to compute net income per share attributable to Vickers ordinary shares, basic</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16,820,548</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic net income per share of Vickers ordinary shares</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.05</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares used to compute net income per share attributable to Vickers ordinary shares, diluted</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16,834,110</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted net income per share of Vickers ordinary shares</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.05</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares used to compute net loss per <br />share attributable to Scilex common stock, basic and diluted</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">197,266,338</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share of Scilex common <br />stock</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(0.45</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares used to compute net loss per share attributable to New Scilex common stockholders, basic and diluted</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">141,098,856</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share of New Scilex common stock</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(0.63</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">104 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">NOTES TO THE UNAUDITED PRO FORMA CONDENSED FINANCIAL INFORMATION </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Note 1 &#8212; Description of the Business Combination </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&#160;17, 2022, Vickers entered into the Merger Agreement with Merger Sub and Legacy Scilex. Pursuant to the Merger Agreement, subject to the terms and conditions set forth therein, Merger Sub merged with and into Legacy Scilex and with Legacy Scilex becoming a wholly owned subsidiary of Vickers. After giving effect to the Business Combination, Vickers owned all of the issued and outstanding equity interests of Legacy Scilex and its subsidiaries. In connection with the consummation of the Business Combination, Vickers was renamed as &#8220;Scilex Holding Company&#8221; (&#8220;New Scilex&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the Closing, each outstanding share of Legacy Scilex Common Stock as of immediately prior to the time the Business Combination became effective as stated in the Merger Agreement was exchanged for shares of Common Stock and each outstanding share of Legacy Scilex Preferred Stock as of immediately prior to the Effective Time was exchanged for the right to receive (a)&#160;one share of Series A Preferred Stock and <span style="white-space:nowrap">(b)&#160;one-tenth</span> of one share of Common Stock. Each Legacy Scilex stock option outstanding immediately prior to the Effective Time was converted into a number of options exercisable for newly issued shares of Common Stock based upon the Exchange Ratio and on substantially the same terms and conditions with respect to existing vesting and termination-related provisions. The exercise price per share for each option for Common Stock is equal to (i)&#160;the existing exercise price per Legacy Scilex stock option, divided by (ii)&#160;the Exchange Ratio (defined below) (rounded up to the nearest whole cent). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares of Common Stock issuable to Legacy Scilex stockholders and optionholders is equal to (i) $1,500,000,000, minus (ii)&#160;the Specified Indebtedness Amount (defined below), divided by $10 (&#8220;Merger Consideration&#8221;). The &#8220;Specified Indebtedness Amount&#8221; had pertained to the aggregate amount owed by Legacy Scilex in respect of senior secured notes due 2026 issued under Scilex Pharmaceuticals Inc. (&#8220;Scilex Pharma&#8221;) and with Sorrento as the parent guarantor. On September&#160;28, 2022, Scilex Pharma repurchased all of the outstanding aggregate principal amount of the Scilex Pharma Notes. As of immediately prior to the repurchase, the aggregate principal amount of the Scilex Pharma Notes was approximately $67.7&#160;million, and Scilex Pharma repurchased the Scilex Pharma Notes for an aggregate cash payment of $39.7&#160;million as the holders of the Scilex Pharma Notes forgave and discharged an aggregate of $28.0&#160;million of principal amount of the Scilex Pharma Notes in connection with the repurchase. This repurchase reduced the Specified Indebtedness Amount to $0, resulting in Merger Consideration transferred to Legacy Scilex common stockholders and optionholders at Closing of 150,000,000 shares of Common Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shares of Legacy Scilex Common Stock and Legacy Scilex stock options were converted into shares of Common Stock and options to acquire shares of Common Stock, respectively, in each case based on the &#8220;Exchange Ratio,&#8221; which is equal to (a)&#160;the number of shares constituting the Merger Consideration, divided by (b)&#160;the sum of (i)&#160;issued and outstanding Legacy Scilex Common Stock and (ii)&#160;issued and outstanding Legacy Scilex stock options as of immediately prior to the Effective Time. As there were 197,566,338 and 25,151,428 shares of Legacy Scilex Common Stock and Legacy Scilex stock options, respectively, the Exchange Ratio was calculated to be 0.673498. Upon the Effective Time, 133,060,532 shares of Common Stock were transferred to Legacy Scilex stockholders as part of the Merger Consideration. The remaining portion of the Merger Consideration, equal to 16,939,379 shares of Common Stock, is reserved for the Legacy Scilex optionholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&#160;12, 2022, Legacy Scilex and Scilex Pharma entered into a Contribution and Satisfaction of Indebtedness Agreement (the &#8220;Debt Exchange Agreement&#8221;) with Sorrento, pursuant to which (i)&#160;Sorrento contributed to Legacy Scilex all amounts (including accrued interest thereon, if any) for certain loans and other amounts provided by Sorrento to Legacy Scilex and Scilex Pharma that remained outstanding as of immediately prior to the Closing of the Business Combination (the &#8220;Aggregate Outstanding Amount&#8221; or &#8220;Outstanding Indebtedness,&#8221;) in exchange for the issuance by Legacy Scilex to Sorrento of preferred stock of Legacy Scilex, (ii)&#160;Legacy Scilex contributed to Scilex Pharma the portion of such Outstanding Indebtedness that is owed by </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">105 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Scilex Pharma to Sorrento as a contribution of capital for no consideration, and (iii)&#160;upon the occurrence of the events described in clauses (i)&#160;and (ii), the Aggregate Outstanding Amount and the Outstanding Indebtedness was deemed satisfied in full. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the Debt Exchange Agreement effective as of immediately prior to, and contingent upon, the Closing of the Business Combination, Sorrento elected to contribute the Outstanding Indebtedness to Legacy Scilex in exchange for the issuance by Legacy Scilex to Sorrento of that number of shares of preferred stock, par value $0.0001 per share, of Legacy Scilex (subject to adjustment for recapitalizations, stock splits, stock dividends and similar transactions) (the &#8220;Exchange Shares&#8221; and such transaction, the &#8220;Debt Contribution&#8221;) that was equal to (i)&#160;the Aggregate Outstanding Amount plus the amount equal to 10% of the Aggregate Outstanding Amount divided by (ii) $11.00 (rounded up to the nearest whole share). In addition, prior to the Closing, Legacy Scilex entered into agreements with certain creditors and Sorrento in which Legacy Scilex was legally released from being the primary obligor under certain liabilities from the creditors. The obligations to these creditors were transferred to Sorrento. Immediately prior to the Closing, the total amount of liabilities transferred from Legacy Scilex to Sorrento was $11,880,945, which were also subject to the Debt Exchange Agreement. The Aggregate Outstanding Amount subject to this conversion at Closing was $290,570,964 which was converted to aggregate number of shares of Legacy Scilex Preferred Stock issued to Sorrento prior to the Effective Time pursuant to the Debt Exchange Agreement of 29,057,097 shares and then at the Effective Time such shares were exchanged for 29,057,097 shares of Series A Preferred Stock and 2,905,710 shares of Common Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&#160;17, 2022, Sorrento and Legacy Scilex entered into a letter agreement (the &#8220;Funding Commitment Letter&#8221;). Pursuant to the terms of the Funding Commitment Letter, to the extent necessary to satisfy the closing condition in the Merger Agreement that requires the combined company to have $5,000,001 in net tangible assets as of immediately following the time in which the Business Combination becomes effective (the &#8220;Net Tangible Assets Condition&#8221;), Sorrento would fund one or more loans to Legacy Scilex up to (a)&#160;$10,000,000 and (b)&#160;an amount that, when taken together with all other Outstanding Indebtedness, will result in the Aggregate Outstanding Amount equaling $310,000,000. At Closing, New Scilex was able to achieve the Net Tangible Assets Condition without requiring a loan from Sorrento under the Funding Commitment Letter. As such, no amount was requested by Legacy Scilex under the Funding Commitment Letter. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below illustrates the number of shares of Series A Preferred Stock and Common Stock held by Legacy Scilex stockholders at the Closing. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:64%"></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center">Series&#160;A<br />Preferred&#160;Stock</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center">Common<br />Stock</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(a) Merger Consideration</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">133,060,532</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(b) Aggregate Outstanding Amount converted under the Debt Exchange Agreement</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">29,057,097</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,905,710</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">29,057,097</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">135,966,242</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of the then-outstanding Public Warrants and Private Placement Warrants has an exercise price of $11.50 per share (the &#8220;Exercise Price&#8221;) to acquire one share of Vickers Ordinary Shares. The exercise price of the warrants is subject to a down-round provision that is only effective prior to the Closing of the Business Combination and is therefore not, on its own, considered to have an impact to the classification of warrant on Legacy Scilex&#8217;s Unaudited Pro Forma Condensed Combined Balance Sheet. Concurrently with the execution of the Merger Agreement, Vickers also entered into the Sponsor Support Agreement. In the event that Vickers&#8217;s public shareholders exercise redemption rights that results in the redemption of 75% or more of the issued and outstanding Vickers Ordinary Shares as were outstanding as of March&#160;17, 2022, the Sponsors agreed to be subject to a 40% forfeiture of Private Placement Warrants held by each Sponsor immediately prior to Closing. At Closing, actual redemption was 91.7% and therefore 40% of the Private Placement Warrants were forfeited pursuant to the Sponsor Support Agreement. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">106 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&#160;17, 2022, as consideration for Sorrento agreeing to provide funding, as necessary, under the Funding Commitment Letter, Vickers, the Sponsors, Sorrento and Maxim entered into the Warrant Transfer Agreement pursuant to which, if, prior to the consummation of the Business Combination, the public shareholders have redeemed 50% or more of the public Vickers Ordinary Shares as were outstanding as of March&#160;17, 2022, then in addition to the forfeiture of Warrants by the Sponsors contemplated by the Sponsor Support Agreement, the Sponsors will transfer to Sorrento, and Sorrento will acquire all rights, title and interest in and to all or a portion of the Private Placement Warrants (as equitably adjusted from time to time in respect of any change in the outstanding Vickers Ordinary Shares into a different number, class or series, including by reason of any reclassification, recapitalization, share split (including a reverse share split), or combination, exchange, readjustment of shares, or similar transaction, or any share dividend or distribution paid in shares) pursuant to the Warrant Transfer Agreement. Actual redemptions were 91.7% at Closing, which resulted in 3,104,000 Private Placement Warrants being transferred to Sorrento and 1,000,000 Private Placement Warrants being retained by Sponsors pursuant to the Warrant Transfer Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, on October&#160;17, 2022, Vickers and the Sponsors entered into the Vickers Debt Agreement, pursuant to which the Working Capital Loans will be cancelled in exchange for the issuance of common stock, par value $0.0001, of Vickers prior to the consummation of the Business Combination. Pursuant to the terms of the Vickers Debt Agreement, the aggregate amount of Working Capital Loans at Closing of $5,330,557 was converted to 533,057 shares of New Scilex Common Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following summarizes the pro forma ownership and voting power of Common Stock and Series A Preferred Stock, excluding the potentially dilutive effect of all the Public Warrants, the Private Placement Warrants, any Working Capital Warrants and all outstanding New Scilex stock options issued to Legacy Scilex option holders in connection with the Business Combination: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:56%"></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Shares of<br />Common<br />Stock</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">%&#160;of<br />Ownership</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Shares of<br />Preferred<br />Stock</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">%&#160;of<br />Ownership</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">%&#160;of<br />Voting<br />Power</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vickers public shareholders</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,149,557</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.8</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.7</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vickers initial shareholders</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,983,057</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2.8</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2.3</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legacy Scilex common stockholders</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">135,966,242</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">96.4</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">79.9</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legacy Scilex preferred stockholders</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">29,057,097</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">100</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="right">17.1</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Shares at the Closing</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">141,098,856</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">29,057,097</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">100</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Expected Accounting Treatment for the Business Combination </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Business Combination was accounted for as a reverse recapitalization, with no goodwill or other intangible assets recorded in accordance with GAAP. Under this method of accounting, Vickers was treated as the &#8220;acquired&#8221; company for financial reporting purposes. Accordingly, the Business Combination was treated as the equivalent of Scilex issuing stock for the net assets of Vickers, accompanied by a recapitalization. The net assets of Vickers will be recognized at historical cost, with no goodwill or other intangible assets recorded. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Legacy Scilex was determined to be the accounting acquirer based on evaluation of the following facts and circumstances: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Legacy Scilex stockholders have the majority of the voting power; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Legacy Scilex appointed the majority of the board of directors of New Scilex; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Legacy Scilex&#8217;s existing management comprise the management of New Scilex; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Legacy Scilex comprise the ongoing operations of New Scilex; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Legacy Scilex is the larger entity based on historical revenues and business operations; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">New Scilex assumes Legacy Scilex&#8217;s name. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">107 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Note 2&#160;&#8212;&#160;Accounting Policies </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of preparing these unaudited pro forma condensed combined financial statements, certain reclassifications were made to align Vickers and Legacy Scilex&#8217;s financial statement presentation. Following the consummation of the Business Combination, we are performing a comprehensive review of the two entities&#8217; accounting policies. As a result of the review, we may identify differences between the accounting policies of the two entities which, when conformed, could have a material impact on the financial statements of the post-combination company. Based on our initial analysis, we did not identify any differences that would have a material impact on the unaudited pro forma condensed combined financial information. As a result, the unaudited pro forma condensed combined financial information does not assume any differences in accounting policies. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:62%"></td>

<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">As of September&#160;30, 2022</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Vickers&#160;Vantage<br />Corp. I<br />(Historical)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Reclassification<br />Adjustments</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Vickers&#160;Vantage<br />Corp. I<br />(Adjusted)</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assets</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">35</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">35</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable, net</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Inventory</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">131</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">131</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">131</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(131</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">166</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">166</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Non-current</span> assets</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease <span style="white-space:nowrap"><span style="white-space:nowrap">right-of-use</span></span> asset</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangibles, net</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goodwill</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term deposit</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and securities held in Trust Account</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">101,293</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">101,293</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">101,459</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">101,459</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liabilities and Stockholders&#8217; Equity</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued payroll</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">809</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">809</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable and accrued expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">809</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(809</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current portion of debt</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Related party payable</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Related party note payable</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current portion of operating lease liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">809</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">809</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Non-current</span> liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mandatorily redeemable ordinary shares liability</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term debt, net of discount</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Related party note payable</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,007</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,007</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Derivative liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,163</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,163</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible note&#160;&#8212; related party, net of debt discount</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,007</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(5,007</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conversion option liability</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrant liability</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,163</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,163</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred underwriting fee payable</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,190</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,190</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12,169</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12,169</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">108 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:62%"></td>

<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">As of September&#160;30, 2022</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Vickers&#160;Vantage<br />Corp. I<br />(Historical)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Reclassification<br />Adjustments</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Vickers&#160;Vantage<br />Corp. I<br />(Adjusted)</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and contingencies</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ordinary shares subject to possible redemption 9,726,395 and 13,800,000 as <br />of September&#160;30, 2022 and December&#160;31, 2021 at redemption value of approximately $10.41 and $10.00, respectively, per share</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">101,293</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">101,293</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#8217; deficit</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preference shares. $0.0001 par value; 1,000,000 shares authorized; none issued or outstanding</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ordinary shares, $0.0001 par value; 200,000,000 shares authorized; 3,450,000 <span style="white-space:nowrap">non-redeemable</span> shares issued and outstanding at September&#160;30, 2022 and December&#160;31, 2021</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New Scilex Preferred stock, $0.0001 par value; 45,000,000 shares <br />authorized</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New Scilex Common stock, $0.0001 par value; 740,000,000 shares <br />authorized</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.0001 par value, 350,000,000 shares authorized; 197,566,338 and 197,266,338 shares issued and outstanding at September&#160;30, 2022 and December&#160;31, 2021, respectively</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <span style="white-space:nowrap">paid-in</span> capital</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(12,003</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(12,003</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#8217; deficit</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(12,003</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(12,003</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities and stockholders&#8217; deficit</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">101,459</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">101,459</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">109 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:62%"></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">For the Nine Months ended September&#160;30, 2022</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Vickers&#160;Vantage<br />Corp. I<br />(Historical)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Reclassification<br />Adjustments</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Vickers&#160;Vantage<br />Corp. I<br />(Adjusted)</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net revenue</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating costs and expenses:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of revenue</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and administrative</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible amortization</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating and formation costs</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,412</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,412</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating costs and expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,412</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,412</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(2,412</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(2,412</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense (income):</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on derivative liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(2,196</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(2,196</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on debt extinguishment, net</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Scilex Pharma Notes principal increase</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on foreign currency exchange</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of warrant liability</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(2,189</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,189</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on initial issuance of private warrants</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of conversion option liability</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(7</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense &#8212; debt discount</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(17</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transaction costs allocated to warrant liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income on mandatorily redeemable ordinary shares liability</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(192</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(192</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest earned on investments held in Trust Account</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(665</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(665</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other expense</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(3,036</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(3,036</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before income taxes</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">624</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">624</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">624</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">624</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares used to compute net loss per share attributable to Vickers ordinary shares, basic</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">15,862,288</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">15,862,288</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic net loss per share of Vickers ordinary shares</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.04</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.04</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares used to compute net loss per share attributable to Vickers ordinary shares, diluted</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">15,862,288</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">15,862,288</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted net loss per share of Vickers ordinary shares</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.04</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.04</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">110 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:62%"></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">For the Year Ended December&#160;31, 2021</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Vickers&#160;Vantage<br />Corp. I<br />(Historical)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Reclassification<br />Adjustments</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Vickers&#160;Vantage<br />Corp. I<br />(Adjusted)</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net revenue</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating costs and expenses:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of revenue</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and administrative</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible amortization</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating and formation costs</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,005</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,005</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating costs and expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,005</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,005</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,005</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,005</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other (income) expense:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on derivative liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,791</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,791</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on debt extinguishment, net</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Scilex Pharma Notes principal increase</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">32</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">32</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on foreign currency exchange</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of warrants</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(4,378</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,378</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on initial issuance of private warrants</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,599</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(2,599</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of conversion option liability</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(12</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense &#8212; debt discount</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(2</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transaction costs allocated to warrant liabilities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">30</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(30</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest earned on investments held in Trust Account</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(31</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(31</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,790</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,790</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain before income taxes</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">785</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">785</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">785</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">785</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares used to compute net income per share attributable to Vickers ordinary shares, basic</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16,820,548</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16,820,548</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic net income per share of Vickers ordinary shares</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.05</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.05</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares used to compute net income per share attributable to Vickers ordinary shares, diluted</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16,834,110</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16,834,110</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted net income per share of Vickers ordinary shares</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.05</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.05</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Note 3 &#8212; Transaction Adjustments to Unaudited Pro Forma Condensed Combined Balance Sheet as of September&#160;30, 2022 </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial information does not give effect to any anticipated synergies, operating efficiencies, tax savings, or cost savings that may be associated with the Business Combination. No tax adjustment has been computed for the pro forma New Scilex financial results, as it expects to maintain a full valuation allowance against its U.S. deferred tax assets. The unaudited pro forma information does not purport to project the future financial position or operating results of New Scilex. The pro forma transaction adjustments included in the unaudited pro forma condensed combined balance sheet as of September&#160;30, 2022 are as follows: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(A)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Reflects reclassification of Vickers Ordinary Shares to permanent equity upon consummation of the Business Combination, after final redemption. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(B)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Reflects release of the restricted investments and cash held in the Trust Account upon consummation of the Business Combination. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">111 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(C)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Reflects the settlement in cash of all deferred underwriting fees payable to Maxim. A reduction of $5.2&#160;million was reflected in cash and cash equivalents. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(D)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Reflects the conversion of Legacy Scilex Common Stock into Common Stock pursuant to the Merger Agreement. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(E)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents transaction costs incurred by Vickers and Legacy Scilex that are allocated between the instruments issued and assumed in the Business Combination and recorded as a reduction to additional <span style="white-space:nowrap">paid-in</span> capital or expense. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(F)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Reflects the elimination of Vickers&#8217;s historical accumulated deficit. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(G)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Reflects $8,337,491 of Legacy Scilex liabilities assumed by Sorrento as of September&#160;30, 2022. Such amount was included in the Outstanding Indebtedness which was contributed to Legacy Scilex as a capital contribution in exchange for the issuance of Legacy Scilex Common Stock pursuant to the Debt Exchange Agreement and at the Effective Time such shares of Legacy Scilex Common Stock were exchanged for shares of Series A Preferred Stock and Common Stock in Note (H). </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(H)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Reflects the conversion of Outstanding Indebtedness of $284.3&#160;million as of September&#160;30, 2022 into shares of Common Stock and Series A Preferred Stock pursuant to the Debt Exchange Agreement. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(I)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Reflects the conversion of the Working Capital Loans of $5.0&#160;million as of September&#160;30, 2022 to Common Stock pursuant to the Vickers Debt Agreement. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(J)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Reflects the forfeiture of 40% of the value of the outstanding Private Placement Warrants. Pursuant to the Sponsor Support Agreement, 40% of the Private Placement Warrants are forfeited if 75% or more of the Vickers&#8217;s public shareholders exercise their right to redeem their Vickers Ordinary Shares. A reduction of $0.5&#160;million was reflected against derivative liabilities with an offset to additional <span style="white-space:nowrap">paid-in</span> capital. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(K)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Reflects a cash payment of $1.2&#160;million made in conjunction with the Closing for costs associated with directors&#8217; and officers&#8217; (&#8220;D&amp;O&#8221;) insurance policies covering current or former directors and officers of Vickers and Legacy Scilex, which are required to be maintained for a period of six (6)&#160;years from the effective date pursuant to the Merger Agreement. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Note 4 &#8212; Transaction Adjustments to Unaudited Pro Forma Condensed Combined Statement of Operations for the nine months ended September&#160;30, 2022 and the year ended December&#160;31, 2021. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:9%;vertical-align:top" align="left">(AA)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Reflects the elimination of interest earned on investment held in the Trust Account. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:9%;vertical-align:top" align="left">(BB)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents an adjustment to reflect previously expensed transaction costs as a reduction to additional <span style="white-space:nowrap">paid-in</span> capital (see Note (E)) as part of the Business Combination. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:9%;vertical-align:top" align="left">(CC)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Reflects the 40% of Private Placement Warrants forfeited, which resulted in a gain from derivative liabilities. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:9%;vertical-align:top" align="left">(DD)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Reflects an incremental amount of transaction costs expensed that are allocated to the Private Placement Warrants. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:9%;vertical-align:top" align="left">(EE)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents the immediate expense of costs incurred on D&amp;O insurance policies obtained in connection with the Business Combination. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:9%;vertical-align:top" align="left">(FF)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Reflects the elimination of interest income on mandatorily redeemable ordinary shares liability related to the redemption of 4,073,605 Vickers Ordinary Shares made in connection with the Extension Proposal. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">112 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Note 5 &#8212; Net Income (Loss) per Share </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net income (loss) per share is calculated based on the weighted average of Common Stock outstanding and the issuance of additional shares in connection with the Business Combination, assuming the shares were outstanding since January&#160;1, 2021. As the Business Combination is being reflected as if it had occurred at the beginning of the period presented, the calculation of weighted average shares outstanding for basic and diluted net income (loss) per share assumes that the shares issuable relating to the Business Combination have been outstanding for the entire periods presented. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following potential outstanding securities were excluded from the computation of pro forma net loss per share, basic and diluted, because their effect would have been anti-dilutive or issuance of such shares is contingent upon the satisfaction of certain conditions which were not satisfied by the end of the period: </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial information has been prepared using the actual redemptions at Closing related to Common Stock for the nine months ended September&#160;30, 2022 and the year ended December&#160;31, 2021 (in thousands, except number of shares and per share amounts): </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">


<tr>

<td style="width:74%"></td>

<td style="vertical-align:bottom;width:16%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Nine&#160;Months<br />Ended<br />September&#160;30,&#160;2022</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net income (loss)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(4,145</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma weighted average shares of common stock outstanding &#8212; basic and diluted</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">141,098,856</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per share &#8212; basic and diluted</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(0.03</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Year ended<br />December&#160;31, 2021</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net (loss) income</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(89,401</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma weighted average shares of common stock outstanding &#8212; basic and diluted</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">141,098,856</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per share &#8212; basic and diluted</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(0.63</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">113 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom428534_29">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">CONDITION AND RESULTS OF OPERATIONS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the section of this prospectus titled &#8220;Unaudited Pro Forma Condensed Combined Financial Statements&#8221; and the consolidated financial statements and related notes thereto included elsewhere in this prospectus. In addition to historical information, this discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from these forward-looking statements as a result of certain factors. We discuss factors that we believe could cause or contribute to these differences below and elsewhere in this prospectus, including those set forth in the sections of this prospectus titled &#8220;Risk Factors&#8221; and &#8220;Cautionary Note Regarding Forward-Looking Statements.&#8221; </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_30">Overview </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an innovative revenue-generating company focused on acquiring, developing and commercializing <span style="white-space:nowrap">non-opioid</span> management products for the treatment of acute and chronic pain. According to the Centers for Disease Control and Prevention, an estimated 51.4&#160;million adults in the United States suffered from chronic pain in 2019. We target indications with high unmet needs and large market opportunities with <span style="white-space:nowrap">non-opioid</span> therapies for the treatment of patients with acute and chronic pain. We launched our first commercial product in October 2018 and are developing our late-stage pipeline. Our commercial product, ZTlido is a prescription lidocaine topical product approved by the FDA for the relief of neuropathic pain associated with PHN, which is a form of post-shingles nerve pain. ZTlido possesses novel delivery and adhesion technology designed to address many of the limitations of current prescription lidocaine patches by providing significantly improved adhesion and continuous pain relief throughout the <span style="white-space:nowrap">12-hour</span> administration period. We market ZTlido through a dedicated sales force of <span style="white-space:nowrap">60-70</span> sales representatives, targeting 10,000 primary care physicians, pain specialists, neurologists and palliative care physicians who we believe treat the majority of PHN patients. We <span style="white-space:nowrap">in-licensed</span> the exclusive right to commercialize GLOPERBA (colchicine USP) oral solution, an <span style="white-space:nowrap">FDA-approved</span> prophylactic treatment for painful gout flares in adults, in the U.S. We are planning to commercialize GLOPERBA in 2023 and believe we are well-positioned to market and distribute the product. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our development pipeline consists of three product candidates, <span style="white-space:nowrap">(i)&#160;SP-102</span> (&#8220;SEMDEXA&#8221;) (10 mg, dexamethasone sodium phosphate viscous gel), a Phase 3, novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, <span style="white-space:nowrap">(ii)&#160;SP-103</span> (lidocaine topical system) 5.4%, a Phase 2, next-generation, triple-strength formulation of ZTlido, for the treatment of acute LBP, and <span style="white-space:nowrap">(iii)&#160;SP-104</span> (4.5 mg, <span style="white-space:nowrap">low-dose</span> naltrexone hydrochloride delayed-release capsules), a novel <span style="white-space:nowrap">low-dose</span> delayed-release naltrexone hydrochloride formulation for treatment of fibromyalgia, for which Phase 1 trials were completed in the second quarter of 2022 and a Phase 2 clinical trial is expected to commence in the first half of 2023. SEMDEXA has been granted fast track designation by the FDA and, if approved, could become the first <span style="white-space:nowrap">FDA-approved</span> alternative to <span style="white-space:nowrap">off-label</span> ESIs, which are administered over 12&#160;million times annually in the United States. <span style="white-space:nowrap">Top-line</span> results from the completed Phase 3 study have been received in November 2021 and reflected achievement of primary and secondary endpoints. <span style="white-space:nowrap">SP-103</span> has also been granted fast track designation by the FDA and, if approved, could become the first <span style="white-space:nowrap">FDA-approved</span> lidocaine topical product for the treatment of acute LBP. <span style="white-space:nowrap">SP-103</span> is a triple-strength lidocaine topical system designed to deliver a dose of lidocaine threefold higher than any lidocaine topical product that we are aware of, either approved or in development. We are examining <span style="white-space:nowrap">SP-103</span> as a treatment for acute LBP, a condition with high unmet need which, as of 2019, affected over 22&#160;million patients in the United States. According to the CDC in 2020, LBP was the most common type of pain reported by patients, with 25% of U.S. adults reporting LBP in the prior 3 months. We initiated a Phase 2 trial of <span style="white-space:nowrap">SP-103</span> in acute LBP in the second quarter of our fiscal year 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently contract with third parties for the manufacture, assembly, testing, packaging, storage and distribution of our product. We obtain our commercial supply of ZTlido, clinical supply of our product candidates and certain of the raw materials used in our product candidates from sole or single source suppliers </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">114 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and manufacturers. Prior to April 2022, we relied on a single third-party logistics distribution provider, Cardinal Health, for ZTlido distribution in the United States. Cardinal Health purchased and shipped ZTlido to customer wholesale distribution centers. Cardinal Health also performed order management services on our behalf. On April&#160;2, 2022, we announced the expansion of our direct distribution network to national and regional wholesalers and pharmacies. Cardinal Health will continue to provide traditional third-party logistics functions for us. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our inception, we have invested substantial efforts and financial resources on acquiring product and technology rights while building our intellectual property portfolio and infrastructure. We acquired Semnur and its lead product candidate, SEMDEXA, in the first quarter of 2019, and we intend to continue to explore and evaluate additional opportunities such as these to grow our business. We have incurred significant operating losses as a result of such investment efforts, including the development of SEMDEXA, conducting of Phase 3 trials for SEMDEXA, and the development of <span style="white-space:nowrap">SP-103.</span> Our ability to generate revenue sufficient to achieve profitability will depend on the successful commercialization of our product, ZTlido, and the development of our product candidates. For the years ended December&#160;31, 2021, 2020 and 2019, our net loss was $88.4&#160;million, $47.5&#160;million and $178.6&#160;million, respectively. For the nine months ended September&#160;30, 2022 and 2021, we had a net loss of $5.5&#160;million and $46.5&#160;million, respectively. As of September&#160;30, 2022, we had an accumulated deficit of $358.0&#160;million. As of September&#160;30, 2022, we had cash and cash equivalents of $2.5&#160;million. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to continue to make investments in our sales and marketing organization and expand digital marketing efforts to broaden awareness of ZTlido and GLOPERBA and in research and development, clinical trials and regulatory affairs to develop our product candidates, SEMDEXA, <span style="white-space:nowrap">SP-103,</span> and <span style="white-space:nowrap">SP-104</span> (which product candidate we acquired from Sorrento in May 2022). As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until we can generate significant revenue, if ever, we expect to finance our operations through a combination of equity offerings, debt financings, collaborations, government contracts or other strategic transactions. We may be unable to raise additional funds or enter into such agreements or arrangements when needed on favorable terms, or at all. If adequate funds on acceptable terms are not available when needed, we may be required to reduce the scope of the commercialization of ZTlido and GLOPERBA or delay, scale back or discontinue the development of one or more of our product candidates. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_31">Business Combination </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&#160;17, 2022, Vickers Vantage Corp. I (&#8220;Vickers&#8221;) entered into an Agreement and Plan of Merger (the &#8220;BCA&#8221;) with Vantage Merger Sub, Inc., a wholly-owned subsidiary of Vickers (&#8220;Vickers Merger Sub&#8221;), and Scilex Holding Company, a Delaware corporation (&#8220;Legacy Scilex&#8221;). Pursuant to the terms of the BCA, Vickers Merger Sub merged with and into Legacy Scilex, with Legacy Scilex surviving the merger and becoming a wholly- owned subsidiary of Vickers (collectively, the &#8220;Business Combination&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&#160;10, 2022, Vickers consummated the Business Combination pursuant to the terms of the BCA, with Legacy Scilex and Vickers Merger Sub. Pursuant to the BCA, Vickers acquired all of the outstanding equity interests of Legacy Scliex. As a result of the Business Combination, New Scilex (as defined below) received gross proceeds of approximately $12.0&#160;million, prior to the settlement of transaction-related costs and expenses. Additionally, all existing related party indebtedness and payables between Legacy Scilex, Scilex Pharma, and Sorrento, totaling $290.6&#160;million, was converted into equity interests of New Scilex in connection with the consummation of the Business Combination and pursuant to the terms of the Debt Exchange Agreement (see Note 10 titled &#8220;Related Party Transactions&#8221; to our consolidated financial statements included elsewhere in this prospectus for additional information). In connection with the Business Combination (as more fully described in the notes to these financial statements), Scilex Holding Company was renamed to Scilex, Inc. These financial statements are those of Scilex Holding Company (now known as Scilex, Inc.) prior to the completion of such Business Combination. Additionally, in connection with the completion of the Business Combination, Vickers was renamed to, and will operate as, &#8220;Scilex Holding Company&#8221; and the Company began trading on Nasdaq </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">115 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
under the new ticker symbol &#8220;SCLX&#8221; on November&#160;11, 2022. Scilex Holding Company following the completion of the Business Combination is sometimes referred to herein as &#8220;New Scilex.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Business Combination will be accounted for as a reverse recapitalization in accordance with U.S. GAAP. Under this method of accounting, Vickers is treated as the &#8220;acquired&#8221; company for accounting purposes and the Business Combination is treated as the equivalent of Legacy Scilex issuing stock for the net assets of Vickers, accompanied by a recapitalization. The net assets of Vickers are stated at historical cost, with no goodwill or other intangible assets recorded. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_32">Recent Developments </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&#160;3, 2023, we filed a Current Report on Form <span style="white-space:nowrap">8-K</span> providing certain preliminary unaudited financial results for the one and twelve months ended December&#160;31, 2022, and as of December&#160;31, 2022, based on then-currently available information. Our independent auditor has not reviewed or audited these preliminary estimated financial results. Our actual results may differ materially from these preliminary financial results, and may be outside the estimated ranges. This preliminary financial data has been prepared by and is the responsibility of the Company. We have not fully completed our review of these preliminary financial results for the one and twelve months ended December&#160;31, 2022, and as of December&#160;31, 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In such Current Report on Form <span style="white-space:nowrap">8-K,</span> we estimated that: ZTlido gross sales for December 2022 were in the range of $10.0&#160;million to $12.0&#160;million; the gross sales for ZTlido in 2022 were in the range of $93.0&#160;million to $98.0&#160;million, compared to $63.9&#160;million in 2021, representing growth in the range of 45% to 53%; net sales for 2022 were in the range of $37.0&#160;million to $42.0&#160;million, compared to net sales of $31.3&#160;million in 2021, representing growth in the range of 18% to 34%; and, as of December&#160;31, 2022, our cash and cash equivalents were in the range of $1.8&#160;million to $2.5&#160;million, and our accounts receivables were in the range of $18.0&#160;million to $22.0&#160;million. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">B. Riley Purchase Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January 8, 2023, we entered into the B. Riley Purchase Agreement with the Selling Securityholder. The Selling Securityholder is a wholly-owned subsidiary of B. Riley Principal Investments, LLC. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the B. Riley Purchase Agreement, we have the right, but not the obligation, to sell to the Selling Securityholder up to $500,000,000 of shares of Common Stock at any time during the 36 months following the date on which this registration statement has been declared effective by the SEC, subject to the terms of the B. Riley Purchase Agreement. To request a purchase, we would submit an Advance Notice to the Selling Securityholder specifying the number of shares we intend to sell to the Selling Securityholder. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares of Common Stock, if any, that we elect to sell to the Selling Securityholder pursuant to an Advance will be purchased at a price equal to 98% of the VWAP (as defined below) during the period (such period, the &#8220;Pricing Period&#8221;) beginning at 9:30:01 a.m., New York City time, on the date of purchase of Advance Shares or such later time publicly announced as the official open of the primary (or &#8220;regular&#8221;) trading session on Nasdaq on such purchase date (the &#8220;Purchase Commencement Time&#8221;) and ending at the earliest of (i) 3:59 p.m., New York City Time, on the purchase date or such earlier time publicly announced as the official close of the primary (or &#8220;regular&#8221;) trading session on Nasdaq on such purchase date, (ii)&#160;immediately at such time following the Purchase Commencement Time for such purchase that the total number (or volume) of shares of Common Stock traded on Nasdaq during such period has exceeded the Advance Share Volume Maximum (as defined below) for such purchase and (iii)&#160;if we so elect in the applicable Advance Notice for such Advance (such election, a &#8220;Limit Order Discontinue Election&#8221;), such time the sale price of the shares of Common Stock traded on the Nasdaq Capital Market during such Pricing Period is less than the applicable minimum price threshold determined in accordance with the B. Riley Purchase Agreement. &#8220;VWAP&#8221; means, for the Common Stock for a specified period, the dollar volume-weighted average price of the Common Stock on Nasdaq for such period as </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">116 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reported by Bloomberg through its &#8220;AOR&#8221; function, subject to certain exceptions, qualifications and limitations. &#8220;Advance Share Volume Maximum&#8221; means, with respect to an Advance, if such Advance is designated in the Advance Notice as a (i)&#160;purchase-Type A, a number of shares of Common Stock that is equal to the quotient obtained by dividing (a)&#160;the Advance Share amount to be purchased by the Selling Securityholder, by (b) 0.10, and (ii)&#160;purchase-Type B, a number of shares of Common Stock that is equal to the quotient obtained by dividing (a)&#160;the Advance Share amount to be purchased by the Selling Securityholder, by (b) 0.25 (in each case, subject to certain adjustments). We may also specify a certain minimum acceptable price per share in each Advance. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While there is no mandatory minimum amount for any Advance, subject to the terms and conditions of the B. Riley Purchase Agreement, an Advance may be for a number of shares of Common Stock not to exceed (i)&#160;with respect to an Advance, purchase-Type A, such number of shares of Common Stock that is equal to the lesser of: (a) 1,000,000, and (b)&#160;the product of (1) 0.10, multiplied by (2)&#160;the total number (or volume) of shares of Common Stock traded on Nasdaq during the Pricing Period for such purchase-Type A, and (ii)&#160;with respect to an Advance, purchase-Type B, such number of shares of Common Stock that is equal to the lesser of: (a) 1,000,000 and (b)&#160;the product of (1) 0.25, multiplied by (2)&#160;the total number (or volume) of shares of Common Stock traded on Nasdaq during the Pricing Period for such purchase-Type B. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The B. Riley Purchase Agreement also provides that we have the right, but not the obligation, to sell to the Selling Securityholder, from time to time subject to certain limitations, at our sole and absolute discretion an Additional Advance. To request an additional purchase, we would submit an Additional Advance Notice to the Selling Securityholder specifying the number of shares we intend to sell to the Selling Securityholder. The purpose of the Additional Advance is to allow us to execute more than one advance request on a purchase date with the Selling Stockholder as each prior advance has been completed under the terms of the B. Riley Purchase Agreement. Each Additional Advance is generally subject to terms and conditions consistent with those of an Advance, except for, among other things, the time period of the pricing period for such Additional Advance. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may also specify a certain minimum acceptable price per share in each Advance or Additional Advance. In no event is the Selling Securityholder obligated to purchase any shares that would result in it owning more than 4.99% of the then-outstanding voting power or number of shares of Common Stock. Moreover, under the applicable Nasdaq Listing Rules, in no event will we issue to the Selling Securityholder shares that, in the aggregate, would exceed the 19.9% Exchange Cap, unless we have received stockholder approval for such issuance or such issuance is otherwise permitted by applicable Nasdaq Listing Rules. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Selling Securityholder&#8217;s obligation to purchase shares of Common Stock pursuant to the B. Riley Purchase Agreement is subject to a number of conditions, including that a registration statement be filed with the SEC registering the resale of the Commitment Shares and the shares to be issued pursuant to any Advance or Additional Advance under the Securities Act, and that the registration statement is declared effective by the SEC. As consideration for the Selling Securityholder&#8217;s commitment to purchase shares of Common Stock at our direction upon the terms and subject to the conditions set forth in the B. Riley Purchase Agreement, we issued to the Selling Securityholder 250,000 shares of Common Stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Yorkville Purchase Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&#160;17, 2022, we entered into the Yorkville Purchase Agreement with YA II. YA II is a fund managed by Yorkville Advisors Global, LP, headquartered in Mountainside, New Jersey. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Yorkville Purchase Agreement, we have the right, but not the obligation, to sell to YA II up to $500,000,000 of shares of Common Stock at any time during the 36 months following the date on which the initial registration statement filed with respect to the Yorkville Purchase Agreement has been declared effective by the SEC, subject to the terms of the Yorkville Purchase Agreement. The registration statement on Form <span style="white-space:nowrap">S-1</span> (File <span style="white-space:nowrap">No.&#160;333-268607)</span> related to the the Yorkville Purchase Agreement was filed with the SEC on November&#160;30, 2022, was declared effective by the SEC on December&#160;9, 2022. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">117 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To request a purchase, we would submit a Yorkville Advance Notice to YA II specifying the number of shares we intend to sell to YA II. While there is no mandatory minimum amount for any Yorkville Advance, a Yorkville Advance may not be for a number of shares of Common Stock exceeding 200% of the average of the daily trading volume of the Common Stock on the Nasdaq Capital Market during regular trading hours as reported by Bloomberg L.P. during the five trading days immediately preceding the Yorkville Advance Notice Date. The shares of Common Stock, if any, that we elect to sell to YA II pursuant to a Yorkville Advance will be purchased at a price equal to 98% of the lowest daily VWAP (as defined below) during the two consecutive trading days commencing on the date of delivery of a Yorkville Advance Notice. &#8220;VWAP&#8221; means, for any trading day, the daily volume weighted average price of the Common Stock for such trading day on the Nasdaq Capital Market as reported by Bloomberg L.P. during regular trading hours. We may also specify a certain minimum acceptable price per share in each Yorkville Advance. In no event is YA II obligated to purchase any shares that would result in it owning more than 4.99% of the then-outstanding voting power or number of shares of Common Stock. Moreover, under the applicable Nasdaq Listing Rules, in no event will we issue to YA II shares that, in the aggregate, would exceed the 19.9% Exchange Cap, unless we have received stockholder approval for such issuance or such issuance is otherwise permitted by applicable Nasdaq Listing Rules. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">YA II&#8217;s obligation to purchase shares of Common Stock pursuant to the Yorkville Purchase Agreement is subject to a number of conditions, including that a registration statement be filed with the SEC registering the resale of the Commitment Shares and the shares to be issued pursuant to any Yorkville Advance under the Securities Act, and that the registration statement is declared effective by the SEC. As consideration for YA II&#8217;s commitment to purchase shares of Common Stock at our direction upon the terms and subject to the conditions set forth in the Yorkville Purchase Agreement, we issued to YA II 250,000 shares of Common Stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_33">Impact of <span style="white-space:nowrap">COVID-19</span> on Our Business </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are closely monitoring the <span style="white-space:nowrap">COVID-19</span> pandemic and its potential impact on our business. In an effort to protect the health and safety of our employees, we took proactive action from the earliest signs of the outbreak, including implementing social distancing policies at our facilities, facilitating remote working arrangements and imposing employee travel restrictions. The extent to which <span style="white-space:nowrap">COVID-19</span> may impact our business, clinical trials and sales of ZTlido will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, the duration of the outbreak, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the disease. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_34">Comparability of Our Results and Our Relationship with Sorrento </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently operate as a majority-owned subsidiary of Sorrento. As a result, our historical financial statements may not be reflective of what our results of operations would have been had we been a stand-alone public company and no longer a majority-owned subsidiary of Sorrento. In particular, certain legal, finance, human resources and other functions have historically been provided to us by Sorrento at cost plus an agreed-upon markup. We expect that Sorrento will continue to provide us with some of the services related to these functions on a transitional basis in exchange for agreed-upon fees, and we expect to incur other costs to replace the services and resources that will not be provided by Sorrento. We will also incur additional costs as a stand-alone public company. As a stand-alone public company, our total costs related to certain support functions may differ from the costs that were historically allocated to us from Sorrento. In addition, in the future, we expect to incur internal costs to implement certain new systems, including infrastructure and an enterprise resource planning system, while our legacy systems are currently being fully supported by Sorrento. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_35">Components of Our Results of Operations </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Net Revenue </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net revenue consists solely of product sales of ZTlido in the United States. For product sales of ZTlido, we record <span style="white-space:nowrap"><span style="white-space:nowrap">gross-to-net</span></span> sales adjustments for government and commercial rebates, chargebacks, wholesaler and </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">118 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
distributor fees, sales returns, special marketing programs, and prompt payment discounts. We expect that any net revenue we generate will fluctuate from year to year as a result of the unpredictability of the demand for our product. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_36">Operating Costs and Expenses </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Cost of Revenue </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cost of revenue consists of the cost of purchasing ZTlido from our manufacturing partners and inventory write-downs related to expiration dates for <span style="white-space:nowrap">on-hand</span> inventory. We expect the cost of revenue to fluctuate with related sales revenue. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Research and Development. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses are expensed when incurred and consist primarily of costs incurred for our research activities, including the development of our product candidates, and include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">costs related to clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">salaries, benefits and other related costs, including stock-based compensation expense for personnel engaged in research and development functions; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">costs related to outside consultants. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect our research and development expenses to increase, as we will incur incremental expenses associated with our product candidates that are currently under development and in clinical trials. Product candidates in later stages of clinical development generally have higher development costs, primarily due to the increased size and duration of later-stage clinical trials. Accordingly, we expect to incur significant research and development expenses in connection with our ongoing Phase 3 clinical trial for SEMDEXA, our planned Phase 2 and Phase 3 clinical trials for <span style="white-space:nowrap">SP-103,</span> and initiation of Phase 2 trials for <span style="white-space:nowrap">SP-104.</span> </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Acquired <span style="white-space:nowrap">In-process</span> Research and Development </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have acquired and may continue to acquire the rights to develop and commercialize new product candidates. The <span style="white-space:nowrap">up-front</span> payments to acquire a new drug compound or drug delivery device, as well as future milestone payments associated with asset acquisitions that do not meet the definition of a derivative and are deemed probable to achieve the milestones, are immediately expensed as acquired <span style="white-space:nowrap">in-process</span> research and development provided that the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, have no alternative future use. Intangible assets acquired in a business combination that are used for <span style="white-space:nowrap">in-process</span> research and development (&#8220;IPR&amp;D&#8221;) activities are considered indefinite-lived until the completion or abandonment of the associated research and development efforts. Upon commercialization of the relevant research and development project, we amortize the acquired IPR&amp;D over its estimated useful life. Capitalized IPR&amp;D is reviewed annually for impairment or more frequently as changes in circumstance or the occurrence of events suggest that the remaining value may not be recoverable. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Selling, General and Administrative </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Selling, general and administrative expenses consist primarily of costs related to our contract sales force, salaries and other related costs, including stock-based compensation, for personnel in our executive, marketing, finance, corporate and business development and administrative functions. Selling, general and administrative expenses also include professional fees for legal, patent, accounting, auditing, tax and consulting services, travel expenses and facility-related expenses, which include direct depreciation costs and allocated expenses from Sorrento for rent and maintenance of facilities and other operating costs. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">119 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that our selling, general and administrative expenses will vary year over year in the future as we adapt our commercial strategies to changes in the business environment. We also expect to incur increased expenses as a result of the Business Combination and operating as a public company, including expenses related to compliance with the rules and regulations of the SEC, and listing standards applicable to companies listed on a national securities exchange, additional insurance expenses, investor relations activities and other administrative and professional services. We also expect to adjust the size of our administrative, finance and legal functions to adapt to the changes above and the anticipated growth of our business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Intangible Amortization Expense </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Intangible amortization expense consists of the amortization expense of intangible assets recognized on a straight-line basis over the estimated useful lives of the assets. Our intangible assets, excluding goodwill, are composed of patent rights, acquired <span style="white-space:nowrap">in-process</span> research and development and assembled workforce. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Other Expense </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Gain on Derivative Liability </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gain on derivative liability consists of the changes to fair value of derivative liabilities between reporting periods relating to certain embedded derivative features within the Scilex Pharma Notes, and is recorded as other income or expense. See Note 6 titled &#8220;Debt&#8221; to our consolidated financial statements appearing elsewhere in this prospectus and the section titled &#8220;Certain Relationships and Related Party Transactions &#8212; Certain Relationships of Legacy Scilex &#8212; Indenture and Letter of Credit&#8221; for a description of the Scilex Pharma Notes. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">(Gain) loss on Debt Extinguishment, Net </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(Gain) loss on debt extinguishment, net consists of gains earned or losses incurred as a result of exercising our optional prepayment rights, which are treated as partial extinguishments, and the Early Paydown Provision, which is treated as a debt extinguishment, under the Scilex Pharma Notes, offset, for the year ended December&#160;31, 2021, by a gain on debt extinguishment as a result of the forgiveness of the loan in the amount of $1.6&#160;million received from Bank of America in May 2020 pursuant to the Paycheck Protection Program of the CARES Act (the &#8220;PPP Loan&#8221;). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Interest Expense </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest expense consists of interest related to the Scilex Pharma Notes and related party note payables to Sorrento. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">(Gain) loss on Foreign Currency Exchange </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(Gain) loss on foreign currency exchange relates to foreign exchange losses on payments made to our foreign supplier, Itochu, a manufacturer and supplier of lidocaine tape products, including ZTlido and <span style="white-space:nowrap">SP-103.</span> </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">120 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_37">Results of Operations </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables summarize our results of operations for the years ended December&#160;31, 2021, 2020 and 2019 and the nine months ended September&#160;30, 2022 and 2021 (in thousands): </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">


<tr>

<td style="width:75%"></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Nine Months Ended<br />September&#160;30,</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">(in thousands, except for per share amounts)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center">2022</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center">2021</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Statements of Operations Data:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net revenue</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">26,115</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">23,054</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating costs and expenses:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of revenue</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,284</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,549</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,457</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,031</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and administrative</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">41,371</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">36,092</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible amortization</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,896</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,803</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating costs and expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">57,008</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">48,475</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(30,893</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(25,421</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other (income) expense:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on derivative liability</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(5,300</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(100</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Gain) loss on debt extinguishment, net</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(28,634</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12,463</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8,596</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8,617</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Gain) loss on foreign currency exchange</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(39</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">48</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other (income) expense</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(25,377</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">21,028</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before income taxes</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(5,516</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(46,449</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax (benefit) expense</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(36</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(5,480</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(46,459</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share &#8212; basic and diluted</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(0.03</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(0.24</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average number of shares during the period &#8212; basic and diluted</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">197,550</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">197,266</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">121 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">


<tr>

<td style="width:63%"></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Year Ended December&#160;31,</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">(in thousands, except for per share amounts)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center">2021</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center">2020</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center">2019</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Statements of Operations Data:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net revenue</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">31,317</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">23,560</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">21,033</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating costs and expenses:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of revenue</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,634</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,149</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,802</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,201</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,961</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10,216</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquired <span style="white-space:nowrap">in-process</span> research and development</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">75,301</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and administrative</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">50,582</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">42,970</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">64,696</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible amortization</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,738</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,738</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,713</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating costs and expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">67,155</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">58,818</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">159,728</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(35,838</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(35,258</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(138,695</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss (gain) on derivative liability</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">300</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(800</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">23,300</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on debt extinguishment, net</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12,463</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Scilex Pharma Notes principal increase</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">28,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11,764</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13,116</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16,889</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(460</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss (gain) on foreign currency exchange</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">54</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(2</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">168</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other expense</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">52,581</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12,314</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">39,897</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before income taxes</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(88,419</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(47,572</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(178,592</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax (benefit) expense</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(53</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(88,424</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(47,519</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(178,594</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_38">Comparison of Nine Months Ended September&#160;30, 2022 and 2021 </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Net Revenue </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net revenue for the nine months ended September&#160;30, 2022 and 2021 was $26.1&#160;million and $23.1&#160;million, respectively. The increase of $3.0&#160;million primarily driven by an increase in gross revenues by approximately 37% offset by increase in rebates. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Cost of Revenue </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cost of revenue for the nine months ended September&#160;30, 2022 and 2021 was $6.3&#160;million and $2.5&#160;million, respectively, and relate to product sales. The increase of $3.8&#160;million was primarily due to an approximately 37% increase in gross revenue for the nine months ended September&#160;30, 2022, compared to the nine months ended September&#160;30, 2021, royalty payments to our manufacturer beginning in the second quarter of 2022, and a $0.5&#160;million inventory reserve reversal in May 2021. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">122 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Research and Development Expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes research and development expenses by project for the nine months ended September&#160;30, 2022 and 2021 (in thousands): </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:78%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Nine Months Ended<br />September&#160;30,</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2022</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2021</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Increase<br />(Decrease)</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">SP-102</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contracted R&amp;D</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,329</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,010</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(3,681</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">444</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(194</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">82</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">82</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">SP-102</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,661</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,454</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(3,793</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">SP-103</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contracted R&amp;D</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,520</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">688</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,832</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">272</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">889</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(617</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">796</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">796</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">SP-103</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,588</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,577</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,011</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">SP-104</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contracted R&amp;D</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">208</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">208</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">SP-104</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">208</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">208</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Research and Development Expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,457</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,031</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(574</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses for the nine months ended September&#160;30, 2022 and 2021 were $6.5&#160;million and $7.0&#160;million, respectively. The $0.5&#160;million decrease in research and development expenses was primarily attributed to the completion of the Phase 3 <span style="white-space:nowrap">SP-102</span> trial in November 2021, and was partially offset by clinical <span style="white-space:nowrap">start-up</span> costs in the development of Phase 2 <span style="white-space:nowrap">SP-103</span> in the fourth quarter of 2021, the Phase 1 <span style="white-space:nowrap">SP-104</span> study in the fourth quarter of 2021, and an additional Phase 1 <span style="white-space:nowrap">SP-104</span> study in the second quarter of 2022. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Selling, General and Administrative Expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Selling, general and administrative expenses for the nine months ended September&#160;30, 2022 and 2021 were $41.4&#160;million and $36.1&#160;million, respectively. The increase of approximately $5.3&#160;million was primarily due to a $7.7&#160;million increase in legal expenses related to the ZTlido patent infringement in which we were the plaintiff in September 2022, $0.9&#160;million increase in travel and entertainment expenses, $0.2&#160;million increase in consulting expenses, and a $0.4&#160;million increase in insurance expense, offset by a $1.2&#160;million decrease in commercial operations caused by fluctuation in fleet and electronics expenses, $2.0&#160;million decrease in personnel expense caused by $1.0&#160;million increase in personnel compensation that was offset by $3.0&#160;million decrease in bonus, a $0.5&#160;million decrease in marketing expense, and a $0.2&#160;million decrease in other expenses. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Intangible Amortization Expense </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Intangible amortization expense for each of the nine months ended September&#160;30, 2022 and 2021 was $2.9&#160;million and $2.8&#160;million, respective. The increase of $0.1 is related to the amortization of acquired licenses for the exclusive license of GLOPERBA. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Gain on Derivative Liability </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gain on derivative liability for the nine months ended September&#160;30, 2022 and 2021 was $5.3&#160;million and $0.1&#160;million, respectively. The gain recognized during the nine months ended September&#160;30, 2022 and 2021 was attributed to changes in the fair value of our derivative liability pertaining to the Scilex Pharma Notes due to revised sales forecasts. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">123 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">(Gain) Loss on Debt Extinguishment, Net </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(Gain) loss on debt extinguishment, net for the nine months ended September&#160;30, 2022 and 2021 was $(28.6) million and $12.5&#160;million, respectively. The gain and loss incurred during the nine months ended September&#160;30, 2022 and 2021, respectively, was attributed to Scilex Pharma&#8217;s repurchase of the Scilex Pharma Notes of $20.0&#160;million and $41.4&#160;million in February 2022 and June 2022, respectively, as well as the Early Paydown Provision of $39.7&#160;million in September 2022 (see Note 6 titled &#8220;Debt&#8221; to our consolidated financial statements included elsewhere in this prospectus for additional information) and $20.0&#160;million in each of February 2021 and April 2021. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Interest Expense </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest expense for the nine months ended September&#160;30, 2022 and 2021 remained consistent and was $8.6&#160;million for each period </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Income Tax (Benefit) Expense </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Income tax (benefit) expense for the nine months ended September&#160;30, 2022 and 2021 was $(36.0) thousand and $10.0&#160;thousand, respectively. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_39">Comparison of Years Ended December&#160;31, 2021 and 2020 </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Net Revenue </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net revenue for the years ended December&#160;31, 2021 and 2020 was $31.3&#160;million and $23.6&#160;million, respectively. The increase of $7.7&#160;million was due to increased product sales of ZTlido. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Cost of Revenue </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cost of revenue for the years ended December&#160;31, 2021 and 2020 was $3.6&#160;million and $2.1&#160;million, respectively, and relate to product sales. The increase of $1.5&#160;million is mainly due to the temporary switch of shipping method from ocean to air shipment in 2021. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Research and Development Expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes research and development expenses by project for the years ended December&#160;31, 2021 and 2020 (in thousands): </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">


<tr>

<td style="width:68%"></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Year Ended December&#160;31,</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center">2021</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center">2020</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center">Increase<br />(Decrease)</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">SP-102</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contracted R&amp;D</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,952</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,641</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(689</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">555</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">395</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">160</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">SP-102</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,507</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,036</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(529</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">SP-103</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contracted R&amp;D</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,816</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,128</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">688</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">878</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,797</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(919</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">SP-103</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,694</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,925</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(231</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Research and Development Expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,201</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,961</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(760</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">124 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses for the years ended December&#160;31, 2021 and 2020 were $9.2&#160;million and $10.0&#160;million, respectively. The $0.8&#160;million decrease in research and development expenses was attributed to the completion of Phase 3 <span style="white-space:nowrap">SP-102</span> trials in November 2021 as well as CMC and regulatory related expenses incurred in 2020 to prepare for <span style="white-space:nowrap">SP-103</span> clinical trials in 2021. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Selling, General and Administrative Expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Selling, general and administrative expenses for the years ended December&#160;31, 2021 and 2020 were $50.6&#160;million and $43.0&#160;million, respectively. The increase of approximately $7.6&#160;million was primarily due to $4.0&#160;million in additional expenses in marketing and commercial operations, $7.6&#160;million in legal and audit fees, and $1.2&#160;million in additional other administrative expenses, offset by $5.2&#160;million of savings in sales expenses as a result of realigning our &#8220;sales force&#8221; territories resulting in the significant reduction of salesforce. The $7.6&#160;million increase in legal and audit fees was primarily due to a $6.6&#160;million increase in litigation expenses related to the ZTlido patent infringement in which we were the plaintiff and $1.0&#160;million increase in legal intellectual property and other legal corporate matters. The $4.0&#160;million increase in marketing and commercial operations was due to $1.4&#160;million increase in product promotion expenses, $1.0&#160;million increase in dues and subscriptions, $1.0&#160;million increase in consulting expenses and $0.6&#160;million increase in personnel cost. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Intangible Amortization Expense </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Intangible amortization expense for each of the years ended December&#160;31, 2021 and 2020 was $3.7&#160;million, which is related to the amortization of developed technology upon commercialization of ZTlido. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Loss (Gain) on Derivative Liability </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Loss (gain) on derivative liability for the years ended December&#160;31, 2021 and 2020 was $0.3&#160;million and $(0.8) million, respectively. The loss incurred during the year ended December&#160;31, 2021 was attributed to changes in the fair value of our derivative liability pertaining to the Scilex Pharma Notes due to revised probabilities related to marketing approval timing for <span style="white-space:nowrap">SP-103</span> and revised sales forecasts. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Loss on Debt Extinguishment, Net </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Loss on debt extinguishment net for the years ended December&#160;31, 2021 was $12.5&#160;million. The loss incurred was attributed to our exercise of the optional principal repurchase payments on the Scilex Pharma Notes, offset by a gain on debt extinguishment of $1.5&#160;million related to the forgiveness on the entire PPP Loan. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Scilex Pharma Notes Principal Increase </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The principal increase on the Scilex Pharma Notes for the years ended December&#160;31, 2021 was $28.0&#160;million. Actual cumulative net sales of ZTlido from the issue date of the Scilex Pharma Notes through December&#160;31, 2021 did not equal or exceed $481.0&#160;million. As a result, we recorded the increase of $28.0&#160;million in principal as <span style="white-space:nowrap">non-operating</span> expense at December&#160;31, 2021. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Interest Expense </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest expense for the years ended December&#160;31, 2021 and 2020 was $11.8&#160;million and $13.1&#160;million, respectively. The $1.3&#160;million decrease in interest expense was primarily due to the $2.8&#160;million decrease in interest expense incurred on the Scilex Pharma Notes partially offset by a $1.1&#160;million increase in interest expense related to related party notes with Sorrento and $0.4&#160;million increase in interest expense related to the CNH Revolving Loan during the year ended December&#160;31, 2021. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">125 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Income Tax Expense (Benefit) </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Income tax expense (benefit) for the years ended December&#160;31, 2021 and 2020 was $5.0&#160;thousand and $(53.0) thousand, respectively. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_40">Comparison of Years Ended December&#160;31, 2020 and 2019 </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Net Revenue </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net revenue for the years ended December&#160;31, 2020 and 2019 was $23.6&#160;million and $21.0&#160;million, respectively. The increase of $2.6&#160;million was due to product sales of ZTlido, which was commercially launched in October 2018. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Cost of Revenue </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cost of revenue for the years ended December&#160;31, 2020 and 2019 was $2.1&#160;million and $5.8&#160;million, respectively, and relate to product sales. The decrease of $3.7&#160;million is mainly due to establishing an E&amp;O inventory provision in 2019 for short-dated products. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Research and Development Expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes research and development expenses by project for the years ended December&#160;31, 2020 and 2019 (in thousands): </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">


<tr>

<td style="width:67%"></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Year Ended December&#160;31,</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center">2020</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center">2019</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center">Increase<br />(Decrease)</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">SP-102</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contracted R&amp;D</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,641</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,249</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(608</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">395</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">22</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">373</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">SP-102</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,036</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,271</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(235</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">SP-103</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contracted R&amp;D</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,128</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">997</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">131</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,797</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,948</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(151</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">SP-103</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,925</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,945</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(20</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Research and Development Expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,961</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10,216</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(255</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses for the years ended December&#160;31, 2020 and 2019 were $10.0&#160;million and $10.2&#160;million, respectively. The $0.2&#160;million decrease was primarily due to a slow down of clinical activities in the development of <span style="white-space:nowrap">SP-102</span> due to the <span style="white-space:nowrap">COVID-19</span> pandemic. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Acquired <span style="white-space:nowrap">In-process</span> Research and Development Expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Acquired IPR&amp;D expenses for the years ended December&#160;31, 2020 and 2019 were $0 and $75.3&#160;million, respectively. The decrease was due to acquired IPR&amp;D expenses associated with our acquisition of Semnur&#8217;s assets in March 2019. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Selling, General and Administrative Expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Selling, general and administrative expenses for the years ended December&#160;31, 2020 and 2019 were $43.0&#160;million and $64.7&#160;million, respectively. The decrease of approximately $21.7&#160;million was primarily due to $16.6&#160;million of savings in sales and marketing as a result of realigning our &#8220;sales force&#8221; territories resulting in </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">126 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the significant reduction of salesforce as well as achieving cost-saving within our marketing programs, a reduction of $2.4&#160;million in third-party services within the market access department, and $2.7&#160;million in savings from lower legal and audit fees. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Intangible Amortization Expense </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Intangible amortization expense remained the same at $3.7&#160;million between the years ended December&#160;31, 2020 and 2019, which is related to the amortization of developed technology upon commercialization of ZTlido. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">(Gain) Loss on Derivative Liability </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(Gain) loss on derivative liability for the years ended December&#160;31, 2020 and 2019 was a gain of $0.8&#160;million and a loss of $23.3&#160;million, respectively. The gain incurred during the year ended December&#160;31, 2020 and loss incurred during the year ended December&#160;31, 2019 was attributed to changes in the fair value of our derivative liability pertaining to the Scilex Pharma Notes due to revised probabilities related to marketing approval timing for <span style="white-space:nowrap">SP-103</span> and revised sales forecasts. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Interest Expense </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest expense for the years ended December&#160;31, 2020 and 2019 was $13.1&#160;million and $16.9&#160;million, respectively. The decrease in interest expense was primarily due to the $4.4&#160;million decrease in interest expense incurred on the Scilex Pharma Notes issued in September 2018 partially offset by a $0.6&#160;million increase in interest expense related to related party notes with Sorrento during the year ended December&#160;31, 2020. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Interest Income </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest income for the years ended December&#160;31, 2020 and 2019 was $0 and $0.5&#160;million, respectively. The decrease in interest income was primarily due to lower cash balances during the year ended December&#160;31, 2020. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Income Tax (Benefit) Expense </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Income tax (benefit) expense for the years ended December&#160;31, 2020 and 2019 was $(53.0) thousand and $2.0&#160;thousand, respectively. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_41">Liquidity and Capital Resources </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September&#160;30, 2022, we had cash and cash equivalents of $2.5&#160;million. In connection with the completion of the Business Combination, we received approximately $3.4&#160;million from the balance of the Trust Account. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have funded our operations primarily through the issuance of the Scilex Pharma Notes, related party notes with Sorrento, and the 2020 revolving credit facility. The following table summarizes the aggregate indebtedness of these issuances as of September&#160;30, 2022, December&#160;31, 2021, and December&#160;31, 2020 (in thousands): </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">


<tr>

<td style="width:55%"></td>

<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">September&#160;30,<br />2022</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">December&#160;31,<br />2021</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">December&#160;31,<br />2020</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Scilex Pharma Notes</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">101,172</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">98,672</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Related Party Notes with Sorrento</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">109,825</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">43,111</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">28,411</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2020 Revolving Credit Facility</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8,815</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,471</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred Consideration with Romeg</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,650</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total indebtedness</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">113,475</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">153,098</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">136,554</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">127 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_42">Debt Financings </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Scilex Pharma Notes </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;2, 2022, Sorrento and the Company entered into a Consent Under and Amendment No.&#160;4 with U.S. Bank Trust Company, National Association (as successor in interest to U.S. Bank National Association), as trustee (the &#8220;Trustee&#8221;) and collateral agent (the &#8220;Agent&#8221;), and the beneficial owners of those certain senior secured notes due 2026 issued by Scilex Pharma in September 2018 (the &#8220;Scilex Pharma Notes&#8221;) listed on the signature pages thereto (the &#8220;Holders&#8221;), which amended that certain Indenture, dated September&#160;7, 2018, by and among Scilex Pharma, Sorrento, the Trustee and the Agent, as amended (the &#8220;Indenture&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the amendment to the Indenture (1)&#160;on June&#160;3, 2022, Scilex Pharma repurchased $41.4&#160;million of the aggregate principal amount of the outstanding Scilex Pharma Notes at 100% of the principal amount thereof, (2)&#160;the Holders agreed that Scilex Pharma can repurchase the remaining principal amount of the Scilex Pharma Notes at any time on or before September&#160;30, 2022 for $41.4&#160;million (subject to reduction for any quarterly royalty payments) and upon such repurchase the Holders will forgive and discharge $28.0&#160;million of the aggregate principal amount of the Scilex Pharma Notes, (3)&#160;the minimum cash requirement under the Indenture was reduced to $5.0&#160;million in aggregate unrestricted cash equivalents at the end of each calendar month, and (4)&#160;the maximum aggregate principal amount of that certain intercompany promissory note issued by Scilex Pharma to Sorrento on October&#160;5, 2018 was increased from up to $25.0&#160;million to up to $50.0&#160;million. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2022, the Company made principal payments towards the outstanding Scilex Pharma Notes totaling $1.7&#160;million. On September&#160;28, 2022, Scilex Pharma repurchased all of the outstanding aggregate principal amount of the Scilex Pharma Notes. As of immediately prior to the repurchase, the aggregate principal amount of the Scilex Pharma Notes was approximately $67.7&#160;million, and Scilex Pharma repurchased the Scilex Pharma Notes for an aggregate cash payment of $39.7&#160;million as the holders of the Scilex Pharma Notes forgave and discharged an aggregate of $28.0&#160;million of principal amount of the Scilex Pharma Notes in connection with the repurchase. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Quarterly principal payments, based on a percentage of projected net sales of ZTlido, optional and contingently accelerated repurchases, and the Early Paydown Provision under the Scilex Pharma Notes since January&#160;1, 2021 are as follows (in thousands): </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">


<tr>

<td style="width:83%"></td>

<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap">Three Months Ended,</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center">Prinicipal<br />Payments</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">March&#160;31, 2021*</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">21,267</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">June&#160;30, 2021*</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">21,174</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">September&#160;31, 2021</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,748</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December&#160;31, 2021</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,686</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">March&#160;31, 2022</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">21,585</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">June&#160;30, 2022*</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">42,970</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">September&#160;30, 2022*</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">41,444</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total payments since January&#160;1, 2021</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">151,874</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:2%;vertical-align:top" align="left">*</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Includes repurchase or Early Paydown Provision during the period (see Note 6 titled &#8220;Debt&#8221; to our consolidated financial statements elsewhere in this prospectus). </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">ZTlido Royalties </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the quarterly royalty payment of net sales of ZTlido associated with the Indenture, Scilex Pharma is a party to the Product Development Agreement with the Developers, pursuant to which the Developers will manufacture and supply lidocaine tape products, including the Products, for Scilex Pharma. Pursuant to the Product Development Agreement, Scilex Pharma is required to make aggregate royalty payments between 25% </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">128 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and 35% to the Developers based on net profits. During the nine months ended September&#160;30, 2022, Scilex Pharma made the first royalty payments in the amount of $0.2&#160;million. As of September&#160;30, 2022, Scilex Pharma had ending balances of accrued royalty payables of $2.1&#160;million. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that Scilex Pharma is in a net profit position, as defined in the Product Development Agreement, Scilex Pharma will first attempt to make aggregate royalty payments with cash generated from its operations. If these sources are insufficient, Scilex Pharma may seek to raise additional funds through equity offerings, debt financings, collaborations, government contracts or other strategic transactions. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Contingent Consideration </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have $280.0&#160;million, $13.0&#160;million, and $23.0&#160;million in aggregate contingent consideration obligations in connection with the Merger of Semnur, Romeg license, and <span style="white-space:nowrap">SP-104</span> acquisitions (see Note 3 titled &#8220;Acquisitions&#8221; to our consolidated financial statements included elsewhere in this prospectus for additional information), respectively, that are contingent upon achieving certain specified milestones or the occurrence of certain events. Contingent consideration obligations are comprised of regulatory milestones and additional payments that will be due upon the achievement of certain amounts of net sales (see Note 3 titled &#8220;Acquisitions&#8221; to our consolidated financial statements included elsewhere in this prospectus for additional information). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Deferred Consideration </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have $3.7&#160;million of deferred consideration related to minimum royalty payments that were included in the initial measurement of consideration transferred for the GLOPERBA license (see Note 3 titled &#8220;Acquisitions&#8221; to our consolidated financial statements included elsewhere in this prospectus for additional information). Deferred consideration minimum royalty payments begin the first full quarter following June&#160;14, 2023. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Standby Equity Purchase Agreements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&#160;17, 2022, we entered into the Yorkville Purchase Agreement with YA II, whereby we have the right, but not the obligation, to sell to YA II up to $500.0&#160;million of shares of Common Stock at our request during the 36 months following the date on which the initial registration statement filed with respect to the shares of Common Stock issuable pursuant thereto has been declared effective by the SEC, subject to the terms therein. The registration statement filed with the SEC in connection with the Yorkville Purchase Agreement was declared effective by the SEC on December&#160;9, 2022 and we are now able to offer and sell shares of our Common Stock under that agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January 8, 2023, we entered into the B. Riley Purchase Agreement with the Selling Securityholder, whereby we have the right, but not the obligation, to sell to the Selling Securityholder up to $500.0&#160;million of shares of Common Stock at our request during the 36 months following the date on which the initial registration statement filed with respect to the shares of Common Stock issuable pursuant thereto has been declared effective by the SEC, subject to the terms therein. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Future Liquidity Needs </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As discussed above, we have principally financed our operations through debt financings, and other debt arrangements. We have based our anticipated operating capital requirements on assumptions that may prove to be incorrect and we may use all our available capital resources sooner than we expect. The amount and timing of our future funding requirements will depend on many factors, some of which are outside of our control, including but not limited to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs and expenses associated with our ongoing commercialization efforts for ZTlido and GLOPERBA; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">129 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the degree of success we experience in commercializing ZTlido and GLOPERBA; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the revenue generated by sales of ZTlido, GLOPERBA, and other products that may be approved, if any; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the scope, progress, results and costs of conducting studies and clinical trials for our product candidates, SEMDEXA, <span style="white-space:nowrap">SP-103,</span> and <span style="white-space:nowrap">SP-104;</span> </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the timing of, and the costs involved in, obtaining regulatory approvals for our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs of manufacturing ZTlido, GLOPERBA and our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the timing and amount of any milestone, royalty or other payments we are required to make pursuant to any current or future collaboration or license agreements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to maintain existing, and establish new, strategic collaborations, licensing or other arrangements and the financial terms of any such agreements, including the timing and amount of any future milestone, royalty or other payments due under any such agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the extent to which ZTlido, GLOPERBA, or any of our product candidates, if approved for commercialization, is adopted by the physician community; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our need to expand our research and development activities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs of acquiring, licensing or investing in businesses, product candidates and technologies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the effect of competing products and product candidates and other market developments; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the number and types of future products we develop and commercialize; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any product liability or other lawsuits related to our products; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the expenses needed to attract, hire and retain skilled personnel; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs associated with being a public company; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our need to implement additional internal systems and infrastructure, including financial and reporting systems; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs of preparing, filing and prosecuting patent applications and maintaining, enforcing and defending intellectual property-related claims; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the extent and scope of our general and administrative expenses. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Should our sales of ZTlido, GLOPERBA and other product candidates not materialize at the anticipated rate contemplated in our business plan, we will need to raise additional capital in order to continue to fund our research and development, including our plans for clinical and preclinical trials and new product development, as well as to fund operations generally. We will seek to raise additional funds through various potential sources, such as equity and debt financings and license agreements. As discussed above, following the completion of the Business Combination, we entered into the Yorkville Purchase Agreement and the B. Riley Purchase Agreement. The registration statement filed with the SEC in connection with the Yorkville Purchase Agreement was declared effective by the SEC on December&#160;9, 2022 and we are now able to offer and sell shares of our Common Stock under that agreement, which will provide us with an additional source of liquidity. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the liquidity provided by revenue generating products, Advances under the Yorkville Purchase Agreement and Advances and Additional Advances under the B. Riley Purchase Agreement, we will receive up to an aggregate of approximately $126.5&#160;million from the exercise of the Warrants (at an exercise price of $11.50 per share of Common Stock), assuming the exercise in full of all of the Warrants for cash, but will not receive any proceeds from the sale of the shares of our Common Stock issuable upon such exercise. However, our ability to generate proceeds will depend on the market price of our Common Stock. On January 11, 2023, the closing </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">130 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
price for our Common Stock was $7.47 per share. If the price of our Common Stock remains below $11.50 per share, we believe warrantholders will be unlikely to cash exercise their Warrants, resulting in little or no cash proceeds to us. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The securities held by Sorrento and the Sponsors that were previously registered for resale on a registration statement on Form <span style="white-space:nowrap">S-1</span> (File <span style="white-space:nowrap">No.&#160;333-268603)</span> filed with the SEC on November&#160;30, 2022, which was declared effective by the SEC on December&#160;27, 2022 represent a substantial percentage of our outstanding Common Stock. After the restrictions on resale end, the Sponsors and Sorrento (who holds 140,217,207 shares of our Common Stock representing approximately 95.3% of the shares of our Common Stock outstanding as of January&#160;11, 2023 (assuming the full exercise of all outstanding Warrants held by Sorrento and the Sponsors), will be able to sell all of the shares of our Common Stock and any Warrants registered for resale thereunder for so long as such registration statement is available for use. The sale, or indication of an intention to sell, substantial amounts of our Common Stock or Warrants could result in a significant decline in the public trading price of our securities and impair our ability to raise capital through the sale of additional equity securities. Even if the current trading price of our Common Stock is at or significantly below the price at which the units were issued in Vickers&#8217;s IPO, the Sponsors and Sorrento may have an incentive to sell because they will still profit on sales due to the lower price at which they purchased their shares compared to the public securityholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We can give no assurances that we will be able to secure additional sources of funds to support our operations on acceptable terms, or at all, or, if such funds are available to us, that such additional financing will be sufficient to meet our needs. These conditions, among others, raise substantial doubt about our ability to continue as a going concern. If we raise additional funds by issuing equity or convertible debt securities, including pursuant to the Yorkville Purchase Agreement and the B. Riley Purchase Agreement, it could result in dilution to our existing stockholders or increased fixed payment obligations. In addition, as a condition to providing additional funds to us, future investors may demand, and may be granted, rights superior to those of existing stockholders. If we incur additional indebtedness, we could become subject to covenants that would restrict our operations and potentially impair our competitiveness, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. Additionally, any future collaborations we enter into with third parties may provide capital in the near term but we may have to relinquish valuable rights to ZTlido, GLOPERBA, or our product candidates or grant licenses on terms that are not favorable to us. Any of the foregoing could significantly harm our business, financial condition and results of operations. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may be required to reduce the scope of the commercialization of ZTlido and GLOPERBA or delay, scale back or discontinue the development of one or more of our product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may also need to take certain other actions to allow us to maintain our projected cash and projected financial position including but not limited to, additional reductions in general and administrative costs, sales and marketing costs, suspension or winding down of clinical development programs for <span style="white-space:nowrap">SP-102</span> and <span style="white-space:nowrap">SP-103,</span> and other discretionary costs. Although we believe such plans, if executed and coupled with the above described sources of liquidity, should provide us with financing to meet our needs, successful completion of such plans is dependent on factors outside of our control. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We anticipate that we will continue to incur net losses into the foreseeable future as we support our clinical development to expand approved indications, continue our development of, and seek regulatory approvals for, our product candidates, and expand our corporate infrastructure. As a result, we have concluded that there is substantial doubt about our ability to continue as a going concern within one year after the date that the consolidated financial statements are issued. See Note 2 titled &#8220;Liquidity and Going Concern&#8221; to our consolidated financial statements included elsewhere in this prospectus for additional information. Proceeds from the Business Combination are dependent on the amount of redemptions by Vickers&#8217;s public shareholders. Net proceeds from the Trust Account in connection with the Business Combination, together with our existing cash and cash equivalents and proceeds from any Yorkville Advances made under the Yorkville Purchase Agreement </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">131 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or any Advances or Additional Advances made under the B. Riley Purchase Agreement, may be insufficient to enable us to fund our operating expenses and capital expenditure requirements for at least the next 12 months. If these sources are insufficient to satisfy our liquidity requirements, we may seek to raise additional funds through equity offerings, debt financings, collaborations, government contracts or other strategic transactions. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Cash Flows </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our cash flows for each of the periods presented: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:55%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Year Ended December&#160;31,</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Nine Months Ended<br />September&#160;30,</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2021</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2020</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2019</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2022</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">2021</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash Flow Data:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used for operating activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(28,664</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(31,461</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(60,421</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(20,533</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(22,707</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used for investing activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(25</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(17,624</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(2,067</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by (used for) financing activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">28,163</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(19,170</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">15,776</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20,745</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">22,073</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net change in cash and cash equivalents</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(501</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(50,656</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(62,269</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(1,855</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(634</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Cash Flows from Operating Activities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&#160;31, 2021, net cash used for operating activities was approximately $28.7&#160;million, primarily from our net loss of $88.4&#160;million offset by other <span style="white-space:nowrap">non-cash</span> reconciling items of $46.1&#160;million related to depreciation and amortization, principal increase to the Scilex Pharma Notes, stock-based compensation, <span style="white-space:nowrap">non-cash</span> operating lease cost, <span style="white-space:nowrap">non-cash</span> interest for debt issuance costs and debt discount, interest payments related to the debt discount on the Scilex Pharma Notes, net loss on debt extinguishment, and a loss on derivative liabilities, and by changes in operating assets and liabilities that provided $13.6&#160;million of cash. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&#160;31, 2020, net cash used for operating activities was approximately $31.5&#160;million, primarily from our net loss of $47.5&#160;million, offset by other <span style="white-space:nowrap">non-cash</span> reconciling items of $9.0&#160;million related to depreciation and amortization, stock based compensation, <span style="white-space:nowrap">non-cash</span> operating lease cost, amortization of debt issuance costs and debt discount, interest on the Scilex Pharma Notes, and a gain on derivative liabilities, and changes in operating assets and liabilities of $7.0&#160;million of cash. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&#160;31, 2019, net cash used for operating activities was approximately $60.4&#160;million, primarily from our net loss of $178.6&#160;million, which was offset by charges related to acquired IPR&amp;D of $75.3&#160;million, a loss on derivative liability of $23.3&#160;million, other <span style="white-space:nowrap">non-cash</span> reconciling items of $23.6&#160;million related to depreciation and amortization, stock based compensation, <span style="white-space:nowrap">non-cash</span> operating lease cost and amortization of debt issuance costs and debt discount, and changes in operating assets and liabilities that used $4.0&#160;million of cash. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the nine months ended September&#160;30, 2022, net cash used for operating activities was approximately $20.5&#160;million, primarily from our net loss of $5.5&#160;million, other <span style="white-space:nowrap">non-cash</span> reconciling items of $44.7&#160;million related to depreciation and amortization, stock-based compensation, <span style="white-space:nowrap">non-cash</span> operating lease cost, <span style="white-space:nowrap">non-cash</span> interest for debt issuance costs and debt discount, interest payments related to the debt discount on the Scilex Pharma Notes, net gain on debt extinguishment, and a gain on derivative liabilities and offset by changes in operating assets and liabilities that provided $29.7&#160;million of cash. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the nine months ended September&#160;30, 2021, net cash used for operating activities was approximately $22.7&#160;million, primarily from our net loss of $46.5&#160;million, offset by other <span style="white-space:nowrap">non-cash</span> reconciling items of $14.0&#160;million related to depreciation and amortization, stock based compensation, <span style="white-space:nowrap">non-cash</span> operating lease cost, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">132 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
amortization of debt issuance costs and debt discount, interest on the Scilex Pharma Notes, net loss on debt extinguishment, and a net loss on derivative liabilities, and changes in operating assets and liabilities of $9.8&#160;million. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Cash Flows from Investing Activities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&#160;31, 2021, no cash was used for investing activities. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&#160;31, 2020, net cash used for investing activities was approximately $25.0&#160;thousand, attributed to property and equipment purchases. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&#160;31, 2019, net cash used for investing activities was approximately $17.6&#160;million, primarily attributed to approximately $17.0&#160;million of cash paid for the acquisition of Semnur-related IPR&amp;D expenses and $0.6&#160;million of property and equipment purchases. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the nine months ended September&#160;30, 2022, net cash used for investing activities was approximately $2.1&#160;million attributed to cash paid for the acquisition of GLOPERBA licenses from Romeg and $7.0&#160;thousand attributed to cash paid for property, plant, and equipment. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the nine months ended September&#160;30, 2021, no cash was used for investing activities. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Cash Flows from Financing Activities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&#160;31, 2021, net cash provided by financing activities was approximately $28.2&#160;million and was primarily related to $47.9&#160;million in proceeds from related party payables, $47.8&#160;million in proceeds from the CNH Revolving Loan, $14.7&#160;million in proceeds from related party note payable with Sorrento, and offset by $48.8&#160;million repayment of the CNH Revolving Loan and $33.4&#160;million repayment of the Scilex Pharma Notes. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&#160;31, 2020, net cash used by financing activities was approximately $19.2&#160;million and is primarily related to $58.9&#160;million repayment of the Scilex Pharma Notes, offset by $18.4&#160;million in proceeds from related party payables, $11.0&#160;million in proceeds from other loans, and $10.3&#160;million in proceeds from related party notes. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&#160;31, 2019, net cash provided by financing activities was approximately $15.8&#160;million and is primarily related to $16.6&#160;million of related party note proceeds, which were utilized to finance the acquisition of Semnur, plus $5.0&#160;million of promissory note proceeds offset by repayment of the related party note payable of $3.5&#160;million and $2.3&#160;million repayment of the Scilex Pharma Notes. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the nine months ended September&#160;30, 2022, net cash provided by financing activities was approximately $20.7&#160;million and is primarily related to $51.9&#160;million in proceeds from related party payables, $62.5&#160;million in proceeds from related party note payables, $9.9&#160;million in proceeds from the CNH Revolving loan, $96.0&#160;thousand in proceeds from the exercise of stock options, offset by $18.8&#160;million repayment on CNH Revolving Loan and $84.8&#160;million repayment of the Scilex Pharma Notes. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the nine months ended September&#160;30, 2021, net cash provided by financing activities was approximately $22.1&#160;million and is primarily related to $45.1&#160;million in proceeds from related party payables, $34.8&#160;million in proceeds from the CNH Revolving Loan, and $11.5&#160;million in proceeds from related party notes, offset by a $32.4&#160;million repayment of the Scilex Pharma Notes and a $36.9&#160;million repayment on CNH Revolving Loan. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_43">Critical Accounting Policies and Estimates </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This management&#8217;s discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements which are prepared in accordance with GAAP. The preparation of </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">133 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
these financial statements requires us to make estimates and judgments that affect the reported amounts of assets and liabilities and the reported amounts of revenue and expenses during the reporting period. We continually evaluate our estimates and judgments, the most critical of which are those related to derivative liabilities, income taxes and stock-based compensation and others listed below. We base our estimates and judgments on historical experience and other factors that we believe to be reasonable under the circumstances. Materially different results can occur as circumstances change and additional information becomes known. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While our significant accounting policies are described in greater detail in the audited financial statements for the years ended December&#160;31, 2021 and 2020 included elsewhere in this prospectus, we believe the following accounting policies and estimates are most critical to aid in understanding and evaluating our reported financial results. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Revenue Recognition </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our revenue to date has been generated from product sales of ZTlido. We do not have significant costs associated with obtaining contracts with our customers. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recognize revenue when control of the products is transferred to the customers in an amount that reflects the consideration we expect to receive from the customers in exchange for those products. This process involves identifying the contract with a customer, determining the performance obligations in the contract and the contract price, allocating the contract price to the distinct performance obligations in the contract and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. We consider a performance obligation satisfied once we have transferred control of a good or service to the customer, meaning the customer has the ability to use and obtain the benefit of the good or service. We recognize revenue for satisfied performance obligations only when we determine there are no uncertainties regarding payment terms or transfer of control. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenue from product sales relates solely to sales of ZTlido. Our performance obligations with respect to sales of ZTlido are satisfied at a certain point in time, and we consider control to have transferred upon delivery to the customer. We consider control to have transferred upon delivery to the customer because, upon delivery, the customer has legal title to the asset, physical possession of the asset has been transferred to the customer, the customer has significant risks and rewards in connection with ownership of the asset, and we have a present right to payment from the customer at that time. Invoicing typically occurs upon shipment and the length of time between invoicing and the date on which payment is due is not significant. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For product sales, we record <span style="white-space:nowrap"><span style="white-space:nowrap">gross-to-net</span></span> sales adjustments for commercial and government rebates, fees, and chargebacks, wholesaler and distributor fees, sales returns and prompt payment discounts. Such variable consideration is estimated in the period of the sale and is estimated using a most likely amount approach based primarily upon provisions included in our customer contracts, customary industry practices and current government regulations. <span style="white-space:nowrap"><span style="white-space:nowrap">Gross-to-net</span></span> adjustments are generally recorded as contract liabilities under accrued expenses within our consolidated balance sheet. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Rebates </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Rebates are discounts that we pay under either government or private health care programs. Government rebate programs include state Medicaid drug rebate programs, the Medicare coverage gap discount programs and the Tricare programs. Commercial rebate and fee programs relate to contractual agreements with commercial healthcare providers, under which we pay rebates and fees for access to and position on that provider&#8217;s patient drug formulary. Rebates and chargebacks paid under government programs are generally mandated under law, whereas private rebates and fees are generally contractually negotiated with commercial healthcare providers. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">134 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Both types of rebates vary over time. We record a reduction to gross product sales at the time the customer takes title to the product based on estimates of expected rebate claims. We monitor the sales trends and adjust for these rebates on a regular basis to reflect the most recent rebate experience and contractual obligations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Service Fees </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We compensate our customers and others in the distribution chain for wholesaler and distribution services. We have determined such services received to date are not distinct from our sale of products to the customers, and therefore, these payments have been recorded as a reduction of revenue. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Product Returns </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are obligated to accept the return of products sold that are damaged or do not meet certain specifications. We may authorize the return of products sold in accordance with the term of its sales contracts, and estimate allowances for such amounts at the time of sale. We estimate the amount of our product sales that may be returned by our customer and record this estimate as a reduction of revenue in the period the related product revenue is recognized. We currently estimate our product returns using historical trends and product return rates typically experienced in the industry. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><span style="white-space:nowrap">Co-payment</span> Assistance </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patients who have commercial insurance or pay cash and meet certain eligibility requirements may receive <span style="white-space:nowrap">co-</span> payment assistance. We accrue for <span style="white-space:nowrap">co-payment</span> assistance based on actual program participation and estimates of program redemption using data provided by third-party administrators. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Derivative Liability </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Derivative liabilities are recorded on our consolidated balance sheets at their fair value on the date of issuance and are revalued on each balance sheet date until such instruments are exercised or expire, with changes in the fair value between reporting periods recorded as other income or expense. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Derivative liabilities result from the Scilex Pharma Notes. For the Scilex Pharma Notes, interest payments and repayments of the principal are based on a percentage of net sales of ZTlido and could be accelerated if certain net sales targets are not met or if marketing approval of <span style="white-space:nowrap">SP-103,</span> or a similar product with a lidocaine concentration of not less than 5%, is delayed or in the event of a qualified initial public offering. In estimating the fair value of such financial instruments, we may apply significant assumptions and estimates, including estimates involving future net product sales and timing and probability of marketing approvals and the probability of a qualified initial public offering event, which could be impacted in the future based on market conditions. As of December&#160;31, 2021, the fair value of the derivative liabilities associated with the Scilex Pharma Notes was estimated using the discounted cash flow method combined with a Monte Carlo simulation model including consideration of the terms of Amendment No.&#160;4 (see Debt note). Significant Level&#160;3 assumptions used in the measurement included a 6.2% risk adjusted net sales forecast and an effective debt yield of 15.0% on December&#160;31, 2021. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We perform a Level&#160;3 based assessment to identify the embedded derivatives that require bifurcation from the Scilex Pharma Notes and separate accounting as a single compound derivative. Certain of these embedded features include default interest provisions, contingent rate increases, contingent put options, optional and automatic acceleration provisions and indemnified taxes. The Scilex Pharma Notes were fully extinguished in September 2022 and, as such, there were no remaining derivative liabilities as of September&#160;30, 2022. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Stock-Based Compensation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We account for stock-based compensation in accordance with FASB ASC Topic 718 &#8220;Compensation &#8211; Stock Compensation&#8221;, which establishes accounting for equity instruments exchanged for employee and </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">135 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
consulting services. Under such provisions, stock-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense, under the straight-line-method, over the employee&#8217;s requisite service period (generally the vesting period of the equity grant) or <span style="white-space:nowrap">non-employee&#8217;s</span> vesting period. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of determining the inputs used in the calculation of stock-based compensation, we use historical data in estimating the expected terms of options and determine an estimate of option volatility based on an assessment of historical volatilities of comparable companies whose share prices are publicly available. We use these estimates as variables in the Black-Scholes option pricing model. Depending upon the number of stock options granted, any fluctuations in these calculations could have a material effect on the results presented in our consolidated statement of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Legacy Scilex Common Stock Valuation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As there has been no public market for the Legacy Scilex Common Stock to date, the estimated fair value of the Legacy Scilex Common Stock was determined by the Legacy Scilex Board, considering our most recently available third-party valuations of the Legacy Scilex Common Stock and the Legacy Scilex Board&#8217;s assessment of additional objective and subjective factors that it believed were relevant, and factors that may have changed from the date of the most recent valuation through the date of the stock option grant. Prior to the Business Combination, given the absence of a public trading market for the Legacy Scilex Common Stock, the valuations of the Legacy Scilex Common Stock were determined in accordance with the &#8220;American Institute of Certified Public Accountants Accounting and Valuation Guide, Valuation of Privately-Held Company Equity Securities Issued as Compensation.&#8221; The Legacy Scilex Board exercised its reasonable judgment and considered numerous objective and subjective factors to determine the best estimate of fair value of the Legacy Scilex Common Stock, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Independent valuations of the Legacy Scilex Common Stock performed at periodic intervals by an independent third-party valuation firm; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The likelihood of achieving a liquidity event, such as an initial public offering or sale of the company and the potential value of a strategic merger or sale at different time points, given prevailing market conditions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our historical operating and financial performance as well as our estimates of future financial performance, including the regulatory status of ZTlido and GLOPERBA and the timing and probability of continuing growth since commercialization of ZTlido and GLOPERBA under different operational scenarios; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The status of research and development efforts; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our stage of development and commercialization and our business strategy; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Industry information such as market trends and macro-economic events; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Valuations of comparable companies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Adjustments to recognize a relative lack of marketability of the Legacy Scilex Common Stock; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Additional objective and subjective factors relating to our business. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The dates of our valuations have not always coincided with the dates of our stock option grants. In determining the exercise prices of the stock options at each grant date, the Legacy Scilex Board considered, among other things, the most recent valuations of the Legacy Scilex Common Stock and the Legacy Scilex Board&#8217;s assessment of additional objective and subjective factors we believed were relevant as of the grant date. The additional factors considered when determining any changes in fair value between the most recent valuation and the grant dates included our operating and financial performance and current business conditions. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">136 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The assumptions underlying the valuations represented management&#8217;s best estimate, which involved inherent uncertainties and the application of management&#8217;s judgment. As a result, if we had used significantly different assumptions or estimates, the fair value of the Legacy Scilex Common Stock and Legacy Scilex&#8217;s stock-based compensation expense could have been materially different. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">March&#160;17 and March&#160;31, 2019 Valuations </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the valuation performed on March&#160;17, 2019 and March&#160;31, 2019, the fair value of the Legacy Scilex Common Stock was estimated using the market and income approaches. Legacy Scilex weighted a guideline public company method, a market approach that uses comparable company data and applies to the subject company, equally with a discounted cash flow method, an income approach that derives value by estimating reasonable future cash flows to the equityholders and discounting them to present value using a risk-adjusted discount rate. Legacy Scilex then used the Option Pricing Method (&#8220;OPM&#8221;) to allocate the concluded equity value amongst the different equity classes and determine the value of Legacy Scilex Common Stock. These valuations resulted in a valuation of Legacy Scilex Common Stock of $1.16 per share as of March&#160;17, 2019 and March&#160;31, 2019. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">May&#160;31, 2019 Valuation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the valuation performed on May&#160;31, 2019, the fair value of the Legacy Scilex Common Stock was estimated using a hybrid Probability Weighted Expected Return Method (&#8220;PWERM&#8221;), which estimates the value by probability-weighting different scenarios. Legacy Scilex used three going public scenarios and one stay-private scenario. For the three public scenarios, Legacy Scilex utilized recent comparable initial public offerings to estimate value, which was allocated on a fully diluted basis to derive a common stock value for each scenario. For the stay-private scenario, Legacy Scilex utilized the income and market approaches in line with the March&#160;31, 2019 valuation and allocated the concluded equity value using an OPM to derive a common stock value for the stay-private scenario. Legacy Scilex then probability weighted (based on Legacy Scilex&#8217;s best estimates at the time) each scenario&#8217;s common stock value to arrive at the concluded value of the Legacy Scilex Common Stock. This valuation resulted in a valuation of Legacy Scilex Common Stock of $1.16 per share as of May&#160;31, 2019. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">December&#160;31, 2019 Valuation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the valuation performed on December&#160;31, 2019, the fair value of the Legacy Scilex Common Stock was estimated using PWERM, which estimates the value by probability-weighting different scenarios. Legacy Scilex used three going public scenarios and one stay-private scenario. For the three public scenarios, Legacy Scilex utilized recent comparable initial public offerings to estimate value, which was allocated on a fully diluted basis to derive a common stock value for each scenario. For the stay-private scenario, Legacy Scilex utilized the income approach in line with the March&#160;31, 2019 valuation and allocated the concluded equity value using an OPM to derive a common stock value for the stay-private scenario. Legacy Scilex then probability weighted (based on Legacy Scilex&#8217;s best estimates at the time) each scenario&#8217;s common stock value to arrive at the concluded value of the Legacy Scilex Common Stock. This valuation resulted in a valuation of the Legacy Scilex Common Stock of $1.16 per share as of December&#160;31, 2019. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">July&#160;31, 2020 Valuation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the valuation performed on July&#160;31, 2020, the fair value of the Legacy Scilex Common Stock was estimated using PWERM, which estimates the value by probability-weighting different scenarios. Legacy Scilex used three going public scenarios and one stay-private scenario. For the three public scenarios, Legacy Scilex utilized recent comparable initial public offerings to estimate value, which was allocated on a fully diluted basis to derive a common stock value for each scenario. For the stay-private scenario, Legacy Scilex utilized the income approach in line with the March&#160;31, 2019, May&#160;31, 2019 and December&#160;31, 2019 valuations and </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">137 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
allocated the concluded equity value using an OPM to derive a common stock value for the stay-private scenario. Legacy Scilex then probability weighted (based on Legacy Scilex&#8217;s best estimates at the time) each scenario&#8217;s common stock value to arrive at the concluded value of the Legacy Scilex Common Stock. This valuation resulted in a valuation of the Legacy Scilex Common Stock of $1.16 per share as of July&#160;31, 2020. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since a public trading market for our Common Stock has been established in connection with the Closing of the Business Combination, it is no longer be necessary for our Board to estimate the fair value of our Common Stock in connection with our accounting for granted stock options and other such awards we may grant, as the fair value of our Common Stock will be determined based on the quoted market price of our Common Stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Debt </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We account for debt as liabilities measured at amortized cost and amortize the resulting debt discount from the allocation of proceeds to interest expense using the effective interest method over the expected term of the debt instrument. We consider whether there are any embedded features in the debt instruments that require bifurcation and separate accounting as derivative financial instruments pursuant to FASB, ASC, Topic 815, &#8220;Derivatives and Hedging.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may enter financing arrangements, the terms of which involve significant assumptions and estimates, including future net product sales, in determining interest expense, as well as the classification between current and long-term portions. In estimating future net product sales, we assessed prevailing market conditions using various external market data against our anticipated sales and planned commercial activities as well as actual ZTlido sales as of the Scilex Pharma Note extinguishment. See Note 6 titled &#8220;Debt&#8221; to our consolidated financial statements appearing elsewhere in this prospectus and the section titled &#8220;Certain Relationships and Related Party Transactions &#8212; Certain Relationships of Legacy Scilex &#8212; Indenture and Letter of Credit&#8221; for a description of the Scilex Pharma Notes, which provide for repayments based on a percentage of net sales of ZTlido. Consequently, we imputed interest on the carrying value of the debt and recorded interest expense using an imputed effective interest rate. We reassessed the expected payments each reporting period and accounted for any changes through an adjustment to the effective interest rate on a prospective basis, with a corresponding impact to the classification of our current and long-term portions. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Leases </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beginning January&#160;1, 2019, at the inception of a contractual agreement and at transition to the new lease standard, we determine whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If both criteria are met, we calculate the associated lease liability and corresponding <span style="white-space:nowrap"><span style="white-space:nowrap">right-of-use</span></span> asset upon lease commencement using a discount rate based on a credit-adjusted secured borrowing rate commensurate with the term of the lease. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Income Taxes </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The provisions of ASC Topic <span style="white-space:nowrap">740-10,</span> Income Taxes &#8212; Overall, address the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC Topic <span style="white-space:nowrap">740-10,</span> we may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based on the technical merits of the position. We have determined that we have immaterial uncertain tax positions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We account for income taxes using the asset and liability method to compute the differences between the tax basis of assets and liabilities and the related financial amounts, using currently enacted tax rates. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">138 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have deferred tax assets, which are subject to periodic recoverability assessments. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount that more likely will not be realized. As of September&#160;30, 2022 and December&#160;31, 2021, we maintained a full valuation allowance against our deferred tax assets, with the exception of an amount equal to our deferred tax liabilities that are scheduled to reverse against Legacy Scilex&#8217;s deferred tax assets. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Intangible Assets </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Intangible assets are carried at their initial valuation or acquisition price and amortized on a straight-line basis over the estimated useful lives of the assets. If the useful life is indefinite, we will <span style="white-space:nowrap">re-evaluate</span> the asset annually for impairment and make adjustments as necessary. Our patents were initially valued using the multi- period excess earnings method and the useful life of 15 years was determined by management based on the patent expiration date. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our developed technology was valued based on a <span style="white-space:nowrap">15-year</span> projection using the excess earnings approach. We commenced amortization of IPR&amp;D upon commercialization of ZTlido in October 2018. We review our long-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the assets&#8217; book value to future net undiscounted cash flows that the assets are expected to generate to determine if a write-down to the recoverable amount is appropriate. If such assets are written down, an impairment will be recognized as the amount by which the book value of the asset group exceeds the recoverable amount. There have not been any impairment losses of long-lived assets through September&#160;30, 2022. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Goodwill </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of net assets acquired. Goodwill is reviewed for impairment at least annually during the fourth quarter, or more frequently if events occur indicating the potential for impairment. We have determined that only one reporting unit exists for examination under impairment review. During our goodwill impairment review, we may assess qualitative factors to determine whether it is more likely than not that the fair value of our reporting units are less than their carrying amounts, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of our company. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair value of our reporting units are less than their carrying amounts, then no additional assessment is deemed necessary. Otherwise, we perform a quantitative goodwill impairment test. We may also elect to bypass the qualitative assessment in a period and elect to proceed to perform the quantitative goodwill impairment test. We performed our annual assessment for goodwill impairment in the fourth quarters of 2021, 2020, and 2019 and determined there was no impairment as of December&#160;31, 2021, 2020 and 2019, respectively. No interim impairment test was considered necessary during the nine months ended September&#160;30, 2022 as we believe that it is more likely than not that the fair value of our goodwill was in excess of the carrying value </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Acquired <span style="white-space:nowrap">In-Process</span> Research and Development Expense </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have acquired and may continue to acquire the rights to develop and commercialize new product candidates. The <span style="white-space:nowrap">up-front</span> payments to acquire a new drug compound or drug delivery device, as well as future milestone payments associated with asset acquisitions that do not meet the definition of derivative and are deemed probable to achieve the milestones, are immediately expensed as acquired IPR&amp;D provided that the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, have no alternative future use. The acquired IPR&amp;D related to the asset acquisition of IPR&amp;D from Semnur in March 2019. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">139 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Material Cash Commitments </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September&#160;30, 2022, our contractual obligations are as follows (in thousands): </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:61%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td rowspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="18" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Payments Due by Period</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Total</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Less than<br />1 year</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="white-space:nowrap">1-3</span> years</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="white-space:nowrap">3-5&#160;years</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">More&#160;than<br />5 years</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease obligations<sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,790</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">215</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,575</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Related Party Notes Payable<sup style="font-size:75%; vertical-align:top">(2)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">109,825</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">47,108</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">62,717</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest on Related Party Notes Payable<sup style="font-size:75%; vertical-align:top">(2)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11,760</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11,760</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred Consideration with Romeg<sup style="font-size:75%; vertical-align:top">(3)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,125</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,575</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,050</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total financial obligations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">130,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">59,083</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">65,792</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,575</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,050</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">See Note 8 titled &#8220;Commitments and Contingencies&#8221; of the notes to our unaudited consolidated financial statements included elsewhere in this prospectus. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The related party notes payable and interest on related party notes payable were eliminated at the close of the Business Combination under the terms of the Debt Exchange Agreement. See Note 10 titled &#8220;Related Party Transactions&#8221; of the notes to our unaudited consolidated financial statements included elsewhere in this prospectus. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">See Note 3 titled &#8220;Acquisitions&#8221; of the notes to our unaudited consolidated financial statements included elsewhere in this prospectus. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_44">Recent Accounting Pronouncements </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2021, the FASB issued ASU <span style="white-space:nowrap">2021-08,</span> Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers, which requires an acquirer in a business combination to recognize and measure contract assets and contract liabilities in accordance with ASC Topic 606. ASU <span style="white-space:nowrap">2021-08</span> is effective for fiscal years beginning after December&#160;15, 2022 and early adoption is permitted. The Company is evaluating the impact the standard will have on its consolidated financial statements. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2019, the FASB issued ASU <span style="white-space:nowrap">No.&#160;2019-12,</span> Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The amendments in this update simplify the accounting for income taxes by removing certain exceptions to the general principles in ASC Topic 740. The amendments also improve consistent application of and simplify U.S. GAAP for other areas of ASC Topic 740 by clarifying and amending existing guidance. The amendments in this update were effective for interim and annual periods for the Company beginning after December&#160;15, 2020. The Company adopted the standard on January&#160;1, 2021. The adoption of the standard had no impact on its consolidated financial statements. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_45">Quantitative and Qualitative Disclosures About Market Risk </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Interest Rate Risk </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our exposure to market risk is confined to our cash and cash equivalents and debt securities. We have cash and cash equivalents and invest primarily in high-quality money market funds, which we believe are subject to limited credit risk. Due to the low risk profile of our investments, an immediate 10% change in interest rates would not have a material effect on the fair market value of our portfolio. Additionally, all interest rates associated with our related party notes outstanding as of September&#160;30, 2022 are capped, therefore we are not subject to interest rate risk. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Concentration Risk </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to April&#160;2, 2022, sales to our sole customer and third-party logistics distribution provider, Cardinal Health, represented 100% of our net revenue. On April&#160;2, 2022, we announced the expansion of our direct </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">140 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
distribution network to national and regional wholesalers and pharmacies. Cardinal Health will continue to provide traditional third-party logistics functions for us. Additionally, during the nine months ended September&#160;30, 2022 and 2021, we purchased inventory from our sole supplier, Itochu. This exposes us to concentration of customer and supplier risk. We monitor the financial condition of our customers, limit our credit exposure by setting credit limits, and have not experienced any credit losses for the nine months ended September&#160;30, 2022 and 2021. As we continue to expand the commercialization of our product, we are not limited to the current customer and have elected to expand our distribution network. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beginning on April&#160;1, 2022, we began selling ZTlido directly to three large distributors, McKesson Corporation, Cardinal Health, and AmerisourceBergen Corporation, as well as to numerous pharmacies. If we are unable to maintain a favorable relationship with Cardinal Health (or with any of our other two distributors), we expect that our revenue would decline and our business would be harmed as a result. We may be unable to control the timing of the delivery of ZTlido to distributors, and any financial uncertainty or loss of key logistic employees of Cardinal Health, as our only third- party logistics provider, may negatively impact our sales. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">Off-Balance</span> Sheet Arrangements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We did not have, during the periods presented, and we do not currently have, any <span style="white-space:nowrap">off-balance</span> sheet arrangements, as defined under applicable SEC rules. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Related Party Transactions </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For a description of our related party transactions, see the section of this prospectus titled &#8220;Certain Relationships and Related Party Transactions&#8221;. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_46">Emerging Growth Company </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A &#8220;emerging growth company&#8221; as defined in the JOBS Act is eligible to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies. Section&#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to <span style="white-space:nowrap">non-emerging</span> growth companies but any such election to opt out is irrevocable. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. As a result, changes in rules of U.S. generally accepted accounting principles or their interpretation, the adoption of new guidance or the application of existing guidance to changes in our business could significantly affect our business, financial condition and results of operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we are in the process of evaluating the benefits of relying on the other exemptions and reduced reporting requirements provided by the JOBS Act. Subject to certain conditions set forth in the JOBS Act, as an emerging growth company we may take advantage of certain exemptions from various reporting requirements and other burdens that are otherwise applicable generally to public companies. These provisions include, but are not limited to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an exemption from compliance with the requirement to obtain an attestation and report from our auditors on the assessment of our internal control over financial reporting pursuant to the Sarbanes-Oxley Act; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an exemption from compliance with any new requirements adopted by the Public Company Accounting Oversight Board requiring mandatory audit firm rotation; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">141 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reduced disclosure about our executive compensation arrangements in our periodic reports, proxy statements and registration statements; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">exemptions from the requirements of holding <span style="white-space:nowrap">non-binding</span> advisory votes on executive compensation or golden parachute arrangements. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will qualify and will remain as an emerging growth company until the earlier of (i)&#160;the last day of the fiscal year (a)&#160;following the fifth anniversary of the closing of the IPO, (b)&#160;in which we have total annual gross revenue of at least $1.235&#160;billion, or (c)&#160;in which we are deemed to be a large accelerated filer, which means the market value of our common equity of that is held by <span style="white-space:nowrap">non-affiliates</span> equals or exceeds $700&#160;million as of the last business day of our most recently completed second fiscal quarter; and (ii)&#160;the date on which we have issued more than $1.00&#160;billion in <span style="white-space:nowrap">non-convertible</span> debt securities during the prior three-year period. References herein to &#8220;emerging growth company&#8221; have the meaning associated with it in the JOBS Act. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_47">Smaller Reporting Company </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Smaller reporting companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements. We expect that we will not be a smaller reporting company to the extent we remain a majority-owned subsidiary of Sorrento. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">142 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom428534_48">BUSINESS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_49">The Company </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an innovative revenue-generating company focused on acquiring, developing and commercializing <span style="white-space:nowrap">non-opioid</span> pain management products for the treatment of acute and chronic pain. We target indications with high unmet needs and large market opportunities with <span style="white-space:nowrap">non-opioid</span> therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. We launched our first commercial product in October 2018 and are developing our late-stage pipeline, which includes a pivotal Phase 3 candidate, a Phase 2 candidate, and a Phase 1 candidate that is expected to enter Phase 2 studies in the first half of 2023. Our commercial product, ZTlido (lidocaine topical system) 1.8% is a prescription lidocaine topical product approved by the FDA for the relief of neuropathic pain associated with postherpetic neuralgia (&#8220;PHN&#8221;), which is a form of post-shingles nerve pain. ZTlido possesses novel delivery and adhesion technology designed to address many of the limitations of current prescription lidocaine patches by providing significantly improved adhesion and continuous pain relief throughout the <span style="white-space:nowrap">12-hour</span> administration period. Scilex licenses the rights to ZTlido from and relies exclusively on Oishi Koseido Co., Ltd. (&#8220;Oishi&#8221;) and Itochu Chemical Frontier Corporation (&#8220;Itochu,&#8221; and together with Oishi, the &#8220;Developers&#8221;) pursuant to the Product Development Agreement and Commercial Supply Agreement. The Developers have the right to terminate the Product Development Agreement and the Commercial Supply Agreement under certain circumstances as more fully described in the sections titled &#8220;<span style="font-style:italic">Business &#8212; Material Agreements &#8212; Itochu and Oishi Product Development Agreement</span>&#8221; and &#8220;<span style="font-style:italic">Business &#8212; Material Agreements &#8212; Itochu and Oishi Commercial Supply Agreement,</span>&#8221; including, among other things, if Scilex&#8217;s total net profits for ZTlido and <span style="white-space:nowrap">SP-103</span> are equal to or less than five percent of our net sales of ZTlido and <span style="white-space:nowrap">SP-103</span> for a period of four or more consecutive quarters. As of the date of this prospectus, Scilex&#8217;s net profits for ZTlido and <span style="white-space:nowrap">SP-103</span> have not exceeded five percent of net sales. Accordingly, Oishi and Itochu have the right to terminate the Product Development Agreement and Commercial Supply Agreement. As of the date of this prospectus, neither Oishi nor Itochu has exercised its right of termination. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our three product candidates are <span style="white-space:nowrap">(i)&#160;SP-102</span> (10 mg, dexamethasone sodium phosphate viscous gel) (&#8220;SEMDEXA&#8221;), a Phase 3, novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica; <span style="white-space:nowrap">(ii)&#160;SP-103</span> (lidocaine topical system) 5.4%, <span style="white-space:nowrap">(&#8220;SP-103&#8221;),</span> a Phase&#160;2, next-generation, triple-strength formulation of ZTlido, for the treatment of LBP; and <span style="white-space:nowrap">(iii)&#160;SP-104</span> (4.5 mg, <span style="white-space:nowrap">low-dose</span> naltrexone hydrochloride delayed-release capsules) <span style="white-space:nowrap">(&#8220;SP-104&#8221;),</span> a novel <span style="white-space:nowrap">low-dose</span> delayed-release naltrexone hydrochloride being developed for the treatment of fibromyalgia, for which Phase 1 trials were completed in the second quarter of 2022 and a Phase 2 clinical trial is expected to commence in the first half of 2023. If these product candidates are approved by the FDA, we believe each of them could become the treatment option for their respective indications in the United States. Most recently, on June&#160;14, 2022, Scilex entered into a License and Commercialization Agreement (the &#8220;Romeg Agreement&#8221;) with RxOmeg Therapeutics, LLC (a/k/a Romeg Therapeutics, Inc.). Pursuant to the Romeg Agreement, among other things, Romeg granted Scilex (1)&#160;the right to manufacture, promote, market, distribute and sell pharmaceutical products comprising liquid formulations of colchicine for the prophylactic treatment of gout in adult humans in the United States and (2)&#160;an exclusive, transferable license to use the trademark &#8220;GLOPERBA&#8221;. GLOPERBA is an <span style="white-space:nowrap">FDA-approved,</span> oral medication for the treatment of gout in adults. Gout is a painful arthritic disorder affecting an estimated 8.7&#160;million people in the United States. Gout pain can be excruciating and is a form of inflammatory arthritis that develops in some people who have high levels of uric acid in their blood. It can cause sudden severe episodes of pain and can be disabling with tenderness, warmth and swelling. <span style="white-space:nowrap">Non-steroidal</span> anti-inflammatory drugs, colchicine and corticosteroids are used a majority of time as the first line to treat acute gout. The U.S. is observed to have a high prevalence of gout, owing to lifestyle issues such as high alcohol intake, obesity, and smoking. Scilex is planning to commercialize GLOPERBA in 2023 and believes it is well-positioned to market and distribute the product. Scilex has a direct distribution network to national and regional wholesalers and pharmacies throughout all U.S. states. For more information on Scilex, please see the sections titled &#8220;<span style="font-style:italic">Business &#8212; Material Agreements &#8212; Romeg License and Commercialization Agreement</span>.&#8221; </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">143 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are focused on identifying treatment options for pain management with established mechanisms that have deficiencies in safety, efficacy or patient experience. We believe this approach allows us to potentially leverage the regulatory approval pathway available under Section&#160;505(b)(2) of the Federal Food, Drug, and Cosmetic Act for each of these pipeline product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe our marketed product, ZTlido, has multiple advantages over currently available prescription and OTC lidocaine patches, of which over 147&#160;million and 136&#160;million of such patches were sold in the United States in 2021 and 2020, respectively, according to Symphony Healthcare. We have sold 6,336,032 and 7,011,112 ZTlido patches in the United States in 2020 and 2021, respectively. We acquired <span style="white-space:nowrap">SP-102</span> from Semnur in March 2019 and are developing it to be an injectable viscous gel formulation of a widely used corticosteroid designed to address the serious risks posed by <span style="white-space:nowrap">off-label</span> epidural steroid injections (&#8220;ESI&#8221;), which are administered over 12&#160;million times annually in the United States. See the section titled &#8220;<span style="font-style:italic">Business &#8212; Material Agreements &#8212; Semnur Merger Agreement</span>&#8221; for a description of our acquisition of Semnur and our ongoing obligations to Semnur&#8217;s former equityholders. SEMDEXA has been granted fast track designation by the FDA and, if approved, could become the only <span style="white-space:nowrap">FDA-approved</span> ESI for the treatment of sciatica. According to a report by Decision Resources Group, it is estimated that over 4.8&#160;million patients will suffer from sciatica in the United States in 2022. <span style="white-space:nowrap">SP-103</span> has also been granted fast track designation by the FDA and, if approved, could become the first <span style="white-space:nowrap">FDA-approved</span> lidocaine topical product for the treatment of acute LBP. We are developing <span style="white-space:nowrap">SP-104</span> as a novel delayed-release formulation of <span style="white-space:nowrap">low-dose</span> naltrexone hydrochloride for the treatment of fibromyalgia, which remains a largely unmet medical need given the low response rates of commercially available therapies. Naltrexone is routinely used <span style="white-space:nowrap">off-label</span> to treat fibromyalgia. There are no <span style="white-space:nowrap">low-dose</span> formulations commercially available in the United States. Our patented formulation is designed to overcome undesirable effects of immediate release naltrexone, such as hyperalgesia, dysphoria, nausea, anxiety and insomnia. We believe our currently approved product and future product candidates, if approved, could uniquely address what we believe are the significant unmet needs of the targeted populations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_50">Our Marketed Product and Pipeline </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following chart illustrates our current commercial product and novel product candidates, for which we have worldwide commercialization rights, except with respect to Japan for ZTlido and <span style="white-space:nowrap">SP-103.</span> </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt">


<img src="g428534g56j49.jpg" alt="LOGO" />
 </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">144 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_51">Our Strategy </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our vision is to become the leading pain management company delivering novel <span style="white-space:nowrap">non-opioid</span> and <span style="white-space:nowrap">non-addictive</span> treatments to provide safe, effective and durable relief of multiple pain conditions. To accomplish this, the principal elements of our strategy are the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Maximize the commercial potential of ZTlido</span>. We have assembled an integrated commercial organization using a dedicated sales force and sales management, marketing and managed care capabilities to support continued uptake of ZTlido. We leverage a sales force of approximately <span style="white-space:nowrap">60-70</span> people, targeting over 10,000 primary care physicians, pain specialists, neurologists, and palliative care physicians who we believe treat the majority of PHN patients. Additionally, we are utilizing <span style="white-space:nowrap"><span style="white-space:nowrap">direct-to-patient</span></span> marketing strategies to expand awareness and utilization of ZTlido. Our managed healthcare account executives have extensive experience in negotiating contracts and have already achieved significant uptake by adding ZTlido to key formularies such as Cigna HealthCare (commercial and Medicare plans), Express Scripts (commercial and Medicare plans), United Healthcare Commercial, Anthem Blue Cross Blue Shield (&#8220;BCBS&#8221;), BCBS of Massachusetts, Louisiana and Kansas, Lifetime/Excellus BCBS, MedImpact, CareFirst, Select Health and Medicaid in California, Florida, Connecticut, Idaho, and North Dakota. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Develop and commercialize SEMDEXA as a novel epidural injection for the first approved treatment of sciatica</span>. We are developing SEMDEXA to address the limitations associated with the available corticosteroid epidural injectable products that are used <span style="white-space:nowrap">off-label.</span> Many of these products contain potentially neurotoxic preservatives and particulates, and are administered over 12&#160;million times annually despite a warning on the label of serious neurologic complications, including loss of vision, stroke, paralysis and death. These products carry warnings required by the FDA that the safety and efficacy of epidural administration has not been established. SEMDEXA has received fast track designation from the FDA and, if approved, could become the first <span style="white-space:nowrap">FDA-approved</span> epidural steroid product with long-term patent protection, which we also believe would create significant barriers to entry. Due to the novelty of our formulation as well as the associated patents and trade secrets, future potential competitors could be required to conduct extensive preclinical studies and costly comparative clinical trials. A full <span style="white-space:nowrap">6-month</span> data analysis was completed in February 2022 and we have recently completed a pivotal Phase 3 study with final results received in March 2022, which results reflect achievement of primary and secondary endpoints. We believe these final results are supportive of a breakthrough therapy designation for sciatica that, in addition to the fast track designation, is expected to allow the FDA to further expedite the overall development program leading to market approval. We have extensive clinical and <span style="white-space:nowrap">pre-clinical</span> data (including those obtained from multiple Phase 2 clinical trials) with the novel viscous gel formulation of <span style="white-space:nowrap">SP-102.</span> We expect to present the robust data collected over the course of our multi-year clinical development program to the FDA as part of a NDA. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Pursue clinical development of <span style="white-space:nowrap">SP-103</span> for the first approved topical treatment in patients with acute LBP</span>. We are developing <span style="white-space:nowrap">SP-103</span> as a triple-strength lidocaine topical system for the treatment of acute LBP, to be used where we believe a high-dose strength and superior adhesive qualities of a topical system may provide a greater therapeutic benefit than currently available therapies. <span style="white-space:nowrap">SP-103</span> is designed to use ZTlido&#8217;s delivery and adhesion technology to deliver a dose of lidocaine that is threefold higher than any other approved lidocaine topical products. We initiated a Phase 2 trial in acute LBP in the second quarter of 2022. <span style="white-space:nowrap">SP-103</span> has been granted fast track designation by the FDA and, if approved, could become the first <span style="white-space:nowrap">FDA-approved</span> lidocaine topical product for the treatment of acute LBP. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Pursue clinical development of <span style="white-space:nowrap">SP-104</span> for the treatment of fibromyalgia, which has very few approved therapies that are marginally effective and have unpleasant side-effects</span>. We are developing <span style="white-space:nowrap">SP-104</span> for fibromyalgia. <span style="white-space:nowrap">Low-dose</span> naltrexone hydrochloride delayed-release capsules are routinely used <span style="white-space:nowrap">off-label</span> to treat fibromyalgia and other chronic pain conditions such as complex regional pain. <span style="white-space:nowrap">SP-104</span> addresses the shortcomings of using the high-dose commercial products and </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">145 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
pharmacy-compounded products by delivering a <span style="white-space:nowrap">low-dose</span> of naltrexone hydrochloride (approximately 11 times less than the commercial product) in a delayed-release formulation that bypasses the stomach and releases the drug in the gut (upper intestine). These product characteristics mitigate against the known safety issues associated with the high-dose commercial products and immediate release pharmacy-compounded products, and the overall reliability issues associated with pharmacy-compounded products. <span style="white-space:nowrap">SP-104</span> has completed two Phase 1 studies to characterize the pharmacokinetics and safety of the product, and we expect to commence Phase 2 studies in the first half of 2023. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Expand our product portfolio by developing or acquiring <span style="white-space:nowrap">non-opioid</span> assets that leverage our novel delivery and adhesion technologies or our existing commercial infrastructure</span>. We are continuously evaluating opportunities to leverage our research and development experience to develop <span style="white-space:nowrap">non-opioid</span> therapeutics for pain management indications that are not adequately served with existing treatment options. We also seek to <span style="white-space:nowrap">in-license</span> or acquire <span style="white-space:nowrap">non-opioid</span> therapeutics that can both complement our existing product portfolio and benefit from our existing commercial infrastructure. In evaluating marketed and clinical-stage expansion opportunities, Scilex intends to pursue therapeutics that address markets served by our established target physician audience and that can be commercialized by our existing sales force. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Leverage our management team&#8217;s experience to further develop and commercialize its current and future product portfolio</span>. Our management team has held senior positions at leading biopharmaceutical companies, including Allergan, Inc., Bristol-Myers Squibb Company, Teva Pharmaceuticals Industries Ltd., Novartis Pharmaceuticals, Cephalon, Inc., Roche AG, PDL BioPharma, Inc., Xenoport, Inc. and Chiron Corp. Our team has substantial experience in rapidly progressing new drugs to clinical proof of concept, completing successful pivotal registration programs and successfully commercializing products. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that our innovative <span style="white-space:nowrap">non-opioid</span> product portfolio has the potential to provide effective pain management therapies that can have a transformative impact on patients&#8217; lives. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_52">Our Management Team </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have assembled a management team of experienced biopharma industry veterans, who have deep scientific, business and leadership expertise in pharmaceutical industry, in addition to strong transactional and business development track records. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management team is led by our Chief Executive Officer and President, Jaisim Shah, with strategic guidance from our Executive Chairperson, Henry Ji, Ph.D. They collectively have over 40 years of global biopharmaceutical and biotechnology experience. Mr.&#160;Shah served as the Chief Executive Officer of Semnur from its inception in 2013 until our acquisition of Semnur in March 2019. He also has over 15 years of senior management experience in leading business development, commercial operations, investor relations, marketing and medical affairs. Dr.&#160;Ji is the holder of several issued and pending patents in the life science research field and is the sole inventor of Sorrento&#8217;s intellectual property. Our Chief Financial Officer, Elizabeth Czerepak, has more than 35 years of finance and operational expertise across pharmaceuticals, biotechnology and venture capital. Our research efforts are guided by highly experienced scientists and experts. Our management team contributes a diverse range of experiences from leading biopharmaceutical companies, including Allergan, Inc., Bristol-Myers Squibb Company, Teva Pharmaceuticals Industries Ltd., Novartis Pharmaceuticals, Cephalon, Inc., Roche AG, PDL BioPharma, Inc., Xenoport, Inc. and Chiron Corp. With this leadership, we believe we are well positioned to achieve our vision of becoming the leading pain management company delivering novel <span style="white-space:nowrap">non-opioid</span> and <span style="white-space:nowrap">non-addictive</span> treatments to provide safe, effective and durable relief of multiple pain conditions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we are supported by impressive teams across all levels of the organization. We hire and develop world-class talent from diverse backgrounds in biopharma, academia, technology and finance to ensure we have all of the capabilities to design and deliver effective first-class pain management therapies. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">146 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_53">Our Product Portfolio </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">ZTlido </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our marketed product, ZTlido, is a lidocaine topical system approved for the relief of neuropathic pain associated with PHN. ZTlido was strategically designed to address the limitations of current prescription lidocaine patches by providing significantly improved adhesion and continuous pain relief throughout the <span style="white-space:nowrap">12-hour</span> administration period. We launched ZTlido in October 2018 with an integrated commercial organization and we believe its differentiated therapeutic profile, combined with our competitive pricing strategy and our active direct marketing efforts have driven, and will continue to drive, accelerated sales growth and increased market uptake. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Prescription Lidocaine Patch Market Overview </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prescription lidocaine patches are approved by the FDA as a local anesthetic and are generally used as a first-line treatment for the relief of neuropathic pain associated with PHN. PHN is a chronic neuropathic pain syndrome that results as a complication following an infection of herpes zoster, also known as shingles. Herpes zoster symptoms resolve after a few weeks, but the pain caused by the nerve injury can persist for months to years surrounding the affected area. According to Evaluate Ltd., there were over 3.5&#160;million people living with PHN conditions in the United States in 2021. Lidocaine patches have also been used in patients with other types of pain, such as diabetic neuropathy, osteoarthritis and pain associated with surgery, cancer or trauma, and often in patients with LBP. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2021, there were more than 147&#160;million prescription lidocaine patches sold in the United States, according to Symphony Healthcare. Of this, five lidocaine patch manufacturers accounted for approximately 92% of the total prescriptions, according to Symphony Healthcare. We believe that the PHN market will continue to expand with the introduction of our lidocaine topical system, ZTlido, which is supported by our commercial organization, by prescribing trends away from opioid use, and by continued growth in the population of patients aged 45 years and older who are at greater risk of suffering from PHN. Unlike Lidoderm, the FDA has not determined that any other products are therapeutically equivalent to ZTlido, and accordingly, a prescription for ZTlido may not be able to be substituted by a generic product. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Current Treatment Landscape and Limitations of Existing Treatments </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Recommended first-line treatment for the relief of neuropathic pain associated with PHN includes topical lidocaine, gabapentinoids (which have been associated with the potential for abuse as well as numerous adverse events), antidepressants and a multi-modal approach. Topical lidocaine and gabapentinoids are preferred for combination therapies due to their low propensity for <span style="white-space:nowrap"><span style="white-space:nowrap">drug-to-drug</span></span> interactions. For example, an eight-week combination use with pregabalin (Lyrica) has been proven to reduce pain in half for patients who had inadequate relief on monotherapy, despite titration of pregabalin to effect. This efficacy boost was achieved without tolerability issues or adding to side effects. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A survey analyzing treatment patterns for neuropathic pain associated with PHN found that recommended first-line therapeutics were used in only 29% of patients examined from 2010 to 2014, while the remaining patients were started on various <span style="white-space:nowrap">off-label</span> treatments, including NSAIDS and opioids. These drugs can have adverse effects, especially on elderly patients, which represent the majority of PHN patients. For example, opioids carry a well-characterized risk of abuse and misuse and the potential for serious side effects, such as respiratory depression, constipation and others, including death. According to the Centers for Disease Control and Prevention, over 75% of the 100,306 drug overdose deaths during the <span style="white-space:nowrap">12-month</span> period ending in April 2021 involved opioids. Similarly, tricyclic antidepressants, which can be effective in managing the neuropathic pain associated with PHN, can result in significant systemic side effects and cardiotoxicity, posing risks to the elderly and patients with heart disease, epilepsy or glaucoma. These side effects make topical lidocaine products an attractive first-line treatment option from a safety perspective. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">147 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The safety of lidocaine patches is well-supported in medical literature. Unlike transdermal medications that are designed to achieve systemic drug levels via absorption through the skin or mucosal membrane, leading to effects away from the application site, topical lidocaine has a local effect at the site of application. Because drug application is localized to the immediate area surrounding the patch, systemic absorption from a topical patch is low, reducing the risk of systemic side effects and lowering the potential for drug interactions relative to other systemic pharmacologic therapies. Due to the low systemic exposure and minimal systemic side effects reported in clinical trials, we believe a topical lidocaine patch is well-suited for patients being treated with multiple medications or at a higher risk of side effects, including the elderly or those with chronic conditions. As a localized treatment, lidocaine patches have been used concomitantly with other medications in patients for whom monotherapy is inadequate. Furthermore, we believe medication administered topically rather than orally can improve patient compliance. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While lidocaine patches have certain advantages over the treatment alternatives discussed above, certain patches have limitations that may impact efficacy. For example, poor adhesion of the patch is a leading problem for topical lidocaine patches cited in the FDA Adverse Event Reporting System (&#8220;FAERS&#8221;). Because the drug is incorporated in the adhesive for these products, patches must maintain adhesion or risk compromising the ability to deliver their full drug dose. As a result, establishing strong adhesion is a key factor for patient compliance and satisfaction. In draft guidance issued in July 2021, the FDA recommended that developers of topical and transdermal delivery systems (&#8220;TDSs&#8221;) conduct studies to characterize the adhesion performance of the product with suggested data requirements. Likewise, the FDA issued a draft guidance in October 2018 outlining the adhesion data requirements for generic TDSs. This guidance, along with Scilex&#8217;s past experience with regulatory agencies, shows the FDA&#8217;s interest and the importance of adhesion performance of these products. There are also dermal safety requirements that force developers to carefully balance adhesion performance against dermal safety. ZTlido is the first TDS product approved by the FDA that was able to demonstrate the targeted adhesion performance with an overall benign dermal safety profile. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following figure depicts data derived from FAERS as of December&#160;31, 2020: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g428534g00a01.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For many of the competing lidocaine patches, a common drawback is the usage of hydrogel technology that limits the overall pharmaceutical efficiency of the product, requiring more total drug to be loaded into the patch </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">148 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to deliver sufficient drug to achieve a therapeutic effect. For example, Lidoderm has a drug load of 700 mg drug but only delivers 3&#177; 2% of that drug load. Consequently, adhesive thickness must be increased in order to have a drug load sufficient to deliver a therapeutic dose of drug to the skin. As adhesive thickness increases, the product&#8217;s pliability can be compromised to the extent that the patch loses adhesion as the skin moves and wrinkles through normal patient activity. The weight of the hydrogel patches (largely due to high water content) further contributes to the challenge in maintaining adhesion. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The greater drug load also poses a risk of accidental exposure. For example, with a bioavailability of 3 &#177; 2% of the 700 mg drug load for Lidoderm, there is over 650 mg of drug remaining on the patch at the end of the <span style="white-space:nowrap">12-hour</span> administration period, as captured in a bolded warning on the product label. If improperly disposed of, the residual drug poses the potential risk to children, pets and others of accidental exposure to a toxic amount of lidocaine, although we believe the risk with this formulation has not been evaluated. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to prescription lidocaine patches, there are commercially-available OTC topical lidocaine products in the market, but none of these OTC products have been reviewed or approved by the FDA. Notably in 2003, the FDA proposed amending the tentative final monograph for OTC external analgesic drug products to clarify the status of patches (and poultices and plasters), noting that the dosage forms had not been determined to be generally recognized as safe and effective for any analgesia at that time. Therefore, the FDA would likely not consider these OTC products to be compliant with the monograph and do not have legal marketing status. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Our Solution </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our novel adhesion and delivery technology provides significantly improved adhesion compared to Lidoderm, manufactured by Endo Pharmaceuticals, and generic alternatives marketed by Mylan N.V. (&#8220;Mylan&#8221;), while providing bioequivalent delivery of lidocaine via an efficient drug delivery system. Our product is lighter, thinner and provides for a better patient experience without compromise to dermal safety and with no presentation of dermal sensitization. Below is a comparison of the key advantages of ZTlido to Lidoderm and generic lidocaine patches manufactured by Teva and by Mylan. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">149 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Key Advantages of ZTlido vs. Lidoderm and Associated Generics </span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g428534g00a03.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Note: DIA = <span style="white-space:nowrap"><span style="white-space:nowrap">Drug-in-adhesive</span></span> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">* Source: A Scilex-sponsored <span style="white-space:nowrap"><span style="white-space:nowrap">head-to-head</span></span> comparative adhesion study <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">(SCI-LIDO-ADH-003)</span></span></span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ZTlido has been strategically designed to address poor adhesion, a leading complaint associated with other currently marketed topical lidocaine products. ZTlido uses an advanced <span style="white-space:nowrap">hot-melt</span> technology, which uses premixing and <span style="white-space:nowrap">hot-melt</span> mixing of various excipients and lidocaine, followed by cGMP compliant coating, lining, cutting and filling processes. In clinical studies, the technology provided significantly improved adhesion over Lidoderm and Mylan&#8217;s generic lidocaine patch at 12 hours after application. In a <span style="white-space:nowrap"><span style="white-space:nowrap">head-to-head</span></span> study of 44 subjects, ZTlido showed statistically significant adhesion at <span style="white-space:nowrap">all-time</span> points compared to Lidoderm. Further, ZTlido maintained greater than 90% mean adhesion over the labeled <span style="white-space:nowrap">12-hour</span> administration period while Lidoderm fell below this benchmark within 3 hours. ZTlido also showed superior adhesion when compared to Mylan&#8217;s generic lidocaine patch. In this <span style="white-space:nowrap"><span style="white-space:nowrap">head-to-head</span></span> study, ZTlido maintained greater than 90% mean adhesion throughout the labeled <span style="white-space:nowrap">12-hour</span> administration period, while Mylan&#8217;s generic product had a mean adhesion score of only 80% immediately after application, which progressively worsened over time. The formulation components are also carefully selected to achieve the target adhesion profile without creating dermal sensitization and maintaining a benign irritation profile. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In two separate studies, adhesion performance of ZTlido was compared to Lidoderm (with 44 subjects) and to Mylan&#8217;s generic lidocaine patch (with 24 subjects), as depicted in the diagrams below. Both studies were performed with healthy volunteers using a standard clinical adhesion protocol where adhesion could not be enhanced (<span style="font-style:italic">i.e.</span>, no reinforcement, pressing or reattaching). The level of adhesion was measured immediately after application (Time 0), and at 3, 6, 9 and 12 hours after application. ZTlido was the only lidocaine product to achieve over 90% adhesion over 12 hours after application in these studies. Maintaining 90% adhesion was a requirement for ZTlido&#8217;s NDA approval. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">150 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt">


<img src="g428534g03v30.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The proprietary adhesive system utilized for ZTlido allows for a more efficient delivery of the drug from the patch to the skin. This was supported by a clinical study in which our product achieved a bioequivalent dose of lidocaine while using a reduced drug load (36 mg for ZTlido versus 700 mg for Lidoderm). The drug delivery efficiency of ZTlido lessens the danger of accidental exposure. After 12 hours after application, ZTlido contains approximately 18 mg of residual lidocaine. In comparison, each Lidoderm patch leaves over 650 mg in the patch at the end of the <span style="white-space:nowrap">12-hour</span> administration period. If improperly disposed of, the residual drug poses a risk of accidental exposure to a toxic amount of lidocaine to children, pets and others, although the risk with this formulation has not been evaluated. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The drug delivery efficiency of ZTlido also enables it to be manufactured as a thinner product relative to Lidoderm and Teva&#8217;s generic lidocaine patch. We strategically leveraged this property of ZTlido by utilizing a thin patch design with a nonwoven backing cloth that allows for better adhesion of the product. The improved adhesion performance, thinner profile and incorporation of a flexible backing material allows for a product that maintains contact with the skin in contoured areas of the body, when encountering torsional strains arising from normal body movements and during contact with clothing and bedding. While Mylan&#8217;s generic lidocaine patch is also thinner than Lidoderm, it incorporates a film backing material that makes the product inflexible with body movements, contributing to its rapid loss in adhesion. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The adhesion profile of ZTlido allows the product to be used under moderate exercise conditions (tested in 4&#160;sessions of <span style="white-space:nowrap">30-minutes</span> of stationary bike exercise, cumulatively 2 hours) as captured in the ZTlido label. No ZTlido patches fell off during the entire <span style="white-space:nowrap">12-hour</span> administration period. Lidoderm and the associated generics have not produced any public data on the use of their products by active pain patients under such conditions. ZTlido is also labeled to allow patients to shower and bathe while wearing the patch, which is supported by an adhesion or pharmacokinetic study showing that while some degree of lifting is observed in these environments, the patches were able to be pressed back down or reattached in the cases where the product completely detached, with no clinically meaningful change in pharmacokinetics. In contrast, Lidoderm and the associated generics are labeled with the effects of water exposure being unknown. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although ZTlido, Lidoderm and the associated generics are all labeled to not be used with heat (<span style="font-style:italic">e.g.</span>, heating pad or blanket), the <span style="white-space:nowrap">FDA-approved</span> ZTlido label states that users may apply ZTlido to a treatment site after moderate heat exposure, such as after 15 minutes of heating pad use on a medium setting. This authorized use of ZTlido is of value as heat therapy is widely used in treating pain. In contrast, Lidoderm and the associated generics are not labeled for use with heat. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">151 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe ZTlido has other favorable features compared to Lidoderm and associated generic lidocaine patches such as the inclusion of a perforated release liner and the absence of cold flow. The perforated release liner allows for easier removal of the liner before application, which we believe provides convenience to patients who have dexterity challenges. In contrast, Lidoderm and generic lidocaine patches incorporate a single-sheet release liner, requiring patients to pick at the corners and edges to breach and remove before application. Cold flow is the propensity of the adhesive to migrate from the edges of the product under normal conditions, either in the product envelope or while on the skin. This can lead to difficulties in removing the product from the envelope and/or movement of the product, while on the skin, away from the intended administration site. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We launched ZTlido in October 2018 with support from an integrated commercial organization using a dedicated sales force and sales management, marketing and managed care capabilities. We market ZTlido through a dedicated <span style="white-space:nowrap">65-person</span> sales force, targeting over 10,000 primary care physicians, pain specialists, neurologists and palliative care physicians who we believe treat the majority of PHN patients. We are utilizing a multi-channel marketing strategy to expand awareness and utilization of ZTlido. Our managed healthcare account executives have achieved success in adding ZTlido to key formularies, including Cigna HealthCare (commercial and Medicare plans), Express Scripts (commercial and Medicare plans), United Healthcare Commercial, Anthem BCBS, BCBS of Massachusetts, Louisiana and Kansas, Lifetime/Excellus BCBS, MedImpact, CareFirst, Select Health and Medicaid in California, Florida, Connecticut, Idaho, and North Dakota. We believe the benefits of ZTlido, combined with our competitive pricing strategy and our active direct marketing efforts have driven, and will continue to drive, accelerated sales growth and increased market uptake. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We plan to support several investigator-initiated research studies to explore the clinical benefits of using ZTlido in patients with carpal tunnel syndrome, neck pain, intercostal neuralgia and other possible indications. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">SP-102</span> (SEMDEXA) </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">SP-102</span> (SEMDEXA) is a Phase 3, novel, injectable viscous gel formulation of a widely used corticosteroid for epidural injections to treat sciatica. No ESIs are currently approved by the FDA. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Sciatica Market Overview </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A particularly debilitating complication of back pathology is sciatica, which is a condition caused by mechanical compression of the nerve root, or by the effects of inflammatory mediators arising from a degenerative disc that results in inflammation and damage to the nerve roots. This nerve root compression in the lumbar segment of the spine causes shock-like or burning LBP combined with pain radiating down along the sciatic nerve through the buttocks and down one leg, sometimes reaching the foot. This often severe and debilitating leg pain is usually associated with symptoms of neuropathy-like numbness and tingling. The estimated lifetime incidence of sciatica ranges from 10% to 40% of the U.S. population, and about <span style="white-space:nowrap">one-third</span> of these cases will develop symptoms lasting over a year. According to a report by Decision Resources Group, it is estimated that over 4.8&#160;million patients will suffer from sciatica in the United States in 2022. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Current Treatment Landscape and Limitations of Existing Treatments </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As the U.S. population ages, the incidence of sciatica and the need for interventions are expected to continue to increase. For example, from 2000 to 2018, ESIs in Medicare beneficiaries increased by more than 125%. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although there are numerous etiologies of sciatica, and therapies may differ based on the etiology, pain management interventions for sciatica are usually multi-modal. Among the pain management interventions, ESI is considered to be efficacious and has been widely used by physicians across multiple specialties, including anesthesiology, physical medicine and rehabilitation and pain medicine. However, there is no ESI therapy approved by the FDA for sciatica to date, and particulate formulations of glucocorticoids have been associated with severe adverse events. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">152 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patients with sciatica have a wide range of invasive and <span style="white-space:nowrap">non-invasive</span> treatment options. Surgical intervention options include such as vertebroplasy, spinal laminectomy, discectomy, microdiscectomy, foraminotomy, intradiscal electrothermal therapy, nucleoplasty, radiofrequency denervation, spinal fusion and artificial disc replacement. These options are generally the last line of treatment because they can result in prolonged recovery time, may not be successful in reducing pain or addressing the underlying cause, and may result in permanent loss of flexibility. For these reasons, less invasive interventions are usually implemented first. Less invasive interventions may include (i)&#160;nonpharmacological therapies such as physical therapy, stretching exercises, spinal manipulations or chiropractic therapy, traction, acupuncture, transcutaneous electrical nerve stimulation, and biofeedback; (ii)&#160;oral pharmaceutical therapies such as NSAIDs, muscle relaxants, opiates, antidepressants, and anticonvulsants; and (iii)&#160;injectable pharmaceutical therapies such as <span style="white-space:nowrap">off-label</span> use of ESIs or nerve blocks. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ESIs for various back pain syndromes are one of the most common procedures performed in the United States and lumbosacral radicular ESI procedures represent 88% of total ESI procedures. ESIs are used when a patient&#8217;s pain is inadequately controlled with oral pain medications, topical systems or interventions such as physical therapy. ESIs have demonstrated efficacy in reducing pain, restoring function, reducing the need for other health care and avoiding back surgery. However, in addition to not being <span style="white-space:nowrap">FDA-approved</span> for the treatment of lumbosacral radicular pain, currently-used ESIs also present various risks and challenges. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When administering an ESI, many physicians use a particulate steroid (including methylprednisolone acetate, triamcinolone acetonide, or betamethasone sodium phosphate or betamethasone sodium acetate) instead of a <span style="white-space:nowrap">non-particulate</span> steroid (dexamethasone sodium phosphate) because early studies suggested that the duration of pain relief was longer with the particulates and fewer repeat injections were required, even though dexamethasone is considered an otherwise potent and therapeutically beneficial therapy. Particulate in injectable products is defined as extraneous undissolved particles present in injectable solution products. An example of such particulate is precipitate of insoluble drug form, or suspended drug particle. These steroid particles or their aggregates have at least two mechanisms for neurological damage: (1)&#160;they can act as emboli if injected into an artery and are of sufficient size to block small terminal arterioles supplying the brain or spinal cord; and (2)&#160;several particulate steroids have an immediate and massive effect on microvascular perfusion because of formation of red blood cell aggregates. These emboli can cause rare but catastrophic neurologic injuries including stroke and spinal cord injury that can result in increased pain, severe permanent disability or death. In addition, fungal meningitis has occurred from the injection of steroids manufactured in a compounding pharmacy that did not adhere to sterility standards. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA has been evaluating serious neurologic events with ESIs since 2009, and in 2014, the FDA required a class warning on the currently <span style="white-space:nowrap">off-label</span> use of injectable corticosteroids to include information about the risk of serious neurologic events with ESIs. The warning on product labels for all injectable glucocorticoids states that the product is to be used for intramuscular or intravenous purposes only, and specifically includes a warning for serious neurologic adverse reactions with epidural administration. These serious neurologic events have been reported with and without use of fluoroscopy. The class warning also includes a statement that safety and effectiveness of epidural administration of these corticosteroids have not been established. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain third-party payors have also provided limited coverage of ESIs to date. Based on coverage criteria established by different health care plans and certain Medicare Administrative Contractors, an ESI is considered medically necessary and therefore reimbursable only when certain specific criteria are met. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Our Solution </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing <span style="white-space:nowrap">SP-102</span> to address problems associated with currently available corticosteroid products that are used in practice but not approved for epidural injection or the treatment of lumbosacral radicular pain. <span style="white-space:nowrap">SP-102</span> is a Phase 3 sterile dexamethasone sodium phosphate viscous gel formulation of 10 mg dexamethasone at a 5 mg/mL concentration in a <span style="white-space:nowrap">pre-filled</span> glass syringe for delivery via an epidural injection. <span style="white-space:nowrap">SP-102</span> allows for the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">153 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
use of the potent dexamethasone and provides for longer residency time at the site of injection through the use of a viscous excipient in lieu of particulates. The product is also formulated without the use of preservatives and packaged in a <span style="white-space:nowrap">pre-filled</span> syringe, so as to confer greater physician convenience. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Currently-used steroids carry a class warning and are not approved to be administered epidurally for the treatment of sciatica. In fact, there are further warnings that the safety and efficacy of the use of these products following epidural administration has not been established. Their formulations include neurotoxic preservatives, surfactants, suspensions or particulates that carry risks of serious neurologic complications. Unlike currently-used steroids, <span style="white-space:nowrap">SP-102</span> does not contain neurotoxic preservatives, surfactants, suspensions or particulates that carry risk of serious neurologic complications, which we believe may improve safety and the extent of pain relief. By using dexamethasone sodium phosphate, the soluble form of the potent dexamethasone, we believe <span style="white-space:nowrap">SP-102</span> may substantially reduce the risk of embolic events in case of inadvertent intra-arterial administration and enable repeat injections. We expect the injectable viscous gel product, <span style="white-space:nowrap">SP-102,</span> which uses a biocompatible, biodegradable, novel excipient and is protected by multiple patents and patent applications and trade secrets, to prolong the residence time at the injection site and result in extended local activity. We believe <span style="white-space:nowrap">SP-102,</span> if successfully developed and approved, has the potential to reduce the disability related to lumbosacral radicular pain and help delay or avoid spine surgery. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If approved, <span style="white-space:nowrap">SP-102</span> could become the first <span style="white-space:nowrap">FDA-approved</span> ESI product. We believe an <span style="white-space:nowrap">FDA-approved</span> therapy for the treatment of sciatica could potentially benefit from <span style="white-space:nowrap"><span style="white-space:nowrap">first-to-market</span></span> advantage if it can be shown to reduce or delay the need for expensive and potentially risky interventions such as spinal surgery and decrease the use of opioids. <span style="white-space:nowrap">SP-102</span> benefits from our substantial intellectual property portfolio and other technical barriers to entry for potential competitors. Further, we are a party to an exclusive supply agreement for a proprietary biocompatible viscosity-enhancing excipient sodium hyaluronate in <span style="white-space:nowrap">SP-102.Our</span> complex manufacturing process, specialized equipment and <span style="white-space:nowrap">know-how</span> for sterile viscous product candidates are also key to our competitive edge. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are currently evaluating data on <span style="white-space:nowrap">SP-102</span> from a pivotal Phase 3 CLEAR trial, which was designed to evaluate the safety and efficacy in the proposed indication. The CLEAR clinical trial is a randomized, double-blind, placebo-controlled Phase 3 trial that enrolled 401 patients with sciatica at over 40 sites across the United States, with a primary objective to evaluate the analgesic effect on average leg pain (as measured by the Numeric Pain Rating Scale in the affected leg) following a single epidural injection of <span style="white-space:nowrap">SP-102,</span> compared to an intramuscular injection of placebo over four weeks. A full <span style="white-space:nowrap">6-months</span> data analysis was completed in February 2022 and we announced final results from the study in March 2022, which results reflect achievement of primary and secondary endpoints. We believe these final results are supportive of a breakthrough therapy designation for sciatica that, in addition to the fast track designation, is expected to allow the FDA to further expedite the overall development program leading to market approval. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Phase 3 CLEAR trial summary results, which results reflect achievement of primary and secondary endpoints, are as follows: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="white-space:nowrap">SP-102</span> (SEMDEXA<sup style="font-size:75%; vertical-align:top">&#8482;</sup>), with 401 patients enrolled in the C.L.E.A.R. trial (Corticosteroid Lumbosacral Epidural Analgesia in Radiculopathy) experienced a rapid onset of pain relief, measured by Numeric Pain Rating Scale of average daily pain in the affected leg, with improvement against placebo over the first 4 weeks, following a single transforaminal injection, LS Mean (SEM) difference <span style="white-space:nowrap">-1.08</span> (0.17), with a <span style="white-space:nowrap">p-value</span> &lt; 0.001. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="white-space:nowrap">SP-102</span> (SEMDEXA<sup style="font-size:75%; vertical-align:top">&#8482;</sup>) showed continued reduction of pain beyond one month, and the median time to open-label repeat injection was 99 days (95% CI: 78, 129 days) according to a Kaplan-Meier estimation. By contrast, <span style="white-space:nowrap">off-label</span> injectable steroids typically provide pain relief for periods ranging from less than a week and up to one month, and then a repeat injection may be required. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The key secondary endpoint of Oswestry Disability Index, the gold standard for measuring degree of disability and estimating quality of life, showed a 28% improvement at 4 weeks on <span style="white-space:nowrap">SP-102</span> </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">154 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
(SEMDEXA<sup style="font-size:75%; vertical-align:top">&#8482;</sup>) compared to baseline (minimal clinically meaningful improvement <span style="white-space:nowrap">8%-12%)15.</span> The LS Mean (SEM) difference as compared to placebo was <span style="white-space:nowrap">-6.28</span> (1.49), with a <span style="white-space:nowrap">p-value</span> &lt; 0.001. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">There were no adverse events (&#8220;AEs&#8221;) of special interest reported, such as paraplegia, hematoma, or infection at the injection site, which events are associated with the <span style="white-space:nowrap">off-label</span> use of <span style="white-space:nowrap">non-approved</span> injectable steroid preparations. Of the 354 patients receiving at least a single injection of <span style="white-space:nowrap">SP-102,</span> there were 125 (35.3%) patients experiencing treatment emergent adverse events (&#8220;TEAEs&#8221;), with 32 (9.0%) patients experiencing treatment-related AEs, 16 (4.5%) patients experiencing medication-related AEs, 23 (6.5%) patients experiencing procedure-related AEs, four (1.1%) patients experiencing serious AEs, and one (0.3%) patients experiencing AEs related to early withdrawal. Of the 47 patients only receiving a single placebo injection (and no repeat injection of <span style="white-space:nowrap">SP-102),</span> there were 14 (29.8%) patients experiencing TEAEs with (i)&#160;two (4.3%) patients experiencing treatment-related AEs, (ii)&#160;two (4.3%) patients experiencing medication-related AEs, (iii)&#160;one (2.1%) patient experiencing procedure-related AEs, (iv)&#160;one (2.1%) patient experiencing serious AEs, (v)&#160;one (2.1%) patient experiencing AEs related to early withdrawal, and (vi)&#160;one (2.1%) patient death. TEAEs occurring in &#8805; two percent of patients were headache <span style="white-space:nowrap">(SP-102:</span> 13 (6.4%), 17 events; placebo: 11 (5.5%), 11 events), injection site pain <span style="white-space:nowrap">(SP-102:</span> 4 (2.0%), four events; placebo: zero (0.0%), 0 events), upper respiratory tract infection <span style="white-space:nowrap">(SP-102:</span> two (1.0%), 2 events; placebo: four (2.0%) events), sinusitis <span style="white-space:nowrap">(SP-102:</span> 4 (2.0%), four events; placebo zero (0.0%), 0 events) and hypertension <span style="white-space:nowrap">(SP-102:</span> four (2.0%), four events; placebo: one (0.5%), two events). The C.L.E.A.R trial also established the safety of repeat injections, as patients who experienced <span style="white-space:nowrap"><span style="white-space:nowrap">moderate-to-severe</span></span> radicular pain between 4 and 23 weeks were allowed to receive open-label additional <span style="white-space:nowrap">SP-102</span> (SEMDEXA<sup style="font-size:75%; vertical-align:top">&#8482;</sup>) injection. The safety analysis was comparable between treatment groups through 4, 12 and 24 weeks of study period. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Phase 3 <span style="white-space:nowrap">SP-102</span> C.L.E.A.R Trial &#8211; Primary Endpoint </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt">


<img src="g428534g07q47.jpg" alt="LOGO" />
 </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">155 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt">


<img src="g428534g00a02.jpg" alt="LOGO" />
 </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">SP-103</span> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing <span style="white-space:nowrap">SP-103</span> to be a triple-strength, <span style="white-space:nowrap">non-aqueous</span> lidocaine topical system for the treatment of acute LBP. <span style="white-space:nowrap">SP-103</span> leverages the same adhesive drug delivery formulation and manufacturing as ZTlido along with comparable backing material, perforated release liner and container-closure system. The increase in drug load is offset by a corresponding decrease in the adhesive diluent. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Acute LBP Market Overview </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The safe and effective treatment of acute LBP represents a high unmet needs and creates large market opportunities. LBP affects about 70% of people in resource-rich countries at some point in their lives. Acute LBP can be self-limiting, however. One year after an initial episode, as many as 33% of people still have moderate-intensity pain and 15% have severe pain. Acute LBP has a high recurrence rate with 75% of those with a first episode having a recurrence. Although acute episodes may resolve completely, they may increase in severity and duration over time. Americans spent approximately $134.5&#160;billion in 2016 on treating LBP and neck pain, which was the highest expenditure among 154 conditions studied by the Department of Institute for Health Metrics and Evaluation at the University of Washington. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Current Treatment Landscape and Limitations of Existing Treatments </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">According to the Centers for Disease Control and Prevention, in 2018, 28.0% of men and 31.6% of women aged 18 years old and older had lower back pain in the past three months. The percentage of women who had lower back pain increased as age increased. Among men, the percentage increased with age through age 74 years and then decreased. Women in the age groups 18 &#8211; 44, 45 &#8211; 64, and 75 years and older were more likely to have lower back pain in the past three months than were men in the same age groups, but percentages were similar between men and women in the age group <span style="white-space:nowrap">65-74</span> years. Although most patients recover quickly with minimal treatment, proper evaluation is imperative to identify rare cases of serious underlying pathology. Certain red flags should prompt aggressive treatment or referral to a spine specialist, whereas others are less concerning. Serious red flags include significant trauma related to age (i.e., injury related to a fall from a height or motor vehicle crash in a young patient, or from a minor fall or heavy lifting in a patient with osteoporosis or possible </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">156 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
osteoporosis), major or progressive motor or sensory deficit, <span style="white-space:nowrap">new-onset</span> bowel or bladder incontinence or urinary retention, loss of anal sphincter tone, saddle anesthesia, history of cancer metastatic to bone and suspected spinal infection. Without clinical signs of serious pathology, diagnostic imaging and laboratory testing often are not required. Although there are numerous treatments for nonspecific acute LBP, most have little evidence of benefit. Patient education and medications such as nonsteroidal anti-inflammatory drugs, acetaminophen and muscle relaxants are beneficial. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Our Solution </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our triple-strength <span style="white-space:nowrap">SP-103</span> is an investigational, <span style="white-space:nowrap">non-aqueous</span> lidocaine topical system undergoing clinical development in acute LBP conditions. If approved, we believe that <span style="white-space:nowrap">SP-103</span> could become the lidocaine topical product for acute LBP indications. All current uses of topical lidocaine products for LBP are <span style="white-space:nowrap">off-label.</span> This program builds on the learnings from ZTlido because both products share the same adhesive drug delivery formulation and manufacturing technology. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing <span style="white-space:nowrap">SP-103</span> to deliver a dose of lidocaine that is at least threefold higher than any approved lidocaine topical products (including the approved ZTlido, which has a drug load of 36 mg lidocaine). We manufacture <span style="white-space:nowrap">SP-103</span> to have a drug load of 108 mg lidocaine in a similar adhesive formulation as ZTlido, along with comparable backing material, perforated release liner and container-closure system. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">SP-103</span> has demonstrated delivery of threefold the level of drug of ZTlido, and consequently delivers threefold the level of drug of Lidoderm and associated generics by extrapolation. <span style="white-space:nowrap">SP-103</span> has been granted fast track designation by the FDA and, if approved, could become the first <span style="white-space:nowrap">FDA-approved</span> lidocaine topical product for the treatment of acute LBP. We believe <span style="white-space:nowrap">SP-103,</span> if successfully developed and approved, may be able to address the limitations of prescription lidocaine patches in treating acute LBP by delivering a higher dose of lidocaine to the application site, but with systemic exposure of drug remaining well below established safety thresholds. <span style="white-space:nowrap">SP-103</span> has three times the drug load of ZTlido (108 mg versus 36 mg) in the adhesive system and can potentially deliver threefold the level of the drug within a targeted area, with the convenience of a single topical system. This level of dosage for <span style="white-space:nowrap">SP-103</span> is comparable to the maximum approved daily dosage of ZTlido, or three topical systems for up to 12 hours during a <span style="white-space:nowrap">24-</span> hour period. By contrast, delivering higher levels of drug with other lidocaine patches is encumbered by the underlying hydrogel technology that constrains the level of drug that can be loaded into the adhesive of those products. The level of drug product in such patches can be increased only with a thicker adhesive layer, which can result in a loss of adhesion performance and flexibility. Further, increasing product dimensions can allow delivery of the drug over a larger area, but does not increase drug delivery to a localized area under the topical system. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe the acute LBP market presents an attractive commercial opportunity due to the large patient population, lack of any approved drugs and high level of unmet medical need. We believe developing and commercializing a topical <span style="white-space:nowrap">non-opioid</span> product targeting this segment of the pain population represents a commercially attractive strategy. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend initially to evaluate <span style="white-space:nowrap">SP-103</span> in a Phase 2 trial in subjects who have acute LBP. The study design is planned as an enriched-enrollment, randomized, double-blind, <span style="white-space:nowrap">two-period</span> cross-over, multicenter study of <span style="white-space:nowrap">SP-103</span> and placebo in subjects with acute LBP. The study consists of a <span style="white-space:nowrap">7-day</span> open-label <span style="white-space:nowrap">run-in</span> period where all subjects receive active treatment. Responders to treatment then will be randomized to blinded Treatment A, consisting of 30 days treatment with <span style="white-space:nowrap">SP-103</span> or Treatment B, consisting of 30 days treatment with placebo patch with no lidocaine. Scilex initiated the Phase 2 trial in the second quarter of 2022. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">SP-104</span> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing <span style="white-space:nowrap">SP-104</span> for the treatment of fibromyalgia. <span style="white-space:nowrap">Low-dose</span> naltrexone hydrochloride delayed-release capsules is routinely used <span style="white-space:nowrap">off-label</span> to treat fibromyalgia and other chronic pain conditions such as complex regional pain. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">157 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Fibromyalgia Market Overview </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Fibromyalgia affects an estimated 10&#160;million people in the United States and an estimated 3% to 6% of the world population. While it is most prevalent in women, it also occurs in men and children of all ethnic groups. Fibromyalgia is the second most common disorder that rheumatologists encounter, seen in 15% of evaluated patients. Approximately 8% of patients cared for in primary care clinics have fibromyalgia. Prominent fibromyalgia researchers and specialists estimate the economic burden of fibromyalgia in the United States to be between $12&#160;billion to $14&#160;billion each year and the condition accounts for a loss of 1% to 2% of the national overall productivity. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Potential Complications of Fibromyalgia </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a <span style="white-space:nowrap">non-exhaustive</span> list of complications of fibromyalgia: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">extreme allodynia with high levels of distress; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">opioid or alcohol dependence; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">marked functional impairment; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">severe depression and anxiety; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">obesity and physical deconditioning; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">metabolic syndrome. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although fibromyalgia is frequently grouped with arthritis-related conditions, there is no apparent inflammation or damage to the joints, muscles or other tissues. The diagnostic criteria for fibromyalgia is detailed in the chart below. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g428534g89q11.jpg" alt="LOGO" />
 </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">158 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Currently approved products for pain in fibromyalgia, including duloxetine, pregabalin and milnacipran, have limited efficacy. Responders applying such products can only demonstrate a 27% to 40% reduction of symptoms, which is far below the commonly accepted threshold of 50% to prove efficacy in treating fibromyalgia. In light of this, we believe new treatments with higher efficacy are needed to improve management of fibromyalgia. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Our Solution </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">SP-104</span> has key clinical data supporting its use in fibromyalgia. There are investigational trials that support use and development of <span style="white-space:nowrap">SP-104</span> for fibromyalgia. Currently there are no <span style="white-space:nowrap">low-dose</span> formulations (i.e., less than 5&#160;mg) available. Physicians currently use the commercially available high-dose tablets (50 mg) and have compounding pharmacies aliquot lower doses for patients. Pharmacy-compounding is inherently inaccurate and does not involve analyses to confirm that the aliquoted product has the target level of drug, and there is no assurance as to content uniformity within a batch as well as other quality attributes critical for pharmaceutical product performance. This can lead to errors in dosing and challenges with titration. The commercial products and pharmacy-compounded products also allow for the immediate release of the drug in the stomach, which can lead to compliance challenges due to severe side effects. Common side effects for naltrexone include hyperalgesia, dysphoria, insomnia and anxiety. All these issues culminate into patient compliance issues and result in the eventual abandonment of an otherwise viable therapy to treat this debilitating disease. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our <span style="white-space:nowrap">SP-104</span> uses delayed burst release technology that bypasses the stomach and releases the drug in the gut (upper intestine). When taking <span style="white-space:nowrap">SP-104</span> at night before bed, peak drug levels are achieved at night during sleep, allowing the patient to avoid conscious perception of hyperalgesia and other side effects. The combination of the delayed-release and administration at night may also maximize efficacy as most endorphin/ enkephalin release is during sleep, which maximizes the product&#8217;s potential to elicit compensatory response. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are committed to develop <span style="white-space:nowrap">SP-104</span> for fibromyalgia. Phase 1 studies are to characterize the pharmacokinetic and safety profile of <span style="white-space:nowrap">SP-104,</span> and Scilex intends to initiate a Phase 2 study in the first half of 2023. If successful, we believe <span style="white-space:nowrap">SP-104</span> can become a pivotal treatment for management of fibromyalgia, which represents a large commercial opportunity with high unmet demands. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_54">Commercialization and Market Access </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Sales&#160;&amp; Marketing </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have built a robust and integrated commercial infrastructure using a dedicated sales force and sales management, marketing and managed care capabilities, to maximize the potential of our marketed product, ZTlido, and to commercialize our product candidates, if approved. We are focused on achieving accelerated sales growth and increased market uptake for ZTlido in the topical lidocaine product market, where we believe we have the only actively promoted product. Our dedicated <span style="white-space:nowrap">65-person</span> sales force has broad experience in pain management and is exclusively focused on promoting ZTlido. Our sales representatives leverage their established relationships to call on over 10,000 target pain specialists, neurologists, select primary care providers and palliative care physicians who Scilex believes treat the majority of PHN patients. We believe these same call points provide treatment for the sciatica and acute LBP patients that could benefit from SEMDEXA and <span style="white-space:nowrap">SP-103,</span> if approved. Our sales representatives typically have over 10 years of experience in promoting a broad scope of pain management products that Scilex intends to leverage as our product candidates are commercialized. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September&#160;30, 2022, ZTlido had gained approximately 11.6% market share of the lidocaine patch prescription market across the territories we cover in the United States. The total prescriptions of ZTlido for the nine months ended September&#160;30, 2022 grew by more than 47.9% over the nine months ended September&#160;30, 2021, according to Symphony Healthcare&#8217;s national prescription data. Our experienced sales representatives and managers are supported by our marketing team, whose members have successfully launched over 20 products </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">159 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with large pharmaceutical, biotechnology and specialty pharmaceutical companies. Our marketing team has developed a multi-channel marketing strategy to promote the continued uptake of ZTlido by highlighting its significantly improved adhesion and continuous pain relief throughout the <span style="white-space:nowrap">12-hour</span> administration period. We are also promoting ZTlido with a marketing campaign that engages patients seeking relief for neuropathic pain associated with PHN through social media and medical and consumer journals. Further, our marketing function is supported by an experienced analytics team that leverages its experience in forecasting and analytics to draw insights from healthcare databases to inform our marketing strategy. As part of our broader commercial strategy, our marketing analytics team is conducting market research to support the launch of <span style="white-space:nowrap">SP-102,</span> <span style="white-space:nowrap">SP-103</span> and <span style="white-space:nowrap">SP-104,</span> if any of these candidates is approved. We believe that our sales force, supporting commercial infrastructure and established relationships with our targeted physician audience will provide a strategic advantage in pursuing potential partnerships to commercialize other <span style="white-space:nowrap">non-opioid</span> pain management therapeutics. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Market Access </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have established a patient-centric market access function with robust capabilities across the market access continuum, including payor sales, contracting and marketing strategies, supplemental patient assistance programs and responsible drug pricing to support patients&#8217; access to ZTlido. Our team of managed healthcare account executives has demonstrated experience in establishing products on formularies and have currently prioritized and targeted select payor accounts representing approximately 275&#160;million of the over 300&#160;million lives, with the remaining 25&#160;million to be considered in the future. Currently, ZTlido is covered for over 200&#160;million lives in the United States and coverage continues to improve. As of January 2021, we have secured coverage for ZTlido on Cigna HealthCare (commercial and Medicare plans), Express Scripts (commercial and Medicare plans), United Healthcare Commercial, Anthem BCBS, BCBS of Massachusetts, Louisiana and Kansas, Lifetime/Excellus BCBS, MedImpact, CareFirst, Select Health and Medicaid in California, Florida, Connecticut, Idaho, and North Dakota. We continue to negotiate coverage with large payors and pharmacy benefit managers in all books of business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">ZTlido Formulary Coverage &#8212; Over 90% of Lives Covered or In Negotiation </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g428534g30m75.jpg" alt="LOGO" />
 </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We utilize an outside vendor to administer a patient assistance program directed at patients with commercial insurance or those paying <span style="white-space:nowrap"><span style="white-space:nowrap">out-of-pocket.</span></span> With the copay assistance program, qualifying patients do not have to pay any copayment for their ZTlido prescription. We utilize an external vendor and train the sales force to work proactively with clinician office managers in completing required forms for prior authorization for ZTlido. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">160 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_55">Clinical Development Overview </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">ZTlido </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Clinical Trial Highlights </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have evaluated ZTlido in over 600 subjects in clinical trials to support marketing approval and promotional campaigns for the relief of neuropathic pain associated with PHN in the United States. Our studies sought to investigate the bioequivalence of ZTlido compared to Lidoderm, adhesion performance and the dermal safety and tolerability of ZTlido under a range of application times and settings. Based on these studies, we concluded that ZTlido: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">demonstrated bioequivalence to Lidoderm in study <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">SCI-LIDO-PK-002A;</span></span></span> </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">showed greater than or equal to 90% adhesion in over 90% of the subjects at the end of the <span style="white-space:nowrap">12-hour</span> administration period in study <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">SCI-LIDO-ADH-001;</span></span></span> </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">showed superior adhesion to Lidoderm and Mylan&#8217;s generic lidocaine patch in studies <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">SCI-LIDO-AHD-002</span></span></span> and <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">SCI-LIDO-ADH-003;</span></span></span> </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">was not meaningfully impacted by heat or exercise in study <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">SCI-LIDO-HEX-001;</span></span></span> </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">was able to be used under showering and bathing conditions in study <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">SCI-LIDO-ADH-004;</span></span></span> and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">did not show clinically meaningful dermal irritation in study <span style="white-space:nowrap"><span style="white-space:nowrap">SCI-LIDO-DERM-001.</span></span> </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">ZTlido Study Details </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Pivotal Bioequivalence Study</span> &#8212; <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">SCI-LIDO-PK-002A</span></span></span> </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted a comparative single-dose pharmacokinetic (&#8220;PK&#8221;) study between ZTlido and Lidoderm designed as a <span style="white-space:nowrap">two-way</span> cross-over in 54 healthy subjects. In this trial design, each subject received a single dose of three ZTlido or three Lidoderm patches followed by a washout period and the administration of the other product. The purpose of this study was to establish bioequivalence between the products, which was determined by the statistical comparability of Cmax and AUC as shown in the figure below. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This was considered the pivotal clinical trial for ZTlido, as it provided the pharmaceutical bridge between the two products and showed that ZTlido had comparable safety and efficacy to Lidoderm. As a result of successfully establishing the pharmaceutical bridge, no stand-alone clinical efficacy studies were required by the FDA to determine ZTlido&#8217;s analgesic effects for ZTlido&#8217;s approval. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">161 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Mean Lidocaine Plasma Concentration Time Profiles &#8212; Semilog Scale </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g428534g47j55.jpg" alt="LOGO" />
 </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Pivotal Adhesion Study</span> &#8212; <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">SCI-LIDO-ADH-001</span></span></span> </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted an open-label, single-treatment, single-period, single-application adhesion performance study in 54 healthy, human subjects to assess the adhesion performance of ZTlido over the <span style="white-space:nowrap">12-hour</span> administration period of the product. The study also investigated whether ZTlido met an FDA established adhesion performance benchmark of greater than or equal to 90% adhesion in greater than or equal to 90% of subjects in the study at the end of the administration period. At the end of the <span style="white-space:nowrap">12-hour</span> administration period, over 90% of the subjects (49&#160;out of the 54 subjects) maintained greater than or equal to 90% adhesion, with no adverse events reported during the study. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">162 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">ZTlido Maintained Greater Than 90% Adhesion Over the <span style="white-space:nowrap">12-Hour</span> Time Period </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g428534g47l56.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This study was considered the pivotal adhesion study for marketing approval and is summarized in the product label. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><span style="white-space:nowrap"><span style="white-space:nowrap">Head-to-Head</span></span> Adhesion Study versus Lidoderm</span> &#8212; <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">SCI-LIDO-ADH-002</span></span></span> </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted an open label, single-treatment, three-period, single-application adhesion performance study in 44 healthy, human subjects to evaluate the adhesion performance of ZTlido compared to the adhesion performance of Lidoderm over a <span style="white-space:nowrap">12-hour</span> administration period. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In this study, ZTlido demonstrated significantly superior mean adhesion scores compared to Lidoderm at 3, 5, 9 and 12 hours after application. ZTlido maintained a mean percent adhesion performance greater than 90% over the <span style="white-space:nowrap">12-hour</span> administration period, while Lidoderm fell below 90% mean adhesion within three hours. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">163 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">ZTlido Demonstrated Superior Adhesion Compared to Lidoderm </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g428534g04a04.jpg" alt="LOGO" />
 </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><span style="white-space:nowrap"><span style="white-space:nowrap">Head-to-Head</span></span> Adhesion Study versus Mylan&#8217;s Generic</span> &#8212; <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">SCI-LIDO-ADH-003</span></span></span> </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted an open-label, single-treatment, <span style="white-space:nowrap">two-period,</span> single-application adhesion performance study in 24 healthy, human subjects to evaluate the adhesion performance of ZTlido compared to the adhesion performance of a generic lidocaine patch 5% manufactured by Mylan over a <span style="white-space:nowrap">12-hour</span> administration period. The purpose of this study was to compare the adhesion performance of ZTlido against a topical lidocaine product involving a <span style="white-space:nowrap">non-aqueous</span> formulation. We selected Mylan&#8217;s generic lidocaine patch as a comparator because it has similar product characteristics, including a <span style="white-space:nowrap">non-aqueous</span> polymer <span style="white-space:nowrap"><span style="white-space:nowrap">drug-in-adhesive</span></span> system allowing for a thinner patch and a lower drug load as compared to Lidoderm. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In this study, ZTlido demonstrated significantly superior adhesion performance compared to Mylan&#8217;s generic lidocaine patch. ZTlido maintained a mean adhesion greater than 90% over the <span style="white-space:nowrap">12-hour</span> administration period, while the generic product had a mean adhesion score of only 80% immediately after application, which declined to a mean adhesion score of 27% at 12 hours after application. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">164 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">ZTlido Demonstrated Superior Adhesion Compared to Mylan&#8217;s Generic Lidocaine Patch </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g428534g05a05.jpg" alt="LOGO" />
 </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">PK and Adhesion Study under Exercise and Heat Conditions</span> &#8212; <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">SCI-LIDO-HEX-001</span></span></span> </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted an open-label, randomized, three-treatment, three-sequence, three-period, cross-over, PK and adhesion performance study of three ZTlido topical systems applied to separate areas in 12 healthy, human subjects during physical exercise, exposure to heat and under normal conditions, respectively. The three treatment periods were as follows: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Treatment A sought to assess the PK and adhesion performance of ZTlido under physical exercise conditions. In this treatment period, subjects were instructed to perform exercise for 30 minutes on a stationary bike achieving a heart rate of 108 beats per minute, with continuous heart monitoring during exercise. Subjects were instructed to perform exercise immediately after the application of the topical system and at 2.5, 5.5 and 8.5 hours following application of the topical system. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Treatment B sought to assess the PK and adhesion performance of ZTlido under heat conditions. In this treatment period, a heating pad adjusted to the medium setting was applied for 20 minutes immediately after application of the topical system and at 8.5 hours following application of the topical system. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Treatment C sought to assess the PK and adhesion performance of ZTlido under normal conditions. In this treatment period, topical systems were applied to the <span style="white-space:nowrap">mid-lower</span> back and worn for 12 hours. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">165 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In treatment A, adhesion and PK performance were not compromised by exercise, as reflected in the product label. In treatment B, heat had an effect on PK but had no effect on adhesion. In Treatment C, normal PKs were observed and greater than 90% of subjects showed greater than 90% adhesion. No meaningful irritation was observed across all treatments across all time points in any of the subjects. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The impact of heat and exercise on PK is presented in the figure below. It was observed that heat had an effect on Cmax, but the drug returned to normal levels after removal of heat and there was no clinically meaningful observed effect on AUC. Heat did not appear to have a deleterious or catastrophic effect on topical system performance, either as a dose-dump (i.e., immediate and complete release of all drug from the product), or as reduced drug delivery (i.e., much lower systemic exposure). There was no significant effect on PK observed with exercise when compared to subjects under normal conditions. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">ZTlido Demonstrated Consistent* PK Performance under Exercise and Heat Conditions </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g428534g43v59.jpg" alt="LOGO" />
 </p> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:2%;vertical-align:top" align="left">*</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Defined as no clinically meaningful changes by meeting bioequivalence criteria </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Dermal Sensitization and Irritation Study</span> &#8212; <span style="white-space:nowrap"><span style="white-space:nowrap">SCI-LIDO-DERM-001</span></span> </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted a provocative dermal sensitization and irritation human clinical trial, also referred to as a repeat insult topical system test, intended to elicit the worst-case dermal safety of ZTlido by extended wearing of the product over multiple days. In this trial, we compared the sensitization potential, and the overall irritation profiles of ZTlido and Lidoderm in 218 normal and healthy subjects. We used a <span style="white-space:nowrap">7-point</span> scale where a score of 0&#160;indicated no irritation and a score of 7 was considered a strong reaction spreading beyond the application site. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">166 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In this study, results showed that the adhesion quality of ZTlido did not compromise dermal safety. The study reported that ZTlido did not show potential for dermal sensitization and showed an overall benign irritation profile. Both ZTlido and Lidoderm had a mean irritation score well below 1, which is defined as barely perceptible erythema. This study allowed for the ZTlido label to adopt the same local tolerance language as labeled for Lidoderm. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Photoallergy and Phototoxicity Studies &#8212; </span><span style="white-space:nowrap"><span style="white-space:nowrap">SCI-LIDO-PHOT0-001</span></span> and <span style="white-space:nowrap"><span style="white-space:nowrap">SCI-LIDO-PHOTO-002</span></span> </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted a <span style="white-space:nowrap">6-week</span> randomized study, <span style="white-space:nowrap"><span style="white-space:nowrap">SCI-LIDO-PHOTO-001,</span></span> to evaluate the potential of ZTlido and its comparator, Lidoderm, to induce a photoallergic skin reaction in 54 healthy volunteers. In this study, we observed that ZTlido was not photoallergenic. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted a <span style="white-space:nowrap">4-day,</span> randomized study, <span style="white-space:nowrap"><span style="white-space:nowrap">SCI-LIDO-PHOTO-002,</span></span> to evaluate the irritation potential of ZTlido and its comparator, Lidoderm, when application to skin is followed by light exposure in 32 healthy volunteers, using a phototoxicity patch test. In this study, we observed that ZTlido was not phototoxic. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Post-Approval Studies for ZTlido </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Water Stress Study (Shower and Swimming) &#8212; <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">SCI-LIDO-ADH-004</span></span></span> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted a single-dose study in 24 subjects to examine the adhesion and lidocaine delivery (pharmacokinetics) of ZTlido when it is exposed to two separate water stress conditions of (1)&#160;showering (10&#160;minutes) and (2)&#160;swimming (15 minutes). The study showed that while some degree of product lifting was observed, the product could be pressed back down or reattached with no further diminished adhesion performance or drug delivery. This study led to a change in the product label indicating that patients may use the product while showering or bathing. This provides significant patient convenience as Lidoderm and the associated generics are labeled to avoid contact with water such as bathing, swimming or showering, as these products may not stick if they get wet. With ZTlido, patients can engage in these activities within the <span style="white-space:nowrap">12-hour</span> administration period. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Investigator-Sponsored Studies </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We plan to support several investigator-initiated research studies to evaluate the clinical benefits of using ZTlido in patients with carpal tunnel syndrome, neck pain, intercostal neuralgia and other possible indications. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">SP-102</span> (SEMDEXA) </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recently conducted a Phase 3 pivotal study of <span style="white-space:nowrap">SP-102.</span> The Corticosteroid Lumbar Epidural Analgesia for Radiculopathy (&#8220;CLEAR&#8221;) study is a randomized, double-blind, placebo-controlled Phase 3 trial that enrolled 401 patients with sciatica to compare the epidural administration of <span style="white-space:nowrap">SP-102</span> to placebo. We announced final results from this study in March 2022. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Clinical Trial Highlights </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">SP-102</span> has been evaluated in a number of preclinical studies and clinical trials as a potential treatment for sciatica. Key findings from the preclinical studies and clinical trials include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Repeat injections of <span style="white-space:nowrap">SP-102</span> showed continued pain reduction with no unexpected adverse events based on preliminary results from the <span style="white-space:nowrap"><span style="white-space:nowrap">SP-102-03</span></span> study; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="white-space:nowrap">SP-102</span> showed an extended local activity with epidural administration in the <span style="white-space:nowrap">ES-1504</span> study; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="white-space:nowrap">SP-102</span> showed an extended residence time and tolerability in the 1014-1512 and the 1014-2847, preclinical studies; and </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">167 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The introduction of <span style="white-space:nowrap">SP-102</span> into blood vessels did not result in neurological complications in the UPD003-IS21 preclinical toxicology study. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><span style="white-space:nowrap">SP-102</span> (SEMDEXA) Study Details Phase 3 Pivotal Clinical Trial &#8212; CLEAR </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recently conducted a pivotal, randomized, double-blind, placebo-controlled Phase 3 trial, CLEAR, that enrolled 401 patients with sciatica at over 40 sites across the United States. The study includes an open-label extension where subjects will be followed for up to 24 weeks after treatment to evaluate the safety of administering <span style="white-space:nowrap">SP-102</span> in a larger patient population. After week 4, subjects who met certain pain criteria received open-label <span style="white-space:nowrap">SP-102</span> to investigate the safety of repeat injections and the duration of pain relief following injection. This well-controlled, randomized trial was designed to demonstrate evidence of the analgesic effect and safety of <span style="white-space:nowrap">SP-102.</span> The schematic of this Phase 3 trial is demonstrated in the flowchart below. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The primary objective of this study was to evaluate the analgesic effect of <span style="white-space:nowrap">SP-102</span> on average leg pain, measured using the Numeric Pain Rating Scale (&#8220;NPRS&#8221;) following a single transforaminal injection. These results were compared to an intra-muscular injection of placebo over a four-week period. The secondary objectives of this study include (i)&#160;evaluation of the degree of disability over time as measured by the Oswestry Disability Index; (ii)&#160;characterization of the change of the subject&#8217;s radiculopathy symptoms and overall condition, using a combination of PainDETECT, modified Brief Pain Inventory, Clinical Global Impression of Change, and Patient Global Impression of Change and (iii)&#160;evaluation of the safety of a single and repeat <span style="white-space:nowrap">SP-102</span> injections. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Schematic of CLEAR &#8212; <span style="white-space:nowrap">SP-102</span> (SEMDEXA) Phase 3 Pivotal Trial </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g428534g64p61.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Enrollment was completed in the second half of 2021. We announced final data from this study in March 2022. The Pivot Phase 3 trial has met the primary efficacy and key secondary efficacy endpoints: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">For the primary endpoint of change in average daily pain (as measured by the Numeric Pain Rating Scale) in the affected leg over four weeks following the initial injection, the LS Mean (SE) group difference of <span style="white-space:nowrap">-1.08</span> (0.17) compared to placebo with a <span style="white-space:nowrap">p-value</span> less than 0.001. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The two key secondary endpoints assessing Oswestry Disability Index (&#8220;ODI&#8221;) and Time to open-label repeat injection have been demonstrated for <span style="white-space:nowrap">SP-102.</span> The LS Mean (SE) group difference in ODI compared to placebo at week 4 was <span style="white-space:nowrap">-6.28</span> (1.49) with a <span style="white-space:nowrap">p-value</span> less than 0.001. A Cox proportional hazard model showed significantly longer duration of initial <span style="white-space:nowrap">SP-102</span> (SEMDEXA) treatment compared to placebo Hazard Ratio (95% CI) 0.49 (0.36, 0.65), with a <span style="white-space:nowrap">p-value</span> less than 0.001. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">168 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Phase 2 Repeat Dose Study</span> &#8212; <span style="white-space:nowrap"><span style="white-space:nowrap">SP-102-03</span></span> </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted an open-label, <span style="white-space:nowrap">single-arm,</span> pharmacodynamics (&#8220;PD&#8221;) and safety study of repeat epidural injections of <span style="white-space:nowrap">SP-102</span> in patients with sciatica. We conducted this study to characterize repeat dose PD with respect to hypothalamic-pituitary-adrenal suppression using plasma cortisol levels, white blood cell count and blood glucose levels. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The study enrolled 19 subjects, of which 15 received repeat <span style="white-space:nowrap">SP-102</span> epidural injections 4 to 8 weeks after the initial injection. Four of the subjects did not experience recurrent pain and thus did not require a repeat injection. The daily average, current and worst pain in the affected leg and back showed continuous reduction throughout the <span style="white-space:nowrap">28-day</span> observation period for both treatments. Based on a preliminary review of the results, <span style="white-space:nowrap">SP-102</span> injections were generally well-tolerated and there were no new unexpected adverse events observed. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Mean Percentage Change in Sciatica-Related Leg Pain as Measured by NPRS </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g428534g42x62.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Phase 1 Trial of <span style="white-space:nowrap">SP-102</span> (SEMDEXA) Compared to Reference Listed Drug </span>&#8212; <span style="white-space:nowrap">ES-1504</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted an open-label, <span style="white-space:nowrap">single-arm,</span> <span style="white-space:nowrap">two-period,</span> fixed sequential-dose study to evaluate the PK, PD and safety of <span style="white-space:nowrap">SP-102</span> when administered by epidural injection. <span style="white-space:nowrap">SP-102</span> was compared to intravenous dexamethasone sodium phosphate injection in subjects with lumbosacral radiculopathy. There were 12 subjects enrolled in this study, all of whom received <span style="white-space:nowrap">SP-102</span> followed by the intravenous dexamethasone sodium phosphate injection (Reference Listed Drug) administered one month later. A Reference Listed Drug is an approved drug product to which new versions are compared to show that they are bioequivalent. The purpose of this study was to establish the pharmaceutical bridge between <span style="white-space:nowrap">SP-102</span> and the Reference Listed Drug. The Tmax observed with the administration of <span style="white-space:nowrap">SP-102</span> was four hours, compared to 15 minutes observed with intravenous dexamethasone. The PD parameters and safety results of both products were similar, and <span style="white-space:nowrap">SP-102</span> did not prolong cortisol suppression time. <span style="white-space:nowrap">SP-102</span> also maintained analgesic effects throughout a <span style="white-space:nowrap">one-month</span> observation period. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The overall systemic exposure of dexamethasone was similar, whether administered as <span style="white-space:nowrap">SP-102</span> or injected intravenously, with a mean AUCinf of 0.916 &#181;g*h/mL (observed with <span style="white-space:nowrap">SP-102)</span> compared to 0.943 &#181;g*h/mL (observed with intravenously-administered dexamethasone). Notably, there was a <span style="white-space:nowrap">16-fold</span> increase in the time to maximum serum concentration (&#8220;Tmax&#8221;) following epidural injection of <span style="white-space:nowrap">SP-102.</span> The median Tmax was 4.00&#160;hours for <span style="white-space:nowrap">SP-102</span> compared to 0.25 hours for the comparison group. All 12 subjects with sciatica showed continuous reduction in back and leg pain during the <span style="white-space:nowrap">one-month</span> observation period following a single epidural injection of <span style="white-space:nowrap">SP-102.</span> </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">169 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This study demonstrated that at an equivalent initial dose of dexamethasone, the systemic exposure to dexamethasone following epidural injection of <span style="white-space:nowrap">SP-102</span> did not exceed the exposure following intravenous injection of the Reference Listed Drug. The PD effects, measured as white blood cell count, cortisol levels and glucose levels, as well as the safety profile, were similar between the two treatments. <span style="white-space:nowrap">SP-102</span> injections were generally well-tolerated and did not result in new unexpected side effects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Toxicology Studies</span> &#8212; Study Nos. 1014-1512 and 1014-2847 </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted PK and toxicology studies in two <span style="white-space:nowrap">non-rodent</span> animal species to assess <span style="white-space:nowrap">SP-102</span> administered via epidural and intrathecal routes with single and multiple dose regimens. Pharmacokinetically, a prolonged increase in the active dexamethasone metabolite was consistent with the extended residence time of the viscous gel formulation of <span style="white-space:nowrap">SP-102</span> at the site of injection. There were no new unexpected toxicology findings apart from well-characterized toxicity findings commonly observed with administration of dexamethasone sodium phosphate. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Preclinical Toxicology Study</span> &#8212; UPD003-IS21 </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted a preclinical toxicology study designed to simulate the accidental introduction of epidural steroids into arterial blood vessels providing blood supply to the spinal cord, which is a major cause of neurological complications associated with current administration of suspension steroids containing particulates.A2 mL (10 mg of dexamethasone) injection of <span style="white-space:nowrap">SP-102</span> was injected over <span style="white-space:nowrap">1-2</span> minutes into the vertebral artery of large animal species. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Pre-</span> and post-dose angiography showed no remarkable changes and all animals survived for approximately 24 hours until euthanasia. The veterinary animal health report and the pathology report concluded there were no vascular, spinal cord or brain injuries associated with injection into the vertebral artery of the animals. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Hydrodynamic Study</span> &#8212; <span style="white-space:nowrap">SP-PC002</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted a hydrodynamic study of <span style="white-space:nowrap">SP-102</span> in <span style="white-space:nowrap">non-rodent</span> animal species, which showed that epidural administration of <span style="white-space:nowrap">SP-102</span> demonstrated an increased local residence half-life and a decreased flow from the injection site. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Intravascular Injection Study</span> &#8212; <span style="white-space:nowrap">SEM-005</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted a study to evaluate the accidental intravascular injection of <span style="white-space:nowrap">SP-102</span> into the vertebral artery of <span style="white-space:nowrap">non-rodent</span> animals. There were no adverse clinical signs associated with the accidental intra-arterial injection of <span style="white-space:nowrap">SP-102</span> following a <span style="white-space:nowrap">24-hour</span> survival period. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">SP-103</span> (lidocaine topical system) 5.4% </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">SP-103</span> is an investigational, <span style="white-space:nowrap">non-aqueous</span> lidocaine topical system undergoing clinical development in acute LBP. As a higher strength topical lidocaine system, <span style="white-space:nowrap">SP-103</span> will build on the learnings from ZTlido because both products share the same adhesive drug delivery formulation and manufacturing technology. The clinical program involves evaluating the safety and efficacy of <span style="white-space:nowrap">SP-103</span> for the treatment of acute LBP. A Phase 1 study was completed that demonstrated bioequivalent pharmacokinetics between the administration of a single <span style="white-space:nowrap">SP-103</span> and the administration of three commercial ZTlido. The study also showed linear kinetics among multiple applications of <span style="white-space:nowrap">SP-103</span> (i.e., 1, 2 or 3 patches) over a <span style="white-space:nowrap">12-hour</span> administration period. Adhesion performance was assessed and found to be comparable between <span style="white-space:nowrap">SP-103</span> and ZTlido. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Specifically, we plan to evaluate <span style="white-space:nowrap">SP-103</span> in the following studies: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="white-space:nowrap"><span style="white-space:nowrap">SP-103-02</span></span> is a Phase 2 study of <span style="white-space:nowrap">SP-103</span> in subjects with acute LBP. The study design is planned as an enriched-enrollment, randomized, double-blind, <span style="white-space:nowrap">two-period,</span> cross-over, multicenter study of <span style="white-space:nowrap">SP-103</span> </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">170 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
versus placebo. The study is expected to consist of a <span style="white-space:nowrap">7-day</span> open-label <span style="white-space:nowrap">run-in</span> period where all subjects receive active treatment. Responders to treatment will then be randomized to receive blinded treatment of either <span style="white-space:nowrap">SP-103</span> or placebo. This study will inform on the pivotal Phase 3 study design to support market approval. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">In addition to a pivotal Phase 3 program, we intend to perform a <span style="white-space:nowrap">3-day</span> PK study of <span style="white-space:nowrap">SP-103,</span> an adhesion performance study of <span style="white-space:nowrap">SP-103</span> and an investigational study to evaluate the effects of heat and exercise on the PK and adhesion of <span style="white-space:nowrap">SP-103</span> to support the NDA submission. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Phase 2 trial of <span style="white-space:nowrap">SP-103</span> was initiated in the second quarter of 2022. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">SP-104</span> (4.5mg, <span style="white-space:nowrap">low-dose</span> naltrexone hydrochloride delayed-release capsules) </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Two Phase 1 trials have been completed for <span style="white-space:nowrap">SP-104</span> at investigative sites in New Zealand: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="white-space:nowrap"><span style="white-space:nowrap">SP-104-01</span></span> is a food effect and bridging pharmacokinetic study comparing <span style="white-space:nowrap">SP-104</span> to Naltrexone HCL Tablets conducted on approximately 18 healthy adult subjects. The study is designed to be an open-label, three-period, three-treatment, randomized study to characterize the PK and safety and tolerability of <span style="white-space:nowrap">SP-104</span> under fasting and fed conditions. Subjects are randomly administered a single dose of one of three treatments and followed for PK and safety for a period of time followed by a washout period before receiving one of the other treatments. All subjects receive all three treatments. The study characterize the single-dose clinical studies and ultimately the commercial label. The study also serves as a &#8220;pharmaceutical bridge&#8221; between <span style="white-space:nowrap">SP-104</span> and the commercial reference listed drug (the &#8220;RLD&#8221;) (Naltrexone HCI tablets, USP 50 mg) to support the eventual Section&#160;505(b)(2) NDA. Assuming that the rate and extent of drug exposure for <span style="white-space:nowrap">SP-104</span> will be lower than that observed for the RLD, this study allows us to rely upon the FDA&#8217;s findings of safety for the RLD instead of having to perform extensive nonclinical animal safety toxicology studies and establish an extensive clinical safety database. Our development program can focus on establishing efficiacy of <span style="white-space:nowrap">SP-104</span> in the treatment of fibromyalgia. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="white-space:nowrap"><span style="white-space:nowrap">SP-104-02</span></span> is a Phase 1 study of <span style="white-space:nowrap">SP-104</span> conducted on approximately 52 healthy human subjects. The study is designed to be a double-blind, randomized, <span style="white-space:nowrap">two-period,</span> <span style="white-space:nowrap">two-treatment</span> crossover study to evaluate the safety of <span style="white-space:nowrap">SP-104,</span> compared to immediate release naltrexone capsules. The primary purpose of the study is to test the hypothesis that, when taken at night, the delayed release of 4.5 mg Naltrexone mitigates against adverse events known for the drug and could affect patient compliance in maintaining treatment for their fibromyalgia. In a small (n=52) cross-over trial in healthy volunteers comparing <span style="white-space:nowrap">SP-104</span> (naltrexone hydrochloride delayed-release 4.5 mg) to naltrexone hydrochloride immediate release 4.5 mg (the &#8220;compared drug&#8221;), there were no serious adverse effects, no AEs leading to discontinuation, no meaningful differences in physical examinations, vital signs, or laboratory parameters between treatments, no severe AEs for either treatment. Of the 52 patients receiving at least a single injection of <span style="white-space:nowrap">SP-104,</span> there were 21 (40%) patients experiencing at least one TEAE, 14 (27%) patients experiencing at least one treatment-related TEAE, 12 (23%) patients experiencing at least one treatment-related TEAE within 72 hours after first administration of <span style="white-space:nowrap">SP-104.</span> Notable AEs of special interest were nausea and headache within 72 hours after first administration of <span style="white-space:nowrap">SP-104.</span> <span style="white-space:nowrap">SP-104</span> administered at night before bed resulted in a lower number of subjects with at least one AE (p = 0.0414), and an even lower number of subjects with at least one AE within 72 hours after the first administration of <span style="white-space:nowrap">SP-140</span> when compared to the compared drug. There was a lower number of subjects with AEs of special interest within 72 hours after administration of <span style="white-space:nowrap">SP-104</span> (n=9; 12 events) versus the compared drug (n=15; 20 events). Notable AEs of special interest observed within 72 hours after administration of the applicable drug are nausea <span style="white-space:nowrap">(SP-104:</span> n=0; the compared drug: n=3) and headache <span style="white-space:nowrap">(SP-104:</span> n=6; the compared drug: n=12). The study randomized subjects to one of two treatments followed by a washout period and then receipt of the other treatment, which allows all subjects to act as their own control. The study will support intellectual property, inform on clinical study design and contribute to safety characterization to support market applications. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">171 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We completed both studies in the second quarter of 2022. We plan to use data collected from these studies to support an Investigational New Drug application with the FDA, which is expected to enable further clinical development and initiation of a planned multi-center placebo-controlled registration trial in the field of fibromyalgia. The registration trial is designed to be a Phase 3, randomized double-blind, placebo-controlled, parallel group, multicenter study that meets the regulatory requirements of an &#8220;adequate and well-controlled&#8221; study to establish the efficacy of <span style="white-space:nowrap">SP-104</span> in the treatment of fibromyalgia. Depending on the outcomes, this registration trial alone may be efficient in supporting market approval of <span style="white-space:nowrap">SP-104</span> or as an additional Phase 3 study may be required. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_56">Medical Affairs </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Medical Affairs team includes <span style="white-space:nowrap">in-house</span> medical expertise, health economics and third-party payor support. The Medical Affairs team works with our clinical team to identify sites for clinical trials, support the investigator teams and develop publication plans for clinical and real-world ZTlido data and our product candidates. Our Medical Affairs team also works with Key Opinion Leaders, professional societies and patient advocacy groups to educate on and support the appropriate use of pain therapeutics, including topical pain products. Further, our Medical Affairs team provides our sales organization with therapeutic knowledge and product training. The Medical Affairs team and Promotional Review Committee review all promotional materials for scientific accuracy. Medical Affairs team also develops lifecycle planning and works with our clinical team to determine registration or supportive studies, oversee post-approval studies and support investigator-sponsored trials. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_57">Manufacturing and Supply Chain </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently contract with third parties for the manufacture, assembly, testing, packaging, storage and distribution of our product. Our technical team has extensive pharmaceutical development, manufacturing, analytical, quality and distribution experience and is qualified and capable of managing manufacturing and supply chain operations. Our Quality System, Standard Operating Procedures and contract manufacturing organizations (&#8220;CMOs&#8221;) comply with cGMP and regulatory requirements. We selected our CMOs for specific competencies having met our development, manufacturing, quality and the FDA regulatory requirements. These CMOs manufacture our clinical supplies and commercial batches. We currently have no plans to build our own manufacturing or distribution infrastructure. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">ZTlido </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ZTlido is a single-layer, <span style="white-space:nowrap"><span style="white-space:nowrap">drug-in-adhesive</span></span> topical delivery system comprised of an adhesive material containing 36 mg lidocaine, which is applied to a pliable nonwoven cloth backing and covered with a polyethylene terephthalate film release liner. ZTlido is commercially manufactured for us by Oishi Koseido Co., Ltd. (&#8220;Oishi&#8221;) in Japan. We have exclusive worldwide rights to Oishi&#8217;s proprietary formulation and manufacturing technologies except with respect to Japan. ZTlido is manufactured using premixing and <span style="white-space:nowrap">hot-melt</span> mixing of various excipients and lidocaine, followed by cGMP compliant coating, lining, cutting and filling processes. ZTlido is packaged as a carton of 30 topical systems, into individual child-resistant envelopes. See the section of this prospectus titled &#8220;<span style="font-style:italic">Business &#8212; Material Agreements &#8212; Itochu and Oishi Product Development Agreement</span>&#8221; and &#8220;<span style="font-style:italic">Business &#8212; Material Agreements &#8212; Itochu and Oishi Commercial Supply Agreement</span>&#8221; for additional information regarding the manufacturing and supply chain of ZTlido. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once production is complete, commercial product shipments are sent to the United States, where our exclusive third-party logistics distribution provider, Cardinal Health 105, ships them to temperature-controlled customer distribution centers, which are generally able to deliver finished product to retail pharmacies on the same day, or within 24 hours. We currently contract with multiple pharmaceutical distributors throughout the United States, including McKesson, Cardinal Health 110 and AmerisourceBergen. Distributors have agreements in place that provide us with access to large retail chains, including CVS, Walgreens, Rite Aid and Walmart, as </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">172 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
well as independent pharmacies. In addition to all order fulfillment, Cardinal Health 105 performs the following services on our behalf: customer service, credit checks, invoicing, chargebacks, distributor fee for service, government reporting, customer returns, accounts receivable, inventory control, product security (DSCSA serialization) inquiries and recall assistance. In the years ended December&#160;31, 2019, 2020, and 2021, and in the first quarter of 2022, Cardinal Health 105 was our only customer and sales to Cardinal Health 105 represented all of our net revenue for such periods. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As we continue to expand the commercialization of ZTlido, we expanded our direct distribution network to national and regional distributors and pharmacies in the second quarter of 2022. We currently hold wholesaler licenses and commenced selling directly to our main distributor customers as well as pharmacies in the second quarter of 2022. In April 2022, we discontinued our use of &#8220;title model&#8221; services provided by Cardinal Health 105, but expect that Cardinal Health 105 will continue to perform other third-party logistics services for us. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">SP-102</span> (SEMDEXA) </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">SP-102</span> is a Phase 3 sterile dexamethasone sodium phosphate injectable viscous gel drug product containing dexamethasone sodium phosphate equivalent to 10 mg dexamethasone in a <span style="white-space:nowrap">pre-filled</span> glass syringe with a 2 mL deliverable volume. <span style="white-space:nowrap">SP-102</span> also contains sodium hyaluronate, which is a novel, biocompatible, viscosity-enhancing excipient and is listed in the European Pharmacopeia. We have an exclusive supply agreement for sodium hyaluronate for <span style="white-space:nowrap">SP-102</span> from the manufacturer and supplier. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">SP-102</span> is manufactured by a single-source manufacturer, which supports the clinical development, including the completed Phase 3 clinical trial of <span style="white-space:nowrap">SP-102.</span> In March 2022, we announced final results of the Phase&#160;3 clinical trial, satisfying the primary efficacy and key secondary efficacy endpoints. The manufacturing process is proprietary and includes trade secrets. We plan to engage our existing contract manufacturer, Lifecore, for the commercial production of <span style="white-space:nowrap">SP-102,</span> if approved. We plan to use the biocompatible proprietary excipient supplied by Sanofi-Aventis U.S. LLC (&#8220;Sanofi&#8221;) sodium hyaluronate, pursuant to the Genzyme Supply Agreement, and engage Sanofi for commercial supply of dexamethasone sodium phosphate for <span style="white-space:nowrap">SP-102,</span> if approved. See the section of prospectus titled &#8220;<span style="font-style:italic">Business &#8212; Material Agreements &#8212; Genzyme Supply Agreement</span>&#8221; and &#8220;<span style="font-style:italic">Business &#8212; Material Agreements &#8212; Lifecore Master Services Agreement</span>&#8221; for additional information regarding the manufacturing and supply of the proprietary excipient and contact manufacturing of <span style="white-space:nowrap">SP-102</span> product, respectively. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">SP-103</span> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">SP-103</span> contains 5.4% lidocaine (108 mg lidocaine) and is manufactured for clinical supply by Oishi, using the same manufacturing processes as used for ZTlido. If our Phase 2 and Phase 3 trials are successful, we plan to submit the <span style="white-space:nowrap">SP-103</span> manufacturing protocols in a supplemental new drug application. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">SP-104</span> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing <span style="white-space:nowrap">SP-104,</span> a novel <span style="white-space:nowrap">low-dose,</span> naltrexone hydrochloride delayed release formulation for treating fibromyalgia. <span style="white-space:nowrap">SP-104</span> is 4.5 mg, <span style="white-space:nowrap">low-dose</span> naltrexone hydrochloride delayed release capsule product in clinical development, currently undergoing Phase 1 studies. It is manufactured by a contract manufacturer, Tulex, located in Cranbury, NJ. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_58">Competition </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our industry is highly competitive and subject to rapid and significant technological change. The large size and expanding scope of the pain management market makes it an attractive therapeutic area for biopharmaceutical businesses. Our potential competitors include pharmaceutical, biotechnology and specialty pharmaceutical companies. Many of these companies have drug pipelines, readily available capital, and established research and development organizations. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">173 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ZTlido and our product candidate, <span style="white-space:nowrap">SP-103,</span> if approved, face and will likely face competition from prescription, generic, and OTC topical lidocaine patches, including Lidoderm and generic lidocaine patches manufactured by Teva, Mylan and Par Pharmaceutical, Inc. Additionally, <span style="white-space:nowrap">SP-103,</span> if approved, will likely compete with various opioid pain medications, NSAIDs, muscle relaxants, antidepressants and anticonvulsants, particularly as we seek approval for the treatment of acute LBP. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">SP-102,</span> if approved, has the potential to become the first <span style="white-space:nowrap">FDA-approved</span> epidural steroid product for the treatment of sciatica. While there are currently no <span style="white-space:nowrap">FDA-approved</span> ESIs indicated for the treatment of sciatica, we are aware of certain <span style="white-space:nowrap">non-steroid</span> product candidates in development. <span style="white-space:nowrap">SP-102,</span> if approved, will compete with various opioid pain medications, NSAIDs, muscle relaxants, antidepressants, anticonvulsants and surgical procedures. Procedures may include nerve blocks and transcutaneous electrical nerve stimulations. We may also face indirect competition from the <span style="white-space:nowrap">off-label</span> and unapproved use of branded and generic injectable steroids. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While there are currently no formulations containing naltrexone in clinical development for the treatment of fibromyalgia, we are aware of certain <span style="white-space:nowrap">non-opioid</span> therapeutics currently in a late-stage phase 3 pipeline containing two 505(b)(2) development programs. Our product candidate, <span style="white-space:nowrap">SP-104,</span> will likely face direct competition from these candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that the market will become increasingly competitive in the future. Many of our competitors, either alone or together with their collaborative partners, operate larger research and development programs and have substantially greater financial resources than we do, as well as significantly greater experience in: developing product candidates and technologies, undertaking preclinical studies and clinical trials, obtaining the FDA and other regulatory approvals of product candidates, formulating and manufacturing product candidates and launching, marketing and selling product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additional mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in our competitors. As a result, these companies may obtain regulatory approval more rapidly than we are able to and may be more effective in selling and marketing their products as well. Smaller or early-stage companies or generic or biosimilar pharmaceutical manufacturers may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these industries. Our commercial opportunity could be reduced or eliminated if our competitors succeed in developing, acquiring or licensing on an exclusive basis, products that are more effective or less costly than any product candidate that we are currently developing or that we may develop. If approved, our product candidates will face competition from commercially available drugs as well as drugs that are in the development pipelines of our competitors and later enter the market. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Established pharmaceutical companies may invest heavily to accelerate discovery and development of novel compounds or to <span style="white-space:nowrap">in-license</span> novel compounds that could make our product candidates less competitive. Accordingly, our competitors may succeed in obtaining patent protection, receiving FDA approval or discovering, developing and commercializing medicines before we do. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The key competitive factors affecting the success of ZTlido, <span style="white-space:nowrap">SP-102,</span> <span style="white-space:nowrap">SP-103</span> and <span style="white-space:nowrap">SP-104</span> are likely to be their efficacy, durability, safety, price and the availability of reimbursement from government and other third-party payors. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">174 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_59">Material Agreements </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Itochu and Oishi Product Development Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are party to the Product Development Agreement with Oishi Koseido Co., Ltd. (&#8220;Oishi&#8221;) and Itochu Chemical Frontier Corporation (&#8220;Itochu,&#8221; and together with Oishi, the &#8220;Developers&#8221;). Pursuant to the Product Development Agreement, the Developers agreed to develop, exclusively for us, lidocaine tape products, including ZTlido and <span style="white-space:nowrap">SP-103</span> (the &#8220;Products&#8221;). Pursuant to the Product Development Agreement, we obtained the rights to market, sell and distribute the Products in global markets outside of Japan. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In carrying out the development responsibilities, the Developers agreed to, among other things, (1)&#160;source and provide the active pharmaceutical ingredient for the Products for manufacturing, (2)&#160;develop a stable final dosage form of the Products suitable for regulatory approvals, (3)&#160;conduct product development activities necessary to support the filing of applications for regulatory approvals for the Products and (4)&#160;conduct manufacturing <span style="white-space:nowrap">scale-up</span> activities and preclinical studies for the Products. We are responsible for, among other things, (a)&#160;conducting all pivotal human clinical trials for the Products, (b)&#160;completing all regulatory filings, correspondence and meetings with the FDA or other applicable governmental authorities with respect to the Products and (c)&#160;commercially launching the Products. We maintain the ultimate responsibility and decision-making control with regard to the marketing and pricing of the Products. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The parties agreed to cooperate in good faith to determine whether to seek or maintain patent protection with respect to the Products, the active pharmaceutical ingredient, any associated method of use, method of manufacturing, or any other invention that could reasonably be expected to affect the commercialization or value of the Products. The Developers have the first right to pursue patent protection for any invention by them. All parties will jointly agree on the appointment of the patent representatives in each country outside of Japan. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until the expiration or termination of the Product Development Agreement, the Developers granted us an exclusive, royalty-free, sublicensable, worldwide license (except with respect to Japan) under its current and future intellectual property rights relating to the Products and the lidocaine in such Products. As consideration for the Developers&#8217; development obligations under the Product Development Agreement, we agreed to pay a contingent quarterly royalty between 25% and 35% to the Developers based on the net quarterly profits of the Products. In the event that the net profits of any of the first four calendar quarters after the commercial launch equals a negative amount (a &#8220;Net Loss&#8221;), we are allowed to carry over such Net Loss to apply against all future calendar quarters until such Net Loss is covered, all calculated in accordance with GAAP. Under the Product Development Agreement, if our total net profits for ZTlido and <span style="white-space:nowrap">SP-103</span> are equal to or less than five percent of our net sales of ZTlido and <span style="white-space:nowrap">SP-103</span> for a period of four or more consecutive quarters, the Developers have the right to terminate the Product Development Agreement and the Commercial Supply Agreement. As of the date of this prospectus, our net profits for ZTlido and <span style="white-space:nowrap">SP-103</span> have not exceeded five percent of net sales. Accordingly, Oishi and Itochu have the right to terminate the Product Development Agreement and Commercial Supply Agreement. As of the date of this prospectus, neither Oishi nor Itochu has exercised its right of termination. Additionally, if we receive any licensing fees from any third-party sublicensees, we are obligated to pay the same proportions of such licensing fee to the Developers. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The current term of the Product Development Agreement will continue until October&#160;2, 2028, which is the 10th anniversary of the first commercial sale of ZTlido. Afterwards, the agreement will renew automatically for subsequent successive <span style="white-space:nowrap">one-year</span> renewal periods unless we or the Developers terminate it upon <span style="white-space:nowrap">six-month</span> written notice. In addition, we or the Developers may terminate the Product Development Agreement if (1)&#160;the other party is in material breach of the agreement and the breach is not curable, or if the breach is curable and the breaching party has not cured such material breach within 180 days after notice requesting to cure; (2)&#160;the FDA determines that the formulation of the Products would not be eligible for FDA approval in the absence of efficacy studies, and the Developers are unable to address the efficacy study requirements despite good faith efforts; (3)&#160;the market conditions are such that (a)&#160;our total net profits of the Products are equal to or less than five percent of our net sales of the Products for a period of four or more consecutive quarters, or (b)&#160;the Products&#8217; </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">175 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
economic viability is affected significantly as evidenced by documentation and substantial information by any external circumstances deemed detrimental to all parties as agreed to by us and the Developers, and the parties are unable to resolve the concerns under the foregoing clauses (a)&#160;and (b)&#160;after 30 days of good-faith discussion; (4)&#160;the parties fail to reach mutual agreement as to who will conduct the clinical studies and how the costs will be allocated; or (5)&#160;we or either one of the Developers are bankrupt or make assignment for the benefit of creditors. Additionally, we may terminate the Product Development Agreement if (i)&#160;any of the pivotal human clinical trials for any of the Products fail, or (ii)&#160;the FDA issues a &#8220;Refusal to File&#8221; for any of the Products&#8217; regulatory approval application and, after reasonable consultation with the Developers, we believe that it is commercially unreasonable to <span style="white-space:nowrap">re-file.</span> The Developers may terminate the Product Development Agreement if we fail to file for regulatory approval for any of the Products within three months of the date on which all required components of the regulatory approval application are received by us. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Product Development Agreement, we and the Developers have agreed, subject to certain exceptions, to indemnify each other against any third-party liabilities arising out of (1)&#160;any breach of our respective representations, warranties or obligations under the Product Development Agreement, (2)&#160;any failure by either of us to comply with all applicable laws, or (3)&#160;our respective negligence or willful misconduct. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing is a summary of the material terms of the Product Development Agreement and its amendments in the forms filed as exhibits to the registration statement of which this prospectus forms a part. You should read the form of the agreement and its amendments for a complete understanding of all of their respective terms. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Itochu and Oishi Commercial Supply Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective February&#160;16, 2017, Scilex Pharma entered into the Commercial Supply Agreement with Itochu and Oishi. Pursuant to the Itochu and Oishi Commercial Supply Agreement, Oishi agreed to manufacture, store, handle and perform quality control testing of the Products (as defined in the Product Development Agreement) at its facility in Japan. Itochu agreed to purchase Products from Oishi and handle the shipping of the Products. Both Oishi and Itochu agreed to provide us with certain technical support regarding the Products as reasonably requested by us, including but not limited to analytical test methods, method development, physical and chemical properties, and use of the Products. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Itochu and Oishi Commercial Supply Agreement, we pay per item transfer prices for ZTlido, ZTlido professional samples and ZTlido placebo samples, in each case subject to certain minimum order quantities. We are required to provide a <span style="white-space:nowrap">12-month</span> rolling purchase forecast of the estimated quantities of the Products in writing on a monthly basis. Oishi is required to promptly notify us and Itochu if it lacks the capacity to meet the forecast. All Products ordered by us will be in the form of a firm written purchase order. During the year ended December&#160;31, 2020, under the Itochu and Oishi Commercial Supply Agreement, we purchased inventory in the amount of $0.8&#160;million. During the year ended December&#160;31, 2021, we purchased inventory in the amount of approximately $5.7&#160;million. The significant increase in inventory purchased was largely due to an excess of in stock inventory in fiscal year 2020 that was sold throughout fiscal year 2020 and the early part of fiscal year 2021. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Itochu and Oishi Commercial Supply Agreement will remain in effect until the termination of the Product Development Agreement. Additionally, either we or the Developers may terminate the Itochu and Oishi Commercial Supply Agreement (1)&#160;if the other party is in material breach of the agreement and the breach is not substantially cured within 60 days after receiving written notice specifying the nature of the breach, or (2)&#160;in the event of any of the parties&#8217; insolvency, bankruptcy or assignment for the benefit of creditors. Any third-party claim arising out of a breach by a party of any representation, warranty or obligation under the Itochu and Oishi Commercial Supply Agreement, or a failure by a party to comply with applicable laws, or the negligence or willful misconduct of a party, will be subject to and governed by the Product Development Agreement. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">176 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing is a summary of the material terms of the Itochu and Oishi Commercial Supply Agreement and its amendments in the forms filed as exhibits to the registration statement of which this prospectus forms a part. You should read the form of the agreement and its amendments for a complete understanding of all of their respective terms. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Genzyme Supply Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&#160;17, 2015, through our wholly owned subsidiary, Semnur, we entered into the Genzyme Supply Agreement with Genzyme, an affiliate of Sanofi-Aventis U.S. LLC. Pursuant to the Genzyme Supply Agreement, Genzyme agreed to produce and provide sodium hyaluronate, one of the excipients for SEMDEXA, and we agreed to purchase 100% of our clinical and commercial requirements for sodium hyaluronate in specified territories, including the United States and all countries of the European Union (&#8220;EU), exclusively from Genzyme. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Genzyme Supply Agreement, we agreed to pay a per gram price for clinical supply of sodium hyaluronate. For commercial supply, the price will depend on the quantity of order. The pricing for both the clinical supply and the commercial supply of sodium hyaluronate is subject to readjustments each year on January&#160;1, provided that in no case will the price be increased by more than 5% each year. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Genzyme Supply Agreement provides for a five year exclusivity period in favor of us and will remain in effect until 10 years after the effective date unless earlier terminated in accordance with the terms thereof, with automatic renewal for additional five year periods (on an exclusive basis), if the respective requirements for exclusivity are met by us as set forth therein, and for additional <span style="white-space:nowrap">two-year</span> periods thereafter unless either party gives notice of a termination not less than 18 months prior to the expiration of the then-current term. Either party may terminate the Genzyme Supply Agreement if (1)&#160;the other party is in material breach of the agreement and fails to cure within 30 days, or (2)&#160;if the development of SEMDEXA is ceased or we do not file for regulatory approval for SEMDEXA by January&#160;1, 2020. Additionally, Genzyme may terminate the Genzyme Supply Agreement if it decides to discontinue manufacturing the product at its facility for economic or strategic reasons and provides us with 24 months&#8217; notice. We did not file for regulatory approval for SEMDEXA by January&#160;1, 2020 and we are only aware of a limited number of suppliers of the excipient. In accordance with Genzyme&#8217;s right terminate the Genzyme Supply Agreement if it decides to discontinue manufacturing the product at its facility for economic or strategic reasons, Genzyme has notified us of its intention to terminate the Genzyme Supply Agreement, effective as of May&#160;31, 2024. Although we are currently in the process of identifying and certifying new suppliers to fulfill our clinical and commercial supply requirements for sodium hyaluronate we may not be able to find an alternative supplier of sodium hyaluronate on commercially reasonable terms. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Genzyme Supply Agreement, we and Genzyme have agreed, subject to certain exceptions, to indemnify each other against any third-party liabilities arising out of (1)&#160;any material breach of our respective representations, warranties and obligations thereunder, or (2)&#160;our respective gross negligence or willful misconduct. In addition, we have agreed to indemnify Genzyme against any third-party liabilities arising out of the development, manufacture, storage, handling, use, marketing, distribution, offer for sale, sale, promotion or other commercialization of sodium hyaluronate by us. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing is a summary of the material terms of the Genzyme Supply Agreement in the form filed as an exhibit to the registration statement of which this prospectus forms a part. You should read the form of the agreement for a complete understanding of all of its terms. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Lifecore Master Services Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&#160;27, 2017, through our wholly owned subsidiary, Semnur, we entered into the Lifecore Master Services Agreement. Pursuant to the Lifecore Master Services Agreement, Lifecore is responsible for clinical trial material manufacturing and development services for SEMDEXA as set forth in each separate statement of work (each a &#8220;Lifecore Statement of Work&#8221;). </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">177 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The parties entered into a Lifecore Statement of Work on January&#160;27, 2017, pursuant to which Lifecore agreed to provide, among other things, (1)&#160;project management support, (2)&#160;development services, (3)&#160;clinical trial materials, and (4)&#160;stability studies. We paid Lifecore for the development and clinical trial material manufacturing services, which was invoiced at the completion of each service. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the purposes of Lifecore&#8217;s development and clinical trial material manufacturing obligations, we granted Lifecore a nonexclusive, worldwide and royalty-free license under our owned or controlled intellectual property rights necessary to manufacture SEMDEXA, without additional right, title or interest in our intellectual property. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Lifecore Master Services Agreement expires on December&#160;31, 2022, unless the parties negotiate and execute a renewal of the agreement. Either party may terminate the Lifecore Master Services Agreement (1)&#160;if the other party is in material breach of the agreement and fails to cure such breach within 30 days of written notice, subject to certain exceptions; or (2)&#160;immediately upon written notice to the other party if the other party (a)&#160;becomes insolvent, (b)&#160;ceases to function as a going concern, (c)&#160;is convicted of or pleads guilty to a charge of violating any law relating to either party&#8217;s business, or (d)&#160;engages in any act which materially impairs goodwill associated with SEMDEXA or materially impairs the terminating party&#8217;s trademark or trade name. In addition, Lifecore may terminate the agreement if (i)&#160;we fail to pay past due invoices upon 30 days&#8217; written notice, or (ii)&#160;we reject or fail to respond to a major change proposed by Lifecore that does not change Semnur&#8217;s written and approved acceptance criteria in its product specifications. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Lifecore Master Services Agreement contains customary reciprocal indemnification obligations for Lifecore and Semnur. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing is a summary of the material terms of the Lifecore Master Services Agreement and the amendment thereto in the forms filed as exhibits to the registration statement of which this prospectus forms a part. You should read the form of the agreement and its amendment for a complete understanding of all of their respective terms. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Semnur Merger Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&#160;18, 2019, Legacy Scilex acquired Semnur pursuant to an Agreement and Plan of Merger with Semnur (as amended, the &#8220;Semnur Merger Agreement&#8221;), Sigma Merger Sub, Inc., a wholly owned subsidiary of Legacy Scilex (&#8220;Sigma Merger Sub&#8221;), Fortis Advisors LLC, solely as representative of the holders of Semnur equity (the &#8220;Semnur Equityholders&#8217; Representative&#8221;), and for limited purposes, Sorrento. Pursuant to the Semnur Merger Agreement, Sigma Merger Sub merged with and into Semnur (the &#8220;Semnur Merger&#8221;), with Semnur surviving as Legacy Scilex&#8217;s wholly owned subsidiary. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with transactions contemplated by the Semnur Merger Agreement, Sorrento and each of the other holders of outstanding shares of capital stock of Scilex Pharma, contributed each share of Scilex Pharma capital stock it owned to Legacy Scilex in exchange for one share of Legacy Scilex Common Stock (the &#8220;Contribution&#8221;). As a result of the Contribution, and prior to the consummation of the Semnur Merger, Scilex Pharma became a wholly owned subsidiary of Legacy Scilex and Sorrento became the owner of approximately 77% of Legacy Scilex&#8217;s issued and outstanding capital stock. As a result of the Semnur Merger, Scilex Pharma and Semnur became wholly owned subsidiaries of Legacy Scilex. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the closing of the Semnur Merger, Legacy Scilex issued to the holders of Semnur&#8217;s capital stock (the &#8220;Semnur Equityholders&#8221;) and options to purchase Semnur&#8217;s common stock, upfront consideration with a value of $70.0&#160;million. The upfront consideration was comprised of the following: (i)&#160;a cash payment of approximately $15.0&#160;million, and (ii) $55.0&#160;million of shares of Legacy Scilex Common Stock (47,039,315 shares issued and 352,972 shares issuable, valued at $1.16 per share) (the &#8220;Stock Consideration&#8221;). A portion of the cash consideration otherwise payable to the Semnur Equityholders was set aside for expenses incurred by the Semnur Equityholders&#8217; Representative, and 4,749,095 shares of Legacy Scilex Common Stock otherwise issuable to </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">178 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Semnur Equityholders were placed in escrow with a third party as security for the indemnification obligations of the Semnur Equityholders under the Semnur Merger Agreement. The expense fund and escrow have since been released per the terms of the escrow agreement. The Semnur Equityholders that received the Stock Consideration were required to sign an exchange and registration rights agreement with Legacy Scilex, which is further described below. Following the issuance of the Stock Consideration, Sorrento ownership in Legacy Scilex was diluted to approximately 58% of Legacy Scilex&#8217;s issued and outstanding capital stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Semnur Merger Agreement, and upon the terms and subject to the conditions contained therein, Legacy Scilex also agreed to pay the Semnur Equityholders up to $280.0&#160;million in aggregate contingent cash consideration based on the achievement of certain milestones, comprised of a $40.0&#160;million payment that will be due upon obtaining the first approval of a NDA of a Semnur product by the FDA and additional payments that will be due upon the achievement of certain amounts of net sales of Semnur products, as follows: (i)&#160;a $20.0&#160;million payment upon the achievement of $100.0&#160;million in cumulative net sales of a Semnur product, (ii)&#160;a $20.0&#160;million payment upon the achievement of $250.0&#160;million in cumulative net sales of a Semnur product, (iii)&#160;a $50.0&#160;million payment upon the achievement of $500.0&#160;million in cumulative net sales of a Semnur product, and (iv)&#160;a $150.0&#160;million payment upon the achievement of $750.0&#160;million in cumulative net sales of a Semnur product. As of the date of this prospectus, none of the foregoing payments have been triggered. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Semnur Merger Agreement also provided that following the consummation of Legacy Scilex&#8217;s first bona fide equity financing with one or more third-party financing sources on an arms&#8217; length basis with gross proceeds to Legacy Scilex of at least $40.0&#160;million, certain of the former Semnur optionholders will be paid cash in lieu of: (i)&#160;the 352,972 shares of Legacy Scilex Common Stock otherwise issuable to such former Semnur optionholders pursuant to the Semnur Merger Agreement, and (ii)&#160;any shares that would otherwise be issued to such former Semnur optionholders upon release of shares held in escrow pursuant to the Semnur Merger Agreement, with such shares in each case valued at $1.16 per share. The Semnur optionholders subsequently agreed, under the terms of the Exchange Agreement (as defined and described below) to forego the foregoing right to any such payment in exchange for the right to participate in the Share Exchange (as defined below). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2019, the Semnur Equityholders that received the Stock Consideration were required to sign an Exchange and Registration Rights Agreement with Legacy Scilex (as amended, the &#8220;Exchange Agreement&#8221;). Pursuant to the Exchange Agreement, and upon the terms and subject to the conditions contained therein, if within 18 months following the closing of the Semnur Merger, 100% of the outstanding equity of Legacy Scilex had not been acquired by a third party or Legacy Scilex had not entered into a definitive agreement with respect to, or otherwise consummated, a firmly underwritten offering of Legacy Scilex capital stock on a major stock exchange that met certain requirements, then holders of the Stock Consideration could collectively elect to exchange, during the <span style="white-space:nowrap">60-day</span> period commencing the date that was the 18 month anniversary of the closing of the Semnur Merger (the &#8220;Share Exchange&#8221;), the Stock Consideration for shares of Sorrento&#8217;s common stock with a value of $55.0&#160;million based on a price per share of Sorrento&#8217;s common stock equal to the greater of (a)&#160;the <span style="white-space:nowrap">30-day</span> trailing volume weighted average price of one share of Sorrento&#8217;s common stock as reported on Nasdaq as of the consummation of the Share Exchange and (b) $5.55 (subject to adjustment for any stock dividend, stock split, stock combination, reclassification or similar transaction) (the &#8220;Exchange Price&#8221;). Pursuant to an amendment to the Exchange Agreement entered into by Sorrento and the Semnur Equityholders&#8217; Representative on September&#160;28, 2020, on October&#160;9, 2020, Sorrento paid $55.0&#160;million in cash to the Semnur Equityholders in lieu of issuing $55.0&#160;million of shares of Sorrento&#8217;s common stock at the Exchange Price. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing is a summary of the material terms of the Semnur Merger Agreement (including the amendment thereto) in the forms filed as exhibits to the registration statement of which this prospectus forms a part. You should read the Semnur Merger Agreement (including the amendment thereto) for a complete understanding of all of their respective terms. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">179 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Aardvark Asset Purchase Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2021, Sorrento entered into an asset purchase agreement (the &#8220;Aardvark Asset Purchase Agreement&#8221;) with Aardvark Therapeutics, Inc. (&#8220;Aardvark&#8221;), pursuant to which, among other things, Sorrento acquired Aardvark&#8217;s Delayed Burst Release Low Dose Naltrexone <span style="white-space:nowrap">(DBR-LDN)</span> asset and intellectual property rights, for the treatment of chronic pain, fibromyalgia and chronic post-COVID syndrome (collectively, the <span style="white-space:nowrap">&#8220;SP-104</span> Assets&#8221;), which includes a Statement of Work dated November&#160;18, 2020 (the &#8220;Tulex Statement of Work&#8221;), pursuant to which Tulex agreed to, among other things, develop, test and manufacture clinical supplies of <span style="white-space:nowrap">SP-104</span> for Sorrento. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subsequent to the acquisition, Sorrento designated Legacy Scilex to lead all development efforts related to <span style="white-space:nowrap">SP-104</span> and on May&#160;12, 2022, Legacy Scilex and Sorrento entered into a bill of sale and assignment and assumption agreement (the &#8220;Bill of Sale&#8221;), pursuant to which Sorrento sold, conveyed, assigned and transferred to Legacy Scilex all of its rights, title and interest in and to the <span style="white-space:nowrap">SP-104</span> Assets (including PCT/US2021/053645 and all patents and patent applications that claim priority rights thereto) and Legacy Scilex assumed all of Sorrento&#8217;s rights, liabilities and obligations under the Aardvark Asset Purchase Agreement (the <span style="white-space:nowrap">&#8220;SP-104</span> Acquisition&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As consideration for the <span style="white-space:nowrap">SP-104</span> Acquisition, Legacy Scilex issued a promissory note in the aggregate principal amount of $5,000,000 to Sorrento (the &#8220;Promissory Note&#8221;). The Promissory Note matures seven years from the date of issuance and bears interest at the rate equal to the lesser of (a) 2.66% simple interest per annum and (b)&#160;the maximum interest rate permitted under law. The Promissory Note is payable in cash, shares of Common Stock (any shares so issued, the &#8220;Consideration Shares&#8221;) or any combination thereof, at Legacy Scilex&#8217;s sole discretion, and may be prepaid in whole or in part at any time without penalty. Legacy Scilex also agreed to file with the SEC, a resale registration statement, relating to the resale by Sorrento of any Consideration Shares that may be issued to Sorrento, within 60 days of the issuance of such Consideration Shares. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As the successor to the Aardvark Asset Purchase Agreement, Legacy Scilex is obligated to pay Aardvark (i) $3,000,000, upon initial approval by the FDA of a new drug application for the LDN Formulation (as defined in the Aardvark Asset Purchase Agreement) (which amount may be paid in shares of Common Stock or cash, in Legacy Scilex&#8217;s sole discretion) (the &#8220;Development Milestone Payment&#8221;) and (ii) $20,000,000, in cash, upon achievement of certain net sales by Legacy Scilex of a commercial product that uses the LDN Formulation (the &#8220;Commercial Product&#8221;). Legacy Scilex will also pay Aardvark certain royalties in the single digits based on percentages of annual net sales by Legacy Scilex of a commercial product that uses the LDN Formulation. The royalty percentage is subject to reduction in certain circumstances. Royalties are due for so long as Commercial Product is covered by a valid patent in the country of sale or for ten years following the first commercial sale of the Commercial Product, whichever is longer. As of the date of this prospectus none of the foregoing payments have been triggered. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with its acquisition of the <span style="white-space:nowrap">SP-104</span> Assets, Legacy Scilex has agreed that if it issues any shares of Common Stock in respect of the Development Milestone Payment, Legacy Scilex will prepare and file one or more registration statements with the SEC for the purpose of registering for resale such shares and is required to file such registration statement with the SEC within 60 days following the date on which any such shares are issued. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Tien-Li</span> Lee, MD, a member of our Board, is the founder, chief executive officer and a member of the board of directors of Aardvark. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing is a summary of the material terms of the Aardvark Asset Purchase Agreement, Bill of Sale and Promissory Note in the forms filed as exhibits to the registration statement of which this prospectus forms a part. You should read the forms of these agreements for a complete understanding of all of their respective terms. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">180 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Tulex Master Services Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As described above, in connection with the <span style="white-space:nowrap">SP-104</span> Acquisition, Legacy Scilex acquired the Tulex Statement of Work, pursuant to which Tulex, among other things, develops, tests and manufactures clinical supplies of <span style="white-space:nowrap">SP-104</span> for Legacy Scilex. The Tulex Statement of Work is governed by the terms of a master services agreement (the &#8220;Tulex Master Services Agreement&#8221;). The Tulex Master Services Agreement was novated to Legacy Scilex on June&#160;15, 2022 and will remain in effect until five years after the effective date, unless terminated early by either party. Either party may terminate the Tulex Master Services Agreement or a Tulex Statement of Work by written notice (1)&#160;if the other party is in material breach of the agreement or a Tulex Statement of Work and fails to cure such breach within 15 days after receipt of notice of such breach (or such other time period expressly stated in the applicable Tulex Statement of Work) or (2)&#160;in the event of the other party&#8217;s insolvency, bankruptcy, reorganization, liquidation or receivership, or a failure to remove any insolvency, bankruptcy, reorganization, liquidation or receivership proceedings within ten days from the date of institution of such proceedings. In addition, we may terminate the agreement or any Tulex Statement of Work (1)&#160;without cause upon 30 days prior written notice to Tulex or (2)&#160;immediately upon written notice in the event Tulex is dissolved or undergoes a change in control. A termination or expiration of a single Tulex Statement of Work will not cause the automatic termination of the agreement or of any other Tulex Statement of Work. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each party under the Tulex Master Services Agreement agreed to indemnify the other party, its affiliates and each of their respective officers, directors, employees, contractors and agents against any third-party liabilities arising out of (1)&#160;such party&#8217;s breach of the Tulex Master Services Agreement or a Tulex Statement of Work or (2)&#160;the negligence or willful misconduct on the part of such party, its officers, directors, employees, agents or other representatives in connection with the Tulex Master Services Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing is a summary of the material terms of the Tulex Master Services Agreement in the form filed as an exhibit to the registration statement of which this prospectus forms a part. You should read the form of the agreement for a complete understanding of all of its terms. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Shah Investor LP Assignment Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&#160;6, 2013, through Semnur, we entered into an Assignment Agreement with Shah Investor LP (&#8220;Shah Investor&#8221;). Mahendra Shah, Ph.D., who served on our board of directors from March 2019 to October 2020, is the managing partner of Shah Investor. Pursuant to the Assignment Agreement, Shah Investor assigned to us certain intellectual property related to pharmaceutical compositions of corticosteroids (the &#8220;Assigned IP&#8221;). As consideration for the Assigned IP, we agreed to pay a contingent quarterly royalty in the <span style="white-space:nowrap">low-single</span> digits to Shah Investor based on the quarterly net sales of any pharmaceutical formulations for local delivery of steroids by injection developed utilizing the Assigned IP (a &#8220;Royalty Product&#8221;). We expect that SEMDEXA, if approved, will constitute a Royalty Product. The royalty percentage is subject to reduction in certain circumstances. Royalties are due for so long as a Royalty Product is covered by a valid patent in the country of sale or for ten years following the first commercial sale of the first Royalty Product in the United States, whichever is longer. We also agreed to use commercially reasonable efforts to maximize the scope and coverage of the patents contained in the Assigned IP. As of the date of this prospectus, no royalty payments have been made as we have not yet commercialized any applicable products and therefore such payments have not been triggered. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Assignment Agreement will remain in effect on a <span style="white-space:nowrap"><span style="white-space:nowrap">country-by-country</span></span> and <span style="white-space:nowrap"><span style="white-space:nowrap">product-by-product</span></span> basis until royalties are no longer due on any Royalty Product. Either party may terminate the Assignment Agreement upon sixty days&#8217; prior written notice, in the event the other party seeks to avoid a provision of the Assignment Agreement by asserting that such provision is invalid, illegal or otherwise unenforceable, unless such assertion is eliminated and the effect of such assertion cured within such sixty day period. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing is a summary of the material terms of the Assignment Agreement in the form filed as an exhibit to the registration statement of which this prospectus forms a part. You should read the form of the agreement for a complete understanding of all of its terms. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">181 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Romeg License and Commercialization Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective June&#160;14, 2022, we entered into a License and Commercialization Agreement (the &#8220;Romeg Agreement&#8221;) with RxOmeg Therapeutics, LLC (a/k/a Romeg Therapeutics, Inc.). Pursuant to the Romeg Agreement, Romeg granted to us (1)&#160;the right to manufacture, promote, market, distribute and sell the Licensed Products (as defined below) in the United States and (2)&#160;an exclusive, transferable license to use the trademark &#8220;GLOPERBA&#8221;. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Romeg Agreement, among other things, Romeg granted us (1)&#160;a transferable license, with the right to sublicense, under the patents and <span style="white-space:nowrap">know-how</span> specified therein to (a)&#160;commercialize the pharmaceutical product comprising liquid formulations of colchicine for the prophylactic treatment of gout in adult humans (the &#8220;Initial Licensed Product&#8221;) in the United States (including its territories) (the &#8220;Territory&#8221;), (b) develop other products comprising the Initial Licensed Product as an active pharmaceutical ingredient (together with the Initial Licensed Product, the &#8220;Licensed Products&#8221;) and commercialize any such products and (c)&#160;manufacture Licensed Products anywhere in the world, solely for commercialization in the Territory; and (2)&#160;an exclusive, transferable license, with right to sublicense, to use the trademark &#8220;GLOPERBA&#8221; and logos, designs, translations, and modifications thereof in connection with the commercialization of the Initial Licensed Product solely in the Territory. The license to <span style="white-space:nowrap">know-how</span> is exclusive for purposes of developing and commercializing Licensed Products in the Territory during the royalty term, but is otherwise <span style="white-space:nowrap">non-exclusive.</span> The license to patents is exclusive for purposes of developing and commercializing Licensed Products in the Territory until July&#160;1, 2027 and, thereafter, is <span style="white-space:nowrap">co-exclusive</span> with Granules Pharmaceuticals, Inc. for the royalty term for such purposes. The royalty term begins on the date of the agreement and ends on the later of (i)&#160;expiration of the last to expire of the patents that covers the manufacture or commercialization of the Licensed Products in the Territory or (ii)&#160;the tenth anniversary of the date of the Romeg Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As consideration for the license under the Romeg Agreement, we agreed to pay Romeg (1)&#160;an <span style="white-space:nowrap">up-front</span> payment of $2.0&#160;million, (2)&#160;upon our achievement of certain net sales milestones, certain milestone payments in the aggregate amount of up to $13.0&#160;million and (3)&#160;certain royalties, at rates that do not exceed ten percent, based on annual net sales of the Licensed Products by us during the royalty term. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Romeg Agreement will remain in effect until it is terminated in accordance with the terms thereof. We may terminate the Romeg Agreement (1)&#160;upon written notice to Romeg, if we elect (or are required) to withdraw the Initial Licensed Product from the market as a result of serious adverse reactions from use of such product, which termination will be effective 30 days following the date of such notice or (2)&#160;at any time, without cause, upon written notice to Romeg, which termination will be effective 120 days following the date of such notice, provided that a termination fee of up to $2.0&#160;million shall be paid to Romeg depending on when during the 10&#160;year period following the date of the agreement any such termination notice set forth in the immediately preceding clause (2)&#160;has been provided. Romeg may terminate the Romeg Agreement (a)&#160;upon notice to us, if we fail to timely pay any milestone payment, percentage royalties or minimum quarterly royalties or fail to timely deliver the requisite quarterly report, which termination will be effective 30 days after the date of such notice, unless we has made such payment in full or delivered such quarterly report within such 30 day period; (b)&#160;immediately, if we challenge the licensed patents under any court action or proceeding or before any patent office or assist any third party to conduct any of these activities; or (c)&#160;by written notice to us if sales of Licensed Products do not commence or continue within specified periods agreed to by the parties. In addition, either party may terminate the Romeg Agreement (1)&#160;in the event the other party materially breaches the agreement, unless the breaching party has cured any such breach within 60 days after any notice thereof was provided or (2)&#160;in the event the other party (a)&#160;files in any court or agency a petition in bankruptcy or insolvency, (b)&#160;is served with an involuntary petition against it in any insolvency proceeding and such involuntary petition has not been stayed or dismissed within 90 days after its filing, or (c)&#160;makes an assignment of substantially all of its assets for the benefit of its creditors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Romeg Agreement contains customary reciprocal indemnification obligations for Romeg and us. Additionally, we agreed, subject to certain exceptions, to indemnify Romeg against any loss arising out of the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">182 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
manufacture or commercialization of any Licensed Product by or on behalf of us or our affiliates, marketing partners, sublicensees or subcontractors on or after the date of the license. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing is a summary of the material terms of the Romeg Agreement, which is in the form filed as an exhibit to the registration statement of which this prospectus forms a part. You should read the form of the agreement for a complete understanding of all of its terms. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_60">Intellectual Property </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success depends in part on our ability to obtain and maintain proprietary protection for our product candidates, technology and <span style="white-space:nowrap">know-how,</span> to operate without infringing the proprietary rights of others and to prevent others from infringing our proprietary rights. Our policy is to seek to protect our proprietary position by, among other methods, pursuing and obtaining patent protection in the United States and in jurisdictions outside of the United States related to our novel adhesion and delivery technology, inventions, improvements and product candidates that are important to the development and implementation of our business. Our patent portfolio is intended to cover our product candidates, their methods of use and processes for their manufacture, and any other inventions that are commercially important to our business. We also rely on trade secret protection of our confidential information and <span style="white-space:nowrap">know-how</span> relating to our novel adhesion and delivery technology, platforms and product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, patents are granted a term of 20 years from the earliest claimed <span style="white-space:nowrap">non-provisional</span> filing date. In certain instances, patent term can be adjusted to recapture a portion of delay by the PTO in examining the patent application or extended to account for term effectively lost as a result of the FDA regulatory review period, or both. We cannot provide any assurance that any patents will be issued from our pending or future applications or that any patents will adequately protect our product or product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our patent portfolio, consisting of owned and/or licensed IP as of November&#160;23, 2022 contains approximately sixteen issued and unexpired U.S. patents, six pending U.S. patent applications, and one pending Patent Cooperation Treaty (PCT) application. Our portfolio also includes certain foreign counterparts of these patents and patent applications including Australia, Brazil, Canada, China, Hong Kong, India, Indonesia, Israel, Japan, Korea, Malaysia, Mexico, New Zealand, Panama, Peru, Philippines, Russian Federation, Singapore, South Africa, Taiwan, Ukraine, and certain countries within the European Patent Convention. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to ZTlido and <span style="white-space:nowrap">SP-103,</span> our patents and patent applications cover compositions and methods of treatment. With respect to our product candidate SEMDEXA, our patents and patent applications include formulations and methods of treatment. The patents are U.S. Pat. Nos. 10,500,284, 10,117,938, and 11,020,485, all of which expire in 2036. With respect to <span style="white-space:nowrap">SP-104,</span> our pending Patent Cooperation Treaty application is WO 2022/076470 (and all patents and patent applications that claim priority rights thereto), which covers oral delayed burst formulations of <span style="white-space:nowrap">low-dose</span> naloxone or naltrexone and related methods of treatment. We continue to seek to maximize the scope of our patent protection for all our programs. We have five issued U.S. patents and two pending U.S. patent applications relating to lidocaine topical system compositions and methods of treating pain with lidocaine topical system compositions. The patents are U.S. Pat. Nos. 9,283,174, 9,925,264, 9,931,403, 10,765,749, 10,765,640 and 11,278,623 all of which expire in 2031. Related to GLOPERBA, our licensed patents include U.S. Pat. Nos. 9,907,751, 10,226,423, 10,383,820, and 10,383,821, which relate to liquid colchicine formulations for oral administration and associated methods of use. U.S. Pat. No.&#160;10,226,423 expires in 2037. The remaining patents related to GLOPERBA expire in 2036. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that we have certain <span style="white-space:nowrap">know-how</span> and trade secrets relating to our technology and product candidates. We rely on trade secrets to protect certain aspects of our technology related to our current and future product candidates. However, trade secrets can be difficult to protect. We seek to protect our trade secrets, in part, by entering into confidentiality agreements with our employees, consultants, scientific advisors, service providers, and contractors. We also seek to preserve the integrity and confidentiality of our data and trade secrets </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">183 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
by maintaining physical security of our premises and physical and electronic security of our information technology systems. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Trademarks, Trade Secrets and Other Proprietary Information </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We file trademark applications and pursue registrations in the United States and abroad when appropriate. We own registered U.S. trademarks for the marks &#8220;SCILEX,&#8221; &#8220;ZTlido&#8221; and &#8220;RESPONSIBLE BY DESIGN.&#8221; We also own pending trademark applications for &#8220;SEMNUR PHARMACEUTICALS&#8221; and &#8220;SEMDEXA&#8221; in the United States. We also license the GLOPERBA trademark as discussed in relation to the Romeg Agreement described above. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also depend upon the skills, knowledge and experience of our scientific and technical personnel, as well as that of our advisors, consultants and other contractors. To help protect our proprietary <span style="white-space:nowrap">know-how,</span> we rely on trade secret protection and confidentiality agreements to protect our interests. Our policy is to require each of our employees, consultants and advisors to execute a confidentiality and inventions assignment agreement before beginning their employment, consulting or advisory relationship with us. The agreements generally provide that the individual must keep confidential and not disclose to other parties any confidential information developed or learned by the individual during the course of the individual&#8217;s relationship with us except in limited circumstances. These agreements generally also provide that we will own all inventions conceived by the individual in the course of rendering services to us. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SEMDEXA benefits from our substantial intellectual property portfolio and other technical barriers to entry for potential competitors. Further, we are a party to an exclusive supply agreement for a proprietary biocompatible excipient with no generic equivalent. Our complex manufacturing process, specialized equipment and <span style="white-space:nowrap">know-how</span> for sterile viscous product candidates are also key to our competitive edge. We believe that our competitors will be required to conduct lengthy and costly preclinical and clinical trials to establish products with comparable safety and efficacy to SEMDEXA. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_61">Government Regulation and Product Approval </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Government authorities in the United States at the federal, state and local levels, and in other countries and jurisdictions, extensively regulate, among other things, the research, development, testing, manufacture, pricing, reimbursement, sales, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of products such as those we are marketing and developing. <span style="white-space:nowrap">SP-102,</span> <span style="white-space:nowrap">SP-103,</span> <span style="white-space:nowrap">SP-104</span> and any other product candidate that we develop must be approved by the FDA or otherwise authorized for marketing before they may be legally marketed in the United States and by the corresponding foreign regulatory agencies before they may be legally marketed in foreign countries. The processes for obtaining marketing approvals, along with subsequent compliance with applicable statutes and regulations and other regulatory authorities, require the expenditure of substantial time and financial resources. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">U.S. Drug Development Process </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, the FDA regulates drugs under the FDCA and implementing regulations. Drugs are also subject to other federal, state and local statutes and regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable requirements at any time during the product development process, approval process or after approval, may subject an applicant or its products to a variety of administrative or judicial sanctions, such as inspection scrutiny, the FDA&#8217;s refusal to approve pending applications, withdrawal of an approval, imposition of a clinical hold, issuance of warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement of profits or civil or </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">184 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
criminal penalties. The process required by the FDA before a drug may be marketed in the United States generally involves the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">completion of preclinical laboratory tests, animal studies and formulation studies according to Good Laboratory Practices (&#8220;GLPs&#8221;) or other applicable regulations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">submission to the FDA of an Investigational New Drug Application (&#8220;IND&#8221;), which must become effective before human clinical trials may begin; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">approval by an IRB covering each clinical site before each trial may be initiated; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">performance of adequate and well-controlled human clinical trials according to the laws and regulations pertaining to the conduct of human clinical trials, collectively referred to as GCP requirements to establish the safety and efficacy of the proposed drug for its intended use; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">submission to the FDA of an NDA or other marketing application (collectively, an &#8220;NDA&#8221;), for a proposed new drug, including its specific formulation and labeling; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">satisfactory completion of an FDA advisory committee review, if applicable; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">satisfactory completion of an FDA inspection of the manufacturing facility or facilities where the drug is produced to assess compliance with the FDA&#8217;s cGMP requirements to assure that the facilities, methods and controls are adequate to preserve the drug&#8217;s identity, strength, quality and purity; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">potential FDA audit of the preclinical study and clinical trial sites that generated the data in support of the NDA; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">FDA review and approval of the NDA prior to any commercial marketing, sale or shipment of the drug. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before testing novel compounds with potential therapeutic value in humans, the drug candidate enters the preclinical testing stage, also referred to as preclinical studies. Preclinical studies include laboratory evaluations of product chemistry, toxicity and formulation, as well as animal studies to assess the potential safety and activity of the drug candidate. The conduct of the preclinical studies must comply with federal laws and requirements including GLPs. The IND sponsor must submit the results of the preclinical studies, together with manufacturing information, analytical data, and any available clinical data or literature, to the FDA as part of the IND. The sponsor will also include a protocol detailing, among other things, the objectives of the first phase of the clinical trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated, if the first phase lends itself to an efficacy evaluation. Some preclinical studies may continue even after the IND is submitted. The IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to one or more proposed clinical trials and places the trial on a clinical hold within that <span style="white-space:nowrap">30-day</span> time period. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. The FDA may also impose clinical holds on a drug candidate at any time before or during clinical trials due to safety concerns, <span style="white-space:nowrap">non-compliance,</span> or for additional reasons. Accordingly, we cannot be sure that submission of an IND will result in the FDA allowing clinical trials to begin, or that, once begun, issues will not arise that suspend or terminate such trial. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical trials involve the administration of the drug candidate to healthy subjects or patients with the target disease under the supervision of qualified investigators, generally physicians not employed by the trial sponsor. Clinical trials are conducted under written study protocols detailing, among other things, the objectives of the clinical trial, subject selection and exclusion criteria, dosing procedures, and the parameters to be used to collect data and to monitor subject safety. Each protocol must be submitted to the FDA as part of the IND, and timely safety reports must be submitted to the FDA and investigators for suspected adverse reactions that are serious and unexpected. Clinical trials must be conducted in accordance with applicable statutes, the FDA&#8217;s regulations and GCP requirements. Further, each clinical trial must be reviewed and approved by an IRB at or servicing each institution at which the clinical trial will be conducted. An IRB is charged with protecting the welfare and rights of trial participants and considers such items as whether the risks to individuals participating in the clinical trials </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">185 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the informed consent form that must be provided to each clinical trial subject or his or her legal representative and must monitor the clinical trial until it is completed. In some instances, additional oversight boards, such as a data safety monitoring board, are required to evaluate interim data and determine whether a study should continue or be modified or terminated. Information about many clinical trials is required to be publicly reported on www.ClinicalTrials.gov or similar databases. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Human clinical trials are typically conducted in three sequential phases that may overlap or be combined: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"><span style="font-style:italic">Phase 1</span></span>. The drug is initially introduced into healthy human subjects and tested for safety, dosage tolerance, absorption, metabolism, distribution and excretion and, if possible, to gain an early indication of its effectiveness. In the case of some products for severe or life-threatening diseases, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing may be conducted only in patients having the specific disease. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"><span style="font-style:italic">Phase 2</span></span>. The drug is evaluated in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance, optimal dosage and dosing schedule for patients having the specific disease. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"><span style="font-style:italic">Phase 3</span></span>. The drug is administered to an expanded patient population in adequate and well-controlled clinical trials to generate sufficient data to statistically confirm the safety and efficacy of the product for potential approval, to establish the overall risk-benefit profile of the product, and to provide adequate information for the labeling of the product. Generally, at least two adequate and well-controlled Phase 3 clinical trials are required by the FDA for approval of an NDA. In some cases, the FDA may approve a drug based on the results of a single adequate and well-controlled Phase 3 trial for excellent design and which provided highly reliable and statistically strong evidence of important clinical benefit. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Post-approval studies, also referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These studies are used to gain additional experience from the treatment of patients in the intended therapeutic indication and may be required by the FDA as part of the approval process. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Progress reports detailing the status of drug development and results of the clinical trials must be submitted at least annually to the FDA, and written IND safety reports must be submitted to the FDA and the investigators for suspected adverse reactions that are serious and unexpected (including increased rate of occurrence of such adverse reactions), findings from other studies that suggest a significant risk in humans exposed to the drug, or any findings from tests in laboratory animals that suggests a significant risk for human subjects or patients. Phase&#160;1, Phase 2 and Phase 3 clinical trials may not yield positive results, or may not be completed successfully within any specified period, if at all. The FDA or the sponsor or its data safety monitoring board may suspend a clinical trial at any time on various grounds, including a finding that the research subjects are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug has been associated with unexpected serious harm to study subjects. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the development of a new drug, sponsors are given opportunities to meet with the FDA at certain points. These points may be prior to submission of an IND, at the end of Phase 2, and before an NDA is submitted. Meetings at other times may be requested. These meetings can provide an opportunity for the sponsor to share information about the data gathered to date, for the FDA to provide advice, and for the sponsor and the FDA to reach agreement on the next phase of development. Sponsors typically use the end of Phase 2 meeting to discuss their Phase 2 clinical results and present their plans for the Phase 3 clinical trials that they believe will support approval of the new drug. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the drug as well as finalize a process </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">186 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the drug candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality and purity of the final drug product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the drug candidate does not undergo unacceptable deterioration over its shelf life. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">FDA Review and Approval Processes </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The results of product development, preclinical studies and clinical trials for the claimed indications are incorporated into an NDA. The FDA may grant deferrals for the development and submission of pediatric data or full or partial waivers after the initial submission of a pediatric study plan following an end of Phase 2 meeting. In addition, descriptions of the manufacturing process and controls, analytical tests conducted on the chemistry of the drug, proposed labeling and other relevant information are also submitted to the FDA as part of an NDA requesting approval to market the product. The submission of an NDA is subject to the payment of substantial user fees and a waiver of such fees may be obtained under certain limited circumstances. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA reviews the NDA to determine, among other things, whether the proposed product is safe and effective for its intended use, and whether the product is being manufactured in accordance with cGMP to assure and preserve the product&#8217;s identity, strength, quality and purity. Under the Prescription Drug User Fee Act (&#8220;PDUFA&#8221;) guidelines that are currently in effect, the FDA has a goal of ten months from the date of &#8220;filing&#8221; of a standard, original NDA for a new molecular entity to review and act on the submission. This review typically takes twelve months from the date the NDA is submitted to the FDA because the FDA has approximately two months to make a &#8220;filing&#8221; decision after the application is submitted. The FDA conducts a preliminary review of all NDAs within the first 60 days after submission, before accepting them for filing, to determine whether they are sufficiently complete to permit substantive review. The FDA may request additional information rather than accepting an NDA for filing. In this event, the NDA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA may refer applications for novel drug products or drug products which present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. During the drug approval process, the FDA also will determine whether a REMS is necessary to assure the safe use of the drug. If the FDA concludes a REMS is needed, the sponsor of the NDA must submit a proposed REMS. The FDA will not approve the NDA without a REMS, if required. A REMS could include medication guides, physician communication plans or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Any of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescription or dispensing of products. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before approving an NDA, the FDA will generally inspect the facilities at which the product is to be manufactured. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP requirements. If the FDA determines that the application, manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the FDA evaluates an NDA, it will issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the drug with prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete, and the application </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">187 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
will not be approved in its present form. A Complete Response Letter usually describes the specific deficiencies in the NDA identified by the FDA and may require additional clinical data, such as an additional pivotal Phase 3 trial or other significant and time-consuming requirements related to clinical trials, preclinical studies or manufacturing. If a Complete Response Letter is issued, the sponsor must resubmit the NDA, addressing all of the deficiencies identified in the letter, or withdraw the application. Even if such data and information are submitted, the FDA may decide that the NDA does not satisfy the criteria for approval. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a product receives regulatory approval, the approval may be significantly limited to specific diseases and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. Further, the FDA may require that certain contraindications, warnings or precautions be included in the product labeling. In addition, the FDA may require post-approval studies, referred to as Phase 4 testing, which involves clinical trials designed to further assess a product&#8217;s safety and effectiveness and may require testing and surveillance programs to monitor the safety of approved products that have been commercialized. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Expedited Development and Review Programs </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA administers a number of different programs that enable the agency and sponsors in various ways to expedite the development or agency review of a new drug product. Among these, the FDA has a fast track designation that is intended to expedite or facilitate the process for reviewing new drug products that meet certain criteria. New drugs are eligible for fast track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. As an example of the modified processes available to a fast track product, the FDA may consider for review sections of the NDA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any product submitted to the FDA for approval, including a product with a fast track designation, may also be eligible for other types of FDA programs intended to expedite development and review, such as priority review and accelerated approval. A product is eligible for priority review if it has the potential to provide safe and effective therapy where no satisfactory alternative therapy exists or a significant improvement in the treatment, diagnosis or prevention of a disease compared to marketed products. The FDA will attempt to direct additional resources to the evaluation of an application for a new drug designated for priority review in an effort to facilitate the review. The FDA endeavors to review applications with priority review designations within six&#160;months of the filing date as compared to ten months for review of other NDAs under its current PDUFA review goals. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, a product may be eligible for accelerated approval. Drug products intended to treat serious or life-threatening diseases or conditions may be eligible for accelerated approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require that a sponsor of a drug receiving accelerated approval perform additional adequate and well-controlled post-marketing clinical trials. In addition, the FDA currently requires as a condition for accelerated approval <span style="white-space:nowrap">pre-use</span> submission of promotional materials, which could adversely impact the timing of the commercial launch of the product. Fast track designation, priority review and accelerated approval do not change the standards for approval but may expedite the development or approval process. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Food and Drug Administration Safety and Innovation Act established a category of drugs referred to as &#8220;breakthrough therapies&#8221; that may be eligible to receive breakthrough therapy designation. A sponsor may seek the FDA designation of a product candidate as a &#8220;breakthrough therapy&#8221; if the product is intended, alone or in </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">188 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
combination with one or more other products, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the fast track program features, as well as more intensive FDA interaction and guidance. The breakthrough therapy designation is a distinct status from both accelerated approval and priority review, which can also be granted to the same drug if relevant criteria are met. If a product is designated as breakthrough therapy, the FDA will work with the sponsor to expedite the development and review of such drug. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With passage of the 21st Century Cures Act in December 2016, Congress authorized the FDA to accelerate review and approval of products designated as regenerative advanced therapies. A product is eligible for this designation if it is a regenerative medicine therapy that is intended to treat, modify, reverse or cure a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product candidate has the potential to address unmet medical needs for such disease or condition. The benefits of a regenerative advanced therapy designation include early interactions with the FDA to expedite development and review, benefits available to breakthrough therapies, potential eligibility for priority review and accelerated approval based on surrogate or intermediate endpoints. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have obtained fast track designation for SEMDEXA for the treatment of lumbosacral radicular pain and have applied for breakthrough therapy designation for the treatment of lumbosacral radicular pain based on the <span style="white-space:nowrap">top-line</span> results obtained from the pivotal Phase 3 trial, which results reflect achievement of primary and secondary endpoints. We have also obtained fast track designation for <span style="white-space:nowrap">SP-103</span> for the treatment of acute LBP. We may seek additional designations for SEMDEXA, <span style="white-space:nowrap">SP-103</span> or our other product candidates. Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Post-Approval Requirements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown risks or problems with a product may result in labeling changes, restrictions on the product or even complete withdrawal of the product from the market. After approval, most changes to the approved product, such as adding new indications, certain manufacturing changes and additional labeling claims, are subject to further FDA review and approval. Drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP regulations and other laws and regulations. In addition, the FDA may impose a number of post-approval requirements as a condition of approval of an NDA. For example, the FDA may require post-marketing testing, including Phase 4 clinical trials, and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any drug products for which we receive FDA approvals are subject to continuing regulation by the FDA, including, among other things, record-keeping requirements, reporting of adverse experiences or quality issues with the product, providing the FDA with updated safety and efficacy information, satisfaction of post-approval requirements or commitments, product sampling and distribution requirements, and complying with FDA promotion and advertising requirements. These promotion and advertising requirements include, among other things, standards for <span style="white-space:nowrap"><span style="white-space:nowrap">direct-to-consumer</span></span> advertising, prohibitions against promoting drugs for uses, or in patient populations, that are not described in the drug&#8217;s approved labeling, which is known as <span style="white-space:nowrap">&#8220;off-label</span> use,&#8221; rules for conducting industry-sponsored scientific and educational activities, and promotional activities involving the internet. Failure to comply with post-approval requirements can have negative consequences, including adverse publicity, enforcement letters from the FDA, mandated corrective advertising or communications with doctors, and civil or criminal penalties. Although physicians may prescribe legally available drugs for <span style="white-space:nowrap">off-label</span> uses, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">189 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
manufacturers may not market or promote such <span style="white-space:nowrap">off-label</span> uses. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant, manufacturer or product to administrative or judicial civil or criminal sanctions and adverse publicity. FDA sanctions could include refusal to approve pending applications, withdrawal of an approval, clinical holds on post-approval clinical trials, warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, mandated corrective advertising or communications with doctors, debarment, restitution, disgorgement of profits, or civil or criminal penalties. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Hatch-Waxman Amendments </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&#160;505 of the FDCA describes three types of NDAs that may be submitted to request marketing authorization for a new drug, the first being a 505(b)(1) NDA. A 505(b)(1) NDA is an application that contains full reports of investigations of safety and effectiveness. A 505(b)(2) NDA likewise contains full reports of investigations of safety and effectiveness relevant to a product, but some of the data are not owned by or licensed to the applicant. Section&#160;505(j) establishes an abbreviated approval process for generic versions of approved drug products through the submission of an abbreviated new drug application (&#8220;ANDA&#8221;). An ANDA generally provides for marketing of a drug product that has the same active ingredients in the same strengths and dosage form, and with the same labeling and route of administration as the listed drug and has been shown to be bioequivalent to the listed drug. ANDA applicants are required to conduct bioequivalence testing to confirm chemical and therapeutic equivalence to the branded reference drug. Generic versions of drugs can often, and sometimes must, be substituted by pharmacists under prescriptions written for the branded reference drug. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A 505(b)(2) NDA is an application that contains full reports of investigations of safety and effectiveness but where at least some of the information required for approval comes from studies not conducted by or for the applicant, and for which the applicant has not obtained a right of reference. This regulatory pathway enables the applicant to rely, in part, on the FDA&#8217;s findings of safety and efficacy for an existing product, or published literature, in support of its application. Additional preclinical and clinical data may also be submitted. The FDA may then approve the new product candidate for all or some of the labeled indications for which the referenced product has been approved, or for any new indication sought by the 505(b)(2) applicant. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon submission of an ANDA or a 505(b)(2) NDA, an applicant must certify to the FDA at least one of the following (1)&#160;no patent information on the drug product that is relied upon by the ANDA or 505(b)(2) NDA (known as the reference drug) has been submitted to the FDA; (2)&#160;such patent has expired; (3)&#160;the date on which such patent expires; or (4)&#160;such patent is invalid, unenforceable, or will not be infringed by the manufacture, use or sale of the drug product for which the ANDA or 505(b)(2) NDA is submitted. This last certification is known as a Paragraph IV Certification. If the NDA holder for the reference drug or patent owner(s) asserts a patent challenge to the Paragraph IV Certification, the FDA may not approve that application until the earlier of 30&#160;months from the receipt of the notice of the Paragraph IV Certification, the expiration of the patent, when the infringement case concerning each such patent was favorably decided in the applicant&#8217;s favor or such shorter or longer period as may be ordered by a court. This prohibition is generally referred to as the <span style="white-space:nowrap">30-month</span> stay. Thus, approval of an ANDA or 505(b)(2) NDA could be delayed for a significant period of time depending on the patent certification the applicant makes and the reference drug sponsor&#8217;s or patent owner&#8217;s decision to initiate patent litigation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to, and distinct from the patent protection provisions, the Hatch-Waxman Amendments establish periods of regulatory exclusivity for certain approved drug products, during which the FDA cannot approve (or in some cases accept) an ANDA or 505(b)(2) application that relies on the branded reference drug. For example, the holder of an NDA may obtain five years of exclusivity upon approval of a new drug containing a new chemical entity that has not been previously approved by the FDA. The Hatch-Waxman Amendments also provide three years of marketing exclusivity to the holder of an NDA (including a 505(b)(2) NDA) for a particular condition of approval, or change to a marketed product, such as a new formulation for a previously approved product, if one </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">190 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or more new clinical trials (other than bioavailability or bioequivalence studies) was essential to the approval of the application and was conducted/sponsored by the applicant. This three-year exclusivity period protects against FDA approval of ANDAs and 505(b)(2) NDAs for drugs that include the innovation that required the new clinical data, but generally allows the approval for <span style="white-space:nowrap">non-protected</span> characteristics and labeling. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Orphan Drug Designation and Exclusivity </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biological product intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making the product available in the United States for this type of disease or condition will be recovered from sales of the product. Orphan drug designation must be requested before submitting an NDA for the drug for the rare disease or condition. After the FDA grants orphan drug designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in or shorten the duration of the regulatory review and approval process. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a product that has orphan drug designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications to market the same drug for the same indication for seven years from the date of such approval, except in limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity by means of greater effectiveness, greater safety or providing a major contribution to patient care or in instances of drug supply issues. Competitors, however, may receive approval of either a different product for the same indication or the same product for a different indication not protected by the exclusive approval, but that could be used <span style="white-space:nowrap">off-label</span> in the orphan indication. The FDA also has authority to withdraw exclusive marketing rights if the holder of an approved orphan drug cannot assure the availability of sufficient quantities of the drug within a reasonable time to meet the needs of patients with the disease or condition for which the drug was designated. Once withdrawn under such circumstances, exclusive approval may not be reinstated for that drug. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Third-Party Payor Coverage, Pricing and Reimbursement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States and markets in other countries, patients who are prescribed treatments for their conditions and providers performing the prescribed services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Thus, sales of a product will depend, in part, on the extent to which third-party payors provide coverage and establish adequate reimbursement levels for the product. Third-party payors include government payor programs at the federal and state levels, including Medicare and Medicaid, managed care providers, private health insurers and other organizations. In the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors. The process for determining whether a payor will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the product. Third-party payors may limit coverage to specific products on an approved list, or formulary, which might not include all of the <span style="white-space:nowrap">FDA-approved</span> products for a particular indication, and which can change over time. Third-party payors are increasingly challenging the price and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. We may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of our products, in addition to the costs required to obtain FDA or other comparable regulatory approvals. Additionally, companies may also need to provide discounts to purchasers, private health plans or government healthcare programs, in order to be considered as a formulary option. Nonetheless, product candidates may not be considered by individual payors to be medically necessary or cost-effective. A payor&#8217;s decision to provide coverage for a product does not imply that a preferred formulary position or an adequate reimbursement rate will be approved. Further, one payor&#8217;s determination to provide coverage for a product does not assure that other payors will also provide coverage and reimbursement for the product, and the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">191 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
level of coverage and reimbursement can differ significantly from payor to payor. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The cost of pharmaceuticals continues to generate substantial governmental and third-party payor interest. We expect that the pharmaceutical industry will experience pricing pressures due to the trend toward managed healthcare, the increasing influence of managed care organizations and additional legislative proposals. The U.S. government, state legislatures and foreign governments have shown significant interest in implementing cost containment programs to limit the growth of government-paid healthcare costs, including price controls, restrictions on reimbursement and requirements for substitution of generic products for branded prescription drugs. Adoption of such controls and measures, and tightening of restrictive policies in jurisdictions with existing controls and measures, could limit payments for pharmaceuticals such as our products and the product candidates that we are developing and could adversely affect our net revenue and results. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Different pricing and reimbursement schemes exist in other countries. In the European Economic Area (&#8220;EEA&#8221;) (which is currently comprised of the 27 Member States of the EU plus Norway, Iceland and Liechtenstein), governments influence the price of pharmaceutical products through their pricing and reimbursement rules and control of national healthcare systems that fund a large part of the cost of those products to consumers. Some EEA countries operate positive and negative list systems under which some medicinal products are selected for coverage (positive list) and others are explicitly listed as excluded from reimbursement (negative list). To obtain reimbursement or pricing approval, some of these EEA countries may require the completion of clinical trials that compare the cost-effectiveness of a particular product to currently available therapies. Other EEA countries allow companies to fix their own prices for medicinal products, but monitor and control company profits. The downward pressure on healthcare costs in general, particularly prescription drugs, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross-border imports from <span style="white-space:nowrap">low-priced</span> markets exert a commercial pressure on pricing within a country. There can be no assurance that any country that has price controls or reimbursement limitations for products will allow favorable reimbursement and pricing arrangements for any of our products. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">U.S. Healthcare Reform </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States there have been, and continue to be, proposals by the federal government, state governments, regulators and third-party payors to control or manage the increased costs of healthcare and, more generally, to reform the U.S. healthcare system. The pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives. For example, in March 2010, the ACA was enacted, which is intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for the healthcare and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms, and which substantially changes the way healthcare is financed by both governmental and private insurers, and significantly impact the U.S. pharmaceutical industry. The ACA, among other things, (1)&#160;subjected therapeutic biologics to potential competition by lower-cost biosimilars by creating a licensure framework for <span style="white-space:nowrap">follow-on</span> biologic products, (2)&#160;prescribed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, (3)&#160;increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extended the rebate program to individuals enrolled in Medicaid managed care organizations, (4)&#160;established annual nondeductible fees and taxes on manufacturers of certain branded prescription drugs, apportioned among these entities according to their market share in certain government healthcare programs, (5)&#160;established a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer <span style="white-space:nowrap"><span style="white-space:nowrap">point-of-sale</span></span> discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D, (6)&#160;expanded eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals and by adding new mandatory </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">192 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
eligibility categories for individuals with income at or below 133% of the federal poverty level, thereby potentially increasing manufacturers&#8217; Medicaid rebate liability, (7)&#160;expanded the entities eligible for discounts under the 340B Public Health Service Act program, (8)&#160;created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research, and (9)&#160;established a Center for Medicare Innovation at the CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since its enactment, there have been judicial, Congressional and Administrative challenges to certain aspects of the ACA, and we expect there will be additional challenges and amendments to the ACA in the future. For example, legislation affecting the implementation of certain taxes under the ACA has been signed into law. The TCJA included a provision that repealed, effective January&#160;1, 2019, the <span style="white-space:nowrap">tax-based</span> shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate&#8221;. Further, the Bipartisan Budget Act of 2018 (the &#8220;BBA&#8221;), among other things, amended the ACA, effective January&#160;1, 2019, to increase from 50% to 70% the <span style="white-space:nowrap"><span style="white-space:nowrap">point-of-sale</span></span> discount that is owned by pharmaceutical manufacturers who participate in Medicare Part D and to close the coverage gap in most Medicare drug plans, commonly referred to as the &#8220;donut hole&#8221;. On June&#160;17, 2021 the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. Thus, the ACA will remain in effect in its current form. Further, prior to the U.S. Supreme Court ruling, on January&#160;28, 2021, President Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. In addition, on August&#160;16, 2022, President Biden signed the Inflation Reduction Act of 2022 into law, which, among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The Inflation Reduction Act also eliminates the &#8220;donut hole&#8221; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum <span style="white-space:nowrap"><span style="white-space:nowrap">out-of-pocket</span></span> cost through a newly established manufacturer discount program. It is unclear how additional healthcare reform measures of the Biden administration or other efforts, if any, to modify or invalidate the ACA or its implementing regulations, or portions thereof, will impact our business. Any health care reform measures will likely take time to unfold, and could have an impact on coverage and reimbursement for healthcare items and services. We cannot predict the ultimate content, timing or effect of any healthcare reform legislation or other policy or the impact of potential legislation or other policy on us. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other legislative and administrative changes have been proposed and adopted in the United States since the ACA was enacted to reduce healthcare expenditures. For example, the Budget Control Act of 2011, among other things, in connection with subsequent legislation, reduced Medicare payments to providers, on average, by 2% per fiscal year. These reductions went into effect on April&#160;1, 2013 and, due to subsequent legislative amendments to the statute, including the BBA, will remain in effect through 2030, with the exception of a temporary suspension from May&#160;1, 2020, through May&#160;31, 2022, due to the <span style="white-space:nowrap">COVID-19</span> pandemic. The law provides for 1% Medicare sequestration in the second quarter of 2022 and allows the full 2% sequestration thereafter until 2030. To offset the temporary suspension during the <span style="white-space:nowrap">COVID-19</span> pandemic, in 2030, the sequestration will be 2.25% for the first half of the year, and 3% in the second half of the year. Moreover, on January&#160;2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. If federal spending is further reduced, anticipated budgetary shortfalls may impact the ability of relevant agencies to continue to function at current levels. Amounts allocated to federal grants and contracts may be reduced or eliminated. These reductions may also impact the ability of relevant agencies to timely review and </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">193 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
approve research and development, manufacturing, and marketing activities, which may delay our ability to develop, market and sell any products we may develop. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. At the federal level, these include proposed measures to permit Medicare to negotiate the price of certain drugs, to establish rebates under Medicare Part B and Part D where the average sales price or the average manufacturer price of a drug respectively increases faster than the pace of inflation and to eliminate the existing manufacturer coverage gap discount program under Part D and replace it with a new program that would require manufacturer discounts in both the initial and catastrophic phases of the program. On May&#160;16, 2019, CMS adopted a final rule that, among other things, will require Part D plans to adopt Real Time Benefit Tools that are capable of integrating with electronic prescribing or electronic health record systems and have the capability to inform prescribers when lower-cost alternative therapies are available under a beneficiary&#8217;s prescription drug benefit. Similarly, since 2021, Part D Explanation of Benefits transmittals to members are required to inform Part D beneficiaries about drug prices and lower cost therapeutic alternatives. On August&#160;16, 2022, President Biden signed into law the Inflation Reduction Act of 2022, which among other things, contains two specific provisions affecting pricing for drugs and biologics. The first provision allows for CMS to negotiate prices for certain single-source drugs and biologics reimbursed under Medicare Part&#160;B and Part&#160;D, beginning with ten high-cost drugs paid for by Medicare Part D starting in 2026, followed by 15 Part&#160;D drugs in 2027, 15 Part&#160;B or Part D drugs in 2028, and 20 Part B or Part D drugs in 2029 and beyond. The legislation subjects drug manufacturers to civil monetary penalties and a potential excise tax for failing to comply with the legislation by offering a price that is not equal to or less than the negotiated &#8220;maximum fair price&#8221; under the law or for taking price increases that exceed inflation. The legislation also caps Medicare beneficiaries&#8217; <span style="white-space:nowrap"><span style="white-space:nowrap">annual&#160;out-of-pocket&#160;drug</span></span> expenses at $2,000. The second provision imposes a requirement that pharma manufacturers provide a rebate to Medicare, if the manufacturer increases price at a rate higher than the measured inflation rate. Medicaid has had a rebate program for several years, but Medicare did not. The intent is to limit price increases. The new rebate applies to drugs covered by Medicare under Part&#160;B or Part&#160;D . The rebate obligation applies if the average sales price (for Part&#160;B) or average manufacturers price (for Part&#160;D) of a single source drug or biologic increases more than the rate of inflation (as measured by the index for urban consumers). The rebate amount is the total number of units sold in Medicare coverage multiplied by the amount by which the price exceeds the inflation adjusted price. The base year against which the inflation adjustment is measured is 2021. If the price exceeds the inflation adjusted price, the difference is multiplied by the units sold in Medicare and that amount is to be rebated. A failure to pay the rebate is subject to a penalty of 125% of the original rebate amount. The provision for Part&#160;D takes effect in 2022, with rebates to be paid beginning in 2023. The provision for Part&#160;B takes effect in 2023. At the state level, legislatures are increasingly passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures. In some cases, states appear interested in public policy designed to encourage drug importation from other countries and bulk purchasing. Furthermore, there has been increased interest by third-party payors and governmental authorities in reference pricing systems and publication of discounts and list prices. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that other healthcare reform measures that may be adopted in the future may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved product, and could seriously harm our future revenue. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our product. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">194 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Other U.S. Healthcare Laws and Compliance Requirements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, our activities are potentially subject to regulation by various federal, state and local authorities in addition to the FDA, including the Centers for Medicare and Medicaid Services, other divisions of the United States Department of Health and Human Services (<span style="font-style:italic">e.g.</span>, the Office of Inspector General), the United States Department of Justice and individual United States Attorney offices within the Department of Justice, and state and local governments. For example, various activities, including but not limited to sales, marketing and scientific/educational grant programs, must comply with the anti-fraud and abuse provisions of the Social Security Act, the federal Anti-Kickback Statute, the federal False Claims Act and similar state laws, each as amended. Failure to comply with such requirements could potentially result in substantial penalties to us. Even if we structure our programs with the intent of compliance with such laws, there can be no certainty that we would not need to defend against enforcement or litigation, in light of the fact that there is significant enforcement interest in pharmaceutical companies in the United States, and some of the applicable laws are quite broad in scope. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The federal Anti-Kickback Statute prohibits any person, including a pharmaceutical manufacturer (or a party acting on its behalf), from knowingly and willfully soliciting, receiving, offering or providing remuneration, directly or indirectly, to induce or reward either the referral of an individual, or the furnishing, recommending, or arranging for a good or service, for which payment may be made under a federal healthcare program such as the Medicare and Medicaid programs. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand and prescribers, purchasers, and formulary managers on the other. The term &#8220;remuneration&#8221; is not defined in the federal Anti-Kickback Statute and has been broadly interpreted to include anything of value, including for example, gifts, discounts, the furnishing of supplies or equipment, credit arrangements, payments of cash, waivers of payments, ownership interests and providing anything at less than its fair market value. Although there are a number of statutory exemptions and regulatory safe harbors protecting certain business arrangements from prosecution, the exemptions and safe harbors are drawn narrowly and practices that involve remuneration intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exemption or safe harbor. Our practices may not in all cases meet all of the criteria for safe harbor protection from federal Anti-Kickback Statute liability. The government can establish a violation of the Anti-Kickback Statute without proving that a person or entity had actual knowledge of this statute or specific intent to violate it. In addition, the ACA provides that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act (discussed below) or the civil monetary penalties statute, which imposes fines against any person who is determined to have presented or caused to be presented claims to a federal healthcare program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent. Additionally, many states have adopted laws similar to the federal Anti-Kickback Statute, and some of these state prohibitions apply to referral of patients for healthcare items or services reimbursed by any third-party payor, not only the Medicare and Medicaid programs in at least some cases, and do not contain safe harbors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The federal False Claims Act imposes liability on any person or entity that, among other things, knowingly presents, or causes to be presented, a false or fraudulent claim for payment of government funds, or knowingly makes, uses, or causes to be made or used a false statement material to a false or fraudulent claim, or knowingly conceals or knowingly and improperly avoids, or decreases an obligation to pay money to the government. The qui tam provisions of the False Claims Act allow a private individual to bring civil actions on behalf of the federal government alleging that the defendant has submitted a false claim to the federal government and to share in any monetary recovery. In recent years, the number of suits brought by private individuals has increased dramatically. In addition, various states have enacted false claims laws analogous to the False Claims Act. Many of these state laws apply where a claim is submitted to any third-party payor and not merely a federal healthcare program. There are many potential bases for liability under the False Claims Act. Liability arises, primarily, when an entity knowingly submits, or causes another to submit, a false claim for reimbursement to the federal government. The False Claims Act has been used to assert liability on the basis of inadequate care, kickbacks and </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">195 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
other improper referrals, improperly reported government pricing metrics such as Best Price or Average Manufacturer Price, improper promotion of <span style="white-space:nowrap">off-label</span> uses (<span style="font-style:italic">i.e.</span>, uses not expressly approved by the FDA in a drug&#8217;s label), and allegations as to misrepresentations with respect to the services rendered. Our activities relating to the reporting of discount and rebate information and other information affecting federal, state and third-party reimbursement of our products, and the sale and marketing of our products and our service arrangements or data purchases, among other activities, may be subject to scrutiny under these laws. We are unable to predict whether we would be subject to actions under the False Claims Act or a similar state law, or the impact of such actions. However, the cost of defending such claims, as well as any sanctions imposed, could adversely affect our financial performance. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The healthcare fraud provisions under the HIPAA impose criminal liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any health care benefit program, including private third-party payors, or falsifying or covering up a material fact or making any materially false or fraudulent statement in connection with the delivery of or payment for health care benefits, items or services. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may be subject to, or our marketing activities may be limited by, data privacy and security regulation by both the federal government and the states in which we conduct our business. For example, HIPAA and its implementing regulations, impose privacy, security and breach reporting obligations with respect to individually identifiable health information upon &#8220;covered entities&#8221; (healthcare providers, health plans and healthcare clearinghouses), and their respective business associates, certain individuals or entities that create, receive, maintain or transmit protected health information in connection with providing a specified service or performing a function for or on behalf of a covered entity. The FTC also sets expectations that failing to take appropriate steps to keep consumers&#8217; personal information secure, or failing to provide a level of security commensurate to promises made to an individual about the security of their personal information (such as in a privacy notice) may constitute unfair or deceptive acts or practices in violation of Section&#160;5(a) of the FTC Act. The FTC expects a company&#8217;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. Individually identifiable health information is considered sensitive data that merits stronger safeguards. With respect to privacy, the FTC also sets expectations that companies honor the privacy promises made to individuals about how the company handles consumers&#8217; personal information; any failure to honor promises, such as the statements made in a privacy policy or on a website, may also constitute unfair or deceptive acts or practices in violation of the FTC Act. While we do not intend to engage in unfair or deceptive acts or practices, the FTC has the power to enforce promises as it interprets them, and events that we cannot fully control, such as data breaches, may be result in FTC enforcement. Enforcement by the FTC under the FTC Act can result in civil penalties or enforcement actions. Further, various states have implemented similar privacy laws and regulations that impose restrictive requirements regulating the use and disclosure of health information and other personally identifiable information. California has also recently adopted the CCPA. The CCPA established a new privacy framework for covered businesses by creating an expanded definition of personal information, establishing new data privacy rights for consumers in the State of California, imposing special rules on the collection of consumer data from minors, and creating a new and potentially severe statutory damages framework for violations of the CCPA and for businesses that fail to implement reasonable security procedures and practices to prevent data breaches of certain personal information. Penalties for violations of the CCPA include civil penalties. In addition, a new California privacy law, CPRA, was passed by California votes on November&#160;3, 2020, introduced significant amendments to the CCPA and established and funded a dedicated California privacy regulator, the CPPA. The amendments introduced by the CPRA are scheduled to take effect on January&#160;1, 2023 (with certain provisions having retroactive effect to January&#160;1, 2022). Further, a new Virginia privacy law, the VCDPA, was signed into law on March&#160;2, 2021 and is also scheduled to take effect on January&#160;1, 2023, and the Colorado Privacy Act (&#8220;CPA&#8221;) will take effect on July&#160;1, 2023. The VCDPA and CPA will impose many similar obligations regarding the processing and storing of personal information as the CCPA and the CPRA. Other states in the United States are considering omnibus privacy legislation, and industry organizations regularly adopt and advocate for new standards in these areas. The uncertainty, ambiguity, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">196 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
complexity and potential inconsistency surrounding the implementation and interpretation of CCPA and other enacted or potential laws in other states exemplify the vulnerability of our business to the evolving regulatory environment related to the privacy, security and confidentiality of personal information and protected health information. We may be subject to fines, penalties, or private actions in the event of <span style="white-space:nowrap">non-compliance</span> with such laws. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our activities outside of the U.S. implicate local and national data protection standards, impose additional compliance requirements and generate additional risks of enforcement for <span style="white-space:nowrap">non-compliance.</span> The European Union&#8217;s GDPR which imposes fines of up to EUR 20&#160;million or 4% of the annual global revenue of a noncompliant company, whichever is greater, and other data protection, privacy and similar national, state/ provincial and local laws may also restrict the access, use and disclosure of patient health information abroad. We may be required to expend significant capital and other resources to ensure ongoing compliance with applicable privacy and data security laws, to protect against security breaches and hackers, or to alleviate problems caused by such breaches. Compliance with these laws is difficult, constantly evolving, time consuming, and requires a flexible privacy framework and substantial resources. Compliance efforts will likely be an increasing and substantial cost in the future. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The U.S. federal Physician Payments Sunshine Act requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to annually report to CMS information related to payments or other transfers of value made to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. In addition to this federal requirement, a number of individual states and foreign jurisdictions require detailed reporting and often public disclosures concerning transfers of value to physicians, other health care providers and family members. Effective January&#160;1, 2022, these reporting obligations are extended to include transfers of value made to certain <span style="white-space:nowrap">non-physician</span> providers such as physician assistants and nurse practitioners. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Compliance with such requirements may require investment in infrastructure to ensure that tracking is performed properly, and some of these laws result in the public disclosure of various types of payments and relationships. Several states have enacted legislation requiring pharmaceutical companies to, among other things, establish marketing compliance programs, file periodic reports with the state, make periodic public disclosures on sales, marketing, pricing, clinical trials and other activities, or register their sales representatives, as well as prohibiting pharmacies and other healthcare entities from providing certain physician prescribing data to pharmaceutical companies for use in sales and marketing, and prohibiting certain other sales and marketing practices. These laws may affect our sales, marketing and other promotional activities by imposing administrative and compliance burdens on us. If we fail to track and report as required by these laws or otherwise comply with these laws, we could be subject to the penalty provisions of the pertinent state and federal authorities. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Where our activities involve foreign government officials, they may also potentially be subject to the FCPA. If we seek to have a product paid for with federal funds under the Medicaid programs or Medicare Part B, various obligations, including government price reporting, are required under the Medicaid rebate provisions of the Omnibus Budget Reconciliation Act of 1990 and the Veterans Health Care Act of 1992, each as amended, which generally require products to be offered at substantial rebates/discounts to such programs and certain purchasers. Government price reporting may also be required with respect to average sales price, which serves as the basis of reimbursement under Medicare Part B. In order to distribute products commercially, we must comply with state laws that require the registration of manufacturers and wholesale distributors of pharmaceutical products in a state, including, in certain states, manufacturers and distributors who ship products into the state even if such manufacturers or distributors have no place of business within the state. Some states also impose requirements on manufacturers and distributors to establish the pedigree of product in the chain of distribution, including some states that require manufacturers and others to adopt new technology capable of tracking and tracing product as it moves through the distribution chain. Many of our current as well as possible future </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">197 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
activities are potentially subject to federal and state consumer protection and unfair competition laws. We must also comply with laws that require clinical trial registration and reporting of clinical trial results on the publicly available clinical trial databank maintained by the National Institutes of Health at <span style="text-decoration:underline">www.ClinicalTrials.gov</span>. We are subject to various environmental, health and safety regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous substances. From time to time, and in the future, our operations may involve the use of hazardous materials. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of the breadth of these laws and the narrowness of available statutory and regulatory exemptions, it is possible that some of our business activities could be subject to challenge under one or more of such laws. If our operations are found to be in violation of any of the federal and state laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including criminal and significant civil monetary penalties, damages, fines, imprisonment, exclusion from participation in government healthcare programs, injunctions, recall or seizure of products, total or partial suspension of production, denial or withdrawal of <span style="white-space:nowrap">pre-marketing</span> product approvals, private &#8220;qui tam&#8221; actions brought by individual whistleblowers in the name of the government or refusal to allow us to enter into supply contracts, including government contracts, integrity oversight and reporting obligations to resolve allegations of <span style="white-space:nowrap">non-compliance,</span> and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. To the extent that any of our products are sold in a foreign country, we may be subject to similar foreign laws and regulations, which may include, for instance, applicable post-marketing requirements, including safety surveillance, anti-fraud and abuse laws, and implementation of corporate compliance programs and reporting of payments or transfers of value to healthcare professionals. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">U.S. Marketing Exclusivity </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Hatch-Waxman Exclusivity</span>. Market exclusivity provisions under the FDCA can also delay the submission or the approval of certain applications of other companies seeking to reference another company&#8217;s NDA. If the new drug is a new chemical entity subject to an NDA, the FDCA provides a five-year period of <span style="white-space:nowrap">non-patent</span> marketing exclusivity within the United States to the first applicant to obtain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. This definition is currently under FDA review. During the exclusivity period, the FDA may not accept for review an ANDA or a Section&#160;505(b)(2) NDA submitted by another company for another version of such drug where the applicant does not own or have a legal right of reference to all the data required for approval. However, such an application may be submitted after four years if it contains a certification of patent invalidity or <span style="white-space:nowrap">non-infringement</span> to one of the patents listed with the FDA by the innovator NDA holder. The FDCA also provides three years of marketing exclusivity for an NDA, or supplement to an existing NDA, if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, such as new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the conditions associated with the new clinical investigations and does not prohibit the FDA from approving ANDAs for drugs containing the original active agent. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Pediatric Exclusivity</span>. Pediatric exclusivity is another type of regulatory market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to any existing exclusivity period or patent term. This <span style="white-space:nowrap">six-month</span> exclusivity may be granted by the FDA based on the completion of a pediatric clinical trial in accordance with provisions of the FDCA. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">198 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Europe/Rest of World Government Regulation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to regulations in the United States, we will be subject to a variety of regulations in other jurisdictions governing, among other things, clinical trials, pricing and reimbursement, anti-bribery, advertising and promotion, data privacy and security and any commercial sales and distribution of our future products. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whether or not we obtain FDA approval for a product, we must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials or marketing of the product in those countries. Certain countries outside of the United States have a similar process that requires the submission of a clinical trial application much like the IND prior to the commencement of human clinical trials. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the EEA, for example, a clinical trial application (&#8220;CTA&#8221;) must be submitted to each country&#8217;s national health authority and an independent ethics committee, much like the FDA and IRB, respectively. Once the CTA is approved in accordance with the EU Clinical Trials Directive 2001/20/EC (the &#8220;Clinical Trials Directive&#8221;) and the related national implementing provisions of the relevant individual EEA country&#8217;s requirements, the clinical trial described in that CTA may proceed. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2014, the new Clinical Trials Regulation, (EU) No 536/2014 (the &#8220;Clinical Trials Regulation&#8221;) was adopted. The Clincial Trials Regulation entered into force on January&#160;31, 2022. The Clinical Trials Regulation is directly applicable in all the EEA countries, repealing the current Clinical Trials Directive. The new Clinical Trials Regulation allows a sponsor to start and conduct a clinical trial in accordance with the Clinical Trials Directive during a transitional period of one year after the application date, i.e. January&#160;31, 2022. The transition period for the trials ongoing at the moment of applicability will be a maximum of 3 years after the date of application of the Clinical Trials Regulation. Clinical trials authorized under the current Clinical Trials Directive before January&#160;31, 2023 can continue to be conducted under the Clinical Trials Directive until January&#160;31, 2025. An application to transition ongoing trials from the current Clinical Trials Directive to the new Clinical Trials Regulation will need to be submitted and authorized in time before the end of the transitional period. The new Clinical Trials Regulation is intended to simplify and streamline the approval of clinical trials in the EEA. The main characteristics of the regulation include: a streamlined application procedure through a single entry point, the &#8220;EU portal&#8221;; a single set of documents to be prepared and submitted for the application as well as simplified reporting procedures for clinical trial sponsors; and a harmonized procedure for the assessment of applications for clinical trials, which is divided into two parts. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For other countries outside of the EEA, such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical trials vary from country to country. Internationally, clinical trials are generally required to be conducted in accordance with GCP, applicable regulatory requirements of each jurisdiction and the medical ethics principles that have their origins in the Declaration of Helsinki. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the EEA, medicinal products can be commercialized only after obtaining a Marketing Authorization (&#8220;MA&#8221;). There are several procedures for requesting marketing authorization which can be more efficient than applying for authorization on a <span style="white-space:nowrap">country-by-country</span> basis. There is a &#8220;centralized&#8221; procedure allowing submission of a single marketing authorization application to the European Medicines Agency (the &#8220;EMA&#8221;). If the EMA issues a positive opinion, the European Commission will grant a centralized marketing authorization that is valid in all EEA countries. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The &#8220;centralized&#8221; procedure is mandatory for certain types of products, such as biotechnology medicinal products, orphan medicinal products, and medicinal products containing a new active substance indicated for the treatment of AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune and viral diseases. The &#8220;centralized&#8221; procedure is optional for products containing a new active substance not yet authorized in the EEA, or for products that constitute a significant therapeutic, scientific or technical innovation or which are in the interest of public health in the EEA. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is also a &#8220;decentralized&#8221; procedure allowing companies to file identical applications to several EEA countries simultaneously for product candidates that have not yet been authorized in any EEA country and a </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">199 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
&#8220;mutual recognition&#8221; procedure allowing companies that have a product already authorized in one EEA country to apply for that authorization to be recognized by the competent authorities in other EEA countries. Under the &#8220;decentralized&#8221; procedure, an identical dossier is submitted to the competent authorities of each of the EEA countries in which the MA is sought, one of which is selected by the applicant as the Reference Member State (&#8220;RMS&#8221;). If the RMS proposes to authorize the product, and the other EEA countries do not raise objections, the product is authorized in all the EEA countries where the authorization was sought. Before granting the MA, the EMA or the competent authorities of the EEA countries make an assessment of the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In many countries outside the United States, procedures to obtain price approvals, coverage and reimbursement can take considerable time after the receipt of a MA. Many EEA countries periodically review their reimbursement of medicinal products, which could have an adverse impact on reimbursement status. In addition, we expect that legislators, policymakers and healthcare insurance funds in the EEA countries will continue to propose and implement cost-containing measures, such as lower maximum prices, lower or lack of reimbursement coverage and incentives to use cheaper, usually generic, products as an alternative to branded products, and/or branded products available through parallel import to keep healthcare costs down. Moreover, in order to obtain reimbursement for our products in some EEA countries, including some EU Member States, we may be required to compile additional data comparing the cost-effectiveness of our products to other available therapies. Health Technology Assessment (&#8220;HTA&#8221;) of medicinal products is becoming an increasingly common part of the pricing and reimbursement procedures in some EEA countries, including those representing the larger markets. The HTA process, which is currently governed by national laws in each EEA country, is the procedure to assess therapeutic, economic and societal impact of a given medicinal product in the national healthcare systems of the individual country. The outcome of an HTA will often influence the pricing and reimbursement status granted to these medicinal products by the competent authorities of individual EEA countries. The extent to which pricing and reimbursement decisions are influenced by the HTA of the specific medicinal product currently varies between EEA countries, although the HTA Regulation, which aims to harmonize the clinical benefit assessment of HTA across the EEA, will apply from January&#160;12, 2025. If we are unable to maintain favorable pricing and reimbursement status in EEA countries that represent significant markets, our anticipated revenue from and growth prospects for our products in the EEA could be negatively affected. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Outside the United States, interactions between pharmaceutical companies and physicians are also governed by strict laws, such as national anti-bribery laws of EEA countries, national sunshine rules, regulations, industry self-regulation codes of conduct and physicians&#8217; codes of professional conduct. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the EEA, the advertising and promotion of our products are subject to laws governing promotion of medicinal products, interactions with physicians, misleading and comparative advertising and unfair commercial practices. For example, applicable laws require that promotional materials and advertising in relation to medicinal products comply with the product&#8217;s Summary of Product Characteristics (&#8220;SmPC&#8221;), as approved by the competent authorities in connection with a marketing authorization approval. The SmPC is the document that provides information to physicians concerning the safe and effective use of the product. Promotional activity that does not comply with the SmPC is considered <span style="white-space:nowrap">off-label</span> and is prohibited in the EEA. Other applicable laws at the EEA level and in the individual EU Member States also apply to the advertising and promotion of medicinal products, including laws that prohibit the <span style="white-space:nowrap"><span style="white-space:nowrap">direct-to-consumer</span></span> advertising of prescription-only medicinal products and further limit or restrict the advertising and promotion of our products to the general public and to health care professionals. Violations of the rules governing the promotion of medicinal products in the EEA could be penalized by administrative measures, fines and imprisonment. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to data privacy and security regulations in the United States, we may be subject to, or our marketing activities may be limited by, data privacy and security regulations in the EEA where the legislative and regulatory landscape continues to evolve. There has been increased attention to privacy and data security issues that could potentially affect our business, including the GDPR which imposes strict obligations on the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">200 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
processing of personal data, including relating to the transfer of personal data from the EEA to third countries such as the United States. If we act in violation of the GDPR we may face significant penalties of up to 10,000,000 Euros or up to 2% of our total worldwide annual turnover for certain violations, or up to 20,000,000 Euros or up to 4% of our total worldwide annual turnover for more serious violations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These data privacy and security regulations, including the GDPR, generally restrict the transfer of personal data from Europe, including the EEA, United Kingdom and Switzerland, to the United States and most other countries unless the parties to the transfer have implemented specific safeguards to protect the transferred personal data. One of the primary safeguards allowing U.S. companies to import personal data from Europe had been certification to the <span style="white-space:nowrap">EU-U.S.</span> Privacy Shield and <span style="white-space:nowrap">Swiss-U.S.</span> Privacy Shield frameworks administered by the U.S. Department of Commerce. However, the <span style="white-space:nowrap">EU-U.S.</span> Privacy Shield was invalidated in July 2020 by the Court of Justice of the European Union (the &#8220;CJEU&#8221;) in a case known colloquially as &#8220;Schrems II.&#8221; Following this decision, the Swiss Federal Data Protection and Information Commissioner (the &#8220;FDPIC&#8221;) announced that the <span style="white-space:nowrap">Swiss-U.S.</span> Privacy Shield does not provide adequate safeguards for the purposes of personal data transfers from Switzerland to the United States. While the FDPIC does not have authority to invalidate the <span style="white-space:nowrap">Swiss-U.S.</span> Privacy Shield regime, the FDPIC&#8217;s announcement casts doubt on the viability of the <span style="white-space:nowrap">Swiss-U.S.</span> Privacy Shield as a future compliance mechanism for <span style="white-space:nowrap">Swiss-U.S.</span> data transfers. The CJEU&#8217;s decision in Schrems II also raised questions about whether one of the primary alternatives to the <span style="white-space:nowrap">EU-U.S.</span> Privacy Shield, namely, the European Commission&#8217;s Standard Contractual Clauses, can lawfully be used for personal data transfers from Europe to the United States or other third countries that are not the subject of an adequacy decision of the European Commission. While the CJEU upheld the adequacy of the Standard Contractual Clauses in principle in Schrems&#160;II, it made clear that reliance on those Clauses alone may not necessarily be sufficient in all circumstances. Use of the Standard Contractual Clauses must now be assessed on a <span style="white-space:nowrap"><span style="white-space:nowrap">case-by-case</span></span> basis taking into account the legal regime applicable in the destination country, in particular regarding applicable surveillance laws and relevant rights of individuals with respect to the transferred data. In the context of any given transfer, where the legal regime applicable in the destination country may or does conflict with the intended operation of the Standard Contractual Clauses and/or applicable European law, the decision in Schrems II and subsequent draft guidance from the European Data Protection Board (the &#8220;EDPB&#8221;) would require the parties to that transfer to implement certain supplementary technical, organizational and/or contractual measures to rely on the Standard Contractual Clauses as a compliant &#8220;transfer mechanism.&#8221; However, the draft guidance from the EDPB on such supplementary technical, organizational and/or contractual measures appears to conclude that no combination of such measures could be sufficient to allow effective reliance on the Standard Contractual Clauses in the context of transfers of personal data &#8220;in the clear&#8221; to recipients in countries where the power granted to public authorities to access the transferred data goes beyond that which is &#8220;necessary and proportionate in a democratic society&#8221; &#8212; which may, following the CJEU&#8217;s conclusions in Schrems II on relevant powers of United States public authorities and commentary in that draft EDPB guidance, include the United States in certain circumstances (e.g., where Section&#160;702 of the US Foreign Intelligence Surveillance Act applies). At present, there are few, if any, viable alternatives to the <span style="white-space:nowrap">EU-U.S.</span> Privacy Shield and the Standard Contractual Clauses. However, the CJEU recently invalidated the <span style="white-space:nowrap">EU-U.S.</span> Privacy Shield. The decision in Schrems II also affects transfers from the United Kingdom to the United States. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As such, if we are unable to implement a valid solution for personal data transfers from Europe, including, for example, obtaining individuals&#8217; explicit consent to transfer their personal data from Europe to the United States or other countries, we will face increased exposure to regulatory actions, substantial fines and injunctions against processing personal data from Europe. Inability to import personal data from Europe may also restrict our clinical trials activities in Europe; limit our ability to collaborate with contract research organizations as well as other service providers, contractors and other companies subject to European data privacy and security laws; and require us to increase our data processing capabilities in Europe at significant expense. Additionally, other countries outside of Europe have enacted or are considering enacting similar cross-border data transfer restrictions and laws requiring local data residency, which could increase the cost and complexity of delivering our services and operating our business. The types of challenges we face in Europe will likely also arise in other </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">201 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
jurisdictions that adopt laws similar in construction to the GDPR or regulatory frameworks of equivalent complexity. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_62">Employees and Human Capital Resources </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September&#160;30, 2022, we had approximately 85 full-time employees, including five employees who have M.D.s or Ph.D.s. Within our workforce, six employees were primarily engaged in research and development, 70 were primarily engaged in sales and marketing and nine were primarily engaged in general management and administration. None of our employees are represented by labor unions or covered by collective bargaining agreements. We believe that we maintain good relationships with our employees. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We focus on identifying, attracting, incentivizing, developing and retaining an exceptional team of highly talented and motivated employees to support our current product pipeline and future business goals. In order to drive innovation, we continuously improve our human capital management strategies and find ways to foster engagement and growth within our company. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We regularly benchmark total rewards we provide against our industry peers to ensure we offer competitive compensation and benefits packages to our employees and potential new hires. The principal purposes of our equity and cash incentive plans are to attract, retain and reward selected personnel through the granting of stock-based and cash-based compensation awards, as well as provide our employees with the opportunity to participate in our employee stock purchase plan, in order to increase stockholder value and the success of our company by motivating such individuals to perform to the best of their abilities and achieve our objectives. We strive to build a diverse environment where our employees can thrive and one that inspires exceptional contributions and professional and personal development in order to achieve our vision to become the leading pain management company that can have a transformative impact on patients&#8217; lives. The success of our business is fundamentally connected to the well-being, health and safety of our employees. In an effort to protect the health and safety of our employees, we took proactive action from the earliest signs of the <span style="white-space:nowrap">COVID-19</span> outbreak, which included implementing social distancing policies at our facilities, facilitating remote working arrangements, requiring proof of vaccination or acceptable exemption, and imposing employee travel restrictions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We plan to continue to develop our efforts related to attracting, retaining and motivating our workforce as we grow and develop. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_63">Facilities and Properties </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our principal executive office is currently located in Palo Alto, California, and consists of approximately 6,000 square feet of leased office space. The lease term expires in October 2024. We also sublease office space in San Diego, California. We believe our facilities are adequate to meet our current needs, although we may seek to negotiate new leases or evaluate additional or alternate space for our operations. We believe appropriate additional or alternative space will be available on commercially reasonable terms. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_64">Legal Proceedings </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time we may become involved in various legal proceedings, including those that may arise in the ordinary course of business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Sanofi-Aventis U.S. LLC and Hisamitsu America, Inc. Litigation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&#160;23, 2021, we filed an action in the U.S. District Court for the Northern District of California against Sanofi-Aventis U.S. LLC and Hisamitsu America, Inc., two manufacturers of OTC lidocaine patch </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">202 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
products, alleging, among other things, false and deceptive advertising and unfair competition under the Lanham Act and California state laws by those companies regarding their respective OTC patch products (the &#8220;Sanofi-Aventis&#160;&amp; Hisamitsu Litigation&#8221;). This lawsuit seeks, among other relief, damages and an injunction enjoining the defendants from continuing to make false or misleading statements of fact about their respective OTC lidocaine patch products. The defendants have filed motions to dismiss, which have narrowed slightly our claims, but which motions the court has largely rejected. Discovery is proceeding. The case is currently scheduled for trial to begin on July&#160;24, 2023. We cannot make any predictions about the outcome in this matter or the timing thereof. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Former Employee Litigation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&#160;12, 2021, we filed an action in the Delaware Court of Chancery against Anthony Mack, former President of Scilex Pharma, and Virpax Pharmaceuticals, Inc. (&#8220;Virpax&#8221;), a company now headed by Mr.&#160;Mack, alleging, among other things, breach by Mr.&#160;Mack of his <span style="white-space:nowrap">non-compete</span> agreement with us, breach of fiduciary duty, and tortious interference by Virpax with that <span style="white-space:nowrap">non-compete</span> agreement (the &#8220;Former Employee Litigation&#8221;). This lawsuit seeks, among other relief, damages and an injunction enjoining Mr.&#160;Mack from further violating his <span style="white-space:nowrap">non-compete</span> agreement and enjoining Virpax from tortiously interfering with Mr.&#160;Mack&#8217;s <span style="white-space:nowrap">non-compete</span> agreement. The case was tried from September&#160;12, 2022 to September&#160;14, 2022. Post-trial briefing is underway and closing arguments remain to be concluded. We cannot make any predictions about the outcome in this matter or the timing thereof. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">ZTlido Patent Litigation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;22, 2022, we filed a complaint against Aveva Drug Delivery Systems, Inc., Apotex Corp., and Apotex, Inc. (together, &#8220;Aveva&#8221;) in the U.S. District Court for the Southern District of Florida (the &#8220;Aveva Patent Litigation&#8221;) alleging infringement of certain Orange Book listed patents covering ZTlido (the &#8220;ZTlido Patents&#8221;). The Aveva Patent Litigation was initiated following the submission by Aveva, in accordance with the procedures set out in the Hatch-Waxman Act, of an ANDA. Aveva&#8217;s ANDA seeks approval to market a generic version of ZTlido prior to the expiration of the ZTlido Patents and alleges that the ZTlido Patents are invalid, unenforceable, and/or not infringed. We are seeking, among other relief, an order that the effective date of any FDA approval of Aveva&#8217;s ANDA be no earlier than the expiration of the asserted patents listed in the Orange Book, the latest of which expires on May&#160;10, 2031, and such further and other relief as the court may deem appropriate. Aveva is subject to a <span style="white-space:nowrap">30-month</span> stay preventing it from selling a generic version of ZTlido during that time. The stay should expire no earlier than November&#160;11, 2024. Trial in the Aveva Patent Litigation has not yet been scheduled. We cannot make any predictions about the final outcome of this matter or the timing thereof. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_65">Our Corporate History </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Legacy Scilex was incorporated in Delaware in February 2019 for the purpose of effecting a corporate reorganization. On March&#160;18, 2019, Legacy Scilex entered into a Contribution and Loan Agreement with Sorrento and the holders of the outstanding shares of capital stock of Scilex Pharma pursuant to which Legacy Scilex acquired 100% of the outstanding shares of capital stock of Scilex Pharma in exchange for shares of Legacy Scilex Common Stock (such transaction, the &#8220;Contribution&#8221;). Pursuant to the Contribution and Loan Agreement, Sorrento provided Legacy Scilex with a loan with an initial principal amount of $16.5&#160;million in the form of a note payable, which loan was used to fund the acquisition of Semnur. Concurrently therewith, Legacy Scilex entered into an Agreement and Plan of Merger with Semnur, Sigma Merger Sub, Inc., Legacy Scilex&#8217;s prior wholly owned subsidiary, Fortis Advisors LLC, solely as representative of the holders of Semnur equity, and Sorrento, for limited purposes (as amended, the &#8220;Semnur Merger Agreement&#8221;). Pursuant to the Semnur Merger Agreement, Sigma Merger Sub, Inc. merged with and into Semnur (such transaction, the &#8220;Semnur Merger&#8221;), with Semnur surviving the Semnur Merger as Legacy Scilex&#8217;s wholly owned subsidiary. As a result of the Contribution and the Semnur Merger, Scilex Pharma and Semnur became Legacy Scilex&#8217;s wholly owned subsidiaries. Prior to the Contribution and the Semnur Merger, operations of Legacy Scilex were conducted through Scilex Pharma, which was formed in September 2012. Semnur was formed in June 2013. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">203 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an &#8220;emerging growth company&#8221; as defined in the JOBS Act. As an emerging growth company, we are eligible for exemptions from various reporting requirements applicable to other public companies that are not emerging growth companies, including, but not limited to, not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act and reduced disclosure obligations regarding executive compensation. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_66">Website </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our website address is <span style="font-style:italic">www.scilexholding.com</span>. We do not incorporate the information on, or accessible through, our website into this prospectus, and you should not consider any information on, or accessible through, our website as part of this prospectus. We have included our website address in this prospectus solely as an inactive textual reference. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">204 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom428534_67">MANAGEMENT </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following sets forth certain information, as of the date of this prospectus, concerning the persons who are serving as our directors and executive officers. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_68">Executive Officers and Directors </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the name, age and position of each of our directors and executive officers, as of December&#160;31, 2022. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:30%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td style="width:60%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Name</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Age</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Position(s)</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Executive Officers</span>:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jaisim Shah</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">62</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Chief Executive Officer, President and Director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Henry Ji, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">58</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Executive Chairperson and Director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Elizabeth A. Czerepak</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">67</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Executive Vice President, Chief Business Officer, Chief Financial Officer and Secretary</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><span style="white-space:nowrap">Non-employee</span> Directors</span>:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dorman Followwill<sup style="font-size:75%; vertical-align:top">(1)(2)(3)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">59</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laura J. Hamill<sup style="font-size:75%; vertical-align:top">(1)(2)(3)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">58</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Tien-Li</span> Lee, M.D.<sup style="font-size:75%; vertical-align:top">(2)(3)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">48</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Lemus<sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">60</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Director</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tommy Thompson</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">&#160;</td>
<td style="vertical-align:top" align="right">81</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Director</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Member of the audit committee. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Member of the compensation committee. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Member of the nominating and corporate governance committee. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Executive Officers </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Jaisim Shah. </span></span>Mr.&#160;Shah has served as our Chief Executive Officer and President and a member of our Board since November&#160;10, 2022. Mr.&#160;Shah has also served as Legacy Scilex&#8217;s President, Chief Executive Officer and a board member since March 2019. He has more than 25 years of global biopharma experience, including over 15&#160;years in senior management leading business development, commercial operations, investor relations, marketing and medical affairs. He also served as the Chief Executive Officer and a board member of Semnur from its inception in 2013 until its acquisition by Scilex in March 2019. Mr.&#160;Shah has served on the board of directors of Scilex Pharma since November 2016. Prior to Semnur, Mr.&#160;Shah was a consultant to several businesses, including Sorrento Therapeutics, Inc., a publicly traded company, and was the Chief Business Officer of Elevation Pharmaceuticals, Inc., where Mr.&#160;Shah led a successful sale of Elevation to Sunovion Pharmaceuticals Inc. in September 2012. Prior to Elevation, Mr.&#160;Shah was president of Zelos Therapeutics, Inc., where he focused on financing and business development. Prior to Zelos, Mr.&#160;Shah was the Senior Vice President and Chief Business Officer at CytRx Corporation, a biopharmaceutical company. Previously, Mr.&#160;Shah was Chief Business Officer at Facet Biotech Corporation and PDL BioPharma, Inc., where he completed numerous licensing/ partnering and strategic transactions with pharmaceutical and biotech companies. Prior to PDL, Mr.&#160;Shah was at Bristol-Myers Squibb, most recently as Vice President of Global Marketing where he received the &#8220;President&#8217;s Award&#8221; for completing one of the most significant collaborations in the company&#8217;s history. Previously, Mr.&#160;Shah was at F. <span style="white-space:nowrap">Hoffman-La</span> Roche AG in international marketing and was global business leader for corporate alliances with Genentech, Inc. and IDEC Corporation. Mr.&#160;Shah previously served as a director of Celularity Inc. from June 2017 to July 2021. He has served as a director of Sorrento Therapeutics, Inc., a publicly traded company, since September 2013. Mr.&#160;Shah holds a M.A. in Economics from the University of Akron and a M.B.A. from Oklahoma University. We believe that Mr.&#160;Shah&#8217;s extensive operational, executive and business development experience qualifies him to serve on our Board. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">205 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Henry Ji, Ph.D. </span></span>Dr.&#160;Ji has served as our Executive Chairperson and a member of our Board since November&#160;10, 2022. Prior to that, he served as Legacy Scilex&#8217;s Executive Chairperson and a board member from March 2019 to November 2022. Dr.&#160;Ji has served on the board of directors of Scilex Pharma since November 2016 and he served as the Chief Executive Officer of Scilex Pharma from November 2016 to March 2019. He <span style="white-space:nowrap">co-founded</span> and has served as a director of Sorrento Therapeutics, Inc., a publicly traded company, since January&#160;2006, served as its Chief Scientific Officer from November 2008 to September 2012, as its Interim Chief Executive Officer from April 2011 to September 2012, as its Secretary from September 2009 to June 2011, as its Chief Executive Officer and President since September 2012 and as Chairman of its board of directors since August 2017. In 2002, Dr.&#160;Ji founded BioVintage, Inc., a research and development company focusing on innovative life sciences technology and product development, and has served as its President since 2002. From 2001 to 2002, Dr.&#160;Ji served as Vice President of CombiMatrix Corporation, a publicly-traded biotechnology company that develops proprietary technologies, including products and services in the areas of drug development, genetic analysis, molecular diagnostics and nanotechnology. During his tenure at CombiMatrix, Dr.&#160;Ji was responsible for strategic technology alliances with biopharmaceutical companies. From 1999 to 2001, Dr.&#160;Ji served as Director of Business Development, and in 2001 as Vice President of Stratagene Corporation (later acquired by Agilent Technologies, Inc.) where he was responsible for novel technology and product licensing and development. In 1997, Dr.&#160;Ji <span style="white-space:nowrap">co-founded</span> Stratagene Genomics, Inc., a wholly owned subsidiary of Stratagene Corporation, and served as its President and Chief Executive Officer from its founding until 1999. Dr.&#160;Ji previously served as a director of Celularity Inc. from June 2017 to July 2021. Dr.&#160;Ji is the holder of several issued and pending patents in the life science research field and is the sole inventor of Sorrento&#8217;s intellectual property. Dr.&#160;Ji has a Ph.D. in Animal Physiology from the University of Minnesota and a B.S. in Biochemistry from Fudan University. Dr.&#160;Ji has demonstrated significant leadership skills as President and Chief Executive Officer of Stratagene Genomics, Inc. and Vice President of CombiMatrix Corporation and Stratagene Corporation and brings more than 20 years of biotechnology and biopharmaceutical experience to his position on the Scilex Board. We believe that Dr.&#160;Ji&#8217;s extensive knowledge of the industry in which we operate allows him to bring to our Board a broad understanding of the operational and strategic issues we face. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Elizabeth A. Czerepak</span></span>. Ms.&#160;Czerepak has served as our Executive Vice President, Chief Business Officer, Chief Financial Officer and Secretary since November&#160;10, 2022. Prior to that, she served on the Legacy Scilex Board from September 2019 to October 2020 and on the board of directors of Sorrento from October 2021 to May 2022. Ms.&#160;Czerepak has over 35 years of experience in big pharma, biotechnology and venture capital. Since September 2020, she has served as the Chief Financial Officer of BeyondSpring Inc., a global biopharmaceutical company focused on developing innovative immuno-oncology cancer therapies. From May&#160;2018 to January 2020, Ms.&#160;Czerepak served as the Chief Financial Officer and the Chief Business Officer of Genevant Sciences, Inc., a technology-focused lipid nanoparticle delivery company, From 2015 to 2018 she served as the Chief Financial Officer and Executive Vice President of Corporate Development of Altimmune, Inc., a clinical stage vaccines company, and from 2014 to 2015, she served as the Chief Financial Officer and the Chief Business Officer of Isarna Therapeutics Inc., which develops selective transforming growth factor beta inhibitors for cancer, ophthalmic and fibrotic diseases. From 2011 to 2014, Ms.&#160;Czerepak served as the Chief Financial Officer, Secretary, Principal Accounting Officer and Head of Human Resources at Cancer Genetics, Inc., a company that develops and commercializes molecular diagnostics. Prior to that, she served as a Managing Director at JPMorgan Chase&#160;&amp; Co. and Bear, Stearns&#160;&amp; Co., a General Partner at Bear Stearns Health Innoventures L.P., a venture capital fund and as a NASD (now FINRA) Registered Representative (Series 7 and Series 63). Since February 2020, Ms.&#160;Czerepak has served as a director and chair of the audit committee of Delcath Systems, Inc., an interventional oncology company focused on the treatment of liver cancer. Ms.&#160;Czerepak previously served on the board of directors of Spectrum Pharmaceuticals, Inc. from June 2019 to December 2020. She holds a B.A. magna cum laude in Spanish and Mathematics Education from Marshall University and a M.B.A. from Rutgers University in 1982. In 2020, Ms.&#160;Czerepak earned a Corporate Director Certificate from Harvard Business School. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">206 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">Non-employee</span> Directors </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Dorman Followwill</span></span>. Mr.&#160;Followwill has served as a member of our Board since November&#160;10, 2022. Prior to that, he served as a director of Legacy Scilex from April 2022 to November 2022, as a director of Sorrento since October 2017 and as its lead independent director since August 2020. Mr.&#160;Followwill was Senior Partner of Transformational Health at Frost&#160;&amp; Sullivan, a business consulting firm involved in market research and analysis, growth strategy consulting and corporate training across multiple industries, from 2016 to September 2020. Prior to that time, he served in various roles at Frost&#160;&amp; Sullivan, including Partner on the Executive Committee managing the P&amp;L of the business in Europe, Israel and Africa, and Partner overseeing the Healthcare and Life Sciences business in North America, since initially joining Frost&#160;&amp; Sullivan to help found the Consulting practice in January 1988. Mr.&#160;Followwill has more than 30 years of organizational leadership and management consulting experience, having worked on hundreds of consulting projects across all major regions and across multiple industry sectors, each project focused around the strategic imperative of growth. He holds a B.A. from Stanford University in The Management of Organizations. We believe that Mr.&#160;Followwill&#8217;s extensive knowledge and understanding of the healthcare and life sciences industries qualify him to serve on our Board. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Laura J. Hamill. </span></span>Ms.&#160;Hamill has served as a member of our Board since November&#160;10, 2022. Prior to that, she served as a director of Legacy Scilex from April 2022 to November 2022 and has extensive experience in the biopharmaceutical industry, with over 30 years of global commercial operational roles in a variety of executive leadership positions. Since <span style="white-space:nowrap">mid-2019,</span> Ms.&#160;Hamill has served as the founder and a consultant at Hamill Advisory Group, LLC. From September 2018 to July 2019, Ms.&#160;Hamill served as the Executive Vice President, Worldwide Commercial Operations at Gilead Sciences, Inc., a research-based biopharmaceutical company, where she was responsible for leading the company&#8217;s global commercial strategic direction and delivering annual revenue of $20&#160;billion. Prior to joining Gilead, Ms.&#160;Hamill held a number of U.S. and international executive positions at Amgen Corporation, a biotechnology company focused on discovering and delivering innovative human therapeutics, from July 2000 to August 2018, most recently as Senior Vice President, U.S. Commercial Operations. During her time at Amgen, Ms.&#160;Hamill established the company&#8217;s intercontinental region and managed the company&#8217;s international marketing and business operations while living abroad in Switzerland for three years. She also served as a member of the company&#8217;s corporate governance team, such as business development, global commercial operations, the Amgen foundation and chair for the company&#8217;s Senior Women&#8217;s Leadership Council. In addition, Ms.&#160;Hamill previously held a variety of executive roles in the biopharmaceutical industry, including positions at Klemtner Inc. and F. <span style="white-space:nowrap">Hoffmann-La</span> Roche AG. Ms.&#160;Hamill has served on the board of directors of a number of public companies, including AnaptysBio, Inc. since September 2019, <span style="white-space:nowrap">Y-mAbs</span> Therapeutics, Inc. since April 2020, Pardes Biosciences, Inc. since August 2021 and BB Biotech AG since March 2022. She previously served as a director at Acceleron Pharma Inc. (acquired by Merck) from September 2020 to December 2021. Ms.&#160;Hamill holds a B.A. in business administration from the University of Arizona. We believe that Ms.&#160;Hamill is qualified to serve on our Board because of her extensive leadership experience in the biopharmaceutical industry and her global commercial operations and strategic planning expertise. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">Tien-Li</span> Lee, M.D. </span></span>Dr.&#160;Lee has served as a member of our Board since November&#160;10, 2022. Prior to that, Dr.&#160;Lee had served as a director of Legacy Scilex from March 2019 to November 2022 and as a director of Scilex Pharma since November 2018. Dr.&#160;Lee has over 20 years of experience as a biotechnology innovator and executive who has been integrally involved with the founding or advancement of several biopharmaceutical companies. He is the founder and has served as the Chief Executive Officer of Aardvark Therapeutics, Inc. since March 2017. Prior to that, Dr.&#160;Lee joined NantKwest, Inc., a publicly-traded immunotherapy company in 2014 and served as its Chief Strategy Officer until March 2017. His experience includes therapeutics for immunology, cardiovascular, oncology, neurology, and infectious disease indications. Dr.&#160;Lee is also an inventor or <span style="white-space:nowrap">co-inventor</span> of multiple biomedical and biotechnology innovations, licensed or assigned to several companies for development including NantKwest, Inc., Simcere Pharmaceutical Group, Cellics Therapeutics, Inc., Sorrento and Aardvark Therapeutics, Inc. Dr.&#160;Lee earned his M.D. degree from the University of California, San Diego and his B.A. degree from the University of California, Berkeley in Molecular Biology. We believe that Dr.&#160;Lee is qualified to serve on our Board because of his experience in management roles at life sciences companies and extensive academic and professional background in the field of biotechnology. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">207 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">David Lemus. </span></span>Mr.&#160;Lemus has served as a member of our Board since November&#160;10, 2022. Prior to that, he served as a director of Legacy Scilex from April 2022 to November 2022 and as a director of Sorrento since October 2017. Mr.&#160;Lemus has served as Chief Executive Officer of IronShore Pharmaceuticals Inc. since January&#160;2020 as well as the founder and Chief Executive Officer of LEMAX LLC since 2017. He also currently serves as a <span style="white-space:nowrap">non-executive</span> board member of Silence Therapeutics, plc and BioHealth Innovation, Inc. and served previously on several other boards of public and private companies as a <span style="white-space:nowrap">non-executive</span> director. He served from November 2017 to September 2018 as the Chief Operating Officer and Chief Financial Officer of Proteros biosciences GmbH. Previously, from January 2016 to May 2017, he served as Interim Chief Financial Officer and Chief Operating Officer of Medigene AG. Prior to that time, at Sigma Tau Pharmaceuticals, Inc., he served as Chief Executive Officer from January 2013 to July 2015, as Chief Operating Officer from March 2012 to December 2012, and as V.P. Finance from July 2011 to February 2012. Mr.&#160;Lemus previously served as Chief Financial Officer and Executive V.P. of MorphoSys AG from January 1998 to May 2011. Prior to his role at MorphoSys AG, he held various positions, including Operations Manager and Controller (Pharma International Division) and Global IT Project Manager (Pharma Division) at F. <span style="white-space:nowrap">Hoffmann-La</span> Roche AG, Group Treasurer of Lindt&#160;&amp; Spruengli AG and Treasury Consultant for Electrolux AB. Mr.&#160;Lemus received a M.S. from the Massachusetts Institute of Technology Sloan School of Management in 1988 and a B.S. in Accounting from the University of Maryland in 1984. Mr.&#160;Lemus is also a certified public accountant licensed in the State of Maryland. We believe that Mr.&#160;Lemus&#8217; extensive accounting and financial background and business experience in the life sciences industry qualify him to serve on our Board. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic">Tommy Thompson. </span></span>Mr.&#160;Thompson has served as a member of our Board since November&#160;10, 2022. Prior to that, Mr.&#160;Thompson served on the Legacy Scilex Board from July 2022 to November 2022. Mr.&#160;Thompson currently serves as the Chief Executive Officer of Thompson Holdings, a consulting firm. From July 2020 to March 2022, Mr.&#160;Thompson served as University of Wisconsin System President. From 2005 to 2012, Mr.&#160;Thompson was a partner in the law firm of Akin Gump Strauss Hauer&#160;&amp; Feld LLP in Washington, D.C, and as an Adjunct Senior Advisor from 2017 to 2020. February 2005 to January 2011, Mr.&#160;Thompson served as President of Logistics Health, Inc., a provider of medical readiness and homeland security solutions. Prior to entering the private sector in 2005, Mr.&#160;Thompson enjoyed a long and distinguished career in public service. From February 2001 to January 2005, Mr.&#160;Thompson served as the former Secretary of the U.S. Department of Health&#160;&amp; Human Services, where he served as the nation&#8217;s leading advocate for the health and welfare of all Americans. Prior to that, Mr.&#160;Thompson served four terms as Governor of Wisconsin from January 1987 to February 2001, where he was best known for his efforts to revitalize the Wisconsin economy, for his national leadership on welfare reform, and for his work toward expanding health care access across all segments of society. Mr.&#160;Thompson currently serves as Chairman of the board of directors of Physicians Realty Trust (NYSE: DOC) and of TherapeuticsMD, Inc. and also serves as a member of the board of directors of United Therapeutics Corporation (Nasdaq: UTHR). He previously served on the boards of directors of various other companies, including Logistics Health, Inc. Health Solutions, a health care consulting company, C. R. Bard, Inc. (NYSE: BCR), Centene Corporation (NYSE: CNC), Plus Therapeutics, Inc. (formerly Cytori Therapeutics, Inc.) (Nasdaq: PSTV), CareView Communications, Inc. (OTCQB: CRVW), Vyant Bio, Inc. (formerly Cancer Genetics, Inc.) (Nasdaq: VYNT), and Pure Bioscience, Inc. (Nasdaq: PURE). Mr.&#160;Thompson received both his B.S. and J.D. from the University of Wisconsin-Madison. We believe that Mr.&#160;Thompson is qualified to serve on our Board because of his experience in public service, particularly his services and knowledge related to the health care industry as a whole, and extensive board experience. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_69">Family Relationships </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are no family relationships among any of the individuals who serve as our directors or executive officers. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_70">Board Composition </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business and affairs are managed under the direction of our Board, which currently consists of seven members. Dr.&#160;Ji serves as Executive Chairperson of our Board. The primary responsibilities of our Board are to </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">208 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
provide oversight, strategic guidance, counseling and direction to our management. Our Board meets on a regular basis and on an <span style="font-style:italic">ad hoc </span>basis as required. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with the terms of the Certificate of Incorporation and the Bylaws, our Board is divided into three classes with staggered three-year terms, as follows: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Class&#160;I directors are Dorman Followwill, David Lemus, and Tommy Thompson, and their term will expire at the annual meeting of stockholders to be held in 2023; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Class&#160;II directors are <span style="white-space:nowrap">Tien-Li</span> Lee, M.D. and Laura J. Hamill and their term will expire at the annual meeting of stockholders to be held in 2024; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Class&#160;III directors are Henry Ji, Ph.D. and Jaisim Shah and their term will expire at the annual meeting of stockholders to be held in 2025. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At each annual meeting of stockholders to be held after the initial classification, the successors to directors whose terms will then expire will be elected to serve from the time of election and qualification until the third annual meeting following their election. The authorized number of directors that shall constitute our Board will be determined exclusively by our Board; <span style="font-style:italic">provided </span>that, at any time the Sorrento Group beneficially owns, in the aggregate, at least 50% in voting power of the then-outstanding shares of our capital stock entitled to vote generally in the election of directors, the stockholders may also fix the number of directors by resolutions adopted by the stockholders. Any increase or decrease in the number of directors will be apportioned among the three classes so that, as nearly equal as practicable, each class will consist of <span style="white-space:nowrap">one-third</span> of the directors. No decrease in the number of directors constituting our Board will shorten the term of any incumbent director. Our directors may be removed with or without cause by the affirmative vote of the holders of a majority in voting power of the then-outstanding shares of our capital stock entitled to vote generally in the election of such directors; <span style="font-style:italic">provided, however</span>, that, from and after the Sorrento Trigger Event any such director or all such directors may be removed only for cause and only by the affirmative vote of the holders of at least 66 2/3% in voting power of all the then-outstanding shares of our capital stock entitled to vote thereon, voting together as a single class. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to applicable law and the Certificate of Incorporation and subject to the rights of the holders of any series of our preferred stock (including pursuant to the Stockholder Agreement), any vacancy on our Board may be filled by our Board or our stockholders; <span style="font-style:italic">provided, however</span>, that from and after the Sorrento Trigger Event, any such vacancy shall be filled only by our Board and not by our stockholders. Any director elected in accordance with the preceding sentence shall hold office until the annual meeting of stockholders for the election of directors of the class to which he or she has been appointed and until his or her successor has been duly elected and qualified, subject, however, to such director&#8217;s earlier death, resignation, retirement, removal or disqualification. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_71">Controlled Company Exemption </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sorrento controls a majority of the voting power for the election of directors. As a result, we are a &#8220;controlled company&#8221; within the meaning of the Nasdaq Listing Rules. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Nasdaq Listing Rules, a company of which more than 50% of the voting power is held by an individual, group or another company is a &#8220;controlled company&#8221; and may elect not to comply with certain corporate governance standards, including, but not limited to, the requirements (i)&#160;that a majority of its board of directors consist of independent directors, (ii)&#160;that its board of directors have a compensation committee that is composed entirely of independent directors with a written charter addressing the committee&#8217;s purpose and responsibilities and (iii)&#160;that director nominees must be selected or recommended for the board&#8217;s selection, either by independent directors constituting a majority of the board&#8217;s independent directors in a vote in which only independent directors participate, or a nominating and corporate governance committee comprised solely of independent directors with a written charter addressing the committee&#8217;s purpose and responsibilities. While we </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">209 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
do not presently intend to rely on these exemptions, we may opt to utilize these exemptions in the future as long as it remains a controlled company. Accordingly, our stockholders may not have the same protections afforded to stockholders of companies that are subject to all of the corporate governance requirements of Nasdaq. If we cease to be a &#8220;controlled company&#8221; and our shares of Common Stock continue to be listed on Nasdaq, we will be required to comply with these standards and, depending on our Board&#8217;s independence determination with respect to its then-current directors, we may be required to add additional directors to our Board in order to achieve such compliance within the applicable transition periods. See the section titled &#8220;<span style="font-style:italic">Risk Factors &#8212; We are a controlled company within the meaning of the Nasdaq Listing Rules and, as a result, qualify for, and may rely on, exemptions from certain corporate governance requirements. Our stockholders may not have the same protection afforded to stockholders of companies that are subject to such governance requirements.</span>&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_72">Director Independence </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Nasdaq Listing Rules, a majority of the members of our Board must satisfy Nasdaq&#8217;s criteria for &#8220;independence.&#8221; As a &#8220;controlled company&#8221;, we are largely exempted from such requirements. Our Board has determined that each of the directors on our Board, other than Dr.&#160;Ji and Mr.&#160;Shah (as a result of their positions as our Executive Chairperson and our Chief Executive Officer, respectively), qualifies as an independent director, as defined by Rule 5605(a)(2) of the Nasdaq Listing Rules and our Board consists of a majority of &#8220;independent directors&#8221; as defined under the rules of the SEC and Nasdaq relating to director independence requirements. In addition, we are subject to the rules of the SEC and Nasdaq relating to the membership, qualifications and operations of the audit committee, as discussed below. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_73">Role of Board in Risk Oversight Process </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Risk assessment and oversight are an integral part of our governance and management processes. Our Board encourages management to promote a culture that incorporates risk management into its corporate strategy and <span style="white-space:nowrap"><span style="white-space:nowrap">day-to-day</span></span> business operations. Management discusses strategic and operational (including cybersecurity) risks at regular management meetings, and conducts specific strategic planning and review sessions during the year that include a focused discussion and analysis of the risks facing the Company. Throughout the year, senior management reviews these risks with our Board at regular board meetings as part of management presentations that focus on particular business functions, operations or strategies, and presents the steps taken by management to mitigate or eliminate such risks. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board is responsible for overseeing our overall risk management process. The responsibility for managing risk rests with executive management while the committees of our Board and our Board as a whole participate in the oversight process. Our Board&#8217;s risk oversight process builds upon management&#8217;s risk assessment and mitigation processes, which include reviews of long-term strategic and operational planning, executive development and evaluation, regulatory and legal compliance and financial reporting and internal controls with respect to areas of potential material risk, including operations, finance, legal, regulatory, cybersecurity, strategic and reputational risk. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_74">Board Leadership Structure </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Bylaws provide our Board with the discretion to combine or separate the positions of Chief Executive Officer and Executive Chairperson of our Board. Our Board is chaired by Dr.&#160;Ji. Our Board believes that separation of the positions of Chief Executive Officer and Executive Chairperson of our Board creates an environment that encourages objective oversight of management&#8217;s performance and enhances the effectiveness of our Board as a whole. We believe that this separation of responsibilities provides a balanced approach to managing our Board and overseeing the Company. However, our Board will continue to periodically review its leadership structure and may make such changes in the future as it deems appropriate. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">210 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_75">Board Diversity </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In evaluating a director candidate&#8217;s qualifications, our Board assesses whether a candidate possesses the integrity, judgment, knowledge, experience, skills and expertise that are likely to enhance our ability, as well as the ability of the committees of our Board, to manage and direct our affairs and business. Our Board may consider many factors, such as personal and professional integrity, ethics and values; experience in corporate management, such as serving as an officer or former officer of a publicly-held company; and experience as a board member or executive officer of another publicly-held company. In addition, our Board may consider diversity in identifying potential director nominees, including diversity of expertise and experience in substantive matters pertaining to our business relative to other board members and diversity of background and perspective, including, but not limited to, with respect to age, gender, race, place of residence and specialized experience. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_76">Committees of our Board </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board has an audit committee, compensation committee and nominating and corporate governance committee. Our Board has adopted a new charter for each of these committees, which complies with the applicable requirements of current Nasdaq Listing Rules. Copies of the charters for each committee are available on the investor relations portion of our website. The composition and responsibilities of each of the committees of our Board are as set forth below. Members will serve on these committees until their resignation or removal or until otherwise determined by our Board. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Audit Committee </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our audit committee consists of David Lemus, Laura J. Hamill and Dorman Followwill, with David Lemus serving as the chairperson of the committee. Each of the members of the audit committee satisfies the independence requirements under the applicable Nasdaq Listing Rules and SEC rules. Each member of the audit committee can read and understand fundamental financial statements under the applicable rules and regulations of the SEC and Nasdaq Listing Rules. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The responsibilities of the audit committee are included in a written charter. The audit committee assists our Board in fulfilling our Board&#8217;s oversight responsibilities with respect to our accounting and financial reporting processes, the systems of internal control over financial reporting and audits of financial statements and reports, the performance of our internal audit function, the quality and integrity of our financial statements and reports, the qualifications, independence and performance of our independent registered public accounting firm, and our compliance with legal and regulatory requirements. For this purpose, the audit committee performs several functions. The audit committee&#8217;s responsibilities include, among others: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">appointing, determining the compensation of, retaining, overseeing and evaluating our independent registered public accounting firm and any other registered public accounting firm engaged for the purpose of performing other review or attest services for the Company; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">prior to commencement of the audit engagement, reviewing and discussing with the independent registered public accounting firm a written disclosure by the prospective independent registered public accounting firm of all relationships between the Company, or persons in financial oversight roles with the Company, and such independent registered public accounting firm or their affiliates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">determining and approving engagements of the independent registered public accounting firm, prior to commencement of the engagement, and the scope of and plans for the audit; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">monitoring the rotation of partners of the independent registered public accounting firm on our audit engagement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing with management and the independent registered public accounting firm any fraud that includes management or other employees who have a significant role in our internal control over financial reporting and any significant changes in internal controls; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">211 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">establishing and overseeing procedures for the receipt, retention and treatment of complaints regarding accounting, internal accounting controls or auditing matters and the confidential and anonymous submission by employees of concerns regarding questionable accounting or auditing matters; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing the results of management&#8217;s efforts to monitor compliance with our programs and policies designed to ensure compliance with laws and rules; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">overseeing our programs, policies and procedures related to our information technology systems, including information asset security and data protection; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and discussing with management and the independent registered public accounting firm the results of the annual audit and the independent registered public accounting firm&#8217;s assessment of the quality and acceptability of our accounting principles and practices and all other matters required to be communicated to the audit committee by the independent registered public accounting firm under generally accepted accounting standards, the results of the independent registered public accounting firm&#8217;s review of our quarterly financial information prior to public disclosure and our disclosures in our periodic reports filed with the SEC. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">David Lemus qualifies as an audit committee financial expert within the meaning of SEC regulations and each of David Lemus, Laura J. Hamill and Dorman Followwill meet the financial sophistication requirements under the Nasdaq Listing Rules. Our independent registered public accounting firm and our management periodically meet separately with the audit committee. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The audit committee reviews, discusses and assesses its own performance and composition at least annually. The audit committee also periodically reviews and assesses the adequacy of its charter, including its role and responsibilities as outlined in its charter, and recommends any proposed changes to our Board for its consideration and approval. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The composition and functioning of the audit committee complies with all applicable requirements of the Sarbanes-Oxley Act and all applicable SEC rules and Nasdaq Listing Rules. We intend to comply with future requirements to the extent they become applicable to the Company. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Compensation Committee </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our compensation committee consists of <span style="white-space:nowrap">Tien-Li</span> Lee, M.D., Dorman Followwill and Laura J. Hamill, with <span style="white-space:nowrap">Tien-Li</span> Lee, M.D. serving as the chairperson of the committee. <span style="white-space:nowrap">Tien-Li</span> Lee, M.D., Dorman Followwill and Laura J. Hamill each satisfy the independence requirements under the Nasdaq Listing Rules. Each of the members of the compensation committee is be a <span style="white-space:nowrap">non-employee</span> director as defined in Rule <span style="white-space:nowrap">16b-3</span> promulgated under the Exchange Act and satisfies Nasdaq independence requirements. The compensation committee acts on behalf of our Board to fulfill our Board&#8217;s responsibilities in overseeing our compensation policies, plans and programs; and in reviewing and determining the compensation to be paid to our executive officers and <span style="white-space:nowrap">non-employee</span> directors. The responsibilities of the compensation committee are included in its written charter. The compensation committee&#8217;s responsibilities include, among others: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing, modifying and approving (or, if it deems appropriate, making recommendations to our Board regarding) our overall compensation strategy and policies, and reviewing, modifying and approving corporate performance goals and objectives relevant to the compensation of our executive officers and other senior management; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">determining and approving (or, if it deems appropriate, recommending to our Board for determination and approval) the compensation and terms of employment of our Chief Executive Officer, including seeking to achieve an appropriate level of risk and reward in determining the long-term incentive component of the compensation of the Chief Executive Officer; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">212 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">determining and approving (or, if it deems appropriate, recommending to our Board for determination and approval) the compensation and terms of employment of our executive officers and other members of senior management; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and approving (or, if it deems appropriate, making recommendations to our Board regarding) the terms of employment agreements and severance agreements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="white-space:nowrap"><span style="white-space:nowrap">change-of-control</span></span> protections and other compensatory arrangements for our executive officers and other members of senior management; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">conducting periodic reviews of the base compensation levels of all of our employees generally; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and approving the type and amount of compensation to be paid or awarded to <span style="white-space:nowrap">non-employee</span> directors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and approving the adoption, amendment and termination of our equity incentive plans, stock appreciation rights plans, pension and profit sharing plans, incentive plans, stock bonus plans, stock purchase plans, bonus plans, deferred compensation plans, 401(k) plans, supplemental retirement plans and similar programs, if any; and administering all such plans, establishing guidelines, interpreting plan documents, selecting participants, approving grants and awards and exercising such other power and authority as may be permitted or required under such plans; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing our incentive compensation arrangements to determine whether such arrangements encourage excessive risk-taking, reviewing and discussing at least annually the relationship between our risk management policies and practices and compensation and evaluating compensation policies and practices that could mitigate any such risk. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, once we cease to be an &#8220;emerging growth company,&#8221; as defined in the JOBS Act, the responsibilities of the compensation committee will also include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and recommending to our Board for approval the frequency with which we conduct a vote on executive compensation, taking into account the results of the most recent stockholder advisory vote on the frequency of the vote on executive compensation, and reviewing and approving the proposals regarding the frequency of the vote on executive compensation to be included in our annual meeting proxy statements; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and discussing with management our Compensation Discussion and Analysis, and recommending to our Board that the Compensation Discussion and Analysis be approved for inclusion in our annual reports on Form <span style="white-space:nowrap">10-K,</span> registration statements and our annual meeting proxy statements. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under its charter, the compensation committee may form, and delegate authority to, subcommittees as appropriate. The compensation committee reviews, discusses and assesses its own performance and composition at least annually. The compensation committee also periodically reviews and assesses the adequacy of its charter, including its role and responsibilities as outlined in its charter, and recommends any proposed changes to our Board for its consideration and approval. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The composition and functioning of the compensation committee complies with all applicable requirements of the Sarbanes-Oxley Act and all applicable SEC rules and Nasdaq Listing Rules. We intend to comply with future requirements to the extent they become applicable to the Company. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Nominating and Corporate Governance Committee </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our nominating and corporate governance committee consists of <span style="white-space:nowrap">Tien-Li</span> Lee, M.D., Dorman Followwill and Laura J. Hamill, with Dorman Followwill serving as the chairperson of the committee. <span style="white-space:nowrap">Tien-Li</span> Lee, M.D., Dorman Followwill and Laura J. Hamill each satisfy the independence requirements under the Nasdaq Listing Rules. The responsibilities of the nominating and corporate governance committee are included in its written </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">213 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
charter. The nominating and corporate governance committee acts on behalf of our Board to fulfill our Board&#8217;s responsibilities in overseeing all aspects of our nominating and corporate governance functions. The responsibilities of the nominating and corporate governance committee include, among others: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">making recommendations to our Board regarding corporate governance issues; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">identifying, reviewing and evaluating qualified candidates to serve as directors (consistent with criteria approved by our Board); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">determining the minimum qualifications for service on our Board; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and evaluating incumbent directors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">instituting and overseeing director orientation and director continuing education programs; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">serving as a focal point for communication between candidates, <span style="white-space:nowrap">non-committee</span> directors and our management; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">recommending to our Board for selection candidates to serve as nominees for director for the annual meeting of stockholders; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">making other recommendations to our Board regarding matters relating to the directors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing succession plans for our Chief Executive Officer and our other executive officers; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reviewing and overseeing matters of corporate responsibility and sustainability, including potential <span style="white-space:nowrap">long-and</span> short-term trends and impacts to our business of environmental, social and governance issues, and our public reporting on these topics; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">considering any recommendations for nominees and proposals submitted by stockholders. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The nominating and corporate governance committee periodically reviews, discusses and assesses the performance of our Board and the committees of our Board. In fulfilling this responsibility, the nominating and corporate governance committee seeks input from senior management, our Board and others. In assessing our Board, the nominating and corporate governance committee evaluates the overall composition of our Board, our Board&#8217;s contribution as a whole and its effectiveness in serving our best interests and the best interests of our stockholders. The nominating and corporate governance committee reviews, discusses and assesses its own performance and composition at least annually. The nominating and corporate governance committee also periodically reviews and assesses the adequacy of its charter, including its role and responsibilities as outlined in its charter, and recommend any proposed changes to our Board for its consideration and approval. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The composition and functioning of the nominating and corporate governance committee complies with all applicable requirements of the Sarbanes-Oxley Act and all applicable SEC rules and Nasdaq Listing Rules. We intend to comply with future requirements to the extent they become applicable to the Company. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_77">Code of Business Conduct and Ethics </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the Closing of the Business Combination, on November&#160;10, 2022, our Board approved and adopted a written code of business conduct and ethics, applicable to directors, officers and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. A current copy of our code of business conduct and ethics is posted on our website at <span style="font-style:italic">www.scilexholding.com</span>. Information contained on or accessible through our website is not a part of this prospectus, and the inclusion of the website address in this prospectus is an inactive textual reference only. We intend to disclose any amendments to our code of business conduct and ethics, or any waivers of its requirements, on our website to the extent required by the applicable rules and exchange requirements. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">214 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_78">Compensation Committee Interlocks and Insider Participation </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None of the members of our compensation committee is currently, or has been at any time in the past year, one of our officers or employees. Other than Dr.&#160;Ji and Mr.&#160;Shah, none of our executive officers currently serves, or has served during the last year, as a member of the board of directors or compensation committee of any entity that has one or more executive officers serving as a member of our Board or compensation committee. Please see the section of this prospectus titled &#8220;<span style="font-style:italic">Executive and Director Compensation</span>&#8221; for information regarding the compensation of Dr.&#160;Ji and Mr.&#160;Shah. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_79">Limitation of Liability and Indemnification of Directors and Officers </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation and the Bylaws contain provisions that limit the liability of our directors for monetary damages to the fullest extent permitted by the DGCL. Consequently, our directors will not be personally liable to us or our stockholders for monetary damages for any breach of fiduciary duties as directors, except liability for the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any breach of their duty of loyalty to us or our stockholders; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">unlawful payments of dividends or unlawful stock repurchases or redemptions in violation of the DGCL; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any transaction from which the director derived an improper personal benefit. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation also provides that if the DGCL is amended to permit further elimination or limitation of the personal liability of directors, then the liability of our directors will be eliminated or limited to the fullest extent permitted by the DGCL, as so amended. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Bylaws provide that we shall indemnify any person who is or was a director or officer of the Company or who is or was serving at our request as a director, officer or trustee of another corporation, limited liability company, partnership, joint venture, employee benefit plan, trust, nonprofit entity or other enterprise (a &#8220;Covered Person&#8221;), and who is or was a party to, is threatened to be made a party to, or is otherwise involved (including as a witness) in any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative, or investigative based on such person&#8217;s actions in his or her official capacity as a director or officer of the Company or as a director, officer or trustee of another corporation, limited liability company, partnership, joint venture, employee benefit plan, trust, nonprofit entity or other enterprise (to the extent serving in such position at our request), in each case against all liability and loss suffered (including, without limitation, any judgments, fines, excise taxes or penalties arising under the Employee Retirement Income Security Act of 1974 and amounts paid in settlement consented to in writing by us) and expenses (including attorneys&#8217; fees), actually and reasonably incurred by such person in connection therewith, subject to certain conditions. In addition, the Bylaws provide that we may, to the fullest extent permitted by law, (i)&#160;advance costs, fees or expenses (including attorneys&#8217; fees) incurred by a Covered Person defending or participating in any proceeding in advance of the final disposition of such proceeding, subject to certain exceptions, and (ii)&#160;purchase and maintain insurance, at our expense, to protect us and any person who is or was our director, officer, employee or agent or is or was our director, officer, employee or agent serving at our request as a director, officer, employee or agent of another corporation, limited liability company, partnership, joint venture, trust, employee benefit plan or other enterprise against any liability, expense or loss, whether or not we would have the power or obligation to indemnify such person against such liability, expense or loss under the DGCL or the provisions of the Bylaws. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into indemnification agreements with each of our directors and executive officers as determined by our Board. These agreements, among other things, require us to indemnify our directors and executive officers against liabilities that may arise by reason of their status or service. These indemnification agreements also require us to advance all expenses actually and reasonably incurred by the directors and </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">215 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
executive officers in connection with any proceeding. We believe that these agreements are necessary to attract and retain qualified individuals to serve as directors and executive officers. We also maintain directors&#8217; and officers&#8217; liability insurance. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The above description of the indemnification provisions of the Certificate of Incorporation, the Bylaws and the indemnification agreements is not complete and is qualified in its entirety by reference to these documents, each of which is filed as an exhibit to the registration statement of which this prospectus is a part. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of our <span style="white-space:nowrap">non-employee</span> directors may, through their relationships with their employers, be insured or indemnified against certain liabilities incurred in their capacity as members of our Board. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The limitation of liability and indemnification provisions in the Certificate of Incorporation and the Bylaws may discourage stockholders from bringing a lawsuit against our directors and officers for breach of their fiduciary duty. They may also reduce the likelihood of derivative litigation against our directors and officers, even though an action, if successful, might benefit us and our stockholders. In addition, a stockholder&#8217;s investment may be adversely affected to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors or executive officers, we have been informed that in the opinion of the SEC, such indemnification is against public policy and is therefore unenforceable. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At present, there is no pending litigation or proceeding involving any of our directors or executive officers as to which indemnification is required or permitted, and we are not aware of any threatened litigation or proceeding that may result in a claim for indemnification. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">216 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom428534_80">EXECUTIVE AND DIRECTOR COMPENSATION </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_81">Executive Compensation </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Vickers Executive Officers and Director Compensation Prior to Completion of the Business Combination </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the Closing of the Business Combination, none of Vickers&#8217;s executive officers or directors received any cash compensation for services rendered to Vickers. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Scilex and Current Executive Compensation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To achieve our goals, we have designed, and intend to modify as necessary, our compensation and benefits programs to attract, retain, incentivize and reward deeply talented and qualified executives who share our philosophy and desire to work towards achieving our goals. We believe our compensation programs should promote the success of the Company and align executive incentives with the long-term interests of our stockholders. This section provides an overview of the material components of our executive compensation programs, including a narrative description of the material factors necessary to understand the information disclosed in the summary compensation table below. The following is a discussion and analysis of the material components of the compensation arrangements of Scilex&#8217;s named executive officers in 2022. As an &#8220;emerging growth company&#8221; as defined in the JOBS Act, we are not required to include a Compensation Discussion and Analysis section and have elected to comply with the scaled disclosure requirements applicable to emerging growth companies. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board or the compensation committee of our Board, with input from our Executive Chairperson and Chief Executive Officer, historically determined the compensation for Scilex&#8217;s named executive officers. Our named executive officers for the year ended December&#160;31, 2022, were Jaisim Shah, our Chief Executive Officer and President, Henry Ji, our Executive Chairperson and Elizabeth Czerepak, our Executive Vice President, Chief Business Officer, Chief Financial Officer and Secretary. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_82">Summary Compensation Table </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth certain information with respect to the compensation paid or accrued to Scilex&#8217;s named executive officers for the fiscal years ended December&#160;31, 2022 and December&#160;31, 2021:<span style="font-weight:bold"><span style="font-style:italic"> </span></span> </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:32%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name and principal position</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Year</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Salary ($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Bonus&#160;($)<sup style="font-size:75%; vertical-align:top">(1)</sup></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Stock<br />awards<br />($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Option<br />awards<br />($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold"><span style="white-space:nowrap">Non-equity</span><br />incentive<br />plan<br />compensation<br />($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold"><span style="white-space:nowrap">Non-qualified</span><br />deferred<br />compensation<br />earnings ($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">All other<br />compensation<br />($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Total ($)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Jaisim Shah</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">773,298</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$<span style="font-weight:bold"></span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12,435<span style="font-weight:bold"></span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"><sup style="font-size:75%; vertical-align:top">(2)</sup></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">785,733</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Chief Executive Officer, President and Director</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2021</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">579,280</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$<span style="font-weight:bold"></span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">290,509<span style="font-weight:bold"></span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"><sup style="font-size:75%; vertical-align:top">(3)</sup></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$<span style="font-weight:bold"></span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11,600<span style="font-weight:bold"></span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"><sup style="font-size:75%; vertical-align:top">(2)</sup></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">881,389</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Henry Ji, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">626,548</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">626,548</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Executive Chairperson</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Elizabeth Czerepak</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">172,917</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$<span style="font-weight:bold"></span></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">50,000<span style="font-weight:bold"></span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"><sup style="font-size:75%; vertical-align:top">(4)</sup></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">222,917</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Executive Vice President, Chief Business Officer, Chief Financial Officer and Secretary</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Does not include for 2022 the amount of any bonuses that may be awarded to our named executive officers as our compensation committee has not, as of the date of the filing of this prospectus, yet determined bonus </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">217 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td align="left" style="vertical-align:top">
amounts, if any, that may be awarded to our named executive officers for 2022. If any such bonus amounts are determined, we will, in accordance with Securities and Exchange Commission rules and regulations, file a Current Report on Form <span style="white-space:nowrap">8-K</span> or otherwise disclose the 2022 bonus amounts within four business days after our compensation committee has assessed 2022 performance and determined any bonus awards for 2022 for our named executive officers. </td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents matching contributions made to Mr.&#160;Shah under the Company&#8217;s 401(k) plan. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents discretionary bonus amount awarded to Mr.&#160;Shah by the Legacy Scilex Board. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents a signing bonus awarded to Ms.&#160;Czerepak in connection with her becoming our Executive Vice President, Chief Business Officer, Chief Financial Officer and Secretary. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_83">Narrative Disclosure to Summary Compensation Table </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Arrangements with Executive Officers </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Scilex has entered into an offer letter with each of Mr.&#160;Shah and Ms.&#160;Czerepak. The material terms of the offer letters are described below. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Shah Offer Letter and Compensation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Scilex entered into an offer letter with Mr.&#160;Shah (the &#8220;Shah Offer Letter&#8221;) dated April&#160;19, 2019, pursuant to which Mr.&#160;Shah serves as the Chief Executive Officer of Scilex Pharma. Under the Shah Offer Letter, Mr.&#160;Shah&#8217;s annual base salary was initially set at $407,925, which was increased to $579,280 in 2020 and to $792,000 on November&#160;11, 2022 (but became effective as of March&#160;17, 2022). Mr.&#160;Shah&#8217;s employment with Scilex is <span style="white-space:nowrap">at-will,</span> and either Scilex or Mr.&#160;Shah may terminate the terms and conditions of the employment relationship at any time, with or without cause and with or without notice. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;6, 2019, Scilex issued to Mr.&#160;Shah an option to purchase 8,126,836 shares of Scilex Common Stock, with an exercise price equal to $1.73 per share, whereby 25% of the shares vested on March&#160;18, 2020, and 1/48th of the total amount of the shares vested and shall vest each month thereafter, subject to Mr.&#160;Shah providing continuous service (as defined in the 2019 Stock Option Plan) on each such vesting date, inclusive. On December&#160;21, 2020, Scilex issued to Mr.&#160;Shah an additional option to purchase 1,626,497 shares of Scilex Common Stock, with an exercise price equal to $1.73 per share, whereby 25% of the shares vested on December&#160;21, 2021, and 1/48th of the total amount of the shares vested and shall vest each month thereafter, subject to Mr.&#160;Shah providing continuous service (as defined in the 2019 Stock Option Plan) on each such vesting date, inclusive. The foregoing number of shares and exercise prices for Mr.&#160;Shah&#8217;s options reflect the application of the Exchange Ratio in the Business Combination. Each of the foregoing options also vest in full if there is a Change in Control (as defined in the 2019 Stock Option Plan) and Mr.&#160;Shah&#8217;s continuous service terminates due to an involuntary termination of employment without &#8220;cause&#8221; or due to a voluntary termination of employment with &#8220;good reason&#8221; (each, as defined in the applicable option agreement) within 13 months after the effective time of such Change in Control. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Ji Compensation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Scilex has not entered into an offer letter or employment agreement in connection with Dr.&#160;Ji&#8217;s service as our Executive Chairperson. On November&#160;11, 2022, our compensation committee approved Dr.&#160;Ji&#8217;s annual base salary of $792,000 and bonus of $554,400, effective as of March&#160;17, 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&#160;20, 2019, Scilex issued to Dr.&#160;Ji, in connection with his service as a director, an option to purchase 2,031,708 shares of Scilex Common Stock, with an exercise price equal to $1.73 per share, whereby 25% of the shares vested on March&#160;18, 2020, and 1/48th of the total amount of the shares vested and shall vest each month thereafter, subject to Dr.&#160;Ji providing continuous service (as defined in the 2019 Stock Option Plan) on each such vesting date, inclusive. The foregoing number of shares and exercise price for Dr.&#160;Ji&#8217;s option reflects the application of the Exchange Ratio in the Business Combination. Each of the foregoing options also </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">218 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
vest in full if there is a Change in Control (as defined in the 2019 Stock Option Plan) and Dr.&#160;Ji&#8217;s continuous service terminates due to an involuntary termination of employment without &#8220;cause&#8221; or due to a voluntary termination of employment with &#8220;good reason&#8221; (each, as defined in the applicable option agreement) within 13&#160;months after the effective time of such Change in Control. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Czerepak Offer Letter and Compensation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Scilex entered into an offer letter with Ms. Czerepak (the &#8220;Czerepak Offer Letter&#8221;) dated April&#160;27, 2022, pursuant to which Ms. Czerepak serves as our Executive Vice President, Chief Business Officer, and Chief Financial Officer. Under the Czerepak Offer Letter, Ms. Czerepak&#8217;s annual base salary is $300,000 and she was awarded a $50,000 signing bonus. Following the closing of the Business Combination and Scilex&#8217;s filing of a Registration Statement on Form <span style="white-space:nowrap">S-8,</span> subject to the Board&#8217;s approval, Scilex shall grant Ms. Czerepak an incentive stock option to purchase 350,000 shares of Scilex Common Stock, which shall vest over a four year period, whereby 1/4<sup style="font-size:75%; vertical-align:top">th</sup> of the shares subject to the option shall vest on the date that is one year after the vesting commencement date and an additional 1/48<sup style="font-size:75%; vertical-align:top">th</sup> of the shares subject to the option shall vest on the same date of each month thereafter, subject to Ms. Czerepak providing continuous service (as defined in the equity incentive plan pursuant to which the option will be granted) on each such vesting date, inclusive. In addition, all of the shares subject to the option will vest upon the occurrence of a change in control (as defined in the Equity Incentive Plan) that occurs prior to the termination of her continuous service. Ms. Czerepak&#8217;s employment with Scilex is <span style="white-space:nowrap">at-will,</span> and either Scilex or Ms. Czerepak may terminate the terms and conditions of the employment relationship at any time, with or without cause and with or without notice. However, if Scilex terminates Ms. Czerepak&#8217;s employment other than for cause or Ms. Czerepak resigns from her employment with Scilex for good reason (each, as defined in the Czerepak Offer Letter), subject to Ms. Czerepak&#8217;s execution and delivery of a release of claims in a form prescribed by Scilex, and so long as Ms. Czerepak has not been offered a full-time position at Sorrento with a base salary and annual bonus potential of not less than the combined base salary and target bonus she received from both Scilex and Sorrento, if any, as of immediately prior to the termination of her employment, Scilex will continue to pay Ms.&#160;Czerepak her base salary for a period of twelve months. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&#160;14, 2019, Scilex issued to Ms.&#160;Czerepak, in connection with her service as a director, an option to purchase 404,098 shares of Scilex Common Stock, with an exercise price equal to $1.73 per share, whereby 1/48th of the shares vested on September&#160;23, 2019<span style="font-weight:bold">, </span>and 1/48th of the total amount of the shares vested and shall vest each month thereafter, subject to Ms.&#160;Czerepak providing continuous service (as defined in the 2019 Stock Option Plan) on each such vesting date, inclusive. The foregoing number of shares and exercise price for Ms.&#160;Czerepak&#8217;s option reflects the application of the Exchange Ratio in the Business Combination. Each of the foregoing options also vest in full if there is a Change in Control (as defined in the 2019 Stock Option Plan) and Ms.&#160;Czerepak&#8217;s continuous service terminates due to an involuntary termination of employment without &#8220;cause&#8221; or due to a voluntary termination of employment with &#8220;good reason&#8221; (each, as defined in the applicable option agreement) within 13 months after the effective time of such Change in Control. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Additional Arrangements with Executive Officers </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based upon the information provided by Compensia, a national compensation consulting firm engaged by our compensation committee to review and advise on our compensation practices, on November&#160;11, 2022, our compensation committee approved the following base salaries and target bonuses (on terms and conditions determined by our Board) of our executive officers, effective as of March&#160;17, 2022. As noted above, however, our compensation committee has not, as of the date of the filing of this prospectus, yet determined bonus amounts, if any, that may be awarded to our named executive officers for 2022: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:76%"></td>

<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Salary</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Target<br />Bonus</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Henry Ji</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">792,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">70</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jaisim Shah</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">792,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">70</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Elizabeth Czerepak</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">300,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">50</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">219 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the filing of the Company&#8217;s Registration Statement on Form <span style="white-space:nowrap">S-8</span> with respect to the 2022 Equity Incentive Plan, we anticipate that our compensation committee will approve the following stock option grants thereunder, subject to the continued service of the individuals: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">


<tr>

<td style="width:82%"></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Stock<br />Options</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Henry Ji</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jaisim Shah</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,700,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Elizabeth Czerepak</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">350,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_84">Potential Payments upon Termination or Change in Control </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended December&#160;31, 2022, Scilex did not have any arrangement with any of its named executive officers providing for potential payments, compensation or other benefits upon termination or the occurrence of a change of control, other than the severance provision for Ms.&#160;Czerepak and the accelerated vesting provisions pursuant to previously granted options as described above. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_85">Perquisites, Health, Welfare and Retirement Benefits </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our executive officers, during their employment with us, are eligible to participate in our employee benefit plans, including our medical, vision and dental insurance plans, in each case on the same basis as all of our other employees. We generally do not provide perquisites or personal benefits to our named executive officers, except in limited circumstances. We do, however, pay the premiums for medical, vision and dental insurance for all of our employees, including our named executive officers. Our Board may elect to adopt qualified or nonqualified benefit plans in the future if it determines that doing so is in our best interests. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_86">Pension Benefits and Nonqualified Deferred Compensation </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mr.&#160;Shah participates in our <span style="white-space:nowrap">tax-qualified</span> Section&#160;401(k) plan and we provide a 4% matching contribution up to an annual compensation limit ($305,000 in 2022). We do not provide any other pension plan for our employees, and none of Scilex&#8217;s named executive officers participated in a nonqualified deferred compensation plan during the year ended December&#160;31, 2022. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_87">Outstanding Equity Awards at Fiscal <span style="white-space:nowrap">Year-End</span> 2022 </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents certain information concerning outstanding equity awards held by each of Scilex&#8217;s named executive officers as of December&#160;31, 2022. Following the Business Combination, each outstanding equity award with respect to our Common Stock reflected in the table below was equitably adjusted in accordance with the terms of the Merger Agreement and the 2019 Stock Option Plan. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:39%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="22" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Option awards<sup style="font-size:75%; vertical-align:top">(1)(2)</sup></span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold">Name</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Option<br />Grant Date</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Vesting<br />Commencement<br />Date</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number of<br />securities<br />underlying<br />unexercised<br />options (#)<br />exercisable</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number of<br />securities<br />underlying<br />unexercised<br />options (#)<br />unexercisable</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Option<br />exercise<br />price<br />per<br />share($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Option<br />expiration<br />date</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jaisim Shah</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6/6/2019</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3/18/2019<span style="font-weight:bold"></span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"><sup style="font-size:75%; vertical-align:top">(3)</sup></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,618,908</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">507,928</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1.73</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6/6/2029</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12/21/2020</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12/21/2020<span style="font-weight:bold"></span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"><sup style="font-size:75%; vertical-align:top">(3)</sup></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">813,248</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">813,249</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1.73</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12/21/2030</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Henry Ji, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9/20/2019</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3/18/2019<span style="font-weight:bold"></span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"><sup style="font-size:75%; vertical-align:top">(3)</sup></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,904,726</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">126,982</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1.73</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9/20/2029</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Elizabeth Czerepak</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10/14/2019</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"></span>&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9/23/2019<span style="font-weight:bold"></span></td>
<td style="white-space:nowrap;vertical-align:bottom"><span style="font-weight:bold"><sup style="font-size:75%; vertical-align:top">(4)</sup></span>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">328,330</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">75,768</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1.73</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10/14/2029</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Pursuant to the terms of the Merger Agreement, effective as of the closing of the Business Combination on November&#160;10, 2022, outstanding equity awards were adjusted as follows: (i)&#160;each option to purchase Legacy Scilex Common Stock that was outstanding as of immediately prior to the Effective Time was converted </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">220 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td align="left" style="vertical-align:top">
into the right to receive an option relating to our Common Stock upon substantially the same terms and conditions as were in effect with respect to such option immediately prior to the Effective Time (the &#8220;Option&#8221;) except that (x)&#160;such Option relates to that whole number of shares of Common Stock (rounded down to the nearest whole share) equal to the number of shares of Legacy Scilex Common Stock subject to such Option, multiplied by the Exchange Ratio of 0.673498:1, and (y)&#160;the exercise price per share for each such share of Common Stock equals the exercise price per share of such Option in effect immediately prior to the Effective Time, divided by the Exchange Ratio (rounded up to the nearest whole cent). The numbers in the table reflect the share numbers outstanding and exercise prices as of December&#160;31, 2022, in each case after giving effect to the Exchange Ratio. </td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Each option was granted under the 2019 Stock Option Plan. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Each option vested as to 1/4th of the shares subject to the option on the one year anniversary of the vesting commencement date and 1/48th of the shares subject to the option vested and shall vest on each monthly anniversary thereafter, subject to full acceleration in the event of an involuntary termination of employment without &#8220;cause&#8221; or due to a voluntary termination of employment with &#8220;good reason&#8221; (each, as defined in the applicable option agreement) within 13 months following a Change in Control (as defined in the 2019 Stock Option Plan). </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">This option vested and shall vest as to 1/48th of the shares subject to the option on each monthly anniversary commencing on September&#160;23, 2019, subject to full acceleration in the event of an involuntary termination of employment without &#8220;cause&#8221; or due to a voluntary termination of employment with &#8220;good reason&#8221; (each, as defined in the applicable option agreement) within 13 months following a Change in Control (as defined in the 2019 Stock Option Plan). </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_88">Equity-Based Incentive Plans </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">2017 Scilex Pharmaceuticals Inc. Equity Incentive Plan </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The board of directors of Scilex Pharma originally adopted and its stockholders approved the 2017 Scilex Pharmaceuticals Inc. Equity Incentive Plan (the &#8220;Scilex Pharma 2017 Plan&#8221;) on June&#160;26, 2017. The Scilex Pharma 2017 Plan was amended and restated on July&#160;5, 2018. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Scilex Pharma 2017 Plan, as amended and restated, provided that Scilex Pharma could grant incentive stock options, <span style="white-space:nowrap">non-statutory</span> stock options, stock awards, stock unit awards, stock appreciation rights and other stock awards. The only form of equity award granted under the Scilex Pharma 2017 Plan was options to purchase shares of common stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of immediately prior to the corporate reorganization that was effected in March 2019, the maximum number of shares of common stock of Scilex Pharma that could be issued under the Scilex Pharma 2017 Plan was 24,000,000, of which 18,099,000 remained available for future grants. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the corporate reorganization in March 2019, the Scilex Pharma 2017 Plan was terminated. Accordingly, after such time, no additional awards were granted under the Scilex Pharma 2017 Plan. Each option to purchase shares of common stock of Scilex Pharma outstanding and unexercised immediately prior to the Contribution was cancelled and substituted for an option to purchase the equivalent number of shares of Legacy Scilex Common Stock. Each new option was subject to the same terms and conditions as were in effect immediately prior to the Contribution. No stock options of Scilex Pharma were outstanding following the reorganization. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2022, options to purchase 744,201 shares of our Common Stock were outstanding pursuant to options previously granted under the Scilex Pharma 2017 Plan. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Scilex Holding Company 2019 Stock Option Plan </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Legacy Scilex Board adopted the Scilex Holding Company 2019 Stock Option Plan (the &#8220;2019 Stock Option Plan&#8221;) on May&#160;28, 2019. The 2019 Stock Option Plan was approved by Legacy Scilex&#8217;s stockholders on </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">221 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
June&#160;24, 2019. Upon adoption, 30,000,000 shares of Legacy Scilex Common Stock were authorized for issuance under the 2019 Stock Option Plan. The Legacy Scilex Board and Legacy Scilex&#8217;s stockholders approved an amendment to the 2019 Stock Option Plan on December&#160;21, 2020 to increase the number of shares authorized thereunder by 15,000,000 shares. As of December&#160;31, 2022, options to purchase 16,195,178 shares of our Common Stock were outstanding under the 2019 Stock Option Plan. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2019 Stock Option Plan has terminated at the Closing, and no further awards has been granted under the 2019 Stock Option Plan thereafter. However, the 2019 Stock Option Plan will continue to govern outstanding awards granted thereunder. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of the material terms of the 2019 Stock Option Plan. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Authorized Shares</span>. Under the 2019 Stock Option Plan, an aggregate of 30,000,000 shares of Legacy Scilex Common Stock were initially reserved for future issuance, which number was increased to 45,000,000 in December 2020. The authorized shares are subject to adjustment in the event of a change that occurs with respect to the common stock without the receipt of consideration by Scilex, including a merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, stock split, reverse stock split, liquidating dividend, combination of shares, exchange of shares, recapitalization, reincorporation, reorganization, change in corporate structure, or similar equity restructuring transaction. Additionally, shares issued pursuant to awards under the 2019 Stock Option Plan that are repurchased or that are forfeited, as well as shares reacquired as consideration for the exercise or purchase price of an award or to satisfy tax withholding obligations related to an award, will become available for future grant under the 2019 Stock Option Plan. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Types of Awards</span>. The 2019 Stock Option Plan provided for the granting of (1)&#160;incentive stock options intended to qualify as incentive stock options under the Code, (2)&#160;nonstatutory stock options that do not qualify as an incentive stock option, (3)&#160;stock appreciation rights, (4)&#160;restricted stock awards, (5)&#160;restricted stock unit awards and (6)&#160;other stock awards. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Eligibility. </span>Incentive stock options could only be granted to Legacy Scilex&#8217;s employees or employees of its affiliates, and stock awards other than incentive stock options may be granted to employees, directors and consultants. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Stock Options and Stock Appreciation Rights</span>. The Legacy Scilex Board determined the exercise price for stock options and stock appreciation rights, provided that the exercise price generally could not be less than 100% of the fair market value of Legacy Scilex Common Stock on the date of grant, subject to certain exceptions relating to the assumption or substitution of options or stock appreciation rights in connection with a corporate transaction in a manner consistent with Section&#160;409A or, if applicable, Section&#160;424(a) of the Code. Unless an award agreement provides otherwise, the termination date shall be: (1)&#160;the earlier of 18 months or upon the expiration of the option or stock appreciation right, if termination is due to death; (2)&#160;the earlier of 12 months or upon the expiration of the option or stock appreciation right, if termination is due to disability; or (3)&#160;three months, if termination is due to reasons other than for death, disability or cause. If the termination of service is due to cause, the stock option or stock appreciation right will terminate immediately upon such termination of service, and the participant will be prohibited from exercising the option or stock appreciation right. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Restricted Stock and Restricted Stock Unit Awards</span>. Each restricted stock and restricted stock unit award agreement is in the form and contains such terms and conditions as the Legacy Scilex Board deemed appropriate. Unless otherwise provided in the award agreement, the Legacy Scilex Board held certificates or, if not certificated, other indicia representing the restricted shares. If a recipient&#8217;s service terminates, Legacy Scilex could receive through a forfeiture condition or a repurchase right, any or all of the shares of common stock held by the recipient as of the date of termination. Restricted stock units not yet vested shall be forfeited upon termination of the recipient&#8217;s employment unless otherwise set forth in the award. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">222 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Transferability</span>. Stock options or stock appreciation rights are generally not transferable except by will or by the laws of descent and distribution or as otherwise provided under the 2019 Stock Option Plan. Restricted stock awards could be transferable by the participant only upon such terms and conditions as are set forth in the restricted stock award agreement, as the Legacy Scilex Board determines in its sole discretion. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Administration</span>. The 2019 Stock Option Plan is administered by our Board, although our Board may delegate the administration of the 2019 Stock Option Plan to a committee. The administrator has full power to determine, among other things: (1)&#160;who will be granted awards; (2)&#160;when and how each award will be granted; (3)&#160;what type of award will be granted; (4)&#160;the provisions of each award (which need not be identical), including when a person will be permitted to exercise or otherwise receive cash or shares of common stock under the award; (5)&#160;the number of shares of common stock subject to an award; and (6)&#160;the fair market value applicable to an award. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Change in Control/Corporate Transactions</span>. The 2019 Stock Option Plan provides that in the event of a change in control transaction (as defined in the 2019 Stock Option Plan), a stock award may be subject to additional acceleration of vesting and exercisability as may be provided in the stock award agreement for such stock award or as may be provided in any other written agreement between us or our affiliate and the participant, but in the absence of such provision, no such acceleration will occur. In addition, the 2019 Stock Option Plan provides that in the event of a corporate transaction (as defined in the 2019 Stock Option Plan), our Board has the discretion to take a number of actions with respect to awards contingent upon the closing of the transaction, including arranging for the assumption or substitution of awards, arranging for the assignment of repurchase rights in respect of awards, accelerating the vesting of awards, canceling awards or making payments in respect of awards. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Amendment</span>. Our Board generally has the authority to amend awards, subject to the award recipient&#8217;s consent if the amendment is not favorable to the participant, except in connection with a capitalization adjustments. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Scilex Holding Company 2022 Equity Incentive Plan </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&#160;17, 2022, our Board adopted, subject to the approval by our stockholders, the Equity Incentive Plan. On November&#160;9, 2022, our stockholders approved the Equity Incentive Plan. The Equity Incentive Plan became effective on November&#160;9, 2022, the day immediately preceding the date on which the Closing occurred. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of the material terms of the Equity Incentive Plan. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Purpose of the Equity Incentive Plan </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purpose of the Equity Incentive Plan is to secure and retain the services of employees, directors and consultants, to provide incentives for such persons to exert maximum efforts for our success and to provide a means by which such persons may be given an opportunity to benefit from increases in value of our Common Stock through the granting of awards under the Equity Incentive Plan. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Awards </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Equity Incentive Plan provides for the grant of incentive stock options (&#8220;ISOs&#8221;) within the meaning of Section&#160;422 of the Code, to our employees and our parent and subsidiary corporations&#8217; employees, and for the grant of nonstatutory stock options (&#8220;NSOs&#8221;), stock appreciation rights, restricted stock awards, restricted stock unit awards, performance awards and other forms of awards to our employees, directors and consultants and any of our affiliates&#8217; employees and consultants. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">223 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Authorized Shares </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Initially, the maximum number of shares of our Common Stock that may be issued under the Equity Incentive Plan after it becomes effective will not exceed (i) 14,622,712 shares of our Common Stock, plus (ii)&#160;an additional number of shares of Common Stock equal to the number of shares subject to outstanding awards granted under the 2019 Stock Option Plan, that, following the effective date of the Equity Incentive Plan, (a)&#160;are not issued because the award or any portion of the award expires or otherwise terminates without all of the shares covered by the award having been issued, (b)&#160;are not issued because the award or any portion thereof is settled in cash, (c)&#160;are forfeited back to or repurchased by us because of the failure to meet a contingency or condition required for the vesting of such shares, (d)&#160;are withheld or reacquired to satisfy the exercise, strike or purchase price or (e)&#160;are withheld or reacquired to satisfy a tax withholding obligation. In addition, the number of shares of our Common Stock that will be reserved for issuance under the Equity Incentive Plan will automatically increase on January&#160;1 of each year for a period of ten years, beginning on January&#160;1, 2023 and ending on (and including) January&#160;1, 2032, in an amount equal to the lesser of (1) 4% of the total number of shares of our Common Stock outstanding on December&#160;31 of the immediately preceding year, (2) 7,311,356 shares of Common Stock, and (3)&#160;such number of shares of our Common Stock determined by our Board or the compensation committee of our Board prior to January&#160;1 of a given year. On January&#160;1, 2023, the authorized number of shares of our Common Stock referenced in the preceding clause (i)&#160;was increased to 20,276,666 based on the foregoing provisions. Notwithstanding anything to the contrary in the foregoing sentence, the aggregate maximum number of shares of our Common Stock that may be issued on the exercise of ISOs under the Equity Incentive Plan is 14,622,712 shares, which amount will be increased commencing on January&#160;1, 2023 and ending on (and including) January&#160;1, 2032, in an amount equal to the lesser of (i) 4% of the total number of shares of Common Stock outstanding on December&#160;31 of the preceding year, (ii) 7,311,356 shares of Common Stock, and (iii)&#160;such number of shares of our Common Stock determined by our Board or the compensation committee of our Board prior to January&#160;1 of a given year. On January&#160;1, 2023, the authorized number of shares of our Common Stock referenced in the preceding clause (i)&#160;regarding ISOs was increased to 20,276,666 based on the foregoing provisions. All of the foregoing share numbers are subject to adjustment as necessary to implement any changes in our capital structure (as described below). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shares subject to awards that will be granted under the Equity Incentive Plan that expire or terminate without being exercised in full will not reduce the number of shares available for issuance under the Equity Incentive Plan. The settlement of any portion of an award in cash will not reduce the number of shares available for issuance under the Equity Incentive Plan. Shares of Common Stock withheld under an award to satisfy the exercise, strike or purchase price of an award or to satisfy a tax withholding obligation will not reduce the number of shares that will be available for issuance under the Equity Incentive Plan. With respect to a stock appreciation right, only shares of common stock that are issued upon settlement of the stock appreciation right will count towards reducing the number of shares available for issuance under the Equity Incentive Plan. If any shares of our Common Stock issued pursuant to an award are forfeited back to or repurchased or reacquired by us (i)&#160;because of a failure to meet a contingency or condition required for the vesting of such shares; (ii)&#160;to satisfy the exercise, strike or purchase price of an award; or (iii)&#160;to satisfy a tax withholding obligation in connection with an award, the shares that are forfeited or repurchased or reacquired will revert to and again become available for issuance under the Equity Incentive Plan. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Plan Administration </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board, or a duly authorized committee of our Board, will administer the Equity Incentive Plan. Our Board, or a duly authorized committee of our Board, may, in accordance with the terms of the Equity Incentive Plan, delegate to one or more of our officers the authority to (i)&#160;designate employees (other than officers) to be recipients of specified awards, and to the extent permitted by applicable law, the terms of such awards; and (ii)&#160;determine the number of shares of Common Stock to be subject to such awards granted to such employees. Under the Equity Incentive Plan, our Board, or a duly authorized committee of our Board, will have the authority to determine: award recipients; how and when each award will be granted; the types of awards to be granted; the provisions of each award, including the period of exercisability and the vesting schedule applicable to an award; </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">224 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the number of shares of Common Stock or cash equivalent subject to each award; the fair market value applicable to an award; and the terms of any performance award that is not valued in whole or in part by reference to, or otherwise based on, Common Stock, including the amount of cash payment or other property that may be earned and the timing of payment. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Equity Incentive Plan, (i)&#160;our Board will not, without stockholder approval, (a)&#160;reduce the exercise or strike price of an option or stock appreciation right (other than in connection with a capitalization adjustment), and (b)&#160;at any time when the exercise or strike price of an option or stock appreciation right is above the fair market value of a share of our Common Stock, cancel and <span style="white-space:nowrap">re-grant</span> or exchange such option or stock appreciation right for a new award with a lower (or no) purchase price or for cash, and (ii)&#160;a participant&#8217;s rights under any award will not be materially adversely impaired by any amendment without the participant&#8217;s written consent. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will also designate a plan administrator to administer the <span style="white-space:nowrap"><span style="white-space:nowrap">day-to-day</span></span> operations of the Equity Incentive Plan. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Stock Options </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Options will be granted under stock option agreements adopted by our Board. Each option will be designated in writing as an ISO or an NSO. Our Board will determine the exercise price for stock options, within the terms and conditions of the Equity Incentive Plan, except the exercise price of a stock option generally will not be less than 100% (or 110% in the case of ISOs granted to a person who owns or is deemed to own stock possessing more than 10% of our total combined voting power or that of any of our parent or subsidiary corporations, or a ten percent stockholder) of the fair market value of our Common Stock on the date of grant. Options granted under the Equity Incentive Plan will vest at the rate specified in the stock option agreement as will be determined by our Board. The terms and conditions of separate options need not be identical. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No option will be exercisable after the expiration of ten years (or five years in the case of ISOs granted to a ten percent stockholder) or a shorter period specified in the applicable award agreement. Unless the terms of an optionholder&#8217;s stock option agreement, or other written agreement between us and the recipient, provide otherwise, if an optionholder&#8217;s service relationship with us or any of our affiliates ceases for any reason other than disability, death or cause, the optionholder may generally exercise any vested options for a period of three months following the cessation of service. If an optionholder&#8217;s service relationship with us or any of our affiliates ceases due to death, or an optionholder dies within a certain period following cessation of service, the optionholder or a beneficiary may generally exercise any vested options for a period of 18 months following the date of death. If an optionholder&#8217;s service relationship with us or any of our affiliates ceases due to disability, the optionholder may generally exercise any vested options for a period of 12 months following the cessation of service. In the event of a termination for cause, options generally terminate upon the termination date. An optionholder may not exercise an option at any time that the issuance of shares upon such exercise would violate applicable law. Unless provided otherwise in the optionholder&#8217;s stock option agreement or other written agreement between an optionholder and us, if an optionholder&#8217;s service relationship with us or any of our affiliates ceases for any reason other than for cause and, at any time during the last thirty days of the applicable post-termination exercise period: (i)&#160;the exercise of the optionholder&#8217;s option would be prohibited solely because the issuance of shares of common stock upon such exercise would violate applicable law, or (ii)&#160;the immediate sale of any shares of common stock issued upon such exercise would violate our trading policy, then the applicable post-termination exercise period will be extended to the last day of the calendar month that begins after the date the award would otherwise expire, with an additional extension of the exercise period to the last day of the next calendar month to apply if any of the foregoing restrictions apply at any time during such extended exercise period. There is no limitation as to the maximum permitted number of extensions. However, in no event may an option be exercised beyond the expiration of its term. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Acceptable consideration for the purchase of common stock issued upon the exercise of a stock option will be determined by our Board and may include (i)&#160;cash or check, bank draft or money order payable to us; (ii)&#160;a </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">225 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
broker-assisted cashless exercise; (iii)&#160;subject to certain conditions, the tender of shares of our Common Stock previously owned by the optionholder; (iv)&#160;a net exercise of the option if it is an NSO; or (v)&#160;other legal consideration acceptable to our Board. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless our Board provides otherwise, options or stock appreciation rights generally will not be transferable except by will or the laws of descent and distribution. Subject to approval of our Board or a duly authorized officer, an option may be transferred pursuant to a domestic relations order. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Limitations on ISOs </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate fair market value, determined at the time of grant, of our Common Stock with respect to ISOs that are exercisable for the first time by an optionholder during any calendar year under all of our stock plans or plans of our affiliates may not exceed $100,000. Options or portions thereof that exceed such limit will generally be treated as NSOs. No ISO may be granted to any person who, at the time of the grant, owns or is deemed to own stock possessing more than 10% of our total combined voting power or that of any of our parent or subsidiary corporations unless (i)&#160;the option exercise price is at least 110% of the fair market value of the stock subject to the option on the date of grant; and (ii)&#160;the term of the ISO does not exceed five years from the date of grant. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Restricted Stock Unit Awards </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the terms of the Equity Incentive Plan, each restricted stock unit award will have such terms and conditions as determined by our Board. A restricted stock unit award represents a participant&#8217;s right to be issued on a future date the number of shares of our Common Stock that is equal to the number of restricted stock units subject to the award. A participant will not have voting or any other rights as a stockholder of ours with respect to any restricted stock unit award (unless and until shares are actually issued in settlement of a vested restricted stock unit award). A restricted stock unit award will be granted in consideration for a participant&#8217;s services to us or an affiliate, such that the participant will not be required to make any payment to us (other than such services) with respect to the grant or vesting of the restricted stock unit award, or the issuance of any shares of common stock pursuant to the restricted stock unit award. Our Board may determine that restricted stock unit awards may be granted in consideration for any form of legal consideration that may be acceptable to our Board and permissible under applicable law. A restricted stock unit award may be settled by cash, delivery of stock (or any combination of our Common Stock and cash), or in any other form of consideration determined by our Board and set forth in the restricted stock unit award agreement. At the time of grant, our Board may impose such restrictions or conditions on the award of restricted stock units that delay delivery to a date following the vesting of the award. Additionally, dividend equivalents may be paid or credited in respect of shares of Common Stock covered by a restricted stock unit award. Except as otherwise provided in the applicable award agreement, or other written agreement between us and the recipient, restricted stock unit awards that have not vested will be forfeited once the participant&#8217;s continuous service ends for any reason. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Restricted Stock Awards </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Restricted stock awards will be granted under restricted stock award agreements adopted by our Board. A restricted stock award may be awarded in consideration for cash, check, bank draft or money order, past services to us or any of our affiliates, or any other form of legal consideration that may be acceptable to our Board and permissible under applicable law. Our Board will determine the terms and conditions of restricted stock awards, including vesting and forfeiture terms. Dividends may be paid or credited with respect to shares subject to a restricted stock award, as determined by our Board and specified in the applicable restricted stock award agreement. If a participant&#8217;s service relationship with us ends for any reason, we may receive any or all of the shares of common stock held by the participant that have not vested as of the date the participant terminates service with us through a forfeiture condition or a repurchase right. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">226 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Stock Appreciation Rights</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock appreciation rights will be granted under stock appreciation right agreements adopted by our Board and denominated in shares of Common Stock equivalents. The terms of separation stock appreciation rights need not be identical. Our Board will determine the purchase price or strike price for a stock appreciation right, which generally will not be less than 100% of the fair market value of our Common Stock on the date of grant. A stock appreciation right granted under the Equity Incentive Plan will vest at the rate specified in the stock appreciation right agreement as will be determined by our Board. Stock appreciation rights may be settled in cash or shares of our Common Stock (or any combination of our Common Stock and cash) or in any other form of payment, as determined by our Board and specified in the stock appreciation right agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board will determine the term of stock appreciation rights granted under the Equity Incentive Plan, up to a maximum of ten years. If a participant&#8217;s service relationship with us or any of our affiliates ceases for any reason other than cause, disability, or death, the participant may generally exercise any vested stock appreciation right for a period of three months following the cessation of service. If a participant&#8217;s service relationship with us or any of our affiliates ceases due to death, or a participant dies within a certain period following cessation of service, the participant or a beneficiary may generally exercise any vested stock appreciation rights for a period of 18 months following the date of death. If a participant&#8217;s service relationship with us or any of our affiliates ceases due to disability, the participant may generally exercise any vested stock appreciation rights for a period of 12 months following the cessation of service. In the event of a termination for cause, stock appreciation rights generally terminate upon the termination date. A holder of a stock appreciation right may not exercise a stock appreciation right at any time that the issuance of shares upon such exercise would violate applicable law. Unless provided otherwise in the stock appreciation right agreement or other written agreement between the participant and us, if a participant&#8217;s service relationship with us or any of our affiliates ceases for any reason other than for cause and, at any time during the last thirty days of the applicable post-termination exercise period: (i)&#160;the exercise of the participant&#8217;s stock appreciation right would be prohibited solely because the issuance of shares upon such exercise would violate applicable law, or (ii)&#160;the immediate sale of any shares issued upon such exercise would violate our trading policy, then the applicable post-termination exercise period will be extended to the last day of the calendar month that begins after the date the award would otherwise expire, with an additional extension of the exercise period to the last day of the next calendar month to apply if any of the foregoing restrictions apply at any time during such extended exercise period. There is no limitation as to the maximum permitted number of extensions. However, in no event may a stock appreciation right be exercised beyond the expiration of its term. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Performance Awards</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Equity Incentive Plan will permit the grant of performance awards that may be settled in stock, cash or other property. Performance awards may be structured so that the stock or cash will be issued or paid only following the achievement of certain <span style="white-space:nowrap">pre-established</span> performance goals during a designated performance period. Performance awards that are settled in cash or other property are not required to be valued in whole or in part by reference to, or otherwise based on, our Common Stock. The performance goals may be based on any measure of performance selected by our Board. The performance goals may be based on company-wide performance or performance of one or more business units, divisions, affiliates, or business segments, and may be either absolute or relative to the performance of one or more comparable companies or the performance of one or more relevant indices. Unless specified otherwise by our Board at the time the performance award is granted, our Board will appropriately make adjustments in the method of calculating the attainment of performance goals for a performance period as follows: (i)&#160;to exclude restructuring and/or other nonrecurring charges; (ii)&#160;to exclude exchange rate effects; (iii)&#160;to exclude the effects of changes to generally accepted accounting principles; (iv)&#160;to exclude the effects of any statutory adjustments to corporate tax rates; (v)&#160;to exclude the effects of items that are &#8220;unusual&#8221; in nature or occur &#8220;infrequently&#8221; as determined under generally accepted accounting principles; (vi)&#160;to exclude the dilutive effects of acquisitions or joint ventures; (vii)&#160;to assume that any business divested by us achieved performance objectives at targeted levels during the balance of a performance period following such divestiture; (viii)&#160;to exclude the effect of any change in the outstanding shares of our Common Stock by reason </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">227 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of any stock dividend or split, stock repurchase, reorganization, recapitalization, merger, consolidation, <span style="white-space:nowrap">spin-off,</span> combination or exchange of shares or other similar corporate change, or any distributions to common stockholders other than regular cash dividends; (ix)&#160;to exclude the effects of stock based compensation and the award of bonuses under our bonus plans; (x)&#160;to exclude costs incurred in connection with potential acquisitions or divestitures that are required to be expensed under generally accepted accounting principles; and (xi)&#160;to exclude the goodwill and intangible asset impairment charges that are required to be recorded under generally accepted accounting principles. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board retains the discretion to reduce or eliminate the compensation or economic benefit due upon attainment of performance goals and to define the manner of calculating the performance criteria it selects to use for the performance period. Partial achievement of the specified criteria may result in the payment or vesting corresponding to the degree of achievement as specified in the performance award agreement or the written terms of a performance cash award. Our Board will determine the length of any performance period, the performance goals to be achieved during a performance period and the other terms and conditions of such awards. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Other Stock Awards</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board will be permitted to grant other awards, based in whole or in part by reference to, or otherwise based on, our Common Stock, either alone or in addition to other awards. Our Board will have the sole and complete discretion to determine the persons to whom and the time or times at which other stock awards will be granted, the number of shares under the other stock award (or cash equivalent) and all other terms and conditions of such awards. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic"><span style="white-space:nowrap">Non-Employee</span> Director Compensation Limit</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate value of all compensation granted or paid following the effective date of the Equity Incentive Plan to any individual for service as a <span style="white-space:nowrap">non-employee</span> director with respect to any fiscal year, including awards granted under the Equity Incentive Plan (valued based on the grant date fair value for financial reporting purposes) and cash fees paid by us to such <span style="white-space:nowrap">non-employee</span> director, will not exceed $750,000 in total value, except such amount will increase to $1,000,000 for the year in which a <span style="white-space:nowrap">non-employee</span> director is first appointed or elected to our Board. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Changes to Capital Structure</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event there is a specified type of change in our capital structure, such as a stock split, reverse stock split, or recapitalization, our Board will appropriately and proportionately adjust (i)&#160;the class(es) and maximum number of shares subject to the Equity Incentive Plan and the maximum number of shares by which the share reserve may annually increase pursuant to the Equity Incentive Plan; (ii)&#160;the class(es) and maximum number of shares that may be issued on the exercise of ISOs; and (iii)&#160;the class(es) and number of shares and exercise price, strike price, or purchase price, if applicable, of all outstanding awards granted under the Equity Incentive Plan. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Corporate Transactions</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of a corporate transaction (as defined below), unless otherwise provided in a participant&#8217;s award agreement or other written agreement with us or one of our affiliates or unless otherwise expressly provided by our Board at the time of grant, any awards outstanding under the Equity Incentive Plan may be assumed, continued or substituted for, in whole or in part, by any surviving or acquiring corporation (or its parent company), and any reacquisition or repurchase rights held by us with respect to our Common Stock issued pursuant to awards may be assigned to the successor (or its parent company). If the surviving or acquiring corporation (or its parent company) does not assume, continue or substitute for such awards, then (i)&#160;with respect to any such awards that are held by participants whose continuous service has not terminated prior to the effective time of the corporate transaction, or current participants, the vesting (and exercisability, if applicable) </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">228 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of such awards will be accelerated in full (or, in the case of performance awards with multiple vesting levels depending on the level of performance, unless provided otherwise in the applicable award agreement, vesting will accelerate at 100% of the target level) to a date prior to the effective time of the corporate transaction (contingent upon the effectiveness of the corporate transaction) as our board of directors determines (or, if our board of directors does not determine such a date, to the date that is five days prior to the effective time of the corporate transaction), and such awards will terminate if not exercised (if applicable) at or prior to the effective time of the corporate transaction, and any reacquisition or repurchase rights held by us with respect to such awards will lapse (contingent upon the effectiveness of the corporate transaction); and (ii)&#160;any such awards that are held by persons other than current participants will terminate if not exercised (if applicable) prior to the occurrence of the corporate transaction, except that any reacquisition or repurchase rights held by us with respect to such awards will not terminate and may continue to be exercised notwithstanding the corporate transaction. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event an award will terminate if not exercised prior to the effective time of a corporate transaction, our Board may provide, in its sole discretion, that the holder of such award may not exercise such award but instead will receive a payment, in such form as may be determined by our Board, equal in value to the excess (if any) of (i)&#160;the value of the property the participant would have received upon the exercise of the award, over (ii)&#160;any per share exercise price payable by such holder, if applicable. As a condition to the receipt of an award, a participant will be deemed to have agreed that the award will be subject to the terms of any agreement under the Equity Incentive Plan governing a corporate transaction involving us. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Equity Incentive Plan, a &#8220;corporate transaction&#8221; generally will be the consummation, in a single transaction or in a series of related transactions, of (i)&#160;a sale or other disposition of all or substantially all, as determined by our board of directors, of the consolidated assets of us and our subsidiaries; (ii)&#160;a sale or other disposition of at least 50% of our outstanding securities; (iii)&#160;a merger, consolidation or similar transaction following which we are not the surviving corporation; or (iv)&#160;a merger, consolidation or similar transaction following which we are the surviving corporation but the shares of our Common Stock outstanding immediately prior to such transaction are converted or exchanged into other property by virtue of the transaction. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Transferability</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as expressly provided in the Equity Incentive Plan or the form of award agreement, awards granted under the Equity Incentive Plan may not be transferred or assigned by a participant. After the vested shares subject to an award have been issued, or in the case of a restricted stock award and similar awards, after the issued shares have vested, the holder of such shares is free to assign, hypothecate, donate, encumber or otherwise dispose of any interest in such shares provided that any such actions are in compliance with the provisions herein, the terms of our trading policy and applicable law. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Clawback/Recovery</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All awards granted under the Equity Incentive Plan will be subject to recoupment in accordance with any clawback policy that we are required to adopt pursuant to the listing standards of any national securities exchange or association on which our securities are listed or as is otherwise required by the Dodd-Frank Act or other applicable law and any clawback policy that we otherwise adopt, to the extent applicable and permissible under applicable law. In addition, our Board may impose such other clawback, recovery or recoupment provisions in an award agreement as our Board determines necessary or appropriate, including but not limited to a reacquisition right in respect of previously acquired shares of Common Stock or other cash or property upon the occurrence of cause. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Amendment or Termination</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board may accelerate the time at which an award granted under the Equity Incentive Plan may first be exercised or the time during which an award grant under the Equity Incentive Plan or any part thereof will vest, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">229 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
notwithstanding the provisions in the award agreement stating the time at which it may first be exercised or the time during which it will vest. Our Board will have the authority to amend, suspend, or terminate the Equity Incentive Plan at any time, provided that such action does not materially impair the existing rights of any participant without such participant&#8217;s written consent. Certain material amendments will also require the approval of our stockholders. No ISOs may be granted after the tenth anniversary of the date our Board adopts the Equity Incentive Plan. No awards may be granted under the Equity Incentive Plan while it is suspended or after it is terminated. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Scilex Holding Company 2022 Employee Stock Purchase Plan </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&#160;17, 2022, our Board adopted, subject to the approval by our stockholders, the ESPP. On November&#160;9, 2022, our stockholders approved the ESPP. The ESPP became effective on November&#160;9, 2022, the day immediately preceding the date on which the Closing occurred. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Purpose </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purpose of the ESPP is to secure and retain the services of new employees, to retain the services of existing employees, and to provide incentives for such individuals to exert maximum efforts toward our success and that of our related corporations. The ESPP includes two components. One component is designed to allow eligible U.S. employees to purchase our Common Stock in a manner that may qualify for favorable tax treatment under Section&#160;423 of the Code (the &#8220;423 Component&#8221;) and accordingly, it will be construed in a manner that is consistent with the requirements of Section&#160;423 of the Code. We intend (but make no undertaking or representation to maintain) the 423 Component to qualify as an employee stock purchase plan, as that term is defined in Section&#160;423(b) of the Code. The other component will permit the grant of purchase rights that do not qualify for such favorable tax treatment (the <span style="white-space:nowrap">&#8220;Non-423</span> Component&#8221;) in order to allow deviations necessary to permit participation by eligible employees who are foreign nationals or employed outside of the U.S. while complying with applicable foreign laws, and except as otherwise provided in the ESPP or determined by our Board, it will operate and be administered in the same manner as the 423 Component. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Share Reserve </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Initially, the maximum number of shares of our Common Stock that may be issued under the ESPP will not exceed&#160;1,462,271 shares of our Common Stock. On January&#160;1, 2023, the maximum number of shares of our Common Stock that may be issued under the ESPP was increased to 2,875,759 based on the following provisions of the ESPP. The ESPP provides that the number of shares of our Common Stock that will be reserved for issuance will automatically increase on January&#160;1 of each year for a period of up to ten years, commencing on January&#160;1, 2023 and ending on (and including) January&#160;1, 2032, in an amount equal to the lesser of (i) 1% of the total number of shares of our Common Stock outstanding on December&#160;31 of the immediately preceding calendar year; (ii) 1,827,839 shares of our Common Stock; and (iii)&#160;such number of shares of our Common Stock determined by our Board or the compensation committee of our Board prior to January&#160;1 of a given year, provided however, that our Board may act prior to January&#160;1 of a given calendar year to provide that there will be no increase for such calendar year or the increase for such year will be a lesser number of shares than the amount set forth in clauses (i)&#160;to (iii)&#160;above. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the avoidance of doubt, up to the maximum number of shares of our Common Stock reserved may be used to satisfy purchases of our Common Stock under the 423 Component and any remaining portion of such maximum number of shares may be used to satisfy the purchases of our Common Stock under the <span style="white-space:nowrap">Non-423</span> Component. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any purchase right granted under the ESPP terminates without having been exercised in full, the shares of our Common Stock not purchased under such purchase right will again become available for issuance under the ESPP. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">230 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Common Stock purchasable under the ESPP will be shares of authorized but unissued or reacquired Common Stock, including shares repurchased by us on the open market. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Administration </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board administers the ESPP. Our Board may delegate some or all of the administration of the ESPP to a committee or committees of our Board. All references to our Board in summary of the ESPP will include a duly authorized committee of our Board except where the context dictates otherwise. Further, to the extent not prohibited by applicable law, our Board may, from time to time, delegate some or all of its authority under the ESPP to one or more of our officers or other persons or groups of persons as it deems necessary, appropriate or advisable under conditions or limitations that it may set at or after the time of the delegation. Our Board will have the authority to determine how and when purchase rights are granted and the provisions of each offering; to designate, from time to time, which of our related corporations will be eligible to participate in the 423 Component or the <span style="white-space:nowrap">Non-423</span> Component, or which related corporations will be eligible to participate in each separate offering; to construe and interpret the ESPP and purchase rights thereunder, and to establish, amend and revoke rules and regulations for the ESPP&#8217;s administration; to settle all controversies regarding the ESPP and purchase rights granted thereunder; to amend, suspend or terminate the ESPP; to exercise such powers and to perform such acts as it deems necessary or expedient to promote the best interests of us and our related corporations and to carry out the intent of the ESPP to be treated as an employee stock purchase plan with respect to the 423 Component; and to adopt such rules, procedures and <span style="white-space:nowrap">sub-plans</span> as are necessary or appropriate to permit or facilitate participation in the ESPP by employees who are foreign nationals or employed or located outside the United States. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All determinations, interpretations and constructions made by our Board in good faith will not be subject to review by any person and will be final, binding and conclusive on all persons. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Offerings </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board may grant or provide for the grant of purchase rights to eligible employees under an offering (consisting of one or more purchase periods) on an offering date or offering dates selected by our Board. Each offering will be in the form and will contain those terms and conditions as our Board deems appropriate, and, with respect to the 423 Component, will comply with the requirements of Section&#160;423(b)(5) of the Code. The provisions of separate offerings do not need to be identical, but each offering will include the period during which the offering will be effective, which period will not exceed 27 months beginning with the offering date, and the substance of the applicable provisions contained in the ESPP. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a participant has more than one purchase right outstanding under the ESPP, unless he or she otherwise indicates in forms delivered to us or a third party designee of ours: (i)&#160;each form will apply to all of his or her purchase rights under the ESPP, and (ii)&#160;a purchase right with a lower exercise price (or an earlier-granted purchase right, if different purchase rights have identical exercise prices) will be exercised to the fullest possible extent before a purchase right with a higher exercise price (or a later-granted purchase right if different purchase rights have identical exercise prices) will be exercised. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board will have the discretion to structure an offering so that if the fair market value of a share of our Common Stock on the first trading day of a new purchase period within that offering is less than or equal to the fair market value of a share of our Common Stock on the first day of that offering, then (i)&#160;that offering will terminate immediately as of that first trading day, and (ii)&#160;the participants in such terminated offering will be automatically enrolled in a new offering beginning on the first trading day of such new purchase period. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Eligibility </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, purchase rights may only be granted to employees, including executive officers, employed by us (or by any of our affiliates or related corporations as designated by our Board) on the first day of an offering if </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">231 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such employee has been employed by us or by one of our designated affiliates or related corporations for such continuous period preceding such date (not to exceed two years) as our Board may require. Our Board may (unless prohibited by applicable law) require that employees have to satisfy one or both of the following service requirements with respect to the 423 Component: (i)&#160;being customarily employed by us, or any of our related corporations or affiliates, for more than 20 hours per week and more than five months per calendar year; or (ii)&#160;such other criteria as our Board may determine consistent with Section&#160;423 of the Code with respect to the 423 Component. Our Board may provide that each person who, during the course of an offering, first becomes an eligible employee will, on the date or dates specified in the offering which coincides with the day on which the person becomes an eligible employee or which occurs thereafter, receive a purchase right under that offering, and the purchase right will thereafter be deemed to be part of the offering with substantially identical characteristics. No employee will be eligible for the grant of any purchase rights under the ESPP if immediately after such rights are granted, such employee owns stock possessing five percent or more of the total combined voting power or value of all classes of our outstanding capital stock (or the stock of any related corporation) determined in accordance with the rules of Section&#160;424(d) of the Code. As specified by Section&#160;423(b)(8) of the Code, an eligible employee may be granted purchase rights only if such purchase rights, together with any other rights granted under all employee stock purchase plans of ours or any of our related corporations, do not permit such eligible employee&#8217;s rights to purchase our stock or the stock of any of our related corporations to accrue at a rate which, when aggregated, exceeds $25,000 (based on the fair market value per share of such common stock on the date that the purchase right is granted) for each calendar year such purchase rights are outstanding at any time. Our Board may also exclude from participation in the ESPP or any offering employees of ours, or of any of our related corporation, who are highly compensated employees, as within the meaning of Section&#160;423(b)(4)(D) of the Code, or a subset of such highly compensated employees. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything in the foregoing paragraph to the contrary, in the case of an offering under the <span style="white-space:nowrap">Non-423</span> Component, an eligible employee (or a group of eligible employees) may be excluded from participation in the ESPP or an offering if our Board has determined, in its sole discretion, that participation of such eligible employee is not advisable or practical for any reason. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Purchase Rights; Purchase Price </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On the first day of each offering, each eligible employee, pursuant to an offering made under the ESPP, will be granted a purchase right to purchase up to that number of shares of our Common Stock purchasable either with a percentage or with a maximum dollar amount, as designated by our Board, which will not exceed 15% of such employee&#8217;s earnings (as defined by our Board) during the period that begins on the first day of the offering (or such later date as our Board determines for a particular offering) and ends on the date stated in the offering, which date will be no later than the end of the offering. Our Board will establish one or more purchase dates during an offering on which purchase rights granted for that offering will be exercised and shares of Common Stock will be purchased in accordance with such offering. Each eligible employee may purchase of up to 10,000 shares of our Common Stock in an offering (or such lesser number of shares determined by our Board prior to the start of the offering). Our Board may also specify (i)&#160;a maximum number of shares of our Common Stock that may be purchased by any participant on any purchase date during an offering, (ii)&#160;a maximum aggregate number of shares of our Common Stock that may be purchased by all participants in an offering and/or (iii)&#160;a maximum aggregate number of shares of our Common Stock that may be purchased by all participants on any purchase date under an offering. If the aggregate number of shares of our Common Stock issuable upon exercise of purchase rights granted under the offering would exceed any such maximum aggregate number, then, in the absence of any action by our Board otherwise, a pro rata allocation of the shares of our Common Stock (rounded down to the nearest whole share) available, based on each participant&#8217;s accumulated contributions, will be made in as nearly a uniform manner as will be practicable and equitable. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purchase price of shares of our Common Stock acquired pursuant to purchase rights will not be less than the lesser of (i) 85% of the fair market value of a share of our Common Stock on the first day of an offering; or (ii) 85% of the fair market value of a share of our Common Stock on the date of purchase. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">232 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Participation; Withdrawal; Termination </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An eligible employee may elect to participate in an offering and authorize payroll deductions as the means of making contributions by completing and delivering to us or our designee, within the time specified in the offering, an enrollment form provided by us or our designee. The enrollment form will specify the amount of contributions not to exceed the maximum amount specified by our Board. Each participant&#8217;s contributions will be credited to a bookkeeping account for the participant under the ESPP and will be deposited with our general funds except where applicable law requires that contributions be deposited with a third party. If permitted in the offering, a participant may begin such contributions with the first payroll occurring on or after the first day of the applicable offering (or, in the case of a payroll date that occurs after the end of the prior offering but before the first day of the next new offering, contributions from such payroll will be included in the new offering). If permitted in the offering, a participant may thereafter reduce (including to zero) or increase his or her contributions. If required under applicable law or if specifically provided in the offering, in addition to or instead of making contributions by payroll deductions, a participant may make contributions through payment by cash, check or wire transfer prior to a purchase date. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During an offering, a participant may cease making contributions and withdraw from the offering by delivering to us or our designee a withdrawal form provided by us. We may impose a deadline before a purchase date for withdrawing. Upon such withdrawal, such participant&#8217;s purchase right in that offering will immediately terminate and we will distribute as soon as practicable to such participant all of his or her accumulated but unused contributions and such participant&#8217;s purchase right in that offering shall then terminate. A participant&#8217;s withdrawal from that offering will have no effect upon his or her eligibility to participate in any other offerings under the ESPP, but such participant will be required to deliver a new enrollment form to participate in subsequent offerings. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise required by applicable law, purchase rights granted pursuant to any offering under the ESPP will terminate immediately if the participant either (i)&#160;is no longer an employee for any reason or for no reason (subject to any post-employment participation period required by applicable law) or (ii)&#160;is otherwise no longer eligible to participate. We will distribute the individual&#8217;s accumulated but unused contributions as soon as practicable to such individual. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise determined by our Board, a participant whose employment transfers or whose employment terminates with an immediate rehire (with no break in service) by or between us and one of our designated companies designated to participate in an offering (or between such designated companies) will not be treated as having terminated employment for purposes of participating in the ESPP or an offering. However, if a participant transfers from an offering under the 423 Component to an offering under the <span style="white-space:nowrap">Non-423</span> Component, the exercise of the participant&#8217;s purchase right will be qualified under the 423 Component only to the extent such exercise complies with Section&#160;423 of the Code. If a participant transfers from an offering under the <span style="white-space:nowrap">Non-423</span> Component to an Offering under the 423 Component, the exercise of the purchase right will remain <span style="white-space:nowrap">non-qualified</span> under the <span style="white-space:nowrap">Non-423</span> Component. Our Board may establish different and additional rules governing transfers between separate offerings within the 423 Component and between offerings under the 423 Component and offerings under the <span style="white-space:nowrap">Non-423</span> Component. Unless otherwise specified in the offering or as required by applicable law, we will have no obligation to pay interest on contributions. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Purchase of Shares </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On each purchase date, each participant&#8217;s accumulated contributions will be applied to the purchase of shares of our Common Stock, up to the maximum number of shares of our Common Stock permitted by the ESPP and the applicable offering, at the purchase price specified in the offering. Unless otherwise provided in the offering, if any amount of accumulated contributions remains in a participant&#8217;s account after the purchase of shares on the final purchase date of an offering, then such remaining amount will not roll over to the next offering and will instead be distributed in full to such participant after the final purchase date of such offering without interest (unless otherwise required by applicable law). No purchase rights may be exercised to any extent </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">233 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
unless the shares of our Common Stock to be issued upon such exercise under the ESPP are covered by an effective registration statement pursuant to the Securities Act and the ESPP is in material compliance with all applicable U.S. federal and state, foreign and other securities, exchange control and other laws applicable to the ESPP. If on a purchase date the shares of our Common Stock are not so registered or the ESPP is not in such compliance, no purchase rights will be exercised on such purchase date, and the purchase date will be delayed until the shares of our Common Stock are subject to such an effective registration statement and the ESPP is in material compliance, except that the purchase date will in no event be more than 27 months from the first day of an offering. If, on the purchase date, as delayed to the maximum extent permissible, the shares of our Common Stock are not registered and the ESPP is not in material compliance with all applicable laws, as determined by us in our sole discretion, no purchase rights will be exercised and all accumulated but unused contributions will be distributed to the ESPP participants without interest (unless the payment of interest is otherwise required by applicable law). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A participant will not be deemed to be the holder of, or to have any of the rights of a holder with respect to, shares of our Common Stock subject to purchase rights unless and until the participant&#8217;s shares of our Common Stock acquired upon exercise of purchase rights are recorded in our books (or the books of our transfer agent). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Changes to Capital Structure </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ESPP provides that in the event of a change in our capital structure through actions such as a merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend, stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure, or similar transaction, our Board will appropriately and proportionately adjust: (i)&#160;the class(es) and maximum number of securities subject to the ESPP; (ii)&#160;the class(es) and maximum number of securities by which the share reserve is to increase automatically each year; (iii)&#160;the class(es) and number of shares subject to, and purchase price applicable to, outstanding offerings and purchase rights; and (iv)&#160;the class(es) and number of securities that are subject to purchase limits under each ongoing offering. Our Board will make these adjustments, and its determination will be final, binding and conclusive. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Corporate Transactions </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ESPP provides that in the event of a corporate transaction (as defined below), any then-outstanding rights to purchase our Common Stock under the ESPP may be assumed, continued, or substituted for by any surviving or acquiring corporation (or its parent company). If the surviving or acquiring corporation (or its parent company) elects not to assume, continue, or substitute for such purchase rights, then (i)&#160;the participants&#8217; accumulated payroll contributions will be used to purchase shares of our Common Stock (rounded down to the nearest whole share) within ten business days (or such other period specified by our Board) before such corporate transaction under the outstanding purchase rights, and such purchase rights will terminate immediately after such purchase, or (ii)&#160;our Board, in its discretion, may terminate outstanding offerings, cancel the outstanding purchase rights and refund the participants&#8217; accumulated contributions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the ESPP, a &#8220;corporate transaction&#8221; is generally the consummation, in a single transaction or in a series of related transactions, of: (i)&#160;a sale or other disposition of all or substantially all, as determined by our Board, of the consolidated assets of us and our subsidiaries; (ii)&#160;a sale or other disposition of at least 50% of our outstanding securities; (iii)&#160;a merger, consolidation or similar transaction following which we are not the surviving corporation; or (iv)&#160;a merger, consolidation or similar transaction following which we are the surviving corporation but the shares of our Common Stock outstanding immediately prior to such transaction are converted or exchanged into other property by virtue of the transaction. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Transferability </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During a participant&#8217;s lifetime, purchase rights will be exercisable only by a participant. Purchase rights are not transferable by a participant, except by will, by the laws of descent and distribution, or, if permitted by us, by a beneficiary designation. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">234 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Tax Withholding </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each participant must make arrangements, satisfactory to us and any applicable related corporation, to enable us or our related corporation to fulfill any withholding obligation for taxes arising out of or in relation to a participant&#8217;s participation in the ESPP. In our sole discretion and subject to applicable law, such withholding obligation may be satisfied in whole or in part by (i)&#160;withholding from the participant&#8217;s salary or any other cash payment due to the participant from us or any related corporation; (ii)&#160;withholding from the proceeds of the sale of shares of our Common Stock acquired under the ESPP, either through a voluntary sale or a mandatory sale arranged by us; or (iii)&#160;any other method deemed acceptable by our Board. We will not be required to issue any shares of our Common Stock under the ESPP until such obligations are satisfied. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Amendment, Suspension or Termination </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board will have the authority to amend, suspend or terminate the ESPP. Any benefits, privileges, entitlements and obligations under any outstanding purchase right granted before an amendment, suspension or termination of the ESPP will not be materially impaired by any such amendment, suspension or termination except (i)&#160;with the consent of the person to whom such purchase rights were granted, (ii)&#160;as necessary to facilitate compliance with any laws, listing requirements, or governmental regulations (including, without limitation, the provisions of Section&#160;423 of the Code), or (iii)&#160;as necessary to obtain or maintain favorable tax, listing, or regulatory treatment. Except with respect to certain changes in our capital structure, stockholder approval is required for any amendment to the ESPP if such approval is required by applicable law or listing requirements. No purchase rights may be granted under the ESPP while it is suspended or after it is terminated. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_89">Emerging Growth Company Status </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an &#8220;emerging growth company&#8221; as defined in the JOBS Act. As an emerging growth company, we are exempted from certain requirements related to executive compensation, including the requirements to hold a nonbinding advisory vote on executive compensation and to provide information relating to the ratio of total compensation of our Chief Executive Officer to the median of the annual total compensation of all of our employees, each as required by the Investor Protection and Securities Reform Act of 2010, which is part of the Dodd-Frank Act. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_90">Director Compensation </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended December&#160;31, 2022, our <span style="white-space:nowrap">non-employee</span> directors received the following compensation: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">


<tr>

<td style="width:48%"></td>

<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold">Name<sup style="font-size:75%; vertical-align:top">(1)</sup></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Fees<br />Earned&#160;or<br />Paid&#160;in<br />Cash&#160;($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Option<br />Awards&#160;($)<sup style="font-size:75%; vertical-align:top">(2)</sup></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">All Other<br />Compensation&#160;($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Total&#160;($)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dorman Followwill</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">65,518</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">65,518</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laura J. Hamill</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">67,614</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">67,614</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Tien-Li</span> Lee, M.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">87,588</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(3)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">87,588</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Lemus</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">61,326</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">61,326</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tommy Thompson</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">40,532</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">40,532</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Dr.&#160;Ji, our Executive Chairperson, and Mr.&#160;Shah, our Chief Executive Officer and President, are not included in this table, as each of them was an employee of Scilex and therefore receives no compensation for his service as a director. Dr.&#160;Ji&#8217;s and Mr.&#160;Shah&#8217;s compensation as named executive officers are included in the section titled &#8220;&#8212; <span style="font-style:italic">Summary Compensation Table</span>&#8221; above. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">As of December&#160;31, 2022, Dr.&#160;Lee held options to purchase an aggregate of 404,098 shares of Scilex Common Stock (which number of options gives effect to the Exchange Ratio) and none of Mr.&#160;Followwill, </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">235 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td align="left" style="vertical-align:top">
Ms.&#160;Hamill, Mr.&#160;Lemus and Mr.&#160;Thompson held any options or other equity awards to acquire shares of Scilex Common Stock. </td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Between January&#160;1, 2022 through April&#160;24, 2022, the fees earned by Dr.&#160;Lee were pursuant to a consulting agreement dated October&#160;27, 2020, as amended on March&#160;17, 2021. Between April&#160;25, 2022 through December&#160;31, 2022, the fees earned by Dr.&#160;Lee were for his service as a member of our board of directors. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_91">Director Compensation Policy </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board has determined the following compensation for our <span style="white-space:nowrap">non-employee</span> directors: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">


<tr>

<td style="width:83%"></td>

<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Annual Cash Compensation</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Amount</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Board Members</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">82,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chairs of the Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">37,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Members of the Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">15,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Equity Compensation</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Initial Stock Options</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">250,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Annual Stock Options</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">100,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All annual cash compensation amounts for our <span style="white-space:nowrap">non-employee</span> directors are payable in equal quarterly installments in arrears, following the end of each quarter in which the service occurred, <span style="white-space:nowrap">pro-rated</span> for any partial months of service. The equity compensation paid to our <span style="white-space:nowrap">non-employee</span> directors will vest monthly over a period of 48 months from the date of grant with respect to the initial stock option grants and over a period of 12 months from the date of grant with respect to the annual stock option grants, in each case, subject to continued service through each vesting date. Additionally, we will reimburse each outside director for reasonable travel expenses related to such director&#8217;s attendance at Board and committee meetings. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">236 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom428534_92">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of transactions since January&#160;1, 2020 and any currently proposed transactions to which Vickers or Legacy Scilex was or is to be a participant in which the amount involved exceeded or will exceed $120,000, and in which any of Vickers&#8217;s or Legacy Scilex&#8217;s directors, executive officers or, to Vickers&#8217;s or Legacy Scilex&#8217;s knowledge, beneficial owners of more than 5% of Vickers&#8217;s or Legacy Scilex&#8217;s capital stock, or their immediate family members have had or will have a direct or indirect material interest, other than compensation and other arrangements that are described under the section of this prospectus titled &#8220;<span style="font-style:italic">Executive and Director Compensation</span>.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_93">Certain Relationships of Vickers </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Founder Shares </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&#160;16, 2020, Vickers issued an aggregate of 3,593,750 Vickers Ordinary Shares to an affiliate of the Sponsors for an aggregate purchase price of $25,000. In August 2020, the affiliate transferred his founder shares to the Sponsors for the same price paid for such shares. On October&#160;8, 2020, Vickers effected a share capitalization of 0.2 shares for each share outstanding, on December&#160;7, 2020, the Sponsors forfeited 1,437,500 Vickers Ordinary Shares, which were cancelled by Vickers, and on January&#160;6, 2021, Vickers effected a share capitalization of 0.2 shares for each share outstanding, resulting in 3,450,000 Vickers Ordinary Shares issued and outstanding. All share and <span style="white-space:nowrap">per-share</span> amounts have been retroactively restated to reflect the share transactions. The founder shares included an aggregate of up to 450,000 shares that were subject to forfeiture depending on the extent to which the underwriters&#8217; over-allotment option is exercised, so that the number of founder shares will equal, on an <span style="white-space:nowrap">as-converted</span> basis, approximately 20% of the issued and outstanding Vickers Ordinary Shares after the IPO. As a result of the underwriters&#8217; election to partially exercise their over-allotment option, no founder shares are currently subject to forfeiture. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Sponsors have agreed, subject to limited exceptions, not to transfer, assign or sell any of their founder shares until six months after the consummation of the Business Combination or earlier if we consummates a liquidation, merger, share exchange or other similar transaction that results in all of the public shareholders having the right to exchange their Vickers Ordinary Shares for cash, securities or other property. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Promissory Note </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&#160;16, 2020, Vickers issued an unsecured promissory note (the &#8220;Promissory Note&#8221;) to an affiliate of the Sponsors, pursuant to which Vickers may borrow up to an aggregate principal amount of $125,000. The Promissory Note is <span style="white-space:nowrap">non-interest</span> bearing and payable on the earlier of (i)&#160;December&#160;31, 2020 or (ii)&#160;the completion of the IPO. The outstanding balance under the Promissory Note of $125,000 was repaid subsequent to the closing of the IPO on January&#160;14, 2021. Borrowings under the Promissory Note are no longer available to Vickers. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Related Party Loans </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&#160;20, 2021, the Sponsors loaned Vickers an aggregate of $500,000 for working capital purposes. On January10, 2022, the Sponsors deposited an aggregate of $1,035,000 into the Trust Account, to provide Vickers with an additional three&#160;months to consummate an initial business combination pursuant to Vickers&#8217;s Amended and Restated Memorandum and Articles of Association (&#8220;Vickers&#8217;s Charter&#8221;). On January&#160;27, 2022, the Sponsors loaned Vickers an additional aggregate principal amount of $500,000 for working capital purposes. On April&#160;10, 2022, the Sponsors deposited an aggregate of $1,035,000 into the Trust Account to provide Vickers with an additional three&#160;months to consummate an initial business combination pursuant to Vickers&#8217;s Charter. On June&#160;30, 2022, Vickers&#8217;s shareholders approved an amendment (the &#8220;Extension Amendment&#8221;) to its amended and restated memorandum and articles of association to extend the deadline by which it must complete an initial business combination from July&#160;11, 2022 to January&#160;11, 2023. Each extension </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">237 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
was made on a monthly basis and was conditioned on the deposit into the Trust Account of a payment equal to $0.0333 per public share outstanding. In connection with the shareholder vote on the Extension Amendment, Vickers was required to provide its shareholders with the right to redeem their public shares. Holders of 4,073,605 public shares elected to redeem their shares at a per share redemption price of $10.27 thereby reducing the amount in the Trust Account by an aggregate of approximately $41.8&#160;million. On July&#160;8, 2022, the Sponsors deposited an aggregate of $323,888.95 into the Trust Account to provide Vickers with an additional calendar month to consummate an initial business combination pursuant to Vickers&#8217;s Charter. After the redemption of the 4,073,605 public shares, there were 9,726,395 public shares remaining. On each of August&#160;11, 2022, September&#160;9, 2022 and October&#160;10, 2022, the Sponsors deposited an additional payment of $323,888.95 into the Trust Account to provide Vickers with an additional calendar month to consummate an initial business combination pursuant to Vickers&#8217;s Charter. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&#160;17, 2022, the Sponsors and Vickers entered into the Vickers Debt Agreement, which provides that, effective as of immediately prior to the Effective Time, all of the issued and outstanding loans made by the Sponsors to Vickers prior to such Effective Time shall be contributed by the Sponsors to Vickers in exchange for a number of shares of our Common Stock determined by dividing the aggregate amount of such indebtedness by $10.00. As of immediately prior to the Effective Time, the outstanding indebtedness was $5.3&#160;million, which resulted in the issuance of an additional 533,057 shares of our Common Stock to the Sponsors, in accordance with the Vickers Debt Agreement. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Advances from Related Party </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During 2020, an affiliate of the Sponsors advanced Vickers an aggregate of $30,000 to fund expenses in connection with the IPO. The advances are <span style="white-space:nowrap">non-interest</span> bearing and payable upon demand. As of June&#160;30, 2022 and December&#160;31, 2021, there were no advances outstanding. The outstanding amount of $30,000 as of December&#160;31, 2020 was repaid on February&#160;26, 2021. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Administrative Service Fee </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Commencing on the effective date of the registration statement of the IPO through the acquisition of a target business, the Sponsors have provided Vickers with office space and certain office and secretarial services at no cost. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No compensation of any kind, including any finder&#8217;s fee, reimbursement, consulting fee or monies in respect of any payment of a loan, will be paid by us to the Sponsors, officers and directors, or any of their affiliates, prior to, or in connection with any services rendered in order to effectuate, the consummation of an initial business combination (regardless of the type of transaction that it is). However, these individuals will be reimbursed for any <span style="white-space:nowrap"><span style="white-space:nowrap">out-of-pocket</span></span> expenses incurred in connection with activities on our behalf such as identifying potential target businesses and performing due diligence on suitable business combinations. Our audit committee will review on a quarterly basis all payments that were made to the Sponsors, officers, directors or our or their affiliates and will determine which expenses and the amount of expenses that will be reimbursed. There is no cap or ceiling on the reimbursement of <span style="white-space:nowrap"><span style="white-space:nowrap">out-of-pocket</span></span> expenses incurred by such persons in connection with activities on our behalf. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Stockholder Agreement with Sorrento </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&#160;12, 2022, Vickers entered into the Stockholder Agreement with Sorrento. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the Stockholder Agreement, from and after the Effective Time, and for so long as the Sorrento Group beneficially owns any shares of Series A Preferred Stock, among other things, (i)&#160;Sorrento shall have the right, but not the obligation, to designate each director to be nominated, elected or appointed to our Board (each, a &#8220;Stockholder Designee&#8221; and collectively, the &#8220;Stockholder Designees&#8221;), regardless of whether </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">238 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such Stockholder Designee is to be elected to our Board at a meeting of stockholders called for the purpose of electing directors (or by consent in lieu of meeting) or appointed by our Board in order to fill any vacancy created by the departure of any director or increase in the authorized number of members of our Board or the size of our Board and (ii)&#160;we are required to take all actions reasonably necessary, and not otherwise prohibited by applicable law, to cause each Stockholder Designee to be so nominated, elected or appointed to our Board as more fully described in the Stockholder Agreement. Notwithstanding the foregoing, the parties have agreed that our Board will continue to satisfy all applicable stock exchange requirements applicable to directors, including with respect to director independence. Sorrento also have the right to designate a replacement director for any Stockholder Designee that has been removed from our Board and the right to appoint a representative of Sorrento to attend all meetings of the committees of the Board. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Stockholder Agreement also provides that we shall not, and shall cause our subsidiaries not to, among others, without the prior written consent of Sorrento: (i)&#160;amend, alter, modify or repeal (whether by merger, consolidation, by operation of law or otherwise) any provisions of the Certificate of Incorporation (including the Certificate of Designations) or our Bylaws that increase or decrease the authorized number of directors constituting our Board; (ii)&#160;take any action that would have the effect of increasing or decreasing the number of directors constituting our Board; (iii)&#160;amend, alter, modify or repeal (whether by merger, consolidation, reclassification, by operation of law or otherwise) any provisions of the respective charters (and any related organizational documents) of any of the committees of our Board; (iv)&#160;file any voluntary petition under any applicable federal or state bankruptcy or insolvency law on behalf of us or any of our subsidiaries; (v)&#160;(A) incur or permit any of our subsidiaries to incur any indebtedness in an aggregate principal amount in excess of $10,000,000) (with &#8220;principal amount&#8221; for purposes of this definition to include undrawn committed or available amounts) or (B)&#160;enter into, modify, amend or renew (or permit any of our subsidiaries enter into, modify, amend or renew) any contract or other agreement in respect of indebtedness in an aggregate principal amount in excess of $10,000,000 (with &#8220;principal amount&#8221; for purposes of this definition to include undrawn committed or available amounts); (vi) consummate or otherwise enter into any other contract or agreement to effect any change of control, joint venture or corporate reorganization by the Company or any of our subsidiaries; (vii)&#160;declare or pay any dividend or distribution on our Common Stock, other Junior Security or Parity Security; or (viii)&#160;purchase, redeem or otherwise acquire for consideration by us, directly or indirectly, any Common Stock, other Junior Security or Parity Security (except as necessary to effect (A)&#160;a reclassification of any Junior Security for or into other Junior Securities, (B)&#160;a reclassification of any Parity Security for or into other Parity Securities with the same or lesser aggregate liquidation preference, (C)&#160;a reclassification of any Parity Security into a Junior Security, (D)&#160;the exchange or conversion of any Junior Security for or into another Junior Security, (E)&#160;the exchange or conversion of any Parity Security for or into another Parity Security with the same or lesser per share liquidation amount, (F)&#160;the exchange or conversion of any Parity Security for or into any Junior Security or (G)&#160;the settlement of incentive equity awards (including any applicable withholdings and the net exercise of options) in accordance with the terms thereof). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Stockholder Agreement will terminate and be of no further force and effect upon the earlier of (i)&#160;mutual written agreement of the parties thereto and (ii)&#160;the date upon which Sorrento (together with its affiliates, subsidiaries, successors and assigns (other than us and our subsidiaries)) ceases to own any shares of Series A Preferred Stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Warrant Transfer Agreement with Sorrento </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrent with the execution of the Funding Commitment Letter, Vickers, the Sponsors, Sorrento and Maxim entered into the Warrant Transfer Agreement pursuant to which, if, prior to the consummation of the Business Combination, the public shareholders had redeemed 50% or more of the public Vickers Ordinary Shares as were outstanding as of March&#160;17, 2022, then in addition to the forfeiture of Warrants by the Sponsors contemplated by the Sponsor Support Agreement, the Sponsors would transfer to Sorrento, and Sorrento would acquire all rights, title and interest in and to all or a portion of the Private Placement Warrants (as equitably adjusted from time to time in respect of any change in the outstanding Vickers Ordinary Shares into a different </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">239 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
number, class or series, including by reason of any reclassification, recapitalization, share split (including a reverse share split), or combination, exchange, readjustment of shares, or similar transaction, or any share dividend or distribution paid in shares) as determined in accordance with the following schedule: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:40%"></td>

<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Redemptions</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number&#160;of&#160;Private<br />Placement<br />Warrants to be<br />Transferred to<br />Sorrento</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number&#160;of&#160;Private<br />Placement<br />Warrants to be<br />Retained by<br />Sponsors</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Total<br />Private<br />Placement<br />Warrants</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">90% or greater</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,104,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,000,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,104,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">85% to 89.99%</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,600,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,504,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,104,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">75% to 84.99%</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,052,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,052,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4,104,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">50% to 74.99%</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,400,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,440,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,840,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Below 50%</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,840,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,840,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Business Combination, the public shareholders redeemed an aggregate of 8,576,838 Vickers Ordinary Shares, which redeemed shares, together with the shares redeemed in connection with the Extension Proposal, represented an aggregate of 91.67% of the public Vickers Ordinary Shares outstanding as of March&#160;17, 2022. Accordingly, the Sponsors transferred 3,104,000 Private Placement Warrants to Sorrento pursuant to the Warrant Transfer Agreement and forfeited 2,736,000 Private Placement Warrants pursuant to the Sponsor Support Agreement. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_94">Certain Relationships of Legacy Scilex </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Corporate Reorganization </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&#160;18, 2019, Legacy Scilex completed a corporate reorganization. In connection with the corporate reorganization, the existing stockholders of Scilex Pharma exchanged their shares for the same number of newly issued shares of Legacy Scilex Common Stock, pursuant to a Contribution and Loan Agreement. As a result, Scilex Pharma and Semnur became Legacy Scilex&#8217;s wholly owned subsidiaries. In connection with the reorganization, each option issued by Scilex Pharma to acquire shares of common stock granted under the Scilex Pharma 2017 Plan was cancelled and substituted for an option to purchase an equivalent number of shares of Legacy Scilex Common Stock. See the section of this prospectus titled &#8220;<span style="font-style:italic">Business &#8212; Our Corporate History</span>&#8221; for further information. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our Relationship with Sorrento </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the Business Combination, Legacy Scilex was a majority-owned subsidiary of Sorrento. Following the Closing of the Business Combination, Sorrento continues to beneficially own a significant percentage of our outstanding Common Stock. In connection with the Business Combination, Legacy Scilex and Sorrento entered into certain agreements that relate to Legacy Scilex&#8217;s relationship with Sorrento prior to the Business Combination and provides a framework for our ongoing relationship with Sorrento. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&#160;1, 2017, Scilex Pharma entered into a transition services agreement with Sorrento. Pursuant to this transition services agreement, Sorrento agreed to provide, directly or indirectly, certain administrative, financial, legal, tax, insurance, facility, information technology and other services to Scilex Pharma. In addition to the services provided under this transition services agreement, Sorrento retains insurance coverage on behalf of Scilex Pharma. For the years ended December&#160;31, 2021 and 2020, the total cost of services and insurance, including an agreed-upon markup, provided to Scilex Pharma was $4.0&#160;million and $2.3&#160;million, respectively. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Itochu and Oishi Product Development Agreement and Commercial Supply Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a party to the Product Development Agreement with Oishi and Itochu, who are responsible for supplying ZTlido and <span style="white-space:nowrap">SP-103</span> for development and commercialization purposes. We are also a party to the Itochu </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">240 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and Oishi Commercial Supply Agreement, pursuant to which Itochu agreed to purchase Products (as defined in the Itochu and Oishi Commercial Supply Agreement) from Oishi and handles the shipping of the Products. As of December&#160;31, 2020, Itochu held approximately 14.7% of Legacy Scilex&#8217;s outstanding capital stock, representing a noncontrolling interest. Itochu ceased to be a shareholder of Legacy Scilex on January&#160;13, 2021. Its Managing Executive Officer, Kenji Hakoda, served on the Legacy Scilex Board from March 2019 to October 2020. During the years ended December&#160;31, 2021 and 2020, pursuant to the aforementioned Product Development Agreement and the Itochu and Oishi Commercial Supply Agreement, Legacy Scilex purchased inventory from Itochu in the amount of $5.7&#160;million and $1.0&#160;million, respectively, on terms Legacy Scilex considers to be arms&#8217; length between the parties. See the sections of this prospectus titled &#8220;<span style="font-style:italic">Business &#8212; Material Agreements &#8212; Itochu and Oishi Product Development Agreement</span>&#8221; and &#8220;<span style="font-style:italic">Business &#8212; Material Agreements &#8212; Itochu and Oishi Commercial Supply Agreement</span>&#8221; for additional information regarding such agreements. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Indenture and Letter of Credit </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&#160;7, 2018, Scilex Pharma entered into the Purchase Agreements with the Purchasers and Sorrento, which is a beneficial owner of more than 5% of Legacy Scilex&#8217;s capital stock. Pursuant to the Purchase Agreements, on September&#160;7, 2018, Scilex Pharma, among other things, issued and sold to the Purchasers the Scilex Pharma Notes for an aggregate purchase price of $140.0&#160;million. The Scilex Pharma Notes are governed by the Indenture with Scilex Pharma, as issuer, U.S. Bank National Association, a national banking association, as the Trustee and Collateral Agent, and Sorrento, as guarantor. The Indenture provides that the holders of the Scilex Pharma Notes will be entitled to receive quarterly payments in an amount equal to a fixed percentage, ranging from 15% to 25%, of the net sales of ZTlido for the prior fiscal quarter on each February&#160;15, May&#160;15, August&#160;15 and November 15. As security for the Scilex Pharma Notes, Scilex Pharma has granted to the Collateral Agent, for the benefit of the Purchasers, a continuing security interest in and lien on Scilex Pharma&#8217;s right, title, and interest in and to ZTlido and all property and assets of Scilex Pharma that are necessary for, or otherwise relevant to, now or in the future, the manufacture and sale of ZTlido, on a worldwide basis (exclusive of Japan). Pursuant to the Indenture, Sorrento agreed to irrevocably and unconditionally guarantee, on a senior unsecured basis, the punctual performance and payment when due of all obligations of Scilex Pharma under the Indenture. Pursuant to the terms of the Indenture, Sorrento issued an irrevocable standby letter of credit to Scilex Pharma (as amended, the &#8220;Letter of Credit&#8221;) which provides that, in the event that (1)&#160;Scilex Pharma does not hold at least $29.0&#160;million in unrestricted cash (inclusive of cash equivalents in the collateral account) as of any calendar month ending March&#160;31, 2020 through and including the month ending March&#160;31, 2021 or at least $35.0&#160;million in unrestricted cash (inclusive of cash equivalents in the collateral account) at the end of any calendar month after March&#160;31, 2021, (2) actual cumulative net sales of ZTlido from September&#160;7, 2018 through December&#160;31, 2021 are less than a specified sales threshold for such period, or (3)&#160;actual cumulative net sales of ZTlido for any calendar year during the term of the Scilex Pharma Notes, beginning with the 2022 calendar year, are less than a specified sales threshold for such calendar year, Scilex Pharma, as beneficiary of the Letter of Credit, will draw, and Sorrento will pay to Scilex Pharma, $35.0&#160;million in a single <span style="white-space:nowrap">lump-sum</span> amount as a subordinated loan. The Letter of Credit will terminate upon the earliest to occur of: (a)&#160;the repayment of the Scilex Pharma Notes in full, (b)&#160;the actual net sales of ZTlido for any calendar year during the term of the Scilex Pharma Notes exceeding a certain threshold, (c)&#160;the consummation of an initial public offering on a major international stock exchange by us that satisfies certain valuation thresholds, and (d)&#160;the replacement of the Letter of Credit with another letter of credit in form and substance, including as to the identity and creditworthiness of issuer, reasonably acceptable to the holders of at least 80% in principal amount of outstanding Scilex Pharma Notes. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&#160;14, 2020, the parties entered into a Consent Under and Amendment No.&#160;3 to Indenture and Letter of Credit (&#8220;Amendment No.&#160;3&#8221;), which amended: (i)&#160;the Indenture, and (ii)&#160;the Letter of Credit. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&#160;14, 2020, and in connection with Amendment No.&#160;3, the aggregate $45.0&#160;million in restricted funds held in previously established reserve and collateral accounts were released and Scilex Pharma utilized such funds to repurchase an aggregate of $45.0&#160;million in principal amount of the Scilex Pharma Notes. Scilex </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">241 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Pharma also repurchased an aggregate of $20.0&#160;million in principal amount of the Scilex Pharma Notes on December&#160;16, 2020. Pursuant to the foregoing repurchases, the aggregate principal amount of the Scilex Pharma Notes was reduced by an aggregate of $65.0&#160;million. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further related to Amendment No.&#160;3, the Purchasers also consented to Scilex Pharma incurring up to $10.0&#160;million of indebtedness in connection with an accounts receivable revolving loan facility with another lender and the incurrence of liens and the pledge of collateral to such lender in connection therewith. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective February&#160;14, 2022, Scilex Pharma issued to Sorrento a draw notice under the Letter of Credit as required under the terms of the Indenture because actual cumulative net sales of ZTlido from the issue date of the Scilex Pharma Notes through December&#160;31, 2021 were less than a specified sales threshold for such period. As a result of the draw notice being issued, Sorrento paid to Scilex Pharma $35.0&#160;million in a single <span style="white-space:nowrap">lump-sum</span> amount as a subordinated loan. Per the terms of the Amendment No.&#160;3, in February 2022, Scilex Pharma repurchased Scilex Pharma Notes in an aggregate amount equal to $20.0&#160;million at a purchase price in cash equal to 100% of the principal amount. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective February&#160;15, 2022, in accordance with the Indenture, the principal amount of the Scilex Pharma Notes was increased by $28.0&#160;million as actual cumulative net sales of ZTlido from the issue date of the Scilex Pharma Notes through December&#160;31, 2021 did not equal or exceed a $481.0&#160;million sales threshold for such period. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&#160;2, 2022, Sorrento and Scilex Pharma, entered into a Consent Under and Amendment No.&#160;4 to Indenture (&#8220;Amendment No.&#160;4&#8221;) with the Trustee, Collateral Agent, and the Purchasers, which amended the Indenture. Pursuant to Amendment No.&#160;4, (1) on June&#160;3, 2022, Scilex Pharma repurchased approximately $41.4&#160;million of the aggregate principal amount of the outstanding Scilex Pharma Notes at 100% of the principal amount thereof (the &#8220;Repurchase&#8221;), (2) the Purchasers agreed that Scilex Pharma can repurchase the remaining principal amount of the Scilex Pharma Notes at any time on or before September&#160;30, 2022 for $41.4&#160;million (subject to reduction for any quarterly royalty payments) and upon such repurchase the Purchasers will forgive and discharge $28.0&#160;million of the aggregate principal amount of the Scilex Pharma Notes, and (3)&#160;the minimum cash requirement under the Indenture was reduced to $5.0&#160;million in aggregate unrestricted cash equivalents at the end of each calendar month. Scilex Pharma funded the Repurchase with <span style="white-space:nowrap"><span style="white-space:nowrap">cash-on-hand</span></span> and $15.0&#160;million received from Sorrento on June&#160;2, 2022. We paid off all the amounts outstanding under the Scilex Pharma Notes as of immediately prior to the Closing of the Business Combination, which payment was funded by Sorrento and treated as intercompany debt in exchange for Series A Preferred Stock pursuant to the terms of the Debt Exchange Agreement described below. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&#160;28, 2022, we repurchased the remaining outstanding principal balance of the Scilex Pharma Notes with <span style="white-space:nowrap"><span style="white-space:nowrap">cash-on-hand</span></span> and $34.0&#160;million received from Sorrento. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Oaktree Guaranty </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&#160;7, 2018, Sorrento and certain of its domestic subsidiaries entered into a Term Loan Agreement, as amended on May&#160;3, 2019 and December&#160;6, 2019 (as amended, the &#8220;Oaktree Loan Agreement&#8221;) with certain funds and accounts managed by Oaktree Capital Management, L.P. and Oaktree Fund Administration, LLC, as administrative and collateral agent, for an initial term loan of $100.0&#160;million and a delayed draw term loan of $20.0&#160;million that was provided to Sorrento on May&#160;3, 2019. On April&#160;12, 2019, Legacy Scilex and Semnur entered into a Joinder Agreement to the Oaktree Loan Agreement whereby each entity became a guarantor under the Oaktree Loan Agreement and pledged all of their respective assets (other than equity of Scilex Pharma) as collateral for the loans made to Sorrento under the Oaktree Loan Agreement. All obligations owed under the Oaktree Loan Agreement were paid off in full on June&#160;12, 2020 and both Legacy Scilex and Semnur ceased to be a guarantor under the Oaktree Loan Agreement as of such date. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">242 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Intercompany Promissory Note and Sale of Shares to Sorrento </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&#160;5, 2018, Scilex Pharma issued to Sorrento an intercompany promissory note in the amount of approximately $21.7&#160;million for certain amounts previously advanced to Scilex Pharma by Sorrento (the &#8220;Intercompany Note&#8221;). On October&#160;22, 2018, Sorrento purchased from Legacy Scilex 24,117,608 shares of Legacy Scilex Common Stock in exchange for the cancellation of $21.7&#160;million of indebtedness under the Intercompany Note. During 2021 and 2020, Sorrento made advances to Scilex Pharma in the amount of $8.1&#160;million and $10.3&#160;million, respectively, under the Intercompany Note. As of December&#160;31, 2021 and 2020, the outstanding principal balance under the Intercompany Note was approximately $23.5&#160;million and $15.4&#160;million, respectively. In connection with Amendment No.&#160;4 to the Indenture, the maximum aggregate principal amount of the Intercompany Note was increased from up to $25.0&#160;million to up to $50.0&#160;million. As of immediately prior to the Closing of the Business Combination, the outstanding principal balance under the Intercompany Note was $23.5&#160;million, which amount was treated as Outstanding Indebtedness (as defined in the Debt Exchange Agreement discussed below) and contributed to Legacy Scilex in exchange for preferred stock as more fully described below. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Note Payable to Sorrento </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&#160;18, 2019, Legacy Scilex entered into a note payable with Sorrento with an initial principal amount of $16.5&#160;million. Legacy Scilex may borrow up to an aggregate of $20.0&#160;million of principal amount under the note payable. The note is interest bearing at the lesser of (i) 10% simple interest per annum, and (ii)&#160;the maximum interest rate permitted under law. Interest is due and payable annually. The note payable is payable upon demand and may be prepaid in whole or in part at any time without penalty or premium. The outstanding principal balance of the note as of December&#160;31, 2021 and 2020 was $19.6&#160;million and $13.0&#160;million, respectively. Accrued interest of $3.9&#160;million and $2.6&#160;million was recognized under related party payable in Legacy Scilex&#8217;s consolidated balance sheet as of December&#160;31, 2021 and 2020, respectively. During the six months ended June&#160;30, 2022 and 2021, Sorrento made advances to Legacy Scilex in the amount of $27.5&#160;million and $0, respectively, under the note payable. The outstanding principal balance of the note on June&#160;30, 2022 and December&#160;31, 2021 was $47.1&#160;million and $19.6&#160;million, respectively, which was recorded under the current related party note payable in Legacy Scilex&#8217;s consolidated balance sheets. As of June&#160;30, 2022 and December&#160;31, 2021, Legacy Scilex had ending balances resulting from the accrued interest on the note payable of $5.6&#160;million and $3.9&#160;million, respectively, which was recorded under the related party payable in Legacy Scilex&#8217;s consolidated balance sheets. The proceeds from the note payable were used to finance the acquisition of Semnur and to finance Legacy Scilex&#8217;s operations. As of immediately prior to the Closing of the Business Combination, the outstanding principal balance under the foregoing notes was $54.3&#160;million, which amount was treated as Outstanding Indebtedness (as defined in the Debt Exchange Agreement discussed below) and contributed to Legacy Scilex in exchange for preferred stock as more fully described below. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Debt Exchange Agreement and Related Matters </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&#160;12, 2022, Legacy Scilex and Scilex Pharma entered into a Contribution and Satisfaction of Indebtedness Agreement with Sorrento (the &#8220;Debt Exchange Agreement&#8221;), pursuant to which (i)&#160;Sorrento shall contribute to Legacy Scilex all amounts (including accrued interest thereon, if any) for certain loans and other amounts provided by Sorrento to Legacy Scilex and Scilex Pharma that remain outstanding as of immediately prior to the Closing of the Business Combination (the &#8220;Aggregate Outstanding Amount&#8221; or &#8220;Outstanding Indebtedness&#8221;), including with respect to the Scilex Pharma Notes, the Intercompany Note, and the other notes payable to Sorrento described above, in exchange for the issuance by Legacy Scilex to Sorrento of preferred stock of Legacy Scilex, (ii)&#160;Legacy Scilex shall contribute to Scilex Pharma the portion of such Outstanding Indebtedness that is owed by Scilex Pharma to Sorrento as a contribution of capital for no consideration, and (iii)&#160;upon the occurrence of the events described in clauses (i)&#160;and (ii), the Aggregate Outstanding Amount and the Outstanding Indebtedness shall be satisfied in full. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">243 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the Debt Exchange Agreement effective as of immediately prior to, and contingent upon, the Closing of the Business Combination, Sorrento has elected to contribute the Outstanding Indebtedness to Legacy Scilex in exchange for the issuance by Legacy Scilex to Sorrento of that number of shares of Legacy Scilex Preferred Stock (subject to adjustment for recapitalizations, stock splits, stock dividends and similar transactions) (the &#8220;Exchange Shares&#8221; and such transaction, the &#8220;Debt Contribution&#8221;) that is equal to (i)&#160;the Aggregate Outstanding Amount plus the amount equal to 10% of the Aggregate Outstanding Amount divided by (ii) $11.00 (rounded up to the nearest whole share); provided, that in no event shall the Aggregate Outstanding Amount exceed $310,000,000. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&#160;17, 2022, Sorrento and Legacy Scilex entered into the Funding Commitment Letter. Pursuant to the terms of the Funding Commitment Letter, upon the written request of Legacy Scilex (which request Legacy Scilex shall make to the extent necessary to satisfy the closing condition in the Merger Agreement that requires the combined company to have $5,000,001 in net tangible assets as of immediately following the Effective Time) (the &#8220;Net Tangible Assets Condition&#8221;), Sorrento shall fund one or more loans to Legacy Scilex in the amount set forth in such written request (a &#8220;Loan Request&#8221;), provided, that any amounts funded by Sorrento in respect of any Loan Request shall be treated as Outstanding Indebtedness for all purposes under the Debt Exchange Agreement and included in the calculation of the Aggregate Outstanding Amount thereunder. The Funding Commitment Letter also provides that in no event shall the aggregate amount of loans made and funded by Sorrento pursuant to Loan Requests exceed the lesser of (a)&#160;$10,000,000 and (b)&#160;an amount that, when taken together with all other Outstanding Indebtedness, will result in the Aggregate Outstanding Amount equaling $310,000,000. As consideration for the execution of the Funding Commitment Letter, Vickers, the Sponsors, Sorrento and Maxim entered into the Warrant Transfer Agreement, which is more fully described elsewhere in this prospectus. No Loan Requests were made under the Funding Commitment Letter. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the Debt Contribution, Legacy Scilex filed, with the Secretary of State of the State of Delaware, (i)&#160;a Certificate of Amendment to its Amended and Restated Certificate of Incorporation to increase the authorized number of shares of preferred stock of Legacy Scilex from 20,000,000 to 45,000,000 and (ii)&#160;a certificate of designation setting forth the designations, powers, rights and preferences and qualifications, limitations and restrictions of the Exchange Shares. Following the issuance thereof to Sorrento and in connection with the Closing of the Business Combination, such shares were converted into the right to receive (i)&#160;one share of Series A Preferred Stock and <span style="white-space:nowrap">(ii)&#160;one-tenth</span> of one share of our Common Stock, which shares of Series A Preferred Stock shall then have the rights set forth in the Certificate of Designations. Sorrento is entitled to the rights set forth in the Stockholder Agreement as a result of Sorrento&#8217;s ownership thereof. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of immediately prior to the Closing, the Outstanding Indebtedness (including amounts related to the transfer of certain liabilities to Sorrento and repayment of Scilex Pharma Notes) was $290,570,964, which was contributed by Sorrento, in accordance with the Debt Exchange Agreement, in exchange for 29,057,097 shares of Legacy Scilex Preferred Stock, which were in turn converted into the right to receive 29,057,097 shares of Series&#160;A Preferred Stock and 2,905,710 shares of our Common Stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Shah Investor LP Assignment Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Legacy Scilex, through Semnur, is a party to the Assignment Agreement with Shah Investor LP, pursuant to which Shah Investor LP assigned Legacy Scilex certain intellectual property and Legacy Scilex agreed to pay Shah Investor LP a contingent quarterly royalty in the <span style="white-space:nowrap">low-single</span> digits based on the quarterly net sales of any pharmaceutical formulations for local delivery of steroids by injection developed utilizing such intellectual property, which would include SEMDEXA. Mahendra Shah, Ph.D., who served on the Legacy Scilex Board from March 2019 to October 2020, is the managing partner of Shah Investor LP. See the section of this prospectus titled &#8220;<span style="font-style:italic">Business &#8212; Material Agreements &#8212; Shah Investor LP Assignment Agreement</span>&#8221; for additional information regarding the Assignment Agreement. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">244 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Acquisition of <span style="white-space:nowrap">SP-104</span> Assets from Sorrento </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2021, Sorrento entered into an asset purchase agreement (the &#8220;Aardvark Asset Purchase Agreement&#8221;) with Aardvark Therapeutics, Inc. (&#8220;Aardvark&#8221;), pursuant to which, among other things, Sorrento acquired Aardvark&#8217;s Delayed Burst Release Low Dose Naltrexone <span style="white-space:nowrap">(DBR-LDN)</span> asset and intellectual property rights, for the treatment of chronic pain, fibromyalgia and chronic post-COVID syndrome (collectively, the <span style="white-space:nowrap">&#8220;SP-104</span> Assets&#8221;), which includes a Statement of Work dated November&#160;18, 2020 (the &#8220;Tulex Statement of Work&#8221;), pursuant to which Tulex agreed to, among other things, develop, test and manufacture clinical supplies of <span style="white-space:nowrap">SP-104.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subsequent to the acquisition, Sorrento designated Legacy Scilex to lead all development efforts related to <span style="white-space:nowrap">SP-104</span> and on May&#160;12, 2022, Legacy Scilex and Sorrento entered into a bill of sale and assignment and assumption agreement, pursuant to which Sorrento sold, conveyed, assigned and transferred to Legacy Scilex all of its rights, title and interest in and to the <span style="white-space:nowrap">SP-104</span> Assets (including PCT/US2021/053645 and all patents and patent applications that claim priority rights thereto) and Legacy Scilex assumed all of Sorrento&#8217;s rights, liabilities and obligations under the Aardvark Asset Purchase Agreement (the <span style="white-space:nowrap">&#8220;SP-104</span> Acquisition&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As consideration for the <span style="white-space:nowrap">SP-104</span> Acquisition, Legacy Scilex issued a promissory note in the aggregate principal amount of $5,000,000 to Sorrento (the &#8220;Promissory Note&#8221;). The Promissory Note matures seven years from the date of issuance and bears interest at the rate equal to the lesser of (a) 2.66% simple interest per annum and (b)&#160;the maximum interest rate permitted under law. The Promissory Note is payable in cash, shares of Common Stock (any shares so issued, the &#8220;Consideration Shares&#8221;) or any combination thereof, at Legacy Scilex&#8217;s sole discretion, and may be prepaid in whole or in part at any time without penalty. Legacy Scilex also agreed to file with the SEC, a resale registration statement, relating to the resale by Sorrento of any Consideration Shares that may be issued to Sorrento, within 60 days of the issuance of such Consideration Shares. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As the successor to the Aardvark Asset Purchase Agreement, Legacy Scilex is obligated to pay Aardvark (i) $3,000,000, upon initial approval by the FDA of a new drug application for the LDN Formulation (as defined in the Aardvark Asset Purchase Agreement) (which amount may be paid in shares of Common Stock or cash, in Legacy Scilex&#8217;s sole discretion) (the &#8220;Development Milestone Payment&#8221;) and (ii) $20,000,000, in cash, upon achievement of certain net sales by Legacy Scilex of a commercial product that uses the LDN Formulation (the &#8220;Commercial Product&#8221;). Legacy Scilex will also pay Aardvark certain royalties in the single digits based on percentages of annual net sales by Legacy Scilex of a commercial product that uses the LDN Formulation. The royalty percentage is subject to reduction in certain circumstances. Royalties are due for so long as Commercial Product is covered by a valid patent in the country of sale or for ten years following the first commercial sale of the Commercial Product, whichever is longer. As of the date of this prospectus none of the foregoing payments have been triggered </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with its acquisition of the <span style="white-space:nowrap">SP-104</span> Assets, Legacy Scilex has agreed that if it issues any shares of Common Stock in respect of the Development Milestone Payment, Legacy Scilex will prepare and file one or more registration statements with the SEC for the purpose of registering for resale such shares and is required to file such registration statement with the SEC within 60 days following the date on which any such shares are issued. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Tien-Li</span> Lee, MD, a member of our Board, is the founder, chief executive officer and a member of the board of directors of Aardvark. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Guaranty of Lease </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&#160;8, 2019, Legacy Scilex entered into a new office lease for approximately 6,000 square feet for its executive offices in Palo Alto, California, as amended on September&#160;15, 2019. The term of the lease commenced on September&#160;15, 2019 and will expire on November&#160;30, 2024. We will be obligated to pay an average of approximately $0.5&#160;million in annual rent over the term of the lease. In connection with the lease, on August&#160;8, 2019, Sorrento executed a Guaranty of Lease, guaranteeing the performance of our obligations under the lease. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">245 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Executive Officer and Director Compensation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Please see the section of this prospectus titled &#8220;<span style="font-style:italic">Executive and Director Compensation</span>&#8221; for information regarding the compensation of our executive officers and <span style="white-space:nowrap">non-employee</span> directors. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Employment Agreements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into an offer letter agreement with our named executive officer that, among other things, provides for certain compensatory and change in control benefits, as well as severance benefits. For a description of such agreement, see the section of this prospectus titled &#8220;<span style="font-style:italic">Executive and Director Compensation &#8212; Arrangements with Executive Officers.</span>&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Limitation of Liability and Indemnification of Officers and Directors </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Please see the section of this prospectus titled &#8220;<span style="font-style:italic">Management &#8212; Limitation of Liability and Indemnification of Directors and Officers</span>&#8221; for information regarding our arrangements to provide indemnification to our officers and directors. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Business Combination Related Agreements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrently with the execution of the Merger Agreement, Vickers, Legacy Scilex and Sorrento entered into a Company Stockholder Support Agreement, pursuant to which Sorrento agreed to vote all Legacy Scilex Common Stock beneficially owned by it, including any additional shares of Legacy Scilex it acquires ownership of or the power to vote, in favor of the Business Combination and related transactions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&#160;10, 2022, in connection with the closing of the Business Combination, Scilex, Sorrento, the Sponsors, and Vickers&#8217;s former directors Pei Wei Woo, Suneel Kaji and Steve Myint, entered into the Registration Rights Agreement, whereby, subject to certain exceptions, the parties agreed, among other things, not to transfer any of our Common Stock or any security convertible into or exercisable or exchanged for our Common Stock beneficially owned or owned of record by such holder until the date that is the earlier of (i)&#160;one hundred eighty (180)&#160;days from the date of the Registration Rights Agreement or (ii)&#160;the date on which we complete a liquidation, merger, stock exchange, reorganization or other similar transaction that results in all of our stockholders having the right to exchange their shares of our Common Stock for cash, securities or other property. The Registration Rights Agreement governs the registration of certain shares of our Common Stock for resale and includes certain customary demand and &#8220;piggy-back&#8221; registration rights with respect to shares of our Common Stock held by the parties thereto. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Related Person Transaction Policy </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have adopted a related person transaction policy that sets forth our procedures for the identification, review, consideration and approval or ratification of related person transactions. For purposes of our policy, a related person transaction is a transaction, arrangement or relationship, or any series of similar transactions, arrangements or relationships, in which we and any related person are, were or will be participants in which the amount involved exceeds $120,000. Transactions involving compensation for services provided to us as an employee or director are not covered by this policy. A related person is any executive officer, director or beneficial owner of more than 5% of any class of our voting securities and any of their respective immediate family members and any entity owned or controlled by such persons. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the policy, if a transaction has been identified as a related person transaction, including any transaction that was not a related person transaction when originally consummated or any transaction that was not initially identified as a related person transaction prior to consummation, our management must present information regarding the related person transaction to our audit committee, or, if audit committee approval would be inappropriate, to another independent body of our Board, for review, consideration and approval or </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">246 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
ratification. The presentation must include a description of, among other things, the material facts, the interests, direct and indirect, of the related persons, the benefits to us of the transaction and whether the transaction is on terms that are comparable to the terms available to or from, as the case may be, an unrelated third party or to or from employees generally. Under the policy, we will collect information that we deem reasonably necessary from each director, executive officer and, to the extent feasible, significant stockholder to enable us to identify any existing or potential related-person transactions and to effectuate the terms of the policy. In addition, under our code of conduct and ethics, our employees and directors have an affirmative responsibility to disclose any transaction or relationship that reasonably could be expected to give rise to a conflict of interest. In considering related person transactions, our audit committee, or other independent body of our Board, will take into account the relevant available facts and circumstances including, but not limited to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the risks, costs and benefits to us; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the impact on a director&#8217;s independence in the event that the related person is a director, immediate family member of a director or an entity with which a director is affiliated; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the availability of other sources for comparable services or products; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the terms available to or from, as the case may be, unrelated third parties or to or from employees generally. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The policy requires that, in determining whether to approve, ratify or reject a related person transaction, our audit committee, or other independent body of our Board, must consider, in light of known circumstances, whether the transaction is in, or is not inconsistent with, our best interests and those of our stockholders, as our audit committee, or other independent body of our Board, determines in the good faith exercise of our discretion. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">247 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom428534_95">PRINCIPAL SECURITYHOLDERS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information regarding the beneficial ownership of our Common Stock as of January&#160;11, 2023 by: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">each person or &#8220;group&#8221; known to be the beneficial owner of more than 5% of our outstanding Common Stock; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">each of our current executive officers and directors; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">all of our executive officers and directors as a group. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beneficial ownership is determined according to the rules of the SEC, which generally provide that a person has beneficial ownership of a security if he, she or it possesses sole or shared voting or investment power over that security, including options and warrants that are currently exercisable or exercisable within 60 days. Shares subject to options and warrants that are currently exercisable or exercisable within 60 days of the Closing Date are considered outstanding and beneficially owned by the person holding such options or warrants for the purpose of computing the percentage ownership of that person, but are not treated as outstanding for the purpose of computing the percentage ownership of any other person. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The beneficial ownership of our Common Stock is based on 141,598,856 shares of such common stock outstanding as of January&#160;11, 2023. Voting power is based on 141,598,856 shares of Common Stock and 29,057,097 shares of Series A Preferred Stock outstanding as of January&#160;11, 2023. Shares of Series&#160;A Preferred Stock are held solely by Sorrento. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, we believe, based on information available to us, that all persons and entities named in the table have sole voting and investment power with respect to all shares shown as beneficially owned by them. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">


<tr>

<td style="width:63%"></td>

<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name and Address of Beneficial Owner<sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number of<br />Common<br />Shares<br />Beneficially<br />Owned</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">% of<br />Total<br />Common<br />Stock</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">% of<br />Total<br />Vote</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic">Directors and Executive Officers</span></span><span style="font-weight:bold"></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jaisim Shah<sup style="font-size:75%; vertical-align:top">(2)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">8,838,544</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5.9</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4.9</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Henry Ji, Ph.D.<sup style="font-size:75%; vertical-align:top">(3)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,989,380</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1.4</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1.2</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Elizabeth Czerepak<sup style="font-size:75%; vertical-align:top">(4)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">345,167</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Tien-Li</span> Lee, M.D.<sup style="font-size:75%; vertical-align:top">(5)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">427,670</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dorman Followwill</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laura J. Hamill</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Lemus</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tommy Thompson</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">All Directors and Executive Officers as a Group (8 individuals)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">11,600,761</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7.6</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6.4</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic">5% Beneficial Owners</span></span><span style="font-weight:bold"></span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sorrento Therapeutics, Inc.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">140,217,207</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(6)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">96</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">96.6</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">*</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Less than 1% </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Unless otherwise indicated, the business address of each of the following individuals is 4955 Directors Place, San Diego, CA 92121. None of the following individuals own shares of Series A Preferred Stock. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Includes 8,838,544 shares subject to options exercisable within 60 days of January&#160;11, 2023. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Includes 1,989,380 shares subject to options exercisable within 60 days of January&#160;11, 2023. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Includes 345,167 shares subject to options exercisable within 60 days of January&#160;11, 2023. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(5)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Includes 427,670 shares subject to options exercisable within 60 days of January&#160;11, 2023. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(6)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Includes 3,104,000 shares subject to Private Warrants and 1,386,617 shares subject to Public Warrants exercisable within 60 days of January&#160;11, 2023. The business address of Sorrento Therapeutics, Inc. is 4955 Directors Place, San Diego, CA 92121. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">248 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom428534_96">SELLING SECURITYHOLDER </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus relates to the offer and sale by the Selling Securityholder of up to 28,128,422 shares of Common Stock that have been and may be issued by us to the Selling Securityholder under the B. Riley Purchase Agreement. For additional information regarding the shares of Common Stock included in this prospectus, see the section titled &#8220;<span style="font-style:italic">Committed Equity Financing</span>&#8221; above. We are registering the shares of Common Stock included in this prospectus pursuant to the provisions of the B. Riley Purchase Agreement we entered into with the Selling Securityholder on January 8, 2023 in order to permit the Selling Securityholder to offer the shares included in this prospectus for resale from time to time. Except for the transactions contemplated by the B. Riley Purchase Agreement, and as set forth in the section titled &#8220;<span style="font-style:italic">Plan of Distribution</span>&#8221; in this prospectus, the Selling Securityholder has not had any material relationship with us within the past three years. As used in this prospectus, the term &#8220;Selling Securityholder&#8221; mean B. Riley Principal Capital II, LLC, a Delaware limited liability company, and the pledgees, donees, transferees, assignees, successors, designees, and others who later come to hold any of the Selling Securityholder&#8217;s interest in the Common Stock other than through a public sale. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below presents information regarding the Selling Securityholder and the shares of Common Stock that may be resold by the Selling Securityholder from time to time under this prospectus. This table is prepared based on information supplied to us by the Selling Securityholder, and reflects holdings as of January 11, 2023. The number of shares in the column titled &#8220;Maximum Number of Shares of Common Stock to be Offered Pursuant to this Prospectus&#8221; represents all of the shares of Common Stock being offered for resale by the Selling Securityholder under this prospectus. The Selling Securityholder may sell some, all, or none of the shares being offered for resale in this offering. We do not know how long the Selling Securityholder will hold the shares before selling them, and we are not aware of any existing arrangements between the Selling Securityholder and any other stockholder, broker, dealer, underwriter, or agent relating to the sale or distribution of the shares of our Common Stock being offered for resale by this prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beneficial ownership is determined in accordance with Rule <span style="white-space:nowrap">13d-3(d)</span> promulgated by the SEC under the Exchange Act, and includes shares of our Common Stock with respect to which the Selling Securityholder has sole or shared voting and investment power. The percentage of shares of our Common Stock beneficially owned by the Selling Securityholder prior to the offering shown in the table below is based on an aggregate of 141,598,856 shares of our Common Stock outstanding on January 11, 2023. Because the purchase price to be paid by the Selling Securityholder for shares of Common Stock, if any, that we may elect to sell to the Selling Securityholder in one or more Advances or Additional Advances from time to time under the B. Riley Purchase Agreement will be determined on the applicable Advance Notice Dates or Additional Advance Notice Dates for such Advances or Additional Advances, the actual number of shares of Common Stock that we may sell to the Selling Securityholder under the B. Riley Purchase Agreement may be fewer than the number of shares being offered for resale under this prospectus. The fourth column in the table below assumes the resale by the Selling Securityholder of all of the shares of Common Stock being offered for resale pursuant to this prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have determined beneficial ownership in accordance with the rules of the SEC. Except as indicated by the footnotes below, we believe, based on the information furnished to us, that the Selling Securityholder has sole voting and investment power with respect to all shares of Common Stock that it beneficially owns, subject to applicable community property laws. Except as otherwise described below, based on the information provided to us by the Selling Securityholder, the Selling Securityholder is not a broker-dealer or an affiliate of a broker-dealer. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:60%"></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td rowspan="2" style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name of Selling Securityholder</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number of Shares<br />of&#160;Common<br />Stock&#160;Beneficially<br />Owned</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" rowspan="2">&#160;&#160;</td>
<td colspan="2" rowspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Maximum<br />Number of<br />Shares of<br />Common<br />Stock Being<br />Offered<sup style="font-size:75%; vertical-align:top">(2)</sup></span></td>
<td style="vertical-align:bottom" rowspan="2">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Shares of Common&#160;Stock<br />Beneficially Owned<br />After&#160;the&#160;Offered<br />Shares&#160;of&#160;Common&#160;Stock&#160;Are<br />Sold</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number<sup style="font-size:75%; vertical-align:top">(1)</sup></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Percent</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Number<sup style="font-size:75%; vertical-align:top">(3)</sup></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Percent</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">B. Riley Principal Capital II, LLC<sup style="font-size:75%; vertical-align:top">(4)</sup></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">250,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">28,128,422</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">*</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Less than one percent. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">249 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents the Commitment Shares we issued to the Selling Securityholder in consideration for entering into the B. Riley Purchase Agreement with us. In accordance with Rule <span style="white-space:nowrap">13d-3(d)</span> under the Exchange Act, we have excluded from the number of shares beneficially owned prior to the offering all of the shares that the Selling Securityholder may be required to purchase under the B. Riley Purchase Agreement, because the issuance of such shares is at our discretion and is subject to conditions contained in the B. Riley Purchase Agreement, the satisfaction of which are entirely outside of the Selling Securityholder&#8217;s control, including the registration statement that includes this prospectus becoming and remaining effective. Furthermore, the Advances and Additional Advances of Common Stock under the B. Riley Purchase Agreement are subject to certain agreed upon maximum amount limitations set forth in the B. Riley Purchase Agreement. Also, the B. Riley Purchase Agreement prohibits us from issuing and selling any shares of our Common Stock to the Selling Securityholder to the extent such shares, when aggregated with all other shares of our Common Stock then beneficially owned by the Selling Securityholder, would cause the Selling Securityholder&#8217;s beneficial ownership of our Common Stock to exceed the 4.99% Beneficial Ownership Limitation. The B. Riley Purchase Agreement also prohibits us from issuing or selling shares of our Common Stock under the B. Riley Purchase Agreement in excess of the 19.9% Exchange Cap, unless we obtain stockholder approval to do so or all applicable sales of shares of Common Stock under the B. Riley Purchase Agreement equal or exceed the &#8220;Minimum Price&#8221; (as such term is defined in Rule 5635 of the Nasdaq Listing Rules). </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Includes the 250,000 Commitment Shares. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Assumes the sale of all shares being offered pursuant to this prospectus. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The business address of B. Riley Principal Capital II, LLC (&#8220;BRPC II&#8221;) is 11100 Santa Monica Blvd., Suite 800, Los Angeles, California 90025. BRPC II&#8217;s principal business is that of a private investor. BRPC II is a wholly-owned subsidiary of B. Riley Principal Investments, LLC (&#8220;BRPI&#8221;). As a result, BRPI may be deemed to indirectly beneficially own the securities of the company held of record by BRPC II. B. Riley Financial, Inc. (&#8220;BRF&#8221;) is the parent company of BRPC II and BRPI. As a result, BRF may be deemed to indirectly beneficially own the securities of the company held of record by BRPC II and indirectly beneficially owned by BRPI. Bryant R. Riley is the <span style="white-space:nowrap">Co-Chief</span> Executive Officer and Chairman of the Board of Directors of BRF. As a result, Bryant R. Riley may be deemed to indirectly beneficially own the securities of the company held of record by BRPC II and indirectly beneficially owned by BRPI. Each of BRF, BRPI and Bryant R. Riley expressly disclaims beneficial ownership of the securities of the company held of record by BRPC II, except to the extent of its/his pecuniary interest therein. We have been advised that none of BRF, BRPI or BRPC II is a member of the Financial Industry Regulatory Authority, Inc. (&#8220;FINRA&#8221;) or an independent broker-dealer; however, each of BRF, BRPI, BRPC II and Bryant R. Riley is an affiliate of B. Riley Securities, Inc. (&#8220;BRS&#8221;), a registered broker-dealer and FINRA member, and Bryant R. Riley is an associated person of BRS. BRS will act as an executing broker that will effectuate resales of our Ordinary shares that may be acquired by BRPC II from us pursuant to the B. Riley Purchase Agreement to the public in this offering. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">250 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom428534_97">PLAN OF DISTRIBUTION </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares of Common Stock offered by this prospectus are being offered by the Selling Securityholder. The shares may be sold or distributed from time to time by the Selling Securityholder directly to one or more purchasers or through brokers, dealers, or underwriters who may act solely as agents at market prices prevailing at the time of sale, at prices related to the prevailing market prices, at negotiated prices, or at fixed prices, which may be changed. We will not receive any of the proceeds from the sale of the securities by the Selling Securityholder. We may receive up to $500,000,000 aggregate gross proceeds under the B. Riley Purchase Agreement from any sales we make to the Selling Securityholder pursuant to the B. Riley Purchase Agreement. The net proceeds from sales, if any, under the B. Riley Purchase Agreement, will depend on the frequency and prices at which we sell shares of Common Stock to the Selling Securityholder after the date of this prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The sale of the shares of our Common Stock offered by this prospectus could be effected in one or more of the following methods: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">ordinary brokers&#8217; transactions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">transactions involving cross or block trades; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">through brokers, dealers, or underwriters who may act solely as agents; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">&#8220;at the market&#8221; into an existing market for our Common Stock; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">in other ways not involving market makers or established business markets, including direct sales to purchasers or sales effected through agents; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">in privately negotiated transactions; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any combination of the foregoing. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to comply with the securities laws of certain states, if applicable, the shares may be sold only through registered or licensed brokers or dealers. In addition, in certain states, the shares may not be sold unless they have been registered or qualified for sale in the state or an exemption from the state&#8217;s registration or qualification requirement is available and complied with. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Selling Securityholder is an &#8220;underwriter&#8221; within the meaning of Section&#160;2(a)(11) of the Securities Act. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Selling Securityholder has informed us that it intends to use one or more registered broker-dealers to effectuate all sales, if any, of our Common Stock that it may acquire from us pursuant to the B. Riley Purchase Agreement. Such sales will be made at prices and at terms then prevailing or at prices related to the then-current market price. Such registered broker-dealer may, in some circumstances (for instance if such registered broker-dealer&#8217;s involvement is not limited to receiving commission not in excess of the usual and customary distributors&#8217; or sellers&#8217; commissions), be considered to be an underwriter within the meaning of Section&#160;2(a)(11) of the Securities Act. The Selling Securityholder has informed us that each such broker-dealer may receive commissions from the Selling Securityholder for executing such sales for the Selling Securityholder and, if so, such commissions will not exceed customary brokerage commissions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Brokers, dealers, underwriters, or agents participating in the distribution of the shares of our Common Stock offered by this prospectus may receive compensation in the form of commissions, discounts, or concessions from the purchasers, for whom the broker-dealers may act as agent, of the shares sold by the Selling Securityholder through this prospectus. The compensation paid to any such particular broker-dealer by any such purchasers of shares of our Common Stock sold by the Selling Securityholder may be less than or in excess of customary commissions. Neither we nor the Selling Securityholder can presently estimate the amount of compensation that any agent will receive from any purchasers of shares of our Common Stock sold by the Selling Securityholder. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">251 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We know of no existing arrangements between the Selling Securityholder or any other stockholder, broker, dealer, underwriter, or agent relating to the sale or distribution of the shares of our Common Stock offered by this prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may from time to time file with the SEC one or more supplements to this prospectus or amendments to the registration statement of which this prospectus forms a part to amend, supplement, or update information contained in this prospectus, including, if and when required under the Securities Act, to disclose certain information relating to a particular sale of shares offered by this prospectus by the Selling Securityholder, including with respect to any compensation paid or payable by the Selling Securityholder to any brokers, dealers, underwriters, or agents that participate in the distribution of such shares by the Selling Securityholder, and any other related information required to be disclosed under the Securities Act. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will pay the expenses incident to the registration under the Securities Act of the offer and sale of the shares of our Common Stock covered by this prospectus by the Selling Securityholder. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As consideration for its irrevocable commitment to purchase our Common Stock under the B. Riley Purchase Agreement, we issued to the Selling Securityholder 250,000 shares of our Common Stock as Commitment Shares in connection with the execution of the B. Riley Purchase Agreement. In addition, we have paid an affiliate of the Selling Securityholder a structuring fee of $10,000 in connection with the structuring of the transactions by the Selling Securityholder under the B. Riley Purchase Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also have agreed to indemnify the Selling Securityholder and certain other persons against certain liabilities in connection with the offering of shares of our Common Stock offered hereby, including liabilities arising under the Securities Act, or, if such indemnity is unavailable, to contribute amounts required to be paid in respect of such liabilities. The Selling Securityholder has agreed to indemnify us against liabilities under the Securities Act that may arise from certain written information furnished to us by the Selling Securityholder specifically for use in this prospectus or, if such indemnity is unavailable, to contribute amounts required to be paid in respect of such liabilities. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers, and controlling persons, we have been advised that, in the opinion of the SEC, this indemnification is against public policy as expressed in the Securities Act, and is therefore unenforceable. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Selling Securityholder has represented to us that at no time prior to the date of the B. Riley Purchase Agreement has the Selling Securityholder or any entity managed or controlled by the Selling Securityholder engaged in or effected, in any manner whatsoever, directly or indirectly, for its own account or for the account of any of its affiliates, any short sale or any transaction that establishes a net short position with respect to our Common Stock. The Selling Securityholder has agreed that, during the term of the B. Riley Purchase Agreement, none of the Selling Securityholder, its officers, its sole member, or any entity managed or controlled by the Selling Securityholder will enter into or effect, directly or indirectly, any of the foregoing transactions for its own account or for the account of any other such person or entity. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have advised the Selling Securityholder that it is required to comply with Regulation M promulgated under the Exchange Act. With certain exceptions, Regulation M precludes the Selling Securityholder, any affiliated purchasers, and any broker-dealer or other person who participates in the distribution from bidding for or purchasing, or attempting to induce any person to bid for or purchase, any security that is the subject of the distribution until the entire distribution is complete. Regulation M also prohibits any bids or purchases made in order to stabilize the price of a security in connection with the distribution of that security. All of the foregoing may affect the marketability of the securities offered by this prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This offering will terminate on the date that all shares of our Common Stock offered by this prospectus have been sold by the Selling Securityholder. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">252 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom428534_98">MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a discussion of certain material U.S. federal income tax considerations generally applicable to the purchase, ownership and disposition of our Common Stock. This discussion is based on provisions of the Code, the Treasury Regulations promulgated thereunder (whether final, temporary, or proposed), administrative rulings of the IRS, and judicial decisions, all as in effect on the date hereof, and all of which are subject to differing interpretations or change, possibly with retroactive effect. This discussion does not purport to be a complete analysis or listing of all potential U.S. federal income tax consequences relating to the purchase, ownership and disposition of our Common Stock. In addition, this discussion does not address all aspects of U.S. federal income tax consequences to particular holders nor does it take into account the individual facts and circumstances of any particular holder that may affect the U.S. federal income tax consequences to such holder, and accordingly, is not intended to be, and should not be construed as, tax advice. This discussion does not address the U.S. federal 3.8% Medicare tax imposed on certain net investment income or any aspects of U.S. federal taxation other than those pertaining to the income tax (such as the gift or estate tax), nor does it address any tax consequences arising under any U.S. state and local, or <span style="white-space:nowrap">non-U.S.</span> tax laws. Holders should consult their own tax advisors regarding such tax consequences in light of their particular circumstances. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No ruling has been requested or will be obtained from the IRS with respect to the U.S. federal income tax consequences to a holder of the purchase, ownership or disposition of our Common Stock; thus, there can be no assurance that the IRS will not challenge the U.S. federal income tax treatment described below or that, if challenged, such treatment will be sustained by a court. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This summary is limited to considerations relevant to holders that hold our Common Stock as &#8220;capital assets&#8221; within the meaning of Section&#160;1221 of the Code (generally, property held for investment). This discussion does not address all aspects of U.S. federal income taxation that may be important to holders in light of their individual circumstances, including holders subject to special treatment under the U.S. tax laws, such as, for example: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">banks or other financial institutions, underwriters, or insurance companies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">traders in securities who elect to apply a <span style="white-space:nowrap"><span style="white-space:nowrap">mark-to-market</span></span> method of accounting; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">real estate investment trusts and regulated investment companies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="white-space:nowrap">tax-exempt</span> organizations, qualified retirement plans, individual retirement accounts, or other <span style="white-space:nowrap">tax-</span> deferred accounts; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">expatriates or former long-term residents of the United States; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">subchapter S corporations, partnerships or other pass-through entities or investors in such entities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">dealers or traders in securities, commodities or currencies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">grantor trusts; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">persons subject to the alternative minimum tax; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">U.S. persons whose &#8220;functional currency&#8221; is not the U.S. dollar; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">persons who received our Common Stock through the issuance of restricted stock under an equity incentive plan or through a <span style="white-space:nowrap">tax-qualified</span> retirement plan or otherwise as compensation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">persons who own (directly or through attribution) 5% or more (by vote or value) of the outstanding securities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">persons holding our Common Stock as a position in a &#8220;straddle,&#8221; as part of a &#8220;synthetic security&#8221; or &#8220;hedge,&#8221; as part of a &#8220;conversion transaction,&#8221; or other integrated investment or risk reduction transaction; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">253 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">controlled foreign corporations, passive foreign investment companies, or foreign corporations with respect to which there are one or more United States shareholders within the meaning of Treasury Regulation <span style="white-space:nowrap">Section&#160;1.367(b)-3(b)(1)(ii);</span> or </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used in this discussion, the term &#8220;U.S. Holder&#8221; means a beneficial owner of our Common Stock that is, for U.S. federal income tax purposes: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an individual who is a citizen or resident of the United States; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a corporation (or other entity that is classified as a corporation for U.S. federal income tax purposes) that is created or organized in or under the laws of the United States or any State thereof or the District of Columbia; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an estate the income of which is subject to U.S. federal income tax regardless of its source; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a trust (i)&#160;if a court within the United States is able to exercise primary supervision over the administration of the trust and one or more U.S. persons have the authority to control all substantial decisions of the trust, or (ii)&#160;that has a valid election in effect under applicable Treasury Regulations to be treated as a U.S. person for U.S. federal income tax purposes. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A <span style="white-space:nowrap">&#8220;Non-U.S.</span> Holder&#8221; means a beneficial owner of our Common Stock, that is neither a U.S. Holder nor a partnership (or an entity or arrangement treated as a partnership) for U.S. federal income tax purposes. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a partnership, including for this purpose any entity or arrangement that is treated as a partnership for U.S. federal income tax purposes, holds our Common Stock, the U.S. federal income tax treatment of a partner in such partnership will generally depend on the status of the partner and the activities of the partnership. A holder that is a partnership and the partners in such partnership should consult their own tax advisors with regard to the U.S. federal income tax consequences of the ownership and disposition of our Common Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">THIS SUMMARY DOES NOT PURPORT TO BE A COMPREHENSIVE ANALYSIS OR DESCRIPTION OF ALL POTENTIAL U.S. FEDERAL INCOME TAX CONSEQUENCES OF THE OWNERSHIP AND DISPOSITION OF OUR COMMON STOCK. IN ADDITION, THE U.S. FEDERAL INCOME TAX TREATMENT OF THE BENEFICIAL OWNERS OF OUR COMMON STOCK MAY BE AFFECTED BY MATTERS NOT DISCUSSED HEREIN AND DEPENDS IN SOME INSTANCES ON DETERMINATIONS OF FACT AND INTERPRETATIONS OF COMPLEX PROVISIONS OF U.S. FEDERAL INCOME TAX LAW FOR WHICH NO CLEAR PRECEDENT OR AUTHORITY MAY BE AVAILABLE. HOLDERS OF OUR COMMON STOCK SHOULD CONSULT WITH THEIR TAX ADVISORS REGARDING THE PARTICULAR TAX CONSEQUENCES TO THEM OF THE OWNERSHIP AND DISPOSITION OF OUR COMMON STOCK INCLUDING THE APPLICABILITY AND EFFECTS OF U.S. FEDERAL, STATE, LOCAL, AND OTHER TAX LAWS. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_207">U.S. Holders </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Taxation of Distributions </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we pay distributions or make constructive distributions (other than certain distributions of our stock or rights to acquire our stock) to U.S. Holders of shares of our Common Stock, such distributions generally will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. Distributions in excess of our current and accumulated earnings and profits will constitute a return of capital that will be applied against and reduce (but not below zero) the U.S. Holder&#8217;s adjusted tax basis in our Common Stock. Any remaining excess will be treated as gain realized on the sale or other disposition of the Common Stock and will be treated as described under &#8220;<span style="font-style:italic">U.S. Holders-Gain or Loss on Sale, Taxable Exchange or Other Taxable Disposition of Common Stock</span>&#8221; below. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">254 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dividends we pay to a U.S. Holder that is a taxable corporation will generally qualify for the dividends received deduction if the requisite holding period is satisfied. With certain exceptions (including dividends treated as investment income for purposes of investment interest deduction limitations), and provided certain holding period requirements are met, dividends we pay to a <span style="white-space:nowrap">non-corporate</span> U.S. Holder will generally constitute &#8220;qualified dividends&#8221; that will be subject to tax at the preferential tax rate accorded to long-term capital gains. <span style="white-space:nowrap">Non-corporate</span> U.S. Holders that do not meet a minimum holding period requirement or that elect to treat the dividend income as &#8220;investment income&#8221; pursuant to Section&#160;163(d)(4) of the Code (dealing with the deduction for investment interest expense) will not be eligible for the reduced rates of taxation applicable to qualified dividends. In addition, the rate reduction will not apply to dividends if the recipient of a dividend is obligated to make related payments with respect to positions in substantially similar or related property. This disallowance applies even if the minimum holding period has been met. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the holding period requirements are not satisfied, a corporation may not be able to qualify for the dividends received deduction and would have taxable income equal to the entire dividend amount, and <span style="white-space:nowrap">non-corporate</span> holders may be subject to tax on such dividend at ordinary income tax rates instead of the preferential rates that apply to qualified dividend income. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Gain or Loss on Sale, Taxable Exchange or Other Taxable Disposition of Common Stock </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A U.S. Holder generally will recognize gain or loss on the sale, taxable exchange or other taxable disposition of our Common Stock, including on a redemption that is treated as a sale or exchange under Section&#160;302 of the Code. Any such gain or loss will be capital gain or loss, and will be long-term capital gain or loss if the U.S. Holder&#8217;s holding period for the Common Stock so disposed of exceeds one year. The amount of gain or loss recognized will generally be equal to the difference between (1)&#160;the sum of the amount of cash and the fair market value of any property received in such disposition and (2)&#160;the U.S. Holder&#8217;s adjusted tax basis in its Common Stock so disposed of. A U.S. Holder&#8217;s adjusted tax basis in its Common Stock will generally equal the U.S. Holder&#8217;s acquisition cost for such Common Stock, less any prior distributions treated as a return of capital. The deductibility of capital losses is subject to limitations. Long-term capital gains recognized by <span style="white-space:nowrap">non-corporate</span> U.S. Holders are generally eligible for reduced rates of tax. If the U.S. Holder&#8217;s holding period for the Common Stock so disposed of is one year or less, any gain on a sale or other taxable disposition of the shares would be subject to short-term capital gain treatment and would be taxed at ordinary income tax rates. The deductibility of capital losses is subject to limitations. Any gain or loss recognized by a U.S. Holder on the sale or exchange of our Common Stock will generally be treated as U.S. source gain or loss. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_208"><span style="white-space:nowrap">Non-U.S.</span> Holders </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Taxation of Distributions </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, any distributions (including constructive distributions) we make to a <span style="white-space:nowrap">Non-U.S.</span> Holder of shares of our Common Stock, to the extent paid out of our current or accumulated earnings and profits (as determined under U.S. federal income tax principles), will constitute dividends for U.S. federal income tax purposes and, provided such dividends are not effectively connected with the <span style="white-space:nowrap">Non-U.S.</span> Holder&#8217;s conduct of a trade or business within the United States, we will be required to withhold tax from the gross amount of the dividend at a rate of 30%, unless such <span style="white-space:nowrap">Non-U.S.</span> Holder is eligible for a reduced rate of withholding tax under an applicable income tax treaty and provides proper certification of its eligibility for such reduced rate (usually on an IRS Form <span style="white-space:nowrap">W-8BEN</span> or <span style="white-space:nowrap"><span style="white-space:nowrap">W-8BEN-E,</span></span> as applicable). Special certification and other requirements apply to certain <span style="white-space:nowrap">Non-U.S.</span> Holders that are pass-through entities rather than corporations or individuals. Any distribution not constituting a dividend will be treated first as reducing (but not below zero) the <span style="white-space:nowrap">Non-U.S.</span> Holder&#8217;s adjusted tax basis in its shares of our Common Stock and, to the extent such distribution exceeds the <span style="white-space:nowrap">Non-U.S.</span> Holder&#8217;s adjusted tax basis, as gain realized from the sale or other disposition of the Common Stock, which will be treated as described under &#8220;<span style="font-style:italic"><span style="white-space:nowrap">Non-U.S.</span> Holders-Gain on Sale, Taxable Exchange or Other Taxable Disposition of Common Stock</span>&#8221; below. In addition, if we determine that we are likely to be classified as a &#8220;United States real property holding </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">255 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
corporation&#8221; (see &#8220;<span style="font-style:italic"><span style="white-space:nowrap">Non-U.S.</span> Holders-Gain on Sale, Exchange or Other Taxable Disposition of Common Stock</span>&#8221; below), we will withhold 15% of any distribution that exceeds our current and accumulated earnings and profits </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dividends we pay to a <span style="white-space:nowrap">Non-U.S.</span> Holder that are effectively connected with such <span style="white-space:nowrap">Non-U.S.</span> Holder&#8217;s conduct of a trade or business within the United States (or if a tax treaty applies are attributable to a U.S. permanent establishment or fixed base maintained by the <span style="white-space:nowrap">Non-U.S.</span> Holder) will generally not be subject to U.S. withholding tax, provided such <span style="white-space:nowrap">Non-U.S.</span> Holder complies with certain certification and disclosure requirements (generally by providing an IRS Form <span style="white-space:nowrap">W-8ECI).</span> Instead, such dividends generally will be subject to U.S. federal income tax, net of certain deductions, at the same graduated individual or corporate rates applicable to U.S. Holders. If the <span style="white-space:nowrap">Non-U.S.</span> Holder is a corporation, dividends that are effectively connected income may also be subject to a &#8220;branch profits tax&#8221; at a rate of 30% (or such lower rate as may be specified by an applicable income tax treaty). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Gain or Loss on Sale, Taxable Exchange or Other Taxable Disposition of Common Stock </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A <span style="white-space:nowrap">Non-U.S.</span> Holder generally will not be subject to U.S. federal income or withholding tax in respect of gain recognized on a sale, taxable exchange or other taxable disposition of our Common Stock, unless: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the gain is effectively connected with the conduct of a trade or business by the <span style="white-space:nowrap">Non-U.S.</span> Holder within the United States (and, if an applicable tax treaty so requires, is attributable to a U.S. permanent establishment or fixed base maintained by the <span style="white-space:nowrap">Non-U.S.</span> Holder); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the <span style="white-space:nowrap">Non-U.S.</span> Holder is an individual who is present in the United States for 183 days or more in the taxable year of disposition and certain other conditions are met; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we are or have been a &#8220;United States real property holding corporation&#8221; for U.S. federal income tax purposes at any time during the shorter of the five-year period ending on the date of disposition or the period that the <span style="white-space:nowrap">Non-U.S.</span> Holder held our Common Stock and, in the case where shares of our Common Stock are regularly traded on an established securities market, the <span style="white-space:nowrap">Non-U.S.</span> Holder has owned, directly or constructively, more than 5% of our Common Stock at any time within the shorter of the five-year period preceding the disposition or such <span style="white-space:nowrap">Non-U.S.</span> Holder&#8217;s holding period for the shares of our Common Stock. There can be no assurance that our Common Stock will be treated as regularly traded on an established securities market for this purpose. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gain described in the first bullet point above will be subject to tax at generally applicable U.S. federal income tax rates as if the <span style="white-space:nowrap">Non-U.S.</span> Holder were a U.S. resident. Any gains described in the first bullet point above of a <span style="white-space:nowrap">Non-U.S.</span> Holder that is a foreign corporation may also be subject to an additional &#8220;branch profits tax&#8221; at a 30% rate (or lower applicable treaty rate). Gain described in the second bullet point above will generally be subject to a flat 30% U.S. federal income tax. <span style="white-space:nowrap">Non-U.S.</span> Holders are urged to consult their tax advisors regarding possible eligibility for benefits under income tax treaties. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the third bullet point above applies to a <span style="white-space:nowrap">Non-U.S.</span> Holder and applicable exceptions are not available, gain recognized by such holder on the sale, exchange or other disposition of our Common Stock will be subject to tax at generally applicable U.S. federal income tax rates. In addition, a buyer of our Common Stock from such holder may be required to withhold U.S. income tax at a rate of 15% of the amount realized upon such disposition. <span style="white-space:nowrap">Non-U.S.</span> Holders are urged to consult their tax advisors regarding the application of these rules. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_209">Foreign Account Tax Compliance Act </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Sections 1471 to 1474 of the Code and the Treasury Regulations and administrative guidance promulgated thereunder (commonly referred to as the &#8220;Foreign Account Tax Compliance Act&#8221; or &#8220;FATCA&#8221;) a 30% withholding tax generally applies with respect to certain dividends in respect of and, subject to the proposed Treasury Regulations described below, gross proceeds from a sale or disposition of, securities which are held by or through certain foreign financial institution (including investment funds), unless any such institution (a)&#160;enters into, and complies with, an agreement with the IRS to report, on an annual basis, information with respect to </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">256 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
interests in, and accounts maintained by, the institution that are owned by certain U.S. persons and by certain <span style="white-space:nowrap">non-U.S.</span> entities that are wholly or partially owned by U.S. persons and to withhold on certain payments, or (b)&#160;if required under an intergovernmental agreement between the United States and an applicable foreign country, reports such information to its local tax authority, which will exchange such information with the U.S. authorities. An intergovernmental agreement between the United States and the applicable foreign country may modify these requirements. Accordingly, the entity through which our Common Stock are held will affect the determination of whether such withholding is required. Similarly, dividends in respect of, and (subject to the proposed Treasury Regulations discussed below) gross proceeds from the sale or other disposition of, Common Stock held by an investor that is a <span style="white-space:nowrap">non-financial</span> <span style="white-space:nowrap">non-U.S.</span> entity that does not qualify under certain exceptions will generally be subject to withholding at a rate of 30%, unless such entity either (i)&#160;certifies to the applicable withholding agent that such entity does not have any &#8220;substantial United States owners&#8221; or (ii)&#160;provides certain information regarding the entity&#8217;s &#8220;substantial United States owners,&#8221; which will in turn be provided to the U.S. Department of Treasury. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the applicable Treasury Regulations and administrative guidance, withholding under FATCA generally applies to payments of dividends. While withholding under FATCA generally would also apply to payments of gross proceeds from the sale or other disposition of securities (including Common Stock), proposed Treasury Regulations eliminate FATCA withholding on payments of gross proceeds entirely. Taxpayers generally may rely on these proposed Treasury Regulations until final Treasury Regulations are issued. All holders should consult their tax advisors regarding the possible implications of FATCA on their investment in our Common Stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Information Reporting and Backup Withholding. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Information returns will be filed with the IRS in connection with payments of dividends and the proceeds from a sale or other disposition of our shares of Common Stock. A <span style="white-space:nowrap">Non-U.S.</span> Holder may have to comply with certification procedures to establish that it is not a United States person in order to avoid information reporting and backup withholding requirements. The certification procedures required to claim a reduced rate of withholding under a treaty generally will satisfy the certification requirements necessary to avoid the backup withholding as well. Backup withholding is not an additional tax. The amount of any backup withholding from a payment to a <span style="white-space:nowrap">Non-U.S.</span> Holder will be allowed as a credit against such holder&#8217;s U.S. federal income tax liability and may entitle such holder to a refund, provided that the required information is timely furnished to the IRS. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">THE DISCUSSION ABOVE IS A GENERAL SUMMARY. IT DOES NOT COVER ALL TAX MATTERS THAT MAY BE IMPORTANT TO YOU. EACH PROSPECTIVE PURCHASER SHOULD CONSULT ITS TAX ADVISOR ABOUT THE TAX CONSEQUENCES OF AN INVESTMENT IN OUR COMMON STOCK BASED ON YOUR CIRCUMSTANCES. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">257 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom428534_99">DESCRIPTION OF OUR SECURITIES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_100">General </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following description summarizes the most important terms of our securities. The following summary does not purport to be complete and is subject to the Certificate of Incorporation, the Bylaws and the provisions of applicable law. A copy of the Certificate of Incorporation and a copy of the Bylaws are attached as exhibits to the registration statement of which this prospectus forms a part. The stockholders are encouraged to read the applicable provisions of the DGCL, the Certificate of Incorporation and the Bylaws in their entirety for a complete description of the rights and preferences of our securities. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_101">Authorized and Outstanding Stock </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation authorizes the issuance of (i) 740,000,000 shares of Common Stock, $0.0001 par value per share and (ii) 45,000,000 shares of preferred stock, $0.0001 par value per share (the &#8220;Preferred Stock&#8221;), of which 29,057,097 shares have been designated as Series A Preferred Stock. As of January&#160;11, 2023, there were 141,598,856 shares of Common Stock and 29,057,097 shares of Series&#160;A Preferred Stock issued and outstanding. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_210">Our Common Stock </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation provides the following with respect to the rights, powers, preferences and privileges of our Common Stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Dividend Rights </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of our Common Stock are entitled to receive ratably those dividends, if any, that may be declared from time to time by our Board upon the shares of our capital stock, which dividends may be paid either in cash, in property or in shares of our capital stock, subject to preferences that may be applicable to preferred stock, if any, then outstanding. Subject to applicable law and the Certificate of Incorporation, our Board will have full power to determine whether any dividends shall be declared and paid to stockholders. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Voting Rights </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each holder of our Common Stock will be entitled to one vote for each share of our Common Stock held of record by such holder on all matters on which stockholders generally are entitled to vote, except for any amendment to the Certificate of Incorporation that relates solely to the terms of one or more outstanding classes or series of our Preferred Stock if the holders of such affected classes or series are entitled, either separately or together with the holders of one or more other such classes or series, to vote thereon pursuant to the Certificate of Incorporation or the DGCL. Any action or matter presented to the stockholders at a duly called or convened meeting, at which a quorum is present, will be decided by the affirmative vote of the holders of a majority of the votes cast affirmatively or negatively (excluding abstentions) at the meeting by the holders entitled to vote thereon, except that our directors will be elected by a plurality of the votes cast. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Right to Receive Liquidation Distributions </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of a liquidation, dissolution or winding up of the Company, the holders of our Common Stock will be entitled to share ratably in all assets remaining after payment of liabilities, subject to prior distribution rights of our Preferred Stock, if any, then outstanding. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">No Preemptive or Similar Rights </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Common Stock have no preemptive or conversion rights or other subscription rights. There are no redemption or sinking fund provisions applicable to our Common Stock. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">258 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Fully Paid and <span style="white-space:nowrap">Non-Assessable</span> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The outstanding Vickers Ordinary Shares and the shares of our Common Stock issued in the Business Combination are fully paid and <span style="white-space:nowrap">non-assessable.</span> </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_102">Our Preferred Stock </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation authorizes our Board, subject to limitations prescribed by Delaware law, to issue up to 45,000,000 shares of preferred stock in one or more series, to determine and fix from time to time the number of shares to be included in each such series and to fix the designations, powers, rights and preferences of the shares of each such series, and the qualifications, limitations and restrictions thereof, including voting rights (if any), dividend rights, dissolution rights, conversion rights, exchange rights and redemption rights, in each case without further vote or action by our stockholders. The number of authorized shares of our Common Stock and our Preferred Stock may be increased or decreased (but not below the number of the shares thereof then outstanding) by the affirmative vote of the holders of a majority in voting power of our outstanding stock entitled to vote thereon. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of our Common Stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying, deferring or preventing a change in control and may adversely affect the market price of our Common Stock and the voting and other rights of the holders of our Common Stock. Other than the Series A Preferred Stock issued to Sorrento in connection with the Closing of the Business Combination, there are no other Preferred Stock outstanding and we have no current plans to issue any other shares of preferred stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Number and Designation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We filed the Certificate of Designations, designating 29,057,097 shares of our preferred stock as &#8220;Series A Preferred Stock&#8221;. As of the date of this prospectus, 29,057,097 shares of the Series A Preferred Stock have been issued to Sorrento pursuant to the terms of the Merger Agreement and such shares have all of the rights, preferences and privileges set forth in the Certificate of Designations as more fully described below. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Rank </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Series A Preferred Stock shall rank (i)&#160;senior to all of our Common Stock, and to all other classes or series of our capital stock, except for any such other class or series, the terms of which expressly provide that it ranks on parity with the Series A Preferred Stock as to dividend rights and rights on liquidation, dissolution or <span style="white-space:nowrap">winding-up</span> of the Company (&#8220;Junior Securities&#8221;); and (ii)&#160;on parity with each class or series of our capital stock, created specifically ranking by its terms on parity with the Series A Preferred Stock as to dividend rights and rights on liquidation, dissolution or <span style="white-space:nowrap">winding-up</span> of the Company (&#8220;Parity Securities&#8221;). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Dividend Rights </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of the Series A Preferred Stock shall not be entitled to dividends unless we pay dividends to holders of the Common Stock and shall be entitled to receive, when, as and if declared by our Board, such dividends (whether in cash or other property) as are paid to holders of our Common Stock to the same extent as if such holders of Series A Preferred Stock had been deemed to convert their shares of Series A Preferred Stock into Common Stock and had held such shares of Common Stock on the record date for such dividends and distributions. Such payments will be made concurrently with the dividend or distribution to the holders of the Common Stock. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">259 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Liquidation Preference </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of a change of control, liquidation, dissolution or <span style="white-space:nowrap">winding-up</span> of the Company, whether voluntary or involuntary, before any payment or distribution of our property or assets (whether capital or surplus) shall be made to or set apart for the holders of Junior Securities, the holders of Series A Preferred Stock shall be entitled to receive an amount per share of Series A Preferred Stock equal to the greater of (i)&#160;the sum of $10.00 (which amount shall be appropriately adjusted in the event of any stock split, stock combination or other similar recapitalization of the Series A Preferred Stock) and all accrued and unpaid dividends and (ii)&#160;the amount such share of Series A Preferred Stock would be entitled to receive pursuant to the change of control, liquidation, dissolution or <span style="white-space:nowrap">winding-up</span> of the Company assuming that such share had been converted into shares of Common Stock in a Deemed Conversion (as defined below). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Conversion and Redemption Rights </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares of Series A Preferred Stock will not be convertible into Common Stock or any of our other securities and will not be redeemable by the Company; provided, however, a number of the rights, preferences and privileges of the Series A Preferred Stock set forth in the Certificate of Designations will be determined based on an <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">as-converted-to-</span></span></span> Common Stock basis or otherwise assume that the shares of Series A Preferred Stock are converted into shares of Common Stock. Accordingly, the number of shares of Common Stock that each share of Series A Preferred Stock is deemed to be (or otherwise being treated as) converted into for the purpose of affecting the various rights, preferences and privileges of the Series A Preferred Stock set forth in the Certificate of Designation (a &#8220;Deemed Conversion&#8221;), whether in connection with a change of control or otherwise, shall be equal to the result obtained by dividing (i)&#160;stated value by (ii) $10.00 (subject to anti-dilution adjustments). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Voting and Other Preferred Rights </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise required by law or as set forth in the Certificate of Designations, the holders of shares of Series A Preferred Stock will be entitled to vote, together with the holders of shares of Common Stock and not separately as a class, on all matters upon which holders of shares of Common Stock have the right to vote. The holders of shares of Series A Preferred Stock will be entitled to one vote for each share of Common Stock that such share of Series A Preferred Stock would otherwise be convertible into pursuant to a Deemed Conversion on the record date for the determination of the stockholders entitled to vote. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As long as any shares of Series A Preferred Stock are outstanding, we shall not, without the affirmative vote of the holders of at least a majority of the outstanding shares of Series A Preferred Stock (a)&#160;change the Series A Preferred Stock (whether by merger, consolidation, reclassification or otherwise) into cash, securities or other property except in accordance with the terms of the Certificate of Designations; (b)&#160;create, authorize or issue any Parity Security or other equity security the terms of which provide that it ranks senior to the Series A Preferred Stock with respect to dividend rights or rights upon liquidation, dissolution or <span style="white-space:nowrap">winding-up</span> of the Company, or increase the authorized amount of any such other class or series; or (c)&#160;amend the Certificate of Incorporation or the Certificate of Designations in any manner that adversely affects the holders of Series A Preferred Stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Stockholder Agreement with Sorrento </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the Stockholder Agreement, from and after the Effective Time, and for so long as the Sorrento Group beneficially owns any shares of New Scilex Series A Preferred Stock, among other things, (i)&#160;Sorrento shall have the right, but not the obligation, to designate each director to be nominated, elected or appointed to our Board (each, a &#8220;Stockholder Designee&#8221; and collectively, the &#8220;Stockholder Designees&#8221;), regardless of whether such Stockholder Designee is to be elected to our Board at a meeting of stockholders called for the purpose of electing directors (or by consent in lieu of meeting) or appointed by the Board in order to fill any vacancy created by the departure of any director or increase in the authorized number of members of the Board, or the size of the Board and (ii)&#160;we will be required to take all actions reasonably necessary, and not </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">260 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
otherwise prohibited by applicable law, to cause each Stockholder Designee to be so nominated, elected or appointed to the Board as more fully described in the Stockholder Agreement. Sorrento shall also have the right to designate a replacement director for any Stockholder Designee that has been removed from the Board and the right to appoint a representative of Sorrento to attend all meetings of the committees of the Board. Notwithstanding the foregoing, the parties have agreed to ensure that the Board complies with all applicable requirements of the stock exchange, including independence requirements. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Stockholder Agreement also provides that we will be prohibited from taking certain actions without the consent of Sorrento. Such actions include, among other things, amendments to the Certificate of Designations, increases or decreases in the size of the Board, the incurrence of certain amounts of indebtedness and the payment of dividends on our Common Stock. For more information on the Stockholder Agreement, see the section titled &#8220;<span style="font-style:italic">Certain Relationships and Related Party Transactions</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;&#8212; Certain Relationships of Vickers</span><span style="font-style:italic"></span><span style="font-style:italic">&#160;&#8212; Stockholder Agreement with Sorrento</span>.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_103">Registration Rights </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Registration Rights Agreement entered into in connection with the Closing of the Business Combination, certain of our stockholders are able to demand that we register their registrable securities under certain circumstances and each also have piggyback registration rights for these securities. In addition, we are required to file and maintain an effective registration statement under the Securities Act covering the resale of all such registrable securities. We have filed the registration statement of which this prospectus forms a part in order to satisfy the foregoing obligations. The registration of these securities will enable the public sale of such securities, subject to certain contractual restrictions imposed by the Registration Rights Agreement and the Merger Agreement. The presence of these additional shares of common stock trading in the public market may have an adverse effect on the market price of our securities. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_104">Anti-Takeover Matters in our Governing Documents and Under Delaware Law </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain provisions of Delaware law, along with the Certificate of Incorporation and the Bylaws, all of which are summarized below, may have the effect of delaying, deferring or discouraging another person from acquiring control of the Company. These provisions are expected to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed, in part, to encourage persons seeking to acquire control of the Company to first negotiate with our Board. However, these provisions could have the effect of delaying, discouraging or preventing attempts to acquire the Company, which could deprive our stockholders of opportunities to sell their shares of our Common Stock at prices higher than prevailing market prices. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Authorized but Unissued Capital Stock </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The authorized but unissued shares of our Common Stock and our Preferred Stock are available for future issuance without stockholder approval, subject to any limitations imposed by the rules of the Nasdaq Listing Rules. These additional shares may be used for a variety of corporate finance transactions, acquisitions and employee benefit plans. The existence of authorized but unissued and unreserved Common Stock and Preferred Stock could make more difficult or discourage an attempt to obtain control of the Company by means of a proxy contest, tender offer, merger or otherwise. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Classified Board of Directors </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation provides that our Board are divided into three classes, with the classes as nearly equal in number as practical and each class serving three-year staggered terms. The directors in each class serve for a three-year term (except that the term of our current Class&#160;I directors shall expire at the first annual meeting of stockholders following the Closing of the Business Combination and the term of our current Class&#160;II directors shall expire at the second annual meeting of stockholders following the Closing of the Business </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">261 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Combination), with one class being elected each year by the stockholders. This system of electing and removing directors may tend to discourage a third party from making a tender offer or otherwise attempting to obtain control of the Company, because it generally makes it more difficult for stockholders to replace a majority of the directors. See the section of this prospectus titled &#8220;<span style="font-style:italic">Management</span>&#8221; for more information on the classified board. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation also provides that the total number of directors shall be determined from time to time exclusively by our Board; provided that, at any time prior to a Sorrento Trigger Event, the stockholders may also fix the number of directors by resolution adopted by the stockholders. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Removal of Directors; Vacancies </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation provides that, except as otherwise required by law or the Certificate of Incorporation, directors may be removed with or without cause by the affirmative vote of the holders of a majority in voting power of the then-outstanding shares of our stock entitled to vote generally in the election of such directors; provided, however, that, from and after the Sorrento Trigger Event, any such director or all such directors may be removed only for cause and only by the affirmative vote of the holders of at least 66 2/3% in voting power of all the then-outstanding shares of our stock entitled to vote thereon, voting together as a single class, in each case subject to the rights of holders of any series of Preferred Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the Certificate of Incorporation provides that, except as otherwise provided therein or by law, any vacancy resulting from the death, resignation, removal or disqualification of a director or other cause, or any newly created directorship in our Board, may be filled by a majority of the directors then in office, although less than a quorum, or by our stockholders; provided, however, that from and after the Sorrento Trigger Event, any vacancy resulting from the death, resignation, removal or disqualification of a director or other cause, or any newly created directorship in our Board, shall be filled only by a majority of the directors then in office, although less than a quorum, and shall not be filled by our stockholders, in each case subject to the rights of the holders of any series of Preferred Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These provisions may have the effect of deferring, delaying, or discouraging hostile takeovers, changes in control of the Company or changes in our management. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Delaware Anti-Takeover Law </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation provides that we will opt out of Section&#160;203 of the DGCL until the occurrence of a Sorrento Trigger Event, at which time we shall immediately and automatically become governed by Section&#160;203 of the DGCL. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&#160;203 of the DGCL prohibits persons deemed to be &#8220;interested stockholders&#8221; from engaging in a &#8220;business combination&#8221; with a publicly held Delaware corporation for three years following the date such persons become interested stockholders, unless the business combination is, or the transaction in which the person became an interested stockholder was, approved in a prescribed manner or another prescribed exception applies. Generally, an &#8220;interested stockholder&#8221; is a person who, together with affiliates and associates, owns, or within three years prior to the determination of interested stockholder status did own, 15% or more of a corporation&#8217;s voting stock. Generally, a &#8220;business combination&#8221; includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. The existence of this provision may have an anti-takeover effect with respect to transactions that are not approved in advance by our Board, including discouraging attempts that might result in a premium over the market price for the shares of Common Stock held by stockholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation provides that the restrictions on business combination of Section&#160;203 of the DGCL will not apply to Sorrento or its current or future Affiliates (as defined in the Certificate of Incorporation) regardless of the percentage of ownership of the total voting power of all the then-outstanding shares of our capital stock entitled to vote generally in the election of directors beneficially owned by them. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">262 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">No Cumulative Voting </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Delaware law, the right to vote cumulatively does not exist unless the certificate of incorporation specifically authorizes cumulative voting. The Certificate of Incorporation does not authorize cumulative voting. Therefore, stockholders holding a majority of the shares of our capital stock entitled to vote generally in the election of directors will be able to elect all of our directors. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Special Stockholder Meetings </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation provides that special meetings of stockholders may only be called by order of the Chairperson of our Board, our Board or the Chief Executive Officer; provided, however, that at any time prior to the Sorrento Trigger Event, special meetings of our stockholders shall also be called by or at the direction of our Board or the Chairperson of our Board at the request of Sorrento, in each case subject to the rights of the holders of any series of Preferred Stock with respect to such series of preferred stock. The Bylaws prohibits the conduct of any business at a special meeting other than as specified in the notice for such meeting. These provisions may have the effect of deferring, delaying, or discouraging hostile takeovers or changes in control or management. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Director Nominations and Stockholder Proposals </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Bylaws establishes advance notice procedures with respect to stockholder proposals and the nomination of candidates for election as directors, other than nominations made by or at the direction of our Board or a committee of our Board. In order for any matter to be &#8220;properly brought&#8221; before a meeting, a stockholder will have to comply with advance notice requirements and provide us with certain information. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, to be timely, a stockholder&#8217;s notice must be delivered to our secretary at our principal executive offices not earlier than the close of business on the 120th day nor later than the close of business on the 90th day prior to the first anniversary of the preceding year&#8217;s annual meeting (in the case of the first annual meeting of stockholders held after January&#160;1, 2023, the date of the preceding year&#8217;s annual meeting of the stockholders shall be deemed to be June&#160;30, 2022); provided, however, that, if the date of the annual meeting is advanced more than 30 days prior to or delayed by more than 60 days after the anniversary of the preceding year&#8217;s annual meeting, or if no annual meeting was held in the preceding year, notice by the stockholder to be timely must be so delivered not earlier than the close of business on the 120th day prior to such annual meeting and not later than the close of business on the later of the 90th day prior to such annual meeting and the 10th day following the day on which public announcement of the date of such meeting is first made by us. The Bylaws also specifies requirements as to the form and content of a stockholder&#8217;s notice. The Bylaws allows any previously scheduled stockholders meeting to be postponed, adjourned or canceled by resolution of our Board; provided, however, that with respect to any special meeting of stockholders scheduled at the request of Sorrento, our Board is not allowed to postpone, reschedule or cancel without the prior written consent of Sorrento. In addition, the Bylaws allows the chair of a meeting of the stockholders to adopt rules and regulations for the conduct of that meeting that may have the effect of precluding the conduct of certain business at that meeting if the rules and regulations are not followed. These provisions may also defer, delay, or discourage a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#8217;s own slate of directors or otherwise attempting to influence or obtain control. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Stockholder Action by Written Consent </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Section&#160;228 of the DGCL and the terms of the Certificate of Incorporation , any action required or permitted to be taken by our stockholders must be effected by a duly called annual or special meeting of such stockholders; provided, however, that prior to the Sorrento Trigger Event, any action required or permitted to be taken at any annual or special meeting of our stockholders may be taken without a meeting, without prior notice and without a vote, if a consent or consents, setting forth the action so taken, is signed by or on behalf of the holders of record of outstanding stock having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were present </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">263 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and voted, is delivered to us in accordance with the DGCL, in each case subject to the rights of the holders of any series of Preferred Stock with respect to such series of preferred stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Amendment of Certificate of Incorporation or Bylaws </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The DGCL provides generally that the affirmative vote of a majority of the shares entitled to vote on any matter is required to amend a corporation&#8217;s certificate of incorporation or bylaws, unless a corporation&#8217;s certificate of incorporation or bylaws, as the case may be, requires a greater percentage. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation provides that, upon the occurrence of the Sorrento Trigger Event, the affirmative vote of the holders of at least 66 2/3% of the voting power of the then-outstanding shares of stock entitled to vote thereon, voting together as a single class, will be required to alter, amend or repeal the following provisions of the Certificate of Incorporation: Article V (Board of Directors), Article VI (Consent of Stockholders in Lieu of Meeting; Special Meetings of Stockholders), Article VII (Limitation of Liability), Article&#160;VIII (Corporate Opportunities and Competition), Article IX (Exclusive Forum), Article X (Section 203 of the DGCL) and Article XI (Amendment of Certificate of Incorporation and Bylaws), and no other provision may be adopted, amended or repealed that would have the effect of modifying or permitting the circumvention of the provisions set forth in any of such Articles. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation and the Bylaws provide that, our Board is authorized to make, alter and repeal the Bylaws, without the consent or vote of the stockholders, by an approval of a majority of the total authorized number of directors. Upon the occurrence of the Sorrento Trigger Event, the affirmative vote of the holders of at least 66 2/3% of the voting power of the then-outstanding shares of stock entitled to vote thereon, voting together as a single class, will be required to alter, amend or repeal the Bylaws. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The provisions of the DGCL, the Certificate of Incorporation and the Bylaws could have the effect of discouraging others from attempting hostile takeovers and, as a consequence, they may also inhibit temporary fluctuations in the market price of our Common Stock that often result from actual or rumored hostile takeover attempts. These provisions may also have the effect of preventing changes in the composition of our Board and our management. It is possible that these provisions could make it more difficult to accomplish transactions that stockholders may otherwise deem to be in their best interests. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Exclusive Forum </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if and only if the Court of Chancery of the State of Delaware lacks subject matter jurisdiction, any state court located within the State of Delaware or, if and only if all such state courts lack subject matter jurisdiction, the federal district court for the District of Delaware) and any appellate court therefrom shall, to the fullest extent permitted by law, be the sole and exclusive forum for (i)&#160;any derivative action or proceeding brought on behalf of the Company, (ii)&#160;any action asserting a claim of breach of a fiduciary duty owed by any of our current or former directors, officers, employees or stockholders to us or our stockholders, (iii)&#160;any action asserting a claim against us or any of our current or former directors, officers, employees or stockholders arising pursuant to any provision of the DGCL or of the Certificate of Incorporation or the Bylaws, (iv)&#160;any claim or cause of action seeking to interpret, apply, enforce or determine the validity of the Certificate of Incorporation or the Bylaws, (v)&#160;any action or proceeding asserting a claim against us or any of our current or former directors, officers, employees or stockholders as to which the DGCL confers jurisdiction to the Court of Chancery of the State of Delaware, or (vi)&#160;any action asserting an &#8220;internal corporate claim,&#8221; as that term is defined in Section&#160;115 of the DGCL. The foregoing exclusive forum provisions will not apply to claims arising under the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">264 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the Certificate of Incorporation provides that, unless we consent in writing to the selection of an alternative forum, to the fullest extent permitted by law, the federal district courts of the United States of America shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we believe these provisions benefit us by providing increased consistency in the application of applicable law in the types of lawsuits to which they apply, the provisions may have the effect of discouraging lawsuits against our directors and officers. The enforceability of similar choice of forum provisions in other companies&#8217; certificates of incorporation has been challenged in legal proceedings and there is uncertainty as to whether a court would enforce such provisions. In addition, investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder. It is possible that, in connection with any applicable action brought against us, a court could find the choice of forum provisions contained in the Certificate of Incorporation to be inapplicable or unenforceable in such action. We may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business, operating results and financial condition. Any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock shall be deemed to have notice of and consented to the forum provisions in the Certificate of Incorporation. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Limitation of Liability and Indemnification of Directors and Officers </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation and the Bylaws contain provisions that limit the liability of our directors for monetary damages to the fullest extent permitted by the DGCL. Consequently, our directors will not be personally liable to us or our stockholders for monetary damages for any breach of fiduciary duties as directors, except liability for the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any breach of their duty of loyalty to us or our stockholders; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">unlawful payments of dividends or unlawful stock repurchases or redemptions in violation of the DGCL; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any transaction from which the director derived an improper personal benefit. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation also provides that if the DGCL is amended to permit further elimination or limitation of the personal liability of directors, then the liability of our directors will be eliminated or limited to the fullest extent permitted by the DGCL, as so amended. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Bylaws provide that we shall indemnify any person who is or was a director or officer of the Company or who is or was serving at our request as a director, officer or trustee of another corporation, limited liability company, partnership, joint venture, employee benefit plan, trust, nonprofit entity or other enterprise (a &#8220;Covered Person&#8221;) and who is or was a party to, is threatened to be made a party to, or is otherwise involved (including as a witness) in any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative, or investigative based on such person&#8217;s actions in his or her official capacity as a director or officer of the Company or as a director, officer or trustee of another corporation, limited liability company, partnership, joint venture, employee benefit plan, trust, nonprofit entity or other enterprise (to the extent serving in such position at our request), in each case against all liability and loss suffered (including, without limitation, any judgments, fines, excise taxes or penalties arising under the Employee Retirement Income Security Act of 1974 and amounts paid in settlement consented to in writing by us) and expenses (including attorneys&#8217; fees), actually and reasonably incurred by such person in connection therewith, subject to certain conditions. In addition, the Bylaws provide that we may, to the fullest extent permitted by law, (i)&#160;advance costs, fees or expenses (including attorneys&#8217; fees) incurred by a Covered Person defending or participating in any proceeding in advance of the final disposition of such proceeding, subject to certain exceptions, and (ii)&#160;purchase and maintain insurance, at our expense, to protect us and any person who is or was a director, officer, employee or </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">265 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
agent of the Company or is or was a director, officer, employee or agent of the Company serving at our request as a director, officer, employee or agent of another corporation, limited liability company, partnership, joint venture, trust, employee benefit plan or other enterprise against any liability, expense or loss, whether or not we would have the power or obligation to indemnify such person against such liability, expense or loss under the DGCL or the provisions of the Bylaws. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into indemnification agreements with each of our directors, executive officers and certain other employees as determined by our Board. These agreements, among other things, require us to indemnify our directors and executive officers against liabilities that may arise by reason of their status or service. These indemnification agreements also require us to advance all expenses actually and reasonably incurred by the directors and executive officers in connection with any proceeding. Our Board believes that these agreements are necessary to attract and retain qualified individuals to serve as directors and executive officers. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The above description of the indemnification provisions of the Certificate of Incorporation, the Bylaws and the indemnification agreements is not complete and is qualified in its entirety by reference to these documents, each of which is filed as an exhibit to the registration statement of which this prospectus is a part. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of our <span style="white-space:nowrap">non-employee</span> directors may, through their relationships with their employers, be insured or indemnified against certain liabilities incurred in their capacity as members of our Board. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The limitation of liability and indemnification provisions in the Certificate of Incorporation and the Bylaws may discourage stockholders from bringing a lawsuit against our directors and officers for breach of their fiduciary duty. They may also reduce the likelihood of derivative litigation against our directors and officers, even though an action, if successful, might benefit us and our stockholders. In addition, a stockholder&#8217;s investment may be adversely affected to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors or executive officers, we have been informed that in the opinion of the SEC, such indemnification is against public policy and is therefore unenforceable. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_105">Conflicts of Interest </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Delaware law permits corporations to adopt provisions renouncing any interest or expectancy in certain opportunities that are presented to the corporation or its officers, directors or stockholders. The Certificate of Incorporation provides that, to the fullest extent permitted by law, no Identified Person (as defined therein) will have any duty to refrain from (i)&#160;engaging in a corporate opportunity in the same or similar business activities or lines of business in which we or our affiliates are engaged or that are deemed to be competing with us or any of our affiliates or (ii)&#160;otherwise investing in or providing services to any person that is engaged in the same or similar business activities as we or our affiliates or competes with us or our affiliates. In addition, to the fullest extent permitted by law, no Identified Person will have any obligation to offer to us or our subsidiaries or affiliates the right to participate in any corporate opportunity in the same or similar business activities or lines of business in which we or our affiliates are engaged or that are deemed to be competing with us or any of our affiliates. Subject to the preceding sentences and to the fullest extent permitted by applicable law, neither we nor any of our subsidiaries shall have any rights in any business interests, activities or ventures of any Identified Person, and we waive and renounce any interest or expectancy therein, except with respect to opportunities offered solely and expressly to our officers in their capacity as such. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_106">Rights of Appraisal and Payment </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the DGCL, with certain exceptions, our stockholders will have appraisal rights in connection with a merger or consolidation of the Company. Pursuant to Section&#160;262 of the DGCL, stockholders who properly demand and perfect appraisal rights in connection with such merger or consolidation will have the right to receive payment of the fair value of their shares as determined by the Delaware Court of Chancery. However, appraisal rights are not available in all circumstances. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">266 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_107">Stockholders&#8217; Derivative Actions </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the DGCL, any of our stockholders may bring an action in the Company&#8217;s name to procure a judgment in its favor, also known as a derivative action, provided that the stockholder bringing the action is a holder of our capital stock at the time of the transaction to which the action relates. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_108">Warrants </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the effective time of the Domestication, each warrant to purchase Vickers Ordinary Shares that was issued and outstanding immediately prior to the effective time of the Domestication and not terminated pursuant to its terms was converted into a warrant to purchase shares of our Common Stock on the same terms and conditions as are in effect with respect to such warrant immediately prior to the effective time of the Domestication. As of the date of this prospectus, there are 6,899,988 outstanding Public Warrants and 4,104,000 outstanding Private Placement Warrants. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Public Warrants </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each Public Warrant entitles the registered holder thereof to purchase one share of our Common Stock at a price of $11.50 per share, subject to adjustment as described in this prospectus. We may, in our sole discretion, lower the warrant exercise price at any time prior to the expiration date for a period of not less than 20 business days and any such reduction will be applied consistently to all of the warrants, provided that we will provide at least 20 days&#8217; prior written notice to registered holders of the warrants. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, no Public Warrants will be exercisable for cash unless we have an effective and current registration statement covering the issuance of the Common Stock issuable upon exercise of the warrants and a current prospectus relating to such Common Stock. Notwithstanding the foregoing, if a registration statement covering the issuance of the Common Stock issuable upon exercise of the Public Warrants is not effective within 90 days from the consummation of the Business Combination, warrantholders may, from the 91st day after the consummation of the Business Combination until such time as there is an effective registration statement and during any period when we shall have failed to maintain an effective registration statement, exercise warrants on a cashless basis pursuant to an available exemption from registration under the Securities Act. If an exemption from registration is not available, holders will not be able to exercise their warrants on a cashless basis. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The warrants will expire five years from the consummation of the Business Combination (i.e., November&#160;10, 2027) at 5:00 p.m., New York City time or earlier upon redemption or liquidation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may call the warrants for redemption (excluding the Private Placement Warrants), in whole and not in part, at a price of $0.01 per warrant: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">at any time while the warrants are exercisable, </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">upon not less than 30 days&#8217; prior written notice of redemption to each warrantholder, </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">if, and only if, the closing price of the Common Stock equals or exceeds $18.00 per share (as adjusted for share <span style="white-space:nowrap">sub-divisions,</span> share dividends, reorganizations and recapitalizations), for any 20 trading days within a 30 trading day period commencing after the warrants become exercisable and ending on the third trading day prior to the date on which notice of redemption is given, and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">if, and only if, there is an effective registration statement covering the Common Stock issuable upon exercise of the Public Warrants, and a current prospectus relating thereto, available throughout the <span style="white-space:nowrap">30-day</span> redemption. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not exercise such redemption right if the issuance of the Common Stock upon exercise of the warrants is not exempt from registration or qualification under applicable state blue sky laws or we are unable to effect such registration or qualification. The right to exercise will be forfeited unless the warrants are exercised </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">267 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
prior to the date specified in the notice of redemption. On and after the redemption date, a record holder of a warrant will have no further rights except to receive the redemption price for such holder&#8217;s warrant upon surrender of such warrant. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The redemption criteria for our warrants have been established at a price which is intended to provide warrantholders a reasonable premium to the initial exercise price and provide a sufficient differential between the then-prevailing per share price of our Common Stock and the warrant exercise price so that if the per share price of our Common Stock declines as a result of our redemption call, the redemption will not cause the per share price of our Common Stock to drop below the exercise price of the warrants. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we call the warrants for redemption as described above, our management will have the option to require all holders of warrants to exercise their warrants on a &#8220;cashless basis.&#8221; In such event, each holder would pay the exercise price by surrendering the warrants for that number of shares of Common Stock equal to the quotient obtained by dividing (x)&#160;the product of the number of shares of Common Stock underlying the warrants, multiplied by the difference between the exercise price of the warrants and the fair market value by (y)&#160;the fair market value. The &#8220;fair market value&#8221; for this purpose shall mean the average reported closing price of the shares of our Common Stock for the 10 trading days ending on the third trading day prior to the date on which the notice of redemption is sent to the holders of warrants. For example, if a holder held 150 warrants to purchase 150 shares of our Common Stock and the fair market value on the trading date prior to exercise was $15.00, that holder would receive 35 shares of our Common Stock without the payment of any additional cash consideration. Whether we will exercise our option to require all holders to exercise their warrants on a &#8220;cashless basis&#8221; will depend on a variety of factors including the price of our Common Stock at the time the warrants are called for redemption, our cash needs at such time and concerns regarding dilutive share issuances. Requiring a cashless exercise in this manner will reduce the number of shares of our Common Stock to be issued and thereby lessen the dilutive effect of a warrant redemption. We believe this feature is an attractive option to use if we do not need the cash from the exercise of the Public Warrants. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The warrants are issued in registered form under a warrant agreement (the &#8220;Warrant Agreement&#8221;) between Continental, as warrant agent, and us. The Warrant Agreement provides that the terms of the warrants may be amended without the consent of any holder to cure any ambiguity or correct any defective provision, but requires the approval, by written consent or vote, of the registered holders of a majority of the then-outstanding warrants (including the Private Placement Warrants) in order to make any change that adversely affects the interests of the registered holders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The exercise price and number of shares of Common Stock issuable on exercise of the warrants may be adjusted in certain circumstances including in the event of (i)&#160;a stock dividend or split up, (ii)&#160;a consolidation, combination, reverse stock split or reclassification of the Common Stock, (iii)&#160;extraordinary dividend or (iv)&#160;reclassification or reorganization of the outstanding Common Stock or an merger or consolidation of us with or into another corporation. However, the warrants will not be adjusted for issuances of shares of Common Stock at a price below the par value per share issuable upon exercise of the warrants. Whenever the number of shares of Common Stock purchasable upon the exercise of the warrants is adjusted, the warrant exercise price will be adjusted by multiplying such warrant exercise price immediately prior to such adjustment by a fraction (x)&#160;the numerator of which will be the number of shares of Common Stock purchasable upon the exercise of the warrants immediately prior to such adjustment, and (y)&#160;the denominator of which will be the number of shares of Common Stock so purchasable immediately thereafter. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The warrants may be exercised upon surrender of the warrant certificate on or prior to the expiration date at the offices of the warrant agent, with the exercise form on the reverse side of the warrant certificate completed and executed as indicated, accompanied by full payment of the exercise price (or on a cashless basis, if applicable), by certified check or bank draft payable to the order of the warrant agent or wire transfer, for the number of warrants being exercised. The warrantholders do not have the rights or privileges of holders of shares of Common Stock and any voting rights until they exercise their warrants and receive shares of Common Stock. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">268 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
After the issuance of shares of Common Stock upon exercise of the warrants, each holder will be entitled to one vote for each share of Common Stock held of record on all matters to be voted on by stockholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as described above, no Public Warrants will be exercisable for cash and we will not be obligated to issue shares of Common Stock upon exercise of a warrant unless the shares of Common Stock issuable upon such warrant exercise have been registered, qualified or deemed to be exempt under the securities laws of the state of residence of the registered holder of the warrants. Under the terms of the Warrant Agreement, we have agreed to use our best efforts to meet these conditions and to maintain a current prospectus relating to the Common Stock issuable upon exercise of the warrants until the expiration of the warrants. However, we cannot assure you that we will be able to do so and, if we do not maintain a current prospectus relating to the Common Stock issuable upon exercise of the warrants, holders will be unable to exercise their warrants and we will not be required to settle any such warrant exercise. If the prospectus relating to the Common Stock issuable upon the exercise of the warrants is not current or if the Common Stock is not qualified or exempt from qualification in the jurisdictions in which the holders of the warrants reside, we will not be required to net cash settle or cash settle the warrant exercise, the warrants may have no value, the market for the warrants may be limited and the warrants may expire worthless. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Warrantholders may elect to be subject to a restriction on the exercise of their warrants such that an electing warrantholder would not be able to exercise their warrants to the extent that, after giving effect to such exercise, such holder (together with such holder&#8217;s affiliates) would beneficially own in excess of 9.8% of the Common Stock outstanding immediately after giving effect to such exercise. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No fractional shares will be issued upon exercise of the warrants. If, upon exercise of the warrants, a holder would be entitled to receive a fractional interest in a share, we will, upon exercise, round up to the nearest whole number of shares of Common Stock to be issued to the warrantholder. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Private Placement Warrants </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Private Placement Warrants are identical to the Public Warrants except that such Private Placement Warrants are exercisable for cash (even if a registration statement covering the issuance of the Common Stock issuable upon exercise of such warrants is not effective) or on a cashless basis, at the holder&#8217;s option, and will not be redeemable by us, in each case so long as they are still held by the initial purchasers or their affiliates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing summary of the terms and conditions of the warrants does not purport to be complete and is qualified in its entirety by reference to the copy of the Warrant Agreement that is filed as an exhibit to the registration statement of which this prospectus forms a part. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_109">Transfer Agent and Registrar </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transfer agent and registrar for our Common Stock is Continental. The transfer agent&#8217;s address is 1 State Street, 30th Floor, New York, New York 10004. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="rom428534_110">Listing </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shares of our Common Stock and Public Warrants are listed on Nasdaq under the symbols &#8220;SCLX&#8221; and &#8220;SCLXW&#8221; respectively. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom428534_111">LEGAL MATTERS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The validity of the securities being offered by this prospectus will be passed upon for us by Paul Hastings LLP, Palo Alto, California. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">269 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom428534_112">EXPERTS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The financial statements of Vickers Vantage Corp. I as of December&#160;31, 2021 and 2020, for the year then ended December&#160;31, 2021, and for the period from February&#160;21, 2020 (inception) through December&#160;31, 2020, and for the period from January&#160;1, 2021 through December&#160;31, 2021, appearing in this prospectus have been audited by WithumSmith+Brown, PC, independent registered public accounting firm, as set forth in their report thereon (which includes explanatory paragraphs relating to the correction of certain misstatements related to the January&#160;11, 2021 financial statement and Vickers Vantage Corp. I&#8217;s ability to continue as a going concern), appearing elsewhere in this prospectus and are included in reliance upon such report given on the authority of such firm as experts in accounting and auditing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of Scilex Holding Company at December&#160;31, 2021 and 2020, and for the years then ended, appearing in this prospectus, have been audited by Ernst&#160;&amp; Young LLP, independent registered public accounting firm, as set forth in their report thereon (which contains an explanatory paragraph describing conditions that raise substantial doubt about our ability to continue as a going concern as described in Note 2 to the consolidated financial statements) appearing elsewhere herein, and are included in reliance upon such report given on the authority of such firm as experts in accounting and auditing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The financial statements of Scilex Holding Company for the period ended December&#160;31, 2019, included in this prospectus have been audited by Deloitte&#160;&amp; Touche LLP, an independent registered public accounting firm, as stated in their report. Such financial statements are included in reliance upon the report of such firm given upon their authority as experts in accounting and auditing. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom428534_113">CHANGE IN AUDITORS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective upon the Closing, on November&#160;10, 2022, the Board dismissed WithumSmith+Brown, PC (&#8220;Withum&#8221;), which served as Vickers&#8217;s independent registered public accounting firm prior to the Business Combination. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The report of Withum on the financial statements of Vickers as of December&#160;31, 2020 and 2021 did not contain an adverse opinion or a disclaimer of opinion, and was not qualified or modified as to uncertainty, audit scope or accounting principles except for an explanatory paragraph in such report regarding substantial doubt about Vickers&#8217;s ability to continue as a going concern and emphasized the restatement of Vickers&#8217;s financial statement as of January&#160;11, 2021 due to its change in accounting for warrants and Vickers Ordinary Shares subject to possible redemption. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the fiscal years ended December&#160;31, 2020 and 2021 and the subsequent interim period through November&#160;10, 2022, there were no disagreements (as defined in Item 304(a)(1)(iv) of Regulation <span style="white-space:nowrap">S-K)</span> with Withum on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedures, which disagreements, if not resolved to the satisfaction of Withum, would have caused Withum to make reference to the subject matter of the disagreements in its reports covering such periods. In addition, no &#8220;reportable events,&#8221; as defined in Item 304(a)(1)(v) of <span style="white-space:nowrap">Regulation&#160;S-K,&#160;occurred</span> within the period of Withum&#8217;s engagement and the subsequent interim period preceding Withum&#8217;s dismissal. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company provided Withum with a copy of the disclosures made by us in response to Item&#160;304(a) of <span style="white-space:nowrap">Regulation&#160;S-K</span> and has requested that Withum furnish the Company with a letter addressed to the SEC stating whether it agrees with the statements made by us in response to Item&#160;304(a) of <span style="white-space:nowrap">Regulation&#160;S-K</span> and, if not, stating the respects in which it does not agree. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&#160;10, 2022, the Board approved the engagement of Ernst&#160;&amp; Young LLP (&#8220;EY&#8221;) as the Company&#8217;s independent registered public accounting firm for the fiscal year ending December&#160;31, 2022. EY </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">270 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
audited the consolidated balance sheets of Scilex as of December&#160;31, 2020 and December&#160;31, 2021 and the related consolidated statements of operations, stockholders&#8217; deficit and cash flows. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the years ended December&#160;31, 2020 and 2021 and the subsequent interim period through November&#160;10, 2022, neither the Company nor anyone on its behalf consulted with EY regarding (i)&#160;the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company&#8217;s financial statements, and no written report or oral advice was provided to the Company that EY concluded was an important factor considered by the Company in reaching a decision as to any accounting, auditing or financial reporting issue, or (ii)&#160;any matter that was the subject of a disagreement within the meaning of Item&#160;304(a)(1)(iv) of <span style="white-space:nowrap">Regulation&#160;S-K&#160;or</span> any reportable event within the meaning of Item&#160;304(a)(1)(v) of <span style="white-space:nowrap">Regulation&#160;S-K.</span> </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="rom428534_114">WHERE YOU CAN FIND MORE INFORMATION </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have filed a registration statement on Form <span style="white-space:nowrap">S-1,</span> including exhibits, under the Securities Act, with respect to the securities offered by this prospectus. This prospectus does not contain all of the information included in the registration statement. For further information pertaining to us and our securities, you should refer to the registration statement of which this prospects is a part and the exhibits to such registration statement. The descriptions in this prospectus of the provisions of documents filed as exhibits to this prospectus are only summaries of those documents&#8217; material terms. You can read copies of such documents, along with copies of reports, proxy statements and other information filed by us with the SEC at the SEC&#8217;s website at<span style="font-style:italic"></span><span style="font-style:italic">&#160;http://www.sec.gov</span>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also maintain a website at www.scilexholding.com. Through our website, we make available, free of charge, annual, quarterly and current reports, proxy statements and other information as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC. The information contained on, or that may be accessed through, our website is not part of, and is not incorporated into, this prospectus and the inclusion of our website address in this prospectus is an inactive textual reference only. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">271 </p>

</div></div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>
<div style='display: none'><ix:header><ix:hidden><ix:nonNumeric name="sclx:NumberOfThresholdTradingDaysPriorToDateOfNoticeToTheShareholdersForDeterminingTheVolumeWeightedAveragePriceOfShares" id="hidden63196045" contextRef="P11_17_2022To11_17_2022_StandbyEquityPurchaseAgreementMemberSCLXAgreementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_YorkvilleMemberSCLXInvesteeAxis">P5D</ix:nonNumeric><ix:nonNumeric name="sclx:NumberOfConsecutiveTradingDaysForDeterminingTheVolumeWeightedAveragePriceOfShares" id="hidden63196046" contextRef="P11_17_2022To11_17_2022_StandbyEquityPurchaseAgreementMemberSCLXAgreementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_YorkvilleMemberSCLXInvesteeAxis">P2D</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="sclx-20220930.xsd" /><link:linkbaseRef xlink:type="simple" xlink:href="sclx-20220930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="sclx-20220930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="sclx-20220930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="sclx-20220930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /></ix:references></ix:header></div><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc"></a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div id="index" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">INDEX TO FINANCIAL STATEMENTS </div></div></div><div id="rom428534_115" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 95%;">&#160;</td>
<td style="width: 1%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Page</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin428534_1">Report of Independent Registered Public Accounting Firm</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-2</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin428534_2">Balance Sheets</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-3</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin428534_3">Statements of Operations</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-4</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin428534_4">Statements of Changes in Shareholders&#8217; (Deficit) Equity</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-5</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin428534_5">Statements of Cash Flows</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-6</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin428534_6">Notes to Financial Statements</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-7</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin428534_7">Condensed Consolidated Balance Sheets</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-25</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin428534_8">Unaudited Condensed Consolidated Statements of Operations</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-26</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin428534_9">Unaudited Condensed Consolidated Statements of Changes in Shareholders&#8217; Equity (Deficit)</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-27</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin428534_10">Unaudited Condensed Consolidated Statements of Cash Flows</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-28</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin428534_11">Notes to Unaudited Condensed Consolidated Financial Statements</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-29</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td colspan="5" style="height: 24pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="4" style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">SCILEX HOLDING COMPANY</div></div></td>
<td style="vertical-align: top;"><div style="text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONSOLIDATED FINANCIAL STATEMENTS</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin428534_12">Report of Independent Registered Public Accounting Firm</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-56</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin428534_13">Consolidated Balance Sheets as of December&#160;31, 2021 and 2020</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-58</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin428534_14">Consolidated Statements of Operations for the Years Ended December&#160;31, 2021, 2020 and 2019</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-59</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin428534_15">Consolidated Statements of Stockholders&#8217; Deficit for the Years Ended December&#160;31, 2021, 2020 and 2019</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-60</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin428534_16">Consolidated Statements of Cash Flows for the Years Ended December&#160;31, 2021, 2020 and 2019</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-61</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin428534_17">Notes to Consolidated Financial Statements</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-62</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin428534_18">Consolidated Balance Sheets as of September&#160;30, 2022 and December&#160;31, 2021</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-90</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin428534_19">Consolidated Statements of Operations as of September&#160;30, 2022 and December&#160;31, 2021</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-91</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin428534_20">Consolidated Statements of Stockholders&#8217; Deficit as of September&#160;30, 2022 and December&#160;31, 2021</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-92</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin428534_21">Consolidated Statements of Cash Flows for the Nine Months Ended September&#160;30, 2022 and 2021</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-93</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin428534_22">Notes to Unaudited Consolidated Financial Statements</a></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-94</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-1 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div id="fin428534_1" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To the Shareholders and the Board of Directors of </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vickers Vantage Corp. I </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Opinion on the Financial Statements </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have audited the accompanying balance sheet of Vickers Vantage Corp. I (the &#8220;Company&#8221;) as of December&#160;31, 2021 and 2020, the related statements of operations, changes in shareholders&#8217; (deficit) equity and cash flows for the year ended December&#160;31, 2021 and for the period from February&#160;21, 2020 (inception) through December&#160;31, 2020, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December&#160;31, 2021 and 2020, and the results of its operations and its cash flows for the year ended December&#160;31, 2021 and for the period from February&#160;21, 2020 (inception) through December&#160;31, 2020, in conformity with accounting principles generally accepted in the United States of America. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Going Concern </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, if the Company is unable to raise additional funds to alleviate liquidity needs as well as complete a Business Combination by the close of business on April&#160;11, 2022, then the Company will cease all operations except for the purpose of liquidating. This date for mandatory liquidation and subsequent dissolution raises substantial doubt about the Company&#8217;s ability to continue as a going concern. Management&#8217;s plans regarding these matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restatement of Previously Issued Financial Statement </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As described in Note 10 to the financial statements, the Company&#8217;s previously issued January&#160;11, 2021 financial statement has ben restated herein to correct certain misstatements. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basis for Opinion </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ WithumSmith+Brown, PC </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have served as the Company&#8217;s auditor since 2020. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">New York, New York </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">February&#160;24, 2022 </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PCAOB ID Number 100 </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-2 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div></div> <div id="fin428534_2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">BALANCE SHEETS </div></div></div></div> <div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 80%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ASSETS</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Cash" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">507,921</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Cash" contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">30,511</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">4,536</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Current Assets</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">512,457</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">30,511</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred offering costs</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredCosts" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredCosts" contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">168,973</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investments held in Trust Account&#160;&#8212;&#160;US Treasury Securities Money Market Fund</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsHeldInTrustNoncurrent" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">139,410,739</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsHeldInTrustNoncurrent" contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TOTAL ASSETS</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">139,923,196</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">199,484</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">LIABILITIES AND SHAREHOLDERS&#8217; (DEFICIT) EQUITY</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable and accrued expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">208,704</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued offering costs</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">25,760</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Advances from related party</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:AdvancesFromRelatedParty" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:AdvancesFromRelatedParty" contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">30,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Promissory note&#160;&#8212;&#160;related party</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NotesPayableRelatedPartiesClassifiedCurrent" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NotesPayableRelatedPartiesClassifiedCurrent" contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">125,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Current Liabilities</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">208,704</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">180,760</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Convertible promissory note&#160;&#8212;&#160;related party, net of discount</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ConvertibleLongTermNotesPayable" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">483,099</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ConvertibleLongTermNotesPayable" contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Conversion option liability</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">6,892</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Warrant liability</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">3,351,600</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred underwriting fee payable</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">5,190,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent" contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Liabilities</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">9,240,295</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">180,760</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commitments and Contingencies</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ordinary shares subject to possible redemption <ix:nonFraction name="sclx:OrdinarySharesSubjectToPossibleRedemption" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">13,800,000</ix:nonFraction> as of December&#160;31, 2021 and <ix:nonFraction name="sclx:OrdinarySharesSubjectToPossibleRedemption" contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction> shares as of December&#160;31, 2020 at redemption value of $<ix:nonFraction name="sclx:SubjectToPossibleRedemptionPerShares" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">10.10</ix:nonFraction></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">139,380,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Shareholders&#8217; (Deficit) Equity</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Preference shares, $<ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">1,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen">none</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> issued or outstanding</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Ordinary shares, $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">200,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">3,450,000</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-redeemable</div> shares issued and outstanding at December&#160;31, 2021 and 2020<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">(1)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="Fact_63193285">345</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="Fact_63193284">345</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital</div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">24,655</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated deficit</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">8,697,444</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">6,276</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Shareholders&#8217; (Deficit) Equity</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">8,697,099</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">18,724</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TOTAL LIABILITIES AND SHAREHOLDERS&#8217; (DEFICIT) EQUITY</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">139,923,196</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">199,484</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At December&#160;31, 2020, includes an aggregate of up to <ix:nonFraction name="sclx:OrdinarySharesRedemptionSubjectedToForfeiture" contextRef="P01_01_2020To12_31_2020_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">450,000</ix:nonFraction> ordinary shares that are subject to forfeiture depending on the extent to which the underwriters&#8217; over-allotment option is exercised (see Note 6). On January&#160;6, 2021, the Company effected a share capitalization of <ix:nonFraction name="sclx:SharesCapitalization" contextRef="PAsOn01_06_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.2</ix:nonFraction> shares for each share outstanding, resulting in <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn01_06_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn01_06_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">3,450,000</ix:nonFraction></ix:nonFraction> ordinary shares issued and outstanding (see Note 6). All share and per share amounts have been retroactively restated to reflect the share capitalization. As a result of the underwriters&#8217; full exercise of their overallotment option on January&#160;11, 2021, <ix:nonFraction name="sclx:OrdinarySharesRedemptionSubjectedToForfeiture" contextRef="P01_11_2021To01_11_2021_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction> shares were forfeited. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 30pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of the financial statements. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-3 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div></div> <div id="fin428534_3" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">STATEMENTS OF OPERATIONS </div></div></div></div> <div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 77%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/>December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the<br/>Period from<br/>February&#160;21,<br/>2020<br/>(Inception)<br/>Through<br/>December&#160;31,<br/>2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 77%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating and formation costs</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingCostsAndExpenses" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,005,498</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingCostsAndExpenses" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">6,276</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 77%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 77%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from operations</div></div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">1,005,498</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">6,276</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 77%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other income:</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 77%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of warrants</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:ChangeInFairValueOfWarrantLiability" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">4,377,600</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt 4pt 0pt 0pt;;text-align:right;"><ix:nonFraction name="sclx:ChangeInFairValueOfWarrantLiability" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" sign="-" xsi:nil="true"></ix:nonFraction>&#160;&#160;&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 77%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss on initial issuance of private warrants</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:GainLossOnSaleOfDerivatives" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">2,599,200</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt 4pt 0pt 0pt;;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnSaleOfDerivatives" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#160;&#160;&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 77%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of conversion option liability</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">11,835</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 77%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest expense&#160;&#8212;&#160;debt discount</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,826</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 77%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transaction costs allocated to warrant liabilities</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="sclx:TransactionCostsAllocatedToWarrantLiabilities" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">30,212</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt 4pt 0pt 0pt;;text-align:right;"><ix:nonFraction name="sclx:TransactionCostsAllocatedToWarrantLiabilities" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" sign="-" xsi:nil="true"></ix:nonFraction>&#160;&#160;&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 77%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest earned on investments held in Trust Account</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InterestIncomeOther" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">30,739</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt 4pt 0pt 0pt;;text-align:right;"><ix:nonFraction name="us-gaap:InterestIncomeOther" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#160;&#160;&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 77%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 77%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total other income, net</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,788,935</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt 4pt 0pt 0pt;;text-align:right;"><ix:nonFraction name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#160;&#160;&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 77%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss)</div></div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">783,438</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">6,276</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 77%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 77%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic weighted average shares outstanding, ordinary shares<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">(1)</div></div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="Fact_63193636">16,820,548</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="Fact_63193637">3,000,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 77%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 77%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic net income (loss) per share, ordinary shares</div></div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.05</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.00</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 77%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 77%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diluted weighted average shares outstanding, ordinary shares</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">16,834,110</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">3,000,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 77%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 77%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diluted net income (loss) per share, ordinary shares</div></div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.05</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.00</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 77%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At December&#160;31, 2020, excludes an aggregate of up to <div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="sclx:OrdinarySharesRedemptionSubjectedToForfeiture" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">450,000</ix:nonFraction></div> ordinary shares that were subject to forfeiture. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 120pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 120pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 120pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of the financial statements. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-4 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div></div> <div id="fin428534_4" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">STATEMENTS OF CHANGES IN SHAREHOLDERS&#8217; (DEFICIT) EQUITY </div></div></div></div> <div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 52%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Ordinary Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Additional<br/>Paid in<br/>Capital</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/>Deficit</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total<br/>Shareholders&#8217;<br/>Equity<br/>(Deficit)</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance&#160;&#8212;&#160;February&#160;21, 2020 (inception)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn02_20_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn02_20_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn02_20_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn02_20_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn02_20_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance of ordinary shares to Sponsor</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P02_21_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P02_21_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P02_21_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P02_21_2020To12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cancellation of ordinary shares</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="P02_21_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="P02_21_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="P02_21_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="P02_21_2020To12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance of ordinary shares to Sponsor</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="P02_21_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">3,450,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="P02_21_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">345</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="P02_21_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">24,655</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 7%; padding: 0pt 4pt 0pt 0pt;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="P02_21_2020To12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" xsi:nil="true"></ix:nonFraction>&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">25,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P02_21_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P02_21_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P02_21_2020To12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">6,276</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">6,276</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance&#160;&#8212;&#160;December&#160;31, 2020 (audited)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">3,450,000</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">345</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">24,655</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">6,276</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">18,724</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accretion of ordinary shares subject to redemption</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="P01_01_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">24,655</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="P01_01_2021To12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">9,474,606</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">9,499,261</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">783,438</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">783,438</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance&#160;&#8212;&#160;December&#160;31, 2021 (audited)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">3,450,000</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">345</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">8,697,444</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">8,697,099</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 120pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 120pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 120pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 120pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 120pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of the financial statements. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-5 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div></div> <div id="fin428534_5" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">STATEMENTS OF CASH FLOWS</div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 75%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/>December&#160;31,<br/>2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the<br/>Period from<br/>February&#160;21,<br/>2020<br/>(Inception)<br/>Through<br/>December&#160;31,<br/>2020</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash Flows from Operating Activities:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">783,438</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">6,276</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustments to reconcile net income (loss) to net cash used in operating activities:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Formation cost paid through advances from affiliate of Sponsor</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt 4pt 0pt 0pt; width: 8%;;text-align:right;"><ix:nonFraction name="sclx:FormationCostPaidThroughAdvancesFromAffiliateOfSponsor" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:FormationCostPaidThroughAdvancesFromAffiliateOfSponsor" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">5,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest earned on investments held in Trust Account</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:InterestAndDividendIncomeSecuritiesHeldToMaturity" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">30,739</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt 5pt 0pt 0pt; width: 5%; text-align: right;"><ix:nonFraction name="us-gaap:InterestAndDividendIncomeSecuritiesHeldToMaturity" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of warrant liability</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">4,377,600</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt 5pt 0pt 0pt; width: 5%;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss on initial issuance of warrant liability</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:LossOnInitialIssuanceOfWarrantLiability" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">2,599,200</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"><ix:nonFraction name="sclx:LossOnInitialIssuanceOfWarrantLiability" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of conversion option liability</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="sclx:ChangeInFairValueOfConversionOptionLiability" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">11,835</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"><ix:nonFraction name="sclx:ChangeInFairValueOfConversionOptionLiability" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amortization of debt discount</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,826</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transaction costs allocated to private warrants</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:TransactionsCostsAllocatedToPrivateWarrants" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">30,212</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt 5pt 0pt 0pt; width: 5%;;text-align:right;"><ix:nonFraction name="sclx:TransactionsCostsAllocatedToPrivateWarrants" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in operating assets and liabilities:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">4,536</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt 5pt 0pt 0pt; width: 5%;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable and accrued expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">208,704</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt 5pt 0pt 0pt; width: 5%;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash used in operating activities</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">801,330</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">1,276</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash Flows from Investing Activities:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment of cash in Trust Account</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="sclx:InvestmentOfCashInTrustAccounts" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">139,380,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt 5pt 0pt 0pt; width: 5%;;text-align:right;"><ix:nonFraction name="sclx:InvestmentOfCashInTrustAccounts" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash used in investing activities</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">139,380,000</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt 5pt 0pt 0pt; width: 5%;;text-align:right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash Flows from Financing Activities:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from sale of Units, net of underwriting discounts paid</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">135,600,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%; padding: 0pt 5pt 0pt 0pt;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from sale of Private Placement Warrants</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">5,130,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%; padding: 0pt 5pt 0pt 0pt;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Advances from related party</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">25,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">25,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Repayment of advances from related party</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RepaymentsOfRelatedPartyDebt" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">55,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%; padding: 0pt 5pt 0pt 0pt;;text-align:right;"><ix:nonFraction name="us-gaap:RepaymentsOfRelatedPartyDebt" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from promissory note &#8212; related party</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt 4pt 0pt 0pt; width: 8%;;text-align:right;"><ix:nonFraction name="sclx:ProceedsFromPromissoryNoteRelatedParty" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:ProceedsFromPromissoryNoteRelatedParty" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">125,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Repayment of promissory note &#8212; related party</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">125,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt 5pt 0pt 0pt; width: 5%;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from convertible promissory note &#8212; related party</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">500,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0pt 5pt 0pt 0pt; width: 5%;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payment of offering costs</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">416,260</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">118,213</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash provided by financing activities</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">140,658,740</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">31,787</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net Change in Cash</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">477,410</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">30,511</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash&#160;&#8212;&#160;Beginning of period</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">30,511</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%; padding: 0pt 5pt 0pt 0pt;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn02_20_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash&#160;&#8212;&#160;End of period</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">507,921</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">30,511</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Cash</div> investing and financing activities:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred underwriting fee payable</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:DeferredUnderwritingFeePayable" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">5,190,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 5%; padding: 0pt 5pt 0pt 0pt;;text-align:right;"><ix:nonFraction name="sclx:DeferredUnderwritingFeePayable" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Offering costs included in accrued offering costs</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 8%; padding: 0pt 4pt 0pt 0pt;;text-align:right;"><ix:nonFraction name="sclx:OfferingCostIncludedInAccruedOfferingCost" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:OfferingCostIncludedInAccruedOfferingCost" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">25,760</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Offering costs paid through promissory note&#160;&#8212;&#160;related party</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 8%; padding: 0pt 4pt 0pt 0pt;;text-align:right;"><ix:nonFraction name="us-gaap:NotesIssued1" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NotesIssued1" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">25,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 60pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of the financial statements. </div></div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-6 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> </div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div></div><div id="fin428534_6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">DECEMBER&#160;31, 2021 </div></div></div></div><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div><ix:nonNumeric name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_63194069"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 1&#160;&#8212;&#160;DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vickers Vantage Corp. I (the &#8220;Company&#8221;) is a blank check company incorporated as a Cayman Islands exempted company on February&#160;21, 2020. The Company was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities (a &#8220;Business Combination&#8221;). </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is not limited to a particular industry or sector for purposes of consummating a Business Combination. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As of December&#160;31, 2021, the Company had not commenced any operations. All activity for the period from February&#160;21, 2020 (inception) through December&#160;31, 2021 relates to the Company&#8217;s formation and the initial public offering (&#8220;Initial Public Offering&#8221;), which is described below, and, subsequent to the Initial Public Offering, identifying a target company for a Business Combination. The Company will not generate any operating revenues until after the completion of a Business Combination, at the earliest. The Company will generate <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-operating</div> income in the form of interest income from the proceeds derived from the Initial Public Offering. The Company has selected December&#160;31 as its fiscal year end. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The registration statement for the Company&#8217;s Initial Public Offering was declared effective on January&#160;6, 2021. On January&#160;11, 2021 the Company consummated the Initial Public Offering of <ix:nonFraction name="sclx:Numberofshares" contextRef="P01_04_2021To01_11_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">13,800,000</ix:nonFraction>&#160;Units (the &#8220;Units&#8221; and, with respect to the ordinary shares included in the Units sold, the &#8220;Public Shares&#8221;), which includes the full exercise by the underwriter of its over-allotment option in the amount of <ix:nonFraction name="sclx:Numberofshares" contextRef="P01_04_2021To01_11_2021_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">1,800,000</ix:nonFraction>&#160;Units, at $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn01_11_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.00</ix:nonFraction> per Unit, generating gross proceeds of $<ix:nonFraction name="sclx:ProceedsOfInitialPublicOffering" contextRef="P01_04_2021To01_11_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">138,000,000</ix:nonFraction> which is described in Note 3. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of <ix:nonFraction name="sclx:Saleofwarrants" contextRef="P01_01_2021To12_31_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">6,840,000</ix:nonFraction> warrants (the &#8220;Private Placement Warrants&#8221;) at a price of $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn12_31_2021_PrivatePlacementWarrantMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.75</ix:nonFraction> per Private Placement Warrant in a private placement to Vickers Venture Fund&#160;VI Pte Ltd and Vickers Venture Fund&#160;VI (Plan) Pte Ltd, (the &#8220;Sponsor&#8221;), generating gross proceeds of $<ix:nonFraction name="sclx:Grossproceedsofwarrants" contextRef="P01_01_2021To12_31_2021_PrivatePlacementWarrantMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">5,130,000</ix:nonFraction>, which is described in Note 4. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transaction costs amounted to $<ix:nonFraction name="sclx:Transactioncostsamount" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">8,149,473</ix:nonFraction>, consisting of $<ix:nonFraction name="us-gaap:OtherUnderwritingExpense" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">2,400,000</ix:nonFraction> in cash underwriting fees, $<ix:nonFraction name="sclx:DeferredUnderwritingFees" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">5,190,000</ix:nonFraction> in deferred underwriting fees, and $<ix:nonFraction name="sclx:Otherofferingcosts" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">559,473</ix:nonFraction> of other offering costs. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Following the closing of the Initial Public Offering on January&#160;11, 2021, an amount of $<ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="P01_04_2021To01_11_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">139,380,000</ix:nonFraction> ($<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn01_11_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.10</ix:nonFraction> per Unit) from the net proceeds of the sale of the Units in the Initial Public Offering and the sale of the Private Placement Warrants was placed in a trust account (the &#8220;Trust Account&#8221;), and invested in U.S. government securities, within the meaning set forth in Section&#160;2(a)(16) of the Investment Company Act, with a maturity of 185&#160;days or less, or in any open-ended investment company that holds itself out as a money market fund investing solely in U.S. Treasuries and meeting certain conditions under <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Rule&#160;2a-7</div> of the Investment Company Act, as determined by the Company, until the earliest of: (i)&#160;the completion of a Business Combination and (ii)&#160;the distribution of the funds in the Trust Account to the Company&#8217;s shareholders, as described below. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">The Company&#8217;s management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and the sale of the Private Placement Warrants, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. <div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="sclx:SaleOfStockDescriptionOfTransactions" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" continuedAt="TextSelection_63195202">The stock exchange listing rules require that the Business Combination must be with one or more operating businesses or assets with a fair market value equal to at least 80% of the assets held in the Trust Account (as defined below) (less any deferred underwriting commissions and taxes payable on the interest earned on the Trust Account). The</ix:nonNumeric></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div> </div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-7 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">DECEMBER&#160;31, 2021 </div></div></div><ix:continuation id="TextSelection_63194069" continuedAt="TextSelectionAppend_63194069_1"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><ix:continuation id="TextSelection_63195202">Company will only complete a Business Combination if the post-Business Combination company owns or acquires 50% or more of the issued and outstanding voting securities of the target or otherwise acquires a controlling interest in the target business sufficient for it not to be required to register as an investment company under the Investment Company Act of 1940, as amended (the &#8220;Investment Company Act&#8221;). There is no assurance that the Company will be able to successfully effect a Business Combination.</ix:continuation> </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;">The Company will provide the holders of the public shares (the &#8220;Public Shareholders&#8221;) with the opportunity to redeem all or a portion of their public shares upon the completion of the Business Combination, either (i)&#160;in connection with a general meeting called to approve the Business Combination or (ii)&#160;by means of a tender offer. The decision as to whether the Company will seek shareholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The Public Shareholders will be entitled to redeem their Public Shares, equal to the aggregate amount then on deposit in the Trust Account, calculated as of <ix:nonFraction name="sclx:Numberofbusinessdays" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_Day" decimals="0" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction> business days prior to the consummation of the Business Combination (initially anticipated to be $<ix:nonFraction name="sclx:PricePerPublicShare" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.10</ix:nonFraction> per Public Share), including interest (which interest shall be net of taxes payable), divided by the number of then issued and outstanding public shares, subject to certain limitations as described in the prospectus. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">per-share</div> amount to be distributed to the Public Shareholders who properly redeem their shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriters (as discussed in Note 6). </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company will proceed with a Business Combination only if the Company has net tangible assets of at least $<ix:nonFraction name="sclx:NetTangibleAssets" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">5,000,001</ix:nonFraction> and, if the Company seeks shareholder approval, it receives an ordinary resolution under Cayman Islands law approving a Business Combination, which requires the affirmative vote of a majority of the shareholders who attend and vote at a general meeting of the Company. If a shareholder vote is not required and the Company does not decide to hold a shareholder vote for business or other legal reasons, the Company will, pursuant to its Amended and Restated Memorandum and Articles of Association, conduct the redemptions pursuant to the tender offer rules of the Securities and Exchange Commission (&#8220;SEC&#8221;), and file tender offer documents containing substantially the same information as would be included in a proxy statement with the SEC prior to completing a Business Combination. If the Company seeks shareholder approval in connection with a Business Combination, the Company&#8217;s Sponsors have agreed to vote its Founder Shares (as defined in Note 5) and any Public Shares purchased during or after the Initial Public Offering in favor of approving a Business Combination. Additionally, each Public Shareholder may elect to redeem their Public Shares, without voting, and if they do vote, irrespective of whether they vote for or against a proposed Business Combination. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notwithstanding the foregoing, if the Company seeks shareholder approval of the Business Combination and the Company does not conduct redemptions pursuant to the tender offer rules, a Public Shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a &#8220;group&#8221; (as defined under Section&#160;13 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;)), will be restricted from redeeming its shares with respect to more than an aggregate of <ix:nonFraction name="sclx:PercentageOfPublicShares" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">20</ix:nonFraction>% of the Public Shares without the Company&#8217;s prior written consent. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;">The Sponsors have agreed (a)&#160;to waive their redemption rights with respect to any Founder Shares and Public Shares held by them in connection with the completion of a Business Combination and (b)&#160;not to propose an amendment to the Amended and Restated Memorandum and Articles of Association (i)&#160;to modify the substance or timing of the Company&#8217;s obligation to allow redemption in connection with the Company&#8217;s initial Business Combination or to redeem <ix:nonFraction name="sclx:BusinessCombinationRedeemPercentage" contextRef="PAsOn12_31_2021_SponsorMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction>% of the Public Shares if the Company does not complete a Business Combination within the Combination Period (as defined below) or (ii)&#160;with respect to any other provision relating to shareholders&#8217; rights or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-initial</div> business combination activity, unless the Company provides the Public<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">Shareholders with the opportunity to redeem their Public Shares upon approval of any such amendment at a&#160;</div> </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:continuation><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-8 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">DECEMBER&#160;31, 2021 </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelectionAppend_63194069_1" continuedAt="TextSelectionAppend_63194069_2"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">per-share</div> price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest (which interest shall be net of taxes payable), divided by the number of then issued and outstanding Public Shares. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On January&#160;10, 2022, the Company extended the period of time to consummate a Business Combination from January&#160;11, 2022 to April&#160;11, 2022. In connection with the extension, the Sponsors deposited $<ix:nonFraction name="sclx:Depositintotrustaccount" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,035,000</ix:nonFraction> into the trust account in the form of a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest</div> bearing loan. The Company will have until April&#160;11, 2022 to consummate a Business Combination. However, if the Company anticipates that it may not be able to consummate a Business Combination by April&#160;11, 2022, the Company may extend the period of time to consummate a Business Combination by an additional three&#160;months (until July&#160;11, 2022 to complete a Business Combination (the &#8220;Combination Period&#8221;). In order to extend the time available for the Company to consummate a Business Combination, the Sponsor or its affiliate or designees must deposit into the Trust Account $<ix:nonFraction name="sclx:Depositintotrustaccount" contextRef="PAsOn12_31_2021_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,035,000</ix:nonFraction> ($<ix:nonFraction name="sclx:PricePerPublicShare" contextRef="P01_01_2021To12_31_2021_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="3" scale="0" format="ixt:num-dot-decimal">0.075</ix:nonFraction> per Public Share), on or prior to the date of the applicable deadline, for the three-month extension. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">If the Company has not completed a Business Combination within the Combination Period, the Company will (i)&#160;cease all operations except for the purpose of winding up, (ii)&#160;as promptly as reasonably possible but not more than ten business days thereafter, redeem <ix:nonFraction name="sclx:BusinessCombinationRedeemPercentage" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction>% of the Public Shares, at a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">per-share</div> price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest (less up to $<ix:nonFraction name="sclx:Interestexpenses" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">50,000</ix:nonFraction> of interest to pay dissolution expenses and which interest shall be net of taxes payable), divided by the number of then issued and outstanding Public Shares, which redemption will completely extinguish the rights of the Public Shareholders as shareholders (including the right to receive further liquidating distributions, if any), and (iii)&#160;as promptly as reasonably possible following such redemption, subject to the approval of the Company&#8217;s remaining Public Shareholders and its Board of Directors, liquidate and dissolve, subject in each case to the Company&#8217;s obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law. There will be no redemption rights or liquidating distributions with respect to the Company&#8217;s warrants, which will expire worthless if the Company fails to complete a Business Combination within the Combination Period. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Sponsors have agreed to waive their rights to liquidating distributions from the Trust Account with respect to the Founder Shares if the Company fails to complete a Business Combination within the Combination Period. However, if the Sponsors or any of their respective affiliates acquire Public Shares, such Public Shares will be entitled to liquidating distributions from the Trust Account if the Company fails to complete a Business Combination within the Combination Period. The underwriters have agreed to waive their rights to their deferred underwriting commission (see Note 6) held in the Trust Account in the event the Company does not complete a Business Combination within the Combination Period, and in such event, such amounts will be included with the other funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the assets remaining available for distribution will be less than the amount of funds deposited into the Trust Account ($10.10 per share). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">In order to protect the amounts held in the Trust Account, the Sponsors have agreed that it will be liable to the Company if and to the extent any claims by a third party (other than the Company&#8217;s independent registered public accounting firm) for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account to below (1)&#160;$10.10 per Public Share or (2)&#160;such lesser amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account due to reductions in the value of trust assets, in each case net of the interest which may be withdrawn to pay taxes, except as to any claims by a third party who<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">executed a waiver of any and all rights to seek access to the Trust Account and except as to any claims under the&#160;</div> </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-9 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">DECEMBER&#160;31, 2021 </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelectionAppend_63194069_2"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Company&#8217;s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). In the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsors will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsors will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (other than the Company&#8217;s independent registered public accounting firm), prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Going Concern and Liquidity </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2021, the Company had $<ix:nonFraction name="us-gaap:Cash" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">507,921</ix:nonFraction> in its operating bank accounts, and working capital of $<ix:nonFraction name="us-gaap:MarketableSecuritiesCurrent" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">303,753</ix:nonFraction>. As of December&#160;31, 2021, approximately $<ix:nonFraction name="us-gaap:InterestIncomeDepositWithFinancialInstitutionIncreaseDecrease" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">31,000</ix:nonFraction> of the amount on deposit in the Trust Account represented interest income, which is available to pay the Company&#8217;s tax obligations. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If the Company is unable to raise additional capital, it may be required to take additional measures to conserve liquidity, which could include, but not necessarily be limited to, suspending the pursuit of a Business Combination. The Company cannot provide any assurance that new financing will be available to it on commercially acceptable terms, if at all. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As a result of the above, in connection with the Company&#8217;s assessment of going concern considerations in accordance with Financial Accounting Standard Board&#8217;s Accounting Standards Update (&#8220;ASU&#8221;) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2014-15,</div> &#8220;Disclosures of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern,&#8221; management has determined that the liquidity condition and date for mandatory liquidation and dissolution raise substantial doubt about the Company&#8217;s ability to continue as a going concern through July&#160;11, 2022 (extension date), the scheduled liquidation date of the Company if it does not complete a Business Combination prior to such date. These financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If the Company is unable to raise additional capital, it may be required to take additional measures to conserve liquidity, which could include, but not necessarily be limited to, suspending the pursuit of a Business Combination. The Company cannot provide any assurance that new financing will be available to it on commercially acceptable terms, if at all. </div></div> </ix:continuation><ix:nonNumeric name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_63193885"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 2&#160;&#8212;&#160;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </div></div></div> <ix:nonNumeric name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and pursuant to the rules and regulations of the SEC. </div></div></ix:nonNumeric><ix:nonNumeric name="us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_63193992"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Emerging Growth Company </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is an &#8220;emerging growth company,&#8221; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></ix:nonNumeric> </ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-10 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> </div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">DECEMBER&#160;31, 2021 </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelection_63193885" continuedAt="TextSelectionAppend_63193885_1"><ix:continuation id="TextSelection_63193992"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">registered public accounting firm attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.</div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Further, Section&#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-emerging</div> growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&#8217;s financial statement with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. </div></ix:continuation> <ix:nonNumeric name="us-gaap:UseOfEstimates" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of the financial statements in conformity with GAAP requires the Company&#8217;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. One of the more significant accounting estimates included in these financial statements is the determination of the fair value of the warrant liabilities. Such estimates may be subject to change as more current information because available and accordingly, the actual results could differ significantly from those estimates. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:DeferredChargesPolicyTextBlock" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Offering Costs </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Offering costs consist of legal, accounting, underwriting fees and other costs incurred through the balance sheet date that are directly related to the Initial Public Offering. Offering costs were allocated to the separable financial instruments issued in the Initial Public Offering based on a relative fair value basis, compared to total proceeds received. Offering costs allocated to warrant liabilities were expensed as incurred in the statements of operations. Offering costs associated with the ordinary shares issued were initially charged to temporary equity and then accreted to ordinary shares subject to redemption upon the completion of the Initial Public Offering. Offering costs amounting to $<ix:nonFraction name="us-gaap:OtherDeferredCostsNet" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">8,119,261</ix:nonFraction> were charged to temporary equity upon the completion of the Initial Public Offering, and $<ix:nonFraction name="us-gaap:OtherDeferredCostsNet" contextRef="PAsOn12_31_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">30,212</ix:nonFraction> of the offering costs were related to the warrant liabilities and charged to the statements of operations. </div><br/></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_63194005"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-11 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">DECEMBER&#160;31, 2021 </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelectionAppend_63193885_1" continuedAt="TextSelectionAppend_63193885_2"><ix:continuation id="TextSelection_63194005"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Ordinary Shares Subject to Possible Redemption </div></div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for its ordinary shares subject to possible redemption in accordance with the guidance in Accounting Standards Codification (&#8220;ASC&#8221;) Topic 480 &#8220;Distinguishing Liabilities from Equity.&#8221; Ordinary shares subject to mandatory redemption is classified as a liability instrument and is measured at fair value. Conditionally redeemable ordinary shares (including ordinary shares that features redemption rights that is either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#8217;s control) is classified as temporary equity. At all other times, ordinary shares are classified as shareholders&#8217; equity. The Company&#8217;s ordinary shares, sold in the IPO, features certain redemption rights that are considered to be outside of the Company&#8217;s control and subject to occurrence of uncertain future events. Accordingly, at December&#160;31, 2021 and 2020, ordinary shares subject to possible redemption is presented as temporary equity, outside of the shareholders&#8217; (deficit) equity section of the Company&#8217;s balance sheets. </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Under ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">480-10-S99,</div></div> the Company has elected to recognize changes in the redemption value immediately as they occur and adjust the carrying value of redeemable ordinary shares subject to possible redemption to equal the redemption value at the end of each reporting period. This method would view the end of the reporting period as if it were also the redemption date for the security. Immediately upon the closing of the Initial Public Offering, the Company recognized the accretion from initial book value to redemption amount value. The change in the carrying value of redeemable ordinary shares resulted in charges against additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital and accumulated deficit. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At December&#160;31, 2021, the ordinary shares reflected in the balance sheets are reconciled in the following table: </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><ix:nonNumeric name="srt:ScheduleOfCondensedBalanceSheetTableTextBlock" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" escape="true">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 77%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 77%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross proceeds</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:GrossProceeds" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">138,000,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 77%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less:</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 77%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ordinary shares issuance costs</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="sclx:OrdinarySharesIssuanceCost" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">8,119,261</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 77%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Plus:</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 77%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accretion of carrying value to redemption value</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">9,499,261</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 77%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 77%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ordinary shares subject to possible redemption</div></div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:SharesSubjectToPossibleRedemption" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">139,380,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 77%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap;"></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 77%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><br/></td>
<td style="vertical-align: bottom;"><br/></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> </ix:continuation> <ix:nonNumeric name="us-gaap:DerivativesPolicyTextBlock" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_63194008"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Warrant Liability </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 480, Distinguishing Liabilities from Equity (&#8220;ASC 480&#8221;) and ASC 815, Derivatives and Hedging (&#8220;ASC 815&#8221;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company&#8217;s own ordinary shares, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. We account for the warrants issued in connection with our Initial Public Offering in accordance with the guidance contained in ASC 815 under which the public warrants meet the criteria for equity treatment and the private warrants do not meet the criteria for equity treatment and must be recorded as liabilities. Accordingly, we classify the private warrants as liabilities at their fair value and adjust the private warrants to fair value at each reporting period. This liability is subject to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-measurement</div> at each balance sheet date until exercised, and any </div><br/></div></ix:nonNumeric> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-12 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">DECEMBER&#160;31, 2021 </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelectionAppend_63193885_2" continuedAt="TextSelectionAppend_63193885_3"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div><ix:continuation id="TextSelection_63194008"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">change in fair value is recognized in our statements of operations. The fair value of the warrants was estimated using a Black-Scholes option pricing formula. </div></div></div></ix:continuation><ix:nonNumeric name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes </div></div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for income taxes under ASC Topic 740, &#8220;Income Taxes,&#8221; which prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company&#8217;s management determined that the Cayman Islands is the Company&#8217;s major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. As of December&#160;31, 2021 and 2020, there were no unrecognized tax benefits and no amounts accrued for interest and penalties. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is considered to be an exempted Cayman Islands company with no connection to any other taxable jurisdiction and is presently not subject to income taxes or income tax filing requirements in the Cayman Islands or the United States. As such, the Company&#8217;s tax provision was zero for the periods presented. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_63194015"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Net income (Loss) per Ordinary Share </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, &#8220;Earnings Per Share&#8221;. Net income (loss) per ordinary share is computed by dividing net income (loss) by the weighted average number of ordinary shares outstanding for the period. Accretion associated with the redeemable shares of ordinary shares is excluded from earnings per share as the redemption value approximates fair value. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The calculation of diluted income (loss) per share does not consider the effect of the warrants issued in connection with the (i)&#160;Initial Public Offering, and (ii)&#160;the private placement since the exercise of the warrants is contingent upon the occurrence of future events. The warrants are exercisable to purchase <ix:nonFraction name="us-gaap:ExcessStockSharesIssued" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">13,740,000</ix:nonFraction> ordinary shares in the aggregate. As of December&#160;31, 2021 and 2020, the Company did not have any dilutive securities or other contracts that could, potentially, be exercised or converted into ordinary shares and then share in the earnings of the Company, except for the <ix:nonFraction name="sclx:Foundershares" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">450,000</ix:nonFraction> founder shares in December&#160;31, 2021 which are no longer forfeitable and thus included for dilutive purposes. As a result, diluted net loss per ordinary share is the same as basic net loss per ordinary share for the periods presented. </div></div></ix:nonNumeric> </ix:continuation><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-13 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">DECEMBER&#160;31, 2021 </div></div></div><ix:continuation id="TextSelectionAppend_63193885_3" continuedAt="TextSelectionAppend_63193885_4"><ix:continuation id="TextSelection_63194015"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table reflects the calculation of basic and diluted net income per ordinary share (in dollars, except per share amounts): </div></div><ix:nonNumeric name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" escape="true"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/>December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the Period<br/>from&#160;February&#160;21,<br/>2020 (Inception)<br/>Through<br/>December&#160;31,<br/>2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Ordinary&#160;Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Ordinary&#160;Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basic net income (loss) per ordinary share</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allocation of net income (loss), as adjusted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityNetIncome" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">783,438</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:TemporaryEquityNetIncome" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">6,276</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic weighted average ordinary shares outstanding</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">16,820,548</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">3,000,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic net income (loss) per ordinary share</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.05</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Diluted net income (loss) per ordinary share</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allocation of net income (loss), as adjusted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityNetIncome" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">783,438</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:TemporaryEquityNetIncome" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">6,276</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diluted weighted average ordinary shares outstanding</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">16,834,110</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">3,000,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diluted net income (loss) per ordinary share</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.05</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.00</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr></table></ix:nonNumeric></ix:continuation><ix:nonNumeric name="us-gaap:ConcentrationRiskCreditRisk" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Concentration of Credit Risk </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times may exceed the Federal Depository Insurance Corporation coverage limit of $<ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">250,000</ix:nonFraction>. The Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such account. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:FairValueOfFinancialInstrumentsPolicy" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value of Financial Instruments </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the Company&#8217;s assets and liabilities, which qualify as financial instruments under ASC Topic 820, &#8220;Fair Value Measurement,&#8221; approximates the carrying amounts represented in the accompanying balance sheets, primarily due to their short-term nature, other than the derivative warrant liability. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_63195231"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recent Accounting Standards </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;">Management does not believe that any other recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company&#8217;s condensed financial statements. In August&#160;2020, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2020-06,</div> Debt&#160;&#8212;&#160;Debt with Conversion and Other Options (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">470-20)</div> and Derivatives and Hedging&#160;&#8212;&#160;Contracts in Entity&#8217; Own Equity (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">815-40):</div> Accounting for Convertible Instruments and Contracts in an Entity&#8217; Own Equity (&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06&#8221;),</div> which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU also removes certain settlement conditions that are required for equity-linked contracts to qualify for the derivative scope exception, and it simplifies the diluted earnings per share calculation in certain areas. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06</div> is effective for fiscal&#160;years beginning after December&#160;15, 2023, including interim periods within those fiscal&#160;years, with early adoption permitted. Management is currently evaluating the new guidance but does not expect the adoption of this guidance to have a material impact on the Company&#8217;s condensed financial statements. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric></ix:continuation><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-14 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">DECEMBER&#160;31, 2021 </div></div></div><ix:continuation id="TextSelection_63195231"><ix:continuation id="TextSelectionAppend_63193885_4"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Management does not believe that any other recently issued, but not yet effective, accounting standard if currently adopted would have a material effect on the accompanying condensed financial statements. </div></div></div></ix:continuation></ix:continuation> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <ix:nonNumeric name="sclx:ProposedPublicOfferingTextBlock" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 3&#160;&#8212;&#160;PUBLIC OFFERING </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Pursuant to the Initial Public Offering, the Company sold to <ix:nonFraction name="sclx:NumberOfSaleUnits" contextRef="PAsOn12_31_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">13,800,000</ix:nonFraction>&#160;Units which includes a full exercise by the underwriters of their over-allotment option in the amount of <ix:nonFraction name="sclx:NumberOfSaleUnits" contextRef="PAsOn12_31_2021_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">1,800,000</ix:nonFraction>&#160;Units, at a purchase price of $<ix:nonFraction name="sclx:PurchasePricePerShare" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">10.00</ix:nonFraction> per Unit. <ix:nonNumeric name="us-gaap:SaleOfStockDescriptionOfTransaction" contextRef="P01_01_2021To12_31_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">Each Unit consists of one ordinary share and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-half</div> of one redeemable warrant (&#8220;Public Warrant&#8221;). Each whole Public Warrant entitles the holder to purchase one ordinary share at an exercise price of $11.50 per whole share (see Note 7).</ix:nonNumeric> </div></ix:nonNumeric> <ix:nonNumeric name="sclx:PrivatePlacementTextBlock" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 4&#160;&#8212;&#160;PRIVATE PLACEMENT </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Simultaneously with the closing of the Initial Public Offering, the Sponsors purchased an aggregate of <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn12_31_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">6,840,000</ix:nonFraction> Private Placement Warrants at a price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn12_31_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.75</ix:nonFraction> per Private Placement Warrant, for an aggregate purchase price of $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="P01_01_2021To12_31_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">5,130,000</ix:nonFraction>, in a private placement. Each Private Placement Warrant is exercisable to purchase one ordinary share at a price of $<ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="PAsOn12_31_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">11.50</ix:nonFraction> per share, subject to adjustment (see Note 9). A portion of the proceeds from the Private Placement Warrants were added to the proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the proceeds from the sale of the Private Placement Warrants will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law) and the Private Placement Warrants will expire worthless. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_63195138"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 5&#160;&#8212;&#160;RELATED PARTY TRANSACTIONS </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Founder Shares </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On July&#160;16, 2020, the Company issued an aggregate of <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P07_02_2020To07_16_2020_FounderSharesMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">3,593,750</ix:nonFraction> ordinary shares to an affiliate of the Sponsors for an aggregate purchase price of $<ix:nonFraction name="sclx:aggregatePurchasePrice" contextRef="P07_02_2020To07_16_2020_FounderSharesMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">25,000</ix:nonFraction>. In August&#160;2020, the affiliate transferred his Founder Shares to the Sponsors for the same price paid for such shares. On October&#160;8, 2020, the Company effected a share capitalization of <ix:nonFraction name="sclx:CapitalizationOfShareOutstanding" contextRef="P10_01_2020To10_08_2020_FounderSharesMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.2</ix:nonFraction> shares for each share outstanding, on December&#160;7, 2020, the Sponsors forfeited <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" contextRef="P12_01_2020To12_07_2020_FounderSharesMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">1,437,500</ix:nonFraction> ordinary shares, which were cancelled by the Company, and on January&#160;6, 2021, the Company effected a share capitalization of <ix:nonFraction name="sclx:CapitalizationOfShareOutstanding" contextRef="P01_01_2021To01_06_2021_FounderSharesMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="1" scale="0" format="ixt:num-dot-decimal">0.2</ix:nonFraction> shares for each share outstanding, resulting in <ix:nonFraction name="sclx:OrdinarySharesIssuedAndOutstanding" contextRef="P01_01_2021To01_06_2021_FounderSharesMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">3,450,000</ix:nonFraction> ordinary shares issued and outstanding (the &#8220;Founder Shares&#8221;). All share and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">per-share</div> amounts have been retroactively restated to reflect the share transactions. The Founder Shares included an aggregate of up to <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" contextRef="P01_01_2021To12_31_2021_FounderSharesMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">450,000</ix:nonFraction> shares that were subject to forfeiture depending on the extent to which the underwriters&#8217; over-allotment option is exercised, so that the number of Founder Shares will equal, on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">as-converted</div> basis, approximately <ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="PAsOn12_31_2021_FounderSharesMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">20</ix:nonFraction>% of the Company&#8217;s issued and outstanding ordinary shares after the Initial Public Offering. As a result of the underwriters&#8217; election to partially exercise their over-allotment option, no Founder Shares are currently subject to forfeiture. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Sponsors have agreed, subject to limited exceptions, not to transfer, assign or sell any of its Founder Shares until six&#160;months after the consummation of a Business Combination or earlier if, subsequent to a Business Combination, the Company consummates a liquidation, merger, share exchange or other similar transaction that results in all of the Public Shareholders having the right to exchange their ordinary shares for cash, securities or other property. </div><br/></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Advances from Related Party </div></div></div></div></div> <div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">During 2020, an affiliate of the Sponsors advanced the Company an aggregate of $<ix:nonFraction name="us-gaap:CostsAndExpensesRelatedParty" contextRef="P12_01_2020To12_31_2020_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">30,000</ix:nonFraction> to fund expenses in connection with the Initial Public Offering. The advances are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest</div> bearing and payable upon demand. As<br/></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></ix:nonNumeric> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-15 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; margin-left: calc(-48.56vw + 48.9%);;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">DECEMBER&#160;31, 2021 </div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><ix:continuation id="TextSelection_63195138" continuedAt="TextSelectionAppend_63195138_1"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">of<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, there was $</div><ix:nonFraction name="us-gaap:DueToAffiliateCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and $</div><ix:nonFraction name="us-gaap:DueToAffiliateCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">30,000</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> advances outstanding, respectively. The outstanding amount of $</div><ix:nonFraction name="sclx:RepaidAmount" contextRef="P02_01_2021To02_26_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">30,000</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> was repaid on February&#160;</div>26<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">.</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Promissory Note&#160;&#8212;&#160;Related Party </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On July&#160;16, 2020, the Company issued an unsecured promissory note (the &#8220;Promissory Note&#8221;) to an affiliate of the Sponsors, pursuant to which the Company may borrow up to an aggregate principal amount of $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn07_16_2020_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">125,000</ix:nonFraction>. The Promissory Note is <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest</div> bearing and payable on the earlier of (i)&#160;December&#160;31, 2020 or (ii)&#160;the completion of the Initial Public Offering. The outstanding balance under the Promissory Note of $<ix:nonFraction name="us-gaap:RepaymentsOfDebt" contextRef="P01_05_2021To01_14_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">125,000</ix:nonFraction> was repaid subsequent to the closing of the Initial Public Offering on January&#160;14, 2021. Borrowings under the Promissory Note are no longer available to the Company. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Related Party Loans </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In order to finance transaction costs in connection with a Business Combination, the Sponsors or an affiliate of the Sponsors, or certain of the Company&#8217;s officers and directors may, but are not obligated to, loan the Company funds as may be required (&#8220;Working Capital Loans&#8221;). Such Working Capital Loans would be evidenced by promissory notes. <ix:nonNumeric name="us-gaap:BusinessCombinationControlObtainedDescription" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis">The notes may be repaid upon completion of a Business Combination, without interest, or, at the lender&#8217;s discretion, up to $1,500,000 of notes may be converted upon completion of a Business Combination into warrants at a price of $0.75 per warrant.</ix:nonNumeric> Such warrants would be identical to the Private Placement Warrants. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. As of December&#160;31, 2021 and 2020, there were no amounts outstanding under the Working Capital Loans. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On December&#160;20, 2021, the Company entered into two convertible promissory notes with the Sponsors pursuant to which the Sponsors agreed to loan the Company up to an aggregate principal amount of $<ix:nonFraction name="sclx:AggregatePrincipalAmount" contextRef="P12_01_2021To12_20_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">500,000</ix:nonFraction> (the &#8220;Convertible Promissory Notes&#8221;). The Convertible Promissory Notes are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest</div> bearing and payable upon Business Combination. If a Business Combination is not consummated, the Convertible Promissory Notes will not be repaid by the Company and all amounts owed thereunder by the Company will&#160;be forgiven except to the extent that the Company has funds available to it outside of its Trust Account. Up to $<ix:nonFraction name="us-gaap:ConvertibleDebt" contextRef="PAsOn12_20_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">500,000</ix:nonFraction> of the Convertible Promissory Notes may be converted into warrants at a price of $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn12_20_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.75</ix:nonFraction> per warrant at the option of the Sponsors. The warrants would be identical to the Private Placement Warrants. As of December&#160;31, 2021, the outstanding principal balance under the Convertible Promissory Notes amounted to an aggregate of $<ix:nonFraction name="sclx:aggregatePurchasePrice" contextRef="P01_01_2021To12_31_2021_ConvertibleNotesPayableMemberusgaapShortTermDebtTypeAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">500,000</ix:nonFraction>. Subsequent to December&#160;31, 2021, on January&#160;10, 2022, the Company borrowed an additional $<ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn01_10_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,035,000</ix:nonFraction>, as discussed below. On January&#160;27, 2022, Company entered into two additional Convertible Promissory Notes with the Sponsors pursuant to which the Sponsors agreed to&#160;loan&#160;the Company up to an aggregate principal amount of $<ix:nonFraction name="sclx:aggregatePurchasePrice" contextRef="P01_01_2022To01_27_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">500,000</ix:nonFraction>. Subsequent to December&#160;31, 2021, the&#160;principal balance of the Convertible Promissory Notes amounted to an aggregate of $<ix:nonFraction name="sclx:aggregatePurchasePrice" contextRef="P01_01_2021To12_31_2021_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">2,035,000</ix:nonFraction> (see Note 11). </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company assessed the provisions of the Convertible Promissory Notes under ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">470-20.</div> The derivative component of the obligation is initially valued and classified as a derivative liability (see Note 9). <br/></div> </ix:continuation></div></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div><ix:continuation id="TextSelectionAppend_63195138_1" continuedAt="TextSelectionAppend_63195138_2"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">The debt discount is being amortized to interest expense as a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash </div> charge over the term of the Convertible Promissory Notes, which is assumed to mature in April&#160;2022, the Company&#8217;s expected Business Combination date. During<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the year ended December&#160;31, 2021, the Company recorded $</div><ix:nonFraction name="us-gaap:RelatedPartyTaxExpenseDueToAffiliatesDeferred" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,826</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> of interest expense related to the amortization of the debt discount. The remaining balance of the debt discount at December&#160;31, 2021&#160;amounted to $</div><ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">16,901</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">.</div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-16 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">DECEMBER&#160;31, 2021 </div></div></div></div><ix:continuation id="TextSelectionAppend_63195138_2"> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Related Party Extension Loans </div></div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">As discussed in Note 1, the Company may extend the period of time to consummate a Business Combination up to two times, each by an additional three&#160;months (until July&#160;11, 2022 to complete a Business Combination). <ix:nonNumeric name="us-gaap:RelatedPartyTransactionDescriptionOfTransaction" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis">In order to extend the time available for the Company to consummate a Business Combination, the Sponsor or its affiliates or designees must deposit into the Trust Account $1,035,000 ($0.075 per Public Share in either case), on or prior to the date of the applicable deadline, for each three-month extension, providing a total possible Business Combination period up until July 11, 2022 for a total payment value of $2,070,000 ($0.15 per unit in either case).</ix:nonNumeric> Any such deposits would be made in the form of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest</div> bearing loans. Such notes would either be paid upon consummation of a Business Combination, or, at the relevant insider&#8217;s discretion, converted upon consummation of a Business Combination into additional Private Placement Warrants at a price of $<ix:nonFraction name="sclx:PricePerWarrants" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.75</ix:nonFraction> per Private Placement Warrant. The Sponsor and its affiliates or designees intend, but are not obligated, to fund the Trust Account to extend the time for the Company to complete a Business Combination. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On January&#160;10, 2022, the Company extended the period of time to consummate a Business Combination to April&#160;11, 2022. The Sponsors deposited $<ix:nonFraction name="us-gaap:AssetsHeldInTrust" contextRef="PAsOn01_10_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,035,000</ix:nonFraction> into the Trust Account made in the form of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest-bearing</div> loans. If the Company completes an initial business combination, the Company will, at the option of the Sponsors, repay the amounts evidenced by the Convertible Promissory Notes or convert a portion or all of the total amount into warrants at a price of $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn01_10_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.75</ix:nonFraction> per warrant, which warrants are identical to the Private Placement Warrants issued. If a Business Combination is not consummated, the Convertible Promissory Notes will not be repaid by the Company and all amounts owed thereunder by the Company will be forgiven except to the extent that the Company has funds available to it outside of its Trust Account. </div> </ix:continuation> <ix:nonNumeric name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_63195136"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 6&#160;&#8212;&#160;COMMITMENTS AND CONTINGENCIES </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Risks and Uncertainties </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Management continues to evaluate the impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company&#8217;s financial position, results of its operations and/or search for a target company, the specific impact is not readily determinable as of the date of these financial statements. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Registration and Shareholder Rights </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to a registration rights agreement entered into on January&#160;6, 2021, the holders of the Founder Shares, Private Placement Warrants and underlying ordinary shares and any securities issued upon conversion of Working Capital Loans will be entitled to registration rights pursuant to a registration rights agreement requiring the Company to register such securities for resale. The holders of these securities will be entitled to demand that the Company register such securities at any time after the Company consummates a Business Combination. In addition, the holders have certain &#8220;piggy-back&#8221; registration rights with respect to registration statements filed subsequent to the consummation of a Business Combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements. </div><br/></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Underwriting Agreement </div></div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="us-gaap:OtherCommitmentsDescription" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" continuedAt="TextSelection_63195135">The underwriters are entitled to a deferred fee of (i)&#160;3.5% of the gross proceeds of the initial 12,000,000&#160;Units sold in the Initial Public Offering, or $4,200,000, and (ii)&#160;5.5% of the gross proceeds from the Units sold</ix:nonNumeric> </div></div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-17 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">DECEMBER&#160;31, 2021 </div></div></div></div><ix:continuation id="TextSelection_63195136"> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:continuation id="TextSelection_63195135">pursuant to the over-allotment option, or $990,000</ix:continuation>. The deferred fee will be paid in cash upon the closing of a Business Combination from the amounts held in the Trust Account, subject to the terms of the underwriting agreement. </div></div></div> </ix:continuation> <ix:nonNumeric name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 7&#160;&#8212;&#160;SHAREHOLDERS&#8217; EQUITY </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Preference Shares</div></div></div></div>&#160;&#8212;&#160;The Company is authorized to issue <ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">1,000,000</ix:nonFraction> preference shares with a par value of $<ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction> per share, with such designations, voting and other rights and preferences as may be determined from time to time by the Company&#8217;s board of directors. At December&#160;31, 2021 and 2020, there were <ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> preference shares issued or outstanding. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Ordinary Shares</div></div></div></div>&#160;&#8212;&#160;The Company is authorized to issue <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">200,000,000</ix:nonFraction> ordinary shares with a par value of $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction> per share. Holders of ordinary shares are entitled to one vote for each share. At December&#160;31, 2021, there were <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">3,450,000</ix:nonFraction> shares of ordinary shares issued and outstanding, excluding <ix:nonFraction name="sclx:OrdinarySharesSubjectToPossibleRedemption" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">13,800,000</ix:nonFraction> ordinary shares subject to possible redemption which are presented as temporary equity. At December&#160;31, 2020, there were <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">3,450,000</ix:nonFraction> ordinary shares issued or outstanding. </div></ix:nonNumeric> <ix:nonNumeric name="sclx:WarrantsTextBlock" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_63195133"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 8&#160;&#8212;&#160;WARRANTS </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2021 and 2020, there were <ix:nonFraction name="sclx:WarrantsOutstandingShares" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis_WarrantMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">6,900,000</ix:nonFraction> and <ix:nonFraction name="sclx:WarrantsOutstandingShares" contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis_WarrantMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">0</ix:nonFraction> Public Warrants outstanding, respectively. Public Warrants may only be exercised for a whole number of shares. No fractional shares will be issued upon exercise of the Public Warrants. The Public Warrants will become exercisable on the later of (a)&#160;the completion of a Business Combination and (b)&#160;12&#160;months from the closing of the Initial Public Offering. The Public Warrants will expire five&#160;years from the completion of a Business Combination or earlier upon redemption or liquidation. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">No Public Warrants will be exercisable for cash unless the Company has an effective and current registration statement covering the issuance of the ordinary shares issuable upon exercise of the warrants and a current prospectus relating to such ordinary shares. Notwithstanding the foregoing, if a registration statement covering the issuance of the ordinary shares issuable upon exercise of the Public Warrants is not effective within 90&#160;days from the closing of a Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company shall have failed to maintain an effective registration statement, exercise warrants on a cashless basis pursuant to an available exemption from registration under the Securities Act. If an exemption from registration is not available, holders will not be able to exercise their warrants on a cashless basis. The Public Warrants will expire five&#160;years after the completion of a Business Combination or earlier upon redemption or liquidation. </div></div> <ix:nonNumeric name="sclx:PublicWarrantsRedemptionDescription" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" continuedAt="TextSelection_63194333"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company may redeem the Public Warrants: </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8226;</div></td>
<td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">in whole and not in part; </div></div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8226;</div></td>
<td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">at a price of $0.01 per warrant; </div></div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8226;</div></td>
<td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">at any time while the warrants become exercisable; </div></div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8226;</div></td>
<td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">upon not less than 30&#160;days&#8217; prior written notice of redemption to each warrant holder; </div></div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8226;</div></td>
<td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">if, and only if, the reported last sale price of the Company&#8217;s ordinary shares equals or exceeds $18.00 per share (subject to adjustment) <div style="display:inline;">fo</div>r any 20 trading days within a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-trading</div> day period commencing after the warrants become exercisable and ending on the third trading business day prior to the notice of redemption to the warrant holders; and </div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> </ix:nonNumeric> </ix:nonNumeric> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-18 </div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">DECEMBER&#160;31, 2021 </div></div></div><ix:continuation id="TextSelection_63195133" continuedAt="TextSelectionAppend_63195133_1"><ix:continuation id="TextSelection_63194333"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><br/></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">if, and only if, there is a current registration statement in effect with respect to the issuance of the ordinary shares underlying such warrants at the time of redemption and for the entire <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-day</div> trading period referred to above and continuing each day thereafter until the date of redemption. </div></td></tr></table></ix:continuation><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If the Company calls the Public Warrants for redemption, management will have the <div style="display:inline;">option </div>to <div style="display:inline;">require </div>all holders that wish to exercise the Public Warrants to do so on a &#8220;cashless basis,&#8221; as described in the warrant agreement. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The exercise price and number of ordinary shares issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a share dividend, extraordinary dividend or recapitalization, reorganization, merger or consolidation. However, the warrants will not be adjusted for issuance of ordinary shares at a price below its exercise price. The Company has agreed to use its best efforts to have declared effective a prospectus relating to the ordinary shares issuable upon exercise of the warrants and keep such prospectus current until the expiration of the warrants. However, if the Company does not maintain a current prospectus relating to the ordinary shares issuable upon exercise of the warrants, holders will be unable to exercise their warrants for cash and the Company will not be required to net cash settle or cash settle the warrant exercise. There will be no redemption rights upon the completion of a Business Combination with respect to the Company&#8217;s warrants. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company&#8217;s assets held outside of the Trust Account with the respect to such warrants. Accordingly, the warrants may expire worthless. </div></div></ix:continuation><ix:continuation id="TextSelectionAppend_63195133_1"> <ix:nonNumeric name="sclx:CapitalRaisingDescription" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, if (x)&#160;the Company issues additional ordinary shares or equity-linked securities for capital raising purposes in connection with the closing of a Business Combination at an issue price or effective issue price of less than $9.20 per ordinary share (with such issue price or effective issue price to be determined in good faith by the Company&#8217;s board of directors and, in the case of any such issuance to the Sponsors or its affiliates, without taking into account any Founder Shares held by the Sponsors or such affiliates, as applicable, prior to such issuance) (the &#8220;Newly Issued Price&#8221;), (y)&#160;the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of a Business Combination on the date of the consummation of a Business Combination (net of redemptions), and (z)&#160;the volume weighted average trading price of its ordinary shares during the 20 trading day period starting on the trading day prior to the day on which the Company consummates its Business Combination (such price, the &#8220;Market Value&#8221;) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, the $18.00 per share redemption trigger price will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price. </div></div></ix:nonNumeric> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At December&#160;31, 2021 and 2020, there were <ix:nonFraction name="sclx:WarrantsOutstandingShares" contextRef="PAsOn12_31_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">6,840,000</ix:nonFraction> and <ix:nonFraction name="sclx:WarrantsOutstandingShares" contextRef="PAsOn12_31_2020_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">0</ix:nonFraction> Private Placement Warrants outstanding, respectively. The Private Placement Warrants are identical to the Public Warrants underlying the Units sold in the Initial Public Offering, except that the Private Placement Warrants will be exercisable for cash (even if a registration statement covering the issuance of the ordinary shares issuable upon exercise of such warrants is not effective) or on a cashless basis, at the holder&#8217;s option and will not be redeemable by the Company, in each case so long as they are held by the initial purchasers or their affiliates. </div></div></ix:continuation> <div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <ix:nonNumeric name="us-gaap:FairValueDisclosuresTextBlock" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_63195137"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 9&#160;&#8212;&#160;FAIR VALUE MEASUREMENTS </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the Company&#8217;s financial assets and liabilities reflects management&#8217;s estimate of amounts that the Company would have received in connection with the sale of the assets or paid in connection with the transfer </div></div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-19 </div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">DECEMBER&#160;31, 2021 </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <ix:continuation id="TextSelection_63195137" continuedAt="TextSelectionAppend_63195137_1"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 9%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td style="width: 89%;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="display:inline;">Level&#160;1:</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"><div style="display:inline;"></div></td>
<td colspan="2" style="height: 6pt;"><div style="display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="display:inline;">Level&#160;2:</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">Observable inputs other than Level&#160;1 inputs. Examples of Level&#160;2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"><div style="display:inline;"></div></td>
<td colspan="2" style="height: 6pt;"><div style="display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="display:inline;">Level&#160;3:</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability.</div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div><div style="clear: both; max-height: 0px;"></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At December&#160;31, 2021, assets held in the Trust Account were comprised of $<ix:nonFraction name="us-gaap:AssetsHeldInTrust" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">139,410,739</ix:nonFraction> in money market funds which are invested primarily in U.S. Treasury Securities. Through December&#160;31, 2021, the Company did not withdraw any of interest earned on the Trust Account. At December&#160;31, 2020, there were no assets in the Trust Account. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents information about the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis at December&#160;31, 2021 and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" escape="true">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 71%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Description</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investments held in Trust Account&#160;&#8212;&#160;U.S. Treasury Securities Money Market Fund</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InterestIncomeSecuritiesUSTreasury" contextRef="P01_01_2021To12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">139,410,739</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Warrant Liability&#160;&#8212;&#160;Private Placement Warrants</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueAdjustment" contextRef="P01_01_2021To12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">3,351,600</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Conversion Option Liability (see Note 5)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">6,892</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table> </ix:nonNumeric> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Warrant Liability Measurement </div></div></div></div> <ix:nonNumeric name="us-gaap:FairValueMeasurementsHighestAndBestUseDescription" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" continuedAt="TextSelection_63194339"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">The Company established the initial fair value for the private warrants on January&#160;11, 2021, the date of the Company&#8217;s Initial Public Offering, using a Monte Carlo simulation and subsequently implemented the Black-Scholes Option Pricing Model that was modified to capture the redemption features of the public warrants. The underlying assumptions in the Black-Scholes option pricing model include the underlying share price, risk-free interest rate, estimated volatility and the expected term. The primary unobservable inputs utilized in determining the fair value of the private warrants are the expected volatility of the Company&#8217;s ordinary shares and the Company&#8217;s ordinary share price. The expected volatility of the ordinary shares was determined based on implied volatilities of public warrants issued by selected guideline companies and was estimated to be 10% before the expected business combination and 20% after the expected business combination. The ordinary share price was<div style="display:inline;">&#160;</div><div style="display:inline;">determined based on an iterative procedure that matched the estimated value of the ordinary shares and fractional&#160;</div> </div></div></ix:nonNumeric> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-20 </div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">DECEMBER&#160;31, 2021 </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelectionAppend_63195137_1" continuedAt="TextSelectionAppend_63195137_2"><ix:continuation id="TextSelection_63194339"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">warrant price to equate to the observed price of the outstanding&#160;units. The risk-free interest rate is based on the U.S. Treasury yield curve in effect on the date of valuation equal to the remaining expected life of the private warrants. The dividend yield&#160;percentage is zero because the Company does not currently pay dividends, nor does it intend to do so during the expected term of the warrants. The expected life of the warrants is assumed to be equivalent to their remaining contractual term. Inputs are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-evaluated</div> each quarterly reporting period to estimate the fair market value of the private placement warrants as of the reporting period. </div> </ix:continuation> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There were no transfers between Levels 1, 2 or 3 during the year ended December&#160;31, 2021. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table provides quantitative information regarding Level&#160;3 fair value measurements: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="us-gaap:FairValueConcentrationOfRiskTextBlock" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" escape="true">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 80%;"></td>
<td style="width: 15%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of<br/>December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock price</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.04</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Strike price</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:FairValueMeasurementStrikePrice" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">11.50</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Term (in&#160;years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" format="ixt-sec:duryear">5.28</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Volatility</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">8.3</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">1.28</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dividend yield</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">0.0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of warrants</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:FairValueOfWarrantsinDollars" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.49</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table> </ix:nonNumeric> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents the changes in the fair value of warrant liabilities: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" escape="true">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 80%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Private<br/>Placement</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value as of January&#160;1, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn12_31_2020_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Initial measurement on January&#160;11, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:InitialMeasurementOne" contextRef="P01_01_2021To12_31_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">7,729,200</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation inputs or other assumptions</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="sclx:ChangeInValuationInputsOrOtherAssumptions" contextRef="P01_01_2021To12_31_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">4,377,600</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value as of December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn12_31_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">3,351,600</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Conversion Option Liability Measurement </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company assessed the provisions of the Convertible Promissory Notes under ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">470-20.</div> The derivative component of the obligation is initially valued and classified as a derivative liability. The conversion option was valued using the compound option pricing model, which is considered to be a Level&#160;3 fair value measurement (See Note 6). </div></ix:continuation> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" escape="true"><ix:continuation id="TextSelectionAppend_63195137_2" continuedAt="TextSelectionAppend_63195137_3">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 65%;"></td>
<td style="width: 12%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 11%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;20,<br/>2021<br/>(Initial<br/>Measurement)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Underlying warrant value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:UnderlyingWarrantValue" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal">0.0103</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:UnderlyingWarrantValue" contextRef="P12_21_2020To12_20_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal">0.0281</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercise price</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.75</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="PAsOn12_20_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.75</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Holding period</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:HoldingPeriod" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.28</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:HoldingPeriod" contextRef="P12_21_2020To12_20_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.31</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free rate %</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">1.28</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P12_21_2020To12_20_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">1.19</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Volatility%</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">8.3</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P12_21_2020To12_20_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">9.3</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dividend yield %</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">0.0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P12_21_2020To12_20_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">0.0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table></ix:continuation> </ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-21 </div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">DECEMBER&#160;31, 2021 </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelectionAppend_63195137_3"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents the change in the fair value of conversion option liability: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="us-gaap:ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" escape="true">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 84%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 9%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value as of January&#160;1, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Initial measurement on December&#160;20, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">18,727</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ServicingLiabilityAtFairValueOtherChangesInFairValue" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">11,835</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value as of December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">6,892</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric> </ix:continuation> <ix:nonNumeric name="us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_63194391"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 10&#160;&#8212;&#160;RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restatement 1 </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company previously accounted for its outstanding Private Placement Warrants (the &#8220;Warrants&#8221;) issued in connection with its Initial Public Offering as components of equity instead of as derivative liabilities. The warrant agreement governing the Warrants includes a provision that provides for potential changes to the settlement amounts dependent upon the characteristics of the holder of the warrant. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On April&#160;12, 2021, the Acting Director of the Division of Corporation Finance and Acting Chief Accountant of the Securities and Exchange Commission together issued a statement regarding the accounting and reporting considerations for warrants issued by special purpose acquisition companies titled &#8220;Staff Statement on Accounting and Reporting Considerations for Warrants Issued by Special Purpose Acquisition Companies (&#8220;SPACs&#8221;)&#8221; (the &#8220;SEC Statement&#8221;). Specifically, the SEC Statement focused on certain settlement terms and provisions related to certain tender offers following a business combination, which terms are similar to those contained in the warrant agreement.</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In further consideration of the SEC Statement, the Company&#8217;s management further evaluated the Warrants under Accounting Standards Codification (&#8220;ASC&#8221;) Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">815-40,</div> Contracts in Entity&#8217;s Own Equity. ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;815-40-15</div></div> addresses equity versus liability treatment and classification of equity-linked financial instruments, including warrants, and states that a warrant may be classified as a component of equity only if, among other things, the warrant is indexed to the issuer&#8217;s ordinary shares. Under ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;815-40-15,</div></div> a warrant is not indexed to the issuer&#8217;s ordinary shares if the terms of the warrant require an adjustment to the exercise price upon a specified event and that event is not an input to the fair value of the warrant. Based on management&#8217;s evaluation, the Company&#8217;s audit committee, in consultation with management, concluded that the Company&#8217;s Private Placement Warrants are not indexed to the Company&#8217;s ordinary shares in the manner contemplated by ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;815-40-15</div></div> because the holder of the instrument is not an input into the pricing of a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">fixed-for-fixed</div></div> option on equity shares. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In accordance with ASC Topic 340, Other Assets and Deferred Costs, as a result of the classification of the private warrants as derivative liabilities, the Company expensed a portion of the offering costs originally recorded as a reduction in equity. The portion of offering costs that was expensed was determined based on the relative fair value of the Private Warrants. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restatement 2 </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In addition, in connection with the preparation of the Company&#8217;s financial statements as of September&#160;30, 2021, the Company concluded it should restate its financial statements to classify all Public Shares in temporary equity. The September&#160;30, 2021 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q/A,</div> filed with the SEC on December&#160;8, 2021, includes the restatement of the unaudited March&#160;31, 2021 and June&#160;30, 2021 financial information. Included in the table below is the restatement </div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-22 </div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">DECEMBER&#160;31, 2021 </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelection_63194391"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">of the audited IPO Balance Sheet as of January&#160;11, 2021 originally filed on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</div> filed with the SEC on January&#160;15, 2021. In accordance with ASC 480, paragraph <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-S99,</div> redemption provisions not solely within the control of the Company require ordinary shares subject to redemption to be classified outside of permanent equity. The Company previously determined the ordinary shares subject to possible redemption to be equal to the redemption value of $<ix:nonFraction name="us-gaap:PreferredStockRedemptionPricePerShare" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.10</ix:nonFraction> per ordinary share while also taking into consideration a redemption cannot result in net tangible assets being less than $<ix:nonFraction name="us-gaap:IntangibleAssetsCurrent" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">5,000,001</ix:nonFraction>. Previously, the Company did not consider redeemable shares classified as temporary equity as part of net tangible assets. Effective with these financial statements, the Company revised this interpretation to include temporary equity in net tangible assets. Accordingly, effective with this filing, the Company presents all redeemable ordinary shares as temporary equity and recognizes accretion from the initial book value to redemption value at the time of its Initial Public Offering and in accordance with ASC 480. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As a result, management has noted a reclassification adjustment related to temporary equity and permanent equity. This resulted in an adjustment to the initial carrying value of the ordinary shares subject </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">to possible redemption with the offset recorded to additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital (to the extent available), accumulated deficit and ordinary shares. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In connection with the change in presentation for the ordinary shares subject to redemption, the Company also revised its income (loss) per ordinary share calculation to allocate net income (loss) to ordinary shares. This presentation contemplates a Business Combination as the most likely outcome, in which case, ordinary shares share pro&#160;rata in the income (loss) of the Company. </div></div><ix:nonNumeric name="srt:ScheduleOfCondensedFinancialStatementsTableTextBlock" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The impact of these adjustments to the financial statement, as previously reported, is presented below. </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 48%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As Previously<br/>Reported</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Adjustments<br/>Restatement&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Adjustments<br/>Restatement 2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As<br/>Restated</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance sheet as of January&#160;11, 2021</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Warrant Liability</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn01_11_2021_ScenarioPreviouslyReportedMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn01_11_2021_RestatementAdjustmentMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">7,729,200</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn01_11_2021_AdjustmentsRestatement2MembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn01_11_2021_AsRestatedMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">7,729,200</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn01_11_2021_ScenarioPreviouslyReportedMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">5,345,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn01_11_2021_RestatementAdjustmentMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">7,729,200</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn01_11_2021_AdjustmentsRestatement2MembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn01_11_2021_AsRestatedMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">13,074,200</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ordinary Shares Subject to Possible Redemption</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn01_11_2021_ScenarioPreviouslyReportedMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">129,999,029</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn01_11_2021_RestatementAdjustmentMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">7,729,200</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn01_11_2021_AdjustmentsRestatement2MembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">17,110,171</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn01_11_2021_AsRestatedMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">139,380,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ordinary Shares</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn01_11_2021_ScenarioPreviouslyReportedMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">438</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn01_11_2021_RestatementAdjustmentMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">76</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn01_11_2021_AdjustmentsRestatement2MembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">169</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn01_11_2021_AsRestatedMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">345</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Paid-in</div> Capital</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn01_11_2021_ScenarioPreviouslyReportedMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">5,006,060</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn01_11_2021_RestatementAdjustmentMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">2,629,336</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn01_11_2021_AdjustmentsRestatement2MembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">7,635,396</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn01_11_2021_AsRestatedMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated Deficit</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn01_11_2021_ScenarioPreviouslyReportedMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">6,490</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn01_11_2021_RestatementAdjustmentMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">2,629,412</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn01_11_2021_AdjustmentsRestatement2MembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">9,474,606</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn01_11_2021_AsRestatedMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">12,110,508</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Shareholders&#8217; Equity (Deficit)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn01_11_2021_ScenarioPreviouslyReportedMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">5,000,008</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn01_11_2021_RestatementAdjustmentMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn01_11_2021_AdjustmentsRestatement2MembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">17,110,171</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn01_11_2021_AsRestatedMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">12,110,163</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr></table></ix:nonNumeric></ix:continuation><ix:nonNumeric name="us-gaap:SubsequentEventsTextBlock" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_63193985"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 11&#160;&#8212;&#160;SUBSEQUENT EVENTS </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the financial statements were issued. The Company did not identify any subsequent events, other than noted below, that would have required adjustment or disclosure in the financial statements. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;">On January&#160;10, 2022, the Company extended the period of time to consummate a Business Combination to April&#160;11, 2022. The Sponsors deposited $<ix:nonFraction name="sclx:SponsorLoan" contextRef="P01_01_2022To01_10_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,035,000</ix:nonFraction> into the Trust Account made in the form of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest-bearing</div> loans. If the Company completes an initial business combination, the Company will, at the option of the Sponsors, repay the amounts evidenced by the Convertible Promissory Notes or convert a portion or all of the<div style="display:inline;">&#160;</div><div style="display:inline;">total amount into warrants at a price of $<ix:nonFraction name="sclx:WarrantExercisePrice" contextRef="P01_01_2022To01_10_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.75</ix:nonFraction> per warrant, which warrants are identical to the Private Placement&#160;</div> </div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-23 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">DECEMBER&#160;31, 2021 </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelection_63193985"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="null;text-indent: 0px;;display:inline;">Warrants issued.</div> If a Business Combination is not consummated, the Convertible Promissory Notes will not be repaid by the Company and all amounts owed thereunder by the Company will be forgiven except to the extent that the Company has funds available to it outside of its Trust Account. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On January&#160;27, 2022, the Company entered into two additional Convertible Promissory Notes with the Sponsors pursuant to which the Sponsors agreed to loan the Company up to an additional aggregate principal amount of $<ix:nonFraction name="sclx:AdditionalPrincipalAmount" contextRef="P01_01_2022To01_27_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">500,000</ix:nonFraction>. The aggregate principal balance of the Convertible Promissory Notes amounted to $<ix:nonFraction name="sclx:ConvertiblePromissoryNote" contextRef="P01_01_2022To01_27_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">2,035,000</ix:nonFraction>. </div></div></ix:continuation><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-24 </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;"></a></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div></div> <div id="fin428534_7" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONDENSED CONSOLIDATED BALANCE SHEETS </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 74%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,<br/>2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Unaudited)</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Audited)</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ASSETS</div></div></div></div> </td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current assets</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Cash" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">34,961</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Cash" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">507,921</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid expenses</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">130,788</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">4,536</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 74%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Current Assets</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">165,749</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">512,457</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investments held in Trust Account <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div> U.S. Treasury Securities Money Market Fund</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsHeldInTrustNoncurrent" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">101,293,086</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsHeldInTrustNoncurrent" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">139,410,739</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 74%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TOTAL ASSETS</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">101,458,835</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">139,923,196</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 74%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">LIABILITIES, ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION, AND SHAREHOLDERS&#8217; DEFICIT</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current liabilities</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable and accrued expenses</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">809,292</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">208,704</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 74%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Current Liabilities</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">809,292</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">208,704</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">Convertible promissory notes<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#8212;&#160;</div>related party, net of discount</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ConvertibleLongTermNotesPayable" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">2,035,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ConvertibleLongTermNotesPayable" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">483,099</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Conversion option liability</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">6,892</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Simple promissory notes</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherLongTermNotesPayable" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">2,971,667</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherLongTermNotesPayable" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Mandatorily redeemable ordinary shares liability</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Warrant liability</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,162,800</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">3,351,600</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred underwriting fee payable</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">5,190,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">5,190,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 74%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Liabilities</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">12,168,759</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">9,240,295</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commitments and Contingencies</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ordinary shares subject to possible redemption&#160;<ix:nonFraction name="sclx:OrdinarySharesSubjectToPossibleRedemption" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">9,726,395</ix:nonFraction>&#160;and&#160;<ix:nonFraction name="sclx:OrdinarySharesSubjectToPossibleRedemption" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">13,800,000</ix:nonFraction> as of September&#160;30, 2022 and December&#160;31, 2021, respectively, at redemption value of $<ix:nonFraction name="us-gaap:TemporaryEquityRedemptionPricePerShare" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">10.41</ix:nonFraction>&#160;and $<ix:nonFraction name="us-gaap:TemporaryEquityRedemptionPricePerShare" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">10.00</ix:nonFraction>, respectively, per share</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">101,293,086</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">139,380,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Shareholders&#8217; Deficit</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Preference shares, $<ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction>&#160;par value;&#160;<ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">1,000,000</ix:nonFraction></ix:nonFraction>&#160;shares authorized;&#160;<ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen">none</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>&#160;issued or outstanding</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Ordinary shares, $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction>&#160;par value;&#160;<ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">200,000,000</ix:nonFraction></ix:nonFraction>&#160;shares authorized;&#160;<ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">3,450,000</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-redeemable</div> shares issued and outstanding at September&#160;30, 2022 and December&#160;31, 2021</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">345</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">345</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated deficit</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">12,003,355</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">8,697,444</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 74%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Shareholders&#8217; Deficit</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">12,003,010</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">8,697,099</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 74%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TOTAL LIABILITIES, ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION, AND SHAREHOLDERS&#8217; DEFICIT</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">101,458,835</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">139,923,196</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 74%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-25 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div> </div> </div> <div style="font-size: 13.28px; margin-top: 0pt; margin-bottom: 0pt;;font-weight: bold;"></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">VICKERS VANTAGE CORP. I </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="fin428534_8">UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 53%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For&#160;the&#160;Three&#160;Months&#160;Ended<br/>September&#160;30,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the Nine Months&#160;Ended<br/>September&#160;30,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating and formation costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingCostsAndExpenses" contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">657,746</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingCostsAndExpenses" contextRef="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">283,346</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingCostsAndExpenses" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">2,412,297</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingCostsAndExpenses" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">620,642</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">loss from operations</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">657,746</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">283,346</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">2,412,297</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">620,642</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other income (expense):</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of warrant liability</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">68,400</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,162,800</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">2,188,800</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">2,872,800</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss on initial issuance of private warrants</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnSaleOfDerivatives" contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnSaleOfDerivatives" contextRef="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnSaleOfDerivatives" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:GainLossOnSaleOfDerivatives" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">2,599,200</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transaction costs allocated to warrant liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:TransactionCostsAllocatedToWarrantLiabilities" contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:TransactionCostsAllocatedToWarrantLiabilities" contextRef="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:TransactionCostsAllocatedToWarrantLiabilities" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="sclx:TransactionCostsAllocatedToWarrantLiabilities" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">30,212</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of conversion option liability</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" contextRef="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">6,892</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest on mandatorily redeemable ordinary shares liability</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DistributionsOnMandatorilyRedeemableSecurities" contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DistributionsOnMandatorilyRedeemableSecurities" contextRef="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DistributionsOnMandatorilyRedeemableSecurities" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">192,049</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DistributionsOnMandatorilyRedeemableSecurities" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest expense &#8212; debt discount</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,155</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">16,901</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income earned on investments held in Trust Account</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InterestIncomeOther" contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">459,114</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InterestIncomeOther" contextRef="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,794</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InterestIncomeOther" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">664,973</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InterestIncomeOther" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">28,006</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total other income (expense), net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">526,359</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">1,161,006</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">3,035,813</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">271,394</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net (loss) income</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">131,387</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">1,444,352</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">623,516</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">349,248</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average shares outstanding, ordinary shares</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">13,176,395</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">17,250,000</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">15,862,288</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">16,675,824</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net (loss) income per share, ordinary shares</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">0.01</ix:nonFraction></ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">0.08</ix:nonFraction></ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.04</ix:nonFraction></ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">0.02</ix:nonFraction></ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying notes are an integral part of <div style="display:inline;">these</div> unaudited condensed consolidated financial statements. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-26 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div></div> <div id="fin428534_9" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS&#8217; EQUITY (DEFICIT) </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER&#160;30, 2022 </div></div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 48%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;<br/>Ordinary Shares</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Additional<br/><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Paid-in</div><br/>Capital</div></div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/>Deficit</div></div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total<br/>Shareholders&#8217;<br/>Deficit</div></div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance &#8212; January&#160;1, 2022</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">3,450,000</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">345</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">8,697,444</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">8,697,099</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accretion of Ordinary shares subject to possible redemption amount</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="P01_01_2022To03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="P01_01_2022To03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="P01_01_2022To03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,035,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="P01_01_2022To03_31_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,035,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">806,222</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To03_31_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">806,222</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div> March&#160;31, 2022 (unaudited)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">3,450,000</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">345</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">10,538,666</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">10,538,321</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Mandatorily redeemable ordinary shares</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetSharesReclassifiedToMandatorilyRedeemableCapitalStockValue" contextRef="P04_01_2022To06_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetSharesReclassifiedToMandatorilyRedeemableCapitalStockValue" contextRef="P04_01_2022To06_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetSharesReclassifiedToMandatorilyRedeemableCapitalStockValue" contextRef="P04_01_2022To06_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">192,049</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetSharesReclassifiedToMandatorilyRedeemableCapitalStockValue" contextRef="P04_01_2022To06_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">192,049</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accretion of Ordinary shares subject to possible redemption amount</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="P04_01_2022To06_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="P04_01_2022To06_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="P04_01_2022To06_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,595,486</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="P04_01_2022To06_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,595,486</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P04_01_2022To06_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P04_01_2022To06_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P04_01_2022To06_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,561,125</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P04_01_2022To06_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,561,125</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div> June&#160;30, 2022 (unaudited)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn06_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">3,450,000</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">345</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">10,765,076</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">10,764,731</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accretion of Ordinary shares subject to possible redemption amount</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="P07_01_2022To09_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="P07_01_2022To09_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="P07_01_2022To09_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,106,892</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,106,892</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2022To09_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2022To09_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2022To09_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">131,387</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">131,387</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div> September&#160;30, 2022 (unaudited)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn09_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">3,450,000</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">345</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">12,003,355</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">12,003,010</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 24pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER&#160;30, 2021 </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 52%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;<br/>&#160;&#160;&#160;&#160;<br/>Ordinary Shares</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Additional<br/><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Paid-in</div><br/>Capital</div></div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/>Deficit</div></div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total<br/>Shareholders&#8217;<br/>Equity<br/>(Deficit)</div></div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance &#8212; January&#160;1, 2021</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">3,450,000</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">345</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">24,655</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">6,276</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">18,724</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accretion of Ordinary shares subject to possible redemption amount</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="P01_01_2021To03_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="P01_01_2021To03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">24,665</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="P01_01_2021To03_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">9,474,606</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockRedeemedOrCalledDuringPeriodValue" contextRef="P01_01_2021To03_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">9,499,261</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To03_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To03_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,328,853</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To03_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,328,853</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div> March&#160;31, 2021 (unaudited)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn03_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">3,450,000</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">345</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">8,152,029</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">8,151,684</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P04_01_2021To06_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P04_01_2021To06_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P04_01_2021To06_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">233,749</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P04_01_2021To06_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">233,749</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div> June&#160;30, 2021 (unaudited)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn06_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">3,450,000</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">345</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">8,385,778</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">8,385,433</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2021To09_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2021To09_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2021To09_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">1,444,352</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">1,444,352</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div> September&#160;30, 2021 (unaudited)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn09_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">3,450,000</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">345</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">9,830,130</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">9,829,785</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-27 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div></div> <div id="fin428534_10" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS </div></div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 74%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the Nine months Ended<br/>September&#160;30,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash Flows from Operating Activities:</div></div></div></div> </td>
<td style="vertical-align: bottom; width: 5%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom; width: 5%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss)</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">623,516</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">349,248</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustments to reconcile net income (loss) to net cash used in operating activities:</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income earned on investments held in Trust Account</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:InterestAndDividendIncomeSecuritiesHeldToMaturity" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">664,973</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:InterestAndDividendIncomeSecuritiesHeldToMaturity" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">28,006</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest on mandatorily redeemable ordinary shares liability</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DistributionsOnMandatorilyRedeemableSecurities" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">192,049</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DistributionsOnMandatorilyRedeemableSecurities" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of warrant liability</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">2,188,800</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">2,872,800</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss on initial issuance of private warrants</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:LossOnInitialIssuanceOfWarrantLiability" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:LossOnInitialIssuanceOfWarrantLiability" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">2,599,200</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of conversion option liability</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="sclx:ChangeInFairValueOfConversionOptionLiability" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">6,892</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:ChangeInFairValueOfConversionOptionLiability" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amortization of debt discount</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">16,901</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transaction costs allocated to warrant liabilities</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:TransactionsCostsAllocatedToPrivateWarrants" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:TransactionsCostsAllocatedToPrivateWarrants" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">30,212</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in operating assets and liabilities:</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid expenses</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">126,252</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">116,536</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable and accrued expenses</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">600,588</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">43,569</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 74%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash used in operating activities</div></div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">1,937,961</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">693,609</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 74%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash Flows from Investing Activities:</div></div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment of cash in Trust Account</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="sclx:InvestmentOfCashInTrustAccounts" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">3,041,666</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="sclx:InvestmentOfCashInTrustAccounts" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">139,380,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash withdrawn from Trust Account in connection with redemption</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromDecommissioningFund" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">41,824,292</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromDecommissioningFund" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 74%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash provided by (used in) investing activities</div></div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">38,782,626</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">139,380,000</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 74%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash Flows from Financing Activities:</div></div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from sale of Units, net of underwriting discounts paid</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">135,600,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from sale of Private Placement Warrants</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">5,130,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Advances from related party</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">25,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Repayment of advances from related party</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RepaymentsOfRelatedPartyDebt" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RepaymentsOfRelatedPartyDebt" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">55,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from convertible promissory note&#160;&#8211;&#160;related party</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,535,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from simple promissory note&#160;&#8211;&#160;related party</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:ProceedsFromSimplePromissoryNoteRelatedParty" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">2,971,667</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:ProceedsFromSimplePromissoryNoteRelatedParty" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Repayment of promissory note&#160;&#8211;&#160;related party</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:RepaymentOfPromissoryNoteRelatedParty" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="sclx:RepaymentOfPromissoryNoteRelatedParty" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">125,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payment of offering costs</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">416,260</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Redemption of ordinary shares</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfOtherEquity" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">41,824,292</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfOtherEquity" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 74%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash (used in) provided by financing activities</div></div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">37,317,625</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">140,158,740</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 74%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net Change in Cash</div></div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">472,960</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">85,131</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div> Beginning of period</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">507,921</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">30,511</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 74%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div> End of period</div></div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">34,961</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">115,642</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 74%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Cash</div> investing and financing activities:</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 74%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred underwriting fee payable</div></div> </td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:DeferredUnderwritingFeePayable" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:DeferredUnderwritingFeePayable" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">5,190,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 74%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-28 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div> </div> </div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div></div><div id="fin428534_11" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SEPTEMBER&#160;30, 2022 </div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <ix:nonNumeric name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_63194060"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 1. DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vickers Vantage Corp. I (the &#8220;Company&#8221;) is a blank check company incorporated as a Cayman Islands exempted company on February&#160;21, 2020. The Company was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities (a &#8220;Business Combination&#8221;). </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has one wholly owned subsidiary which was formed on February&#160;2, 2022, Vantage Merger Sub Inc., a Delaware corporation. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is not limited to a particular industry or sector for purposes of consummating a Business Combination. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As of September&#160;30, 2022, the Company had not commenced any operations. All activity for the period from February&#160;21, 2020 (inception) through September&#160;30, 2022 relates to the Company&#8217;s formation and the initial public offering (&#8220;Initial Public Offering&#8221;), which is described below, and, subsequent to the Initial Public Offering, identifying a target company for a Business Combination and in connection therewith entering into the Merger Agreement, which is described below in Note 6. The Company will not generate any operating revenues until after the completion of a Business Combination, at the earliest. The Company will generate <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-operating</div> income in the form of interest income from the proceeds derived from the Initial Public Offering. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The registration statement for the Company&#8217;s Initial Public Offering was declared effective on January&#160;6, 2021. On January&#160;11, 2021 the Company consummated the Initial Public Offering of&#160;<ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn01_11_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">13,800,000</ix:nonFraction>&#160;Units (the &#8220;Units&#8221; and, with respect to the ordinary shares included in the Units sold, the &#8220;Public Shares&#8221;), which includes the full exercise by the underwriter of its over-allotment option in the amount of&#160;<ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn01_11_2021_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">1,800,000</ix:nonFraction>&#160;Units, at $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn01_11_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.00</ix:nonFraction>&#160;per Unit, generating gross proceeds of $<ix:nonFraction name="us-gaap:DemutualizationByInsuranceEntitySecuritiesIssuedGrossCashProceeds" contextRef="P01_04_2021To01_11_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">138,000,000</ix:nonFraction>&#160;which is described in Note 3. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of&#160;<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">6,840,000</ix:nonFraction> warrants (the &#8220;Private Placement Warrants&#8221;) at a price of $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn09_30_2022_PrivatePlacementWarrantMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.75</ix:nonFraction>&#160;per Private Placement Warrant in a private placement to Vickers Venture Fund VI Pte Ltd and Vickers Venture Fund VI (Plan) Pte Ltd, (the &#8220;Sponsor&#8221;), generating gross proceeds of $<ix:nonFraction name="us-gaap:DemutualizationByInsuranceEntitySecuritiesIssuedGrossCashProceeds" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">5,130,000</ix:nonFraction>, which is described in Note 4. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transaction costs amounted to $<ix:nonFraction name="us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">8,149,473</ix:nonFraction>, consisting of $<ix:nonFraction name="us-gaap:OtherUnderwritingExpense" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">2,400,000</ix:nonFraction>&#160;in cash underwriting fees, $<ix:nonFraction name="sclx:DeferredUnderwritingFees" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">5,190,000</ix:nonFraction>&#160;in deferred underwriting fees, and $<ix:nonFraction name="us-gaap:OtherOwnershipInterestsOfferingCosts" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">559,473</ix:nonFraction>&#160;of other offering costs </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Following the closing of the Initial Public Offering on January&#160;11, 2021, an amount of $<ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="P01_04_2021To01_11_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">139,380,000</ix:nonFraction>&#160;($<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn01_11_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.10</ix:nonFraction>&#160;per Unit) from the net proceeds of the sale of the Units in the Initial Public Offering and the sale of the Private Placement Warrants was placed in a trust account (the &#8220;Trust Account&#8221;), and invested in U.S. government securities, within the meaning set forth in Section&#160;2(a)(16) of the Investment Company Act, with a maturity of 185 days or less, or in any open-ended investment company that holds itself out as a money market fund investing solely in U.S.&#160;Treasuries and meeting certain conditions under Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2a-7</div> of the Investment Company Act, as determined by the Company, until the earliest of: (i)&#160;the completion of a Business Combination and (ii)&#160;the distribution of the funds in the Trust Account to the Company&#8217;s shareholders, as described below. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On January&#160;10, 2022, the Company extended the period of time to consummate a Business Combination from January&#160;11, 2022 to April&#160;11, 2022. On April&#160;11, 2022, the Company extended the period of time to consummate a Business Combination to July&#160;11, 2022. On July&#160;11, 2022, the Company extended the period of time to </div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-29 </div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SEPTEMBER&#160;30, 2022 </div></div></div></div><ix:continuation id="TextSelection_63194060" continuedAt="TextSelectionAppend_63194060_1"> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">consummate a Business Combination to August&#160;11, 2022 and without another shareholder vote, to elect to extend the date to consummate a business combination on a monthly basis for up to five times by an additional one month each time after, upon five days&#8217; advance notice prior to the applicable deadlines, until January&#160;11, 2023. As of the date of this filing, the Company has extended the period of time to consummate a Business Combination to November&#160;11, 2022. In connection with the extensions, the Sponsors deposited an aggregate of $<ix:nonFraction name="us-gaap:NoninterestBearingDepositLiabilities" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">3,365,554</ix:nonFraction> into the trust account in the form of a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest-bearing</div> loans as of the date of this filing. The Company will have until November&#160;11, 2022 to consummate a Business Combination. As a result, an aggregate of $<ix:nonFraction name="us-gaap:AssetsHeldInTrust" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">101,293,086</ix:nonFraction>&#160;as of September&#160;30, 2022 is held in the Trust Account. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and the sale of the Private Placement Warrants, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination.&#160;<ix:nonNumeric name="sclx:SaleOfStockDescriptionOfTransactions" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">The stock exchange listing rules require that the Business Combination must be with one or more operating businesses or assets with a fair market value equal to at least 80% of the assets held in the Trust Account (as defined below) (less any deferred underwriting commissions and taxes payable on the interest earned on the Trust Account). The Company will only complete a Business Combination if the post-Business Combination company owns or acquires 50% or more of the issued and outstanding voting securities of the target or otherwise acquires a controlling interest in the target business sufficient for it not to be required to register as an investment company under the Investment Company Act of 1940, as amended (the &#8220;Investment Company Act&#8221;). There is no assurance that the Company will be able to successfully effect a Business Combination.</ix:nonNumeric> </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company will provide the holders of the public shares (the &#8220;Public Shareholders&#8221;) with the opportunity to redeem all or a portion of their public shares upon the completion of the Business Combination, either (i)&#160;in connection with a general meeting called to approve the Business Combination or (ii)&#160;by means of a tender offer. The decision as to whether the Company will seek shareholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The Public Shareholders will be entitled to redeem their Public Shares, equal to the aggregate amount then on deposit in the Trust Account, calculated as of two business days prior to the consummation of the Business Combination (anticipated to be $<ix:nonFraction name="sclx:PricePerPublicShare" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.38</ix:nonFraction>&#160;per Public Share as of the date of this filing), including interest (which interest shall be net of taxes payable), divided by the number of then issued and outstanding public shares, subject to certain limitations as described in the prospectus. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">per-share</div> amount to be distributed to the Public Shareholders who properly redeem their shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriters (as discussed in Note 6). </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company will proceed with a Business Combination only if the Company has net tangible assets of at least $<ix:nonFraction name="us-gaap:OtherIntangibleAssetsNet" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">5,000,001</ix:nonFraction>&#160;and, if the Company seeks shareholder approval, it receives an ordinary resolution under Cayman Islands law approving a Business Combination, which requires the affirmative vote of a majority of the shareholders who attend and vote at a general meeting of the Company. If a shareholder vote is not required and the Company does not decide to hold a shareholder vote for business or other legal reasons, the Company will, pursuant to its Amended and Restated Memorandum and Articles of Association, conduct the redemptions pursuant to the tender offer rules of the Securities and Exchange Commission (&#8220;SEC&#8221;), and file tender offer documents containing substantially the same information as would be included in a proxy statement with the SEC prior to completing a Business Combination. If the Company seeks shareholder approval in connection with a Business Combination, the Company&#8217;s Sponsors have agreed to vote its Founder Shares (as defined in Note 5) and any Public Shares purchased during or after the Initial Public Offering in favor of approving a Business Combination. Additionally, each Public Shareholder may elect to redeem their Public Shares, without voting, and if they do vote, irrespective of whether they vote for or against a proposed Business Combination. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:continuation><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-30 </div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SEPTEMBER&#160;30, 2022 </div></div></div></div><ix:continuation id="TextSelectionAppend_63194060_1" continuedAt="TextSelectionAppend_63194060_2"> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notwithstanding the foregoing, if the Company seeks shareholder approval of the Business Combination and the Company does not conduct redemptions pursuant to the tender offer rules, a Public Shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a &#8220;group&#8221; (as defined under Section&#160;13 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;)), will be restricted from redeeming its shares with respect to more than an aggregate of&#160;<ix:nonFraction name="sclx:PercentageOfPublicShares" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">20</ix:nonFraction>% of the Public Shares without the Company&#8217;s prior written consent. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Sponsors have agreed (a)&#160;to waive their redemption rights with respect to any Founder Shares and Public Shares held by them in connection with the completion of a Business Combination and (b)&#160;not to propose an amendment to the Amended and Restated Memorandum and Articles of Association (i)&#160;to modify the substance or timing of the Company&#8217;s obligation to allow redemption in connection with the Company&#8217;s initial Business Combination or to redeem&#160;<ix:nonFraction name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" contextRef="PAsOn09_30_2022_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMemberusgaapBusinessAcquisitionAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction>% of the Public Shares if the Company does not complete a Business Combination within the Combination Period (as defined below) or (ii)&#160;with respect to any other provision relating to shareholders&#8217; rights or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-initial</div> business combination activity, unless the Company provides the Public Shareholders with the opportunity to redeem their Public Shares upon approval of any such amendment at a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">per-share</div> price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest (which interest shall be net of taxes payable), divided by the number of then issued and outstanding Public Shares. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">If the Company has not completed a Business Combination within the Combination Period and shareholders do not further extend such period, the Company will (i)&#160;cease all operations except for the purpose of winding up, (ii)&#160;as promptly as reasonably possible but not more than ten business days thereafter, redeem&#160;<ix:nonFraction name="sclx:BusinessCombinationRedeemPercentage" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction>% of the Public Shares, at a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">per-share</div> price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest (less up to $<ix:nonFraction name="us-gaap:OtherExpenses" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">50,000</ix:nonFraction>&#160;of interest to pay dissolution expenses and which interest shall be net of taxes payable), divided by the number of then issued and outstanding Public Shares, which redemption will completely extinguish the rights of the Public Shareholders as shareholders (including the right to receive further liquidating distributions, if any), and (iii)&#160;as promptly as reasonably possible following such redemption, subject to the approval of the Company&#8217;s remaining Public Shareholders and its Board of Directors, liquidate and dissolve, subject in each case to the Company&#8217;s obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law. There will be no redemption rights or liquidating distributions with respect to the Company&#8217;s warrants, which will expire worthless if the Company fails to complete a Business Combination within the Combination Period. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Sponsors have agreed to waive their rights to liquidating distributions from the Trust Account with respect to the Founder Shares if the Company fails to complete a Business Combination within the Combination Period. However, if the Sponsors or any of their respective affiliates acquire Public Shares, such Public Shares will be entitled to liquidating distributions from the Trust Account if the Company fails to complete a Business Combination within the Combination Period. The underwriters have agreed to waive their rights to their deferred underwriting commission (see Note 6) held in the Trust Account in the event the Company does not complete a Business Combination within the Combination Period, and in such event, such amounts will be included with the other funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the assets remaining available for distribution will be less than the amount of funds deposited into the Trust Account ($<ix:nonFraction name="sclx:DepositIntoTheTrustAccountPerShare" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.38</ix:nonFraction>&#160;per share). </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In order to protect the amounts held in the Trust Account, the Sponsors have agreed that it will be liable to the Company if and to the extent any claims by a third party (other than the Company&#8217;s independent registered public accounting firm) for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:continuation><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-31 </div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div></div></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SEPTEMBER&#160;30, 2022 </div></div></div><ix:continuation id="TextSelectionAppend_63194060_2" continuedAt="TextSelectionAppend_63194060_3"> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Trust Account to below (1) $<ix:nonFraction name="sclx:LesserPublicPerShare" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.10</ix:nonFraction>&#160;per Public Share or (2)&#160;such lesser amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account due to reductions in the value of trust assets, in each case net of the interest which may be withdrawn to pay taxes, except as to any claims by a third party who executed a waiver of any and all rights to seek access to the Trust Account and except as to any claims under the Company&#8217;s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). In the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsors will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsors will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (other than the Company&#8217;s independent registered public accounting firm), prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On June&#160;30, 2022, the Company held an extraordinary general meeting of its shareholders (the &#8220;Meeting&#8221;), to amend the Company&#8217;s Amended and Restated Memorandum and Articles of Association (the &#8220;Extension Amendment&#8221;) to (i)&#160;extend the date by which the Company has to consummate an initial business combination from July&#160;11, 2022 (the &#8220;Original Termination Date&#8221;) to August&#160;11, 2022 (the &#8220;Extended Date&#8221;) and (ii)&#160;allow the Company without another shareholder vote, to elect to extend the date to consummate a business combination on a monthly basis for up to five times by an additional one month each time after the Extended Date, upon five days&#8217; advance notice prior to the applicable deadlines, until January&#160;11, 2023 or a total of up to nine months after the Original Termination Date (the &#8220;Extension Proposal&#8221;). The Company&#8217;s shareholders approved the Extension Amendment at the Meeting. On July&#160;5, 2022, the Company filed the Extension Amendment with the Cayman Islands Registrar of Companies. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="us-gaap:BusinessCombinationAcquiredReceivablesDescription" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">In connection with its solicitation of proxies in connection with the Extension Proposal, the Company was required to permit its public shareholders to redeem their ordinary shares. Of the 13,800,000 ordinary shares outstanding with redemption rights, the holders of 4,073,605 ordinary shares elected to redeem their shares at a per share redemption price of $10.25. As a result, approximately $41.8 million was removed from the Trust Account to pay such holders and approximately $99.8 million remained in the Trust Account. Following the redemptions, the Company has 9,726,395 ordinary shares with redemption rights outstanding and the Company will deposit $323,888 (or approximately $0.0333 per ordinary share that remains outstanding) for each calendar month, or portion thereof, that is needed by the Company to complete an initial business combination from July 11, 2022.</ix:nonNumeric></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has deposited an aggregate of $<ix:nonFraction name="us-gaap:AssetsHeldInTrust" contextRef="PAsOn11_11_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,295,556</ix:nonFraction>&#160;into the Trust Account to extend the date to consummate a business combination to November&#160;11, 2022 (the &#8220;Combination Period&#8221;). </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Going Concern and Liquidity </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of September&#160;30, 2022, the Company had $<ix:nonFraction name="us-gaap:RestrictedCashCurrent" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">34,961</ix:nonFraction>&#160;in its operating bank accounts, and working capital deficit of $<ix:nonFraction name="sclx:WorkingCapital" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">643,543</ix:nonFraction>. As of September&#160;30, 2022, approximately $<ix:nonFraction name="us-gaap:InterestIncomeDepositWithFinancialInstitutionIncreaseDecrease" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">696,000</ix:nonFraction>&#160;of the amount on deposit in the Trust Account represented interest income, which is available to pay the Company&#8217;s tax obligations. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If the Company is unable to raise additional capital, it may be required to take additional measures to conserve liquidity, which could include, but not necessarily be limited to, suspending the pursuit of a Business Combination. The Company cannot provide any assurance that new financing will be available to it on commercially acceptable terms, if at all. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </ix:continuation><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-32 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SEPTEMBER&#160;30, 2022 </div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelectionAppend_63194060_3"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;">As a result of the above, in connection with the Company&#8217;s assessment of going concern considerations in accordance with Financial Accounting Standard Board&#8217;s Accounting Standards Codification Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">205-40,</div> &#8220;Presentation of Financial Statements &#8212; Going Concern,&#8221; management has determined that the liquidity condition and date for mandatory liquidation and dissolution raise substantial doubt about the Company&#8217;s ability to continue as a going concern through November&#160;11, 2022 (extension date), the scheduled liquidation date of the Company if it does not complete a Business Combination prior to such date. These condensed consolidated financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If the Company is unable to raise additional capital, it may be required to take additional measures to conserve liquidity, which could include, but not necessarily be limited to, suspending the pursuit of a Business Combination. The Company cannot provide any assurance that new financing will be available to it on commercially acceptable terms, if at all. </div></div> </ix:continuation> <ix:nonNumeric name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_63194098"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </div></div></div> <ix:nonNumeric name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) for interim financial information and in accordance with the instructions to Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</div> and Article 8 of Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-X</div> of the SEC. Certain information or footnote disclosures normally included in condensed financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the Company&#8217;s Annual Report on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Form&#160;10-K</div> as filed with the SEC on February&#160;24, 2022. The interim results for the three and nine months ended September&#160;30, 2022 are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2022 or for any future periods. </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:ConsolidationPolicyTextBlock" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Principles of Consolidation </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All significant intercompany balances and transactions have been eliminated in consolidation. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_63193991"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Emerging Growth Company </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is an &#8220;emerging growth company,&#8221; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced </div></div></ix:nonNumeric> </ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-33 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SEPTEMBER&#160;30, 2022 </div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelection_63194098" continuedAt="TextSelectionAppend_63194098_1"><ix:continuation id="TextSelection_63193991"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Further, Section&#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-emerging</div> growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&#8217;s financial statement with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. </div> </ix:continuation> <ix:nonNumeric name="us-gaap:UseOfEstimates" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of the condensed consolidated financial statements in conformity with GAAP requires the Company&#8217;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the condensed consolidated financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. One of the more significant accounting estimates included in these condensed consolidated financial statements is the determination of the fair value of the warrant liabilities. Such estimates may be subject to change as more current information because available and accordingly, the actual results could differ significantly from those estimates. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cash and Cash Equivalents </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of September&#160;30, 2022 and December&#160;31, 2021. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:EquityMethodInvestmentsPolicy" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Investments Held in Trust Account </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At September&#160;30, 2022 and December&#160;31, 2021, the majority of the assets held in the Trust Account were held in money market funds, which are invested primarily in U.S. Treasury securities. The Company presents its investments in money market funds on the condensed consolidated balance sheets at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of these securities is included in interest income in the accompanying unaudited condensed consolidated statements of operations. The estimated fair value of investments held in the Trust Account are determined using available market information. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric> </ix:continuation> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-34 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SEPTEMBER&#160;30, 2022 </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="display:inline;"><ix:continuation id="TextSelectionAppend_63194098_1" continuedAt="TextSelectionAppend_63194098_2"><ix:nonNumeric name="us-gaap:DeferredChargesPolicyTextBlock" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Offering Costs </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Offering costs consist of legal, accounting, underwriting fees and other costs incurred through the balance sheet date that are directly related to the Initial Public Offering. Offering costs were allocated to the separable financial instruments issued in the Initial Public Offering based on a relative fair value basis, compared to total proceeds received. Offering costs allocated to warrant liabilities were expensed as incurred in the statements of operations. Offering costs associated with the ordinary shares issued were initially charged to temporary equity and then accreted to ordinary shares subject to redemption upon the completion of the Initial Public Offering. Offering costs amounting to $<ix:nonFraction name="us-gaap:OtherDeferredCostsNet" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">8,119,261</ix:nonFraction>&#160;were charged to temporary equity upon the completion of the Initial Public Offering, and $<ix:nonFraction name="us-gaap:OtherDeferredCostsNet" contextRef="PAsOn09_30_2022_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">30,212</ix:nonFraction>&#160;of the offering costs were related to the warrant liabilities and charged to the condensed consolidated statement of operations for the period ended September&#160;30, 2021. The Company classifies deferred underwriting commissions as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> liabilities as their liquidation is not reasonably expected to require the use of current assets or require the creation of current liabilities. </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_63195167"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Ordinary Shares Subject to Possible Redemption </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for its ordinary shares subject to possible redemption in accordance with the guidance in Accounting Standards Codification (&#8220;ASC&#8221;) Topic 480 &#8220;Distinguishing Liabilities from Equity.&#8221; Ordinary shares subject to mandatory redemption is classified as a liability instrument and is measured at fair value. Conditionally redeemable ordinary shares (including ordinary shares that features redemption rights that is either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#8217;s control) is classified as temporary equity. At all other times, ordinary shares are classified as shareholders&#8217; equity. The Company&#8217;s ordinary shares features certain redemption rights that are considered to be outside of the Company&#8217;s control and subject to occurrence of uncertain future events. Accordingly, at September&#160;30, 2022 and December&#160;31, 2021, ordinary shares subject to possible redemption is presented as temporary equity, outside of the shareholders&#8217; deficit section of the Company&#8217;s condensed consolidated balance sheets. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Under ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">480-10-S99,</div></div> the Company has elected to recognize changes in the redemption value immediately as they occur and adjust the carrying value of redeemable ordinary shares to equal the redemption value at the end of each reporting period. This method would view the end of the reporting period as if it were also the redemption date for the security. Immediately upon the closing of the Initial Public Offering, the Company recognized the accretion from initial book value to redemption amount value. The change in the carrying value of redeemable ordinary shares resulted in charges against additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital and accumulated deficit. </div></div></ix:nonNumeric> </ix:continuation></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-35 </div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SEPTEMBER&#160;30, 2022 </div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="display:inline;"><ix:continuation id="TextSelection_63195167"><ix:continuation id="TextSelectionAppend_63194098_2" continuedAt="TextSelectionAppend_63194098_3"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At September&#160;30, 2022 and December&#160;31, 2021, the ordinary shares reflected in the condensed consolidated balance sheets are reconciled in the following table: </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:nonNumeric name="srt:ScheduleOfCondensedBalanceSheetTableTextBlock" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" escape="true">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 77%; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross proceeds</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:GrossProceeds" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">138,000,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ordinary shares issuance costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="sclx:OrdinarySharesIssuanceCost" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">8,119,261</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Plus:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accretion of carrying value to redemption value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:AccretionOfCarryingValueToRedemptionValue" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">9,499,261</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ordinary shares subject to possible redemption as of December&#160;31, 2021</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="sclx:SharesSubjectToPossibleRedemption" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">139,380,000</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Mandatorily redeemable ordinary shares</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:TemporaryEquityOtherChanges" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">41,824,292</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Plus:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accretion of carrying value to redemption value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:AccretionOfCarryingValueToRedemptionValue" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">3,737,378</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ordinary shares subject to possible redemption as of September&#160;30, 2022</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="sclx:SharesSubjectToPossibleRedemption" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">101,293,086</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric></ix:continuation></ix:continuation></div><div style="display:inline;"><ix:continuation id="TextSelectionAppend_63194098_3" continuedAt="TextSelectionAppend_63194098_4"><ix:nonNumeric name="us-gaap:DerivativesPolicyTextBlock" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Warrant Liability </div></div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 480, Distinguishing Liabilities from Equity (&#8220;ASC 480&#8221;) and ASC 815,&#160;Derivatives and Hedging&#160;(&#8220;ASC 815&#8221;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company&#8217;s own ordinary shares, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. We account for the warrants issued in connection with our Initial Public Offering in accordance with the guidance contained in ASC 815 under which the public warrants meet the criteria for equity treatment and the private warrants do not meet the criteria for equity treatment and must be recorded as liabilities. Accordingly, we classify the private warrants as liabilities at their fair value and adjust the private warrants to fair value at each reporting period. This liability is subject to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-measurement</div> at each balance sheet date until exercised, and any change in fair value is recognized in our statement of operations. The fair value of the warrants was estimated using a Black-Scholes option pricing formula. </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_63195169"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes </div></div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for income taxes under ASC Topic 740, &#8220;Income Taxes,&#8221; which prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company&#8217;s management determined that the Cayman Islands is the Company&#8217;s major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. As of September&#160;30, 2022 and December&#160;31, 2021, there were no unrecognized tax benefits and no amounts accrued for interest and penalties. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. </div></div></div></ix:nonNumeric> </ix:continuation></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-36 </div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SEPTEMBER&#160;30, 2022 </div></div></div></div><div style="display:inline;"><ix:continuation id="TextSelectionAppend_63194098_4" continuedAt="TextSelectionAppend_63194098_5"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><ix:continuation id="TextSelection_63195169"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is considered to be an exempted Cayman Islands company with no connection to any other taxable jurisdiction and is presently not subject to income taxes or income tax filing requirements in the Cayman Islands or the United States. As such, the Company&#8217;s tax provision was zero for the periods presented. </div></div></div></ix:continuation><ix:nonNumeric name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Net Income (Loss) per Ordinary Share </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, &#8220;Earnings Per Share&#8221;. Net income (loss) per ordinary share is computed by dividing net income (loss) by the weighted average number of ordinary shares outstanding for the period. Accretion associated with the redeemable shares of ordinary shares is excluded from earnings per share as the redemption value approximates fair value. Mandatorily redeemable ordinary shares are excluded from the weighted average number of ordinary shares outstanding. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The calculation of diluted income (loss) per share does not consider the effect of the warrants issued in connection with the (i)&#160;Initial Public Offering, and (ii)&#160;the private placement since the exercise of the warrants is contingent upon the occurrence of future events. The warrants are exercisable to purchase&#160;<ix:nonFraction name="us-gaap:ExcessStockSharesIssued" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">13,740,000</ix:nonFraction>&#160;ordinary shares in the aggregate. As of September&#160;30, 2022 and 2021, the Company did not have any dilutive securities or </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">other contracts that could, potentially, be exercised or converted into ordinary shares and then share in the earnings of the Company. As a result, diluted net income (loss) per ordinary share is the same as basic net income (loss) per ordinary share for the periods presented. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table reflects the calculation of basic and diluted net income (loss) per ordinary share (in dollars, except per share amounts): </div></div><ix:nonNumeric name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" escape="true"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 48%;">&#160;</td>
<td style="width: 4%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="width: 4%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="width: 4%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="width: 4%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For&#160;the&#160;Three&#160;Months&#160;Ended</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the Nine Months Ended</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Ordinary Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basic and diluted net income (loss) per ordinary share</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allocation of net income (loss)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:TemporaryEquityNetIncome" contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">131,387</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:TemporaryEquityNetIncome" contextRef="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">1,444,352</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityNetIncome" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">623,516</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:TemporaryEquityNetIncome" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">349,248</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted weighted average ordinary shares outstanding</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">13,176,395</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">17,250,000</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">15,862,288</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesIssuedBasic" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">16,675,824</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net income (loss) per ordinary share</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">0.01</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">0.08</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.04</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">0.02</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric></ix:nonNumeric><ix:nonNumeric name="us-gaap:ConcentrationRiskCreditRisk" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Concentration of Credit Risk </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times may exceed the Federal Deposit Insurance Corporation coverage limit of $<ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">250,000</ix:nonFraction>. As of September&#160;30, 2022 and December&#160;31, 2021, the Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such account.</div></div></ix:nonNumeric></ix:continuation></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-37 </div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SEPTEMBER&#160;30, 2022 </div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="display:inline;"><ix:continuation id="TextSelectionAppend_63194098_5" continuedAt="TextSelectionAppend_63194098_6"><ix:nonNumeric name="us-gaap:FairValueOfFinancialInstrumentsPolicy" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value of Financial Instruments </div></div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the Company&#8217;s assets and liabilities, which qualify as financial instruments under ASC Topic 820, &#8220;Fair Value Measurement,&#8221; approximates the carrying amounts represented in the accompanying condensed consolidated balance sheets, primarily due to their short-term nature, other than the derivative warrant liability and conversion option liability (Note 9). </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_63195173"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recent Accounting Standards </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In August 2020, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06,</div> Debt &#8212; Debt with Conversion and Other Options (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">470-20)</div> and Derivatives and Hedging &#8212; Contracts in Entity&#8217; Own Equity (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">815-40):</div> Accounting for Convertible Instruments and Contracts in an Entity&#8217; Own Equity (&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06&#8221;),</div> which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU also removes certain settlement conditions that are required for equity-linked contracts to qualify for the derivative scope exception, and it simplifies the diluted earnings per share calculation in certain areas. Management is currently evaluating the new guidance but does not expect the adoption of this guidance to have a material impact on the Company&#8217;s condensed consolidated financial statements. <br/></div></ix:nonNumeric> </ix:continuation></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="font-size: 10pt; letter-spacing: 0px;;display:inline;"></div> <ix:continuation id="TextSelectionAppend_63194098_6"><ix:continuation id="TextSelection_63195173"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 10pt; letter-spacing: 0px;;display:inline;">Management does not believe that any other recently issued, but not yet effective, accounting standard if currently adopted would have a material effect on the accompanying condensed consolidated financial statements.</div></div></ix:continuation></ix:continuation> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <ix:nonNumeric name="sclx:ProposedPublicOfferingTextBlock" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 3. PUBLIC OFFERING </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Pursuant to the Initial Public Offering, the Company sold to&#160;<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="P01_01_2022To09_30_2022_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">13,800,000</ix:nonFraction>&#160;Units which includes a full exercise by the underwriters of their over-allotment option in the amount of&#160;<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="P01_01_2022To09_30_2022_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">1,800,000</ix:nonFraction>&#160;Units, at a purchase price of $<ix:nonFraction name="sclx:PurchasePricePerShare" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">10.00</ix:nonFraction> per Unit. <ix:nonNumeric name="us-gaap:SaleOfStockDescriptionOfTransaction" contextRef="P01_01_2022To09_30_2022_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">Each Unit consists of one ordinary share and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-half</div> of one redeemable warrant (&#8220;Public Warrant&#8221;). Each whole Public Warrant entitles the holder to purchase one ordinary share at an exercise price of $11.50 per whole share (see Note 7).</ix:nonNumeric> </div></ix:nonNumeric> <ix:nonNumeric name="sclx:PrivatePlacementTextBlock" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 4. PRIVATE PLACEMENT </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Simultaneously with the closing of the Initial Public Offering, the Sponsors purchased an aggregate of&#160;<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn09_30_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">6,840,000</ix:nonFraction> Private Placement Warrants at a price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn09_30_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.75</ix:nonFraction>&#160;per Private Placement Warrant, for an aggregate purchase price of $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="P01_01_2022To09_30_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">5,130,000</ix:nonFraction>, in a private placement. Each Private Placement Warrant is exercisable to purchase one ordinary share at a price of $<ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="PAsOn09_30_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">11.50</ix:nonFraction>&#160;per share, subject to adjustment (see Note 7). A portion of the proceeds from the Private Placement Warrants were added to the proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the proceeds from the sale of the Private Placement Warrants will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law) and the Private Placement Warrants will expire worthless. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_63195179"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 5. RELATED PARTY TRANSACTIONS </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Founder Shares </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On July&#160;16, 2020, the Company issued an aggregate of&#160;<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P07_02_2020To07_16_2020_FounderSharesMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">3,593,750</ix:nonFraction>&#160;ordinary shares to an affiliate of the Sponsors for an aggregate purchase price of $<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="P07_02_2020To07_16_2020_FounderSharesMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">25,000</ix:nonFraction>. In August 2020, the affiliate transferred his Founder Shares to the Sponsors for the same price paid for such shares. On October 8. 2020, the Company effected a share<br/></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></ix:nonNumeric> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-38 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SEPTEMBER&#160;30, 2022 </div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><ix:continuation id="TextSelection_63195179" continuedAt="TextSelectionAppend_63195179_1"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">capitalization<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">of </div><ix:nonFraction name="sclx:CapitalizationOfShareOutstanding" contextRef="P10_01_2020To10_08_2020_FounderSharesMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="1" scale="0" format="ixt:num-dot-decimal">0.2</ix:nonFraction>&#160;<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">shares for each share outstanding, on December&#160;7, 2020, the Sponsors forfeited </div><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" contextRef="P12_01_2020To12_07_2020_FounderSharesMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">1,437,500</ix:nonFraction> <div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ordinary shares, which were cancelled by the Company, and on January&#160;6, 2021, the Company effected a share capitalization of&#160;</div><ix:nonFraction name="sclx:CapitalizationOfShareOutstanding" contextRef="P01_03_2021To01_06_2021_FounderSharesMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="1" scale="0" format="ixt:num-dot-decimal">0.2</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;shares for each share outstanding, resulting in&#160;</div><ix:nonFraction name="sclx:OrdinarySharesIssuedAndOutstanding" contextRef="P01_03_2021To01_06_2021_FounderSharesMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">3,450,000</ix:nonFraction>&#160;<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ordinary shares issued and outstanding (the &#8220;Founder Shares&#8221;). All share and </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">per-share</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> amounts have been retroactively restated to reflect the share transactions. The Founder Shares included an aggregate of up to&#160;</div><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" contextRef="P01_01_2022To09_30_2022_FounderSharesMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">450,000</ix:nonFraction>&#160;<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">shares that were subject to forfeiture depending on the extent to which the underwriters&#8217; over-allotment option is exercised, so that the number of Founder Shares will equal, on an </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">as-converted</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> basis, approximately&#160;</div><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="PAsOn09_30_2022_FounderSharesMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">20</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the Company&#8217;s issued and outstanding ordinary shares after the Initial Public Offering. As a result of the underwriters&#8217; election to partially exercise their over-allotment option, no Founder Shares are currently subject to forfeiture.</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Sponsors have agreed, subject to limited exceptions, not to transfer, assign or sell any of its Founder Shares until six months after the consummation of a Business Combination or earlier if, subsequent to a Business Combination, the Company consummates a liquidation, merger, share exchange or other similar transaction that results in all of the Public Shareholders having the right to exchange their ordinary shares for cash, securities or other property. </div><br/></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Advances from Related Party </div></div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">During 2020, an affiliate of the Sponsors advanced the Company an aggregate of $<ix:nonFraction name="us-gaap:CostsAndExpensesRelatedParty" contextRef="P12_01_2020To12_31_2020_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">30,000</ix:nonFraction>&#160;to fund expenses in connection with the Initial Public Offering. The advances were <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest</div> bearing and payable upon demand. Such advances were repaid in connection with the closing of the Initial Public Offering. Accordingly, as of September&#160;30, 2022 and December&#160;31, 2021, there were no advances outstanding. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Promissory Note &#8212; Related Party </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On July&#160;16, 2020, the Company issued an unsecured promissory note (the &#8220;Promissory Note&#8221;) to an affiliate of the Sponsors, pursuant to which the Company may borrow up to an aggregate principal amount of $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn07_16_2020_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">125,000</ix:nonFraction>. The Promissory Note is <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest</div> bearing and payable on the earlier of (i)&#160;December&#160;31, 2020 or (ii)&#160;the completion of the Initial Public Offering. The outstanding balance under the Promissory Note of $<ix:nonFraction name="us-gaap:RepaymentsOfDebt" contextRef="P01_04_2021To01_11_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">125,000</ix:nonFraction>&#160;was repaid subsequent to the closing of the Initial Public Offering on January&#160;14, 2021. Borrowings under the Promissory Note are no longer available to the Company. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Related Party Loans </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In order to finance transaction costs in connection with a Business Combination, the Sponsors or an affiliate of the Sponsors, or certain of the Company&#8217;s officers and directors may, but are not obligated to, loan the Company funds as may be required (&#8220;Working Capital Loans&#8221;). Such Working Capital Loans would be evidenced by promissory notes.&#160;<ix:nonNumeric name="us-gaap:BusinessCombinationControlObtainedDescription" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">The notes may be repaid upon completion of a Business Combination, without interest, or, at the lender&#8217;s discretion, up to $1,500,000 of notes may be converted upon completion of a Business Combination into warrants at a price of $0.75 per warrant.</ix:nonNumeric>&#160;Such warrants would be identical to the Private Placement Warrants. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On December&#160;20, 2021, the Company entered issued two convertible promissory notes to the Sponsors to evidence Working Capital Loans pursuant to which the Sponsors agreed to loan the Company up to an aggregate principal amount of $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn12_20_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">500,000</ix:nonFraction>&#160;(the &#8220;Convertible Promissory Notes&#8221;). The Convertible Promissory Notes are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest</div> bearing and payable upon Business Combination. If a Business Combination is not consummated,<br/></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-39 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SEPTEMBER&#160;30, 2022 </div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><ix:continuation id="TextSelectionAppend_63195179_1" continuedAt="TextSelectionAppend_63195179_2"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">the<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Convertible Promissory Notes will not be repaid by the Company and all amounts owed thereunder by the Company will be forgiven except to the extent that the Company has funds available to it outside of its Trust Account. Up to $</div><ix:nonFraction name="us-gaap:ConvertibleDebt" contextRef="PAsOn12_20_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">500,000</ix:nonFraction>&#160;<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">of the Convertible Promissory Notes may be converted into warrants at a price of $</div><ix:nonFraction name="sclx:WarrantsExercisePrice" contextRef="P12_01_2021To12_20_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.75</ix:nonFraction>&#160;<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">per warrant at the option of the Sponsors. The warrants would be identical to the Private Placement Warrants.</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On January&#160;10, 2022, the Company borrowed an additional $<ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn01_10_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,035,000</ix:nonFraction>, as discussed below. On January&#160;27, 2022, Company entered into two additional Convertible Promissory Notes with the Sponsors pursuant to which the Sponsors agreed to loan the Company up to an aggregate principal amount of $<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" contextRef="P01_01_2022To01_27_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">500,000</ix:nonFraction>. As of September&#160;30, 2022 and December&#160;31, 2021, the principal balance of the Convertible Promissory Notes amounted to an aggregate of $<ix:nonFraction name="sclx:aggregatePurchasePrice" contextRef="P01_01_2022To09_30_2022_ConvertiblePromisoryNoteMemberusgaapShortTermDebtTypeAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">2,035,000</ix:nonFraction>&#160;and $<ix:nonFraction name="sclx:aggregatePurchasePrice" contextRef="P01_01_2021To12_31_2021_ConvertiblePromisoryNoteMemberusgaapShortTermDebtTypeAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">500,000</ix:nonFraction>, respectively. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company assessed the provisions of the Convertible Promissory Notes under ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">470-20.</div> The derivative component of the obligation is initially valued and classified as a derivative liability (see Note 9). </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The debt discount is being amortized to interest expense as a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> charge over the term of the Convertible Promissory Notes, which is assumed to mature in at Business Combination. During the three and nine months<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ended September&#160;30, 2022, the Company recorded $</div><ix:nonFraction name="us-gaap:InterestExpenseRelatedParty" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,155</ix:nonFraction>&#160;<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">and $</div><ix:nonFraction name="us-gaap:InterestExpenseRelatedParty" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">16,901</ix:nonFraction>&#160;<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">of interest expense related to the amortization of the debt discount. The remaining balance of the debt discount at September&#160;30, 2022 and December&#160;31, 2021 amounted to $</div><ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">0 </ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">and $</div><ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">16,901</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, respectively.</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On April&#160;11, 2022, the Company entered into two simple promissory notes with the Sponsors pursuant to which the Sponsors agreed to loan the Company up to an aggregate principal amount of $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn04_11_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,500,000</ix:nonFraction>&#160;(the &#8220;Simple Promissory Notes&#8221;). The Simple Promissory Notes are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest</div> bearing and payable upon Business Combination. If a Business Combination is not consummated, the Simple Promissory Notes will not be repaid by the Company and all amounts owed thereunder by the Company will be forgiven except to the extent that the Company has funds available to it outside of its Trust Account. On April&#160;18, 2022, the Company entered into two additional Simple Promissory Notes with the Sponsor pursuant to which the Sponsor agreed to loan the Company up to an aggregate principal amount of $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn04_18_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">500,000</ix:nonFraction>. As of September&#160;30, 2022 and December&#160;31, 2021, the principal balance of the Simple Promissory Notes amounted to an aggregate of $<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">2,971,667</ix:nonFraction>&#160;and $<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">0</ix:nonFraction>, respectively. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Related Party Extension Loans </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As discussed in Note 1, the Company may extend the period of time to consummate a Business Combination by an additional three months.&#160;<ix:nonNumeric name="us-gaap:RelatedPartyTransactionDescriptionOfTransaction" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">In order to extend the time available for the Company to consummate a Business Combination, the Sponsor or its affiliates or designees must deposit into the Trust Account $<ix:nonFraction name="sclx:DepositedInTrustAccount" contextRef="P01_10_2022To01_10_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,035,000</ix:nonFraction> ($0.075 per Public Share in either case), on or prior to the date of the applicable deadline, for each three-month extension.</ix:nonNumeric>, </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On January&#160;10, 2022, the Company extended the period of time to consummate a Business Combination to April&#160;11, 2022. The Sponsors deposited $<ix:nonFraction name="sclx:DepositedInTrustAccount" contextRef="P04_11_2022To07_11_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,035,000</ix:nonFraction>&#160;into the Trust Account made in the form of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest-bearing</div> loans. If the Company completes an initial business combination, the Company will, at the option of the Sponsors, repay the amounts evidenced by the Convertible Promissory Notes or convert a portion or all of the total amount into warrants at a price of $<ix:nonFraction name="sclx:WarrantsExercisePrice" contextRef="P04_01_2022To04_01_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.75</ix:nonFraction>&#160;per warrant, which warrants are identical to the Private Placement Warrants issued. If a Business Combination is not consummated, the Convertible Promissory Notes will not be repaid by the Company and all amounts owed thereunder by the Company will be forgiven except to the extent that the Company has funds available to it outside of its Trust Account. <br/></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-40 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SEPTEMBER&#160;30, 2022 </div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><ix:continuation id="TextSelectionAppend_63195179_2" continuedAt="TextSelectionAppend_63195179_3"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">April&#160;11, 2022, the Company extended the period of time to consummate a Business Combination to July&#160;11, 2022. The Sponsors deposited $</div><ix:nonFraction name="sclx:DepositedInTrustAccount" contextRef="P07_11_2022To07_11_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,035,000</ix:nonFraction>&#160;<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">into the Trust Account made in the form of </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest-bearing</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> loans. If the Company completes an initial business combination, the Company will, at the option of the Sponsors, repay the amounts evidenced by simple promissory notes. If a Business Combination is not consummated, the simple promissory notes will not be repaid by the Company and all amounts owed thereunder by the Company will be forgiven except to the extent that the Company has funds available to it outside of its Trust Account.</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On July&#160;11, 2022, the Company extended the period of time to consummate a Business Combination to August&#160;11, 2022. The Sponsors deposited $<ix:nonFraction name="sclx:DepositedInTrustAccount" contextRef="P08_01_2022To08_11_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">323,889</ix:nonFraction>&#160;into the Trust Account made in the form of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest-bearing</div> loans. If the Company completes an initial business combination, the Company will, at the option of the Sponsors, repay the amounts evidenced by simple promissory notes. If a Business Combination is not consummated, the simple promissory notes will not be repaid by the Company and all amounts owed thereunder by the Company will be forgiven except to the extent that the Company has funds available to it outside of its Trust Account. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&#160;10, 2022, the Company extended the period of time to consummate a Business Combination to&#160;September&#160;11, 2022. The Sponsors deposited $<ix:nonFraction name="sclx:DepositedInTrustAccount" contextRef="P08_10_2022To09_11_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">323,889</ix:nonFraction>&#160;into the Trust Account made in the form of non-interest-bearing loans. If the Company completes an initial business combination, the Company will, at the option of the Sponsors, repay the amounts evidenced by simple promissory notes. If a Business Combination is not consummated, the simple promissory notes will not be repaid by the Company and all amounts owed thereunder by the Company will be forgiven except to the extent that the Company has funds available to it outside of its Trust Account. </div> </ix:continuation><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div> </div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div> </div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_63195179_3"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On</div></div><div style="font-size: 10pt; text-align: center; letter-spacing: 0px; top: 0px;;display:inline;">&#160;September&#160;9, 2022, the Company extended the period of time to consummate a Business Combination to October&#160;11, 2022. The Sponsors deposited $</div><ix:nonFraction name="sclx:DepositedInTrustAccount" contextRef="P09_09_2022To09_09_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">323,889</ix:nonFraction><div style="font-size: 10pt; text-align: center; letter-spacing: 0px; top: 0px;;display:inline;">&#160;into the Trust Account made in the form of </div><div style="font-size: 10pt; text-align: center; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest-bearing</div><div style="font-size: 10pt; text-align: center; letter-spacing: 0px; top: 0px;;display:inline;"> loans. If the Company completes an initial business combination, the Company will, at the option of the Sponsors, repay the amounts evidenced by simple promissory notes. If a Business Combination is not consummated, the simple promissory notes will not be repaid by the Company and all amounts owed thereunder by the Company will be forgiven except to the extent that the Company has funds available to it outside of its Trust Account.</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On October&#160;10, 2022, the Company extended the period of time to consummate a Business Combination to November&#160;11, 2022. The Sponsors deposited $<ix:nonFraction name="sclx:DepositedInTrustAccount" contextRef="P10_10_2022To10_10_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">323,889</ix:nonFraction>&#160;into the Trust Account made in the form of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest-bearing</div> loans. If the Company completes an initial business combination, the Company will, at the option of the Sponsors, repay the amounts evidenced by simple promissory notes. If a Business Combination is not consummated, the simple promissory notes will not be repaid by the Company and all amounts owed thereunder by the Company will be forgiven except to the extent that the Company has funds available to it outside of its Trust Account. </div></ix:continuation><ix:nonNumeric name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_63195181"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 6. COMMITMENTS AND CONTINGENCIES </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Risks and Uncertainties </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Management continues to evaluate the impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company&#8217;s financial position, results of its operations and/or search for a target company, the specific impact is not readily determinable as of the date of these condensed consolidated financial statements. The condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. </div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-41 </div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SEPTEMBER&#160;30, 2022 </div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><ix:continuation id="TextSelection_63195181" continuedAt="TextSelectionAppend_63195181_1"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Registration and Shareholder Rights </div></div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to a registration rights agreement entered into on January&#160;6, 2021, the holders of the Founder Shares, Private Placement Warrants and underlying ordinary shares and any securities issued upon conversion of Working Capital Loans will be entitled to registration rights pursuant to a registration rights agreement requiring the Company to register such securities for resale. The holders of these securities will be entitled to demand that the Company register such securities at any time after the Company consummates a Business Combination. In addition, the holders have certain &#8220;piggy-back&#8221; registration rights with respect to registration statements filed subsequent to the consummation of a Business Combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Underwriting Agreement </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="us-gaap:OtherCommitmentsDescription" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">The underwriters are entitled to a deferred fee of (i) 3.5% of the gross proceeds of the initial 12,000,000 Units sold in the Initial Public Offering, or $4,200,000, and (ii) 5.5% of the gross proceeds from the Units sold pursuant to the over-allotment option, or $990,000.</ix:nonNumeric>&#160;The deferred fee will be paid in cash upon the closing of a Business Combination from the amounts held in the Trust Account, subject to the terms of the underwriting agreement. </div><br/></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Business Combination Merger Agreement </div></div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;17, 2022, the Company entered into an agreement and plan of merger (the &#8220;Merger Agreement&#8221;) by and among Scilex Holding Company (&#8220;Scilex&#8221;), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE) (&#8220;Sorrento&#8221;), VCKA, and Vantage Merger Sub Inc., a Delaware corporation and a wholly owned subsidiary of VCKA (&#8220;Merger Sub&#8221;). Parent and Merger Sub are sometimes referred to collectively as the &#8220;Parent Parties.&#8221; Pursuant to the Merger Agreement, VCKA will, prior to the closing of the Merger, migrate to and domesticate as a Delaware corporation in accordance with Section&#160;388 of the Delaware General Corporation Law, as amended and the Cayman Islands Companies Law (the &#8220;Domestication&#8221;). Thereafter, a business combination between VCKA and Scilex will be effected through the merger of Merger Sub with and into Scilex with Scilex surviving the merger as a wholly owned subsidiary of VCKA (the &#8220;Merger&#8221;). Upon the closing of the Merger (the &#8220;Closing&#8221;), it is anticipated that VCKA will change its name to &#8220;Scilex Holding Company&#8221;. The board of directors of VCKA has (i)&#160;approved and declared advisable the Merger Agreement, the Additional Agreements (as defined in the Merger Agreement) and the transactions contemplated thereby and (ii)&#160;resolved to recommend approval of the Merger Agreement and related transactions by the shareholders of VCKA. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">On September&#160;12, 2022, Vickers, Merger Sub and Scilex entered into Amendment No.&#160;1 to the Merger Agreement (the &#8220;Amendment&#8221;). The Amendment amends the Merger Agreement to, among other things, provide that: (i)&#160;the Plan of Domestication attached to the Merger Agreement shall constitute a plan of domestication for purposes of Section&#160;388 of the DGCL and shall include the corporate acts identified therein and any act or transaction contemplated by the Merger Agreement; (ii)&#160;at the Effective Time, each Domesticated Parent Unit shall separate automatically into its component parts, comprised of one share of Domesticated Parent Common Share and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-half</div> of one Domesticated Parent Warrant (provided that no fractional Domesticated Parent Warrants shall be issued and any holder who would be entitled to receive a fractional Domesticated Parent Warrant will have such fraction rounded down to the nearest whole number of Domesticated Parent Warrants); (iii) immediately after Closing, New Scilex&#8217;s board of directors shall consist of seven directors, five of whom will be designated by Scilex (including one director who shall satisfy the independence requirements of the applicable Stock Exchange (which shall be Nasdaq, unless the parties otherwise agree to list on another national securities exchange, which may include the New York Stock Exchange, prior to the Closing)) and two of whom </div></div></ix:continuation><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-42 </div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SEPTEMBER&#160;30, 2022 </div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"></div><ix:continuation id="TextSelectionAppend_63195181_1" continuedAt="TextSelectionAppend_63195181_2"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">will be independent directors to be designated by Scilex and agreed to by Vickers prior to the Closing; (iv)&#160;at the Effective Time, by virtue of the Merger, each share of Series A Preferred Stock of Scilex issued and outstanding immediately prior to the Effective Time shall be canceled and automatically converted into the right to receive, without interest, one Domesticated Parent Preferred Share and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">one-tenth</div> of one Domesticated Parent Common Share; (v)&#160;Vickers shall use its reasonable best efforts to ensure that Vickers remains listed as a public company, and that the Parent Ordinary Shares and public Parent Warrants remain listed on Nasdaq through the Closing and Scilex shall use its reasonable best efforts to prepare and file an initial listing application with the Stock Exchange in connection with the transactions contemplated by the Merger Agreement; (vi)&#160;each party shall use its reasonable best efforts to, among other things, obtain approval for the listing of the Domesticated Parent Common Shares and Domesticated Parent Warrants issued pursuant to the Merger Agreement on the Stock Exchange; (vii)&#160;following the consummation of the Domestication, and the filing of the Parent Certificate of Incorporation, but prior to the Effective Time, Vickers shall file with the Secretary of State of Delaware a certificate of designations, in the form attached to the Merger Agreement as a new Exhibit F, which provides for, among other things, the designations, powers, rights and preferences and qualifications, limitations and restrictions of certain preferred stock of Vickers; (viii)&#160;as a condition of Scilex to the Closing, that the shares of Domesticated Parent Common Shares and Domesticated Parent Warrants shall remain listed on Nasdaq through the Effective Time, the listing application for the listing of the Domesticated Parent Common Shares and Domesticated Parent Warrants following the Effective Time shall have been approved by the applicable Stock Exchange, and, as of the Closing Date, Vickers shall not have received any written notice from Nasdaq of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">non</div></div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">-compliance</div> with Nasdaq&#8217;s applicable continued listing requirements for any reason, where such notice has not been subsequently withdrawn by Nasdaq or the underlying failure appropriately remedied or satisfied; and (ix)&#160;extend the Outside Date to November&#160;11, 2022. The Amendment also sets forth the agreement of Vickers and Scilex to amend the Parent Certificate of Incorporation to increase the number of authorized shares of preferred stock set forth therein from&#160;<ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn09_30_2022_MinimumMembersrtRangeAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">20,000,000</ix:nonFraction>&#160;to&#160;<ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn09_30_2022_MaximumMembersrtRangeAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">45,000,000</ix:nonFraction>&#160;and, as a result, increase the total number of shares of all classes of stock that Vickers shall have authority to issue from&#160;<ix:nonFraction name="us-gaap:PreferredUnitsAuthorized" contextRef="PAsOn09_30_2022_MinimumMembersrtRangeAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">750,000,000</ix:nonFraction>&#160;to&#160;<ix:nonFraction name="us-gaap:PreferredUnitsAuthorized" contextRef="PAsOn09_30_2022_MaximumMembersrtRangeAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">785,000,000</ix:nonFraction>&#160;and, in connection with the Domestication, to name the initial incorporator and initial board of directors of Vickers for the period between the Domestication and the Effective Time. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Merger is expected to be consummated by the fourth quarter of 2022, following the receipt of the required approval by the shareholders of VCKA and Scilex and the satisfaction of certain other customary closing conditions. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Merger Consideration </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><ix:nonNumeric name="sclx:MergerConsiderationDescription" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">The total consideration to be paid to the holders of Scilex common stock at Closing (the &#8220;Merger Consideration&#8221;) by VCKA twill be an amount equal to the quotient of (a) the sum of (i) $1,500,000,000 minus (ii) the aggregate amount of Scilex long term debt excluding intercompany debt owed to Sorrento existing as of immediately prior to the date of the closing of the transaction (the &#8220;Closing Date&#8221;); divided by (b) $10.00, and will be payable in shares of common stock, par value $0.0001 per shares, of VCKA upon its domestication in Delaware (&#8220;VCKA Common Stock&#8221;).</ix:nonNumeric>&#160;The number of shares of VCKA Common Stock to be paid as Merger Consideration will be determined in accordance with the terms of the Business Combination Agreement. In addition, each outstanding share of Scilex Preferred Stock as of immediately prior to the Effective Time of the Business Combination will be cancelled in exchange for the right to receive (a)&#160;<ix:nonFraction name="us-gaap:SharesIssued" contextRef="PAsOn09_30_2022_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction>&#160;share of Series A Preferred Stock of Vickers (following the Domestication), par value $<ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="PAsOn09_30_2022_ScilexCommonStockMemberusgaapRelatedPartyTransactionAxis_SeriesAPreferredStockMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction>&#160;per share (the &#8220;New Scilex Series A Preferred Stock&#8221;), and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(b)&#160;one-tenth</div> of one share of New Scilex Common Stock, and (iii)&#160;each option to purchase Scilex Common Stock that is outstanding as of immediately prior to the Effective Time will be exchanged for a number of options exercisable for newly issued shares of New Scilex Common Stock based upon the Exchange Ratio. The total consideration to be received by holders of Scilex Common Stock and Scilex options at the Closing will be newly issued shares of <br/></div></ix:continuation><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-43 </div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SEPTEMBER&#160;30, 2022 </div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><ix:continuation id="TextSelectionAppend_63195181_2" continuedAt="TextSelectionAppend_63195181_3"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">New</div></div> Scilex Common Stock with an aggregate value equal to $<ix:nonFraction name="sclx:CommonStockAggregateValue" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-8" scale="9" format="ixt:num-dot-decimal">1.5</ix:nonFraction>&#160;billion, subject to adjustments for certain debt obligations of Scilex (the &#8220;Merger Consideration&#8221;).&#160;<ix:nonNumeric name="us-gaap:BusinessCombinationReasonForBusinessCombination" contextRef="P01_01_2022To09_30_2022_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMemberusgaapBusinessAcquisitionAxis_VickersVantageMemberdeiLegalEntityAxis">The maximum number of shares of New Scilex Series A Preferred Stock and New Scilex Common Stock to be issued to the holders of Scilex Preferred Stock at the Closing shall not exceed 31,000,000 and 3,100,000, respectively, such newly issued shares being collectively referred to herein as the &#8220;Preferred Consideration&#8221;. It is anticipated that upon completion of the Business Combination, if none of the 9,726,395 VCKA Ordinary Shares are redeemed, VCKA&#8217;s public shareholders would retain an ownership interest of approximately 5.6% in New Scilex, the Sponsors, officers, directors and other holders of founder shares will retain an ownership interest of approximately 2.2% of New Scilex, and the Scilex stockholders will own approximately (i) 77.2% of New Scilex in the form of New Scilex Common Stock and (ii) 15.0% of New Scilex in the form of New Scilex Series A Preferred Stock.</ix:nonNumeric> </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of the Effective Time, each Scilex stock option that is then outstanding shall be converted into the right to receive an option relating to VCKA Common Stock upon substantially the same terms and conditions as are in effect with respect to such option immediately prior to the Effective Time; provided that the exercise price per share for each such Scilex stock option shall be equal to the exercise price per share of such Scilex stock option in effect immediately prior to the Effective Time, divided by the Exchange Ratio.</div><br/></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Representations and Warranties </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Merger Agreement contains customary representations and warranties of Scilex with respect to, among other things: (i)&#160;corporate existence and power; (ii)&#160;authorization to enter into the Merger Agreement and related transactions; (iii)&#160;governmental authorization; <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(iv)&#160;non-contravention;</div> (v)&#160;capital structure; (vi)&#160;organizational documents; (vii)&#160;assumed names; (viii)&#160;subsidiaries; (ix) financial statements; (x)&#160;absence of certain changes; (xi)&#160;properties and title to assets; (xii)&#160;litigation; (xiii) contracts; (xiv)&#160;licenses and permits; (xv)&#160;compliance with laws; (xvi)&#160;intellectual property; (xvii)&#160;customers and suppliers; (xviii)&#160;employees and employee benefits; (xix)&#160;employment matters; (xx)&#160;withholding; (xxi) real property; (xxii)&#160;tax matters; (xxiii)&#160;environmental laws; (xiv)&#160;finders&#8217; fees; (xv)&#160;directors and officers; (xvi)&#160;certain business practices; (xvii)&#160;international trade matters and anti-bribery compliance; (xviii)&#160;that Scilex is not an investment company; (xvix) compliance with health care laws and certain contracts; (xxx)&#160;insurance; (xxxi)&#160;related party transactions; (xxxii)&#160;privacy and data security and (xxxiii)&#160;exclusivity of representations and warranties. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Merger Agreement contains customary representations and warranties of the Parent Parties with respect to, among other things: (i)&#160;corporate existence and power; (ii)&#160;authorization to enter into the Merger Agreement and related transactions; (iii)&#160;governmental authorization; <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(iv)&#160;non-contravention;</div> (v)&#160;finders&#8217; fees; (vi)&#160;issuance of shares; (vii)&#160;capitalization; (viii) information supplied; (ix)&#160;amount in the trust account; (x)&#160;listing of VCKA securities; (xi)&#160;that VCKA is a reporting company; (xii)&#160;no market manipulation; (xiii)&#160;board approval; (xiv)&#160;SEC documents and financial statements; (xv)&#160;absence of changes; (xvi)&#160;litigation; (xvii) compliance with laws; (xviii)&#160;money laundering laws; (xix)&#160;OFAC; (xx) that VCKA is not an investment company; (xxi)&#160;tax matters; (xxii)&#160;contracts; (xxiii) investigation; and (xiv)&#160;exclusivity of representations and warranties. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">All representations and warranties by all parties shall terminate upon the Effective Time, and no representations, warranties, covenants, obligations or other agreements contained in the Merger Agreement shall survive the Effective Time. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Covenants </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Merger Agreement includes customary covenants of the parties with respect to operation of their respective businesses prior to consummation of the Merger and efforts to satisfy conditions to consummation of the Merger. </div></div></div></ix:continuation><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-44 </div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SEPTEMBER&#160;30, 2022 </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelectionAppend_63195181_3" continuedAt="TextSelectionAppend_63195181_4"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Merger Agreement also contains additional covenants of the parties, including, among others, access to information, cooperation in the preparation of the Registration Statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</div> (the &#8220;Registration Statement&#8221;) and Proxy Statement (as each such term is defined in the Merger Agreement) required to be filed in connection with the Merger and to obtain all requisite approvals of each party&#8217;s respective stockholders. VCKA has also agreed to include in the Proxy Statement the recommendation of its board that its stockholders approve all of the proposals to be presented at the special meeting. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Conduct between Signing and Closing </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Each of VCKA, Merger Sub and Scilex has agreed that from the date of the Merger Agreement until the Closing Date or, if earlier, the valid termination of the Merger Agreement in accordance with its terms, it will not initiate, encourage or engage in any negotiations with any party relating to an Alternative Transaction (as defined in the Merger Agreement), take any action intended to facilitate an Alternative Transaction or approve, recommend or enter into any agreement relating to an Alternative Transaction. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Conditions to Closing </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consummation of the Merger is conditioned upon, among other things, (i)&#160;the absence of any applicable law or order that makes the transactions contemplated by the Merger Agreement illegal or otherwise prohibits consummation of such transactions; (ii)&#160;the Registration Statement shall have become effective under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;); (iii) approval by VCKA&#8217;s shareholders of the Merger and related transactions; (iv)&#160;approval by Scilex&#8217;s stockholders of the Merger and related transactions; and (v)&#160;all required filings under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and with any other governmental authority shall have been completed and cleared. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Solely with respect to the Parent Parties, the consummation of the Merger is conditioned upon, among other things: (i)&#160;Scilex having duly performed or complied with all of its obligations under the Merger Agreement in all material respects; (ii)&#160;the representations and warranties of Scilex being true and correct in all respects unless failure to be true and correct would not have or reasonably be expected to have a Company Material Adverse Effect (as defined in the Merger Agreement) on Scilex&#8217;s ability to consummate the Merger and related transactions; (iii)&#160;no event having occurred that would result in a Company Material Adverse Effect; (iv)&#160;Scilex providing VCKA a certificate from the chief executive officer and chief financial officer of Scilex as to the accuracy of the foregoing conditions; (v)&#160;Scilex providing VCKA a certificate from the secretary which has attached true and complete copies of (a)&#160;Scilex&#8217;s organizational documents, (b)&#160;Scilex&#8217;s board resolutions approving the Merger Agreement and the transactions contemplated thereby, (c)&#160;Scilex&#8217;s stockholder written consent approving the Merger Agreement and the transactions contemplated thereby and (d)&#160;certified certificate of good standing; (vi)&#160;Scilex shall have executed and delivered to VCKA each Additional Agreement to which it is a party; (vi)&#160;Sorrento shall have executed the Registration Rights Agreement (as defined below). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Solely with respect to Scilex, the consummation of the Merger is conditioned upon, among other things: (i)&#160;the Parent Parties having duly performed or complied with all of their obligations under the Merger Agreement in all material respects; (ii)&#160;the representations and warranties of the Parent Parties being true and correct in all respects unless failure to be true and correct would not have or reasonably be expected to have a Parent Material Adverse Effect (as defined in the Merger Agreement) on the ability of VCKA or Merger Sub to consummate the Merger and related transactions; (iii)&#160;no event having occurred that would result in a Parent Material Adverse Effect; (iv)&#160;each of the Parent Parties providing Scilex a certificate from an authorized officer as to the accuracy of the foregoing conditions; (v)&#160;VCKA having been in material compliance with reporting requirements under the Securities Act and the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;); (vi)&#160;each of VCKA </div></div></div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-45 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SEPTEMBER&#160;30, 2022 </div></div></div></div><ix:continuation id="TextSelectionAppend_63195181_4" continuedAt="TextSelectionAppend_63195181_5"> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">the Parent Parties shall have executed and delivered to Scilex each Additional Agreement to which it is a party; (vii)&#160;the directors designated by Scilex shall have been appointed to the board of directors of VCKA in accordance with the terms of the Merger Agreement, effective as of the Closing Date; (viii)&#160;VCKA shall remain listed on Nasdaq and the additional listing application for the VCKA Common Stock issued in connection with the Merger shall have been approved by Nasdaq, and VCKA not having received any written notice from Nasdaq that it has failed, or would reasonably be expected to fail to meet the Nasdaq listing requirements as of the Closing Date for any reason, where such notice has not been subsequently withdrawn by Nasdaq or the underlying failure appropriately remedied or satisfied; (ix)&#160;after giving effect to the Merger, VCKA shall have at least $5,000,001 in net tangible assets (as determined in accordance with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Rule&#160;3a51-1(g)(1)&#160;of</div> the Exchange Act); (x) the Domestication shall have been completed as provided in the Merger Agreement and a time-stamped copy of the certificate issued by the Secretary of State of the State of Delaware in relation thereto shall have been delivered to the Company; and (xi)&#160;the Investment Management Trust Agreement (as defined in the Merger Agreement) shall have been amended solely to the extent necessary to enable the intended effects of the Amended Underwriting Agreement (as defined in the Merger Agreement) without breach of, or other conflict with, the Investment Management Trust Agreement as so amended. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">Scilex</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Scilex Pharmaceuticals, Inc. and Sorrento entered into a Contribution and Satisfaction of Indebtedness Agreement dated September&#160;</div>12<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> (the &#8220;Debt Exchange Agreement&#8221;), in order to facilitate the satisfaction of the closing condition under the Merger Agreement that requires Vickers to have at least $</div><ix:nonFraction name="sclx:NetTangibleAssets" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">5,000,001</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;in net tangible assets (as determined in accordance with Rule </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3a51-1(g)(1)</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> of the United States Securities and Exchange Act of </div>1934)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> (the &#8220;Net Tangible Assets Condition&#8221;).</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Termination </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Merger Agreement may be terminated as follows: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">i.</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">By the mutual consent of VCKA and Scilex; </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">ii.</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">by VCKA, if any of the representations or warranties of Scilex set forth in the Merger Agreement shall not be true and correct, or if Scilex has failed to perform any covenant or agreement set forth in the Merger Agreement (including an obligation to consummate the Merger), in each case such that the conditions to closing would not be satisfied and the breach or breaches causing such representations or warranties not to be true and correct, or the failure to perform any covenant or agreement, as applicable, are not cured (or waived by VCKA) by the earlier of (i)&#160;the Outside Date (as defined below) or (ii) 30 days after written notice thereof is delivered to Scilex; provided, however that VCKA is not then in material breach of any representation, warranty, covenant, or obligation in the Merger Agreement, which breach has not been cured; </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">iii.</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">by Scilex, if any of the representations or warranties of VCKA or Merger Sub set forth in the Merger Agreement shall not be true and correct, or if VCKA or Merger Sub has failed to perform any covenant or agreement set forth in the Merger Agreement (including an obligation to consummate the Merger), in each case such that the conditions to closing would not be satisfied and the breach or breaches causing such representations or warranties not to be true and correct, or the failure to perform any covenant or agreement, as applicable, are not cured (or waived by Scilex) by the earlier of (i)&#160;the Outside Date or (ii) 30 days after written notice thereof is delivered to VCKA; provided, however that Scilex is not then in material breach of any representation, warranty, covenant, or obligation in the Merger Agreement, which breach has not been cured; </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </ix:continuation><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-46 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SEPTEMBER&#160;30, 2022 </div></div></div><br/></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div><ix:continuation id="TextSelectionAppend_63195181_5" continuedAt="TextSelectionAppend_63195181_6"> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 5%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">iv.</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">by either VCKA or Scilex </div></div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">a.</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">on or after November&#160;11, 2022 (the &#8220;Outside Date&#8221;), if the Merger shall not have been consummated prior to the Outside Date; provided that if an Extension Amendment (as defined in the Merger Agreement) shall be in effect, the Outside Date shall be the Extension Date (as defined in the Merger Agreement); provided, however, that the right to terminate this Agreement under Section&#160;9.1(d)(i) of the Merger Agreement shall not be available to a party if the failure of the Merger to have been consummated before the Outside Date (or the Extension Date if applicable) was due to such party&#8217;s breach of or failure to perform any of its covenants or agreements set forth in the Merger Agreement; or </div></div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">b.</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">if any applicable law or order that makes the transactions contemplated by the Merger Agreement illegal or otherwise prohibits consummation of such transactions shall have become final and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-appealable;</div> </div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 5%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">v.</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">by Scilex if VCKA has not received approval from its stockholders of the Merger and related transactions at the Parent Special Meeting (as defined in the Merger Agreement), unless such meeting has been adjourned or postponed, in which case at the final adjournment or postponement thereof; </div></div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 5%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">vi.</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">by VCKA if the Scilex stockholder written consent approving the Merger and related transactions shall not have been obtained within five business days following the Registration Statement being declared effective by the Securities and Exchange Commission (the &#8220;SEC&#8221;), provided that upon Scilex receiving such stockholder approval, prior to the termination by VCKA of the Merger Agreement, VCKA will no longer have this right to so terminate; or </div></div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 5%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">vii.</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">by VCKA, in the event that Scilex&#8217;s audited financial statements for 2020 and 2021 have not been delivered to the Parent Parties on or before March&#160;31, 2022 and remain undelivered prior to the termination of the Merger Agreement </div></div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Sponsor Support Agreement </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Concurrently with the execution of the Merger Agreement, VCKA, Scilex and certain stockholders of VCKA entered into a certain Sponsor Support Agreement dated March&#160;17, 2022 (the &#8220;Sponsor Support Agreement&#8221;) pursuant to which those certain VCKA shareholders who are parties thereto agreed to vote all shares of VCKA Ordinary Shares beneficially owned by them, including any additional shares of VCKA they acquire ownership of or the power to vote, in favor of the Merger and related transactions. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On September&#160;12, 2022, Vickers and Scilex entered into Amendment No.&#160;1 to the Original Support Agreement with the Vickers Shareholders (the &#8220;Support Agreement Amendment&#8221;). The Support Agreement Amendment amends the Original Support Agreement to, among other things, provide that if, as of immediately prior to the Closing, the holders of more than seventy-five percent (<ix:nonFraction name="sclx:AggregatePercentage" contextRef="PAsOn03_17_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">75</ix:nonFraction>%) of the aggregate amount of Parent Ordinary Shares issued and outstanding as of March&#160;17, 2022 shall have exercised redemption rights in conjunction with the shareholder vote on the Extension Amendment or the Parent Shareholder Approval Matters, then automatically and without any further action by any other Person, such Vickers Shareholder shall forfeit a number of Parent Warrants equal to forty percent (<ix:nonFraction name="sclx:WarrantsPercentage" contextRef="PAsOn03_17_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">40</ix:nonFraction>%) of all Parent Warrants held by such Vickers Shareholder immediately prior to Closing, and all such Parent Warrants shall be cancelled and forfeited for no consideration, and shall cease to exist.</div></div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-47 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SEPTEMBER&#160;30, 2022 </div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><ix:continuation id="TextSelectionAppend_63195181_6" continuedAt="TextSelectionAppend_63195181_7"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Company Stockholder Support Agreement </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Concurrently with the execution of the Merger Agreement, VCKA, Scilex and Sorrento entered into a certain Company Stockholder Support Agreement dated March&#160;17, 2022 (the &#8220;Company Stockholder Support Agreements&#8221;), pursuant to which Sorrento agreed to vote all Scilex Common Stock beneficially owned by it, including any additional shares of Scilex it acquires ownership of or the power to vote, in favor of the Merger and related transactions. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">On September&#160;12, 2022, Vickers entered into a Stockholder Agreement with Sorrento (the &#8220;Stockholder Agreement&#8221;). Pursuant to the Stockholder Agreement, from and after the Effective Time, and for so long as Sorrento beneficially owns any shares of Vickers Series A Preferred Stock, par value $<ix:nonFraction name="us-gaap:PreferredStockNoParValue" contextRef="PAsOn09_12_2022_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction>&#160;per share (&#8220;New Scilex Series A Preferred Stock&#8221;), among other things, (i)&#160;Sorrento shall have the right, but not the obligation, to designate each director to be nominated, elected or appointed to the Board of Directors of New Scilex (each, a &#8220;Stockholder Designee&#8221; and collectively, the &#8220;Stockholder Designees&#8221;), regardless of (i)&#160;whether such Stockholder Designee is to be elected to the Board of Directors of New Scilex (&#8220;New Scilex Board&#8221;) at a meeting of stockholders called for the purpose of electing directors (or by consent in lieu of meeting) or appointed by the New Scilex Board in order to fill any vacancy created by the departure of any director or increase in the authorized number of members of the New Scilex Board, or (ii)&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">the size of the New Scilex Board and New Scilex will be required to take all actions reasonably necessary, and not otherwise prohibited by applicable law, to cause each Stockholder Designee to be so nominated, elected or appointed to the New Scilex Board as more fully described in the Stockholder Agreement. Sorrento shall also have the right to designate a replacement director for any Stockholder Designee that has been removed from the New Scilex Board and the right to appoint a representative of Sorrento to attend all meetings of the committees of the New Scilex Board. The Stockholder Agreement also provides that New Scilex will be prohibited from taking certain actions without the consent of Sorrento. Such actions include, among other things, amendments to the certificate of designations designating the New Scilex Series A Preferred Stock, increases or decreases in the size of the New Scilex Board, the incurrence of certain amounts of indebtedness and the payment of dividends on New Scilex Common Stock.&#160;</div> </div><br/></div> </ix:continuation> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div> </div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_63195181_7" continuedAt="TextSelectionAppend_63195181_8"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Underwriting Agreement Amendment </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;17, 2022, VCKA and Maxim Group, LLC, the representative of the underwriters for the VCKA initial public offering (&#8220;Maxim&#8221;) entered into an amendment (the &#8220;UWA Amendment&#8221;) of the underwriting agreement between VCKA and Maxim dated January&#160;6, 2021. The UWA Amendment provides for a potential deferral of the Deferred Underwriting Commission&#160;(as defined in the UWA Amendment) as follows: </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If in connection with the consummation of a business combination, after redemptions of Ordinary Shares by VCKA&#8217;s shareholders, the balance in the trust account is $<ix:nonFraction name="sclx:BalanceInTheTrustAccount" contextRef="PAsOn03_17_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">25,000,000</ix:nonFraction>&#160;or less, then the Deferred Underwriting Commission will be payable as follows: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(A)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="sclx:DeferredUnderwritingCommission" contextRef="P03_17_2022To03_17_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">50</ix:nonFraction>% of the Deferred Underwriting Commission will be payable to Maxim directly from the trust account; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(B)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the remaining&#160;<ix:nonFraction name="sclx:DeferredUnderwritingCommissionPayable" contextRef="P03_17_2022To03_17_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">50</ix:nonFraction>% of the Deferred Underwriting Commission will be payable to Maxim in the form of a Promissory Note on or before the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-year</div> anniversary of the effective date of a Business Combination. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Maxim has also agreed to enter into any such amendment to the Investment Management Trust Agreement (as defined in the Merger Agreement) as may be required to effectuate the intent of the UWA Amendment. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-48 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SEPTEMBER&#160;30, 2022 </div></div></div></div> <ix:continuation id="TextSelectionAppend_63195181_8"> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Agreements to be Executed at Closing </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Merger Agreement contemplates that, at or prior to the Closing, VCKA and Sorrento will enter into an Amended and Restated Registration Rights Agreement (the &#8220;Registration Rights Agreement&#8221;), whereby, subject to certain customary exceptions, the parties will agree, among other things, not to transfer any shares of VCKA Common Stock or any security convertible into or exercisable or exchanged for VCKA Common Stock beneficially owned or owned of record by such holder until the date that is the earlier of (i)&#160;one hundred eighty (180)&#160;days from the date of the Registration Rights Agreement or (ii)&#160;the date on which the Company completes a liquidation, merger, stock exchange, reorganization or other similar transaction that results in all of the Company&#8217;s stockholders having the right to exchange their shares of VCKA Common Stock for cash, securities or other property. The Registration Rights Agreement will govern the registration of certain shares of VCKA Common Stock for resale and be effective as of the Closing. </div></div> </ix:continuation><ix:nonNumeric name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 7. SHAREHOLDERS&#8217; DEFICIT </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Preference Shares</div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#8212;</div></div>&#160;The Company is authorized to issue&#160;<ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">1,000,000</ix:nonFraction></ix:nonFraction>&#160;preference shares with a par value of $<ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction>&#160;per share, with such designations, voting and other rights and preferences as may be determined from time to time by the Company&#8217;s board of directors. At September&#160;30, 2022 and December&#160;31, 2021, there were&#160;<ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>&#160;preference shares issued or outstanding. <br/></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Ordinary Shares</div></div></div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#8212; The Company is authorized to issue&#160;</div><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">200,000,000</ix:nonFraction></ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;ordinary shares with a par value of $</div><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;per share. Holders of ordinary shares are entitled to one vote for each share. At September&#160;30, 2022, there were&#160;</div><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">3,450,000</ix:nonFraction></ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;shares of ordinary shares issued and outstanding, excluding&#160;</div><ix:nonFraction name="sclx:OrdinarySharesSubjectToPossibleRedemption" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">9,726,395</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;ordinary shares subject to possible redemption which are presented as temporary equity. At December&#160;31, 2021, there were&#160;</div><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">3,450,000</ix:nonFraction></ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;shares of ordinary shares issued and outstanding, excluding&#160;</div><ix:nonFraction name="sclx:OrdinarySharesSubjectToPossibleRedemption" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">13,800,000</ix:nonFraction>&#160;<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ordinary shares subject to possible redemption which are presented as temporary equity.</div></div></ix:nonNumeric><ix:nonNumeric name="sclx:WarrantsTextBlock" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_63195183"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 8. WARRANTS </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of September&#160;30, 2022 and December&#160;31, 2021, there were&#160;<ix:nonFraction name="sclx:WarrantsOutstandingShares" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis_WarrantMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="sclx:WarrantsOutstandingShares" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis_WarrantMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">6,900,000</ix:nonFraction></ix:nonFraction>&#160;Public Warrants outstanding. Public Warrants may only be exercised for a whole number of shares. No fractional shares will be issued upon exercise of the Public Warrants. The Public Warrants will become exercisable on the later of (a)&#160;the completion of a Business Combination and (b) 12 months from the closing of the Initial Public Offering. The Public Warrants will expire five years from the completion of a Business Combination or earlier upon redemption or liquidation. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">No Public Warrants will be exercisable for cash unless the Company has an effective and current registration statement covering the issuance of the ordinary shares issuable upon exercise of the warrants and a current prospectus relating to such ordinary shares. Notwithstanding the foregoing, if a registration statement covering the issuance of the ordinary shares issuable upon exercise of the Public Warrants is not effective within 90 days from the closing of a Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company shall have failed to maintain an effective registration statement, exercise warrants on a cashless basis pursuant to an available exemption from registration under the Securities Act. If an exemption from registration is not available, holders will not be able to exercise their warrants on a cashless basis. The Public Warrants will expire five years after the completion of a Business Combination or earlier upon redemption or liquidation. </div></div> <ix:nonNumeric name="sclx:PublicWarrantsRedemptionDescription" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" continuedAt="TextSelection_63194332"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company may redeem the Public Warrants: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">in whole and not in part; </div></div> </td> </tr> </table> </ix:nonNumeric></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-49 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SEPTEMBER&#160;30, 2022 </div></div></div></div> <ix:continuation id="TextSelection_63195183" continuedAt="TextSelectionAppend_63195183_1"><ix:continuation id="TextSelection_63194332"> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8226;</div></td>
<td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">at a price of $0.01 per warrant; </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8226;</div></td>
<td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">at any time while the warrants become exercisable; </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8226;</div></td>
<td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">upon not less than 30 days&#8217; prior written notice of redemption to each warrant holder; </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8226;</div></td>
<td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">if, and only if, the reported last sale price of the Company&#8217;s ordinary shares equals or exceeds $18.00&#160;per share (subject to adjustment) for any 20 trading days within a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-trading</div> day period commencing after the warrants become exercisable and ending on the third trading business day prior to the notice of redemption to the warrant holders; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8226;</div></td>
<td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">if, and only if, there is a current registration statement in effect with respect to the issuance of the ordinary shares underlying such warrants at the time of redemption and for the entire <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-day</div> trading period referred to above and continuing each day thereafter until the date of redemption. </div></div> </td> </tr> </table> </ix:continuation> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If the Company calls the Public Warrants for redemption, management will have the option to require all holders that wish to exercise the Public Warrants to do so on a &#8220;cashless basis,&#8221; as described in the warrant agreement. </div></div></div> <div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The exercise price and number of ordinary shares issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a share dividend, extraordinary dividend or recapitalization, reorganization, merger or consolidation. However, the warrants will not be adjusted for issuance of ordinary shares at a price below its exercise price. The Company has agreed to use its best efforts to have declared effective a prospectus relating to the ordinary shares issuable upon exercise of the warrants and keep such prospectus current until the expiration of the warrants. However, if the Company does not maintain a current prospectus relating to the ordinary shares issuable upon exercise of the warrants, holders will be unable to exercise their warrants for cash and the Company will not be required to net cash settle or cash settle the warrant exercise. There will be no redemption rights upon the completion of a Business Combination with respect to the Company&#8217;s warrants. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company&#8217;s assets held outside of the Trust Account with the respect to such warrants. Accordingly, the warrants may expire worthless. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><ix:nonNumeric name="sclx:CapitalRaisingDescription" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, if (x)&#160;the Company issues additional ordinary shares or equity-linked securities for capital raising purposes in connection with the closing of a Business Combination at an issue price or effective issue price of less than $<div style="letter-spacing: 0px; top: 0px;;display:inline;">9.20 </div>per ordinary share (with such issue price or effective issue price to be determined in good faith by the Company&#8217;s board of directors and, in the case of any such issuance to the Sponsors or its affiliates, without taking into account any Founder Shares held by the Sponsors or such affiliates, as applicable, prior to such issuance) (the &#8220;Newly Issued Price&#8221;), (y) the aggregate gross proceeds from such issuances represent more than <div style="letter-spacing: 0px; top: 0px;;display:inline;">60</div>% of the total equity proceeds, and interest thereon, available for the funding of a Business Combination on the date of the consummation of a Business Combination (net of redemptions), and (z)&#160;the volume weighted average trading price of its ordinary shares during the <div style="letter-spacing: 0px; top: 0px;;display:inline;">20 </div>trading day period starting on the trading day prior to the day on which the Company consummates its Business Combination (such price, the &#8220;Market Value&#8221;) is below $<div style="letter-spacing: 0px; top: 0px;;display:inline;">9.20 </div>per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to <div style="letter-spacing: 0px; top: 0px;;display:inline;">115</div>% of the higher of the Market Value and the Newly Issued Price, the $<div style="letter-spacing: 0px; top: 0px;;display:inline;">18.00 </div>per share redemption trigger price will be adjusted (to the nearest cent) to be equal to <div style="letter-spacing: 0px; top: 0px;;display:inline;">180</div>% of the higher of the Market Value and the Newly Issued Price. </div></div></ix:nonNumeric> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At September&#160;30, 2022 and December&#160;31, 2021, there were&#160;<ix:nonFraction name="sclx:WarrantsOutstandingShares" contextRef="PAsOn12_31_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="sclx:WarrantsOutstandingShares" contextRef="PAsOn09_30_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">6,840,000</ix:nonFraction></ix:nonFraction>&#160;Private Placement Warrants outstanding. The Private Placement Warrants are identical to the Public Warrants underlying the Units sold in the Initial Public Offering, except that the Private Placement Warrants will be exercisable for cash (even if a registration</div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-50 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SEPTEMBER&#160;30, 2022 </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:continuation id="TextSelectionAppend_63195183_1">statement covering the issuance of the ordinary shares issuable upon exercise of such warrants is not effective) or on a cashless basis, at the holder&#8217;s option and will not be redeemable by the Company, in each case so long as they are held by the initial purchasers or their affiliates.</ix:continuation> </div></div></div> <ix:nonNumeric name="us-gaap:FairValueDisclosuresTextBlock" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_63195184"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 9. FAIR VALUE MEASUREMENTS </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the Company&#8217;s financial assets and liabilities reflects management&#8217;s estimate of amounts that the Company would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 10%; vertical-align: top;;text-align:left;">Level&#160;1:</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis. </div></div> </td> </tr> </table> </ix:nonNumeric> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div> </div> </div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="display:inline;"><ix:continuation id="TextSelection_63195184" continuedAt="TextSelectionAppend_63195184_1">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 10%; vertical-align: top;;text-align:left;">Level&#160;2:</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Observable inputs other than Level&#160;1 inputs. Examples of Level&#160;2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active. </div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 10%; vertical-align: top;;text-align:left;">Level&#160;3:</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability. </div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At September&#160;30, 2022 and December&#160;31, 2021, assets held in the Trust Account were comprised of $<ix:nonFraction name="us-gaap:AssetsHeldInTrustCurrent" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">101,293,086</ix:nonFraction>&#160;and $<ix:nonFraction name="us-gaap:AssetsHeldInTrustCurrent" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">139,410,739</ix:nonFraction>, respectively, in money market funds which are invested primarily in U.S. Treasury Securities.&#160;Through September&#160;30, 2022, the Company did not withdraw any interest earned on the Trust Account. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents information about the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis at September&#160;30, 2022 and December&#160;31, 2021 and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:nonNumeric name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" escape="true">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 58%; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Description</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investments held in Trust Account <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div> U.S. Treasury Securities Money Market Fund</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InterestIncomeSecuritiesUSTreasury" contextRef="P01_01_2022To09_30_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">101,293,086</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InterestIncomeSecuritiesUSTreasury" contextRef="P01_01_2021To12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">139,410,739</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Warrant Liability <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div>&#160;Private Placement Warrants</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueAdjustment" contextRef="P01_01_2022To09_30_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,162,800</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueAdjustment" contextRef="P01_01_2021To12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">3,351,600</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Conversion Option Liability (see Note 5)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn09_30_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">6,892</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table></ix:nonNumeric></ix:continuation></div><div style="display:inline;"><ix:continuation id="TextSelectionAppend_63195184_1" continuedAt="TextSelectionAppend_63195184_2"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Private Placement Warrants were accounted for as liabilities in accordance with ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">815-40</div> and are presented within warrant liabilities on our accompanying September&#160;30, 2022 unaudited condensed consolidated balance sheets. The warrant liabilities are measured at fair value at inception and on a recurring basis, with changes in fair value presented within change in fair value of warrant liabilities in the unaudited condensed consolidated statements of operations. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></ix:continuation></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-51 </div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SEPTEMBER&#160;30, 2022 </div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="display:inline;"><ix:continuation id="TextSelectionAppend_63195184_2" continuedAt="TextSelectionAppend_63195184_3"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Warrant Liability Measurement </div></div></div></div></div> <ix:nonNumeric name="us-gaap:FairValueMeasurementsHighestAndBestUseDescription" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company established the initial fair value for the private warrants on January&#160;11, 2021, the date of the Company&#8217;s Initial Public Offering, using a Monte Carlo simulation and subsequently implemented the Black-Scholes Option Pricing Model that was modified to capture the redemption features of the public warrants. The underlying assumptions in the Black-Scholes option pricing model include the underlying share price, risk-free interest rate, estimated volatility and the expected term. The primary unobservable inputs utilized in determining the fair value of the private warrants are the expected volatility of the Company&#8217;s ordinary shares and the Company&#8217;s ordinary share price. The expected volatility of the ordinary shares was determined based on implied volatilities of public warrants issued by selected guideline companies and was estimated to be 10% before the expected business combination and 20% after the expected business combination. The ordinary share price was determined based on an iterative procedure that matched the estimated value of the ordinary shares and fractional warrant price to equate to the observed price of the outstanding units. The risk-free interest rate is based on the U.S. Treasury yield curve in effect on the date of valuation equal to the remaining expected life of the private warrants. The dividend yield percentage is zero because the Company does not currently pay dividends, nor does it intend to do so during the expected term of the warrants. The expected life of the warrants is assumed to be </div>equivalent to their remaining contractual term. Inputs are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-evaluated</div> each quarterly reporting period to estimate the fair market value of the private placement warrants as of the reporting <div style="letter-spacing: 0px; top: 0px;;display:inline;">period</div>. </div></ix:nonNumeric> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There were no transfers between Levels 1, 2 or 3 during the three and nine months ended September&#160;30, 2022 and 2021. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table provides quantitative information regarding Level&#160;3 fair value measurements: </div></div><ix:nonNumeric name="us-gaap:FairValueConcentrationOfRiskTextBlock" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" escape="true"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 65%;">&#160;</td>
<td style="width: 13%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="width: 12%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock price</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.33</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.04</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Strike price</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:FairValueMeasurementStrikePrice" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">11.50</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:FairValueMeasurementStrikePrice" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">11.50</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Term (in years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" format="ixt-sec:duryear">5.00</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" format="ixt-sec:duryear">5.28</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Volatility</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">0.0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">8.3</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">4.03</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">1.28</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dividend yield</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">0.0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">0.0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of warrants</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:FairValueOfWarrantsinDollars" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.17</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:FairValueOfWarrantsinDollars" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.49</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table></ix:nonNumeric></ix:continuation></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-52 </div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SEPTEMBER&#160;30, 2022 </div></div></div></div><div style="display:inline;"><ix:continuation id="TextSelectionAppend_63195184_3" continuedAt="TextSelectionAppend_63195184_4"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents the changes in the fair value of warrant liabilities: </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:nonNumeric name="us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_63195187">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 80%;">&#160;</td>
<td style="width: 7%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Private</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Placement</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value as of January&#160;1, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn12_31_2020_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Initial measurement on January&#160;11, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:InitialMeasurementOne" contextRef="P01_01_2021To03_31_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">7,729,200</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation inputs or other assumptions</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="sclx:ChangeInValuationInputsOrOtherAssumptions" contextRef="P01_01_2021To03_31_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">4,104,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of as of March&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn03_31_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">3,625,200</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation inputs or other assumptions</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:ChangeInValuationInputsOrOtherAssumptions" contextRef="P04_01_2021To06_30_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">68,400</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of as of June&#160;30, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn06_30_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">3,693,600</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation inputs or other assumptions</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:ChangeInValuationInputsOrOtherAssumptions" contextRef="P07_01_2021To09_30_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,162,800</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of as of September&#160;30, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn09_30_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">4,856,400</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation inputs or other assumptions</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="sclx:ChangeInValuationInputsOrOtherAssumptions" contextRef="P10_01_2021To12_31_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">1,504,800</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of as of December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn12_31_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">3,351,600</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation inputs or other assumptions</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:ChangeInValuationInputsOrOtherAssumptions" contextRef="P01_01_2022To03_31_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">410,400</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value as of March&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn03_31_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">3,762,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation inputs or other assumptions</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="sclx:ChangeInValuationInputsOrOtherAssumptions" contextRef="P04_01_2022To06_30_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">2,530,800</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value as of June&#160;30, 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn06_30_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,231,200</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation inputs or other assumptions</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="sclx:ChangeInValuationInputsOrOtherAssumptions" contextRef="P07_01_2022To09_30_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">68,400</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value as of September&#160;30, 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn09_30_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,162,800</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Conversion Option Liability Measurement </div></div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company assessed the provisions of the Convertible Promissory Notes under ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">470-20.</div> The derivative component of the obligation is initially valued and classified as a derivative liability. The conversion option was valued using the compound option pricing model, which is considered to be a Level&#160;3 fair value measurement (See Note 6). </div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:nonNumeric name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" escape="true">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 65%;">&#160;</td>
<td style="width: 12%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="width: 11%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,<br/>2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Underlying warrant value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:UnderlyingWarrantValue" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal">0.0000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:UnderlyingWarrantValue" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal">0.0103</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercise price</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.75</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.75</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Holding period</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:HoldingPeriod" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.50</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:HoldingPeriod" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.28</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">4.03</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">1.28</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Volatility</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">5.3</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">8.3</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dividend yield</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">0.0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">0.0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table></ix:nonNumeric></ix:continuation></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-53 </div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SEPTEMBER&#160;30, 2022 </div></div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="display:inline;"><ix:continuation id="TextSelectionAppend_63195184_4"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents the change in the fair value of conversion option liability: </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><ix:continuation id="TextSelection_63195187">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 83%;">&#160;</td>
<td style="width: 13%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Conversion</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Option</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Liability</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value as of January&#160;1, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn12_31_2020_ConversionOptionLiabilityMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Initial measurement on December&#160;20, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:InitialMeasurementOne" contextRef="P01_01_2021To12_31_2021_ConversionOptionLiabilityMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">18,727</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation inputs or other assumptions</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="sclx:ChangeInValuationInputsOrOtherAssumptions" contextRef="P01_01_2021To12_31_2021_ConversionOptionLiabilityMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">11,835</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of as of December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn12_31_2021_ConversionOptionLiabilityMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">6,892</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Initial measurement on January&#160;10, 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:InitialMeasurementOne" contextRef="P01_01_2022To03_31_2022_ConversionOptionLiabilityMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Initial measurement on January&#160;27, 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:InitialMeasurementOne" contextRef="P01_01_2022To03_31_2022_ConversionOptionLiabilityMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation inputs or other assumptions</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:ChangeInValuationInputsOrOtherAssumptions" contextRef="P01_01_2022To03_31_2022_ConversionOptionLiabilityMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">69,896</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value as of March&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn03_31_2022_ConversionOptionLiabilityMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">76,788</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation inputs or other assumptions</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="sclx:ChangeInValuationInputsOrOtherAssumptions" contextRef="P04_01_2022To09_30_2022_ConversionOptionLiabilityMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">76,788</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value as of June&#160;30, 2022 and September&#160;30, 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn09_30_2022_ConversionOptionLiabilityMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:continuation></ix:continuation></div><div style="display:inline;"><ix:nonNumeric name="us-gaap:SubsequentEventsTextBlock" contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_63195180"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 10. SUBSEQUENT EVENTS </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the unaudited condensed consolidated financial statements were issued. Based upon this review, other than as described below and elsewhere in these unaudited condensed consolidated financial statements, the Company did not identify any subsequent events that would have required adjustment or disclosure in the unaudited condensed consolidated financial statements. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On October&#160;10, 2022, the Company extended the period of time to consummate a Business Combination to November&#160;11, 2022. The Sponsors deposited $<ix:nonFraction name="us-gaap:LeaseDepositLiability" contextRef="PAsOn10_10_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">323,889</ix:nonFraction>&#160;into the Trust Account made in the form of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest-bearing</div> loans. If the Company completes an initial business combination, the Company will, at the option of the Sponsors, repay the amounts evidenced by simple promissory notes. If a Business Combination is not consummated, the simple promissory notes will not be repaid by the Company and all amounts owed thereunder by the Company will be forgiven except to the extent that the Company has funds available to it outside of its Trust Account. <br/></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">On<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">October&#160;17, 2022, the Company and its Sponsors entered into a Debt Contribution Agreement (the &#8220;Debt Contribution Agreement&#8221;). The Debt Contribution Agreement relates to certain amounts owed by the Company to the Sponsors for payment of certain outstanding loans (the &#8220;Company Obligations&#8221;) as set forth in the Debt Contribution Agreement. Pursuant to the Debt </div>Contribu<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">tion Agreement, the Sponsors have agreed to contribute the Company Obligations to the Company in</div> exc<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">hange for the issuance of that number of shares of shares of common stock, par value $</div><ix:nonFraction name="us-gaap:CommonStockNoParValue" contextRef="PAsOn10_17_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;per share, of the Company, determined by dividing the Company Obligations by $</div><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn10_17_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">10.00</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;(the &#8220;Contribution Shares&#8221;) to the Sponsors immediately prior to the consummation of the Business Combination but after the Domestication (as defined in the Merger Agreement). Upon the occurrence of the debt contribution and issuance of the Contribution Shares to the Sponsors pursuant to the Debt Contribution Agreement, the Company Obligation owed to the Sponsors shall be extinguished in its entirety and shall be of no further force or effect and shall be deemed satisfied in full.</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In connection with the Debt Exchange Agreement, on October&#160;17, 2022, Sorrento and Scilex entered into a letter agreement (the &#8220;Funding Commitment Letter&#8221;) pursuant to which, upon the written request of the Company (which request the Company shall make to the extent necessary to satisfy Net Tangible Asset Condition), Sorrento shall fund one or more loans to the Company in the amount set forth in such written request. </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></ix:nonNumeric></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-54 </div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VICKERS VANTAGE CORP. I </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SEPTEMBER&#160;30, 2022 </div></div></div></div><div style="display:inline;"><ix:continuation id="TextSelection_63195180" continuedAt="TextSelectionAppend_63195180_1"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On October&#160;17, 2022, as consideration for Sorrento agreeing to provide for funding under the Funding Commitment Letter, Vickers, the Sponsors, Sorrento and Maxim Group LLC, entered into the Warrant Transfer Agreement (the &#8220;Warrant Transfer Agreement&#8221;) for the transfer of certain private placement warrants held by the Sponsors to Sorrento in the event redemptions exceed certain thresholds specified in the Warrant Transfer Agreement. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;">On October&#160;17, 2022, the Company entered into a Letter Agreement with Sorrento and the Sponsors (the &#8220;Letter Agreement&#8221;) to provide that certain shares held by the Sponsors will be released from the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up</div> restrictions only in an amount necessary to help satisfy the minimum public float requirement under the Listing Standards of the Nasdaq Stock Market LLC, which amount shall not exceed&#160;<ix:nonFraction name="sclx:NumberOfSharesLimits" contextRef="P10_17_2022To10_17_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis_VickersVantageMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">1,500,000</ix:nonFraction>&#160;shares. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On October&#160;28, 2022, the proxy statement/prospectus was declared effective and the Company commenced with mailing the proxy materials to the Company&#8217;s shareholders ahead of the extraordinary general meeting of the Company&#8217;s shareholders on November&#160;9, 2022. </div></div></ix:continuation></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-5<div style="letter-spacing: 0px; top: 0px;;display:inline;">5</div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">&#160;</div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div id="fin428534_12" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Report of Independent Registered Public Accounting Firm </div></div></div><ix:continuation id="TextSelectionAppend_63195180_1" continuedAt="TextSelectionAppend_63195180_2"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To the Board of Directors and Stockholders of Scilex Holding Company </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Opinion on the Financial Statements </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have audited the accompanying consolidated balance sheets of Scilex Holding Company (the Company) as of December&#160;31, 2021 and 2020, the related consolidated statements of operations, stockholders&#8217; deficit and cash flows for each of the two years in the period ended December&#160;31, 2021, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December&#160;31, 2021 and 2020, and the results of its operations and its cash flows for the years then ended in conformity with U.S. generally accepted accounting principles. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s Ability to Continue as a Going Concern </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company has suffered recurring losses from operations, has a working capital deficiency, and has stated that substantial doubt exists about the Company&#8217;s ability to continue as a going concern. Management&#8217;s evaluation of the events and conditions and management&#8217;s plans regarding these matters are also described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basis for Opinion </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We conducted our audits in accordance with the standards of the PCAOB and in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Ernst&#160;&amp; Young LLP </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have served as the Company&#8217;s auditor since 2020. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">San Diego, California </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">May&#160;13, 2022 </div></div></ix:continuation><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-56 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </div></div></div><ix:continuation id="TextSelectionAppend_63195180_2"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To the stockholders and the Board of Directors of </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Scilex Holding Company </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Opinion on the Financial Statements </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have audited the accompanying consolidated statements of operations, stockholders&#8217; equity, and cash flows of Scilex Holding Company and subsidiaries (the &#8220;Company&#8221;) for the year ended December&#160;31, 2019, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the results of the Company&#8217;s operations and cash flows for the year ended December&#160;31, 2019, in conformity with accounting principles generally accepted in the United States of America. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Going Concern </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company has suffered negative working capital, recurring losses from operations, recurring negative cash flows from operations and cumulative net losses that raise substantial doubt about its ability to continue as a going concern. Management&#8217;s plans in regard to these matters are also described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basis for Opinion </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We conducted our audit in accordance with the standards of the PCAOB and in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provide a reasonable basis for our opinion. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other Matter </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As discussed in Note 1 to the financial statements, the accompanying financial statements have been prepared from the separate records maintained by the Company and may not necessarily be indicative of the conditions that would have existed or the results of operations if the Company had been operated as an unaffiliated company of Sorrento Therapeutics, Inc. Portions of certain income and expenses represent allocations made from home-office items applicable to the Company as a whole. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Deloitte&#160;&amp; Touche LLP </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">San Diego, California </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">April&#160;23, 2020 </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We began serving as the Company&#8217;s auditor in 2018. In 2020 we became the predecessor auditor. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:continuation><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-57 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SCILEX HOLDING COMPANY </div></div></div></div> <div id="fin428534_13" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONSOLIDATED BALANCE SHEETS </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AS OF DECEMBER&#160;31, 2021 AND 2020 </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(in thousands, except for par value and share amounts) </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated Balance Sheets as of December&#160;31, 2021 and 2020 </div></div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 80%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 7pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8pt;;display:inline;"><div style="line-height: 8pt; font-size: 8pt;;font-weight:bold;display:inline;">December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;">ASSETS</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Current assets</div></div>:</div></div> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,338</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,839</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;">Accounts receivable, net</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">14,268</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,126</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;">Inventory</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,562</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,145</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid expenses and other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,835</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,314</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current assets:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">23,003</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">22,424</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Property and equipment, net</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">805</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">846</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset</div></div> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,303</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,675</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;">Intangibles, net</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">38,802</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">42,540</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;">Goodwill</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,481</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,481</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;">Long-term deposit</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermInvestments" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">538</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermInvestments" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">538</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">77,932</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">81,504</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;">LIABILITIES AND STOCKHOLDERS&#8217; DEFICIT</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current liabilities:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;">Accounts payable</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,284</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,120</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;">Accrued payroll</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:AccruedPayroll" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,733</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:AccruedPayroll" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,754</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;">Accrued expenses</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,621</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,622</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;">Current portion of debt</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">37,950</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">15,888</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;">Related party payable</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DueToRelatedPartiesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">92,724</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DueToRelatedPartiesCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">26,664</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;">Related party note payable</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:RelatedPartyNotePayableCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">19,608</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:RelatedPartyNotePayableCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,008</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current portion of operating lease liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">424</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current liabilities:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">169,420</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">78,480</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Long-term debt, net of discount</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">72,037</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">92,255</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;">Related party note payable</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:RelatedPartyNotePayableNoncurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">23,503</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:RelatedPartyNotePayableNoncurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">15,403</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;">Derivative liabilities</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:DerivativeLiabilityNoncurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">35,700</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:DerivativeLiabilityNoncurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">35,400</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;">Operating lease liabilities</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,148</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,649</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">301,808</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">223,187</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commitments and contingencies (See Note 11)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stockholders&#8217; Deficit:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Preferred stock, $<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2020" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2021" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2020" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">20,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2020" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2020" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen">no </ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>shares issued or outstanding at December&#160;31, 2021 and 2020</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Common stock, $<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2020_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2020_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">350,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2020_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2020_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">197,266,338</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding at December&#160;31, 2021 and 2020</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital</div></div> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">128,654</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">122,423</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;">Accumulated deficit</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">352,550</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">264,126</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total stockholders&#8217; deficit</div></div></div> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">223,876</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">141,683</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities and stockholders&#8217; deficit</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">77,932</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">81,504</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">See accompanying notes to consolidated financial statements </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-5<div style="letter-spacing: 0px; top: 0px;;display:inline;">8</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SCILEX HOLDING COMPANY </div></div></div></div> <div id="fin428534_14" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONSOLIDATED STATEMENTS OF OPERATIONS </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FOR THE YEARS ENDED DECEMBER&#160;31, 2021, 2020 AND 2019 </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(in thousands, except for net loss per share amounts) </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated Statements of Operations for the Years Ended December&#160;31, 2021, 2020 and 2019</div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 72%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net revenue</div></div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Revenues" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">31,317</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Revenues" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">23,560</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Revenues" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">21,033</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating costs and expenses:</div></div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost of revenue</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,634</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,149</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,802</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,201</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,961</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,216</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:AcquiredinprocessresearchAndDevelopment" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:AcquiredinprocessresearchAndDevelopment" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:AcquiredinprocessresearchAndDevelopment" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">75,301</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Selling, general and administrative</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">50,582</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">42,970</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">64,696</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible amortization</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,738</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,738</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,713</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating costs and expenses</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingCostsAndExpenses" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">67,155</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingCostsAndExpenses" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">58,818</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingCostsAndExpenses" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">159,728</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from operations</div></div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">35,838</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">35,258</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">138,695</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other expense</div></div>:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss (gain) on derivative liability</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:GainLossOnDerivative" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">300</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="sclx:GainLossOnDerivative" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">800</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:GainLossOnDerivative" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">23,300</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss on debt extinguishment, net</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:GainLossOnExtinguishmentOfDebtt" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,463</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:GainLossOnExtinguishmentOfDebtt" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:GainLossOnExtinguishmentOfDebtt" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Scilex Pharma Notes principal increase</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:ScilexPharmaNotesPrincipalIncrease" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">28,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:ScilexPharmaNotesPrincipalIncrease" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:ScilexPharmaNotesPrincipalIncrease" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest expense</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,764</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,116</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">16,889</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest income</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">460</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss (gain) on foreign currency exchange</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">54</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">168</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total other expense</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">52,581</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,314</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">39,897</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss before income taxes</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">88,419</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">47,572</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">178,592</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax expense (benefit)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">53</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-comma-decimal">88.424</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">47,519</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">178,594</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss per share&#160;&#8212;&#160;basic and diluted</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" sign="-" format="ixt:num-dot-decimal">0.45</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" sign="-" format="ixt:num-dot-decimal">0.24</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" sign="-" format="ixt:num-dot-decimal">0.95</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average number of shares during the period&#160;&#8212;&#160;basic and diluted</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">197,266</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">197,315</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">187,524</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="font-size: 10pt; letter-spacing: 0px; text-align: center; top: 0px;;display:inline;"></div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 200pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">See accompanying notes to consolidated financial statements </div></div></div> <div style="font-size: 10pt; letter-spacing: 0px; text-align: center; top: 0px;;display:inline;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-5<div style="letter-spacing: 0px; top: 0px;;display:inline;">9</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> <div style="font-size: 13.28px; margin-top: 0pt; margin-bottom: 17pt; text-align: center;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SCILEX HOLDING COMPANY </div></div></div></div> <div id="fin428534_15" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; DEFICIT </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FOR THE YEARS ENDED DECEMBER&#160;31, 2021, 2020 AND 2019 </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(in thousands) </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated Statements of Operations for the Years Ended December&#160;31, 2021, 2020 and 2019 </div></div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 58%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Common&#160;Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Additional</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Paid-in</div></div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Capital</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Deficit</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance, December&#160;31, 2018</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">150,270</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">15</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">73,462</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2018_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">38,013</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">35,464</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Shares issued related to Semnur Acquisition</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" contextRef="P01_01_2019To12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">47,040</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="P01_01_2019To12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="P01_01_2019To12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">54,586</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">54,591</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Distribution to Sorrento</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2019To12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">5,800</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">5,800</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="P01_01_2019To12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,330</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,330</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-align:right;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2019To12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">178,594</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">178,594</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance, December&#160;31, 2019</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">197,310</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">126,578</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">216,607</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">90,009</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock options excercised</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">56</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">50</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">50</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,395</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,395</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Distribution to Sorrento</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">9,600</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">9,600</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cancellation of shares held in escrow related to Semnur Acquisition</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">100</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2020To12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">47,519</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">47,519</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance, December&#160;31, 2020</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">197,266</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">122,423</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">264,126</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">141,683</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock based compensation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,822</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,822</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustment to shares issued in Semnur Acquisition</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:AdjustmentsToAdditionalPaidInCapitalSharesIssuedInSemnurAcquisition" contextRef="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">409</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:AdjustmentsToAdditionalPaidInCapitalSharesIssuedInSemnurAcquisition" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">409</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">88,424</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">88,424</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance, December&#160;31, 2021</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">197,266</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">128,654</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">352,550</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">223,876</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 265pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">See accompanying notes to consolidated financial statements</div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">60</div> </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SCILEX HOLDING COMPANY </div></div></div></div> <div id="fin428534_16" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONSOLIDATED STATEMENTS OF CASH FLOWS </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FOR THE YEARS ENDED DECEMBER&#160;31, 2021, 2020 AND 2019 </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(in thousands) </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated Statements of Operations for the Years Ended December&#160;31, 2021, 2020 and 2019 </div></div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 75%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating activities</div></div></div></div> </td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">88,424</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">47,519</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">178,594</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustments to reconcile net loss to net cash used for operating activities:</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation and amortization</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,779</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,777</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,750</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Amortization of debt issuance costs and debt discount</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,909</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,664</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">15,033</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Scilex Pharma Notes principal increase</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="sclx:IncreaseInNotesPayableOne" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">28,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="sclx:IncreaseInNotesPayableOne" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="sclx:IncreaseInNotesPayableOne" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Payment on the Scilex Pharma Notes attributed to accreted interest related to the debt discount</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;">(<ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,487</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;">(<ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,866</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss on debt extinguishment, net</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">12,463</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-cash</div> operating lease cost</div></div> </td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="sclx:NonCashOperatingLeaseCosts" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">372</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="sclx:NonCashOperatingLeaseCosts" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">825</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="sclx:NonCashOperatingLeaseCosts" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">528</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,822</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,395</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,330</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss (gain) on derivative liability</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">300</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;">(<ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">800</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">23,300</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Semnur-related IPR&amp;D</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentInProcess" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentInProcess" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentInProcess" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">75,301</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in operating assets and liabilities:</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Trade receivables, net</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,142</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">598</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,356</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Inventory</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,417</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">2,379</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,116</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid expenses and other</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,479</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,035</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,307</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term deposits</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInSecurityDeposits" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInSecurityDeposits" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,580</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInSecurityDeposits" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">88</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">3,836</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">4,062</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,271</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued payroll</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">21</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,247</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,131</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued expenses</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">409</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,051</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,689</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Other liabilities</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">80</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">604</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">147</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Related party payable</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">18,210</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,105</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,854</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 75%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 8.5pt; font-size: 8.5pt;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">Net cash used for operating activities</div></div></div></div> </td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">28,664</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">31,461</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">60,421</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Investing activities</div></div></div></div> </td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Purchases of property and equipment</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">25</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">584</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquisition of Semnur, net of cash acquired</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">17,040</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 75%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 8.5pt; font-size: 8.5pt;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">Net cash used for investing activities</div></div></div></div> </td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;">&#8212;<div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">25</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">17,624</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Financing activities</div></div></div></div> </td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Repayment of principal on the Scilex Pharma Notes</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;">(<ix:nonFraction name="us-gaap:RepaymentsOfSeniorDebt" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">33,387</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;">(<ix:nonFraction name="us-gaap:RepaymentsOfSeniorDebt" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">58,927</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;">(<ix:nonFraction name="us-gaap:RepaymentsOfSeniorDebt" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,334</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Repayment on other loans</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;">(<ix:nonFraction name="us-gaap:RepaymentsOfOtherLongTermDebt" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">48,832</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:RepaymentsOfOtherLongTermDebt" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:RepaymentsOfOtherLongTermDebt" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from other loans</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">47,832</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,007</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from stock options exercised</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">50</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from related party payable</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">47,850</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">18,400</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from related party note payable</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfMediumTermNotes" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">14,700</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfMediumTermNotes" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,300</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfMediumTermNotes" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">21,628</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Repayment of related party note payable</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:RepaymentsOfMediumTermNotes" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:RepaymentsOfMediumTermNotes" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;">(<ix:nonFraction name="us-gaap:RepaymentsOfMediumTermNotes" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,518</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash provided by (used for) financing activities</div></div></div></div> </td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">28,163</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">19,170</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">15,776</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Net change in cash, cash equivalents and restricted cash</div></div></div></div> </td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">501</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">50,656</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">62,269</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash, cash equivalents and restricted cash at beginning of year</div></div></div></div> </td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,839</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">55,495</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">117,764</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-size: 0px; width: 75%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash, cash equivalents and restricted cash at end of year</div></div></div></div> </td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,338</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,839</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">55,495</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplemental disclosures:</div></div></div></div> </td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Supplemental disclosures of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> investing and financing activities</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-cash</div> consideration in Semnur acquisition</div></div> </td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><ix:nonFraction name="us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationGiven1" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">409</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><ix:nonFraction name="us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationGiven1" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div><div style="line-height: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><ix:nonFraction name="us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationGiven1" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">54,591</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 8.5pt; line-height: 8.5pt; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Semnur acquisition costs incurred but not paid in accounts payable</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><ix:nonFraction name="sclx:AcquistionCostsIncurredButNotPaidIncludedInAccountsPayable" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div><div style="line-height: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><ix:nonFraction name="sclx:AcquistionCostsIncurredButNotPaidIncludedInAccountsPayable" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div><div style="line-height: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><ix:nonFraction name="sclx:AcquistionCostsIncurredButNotPaidIncludedInAccountsPayable" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">601</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; font-size: 8.5pt; line-height: 8.5pt; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Other loan forgiveness</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><ix:nonFraction name="sclx:OtherLoanForgiveness" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,536</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><ix:nonFraction name="sclx:OtherLoanForgiveness" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div><div style="line-height: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><ix:nonFraction name="sclx:OtherLoanForgiveness" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div><div style="line-height: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-cash</div> distribution to Sorrento</div></div> </td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><ix:nonFraction name="sclx:NonCashDistributionToAcquiree" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div><div style="line-height: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><ix:nonFraction name="sclx:NonCashDistributionToAcquiree" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,600</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><ix:nonFraction name="sclx:NonCashDistributionToAcquiree" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,800</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td> </tr>
<tr>
<td style="vertical-align: top; font-size: 8.5pt; line-height: 8.5pt; width: 75%; padding-bottom: 0.375pt;"> <div style="text-indent: -1em; font-size: 8.5pt; margin-top: 0px; margin-bottom: 0px; margin-left: 3em; line-height: 1pt;">&#160;</div> </td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%; padding-bottom: 0.375pt;"> <div style="font-size: 8.5pt; margin-top: 0px; margin-bottom: 0px; line-height: 1pt;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt; border-bottom: 0.75pt solid black;"> <div style="font-size: 8.5pt; margin-top: 0px; margin-bottom: 0px; line-height: 1pt;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt; border-bottom: 0.75pt solid black;"> <div style="font-size: 8.5pt; margin-top: 0px; margin-bottom: 0px; line-height: 1pt;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt; padding-bottom: 0.375pt;"> <div style="font-size: 8.5pt; margin-top: 0px; margin-bottom: 0px; line-height: 1pt;">&#160;</div> </td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%; padding-bottom: 0.375pt;"> <div style="font-size: 8.5pt; margin-top: 0px; margin-bottom: 0px; line-height: 1pt;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt; border-bottom: 0.75pt solid black;"> <div style="font-size: 8.5pt; margin-top: 0px; margin-bottom: 0px; line-height: 1pt;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt; border-bottom: 0.75pt solid black;"> <div style="font-size: 8.5pt; margin-top: 0px; margin-bottom: 0px; line-height: 1pt;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt; padding-bottom: 0.375pt;"> <div style="font-size: 8.5pt; margin-top: 0px; margin-bottom: 0px; line-height: 1pt;">&#160;</div> </td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%; padding-bottom: 0.375pt;"> <div style="font-size: 8.5pt; margin-top: 0px; margin-bottom: 0px; line-height: 1pt;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt; border-bottom: 0.75pt solid black;"> <div style="font-size: 8.5pt; margin-top: 0px; margin-bottom: 0px; line-height: 1pt;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt; border-bottom: 0.75pt solid black;"> <div style="font-size: 8.5pt; margin-top: 0px; margin-bottom: 0px; line-height: 1pt;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt; padding-bottom: 0.375pt;"> <div style="font-size: 8.5pt; margin-top: 0px; margin-bottom: 0px; line-height: 1pt;">&#160;</div> </td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; font-size: 8.5pt; line-height: 8.5pt; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Scilex Pharma Notes principal increase</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><ix:nonFraction name="sclx:NonCashIncreaseInPrincipal" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">28,000</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><ix:nonFraction name="sclx:NonCashIncreaseInPrincipal" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div><div style="line-height: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><ix:nonFraction name="sclx:NonCashIncreaseInPrincipal" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div><div style="line-height: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Reconciliation of cash, cash equivalents and restricted cash within the Company&#8217;s balance sheet</div></div></div></div> </td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; font-size: 8.5pt; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; font-size: 8.5pt; line-height: 8.5pt; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,338</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,839</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,295</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 8.5pt; line-height: 8.5pt; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted cash</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><ix:nonFraction name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div><div style="line-height: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><ix:nonFraction name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div><div style="line-height: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><ix:nonFraction name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">45,200</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-size: 0px; width: 75%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; font-size: 8.5pt; line-height: 8.5pt; width: 75%;"> <div style="text-indent: -1em; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">Cash, cash equivalents and restricted cash</div></div></div></div> </td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,338</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,839</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt; width: 2%;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">55,495</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">&#160;</div></div></td> </tr> </table> <div style="margin-block: 0em; margin-bottom: 0px; margin-top: 0px;;text-indent: 0px;">&#160;</div> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div> <div style="margin-block: 0em; text-indent: 0px; text-align: center;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">See accompanying notes to consolidated financial statements </div></div> <div style="clear: both; max-height: 0px;;text-indent: 0px;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-6<div style="letter-spacing: 0px; top: 0px;;display:inline;">1</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="clear: both; max-height: 0px;"></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SCILEX HOLDING COMPANY </div></div></div></div> <div id="fin428534_17" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"></div><br/></div> <ix:nonNumeric name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Nature of Operations and Basis of Presentation </div></div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Organization and Principal Activities </div></div></div></div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Scilex Holding Company (&#8220;Scilex Holding&#8221; and together with its wholly owned subsidiaries, <div style="letter-spacing: 0px; top: 0px;;display:inline;">the</div> &#8220;Company&#8221;) was incorporated in </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div> <ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="P02_01_2019To02_28_2019" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric> in February&#160;2019 and is a majority-owned subsidiary of Sorrento Therapeutics, Inc. (&#8220;Sorrento&#8221;). The Company is a commercial-stage, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-opioid</div> pain management company focused on the development and commercialization of topical and injectable therapies. The Company launched its first commercial product in October&#160;2018, ZTlido (lidocaine topical system) 1.8% (&#8220;ZTlido&#8221;), a prescription lidocaine topical system that is designed with novel technology to address the limitations of current prescription lidocaine therapies by providing significantly improved adhesion and continuous pain relief throughout the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12-hour</div> administration period. The Company is currently developing two product candidates, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-102</div> (10 mg, dexamethasone sodium phosphate viscous gel), a Phase&#160;3, novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;SP-102&#8221;),</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-103</div> (lidocaine topical system) 5.4% <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;SP-103&#8221;),</div> for the treatment of acute low back pain. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">&#160;18, 2019, the Company entered into a Contribution and Loan Agreement with Sorrento and the holders of the outstanding shares of capital stock of Scilex Pharmaceuticals Inc. (&#8220;Scilex Pharma&#8221;) pursuant to which the Company acquired <ix:nonFraction name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" contextRef="PAsOn03_18_2019_ContributionAndLoanAgreementMemberSCLXAgreementAxis_ReorganizationMemberSCLXEventAxis_ScilexPharmaMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction>% of the outstanding shares of capital stock of Scilex Pharma in exchange for shares of the Company&#8217;s common stock (the &#8220;Contribution&#8221;), which was accounted for as a reorganization of entities under common control. Pursuant to the Contribution and Loan Agreement, Sorrento provided the Company with a loan with an initial principal amount of $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn03_18_2019_ReorganizationMemberSCLXEventAxis_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">16.5</ix:nonFraction>&#160;million <div style="letter-spacing: 0px; top: 0px;;display:inline;">in the form of a note payable, which was used by the Company to fund the acquisition of Semnur Pharmaceuticals, Inc. (&#8220;Semnur&#8221;). Concurrently therewith, the Company entered into an Agreement and Plan of Merger with Semnur, Sigma Merger Sub, Inc., the Company&#8217;s prior wholly owned subsidiary (&#8220;Merger Sub&#8221;), Fortis Advisors LLC, solely as representative of the holders of Semnur equity (the &#8220;Semnur Equityholders&#8217; Representative&#8221;), and Sorrento, for limited purposes (the &#8220;Merger Agreement&#8221;), which was accounted for as an asset acquisition. Pursuant to the Merger Agreement, Merger Sub merged with and into Semnur (the &#8220;Merger&#8221;), with Semnur surviving as the Company&#8217;s wholly owned subsidiary. As a result of the Contribution and the Merger, Scilex Pharma and Semnur became wholly owned subsidiaries of the Company. Upon completion of the Contribution and the Merger, the historical consolidated financial statements of Scilex Pharma became the historical consolidated financial statements of Scilex Holding.</div> </div></div> <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Since inception, the Company had devoted substantially all of its efforts to the product development of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">SP</div></div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">-102</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">SP-103</div> and the commercialization of ZTlido. </div> <ix:nonNumeric name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and include all adjustments necessary for the fair presentation of the Company&#8217;s financial position for the periods presented. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying consolidated financial statements include the accounts of the Company&#8217;s subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></ix:nonNumeric> </ix:nonNumeric> <ix:nonNumeric name="sclx:LiquidityAndGoingConcernTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_63194767"><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liquidity and Going Concern </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Management has assessed the Company&#8217;s ability to continue as a going concern at least one year after the date the financial statements are issued. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-6<div style="letter-spacing: 0px; top: 0px;;display:inline;">2</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_63194767"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">31, 2021, the Company&#8217;s negative working capital was $<ix:nonFraction name="sclx:NetWorkingCapital" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">146.4</ix:nonFraction>&#160;million, including cash and cash equivalents of approximately $<ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">4.3</ix:nonFraction>&#160;million. During the year ended December&#160;31, 2021, the Company<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>had operating losses of $<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal">35.8</ix:nonFraction>&#160;million and negative cash flows from operations of $<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal">28.7</ix:nonFraction>&#160;million. The Company had an accumulated deficit of approximately $<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal">352.6</ix:nonFraction>&#160;million as of December&#160;31, 2021. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In September </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2018, Scilex Pharma issued $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn09_30_2018_ScilexPharmaMemberdeiLegalEntityAxis_SeniorSecuredNotesDueTwoThousandAndTwentySixMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">224.0</ix:nonFraction>&#160;million of the Scilex Pharma Notes (see Note 8) for a purchase price of $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfSecuredDebt" contextRef="P09_01_2018To09_30_2018_ScilexPharmaMemberdeiLegalEntityAxis_SeniorSecuredNotesDueTwoThousandAndTwentySixMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">140.0</ix:nonFraction>&#160;million. Pursuant to the Indenture, as amended (see Note 8), Scilex Pharma is required to maintain a minimum unrestricted cash balance of $<ix:nonFraction name="sclx:MinimumUnrestrictedCashBalance" contextRef="PAsOn09_30_2018_ScilexPharmaMemberdeiLegalEntityAxis_SeniorSecuredNotesDueTwoThousandAndTwentySixMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">4.0</ix:nonFraction>&#160;million at the end of each month. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In December </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">2020, Scilex Pharma repurchased an aggregate of $<ix:nonFraction name="us-gaap:DebtInstrumentRepurchasedFaceAmount" contextRef="PAsOn09_30_2020_ScilexPharmaMemberdeiLegalEntityAxis_SeniorSecuredNotesDueTwoThousandAndTwentySixMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">65.0</ix:nonFraction>&#160;million of the Scilex Pharma Notes (see Note 8) and amended the terms of the Scilex Pharma Notes to release $<ix:nonFraction name="sclx:RestrictedFundsRelesableForFutureRepurchaseOfDebt" contextRef="PAsOn09_30_2020_ScilexPharmaMemberdeiLegalEntityAxis_SeniorSecuredNotesDueTwoThousandAndTwentySixMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">45.0</ix:nonFraction>&#160;million in restricted funds held in the Reserve Account (see Note 8) and Collateral Account (see Note 8) for the purpose of consummating the repurchase of an aggregate of $45.0&#160;million of principal amount. <div style="letter-spacing: 0px; top: 0px;;display:inline;">In February&#160;</div>2021 and <div style="letter-spacing: 0px; top: 0px;;display:inline;">April&#160;</div>2021, Scilex Pharma effected specified principal repurchases totaling $<ix:nonFraction name="us-gaap:DebtInstrumentRepurchasedFaceAmount" contextRef="PAsOn04_30_2021_ScilexPharmaMemberdeiLegalEntityAxis_SeniorSecuredNotesDueTwoThousandAndTwentySixMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">40.0</ix:nonFraction>&#160;million of the principal amount of the Scilex Pharma Notes. On December&#160;31, 2021, Scilex Pharma triggered a cumulative sales-related contingency that triggered an increase in the principal amount of the Scilex Pharma Notes by $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn12_31_2021_CumulativeSalesRelatedContingencyMemberSCLXEventAxis_ScilexPharmaMemberdeiLegalEntityAxis_SeniorSecuredNotesDueTwoThousandAndTwentySixMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">28.0</ix:nonFraction>&#160;million. <div style="letter-spacing: 0px; top: 0px;;display:inline;">In February&#160;</div>2022, Scilex Pharma drew down on the Letter of Credit (see Note 8) with Sorrento, which also triggered Scilex Pharma&#8217;s obligation to repurchase $<ix:nonFraction name="sclx:DebtInstrumentRepurchaseObligation" contextRef="PAsOn02_28_2022_LetterOfCreditDrawnDownMemberSCLXEventAxis_ScilexPharmaMemberdeiLegalEntityAxis_SeniorSecuredNotesDueTwoThousandAndTwentySixMemberusgaapLongtermDebtTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">20.0</ix:nonFraction>&#160;million of the outstanding principal amount of the Scilex Pharma Notes and to maintain a minimum unrestricted cash balance of $<ix:nonFraction name="sclx:MinimumUnrestrictedCashBalance" contextRef="PAsOn02_28_2022_LetterOfCreditDrawnDownMemberSCLXEventAxis_ScilexPharmaMemberdeiLegalEntityAxis_SeniorSecuredNotesDueTwoThousandAndTwentySixMemberusgaapLongtermDebtTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">10.0</ix:nonFraction>&#160;million. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;</div></div>18, 2019, the Company acquired Semnur and the acquisition was accounted for as an asset acquisition (See Note 4). The Company anticipates the cash needed for the development of Semnur&#8217;s primary product candidate in development, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-102,</div> as well in the development of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-103,</div> will be in excess of the Company&#8217;s cash available within one year after the date these consolidated financial statements are issued. Semnur has no historical revenue and the Company will be responsible for funding all development and commercialization efforts and capital funding needs possibly through private or public equity or debt financings, strategic collaborations or other arrangements. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has plans to obtain additional resources to fund its currently planned operations and expenditures for at least </div></div>twelve&#160;months from the issuance of these consolidated financial statements through debt and equity financing. The Company&#8217;s plans are also dependent upon the success of future sales of ZTlido, which is still in the early stages of commercialization, and are dependent upon, among other things, the success of the Company&#8217;s marketing of ZTlido. Should the Company&#8217;s sales of ZTlido not materialize at the expected rate contemplated in the Company&#8217;s business plan, due to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic or other factors, the Company believes that there are a number of ongoing and potential actions that would maintain its projected cash and projected financial position including but not limited to, additional reductions in general and administrative costs, sales and marketing costs, suspension or winding down of clinical development programs for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-102</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-103,</div> and other discretionary costs. Although the Company believes such plans, if executed, should provide the Company with financing to meet its needs, successful completion of such plans is dependent on factors outside the Company&#8217;s control. As such, management cannot conclude that such plans will be effectively implemented within one year after the date that these consolidated financial statements are issued. As a result, management has concluded that the aforementioned conditions, among other things, raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date the financial statements are issued. </div> </ix:continuation><ix:nonNumeric name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_63194099"><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Significant Accounting Policies </div></div></div> </td> </tr> </table> <ix:nonNumeric name="us-gaap:UseOfEstimates" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of these consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of these consolidated financial statements and the reported amounts of expenses during the reporting period. Management believes that these estimates are reasonable; however, actual results may differ from these estimates. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-6<div style="display:inline;">3</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_63194099" continuedAt="TextSelectionAppend_63194099_1"> <ix:nonNumeric name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cash and Cash Equivalents </div></div></div></div></div> <div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company considers all highly liquid investments purchased with original maturities of three months or less to be cash equivalents. The Company minimizes its credit risk associated with cash and cash equivalents by periodically evaluating the credit quality of its primary financial institution. Although the balance at times may exceed federally-insured limits, the Company has not experienced any losses on such accounts. </div></div></div></ix:nonNumeric> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <ix:nonNumeric name="us-gaap:FairValueOfFinancialInstrumentsPolicy" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value of Financial Instruments </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company follows accounting guidance on fair value measurements for financial instruments measured on a recurring basis, as well as for certain assets and liabilities that are initially recorded at their estimated fair values. Fair value is defined as the exit price, or the amount that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company uses the following three-level hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs to value its financial instruments: </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 5%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">a.</div></td>
<td style="vertical-align: top; font-size: 10pt;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;1: Observable inputs such as unadjusted quoted prices in active markets for identical instruments. </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 5%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">b.</div></td>
<td style="vertical-align: top; font-size: 10pt;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;2: Quoted prices for similar instruments that are directly or indirectly observable in the marketplace. </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 5%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">c.</div></td>
<td style="vertical-align: top; font-size: 10pt;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;3: Significant unobservable inputs which are supported by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation. </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety requires it to make judgments and consider factors specific to the asset or liability. The use of different assumptions and/or estimation methodologies may have a material effect on estimated fair values. Accordingly, the fair value estimates disclosed or initial amounts recorded may not be indicative of the amount that the Company or holders of the instruments could realize in a current market exchange. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2021 and 2020, the carrying amount of cash equivalents approximates their fair value based upon quoted market prices. Certain of the Company&#8217;s financial instruments are not measured at fair value on a recurring basis, but are recorded at amounts that approximate their fair value due to their liquid or short-term nature, such as cash, prepaid expenses, accounts receivable, and accounts payable. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:TradeAndOtherAccountsReceivablePolicy" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accounts Receivable, Net </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable are presented net of allowances for expected credit losses and consist of trade receivables from product sales to one customer, which are generally unsecured. Estimated credit losses related to trade accounts receivable are recorded as general and administrative expenses and as an allowance for expected credit losses within accounts receivable, net. The Company reviews reserves and makes adjustments based on historical experience and known collectability issues and disputes. When internal collection efforts on accounts have been exhausted, the accounts are written off by reducing the allowance for expected credit losses. </div></div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:InventoryPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Inventory </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company determines inventory cost on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-in,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-out</div> basis. The Company reduces the carrying value of inventories to a lower of cost or net realizable value for those items that are potentially excess, obsolete or slow-moving. The Company reserves for excess and obsolete inventory based upon historical experience, sales trends, and specific categories of inventory and expiration dates for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">on-hand</div> inventory. As of December&#160;31, 2021 and 2020, the Company&#8217;s inventory was primarily comprised of finished goods. </div></div></ix:nonNumeric> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-6<div style="display:inline;">4</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_63194099_1" continuedAt="TextSelectionAppend_63194099_2"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px;"></div> <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Property and Equipment </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment are carried at cost less accumulated depreciation. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the assets, which are generally five to seven years. Leasehold improvements are amortized over the lesser of their estimated useful lives or the term of the respective lease on a straight-line basis. The cost of repairs and maintenance is expensed as incurred. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Goodwill and Other Long-Lived Assets </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill, which has an indefinite life, represents the excess cost over fair value of net assets acquired. Goodwill is reviewed for impairment at least annually during the fourth quarter, or more frequently if events occur indicating the potential for impairment. The Company has determined that only one reporting unit exists for examination under impairment review. During its goodwill impairment review, the Company may assess qualitative factors to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company. If, after assessing the totality of these qualitative factors, the Company determines that it is not more likely than not that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company performs a quantitative goodwill impairment test. The Company may also elect to bypass the qualitative assessment in a period and elect to proceed to perform the quantitative goodwill impairment test. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company evaluates its long-lived and intangible assets with definite lives, such as property and equipment, patent rights, and acquired technology, for impairment by considering competition by products prescribed for the same indication, the likelihood and estimated future entry of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-generic</div> and generic competition with the same or similar indication and other related factors. The factors that drive the estimate of useful life are often uncertain and are reviewed on a periodic basis or when events occur that warrant review. Recoverability is measured by comparison of the assets&#8217; book value to future net undiscounted cash flows that the assets are expected to generate to determine if a write-down to the recoverable amount is appropriate. If such assets are written down, an impairment will be recognized as the amount by which the book value of the asset group exceeds the recoverable amount. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:DebtPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Debt </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company may enter financing arrangements, the terms of which involve significant assumptions and estimates. This involves estimating future net product sales, determining interest expense, determining the amortization period of the debt discount, as well as determining the classification between current and long-term portions. In estimating future net product sales, the Company assesses prevailing market conditions using various external market data against the Company&#8217;s anticipated sales and planned commercial activities as well as actual ZTlido sales up to the date the financial statements were issued. See Note 8 for discussion of the Scilex Pharma Notes, which include repayments based on a percentage of net sales of ZTlido. Consequently, the Company imputes interest on the carrying value of the debt and records interest expense using an imputed effective interest rate. The Company reassesses the expected payments each reporting period and accounts for any changes through an adjustment to the effective interest rate on a prospective basis, with a corresponding impact to the classification of the Company&#8217;s current and long-term portions. </div></div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:ResearchAndDevelopmentExpensePolicy" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_63195163"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research and Development Costs </div></div></div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company expenses the cost of research and development as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including clinical trial costs, manufacturing costs for both clinical and preclinical materials as well as other contracted services, </div></div></div> <div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div></ix:nonNumeric> <div style="background: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-6<div style="letter-spacing: 0px; top: 0px;;display:inline;">5</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_63194099_2" continuedAt="TextSelectionAppend_63194099_3"> <ix:continuation id="TextSelection_63195163"> <div style="letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">license fees and other external costs. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity is performed or when the goods have been received, rather than when payment is made, in accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic 730, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research and Development</div></div>. </div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div> </ix:continuation> <ix:nonNumeric name="us-gaap:InProcessResearchAndDevelopmentPolicy" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">In-Process</div> Research and Development Expense </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company has acquired and may continue to acquire the rights to develop and commercialize new product candidates. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">up-front</div> payments to acquire a new drug compound or drug delivery device, as well as future milestone payments associated with asset acquisitions that do not meet the definition of a derivative and are deemed probable to achieve the milestones, are immediately expensed as acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development provided that the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, have no alternative future use. Intangible assets acquired in a business combination that are used for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development (&#8220;IPR&amp;D&#8221;) activities are considered indefinite-lived until the completion or abandonment of the associated research and development efforts. Upon commercialization of the relevant research and development project, the Company amortizes the acquired IPR&amp;D over its estimated useful life. Capitalized IPR&amp;D is reviewed annually for impairment or more frequently as changes in circumstance or the occurrence of events suggest that the remaining value may not be recoverable. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The provisions of the FASB ASC Topic 740, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes</div></div>, addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC Topic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">740-10,</div> the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based on the technical merits of the position. The Company has determined that it has uncertain tax positions. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for income taxes using the asset and liability method to compute the differences between the tax basis of assets and liabilities and the related financial amounts, using currently enacted tax rates. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has deferred tax assets, which are subject to periodic recoverability assessments. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount that more likely than not will be realized. As of December&#160;31, 2021 and 2020, the Company maintained a full valuation allowance against its deferred tax assets, with the exception of an amount equal to its deferred tax liabilities that are scheduled to reverse against the Company&#8217;s deferred tax assets. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:LesseeLeasesPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Leases </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company determines if an arrangement is a lease at inception. Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> (&#8220;ROU&#8221;) assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As the Company&#8217;s leases do not provide an implicit rate, it uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any lease payments made and is reduced by lease incentives. The Company&#8217;s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term in selling, general and administrative expenses. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:DerivativesPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Derivative Liabilities </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivative liabilities are recorded on the Company&#8217;s consolidated balance sheets at their fair value on the date of issuance and are revalued on each balance sheet date until such instruments are exercised or expire, with changes in the fair value between reporting periods recorded as other income or expense. </div></div></div></ix:nonNumeric> <div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-6<div style="letter-spacing: 0px; top: 0px;;display:inline;">6</div></div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a><br/></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_63194099_3" continuedAt="TextSelectionAppend_63194099_4"><ix:nonNumeric name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="null;text-indent: 0px;;font-style:italic;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Revenue Recognition&#160;</div> </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s revenue is generated from product sales within the United States. The Company does not have significant costs associated with costs to obtain a contract with its customer. All of the Company&#8217;s revenue and accounts receivable result from a sole customer. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue from product sales is fully comprised of sales of ZTlido. The Company&#8217;s performance obligation with respect to sales of ZTlido is satisfied at a point in time, which transfers control upon delivery of product to the customer. The Company considers control to have transferred upon delivery because the customer has legal title to the product, physical possession of the product has been transferred to the customer, the customer has significant risks and rewards of ownership of the product, and the Company has a present right to payment at that time. Invoicing typically occurs upon shipment and the length of time between invoicing and when payment is due is not significant. The aggregate dollar value of unfulfilled orders as of December&#160;31, 2021 and 2020 were not material. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">For product sales, the Company records <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">gross-to-net</div></div> sales adjustments for commercial and government rebates, fees and chargebacks, wholesaler and distributor fees, sales returns and prompt payment discounts. Such variable consideration is estimated in the period of the sale and is estimated using a most likely amount approach based primarily upon provisions included in the Company&#8217;s customer contract, customary industry practices and current government regulations. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Gross-to-net</div></div> adjustments are generally recorded as contract liabilities under accrued expenses within the Company&#8217;s consolidated balance sheet. </div></div></ix:nonNumeric><ix:nonNumeric name="sclx:RebatesPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Rebates </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">Rebates are discounts which the Company pays under either government or private health care programs. Government rebate programs include state Medicaid drug rebate programs, the Medicare coverage gap discount programs and the Tricare programs. Commercial rebate and fee programs relate to contractual agreements with commercial healthcare providers, under which the Company pays rebates and fees for access to and position on that provider&#8217;s patient drug formulary. Rebates and chargebacks paid under government programs are generally mandated under law, whereas private rebates and fees are generally contractually negotiated by the Company with commercial healthcare providers. Both types of rebates vary over time. The Company records a reduction to gross product sales at the time the customer takes title to the product based on estimates of expected rebate claims. The Company monitors the sales trends and adjust for these rebates on a regular basis to reflect the most recent rebate experience and contractual obligations.</div></div></div></ix:nonNumeric><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><ix:nonNumeric name="sclx:ServiceFeesPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Service Fees </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company compensates its customer and others in the distribution chain for wholesaler and distribution services. The Company has determined such services received up to the date the financial statements were issued are not distinct from the Company&#8217;s sale of products to the customer and, therefore, these payments have been recorded as a reduction of revenue. </div></div></div></ix:nonNumeric><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><ix:nonNumeric name="sclx:SalesReturnsPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Product Returns </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is obligated to accept the return of products sold that are expiring within six months, damaged or do not meet certain specifications. The Company may authorize the return of products sold in accordance with the term of its sales contracts, and estimates allowances for such amounts at the time of sale. The Company estimates the amount of its product sales that may be returned by its customer and record this estimate as a reduction of revenue in the period the related product revenue is recognized.</div></div></div></ix:nonNumeric><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div><ix:nonNumeric name="sclx:CoPaymentAssistancePolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Co-Payment</div> Assistance </div></div></div></div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Patients who have commercial insurance or pay cash and meet certain eligibility requirements may receive <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-payment</div> assistance. The Company accrues for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-payment</div> assistance based on actual program participation and estimates of program redemption using data provided by third-party </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">administrators. </div></div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </ix:continuation><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-6<div style="letter-spacing: 0px; top: 0px;;display:inline;">7</div></div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_63194099_4" continuedAt="TextSelectionAppend_63194099_5"><ix:nonNumeric name="us-gaap:ConcentrationRiskCreditRisk" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Customer Concentration Risk </div></div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">During the fiscal years ended December<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">31, 2021, 2020 and 2019, sales to the Company&#8217;s sole distributor represented <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2020To12_31_2020_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_SoleDistributorMembersrtMajorCustomersAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2019To12_31_2019_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_SoleDistributorMembersrtMajorCustomersAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="P01_01_2021To12_31_2021_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_SoleDistributorMembersrtMajorCustomersAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction></ix:nonFraction></ix:nonFraction>% of net revenue. This exposes the Company to concentration of customer risk. The Company monitors the financial condition of its sole customer, limits its credit exposure by setting credit limits, and has <ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction>t experienced any credit losses for the&#160;years ended December&#160;31, 2021, 2020 and 2019. As the Company continues to expand the commercialization of its product, the Company is not limited to the current customer and has the option of expanding its distribution network with additional distributors through establishing its own affiliates, by acquiring existing third-party business or product rights or by partnering with additional third parties. </div></div></ix:nonNumeric><ix:nonNumeric name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock-Based Compensation </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts </div></div> for stock-based compensation in accordance with FASB ASC Topic 718,<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> Compensation</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#8212;</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock Compensation </div></div>which establishes accounting for equity instruments exchanged for employee and consulting services. Under such provisions, stock-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense, under the straight-line method, over the employee&#8217;s requisite service period (generally the vesting period of the equity grant) or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee&#8217;s</div> vesting period. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For purposes of determining </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> the inputs used in the calculation of stock-based compensation, the Company uses historical data in estimating the expected term of options and determines an estimate of option volatility based on an assessment of historical volatilities of comparable companies whose share prices are publicly available. The Company uses these estimates as inputs in the Black-Scholes option pricing model. Depending upon the number of stock options granted, any fluctuations in these calculations could have a material effect on the results presented in the Company&#8217;s consolidated statement of operations. </div></div></ix:nonNumeric><ix:nonNumeric name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Net Loss per Share </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic net loss </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">per share is computed by dividing net loss for the period by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share reflects the additional dilution from potential issuances of common stock, such as stock issuable pursuant to the exercise of stock options. The treasury stock method is used to calculate the potential dilutive effect of these common stock equivalents. Potentially dilutive shares are excluded from the computation of diluted net loss per share when their effect is anti-dilutive. In periods where a net loss is presented, all potentially dilutive securities are anti-dilutive and are excluded from the computation of diluted net loss per share. </div></div></ix:nonNumeric><ix:nonNumeric name="us-gaap:SegmentReportingPolicyPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Segments </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating segments </div></div> are identified as components of an entity where separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions on how to allocate resources and assesses performance. The Company has determined that its chief operating decision maker is its Chief Executive Officer, as he is responsible for making decisions regarding the allocation of resources and assessing performance as well as for strategic operational decisions. The Company is engaged primarily in the development of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">non-opioid<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">products focused on pain management based on its platform technologies and all sales are based in the United States. Accordingly, the Company has determined that it operates its business as a single reportable segment.</div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"></div> <br/></div></ix:nonNumeric></ix:continuation></div> </div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:nonNumeric name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_63195230"><ix:continuation id="TextSelectionAppend_63194099_5" continuedAt="TextSelectionAppend_63194099_6"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recent Accounting Pronouncements </div></div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In October 2021, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2021-08,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers</div></div>, which requires an acquirer in a </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">business </div></div></div></ix:continuation></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-68 </div></div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a><br/></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <ix:continuation id="TextSelection_63195230"><ix:continuation id="TextSelectionAppend_63194099_6"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">combination to recognize and measure contract assets and contract liabilities in accordance with ASC Topic 606. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2021-08</div> is effective for fiscal years beginning after December&#160;15, 2022 and early adoption is permitted. The Company is evaluating the impact the standard will have on its consolidated financial statements. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In December 2019, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2019-12,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</div></div>. The amendments in this update simplify the accounting for income taxes by removing certain exceptions to the general principles in ASC Topic 740. The amendments also improve consistent application of and simplify U.S. GAAP for other areas of ASC Topic 740 by clarifying and amending existing guidance. The amendments in this update were effective for interim and annual periods for the Company beginning after December&#160;15, 2020. The Company adopted the standard on January&#160;1, 2021. The adoption of the standard had no impact on its consolidated financial statements. </div></div></ix:continuation></ix:continuation> <ix:nonNumeric name="us-gaap:AssetAcquisitionTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_63196065"><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4.</div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Semnur Acquisition </div></div></div></td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">On March</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;18, 2019, the Company completed the Merger. At the closing of the Merger, the Company issued to the holders of Semnur&#8217;s capital stock and options to purchase Semnur&#8217;s common stock, upfront consideration with a value of $<ix:nonFraction name="us-gaap:AssetAcquisitionConsiderationTransferred" contextRef="P03_18_2019To03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">70.0</ix:nonFraction>&#160;million. The upfront consideration was comprised of the following: (a)&#160;a cash payment of approximately $<ix:nonFraction name="us-gaap:PaymentsToAcquireProductiveAssets" contextRef="P03_18_2019To03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">15.0</ix:nonFraction>&#160;million, and (b)&#160;$<ix:nonFraction name="us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" contextRef="P03_18_2019To03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">55.0</ix:nonFraction>&#160;million of shares of the Company&#8217;s common stock (<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets" contextRef="P03_18_2019To03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">47,039,315</ix:nonFraction> shares issued and <ix:nonFraction name="us-gaap:CommonStockSharesSubscribedButUnissued" contextRef="PAsOn03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">352,972</ix:nonFraction> shares issuable, valued at $<ix:nonFraction name="sclx:AssetAcquisitionPricePerShare" contextRef="PAsOn03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">1.16</ix:nonFraction> per share) (the &#8220;Stock Consideration&#8221;). Following the issuance of the Stock Consideration, Sorrento ownership in the Company diluted to approximately <ix:nonFraction name="sclx:PercentageOfOwnershipInterest" contextRef="PAsOn03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">58</ix:nonFraction>% of the Company&#8217;s issued and outstanding capital stock. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Merger Agreement, and upon the terms and subject to the conditions contained therein, the Company also agreed to pay the Semnur Equityholders up to $<ix:nonFraction name="us-gaap:AssetAcquisitionContingentConsiderationLiability" contextRef="PAsOn03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">280.0</ix:nonFraction>&#160;million in aggregate contingent cash consideration based on the achievement of certain milestones, comprised of a $<ix:nonFraction name="us-gaap:AssetAcquisitionContingentConsiderationLiability" contextRef="PAsOn03_18_2019_RegulatoryBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">40.0</ix:nonFraction>&#160;million payment that will be due upon obtaining the first approval of a New Drug Application (&#8220;NDA&#8221;) of a Semnur product by the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) and additional payments that will be due upon the achievement of certain amounts of net sales of Semnur products, as follows: (1)&#160;a $<ix:nonFraction name="us-gaap:AssetAcquisitionContingentConsiderationLiability" contextRef="PAsOn03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheOneMemberSCLXTrancheAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">20.0</ix:nonFraction>&#160;million payment upon the achievement of $<ix:nonFraction name="sclx:RevenueToBeEarnedByTheAcquireeValue" contextRef="P03_18_2019To03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheOneMemberSCLXTrancheAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">100.0</ix:nonFraction>&#160;million in cumulative net sales of a Semnur product, (2)&#160;a $<ix:nonFraction name="us-gaap:AssetAcquisitionContingentConsiderationLiability" contextRef="PAsOn03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheTwoMemberSCLXTrancheAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">20.0</ix:nonFraction>&#160;million payment upon the achievement of $<ix:nonFraction name="sclx:RevenueToBeEarnedByTheAcquireeValue" contextRef="P03_18_2019To03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheTwoMemberSCLXTrancheAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">250.0</ix:nonFraction>&#160;million in cumulative net sales of a Semnur product, (3)&#160;a $<ix:nonFraction name="us-gaap:AssetAcquisitionContingentConsiderationLiability" contextRef="PAsOn03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheThreeMemberSCLXTrancheAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">50.0</ix:nonFraction>&#160;million payment upon the achievement of $<ix:nonFraction name="sclx:RevenueToBeEarnedByTheAcquireeValue" contextRef="P03_18_2019To03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheThreeMemberSCLXTrancheAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">500.0</ix:nonFraction>&#160;million in cumulative net sales of a Semnur product, and (4)&#160;a $<ix:nonFraction name="us-gaap:AssetAcquisitionContingentConsiderationLiability" contextRef="PAsOn03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheFourMemberSCLXTrancheAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">150.0</ix:nonFraction>&#160;million payment upon the achievement of $<ix:nonFraction name="sclx:RevenueToBeEarnedByTheAcquireeValue" contextRef="P03_18_2019To03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheFourMemberSCLXTrancheAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">750.0</ix:nonFraction>&#160;million in cumulative net sales of a Semnur product. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On August&#160;7, 2019, the Company </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">entered into an amendment to the Merger Agreement to provide that, following the consummation of the Company&#8217;s first bona fide equity financing with one or more third-party financing sources on an arms&#8217; length basis with gross proceeds to the Company of at least $</div><ix:nonFraction name="us-gaap:ProceedsFromDivestitureOfBusinesses" contextRef="P08_07_2019To08_07_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">40.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, certain of the former Semnur optionholders will be paid cash in lieu of: (1)&#160;the </div><ix:nonFraction name="us-gaap:CommonStockSharesSubscribedButUnissued" contextRef="PAsOn08_07_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">352,972</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares of the Company&#8217;s common stock otherwise issuable to such former Semnur optionholders pursuant to the Merger Agreement, and (2)&#160;any shares that would otherwise be issued to such former Semnur optionholders upon release of shares held in escrow pursuant to the Merger Agreement, with such shares in each case valued at $</div><ix:nonFraction name="sclx:AssetAcquisitionPricePerShare" contextRef="PAsOn08_07_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">1.16</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> per share. The amendment resulted in a reclassification of $</div><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" contextRef="PAsOn08_07_2019_AsRestatedMembersrtRestatementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.4</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million from additional </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> capital to accrued liabilities.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In March 2019, the </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Semnur Equityholders that received the Stock Consideration were required to sign an Exchange and Registration Rights Agreement with the Company (the &#8220;Exchange Agreement&#8221;).Pursuant to the Exchange Agreement, and upon the terms and subject to the conditions contained therein, if within </div>18<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;months</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>following the closing of the Merger, </div><ix:nonFraction name="sclx:PercentageOfSharesIssuedSubjectToRestrictionOfTransfer" contextRef="PAsOn03_01_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the outstanding equity of the Company has not been acquired by a third party or the Company has not entered into a definitive agreement with respect to, or otherwise consummated, a firmly underwritten offering of the Company capital stock on a major stock exchange that meets certain requirements, then holders of the Stock Consideration may collectively elect to exchange, during the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="sclx:PeriodDuringWhichTheSharesMayBeExchanged" contextRef="P03_01_2019To03_31_2019_SenmurMemberusgaapAssetAcquisitionAxis" format="ixt-sec:durday">60</ix:nonNumeric>-day</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> period commencing the date that is the </div><ix:nonNumeric name="sclx:PeriodDuringWhichShareTransferIsRestricted" contextRef="P03_01_2019To03_31_2019_SenmurMemberusgaapAssetAcquisitionAxis" format="ixt-sec:durmonth">18</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> month anniversary of the Closing (the &#8220;Share Exchange&#8221;), the Stock Consideration for shares of Sorrento&#8217;s common stock with a value of $</div><ix:nonFraction name="sclx:CommonStockValueToBeExchanged" contextRef="P03_01_2019To03_31_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">55.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million based on a price per share of Sorrento&#8217;s common stock equal to the greater of (a)&#160;the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="sclx:NumberOfDaysForDeterminingTheWeightedVolumeAveragePriceForShares" contextRef="P03_01_2019To03_31_2019_SenmurMemberusgaapAssetAcquisitionAxis" format="ixt-sec:durday">30</ix:nonNumeric>-day</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> trailing volume weighted average price</div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-69 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_63196065"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">of<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">one share of Sorrento&#8217;s common stock as reported on The Nasdaq Stock Market LLC as of the consummation of the Share Exchange and (b)&#160;$</div><ix:nonFraction name="sclx:PricePerShareForDeterminingTheExchangeOfShares" contextRef="PAsOn03_01_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">5.55</ix:nonFraction><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"> (subject to adjustment for any stock dividend, stock split, stock combination, reclassification or similar transaction) (the &#8220;Exchange Price&#8221;). Pursuant to an amendment to the Exchange Agreement entered into by Sorrento on September&#160;</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">28</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">, </div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">2020</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">, on October&#160;</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">9</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">, </div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">2020</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">, Sorrento paid $</div><ix:nonFraction name="sclx:PaymentMadeInSurrenderingTheShares" contextRef="P03_01_2019To03_31_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">55.0</ix:nonFraction><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in cash to the Semnur Equityholders in lieu of issuing $</div><ix:nonFraction name="sclx:PaymentMadeInSurrenderingTheShares" contextRef="P03_01_2019To03_31_2019_SenmurMemberusgaapAssetAcquisitionAxis_SorrentoMemberSCLXInvesteeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">55.0</ix:nonFraction><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million of shares of Sorrento&#8217;s<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">common stock at the Exchange Price. Following the completion of the Share Exchange and as of December&#160;31, 2020, Sorrento held approximately </div><ix:nonFraction name="sclx:PercentageOfSharesOutstanding" contextRef="PAsOn12_31_2020_SenmurMemberusgaapAssetAcquisitionAxis_SorrentoMemberSCLXInvesteeAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">82.3</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the outstanding common stock of the Company. On January&#160;29, 2021, Sorrento acquired additional shares of the Company, resulting in Sorrento holding approximately </div><ix:nonFraction name="sclx:PercentageOfSharesOutstanding" contextRef="PAsOn01_29_2021_SenmurMemberusgaapAssetAcquisitionAxis_SorrentoMemberSCLXInvesteeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">99.97</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the outstanding common stock of the </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Company.</div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The transaction was accounted for as an asset acquisition since substantially all the value of the gross assets was concentrated in the single asset, </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-102.</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> As a result, approximately $</div><ix:nonFraction name="us-gaap:ResearchAndDevelopmentInProcess" contextRef="P01_01_2019To12_31_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">75.3</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">million was expensed as a component of acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development during the year ended December&#160;31, 2019. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><ix:nonFraction name="us-gaap:AssetAcquisitionContingentConsiderationLiability" contextRef="PAsOn12_31_2021_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:AssetAcquisitionContingentConsiderationLiability" contextRef="PAsOn12_31_2020_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> contingent consideration was recorded as of December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> since the related regulatory approval milestones are not deemed probable until they actually occur.</div></div> </ix:continuation> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:nonNumeric name="us-gaap:FairValueDisclosuresTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_63195193">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">5</div>.</div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair Value Measurements </div></div></div></td></tr></table> <ix:nonNumeric name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents the Company&#8217;s financial assets and liabilities that are measured at fair value (in </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">thousands): </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 52%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair value measurements at December&#160;31, 2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Balance</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Quoted&#160;Prices<br/>in&#160;Active<br/>Markets<br/>(Level 1)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level&#160;2)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 0px;">
<td style="width: 52%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-size: 0px;">
<td style="width: 52%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 52%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 52%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,338</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,338</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 52%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 52%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets measured at fair value</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,338</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,338</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 52%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 52%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivative liabilities</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">35,700</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">35,700</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 52%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 52%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities measured at fair value</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">35,700</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">35,700</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap;"></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 52%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair value measurements at December&#160;31, 2020</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Balance</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Quoted&#160;Prices<br/>in&#160;Active<br/>Markets<br/>(Level&#160;1)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level&#160;2)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 52%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 52%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,839</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn12_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,839</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 52%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 52%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets measured at fair value</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,839</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,839</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 52%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 52%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivative liabilities</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">35,400</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn12_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">35,400</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 52%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Total liabilities measured at fair value</div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">35,400</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">35,400</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table></ix:nonNumeric> </ix:nonNumeric> </div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div><ix:continuation id="TextSelection_63195193" continuedAt="TextSelectionAppend_63195193_1"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s financial assets carried at fair value are comprised of cash and cash equivalents. Cash and cash equivalents consist of money market accounts and bank deposits which are highly liquid and readily tradable. These assets are valued using inputs observable in active markets for identical securities. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-70 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_63195193_1"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="null;text-indent: 0px;;font-style:italic;display:inline;">Derivative liabilities</div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company recorded a loss of $</div><ix:nonFraction name="us-gaap:DerivativeLossOnDerivative" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.3</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, a gain of $</div><ix:nonFraction name="us-gaap:DerivativeGainOnDerivative" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="1" scale="0" format="ixt:num-dot-decimal">0.8</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and a loss of $</div><ix:nonFraction name="us-gaap:DerivativeLossOnDerivative" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">23.3</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million on derivative liabilities for the&#160;years ended December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, respectively, which was attributed to compound derivative liabilities associated with the Scilex Pharma Notes. The compound derivative liabilities consist of the fair value of various embedded features as further described in Note </div>8<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. The fair value of the derivative liabilities associated with the Scilex Pharma Notes was estimated using the discounted cash flow method under the income approach combined with a Monte Carlo simulation model. This involves significant Level&#160;</div>3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> inputs and assumptions.</div><br/></div> <div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">The<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">key assumptions for the compound derivative liabilities associated with the Scilex Pharma Notes for the year ended December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> included a </div><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="PAsOn12_20_2021_MeasurementInputRiskadjustedNetSalesForecastMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_pure" decimals="1" scale="0" format="ixt:num-dot-decimal">6.2</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% risk-adjusted net sales forecast and an effective debt yield of </div><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="PAsOn12_20_2021_MeasurementInputEffectiveDebtYieldMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_pure" decimals="1" scale="0" format="ixt:num-dot-decimal">15.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">%. The key assumptions for the compound derivative liabilities associated with the Scilex Pharma Notes for the year ended December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> included a </div><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="PAsOn12_31_2020_MeasurementInputRiskadjustedNetSalesForecastMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_pure" decimals="0" scale="0" format="ixt:num-dot-decimal">7</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% risk-adjusted net sales forecast, an effective debt yield of </div><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="PAsOn12_31_2020_MeasurementInputEffectiveDebtYieldMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_pure" decimals="0" scale="0" format="ixt:num-dot-decimal">15</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% and an estimated probability of </div><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="PAsOn12_31_2020_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeMarch312021MemberusgaapMeasurementInputTypeAxis" unitRef="Unit_pure" decimals="0" scale="0" format="ixt:num-dot-decimal">100</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of not obtaining marketing approval before March&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. The key assumptions for the compound derivative liabilities associated with the Scilex Pharma Notes for the year ended December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> included an </div><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="PAsOn12_31_2019_MeasurementInputRiskadjustedNetSalesForecastMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_pure" decimals="0" scale="0" format="ixt:num-dot-decimal">8</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% risk adjusted net sales forecast, an effective debt yield of </div><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="PAsOn12_31_2019_MeasurementInputEffectiveDebtYieldMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_pure" decimals="1" scale="0" format="ixt:num-dot-decimal">19.7</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% and estimated probabilities of </div><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="PAsOn12_31_2019_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeMarch312021MemberusgaapMeasurementInputTypeAxis" unitRef="Unit_pure" decimals="0" scale="0" format="ixt:num-dot-decimal">100</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% and </div><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="PAsOn12_31_2019_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeJuly12023MemberusgaapMeasurementInputTypeAxis" unitRef="Unit_pure" decimals="0" scale="0" format="ixt:num-dot-decimal">55</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of not obtaining marketing approval before March&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and July&#160;</div>1<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2023<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, respectively, and an estimated high probability of an initial public offering of the Company that satisfies certain valuation thresholds occurring prior to October&#160;</div>1<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">.</div></div> <ix:nonNumeric name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table includes a summary of the derivative liabilities measured at fair value using significant unobservable inputs (Level 3) during the years ended December&#160;31, 2021, 2020 and 2019: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 84%;"></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 84%; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Beginning Balance at December&#160;31, 2018</div></div></div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 84%; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additions</div></div></div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" contextRef="P01_01_2019To12_31_2019_DerivativeFinancialInstrumentsLiabilitiesMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,100</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 84%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-measurement</div> of fair value</div></div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P01_01_2019To12_31_2019_DerivativeFinancialInstrumentsLiabilitiesMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">23,300</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 84%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 84%; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ending Balance at December&#160;31, 2019</div></div></div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn12_31_2019_DerivativeFinancialInstrumentsLiabilitiesMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">33,400</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 84%; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additions</div></div></div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" contextRef="P01_01_2020To12_31_2020_DerivativeFinancialInstrumentsLiabilitiesMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,800</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 84%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-measurement</div> of fair value</div></div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P01_01_2020To12_31_2020_DerivativeFinancialInstrumentsLiabilitiesMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">800</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 84%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 84%; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ending Balance at December&#160;31, 2020</div></div></div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn12_31_2020_DerivativeFinancialInstrumentsLiabilitiesMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">35,400</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 84%; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additions</div></div></div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 84%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-measurement</div> of fair value</div></div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P01_01_2021To12_31_2021_DerivativeFinancialInstrumentsLiabilitiesMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">300</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 84%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em;">Ending Balance at December&#160;31, 2021</div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn12_31_2021_DerivativeFinancialInstrumentsLiabilitiesMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">35,700</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric> </ix:continuation> <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and Equipment </div></div></div></div></td></tr></table> <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment consisted of the following as of December&#160;31, 2021 and 2020 (in thousands): </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 80%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Computers&#160;&amp; equipment</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">77</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2020_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">77</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Furniture</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2021_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">118</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2020_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">118</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leasehold improvements</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2021_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">48</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2020_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">48</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Construction in progress</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2021_ConstructionInProgressMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">689</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2020_ConstructionInProgressMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">691</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment, gross</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">932</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">934</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: Accumulated depreciation</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">127</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">88</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment, <div style="letter-spacing: 0px; top: 0px;;display:inline;">net</div></div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">805</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">846</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table></ix:nonNumeric> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation expense<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">for each of the&#160;years ended December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> was $</div><ix:nonFraction name="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseGross" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">39</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;thousand, $</div><ix:nonFraction name="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseGross" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">40</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;thousand and $</div><ix:nonFraction name="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseGross" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">40</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;thousand, respectively.</div><br/></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></ix:nonNumeric> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-71 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:nonNumeric name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_63195229">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill and Intangible Assets </div></div></div></div></td></tr></table><div style="clear: both; max-height: 0px; text-indent: 0px;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company had recorded goodwill of $</div><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">13.5</ix:nonFraction></ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million. The Company performed a qualitative test for goodwill impairment during the fourth quarter of </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. Based upon the results of the qualitative testing, the Company concluded that it is </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">more-likely-than-not</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> that the fair value of the Company&#8217;s goodwill was in excess of the carrying value and therefore performing the first step of the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-step</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> impairment test was unnecessary. </div><ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction></ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> goodwill impairment was recognized for the&#160;years ended December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, and </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">.</div><br/></div></ix:nonNumeric></div></div><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <ix:continuation id="TextSelection_63195229" continuedAt="TextSelectionAppend_63195229_1"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">The</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;Company&#8217;s intangible assets, excluding goodwill, are composed of patent rights, acquired technology and assembled workforce. Amortization of the intangible assets that have finite useful lives is generally recorded on a straight-line basis over their useful lives. </div><ix:nonNumeric name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_63195218">A summary of the Company&#8217;s identifiable intangible assets as of December&#160;31, 2021 and 2020 is as follows (in thousands):</ix:nonNumeric></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelection_63195218">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 61%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross&#160;<br/>carrying</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">amortization</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Intangibles,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">net</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 61%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Patent rights</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2021_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">32,630</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn12_31_2021_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,239</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2021_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">21,391</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 61%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquired technology</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2021_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">21,940</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn12_31_2021_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,754</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2021_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">17,186</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em;">Assembled workforce</div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2021_AssembledWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn12_31_2021_AssembledWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">275</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2021_AssembledWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">225</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 61%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em;">Total intangible assets</div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">55,070</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">16,268</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">38,802</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 61%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross&#160;<br/>carrying</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">amortization</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Intangibles,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">net</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 61%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Patent rights</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2020_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">32,630</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn12_31_2020_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,064</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2020_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">23,566</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 61%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquired technology</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2020_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">21,940</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn12_31_2020_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,291</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2020_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">18,649</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em;">Assembled workforce</div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2020_AssembledWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn12_31_2020_AssembledWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">175</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2020_AssembledWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">325</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 61%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em;">Total intangible assets</div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">55,070</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,530</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">42,540</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table> </ix:continuation> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the weighted average remaining life for identifiable intangible assets is </div><ix:nonNumeric name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" contextRef="P01_01_2021To12_31_2021_WeightedAverageMembersrtRangeAxis" format="ixt-sec:duryear">10.6</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;years. Aggregate amortization expense was $</div><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.7</ix:nonFraction></ix:nonFraction></ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million for each of the&#160;years ended December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, and </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. Patent rights and acquired technology are amortized over a </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" contextRef="P01_01_2021To12_31_2021_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" format="ixt-sec:duryear"><ix:nonNumeric name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" contextRef="P01_01_2021To12_31_2021_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" format="ixt-sec:duryear">15</ix:nonNumeric></ix:nonNumeric>-year</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> period. Assembled workforce is amortized over a </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" contextRef="P01_01_2021To12_31_2021_AssembledWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" format="ixt-sec:duryear">5</ix:nonNumeric>-year</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> period.</div></div></ix:continuation> <ix:nonNumeric name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><ix:continuation id="TextSelectionAppend_63195229_1" continuedAt="TextSelectionAppend_63195229_2"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Estimated future amortization expense related to intangible assets at December&#160;31, 2021 is as follows (in thousands): </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 85%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ending December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,738</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,738</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,663</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,638</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2026</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,638</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Thereafter</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20,387</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">38,802</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table></ix:continuation></ix:nonNumeric> <ix:continuation id="TextSelectionAppend_63195229_2"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> impairment charges related to intangible assets were recorded during the&#160;years ended </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">December&#160;31, 2021 and 2020. </div></div><br/></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-72 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <ix:nonNumeric name="us-gaap:DebtDisclosureTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_63196069">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">8.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Debt </div></div></div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2018 Purchase Agreements and Indenture </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On September&#160;</div>7<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2018<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Scilex Pharma and Sorrento entered into Purchase Agreements (the &#8220;</div>2018<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Purchase Agreements&#8221;) with certain investors (collectively, the &#8220;Scilex Pharma Note Purchasers&#8221;). Pursuant to the </div>2018<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Purchase Agreements, on September&#160;</div>7<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2018<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Scilex Pharma, among other things, issued and sold to the Scilex Pharma Note Purchasers senior secured notes due </div><ix:nonNumeric name="us-gaap:DebtInstrumentTerm" contextRef="P09_07_2018To09_07_2018_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis" format="ixt-sec:duryear">2026</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> in an aggregate principal amount of $</div><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn09_07_2018_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">224.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million (the &#8220;Scilex Pharma Notes&#8221;) for an aggregate purchase price of $</div><ix:nonFraction name="us-gaap:DebtInstrumentRepurchaseAmount" contextRef="PAsOn09_07_2018_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">140.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million (the &#8220;Offering&#8221;). The Scilex Pharma Notes are governed by an indenture (as amended, the &#8220;Indenture&#8221;) with Scilex Pharma, as issuer, U.S. </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bank </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">National</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;Association, a national banking association, as trustee (the &#8220;Trustee&#8221;) and collateral agent (the &#8220;Collateral Agent&#8221;), and Sorrento, as guarantor. Pursuant to the Indenture, Sorrento agreed to irrevocably and unconditionally guarantee, on a senior unsecured basis, the punctual performance and payment when due of all obligations of Scilex Pharma under the Indenture (the &#8220;Guarantee&#8221;).</div></div> <div style="clear: both; max-height: 0px;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The net proceeds of the Offering were approximately $</div><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" contextRef="P09_07_2018To09_07_2018_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">89.3</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, after deducting the Offering expenses payable by Scilex Pharma and funding a segregated reserve account with $</div><ix:nonFraction name="sclx:PaymentToDepositIntoASeggregateReserveFund" contextRef="P09_07_2018To09_07_2018_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">20.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million (the &#8220;Reserve Account&#8221;) and a segregated collateral account with $</div><ix:nonFraction name="sclx:PaymentToDepositIntoASegregatedCollateralAccount" contextRef="P09_07_2018To09_07_2018_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">25.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million (the &#8220;Collateral Account&#8221;) pursuant to the terms of the Indenture. Funds in the Reserve Account were to be released to Scilex Pharma upon receipt by the Trustee of an officer&#8217;s certificate under the Indenture from Scilex Pharma confirming receipt of a marketing approval letter from the FDA with respect to </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-103</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> or a similar product with a concentration of not less than </div><ix:nonFraction name="sclx:PercentageOfConcentrationOnASimilarProduct" contextRef="P09_07_2018To09_07_2018_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">5</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% (the &#8220;Marketing Approval Letter&#8221;) on or prior to July&#160;</div>1<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2023<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. Funds in the Collateral Account were to be released to Scilex Pharma only upon receipt of a written consent authorizing such release from the holders of a majority in principal amount of the Scilex Pharma Notes issued, upon the occurrence and during the continuance of an event of default at the direction of the holders of a majority in principal amount of the Scilex Pharma Notes issued or upon the repayment in full of all amounts owed under the Scilex Pharma Notes.</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On each February&#160;</div>15<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, May&#160;</div>15<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, August&#160;</div>15<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and November&#160;</div>15<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, beginning with February&#160;</div>15<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the holders of the Scilex Pharma Notes were initially entitled to receive quarterly payments of the principal of the Scilex Pharma Notes equal to a fixed&#160;percentage, ranging from </div><ix:nonFraction name="sclx:PercentageOfQuarterlyPaymentsOfThePrincipalNotesEqualToAFixedPercentage" contextRef="P02_15_2019To02_15_2019_MinimumMembersrtRangeAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">10</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% to </div><ix:nonFraction name="sclx:PercentageOfQuarterlyPaymentsOfThePrincipalNotesEqualToAFixedPercentage" contextRef="P02_15_2019To02_15_2019_MaximumMembersrtRangeAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">20</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">%, of the net sales of ZTlido for the prior fiscal quarter. However, because Scilex Pharma did not receive the Marketing Approval Letter by March&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the&#160;percentage of net sales payable was increased to be in the range of </div><ix:nonFraction name="sclx:PercentageOfNetSalesPayable" contextRef="P02_15_2019To02_15_2019_MinimumMembersrtRangeAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">15</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% to </div><ix:nonFraction name="sclx:PercentageOfNetSalesPayable" contextRef="P02_15_2019To02_15_2019_MaximumMembersrtRangeAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">25</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">%. If actual cumulative net sales of ZTlido from October&#160;</div>1<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> through September&#160;</div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2023<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> are less than approximately $</div><ix:nonFraction name="us-gaap:RevenueNotFromContractWithCustomer" contextRef="P10_01_2022To09_30_2023_DebtInstrumentRedemptionPeriodOneMemberusgaapDebtInstrumentRedemptionPeriodAxis_ScenarioAdjustmentMembersrtStatementScenarioAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">218.1</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, then Scilex Pharma will be obligated to pay an additional installment of the principal of the Scilex Pharma Notes each quarter in an amount between approximately $</div><ix:nonFraction name="us-gaap:RepaymentsOfDebt" contextRef="P10_01_2022To09_30_2023_DebtInstrumentRedemptionPeriodOneMemberusgaapDebtInstrumentRedemptionPeriodAxis_MinimumMembersrtRangeAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">10.1</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and approximately $</div><ix:nonFraction name="us-gaap:RepaymentsOfDebt" contextRef="P10_01_2022To09_30_2023_DebtInstrumentRedemptionPeriodOneMemberusgaapDebtInstrumentRedemptionPeriodAxis_MaximumMembersrtRangeAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">30.6</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, with the amount of the additional installment of principal to be determined by reference to the amount by which cumulative net sales of ZTlido from October&#160;</div>1<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> through September&#160;</div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2023<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> are less than approximately $</div><ix:nonFraction name="us-gaap:RevenueNotFromContractWithCustomer" contextRef="P10_01_2022To09_30_2023_DebtInstrumentRedemptionPeriodOneMemberusgaapDebtInstrumentRedemptionPeriodAxis_ScenarioAdjustmentMembersrtStatementScenarioAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">218.1</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million.</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the terms of the Indenture, the aggregate principal amount due under the Scilex Pharma Notes was to be increased by $</div><ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPayment" contextRef="P02_15_2022To02_15_2022_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">28.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million on February&#160;</div>15<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> if actual cumulative net sales of ZTlido from September&#160;</div>7<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2018<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> through December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> were less than approximately $</div><ix:nonFraction name="us-gaap:RevenueNotFromContractWithCustomer" contextRef="P09_07_2018To12_31_2021_DebtInstrumentRedemptionPeriodTwoMemberusgaapDebtInstrumentRedemptionPeriodAxis_ScenarioAdjustmentMembersrtStatementScenarioAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">481.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million. As actual cumulative net sales of ZTlido from the issue date of the Scilex Pharma Notes through December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> did not equal or exceed the $</div>481.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million threshold for such period, the Company recorded the increase of $</div><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn02_15_2022_MaximumMembersrtRangeAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">28.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in the debt principal balance with an offset to Scilex Pharma Notes principal increase at December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">.</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If actual cumulative net sales of ZTlido for the period from October&#160;</div>1<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> through September&#160;</div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2023<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> are less than approximately $</div><ix:nonFraction name="us-gaap:RevenueNotFromContractWithCustomer" contextRef="P10_01_2022To09_30_2023_DebtInstrumentRedemptionPeriodThreeMemberusgaapDebtInstrumentRedemptionPeriodAxis_ScenarioAdjustmentMembersrtStatementScenarioAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">290.7</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, then the aggregate principal amount due under the Scilex Pharma Notes will be increased on </div><ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" contextRef="P10_01_2022To09_30_2023_DebtInstrumentRedemptionPeriodThreeMemberusgaapDebtInstrumentRedemptionPeriodAxis_ScenarioAdjustmentMembersrtStatementScenarioAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis" format="ixt:date-monthname-day-year-en">November 15, 2023</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> by between approximately $</div><ix:nonFraction name="us-gaap:RepaymentsOfDebt" contextRef="P10_01_2022To09_30_2023_DebtInstrumentRedemptionPeriodThreeMemberusgaapDebtInstrumentRedemptionPeriodAxis_MinimumMembersrtRangeAxis_ScenarioAdjustmentMembersrtStatementScenarioAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.6</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and approximately $</div><ix:nonFraction name="us-gaap:RepaymentsOfDebt" contextRef="P10_01_2022To09_30_2023_DebtInstrumentRedemptionPeriodThreeMemberusgaapDebtInstrumentRedemptionPeriodAxis_MaximumMembersrtRangeAxis_ScenarioAdjustmentMembersrtStatementScenarioAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">84.8</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, with the amount of the principal increase to be determined by reference to the amount by which the cumulative net sales of ZTlido from October&#160;</div>1<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> through September&#160;</div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2023<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> is less than approximately $</div>290.7<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million.</div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></ix:nonNumeric> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-73 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_63196069" continuedAt="TextSelectionAppend_63196069_1"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">final maturity date of the Scilex Pharma Notes is </div><ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" contextRef="P02_15_2019To02_15_2019_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" format="ixt:date-monthname-day-year-en">August 15, 2026</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. The Scilex Pharma Notes may be redeemed in whole at any time upon </div><ix:nonNumeric name="sclx:DebtInstrumentredemptionPeriod" contextRef="P02_15_2019To02_15_2019_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" format="ixt-sec:durday">30</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;days&#8217; written notice at Scilex Pharma&#8217;s option prior to August&#160;</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">15</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2026</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">at a redemption price equal to <ix:nonFraction name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" contextRef="P02_15_2019To02_15_2019_MinimumMembersrtRangeAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction>% of the then-outstanding principal amount of the Scilex Pharma Notes. In addition, upon a change of control of Scilex Pharma (as defined in the Indenture), each holder of a Scilex Pharma Note shall have the right to require Scilex Pharma to repurchase all or any part of such holder&#8217;s Scilex Pharma Note at a repurchase price in cash equal to <ix:nonFraction name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" contextRef="P02_15_2019To02_15_2019_MaximumMembersrtRangeAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">101</ix:nonFraction>% of the then-outstanding principal amount </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">thereof.</div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">The 2018 Purchase&#160;</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Agreements include the terms and conditions of the offer and sale of the Scilex Pharma Notes, representations and warranties of the parties, indemnification and contribution obligations and other terms and conditions customary in agreements of this </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">type. </div></div><br/></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">The<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Indenture governing the Scilex Pharma Notes contains customary events of default with respect to the Scilex Pharma Notes (including a failure to make any payment of principal on the Scilex Pharma Notes when due and payable), and, upon certain events of default occurring and continuing, the Trustee by notice to Scilex Pharma, or the holders of at least </div><ix:nonFraction name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" contextRef="P02_15_2019To02_15_2019_IndebentureMemberSCLXAgreementAxis_MinimumMembersrtRangeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">25</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% in principal amount of the outstanding Scilex Pharma Notes by notice to Scilex Pharma and the Trustee, may (subject to the provisions of the Indenture) declare </div><ix:nonFraction name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" contextRef="P02_15_2019To02_15_2019_IndebentureMemberSCLXAgreementAxis_MaximumMembersrtRangeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the then-outstanding principal amount of the Scilex Pharma Notes to be due and payable. Upon such a declaration of acceleration, such principal will be due and payable immediately. In the case of certain events, including bankruptcy, insolvency or reorganization involving Sorrento or Scilex Pharma, the Scilex Pharma Notes will automatically become due and payable.</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the Indenture, the Company and Scilex Pharma must also comply with certain covenants with respect to the commercialization of ZTlido, as well as customary additional affirmative covenants, such as furnishing financial statements to the holders of the Scilex Pharma Notes, minimum cash requirements and net sales reports; and negative covenants, including limitations on the following: the incurrence of debt; the payment of dividends, the repurchase of shares and under certain conditions making certain other restricted payments; the prepayment, redemption or repurchase of subordinated debt; a merger, amalgamation or consolidation involving Scilex Pharma; engaging in certain transactions with affiliates; and the making of investments other than those permitted by the Indenture.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Scilex Pharma Notes and related Guarantee have not been, and will not be, registered under the Securities Act or the securities laws of any other jurisdiction and may not be offered or sold in the United States without registration or an applicable exemption from registration requirements. The holders of the Scilex Pharma Notes do not have any registration rights. Pursuant to a Collateral Agreement by and among Scilex Pharma, the Trustee and the Collateral Agent (the &#8220;Collateral Agreement&#8221;), the Scilex Pharma Notes will be secured by ZTlido and all of the existing and future property and assets of Scilex Pharma necessary for, or otherwise relevant to, now or in the future, the manufacture and sale of ZTlido, on a worldwide basis (exclusive of Japan), including, but not limited to, the intellectual property related to ZTlido, the marketing or similar regulatory approvals related to ZTlido, any licenses, agreements and other contracts related to ZTlido, and the current assets related to ZTlido such as inventory, accounts receivable and cash and any and all future iterations, improvements or modifications of such product made, developed or licensed (or </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-licensed)</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> by Scilex Pharma or any of its affiliates or licensees (or </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-licensees)</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> (including </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-103).</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the terms of the Indenture, Sorrento issued an irrevocable standby letter of credit to Scilex Pharma (the &#8220;Letter of Credit&#8221;), which provides that, in the event that </div>(1)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;Scilex Pharma did not hold at least $</div><ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" contextRef="P09_07_2018To12_31_2021_LetterOfCreditMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">4.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in unrestricted cash as of the end of any calendar month during the term of the Scilex Pharma Notes, </div>(2)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;actual cumulative net sales of ZTlido from September&#160;</div>7<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2018<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> through December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> were less than a specified sales threshold for such period, or </div>(3)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;actual cumulative net sales of ZTlido for any calendar year during the term of the Scilex Pharma Notes, beginning with the </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> calendar year, were less than a specified sales threshold for such calendar year, Scilex Pharma as beneficiary of the Letter of Credit, would be required to draw, and Sorrento would be required to pay to Scilex Pharma, $</div><ix:nonFraction name="us-gaap:RepaymentsOfLinesOfCredit" contextRef="P09_07_2018To12_31_2021_LetterOfCreditMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">35.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in a single </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lump-su</div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">m</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> amo</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">unt as a subordinated loan. The Letter of Credit was to terminate upon the earliest to occur of: (a)&#160;the repayment of the</div></div></ix:continuation> <div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-74 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_63196069_1" continuedAt="TextSelectionAppend_63196069_2"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">Scilex<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">Pharma Notes in full, (b)&#160;the actual net sales of ZTlido for any calendar year during the term of the Scilex Pharma Notes exceeding a certain threshold, (c)&#160;the consummation of an initial public offering on a major international stock&#160;</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">exchange by the Company that satisfies certain valuation thresholds, and (d)&#160;the replacement of the Letter of Credit with another letter of credit in form and substance, including as to the identity and creditworthiness of issuer, reasonably acceptable to the holders of at least 80% in principal amount of outstanding Scilex Pharma Notes.</div></div></div></ix:continuation></div><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"></div></div><ix:continuation id="TextSelectionAppend_63196069_2" continuedAt="TextSelectionAppend_63196069_3"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">On<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">December&#160;14, 2020, Scilex,</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Sorrento, the Trustee and the Agent, and the beneficial owners of the Scilex Pharma Notes and the Scilex Note Purchasers entered into a Consent Under and Amendment No.&#160;</div>3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> to Indenture and Letter of Credit (&#8220;Amendment No.&#160;</div>3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8221;), which amended: (i)&#160;the Indenture, and (ii)&#160;the Letter of </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Credit.</div></div><br/></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> to Amendment No.&#160;</div>3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Holders agreed to release all of the aggregate $</div><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn12_14_2020_IndebentureMemberSCLXAgreementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">45.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in restricted funds held in the Reserve Account and the Collateral Account for the purpose of consummating the repurchase of an aggregate of $</div><ix:nonFraction name="us-gaap:DebtInstrumentRepurchasedFaceAmount" contextRef="PAsOn12_14_2020_IndebentureMemberSCLXAgreementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">45.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million of principal amount of the Scilex Pharma Notes from the Holders on a pro&#160;rata basis at a purchase price equal to </div><ix:nonFraction name="sclx:PercentageOfThePrincipalAmountFromHoldersOnProRataBasis" contextRef="P12_14_2020To12_14_2020_IndebentureMemberSCLXAgreementAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the principal amount thereof (such repurchase, the &#8220;Scilex Repurchase&#8221;). In connection with the Scilex Repurchase, the parties also agreed to remove (i)&#160;Sorrento&#8217;s obligations under the Indenture to repurchase $</div><ix:nonFraction name="us-gaap:DebtInstrumentRepurchasedFaceAmount" contextRef="PAsOn12_14_2020_IfLetterOfCreditIsDrawnMembersrtStatementScenarioAxis_IndebentureMemberSCLXAgreementAxis_LetterOfCreditMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">25.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million of Scilex Pharma Notes from the Holders if the Letter of Credit is drawn on and (ii)&#160;Scilex Pharma&#8217;s obligation to repurchase $</div><ix:nonFraction name="us-gaap:DebtInstrumentRepurchasedFaceAmount" contextRef="PAsOn12_14_2020_IndebentureMemberSCLXAgreementAxis_LetterOfCreditMemberusgaapCreditFacilityAxis_MarketingApprovalLetterMembersrtStatementScenarioAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">20.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million of Scilex Pharma Notes from the Holders if Scilex Pharma did not receive the Marketing Approval Letter on or prior to</div> <ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" contextRef="P12_14_2020To12_14_2020_IndebentureMemberSCLXAgreementAxis" format="ixt:date-monthname-day-year-en">July 1, 2023</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. On December&#160;</div>14<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the restricted funds in the Reserve Account and the Collateral Account were released and the Scilex Repurchase was effected.</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">Amendment</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;No.&#160;</div>3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> also revised the minimum cash covenant in the Indenture to provide that the amount of cash equivalents in bank accounts that Scilex Pharma is required to have as of the end of any calendar month shall, commencing with the month ending December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, be equal to at least $</div><ix:nonFraction name="sclx:MinimumCashRequirementsToRepurchaseOfNotes" contextRef="P04_30_2021To04_30_2021_LetterOfCreditMemberusgaapCreditFacilityAxis_MinimumMembersrtRangeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">4.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in the aggregate, provided that if Scilex Pharma did not effectuate (i)&#160;the December Optional Repurchase (as defined below) and (ii)&#160;at least one of either (x)&#160;the February Optional Repurchase (as defined below) or (y)&#160;the April Optional Repurchase (as defined below), then, commencing with the month ending April&#160;</div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, and for each month thereafter, such amount would have been required to be at least $</div><ix:nonFraction name="sclx:MinimumCashRequirementsToRepurchaseOfNotes" contextRef="P04_30_2021To04_30_2021_LetterOfCreditMemberusgaapCreditFacilityAxis_MaximumMembersrtRangeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">10.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in the aggregate. If Scilex Pharma fails to meet the foregoing minimum cash requirements, then Scilex Pharma will be required to draw on the Letter of Credit.</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">Amendment</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> No.&#160;</div>3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> also provided Scilex Pharma with the option, in its sole and absolute discretion, to repurchase Scilex Pharma Notes from the holders thereof on a pro&#160;rata basis on each of December&#160;</div>16<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> (the &#8220;December Optional Repurchase&#8221;), February&#160;</div>12<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> (the &#8220;February Optional Repurchase&#8221;) and April&#160;</div>13<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> (the &#8220;April Optional Repurchase&#8221;), in each case in an aggregate amount equal to the lesser of $</div><ix:nonFraction name="us-gaap:DebtInstrumentRepurchasedFaceAmount" contextRef="PAsOn09_30_2022_DecemberOptionalRepurchaseMemberSCLXStatementAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:DebtInstrumentRepurchasedFaceAmount" contextRef="PAsOn09_30_2022_FebruaryOptionalRepurchaseMemberSCLXStatementAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:DebtInstrumentRepurchasedFaceAmount" contextRef="PAsOn09_30_2022_AprilOptionalRepurchaseMemberSCLXStatementAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">20.0</ix:nonFraction></ix:nonFraction></ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million or the then-outstanding principal amount of the Scilex Pharma Notes, at a purchase price in cash equal to </div><ix:nonFraction name="sclx:PercentageOfThePrincipalAmountOfTheNotes" contextRef="P09_30_2022To09_30_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the principal amount thereof. Scilex Pharma effectuated the December Optional Repurchase, the February Optional Repurchase, and the April Optional Repurchase, which reduced the aggregate principal amount of the Scilex Pharma Notes by $</div><ix:nonFraction name="us-gaap:DebtInstrumentRepurchasedFaceAmount" contextRef="PAsOn09_30_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">60.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and resulted in the minimum unrestricted requirement remaining at $</div><ix:nonFraction name="sclx:MinimumUnrestrictedCashRequirementsToRepurchaseOfNotes" contextRef="P09_30_2022To09_30_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">4.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million.</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">Amendment</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> No.&#160;</div>3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> further provided that in the event that the Letter of Credit is drawn upon by Scilex Pharma, then Scilex Pharma had to, within five business days of such draw, repurchase the Scilex Pharma Notes from the holders thereof on a pro&#160;rata basis in an aggregate amount equal to the lesser of $</div><ix:nonFraction name="us-gaap:DebtInstrumentRepurchasedFaceAmount" contextRef="PAsOn09_30_2022_LetterOfCreditMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">20.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million or the then-outstanding principal amount of Scilex Pharma Notes, at a purchase price in cash equal to </div><ix:nonFraction name="sclx:PercentageOfThePrincipalAmountOfTheNotes" contextRef="P09_30_2022To09_30_2022_LetterOfCreditMemberusgaapCreditFacilityAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the principal amount thereof. In addition, upon the Letter of Credit being drawn on, Scilex Pharma is required to have minimum cash of $</div><ix:nonFraction name="sclx:MinimumCashRequirementsToRepurchaseOfNotes" contextRef="P09_30_2022To09_30_2022_LetterOfCreditMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">10.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million at all times thereafter. In February&#160;</div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Scilex Pharma drew upon the Letter of Credit with Sorrento and, as such, repaid $</div><ix:nonFraction name="us-gaap:RepaymentsOfDebt" contextRef="P09_30_2022To09_30_2022_LetterOfCreditMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">20.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million of the principal amount of the Scilex Pharma Notes and became subject to a minimum cash requirement of $</div><ix:nonFraction name="sclx:MinimumCashRequirementsToRepurchaseOfNotes" contextRef="P09_30_2022To09_30_2022_LetterOfCreditMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">10.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million.</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">Pursuant</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;to Amendment No.&#160;</div>3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Holders also consented to Scilex Pharma incurring up to $</div><ix:nonFraction name="sclx:LineOfCreditFacilityindebtednessAmount" contextRef="PAsOn09_30_2022_AccountsReceivableRevolvingLoanFacilityMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">10.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million of indebtedness in connection with an accounts receivable revolving loan facility (discussed below).</div></div></ix:continuation><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-75 </div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_63196069_3" continuedAt="TextSelectionAppend_63196069_4"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">The</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Company accounted for Amendment No.&#160;</div>3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> as a debt modification under ASC Topic </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">470-50</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> as modified terms were not substantially different than the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-modified</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> terms. The execution of Amendment No.&#160;</div>3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> resulted</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>in an additional derivative liability of $</div><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn12_31_2021_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.8</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, which pertains to a $</div><ix:nonFraction name="sclx:AmountDistributionToAcquireRelatedContingentAcceleratedRepaymentNotes" contextRef="P01_01_2021To12_31_2021_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">9.6</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million distribution to Sorrento with respect to a contingent accelerated repayment on the Scilex Pharma Notes in connection with the Letter of Credit and $</div><ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscountCurrent" contextRef="PAsOn12_31_2021_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">6.8</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million reduction to the debt discount on the Scilex Pharma Notes.</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">To</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;estimate the fair value of the Scilex Pharma Notes, the Company uses the discounted cash flow method under the income approach, which involves significant Level&#160;</div>3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> inputs and assumptions, combined with a Monte Carlo simulation, as appropriate. The value of the debt instrument is based on the present value of future principal payments and the discounted rate of return reflective of the Company&#8217;s credit </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">risk. </div></div><br/></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div><ix:nonNumeric name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Borrowings of the Scilex Pharma Notes are as follows (in thousands): </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 72%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Principal</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="PAsOn12_31_2021_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">133,997</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="PAsOn12_31_2020_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">151,872</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unamortized debt discount</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="PAsOn12_31_2021_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">30,597</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="PAsOn12_31_2020_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">51,022</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unamortized debt issuance costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:UnamortizedDebtIssuanceExpense" contextRef="PAsOn12_31_2021_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,228</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:UnamortizedDebtIssuanceExpense" contextRef="PAsOn12_31_2020_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,711</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Carrying value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebt" contextRef="PAsOn12_31_2021_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">101,172</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebt" contextRef="PAsOn12_31_2020_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">97,139</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current portion</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:LongTermDebtCurrent" contextRef="PAsOn12_31_2021_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">29,135</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:LongTermDebtCurrent" contextRef="PAsOn12_31_2020_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,881</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long term portion</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="PAsOn12_31_2021_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">72,037</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="PAsOn12_31_2020_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">92,258</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Estimated fair value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtFairValue" contextRef="PAsOn12_31_2021_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">115,400</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtFairValue" contextRef="PAsOn12_31_2020_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">122,300</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table></ix:nonNumeric><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div><ix:nonNumeric name="sclx:ScheduleOfFutureMinimumPaymentsOfLongTermDebtTableTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Future minimum payments under the Scilex Pharma Notes, based on a percentage of projected net sales of ZTlido are estimated as follows (in thousands): </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 83%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ending December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 83%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:LongtermDebtfutureMinimumPaymentYearOne" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">29,135</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 83%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:LongtermDebtFutureMinimumPaymentYearTwo" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,005</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 83%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:LongtermDebtFutureMinimumPaymentYearThree" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,637</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 83%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:LongtermDebtFutureMinimumPaymentYearFour" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">14,746</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 83%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2026</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:LongtermDebtFutureMinimumPaymentYearFive" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">64,474</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 83%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 83%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total minimum future payments</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:LongtermDebtFutureMinimumPayment" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">133,997</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table></ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">The</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Company made principal payments of $</div><ix:nonFraction name="us-gaap:DebtInstrumentAnnualPrincipalPayment" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">45.9</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, $</div><ix:nonFraction name="us-gaap:DebtInstrumentAnnualPrincipalPayment" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">69.8</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, and $</div><ix:nonFraction name="us-gaap:DebtInstrumentAnnualPrincipalPayment" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.3</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million during the fiscal&#160;years ended December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, and </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, respectively.</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Debt </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> discount and debt issuance costs, which are presented as a direct reduction of the Scilex Pharma Notes in the consolidated balance sheets, are amortized as interest expense using the effective interest method. As principal repayments on the Scilex Pharma Notes are based on a&#160;percentage of net sales of ZTlido and </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-103,</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> if the Marketing Approval Letter is received, the Company has elected to account for changes in estimated cash flows from future net sales prospectively. Specifically, a new effective interest rate will be determined based on revised estimates of remaining cash flows and changes in expected cash flows will be recognized prospectively. The imputed effective interest rate at December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> was </div><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="PAsOn12_31_2021_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">7.7</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% and </div><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="PAsOn12_31_2020_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">9.15</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">%, respectively. The amount of debt discount and debt issuance costs included in interest expense for the&#160;years ended December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> was approximately $</div><ix:nonFraction name="us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts" contextRef="P01_01_2021To12_31_2021_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">7.9</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, $</div><ix:nonFraction name="us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts" contextRef="P01_01_2020To12_31_2020_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">10.7</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div><ix:nonFraction name="us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts" contextRef="P01_01_2019To12_31_2019_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">15.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, respectively.</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">The</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Company identified a number of embedded derivatives that require bifurcation from the Scilex Pharma Notes and separate accounting in the consolidated financial statements as derivative liabilities. Certain of these embedded features included default interest provisions, contingent rate increases, contingent put options, optional and automatic acceleration provisions and indemnified taxes. The Company recorded this derivative within its consolidated financial statements (See Note </div>5)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. The Company </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-evaluates</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> this assessment each reporting period.</div><br/></div></ix:continuation><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-76 </div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_63196069_4"><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Scilex Pharma Notes also provide that, upon the occurrence of an event of default, the holders of at least </div><ix:nonFraction name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" contextRef="P01_01_2021To12_31_2021_IndebentureMemberSCLXAgreementAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">25</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% in principal amount of the outstanding Scilex Pharma Notes may, by written notice to Scilex Pharma, declare all of the outstanding principal and premium under such Scilex Pharma Notes immediately due and payable. For purposes of the Scilex Pharma Notes, an event of default includes, among other things, (i)&#160;Scilex Pharma&#8217;s failure to pay outstanding material indebtedness, including the Scilex Pharma Notes, when due (ii)&#160;Scilex Pharma&#8217;s breach of its representations and warranties or failure to comply with its covenants and obligations under the Scilex Pharma Notes or (iii)&#160;the occurrence of certain insolvency or bankruptcy events (both voluntary and involuntary) involving Scilex Pharma. The Company is in compliance with event of default clauses.</div><br/></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Related Party Notes Payable </div></div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On October&#160;</div>5<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2018<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Scilex Pharma issued to Sorrento a promissory note (see Note </div>13)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. On March&#160;</div>18<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company entered into a note payable with Sorrento (see Note </div>13)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">.</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2020 Revolving Credit Facility </div></div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On December&#160;</div>14<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Scilex Pharma entered into the Credit and Security Agreement (the &#8220;Credit Agreement&#8221;) with CNH Finance Fund&#160;I, L.P. (&#8220;CNH&#8221;) which provides Scilex Pharma with the ability to incur indebtedness under an accounts receivable revolving loan facility in an aggregate amount of $</div><ix:nonFraction name="sclx:LineOfCreditFacilityindebtednessAmount" contextRef="PAsOn12_14_2020_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">10.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and the incurrence of liens and the pledge of collateral to CNH in connection with the revolving loan facility. Under the terms of the Credit Agreement, interest will accrue daily on the principal amount outstanding at a rate per annum equal to the Wall Street Journal Prime Rate plus </div><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="PAsOn12_14_2020_PrimeRateMemberusgaapVariableRateAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">1.75</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">%. All indebtedness incurred and outstanding will be due and payable in full on January&#160;</div>1<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2024<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">; unless the Credit Agreement is earlier terminated. As of December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the outstanding balance was $</div><ix:nonFraction name="us-gaap:LongTermDebt" contextRef="PAsOn12_31_2021_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">8.8</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div><ix:nonFraction name="us-gaap:LongTermDebt" contextRef="PAsOn12_31_2020_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">9.5</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, respectively. On February&#160;</div>16<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company notified CNH that it was terminating the Credit Agreement, effective </div><ix:nonNumeric name="sclx:DebtInstrumentTerminationDate" contextRef="P02_16_2022To02_16_2022_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" format="ixt:date-monthname-day-year-en">March 18, 2022</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. Upon termination, all principal balances and interest accrued were </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">settled.</div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Paycheck Protection Program </div></div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In May&#160;</div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company received the proceeds from a loan in the amount of $</div><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="P05_01_2020To05_31_2020_PaycheckProtectionProgramMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.6</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million (the &#8220;PPP Loan&#8221;) from Bank of America, as the lender, pursuant to the Paycheck Protection Program (&#8220;PPP&#8221;) of the Coronavirus Aid, Relief, and Economic Security Act (the &#8220;CARES Act&#8221;). The PPP Loan matures on </div><ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" contextRef="P05_01_2020To05_31_2020_PaycheckProtectionProgramMemberusgaapLongtermDebtTypeAxis" format="ixt:date-monthname-day-year-en">May 05, 2022</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and bears interest at a rate of </div><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="PAsOn05_31_2020_PaycheckProtectionProgramMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">1.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% per annum. The PPP Loan is evidenced by a promissory note dated May </div>03<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> (the &#8220;Note&#8221;), which contains customary events of default relating to, among other things, payment defaults and breaches of representations and </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">warranties.</div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the CARES Act, loan forgiveness is available for the sum of documented payroll costs, covered rent payments, covered mortgage interest and covered utilities during the twenty-four-week period, beginning on the date of loan approval. For purposes of the CARES Act, payroll costs exclude compensation of an individual employee in excess of $</div><ix:nonFraction name="sclx:MaximumCompensationCostToBeAvailableProratedBasis" contextRef="P01_01_2021To12_31_2021_CoronavirusAidReliefAndEconomicSecurityActMemberSCLXEventTypeAxis_NonPayrollCostsMemberSCLXClassificationOfCostAxis_PaycheckProtectionProgramMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">100,000</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, prorated annually. Not more than </div><ix:nonFraction name="sclx:PercentageOfLoanForgivenessUnderTheAct" contextRef="P01_01_2021To12_31_2021_CoronavirusAidReliefAndEconomicSecurityActMemberSCLXEventTypeAxis_NonPayrollCostsMemberSCLXClassificationOfCostAxis_PaycheckProtectionProgramMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">25</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the forgiven amount may be for </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-payroll</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> costs. Forgiveness is reduced if full-time headcount declines, or if salaries and wages for employees with salaries of $</div><ix:nonFraction name="sclx:MinimumPayrollCostToBeAvailable" contextRef="P01_01_2021To12_31_2021_CoronavirusAidReliefAndEconomicSecurityActMemberSCLXEventTypeAxis_PaycheckProtectionProgramMemberusgaapLongtermDebtTypeAxis_PayrollCostsBasisMemberSCLXClassificationOfCostAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">100,000</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> or less annually are reduced by more than </div><ix:nonFraction name="sclx:PercentageOfLoanForgivenessUnderTheAct" contextRef="P01_01_2021To12_31_2021_CoronavirusAidReliefAndEconomicSecurityActMemberSCLXEventTypeAxis_PaycheckProtectionProgramMemberusgaapLongtermDebtTypeAxis_PayrollCostsBasisMemberSCLXClassificationOfCostAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">25</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">%. In the event the PPP Loan, or any portion thereof, is forgiven pursuant to the PPP, the amount forgiven is applied to outstanding principal. The Company used all of the proceeds from the PPP Loan to retain employees and maintain payroll. In May&#160;</div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company received confirmation from the SBA that the entire PPP Loan was forgiven and recorded a gain on debt extinguishment of $</div><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="P05_01_2020To05_31_2020_PaycheckProtectionProgramMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.6</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, which is included in loss on debt extinguishment, net, on the consolidated statements of operations for the year ended </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">December&#160;31, 2021. </div></div></div><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></ix:continuation><ix:nonNumeric name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_63195210">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">9.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stockholders&#8217; Equity </div></div></div></div></td></tr></table><div style="clear: both; max-height: 0px; text-indent: 0px;"></div><div style="clear: both; max-height: 0px; text-indent: 0px;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The total number of authorized shares of preferred stock of Scilex Holding is </div><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2020" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">20,000,000</ix:nonFraction></ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, of which </div><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2020" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2020" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;shares were issued and outstanding at December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. The total number of authorized shares of</div></div></ix:nonNumeric><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-77 </div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_63195210"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">common<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">stock of Scilex Holding is </div><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2020" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">350,000,000</ix:nonFraction></ix:nonFraction><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">, of which </div><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2020" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2020" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">197,266,338</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"> shares were issued and outstanding at&#160;</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">December&#160;31, 2021 and 2020.</div></div></div><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></ix:continuation><ix:nonNumeric name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_63195211">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock Incentive and Employee Benefit Plans </div></div></div></div></td></tr></table><div style="clear: both; max-height: 0px; text-indent: 0px;"></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2017 Equity Incentive Plan </div></div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In June&#160;</div>2017<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Scilex Pharma adopted the Scilex Pharmaceuticals Inc. </div>2017<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Equity Incentive Plan (the &#8220;Scilex Pharma </div>2017<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Plan&#8221;). The Scilex Pharma </div>2017<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Plan reserved </div><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn06_30_2017_ScilexPharmaTwoThousandSeventeenPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="-5" scale="6" format="ixt:num-dot-decimal">24.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million shares of Scilex Pharma common stock. </div><ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" contextRef="P06_30_2017To06_30_2017_ScilexPharmaTwoThousandSeventeenPlanMemberusgaapPlanNameAxis">Stock options granted under the Scilex Pharma 2017 Plan typically vest 1/4th of the shares on the first anniversary of the vesting commencement date and 1/48th of the remaining options vest each month thereafter.</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> The Scilex Pharma </div>2017<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Plan was amended and restated on July&#160;</div>5<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2018<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">.</div><br/></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">Upon<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the Merger Closing, the Scilex Pharma </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2017</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Equity Incentive Plan was terminated, and each option to purchase Scilex Pharma&#8217;s common stock outstanding and unexercised immediately prior to the Merger Closing was cancelled and substituted for that number of options to acquire common stock of Scilex Holding.</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Scilex Holding Company 2019 Stock Option Plan </div></div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The board of directors of the Company adopted the Scilex Holding Company </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Stock Option Plan (the &#8220;</div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Stock Option Plan&#8221;) on May&#160;</div>28<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. The </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Stock Option Plan was approved by the Company&#8217;s stockholders on June&#160;</div>7<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. As of December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2019_TwoThousandNineteenStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="-5" scale="6" format="ixt:num-dot-decimal">30.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million shares of common stock of the Company were reserved for issuance pursuant to the </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Stock Option Plan. On December&#160;</div>21<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the board of directors approved an amendment to the </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Stock Option Plan to reserve an additional </div><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2020_AmendmentToTwoThousandNineteenStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="-5" scale="6" format="ixt:num-dot-decimal">15.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million shares of common stock for issuance under the </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Stock Option Plan. As of December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2020_TwoThousandNineteenStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="-5" scale="6" format="ixt:num-dot-decimal">45.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million shares of common stock of the Company were reserved for issuance pursuant to the </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Stock Option Plan. </div><ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" contextRef="P01_01_2020To12_31_2020_TwoThousandNineteenStockOptionPlanMemberusgaapPlanNameAxis">Stock options granted under the 2019 Stock Option Plan typically vest with respect to 1/4th of the shares on the first anniversary of the vesting commencement date and 1/48th of the remaining shares on each monthly anniversary thereafter.</ix:nonNumeric></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, options to purchase </div><ix:nonFraction name="sclx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingNumber" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">28,163,510</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares of the common stock of Scilex Holding were outstanding, which is comprised of options to purchase </div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn12_31_2021_TwoThousandNineteenStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">26,743,510</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares of common stock that were outstanding under the </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Stock Option Plan and options to purchase </div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn12_31_2021_ScilexPharmaTwoThousandSeventeenPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">1,420,000</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares of common stock that were outstanding pursuant to options previously granted under the Scilex Pharma </div>2017<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Plan. As of December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div><ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" contextRef="P01_01_2021To12_31_2021_TwoThousandNineteenStockOptionPlanMemberusgaapPlanNameAxis">18,256,490</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares of the Company&#8217;s common stock were reserved for awards available for future issuance under the </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Stock Option Plan.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total stock-based compensation recorded within operating expenses was $</div><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2021To12_31_2021_OperatingExpensesMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">5.8</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, $</div><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2020To12_31_2020_OperatingExpensesMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">5.4</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2019To12_31_2019_OperatingExpensesMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">4.3</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million for the&#160;years ended December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, respectively.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The total unrecognized compensation costs related to unvested employee and nonemployee stock option grants as of December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> was $</div><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">8.8</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and the weighted average period over which these grants are expected to vest is </div><ix:nonNumeric name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="P01_01_2021To12_31_2021" format="ixt-sec:duryear">1.8</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;years.</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Option Valuation </div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company calculates the fair value of stock-based compensation awards granted to employees and nonemployees using the Black-Scholes option-pricing method. The Black-Scholes option-pricing method requires the use of subjective assumptions, including stock price volatility, the expected life of stock options, risk free interest rate and the fair value per share of the underlying common stock on the date of grant. The </div></div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-78 </div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div><ix:continuation id="TextSelection_63195211" continuedAt="TextSelectionAppend_63195211_1"><ix:nonNumeric name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">assumptions used in the Black-Scholes option-pricing method related to options issued to employees and nonemployees for the years ended 2020 and 2019 is set forth below: </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 67%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average grant date fair value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">$<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="PAsOn12_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.83</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;&#160;$<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="PAsOn12_31_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.87</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected dividend yield</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">0.00</ix:nonFraction>%</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">0.00</ix:nonFraction>%</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;;text-indent: 0px;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected stock-price volatility</div></div></td>
<td style="vertical-align: bottom;;text-indent: 0px;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-indent: 0px;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">90.00</ix:nonFraction>%</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-indent: 0px;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">89.00</ix:nonFraction>%<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;-&#160;</div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">104.00</ix:nonFraction>%</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-indent: 0px;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free interest rate</div></div></td>
<td style="vertical-align: bottom;;text-indent: 0px;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-indent: 0px;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">0.53</ix:nonFraction>%</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-indent: 0px;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">1.63</ix:nonFraction>%<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;-&#160;</div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">2.50</ix:nonFraction>%</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;;text-indent: 0px;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Term of options</div></div></td>
<td style="vertical-align: bottom;;text-indent: 0px;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-indent: 0px;;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2020To12_31_2020" format="ixt-sec:duryear">5.60</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-indent: 0px;;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2019To12_31_2019_MinimumMembersrtRangeAxis" format="ixt-sec:duryear">5.76</ix:nonNumeric><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;-&#160;</div><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2019To12_31_2019_MaximumMembersrtRangeAxis" format="ixt-sec:duryear">6.08</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value per share of common stock on date of grant</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">$<ix:nonFraction name="sclx:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant" contextRef="PAsOn12_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">1.16</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">$<ix:nonFraction name="sclx:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant" contextRef="PAsOn12_31_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">1.16</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercise price</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">$<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="PAsOn12_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">1.16</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">$<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="PAsOn12_31_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">1.16</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table></ix:nonNumeric><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expected<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div><div style="font-size: 10pt; letter-spacing: 0px;;font-style:italic;display:inline;">dividend yield</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. The Company bases the expected dividend yield assumption on the fact that the Company has never paid cash dividends and has no present intention to pay cash dividends on the Company&#8217;s common stock.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expected stock-price volatility</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. The expected stock-price volatility assumption is based on volatilities of a peer group of similar companies whose share prices are publicly available. The peer group was developed based on companies in the transdermal patch industry. In selecting the peer group, management considered publicly-traded transdermal patch companies with existing clinical stage branded and generic transdermal patches. Management further considered the development stage of the peer group companies.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Risk-free interest rate</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. The Company bases the risk-free interest rate assumption on the U.S. Treasury&#8217;s rates for U.S. Treasury </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">zero-coupon</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> bonds with maturities similar to those of the expected term of the award being valued.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expected term of options</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. The expected term of options represents the period of time when options are expected to be outstanding. Because the Company does not have historic exercise behavior, the Company determines the expected life assumption for options issued to directors and employees using the simplified method, which is an average of the contractual term of the option and its ordinary vesting period.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the&#160;years ended December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Scilex Holding issued stock options to certain employees and nonemployees. Significant inputs utilized in determining the fair value of the common shares are as </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">follows: </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">March&#160;17 and March&#160;31, 2019 Valuations </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the valuation </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">performed on March&#160;</div>17<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and March&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the fair value of the Company&#8217;s common stock was estimated using the market and income approaches. The Company weighted a guideline public company method, a market approach that uses comparable company data and applies to the subject company, equally with a discounted cash flow method, an income approach that derives value by estimating reasonable future cash flows to the equityholders and discounting them to present value using a risk-adjusted discount rate. The Company then used the Option Pricing Method (&#8220;OPM&#8221;) to allocate the concluded equity value amongst the different equity classes and determine the common stock value. These valuations resulted in a valuation of the Company&#8217;s common stock of $</div><ix:nonFraction name="sclx:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant" contextRef="PAsOn03_17_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="sclx:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant" contextRef="PAsOn03_31_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">1.16</ix:nonFraction></ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> per share as of March&#160;</div>17<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and March&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">.</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">May&#160;31, 2019 Valuation </div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the valuation performed on May&#160;31, 2019, the fair value of the Company&#8217;s common stock was estimated using a hybrid Probability Weighted Expected Return Method (&#8220;PWERM&#8221;), which estimates the value by </div></div></div></ix:continuation><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-79 </div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_63195211_1" continuedAt="TextSelectionAppend_63195211_2"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">probability</div></div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">-weighting different scenarios. The Company used three going public scenarios and one stay-private scenario. For the three public scenarios, the Company utilized recent comparable initial public offerings to estimate value, which was allocated on a fully diluted basis to derive a common stock value for each scenario. For the stay-private scenario, the Company utilized the income and market approaches in line with the March&#160;</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">31</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">, </div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">2019</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"> valuation then allocated the concluded equity value using an OPM to derive a common stock value for the stay-private scenario. The Company then probability weighted (based on the Company&#8217;s best estimates at the time) each scenario&#8217;s common stock value to arrive at the Company&#8217;s concluded common stock value. This valuation resulted in a valuation of the Company&#8217;s common stock of $</div><ix:nonFraction name="sclx:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant" contextRef="PAsOn05_31_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">1.16</ix:nonFraction><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"> per share as of May&#160;</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">31</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">, </div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">2019</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">.</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">December&#160;31, 2019 Valuation </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the valuation performed on December&#160;31, 2019, the fair value of the Company&#8217;s common stock was estimated using PWERM, which estimates the value by probability-weighting different scenarios. The Company used three going public scenarios and one stay-private scenario. For the three public scenarios, the </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Company<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 0px; top: 0px;;display:inline;">utilized recent comparable initial public offerings to estimate value, which was allocated on a fully diluted basis to derive a common stock value for each scenario. For the stay-private scenario, the Company utilized the income approach in line with the March&#160;31, 2019 valuation then allocated the concluded equity value using an OPM to derive a common stock value for the stay-private scenario. The Company then probability weighted (based on the Company&#8217;s best estimates at the time) each scenario&#8217;s common stock value to arrive at the Company&#8217;s concluded common stock value. This valuation resulted in a valuation of the Company&#8217;s common stock of $</div><ix:nonFraction name="sclx:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant" contextRef="PAsOn12_31_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">1.16</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 0px; top: 0px;;display:inline;"> per share as of December&#160;31, 2019.</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">July&#160;31, 2020 Valuation </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the valuation performed on July&#160;31, 2020, the fair value of the Company&#8217;s common stock was estimated using PWERM, which estimates the value by probability-weighting different scenarios. The Company used three going public scenarios and one stay-private scenario. For the three public scenarios, the Company utilized recent comparable initial public offerings to estimate value, which was allocated on a fully diluted basis to derive a common stock value for each scenario. For the stay-private scenario, the Company utilized the income approach in line with the March&#160;31, 2019, May&#160;31, 2019 and December&#160;31, 2019 valuations then allocated the concluded equity value using an OPM to derive a common stock value for the stay-private scenario. The Company then probability weighted (based on the Company&#8217;s best estimates at the time) each scenario&#8217;s common stock value to arrive at the Company&#8217;s concluded common stock value. This valuation resulted in a valuation of the Company&#8217;s common stock of $<ix:nonFraction name="sclx:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant" contextRef="PAsOn07_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">1.16</ix:nonFraction> per share as of July&#160;31, 2020.</div></div></div></ix:continuation><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-80 </div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_63195211_2" continuedAt="TextSelectionAppend_63195211_3"><ix:nonNumeric name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following represents a summary of the options outstanding at December&#160;31, 2021, 2020, and 2019 changes during the years then ended (in thousands, other than weighted-average exercise price): </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 62%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Options</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/>average<br/>exercise&#160;price</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate<br/>Intrinsic<br/>Value</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 0px;">
<td style="width: 62%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 62%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at December&#160;31, 2018</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn12_31_2018" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,781</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2018" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.63</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,291</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 62%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">21,468</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">1.16</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 62%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercised</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 62%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited/Cancelled</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">838</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.94</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 62%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 62%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at December&#160;31, 2019</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn12_31_2019" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">25,411</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">1.07</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">2,183</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 62%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,194</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">1.16</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 62%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercised</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">56</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.90</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 62%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited/Cancelled</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">745</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.94</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 62%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 62%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn12_31_2020" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">30,804</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">1.10</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">2,172</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt; width: 62%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt; width: 62%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercised</div></div></div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt; width: 62%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited/Cancelled</div></div></div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,641</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.68</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; width: 62%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt; width: 62%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at December&#160;31, 2021</div></div></div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">28,163</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">1.13</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">915</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt; width: 62%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercisable at December&#160;31, 2021</div></div></div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">17,177</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="PAsOn12_31_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">1.11</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr></table></ix:nonNumeric></ix:continuation></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_63195211_3"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Employee Benefit Plan </div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div><br/></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color:#ffffff;;display:inline;">The </div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Company maintains a defined contribution </div>401<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(k) plan available to eligible employees, which is administered by Sorrento. Employee contributions are voluntary and are determined on an individual basis, limited to the maximum amount allowable under federal tax regulations. The Company made matching contributions to the </div>401<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(k) plan totaling $</div><ix:nonFraction name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" contextRef="P01_01_2021To12_31_2021_FourHundredAndOneKPlanMemberusgaapRetirementPlanNameAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" contextRef="P01_01_2020To12_31_2020_FourHundredAndOneKPlanMemberusgaapRetirementPlanNameAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" contextRef="P01_01_2019To12_31_2019_FourHundredAndOneKPlanMemberusgaapRetirementPlanNameAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.3</ix:nonFraction></ix:nonFraction></ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million for each of the&#160;years ended December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">.</div></div></ix:continuation><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><br/></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <ix:nonNumeric name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_63195191">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">11.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commitments and Contingencies </div></div></div></div></td></tr></table> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Product Development Agreement </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In February&#160;</div>2013<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Scilex Pharma became a party to a product development agreement (as amended, the &#8220;Product Development Agreement&#8221;) with </div>two<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> parties (the &#8220;Developers&#8221;), </div>one<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> of which is ITOCHU CHEMICAL FRONTIER Corporation (&#8220;Itochu&#8221;), pursuant to which the Developers will manufacture and supply lidocaine tape products, including ZTlido and </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-103</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> (the &#8220;Products&#8221;), for Scilex Pharma. The Developers initially developed, and have intellectual property rights relating to, the Products. Pursuant to the Product Development Agreement, Scilex Pharma acquired an exclusive right to develop and commercialize the Products worldwide except for Japan. The Developers are responsible for sourcing and supplying lidocaine for development and commercialization purposes.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the Product Development Agreement, Scilex Pharma is required to make aggregate royalty payments between </div><ix:nonFraction name="sclx:PercentageOfAggregateRoyalityPayments" contextRef="P12_31_2021To12_31_2021_MinimumMembersrtRangeAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">25</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% and </div><ix:nonFraction name="sclx:PercentageOfAggregateRoyalityPayments" contextRef="P12_31_2021To12_31_2021_MaximumMembersrtRangeAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">35</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% to the Developers based on net profits. Up to the date the financial statements were issued, the Company made </div>no<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> aggregate royalty payments. Net profits are defined as net sales, less cost of goods and marketing expenses. Net sales are defined as total gross sales of any Product, less all applicable deductions, to the extent accrued, paid or allowed in the ordinary course of business with respect to the sale of such Product, and to the extent that they are in accordance with U.S. GAAP. If Scilex Pharma were to sublicense the licensed technologies, the Developers will receive the same proportion of any sublicensing fees received therefrom. The Product Development Agreement will continue in full force and effect until </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="sclx:AgreementExpirationDate" contextRef="P12_31_2021To12_31_2021_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis" format="ixt:date-monthname-day-year-en">October 2, 2028</ix:nonNumeric></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the date that is </div><ix:nonNumeric name="sclx:AgreementExpirationTerm" contextRef="P12_31_2021To12_31_2021_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis" format="ixt-sec:durwordsen"><div style="letter-spacing: 0px; top: 0px;;display:inline;">ten</div> years</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> from the date of the first commercial sale of ZTlido. The Product Development Agreement will renew automatically for subsequent successive </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="sclx:AgreementAutomaticRenewalPeriodOnExpirationOfInitialTerm" contextRef="P12_31_2021To12_31_2021_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis" format="ixt-sec:durwordsen">one-year</ix:nonNumeric></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> renewal periods unless Scilex Pharma or the </div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-81 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div><ix:continuation id="TextSelection_63195191" continuedAt="TextSelectionAppend_63195191_1"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">Developers terminate it upon </div><div style="font-size: 10pt; text-indent: 4%; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="sclx:NoticeOfTerminationPeriodForCancellationOfAutomaticRenewal" contextRef="P12_31_2021To12_31_2021_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis" format="ixt-sec:durwordsen">6-month</ix:nonNumeric></div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"> written notice. In addition, Scilex Pharma or the Developers may terminate the Product Development Agreement if </div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">(1)</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">&#160;the other party is in material breach of the agreement and the breach is not curable, or if the breach is curable and the breaching party has not cured such material breach within </div><ix:nonNumeric name="sclx:TerminationOfAgreementNoticePeriodForARequestToCureMaterialBreachOfTheAgreement" contextRef="P12_31_2021To12_31_2021_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis" format="ixt-sec:durday">180</ix:nonNumeric><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">&#160;days after notice requesting to cure; </div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">(2)</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">&#160;the FDA determines that the formulation of the Products would not be eligible for FDA approval in the absence of efficacy studies, and the Developers are unable to address the efficacy study requirements despite good faith efforts; </div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">(3)</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">&#160;the market conditions are such that (a)&#160;commencing with the quarter ending March&#160;</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">31</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">, </div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">2023</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">, Scilex Pharma&#8217;s total net profits of the Products are equal to or less than </div><ix:nonFraction name="sclx:ThresholdMinimumPercentageOfSales" contextRef="P12_31_2021To12_31_2021_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">5</ix:nonFraction><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">% of Scilex Pharma&#8217;s net sales of the Products for a period of </div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">four</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"> or more consecutive quarters, or (b)&#160;the Products&#8217; economic viability is affected by documented external circumstances deemed detrimental to all parties as agreed to by Scilex Pharma and the Developers, and the parties are unable to resolve the economic viability concerns under the foregoing clauses (a)&#160;and (b)&#160;after </div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">30</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">&#160;days of good-faith discussion; </div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">(4)</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">&#160;the parties fail to reach mutual agreement as to who will conduct the clinical studies and how the costs will be allocated; or </div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">(5)</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">&#160;Scilex Pharma or either </div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">one</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"> of the Developers are bankrupt or make assignment for the benefit of creditors.<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>Up to the date the financial statements were issued, Scilex&#8217;s net profits for ZTlido and </div><div style="font-size: 10pt; text-indent: 4%; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-103</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"> have not exceeded </div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">five</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"> percent of net sales. Accordingly, Oishi and Itochu have the right to terminate the Product Development Agreement and Commercial Supply Agreement. As of the date of this prospectus, neither Oishi nor Itochu has exercised its right of termination. Additionally, Scilex Pharma may terminate the Product Development Agreement if (i)&#160;any of the pivotal human clinical trials for any of the Products fail, or (ii)&#160;the FDA issues a &#8220;Refusal to File&#8221; for any of the Products&#8217; regulatory approval application and, after reasonable consultation with the Developers, Scilex Pharma believes that it is commercially unreasonable to </div><div style="font-size: 10pt; text-indent: 4%; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-file.</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"> The Developers may terminate the Product Development Agreement if Scilex Pharma fails to file for regulatory approval for any of the Products within </div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">three</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">&#160;months of the date on which all required components of the regulatory approval application are received by Scilex Pharma.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On February&#160;</div>16<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2017<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Scilex Pharma entered into a Commercial Supply Agreement (as amended, the &#8220;Supply Agreement&#8221;) with the </div>two<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Developers to provide commercial supply of ZTlido and </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-103</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> to Scilex Pharma. The Supply Agreement contains standard terms regarding term, termination, payment, product quality and supply. In addition, the agreement provides additional terms regarding the calculation and amount of marketing expenses that may be deducted from net sales for purposes of determining the amount of net profit under the Product Development Agreement.</div><br/></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-size: 10pt;;font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Exclusive Distribution Agreement</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color:#ffffff;;display:inline;">In </div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> August&#160;</div>2015<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Scilex Pharma entered into an Exclusive Distribution Agreement (the &#8220;Distribution Agreement&#8221;) to appoint an exclusive third-party logistics distribution provider (the &#8220;Distributor&#8221;) and as an authorized distributor of record of ZTlido (&#8220;Product&#8221;) in the United States, its territories, possessions and commonwealths for an agreed schedule of fees, subject to a </div><ix:nonFraction name="sclx:PercentageOfAnnualAdjustmentToFees" contextRef="P12_31_2021To12_31_2021_ExclusiveDistributionAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">3</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% annual adjustment. The Distribution Agreement has an initial term of </div><ix:nonNumeric name="sclx:AgreementExpirationTerm" contextRef="P12_31_2021To12_31_2021_ExclusiveDistributionAgreementMemberusgaapTypeOfArrangementAxis" format="ixt-sec:durwordsen"><div style="letter-spacing: 0px; top: 0px;;display:inline;">three</div> years</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> following the first shipment of </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FDA-approved</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Product to a commercial customer and shall automatically renew for additional terms of </div>one<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> year each, unless written notice of termination is given by either party at least </div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;days prior to the end of the initial term or any renewal term. In the event of Product recalls, Scilex Pharma is solely responsible for all product recalls, except in the event where the recalls arise from the Distributor&#8217;s negligence or willful misconduct. Pursuant to the Distribution Agreement, Scilex Pharma will be responsible for delivery of Product to and from the Distributor&#8217;s facility, including all costs, expenses and risk of loss associated with such delivery. From late </div>2018<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> to early </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, ZTlido was sold, and title was transferred, to the Distributor for distribution and sale to wholesalers for a fee of between </div><ix:nonFraction name="sclx:PercentageOfDistributionFeeReceivedOverThePeriod" contextRef="P12_31_2021To12_31_2021_ExclusiveDistributionAgreementMemberusgaapTypeOfArrangementAxis_MinimumMembersrtRangeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">1</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% to </div><ix:nonFraction name="sclx:PercentageOfDistributionFeeReceivedOverThePeriod" contextRef="P12_31_2021To12_31_2021_ExclusiveDistributionAgreementMemberusgaapTypeOfArrangementAxis_MaximumMembersrtRangeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">2</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% which was recorded as a </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">gross-to-net</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> sales adjustment. Beginning in </div>April 2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Scilex Pharma began directly selling and transferring title to distributors.</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Sales Operations Services </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In January&#160;</div>2016<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Scilex Pharma entered into a project agreement with a vendor to provide sales operations services and detailing services, which was subsequently superseded by a new project agreement entered into in</div></div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-82 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_63195191_1" continuedAt="TextSelectionAppend_63195191_2"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">September&#160;</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">2018</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"> (the &#8220;Project Agreement&#8221;). In connection with the detailing services, the Project Agreement provides that the vendor will provide Scilex Pharma with full-time sales representatives who shall detail the Product by making calls pursuant to a call plan on targets. These sales representatives are to be managed by field talent managers and a national project director, each of whom will also be provided by the vendor. In connection with the sales operation services, the vendor will provide certain services required for the initial implementation and ongoing operation of the sales force.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On July&#160;</div>1<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Scilex Pharma and the vendor entered into a work order in which the parties agreed to convert substantially all of the sales representatives allocated under the Project Agreement to become employees of Scilex Pharma. The vendor will continue to provide sales operations services and fleet management services and sample accountability services. The work order will remain in effect until June&#160;</div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, and may be extended for additional periods of </div>one<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> year upon the mutual agreement of both parties. Either party may terminate the work order with </div><ix:nonNumeric name="sclx:NoticePeriodForTerminationOfWorkOrder" contextRef="P12_31_2021To12_31_2021_ProjectAgreementMemberusgaapTypeOfArrangementAxis" format="ixt-sec:durday">90</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;days&#8217; notice. Scilex Pharma paid an implementation fee of $</div><ix:nonFraction name="sclx:WorkOrderImplementationFee" contextRef="P12_31_2021To12_31_2021_ProjectAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-2" scale="3" format="ixt:num-dot-decimal">59.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;thousand and will pay fixed monthly fees of $</div><ix:nonFraction name="sclx:SalesOperationsServicesMonthlyFee" contextRef="PAsOn12_31_2021_MinimumMembersrtRangeAxis_ProjectAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-2" scale="3" format="ixt:num-dot-decimal">63.7</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;thousand to $</div><ix:nonFraction name="sclx:SalesOperationsServicesMonthlyFee" contextRef="PAsOn12_31_2021_MaximumMembersrtRangeAxis_ProjectAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-2" scale="3" format="ixt:num-dot-decimal">65.8</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;thousand for ongoing services.</div><br/></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company recognized an expense of $</div><ix:nonFraction name="sclx:SellingGeneralAndAdministrativeExpenses" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.9</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, $</div><ix:nonFraction name="sclx:SellingGeneralAndAdministrativeExpenses" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">10.5</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, and $</div><ix:nonFraction name="sclx:SellingGeneralAndAdministrativeExpenses" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">25.3</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million within selling, general and administrative expenses for services performed for the&#160;years ended December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, and </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, respectively, including implementation fees, fixed monthly fees and pass-through costs.</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Litigation </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the normal course of business, the Company may be named as a defendant in </div>one<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> or more lawsuits. Other than the following </div>two<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> lawsuits, the Company is not a party to any outstanding material litigation and management is currently not aware of any legal proceedings that, individually or in the aggregate, are deemed to be material to the Company&#8217;s financial condition or results of operations.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In February&#160;</div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company filed a lawsuit in the U.S. District Court for the Northern District of California against Sanofi-Aventis U.S. LLC and Hisamitsu America, Inc., </div>two<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> manufacturers of </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">over-the-counter</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> (OTC) lidocaine patch products, alleging, among other things, false and deceptive advertising and unfair competition under the Lanham Act and California state laws by those companies regarding those patch products.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In March&#160;</div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company filed a lawsuit in the Delaware Court of Chancery against Anthony Mack, former President of the Company, and Virpax Pharmaceuticals, Inc., a company now headed by Mr.&#160;Mack,<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">alleging</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, among other things, breach by Mr.&#160;Mack of his </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compete</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> agreement with the Company and his fiduciary duties to the Company, and tortious interference by Virpax with that </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compete</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> agreement. Both lawsuits are ongoing.</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Operating Leases </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company leases administrative and research and development facilities under various </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cancelable</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> lease agreements. Facility leases generally provide for periodic rent increases and may include options to extend. As of December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company&#8217;s leases have remaining lease terms of approximately </div><ix:nonNumeric name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" contextRef="PAsOn12_31_2021_MinimumMembersrtRangeAxis" format="ixt-sec:duryear">2.7</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> to </div><ix:nonNumeric name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" contextRef="PAsOn12_31_2021_MaximumMembersrtRangeAxis" format="ixt-sec:duryear">2.9</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;years. The term of the Company&#8217;s leases does not include extension options that were not reasonably certain to be exercised from its lease terms, ranging from </div><ix:nonNumeric name="us-gaap:LesseeOperatingLeaseRenewalTerm" contextRef="PAsOn12_31_2021_MinimumMembersrtRangeAxis" format="ixt-sec:duryear">3</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> to </div><ix:nonNumeric name="us-gaap:LesseeOperatingLeaseRenewalTerm" contextRef="PAsOn12_31_2021_MaximumMembersrtRangeAxis" format="ixt-sec:duryear">5</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;years. Many of the Company&#8217;s leases are subject to variable lease payments. Variable lease payments are recognized in the period in which the obligation for those payments are incurred, are not included in the measurement of the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> assets or lease liabilities and are immaterial. Additionally, the Company subleases certain properties to third parties. Sublease income is recognized on a straight-line basis and is immaterial.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As the Company&#8217;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The Company calculates the associated lease liability and corresponding </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> asset upon lease commencement using a discount rate based on a credit-adjusted secured borrowing rate commensurate with the term of the lease. As of December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company has </div>no<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> finance leases.</div></div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-83 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div><ix:continuation id="TextSelectionAppend_63195191_2" continuedAt="TextSelectionAppend_63195191_3"> <ix:nonNumeric name="us-gaap:LeaseCostTableTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The components of lease expense were as follows (in thousands):</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 76%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease cost*</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_63195336">623</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_63195335">904</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="Fact_63195334">776</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">*</div></td>
<td style="vertical-align: top; font-size: 10pt;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inclusive of variable lease costs, sublease income, and impairment, which were immaterial for the periods presented. </div></div></div></td></tr></table></ix:nonNumeric> </ix:continuation> </div></div> <div style="text-align: center;"><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_63195191_3" continuedAt="TextSelectionAppend_63195191_4"><ix:nonNumeric name="sclx:ScheduleOfSupplementalQuantitativeInformationRelatedToLeasesTableTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplemental quantitative information related to leases includes the following: </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 74%;"></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;Ended&#160;December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;2021&#160;&#160;&#160;&#160;&#160;&#160;</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;2020&#160;&#160;&#160;&#160;&#160;&#160;</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 0px;">
<td style="width: 74%;"></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 74%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash paid for amounts included in the measurement of lease <br/>liabilities:</div></div></td>
<td style="vertical-align: bottom; width: 10%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 74%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating cash flows from operating leases</div></div></td>
<td style="vertical-align: bottom; width: 10%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="sclx:OperatingCashFlowsFromOperatingLeases" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">654</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="sclx:OperatingCashFlowsFromOperatingLeases" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">833</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 74%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average remaining lease term in&#160;years&#160;&#8212;&#160;operating <br/>leases</div></div></td>
<td style="vertical-align: bottom; width: 10%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="PAsOn12_31_2021" format="ixt-sec:duryear">2.8</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="PAsOn12_31_2020" format="ixt-sec:duryear">3.8</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 74%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average discount rate&#160;&#8212;&#160;operating leases</div></div></td>
<td style="vertical-align: bottom; width: 10%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="PAsOn12_31_2021" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">12.2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="PAsOn12_31_2020" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">12.2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table></ix:nonNumeric></ix:continuation><div style="clear: both; max-height: 0px; text-indent: 0px;"></div></div></div><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_63195191_4"><ix:nonNumeric name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Maturities of lease liabilities were as follows (in thousands): </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 86%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Year Ending December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">674</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">694</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">596</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2026</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total lease payments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,964</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less imputed interest</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">316</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total lease liabilities as of December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,648</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table></ix:nonNumeric><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Operating</div> lease expense totaled approximately $</div><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.7</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, $</div><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.1</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.8</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million for the&#160;years ended December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, respectively.</div></div></ix:continuation>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap;"></td></tr></table><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><br/></div><ix:nonNumeric name="us-gaap:IncomeTaxDisclosureTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_63196058">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">12.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income Taxes </div></div></div></div></td></tr></table><ix:nonNumeric name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total loss before income taxes for the&#160;years ended December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> did not include a foreign component. The components of benefits for income taxes were as follows for the period ended December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> (in thousands):</div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 76%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current expense:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Federal</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">State</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">53</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">53</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Federal</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">State</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">53</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table></ix:nonNumeric></ix:nonNumeric><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-84 </div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div><ix:continuation id="TextSelection_63196058" continuedAt="TextSelectionAppend_63196058_1"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.</div></div><ix:nonNumeric name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The components of the Company&#8217;s net deferred tax liabilities and related valuation allowance are as follows at December&#160;31 (in thousands): </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 73%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 73%; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax assets</div></div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 73%; background-color: rgb(255, 255, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest expense limitations</div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="sclx:DeferredTaxAssetsInterestExpenseLimitations" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,205</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="sclx:DeferredTaxAssetsInterestExpenseLimitations" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,225</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 73%; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tax credit carryforwards</div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,630</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,623</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 73%; background-color: rgb(255, 255, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net operating loss carryforwards</div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">39,714</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">31,732</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 73%; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock based compensation</div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,233</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,037</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 73%; background-color: rgb(255, 255, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease liabilities</div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="sclx:DeferredTaxAssetsOperatingLeaseLiabilities" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">404</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="sclx:DeferredTaxAssetsOperatingLeaseLiabilities" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">510</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em;">Others</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,753</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,285</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(255, 255, 255); width: 73%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 73%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Deferred Tax Assets</div></div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">58,939</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">46,412</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr>
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 73%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Valuation allowance</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="line-height: normal;"><div style="null;text-indent: 0px;;font-weight:bold;display:inline;width:100%;">&#160;</div><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">56,643</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">43,514</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="line-height: normal;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td>
<td style="background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td>
<td style="background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255);"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Deferred Tax Assets</div></div></div></div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,296</ix:nonFraction></div></div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,898</ix:nonFraction></div></div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td>
<td style="background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td>
<td style="background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred Tax Liabilities:</div></div></div></div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr>
<td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 73%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amortization of intangibles</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; text-align: right; background-color: rgb(255, 255, 255);">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,975</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,486</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">)&#160;</td></tr>
<tr>
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em;">Other</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; text-align: right; background-color: rgb(204, 238, 255);">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesOther" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesOther" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr>
<td style="vertical-align: top; background-color: rgb(255, 255, 255); padding-bottom: 0.375pt; width: 73%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); padding-bottom: 0.375pt; width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; text-align: right; background-color: rgb(255, 255, 255); border-bottom: 0.75pt solid black;">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">319</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); padding-bottom: 0.375pt;">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); padding-bottom: 0.375pt; width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); border-bottom: 0.75pt solid black;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">412</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); padding-bottom: 0.375pt;">)&#160;</td></tr>
<tr>
<td style="vertical-align: top; background-color: rgb(204, 238, 255); padding-bottom: 0.75pt; width: 73%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Deferred Tax Liabilities</div></div></div></td>
<td style="vertical-align: bottom; padding: 0px 0px 0.75pt; background-color: rgb(204, 238, 255); width: 6%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px; text-align: right; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilities" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,296</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.75pt; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; padding: 0px 0px 0.75pt; background-color: rgb(204, 238, 255); width: 6%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilities" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,898</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); padding-bottom: 0.75pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td>
<td style="background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td></tr></table></ix:nonNumeric><div style="clear: both; max-height: 0px; text-indent: 0px;"></div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color:#ffffff;;display:inline;">The</div><div style="display:inline;"><div style="background-color:#ffffff;;display:inline;">&#160;</div></div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Company </div>has evaluated the available evidence supporting the realization of its gross deferred tax assets, including the amount and timing of future taxable income, and has determined that it is more likely than not that the deferred tax assets will not be realized. Due to such uncertainties surrounding the realization of the domestic deferred tax assets, the Company maintains a valuation allowance of $</div><ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">56.6</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div><ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">43.5</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million against its deferred tax assets as of December&#160;</div><div style="font-size: 10pt;;display:inline;">31</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div><div style="font-size: 10pt;;display:inline;">2021</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div><div style="font-size: 10pt;;display:inline;">2020</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, respectively. Realization of the deferred tax assets will <div style="letter-spacing: 0px; top: 0px;;display:inline;">b</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">e<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">primarily<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">dependent upon the Company&#8217;s ability to generate sufficient taxable income prior to the expiration of its net operating losses.</div></div><ix:nonNumeric name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The reconciliation between U.S. federal income taxes at the statutory rate and the Company&#8217;s benefit from income taxes are as follows for the year ended December 31: </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 75%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Statutory Federal Income Tax Rate</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">21.0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">21.0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">21.0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">State taxes, net of federal tax benefit</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">2.8</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">2.7</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">5.0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Debt discount and interest limitation</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="sclx:EffectiveIncomeTaxRateReconciliationDebtDiscountAndInterestLimitation" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:num-dot-decimal">10.1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:EffectiveIncomeTaxRateReconciliationDebtDiscountAndInterestLimitation" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">1.7</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:EffectiveIncomeTaxRateReconciliationDebtDiscountAndInterestLimitation" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">0.0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">In-process</div> research and development</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">0.0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">0.0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:num-dot-decimal">11.0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Return to provision adjustments and carryback</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustmentsAndCarryback" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">2.7</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="sclx:EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustmentsAndCarryback" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:num-dot-decimal">11.2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustmentsAndCarryback" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">0.0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Others</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:num-dot-decimal">1.6</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:num-dot-decimal">0.8</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:num-dot-decimal">0.8</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation allowance</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:num-dot-decimal">14.8</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:num-dot-decimal">13.2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:num-dot-decimal">14.2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4.8em;">Income Tax Benefit</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">0.0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">0.2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">0.0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table></ix:nonNumeric><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company had net operating loss carryforwards of approximately $</div><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="PAsOn12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">167.5</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million for federal and $</div><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="PAsOn12_31_2021_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">81.7</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million for state income tax purposes, respectively. These may be used to offset future taxable income and will begin to expire in </div><ix:nonNumeric name="sclx:OperatingLossCarryforwardsExpirationYear" contextRef="P01_01_2021To12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis">2034</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> for state and </div><ix:nonNumeric name="sclx:OperatingLossCarryforwardsExpirationYear" contextRef="P01_01_2021To12_31_2021_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">2035</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> for federal, except for $</div><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="PAsOn12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_IndefiniteCarryforwardPeriodMemberusgaapTaxPeriodAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">154.8</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million of the federal net operating losses that have an indefinite carryforward period.</div></div></ix:continuation><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-85 </div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_63196058_1"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Internal Revenue Code Section&#160;382 rules apply to limit a corporation&#8217;s ability to utilize existing net operating loss and tax credit carryforwards once the corporation experiences an ownership change as defined in Section&#160;382. For the&#160;years ended December&#160;31, 2021, 2020, and 2019, there was no impact of such limitations on the Company&#8217;s income tax provision.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company also has research and development and orphan drug credits of approximately $</div><ix:nonFraction name="us-gaap:TaxCreditCarryforwardAmount" contextRef="PAsOn12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_ResearchMemberusgaapTaxCreditCarryforwardAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million for federal income taxes purposes. The federal credits may be used to offset future income tax and will begin to expire in </div><ix:nonNumeric name="sclx:TaxCreditCarryforwardExpirationYear" contextRef="P01_01_2021To12_31_2021">2035</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is subject to taxation in the U.S., various state tax jurisdictions and various foreign tax jurisdictions. All of the Company&#8217;s tax&#160;years will remain open for three year for examination by the Federal and state tax authorities from the date of utilization of the net operating loss. The Company does not have any tax audits pending.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company applies the accounting guidance for uncertainty in income taxes pursuant to </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">ASC-740-10.</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Under ASC 740, the impact of an uncertain income tax position taken on a tax return must be recognized at the largest amount that is cumulatively &#8220;more likely than not&#8221; to be sustained upon audit by relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a </div><ix:nonFraction name="sclx:MinimumThresholdPercentageForRecognitionOfUncertainIncomeTaxPosition" contextRef="PAsOn12_31_2021" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">50</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% likelihood of being sustained.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The unrecognized tax benefits balances as of December&#160;31, 2021, 2020 and 2019 and the related increases and decreases to the balances were immaterial.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s policy is to recognize interest and penalties related to income tax matters in income tax expense. </div><ix:nonFraction name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction></ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> interest and penalties have been recognized as of and for the periods ended December&#160;31, 2021, 2020 and 2019.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company believes that no material amount of liabilities for uncertain tax positions will expire within 12&#160;months of December&#160;31, 2021.</div></div></ix:continuation><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><br/></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <ix:nonNumeric name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_63195190">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">13.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Related Party Transactions&#160;</div></div></div></div></td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;18, 2019, the Company entered into a merger agreement with Sorrento, Semnur, Merger Sub, and Fortis Advisors LLC. Jaisim Shah, a member of Sorrento&#8217;s board of directors, was Semnur&#8217;s Chief Executive Officer, a member of its board of directors and a stockholder of Semnur prior to the acquisition transaction. The upfront consideration was comprised of the following: (a)&#160;a cash payment of approximately $</div><ix:nonFraction name="us-gaap:PaymentsToAcquireProductiveAssets" contextRef="P03_18_2019To03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">15.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, and (b)&#160;$</div><ix:nonFraction name="us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" contextRef="P03_18_2019To03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">55.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million of shares of the Company&#8217;s common stock (</div><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets" contextRef="P03_18_2019To03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">47,039,315</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares issued and </div><ix:nonFraction name="us-gaap:CommonStockSharesSubscribedButUnissued" contextRef="PAsOn03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">352,972</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares issuable, valued at $</div><ix:nonFraction name="sclx:AssetAcquisitionPricePerShare" contextRef="PAsOn03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">1.16</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> per share) (i.e., the Stock Consideration). Following the issuance of the Stock Consideration, Sorrento was the owner of approximately </div><ix:nonFraction name="sclx:PercentageOfOwnershipInterest" contextRef="PAsOn03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">58</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the Company&#8217;s issued and outstanding capital stock as of December&#160;31, 2019. Following the completion of the Semnur Share Exchange and as of December&#160;31, 2020, Sorrento held approximately </div><ix:nonFraction name="sclx:PercentageOfSharesOutstanding" contextRef="PAsOn12_31_2020_SenmurMemberusgaapAssetAcquisitionAxis_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">82.3</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the outstanding common stock of the Company.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the year ended December&#160;31, 2021, 2020 and 2019, the Company purchased approximately $</div><ix:nonFraction name="sclx:PaymentToAcquireInventory" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">5.7</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, $</div><ix:nonFraction name="sclx:PaymentToAcquireInventory" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, and $</div><ix:nonFraction name="sclx:PaymentToAcquireInventory" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">8.4</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, respectively, of inventory from Itochu, a previous minority shareholder of the Company and a Developer in the aforementioned Product Development Agreement. These costs are recorded within cost of revenues and selling, general and administrative expenses in the Company&#8217;s statement of operations. As of December&#160;31, 2020, approximately </div><ix:nonFraction name="sclx:PercentageOfSharesOutstanding" contextRef="PAsOn12_31_2020_ItochuMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">14.7</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the outstanding capital stock of the Company was held by Itochu. On January&#160;13, 2021, </div><ix:nonFraction name="sclx:NumberOfSharesOutstanding" contextRef="PAsOn01_13_2021_ItochuMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">34,889,868</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares of the Company representing all outstanding capital stock of the Company held by Itochu were acquired by </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-related</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> minority shareholders. Thus, Itochu is not a shareholder subsequent to January&#160;13, 2021. On January&#160;29, 2021, Sorrento acquired </div><ix:nonFraction name="sclx:NumberOfSharesAcquired" contextRef="PAsOn01_29_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">34,889,868</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares of the Company, resulting in Sorrento holding approximately </div><ix:nonFraction name="sclx:PercentageOfSharesOutstanding" contextRef="PAsOn01_29_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">99.97</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the Company.</div><br/></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></ix:nonNumeric> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-86 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div><ix:continuation id="TextSelection_63195190"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Semnur is party to an Assignment Agreement, dated August&#160;6, 2013 (the &#8220;Assignment Agreement&#8221;), with Shah Investor LP (&#8220;Shah Investor&#8221;). Mahendra Shah, Ph.D., who has served on the Company&#8217;s board of directors since March&#160;2019, is the managing partner of Shah Investor. Pursuant to the Assignment Agreement, Shah Investor assigned certain intellectual property to Semnur and Semnur agreed to pay Shah Investor a contingent quarterly royalty in the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-single</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> digits based on quarterly net sales of any pharmaceutical formulations for local delivery of steroids by injection developed using such intellectual property, which would include </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-102.</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> To date, the Company has made no royalty payments pursuant to the Assignment Agreement.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On January&#160;1, 2017, a Transition Services Agreement (&#8220;TSA&#8221;) was executed between Scilex Pharma and Sorrento. Pursuant to the TSA, Sorrento agreed, at the Company&#8217;s request, to provide directly or indirectly certain administrative, financial, legal, tax, insurance, facility, information technology and other services. In addition to the services provided under the TSA, Sorrento retains insurance coverage on behalf of the Company. During the&#160;years ended December&#160;31, 2021, 2020, and 2019, the total cost of services and insurance, including an agreed-upon markup, provided to the Company and recognized in general and administrative expenses was $</div><ix:nonFraction name="us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" contextRef="P01_01_2021To12_31_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">4.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, $</div><ix:nonFraction name="us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" contextRef="P01_01_2020To12_31_2020_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.3</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, and $</div><ix:nonFraction name="us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" contextRef="P01_01_2019To12_31_2019_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.9</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, respectively.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;18, 2019, the Company entered into a note payable with Sorrento with an initial principal amount of $</div><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn03_18_2019_ReorganizationMemberSCLXEventAxis_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">16.5</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million. The note is interest bearing at the lesser of (a)&#160;</div><ix:nonFraction name="sclx:PercentageOfSimpleInterest" contextRef="PAsOn03_18_2019_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">10</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% simple interest per annum, and (b)&#160;the maximum interest rate permitted under law. Interest is due and payable annually. The note payable is payable upon demand and may be prepaid in whole or in part at any time without penalty or premium. The outstanding principal balance of the note on December&#160;31, 2021 and 2020 was $</div><ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="PAsOn12_31_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">19.6</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div><ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="PAsOn12_31_2020_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">13.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, respectively, which was recorded under the current related party note<div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div> payable in the Company&#8217;s consolidated balance sheets. As of December&#160;31, 2021 and 2020, the Company had ending balances resulting from the accrued interest on the note payable of $</div><ix:nonFraction name="us-gaap:DueToRelatedPartiesCurrent" contextRef="PAsOn12_31_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.9</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div><ix:nonFraction name="us-gaap:DueToRelatedPartiesCurrent" contextRef="PAsOn12_31_2020_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.6</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, respectively, which was recorded under related party payable in the Company&#8217;s consolidated balance sheets. The proceeds from the note payable were used to finance the acquisition of Semnur.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On October&#160;5, 2018, Scilex Pharma issued to Sorrento a promissory note in the amount of approximately $</div><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn10_05_2018_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">21.7</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million for certain amounts previously advanced to Scilex Pharma by Sorrento (the &#8220;Intercompany Note&#8221;). Scilex Pharma may borrow up to an aggregate of $</div><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn10_05_2018_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">25.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million of principal amount under the note payable. The promissory note is interest bearing at the lesser of (a)&#160;</div><ix:nonFraction name="sclx:PercentageOfSimpleInterest" contextRef="PAsOn10_05_2018_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">10</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% simple interest per annum, and (b)&#160;the </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">maximum<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">interest rate permitted under law. All outstanding principal amounts and accrued interest are due upon maturity on August&#160;31, 2026. On October&#160;22, 2018, Sorrento purchased from the Company </div><ix:nonFraction name="sclx:NumberOfSharesAcquired" contextRef="PAsOn10_02_2018" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">24,117,608</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares of the Company&#8217;s common stock in exchange for the repayment of $</div><ix:nonFraction name="us-gaap:RepaymentsOfDebt" contextRef="P10_02_2018To10_02_2018_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">21.7</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million of indebtedness under this promissory note. During 2021 and 2020, Sorrento made advances to Scilex Pharma in the amount of $</div><ix:nonFraction name="sclx:AccruedInterest" contextRef="PAsOn12_31_2021_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">8.1</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div><ix:nonFraction name="sclx:AccruedInterest" contextRef="PAsOn12_31_2020_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">10.3</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, respectively, under the promissory note. As of December&#160;31, 2021 and 2020, the Company had ending balances resulting from the accrued interest on the promissory note of $</div><ix:nonFraction name="us-gaap:DueToRelatedPartiesCurrent" contextRef="PAsOn12_31_2021_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.1</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div><ix:nonFraction name="us-gaap:DueToRelatedPartiesCurrent" contextRef="PAsOn12_31_2020_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, respectively, which was recorded under related party payable in the Company&#8217;s consolidated balance sheets. As of December&#160;31, 2021 and 2020, Scilex Pharma&#8217;s outstanding principal balance under the promissory note was $</div><ix:nonFraction name="us-gaap:LongTermNotesPayable" contextRef="PAsOn12_20_2021_ScilexPharmaMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">23.5</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div><ix:nonFraction name="us-gaap:LongTermNotesPayable" contextRef="PAsOn12_31_2020_ScilexPharmaMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">15.4</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, respectively, which was recorded under the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> related party note payable in the Company&#8217;s consolidated balance sheets.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company received $</div><ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="P02_28_2021To02_28_2021_SorrentoMemberSCLXInvesteeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">17.3</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div><ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="P04_30_2021To04_30_2021_SorrentoMemberSCLXInvesteeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">20.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, in February&#160;2021 and April&#160;2021, respectively, from Sorrento to fund the payment of Scilex Pharma Notes in February&#160;2021 and April&#160;2021, totaling $</div><ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="P02_28_2021To02_28_2021_ScilexPharmaMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">40.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, as described in Note 8. The $</div><ix:nonFraction name="us-gaap:DueToRelatedPartiesCurrent" contextRef="PAsOn02_28_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">37.3</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million received in February&#160;2021 and April 2021 is due on demand to Sorrento and was recorded under the related party payables in the Company&#8217;s consolidated balance sheets. As of December&#160;31, 2021, related party payables due to Sorrento included $</div><ix:nonFraction name="sclx:WorkingCapitalRequirements" contextRef="PAsOn12_31_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">35.7</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million to cover working capital requirements, $</div><ix:nonFraction name="us-gaap:DebtInstrumentRepurchaseAmount" contextRef="PAsOn12_20_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">51.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million for repurchases of Scilex Pharma Notes, and $</div><ix:nonFraction name="us-gaap:LegalFees" contextRef="P01_01_2021To12_31_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">6.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million to pay litigation fees (see Note 11). As of December&#160;31, 2020, related party payables due to Sorrento consisted of $</div><ix:nonFraction name="sclx:WorkingCapitalRequirements" contextRef="PAsOn12_31_2020_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">13.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million to cover working capital requirements and $</div><ix:nonFraction name="us-gaap:DebtInstrumentRepurchaseAmount" contextRef="PAsOn12_31_2020_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">13.7</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million for repurchases of Scilex Pharma Notes.</div><br/></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-87 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <ix:nonNumeric name="us-gaap:EarningsPerShareTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">14.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss Per Share </div></div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div></div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the&#160;years ended December&#160;31, 2021, 2020 and 2019, basic loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. Diluted loss per common share is calculated to give effect to all dilutive securities, using the treasury stock method.</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <ix:nonNumeric name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth the reconciliation of basic and diluted loss per share for the&#160;years ended December&#160;31, 2021, 2020, and 2019 (in thousands except per share data):</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 60%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt; border-bottom: 0.75pt solid black;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt; border-bottom: 0.75pt solid black;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">88,424</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">47,519</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">178,594</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator for Basic Loss Per Share</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">197,266</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">197,315</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">187,524</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Effect of Dilutive Securities</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:DilutiveSecurities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-2" scale="3" format="ixt:num-dot-decimal">0.0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:DilutiveSecurities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-2" scale="3" format="ixt:num-dot-decimal">0.0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:DilutiveSecurities" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-2" scale="3" format="ixt:num-dot-decimal">0.0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Denominator for Diluted Loss per Share &#8212; Adjusted for Dilutive Securities</div><br/></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">197,266</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">197,315</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">187,524</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic Loss Per Share</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">0.45</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">0.24</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">0.95</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dilutive Loss Per Share</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">0.45</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">0.24</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">0.95</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">)&#160;</td> </tr> </table> </ix:nonNumeric> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The stock options that could potentially dilute basic earnings per share in the future were excluded from the computation of diluted net loss per share because the effect would have been anti-dilutive due to the net loss for the&#160;years ended December&#160;31, 2021, 2020, and 2019 of </div><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_shares" decimals="-5" scale="6" format="ixt:num-dot-decimal">28.2</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, </div><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_shares" decimals="-5" scale="6" format="ixt:num-dot-decimal">30.8</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, and </div><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2019To12_31_2019" unitRef="Unit_shares" decimals="-5" scale="6" format="ixt:num-dot-decimal">25.4</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">respectively. </div></div></div></ix:nonNumeric> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <ix:nonNumeric name="us-gaap:SubsequentEventsTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_63194942">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">15.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Subsequent Events </div></div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following events were identified subsequent to the balance sheet date. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">SPAC Transaction </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;17, 2022, the Company entered into an Agreement and Plan of Merger (as amended, the &#8220;Merger Agreement&#8221;) with Vickers Vantage Corp. I (&#8220;Vickers&#8221;), a SPAC, and Vantage Merger Sub, Inc., a wholly owned subsidiary of Vickers (&#8220;Merger Sub&#8221;). Pursuant to the terms of the Merger Agreement, (i)&#160;Merger </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sub will </div></div><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;">merge with and into the Company</div><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;">, with the Company surviving the merger (&#8220;combined company&#8221;) and (ii)&#160;become a wholly<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>owned subsidiary of Vickers (collectively, the &#8220;SPAC Transaction&#8221;). The Merger is expected to close during the fourth quarter of 2022, and the Combined Company is expected to be listed on the Nasdaq Capital Market under the new ticker symbol &#8220;SCLX&#8221;. Completion of the SPAC Transaction is subject to the approval of Vickers and Company shareholders and the satisfaction or waiver of certain other closing conditions.</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Scilex Pharma Note </div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color:rgba(255, 255, 255, .0);;display:inline;">Effective </div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> February&#160;14, 2022, Scilex Pharma issued to Sorrento a draw notice under the Letter of Credit as required under the terms of the Indenture because actual cumulative net sales of ZTlido from the issue date of the Scilex Pharma Notes through December&#160;31, 2021 were less than a specified sales threshold for such period. As a result of the draw notice being issued, the Company paid to Scilex Pharma $</div><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn02_14_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_SubordinatedDebtMemberusgaapLongtermDebtTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">35.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in a single </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lump-sum</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> amount as a subordinated loan. Per the terms of the Amendment No.&#160;3, in February&#160;2022, Scilex Pharma repurchased Scilex Pharma Notes in an aggregate amount equal to $</div><ix:nonFraction name="us-gaap:DebtInstrumentRepurchaseAmount" contextRef="PAsOn02_28_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_SubordinatedDebtMemberusgaapLongtermDebtTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">20.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million at a purchase price in cash equal</div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>to <ix:nonFraction name="sclx:PercentageOfPurchasePriceInCashEqualIsToPrincipalAmountOfTheLoan" contextRef="PAsOn02_28_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_SubordinatedDebtMemberusgaapLongtermDebtTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction>% of the principal amount. In addition, the draw down of the Letter of Credit triggered a requirement for Scilex Pharma to maintain a minimum cash balance of $<ix:nonFraction name="us-gaap:RestrictedCash" contextRef="PAsOn02_28_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_SubordinatedDebtMemberusgaapLongtermDebtTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">10.0</ix:nonFraction>&#160;million at all times going </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">forward. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Effective</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;February&#160;15, 2022, in accordance with the Indenture, the principal amount of the Scilex Pharma Notes was increased by $</div><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn02_15_2022_MaximumMembersrtRangeAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_SubordinatedDebtMemberusgaapLongtermDebtTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">28.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million as actual cumulative net sales of ZTlido from the issue date of the Scilex Pharma Notes through December&#160;31, 2021 did not equal or exceed a $</div><ix:nonFraction name="sclx:SalesThresholdLimit" contextRef="P02_15_2022To02_15_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_SubordinatedDebtMemberusgaapLongtermDebtTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">481.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million sales threshold for such period<div style="display:inline;">.</div></div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-88 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div><ix:continuation id="TextSelection_63194942"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; font-size: 10pt;;font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Advances on Related Party Note Payable</div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;30, 2022, Sorrento made advances to the Company in the amount of $</div><ix:nonFraction name="us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent" contextRef="PAsOn03_30_2022_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">23.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million under the related party note payable entered into on March&#160;18, 2019 with Sorrento. See Note 13 for further discussion of the related party note </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">payable. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-104</div> Acquisition from Sorrento </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">On May&#160;12, 2022</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company and Sorrento entered into a bill of sale and assignment and assumption agreement (the &#8220;Bill of Sale&#8221;), pursuant to which Sorrento sold, conveyed, assigned and transferred to Scilex all of its rights, title and interest in and to Sorrento&#8217;s Delayed Burst Release Low Dose Naltrexone </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(DBR-LDN)</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> asset and intellectual property rights, for the treatment of chronic pain, fibromyalgia and chronic post-COVID syndrome (collectively, the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;SP-104</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Assets&#8221;) and the Company is currently analyzing the accounting treatment for the transaction. These assets had previously been acquired by Sorrento from Aardvark Therapeutics, Inc. (&#8220;Aardvark&#8221;) in April 2021 pursuant to an asset purchase agreement (the &#8220;Aardvark Asset Purchase Agreement&#8221;). Pursuant to the Bill of Sale, the Company assumed all of Sorrento&#8217;s rights, liabilities and obligations under the Aardvark Asset Purchase Agreement (the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;SP-104</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Acquisition&#8221;).</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As consideration for the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-104</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Acquisition, the Company issued a promissory note in the aggregate principal amount of $</div><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn05_12_2022_SorrentoMemberusgaapBusinessAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_TwoThousandAndTwentyTwoPromissoryNoteMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">5.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million to Sorrento (the &#8220;2022 Promissory Note&#8221;). The 2022 Promissory Note matures </div><ix:nonNumeric name="us-gaap:DebtInstrumentTerm" contextRef="P05_12_2022To05_12_2022_SorrentoMemberusgaapBusinessAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_TwoThousandAndTwentyTwoPromissoryNoteMemberusgaapLongtermDebtTypeAxis" format="ixt-sec:durwordsen">seven years</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> from the date of issuance and bears interest at the rate equal to the lesser of (a) </div><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="PAsOn05_12_2022_SorrentoMemberusgaapBusinessAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_TwoThousandAndTwentyTwoPromissoryNoteMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">2.66</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% simple interest per annum and (b)&#160;the maximum interest rate permitted under law. The 2022 Promissory Note is payable in cash, shares of the Company common stock (any shares so issued, the </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">&#8220;</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consideration Shares&#8221;) or any combination thereof, at the Company&#8217;s sole discretion, and may be prepaid in whole or in part at any time without penalty. The Company also agreed to file with the SEC, a resale registration statement, relating to the resale by Sorrento of any Consideration Shares that may be issued to Sorrento, within </div><ix:nonNumeric name="sclx:MinimumTimeDeclaredToFileWithSecRegardingResaleRegistrationStatement" contextRef="P05_12_2022To05_12_2022_SorrentoMemberusgaapBusinessAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_TwoThousandAndTwentyTwoPromissoryNoteMemberusgaapLongtermDebtTypeAxis" format="ixt-sec:durday">60</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> days of the issuance of such Consideration Shares.</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As the successor to the Aardvark Asset Purchase Agreement, the Company is obligated to pay Aardvark (i)&#160;$</div><ix:nonFraction name="us-gaap:AssetAcquisitionConsiderationTransferred" contextRef="P05_12_2022To05_12_2022_AardvarkMemberusgaapAssetAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">3,000,000</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, upon initial approval by the FDA of a new drug application for the LDN Formulation (as defined in<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;Aardvark Asset Purchase Agreement) (which amount may be paid in shares of the Company&#8217;s common stock or cash, in the Company&#8217;s sole discretion) (the &#8220;Development Milestone Payment&#8221;) and (ii)&#160;$</div><ix:nonFraction name="us-gaap:PaymentsToAcquireProductiveAssets" contextRef="P05_12_2022To05_12_2022_AardvarkMemberusgaapAssetAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">20,000,000</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, in cash, upon achievement of certain net sales by the Company of a commercial product that uses the LDN Formulation (the &#8220;Commercial Product&#8221;). The Company will also pay Aardvark certain royalties in the single digits based on percentages of annual net sales by the Company of a commercial product that uses the LDN Formulation. The royalty percentage is subject to reduction in certain circumstances. Royalties are due for so long as Commercial Product is covered by a valid patent in the country of sale or for ten years following the first commercial sale of the Commercial Product, whichever is longer.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In connection with its acquisition of the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-104</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Assets, the Company has agreed that if it issues any shares of the Company&#8217;s common stock in respect of the Development Milestone Payment, the Company will prepare and file one or more registration statements with the SEC for the purpose of registering for resale such shares and is required to file such registration statement with the SEC within </div><ix:nonNumeric name="sclx:MinimumTimeDeclaredToFileWithSecRegardingResaleRegistrationStatement" contextRef="P05_12_2022To05_12_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis" format="ixt-sec:durday">60</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>days following the date on which any such shares are issued.</div></div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Tien-Li</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Lee, MD, a member of the board of directors of the Company, is the founder, chief executive officer and a member of the board of directors of Aardvark.</div></div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-8<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">9</div></div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SCILEX HOLDING COMPANY </div></div></div></div> <div id="fin428534_18" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONSOLIDATED BALANCE SHEETS </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AS OF SEPTEMBER&#160;30, 2022 AND DECEMBER&#160;31, 2021 </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(In thousands, except for par value and share amounts; unaudited) </div></div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated Balance Sheets as of September&#160;30, 2022 and December&#160;31, 2021 </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div><br/></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 78%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">September&#160;30,<br/>2022</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">December&#160;31,<br/>2021</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; padding: 0pt; line-height: 10pt; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap; line-height: 10pt;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px; line-height: 10pt; white-space: nowrap;;display:inline;">ASSETS</div></div></div></div></td>
<td style="vertical-align: bottom; padding: 0pt; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0pt; line-height: 10pt;"><div style="font-size:10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0pt; line-height: 10pt;"><div style="font-size:10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0pt; line-height: 10pt;"><div style="font-size:10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding: 0pt; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0pt; line-height: 10pt;"><div style="font-size:10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding: 0pt; line-height: 10pt;"><div style="font-size:10pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; height: 10px; padding: 0pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; padding: 0pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="white-space: nowrap; line-height: 10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt; white-space: nowrap;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px; line-height: 10pt; white-space: nowrap;;display:inline;">Current assets:</div></div></div></div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; padding: 0pt;"><div style="font-size:10pt;;display:inline;"><div style="white-space: nowrap; line-height: 10pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 10pt; line-height: 10pt; padding: 0pt;"><div style="font-size:10pt;;display:inline;"><div style="white-space: nowrap; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 10pt; line-height: 10pt; padding: 0pt;"><div style="font-size:10pt;;display:inline;"><div style="white-space: nowrap; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 10pt; line-height: 10pt; padding: 0pt;"><div style="font-size:10pt;;display:inline;"><div style="white-space: nowrap; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; padding: 0pt;"><div style="font-size:10pt;;display:inline;"><div style="white-space: nowrap; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 10pt; line-height: 10pt; padding: 0pt;"><div style="font-size:10pt;;display:inline;"><div style="white-space: nowrap; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 10pt; line-height: 10pt; padding: 0pt;"><div style="font-size:10pt;;display:inline;"><div style="white-space: nowrap; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 10pt; line-height: 10pt; height: 10px; padding: 0pt;"><div style="font-size: 10pt; white-space: nowrap;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; padding: 0pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="white-space: nowrap; line-height: 10pt;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px; line-height: 10pt; white-space: nowrap;;display:inline;">Cash and cash equivalents</div></div></div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; padding: 0pt;"><div style="font-size:10pt;;display:inline;"><div style="white-space: nowrap; line-height: 10pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt; padding: 0pt;"><div style="font-size:10pt;;display:inline;"><div style="white-space: nowrap; line-height: 10pt;;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt; padding: 0pt;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,483</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt; padding: 0pt;"><div style="font-size:10pt;;display:inline;"><div style="white-space: nowrap; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; padding: 0pt;"><div style="font-size:10pt;;display:inline;"><div style="white-space: nowrap; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt; padding: 0pt;"><div style="font-size:10pt;;display:inline;"><div style="white-space: nowrap; line-height: 10pt;;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt; padding: 0pt;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,338</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt; height: 10px; padding: 0pt;"><div style="font-size: 10pt; white-space: nowrap;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; padding: 0pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="white-space: nowrap; line-height: 10pt;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px; line-height: 10pt; white-space: nowrap;;display:inline;">Accounts receivable, net</div></div></div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; padding: 0pt;"><div style="font-size:10pt;;display:inline;"><div style="white-space: nowrap; line-height: 10pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt; padding: 0pt;"><div style="font-size:10pt;;display:inline;"><div style="white-space: nowrap; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt; padding: 0pt;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">17,474</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt; padding: 0pt;"><div style="font-size:10pt;;display:inline;"><div style="white-space: nowrap; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; padding: 0pt;"><div style="font-size:10pt;;display:inline;"><div style="white-space: nowrap; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt; padding: 0pt;"><div style="font-size:10pt;;display:inline;"><div style="white-space: nowrap; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt; padding: 0pt;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">14,268</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt; height: 10px; padding: 0pt;"><div style="font-size: 10pt; white-space: nowrap;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; padding: 0pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="white-space: nowrap; line-height: 10pt;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px; line-height: 10pt; white-space: nowrap;;display:inline;">Inventory</div></div></div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; padding: 0pt;"><div style="font-size:10pt;;display:inline;"><div style="white-space: nowrap; line-height: 10pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt; padding: 0pt;"><div style="font-size:10pt;;display:inline;"><div style="white-space: nowrap; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt; padding: 0pt;;text-align:right;"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">933</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt; padding: 0pt;"><div style="font-size:10pt;;display:inline;"><div style="white-space: nowrap; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; padding: 0pt;"><div style="font-size:10pt;;display:inline;"><div style="white-space: nowrap; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt; padding: 0pt;"><div style="font-size:10pt;;display:inline;"><div style="white-space: nowrap; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt; padding: 0pt;;text-align:right;"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,562</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt; height: 10px; padding: 0pt;"><div style="font-size: 10pt; white-space: nowrap;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; padding: 0pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="white-space: nowrap; line-height: 10pt;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px; line-height: 10pt; white-space: nowrap;;display:inline;">Prepaid expenses and other</div></div></div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; padding: 0pt;"><div style="font-size:10pt;;display:inline;"><div style="white-space: nowrap; line-height: 10pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt; padding: 0pt;"><div style="font-size:10pt;;display:inline;"><div style="white-space: nowrap; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt; padding: 0pt;;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,583</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt; padding: 0pt;"><div style="font-size:10pt;;display:inline;"><div style="white-space: nowrap; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; padding: 0pt;"><div style="font-size:10pt;;display:inline;"><div style="white-space: nowrap; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt; padding: 0pt;"><div style="font-size:10pt;;display:inline;"><div style="white-space: nowrap; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt; padding: 0pt;;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,835</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt; height: 10px; padding: 0pt;"><div style="font-size: 10pt; white-space: nowrap;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 0pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 0pt;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 0pt;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 0pt;;display:inline;">&#160;</div></div></div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 0pt;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 0pt;;display:inline;">&#160;</div></div></div></td>
<td style="line-height: 0pt; font-size: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; height: 10px; padding: 0pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 10pt;"><div style="font-size: 10pt; white-space: nowrap;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt; white-space: nowrap;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt; white-space: nowrap;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px; line-height: 10pt; white-space: nowrap;;display:inline;">Total current assets:</div></div></div></div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; height: 10px; padding: 0pt;"><div style="font-size: 10pt; white-space: nowrap;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt; white-space: nowrap;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt; height: 10px; padding: 0pt;"><div style="font-size: 10pt; white-space: nowrap;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt; height: 10px; padding: 0pt;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">31,473</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt; height: 10px; padding: 0pt;"><div style="font-size: 10pt; white-space: nowrap;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; height: 10px; padding: 0pt;"><div style="font-size: 10pt; white-space: nowrap;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt; height: 10px; padding: 0pt;"><div style="font-size: 10pt; white-space: nowrap;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt; height: 10px; padding: 0pt;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">23,003</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt; height: 10px; padding: 0pt;"><div style="font-size: 10pt; white-space: nowrap;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt; white-space: nowrap;;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; height: 10px; padding: 0pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 10pt;"><div style="font-size: 10pt; white-space: nowrap;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px; line-height: 10pt; white-space: nowrap;;display:inline;">Property and equipment, net</div></div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; height: 10px; padding: 0pt;"><div style="font-size: 10pt; white-space: nowrap;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt; white-space: nowrap;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt; height: 10px; padding: 0pt;"><div style="font-size: 10pt; white-space: nowrap;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt; height: 10px; padding: 0pt;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">782</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt; height: 10px; padding: 0pt;"><div style="font-size: 10pt; white-space: nowrap;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; height: 10px; padding: 0pt;"><div style="font-size: 10pt; white-space: nowrap;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt; height: 10px; padding: 0pt;"><div style="font-size: 10pt; white-space: nowrap;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt; height: 10px; padding: 0pt;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">805</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt; height: 10px; padding: 0pt;"><div style="font-size: 10pt; white-space: nowrap;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt; white-space: nowrap;;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; height: 10px; padding: 0pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 10pt;"><div style="font-size: 10pt; white-space: nowrap;;display:inline;">Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">right-of-use</div></div> asset</div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; height: 10px; padding: 0pt;"><div style="font-size: 10pt; white-space: nowrap;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt; white-space: nowrap;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt; height: 10px; padding: 0pt;"><div style="font-size: 10pt; white-space: nowrap;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt; height: 10px; padding: 0pt;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,271</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt; height: 10px; padding: 0pt;"><div style="font-size: 10pt; white-space: nowrap;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; height: 10px; padding: 0pt;"><div style="font-size: 10pt; white-space: nowrap;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt; height: 10px; padding: 0pt;"><div style="font-size: 10pt; white-space: nowrap;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt; height: 10px; padding: 0pt;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,303</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt; height: 10px; padding: 0pt;"><div style="font-size: 10pt; white-space: nowrap;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt; white-space: nowrap;;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; height: 10px; padding: 0pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 10pt;"><div style="font-size: 10pt; white-space: nowrap;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px; line-height: 10pt; white-space: nowrap;;display:inline;">Intangibles, net</div></div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; height: 10px; padding: 0pt;"><div style="font-size: 10pt; white-space: nowrap;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt; white-space: nowrap;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt; height: 10px; padding: 0pt;"><div style="font-size: 10pt; white-space: nowrap;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt; height: 10px; padding: 0pt;;text-align:right;"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">41,617</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt; height: 10px; padding: 0pt;"><div style="font-size: 10pt; white-space: nowrap;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; height: 10px; padding: 0pt;"><div style="font-size: 10pt; white-space: nowrap;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt; height: 10px; padding: 0pt;"><div style="font-size: 10pt; white-space: nowrap;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt; height: 10px; padding: 0pt;;text-align:right;"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">38,802</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt; height: 10px; padding: 0pt;"><div style="font-size: 10pt; white-space: nowrap;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt; white-space: nowrap;;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; height: 10px; padding: 0pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 10pt;"><div style="font-size: 10pt; white-space: nowrap;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px; line-height: 10pt; white-space: nowrap;;display:inline;">Goodwill</div></div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; height: 10px; padding: 0pt;"><div style="font-size: 10pt; white-space: nowrap;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt; white-space: nowrap;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt; height: 10px; padding: 0pt;"><div style="font-size: 10pt; white-space: nowrap;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt; height: 10px; padding: 0pt;;text-align:right;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,481</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt; height: 10px; padding: 0pt;"><div style="font-size: 10pt; white-space: nowrap;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; height: 10px; padding: 0pt;"><div style="font-size: 10pt; white-space: nowrap;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt; height: 10px; padding: 0pt;"><div style="font-size: 10pt; white-space: nowrap;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt; height: 10px; padding: 0pt;;text-align:right;"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,481</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt; height: 10px; padding: 0pt;"><div style="font-size: 10pt; white-space: nowrap;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt; white-space: nowrap;;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; padding: 0pt; height: 10px;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 10pt;"><div style="font-size: 10pt; white-space: nowrap;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px; line-height: 10pt; white-space: nowrap;;display:inline;">Long-term deposit</div></div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; padding: 0pt; height: 10px;"><div style="font-size: 10pt; white-space: nowrap;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt; white-space: nowrap;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt; border-bottom: 0.75pt solid black; height: 10px; padding: 0pt;"><div style="font-size: 10pt; white-space: nowrap;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt; border-bottom: 0.75pt solid black; height: 10px; padding: 0pt;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermInvestments" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">153</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt; padding: 0pt; height: 10px;"><div style="font-size: 10pt; white-space: nowrap;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; padding: 0pt; height: 10px;"><div style="font-size: 10pt; white-space: nowrap;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt; border-bottom: 0.75pt solid black; height: 10px; padding: 0pt;"><div style="font-size: 10pt; white-space: nowrap;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt; white-space: nowrap;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt; border-bottom: 0.75pt solid black; height: 10px; padding: 0pt;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermInvestments" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">538</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt; padding: 0pt; height: 10px;"><div style="font-size: 10pt; white-space: nowrap;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt; white-space: nowrap;;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">Total assets</div></div></div></div></div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">88,777</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">77,932</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">LIABILITIES AND STOCKHOLDERS&#8217; DEFICIT</div></div></div></div></div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 10pt; line-height: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 10pt; line-height: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 10pt; line-height: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 10pt; line-height: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 10pt; line-height: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">Current liabilities:</div></div></div></div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 10pt; line-height: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 10pt; line-height: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 10pt; line-height: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 10pt; line-height: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 10pt; line-height: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">Accounts payable</div></div></div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,684</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,284</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">Accrued payroll</div></div></div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="sclx:AccruedPayroll" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,426</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="sclx:AccruedPayroll" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,733</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">Accrued expenses</div></div></div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">23,862</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,621</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">Current portion of deferred consideration</div></div></div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredRevenueCurrent" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">133</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredRevenueCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">Current portion of debt</div></div></div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtCurrent" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">37,950</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">Related party payable</div></div></div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:DueToRelatedPartiesCurrent" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">166,145</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:DueToRelatedPartiesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">92,724</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">Related party note payable</div></div></div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="sclx:RelatedPartyNotePayableCurrent" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">47,108</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="sclx:RelatedPartyNotePayableCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">19,608</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">Current portion of operating lease liabilities</div></div></div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">717</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">Total current liabilities:</div></div></div></div></div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">251,075</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">169,420</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">Long-term deferred consideration</div></div></div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredRevenueNoncurrent" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,517</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredRevenueNoncurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">Long-term debt, net</div></div></div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">72,037</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9.5pt; font-size: 9.5pt;"><div style="font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">Related party note payable, net</div></div></div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="sclx:RelatedPartyNotePayableNoncurrent" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">62,717</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="sclx:RelatedPartyNotePayableNoncurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">23,503</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">Derivative liabilities</div></div></div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="sclx:DerivativeLiabilityNoncurrent" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="sclx:DerivativeLiabilityNoncurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">35,700</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">Operating lease liabilities</div></div></div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">863</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,148</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">Total liabilities</div></div></div></div></div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">318,172</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">301,808</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">Commitments and contingencies (See Note 8)</div></div></div></div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 10pt; line-height: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 10pt; line-height: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 10pt; line-height: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">Stockholders&#8217; Deficit:</div></div></div></div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 10pt; line-height: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 10pt; line-height: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 10pt; line-height: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 10pt; line-height: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 10pt; line-height: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 10pt; line-height: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; white-space: nowrap;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; white-space: nowrap;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt; white-space: nowrap; font-size: 10pt;;display:inline;">Preferred stock, $<ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn09_30_2022" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2021" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction></div><div style="line-height: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px; font-size: 10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt; white-space: nowrap; font-size: 10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt; white-space: nowrap;;display:inline;"> par value, <ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn09_30_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">20,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn09_30_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn09_30_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></div></div></div><div style="line-height: 9.5pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 9.5pt; white-space: nowrap;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 9.5pt; white-space: nowrap;;display:inline;"></div></div></div><div style="line-height: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt; white-space: nowrap; font-size: 10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt; white-space: nowrap; font-size: 10pt;;display:inline;">ne</div></div><div style="line-height: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px; font-size: 10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt; white-space: nowrap; font-size: 10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt; white-space: nowrap;;display:inline;"><div style="line-height: 10pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="line-height: 10pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px; line-height: 10pt; white-space: nowrap;;display:inline;"> issued or outstanding <div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">at</div> September&#160;30, 2022 <br/>and December&#160;31, 2021</div></div></div></div></div></div></div></div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; white-space: nowrap;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; white-space: nowrap;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt; white-space: nowrap; font-size: 10pt;;display:inline;">Common stock, $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn09_30_2022" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2021" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction></div><div style="line-height: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px; font-size: 10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt; white-space: nowrap; font-size: 10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt; white-space: nowrap;;display:inline;"> par value, <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn09_30_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">350,000,000</ix:nonFraction></ix:nonFraction></div></div><div style="line-height: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px; font-size: 10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt; white-space: nowrap;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt; white-space: nowrap;;display:inline;"> shares authorized; <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn09_30_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn09_30_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">197,566,338</ix:nonFraction></ix:nonFraction></div></div></div></div><div style="line-height: 10pt;;display:inline;"><div style="line-height: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt; white-space: nowrap;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt; white-space: nowrap;;display:inline;"> and <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">197,266,338</ix:nonFraction></ix:nonFraction></div></div></div></div><div style="line-height: 10pt;;display:inline;"><div style="line-height: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt; white-space: nowrap;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt; white-space: nowrap;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px; line-height: 10pt; white-space: nowrap;;display:inline;"> shares issued and <br/>outstanding at September&#160;30, 2022 and December&#160;31, 2021, respectively</div></div></div></div></div></div></div></div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">Additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">paid-in</div> capital</div></div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">128,615</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">128,654</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">Accumulated deficit</div></div></div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">358,030</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">352,550</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9.5pt; font-size: 9.5pt;"><div style="font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">Total stockholders&#8217; deficit</div></div></div></div></div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">229,395</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">223,876</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9.5pt; font-size: 9.5pt;"><div style="font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">Total liabilities and stockholders&#8217; deficit</div></div></div></div></div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">88,777</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size:10pt;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">77,932</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">See accompanying notes to unaudited consolidated financial statements</div></div> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="letter-spacing: 0px; top: 0px;;display:inline;">90</div></div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SCILEX HOLDING COMPANY </div></div></div></div> <div id="fin428534_19" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONSOLIDATED STATEMENTS OF OPERATIONS </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FOR THE NINE MONTHS ENDED SEPTEMBER&#160;30, 2022 AND 2021 </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(In thousands, except for net loss per share amounts; unaudited) </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated Balance Sheets as of September&#160;30, 2022 and December&#160;31, 2021</div></div></div><div style="font-size: 12pt; letter-spacing: 0px; text-align: left;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 75%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-size: 0px;">
<td style="width: 75%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Nine&#160;Months&#160;Ended&#160;September&#160;30,</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2022&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;2021&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net revenue</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Revenues" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">26,115</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Revenues" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">23,054</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating costs and expenses:</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost of revenue</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,284</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,549</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,457</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,031</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Selling, general and administrative</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">41,371</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">36,092</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible amortization</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,896</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,803</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 75%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating costs and expenses</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingCostsAndExpenses" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">57,008</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingCostsAndExpenses" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">48,475</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 75%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from operations</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">30,893</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">25,421</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other (income) expense:</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gain on derivative liability</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="sclx:GainLossOnDerivative" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">5,300</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="sclx:GainLossOnDerivative" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">100</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Gain) loss on debt extinguishment, net</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="sclx:GainLossOnExtinguishmentOfDebtt" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">28,634</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:GainLossOnExtinguishmentOfDebtt" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,463</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest expense</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,596</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,617</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Gain) loss on foreign currency exchange</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">39</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">48</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 75%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total other (income) expense</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">25,377</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">21,028</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 75%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss before income taxes</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">5,516</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">46,449</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax (benefit) expense</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">36</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">10</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 75%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">5,480</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">46,459</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 75%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss per share &#8212; basic and diluted</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" sign="-" format="ixt:num-dot-decimal">0.03</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" sign="-" format="ixt:num-dot-decimal">0.24</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 75%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average number of shares during the period &#8212; basic and diluted</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">197,550</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">197,266</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">See accompanying notes to unaudited consolidated financial statements </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-9<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1</div></div></div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SCILEX HOLDING COMPANY </div></div></div></div> <div id="fin428534_20" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; DEFICIT </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FOR THE NINE MONTHS ENDED SEPTEMBER&#160;30, 2022 AND 2021 </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(In thousands; unaudited) </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated Balance Sheets as of September&#160;30, 2022 and December&#160;31, 2021 </div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div><br/></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 58%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Common Stock</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Additional<br/><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Paid-in</div><br/>Capital</div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Accumulated<br/>Deficit</div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Total</div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Shares</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Amount</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance, December&#160;31, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">197,266</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">128,654</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">352,550</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">223,876</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock options exercised</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="P01_01_2022To09_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">300</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2022To09_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2022To09_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">96</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2022To09_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">96</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Aardvark <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-104</div> license transfer from Sorrento, net of discount</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="sclx:AdjustmentsToAdditionalPaidInCapitalNetOfDiscount" contextRef="P01_01_2022To09_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">4,127</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="sclx:AdjustmentsToAdditionalPaidInCapitalNetOfDiscount" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">4,127</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Aardvark <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-104</div> discount amortization</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="sclx:AdjustmentsToAdditionalPaidInCapitalDiscountAmortization" contextRef="P01_01_2022To09_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">35</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="sclx:AdjustmentsToAdditionalPaidInCapitalDiscountAmortization" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">35</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock based compensation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="P01_01_2022To09_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,027</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,027</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To09_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">5,480</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">5,480</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance, September&#160;30, 2022</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn09_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">197,566</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">128,615</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">358,030</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">229,395</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-size: 0px;">
<td style="width: 58%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;">Common Stock</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;">Additional<br/><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Paid-in</div><br/>Capital</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;">Accumulated<br/>Deficit</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;">Total</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;">Shares</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;">Amount</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance, December&#160;31, 2020</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">197,266</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">122,423</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">264,126</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">141,683</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="P01_01_2021To09_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="P01_01_2021To09_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,368</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="P01_01_2021To09_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,368</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustment to shares issued in Semnur Acquisition</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:AdjustmentsToAdditionalPaidInCapitalSharesIssuedInSemnurAcquisition" contextRef="P01_01_2021To09_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">409</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:AdjustmentsToAdditionalPaidInCapitalSharesIssuedInSemnurAcquisition" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">409</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To09_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">46,459</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">46,459</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance, September&#160;30, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn09_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">197,266</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">127,200</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">310,585</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">183,365</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">See accompanying notes to unaudited consolidated financial statements</div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-9<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2</div></div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SCILEX HOLDING COMPANY </div></div></div></div> <div id="fin428534_21" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONSOLIDATED STATEMENTS OF CASH FLOWS </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FOR THE NINE MONTHS ENDED SEPTEMBER&#160;30, 2022 AND 2021 </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(In thousands; Unaudited) </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated Statements of Cash Flows for the Nine Months Ended September&#160;30, 2022 and 2021 </div></div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 83%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Nine Months Ended<br/>September&#160;30,</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2022</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2021</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 0px;">
<td style="width: 83%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">Operating activities</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 9pt; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 9pt; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 9pt; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 9pt; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 9pt; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 9pt; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">5,480</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">46,459</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustments to reconcile net loss to net cash used for operating activities:</div></div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 9pt; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 9pt; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 9pt; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 9pt; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 9pt; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 9pt; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation and amortization</div></div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,926</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,832</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Amortization of debt issuance costs and debt discount</div></div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,108</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,904</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Payment on the Scilex Pharma Notes attributed to accreted interest related to the debt discount</div></div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;">(<ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">21,190</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;">(<ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,813</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">(Gain) loss on debt extinguishment, net</div></div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;">(<ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">28,634</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">12,463</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-cash</div> operating lease cost</div></div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="sclx:NonCashOperatingLeaseCosts" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">351</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="sclx:NonCashOperatingLeaseCosts" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">276</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation</div></div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,027</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,368</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Gain on derivative liability</div></div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;">(<ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,300</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;">(<ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">100</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in operating assets and liabilities:</div></div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 9pt; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 9pt; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 9pt; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 9pt; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 9pt; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 9pt; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivables, net</div></div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,206</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">517</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Inventory</div></div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,629</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">186</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid expenses and other</div></div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,478</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,647</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term deposits</div></div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInSecurityDeposits" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">385</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInSecurityDeposits" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable</div></div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,967</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">2,784</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued payroll</div></div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">2,307</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">360</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued expenses</div></div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,403</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">522</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Other liabilities</div></div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">255</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">53</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">Related party payable</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">21,521</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,765</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">Net cash used for operating activities</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">20,533</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">22,707</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">Investing activities</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 9pt; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 9pt; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 9pt; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 9pt; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 9pt; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 9pt; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquisition consideration paid in cash for Romeg intangible asset acquisition</div></div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquireBusinessesGross" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,060</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:PaymentsToAcquireBusinessesGross" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">Purchase of property, plant, and equipment</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 9pt; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 9pt; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 9pt; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">Net cash used for investing activities</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">2,067</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Financing activities</div></div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 9pt; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 9pt; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 9pt; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 9pt; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 9pt; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 9pt; line-height: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Repayment of principal on the Scilex Pharma Notes</div></div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;">(<ix:nonFraction name="us-gaap:RepaymentsOfSeniorDebt" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">84,808</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;">(<ix:nonFraction name="us-gaap:RepaymentsOfSeniorDebt" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">32,376</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Repayment on other loans</div></div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;">(<ix:nonFraction name="us-gaap:RepaymentsOfOtherLongTermDebt" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">18,800</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;">(<ix:nonFraction name="us-gaap:RepaymentsOfOtherLongTermDebt" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">36,900</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from other loans</div></div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,857</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">34,799</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from stock options exercised</div></div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">96</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from related party payable</div></div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">51,900</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">45,050</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from related party note payable</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfMediumTermNotes" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">62,500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfMediumTermNotes" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">Net cash provided by financing activities</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20,745</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">22,073</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">Net change in cash and cash equivalents</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,855</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">634</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents at beginning of period</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,338</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,839</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents at end of period</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,483</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,205</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr>
<td style="vertical-align: top; line-height: 9pt; font-size: 9pt; padding-bottom: 0.875pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0px; margin-bottom: 0px; margin-left: 1em; line-height: 1pt;">&#160;</div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt; padding-bottom: 0.875pt;"> <div style="font-size: 9pt; margin-top: 0px; margin-bottom: 0px; line-height: 1pt;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt; border-bottom: 1.75pt double black;"> <div style="font-size: 9pt; margin-top: 0px; margin-bottom: 0px; line-height: 1pt;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt; border-bottom: 1.75pt double black;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: 1pt;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt; padding-bottom: 0.875pt;"> <div style="font-size: 9pt; margin-top: 0px; margin-bottom: 0px; line-height: 1pt;">&#160;</div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt; padding-bottom: 0.875pt;"> <div style="font-size: 9pt; margin-top: 0px; margin-bottom: 0px; line-height: 1pt;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt; border-bottom: 1.75pt double black;"> <div style="font-size: 9pt; margin-top: 0px; margin-bottom: 0px; line-height: 1pt;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt; border-bottom: 1.75pt double black;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: 1pt;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.875pt;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: 1pt;">&#160;</div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 9pt; line-height: 9pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">Supplemental disclosures:</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 9pt; font-size: 9pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;">&#160;</td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;">&#160;</td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;">&#160;</td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 9pt; font-size: 9pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;">&#160;</td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px;;display:inline;">Supplemental disclosures of non-cash investing and financing activities</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 9pt; font-size: 9pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;">&#160;</td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;">&#160;</td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;">&#160;</td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 9pt; font-size: 9pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;">&#160;</td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;">&#160;</td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Deferred consideration for Romeg intangible asset acquisition</div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 9pt; font-size: 9pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,650</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 9pt; font-size: 9pt;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Non-cash consideration in Semnur acquisition</div></div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 9pt; font-size: 9pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationGiven1" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationGiven1" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">409</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 9pt; font-size: 9pt;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 9pt; line-height: 9pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Other loan forgiveness</div></div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 9pt; font-size: 9pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="sclx:OtherLoanForgiveness" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="sclx:OtherLoanForgiveness" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,536</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 9pt; font-size: 9pt;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Promissory Note issued to Sorrento in exchange for the SP-104 license, net of discount</div></div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 9pt; font-size: 9pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="sclx:PromissoryNoteIssuedNetOfDiscount" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,162</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="sclx:PromissoryNoteIssuedNetOfDiscount" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 9pt; font-size: 9pt;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="line-height: 9pt; font-size: 9pt;"> <div style="margin-left: 0in; font-size: 9pt; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 9pt; font-size: 9pt;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px; line-height: 9pt; font-size: 9pt;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px; line-height: 9pt; font-size: 9pt;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px; line-height: 9pt; font-size: 9pt;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px; line-height: 9pt; font-size: 9pt;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px; line-height: 9pt; font-size: 9pt;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px; line-height: 9pt; font-size: 9pt;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px; line-height: 9pt; font-size: 9pt;;display:inline;">&#160;</div>Fair value adjustment to derivative liability in troubled debt restructuring</div></div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 9pt; font-size: 9pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="sclx:NonCashFairValueAdjustmentToDerivativeLiability" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">30,400</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="sclx:NonCashFairValueAdjustmentToDerivativeLiability" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 9pt; font-size: 9pt;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 9pt; font-size: 9pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 11pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Live Action right-of-use asset in Palo Alto</div></div> </td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 9pt; font-size: 9pt;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="sclx:NonCashRightOfUseAsset" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">320</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;;text-align:right;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="sclx:NonCashRightOfUseAsset" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 9pt; font-size: 9pt;"><div style="font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 9pt; font-size: 9pt;;display:inline;">&#160;</div></div></td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">See accompanying notes to unaudited consolidated financial statement </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-9<div style="letter-spacing: 0px; top: 0px;;display:inline;">3</div></div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"><div style="width: 8.5in; margin-right: auto; margin-left: auto;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SCILEX HOLDING COMPANY </div></div></div></div><div id="fin428534_22" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Unaudited Consolidated Financial Statements </div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px; text-align: left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">In connection with the business combination with Vickers Vantage Corp. I (as more fully described in these notes to the financial statements), Scilex Holding Company was renamed Scilex, Inc. These financial statements are those of Scilex Holding Company (now known as Scilex, Inc.) prior <div style="letter-spacing: 0px; top: 0px;;display:inline;">to</div> the completion of such business combination. </div></div></div></div><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><br/></div><ix:nonNumeric name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" contextRef="P01_01_2022To09_30_2022" escape="true" continuedAt="TextSelection_63195226">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Nature of Operations and Basis of Presentation </div></div></div></div></td></tr></table><div style="clear: both; max-height: 0px; text-indent: 0px;"></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-indent: 0px; text-align: left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Organization and Principal Activities </div></div></div></div><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-align: left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Scilex Holding Company (&#8220;Scilex Holding&#8221; (now known as Scilex, Inc.) and together with its wholly owned subsidiaries, the &#8220;Company&#8221;) was incorporated in Delaware in February 2019 and is a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, &#8220;Sorrento&#8221;). The Company is a commercial biopharmaceutical company focused on acquiring, developing and commercializing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-opioid</div> management products for the treatment of acute and chronic pain. The Company launched its first commercial product in October 2018, ZTlido (lidocaine topical system) 1.8% (&#8220;ZTlido&#8221;), a prescription lidocaine topical system that is designed with novel technology to address the limitations of current prescription lidocaine therapies by providing significantly improved adhesion and continuous pain relief throughout the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12-hour</div> administration period. The Company <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> the exclusive right to commercialize GLOPERBA (colchicine USP) oral solution, an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FDA-approved</div> prophylactic treatment for painful gout flares in adults, in the U.S. (see Note 2). The Company is planning to commercialize GLOPERBA in 2023. The Company is currently developing three product candidates, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-102</div> (10&#160;mg, dexamethasone sodium phosphate viscous gel), a Phase 3, novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;SP-102&#8221;</div> or &#8220;SEMDEXA&#8221;) and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-103</div> (lidocaine topical system) 5.4% <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;SP-103&#8221;),</div> for the treatment of acute low back pain, and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-104</div> (4.5 mg, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-dose</div> naltrexone hydrochloride delayed-release capsules) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;SP-104&#8221;),</div> a novel formulation for the treatment of </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">fibromyalgia. </div></div></div><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-align: left;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;18, 2019, the Company entered into a Contribution and Loan Agreement with Sorrento and the holders of the outstanding shares of capital stock of Scilex Pharmaceuticals Inc. (&#8220;Scilex Pharma&#8221;) pursuant to which the Company acquired </div><ix:nonFraction name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" contextRef="PAsOn03_18_2019_ContributionAndLoanAgreementMemberSCLXAgreementAxis_ReorganizationMemberSCLXEventAxis_ScilexPharmaMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the outstanding shares of capital stock of Scilex Pharma in exchange for shares of the Company&#8217;s common stock (the &#8220;Contribution&#8221;), which was accounted for as a reorganization of entities under common control. Pursuant to the Contribution and Loan Agreement, Sorrento provided the Company with a loan with an initial principal amount of $</div><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn03_18_2019_ReorganizationMemberSCLXEventAxis_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">16.5</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in the form of a note payable, which was used by the Company to fund the acquisition of Semnur Pharmaceuticals, Inc. (&#8220;Semnur&#8221;). Concurrently therewith, the Company entered into an Agreement and Plan of Merger with Semnur, Sigma Merger Sub, Inc., the Company&#8217;s prior wholly-owned subsidiary (&#8220;Merger Sub&#8221;), Fortis Advisors LLC, solely as representative of the holders of Semnur equity (the &#8220;Semnur Equityholders&#8217; Representative&#8221;), and Sorrento, for limited purposes (the &#8220;Merger Agreement&#8221;), which was accounted for as an asset acquisition. Pursuant to the Merger Agreement, Merger Sub merged with and into Semnur (the &#8220;Merger of Semnur&#8221;), with Semnur surviving as the Company&#8217;s wholly-owned subsidiary. As a result of the Contribution and the Merger of Semnur, Scilex Pharma and Semnur became wholly-owned subsidiaries of the Company. Upon completion of the Contribution and the Merger of Semnur, the historical consolidated financial statements of Scilex Pharma became the historical consolidated financial statements of </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Scilex Holding. </div></div></div><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-align: left;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Since inception, the Company had devoted substantially all of its efforts to the product development of </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-102</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-103</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and the commercialization of ZTlido.</div></div><div style="text-align: left; margin-bottom: 1em; margin-top: 1em"></div><div style="text-align: left; margin-bottom: 1em; margin-top: 1em"></div><ix:nonNumeric name="us-gaap:BusinessCombinationsPolicy" contextRef="P01_01_2022To09_30_2022" escape="true" continuedAt="TextSelection_63196085"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px; text-align: left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Business Combination </div></div></div></div><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-align: left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;17, 2022, the Company entered into an Agreement and Plan of Merger (as amended on September&#160;12, 2022, the &#8220;BCA&#8221;) with Vickers Vantage Corp. I (&#8220;Vickers&#8221;), a special purpose acquisition</div></div></ix:nonNumeric><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-9<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">4</div></div></div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_63195226" continuedAt="TextSelectionAppend_63195226_1"><ix:continuation id="TextSelection_63196085"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">company, and<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vantage Merger Sub, Inc., a wholly-owned subsidiary of Vickers (&#8220;Vickers Merger Sub&#8221;). Pursuant to the terms of the BCA, Vickers Merger Sub merged with and into the Company, with the Company surviving the merger (&#8220;Legacy Scilex&#8221;) and becoming a wholly-owned subsidiary of Vickers (collectively, the &#8220;Business Combination&#8221;).</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On November&#160;</div>10<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Vickers consummated the Business Combination pursuant to the terms of the BCA. Vickers acquired all of the outstanding equity interests of Legacy Scilex. As a result of the Business Combination, New Scilex (as defined below) received gross proceeds of approximately $</div><ix:nonFraction name="us-gaap:ProceedsFromDivestitureOfBusinesses" contextRef="P11_10_2020To11_10_2020_VantageMergerSubIncMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">12.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, prior to the settlement of transaction-related costs and expenses. Additionally, all existing related party indebtedness between the Company, Scilex Pharma, and Sorrento totaling $</div><ix:nonFraction name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" contextRef="P11_10_2020To11_10_2020_DebtExchangeAgreementMemberSCLXAgreementAxis_VantageMergerSubIncMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">290.6</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million was converted into equity interests in Vickers in connection with the consummation of the Business Combination and pursuant to the terms of the Debt Exchange Agreement (see Note </div>10)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. In connection with the Business Combination (as more fully described in the notes to these financial statements), Scilex Holding Company was renamed to Scilex, Inc. These financial statements are those of Scilex Holding Company (now known as Scilex, Inc.) prior to the completion of such Business Combination. Additionally, in connection with the completion of the Business Combination, Vickers was renamed to, and will operate as, &#8220;Scilex Holding Company&#8221; and the Company began trading on the Nasdaq Capital Market under the new ticker symbol &#8220;SCLX&#8221; on November&#160;</div>11<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. Scilex Holding Company following the completion of the Business Combination is sometimes referred to herein as &#8220;New Scilex.&#8221;</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Business Combination will be accounted for as a reverse recapitalization in accordance with U.S. GAAP. Under this method of accounting, Vickers is treated as the &#8220;acquired&#8221; company for accounting purposes and the Business Combination is treated as the equivalent of the Company issuing stock for the net assets of Vickers, accompanied by a recapitalization. The net assets of Vickers are stated at historical cost, with </div>no<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> goodwill or other intangible assets recorded.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s legal, accounting and other fees directly attributable to the Business Combination were capitalized within prepaid expenses and other current assets on the consolidated balance sheets. As of September&#160;</div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company had capitalized $</div><ix:nonFraction name="us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" contextRef="PAsOn09_30_2022_VantageMergerSubIncMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">7.3</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million of costs incurred in relation to the Business Combination. There were </div><ix:nonFraction name="us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" contextRef="PAsOn12_31_2021_VantageMergerSubIncMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt-sec:numwordsen">no</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> capitalized costs in relation to the Business Combination as of December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">.</div></div></ix:continuation><ix:nonNumeric name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" contextRef="P01_01_2022To09_30_2022" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and include all adjustments necessary for the fair presentation of the Company&#8217;s financial position for the periods presented.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying consolidated financial statements include the accounts of the Company&#8217;s subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These consolidated financial statements should be read in conjunction with the consolidated financial statements for the fiscal year ended December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. Operating results for quarter periods are not expected to be indicative of operating results for the Company&#8217;s </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> fiscal year, or any subsequent period.</div></div></ix:nonNumeric><ix:nonNumeric name="us-gaap:UseOfEstimates" contextRef="P01_01_2022To09_30_2022" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of these consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of these consolidated financial statements and the reported amounts of expenses during the reporting period. Management believes that these estimates are reasonable; however, actual results may differ from these estimates.</div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric></ix:continuation><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-9<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="display:inline;">5</div></div></div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_63195226_1"><ix:nonNumeric name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" contextRef="P01_01_2022To09_30_2022" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Significant Accounting Policies </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the </div>nine<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> months ended September&#160;</div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, there have been </div>no<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> changes to the Company`s significant accounting policies as described in the notes to the audited financial statements for the years ended December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> included in the proxy statement/prospectus filed by Vickers with the SEC on October&#160;</div>28<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> beginning on page </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-48</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> thereof.</div></div></ix:nonNumeric><ix:nonNumeric name="us-gaap:SegmentReportingPolicyPolicyTextBlock" contextRef="P01_01_2022To09_30_2022" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Segments </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating segments </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">are identified as components of an entity where separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions on how to allocate resources and assesses performance. The Company has determined that its chief operating decision maker is its Chief Executive Officer, as he is responsible for making decisions regarding the allocation of resources and assessing performance as well as for strategic operational decisions. The Company is engaged primarily in the development of </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-opioid</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> products focused on pain management based on its platform technologies and all sales are based in the United States. Accordingly, the Company has determined that it operates its business as a single reportable segment.</div></div></ix:nonNumeric></ix:continuation><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><ix:nonNumeric name="sclx:LiquidityAndGoingConcernTextBlock" contextRef="P01_01_2022To09_30_2022" escape="true" continuedAt="TextSelection_63195227">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liquidity and Going Concern </div></div></div></div></td></tr></table><div style="clear: both; max-height: 0px; text-indent: 0px;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Management has assessed the Company&#8217;s ability to continue as a going concern for at least </div>one<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> year after the date the financial statements are issued.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of September&#160;</div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company&#8217;s negative working capital was $</div><ix:nonFraction name="sclx:NetWorkingCapital" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">219.6</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, including cash and cash equivalents of approximately $</div><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.5</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million. During the </div>nine<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> months ended September&#160;</div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company had operating losses of $</div><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal">30.9</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and cash flows used for operations of $</div><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal">20.5</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million. The Company had an accumulated deficit of approximately $</div><ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal">358.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million as of September&#160;</div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In </div>September 2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company exercised the Early Paydown Provision to fully extinguish the Scilex Pharma Notes (see Note </div>6)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. In </div>August 2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div>September 2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company made principal payments towards the outstanding Scilex Pharma Notes totaling $</div><ix:nonFraction name="us-gaap:DebtInstrumentAnnualPrincipalPayment" contextRef="PAsOn09_30_2022_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">41.4</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million. Pursuant to Amendment </div>No<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">.&#160;</div>4<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, a principal balance of $</div><ix:nonFraction name="us-gaap:DebtInstrumentDecreaseForgiveness" contextRef="P01_01_2022To09_30_2022_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">28.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million was forgiven by the Scilex Pharma Note Purchasers (see Note </div>6)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> upon the Company&#8217;s exercise of the Early Paydown Provision. The Company funded the principal payments with </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">cash-on</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> hand and $</div><ix:nonFraction name="us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent" contextRef="PAsOn09_28_2022_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">34.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million received from Sorrento on September&#160;</div>28<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> (see Note </div>10)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On September&#160;</div>12<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company and Scilex Pharma entered into a Debt Exchange Agreement with Sorrento, pursuant to which all related party payables and related party note payables that remain outstanding as of immediately prior to, and contingent upon, the closing of the Business Combination were contributed by Sorrento to the Company in exchange for the issuance by the Company to Sorrento of preferred stock of the Company and such shares were subsequently converted into shares of New Scliex common stock and preferred stock (see Note </div>10)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On October&#160;</div>17<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Sorrento and Scilex entered into a Funding Commitment Letter (see Note </div>10)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. Pursuant to the terms of the Funding Commitment Letter, upon the written request of the Company, Sorrento shall fund </div>one<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> or more loans to the Company in the amount to achieve $</div><ix:nonFraction name="us-gaap:MinimumNetWorthRequiredForCompliance" contextRef="PAsOn10_17_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">5,000,001</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> in net tangible assets immediately following the effective time of the Business Combination. Such related party payables or related party note payables will be converted into shares of preferred stock pursuant to the Debt Exchange Agreement. Any loans made under the Funding Commitment Letter will not exceed the lesser of (a) $</div><ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="PAsOn10_17_2022_FundingCommitmentLetterMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and (b)&#160;an amount that, when taken together with all other Outstanding Indebtedness, will result in the Aggregate Outstanding Amount equaling $</div><ix:nonFraction name="sclx:AggregateOutstandingAmount" contextRef="PAsOn10_17_2022_FundingCommitmentLetterMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">310,000,000</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> (see Note </div>10)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. The Company did not draw funds from the Funding Commitment Letter at the effective time of the Business Combination.</div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-9<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="display:inline;">6</div></div></div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_63195227"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;18, 2019, the Company acquired Semnur and the acquisition was accounted for as an asset acquisition (see Note 3). The Company anticipates the cash needed for the development of Semnur&#8217;s primary product candidate in development, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-102,</div> as well in the development of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-103,</div> will be in excess of the Company&#8217;s cash available within one year after the date these consolidated financial statements are issued. Semnur has no historical revenue and the Company will be responsible for funding all development and commercialization efforts and capital funding needs possibly through private or public equity or debt financings, strategic collaborations or other arrangements. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">On May&#160;12, 2022, the Company entered into a Bill of Sale (see Note 3), with Sorrento to acquire rights, title and interest in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-104</div> Assets (see Note 3). <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-104</div> has not been approved for commercialization and, as such, no revenues have been generated to date by the asset. The Company will be responsible for funding all development and commercialization efforts. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On June&#160;14, 2022, the Company entered into a license and commercialization agreement with Romeg (see Note 3). The transaction was accounted for as an asset acquisition since substantially all the value of the gross assets was concentrated in the single asset, acquired licenses. The Company anticipates incurring costs related to the commercial launch and marketing of the acquired licenses. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company has plans to obtain additional resources to fund its currently planned operations and expenditures for at least twelve months from the issuance of these consolidated financial statements through a combination of equity offerings, debt financings, collaborations, government contracts or other strategic transactions. The Company&#8217;s plans are also dependent upon the success of future sales of ZTlido, which is still in the early stages of commercialization, and are dependent upon, among other things, the success of the Company&#8217;s marketing of ZTlido. Should the Company&#8217;s sales of ZTlido not materialize at the expected rate contemplated in the Company&#8217;s business plan, due to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic or other factors, the Company believes that there are a number of ongoing and potential actions that would maintain its projected cash and projected financial position including but not limited to, additional reductions in general and administrative costs, sales and marketing costs, suspension or winding down of clinical development programs for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-102,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-103,</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-104,</div> and other discretionary costs. Although the Company believes such plans, if executed, should provide the Company with financing to meet its needs, successful completion of such plans is dependent on factors outside the Company&#8217;s control. As such, management cannot conclude that such plans will be effectively implemented within one year after the date that these consolidated financial statements are issued. As a result, management has concluded that the aforementioned conditions, among other things, raise substantial doubt about the Company&#8217;s ability to continue as a going concern for one year after the date the financial statements </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">are issued. </div></div></div></ix:continuation><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><ix:nonNumeric name="us-gaap:AssetAcquisitionTextBlock" contextRef="P01_01_2022To09_30_2022" escape="true" continuedAt="TextSelection_63196074">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquisitions </div></div></div></div></td></tr></table><div style="clear: both; max-height: 0px; text-indent: 0px;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Semnur Acquisition</div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;</div>18<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company completed the Merger of Semnur. At the closing of the Merger of Semnur, the Company issued to the holders of Semnur&#8217;s capital stock and options to purchase Semnur&#8217;s common stock, upfront consideration with a value of $</div><ix:nonFraction name="us-gaap:AssetAcquisitionConsiderationTransferred" contextRef="P03_18_2019To03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">70.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million. The upfront consideration was comprised of the following: (a)&#160;a cash payment of approximately $</div><ix:nonFraction name="us-gaap:PaymentsToAcquireProductiveAssets" contextRef="P03_18_2019To03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">15.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, and (b) $</div><ix:nonFraction name="us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" contextRef="P03_18_2019To03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">55.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million of shares of the Company&#8217;s common stock </div>(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets" contextRef="P03_18_2019To03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">47,039,315</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares issued and </div><ix:nonFraction name="us-gaap:CommonStockSharesSubscribedButUnissued" contextRef="PAsOn03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">352,972</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares issuable, valued at $</div><ix:nonFraction name="sclx:AssetAcquisitionPricePerShare" contextRef="PAsOn03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">1.16</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> per share) (the &#8220;Stock Consideration&#8221;). Following the issuance of the Stock Consideration, Sorrento ownership in the Company diluted to approximately </div><ix:nonFraction name="sclx:PercentageOfOwnershipInterest" contextRef="PAsOn03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">58</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the Company&#8217;s issued and outstanding capital </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">stock. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">Pursuant to the Merger Agreement, and upon the terms and subject to the conditions contained therein, the Company also agreed to pay the holders of Semnur equity (the &#8220;Semnur Equityholders&#8221;) up to $</div><ix:nonFraction name="us-gaap:AssetAcquisitionContingentConsiderationLiability" contextRef="PAsOn03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">280.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">&#160;million in aggregate contingent cash consideration based on the achievement of certain milestones, comprised of a $</div><ix:nonFraction name="us-gaap:AssetAcquisitionContingentConsiderationLiability" contextRef="PAsOn03_18_2019_RegulatoryBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">40.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">&#160;<div style="display:inline;">million payment that will be due upon obtaining the first approval of a New Drug Application (&#8220;NDA&#8221;) of a Semnur product by the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) and additional payments that will be</div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></ix:nonNumeric><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-9<div style="display:inline;">7</div> </div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_63196074" continuedAt="TextSelectionAppend_63196074_1"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="null;text-indent: 0px;;display:inline;">due upon the achievement of certain amounts of net sales of Semnur products, as follows: (1) a<div style="display:inline;">&#160;</div></div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div><ix:nonFraction name="us-gaap:AssetAcquisitionContingentConsiderationLiability" contextRef="PAsOn03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheOneMemberSCLXTrancheAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">20.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>payment upon the achievement of $</div><ix:nonFraction name="sclx:RevenueToBeEarnedByTheAcquireeValue" contextRef="P03_18_2019To03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheOneMemberSCLXTrancheAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">100.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in cumulative net sales of a Semnur product, </div>(2)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;a $</div><ix:nonFraction name="us-gaap:AssetAcquisitionContingentConsiderationLiability" contextRef="PAsOn03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheTwoMemberSCLXTrancheAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">20.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million payment upon the achievement of $</div><ix:nonFraction name="sclx:RevenueToBeEarnedByTheAcquireeValue" contextRef="P03_18_2019To03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheTwoMemberSCLXTrancheAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">250.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in cumulative net sales of a Semnur product, </div>(3)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;a $</div><ix:nonFraction name="us-gaap:AssetAcquisitionContingentConsiderationLiability" contextRef="PAsOn03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheThreeMemberSCLXTrancheAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">50.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million payment upon the achievement of $</div><ix:nonFraction name="sclx:RevenueToBeEarnedByTheAcquireeValue" contextRef="P03_18_2019To03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheThreeMemberSCLXTrancheAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">500.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in cumulative net sales of a Semnur product, and </div>(4)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;a $</div><ix:nonFraction name="us-gaap:AssetAcquisitionContingentConsiderationLiability" contextRef="PAsOn03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheFourMemberSCLXTrancheAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">150.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million payment upon the achievement of $</div><ix:nonFraction name="sclx:RevenueToBeEarnedByTheAcquireeValue" contextRef="P03_18_2019To03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheFourMemberSCLXTrancheAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">750.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in cumulative net sales of a Semnur </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">product. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On August&#160;</div>7<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company entered into an amendment to the Merger Agreement to provide that, following the consummation of the Company&#8217;s first bona fide equity financing with </div>one<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> or more third-party financing sources on an arms&#8217; length basis with gross proceeds to the Company of at least $</div><ix:nonFraction name="us-gaap:ProceedsFromDivestitureOfBusinesses" contextRef="P08_07_2019To08_07_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">40.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, certain of the former Semnur optionholders will be paid cash in lieu of: </div>(1)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;the </div><ix:nonFraction name="us-gaap:CommonStockSharesSubscribedButUnissued" contextRef="PAsOn08_07_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">352,972</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares of the Company&#8217;s common stock otherwise issuable to such former Semnur optionholders pursuant to the Merger Agreement, and </div>(2)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;any shares that would otherwise be issued to such former Semnur optionholders upon release of shares held in escrow pursuant to the Merger Agreement, with such shares in each case valued at $</div><ix:nonFraction name="sclx:AssetAcquisitionPricePerShare" contextRef="PAsOn08_07_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">1.16</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> per share. The amendment resulted in a reclassification of $</div><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" contextRef="PAsOn08_07_2019_AsRestatedMembersrtRestatementAxis_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.4</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million from additional </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> capital to accrued </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">liabilities. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In </div>March 2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Semnur Equityholders that received the Stock Consideration were required to sign an Exchange and Registration Rights Agreement with the Company (the &#8220;Exchange Agreement&#8221;). Pursuant to the Exchange Agreement, and upon the terms and subject to the conditions contained therein, if within </div>18<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> months following the closing of the Merger, </div><ix:nonFraction name="sclx:PercentageOfSharesIssuedSubjectToRestrictionOfTransfer" contextRef="PAsOn03_01_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the outstanding equity of the Company has not been acquired by a third party or the Company has not entered into a definitive agreement with respect to, or otherwise consummated, a firmly underwritten offering of the Company capital stock on a major stock exchange that meets certain requirements, then holders of the Stock Consideration may collectively elect to exchange, during the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="sclx:PeriodDuringWhichTheSharesMayBeExchanged" contextRef="P03_01_2019To03_31_2019" format="ixt-sec:durday">60</ix:nonNumeric>-day</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> period commencing the date that is the </div><ix:nonNumeric name="sclx:PeriodDuringWhichShareTransferIsRestricted" contextRef="P03_01_2019To03_31_2019" format="ixt-sec:durmonth">18</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> month anniversary of the Closing (the &#8220;Share Exchange&#8221;), the Stock Consideration for shares of Sorrento&#8217;s common stock with a value of $</div><ix:nonFraction name="sclx:CommonStockValueToBeExchanged" contextRef="P03_01_2019To03_31_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">55.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million based on a price per share of Sorrento&#8217;s common stock equal to the greater of (a)&#160;the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="sclx:NumberOfDaysForDeterminingTheWeightedVolumeAveragePriceForShares" contextRef="P03_01_2019To03_31_2019_SenmurMemberusgaapAssetAcquisitionAxis" format="ixt-sec:durday">30</ix:nonNumeric>-day</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> trailing volume weighted average price of </div>one<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> share of Sorrento&#8217;s common stock as reported on The Nasdaq Stock Market LLC as of the consummation of the Share Exchange and (b) $</div><ix:nonFraction name="sclx:PricePerShareForDeterminingTheExchangeOfShares" contextRef="PAsOn03_01_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">5.55</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> (subject to adjustment for any stock dividend, stock split, stock combination, reclassification or similar transaction) (the &#8220;Exchange Price&#8221;). Pursuant to an amendment to the Exchange Agreement entered into by Sorrento on September&#160;</div>28<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, on October&#160;</div>9<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Sorrento paid $</div><ix:nonFraction name="sclx:PaymentMadeInSurrenderingTheShares" contextRef="P03_01_2019To03_31_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">55.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in cash to the Semnur Equityholders in lieu of issuing $</div><ix:nonFraction name="sclx:PaymentMadeInSurrenderingTheShares" contextRef="P03_01_2019To03_31_2019_SenmurMemberusgaapAssetAcquisitionAxis_SorrentoMemberSCLXInvesteeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">55.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million of shares of Sorrento&#8217;s common stock at the Exchange Price. Following the completion of the Share Exchange and as of December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Sorrento held approximately </div><ix:nonFraction name="sclx:PercentageOfSharesOutstanding" contextRef="PAsOn12_31_2020_SenmurMemberusgaapAssetAcquisitionAxis_SorrentoMemberSCLXInvesteeAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">82.3</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the outstanding common stock of the Company. On January&#160;</div>29<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Sorrento acquired additional shares of the Company, resulting in Sorrento holding approximately </div><ix:nonFraction name="sclx:PercentageOfSharesOutstanding" contextRef="PAsOn01_29_2021_SenmurMemberusgaapAssetAcquisitionAxis_SorrentoMemberSCLXInvesteeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">99.97</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the outstanding common stock of the </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Company. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The </div>March 2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> transaction was accounted for as an asset acquisition since substantially all the value of the gross assets was concentrated in the single asset, </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-102.</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> As a result, approximately $</div><ix:nonFraction name="us-gaap:ResearchAndDevelopmentInProcess" contextRef="P01_01_2019To12_31_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">75.3</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million was expensed as a component of acquired </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> research and development during the year ended </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">December&#160;31, 2019. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><ix:nonFraction name="us-gaap:AssetAcquisitionContingentConsiderationLiability" contextRef="PAsOn09_30_2022_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:AssetAcquisitionContingentConsiderationLiability" contextRef="PAsOn12_31_2021_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> contingent consideration was recorded as of September&#160;</div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> since the related regulatory approval milestones are not deemed probable until they actually occur.</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; font-size: 10pt;;font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-104</div> Acquisition</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;">On May&#160;12, 2022, the Company entered into a bill of sale and assignment and assumption agreement (the &#8220;Bill of Sale&#8221;), with Sorrento. Pursuant to the Bill of Sale, Sorrento sold, conveyed, assigned and transferred to the Company all of its rights, title and interest in and to Sorrento&#8217;s Delayed Burst Release Low Dose Naltrexone <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;DBR-LDN&#8221;)</div> asset and intellectual property rights, for the treatment of chronic pain, fibromyalgia and chronic post- COVID syndrome (collectively, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;SP-104</div> Assets&#8221;). These assets had previously been acquired by Sorrento from Aardvark Therapeutics, Inc. (&#8220;Aardvark&#8221;) in April 2021 pursuant to an asset purchase agreement (the &#8220;Aardvark Asset Purchase Agreement&#8221;). Pursuant to the Bill of Sale, the Company assumed all of Sorrento&#8217;s rights, liabilities and obligations under the Aardvark Asset Purchase Agreement (the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;SP-104</div> Acquisition&#8221;). </div></div></ix:continuation><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-9<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="display:inline;">8</div></div></div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div><ix:continuation id="TextSelectionAppend_63196074_1" continuedAt="TextSelectionAppend_63196074_2"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">consideration for the </div><div style="font-size: 10pt; text-indent: 0px; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-104</div><div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"> Acquisition, the Company issued a promissory note in the aggregate principal amount of $</div><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn09_30_2022_SorrentoMemberSCLXInvesteeAxis_TwoThousandTwentyTwoPromissoryNoteMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">5.0</ix:nonFraction><div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million to Sorrento (the &#8220;</div>2022<div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"> Promissory Note&#8221;). Upon issuance of the note, the Company recorded a related party note payable liability of $</div><ix:nonFraction name="us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent" contextRef="PAsOn09_30_2022_SorrentoMemberSCLXInvesteeAxis_TwoThousandTwentyTwoPromissoryNoteMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">4.1</ix:nonFraction><div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, net of discount, with an offset to additional paid in capital, given the common control relationship between Sorrento and the Company. The </div>2022<div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"> Promissory Note matures </div><ix:nonNumeric name="us-gaap:DebtInstrumentTerm" contextRef="P01_01_2022To09_30_2022_SorrentoMemberSCLXInvesteeAxis_TwoThousandTwentyTwoPromissoryNoteMemberusgaapLongtermDebtTypeAxis" format="ixt-sec:durwordsen">seven years</ix:nonNumeric><div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"> from the date of issuance and bears interest at the rate equal to the lesser of (a) </div><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="PAsOn09_30_2022_SorrentoMemberSCLXInvesteeAxis_TwoThousandTwentyTwoPromissoryNoteMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">2.66</ix:nonFraction><div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">% simple interest per annum and (b)&#160;the maximum interest rate permitted under law. The </div>2022<div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"> Promissory Note is payable in cash, shares of the Company&#8217;s common stock or any combination thereof, at the Company&#8217;s sole discretion, and may be prepaid in whole or in part at any time without </div><div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">penalty.</div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As the successor to the Aardvark Asset Purchase Agreement, the Company is obligated to pay Aardvark (i) $</div><ix:nonFraction name="us-gaap:AssetAcquisitionContingentConsiderationLiability" contextRef="PAsOn09_30_2022_AardvarkMemberusgaapAssetAcquisitionAxis_ApprovalBasedMilestoneMemberSCLXMilestoneAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">3,000,000</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, upon initial approval by the FDA of a new drug application for the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-104</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Assets (which amount may be paid in shares of the Company&#8217;s common stock or cash, in the Company&#8217;s sole discretion) (the &#8220;Development Milestone Payment&#8221;) and (ii) $</div><ix:nonFraction name="us-gaap:AssetAcquisitionContingentConsiderationLiability" contextRef="PAsOn09_30_2022_AardvarkMemberusgaapAssetAcquisitionAxis_ReveueBasedMilestoneMemberSCLXMilestoneAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">20,000,000</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, in cash, upon achievement of certain net sales by the Company of a commercial product that uses the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-104</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company will also pay Aardvark certain royalties in the single digits based on percentages of annual net sales by the Company of a commercial product that uses the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-104</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Assets. The transaction was accounted for as an asset acquisition as substantially all the value of the gross assets was concentrated in a single asset, </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-104</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Assets. The contingent milestones and sale volume-based future royalties were determined to meet a scope exception for derivative under ASC Topic </div>815<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Derivatives and Hedging, and will not be recognized until the contingencies are realized in accordance with the Company&#8217;s accounting policy for contingent consideration in an asset acquisition. </div><ix:nonFraction name="us-gaap:AssetAcquisitionContingentConsiderationLiability" contextRef="PAsOn09_30_2022_AardvarkMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen">No</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> contingent consideration was recognized at September&#160;</div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">,&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Tien-Li</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Lee, MD, a member of the board of directors of the Company, is the founder and chief executive officer of Aardvark. Kim D. Janda, Ph.D., a member of the Board of Directors of Sorrento, is a member of the advisory board of </div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">Aardvark.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">GLOPERBA License Agreement </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On June&#160;</div>14<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company entered into a license agreement (the &#8220;Romeg License Agreement&#8221;) with RxOmeg Therapeutics, LLC (a/k/a Romeg Therapeutics, Inc.) (&#8220;Romeg&#8221;). Pursuant to the Romeg License Agreement, among other things, Romeg granted the Company (a)&#160;a transferable license, with the right to sublicense, under the patents and </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> specified therein (with such license to </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> being exclusive for the limited purposes specified therein) to (i)&#160;commercialize the pharmaceutical product comprising liquid formulations of colchicine for the prophylactic treatment of gout in adult humans (the &#8220;Initial Licensed Product&#8221; or &#8220;GLOPERBA&#8221;) in the United States of America (including its territories) (the &#8220;Territory&#8221;), (ii) develop other products comprising the Initial Licensed Product as an active pharmaceutical ingredient (the &#8220;Licensed Products&#8221;) and commercialize any such products and (iii)&#160;manufacture Licensed Products anywhere in the world, solely for commercialization in the Territory and (b)&#160;an exclusive, transferable license, with right to sublicense, to use the trademark GLOPERBA and logos, designs, translations, and modifications thereof in connection with the commercialization of the Initial Licensed Product solely in the Territory. The Initial Licensed Product, GLOPERBA, was approved and made available in the </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">United States in 2020. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As consideration </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">for the license under the Romeg License Agreement, the Company paid Romeg an </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">up-front</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"> license fee of $</div><ix:nonFraction name="sclx:UpfrontlicenseFee" contextRef="P01_01_2022To09_30_2022_RomegLicenseAgreementMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">&#160;million, and has agreed to pay Romeg (a)&#160;upon the Company&#8217;s achievement of certain net sales milestones, certain milestone payments in the aggregate amount of up to $</div><ix:nonFraction name="sclx:MilestonePayment" contextRef="P01_01_2022To09_30_2022_RomegLicenseAgreementMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">13.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">&#160;million, (b)&#160;certain royalties in the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">mid-single</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"> digit to </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">low-double</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"> digit percentages based on annual net sales of the Licensed Product by the Company during the applicable royalty term under the Romeg License Agreement, and (c)&#160;minimum quarterly royalty payments totaling $</div><ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="P01_01_2022To09_30_2022_RomegLicenseAgreementMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">7.1</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">million commencing on the first year anniversary of the effective date of the Romeg License Agreement and ending on the later of (i) expiration of the last to expire of the licensed patents covering the Licensed Products in the Territory or (ii) the tenth anniversary of the effective date of the Romeg License Agreement.&#160;</div></div></div></ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">9<div style="letter-spacing: 0px; top: 0px;;display:inline;">9</div></div></div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_63196074_2"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The transaction was accounted for as an asset acquisition since substantially all the value of the gross assets was concentrated in a single asset, which is the Initial Licensed Product. In connection with the Romeg License Agreement, the Company recorded an intangible asset for acquired licenses of $</div><ix:nonFraction name="us-gaap:AcquiredFiniteLivedIntangibleAssetResidualValue" contextRef="PAsOn09_30_2022_RomegLicenseAgreementMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">5.7</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, which is comprised of the upfront license fee of $</div><ix:nonFraction name="sclx:UpfrontlicenseFee" contextRef="P01_01_2022To09_30_2022_RomegLicenseAgreementMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and a deferred consideration of $</div><ix:nonFraction name="sclx:DeferredConsideration" contextRef="PAsOn09_30_2022_RomegLicenseAgreementMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.7</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million that is the present value of the future minimum royalty payments and immaterial transaction costs. The contingent s</div>ale<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">s milestones and sales volume-based future royalties were determined to meet a scope exception for derivative under ASC Topic </div>815<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, and will not be recognized until the contingencies are realized. </div><ix:nonFraction name="us-gaap:AssetAcquisitionContingentConsiderationLiability" contextRef="PAsOn09_30_2022_RomegLicenseAgreementMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen">No</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> contingent consideration was recognized as a liability or included in the fair value of the asset as of September&#160;</div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. The Company determined the useful life of the intangible asset to be approximately </div><ix:nonNumeric name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" contextRef="P01_01_2022To09_30_2022_RomegLicenseAgreementMemberusgaapAssetAcquisitionAxis" format="ixt-sec:durwordsen">15 years</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, which approximates the life of the licensed patents covering the Initial Licensed Product.</div></div><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></ix:continuation><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div><ix:nonNumeric name="us-gaap:FairValueDisclosuresTextBlock" contextRef="P01_01_2022To09_30_2022" escape="true" continuedAt="TextSelection_63195224">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair Value Measurements </div></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div></div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div><ix:nonNumeric name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" contextRef="P01_01_2022To09_30_2022" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The follo<div style="display:inline;">w</div>ing t<div style="letter-spacing: 0px; top: 0px;;display:inline;">a</div>ble presents the Company&#8217;s financial assets and liabilities that are measured at fair value (in thousands):</div><br/></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><br/></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 40%;"></td>
<td style="width: 11%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 11%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 11%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 11%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Fair value measurements at September&#160;30, 2022</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Balance</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Quoted&#160;Prices&#160;in<br/>Active Markets<br/>(Level&#160;1)</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level&#160;2)</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Significant<br/>Unobservable&#160;Inputs<br/>(Level&#160;3)</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr>
<td style="vertical-align: top; font-size: 10pt; background-color: rgba(255, 255, 255, 0);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,483</ix:nonFraction></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn09_30_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,483</ix:nonFraction><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr>
<td style="vertical-align: top; font-size: 0pt; line-height: 0pt; background-color: rgba(255, 255, 255, 0);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 0pt;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; padding-bottom: 0.375pt; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets measured at fair value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,483</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn09_30_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,483</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"> <div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"> <div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"> <div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"> <div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td></tr></table><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><br/></div><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 40%;"></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;">Fair&#160;value&#160;measurements&#160;at&#160;December&#160;31.&#160;2021</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt; border-bottom: 0.75pt solid black;;text-align:center;">Balance</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;">Quoted&#160;Prices&#160;in<br/>Active&#160;Markets<br/>(Level&#160;1)</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level&#160;2)</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;">Significant<br/>Unobservable&#160;Inputs<br/>(Level&#160;3)</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,338</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,338</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets measured at fair value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,338</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,338</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivative liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">35,700</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">35,700</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Total liabilities measured at fair <br/>value</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">35,700</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">35,700</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Company&#8217;s financial assets carried at fair value are comprised of cash and cash equivalents. Cash and cash equivalents consist of money market accounts and bank deposits which are highly liquid and readily tradable. These assets are valued using inputs observable in active markets for identical securities.</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Derivative liabilities </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">The Company recorded a gain of $</div><ix:nonFraction name="us-gaap:DerivativeGainOnDerivative" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="1" scale="0" format="ixt:num-dot-decimal">5.3</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">&#160;million and $</div><ix:nonFraction name="us-gaap:DerivativeLossOnDerivative" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="1" scale="0" format="ixt:num-dot-decimal">0.1</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">&#160;million on derivative liabilities for the </div>nine<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"> months ended September&#160;</div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"> and </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">, respectively, which was attributed to compound derivative liabilities associated with the Scilex Pharma Notes (see Note </div>6)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">. The fair value of the derivative liability associated with the Scilex Pharma Notes decreased by $</div><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" contextRef="P01_01_2022To06_30_2022_DerivativeFinancialInstrumentsLiabilitiesMemberusgaapFairValueByLiabilityClassAxis_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">30.4</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">million immediately after the entry into Amendment No. 4 (see Note 6) associated with the Scilex Pharma Notes on June 2, 2022 (see Note 6). Amendment No. 4 was accounted for as troubled debt restructuring; therefore, the carrying amount of the Scilex Pharma Notes, net, was adjusted to reflect the aforementioned change in fair value of the derivative liability. The fair value of the derivative liability associated with the Scilex Pharma Notes was estimated using the discounted cash flow method combined with a&#160;</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">100</div></div></div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_63195224"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">Monte Carlo simulation model including consideration of the terms of Amendment No. 4. Significant Level 3 assumptions used in the measurement included a</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="PAsOn06_30_2022_MeasurementInputRiskadjustedNetSalesForecastMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_pure" decimals="1" scale="0" format="ixt:num-dot-decimal">6.1</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% risk adjusted net sales forecast and an effective debt yield of </div><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="PAsOn06_30_2022_MeasurementInputEffectiveDebtYieldMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_pure" decimals="1" scale="0" format="ixt:num-dot-decimal">21.5</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% as of June&#160;30, 2022. The Scilex Pharma Notes were fully extinguished in September 2022 (see Note 6) and, as such, there were </div><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> remaining derivative liabilities as of September&#160;30, 2022.</div></div> <ix:nonNumeric name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" contextRef="P01_01_2022To09_30_2022" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table includes a summary of the derivative liabilities measured at fair value using significant unobservable inputs (Level 3) during the nine months ended September&#160;30, 2022:</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 84%;"></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;">Fair<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>value</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn12_31_2021_DerivativeFinancialInstrumentsLiabilitiesMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">35,700</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value measurement</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" contextRef="P01_01_2022To09_30_2022_DerivativeFinancialInstrumentsLiabilitiesMemberusgaapFairValueByLiabilityClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">35,700</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at September&#160;30, 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric> </ix:continuation> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <ix:nonNumeric name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" contextRef="P01_01_2022To09_30_2022" escape="true" continuedAt="TextSelection_63195192">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill and Intangible Assets </div></div></div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of September&#160;30, 2022 and December&#160;31, 2021, the Company had recorded goodwill of $</div><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:Goodwill" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">13.5</ix:nonFraction></ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million. The Company performed a qualitative test for goodwill impairment during the fourth quarter of 2021. Based upon the results of the qualitative testing, the Company concluded that it is </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">more-likely-than-not</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> that the fair value of the Company&#8217;s goodwill was in excess of the carrying value and therefore performing the first step of the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-step</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> impairment test was unnecessary. The conclusion has not changed as of September&#160;30, 2022 and </div><ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> goodwill impairment was recognized for the nine months ended September&#160;30, 2022 and 2021.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s intangible assets, excluding goodwill, are composed of patent rights, acquired technology, acquired licenses, and assembled workforce. Amortization of the intangible assets that have finite useful lives is generally recorded on a straight-line basis over their useful lives. </div><ix:nonNumeric name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" contextRef="P01_01_2022To09_30_2022" escape="true" continuedAt="TextSelection_63195220">A summary of the Company&#8217;s identifiable intangible assets as of September&#160;30, 2022 and December&#160;31, 2021 is as follows (in thousands):</ix:nonNumeric></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelection_63195220">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 55%;"></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Nine<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>months<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>ended<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>September<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>30,<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Gross&#160;carrying<br/> amount</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Accumulated<br/> amortization</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Intangibles,&#160;net</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Patent rights</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn09_30_2022_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">32,630</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn09_30_2022_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,871</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn09_30_2022_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">19,759</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquired technology</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn09_30_2022_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">21,940</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn09_30_2022_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,851</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn09_30_2022_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">16,089</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquired licenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn09_30_2022_LicensingAgreementsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,711</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn09_30_2022_LicensingAgreementsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">92</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn09_30_2022_LicensingAgreementsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,619</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assembled workforce</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn09_30_2022_AssembledWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn09_30_2022_AssembledWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">350</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn09_30_2022_AssembledWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">150</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total intangible assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">60,781</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">19,164</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">41,617</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 55%;"></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">December<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>31.<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>2021</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Gross&#160;carrying<br/> amount</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Accumulated<br/> amortization</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Intangibles,&#160;net</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Patent rights</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2021_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">32,630</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn12_31_2021_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,239</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2021_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">21,391</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquired technology</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2021_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">21,940</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn12_31_2021_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,754</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2021_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">17,186</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assembled workforce</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2021_AssembledWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn12_31_2021_AssembledWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">275</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2021_AssembledWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">225</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total intangible assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">55,070</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">16,268</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">38,802</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> </ix:continuation> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On June&#160;14, 2022, the Company entered into Romeg License Agreement to acquire an exclusive license to use GLOPERBA from Romeg (see Note 3). The Company determined the acquisition of licenses to be an asset acquisition. The fair value of consideration transferred of $</div><ix:nonFraction name="us-gaap:FinitelivedIntangibleAssetsAcquired1" contextRef="P06_14_2022To06_14_2022_LicensingAgreementsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">5.7</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million was assigned to acquired licenses with an amortization period of approximately </div><ix:nonNumeric name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" contextRef="P06_14_2022To06_14_2022_LicensingAgreementsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" format="ixt-sec:duryear">15</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">years. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">As of September&#160;30, 2022, the weighted average remaining life for identifiable intangible assets was </div></div><ix:nonNumeric name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" contextRef="P01_01_2022To09_30_2022_WeightedAverageMembersrtRangeAxis" format="ixt-sec:duryear">10.6</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">years. Aggregate amortization expense was $</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.9</ix:nonFraction></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">million and $</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.8</ix:nonFraction></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;million for the nine months ended September&#160;30,</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022 and 2021, respectively. Patent rights and acquired technology are amortized over a </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" contextRef="P01_01_2022To09_30_2022_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" format="ixt-sec:duryear">15</ix:nonNumeric>-year</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> period. Assembled workforce is amortized over a </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">5-year</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> period.</div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></ix:nonNumeric> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-101 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_63195192"> <ix:nonNumeric name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" contextRef="P01_01_2022To09_30_2022" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; font-size: 10pt; top: 0px;;display:inline;">Estimated future amortization expense related to intangible assets at September&#160;30, 2022 is as follows (in tho</div>us<div style="letter-spacing: 0px; font-size: 10pt; top: 0px;;display:inline;">ands):</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 85%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap;">Year ended December&#160;31,</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Amount</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022 (remaining three months)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,027</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,106</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,031</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,006</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2026</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,006</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Thereafter</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">24,441</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">41,617</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table></ix:nonNumeric> </ix:continuation> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <ix:nonNumeric name="us-gaap:DebtDisclosureTextBlock" contextRef="P01_01_2022To09_30_2022" escape="true" continuedAt="TextSelection_63196070">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Debt </div></div></div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2018 Purchase Agreements and Indenture </div></div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On September&#160;7, 2018, Scilex Pharma and Sorrento entered into Purchase Agreements (the &#8220;2018 Purchase Agreements&#8221;) with certain investors (collectively, the &#8220;Scilex Pharma Note Purchasers&#8221;). Pursuant to the 2018 Purchase Agreements, on September&#160;7, 2018, Scilex Pharma, among other things, issued and sold to the Scilex Pharma Note Purchasers senior secured notes due </div><ix:nonNumeric name="us-gaap:DebtInstrumentTerm" contextRef="P09_07_2018To09_07_2018_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis" format="ixt-sec:duryear">2026</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> in an aggregate principal amount of $</div><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn09_07_2018_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">224.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million (the &#8220;Scilex Pharma Notes&#8221;) for an aggregate purchase price of $</div><ix:nonFraction name="us-gaap:DebtInstrumentRepurchaseAmount" contextRef="PAsOn09_07_2018_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">140.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million (the &#8220;Offering&#8221;). The Scilex Pharma Notes are governed by an indenture (as amended, the &#8220;Indenture&#8221;) with Scilex Pharma, as issuer, U.S. Bank National Association, a national banking association, as trustee (the &#8220;Trustee&#8221;) and collateral agent (the &#8220;Collateral Agent&#8221;), and Sorrento, as guarantor. Pursuant to the Indenture, Sorrento agreed to irrevocably and unconditionally guarantee, on a senior unsecured basis, the punctual performance and payment when due of all obligations of Scilex Pharma under the Indenture (the &#8220;Guarantee&#8221;).</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Actual cumulative net sales of ZTlido from the issue date of the Scilex Pharma Notes through December&#160;31, 2021 did not equal or exceed $</div><ix:nonFraction name="us-gaap:RevenueNotFromContractWithCustomer" contextRef="P09_07_2018To12_31_2021_DebtInstrumentRedemptionPeriodTwoMemberusgaapDebtInstrumentRedemptionPeriodAxis_ScenarioAdjustmentMembersrtStatementScenarioAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">481.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, which resulted in a $</div><ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPayment" contextRef="P02_15_2022To02_15_2022_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">28.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million increase in the principal amount of the Scilex Pharma Notes, effective <div style="letter-spacing: 0px; top: 0px;;display:inline;">February&#160;15, 2022</div>. As a result, the Company recorded the increase of $</div><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn02_15_2022_MaximumMembersrtRangeAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">28.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in principal and </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-operating</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> expense at December&#160;31, 2021.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Effective February&#160;14, 2022, Scilex Pharma issued to Sorrento a draw notice under the Letter of Credit as required under the terms of the Indenture because actual cumulative net sales of ZTlido from the issue date of the Scilex Pharma Notes through December&#160;31, 2021 were less than a specified sales threshold for such period. As a result of the draw notice being issued, Sorrento paid to Scilex Pharma $</div><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn02_14_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_SubordinatedDebtMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">35.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in a single </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lump-sum</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> amount as a subordinated loan and Scilex Pharma became subject to a minimum cash requirement of $</div><ix:nonFraction name="us-gaap:RestrictedCash" contextRef="PAsOn02_28_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_SubordinatedDebtMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">10.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million. In February 2022, Scilex Pharma repurchased Scilex Pharma Notes from the holders thereof on a pro rata basis in an aggregate amount equal to $</div><ix:nonFraction name="us-gaap:DebtInstrumentRepurchaseAmount" contextRef="PAsOn02_28_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_SubordinatedDebtMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">20.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">On June&#160;2, 2022, Sorrento and Scilex Pharma entered into a Consent Under and Amendment No.&#160;4 to Indenture (the &#8220;Amendment No.&#160;4&#8221;) with U.S. Bank Trust Company, National Association (as successor in interest to U.S. Bank National Association) and the Scilex Note Purchasers. Pursuant to Amendment </div><div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;4, (1)&#160;on </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"> June&#160;3, 2022, Scilex Pharma repurchased approximately $<ix:nonFraction name="us-gaap:DebtInstrumentRepurchaseAmount" contextRef="PAsOn06_03_2022_AmendmentNoFourMemberSCLXAmendmentAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">41.4</ix:nonFraction>&#160;million of the aggregate principal amount of the outstanding Scilex Pharma Notes at <ix:nonFraction name="sclx:DebtInstrumentPercentageOfPrincipalAmountRepurchased" contextRef="PAsOn06_03_2022_AmendmentNoFourMemberSCLXAmendmentAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction>% of the principal amount thereof, (2)&#160;the Scilex Note Purchasers agreed that Scilex Pharma can repurchase the remaining principal amount of the Scilex Pharma Notes at any time on or before <ix:nonNumeric name="us-gaap:DebtInstrumentRepurchaseDate" contextRef="P06_02_2022To06_02_2022_AmendmentNoFourMemberSCLXAmendmentAxis_MaximumMembersrtRangeAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" format="ixt:date-monthname-day-year-en">September 30, 2022</ix:nonNumeric> for $<ix:nonFraction name="us-gaap:DebtInstrumentRepurchasedFaceAmount" contextRef="PAsOn06_02_2022_AmendmentNoFourMemberSCLXAmendmentAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">41.4</ix:nonFraction>&#160;million (subject to reduction for any quarterly royalty payments) and upon such repurchase the Scilex Note Purchasers will forgive and discharge $<ix:nonFraction name="us-gaap:DebtInstrumentDecreaseForgiveness" contextRef="P06_02_2022To06_02_2022_AmendmentNoFourMemberSCLXAmendmentAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">28.0</ix:nonFraction>&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">million of the aggregate principal amount of the Scilex Pharma Notes (the &#8220;Early Paydown Provision&#8221;), (3) the minimum cash requirement under the Indenture was reduced to $<ix:nonFraction name="us-gaap:DebtInstrumentCollateralAmount" contextRef="PAsOn06_02_2022_AmendmentNoFourMemberSCLXAmendmentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">5.0</ix:nonFraction> million in aggregate unrestricted cash equivalents at the end of each calendar month, and (4) the maximum aggregate principal amount on the promissory note issued by Scilex Pharma to Sorrento on October 5, 2018 was increased from up to $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn10_05_2018_AmendmentNoFourMemberSCLXAmendmentAxis_PromissoryNoteMemberusgaapRelatedPartyTransactionAxis_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">25.0</ix:nonFraction> million to up to $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn06_02_2022_AmendmentNoFourMemberSCLXAmendmentAxis_PromissoryNoteMemberusgaapRelatedPartyTransactionAxis_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">50.0</ix:nonFraction> million. The Company funded the repurchase with cash-on-hand and $<ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="P06_02_2022To06_02_2022_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">15.0</ix:nonFraction> million received from Sorrento on June 2, 2022,</div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></ix:nonNumeric> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-10<div style="letter-spacing: 0px; top: 0px;;display:inline;">2</div></div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a>&#160;</div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div><ix:continuation id="TextSelection_63196070" continuedAt="TextSelectionAppend_63196070_1"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">which was recorded under the current related party notes payable in the Company&#8217;s consolidated balance sheets (see Note 10). The Company concluded that the Amendment No.&#160;4 was a troubled debt restructuring for accounting purposes. The future undiscounted cash flows of the Scilex Pharma Notes were higher than the carrying value of the Scilex Pharma Notes at the time of the entry into the Amendment No.&#160;4, and accordingly, </div><ix:nonFraction name="us-gaap:GainsLossesOnRestructuringOfDebt" contextRef="P04_01_2022To06_30_2022_AmendmentNoFourMemberSCLXAmendmentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt-sec:numwordsen">no</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> gain was recognized in the quarter ended June&#160;30, 2022. Due to a decrease of $</div><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" contextRef="P06_02_2022To06_02_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">30.4</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in the fair value of the Scilex Notes Derivative caused by the Amendment No.&#160;4, the carrying value of the Scilex Notes was increased by $</div><ix:nonFraction name="us-gaap:DebtInstrumentIncreaseDecreaseForPeriodNet" contextRef="P06_02_2022To06_02_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">30.4</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In September 2022, the Company exercised the Early Paydown Provision to fully extinguish the Scilex Pharma Notes. In August and September 2022, the Company made principal payments towards the outstanding Scilex Pharma Notes totaling $</div><ix:nonFraction name="us-gaap:RepaymentsOfDebt" contextRef="P08_01_2022To09_30_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.7</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div><ix:nonFraction name="us-gaap:RepaymentsOfDebt" contextRef="P09_01_2022To09_30_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">39.7</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, respectively. Pursuant to Amendment No.&#160;4, $</div><ix:nonFraction name="us-gaap:DebtInstrumentDecreaseForgiveness" contextRef="P06_02_2022To06_02_2022_AmendmentNoFourMemberSCLXAmendmentAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">28.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million of principal amount on the Scilex Pharma Notes was forgiven by the Scilex Pharma Note Purchasers and the Scilex Pharma Notes were fully extinguished in September 2022. The C<div style="letter-spacing: 0px; top: 0px;;display:inline;">o</div>mpany recorded a gain on debt extinguishment of $</div><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="P09_01_2022To09_30_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">33.4</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million as a result of the extinguishment. There are </div><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt-sec:numwordsen">no</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> derivative liabilities as of September&#160;30, 2022.</div></div><ix:nonNumeric name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" contextRef="P01_01_2022To09_30_2022" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Borrowings of the Scilex Notes consisted of the following (in thousands):</div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><br/></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 67%;"></td>
<td style="width: 11%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 11%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">September&#160;30,<br/>2022</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">December&#160;31,<br/>2021</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Principal</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="PAsOn09_30_2022_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="PAsOn12_31_2021_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">133,997</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unamortized debt discount</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="PAsOn09_30_2022_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="PAsOn12_31_2021_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">30,597</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unamortized debt issuance costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:UnamortizedDebtIssuanceExpense" contextRef="PAsOn09_30_2022_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:UnamortizedDebtIssuanceExpense" contextRef="PAsOn12_31_2021_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,228</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Carrying value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebt" contextRef="PAsOn09_30_2022_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebt" contextRef="PAsOn12_31_2021_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">101,172</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current portion</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtCurrent" contextRef="PAsOn09_30_2022_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:LongTermDebtCurrent" contextRef="PAsOn12_31_2021_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">29,135</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long term portion</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="PAsOn09_30_2022_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="PAsOn12_31_2021_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">72,037</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Estimated fair value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtFairValue" contextRef="PAsOn09_30_2022_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtFairValue" contextRef="PAsOn12_31_2021_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">115,400</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table></ix:nonNumeric><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company made principal payments of $</div><ix:nonFraction name="us-gaap:RepaymentsOfDebt" contextRef="P01_01_2022To09_30_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_TwoThousandAndEighteenPurchaseAgreementsAndIndentureMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">106.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div><ix:nonFraction name="us-gaap:RepaymentsOfDebt" contextRef="P01_01_2021To09_30_2021_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_TwoThousandAndEighteenPurchaseAgreementsAndIndentureMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">44.2</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million during the nine months ended September&#160;30, 2022 and 2021, respectively. The imputed effective interest rate at December&#160;31, 2021 was </div><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="PAsOn12_31_2021_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">7.7</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">%. The amount of debt discount and debt issuance costs included in interest expense for the nine months ended September&#160;30, 2022 and 2021 was approximately $</div><ix:nonFraction name="us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts" contextRef="P01_01_2022To09_30_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.1</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div><ix:nonFraction name="us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts" contextRef="P01_01_2021To09_30_2021_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">5.9</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, respectively. The Company recorded a gain on debt extinguishment of $</div><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="P01_01_2022To09_30_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_TwoThousandAndEighteenPurchaseAgreementsAndIndentureMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">28.6</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and a loss on debt extinguishment of $</div><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="P01_01_2021To09_30_2021_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_TwoThousandAndEighteenPurchaseAgreementsAndIndentureMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">14.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in connection with its repayments of principal made during the nine months ended September&#160;30, 2022 and 2021, respectively.</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Related Party Notes Payable </div></div></div><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On October&#160;5, 2018, Scilex Pharma issued to Sorrento a promissory note (see Note 10). On March&#160;18, 2019, the Company entered into a note payable with Sorrento (see Note 10). On February&#160;14, 2022, Sorrento paid to Scilex Pharma $</div><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn02_14_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_SubordinatedDebtMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">35.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in a single </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lump-sum</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> amount as a subordinated loan (see Note 10). On May&#160;12, 2022, the Company issued Sorrento a promissory note of $</div><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn05_12_2022_PromissoryNoteMemberusgaapRelatedPartyTransactionAxis_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">5.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in exchange for the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-104</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Assets (see Note 3).</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2020 Revolving Credit Facility </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On December&#160;</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">14, 2020, Scilex Pharma entered into the Credit and Security Agreement (the &#8220;Credit Agreement&#8221;) with CNH Finance Fund I, L.P. (&#8220;CNH&#8221;) which provides Scilex Pharma with the ability to incur<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>indebtedness under an accounts receivable revolving loan facility in an aggregate amount of $<ix:nonFraction name="sclx:LineOfCreditFacilityindebtednessAmount" contextRef="PAsOn12_14_2020_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">10.0</ix:nonFraction>&#160;million and the incurrence of liens and the pledge of collateral to CNH in connection with the revolving loan facility. Under the terms of the Credit Agreement, interest will accrue daily on the principal amount outstanding at a rate per annum equal to the Wall Street Journal Prime Rate plus <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="PAsOn12_14_2020_PrimeRateMemberusgaapVariableRateAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">1.75</ix:nonFraction>%. All indebtedness incurred and outstanding will be</div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></ix:continuation><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-103 </div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_63196070_1"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;">due and payable in full on January&#160;1, 2024; unless the Credit Agreement is earlier terminated. As of December&#160;31, 2021, the outstanding balance was $</div><ix:nonFraction name="us-gaap:LongTermDebt" contextRef="PAsOn12_14_2020_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">8.8</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;">&#160;million. On February&#160;16, 2022, the Company notified CNH that it was terminating the Credit Agreement, effective</div> <ix:nonNumeric name="sclx:DebtInstrumentTerminationDate" contextRef="P02_16_2022To02_16_2022_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis" format="ixt:date-monthname-day-year-en">March 18, 2022</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;">. Upon termination, all principal balances and interest accrued were settled.</div></div><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></ix:continuation><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <ix:nonNumeric name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" contextRef="P01_01_2022To09_30_2022" escape="true">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock Incentive and Employee Benefit Plans </div></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2017 Equity Incentive Plan </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">In June </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2017, Scilex Pharma adopted the Scilex Pharmaceuticals Inc. 2017 Equity Incentive Plan (the &#8220;Scilex Pharma 2017 Plan&#8221;). The Scilex Pharma 2017 Plan reserved </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn06_30_2017_ScilexPharmaTwoThousandSeventeenPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="-5" scale="6" format="ixt:num-dot-decimal">24.0</ix:nonFraction></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million shares of Scilex Pharma common stock. </div><ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" contextRef="P06_30_2017To06_30_2017_ScilexPharmaTwoThousandSeventeenPlanMemberusgaapPlanNameAxis">Stock options granted under the Scilex Pharma 2017 Plan typically vest 1/4th of the shares on the first anniversary of the vesting commencement date and 1/48th of the remaining options vest each month thereafter.</ix:nonNumeric> <div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Scilex Pharma 2017 Plan was amended and restated on July&#160;5, 2018.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Upon the closing of the Merger of Semnur, the Scilex Pharma 2017 Plan was terminated, and each option to purchase Scilex Pharma&#8217;s common stock outstanding and unexercised immediately prior to the closing of the Merger of Semnur was cancelled and substituted for that number of options <div style="letter-spacing: 0px; top: 0px;;display:inline;">to</div> acquire common stock of Scilex </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Holding. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Scilex Holding Company 2019 Stock Option Plan </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The board of </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">directors of the Company adopted the Scilex Holding Company 2019 Stock Option Plan (the &#8220;2019 Stock Option Plan&#8221;) on May&#160;28, 2019. The 2019 Stock Option Plan was approved by the Company&#8217;s stockholders on June&#160;7, 2019. As of December&#160;31, 2019, <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2019_TwoThousandNineteenStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="-5" scale="6" format="ixt:num-dot-decimal">30.0</ix:nonFraction>&#160;million shares of common stock of the Company were reserved for issuance pursuant to the 2019 Stock Option Plan. On December&#160;21, 2020, the board of directors approved an amendment to the 2019 Stock Option Plan to reserve an additional </div><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2020_AmendmentToTwoThousandNineteenStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="-5" scale="6" format="ixt:num-dot-decimal">15.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million shares of common stock for issuance under the 2019 Stock Option Plan. As of December&#160;31, 2020, </div><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2020_TwoThousandNineteenStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="-5" scale="6" format="ixt:num-dot-decimal">45.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million shares of common stock of the Company were reserved for issuance pursuant to the 2019 Stock Option Plan. </div><ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" contextRef="P12_01_2020To12_31_2020_TwoThousandNineteenStockOptionPlanMemberusgaapPlanNameAxis">Stock options granted under the 2019 Stock Option Plan typically vest with respect to 1/4th of the shares on the first anniversary of the vesting commencement date and 1/48th of the remaining shares on each monthly anniversary thereafter.</ix:nonNumeric></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of September&#160;30, 2022, options to purchase </div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn09_30_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">25,159,760</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares of the common stock of Scilex Holding were outstanding, which is comprised of options to purchase </div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn09_30_2022_TwoThousandNineteenStockOptionPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">24,054,760</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares of common stock that were outstanding under the 2019 Stock Option Plan and options to purchase </div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn09_30_2022_ScilexPharmaTwoThousandSeventeenPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">1,105,000</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares of common stock that were outstanding pursuant to options previously granted under the Scilex Pharma 2017 Plan. As of September&#160;30, 2022, </div><ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" contextRef="P01_01_2022To09_30_2022_TwoThousandNineteenStockOptionPlanMemberusgaapPlanNameAxis">20,945,240</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares of the Company&#8217;s common stock were reserved for awards available for future issuance under the 2019 Stock Option Plan.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total stock-based compensation recorded within operating expenses was $</div><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2022To09_30_2022_OperatingExpensesMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">4.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2021To09_30_2021_OperatingExpensesMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">4.4</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million for the nine months ended September&#160;30, 2022 and 2021, respectively.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">T</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">he total unrecognized compensation costs related to unvested employee and </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> stock option grants as of September&#160;30, 2022 was $</div><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.9</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and the weighted average period over which these grants are expected to vest is </div><ix:nonNumeric name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="P01_01_2022To09_30_2022" format="ixt-sec:duryear">1.4</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> years.</div><br/></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Employee Benefit Plan </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company maintains a defined contribution 401(k) plan available to eligible employees, which is administered by Sorrento. Employee contributions are voluntary and are determined on an individual basis, limited to the maximum amount allowable under federal tax regulations. The Company made matching contributions to the 401(k) plan totaling $</div><ix:nonFraction name="us-gaap:PaymentsToEmployees" contextRef="P01_01_2022To09_30_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.3</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div><ix:nonFraction name="us-gaap:PaymentsToEmployees" contextRef="P01_01_2021To09_30_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.2</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million for each of the nine months ended September&#160;30, 2022 and 2021, respectively.</div><br/></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></ix:nonNumeric><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-104 </div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:nonNumeric name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="P01_01_2022To09_30_2022" escape="true" continuedAt="TextSelection_63195216">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">8.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commitments and Contingencies </div></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; font-size: 10pt;;font-style:italic;display:inline;">Product Development Agreement</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In February 2013, Scilex Pharma became a party to a product development agreement (as amended, the &#8220;Product Development Agreement&#8221;) with two parties (the &#8220;Developers&#8221;), one of which is ITOCHU CHEMICAL FRONTIER Corporation (&#8220;Itochu&#8221;), pursuant to which the Developers will manufacture and supply lidocaine tape products, including ZTlido and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-103</div> (the &#8220;Products&#8221;), for Scilex Pharma. The Developers initially developed, and have intellectual property rights relating to, the Products. Pursuant to the Product Development Agreement, Scilex Pharma acquired an exclusive right to develop and commercialize the Products worldwide except for Japan. The Developers are responsible for sourcing and supplying lidocaine for development and commercialization purposes. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the Product Development Agreement, Scilex Pharma is required to make aggregate royalty payments </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">between </div><ix:nonFraction name="sclx:PercentageOfAggregateRoyalityPayments" contextRef="P01_01_2022To09_30_2022_MinimumMembersrtRangeAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">25</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% and </div><ix:nonFraction name="sclx:PercentageOfAggregateRoyalityPayments" contextRef="P01_01_2022To09_30_2022_MaximumMembersrtRangeAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">35</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% to the Developers based on net profits. During the nine months ended September&#160;30, 2022, Scilex Pharma made the first royalty payments in the amount of $0.2&#160;million. Net profits are defined as net sales, less cost of goods and marketing expenses. Net sales are defined as total gross sales of any Product, less all applicable deductions, to the extent accrued, paid or allowed in the ordinary course of business with respect to the sale of such Product, and to the extent that they are in accordance with U.S. GAAP. If Scilex Pharma were to sublicense the licensed technologies, the Developers will receive the same proportion of any sublicensing fees received therefrom. The Product Development Agreement will continue in full force and effect until </div><ix:nonNumeric name="sclx:AgreementExpirationDate" contextRef="P01_01_2022To09_30_2022_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis" format="ixt:date-monthname-day-year-en">October 2, 2028</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the date that is </div><ix:nonNumeric name="sclx:AgreementExpirationTerm" contextRef="P01_01_2022To09_30_2022_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis" format="ixt-sec:durwordsen">ten years</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> from the date of the first commercial sale of ZTlido. The Product Development Agreement will renew automatically for subsequent successive </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="sclx:AgreementAutomaticRenewalPeriodOnExpirationOfInitialTerm" contextRef="P01_01_2022To09_30_2022_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis" format="ixt-sec:durwordsen">one-year</ix:nonNumeric></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> renewal periods unless Scilex Pharma or the Developers terminate it upon </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="sclx:NoticeOfTerminationPeriodForCancellationOfAutomaticRenewal" contextRef="P01_01_2022To09_30_2022_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis" format="ixt-sec:durwordsen">6-month</ix:nonNumeric></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> written notice. In addition, Scilex Pharma or the Developers may terminate the Product Development Agreement if (1)&#160;the other party is in material breach of the agreement and the breach is not curable, or if the breach is curable and the breaching party has not cured such material breach within </div><ix:nonNumeric name="sclx:TerminationOfAgreementNoticePeriodForARequestToCureMaterialBreachOfTheAgreement" contextRef="P01_01_2022To09_30_2022_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis" format="ixt-sec:durday">180</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> days after notice requesting to cure; (2)&#160;the FDA determines that the formulation of the Products would not be eligible for FDA approval in the absence of efficacy studies, and the Developers are unable to address the efficacy study requirements despite good faith efforts; (3)&#160;the market conditions are such that (a)&#160;commencing with the quarter ending March&#160;31, 2023, Scilex Pharma&#8217;s total net profits of the Products are equal to or less than </div><ix:nonFraction name="sclx:ThresholdMinimumPercentageOfSales" contextRef="P01_01_2022To09_30_2022_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">5</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="letter-spacing: 0px; top: 0px;;display:inline;">% of Scilex Pharma&#8217;s net sales of the Products for a period of four or more consecutive quarters, or (b)&#160;the Products&#8217; economic viability is affected by documented external circumstances deemed detrimental to all parties as agreed to by Scilex Pharma and the Developers, and the parties are unable to resolve the economic viability concerns under the foregoing clauses (a)&#160;and (b) after 30 days of good-faith discussion; (4)&#160;the parties fail to reach mutual agreement as to who will conduct the clinical studies and how the costs will be allocated; or (5)&#160;Scilex Pharma or either one of the Developers are bankrupt or make assignment for the benefit of creditors. Up to the date the financial statements were issued, the Company&#8217;s net profits for ZTlido and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-103</div> have not exceeded five percent of net sales. Accordingly, Oishi and Itochu have the right to terminate the Product Development Agreement and Commercial Supply Agreement. As of the date of this prospectus, neither Oishi nor Itochu has exercised its right of termination. Additionally, Scilex Pharma may terminate the Product Development Agreement if (i)&#160;any of the pivotal human clinical trials for any of the Products fail, or (ii)&#160;the FDA issues a &#8220;Refusal to File&#8221; for any of the Products&#8217; regulatory approval application and, after reasonable consultation with the Developers, Scilex Pharma believes that it is commercially unreasonable to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-file.</div> The Developers may terminate the Product Development Agreement if Scilex Pharma fails to file for regulatory approval for any of the Products within three months of the date on which all required components of the regulatory approval application are received by Scilex Pharma.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">On February&#160;16, 2017, Scilex Pharma entered into a Commercial Supply Agreement (as amended, the &#8220;Supply Agreement&#8221;) with the two Developers to provide commercial supply of ZTlido and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-103</div> to Scilex Pharma. The Supply Agreement contains standard terms regarding term, termination, payment, product quality and supply. In addition, the agreement provides additional terms regarding the calculation and amount of marketing expenses that may be deducted from net sales for purposes of determining the amount of net profit under the Product Development Agreement. </div></div></ix:nonNumeric> <div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div><br/></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-10<div style="letter-spacing: 0px; top: 0px;;display:inline;">5</div> </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><ix:continuation id="TextSelection_63195216" continuedAt="TextSelectionAppend_63195216_1"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; font-size: 10pt;;font-style:italic;display:inline;">Exclusive Distribution Agreement</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In August 2015, Scilex Pharma entered into an Exclusive Distribution Agreement (the &#8220;Distribution Agreement&#8221;) to appoint an exclusive third-party logistics distribution provider (the &#8220;Distributor&#8221;) and as an authorized distributor of record of ZTlido (&#8220;Product&#8221;) in the United States, its territories, possessions and commonwealths for an agreed schedule of fees, subject to a </div><ix:nonFraction name="sclx:PercentageOfAnnualAdjustmentToFees" contextRef="P01_01_2022To09_30_2022_ExclusiveDistributionAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">3</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% annual adjustment. The Distribution Agreement has an initial term of </div><ix:nonNumeric name="sclx:AgreementExpirationTerm" contextRef="P01_01_2022To09_30_2022_ExclusiveDistributionAgreementMemberusgaapTypeOfArrangementAxis" format="ixt-sec:durwordsen">three years</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> following the first shipment of </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FDA-approved</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Product to a commercial customer and shall automatically renew for additional terms of one year each, unless written notice of termination is given by either party at least 30 days prior to the end of the initial term or any renewal term. In the event of Product recalls, Scilex Pharma is solely responsible for all Product recalls, except in the event where the recalls arise from the Distributor&#8217;s negligence or willful misconduct. Pursuant to the Distribution Agreement, Scilex Pharma will be responsible for delivery of Product to and from the Distributor&#8217;s facility, including all costs, expenses and risk of loss associated with such delivery. From late 2018 to early 2022, ZTlido was sold, and title was transferred, to the Distributor for distribution and sale to wholesalers for a fee of between </div><ix:nonFraction name="sclx:PercentageOfDistributionFeeReceivedOverThePeriod" contextRef="P01_01_2022To09_30_2022_ExclusiveDistributionAgreementMemberusgaapTypeOfArrangementAxis_MinimumMembersrtRangeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">1</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% to </div><ix:nonFraction name="sclx:PercentageOfDistributionFeeReceivedOverThePeriod" contextRef="P01_01_2022To09_30_2022_ExclusiveDistributionAgreementMemberusgaapTypeOfArrangementAxis_MaximumMembersrtRangeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">2</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% which was recorded as a </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">gross-to-net</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> sales adjustment. Beginning in April 2022, Scilex Pharma began directly selling and transferring title to distributors.</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Sales Operations Services </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In January 2016, Scilex Pharma entered into a project agreement with a vendor to provide sales operations services and detailing services, which was subsequently superseded by a new project agreement entered into in September 2018 (the &#8220;Project Agreement&#8221;). In connection with the detailing services, the Project Agreement provides that the vendor will provide Scilex Pharma with full-time sales representatives who shall detail the Product by making calls pursuant to a call plan on targets. These sales representatives are to be managed by field talent managers and a national project director, each of whom will also be provided by the vendor. In connection with the sales operation services, the vendor will provide certain services required for the initial implementation and ongoing operation of the sales force.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color:#ffffff;;display:inline;">On </div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">July&#160;1, 2020, Scilex Pharma and the vendor entered into a work order in which the parties agreed to convert substantially all of the sales representatives allocated under the Project Agreement to become employees of Scilex Pharma. The vendor will continue to provide sales operations services, fleet management services and sample accountability services. The work order was in effect until June&#160;30, 2022 and was extended for one year upon the mutual agreement of both parties. Either party may terminate the work order with </div><ix:nonNumeric name="sclx:NoticePeriodForTerminationOfWorkOrder" contextRef="P01_01_2022To09_30_2022_ProjectAgreementMemberusgaapTypeOfArrangementAxis" format="ixt-sec:durday">90</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> days&#8217; notice. Scilex Pharma paid an implementation fee of $</div><ix:nonFraction name="sclx:WorkOrderImplementationFee" contextRef="P01_01_2022To09_30_2022_ProjectAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-2" scale="3" format="ixt:num-dot-decimal">59.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;thousand and will pay fixed monthly fees of $</div><ix:nonFraction name="sclx:SalesOperationsServicesMonthlyFee" contextRef="PAsOn09_30_2022_MinimumMembersrtRangeAxis_ProjectAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-2" scale="3" format="ixt:num-dot-decimal">63.7</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;thousand to $</div><ix:nonFraction name="sclx:SalesOperationsServicesMonthlyFee" contextRef="PAsOn09_30_2022_MaximumMembersrtRangeAxis_ProjectAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-2" scale="3" format="ixt:num-dot-decimal">65.8</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;thousand for ongoing </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">services.</div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company recognized an expense of $</div><ix:nonFraction name="sclx:SellingGeneralAndAdministrativeExpenses" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.5</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div><ix:nonFraction name="sclx:SellingGeneralAndAdministrativeExpenses" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.6</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million within selling, general and administrative expenses for services performed for the nine months ended September&#160;30, 2022 and 2021, respectively, including implementation fees, fixed monthly fees and pass-through costs.</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Litigation </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the normal course of business, the Company may be named as a defendant in one or more lawsuits. Other than the following three lawsuits, the Company is not a party to any outstanding material litigation and management is not aware of any legal proceedings that, individually or in the aggregate, are deemed to be material to the Company&#8217;s financial condition or results of operations. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Sanofi-Aventis U.S. LLC and Hisamitsu America, Inc. Litigation </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On February&#160;23, 2021, the Company filed an action in the U.S. District Court for the Northern District of California against Sanofi-Aventis U.S. LLC and Hisamitsu America, Inc., two manufacturers of OTC lidocaine patch products, alleging, among other things, false and deceptive advertising and unfair competition under the Lanham Act and California state laws by those companies regarding their respective OTC patch products (the </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></ix:continuation><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-10<div style="letter-spacing: 0px; top: 0px;;display:inline;">6</div> </div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto; font-size: 10pt; background: none;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_63195216_1" continuedAt="TextSelectionAppend_63195216_2"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Sanofi- Aventis&#160;&amp; Hisamitsu Litigation&#8221;). This lawsuit seeks, among other relief, damages and an injunction enjoining the defendants from continuing to make false or misleading statements of fact about their respective OTC lidocaine patch products. The defendants have filed motions to dismiss, which have narrowed slightly our claims, but which motions the court has largely rejected. Discovery is proceeding. The case is currently scheduled for trial to begin on July&#160;24, 2023. The Company cannot make any predictions about the outcome in this matter or the timing thereof. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Former Employee Litigation </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;12, 2021, the Company filed an action in the Delaware Court of Chancery against Anthony Mack, former President of Scilex Pharma, and Virpax Pharmaceuticals, Inc. (&#8220;Virpax&#8221;), a company now headed by Mr.&#160;Mack, alleging, among other things, breach by Mr.&#160;Mack of his <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compete</div> agreement with us, breach of fiduciary duty, and tortious interference by Virpax with that <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compete</div> agreement (the &#8220;Former Employee Litigation&#8221;). This lawsuit seeks, among other relief, damages and an injunction enjoining Mr.&#160;Mack from further violating his <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compete</div> agreement and enjoining Virpax from tortiously interfering with Mr.&#160;Mack&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compete</div> agreement. The case was tried from September <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12-14,</div> 2022. Post-trial briefing is completed and closing arguments remain. The Company cannot make any predictions about the outcome in this matter or the timing thereof. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">ZTlido Patent Litigation </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">On June&#160;22, 2022, the Company filed a complaint against Aveva Drug Delivery Systems, Inc., Apotex Corp., and Apotex, Inc. (together, &#8220;Aveva&#8221;) in the U.S. District Court for the Southern District of Florida (the &#8220;Aveva Patent Litigation&#8221;) alleging infringement of certain Orange Book listed patents covering ZTlido (the &#8220;ZTlido Patents&#8221;). The Aveva Patent Litigation was initiated following the submission by Aveva, in accordance with the procedures set out in the Hatch-Waxman Act, of an ANDA. Aveva&#8217;s ANDA seeks approval to market a generic version of ZTlido prior to the expiration of the ZTlido Patents and alleges that the ZTlido Patents are invalid, unenforceable, and/or not infringed. The Company is seeking, among other relief, an order that the effective date of any FDA approval of Aveva&#8217;s ANDA be no earlier than the expiration of the asserted patents listed in the Orange Book, the latest of which expires on May&#160;10, 2031, and such further and other relief as the court may deem appropriate. Aveva is subject to a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-month</div> stay preventing it from selling a generic version of ZTlido during that time. The stay should expire no earlier than November&#160;11, 2024. Trial in the Aveva Patent Litigation has not yet been scheduled. The Company cannot make any predictions about the final outcome of this matter or the timing thereof.</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; font-size: 10pt;;font-style:italic;display:inline;">Operating Leases</div></div><ix:nonNumeric name="sclx:ScheduleOfSupplementalQuantitativeInformationRelatedToLeasesTableTextBlock" contextRef="P01_01_2022To09_30_2022" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplemental quantitative information related to leases includes the following: </div></div><br/></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><br/></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 81%;"></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Nine&#160;Months&#160;Ended<br/>September&#160;30,</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2022</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2021</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 0px;">
<td style="width: 69%;"></td>
<td style="width: 14%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 13%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt; width: 69%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash paid for amounts included in the measurement of lease liabilities:</div></div></div></td>
<td style="vertical-align: bottom; width: 14%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-size: 0px;">
<td style="width: 69%;"></td>
<td style="width: 14%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 13%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 69%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Operating cash flows from operating leases</div></td>
<td style="vertical-align: bottom; width: 14%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:OperatingCashFlowsFromOperatingLeases" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">531</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="sclx:OperatingCashFlowsFromOperatingLeases" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">489</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 69%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">ROU assets obtained in exchange for new operating lease<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>liabilities</div></td>
<td style="vertical-align: bottom; width: 14%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">320</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 69%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Weighted average remaining lease term in years &#8212; operating leases</div></td>
<td style="vertical-align: bottom; width: 14%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="PAsOn09_30_2022" format="ixt-sec:duryear">2.0</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="PAsOn09_30_2021" format="ixt-sec:duryear">3.1</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 69%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Weighted average discount rate &#8212; operating leases</div></td>
<td style="vertical-align: bottom; width: 14%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="PAsOn09_30_2022" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">11.8</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="PAsOn09_30_2021" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">12.2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table></ix:nonNumeric><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></ix:continuation><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-107 </div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_63195216_2"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">June 2022</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company entered into a new </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cancelable</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> lease agreement for an administrative facility in Palo Alto. The lease includes annual rent increases and the option to extend. The term of the new lease is </div><ix:nonNumeric name="us-gaap:LessorOperatingLeaseTermOfContract" contextRef="PAsOn06_01_2022_PaloAltoAadministrativeFacilityMemberusgaapPropertyPlantAndEquipmentByTypeAxis" format="ixt-sec:durmonth">26</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> months and the Company expects to exercise the extension option at the end of the lease.</div></div><ix:nonNumeric name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" contextRef="P01_01_2022To09_30_2022" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Maturities of lease liabilities were as follows (in thousands):</div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 87%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Year Ending December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); text-align: center;">Amount</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022 (Remaining three months)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">215</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">872</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">703</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2026</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total lease payments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,790</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less imputed interest</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">210</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total lease liabilities as of September&#160;30, 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="PAsOn09_30_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,580</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric></ix:continuation><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div><ix:nonNumeric name="us-gaap:IncomeTaxDisclosureTextBlock" contextRef="P01_01_2022To09_30_2022" escape="true">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">9.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income Taxes </div></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">maintains deferred tax assets that reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. These deferred tax assets include net operating loss carryforwards, research credits and temporary differences. In assessing the Company&#8217;s ability to realize deferred tax assets, management considers, on a periodic basis, whether it is more likely than not that some portion or all the deferred tax assets will not be realized. As such, management has determined that it is appropriate to maintain a valuation allowance against the Company&#8217;s deferred tax assets.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s income tax (benefit) expense of $</div>(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-2" scale="3" sign="-" format="ixt:num-dot-decimal">36.4</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">) thousand and $</div><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-2" scale="3" format="ixt:num-dot-decimal">10.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;thousand reflect effective tax rates of </div><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">0.7</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% and </div><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">0.02</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% for the </div>nine<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> months ended September&#160;</div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, respectively.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The difference between the expected statutory federal tax rate of </div><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">21.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% and the </div><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">0.7</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% effective tax rate for the </div>nine<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> months ended September&#160;</div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> was primarily attributable to income tax expense associated with changes in a valuation </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">allowance. </div></div></div></ix:nonNumeric> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div><ix:nonNumeric name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" contextRef="P01_01_2022To09_30_2022" escape="true" continuedAt="TextSelection_63195214">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Related Party Transactions </div></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div></div><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;18, 2019, the Company </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">entered into a merger agreement with Sorrento, Semnur, Merger Sub, and Fortis Advisors LLC. Jaisim Shah, a member of Sorrento&#8217;s board of directors, was Semnur&#8217;s Chief Executive<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Officer, a member of its board of directors and a stockholder of Semnur prior to the acquisition transaction. The upfront consideration was comprised of the following: (a)&#160;a cash payment of approximately $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:PaymentsToAcquireProductiveAssets" contextRef="P03_18_2019To03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">15.0</ix:nonFraction></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, and (b) $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" contextRef="P03_18_2019To03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">55.0</ix:nonFraction></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million of shares of the Company&#8217;s common stock (</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets" contextRef="P03_18_2019To03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">47,039,315</ix:nonFraction></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares issued and </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:CommonStockSharesSubscribedButUnissued" contextRef="PAsOn03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">352,972</ix:nonFraction></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares issuable, valued at $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="sclx:AssetAcquisitionPricePerShare" contextRef="PAsOn03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">1.16</ix:nonFraction></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> per share) (i.e., the Stock Consideration). Following the issuance of the Stock Consideration, Sorrento was the owner of approximately </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="sclx:PercentageOfOwnershipInterest" contextRef="PAsOn03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">58</ix:nonFraction></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the Company&#8217;s issued and outstanding capital stock as of December&#160;</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">31</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2019</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. Following the completion of the Share Exchange and as of December&#160;</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">31</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2020</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Sorrento held approximately </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="sclx:PercentageOfSharesOutstanding" contextRef="PAsOn12_31_2020_SenmurMemberusgaapAssetAcquisitionAxis_SorrentoMemberSCLXInvesteeAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">82.3</ix:nonFraction></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the outstanding common stock of the Company.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;of December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, approximately </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="sclx:PercentageOfCapitalSharesOutstanding" contextRef="PAsOn12_31_2020_ItochuMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">14.7</ix:nonFraction></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the outstanding capital stock of the Company was held by Itochu. On January&#160;</div>13<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="sclx:NumberOfSharesOutstanding" contextRef="PAsOn01_13_2021_ItochuMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">34,889,868</ix:nonFraction></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares of the Company representing all outstanding capital stock of the Company held by Itochu were acquired by </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-related</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> minority shareholders. Thus, Itochu is not a shareholder subsequent to January&#160;</div>13<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. On January&#160;</div>29<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Sorrento acquired </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="sclx:NumberOfSharesAcquired" contextRef="PAsOn01_29_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">34,889,868</ix:nonFraction></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares of the Company, resulting in Sorrento holding approximately </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="sclx:PercentageOfSharesOutstanding" contextRef="PAsOn01_29_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">99.97</ix:nonFraction></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the Company. During the </div>nine<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> months ended September&#160;</div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company purchased approximately $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="sclx:PaymentToAcquireInventory" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">4.0</ix:nonFraction></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="sclx:PaymentToAcquireInventory" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">4.8</ix:nonFraction>&#160;million,</div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></ix:nonNumeric><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-108 </div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="margin-top: 1em; margin-bottom: 1em"></div></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="display:inline;"><ix:continuation id="TextSelection_63195214" continuedAt="TextSelectionAppend_63195214_1"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">respectively, of inventory from Itochu, a previous minority shareholder of the Company and a Developer in the aforementioned Product Development Agreement. These costs are recorded within cost of revenues and selling, general and administrative expenses in the Company&#8217;s statement of operations. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; font-size: 10pt; top: 0px;;display:inline;">Semnur is party to an Assignment Agreement, dated August&#160;6, 2013 (the &#8220;Assignment Agreement&#8221;), with Shah Investor LP (&#8220;Shah Investor&#8221;). Mahendra Shah, Ph.D., who served on the Company&#8217;s board of directors from March 2019 through September 2020, is the managing partner of Shah Investor. Pursuant to the Assignment Agreement, Shah Investor assigned certain intellectual property to Semnur and Semnur agreed to pay Shah Investor a contingent quarterly royalty in the </div><div style="letter-spacing: 0px; font-size: 10pt; white-space: nowrap; top: 0px;;display:inline;">low-single</div><div style="letter-spacing: 0px; font-size: 10pt; top: 0px;;display:inline;"> digits based on quarterly net sales of any pharmaceutical formulations for local delivery of steroids by injection developed using such intellectual property, which would include </div><div style="letter-spacing: 0px; font-size: 10pt; white-space: nowrap; top: 0px;;display:inline;">SP-102.</div><div style="letter-spacing: 0px; font-size: 10pt; top: 0px;;display:inline;"> Through September&#160;30, 2022, the Company has made no royalty payments pursuant to the Assignment Agreement.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On January&#160;1, 2017, a Transition Services Agreement (&#8220;TSA&#8221;) was executed between Scilex Pharma and Sorrento. Pursuant to the TSA, Sorrento agreed, at the Company&#8217;s request, to provide directly or indirectly certain administrative, financial, legal, tax, insurance, facility, information technology and other services. In addition to the services provided under the TSA, Sorrento retains insurance coverage on behalf of the Company. During the nine months ended September&#160;30, 2022 and 2021, the total cost of services and insurance, including an agreed-upon markup, provided to the Company and recognized in general and administrative expenses was $<div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" contextRef="P01_01_2022To09_30_2022_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.2</ix:nonFraction></div>&#160;million and $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" contextRef="P01_01_2021To09_30_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.0</ix:nonFraction></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, respectively.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;18, 2019, the Company entered into a note payable with Sorrento with an initial principal amount of $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn03_18_2019_ReorganizationMemberSCLXEventAxis_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">16.5</ix:nonFraction></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million for the acquisition of Semnur. The note is interest bearing at the lesser of (a) </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="sclx:PercentageOfSimpleInterest" contextRef="PAsOn03_18_2019_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">10</ix:nonFraction></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% simple interest per annum, and (b)&#160;the maximum interest rate permitted under law. Interest is due and payable annually. The note payable is payable upon demand and may be prepaid in whole or in part at any time without penalty or premium. During the nine months ended September&#160;30, 2022 and 2021, Sorrento made advances to the Company in the amount of $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" contextRef="P01_01_2022To09_30_2022_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">27.5</ix:nonFraction></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" contextRef="P01_01_2021To09_30_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.4</ix:nonFraction></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, respectively, under the note payable. The outstanding principal balance of the note on September&#160;30, 2022 and December&#160;31, 2021 was $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="PAsOn09_30_2022_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">47.1</ix:nonFraction></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="PAsOn12_31_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">19.6</ix:nonFraction></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, respectively, which was recorded under the current related party note payable in the Company&#8217;s consolidated balance sheets. As of September&#160;30, 2022 and December&#160;31, 2021, the Company had ending balances resulting from the accrued interest on the note payable of $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DueToRelatedPartiesCurrent" contextRef="PAsOn09_30_2022_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">6.8</ix:nonFraction></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DueToRelatedPartiesCurrent" contextRef="PAsOn12_31_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.9</ix:nonFraction></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, respectively, which was recorded under related party payable in the Company&#8217;s consolidated balance sheets. During the nine months ended September&#160;30, 2022, the proceeds from the note payable were used to finance the operations of the Company.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On October&#160;5, 2018, Scilex Pharma issued to Sorrento a promissory note i</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">n the amount of approximately $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn10_05_2018_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">21.7</ix:nonFraction></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million for certain amounts previously advanced to Scilex Pharma by Sorrento. Scilex Pharma may borrow up to an aggregate of $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn10_05_2018_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">25.0</ix:nonFraction></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million of principal amount under the note payable. The promissory note is interest bearing at the lesser of (a) </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="sclx:PercentageOfSimpleInterest" contextRef="PAsOn10_05_2018_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">10</ix:nonFraction></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% simple interest per annum, and (b)&#160;the maximum interest rate permitted under<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">law. All outstanding principal amounts and accrued interest are due upon maturity on August&#160;31, 2026. On October&#160;22, 2018, Sorrento purchased from the Company </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="sclx:NumberOfSharesAcquired" contextRef="PAsOn10_22_2018_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">24,117,608</ix:nonFraction></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares of the Company&#8217;s common stock in exchange for the repayment of $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:RepaymentsOfDebt" contextRef="P10_22_2018To10_22_2018_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">21.7</ix:nonFraction></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million of indebtedness under this promissory note. During the nine months ended September&#160;30, 2022 and 2021, Sorrento made advances to Scilex Pharma in the amount of $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="sclx:AccruedInterest" contextRef="PAsOn09_30_2022_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">0</ix:nonFraction></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="sclx:AccruedInterest" contextRef="PAsOn09_30_2021_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">8.1</ix:nonFraction></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, respectively, under the promissory note. As of September&#160;30, 2022 and December&#160;31, 2021, the Company had ending balances resulting from the accrued interest on the note payable of $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DueToRelatedPartiesCurrent" contextRef="PAsOn09_30_2022_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">4.9</ix:nonFraction></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DueToRelatedPartiesCurrent" contextRef="PAsOn12_31_2021_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.1</ix:nonFraction></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, respectively, which was recorded under related party payable in the Company&#8217;s consolidated balance sheets. As of September&#160;30, 2022 and December&#160;31, 2021, Scilex Pharma&#8217;s outstanding principal balance under the promissory note was $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:LongTermNotesPayable" contextRef="PAsOn12_31_2021_ScilexPharmaMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:LongTermNotesPayable" contextRef="PAsOn09_30_2022_ScilexPharmaMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">23.5</ix:nonFraction></ix:nonFraction></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, which was recorded under the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> related party note payable in the Company&#8217;s consolidated balance sheets.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company received $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="P02_01_2022To02_28_2022_ScilexPharmaMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">35.0</ix:nonFraction></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in February 2022 to fund the payment of Scilex Pharma Notes in February 2022 totaling $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="P01_01_2022To09_30_2022_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">20.0</ix:nonFraction></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, as described in Note 6. The $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfMediumTermNotes" contextRef="P02_01_2022To02_28_2022_DueOnOrAfterFebruaryTwoThousandAndThirtyMemberSCLXPeriodAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">35.0</ix:nonFraction></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million received in February 2022 is due no earlier than February 2030 and was recorded under the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> related party note payable in the Company&#8217;s consolidated balance sheets.</div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></ix:continuation></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-109 </div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="display:inline;"><ix:continuation id="TextSelectionAppend_63195214_1"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additional funding received from Sorrento is due on demand and recorded under the related party payable in the Company&#8217;s consolidated balance sheets. As of September&#160;30, 2022, related party payables due to Sorrento included $<div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="sclx:WorkingCapitalRequirements" contextRef="PAsOn09_30_2022_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">48.7</ix:nonFraction></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million to cover working capital requirements, $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DebtInstrumentRepurchaseAmount" contextRef="PAsOn09_30_2022_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">100.0</ix:nonFraction></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million for repurchases of Scilex Pharma Notes, and $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:LegalFees" contextRef="P09_30_2022To09_30_2022_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">17.5</ix:nonFraction></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million for litigation fees (see Note 8). As of December&#160;31, 2021, related party payables due to Sorrento consisted of $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="sclx:WorkingCapitalRequirements" contextRef="PAsOn12_31_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">35.7</ix:nonFraction></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million to cover working capital requirements, $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DebtInstrumentRepurchaseAmount" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">51.0</ix:nonFraction></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million for repurchases of Scilex Pharma Notes, and $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:LegalFees" contextRef="P01_01_2021To12_31_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">6.0</ix:nonFraction></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million to pay litigation fees (see Note 8).</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">On</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;May&#160;12, 2022, the Company entered into the Bill of Sale, with Sorrento (see Note 3). Pursuant to the Bill of Sale, the Company assumed all of Sorrento&#8217;s rights, liabilities and obligations under Aardvark Asset Purchase Agreement. The Company issued the 2022 Promissory Note to Sorrento as consideration transferred. The 2022 Promissory Note matures </div><ix:nonNumeric name="us-gaap:DebtInstrumentTerm" contextRef="P05_12_2022To05_12_2022_SorrentoMemberusgaapBusinessAcquisitionAxis_TwoThousandAndTwentyTwoPromissoryNoteMemberusgaapLongtermDebtTypeAxis" format="ixt-sec:durwordsen">seven years</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> from the date of issuance and bears interest at the rate equal to the lesser of (a) </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="PAsOn05_12_2022_SorrentoMemberusgaapBusinessAcquisitionAxis_TwoThousandAndTwentyTwoPromissoryNoteMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">2.66</ix:nonFraction></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% simple interest per annum and (b)&#160;the maximum interest rate permitted under law. As of September&#160;30, 2022, the outstanding balance, net of discount, under the 2022 Promissory Note was $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:LongTermNotesPayable" contextRef="PAsOn09_30_2022_TwoThousandAndTwentyTwoPromissoryNoteMemberusgaapLongtermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">4.2</ix:nonFraction></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, which was recorded under the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> related party note payable in the Company&#8217;s consolidated balance sheets.</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Debt Exchange Agreement </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On September</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;12, 2022, the Company and Scilex Pharma entered into a Contribution and Satisfaction of Indebtedness Agreement (the &#8220;Debt Exchange Agreement&#8221;) with Sorrento, pursuant to which (i)&#160;Sorrento shall contribute to the Company all amounts (including accrued interest thereon, if any) for certain loans and other amounts provided by Sorrento to the Company and Scilex Pharma that remain outstanding as of immediately prior to the closing of the Business Combination (the &#8220;Aggregate Outstanding Amount&#8221; or &#8220;Outstanding Indebtedness), including with respect to the Scilex Pharma Notes, an intercompany promissory note issued by Scilex Pharma to Sorrento in the amount of approximately $<div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:RepaymentsOfDebt" contextRef="P09_12_2022To09_12_2022_DebtExchangeAgreementMemberSCLXAgreementAxis_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="1" scale="0" format="ixt:num-dot-decimal">27.5</ix:nonFraction></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million for certain amounts previously advanced to Scilex Pharma by Sorrento, and the other notes payable to Sorrento described above (see Note 6), in exchange for the issuance by the Company to Sorrento of preferred stock of the Company, </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(ii)&#160;the Company shall contribute to Scilex Pharma the portion of such Outstanding Indebtedness that is owed by Scilex Pharma to Sorrento as a</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">contribution of capital for no consideration, and (iii)&#160;upon the occurrence of the events described in clauses (i)&#160;and (ii), the Aggregate Outstanding Amount and the Outstanding Indebtedness shall be satisfied in full.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the terms of the Debt Exchange Agreement effective</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">as of immediately prior to, and contingent upon, the closing of the</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Business Combination, </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sorrento has elected to contribute the Outstanding Indebtedness</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">to the Company in exchange for the issuance by the Company to</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Sorrento of that number of shares of preferred stock, par value $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn09_12_2022_DebtExchangeAgreementMemberSCLXAgreementAxis_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></div> per share, of the Company (subject to adjustment for recapitalizations, stock splits, stock dividends and similar transactions) (the &#8220;Exchange Shares&#8221; and such transaction, the &#8220;Debt Contribution&#8221;) </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">tha</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">t is equal to (i)&#160;the Aggregate Outstanding Amount plus the amount equal to </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="sclx:PercentageOfOutstandingAmountIndebtedness" contextRef="PAsOn09_12_2022_DebtExchangeAgreementMemberSCLXAgreementAxis_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">10</ix:nonFraction></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the Aggregate Outstanding Amount divided by (ii) $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="sclx:PerShareCalculationOfOutstandingAmountInExchangeOfShares" contextRef="PAsOn09_12_2022_DebtExchangeAgreementMemberSCLXAgreementAxis_SorrentoMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">11.00</ix:nonFraction></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> (rounded up to the nearest whole share); provided, that in no event shall the Aggregate Outstanding Amount exceed $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="sclx:LimitationOfOutstandingAmountInExchangeOfShares" contextRef="PAsOn09_12_2022_DebtExchangeAgreementMemberSCLXAgreementAxis_SorrentoMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">310,000,000</ix:nonFraction></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. As of September&#160;30, 2022, the Aggregate Outstanding Amount was $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:LongTermDebt" contextRef="PAsOn09_30_2022_DebtExchangeAgreementMemberSCLXAgreementAxis_SorrentoMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="1" scale="0" format="ixt:num-dot-decimal">276.8</ix:nonFraction></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million.</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">On</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;November&#160;10, 2022, pursuant to the terms of the Debt Exchange Agreement, all existing related party indebtedness between the Company, Scilex Pharma, and Sorrento, totaling $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:LongTermDebt" contextRef="PAsOn11_10_2022_DebtExchangeAgreementMemberSCLXAgreementAxis_SorrentoMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="1" scale="0" format="ixt:num-dot-decimal">290.6</ix:nonFraction></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, was contributed by Sorrento to the Company in exchange for </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="P11_10_2022To11_10_2022_DebtExchangeAgreementMemberSCLXAgreementAxis_PreferredStockMemberusgaapStatementEquityComponentsAxis_SorrentoMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">29,057,097</ix:nonFraction></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares of the Company&#8217;s preferred stock. At the Effective Time, such shares were then exchanged for </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="P11_10_2022To11_10_2022_DebtExchangeAgreementMemberSCLXAgreementAxis_PreferredStockMemberusgaapStatementEquityComponentsAxis_SorrentoMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">29,057,097</ix:nonFraction></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares of New Scilex preferred stock and </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="P11_10_2022To11_10_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_DebtExchangeAgreementMemberSCLXAgreementAxis_SorrentoMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">2,905,710</ix:nonFraction></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares of New Scilex common stock.</div></div></ix:continuation></div><div style="display:inline;"><ix:nonNumeric name="us-gaap:EarningsPerShareTextBlock" contextRef="P01_01_2022To09_30_2022" escape="true" continuedAt="TextSelection_63195222"><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">11.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss Per Share </div></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div></div><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the nine months ended September&#160;30, 2022 and 2021, basic loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. Diluted loss per common share is calculated to give effect to all dilutive securities, using the treasury stock method.</div></div></ix:nonNumeric></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-110 </div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">&#160;</div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_63195222"><ix:nonNumeric name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" contextRef="P01_01_2022To09_30_2022" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> table sets forth the reconciliation of basic and diluted loss per share for the nine months ended September&#160;30, 2022 and 2021 (in thousands except per share data):</div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 72%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Nine&#160;Months&#160;Ended<br/>September&#160;30,</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">2021</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">5,480</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">46,459</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator for Basic Loss Per Share</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">197,550</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">197,266</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Effect of Dilutive Securities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DilutiveSecurities" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DilutiveSecurities" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator for Diluted Loss per Share &#8212; Adjusted for Dilutive Securities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">197,550</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">197,266</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic Loss Per Share</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">0.03</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">0.24</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dilutive Loss Per Share</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">0.03</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">0.24</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr></table></ix:nonNumeric> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The stock </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">options that could potentially dilute basic earnings per share in the future were excluded from the computation of diluted net loss per share because the effect would have been anti-dilutive due to the net loss for the nine months ended September&#160;30, 2022 and 2021 were </div><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2022To09_30_2022" unitRef="Unit_shares" decimals="-5" scale="6" format="ixt:num-dot-decimal">25.2</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and </div><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2021To09_30_2021" unitRef="Unit_shares" decimals="-5" scale="6" format="ixt:num-dot-decimal">30.3</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, respectively.</div></div><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></ix:continuation><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <ix:nonNumeric name="us-gaap:SubsequentEventsTextBlock" contextRef="P01_01_2022To09_30_2022" escape="true" continuedAt="TextSelection_63195215">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">12.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Subsequent Events </div></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="background: none;;text-indent: 0px;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"></div></div><div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has evaluated subsequent events for recognition and disclosure purposes in the unaudited consolidated financial statements as of September&#160;30, 2022, and the nine months then ended, through November&#160;17, 2022, the date the financial statements were available to be issued and, for disclosure purpose, through January&#160;12, 2023. Except as described below, or as otherwise indicated in the footnotes, the Company has concluded that no events or transactions have occurred that require disclosure. </div><div style="letter-spacing: 0px; top: 0px; background: none;;text-indent: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="letter-spacing: 0px; top: 0px; background: none;;text-indent: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Funding Commitment Letter </div></div></div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">On</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;October&#160;17, 2022, Sorrento and the Company entered into a letter agreement (the &#8220;Funding Commitment Letter&#8221;). Pursuant to the terms of the Funding Commitment Letter, upon the written request of the Company (which request the Company shall make to the extent necessary to satisfy the closing condition in the BCA that requires the combined company to have $</div><ix:nonFraction name="us-gaap:MinimumNetWorthRequiredForCompliance" contextRef="PAsOn10_17_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">5,000,001</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> in net tangible assets as of immediately following the effective time of the Business Combination (the &#8220;Effective Time&#8221;) under the BCA (the &#8220;Net Tangible Assets Condition&#8221;)), Sorrento agreed to fund one or more loans to the Company in the amount set forth in such written request (a &#8220;Loan Request&#8221;); provided, that any amounts funded by Sorrento in respect of any Loan Request were to be treated as Outstanding Indebtedness for all purposes under the Debt Exchange Agreement and </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">included in </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the calculation of the Aggregate Outstanding Amount thereunder with such amount to be contributed to the Company in exchange for shares of Legacy Scilex preferred stock. The Funding Commitment Letter also provides that, in no event shall the aggregate amount of loans made and funded by Sorrento pursuant to Loan Requests exceed the lesser of (a) $<ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="PAsOn10_17_2022_FundingCommitmentLetterMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction> and (b)&#160;an amount that, when taken together with all other Outstanding Indebtedness, will result in the Aggregate Outstanding Amount equaling $<ix:nonFraction name="sclx:AggregateOutstandingAmount" contextRef="PAsOn10_17_2022_FundingCommitmentLetterMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">310,000,000</ix:nonFraction>. The Company did not draw funds from the Funding Commitment Letter at the Effective Time. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Amendment to Amended and Restated Certificate of Incorporation</div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;November&#160;10, 2022, the Company filed with the Secretary of State of the State of Delaware (i)&#160;a Certificate of Amendment to its Amended and Restated Certificate of Incorporation to increase the authorized number of shares of preferred stock of the Company from </div><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn11_10_2022_MinimumMembersrtRangeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">20,000,000</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> to </div><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn11_10_2022_MaximumMembersrtRangeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">45,000,000</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and (ii)&#160;a certificate of designation setting forth the designations, powers, rights and preferences and qualifications, limitations and restrictions of the Series A Preferred Stock, par value $</div><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn11_10_2022_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> per share, of Legacy </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Scilex.</div></div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-111 </div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_63195215" continuedAt="TextSelectionAppend_63195215_1"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; font-size: 10pt;;font-style:italic;display:inline;">Sorrento Absorbed Liabilities</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In October </div></div><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 0px; top: 0px;;display:inline;">and November 2022, Sorrento entered into agreements with certain of the Company&#8217;s third party professional service providers to assume $</div><ix:nonFraction name="us-gaap:LiabilitiesAssumed1" contextRef="P10_01_2022To11_30_2022_AgreementWithCertainOfTheThirdPartyProfessionalServiceProvidersMemberSCLXAgreementAxis_SorrentoMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">11.9</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 0px; top: 0px;;display:inline;">&#160;million of liabilities accrued by the Company, of which $</div><ix:nonFraction name="us-gaap:LiabilitiesAssumed1" contextRef="P10_01_2022To11_30_2022_AccountsPayableMemberusgaapBalanceSheetLocationAxis_AgreementWithCertainOfTheThirdPartyProfessionalServiceProvidersMemberSCLXAgreementAxis_SorrentoMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">10.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 0px; top: 0px;;display:inline;">&#160;million and $</div><ix:nonFraction name="us-gaap:LiabilitiesAssumed1" contextRef="P10_01_2022To11_30_2022_AccruedLiabilitiesMemberusgaapBalanceSheetLocationAxis_AgreementWithCertainOfTheThirdPartyProfessionalServiceProvidersMemberSCLXAgreementAxis_SorrentoMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.9</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 0px; top: 0px;;display:inline;">&#160;million were recorded under accounts payable and accrued expenses, respectively, within the consolidated balance sheet. The liabilities assumed by Sorrento were reclassified under related party payable within the consolidated balance sheet and subsequently exchanged on November&#160;10, 2022 under the terms of the Debt Exchange<div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">Agreement (see Note 10).</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Committed Equity Financings </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&#160;17, 2022, the Company entered into a standby equity purchase agreement (the &#8220;Yorkville Purchase Agreement&#8221;) with YA II PN, Ltd., a Cayman Islands exempt limited partnership (&#8220;YA II&#8221;). Pursuant to the Yorkville Purchase Agreement, the Company has the right to sell to YA II, from time to time during the term of the Yorkville Purchase Agreement, up to $<ix:nonFraction name="us-gaap:CommonStockSharesSubscriptions" contextRef="PAsOn11_17_2022_StandbyEquityPurchaseAgreementMemberSCLXAgreementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_YorkvilleMemberSCLXInvesteeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">500,000,000</ix:nonFraction> of shares of New Scilex common stock, subject to certain limitations and conditions set forth therein. Upon the satisfaction of the conditions to YA II&#8217;s purchase obligation set forth in the Yorkville Purchase Agreement, including that a registration statement with respect to the shares to be issued to YA II thereunder be declared effective by the SEC, the Company will have the right, but not the obligation, from time to time at its discretion until the first day of the month next following the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="sclx:PeriodAfterRegistrationWhenTheRequestCouldBeMadeToTheInvesteeToPurchaseTheShares" contextRef="P11_17_2022To11_17_2022_StandbyEquityPurchaseAgreementMemberSCLXAgreementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_YorkvilleMemberSCLXInvesteeAxis" format="ixt-sec:durwordsen">36-month</ix:nonNumeric></div> anniversary of the date on which such registration statement has been declared effective by the SEC, to direct the YA II to purchase a specified amount of shares of Common Stock (each such sale, a &#8220;Yorkville Advance&#8221;) by delivering written notice to YA II (each, a &#8220;Yorkville Advance Notice&#8221;). </div><div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">While there is no mandatory minimum amount for any Yorkville Advance, Yorkville Advance may be for a number of shares of New Scilex common stock not to exceed<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><ix:nonFraction name="sclx:MaximumPercentageOfVolumeWeightedAveragePriceOfSharesMeasuredOnADailyBasisThatIsEligibleToBeReceivedAsAdvance" contextRef="P11_17_2022To11_17_2022_StandbyEquityPurchaseAgreementMemberSCLXAgreementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_YorkvilleMemberSCLXInvesteeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">200</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 0px; top: 0px;;display:inline;">% of the average of the daily trading volume of the New Scilex common stock on the Nasdaq Capital Market during regular trading hours as reported by Bloomberg L.P. during the </div><span style="-sec-ix-hidden:hidden63196045">five</span><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 0px; top: 0px;;display:inline;"> trading <div style="letter-spacing: 0px; top: 0px;;display:inline;">days immediately preceding the date of the Yorkville Advance Notice. The shares of New Scilex common stock, if any, that the Company elects to sell to YA II pursuant to a Yorkville Advance will be purchased at a price equal</div>&#160;to </div><ix:nonFraction name="sclx:PercentageOfDailyVolumeWeightedAveragePriceOfSharesAtWhichTheSharesAreEligibleToBePurchased" contextRef="P11_17_2022To11_17_2022_StandbyEquityPurchaseAgreementMemberSCLXAgreementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_YorkvilleMemberSCLXInvesteeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">98</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 0px; top: 0px;;display:inline;">% <div style="letter-spacing: 0px; top: 0px;;display:inline;">of the lowest daily VWAP (as defined below) during the</div>&#160;</div><span style="-sec-ix-hidden:hidden63196046">two</span><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 0px; top: 0px;;display:inline;"> <div style="letter-spacing: 0px; top: 0px;;display:inline;">consecutive trading days commencing on the date of delivery of a Yorkville Advance Notice. &#8220;VWAP&#8221; means, for any trading day, the daily volume weighted average price of the New Scilex common stock for such trading day on the Nasdaq Capital Market as reported by Bloomberg L.P. during regular trading hours. The Company may also specify a certain minimum acceptable price per share in each Yorkville Advance.&#160;</div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">As consideration for YA II&#8217;s commitment to purchase shares of New Scilex common stock at the Company&#8217;s direction upon the terms and subject to the conditions set forth in the Yorkville Purchase Agreement, the Company issued</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 0px; top: 0px;;display:inline;"> </div><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2022To09_30_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis_YorkvilleMemberSCLXInvesteeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">250,000</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 0px; top: 0px;;display:inline;"> <div style="letter-spacing: 0px; top: 0px;;display:inline;">shares of New Scilex common stock to YA II in connection with the execution of the Yorkville Purchase Agreement<div style="letter-spacing: 0px; top: 0px;;display:inline;">. </div></div></div></div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January 8, 2023, the Company entered into a standby equity purchase agreement (the &#8220;B. Riley Purchase Agreement&#8221;) with B. Riley Principal Capital II, LLC, a Delaware limited liability company (&#8220;B.&#160;Riley&#8221;). Pursuant to the B. Riley Purchase Agreement, the Company has the right to sell to B. Riley, from time to time during the term of the B. Riley Purchase Agreement, up to $<ix:nonFraction name="us-gaap:CommonStockSharesSubscriptions" contextRef="PAsOn01_08_2023_B.RileyMemberSCLXInvesteeAxis_StandbyEquityPurchaseAgreementMemberSCLXAgreementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">500,000,000</ix:nonFraction> of shares of New Scilex common stock, subject to certain limitations and conditions set forth therein. Upon the satisfaction of the conditions to B. Riley&#8217;s purchase obligation set forth in the B. Riley Purchase Agreement, including that a registration statement with respect to the shares to be issued to B. Riley thereunder be declared effective by the SEC, the Company will have the right, but not the obligation, from time to time at its discretion until the first day of the month next following the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="sclx:PeriodAfterRegistrationWhenTheRequestCouldBeMadeToTheInvesteeToPurchaseTheShares" contextRef="P01_08_2023To01_08_2023_B.RileyMemberSCLXInvesteeAxis_StandbyEquityPurchaseAgreementMemberSCLXAgreementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" format="ixt-sec:durmonth">36</ix:nonNumeric>-month</div> anniversary of the date on which such registration statement has been declared effective by the SEC, to direct the B. Riley to purchase a specified amount of shares of New Scilex common stock (each such sale, an &#8220;Advance&#8221;) by delivering an irrevocable written notice to B. Riley (each, an &#8220;Advance Notice&#8221;). </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The shares of New Scilex common stock, if any, that the Company elects to sell to B. Riley pursuant to an Advance will be purchased at a price equal to <ix:nonFraction name="sclx:PercentageOfDailyVolumeWeightedAveragePriceOfSharesAtWhichTheSharesAreEligibleToBePurchased" contextRef="P01_31_2023To01_31_2023_B.RileyMemberSCLXInvesteeAxis_StandbyEquityPurchaseAgreementMemberSCLXAgreementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">98</ix:nonFraction>% of the VWAP (as defined below) during the period (such </div></div></div></ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-112 </div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_63195215_1"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">period, the &#8220;Pricing Period&#8221;) beginning at 9:30:01 a.m., New York City time, on the date of purchase of Advance Shares or such later time publicly announced as the official open of the primary (or &#8220;regular&#8221;) trading session on the Nasdaq Capital Market on such purchase date (the &#8220;Purchase Commencement Time&#8221;) and ending at the earliest of (i) 3:59 p.m., New York City Time, on the purchase date or such earlier time publicly announced as the official close of the primary (or &#8220;regular&#8221;) trading session on the Nasdaq Capital Market on such purchase date, (ii)&#160;immediately at such time following the Purchase Commencement Time for such purchase that the total number (or volume) of shares of New Scilex common stock traded on the Nasdaq Capital Market during such period has exceeded the Advance Share Volume Maximum (as defined below) for such purchase and (iii)&#160;if the Company so elects in the applicable Advance Notice for such Advance (such election, a &#8220;Limit Order Discontinue Election&#8221;), such time the sale price of the shares of New Scilex common stock traded on the Nasdaq Capital Market during such Pricing Period is less than the applicable minimum price threshold determined in accordance with the B. Riley Purchase Agreement. &#8220;VWAP&#8221; means, for the New Scilex common stock for a specified period, the dollar volume-weighted average price of the New Scilex common stock on the Nasdaq Capital Market for such period as reported by Bloomberg through its &#8220;AOR&#8221; function, subject to certain exceptions, qualifications and limitations. &#8220;Advance Share Volume Maximum&#8221; means, with respect to an Advance, if such Advance is a (i)&#160;purchase-Type A, a number of shares of New Scilex common stock that is equal to the quotient obtained by dividing (a)&#160;the Advance Share amount to be purchased by B. Riley, by (b) <ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="PAsOn01_31_2023_B.RileyMemberSCLXInvesteeAxis_PurchasetypeAMembersrtProductOrServiceAxis_ScilexCommonStockMemberusgaapRelatedPartyTransactionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.10</ix:nonFraction>, and (ii)&#160;purchase-Type B, a number of shares of New Scilex common stock that is equal to the quotient obtained by dividing (a)&#160;the Advance Share amount to be purchased by B. Riley, by (b) <ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="PAsOn01_31_2023_B.RileyMemberSCLXInvesteeAxis_PurchasetypeBMembersrtProductOrServiceAxis_ScilexCommonStockMemberusgaapRelatedPartyTransactionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.25</ix:nonFraction> (in each case, subject to certain adjustments). The Company may also specify a certain minimum acceptable price per share in each Advance. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">While there is no mandatory minimum amount for any Advance, subject to the terms and conditions of the B. Riley Purchase Agreement, an Advance may be for a number of shares of New Scilex common stock not to exceed (i)&#160;with respect to an Advance, purchase-Type A, such number of shares of New Scilex common stock that is equal to the lesser of: (a) <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="P01_31_2023To01_31_2023_B.RileyMemberSCLXInvesteeAxis_PurchasetypeAMembersrtProductOrServiceAxis_ScilexCommonStockMemberusgaapRelatedPartyTransactionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">1,000,000</ix:nonFraction>, and (b)&#160;the product of (1) <ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="PAsOn01_31_2023_B.RileyMemberSCLXInvesteeAxis_PurchasetypeAMembersrtProductOrServiceAxis_ScilexCommonStockMemberusgaapRelatedPartyTransactionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.10</ix:nonFraction>, multiplied by (2)&#160;the total number (or volume) of shares of New Scilex common stock traded on the Nasdaq Capital Market during the Pricing Period for such purchase-Type A, and (ii)&#160;with respect to an Advance, purchase-Type B, such number of shares of New Scilex common stock equal to the lesser of: (a) <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="P01_31_2023To01_31_2023_B.RileyMemberSCLXInvesteeAxis_PurchasetypeBMembersrtProductOrServiceAxis_ScilexCommonStockMemberusgaapRelatedPartyTransactionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">1,000,000</ix:nonFraction> and (b)&#160;the product of (1) <ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="PAsOn01_31_2023_B.RileyMemberSCLXInvesteeAxis_PurchasetypeBMembersrtProductOrServiceAxis_ScilexCommonStockMemberusgaapRelatedPartyTransactionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.25</ix:nonFraction>, multiplied by (2)&#160;the total number (or volume) of shares of New Scilex common stock traded on the Nasdaq Capital Market during the Pricing Period for such purchase-Type B. The Company may also specify a certain minimum acceptable price per share in each Advance. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The B. Riley Purchase Agreement also provides that the Company has the right, but not the obligation, to sell to B. Riley, from time to time subject to certain limitations, at the Company&#8217;s sole and absolute discretion an additional number of shares of New Scilex common stock (each such additional sale, an &#8220;Additional Advance&#8221;) by delivering an irrevocable written notice to B. Riley. The purpose of the Additional Advance is to allow the Company to execute more than one advance request on a purchase date with B. Riley as each prior advance has been completed under the terms of the B. Riley Purchase Agreement. Each Additional Advance is generally subject to terms and conditions consistent with those of an Advance, except for, among other things, the time period of the pricing period for such Additional Advance. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As consideration for B. Riley&#8217;s commitment to purchase shares of New Scilex common stock at the Company&#8217;s direction upon the terms and subject to the conditions set forth in the B. Riley Purchase Agreement, the Company issued <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_31_2023To01_31_2023_B.RileyMemberSCLXInvesteeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">250,000</ix:nonFraction> shares of New Scilex common stock to B. Riley in connection with the execution of the B. Riley Purchase Agreement. </div></div></div></ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-113</div></div></div></div></div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">PART II </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">INFORMATION NOT REQUIRED IN THE PROSPECTUS </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;13.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Other Expenses of Issuance and Distribution. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth all expenses to be paid by Scilex Holding Company (the &#8220;Registrant&#8221;) in connection with the sale of the Common Stock being registered. The security holders will not bear any portion of such expenses. All amounts shown are estimates except for the registration fee. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">


<tr>

<td style="width:79%"></td>

<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SEC registration fee</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">15,095.80</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal fees and expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">50,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounting fees and expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">37,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Printing, transfer agent fees and miscellaneous expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">17,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">120,095.80</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;14.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Indemnification of Directors and Officers. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&#160;102 of the General Corporation Law of the State of Delaware (&#8220;DGCL&#8221;) permits a corporation to eliminate or limit the personal liability of directors and officers of a corporation to the corporation or its stockholders for monetary damages for a breach of fiduciary duty as a director or officer, except where the director or officer breached his or her duty of loyalty to the corporation or its stockholders, failed to act in good faith, engaged in intentional misconduct or knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase or redemption in violation of the DGCL or derived an improper personal benefit, or, with respect to any officer, any action by or in the right of the corporation. The Registrant&#8217;s restated certificate of incorporation (the &#8220;Certificate of Incorporation&#8221;) contains provisions that limit the liability of our directors and officers for monetary damages to the fullest extent permitted by the DGCL. Consequently, the Registrant&#8217;s directors and officers will not be personally liable to the Registratnt or its stockholders for monetary damages for any breach of fiduciary duty as a director, except liability for the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any breach of their duty of loyalty to the Registrant or its stockholders; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">unlawful payments of dividends or unlawful stock repurchases or redemptions in violation of the DGCL; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any transaction from which the director derived an improper personal benefit; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">with respect to any officer, any action by or in the right of the corporation. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Certificate of Incorporation also provides that if the DGCL is amended to permit further elimination or limitation of the personal liability of directors or officers, then the liability of the Registrant&#8217;s directors and officers will be eliminated or limited to the fullest extent permitted by the DGCL, as so amended. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&#160;145 of the DGCL provides that a corporation has the power to indemnify a director, officer, employee or agent of the corporation, or a person serving at the request of the corporation for another corporation, partnership, joint venture, trust or other enterprise in related capacities against expenses (including attorneys&#8217; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with an action, suit or proceeding to which he or she was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding by reason of such position, if such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation, and, in any criminal action or proceeding, had no reasonable cause to believe his or </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-1 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
her conduct was unlawful, except that, in the case of actions brought by or in the right of the corporation, no indemnification shall be made with respect to judgments, fines and amounts paid in settlement in connection with such action, suit or proceeding or with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper. The Certificate of Incorporation permits the Registrant to indemnify its directors, officers, employees and other agents to the maximum extent permitted by the DGCL, and the Registrant&#8217;s bylaws (the &#8220;Bylaws&#8221;) provide that the Registrant will indemnify its directors and officers and permit the Registrant to indemnify its employees and other agents, in each case to the extent not prohibited by the DGCL or any other applicable law. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Registrant has entered, and expects to continue to enter, into indemnification agreements with its directors and officers, that may be broader than the specific indemnification provisions contained in the DGCL. These agreements, among other things, require the Registrant to indemnify its directors and officers against liabilities that may arise by reason of their status or service. These indemnification agreements also require the Registrant to advance all expenses actually and reasonably incurred by the directors and executive officers in connection with any proceeding. The Registrant also maintains directors&#8217; and officers&#8217; liability insurance. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;15.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Recent Sales of Unregistered Securities </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following list sets forth information as to all of the Registrant&#8217;s securities sold in the last three years which were not registered under the U.S. Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). The descriptions of these issuances are historical and have not been adjusted to give effect to the Business Combination. Capitalized terms used and not defined in this Item 15 have the meaning given to them in the prospectus which forms a part of this registration statement. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">On July&#160;16, 2020, the Registrant issued an aggregate of 3,593,750 Vickers Ordinary Shares to an affiliate of Venture Fund VI (Plan) Pte Ltd (&#8220;Sponsor One&#8221;) and Vickers Venture Fund VI Pte Ltd (&#8220;Sponsor Two&#8221; and, together with Sponsor One, the &#8220;Sponsors&#8221;) for an aggregate purchase price of $25,000, or approximately $0.007 per share. In August 2020, the affiliate transferred his founder shares to the Sponsors for the same price paid for such shares. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">On January&#160;11, 2021, the Registrant consummated the sale of 6,840,000 private placement warrants at a price of $0.75 per private placement warrant in a private placement to the Sponsors, generating gross proceeds of $5,130,000. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">On October&#160;17, 2022, the Registrant issued an aggregate of 533,057 shares of Common Stock to the Sponsors pursuant to the Debt Contribution Agreement (the &#8220;Debt Contribution Agreement&#8221;), dated as of October&#160;17, 2022, between the Sponsors and the Registrant, in exchange for the Sponsors&#8217; contribution to the Registrant of approximately $5.3&#160;million of indebtedness described in the Debt Contribution Agreement. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">On November&#160;17, 2022, the Registrant issued 250,000 shares of Common Stock to YA II PN, Ltd., a Cayman Islands exempt limited partnership (&#8220;Yorkville&#8221;) in consideration for Yorkville&#8217;s irrevocable commitment to purchase shares of Common Stock. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">On January&#160;11, 2023, the Registrant issued 250,000 shares of Common Stock to the Selling Securityholder in consideration for the Selling Securityholder&#8217;s irrevocable commitment to purchase shares of Common Stock. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Registrant issued the foregoing securities in transactions not involving an underwriter and not requiring registration under Section&#160;5 of the Securities Act in reliance on the exemption afforded by Section&#160;4(a)(2) thereof. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-2 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;16.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Exhibits and Financial Statements Schedules </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">(a) Exhibits </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following exhibits are filed as part of this registration statement: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td style="width:89%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Exhibit <br />Number</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;2.1#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex2d1.htm">Agreement and Plan of Merger, dated as of March<span style="text-decoration:underline"></span>&#160;18, 2019, by and among Scilex Holding Company, Sigma Merger Sub, Inc., Semnur Pharmaceuticals, Inc., Fortis Advisors LLC, solely as the representative of the Equityholders and, solely with respect to Section<span style="text-decoration:underline"></span>&#160;1.8(a), Section<span style="text-decoration:underline"></span>&#160;3.11 and Article X, Sorrento Therapeutics, Inc. (incorporated by reference to Exhibit 2.1 of Amendment No.<span style="text-decoration:underline"></span>&#160;1 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;333-264941),</span> filed with the SEC on June<span style="text-decoration:underline"></span>&#160;27, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;2.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex2d2.htm">Amendment No.<span style="text-decoration:underline"></span>&#160;1 to Agreement and Plan of Merger, dated as of August<span style="text-decoration:underline"></span>&#160;7, 2019, by and among Semnur Pharmaceuticals, Inc., Scilex Holding Company, Sigma Merger Sub, Inc., Fortis Advisors, LLC, solely as the representative of the Equityholders and, solely with respect to Section<span style="text-decoration:underline"></span>&#160;1.8(a), 3.11 and Article X of the Agreement and Plan of Merger, Sorrento Therapeutics, Inc. (incorporated by reference to Exhibit 2.2 of Amendment No.<span style="text-decoration:underline"></span>&#160;1 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;333-264941),</span> filed with the SEC on October June<span style="text-decoration:underline"></span>&#160;27, 2022).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;2.3#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex2d3.htm">Bill of Sale and Assignment and Assumption Agreement, dated May<span style="text-decoration:underline"></span>&#160;12, 2022, by and between Scilex Holding Company and Sorrento Therapeutics, Inc. (incorporated by reference to Exhibit 2.3 of Amendment No.<span style="text-decoration:underline"></span>&#160;1 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;333-264941),</span> filed with the SEC on June<span style="text-decoration:underline"></span>&#160;27, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;2.4&#094;#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex2d4.htm">Asset Purchase Agreement, dated April<span style="text-decoration:underline"></span>&#160;23, 2021, between Sorrento Therapeutics, Inc. and Aardvark Therapeutics, Inc., as assumed by Scilex Holding Company on May<span style="text-decoration:underline"></span>&#160;12, 2022, pursuant to the Bill of Sale and Assignment and Assumption Agreement, dated as of such date, by and between Scilex Holding Company and Sorrento Therapeutics, Inc. (incorporated by reference to Exhibit 2.4 of Amendment No.<span style="text-decoration:underline"></span>&#160;1 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;333-264941),</span> filed with the SEC on June<span style="text-decoration:underline"></span>&#160;27, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;2.5#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000121390022013697/ea157097ex2-1_vickers1.htm">Agreement and Plan of Merger, dated as of March<span style="text-decoration:underline"></span>&#160;17, 2022, by and among Vickers Vantage Corp. I, Vickers Merger Sub, Inc. and Scilex Holding Company (incorporated by reference to Exhibit 2.1 of Vickers&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;001-39852),</span> filed with the SEC on March<span style="text-decoration:underline"></span>&#160;21, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;2.6#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922099785/tm2225830d1_ex2-1.htm">Amendment No.<span style="text-decoration:underline"></span>&#160;1 to Agreement and Plan of Merger, dated as of September<span style="text-decoration:underline"></span>&#160;12, 2022, by and among Vickers Vantage Corp. I, Vickers Merger Sub, Inc. and Scilex Holding Company (incorporated by reference to Exhibit 2.1 of Vickers&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;001-39852),</span> filed with the SEC on September<span style="text-decoration:underline"></span>&#160;14, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;3.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312522287783/d374632dex31.htm">Restated Certificate of Incorporation of Scilex Holding Company (incorporated by reference to Exhibit 3.1 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;001-39852),</span> filed with the SEC on November<span style="text-decoration:underline"></span>&#160;17, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;3.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312522287783/d374632dex32.htm">Certificate of Designations of Scilex Holding Company (incorporated by reference to Exhibit 3.2 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;001-39852),</span> filed with the SEC on November<span style="text-decoration:underline"></span>&#160;17, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;3.3</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312522287783/d374632dex33.htm">Bylaws of Scilex Holding Company (incorporated by reference to Exhibit 3.3 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;001-39852),</span> filed with the SEC on November<span style="text-decoration:underline"></span>&#160;17, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;4.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000121390021001411/ea133037ex4-1_vickers1.htm">Warrant Agreement, dated as of January<span style="text-decoration:underline"></span>&#160;6, 2021, by and between Vickers Vantage Corp. I and Continental Stock Transfer<span style="text-decoration:underline"></span>&#160;&amp; Trust Company (incorporated by reference to Exhibit 4.1 of Vickers&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;001-39852),</span> filed with the SEC on January<span style="text-decoration:underline"></span>&#160;11, 2021). </a></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-3 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td style="width:91%"></td></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;&#160;&#160;5.1+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d428534dex51.htm">Opinion of Paul Hastings LLP.</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312522287783/d374632dex101.htm">Amended and Restated Registration Rights Agreement, dated as of November<span style="text-decoration:underline"></span>&#160;10, 2022, by and among Scilex Holding Company, Vickers Venture Fund VI Pte Ltd, Vickers Venture Fund VI (Plan) Pte Ltd, Sorrento Therapeutics, Inc. and certain security holders set forth on the signature pages thereto (incorporated by reference to Exhibit 10.1 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;001-39852),</span> filed with the SEC on November<span style="text-decoration:underline"></span>&#160;17, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.2*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312522287783/d374632dex102.htm">Form of Indemnification Agreement of Scilex Holding Company (incorporated by reference to Exhibit 10.2 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;001-39852),</span> filed with the SEC on November<span style="text-decoration:underline"></span>&#160;17, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.3*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex10d7.htm">Scilex Pharmaceuticals, Inc. Amended and Restated 2017 Equity Incentive Plan (incorporated by reference to Exhibit 10.7 of Amendment No.<span style="text-decoration:underline"></span>&#160;1 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;333-264941),</span> filed with the SEC June<span style="text-decoration:underline"></span>&#160;27, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.4*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex10d8.htm">Form of Option Agreement and Stock Option Grant Notice under the Scilex Pharmaceuticals Inc. 2017 Equity Incentive Plan (incorporated by reference to Exhibit 10.8 of Amendment No.<span style="text-decoration:underline"></span>&#160;1 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;333-264941),</span> filed with the SEC June<span style="text-decoration:underline"></span>&#160;27, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.5*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex10d9.htm">Scilex Holding Company 2019 Stock Option Plan, as amended (incorporated by reference to Exhibit&#160;10.9 of Amendment No.<span style="text-decoration:underline"></span>&#160;1 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;333-264941),</span> filed with the SEC June<span style="text-decoration:underline"></span>&#160;27, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.6*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex10d10.htm">Form of Option Agreement and Stock Option Grant Notice under the Scilex Holding Company 2019 Stock Option Plan, as amended (incorporated by reference to Exhibit 10.10 of Amendment No.<span style="text-decoration:underline"></span>&#160;1 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;333-264941),</span> filed with the SEC June<span style="text-decoration:underline"></span>&#160;27, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.7*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312522287783/d374632dex105.htm">Scilex Holding Company 2022 Equity Incentive Plan (incorporated by reference to Exhibit 10.5 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;001-39852),</span> filed with the SEC on November<span style="text-decoration:underline"></span>&#160;17, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.8*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312522287783/d374632dex106.htm">Form of Stock Option Grant Notice and Stock Option Agreement under the Scilex Holding Company 2022 Equity Incentive Plan (incorporated by reference to Exhibit 10.6 of our Current Report on Form<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;8-K</span> (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;001-39852),</span> filed with the SEC on November<span style="text-decoration:underline"></span>&#160;17, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.9*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312522287783/d374632dex107.htm">Form of Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement under the Scilex Holding Company 2022 Equity Incentive Plan (incorporated by reference to Exhibit&#160;10.7 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;001-39852),</span> filed with the SEC on November<span style="text-decoration:underline"></span>&#160;17, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.10*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312522287783/d374632dex108.htm">Scilex Holding Company 2022 Employee Stock Purchase Plan (incorporated by reference to Exhibit&#160;10.8 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;001-39852),</span> filed with the SEC on November<span style="text-decoration:underline"></span>&#160;17, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.11</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000121390022013697/ea157097ex10-1_vickers1.htm">Sponsor Support Agreement, dated as of March<span style="text-decoration:underline"></span>&#160;17, 2022, by and among Vickers Vantage Corp. I and certain stockholders (incorporated by reference to Exhibit 10.1 of Vickers&#8217;s Current Report on <span style="white-space:nowrap">Form&#160;8-K</span> (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;001-39852),</span> filed with the SEC on March<span style="text-decoration:underline"></span>&#160;21, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.12</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922099785/tm2225830d1_ex10-2.htm">Amendment No.<span style="text-decoration:underline"></span>&#160;1 to Sponsor Support Agreement, dated as of September<span style="text-decoration:underline"></span>&#160;12, 2022, by and among Vickers Vantage Corp. I and certain stockholders (incorporated by reference to Exhibit 10.2 of Vickers&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;001-39852),</span> filed with the SEC on September<span style="text-decoration:underline"></span>&#160;14, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.13</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000121390022013697/ea157097ex10-2_vickers1.htm">Company Stockholder Support Agreement, dated as of March<span style="text-decoration:underline"></span>&#160;17, 2022, by and among Vickers Vantage Corp. I, Scilex Holding Company and Sorrento Therapeutics, Inc. (incorporated by reference to Exhibit 10.2 of Vickers&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;001-39852),</span> filed with the SEC on March<span style="text-decoration:underline"></span>&#160;21, 2022). </a></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-4 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td style="width:88%"></td></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.14*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex10d17.htm">Offer Letter, dated as of April<span style="text-decoration:underline"></span>&#160;19, 2019, between Scilex Pharmaceuticals Inc. and Jaisim Shah (incorporated by reference to Exhibit 10.17 of Amendment No.<span style="text-decoration:underline"></span>&#160;1 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File<span style="text-decoration:underline"></span>&#160;No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;333-264941),</span> filed with the SEC on June<span style="text-decoration:underline"></span>&#160;27, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.15*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex10d21.htm">Offer Letter, dated as of April<span style="text-decoration:underline"></span>&#160;27, 2022, by and between Scilex Holding Company and Elizabeth Czerepak (incorporated by reference to Exhibit 10.21 of Amendment No.<span style="text-decoration:underline"></span>&#160;1 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;333-264941),</span> filed with the SEC on June<span style="text-decoration:underline"></span>&#160;27, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.16&#094;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-22.htm">Commercial Supply Agreement, dated as of February<span style="text-decoration:underline"></span>&#160;16, 2017, by and among Scilex Pharmaceuticals Inc., Oishi Koseido Co., Ltd. and Itochu Chemical Frontier Corporation (incorporated by reference to Exhibit 10.22 of Amendment No.<span style="text-decoration:underline"></span>&#160;2 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File<span style="text-decoration:underline"></span>&#160;No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;333-264941),</span> filed with the SEC on July<span style="text-decoration:underline"></span>&#160;21, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.17&#094;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-23.htm">First Addendum to Commercial Supply Agreement, dated as of August<span style="text-decoration:underline"></span>&#160;31, 2017, by and among Scilex Pharmaceuticals Inc., Oishi Koseido Co., Ltd. and Itochu Chemical Frontier Corporation (incorporated by reference to Exhibit 10.23 of Amendment No.<span style="text-decoration:underline"></span>&#160;2 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File<span style="text-decoration:underline"></span>&#160;No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;333-264941),</span> filed with the SEC on July<span style="text-decoration:underline"></span>&#160;21, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.18&#094;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-24.htm">Second Addendum to Commercial Supply Agreement, dated as of May<span style="text-decoration:underline"></span>&#160;9, 2018, by and among Scilex Pharmaceuticals Inc., Oishi Koseido Co., Ltd. and Itochu Chemical Frontier Corporation (incorporated by reference to Exhibit 10.24 of Amendment No.<span style="text-decoration:underline"></span>&#160;2 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File<span style="text-decoration:underline"></span>&#160;No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;333-264941),</span> filed with the SEC on July<span style="text-decoration:underline"></span>&#160;21, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.19</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-25.htm">Third Addendum to Commercial Supply Agreement, dated as of August<span style="text-decoration:underline"></span>&#160;30, 2018, by and among Scilex Pharmaceuticals Inc., Oishi Koseido Co., Ltd. and Itochu Chemical Frontier Corporation (incorporated by reference to Exhibit 10.25 of Amendment No.<span style="text-decoration:underline"></span>&#160;2 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File<span style="text-decoration:underline"></span>&#160;No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;333-264941),</span> filed with the SEC on July<span style="text-decoration:underline"></span>&#160;21, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.20#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922099735/vcka-20220623xex10d26.htm">Exclusive Distribution Agreement, dated as of August<span style="text-decoration:underline"></span>&#160;6, 2015, by and among Scilex Pharmaceuticals Inc. and Cardinal Health 105, Inc. (incorporated by reference to Exhibit 10.26 of Amendment No.<span style="text-decoration:underline"></span>&#160;4 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;333-264941),</span> filed with the SEC on September<span style="text-decoration:underline"></span>&#160;13, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.21</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922099735/vcka-20220623xex10d27.htm">Amendment to Exclusive Distribution Agreement, dated as of May<span style="text-decoration:underline"></span>&#160;24, 2018, by and among Scilex Pharmaceuticals Inc. and Cardinal Health 105, Inc. (incorporated by reference to Exhibit 10.27 of Amendment No.<span style="text-decoration:underline"></span>&#160;4 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;333-264941),</span> filed with the SEC on September<span style="text-decoration:underline"></span>&#160;13, 2022).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.22#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922099735/vcka-20220623xex10d28.htm">Second Amendment to Exclusive Distribution Agreement, dated as of September<span style="text-decoration:underline"></span>&#160;19, 2018, by and among Scilex Pharmaceuticals Inc. and Cardinal Health 105, Inc. (incorporated by reference to Exhibit 10.28 of Amendment No.<span style="text-decoration:underline"></span>&#160;4 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;333-264941),</span> filed with the SEC on September<span style="text-decoration:underline"></span>&#160;13, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.23</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922099735/vcka-20220623xex10d29.htm">Third Amendment to Exclusive Distribution Agreement, dated as of October<span style="text-decoration:underline"></span>&#160;1, 2021, by and among Scilex Pharmaceuticals Inc. and Cardinal Health 105, LLC (f/k/a Cardinal Health 105, Inc.). (incorporated by reference to Exhibit 10.29 of Amendment No.<span style="text-decoration:underline"></span>&#160;4 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File<span style="text-decoration:underline"></span>&#160;No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;333-264941),</span> filed with the SEC on September<span style="text-decoration:underline"></span>&#160;13, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.24&#094;#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-33.htm">Supply Agreement, dated as of December<span style="text-decoration:underline"></span>&#160;17, 2015, by and between Genzyme Corporation and Semnur Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.33 of Amendment No.<span style="text-decoration:underline"></span>&#160;2 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;333-264941),</span> filed with the SEC on July<span style="text-decoration:underline"></span>&#160;21, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.25&#094;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-34.htm">Product Development Agreement, dated as of May<span style="text-decoration:underline"></span>&#160;11, 2011, by and between Scilex Pharmaceuticals, Inc. (as successor to Stason Pharmaceuticals, Inc.), Oishi Koseido Co., Ltd. and Itochu Chemical Frontier Corporation. (incorporated by reference to Exhibit 10.34 of Amendment No.<span style="text-decoration:underline"></span>&#160;2 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;333-264941),</span> filed with the SEC on July<span style="text-decoration:underline"></span>&#160;21, 2022). </a></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-5 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td style="width:88%"></td></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.26</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-35.htm">First Amendment to Product Development Agreement, dated as of April<span style="text-decoration:underline"></span>&#160;2, 2013, by and between Scilex Pharmaceuticals Inc., Oishi Koseido Co., Ltd. and Itochu Chemical Frontier Corporation (incorporated by reference to Exhibit 10.35 of Amendment No.<span style="text-decoration:underline"></span>&#160;2 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File<span style="text-decoration:underline"></span>&#160;No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;333-264941),</span> filed with the SEC on July<span style="text-decoration:underline"></span>&#160;21, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.27&#094;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-36.htm">Second Amendment to Product Development Agreement, dated as of February<span style="text-decoration:underline"></span>&#160;20, 2017, by and between Scilex Pharmaceuticals Inc., Oishi Koseido Co., Ltd. and Itochu Chemical Frontier Corporation (incorporated by reference to Exhibit 10.36 of Amendment No.<span style="text-decoration:underline"></span>&#160;2 of Vickers&#8217;s Form<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;S-4</span> (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;333-264941),</span> filed with the SEC on July<span style="text-decoration:underline"></span>&#160;21, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.28&#094;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-37.htm">Third Amendment to Product Development Agreement, dated as of August<span style="text-decoration:underline"></span>&#160;29, 2018, by and between Scilex Pharmaceuticals Inc., Oishi Koseido Co., Ltd. and Itochu Chemical Frontier Corporation (incorporated by reference to Exhibit 10.37 of Amendment No.<span style="text-decoration:underline"></span>&#160;2 of Vickers&#8217;s Form<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;S-4</span> (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;333-264941),</span> filed with the SEC on July<span style="text-decoration:underline"></span>&#160;21, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.29</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-38.htm">Fourth Amendment to Product Development Agreement, dated as of December<span style="text-decoration:underline"></span>&#160;13, 2019, by and between Scilex Pharmaceuticals Inc., Oishi Koseido Co., Ltd. and Itochu Chemical Frontier Corporation (incorporated by reference to Exhibit 10.38 of Amendment No.<span style="text-decoration:underline"></span>&#160;2 of Vickers&#8217;s Form<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;S-4</span> (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;333-264941),</span> filed with the SEC on July<span style="text-decoration:underline"></span>&#160;21, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.30</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-39.htm">Fifth Amendment to Product Development Agreement, dated as of April<span style="text-decoration:underline"></span>&#160;30, 2021, by and between Scilex Pharmaceuticals Inc., Oishi Koseido Co., Ltd. and Itochu Chemical Frontier Corporation (incorporated by reference to Exhibit 10.39 of Amendment No.<span style="text-decoration:underline"></span>&#160;2 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File<span style="text-decoration:underline"></span>&#160;No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;333-264941),</span> filed with the SEC on July<span style="text-decoration:underline"></span>&#160;21, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.31&#094;#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex10d40.htm">Master Services Agreement<span style="text-decoration:underline"></span>&#160;&#8212;<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;SP-102,</span> dated as of January<span style="text-decoration:underline"></span>&#160;27, 2017, by and between Semnur Pharmaceuticals, Inc. and Lifecore Biomedical, LLC (incorporated by reference to Exhibit 10.40 of Amendment No.<span style="text-decoration:underline"></span>&#160;1 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;333-264941),</span> filed with the SEC on June<span style="text-decoration:underline"></span>&#160;27, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.32</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex10d41.htm">Amendment No.<span style="text-decoration:underline"></span>&#160;1 to Master Services Agreement, dated as of April<span style="text-decoration:underline"></span>&#160;26, 2018, by and between Semnur Pharmaceuticals, Inc. and Lifecore Biomedical, LLC (incorporated by reference to Exhibit&#160;10.41 of Amendment No.<span style="text-decoration:underline"></span>&#160;1 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;333-264941),</span> filed with the SEC on June<span style="text-decoration:underline"></span>&#160;27, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.33</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex10d42.htm">Novation Agreement re Master Services Agreement, dated as of June<span style="text-decoration:underline"></span>&#160;15, 2022, by and among Scilex Holding Company, Tulex Pharmaceuticals Inc. and Aardvark Therapeutics Inc. (incorporated by reference to Exhibit 10.42 of Amendment No.<span style="text-decoration:underline"></span>&#160;1 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;333-264941),</span> filed with the SEC on June<span style="text-decoration:underline"></span>&#160;27, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.34#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex10d43.htm">Master Services Agreement, dated as of November<span style="text-decoration:underline"></span>&#160;23, 2020, by and between Aardvark Therapeutics Inc. and Tulex Pharmaceuticals Inc. as assumed by Scilex Holding Company on May<span style="text-decoration:underline"></span>&#160;12, 2022, as novated to Scilex Holding Company, pursuant to the Novation Agreement re Master Services Agreement, dated as of June<span style="text-decoration:underline"></span>&#160;15, 2022, by and among Scilex Holding Company, Tulex Pharmaceuticals Inc. and Aardvark Therapeutics Inc. (incorporated by reference to Exhibit<span style="text-decoration:underline"></span>&#160;10.43 of Amendment No.<span style="text-decoration:underline"></span>&#160;1 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;333-264941),</span> filed with the SEC on June<span style="text-decoration:underline"></span>&#160;27, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.35&#094;#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex10d44.htm">License and Commercialization Agreement, dated as of June<span style="text-decoration:underline"></span>&#160;14, 2022, by and between Scilex Holding Company and RxOmeg Therapeutics LLC, a/k/a Romeg Therapeutics, LLC (incorporated by reference to Exhibit 10.44 of Amendment No.<span style="text-decoration:underline"></span>&#160;1 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;333-264941),</span> filed with the SEC on June<span style="text-decoration:underline"></span>&#160;27, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.36&#094;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-45.htm">Indenture, dated as of September<span style="text-decoration:underline"></span>&#160;7, 2018, among Scilex Pharmaceuticals Inc., Sorrento Therapeutics, Inc. and U.S. Bank National Association, as trustee and collateral agent (incorporated by reference to Exhibit 10.45 of Amendment No.<span style="text-decoration:underline"></span>&#160;2 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File<span style="text-decoration:underline"></span>&#160;No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;333-264941),</span> filed with the SEC on July<span style="text-decoration:underline"></span>&#160;21, 2022). </a></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-6 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td style="width:89%"></td></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.37#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-46.htm">Omnibus Amendment No.<span style="text-decoration:underline"></span>&#160;1 to Indenture and Letter of Credit, dated as of October<span style="text-decoration:underline"></span>&#160;1, 2019, among Scilex Pharmaceuticals Inc., Sorrento Therapeutics, Inc. and U.S. Bank National Association, as trustee and collateral agent, and the beneficial owners of the securities and the holders listed on the signature pages thereof (incorporated by reference to Exhibit 10.46 of Amendment No.<span style="text-decoration:underline"></span>&#160;2 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;333-264941),</span> filed with the SEC on July<span style="text-decoration:underline"></span>&#160;21, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.38&#094;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-47.htm">Omnibus Amendment No.<span style="text-decoration:underline"></span>&#160;2 to Indenture and Letter of Credit, dated as of March<span style="text-decoration:underline"></span>&#160;30, 2020, among Scilex Pharmaceuticals Inc., Sorrento Therapeutics, Inc. and U.S. Bank National Association, as trustee and collateral agent, and the beneficial owners of the securities and the holders listed on the signature pages thereof (incorporated by reference to Exhibit 10.47 of Amendment No.<span style="text-decoration:underline"></span>&#160;2 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;333-264941),</span> filed with the SEC on July<span style="text-decoration:underline"></span>&#160;21, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.39#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-48.htm">Consent Under and Amendment No.<span style="text-decoration:underline"></span>&#160;3 to Indenture and Letter of Credit, dated as of December<span style="text-decoration:underline"></span>&#160;14, 2020, among Scilex Pharmaceuticals Inc., Sorrento Therapeutics, Inc. and U.S. Bank National Association, as trustee and collateral agent, and the beneficial owners of the securities and the holders listed on the signature pages thereof (incorporated by reference to Exhibit 10.48 of Amendment No.<span style="text-decoration:underline"></span>&#160;2 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;333-264941),</span> filed with the SEC on July<span style="text-decoration:underline"></span>&#160;21, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.40#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-49.htm">Consent Under and Amendment No.<span style="text-decoration:underline"></span>&#160;4 to Indenture, dated June<span style="text-decoration:underline"></span>&#160;2, 2022, among Sorrento Therapeutics, Inc., Scilex Pharmaceuticals Inc., U.S. Bank Trust Company, National Association, as trustee and collateral agent, and the beneficial owners of the securities and the holders listed on the signature pages thereof (incorporated by reference to Exhibit 10.49 of Amendment No.<span style="text-decoration:underline"></span>&#160;2 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;333-264941),</span> filed with the SEC on July<span style="text-decoration:underline"></span>&#160;21, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.41#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-50.htm">Collateral Agreement, dated as of September<span style="text-decoration:underline"></span>&#160;7, 2018, by and between Scilex Pharmaceuticals Inc. and U.S. Bank National Association (incorporated by reference to Exhibit 10.50 of Amendment No.<span style="text-decoration:underline"></span>&#160;2 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;333-264941),</span> filed with the SEC on July<span style="text-decoration:underline"></span>&#160;21, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.42&#094;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-51.htm">Irrevocable Standby Letter of Credit, dated as of September<span style="text-decoration:underline"></span>&#160;7, 2018, issued by Sorrento Therapeutics, Inc. in favor of Scilex Pharmaceuticals Inc. (incorporated by reference to Exhibit&#160;10.51 of Amendment No.<span style="text-decoration:underline"></span>&#160;2 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;333-264941),</span> filed with the SEC on July<span style="text-decoration:underline"></span>&#160;21, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.43</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-52.htm">Subordinated Promissory Note, dated as of February<span style="text-decoration:underline"></span>&#160;14, 2022, issued by Scilex Pharmaceuticals Inc. in favor of Sorrento Therapeutics, Inc. (incorporated by reference to Exhibit 10.52 of Amendment No.<span style="text-decoration:underline"></span>&#160;2 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;333-264941),</span> filed with the SEC on July<span style="text-decoration:underline"></span>&#160;21, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.44#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-53.htm">Contribution and Loan Agreement, dated as of March<span style="text-decoration:underline"></span>&#160;18, 2019, by and among Scilex Holding Company, Sorrento Therapeutics, Inc., the stockholders of Scilex Pharmaceuticals Inc. signatories thereto, and Scilex Pharmaceuticals Inc. (incorporated by reference to Exhibit 10.53 of Amendment No.<span style="text-decoration:underline"></span>&#160;2 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;333-264941),</span> filed with the SEC on July<span style="text-decoration:underline"></span>&#160;21, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.45</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-54.htm">Promissory Note, dated as of March<span style="text-decoration:underline"></span>&#160;18, 2019, issued by Scilex Holding Company in favor of Sorrento Therapeutics, Inc. (incorporated by reference to Exhibit 10.54 of Amendment No.<span style="text-decoration:underline"></span>&#160;2 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;333-264941),</span> filed with the SEC on July<span style="text-decoration:underline"></span>&#160;21, 2022).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.46</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-55.htm">Intercompany Promissory Note, dated as of October<span style="text-decoration:underline"></span>&#160;5, 2018, issued by Scilex Pharmaceuticals Inc. in favor of Sorrento Therapeutics, Inc. (incorporated by reference to Exhibit 10.55 of Amendment No.<span style="text-decoration:underline"></span>&#160;2 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;333-264941),</span> filed with the SEC on July<span style="text-decoration:underline"></span>&#160;21, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.47#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-56.htm">Credit and Security Agreement, dated as of December<span style="text-decoration:underline"></span>&#160;14, 2020, by and between Scilex Pharmaceuticals Inc. and CNH Finance Fund I, L.P. (incorporated by reference to Exhibit 10.56 of Amendment No.<span style="text-decoration:underline"></span>&#160;2 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;333-264941),</span> filed with the SEC on July<span style="text-decoration:underline"></span>&#160;21, 2022). </a></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-7 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td style="width:89%"></td></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.48&#094;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922074469/vcka-20220331xex10d57.htm">Assignment Agreement, dated August<span style="text-decoration:underline"></span>&#160;6, 2013, between Semnur Pharmaceuticals, Inc. and Shah Investor LP (incorporated by reference to Exhibit 10.57 of Amendment No.<span style="text-decoration:underline"></span>&#160;1 of Vickers&#8217;s <span style="white-space:nowrap">Form&#160;S-4</span> (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;333-264941),</span> filed with the SEC on June<span style="text-decoration:underline"></span>&#160;27, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.49#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-58.htm">Promissory Note, dated as of May<span style="text-decoration:underline"></span>&#160;12, 2022, issued by Scilex Holding Company in favor of Sorrento Therapeutics, Inc. (incorporated by reference to Exhibit 10.58 of Amendment No.<span style="text-decoration:underline"></span>&#160;2 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;333-264941),</span> filed with the SEC on July<span style="text-decoration:underline"></span>&#160;21, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.50&#094;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-59.htm">Office Lease, dated as of August<span style="text-decoration:underline"></span>&#160;8, 2019, by and between Scilex Pharmaceuticals Inc. and 960&#160;San<span style="text-decoration:underline"></span>&#160;Antonio LLC (incorporated by reference to Exhibit 10.59 of Amendment No.<span style="text-decoration:underline"></span>&#160;2 of Vickers&#8217;s Form<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;S-4</span> (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;333-264941),</span> filed with the SEC on July<span style="text-decoration:underline"></span>&#160;21, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.51&#094;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-60.htm">First Amendment to Office Lease, dated as of September<span style="text-decoration:underline"></span>&#160;15, 2019, by and between Scilex Pharmaceuticals Inc. and 960 San Antonio LLC (incorporated by reference to Exhibit 10.60 of Amendment No.<span style="text-decoration:underline"></span>&#160;2 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;333-264941),</span> filed with the SEC on July<span style="text-decoration:underline"></span>&#160;21, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.52&#094;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922081279/tm2214659d7_ex10-61.htm">Sublease Agreement, dated as of May<span style="text-decoration:underline"></span>&#160;18, 2022, by and between Scilex Holding Company and Live Action, Inc. (incorporated by reference to Exhibit 10.61 of Amendment No.<span style="text-decoration:underline"></span>&#160;2 of Vickers&#8217;s Form<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;S-4</span> (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;333-264941),</span> filed with the SEC on July<span style="text-decoration:underline"></span>&#160;21, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.53</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922099735/vcka-20220623xex10d59.htm">Stockholder Agreement, dated as of September<span style="text-decoration:underline"></span>&#160;12, 2022, between Vickers Vantage Corp. I and Sorrento Therapeutics, Inc. (incorporated by reference to Exhibit 10.59 of Amendment No.<span style="text-decoration:underline"></span>&#160;4 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;333-264941),</span> filed with the SEC on September<span style="text-decoration:underline"></span>&#160;13, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.54#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922099735/vcka-20220623xex10d60.htm">Contribution and Satisfaction of Indebtedness Agreement, dated as of September<span style="text-decoration:underline"></span>&#160;12, 2022, by and among Sorrento Therapeutics, Inc., Scilex Holding Company and Scilex Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.60 of Amendment No.<span style="text-decoration:underline"></span>&#160;4 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File<span style="text-decoration:underline"></span>&#160;No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;333-264941),</span> filed with the SEC on September<span style="text-decoration:underline"></span>&#160;13, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.55</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922109540/tm2214659d18_ex10-61.htm">Letter Agreement, dated October<span style="text-decoration:underline"></span>&#160;17, 2022, between Scilex Holding Company and Sorrento Therapeutics, Inc. (incorporated by reference to Exhibit 10.61 of Amendment No.<span style="text-decoration:underline"></span>&#160;5 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;333-264941),</span> filed with the SEC on October<span style="text-decoration:underline"></span>&#160;18, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.56#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922109540/tm2214659d18_ex10-62.htm">Warrant Transfer Agreement, dated October<span style="text-decoration:underline"></span>&#160;17, 2022, by and among Sorrento Therapeutics, Inc., Vickers Venture Fund VI Pte Ltd, Vickers Venture Fund VI (Plan) Pte Ltd and for the limited purposes set forth therein, Vickers Vantage Corp. I and Maxim Group LLC. (incorporated by reference to Exhibit 10.62 of Amendment No.<span style="text-decoration:underline"></span>&#160;5 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;333-264941),</span> filed with the SEC on October<span style="text-decoration:underline"></span>&#160;18, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.57#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922109540/tm2214659d18_ex10-63.htm">Debt Contribution Agreement, dated October<span style="text-decoration:underline"></span>&#160;17, 2022, by and among Vickers Vantage Corp. I, Vickers Venture Fund VI Pte Ltd and Vickers Venture Fund VI (Plan) Pte Ltd (incorporated by reference to Exhibit 10.63 of Amendment No.<span style="text-decoration:underline"></span>&#160;5 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;333-264941),</span> filed with the SEC on October<span style="text-decoration:underline"></span>&#160;18, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.58</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000110465922109540/tm2214659d18_ex10-64.htm">Letter Agreement, dated October<span style="text-decoration:underline"></span>&#160;17, 2022, by and among Sorrento Therapeutics, Inc., Vickers Venture Fund VI Pte Ltd, Vickers Venture Fund VI (Plan) Pte Ltd, Vickers Vantage Corp. I and Maxim Group LLC. (incorporated by reference to Exhibit 10.64 of Amendment No.<span style="text-decoration:underline"></span>&#160;5 of Vickers&#8217;s Form <span style="white-space:nowrap">S-4</span> (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;333-264941),</span> filed with the SEC on October<span style="text-decoration:underline"></span>&#160;18, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.59</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312522287974/d401087dex101.htm">Standby Equity Purchase Agreement, dated as of November<span style="text-decoration:underline"></span>&#160;17, 2022, by and between Scilex Holding Company and YA II PN, LTD. (incorporated by reference to Exhibit 10.1 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;001-39852),</span> filed with the SEC on November<span style="text-decoration:underline"></span>&#160;18, 2022) </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;10.60</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312523004041/d371589dex101.htm">Standby Equity Purchase Agreement, dated as of January 8, 2023, by and between Scilex Holding Company and B. Riley Principal Capital II, LLC (incorporated by reference to Exhibit&#160;10.1 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;001-39852),</span> filed with the SEC on January 9, 2023) </a></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-8 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td style="width:87%"></td></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;16.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312522287783/d374632dex161.htm">Letter from WithumSmith+Brown, PC. to the Securities and Exchange Commission (incorporated by reference to Exhibit 16.1 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;001-39852),</span> filed with the SEC on November<span style="text-decoration:underline"></span>&#160;17, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;21.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1820190/000119312522287783/d374632dex211.htm">List of Subsidiaries of the Registrant (incorporated by reference to Exhibit 21.1 of our Current Report on Form <span style="white-space:nowrap">8-K</span> (File No.<span style="text-decoration:underline"></span><span style="white-space:nowrap">&#160;001-39852),</span> filed with the SEC on November<span style="text-decoration:underline"></span>&#160;17, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;23.1+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d428534dex231.htm">Consent of WithumSmith+Brown, PC, independent registered public accounting firm of Vickers Vantage Corp,&#160;I.</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;23.2+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d428534dex232.htm">Consent of Ernst<span style="text-decoration:underline"></span>&#160;&amp; Young LLP, independent registered public accounting firm of Scilex Holding Company</a>.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;23.3+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d428534dex233.htm">Consent of Deloitte<span style="text-decoration:underline"></span>&#160;&amp; Touche LLP, former independent registered public accounting firm of Scilex Holding Company</a>.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;23.4+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d428534dex51.htm">Consent of Paul Hastings LLP (included in Exhibit&#160;5.1).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;24.1+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="#sig">Power of Attorney (included on the signature page to this Registration Statement). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.INS+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Instance Document.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.SCH+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Schema Document.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.CAL+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.DEF+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Definition Linkbase Document.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.LAB+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Labels Linkbase Document.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.PRE+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">107+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d428534dexfilingfees.htm">Filing Fee Table.</a></td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">+</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Filed herewith. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">*</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Indicates management contract or compensatory plan or arrangement. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">&#094;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Certain identified information has been omitted pursuant to Item 601(b)(10) of Regulation <span style="white-space:nowrap">S-K</span> because such information is both (i)&#160;not material and (ii)&#160;information that the Registrant treats as private or confidential. The Registrant hereby undertakes to furnish supplemental copies of the unredacted exhibit upon request by the SEC. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">#</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Certain of the exhibits and schedules to this Exhibit have been omitted in accordance with Regulation <span style="white-space:nowrap">S-K</span> Item 601. The Registrant agrees to furnish a copy of all omitted exhibits and schedules to the SEC upon its request. </p></td></tr></table> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;17.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Undertakings. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned registrant hereby undertakes: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(i)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To include any prospectus required by Section&#160;10(a)(3) of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(ii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-9 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:13%">&#160;</td>
<td align="left" style="vertical-align:top">
(if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration Fee&#8221; table in the effective registration statement; and </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(iii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">provided, however, </span>that: Paragraphs (a)(1)(i), (a)(1)(ii) and (a)(1)(iii) of this section do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the SEC by the registrant pursuant to Section&#160;13 or Section&#160;15(d) of the Securities and Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), that are incorporated by reference in the registration statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the registration statement. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">That, for the purpose of determining liability under the Securities Act to any purchaser, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(5)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">That, for the purpose of determining liability of the registrant under the Securities Act to any purchaser in the initial distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(i)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(ii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(iii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top" align="left">(iv)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-10 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-11 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="sig">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Palo Alto, State of California, on the 12th day of January 2023. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border:0;margin-left:auto">


<tr>

<td style="width:7%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:92%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"><span style="font-weight:bold">Scilex Holding Company</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">By:</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">/s/ Jaisim Shah</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Name:&#160;&#160;&#160;&#160;&#160;&#160;Jaisim Shah</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Title:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Chief Executive Officer and President</td></tr>
</table></div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each person whose signature appears below constitutes and appoints each of Jaisim Shah and Elizabeth Czerepak, acting alone or together with another <span style="white-space:nowrap"><span style="white-space:nowrap">attorney-in-fact,</span></span> as his or her true and lawful <span style="white-space:nowrap"><span style="white-space:nowrap">attorney-in-fact</span></span> and agent, with full power of substitution and resubstitution, for such person and in his or her name, place and stead, in any and all capacities, to sign any or all further amendments (including post-effective amendments) to this registration statement (and any additional registration statement related hereto permitted by Rule 426(b) promulgated under the Securities Act (and all further amendments, including post-effective amendments thereto)), and to file the same, with all exhibits thereto, and other documents in connection therewith, with the SEC, granting unto said <span style="white-space:nowrap"><span style="white-space:nowrap">attorneys-in-fact</span></span> and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said <span style="white-space:nowrap"><span style="white-space:nowrap">attorney-in-fact</span></span> and agent, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act, this registration statement has been signed by the following persons in the capacities and on the dates indicated. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:33%"></td>

<td style="vertical-align:bottom"></td>
<td style="width:47%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:18%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Signature</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jaisim Shah</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">Jaisim Shah</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Chief Executive Officer, President and Director</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">(Principal Executive Officer)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">January&#160;12, 2023</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Elizabeth A. Czerepak</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">Elizabeth A. Czerepak</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Chief Financial Officer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">(Principal&#160;Financial and Accounting Officer)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">January&#160;12, 2023</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Henry Ji, Ph.D.</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">Henry Ji, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">Executive Chairperson and Director</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">January&#160;12, 2023</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Dorman Followwill</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">Dorman Followwill</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">Director</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">January&#160;12, 2023</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Laura J. Hamill</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">Laura J. Hamill</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">Director</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">January&#160;12, 2023</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ <span style="white-space:nowrap">Tien-Li</span> Lee, M.D.</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="white-space:nowrap">Tien-Li</span> Lee, M.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">Director</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">January&#160;12, 2023</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ David Lemus</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">David Lemus</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">Director</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">January&#160;12, 2023</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Tommy Thompson</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">Tommy Thompson</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">Director</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" align="center">January&#160;12, 2023</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-12 </p>

</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>d428534dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g428534dsp01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL">January&nbsp;12, 2023 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Scilex Holding Company </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">960 San Antonio Road </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Palo Alto, CA 94303 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">Re:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Ladies and Gentlemen: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">We have acted as counsel to
Scilex Holding Company, a Delaware corporation (the &#147;<B><I>Company</I></B>&#148;), in connection with the preparation and filing on the date hereof with the Securities and Exchange Commission (the &#147;<B><I>Commission</I></B>&#148;) of a
Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (the &#147;<B><I>Registration Statement</I></B>&#148;) under the Securities Act of 1933, as amended (the &#147;<B><I>Act</I></B>&#148;), including a related prospectus filed
with the Registration <I>Statement (the &#147;</I><B><I>Prospectus</I></B><I>&#148;), relating to the registration of the offer and sale from time to time, in each</I> case, by the selling securityholder named in the Registration Statement (the
&#147;<B><I>Selling Securityholder</I></B>&#148;) of (i) 250,000 outstanding shares (the &#147;<B><I>Commitment Shares</I></B>&#148;) of common stock, par value $0.0001 per share, of the Company (the &#147;<B><I>Common Stock</I></B>&#148;) that were
issued to the Selling Securityholder by the Company as consideration for the Selling Securityholder&#146;s commitment to purchase shares of Common Stock pursuant to that certain Standby Equity Purchase Agreement, dated as of January&nbsp;8, 2023, by
and between the Company and the Selling Securityholder (the &#147;<B><I>Purchase Agreement</I></B>&#148;), and (ii)&nbsp;up to 27,878,422 shares of Common Stock (the &#147;<B><I>Advance Shares</I></B>&#148; and, together with the Commitment Shares,
the &#147;<B><I>Shares</I></B>&#148;) that may be issued and sold to the Selling Stockholder from time to time by the Company pursuant to the Purchase Agreement. This opinion letter is being furnished in accordance with the requirements of Item 601
of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> under the Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">As such counsel and for purposes of our opinion set forth below, we have
examined and relied upon originals or copies, certified or otherwise identified to our satisfaction, of such documents, resolutions, certificates and other instruments of the Company and corporate records furnished to us by the Company, and have
reviewed certificates of public officials, statutes, records and such other instruments and documents as we have deemed necessary or appropriate as a basis for the opinion set forth below, including without limitation: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">the Registration Statement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">the Prospectus; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">the Restated Certificate of Incorporation of the Company, as amended, certified by the Secretary of State of the State
of Delaware as of January&nbsp;11, 2023 (the &#147;<B><I>Charter</I></B>&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">the Bylaws of the Company as presently in effect, certified by an officer of the Company as of January&nbsp;12, 2023;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">the Purchase Agreement; </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g428534dsp1.jpg" ALT="LOGO">
 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="justify">


<IMG SRC="g428534g0110085822104.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">January&nbsp;12, 2023 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify"> Page&nbsp;
 2
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">a certificate, dated as of January&nbsp;12, 2023, from the Secretary of State of the State of Delaware certifying as
to the existence and good standing of the Company in the State of Delaware (the &#147;<B><I>Good Standing Certificate</I></B>&#148;); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(vii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="justify">resolutions adopted by the board of directors of the Company on January 5, 2023, certified by an officer of the
Company, relating to, among other things, the approval of the Purchase Agreement, the filing of the Registration Statement and the registration, sale and issuance of the Shares (the &#147;<B><I>Resolutions</I></B>&#148;). </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">In addition to the foregoing, we have made such investigations of law as we have deemed necessary or appropriate as a basis for the opinion set forth in
this opinion letter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">In such examination and in rendering the opinion expressed below, we have assumed, without independent investigation or
verification: (i)&nbsp;the genuineness of all signatures on all agreements, instruments, corporate records, certificates and other documents submitted to us; (ii)&nbsp;the authenticity and completeness of all agreements, instruments, corporate
records, certificates and other documents submitted to us as originals; (iii)&nbsp;that all agreements, instruments, corporate records, certificates and other documents submitted to us as certified, electronic, facsimile, conformed, photostatic or
other copies conform to originals thereof, and that such originals are authentic and complete; (iv)&nbsp;the legal capacity, competency and authority of all persons executing all agreements, instruments, corporate records, certificates and other
documents submitted to us; (v)&nbsp;the due authorization, execution and delivery of all agreements, instruments, corporate records, certificates and other documents by all parties thereto (other than the Company); (vi) that no documents submitted
to us have been amended or terminated orally or in writing except as has been disclosed to us in writing; (vii)&nbsp;that the statements contained in the certificates and comparable documents of public officials, officers and representatives of the
Company and other persons on which we have relied for the purposes of this opinion letter are true and correct on and as of the date hereof; (viii)&nbsp;that there has not been any change in the good standing status of the Company from that reported
in the Good Standing Certificate; (ix)&nbsp;that each of the officers and directors of the Company has properly exercised his or her fiduciary duties; (x)&nbsp;the Shares will not be issued or transferred in violation of any restriction contained in
the Charter and that upon the issuance of any of the Shares, the total number of shares of Common Stock issued and outstanding will not exceed the total number of shares of Common Stock that the Company is then authorized to issue under the Charter;
and (xi)&nbsp;that prior to the issuance of any of the Shares, the Board of Directors of the Company (or the duly authorized persons thereof) will determine the price and certain other terms of issuance of such Shares in accordance with the
Resolutions (the &#147;<B><I>Board Proceedings</I></B>&#148;). As to all questions of fact material to this opinion letter, and as to the materiality of any fact or other matter referred to herein, we have relied (without independent investigation
or verification) upon representations and certificates or comparable documents of officers and representatives of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Based upon the
foregoing, and in reliance thereon, and subject to the assumptions, limitations, qualifications and exceptions set forth herein, we are of the opinion that<I> </I>upon completion of all of the Board Proceedings, the Shares will be duly authorized
for issuance and, when and if issued and delivered by the Company in accordance with the Resolutions, and the Board Proceedings against payment therefor in accordance with the Purchase Agreement, the Shares will be validly issued, fully paid and
nonassessable. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="justify">


<IMG SRC="g428534g0110085822104.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">January&nbsp;12, 2023 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify"> Page&nbsp;
 3
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Without limiting any of the other limitations, exceptions, assumptions and qualifications stated
elsewhere herein, we express no opinion with regard to the applicability or effect of the laws of any jurisdiction other than the General Corporation Law of the State of Delaware, as in effect on the date of this opinion letter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">This opinion letter deals only with the specified legal issues expressly addressed herein, and you should not infer any opinion that is not explicitly
stated herein from any matter addressed in this opinion letter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">This opinion letter is rendered solely in connection with the filing of the
Registration Statement. This opinion letter is rendered as of the date hereof, and we assume no obligation to advise you or any other person with regard to any change after the date hereof in the circumstances or the law that may bear on the matters
set forth herein, even if the change may affect the legal analysis or a legal conclusion or other matters in this opinion letter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">We hereby consent
to the filing of this opinion letter as Exhibit 5.1 to the Registration Statement, and to the reference to our firm under the heading &#147;Legal Matters&#148; in the Registration Statement. In giving such consent, we do not hereby admit that we are
within the category of persons whose consent is required under Section&nbsp;7 of the Act or the rules or regulations of the Commission thereunder. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Very truly yours,</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">/s/ Paul Hastings LLP</P></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>d428534dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We hereby consent to the use in the Prospectus constituting a part of this Registration Statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-1</FONT> of
our report dated February&nbsp;24, 2022, (which includes explanatory paragraphs relating to the correction of certain misstatements related to the January&nbsp;11, 2021 financial statement and Vickers Vantage Corp. I&#146;s ability to continue as a
going concern) relating to the financial statements of Vickers Vantage Corp. I, which is contained in that Prospectus. We also consent to the reference to our Firm under the caption &#147;Experts&#148; in the Prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ WithumSmith+Brown, PC </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">January&nbsp;12, 2023 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>4
<FILENAME>d428534dex232.htm
<DESCRIPTION>EX-23.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Consent of </B><B>Ernst &amp; Young LLP, </B><B>Independent Registered Public Accounting Firm</B><B> of Scilex Holding Company</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the reference to our firm under the caption &#147;Experts&#148; and to the use of our report dated May 13, 2022, in the Registration Statement
(Form S-1) and related Prospectus of Scilex Holding Company for the registration of up to 28,128,422 shares of its common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Ernst &amp; Young
LLP </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Diego, California </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">January 12, 2023 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.3
<SEQUENCE>5
<FILENAME>d428534dex233.htm
<DESCRIPTION>EX-23.3
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.3 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the use in this Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> of our report dated April&nbsp;23, 2020, relating to
the financial statements of Scilex Holding Company. We also consent to the reference to us under the heading &#147;Experts&#148; in such Registration Statement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Deloitte&nbsp;&amp; Touche LLP </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Diego, California </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">January&nbsp;12, 2023 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>6
<FILENAME>d428534dexfilingfees.htm
<DESCRIPTION>EX-FILING FEES
<TEXT>
<HTML><HEAD>
<TITLE>EX-FILING FEES</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit&nbsp;107 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Calculation of Filing Fee Tables </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U><FONT STYLE="white-space:nowrap">Form&nbsp;S-1</FONT> </U></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Form&nbsp;Type) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Scilex
Holding Company </U></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Exact Name of Registrant as Specified in its Charter) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Table&nbsp;1: Newly Registered Securities </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="99%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="8%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"><B>Security<BR>Type</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Security Class</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"><B>Fee<BR>Calculation<BR>Rule</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"><B>Amount<BR>Registered<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"><B>Proposed<BR>Maximum<BR>Offering<BR>Price<BR>Per<BR>Share</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"><B>Proposed<BR>Maximum<BR>Aggregate<BR>Offering<BR>Price</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Fee</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Rate</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt"><B>Amount of<BR>Registration<BR>Fee</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Fees to be</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Paid</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">Equity</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">Common Stock, par value $0.0001&nbsp;per share</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">457(c)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">28,128,422<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">$4.87<SUP STYLE="font-size:75%; vertical-align:top">(3) </SUP></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">$136,985,415.14</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">$0.00011020</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt">$15,095.80</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Fees</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Previously</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Paid</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">N/A</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;">N/A</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">N/A</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">N/A</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">N/A</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">N/A</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">N/A</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt">N/A</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">Total Offering Amounts</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">$136,985,415.14</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt">$15,095.80</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">Total Fees Previously Paid</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt">&#151;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;">Total Fee Offsets</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt">&#151;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="7" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-BOTTOM:1px solid #000000">Net Fee Due</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">$15,095.80</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Pursuant to Rule 416(a) promulgated under the U.S. Securities Act of 1933, as amended (the &#147;Securities
Act&#148;), there are also being registered an indeterminable number of additional securities as may be issued to prevent dilution resulting from stock splits, stock dividends, or similar transactions. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 250,000 shares of common stock, par value $0.0001 per share (the &#147;Common Stock&#148;) of Scilex
Holding Company, a Delaware corporation (the &#147;Company&#148;), previously issued by the Company to the selling securityholder named herein (the &#147;Selling Securityholder&#148;) and 27,878,422 shares of Common Stock that are available to be
issued and sold by the Company to the Selling Securityholder from time to time at the Company&#146;s election pursuant to a standby equity purchase agreement, dated as of January&nbsp;8, 2023, between the Company and the Selling Securityholder,
subject to satisfaction of the conditions set forth therein. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Estimated solely for the purpose of calculating the registration fee in accordance with Rule 457(c) under the
Securities Act. The proposed maximum offering price per share and the proposed maximum aggregate offering price are based on the average of the high and low prices of the Common Stock on the Nasdaq Capital Market on January&nbsp;5, 2023 (such date
being within five business days prior to the date that this registration statement was filed with the U.S. Securities and Exchange Commission). </P></TD></TR></TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>sclx-20220930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 12-January-2023 [12:41:39] {PM}-->
<schema targetNamespace="http://www.vickersvantagecorp.com/20220930" elementFormDefault="qualified" xmlns:sclx="http://www.vickersvantagecorp.com/20220930" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:srt="http://fasb.org/srt/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21">
<annotation>
<appinfo>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/CoverPage" id="CoverPage">
<link:definition>1001 - Document - Cover Page</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets" id="CondensedConsolidatedBalanceSheets">
<link:definition>1002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheetsParentheticals" id="CondensedConsolidatedBalanceSheetsParentheticals">
<link:definition>1003 - Statement - Condensed Consolidated Balance Sheets (Parentheticals)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" id="UnauditedCondensedConsolidatedStatementsOfOperations">
<link:definition>1004 - Statement - Unaudited Condensed Consolidated Statements of Operations</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsParentheticals" id="UnauditedCondensedConsolidatedStatementsOfOperationsParentheticals">
<link:definition>1005 - Statement - Unaudited Condensed Consolidated Statements of Operations (Parentheticals)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit" id="UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit">
<link:definition>1006 - Statement - Unaudited Condensed Consolidated Statements of Changes in Shareholders' Equity (Deficit)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" id="UnauditedCondensedConsolidatedStatementsOfCashFlows">
<link:definition>1007 - Statement - Unaudited Condensed Consolidated Statements of Cash Flows</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperations" id="DescriptionOfOrganizationAndBusinessOperations">
<link:definition>1008 - Disclosure - Description of Organization and Business Operations</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
<link:definition>1009 - Disclosure - Summary of Significant Accounting Policies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcern" id="LiquidityAndGoingConcern">
<link:definition>1010 - Disclosure - Liquidity and Going Concern</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/PublicOffering" id="PublicOffering">
<link:definition>1011 - Disclosure - Public Offering</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/PrivatePlacement" id="PrivatePlacement">
<link:definition>1012 - Disclosure - Private Placement</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/Acquisitions" id="Acquisitions">
<link:definition>1013 - Disclosure - Acquisitions</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
<link:definition>1014 - Disclosure - Related Party Transactions</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/FairValueMeasurements" id="FairValueMeasurements">
<link:definition>1015 - Disclosure - Fair Value Measurements</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/PropertyAndEquipment" id="PropertyAndEquipment">
<link:definition>1016 - Disclosure - Property and Equipment</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssets" id="GoodwillAndIntangibleAssets">
<link:definition>1017 - Disclosure - Goodwill and Intangible Assets</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/Debt" id="Debt">
<link:definition>1018 - Disclosure - Debt</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/Warrants" id="Warrants">
<link:definition>1019 - Disclosure - Warrants</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/ShareholdersDeficit" id="ShareholdersDeficit">
<link:definition>1020 - Disclosure - Shareholders' Deficit</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlans" id="StockIncentiveAndEmployeeBenefitPlans">
<link:definition>1021 - Disclosure - Stock Incentive and Employee Benefit Plans</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
<link:definition>1022 - Disclosure - Commitments and Contingencies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatements" id="RestatementOfPreviouslyIssuedFinancialStatements">
<link:definition>1023 - Disclosure - Restatement of Previously Issued Financial Statements</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/IncomeTaxes" id="IncomeTaxes">
<link:definition>1024 - Disclosure - Income Taxes</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/LossPerShare" id="LossPerShare">
<link:definition>1025 - Disclosure - Loss Per Share</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/SubsequentEvents" id="SubsequentEvents">
<link:definition>1026 - Disclosure - Subsequent Events</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/AccountingPoliciesByPolicyPolicies" id="AccountingPoliciesByPolicyPolicies">
<link:definition>1027 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
<link:definition>1028 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/FairValueMeasurementsTables" id="FairValueMeasurementsTables">
<link:definition>1029 - Disclosure - Fair Value Measurements (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/PropertyAndEquipmentTables" id="PropertyAndEquipmentTables">
<link:definition>1030 - Disclosure - Property and Equipment  (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsTables" id="GoodwillAndIntangibleAssetsTables">
<link:definition>1031 - Disclosure - Goodwill and Intangible Assets (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/DebtTables" id="DebtTables">
<link:definition>1032 - Disclosure - Debt (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansTables" id="StockIncentiveAndEmployeeBenefitPlansTables">
<link:definition>1033 - Disclosure - Stock Incentive and Employee Benefit Plans (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
<link:definition>1034 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsTables" id="RestatementOfPreviouslyIssuedFinancialStatementsTables">
<link:definition>1035 - Disclosure - Restatement of Previously Issued Financial Statements (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
<link:definition>1036 - Disclosure - Income Taxes (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/LossPerShareTables" id="LossPerShareTables">
<link:definition>1037 - Disclosure - Loss Per Share (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails" id="DescriptionOfOrganizationAndBusinessOperationsDetails">
<link:definition>1038 - Disclosure - Description of Organization and Business Operations (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetails" id="SummaryOfSignificantAccountingPoliciesDetails">
<link:definition>1039 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfOrdinarySharesReflectedInCondensedConsolidatedBalanceSheetsAreReconciled" id="SummaryOfSignificantAccountingPoliciesDetailsScheduleOfOrdinarySharesReflectedInCondensedConsolidatedBalanceSheetsAreReconciled">
<link:definition>1040 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of ordinary shares reflected in condensed consolidated balance sheets are reconciled</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShare" id="SummaryOfSignificantAccountingPoliciesDetailsScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShare">
<link:definition>1041 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of reflects the calculation of basic and diluted net income (loss) per ordinary share</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareParentheticals" id="SummaryOfSignificantAccountingPoliciesDetailsScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareParentheticals">
<link:definition>1042 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of reflects the calculation of basic and diluted net income (loss) per ordinary share (Parentheticals)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails" id="LiquidityAndGoingConcernDetails">
<link:definition>1043 - Disclosure - Liquidity and Going Concern (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/PublicOfferingDetails" id="PublicOfferingDetails">
<link:definition>1044 - Disclosure - Public Offering (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/PrivatePlacementDetails" id="PrivatePlacementDetails">
<link:definition>1045 - Disclosure - Private Placement (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails" id="RelatedPartyTransactionsDetails">
<link:definition>1046 - Disclosure - Related Party Transactions (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails" id="CommitmentsAndContingenciesDetails">
<link:definition>1047 - Disclosure - Commitments and Contingencies (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesSummaryOfComponentsOfLeaseExpenseDetail" id="CommitmentsAndContingenciesSummaryOfComponentsOfLeaseExpenseDetail">
<link:definition>1048 - Disclosure - Commitments and Contingencies - Summary of Components of Lease Expense (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetail" id="CommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetail">
<link:definition>1049 - Disclosure - Commitments and Contingencies - Summary of Maturities of Lease Liabilities (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesSummaryOfSupplementalQuantitativeInformationRelatedToLeasesDetail" id="CommitmentsAndContingenciesSummaryOfSupplementalQuantitativeInformationRelatedToLeasesDetail">
<link:definition>1050 - Disclosure - Commitments and Contingencies - Summary of Supplemental Quantitative Information Related To Leases (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/ShareholdersDeficitDetails" id="ShareholdersDeficitDetails">
<link:definition>1051 - Disclosure - Shareholders' Deficit (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/WarrantsDetails" id="WarrantsDetails">
<link:definition>1052 - Disclosure - Warrants (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetails" id="FairValueMeasurementsDetails">
<link:definition>1053 - Disclosure - Fair Value Measurements (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfFairValueHierarchyOfTheValuationInputs" id="FairValueMeasurementsDetailsScheduleOfFairValueHierarchyOfTheValuationInputs">
<link:definition>1054 - Disclosure - Fair Value Measurements  (Details) - Schedule of fair value hierarchy of the valuation inputs</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfChangesInTheFairValueOfWarrantLiabilitiesAndConversionOptionLiability" id="FairValueMeasurementsDetailsScheduleOfChangesInTheFairValueOfWarrantLiabilitiesAndConversionOptionLiability">
<link:definition>1055 - Disclosure - Fair Value Measurements  (Details) - Schedule of changes in the fair value of warrant liabilities and conversion option liability:</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfValuedUsingTheCompoundOptionPricingModel" id="FairValueMeasurementsDetailsScheduleOfValuedUsingTheCompoundOptionPricingModel">
<link:definition>1056 - Disclosure - Fair Value Measurements  (Details) - Schedule of valued using the compound option pricing model</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsFinancialAssetsAndLiabilitiesThatAreMeasuredAtFairValue" id="FairValueMeasurementsDetailsFinancialAssetsAndLiabilitiesThatAreMeasuredAtFairValue">
<link:definition>1057 - Disclosure - Fair Value Measurements  (Details) - Financial assets and liabilities that are measured at fair value</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsDerivativeLiabilitiesMeasuredAtFairValueUsingSignificantUnobservableInputs" id="FairValueMeasurementsDetailsDerivativeLiabilitiesMeasuredAtFairValueUsingSignificantUnobservableInputs">
<link:definition>1058 - Disclosure - Fair Value Measurements (Details) - Derivative liabilities measured at fair value using significant unobservable inputs</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurements" id="FairValueMeasurementsDetailsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurements">
<link:definition>1059 - Disclosure - Fair Value Measurements  (Details) - Schedule of quantitative information regarding Level 3 fair value measurements</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfChangeInTheFairValueOfConversionOptionLiability" id="FairValueMeasurementsDetailsScheduleOfChangeInTheFairValueOfConversionOptionLiability">
<link:definition>1060 - Disclosure - Fair Value Measurements (Details) - Schedule of change in the fair value of conversion option liability</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/PropertyAndEquipmentDetailsPropertyAndEquipmentConsisted" id="PropertyAndEquipmentDetailsPropertyAndEquipmentConsisted">
<link:definition>1061 - Disclosure - Property and Equipment (Details) - Property and equipment consisted</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/PropertyAndEquipmentDetails" id="PropertyAndEquipmentDetails">
<link:definition>1062 - Disclosure - Property and Equipment (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfTheCompanysIdentifiableIntangibleAssets" id="GoodwillAndIntangibleAssetsDetailsSummaryOfTheCompanysIdentifiableIntangibleAssets">
<link:definition>1063 - Disclosure - Goodwill and Intangible Assets (Details) - Summary of the company's identifiable intangible assets</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfEstimatedFutureAmortizationExpense" id="GoodwillAndIntangibleAssetsDetailsSummaryOfEstimatedFutureAmortizationExpense">
<link:definition>1064 - Disclosure - Goodwill and Intangible Assets (Details) - Summary of estimated future amortization expense</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetails" id="GoodwillAndIntangibleAssetsDetails">
<link:definition>1065 - Disclosure - Goodwill and Intangible Assets (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/DebtDetails" id="DebtDetails">
<link:definition>1066 - Disclosure - Debt (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/DebtDetailsSummaryOfBorrowingsOfTheScilexPharmaNotes" id="DebtDetailsSummaryOfBorrowingsOfTheScilexPharmaNotes">
<link:definition>1067 - Disclosure - Debt (Details) - Summary of borrowings of the scilex pharma notes</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/DebtDetailsSummaryOfFutureMinimumPaymentsUnderTheScilexPharmaNotes" id="DebtDetailsSummaryOfFutureMinimumPaymentsUnderTheScilexPharmaNotes">
<link:definition>1068 - Disclosure - Debt (Details)  - Summary of future minimum payments under the scilex pharma notes</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetails" id="StockIncentiveAndEmployeeBenefitPlansDetails">
<link:definition>1069 - Disclosure - Stock Incentive and Employee Benefit Plans (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfShareBasedPaymentAwardOptionsIssuedToEmployeesAndNonemployeesValuationAssumptions" id="StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfShareBasedPaymentAwardOptionsIssuedToEmployeesAndNonemployeesValuationAssumptions">
<link:definition>1070 - Disclosure - Stock Incentive and Employee Benefit Plans (Details) - Summary of share based payment award options issued to employees and nonemployees valuation assumptions</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfTheOptionsOutstanding" id="StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfTheOptionsOutstanding">
<link:definition>1071 - Disclosure - Stock Incentive and Employee Benefit Plans (Details) - Summary of the options outstanding</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/AcquisitionsDetails" id="AcquisitionsDetails">
<link:definition>1072 - Disclosure - Acquisitions (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsDetails" id="RestatementOfPreviouslyIssuedFinancialStatementsDetails">
<link:definition>1073 - Disclosure - Restatement of Previously Issued Financial Statements (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsDetailsScheduleOfImpactOfTheseAdjustmentsToTheFinancialStatementAsPreviouslyReported" id="RestatementOfPreviouslyIssuedFinancialStatementsDetailsScheduleOfImpactOfTheseAdjustmentsToTheFinancialStatementAsPreviouslyReported">
<link:definition>1074 - Disclosure - Restatement of Previously Issued Financial Statements (Details) - Schedule of impact of these adjustments to the financial statement, as previously reported</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/IncomeTaxesDetails" id="IncomeTaxesDetails">
<link:definition>1075 - Disclosure - Income Taxes (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfComponentsOfIncomeTaxExpenseBenefit" id="IncomeTaxesDetailsScheduleOfComponentsOfIncomeTaxExpenseBenefit">
<link:definition>1076 - Disclosure - Income Taxes (Details) - Schedule of components of income tax expense (benefit)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfDeferredTaxAssetsAndLiabilities" id="IncomeTaxesDetailsScheduleOfDeferredTaxAssetsAndLiabilities">
<link:definition>1077 - Disclosure - Income Taxes (Details) - Schedule of deferred tax assets and liabilities</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfEffectiveIncomeTaxRateReconciliation" id="IncomeTaxesDetailsScheduleOfEffectiveIncomeTaxRateReconciliation">
<link:definition>1078 - Disclosure - Income Taxes (Details) - Schedule of effective income tax rate reconciliation</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/LossPerShareDetails" id="LossPerShareDetails">
<link:definition>1079 - Disclosure - Loss Per Share (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/LossPerShareDetailsSummaryOfReconciliationOfBasicAndDilutedLossPerShare" id="LossPerShareDetailsSummaryOfReconciliationOfBasicAndDilutedLossPerShare">
<link:definition>1080 - Disclosure - Loss Per Share (Details) - Summary of reconciliation of basic and diluted loss per share</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.vickersvantagecorp.com/role/SubsequentEventsDetails" id="SubsequentEventsDetails">
<link:definition>1081 - Disclosure - Subsequent Events (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:type="simple" xlink:href="sclx-20220930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="sclx-20220930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="sclx-20220930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="sclx-20220930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
</appinfo>
</annotation>
<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
<import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
<import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
<import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
<import namespace="http://xbrl.sec.gov/currency/2022" schemaLocation="https://xbrl.sec.gov/currency/2022/currency-2022.xsd" />
<import namespace="http://xbrl.sec.gov/exch/2022" schemaLocation="https://xbrl.sec.gov/exch/2022/exch-2022.xsd" />
<import namespace="http://xbrl.sec.gov/naics/2022" schemaLocation="https://xbrl.sec.gov/naics/2022/naics-2022.xsd" />
<import namespace="http://xbrl.sec.gov/sic/2022" schemaLocation="https://xbrl.sec.gov/sic/2022/sic-2022.xsd" />
<import namespace="http://xbrl.sec.gov/stpr/2022" schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" />
<import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
<import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
<import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" />
<import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" />
<import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
<import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
<element name="AccruedPayroll" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_AccruedPayroll" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="RelatedPartyNotePayableCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_RelatedPartyNotePayableCurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AdvancesFromRelatedParty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_AdvancesFromRelatedParty" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DerivativeLiabilityNoncurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_DerivativeLiabilityNoncurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="RelatedPartyNotePayableNoncurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_RelatedPartyNotePayableNoncurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="VickersVantageMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_VickersVantageMember" substitutionGroup="xbrli:item" />
<element name="OrdinarySharesSubjectToPossibleRedemption" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_OrdinarySharesSubjectToPossibleRedemption" substitutionGroup="xbrli:item" />
<element name="SubjectToPossibleRedemptionPerShares" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_SubjectToPossibleRedemptionPerShares" substitutionGroup="xbrli:item" />
<element name="OrdinarySharesRedemptionSubjectedToForfeiture" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_OrdinarySharesRedemptionSubjectedToForfeiture" substitutionGroup="xbrli:item" />
<element name="SharesCapitalization" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_SharesCapitalization" substitutionGroup="xbrli:item" />
<element name="TransactionCostsAllocatedToWarrantLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_TransactionCostsAllocatedToWarrantLiabilities" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ScilexPharmaNotesPrincipalIncrease" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_ScilexPharmaNotesPrincipalIncrease" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ChangeInFairValueOfWarrantLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_ChangeInFairValueOfWarrantLiability" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="GainLossOnDerivative" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_GainLossOnDerivative" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="GainLossOnExtinguishmentOfDebtt" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_GainLossOnExtinguishmentOfDebtt" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AcquiredinprocessresearchAndDevelopment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_AcquiredinprocessresearchAndDevelopment" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AdjustmentsToAdditionalPaidInCapitalNetOfDiscount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_AdjustmentsToAdditionalPaidInCapitalNetOfDiscount" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AdjustmentsToAdditionalPaidInCapitalDiscountAmortization" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_AdjustmentsToAdditionalPaidInCapitalDiscountAmortization" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AdjustmentsToAdditionalPaidInCapitalSharesIssuedInSemnurAcquisition" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_AdjustmentsToAdditionalPaidInCapitalSharesIssuedInSemnurAcquisition" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="LossOnInitialIssuanceOfWarrantLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_LossOnInitialIssuanceOfWarrantLiability" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ChangeInFairValueOfConversionOptionLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_ChangeInFairValueOfConversionOptionLiability" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="TransactionsCostsAllocatedToPrivateWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_TransactionsCostsAllocatedToPrivateWarrants" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="IncreaseInNotesPayableOne" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_IncreaseInNotesPayableOne" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="NonCashOperatingLeaseCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_NonCashOperatingLeaseCosts" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="FormationCostPaidThroughAdvancesFromAffiliateOfSponsor" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_FormationCostPaidThroughAdvancesFromAffiliateOfSponsor" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="InvestmentOfCashInTrustAccounts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_InvestmentOfCashInTrustAccounts" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ProceedsFromSimplePromissoryNoteRelatedParty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_ProceedsFromSimplePromissoryNoteRelatedParty" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="RepaymentOfPromissoryNoteRelatedParty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_RepaymentOfPromissoryNoteRelatedParty" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ProceedsFromPromissoryNoteRelatedParty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_ProceedsFromPromissoryNoteRelatedParty" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DeferredUnderwritingFeePayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_DeferredUnderwritingFeePayable" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="OfferingCostIncludedInAccruedOfferingCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_OfferingCostIncludedInAccruedOfferingCost" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="OtherLoanForgiveness" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_OtherLoanForgiveness" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PromissoryNoteIssuedNetOfDiscount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_PromissoryNoteIssuedNetOfDiscount" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="NonCashFairValueAdjustmentToDerivativeLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_NonCashFairValueAdjustmentToDerivativeLiability" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="NonCashRightOfUseAsset" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_NonCashRightOfUseAsset" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AcquistionCostsIncurredButNotPaidIncludedInAccountsPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_AcquistionCostsIncurredButNotPaidIncludedInAccountsPayable" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="NonCashDistributionToAcquiree" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_NonCashDistributionToAcquiree" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="NonCashIncreaseInPrincipal" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_NonCashIncreaseInPrincipal" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DescriptionofOrganizationandBusinessOperationsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_DescriptionofOrganizationandBusinessOperationsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="DescriptionOfOrganizationAndBusinessOperationsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_DescriptionOfOrganizationAndBusinessOperationsLineItems" substitutionGroup="xbrli:item" />
<element name="SummaryofSignificantAccountingPoliciesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_SummaryofSignificantAccountingPoliciesDetailsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="SummaryofSignificantAccountingPoliciesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems" substitutionGroup="xbrli:item" />
<element name="LiquidityAndGoingConcernAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_LiquidityAndGoingConcernAbstract" substitutionGroup="xbrli:item" />
<element name="LiquidityAndGoingConcernTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_LiquidityAndGoingConcernTextBlock" substitutionGroup="xbrli:item" />
<element name="ProposedPublicOfferingAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ProposedPublicOfferingAbstract" substitutionGroup="xbrli:item" />
<element name="PublicOfferingDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_PublicOfferingDetailsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="PublicOfferingDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_PublicOfferingDetailsLineItems" substitutionGroup="xbrli:item" />
<element name="ProposedPublicOfferingTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_ProposedPublicOfferingTextBlock" substitutionGroup="xbrli:item" />
<element name="PrivatePlacementAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_PrivatePlacementAbstract" substitutionGroup="xbrli:item" />
<element name="PrivatePlacementDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_PrivatePlacementDetailsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="PrivatePlacementDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_PrivatePlacementDetailsLineItems" substitutionGroup="xbrli:item" />
<element name="PrivatePlacementTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_PrivatePlacementTextBlock" substitutionGroup="xbrli:item" />
<element name="RelatedPartyTransactionsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_RelatedPartyTransactionsDetailsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="RelatedPartyTransactionsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_RelatedPartyTransactionsDetailsLineItems" substitutionGroup="xbrli:item" />
<element name="WarrantsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_WarrantsAbstract" substitutionGroup="xbrli:item" />
<element name="WarrantsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_WarrantsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="WarrantsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_WarrantsLineItems" substitutionGroup="xbrli:item" />
<element name="WarrantsTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_WarrantsTextBlock" substitutionGroup="xbrli:item" />
<element name="CompensationAndEmployeeBenefitPlansAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_CompensationAndEmployeeBenefitPlansAbstract" substitutionGroup="xbrli:item" />
<element name="CommitmentsandContingenciesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_CommitmentsandContingenciesDetailsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="CommitmentsandContingenciesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_CommitmentsandContingenciesDetailsLineItems" substitutionGroup="xbrli:item" />
<element name="RebatesPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_RebatesPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="ServiceFeesPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_ServiceFeesPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="SalesReturnsPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_SalesReturnsPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="CoPaymentAssistancePolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_CoPaymentAssistancePolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfFutureMinimumPaymentsOfLongTermDebtTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtTableTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfSupplementalQuantitativeInformationRelatedToLeasesTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_ScheduleOfSupplementalQuantitativeInformationRelatedToLeasesTableTextBlock" substitutionGroup="xbrli:item" />
<element name="DescriptionofOrganizationandBusinessOperationsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="DescriptionofOrganizationandBusinessOperationsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" substitutionGroup="xbrli:item" />
<element name="PercentageOfPublicShares" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_PercentageOfPublicShares" substitutionGroup="xbrli:item" />
<element name="DeferredUnderwritingFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_DeferredUnderwritingFees" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="SaleOfStockDescriptionOfTransactions" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_SaleOfStockDescriptionOfTransactions" substitutionGroup="xbrli:item" />
<element name="PricePerPublicShare" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_PricePerPublicShare" substitutionGroup="xbrli:item" />
<element name="BusinessCombinationRedeemPercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_BusinessCombinationRedeemPercentage" substitutionGroup="xbrli:item" />
<element name="Numberofshares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_Numberofshares" substitutionGroup="xbrli:item" />
<element name="ProceedsOfInitialPublicOffering" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_ProceedsOfInitialPublicOffering" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="Saleofwarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_Saleofwarrants" substitutionGroup="xbrli:item" />
<element name="Grossproceedsofwarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_Grossproceedsofwarrants" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="Transactioncostsamount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_Transactioncostsamount" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="Otherofferingcosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_Otherofferingcosts" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DepositIntoTheTrustAccountPerShare" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_DepositIntoTheTrustAccountPerShare" substitutionGroup="xbrli:item" />
<element name="LesserPublicPerShare" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_LesserPublicPerShare" substitutionGroup="xbrli:item" />
<element name="WorkingCapital" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_WorkingCapital" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="Numberofbusinessdays" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_Numberofbusinessdays" substitutionGroup="xbrli:item" />
<element name="NetTangibleAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_NetTangibleAssets" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="Depositintotrustaccount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_Depositintotrustaccount" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="Interestexpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_Interestexpenses" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ScilexPharmaMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ScilexPharmaMember" substitutionGroup="xbrli:item" />
<element name="VantageMergerSubIncMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_VantageMergerSubIncMember" substitutionGroup="xbrli:item" />
<element name="PrivatePlacementWarrantMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_PrivatePlacementWarrantMember" substitutionGroup="xbrli:item" />
<element name="SorrentoMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_SorrentoMember" substitutionGroup="xbrli:item" />
<element name="SponsorMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_SponsorMember" substitutionGroup="xbrli:item" />
<element name="AgreementAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_AgreementAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="AgreementDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_AgreementDomain" substitutionGroup="xbrli:item" />
<element name="ContributionAndLoanAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ContributionAndLoanAgreementMember" substitutionGroup="xbrli:item" />
<element name="DebtExchangeAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_DebtExchangeAgreementMember" substitutionGroup="xbrli:item" />
<element name="EventAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_EventAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="EventDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_EventDomain" substitutionGroup="xbrli:item" />
<element name="ReorganizationMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ReorganizationMember" substitutionGroup="xbrli:item" />
<element name="Foundershares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_Foundershares" substitutionGroup="xbrli:item" />
<element name="SoleDistributorMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_SoleDistributorMember" substitutionGroup="xbrli:item" />
<element name="ScheduleOfOrdinarySharesReflectedInCondensedConsolidatedBalanceSheetsAreReconciledAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ScheduleOfOrdinarySharesReflectedInCondensedConsolidatedBalanceSheetsAreReconciledAbstract" substitutionGroup="xbrli:item" />
<element name="GrossProceeds" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_GrossProceeds" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="LessAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_LessAbstract" substitutionGroup="xbrli:item" />
<element name="OrdinarySharesIssuanceCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_OrdinarySharesIssuanceCost" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PlusAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_PlusAbstract" substitutionGroup="xbrli:item" />
<element name="AccretionOfCarryingValueToRedemptionValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_AccretionOfCarryingValueToRedemptionValue" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="SharesSubjectToPossibleRedemption" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_SharesSubjectToPossibleRedemption" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="LessAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_LessAbstract0" substitutionGroup="xbrli:item" />
<element name="ScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareAbstract" substitutionGroup="xbrli:item" />
<element name="NumeratorAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_NumeratorAbstract" substitutionGroup="xbrli:item" />
<element name="DenominatorAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_DenominatorAbstract" substitutionGroup="xbrli:item" />
<element name="LiquidityAndGoingConcernTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_LiquidityAndGoingConcernTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="SeniorSecuredNotesDueTwoThousandAndTwentySixMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_SeniorSecuredNotesDueTwoThousandAndTwentySixMember" substitutionGroup="xbrli:item" />
<element name="CumulativeSalesRelatedContingencyMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_CumulativeSalesRelatedContingencyMember" substitutionGroup="xbrli:item" />
<element name="LetterOfCreditDrawnDownMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_LetterOfCreditDrawnDownMember" substitutionGroup="xbrli:item" />
<element name="LiquidityAndGoingConcernLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_LiquidityAndGoingConcernLineItems" substitutionGroup="xbrli:item" />
<element name="MinimumUnrestrictedCashBalance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_MinimumUnrestrictedCashBalance" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="NetWorkingCapital" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_NetWorkingCapital" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="RestrictedFundsRelesableForFutureRepurchaseOfDebt" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_RestrictedFundsRelesableForFutureRepurchaseOfDebt" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DebtInstrumentRepurchaseObligation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_DebtInstrumentRepurchaseObligation" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AggregateOutstandingAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_AggregateOutstandingAmount" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ScilexPharmaNotesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ScilexPharmaNotesMember" substitutionGroup="xbrli:item" />
<element name="FundingCommitmentLetterMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_FundingCommitmentLetterMember" substitutionGroup="xbrli:item" />
<element name="NumberOfSaleUnits" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_NumberOfSaleUnits" substitutionGroup="xbrli:item" />
<element name="PurchasePricePerShare" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_PurchasePricePerShare" substitutionGroup="xbrli:item" />
<element name="FounderSharesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_FounderSharesMember" substitutionGroup="xbrli:item" />
<element name="PromissoryNoteRelatedPartyMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_PromissoryNoteRelatedPartyMember" substitutionGroup="xbrli:item" />
<element name="ConvertiblePromisoryNoteMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ConvertiblePromisoryNoteMember" substitutionGroup="xbrli:item" />
<element name="WarrantsExercisePrice" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_WarrantsExercisePrice" substitutionGroup="xbrli:item" />
<element name="CapitalizationOfShareOutstanding" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_CapitalizationOfShareOutstanding" substitutionGroup="xbrli:item" />
<element name="OrdinarySharesIssuedAndOutstanding" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_OrdinarySharesIssuedAndOutstanding" substitutionGroup="xbrli:item" />
<element name="aggregatePurchasePrice" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_aggregatePurchasePrice" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="NumberOfSharesOutstanding" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_NumberOfSharesOutstanding" substitutionGroup="xbrli:item" />
<element name="NumberOfSharesAcquired" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_NumberOfSharesAcquired" substitutionGroup="xbrli:item" />
<element name="AssetAcquisitionPricePerShare" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_AssetAcquisitionPricePerShare" substitutionGroup="xbrli:item" />
<element name="PercentageOfOwnershipInterest" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_PercentageOfOwnershipInterest" substitutionGroup="xbrli:item" />
<element name="PercentageOfSharesOutstanding" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_PercentageOfSharesOutstanding" substitutionGroup="xbrli:item" />
<element name="AggregatePrincipalAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_AggregatePrincipalAmount" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PercentageOfSimpleInterest" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_PercentageOfSimpleInterest" substitutionGroup="xbrli:item" />
<element name="AccruedInterest" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_AccruedInterest" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PricePerWarrants" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_PricePerWarrants" substitutionGroup="xbrli:item" />
<element name="RepaidAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_RepaidAmount" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PercentageOfCapitalSharesOutstanding" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_PercentageOfCapitalSharesOutstanding" substitutionGroup="xbrli:item" />
<element name="WorkingCapitalRequirements" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_WorkingCapitalRequirements" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DepositedInTrustAccount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_DepositedInTrustAccount" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PaymentToAcquireInventory" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_PaymentToAcquireInventory" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PercentageOfOutstandingAmountIndebtedness" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_PercentageOfOutstandingAmountIndebtedness" substitutionGroup="xbrli:item" />
<element name="PerShareCalculationOfOutstandingAmountInExchangeOfShares" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_PerShareCalculationOfOutstandingAmountInExchangeOfShares" substitutionGroup="xbrli:item" />
<element name="LimitationOfOutstandingAmountInExchangeOfShares" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_LimitationOfOutstandingAmountInExchangeOfShares" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="SenmurMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_SenmurMember" substitutionGroup="xbrli:item" />
<element name="InvesteeAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_InvesteeAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="InvesteeDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_InvesteeDomain" substitutionGroup="xbrli:item" />
<element name="TwoThousandAndTwentyTwoPromissoryNoteMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_TwoThousandAndTwentyTwoPromissoryNoteMember" substitutionGroup="xbrli:item" />
<element name="ItochuMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ItochuMember" substitutionGroup="xbrli:item" />
<element name="PeriodAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_PeriodAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="PeriodDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_PeriodDomain" substitutionGroup="xbrli:item" />
<element name="DueOnOrAfterFebruaryTwoThousandAndThirtyMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_DueOnOrAfterFebruaryTwoThousandAndThirtyMember" substitutionGroup="xbrli:item" />
<element name="AggregatePercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_AggregatePercentage" substitutionGroup="xbrli:item" />
<element name="WarrantsPercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_WarrantsPercentage" substitutionGroup="xbrli:item" />
<element name="BalanceInTheTrustAccount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_BalanceInTheTrustAccount" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="MergerConsiderationDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_MergerConsiderationDescription" substitutionGroup="xbrli:item" />
<element name="CommonStockAggregateValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_CommonStockAggregateValue" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DeferredUnderwritingCommission" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_DeferredUnderwritingCommission" substitutionGroup="xbrli:item" />
<element name="AgreementExpirationTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_AgreementExpirationTerm" substitutionGroup="xbrli:item" />
<element name="AgreementAutomaticRenewalPeriodOnExpirationOfInitialTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_AgreementAutomaticRenewalPeriodOnExpirationOfInitialTerm" substitutionGroup="xbrli:item" />
<element name="NoticeOfTerminationPeriodForCancellationOfAutomaticRenewal" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_NoticeOfTerminationPeriodForCancellationOfAutomaticRenewal" substitutionGroup="xbrli:item" />
<element name="DeferredUnderwritingCommissionPayable" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_DeferredUnderwritingCommissionPayable" substitutionGroup="xbrli:item" />
<element name="PercentageOfAggregateRoyalityPayments" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_PercentageOfAggregateRoyalityPayments" substitutionGroup="xbrli:item" />
<element name="AgreementExpirationDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_AgreementExpirationDate" substitutionGroup="xbrli:item" />
<element name="TerminationOfAgreementNoticePeriodForARequestToCureMaterialBreachOfTheAgreement" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_TerminationOfAgreementNoticePeriodForARequestToCureMaterialBreachOfTheAgreement" substitutionGroup="xbrli:item" />
<element name="NoticePeriodForTerminationOfWorkOrder" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_NoticePeriodForTerminationOfWorkOrder" substitutionGroup="xbrli:item" />
<element name="ThresholdMinimumPercentageOfSales" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_ThresholdMinimumPercentageOfSales" substitutionGroup="xbrli:item" />
<element name="PercentageOfAnnualAdjustmentToFees" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_PercentageOfAnnualAdjustmentToFees" substitutionGroup="xbrli:item" />
<element name="PercentageOfDistributionFeeReceivedOverThePeriod" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_PercentageOfDistributionFeeReceivedOverThePeriod" substitutionGroup="xbrli:item" />
<element name="WorkOrderImplementationFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_WorkOrderImplementationFee" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="SalesOperationsServicesMonthlyFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_SalesOperationsServicesMonthlyFee" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="SellingGeneralAndAdministrativeExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_SellingGeneralAndAdministrativeExpenses" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ScilexCommonStockMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ScilexCommonStockMember" substitutionGroup="xbrli:item" />
<element name="ProductDevelopmentAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ProductDevelopmentAgreementMember" substitutionGroup="xbrli:item" />
<element name="ExclusiveDistributionAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ExclusiveDistributionAgreementMember" substitutionGroup="xbrli:item" />
<element name="ProjectAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ProjectAgreementMember" substitutionGroup="xbrli:item" />
<element name="PaloAltoAadministrativeFacilityMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_PaloAltoAadministrativeFacilityMember" substitutionGroup="xbrli:item" />
<element name="OperatingCashFlowsFromOperatingLeases" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_OperatingCashFlowsFromOperatingLeases" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="WarrantsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_WarrantsDetailsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="WarrantsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_WarrantsDetailsLineItems" substitutionGroup="xbrli:item" />
<element name="WarrantsOutstandingShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_WarrantsOutstandingShares" substitutionGroup="xbrli:item" />
<element name="PublicWarrantsRedemptionDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_PublicWarrantsRedemptionDescription" substitutionGroup="xbrli:item" />
<element name="CapitalRaisingDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_CapitalRaisingDescription" substitutionGroup="xbrli:item" />
<element name="MeasurementInputRiskadjustedNetSalesForecastMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_MeasurementInputRiskadjustedNetSalesForecastMember" substitutionGroup="xbrli:item" />
<element name="MeasurementInputEffectiveDebtYieldMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_MeasurementInputEffectiveDebtYieldMember" substitutionGroup="xbrli:item" />
<element name="MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeMarch312021Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeMarch312021Member" substitutionGroup="xbrli:item" />
<element name="MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeJuly12023Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeJuly12023Member" substitutionGroup="xbrli:item" />
<element name="ScheduleOfFairValueHierarchyOfTheValuationInputsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ScheduleOfFairValueHierarchyOfTheValuationInputsAbstract" substitutionGroup="xbrli:item" />
<element name="FairValueMeasurementsDetailsScheduleoffairvaluehierarchyofthevaluationinputsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_FairValueMeasurementsDetailsScheduleoffairvaluehierarchyofthevaluationinputsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="FairValueMeasurementsDetailsScheduleoffairvaluehierarchyofthevaluationinputsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_FairValueMeasurementsDetailsScheduleoffairvaluehierarchyofthevaluationinputsLineItems" substitutionGroup="xbrli:item" />
<element name="ScheduleOfChangesInTheFairValueOfWarrantLiabilitiesAndConversionOptionLiabilityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ScheduleOfChangesInTheFairValueOfWarrantLiabilitiesAndConversionOptionLiabilityAbstract" substitutionGroup="xbrli:item" />
<element name="FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityLineItems" substitutionGroup="xbrli:item" />
<element name="InitialMeasurementOne" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_InitialMeasurementOne" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ChangeInValuationInputsOrOtherAssumptions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_ChangeInValuationInputsOrOtherAssumptions" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ConversionOptionLiabilityMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ConversionOptionLiabilityMember" substitutionGroup="xbrli:item" />
<element name="ScheduleOfValuedUsingTheCompoundOptionPricingModelAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ScheduleOfValuedUsingTheCompoundOptionPricingModelAbstract" substitutionGroup="xbrli:item" />
<element name="UnderlyingWarrantValue" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_UnderlyingWarrantValue" substitutionGroup="xbrli:item" />
<element name="HoldingPeriod" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_HoldingPeriod" substitutionGroup="xbrli:item" />
<element name="ScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurementsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurementsAbstract" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1" substitutionGroup="xbrli:item" />
<element name="FairValueMeasurementStrikePrice" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_FairValueMeasurementStrikePrice" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1" substitutionGroup="xbrli:item" />
<element name="FairValueOfWarrantsinDollars" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_FairValueOfWarrantsinDollars" substitutionGroup="xbrli:item" />
<element name="ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityAbstract" substitutionGroup="xbrli:item" />
<element name="ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityLineItems" substitutionGroup="xbrli:item" />
<element name="AssembledWorkforceMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_AssembledWorkforceMember" substitutionGroup="xbrli:item" />
<element name="FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PercentageOfQuarterlyPaymentsOfThePrincipalNotesEqualToAFixedPercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_PercentageOfQuarterlyPaymentsOfThePrincipalNotesEqualToAFixedPercentage" substitutionGroup="xbrli:item" />
<element name="DebtInstrumentredemptionPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_DebtInstrumentredemptionPeriod" substitutionGroup="xbrli:item" />
<element name="PercentageOfNetSalesPayable" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_PercentageOfNetSalesPayable" substitutionGroup="xbrli:item" />
<element name="PaymentToDepositIntoASeggregateReserveFund" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_PaymentToDepositIntoASeggregateReserveFund" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PaymentToDepositIntoASegregatedCollateralAccount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_PaymentToDepositIntoASegregatedCollateralAccount" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PercentageOfConcentrationOnASimilarProduct" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_PercentageOfConcentrationOnASimilarProduct" substitutionGroup="xbrli:item" />
<element name="MinimumCashRequirementsToRepurchaseOfNotes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_MinimumCashRequirementsToRepurchaseOfNotes" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PercentageOfThePrincipalAmountFromHoldersOnProRataBasis" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_PercentageOfThePrincipalAmountFromHoldersOnProRataBasis" substitutionGroup="xbrli:item" />
<element name="AmountDistributionToAcquireRelatedContingentAcceleratedRepaymentNotes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_AmountDistributionToAcquireRelatedContingentAcceleratedRepaymentNotes" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DebtInstrumentTerminationDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_DebtInstrumentTerminationDate" substitutionGroup="xbrli:item" />
<element name="MaximumCompensationCostToBeAvailableProratedBasis" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_MaximumCompensationCostToBeAvailableProratedBasis" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PercentageOfLoanForgivenessUnderTheAct" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_PercentageOfLoanForgivenessUnderTheAct" substitutionGroup="xbrli:item" />
<element name="MinimumPayrollCostToBeAvailable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_MinimumPayrollCostToBeAvailable" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="MinimumUnrestrictedCashRequirementsToRepurchaseOfNotes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_MinimumUnrestrictedCashRequirementsToRepurchaseOfNotes" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DebtInstrumentPercentageOfPrincipalAmountRepurchased" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_DebtInstrumentPercentageOfPrincipalAmountRepurchased" substitutionGroup="xbrli:item" />
<element name="PercentageOfThePrincipalAmountOfTheNotes" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_PercentageOfThePrincipalAmountOfTheNotes" substitutionGroup="xbrli:item" />
<element name="LineOfCreditFacilityindebtednessAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_LineOfCreditFacilityindebtednessAmount" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ScilexPharmaNoteMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ScilexPharmaNoteMember" substitutionGroup="xbrli:item" />
<element name="TwoThousandAndEighteenPurchaseAgreementsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_TwoThousandAndEighteenPurchaseAgreementsMember" substitutionGroup="xbrli:item" />
<element name="AccountsReceivableRevolvingLoanFacilityMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_AccountsReceivableRevolvingLoanFacilityMember" substitutionGroup="xbrli:item" />
<element name="IfLetterOfCreditIsDrawnMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_IfLetterOfCreditIsDrawnMember" substitutionGroup="xbrli:item" />
<element name="MarketingApprovalLetterMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_MarketingApprovalLetterMember" substitutionGroup="xbrli:item" />
<element name="StatementAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_StatementAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="StatementDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_StatementDomain" substitutionGroup="xbrli:item" />
<element name="DecemberOptionalRepurchaseMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_DecemberOptionalRepurchaseMember" substitutionGroup="xbrli:item" />
<element name="FebruaryOptionalRepurchaseMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_FebruaryOptionalRepurchaseMember" substitutionGroup="xbrli:item" />
<element name="AprilOptionalRepurchaseMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_AprilOptionalRepurchaseMember" substitutionGroup="xbrli:item" />
<element name="EventTypeAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_EventTypeAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="EventTypeDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_EventTypeDomain" substitutionGroup="xbrli:item" />
<element name="CoronavirusAidReliefAndEconomicSecurityActMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_CoronavirusAidReliefAndEconomicSecurityActMember" substitutionGroup="xbrli:item" />
<element name="ClassificationOfCostAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ClassificationOfCostAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="ClassificationOfCostDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ClassificationOfCostDomain" substitutionGroup="xbrli:item" />
<element name="NonPayrollCostsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_NonPayrollCostsMember" substitutionGroup="xbrli:item" />
<element name="PayrollCostsBasisMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_PayrollCostsBasisMember" substitutionGroup="xbrli:item" />
<element name="PaycheckProtectionProgramMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_PaycheckProtectionProgramMember" substitutionGroup="xbrli:item" />
<element name="IndebentureMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_IndebentureMember" substitutionGroup="xbrli:item" />
<element name="AmendmentAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_AmendmentAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="AmendmentDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_AmendmentDomain" substitutionGroup="xbrli:item" />
<element name="AmendmentNoFourMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_AmendmentNoFourMember" substitutionGroup="xbrli:item" />
<element name="PromissoryNoteMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_PromissoryNoteMember" substitutionGroup="xbrli:item" />
<element name="TwoThousandAndEighteenPurchaseAgreementsAndIndentureMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_TwoThousandAndEighteenPurchaseAgreementsAndIndentureMember" substitutionGroup="xbrli:item" />
<element name="ScheduleOfFutureMinimumPaymentsOfLongTermDebtTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="ScheduleOfFutureMinimumPaymentsOfLongTermDebtLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtLineItems" substitutionGroup="xbrli:item" />
<element name="LongtermDebtFutureMinimumPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_LongtermDebtFutureMinimumPayment" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="LongtermDebtFutureMinimumPaymentYearFive" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_LongtermDebtFutureMinimumPaymentYearFive" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="LongtermDebtFutureMinimumPaymentYearFour" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_LongtermDebtFutureMinimumPaymentYearFour" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="LongtermDebtFutureMinimumPaymentYearThree" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_LongtermDebtFutureMinimumPaymentYearThree" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="LongtermDebtFutureMinimumPaymentYearTwo" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_LongtermDebtFutureMinimumPaymentYearTwo" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="LongtermDebtfutureMinimumPaymentYearOne" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_LongtermDebtfutureMinimumPaymentYearOne" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="CompensationAndEmployeeBenefitPlansTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_CompensationAndEmployeeBenefitPlansTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="CompensationAndEmployeeBenefitPlansLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_CompensationAndEmployeeBenefitPlansLineItems" substitutionGroup="xbrli:item" />
<element name="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant" substitutionGroup="xbrli:item" />
<element name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingNumber" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingNumber" substitutionGroup="xbrli:item" />
<element name="ScilexPharmaTwoThousandSeventeenPlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ScilexPharmaTwoThousandSeventeenPlanMember" substitutionGroup="xbrli:item" />
<element name="TwoThousandNineteenStockOptionPlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_TwoThousandNineteenStockOptionPlanMember" substitutionGroup="xbrli:item" />
<element name="AmendmentToTwoThousandNineteenStockOptionPlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_AmendmentToTwoThousandNineteenStockOptionPlanMember" substitutionGroup="xbrli:item" />
<element name="FourHundredAndOneKPlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_FourHundredAndOneKPlanMember" substitutionGroup="xbrli:item" />
<element name="OperatingExpensesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_OperatingExpensesMember" substitutionGroup="xbrli:item" />
<element name="PercentageOfSharesIssuedSubjectToRestrictionOfTransfer" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_PercentageOfSharesIssuedSubjectToRestrictionOfTransfer" substitutionGroup="xbrli:item" />
<element name="PeriodDuringWhichShareTransferIsRestricted" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_PeriodDuringWhichShareTransferIsRestricted" substitutionGroup="xbrli:item" />
<element name="PeriodDuringWhichTheSharesMayBeExchanged" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_PeriodDuringWhichTheSharesMayBeExchanged" substitutionGroup="xbrli:item" />
<element name="CommonStockValueToBeExchanged" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_CommonStockValueToBeExchanged" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="RevenueToBeEarnedByTheAcquireeValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_RevenueToBeEarnedByTheAcquireeValue" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="NumberOfDaysForDeterminingTheWeightedVolumeAveragePriceForShares" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_NumberOfDaysForDeterminingTheWeightedVolumeAveragePriceForShares" substitutionGroup="xbrli:item" />
<element name="PricePerShareForDeterminingTheExchangeOfShares" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_PricePerShareForDeterminingTheExchangeOfShares" substitutionGroup="xbrli:item" />
<element name="PaymentMadeInSurrenderingTheShares" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_PaymentMadeInSurrenderingTheShares" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DeferredConsideration" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_DeferredConsideration" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="UpfrontlicenseFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_UpfrontlicenseFee" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="MilestonePayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_MilestonePayment" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="TrancheAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_TrancheAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="TrancheDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_TrancheDomain" substitutionGroup="xbrli:item" />
<element name="TrancheOneMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_TrancheOneMember" substitutionGroup="xbrli:item" />
<element name="TrancheTwoMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_TrancheTwoMember" substitutionGroup="xbrli:item" />
<element name="TrancheThreeMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_TrancheThreeMember" substitutionGroup="xbrli:item" />
<element name="TrancheFourMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_TrancheFourMember" substitutionGroup="xbrli:item" />
<element name="AardvarkMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_AardvarkMember" substitutionGroup="xbrli:item" />
<element name="RomegLicenseAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_RomegLicenseAgreementMember" substitutionGroup="xbrli:item" />
<element name="MilestoneAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_MilestoneAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="MilestoneDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_MilestoneDomain" substitutionGroup="xbrli:item" />
<element name="RegulatoryBasedMilestoneMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_RegulatoryBasedMilestoneMember" substitutionGroup="xbrli:item" />
<element name="ReveueBasedMilestoneMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ReveueBasedMilestoneMember" substitutionGroup="xbrli:item" />
<element name="ApprovalBasedMilestoneMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_ApprovalBasedMilestoneMember" substitutionGroup="xbrli:item" />
<element name="AsRestatedMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_AsRestatedMember" substitutionGroup="xbrli:item" />
<element name="TwoThousandTwentyTwoPromissoryNoteMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_TwoThousandTwentyTwoPromissoryNoteMember" substitutionGroup="xbrli:item" />
<element name="AdjustmentsRestatement2Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_AdjustmentsRestatement2Member" substitutionGroup="xbrli:item" />
<element name="IncomeTaxDisclosureTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_IncomeTaxDisclosureTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="IndefiniteCarryforwardPeriodMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_IndefiniteCarryforwardPeriodMember" substitutionGroup="xbrli:item" />
<element name="IncomeTaxDisclosureLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_IncomeTaxDisclosureLineItems" substitutionGroup="xbrli:item" />
<element name="OperatingLossCarryforwardsExpirationYear" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_OperatingLossCarryforwardsExpirationYear" substitutionGroup="xbrli:item" />
<element name="TaxCreditCarryforwardExpirationYear" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_TaxCreditCarryforwardExpirationYear" substitutionGroup="xbrli:item" />
<element name="MinimumThresholdPercentageForRecognitionOfUncertainIncomeTaxPosition" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_MinimumThresholdPercentageForRecognitionOfUncertainIncomeTaxPosition" substitutionGroup="xbrli:item" />
<element name="DeferredTaxAssetsOperatingLeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_DeferredTaxAssetsOperatingLeaseLiabilities" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DeferredTaxAssetsInterestExpenseLimitations" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_DeferredTaxAssetsInterestExpenseLimitations" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustmentsAndCarryback" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustmentsAndCarryback" substitutionGroup="xbrli:item" />
<element name="EffectiveIncomeTaxRateReconciliationDebtDiscountAndInterestLimitation" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_EffectiveIncomeTaxRateReconciliationDebtDiscountAndInterestLimitation" substitutionGroup="xbrli:item" />
<element name="SubsequentEventsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_SubsequentEventsDetailsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="SubsequentEventsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_SubsequentEventsDetailsLineItems" substitutionGroup="xbrli:item" />
<element name="SponsorLoan" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_SponsorLoan" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="WarrantExercisePrice" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_WarrantExercisePrice" substitutionGroup="xbrli:item" />
<element name="AdditionalPrincipalAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_AdditionalPrincipalAmount" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ConvertiblePromissoryNote" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_ConvertiblePromissoryNote" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="NumberOfSharesLimits" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_NumberOfSharesLimits" substitutionGroup="xbrli:item" />
<element name="SalesThresholdLimit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_SalesThresholdLimit" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PercentageOfPurchasePriceInCashEqualIsToPrincipalAmountOfTheLoan" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="sclx_PercentageOfPurchasePriceInCashEqualIsToPrincipalAmountOfTheLoan" substitutionGroup="xbrli:item" />
<element name="MinimumTimeDeclaredToFileWithSecRegardingResaleRegistrationStatement" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_MinimumTimeDeclaredToFileWithSecRegardingResaleRegistrationStatement" substitutionGroup="xbrli:item" />
<element name="PeriodAfterRegistrationWhenTheRequestCouldBeMadeToTheInvesteeToPurchaseTheShares" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_PeriodAfterRegistrationWhenTheRequestCouldBeMadeToTheInvesteeToPurchaseTheShares" substitutionGroup="xbrli:item" />
<element name="MaximumPercentageOfVolumeWeightedAveragePriceOfSharesMeasuredOnADailyBasisThatIsEligibleToBeReceivedAsAdvance" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_MaximumPercentageOfVolumeWeightedAveragePriceOfSharesMeasuredOnADailyBasisThatIsEligibleToBeReceivedAsAdvance" substitutionGroup="xbrli:item" />
<element name="NumberOfThresholdTradingDaysPriorToDateOfNoticeToTheShareholdersForDeterminingTheVolumeWeightedAveragePriceOfShares" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_NumberOfThresholdTradingDaysPriorToDateOfNoticeToTheShareholdersForDeterminingTheVolumeWeightedAveragePriceOfShares" substitutionGroup="xbrli:item" />
<element name="PercentageOfDailyVolumeWeightedAveragePriceOfSharesAtWhichTheSharesAreEligibleToBePurchased" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_PercentageOfDailyVolumeWeightedAveragePriceOfSharesAtWhichTheSharesAreEligibleToBePurchased" substitutionGroup="xbrli:item" />
<element name="NumberOfConsecutiveTradingDaysForDeterminingTheVolumeWeightedAveragePriceOfShares" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="sclx_NumberOfConsecutiveTradingDaysForDeterminingTheVolumeWeightedAveragePriceOfShares" substitutionGroup="xbrli:item" />
<element name="YorkvilleMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_YorkvilleMember" substitutionGroup="xbrli:item" />
<element name="B.RileyMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_B.RileyMember" substitutionGroup="xbrli:item" />
<element name="StandbyEquityPurchaseAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_StandbyEquityPurchaseAgreementMember" substitutionGroup="xbrli:item" />
<element name="AgreementWithCertainOfTheThirdPartyProfessionalServiceProvidersMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_AgreementWithCertainOfTheThirdPartyProfessionalServiceProvidersMember" substitutionGroup="xbrli:item" />
<element name="PurchasetypeAMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_PurchasetypeAMember" substitutionGroup="xbrli:item" />
<element name="PurchasetypeBMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="sclx_PurchasetypeBMember" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>sclx-20220930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 12-January-2023 [12:41:38] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#CondensedConsolidatedBalanceSheets" roleURI="http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#UnauditedCondensedConsolidatedStatementsOfOperations" roleURI="http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#UnauditedCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#CommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetail" roleURI="http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#GoodwillAndIntangibleAssetsDetailsSummaryOfEstimatedFutureAmortizationExpense" roleURI="http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfEstimatedFutureAmortizationExpense" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#DebtDetailsSummaryOfFutureMinimumPaymentsUnderTheScilexPharmaNotes" roleURI="http://www.vickersvantagecorp.com/role/DebtDetailsSummaryOfFutureMinimumPaymentsUnderTheScilexPharmaNotes" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#IncomeTaxesDetailsScheduleOfComponentsOfIncomeTaxExpenseBenefit" roleURI="http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfComponentsOfIncomeTaxExpenseBenefit" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#IncomeTaxesDetailsScheduleOfDeferredTaxAssetsAndLiabilities" roleURI="http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfDeferredTaxAssetsAndLiabilities" />
<calculationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="loc_us-gaap_OperatingCostsAndExpenses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_OperatingCostsAndExpenses" use="optional" order="1" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses" xlink:to="loc_us-gaap_CostOfRevenue" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AcquiredinprocessresearchAndDevelopment" xlink:label="loc_SCLX_AcquiredinprocessresearchAndDevelopment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses" xlink:to="loc_SCLX_AcquiredinprocessresearchAndDevelopment" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_Revenues" use="optional" order="7" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit" use="optional" order="9" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_GainLossOnDerivative" xlink:label="loc_SCLX_GainLossOnDerivative" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="loc_SCLX_GainLossOnDerivative" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_GainLossOnExtinguishmentOfDebtt" xlink:label="loc_SCLX_GainLossOnExtinguishmentOfDebtt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="loc_SCLX_GainLossOnExtinguishmentOfDebtt" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="loc_us-gaap_InterestExpense" use="optional" order="12" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ChangeInFairValueOfWarrantLiability" xlink:label="loc_SCLX_ChangeInFairValueOfWarrantLiability" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="loc_SCLX_ChangeInFairValueOfWarrantLiability" use="optional" order="14" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants" use="optional" order="15" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfDerivatives" xlink:label="loc_us-gaap_GainLossOnSaleOfDerivatives" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="loc_us-gaap_GainLossOnSaleOfDerivatives" use="optional" order="16" weight="1" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TransactionCostsAllocatedToWarrantLiabilities" xlink:label="loc_SCLX_TransactionCostsAllocatedToWarrantLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="loc_SCLX_TransactionCostsAllocatedToWarrantLiabilities" use="optional" order="17" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:label="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1" use="optional" order="18" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DistributionsOnMandatorilyRedeemableSecurities" xlink:label="loc_us-gaap_DistributionsOnMandatorilyRedeemableSecurities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="loc_us-gaap_DistributionsOnMandatorilyRedeemableSecurities" use="optional" order="19" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaap_InterestIncomeOther" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="loc_us-gaap_InterestIncomeOther" use="optional" order="20" weight="1" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScilexPharmaNotesPrincipalIncrease" xlink:label="loc_SCLX_ScilexPharmaNotesPrincipalIncrease" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="loc_SCLX_ScilexPharmaNotesPrincipalIncrease" use="optional" order="21" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="loc_us-gaap_InvestmentIncomeInterest" use="optional" order="22" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_InventoryNet" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_PrepaidExpenseCurrent" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_Cash" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsHeldInTrustNoncurrent" xlink:label="loc_us-gaap_AssetsHeldInTrustNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsHeldInTrustNoncurrent" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_Goodwill" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_LongTermInvestments" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCosts" xlink:label="loc_us-gaap_DeferredCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_DeferredCosts" use="optional" order="13" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquity" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_PreferredStockValue" use="optional" order="16" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockValue" use="optional" order="17" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AdditionalPaidInCapital" use="optional" order="18" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit" use="optional" order="19" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_CommitmentsAndContingencies" use="optional" order="20" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_Liabilities" use="optional" order="21" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LiabilitiesCurrent" use="optional" order="22" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableCurrent" use="optional" order="23" weight="1" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AccruedPayroll" xlink:label="loc_SCLX_AccruedPayroll" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_SCLX_AccruedPayroll" use="optional" order="24" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent" use="optional" order="25" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_LongTermDebtCurrent" use="optional" order="26" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent" use="optional" order="27" weight="1" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_RelatedPartyNotePayableCurrent" xlink:label="loc_SCLX_RelatedPartyNotePayableCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_SCLX_RelatedPartyNotePayableCurrent" use="optional" order="28" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent" use="optional" order="29" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_DeferredRevenueCurrent" use="optional" order="30" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_ConvertibleLongTermNotesPayable" use="optional" order="31" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent" use="optional" order="32" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLongTermNotesPayable" xlink:label="loc_us-gaap_OtherLongTermNotesPayable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_OtherLongTermNotesPayable" use="optional" order="33" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent" xlink:label="loc_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent" use="optional" order="34" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_DerivativeLiabilities" use="optional" order="35" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:label="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" use="optional" order="36" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LongTermDebtNoncurrent" use="optional" order="37" weight="1" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_RelatedPartyNotePayableNoncurrent" xlink:label="loc_SCLX_RelatedPartyNotePayableNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_SCLX_RelatedPartyNotePayableNoncurrent" use="optional" order="38" weight="1" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DerivativeLiabilityNoncurrent" xlink:label="loc_SCLX_DerivativeLiabilityNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_SCLX_DerivativeLiabilityNoncurrent" use="optional" order="39" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" use="optional" order="40" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent" use="optional" order="41" weight="1" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AdvancesFromRelatedParty" xlink:label="loc_SCLX_AdvancesFromRelatedParty" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_SCLX_AdvancesFromRelatedParty" use="optional" order="42" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:label="loc_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" use="optional" order="43" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" use="optional" order="44" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent" use="optional" order="45" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" use="optional" order="2" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross" use="optional" order="3" weight="-1" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_InvestmentOfCashInTrustAccounts" xlink:label="loc_SCLX_InvestmentOfCashInTrustAccounts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_SCLX_InvestmentOfCashInTrustAccounts" use="optional" order="4" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDecommissioningFund" xlink:label="loc_us-gaap_ProceedsFromDecommissioningFund" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_ProceedsFromDecommissioningFund" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" use="optional" order="6" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfSeniorDebt" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_RepaymentsOfSeniorDebt" use="optional" order="8" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfOtherLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfOtherLongTermDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_RepaymentsOfOtherLongTermDebt" use="optional" order="9" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfMediumTermNotes" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfMediumTermNotes" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfMediumTermNotes" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_RepaymentsOfRelatedPartyDebt" use="optional" order="16" weight="-1" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ProceedsFromSimplePromissoryNoteRelatedParty" xlink:label="loc_SCLX_ProceedsFromSimplePromissoryNoteRelatedParty" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_SCLX_ProceedsFromSimplePromissoryNoteRelatedParty" use="optional" order="17" weight="1" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_RepaymentOfPromissoryNoteRelatedParty" xlink:label="loc_SCLX_RepaymentOfPromissoryNoteRelatedParty" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_SCLX_RepaymentOfPromissoryNoteRelatedParty" use="optional" order="18" weight="-1" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ProceedsFromPromissoryNoteRelatedParty" xlink:label="loc_SCLX_ProceedsFromPromissoryNoteRelatedParty" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_SCLX_ProceedsFromPromissoryNoteRelatedParty" use="optional" order="19" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" use="optional" order="20" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts" use="optional" order="21" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfOtherEquity" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfOtherEquity" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfOtherEquity" use="optional" order="22" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfMediumTermNotes" xlink:label="loc_us-gaap_RepaymentsOfMediumTermNotes" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_RepaymentsOfMediumTermNotes" use="optional" order="23" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" use="optional" order="24" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" use="optional" order="25" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" use="optional" order="26" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories" use="optional" order="27" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" use="optional" order="28" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:label="loc_us-gaap_IncreaseDecreaseInSecurityDeposits" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInSecurityDeposits" use="optional" order="29" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" use="optional" order="30" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" use="optional" order="31" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" use="optional" order="32" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" use="optional" order="33" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:label="loc_us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" use="optional" order="34" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" use="optional" order="35" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndDividendIncomeSecuritiesHeldToMaturity" xlink:label="loc_us-gaap_InterestAndDividendIncomeSecuritiesHeldToMaturity" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_InterestAndDividendIncomeSecuritiesHeldToMaturity" use="optional" order="36" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DistributionsOnMandatorilyRedeemableSecurities" xlink:label="loc_us-gaap_DistributionsOnMandatorilyRedeemableSecurities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_DistributionsOnMandatorilyRedeemableSecurities" use="optional" order="37" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants" use="optional" order="38" weight="1" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LossOnInitialIssuanceOfWarrantLiability" xlink:label="loc_SCLX_LossOnInitialIssuanceOfWarrantLiability" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_SCLX_LossOnInitialIssuanceOfWarrantLiability" use="optional" order="39" weight="1" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ChangeInFairValueOfConversionOptionLiability" xlink:label="loc_SCLX_ChangeInFairValueOfConversionOptionLiability" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_SCLX_ChangeInFairValueOfConversionOptionLiability" use="optional" order="40" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium" use="optional" order="41" weight="1" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TransactionsCostsAllocatedToPrivateWarrants" xlink:label="loc_SCLX_TransactionsCostsAllocatedToPrivateWarrants" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_SCLX_TransactionsCostsAllocatedToPrivateWarrants" use="optional" order="42" weight="1" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_IncreaseInNotesPayableOne" xlink:label="loc_SCLX_IncreaseInNotesPayableOne" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_SCLX_IncreaseInNotesPayableOne" use="optional" order="43" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_InterestPaidNet" use="optional" order="44" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" use="optional" order="45" weight="-1" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NonCashOperatingLeaseCosts" xlink:label="loc_SCLX_NonCashOperatingLeaseCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_SCLX_NonCashOperatingLeaseCosts" use="optional" order="46" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ShareBasedCompensation" use="optional" order="47" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet" use="optional" order="48" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess" use="optional" order="49" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" use="optional" order="50" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" use="optional" order="51" weight="1" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_FormationCostPaidThroughAdvancesFromAffiliateOfSponsor" xlink:label="loc_SCLX_FormationCostPaidThroughAdvancesFromAffiliateOfSponsor" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_SCLX_FormationCostPaidThroughAdvancesFromAffiliateOfSponsor" use="optional" order="52" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_NetIncomeLoss" use="optional" order="53" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfDeferredTaxAssetsAndLiabilities">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance" use="optional" order="1" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="loc_us-gaap_DeferredTaxAssetsGross" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DeferredTaxAssetsInterestExpenseLimitations" xlink:label="loc_SCLX_DeferredTaxAssetsInterestExpenseLimitations" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_SCLX_DeferredTaxAssetsInterestExpenseLimitations" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="loc_SCLX_DeferredTaxAssetsOperatingLeaseLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_SCLX_DeferredTaxAssetsOperatingLeaseLiabilities" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsOther" use="optional" order="8" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfDeferredTaxAssetsAndLiabilities">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" use="optional" order="11" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/DebtDetailsSummaryOfFutureMinimumPaymentsUnderTheScilexPharmaNotes">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LongtermDebtFutureMinimumPayment" xlink:label="loc_SCLX_LongtermDebtFutureMinimumPayment" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LongtermDebtfutureMinimumPaymentYearOne" xlink:label="loc_SCLX_LongtermDebtfutureMinimumPaymentYearOne" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_SCLX_LongtermDebtFutureMinimumPayment" xlink:to="loc_SCLX_LongtermDebtfutureMinimumPaymentYearOne" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LongtermDebtFutureMinimumPaymentYearTwo" xlink:label="loc_SCLX_LongtermDebtFutureMinimumPaymentYearTwo" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_SCLX_LongtermDebtFutureMinimumPayment" xlink:to="loc_SCLX_LongtermDebtFutureMinimumPaymentYearTwo" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LongtermDebtFutureMinimumPaymentYearThree" xlink:label="loc_SCLX_LongtermDebtFutureMinimumPaymentYearThree" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_SCLX_LongtermDebtFutureMinimumPayment" xlink:to="loc_SCLX_LongtermDebtFutureMinimumPaymentYearThree" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LongtermDebtFutureMinimumPaymentYearFour" xlink:label="loc_SCLX_LongtermDebtFutureMinimumPaymentYearFour" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_SCLX_LongtermDebtFutureMinimumPayment" xlink:to="loc_SCLX_LongtermDebtFutureMinimumPaymentYearFour" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LongtermDebtFutureMinimumPaymentYearFive" xlink:label="loc_SCLX_LongtermDebtFutureMinimumPaymentYearFive" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_SCLX_LongtermDebtFutureMinimumPayment" xlink:to="loc_SCLX_LongtermDebtFutureMinimumPaymentYearFive" use="optional" order="5" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfComponentsOfIncomeTaxExpenseBenefit">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" use="optional" order="6" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfEstimatedFutureAmortizationExpense">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" xlink:label="loc_SCLX_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="loc_SCLX_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" use="optional" order="8" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" use="optional" order="6" weight="1" />
</calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>sclx-20220930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 12-January-2023 [12:41:39] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#CondensedConsolidatedBalanceSheets" roleURI="http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#CondensedConsolidatedBalanceSheetsParentheticals" roleURI="http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheetsParentheticals" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#UnauditedCondensedConsolidatedStatementsOfOperations" roleURI="http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#UnauditedCondensedConsolidatedStatementsOfOperationsParentheticals" roleURI="http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsParentheticals" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit" roleURI="http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#UnauditedCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#DescriptionOfOrganizationAndBusinessOperations" roleURI="http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperations" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPolicies" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#PublicOffering" roleURI="http://www.vickersvantagecorp.com/role/PublicOffering" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#PrivatePlacement" roleURI="http://www.vickersvantagecorp.com/role/PrivatePlacement" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#RelatedPartyTransactions" roleURI="http://www.vickersvantagecorp.com/role/RelatedPartyTransactions" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#FairValueMeasurements" roleURI="http://www.vickersvantagecorp.com/role/FairValueMeasurements" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#Warrants" roleURI="http://www.vickersvantagecorp.com/role/Warrants" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#ShareholdersDeficit" roleURI="http://www.vickersvantagecorp.com/role/ShareholdersDeficit" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#CommitmentsAndContingencies" roleURI="http://www.vickersvantagecorp.com/role/CommitmentsAndContingencies" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#RestatementOfPreviouslyIssuedFinancialStatements" roleURI="http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatements" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#SubsequentEvents" roleURI="http://www.vickersvantagecorp.com/role/SubsequentEvents" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#AccountingPoliciesByPolicyPolicies" roleURI="http://www.vickersvantagecorp.com/role/AccountingPoliciesByPolicyPolicies" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesTables" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#FairValueMeasurementsTables" roleURI="http://www.vickersvantagecorp.com/role/FairValueMeasurementsTables" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#RestatementOfPreviouslyIssuedFinancialStatementsTables" roleURI="http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsTables" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#DescriptionOfOrganizationAndBusinessOperationsDetails" roleURI="http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#SummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#SummaryOfSignificantAccountingPoliciesDetailsScheduleOfOrdinarySharesReflectedInCondensedConsolidatedBalanceSheetsAreReconciled" roleURI="http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfOrdinarySharesReflectedInCondensedConsolidatedBalanceSheetsAreReconciled" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#SummaryOfSignificantAccountingPoliciesDetailsScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShare" roleURI="http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShare" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#SummaryOfSignificantAccountingPoliciesDetailsScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareParentheticals" roleURI="http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareParentheticals" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#LiquidityAndGoingConcernDetails" roleURI="http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#PublicOfferingDetails" roleURI="http://www.vickersvantagecorp.com/role/PublicOfferingDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#PrivatePlacementDetails" roleURI="http://www.vickersvantagecorp.com/role/PrivatePlacementDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#RelatedPartyTransactionsDetails" roleURI="http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#CommitmentsAndContingenciesDetails" roleURI="http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#ShareholdersDeficitDetails" roleURI="http://www.vickersvantagecorp.com/role/ShareholdersDeficitDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#WarrantsDetails" roleURI="http://www.vickersvantagecorp.com/role/WarrantsDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#FairValueMeasurementsDetails" roleURI="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#FairValueMeasurementsDetailsScheduleOfFairValueHierarchyOfTheValuationInputs" roleURI="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfFairValueHierarchyOfTheValuationInputs" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#FairValueMeasurementsDetailsScheduleOfChangesInTheFairValueOfWarrantLiabilitiesAndConversionOptionLiability" roleURI="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfChangesInTheFairValueOfWarrantLiabilitiesAndConversionOptionLiability" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#FairValueMeasurementsDetailsScheduleOfValuedUsingTheCompoundOptionPricingModel" roleURI="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfValuedUsingTheCompoundOptionPricingModel" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#FairValueMeasurementsDetailsFinancialAssetsAndLiabilitiesThatAreMeasuredAtFairValue" roleURI="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsFinancialAssetsAndLiabilitiesThatAreMeasuredAtFairValue" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#FairValueMeasurementsDetailsDerivativeLiabilitiesMeasuredAtFairValueUsingSignificantUnobservableInputs" roleURI="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsDerivativeLiabilitiesMeasuredAtFairValueUsingSignificantUnobservableInputs" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#FairValueMeasurementsDetailsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurements" roleURI="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurements" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#FairValueMeasurementsDetailsScheduleOfChangeInTheFairValueOfConversionOptionLiability" roleURI="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfChangeInTheFairValueOfConversionOptionLiability" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#PropertyAndEquipmentDetailsPropertyAndEquipmentConsisted" roleURI="http://www.vickersvantagecorp.com/role/PropertyAndEquipmentDetailsPropertyAndEquipmentConsisted" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#GoodwillAndIntangibleAssetsDetailsSummaryOfTheCompanysIdentifiableIntangibleAssets" roleURI="http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfTheCompanysIdentifiableIntangibleAssets" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#GoodwillAndIntangibleAssetsDetails" roleURI="http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#DebtDetails" roleURI="http://www.vickersvantagecorp.com/role/DebtDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#DebtDetailsSummaryOfBorrowingsOfTheScilexPharmaNotes" roleURI="http://www.vickersvantagecorp.com/role/DebtDetailsSummaryOfBorrowingsOfTheScilexPharmaNotes" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#DebtDetailsSummaryOfFutureMinimumPaymentsUnderTheScilexPharmaNotes" roleURI="http://www.vickersvantagecorp.com/role/DebtDetailsSummaryOfFutureMinimumPaymentsUnderTheScilexPharmaNotes" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#StockIncentiveAndEmployeeBenefitPlansDetails" roleURI="http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfShareBasedPaymentAwardOptionsIssuedToEmployeesAndNonemployeesValuationAssumptions" roleURI="http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfShareBasedPaymentAwardOptionsIssuedToEmployeesAndNonemployeesValuationAssumptions" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#AcquisitionsDetails" roleURI="http://www.vickersvantagecorp.com/role/AcquisitionsDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#RestatementOfPreviouslyIssuedFinancialStatementsDetails" roleURI="http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#RestatementOfPreviouslyIssuedFinancialStatementsDetailsScheduleOfImpactOfTheseAdjustmentsToTheFinancialStatementAsPreviouslyReported" roleURI="http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsDetailsScheduleOfImpactOfTheseAdjustmentsToTheFinancialStatementAsPreviouslyReported" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#IncomeTaxesDetails" roleURI="http://www.vickersvantagecorp.com/role/IncomeTaxesDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#SubsequentEventsDetails" roleURI="http://www.vickersvantagecorp.com/role/SubsequentEventsDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#CoverPage" roleURI="http://www.vickersvantagecorp.com/role/CoverPage" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#StockIncentiveAndEmployeeBenefitPlans" roleURI="http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlans" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#StockIncentiveAndEmployeeBenefitPlansTables" roleURI="http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansTables" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#LiquidityAndGoingConcern" roleURI="http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcern" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#GoodwillAndIntangibleAssets" roleURI="http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssets" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#GoodwillAndIntangibleAssetsTables" roleURI="http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsTables" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#GoodwillAndIntangibleAssetsDetailsSummaryOfEstimatedFutureAmortizationExpense" roleURI="http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfEstimatedFutureAmortizationExpense" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#LossPerShare" roleURI="http://www.vickersvantagecorp.com/role/LossPerShare" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#LossPerShareTables" roleURI="http://www.vickersvantagecorp.com/role/LossPerShareTables" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#LossPerShareDetailsSummaryOfReconciliationOfBasicAndDilutedLossPerShare" roleURI="http://www.vickersvantagecorp.com/role/LossPerShareDetailsSummaryOfReconciliationOfBasicAndDilutedLossPerShare" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#LossPerShareDetails" roleURI="http://www.vickersvantagecorp.com/role/LossPerShareDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfTheOptionsOutstanding" roleURI="http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfTheOptionsOutstanding" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#Acquisitions" roleURI="http://www.vickersvantagecorp.com/role/Acquisitions" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#PropertyAndEquipment" roleURI="http://www.vickersvantagecorp.com/role/PropertyAndEquipment" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#PropertyAndEquipmentTables" roleURI="http://www.vickersvantagecorp.com/role/PropertyAndEquipmentTables" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#PropertyAndEquipmentDetails" roleURI="http://www.vickersvantagecorp.com/role/PropertyAndEquipmentDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#CommitmentsAndContingenciesTables" roleURI="http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesTables" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#CommitmentsAndContingenciesSummaryOfComponentsOfLeaseExpenseDetail" roleURI="http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesSummaryOfComponentsOfLeaseExpenseDetail" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#CommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetail" roleURI="http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#CommitmentsAndContingenciesSummaryOfSupplementalQuantitativeInformationRelatedToLeasesDetail" roleURI="http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesSummaryOfSupplementalQuantitativeInformationRelatedToLeasesDetail" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#IncomeTaxes" roleURI="http://www.vickersvantagecorp.com/role/IncomeTaxes" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#Debt" roleURI="http://www.vickersvantagecorp.com/role/Debt" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#IncomeTaxesTables" roleURI="http://www.vickersvantagecorp.com/role/IncomeTaxesTables" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#IncomeTaxesDetailsScheduleOfComponentsOfIncomeTaxExpenseBenefit" roleURI="http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfComponentsOfIncomeTaxExpenseBenefit" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#IncomeTaxesDetailsScheduleOfDeferredTaxAssetsAndLiabilities" roleURI="http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfDeferredTaxAssetsAndLiabilities" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#IncomeTaxesDetailsScheduleOfEffectiveIncomeTaxRateReconciliation" roleURI="http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfEffectiveIncomeTaxRateReconciliation" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#DebtTables" roleURI="http://www.vickersvantagecorp.com/role/DebtTables" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" />
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2146635010" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_41" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635010" xlink:to="loc_us-gaap_Assets_41" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_34" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635010" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_34" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_35" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_34" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_35" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_42" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_35" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_42" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_43" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_35" xlink:to="loc_us-gaap_LiabilitiesCurrent_43" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_2146635268" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_35" xlink:to="loc_us-gaap_AccountsPayableCurrent_2146635268" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AccruedPayroll" xlink:label="loc_sclx_AccruedPayroll_2146635274" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_35" xlink:to="loc_sclx_AccruedPayroll_2146635274" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_2146635277" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_35" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_2146635277" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_2146635280" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_35" xlink:to="loc_us-gaap_LongTermDebtCurrent_2146635280" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_2146635284" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_35" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_2146635284" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_RelatedPartyNotePayableCurrent" xlink:label="loc_sclx_RelatedPartyNotePayableCurrent_2146635287" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_35" xlink:to="loc_sclx_RelatedPartyNotePayableCurrent_2146635287" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_2146635288" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_35" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_2146635288" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_2146635615" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_35" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_2146635615" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AdvancesFromRelatedParty" xlink:label="loc_sclx_AdvancesFromRelatedParty_2146635619" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_35" xlink:to="loc_sclx_AdvancesFromRelatedParty_2146635619" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:label="loc_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent_2146635621" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_35" xlink:to="loc_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent_2146635621" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_2146635886" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_35" xlink:to="loc_us-gaap_DeferredRevenueCurrent_2146635886" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable_44" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_34" xlink:to="loc_us-gaap_ConvertibleLongTermNotesPayable_44" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_45" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_34" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_45" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLongTermNotesPayable" xlink:label="loc_us-gaap_OtherLongTermNotesPayable_46" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_34" xlink:to="loc_us-gaap_OtherLongTermNotesPayable_46" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent" xlink:label="loc_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent_47" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_34" xlink:to="loc_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent_47" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_48" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_34" xlink:to="loc_us-gaap_DerivativeLiabilities_48" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:label="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_49" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_34" xlink:to="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_49" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_2146635294" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_34" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_2146635294" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DerivativeLiabilityNoncurrent" xlink:label="loc_sclx_DerivativeLiabilityNoncurrent_2146635299" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_34" xlink:to="loc_sclx_DerivativeLiabilityNoncurrent_2146635299" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2146635300" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_34" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2146635300" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_2146635887" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_34" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_2146635887" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_RelatedPartyNotePayableNoncurrent" xlink:label="loc_sclx_RelatedPartyNotePayableNoncurrent_2146635295" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_34" xlink:to="loc_sclx_RelatedPartyNotePayableNoncurrent_2146635295" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_32" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635010" xlink:to="loc_us-gaap_AssetsAbstract_32" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsHeldInTrustNoncurrent" xlink:label="loc_us-gaap_AssetsHeldInTrustNoncurrent_40" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_32" xlink:to="loc_us-gaap_AssetsHeldInTrustNoncurrent_40" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_33" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_32" xlink:to="loc_us-gaap_AssetsCurrentAbstract_33" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_37" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_33" xlink:to="loc_us-gaap_Cash_37" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_38" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_33" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_38" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_39" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_33" xlink:to="loc_us-gaap_AssetsCurrent_39" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2146635253" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_33" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2146635253" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_2146635255" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_33" xlink:to="loc_us-gaap_InventoryNet_2146635255" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_2146635260" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_33" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_2146635260" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2146635263" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_32" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_2146635263" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_2146635264" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_32" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_2146635264" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_2146635265" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_32" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_2146635265" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_2146635266" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_32" xlink:to="loc_us-gaap_Goodwill_2146635266" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments_2146635267" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_32" xlink:to="loc_us-gaap_LongTermInvestments_2146635267" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCosts" xlink:label="loc_us-gaap_DeferredCosts_2146635611" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_32" xlink:to="loc_us-gaap_DeferredCosts_2146635611" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_36" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635010" xlink:to="loc_us-gaap_StockholdersEquityAbstract_36" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_53" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_36" xlink:to="loc_us-gaap_PreferredStockValue_53" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_54" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_36" xlink:to="loc_us-gaap_CommonStockValue_54" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_55" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_36" xlink:to="loc_us-gaap_AdditionalPaidInCapital_55" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_56" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_36" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_56" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_50" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635010" xlink:to="loc_us-gaap_Liabilities_50" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_51" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635010" xlink:to="loc_us-gaap_CommitmentsAndContingencies_51" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_52" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635010" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_52" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_57" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635010" xlink:to="loc_us-gaap_StockholdersEquity_57" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_58" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635010" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_58" use="optional" order="52" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_2146635007" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_2146635010" xlink:to="loc_us-gaap_StatementTable_2146635007" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="53" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635012" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2146635007" xlink:to="loc_dei_LegalEntityAxis_2146635012" use="optional" order="54" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635013" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2146635012" xlink:to="loc_dei_EntityDomain_2146635013" use="optional" order="55" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635013_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2146635012" xlink:to="loc_dei_EntityDomain_2146635013_default" use="optional" order="56" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635014" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146635013" xlink:to="loc_sclx_VickersVantageMember_2146635014" use="optional" order="57" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheetsParentheticals">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2146635028" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_81" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635028" xlink:to="loc_us-gaap_CommonStockSharesIssued_81" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_82" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635028" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_82" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_2146635025" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_2146635028" xlink:to="loc_us-gaap_StatementTable_2146635025" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635031" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2146635025" xlink:to="loc_dei_LegalEntityAxis_2146635031" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635032" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2146635031" xlink:to="loc_dei_EntityDomain_2146635032" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635032_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2146635031" xlink:to="loc_dei_EntityDomain_2146635032_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635033" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146635032" xlink:to="loc_sclx_VickersVantageMember_2146635033" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2146635316" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2146635025" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2146635316" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2146635317" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2146635316" xlink:to="loc_us-gaap_ClassOfStockDomain_2146635317" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2146635317_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2146635316" xlink:to="loc_us-gaap_ClassOfStockDomain_2146635317_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_2146635318" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_2146635317" xlink:to="loc_us-gaap_CommonClassAMember_2146635318" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_2146637179" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2146635025" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_2146637179" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2146637180" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2146637179" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2146637180" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2146637180_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2146637179" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2146637180_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_2146637181" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2146637180" xlink:to="loc_us-gaap_OverAllotmentOptionMember_2146637181" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_OrdinarySharesSubjectToPossibleRedemption" xlink:label="loc_sclx_OrdinarySharesSubjectToPossibleRedemption_73" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635028" xlink:to="loc_sclx_OrdinarySharesSubjectToPossibleRedemption_73" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityRedemptionPricePerShare" xlink:label="loc_us-gaap_TemporaryEquityRedemptionPricePerShare_74" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635028" xlink:to="loc_us-gaap_TemporaryEquityRedemptionPricePerShare_74" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_75" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635028" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_75" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_76" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635028" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_76" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_77" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635028" xlink:to="loc_us-gaap_PreferredStockSharesIssued_77" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_78" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635028" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_78" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_79" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635028" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_79" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_80" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635028" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_80" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SubjectToPossibleRedemptionPerShares" xlink:label="loc_sclx_SubjectToPossibleRedemptionPerShares_2146635676" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635028" xlink:to="loc_sclx_SubjectToPossibleRedemptionPerShares_2146635676" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_OrdinarySharesRedemptionSubjectedToForfeiture" xlink:label="loc_sclx_OrdinarySharesRedemptionSubjectedToForfeiture_2146637178" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635028" xlink:to="loc_sclx_OrdinarySharesRedemptionSubjectedToForfeiture_2146637178" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SharesCapitalization" xlink:label="loc_sclx_SharesCapitalization_2146637182" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635028" xlink:to="loc_sclx_SharesCapitalization_2146637182" use="optional" order="26" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2146635039" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_113" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635039" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_113" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_114" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635039" xlink:to="loc_us-gaap_EarningsPerShareBasic_114" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_103" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635039" xlink:to="loc_us-gaap_OperatingIncomeLoss_103" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAbstract" xlink:label="loc_us-gaap_OtherIncomeAbstract_102" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635039" xlink:to="loc_us-gaap_OtherIncomeAbstract_102" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_104" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAbstract_102" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_104" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfDerivatives" xlink:label="loc_us-gaap_GainLossOnSaleOfDerivatives_105" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAbstract_102" xlink:to="loc_us-gaap_GainLossOnSaleOfDerivatives_105" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TransactionCostsAllocatedToWarrantLiabilities" xlink:label="loc_sclx_TransactionCostsAllocatedToWarrantLiabilities_106" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAbstract_102" xlink:to="loc_sclx_TransactionCostsAllocatedToWarrantLiabilities_106" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:label="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_107" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAbstract_102" xlink:to="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_107" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DistributionsOnMandatorilyRedeemableSecurities" xlink:label="loc_us-gaap_DistributionsOnMandatorilyRedeemableSecurities_108" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAbstract_102" xlink:to="loc_us-gaap_DistributionsOnMandatorilyRedeemableSecurities_108" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_109" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAbstract_102" xlink:to="loc_us-gaap_InterestExpense_109" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaap_InterestIncomeOther_110" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAbstract_102" xlink:to="loc_us-gaap_InterestIncomeOther_110" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScilexPharmaNotesPrincipalIncrease" xlink:label="loc_sclx_ScilexPharmaNotesPrincipalIncrease_2146635369" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAbstract_102" xlink:to="loc_sclx_ScilexPharmaNotesPrincipalIncrease_2146635369" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_2146635371" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAbstract_102" xlink:to="loc_us-gaap_InvestmentIncomeInterest_2146635371" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_2146635372" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAbstract_102" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_2146635372" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ChangeInFairValueOfWarrantLiability" xlink:label="loc_sclx_ChangeInFairValueOfWarrantLiability_2146635688" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAbstract_102" xlink:to="loc_sclx_ChangeInFairValueOfWarrantLiability_2146635688" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_GainLossOnDerivative" xlink:label="loc_sclx_GainLossOnDerivative_2146635366" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAbstract_102" xlink:to="loc_sclx_GainLossOnDerivative_2146635366" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_GainLossOnExtinguishmentOfDebtt" xlink:label="loc_sclx_GainLossOnExtinguishmentOfDebtt_2146635367" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAbstract_102" xlink:to="loc_sclx_GainLossOnExtinguishmentOfDebtt_2146635367" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_111" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635039" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_111" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_112" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635039" xlink:to="loc_us-gaap_NetIncomeLoss_112" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_2146635036" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_2146635039" xlink:to="loc_us-gaap_StatementTable_2146635036" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635042" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2146635036" xlink:to="loc_dei_LegalEntityAxis_2146635042" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635043" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2146635042" xlink:to="loc_dei_EntityDomain_2146635043" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635043_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2146635042" xlink:to="loc_dei_EntityDomain_2146635043_default" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635044" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146635043" xlink:to="loc_sclx_VickersVantageMember_2146635044" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_2146635331" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635039" xlink:to="loc_us-gaap_Revenues_2146635331" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingCostsAndExpensesAbstract" xlink:label="loc_us-gaap_OperatingCostsAndExpensesAbstract_2146635335" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635039" xlink:to="loc_us-gaap_OperatingCostsAndExpensesAbstract_2146635335" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue_2146635336" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_2146635335" xlink:to="loc_us-gaap_CostOfRevenue_2146635336" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_2146635337" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_2146635335" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_2146635337" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AcquiredinprocessresearchAndDevelopment" xlink:label="loc_sclx_AcquiredinprocessresearchAndDevelopment_2146635338" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_2146635335" xlink:to="loc_sclx_AcquiredinprocessresearchAndDevelopment_2146635338" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_2146635339" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_2146635335" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_2146635339" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_2146635340" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_2146635335" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_2146635340" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="loc_us-gaap_OperatingCostsAndExpenses_2146635341" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_2146635335" xlink:to="loc_us-gaap_OperatingCostsAndExpenses_2146635341" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2146635344" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635039" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2146635344" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_2146635345" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635039" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_2146635345" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_2146635350" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635039" xlink:to="loc_us-gaap_EarningsPerShareDiluted_2146635350" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2146635352" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635039" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2146635352" use="optional" order="36" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsParentheticals">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2146635051" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_OrdinarySharesRedemptionSubjectedToForfeiture" xlink:label="loc_sclx_OrdinarySharesRedemptionSubjectedToForfeiture_2146637241" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635051" xlink:to="loc_sclx_OrdinarySharesRedemptionSubjectedToForfeiture_2146637241" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_121" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635051" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_121" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_122" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635051" xlink:to="loc_us-gaap_EarningsPerShareDiluted_122" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_2146635048" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_2146635051" xlink:to="loc_us-gaap_StatementTable_2146635048" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635054" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2146635048" xlink:to="loc_dei_LegalEntityAxis_2146635054" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635055" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2146635054" xlink:to="loc_dei_EntityDomain_2146635055" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635055_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2146635054" xlink:to="loc_dei_EntityDomain_2146635055_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635056" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146635055" xlink:to="loc_sclx_VickersVantageMember_2146635056" use="optional" order="8" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_143" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_141" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_143" xlink:to="loc_us-gaap_StatementTable_141" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_142" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_141" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_142" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_147" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_142" xlink:to="loc_us-gaap_EquityComponentDomain_147" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_147_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_142" xlink:to="loc_us-gaap_EquityComponentDomain_147_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_144" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_147" xlink:to="loc_us-gaap_CommonStockMember_144" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_145" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_147" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_145" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_146" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_147" xlink:to="loc_us-gaap_RetainedEarningsMember_146" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635061" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_141" xlink:to="loc_dei_LegalEntityAxis_2146635061" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635062" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2146635061" xlink:to="loc_dei_EntityDomain_2146635062" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635062_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2146635061" xlink:to="loc_dei_EntityDomain_2146635062_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635063" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146635062" xlink:to="loc_sclx_VickersVantageMember_2146635063" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_148" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_143" xlink:to="loc_us-gaap_StockholdersEquity_148" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_149" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_143" xlink:to="loc_us-gaap_SharesOutstanding_149" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetSharesReclassifiedToMandatorilyRedeemableCapitalStockValue" xlink:label="loc_us-gaap_NetSharesReclassifiedToMandatorilyRedeemableCapitalStockValue_150" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_143" xlink:to="loc_us-gaap_NetSharesReclassifiedToMandatorilyRedeemableCapitalStockValue_150" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodValue" xlink:label="loc_us-gaap_StockRedeemedOrCalledDuringPeriodValue_151" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_143" xlink:to="loc_us-gaap_StockRedeemedOrCalledDuringPeriodValue_151" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_152" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_143" xlink:to="loc_us-gaap_NetIncomeLoss_152" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_2146635387" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_143" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_2146635387" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_2146635637" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_143" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_2146635637" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_2146635647" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_143" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_2146635647" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_2146635648" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_143" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_2146635648" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AdjustmentsToAdditionalPaidInCapitalNetOfDiscount" xlink:label="loc_sclx_AdjustmentsToAdditionalPaidInCapitalNetOfDiscount_2146635931" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_143" xlink:to="loc_sclx_AdjustmentsToAdditionalPaidInCapitalNetOfDiscount_2146635931" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AdjustmentsToAdditionalPaidInCapitalDiscountAmortization" xlink:label="loc_sclx_AdjustmentsToAdditionalPaidInCapitalDiscountAmortization_2146635942" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_143" xlink:to="loc_sclx_AdjustmentsToAdditionalPaidInCapitalDiscountAmortization_2146635942" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_2146635388" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_143" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_2146635388" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_2146635390" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_143" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_2146635390" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2146635391" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_143" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2146635391" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_2146635392" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_143" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_2146635392" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2146635394" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_143" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2146635394" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2146635395" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_143" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2146635395" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_2146635397" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_143" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_2146635397" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AdjustmentsToAdditionalPaidInCapitalSharesIssuedInSemnurAcquisition" xlink:label="loc_sclx_AdjustmentsToAdditionalPaidInCapitalSharesIssuedInSemnurAcquisition_2146635398" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_143" xlink:to="loc_sclx_AdjustmentsToAdditionalPaidInCapitalSharesIssuedInSemnurAcquisition_2146635398" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_2146635635" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_143" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_2146635635" use="optional" order="31" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2146635069" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_193" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635069" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_193" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_203" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_193" xlink:to="loc_us-gaap_NetIncomeLoss_203" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_212" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_193" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_212" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_194" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_193" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_194" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_195" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_194" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_195" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_211" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_195" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_211" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_196" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_195" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_196" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_2146635642" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_195" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_2146635642" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2146635645" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_195" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2146635645" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:label="loc_us-gaap_IncreaseDecreaseInSecurityDeposits_2146635646" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_195" xlink:to="loc_us-gaap_IncreaseDecreaseInSecurityDeposits_2146635646" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_2146635671" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_195" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_2146635671" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_2146635674" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_195" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_2146635674" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_2146635675" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_195" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_2146635675" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_2146635678" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_195" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_2146635678" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:label="loc_us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_2146635684" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_195" xlink:to="loc_us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_2146635684" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2146635840" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_195" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2146635840" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndDividendIncomeSecuritiesHeldToMaturity" xlink:label="loc_us-gaap_InterestAndDividendIncomeSecuritiesHeldToMaturity_204" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_194" xlink:to="loc_us-gaap_InterestAndDividendIncomeSecuritiesHeldToMaturity_204" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DistributionsOnMandatorilyRedeemableSecurities" xlink:label="loc_us-gaap_DistributionsOnMandatorilyRedeemableSecurities_205" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_194" xlink:to="loc_us-gaap_DistributionsOnMandatorilyRedeemableSecurities_205" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_206" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_194" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_206" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LossOnInitialIssuanceOfWarrantLiability" xlink:label="loc_sclx_LossOnInitialIssuanceOfWarrantLiability_207" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_194" xlink:to="loc_sclx_LossOnInitialIssuanceOfWarrantLiability_207" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ChangeInFairValueOfConversionOptionLiability" xlink:label="loc_sclx_ChangeInFairValueOfConversionOptionLiability_208" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_194" xlink:to="loc_sclx_ChangeInFairValueOfConversionOptionLiability_208" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_209" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_194" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_209" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TransactionsCostsAllocatedToPrivateWarrants" xlink:label="loc_sclx_TransactionsCostsAllocatedToPrivateWarrants_210" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_194" xlink:to="loc_sclx_TransactionsCostsAllocatedToPrivateWarrants_210" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_IncreaseInNotesPayableOne" xlink:label="loc_sclx_IncreaseInNotesPayableOne_2146635581" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_194" xlink:to="loc_sclx_IncreaseInNotesPayableOne_2146635581" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_2146635594" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_194" xlink:to="loc_us-gaap_InterestPaidNet_2146635594" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_2146635601" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_194" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_2146635601" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NonCashOperatingLeaseCosts" xlink:label="loc_sclx_NonCashOperatingLeaseCosts_2146635610" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_194" xlink:to="loc_sclx_NonCashOperatingLeaseCosts_2146635610" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_2146635613" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_194" xlink:to="loc_us-gaap_ShareBasedCompensation_2146635613" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_2146635616" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_194" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_2146635616" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_2146635618" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_194" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_2146635618" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_2146635627" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_194" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_2146635627" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_2146635628" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_194" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_2146635628" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_FormationCostPaidThroughAdvancesFromAffiliateOfSponsor" xlink:label="loc_sclx_FormationCostPaidThroughAdvancesFromAffiliateOfSponsor_2146635719" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_194" xlink:to="loc_sclx_FormationCostPaidThroughAdvancesFromAffiliateOfSponsor_2146635719" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_197" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635069" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_197" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_InvestmentOfCashInTrustAccounts" xlink:label="loc_sclx_InvestmentOfCashInTrustAccounts_213" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_197" xlink:to="loc_sclx_InvestmentOfCashInTrustAccounts_213" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDecommissioningFund" xlink:label="loc_us-gaap_ProceedsFromDecommissioningFund_198" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_197" xlink:to="loc_us-gaap_ProceedsFromDecommissioningFund_198" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_214" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_197" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_214" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2146635708" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_197" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2146635708" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_2146635893" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_197" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_2146635893" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_2146635853" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_197" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_2146635853" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_199" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635069" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_199" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_222" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_199" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_222" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfOtherEquity" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfOtherEquity_200" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_199" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfOtherEquity_200" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_215" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_199" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_215" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_216" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_199" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_216" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt_217" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_199" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt_217" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt_218" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_199" xlink:to="loc_us-gaap_RepaymentsOfRelatedPartyDebt_218" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_219" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_199" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_219" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ProceedsFromSimplePromissoryNoteRelatedParty" xlink:label="loc_sclx_ProceedsFromSimplePromissoryNoteRelatedParty_220" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_199" xlink:to="loc_sclx_ProceedsFromSimplePromissoryNoteRelatedParty_220" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_RepaymentOfPromissoryNoteRelatedParty" xlink:label="loc_sclx_RepaymentOfPromissoryNoteRelatedParty_221" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_199" xlink:to="loc_sclx_RepaymentOfPromissoryNoteRelatedParty_221" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_223" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_199" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_223" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfMediumTermNotes" xlink:label="loc_us-gaap_RepaymentsOfMediumTermNotes_2146635819" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_199" xlink:to="loc_us-gaap_RepaymentsOfMediumTermNotes_2146635819" use="optional" order="52" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfSeniorDebt" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt_2146635710" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_199" xlink:to="loc_us-gaap_RepaymentsOfSeniorDebt_2146635710" use="optional" order="53" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfOtherLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfOtherLongTermDebt_2146635713" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_199" xlink:to="loc_us-gaap_RepaymentsOfOtherLongTermDebt_2146635713" use="optional" order="54" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ProceedsFromPromissoryNoteRelatedParty" xlink:label="loc_sclx_ProceedsFromPromissoryNoteRelatedParty_2146635742" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_199" xlink:to="loc_sclx_ProceedsFromPromissoryNoteRelatedParty_2146635742" use="optional" order="55" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt_2146635746" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_199" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt_2146635746" use="optional" order="56" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_2146635796" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_199" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_2146635796" use="optional" order="57" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfMediumTermNotes" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfMediumTermNotes_2146635811" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_199" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfMediumTermNotes_2146635811" use="optional" order="58" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_201" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635069" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_201" use="optional" order="59" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_224" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635069" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_224" use="optional" order="60" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_202" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635069" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_202" use="optional" order="61" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DeferredUnderwritingFeePayable" xlink:label="loc_sclx_DeferredUnderwritingFeePayable_226" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_202" xlink:to="loc_sclx_DeferredUnderwritingFeePayable_226" use="optional" order="62" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_OfferingCostIncludedInAccruedOfferingCost" xlink:label="loc_sclx_OfferingCostIncludedInAccruedOfferingCost_2146635732" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_202" xlink:to="loc_sclx_OfferingCostIncludedInAccruedOfferingCost_2146635732" use="optional" order="63" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesIssued1" xlink:label="loc_us-gaap_NotesIssued1_2146635734" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_202" xlink:to="loc_us-gaap_NotesIssued1_2146635734" use="optional" order="64" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_2146635864" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_202" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_2146635864" use="optional" order="65" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1" xlink:label="loc_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1_2146635869" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_202" xlink:to="loc_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1_2146635869" use="optional" order="66" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_OtherLoanForgiveness" xlink:label="loc_sclx_OtherLoanForgiveness_2146635873" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_202" xlink:to="loc_sclx_OtherLoanForgiveness_2146635873" use="optional" order="67" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PromissoryNoteIssuedNetOfDiscount" xlink:label="loc_sclx_PromissoryNoteIssuedNetOfDiscount_2146635877" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_202" xlink:to="loc_sclx_PromissoryNoteIssuedNetOfDiscount_2146635877" use="optional" order="68" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NonCashFairValueAdjustmentToDerivativeLiability" xlink:label="loc_sclx_NonCashFairValueAdjustmentToDerivativeLiability_2146635878" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_202" xlink:to="loc_sclx_NonCashFairValueAdjustmentToDerivativeLiability_2146635878" use="optional" order="69" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NonCashRightOfUseAsset" xlink:label="loc_sclx_NonCashRightOfUseAsset_2146635880" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_202" xlink:to="loc_sclx_NonCashRightOfUseAsset_2146635880" use="optional" order="70" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AcquistionCostsIncurredButNotPaidIncludedInAccountsPayable" xlink:label="loc_sclx_AcquistionCostsIncurredButNotPaidIncludedInAccountsPayable_2146635900" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_202" xlink:to="loc_sclx_AcquistionCostsIncurredButNotPaidIncludedInAccountsPayable_2146635900" use="optional" order="71" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NonCashDistributionToAcquiree" xlink:label="loc_sclx_NonCashDistributionToAcquiree_2146635904" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_202" xlink:to="loc_sclx_NonCashDistributionToAcquiree_2146635904" use="optional" order="72" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NonCashIncreaseInPrincipal" xlink:label="loc_sclx_NonCashIncreaseInPrincipal_2146635907" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_202" xlink:to="loc_sclx_NonCashIncreaseInPrincipal_2146635907" use="optional" order="73" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_2146635066" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_2146635069" xlink:to="loc_us-gaap_StatementTable_2146635066" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="74" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635072" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2146635066" xlink:to="loc_dei_LegalEntityAxis_2146635072" use="optional" order="75" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635073" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2146635072" xlink:to="loc_dei_EntityDomain_2146635073" use="optional" order="76" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635073_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2146635072" xlink:to="loc_dei_EntityDomain_2146635073_default" use="optional" order="77" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635074" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146635073" xlink:to="loc_sclx_VickersVantageMember_2146635074" use="optional" order="78" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_2146635910" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635069" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_2146635910" use="optional" order="79" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2146635911" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_2146635910" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2146635911" use="optional" order="80" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_2146635913" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_2146635910" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_2146635913" use="optional" order="81" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperations">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DescriptionOfOrganizationAndBusinessOperationsLineItems" xlink:label="loc_sclx_DescriptionOfOrganizationAndBusinessOperationsLineItems_235" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DescriptionofOrganizationandBusinessOperationsTable" xlink:label="loc_sclx_DescriptionofOrganizationandBusinessOperationsTable_234" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sclx_DescriptionOfOrganizationAndBusinessOperationsLineItems_235" xlink:to="loc_sclx_DescriptionofOrganizationandBusinessOperationsTable_234" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635117" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsTable_234" xlink:to="loc_dei_LegalEntityAxis_2146635117" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635118" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2146635117" xlink:to="loc_dei_EntityDomain_2146635118" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635118_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2146635117" xlink:to="loc_dei_EntityDomain_2146635118_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635119" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146635118" xlink:to="loc_sclx_VickersVantageMember_2146635119" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_236" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionOfOrganizationAndBusinessOperationsLineItems_235" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_236" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPolicies">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:label="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635077" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_242" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635077" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_242" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:label="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_2146635076" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635077" xlink:to="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_2146635076" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635078" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_2146635076" xlink:to="loc_dei_LegalEntityAxis_2146635078" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635079" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2146635078" xlink:to="loc_dei_EntityDomain_2146635079" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635079_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2146635078" xlink:to="loc_dei_EntityDomain_2146635079_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635080" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146635079" xlink:to="loc_sclx_VickersVantageMember_2146635080" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/PublicOffering">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PublicOfferingDetailsLineItems" xlink:label="loc_sclx_PublicOfferingDetailsLineItems_2146634968" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PublicOfferingDetailsTable" xlink:label="loc_sclx_PublicOfferingDetailsTable_2146634966" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sclx_PublicOfferingDetailsLineItems_2146634968" xlink:to="loc_sclx_PublicOfferingDetailsTable_2146634966" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146634972" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_PublicOfferingDetailsTable_2146634966" xlink:to="loc_dei_LegalEntityAxis_2146634972" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146634973" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2146634972" xlink:to="loc_dei_EntityDomain_2146634973" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146634973_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2146634972" xlink:to="loc_dei_EntityDomain_2146634973_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146634975" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146634973" xlink:to="loc_sclx_VickersVantageMember_2146634975" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ProposedPublicOfferingTextBlock" xlink:label="loc_sclx_ProposedPublicOfferingTextBlock_248" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_PublicOfferingDetailsLineItems_2146634968" xlink:to="loc_sclx_ProposedPublicOfferingTextBlock_248" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/PrivatePlacement">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PrivatePlacementDetailsLineItems" xlink:label="loc_sclx_PrivatePlacementDetailsLineItems_2146635095" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PrivatePlacementTextBlock" xlink:label="loc_sclx_PrivatePlacementTextBlock_254" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_PrivatePlacementDetailsLineItems_2146635095" xlink:to="loc_sclx_PrivatePlacementTextBlock_254" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PrivatePlacementDetailsTable" xlink:label="loc_sclx_PrivatePlacementDetailsTable_2146635094" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sclx_PrivatePlacementDetailsLineItems_2146635095" xlink:to="loc_sclx_PrivatePlacementDetailsTable_2146635094" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635096" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_PrivatePlacementDetailsTable_2146635094" xlink:to="loc_dei_LegalEntityAxis_2146635096" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635097" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2146635096" xlink:to="loc_dei_EntityDomain_2146635097" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635097_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2146635096" xlink:to="loc_dei_EntityDomain_2146635097_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635098" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146635097" xlink:to="loc_sclx_VickersVantageMember_2146635098" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/RelatedPartyTransactions">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_RelatedPartyTransactionsDetailsLineItems" xlink:label="loc_sclx_RelatedPartyTransactionsDetailsLineItems_2146634967" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_260" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_2146634967" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_260" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_RelatedPartyTransactionsDetailsTable" xlink:label="loc_sclx_RelatedPartyTransactionsDetailsTable_2146634965" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_2146634967" xlink:to="loc_sclx_RelatedPartyTransactionsDetailsTable_2146634965" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146634969" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsTable_2146634965" xlink:to="loc_dei_LegalEntityAxis_2146634969" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146634970" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2146634969" xlink:to="loc_dei_EntityDomain_2146634970" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146634970_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2146634969" xlink:to="loc_dei_EntityDomain_2146634970_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146634971" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146634970" xlink:to="loc_sclx_VickersVantageMember_2146634971" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/FairValueMeasurements">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2146635166" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_288" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635166" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_288" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_2146635163" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_2146635166" xlink:to="loc_us-gaap_StatementTable_2146635163" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2146635164" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2146635163" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2146635164" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2146635165" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2146635164" xlink:to="loc_us-gaap_ClassOfStockDomain_2146635165" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2146635165_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2146635164" xlink:to="loc_us-gaap_ClassOfStockDomain_2146635165_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635167" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2146635163" xlink:to="loc_dei_LegalEntityAxis_2146635167" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635168" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2146635167" xlink:to="loc_dei_EntityDomain_2146635168" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635168_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2146635167" xlink:to="loc_dei_EntityDomain_2146635168_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635169" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146635168" xlink:to="loc_sclx_VickersVantageMember_2146635169" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/Warrants">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_WarrantsLineItems" xlink:label="loc_sclx_WarrantsLineItems_2146634997" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_WarrantsTable" xlink:label="loc_sclx_WarrantsTable_280" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sclx_WarrantsLineItems_2146634997" xlink:to="loc_sclx_WarrantsTable_280" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146634994" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_WarrantsTable_280" xlink:to="loc_dei_LegalEntityAxis_2146634994" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146634995" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2146634994" xlink:to="loc_dei_EntityDomain_2146634995" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146634995_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2146634994" xlink:to="loc_dei_EntityDomain_2146634995_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146634996" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146634995" xlink:to="loc_sclx_VickersVantageMember_2146634996" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_WarrantsTextBlock" xlink:label="loc_sclx_WarrantsTextBlock_282" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_WarrantsLineItems_2146634997" xlink:to="loc_sclx_WarrantsTextBlock_282" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/ShareholdersDeficit">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_2146635183" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_272" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2146635183" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_272" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_2146635181" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_2146635183" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_2146635181" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635184" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2146635181" xlink:to="loc_dei_LegalEntityAxis_2146635184" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635185" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2146635184" xlink:to="loc_dei_EntityDomain_2146635185" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635185_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2146635184" xlink:to="loc_dei_EntityDomain_2146635185_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635186" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146635185" xlink:to="loc_sclx_VickersVantageMember_2146635186" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/CommitmentsAndContingencies">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_CommitmentsandContingenciesDetailsLineItems" xlink:label="loc_sclx_CommitmentsandContingenciesDetailsLineItems_2146635100" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_CommitmentsandContingenciesDetailsTable" xlink:label="loc_sclx_CommitmentsandContingenciesDetailsTable_2146635099" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_2146635100" xlink:to="loc_sclx_CommitmentsandContingenciesDetailsTable_2146635099" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635101" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsTable_2146635099" xlink:to="loc_dei_LegalEntityAxis_2146635101" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635102" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2146635101" xlink:to="loc_dei_EntityDomain_2146635102" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635102_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2146635101" xlink:to="loc_dei_EntityDomain_2146635102_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635104" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146635102" xlink:to="loc_sclx_VickersVantageMember_2146635104" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_266" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_2146635100" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_266" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatements">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedFinancialStatementsCaptionsLineItems" xlink:label="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2146635270" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" xlink:label="loc_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock_2146635261" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2146635270" xlink:to="loc_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock_2146635261" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedFinancialStatementsTable" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTable_2146635269" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2146635270" xlink:to="loc_srt_ScheduleOfCondensedFinancialStatementsTable_2146635269" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635271" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_2146635269" xlink:to="loc_dei_LegalEntityAxis_2146635271" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635272" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2146635271" xlink:to="loc_dei_EntityDomain_2146635272" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635272_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2146635271" xlink:to="loc_dei_EntityDomain_2146635272_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635273" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146635272" xlink:to="loc_sclx_VickersVantageMember_2146635273" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/SubsequentEvents">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2146635158" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_294" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635158" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_294" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_2146635155" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_2146635158" xlink:to="loc_us-gaap_StatementTable_2146635155" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2146635156" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2146635155" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2146635156" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2146635157" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2146635156" xlink:to="loc_us-gaap_ClassOfStockDomain_2146635157" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2146635157_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2146635156" xlink:to="loc_us-gaap_ClassOfStockDomain_2146635157_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635159" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2146635155" xlink:to="loc_dei_LegalEntityAxis_2146635159" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635160" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2146635159" xlink:to="loc_dei_EntityDomain_2146635160" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635160_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2146635159" xlink:to="loc_dei_EntityDomain_2146635160_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635161" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146635160" xlink:to="loc_sclx_VickersVantageMember_2146635161" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/AccountingPoliciesByPolicyPolicies">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:label="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock" xlink:label="loc_us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock_320" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock_320" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_321" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_321" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_322" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_322" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_323" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_323" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_324" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_324" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_325" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_325" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_326" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_326" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="loc_us-gaap_DeferredChargesPolicyTextBlock_319" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_DeferredChargesPolicyTextBlock_319" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsPolicy" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy_318" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_EquityMethodInvestmentsPolicy_318" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_317" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_317" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2146635401" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2146635401" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_2146635651" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_2146635651" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_2146635668" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_2146635668" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_2146635669" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_2146635669" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2146635670" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2146635670" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_316" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_UseOfEstimates_316" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_315" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_315" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_314" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_314" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_313" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_313" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_2146635673" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_2146635673" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="loc_us-gaap_DebtPolicyTextBlock_2146635679" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_DebtPolicyTextBlock_2146635679" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:label="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_2146635052" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_2146635052" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635059" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_2146635052" xlink:to="loc_dei_LegalEntityAxis_2146635059" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635060" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2146635059" xlink:to="loc_dei_EntityDomain_2146635060" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635060_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2146635059" xlink:to="loc_dei_EntityDomain_2146635060_default" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635064" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146635060" xlink:to="loc_sclx_VickersVantageMember_2146635064" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_2146635680" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_2146635680" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_2146635681" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_2146635681" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_2146635696" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_2146635696" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_2146635699" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_2146635699" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_RebatesPolicyTextBlock" xlink:label="loc_sclx_RebatesPolicyTextBlock_2146635702" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_sclx_RebatesPolicyTextBlock_2146635702" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ServiceFeesPolicyTextBlock" xlink:label="loc_sclx_ServiceFeesPolicyTextBlock_2146635703" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_sclx_ServiceFeesPolicyTextBlock_2146635703" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SalesReturnsPolicyTextBlock" xlink:label="loc_sclx_SalesReturnsPolicyTextBlock_2146635705" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_sclx_SalesReturnsPolicyTextBlock_2146635705" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_CoPaymentAssistancePolicyTextBlock" xlink:label="loc_sclx_CoPaymentAssistancePolicyTextBlock_2146635706" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_sclx_CoPaymentAssistancePolicyTextBlock_2146635706" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2146635717" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2146635717" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_2146635859" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_2146635859" use="optional" order="36" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesTables">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:label="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635015" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:label="loc_srt_ScheduleOfCondensedBalanceSheetTableTextBlock_333" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635015" xlink:to="loc_srt_ScheduleOfCondensedBalanceSheetTableTextBlock_333" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_334" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635015" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_334" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:label="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_2146635011" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635015" xlink:to="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_2146635011" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635016" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_2146635011" xlink:to="loc_dei_LegalEntityAxis_2146635016" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635017" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2146635016" xlink:to="loc_dei_EntityDomain_2146635017" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635017_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2146635016" xlink:to="loc_dei_EntityDomain_2146635017_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635018" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146635017" xlink:to="loc_sclx_VickersVantageMember_2146635018" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/FairValueMeasurementsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2146635175" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock_2146635333" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635175" xlink:to="loc_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock_2146635333" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_2146635442" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635175" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_2146635442" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_343" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635175" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_343" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueConcentrationOfRiskTextBlock" xlink:label="loc_us-gaap_FairValueConcentrationOfRiskTextBlock_344" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635175" xlink:to="loc_us-gaap_FairValueConcentrationOfRiskTextBlock_344" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_345" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635175" xlink:to="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_345" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_346" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635175" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_346" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_2146635172" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_2146635175" xlink:to="loc_us-gaap_StatementTable_2146635172" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635176" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2146635172" xlink:to="loc_dei_LegalEntityAxis_2146635176" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635177" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2146635176" xlink:to="loc_dei_EntityDomain_2146635177" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635177_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2146635176" xlink:to="loc_dei_EntityDomain_2146635177_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635178" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146635177" xlink:to="loc_sclx_VickersVantageMember_2146635178" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2146635173" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2146635172" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2146635173" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2146635174" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2146635173" xlink:to="loc_us-gaap_ClassOfStockDomain_2146635174" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2146635174_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2146635173" xlink:to="loc_us-gaap_ClassOfStockDomain_2146635174_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_2146635476" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635175" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_2146635476" use="optional" order="15" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedFinancialStatementsCaptionsLineItems" xlink:label="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2146635279" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTableTextBlock_2146635286" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2146635279" xlink:to="loc_srt_ScheduleOfCondensedFinancialStatementsTableTextBlock_2146635286" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedFinancialStatementsTable" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTable_2146635278" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2146635279" xlink:to="loc_srt_ScheduleOfCondensedFinancialStatementsTable_2146635278" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635281" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_2146635278" xlink:to="loc_dei_LegalEntityAxis_2146635281" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635282" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2146635281" xlink:to="loc_dei_EntityDomain_2146635282" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635282_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2146635281" xlink:to="loc_dei_EntityDomain_2146635282_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635283" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146635282" xlink:to="loc_sclx_VickersVantageMember_2146635283" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:label="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_517" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_SharesIssued_517" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_518" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_518" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable" xlink:label="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_507" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_507" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_508" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_507" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_508" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_511" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_508" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_511" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_511_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_508" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_511_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:label="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_512" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_511" xlink:to="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_512" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScilexPharmaMember" xlink:label="loc_sclx_ScilexPharmaMember_2146635406" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_511" xlink:to="loc_sclx_ScilexPharmaMember_2146635406" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VantageMergerSubIncMember" xlink:label="loc_sclx_VantageMergerSubIncMember_2146635932" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_511" xlink:to="loc_sclx_VantageMergerSubIncMember_2146635932" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_509" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_507" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_509" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_513" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_509" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_513" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_513_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_509" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_513_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PrivatePlacementWarrantMember" xlink:label="loc_sclx_PrivatePlacementWarrantMember_516" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_513" xlink:to="loc_sclx_PrivatePlacementWarrantMember_516" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_514" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_513" xlink:to="loc_us-gaap_IPOMember_514" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_515" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_513" xlink:to="loc_us-gaap_OverAllotmentOptionMember_515" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146634946" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_507" xlink:to="loc_dei_LegalEntityAxis_2146634946" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146634948" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2146634946" xlink:to="loc_dei_EntityDomain_2146634948" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146634948_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2146634946" xlink:to="loc_dei_EntityDomain_2146634948_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635075" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146634948" xlink:to="loc_sclx_VickersVantageMember_2146635075" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2146635407" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_507" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2146635407" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_2146635408" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2146635407" xlink:to="loc_us-gaap_RelatedPartyDomain_2146635408" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_2146635408_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2146635407" xlink:to="loc_us-gaap_RelatedPartyDomain_2146635408_default" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SorrentoMember" xlink:label="loc_sclx_SorrentoMember_2146635409" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_2146635408" xlink:to="loc_sclx_SorrentoMember_2146635409" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_2146635347" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_507" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_2146635347" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_2146635348" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_2146635347" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_2146635348" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_2146635348_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_2146635347" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_2146635348_default" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SponsorMember" xlink:label="loc_sclx_SponsorMember_2146635351" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_2146635348" xlink:to="loc_sclx_SponsorMember_2146635351" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AgreementAxis" xlink:label="loc_sclx_AgreementAxis_2146635403" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_507" xlink:to="loc_sclx_AgreementAxis_2146635403" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AgreementDomain" xlink:label="loc_sclx_AgreementDomain_2146635404" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sclx_AgreementAxis_2146635403" xlink:to="loc_sclx_AgreementDomain_2146635404" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AgreementDomain" xlink:label="loc_sclx_AgreementDomain_2146635404_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sclx_AgreementAxis_2146635403" xlink:to="loc_sclx_AgreementDomain_2146635404_default" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ContributionAndLoanAgreementMember" xlink:label="loc_sclx_ContributionAndLoanAgreementMember_2146635405" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_AgreementDomain_2146635404" xlink:to="loc_sclx_ContributionAndLoanAgreementMember_2146635405" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DebtExchangeAgreementMember" xlink:label="loc_sclx_DebtExchangeAgreementMember_2146635936" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_AgreementDomain_2146635404" xlink:to="loc_sclx_DebtExchangeAgreementMember_2146635936" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_EventAxis" xlink:label="loc_sclx_EventAxis_2146635410" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_507" xlink:to="loc_sclx_EventAxis_2146635410" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_EventDomain" xlink:label="loc_sclx_EventDomain_2146635411" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sclx_EventAxis_2146635410" xlink:to="loc_sclx_EventDomain_2146635411" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_EventDomain" xlink:label="loc_sclx_EventDomain_2146635411_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sclx_EventAxis_2146635410" xlink:to="loc_sclx_EventDomain_2146635411_default" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ReorganizationMember" xlink:label="loc_sclx_ReorganizationMember_2146635412" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_EventDomain_2146635411" xlink:to="loc_sclx_ReorganizationMember_2146635412" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DemutualizationByInsuranceEntitySecuritiesIssuedGrossCashProceeds" xlink:label="loc_us-gaap_DemutualizationByInsuranceEntitySecuritiesIssuedGrossCashProceeds_519" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_DemutualizationByInsuranceEntitySecuritiesIssuedGrossCashProceeds_519" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsNet" xlink:label="loc_us-gaap_OtherIntangibleAssetsNet_530" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_OtherIntangibleAssetsNet_530" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfPublicShares" xlink:label="loc_sclx_PercentageOfPublicShares_531" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_sclx_PercentageOfPublicShares_531" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_532" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_532" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_520" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_520" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:label="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_521" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_521" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherUnderwritingExpense" xlink:label="loc_us-gaap_OtherUnderwritingExpense_522" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_OtherUnderwritingExpense_522" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DeferredUnderwritingFees" xlink:label="loc_sclx_DeferredUnderwritingFees_523" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_sclx_DeferredUnderwritingFees_523" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOwnershipInterestsOfferingCosts" xlink:label="loc_us-gaap_OtherOwnershipInterestsOfferingCosts_524" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_OtherOwnershipInterestsOfferingCosts_524" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_525" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_525" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoninterestBearingDepositLiabilities" xlink:label="loc_us-gaap_NoninterestBearingDepositLiabilities_526" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_NoninterestBearingDepositLiabilities_526" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsHeldInTrust" xlink:label="loc_us-gaap_AssetsHeldInTrust_527" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_AssetsHeldInTrust_527" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SaleOfStockDescriptionOfTransactions" xlink:label="loc_sclx_SaleOfStockDescriptionOfTransactions_528" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_sclx_SaleOfStockDescriptionOfTransactions_528" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PricePerPublicShare" xlink:label="loc_sclx_PricePerPublicShare_529" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_sclx_PricePerPublicShare_529" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_BusinessCombinationRedeemPercentage" xlink:label="loc_sclx_BusinessCombinationRedeemPercentage_533" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_sclx_BusinessCombinationRedeemPercentage_533" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_Numberofshares" xlink:label="loc_sclx_Numberofshares_2146635285" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_sclx_Numberofshares_2146635285" use="optional" order="52" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ProceedsOfInitialPublicOffering" xlink:label="loc_sclx_ProceedsOfInitialPublicOffering_2146635290" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_sclx_ProceedsOfInitialPublicOffering_2146635290" use="optional" order="53" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_Saleofwarrants" xlink:label="loc_sclx_Saleofwarrants_2146635310" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_sclx_Saleofwarrants_2146635310" use="optional" order="54" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_Grossproceedsofwarrants" xlink:label="loc_sclx_Grossproceedsofwarrants_2146635319" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_sclx_Grossproceedsofwarrants_2146635319" use="optional" order="55" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_Transactioncostsamount" xlink:label="loc_sclx_Transactioncostsamount_2146635332" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_sclx_Transactioncostsamount_2146635332" use="optional" order="56" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_Otherofferingcosts" xlink:label="loc_sclx_Otherofferingcosts_2146635334" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_sclx_Otherofferingcosts_2146635334" use="optional" order="57" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherExpenses" xlink:label="loc_us-gaap_OtherExpenses_534" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_OtherExpenses_534" use="optional" order="58" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DepositIntoTheTrustAccountPerShare" xlink:label="loc_sclx_DepositIntoTheTrustAccountPerShare_535" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_sclx_DepositIntoTheTrustAccountPerShare_535" use="optional" order="59" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LesserPublicPerShare" xlink:label="loc_sclx_LesserPublicPerShare_536" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_sclx_LesserPublicPerShare_536" use="optional" order="60" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAcquiredReceivablesDescription" xlink:label="loc_us-gaap_BusinessCombinationAcquiredReceivablesDescription_537" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_BusinessCombinationAcquiredReceivablesDescription_537" use="optional" order="61" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_538" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_RestrictedCashCurrent_538" use="optional" order="62" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_WorkingCapital" xlink:label="loc_sclx_WorkingCapital_539" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_sclx_WorkingCapital_539" use="optional" order="63" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeDepositWithFinancialInstitutionIncreaseDecrease" xlink:label="loc_us-gaap_InterestIncomeDepositWithFinancialInstitutionIncreaseDecrease_540" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_InterestIncomeDepositWithFinancialInstitutionIncreaseDecrease_540" use="optional" order="64" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_Numberofbusinessdays" xlink:label="loc_sclx_Numberofbusinessdays_2146635343" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_sclx_Numberofbusinessdays_2146635343" use="optional" order="65" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NetTangibleAssets" xlink:label="loc_sclx_NetTangibleAssets_2146635346" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_sclx_NetTangibleAssets_2146635346" use="optional" order="66" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_Depositintotrustaccount" xlink:label="loc_sclx_Depositintotrustaccount_2146635354" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_sclx_Depositintotrustaccount_2146635354" use="optional" order="67" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_Interestexpenses" xlink:label="loc_sclx_Interestexpenses_2146635365" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_sclx_Interestexpenses_2146635365" use="optional" order="68" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_2146635368" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_Cash_2146635368" use="optional" order="69" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_2146635373" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_2146635373" use="optional" order="70" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_2146635402" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_dei_EntityIncorporationStateCountryCode_2146635402" use="optional" order="71" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_2146635415" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_2146635415" use="optional" order="72" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_2146635417" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_2146635417" use="optional" order="73" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_2146635937" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_2146635937" use="optional" order="74" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_2146635938" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_2146635938" use="optional" order="75" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetails">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:label="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_555" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaap_CashFDICInsuredAmount_560" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_555" xlink:to="loc_us-gaap_CashFDICInsuredAmount_560" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:label="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_553" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_555" xlink:to="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_553" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146634981" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_553" xlink:to="loc_dei_LegalEntityAxis_2146634981" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146634982" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2146634981" xlink:to="loc_dei_EntityDomain_2146634982" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146634982_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2146634981" xlink:to="loc_dei_EntityDomain_2146634982_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146634983" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146634982" xlink:to="loc_sclx_VickersVantageMember_2146634983" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_554" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_553" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_554" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_556" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_554" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_556" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_556_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_554" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_556_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_557" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_556" xlink:to="loc_us-gaap_IPOMember_557" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_2146635767" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_553" xlink:to="loc_srt_MajorCustomersAxis_2146635767" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_2146635768" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_2146635767" xlink:to="loc_srt_NameOfMajorCustomerDomain_2146635768" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_2146635768_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_2146635767" xlink:to="loc_srt_NameOfMajorCustomerDomain_2146635768_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SoleDistributorMember" xlink:label="loc_sclx_SoleDistributorMember_2146635769" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_2146635768" xlink:to="loc_sclx_SoleDistributorMember_2146635769" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_2146635758" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_553" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_2146635758" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_2146635759" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_2146635758" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_2146635759" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_2146635759_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_2146635758" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_2146635759_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_2146635761" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_2146635759" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_2146635761" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_2146635763" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_553" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_2146635763" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2146635764" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_2146635763" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2146635764" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2146635764_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_2146635763" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2146635764_default" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaap_SalesRevenueNetMember_2146635766" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2146635764" xlink:to="loc_us-gaap_SalesRevenueNetMember_2146635766" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherDeferredCostsNet" xlink:label="loc_us-gaap_OtherDeferredCostsNet_558" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_555" xlink:to="loc_us-gaap_OtherDeferredCostsNet_558" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExcessStockSharesIssued" xlink:label="loc_us-gaap_ExcessStockSharesIssued_559" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_555" xlink:to="loc_us-gaap_ExcessStockSharesIssued_559" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_Foundershares" xlink:label="loc_sclx_Foundershares_2146635399" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_555" xlink:to="loc_sclx_Foundershares_2146635399" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_2146635724" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_555" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_2146635724" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_2146635754" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_555" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_2146635754" use="optional" order="27" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfOrdinarySharesReflectedInCondensedConsolidatedBalanceSheetsAreReconciled">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:label="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146634985" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_GrossProceeds" xlink:label="loc_sclx_GrossProceeds_362" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146634985" xlink:to="loc_sclx_GrossProceeds_362" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LessAbstract" xlink:label="loc_sclx_LessAbstract_359" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146634985" xlink:to="loc_sclx_LessAbstract_359" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_OrdinarySharesIssuanceCost" xlink:label="loc_sclx_OrdinarySharesIssuanceCost_363" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_LessAbstract_359" xlink:to="loc_sclx_OrdinarySharesIssuanceCost_363" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PlusAbstract" xlink:label="loc_sclx_PlusAbstract_360" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146634985" xlink:to="loc_sclx_PlusAbstract_360" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AccretionOfCarryingValueToRedemptionValue" xlink:label="loc_sclx_AccretionOfCarryingValueToRedemptionValue_364" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_PlusAbstract_360" xlink:to="loc_sclx_AccretionOfCarryingValueToRedemptionValue_364" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="loc_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_2146635381" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_PlusAbstract_360" xlink:to="loc_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_2146635381" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SharesSubjectToPossibleRedemption" xlink:label="loc_sclx_SharesSubjectToPossibleRedemption_365" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146634985" xlink:to="loc_sclx_SharesSubjectToPossibleRedemption_365" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LessAbstract0" xlink:label="loc_sclx_LessAbstract0_361" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146634985" xlink:to="loc_sclx_LessAbstract0_361" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityOtherChanges" xlink:label="loc_us-gaap_TemporaryEquityOtherChanges_366" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_LessAbstract0_361" xlink:to="loc_us-gaap_TemporaryEquityOtherChanges_366" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:label="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_2146634984" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146634985" xlink:to="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_2146634984" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146634986" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_2146634984" xlink:to="loc_dei_LegalEntityAxis_2146634986" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146634987" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2146634986" xlink:to="loc_dei_EntityDomain_2146634987" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146634987_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2146634986" xlink:to="loc_dei_EntityDomain_2146634987_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146634988" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146634987" xlink:to="loc_sclx_VickersVantageMember_2146634988" use="optional" order="14" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShare">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:label="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146634990" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NumeratorAbstract" xlink:label="loc_sclx_NumeratorAbstract_376" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146634990" xlink:to="loc_sclx_NumeratorAbstract_376" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityNetIncome" xlink:label="loc_us-gaap_TemporaryEquityNetIncome_378" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_NumeratorAbstract_376" xlink:to="loc_us-gaap_TemporaryEquityNetIncome_378" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DenominatorAbstract" xlink:label="loc_sclx_DenominatorAbstract_377" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146634990" xlink:to="loc_sclx_DenominatorAbstract_377" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2146635636" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DenominatorAbstract_377" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2146635636" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2146635657" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DenominatorAbstract_377" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2146635657" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_2146635665" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DenominatorAbstract_377" xlink:to="loc_us-gaap_EarningsPerShareDiluted_2146635665" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_379" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DenominatorAbstract_377" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_379" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_380" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_DenominatorAbstract_377" xlink:to="loc_us-gaap_EarningsPerShareBasic_380" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:label="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_2146634989" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146634990" xlink:to="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_2146634989" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146634991" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_2146634989" xlink:to="loc_dei_LegalEntityAxis_2146634991" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146634992" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2146634991" xlink:to="loc_dei_EntityDomain_2146634992" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146634992_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2146634991" xlink:to="loc_dei_EntityDomain_2146634992_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146634993" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146634992" xlink:to="loc_sclx_VickersVantageMember_2146634993" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareParentheticals">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:label="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635002" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:label="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_2146635001" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635002" xlink:to="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_2146635001" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635003" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_2146635001" xlink:to="loc_dei_LegalEntityAxis_2146635003" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635004" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2146635003" xlink:to="loc_dei_EntityDomain_2146635004" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635004_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2146635003" xlink:to="loc_dei_EntityDomain_2146635004_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635005" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146635004" xlink:to="loc_sclx_VickersVantageMember_2146635005" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_387" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635002" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_387" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_388" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635002" xlink:to="loc_us-gaap_EarningsPerShareDiluted_388" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LiquidityAndGoingConcernLineItems" xlink:label="loc_sclx_LiquidityAndGoingConcernLineItems_2146635456" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2146635467" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_2146635456" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2146635467" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2146635469" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_2146635456" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2146635469" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_2146635470" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_2146635456" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_2146635470" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_2146635473" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_2146635456" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_2146635473" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MinimumUnrestrictedCashBalance" xlink:label="loc_sclx_MinimumUnrestrictedCashBalance_2146635477" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_2146635456" xlink:to="loc_sclx_MinimumUnrestrictedCashBalance_2146635477" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_2146635479" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_2146635456" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_2146635479" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NetWorkingCapital" xlink:label="loc_sclx_NetWorkingCapital_2146635459" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_2146635456" xlink:to="loc_sclx_NetWorkingCapital_2146635459" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_RestrictedFundsRelesableForFutureRepurchaseOfDebt" xlink:label="loc_sclx_RestrictedFundsRelesableForFutureRepurchaseOfDebt_2146635491" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_2146635456" xlink:to="loc_sclx_RestrictedFundsRelesableForFutureRepurchaseOfDebt_2146635491" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DebtInstrumentRepurchaseObligation" xlink:label="loc_sclx_DebtInstrumentRepurchaseObligation_2146635498" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_2146635456" xlink:to="loc_sclx_DebtInstrumentRepurchaseObligation_2146635498" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LiquidityAndGoingConcernTable" xlink:label="loc_sclx_LiquidityAndGoingConcernTable_2146635455" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_2146635456" xlink:to="loc_sclx_LiquidityAndGoingConcernTable_2146635455" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2146635528" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_LiquidityAndGoingConcernTable_2146635455" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2146635528" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2146635529" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2146635528" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2146635529" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2146635529_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2146635528" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2146635529_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_2146635530" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_2146635529" xlink:to="loc_us-gaap_SubsequentEventMember_2146635530" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_2146635518" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_LiquidityAndGoingConcernTable_2146635455" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_2146635518" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2146635519" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2146635518" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2146635519" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2146635519_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2146635518" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2146635519_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SeniorSecuredNotesDueTwoThousandAndTwentySixMember" xlink:label="loc_sclx_SeniorSecuredNotesDueTwoThousandAndTwentySixMember_2146635521" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2146635519" xlink:to="loc_sclx_SeniorSecuredNotesDueTwoThousandAndTwentySixMember_2146635521" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_EventAxis" xlink:label="loc_sclx_EventAxis_2146635523" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_LiquidityAndGoingConcernTable_2146635455" xlink:to="loc_sclx_EventAxis_2146635523" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_EventDomain" xlink:label="loc_sclx_EventDomain_2146635524" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sclx_EventAxis_2146635523" xlink:to="loc_sclx_EventDomain_2146635524" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_EventDomain" xlink:label="loc_sclx_EventDomain_2146635524_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sclx_EventAxis_2146635523" xlink:to="loc_sclx_EventDomain_2146635524_default" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_CumulativeSalesRelatedContingencyMember" xlink:label="loc_sclx_CumulativeSalesRelatedContingencyMember_2146635525" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_EventDomain_2146635524" xlink:to="loc_sclx_CumulativeSalesRelatedContingencyMember_2146635525" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LetterOfCreditDrawnDownMember" xlink:label="loc_sclx_LetterOfCreditDrawnDownMember_2146635526" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_EventDomain_2146635524" xlink:to="loc_sclx_LetterOfCreditDrawnDownMember_2146635526" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635514" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_LiquidityAndGoingConcernTable_2146635455" xlink:to="loc_dei_LegalEntityAxis_2146635514" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635515" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2146635514" xlink:to="loc_dei_EntityDomain_2146635515" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635515_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2146635514" xlink:to="loc_dei_EntityDomain_2146635515_default" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScilexPharmaMember" xlink:label="loc_sclx_ScilexPharmaMember_2146635517" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146635515" xlink:to="loc_sclx_ScilexPharmaMember_2146635517" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_2146636050" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_LiquidityAndGoingConcernTable_2146635455" xlink:to="loc_us-gaap_DebtInstrumentAxis_2146636050" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2146636051" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_2146636050" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2146636051" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2146636051_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_2146636050" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2146636051_default" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScilexPharmaNotesMember" xlink:label="loc_sclx_ScilexPharmaNotesMember_2146636052" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2146636051" xlink:to="loc_sclx_ScilexPharmaNotesMember_2146636052" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_2146636053" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_LiquidityAndGoingConcernTable_2146635455" xlink:to="loc_us-gaap_CreditFacilityAxis_2146636053" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_2146636054" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_2146636053" xlink:to="loc_us-gaap_CreditFacilityDomain_2146636054" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_2146636054_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_2146636053" xlink:to="loc_us-gaap_CreditFacilityDomain_2146636054_default" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_FundingCommitmentLetterMember" xlink:label="loc_sclx_FundingCommitmentLetterMember_2146636055" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_2146636054" xlink:to="loc_sclx_FundingCommitmentLetterMember_2146636055" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinimumNetWorthRequiredForCompliance" xlink:label="loc_us-gaap_MinimumNetWorthRequiredForCompliance_2146636047" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_2146635456" xlink:to="loc_us-gaap_MinimumNetWorthRequiredForCompliance_2146636047" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_2146636048" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_2146635456" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_2146636048" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AggregateOutstandingAmount" xlink:label="loc_sclx_AggregateOutstandingAmount_2146636049" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_2146635456" xlink:to="loc_sclx_AggregateOutstandingAmount_2146636049" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_2146635573" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_2146635456" xlink:to="loc_us-gaap_OperatingIncomeLoss_2146635573" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2146635574" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_2146635456" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2146635574" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:label="loc_us-gaap_DebtInstrumentAnnualPrincipalPayment_2146636044" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_2146635456" xlink:to="loc_us-gaap_DebtInstrumentAnnualPrincipalPayment_2146636044" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentDecreaseForgiveness" xlink:label="loc_us-gaap_DebtInstrumentDecreaseForgiveness_2146636045" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_2146635456" xlink:to="loc_us-gaap_DebtInstrumentDecreaseForgiveness_2146636045" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_2146636046" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_2146635456" xlink:to="loc_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_2146636046" use="optional" order="43" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/PublicOfferingDetails">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PublicOfferingDetailsLineItems" xlink:label="loc_sclx_PublicOfferingDetailsLineItems_576" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NumberOfSaleUnits" xlink:label="loc_sclx_NumberOfSaleUnits_2146636382" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_PublicOfferingDetailsLineItems_576" xlink:to="loc_sclx_NumberOfSaleUnits_2146636382" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PublicOfferingDetailsTable" xlink:label="loc_sclx_PublicOfferingDetailsTable_574" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sclx_PublicOfferingDetailsLineItems_576" xlink:to="loc_sclx_PublicOfferingDetailsTable_574" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146634940" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_PublicOfferingDetailsTable_574" xlink:to="loc_dei_LegalEntityAxis_2146634940" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146634941" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2146634940" xlink:to="loc_dei_EntityDomain_2146634941" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146634941_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2146634940" xlink:to="loc_dei_EntityDomain_2146634941_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146634945" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146634941" xlink:to="loc_sclx_VickersVantageMember_2146634945" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_575" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_PublicOfferingDetailsTable_574" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_575" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_577" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_575" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_577" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_577_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_575" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_577_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_578" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_577" xlink:to="loc_us-gaap_IPOMember_578" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_579" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_577" xlink:to="loc_us-gaap_OverAllotmentOptionMember_579" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_580" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_PublicOfferingDetailsLineItems_576" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_580" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PurchasePricePerShare" xlink:label="loc_sclx_PurchasePricePerShare_581" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_PublicOfferingDetailsLineItems_576" xlink:to="loc_sclx_PurchasePricePerShare_581" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="loc_us-gaap_SaleOfStockDescriptionOfTransaction_582" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_PublicOfferingDetailsLineItems_576" xlink:to="loc_us-gaap_SaleOfStockDescriptionOfTransaction_582" use="optional" order="14" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/PrivatePlacementDetails">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PrivatePlacementDetailsLineItems" xlink:label="loc_sclx_PrivatePlacementDetailsLineItems_597" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PrivatePlacementDetailsTable" xlink:label="loc_sclx_PrivatePlacementDetailsTable_595" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sclx_PrivatePlacementDetailsLineItems_597" xlink:to="loc_sclx_PrivatePlacementDetailsTable_595" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_596" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_PrivatePlacementDetailsTable_595" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_596" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2146634687" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_596" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2146634687" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2146634687_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_596" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2146634687_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_598" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2146634687" xlink:to="loc_us-gaap_PrivatePlacementMember_598" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635105" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_PrivatePlacementDetailsTable_595" xlink:to="loc_dei_LegalEntityAxis_2146635105" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635107" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2146635105" xlink:to="loc_dei_EntityDomain_2146635107" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635107_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2146635105" xlink:to="loc_dei_EntityDomain_2146635107_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635108" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146635107" xlink:to="loc_sclx_VickersVantageMember_2146635108" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_599" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_PrivatePlacementDetailsLineItems_597" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_599" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_600" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_PrivatePlacementDetailsLineItems_597" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_600" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_601" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_PrivatePlacementDetailsLineItems_597" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_601" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_602" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_PrivatePlacementDetailsLineItems_597" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_602" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_RelatedPartyTransactionsDetailsLineItems" xlink:label="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_RelatedPartyTransactionsDetailsTable" xlink:label="loc_sclx_RelatedPartyTransactionsDetailsTable_644" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_sclx_RelatedPartyTransactionsDetailsTable_644" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_646" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsTable_644" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_646" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_653" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_646" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_653" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_653_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_646" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_653_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_FounderSharesMember" xlink:label="loc_sclx_FounderSharesMember_654" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_653" xlink:to="loc_sclx_FounderSharesMember_654" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_FounderSharesMember" xlink:label="loc_sclx_FounderSharesMember_661" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_660" xlink:to="loc_sclx_FounderSharesMember_661" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PromissoryNoteRelatedPartyMember" xlink:label="loc_sclx_PromissoryNoteRelatedPartyMember_655" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_653" xlink:to="loc_sclx_PromissoryNoteRelatedPartyMember_655" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_645" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsTable_644" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_645" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_651" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_645" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_651" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_651_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_645" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_651_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ConvertiblePromisoryNoteMember" xlink:label="loc_sclx_ConvertiblePromisoryNoteMember_652" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_651" xlink:to="loc_sclx_ConvertiblePromisoryNoteMember_652" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_2146635998" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_651" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_2146635998" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_649" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsTable_644" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_649" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_660" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_649" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_660" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_660_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_649" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_660_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_647" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsTable_644" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_647" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_656" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_647" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_656" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_656_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_647" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_656_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_657" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_656" xlink:to="loc_us-gaap_SubsequentEventMember_657" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_648" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsTable_644" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_648" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_658" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_648" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_658" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_658_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_648" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_658_default" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_659" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_658" xlink:to="loc_us-gaap_IPOMember_659" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="loc_us-gaap_AssetAcquisitionAxis_2146635807" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsTable_644" xlink:to="loc_us-gaap_AssetAcquisitionAxis_2146635807" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaap_AssetAcquisitionDomain_2146635809" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_2146635807" xlink:to="loc_us-gaap_AssetAcquisitionDomain_2146635809" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaap_AssetAcquisitionDomain_2146635809_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_2146635807" xlink:to="loc_us-gaap_AssetAcquisitionDomain_2146635809_default" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SenmurMember" xlink:label="loc_sclx_SenmurMember_2146635810" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_2146635809" xlink:to="loc_sclx_SenmurMember_2146635810" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146634976" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsTable_644" xlink:to="loc_dei_LegalEntityAxis_2146634976" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146634977" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2146634976" xlink:to="loc_dei_EntityDomain_2146634977" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146634977_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2146634976" xlink:to="loc_dei_EntityDomain_2146634977_default" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScilexPharmaMember" xlink:label="loc_sclx_ScilexPharmaMember_2146635920" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146634977" xlink:to="loc_sclx_ScilexPharmaMember_2146635920" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146634979" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146634977" xlink:to="loc_sclx_VickersVantageMember_2146634979" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_EventAxis" xlink:label="loc_sclx_EventAxis_2146635901" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsTable_644" xlink:to="loc_sclx_EventAxis_2146635901" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_EventDomain" xlink:label="loc_sclx_EventDomain_2146635902" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sclx_EventAxis_2146635901" xlink:to="loc_sclx_EventDomain_2146635902" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_EventDomain" xlink:label="loc_sclx_EventDomain_2146635902_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sclx_EventAxis_2146635901" xlink:to="loc_sclx_EventDomain_2146635902_default" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ReorganizationMember" xlink:label="loc_sclx_ReorganizationMember_2146635903" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_EventDomain_2146635902" xlink:to="loc_sclx_ReorganizationMember_2146635903" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_2146636076" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsTable_644" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_2146636076" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2146636077" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2146636076" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2146636077" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2146636077_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2146636076" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2146636077_default" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SorrentoMember" xlink:label="loc_sclx_SorrentoMember_2146635876" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_2146635852" xlink:to="loc_sclx_SorrentoMember_2146635876" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SorrentoMember" xlink:label="loc_sclx_SorrentoMember_2146636067" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_InvesteeDomain_2146636066" xlink:to="loc_sclx_SorrentoMember_2146636067" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SorrentoMember" xlink:label="loc_sclx_SorrentoMember_2146636078" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2146636077" xlink:to="loc_sclx_SorrentoMember_2146636078" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_InvesteeAxis" xlink:label="loc_sclx_InvesteeAxis_2146636065" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsTable_644" xlink:to="loc_sclx_InvesteeAxis_2146636065" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_InvesteeDomain" xlink:label="loc_sclx_InvesteeDomain_2146636066" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sclx_InvesteeAxis_2146636065" xlink:to="loc_sclx_InvesteeDomain_2146636066" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_InvesteeDomain" xlink:label="loc_sclx_InvesteeDomain_2146636066_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sclx_InvesteeAxis_2146636065" xlink:to="loc_sclx_InvesteeDomain_2146636066_default" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_2146636071" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsTable_644" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_2146636071" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2146636072" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2146636071" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2146636072" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2146636072_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2146636071" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2146636072_default" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TwoThousandAndTwentyTwoPromissoryNoteMember" xlink:label="loc_sclx_TwoThousandAndTwentyTwoPromissoryNoteMember_2146636073" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2146636072" xlink:to="loc_sclx_TwoThousandAndTwentyTwoPromissoryNoteMember_2146636073" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2146635851" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsTable_644" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2146635851" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_2146635852" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2146635851" xlink:to="loc_us-gaap_RelatedPartyDomain_2146635852" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_2146635852_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2146635851" xlink:to="loc_us-gaap_RelatedPartyDomain_2146635852_default" use="optional" order="52" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ItochuMember" xlink:label="loc_sclx_ItochuMember_2146635854" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_2146635852" xlink:to="loc_sclx_ItochuMember_2146635854" use="optional" order="53" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AgreementAxis" xlink:label="loc_sclx_AgreementAxis_2146636315" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsTable_644" xlink:to="loc_sclx_AgreementAxis_2146636315" use="optional" order="54" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AgreementDomain" xlink:label="loc_sclx_AgreementDomain_2146636319" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sclx_AgreementAxis_2146636315" xlink:to="loc_sclx_AgreementDomain_2146636319" use="optional" order="55" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AgreementDomain" xlink:label="loc_sclx_AgreementDomain_2146636319_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sclx_AgreementAxis_2146636315" xlink:to="loc_sclx_AgreementDomain_2146636319_default" use="optional" order="56" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DebtExchangeAgreementMember" xlink:label="loc_sclx_DebtExchangeAgreementMember_2146636320" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_AgreementDomain_2146636319" xlink:to="loc_sclx_DebtExchangeAgreementMember_2146636320" use="optional" order="57" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2146636348" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsTable_644" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2146636348" use="optional" order="58" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_2146636349" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2146636348" xlink:to="loc_us-gaap_EquityComponentDomain_2146636349" use="optional" order="59" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_2146636349_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2146636348" xlink:to="loc_us-gaap_EquityComponentDomain_2146636349_default" use="optional" order="60" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_2146636350" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2146636349" xlink:to="loc_us-gaap_PreferredStockMember_2146636350" use="optional" order="61" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_2146636351" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2146636349" xlink:to="loc_us-gaap_CommonStockMember_2146636351" use="optional" order="62" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PeriodAxis" xlink:label="loc_sclx_PeriodAxis_2146636629" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsTable_644" xlink:to="loc_sclx_PeriodAxis_2146636629" use="optional" order="63" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PeriodDomain" xlink:label="loc_sclx_PeriodDomain_2146636630" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sclx_PeriodAxis_2146636629" xlink:to="loc_sclx_PeriodDomain_2146636630" use="optional" order="64" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PeriodDomain" xlink:label="loc_sclx_PeriodDomain_2146636630_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sclx_PeriodAxis_2146636629" xlink:to="loc_sclx_PeriodDomain_2146636630_default" use="optional" order="65" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DueOnOrAfterFebruaryTwoThousandAndThirtyMember" xlink:label="loc_sclx_DueOnOrAfterFebruaryTwoThousandAndThirtyMember_2146636631" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_PeriodDomain_2146636630" xlink:to="loc_sclx_DueOnOrAfterFebruaryTwoThousandAndThirtyMember_2146636631" use="optional" order="66" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt_670" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_RepaymentsOfDebt_670" use="optional" order="67" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationControlObtainedDescription" xlink:label="loc_us-gaap_BusinessCombinationControlObtainedDescription_671" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_BusinessCombinationControlObtainedDescription_671" use="optional" order="68" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaap_ConvertibleDebt_672" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_ConvertibleDebt_672" use="optional" order="69" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_667" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_667" use="optional" order="70" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_WarrantsExercisePrice" xlink:label="loc_sclx_WarrantsExercisePrice_673" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_sclx_WarrantsExercisePrice_673" use="optional" order="71" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_662" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_662" use="optional" order="72" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_663" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_663" use="optional" order="73" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_CapitalizationOfShareOutstanding" xlink:label="loc_sclx_CapitalizationOfShareOutstanding_664" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_sclx_CapitalizationOfShareOutstanding_664" use="optional" order="74" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_665" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_665" use="optional" order="75" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_OrdinarySharesIssuedAndOutstanding" xlink:label="loc_sclx_OrdinarySharesIssuedAndOutstanding_666" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_sclx_OrdinarySharesIssuedAndOutstanding_666" use="optional" order="76" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_2146635821" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_2146635821" use="optional" order="77" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_aggregatePurchasePrice" xlink:label="loc_sclx_aggregatePurchasePrice_676" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_sclx_aggregatePurchasePrice_676" use="optional" order="78" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NumberOfSharesOutstanding" xlink:label="loc_sclx_NumberOfSharesOutstanding_2146635879" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_sclx_NumberOfSharesOutstanding_2146635879" use="optional" order="79" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NumberOfSharesAcquired" xlink:label="loc_sclx_NumberOfSharesAcquired_2146635888" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_sclx_NumberOfSharesAcquired_2146635888" use="optional" order="80" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_2146635824" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_2146635824" use="optional" order="81" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_2146635829" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_2146635829" use="optional" order="82" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesSubscribedButUnissued" xlink:label="loc_us-gaap_CommonStockSharesSubscribedButUnissued_2146635834" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_CommonStockSharesSubscribedButUnissued_2146635834" use="optional" order="83" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AssetAcquisitionPricePerShare" xlink:label="loc_sclx_AssetAcquisitionPricePerShare_2146635838" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_sclx_AssetAcquisitionPricePerShare_2146635838" use="optional" order="84" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfOwnershipInterest" xlink:label="loc_sclx_PercentageOfOwnershipInterest_2146635839" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_sclx_PercentageOfOwnershipInterest_2146635839" use="optional" order="85" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfSharesOutstanding" xlink:label="loc_sclx_PercentageOfSharesOutstanding_2146635849" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_sclx_PercentageOfSharesOutstanding_2146635849" use="optional" order="86" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:label="loc_us-gaap_CostsAndExpensesRelatedParty_668" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_CostsAndExpensesRelatedParty_668" use="optional" order="87" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_669" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_669" use="optional" order="88" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_674" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_AdditionalPaidInCapital_674" use="optional" order="89" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_675" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_675" use="optional" order="90" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xlink:label="loc_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_2146635894" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_2146635894" use="optional" order="91" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_2146635983" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_2146635983" use="optional" order="92" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTaxExpenseDueToAffiliatesDeferred" xlink:label="loc_us-gaap_RelatedPartyTaxExpenseDueToAffiliatesDeferred_2146635986" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_RelatedPartyTaxExpenseDueToAffiliatesDeferred_2146635986" use="optional" order="93" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_2146635988" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_2146635988" use="optional" order="94" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AggregatePrincipalAmount" xlink:label="loc_sclx_AggregatePrincipalAmount_2146635990" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_sclx_AggregatePrincipalAmount_2146635990" use="optional" order="95" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfSimpleInterest" xlink:label="loc_sclx_PercentageOfSimpleInterest_2146635906" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_sclx_PercentageOfSimpleInterest_2146635906" use="optional" order="96" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent_2146635908" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_NotesPayableCurrent_2146635908" use="optional" order="97" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_2146635909" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_2146635909" use="optional" order="98" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AccruedInterest" xlink:label="loc_sclx_AccruedInterest_2146635924" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_sclx_AccruedInterest_2146635924" use="optional" order="99" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PricePerWarrants" xlink:label="loc_sclx_PricePerWarrants_2146635981" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_sclx_PricePerWarrants_2146635981" use="optional" order="100" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsHeldInTrust" xlink:label="loc_us-gaap_AssetsHeldInTrust_2146635982" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_AssetsHeldInTrust_2146635982" use="optional" order="101" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm_2146636074" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_DebtInstrumentTerm_2146636074" use="optional" order="102" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_2146636075" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_2146636075" use="optional" order="103" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseRelatedParty" xlink:label="loc_us-gaap_InterestExpenseRelatedParty_677" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_InterestExpenseRelatedParty_677" use="optional" order="104" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToAffiliateCurrent" xlink:label="loc_us-gaap_DueToAffiliateCurrent_2146636008" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_DueToAffiliateCurrent_2146636008" use="optional" order="105" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_RepaidAmount" xlink:label="loc_sclx_RepaidAmount_2146636011" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_sclx_RepaidAmount_2146636011" use="optional" order="106" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfCapitalSharesOutstanding" xlink:label="loc_sclx_PercentageOfCapitalSharesOutstanding_2146636020" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_sclx_PercentageOfCapitalSharesOutstanding_2146636020" use="optional" order="107" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable_2146636059" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_LongTermNotesPayable_2146636059" use="optional" order="108" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_2146636070" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_2146636070" use="optional" order="109" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_678" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_678" use="optional" order="110" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_WorkingCapitalRequirements" xlink:label="loc_sclx_WorkingCapitalRequirements_2146636097" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_sclx_WorkingCapitalRequirements_2146636097" use="optional" order="111" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchaseAmount" xlink:label="loc_us-gaap_DebtInstrumentRepurchaseAmount_2146636099" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_DebtInstrumentRepurchaseAmount_2146636099" use="optional" order="112" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionDescriptionOfTransaction_679" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_RelatedPartyTransactionDescriptionOfTransaction_679" use="optional" order="113" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DepositedInTrustAccount" xlink:label="loc_sclx_DepositedInTrustAccount_680" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_sclx_DepositedInTrustAccount_680" use="optional" order="114" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PaymentToAcquireInventory" xlink:label="loc_sclx_PaymentToAcquireInventory_2146635855" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_sclx_PaymentToAcquireInventory_2146635855" use="optional" order="115" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaap_LegalFees_2146636101" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_LegalFees_2146636101" use="optional" order="116" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfMediumTermNotes" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfMediumTermNotes_2146636628" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfMediumTermNotes_2146636628" use="optional" order="117" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2146636333" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2146636333" use="optional" order="118" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfOutstandingAmountIndebtedness" xlink:label="loc_sclx_PercentageOfOutstandingAmountIndebtedness_2146636337" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_sclx_PercentageOfOutstandingAmountIndebtedness_2146636337" use="optional" order="119" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PerShareCalculationOfOutstandingAmountInExchangeOfShares" xlink:label="loc_sclx_PerShareCalculationOfOutstandingAmountInExchangeOfShares_2146636342" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_sclx_PerShareCalculationOfOutstandingAmountInExchangeOfShares_2146636342" use="optional" order="120" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LimitationOfOutstandingAmountInExchangeOfShares" xlink:label="loc_sclx_LimitationOfOutstandingAmountInExchangeOfShares_2146636343" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_sclx_LimitationOfOutstandingAmountInExchangeOfShares_2146636343" use="optional" order="121" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_2146636345" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_LongTermDebt_2146636345" use="optional" order="122" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_2146636347" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_2146636347" use="optional" order="123" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_CommitmentsandContingenciesDetailsLineItems" xlink:label="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_CommitmentsandContingenciesDetailsTable" xlink:label="loc_sclx_CommitmentsandContingenciesDetailsTable_718" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_sclx_CommitmentsandContingenciesDetailsTable_718" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_719" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsTable_718" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_719" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_725" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_719" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_725" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_725_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_719" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_725_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScilexCommonStockMember" xlink:label="loc_sclx_ScilexCommonStockMember_726" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_725" xlink:to="loc_sclx_ScilexCommonStockMember_726" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_720" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsTable_718" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_720" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_727" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_720" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_727" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_727_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_720" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_727_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:label="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_728" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_727" xlink:to="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_728" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635081" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsTable_718" xlink:to="loc_dei_LegalEntityAxis_2146635081" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635082" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2146635081" xlink:to="loc_dei_EntityDomain_2146635082" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635082_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2146635081" xlink:to="loc_dei_EntityDomain_2146635082_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635083" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146635082" xlink:to="loc_sclx_VickersVantageMember_2146635083" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_2146635917" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsTable_718" xlink:to="loc_us-gaap_TypeOfArrangementAxis_2146635917" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2146635918" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2146635917" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2146635918" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2146635918_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2146635917" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2146635918_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ProductDevelopmentAgreementMember" xlink:label="loc_sclx_ProductDevelopmentAgreementMember_2146635919" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2146635918" xlink:to="loc_sclx_ProductDevelopmentAgreementMember_2146635919" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ExclusiveDistributionAgreementMember" xlink:label="loc_sclx_ExclusiveDistributionAgreementMember_2146635961" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2146635918" xlink:to="loc_sclx_ExclusiveDistributionAgreementMember_2146635961" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ProjectAgreementMember" xlink:label="loc_sclx_ProjectAgreementMember_2146635962" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2146635918" xlink:to="loc_sclx_ProjectAgreementMember_2146635962" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_721" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsTable_718" xlink:to="loc_us-gaap_StatementClassOfStockAxis_721" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_729" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_721" xlink:to="loc_us-gaap_ClassOfStockDomain_729" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_729_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_721" xlink:to="loc_us-gaap_ClassOfStockDomain_729_default" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_730" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_729" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_730" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_732" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_731" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_732" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_722" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsTable_718" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_722" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_731" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_722" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_731" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_731_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_722" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_731_default" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_723" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsTable_718" xlink:to="loc_srt_RangeAxis_723" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_733" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_723" xlink:to="loc_srt_RangeMember_733" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_733_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_723" xlink:to="loc_srt_RangeMember_733_default" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_735" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_733" xlink:to="loc_srt_MaximumMember_735" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_734" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_733" xlink:to="loc_srt_MinimumMember_734" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2146636110" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsTable_718" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2146636110" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2146636111" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2146636110" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2146636111" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2146636111_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2146636110" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2146636111_default" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PaloAltoAadministrativeFacilityMember" xlink:label="loc_sclx_PaloAltoAadministrativeFacilityMember_2146636112" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2146636111" xlink:to="loc_sclx_PaloAltoAadministrativeFacilityMember_2146636112" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationReasonForBusinessCombination" xlink:label="loc_us-gaap_BusinessCombinationReasonForBusinessCombination_743" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_us-gaap_BusinessCombinationReasonForBusinessCombination_743" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NetTangibleAssets" xlink:label="loc_sclx_NetTangibleAssets_744" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_sclx_NetTangibleAssets_744" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AggregatePercentage" xlink:label="loc_sclx_AggregatePercentage_745" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_sclx_AggregatePercentage_745" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_WarrantsPercentage" xlink:label="loc_sclx_WarrantsPercentage_746" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_sclx_WarrantsPercentage_746" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockNoParValue" xlink:label="loc_us-gaap_PreferredStockNoParValue_747" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_us-gaap_PreferredStockNoParValue_747" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_BalanceInTheTrustAccount" xlink:label="loc_sclx_BalanceInTheTrustAccount_748" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_sclx_BalanceInTheTrustAccount_748" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDescription" xlink:label="loc_us-gaap_OtherCommitmentsDescription_736" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_us-gaap_OtherCommitmentsDescription_736" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_737" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_737" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredUnitsAuthorized" xlink:label="loc_us-gaap_PreferredUnitsAuthorized_738" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_us-gaap_PreferredUnitsAuthorized_738" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MergerConsiderationDescription" xlink:label="loc_sclx_MergerConsiderationDescription_739" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_sclx_MergerConsiderationDescription_739" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_740" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_us-gaap_SharesIssued_740" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_741" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_741" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_CommonStockAggregateValue" xlink:label="loc_sclx_CommonStockAggregateValue_742" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_sclx_CommonStockAggregateValue_742" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DeferredUnderwritingCommission" xlink:label="loc_sclx_DeferredUnderwritingCommission_749" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_sclx_DeferredUnderwritingCommission_749" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AgreementExpirationTerm" xlink:label="loc_sclx_AgreementExpirationTerm_2146635922" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_sclx_AgreementExpirationTerm_2146635922" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AgreementAutomaticRenewalPeriodOnExpirationOfInitialTerm" xlink:label="loc_sclx_AgreementAutomaticRenewalPeriodOnExpirationOfInitialTerm_2146635925" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_sclx_AgreementAutomaticRenewalPeriodOnExpirationOfInitialTerm_2146635925" use="optional" order="52" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NoticeOfTerminationPeriodForCancellationOfAutomaticRenewal" xlink:label="loc_sclx_NoticeOfTerminationPeriodForCancellationOfAutomaticRenewal_2146635928" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_sclx_NoticeOfTerminationPeriodForCancellationOfAutomaticRenewal_2146635928" use="optional" order="53" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DeferredUnderwritingCommissionPayable" xlink:label="loc_sclx_DeferredUnderwritingCommissionPayable_750" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_sclx_DeferredUnderwritingCommissionPayable_750" use="optional" order="54" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfAggregateRoyalityPayments" xlink:label="loc_sclx_PercentageOfAggregateRoyalityPayments_2146635915" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_sclx_PercentageOfAggregateRoyalityPayments_2146635915" use="optional" order="55" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AgreementExpirationDate" xlink:label="loc_sclx_AgreementExpirationDate_2146635921" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_sclx_AgreementExpirationDate_2146635921" use="optional" order="56" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TerminationOfAgreementNoticePeriodForARequestToCureMaterialBreachOfTheAgreement" xlink:label="loc_sclx_TerminationOfAgreementNoticePeriodForARequestToCureMaterialBreachOfTheAgreement_2146635941" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_sclx_TerminationOfAgreementNoticePeriodForARequestToCureMaterialBreachOfTheAgreement_2146635941" use="optional" order="57" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NoticePeriodForTerminationOfWorkOrder" xlink:label="loc_sclx_NoticePeriodForTerminationOfWorkOrder_2146635952" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_sclx_NoticePeriodForTerminationOfWorkOrder_2146635952" use="optional" order="58" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ThresholdMinimumPercentageOfSales" xlink:label="loc_sclx_ThresholdMinimumPercentageOfSales_2146635946" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_sclx_ThresholdMinimumPercentageOfSales_2146635946" use="optional" order="59" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfAnnualAdjustmentToFees" xlink:label="loc_sclx_PercentageOfAnnualAdjustmentToFees_2146635948" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_sclx_PercentageOfAnnualAdjustmentToFees_2146635948" use="optional" order="60" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfDistributionFeeReceivedOverThePeriod" xlink:label="loc_sclx_PercentageOfDistributionFeeReceivedOverThePeriod_2146635950" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_sclx_PercentageOfDistributionFeeReceivedOverThePeriod_2146635950" use="optional" order="61" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_WorkOrderImplementationFee" xlink:label="loc_sclx_WorkOrderImplementationFee_2146635953" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_sclx_WorkOrderImplementationFee_2146635953" use="optional" order="62" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SalesOperationsServicesMonthlyFee" xlink:label="loc_sclx_SalesOperationsServicesMonthlyFee_2146635954" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_sclx_SalesOperationsServicesMonthlyFee_2146635954" use="optional" order="63" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SellingGeneralAndAdministrativeExpenses" xlink:label="loc_sclx_SellingGeneralAndAdministrativeExpenses_2146635955" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_sclx_SellingGeneralAndAdministrativeExpenses_2146635955" use="optional" order="64" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_2146635956" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_2146635956" use="optional" order="65" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_2146635957" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_2146635957" use="optional" order="66" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaap_OperatingLeaseExpense_2146635959" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_us-gaap_OperatingLeaseExpense_2146635959" use="optional" order="67" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LessorOperatingLeaseTermOfContract_2146636108" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_us-gaap_LessorOperatingLeaseTermOfContract_2146636108" use="optional" order="68" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/ShareholdersDeficitDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_2146635127" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_764" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2146635127" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_764" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_765" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2146635127" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_765" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_766" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2146635127" xlink:to="loc_us-gaap_PreferredStockSharesIssued_766" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_767" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2146635127" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_767" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_768" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2146635127" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_768" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_769" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2146635127" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_769" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_770" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2146635127" xlink:to="loc_us-gaap_CommonStockSharesIssued_770" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_771" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2146635127" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_771" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_OrdinarySharesSubjectToPossibleRedemption" xlink:label="loc_sclx_OrdinarySharesSubjectToPossibleRedemption_772" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2146635127" xlink:to="loc_sclx_OrdinarySharesSubjectToPossibleRedemption_772" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_2146635126" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_2146635127" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_2146635126" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635128" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2146635126" xlink:to="loc_dei_LegalEntityAxis_2146635128" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635129" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2146635128" xlink:to="loc_dei_EntityDomain_2146635129" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635129_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2146635128" xlink:to="loc_dei_EntityDomain_2146635129_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635130" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146635129" xlink:to="loc_sclx_VickersVantageMember_2146635130" use="optional" order="14" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/WarrantsDetails">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_WarrantsDetailsLineItems" xlink:label="loc_sclx_WarrantsDetailsLineItems_791" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_WarrantsOutstandingShares" xlink:label="loc_sclx_WarrantsOutstandingShares_796" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_WarrantsDetailsLineItems_791" xlink:to="loc_sclx_WarrantsOutstandingShares_796" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PublicWarrantsRedemptionDescription" xlink:label="loc_sclx_PublicWarrantsRedemptionDescription_797" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_WarrantsDetailsLineItems_791" xlink:to="loc_sclx_PublicWarrantsRedemptionDescription_797" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_CapitalRaisingDescription" xlink:label="loc_sclx_CapitalRaisingDescription_798" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_WarrantsDetailsLineItems_791" xlink:to="loc_sclx_CapitalRaisingDescription_798" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_WarrantsDetailsTable" xlink:label="loc_sclx_WarrantsDetailsTable_788" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sclx_WarrantsDetailsLineItems_791" xlink:to="loc_sclx_WarrantsDetailsTable_788" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146634998" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_WarrantsDetailsTable_788" xlink:to="loc_dei_LegalEntityAxis_2146634998" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146634999" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2146634998" xlink:to="loc_dei_EntityDomain_2146634999" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146634999_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2146634998" xlink:to="loc_dei_EntityDomain_2146634999_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635000" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146634999" xlink:to="loc_sclx_VickersVantageMember_2146635000" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_789" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_WarrantsDetailsTable_788" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_789" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_792" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_789" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_792" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_792_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_789" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_792_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_793" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_792" xlink:to="loc_us-gaap_PrivatePlacementMember_793" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_790" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_WarrantsDetailsTable_788" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_790" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_794" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_790" xlink:to="loc_us-gaap_EquityComponentDomain_794" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_794_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_790" xlink:to="loc_us-gaap_EquityComponentDomain_794_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_795" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_794" xlink:to="loc_us-gaap_WarrantMember_795" use="optional" order="16" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2146634958" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsHeldInTrustCurrent" xlink:label="loc_us-gaap_AssetsHeldInTrustCurrent_805" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146634958" xlink:to="loc_us-gaap_AssetsHeldInTrustCurrent_805" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsHighestAndBestUseDescription" xlink:label="loc_us-gaap_FairValueMeasurementsHighestAndBestUseDescription_806" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146634958" xlink:to="loc_us-gaap_FairValueMeasurementsHighestAndBestUseDescription_806" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLossOnDerivative" xlink:label="loc_us-gaap_DerivativeLossOnDerivative_2146635649" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146634958" xlink:to="loc_us-gaap_DerivativeLossOnDerivative_2146635649" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainOnDerivative" xlink:label="loc_us-gaap_DerivativeGainOnDerivative_2146635774" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146634958" xlink:to="loc_us-gaap_DerivativeGainOnDerivative_2146635774" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="loc_us-gaap_DerivativeLiabilityMeasurementInput_2146635778" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146634958" xlink:to="loc_us-gaap_DerivativeLiabilityMeasurementInput_2146635778" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsHeldInTrust" xlink:label="loc_us-gaap_AssetsHeldInTrust_2146636312" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146634958" xlink:to="loc_us-gaap_AssetsHeldInTrust_2146636312" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_2146634955" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_2146634958" xlink:to="loc_us-gaap_StatementTable_2146634955" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_2146635787" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2146634955" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_2146635787" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_2146635789" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_2146635787" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_2146635789" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_2146635789_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_2146635787" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_2146635789_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MeasurementInputRiskadjustedNetSalesForecastMember" xlink:label="loc_sclx_MeasurementInputRiskadjustedNetSalesForecastMember_2146635794" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_2146635789" xlink:to="loc_sclx_MeasurementInputRiskadjustedNetSalesForecastMember_2146635794" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MeasurementInputEffectiveDebtYieldMember" xlink:label="loc_sclx_MeasurementInputEffectiveDebtYieldMember_2146635799" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_2146635789" xlink:to="loc_sclx_MeasurementInputEffectiveDebtYieldMember_2146635799" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeMarch312021Member" xlink:label="loc_sclx_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeMarch312021Member_2146635806" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_2146635789" xlink:to="loc_sclx_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeMarch312021Member_2146635806" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeJuly12023Member" xlink:label="loc_sclx_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeJuly12023Member_2146635808" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_2146635789" xlink:to="loc_sclx_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeJuly12023Member_2146635808" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2146634956" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2146634955" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2146634956" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2146634957" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2146634956" xlink:to="loc_us-gaap_ClassOfStockDomain_2146634957" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2146634957_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2146634956" xlink:to="loc_us-gaap_ClassOfStockDomain_2146634957_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635089" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2146634955" xlink:to="loc_dei_LegalEntityAxis_2146635089" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635090" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2146635089" xlink:to="loc_dei_EntityDomain_2146635090" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635090_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2146635089" xlink:to="loc_dei_EntityDomain_2146635090_default" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635091" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146635090" xlink:to="loc_sclx_VickersVantageMember_2146635091" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_2146636091" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2146634955" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_2146636091" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2146636092" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_2146636091" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2146636092" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2146636092_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_2146636091" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2146636092_default" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_2146636093" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2146636092" xlink:to="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_2146636093" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_2146636094" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2146634955" xlink:to="loc_us-gaap_DebtInstrumentAxis_2146636094" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2146636095" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_2146636094" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2146636095" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2146636095_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_2146636094" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2146636095_default" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScilexPharmaNotesMember" xlink:label="loc_sclx_ScilexPharmaNotesMember_2146636096" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2146636095" xlink:to="loc_sclx_ScilexPharmaNotesMember_2146636096" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_2146636089" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146634958" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_2146636089" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_2146636100" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146634958" xlink:to="loc_us-gaap_DerivativeLiabilities_2146636100" use="optional" order="31" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfFairValueHierarchyOfTheValuationInputs">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_FairValueMeasurementsDetailsScheduleoffairvaluehierarchyofthevaluationinputsLineItems" xlink:label="loc_sclx_FairValueMeasurementsDetailsScheduleoffairvaluehierarchyofthevaluationinputsLineItems_405" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract" xlink:label="loc_us-gaap_LiabilitiesAbstract_407" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_FairValueMeasurementsDetailsScheduleoffairvaluehierarchyofthevaluationinputsLineItems_405" xlink:to="loc_us-gaap_LiabilitiesAbstract_407" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="loc_us-gaap_LiabilitiesFairValueAdjustment_411" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_407" xlink:to="loc_us-gaap_LiabilitiesFairValueAdjustment_411" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_412" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_407" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_412" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_FairValueMeasurementsDetailsScheduleoffairvaluehierarchyofthevaluationinputsTable" xlink:label="loc_sclx_FairValueMeasurementsDetailsScheduleoffairvaluehierarchyofthevaluationinputsTable_403" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sclx_FairValueMeasurementsDetailsScheduleoffairvaluehierarchyofthevaluationinputsLineItems_405" xlink:to="loc_sclx_FairValueMeasurementsDetailsScheduleoffairvaluehierarchyofthevaluationinputsTable_403" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_404" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_FairValueMeasurementsDetailsScheduleoffairvaluehierarchyofthevaluationinputsTable_403" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_404" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2146634686" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_404" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2146634686" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2146634686_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_404" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2146634686_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_408" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2146634686" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_408" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_409" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2146634686" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_409" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635112" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_FairValueMeasurementsDetailsScheduleoffairvaluehierarchyofthevaluationinputsTable_403" xlink:to="loc_dei_LegalEntityAxis_2146635112" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635113" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2146635112" xlink:to="loc_dei_EntityDomain_2146635113" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635113_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2146635112" xlink:to="loc_dei_EntityDomain_2146635113_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635115" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146635113" xlink:to="loc_sclx_VickersVantageMember_2146635115" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_406" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_FairValueMeasurementsDetailsScheduleoffairvaluehierarchyofthevaluationinputsLineItems_405" xlink:to="loc_us-gaap_AssetsAbstract_406" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeSecuritiesUSTreasury" xlink:label="loc_us-gaap_InterestIncomeSecuritiesUSTreasury_410" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_406" xlink:to="loc_us-gaap_InterestIncomeSecuritiesUSTreasury_410" use="optional" order="15" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfChangesInTheFairValueOfWarrantLiabilitiesAndConversionOptionLiability">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityLineItems" xlink:label="loc_sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityLineItems_446" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_449" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityLineItems_446" xlink:to="loc_us-gaap_DerivativeLiabilities_449" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_InitialMeasurementOne" xlink:label="loc_sclx_InitialMeasurementOne_450" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityLineItems_446" xlink:to="loc_sclx_InitialMeasurementOne_450" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ChangeInValuationInputsOrOtherAssumptions" xlink:label="loc_sclx_ChangeInValuationInputsOrOtherAssumptions_451" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityLineItems_446" xlink:to="loc_sclx_ChangeInValuationInputsOrOtherAssumptions_451" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityTable" xlink:label="loc_sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityTable_444" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityLineItems_446" xlink:to="loc_sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityTable_444" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_445" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityTable_444" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_445" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2146634698" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_445" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2146634698" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2146634698_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_445" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2146634698_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_447" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2146634698" xlink:to="loc_us-gaap_PrivatePlacementMember_447" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ConversionOptionLiabilityMember" xlink:label="loc_sclx_ConversionOptionLiabilityMember_448" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2146634698" xlink:to="loc_sclx_ConversionOptionLiabilityMember_448" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635139" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityTable_444" xlink:to="loc_dei_LegalEntityAxis_2146635139" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635140" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2146635139" xlink:to="loc_dei_EntityDomain_2146635140" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635140_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2146635139" xlink:to="loc_dei_EntityDomain_2146635140_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635141" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146635140" xlink:to="loc_sclx_VickersVantageMember_2146635141" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfValuedUsingTheCompoundOptionPricingModel">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2146635146" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_UnderlyingWarrantValue" xlink:label="loc_sclx_UnderlyingWarrantValue_463" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635146" xlink:to="loc_sclx_UnderlyingWarrantValue_463" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_2146635143" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_2146635146" xlink:to="loc_us-gaap_StatementTable_2146635143" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2146635144" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2146635143" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2146635144" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2146635145" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2146635144" xlink:to="loc_us-gaap_ClassOfStockDomain_2146635145" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2146635145_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2146635144" xlink:to="loc_us-gaap_ClassOfStockDomain_2146635145_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635147" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2146635143" xlink:to="loc_dei_LegalEntityAxis_2146635147" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635148" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2146635147" xlink:to="loc_dei_EntityDomain_2146635148" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635148_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2146635147" xlink:to="loc_dei_EntityDomain_2146635148_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635149" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146635148" xlink:to="loc_sclx_VickersVantageMember_2146635149" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_464" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635146" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_464" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_HoldingPeriod" xlink:label="loc_sclx_HoldingPeriod_465" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635146" xlink:to="loc_sclx_HoldingPeriod_465" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_466" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635146" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_466" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_467" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635146" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_467" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_468" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635146" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_468" use="optional" order="14" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsFinancialAssetsAndLiabilitiesThatAreMeasuredAtFairValue">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2146635513" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_2146635516" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2146635513" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_2146635516" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_2146635520" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2146635513" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_2146635520" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_2146635527" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2146635513" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_2146635527" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_2146635531" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_2146635527" xlink:to="loc_us-gaap_DerivativeLiabilities_2146635531" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_2146635558" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_2146635527" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_2146635558" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2146635511" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2146635513" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2146635511" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2146635559" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2146635511" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2146635559" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2146635560" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2146635559" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2146635560" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2146635560_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2146635559" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2146635560_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_2146635565" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2146635560" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_2146635565" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_2146635567" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2146635560" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_2146635567" use="optional" order="11" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsDerivativeLiabilitiesMeasuredAtFairValueUsingSignificantUnobservableInputs">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2146635624" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2146635623" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2146635624" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2146635623" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_2146635638" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2146635623" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_2146635638" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2146635639" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_2146635638" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2146635639" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2146635639_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_2146635638" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2146635639_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_2146635640" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2146635639" xlink:to="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_2146635640" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2146635626" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2146635624" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2146635626" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_2146635629" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2146635624" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_2146635629" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_2146635630" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2146635624" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_2146635630" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_2146635862" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2146635624" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_2146635862" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurements">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2146635135" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_426" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635135" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_426" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_427" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635135" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_427" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1" xlink:label="loc_sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1_428" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635135" xlink:to="loc_sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1_428" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_424" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635135" xlink:to="loc_us-gaap_SharePrice_424" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_FairValueMeasurementStrikePrice" xlink:label="loc_sclx_FairValueMeasurementStrikePrice_425" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635135" xlink:to="loc_sclx_FairValueMeasurementStrikePrice_425" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1" xlink:label="loc_sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1_429" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635135" xlink:to="loc_sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1_429" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_2146635132" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_2146635135" xlink:to="loc_us-gaap_StatementTable_2146635132" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635136" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2146635132" xlink:to="loc_dei_LegalEntityAxis_2146635136" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635137" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2146635136" xlink:to="loc_dei_EntityDomain_2146635137" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635137_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2146635136" xlink:to="loc_dei_EntityDomain_2146635137_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635138" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146635137" xlink:to="loc_sclx_VickersVantageMember_2146635138" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2146635133" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2146635132" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2146635133" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2146635134" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2146635133" xlink:to="loc_us-gaap_ClassOfStockDomain_2146635134" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2146635134_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2146635133" xlink:to="loc_us-gaap_ClassOfStockDomain_2146635134_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_FairValueOfWarrantsinDollars" xlink:label="loc_sclx_FairValueOfWarrantsinDollars_430" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2146635135" xlink:to="loc_sclx_FairValueOfWarrantsinDollars_430" use="optional" order="15" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfChangeInTheFairValueOfConversionOptionLiability">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityLineItems" xlink:label="loc_sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityLineItems_2146635357" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetAssetLiability" xlink:label="loc_us-gaap_FairValueNetAssetLiability_2146635361" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityLineItems_2146635357" xlink:to="loc_us-gaap_FairValueNetAssetLiability_2146635361" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_2146635363" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityLineItems_2146635357" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_2146635363" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue" xlink:label="loc_us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue_2146635364" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityLineItems_2146635357" xlink:to="loc_us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue_2146635364" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityTable" xlink:label="loc_sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityTable_2146635356" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityLineItems_2146635357" xlink:to="loc_sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityTable_2146635356" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635358" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityTable_2146635356" xlink:to="loc_dei_LegalEntityAxis_2146635358" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635359" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2146635358" xlink:to="loc_dei_EntityDomain_2146635359" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635359_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2146635358" xlink:to="loc_dei_EntityDomain_2146635359_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635360" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146635359" xlink:to="loc_sclx_VickersVantageMember_2146635360" use="optional" order="8" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/PropertyAndEquipmentDetailsPropertyAndEquipmentConsisted">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2146635826" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2146635828" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2146635826" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2146635828" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2146635830" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2146635826" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_2146635830" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2146635825" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2146635826" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2146635825" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2146635831" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2146635825" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2146635831" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2146635832" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2146635831" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2146635832" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2146635832_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2146635831" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2146635832_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_2146635833" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2146635832" xlink:to="loc_us-gaap_ComputerEquipmentMember_2146635833" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_2146635835" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2146635832" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_2146635835" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_2146635836" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2146635832" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_2146635836" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_2146635837" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2146635832" xlink:to="loc_us-gaap_ConstructionInProgressMember_2146635837" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_2146635827" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2146635826" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_2146635827" use="optional" order="11" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfTheCompanysIdentifiableIntangibleAssets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2146635535" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2146635534" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2146635535" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2146635534" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2146635540" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2146635534" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2146635540" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2146635541" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2146635540" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2146635541" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2146635541_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2146635540" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2146635541_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AssembledWorkforceMember" xlink:label="loc_sclx_AssembledWorkforceMember_2146635548" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2146635541" xlink:to="loc_sclx_AssembledWorkforceMember_2146635548" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember" xlink:label="loc_us-gaap_LicensingAgreementsMember_2146636056" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2146635541" xlink:to="loc_us-gaap_LicensingAgreementsMember_2146636056" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaap_PatentsMember_2146635542" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2146635541" xlink:to="loc_us-gaap_PatentsMember_2146635542" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_2146635545" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2146635541" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_2146635545" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_2146635537" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2146635535" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_2146635537" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2146635538" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2146635535" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2146635538" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2146635539" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2146635535" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2146635539" use="optional" order="11" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_2146635569" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_2146635568" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_2146635569" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_2146635568" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2146635592" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_2146635568" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2146635592" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2146635593" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2146635592" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2146635593" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2146635593_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2146635592" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2146635593_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember" xlink:label="loc_us-gaap_LicensingAgreementsMember_2146636064" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2146635593" xlink:to="loc_us-gaap_LicensingAgreementsMember_2146636064" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaap_PatentsMember_2146635595" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2146635593" xlink:to="loc_us-gaap_PatentsMember_2146635595" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_2146635596" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2146635593" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_2146635596" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AssembledWorkforceMember" xlink:label="loc_sclx_AssembledWorkforceMember_2146635597" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2146635593" xlink:to="loc_sclx_AssembledWorkforceMember_2146635597" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_2146635600" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_2146635568" xlink:to="loc_srt_RangeAxis_2146635600" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_2146635602" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_2146635600" xlink:to="loc_srt_RangeMember_2146635602" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_2146635602_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_2146635600" xlink:to="loc_srt_RangeMember_2146635602_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_WeightedAverageMember" xlink:label="loc_srt_WeightedAverageMember_2146635603" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2146635602" xlink:to="loc_srt_WeightedAverageMember_2146635603" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_2146635582" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_2146635569" xlink:to="loc_us-gaap_Goodwill_2146635582" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_2146635585" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_2146635569" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_2146635585" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_2146635586" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_2146635569" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_2146635586" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_2146635588" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_2146635569" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_2146635588" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_2146636061" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_2146635569" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_2146636061" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_2146636062" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_2146635569" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_2146636062" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_2146635589" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_2146635569" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_2146635589" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_2146635590" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_2146635569" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_2146635590" use="optional" order="20" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/DebtDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaap_ShortTermDebtLineItems_2146636083" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_2146636082" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTable_2146636082" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_2146636084" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_2146636082" xlink:to="loc_us-gaap_DebtInstrumentAxis_2146636084" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2146636085" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_2146636084" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2146636085" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2146636085_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_2146636084" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2146636085_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScilexPharmaNoteMember" xlink:label="loc_sclx_ScilexPharmaNoteMember_2146636174" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2146636085" xlink:to="loc_sclx_ScilexPharmaNoteMember_2146636174" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TwoThousandAndEighteenPurchaseAgreementsMember" xlink:label="loc_sclx_TwoThousandAndEighteenPurchaseAgreementsMember_2146636086" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2146636085" xlink:to="loc_sclx_TwoThousandAndEighteenPurchaseAgreementsMember_2146636086" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_2146636141" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_2146636082" xlink:to="loc_srt_RangeAxis_2146636141" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_2146636142" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_2146636141" xlink:to="loc_srt_RangeMember_2146636142" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_2146636142_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_2146636141" xlink:to="loc_srt_RangeMember_2146636142_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_2146636143" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2146636142" xlink:to="loc_srt_MaximumMember_2146636143" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_2146636144" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2146636142" xlink:to="loc_srt_MinimumMember_2146636144" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_2146636207" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_2146636082" xlink:to="loc_us-gaap_CreditFacilityAxis_2146636207" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_2146636208" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_2146636207" xlink:to="loc_us-gaap_CreditFacilityDomain_2146636208" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_2146636208_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_2146636207" xlink:to="loc_us-gaap_CreditFacilityDomain_2146636208_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember" xlink:label="loc_us-gaap_LetterOfCreditMember_2146636219" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_2146636208" xlink:to="loc_us-gaap_LetterOfCreditMember_2146636219" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_2146636381" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_2146636208" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_2146636381" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AccountsReceivableRevolvingLoanFacilityMember" xlink:label="loc_sclx_AccountsReceivableRevolvingLoanFacilityMember_2146636322" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_2146636208" xlink:to="loc_sclx_AccountsReceivableRevolvingLoanFacilityMember_2146636322" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_2146636383" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_2146636082" xlink:to="loc_us-gaap_VariableRateAxis_2146636383" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_2146636384" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_2146636383" xlink:to="loc_us-gaap_VariableRateDomain_2146636384" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_2146636384_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_2146636383" xlink:to="loc_us-gaap_VariableRateDomain_2146636384_default" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrimeRateMember" xlink:label="loc_us-gaap_PrimeRateMember_2146636385" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_2146636384" xlink:to="loc_us-gaap_PrimeRateMember_2146636385" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_2146636145" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_2146636082" xlink:to="loc_srt_StatementScenarioAxis_2146636145" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_2146636146" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_2146636145" xlink:to="loc_srt_ScenarioUnspecifiedDomain_2146636146" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_2146636146_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_2146636145" xlink:to="loc_srt_ScenarioUnspecifiedDomain_2146636146_default" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_IfLetterOfCreditIsDrawnMember" xlink:label="loc_sclx_IfLetterOfCreditIsDrawnMember_2146636246" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_2146636146" xlink:to="loc_sclx_IfLetterOfCreditIsDrawnMember_2146636246" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MarketingApprovalLetterMember" xlink:label="loc_sclx_MarketingApprovalLetterMember_2146636248" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_2146636146" xlink:to="loc_sclx_MarketingApprovalLetterMember_2146636248" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScenarioAdjustmentMember" xlink:label="loc_us-gaap_ScenarioAdjustmentMember_2146636147" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_2146636146" xlink:to="loc_us-gaap_ScenarioAdjustmentMember_2146636147" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_2146636148" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_2146636082" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_2146636148" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_2146636149" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_2146636148" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_2146636149" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_2146636149_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_2146636148" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_2146636149_default" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_2146636170" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_2146636149" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_2146636170" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_2146636156" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_2146636149" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_2146636156" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_2146636150" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_2146636149" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_2146636150" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_StatementAxis" xlink:label="loc_sclx_StatementAxis_2146636282" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_2146636082" xlink:to="loc_sclx_StatementAxis_2146636282" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_StatementDomain" xlink:label="loc_sclx_StatementDomain_2146636283" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sclx_StatementAxis_2146636282" xlink:to="loc_sclx_StatementDomain_2146636283" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_StatementDomain" xlink:label="loc_sclx_StatementDomain_2146636283_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sclx_StatementAxis_2146636282" xlink:to="loc_sclx_StatementDomain_2146636283_default" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DecemberOptionalRepurchaseMember" xlink:label="loc_sclx_DecemberOptionalRepurchaseMember_2146636287" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_StatementDomain_2146636283" xlink:to="loc_sclx_DecemberOptionalRepurchaseMember_2146636287" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_FebruaryOptionalRepurchaseMember" xlink:label="loc_sclx_FebruaryOptionalRepurchaseMember_2146636291" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_StatementDomain_2146636283" xlink:to="loc_sclx_FebruaryOptionalRepurchaseMember_2146636291" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AprilOptionalRepurchaseMember" xlink:label="loc_sclx_AprilOptionalRepurchaseMember_2146636294" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_StatementDomain_2146636283" xlink:to="loc_sclx_AprilOptionalRepurchaseMember_2146636294" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_EventTypeAxis" xlink:label="loc_sclx_EventTypeAxis_2146636396" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_2146636082" xlink:to="loc_sclx_EventTypeAxis_2146636396" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_EventTypeDomain" xlink:label="loc_sclx_EventTypeDomain_2146636397" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sclx_EventTypeAxis_2146636396" xlink:to="loc_sclx_EventTypeDomain_2146636397" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_EventTypeDomain" xlink:label="loc_sclx_EventTypeDomain_2146636397_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sclx_EventTypeAxis_2146636396" xlink:to="loc_sclx_EventTypeDomain_2146636397_default" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_CoronavirusAidReliefAndEconomicSecurityActMember" xlink:label="loc_sclx_CoronavirusAidReliefAndEconomicSecurityActMember_2146636398" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_EventTypeDomain_2146636397" xlink:to="loc_sclx_CoronavirusAidReliefAndEconomicSecurityActMember_2146636398" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ClassificationOfCostAxis" xlink:label="loc_sclx_ClassificationOfCostAxis_2146636400" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_2146636082" xlink:to="loc_sclx_ClassificationOfCostAxis_2146636400" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ClassificationOfCostDomain" xlink:label="loc_sclx_ClassificationOfCostDomain_2146636437" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sclx_ClassificationOfCostAxis_2146636400" xlink:to="loc_sclx_ClassificationOfCostDomain_2146636437" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ClassificationOfCostDomain" xlink:label="loc_sclx_ClassificationOfCostDomain_2146636437_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sclx_ClassificationOfCostAxis_2146636400" xlink:to="loc_sclx_ClassificationOfCostDomain_2146636437_default" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NonPayrollCostsMember" xlink:label="loc_sclx_NonPayrollCostsMember_2146636438" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_ClassificationOfCostDomain_2146636437" xlink:to="loc_sclx_NonPayrollCostsMember_2146636438" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PayrollCostsBasisMember" xlink:label="loc_sclx_PayrollCostsBasisMember_2146636439" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_ClassificationOfCostDomain_2146636437" xlink:to="loc_sclx_PayrollCostsBasisMember_2146636439" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_2146636389" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_2146636082" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_2146636389" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2146636390" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2146636389" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2146636390" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2146636390_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2146636389" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2146636390_default" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PaycheckProtectionProgramMember" xlink:label="loc_sclx_PaycheckProtectionProgramMember_2146636391" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2146636390" xlink:to="loc_sclx_PaycheckProtectionProgramMember_2146636391" use="optional" order="52" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubordinatedDebtMember" xlink:label="loc_us-gaap_SubordinatedDebtMember_2146636404" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2146636390" xlink:to="loc_us-gaap_SubordinatedDebtMember_2146636404" use="optional" order="53" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AgreementAxis" xlink:label="loc_sclx_AgreementAxis_2146636183" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_2146636082" xlink:to="loc_sclx_AgreementAxis_2146636183" use="optional" order="54" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AgreementDomain" xlink:label="loc_sclx_AgreementDomain_2146636184" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sclx_AgreementAxis_2146636183" xlink:to="loc_sclx_AgreementDomain_2146636184" use="optional" order="55" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AgreementDomain" xlink:label="loc_sclx_AgreementDomain_2146636184_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sclx_AgreementAxis_2146636183" xlink:to="loc_sclx_AgreementDomain_2146636184_default" use="optional" order="56" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_IndebentureMember" xlink:label="loc_sclx_IndebentureMember_2146636188" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_AgreementDomain_2146636184" xlink:to="loc_sclx_IndebentureMember_2146636188" use="optional" order="57" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AmendmentAxis" xlink:label="loc_sclx_AmendmentAxis_2146636421" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_2146636082" xlink:to="loc_sclx_AmendmentAxis_2146636421" use="optional" order="58" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AmendmentDomain" xlink:label="loc_sclx_AmendmentDomain_2146636423" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sclx_AmendmentAxis_2146636421" xlink:to="loc_sclx_AmendmentDomain_2146636423" use="optional" order="59" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AmendmentDomain" xlink:label="loc_sclx_AmendmentDomain_2146636423_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sclx_AmendmentAxis_2146636421" xlink:to="loc_sclx_AmendmentDomain_2146636423_default" use="optional" order="60" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AmendmentNoFourMember" xlink:label="loc_sclx_AmendmentNoFourMember_2146636424" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_AmendmentDomain_2146636423" xlink:to="loc_sclx_AmendmentNoFourMember_2146636424" use="optional" order="61" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2146636425" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_2146636082" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2146636425" use="optional" order="62" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_2146636426" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2146636425" xlink:to="loc_us-gaap_RelatedPartyDomain_2146636426" use="optional" order="63" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_2146636426_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2146636425" xlink:to="loc_us-gaap_RelatedPartyDomain_2146636426_default" use="optional" order="64" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SorrentoMember" xlink:label="loc_sclx_SorrentoMember_2146636427" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_2146636426" xlink:to="loc_sclx_SorrentoMember_2146636427" use="optional" order="65" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_2146636428" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_2146636082" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_2146636428" use="optional" order="66" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_2146636429" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_2146636428" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_2146636429" use="optional" order="67" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_2146636429_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_2146636428" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_2146636429_default" use="optional" order="68" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PromissoryNoteMember" xlink:label="loc_sclx_PromissoryNoteMember_2146636430" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_2146636429" xlink:to="loc_sclx_PromissoryNoteMember_2146636430" use="optional" order="69" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_2146636431" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_2146636082" xlink:to="loc_us-gaap_TypeOfArrangementAxis_2146636431" use="optional" order="70" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2146636432" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2146636431" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2146636432" use="optional" order="71" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2146636432_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2146636431" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2146636432_default" use="optional" order="72" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TwoThousandAndEighteenPurchaseAgreementsAndIndentureMember" xlink:label="loc_sclx_TwoThousandAndEighteenPurchaseAgreementsAndIndentureMember_2146636434" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2146636432" xlink:to="loc_sclx_TwoThousandAndEighteenPurchaseAgreementsAndIndentureMember_2146636434" use="optional" order="73" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_2146636087" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_2146636087" use="optional" order="74" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchaseAmount" xlink:label="loc_us-gaap_DebtInstrumentRepurchaseAmount_2146636088" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_DebtInstrumentRepurchaseAmount_2146636088" use="optional" order="75" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm_2146636090" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_DebtInstrumentTerm_2146636090" use="optional" order="76" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfQuarterlyPaymentsOfThePrincipalNotesEqualToAFixedPercentage" xlink:label="loc_sclx_PercentageOfQuarterlyPaymentsOfThePrincipalNotesEqualToAFixedPercentage_2146636137" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_sclx_PercentageOfQuarterlyPaymentsOfThePrincipalNotesEqualToAFixedPercentage_2146636137" use="optional" order="77" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DebtInstrumentredemptionPeriod" xlink:label="loc_sclx_DebtInstrumentredemptionPeriod_2146636171" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_sclx_DebtInstrumentredemptionPeriod_2146636171" use="optional" order="78" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfNetSalesPayable" xlink:label="loc_sclx_PercentageOfNetSalesPayable_2146636138" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_sclx_PercentageOfNetSalesPayable_2146636138" use="optional" order="79" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueNotFromContractWithCustomer" xlink:label="loc_us-gaap_RevenueNotFromContractWithCustomer_2146636139" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_RevenueNotFromContractWithCustomer_2146636139" use="optional" order="80" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt_2146636140" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_RepaymentsOfDebt_2146636140" use="optional" order="81" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_2146636151" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_2146636151" use="optional" order="82" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PaymentToDepositIntoASeggregateReserveFund" xlink:label="loc_sclx_PaymentToDepositIntoASeggregateReserveFund_2146636152" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_sclx_PaymentToDepositIntoASeggregateReserveFund_2146636152" use="optional" order="83" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PaymentToDepositIntoASegregatedCollateralAccount" xlink:label="loc_sclx_PaymentToDepositIntoASegregatedCollateralAccount_2146636153" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_sclx_PaymentToDepositIntoASegregatedCollateralAccount_2146636153" use="optional" order="84" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfConcentrationOnASimilarProduct" xlink:label="loc_sclx_PercentageOfConcentrationOnASimilarProduct_2146636154" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_sclx_PercentageOfConcentrationOnASimilarProduct_2146636154" use="optional" order="85" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPayment_2146636155" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPayment_2146636155" use="optional" order="86" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_2146636159" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_2146636159" use="optional" order="87" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_2146636176" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_2146636176" use="optional" order="88" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MinimumCashRequirementsToRepurchaseOfNotes" xlink:label="loc_sclx_MinimumCashRequirementsToRepurchaseOfNotes_2146636277" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_sclx_MinimumCashRequirementsToRepurchaseOfNotes_2146636277" use="optional" order="89" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_2146636197" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_2146636197" use="optional" order="90" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_2146636203" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_2146636203" use="optional" order="91" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_2146636239" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_2146636239" use="optional" order="92" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfThePrincipalAmountFromHoldersOnProRataBasis" xlink:label="loc_sclx_PercentageOfThePrincipalAmountFromHoldersOnProRataBasis_2146636241" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_sclx_PercentageOfThePrincipalAmountFromHoldersOnProRataBasis_2146636241" use="optional" order="93" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AmountDistributionToAcquireRelatedContingentAcceleratedRepaymentNotes" xlink:label="loc_sclx_AmountDistributionToAcquireRelatedContingentAcceleratedRepaymentNotes_2146636335" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_sclx_AmountDistributionToAcquireRelatedContingentAcceleratedRepaymentNotes_2146636335" use="optional" order="94" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_2146636338" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_2146636338" use="optional" order="95" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_2146636395" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_2146636395" use="optional" order="96" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_2146636386" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_LongTermDebt_2146636386" use="optional" order="97" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DebtInstrumentTerminationDate" xlink:label="loc_sclx_DebtInstrumentTerminationDate_2146636387" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_sclx_DebtInstrumentTerminationDate_2146636387" use="optional" order="98" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_2146636388" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_2146636388" use="optional" order="99" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MaximumCompensationCostToBeAvailableProratedBasis" xlink:label="loc_sclx_MaximumCompensationCostToBeAvailableProratedBasis_2146636392" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_sclx_MaximumCompensationCostToBeAvailableProratedBasis_2146636392" use="optional" order="100" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfLoanForgivenessUnderTheAct" xlink:label="loc_sclx_PercentageOfLoanForgivenessUnderTheAct_2146636393" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_sclx_PercentageOfLoanForgivenessUnderTheAct_2146636393" use="optional" order="101" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MinimumPayrollCostToBeAvailable" xlink:label="loc_sclx_MinimumPayrollCostToBeAvailable_2146636394" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_sclx_MinimumPayrollCostToBeAvailable_2146636394" use="optional" order="102" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MinimumUnrestrictedCashRequirementsToRepurchaseOfNotes" xlink:label="loc_sclx_MinimumUnrestrictedCashRequirementsToRepurchaseOfNotes_2146636314" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_sclx_MinimumUnrestrictedCashRequirementsToRepurchaseOfNotes_2146636314" use="optional" order="103" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaap_RestrictedCash_2146636405" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_RestrictedCash_2146636405" use="optional" order="104" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DebtInstrumentPercentageOfPrincipalAmountRepurchased" xlink:label="loc_sclx_DebtInstrumentPercentageOfPrincipalAmountRepurchased_2146636406" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_sclx_DebtInstrumentPercentageOfPrincipalAmountRepurchased_2146636406" use="optional" order="105" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchaseDate" xlink:label="loc_us-gaap_DebtInstrumentRepurchaseDate_2146636407" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_DebtInstrumentRepurchaseDate_2146636407" use="optional" order="106" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentDecreaseForgiveness" xlink:label="loc_us-gaap_DebtInstrumentDecreaseForgiveness_2146636408" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_DebtInstrumentDecreaseForgiveness_2146636408" use="optional" order="107" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCollateralAmount" xlink:label="loc_us-gaap_DebtInstrumentCollateralAmount_2146636409" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_DebtInstrumentCollateralAmount_2146636409" use="optional" order="108" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt_2146636410" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt_2146636410" use="optional" order="109" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnRestructuringOfDebt" xlink:label="loc_us-gaap_GainsLossesOnRestructuringOfDebt_2146636411" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_GainsLossesOnRestructuringOfDebt_2146636411" use="optional" order="110" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_2146636412" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_2146636412" use="optional" order="111" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfThePrincipalAmountOfTheNotes" xlink:label="loc_sclx_PercentageOfThePrincipalAmountOfTheNotes_2146636313" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_sclx_PercentageOfThePrincipalAmountOfTheNotes_2146636313" use="optional" order="112" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" xlink:label="loc_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet_2146636413" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet_2146636413" use="optional" order="113" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_2146636414" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_2146636414" use="optional" order="114" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LineOfCreditFacilityindebtednessAmount" xlink:label="loc_sclx_LineOfCreditFacilityindebtednessAmount_2146636321" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_sclx_LineOfCreditFacilityindebtednessAmount_2146636321" use="optional" order="115" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_2146636334" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_DerivativeLiabilities_2146636334" use="optional" order="116" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:label="loc_us-gaap_DebtInstrumentAnnualPrincipalPayment_2146636377" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_DebtInstrumentAnnualPrincipalPayment_2146636377" use="optional" order="117" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_2146636378" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_2146636378" use="optional" order="118" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:label="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_2146636379" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_2146636379" use="optional" order="119" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/DebtDetailsSummaryOfBorrowingsOfTheScilexPharmaNotes">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_2146636356" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_2146636363" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2146636356" xlink:to="loc_us-gaap_LongTermDebt_2146636363" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_2146636364" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2146636356" xlink:to="loc_us-gaap_LongTermDebtCurrent_2146636364" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_2146636365" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2146636356" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_2146636365" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtFairValue" xlink:label="loc_us-gaap_LongTermDebtFairValue_2146636366" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2146636356" xlink:to="loc_us-gaap_LongTermDebtFairValue_2146636366" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_2146636355" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2146636356" xlink:to="loc_us-gaap_DebtInstrumentTable_2146636355" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_2146636357" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_2146636355" xlink:to="loc_us-gaap_DebtInstrumentAxis_2146636357" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2146636358" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_2146636357" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2146636358" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2146636358_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_2146636357" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2146636358_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScilexPharmaNotesMember" xlink:label="loc_sclx_ScilexPharmaNotesMember_2146636359" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2146636358" xlink:to="loc_sclx_ScilexPharmaNotesMember_2146636359" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_2146636360" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2146636356" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_2146636360" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_2146636361" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2146636356" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_2146636361" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_2146636362" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2146636356" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_2146636362" use="optional" order="12" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/DebtDetailsSummaryOfFutureMinimumPaymentsUnderTheScilexPharmaNotes">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtLineItems" xlink:label="loc_sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtLineItems_2146636370" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LongtermDebtFutureMinimumPayment" xlink:label="loc_sclx_LongtermDebtFutureMinimumPayment_2146636376" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtLineItems_2146636370" xlink:to="loc_sclx_LongtermDebtFutureMinimumPayment_2146636376" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LongtermDebtFutureMinimumPaymentYearFive" xlink:label="loc_sclx_LongtermDebtFutureMinimumPaymentYearFive_2146636375" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtLineItems_2146636370" xlink:to="loc_sclx_LongtermDebtFutureMinimumPaymentYearFive_2146636375" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LongtermDebtFutureMinimumPaymentYearFour" xlink:label="loc_sclx_LongtermDebtFutureMinimumPaymentYearFour_2146636374" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtLineItems_2146636370" xlink:to="loc_sclx_LongtermDebtFutureMinimumPaymentYearFour_2146636374" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LongtermDebtFutureMinimumPaymentYearThree" xlink:label="loc_sclx_LongtermDebtFutureMinimumPaymentYearThree_2146636373" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtLineItems_2146636370" xlink:to="loc_sclx_LongtermDebtFutureMinimumPaymentYearThree_2146636373" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LongtermDebtFutureMinimumPaymentYearTwo" xlink:label="loc_sclx_LongtermDebtFutureMinimumPaymentYearTwo_2146636372" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtLineItems_2146636370" xlink:to="loc_sclx_LongtermDebtFutureMinimumPaymentYearTwo_2146636372" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LongtermDebtfutureMinimumPaymentYearOne" xlink:label="loc_sclx_LongtermDebtfutureMinimumPaymentYearOne_2146636371" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtLineItems_2146636370" xlink:to="loc_sclx_LongtermDebtfutureMinimumPaymentYearOne_2146636371" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtTable" xlink:label="loc_sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtTable_2146636369" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtLineItems_2146636370" xlink:to="loc_sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtTable_2146636369" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetails">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_CompensationAndEmployeeBenefitPlansLineItems" xlink:label="loc_sclx_CompensationAndEmployeeBenefitPlansLineItems_2146635462" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2146635625" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CompensationAndEmployeeBenefitPlansLineItems_2146635462" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2146635625" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_CompensationAndEmployeeBenefitPlansTable" xlink:label="loc_sclx_CompensationAndEmployeeBenefitPlansTable_2146635460" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sclx_CompensationAndEmployeeBenefitPlansLineItems_2146635462" xlink:to="loc_sclx_CompensationAndEmployeeBenefitPlansTable_2146635460" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_2146635463" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_CompensationAndEmployeeBenefitPlansTable_2146635460" xlink:to="loc_us-gaap_PlanNameAxis_2146635463" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_2146635464" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_2146635463" xlink:to="loc_us-gaap_PlanNameDomain_2146635464" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_2146635464_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_2146635463" xlink:to="loc_us-gaap_PlanNameDomain_2146635464_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScilexPharmaTwoThousandSeventeenPlanMember" xlink:label="loc_sclx_ScilexPharmaTwoThousandSeventeenPlanMember_2146635465" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_2146635464" xlink:to="loc_sclx_ScilexPharmaTwoThousandSeventeenPlanMember_2146635465" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TwoThousandNineteenStockOptionPlanMember" xlink:label="loc_sclx_TwoThousandNineteenStockOptionPlanMember_2146635587" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_2146635464" xlink:to="loc_sclx_TwoThousandNineteenStockOptionPlanMember_2146635587" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AmendmentToTwoThousandNineteenStockOptionPlanMember" xlink:label="loc_sclx_AmendmentToTwoThousandNineteenStockOptionPlanMember_2146635591" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_2146635464" xlink:to="loc_sclx_AmendmentToTwoThousandNineteenStockOptionPlanMember_2146635591" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2146636114" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_CompensationAndEmployeeBenefitPlansTable_2146635460" xlink:to="loc_us-gaap_AwardTypeAxis_2146636114" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2146636115" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2146636114" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2146636115" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2146636115_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2146636114" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2146636115_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_2146636116" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2146636115" xlink:to="loc_us-gaap_EmployeeStockOptionMember_2146636116" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanNameAxis" xlink:label="loc_us-gaap_RetirementPlanNameAxis_2146635605" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_CompensationAndEmployeeBenefitPlansTable_2146635460" xlink:to="loc_us-gaap_RetirementPlanNameAxis_2146635605" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanNameDomain" xlink:label="loc_us-gaap_RetirementPlanNameDomain_2146635606" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanNameAxis_2146635605" xlink:to="loc_us-gaap_RetirementPlanNameDomain_2146635606" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanNameDomain" xlink:label="loc_us-gaap_RetirementPlanNameDomain_2146635606_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanNameAxis_2146635605" xlink:to="loc_us-gaap_RetirementPlanNameDomain_2146635606_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_FourHundredAndOneKPlanMember" xlink:label="loc_sclx_FourHundredAndOneKPlanMember_2146635607" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanNameDomain_2146635606" xlink:to="loc_sclx_FourHundredAndOneKPlanMember_2146635607" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2146635598" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_CompensationAndEmployeeBenefitPlansTable_2146635460" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2146635598" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2146635599" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2146635598" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2146635599" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2146635599_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2146635598" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2146635599_default" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_OperatingExpensesMember" xlink:label="loc_sclx_OperatingExpensesMember_2146635604" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2146635599" xlink:to="loc_sclx_OperatingExpensesMember_2146635604" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2146635634" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CompensationAndEmployeeBenefitPlansLineItems_2146635462" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2146635634" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant" xlink:label="loc_sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant_2146635641" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CompensationAndEmployeeBenefitPlansLineItems_2146635462" xlink:to="loc_sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant_2146635641" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_2146635650" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CompensationAndEmployeeBenefitPlansLineItems_2146635462" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_2146635650" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToEmployees" xlink:label="loc_us-gaap_PaymentsToEmployees_2146636113" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CompensationAndEmployeeBenefitPlansLineItems_2146635462" xlink:to="loc_us-gaap_PaymentsToEmployees_2146636113" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingNumber" xlink:label="loc_sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingNumber_2146637266" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CompensationAndEmployeeBenefitPlansLineItems_2146635462" xlink:to="loc_sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingNumber_2146637266" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2146635609" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CompensationAndEmployeeBenefitPlansLineItems_2146635462" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2146635609" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_2146635612" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CompensationAndEmployeeBenefitPlansLineItems_2146635462" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_2146635612" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_2146635631" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CompensationAndEmployeeBenefitPlansLineItems_2146635462" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_2146635631" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_2146635633" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_CompensationAndEmployeeBenefitPlansLineItems_2146635462" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_2146635633" use="optional" order="29" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfShareBasedPaymentAwardOptionsIssuedToEmployeesAndNonemployeesValuationAssumptions">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2146635660" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2146635666" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2146635660" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2146635666" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2146635667" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2146635660" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2146635667" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2146635672" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2146635660" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2146635672" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_2146635707" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2146635660" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_2146635707" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2146635659" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2146635660" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2146635659" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_2146635661" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2146635659" xlink:to="loc_srt_RangeAxis_2146635661" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_2146635662" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_2146635661" xlink:to="loc_srt_RangeMember_2146635662" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_2146635662_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_2146635661" xlink:to="loc_srt_RangeMember_2146635662_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_2146635663" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2146635662" xlink:to="loc_srt_MinimumMember_2146635663" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_2146635664" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2146635662" xlink:to="loc_srt_MaximumMember_2146635664" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_2146635682" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2146635660" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_2146635682" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2146635690" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2146635660" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2146635690" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_2146635692" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2146635660" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_2146635692" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_2146635693" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2146635660" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_2146635693" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2146635695" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2146635660" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2146635695" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant" xlink:label="loc_sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant_2146635704" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2146635660" xlink:to="loc_sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant_2146635704" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_2146635677" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2146635660" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_2146635677" use="optional" order="17" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/AcquisitionsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="loc_us-gaap_AssetAcquisitionLineItems_2146635723" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred_2146635726" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferred_2146635726" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_2146635727" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_2146635727" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_2146635728" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_2146635728" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_2146635729" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_2146635729" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesSubscribedButUnissued" xlink:label="loc_us-gaap_CommonStockSharesSubscribedButUnissued_2146635730" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_us-gaap_CommonStockSharesSubscribedButUnissued_2146635730" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTable" xlink:label="loc_us-gaap_AssetAcquisitionTable_2146635722" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_us-gaap_AssetAcquisitionTable_2146635722" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TrancheAxis" xlink:label="loc_sclx_TrancheAxis_2146635755" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AssetAcquisitionTable_2146635722" xlink:to="loc_sclx_TrancheAxis_2146635755" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TrancheDomain" xlink:label="loc_sclx_TrancheDomain_2146635756" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sclx_TrancheAxis_2146635755" xlink:to="loc_sclx_TrancheDomain_2146635756" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TrancheDomain" xlink:label="loc_sclx_TrancheDomain_2146635756_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sclx_TrancheAxis_2146635755" xlink:to="loc_sclx_TrancheDomain_2146635756_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TrancheOneMember" xlink:label="loc_sclx_TrancheOneMember_2146635757" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_TrancheDomain_2146635756" xlink:to="loc_sclx_TrancheOneMember_2146635757" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TrancheTwoMember" xlink:label="loc_sclx_TrancheTwoMember_2146635760" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_TrancheDomain_2146635756" xlink:to="loc_sclx_TrancheTwoMember_2146635760" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TrancheThreeMember" xlink:label="loc_sclx_TrancheThreeMember_2146635762" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_TrancheDomain_2146635756" xlink:to="loc_sclx_TrancheThreeMember_2146635762" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TrancheFourMember" xlink:label="loc_sclx_TrancheFourMember_2146635765" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_TrancheDomain_2146635756" xlink:to="loc_sclx_TrancheFourMember_2146635765" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="loc_us-gaap_AssetAcquisitionAxis_2146635739" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AssetAcquisitionTable_2146635722" xlink:to="loc_us-gaap_AssetAcquisitionAxis_2146635739" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaap_AssetAcquisitionDomain_2146635740" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_2146635739" xlink:to="loc_us-gaap_AssetAcquisitionDomain_2146635740" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaap_AssetAcquisitionDomain_2146635740_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_2146635739" xlink:to="loc_us-gaap_AssetAcquisitionDomain_2146635740_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SenmurMember" xlink:label="loc_sclx_SenmurMember_2146635743" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_2146635740" xlink:to="loc_sclx_SenmurMember_2146635743" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AardvarkMember" xlink:label="loc_sclx_AardvarkMember_2146636180" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_2146635740" xlink:to="loc_sclx_AardvarkMember_2146636180" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_RomegLicenseAgreementMember" xlink:label="loc_sclx_RomegLicenseAgreementMember_2146636237" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_2146635740" xlink:to="loc_sclx_RomegLicenseAgreementMember_2146636237" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MilestoneAxis" xlink:label="loc_sclx_MilestoneAxis_2146635745" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AssetAcquisitionTable_2146635722" xlink:to="loc_sclx_MilestoneAxis_2146635745" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MilestoneDomain" xlink:label="loc_sclx_MilestoneDomain_2146635747" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sclx_MilestoneAxis_2146635745" xlink:to="loc_sclx_MilestoneDomain_2146635747" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MilestoneDomain" xlink:label="loc_sclx_MilestoneDomain_2146635747_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sclx_MilestoneAxis_2146635745" xlink:to="loc_sclx_MilestoneDomain_2146635747_default" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_RegulatoryBasedMilestoneMember" xlink:label="loc_sclx_RegulatoryBasedMilestoneMember_2146635749" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_MilestoneDomain_2146635747" xlink:to="loc_sclx_RegulatoryBasedMilestoneMember_2146635749" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ReveueBasedMilestoneMember" xlink:label="loc_sclx_ReveueBasedMilestoneMember_2146635751" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_MilestoneDomain_2146635747" xlink:to="loc_sclx_ReveueBasedMilestoneMember_2146635751" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ApprovalBasedMilestoneMember" xlink:label="loc_sclx_ApprovalBasedMilestoneMember_2146636609" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_MilestoneDomain_2146635747" xlink:to="loc_sclx_ApprovalBasedMilestoneMember_2146636609" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_InvesteeAxis" xlink:label="loc_sclx_InvesteeAxis_2146635798" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AssetAcquisitionTable_2146635722" xlink:to="loc_sclx_InvesteeAxis_2146635798" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_InvesteeDomain" xlink:label="loc_sclx_InvesteeDomain_2146635801" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sclx_InvesteeAxis_2146635798" xlink:to="loc_sclx_InvesteeDomain_2146635801" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_InvesteeDomain" xlink:label="loc_sclx_InvesteeDomain_2146635801_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sclx_InvesteeAxis_2146635798" xlink:to="loc_sclx_InvesteeDomain_2146635801_default" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SorrentoMember" xlink:label="loc_sclx_SorrentoMember_2146635803" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_InvesteeDomain_2146635801" xlink:to="loc_sclx_SorrentoMember_2146635803" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_2146635897" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AssetAcquisitionTable_2146635722" xlink:to="loc_srt_RestatementAxis_2146635897" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_2146635898" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_2146635897" xlink:to="loc_srt_RestatementDomain_2146635898" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_2146635898_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_2146635897" xlink:to="loc_srt_RestatementDomain_2146635898_default" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AsRestatedMember" xlink:label="loc_sclx_AsRestatedMember_2146635899" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_2146635898" xlink:to="loc_sclx_AsRestatedMember_2146635899" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_2146636133" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AssetAcquisitionTable_2146635722" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_2146636133" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2146636134" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2146636133" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2146636134" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2146636134_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2146636133" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2146636134_default" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TwoThousandTwentyTwoPromissoryNoteMember" xlink:label="loc_sclx_TwoThousandTwentyTwoPromissoryNoteMember_2146636135" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2146636134" xlink:to="loc_sclx_TwoThousandTwentyTwoPromissoryNoteMember_2146636135" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AssetAcquisitionPricePerShare" xlink:label="loc_sclx_AssetAcquisitionPricePerShare_2146635731" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_sclx_AssetAcquisitionPricePerShare_2146635731" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfSharesIssuedSubjectToRestrictionOfTransfer" xlink:label="loc_sclx_PercentageOfSharesIssuedSubjectToRestrictionOfTransfer_2146635770" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_sclx_PercentageOfSharesIssuedSubjectToRestrictionOfTransfer_2146635770" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PeriodDuringWhichShareTransferIsRestricted" xlink:label="loc_sclx_PeriodDuringWhichShareTransferIsRestricted_2146635775" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_sclx_PeriodDuringWhichShareTransferIsRestricted_2146635775" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PeriodDuringWhichTheSharesMayBeExchanged" xlink:label="loc_sclx_PeriodDuringWhichTheSharesMayBeExchanged_2146635776" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_sclx_PeriodDuringWhichTheSharesMayBeExchanged_2146635776" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_CommonStockValueToBeExchanged" xlink:label="loc_sclx_CommonStockValueToBeExchanged_2146635780" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_sclx_CommonStockValueToBeExchanged_2146635780" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfOwnershipInterest" xlink:label="loc_sclx_PercentageOfOwnershipInterest_2146635733" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_sclx_PercentageOfOwnershipInterest_2146635733" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiability" xlink:label="loc_us-gaap_AssetAcquisitionContingentConsiderationLiability_2146635735" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_us-gaap_AssetAcquisitionContingentConsiderationLiability_2146635735" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_RevenueToBeEarnedByTheAcquireeValue" xlink:label="loc_sclx_RevenueToBeEarnedByTheAcquireeValue_2146635737" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_sclx_RevenueToBeEarnedByTheAcquireeValue_2146635737" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NumberOfDaysForDeterminingTheWeightedVolumeAveragePriceForShares" xlink:label="loc_sclx_NumberOfDaysForDeterminingTheWeightedVolumeAveragePriceForShares_2146635783" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_sclx_NumberOfDaysForDeterminingTheWeightedVolumeAveragePriceForShares_2146635783" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_2146635912" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_2146635912" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_2146636126" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_2146636126" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PricePerShareForDeterminingTheExchangeOfShares" xlink:label="loc_sclx_PricePerShareForDeterminingTheExchangeOfShares_2146635785" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_sclx_PricePerShareForDeterminingTheExchangeOfShares_2146635785" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PaymentMadeInSurrenderingTheShares" xlink:label="loc_sclx_PaymentMadeInSurrenderingTheShares_2146635790" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_sclx_PaymentMadeInSurrenderingTheShares_2146635790" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfSharesOutstanding" xlink:label="loc_sclx_PercentageOfSharesOutstanding_2146635793" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_sclx_PercentageOfSharesOutstanding_2146635793" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_2146635797" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_2146635797" use="optional" order="52" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_2146635895" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_2146635895" use="optional" order="53" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_2146636127" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_2146636127" use="optional" order="54" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue_2146636243" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue_2146636243" use="optional" order="55" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DeferredConsideration" xlink:label="loc_sclx_DeferredConsideration_2146636247" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_sclx_DeferredConsideration_2146636247" use="optional" order="56" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_2146636266" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_2146636266" use="optional" order="57" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm_2146636128" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_us-gaap_DebtInstrumentTerm_2146636128" use="optional" order="58" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_2146636129" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_2146636129" use="optional" order="59" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_UpfrontlicenseFee" xlink:label="loc_sclx_UpfrontlicenseFee_2146636214" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_sclx_UpfrontlicenseFee_2146636214" use="optional" order="60" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MilestonePayment" xlink:label="loc_sclx_MilestonePayment_2146636223" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_sclx_MilestonePayment_2146636223" use="optional" order="61" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_2146636233" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_us-gaap_RoyaltyExpense_2146636233" use="optional" order="62" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedFinancialStatementsCaptionsLineItems" xlink:label="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2146635324" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedFinancialStatementsTable" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTable_2146635323" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2146635324" xlink:to="loc_srt_ScheduleOfCondensedFinancialStatementsTable_2146635323" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635325" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_2146635323" xlink:to="loc_dei_LegalEntityAxis_2146635325" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635326" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2146635325" xlink:to="loc_dei_EntityDomain_2146635326" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635326_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2146635325" xlink:to="loc_dei_EntityDomain_2146635326_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635327" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146635326" xlink:to="loc_sclx_VickersVantageMember_2146635327" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockRedemptionPricePerShare" xlink:label="loc_us-gaap_PreferredStockRedemptionPricePerShare_2146635328" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2146635324" xlink:to="loc_us-gaap_PreferredStockRedemptionPricePerShare_2146635328" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsCurrent" xlink:label="loc_us-gaap_IntangibleAssetsCurrent_2146635329" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2146635324" xlink:to="loc_us-gaap_IntangibleAssetsCurrent_2146635329" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsDetailsScheduleOfImpactOfTheseAdjustmentsToTheFinancialStatementAsPreviouslyReported">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedFinancialStatementsCaptionsLineItems" xlink:label="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2146635293" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_2146635306" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2146635293" xlink:to="loc_us-gaap_DerivativeLiabilities_2146635306" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_2146635307" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2146635293" xlink:to="loc_us-gaap_Liabilities_2146635307" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_2146635308" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2146635293" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_2146635308" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_2146635309" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2146635293" xlink:to="loc_us-gaap_CommonStockValue_2146635309" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_2146635311" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2146635293" xlink:to="loc_us-gaap_AdditionalPaidInCapital_2146635311" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2146635312" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2146635293" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2146635312" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_2146635314" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2146635293" xlink:to="loc_us-gaap_StockholdersEquity_2146635314" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedFinancialStatementsTable" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTable_2146635292" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2146635293" xlink:to="loc_srt_ScheduleOfCondensedFinancialStatementsTable_2146635292" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_2146635301" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_2146635292" xlink:to="loc_srt_RestatementAxis_2146635301" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_2146635302" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_2146635301" xlink:to="loc_srt_RestatementDomain_2146635302" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_2146635302_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_2146635301" xlink:to="loc_srt_RestatementDomain_2146635302_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_2146635303" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_2146635302" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_2146635303" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAdjustmentMember" xlink:label="loc_srt_RestatementAdjustmentMember_2146635304" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_2146635302" xlink:to="loc_srt_RestatementAdjustmentMember_2146635304" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AdjustmentsRestatement2Member" xlink:label="loc_sclx_AdjustmentsRestatement2Member_2146635305" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_2146635302" xlink:to="loc_sclx_AdjustmentsRestatement2Member_2146635305" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AsRestatedMember" xlink:label="loc_sclx_AsRestatedMember_2146635320" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_2146635302" xlink:to="loc_sclx_AsRestatedMember_2146635320" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635296" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_2146635292" xlink:to="loc_dei_LegalEntityAxis_2146635296" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635297" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2146635296" xlink:to="loc_dei_EntityDomain_2146635297" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635297_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2146635296" xlink:to="loc_dei_EntityDomain_2146635297_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635298" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146635297" xlink:to="loc_sclx_VickersVantageMember_2146635298" use="optional" order="19" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/IncomeTaxesDetails">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_IncomeTaxDisclosureLineItems" xlink:label="loc_sclx_IncomeTaxDisclosureLineItems_2146636022" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_2146635944" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems_2146636022" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_2146635944" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_2146636034" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems_2146636022" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_2146636034" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_2146636035" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems_2146636022" xlink:to="loc_us-gaap_OperatingLossCarryforwards_2146636035" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_OperatingLossCarryforwardsExpirationYear" xlink:label="loc_sclx_OperatingLossCarryforwardsExpirationYear_2146636037" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems_2146636022" xlink:to="loc_sclx_OperatingLossCarryforwardsExpirationYear_2146636037" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_2146636039" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems_2146636022" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_2146636039" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TaxCreditCarryforwardExpirationYear" xlink:label="loc_sclx_TaxCreditCarryforwardExpirationYear_2146636040" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems_2146636022" xlink:to="loc_sclx_TaxCreditCarryforwardExpirationYear_2146636040" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MinimumThresholdPercentageForRecognitionOfUncertainIncomeTaxPosition" xlink:label="loc_sclx_MinimumThresholdPercentageForRecognitionOfUncertainIncomeTaxPosition_2146636041" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems_2146636022" xlink:to="loc_sclx_MinimumThresholdPercentageForRecognitionOfUncertainIncomeTaxPosition_2146636041" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_2146636057" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems_2146636022" xlink:to="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_2146636057" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2146635945" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems_2146636022" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2146635945" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2146635947" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems_2146636022" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2146635947" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_IncomeTaxDisclosureTable" xlink:label="loc_sclx_IncomeTaxDisclosureTable_2146636021" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems_2146636022" xlink:to="loc_sclx_IncomeTaxDisclosureTable_2146636021" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_2146636031" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_IncomeTaxDisclosureTable_2146636021" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_2146636031" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_2146636032" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_2146636031" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_2146636032" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_2146636032_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_2146636031" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_2146636032_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember_2146636033" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_2146636032" xlink:to="loc_us-gaap_ResearchMember_2146636033" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaap_TaxPeriodAxis_2146636028" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_IncomeTaxDisclosureTable_2146636021" xlink:to="loc_us-gaap_TaxPeriodAxis_2146636028" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain_2146636029" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxPeriodAxis_2146636028" xlink:to="loc_us-gaap_TaxPeriodDomain_2146636029" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain_2146636029_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxPeriodAxis_2146636028" xlink:to="loc_us-gaap_TaxPeriodDomain_2146636029_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_IndefiniteCarryforwardPeriodMember" xlink:label="loc_sclx_IndefiniteCarryforwardPeriodMember_2146636030" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_2146636029" xlink:to="loc_sclx_IndefiniteCarryforwardPeriodMember_2146636030" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_2146636023" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_IncomeTaxDisclosureTable_2146636021" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_2146636023" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_2146636024" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_2146636023" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_2146636024" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_2146636024_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_2146636023" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_2146636024_default" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_2146636025" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_2146636024" xlink:to="loc_us-gaap_DomesticCountryMember_2146636025" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_2146636026" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_2146636024" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_2146636026" use="optional" order="24" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/SubsequentEventsDetails">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SubsequentEventsDetailsLineItems" xlink:label="loc_sclx_SubsequentEventsDetailsLineItems_821" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SubsequentEventsDetailsTable" xlink:label="loc_sclx_SubsequentEventsDetailsTable_819" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_sclx_SubsequentEventsDetailsTable_819" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_2146635413" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_SubsequentEventsDetailsTable_819" xlink:to="loc_us-gaap_DebtInstrumentAxis_2146635413" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2146635414" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_2146635413" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2146635414" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2146635414_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_2146635413" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2146635414_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScilexPharmaNoteMember" xlink:label="loc_sclx_ScilexPharmaNoteMember_2146635416" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2146635414" xlink:to="loc_sclx_ScilexPharmaNoteMember_2146635416" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_820" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_SubsequentEventsDetailsTable_819" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_820" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2146634684" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_820" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2146634684" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2146634684_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_820" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2146634684_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_822" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_2146634684" xlink:to="loc_us-gaap_SubsequentEventMember_822" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635150" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_SubsequentEventsDetailsTable_819" xlink:to="loc_dei_LegalEntityAxis_2146635150" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635151" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2146635150" xlink:to="loc_dei_EntityDomain_2146635151" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635151_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2146635150" xlink:to="loc_dei_EntityDomain_2146635151_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635152" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146635151" xlink:to="loc_sclx_VickersVantageMember_2146635152" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SorrentoMember" xlink:label="loc_sclx_SorrentoMember_2146635420" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_2146635419" xlink:to="loc_sclx_SorrentoMember_2146635420" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SorrentoMember" xlink:label="loc_sclx_SorrentoMember_2146635423" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2146635422" xlink:to="loc_sclx_SorrentoMember_2146635423" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SorrentoMember" xlink:label="loc_sclx_SorrentoMember_2146636600" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2146635151" xlink:to="loc_sclx_SorrentoMember_2146636600" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="loc_us-gaap_AssetAcquisitionAxis_2146635427" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_SubsequentEventsDetailsTable_819" xlink:to="loc_us-gaap_AssetAcquisitionAxis_2146635427" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaap_AssetAcquisitionDomain_2146635428" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_2146635427" xlink:to="loc_us-gaap_AssetAcquisitionDomain_2146635428" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaap_AssetAcquisitionDomain_2146635428_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_2146635427" xlink:to="loc_us-gaap_AssetAcquisitionDomain_2146635428_default" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AardvarkMember" xlink:label="loc_sclx_AardvarkMember_2146635429" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_2146635428" xlink:to="loc_sclx_AardvarkMember_2146635429" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2146635418" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_SubsequentEventsDetailsTable_819" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2146635418" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_2146635419" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2146635418" xlink:to="loc_us-gaap_RelatedPartyDomain_2146635419" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_2146635419_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2146635418" xlink:to="loc_us-gaap_RelatedPartyDomain_2146635419_default" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_2146635421" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_SubsequentEventsDetailsTable_819" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_2146635421" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2146635422" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2146635421" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2146635422" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2146635422_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2146635421" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2146635422_default" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_2146635424" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_SubsequentEventsDetailsTable_819" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_2146635424" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2146635425" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2146635424" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2146635425" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2146635425_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2146635424" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2146635425_default" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TwoThousandAndTwentyTwoPromissoryNoteMember" xlink:label="loc_sclx_TwoThousandAndTwentyTwoPromissoryNoteMember_2146635426" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2146635425" xlink:to="loc_sclx_TwoThousandAndTwentyTwoPromissoryNoteMember_2146635426" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubordinatedDebtMember" xlink:label="loc_us-gaap_SubordinatedDebtMember_2146635482" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2146635425" xlink:to="loc_us-gaap_SubordinatedDebtMember_2146635482" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_2146635501" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_SubsequentEventsDetailsTable_819" xlink:to="loc_srt_RangeAxis_2146635501" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_2146635503" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_2146635501" xlink:to="loc_srt_RangeMember_2146635503" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_2146635503_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_2146635501" xlink:to="loc_srt_RangeMember_2146635503_default" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_2146635504" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2146635503" xlink:to="loc_srt_MaximumMember_2146635504" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_2146636323" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2146635503" xlink:to="loc_srt_MinimumMember_2146636323" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_2146636330" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_SubsequentEventsDetailsTable_819" xlink:to="loc_us-gaap_CreditFacilityAxis_2146636330" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_2146636331" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_2146636330" xlink:to="loc_us-gaap_CreditFacilityDomain_2146636331" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_2146636331_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_2146636330" xlink:to="loc_us-gaap_CreditFacilityDomain_2146636331_default" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_FundingCommitmentLetterMember" xlink:label="loc_sclx_FundingCommitmentLetterMember_2146636332" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_2146636331" xlink:to="loc_sclx_FundingCommitmentLetterMember_2146636332" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2146636324" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_SubsequentEventsDetailsTable_819" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2146636324" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2146636325" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2146636324" xlink:to="loc_us-gaap_ClassOfStockDomain_2146636325" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2146636325_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2146636324" xlink:to="loc_us-gaap_ClassOfStockDomain_2146636325_default" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_2146636326" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_2146636325" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_2146636326" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_InvesteeAxis" xlink:label="loc_sclx_InvesteeAxis_2146636610" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_SubsequentEventsDetailsTable_819" xlink:to="loc_sclx_InvesteeAxis_2146636610" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_InvesteeDomain" xlink:label="loc_sclx_InvesteeDomain_2146636611" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sclx_InvesteeAxis_2146636610" xlink:to="loc_sclx_InvesteeDomain_2146636611" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_InvesteeDomain" xlink:label="loc_sclx_InvesteeDomain_2146636611_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sclx_InvesteeAxis_2146636610" xlink:to="loc_sclx_InvesteeDomain_2146636611_default" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_YorkvilleMember" xlink:label="loc_sclx_YorkvilleMember_2146636612" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_InvesteeDomain_2146636611" xlink:to="loc_sclx_YorkvilleMember_2146636612" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_B.RileyMember" xlink:label="loc_sclx_B.RileyMember_2147435892" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_InvesteeDomain_2146636611" xlink:to="loc_sclx_B.RileyMember_2147435892" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AgreementAxis" xlink:label="loc_sclx_AgreementAxis_2146636593" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_SubsequentEventsDetailsTable_819" xlink:to="loc_sclx_AgreementAxis_2146636593" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AgreementDomain" xlink:label="loc_sclx_AgreementDomain_2146636594" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sclx_AgreementAxis_2146636593" xlink:to="loc_sclx_AgreementDomain_2146636594" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AgreementDomain" xlink:label="loc_sclx_AgreementDomain_2146636594_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sclx_AgreementAxis_2146636593" xlink:to="loc_sclx_AgreementDomain_2146636594_default" use="optional" order="52" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_StandbyEquityPurchaseAgreementMember" xlink:label="loc_sclx_StandbyEquityPurchaseAgreementMember_2146636608" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_AgreementDomain_2146636594" xlink:to="loc_sclx_StandbyEquityPurchaseAgreementMember_2146636608" use="optional" order="53" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AgreementWithCertainOfTheThirdPartyProfessionalServiceProvidersMember" xlink:label="loc_sclx_AgreementWithCertainOfTheThirdPartyProfessionalServiceProvidersMember_2146636595" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_AgreementDomain_2146636594" xlink:to="loc_sclx_AgreementWithCertainOfTheThirdPartyProfessionalServiceProvidersMember_2146636595" use="optional" order="54" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_2146636601" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_SubsequentEventsDetailsTable_819" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_2146636601" use="optional" order="55" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_2146636602" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_2146636601" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_2146636602" use="optional" order="56" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_2146636602_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_2146636601" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_2146636602_default" use="optional" order="57" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableMember" xlink:label="loc_us-gaap_AccountsPayableMember_2146636603" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2146636602" xlink:to="loc_us-gaap_AccountsPayableMember_2146636603" use="optional" order="58" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_2146636604" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2146636602" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_2146636604" use="optional" order="59" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_2147435908" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_SubsequentEventsDetailsTable_819" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_2147435908" use="optional" order="60" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_2147435909" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_2147435908" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_2147435909" use="optional" order="61" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_2147435909_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_2147435908" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_2147435909_default" use="optional" order="62" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScilexCommonStockMember" xlink:label="loc_sclx_ScilexCommonStockMember_2147435910" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_2147435909" xlink:to="loc_sclx_ScilexCommonStockMember_2147435910" use="optional" order="63" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_2147435900" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sclx_SubsequentEventsDetailsTable_819" xlink:to="loc_srt_ProductOrServiceAxis_2147435900" use="optional" order="64" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_2147435901" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_2147435900" xlink:to="loc_srt_ProductsAndServicesDomain_2147435901" use="optional" order="65" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_2147435901_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_2147435900" xlink:to="loc_srt_ProductsAndServicesDomain_2147435901_default" use="optional" order="66" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PurchasetypeAMember" xlink:label="loc_sclx_PurchasetypeAMember_2147435902" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2147435901" xlink:to="loc_sclx_PurchasetypeAMember_2147435902" use="optional" order="67" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PurchasetypeBMember" xlink:label="loc_sclx_PurchasetypeBMember_2147435903" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2147435901" xlink:to="loc_sclx_PurchasetypeBMember_2147435903" use="optional" order="68" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SponsorLoan" xlink:label="loc_sclx_SponsorLoan_2146635252" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_sclx_SponsorLoan_2146635252" use="optional" order="69" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_WarrantExercisePrice" xlink:label="loc_sclx_WarrantExercisePrice_2146635254" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_sclx_WarrantExercisePrice_2146635254" use="optional" order="70" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AdditionalPrincipalAmount" xlink:label="loc_sclx_AdditionalPrincipalAmount_2146635256" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_sclx_AdditionalPrincipalAmount_2146635256" use="optional" order="71" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ConvertiblePromissoryNote" xlink:label="loc_sclx_ConvertiblePromissoryNote_2146635257" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_sclx_ConvertiblePromissoryNote_2146635257" use="optional" order="72" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseDepositLiability" xlink:label="loc_us-gaap_LeaseDepositLiability_823" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_us-gaap_LeaseDepositLiability_823" use="optional" order="73" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockNoParValue" xlink:label="loc_us-gaap_CommonStockNoParValue_824" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_us-gaap_CommonStockNoParValue_824" use="optional" order="74" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_825" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_825" use="optional" order="75" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NumberOfSharesLimits" xlink:label="loc_sclx_NumberOfSharesLimits_826" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_sclx_NumberOfSharesLimits_826" use="optional" order="76" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SalesThresholdLimit" xlink:label="loc_sclx_SalesThresholdLimit_2146635461" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_sclx_SalesThresholdLimit_2146635461" use="optional" order="77" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_2146635432" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_2146635432" use="optional" order="78" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchaseAmount" xlink:label="loc_us-gaap_DebtInstrumentRepurchaseAmount_2146635433" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_us-gaap_DebtInstrumentRepurchaseAmount_2146635433" use="optional" order="79" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfPurchasePriceInCashEqualIsToPrincipalAmountOfTheLoan" xlink:label="loc_sclx_PercentageOfPurchasePriceInCashEqualIsToPrincipalAmountOfTheLoan_2146635435" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_sclx_PercentageOfPurchasePriceInCashEqualIsToPrincipalAmountOfTheLoan_2146635435" use="optional" order="80" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaap_RestrictedCash_2146635436" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_us-gaap_RestrictedCash_2146635436" use="optional" order="81" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_2146635438" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_2146635438" use="optional" order="82" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm_2146635440" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_us-gaap_DebtInstrumentTerm_2146635440" use="optional" order="83" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_2146635448" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_2146635448" use="optional" order="84" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MinimumTimeDeclaredToFileWithSecRegardingResaleRegistrationStatement" xlink:label="loc_sclx_MinimumTimeDeclaredToFileWithSecRegardingResaleRegistrationStatement_2146635451" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_sclx_MinimumTimeDeclaredToFileWithSecRegardingResaleRegistrationStatement_2146635451" use="optional" order="85" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred_2146635454" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferred_2146635454" use="optional" order="86" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_2146635458" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_2146635458" use="optional" order="87" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AggregateOutstandingAmount" xlink:label="loc_sclx_AggregateOutstandingAmount_2146636329" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_sclx_AggregateOutstandingAmount_2146636329" use="optional" order="88" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_2146636317" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_2146636317" use="optional" order="89" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2146636318" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2146636318" use="optional" order="90" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinimumNetWorthRequiredForCompliance" xlink:label="loc_us-gaap_MinimumNetWorthRequiredForCompliance_2146636327" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_us-gaap_MinimumNetWorthRequiredForCompliance_2146636327" use="optional" order="91" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_2146636328" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_2146636328" use="optional" order="92" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAssumed1" xlink:label="loc_us-gaap_LiabilitiesAssumed1_2146636592" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_us-gaap_LiabilitiesAssumed1_2146636592" use="optional" order="93" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PeriodAfterRegistrationWhenTheRequestCouldBeMadeToTheInvesteeToPurchaseTheShares" xlink:label="loc_sclx_PeriodAfterRegistrationWhenTheRequestCouldBeMadeToTheInvesteeToPurchaseTheShares_2146636607" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_sclx_PeriodAfterRegistrationWhenTheRequestCouldBeMadeToTheInvesteeToPurchaseTheShares_2146636607" use="optional" order="94" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MaximumPercentageOfVolumeWeightedAveragePriceOfSharesMeasuredOnADailyBasisThatIsEligibleToBeReceivedAsAdvance" xlink:label="loc_sclx_MaximumPercentageOfVolumeWeightedAveragePriceOfSharesMeasuredOnADailyBasisThatIsEligibleToBeReceivedAsAdvance_2146636613" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_sclx_MaximumPercentageOfVolumeWeightedAveragePriceOfSharesMeasuredOnADailyBasisThatIsEligibleToBeReceivedAsAdvance_2146636613" use="optional" order="95" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NumberOfThresholdTradingDaysPriorToDateOfNoticeToTheShareholdersForDeterminingTheVolumeWeightedAveragePriceOfShares" xlink:label="loc_sclx_NumberOfThresholdTradingDaysPriorToDateOfNoticeToTheShareholdersForDeterminingTheVolumeWeightedAveragePriceOfShares_2146636616" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_sclx_NumberOfThresholdTradingDaysPriorToDateOfNoticeToTheShareholdersForDeterminingTheVolumeWeightedAveragePriceOfShares_2146636616" use="optional" order="96" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfDailyVolumeWeightedAveragePriceOfSharesAtWhichTheSharesAreEligibleToBePurchased" xlink:label="loc_sclx_PercentageOfDailyVolumeWeightedAveragePriceOfSharesAtWhichTheSharesAreEligibleToBePurchased_2146636617" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_sclx_PercentageOfDailyVolumeWeightedAveragePriceOfSharesAtWhichTheSharesAreEligibleToBePurchased_2146636617" use="optional" order="97" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NumberOfConsecutiveTradingDaysForDeterminingTheVolumeWeightedAveragePriceOfShares" xlink:label="loc_sclx_NumberOfConsecutiveTradingDaysForDeterminingTheVolumeWeightedAveragePriceOfShares_2146636618" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_sclx_NumberOfConsecutiveTradingDaysForDeterminingTheVolumeWeightedAveragePriceOfShares_2146636618" use="optional" order="98" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2146636625" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2146636625" use="optional" order="99" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_2147435904" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_2147435904" use="optional" order="100" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_2147435905" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_2147435905" use="optional" order="101" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesSubscriptions" xlink:label="loc_us-gaap_CommonStockSharesSubscriptions_2147436126" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_us-gaap_CommonStockSharesSubscriptions_2147436126" use="optional" order="102" />
</definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>sclx-20220930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 12-January-2023 [12:41:39] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
<labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CoverAbstract" xml:lang="en-US">Cover [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntitySmallBusiness" xml:lang="en-US">Entity Small Business</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityEmergingGrowthCompany" xml:lang="en-US">Entity Emerging Growth Company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityExTransitionPeriod" xml:lang="en-US">Entity Ex Transition Period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Total assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' DEFICIT</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Liabilities, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Current liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xml:lang="en-US">Accounts payable and accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total current liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts Payable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AccruedPayroll" xlink:label="loc_sclx_AccruedPayroll" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AccruedPayroll" xml:lang="en-US">Accrued payroll</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_AccruedPayroll" xml:lang="en-US">Accrued payroll</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AccruedPayroll" xlink:to="lab_sclx_AccruedPayroll" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AccruedPayroll" xml:lang="en-US">Accrued payroll</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebtCurrent" xml:lang="en-US">Long-Term Debt, Current Maturities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermDebtCurrent" xml:lang="en-US">Current portion of debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_LongTermDebtCurrent" xml:lang="en-US">Current portion</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent" xml:lang="en-US">Due to Related Parties, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent" xml:lang="en-US">Related party payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrent" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrent" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_RelatedPartyNotePayableCurrent" xlink:label="loc_sclx_RelatedPartyNotePayableCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_RelatedPartyNotePayableCurrent" xml:lang="en-US">Related Party Note Payable Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_RelatedPartyNotePayableCurrent" xml:lang="en-US">Related party note payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_RelatedPartyNotePayableCurrent" xlink:to="lab_sclx_RelatedPartyNotePayableCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_RelatedPartyNotePayableCurrent" xml:lang="en-US">Related party note payable, current.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Operating Lease, Liability, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Current portion of operating lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xml:lang="en-US">Other Accrued Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xml:lang="en-US">Accrued offering costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AdvancesFromRelatedParty" xlink:label="loc_sclx_AdvancesFromRelatedParty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AdvancesFromRelatedParty" xml:lang="en-US">Advances From Related Party</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_AdvancesFromRelatedParty" xml:lang="en-US">Advances from related party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AdvancesFromRelatedParty" xlink:to="lab_sclx_AdvancesFromRelatedParty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AdvancesFromRelatedParty" xml:lang="en-US">Advances from related party.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:label="loc_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xml:lang="en-US">Notes Payable, Related Parties, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xml:lang="en-US">Promissory note &#8212; related party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:to="lab_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredRevenueCurrent" xml:lang="en-US">Deferred Revenue, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredRevenueCurrent" xml:lang="en-US">Current portion of deferred consideration</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueCurrent" xlink:to="lab_us-gaap_DeferredRevenueCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertibleLongTermNotesPayable" xml:lang="en-US">Convertible Notes Payable, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConvertibleLongTermNotesPayable" xml:lang="en-US">Convertible promissory notes &#8212; related party, net of discount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleLongTermNotesPayable" xlink:to="lab_us-gaap_ConvertibleLongTermNotesPayable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xml:lang="en-US">Other Liabilities, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xml:lang="en-US">Conversion option liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xml:lang="en-US">Conversion Option Liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLongTermNotesPayable" xlink:label="loc_us-gaap_OtherLongTermNotesPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherLongTermNotesPayable" xml:lang="en-US">Other Notes Payable, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherLongTermNotesPayable" xml:lang="en-US">Simple promissory notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLongTermNotesPayable" xlink:to="lab_us-gaap_OtherLongTermNotesPayable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent" xlink:label="loc_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent" xml:lang="en-US">Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent" xml:lang="en-US">Mandatorily redeemable ordinary shares liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent" xlink:to="lab_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeLiabilities" xml:lang="en-US">Derivative Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativeLiabilities" xml:lang="en-US">Warrant liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DerivativeLiabilities" xml:lang="en-US">Derivative liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_DerivativeLiabilities" xml:lang="en-US">Fair value beginning</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_DerivativeLiabilities" xml:lang="en-US">Fair value ending</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:label="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xml:lang="en-US">Deferred Compensation Liability, Classified, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xml:lang="en-US">Deferred underwriting fee payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:to="lab_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xml:lang="en-US">Long-term debt, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xml:lang="en-US">Long term portion</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DerivativeLiabilityNoncurrent" xlink:label="loc_sclx_DerivativeLiabilityNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DerivativeLiabilityNoncurrent" xml:lang="en-US">Derivative Liability Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_DerivativeLiabilityNoncurrent" xml:lang="en-US">Derivative liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DerivativeLiabilityNoncurrent" xlink:to="lab_sclx_DerivativeLiabilityNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_DerivativeLiabilityNoncurrent" xml:lang="en-US">Derivative liability, noncurrent.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Operating lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredRevenueNoncurrent" xml:lang="en-US">Deferred Revenue, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredRevenueNoncurrent" xml:lang="en-US">Long-term deferred consideration</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueNoncurrent" xlink:to="lab_us-gaap_DeferredRevenueNoncurrent" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_RelatedPartyNotePayableNoncurrent" xlink:label="loc_sclx_RelatedPartyNotePayableNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_RelatedPartyNotePayableNoncurrent" xml:lang="en-US">Related Party Note Payable Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_RelatedPartyNotePayableNoncurrent" xml:lang="en-US">Related party note payable, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_RelatedPartyNotePayableNoncurrent" xlink:to="lab_sclx_RelatedPartyNotePayableNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_RelatedPartyNotePayableNoncurrent" xml:lang="en-US">Related party note payable, non current.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">ASSETS</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsHeldInTrustNoncurrent" xlink:label="loc_us-gaap_AssetsHeldInTrustNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsHeldInTrustNoncurrent" xml:lang="en-US">Assets Held-in-trust, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsHeldInTrustNoncurrent" xml:lang="en-US">Investments held in Trust Account &#8211; U.S. Treasury Securities Money Market Fund</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsHeldInTrustNoncurrent" xlink:to="lab_us-gaap_AssetsHeldInTrustNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Assets, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Current assets:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Cash" xml:lang="en-US">Cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_Cash" xml:lang="en-US">Cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Cash" xlink:to="lab_us-gaap_Cash" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xml:lang="en-US">Prepaid Expense, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xml:lang="en-US">Prepaid expenses and other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Total current assets:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryNet" xml:lang="en-US">Inventory</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Accounts receivable, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Operating lease right-of-use asset</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xml:lang="en-US">Intangibles, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Goodwill" xml:lang="en-US">Goodwill</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_Goodwill" xml:lang="en-US">Goodwill</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermInvestments" xml:lang="en-US">Long-Term Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermInvestments" xml:lang="en-US">Long-term deposit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestments" xlink:to="lab_us-gaap_LongTermInvestments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCosts" xlink:label="loc_us-gaap_DeferredCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredCosts" xml:lang="en-US">Deferred Costs, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredCosts" xml:lang="en-US">Deferred offering costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCosts" xlink:to="lab_us-gaap_DeferredCosts" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' Deficit:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred stock, $0.0001 par value, 20,000,000 shares authorized; none issued or outstanding at September 30, 2022 and December 31, 2021</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common stock, $0.0001 par value, 350,000,000 shares authorized; 197,566,338 and 197,266,338 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Ordinary Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional Paid in Capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional paid-in capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional amount borrowed</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional Paid-in Capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained earnings accumulated deficit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated Deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Total liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Total Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and Contingencies</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and contingencies (See Note 8)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xml:lang="en-US">Temporary Equity, Carrying Amount, Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xml:lang="en-US">Ordinary shares subject to possible redemption 9,726,395 and 13,800,000 as of September 30, 2022 and December 31, 2021, respectively, at redemption value of $10.41 and $10.00, respectively, per share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xml:lang="en-US">Ordinary Shares Subject to Possible Redemption</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Total stockholders' deficit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Total Shareholders' Equity (Deficit)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total liabilities and stockholders' deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LegalEntityAxis" xml:lang="en-US">Legal Entity [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityDomain" xml:lang="en-US">Entity [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_VickersVantageMember" xml:lang="en-US">Vickers Vantage [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_VickersVantageMember" xml:lang="en-US">Vicker's Vantage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_VickersVantageMember" xlink:to="lab_sclx_VickersVantageMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_VickersVantageMember" xml:lang="en-US">Vickers vantage .</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Ordinary shares, issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Ordinary shares, outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_OrdinarySharesSubjectToPossibleRedemption" xlink:label="loc_sclx_OrdinarySharesSubjectToPossibleRedemption" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_OrdinarySharesSubjectToPossibleRedemption" xml:lang="en-US">Ordinary Shares Subject To Possible Redemption</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_OrdinarySharesSubjectToPossibleRedemption" xml:lang="en-US">Subject to possible redemption shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_sclx_OrdinarySharesSubjectToPossibleRedemption" xml:lang="en-US">Ordinary shares subject to possible redemption</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_OrdinarySharesSubjectToPossibleRedemption" xlink:to="lab_sclx_OrdinarySharesSubjectToPossibleRedemption" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityRedemptionPricePerShare" xlink:label="loc_us-gaap_TemporaryEquityRedemptionPricePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquityRedemptionPricePerShare" xml:lang="en-US">Temporary Equity, Redemption Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TemporaryEquityRedemptionPricePerShare" xml:lang="en-US">Ordinary shares subject to possible redemption per share (in Dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityRedemptionPricePerShare" xlink:to="lab_us-gaap_TemporaryEquityRedemptionPricePerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preference shares, par value (in Dollars per share)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preference shares, authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred stock shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred Stock, Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preference shares, shares issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred stock, shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preference shares, shares outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred stock, shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common stock, par value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Ordinary shares, par value (in Dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common stock, shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SubjectToPossibleRedemptionPerShares" xlink:label="loc_sclx_SubjectToPossibleRedemptionPerShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SubjectToPossibleRedemptionPerShares" xml:lang="en-US">Subject To Possible Redemption Per Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_SubjectToPossibleRedemptionPerShares" xml:lang="en-US">Subject to possible redemption per shares (in Dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SubjectToPossibleRedemptionPerShares" xlink:to="lab_sclx_SubjectToPossibleRedemptionPerShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_SubjectToPossibleRedemptionPerShares" xml:lang="en-US">Subject To possible redemption per shares.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_OrdinarySharesRedemptionSubjectedToForfeiture" xlink:label="loc_sclx_OrdinarySharesRedemptionSubjectedToForfeiture" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_OrdinarySharesRedemptionSubjectedToForfeiture" xml:lang="en-US">Ordinary Shares Redemption Subjected To Forfeiture</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_OrdinarySharesRedemptionSubjectedToForfeiture" xml:lang="en-US">Ordinary shares redemption subjected to forfeiture</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_OrdinarySharesRedemptionSubjectedToForfeiture" xlink:to="lab_sclx_OrdinarySharesRedemptionSubjectedToForfeiture" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_OrdinarySharesRedemptionSubjectedToForfeiture" xml:lang="en-US">Redemption subjected to forfeiture.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SharesCapitalization" xlink:label="loc_sclx_SharesCapitalization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SharesCapitalization" xml:lang="en-US">Shares Capitalization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_SharesCapitalization" xml:lang="en-US">Shares capitalization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SharesCapitalization" xlink:to="lab_sclx_SharesCapitalization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_SharesCapitalization" xml:lang="en-US">Shares capitalization.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xml:lang="en-US">Class of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockDomain" xml:lang="en-US">Class of Stock [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonClassAMember" xml:lang="en-US">Common Class A [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassAMember" xlink:to="lab_us-gaap_CommonClassAMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xml:lang="en-US">Sale of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xml:lang="en-US">Sale of Stock [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xml:lang="en-US">Over-Allotment Option [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xml:lang="en-US">Over-Allotment Option [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement Abstract</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted average shares outstanding, ordinary shares (in Shares) , Basic</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Earnings Per Share, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Basic net (loss) income per share, ordinary shares (in Dollars per share)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Basic and diluted net income (loss) per ordinary share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Basic Loss Per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating Income (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Loss from operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAbstract" xlink:label="loc_us-gaap_OtherIncomeAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherIncomeAbstract" xml:lang="en-US">Component of Operating Income [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherIncomeAbstract" xml:lang="en-US">Other income (expense):</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAbstract" xlink:to="lab_us-gaap_OtherIncomeAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xml:lang="en-US">Fair Value Adjustment of Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xml:lang="en-US">Change in fair value of warrant liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xml:lang="en-US">Change in fair value of warrant liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfDerivatives" xlink:label="loc_us-gaap_GainLossOnSaleOfDerivatives" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainLossOnSaleOfDerivatives" xml:lang="en-US">Gain (Loss) on Sale of Derivatives</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GainLossOnSaleOfDerivatives" xml:lang="en-US">Loss on initial issuance of private warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfDerivatives" xlink:to="lab_us-gaap_GainLossOnSaleOfDerivatives" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TransactionCostsAllocatedToWarrantLiabilities" xlink:label="loc_sclx_TransactionCostsAllocatedToWarrantLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_TransactionCostsAllocatedToWarrantLiabilities" xml:lang="en-US">Transaction Costs Allocated To Warrant Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_sclx_TransactionCostsAllocatedToWarrantLiabilities" xml:lang="en-US">Transaction costs allocated to warrant liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_TransactionCostsAllocatedToWarrantLiabilities" xlink:to="lab_sclx_TransactionCostsAllocatedToWarrantLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_TransactionCostsAllocatedToWarrantLiabilities" xml:lang="en-US">Transaction costs allocated to warrant liabilities.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:label="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueOptionChangesInFairValueGainLoss1" xml:lang="en-US">Fair Value, Option, Changes in Fair Value, Gain (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueOptionChangesInFairValueGainLoss1" xml:lang="en-US">Change in fair value of conversion option liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:to="lab_us-gaap_FairValueOptionChangesInFairValueGainLoss1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DistributionsOnMandatorilyRedeemableSecurities" xlink:label="loc_us-gaap_DistributionsOnMandatorilyRedeemableSecurities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DistributionsOnMandatorilyRedeemableSecurities" xml:lang="en-US">Distributions on Mandatorily Redeemable Securities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DistributionsOnMandatorilyRedeemableSecurities" xml:lang="en-US">Interest on mandatorily redeemable ordinary shares liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DistributionsOnMandatorilyRedeemableSecurities" xml:lang="en-US">Interest on mandatorily redeemable ordinary shares liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DistributionsOnMandatorilyRedeemableSecurities" xlink:to="lab_us-gaap_DistributionsOnMandatorilyRedeemableSecurities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestExpense" xml:lang="en-US">Interest Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_InterestExpense" xml:lang="en-US">Interest expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaap_InterestIncomeOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestIncomeOther" xml:lang="en-US">Interest Income, Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestIncomeOther" xml:lang="en-US">Income earned on investments held in Trust Account</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOther" xlink:to="lab_us-gaap_InterestIncomeOther" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScilexPharmaNotesPrincipalIncrease" xlink:label="loc_sclx_ScilexPharmaNotesPrincipalIncrease" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ScilexPharmaNotesPrincipalIncrease" xml:lang="en-US">Scilex Pharma Notes principal increase</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ScilexPharmaNotesPrincipalIncrease" xml:lang="en-US">Scilex Pharma Notes principal increase</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ScilexPharmaNotesPrincipalIncrease" xlink:to="lab_sclx_ScilexPharmaNotesPrincipalIncrease" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ScilexPharmaNotesPrincipalIncrease" xml:lang="en-US">Scilex Pharma Notes principal increase</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xml:lang="en-US">Investment Income, Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xml:lang="en-US">Interest income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xml:lang="en-US">(Gain) loss on foreign currency exchange</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ChangeInFairValueOfWarrantLiability" xlink:label="loc_sclx_ChangeInFairValueOfWarrantLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ChangeInFairValueOfWarrantLiability" xml:lang="en-US">Change In Fair Value Of Warrant Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_sclx_ChangeInFairValueOfWarrantLiability" xml:lang="en-US">Change in fair value of warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ChangeInFairValueOfWarrantLiability" xlink:to="lab_sclx_ChangeInFairValueOfWarrantLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ChangeInFairValueOfWarrantLiability" xml:lang="en-US">Change in fair value of warrant liability.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_GainLossOnDerivative" xlink:label="loc_sclx_GainLossOnDerivative" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_GainLossOnDerivative" xml:lang="en-US">Gain (Loss) on Derivative</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_sclx_GainLossOnDerivative" xml:lang="en-US">Gain on derivative liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_GainLossOnDerivative" xlink:to="lab_sclx_GainLossOnDerivative" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_GainLossOnDerivative" xml:lang="en-US">Gain (Loss) on derivative.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_GainLossOnExtinguishmentOfDebtt" xlink:label="loc_sclx_GainLossOnExtinguishmentOfDebtt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_GainLossOnExtinguishmentOfDebtt" xml:lang="en-US">Gain (Loss) on Extinguishment of Debtt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_GainLossOnExtinguishmentOfDebtt" xml:lang="en-US">(Gain) loss on debt extinguishment, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_GainLossOnExtinguishmentOfDebtt" xlink:to="lab_sclx_GainLossOnExtinguishmentOfDebtt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_GainLossOnExtinguishmentOfDebtt" xml:lang="en-US">Gain (Loss) on extinguishment of debtt.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xml:lang="en-US">Other Operating Income (Expense), Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xml:lang="en-US">Total other (income) expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="lab_us-gaap_OtherOperatingIncomeExpenseNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Revenues" xml:lang="en-US">Revenues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_Revenues" xml:lang="en-US">Net revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingCostsAndExpensesAbstract" xlink:label="loc_us-gaap_OperatingCostsAndExpensesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingCostsAndExpensesAbstract" xml:lang="en-US">Operating Costs and Expenses [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingCostsAndExpensesAbstract" xml:lang="en-US">Operating costs and expenses:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="lab_us-gaap_OperatingCostsAndExpensesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CostOfRevenue" xml:lang="en-US">Cost of Revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CostOfRevenue" xml:lang="en-US">Cost of revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenue" xlink:to="lab_us-gaap_CostOfRevenue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and Development Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and development</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AcquiredinprocessresearchAndDevelopment" xlink:label="loc_sclx_AcquiredinprocessresearchAndDevelopment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AcquiredinprocessresearchAndDevelopment" xml:lang="en-US">Acquiredinprocessresearch and development</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_AcquiredinprocessresearchAndDevelopment" xml:lang="en-US">Acquired&#160;in-process&#160;research and development</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AcquiredinprocessresearchAndDevelopment" xlink:to="lab_sclx_AcquiredinprocessresearchAndDevelopment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AcquiredinprocessresearchAndDevelopment" xml:lang="en-US">Acquired&#160;in-process&#160;research and development</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xml:lang="en-US">Selling, General and Administrative Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xml:lang="en-US">Selling, general and administrative</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xml:lang="en-US">Amortization of Intangible Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xml:lang="en-US">Intangible amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xml:lang="en-US">Amortization of intangible assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="loc_us-gaap_OperatingCostsAndExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingCostsAndExpenses" xml:lang="en-US">Operating Costs and Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingCostsAndExpenses" xml:lang="en-US">Total operating costs and expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingCostsAndExpenses" xlink:to="lab_us-gaap_OperatingCostsAndExpenses" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Loss before income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income tax (benefit) expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Earnings Per Share, Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Diluted net (loss) income per share, ordinary shares (in Dollars per share)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Diluted net income (loss) per ordinary share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Basic and diluted net income (loss) per ordinary share (in Dollars per share)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Dilutive Loss Per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Weighted average shares outstanding, ordinary shares (in Shares) , diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Basic and diluted weighted average ordinary shares outstanding (in Shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Balance (in Shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Balance (in Shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetSharesReclassifiedToMandatorilyRedeemableCapitalStockValue" xlink:label="loc_us-gaap_NetSharesReclassifiedToMandatorilyRedeemableCapitalStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetSharesReclassifiedToMandatorilyRedeemableCapitalStockValue" xml:lang="en-US">Net Shares Reclassified to Mandatorily Redeemable Capital Stock, Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetSharesReclassifiedToMandatorilyRedeemableCapitalStockValue" xml:lang="en-US">Mandatorily redeemable ordinary shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetSharesReclassifiedToMandatorilyRedeemableCapitalStockValue" xlink:to="lab_us-gaap_NetSharesReclassifiedToMandatorilyRedeemableCapitalStockValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodValue" xlink:label="loc_us-gaap_StockRedeemedOrCalledDuringPeriodValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockRedeemedOrCalledDuringPeriodValue" xml:lang="en-US">Stock Redeemed or Called During Period, Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_StockRedeemedOrCalledDuringPeriodValue" xml:lang="en-US">Accretion of Ordinary shares subject to possible redemption amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRedeemedOrCalledDuringPeriodValue" xlink:to="lab_us-gaap_StockRedeemedOrCalledDuringPeriodValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xml:lang="en-US">Shares issued related to Semnur Acquisition , shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesOther" xml:lang="en-US">Stock Issued During Period, Shares, Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesOther" xml:lang="en-US">Cancellation of ordinary shares (in Shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesOther" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xml:lang="en-US">Issuance of ordinary shares to Sponsor</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xml:lang="en-US">Issuance of ordinary shares to Sponsor (in Shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AdjustmentsToAdditionalPaidInCapitalNetOfDiscount" xlink:label="loc_sclx_AdjustmentsToAdditionalPaidInCapitalNetOfDiscount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AdjustmentsToAdditionalPaidInCapitalNetOfDiscount" xml:lang="en-US">Adjustments To Additional Paid In Capital Net Of Discount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_AdjustmentsToAdditionalPaidInCapitalNetOfDiscount" xml:lang="en-US">Aardvark SP-104 license transfer from Sorrento, net of discount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AdjustmentsToAdditionalPaidInCapitalNetOfDiscount" xlink:to="lab_sclx_AdjustmentsToAdditionalPaidInCapitalNetOfDiscount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AdjustmentsToAdditionalPaidInCapitalNetOfDiscount" xml:lang="en-US">Adjustments to additional paid in capital net of discount.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AdjustmentsToAdditionalPaidInCapitalDiscountAmortization" xlink:label="loc_sclx_AdjustmentsToAdditionalPaidInCapitalDiscountAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AdjustmentsToAdditionalPaidInCapitalDiscountAmortization" xml:lang="en-US">Adjustments To Additional Paid In Capital Discount Amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_AdjustmentsToAdditionalPaidInCapitalDiscountAmortization" xml:lang="en-US">Aardvark SP-104 discount amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AdjustmentsToAdditionalPaidInCapitalDiscountAmortization" xlink:to="lab_sclx_AdjustmentsToAdditionalPaidInCapitalDiscountAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AdjustmentsToAdditionalPaidInCapitalDiscountAmortization" xml:lang="en-US">Adjustments to additional paid in capital discount amortization.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xml:lang="en-US">Shares issued related to Semnur Acquisition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xml:lang="en-US">Aggregate purchase price value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Distribution to Sorrento</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Distribution to Sorrento , shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Issuance of aggregate ordinary shares (in Shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xml:lang="en-US">Stock-based compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Stock options excercised , shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Exercised, Options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xml:lang="en-US">Stock options excercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, Forfeited</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xml:lang="en-US">Cancellation of shares held in escrow related to Semnur Acquisition , shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xml:lang="en-US">Ordinary shares, subject to forfeiture (in Shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AdjustmentsToAdditionalPaidInCapitalSharesIssuedInSemnurAcquisition" xlink:label="loc_sclx_AdjustmentsToAdditionalPaidInCapitalSharesIssuedInSemnurAcquisition" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AdjustmentsToAdditionalPaidInCapitalSharesIssuedInSemnurAcquisition" xml:lang="en-US">Adjustments To Additional Paid In Capital shares issued in Semnur Acquisition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_AdjustmentsToAdditionalPaidInCapitalSharesIssuedInSemnurAcquisition" xml:lang="en-US">Adjustment to shares issued in Semnur Acquisition</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AdjustmentsToAdditionalPaidInCapitalSharesIssuedInSemnurAcquisition" xlink:to="lab_sclx_AdjustmentsToAdditionalPaidInCapitalSharesIssuedInSemnurAcquisition" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AdjustmentsToAdditionalPaidInCapitalSharesIssuedInSemnurAcquisition" xml:lang="en-US">Adjustments To Additional Paid In Capital shares issued in Semnur Acquisition</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueOther" xml:lang="en-US">Stock Issued During Period, Value, Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueOther" xml:lang="en-US">Cancellation of ordinary shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueOther" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Ordinary Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Retained Earnings [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Accumulated Deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Operating activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net cash used for operating activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Cash flow from operation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to reconcile net loss to net cash used for operating activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Changes in operating assets and liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xml:lang="en-US">Prepaid expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Accounts payable and accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xml:lang="en-US">Increase (Decrease) in Inventories</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xml:lang="en-US">Inventory</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Prepaid expenses and other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:label="loc_us-gaap_IncreaseDecreaseInSecurityDeposits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInSecurityDeposits" xml:lang="en-US">Increase (Decrease) in Security Deposits</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInSecurityDeposits" xml:lang="en-US">Long-term deposits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:to="lab_us-gaap_IncreaseDecreaseInSecurityDeposits" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Trade</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xml:lang="en-US">Accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xml:lang="en-US">Accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xml:lang="en-US">Increase (Decrease) in Other Current Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:label="loc_us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xml:lang="en-US">Increase (Decrease) in Due to Related Parties, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xml:lang="en-US">Related party payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:to="lab_us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US">Accounts receivables, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndDividendIncomeSecuritiesHeldToMaturity" xlink:label="loc_us-gaap_InterestAndDividendIncomeSecuritiesHeldToMaturity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestAndDividendIncomeSecuritiesHeldToMaturity" xml:lang="en-US">Interest Income, Debt Securities, Held-to-Maturity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_InterestAndDividendIncomeSecuritiesHeldToMaturity" xml:lang="en-US">Income earned on investments held in Trust Account</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestAndDividendIncomeSecuritiesHeldToMaturity" xlink:to="lab_us-gaap_InterestAndDividendIncomeSecuritiesHeldToMaturity" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LossOnInitialIssuanceOfWarrantLiability" xlink:label="loc_sclx_LossOnInitialIssuanceOfWarrantLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_LossOnInitialIssuanceOfWarrantLiability" xml:lang="en-US">Loss On Initial Issuance Of Warrant Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_LossOnInitialIssuanceOfWarrantLiability" xml:lang="en-US">Loss on initial issuance of private warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_LossOnInitialIssuanceOfWarrantLiability" xlink:to="lab_sclx_LossOnInitialIssuanceOfWarrantLiability" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ChangeInFairValueOfConversionOptionLiability" xlink:label="loc_sclx_ChangeInFairValueOfConversionOptionLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ChangeInFairValueOfConversionOptionLiability" xml:lang="en-US">Change In Fair Value Of Conversion Option Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ChangeInFairValueOfConversionOptionLiability" xml:lang="en-US">Change in fair value of conversion option liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ChangeInFairValueOfConversionOptionLiability" xlink:to="lab_sclx_ChangeInFairValueOfConversionOptionLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ChangeInFairValueOfConversionOptionLiability" xml:lang="en-US">The amount of change in fair value of conversion option liability.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xml:lang="en-US">Amortization of Debt Discount (Premium)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xml:lang="en-US">Amortization of debt discount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TransactionsCostsAllocatedToPrivateWarrants" xlink:label="loc_sclx_TransactionsCostsAllocatedToPrivateWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_TransactionsCostsAllocatedToPrivateWarrants" xml:lang="en-US">Transactions Costs Allocated To Private Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_TransactionsCostsAllocatedToPrivateWarrants" xml:lang="en-US">Transaction costs allocated to warrant liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_TransactionsCostsAllocatedToPrivateWarrants" xlink:to="lab_sclx_TransactionsCostsAllocatedToPrivateWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_TransactionsCostsAllocatedToPrivateWarrants" xml:lang="en-US">Transaction costs allocated to warrant liabilities.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_IncreaseInNotesPayableOne" xlink:label="loc_sclx_IncreaseInNotesPayableOne" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_IncreaseInNotesPayableOne" xml:lang="en-US">Increase In Notes Payable One</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_IncreaseInNotesPayableOne" xml:lang="en-US">Scilex Pharma Notes principal increase</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_IncreaseInNotesPayableOne" xlink:to="lab_sclx_IncreaseInNotesPayableOne" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_IncreaseInNotesPayableOne" xml:lang="en-US">Increase in notes payable one.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestPaidNet" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_InterestPaidNet" xml:lang="en-US">Payment on the Scilex Pharma Notes attributed to accreted interest related to the debt discount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xml:lang="en-US">(Gain) loss on debt extinguishment, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xml:lang="en-US">Gain on debt extinguishment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NonCashOperatingLeaseCosts" xlink:label="loc_sclx_NonCashOperatingLeaseCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_NonCashOperatingLeaseCosts" xml:lang="en-US">Non Cash Operating Lease Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_NonCashOperatingLeaseCosts" xml:lang="en-US">Non-cash operating lease cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_NonCashOperatingLeaseCosts" xlink:to="lab_sclx_NonCashOperatingLeaseCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_NonCashOperatingLeaseCosts" xml:lang="en-US">Non cash operating lease costs.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Stock-based compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xml:lang="en-US">Derivative, Gain (Loss) on Derivative, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xml:lang="en-US">Gain on derivative liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="lab_us-gaap_DerivativeGainLossOnDerivativeNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xml:lang="en-US">Research and Development in Process</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xml:lang="en-US">Semnur-related IPR&amp;D</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xml:lang="en-US">In process research and development costs expensed</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:to="lab_us-gaap_ResearchAndDevelopmentInProcess" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xml:lang="en-US">Cost, Depreciation and Amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xml:lang="en-US">Depreciation and amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xml:lang="en-US">Amortization of debt issuance costs and debt discount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_FormationCostPaidThroughAdvancesFromAffiliateOfSponsor" xlink:label="loc_sclx_FormationCostPaidThroughAdvancesFromAffiliateOfSponsor" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_FormationCostPaidThroughAdvancesFromAffiliateOfSponsor" xml:lang="en-US">Formation Cost Paid Through Advances From Affiliate Of Sponsor</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_FormationCostPaidThroughAdvancesFromAffiliateOfSponsor" xml:lang="en-US">Formation cost paid through advances from affiliate of Sponsor</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_FormationCostPaidThroughAdvancesFromAffiliateOfSponsor" xlink:to="lab_sclx_FormationCostPaidThroughAdvancesFromAffiliateOfSponsor" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_FormationCostPaidThroughAdvancesFromAffiliateOfSponsor" xml:lang="en-US">Formation cost paid through advances from affiliate of Sponsor.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Investing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_InvestmentOfCashInTrustAccounts" xlink:label="loc_sclx_InvestmentOfCashInTrustAccounts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_InvestmentOfCashInTrustAccounts" xml:lang="en-US">Investment Of Cash In Trust Accounts</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_sclx_InvestmentOfCashInTrustAccounts" xml:lang="en-US">Investment of cash in Trust Account</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_InvestmentOfCashInTrustAccounts" xlink:to="lab_sclx_InvestmentOfCashInTrustAccounts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_InvestmentOfCashInTrustAccounts" xml:lang="en-US">Investment of cash in Trust Account.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDecommissioningFund" xlink:label="loc_us-gaap_ProceedsFromDecommissioningFund" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromDecommissioningFund" xml:lang="en-US">Proceeds from Decommissioning Trust Fund Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromDecommissioningFund" xml:lang="en-US">Cash withdrawn from Trust Account in connection with redemption</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDecommissioningFund" xlink:to="lab_us-gaap_ProceedsFromDecommissioningFund" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net cash used for investing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Purchase of property, plant, and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xml:lang="en-US">Acquisition of Semnur, net of cash acquired</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xml:lang="en-US">Payments to Acquire Businesses, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xml:lang="en-US">Acquisition consideration paid in cash for Romeg intangible asset acquisition</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US">Payments of Stock Issuance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US">Payment of offering costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfOtherEquity" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfOtherEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfOtherEquity" xml:lang="en-US">Payments for Repurchase of Other Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfOtherEquity" xml:lang="en-US">Redemption of ordinary shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfOtherEquity" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfOtherEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds from sale of Units, net of underwriting discounts paid</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xml:lang="en-US">Proceeds from Issuance of Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xml:lang="en-US">Proceeds from sale of Private Placement Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xml:lang="en-US">Aggregate purchase price (in Dollars)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfWarrants" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromRelatedPartyDebt" xml:lang="en-US">Proceeds from Related Party Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromRelatedPartyDebt" xml:lang="en-US">Proceeds from related party payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="lab_us-gaap_ProceedsFromRelatedPartyDebt" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RepaymentsOfRelatedPartyDebt" xml:lang="en-US">Repayments of Related Party Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_RepaymentsOfRelatedPartyDebt" xml:lang="en-US">Repayment of advances from related party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="lab_us-gaap_RepaymentsOfRelatedPartyDebt" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xml:lang="en-US">Proceeds from Issuance of Other Long-Term Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xml:lang="en-US">Proceeds from other loans</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ProceedsFromSimplePromissoryNoteRelatedParty" xlink:label="loc_sclx_ProceedsFromSimplePromissoryNoteRelatedParty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ProceedsFromSimplePromissoryNoteRelatedParty" xml:lang="en-US">Proceeds From Simple Promissory Note Related Party</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ProceedsFromSimplePromissoryNoteRelatedParty" xml:lang="en-US">Proceeds from simple promissory note &#8211; related party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ProceedsFromSimplePromissoryNoteRelatedParty" xlink:to="lab_sclx_ProceedsFromSimplePromissoryNoteRelatedParty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ProceedsFromSimplePromissoryNoteRelatedParty" xml:lang="en-US">Proceeds from simple promissory note &#8211; related party.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_RepaymentOfPromissoryNoteRelatedParty" xlink:label="loc_sclx_RepaymentOfPromissoryNoteRelatedParty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_RepaymentOfPromissoryNoteRelatedParty" xml:lang="en-US">Repayment Of Promissory Note Related Party</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_sclx_RepaymentOfPromissoryNoteRelatedParty" xml:lang="en-US">Repayment of promissory note &#8211; related party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_RepaymentOfPromissoryNoteRelatedParty" xlink:to="lab_sclx_RepaymentOfPromissoryNoteRelatedParty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_RepaymentOfPromissoryNoteRelatedParty" xml:lang="en-US">Repayment of promissory note &#8211; related party.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net cash provided by financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfMediumTermNotes" xlink:label="loc_us-gaap_RepaymentsOfMediumTermNotes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RepaymentsOfMediumTermNotes" xml:lang="en-US">Repayments of Medium-term Notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_RepaymentsOfMediumTermNotes" xml:lang="en-US">Repayment of related party note payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfMediumTermNotes" xlink:to="lab_us-gaap_RepaymentsOfMediumTermNotes" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfSeniorDebt" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RepaymentsOfSeniorDebt" xml:lang="en-US">Repayments of Senior Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_RepaymentsOfSeniorDebt" xml:lang="en-US">Repayment of principal on the Scilex Pharma Notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfSeniorDebt" xlink:to="lab_us-gaap_RepaymentsOfSeniorDebt" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfOtherLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfOtherLongTermDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RepaymentsOfOtherLongTermDebt" xml:lang="en-US">Repayments of Other Long-Term Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_RepaymentsOfOtherLongTermDebt" xml:lang="en-US">Repayment on other loans</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfOtherLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfOtherLongTermDebt" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ProceedsFromPromissoryNoteRelatedParty" xlink:label="loc_sclx_ProceedsFromPromissoryNoteRelatedParty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ProceedsFromPromissoryNoteRelatedParty" xml:lang="en-US">Proceeds From Promissory Note Related Party</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ProceedsFromPromissoryNoteRelatedParty" xml:lang="en-US">Proceeds from promissory note &#8211; related party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ProceedsFromPromissoryNoteRelatedParty" xlink:to="lab_sclx_ProceedsFromPromissoryNoteRelatedParty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ProceedsFromPromissoryNoteRelatedParty" xml:lang="en-US">Proceeds from promissory note related party.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xml:lang="en-US">Proceeds from (Repayments of) Related Party Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xml:lang="en-US">Repayment of promissory note &#8211; related party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:to="lab_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xml:lang="en-US">Proceeds from Stock Options Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xml:lang="en-US">Proceeds from stock options exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfMediumTermNotes" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfMediumTermNotes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfMediumTermNotes" xml:lang="en-US">Proceeds from Issuance of Medium-term Notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfMediumTermNotes" xml:lang="en-US">Proceeds from related party note payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfMediumTermNotes" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfMediumTermNotes" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xml:lang="en-US">Net change in cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash and cash equivalents at beginning of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash and cash equivalents at end of period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xml:lang="en-US">Supplemental disclosures of non-cash investing and financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DeferredUnderwritingFeePayable" xlink:label="loc_sclx_DeferredUnderwritingFeePayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DeferredUnderwritingFeePayable" xml:lang="en-US">Deferred Underwriting Fee Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_DeferredUnderwritingFeePayable" xml:lang="en-US">Deferred underwriting fee payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DeferredUnderwritingFeePayable" xlink:to="lab_sclx_DeferredUnderwritingFeePayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_DeferredUnderwritingFeePayable" xml:lang="en-US">Deferred Underwriting Fees means the amount of deferred underwriting fees held in the Trust Account in connection with SPAC's initial public offering payable to the underwriters upon consummation of a business combination.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_OfferingCostIncludedInAccruedOfferingCost" xlink:label="loc_sclx_OfferingCostIncludedInAccruedOfferingCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_OfferingCostIncludedInAccruedOfferingCost" xml:lang="en-US">Offering Cost Included In Accrued Offering Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_OfferingCostIncludedInAccruedOfferingCost" xml:lang="en-US">Offering costs included in accrued offering costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_OfferingCostIncludedInAccruedOfferingCost" xlink:to="lab_sclx_OfferingCostIncludedInAccruedOfferingCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_OfferingCostIncludedInAccruedOfferingCost" xml:lang="en-US">Offering cost included in accrued offering cost.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesIssued1" xlink:label="loc_us-gaap_NotesIssued1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NotesIssued1" xml:lang="en-US">Notes Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NotesIssued1" xml:lang="en-US">Offering costs paid through promissory note &#8211; related party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesIssued1" xlink:to="lab_us-gaap_NotesIssued1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xml:lang="en-US">Noncash or Part Noncash Acquisition, Intangible Assets Acquired</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xml:lang="en-US">Deferred consideration for Romeg intangible asset acquisition</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1" xlink:label="loc_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1" xml:lang="en-US">Other Significant Noncash Transaction, Value of Consideration Given</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1" xml:lang="en-US">Non-cash&#160;consideration in Semnur acquisition</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1" xlink:to="lab_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_OtherLoanForgiveness" xlink:label="loc_sclx_OtherLoanForgiveness" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_OtherLoanForgiveness" xml:lang="en-US">Other Loan Forgiveness</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_OtherLoanForgiveness" xml:lang="en-US">Other loan forgiveness</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_OtherLoanForgiveness" xlink:to="lab_sclx_OtherLoanForgiveness" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_OtherLoanForgiveness" xml:lang="en-US">Other loan forgiveness.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PromissoryNoteIssuedNetOfDiscount" xlink:label="loc_sclx_PromissoryNoteIssuedNetOfDiscount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PromissoryNoteIssuedNetOfDiscount" xml:lang="en-US">Promissory Note Issued Net Of Discount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PromissoryNoteIssuedNetOfDiscount" xml:lang="en-US">Promissory Note issued to Sorrento in exchange for the&#160;SP-104&#160;license, net of discount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PromissoryNoteIssuedNetOfDiscount" xlink:to="lab_sclx_PromissoryNoteIssuedNetOfDiscount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PromissoryNoteIssuedNetOfDiscount" xml:lang="en-US">Promissory note issued net of discount.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NonCashFairValueAdjustmentToDerivativeLiability" xlink:label="loc_sclx_NonCashFairValueAdjustmentToDerivativeLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_NonCashFairValueAdjustmentToDerivativeLiability" xml:lang="en-US">Non Cash Fair Value Adjustment To Derivative Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_NonCashFairValueAdjustmentToDerivativeLiability" xml:lang="en-US">Fair value adjustment to derivative liability in troubled debt restructuring</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_NonCashFairValueAdjustmentToDerivativeLiability" xlink:to="lab_sclx_NonCashFairValueAdjustmentToDerivativeLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_NonCashFairValueAdjustmentToDerivativeLiability" xml:lang="en-US">Non cash fair value adjustment to derivative liability.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NonCashRightOfUseAsset" xlink:label="loc_sclx_NonCashRightOfUseAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_NonCashRightOfUseAsset" xml:lang="en-US">Non Cash Right Of Use Asset</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_NonCashRightOfUseAsset" xml:lang="en-US">Live Action&#160;right-of-use&#160;asset in Palo Alto</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_NonCashRightOfUseAsset" xlink:to="lab_sclx_NonCashRightOfUseAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_NonCashRightOfUseAsset" xml:lang="en-US">Non cash right of use asset.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AcquistionCostsIncurredButNotPaidIncludedInAccountsPayable" xlink:label="loc_sclx_AcquistionCostsIncurredButNotPaidIncludedInAccountsPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AcquistionCostsIncurredButNotPaidIncludedInAccountsPayable" xml:lang="en-US">Acquistion Costs Incurred But Not Paid Included In Accounts Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_AcquistionCostsIncurredButNotPaidIncludedInAccountsPayable" xml:lang="en-US">Semnur acquisition costs incurred but not paid in accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AcquistionCostsIncurredButNotPaidIncludedInAccountsPayable" xlink:to="lab_sclx_AcquistionCostsIncurredButNotPaidIncludedInAccountsPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AcquistionCostsIncurredButNotPaidIncludedInAccountsPayable" xml:lang="en-US">Acquistion costs incurred but not paid included in accounts payable.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NonCashDistributionToAcquiree" xlink:label="loc_sclx_NonCashDistributionToAcquiree" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_NonCashDistributionToAcquiree" xml:lang="en-US">Non Cash Distribution To Acquiree</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_NonCashDistributionToAcquiree" xml:lang="en-US">Non-cash distribution to Sorrento</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_NonCashDistributionToAcquiree" xlink:to="lab_sclx_NonCashDistributionToAcquiree" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_NonCashDistributionToAcquiree" xml:lang="en-US">Non cash distribution to acquiree.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NonCashIncreaseInPrincipal" xlink:label="loc_sclx_NonCashIncreaseInPrincipal" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_NonCashIncreaseInPrincipal" xml:lang="en-US">Non Cash Increase In Principal</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_NonCashIncreaseInPrincipal" xml:lang="en-US">Scilex Pharma Notes principal increase</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_NonCashIncreaseInPrincipal" xlink:to="lab_sclx_NonCashIncreaseInPrincipal" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_NonCashIncreaseInPrincipal" xml:lang="en-US">Non cash increase in principal.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xml:lang="en-US">Reconciliation of cash, cash equivalents and restricted cash within the Company's balance sheet</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Restricted cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Accounting Policies [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DescriptionofOrganizationandBusinessOperationsTable" xlink:label="loc_sclx_DescriptionofOrganizationandBusinessOperationsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DescriptionofOrganizationandBusinessOperationsTable" xml:lang="en-US">Description of Organization and Business Operations [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsTable" xlink:to="lab_sclx_DescriptionofOrganizationandBusinessOperationsTable" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DescriptionOfOrganizationAndBusinessOperationsLineItems" xlink:label="loc_sclx_DescriptionOfOrganizationAndBusinessOperationsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DescriptionOfOrganizationAndBusinessOperationsLineItems" xml:lang="en-US">Description of Organization and Business Operations [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DescriptionOfOrganizationAndBusinessOperationsLineItems" xlink:to="lab_sclx_DescriptionOfOrganizationAndBusinessOperationsLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xml:lang="en-US">DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:label="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SummaryofSignificantAccountingPoliciesDetailsTable" xml:lang="en-US">Summary of Significant Accounting Policies (Details) [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="lab_sclx_SummaryofSignificantAccountingPoliciesDetailsTable" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:label="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems" xml:lang="en-US">Summary of Significant Accounting Policies (Details) [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="lab_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LiquidityAndGoingConcernAbstract" xlink:label="loc_sclx_LiquidityAndGoingConcernAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_LiquidityAndGoingConcernAbstract" xml:lang="en-US">Liquidity And Going Concern [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_LiquidityAndGoingConcernAbstract" xlink:to="lab_sclx_LiquidityAndGoingConcernAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_LiquidityAndGoingConcernAbstract" xml:lang="en-US">Liquidity and going Concern.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LiquidityAndGoingConcernTextBlock" xlink:label="loc_sclx_LiquidityAndGoingConcernTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_LiquidityAndGoingConcernTextBlock" xml:lang="en-US">Liquidity And Going Concern [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_LiquidityAndGoingConcernTextBlock" xml:lang="en-US">Liquidity and Going Concern</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_LiquidityAndGoingConcernTextBlock" xlink:to="lab_sclx_LiquidityAndGoingConcernTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_LiquidityAndGoingConcernTextBlock" xml:lang="en-US">Liquidity and going concern.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ProposedPublicOfferingAbstract" xlink:label="loc_sclx_ProposedPublicOfferingAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ProposedPublicOfferingAbstract" xml:lang="en-US">Public Offering [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ProposedPublicOfferingAbstract" xlink:to="lab_sclx_ProposedPublicOfferingAbstract" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PublicOfferingDetailsTable" xlink:label="loc_sclx_PublicOfferingDetailsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PublicOfferingDetailsTable" xml:lang="en-US">Public Offering (Details) [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PublicOfferingDetailsTable" xlink:to="lab_sclx_PublicOfferingDetailsTable" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PublicOfferingDetailsLineItems" xlink:label="loc_sclx_PublicOfferingDetailsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PublicOfferingDetailsLineItems" xml:lang="en-US">Public Offering (Details) [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PublicOfferingDetailsLineItems" xlink:to="lab_sclx_PublicOfferingDetailsLineItems" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ProposedPublicOfferingTextBlock" xlink:label="loc_sclx_ProposedPublicOfferingTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ProposedPublicOfferingTextBlock" xml:lang="en-US">Proposed Public Offering Text Block</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ProposedPublicOfferingTextBlock" xml:lang="en-US">PUBLIC OFFERING</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ProposedPublicOfferingTextBlock" xlink:to="lab_sclx_ProposedPublicOfferingTextBlock" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PrivatePlacementAbstract" xlink:label="loc_sclx_PrivatePlacementAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PrivatePlacementAbstract" xml:lang="en-US">Private Placement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PrivatePlacementAbstract" xlink:to="lab_sclx_PrivatePlacementAbstract" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PrivatePlacementDetailsTable" xlink:label="loc_sclx_PrivatePlacementDetailsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PrivatePlacementDetailsTable" xml:lang="en-US">Private Placement (Details) [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PrivatePlacementDetailsTable" xlink:to="lab_sclx_PrivatePlacementDetailsTable" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PrivatePlacementDetailsLineItems" xlink:label="loc_sclx_PrivatePlacementDetailsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PrivatePlacementDetailsLineItems" xml:lang="en-US">Private Placement (Details) [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PrivatePlacementDetailsLineItems" xlink:to="lab_sclx_PrivatePlacementDetailsLineItems" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PrivatePlacementTextBlock" xlink:label="loc_sclx_PrivatePlacementTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PrivatePlacementTextBlock" xml:lang="en-US">Private Placement Text Block</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PrivatePlacementTextBlock" xml:lang="en-US">PRIVATE PLACEMENT</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PrivatePlacementTextBlock" xlink:to="lab_sclx_PrivatePlacementTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PrivatePlacementTextBlock" xml:lang="en-US">The entire disclosure for private placement.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAbstract" xlink:label="loc_us-gaap_AssetAcquisitionAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetAcquisitionAbstract" xml:lang="en-US">Asset Acquisition [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionAbstract" xlink:to="lab_us-gaap_AssetAcquisitionAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTextBlock" xlink:label="loc_us-gaap_AssetAcquisitionTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetAcquisitionTextBlock" xml:lang="en-US">Asset Acquisition [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetAcquisitionTextBlock" xml:lang="en-US">Acquisitions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionTextBlock" xlink:to="lab_us-gaap_AssetAcquisitionTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xml:lang="en-US">Related Party Transactions [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_RelatedPartyTransactionsDetailsTable" xlink:label="loc_sclx_RelatedPartyTransactionsDetailsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_RelatedPartyTransactionsDetailsTable" xml:lang="en-US">Related Party Transactions (Details) [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_sclx_RelatedPartyTransactionsDetailsTable" xml:lang="en-US">Related Party Transactions [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsTable" xlink:to="lab_sclx_RelatedPartyTransactionsDetailsTable" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_RelatedPartyTransactionsDetailsLineItems" xlink:label="loc_sclx_RelatedPartyTransactionsDetailsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_RelatedPartyTransactionsDetailsLineItems" xml:lang="en-US">Related Party Transactions (Details) [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_sclx_RelatedPartyTransactionsDetailsLineItems" xml:lang="en-US">Related Party Transactions [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems" xlink:to="lab_sclx_RelatedPartyTransactionsDetailsLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">RELATED PARTY TRANSACTIONS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xml:lang="en-US">Fair Value Disclosures [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xml:lang="en-US">FAIR VALUE MEASUREMENTS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xml:lang="en-US">Property, Plant and Equipment [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US">Property and Equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xml:lang="en-US">Goodwill and Intangible Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xml:lang="en-US">Debt Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xml:lang="en-US">Debt Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xml:lang="en-US">Debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_WarrantsAbstract" xlink:label="loc_sclx_WarrantsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_WarrantsAbstract" xml:lang="en-US">Warrants Abstract</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_WarrantsAbstract" xlink:to="lab_sclx_WarrantsAbstract" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_WarrantsTable" xlink:label="loc_sclx_WarrantsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_WarrantsTable" xml:lang="en-US">Warrants [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_WarrantsTable" xlink:to="lab_sclx_WarrantsTable" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_WarrantsLineItems" xlink:label="loc_sclx_WarrantsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_WarrantsLineItems" xml:lang="en-US">Warrants [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_WarrantsLineItems" xlink:to="lab_sclx_WarrantsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_WarrantsLineItems" xml:lang="en-US">Warrants [Line item]</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_WarrantsTextBlock" xlink:label="loc_sclx_WarrantsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_WarrantsTextBlock" xml:lang="en-US">Warrants Text Block</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_WarrantsTextBlock" xml:lang="en-US">WARRANTS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_WarrantsTextBlock" xlink:to="lab_sclx_WarrantsTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xml:lang="en-US">Stockholders' Equity Note [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xml:lang="en-US">Schedule of Stock by Class [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockLineItems" xml:lang="en-US">Class of Stock [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">SHAREHOLDERS' DEFICIT</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_CompensationAndEmployeeBenefitPlansAbstract" xlink:label="loc_sclx_CompensationAndEmployeeBenefitPlansAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_CompensationAndEmployeeBenefitPlansAbstract" xml:lang="en-US">Compensation And Employee Benefit Plans [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_CompensationAndEmployeeBenefitPlansAbstract" xlink:to="lab_sclx_CompensationAndEmployeeBenefitPlansAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_CompensationAndEmployeeBenefitPlansAbstract" xml:lang="en-US">Compensation and employee benefit plans.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xml:lang="en-US">Compensation and Employee Benefit Plans [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xml:lang="en-US">Stock Incentive and Employee Benefit Plans</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_CommitmentsandContingenciesDetailsTable" xlink:label="loc_sclx_CommitmentsandContingenciesDetailsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_CommitmentsandContingenciesDetailsTable" xml:lang="en-US">Commitments and Contingencies (Details) [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsTable" xlink:to="lab_sclx_CommitmentsandContingenciesDetailsTable" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_CommitmentsandContingenciesDetailsLineItems" xlink:label="loc_sclx_CommitmentsandContingenciesDetailsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_CommitmentsandContingenciesDetailsLineItems" xml:lang="en-US">Commitments and Contingencies (Details) [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems" xlink:to="lab_sclx_CommitmentsandContingenciesDetailsLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:label="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xml:lang="en-US">Condensed Financial Information Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:to="lab_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedFinancialStatementsTable" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ScheduleOfCondensedFinancialStatementsTable" xml:lang="en-US">Condensed Financial Statements [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="lab_srt_ScheduleOfCondensedFinancialStatementsTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedFinancialStatementsCaptionsLineItems" xlink:label="loc_srt_CondensedFinancialStatementsCaptionsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_CondensedFinancialStatementsCaptionsLineItems" xml:lang="en-US">Condensed Financial Statements, Captions [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="lab_srt_CondensedFinancialStatementsCaptionsLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" xlink:label="loc_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" xml:lang="en-US">Condensed Financial Information of Parent Company Only Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" xml:lang="en-US">RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" xlink:to="lab_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xml:lang="en-US">Earnings Per Share [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xml:lang="en-US">Earnings Per Share [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xml:lang="en-US">Loss Per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xml:lang="en-US">Subsequent Events [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">SUBSEQUENT EVENTS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock" xlink:label="loc_us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock" xml:lang="en-US">Shares Subject to Mandatory Redemption, Changes in Redemption Value, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock" xml:lang="en-US">Ordinary Shares Subject to Possible Redemption</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock" xlink:to="lab_us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xml:lang="en-US">Warrant Liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Net Income (Loss) per Ordinary Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xml:lang="en-US">Concentration of Credit Risk</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xml:lang="en-US">Fair Value of Financial Instruments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">Recent Accounting Standards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="loc_us-gaap_DeferredChargesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredChargesPolicyTextBlock" xml:lang="en-US">Deferred Charges, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredChargesPolicyTextBlock" xml:lang="en-US">Offering Costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredChargesPolicyTextBlock" xlink:to="lab_us-gaap_DeferredChargesPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsPolicy" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xml:lang="en-US">Equity Method Investments [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xml:lang="en-US">Investments Held in Trust Account</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:to="lab_us-gaap_EquityMethodInvestmentsPolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and Cash Equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US">Significant Accounting Policies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xml:lang="en-US">Segments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xml:lang="en-US">Accounts Receivable [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xml:lang="en-US">Accounts Receivable, Net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xml:lang="en-US">Inventory, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xml:lang="en-US">Inventory</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property and Equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xml:lang="en-US">Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xml:lang="en-US">Emerging Growth Company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xml:lang="en-US">Principles of Consolidation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xml:lang="en-US">Basis of Presentation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xml:lang="en-US">Goodwill and Other Long-Lived Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="loc_us-gaap_DebtPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtPolicyTextBlock" xml:lang="en-US">Debt, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtPolicyTextBlock" xml:lang="en-US">Debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtPolicyTextBlock" xlink:to="lab_us-gaap_DebtPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xml:lang="en-US">In Process Research and Development, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xml:lang="en-US">Acquired In-Process Research and Development Expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xml:lang="en-US">Leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xml:lang="en-US">Revenue Recognition</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_RebatesPolicyTextBlock" xlink:label="loc_sclx_RebatesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_RebatesPolicyTextBlock" xml:lang="en-US">Rebates [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_RebatesPolicyTextBlock" xml:lang="en-US">Rebates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_RebatesPolicyTextBlock" xlink:to="lab_sclx_RebatesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_RebatesPolicyTextBlock" xml:lang="en-US">Rebates.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ServiceFeesPolicyTextBlock" xlink:label="loc_sclx_ServiceFeesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ServiceFeesPolicyTextBlock" xml:lang="en-US">Service Fees [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ServiceFeesPolicyTextBlock" xml:lang="en-US">Service Fees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ServiceFeesPolicyTextBlock" xlink:to="lab_sclx_ServiceFeesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ServiceFeesPolicyTextBlock" xml:lang="en-US">Service fees.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SalesReturnsPolicyTextBlock" xlink:label="loc_sclx_SalesReturnsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SalesReturnsPolicyTextBlock" xml:lang="en-US">Sales Returns [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_SalesReturnsPolicyTextBlock" xml:lang="en-US">Product Returns</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SalesReturnsPolicyTextBlock" xlink:to="lab_sclx_SalesReturnsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_SalesReturnsPolicyTextBlock" xml:lang="en-US">Sales returns.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_CoPaymentAssistancePolicyTextBlock" xlink:label="loc_sclx_CoPaymentAssistancePolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_CoPaymentAssistancePolicyTextBlock" xml:lang="en-US">Co Payment Assistance [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_CoPaymentAssistancePolicyTextBlock" xml:lang="en-US">Co-Payment Assistance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_CoPaymentAssistancePolicyTextBlock" xlink:to="lab_sclx_CoPaymentAssistancePolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_CoPaymentAssistancePolicyTextBlock" xml:lang="en-US">Co payment assistance.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US">Stock-Based Compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xml:lang="en-US">Business Combination</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:label="loc_srt_ScheduleOfCondensedBalanceSheetTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xml:lang="en-US">Condensed Balance Sheet [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xml:lang="en-US">Schedule of ordinary shares reflected in condensed consolidated balance sheets are reconciled</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:to="lab_srt_ScheduleOfCondensedBalanceSheetTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xml:lang="en-US">Schedule of reflects the calculation of basic and diluted net income (loss) per ordinary share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xml:lang="en-US">Summary of reconciliation of basic and diluted loss per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock" xml:lang="en-US">Schedule of Changes in Fair Value of Plan Assets [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock" xml:lang="en-US">Schedule of change in the fair value of conversion option liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xml:lang="en-US">Schedule of fair value hierarchy of the valuation inputs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueConcentrationOfRiskTextBlock" xlink:label="loc_us-gaap_FairValueConcentrationOfRiskTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueConcentrationOfRiskTextBlock" xml:lang="en-US">Fair Value, Concentration of Risk [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueConcentrationOfRiskTextBlock" xml:lang="en-US">Schedule of quantitative information regarding Level 3 fair value measurements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueConcentrationOfRiskTextBlock" xlink:to="lab_us-gaap_FairValueConcentrationOfRiskTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xml:lang="en-US">Schedule of Derivative Liabilities at Fair Value [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xml:lang="en-US">Schedule of changes in the fair value of warrant liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US">Schedule of valued using the compound option pricing model</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US">Summary Of Share Based Payment Award Options Issued To Employees And Nonemployees Valuation Assumptions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Property and Equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xml:lang="en-US">Summary of Estimated Future Amortization Expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xml:lang="en-US">Summary of the Company's Identifiable Intangible Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xml:lang="en-US">Summary of Borrowings of the Scilex Pharma Notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtTableTextBlock" xlink:label="loc_sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtTableTextBlock" xml:lang="en-US">Schedule Of Future minimum payments Of Long Term Debt [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtTableTextBlock" xml:lang="en-US">Summary of Future Minimum Payments Under the Scilex Pharma Notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtTableTextBlock" xlink:to="lab_sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtTableTextBlock" xml:lang="en-US">Schedule of future minimum payments of long term debt.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Summary Of The Options Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScheduleOfSupplementalQuantitativeInformationRelatedToLeasesTableTextBlock" xlink:label="loc_sclx_ScheduleOfSupplementalQuantitativeInformationRelatedToLeasesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ScheduleOfSupplementalQuantitativeInformationRelatedToLeasesTableTextBlock" xml:lang="en-US">Schedule Of Supplemental Quantitative Information Related To Leases [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ScheduleOfSupplementalQuantitativeInformationRelatedToLeasesTableTextBlock" xml:lang="en-US">Summary of Supplemental Quantitative Information Related To Leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ScheduleOfSupplementalQuantitativeInformationRelatedToLeasesTableTextBlock" xlink:to="lab_sclx_ScheduleOfSupplementalQuantitativeInformationRelatedToLeasesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ScheduleOfSupplementalQuantitativeInformationRelatedToLeasesTableTextBlock" xml:lang="en-US">Schedule of supplemental quantitative information related to leases.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xml:lang="en-US">Maturities of Lease Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xml:lang="en-US">Lease, Cost [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xml:lang="en-US">Summary of Components of Lease Expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" xml:lang="en-US">Condensed Financial Statements [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" xml:lang="en-US">Schedule of impact of these adjustments to the financial statement, as previously reported</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" xlink:to="lab_srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xml:lang="en-US">Schedule of components of income tax expense (benefit)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xml:lang="en-US">Schedule of effective income tax rate reconciliation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of deferred tax assets and liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable" xlink:label="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable" xml:lang="en-US">Description of Organization and Business Operations (Details) [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable" xlink:to="lab_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:label="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xml:lang="en-US">Description of Organization and Business Operations (Details) [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:to="lab_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesIssued" xml:lang="en-US">Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharesIssued" xml:lang="en-US">Number of shares (in Shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharesIssued" xml:lang="en-US">Preferred Stock shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xml:lang="en-US">Sale of Stock, Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xml:lang="en-US">Warrant price per share (in Dollars per share)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xml:lang="en-US">Contribution per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DemutualizationByInsuranceEntitySecuritiesIssuedGrossCashProceeds" xlink:label="loc_us-gaap_DemutualizationByInsuranceEntitySecuritiesIssuedGrossCashProceeds" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DemutualizationByInsuranceEntitySecuritiesIssuedGrossCashProceeds" xml:lang="en-US">Demutualization by Insurance Entity, Securities Issued, Gross Cash Proceeds</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DemutualizationByInsuranceEntitySecuritiesIssuedGrossCashProceeds" xml:lang="en-US">Gross proceeds</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DemutualizationByInsuranceEntitySecuritiesIssuedGrossCashProceeds" xlink:to="lab_us-gaap_DemutualizationByInsuranceEntitySecuritiesIssuedGrossCashProceeds" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsNet" xlink:label="loc_us-gaap_OtherIntangibleAssetsNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherIntangibleAssetsNet" xml:lang="en-US">Other Intangible Assets, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherIntangibleAssetsNet" xml:lang="en-US">Net tangible assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIntangibleAssetsNet" xlink:to="lab_us-gaap_OtherIntangibleAssetsNet" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfPublicShares" xlink:label="loc_sclx_PercentageOfPublicShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PercentageOfPublicShares" xml:lang="en-US">Percentage Of Public Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PercentageOfPublicShares" xml:lang="en-US">Percentage of public shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PercentageOfPublicShares" xlink:to="lab_sclx_PercentageOfPublicShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PercentageOfPublicShares" xml:lang="en-US">Percentage of public shares.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xml:lang="en-US">Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xml:lang="en-US">Redeem percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:to="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US">Sale of warrants (in Shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US">Aggregate purchase of private placement warrants (in Shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:label="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xml:lang="en-US">Business Acquisition, Transaction Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xml:lang="en-US">Transaction costs amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:to="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherUnderwritingExpense" xlink:label="loc_us-gaap_OtherUnderwritingExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherUnderwritingExpense" xml:lang="en-US">Other Underwriting Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherUnderwritingExpense" xml:lang="en-US">Cash underwriting fees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherUnderwritingExpense" xlink:to="lab_us-gaap_OtherUnderwritingExpense" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DeferredUnderwritingFees" xlink:label="loc_sclx_DeferredUnderwritingFees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DeferredUnderwritingFees" xml:lang="en-US">Deferred Underwriting Fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_DeferredUnderwritingFees" xml:lang="en-US">Deferred underwriting fees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DeferredUnderwritingFees" xlink:to="lab_sclx_DeferredUnderwritingFees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_DeferredUnderwritingFees" xml:lang="en-US">Deferred underwriting fees.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOwnershipInterestsOfferingCosts" xlink:label="loc_us-gaap_OtherOwnershipInterestsOfferingCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherOwnershipInterestsOfferingCosts" xml:lang="en-US">Other Ownership Interests, Offering Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherOwnershipInterestsOfferingCosts" xml:lang="en-US">Other offering costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOwnershipInterestsOfferingCosts" xlink:to="lab_us-gaap_OtherOwnershipInterestsOfferingCosts" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xml:lang="en-US">Sale of units amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoninterestBearingDepositLiabilities" xlink:label="loc_us-gaap_NoninterestBearingDepositLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NoninterestBearingDepositLiabilities" xml:lang="en-US">Noninterest-Bearing Deposit Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NoninterestBearingDepositLiabilities" xml:lang="en-US">Non-interest-bearing loans</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoninterestBearingDepositLiabilities" xlink:to="lab_us-gaap_NoninterestBearingDepositLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsHeldInTrust" xlink:label="loc_us-gaap_AssetsHeldInTrust" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsHeldInTrust" xml:lang="en-US">Assets Held-in-trust</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsHeldInTrust" xml:lang="en-US">Deposited trust account</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetsHeldInTrust" xml:lang="en-US">Trust account</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_AssetsHeldInTrust" xml:lang="en-US">Assets Held-in-trust</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsHeldInTrust" xlink:to="lab_us-gaap_AssetsHeldInTrust" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SaleOfStockDescriptionOfTransactions" xlink:label="loc_sclx_SaleOfStockDescriptionOfTransactions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SaleOfStockDescriptionOfTransactions" xml:lang="en-US">Sale Of Stock Description Of Transactions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_SaleOfStockDescriptionOfTransactions" xml:lang="en-US">Sale of stock, description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SaleOfStockDescriptionOfTransactions" xlink:to="lab_sclx_SaleOfStockDescriptionOfTransactions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_SaleOfStockDescriptionOfTransactions" xml:lang="en-US">Sale of stock description of transaction.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PricePerPublicShare" xlink:label="loc_sclx_PricePerPublicShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PricePerPublicShare" xml:lang="en-US">Price Per Public Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PricePerPublicShare" xml:lang="en-US">Anticipated public share (in Dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PricePerPublicShare" xlink:to="lab_sclx_PricePerPublicShare" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_BusinessCombinationRedeemPercentage" xlink:label="loc_sclx_BusinessCombinationRedeemPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_BusinessCombinationRedeemPercentage" xml:lang="en-US">Business Combination Redeem Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_BusinessCombinationRedeemPercentage" xml:lang="en-US">Business combination redeem percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_BusinessCombinationRedeemPercentage" xlink:to="lab_sclx_BusinessCombinationRedeemPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_BusinessCombinationRedeemPercentage" xml:lang="en-US">Business combination redeem percentage.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_Numberofshares" xlink:label="loc_sclx_Numberofshares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_Numberofshares" xml:lang="en-US">NumberOfShares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_Numberofshares" xml:lang="en-US">Number of shares (in Shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_Numberofshares" xlink:to="lab_sclx_Numberofshares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_Numberofshares" xml:lang="en-US">Number of shares.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ProceedsOfInitialPublicOffering" xlink:label="loc_sclx_ProceedsOfInitialPublicOffering" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ProceedsOfInitialPublicOffering" xml:lang="en-US">Proceeds Of Initial Public Offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ProceedsOfInitialPublicOffering" xml:lang="en-US">Proceeds of initial public offering</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ProceedsOfInitialPublicOffering" xlink:to="lab_sclx_ProceedsOfInitialPublicOffering" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ProceedsOfInitialPublicOffering" xml:lang="en-US">Proceeds Of Initial Public Offering.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_Saleofwarrants" xlink:label="loc_sclx_Saleofwarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_Saleofwarrants" xml:lang="en-US">SaleOfWarrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_Saleofwarrants" xml:lang="en-US">Sale of warrants (in Shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_Saleofwarrants" xlink:to="lab_sclx_Saleofwarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_Saleofwarrants" xml:lang="en-US">Sale Of Warrants.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_Grossproceedsofwarrants" xlink:label="loc_sclx_Grossproceedsofwarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_Grossproceedsofwarrants" xml:lang="en-US">GrossProceedsOfWarrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_Grossproceedsofwarrants" xml:lang="en-US">Gross proceeds of amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_Grossproceedsofwarrants" xlink:to="lab_sclx_Grossproceedsofwarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_Grossproceedsofwarrants" xml:lang="en-US">Gross Proceeds Of Warrants.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_Transactioncostsamount" xlink:label="loc_sclx_Transactioncostsamount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_Transactioncostsamount" xml:lang="en-US">TransactionCostsAmount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_Transactioncostsamount" xml:lang="en-US">Transaction costs amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_Transactioncostsamount" xlink:to="lab_sclx_Transactioncostsamount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_Transactioncostsamount" xml:lang="en-US">Transaction Costs Amount.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_Otherofferingcosts" xlink:label="loc_sclx_Otherofferingcosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_Otherofferingcosts" xml:lang="en-US">OtherOfferingCosts</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_Otherofferingcosts" xlink:to="lab_sclx_Otherofferingcosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_Otherofferingcosts" xml:lang="en-US">OtherOfferingCosts.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherExpenses" xlink:label="loc_us-gaap_OtherExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherExpenses" xml:lang="en-US">Other Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherExpenses" xml:lang="en-US">Dissolution expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherExpenses" xlink:to="lab_us-gaap_OtherExpenses" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DepositIntoTheTrustAccountPerShare" xlink:label="loc_sclx_DepositIntoTheTrustAccountPerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DepositIntoTheTrustAccountPerShare" xml:lang="en-US">Deposit Into The Trust Account Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_DepositIntoTheTrustAccountPerShare" xml:lang="en-US">Deposit into the trust account per share (in Dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DepositIntoTheTrustAccountPerShare" xlink:to="lab_sclx_DepositIntoTheTrustAccountPerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_DepositIntoTheTrustAccountPerShare" xml:lang="en-US">Deposit into the trust account per share.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LesserPublicPerShare" xlink:label="loc_sclx_LesserPublicPerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_LesserPublicPerShare" xml:lang="en-US">Lesser Public Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_LesserPublicPerShare" xml:lang="en-US">Lesser public per share (in Dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_LesserPublicPerShare" xlink:to="lab_sclx_LesserPublicPerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_LesserPublicPerShare" xml:lang="en-US">Lesser public per share</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAcquiredReceivablesDescription" xlink:label="loc_us-gaap_BusinessCombinationAcquiredReceivablesDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationAcquiredReceivablesDescription" xml:lang="en-US">Business Combination, Acquired Receivables, Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationAcquiredReceivablesDescription" xml:lang="en-US">Business combination description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAcquiredReceivablesDescription" xlink:to="lab_us-gaap_BusinessCombinationAcquiredReceivablesDescription" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCashCurrent" xml:lang="en-US">Restricted Cash, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedCashCurrent" xml:lang="en-US">Opening bank account</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent" xlink:to="lab_us-gaap_RestrictedCashCurrent" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_WorkingCapital" xlink:label="loc_sclx_WorkingCapital" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_WorkingCapital" xml:lang="en-US">Working Capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_WorkingCapital" xml:lang="en-US">Working capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_WorkingCapital" xlink:to="lab_sclx_WorkingCapital" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_WorkingCapital" xml:lang="en-US">Working capital.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeDepositWithFinancialInstitutionIncreaseDecrease" xlink:label="loc_us-gaap_InterestIncomeDepositWithFinancialInstitutionIncreaseDecrease" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestIncomeDepositWithFinancialInstitutionIncreaseDecrease" xml:lang="en-US">Interest Income, Deposit with Financial Institution, Increase (Decrease)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestIncomeDepositWithFinancialInstitutionIncreaseDecrease" xml:lang="en-US">Deposit interest income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeDepositWithFinancialInstitutionIncreaseDecrease" xlink:to="lab_us-gaap_InterestIncomeDepositWithFinancialInstitutionIncreaseDecrease" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_Numberofbusinessdays" xlink:label="loc_sclx_Numberofbusinessdays" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_Numberofbusinessdays" xml:lang="en-US">NumberOfBusinessDays</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_Numberofbusinessdays" xml:lang="en-US">Number of business days</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_Numberofbusinessdays" xlink:to="lab_sclx_Numberofbusinessdays" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_Numberofbusinessdays" xml:lang="en-US">Number Of Business Days.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NetTangibleAssets" xlink:label="loc_sclx_NetTangibleAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_NetTangibleAssets" xml:lang="en-US">Net Tangible Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_NetTangibleAssets" xml:lang="en-US">Net tangible assets (in Dollars)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_NetTangibleAssets" xlink:to="lab_sclx_NetTangibleAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_NetTangibleAssets" xml:lang="en-US">Net tangible assets.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_Depositintotrustaccount" xlink:label="loc_sclx_Depositintotrustaccount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_Depositintotrustaccount" xml:lang="en-US">DepositIntoTrustAccount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_Depositintotrustaccount" xml:lang="en-US">Deposit into trust account</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_Depositintotrustaccount" xlink:to="lab_sclx_Depositintotrustaccount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_Depositintotrustaccount" xml:lang="en-US">Deposit Into Trust Account.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_Interestexpenses" xlink:label="loc_sclx_Interestexpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_Interestexpenses" xml:lang="en-US">InterestExpenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_Interestexpenses" xml:lang="en-US">Interest Expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_Interestexpenses" xlink:to="lab_sclx_Interestexpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_Interestexpenses" xml:lang="en-US">Interest expenses.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xml:lang="en-US">Marketable Securities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xml:lang="en-US">Working capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xml:lang="en-US">Company place of incorporation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xml:lang="en-US">Business combination equity interest acquired</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Debt Instrument, Face Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Debt instrument face amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Aggregate principal amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Debt Instrument, Face Amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xml:lang="en-US">Proceeds from Divestiture of Businesses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xml:lang="en-US">Gross proceeds from business combination</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xml:lang="en-US">Proceeds from Divestiture of Businesses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xml:lang="en-US">Equity interest from business combination</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xml:lang="en-US">Business Acquisition [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:label="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xml:lang="en-US">Series of Individually Immaterial Business Acquisitions [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xml:lang="en-US">Business Combination [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xml:lang="en-US">Series of Individually Immaterial Business Acquisitions [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:to="lab_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScilexPharmaMember" xlink:label="loc_sclx_ScilexPharmaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ScilexPharmaMember" xml:lang="en-US">Scilex Pharma [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ScilexPharmaMember" xlink:to="lab_sclx_ScilexPharmaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ScilexPharmaMember" xml:lang="en-US">Scilex pharma.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VantageMergerSubIncMember" xlink:label="loc_sclx_VantageMergerSubIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_VantageMergerSubIncMember" xml:lang="en-US">Vantage Merger Sub Inc [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_VantageMergerSubIncMember" xlink:to="lab_sclx_VantageMergerSubIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_VantageMergerSubIncMember" xml:lang="en-US">Vantage merger sub inc.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PrivatePlacementWarrantMember" xlink:label="loc_sclx_PrivatePlacementWarrantMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PrivatePlacementWarrantMember" xml:lang="en-US">Private Placement Warrant Member</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PrivatePlacementWarrantMember" xml:lang="en-US">Private Placement Warrant [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PrivatePlacementWarrantMember" xlink:to="lab_sclx_PrivatePlacementWarrantMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PrivatePlacementWarrantMember" xml:lang="en-US">Private Placement Warrant [Member].</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IPOMember" xml:lang="en-US">IPO [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IPOMember" xml:lang="en-US">IPO [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IPOMember" xml:lang="en-US">Initial Public Offering [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember" xlink:to="lab_us-gaap_IPOMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US">Related Party [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyDomain" xml:lang="en-US">Related Party [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SorrentoMember" xlink:label="loc_sclx_SorrentoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SorrentoMember" xml:lang="en-US">Sorrento [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SorrentoMember" xlink:to="lab_sclx_SorrentoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_SorrentoMember" xml:lang="en-US">Sorrento.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xml:lang="en-US">Related Party Transaction [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xml:lang="en-US">Related Party Transaction [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SponsorMember" xlink:label="loc_sclx_SponsorMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SponsorMember" xml:lang="en-US">Sponsor [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SponsorMember" xlink:to="lab_sclx_SponsorMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_SponsorMember" xml:lang="en-US">Sponsor Member.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AgreementAxis" xlink:label="loc_sclx_AgreementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AgreementAxis" xml:lang="en-US">Agreement [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AgreementAxis" xlink:to="lab_sclx_AgreementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AgreementAxis" xml:lang="en-US">Agreement.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AgreementDomain" xlink:label="loc_sclx_AgreementDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AgreementDomain" xml:lang="en-US">Agreement [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AgreementDomain" xlink:to="lab_sclx_AgreementDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AgreementDomain" xml:lang="en-US">Agreement.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ContributionAndLoanAgreementMember" xlink:label="loc_sclx_ContributionAndLoanAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ContributionAndLoanAgreementMember" xml:lang="en-US">Contribution And Loan Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ContributionAndLoanAgreementMember" xlink:to="lab_sclx_ContributionAndLoanAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ContributionAndLoanAgreementMember" xml:lang="en-US">Contribution and loan agreement.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DebtExchangeAgreementMember" xlink:label="loc_sclx_DebtExchangeAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DebtExchangeAgreementMember" xml:lang="en-US">Debt Exchange Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DebtExchangeAgreementMember" xlink:to="lab_sclx_DebtExchangeAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_DebtExchangeAgreementMember" xml:lang="en-US">Debt exchange agreement.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_EventAxis" xlink:label="loc_sclx_EventAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_EventAxis" xml:lang="en-US">Event [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_EventAxis" xlink:to="lab_sclx_EventAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_EventAxis" xml:lang="en-US">Event.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_EventDomain" xlink:label="loc_sclx_EventDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_EventDomain" xml:lang="en-US">Event [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_EventDomain" xlink:to="lab_sclx_EventDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_EventDomain" xml:lang="en-US">Event.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ReorganizationMember" xlink:label="loc_sclx_ReorganizationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ReorganizationMember" xml:lang="en-US">Reorganization [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ReorganizationMember" xlink:to="lab_sclx_ReorganizationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ReorganizationMember" xml:lang="en-US">Reorganization.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaap_CashFDICInsuredAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashFDICInsuredAmount" xml:lang="en-US">Cash, FDIC Insured Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashFDICInsuredAmount" xml:lang="en-US">Federal depository insurance coverage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFDICInsuredAmount" xlink:to="lab_us-gaap_CashFDICInsuredAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherDeferredCostsNet" xlink:label="loc_us-gaap_OtherDeferredCostsNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherDeferredCostsNet" xml:lang="en-US">Other Deferred Costs, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherDeferredCostsNet" xml:lang="en-US">Offering costs amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherDeferredCostsNet" xlink:to="lab_us-gaap_OtherDeferredCostsNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExcessStockSharesIssued" xlink:label="loc_us-gaap_ExcessStockSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ExcessStockSharesIssued" xml:lang="en-US">Excess Stock, Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ExcessStockSharesIssued" xml:lang="en-US">Purchase of ordinary shares (in Shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExcessStockSharesIssued" xlink:to="lab_us-gaap_ExcessStockSharesIssued" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_Foundershares" xlink:label="loc_sclx_Foundershares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_Foundershares" xml:lang="en-US">FounderShares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_Foundershares" xml:lang="en-US">Founder shares (in Shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_Foundershares" xlink:to="lab_sclx_Foundershares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_Foundershares" xml:lang="en-US">Founder Shares.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xml:lang="en-US">Concentration Risk, Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xml:lang="en-US">Concentration risk percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xml:lang="en-US">Credit losses on accounts receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MajorCustomersAxis" xml:lang="en-US">Customer [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_NameOfMajorCustomerDomain" xml:lang="en-US">Customer [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SoleDistributorMember" xlink:label="loc_sclx_SoleDistributorMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SoleDistributorMember" xml:lang="en-US">Sole Distributor [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SoleDistributorMember" xlink:to="lab_sclx_SoleDistributorMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_SoleDistributorMember" xml:lang="en-US">Sole distributor.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xml:lang="en-US">Concentration Risk Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xml:lang="en-US">Concentration Risk Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xml:lang="en-US">Customer Concentration Risk [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xml:lang="en-US">Concentration Risk Benchmark [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xml:lang="en-US">Concentration Risk Benchmark [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaap_SalesRevenueNetMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SalesRevenueNetMember" xml:lang="en-US">Revenue Benchmark [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScheduleOfOrdinarySharesReflectedInCondensedConsolidatedBalanceSheetsAreReconciledAbstract" xlink:label="loc_sclx_ScheduleOfOrdinarySharesReflectedInCondensedConsolidatedBalanceSheetsAreReconciledAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ScheduleOfOrdinarySharesReflectedInCondensedConsolidatedBalanceSheetsAreReconciledAbstract" xml:lang="en-US">Schedule Of Ordinary Shares Reflected In Condensed Consolidated Balance Sheets Are Reconciled Abstract</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ScheduleOfOrdinarySharesReflectedInCondensedConsolidatedBalanceSheetsAreReconciledAbstract" xlink:to="lab_sclx_ScheduleOfOrdinarySharesReflectedInCondensedConsolidatedBalanceSheetsAreReconciledAbstract" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_GrossProceeds" xlink:label="loc_sclx_GrossProceeds" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_GrossProceeds" xml:lang="en-US">Gross Proceeds</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_GrossProceeds" xml:lang="en-US">Gross proceeds</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_GrossProceeds" xlink:to="lab_sclx_GrossProceeds" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LessAbstract" xlink:label="loc_sclx_LessAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_LessAbstract" xml:lang="en-US">Less Abstract</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_LessAbstract" xml:lang="en-US">Less:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_LessAbstract" xlink:to="lab_sclx_LessAbstract" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_OrdinarySharesIssuanceCost" xlink:label="loc_sclx_OrdinarySharesIssuanceCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_OrdinarySharesIssuanceCost" xml:lang="en-US">Ordinary Shares Issuance Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_sclx_OrdinarySharesIssuanceCost" xml:lang="en-US">Ordinary shares issuance costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_OrdinarySharesIssuanceCost" xlink:to="lab_sclx_OrdinarySharesIssuanceCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_OrdinarySharesIssuanceCost" xml:lang="en-US">The cash inflow from the additional capital contribution to the entity.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PlusAbstract" xlink:label="loc_sclx_PlusAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PlusAbstract" xml:lang="en-US">Plus Abstract</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PlusAbstract" xml:lang="en-US">Plus:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PlusAbstract" xlink:to="lab_sclx_PlusAbstract" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AccretionOfCarryingValueToRedemptionValue" xlink:label="loc_sclx_AccretionOfCarryingValueToRedemptionValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AccretionOfCarryingValueToRedemptionValue" xml:lang="en-US">Accretion Of Carrying Value To Redemption Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_AccretionOfCarryingValueToRedemptionValue" xml:lang="en-US">Accretion of carrying value to redemption value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AccretionOfCarryingValueToRedemptionValue" xlink:to="lab_sclx_AccretionOfCarryingValueToRedemptionValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="loc_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xml:lang="en-US">Temporary Equity, Accretion to Redemption Value, Adjustment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xml:lang="en-US">Accretion of carrying value to redemption value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:to="lab_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SharesSubjectToPossibleRedemption" xlink:label="loc_sclx_SharesSubjectToPossibleRedemption" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SharesSubjectToPossibleRedemption" xml:lang="en-US">Shares Subject To Possible Redemption</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_SharesSubjectToPossibleRedemption" xml:lang="en-US">Ordinary shares subject to possible redemption</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SharesSubjectToPossibleRedemption" xlink:to="lab_sclx_SharesSubjectToPossibleRedemption" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_SharesSubjectToPossibleRedemption" xml:lang="en-US">Ordinary shares subject to possible redemption.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LessAbstract0" xlink:label="loc_sclx_LessAbstract0" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_LessAbstract0" xml:lang="en-US">Less Abstract0</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_LessAbstract0" xml:lang="en-US">Less:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_LessAbstract0" xlink:to="lab_sclx_LessAbstract0" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityOtherChanges" xlink:label="loc_us-gaap_TemporaryEquityOtherChanges" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquityOtherChanges" xml:lang="en-US">Temporary Equity, Other Changes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TemporaryEquityOtherChanges" xml:lang="en-US">Mandatorily redeemable ordinary shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityOtherChanges" xlink:to="lab_us-gaap_TemporaryEquityOtherChanges" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareAbstract" xlink:label="loc_sclx_ScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareAbstract" xml:lang="en-US">Schedule Of Reflects The Calculation Of Basic And Diluted Net Income Loss Per Ordinary Share Abstract</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareAbstract" xlink:to="lab_sclx_ScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareAbstract" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NumeratorAbstract" xlink:label="loc_sclx_NumeratorAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_NumeratorAbstract" xml:lang="en-US">Numerator Abstract</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_NumeratorAbstract" xml:lang="en-US">Numerator:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_NumeratorAbstract" xlink:to="lab_sclx_NumeratorAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityNetIncome" xlink:label="loc_us-gaap_TemporaryEquityNetIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquityNetIncome" xml:lang="en-US">Temporary Equity, Net Income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TemporaryEquityNetIncome" xml:lang="en-US">Allocation of net income (loss)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityNetIncome" xlink:to="lab_us-gaap_TemporaryEquityNetIncome" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DenominatorAbstract" xlink:label="loc_sclx_DenominatorAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DenominatorAbstract" xml:lang="en-US">Denominator Abstract</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_DenominatorAbstract" xml:lang="en-US">Denominator:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DenominatorAbstract" xlink:to="lab_sclx_DenominatorAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xml:lang="en-US">Weighted Average Number of Shares Issued, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xml:lang="en-US">Basic and diluted weighted average ordinary shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesIssuedBasic" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LiquidityAndGoingConcernTable" xlink:label="loc_sclx_LiquidityAndGoingConcernTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_LiquidityAndGoingConcernTable" xml:lang="en-US">Liquidity And Going Concern [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_LiquidityAndGoingConcernTable" xlink:to="lab_sclx_LiquidityAndGoingConcernTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_LiquidityAndGoingConcernTable" xml:lang="en-US">Liquidity and going concern.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xml:lang="en-US">Subsequent Event Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xml:lang="en-US">Subsequent Event Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xml:lang="en-US">Long-Term Debt, Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xml:lang="en-US">Long-Term Debt, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SeniorSecuredNotesDueTwoThousandAndTwentySixMember" xlink:label="loc_sclx_SeniorSecuredNotesDueTwoThousandAndTwentySixMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SeniorSecuredNotesDueTwoThousandAndTwentySixMember" xml:lang="en-US">Senior Secured Notes Due Two Thousand And Twenty Six [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SeniorSecuredNotesDueTwoThousandAndTwentySixMember" xlink:to="lab_sclx_SeniorSecuredNotesDueTwoThousandAndTwentySixMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_SeniorSecuredNotesDueTwoThousandAndTwentySixMember" xml:lang="en-US">Senior secured notes due two thousand and twenty six.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_CumulativeSalesRelatedContingencyMember" xlink:label="loc_sclx_CumulativeSalesRelatedContingencyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_CumulativeSalesRelatedContingencyMember" xml:lang="en-US">Cumulative Sales Related Contingency [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_CumulativeSalesRelatedContingencyMember" xlink:to="lab_sclx_CumulativeSalesRelatedContingencyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_CumulativeSalesRelatedContingencyMember" xml:lang="en-US">Cumulative sales related contingency.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LetterOfCreditDrawnDownMember" xlink:label="loc_sclx_LetterOfCreditDrawnDownMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_LetterOfCreditDrawnDownMember" xml:lang="en-US">Letter Of Credit Drawn Down [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_LetterOfCreditDrawnDownMember" xlink:to="lab_sclx_LetterOfCreditDrawnDownMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_LetterOfCreditDrawnDownMember" xml:lang="en-US">Letter of credit drawn down.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LiquidityAndGoingConcernLineItems" xlink:label="loc_sclx_LiquidityAndGoingConcernLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_LiquidityAndGoingConcernLineItems" xml:lang="en-US">Liquidity And Going Concern [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems" xlink:to="lab_sclx_LiquidityAndGoingConcernLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_LiquidityAndGoingConcernLineItems" xml:lang="en-US">Liquidity and going concern.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xml:lang="en-US">Proceeds from Issuance of Secured Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xml:lang="en-US">Proceeds from senior secured notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MinimumUnrestrictedCashBalance" xlink:label="loc_sclx_MinimumUnrestrictedCashBalance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_MinimumUnrestrictedCashBalance" xml:lang="en-US">Minimum Unrestricted Cash Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_MinimumUnrestrictedCashBalance" xml:lang="en-US">Minimum unrestricted cash balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_MinimumUnrestrictedCashBalance" xlink:to="lab_sclx_MinimumUnrestrictedCashBalance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_MinimumUnrestrictedCashBalance" xml:lang="en-US">Minimum unrestricted cash balance.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xml:lang="en-US">Debt Instrument, Repurchased Face Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xml:lang="en-US">Debt instrument face amount of debt repurchased</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NetWorkingCapital" xlink:label="loc_sclx_NetWorkingCapital" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_NetWorkingCapital" xml:lang="en-US">Net Working Capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_NetWorkingCapital" xml:lang="en-US">Net working capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_NetWorkingCapital" xlink:to="lab_sclx_NetWorkingCapital" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_NetWorkingCapital" xml:lang="en-US">Net working capital.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_RestrictedFundsRelesableForFutureRepurchaseOfDebt" xlink:label="loc_sclx_RestrictedFundsRelesableForFutureRepurchaseOfDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_RestrictedFundsRelesableForFutureRepurchaseOfDebt" xml:lang="en-US">Restricted Funds Relesable For Future Repurchase Of Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_RestrictedFundsRelesableForFutureRepurchaseOfDebt" xml:lang="en-US">Restricted funds releasable for future repurchase of debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_RestrictedFundsRelesableForFutureRepurchaseOfDebt" xlink:to="lab_sclx_RestrictedFundsRelesableForFutureRepurchaseOfDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_RestrictedFundsRelesableForFutureRepurchaseOfDebt" xml:lang="en-US">Restricted funds relesable for future repurchase of debt.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DebtInstrumentRepurchaseObligation" xlink:label="loc_sclx_DebtInstrumentRepurchaseObligation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DebtInstrumentRepurchaseObligation" xml:lang="en-US">Debt Instrument Repurchase Obligation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_DebtInstrumentRepurchaseObligation" xml:lang="en-US">Debt instrument repurchase obligation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DebtInstrumentRepurchaseObligation" xlink:to="lab_sclx_DebtInstrumentRepurchaseObligation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_DebtInstrumentRepurchaseObligation" xml:lang="en-US">Debt Instrument Repurchase Obligation</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinimumNetWorthRequiredForCompliance" xlink:label="loc_us-gaap_MinimumNetWorthRequiredForCompliance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MinimumNetWorthRequiredForCompliance" xml:lang="en-US">Banking Regulation, Mortgage Banking, Net Worth, Minimum</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MinimumNetWorthRequiredForCompliance" xml:lang="en-US">Minimum net worth to consummate business combination</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_MinimumNetWorthRequiredForCompliance" xml:lang="en-US">Minimum net worth to consummate business combination</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinimumNetWorthRequiredForCompliance" xlink:to="lab_us-gaap_MinimumNetWorthRequiredForCompliance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AggregateOutstandingAmount" xlink:label="loc_sclx_AggregateOutstandingAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AggregateOutstandingAmount" xml:lang="en-US">Aggregate Outstanding Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_AggregateOutstandingAmount" xml:lang="en-US">Aggregate Outstanding Amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AggregateOutstandingAmount" xlink:to="lab_sclx_AggregateOutstandingAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AggregateOutstandingAmount" xml:lang="en-US">Aggregate outstanding amount.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:label="loc_us-gaap_DebtInstrumentAnnualPrincipalPayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentAnnualPrincipalPayment" xml:lang="en-US">Debt Instrument, Annual Principal Payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentAnnualPrincipalPayment" xml:lang="en-US">Debt Instrument, Annual Principal Payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtInstrumentAnnualPrincipalPayment" xml:lang="en-US">Debt instrument, annual principal payment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:to="lab_us-gaap_DebtInstrumentAnnualPrincipalPayment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentDecreaseForgiveness" xlink:label="loc_us-gaap_DebtInstrumentDecreaseForgiveness" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentDecreaseForgiveness" xml:lang="en-US">Debt Instrument, Decrease, Forgiveness</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentDecreaseForgiveness" xml:lang="en-US">Debt instrument, decrease, forgiveness</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentDecreaseForgiveness" xlink:to="lab_us-gaap_DebtInstrumentDecreaseForgiveness" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent" xml:lang="en-US">Notes Payable, Related Parties</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent" xml:lang="en-US">Notes Payable, Related Parties</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent" xml:lang="en-US">Notes Payable, Related Parties</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent" xml:lang="en-US">Notes payable, related parties</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentAxis" xml:lang="en-US">Debt Instrument [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScilexPharmaNotesMember" xlink:label="loc_sclx_ScilexPharmaNotesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ScilexPharmaNotesMember" xml:lang="en-US">Scilex Pharma Notes [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ScilexPharmaNotesMember" xlink:to="lab_sclx_ScilexPharmaNotesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ScilexPharmaNotesMember" xml:lang="en-US">Scilex pharma notes.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CreditFacilityAxis" xml:lang="en-US">Credit Facility [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CreditFacilityDomain" xml:lang="en-US">Credit Facility [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_FundingCommitmentLetterMember" xlink:label="loc_sclx_FundingCommitmentLetterMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_FundingCommitmentLetterMember" xml:lang="en-US">Funding Commitment Letter [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_FundingCommitmentLetterMember" xlink:to="lab_sclx_FundingCommitmentLetterMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_FundingCommitmentLetterMember" xml:lang="en-US">Funding commitment letter.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NumberOfSaleUnits" xlink:label="loc_sclx_NumberOfSaleUnits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_NumberOfSaleUnits" xml:lang="en-US">Number Of Sale Units</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_NumberOfSaleUnits" xml:lang="en-US">Number of sale units</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_NumberOfSaleUnits" xlink:to="lab_sclx_NumberOfSaleUnits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_NumberOfSaleUnits" xml:lang="en-US">Number of sale units</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PurchasePricePerShare" xlink:label="loc_sclx_PurchasePricePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PurchasePricePerShare" xml:lang="en-US">Purchase Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PurchasePricePerShare" xml:lang="en-US">Purchase price per unit (in Dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PurchasePricePerShare" xlink:to="lab_sclx_PurchasePricePerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="loc_us-gaap_SaleOfStockDescriptionOfTransaction" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockDescriptionOfTransaction" xml:lang="en-US">Sale of Stock, Description of Transaction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SaleOfStockDescriptionOfTransaction" xml:lang="en-US">Sale of stock, description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockDescriptionOfTransaction" xlink:to="lab_us-gaap_SaleOfStockDescriptionOfTransaction" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Price per warrant</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xml:lang="en-US">Shares Issued, Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xml:lang="en-US">Ordinary share, per share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xml:lang="en-US">Preferred Stock, par value (in Dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare" xlink:to="lab_us-gaap_SharesIssuedPricePerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrivatePlacementMember" xml:lang="en-US">Private Placement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PrivatePlacementMember" xml:lang="en-US">Private Placement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PrivatePlacementMember" xml:lang="en-US">Private Placement Warrants [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember" xlink:to="lab_us-gaap_PrivatePlacementMember" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_FounderSharesMember" xlink:label="loc_sclx_FounderSharesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_FounderSharesMember" xml:lang="en-US">Founder Shares Member</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_FounderSharesMember" xml:lang="en-US">Founder Shares [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_FounderSharesMember" xlink:to="lab_sclx_FounderSharesMember" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PromissoryNoteRelatedPartyMember" xlink:label="loc_sclx_PromissoryNoteRelatedPartyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PromissoryNoteRelatedPartyMember" xml:lang="en-US">Promissory Note Related Party Member</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PromissoryNoteRelatedPartyMember" xml:lang="en-US">Promissory Note - Related Party [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PromissoryNoteRelatedPartyMember" xlink:to="lab_sclx_PromissoryNoteRelatedPartyMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xml:lang="en-US">Short-Term Debt, Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis" xlink:to="lab_us-gaap_ShortTermDebtTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xml:lang="en-US">Short-Term Debt, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain" xlink:to="lab_us-gaap_ShortTermDebtTypeDomain" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ConvertiblePromisoryNoteMember" xlink:label="loc_sclx_ConvertiblePromisoryNoteMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ConvertiblePromisoryNoteMember" xml:lang="en-US">Convertible Promisory Note Member</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ConvertiblePromisoryNoteMember" xml:lang="en-US">Convertible Promissory Note [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ConvertiblePromisoryNoteMember" xlink:to="lab_sclx_ConvertiblePromisoryNoteMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertibleNotesPayableMember" xml:lang="en-US">Convertible Notes Payable [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleNotesPayableMember" xlink:to="lab_us-gaap_ConvertibleNotesPayableMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RepaymentsOfDebt" xml:lang="en-US">Repayments of Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RepaymentsOfDebt" xml:lang="en-US">Outstanding balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RepaymentsOfDebt" xml:lang="en-US">Repayments of debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt" xlink:to="lab_us-gaap_RepaymentsOfDebt" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationControlObtainedDescription" xlink:label="loc_us-gaap_BusinessCombinationControlObtainedDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationControlObtainedDescription" xml:lang="en-US">Business Combination, Control Obtained Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationControlObtainedDescription" xml:lang="en-US">Business combination, description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationControlObtainedDescription" xlink:to="lab_us-gaap_BusinessCombinationControlObtainedDescription" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaap_ConvertibleDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertibleDebt" xml:lang="en-US">Convertible Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConvertibleDebt" xml:lang="en-US">Convertible promissory notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebt" xlink:to="lab_us-gaap_ConvertibleDebt" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xml:lang="en-US">Equity Method Investment, Ownership Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xml:lang="en-US">Shareholder issued and outstanding shares percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_WarrantsExercisePrice" xlink:label="loc_sclx_WarrantsExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_WarrantsExercisePrice" xml:lang="en-US">Warrants Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_WarrantsExercisePrice" xml:lang="en-US">Warrant price per share (in Dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_WarrantsExercisePrice" xlink:to="lab_sclx_WarrantsExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_WarrantsExercisePrice" xml:lang="en-US">Warrants Exercise Price</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_CapitalizationOfShareOutstanding" xlink:label="loc_sclx_CapitalizationOfShareOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_CapitalizationOfShareOutstanding" xml:lang="en-US">Capitalization Of Share Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_CapitalizationOfShareOutstanding" xml:lang="en-US">Capitalization of share outstanding (in Shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_CapitalizationOfShareOutstanding" xlink:to="lab_sclx_CapitalizationOfShareOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_CapitalizationOfShareOutstanding" xml:lang="en-US">Capitalization of share outstanding.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_OrdinarySharesIssuedAndOutstanding" xlink:label="loc_sclx_OrdinarySharesIssuedAndOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_OrdinarySharesIssuedAndOutstanding" xml:lang="en-US">Ordinary Shares Issued And Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_OrdinarySharesIssuedAndOutstanding" xml:lang="en-US">Ordinary shares issued and outstanding (in Shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_OrdinarySharesIssuedAndOutstanding" xlink:to="lab_sclx_OrdinarySharesIssuedAndOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_OrdinarySharesIssuedAndOutstanding" xml:lang="en-US">Ordinary shares issued and outstanding.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xml:lang="en-US">Payments to Acquire Productive Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xml:lang="en-US">Payments to acquire productive assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="lab_us-gaap_PaymentsToAcquireProductiveAssets" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_aggregatePurchasePrice" xlink:label="loc_sclx_aggregatePurchasePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_aggregatePurchasePrice" xml:lang="en-US">aggregate Purchase Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_aggregatePurchasePrice" xml:lang="en-US">Aggregate purchase price value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_aggregatePurchasePrice" xlink:to="lab_sclx_aggregatePurchasePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_aggregatePurchasePrice" xml:lang="en-US">aggregate purchase price.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NumberOfSharesOutstanding" xlink:label="loc_sclx_NumberOfSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_NumberOfSharesOutstanding" xml:lang="en-US">Number Of Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_NumberOfSharesOutstanding" xml:lang="en-US">Capital stock, shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_NumberOfSharesOutstanding" xlink:to="lab_sclx_NumberOfSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_NumberOfSharesOutstanding" xml:lang="en-US">Number of shares outstanding.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NumberOfSharesAcquired" xlink:label="loc_sclx_NumberOfSharesAcquired" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_NumberOfSharesAcquired" xml:lang="en-US">Number Of Shares Acquired</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_NumberOfSharesAcquired" xml:lang="en-US">Number of shares acquired</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_NumberOfSharesAcquired" xlink:to="lab_sclx_NumberOfSharesAcquired" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_NumberOfSharesAcquired" xml:lang="en-US">Number of shares acquired.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xml:lang="en-US">Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xml:lang="en-US">Asset acquistion consideration transferred equity interest issued and issuable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:to="lab_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xml:lang="en-US">Stock Issued During Period, Shares, Purchase of Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xml:lang="en-US">Stock issued during period shares purchase of assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesSubscribedButUnissued" xlink:label="loc_us-gaap_CommonStockSharesSubscribedButUnissued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesSubscribedButUnissued" xml:lang="en-US">Common Stock, Shares Subscribed but Unissued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesSubscribedButUnissued" xml:lang="en-US">Common stock shares subscribed but not issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesSubscribedButUnissued" xlink:to="lab_us-gaap_CommonStockSharesSubscribedButUnissued" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AssetAcquisitionPricePerShare" xlink:label="loc_sclx_AssetAcquisitionPricePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AssetAcquisitionPricePerShare" xml:lang="en-US">Asset Acquisition Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_AssetAcquisitionPricePerShare" xml:lang="en-US">Asset acquisition price per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AssetAcquisitionPricePerShare" xlink:to="lab_sclx_AssetAcquisitionPricePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AssetAcquisitionPricePerShare" xml:lang="en-US">Asset acquisition price per share.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfOwnershipInterest" xlink:label="loc_sclx_PercentageOfOwnershipInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PercentageOfOwnershipInterest" xml:lang="en-US">Percentage Of Ownership Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PercentageOfOwnershipInterest" xml:lang="en-US">Percentage of ownership interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PercentageOfOwnershipInterest" xlink:to="lab_sclx_PercentageOfOwnershipInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PercentageOfOwnershipInterest" xml:lang="en-US">Percentage of ownership interest.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfSharesOutstanding" xlink:label="loc_sclx_PercentageOfSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PercentageOfSharesOutstanding" xml:lang="en-US">Percentage Of Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PercentageOfSharesOutstanding" xml:lang="en-US">Percentage of shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PercentageOfSharesOutstanding" xlink:to="lab_sclx_PercentageOfSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PercentageOfSharesOutstanding" xml:lang="en-US">Percentage of shares outstanding.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:label="loc_us-gaap_CostsAndExpensesRelatedParty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CostsAndExpensesRelatedParty" xml:lang="en-US">Costs and Expenses, Related Party</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CostsAndExpensesRelatedParty" xml:lang="en-US">Fund expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesRelatedParty" xlink:to="lab_us-gaap_CostsAndExpensesRelatedParty" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xml:lang="en-US">Stock Issued During Period, Value, Purchase of Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xml:lang="en-US">Aggregate principal amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xlink:label="loc_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xml:lang="en-US">Related Party Transaction, Selling, General and Administrative Expenses from Transactions with Related Party</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xml:lang="en-US">Related Party transaction, selling, general and administrative expenses from transactions with related party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xlink:to="lab_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTaxExpenseDueToAffiliatesDeferred" xlink:label="loc_us-gaap_RelatedPartyTaxExpenseDueToAffiliatesDeferred" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTaxExpenseDueToAffiliatesDeferred" xml:lang="en-US">Related Party Tax Expense, Due to Affiliates, Deferred</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyTaxExpenseDueToAffiliatesDeferred" xml:lang="en-US">Interest expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTaxExpenseDueToAffiliatesDeferred" xlink:to="lab_us-gaap_RelatedPartyTaxExpenseDueToAffiliatesDeferred" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xml:lang="en-US">Debt discount amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AggregatePrincipalAmount" xlink:label="loc_sclx_AggregatePrincipalAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AggregatePrincipalAmount" xml:lang="en-US">Aggregate Principal Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_AggregatePrincipalAmount" xml:lang="en-US">Aggregate principal amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AggregatePrincipalAmount" xlink:to="lab_sclx_AggregatePrincipalAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AggregatePrincipalAmount" xml:lang="en-US">Aggregate Principal Amount.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfSimpleInterest" xlink:label="loc_sclx_PercentageOfSimpleInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PercentageOfSimpleInterest" xml:lang="en-US">Percentage Of Simple Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PercentageOfSimpleInterest" xml:lang="en-US">Percentage of simple interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PercentageOfSimpleInterest" xlink:to="lab_sclx_PercentageOfSimpleInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PercentageOfSimpleInterest" xml:lang="en-US">Percentage of simple interest.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NotesPayableCurrent" xml:lang="en-US">Notes Payable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NotesPayableCurrent" xml:lang="en-US">Related party note payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableCurrent" xlink:to="lab_us-gaap_NotesPayableCurrent" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AccruedInterest" xlink:label="loc_sclx_AccruedInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AccruedInterest" xml:lang="en-US">Accrued Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_AccruedInterest" xml:lang="en-US">Accrued interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AccruedInterest" xlink:to="lab_sclx_AccruedInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AccruedInterest" xml:lang="en-US">Accrued interest.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PricePerWarrants" xlink:label="loc_sclx_PricePerWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PricePerWarrants" xml:lang="en-US">Price Per Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PricePerWarrants" xml:lang="en-US">Price per warrant (in Dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PricePerWarrants" xlink:to="lab_sclx_PricePerWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PricePerWarrants" xml:lang="en-US">Price per warrant.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentTerm" xml:lang="en-US">Debt Instrument, Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentTerm" xml:lang="en-US">Debt instrument, term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US">Debt instrument, interest rate, stated percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseRelatedParty" xlink:label="loc_us-gaap_InterestExpenseRelatedParty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestExpenseRelatedParty" xml:lang="en-US">Interest Expense, Related Party</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestExpenseRelatedParty" xml:lang="en-US">Interest expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseRelatedParty" xlink:to="lab_us-gaap_InterestExpenseRelatedParty" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToAffiliateCurrent" xlink:label="loc_us-gaap_DueToAffiliateCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DueToAffiliateCurrent" xml:lang="en-US">Due to Affiliate, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DueToAffiliateCurrent" xml:lang="en-US">Advances outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToAffiliateCurrent" xlink:to="lab_us-gaap_DueToAffiliateCurrent" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_RepaidAmount" xlink:label="loc_sclx_RepaidAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_RepaidAmount" xml:lang="en-US">Repaid Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_RepaidAmount" xml:lang="en-US">Repaid amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_RepaidAmount" xlink:to="lab_sclx_RepaidAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_RepaidAmount" xml:lang="en-US">Repaid Amount.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfCapitalSharesOutstanding" xlink:label="loc_sclx_PercentageOfCapitalSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PercentageOfCapitalSharesOutstanding" xml:lang="en-US">Percentage Of Capital Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PercentageOfCapitalSharesOutstanding" xml:lang="en-US">Percentage of capital shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PercentageOfCapitalSharesOutstanding" xlink:to="lab_sclx_PercentageOfCapitalSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PercentageOfCapitalSharesOutstanding" xml:lang="en-US">Percentage of capital shares outstanding.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermNotesPayable" xml:lang="en-US">Notes Payable, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LongTermNotesPayable" xml:lang="en-US">Notes payable, noncurrent</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermNotesPayable" xlink:to="lab_us-gaap_LongTermNotesPayable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromNotesPayable" xml:lang="en-US">Proceeds from Notes Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromNotesPayable" xml:lang="en-US">Proceeds from notes payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromNotesPayable" xlink:to="lab_us-gaap_ProceedsFromNotesPayable" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_WorkingCapitalRequirements" xlink:label="loc_sclx_WorkingCapitalRequirements" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_WorkingCapitalRequirements" xml:lang="en-US">Working Capital Requirements</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_WorkingCapitalRequirements" xml:lang="en-US">Working capital requirements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_WorkingCapitalRequirements" xlink:to="lab_sclx_WorkingCapitalRequirements" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_WorkingCapitalRequirements" xml:lang="en-US">Working capital requirements.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchaseAmount" xlink:label="loc_us-gaap_DebtInstrumentRepurchaseAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentRepurchaseAmount" xml:lang="en-US">Debt Instrument, Repurchase Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentRepurchaseAmount" xml:lang="en-US">Debt instrument, repurchase amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRepurchaseAmount" xlink:to="lab_us-gaap_DebtInstrumentRepurchaseAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionDescriptionOfTransaction" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xml:lang="en-US">Related Party Transaction, Description of Transaction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xml:lang="en-US">Description of related party extension loans</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:to="lab_us-gaap_RelatedPartyTransactionDescriptionOfTransaction" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DepositedInTrustAccount" xlink:label="loc_sclx_DepositedInTrustAccount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DepositedInTrustAccount" xml:lang="en-US">Deposited In Trust Account</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_DepositedInTrustAccount" xml:lang="en-US">Trust account</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DepositedInTrustAccount" xlink:to="lab_sclx_DepositedInTrustAccount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_DepositedInTrustAccount" xml:lang="en-US">Deposited in trust account</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PaymentToAcquireInventory" xlink:label="loc_sclx_PaymentToAcquireInventory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PaymentToAcquireInventory" xml:lang="en-US">Payment To Acquire Inventory</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PaymentToAcquireInventory" xml:lang="en-US">Payment to acquire inventory</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PaymentToAcquireInventory" xlink:to="lab_sclx_PaymentToAcquireInventory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PaymentToAcquireInventory" xml:lang="en-US">Payment to acquire inventory.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaap_LegalFees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LegalFees" xml:lang="en-US">Legal Fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LegalFees" xml:lang="en-US">Legal fees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalFees" xlink:to="lab_us-gaap_LegalFees" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfOutstandingAmountIndebtedness" xlink:label="loc_sclx_PercentageOfOutstandingAmountIndebtedness" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PercentageOfOutstandingAmountIndebtedness" xml:lang="en-US">Percentage of Outstanding Amount Indebtedness</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PercentageOfOutstandingAmountIndebtedness" xml:lang="en-US">Percentage of Outstanding Amount Indebtedness</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PercentageOfOutstandingAmountIndebtedness" xlink:to="lab_sclx_PercentageOfOutstandingAmountIndebtedness" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PercentageOfOutstandingAmountIndebtedness" xml:lang="en-US">Percentage of outstanding amount indebtedness</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PerShareCalculationOfOutstandingAmountInExchangeOfShares" xlink:label="loc_sclx_PerShareCalculationOfOutstandingAmountInExchangeOfShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PerShareCalculationOfOutstandingAmountInExchangeOfShares" xml:lang="en-US">Per share calculation of Outstanding Amount In Exchange of Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PerShareCalculationOfOutstandingAmountInExchangeOfShares" xml:lang="en-US">Per share calculation of Outstanding Amount In Exchange of Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PerShareCalculationOfOutstandingAmountInExchangeOfShares" xlink:to="lab_sclx_PerShareCalculationOfOutstandingAmountInExchangeOfShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PerShareCalculationOfOutstandingAmountInExchangeOfShares" xml:lang="en-US">Per share calculation of Outstanding Amount In Exchange of Shares</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LimitationOfOutstandingAmountInExchangeOfShares" xlink:label="loc_sclx_LimitationOfOutstandingAmountInExchangeOfShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_LimitationOfOutstandingAmountInExchangeOfShares" xml:lang="en-US">Limitation of Outstanding Amount In Exchange of Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_LimitationOfOutstandingAmountInExchangeOfShares" xml:lang="en-US">Limitation of Outstanding Amount In Exchange of Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_LimitationOfOutstandingAmountInExchangeOfShares" xlink:to="lab_sclx_LimitationOfOutstandingAmountInExchangeOfShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_LimitationOfOutstandingAmountInExchangeOfShares" xml:lang="en-US">Limitation of Outstanding Amount In Exchange of Shares</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebt" xml:lang="en-US">Long-Term Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermDebt" xml:lang="en-US">Long-term debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LongTermDebt" xml:lang="en-US">Carrying value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xml:lang="en-US">Investment, Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xml:lang="en-US">Investment, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="loc_us-gaap_AssetAcquisitionAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xml:lang="en-US">Asset Acquisition [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionAxis" xlink:to="lab_us-gaap_AssetAcquisitionAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaap_AssetAcquisitionDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xml:lang="en-US">Asset Acquisition [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionDomain" xlink:to="lab_us-gaap_AssetAcquisitionDomain" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SenmurMember" xlink:label="loc_sclx_SenmurMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SenmurMember" xml:lang="en-US">Senmur [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SenmurMember" xlink:to="lab_sclx_SenmurMember" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_InvesteeAxis" xlink:label="loc_sclx_InvesteeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_InvesteeAxis" xml:lang="en-US">Investee [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_InvesteeAxis" xlink:to="lab_sclx_InvesteeAxis" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_InvesteeDomain" xlink:label="loc_sclx_InvesteeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_InvesteeDomain" xml:lang="en-US">Investee [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_InvesteeDomain" xlink:to="lab_sclx_InvesteeDomain" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TwoThousandAndTwentyTwoPromissoryNoteMember" xlink:label="loc_sclx_TwoThousandAndTwentyTwoPromissoryNoteMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_TwoThousandAndTwentyTwoPromissoryNoteMember" xml:lang="en-US">Two Thousand And Twenty Two Promissory Note [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_TwoThousandAndTwentyTwoPromissoryNoteMember" xlink:to="lab_sclx_TwoThousandAndTwentyTwoPromissoryNoteMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_TwoThousandAndTwentyTwoPromissoryNoteMember" xml:lang="en-US">Two thousand and twenty two promissory note.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ItochuMember" xlink:label="loc_sclx_ItochuMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ItochuMember" xml:lang="en-US">Itochu [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ItochuMember" xlink:to="lab_sclx_ItochuMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ItochuMember" xml:lang="en-US">Itochu.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockMember" xml:lang="en-US">Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockMember" xml:lang="en-US">Preferred Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PeriodAxis" xlink:label="loc_sclx_PeriodAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PeriodAxis" xml:lang="en-US">Period [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PeriodAxis" xlink:to="lab_sclx_PeriodAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PeriodAxis" xml:lang="en-US">Period.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PeriodDomain" xlink:label="loc_sclx_PeriodDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PeriodDomain" xml:lang="en-US">Period [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PeriodDomain" xlink:to="lab_sclx_PeriodDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PeriodDomain" xml:lang="en-US">Period.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DueOnOrAfterFebruaryTwoThousandAndThirtyMember" xlink:label="loc_sclx_DueOnOrAfterFebruaryTwoThousandAndThirtyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DueOnOrAfterFebruaryTwoThousandAndThirtyMember" xml:lang="en-US">Due On Or After February Two Thousand And Thirty [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DueOnOrAfterFebruaryTwoThousandAndThirtyMember" xlink:to="lab_sclx_DueOnOrAfterFebruaryTwoThousandAndThirtyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_DueOnOrAfterFebruaryTwoThousandAndThirtyMember" xml:lang="en-US">Due on or after february two thousand and thirty.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationReasonForBusinessCombination" xlink:label="loc_us-gaap_BusinessCombinationReasonForBusinessCombination" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationReasonForBusinessCombination" xml:lang="en-US">Business Combination, Reason for Business Combination</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationReasonForBusinessCombination" xml:lang="en-US">Business combination, description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationReasonForBusinessCombination" xlink:to="lab_us-gaap_BusinessCombinationReasonForBusinessCombination" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AggregatePercentage" xlink:label="loc_sclx_AggregatePercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AggregatePercentage" xml:lang="en-US">Aggregate Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_AggregatePercentage" xml:lang="en-US">Aggregate percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AggregatePercentage" xlink:to="lab_sclx_AggregatePercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AggregatePercentage" xml:lang="en-US">Aggregate Percentage.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_WarrantsPercentage" xlink:label="loc_sclx_WarrantsPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_WarrantsPercentage" xml:lang="en-US">Warrants Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_WarrantsPercentage" xml:lang="en-US">Warrants percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_WarrantsPercentage" xlink:to="lab_sclx_WarrantsPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_WarrantsPercentage" xml:lang="en-US">Warrants Percentage.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockNoParValue" xlink:label="loc_us-gaap_PreferredStockNoParValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockNoParValue" xml:lang="en-US">Preferred Stock, No Par Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockNoParValue" xml:lang="en-US">Series A preferred stock, par value (in Dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockNoParValue" xlink:to="lab_us-gaap_PreferredStockNoParValue" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_BalanceInTheTrustAccount" xlink:label="loc_sclx_BalanceInTheTrustAccount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_BalanceInTheTrustAccount" xml:lang="en-US">Balance In The Trust Account</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_BalanceInTheTrustAccount" xml:lang="en-US">Balance in the trust account (in Dollars)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_BalanceInTheTrustAccount" xlink:to="lab_sclx_BalanceInTheTrustAccount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_BalanceInTheTrustAccount" xml:lang="en-US">Balance in the trust account.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDescription" xlink:label="loc_us-gaap_OtherCommitmentsDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherCommitmentsDescription" xml:lang="en-US">Other Commitments, Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherCommitmentsDescription" xml:lang="en-US">Underwriting agreement, description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsDescription" xlink:to="lab_us-gaap_OtherCommitmentsDescription" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredUnitsAuthorized" xlink:label="loc_us-gaap_PreferredUnitsAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredUnitsAuthorized" xml:lang="en-US">Preferred Units, Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredUnitsAuthorized" xml:lang="en-US">Stock authority to issue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredUnitsAuthorized" xlink:to="lab_us-gaap_PreferredUnitsAuthorized" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MergerConsiderationDescription" xlink:label="loc_sclx_MergerConsiderationDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_MergerConsiderationDescription" xml:lang="en-US">Merger Consideration Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_MergerConsiderationDescription" xml:lang="en-US">Merger consideration description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_MergerConsiderationDescription" xlink:to="lab_sclx_MergerConsiderationDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_MergerConsiderationDescription" xml:lang="en-US">Merger consideration description.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_CommonStockAggregateValue" xlink:label="loc_sclx_CommonStockAggregateValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_CommonStockAggregateValue" xml:lang="en-US">Common Stock Aggregate Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_CommonStockAggregateValue" xml:lang="en-US">Common stock aggregate value (in Dollars)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_CommonStockAggregateValue" xlink:to="lab_sclx_CommonStockAggregateValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_CommonStockAggregateValue" xml:lang="en-US">Common Stock with an aggregate value.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DeferredUnderwritingCommission" xlink:label="loc_sclx_DeferredUnderwritingCommission" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DeferredUnderwritingCommission" xml:lang="en-US">Deferred Underwriting Commission</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_DeferredUnderwritingCommission" xml:lang="en-US">Deferred underwriting commission percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DeferredUnderwritingCommission" xlink:to="lab_sclx_DeferredUnderwritingCommission" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_DeferredUnderwritingCommission" xml:lang="en-US">Deferred Underwriting Commission.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AgreementExpirationTerm" xlink:label="loc_sclx_AgreementExpirationTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AgreementExpirationTerm" xml:lang="en-US">Agreement Expiration Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_AgreementExpirationTerm" xml:lang="en-US">Agreement expiration term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AgreementExpirationTerm" xlink:to="lab_sclx_AgreementExpirationTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AgreementExpirationTerm" xml:lang="en-US">Agreement expiration term.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AgreementAutomaticRenewalPeriodOnExpirationOfInitialTerm" xlink:label="loc_sclx_AgreementAutomaticRenewalPeriodOnExpirationOfInitialTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AgreementAutomaticRenewalPeriodOnExpirationOfInitialTerm" xml:lang="en-US">Agreement Automatic Renewal Period On Expiration Of Initial Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_AgreementAutomaticRenewalPeriodOnExpirationOfInitialTerm" xml:lang="en-US">Agreement automatic renewal period on expiration of initial term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AgreementAutomaticRenewalPeriodOnExpirationOfInitialTerm" xlink:to="lab_sclx_AgreementAutomaticRenewalPeriodOnExpirationOfInitialTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AgreementAutomaticRenewalPeriodOnExpirationOfInitialTerm" xml:lang="en-US">Agreement automatic renewal period on expiration of initial term.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NoticeOfTerminationPeriodForCancellationOfAutomaticRenewal" xlink:label="loc_sclx_NoticeOfTerminationPeriodForCancellationOfAutomaticRenewal" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_NoticeOfTerminationPeriodForCancellationOfAutomaticRenewal" xml:lang="en-US">Notice of Termination Period for Cancellation of Automatic Renewal</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_NoticeOfTerminationPeriodForCancellationOfAutomaticRenewal" xml:lang="en-US">Notice of termination period for cancellation of automatic renewal</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_NoticeOfTerminationPeriodForCancellationOfAutomaticRenewal" xlink:to="lab_sclx_NoticeOfTerminationPeriodForCancellationOfAutomaticRenewal" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_NoticeOfTerminationPeriodForCancellationOfAutomaticRenewal" xml:lang="en-US">Notice of termination period for cancellation of automatic renewal.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DeferredUnderwritingCommissionPayable" xlink:label="loc_sclx_DeferredUnderwritingCommissionPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DeferredUnderwritingCommissionPayable" xml:lang="en-US">Deferred Underwriting Commission Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_DeferredUnderwritingCommissionPayable" xml:lang="en-US">Underwriting commission payable percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DeferredUnderwritingCommissionPayable" xlink:to="lab_sclx_DeferredUnderwritingCommissionPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_DeferredUnderwritingCommissionPayable" xml:lang="en-US">Deferred Underwriting Commission Payable.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfAggregateRoyalityPayments" xlink:label="loc_sclx_PercentageOfAggregateRoyalityPayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PercentageOfAggregateRoyalityPayments" xml:lang="en-US">Percentage of Aggregate Royality Payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PercentageOfAggregateRoyalityPayments" xml:lang="en-US">Percentage of aggregate royality payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PercentageOfAggregateRoyalityPayments" xlink:to="lab_sclx_PercentageOfAggregateRoyalityPayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PercentageOfAggregateRoyalityPayments" xml:lang="en-US">Percentage of aggregate royality payments.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AgreementExpirationDate" xlink:label="loc_sclx_AgreementExpirationDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AgreementExpirationDate" xml:lang="en-US">Agreement Expiration Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_AgreementExpirationDate" xml:lang="en-US">Agreement expiration date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AgreementExpirationDate" xlink:to="lab_sclx_AgreementExpirationDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AgreementExpirationDate" xml:lang="en-US">Agreement expiration date.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TerminationOfAgreementNoticePeriodForARequestToCureMaterialBreachOfTheAgreement" xlink:label="loc_sclx_TerminationOfAgreementNoticePeriodForARequestToCureMaterialBreachOfTheAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_TerminationOfAgreementNoticePeriodForARequestToCureMaterialBreachOfTheAgreement" xml:lang="en-US">Termination Of Agreement Notice Period For a Request To Cure Material Breach Of The Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_TerminationOfAgreementNoticePeriodForARequestToCureMaterialBreachOfTheAgreement" xml:lang="en-US">Termination of aggrement notice period for a request to cure material breach of the agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_TerminationOfAgreementNoticePeriodForARequestToCureMaterialBreachOfTheAgreement" xlink:to="lab_sclx_TerminationOfAgreementNoticePeriodForARequestToCureMaterialBreachOfTheAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_TerminationOfAgreementNoticePeriodForARequestToCureMaterialBreachOfTheAgreement" xml:lang="en-US">Termination of agreement notice period for a request to cure material breach of the agreement.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NoticePeriodForTerminationOfWorkOrder" xlink:label="loc_sclx_NoticePeriodForTerminationOfWorkOrder" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_NoticePeriodForTerminationOfWorkOrder" xml:lang="en-US">Notice Period for Termination of Work Order</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_NoticePeriodForTerminationOfWorkOrder" xml:lang="en-US">Notice period for termination of work order</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_NoticePeriodForTerminationOfWorkOrder" xlink:to="lab_sclx_NoticePeriodForTerminationOfWorkOrder" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_NoticePeriodForTerminationOfWorkOrder" xml:lang="en-US">Notice period for termination of work order.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ThresholdMinimumPercentageOfSales" xlink:label="loc_sclx_ThresholdMinimumPercentageOfSales" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ThresholdMinimumPercentageOfSales" xml:lang="en-US">Threshold Minimum Percentage Of Sales</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ThresholdMinimumPercentageOfSales" xml:lang="en-US">Threshold minimum percentage of sales</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ThresholdMinimumPercentageOfSales" xlink:to="lab_sclx_ThresholdMinimumPercentageOfSales" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ThresholdMinimumPercentageOfSales" xml:lang="en-US">Threshold minimum percentage of sales.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfAnnualAdjustmentToFees" xlink:label="loc_sclx_PercentageOfAnnualAdjustmentToFees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PercentageOfAnnualAdjustmentToFees" xml:lang="en-US">Percentage Of Annual Adjustment To Fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PercentageOfAnnualAdjustmentToFees" xml:lang="en-US">Percentage of annual adjustment to fees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PercentageOfAnnualAdjustmentToFees" xlink:to="lab_sclx_PercentageOfAnnualAdjustmentToFees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PercentageOfAnnualAdjustmentToFees" xml:lang="en-US">Percentage of annual adjustment to fees.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfDistributionFeeReceivedOverThePeriod" xlink:label="loc_sclx_PercentageOfDistributionFeeReceivedOverThePeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PercentageOfDistributionFeeReceivedOverThePeriod" xml:lang="en-US">Percentage Of Distribution Fee Received Over The Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PercentageOfDistributionFeeReceivedOverThePeriod" xml:lang="en-US">Percentage of distribution fee received over the period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PercentageOfDistributionFeeReceivedOverThePeriod" xlink:to="lab_sclx_PercentageOfDistributionFeeReceivedOverThePeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PercentageOfDistributionFeeReceivedOverThePeriod" xml:lang="en-US">Percentage of distribution fee received over the period.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_WorkOrderImplementationFee" xlink:label="loc_sclx_WorkOrderImplementationFee" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_WorkOrderImplementationFee" xml:lang="en-US">Work Order Implementation Fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_WorkOrderImplementationFee" xml:lang="en-US">Work order implementation fee</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_WorkOrderImplementationFee" xlink:to="lab_sclx_WorkOrderImplementationFee" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_WorkOrderImplementationFee" xml:lang="en-US">Work order implementation fee.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SalesOperationsServicesMonthlyFee" xlink:label="loc_sclx_SalesOperationsServicesMonthlyFee" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SalesOperationsServicesMonthlyFee" xml:lang="en-US">Sales Operations Services Monthly Fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_SalesOperationsServicesMonthlyFee" xml:lang="en-US">Sales operations services monthly fee</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SalesOperationsServicesMonthlyFee" xlink:to="lab_sclx_SalesOperationsServicesMonthlyFee" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_SalesOperationsServicesMonthlyFee" xml:lang="en-US">Sales operations services monthly fee.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SellingGeneralAndAdministrativeExpenses" xlink:label="loc_sclx_SellingGeneralAndAdministrativeExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SellingGeneralAndAdministrativeExpenses" xml:lang="en-US">Selling, General And Administrative Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_SellingGeneralAndAdministrativeExpenses" xml:lang="en-US">Selling, general and administrative</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SellingGeneralAndAdministrativeExpenses" xlink:to="lab_sclx_SellingGeneralAndAdministrativeExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_SellingGeneralAndAdministrativeExpenses" xml:lang="en-US">Selling, general and administrative expense.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xml:lang="en-US">Leases remaining lease terms</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xml:lang="en-US">Lessee, Operating Lease, renewal term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaap_OperatingLeaseExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseExpense" xml:lang="en-US">Operating Lease, Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseExpense" xml:lang="en-US">Operating lease, expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LessorOperatingLeaseTermOfContract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LessorOperatingLeaseTermOfContract" xml:lang="en-US">Lessor, Operating Lease, Term of Contract</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LessorOperatingLeaseTermOfContract" xml:lang="en-US">Lease term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LessorOperatingLeaseTermOfContract" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScilexCommonStockMember" xlink:label="loc_sclx_ScilexCommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ScilexCommonStockMember" xml:lang="en-US">Scilex Common Stock Member</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ScilexCommonStockMember" xml:lang="en-US">Scilex Common Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ScilexCommonStockMember" xlink:to="lab_sclx_ScilexCommonStockMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ProductDevelopmentAgreementMember" xlink:label="loc_sclx_ProductDevelopmentAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ProductDevelopmentAgreementMember" xml:lang="en-US">Product Development Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ProductDevelopmentAgreementMember" xlink:to="lab_sclx_ProductDevelopmentAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ProductDevelopmentAgreementMember" xml:lang="en-US">Product development agreement.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ExclusiveDistributionAgreementMember" xlink:label="loc_sclx_ExclusiveDistributionAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ExclusiveDistributionAgreementMember" xml:lang="en-US">Exclusive Distribution Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ExclusiveDistributionAgreementMember" xlink:to="lab_sclx_ExclusiveDistributionAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ExclusiveDistributionAgreementMember" xml:lang="en-US">Exclusive distribution agreement.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ProjectAgreementMember" xlink:label="loc_sclx_ProjectAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ProjectAgreementMember" xml:lang="en-US">Project Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ProjectAgreementMember" xml:lang="en-US">Project Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ProjectAgreementMember" xlink:to="lab_sclx_ProjectAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ProjectAgreementMember" xml:lang="en-US">Project agreement.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xml:lang="en-US">Series A Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xml:lang="en-US">Series A Preferred Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember" xlink:to="lab_us-gaap_SeriesAPreferredStockMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeAxis" xml:lang="en-US">Statistical Measurement [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeMember" xml:lang="en-US">Statistical Measurement [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PaloAltoAadministrativeFacilityMember" xlink:label="loc_sclx_PaloAltoAadministrativeFacilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PaloAltoAadministrativeFacilityMember" xml:lang="en-US">Palo Alto Aadministrative Facility [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PaloAltoAadministrativeFacilityMember" xlink:to="lab_sclx_PaloAltoAadministrativeFacilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PaloAltoAadministrativeFacilityMember" xml:lang="en-US">Palo Alto Aadministrative Facility</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostAbstract" xlink:label="loc_us-gaap_LeaseCostAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseCostAbstract" xml:lang="en-US">Lease, Cost [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostAbstract" xlink:to="lab_us-gaap_LeaseCostAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseCost" xml:lang="en-US">Operating Lease, Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseCost" xml:lang="en-US">Operating lease cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xml:lang="en-US">2025</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xml:lang="en-US">2026</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xml:lang="en-US">2026</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xml:lang="en-US">Total lease payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xml:lang="en-US">2022 (Remaining three months)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiability" xml:lang="en-US">Operating Lease, Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiability" xml:lang="en-US">Total lease liabilities as of December&#160;31, 2021</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xml:lang="en-US">Less imputed interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xml:lang="en-US">2024</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xml:lang="en-US">2023</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:label="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xml:lang="en-US">Cash Flow, Operating Activities, Lessee [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:to="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_OperatingCashFlowsFromOperatingLeases" xlink:label="loc_sclx_OperatingCashFlowsFromOperatingLeases" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_OperatingCashFlowsFromOperatingLeases" xml:lang="en-US">Operating Cash Flows From Operating Leases</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_OperatingCashFlowsFromOperatingLeases" xml:lang="en-US">Operating cash flows from operating leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_OperatingCashFlowsFromOperatingLeases" xlink:to="lab_sclx_OperatingCashFlowsFromOperatingLeases" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_OperatingCashFlowsFromOperatingLeases" xml:lang="en-US">Operating cash flows from operating leases.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xml:lang="en-US">Weighted average remaining lease term in&#160;years&#160;&#8212;&#160;operating leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xml:lang="en-US">Weighted average discount rate&#160;&#8212;&#160;operating leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xml:lang="en-US">ROU assets obtained in exchange for new operating lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_WarrantsDetailsTable" xlink:label="loc_sclx_WarrantsDetailsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_WarrantsDetailsTable" xml:lang="en-US">Warrants (Details) [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_WarrantsDetailsTable" xlink:to="lab_sclx_WarrantsDetailsTable" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_WarrantsDetailsLineItems" xlink:label="loc_sclx_WarrantsDetailsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_WarrantsDetailsLineItems" xml:lang="en-US">Warrants (Details) [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_WarrantsDetailsLineItems" xlink:to="lab_sclx_WarrantsDetailsLineItems" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_WarrantsOutstandingShares" xlink:label="loc_sclx_WarrantsOutstandingShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_WarrantsOutstandingShares" xml:lang="en-US">Warrants Outstanding Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_WarrantsOutstandingShares" xml:lang="en-US">Warrants outstanding shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_WarrantsOutstandingShares" xlink:to="lab_sclx_WarrantsOutstandingShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_WarrantsOutstandingShares" xml:lang="en-US">Warrants outstanding shares.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PublicWarrantsRedemptionDescription" xlink:label="loc_sclx_PublicWarrantsRedemptionDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PublicWarrantsRedemptionDescription" xml:lang="en-US">Public Warrants Redemption Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PublicWarrantsRedemptionDescription" xml:lang="en-US">Public warrants redemption, description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PublicWarrantsRedemptionDescription" xlink:to="lab_sclx_PublicWarrantsRedemptionDescription" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_CapitalRaisingDescription" xlink:label="loc_sclx_CapitalRaisingDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_CapitalRaisingDescription" xml:lang="en-US">Capital Raising Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_CapitalRaisingDescription" xml:lang="en-US">Capital raising, description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_CapitalRaisingDescription" xlink:to="lab_sclx_CapitalRaisingDescription" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantMember" xml:lang="en-US">Warrant [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WarrantMember" xml:lang="en-US">Public Warrant [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xml:lang="en-US">Measurement Input Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xml:lang="en-US">Measurement Input Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MeasurementInputRiskadjustedNetSalesForecastMember" xlink:label="loc_sclx_MeasurementInputRiskadjustedNetSalesForecastMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_MeasurementInputRiskadjustedNetSalesForecastMember" xml:lang="en-US">Measurement Input, RiskAdjusted Net Sales Forecast [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_MeasurementInputRiskadjustedNetSalesForecastMember" xlink:to="lab_sclx_MeasurementInputRiskadjustedNetSalesForecastMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_MeasurementInputRiskadjustedNetSalesForecastMember" xml:lang="en-US">Measurement input, risk-adjusted net sales forecast .</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MeasurementInputEffectiveDebtYieldMember" xlink:label="loc_sclx_MeasurementInputEffectiveDebtYieldMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_MeasurementInputEffectiveDebtYieldMember" xml:lang="en-US">Measurement Input, Effective Debt Yield [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_MeasurementInputEffectiveDebtYieldMember" xlink:to="lab_sclx_MeasurementInputEffectiveDebtYieldMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_MeasurementInputEffectiveDebtYieldMember" xml:lang="en-US">Measurement input, effective debt yield .</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeMarch312021Member" xlink:label="loc_sclx_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeMarch312021Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeMarch312021Member" xml:lang="en-US">Measurement Input, Estimated Probability Of Not Obtaining Marketing Approval Before March 31, 2021 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeMarch312021Member" xlink:to="lab_sclx_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeMarch312021Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeMarch312021Member" xml:lang="en-US">Measurement input, estimated probability of not obtaining marketing approval before march 31, 2021 .</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeJuly12023Member" xlink:label="loc_sclx_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeJuly12023Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeJuly12023Member" xml:lang="en-US">Measurement Input, Estimated Probability Of Not Obtaining Marketing Approval Before July 1, 2023 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeJuly12023Member" xlink:to="lab_sclx_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeJuly12023Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeJuly12023Member" xml:lang="en-US">Measurement input, estimated probability of not obtaining marketing approval before july 1, 2023 .</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsHeldInTrustCurrent" xlink:label="loc_us-gaap_AssetsHeldInTrustCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsHeldInTrustCurrent" xml:lang="en-US">Assets Held-in-trust, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsHeldInTrustCurrent" xml:lang="en-US">Assets held in the trust account</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsHeldInTrustCurrent" xlink:to="lab_us-gaap_AssetsHeldInTrustCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsHighestAndBestUseDescription" xlink:label="loc_us-gaap_FairValueMeasurementsHighestAndBestUseDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementsHighestAndBestUseDescription" xml:lang="en-US">Fair Value Measurements, Highest and Best Use, Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementsHighestAndBestUseDescription" xml:lang="en-US">Initial measurement, description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsHighestAndBestUseDescription" xlink:to="lab_us-gaap_FairValueMeasurementsHighestAndBestUseDescription" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLossOnDerivative" xlink:label="loc_us-gaap_DerivativeLossOnDerivative" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeLossOnDerivative" xml:lang="en-US">Derivative, Loss on Derivative</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativeLossOnDerivative" xml:lang="en-US">Derivative, Loss on derivative</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLossOnDerivative" xlink:to="lab_us-gaap_DerivativeLossOnDerivative" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainOnDerivative" xlink:label="loc_us-gaap_DerivativeGainOnDerivative" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeGainOnDerivative" xml:lang="en-US">Derivative, Gain on Derivative</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativeGainOnDerivative" xml:lang="en-US">Derivative, Gain on Derivative</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeGainOnDerivative" xlink:to="lab_us-gaap_DerivativeGainOnDerivative" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="loc_us-gaap_DerivativeLiabilityMeasurementInput" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeLiabilityMeasurementInput" xml:lang="en-US">Derivative Liability, Measurement Input</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativeLiabilityMeasurementInput" xml:lang="en-US">Derivative liability, Measurement input</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityMeasurementInput" xlink:to="lab_us-gaap_DerivativeLiabilityMeasurementInput" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xml:lang="en-US">Fair value, Measurement with unobservable inputs reconciliation, Recurring basis, Liability, Period increase decrease</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xml:lang="en-US">Change in fair value measurement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xml:lang="en-US">Liability Class [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xml:lang="en-US">Fair Value by Liability Class [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xml:lang="en-US">Derivative Financial Instruments, Liabilities [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:to="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScheduleOfFairValueHierarchyOfTheValuationInputsAbstract" xlink:label="loc_sclx_ScheduleOfFairValueHierarchyOfTheValuationInputsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ScheduleOfFairValueHierarchyOfTheValuationInputsAbstract" xml:lang="en-US">Schedule Of Fair Value Hierarchy Of The Valuation Inputs Abstract</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ScheduleOfFairValueHierarchyOfTheValuationInputsAbstract" xlink:to="lab_sclx_ScheduleOfFairValueHierarchyOfTheValuationInputsAbstract" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_FairValueMeasurementsDetailsScheduleoffairvaluehierarchyofthevaluationinputsTable" xlink:label="loc_sclx_FairValueMeasurementsDetailsScheduleoffairvaluehierarchyofthevaluationinputsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_FairValueMeasurementsDetailsScheduleoffairvaluehierarchyofthevaluationinputsTable" xml:lang="en-US">Fair Value Measurements (Details) - Schedule of fair value hierarchy of the valuation inputs [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_FairValueMeasurementsDetailsScheduleoffairvaluehierarchyofthevaluationinputsTable" xlink:to="lab_sclx_FairValueMeasurementsDetailsScheduleoffairvaluehierarchyofthevaluationinputsTable" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_FairValueMeasurementsDetailsScheduleoffairvaluehierarchyofthevaluationinputsLineItems" xlink:label="loc_sclx_FairValueMeasurementsDetailsScheduleoffairvaluehierarchyofthevaluationinputsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_FairValueMeasurementsDetailsScheduleoffairvaluehierarchyofthevaluationinputsLineItems" xml:lang="en-US">Fair Value Measurements (Details) - Schedule of fair value hierarchy of the valuation inputs [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_FairValueMeasurementsDetailsScheduleoffairvaluehierarchyofthevaluationinputsLineItems" xlink:to="lab_sclx_FairValueMeasurementsDetailsScheduleoffairvaluehierarchyofthevaluationinputsLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract" xlink:label="loc_us-gaap_LiabilitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAbstract" xml:lang="en-US">Liabilities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesAbstract" xml:lang="en-US">Liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="lab_us-gaap_LiabilitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="loc_us-gaap_LiabilitiesFairValueAdjustment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesFairValueAdjustment" xml:lang="en-US">Liabilities, Fair Value Adjustment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesFairValueAdjustment" xml:lang="en-US">Warrant Liability &#8211; Private Placement Warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueAdjustment" xlink:to="lab_us-gaap_LiabilitiesFairValueAdjustment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeSecuritiesUSTreasury" xlink:label="loc_us-gaap_InterestIncomeSecuritiesUSTreasury" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestIncomeSecuritiesUSTreasury" xml:lang="en-US">Interest Income, Securities, US Treasury</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestIncomeSecuritiesUSTreasury" xml:lang="en-US">Investments held in Trust Account &#8211; U.S. Treasury Securities Money Market Fund</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeSecuritiesUSTreasury" xlink:to="lab_us-gaap_InterestIncomeSecuritiesUSTreasury" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Level 1 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xml:lang="en-US">Level 3 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScheduleOfChangesInTheFairValueOfWarrantLiabilitiesAndConversionOptionLiabilityAbstract" xlink:label="loc_sclx_ScheduleOfChangesInTheFairValueOfWarrantLiabilitiesAndConversionOptionLiabilityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ScheduleOfChangesInTheFairValueOfWarrantLiabilitiesAndConversionOptionLiabilityAbstract" xml:lang="en-US">Schedule Of Changes In The Fair Value Of Warrant Liabilities And Conversion Option Liability Abstract</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ScheduleOfChangesInTheFairValueOfWarrantLiabilitiesAndConversionOptionLiabilityAbstract" xlink:to="lab_sclx_ScheduleOfChangesInTheFairValueOfWarrantLiabilitiesAndConversionOptionLiabilityAbstract" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityTable" xlink:label="loc_sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityTable" xml:lang="en-US">Fair Value Measurements (Details) - Schedule of changes in the fair value of warrant liabilities and conversion option liability: [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityTable" xlink:to="lab_sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityTable" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityLineItems" xlink:label="loc_sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityLineItems" xml:lang="en-US">Fair Value Measurements (Details) - Schedule of changes in the fair value of warrant liabilities and conversion option liability: [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityLineItems" xlink:to="lab_sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityLineItems" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_InitialMeasurementOne" xlink:label="loc_sclx_InitialMeasurementOne" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_InitialMeasurementOne" xml:lang="en-US">Initial Measurement One</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_InitialMeasurementOne" xml:lang="en-US">Initial measurement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_InitialMeasurementOne" xlink:to="lab_sclx_InitialMeasurementOne" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ChangeInValuationInputsOrOtherAssumptions" xlink:label="loc_sclx_ChangeInValuationInputsOrOtherAssumptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ChangeInValuationInputsOrOtherAssumptions" xml:lang="en-US">Change In Valuation Inputs Or Other Assumptions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ChangeInValuationInputsOrOtherAssumptions" xml:lang="en-US">Change in valuation inputs or other assumptions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ChangeInValuationInputsOrOtherAssumptions" xlink:to="lab_sclx_ChangeInValuationInputsOrOtherAssumptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ChangeInValuationInputsOrOtherAssumptions" xml:lang="en-US">Change in valuation inputs or other assumptions.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ConversionOptionLiabilityMember" xlink:label="loc_sclx_ConversionOptionLiabilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ConversionOptionLiabilityMember" xml:lang="en-US">Conversion Option Liability Member</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ConversionOptionLiabilityMember" xml:lang="en-US">Conversion Option Liability [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ConversionOptionLiabilityMember" xlink:to="lab_sclx_ConversionOptionLiabilityMember" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScheduleOfValuedUsingTheCompoundOptionPricingModelAbstract" xlink:label="loc_sclx_ScheduleOfValuedUsingTheCompoundOptionPricingModelAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ScheduleOfValuedUsingTheCompoundOptionPricingModelAbstract" xml:lang="en-US">Schedule Of Valued Using The Compound Option Pricing Model Abstract</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ScheduleOfValuedUsingTheCompoundOptionPricingModelAbstract" xlink:to="lab_sclx_ScheduleOfValuedUsingTheCompoundOptionPricingModelAbstract" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_UnderlyingWarrantValue" xlink:label="loc_sclx_UnderlyingWarrantValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_UnderlyingWarrantValue" xml:lang="en-US">Underlying Warrant Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_UnderlyingWarrantValue" xml:lang="en-US">Underlying warrant value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_UnderlyingWarrantValue" xlink:to="lab_sclx_UnderlyingWarrantValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_UnderlyingWarrantValue" xml:lang="en-US">Underlying warrant value</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xml:lang="en-US">Exercise price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xml:lang="en-US">Exercise price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_HoldingPeriod" xlink:label="loc_sclx_HoldingPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_HoldingPeriod" xml:lang="en-US">Holding Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_HoldingPeriod" xml:lang="en-US">Holding period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_HoldingPeriod" xlink:to="lab_sclx_HoldingPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_HoldingPeriod" xml:lang="en-US">Holding period return is the total return received from holding an asset or portfolio of assets over a period of time, generally expressed as a percentage.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Risk-free rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Risk-free interest rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Volatility</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Expected stock-price volatility</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Dividend yield</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Expected dividend yield</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xml:lang="en-US">Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xml:lang="en-US">Cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xml:lang="en-US">Assets, Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xml:lang="en-US">Total assets measured at fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xml:lang="en-US">Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xml:lang="en-US">Liabilities, Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xml:lang="en-US">Total liabilities measured at fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xml:lang="en-US">Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xml:lang="en-US">Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xml:lang="en-US">Additions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xml:lang="en-US">Re-measurement&#160;of fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurementsAbstract" xlink:label="loc_sclx_ScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurementsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurementsAbstract" xml:lang="en-US">Schedule Of Quantitative Information Regarding Level3 Fair Value Measurements Abstract</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurementsAbstract" xlink:to="lab_sclx_ScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurementsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Term (in years)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Term of options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xml:lang="en-US">Volatility</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1" xlink:label="loc_sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate1</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1" xml:lang="en-US">Risk-free rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1" xlink:to="lab_sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharePrice" xml:lang="en-US">Share Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharePrice" xml:lang="en-US">Stock price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_FairValueMeasurementStrikePrice" xlink:label="loc_sclx_FairValueMeasurementStrikePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_FairValueMeasurementStrikePrice" xml:lang="en-US">Fair Value Measurement Strike Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_FairValueMeasurementStrikePrice" xml:lang="en-US">Strike price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_FairValueMeasurementStrikePrice" xlink:to="lab_sclx_FairValueMeasurementStrikePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_FairValueMeasurementStrikePrice" xml:lang="en-US">Strike price.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1" xlink:label="loc_sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate1</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1" xml:lang="en-US">Dividend yield</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1" xlink:to="lab_sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_FairValueOfWarrantsinDollars" xlink:label="loc_sclx_FairValueOfWarrantsinDollars" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_FairValueOfWarrantsinDollars" xml:lang="en-US">Fair Value Of Warrantsin Dollars</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_FairValueOfWarrantsinDollars" xml:lang="en-US">Fair value of warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_FairValueOfWarrantsinDollars" xlink:to="lab_sclx_FairValueOfWarrantsinDollars" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityAbstract" xlink:label="loc_sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityAbstract" xml:lang="en-US">Schedule Of Change In The Fair Value Of Conversion Option Liability [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityAbstract" xlink:to="lab_sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityAbstract" xml:lang="en-US">Schedule of change in the fair value of conversion option liability.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityTable" xlink:label="loc_sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityTable" xml:lang="en-US">Schedule Of Change In The Fair Value Of Conversion Option Liability [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityTable" xlink:to="lab_sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityTable" xml:lang="en-US">Schedule of change in the fair value of conversion option liability.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityLineItems" xlink:label="loc_sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityLineItems" xml:lang="en-US">Schedule Of Change In The Fair Value Of Conversion Option Liability [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityLineItems" xlink:to="lab_sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityLineItems" xml:lang="en-US">Schedule of change in the fair value of conversion option liability.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetAssetLiability" xlink:label="loc_us-gaap_FairValueNetAssetLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueNetAssetLiability" xml:lang="en-US">Fair Value, Net Asset (Liability)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_FairValueNetAssetLiability" xml:lang="en-US">Fair value, beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_FairValueNetAssetLiability" xml:lang="en-US">Fair value, ending balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueNetAssetLiability" xlink:to="lab_us-gaap_FairValueNetAssetLiability" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xml:lang="en-US">Initial measurement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue" xlink:label="loc_us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue" xml:lang="en-US">Servicing Liability at Fair Value, Other Changes in Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue" xml:lang="en-US">Change in fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue" xlink:to="lab_us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComputerEquipmentMember" xml:lang="en-US">Computer Equipment [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xml:lang="en-US">Furniture and Fixtures [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xml:lang="en-US">Leasehold Improvements [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConstructionInProgressMember" xml:lang="en-US">Construction in Progress [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseGross" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseGross" xml:lang="en-US">Property, Plant, and Equipment, Lessor Asset under Operating Lease, before Accumulated Depreciation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseGross" xml:lang="en-US">Depreciation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseGross" xlink:to="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xml:lang="en-US">Gross carrying amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xml:lang="en-US">Accumulated amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xml:lang="en-US">Finite-Lived Intangible Assets, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xml:lang="en-US">Intangibles, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AssembledWorkforceMember" xlink:label="loc_sclx_AssembledWorkforceMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AssembledWorkforceMember" xml:lang="en-US">Assembled Workforce [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_AssembledWorkforceMember" xml:lang="en-US">Assembled workforce</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AssembledWorkforceMember" xlink:to="lab_sclx_AssembledWorkforceMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember" xlink:label="loc_us-gaap_LicensingAgreementsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LicensingAgreementsMember" xml:lang="en-US">Licensing Agreements [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LicensingAgreementsMember" xml:lang="en-US">Acquired licenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember" xlink:to="lab_us-gaap_LicensingAgreementsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaap_PatentsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PatentsMember" xml:lang="en-US">Patents [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PatentsMember" xml:lang="en-US">Patent rights</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PatentsMember" xlink:to="lab_us-gaap_PatentsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xml:lang="en-US">Technology-Based Intangible Assets [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xml:lang="en-US">Acquired technology</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:to="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xml:lang="en-US">2025</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xml:lang="en-US">2026</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xml:lang="en-US">2026</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, after Year Five</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xml:lang="en-US">Thereafter</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" xlink:label="loc_sclx_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" xml:lang="en-US">Finite Lived Intangible Assets Amortization Expense After Year Four</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" xml:lang="en-US">Thereafter</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" xlink:to="lab_sclx_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" xml:lang="en-US">Finite lived intangible assets amortization expense after year four.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xml:lang="en-US">2022 (Remaining three months)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xml:lang="en-US">2023</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xml:lang="en-US">2024</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xml:lang="en-US">Indefinite-Lived Intangible Assets [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xml:lang="en-US">Goodwill, Impairment Loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xml:lang="en-US">Goodwill, Impairment loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xml:lang="en-US">Finite lived intangible asset, useful life</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xml:lang="en-US">Finite lived intangible asset, Useful life</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xml:lang="en-US">Finite-Lived Intangible Assets Acquired</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xml:lang="en-US">Finite lived intangible assets acquired</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:to="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xml:lang="en-US">Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xml:lang="en-US">Acquired finite lived intangible assets, weighted average useful life</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xml:lang="en-US">Finite-Lived Intangible Assets, Remaining Amortization Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xml:lang="en-US">Finite lived intangible assets, remaining amortization period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xml:lang="en-US">Impairment of Intangible assets excluding goodwill</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_WeightedAverageMember" xlink:label="loc_srt_WeightedAverageMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_WeightedAverageMember" xml:lang="en-US">Weighted Average [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_WeightedAverageMember" xlink:to="lab_srt_WeightedAverageMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShortTermDebtTable" xml:lang="en-US">Schedule of Short-Term Debt [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable" xlink:to="lab_us-gaap_ScheduleOfShortTermDebtTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaap_ShortTermDebtLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermDebtLineItems" xml:lang="en-US">Short-Term Debt [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtLineItems" xlink:to="lab_us-gaap_ShortTermDebtLineItems" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfQuarterlyPaymentsOfThePrincipalNotesEqualToAFixedPercentage" xlink:label="loc_sclx_PercentageOfQuarterlyPaymentsOfThePrincipalNotesEqualToAFixedPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PercentageOfQuarterlyPaymentsOfThePrincipalNotesEqualToAFixedPercentage" xml:lang="en-US">Percentage Of Quarterly Payments Of The Principal Notes Equal To A Fixed Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PercentageOfQuarterlyPaymentsOfThePrincipalNotesEqualToAFixedPercentage" xml:lang="en-US">Percentage of quarterly payments of the principal Notes equal to a fixed percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PercentageOfQuarterlyPaymentsOfThePrincipalNotesEqualToAFixedPercentage" xlink:to="lab_sclx_PercentageOfQuarterlyPaymentsOfThePrincipalNotesEqualToAFixedPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PercentageOfQuarterlyPaymentsOfThePrincipalNotesEqualToAFixedPercentage" xml:lang="en-US">Percentage of quarterly payments of the principal notes equal to a fixed percentage.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DebtInstrumentredemptionPeriod" xlink:label="loc_sclx_DebtInstrumentredemptionPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DebtInstrumentredemptionPeriod" xml:lang="en-US">Debt Instrument,Redemption period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_DebtInstrumentredemptionPeriod" xml:lang="en-US">Debt instrument,redemption period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DebtInstrumentredemptionPeriod" xlink:to="lab_sclx_DebtInstrumentredemptionPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_DebtInstrumentredemptionPeriod" xml:lang="en-US">Debt instrument,redemption period.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfNetSalesPayable" xlink:label="loc_sclx_PercentageOfNetSalesPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PercentageOfNetSalesPayable" xml:lang="en-US">Percentage Of Net Sales Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PercentageOfNetSalesPayable" xml:lang="en-US">Percentage of net sales payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PercentageOfNetSalesPayable" xlink:to="lab_sclx_PercentageOfNetSalesPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PercentageOfNetSalesPayable" xml:lang="en-US">Percentage of net sales payable.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueNotFromContractWithCustomer" xlink:label="loc_us-gaap_RevenueNotFromContractWithCustomer" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueNotFromContractWithCustomer" xml:lang="en-US">Revenue Not from Contract with Customer</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenueNotFromContractWithCustomer" xml:lang="en-US">Revenue not from contract with customer</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueNotFromContractWithCustomer" xlink:to="lab_us-gaap_RevenueNotFromContractWithCustomer" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xml:lang="en-US">Proceeds from Issuance of Long-Term Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xml:lang="en-US">Proceeds from issuance of long-term debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PaymentToDepositIntoASeggregateReserveFund" xlink:label="loc_sclx_PaymentToDepositIntoASeggregateReserveFund" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PaymentToDepositIntoASeggregateReserveFund" xml:lang="en-US">Payment To Deposit Into A Seggregate Reserve Fund</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PaymentToDepositIntoASeggregateReserveFund" xml:lang="en-US">Payment to deposit into a seggregate reserve fund</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PaymentToDepositIntoASeggregateReserveFund" xlink:to="lab_sclx_PaymentToDepositIntoASeggregateReserveFund" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PaymentToDepositIntoASeggregateReserveFund" xml:lang="en-US">Payment to deposit into a seggregate reserve fund.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PaymentToDepositIntoASegregatedCollateralAccount" xlink:label="loc_sclx_PaymentToDepositIntoASegregatedCollateralAccount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PaymentToDepositIntoASegregatedCollateralAccount" xml:lang="en-US">Payment To Deposit Into A Segregated Collateral Account</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PaymentToDepositIntoASegregatedCollateralAccount" xml:lang="en-US">Payment to deposit into a segregated collateral account</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PaymentToDepositIntoASegregatedCollateralAccount" xlink:to="lab_sclx_PaymentToDepositIntoASegregatedCollateralAccount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PaymentToDepositIntoASegregatedCollateralAccount" xml:lang="en-US">Payment to deposit into a segregated collateral account.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfConcentrationOnASimilarProduct" xlink:label="loc_sclx_PercentageOfConcentrationOnASimilarProduct" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PercentageOfConcentrationOnASimilarProduct" xml:lang="en-US">Percentage of concentration on a similar product</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PercentageOfConcentrationOnASimilarProduct" xml:lang="en-US">Percentage of concentration on a similar product</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PercentageOfConcentrationOnASimilarProduct" xlink:to="lab_sclx_PercentageOfConcentrationOnASimilarProduct" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PercentageOfConcentrationOnASimilarProduct" xml:lang="en-US">Percentage of concentration on a similar product.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPayment" xml:lang="en-US">Debt Instrument, Periodic Payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentPeriodicPayment" xml:lang="en-US">Debt instrument, periodic payment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentPeriodicPayment" xlink:to="lab_us-gaap_DebtInstrumentPeriodicPayment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate" xml:lang="en-US">Debt Instrument, Maturity Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate" xml:lang="en-US">Debt instrument, maturity date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentMaturityDate" xlink:to="lab_us-gaap_DebtInstrumentMaturityDate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xml:lang="en-US">Debt instrument, redemption price, percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MinimumCashRequirementsToRepurchaseOfNotes" xlink:label="loc_sclx_MinimumCashRequirementsToRepurchaseOfNotes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_MinimumCashRequirementsToRepurchaseOfNotes" xml:lang="en-US">Minimum Cash Requirements To Repurchase Of Notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_MinimumCashRequirementsToRepurchaseOfNotes" xml:lang="en-US">Minimum cash requirements to repurchase of Notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_MinimumCashRequirementsToRepurchaseOfNotes" xlink:to="lab_sclx_MinimumCashRequirementsToRepurchaseOfNotes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_MinimumCashRequirementsToRepurchaseOfNotes" xml:lang="en-US">Minimum cash requirements to repurchase of notes.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xml:lang="en-US">Proceeds from Lines of Credit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xml:lang="en-US">Proceeds from lines of credit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromLinesOfCredit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RepaymentsOfLinesOfCredit" xml:lang="en-US">Repayments of Lines of Credit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RepaymentsOfLinesOfCredit" xml:lang="en-US">Repayments of lines of credit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLinesOfCredit" xlink:to="lab_us-gaap_RepaymentsOfLinesOfCredit" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfThePrincipalAmountFromHoldersOnProRataBasis" xlink:label="loc_sclx_PercentageOfThePrincipalAmountFromHoldersOnProRataBasis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PercentageOfThePrincipalAmountFromHoldersOnProRataBasis" xml:lang="en-US">Percentage Of The Principal Amount From Holders On Pro Rata Basis</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PercentageOfThePrincipalAmountFromHoldersOnProRataBasis" xml:lang="en-US">Percentage of the principal amount from Holders on pro rata basis</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PercentageOfThePrincipalAmountFromHoldersOnProRataBasis" xlink:to="lab_sclx_PercentageOfThePrincipalAmountFromHoldersOnProRataBasis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PercentageOfThePrincipalAmountFromHoldersOnProRataBasis" xml:lang="en-US">Percentage of the principal amount from Holders on pro rata basis.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AmountDistributionToAcquireRelatedContingentAcceleratedRepaymentNotes" xlink:label="loc_sclx_AmountDistributionToAcquireRelatedContingentAcceleratedRepaymentNotes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AmountDistributionToAcquireRelatedContingentAcceleratedRepaymentNotes" xml:lang="en-US">Amount Distribution To Acquire Related Contingent Accelerated Repayment Notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_AmountDistributionToAcquireRelatedContingentAcceleratedRepaymentNotes" xml:lang="en-US">Amount distribution to acquire related contingent accelerated repayment notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AmountDistributionToAcquireRelatedContingentAcceleratedRepaymentNotes" xlink:to="lab_sclx_AmountDistributionToAcquireRelatedContingentAcceleratedRepaymentNotes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AmountDistributionToAcquireRelatedContingentAcceleratedRepaymentNotes" xml:lang="en-US">Amount distribution to acquire related contingent accelerated repayment notes.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xml:lang="en-US">Debt Instrument, Unamortized Discount, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xml:lang="en-US">Debt instrument, unamortized discount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountCurrent" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DebtInstrumentTerminationDate" xlink:label="loc_sclx_DebtInstrumentTerminationDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DebtInstrumentTerminationDate" xml:lang="en-US">Debt Instrument, termination Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_DebtInstrumentTerminationDate" xml:lang="en-US">Debt instrument, termination date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DebtInstrumentTerminationDate" xlink:to="lab_sclx_DebtInstrumentTerminationDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_DebtInstrumentTerminationDate" xml:lang="en-US">Debt instrument, termination date.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xml:lang="en-US">Proceeds from Issuance of Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xml:lang="en-US">Proceeds from issuance of debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfDebt" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MaximumCompensationCostToBeAvailableProratedBasis" xlink:label="loc_sclx_MaximumCompensationCostToBeAvailableProratedBasis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_MaximumCompensationCostToBeAvailableProratedBasis" xml:lang="en-US">Maximum Compensation Cost To Be Available, Prorated Basis</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_MaximumCompensationCostToBeAvailableProratedBasis" xml:lang="en-US">Maximum compensation cost to be available, prorated basis</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_MaximumCompensationCostToBeAvailableProratedBasis" xlink:to="lab_sclx_MaximumCompensationCostToBeAvailableProratedBasis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_MaximumCompensationCostToBeAvailableProratedBasis" xml:lang="en-US">Maximum compensation cost to be available, prorated basis.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfLoanForgivenessUnderTheAct" xlink:label="loc_sclx_PercentageOfLoanForgivenessUnderTheAct" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PercentageOfLoanForgivenessUnderTheAct" xml:lang="en-US">Percentage Of Loan Forgiveness Under The Act</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PercentageOfLoanForgivenessUnderTheAct" xml:lang="en-US">Percentage of loan forgiveness under the act</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PercentageOfLoanForgivenessUnderTheAct" xlink:to="lab_sclx_PercentageOfLoanForgivenessUnderTheAct" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PercentageOfLoanForgivenessUnderTheAct" xml:lang="en-US">Percentage of loan forgiveness under the act.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MinimumPayrollCostToBeAvailable" xlink:label="loc_sclx_MinimumPayrollCostToBeAvailable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_MinimumPayrollCostToBeAvailable" xml:lang="en-US">Minimum payroll cost to be available</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_MinimumPayrollCostToBeAvailable" xml:lang="en-US">Minimum payroll cost to be available</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_MinimumPayrollCostToBeAvailable" xlink:to="lab_sclx_MinimumPayrollCostToBeAvailable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_MinimumPayrollCostToBeAvailable" xml:lang="en-US">Minimum payroll cost to be available.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MinimumUnrestrictedCashRequirementsToRepurchaseOfNotes" xlink:label="loc_sclx_MinimumUnrestrictedCashRequirementsToRepurchaseOfNotes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_MinimumUnrestrictedCashRequirementsToRepurchaseOfNotes" xml:lang="en-US">Minimum Unrestricted Cash Requirements To Repurchase Of Notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_MinimumUnrestrictedCashRequirementsToRepurchaseOfNotes" xml:lang="en-US">Minimum unrestricted cash requirements to repurchase of Notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_MinimumUnrestrictedCashRequirementsToRepurchaseOfNotes" xlink:to="lab_sclx_MinimumUnrestrictedCashRequirementsToRepurchaseOfNotes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_MinimumUnrestrictedCashRequirementsToRepurchaseOfNotes" xml:lang="en-US">Minimum unrestricted cash requirements to repurchase of notes.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaap_RestrictedCash" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCash" xml:lang="en-US">Restricted Cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedCash" xml:lang="en-US">Restricted cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DebtInstrumentPercentageOfPrincipalAmountRepurchased" xlink:label="loc_sclx_DebtInstrumentPercentageOfPrincipalAmountRepurchased" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DebtInstrumentPercentageOfPrincipalAmountRepurchased" xml:lang="en-US">Debt Instrument, Percentage of Principal Amount Repurchased</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_DebtInstrumentPercentageOfPrincipalAmountRepurchased" xml:lang="en-US">Debt instrument, percentage of principal amount repurchased</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DebtInstrumentPercentageOfPrincipalAmountRepurchased" xlink:to="lab_sclx_DebtInstrumentPercentageOfPrincipalAmountRepurchased" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_DebtInstrumentPercentageOfPrincipalAmountRepurchased" xml:lang="en-US">Debt instrument, percentage of principal amount repurchased.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchaseDate" xlink:label="loc_us-gaap_DebtInstrumentRepurchaseDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentRepurchaseDate" xml:lang="en-US">Debt Instrument, Repurchase Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentRepurchaseDate" xml:lang="en-US">Debt instrument, repurchase date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRepurchaseDate" xlink:to="lab_us-gaap_DebtInstrumentRepurchaseDate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCollateralAmount" xlink:label="loc_us-gaap_DebtInstrumentCollateralAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentCollateralAmount" xml:lang="en-US">Debt Instrument, Collateral Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentCollateralAmount" xml:lang="en-US">Debt instrument, collateral amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCollateralAmount" xlink:to="lab_us-gaap_DebtInstrumentCollateralAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnRestructuringOfDebt" xlink:label="loc_us-gaap_GainsLossesOnRestructuringOfDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainsLossesOnRestructuringOfDebt" xml:lang="en-US">Gains (Losses) on Restructuring of Debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnRestructuringOfDebt" xlink:to="lab_us-gaap_GainsLossesOnRestructuringOfDebt" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfThePrincipalAmountOfTheNotes" xlink:label="loc_sclx_PercentageOfThePrincipalAmountOfTheNotes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PercentageOfThePrincipalAmountOfTheNotes" xml:lang="en-US">Percentage Of The Principal Amount Of The Notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PercentageOfThePrincipalAmountOfTheNotes" xml:lang="en-US">Percentage of the principal amount of the Notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PercentageOfThePrincipalAmountOfTheNotes" xlink:to="lab_sclx_PercentageOfThePrincipalAmountOfTheNotes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PercentageOfThePrincipalAmountOfTheNotes" xml:lang="en-US">Percentage of the principal amount of the notes.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" xlink:label="loc_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" xml:lang="en-US">Debt Instrument, Increase (Decrease), Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" xml:lang="en-US">Debt instrument, increase (decrease), net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" xlink:to="lab_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xml:lang="en-US">Debt instrument interest rate effective percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LineOfCreditFacilityindebtednessAmount" xlink:label="loc_sclx_LineOfCreditFacilityindebtednessAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_LineOfCreditFacilityindebtednessAmount" xml:lang="en-US">Line of Credit Facility ,indebtedness Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_LineOfCreditFacilityindebtednessAmount" xml:lang="en-US">Line of credit facility, indebtedness amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_LineOfCreditFacilityindebtednessAmount" xlink:to="lab_sclx_LineOfCreditFacilityindebtednessAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_LineOfCreditFacilityindebtednessAmount" xml:lang="en-US">Line of credit facility ,indebtedness amount.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:label="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xml:lang="en-US">Debt Related Commitment Fees and Debt Issuance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xml:lang="en-US">Debt related commitment Fees and debt issuance costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:to="lab_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScilexPharmaNoteMember" xlink:label="loc_sclx_ScilexPharmaNoteMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ScilexPharmaNoteMember" xml:lang="en-US">Scilex Pharma Note [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ScilexPharmaNoteMember" xlink:to="lab_sclx_ScilexPharmaNoteMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ScilexPharmaNoteMember" xml:lang="en-US">Scilex pharma note.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TwoThousandAndEighteenPurchaseAgreementsMember" xlink:label="loc_sclx_TwoThousandAndEighteenPurchaseAgreementsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_TwoThousandAndEighteenPurchaseAgreementsMember" xml:lang="en-US">Two Thousand and Eighteen Purchase Agreements [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_TwoThousandAndEighteenPurchaseAgreementsMember" xml:lang="en-US">2018 Purchase Agreements [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_TwoThousandAndEighteenPurchaseAgreementsMember" xlink:to="lab_sclx_TwoThousandAndEighteenPurchaseAgreementsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember" xlink:label="loc_us-gaap_LetterOfCreditMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LetterOfCreditMember" xml:lang="en-US">Letter of Credit [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LetterOfCreditMember" xlink:to="lab_us-gaap_LetterOfCreditMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xml:lang="en-US">Revolving Credit Facility [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AccountsReceivableRevolvingLoanFacilityMember" xlink:label="loc_sclx_AccountsReceivableRevolvingLoanFacilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AccountsReceivableRevolvingLoanFacilityMember" xml:lang="en-US">Accounts receivable revolving loan facility [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AccountsReceivableRevolvingLoanFacilityMember" xlink:to="lab_sclx_AccountsReceivableRevolvingLoanFacilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AccountsReceivableRevolvingLoanFacilityMember" xml:lang="en-US">Accounts receivable revolving loan facility.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VariableRateAxis" xml:lang="en-US">Variable Rate [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VariableRateDomain" xml:lang="en-US">Variable Rate [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrimeRateMember" xlink:label="loc_us-gaap_PrimeRateMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrimeRateMember" xml:lang="en-US">Prime Rate [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrimeRateMember" xlink:to="lab_us-gaap_PrimeRateMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_StatementScenarioAxis" xml:lang="en-US">Scenario [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xml:lang="en-US">Scenario [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_IfLetterOfCreditIsDrawnMember" xlink:label="loc_sclx_IfLetterOfCreditIsDrawnMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_IfLetterOfCreditIsDrawnMember" xml:lang="en-US">If Letter Of Credit Is Drawn [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_IfLetterOfCreditIsDrawnMember" xlink:to="lab_sclx_IfLetterOfCreditIsDrawnMember" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MarketingApprovalLetterMember" xlink:label="loc_sclx_MarketingApprovalLetterMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_MarketingApprovalLetterMember" xml:lang="en-US">Marketing Approval Letter [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_MarketingApprovalLetterMember" xlink:to="lab_sclx_MarketingApprovalLetterMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_MarketingApprovalLetterMember" xml:lang="en-US">Marketing approval letter.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScenarioAdjustmentMember" xlink:label="loc_us-gaap_ScenarioAdjustmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScenarioAdjustmentMember" xml:lang="en-US">Scenario, Adjustment [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScenarioAdjustmentMember" xlink:to="lab_us-gaap_ScenarioAdjustmentMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xml:lang="en-US">Debt Instrument, Redemption, Period Three [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xml:lang="en-US">Debt Instrument, Redemption, Period Two [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xml:lang="en-US">Debt Instrument, Redemption, Period One [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_StatementAxis" xlink:label="loc_sclx_StatementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_StatementAxis" xml:lang="en-US">Statement [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_StatementAxis" xlink:to="lab_sclx_StatementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_StatementAxis" xml:lang="en-US">Statement .</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_StatementDomain" xlink:label="loc_sclx_StatementDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_StatementDomain" xml:lang="en-US">Statement [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_StatementDomain" xlink:to="lab_sclx_StatementDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_StatementDomain" xml:lang="en-US">Statement.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DecemberOptionalRepurchaseMember" xlink:label="loc_sclx_DecemberOptionalRepurchaseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DecemberOptionalRepurchaseMember" xml:lang="en-US">December Optional Repurchase [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DecemberOptionalRepurchaseMember" xlink:to="lab_sclx_DecemberOptionalRepurchaseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_DecemberOptionalRepurchaseMember" xml:lang="en-US">December optional repurchase.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_FebruaryOptionalRepurchaseMember" xlink:label="loc_sclx_FebruaryOptionalRepurchaseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_FebruaryOptionalRepurchaseMember" xml:lang="en-US">February Optional Repurchase [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_FebruaryOptionalRepurchaseMember" xlink:to="lab_sclx_FebruaryOptionalRepurchaseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_FebruaryOptionalRepurchaseMember" xml:lang="en-US">February optional repurchase.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AprilOptionalRepurchaseMember" xlink:label="loc_sclx_AprilOptionalRepurchaseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AprilOptionalRepurchaseMember" xml:lang="en-US">April Optional Repurchase [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AprilOptionalRepurchaseMember" xlink:to="lab_sclx_AprilOptionalRepurchaseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AprilOptionalRepurchaseMember" xml:lang="en-US">April optional repurchase.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_EventTypeAxis" xlink:label="loc_sclx_EventTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_EventTypeAxis" xml:lang="en-US">Event Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_EventTypeAxis" xlink:to="lab_sclx_EventTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_EventTypeAxis" xml:lang="en-US">Event type.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_EventTypeDomain" xlink:label="loc_sclx_EventTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_EventTypeDomain" xml:lang="en-US">Event Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_EventTypeDomain" xlink:to="lab_sclx_EventTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_EventTypeDomain" xml:lang="en-US">Event type.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_CoronavirusAidReliefAndEconomicSecurityActMember" xlink:label="loc_sclx_CoronavirusAidReliefAndEconomicSecurityActMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_CoronavirusAidReliefAndEconomicSecurityActMember" xml:lang="en-US">Coronavirus Aid, Relief, and Economic Security Act [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_CoronavirusAidReliefAndEconomicSecurityActMember" xlink:to="lab_sclx_CoronavirusAidReliefAndEconomicSecurityActMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_CoronavirusAidReliefAndEconomicSecurityActMember" xml:lang="en-US">Coronavirus aid, relief, and economic security act.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ClassificationOfCostAxis" xlink:label="loc_sclx_ClassificationOfCostAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ClassificationOfCostAxis" xml:lang="en-US">Classification of cost [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ClassificationOfCostAxis" xlink:to="lab_sclx_ClassificationOfCostAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ClassificationOfCostAxis" xml:lang="en-US">Classification of cost.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ClassificationOfCostDomain" xlink:label="loc_sclx_ClassificationOfCostDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ClassificationOfCostDomain" xml:lang="en-US">Classification of cost [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ClassificationOfCostDomain" xlink:to="lab_sclx_ClassificationOfCostDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ClassificationOfCostDomain" xml:lang="en-US">Classification of cost.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NonPayrollCostsMember" xlink:label="loc_sclx_NonPayrollCostsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_NonPayrollCostsMember" xml:lang="en-US">Non Payroll Costs [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_NonPayrollCostsMember" xlink:to="lab_sclx_NonPayrollCostsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_NonPayrollCostsMember" xml:lang="en-US">Non-payroll costs.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PayrollCostsBasisMember" xlink:label="loc_sclx_PayrollCostsBasisMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PayrollCostsBasisMember" xml:lang="en-US">Payroll Costs Basis [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PayrollCostsBasisMember" xlink:to="lab_sclx_PayrollCostsBasisMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PayrollCostsBasisMember" xml:lang="en-US">Payroll costs basis.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PaycheckProtectionProgramMember" xlink:label="loc_sclx_PaycheckProtectionProgramMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PaycheckProtectionProgramMember" xml:lang="en-US">Paycheck Protection Program [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PaycheckProtectionProgramMember" xlink:to="lab_sclx_PaycheckProtectionProgramMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PaycheckProtectionProgramMember" xml:lang="en-US">Paycheck protection program.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubordinatedDebtMember" xlink:label="loc_us-gaap_SubordinatedDebtMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubordinatedDebtMember" xml:lang="en-US">Subordinated Debt [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubordinatedDebtMember" xlink:to="lab_us-gaap_SubordinatedDebtMember" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_IndebentureMember" xlink:label="loc_sclx_IndebentureMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_IndebentureMember" xml:lang="en-US">Indebenture [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_IndebentureMember" xlink:to="lab_sclx_IndebentureMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_IndebentureMember" xml:lang="en-US">Indebenture.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AmendmentAxis" xlink:label="loc_sclx_AmendmentAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AmendmentAxis" xml:lang="en-US">Amendment [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AmendmentAxis" xlink:to="lab_sclx_AmendmentAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AmendmentAxis" xml:lang="en-US">Amendment.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AmendmentDomain" xlink:label="loc_sclx_AmendmentDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AmendmentDomain" xml:lang="en-US">Amendment [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AmendmentDomain" xlink:to="lab_sclx_AmendmentDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AmendmentDomain" xml:lang="en-US">Amendment.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AmendmentNoFourMember" xlink:label="loc_sclx_AmendmentNoFourMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AmendmentNoFourMember" xml:lang="en-US">Amendment No Four [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AmendmentNoFourMember" xlink:to="lab_sclx_AmendmentNoFourMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AmendmentNoFourMember" xml:lang="en-US">Amendment no four.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PromissoryNoteMember" xlink:label="loc_sclx_PromissoryNoteMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PromissoryNoteMember" xml:lang="en-US">Promissory Note [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PromissoryNoteMember" xlink:to="lab_sclx_PromissoryNoteMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PromissoryNoteMember" xml:lang="en-US">Promissory note.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TwoThousandAndEighteenPurchaseAgreementsAndIndentureMember" xlink:label="loc_sclx_TwoThousandAndEighteenPurchaseAgreementsAndIndentureMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_TwoThousandAndEighteenPurchaseAgreementsAndIndentureMember" xml:lang="en-US">Two Thousand and Eighteen Purchase Agreements and Indenture [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_TwoThousandAndEighteenPurchaseAgreementsAndIndentureMember" xml:lang="en-US">2018 Purchase Agreements and Indenture [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_TwoThousandAndEighteenPurchaseAgreementsAndIndentureMember" xlink:to="lab_sclx_TwoThousandAndEighteenPurchaseAgreementsAndIndentureMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_TwoThousandAndEighteenPurchaseAgreementsAndIndentureMember" xml:lang="en-US">Two thousand and eighteen purchase agreements and indenture.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentTable" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xml:lang="en-US">Debt Instrument [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtFairValue" xlink:label="loc_us-gaap_LongTermDebtFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebtFairValue" xml:lang="en-US">Long-Term Debt, Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermDebtFairValue" xml:lang="en-US">Estimated fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtFairValue" xlink:to="lab_us-gaap_LongTermDebtFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xml:lang="en-US">Long-Term Debt, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xml:lang="en-US">Principal</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xml:lang="en-US">Debt Instrument, Unamortized Discount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xml:lang="en-US">Unamortized debt discount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnamortizedDebtIssuanceExpense" xml:lang="en-US">Unamortized Debt Issuance Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_UnamortizedDebtIssuanceExpense" xml:lang="en-US">Unamortized debt issuance costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnamortizedDebtIssuanceExpense" xlink:to="lab_us-gaap_UnamortizedDebtIssuanceExpense" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtTable" xlink:label="loc_sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtTable" xml:lang="en-US">Schedule Of Future minimum payments Of Long Term Debt [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtTable" xlink:to="lab_sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtTable" xml:lang="en-US">Schedule of future minimum payments of long term debt.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtLineItems" xlink:label="loc_sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtLineItems" xml:lang="en-US">Schedule Of Future minimum payments Of Long Term Debt [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtLineItems" xlink:to="lab_sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtLineItems" xml:lang="en-US">Schedule of future minimum payments of long term debt.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LongtermDebtFutureMinimumPayment" xlink:label="loc_sclx_LongtermDebtFutureMinimumPayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_LongtermDebtFutureMinimumPayment" xml:lang="en-US">LongTerm Debt, Future Minimum Payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_sclx_LongtermDebtFutureMinimumPayment" xml:lang="en-US">Total minimum future payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_LongtermDebtFutureMinimumPayment" xlink:to="lab_sclx_LongtermDebtFutureMinimumPayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_LongtermDebtFutureMinimumPayment" xml:lang="en-US">Long-term debt, future minimum payment.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LongtermDebtFutureMinimumPaymentYearFive" xlink:label="loc_sclx_LongtermDebtFutureMinimumPaymentYearFive" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_LongtermDebtFutureMinimumPaymentYearFive" xml:lang="en-US">LongTerm Debt, Future Minimum Payment , Year Five</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_LongtermDebtFutureMinimumPaymentYearFive" xml:lang="en-US">2026</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_LongtermDebtFutureMinimumPaymentYearFive" xlink:to="lab_sclx_LongtermDebtFutureMinimumPaymentYearFive" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_LongtermDebtFutureMinimumPaymentYearFive" xml:lang="en-US">Long-term debt, future minimum payment , year five.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LongtermDebtFutureMinimumPaymentYearFour" xlink:label="loc_sclx_LongtermDebtFutureMinimumPaymentYearFour" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_LongtermDebtFutureMinimumPaymentYearFour" xml:lang="en-US">LongTerm Debt, Future Minimum Payment , Year Four</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_LongtermDebtFutureMinimumPaymentYearFour" xml:lang="en-US">2025</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_LongtermDebtFutureMinimumPaymentYearFour" xlink:to="lab_sclx_LongtermDebtFutureMinimumPaymentYearFour" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_LongtermDebtFutureMinimumPaymentYearFour" xml:lang="en-US">Long-term debt, future minimum payment , year four.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LongtermDebtFutureMinimumPaymentYearThree" xlink:label="loc_sclx_LongtermDebtFutureMinimumPaymentYearThree" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_LongtermDebtFutureMinimumPaymentYearThree" xml:lang="en-US">LongTerm Debt, Future Minimum Payment , Year Three</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_LongtermDebtFutureMinimumPaymentYearThree" xml:lang="en-US">2024</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_LongtermDebtFutureMinimumPaymentYearThree" xlink:to="lab_sclx_LongtermDebtFutureMinimumPaymentYearThree" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_LongtermDebtFutureMinimumPaymentYearThree" xml:lang="en-US">Long-term debt, future minimum payment , year three.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LongtermDebtFutureMinimumPaymentYearTwo" xlink:label="loc_sclx_LongtermDebtFutureMinimumPaymentYearTwo" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_LongtermDebtFutureMinimumPaymentYearTwo" xml:lang="en-US">LongTerm Debt, Future Minimum Payment , Year Two</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_LongtermDebtFutureMinimumPaymentYearTwo" xml:lang="en-US">2023</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_LongtermDebtFutureMinimumPaymentYearTwo" xlink:to="lab_sclx_LongtermDebtFutureMinimumPaymentYearTwo" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_LongtermDebtFutureMinimumPaymentYearTwo" xml:lang="en-US">Long-term debt, future minimum payment , year two.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LongtermDebtfutureMinimumPaymentYearOne" xlink:label="loc_sclx_LongtermDebtfutureMinimumPaymentYearOne" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_LongtermDebtfutureMinimumPaymentYearOne" xml:lang="en-US">LongTerm Debt,Future minimum payment , year one</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_LongtermDebtfutureMinimumPaymentYearOne" xml:lang="en-US">2022</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_LongtermDebtfutureMinimumPaymentYearOne" xlink:to="lab_sclx_LongtermDebtfutureMinimumPaymentYearOne" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_LongtermDebtfutureMinimumPaymentYearOne" xml:lang="en-US">Long-Term Debt,&#160;Future minimum payment , year one.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_CompensationAndEmployeeBenefitPlansTable" xlink:label="loc_sclx_CompensationAndEmployeeBenefitPlansTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_CompensationAndEmployeeBenefitPlansTable" xml:lang="en-US">Compensation And Employee Benefit Plans [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_CompensationAndEmployeeBenefitPlansTable" xlink:to="lab_sclx_CompensationAndEmployeeBenefitPlansTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_CompensationAndEmployeeBenefitPlansTable" xml:lang="en-US">Compensation and employee benefit plans.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_CompensationAndEmployeeBenefitPlansLineItems" xlink:label="loc_sclx_CompensationAndEmployeeBenefitPlansLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_CompensationAndEmployeeBenefitPlansLineItems" xml:lang="en-US">Compensation And Employee Benefit Plans [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_CompensationAndEmployeeBenefitPlansLineItems" xlink:to="lab_sclx_CompensationAndEmployeeBenefitPlansLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_CompensationAndEmployeeBenefitPlansLineItems" xml:lang="en-US">Compensation and employee benefit plans.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Share based compensation arrangement,Options outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Outstanding, Ending, Options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Outstanding, Beginning, Options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US">Weighted average period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant" xlink:label="loc_sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Per Share Of Common Stock On Date Of Grant</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant" xml:lang="en-US">Fair value per share of common stock on date of grant</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant" xml:lang="en-US">Fair value per share of common stock on date of grant</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant" xlink:to="lab_sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant" xml:lang="en-US">Sharebased compensation arrangement by sharebased payment award fair value assumptions per share of common stock on date of grant.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Contribution Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xml:lang="en-US">Defined contribution plan matching contribution amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToEmployees" xlink:label="loc_us-gaap_PaymentsToEmployees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToEmployees" xml:lang="en-US">Payments to Employees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PaymentsToEmployees" xml:lang="en-US">Payment to employees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToEmployees" xlink:to="lab_us-gaap_PaymentsToEmployees" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingNumber" xlink:label="loc_sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingNumber" xml:lang="en-US">ShareBased Compensation Arrangement by ShareBased Payment Award, Option, Outstanding, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingNumber" xml:lang="en-US">Share based compensation arrangement,Options outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingNumber" xlink:to="lab_sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingNumber" xml:lang="en-US">Number of options outstanding, including both vested and non-vested options.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Number of shares reserved for issuance under plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xml:lang="en-US">Share based compensation arrangement,vesting rights</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Share-Based Payment Arrangement, Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Stock based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xml:lang="en-US">Total unrecognized compensation costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameAxis" xml:lang="en-US">Plan Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameDomain" xml:lang="en-US">Plan Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScilexPharmaTwoThousandSeventeenPlanMember" xlink:label="loc_sclx_ScilexPharmaTwoThousandSeventeenPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ScilexPharmaTwoThousandSeventeenPlanMember" xml:lang="en-US">Scilex Pharma two thousand seventeen Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_ScilexPharmaTwoThousandSeventeenPlanMember" xml:lang="en-US">Scilex Pharma 2017 Plan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ScilexPharmaTwoThousandSeventeenPlanMember" xlink:to="lab_sclx_ScilexPharmaTwoThousandSeventeenPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ScilexPharmaTwoThousandSeventeenPlanMember" xml:lang="en-US">Scilex pharma two thousand seventeen plan.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TwoThousandNineteenStockOptionPlanMember" xlink:label="loc_sclx_TwoThousandNineteenStockOptionPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_TwoThousandNineteenStockOptionPlanMember" xml:lang="en-US">Two thousand nineteen Stock Option Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_TwoThousandNineteenStockOptionPlanMember" xml:lang="en-US">2019 Stock Option Plan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_TwoThousandNineteenStockOptionPlanMember" xlink:to="lab_sclx_TwoThousandNineteenStockOptionPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_TwoThousandNineteenStockOptionPlanMember" xml:lang="en-US">Two thousand nineteen stock option Plan .</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AmendmentToTwoThousandNineteenStockOptionPlanMember" xlink:label="loc_sclx_AmendmentToTwoThousandNineteenStockOptionPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AmendmentToTwoThousandNineteenStockOptionPlanMember" xml:lang="en-US">Amendment to two thousand nineteen Stock Option Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_AmendmentToTwoThousandNineteenStockOptionPlanMember" xml:lang="en-US">Amendment to 2019 Stock Option Plan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AmendmentToTwoThousandNineteenStockOptionPlanMember" xlink:to="lab_sclx_AmendmentToTwoThousandNineteenStockOptionPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AmendmentToTwoThousandNineteenStockOptionPlanMember" xml:lang="en-US">Amendment to two thousand nineteen stock option plan.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AwardTypeAxis" xml:lang="en-US">Award Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">Award Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanNameAxis" xlink:label="loc_us-gaap_RetirementPlanNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetirementPlanNameAxis" xml:lang="en-US">Retirement Plan Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanNameAxis" xlink:to="lab_us-gaap_RetirementPlanNameAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanNameDomain" xlink:label="loc_us-gaap_RetirementPlanNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetirementPlanNameDomain" xml:lang="en-US">Retirement Plan Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanNameDomain" xlink:to="lab_us-gaap_RetirementPlanNameDomain" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_FourHundredAndOneKPlanMember" xlink:label="loc_sclx_FourHundredAndOneKPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_FourHundredAndOneKPlanMember" xml:lang="en-US">Four hundred and one (k) Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_FourHundredAndOneKPlanMember" xml:lang="en-US">401(k) Plan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_FourHundredAndOneKPlanMember" xlink:to="lab_sclx_FourHundredAndOneKPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_FourHundredAndOneKPlanMember" xml:lang="en-US">Four hundred and one (k) Plan .</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xml:lang="en-US">Income Statement Location [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xml:lang="en-US">Income Statement Location [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_OperatingExpensesMember" xlink:label="loc_sclx_OperatingExpensesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_OperatingExpensesMember" xml:lang="en-US">Operating Expenses [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_OperatingExpensesMember" xlink:to="lab_sclx_OperatingExpensesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_OperatingExpensesMember" xml:lang="en-US">Operating expenses.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted-average grant date fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xml:lang="en-US">Expected stock-price volatility, maximum</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xml:lang="en-US">Risk-free interest rate, minimum</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xml:lang="en-US">Risk-free interest rate, maximum</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xml:lang="en-US">Expected stock-price volatility, minimum</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:label="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xml:lang="en-US">Share-Based Payment Arrangement, Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="lab_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xml:lang="en-US">Forfeited/Cancelled, Options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Exercisable, Options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Outstanding, Beginning, Weighted average exercise price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Outstanding, Ending, Weighted average exercise price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Granted, Weighted average exercise price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Exercised, Weighted average exercise price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Forfeited/Cancelled, Weighted average exercise price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Exercisable, Weighted average exercise price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Outstanding, Beginning, Aggregate Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Outstanding, Ending, Aggregate Intrinsic Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Granted, Options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTable" xlink:label="loc_us-gaap_AssetAcquisitionTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetAcquisitionTable" xml:lang="en-US">Asset Acquisition [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionTable" xlink:to="lab_us-gaap_AssetAcquisitionTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="loc_us-gaap_AssetAcquisitionLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetAcquisitionLineItems" xml:lang="en-US">Asset Acquisition [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionLineItems" xlink:to="lab_us-gaap_AssetAcquisitionLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferred" xml:lang="en-US">Asset Acquisition, Consideration Transferred</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferred" xml:lang="en-US">Asset acquisition total consideration transferred</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferred" xml:lang="en-US">Asset acquisition, consideration transferred</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="lab_us-gaap_AssetAcquisitionConsiderationTransferred" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfSharesIssuedSubjectToRestrictionOfTransfer" xlink:label="loc_sclx_PercentageOfSharesIssuedSubjectToRestrictionOfTransfer" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PercentageOfSharesIssuedSubjectToRestrictionOfTransfer" xml:lang="en-US">Percentage Of Shares Issued Subject To Restriction Of Transfer</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PercentageOfSharesIssuedSubjectToRestrictionOfTransfer" xml:lang="en-US">Percentage of shares issued subject to restriction of transfer</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PercentageOfSharesIssuedSubjectToRestrictionOfTransfer" xlink:to="lab_sclx_PercentageOfSharesIssuedSubjectToRestrictionOfTransfer" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PercentageOfSharesIssuedSubjectToRestrictionOfTransfer" xml:lang="en-US">Percentage of shares issued subject to restriction of transfer.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PeriodDuringWhichShareTransferIsRestricted" xlink:label="loc_sclx_PeriodDuringWhichShareTransferIsRestricted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PeriodDuringWhichShareTransferIsRestricted" xml:lang="en-US">Period During Which Share Transfer Is Restricted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PeriodDuringWhichShareTransferIsRestricted" xml:lang="en-US">Period during which share transfer is restricted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PeriodDuringWhichShareTransferIsRestricted" xlink:to="lab_sclx_PeriodDuringWhichShareTransferIsRestricted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PeriodDuringWhichShareTransferIsRestricted" xml:lang="en-US">Period during which share transfer is restricted.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PeriodDuringWhichTheSharesMayBeExchanged" xlink:label="loc_sclx_PeriodDuringWhichTheSharesMayBeExchanged" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PeriodDuringWhichTheSharesMayBeExchanged" xml:lang="en-US">Period During Which The Shares May Be Exchanged</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PeriodDuringWhichTheSharesMayBeExchanged" xml:lang="en-US">Period during which the shares may be exchanged</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PeriodDuringWhichTheSharesMayBeExchanged" xlink:to="lab_sclx_PeriodDuringWhichTheSharesMayBeExchanged" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PeriodDuringWhichTheSharesMayBeExchanged" xml:lang="en-US">Period during which the shares may be exchanged.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_CommonStockValueToBeExchanged" xlink:label="loc_sclx_CommonStockValueToBeExchanged" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_CommonStockValueToBeExchanged" xml:lang="en-US">Common Stock Value To Be Exchanged</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_CommonStockValueToBeExchanged" xml:lang="en-US">Common stock value to be exchanged</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_CommonStockValueToBeExchanged" xlink:to="lab_sclx_CommonStockValueToBeExchanged" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_CommonStockValueToBeExchanged" xml:lang="en-US">Common stock value to be exchanged.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiability" xlink:label="loc_us-gaap_AssetAcquisitionContingentConsiderationLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetAcquisitionContingentConsiderationLiability" xml:lang="en-US">Asset Acquisition, Contingent Consideration, Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetAcquisitionContingentConsiderationLiability" xml:lang="en-US">Asset acquistion contingent consideration</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionContingentConsiderationLiability" xlink:to="lab_us-gaap_AssetAcquisitionContingentConsiderationLiability" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_RevenueToBeEarnedByTheAcquireeValue" xlink:label="loc_sclx_RevenueToBeEarnedByTheAcquireeValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_RevenueToBeEarnedByTheAcquireeValue" xml:lang="en-US">Revenue To Be Earned By The Acquiree Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_RevenueToBeEarnedByTheAcquireeValue" xml:lang="en-US">Revenue to be earned by the acquiree value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_RevenueToBeEarnedByTheAcquireeValue" xlink:to="lab_sclx_RevenueToBeEarnedByTheAcquireeValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_RevenueToBeEarnedByTheAcquireeValue" xml:lang="en-US">Revenue to be earned by the acquiree value.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NumberOfDaysForDeterminingTheWeightedVolumeAveragePriceForShares" xlink:label="loc_sclx_NumberOfDaysForDeterminingTheWeightedVolumeAveragePriceForShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_NumberOfDaysForDeterminingTheWeightedVolumeAveragePriceForShares" xml:lang="en-US">Number Of Days For Determining The Weighted Volume Average Price For Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_NumberOfDaysForDeterminingTheWeightedVolumeAveragePriceForShares" xml:lang="en-US">Number of days for determining the weighted volume averge price of shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_NumberOfDaysForDeterminingTheWeightedVolumeAveragePriceForShares" xlink:to="lab_sclx_NumberOfDaysForDeterminingTheWeightedVolumeAveragePriceForShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_NumberOfDaysForDeterminingTheWeightedVolumeAveragePriceForShares" xml:lang="en-US">Number of days for determining the weighted volume average price for shares.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PricePerShareForDeterminingTheExchangeOfShares" xlink:label="loc_sclx_PricePerShareForDeterminingTheExchangeOfShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PricePerShareForDeterminingTheExchangeOfShares" xml:lang="en-US">Price Per Share For Determining The Exchange Of Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PricePerShareForDeterminingTheExchangeOfShares" xml:lang="en-US">Price per share for determining the exchange of shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PricePerShareForDeterminingTheExchangeOfShares" xlink:to="lab_sclx_PricePerShareForDeterminingTheExchangeOfShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PricePerShareForDeterminingTheExchangeOfShares" xml:lang="en-US">Price per share for determining the exchange of shares.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PaymentMadeInSurrenderingTheShares" xlink:label="loc_sclx_PaymentMadeInSurrenderingTheShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PaymentMadeInSurrenderingTheShares" xml:lang="en-US">Payment Made In Surrendering The Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PaymentMadeInSurrenderingTheShares" xml:lang="en-US">Payment made in surrendering the shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PaymentMadeInSurrenderingTheShares" xlink:to="lab_sclx_PaymentMadeInSurrenderingTheShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PaymentMadeInSurrenderingTheShares" xml:lang="en-US">Payment made in surrendering the shares.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xml:lang="en-US">Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xml:lang="en-US">Accrued Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue" xml:lang="en-US">Acquired Finite-Lived Intangible Asset, Residual Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue" xml:lang="en-US">Acquired Finite-Lived Intangible Asset, Residual Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DeferredConsideration" xlink:label="loc_sclx_DeferredConsideration" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DeferredConsideration" xml:lang="en-US">Deferred Consideration</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_DeferredConsideration" xml:lang="en-US">Deferred consideration</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DeferredConsideration" xlink:to="lab_sclx_DeferredConsideration" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_DeferredConsideration" xml:lang="en-US">deferred consideration</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_UpfrontlicenseFee" xlink:label="loc_sclx_UpfrontlicenseFee" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_UpfrontlicenseFee" xml:lang="en-US">Upfront License Fee</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_UpfrontlicenseFee" xlink:to="lab_sclx_UpfrontlicenseFee" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_UpfrontlicenseFee" xml:lang="en-US">up-front&#160;license fee</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MilestonePayment" xlink:label="loc_sclx_MilestonePayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_MilestonePayment" xml:lang="en-US">Milestone Payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_MilestonePayment" xml:lang="en-US">Milestone payment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_MilestonePayment" xlink:to="lab_sclx_MilestonePayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_MilestonePayment" xml:lang="en-US">milestone payment</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RoyaltyExpense" xml:lang="en-US">Royalty Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RoyaltyExpense" xml:lang="en-US">Royalty payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyExpense" xlink:to="lab_us-gaap_RoyaltyExpense" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TrancheAxis" xlink:label="loc_sclx_TrancheAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_TrancheAxis" xml:lang="en-US">Tranche [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_TrancheAxis" xlink:to="lab_sclx_TrancheAxis" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TrancheDomain" xlink:label="loc_sclx_TrancheDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_TrancheDomain" xml:lang="en-US">Tranche [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_TrancheDomain" xlink:to="lab_sclx_TrancheDomain" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TrancheOneMember" xlink:label="loc_sclx_TrancheOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_TrancheOneMember" xml:lang="en-US">Tranche One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_TrancheOneMember" xml:lang="en-US">Tranche 1 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_TrancheOneMember" xlink:to="lab_sclx_TrancheOneMember" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TrancheTwoMember" xlink:label="loc_sclx_TrancheTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_TrancheTwoMember" xml:lang="en-US">Tranche Two [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_TrancheTwoMember" xml:lang="en-US">Tranche 2 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_TrancheTwoMember" xlink:to="lab_sclx_TrancheTwoMember" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TrancheThreeMember" xlink:label="loc_sclx_TrancheThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_TrancheThreeMember" xml:lang="en-US">Tranche Three [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_TrancheThreeMember" xml:lang="en-US">Tranche 3 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_TrancheThreeMember" xlink:to="lab_sclx_TrancheThreeMember" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TrancheFourMember" xlink:label="loc_sclx_TrancheFourMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_TrancheFourMember" xml:lang="en-US">Tranche Four [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_TrancheFourMember" xml:lang="en-US">Tranche 4 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_TrancheFourMember" xlink:to="lab_sclx_TrancheFourMember" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AardvarkMember" xlink:label="loc_sclx_AardvarkMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AardvarkMember" xml:lang="en-US">Aardvark [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AardvarkMember" xlink:to="lab_sclx_AardvarkMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AardvarkMember" xml:lang="en-US">Aardvark.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_RomegLicenseAgreementMember" xlink:label="loc_sclx_RomegLicenseAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_RomegLicenseAgreementMember" xml:lang="en-US">Romeg License Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_RomegLicenseAgreementMember" xlink:to="lab_sclx_RomegLicenseAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_RomegLicenseAgreementMember" xml:lang="en-US">Romeg License Agreement</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MilestoneAxis" xlink:label="loc_sclx_MilestoneAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_MilestoneAxis" xml:lang="en-US">Milestone [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_MilestoneAxis" xlink:to="lab_sclx_MilestoneAxis" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MilestoneDomain" xlink:label="loc_sclx_MilestoneDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_MilestoneDomain" xml:lang="en-US">Milestone [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_MilestoneDomain" xlink:to="lab_sclx_MilestoneDomain" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_RegulatoryBasedMilestoneMember" xlink:label="loc_sclx_RegulatoryBasedMilestoneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_RegulatoryBasedMilestoneMember" xml:lang="en-US">Regulatory Based Milestone [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_RegulatoryBasedMilestoneMember" xlink:to="lab_sclx_RegulatoryBasedMilestoneMember" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ReveueBasedMilestoneMember" xlink:label="loc_sclx_ReveueBasedMilestoneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ReveueBasedMilestoneMember" xml:lang="en-US">Reveue Based Milestone [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ReveueBasedMilestoneMember" xlink:to="lab_sclx_ReveueBasedMilestoneMember" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ApprovalBasedMilestoneMember" xlink:label="loc_sclx_ApprovalBasedMilestoneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ApprovalBasedMilestoneMember" xml:lang="en-US">Approval Based Milestone [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ApprovalBasedMilestoneMember" xlink:to="lab_sclx_ApprovalBasedMilestoneMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RestatementAxis" xml:lang="en-US">Revision of Prior Period [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementAxis" xlink:to="lab_srt_RestatementAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RestatementDomain" xml:lang="en-US">Revision of Prior Period [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementDomain" xlink:to="lab_srt_RestatementDomain" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AsRestatedMember" xlink:label="loc_sclx_AsRestatedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AsRestatedMember" xml:lang="en-US">As Restated [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_AsRestatedMember" xml:lang="en-US">As Restated [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AsRestatedMember" xlink:to="lab_sclx_AsRestatedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AsRestatedMember" xml:lang="en-US">As restated.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TwoThousandTwentyTwoPromissoryNoteMember" xlink:label="loc_sclx_TwoThousandTwentyTwoPromissoryNoteMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_TwoThousandTwentyTwoPromissoryNoteMember" xml:lang="en-US">Two Thousand Twenty Two Promissory Note [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_TwoThousandTwentyTwoPromissoryNoteMember" xml:lang="en-US">2022 Promissory Note [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_TwoThousandTwentyTwoPromissoryNoteMember" xlink:to="lab_sclx_TwoThousandTwentyTwoPromissoryNoteMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockRedemptionPricePerShare" xlink:label="loc_us-gaap_PreferredStockRedemptionPricePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockRedemptionPricePerShare" xml:lang="en-US">Preferred Stock, Redemption Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockRedemptionPricePerShare" xml:lang="en-US">Ordinary per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockRedemptionPricePerShare" xlink:to="lab_us-gaap_PreferredStockRedemptionPricePerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsCurrent" xlink:label="loc_us-gaap_IntangibleAssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IntangibleAssetsCurrent" xml:lang="en-US">Intangible Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IntangibleAssetsCurrent" xml:lang="en-US">Net tangible assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsCurrent" xlink:to="lab_us-gaap_IntangibleAssetsCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srt_ScenarioPreviouslyReportedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ScenarioPreviouslyReportedMember" xml:lang="en-US">Previously Reported [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ScenarioPreviouslyReportedMember" xml:lang="en-US">Previously Reported [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioPreviouslyReportedMember" xlink:to="lab_srt_ScenarioPreviouslyReportedMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAdjustmentMember" xlink:label="loc_srt_RestatementAdjustmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RestatementAdjustmentMember" xml:lang="en-US">Revision of Prior Period, Adjustment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_RestatementAdjustmentMember" xml:lang="en-US">Adjustments Restatement 1 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementAdjustmentMember" xlink:to="lab_srt_RestatementAdjustmentMember" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AdjustmentsRestatement2Member" xlink:label="loc_sclx_AdjustmentsRestatement2Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AdjustmentsRestatement2Member" xml:lang="en-US">Adjustments Restatement 2 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_AdjustmentsRestatement2Member" xml:lang="en-US">Adjustments Restatement 2 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AdjustmentsRestatement2Member" xlink:to="lab_sclx_AdjustmentsRestatement2Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AdjustmentsRestatement2Member" xml:lang="en-US">Adjustments restatement 2.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_IncomeTaxDisclosureTable" xlink:label="loc_sclx_IncomeTaxDisclosureTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_IncomeTaxDisclosureTable" xml:lang="en-US">Income Tax Disclosure [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_IncomeTaxDisclosureTable" xlink:to="lab_sclx_IncomeTaxDisclosureTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_IncomeTaxDisclosureTable" xml:lang="en-US">Income tax disclosure.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xml:lang="en-US">Tax Credit Carryforward [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchMember" xml:lang="en-US">Research Tax Credit Carryforward [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember" xlink:to="lab_us-gaap_ResearchMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaap_TaxPeriodAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxPeriodAxis" xml:lang="en-US">Tax Period [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodAxis" xlink:to="lab_us-gaap_TaxPeriodAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxPeriodDomain" xml:lang="en-US">Tax Period [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodDomain" xlink:to="lab_us-gaap_TaxPeriodDomain" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_IndefiniteCarryforwardPeriodMember" xlink:label="loc_sclx_IndefiniteCarryforwardPeriodMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_IndefiniteCarryforwardPeriodMember" xml:lang="en-US">Indefinite Carryforward Period [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_IndefiniteCarryforwardPeriodMember" xlink:to="lab_sclx_IndefiniteCarryforwardPeriodMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_IndefiniteCarryforwardPeriodMember" xml:lang="en-US">indefinite carryforward period.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_IncomeTaxDisclosureLineItems" xlink:label="loc_sclx_IncomeTaxDisclosureLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_IncomeTaxDisclosureLineItems" xml:lang="en-US">Income Tax Disclosure [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems" xlink:to="lab_sclx_IncomeTaxDisclosureLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_IncomeTaxDisclosureLineItems" xml:lang="en-US">Income tax disclosure.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Valuation allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Valuation allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xml:lang="en-US">Operating Loss Carryforwards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xml:lang="en-US">Operating loss carryforward</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_OperatingLossCarryforwardsExpirationYear" xlink:label="loc_sclx_OperatingLossCarryforwardsExpirationYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_OperatingLossCarryforwardsExpirationYear" xml:lang="en-US">Operating Loss Carryforwards Expiration Year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_OperatingLossCarryforwardsExpirationYear" xml:lang="en-US">Operating loss carryforward expiration year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_OperatingLossCarryforwardsExpirationYear" xlink:to="lab_sclx_OperatingLossCarryforwardsExpirationYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_OperatingLossCarryforwardsExpirationYear" xml:lang="en-US">Operating loss carryforwards expiration year.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xml:lang="en-US">Tax Credit Carryforward, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xml:lang="en-US">Tax credit carryforward</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TaxCreditCarryforwardExpirationYear" xlink:label="loc_sclx_TaxCreditCarryforwardExpirationYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_TaxCreditCarryforwardExpirationYear" xml:lang="en-US">Tax Credit Carryforward, Expiration Year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_TaxCreditCarryforwardExpirationYear" xml:lang="en-US">Tax credit carryforward expiration year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_TaxCreditCarryforwardExpirationYear" xlink:to="lab_sclx_TaxCreditCarryforwardExpirationYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_TaxCreditCarryforwardExpirationYear" xml:lang="en-US">Tax credit carryforward, expiration year.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MinimumThresholdPercentageForRecognitionOfUncertainIncomeTaxPosition" xlink:label="loc_sclx_MinimumThresholdPercentageForRecognitionOfUncertainIncomeTaxPosition" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_MinimumThresholdPercentageForRecognitionOfUncertainIncomeTaxPosition" xml:lang="en-US">Minimum Threshold Percentage for Recognition of Uncertain Income Tax Position</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_MinimumThresholdPercentageForRecognitionOfUncertainIncomeTaxPosition" xml:lang="en-US">Minimum threshold percentage for recognition of uncertain income tax position</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_MinimumThresholdPercentageForRecognitionOfUncertainIncomeTaxPosition" xlink:to="lab_sclx_MinimumThresholdPercentageForRecognitionOfUncertainIncomeTaxPosition" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_MinimumThresholdPercentageForRecognitionOfUncertainIncomeTaxPosition" xml:lang="en-US">Minimum threshold percentage for recognition of uncertain income tax position.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xml:lang="en-US">Income Tax Examination, Penalties and Interest Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xml:lang="en-US">Income tax examination, penalties and interest expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:to="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xml:lang="en-US">Effective tax rates</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xml:lang="en-US">Income Tax Benefit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Statutory federal tax rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Statutory Federal Income Tax Rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xml:lang="en-US">Income Tax Authority [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xml:lang="en-US">Income Tax Authority [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DomesticCountryMember" xml:lang="en-US">Domestic Tax Authority [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DomesticCountryMember" xml:lang="en-US">Federal [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xml:lang="en-US">State and Local Jurisdiction [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xml:lang="en-US">State [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xml:lang="en-US">Income Tax Expense (Benefit), Continuing Operations [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xml:lang="en-US">Current expense:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xml:lang="en-US">Current Federal Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xml:lang="en-US">Federal</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xml:lang="en-US">Current Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xml:lang="en-US">Current income tax expense (benefit)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xml:lang="en-US">State</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xml:lang="en-US">Deferred</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xml:lang="en-US">Federal</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xml:lang="en-US">State</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred income tax expense (benefit)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xml:lang="en-US">Components of Deferred Tax Assets and Liabilities [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xml:lang="en-US">Deferred Tax Liabilities, Net [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xml:lang="en-US">Deferred Tax Liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xml:lang="en-US">Amortization of intangibles</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xml:lang="en-US">Deferred Tax Liabilities, Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xml:lang="en-US">Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xml:lang="en-US">Deferred Tax Liabilities, Leasing Arrangements</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xml:lang="en-US">Operating lease&#160;right-of-use&#160;assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xml:lang="en-US">Deferred Tax Liabilities, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xml:lang="en-US">Total Deferred Tax Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xml:lang="en-US">Components of Deferred Tax Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xml:lang="en-US">Deferred tax assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xml:lang="en-US">Total Deferred Tax Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xml:lang="en-US">Stock based compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="loc_sclx_DeferredTaxAssetsOperatingLeaseLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DeferredTaxAssetsOperatingLeaseLiabilities" xml:lang="en-US">Deferred Tax Assets Operating Lease Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_DeferredTaxAssetsOperatingLeaseLiabilities" xml:lang="en-US">Operating lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:to="lab_sclx_DeferredTaxAssetsOperatingLeaseLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_DeferredTaxAssetsOperatingLeaseLiabilities" xml:lang="en-US">Deferred tax assets operating lease liabilities.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xml:lang="en-US">Deferred Tax Assets, Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xml:lang="en-US">Others</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xml:lang="en-US">Deferred Tax Assets, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xml:lang="en-US">Total Deferred Tax Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DeferredTaxAssetsInterestExpenseLimitations" xlink:label="loc_sclx_DeferredTaxAssetsInterestExpenseLimitations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_DeferredTaxAssetsInterestExpenseLimitations" xml:lang="en-US">Deferred Tax Assets Interest expense limitations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_DeferredTaxAssetsInterestExpenseLimitations" xml:lang="en-US">Interest expense limitations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_DeferredTaxAssetsInterestExpenseLimitations" xlink:to="lab_sclx_DeferredTaxAssetsInterestExpenseLimitations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_DeferredTaxAssetsInterestExpenseLimitations" xml:lang="en-US">Deferred tax assets interest expense limitations.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xml:lang="en-US">Tax credit carryforwards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xml:lang="en-US">Net operating loss carryforwards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xml:lang="en-US">In-process&#160;research and development</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustmentsAndCarryback" xlink:label="loc_sclx_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustmentsAndCarryback" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustmentsAndCarryback" xml:lang="en-US">Effective Income Tax Rate Reconciliation Return to Provision Adjustments and Carryback</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustmentsAndCarryback" xml:lang="en-US">Return to provision adjustments and carryback</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustmentsAndCarryback" xlink:to="lab_sclx_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustmentsAndCarryback" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustmentsAndCarryback" xml:lang="en-US">Effective income tax rate reconciliation return to provision adjustments and carryback.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xml:lang="en-US">Others</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Change in valuation allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xml:lang="en-US">State taxes, net of federal tax benefit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_EffectiveIncomeTaxRateReconciliationDebtDiscountAndInterestLimitation" xlink:label="loc_sclx_EffectiveIncomeTaxRateReconciliationDebtDiscountAndInterestLimitation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_EffectiveIncomeTaxRateReconciliationDebtDiscountAndInterestLimitation" xml:lang="en-US">Effective Income Tax Rate Reconciliation Debt Discount and Interest Limitation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_EffectiveIncomeTaxRateReconciliationDebtDiscountAndInterestLimitation" xml:lang="en-US">Debt discount and interest limitation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_EffectiveIncomeTaxRateReconciliationDebtDiscountAndInterestLimitation" xlink:to="lab_sclx_EffectiveIncomeTaxRateReconciliationDebtDiscountAndInterestLimitation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_EffectiveIncomeTaxRateReconciliationDebtDiscountAndInterestLimitation" xml:lang="en-US">Effective income tax rate reconciliation debt discount and interest limitation.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share, amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xml:lang="en-US">Denominator for Basic Loss Per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DilutiveSecurities" xlink:label="loc_us-gaap_DilutiveSecurities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DilutiveSecurities" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DilutiveSecurities" xml:lang="en-US">Effect of Dilutive Securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DilutiveSecurities" xlink:to="lab_us-gaap_DilutiveSecurities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xml:lang="en-US">Denominator for Diluted Loss per Share &#8212; Adjusted for Dilutive Securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SubsequentEventsDetailsTable" xlink:label="loc_sclx_SubsequentEventsDetailsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SubsequentEventsDetailsTable" xml:lang="en-US">Subsequent Events (Details) [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SubsequentEventsDetailsTable" xlink:to="lab_sclx_SubsequentEventsDetailsTable" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SubsequentEventsDetailsLineItems" xlink:label="loc_sclx_SubsequentEventsDetailsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SubsequentEventsDetailsLineItems" xml:lang="en-US">Subsequent Events (Details) [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems" xlink:to="lab_sclx_SubsequentEventsDetailsLineItems" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SponsorLoan" xlink:label="loc_sclx_SponsorLoan" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SponsorLoan" xml:lang="en-US">Sponsor Loan</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_SponsorLoan" xml:lang="en-US">Sponsor loan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SponsorLoan" xlink:to="lab_sclx_SponsorLoan" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_SponsorLoan" xml:lang="en-US">Sponsor loan.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_WarrantExercisePrice" xlink:label="loc_sclx_WarrantExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_WarrantExercisePrice" xml:lang="en-US">Warrant Exercise Price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_WarrantExercisePrice" xlink:to="lab_sclx_WarrantExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_WarrantExercisePrice" xml:lang="en-US">Warrant exercise price.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AdditionalPrincipalAmount" xlink:label="loc_sclx_AdditionalPrincipalAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AdditionalPrincipalAmount" xml:lang="en-US">Additional Principal Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_AdditionalPrincipalAmount" xml:lang="en-US">Additional principal amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AdditionalPrincipalAmount" xlink:to="lab_sclx_AdditionalPrincipalAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AdditionalPrincipalAmount" xml:lang="en-US">Additional principal amount.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ConvertiblePromissoryNote" xlink:label="loc_sclx_ConvertiblePromissoryNote" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_ConvertiblePromissoryNote" xml:lang="en-US">Convertible Promissory Note</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_ConvertiblePromissoryNote" xlink:to="lab_sclx_ConvertiblePromissoryNote" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_ConvertiblePromissoryNote" xml:lang="en-US">Convertible promissory note.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseDepositLiability" xlink:label="loc_us-gaap_LeaseDepositLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseDepositLiability" xml:lang="en-US">Lease Deposit Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeaseDepositLiability" xml:lang="en-US">Sponsors deposited (in Dollars)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseDepositLiability" xlink:to="lab_us-gaap_LeaseDepositLiability" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockNoParValue" xlink:label="loc_us-gaap_CommonStockNoParValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockNoParValue" xml:lang="en-US">Common Stock, No Par Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockNoParValue" xml:lang="en-US">Common stock par value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNoParValue" xlink:to="lab_us-gaap_CommonStockNoParValue" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NumberOfSharesLimits" xlink:label="loc_sclx_NumberOfSharesLimits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_NumberOfSharesLimits" xml:lang="en-US">Number Of Shares Limits</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_NumberOfSharesLimits" xml:lang="en-US">Number of shares (in Shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_NumberOfSharesLimits" xlink:to="lab_sclx_NumberOfSharesLimits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_NumberOfSharesLimits" xml:lang="en-US">Number of shares limits.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SalesThresholdLimit" xlink:label="loc_sclx_SalesThresholdLimit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_SalesThresholdLimit" xml:lang="en-US">Sales Threshold Limit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_SalesThresholdLimit" xml:lang="en-US">Sales threshold limit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_SalesThresholdLimit" xlink:to="lab_sclx_SalesThresholdLimit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_SalesThresholdLimit" xml:lang="en-US">Sales threshold limit.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfPurchasePriceInCashEqualIsToPrincipalAmountOfTheLoan" xlink:label="loc_sclx_PercentageOfPurchasePriceInCashEqualIsToPrincipalAmountOfTheLoan" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PercentageOfPurchasePriceInCashEqualIsToPrincipalAmountOfTheLoan" xml:lang="en-US">Percentage Of Purchase Price In Cash Equal Is To Principal Amount Of The Loan</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_PercentageOfPurchasePriceInCashEqualIsToPrincipalAmountOfTheLoan" xml:lang="en-US">Percentage of purchase price in cash equal is to principal amount of the loan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PercentageOfPurchasePriceInCashEqualIsToPrincipalAmountOfTheLoan" xlink:to="lab_sclx_PercentageOfPurchasePriceInCashEqualIsToPrincipalAmountOfTheLoan" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PercentageOfPurchasePriceInCashEqualIsToPrincipalAmountOfTheLoan" xml:lang="en-US">Percentage of purchase price in cash equal is to principal amount of the loan.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MinimumTimeDeclaredToFileWithSecRegardingResaleRegistrationStatement" xlink:label="loc_sclx_MinimumTimeDeclaredToFileWithSecRegardingResaleRegistrationStatement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_MinimumTimeDeclaredToFileWithSecRegardingResaleRegistrationStatement" xml:lang="en-US">Minimum Time Declared To File With SEC Regarding Resale Registration Statement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_sclx_MinimumTimeDeclaredToFileWithSecRegardingResaleRegistrationStatement" xml:lang="en-US">Minimum time declared to file with sec regarding resale registration statement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_MinimumTimeDeclaredToFileWithSecRegardingResaleRegistrationStatement" xlink:to="lab_sclx_MinimumTimeDeclaredToFileWithSecRegardingResaleRegistrationStatement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_MinimumTimeDeclaredToFileWithSecRegardingResaleRegistrationStatement" xml:lang="en-US">Minimum time declared to file with sec regarding resale registration statement.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAssumed1" xlink:label="loc_us-gaap_LiabilitiesAssumed1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAssumed1" xml:lang="en-US">Liabilities Assumed</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesAssumed1" xml:lang="en-US">Liabilities assumed in a non cash transaction</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAssumed1" xlink:to="lab_us-gaap_LiabilitiesAssumed1" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PeriodAfterRegistrationWhenTheRequestCouldBeMadeToTheInvesteeToPurchaseTheShares" xlink:label="loc_sclx_PeriodAfterRegistrationWhenTheRequestCouldBeMadeToTheInvesteeToPurchaseTheShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PeriodAfterRegistrationWhenTheRequestCouldBeMadeToTheInvesteeToPurchaseTheShares" xml:lang="en-US">Period After Registration When The Request Could Be Made To The Investee To Purchase The Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PeriodAfterRegistrationWhenTheRequestCouldBeMadeToTheInvesteeToPurchaseTheShares" xlink:to="lab_sclx_PeriodAfterRegistrationWhenTheRequestCouldBeMadeToTheInvesteeToPurchaseTheShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PeriodAfterRegistrationWhenTheRequestCouldBeMadeToTheInvesteeToPurchaseTheShares" xml:lang="en-US">Period after registration when the request could be made to the investee to purchase the shares.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MaximumPercentageOfVolumeWeightedAveragePriceOfSharesMeasuredOnADailyBasisThatIsEligibleToBeReceivedAsAdvance" xlink:label="loc_sclx_MaximumPercentageOfVolumeWeightedAveragePriceOfSharesMeasuredOnADailyBasisThatIsEligibleToBeReceivedAsAdvance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_MaximumPercentageOfVolumeWeightedAveragePriceOfSharesMeasuredOnADailyBasisThatIsEligibleToBeReceivedAsAdvance" xml:lang="en-US">Maximum Percentage Of Volume Weighted Average Price Of Shares Measured On A Daily Basis That Is Eligible To Be Received As Advance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_MaximumPercentageOfVolumeWeightedAveragePriceOfSharesMeasuredOnADailyBasisThatIsEligibleToBeReceivedAsAdvance" xlink:to="lab_sclx_MaximumPercentageOfVolumeWeightedAveragePriceOfSharesMeasuredOnADailyBasisThatIsEligibleToBeReceivedAsAdvance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_MaximumPercentageOfVolumeWeightedAveragePriceOfSharesMeasuredOnADailyBasisThatIsEligibleToBeReceivedAsAdvance" xml:lang="en-US">Maximum percentage of volume weighted average price of shares measured on a daily basis that is eligible to be received as advance.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NumberOfThresholdTradingDaysPriorToDateOfNoticeToTheShareholdersForDeterminingTheVolumeWeightedAveragePriceOfShares" xlink:label="loc_sclx_NumberOfThresholdTradingDaysPriorToDateOfNoticeToTheShareholdersForDeterminingTheVolumeWeightedAveragePriceOfShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_NumberOfThresholdTradingDaysPriorToDateOfNoticeToTheShareholdersForDeterminingTheVolumeWeightedAveragePriceOfShares" xml:lang="en-US">Number Of Threshold Trading Days Prior To Date Of Notice To The Shareholders For Determining The Volume Weighted Average Price Of Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_NumberOfThresholdTradingDaysPriorToDateOfNoticeToTheShareholdersForDeterminingTheVolumeWeightedAveragePriceOfShares" xlink:to="lab_sclx_NumberOfThresholdTradingDaysPriorToDateOfNoticeToTheShareholdersForDeterminingTheVolumeWeightedAveragePriceOfShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_NumberOfThresholdTradingDaysPriorToDateOfNoticeToTheShareholdersForDeterminingTheVolumeWeightedAveragePriceOfShares" xml:lang="en-US">Number of threshold trading days prior to date of notice to the shareholders for determining the volume weighted average price of shares.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfDailyVolumeWeightedAveragePriceOfSharesAtWhichTheSharesAreEligibleToBePurchased" xlink:label="loc_sclx_PercentageOfDailyVolumeWeightedAveragePriceOfSharesAtWhichTheSharesAreEligibleToBePurchased" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PercentageOfDailyVolumeWeightedAveragePriceOfSharesAtWhichTheSharesAreEligibleToBePurchased" xml:lang="en-US">Percentage Of Daily Volume Weighted Average Price Of Shares At Which The Shares Are Eligible To Be Purchased</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PercentageOfDailyVolumeWeightedAveragePriceOfSharesAtWhichTheSharesAreEligibleToBePurchased" xlink:to="lab_sclx_PercentageOfDailyVolumeWeightedAveragePriceOfSharesAtWhichTheSharesAreEligibleToBePurchased" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PercentageOfDailyVolumeWeightedAveragePriceOfSharesAtWhichTheSharesAreEligibleToBePurchased" xml:lang="en-US">Percentage of daily volume weighted average price of shares at which the shares are eligible to be purchased.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NumberOfConsecutiveTradingDaysForDeterminingTheVolumeWeightedAveragePriceOfShares" xlink:label="loc_sclx_NumberOfConsecutiveTradingDaysForDeterminingTheVolumeWeightedAveragePriceOfShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_NumberOfConsecutiveTradingDaysForDeterminingTheVolumeWeightedAveragePriceOfShares" xml:lang="en-US">Number Of Consecutive Trading Days For Determining The Volume Weighted Average Price Of Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_NumberOfConsecutiveTradingDaysForDeterminingTheVolumeWeightedAveragePriceOfShares" xlink:to="lab_sclx_NumberOfConsecutiveTradingDaysForDeterminingTheVolumeWeightedAveragePriceOfShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_NumberOfConsecutiveTradingDaysForDeterminingTheVolumeWeightedAveragePriceOfShares" xml:lang="en-US">Number of consecutive trading days for determining the volume weighted average price of shares.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesSubscriptions" xlink:label="loc_us-gaap_CommonStockSharesSubscriptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesSubscriptions" xml:lang="en-US">Common Stock, Value, Subscriptions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesSubscriptions" xml:lang="en-US">Common stock shares subscribed but not issued value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesSubscriptions" xlink:to="lab_us-gaap_CommonStockSharesSubscriptions" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_YorkvilleMember" xlink:label="loc_sclx_YorkvilleMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_YorkvilleMember" xml:lang="en-US">Yorkville [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_YorkvilleMember" xlink:to="lab_sclx_YorkvilleMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_YorkvilleMember" xml:lang="en-US">Yorkville.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_B.RileyMember" xlink:label="loc_sclx_B.RileyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_B.RileyMember" xml:lang="en-US">B. Riley [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_B.RileyMember" xlink:to="lab_sclx_B.RileyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_B.RileyMember" xml:lang="en-US">B. Riley.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_StandbyEquityPurchaseAgreementMember" xlink:label="loc_sclx_StandbyEquityPurchaseAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_StandbyEquityPurchaseAgreementMember" xml:lang="en-US">Standby Equity Purchase Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_StandbyEquityPurchaseAgreementMember" xlink:to="lab_sclx_StandbyEquityPurchaseAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_StandbyEquityPurchaseAgreementMember" xml:lang="en-US">Standby equity purchase agreement.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AgreementWithCertainOfTheThirdPartyProfessionalServiceProvidersMember" xlink:label="loc_sclx_AgreementWithCertainOfTheThirdPartyProfessionalServiceProvidersMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_AgreementWithCertainOfTheThirdPartyProfessionalServiceProvidersMember" xml:lang="en-US">Agreement With Certain Of The Third Party Professional Service Providers [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_AgreementWithCertainOfTheThirdPartyProfessionalServiceProvidersMember" xlink:to="lab_sclx_AgreementWithCertainOfTheThirdPartyProfessionalServiceProvidersMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_AgreementWithCertainOfTheThirdPartyProfessionalServiceProvidersMember" xml:lang="en-US">Agreement with certain of the third party professional service providers.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xml:lang="en-US">Balance Sheet Location [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xml:lang="en-US">Balance Sheet Location [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableMember" xlink:label="loc_us-gaap_AccountsPayableMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableMember" xml:lang="en-US">Accounts Payable [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableMember" xlink:to="lab_us-gaap_AccountsPayableMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="loc_us-gaap_AccruedLiabilitiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedLiabilitiesMember" xml:lang="en-US">Accrued Liabilities [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesMember" xlink:to="lab_us-gaap_AccruedLiabilitiesMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ProductOrServiceAxis" xml:lang="en-US">Product and Service [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ProductsAndServicesDomain" xml:lang="en-US">Product and Service [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PurchasetypeAMember" xlink:label="loc_sclx_PurchasetypeAMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PurchasetypeAMember" xml:lang="en-US">PurchaseType A [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PurchasetypeAMember" xlink:to="lab_sclx_PurchasetypeAMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PurchasetypeAMember" xml:lang="en-US">Purchase-type A.</label>
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PurchasetypeBMember" xlink:label="loc_sclx_PurchasetypeBMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_sclx_PurchasetypeBMember" xml:lang="en-US">PurchaseType B [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sclx_PurchasetypeBMember" xlink:to="lab_sclx_PurchasetypeBMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_sclx_PurchasetypeBMember" xml:lang="en-US">Purchase-Type B</label>
</labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>sclx-20220930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 12-January-2023 [12:41:39] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#CoverPage" roleURI="http://www.vickersvantagecorp.com/role/CoverPage" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#CondensedConsolidatedBalanceSheets" roleURI="http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#CondensedConsolidatedBalanceSheetsParentheticals" roleURI="http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheetsParentheticals" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#UnauditedCondensedConsolidatedStatementsOfOperations" roleURI="http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#UnauditedCondensedConsolidatedStatementsOfOperationsParentheticals" roleURI="http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsParentheticals" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit" roleURI="http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#UnauditedCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#DescriptionOfOrganizationAndBusinessOperations" roleURI="http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperations" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPolicies" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#LiquidityAndGoingConcern" roleURI="http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcern" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#PublicOffering" roleURI="http://www.vickersvantagecorp.com/role/PublicOffering" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#PrivatePlacement" roleURI="http://www.vickersvantagecorp.com/role/PrivatePlacement" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#Acquisitions" roleURI="http://www.vickersvantagecorp.com/role/Acquisitions" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#RelatedPartyTransactions" roleURI="http://www.vickersvantagecorp.com/role/RelatedPartyTransactions" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#FairValueMeasurements" roleURI="http://www.vickersvantagecorp.com/role/FairValueMeasurements" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#PropertyAndEquipment" roleURI="http://www.vickersvantagecorp.com/role/PropertyAndEquipment" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#GoodwillAndIntangibleAssets" roleURI="http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssets" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#Debt" roleURI="http://www.vickersvantagecorp.com/role/Debt" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#Warrants" roleURI="http://www.vickersvantagecorp.com/role/Warrants" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#ShareholdersDeficit" roleURI="http://www.vickersvantagecorp.com/role/ShareholdersDeficit" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#StockIncentiveAndEmployeeBenefitPlans" roleURI="http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlans" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#CommitmentsAndContingencies" roleURI="http://www.vickersvantagecorp.com/role/CommitmentsAndContingencies" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#RestatementOfPreviouslyIssuedFinancialStatements" roleURI="http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatements" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#IncomeTaxes" roleURI="http://www.vickersvantagecorp.com/role/IncomeTaxes" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#LossPerShare" roleURI="http://www.vickersvantagecorp.com/role/LossPerShare" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#SubsequentEvents" roleURI="http://www.vickersvantagecorp.com/role/SubsequentEvents" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#AccountingPoliciesByPolicyPolicies" roleURI="http://www.vickersvantagecorp.com/role/AccountingPoliciesByPolicyPolicies" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesTables" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#FairValueMeasurementsTables" roleURI="http://www.vickersvantagecorp.com/role/FairValueMeasurementsTables" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#PropertyAndEquipmentTables" roleURI="http://www.vickersvantagecorp.com/role/PropertyAndEquipmentTables" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#GoodwillAndIntangibleAssetsTables" roleURI="http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsTables" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#DebtTables" roleURI="http://www.vickersvantagecorp.com/role/DebtTables" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#StockIncentiveAndEmployeeBenefitPlansTables" roleURI="http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansTables" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#CommitmentsAndContingenciesTables" roleURI="http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesTables" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#RestatementOfPreviouslyIssuedFinancialStatementsTables" roleURI="http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsTables" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#IncomeTaxesTables" roleURI="http://www.vickersvantagecorp.com/role/IncomeTaxesTables" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#LossPerShareTables" roleURI="http://www.vickersvantagecorp.com/role/LossPerShareTables" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#DescriptionOfOrganizationAndBusinessOperationsDetails" roleURI="http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#SummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#SummaryOfSignificantAccountingPoliciesDetailsScheduleOfOrdinarySharesReflectedInCondensedConsolidatedBalanceSheetsAreReconciled" roleURI="http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfOrdinarySharesReflectedInCondensedConsolidatedBalanceSheetsAreReconciled" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#SummaryOfSignificantAccountingPoliciesDetailsScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShare" roleURI="http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShare" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#SummaryOfSignificantAccountingPoliciesDetailsScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareParentheticals" roleURI="http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareParentheticals" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#LiquidityAndGoingConcernDetails" roleURI="http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#PublicOfferingDetails" roleURI="http://www.vickersvantagecorp.com/role/PublicOfferingDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#PrivatePlacementDetails" roleURI="http://www.vickersvantagecorp.com/role/PrivatePlacementDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#RelatedPartyTransactionsDetails" roleURI="http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#CommitmentsAndContingenciesDetails" roleURI="http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#CommitmentsAndContingenciesSummaryOfComponentsOfLeaseExpenseDetail" roleURI="http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesSummaryOfComponentsOfLeaseExpenseDetail" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#CommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetail" roleURI="http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#CommitmentsAndContingenciesSummaryOfSupplementalQuantitativeInformationRelatedToLeasesDetail" roleURI="http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesSummaryOfSupplementalQuantitativeInformationRelatedToLeasesDetail" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#ShareholdersDeficitDetails" roleURI="http://www.vickersvantagecorp.com/role/ShareholdersDeficitDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#WarrantsDetails" roleURI="http://www.vickersvantagecorp.com/role/WarrantsDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#FairValueMeasurementsDetails" roleURI="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#FairValueMeasurementsDetailsScheduleOfFairValueHierarchyOfTheValuationInputs" roleURI="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfFairValueHierarchyOfTheValuationInputs" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#FairValueMeasurementsDetailsScheduleOfChangesInTheFairValueOfWarrantLiabilitiesAndConversionOptionLiability" roleURI="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfChangesInTheFairValueOfWarrantLiabilitiesAndConversionOptionLiability" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#FairValueMeasurementsDetailsScheduleOfValuedUsingTheCompoundOptionPricingModel" roleURI="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfValuedUsingTheCompoundOptionPricingModel" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#FairValueMeasurementsDetailsFinancialAssetsAndLiabilitiesThatAreMeasuredAtFairValue" roleURI="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsFinancialAssetsAndLiabilitiesThatAreMeasuredAtFairValue" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#FairValueMeasurementsDetailsDerivativeLiabilitiesMeasuredAtFairValueUsingSignificantUnobservableInputs" roleURI="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsDerivativeLiabilitiesMeasuredAtFairValueUsingSignificantUnobservableInputs" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#FairValueMeasurementsDetailsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurements" roleURI="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurements" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#FairValueMeasurementsDetailsScheduleOfChangeInTheFairValueOfConversionOptionLiability" roleURI="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfChangeInTheFairValueOfConversionOptionLiability" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#PropertyAndEquipmentDetailsPropertyAndEquipmentConsisted" roleURI="http://www.vickersvantagecorp.com/role/PropertyAndEquipmentDetailsPropertyAndEquipmentConsisted" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#PropertyAndEquipmentDetails" roleURI="http://www.vickersvantagecorp.com/role/PropertyAndEquipmentDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#GoodwillAndIntangibleAssetsDetailsSummaryOfTheCompanysIdentifiableIntangibleAssets" roleURI="http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfTheCompanysIdentifiableIntangibleAssets" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#GoodwillAndIntangibleAssetsDetailsSummaryOfEstimatedFutureAmortizationExpense" roleURI="http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfEstimatedFutureAmortizationExpense" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#GoodwillAndIntangibleAssetsDetails" roleURI="http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#DebtDetails" roleURI="http://www.vickersvantagecorp.com/role/DebtDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#DebtDetailsSummaryOfBorrowingsOfTheScilexPharmaNotes" roleURI="http://www.vickersvantagecorp.com/role/DebtDetailsSummaryOfBorrowingsOfTheScilexPharmaNotes" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#DebtDetailsSummaryOfFutureMinimumPaymentsUnderTheScilexPharmaNotes" roleURI="http://www.vickersvantagecorp.com/role/DebtDetailsSummaryOfFutureMinimumPaymentsUnderTheScilexPharmaNotes" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#StockIncentiveAndEmployeeBenefitPlansDetails" roleURI="http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfShareBasedPaymentAwardOptionsIssuedToEmployeesAndNonemployeesValuationAssumptions" roleURI="http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfShareBasedPaymentAwardOptionsIssuedToEmployeesAndNonemployeesValuationAssumptions" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfTheOptionsOutstanding" roleURI="http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfTheOptionsOutstanding" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#AcquisitionsDetails" roleURI="http://www.vickersvantagecorp.com/role/AcquisitionsDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#RestatementOfPreviouslyIssuedFinancialStatementsDetails" roleURI="http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#RestatementOfPreviouslyIssuedFinancialStatementsDetailsScheduleOfImpactOfTheseAdjustmentsToTheFinancialStatementAsPreviouslyReported" roleURI="http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsDetailsScheduleOfImpactOfTheseAdjustmentsToTheFinancialStatementAsPreviouslyReported" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#IncomeTaxesDetails" roleURI="http://www.vickersvantagecorp.com/role/IncomeTaxesDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#IncomeTaxesDetailsScheduleOfComponentsOfIncomeTaxExpenseBenefit" roleURI="http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfComponentsOfIncomeTaxExpenseBenefit" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#IncomeTaxesDetailsScheduleOfDeferredTaxAssetsAndLiabilities" roleURI="http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfDeferredTaxAssetsAndLiabilities" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#IncomeTaxesDetailsScheduleOfEffectiveIncomeTaxRateReconciliation" roleURI="http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfEffectiveIncomeTaxRateReconciliation" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#LossPerShareDetails" roleURI="http://www.vickersvantagecorp.com/role/LossPerShareDetails" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#LossPerShareDetailsSummaryOfReconciliationOfBasicAndDilutedLossPerShare" roleURI="http://www.vickersvantagecorp.com/role/LossPerShareDetailsSummaryOfReconciliationOfBasicAndDilutedLossPerShare" />
<roleRef xlink:type="simple" xlink:href="sclx-20220930.xsd#SubsequentEventsDetails" roleURI="http://www.vickersvantagecorp.com/role/SubsequentEventsDetails" />
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/CoverPage">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_2146634689" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_2146634690" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2146634689" xlink:to="loc_dei_DocumentType_2146634690" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_2146634691" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2146634689" xlink:to="loc_dei_AmendmentFlag_2146634691" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_2146634692" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2146634689" xlink:to="loc_dei_EntityRegistrantName_2146634692" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_2146634693" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2146634689" xlink:to="loc_dei_EntityCentralIndexKey_2146634693" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_2146634810" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2146634689" xlink:to="loc_dei_EntityFilerCategory_2146634810" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_2146634811" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2146634689" xlink:to="loc_dei_EntitySmallBusiness_2146634811" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_2146634812" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2146634689" xlink:to="loc_dei_EntityEmergingGrowthCompany_2146634812" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_2146634813" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2146634689" xlink:to="loc_dei_EntityExTransitionPeriod_2146634813" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_2146635007" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_31" xlink:to="loc_us-gaap_StatementTable_2146635007" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635012" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2146635007" xlink:to="loc_dei_LegalEntityAxis_2146635012" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635013" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2146635012" xlink:to="loc_dei_EntityDomain_2146635013" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635014" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146635013" xlink:to="loc_sclx_VickersVantageMember_2146635014" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2146635010" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2146635007" xlink:to="loc_us-gaap_StatementLineItems_2146635010" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_32" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635010" xlink:to="loc_us-gaap_AssetsAbstract_32" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_33" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_32" xlink:to="loc_us-gaap_AssetsCurrentAbstract_33" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2146635253" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_33" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2146635253" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_2146635260" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_33" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_2146635260" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_2146635255" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_33" xlink:to="loc_us-gaap_InventoryNet_2146635255" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_37" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_33" xlink:to="loc_us-gaap_Cash_37" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_38" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_33" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_38" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_39" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_33" xlink:to="loc_us-gaap_AssetsCurrent_39" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2146635263" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_32" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_2146635263" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_2146635264" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_32" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_2146635264" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_2146635265" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_32" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_2146635265" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_2146635266" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_32" xlink:to="loc_us-gaap_Goodwill_2146635266" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments_2146635267" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_32" xlink:to="loc_us-gaap_LongTermInvestments_2146635267" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCosts" xlink:label="loc_us-gaap_DeferredCosts_2146635611" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_32" xlink:to="loc_us-gaap_DeferredCosts_2146635611" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsHeldInTrustNoncurrent" xlink:label="loc_us-gaap_AssetsHeldInTrustNoncurrent_40" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_32" xlink:to="loc_us-gaap_AssetsHeldInTrustNoncurrent_40" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_41" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635010" xlink:to="loc_us-gaap_Assets_41" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_34" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635010" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_34" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_35" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_34" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_35" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_2146635268" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_35" xlink:to="loc_us-gaap_AccountsPayableCurrent_2146635268" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AccruedPayroll" xlink:label="loc_sclx_AccruedPayroll_2146635274" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_35" xlink:to="loc_sclx_AccruedPayroll_2146635274" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_2146635277" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_35" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_2146635277" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_2146635886" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_35" xlink:to="loc_us-gaap_DeferredRevenueCurrent_2146635886" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_2146635280" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_35" xlink:to="loc_us-gaap_LongTermDebtCurrent_2146635280" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_2146635284" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_35" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_2146635284" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_RelatedPartyNotePayableCurrent" xlink:label="loc_sclx_RelatedPartyNotePayableCurrent_2146635287" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_35" xlink:to="loc_sclx_RelatedPartyNotePayableCurrent_2146635287" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_2146635288" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_35" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_2146635288" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_43" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_35" xlink:to="loc_us-gaap_LiabilitiesCurrent_43" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_42" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_35" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_42" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_2146635615" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_35" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_2146635615" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AdvancesFromRelatedParty" xlink:label="loc_sclx_AdvancesFromRelatedParty_2146635619" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_35" xlink:to="loc_sclx_AdvancesFromRelatedParty_2146635619" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:label="loc_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent_2146635621" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_35" xlink:to="loc_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent_2146635621" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_2146635887" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_34" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_2146635887" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_2146635294" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_34" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_2146635294" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_RelatedPartyNotePayableNoncurrent" xlink:label="loc_sclx_RelatedPartyNotePayableNoncurrent_2146635295" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_34" xlink:to="loc_sclx_RelatedPartyNotePayableNoncurrent_2146635295" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DerivativeLiabilityNoncurrent" xlink:label="loc_sclx_DerivativeLiabilityNoncurrent_2146635299" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_34" xlink:to="loc_sclx_DerivativeLiabilityNoncurrent_2146635299" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2146635300" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_34" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2146635300" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable_44" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_34" xlink:to="loc_us-gaap_ConvertibleLongTermNotesPayable_44" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_45" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_34" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_45" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLongTermNotesPayable" xlink:label="loc_us-gaap_OtherLongTermNotesPayable_46" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_34" xlink:to="loc_us-gaap_OtherLongTermNotesPayable_46" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent" xlink:label="loc_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent_47" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_34" xlink:to="loc_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent_47" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_48" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_34" xlink:to="loc_us-gaap_DerivativeLiabilities_48" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:label="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_49" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_34" xlink:to="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_49" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_50" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635010" xlink:to="loc_us-gaap_Liabilities_50" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_51" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635010" xlink:to="loc_us-gaap_CommitmentsAndContingencies_51" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_36" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635010" xlink:to="loc_us-gaap_StockholdersEquityAbstract_36" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_53" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_36" xlink:to="loc_us-gaap_PreferredStockValue_53" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_54" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_36" xlink:to="loc_us-gaap_CommonStockValue_54" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_55" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_36" xlink:to="loc_us-gaap_AdditionalPaidInCapital_55" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_56" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_36" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_56" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_52" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635010" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_52" use="optional" order="55" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_57" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635010" xlink:to="loc_us-gaap_StockholdersEquity_57" use="optional" order="56" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_58" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635010" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_58" use="optional" order="57" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheetsParentheticals">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_72" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_2146635025" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_72" xlink:to="loc_us-gaap_StatementTable_2146635025" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635031" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2146635025" xlink:to="loc_dei_LegalEntityAxis_2146635031" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635032" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2146635031" xlink:to="loc_dei_EntityDomain_2146635032" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635033" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146635032" xlink:to="loc_sclx_VickersVantageMember_2146635033" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2146635316" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2146635025" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2146635316" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2146635317" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2146635316" xlink:to="loc_us-gaap_ClassOfStockDomain_2146635317" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_2146635318" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_2146635317" xlink:to="loc_us-gaap_CommonClassAMember_2146635318" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_2146637179" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2146635025" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_2146637179" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2146637180" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2146637179" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2146637180" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_2146637181" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2146637180" xlink:to="loc_us-gaap_OverAllotmentOptionMember_2146637181" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2146635028" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2146635025" xlink:to="loc_us-gaap_StatementLineItems_2146635028" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_OrdinarySharesSubjectToPossibleRedemption" xlink:label="loc_sclx_OrdinarySharesSubjectToPossibleRedemption_73" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635028" xlink:to="loc_sclx_OrdinarySharesSubjectToPossibleRedemption_73" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityRedemptionPricePerShare" xlink:label="loc_us-gaap_TemporaryEquityRedemptionPricePerShare_74" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635028" xlink:to="loc_us-gaap_TemporaryEquityRedemptionPricePerShare_74" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_75" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635028" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_75" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_76" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635028" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_76" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_77" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635028" xlink:to="loc_us-gaap_PreferredStockSharesIssued_77" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_78" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635028" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_78" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_79" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635028" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_79" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_80" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635028" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_80" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_81" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635028" xlink:to="loc_us-gaap_CommonStockSharesIssued_81" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_82" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635028" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_82" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SubjectToPossibleRedemptionPerShares" xlink:label="loc_sclx_SubjectToPossibleRedemptionPerShares_2146635676" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635028" xlink:to="loc_sclx_SubjectToPossibleRedemptionPerShares_2146635676" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_OrdinarySharesRedemptionSubjectedToForfeiture" xlink:label="loc_sclx_OrdinarySharesRedemptionSubjectedToForfeiture_2146637178" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635028" xlink:to="loc_sclx_OrdinarySharesRedemptionSubjectedToForfeiture_2146637178" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SharesCapitalization" xlink:label="loc_sclx_SharesCapitalization_2146637182" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635028" xlink:to="loc_sclx_SharesCapitalization_2146637182" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_100" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_2146635036" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_100" xlink:to="loc_us-gaap_StatementTable_2146635036" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635042" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2146635036" xlink:to="loc_dei_LegalEntityAxis_2146635042" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635043" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2146635042" xlink:to="loc_dei_EntityDomain_2146635043" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635044" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146635043" xlink:to="loc_sclx_VickersVantageMember_2146635044" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2146635039" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2146635036" xlink:to="loc_us-gaap_StatementLineItems_2146635039" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_2146635331" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635039" xlink:to="loc_us-gaap_Revenues_2146635331" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingCostsAndExpensesAbstract" xlink:label="loc_us-gaap_OperatingCostsAndExpensesAbstract_2146635335" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635039" xlink:to="loc_us-gaap_OperatingCostsAndExpensesAbstract_2146635335" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue_2146635336" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_2146635335" xlink:to="loc_us-gaap_CostOfRevenue_2146635336" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_2146635337" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_2146635335" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_2146635337" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AcquiredinprocessresearchAndDevelopment" xlink:label="loc_sclx_AcquiredinprocessresearchAndDevelopment_2146635338" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_2146635335" xlink:to="loc_sclx_AcquiredinprocessresearchAndDevelopment_2146635338" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_2146635339" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_2146635335" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_2146635339" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_2146635340" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_2146635335" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_2146635340" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="loc_us-gaap_OperatingCostsAndExpenses_2146635341" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_2146635335" xlink:to="loc_us-gaap_OperatingCostsAndExpenses_2146635341" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_103" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635039" xlink:to="loc_us-gaap_OperatingIncomeLoss_103" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAbstract" xlink:label="loc_us-gaap_OtherIncomeAbstract_102" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635039" xlink:to="loc_us-gaap_OtherIncomeAbstract_102" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ChangeInFairValueOfWarrantLiability" xlink:label="loc_sclx_ChangeInFairValueOfWarrantLiability_2146635688" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAbstract_102" xlink:to="loc_sclx_ChangeInFairValueOfWarrantLiability_2146635688" use="optional" order="16" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_104" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAbstract_102" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_104" use="optional" order="17" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfDerivatives" xlink:label="loc_us-gaap_GainLossOnSaleOfDerivatives_105" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAbstract_102" xlink:to="loc_us-gaap_GainLossOnSaleOfDerivatives_105" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TransactionCostsAllocatedToWarrantLiabilities" xlink:label="loc_sclx_TransactionCostsAllocatedToWarrantLiabilities_106" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAbstract_102" xlink:to="loc_sclx_TransactionCostsAllocatedToWarrantLiabilities_106" use="optional" order="19" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:label="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_107" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAbstract_102" xlink:to="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_107" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DistributionsOnMandatorilyRedeemableSecurities" xlink:label="loc_us-gaap_DistributionsOnMandatorilyRedeemableSecurities_108" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAbstract_102" xlink:to="loc_us-gaap_DistributionsOnMandatorilyRedeemableSecurities_108" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaap_InterestIncomeOther_110" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAbstract_102" xlink:to="loc_us-gaap_InterestIncomeOther_110" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_GainLossOnDerivative" xlink:label="loc_sclx_GainLossOnDerivative_2146635366" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAbstract_102" xlink:to="loc_sclx_GainLossOnDerivative_2146635366" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_GainLossOnExtinguishmentOfDebtt" xlink:label="loc_sclx_GainLossOnExtinguishmentOfDebtt_2146635367" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAbstract_102" xlink:to="loc_sclx_GainLossOnExtinguishmentOfDebtt_2146635367" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScilexPharmaNotesPrincipalIncrease" xlink:label="loc_sclx_ScilexPharmaNotesPrincipalIncrease_2146635369" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAbstract_102" xlink:to="loc_sclx_ScilexPharmaNotesPrincipalIncrease_2146635369" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_109" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAbstract_102" xlink:to="loc_us-gaap_InterestExpense_109" use="optional" order="26" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_2146635371" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAbstract_102" xlink:to="loc_us-gaap_InvestmentIncomeInterest_2146635371" use="optional" order="27" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_2146635372" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAbstract_102" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_2146635372" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_111" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635039" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_111" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2146635344" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635039" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2146635344" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_2146635345" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635039" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_2146635345" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_112" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635039" xlink:to="loc_us-gaap_NetIncomeLoss_112" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_114" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635039" xlink:to="loc_us-gaap_EarningsPerShareBasic_114" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_2146635350" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635039" xlink:to="loc_us-gaap_EarningsPerShareDiluted_2146635350" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_113" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635039" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_113" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2146635352" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635039" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2146635352" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsParentheticals">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_120" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_2146635048" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_120" xlink:to="loc_us-gaap_StatementTable_2146635048" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635054" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2146635048" xlink:to="loc_dei_LegalEntityAxis_2146635054" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635055" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2146635054" xlink:to="loc_dei_EntityDomain_2146635055" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635056" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146635055" xlink:to="loc_sclx_VickersVantageMember_2146635056" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2146635051" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2146635048" xlink:to="loc_us-gaap_StatementLineItems_2146635051" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_121" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635051" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_121" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_122" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635051" xlink:to="loc_us-gaap_EarningsPerShareDiluted_122" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_OrdinarySharesRedemptionSubjectedToForfeiture" xlink:label="loc_sclx_OrdinarySharesRedemptionSubjectedToForfeiture_2146637241" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635051" xlink:to="loc_sclx_OrdinarySharesRedemptionSubjectedToForfeiture_2146637241" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_140" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_141" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_140" xlink:to="loc_us-gaap_StatementTable_141" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_142" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_141" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_142" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_147" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_142" xlink:to="loc_us-gaap_EquityComponentDomain_147" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_144" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_147" xlink:to="loc_us-gaap_CommonStockMember_144" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_145" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_147" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_145" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_146" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_147" xlink:to="loc_us-gaap_RetainedEarningsMember_146" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635061" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_141" xlink:to="loc_dei_LegalEntityAxis_2146635061" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635062" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2146635061" xlink:to="loc_dei_EntityDomain_2146635062" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635063" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146635062" xlink:to="loc_sclx_VickersVantageMember_2146635063" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_143" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_141" xlink:to="loc_us-gaap_StatementLineItems_143" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_148" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_143" xlink:to="loc_us-gaap_StockholdersEquity_148" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_149" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_143" xlink:to="loc_us-gaap_SharesOutstanding_149" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetSharesReclassifiedToMandatorilyRedeemableCapitalStockValue" xlink:label="loc_us-gaap_NetSharesReclassifiedToMandatorilyRedeemableCapitalStockValue_150" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_143" xlink:to="loc_us-gaap_NetSharesReclassifiedToMandatorilyRedeemableCapitalStockValue_150" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRedeemedOrCalledDuringPeriodValue" xlink:label="loc_us-gaap_StockRedeemedOrCalledDuringPeriodValue_151" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_143" xlink:to="loc_us-gaap_StockRedeemedOrCalledDuringPeriodValue_151" use="optional" order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_152" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_143" xlink:to="loc_us-gaap_NetIncomeLoss_152" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_2146635387" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_143" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_2146635387" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_2146635388" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_143" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_2146635388" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_2146635390" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_143" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_2146635390" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2146635391" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_143" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2146635391" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_2146635635" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_143" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_2146635635" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_2146635637" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_143" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_2146635637" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_2146635647" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_143" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_2146635647" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_2146635648" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_143" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_2146635648" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_2146635392" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_143" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_2146635392" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2146635394" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_143" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2146635394" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2146635395" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_143" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2146635395" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_2146635397" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_143" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_2146635397" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AdjustmentsToAdditionalPaidInCapitalSharesIssuedInSemnurAcquisition" xlink:label="loc_sclx_AdjustmentsToAdditionalPaidInCapitalSharesIssuedInSemnurAcquisition_2146635398" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_143" xlink:to="loc_sclx_AdjustmentsToAdditionalPaidInCapitalSharesIssuedInSemnurAcquisition_2146635398" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AdjustmentsToAdditionalPaidInCapitalNetOfDiscount" xlink:label="loc_sclx_AdjustmentsToAdditionalPaidInCapitalNetOfDiscount_2146635931" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_143" xlink:to="loc_sclx_AdjustmentsToAdditionalPaidInCapitalNetOfDiscount_2146635931" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AdjustmentsToAdditionalPaidInCapitalDiscountAmortization" xlink:label="loc_sclx_AdjustmentsToAdditionalPaidInCapitalDiscountAmortization_2146635942" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_143" xlink:to="loc_sclx_AdjustmentsToAdditionalPaidInCapitalDiscountAmortization_2146635942" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_153" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_143" xlink:to="loc_us-gaap_StockholdersEquity_153" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_154" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_143" xlink:to="loc_us-gaap_SharesOutstanding_154" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_192" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_2146635066" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_192" xlink:to="loc_us-gaap_StatementTable_2146635066" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635072" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2146635066" xlink:to="loc_dei_LegalEntityAxis_2146635072" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635073" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2146635072" xlink:to="loc_dei_EntityDomain_2146635073" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635074" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146635073" xlink:to="loc_sclx_VickersVantageMember_2146635074" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2146635069" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2146635066" xlink:to="loc_us-gaap_StatementLineItems_2146635069" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_193" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635069" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_193" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_203" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_193" xlink:to="loc_us-gaap_NetIncomeLoss_203" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_194" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_193" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_194" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_FormationCostPaidThroughAdvancesFromAffiliateOfSponsor" xlink:label="loc_sclx_FormationCostPaidThroughAdvancesFromAffiliateOfSponsor_2146635719" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_194" xlink:to="loc_sclx_FormationCostPaidThroughAdvancesFromAffiliateOfSponsor_2146635719" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_2146635627" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_194" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_2146635627" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_2146635628" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_194" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_2146635628" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_2146635594" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_194" xlink:to="loc_us-gaap_InterestPaidNet_2146635594" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_2146635601" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_194" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_2146635601" use="optional" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NonCashOperatingLeaseCosts" xlink:label="loc_sclx_NonCashOperatingLeaseCosts_2146635610" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_194" xlink:to="loc_sclx_NonCashOperatingLeaseCosts_2146635610" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_2146635613" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_194" xlink:to="loc_us-gaap_ShareBasedCompensation_2146635613" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_2146635616" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_194" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_2146635616" use="optional" order="16" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndDividendIncomeSecuritiesHeldToMaturity" xlink:label="loc_us-gaap_InterestAndDividendIncomeSecuritiesHeldToMaturity_204" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_194" xlink:to="loc_us-gaap_InterestAndDividendIncomeSecuritiesHeldToMaturity_204" use="optional" order="17" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DistributionsOnMandatorilyRedeemableSecurities" xlink:label="loc_us-gaap_DistributionsOnMandatorilyRedeemableSecurities_205" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_194" xlink:to="loc_us-gaap_DistributionsOnMandatorilyRedeemableSecurities_205" use="optional" order="18" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_206" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_194" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_206" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LossOnInitialIssuanceOfWarrantLiability" xlink:label="loc_sclx_LossOnInitialIssuanceOfWarrantLiability_207" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_194" xlink:to="loc_sclx_LossOnInitialIssuanceOfWarrantLiability_207" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ChangeInFairValueOfConversionOptionLiability" xlink:label="loc_sclx_ChangeInFairValueOfConversionOptionLiability_208" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_194" xlink:to="loc_sclx_ChangeInFairValueOfConversionOptionLiability_208" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_209" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_194" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_209" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TransactionsCostsAllocatedToPrivateWarrants" xlink:label="loc_sclx_TransactionsCostsAllocatedToPrivateWarrants_210" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_194" xlink:to="loc_sclx_TransactionsCostsAllocatedToPrivateWarrants_210" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_IncreaseInNotesPayableOne" xlink:label="loc_sclx_IncreaseInNotesPayableOne_2146635581" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_194" xlink:to="loc_sclx_IncreaseInNotesPayableOne_2146635581" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_2146635618" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_194" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_2146635618" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_195" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_194" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_195" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_2146635642" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_195" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_2146635642" use="optional" order="27" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2146635840" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_195" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2146635840" use="optional" order="28" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2146635645" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_195" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2146635645" use="optional" order="29" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:label="loc_us-gaap_IncreaseDecreaseInSecurityDeposits_2146635646" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_195" xlink:to="loc_us-gaap_IncreaseDecreaseInSecurityDeposits_2146635646" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_211" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_195" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_211" use="optional" order="31" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_2146635671" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_195" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_2146635671" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_2146635674" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_195" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_2146635674" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_2146635675" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_195" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_2146635675" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_2146635678" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_195" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_2146635678" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:label="loc_us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_2146635684" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_195" xlink:to="loc_us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_2146635684" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_196" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_195" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_196" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_212" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_193" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_212" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_197" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635069" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_197" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2146635708" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_197" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2146635708" use="optional" order="40" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_2146635853" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_197" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_2146635853" use="optional" order="41" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_InvestmentOfCashInTrustAccounts" xlink:label="loc_sclx_InvestmentOfCashInTrustAccounts_213" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_197" xlink:to="loc_sclx_InvestmentOfCashInTrustAccounts_213" use="optional" order="42" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDecommissioningFund" xlink:label="loc_us-gaap_ProceedsFromDecommissioningFund_198" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_197" xlink:to="loc_us-gaap_ProceedsFromDecommissioningFund_198" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_2146635893" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_197" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_2146635893" use="optional" order="44" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_214" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_197" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_214" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_199" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635069" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_199" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfSeniorDebt" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt_2146635710" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_199" xlink:to="loc_us-gaap_RepaymentsOfSeniorDebt_2146635710" use="optional" order="47" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfOtherLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfOtherLongTermDebt_2146635713" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_199" xlink:to="loc_us-gaap_RepaymentsOfOtherLongTermDebt_2146635713" use="optional" order="48" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_219" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_199" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_219" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_2146635796" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_199" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_2146635796" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt_217" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_199" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt_217" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfMediumTermNotes" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfMediumTermNotes_2146635811" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_199" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfMediumTermNotes_2146635811" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_215" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_199" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_215" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_216" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_199" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_216" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt_218" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_199" xlink:to="loc_us-gaap_RepaymentsOfRelatedPartyDebt_218" use="optional" order="55" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ProceedsFromSimplePromissoryNoteRelatedParty" xlink:label="loc_sclx_ProceedsFromSimplePromissoryNoteRelatedParty_220" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_199" xlink:to="loc_sclx_ProceedsFromSimplePromissoryNoteRelatedParty_220" use="optional" order="56" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_RepaymentOfPromissoryNoteRelatedParty" xlink:label="loc_sclx_RepaymentOfPromissoryNoteRelatedParty_221" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_199" xlink:to="loc_sclx_RepaymentOfPromissoryNoteRelatedParty_221" use="optional" order="57" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ProceedsFromPromissoryNoteRelatedParty" xlink:label="loc_sclx_ProceedsFromPromissoryNoteRelatedParty_2146635742" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_199" xlink:to="loc_sclx_ProceedsFromPromissoryNoteRelatedParty_2146635742" use="optional" order="58" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt_2146635746" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_199" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt_2146635746" use="optional" order="59" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_222" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_199" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_222" use="optional" order="60" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfOtherEquity" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfOtherEquity_200" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_199" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfOtherEquity_200" use="optional" order="61" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfMediumTermNotes" xlink:label="loc_us-gaap_RepaymentsOfMediumTermNotes_2146635819" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_199" xlink:to="loc_us-gaap_RepaymentsOfMediumTermNotes_2146635819" use="optional" order="62" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_223" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_199" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_223" use="optional" order="63" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_201" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635069" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_201" use="optional" order="64" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_224" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635069" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_224" use="optional" order="65" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_225" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635069" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_225" use="optional" order="66" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_202" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635069" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_202" use="optional" order="67" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_2146635864" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_202" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_2146635864" use="optional" order="68" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1" xlink:label="loc_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1_2146635869" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_202" xlink:to="loc_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1_2146635869" use="optional" order="69" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_OtherLoanForgiveness" xlink:label="loc_sclx_OtherLoanForgiveness_2146635873" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_202" xlink:to="loc_sclx_OtherLoanForgiveness_2146635873" use="optional" order="70" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PromissoryNoteIssuedNetOfDiscount" xlink:label="loc_sclx_PromissoryNoteIssuedNetOfDiscount_2146635877" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_202" xlink:to="loc_sclx_PromissoryNoteIssuedNetOfDiscount_2146635877" use="optional" order="71" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NonCashFairValueAdjustmentToDerivativeLiability" xlink:label="loc_sclx_NonCashFairValueAdjustmentToDerivativeLiability_2146635878" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_202" xlink:to="loc_sclx_NonCashFairValueAdjustmentToDerivativeLiability_2146635878" use="optional" order="72" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NonCashRightOfUseAsset" xlink:label="loc_sclx_NonCashRightOfUseAsset_2146635880" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_202" xlink:to="loc_sclx_NonCashRightOfUseAsset_2146635880" use="optional" order="73" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DeferredUnderwritingFeePayable" xlink:label="loc_sclx_DeferredUnderwritingFeePayable_226" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_202" xlink:to="loc_sclx_DeferredUnderwritingFeePayable_226" use="optional" order="74" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_OfferingCostIncludedInAccruedOfferingCost" xlink:label="loc_sclx_OfferingCostIncludedInAccruedOfferingCost_2146635732" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_202" xlink:to="loc_sclx_OfferingCostIncludedInAccruedOfferingCost_2146635732" use="optional" order="75" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesIssued1" xlink:label="loc_us-gaap_NotesIssued1_2146635734" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_202" xlink:to="loc_us-gaap_NotesIssued1_2146635734" use="optional" order="76" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AcquistionCostsIncurredButNotPaidIncludedInAccountsPayable" xlink:label="loc_sclx_AcquistionCostsIncurredButNotPaidIncludedInAccountsPayable_2146635900" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_202" xlink:to="loc_sclx_AcquistionCostsIncurredButNotPaidIncludedInAccountsPayable_2146635900" use="optional" order="77" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NonCashDistributionToAcquiree" xlink:label="loc_sclx_NonCashDistributionToAcquiree_2146635904" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_202" xlink:to="loc_sclx_NonCashDistributionToAcquiree_2146635904" use="optional" order="78" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NonCashIncreaseInPrincipal" xlink:label="loc_sclx_NonCashIncreaseInPrincipal_2146635907" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_202" xlink:to="loc_sclx_NonCashIncreaseInPrincipal_2146635907" use="optional" order="79" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_2146635910" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635069" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_2146635910" use="optional" order="80" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2146635911" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_2146635910" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2146635911" use="optional" order="81" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_2146635913" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_2146635910" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_2146635913" use="optional" order="82" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperations">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_233" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DescriptionofOrganizationandBusinessOperationsTable" xlink:label="loc_sclx_DescriptionofOrganizationandBusinessOperationsTable_234" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_233" xlink:to="loc_sclx_DescriptionofOrganizationandBusinessOperationsTable_234" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635117" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsTable_234" xlink:to="loc_dei_LegalEntityAxis_2146635117" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635118" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2146635117" xlink:to="loc_dei_EntityDomain_2146635118" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635119" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146635118" xlink:to="loc_sclx_VickersVantageMember_2146635119" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DescriptionOfOrganizationAndBusinessOperationsLineItems" xlink:label="loc_sclx_DescriptionOfOrganizationAndBusinessOperationsLineItems_235" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsTable_234" xlink:to="loc_sclx_DescriptionOfOrganizationAndBusinessOperationsLineItems_235" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_236" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionOfOrganizationAndBusinessOperationsLineItems_235" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_236" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPolicies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_241" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:label="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_2146635076" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_241" xlink:to="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_2146635076" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635078" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_2146635076" xlink:to="loc_dei_LegalEntityAxis_2146635078" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635079" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2146635078" xlink:to="loc_dei_EntityDomain_2146635079" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635080" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146635079" xlink:to="loc_sclx_VickersVantageMember_2146635080" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:label="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635077" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_2146635076" xlink:to="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635077" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_242" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635077" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_242" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcern">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LiquidityAndGoingConcernAbstract" xlink:label="loc_sclx_LiquidityAndGoingConcernAbstract_2146635445" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LiquidityAndGoingConcernTextBlock" xlink:label="loc_sclx_LiquidityAndGoingConcernTextBlock_2146635446" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernAbstract_2146635445" xlink:to="loc_sclx_LiquidityAndGoingConcernTextBlock_2146635446" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/PublicOffering">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ProposedPublicOfferingAbstract" xlink:label="loc_sclx_ProposedPublicOfferingAbstract_247" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PublicOfferingDetailsTable" xlink:label="loc_sclx_PublicOfferingDetailsTable_2146634966" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ProposedPublicOfferingAbstract_247" xlink:to="loc_sclx_PublicOfferingDetailsTable_2146634966" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146634972" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_PublicOfferingDetailsTable_2146634966" xlink:to="loc_dei_LegalEntityAxis_2146634972" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146634973" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2146634972" xlink:to="loc_dei_EntityDomain_2146634973" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146634975" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146634973" xlink:to="loc_sclx_VickersVantageMember_2146634975" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PublicOfferingDetailsLineItems" xlink:label="loc_sclx_PublicOfferingDetailsLineItems_2146634968" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_PublicOfferingDetailsTable_2146634966" xlink:to="loc_sclx_PublicOfferingDetailsLineItems_2146634968" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ProposedPublicOfferingTextBlock" xlink:label="loc_sclx_ProposedPublicOfferingTextBlock_248" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_PublicOfferingDetailsLineItems_2146634968" xlink:to="loc_sclx_ProposedPublicOfferingTextBlock_248" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/PrivatePlacement">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PrivatePlacementAbstract" xlink:label="loc_sclx_PrivatePlacementAbstract_253" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PrivatePlacementDetailsTable" xlink:label="loc_sclx_PrivatePlacementDetailsTable_2146635094" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_PrivatePlacementAbstract_253" xlink:to="loc_sclx_PrivatePlacementDetailsTable_2146635094" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635096" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_PrivatePlacementDetailsTable_2146635094" xlink:to="loc_dei_LegalEntityAxis_2146635096" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635097" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2146635096" xlink:to="loc_dei_EntityDomain_2146635097" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635098" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146635097" xlink:to="loc_sclx_VickersVantageMember_2146635098" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PrivatePlacementDetailsLineItems" xlink:label="loc_sclx_PrivatePlacementDetailsLineItems_2146635095" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_PrivatePlacementDetailsTable_2146635094" xlink:to="loc_sclx_PrivatePlacementDetailsLineItems_2146635095" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PrivatePlacementTextBlock" xlink:label="loc_sclx_PrivatePlacementTextBlock_254" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_PrivatePlacementDetailsLineItems_2146635095" xlink:to="loc_sclx_PrivatePlacementTextBlock_254" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/Acquisitions">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAbstract" xlink:label="loc_us-gaap_AssetAcquisitionAbstract_2146635653" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTextBlock" xlink:label="loc_us-gaap_AssetAcquisitionTextBlock_2146635716" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAbstract_2146635653" xlink:to="loc_us-gaap_AssetAcquisitionTextBlock_2146635716" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/RelatedPartyTransactions">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_259" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_RelatedPartyTransactionsDetailsTable" xlink:label="loc_sclx_RelatedPartyTransactionsDetailsTable_2146634965" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_259" xlink:to="loc_sclx_RelatedPartyTransactionsDetailsTable_2146634965" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146634969" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsTable_2146634965" xlink:to="loc_dei_LegalEntityAxis_2146634969" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146634970" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2146634969" xlink:to="loc_dei_EntityDomain_2146634970" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146634971" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146634970" xlink:to="loc_sclx_VickersVantageMember_2146634971" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_RelatedPartyTransactionsDetailsLineItems" xlink:label="loc_sclx_RelatedPartyTransactionsDetailsLineItems_2146634967" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsTable_2146634965" xlink:to="loc_sclx_RelatedPartyTransactionsDetailsLineItems_2146634967" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_260" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_2146634967" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_260" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/FairValueMeasurements">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_287" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_2146635163" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_287" xlink:to="loc_us-gaap_StatementTable_2146635163" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2146635164" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2146635163" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2146635164" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2146635165" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2146635164" xlink:to="loc_us-gaap_ClassOfStockDomain_2146635165" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635167" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2146635163" xlink:to="loc_dei_LegalEntityAxis_2146635167" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635168" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2146635167" xlink:to="loc_dei_EntityDomain_2146635168" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635169" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146635168" xlink:to="loc_sclx_VickersVantageMember_2146635169" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2146635166" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2146635163" xlink:to="loc_us-gaap_StatementLineItems_2146635166" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_288" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635166" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_288" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/PropertyAndEquipment">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2146635813" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_2146635814" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2146635813" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_2146635814" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2146635472" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_2146635474" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2146635472" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_2146635474" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/Debt">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_2146635927" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_2146635929" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_2146635927" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_2146635929" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/Warrants">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_WarrantsAbstract" xlink:label="loc_sclx_WarrantsAbstract_279" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_WarrantsTable" xlink:label="loc_sclx_WarrantsTable_280" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_WarrantsAbstract_279" xlink:to="loc_sclx_WarrantsTable_280" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146634994" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_WarrantsTable_280" xlink:to="loc_dei_LegalEntityAxis_2146634994" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146634995" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2146634994" xlink:to="loc_dei_EntityDomain_2146634995" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146634996" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146634995" xlink:to="loc_sclx_VickersVantageMember_2146634996" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_WarrantsLineItems" xlink:label="loc_sclx_WarrantsLineItems_2146634997" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_WarrantsTable_280" xlink:to="loc_sclx_WarrantsLineItems_2146634997" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_WarrantsTextBlock" xlink:label="loc_sclx_WarrantsTextBlock_282" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_WarrantsLineItems_2146634997" xlink:to="loc_sclx_WarrantsTextBlock_282" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/ShareholdersDeficit">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_271" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_2146635181" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_271" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_2146635181" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635184" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2146635181" xlink:to="loc_dei_LegalEntityAxis_2146635184" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635185" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2146635184" xlink:to="loc_dei_EntityDomain_2146635185" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635186" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146635185" xlink:to="loc_sclx_VickersVantageMember_2146635186" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_2146635183" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2146635181" xlink:to="loc_us-gaap_ClassOfStockLineItems_2146635183" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_272" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2146635183" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_272" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlans">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_CompensationAndEmployeeBenefitPlansAbstract" xlink:label="loc_sclx_CompensationAndEmployeeBenefitPlansAbstract_2146635431" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_2146635434" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CompensationAndEmployeeBenefitPlansAbstract_2146635431" xlink:to="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_2146635434" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/CommitmentsAndContingencies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_265" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_CommitmentsandContingenciesDetailsTable" xlink:label="loc_sclx_CommitmentsandContingenciesDetailsTable_2146635099" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_265" xlink:to="loc_sclx_CommitmentsandContingenciesDetailsTable_2146635099" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635101" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsTable_2146635099" xlink:to="loc_dei_LegalEntityAxis_2146635101" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635102" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2146635101" xlink:to="loc_dei_EntityDomain_2146635102" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635104" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146635102" xlink:to="loc_sclx_VickersVantageMember_2146635104" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_CommitmentsandContingenciesDetailsLineItems" xlink:label="loc_sclx_CommitmentsandContingenciesDetailsLineItems_2146635100" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsTable_2146635099" xlink:to="loc_sclx_CommitmentsandContingenciesDetailsLineItems_2146635100" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_266" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_2146635100" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_266" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatements">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:label="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_2146635259" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedFinancialStatementsTable" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTable_2146635269" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_2146635259" xlink:to="loc_srt_ScheduleOfCondensedFinancialStatementsTable_2146635269" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635271" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_2146635269" xlink:to="loc_dei_LegalEntityAxis_2146635271" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635272" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2146635271" xlink:to="loc_dei_EntityDomain_2146635272" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635273" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146635272" xlink:to="loc_sclx_VickersVantageMember_2146635273" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedFinancialStatementsCaptionsLineItems" xlink:label="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2146635270" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_2146635269" xlink:to="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2146635270" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" xlink:label="loc_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock_2146635261" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2146635270" xlink:to="loc_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock_2146635261" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/IncomeTaxes">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_2146635890" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_2146635892" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2146635890" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_2146635892" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/LossPerShare">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_2146635543" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_2146635547" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2146635543" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_2146635547" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/SubsequentEvents">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_293" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_2146635155" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_293" xlink:to="loc_us-gaap_StatementTable_2146635155" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2146635156" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2146635155" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2146635156" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2146635157" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2146635156" xlink:to="loc_us-gaap_ClassOfStockDomain_2146635157" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635159" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2146635155" xlink:to="loc_dei_LegalEntityAxis_2146635159" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635160" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2146635159" xlink:to="loc_dei_EntityDomain_2146635160" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635161" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146635160" xlink:to="loc_sclx_VickersVantageMember_2146635161" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2146635158" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2146635155" xlink:to="loc_us-gaap_StatementLineItems_2146635158" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_294" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635158" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_294" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/AccountingPoliciesByPolicyPolicies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_312" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:label="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_2146635052" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_312" xlink:to="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_2146635052" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635059" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_2146635052" xlink:to="loc_dei_LegalEntityAxis_2146635059" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635060" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2146635059" xlink:to="loc_dei_EntityDomain_2146635060" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635064" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146635060" xlink:to="loc_sclx_VickersVantageMember_2146635064" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:label="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_2146635052" xlink:to="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_313" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_313" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2146635401" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2146635401" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_2146635859" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_2146635859" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_314" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_314" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_315" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_315" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_316" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_UseOfEstimates_316" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_317" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_317" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsPolicy" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy_318" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_EquityMethodInvestmentsPolicy_318" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="loc_us-gaap_DeferredChargesPolicyTextBlock_319" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_DeferredChargesPolicyTextBlock_319" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock" xlink:label="loc_us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock_320" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock_320" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_321" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_321" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_2146635668" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_2146635668" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_2146635669" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_2146635669" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2146635670" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2146635670" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_2146635673" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_2146635673" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_2146635681" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_2146635681" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_322" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_322" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="loc_us-gaap_DebtPolicyTextBlock_2146635679" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_DebtPolicyTextBlock_2146635679" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_2146635680" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_2146635680" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_323" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_323" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_RebatesPolicyTextBlock" xlink:label="loc_sclx_RebatesPolicyTextBlock_2146635702" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_sclx_RebatesPolicyTextBlock_2146635702" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ServiceFeesPolicyTextBlock" xlink:label="loc_sclx_ServiceFeesPolicyTextBlock_2146635703" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_sclx_ServiceFeesPolicyTextBlock_2146635703" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SalesReturnsPolicyTextBlock" xlink:label="loc_sclx_SalesReturnsPolicyTextBlock_2146635705" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_sclx_SalesReturnsPolicyTextBlock_2146635705" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_CoPaymentAssistancePolicyTextBlock" xlink:label="loc_sclx_CoPaymentAssistancePolicyTextBlock_2146635706" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_sclx_CoPaymentAssistancePolicyTextBlock_2146635706" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_324" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_324" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_325" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_325" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_2146635651" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_2146635651" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_326" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_326" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_2146635696" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_2146635696" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_2146635699" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_2146635699" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2146635717" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635053" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2146635717" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_332" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:label="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_2146635011" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_332" xlink:to="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_2146635011" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635016" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_2146635011" xlink:to="loc_dei_LegalEntityAxis_2146635016" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635017" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2146635016" xlink:to="loc_dei_EntityDomain_2146635017" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635018" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146635017" xlink:to="loc_sclx_VickersVantageMember_2146635018" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:label="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635015" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_2146635011" xlink:to="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635015" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:label="loc_srt_ScheduleOfCondensedBalanceSheetTableTextBlock_333" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635015" xlink:to="loc_srt_ScheduleOfCondensedBalanceSheetTableTextBlock_333" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_334" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635015" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_334" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/FairValueMeasurementsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_2146635170" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_2146635172" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2146635170" xlink:to="loc_us-gaap_StatementTable_2146635172" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635176" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2146635172" xlink:to="loc_dei_LegalEntityAxis_2146635176" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635177" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2146635176" xlink:to="loc_dei_EntityDomain_2146635177" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635178" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146635177" xlink:to="loc_sclx_VickersVantageMember_2146635178" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2146635173" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2146635172" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2146635173" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2146635174" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2146635173" xlink:to="loc_us-gaap_ClassOfStockDomain_2146635174" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2146635175" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2146635172" xlink:to="loc_us-gaap_StatementLineItems_2146635175" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_343" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635175" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_343" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueConcentrationOfRiskTextBlock" xlink:label="loc_us-gaap_FairValueConcentrationOfRiskTextBlock_344" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635175" xlink:to="loc_us-gaap_FairValueConcentrationOfRiskTextBlock_344" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_345" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635175" xlink:to="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_345" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_346" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635175" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_346" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock_2146635333" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635175" xlink:to="loc_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock_2146635333" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_2146635442" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635175" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_2146635442" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_2146635476" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635175" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_2146635476" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/PropertyAndEquipmentTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2146635816" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_2146635820" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2146635816" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_2146635820" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2146635485" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_2146635488" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2146635485" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_2146635488" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_2146635489" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2146635485" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_2146635489" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/DebtTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_2146636344" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_2146636346" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_2146636344" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_2146636346" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtTableTextBlock" xlink:label="loc_sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtTableTextBlock_2146636352" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_2146636344" xlink:to="loc_sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtTableTextBlock_2146636352" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansTables">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_CompensationAndEmployeeBenefitPlansAbstract" xlink:label="loc_sclx_CompensationAndEmployeeBenefitPlansAbstract_2146635439" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_2146635441" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CompensationAndEmployeeBenefitPlansAbstract_2146635439" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_2146635441" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_2146635444" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CompensationAndEmployeeBenefitPlansAbstract_2146635439" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_2146635444" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2146635841" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_2146635844" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2146635841" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_2146635844" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScheduleOfSupplementalQuantitativeInformationRelatedToLeasesTableTextBlock" xlink:label="loc_sclx_ScheduleOfSupplementalQuantitativeInformationRelatedToLeasesTableTextBlock_2146635848" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2146635841" xlink:to="loc_sclx_ScheduleOfSupplementalQuantitativeInformationRelatedToLeasesTableTextBlock_2146635848" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_2146635850" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2146635841" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_2146635850" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:label="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_2146635276" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedFinancialStatementsTable" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTable_2146635278" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_2146635276" xlink:to="loc_srt_ScheduleOfCondensedFinancialStatementsTable_2146635278" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635281" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_2146635278" xlink:to="loc_dei_LegalEntityAxis_2146635281" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635282" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2146635281" xlink:to="loc_dei_EntityDomain_2146635282" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635283" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146635282" xlink:to="loc_sclx_VickersVantageMember_2146635283" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedFinancialStatementsCaptionsLineItems" xlink:label="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2146635279" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_2146635278" xlink:to="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2146635279" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTableTextBlock_2146635286" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2146635279" xlink:to="loc_srt_ScheduleOfCondensedFinancialStatementsTableTextBlock_2146635286" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/IncomeTaxesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_2146635964" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_2146635965" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2146635964" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_2146635965" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_2146635966" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2146635964" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_2146635966" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_2146635967" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2146635964" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_2146635967" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/LossPerShareTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_2146635551" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_2146635553" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2146635551" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_2146635553" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_506" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable" xlink:label="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_507" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_506" xlink:to="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_507" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_2146635347" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_507" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_2146635347" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_2146635348" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_2146635347" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_2146635348" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SponsorMember" xlink:label="loc_sclx_SponsorMember_2146635351" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_2146635348" xlink:to="loc_sclx_SponsorMember_2146635351" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_508" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_507" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_508" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_511" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_508" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_511" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:label="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_512" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_511" xlink:to="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_512" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScilexPharmaMember" xlink:label="loc_sclx_ScilexPharmaMember_2146635406" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_511" xlink:to="loc_sclx_ScilexPharmaMember_2146635406" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VantageMergerSubIncMember" xlink:label="loc_sclx_VantageMergerSubIncMember_2146635932" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_511" xlink:to="loc_sclx_VantageMergerSubIncMember_2146635932" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_509" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_507" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_509" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_513" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_509" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_513" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_514" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_513" xlink:to="loc_us-gaap_IPOMember_514" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_515" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_513" xlink:to="loc_us-gaap_OverAllotmentOptionMember_515" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PrivatePlacementWarrantMember" xlink:label="loc_sclx_PrivatePlacementWarrantMember_516" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_513" xlink:to="loc_sclx_PrivatePlacementWarrantMember_516" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146634946" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_507" xlink:to="loc_dei_LegalEntityAxis_2146634946" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146634948" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2146634946" xlink:to="loc_dei_EntityDomain_2146634948" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635075" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146634948" xlink:to="loc_sclx_VickersVantageMember_2146635075" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AgreementAxis" xlink:label="loc_sclx_AgreementAxis_2146635403" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_507" xlink:to="loc_sclx_AgreementAxis_2146635403" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AgreementDomain" xlink:label="loc_sclx_AgreementDomain_2146635404" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_AgreementAxis_2146635403" xlink:to="loc_sclx_AgreementDomain_2146635404" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ContributionAndLoanAgreementMember" xlink:label="loc_sclx_ContributionAndLoanAgreementMember_2146635405" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_AgreementDomain_2146635404" xlink:to="loc_sclx_ContributionAndLoanAgreementMember_2146635405" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DebtExchangeAgreementMember" xlink:label="loc_sclx_DebtExchangeAgreementMember_2146635936" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_AgreementDomain_2146635404" xlink:to="loc_sclx_DebtExchangeAgreementMember_2146635936" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2146635407" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_507" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2146635407" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_2146635408" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2146635407" xlink:to="loc_us-gaap_RelatedPartyDomain_2146635408" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SorrentoMember" xlink:label="loc_sclx_SorrentoMember_2146635409" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_2146635408" xlink:to="loc_sclx_SorrentoMember_2146635409" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_EventAxis" xlink:label="loc_sclx_EventAxis_2146635410" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_507" xlink:to="loc_sclx_EventAxis_2146635410" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_EventDomain" xlink:label="loc_sclx_EventDomain_2146635411" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_EventAxis_2146635410" xlink:to="loc_sclx_EventDomain_2146635411" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ReorganizationMember" xlink:label="loc_sclx_ReorganizationMember_2146635412" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_EventDomain_2146635411" xlink:to="loc_sclx_ReorganizationMember_2146635412" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems" xlink:label="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable_507" xlink:to="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_517" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_SharesIssued_517" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_518" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_518" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DemutualizationByInsuranceEntitySecuritiesIssuedGrossCashProceeds" xlink:label="loc_us-gaap_DemutualizationByInsuranceEntitySecuritiesIssuedGrossCashProceeds_519" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_DemutualizationByInsuranceEntitySecuritiesIssuedGrossCashProceeds_519" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_520" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_520" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:label="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_521" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_521" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherUnderwritingExpense" xlink:label="loc_us-gaap_OtherUnderwritingExpense_522" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_OtherUnderwritingExpense_522" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DeferredUnderwritingFees" xlink:label="loc_sclx_DeferredUnderwritingFees_523" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_sclx_DeferredUnderwritingFees_523" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOwnershipInterestsOfferingCosts" xlink:label="loc_us-gaap_OtherOwnershipInterestsOfferingCosts_524" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_OtherOwnershipInterestsOfferingCosts_524" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_525" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_525" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoninterestBearingDepositLiabilities" xlink:label="loc_us-gaap_NoninterestBearingDepositLiabilities_526" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_NoninterestBearingDepositLiabilities_526" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsHeldInTrust" xlink:label="loc_us-gaap_AssetsHeldInTrust_527" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_AssetsHeldInTrust_527" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SaleOfStockDescriptionOfTransactions" xlink:label="loc_sclx_SaleOfStockDescriptionOfTransactions_528" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_sclx_SaleOfStockDescriptionOfTransactions_528" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PricePerPublicShare" xlink:label="loc_sclx_PricePerPublicShare_529" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_sclx_PricePerPublicShare_529" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsNet" xlink:label="loc_us-gaap_OtherIntangibleAssetsNet_530" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_OtherIntangibleAssetsNet_530" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfPublicShares" xlink:label="loc_sclx_PercentageOfPublicShares_531" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_sclx_PercentageOfPublicShares_531" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_532" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_532" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_BusinessCombinationRedeemPercentage" xlink:label="loc_sclx_BusinessCombinationRedeemPercentage_533" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_sclx_BusinessCombinationRedeemPercentage_533" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherExpenses" xlink:label="loc_us-gaap_OtherExpenses_534" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_OtherExpenses_534" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DepositIntoTheTrustAccountPerShare" xlink:label="loc_sclx_DepositIntoTheTrustAccountPerShare_535" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_sclx_DepositIntoTheTrustAccountPerShare_535" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LesserPublicPerShare" xlink:label="loc_sclx_LesserPublicPerShare_536" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_sclx_LesserPublicPerShare_536" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAcquiredReceivablesDescription" xlink:label="loc_us-gaap_BusinessCombinationAcquiredReceivablesDescription_537" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_BusinessCombinationAcquiredReceivablesDescription_537" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_538" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_RestrictedCashCurrent_538" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_WorkingCapital" xlink:label="loc_sclx_WorkingCapital_539" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_sclx_WorkingCapital_539" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeDepositWithFinancialInstitutionIncreaseDecrease" xlink:label="loc_us-gaap_InterestIncomeDepositWithFinancialInstitutionIncreaseDecrease_540" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_InterestIncomeDepositWithFinancialInstitutionIncreaseDecrease_540" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_Numberofshares" xlink:label="loc_sclx_Numberofshares_2146635285" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_sclx_Numberofshares_2146635285" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ProceedsOfInitialPublicOffering" xlink:label="loc_sclx_ProceedsOfInitialPublicOffering_2146635290" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_sclx_ProceedsOfInitialPublicOffering_2146635290" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_Saleofwarrants" xlink:label="loc_sclx_Saleofwarrants_2146635310" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_sclx_Saleofwarrants_2146635310" use="optional" order="55" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_Grossproceedsofwarrants" xlink:label="loc_sclx_Grossproceedsofwarrants_2146635319" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_sclx_Grossproceedsofwarrants_2146635319" use="optional" order="56" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_Transactioncostsamount" xlink:label="loc_sclx_Transactioncostsamount_2146635332" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_sclx_Transactioncostsamount_2146635332" use="optional" order="57" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_Otherofferingcosts" xlink:label="loc_sclx_Otherofferingcosts_2146635334" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_sclx_Otherofferingcosts_2146635334" use="optional" order="58" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_Numberofbusinessdays" xlink:label="loc_sclx_Numberofbusinessdays_2146635343" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_sclx_Numberofbusinessdays_2146635343" use="optional" order="59" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NetTangibleAssets" xlink:label="loc_sclx_NetTangibleAssets_2146635346" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_sclx_NetTangibleAssets_2146635346" use="optional" order="60" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_Depositintotrustaccount" xlink:label="loc_sclx_Depositintotrustaccount_2146635354" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_sclx_Depositintotrustaccount_2146635354" use="optional" order="61" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_Interestexpenses" xlink:label="loc_sclx_Interestexpenses_2146635365" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_sclx_Interestexpenses_2146635365" use="optional" order="62" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_2146635368" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_Cash_2146635368" use="optional" order="63" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_2146635373" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_2146635373" use="optional" order="64" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_2146635402" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_dei_EntityIncorporationStateCountryCode_2146635402" use="optional" order="65" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_2146635415" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_2146635415" use="optional" order="66" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_2146635417" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_2146635417" use="optional" order="67" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_2146635937" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_2146635937" use="optional" order="68" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_2146635938" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems_510" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_2146635938" use="optional" order="69" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_552" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:label="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_553" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_552" xlink:to="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_553" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146634981" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_553" xlink:to="loc_dei_LegalEntityAxis_2146634981" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146634982" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2146634981" xlink:to="loc_dei_EntityDomain_2146634982" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146634983" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146634982" xlink:to="loc_sclx_VickersVantageMember_2146634983" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_554" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_553" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_554" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_556" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_554" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_556" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_557" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_556" xlink:to="loc_us-gaap_IPOMember_557" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_2146635758" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_553" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_2146635758" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_2146635759" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_2146635758" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_2146635759" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_2146635761" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_2146635759" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_2146635761" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_2146635763" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_553" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_2146635763" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2146635764" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_2146635763" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2146635764" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaap_SalesRevenueNetMember_2146635766" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2146635764" xlink:to="loc_us-gaap_SalesRevenueNetMember_2146635766" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_2146635767" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_553" xlink:to="loc_srt_MajorCustomersAxis_2146635767" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_2146635768" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_2146635767" xlink:to="loc_srt_NameOfMajorCustomerDomain_2146635768" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SoleDistributorMember" xlink:label="loc_sclx_SoleDistributorMember_2146635769" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_2146635768" xlink:to="loc_sclx_SoleDistributorMember_2146635769" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:label="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_555" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_553" xlink:to="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_555" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherDeferredCostsNet" xlink:label="loc_us-gaap_OtherDeferredCostsNet_558" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_555" xlink:to="loc_us-gaap_OtherDeferredCostsNet_558" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExcessStockSharesIssued" xlink:label="loc_us-gaap_ExcessStockSharesIssued_559" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_555" xlink:to="loc_us-gaap_ExcessStockSharesIssued_559" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaap_CashFDICInsuredAmount_560" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_555" xlink:to="loc_us-gaap_CashFDICInsuredAmount_560" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_Foundershares" xlink:label="loc_sclx_Foundershares_2146635399" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_555" xlink:to="loc_sclx_Foundershares_2146635399" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_2146635724" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_555" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_2146635724" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_2146635754" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_555" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_2146635754" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfOrdinarySharesReflectedInCondensedConsolidatedBalanceSheetsAreReconciled">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScheduleOfOrdinarySharesReflectedInCondensedConsolidatedBalanceSheetsAreReconciledAbstract" xlink:label="loc_sclx_ScheduleOfOrdinarySharesReflectedInCondensedConsolidatedBalanceSheetsAreReconciledAbstract_358" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:label="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_2146634984" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ScheduleOfOrdinarySharesReflectedInCondensedConsolidatedBalanceSheetsAreReconciledAbstract_358" xlink:to="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_2146634984" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146634986" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_2146634984" xlink:to="loc_dei_LegalEntityAxis_2146634986" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146634987" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2146634986" xlink:to="loc_dei_EntityDomain_2146634987" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146634988" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146634987" xlink:to="loc_sclx_VickersVantageMember_2146634988" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:label="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146634985" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_2146634984" xlink:to="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146634985" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_GrossProceeds" xlink:label="loc_sclx_GrossProceeds_362" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146634985" xlink:to="loc_sclx_GrossProceeds_362" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LessAbstract" xlink:label="loc_sclx_LessAbstract_359" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146634985" xlink:to="loc_sclx_LessAbstract_359" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_OrdinarySharesIssuanceCost" xlink:label="loc_sclx_OrdinarySharesIssuanceCost_363" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LessAbstract_359" xlink:to="loc_sclx_OrdinarySharesIssuanceCost_363" use="optional" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PlusAbstract" xlink:label="loc_sclx_PlusAbstract_360" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146634985" xlink:to="loc_sclx_PlusAbstract_360" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AccretionOfCarryingValueToRedemptionValue" xlink:label="loc_sclx_AccretionOfCarryingValueToRedemptionValue_364" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_PlusAbstract_360" xlink:to="loc_sclx_AccretionOfCarryingValueToRedemptionValue_364" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="loc_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_2146635381" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_PlusAbstract_360" xlink:to="loc_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_2146635381" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SharesSubjectToPossibleRedemption" xlink:label="loc_sclx_SharesSubjectToPossibleRedemption_365" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146634985" xlink:to="loc_sclx_SharesSubjectToPossibleRedemption_365" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LessAbstract0" xlink:label="loc_sclx_LessAbstract0_361" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146634985" xlink:to="loc_sclx_LessAbstract0_361" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityOtherChanges" xlink:label="loc_us-gaap_TemporaryEquityOtherChanges_366" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LessAbstract0_361" xlink:to="loc_us-gaap_TemporaryEquityOtherChanges_366" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShare">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareAbstract" xlink:label="loc_sclx_ScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareAbstract_375" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:label="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_2146634989" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareAbstract_375" xlink:to="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_2146634989" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146634991" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_2146634989" xlink:to="loc_dei_LegalEntityAxis_2146634991" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146634992" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2146634991" xlink:to="loc_dei_EntityDomain_2146634992" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146634993" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146634992" xlink:to="loc_sclx_VickersVantageMember_2146634993" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:label="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146634990" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_2146634989" xlink:to="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146634990" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NumeratorAbstract" xlink:label="loc_sclx_NumeratorAbstract_376" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146634990" xlink:to="loc_sclx_NumeratorAbstract_376" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityNetIncome" xlink:label="loc_us-gaap_TemporaryEquityNetIncome_378" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_NumeratorAbstract_376" xlink:to="loc_us-gaap_TemporaryEquityNetIncome_378" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DenominatorAbstract" xlink:label="loc_sclx_DenominatorAbstract_377" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146634990" xlink:to="loc_sclx_DenominatorAbstract_377" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesIssuedBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_379" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DenominatorAbstract_377" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesIssuedBasic_379" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_380" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DenominatorAbstract_377" xlink:to="loc_us-gaap_EarningsPerShareBasic_380" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2146635636" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DenominatorAbstract_377" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2146635636" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2146635657" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DenominatorAbstract_377" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2146635657" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_2146635665" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_DenominatorAbstract_377" xlink:to="loc_us-gaap_EarningsPerShareDiluted_2146635665" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/disclosureGuidance" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareParentheticals">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareAbstract" xlink:label="loc_sclx_ScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareAbstract_386" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:label="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_2146635001" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareAbstract_386" xlink:to="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_2146635001" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635003" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_2146635001" xlink:to="loc_dei_LegalEntityAxis_2146635003" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635004" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2146635003" xlink:to="loc_dei_EntityDomain_2146635004" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635005" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146635004" xlink:to="loc_sclx_VickersVantageMember_2146635005" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:label="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635002" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsTable_2146635001" xlink:to="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635002" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_387" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635002" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_387" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_388" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems_2146635002" xlink:to="loc_us-gaap_EarningsPerShareDiluted_388" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LiquidityAndGoingConcernAbstract" xlink:label="loc_sclx_LiquidityAndGoingConcernAbstract_2146635452" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LiquidityAndGoingConcernTable" xlink:label="loc_sclx_LiquidityAndGoingConcernTable_2146635455" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernAbstract_2146635452" xlink:to="loc_sclx_LiquidityAndGoingConcernTable_2146635455" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635514" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernTable_2146635455" xlink:to="loc_dei_LegalEntityAxis_2146635514" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635515" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2146635514" xlink:to="loc_dei_EntityDomain_2146635515" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScilexPharmaMember" xlink:label="loc_sclx_ScilexPharmaMember_2146635517" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146635515" xlink:to="loc_sclx_ScilexPharmaMember_2146635517" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_2146635518" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernTable_2146635455" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_2146635518" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2146635519" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2146635518" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2146635519" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SeniorSecuredNotesDueTwoThousandAndTwentySixMember" xlink:label="loc_sclx_SeniorSecuredNotesDueTwoThousandAndTwentySixMember_2146635521" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2146635519" xlink:to="loc_sclx_SeniorSecuredNotesDueTwoThousandAndTwentySixMember_2146635521" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_EventAxis" xlink:label="loc_sclx_EventAxis_2146635523" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernTable_2146635455" xlink:to="loc_sclx_EventAxis_2146635523" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_EventDomain" xlink:label="loc_sclx_EventDomain_2146635524" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_EventAxis_2146635523" xlink:to="loc_sclx_EventDomain_2146635524" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_CumulativeSalesRelatedContingencyMember" xlink:label="loc_sclx_CumulativeSalesRelatedContingencyMember_2146635525" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_EventDomain_2146635524" xlink:to="loc_sclx_CumulativeSalesRelatedContingencyMember_2146635525" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LetterOfCreditDrawnDownMember" xlink:label="loc_sclx_LetterOfCreditDrawnDownMember_2146635526" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_EventDomain_2146635524" xlink:to="loc_sclx_LetterOfCreditDrawnDownMember_2146635526" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2146635528" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernTable_2146635455" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2146635528" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2146635529" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2146635528" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2146635529" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_2146635530" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_2146635529" xlink:to="loc_us-gaap_SubsequentEventMember_2146635530" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_2146636050" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernTable_2146635455" xlink:to="loc_us-gaap_DebtInstrumentAxis_2146636050" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2146636051" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_2146636050" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2146636051" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScilexPharmaNotesMember" xlink:label="loc_sclx_ScilexPharmaNotesMember_2146636052" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2146636051" xlink:to="loc_sclx_ScilexPharmaNotesMember_2146636052" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_2146636053" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernTable_2146635455" xlink:to="loc_us-gaap_CreditFacilityAxis_2146636053" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_2146636054" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_2146636053" xlink:to="loc_us-gaap_CreditFacilityDomain_2146636054" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_FundingCommitmentLetterMember" xlink:label="loc_sclx_FundingCommitmentLetterMember_2146636055" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_2146636054" xlink:to="loc_sclx_FundingCommitmentLetterMember_2146636055" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LiquidityAndGoingConcernLineItems" xlink:label="loc_sclx_LiquidityAndGoingConcernLineItems_2146635456" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernTable_2146635455" xlink:to="loc_sclx_LiquidityAndGoingConcernLineItems_2146635456" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NetWorkingCapital" xlink:label="loc_sclx_NetWorkingCapital_2146635459" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_2146635456" xlink:to="loc_sclx_NetWorkingCapital_2146635459" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2146635467" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_2146635456" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2146635467" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_2146635573" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_2146635456" xlink:to="loc_us-gaap_OperatingIncomeLoss_2146635573" use="optional" order="24" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2146635574" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_2146635456" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2146635574" use="optional" order="25" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2146635469" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_2146635456" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2146635469" use="optional" order="26" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_2146635470" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_2146635456" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_2146635470" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_2146635473" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_2146635456" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_2146635473" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MinimumUnrestrictedCashBalance" xlink:label="loc_sclx_MinimumUnrestrictedCashBalance_2146635477" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_2146635456" xlink:to="loc_sclx_MinimumUnrestrictedCashBalance_2146635477" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_2146635479" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_2146635456" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_2146635479" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_RestrictedFundsRelesableForFutureRepurchaseOfDebt" xlink:label="loc_sclx_RestrictedFundsRelesableForFutureRepurchaseOfDebt_2146635491" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_2146635456" xlink:to="loc_sclx_RestrictedFundsRelesableForFutureRepurchaseOfDebt_2146635491" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DebtInstrumentRepurchaseObligation" xlink:label="loc_sclx_DebtInstrumentRepurchaseObligation_2146635498" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_2146635456" xlink:to="loc_sclx_DebtInstrumentRepurchaseObligation_2146635498" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:label="loc_us-gaap_DebtInstrumentAnnualPrincipalPayment_2146636044" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_2146635456" xlink:to="loc_us-gaap_DebtInstrumentAnnualPrincipalPayment_2146636044" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentDecreaseForgiveness" xlink:label="loc_us-gaap_DebtInstrumentDecreaseForgiveness_2146636045" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_2146635456" xlink:to="loc_us-gaap_DebtInstrumentDecreaseForgiveness_2146636045" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_2146636046" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_2146635456" xlink:to="loc_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_2146636046" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinimumNetWorthRequiredForCompliance" xlink:label="loc_us-gaap_MinimumNetWorthRequiredForCompliance_2146636047" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_2146635456" xlink:to="loc_us-gaap_MinimumNetWorthRequiredForCompliance_2146636047" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_2146636048" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_2146635456" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_2146636048" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AggregateOutstandingAmount" xlink:label="loc_sclx_AggregateOutstandingAmount_2146636049" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_LiquidityAndGoingConcernLineItems_2146635456" xlink:to="loc_sclx_AggregateOutstandingAmount_2146636049" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/PublicOfferingDetails">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ProposedPublicOfferingAbstract" xlink:label="loc_sclx_ProposedPublicOfferingAbstract_573" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PublicOfferingDetailsTable" xlink:label="loc_sclx_PublicOfferingDetailsTable_574" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ProposedPublicOfferingAbstract_573" xlink:to="loc_sclx_PublicOfferingDetailsTable_574" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146634940" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_PublicOfferingDetailsTable_574" xlink:to="loc_dei_LegalEntityAxis_2146634940" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146634941" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2146634940" xlink:to="loc_dei_EntityDomain_2146634941" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146634945" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146634941" xlink:to="loc_sclx_VickersVantageMember_2146634945" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_575" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_PublicOfferingDetailsTable_574" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_575" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_577" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_575" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_577" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_578" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_577" xlink:to="loc_us-gaap_IPOMember_578" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_579" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_577" xlink:to="loc_us-gaap_OverAllotmentOptionMember_579" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PublicOfferingDetailsLineItems" xlink:label="loc_sclx_PublicOfferingDetailsLineItems_576" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_PublicOfferingDetailsTable_574" xlink:to="loc_sclx_PublicOfferingDetailsLineItems_576" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_580" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_PublicOfferingDetailsLineItems_576" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_580" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PurchasePricePerShare" xlink:label="loc_sclx_PurchasePricePerShare_581" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_PublicOfferingDetailsLineItems_576" xlink:to="loc_sclx_PurchasePricePerShare_581" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="loc_us-gaap_SaleOfStockDescriptionOfTransaction_582" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_PublicOfferingDetailsLineItems_576" xlink:to="loc_us-gaap_SaleOfStockDescriptionOfTransaction_582" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NumberOfSaleUnits" xlink:label="loc_sclx_NumberOfSaleUnits_2146636382" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_PublicOfferingDetailsLineItems_576" xlink:to="loc_sclx_NumberOfSaleUnits_2146636382" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/PrivatePlacementDetails">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PrivatePlacementAbstract" xlink:label="loc_sclx_PrivatePlacementAbstract_594" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PrivatePlacementDetailsTable" xlink:label="loc_sclx_PrivatePlacementDetailsTable_595" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_PrivatePlacementAbstract_594" xlink:to="loc_sclx_PrivatePlacementDetailsTable_595" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635105" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_PrivatePlacementDetailsTable_595" xlink:to="loc_dei_LegalEntityAxis_2146635105" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635107" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2146635105" xlink:to="loc_dei_EntityDomain_2146635107" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635108" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146635107" xlink:to="loc_sclx_VickersVantageMember_2146635108" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_596" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_PrivatePlacementDetailsTable_595" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_596" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2146634687" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_596" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2146634687" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_598" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2146634687" xlink:to="loc_us-gaap_PrivatePlacementMember_598" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PrivatePlacementDetailsLineItems" xlink:label="loc_sclx_PrivatePlacementDetailsLineItems_597" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_PrivatePlacementDetailsTable_595" xlink:to="loc_sclx_PrivatePlacementDetailsLineItems_597" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_599" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_PrivatePlacementDetailsLineItems_597" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_599" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_600" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_PrivatePlacementDetailsLineItems_597" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_600" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_601" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_PrivatePlacementDetailsLineItems_597" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_601" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_602" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_PrivatePlacementDetailsLineItems_597" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_602" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_643" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_RelatedPartyTransactionsDetailsTable" xlink:label="loc_sclx_RelatedPartyTransactionsDetailsTable_644" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_643" xlink:to="loc_sclx_RelatedPartyTransactionsDetailsTable_644" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146634976" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsTable_644" xlink:to="loc_dei_LegalEntityAxis_2146634976" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146634977" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2146634976" xlink:to="loc_dei_EntityDomain_2146634977" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146634979" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146634977" xlink:to="loc_sclx_VickersVantageMember_2146634979" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScilexPharmaMember" xlink:label="loc_sclx_ScilexPharmaMember_2146635920" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146634977" xlink:to="loc_sclx_ScilexPharmaMember_2146635920" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_645" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsTable_644" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_645" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_651" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_645" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_651" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ConvertiblePromisoryNoteMember" xlink:label="loc_sclx_ConvertiblePromisoryNoteMember_652" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_651" xlink:to="loc_sclx_ConvertiblePromisoryNoteMember_652" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_2146635998" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_651" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_2146635998" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_646" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsTable_644" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_646" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_653" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_646" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_653" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_FounderSharesMember" xlink:label="loc_sclx_FounderSharesMember_654" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_653" xlink:to="loc_sclx_FounderSharesMember_654" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PromissoryNoteRelatedPartyMember" xlink:label="loc_sclx_PromissoryNoteRelatedPartyMember_655" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_653" xlink:to="loc_sclx_PromissoryNoteRelatedPartyMember_655" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_647" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsTable_644" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_647" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_656" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_647" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_656" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_657" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_656" xlink:to="loc_us-gaap_SubsequentEventMember_657" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_648" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsTable_644" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_648" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_658" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_648" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_658" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_659" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_658" xlink:to="loc_us-gaap_IPOMember_659" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_649" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsTable_644" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_649" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_660" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_649" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_660" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_FounderSharesMember" xlink:label="loc_sclx_FounderSharesMember_661" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_660" xlink:to="loc_sclx_FounderSharesMember_661" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="loc_us-gaap_AssetAcquisitionAxis_2146635807" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsTable_644" xlink:to="loc_us-gaap_AssetAcquisitionAxis_2146635807" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaap_AssetAcquisitionDomain_2146635809" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_2146635807" xlink:to="loc_us-gaap_AssetAcquisitionDomain_2146635809" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SenmurMember" xlink:label="loc_sclx_SenmurMember_2146635810" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_2146635809" xlink:to="loc_sclx_SenmurMember_2146635810" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2146635851" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsTable_644" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2146635851" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_2146635852" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2146635851" xlink:to="loc_us-gaap_RelatedPartyDomain_2146635852" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ItochuMember" xlink:label="loc_sclx_ItochuMember_2146635854" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_2146635852" xlink:to="loc_sclx_ItochuMember_2146635854" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SorrentoMember" xlink:label="loc_sclx_SorrentoMember_2146635876" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_2146635852" xlink:to="loc_sclx_SorrentoMember_2146635876" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_EventAxis" xlink:label="loc_sclx_EventAxis_2146635901" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsTable_644" xlink:to="loc_sclx_EventAxis_2146635901" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_EventDomain" xlink:label="loc_sclx_EventDomain_2146635902" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_EventAxis_2146635901" xlink:to="loc_sclx_EventDomain_2146635902" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ReorganizationMember" xlink:label="loc_sclx_ReorganizationMember_2146635903" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_EventDomain_2146635902" xlink:to="loc_sclx_ReorganizationMember_2146635903" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_InvesteeAxis" xlink:label="loc_sclx_InvesteeAxis_2146636065" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsTable_644" xlink:to="loc_sclx_InvesteeAxis_2146636065" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_InvesteeDomain" xlink:label="loc_sclx_InvesteeDomain_2146636066" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_InvesteeAxis_2146636065" xlink:to="loc_sclx_InvesteeDomain_2146636066" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SorrentoMember" xlink:label="loc_sclx_SorrentoMember_2146636067" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_InvesteeDomain_2146636066" xlink:to="loc_sclx_SorrentoMember_2146636067" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_2146636071" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsTable_644" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_2146636071" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2146636072" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2146636071" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2146636072" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TwoThousandAndTwentyTwoPromissoryNoteMember" xlink:label="loc_sclx_TwoThousandAndTwentyTwoPromissoryNoteMember_2146636073" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2146636072" xlink:to="loc_sclx_TwoThousandAndTwentyTwoPromissoryNoteMember_2146636073" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_2146636076" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsTable_644" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_2146636076" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2146636077" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2146636076" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2146636077" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SorrentoMember" xlink:label="loc_sclx_SorrentoMember_2146636078" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2146636077" xlink:to="loc_sclx_SorrentoMember_2146636078" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AgreementAxis" xlink:label="loc_sclx_AgreementAxis_2146636315" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsTable_644" xlink:to="loc_sclx_AgreementAxis_2146636315" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AgreementDomain" xlink:label="loc_sclx_AgreementDomain_2146636319" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_AgreementAxis_2146636315" xlink:to="loc_sclx_AgreementDomain_2146636319" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DebtExchangeAgreementMember" xlink:label="loc_sclx_DebtExchangeAgreementMember_2146636320" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_AgreementDomain_2146636319" xlink:to="loc_sclx_DebtExchangeAgreementMember_2146636320" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2146636348" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsTable_644" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2146636348" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_2146636349" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2146636348" xlink:to="loc_us-gaap_EquityComponentDomain_2146636349" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_2146636350" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2146636349" xlink:to="loc_us-gaap_PreferredStockMember_2146636350" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_2146636351" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2146636349" xlink:to="loc_us-gaap_CommonStockMember_2146636351" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PeriodAxis" xlink:label="loc_sclx_PeriodAxis_2146636629" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsTable_644" xlink:to="loc_sclx_PeriodAxis_2146636629" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PeriodDomain" xlink:label="loc_sclx_PeriodDomain_2146636630" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_PeriodAxis_2146636629" xlink:to="loc_sclx_PeriodDomain_2146636630" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DueOnOrAfterFebruaryTwoThousandAndThirtyMember" xlink:label="loc_sclx_DueOnOrAfterFebruaryTwoThousandAndThirtyMember_2146636631" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_PeriodDomain_2146636630" xlink:to="loc_sclx_DueOnOrAfterFebruaryTwoThousandAndThirtyMember_2146636631" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_RelatedPartyTransactionsDetailsLineItems" xlink:label="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsTable_644" xlink:to="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_662" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_662" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_663" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_663" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_CapitalizationOfShareOutstanding" xlink:label="loc_sclx_CapitalizationOfShareOutstanding_664" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_sclx_CapitalizationOfShareOutstanding_664" use="optional" order="55" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_665" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_665" use="optional" order="56" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_OrdinarySharesIssuedAndOutstanding" xlink:label="loc_sclx_OrdinarySharesIssuedAndOutstanding_666" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_sclx_OrdinarySharesIssuedAndOutstanding_666" use="optional" order="57" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_667" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_667" use="optional" order="58" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:label="loc_us-gaap_CostsAndExpensesRelatedParty_668" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_CostsAndExpensesRelatedParty_668" use="optional" order="59" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_669" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_669" use="optional" order="60" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt_670" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_RepaymentsOfDebt_670" use="optional" order="61" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationControlObtainedDescription" xlink:label="loc_us-gaap_BusinessCombinationControlObtainedDescription_671" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_BusinessCombinationControlObtainedDescription_671" use="optional" order="62" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaap_ConvertibleDebt_672" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_ConvertibleDebt_672" use="optional" order="63" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_WarrantsExercisePrice" xlink:label="loc_sclx_WarrantsExercisePrice_673" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_sclx_WarrantsExercisePrice_673" use="optional" order="64" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_674" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_AdditionalPaidInCapital_674" use="optional" order="65" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_675" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_675" use="optional" order="66" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_aggregatePurchasePrice" xlink:label="loc_sclx_aggregatePurchasePrice_676" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_sclx_aggregatePurchasePrice_676" use="optional" order="67" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseRelatedParty" xlink:label="loc_us-gaap_InterestExpenseRelatedParty_677" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_InterestExpenseRelatedParty_677" use="optional" order="68" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_678" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_678" use="optional" order="69" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionDescriptionOfTransaction_679" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_RelatedPartyTransactionDescriptionOfTransaction_679" use="optional" order="70" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DepositedInTrustAccount" xlink:label="loc_sclx_DepositedInTrustAccount_680" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_sclx_DepositedInTrustAccount_680" use="optional" order="71" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_2146635821" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_2146635821" use="optional" order="72" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_2146635824" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_2146635824" use="optional" order="73" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_2146635829" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_2146635829" use="optional" order="74" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesSubscribedButUnissued" xlink:label="loc_us-gaap_CommonStockSharesSubscribedButUnissued_2146635834" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_CommonStockSharesSubscribedButUnissued_2146635834" use="optional" order="75" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AssetAcquisitionPricePerShare" xlink:label="loc_sclx_AssetAcquisitionPricePerShare_2146635838" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_sclx_AssetAcquisitionPricePerShare_2146635838" use="optional" order="76" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfOwnershipInterest" xlink:label="loc_sclx_PercentageOfOwnershipInterest_2146635839" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_sclx_PercentageOfOwnershipInterest_2146635839" use="optional" order="77" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfSharesOutstanding" xlink:label="loc_sclx_PercentageOfSharesOutstanding_2146635849" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_sclx_PercentageOfSharesOutstanding_2146635849" use="optional" order="78" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PaymentToAcquireInventory" xlink:label="loc_sclx_PaymentToAcquireInventory_2146635855" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_sclx_PaymentToAcquireInventory_2146635855" use="optional" order="79" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfCapitalSharesOutstanding" xlink:label="loc_sclx_PercentageOfCapitalSharesOutstanding_2146636020" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_sclx_PercentageOfCapitalSharesOutstanding_2146636020" use="optional" order="80" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NumberOfSharesOutstanding" xlink:label="loc_sclx_NumberOfSharesOutstanding_2146635879" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_sclx_NumberOfSharesOutstanding_2146635879" use="optional" order="81" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NumberOfSharesAcquired" xlink:label="loc_sclx_NumberOfSharesAcquired_2146635888" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_sclx_NumberOfSharesAcquired_2146635888" use="optional" order="82" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xlink:label="loc_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_2146635894" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_2146635894" use="optional" order="83" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfSimpleInterest" xlink:label="loc_sclx_PercentageOfSimpleInterest_2146635906" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_sclx_PercentageOfSimpleInterest_2146635906" use="optional" order="84" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent_2146635908" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_NotesPayableCurrent_2146635908" use="optional" order="85" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_2146635909" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_2146635909" use="optional" order="86" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AccruedInterest" xlink:label="loc_sclx_AccruedInterest_2146635924" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_sclx_AccruedInterest_2146635924" use="optional" order="87" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PricePerWarrants" xlink:label="loc_sclx_PricePerWarrants_2146635981" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_sclx_PricePerWarrants_2146635981" use="optional" order="88" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsHeldInTrust" xlink:label="loc_us-gaap_AssetsHeldInTrust_2146635982" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_AssetsHeldInTrust_2146635982" use="optional" order="89" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_2146635983" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_2146635983" use="optional" order="90" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTaxExpenseDueToAffiliatesDeferred" xlink:label="loc_us-gaap_RelatedPartyTaxExpenseDueToAffiliatesDeferred_2146635986" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_RelatedPartyTaxExpenseDueToAffiliatesDeferred_2146635986" use="optional" order="91" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_2146635988" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_2146635988" use="optional" order="92" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AggregatePrincipalAmount" xlink:label="loc_sclx_AggregatePrincipalAmount_2146635990" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_sclx_AggregatePrincipalAmount_2146635990" use="optional" order="93" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToAffiliateCurrent" xlink:label="loc_us-gaap_DueToAffiliateCurrent_2146636008" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_DueToAffiliateCurrent_2146636008" use="optional" order="94" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_RepaidAmount" xlink:label="loc_sclx_RepaidAmount_2146636011" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_sclx_RepaidAmount_2146636011" use="optional" order="95" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable_2146636059" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_LongTermNotesPayable_2146636059" use="optional" order="96" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_2146636070" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_2146636070" use="optional" order="97" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm_2146636074" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_DebtInstrumentTerm_2146636074" use="optional" order="98" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_2146636075" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_2146636075" use="optional" order="99" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_WorkingCapitalRequirements" xlink:label="loc_sclx_WorkingCapitalRequirements_2146636097" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_sclx_WorkingCapitalRequirements_2146636097" use="optional" order="100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchaseAmount" xlink:label="loc_us-gaap_DebtInstrumentRepurchaseAmount_2146636099" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_DebtInstrumentRepurchaseAmount_2146636099" use="optional" order="101" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaap_LegalFees_2146636101" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_LegalFees_2146636101" use="optional" order="102" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2146636333" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2146636333" use="optional" order="103" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfOutstandingAmountIndebtedness" xlink:label="loc_sclx_PercentageOfOutstandingAmountIndebtedness_2146636337" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_sclx_PercentageOfOutstandingAmountIndebtedness_2146636337" use="optional" order="104" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PerShareCalculationOfOutstandingAmountInExchangeOfShares" xlink:label="loc_sclx_PerShareCalculationOfOutstandingAmountInExchangeOfShares_2146636342" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_sclx_PerShareCalculationOfOutstandingAmountInExchangeOfShares_2146636342" use="optional" order="105" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LimitationOfOutstandingAmountInExchangeOfShares" xlink:label="loc_sclx_LimitationOfOutstandingAmountInExchangeOfShares_2146636343" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_sclx_LimitationOfOutstandingAmountInExchangeOfShares_2146636343" use="optional" order="106" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_2146636345" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_LongTermDebt_2146636345" use="optional" order="107" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_2146636347" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_2146636347" use="optional" order="108" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfMediumTermNotes" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfMediumTermNotes_2146636628" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_RelatedPartyTransactionsDetailsLineItems_650" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfMediumTermNotes_2146636628" use="optional" order="109" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_717" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_CommitmentsandContingenciesDetailsTable" xlink:label="loc_sclx_CommitmentsandContingenciesDetailsTable_718" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_717" xlink:to="loc_sclx_CommitmentsandContingenciesDetailsTable_718" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635081" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsTable_718" xlink:to="loc_dei_LegalEntityAxis_2146635081" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635082" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2146635081" xlink:to="loc_dei_EntityDomain_2146635082" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635083" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146635082" xlink:to="loc_sclx_VickersVantageMember_2146635083" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_719" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsTable_718" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_719" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_725" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_719" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_725" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScilexCommonStockMember" xlink:label="loc_sclx_ScilexCommonStockMember_726" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_725" xlink:to="loc_sclx_ScilexCommonStockMember_726" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_720" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsTable_718" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_720" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_727" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_720" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_727" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:label="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_728" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_727" xlink:to="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_728" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_721" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsTable_718" xlink:to="loc_us-gaap_StatementClassOfStockAxis_721" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_729" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_721" xlink:to="loc_us-gaap_ClassOfStockDomain_729" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_730" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_729" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_730" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_722" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsTable_718" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_722" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_731" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_722" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_731" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_732" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_731" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_732" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_723" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsTable_718" xlink:to="loc_srt_RangeAxis_723" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_733" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_723" xlink:to="loc_srt_RangeMember_733" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_734" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_733" xlink:to="loc_srt_MinimumMember_734" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_735" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_733" xlink:to="loc_srt_MaximumMember_735" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_2146635917" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsTable_718" xlink:to="loc_us-gaap_TypeOfArrangementAxis_2146635917" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2146635918" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2146635917" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2146635918" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ProductDevelopmentAgreementMember" xlink:label="loc_sclx_ProductDevelopmentAgreementMember_2146635919" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2146635918" xlink:to="loc_sclx_ProductDevelopmentAgreementMember_2146635919" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ExclusiveDistributionAgreementMember" xlink:label="loc_sclx_ExclusiveDistributionAgreementMember_2146635961" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2146635918" xlink:to="loc_sclx_ExclusiveDistributionAgreementMember_2146635961" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ProjectAgreementMember" xlink:label="loc_sclx_ProjectAgreementMember_2146635962" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2146635918" xlink:to="loc_sclx_ProjectAgreementMember_2146635962" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2146636110" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsTable_718" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2146636110" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2146636111" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2146636110" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2146636111" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PaloAltoAadministrativeFacilityMember" xlink:label="loc_sclx_PaloAltoAadministrativeFacilityMember_2146636112" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2146636111" xlink:to="loc_sclx_PaloAltoAadministrativeFacilityMember_2146636112" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_CommitmentsandContingenciesDetailsLineItems" xlink:label="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsTable_718" xlink:to="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDescription" xlink:label="loc_us-gaap_OtherCommitmentsDescription_736" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_us-gaap_OtherCommitmentsDescription_736" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_737" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_737" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredUnitsAuthorized" xlink:label="loc_us-gaap_PreferredUnitsAuthorized_738" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_us-gaap_PreferredUnitsAuthorized_738" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MergerConsiderationDescription" xlink:label="loc_sclx_MergerConsiderationDescription_739" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_sclx_MergerConsiderationDescription_739" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_740" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_us-gaap_SharesIssued_740" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_741" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_741" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_CommonStockAggregateValue" xlink:label="loc_sclx_CommonStockAggregateValue_742" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_sclx_CommonStockAggregateValue_742" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationReasonForBusinessCombination" xlink:label="loc_us-gaap_BusinessCombinationReasonForBusinessCombination_743" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_us-gaap_BusinessCombinationReasonForBusinessCombination_743" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NetTangibleAssets" xlink:label="loc_sclx_NetTangibleAssets_744" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_sclx_NetTangibleAssets_744" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AggregatePercentage" xlink:label="loc_sclx_AggregatePercentage_745" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_sclx_AggregatePercentage_745" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_WarrantsPercentage" xlink:label="loc_sclx_WarrantsPercentage_746" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_sclx_WarrantsPercentage_746" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockNoParValue" xlink:label="loc_us-gaap_PreferredStockNoParValue_747" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_us-gaap_PreferredStockNoParValue_747" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_BalanceInTheTrustAccount" xlink:label="loc_sclx_BalanceInTheTrustAccount_748" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_sclx_BalanceInTheTrustAccount_748" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DeferredUnderwritingCommission" xlink:label="loc_sclx_DeferredUnderwritingCommission_749" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_sclx_DeferredUnderwritingCommission_749" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DeferredUnderwritingCommissionPayable" xlink:label="loc_sclx_DeferredUnderwritingCommissionPayable_750" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_sclx_DeferredUnderwritingCommissionPayable_750" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfAggregateRoyalityPayments" xlink:label="loc_sclx_PercentageOfAggregateRoyalityPayments_2146635915" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_sclx_PercentageOfAggregateRoyalityPayments_2146635915" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AgreementExpirationDate" xlink:label="loc_sclx_AgreementExpirationDate_2146635921" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_sclx_AgreementExpirationDate_2146635921" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AgreementExpirationTerm" xlink:label="loc_sclx_AgreementExpirationTerm_2146635922" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_sclx_AgreementExpirationTerm_2146635922" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AgreementAutomaticRenewalPeriodOnExpirationOfInitialTerm" xlink:label="loc_sclx_AgreementAutomaticRenewalPeriodOnExpirationOfInitialTerm_2146635925" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_sclx_AgreementAutomaticRenewalPeriodOnExpirationOfInitialTerm_2146635925" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NoticeOfTerminationPeriodForCancellationOfAutomaticRenewal" xlink:label="loc_sclx_NoticeOfTerminationPeriodForCancellationOfAutomaticRenewal_2146635928" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_sclx_NoticeOfTerminationPeriodForCancellationOfAutomaticRenewal_2146635928" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TerminationOfAgreementNoticePeriodForARequestToCureMaterialBreachOfTheAgreement" xlink:label="loc_sclx_TerminationOfAgreementNoticePeriodForARequestToCureMaterialBreachOfTheAgreement_2146635941" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_sclx_TerminationOfAgreementNoticePeriodForARequestToCureMaterialBreachOfTheAgreement_2146635941" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ThresholdMinimumPercentageOfSales" xlink:label="loc_sclx_ThresholdMinimumPercentageOfSales_2146635946" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_sclx_ThresholdMinimumPercentageOfSales_2146635946" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfAnnualAdjustmentToFees" xlink:label="loc_sclx_PercentageOfAnnualAdjustmentToFees_2146635948" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_sclx_PercentageOfAnnualAdjustmentToFees_2146635948" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfDistributionFeeReceivedOverThePeriod" xlink:label="loc_sclx_PercentageOfDistributionFeeReceivedOverThePeriod_2146635950" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_sclx_PercentageOfDistributionFeeReceivedOverThePeriod_2146635950" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NoticePeriodForTerminationOfWorkOrder" xlink:label="loc_sclx_NoticePeriodForTerminationOfWorkOrder_2146635952" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_sclx_NoticePeriodForTerminationOfWorkOrder_2146635952" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_WorkOrderImplementationFee" xlink:label="loc_sclx_WorkOrderImplementationFee_2146635953" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_sclx_WorkOrderImplementationFee_2146635953" use="optional" order="55" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SalesOperationsServicesMonthlyFee" xlink:label="loc_sclx_SalesOperationsServicesMonthlyFee_2146635954" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_sclx_SalesOperationsServicesMonthlyFee_2146635954" use="optional" order="56" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SellingGeneralAndAdministrativeExpenses" xlink:label="loc_sclx_SellingGeneralAndAdministrativeExpenses_2146635955" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_sclx_SellingGeneralAndAdministrativeExpenses_2146635955" use="optional" order="57" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_2146635956" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_2146635956" use="optional" order="58" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_2146635957" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_2146635957" use="optional" order="59" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaap_OperatingLeaseExpense_2146635959" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_us-gaap_OperatingLeaseExpense_2146635959" use="optional" order="60" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LessorOperatingLeaseTermOfContract_2146636108" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CommitmentsandContingenciesDetailsLineItems_724" xlink:to="loc_us-gaap_LessorOperatingLeaseTermOfContract_2146636108" use="optional" order="61" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesSummaryOfComponentsOfLeaseExpenseDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostAbstract" xlink:label="loc_us-gaap_LeaseCostAbstract_2146635857" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_2146635858" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_2146635857" xlink:to="loc_us-gaap_OperatingLeaseCost_2146635858" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_2146635865" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_2146636069" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_2146635865" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_2146636069" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2146635866" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_2146635865" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2146635866" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2146635867" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_2146635865" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2146635867" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2146635868" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_2146635865" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2146635868" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_2146635870" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_2146635865" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_2146635870" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_2146635871" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_2146635865" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_2146635871" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2146635872" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_2146635865" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2146635872" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2146637275" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_2146635865" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2146637275" use="optional" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_2146635875" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_2146635865" xlink:to="loc_us-gaap_OperatingLeaseLiability_2146635875" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesSummaryOfSupplementalQuantitativeInformationRelatedToLeasesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:label="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_2146635882" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_OperatingCashFlowsFromOperatingLeases" xlink:label="loc_sclx_OperatingCashFlowsFromOperatingLeases_2146635883" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_2146635882" xlink:to="loc_sclx_OperatingCashFlowsFromOperatingLeases_2146635883" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_2146636068" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_2146635882" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_2146636068" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_2146635884" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_2146635882" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_2146635884" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_2146635885" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_2146635882" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_2146635885" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/ShareholdersDeficitDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_763" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_2146635126" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_763" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_2146635126" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635128" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2146635126" xlink:to="loc_dei_LegalEntityAxis_2146635128" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635129" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2146635128" xlink:to="loc_dei_EntityDomain_2146635129" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635130" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146635129" xlink:to="loc_sclx_VickersVantageMember_2146635130" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_2146635127" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2146635126" xlink:to="loc_us-gaap_ClassOfStockLineItems_2146635127" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_764" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2146635127" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_764" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_765" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2146635127" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_765" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_766" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2146635127" xlink:to="loc_us-gaap_PreferredStockSharesIssued_766" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_767" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2146635127" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_767" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_768" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2146635127" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_768" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_769" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2146635127" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_769" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_770" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2146635127" xlink:to="loc_us-gaap_CommonStockSharesIssued_770" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_771" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2146635127" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_771" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_OrdinarySharesSubjectToPossibleRedemption" xlink:label="loc_sclx_OrdinarySharesSubjectToPossibleRedemption_772" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2146635127" xlink:to="loc_sclx_OrdinarySharesSubjectToPossibleRedemption_772" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/WarrantsDetails">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_WarrantsAbstract" xlink:label="loc_sclx_WarrantsAbstract_787" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_WarrantsDetailsTable" xlink:label="loc_sclx_WarrantsDetailsTable_788" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_WarrantsAbstract_787" xlink:to="loc_sclx_WarrantsDetailsTable_788" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_789" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_WarrantsDetailsTable_788" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_789" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_792" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_789" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_792" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_793" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_792" xlink:to="loc_us-gaap_PrivatePlacementMember_793" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_790" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_WarrantsDetailsTable_788" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_790" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_794" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_790" xlink:to="loc_us-gaap_EquityComponentDomain_794" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_795" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_794" xlink:to="loc_us-gaap_WarrantMember_795" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146634998" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_WarrantsDetailsTable_788" xlink:to="loc_dei_LegalEntityAxis_2146634998" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146634999" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2146634998" xlink:to="loc_dei_EntityDomain_2146634999" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635000" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146634999" xlink:to="loc_sclx_VickersVantageMember_2146635000" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_WarrantsDetailsLineItems" xlink:label="loc_sclx_WarrantsDetailsLineItems_791" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_WarrantsDetailsTable_788" xlink:to="loc_sclx_WarrantsDetailsLineItems_791" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_WarrantsOutstandingShares" xlink:label="loc_sclx_WarrantsOutstandingShares_796" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_WarrantsDetailsLineItems_791" xlink:to="loc_sclx_WarrantsOutstandingShares_796" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PublicWarrantsRedemptionDescription" xlink:label="loc_sclx_PublicWarrantsRedemptionDescription_797" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_WarrantsDetailsLineItems_791" xlink:to="loc_sclx_PublicWarrantsRedemptionDescription_797" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_CapitalRaisingDescription" xlink:label="loc_sclx_CapitalRaisingDescription_798" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_WarrantsDetailsLineItems_791" xlink:to="loc_sclx_CapitalRaisingDescription_798" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_804" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_2146634955" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_804" xlink:to="loc_us-gaap_StatementTable_2146634955" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2146634956" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2146634955" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2146634956" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2146634957" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2146634956" xlink:to="loc_us-gaap_ClassOfStockDomain_2146634957" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635089" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2146634955" xlink:to="loc_dei_LegalEntityAxis_2146635089" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635090" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2146635089" xlink:to="loc_dei_EntityDomain_2146635090" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635091" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146635090" xlink:to="loc_sclx_VickersVantageMember_2146635091" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_2146635787" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2146634955" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_2146635787" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_2146635789" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_2146635787" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_2146635789" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MeasurementInputRiskadjustedNetSalesForecastMember" xlink:label="loc_sclx_MeasurementInputRiskadjustedNetSalesForecastMember_2146635794" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_2146635789" xlink:to="loc_sclx_MeasurementInputRiskadjustedNetSalesForecastMember_2146635794" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MeasurementInputEffectiveDebtYieldMember" xlink:label="loc_sclx_MeasurementInputEffectiveDebtYieldMember_2146635799" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_2146635789" xlink:to="loc_sclx_MeasurementInputEffectiveDebtYieldMember_2146635799" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeMarch312021Member" xlink:label="loc_sclx_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeMarch312021Member_2146635806" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_2146635789" xlink:to="loc_sclx_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeMarch312021Member_2146635806" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeJuly12023Member" xlink:label="loc_sclx_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeJuly12023Member_2146635808" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_2146635789" xlink:to="loc_sclx_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeJuly12023Member_2146635808" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_2146636091" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2146634955" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_2146636091" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2146636092" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_2146636091" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2146636092" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_2146636093" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2146636092" xlink:to="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_2146636093" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_2146636094" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2146634955" xlink:to="loc_us-gaap_DebtInstrumentAxis_2146636094" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2146636095" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_2146636094" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2146636095" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScilexPharmaNotesMember" xlink:label="loc_sclx_ScilexPharmaNotesMember_2146636096" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2146636095" xlink:to="loc_sclx_ScilexPharmaNotesMember_2146636096" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2146634958" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2146634955" xlink:to="loc_us-gaap_StatementLineItems_2146634958" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsHeldInTrust" xlink:label="loc_us-gaap_AssetsHeldInTrust_2146636312" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146634958" xlink:to="loc_us-gaap_AssetsHeldInTrust_2146636312" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsHeldInTrustCurrent" xlink:label="loc_us-gaap_AssetsHeldInTrustCurrent_805" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146634958" xlink:to="loc_us-gaap_AssetsHeldInTrustCurrent_805" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsHighestAndBestUseDescription" xlink:label="loc_us-gaap_FairValueMeasurementsHighestAndBestUseDescription_806" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146634958" xlink:to="loc_us-gaap_FairValueMeasurementsHighestAndBestUseDescription_806" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLossOnDerivative" xlink:label="loc_us-gaap_DerivativeLossOnDerivative_2146635649" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146634958" xlink:to="loc_us-gaap_DerivativeLossOnDerivative_2146635649" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainOnDerivative" xlink:label="loc_us-gaap_DerivativeGainOnDerivative_2146635774" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146634958" xlink:to="loc_us-gaap_DerivativeGainOnDerivative_2146635774" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="loc_us-gaap_DerivativeLiabilityMeasurementInput_2146635778" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146634958" xlink:to="loc_us-gaap_DerivativeLiabilityMeasurementInput_2146635778" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_2146636089" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146634958" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_2146636089" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_2146636100" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146634958" xlink:to="loc_us-gaap_DerivativeLiabilities_2146636100" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfFairValueHierarchyOfTheValuationInputs">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScheduleOfFairValueHierarchyOfTheValuationInputsAbstract" xlink:label="loc_sclx_ScheduleOfFairValueHierarchyOfTheValuationInputsAbstract_402" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_FairValueMeasurementsDetailsScheduleoffairvaluehierarchyofthevaluationinputsTable" xlink:label="loc_sclx_FairValueMeasurementsDetailsScheduleoffairvaluehierarchyofthevaluationinputsTable_403" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ScheduleOfFairValueHierarchyOfTheValuationInputsAbstract_402" xlink:to="loc_sclx_FairValueMeasurementsDetailsScheduleoffairvaluehierarchyofthevaluationinputsTable_403" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_404" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_FairValueMeasurementsDetailsScheduleoffairvaluehierarchyofthevaluationinputsTable_403" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_404" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2146634686" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_404" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2146634686" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_408" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2146634686" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_408" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_409" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2146634686" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_409" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635112" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_FairValueMeasurementsDetailsScheduleoffairvaluehierarchyofthevaluationinputsTable_403" xlink:to="loc_dei_LegalEntityAxis_2146635112" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635113" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2146635112" xlink:to="loc_dei_EntityDomain_2146635113" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635115" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146635113" xlink:to="loc_sclx_VickersVantageMember_2146635115" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_FairValueMeasurementsDetailsScheduleoffairvaluehierarchyofthevaluationinputsLineItems" xlink:label="loc_sclx_FairValueMeasurementsDetailsScheduleoffairvaluehierarchyofthevaluationinputsLineItems_405" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_FairValueMeasurementsDetailsScheduleoffairvaluehierarchyofthevaluationinputsTable_403" xlink:to="loc_sclx_FairValueMeasurementsDetailsScheduleoffairvaluehierarchyofthevaluationinputsLineItems_405" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_406" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_FairValueMeasurementsDetailsScheduleoffairvaluehierarchyofthevaluationinputsLineItems_405" xlink:to="loc_us-gaap_AssetsAbstract_406" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeSecuritiesUSTreasury" xlink:label="loc_us-gaap_InterestIncomeSecuritiesUSTreasury_410" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_406" xlink:to="loc_us-gaap_InterestIncomeSecuritiesUSTreasury_410" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract" xlink:label="loc_us-gaap_LiabilitiesAbstract_407" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_FairValueMeasurementsDetailsScheduleoffairvaluehierarchyofthevaluationinputsLineItems_405" xlink:to="loc_us-gaap_LiabilitiesAbstract_407" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="loc_us-gaap_LiabilitiesFairValueAdjustment_411" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_407" xlink:to="loc_us-gaap_LiabilitiesFairValueAdjustment_411" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_412" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_407" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_412" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfChangesInTheFairValueOfWarrantLiabilitiesAndConversionOptionLiability">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScheduleOfChangesInTheFairValueOfWarrantLiabilitiesAndConversionOptionLiabilityAbstract" xlink:label="loc_sclx_ScheduleOfChangesInTheFairValueOfWarrantLiabilitiesAndConversionOptionLiabilityAbstract_443" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityTable" xlink:label="loc_sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityTable_444" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ScheduleOfChangesInTheFairValueOfWarrantLiabilitiesAndConversionOptionLiabilityAbstract_443" xlink:to="loc_sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityTable_444" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_445" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityTable_444" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_445" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2146634698" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_445" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2146634698" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_447" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2146634698" xlink:to="loc_us-gaap_PrivatePlacementMember_447" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ConversionOptionLiabilityMember" xlink:label="loc_sclx_ConversionOptionLiabilityMember_448" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2146634698" xlink:to="loc_sclx_ConversionOptionLiabilityMember_448" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635139" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityTable_444" xlink:to="loc_dei_LegalEntityAxis_2146635139" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635140" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2146635139" xlink:to="loc_dei_EntityDomain_2146635140" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635141" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146635140" xlink:to="loc_sclx_VickersVantageMember_2146635141" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityLineItems" xlink:label="loc_sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityLineItems_446" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityTable_444" xlink:to="loc_sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityLineItems_446" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_449" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityLineItems_446" xlink:to="loc_us-gaap_DerivativeLiabilities_449" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_InitialMeasurementOne" xlink:label="loc_sclx_InitialMeasurementOne_450" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityLineItems_446" xlink:to="loc_sclx_InitialMeasurementOne_450" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ChangeInValuationInputsOrOtherAssumptions" xlink:label="loc_sclx_ChangeInValuationInputsOrOtherAssumptions_451" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityLineItems_446" xlink:to="loc_sclx_ChangeInValuationInputsOrOtherAssumptions_451" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_452" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityLineItems_446" xlink:to="loc_us-gaap_DerivativeLiabilities_452" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfValuedUsingTheCompoundOptionPricingModel">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScheduleOfValuedUsingTheCompoundOptionPricingModelAbstract" xlink:label="loc_sclx_ScheduleOfValuedUsingTheCompoundOptionPricingModelAbstract_462" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_2146635143" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ScheduleOfValuedUsingTheCompoundOptionPricingModelAbstract_462" xlink:to="loc_us-gaap_StatementTable_2146635143" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2146635144" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2146635143" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2146635144" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2146635145" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2146635144" xlink:to="loc_us-gaap_ClassOfStockDomain_2146635145" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635147" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2146635143" xlink:to="loc_dei_LegalEntityAxis_2146635147" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635148" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2146635147" xlink:to="loc_dei_EntityDomain_2146635148" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635149" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146635148" xlink:to="loc_sclx_VickersVantageMember_2146635149" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2146635146" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2146635143" xlink:to="loc_us-gaap_StatementLineItems_2146635146" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_UnderlyingWarrantValue" xlink:label="loc_sclx_UnderlyingWarrantValue_463" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635146" xlink:to="loc_sclx_UnderlyingWarrantValue_463" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_464" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635146" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_464" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_HoldingPeriod" xlink:label="loc_sclx_HoldingPeriod_465" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635146" xlink:to="loc_sclx_HoldingPeriod_465" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_466" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635146" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_466" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_467" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635146" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_467" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_468" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635146" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_468" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsFinancialAssetsAndLiabilitiesThatAreMeasuredAtFairValue">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_2146635509" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2146635511" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_2146635509" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2146635511" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2146635559" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2146635511" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2146635559" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2146635560" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2146635559" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2146635560" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_2146635565" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2146635560" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_2146635565" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_2146635567" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2146635560" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_2146635567" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2146635513" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2146635511" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2146635513" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_2146635516" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2146635513" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_2146635516" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_2146635520" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2146635513" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_2146635520" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_2146635527" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2146635513" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_2146635527" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_2146635531" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_2146635527" xlink:to="loc_us-gaap_DerivativeLiabilities_2146635531" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_2146635558" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_2146635527" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_2146635558" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsDerivativeLiabilitiesMeasuredAtFairValueUsingSignificantUnobservableInputs">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_2146635622" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2146635623" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2146635622" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2146635623" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_2146635638" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2146635623" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_2146635638" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2146635639" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_2146635638" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2146635639" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_2146635640" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2146635639" xlink:to="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_2146635640" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2146635624" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2146635623" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2146635624" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2146635626" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2146635624" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2146635626" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_2146635629" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2146635624" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_2146635629" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_2146635630" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2146635624" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_2146635630" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_2146635862" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2146635624" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_2146635862" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2146635632" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_2146635624" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2146635632" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurements">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurementsAbstract" xlink:label="loc_sclx_ScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurementsAbstract_423" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_2146635132" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurementsAbstract_423" xlink:to="loc_us-gaap_StatementTable_2146635132" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635136" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2146635132" xlink:to="loc_dei_LegalEntityAxis_2146635136" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635137" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2146635136" xlink:to="loc_dei_EntityDomain_2146635137" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635138" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146635137" xlink:to="loc_sclx_VickersVantageMember_2146635138" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2146635133" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2146635132" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2146635133" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2146635134" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2146635133" xlink:to="loc_us-gaap_ClassOfStockDomain_2146635134" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2146635135" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2146635132" xlink:to="loc_us-gaap_StatementLineItems_2146635135" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_424" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635135" xlink:to="loc_us-gaap_SharePrice_424" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_FairValueMeasurementStrikePrice" xlink:label="loc_sclx_FairValueMeasurementStrikePrice_425" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635135" xlink:to="loc_sclx_FairValueMeasurementStrikePrice_425" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_426" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635135" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_426" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_427" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635135" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_427" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1" xlink:label="loc_sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1_428" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635135" xlink:to="loc_sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1_428" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1" xlink:label="loc_sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1_429" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635135" xlink:to="loc_sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1_429" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_FairValueOfWarrantsinDollars" xlink:label="loc_sclx_FairValueOfWarrantsinDollars_430" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2146635135" xlink:to="loc_sclx_FairValueOfWarrantsinDollars_430" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfChangeInTheFairValueOfConversionOptionLiability">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityAbstract" xlink:label="loc_sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityAbstract_2146635355" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityTable" xlink:label="loc_sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityTable_2146635356" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityAbstract_2146635355" xlink:to="loc_sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityTable_2146635356" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635358" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityTable_2146635356" xlink:to="loc_dei_LegalEntityAxis_2146635358" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635359" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2146635358" xlink:to="loc_dei_EntityDomain_2146635359" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635360" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146635359" xlink:to="loc_sclx_VickersVantageMember_2146635360" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityLineItems" xlink:label="loc_sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityLineItems_2146635357" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityTable_2146635356" xlink:to="loc_sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityLineItems_2146635357" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetAssetLiability" xlink:label="loc_us-gaap_FairValueNetAssetLiability_2146635361" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityLineItems_2146635357" xlink:to="loc_us-gaap_FairValueNetAssetLiability_2146635361" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_2146635363" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityLineItems_2146635357" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_2146635363" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue" xlink:label="loc_us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue_2146635364" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityLineItems_2146635357" xlink:to="loc_us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue_2146635364" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetAssetLiability" xlink:label="loc_us-gaap_FairValueNetAssetLiability_2146635362" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityLineItems_2146635357" xlink:to="loc_us-gaap_FairValueNetAssetLiability_2146635362" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/PropertyAndEquipmentDetailsPropertyAndEquipmentConsisted">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2146635823" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2146635825" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2146635823" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2146635825" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2146635831" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2146635825" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2146635831" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2146635832" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2146635831" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2146635832" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_2146635833" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2146635832" xlink:to="loc_us-gaap_ComputerEquipmentMember_2146635833" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_2146635835" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2146635832" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_2146635835" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_2146635836" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2146635832" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_2146635836" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_2146635837" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2146635832" xlink:to="loc_us-gaap_ConstructionInProgressMember_2146635837" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2146635826" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2146635825" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2146635826" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_2146635827" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2146635826" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_2146635827" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2146635828" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2146635826" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2146635828" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2146635830" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2146635826" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_2146635830" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/PropertyAndEquipmentDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2146635842" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseGross" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseGross_2146635843" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2146635842" xlink:to="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseGross_2146635843" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfTheCompanysIdentifiableIntangibleAssets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2146635533" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2146635534" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2146635533" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2146635534" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2146635540" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2146635534" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2146635540" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2146635541" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2146635540" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2146635541" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaap_PatentsMember_2146635542" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2146635541" xlink:to="loc_us-gaap_PatentsMember_2146635542" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_2146635545" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2146635541" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_2146635545" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember" xlink:label="loc_us-gaap_LicensingAgreementsMember_2146636056" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2146635541" xlink:to="loc_us-gaap_LicensingAgreementsMember_2146636056" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AssembledWorkforceMember" xlink:label="loc_sclx_AssembledWorkforceMember_2146635548" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2146635541" xlink:to="loc_sclx_AssembledWorkforceMember_2146635548" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2146635535" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2146635534" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2146635535" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_2146635537" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2146635535" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_2146635537" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2146635538" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2146635535" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2146635538" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2146635539" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2146635535" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2146635539" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfEstimatedFutureAmortizationExpense">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2146635495" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_2146636058" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2146635495" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_2146636058" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_2146635502" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2146635495" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_2146635502" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_2146635506" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2146635495" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_2146635506" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_2146635507" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2146635495" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_2146635507" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_2146635508" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2146635495" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_2146635508" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_2146635509" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2146635495" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_2146635509" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_2146635510" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2146635495" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_2146635510" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour" xlink:label="loc_sclx_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour_2146636060" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2146635495" xlink:to="loc_sclx_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour_2146636060" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2146635512" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2146635495" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2146635512" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2146635564" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_2146635568" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2146635564" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_2146635568" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2146635592" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_2146635568" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2146635592" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2146635593" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2146635592" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2146635593" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaap_PatentsMember_2146635595" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2146635593" xlink:to="loc_us-gaap_PatentsMember_2146635595" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_2146635596" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2146635593" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_2146635596" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AssembledWorkforceMember" xlink:label="loc_sclx_AssembledWorkforceMember_2146635597" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2146635593" xlink:to="loc_sclx_AssembledWorkforceMember_2146635597" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember" xlink:label="loc_us-gaap_LicensingAgreementsMember_2146636064" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2146635593" xlink:to="loc_us-gaap_LicensingAgreementsMember_2146636064" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_2146635600" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_2146635568" xlink:to="loc_srt_RangeAxis_2146635600" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_2146635602" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_2146635600" xlink:to="loc_srt_RangeMember_2146635602" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_WeightedAverageMember" xlink:label="loc_srt_WeightedAverageMember_2146635603" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2146635602" xlink:to="loc_srt_WeightedAverageMember_2146635603" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_2146635569" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_2146635568" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_2146635569" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_2146635582" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_2146635569" xlink:to="loc_us-gaap_Goodwill_2146635582" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_2146635585" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_2146635569" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_2146635585" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_2146635586" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_2146635569" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_2146635586" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_2146635588" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_2146635569" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_2146635588" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_2146635589" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_2146635569" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_2146635589" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_2146635590" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_2146635569" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_2146635590" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_2146636061" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_2146635569" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_2146636061" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_2146636062" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_2146635569" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_2146636062" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/DebtDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_2146636080" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_2146636082" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_2146636080" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTable_2146636082" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_2146636084" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_2146636082" xlink:to="loc_us-gaap_DebtInstrumentAxis_2146636084" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2146636085" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_2146636084" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2146636085" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TwoThousandAndEighteenPurchaseAgreementsMember" xlink:label="loc_sclx_TwoThousandAndEighteenPurchaseAgreementsMember_2146636086" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2146636085" xlink:to="loc_sclx_TwoThousandAndEighteenPurchaseAgreementsMember_2146636086" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScilexPharmaNoteMember" xlink:label="loc_sclx_ScilexPharmaNoteMember_2146636174" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2146636085" xlink:to="loc_sclx_ScilexPharmaNoteMember_2146636174" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_2146636141" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_2146636082" xlink:to="loc_srt_RangeAxis_2146636141" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_2146636142" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_2146636141" xlink:to="loc_srt_RangeMember_2146636142" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_2146636143" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2146636142" xlink:to="loc_srt_MaximumMember_2146636143" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_2146636144" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2146636142" xlink:to="loc_srt_MinimumMember_2146636144" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_2146636145" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_2146636082" xlink:to="loc_srt_StatementScenarioAxis_2146636145" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_2146636146" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_2146636145" xlink:to="loc_srt_ScenarioUnspecifiedDomain_2146636146" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScenarioAdjustmentMember" xlink:label="loc_us-gaap_ScenarioAdjustmentMember_2146636147" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_2146636146" xlink:to="loc_us-gaap_ScenarioAdjustmentMember_2146636147" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_IfLetterOfCreditIsDrawnMember" xlink:label="loc_sclx_IfLetterOfCreditIsDrawnMember_2146636246" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_2146636146" xlink:to="loc_sclx_IfLetterOfCreditIsDrawnMember_2146636246" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MarketingApprovalLetterMember" xlink:label="loc_sclx_MarketingApprovalLetterMember_2146636248" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_2146636146" xlink:to="loc_sclx_MarketingApprovalLetterMember_2146636248" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_2146636148" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_2146636082" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_2146636148" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_2146636149" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_2146636148" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_2146636149" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_2146636150" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_2146636149" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_2146636150" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_2146636156" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_2146636149" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_2146636156" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_2146636170" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_2146636149" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_2146636170" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AgreementAxis" xlink:label="loc_sclx_AgreementAxis_2146636183" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_2146636082" xlink:to="loc_sclx_AgreementAxis_2146636183" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AgreementDomain" xlink:label="loc_sclx_AgreementDomain_2146636184" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_AgreementAxis_2146636183" xlink:to="loc_sclx_AgreementDomain_2146636184" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_IndebentureMember" xlink:label="loc_sclx_IndebentureMember_2146636188" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_AgreementDomain_2146636184" xlink:to="loc_sclx_IndebentureMember_2146636188" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_2146636207" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_2146636082" xlink:to="loc_us-gaap_CreditFacilityAxis_2146636207" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_2146636208" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_2146636207" xlink:to="loc_us-gaap_CreditFacilityDomain_2146636208" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember" xlink:label="loc_us-gaap_LetterOfCreditMember_2146636219" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_2146636208" xlink:to="loc_us-gaap_LetterOfCreditMember_2146636219" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AccountsReceivableRevolvingLoanFacilityMember" xlink:label="loc_sclx_AccountsReceivableRevolvingLoanFacilityMember_2146636322" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_2146636208" xlink:to="loc_sclx_AccountsReceivableRevolvingLoanFacilityMember_2146636322" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_2146636381" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_2146636208" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_2146636381" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_StatementAxis" xlink:label="loc_sclx_StatementAxis_2146636282" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_2146636082" xlink:to="loc_sclx_StatementAxis_2146636282" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_StatementDomain" xlink:label="loc_sclx_StatementDomain_2146636283" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_StatementAxis_2146636282" xlink:to="loc_sclx_StatementDomain_2146636283" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DecemberOptionalRepurchaseMember" xlink:label="loc_sclx_DecemberOptionalRepurchaseMember_2146636287" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_StatementDomain_2146636283" xlink:to="loc_sclx_DecemberOptionalRepurchaseMember_2146636287" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_FebruaryOptionalRepurchaseMember" xlink:label="loc_sclx_FebruaryOptionalRepurchaseMember_2146636291" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_StatementDomain_2146636283" xlink:to="loc_sclx_FebruaryOptionalRepurchaseMember_2146636291" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AprilOptionalRepurchaseMember" xlink:label="loc_sclx_AprilOptionalRepurchaseMember_2146636294" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_StatementDomain_2146636283" xlink:to="loc_sclx_AprilOptionalRepurchaseMember_2146636294" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_2146636383" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_2146636082" xlink:to="loc_us-gaap_VariableRateAxis_2146636383" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_2146636384" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_2146636383" xlink:to="loc_us-gaap_VariableRateDomain_2146636384" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrimeRateMember" xlink:label="loc_us-gaap_PrimeRateMember_2146636385" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_2146636384" xlink:to="loc_us-gaap_PrimeRateMember_2146636385" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_2146636389" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_2146636082" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_2146636389" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2146636390" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2146636389" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2146636390" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PaycheckProtectionProgramMember" xlink:label="loc_sclx_PaycheckProtectionProgramMember_2146636391" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2146636390" xlink:to="loc_sclx_PaycheckProtectionProgramMember_2146636391" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubordinatedDebtMember" xlink:label="loc_us-gaap_SubordinatedDebtMember_2146636404" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2146636390" xlink:to="loc_us-gaap_SubordinatedDebtMember_2146636404" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_EventTypeAxis" xlink:label="loc_sclx_EventTypeAxis_2146636396" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_2146636082" xlink:to="loc_sclx_EventTypeAxis_2146636396" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_EventTypeDomain" xlink:label="loc_sclx_EventTypeDomain_2146636397" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_EventTypeAxis_2146636396" xlink:to="loc_sclx_EventTypeDomain_2146636397" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_CoronavirusAidReliefAndEconomicSecurityActMember" xlink:label="loc_sclx_CoronavirusAidReliefAndEconomicSecurityActMember_2146636398" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_EventTypeDomain_2146636397" xlink:to="loc_sclx_CoronavirusAidReliefAndEconomicSecurityActMember_2146636398" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ClassificationOfCostAxis" xlink:label="loc_sclx_ClassificationOfCostAxis_2146636400" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_2146636082" xlink:to="loc_sclx_ClassificationOfCostAxis_2146636400" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ClassificationOfCostDomain" xlink:label="loc_sclx_ClassificationOfCostDomain_2146636437" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ClassificationOfCostAxis_2146636400" xlink:to="loc_sclx_ClassificationOfCostDomain_2146636437" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NonPayrollCostsMember" xlink:label="loc_sclx_NonPayrollCostsMember_2146636438" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ClassificationOfCostDomain_2146636437" xlink:to="loc_sclx_NonPayrollCostsMember_2146636438" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PayrollCostsBasisMember" xlink:label="loc_sclx_PayrollCostsBasisMember_2146636439" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ClassificationOfCostDomain_2146636437" xlink:to="loc_sclx_PayrollCostsBasisMember_2146636439" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AmendmentAxis" xlink:label="loc_sclx_AmendmentAxis_2146636421" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_2146636082" xlink:to="loc_sclx_AmendmentAxis_2146636421" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AmendmentDomain" xlink:label="loc_sclx_AmendmentDomain_2146636423" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_AmendmentAxis_2146636421" xlink:to="loc_sclx_AmendmentDomain_2146636423" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AmendmentNoFourMember" xlink:label="loc_sclx_AmendmentNoFourMember_2146636424" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_AmendmentDomain_2146636423" xlink:to="loc_sclx_AmendmentNoFourMember_2146636424" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2146636425" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_2146636082" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2146636425" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_2146636426" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2146636425" xlink:to="loc_us-gaap_RelatedPartyDomain_2146636426" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SorrentoMember" xlink:label="loc_sclx_SorrentoMember_2146636427" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_2146636426" xlink:to="loc_sclx_SorrentoMember_2146636427" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_2146636428" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_2146636082" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_2146636428" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_2146636429" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_2146636428" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_2146636429" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PromissoryNoteMember" xlink:label="loc_sclx_PromissoryNoteMember_2146636430" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_2146636429" xlink:to="loc_sclx_PromissoryNoteMember_2146636430" use="optional" order="55" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_2146636431" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_2146636082" xlink:to="loc_us-gaap_TypeOfArrangementAxis_2146636431" use="optional" order="56" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2146636432" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2146636431" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2146636432" use="optional" order="57" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TwoThousandAndEighteenPurchaseAgreementsAndIndentureMember" xlink:label="loc_sclx_TwoThousandAndEighteenPurchaseAgreementsAndIndentureMember_2146636434" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2146636432" xlink:to="loc_sclx_TwoThousandAndEighteenPurchaseAgreementsAndIndentureMember_2146636434" use="optional" order="58" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaap_ShortTermDebtLineItems_2146636083" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_2146636082" xlink:to="loc_us-gaap_ShortTermDebtLineItems_2146636083" use="optional" order="59" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_2146636087" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_2146636087" use="optional" order="60" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchaseAmount" xlink:label="loc_us-gaap_DebtInstrumentRepurchaseAmount_2146636088" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_DebtInstrumentRepurchaseAmount_2146636088" use="optional" order="61" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm_2146636090" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_DebtInstrumentTerm_2146636090" use="optional" order="62" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfQuarterlyPaymentsOfThePrincipalNotesEqualToAFixedPercentage" xlink:label="loc_sclx_PercentageOfQuarterlyPaymentsOfThePrincipalNotesEqualToAFixedPercentage_2146636137" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_sclx_PercentageOfQuarterlyPaymentsOfThePrincipalNotesEqualToAFixedPercentage_2146636137" use="optional" order="63" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfNetSalesPayable" xlink:label="loc_sclx_PercentageOfNetSalesPayable_2146636138" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_sclx_PercentageOfNetSalesPayable_2146636138" use="optional" order="64" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueNotFromContractWithCustomer" xlink:label="loc_us-gaap_RevenueNotFromContractWithCustomer_2146636139" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_RevenueNotFromContractWithCustomer_2146636139" use="optional" order="65" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt_2146636140" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_RepaymentsOfDebt_2146636140" use="optional" order="66" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_2146636151" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_2146636151" use="optional" order="67" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PaymentToDepositIntoASeggregateReserveFund" xlink:label="loc_sclx_PaymentToDepositIntoASeggregateReserveFund_2146636152" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_sclx_PaymentToDepositIntoASeggregateReserveFund_2146636152" use="optional" order="68" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PaymentToDepositIntoASegregatedCollateralAccount" xlink:label="loc_sclx_PaymentToDepositIntoASegregatedCollateralAccount_2146636153" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_sclx_PaymentToDepositIntoASegregatedCollateralAccount_2146636153" use="optional" order="69" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfConcentrationOnASimilarProduct" xlink:label="loc_sclx_PercentageOfConcentrationOnASimilarProduct_2146636154" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_sclx_PercentageOfConcentrationOnASimilarProduct_2146636154" use="optional" order="70" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="loc_us-gaap_DebtInstrumentPeriodicPayment_2146636155" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_DebtInstrumentPeriodicPayment_2146636155" use="optional" order="71" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_2146636159" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_2146636159" use="optional" order="72" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DebtInstrumentredemptionPeriod" xlink:label="loc_sclx_DebtInstrumentredemptionPeriod_2146636171" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_sclx_DebtInstrumentredemptionPeriod_2146636171" use="optional" order="73" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_2146636176" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_2146636176" use="optional" order="74" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_2146636197" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_2146636197" use="optional" order="75" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_2146636203" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_2146636203" use="optional" order="76" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_2146636239" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_2146636239" use="optional" order="77" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfThePrincipalAmountFromHoldersOnProRataBasis" xlink:label="loc_sclx_PercentageOfThePrincipalAmountFromHoldersOnProRataBasis_2146636241" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_sclx_PercentageOfThePrincipalAmountFromHoldersOnProRataBasis_2146636241" use="optional" order="78" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MinimumCashRequirementsToRepurchaseOfNotes" xlink:label="loc_sclx_MinimumCashRequirementsToRepurchaseOfNotes_2146636277" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_sclx_MinimumCashRequirementsToRepurchaseOfNotes_2146636277" use="optional" order="79" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfThePrincipalAmountOfTheNotes" xlink:label="loc_sclx_PercentageOfThePrincipalAmountOfTheNotes_2146636313" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_sclx_PercentageOfThePrincipalAmountOfTheNotes_2146636313" use="optional" order="80" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MinimumUnrestrictedCashRequirementsToRepurchaseOfNotes" xlink:label="loc_sclx_MinimumUnrestrictedCashRequirementsToRepurchaseOfNotes_2146636314" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_sclx_MinimumUnrestrictedCashRequirementsToRepurchaseOfNotes_2146636314" use="optional" order="81" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LineOfCreditFacilityindebtednessAmount" xlink:label="loc_sclx_LineOfCreditFacilityindebtednessAmount_2146636321" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_sclx_LineOfCreditFacilityindebtednessAmount_2146636321" use="optional" order="82" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_2146636334" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_DerivativeLiabilities_2146636334" use="optional" order="83" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AmountDistributionToAcquireRelatedContingentAcceleratedRepaymentNotes" xlink:label="loc_sclx_AmountDistributionToAcquireRelatedContingentAcceleratedRepaymentNotes_2146636335" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_sclx_AmountDistributionToAcquireRelatedContingentAcceleratedRepaymentNotes_2146636335" use="optional" order="84" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_2146636338" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_2146636338" use="optional" order="85" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:label="loc_us-gaap_DebtInstrumentAnnualPrincipalPayment_2146636377" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_DebtInstrumentAnnualPrincipalPayment_2146636377" use="optional" order="86" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_2146636378" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_2146636378" use="optional" order="87" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:label="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_2146636379" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_2146636379" use="optional" order="88" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_2146636386" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_LongTermDebt_2146636386" use="optional" order="89" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DebtInstrumentTerminationDate" xlink:label="loc_sclx_DebtInstrumentTerminationDate_2146636387" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_sclx_DebtInstrumentTerminationDate_2146636387" use="optional" order="90" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_2146636388" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_2146636388" use="optional" order="91" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MaximumCompensationCostToBeAvailableProratedBasis" xlink:label="loc_sclx_MaximumCompensationCostToBeAvailableProratedBasis_2146636392" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_sclx_MaximumCompensationCostToBeAvailableProratedBasis_2146636392" use="optional" order="92" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfLoanForgivenessUnderTheAct" xlink:label="loc_sclx_PercentageOfLoanForgivenessUnderTheAct_2146636393" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_sclx_PercentageOfLoanForgivenessUnderTheAct_2146636393" use="optional" order="93" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MinimumPayrollCostToBeAvailable" xlink:label="loc_sclx_MinimumPayrollCostToBeAvailable_2146636394" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_sclx_MinimumPayrollCostToBeAvailable_2146636394" use="optional" order="94" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_2146636395" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_2146636395" use="optional" order="95" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaap_RestrictedCash_2146636405" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_RestrictedCash_2146636405" use="optional" order="96" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DebtInstrumentPercentageOfPrincipalAmountRepurchased" xlink:label="loc_sclx_DebtInstrumentPercentageOfPrincipalAmountRepurchased_2146636406" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_sclx_DebtInstrumentPercentageOfPrincipalAmountRepurchased_2146636406" use="optional" order="97" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchaseDate" xlink:label="loc_us-gaap_DebtInstrumentRepurchaseDate_2146636407" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_DebtInstrumentRepurchaseDate_2146636407" use="optional" order="98" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentDecreaseForgiveness" xlink:label="loc_us-gaap_DebtInstrumentDecreaseForgiveness_2146636408" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_DebtInstrumentDecreaseForgiveness_2146636408" use="optional" order="99" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCollateralAmount" xlink:label="loc_us-gaap_DebtInstrumentCollateralAmount_2146636409" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_DebtInstrumentCollateralAmount_2146636409" use="optional" order="100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt_2146636410" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt_2146636410" use="optional" order="101" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnRestructuringOfDebt" xlink:label="loc_us-gaap_GainsLossesOnRestructuringOfDebt_2146636411" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_GainsLossesOnRestructuringOfDebt_2146636411" use="optional" order="102" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_2146636412" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_2146636412" use="optional" order="103" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" xlink:label="loc_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet_2146636413" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet_2146636413" use="optional" order="104" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_2146636414" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_2146636083" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_2146636414" use="optional" order="105" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/DebtDetailsSummaryOfBorrowingsOfTheScilexPharmaNotes">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_2146636354" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_2146636355" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_2146636354" xlink:to="loc_us-gaap_DebtInstrumentTable_2146636355" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_2146636357" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_2146636355" xlink:to="loc_us-gaap_DebtInstrumentAxis_2146636357" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2146636358" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_2146636357" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2146636358" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScilexPharmaNotesMember" xlink:label="loc_sclx_ScilexPharmaNotesMember_2146636359" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2146636358" xlink:to="loc_sclx_ScilexPharmaNotesMember_2146636359" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_2146636356" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_2146636355" xlink:to="loc_us-gaap_DebtInstrumentLineItems_2146636356" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_2146636360" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2146636356" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_2146636360" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_2146636361" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2146636356" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_2146636361" use="optional" order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="loc_us-gaap_UnamortizedDebtIssuanceExpense_2146636362" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2146636356" xlink:to="loc_us-gaap_UnamortizedDebtIssuanceExpense_2146636362" use="optional" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_2146636363" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2146636356" xlink:to="loc_us-gaap_LongTermDebt_2146636363" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_2146636364" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2146636356" xlink:to="loc_us-gaap_LongTermDebtCurrent_2146636364" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_2146636365" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2146636356" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_2146636365" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtFairValue" xlink:label="loc_us-gaap_LongTermDebtFairValue_2146636366" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2146636356" xlink:to="loc_us-gaap_LongTermDebtFairValue_2146636366" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/DebtDetailsSummaryOfFutureMinimumPaymentsUnderTheScilexPharmaNotes">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_2146636368" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtTable" xlink:label="loc_sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtTable_2146636369" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_2146636368" xlink:to="loc_sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtTable_2146636369" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtLineItems" xlink:label="loc_sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtLineItems_2146636370" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtTable_2146636369" xlink:to="loc_sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtLineItems_2146636370" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LongtermDebtfutureMinimumPaymentYearOne" xlink:label="loc_sclx_LongtermDebtfutureMinimumPaymentYearOne_2146636371" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtLineItems_2146636370" xlink:to="loc_sclx_LongtermDebtfutureMinimumPaymentYearOne_2146636371" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LongtermDebtFutureMinimumPaymentYearTwo" xlink:label="loc_sclx_LongtermDebtFutureMinimumPaymentYearTwo_2146636372" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtLineItems_2146636370" xlink:to="loc_sclx_LongtermDebtFutureMinimumPaymentYearTwo_2146636372" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LongtermDebtFutureMinimumPaymentYearThree" xlink:label="loc_sclx_LongtermDebtFutureMinimumPaymentYearThree_2146636373" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtLineItems_2146636370" xlink:to="loc_sclx_LongtermDebtFutureMinimumPaymentYearThree_2146636373" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LongtermDebtFutureMinimumPaymentYearFour" xlink:label="loc_sclx_LongtermDebtFutureMinimumPaymentYearFour_2146636374" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtLineItems_2146636370" xlink:to="loc_sclx_LongtermDebtFutureMinimumPaymentYearFour_2146636374" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LongtermDebtFutureMinimumPaymentYearFive" xlink:label="loc_sclx_LongtermDebtFutureMinimumPaymentYearFive_2146636375" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtLineItems_2146636370" xlink:to="loc_sclx_LongtermDebtFutureMinimumPaymentYearFive_2146636375" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_LongtermDebtFutureMinimumPayment" xlink:label="loc_sclx_LongtermDebtFutureMinimumPayment_2146636376" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtLineItems_2146636370" xlink:to="loc_sclx_LongtermDebtFutureMinimumPayment_2146636376" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetails">
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_CompensationAndEmployeeBenefitPlansAbstract" xlink:label="loc_sclx_CompensationAndEmployeeBenefitPlansAbstract_2146635457" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_CompensationAndEmployeeBenefitPlansTable" xlink:label="loc_sclx_CompensationAndEmployeeBenefitPlansTable_2146635460" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CompensationAndEmployeeBenefitPlansAbstract_2146635457" xlink:to="loc_sclx_CompensationAndEmployeeBenefitPlansTable_2146635460" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_2146635463" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CompensationAndEmployeeBenefitPlansTable_2146635460" xlink:to="loc_us-gaap_PlanNameAxis_2146635463" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_2146635464" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_2146635463" xlink:to="loc_us-gaap_PlanNameDomain_2146635464" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScilexPharmaTwoThousandSeventeenPlanMember" xlink:label="loc_sclx_ScilexPharmaTwoThousandSeventeenPlanMember_2146635465" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_2146635464" xlink:to="loc_sclx_ScilexPharmaTwoThousandSeventeenPlanMember_2146635465" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TwoThousandNineteenStockOptionPlanMember" xlink:label="loc_sclx_TwoThousandNineteenStockOptionPlanMember_2146635587" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_2146635464" xlink:to="loc_sclx_TwoThousandNineteenStockOptionPlanMember_2146635587" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AmendmentToTwoThousandNineteenStockOptionPlanMember" xlink:label="loc_sclx_AmendmentToTwoThousandNineteenStockOptionPlanMember_2146635591" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_2146635464" xlink:to="loc_sclx_AmendmentToTwoThousandNineteenStockOptionPlanMember_2146635591" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2146635598" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CompensationAndEmployeeBenefitPlansTable_2146635460" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2146635598" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2146635599" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2146635598" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2146635599" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_OperatingExpensesMember" xlink:label="loc_sclx_OperatingExpensesMember_2146635604" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2146635599" xlink:to="loc_sclx_OperatingExpensesMember_2146635604" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanNameAxis" xlink:label="loc_us-gaap_RetirementPlanNameAxis_2146635605" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CompensationAndEmployeeBenefitPlansTable_2146635460" xlink:to="loc_us-gaap_RetirementPlanNameAxis_2146635605" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanNameDomain" xlink:label="loc_us-gaap_RetirementPlanNameDomain_2146635606" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanNameAxis_2146635605" xlink:to="loc_us-gaap_RetirementPlanNameDomain_2146635606" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_FourHundredAndOneKPlanMember" xlink:label="loc_sclx_FourHundredAndOneKPlanMember_2146635607" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanNameDomain_2146635606" xlink:to="loc_sclx_FourHundredAndOneKPlanMember_2146635607" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2146636114" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CompensationAndEmployeeBenefitPlansTable_2146635460" xlink:to="loc_us-gaap_AwardTypeAxis_2146636114" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2146636115" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2146636114" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2146636115" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_2146636116" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2146636115" xlink:to="loc_us-gaap_EmployeeStockOptionMember_2146636116" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_CompensationAndEmployeeBenefitPlansLineItems" xlink:label="loc_sclx_CompensationAndEmployeeBenefitPlansLineItems_2146635462" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CompensationAndEmployeeBenefitPlansTable_2146635460" xlink:to="loc_sclx_CompensationAndEmployeeBenefitPlansLineItems_2146635462" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2146635609" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CompensationAndEmployeeBenefitPlansLineItems_2146635462" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2146635609" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_2146635612" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CompensationAndEmployeeBenefitPlansLineItems_2146635462" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_2146635612" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingNumber" xlink:label="loc_sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingNumber_2146637266" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CompensationAndEmployeeBenefitPlansLineItems_2146635462" xlink:to="loc_sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingNumber_2146637266" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2146635625" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CompensationAndEmployeeBenefitPlansLineItems_2146635462" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2146635625" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_2146635631" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CompensationAndEmployeeBenefitPlansLineItems_2146635462" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_2146635631" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_2146635633" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CompensationAndEmployeeBenefitPlansLineItems_2146635462" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_2146635633" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2146635634" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CompensationAndEmployeeBenefitPlansLineItems_2146635462" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2146635634" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant" xlink:label="loc_sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant_2146635641" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CompensationAndEmployeeBenefitPlansLineItems_2146635462" xlink:to="loc_sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant_2146635641" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_2146635650" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CompensationAndEmployeeBenefitPlansLineItems_2146635462" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_2146635650" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToEmployees" xlink:label="loc_us-gaap_PaymentsToEmployees_2146636113" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_CompensationAndEmployeeBenefitPlansLineItems_2146635462" xlink:to="loc_us-gaap_PaymentsToEmployees_2146636113" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfShareBasedPaymentAwardOptionsIssuedToEmployeesAndNonemployeesValuationAssumptions">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_2146635658" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2146635659" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_2146635658" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2146635659" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_2146635661" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2146635659" xlink:to="loc_srt_RangeAxis_2146635661" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_2146635662" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_2146635661" xlink:to="loc_srt_RangeMember_2146635662" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_2146635663" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2146635662" xlink:to="loc_srt_MinimumMember_2146635663" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_2146635664" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2146635662" xlink:to="loc_srt_MaximumMember_2146635664" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2146635660" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2146635659" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2146635660" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2146635666" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2146635660" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2146635666" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2146635667" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2146635660" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2146635667" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2146635672" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2146635660" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2146635672" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_2146635677" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2146635660" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_2146635677" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_2146635682" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2146635660" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_2146635682" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2146635690" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2146635660" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2146635690" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_2146635692" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2146635660" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_2146635692" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_2146635693" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2146635660" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_2146635693" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2146635695" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2146635660" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2146635695" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant" xlink:label="loc_sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant_2146635704" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2146635660" xlink:to="loc_sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant_2146635704" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_2146635707" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2146635660" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_2146635707" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfTheOptionsOutstanding">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:label="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_2146635711" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2146635712" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_2146635711" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2146635712" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2146635714" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_2146635711" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2146635714" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2146635715" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_2146635711" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2146635715" use="optional" order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2146635772" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_2146635711" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2146635772" use="optional" order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2146635773" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_2146635711" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2146635773" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2146635779" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_2146635711" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2146635779" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2146635782" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_2146635711" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2146635782" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2146635784" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_2146635711" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2146635784" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2146635788" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_2146635711" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2146635788" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_2146635792" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_2146635711" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_2146635792" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2146635795" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_2146635711" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2146635795" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2146635800" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_2146635711" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2146635800" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2146635802" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_2146635711" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2146635802" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2146635804" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_2146635711" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2146635804" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/AcquisitionsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAbstract" xlink:label="loc_us-gaap_AssetAcquisitionAbstract_2146635721" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTable" xlink:label="loc_us-gaap_AssetAcquisitionTable_2146635722" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAbstract_2146635721" xlink:to="loc_us-gaap_AssetAcquisitionTable_2146635722" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="loc_us-gaap_AssetAcquisitionAxis_2146635739" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_2146635722" xlink:to="loc_us-gaap_AssetAcquisitionAxis_2146635739" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaap_AssetAcquisitionDomain_2146635740" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_2146635739" xlink:to="loc_us-gaap_AssetAcquisitionDomain_2146635740" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SenmurMember" xlink:label="loc_sclx_SenmurMember_2146635743" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_2146635740" xlink:to="loc_sclx_SenmurMember_2146635743" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AardvarkMember" xlink:label="loc_sclx_AardvarkMember_2146636180" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_2146635740" xlink:to="loc_sclx_AardvarkMember_2146636180" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_RomegLicenseAgreementMember" xlink:label="loc_sclx_RomegLicenseAgreementMember_2146636237" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_2146635740" xlink:to="loc_sclx_RomegLicenseAgreementMember_2146636237" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MilestoneAxis" xlink:label="loc_sclx_MilestoneAxis_2146635745" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_2146635722" xlink:to="loc_sclx_MilestoneAxis_2146635745" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MilestoneDomain" xlink:label="loc_sclx_MilestoneDomain_2146635747" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_MilestoneAxis_2146635745" xlink:to="loc_sclx_MilestoneDomain_2146635747" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_RegulatoryBasedMilestoneMember" xlink:label="loc_sclx_RegulatoryBasedMilestoneMember_2146635749" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_MilestoneDomain_2146635747" xlink:to="loc_sclx_RegulatoryBasedMilestoneMember_2146635749" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ReveueBasedMilestoneMember" xlink:label="loc_sclx_ReveueBasedMilestoneMember_2146635751" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_MilestoneDomain_2146635747" xlink:to="loc_sclx_ReveueBasedMilestoneMember_2146635751" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ApprovalBasedMilestoneMember" xlink:label="loc_sclx_ApprovalBasedMilestoneMember_2146636609" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_MilestoneDomain_2146635747" xlink:to="loc_sclx_ApprovalBasedMilestoneMember_2146636609" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TrancheAxis" xlink:label="loc_sclx_TrancheAxis_2146635755" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_2146635722" xlink:to="loc_sclx_TrancheAxis_2146635755" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TrancheDomain" xlink:label="loc_sclx_TrancheDomain_2146635756" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_TrancheAxis_2146635755" xlink:to="loc_sclx_TrancheDomain_2146635756" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TrancheOneMember" xlink:label="loc_sclx_TrancheOneMember_2146635757" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_TrancheDomain_2146635756" xlink:to="loc_sclx_TrancheOneMember_2146635757" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TrancheTwoMember" xlink:label="loc_sclx_TrancheTwoMember_2146635760" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_TrancheDomain_2146635756" xlink:to="loc_sclx_TrancheTwoMember_2146635760" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TrancheThreeMember" xlink:label="loc_sclx_TrancheThreeMember_2146635762" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_TrancheDomain_2146635756" xlink:to="loc_sclx_TrancheThreeMember_2146635762" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TrancheFourMember" xlink:label="loc_sclx_TrancheFourMember_2146635765" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_TrancheDomain_2146635756" xlink:to="loc_sclx_TrancheFourMember_2146635765" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_InvesteeAxis" xlink:label="loc_sclx_InvesteeAxis_2146635798" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_2146635722" xlink:to="loc_sclx_InvesteeAxis_2146635798" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_InvesteeDomain" xlink:label="loc_sclx_InvesteeDomain_2146635801" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_InvesteeAxis_2146635798" xlink:to="loc_sclx_InvesteeDomain_2146635801" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SorrentoMember" xlink:label="loc_sclx_SorrentoMember_2146635803" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_InvesteeDomain_2146635801" xlink:to="loc_sclx_SorrentoMember_2146635803" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_2146635897" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_2146635722" xlink:to="loc_srt_RestatementAxis_2146635897" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_2146635898" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_2146635897" xlink:to="loc_srt_RestatementDomain_2146635898" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AsRestatedMember" xlink:label="loc_sclx_AsRestatedMember_2146635899" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_2146635898" xlink:to="loc_sclx_AsRestatedMember_2146635899" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_2146636133" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_2146635722" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_2146636133" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2146636134" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2146636133" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2146636134" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TwoThousandTwentyTwoPromissoryNoteMember" xlink:label="loc_sclx_TwoThousandTwentyTwoPromissoryNoteMember_2146636135" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2146636134" xlink:to="loc_sclx_TwoThousandTwentyTwoPromissoryNoteMember_2146636135" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="loc_us-gaap_AssetAcquisitionLineItems_2146635723" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_2146635722" xlink:to="loc_us-gaap_AssetAcquisitionLineItems_2146635723" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred_2146635726" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferred_2146635726" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_2146635727" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_2146635727" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_2146635728" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_2146635728" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_2146635729" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_2146635729" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesSubscribedButUnissued" xlink:label="loc_us-gaap_CommonStockSharesSubscribedButUnissued_2146635730" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_us-gaap_CommonStockSharesSubscribedButUnissued_2146635730" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AssetAcquisitionPricePerShare" xlink:label="loc_sclx_AssetAcquisitionPricePerShare_2146635731" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_sclx_AssetAcquisitionPricePerShare_2146635731" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfOwnershipInterest" xlink:label="loc_sclx_PercentageOfOwnershipInterest_2146635733" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_sclx_PercentageOfOwnershipInterest_2146635733" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiability" xlink:label="loc_us-gaap_AssetAcquisitionContingentConsiderationLiability_2146635735" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_us-gaap_AssetAcquisitionContingentConsiderationLiability_2146635735" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_RevenueToBeEarnedByTheAcquireeValue" xlink:label="loc_sclx_RevenueToBeEarnedByTheAcquireeValue_2146635737" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_sclx_RevenueToBeEarnedByTheAcquireeValue_2146635737" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfSharesIssuedSubjectToRestrictionOfTransfer" xlink:label="loc_sclx_PercentageOfSharesIssuedSubjectToRestrictionOfTransfer_2146635770" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_sclx_PercentageOfSharesIssuedSubjectToRestrictionOfTransfer_2146635770" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PeriodDuringWhichShareTransferIsRestricted" xlink:label="loc_sclx_PeriodDuringWhichShareTransferIsRestricted_2146635775" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_sclx_PeriodDuringWhichShareTransferIsRestricted_2146635775" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PeriodDuringWhichTheSharesMayBeExchanged" xlink:label="loc_sclx_PeriodDuringWhichTheSharesMayBeExchanged_2146635776" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_sclx_PeriodDuringWhichTheSharesMayBeExchanged_2146635776" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_CommonStockValueToBeExchanged" xlink:label="loc_sclx_CommonStockValueToBeExchanged_2146635780" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_sclx_CommonStockValueToBeExchanged_2146635780" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NumberOfDaysForDeterminingTheWeightedVolumeAveragePriceForShares" xlink:label="loc_sclx_NumberOfDaysForDeterminingTheWeightedVolumeAveragePriceForShares_2146635783" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_sclx_NumberOfDaysForDeterminingTheWeightedVolumeAveragePriceForShares_2146635783" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PricePerShareForDeterminingTheExchangeOfShares" xlink:label="loc_sclx_PricePerShareForDeterminingTheExchangeOfShares_2146635785" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_sclx_PricePerShareForDeterminingTheExchangeOfShares_2146635785" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PaymentMadeInSurrenderingTheShares" xlink:label="loc_sclx_PaymentMadeInSurrenderingTheShares_2146635790" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_sclx_PaymentMadeInSurrenderingTheShares_2146635790" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfSharesOutstanding" xlink:label="loc_sclx_PercentageOfSharesOutstanding_2146635793" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_sclx_PercentageOfSharesOutstanding_2146635793" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_2146635797" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_2146635797" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_2146635895" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_2146635895" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_2146635912" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_2146635912" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_2146636126" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_2146636126" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/disclosureGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_2146636127" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_2146636127" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm_2146636128" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_us-gaap_DebtInstrumentTerm_2146636128" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_2146636129" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_2146636129" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_UpfrontlicenseFee" xlink:label="loc_sclx_UpfrontlicenseFee_2146636214" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_sclx_UpfrontlicenseFee_2146636214" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MilestonePayment" xlink:label="loc_sclx_MilestonePayment_2146636223" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_sclx_MilestonePayment_2146636223" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_2146636233" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_us-gaap_RoyaltyExpense_2146636233" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue_2146636243" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue_2146636243" use="optional" order="55" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DeferredConsideration" xlink:label="loc_sclx_DeferredConsideration_2146636247" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_sclx_DeferredConsideration_2146636247" use="optional" order="56" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_2146636266" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_2146635723" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_2146636266" use="optional" order="57" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:label="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_2146635322" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedFinancialStatementsTable" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTable_2146635323" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_2146635322" xlink:to="loc_srt_ScheduleOfCondensedFinancialStatementsTable_2146635323" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635325" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_2146635323" xlink:to="loc_dei_LegalEntityAxis_2146635325" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635326" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2146635325" xlink:to="loc_dei_EntityDomain_2146635326" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635327" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146635326" xlink:to="loc_sclx_VickersVantageMember_2146635327" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedFinancialStatementsCaptionsLineItems" xlink:label="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2146635324" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_2146635323" xlink:to="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2146635324" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockRedemptionPricePerShare" xlink:label="loc_us-gaap_PreferredStockRedemptionPricePerShare_2146635328" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2146635324" xlink:to="loc_us-gaap_PreferredStockRedemptionPricePerShare_2146635328" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsCurrent" xlink:label="loc_us-gaap_IntangibleAssetsCurrent_2146635329" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2146635324" xlink:to="loc_us-gaap_IntangibleAssetsCurrent_2146635329" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsDetailsScheduleOfImpactOfTheseAdjustmentsToTheFinancialStatementAsPreviouslyReported">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:label="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_2146635291" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedFinancialStatementsTable" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTable_2146635292" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_2146635291" xlink:to="loc_srt_ScheduleOfCondensedFinancialStatementsTable_2146635292" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635296" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_2146635292" xlink:to="loc_dei_LegalEntityAxis_2146635296" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635297" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2146635296" xlink:to="loc_dei_EntityDomain_2146635297" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635298" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146635297" xlink:to="loc_sclx_VickersVantageMember_2146635298" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_2146635301" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_2146635292" xlink:to="loc_srt_RestatementAxis_2146635301" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_2146635302" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_2146635301" xlink:to="loc_srt_RestatementDomain_2146635302" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_2146635303" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_2146635302" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_2146635303" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAdjustmentMember" xlink:label="loc_srt_RestatementAdjustmentMember_2146635304" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_2146635302" xlink:to="loc_srt_RestatementAdjustmentMember_2146635304" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AdjustmentsRestatement2Member" xlink:label="loc_sclx_AdjustmentsRestatement2Member_2146635305" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_2146635302" xlink:to="loc_sclx_AdjustmentsRestatement2Member_2146635305" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AsRestatedMember" xlink:label="loc_sclx_AsRestatedMember_2146635320" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_2146635302" xlink:to="loc_sclx_AsRestatedMember_2146635320" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedFinancialStatementsCaptionsLineItems" xlink:label="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2146635293" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_2146635292" xlink:to="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2146635293" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_2146635306" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2146635293" xlink:to="loc_us-gaap_DerivativeLiabilities_2146635306" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_2146635307" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2146635293" xlink:to="loc_us-gaap_Liabilities_2146635307" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_2146635308" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2146635293" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_2146635308" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_2146635309" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2146635293" xlink:to="loc_us-gaap_CommonStockValue_2146635309" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_2146635311" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2146635293" xlink:to="loc_us-gaap_AdditionalPaidInCapital_2146635311" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2146635312" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2146635293" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2146635312" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_2146635314" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_2146635293" xlink:to="loc_us-gaap_StockholdersEquity_2146635314" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/IncomeTaxesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_2146635943" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_IncomeTaxDisclosureTable" xlink:label="loc_sclx_IncomeTaxDisclosureTable_2146636021" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2146635943" xlink:to="loc_sclx_IncomeTaxDisclosureTable_2146636021" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_2146636023" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_IncomeTaxDisclosureTable_2146636021" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_2146636023" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_2146636024" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_2146636023" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_2146636024" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_2146636025" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_2146636024" xlink:to="loc_us-gaap_DomesticCountryMember_2146636025" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_2146636026" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_2146636024" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_2146636026" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaap_TaxPeriodAxis_2146636028" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_IncomeTaxDisclosureTable_2146636021" xlink:to="loc_us-gaap_TaxPeriodAxis_2146636028" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaap_TaxPeriodDomain_2146636029" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodAxis_2146636028" xlink:to="loc_us-gaap_TaxPeriodDomain_2146636029" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_IndefiniteCarryforwardPeriodMember" xlink:label="loc_sclx_IndefiniteCarryforwardPeriodMember_2146636030" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_2146636029" xlink:to="loc_sclx_IndefiniteCarryforwardPeriodMember_2146636030" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_2146636031" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_IncomeTaxDisclosureTable_2146636021" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_2146636031" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_2146636032" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_2146636031" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_2146636032" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember_2146636033" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_2146636032" xlink:to="loc_us-gaap_ResearchMember_2146636033" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_IncomeTaxDisclosureLineItems" xlink:label="loc_sclx_IncomeTaxDisclosureLineItems_2146636022" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_IncomeTaxDisclosureTable_2146636021" xlink:to="loc_sclx_IncomeTaxDisclosureLineItems_2146636022" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_2146635944" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems_2146636022" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_2146635944" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2146635945" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems_2146636022" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2146635945" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2146635947" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems_2146636022" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2146635947" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_2146636034" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems_2146636022" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_2146636034" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_2146636035" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems_2146636022" xlink:to="loc_us-gaap_OperatingLossCarryforwards_2146636035" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_OperatingLossCarryforwardsExpirationYear" xlink:label="loc_sclx_OperatingLossCarryforwardsExpirationYear_2146636037" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems_2146636022" xlink:to="loc_sclx_OperatingLossCarryforwardsExpirationYear_2146636037" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_2146636039" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems_2146636022" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_2146636039" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TaxCreditCarryforwardExpirationYear" xlink:label="loc_sclx_TaxCreditCarryforwardExpirationYear_2146636040" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems_2146636022" xlink:to="loc_sclx_TaxCreditCarryforwardExpirationYear_2146636040" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MinimumThresholdPercentageForRecognitionOfUncertainIncomeTaxPosition" xlink:label="loc_sclx_MinimumThresholdPercentageForRecognitionOfUncertainIncomeTaxPosition_2146636041" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems_2146636022" xlink:to="loc_sclx_MinimumThresholdPercentageForRecognitionOfUncertainIncomeTaxPosition_2146636041" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_2146636057" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_IncomeTaxDisclosureLineItems_2146636022" xlink:to="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_2146636057" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfComponentsOfIncomeTaxExpenseBenefit">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_2146635970" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_2146635971" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_2146635970" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_2146635971" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_2146635972" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_2146635971" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_2146635972" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_2146635973" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_2146635971" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_2146635973" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_2146635974" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_2146635971" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_2146635974" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_2146635975" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_2146635970" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_2146635975" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_2146635976" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_2146635975" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_2146635976" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_2146635977" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_2146635975" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_2146635977" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_2146635978" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_2146635975" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_2146635978" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_2146635980" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_2146635970" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_2146635980" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfDeferredTaxAssetsAndLiabilities">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_2146635985" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_2146635987" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_2146635985" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_2146635987" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DeferredTaxAssetsInterestExpenseLimitations" xlink:label="loc_sclx_DeferredTaxAssetsInterestExpenseLimitations_2146635989" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_2146635987" xlink:to="loc_sclx_DeferredTaxAssetsInterestExpenseLimitations_2146635989" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_2146635991" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_2146635987" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_2146635991" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_2146635992" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_2146635987" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_2146635992" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2146635993" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_2146635987" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2146635993" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="loc_sclx_DeferredTaxAssetsOperatingLeaseLiabilities_2146635994" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_2146635987" xlink:to="loc_sclx_DeferredTaxAssetsOperatingLeaseLiabilities_2146635994" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_2146635995" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_2146635987" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_2146635995" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_2146635996" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_2146635987" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_2146635996" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_2146635997" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_2146635987" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_2146635997" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_2146635999" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_2146635987" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_2146635999" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_2146636000" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_2146635985" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_2146636000" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_2146636001" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_2146636000" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_2146636001" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_2146636002" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_2146636000" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_2146636002" use="optional" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_2146636003" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_2146636000" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_2146636003" use="optional" order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_2146636004" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_2146636000" xlink:to="loc_us-gaap_DeferredTaxLiabilities_2146636004" use="optional" order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfEffectiveIncomeTaxRateReconciliation">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_2146636010" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2146636012" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_2146636010" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2146636012" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_2146636013" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_2146636010" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_2146636013" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_EffectiveIncomeTaxRateReconciliationDebtDiscountAndInterestLimitation" xlink:label="loc_sclx_EffectiveIncomeTaxRateReconciliationDebtDiscountAndInterestLimitation_2146636014" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_2146636010" xlink:to="loc_sclx_EffectiveIncomeTaxRateReconciliationDebtDiscountAndInterestLimitation_2146636014" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_2146636015" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_2146636010" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_2146636015" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustmentsAndCarryback" xlink:label="loc_sclx_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustmentsAndCarryback_2146636016" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_2146636010" xlink:to="loc_sclx_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustmentsAndCarryback_2146636016" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_2146636017" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_2146636010" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_2146636017" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_2146636018" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_2146636010" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_2146636018" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2146636019" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_2146636010" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2146636019" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/LossPerShareDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_2146635608" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2146635614" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2146635608" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2146635614" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/LossPerShareDetailsSummaryOfReconciliationOfBasicAndDilutedLossPerShare">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_2146635575" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_2146635577" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2146635575" xlink:to="loc_us-gaap_NetIncomeLoss_2146635577" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2146635578" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2146635575" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2146635578" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DilutiveSecurities" xlink:label="loc_us-gaap_DilutiveSecurities_2146635579" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2146635575" xlink:to="loc_us-gaap_DilutiveSecurities_2146635579" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_2146635580" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2146635575" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_2146635580" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_2146635583" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2146635575" xlink:to="loc_us-gaap_EarningsPerShareBasic_2146635583" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_2146635584" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2146635575" xlink:to="loc_us-gaap_EarningsPerShareDiluted_2146635584" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.vickersvantagecorp.com/role/SubsequentEventsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_818" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SubsequentEventsDetailsTable" xlink:label="loc_sclx_SubsequentEventsDetailsTable_819" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_818" xlink:to="loc_sclx_SubsequentEventsDetailsTable_819" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_820" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsTable_819" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_820" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2146634684" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_820" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2146634684" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_822" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_2146634684" xlink:to="loc_us-gaap_SubsequentEventMember_822" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2146635150" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsTable_819" xlink:to="loc_dei_LegalEntityAxis_2146635150" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_2146635151" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2146635150" xlink:to="loc_dei_EntityDomain_2146635151" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_VickersVantageMember" xlink:label="loc_sclx_VickersVantageMember_2146635152" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146635151" xlink:to="loc_sclx_VickersVantageMember_2146635152" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SorrentoMember" xlink:label="loc_sclx_SorrentoMember_2146636600" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2146635151" xlink:to="loc_sclx_SorrentoMember_2146636600" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_2146635413" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsTable_819" xlink:to="loc_us-gaap_DebtInstrumentAxis_2146635413" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2146635414" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_2146635413" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2146635414" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScilexPharmaNoteMember" xlink:label="loc_sclx_ScilexPharmaNoteMember_2146635416" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2146635414" xlink:to="loc_sclx_ScilexPharmaNoteMember_2146635416" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2146635418" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsTable_819" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2146635418" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_2146635419" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2146635418" xlink:to="loc_us-gaap_RelatedPartyDomain_2146635419" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SorrentoMember" xlink:label="loc_sclx_SorrentoMember_2146635420" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_2146635419" xlink:to="loc_sclx_SorrentoMember_2146635420" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_2146635421" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsTable_819" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_2146635421" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2146635422" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2146635421" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2146635422" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SorrentoMember" xlink:label="loc_sclx_SorrentoMember_2146635423" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2146635422" xlink:to="loc_sclx_SorrentoMember_2146635423" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_2146635424" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsTable_819" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_2146635424" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2146635425" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2146635424" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2146635425" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubordinatedDebtMember" xlink:label="loc_us-gaap_SubordinatedDebtMember_2146635482" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2146635425" xlink:to="loc_us-gaap_SubordinatedDebtMember_2146635482" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_TwoThousandAndTwentyTwoPromissoryNoteMember" xlink:label="loc_sclx_TwoThousandAndTwentyTwoPromissoryNoteMember_2146635426" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2146635425" xlink:to="loc_sclx_TwoThousandAndTwentyTwoPromissoryNoteMember_2146635426" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="loc_us-gaap_AssetAcquisitionAxis_2146635427" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsTable_819" xlink:to="loc_us-gaap_AssetAcquisitionAxis_2146635427" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaap_AssetAcquisitionDomain_2146635428" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_2146635427" xlink:to="loc_us-gaap_AssetAcquisitionDomain_2146635428" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AardvarkMember" xlink:label="loc_sclx_AardvarkMember_2146635429" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_2146635428" xlink:to="loc_sclx_AardvarkMember_2146635429" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_2146635501" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsTable_819" xlink:to="loc_srt_RangeAxis_2146635501" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_2146635503" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_2146635501" xlink:to="loc_srt_RangeMember_2146635503" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_2146635504" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2146635503" xlink:to="loc_srt_MaximumMember_2146635504" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_2146636323" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2146635503" xlink:to="loc_srt_MinimumMember_2146636323" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2146636324" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsTable_819" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2146636324" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_2146636325" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2146636324" xlink:to="loc_us-gaap_ClassOfStockDomain_2146636325" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_2146636326" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_2146636325" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_2146636326" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_2146636330" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsTable_819" xlink:to="loc_us-gaap_CreditFacilityAxis_2146636330" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_2146636331" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_2146636330" xlink:to="loc_us-gaap_CreditFacilityDomain_2146636331" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_FundingCommitmentLetterMember" xlink:label="loc_sclx_FundingCommitmentLetterMember_2146636332" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_2146636331" xlink:to="loc_sclx_FundingCommitmentLetterMember_2146636332" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AgreementAxis" xlink:label="loc_sclx_AgreementAxis_2146636593" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsTable_819" xlink:to="loc_sclx_AgreementAxis_2146636593" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AgreementDomain" xlink:label="loc_sclx_AgreementDomain_2146636594" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_AgreementAxis_2146636593" xlink:to="loc_sclx_AgreementDomain_2146636594" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AgreementWithCertainOfTheThirdPartyProfessionalServiceProvidersMember" xlink:label="loc_sclx_AgreementWithCertainOfTheThirdPartyProfessionalServiceProvidersMember_2146636595" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_AgreementDomain_2146636594" xlink:to="loc_sclx_AgreementWithCertainOfTheThirdPartyProfessionalServiceProvidersMember_2146636595" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_StandbyEquityPurchaseAgreementMember" xlink:label="loc_sclx_StandbyEquityPurchaseAgreementMember_2146636608" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_AgreementDomain_2146636594" xlink:to="loc_sclx_StandbyEquityPurchaseAgreementMember_2146636608" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_2146636601" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsTable_819" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_2146636601" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_2146636602" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_2146636601" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_2146636602" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableMember" xlink:label="loc_us-gaap_AccountsPayableMember_2146636603" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2146636602" xlink:to="loc_us-gaap_AccountsPayableMember_2146636603" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_2146636604" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2146636602" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_2146636604" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_InvesteeAxis" xlink:label="loc_sclx_InvesteeAxis_2146636610" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsTable_819" xlink:to="loc_sclx_InvesteeAxis_2146636610" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_InvesteeDomain" xlink:label="loc_sclx_InvesteeDomain_2146636611" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_InvesteeAxis_2146636610" xlink:to="loc_sclx_InvesteeDomain_2146636611" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_YorkvilleMember" xlink:label="loc_sclx_YorkvilleMember_2146636612" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_InvesteeDomain_2146636611" xlink:to="loc_sclx_YorkvilleMember_2146636612" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_B.RileyMember" xlink:label="loc_sclx_B.RileyMember_2147435892" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_InvesteeDomain_2146636611" xlink:to="loc_sclx_B.RileyMember_2147435892" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_2147435900" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsTable_819" xlink:to="loc_srt_ProductOrServiceAxis_2147435900" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_2147435901" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_2147435900" xlink:to="loc_srt_ProductsAndServicesDomain_2147435901" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PurchasetypeAMember" xlink:label="loc_sclx_PurchasetypeAMember_2147435902" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2147435901" xlink:to="loc_sclx_PurchasetypeAMember_2147435902" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PurchasetypeBMember" xlink:label="loc_sclx_PurchasetypeBMember_2147435903" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2147435901" xlink:to="loc_sclx_PurchasetypeBMember_2147435903" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_2147435908" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsTable_819" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_2147435908" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_2147435909" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_2147435908" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_2147435909" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ScilexCommonStockMember" xlink:label="loc_sclx_ScilexCommonStockMember_2147435910" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_2147435909" xlink:to="loc_sclx_ScilexCommonStockMember_2147435910" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SubsequentEventsDetailsLineItems" xlink:label="loc_sclx_SubsequentEventsDetailsLineItems_821" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsTable_819" xlink:to="loc_sclx_SubsequentEventsDetailsLineItems_821" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseDepositLiability" xlink:label="loc_us-gaap_LeaseDepositLiability_823" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_us-gaap_LeaseDepositLiability_823" use="optional" order="55" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockNoParValue" xlink:label="loc_us-gaap_CommonStockNoParValue_824" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_us-gaap_CommonStockNoParValue_824" use="optional" order="56" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_825" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_825" use="optional" order="57" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NumberOfSharesLimits" xlink:label="loc_sclx_NumberOfSharesLimits_826" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_sclx_NumberOfSharesLimits_826" use="optional" order="58" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SponsorLoan" xlink:label="loc_sclx_SponsorLoan_2146635252" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_sclx_SponsorLoan_2146635252" use="optional" order="59" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_WarrantExercisePrice" xlink:label="loc_sclx_WarrantExercisePrice_2146635254" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_sclx_WarrantExercisePrice_2146635254" use="optional" order="60" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AdditionalPrincipalAmount" xlink:label="loc_sclx_AdditionalPrincipalAmount_2146635256" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_sclx_AdditionalPrincipalAmount_2146635256" use="optional" order="61" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_ConvertiblePromissoryNote" xlink:label="loc_sclx_ConvertiblePromissoryNote_2146635257" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_sclx_ConvertiblePromissoryNote_2146635257" use="optional" order="62" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_2146635432" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_2146635432" use="optional" order="63" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRepurchaseAmount" xlink:label="loc_us-gaap_DebtInstrumentRepurchaseAmount_2146635433" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_us-gaap_DebtInstrumentRepurchaseAmount_2146635433" use="optional" order="64" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfPurchasePriceInCashEqualIsToPrincipalAmountOfTheLoan" xlink:label="loc_sclx_PercentageOfPurchasePriceInCashEqualIsToPrincipalAmountOfTheLoan_2146635435" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_sclx_PercentageOfPurchasePriceInCashEqualIsToPrincipalAmountOfTheLoan_2146635435" use="optional" order="65" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaap_RestrictedCash_2146635436" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_us-gaap_RestrictedCash_2146635436" use="optional" order="66" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_SalesThresholdLimit" xlink:label="loc_sclx_SalesThresholdLimit_2146635461" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_sclx_SalesThresholdLimit_2146635461" use="optional" order="67" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_2146635438" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent_2146635438" use="optional" order="68" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm_2146635440" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_us-gaap_DebtInstrumentTerm_2146635440" use="optional" order="69" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_2146635448" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_2146635448" use="optional" order="70" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MinimumTimeDeclaredToFileWithSecRegardingResaleRegistrationStatement" xlink:label="loc_sclx_MinimumTimeDeclaredToFileWithSecRegardingResaleRegistrationStatement_2146635451" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_sclx_MinimumTimeDeclaredToFileWithSecRegardingResaleRegistrationStatement_2146635451" use="optional" order="71" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred_2146635454" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferred_2146635454" use="optional" order="72" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_2146635458" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_2146635458" use="optional" order="73" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_2146636317" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_2146636317" use="optional" order="74" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2146636318" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2146636318" use="optional" order="75" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinimumNetWorthRequiredForCompliance" xlink:label="loc_us-gaap_MinimumNetWorthRequiredForCompliance_2146636327" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_us-gaap_MinimumNetWorthRequiredForCompliance_2146636327" use="optional" order="76" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_2146636328" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_2146636328" use="optional" order="77" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_AggregateOutstandingAmount" xlink:label="loc_sclx_AggregateOutstandingAmount_2146636329" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_sclx_AggregateOutstandingAmount_2146636329" use="optional" order="78" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAssumed1" xlink:label="loc_us-gaap_LiabilitiesAssumed1_2146636592" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_us-gaap_LiabilitiesAssumed1_2146636592" use="optional" order="79" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PeriodAfterRegistrationWhenTheRequestCouldBeMadeToTheInvesteeToPurchaseTheShares" xlink:label="loc_sclx_PeriodAfterRegistrationWhenTheRequestCouldBeMadeToTheInvesteeToPurchaseTheShares_2146636607" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_sclx_PeriodAfterRegistrationWhenTheRequestCouldBeMadeToTheInvesteeToPurchaseTheShares_2146636607" use="optional" order="80" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_MaximumPercentageOfVolumeWeightedAveragePriceOfSharesMeasuredOnADailyBasisThatIsEligibleToBeReceivedAsAdvance" xlink:label="loc_sclx_MaximumPercentageOfVolumeWeightedAveragePriceOfSharesMeasuredOnADailyBasisThatIsEligibleToBeReceivedAsAdvance_2146636613" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_sclx_MaximumPercentageOfVolumeWeightedAveragePriceOfSharesMeasuredOnADailyBasisThatIsEligibleToBeReceivedAsAdvance_2146636613" use="optional" order="81" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NumberOfThresholdTradingDaysPriorToDateOfNoticeToTheShareholdersForDeterminingTheVolumeWeightedAveragePriceOfShares" xlink:label="loc_sclx_NumberOfThresholdTradingDaysPriorToDateOfNoticeToTheShareholdersForDeterminingTheVolumeWeightedAveragePriceOfShares_2146636616" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_sclx_NumberOfThresholdTradingDaysPriorToDateOfNoticeToTheShareholdersForDeterminingTheVolumeWeightedAveragePriceOfShares_2146636616" use="optional" order="82" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_PercentageOfDailyVolumeWeightedAveragePriceOfSharesAtWhichTheSharesAreEligibleToBePurchased" xlink:label="loc_sclx_PercentageOfDailyVolumeWeightedAveragePriceOfSharesAtWhichTheSharesAreEligibleToBePurchased_2146636617" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_sclx_PercentageOfDailyVolumeWeightedAveragePriceOfSharesAtWhichTheSharesAreEligibleToBePurchased_2146636617" use="optional" order="83" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="sclx-20220930.xsd#sclx_NumberOfConsecutiveTradingDaysForDeterminingTheVolumeWeightedAveragePriceOfShares" xlink:label="loc_sclx_NumberOfConsecutiveTradingDaysForDeterminingTheVolumeWeightedAveragePriceOfShares_2146636618" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_sclx_NumberOfConsecutiveTradingDaysForDeterminingTheVolumeWeightedAveragePriceOfShares_2146636618" use="optional" order="84" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2146636625" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2146636625" use="optional" order="85" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_2147435904" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_2147435904" use="optional" order="86" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_2147435905" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_2147435905" use="optional" order="87" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesSubscriptions" xlink:label="loc_us-gaap_CommonStockSharesSubscriptions_2147436126" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sclx_SubsequentEventsDetailsLineItems_821" xlink:to="loc_us-gaap_CommonStockSharesSubscriptions_2147436126" use="optional" order="88" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g428534dsp01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g428534dsp01.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MF2/RP-P]*TBI=693J89KW86/0DSQDFM3S6M=!] !0 4 % !0 4 % !0 4 %
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M(U+Q1H^DR>7>7T<<@_ASDT 1:=XOT/5)!%:ZA&9#T0G!- &ZO2@!: ,KQ/\
M\BGK/_7E-_Z : .$^%NIV-GHEW'<W<43&4$*[ 'I0!WHU_2!_P Q*W]?]8*
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M@=?,6@#HM"_Y 5C_ -<5_E0!HT ><:*?^+P:O[1'_P!EH ]%?[C?2@#S[X;
M-<:^"!M-S_5N* *FLV-QX$U[^W-.!.F7+[;F(=$)[^U #?#=[!J/Q6O;RW??
M%+;[@1]%H ])O(S+93Q+]YXV4?B* .#^&-U';6M_HTQ"75O<,2A."1@#/Z4
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MK;2[1;:UC"1KC@=S@#/Z4 6J "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
A * "@ H * "@ H * "@ H * "@ H * "@ H * "@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g428534dsp1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g428534dsp1.jpg
M_]C_X  02D9)1@ !  $ 8 !@  #__@ ?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$  @&!@<&!0@'!P<*"0@*#18.#0P,#1L3%! 6(!PB(1\<
M'QXC*#,K(R8P)AX?+#TM,#4V.3HY(BL_0SXX0S,X.3<!"0H*#0L-&@X.&C<D
M'R0W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W
M-S<W-S<W-__$ "P   ,! 0$!               " P0!!08! 0
M          #_P@ 1"  = 9(# 1$  A$! Q$!_]H # ,!  (0 Q    '[@0T$
M1@$' Z=)%@$.'!B98F*!4X.1*BE!3HI(8J1%-)$"1H% 8D!T<L92(A44D= 0
MU"G3:3%.DRY@-1$S&@D,6(BE"10V"DC(;C*<-)TRG0*D#29R@%#8
M     'GF@SG3(<-AA&-AE H;@//.BFDQCG!3A8F:R PQZ0
M !P  #IP .@  3' Z< Z0+ !T #_Q  C$  " 04!  $% 0         ! @,
M!!$2$Q0A$" B(T D_]H " $!  $% GET87$>-A79>1D57ZQZ]XRXEC-=H\-(
MJJ7 <S8D1Q(BL'!E42B56D697"2!PDX>G<1J)?DSQBEN(FHRQBNJ&E=7KNG4
MNHKM&!LM!T9F8+4CB*/N-NT>5=7'=.B7,3A6#!I</V3#74:CJF>T5=4%.X2C
M<((FG5:[KLLJM)4D(DDDMLT+9POG_P [VV6\SY\K4]L=!#([F%O.8YBXM]I
M,"--%9-I-/W\B%"A46W8.\9DC>.60&S9B(&5Q9X22V+R11,CBUP/)\1VVKBU
M=8XK8QLZ;5-'UA>W&OC;9$8/Y,*MJRTB.C&-EDDMI'46IV-LQC\_QY6HPGCX
M_P '@=EX-B.#E)_+NPN)I#%%.S\+ER%V.>FRLX*=?P+L$N6/GN'82%SB)OSD
M.'E<QQBYE:A<N["[<U)-^XWC:27)XQRR*OK>FG?(GDU]3XCGROH;432--#-(
MY_IP,8K%8%8'TQ6/G'W%%+8%8'TP*P/HL**< 5@?8/_$ !00 0
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ME:;)$L3N<ASI^:HJ!&Q(N%15R55=U4'F*8C[MJCB -#6Q*<X-J@*H%S#(_5
M-/XA5? 5'$B'&]1O9.+G%D,Y>;^2F!SZ7;B8O&$ [4-5X%4;YE/)U/M6D4WR
MG.TWQ'1:D.BEHCFC_JJ#CQJXIG]O):-+RZIO/=:7Q?LJQMGR4-:*O$/AV4,
MY_ >VZLT7Y1\6_\ .R8QKV@$&Y[*JUAZJQ%1+AZ2JBZ6\2(66W;/S0YK /D1
ME56@/#83>9A+FDQ_:GS=PP.J!XC#5&WA7#!;OS0M*J.=LV&/O41[<>Y/OU$7
M]S'MF_YGWO_$ "<0 0$  @(! P0" P$       $1 "$Q05%A<9&!H;'1$/!
MP?$@_]H " $!  $_(2,NH3U[N,2;H0$?ZYI>IG/>#\AC3RPS?,NWB?UR?HVX
M",6$/%P=*!6#1GT87%"4 [<L/SBLL%/I_P!R14CH[]WTQ+*=,WFE3?HS$RNU
M->,>AD:/[XPF-[)-_7WPF 4Q9A;7"/Z^N-:SC7*^,&NU$R>YGG#<CK!+1V&T
MS@5J[&$T!4H(:N%*2>5PV=*B\>N_J?.#TR7;UB(@'8QFI=0QWCCET#LQ4UQ,
M,51X.<!HO@1/H^IFJ D Z)+^<H"?5<$[X-:?,^3YQ%$E4DI3(<^0<!!8HC7S
MA/'1L91P/!VX%>JY(UB7Z^-^@70ZP353G(<AB$D.7C*JJ0@:K-(VY3]#$W4#
MAK^Z_C?Z'N7.0H<;)>]<YR'T/+P8V*(KIS5P]I\1RT?]8%>J<@E [7K/,';N
MFQ,!?0D.45@V4%+5J.FF-"U0T96<3N2IN?K!!306:O[P  !H#.3W\A7.-6^O
M-,)Z0GV7]Y$7:#P'^L,\0)UGFPT&G9A$5 #4>GC%AK]:#LY^,80;^64#M],!
M+5J-2F% /=ZEPX2]S 6K!*LE[??-K%].D^'KO+!R#V(;/N?MD-*X;>7U]LD%
M:'E@L! FS7[S+79BWQ)ERE"$]P-ERE(4=+OWN_WR(8!!HE_>;NK4E1/AZW-B
M3)3O!6KXCK@3X,T5(A\=X*78PDY\<\\. 8:'#$U,R4[7GYQ,0$CX2_O)@#-W
M)+[<XGB%O9P3Z8#M%4XHG>7:2<@^3+"<[@\K/G+B$BITO[_QE\4 .BKC5TC#
MVQ@,K&MZ8;<8<%._3!]$;"&C0_7BX:WXFO7?P,\"(/(4]8#H[T7Y!UB"4 D&
MIUW6XQ"GS/G9G+.E)#Z'^V;=JA]+Q]S+T5$-?6=;Q "@P_+& "2_D^V4]72G
M,?<N&I+K'3D_WLQ,B[_Q>W/RR*7UW;03[N%6F2D\G>WA/?-:!N'("'[&)R<R
M%8SO#1MU5U-#SZ]S%I,+0H!.'\9W7J/:,[^N)(.+$HFGYQ:HM TZ6<N1TFI%
MR>7!#Q=/* ^?7.(-YA1/W_C0\?S#QG4)XF(90UQB$B".4Y&;!A3C)B%%"F1P
M%\X 5 +_ .A 4"'L_P#,HV%S987^)=/C( 0ADR#B0A1A@" &0NC?. ! A_+_
MV@ , P$  A #$   $! (!!  !! !  ) ())!!( )! ) () )!!!!)!!!!) !
M!) (!!!)))))))))))!)( 9  ) !((1!!))))))))))() )!!)) !( (!!!
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ML-N]8AQA>K8)/[FBIL19O$DL*A4#V"SIQWFJD!*)0.P7;WZ9/%.R6A?*U;]
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M$U$WK2A5G#]80&' ),-07H._>#A!P"3($AS_ (#_Q  4$ $
M      !P_]H " $#  $_$$S_Q  4$ $                   !P_]H " $"
'  $_$$S_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g428534g00a01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g428534g00a01.jpg
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M(&-H87)A8W1E<G,@8VAA;F=E9"!T;R!G<F%Y<V-A;&4N)B-X03LF(WA!.^*
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ME'::]C:N*C:MRH[[4NI+5-;UAKIFIV74M2+>Z]U!-3*]'U<=/&R5\>O/.+D
M0)P 1!XD?DI*5;9,ZM.,4WD-R6 $8[&7,I())O$II8"2<$!5QS\,^'&GH)9@
MN\NX(IEFF 9QJ&84GCBKYJVJ@IHZ6UPW.%ZLK$2HCJ*EM+&JL=1[_&V.739,
MR2%DR/1FC&L3EF;H9=TJBFJ+-36FVUM?/<<25>'JN%LEK5]'/0T$EQG:DK;J
ME'.^:FWB:EF@JYJ1T+Y=.9M3$E*_:^)@_N.. 8.]T>Z'K3-Y-[,/FJ::C50L
MS&LHK)Y:^C[EXZ:9OQ9 @C%<APE^/)#,$G)#*SU:R=TG;'2X<@M%1/6LO39&
MT;*+3[*A=(DU'*^JIJ6.=K&O2.6-CJI))8Y(Y%5L::"9HK7[ECVLQ10T=IEP
ME) ZZ27;>>UU7' ZDNM/%;KA<IJ*25\2ST\TS+<L%--!/3HV294F<C5;)#I$
M2XEH]L)Q$9^QEQ.'PH/ -M'-NP@J.#>$8=)=9N(3B5#R:SD*M(QSH,A)"JSE
M)DY:V*MVHETT02Q4<).];58=J*!M50/I(ZRLFK[5#::V*2;>ZRFN+:U8I:;1
MF;3R-F=3Q(U7M<L3G2L>Y51JLVFVX\HKU);+S#<JBV6JFLN)*O$MIJ8*7?[7
M7V!]I2HIKAITKZZ"2E97U#GMADC2H9'321,:CGMESK3C*TXX9NU5W!0>22<0
M-L.!/740N^.Y;(N\M%\QQ%E+'D8:6S\&%<C"1^0!7,<3&.ECR Y'-HHY^#L(
MW=KV(UL<D:MKG23,;5HR#M=H=DI)&^E94O5-\BWI8()FU"RL; Z1R/1FKCW4
M<+OBD<]]1!.V2SQP4<LELWZK6^[YVO6&>*Y2T$2+O%0M4VLK:22A;3R.K&0-
M6-TF49\34&F8L<Q@R4K,RR1MMAHH 0#>*N)!%\]=N<0TH+%5BQR\0LV$FG@M
MJ.70*G&4@7(L%0Z)D=FY61^;\-UM'+(^M6EAI:=UO5T\[JIM/4I<&K-311)%
M#V5I30LE=(UT4+Z=L;TF=#)HM7418^M%T@@AM#;C57*NCO;645&RW/K;>MDD
M2EN%34/J:OM8D=-52T\<#V5-7#6OGA=2MJH%D<W$Z7VE*Y/P?Q_;4N-/'4L=
MZSD$G+R :$"+/47;+ PI<HSCUL@H-VJ-1:IN4A5\F3=[WK9MEEW:U[Y?6\6R
MEIL65%JI(6-I67*"FAIY)ID8K'K$F]/J%WZ9B2*Y6K+D]S-+2RR0TV%<0W&X
M;F5%B6YU<C[C+8*VX55;!24KI62Q)5.[(BHD6EI)'0-C1[:95B9+O:1JN;E5
M<.*XKP 6+1-N1!;,V&>RX<H[Q F#HB-P4(H4@RS%IB5DSH2XG3 8)*]\W=.W
MD6'.W>2&6"K0)F5MWEWU]9<+SS554Z.>VV^#NAJ+##!+45LZ15J2/6*F9*VB
MDDEBT=!C*F1K-)%:^9(EWS0TU-NC4=);K:R>COU[JUP/0XTJJVFH;/2+46A\
M,?9%PDII+Q#!35&GODLMO@DD5BHZ*D6H3>=\J>SMX#(1H UOD$+>R80A!6<T
M!,T\6[11XU-CVSL&N_P?/&.;=CW1!DJ4P046(HM+K]Z-'3K#!#/;+;99*V^P
MV.>5E-*ZN=1SO57/1CH9',F;&L;)$<_\QZ1*Y$C<_1TWL8JN3D.(,6T]IP95
MXQHZ>6X4S+1%=:.)J,B=+'5PQR4CYDFEA5D.<T3JA&.=.V+3WJ*21&L6#R3B
M.F,'W>83/QZ;D=>BN%EON0U! X_7;@Y&2#6;%Q9T^J24D3%!V/:1X'=UB);2
M\R[6S=J8L![IY?!HTWNGP]25MFBWBHHHZ^7$SK1#7327!L-3&ZCBE@@2-*=Z
ML>ZHFT5E=20M1&IIR-9F]_#Z['%TM.+*E*RBNT]DI]SUF**NSTT-C?5T$T=V
MJ:>LKG3NKH6201T-(LB4T=SJI7+*Y(8))52**GF.+K389^P:+$WSEJX':W*$
MBJ'@9%K'F6V,T;0I4H.)&F$C>=^(N6;XEC&P1^X <]:D#G@]HM96VVQ84N\T
M<CTC8US9+C%'$[?E=.^UHO9B1R1PR4[-!S7LC[(G@W^1CXX=-[<CD%3NE87I
MIH8W3S21O@L53/4L[%9'118C5G:IU1!45<%=+OK9(I9TH:.L6C@ECFJ]XB=I
M'B\3L]F\#=\/V$-DC@"GL+B$@>KI-@D, $;.8W*FQQP05:Y&A)+)F40N(1P9
M.D;V03P7<77:N<N9R1SPW0T5<R_+64S9UH+!77.F599X]&HIGP-C1V\RQZ<3
MM^57M7A56MT7-X<_EN@7F[6:7!3;77OHVWO&UGP]7HVGHI].@N,=6^9T:U=-
M4+%4,6F:D4C5T&H]^G'(NBK=TW=.W$%\4::,A-1VTOW3 (2LZ%Q<%*,#>)YV
MY0RBQ7$L4%YQ\>=QPSNYE(E%^0#X,L[M&*R[A!!71V:A;7=M56GAJ%I+/7UK
M62U,],L*P,:[LJ)8HI4J)(%5-&EE='',KTTGHUKG)NV++Q):.YI&UM50I<\5
M6:TODI[?27!M6E9)(SM=4)4U-.M%#69*K[C3-FFI6Q.WN)SY&-=&YIQ"EC4\
MT&EK5>1-(++-XR+6LB/N!<25B\V;1L1)4C#8*N[7?RQOB/DT?<,6Q5NQ!M"&
M(\IDV<OFF3)PMN])88H:&^K<6T[JVELM-<:>!LM4E31.J9J98G3-:V.E=OE-
M4->Z)SYWQ[Y%I-C?IM3BMVQM4U5XP:VPOKH[1<<7UEAKJU]/;7VZ[1T5-7MJ
MHZ5\CYKDQ(:^B?#'4LAI(IT@J%CDECWE[J4.XIM6/< 1-RN8#0^6*3Y*)3\N
MV&H1*2Y:U3).)3FP5;%G9MDBDS"&WXUP<""$##,2Z5&J..=8XN]NDPS<V+/&
MUL4U72I0K5T$+I'55,EQ6-M,CT=$V%ZJ^:!DC8)Y70OE:DB-RDT-_@W0\.RI
M1U$CZJEMEQ6\I;;S4QP,MM?VA;427%871U,M7$UL-)5S0/K*2F9514TCH'/5
MT229E#? ]=L3<6UMMS'O1C!28G#"(-GF$J'["?XC@CD$_'&7HE"S)Q>ZDD0D
MA"/NHTSPS(&4&C&W?%_BZQR-=$WMC:ETWUT<JK5N8M*^@C629L\<D+)G:;4R
MIW4\<[*EZI'"Y[_S35,QA"]E0]+%B5-[BM$],B6R.1+C#>YD@I)*.:&JEIV)
M"]=*O97344EOB19JMD47YY-B_$B!DOBY7BIN513%SQ*)Z1E#*\5BDDR?R0:/
M(.'T(*/OG.LQ$BR[7-L=;32*/#^:#0?9LFG9R\S:UN$6'IZ;L]M5#2U6CAU;
MS3/[*JJ?0IY)(VLK(F=C(^66%^E ZCJF0(Y\FDJZ+$<;%4XZHJ_M&^W5=QMR
M28[3"=PB6W6ZNWZN@AG?-::B7M@Z&FIZF-8ZN.ZVZ6M5D<.]HW3E6,ST?XKH
M0?-1T5\T=AB&,FV5)=0L),7'19,"EL*+8%5'X!U9A+B!O&SBP9_9B4;A7(97
M-+FUR#=2V6.'QJ,+UL$-1)V50324UNIKM)30R5*SK;ZI8DCG;ITL</YN_1[Y
M$Z9LS47-(W)DJZRBW1K3655%3]K;U2PU]_K\,0U]3#;THVWNW)4NFHI-XN<]
M6B/[%F2*I92R4KG-T73L7-$SFN.)O5^TI2RBD6>/5'1D*=D,8?KJ U1\G#QP
MPD%*NQ^ PV2+#<TEG#1ZV92@7'R#\4ZP(L&CENB[R;?"X8;N=LI7U52QB-AF
M@@J8VI,DE-+41+-$R3?88XI$<C7L<^FEJ(XY6+'(]KE8CM78\?8?Q#<(K=;Y
M95DJJ6LK;?,]U(Z&X4M#5)2U$L#:>KGJ8%:Y\<T<5PIZ*::FD2>&.1C)5C@V
MSMT2R+[]VC!'>WLH/& &AQVQ8DV4!PE^Y<S1X;(C$@S=L0CSDU)&CG!@E9("
M-<XG'2KA5-H03RR0YG?+;9Z6IL5LK66E*RIJ+Y);ZIZ3UD;6T;(8I5F<YE0V
M&G>U9'9SR-WAJ-171KD[/AV(,4W*WXSQ!9Y<3+:;?1X.@OEMC=26F:22ZRU=
M13MI61ST,E77QR) U6T<$B5<CGO;%.U59H;K'^*AQ&M51&7[P@$SB1G.+0$K
M/G[2/I#XT (3LVXCXQ)NC(#3$V1<V6;IEC@&/,I&6BH]ZWQ,)X*VY,M'/AEM
M3=*NDLM=1U4*55=%0L?4+)43QT,+9Y%<Z"%\,;5:Y8H9ZA]/%4R,=O2JANU%
MNAR4&';;<\766Z6RJ6WV>HO,T=$V&@HI[O5/HX&L;65457._2C;4U='0Q5]3
M;H)F)5-1_ NVL>)(?::;L!G8N:"QW4)B'16QS/,$Y4/RR78#/! =BU;2)9]F
MZDSF1@&L91R&HMD^5TI("8ERLF.:Z5^'9.P[-/!4PS5%VAK*K>$2=J04M(LN
M_32/=3MC1M,VGG=4NWQ7*FBD$<K461VY18ZA2ZXKI*RW5=+189JK7;DJU6CD
M=6W&YMIUI:6&..N=,LEP?7T<= Q8&,3^D6MGII'I!'H>T-^S%C*M,(QB.;#C
M6!'>9G6<UA!N-11$K+VC*$D9&TRCI,@^>A7(UZNF.5&R(-+AXZZ>;YL6>-<V
MKE-IKK;8J1]+>'5-1;ZE8[)#<J.MAJ:IT5(]];'3O2HBC8R9LC&K(DE/-222
M9HQT3'(YJOV;$.,KI#<<*MM]#>Z!)\755@NMIJZ"W,J;G%%:9ZZ-:&HFEEI)
M()GM@=!74MSA@R69E1+&Z-Z1=BM8[,![CAJTGC:)X#CB6DD7(,#346A((](8
MV4> R[-TDU='P:KMB^:YJ(*M7A<8XPNBIW;A/+-*N/W*VSVBL2FJ%@G58J>I
MCDA=*Z"HIZF)D\3VJ]D$Z->QR(Y'LBE:N:9-5$4YQ8+_ $F*+6^OH&UE&B5-
M?;IX:J.G96T5;05$M)4Q2-CDK*1TD,T:N8YDE3 ]-%V;VJK3J#I/B)V41"[0
MA.PB; OM-AC!S6K2-Q# 6WD,<VZQ8CHBX6&#$6J#U"'RJY!&7/FS=&V#!LNO
MDG@DVSSKE=YL%N9-;*V@C?#;).S8;G'OTDJT]1:7ODJFI)*YSF.JZ7>UI&.<
MN<CFHBJKD0ZRPGCB_3TE_M5[GAJ<10ML]9AZ=:>&!E=0XFBBAMCWP4[(FRLM
MEQ69ESFCC;HPQO?HHUBN79^'CB+DI7APU?LO9#.6SV4SIKL$N3=QB/QD:("L
M(8:.-,^_WSAS%(R#:J,!;-$<F6+9$S)AVNDQ[X2PS28Z:_X?IHL0W*W6Y]+0
MTU$ZWQ1LJ9ZF26:2LA@>F]L:VJJ9G))*]9%BB2.&%C5?HJJ*_<,$XXKZG V'
M[]?8KE>+A=X[W4U$M!14$%-2PVJKK(U6:9[[;;Z2-8:>)L+:FI6HJJF1[8=-
MJ.;#16W%=!2Q*!BXM$]DS)SL;7[#9L>^;,=&N[8Q1X>$QUT[)I/3[!RP6"OB
MZ:I=+-OG@BU:NLVJKQ:[1!WM[L+UT4==+4U5NI&V^ODMM1V342-SJF035#61
MJR![9$F9"J1*CD57.:CD8FFYF]LW1K/4SV>GMUMOUTDOEEAO]#V!0T\F5MEK
M*>ADDG;+60OA?2S5+75+7,5K(XY%C=*[>V2:EP];X/2C$Q%Y1D>GTK1VUMR/
MYD0[&',T(?"(=+W0 "5FB;=Y&TQS)TBU6;CG388]('GC MBR;.U6#G!'5W^Q
MP4RPU--O%#2K:K3.D<KZM[JNMJZ-E1/%1JYE0LCVN>CI&NE9' R2+3<UKVJN
MW8*QA6W#LNW7!:R\W%F)L2T*STT-KB9;+3:[G)14=1=4CEH&P12-C>R"2.GE
MGK)8:E(8Y'0R(WE(\;6JK1R6'8ZT-2','KZ6[& (-G$7Q2F,?AQ#$87=CLDY
M*N]$XME%FA/)E)V (V\ KW(AA!51!9IA(\&W3LBD@J'0TZ3U]);IU<VISI)Z
MR-9(6R9TZ,ETD:^)'TKYX63MWN:6)%1ZY3[J^'4H;E644576NH[+<K[1L8^W
MHVZ45KFWBID@5M>^6F1CG1U"Q7"&CJI:-^_TM-4*UT:=F-?R(C+83%9,6#N0
M!$X#'DG@IUD/S4;+.F^"F6:=Q98XTLT=6O9XQP\*.7*;)=NF_LW?8N6R/'*^
MGCI*VJIHIFSQP3R1LE:DB(Y&N5,EWV*!^FWXCUWIK5>URQZ3%:Y>>V6NGN5I
MMU?4TLE'/5TD$\M/(L"JQTC$<JM['J:N-(I,]]A3LB21L3V-F1DR/C;M]:0W
M,4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H#"244Y.QXX%:/$1S@N*?C$W
MSAGF02:=_-E&N2^3)-X/R<\W@KEEBE9XWMEG;'NL^YM?&_VIY6PSPS/8LC8I
M62*QKTC5V@Y'(U'JR1&YJB(JZ#N#BXS25],^LH:NDCE; ^JIIJ=LSXEF;%OT
M;HU>L22PK)HHY51N^LS7+-<N!9GJ;4SG56F0FHFTD1-6C@!]'Q,@7!YLLN]W
M%G-VBY 6F9<8NUFRKG+)>S8@PP=)X8IX8M,^Z5ON5UNC;I>)[LZG6'LBH942
MP-F1_P"<BMTVQRK"W11R-_-THWJU555TDX#8<-X<DPYA:DPU'7MJDH*.6BIJ
MU](L2Z#]\WI\].VJ>DCHW2?G[W-"DK41$2)<W$]C_#$VCVO]&Q5K+[JR3A^+
M^%(1+%H__P!F=HJCR@9^-D$?P.8W>-"0@LN@YS8&A;C!XW9/6RJ&"2[1SKZC
M$CJBOO=4ZDRI[]%O=;2I/^<Q4DBFCDIZA8?S'QRQ-5N^0RM5CGL<URJUS=DH
ML 1T-EPC;HKGI5V"ZKLBTW)]%^9(UT-12S05M$E6F^QSTM2]DBPU5.])612Q
MN8C71/PX3A/QA\L!;&A6P%A.PTCVSSDU+E(PD: S:^VS+0])FBL=2."7 1,:
M0'#;QA1D=7S'H,442UCU\E5%/K-BCLNDGMU90)+;U@ML-'#'4NAGHNU4+X*=
M[:AT,K9EDCDE2I1\")(Z171;QDF6FI=SA+9<J2^6J\NIKVVLO]7=:JHH&U='
M=NZ2JCK*^)U"VKIGTC8)X*=;>Z*K>Z!D+&5/9F;E=XD2X2WD'$Z%;1W9N:1G
M10>?QEB7?0YL];R"/;%R:J%T7 JQ]OB/+#U6B2@<E@\>M$KV[DB))X7RQRSJ
M\5,K9;ZZHMR.AODU#4R1,JW,=!46]'I$K9>QUWR*1'JDL:L8Y=<<L:Y9?*W;
MFTMIIL&LHK^K:K!]+>:"&IFM<<K*VBOF]K5,?3I6L2"IA=$U:6=)9HVY93TT
MZ*J+X>O^$0SJNVO'D!W(2"'(? <]82%^M"Q)1A,H:G)RLL&8J!GQ55 +(PI0
MX4\''4ER"7>SC%L[%ND+.$W.5=BN&Y]L&5UHBF@JZ]+G3QMK)8I*.L6FBI9<
MIF1HZ:GFB@BWR!6QNTFZ3)6NT5;\K-N:56'NT<MFQ144E9:[,[#]=.ZU4U1#
M=+6EPJ;E3HZEFJ',I:ZDJ*NHWBK:^=N@]&2T\C--K[5"M.N87MK:.RVTS?$&
M&TD88J5C#L.PQS;&8;%V,2;$[GL%.?<)/!['%RLQ2'L;8/UE5>^56_-M<-GK
M+LVLM=MMSJ-D<EM=6)%4LEDR=#653ZMT>\*FBU622*U'J]^<:(FBCLW+RNU8
M8DM6),0WYETEGAQ"VUNJ+?)2PHZ.JM=OAML=1V8UVF]LL$*/="V&)$F<YVFY
MF4:>)(M#Q^;%]BEYZTALT6F(1K&X[C((,U?J0H"T8D6Z8QHZ=%W#AXDJ_*D#
M3I9CF!=+$7BU\5TD4F";'.GOE1116^*A?64:4DSJBH['K71I63ND8Y97M;$U
MK')'%'"U'I.U(V)^:JK(K_E78/HKM4WRJO,5KNK[I21T%%V;:(YG6JCCAG8V
MGCDDJ9'R-=-4S54KH5HY'SRO5'M8V!L,SB'"U(H0EIQ^%VZLO+-/1,]KAH<,
M0M-^PDVMS:S!PWCIH*E*&:B)&/JC65@9L:6:)IHM&J)$22Q34NMN57B:GK5N
M[);4UM+=ZJGN+H(:Q8WTUQ@;(UU1#,M,]%CJ$D>L\,D3E5SW+'+'FF6PVS<]
MKK2W"\U)B5[[EABVUEBBK*NUMGAK[%5NA>RAJZ5MPA<V>B?3P]B5<%3$C611
MLGIIT:Y7<FO.%-QKS+063+86!*^@8OL:-!>_8CS?A[#8O>V3UT3[WD^'>_@S
M-DT[S0:_O53Q7P<.,LUL%4,;AB=MP2^H^@6/M[56^IFT*K/>%M^FC&1:5,NE
MOF^/TW.U*K5:U$3);9-SI]D7!BPWI)UP9;[Y04BRVW+LQ+YH++)4:%>FAV.L
M46],CX7-21'O57M='A(%P?E-7>+=_ =P/P4C@\ (:K+EUH6+*LY;!74M(S-B
MV5#$"RK<1(0YDJ_58G4%WB&>"MD70A=MSK=;[5V+(KGVQ976EDU/6U[+I%"V
MLEB?2US:5E'(Y)HXD=-!-#%&CX'-:J*W29*UV2II+/N8U&'NT4UEQ/-1UUHL
MLV':FI?:J:ICN5HDN4]UA8ZFFJ7,IJVEJJF9T-6Q\K%1VC)3/CTF.V60<+"<
MBF*TX>S%EA), ^P #:2-H=@SE14%.(\3CC4#.S ^1LV<V"Q9N3L^"-W08<]2
M(BPZF!%!LT6:.]/3XF6GI$HF4CUIUFH)W4[JM7TT4]%41U#IZ**2G>^BFJ71
MK'.YLTC'12RHL:N<CV[A6[GB5UT?=IKG"E<E->J..NCM:17&HH[O13T,='>*
MJ&NBBNU+;HY]]I&24L$K9Z>F<D[(XWQ2XH?PAH!HPXC@>?JL<Y!H@+P^3DC>
M,)KJ'8C'FK\2).!F^9['"/2Y$$5(C5G[C,^'644;/,02637F5?K)BQTU2E1-
M0H](+Y-?J*/LE6I!5U#XY989G)#G44BS11R-8U()41'-6=4=FFF@W,V4E ^A
MI;RZ%:W!]+@J[SK;VO=66RACFIJ6KI6+6(E%<V4=3/3OF>M92O5T<J4;%CT7
M>+(>#4:5 [JBPJ;W!1_<$7U%#\6>,9R(.(H$TX/0%1])D[5D:-B3AZ/0Q2?K
M.VZ5N=MBJBEA:V2>>4&+I(Y[/4RT6_5%IJ;K5J_LG>VU4UWD=+.KV)3KO362
M.58T:YW!FCE7@5/G6[ET%11XJM]/=EI*+$UOPS;&Q)0+,^VTF%H64]$V*5U<
MSLA\L+-&9\C&_G9.:U,E:ZT[\T^XWOJ*0:G>R9*.-Y4D'1-&VH+,BM; 46&F
M[^"V*QIK@SR</AB&'*[<DK(M%%D>Y47O@Z3V>Q79MDNL%T93+4.IEF6&%TZ1
MIG+%)#_2/2%ZO1K)7+DUL>;T1<T;FU>5XQPR_%^&JW#DM>VA9<6TS:JKCI%G
M>B4]3!5_X/$ZJC;$KYJ=B9R23Z,2N;DYZI(FE37AQ<3^7QJ9GY<(2.1$]&Y!
M'#X:$Y"Y@ 4 LFR+T &E*<J5<)PZ2O6ZKPY'"[,TDJF2*MVKILJZ2>-M91X@
M;04E31P4LJPU<%1!402UF^TDZ3O<K)YJ9:9&K5TS%:R&HA?"J+%$YS'(U6.V
MFZX&?>;G072MN5,VKMM905M#6TMI6GNE&ZCBC;+1TMP2XN>EKKYF/EJZ&IAJ
MVN;45#(Y(WR-FCT0AP7BR(N=IXS!B!/3>^M2#E_$84C'X\K+-:2A64M)N=AV
M,B>C"TFD3K))G(W(QQ'&CIHE?)LS:NUUG.>NCQA+'+1*M(^>"C2XQM95UCJB
MH2EN-,E*^B@JU@9)%34[45].V1M0YCW?G/>U$:;//N5TT]/>&I<X:*LN_:&:
M6:V6IM%1/N5AN#KC%=JRUI72T]37ULBMBKGT[Z".2)JK'''*]TB\Y+A#(E#$
MGF2NV'3/8)?:,.V^!DHV&,4&,;EL3BMX>HTR .CCY,U&2X95PW<"G1!N]3PR
M0[HNY5266=8QXKCBBIJ1+6U]!%;*NTSTTE8]SZFDJJKLQ').V!BPU,4R-<V5
ML;F+D[*)J*U&9U&YI/4U5PNCL2217JIQ#:\3T=?!:XF0T%RMMM[5NC6BDK)6
MU5!4TKGL?3RS-E:BLSJ9'->Z3L2!B,]'' !0SM1_(!S($992(!G%(^-82&0$
M7S)R/.M7#7',@!: 6;=<8Q"-W+S!T@YLZ)OWI'%P[>;!/5T,D$\4-L9!(^>%
M]/.E54224\$;)&R0.:Y4CG=.]S9'S.:Q6N9HQQLC5K&<WH[9>(*NBJ*K$,U;
M!%1U45=1+;J*"&MK9YHI(:R-\:+/1QT<3'T\-(R25KV2))432SI)++BS>H \
MMG):63AI$9J+4B[*-1:-2:$LC"$4[AV\?&2#=V2(O$G:TG7<,DS::0X===G'
MX^V252R9.5GWTANTU+114M$^KHY$J7U-544U8^%U5FUC(8W,CC8K$IFM>L*K
M))D^>=RHNFUK-/5X9I;E=ZFY7>.VW6G6WQ4%OH*^U15++=E++-53LEGGE;(^
MO>^)M6C((-.*CHHVN:L,CYHG#^$M_$HWIR)X[-\)!=*;0([&BR*\04P7NU?H
M&T,(DHXREB^> D?:1E_![G*R[M%/)@AE=1!E=-QO-7BIE54W>J[6[W->;9';
MZI6U:*W38Z!RU:-[%1%ED6GBWQJ:+%7?')DY^;>*6O<WFMM!A>VI?]_I,*8@
MFOMN:^V*C]"9E6Q+:Y_;%ZI30I7U6\/5'RL18&*KF0JV2VZ9U4IJ0+*@^<@P
MD7SHV%,]A*.<1%P_>;R:EE#+\=@C<J5YYLT=K*8,U<E4U;-^XP6LJICDMGLU
MXNB76:EF2!:?L:WT= C=]WW3910I"R15WJ+)SV-17IDJ:6:IDBY)RO"V'5PU
M27&E6M2N[87NZ7MTB4RTN]2W:I=530(SLBHTHXY7N2)RN1V]Z+7Z3D5[IV X
M=SL/0V/%HELA$9K39\JE,J,QY[#;$98!<3?DO*6,0F:4G'L!S)WGDOD.N:AT
MC="KK7NFX7SPPSMN%1?X:MUNJ:JWK)<;;2TM+#4,J][I9VT7!2OJZ-::2221
MB(F^;S64[9<DS:U,T79*+!%9:V7VW6V^L@L.(+C<;C544UKW^Y4<EV_K&*V7
M1EP@A@BE57K!V7:ZZ2F5ZJV1RHBIY$^X<KS:6[%DR,O2"H; X?W?#YD*PC63
MW$-'WCPR\4--W=Y T[Z)IYGGZ2"&;9%I@E@RMGBKD@MDZQH<0]ATMOIW4BS.
MH+\R_;ZM0C-^G8R%B0N9O#]&-4@8KG(Y7*JORR141OTO&!^VMSO=P9<VTK+S
M@R7!?8Z4*RI2T4LM3*M6R7LV/?*AJU<[6,=&V-&I%FCE8]9=-(\(ZY)A+V"V
MQ4\,)=P]1CAY743AV5LV82-6<X)R%*V4JRLJ5=X$"%LV^?<M$<LVF6-E+-EL
M'FLCQ4D<E'(EO55I+_4W]J+5ID^:IT%6G7*EX(F+''DY,WJFFG KFJS:I]S5
MT\%S@?>VHVY8)M^"7N;;%18J2@21&UK<[BJ.J94GGS8N4356)41R1O27CEG!
MXVF;L\]*;"=LG9/7NK8:(>A8XDT>QTUJ,U:11B6M%'ILFW=K*%\W%R(ERTN@
ML/5P:(NV[A+)\JI<6OI&0,BH&/;'7W2KE9-4*]E1#=H>QZFD<C(8W,1(D;O<
MK'Z22(KE:YJ[VDN6YA'=)*R6HO4L4D]DP]:J66EH6Q2T-5AJK[.M]RC=+5SL
ME>M4Z19Z:2/0?"YL39&/:LSMXD>AYE+L]7&Y#N!T[FVM)RM+V\A;0<*S%NFK
MN.$(P]##XUB_50&9*,R"[Y$F0(2!1(JHJHLU=#;,A;'14]\HZ3MG#3VEK**Y
M424CJ=U;,^5CF5,=2R:2IWM'2(CXT8L4<<"+$B(CVR:<K]VKL'W2Y+AZKK<3
MR27:P7=]S96QVFDBIY(Y:":WS4L- DSF4ZNBG?,RHFFK7-J'.<^.2!(J>&N3
M2(%9.4@)$<>9!L(5+;RI=!T#5+Y&+Y1X[&KC\5DS0JPY.["1$5;N+(O5._,&
M*F.&*"#AN\VJCJHJ:*NCD@?-V92I3-<R9(MZRJ(*E)%189=\73IXTT<V)H*]
M,\W-<SDUTMM17U%FG@K(J5+5<EN#V24CJE:I5HJN@WE'MJZ?>&[S73NT]"9V
M^I"[)&,DCEC\JX4-:2G8TYV)E@\$.=H:HE>JMB"Q/<-FTB;R10+BA*<<^6^#
M&3"V0M9CW[9LYQ?IKM%5\<%6*F3[=J;%%RIK?16_-LK;9=*6Z6^67-SZ9U.D
MVE3<KZ:5\K7Z&DW>U:]&YI(FAQ>X[G-AN%\N][5)*9^(,.7+#M[IJ=&LCKF5
MZTJ-N.>J*OIXJ=T*RZ$F_-?&YZ(Z%5EUY]PPRL[KZ)1"2;P-DSNL9##9+JF6
M-8:!&WBY6"I.6@9\=#8NW*<R>.ACM<69S>D![-ZUOW;=BQ=+/G#S4,Q)2P5]
M55T]EAC@N5/64UTI7UD\O9,5:K7S,@F5K5I&-E:V6%&1R/8Y,G22-1B,T4VY
M_<JRR6VV5V+:NHK,/UMKK\.W*.U4<"V^HM#9(J66LI4DD2Z2R4\CZ>J66>&*
M:/A9##(Z5\NRE-#2U],(9LQ+;"EMD1Z.26'2 L_A3%W&I/$Y0X'O7(="+L38
MA8#X*("VC\([2/$5TW5E<C'AK!6^%M/'?*5E'66U;6G:^HJ*:LIXHZQ[:BFJ
MJ9LC&S+4R0RMGWV.5\<[5@C169)#O*IF:^?!UREN=KO[<1N[>T5#7VNMJ9K5
M%)07"VW"2"9]*RWPU=,ZC[&FIXIJ25E9,])-):KLMKE:F<@VCLH/P](Z#;2N
MY!%K"S<+;2EP#Q26Q:&D2"&;Q4.D5YM5=K@15YK#$BEAG=-*ZE[\F?.?"MO7
M9M_=?74N]N?60UCJ9LV::<+HW:#9EBS1KEC3-5C<J9KEQ9:NT81[48)9@UEQ
M6=D=JJ[4RX/I$:Y(JMDS%E=3-J-%SXTG=HHD[4=HMS77G-!_"8N/;MV]MAI*
MV:\+6'"PEE>'Y87O&TLLN9E&=K2K+NC>*?<8J-L;XL%,L<L\<$K96PQW*3%3
M9'N<MO5%=B9<3JG9:+_A"Y:5,G^"_P"05>%'+G(B<&:ZUV&#<W?#&R-+VUR1
M[GJ;GC56V*B]@-S1EP=E<>&K1N2.8F4+E151&HN24J0:(;R3ANRX=WTE62:^
M+@1KS"5M16&#C%$&.8CAY7,0J_63S5OB.;*O&EB.&"^5U\45VF*B?,[;3WMU
M-B%+^RF:KDN,MP6E=*JM59I'R21)*C$5$_I'-8_>U5J:*JURHN>_5N#XZ_ J
MX(FKWMC6Q4]D2XQTZ(]&TD$4$%0M,Z9[5=E!&Z6-)T1ZZ:,?&CDT=-/<,Y:2
MFY5(3&R<'167\.C_ (>":]H8B@FF,)DBQ1U)&B#:1(I)O$5S+MLP'J65219(
MLL'KPB\2=/GNL@Q'%30TL$5N5L5)B"._QM[,5562*.*)M.YSJ=RJQ6PM=)(B
MHJO<]6-C8K6,VNLP%4U]5<:VJOJ25%SP//@FH?VK8Q&T]1/45$E=&R.M8ULK
M'U,C(8%1S6Q-A266>5LDTO'"^&0UKN3-C\+VT2!MB\(US"]C"TXF)>VEMM8
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M>6#2@G%3)<80LV#)??IV&LNN,C0")80&:R@\6=EYI+(!9<1K^?O!8R1P,?M
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MK=TU'RH3$)0/($!!L;)A*C9@BY8(RT"I%I(7BMU'94:)E[YI[_?Q&..<6>C
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MLJN0< 9@'(R\I+A. ATW !7$HAC.4 J9<?+GP:LN+YUY>).4N>GN)N.[:>1
M:S8(-7,M=\4 YB\9E+$13YSPN;R'Z.DST,Z[S;>$A,G)OKR,$\QMA9,1ACAE
M=WDI9S8,O1]J9G9VA!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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MD"X7M?ZYV*TV:"+2U>0-<-\W40)O 3@>^><1>V!.W]AD7V2$=:%EG=CL<BP
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MYM<?SM!FJ)E\^?E.!GPL:W:,IN-P-;29,9WLG'9Y!.&[6G6H70TLVA4>UX+
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M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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MVH>/S1?IIU-[1H?^LT[17OP-=>KJOU([LL(>-6&^O+7[4/'YHOTTZF]HT/\
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M_P!&,._OY_\ +ZD^?NN^CQ:* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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M * 4 H!0"@% * 4 H!0"@% * 4!W4^3N_P!<C3'_ ,U-?=O,:X;N@?HA>/\
MZ:+^8T9VMN(?\Z.%?]I=OY%=#Z-Y]"3\KVCJDZJQ9D()K09LF9*#[N4$B13:
M12/--?PELDBXQLW7"X0.9;@;EK/EF[;$J1B[BW.V:K9-_,)^B1#=< =\K-=J
MG99H: Q;8>YBR+>3DC&SF,[C38:QUK)0L;2>!6$5'KE81%7XB(1A>-X/4"4F
M6FTVF6>(/'!40]%X/GR3WY5R_N0@NC.!^4Z^UD9C11%^[(Q\W&I!I=&9R]K(
M9!!Y.8T@AH[930Q+ .#1S*=,C@I(LUU_$2;N\I P5%:&QQU#0K2#QR* J\_S
M\6:9YIR\/+\_*N:KVSX7M6;.U8$D@G8TE<G\\I%*L V:AC$BV<A\]ASDE%BB
M+)%DR:L'Z^OR<+;RHFHBE(IA/D)C*):J5(OVIE^(6'<'1+M'JZFW9HG5;K3G
M3:1VI>9=A1:A10"@% * 4 H!0"@% * 4 H!0"@% * 4!Z]OE!-#33B*C6J]?
M01W'V9RTP,F^>DKYZ/'=Z#HT]Q7PLNP&%5^?RNXPNGAWKW&5K9=TIA>UK9<X
MP+B*@PW7UM5<&5+XYZ1*=B4T<<CT?OT<F;DDEB1&Z+%X4<JYY)EEPG3V[)@.
M]8_LUIM]DFM\,]%<W5DRW&>>"-85I)H,HW04M4YS].1OYJL:FCFNEFF1ZS?)
M,<37V@U!^:9/\$5V=WU,-_L+MYK3>VGGGX-N/OEV&.L+C^$#R3'$U]H-0?FF
M3_!%.^IAO]A=O-:;VT?!MQ]\NPQUA<?P@>28XFOM!J#\TR?X(IWU,-_L+MYK
M3>VCX-N/OEV&.L+C^$#R3'$U]H-0?FF3_!%.^IAO]A=O-:;VT?!MQ]\NPQUA
M<?P@>28XFOM!J#\TR?X(IWU,-_L+MYK3>VCX-N/OEV&.L+C^$#R3'$U]H-0?
MFF3_  13OJ8;_87;S6F]M'P;<??+L,=87'\(,*?^2VXC8XQ0(/SNJ,T'!J-
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M#\TR?X(IWU,-_L+MYK3>VCX-N/OEV&.L+C^$#R3'$U]H-0?FF3_!%.^IAO\
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MP;<??+L,=87'\('DF.)K[0:@_-,G^"*=]3#?["[>:TWMH^#;C[Y=ACK"X_A
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M6+\2'DV^,CT4-O:!K;XNIWQ,(>%7>87'V0=XC=1\7(^NK%^)#R;?&1Z*&WM
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MUYDVN*74** 4 H!0"@)M*>D'5OKYEV<O62?%=]':8K\9OTMA2:Q,A0"@% *
M4!-=K>;(CK*TY[W(3537Y';%(NKRMVH4JH44 H!0"@% 3K<'1+M'JZFW9HG5
M;K3G3:1VI>9=A1:A10"@% * 4 H!0"@% * 4 H!0"@% * 4!ZI_E7Y-)(GK#
M516+2 Y&B?C"?-O"4?+/PS_O=6,DKJH=^#G#9QS*M\,+J)<YW&=\<;Y8W[FW
M)V=N74E+5W6XLJZ:GJF-MZ.:RHACF:UW9,*:36R-<B.R54S1$7)53/)3SO\
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MF]*D36[G]"%*J%% * 4 H!0$T&],4SZM-9=J=M5>).==C2<:\R;7%+J%% *
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MU^1VQ2+J\K=J%*J%% * 4 H!0$ZW!T2[1ZNIMV:)U6ZTYTVD=J7F7846H44
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MQQL8JIKR56M153/AR4T/:_FN*ZRM,>^&"UBFOR.V*?1=7E;M0I50HH!0"@%
M* G6X.B7:/5U-NS1.JW6G.FTCM2\R["@(?P$?5)_R8U"G+0"@% * 4 H":Z@
MZ/ 'K#?: K577Y&[$!2J@% * 4 H!0$U@OG1N?K*%>Y[5%5=3>;TJ1-;N?T(
M4JH44 H!0"@% 30;TQ3/JTUEVIVU5XDYUV-)QKS)M<4NH44 H!0"@% 3:4](
M.K?7S+LY>LD^*[Z.TQ7XS?I;"DUB9"@% * 4 H":[6\V1'65ISWN0FJFOR.V
M*1=7E;M0I50HH!0"@% * G6X.B7:/5U-NS1.JW6G.FTCM2\R["BU"B@% * 4
M H!0"@% * 4 H!0"@% * 4 H#U^\?F_9=PWQ[5>PX4+CA<S>7F0=VDI:DW8S
MO0C&GN2ZG-"2P9UWQA=OAS67?G-XVOGW:6=[VOCS7!&&Z+$U=64M;-50QT](
ME0QU*Z)CU?OS(\G+-#,U6Z+U7)&HN:)PY9HO46Z_C^[;GUGM5QM%+;JN>NN3
MJ*5ERCJ98F1)2RSZ4;:6JI'I)IQ-3-SW-T57\W/)4];GE=>(G[":6_Y%.?\
M[A5V7WI[!\NO']M1>P'G[X3&-_ ^%?-+O^-#RNO$3]A-+?\ (IS_ /<*G>GL
M'RZ\?VU%[ /A,8W\#X5\TN_XT>]C2TT)['U#K#8!INP:&)K HI*2C46FX1&M
MWYT(R).T&"3MR]=)LTEW.>#?!P[<K8I6QQ575SM?/+I&\4<=NNURH(7/?%15
MU52Q.E5JR.9!,^-KI%8UC5>K6HKE:QJ*N>343@/7^%;K47W#.'[U5LABJ;M9
MK;<:B.G:]L$<U9215$C(6R22R-B:^148CY)'HU$1SW+FJTVMM-_% * FNU_-
M<5UE:8]\,%JIK\CMBD75Y6[4*54** 4 H!0"@)UN#HEVCU=3;LT3JMUISIM(
M[4O,NPH"'\!'U2?\F-0IRT H!0"@% * FNH.CP!ZPWV@*U5U^1NQ 4JH!0"@
M% * 4!-8+YT;GZRA7N>U1574WF]*D36[G]"%*J%% * 4 H!0$T&],4SZM-9=
MJ=M5>).==C2<:\R;7%+J%% * 4 H!0$VE/2#JWU\R[.7K)/BN^CM,5^,WZ6P
MI-8F0H!0"@% * FNUO-D1UE:<][D)JIK\CMBD75Y6[4*54** 4 H!0"@)UN#
MHEVCU=3;LT3JMUISIM([4O,NPHM0HH!0"@% * 4 H!0"@% * 4 H!0&L38P]
MCT,EQ\;9KD1!Q@^888OD57#+)Z,%.WK6SQ!!RS76:W703LX11=M55$>[P3<H
M9Y8JX@>N^%<=DR8P$ <W1KSP&5V-#D)MK M#QP=PV) E>'YIMAP3/:[+;2RE
M8AA:9"-A0:-KESX!O,/FNW?6=1QF^\)8"JG1J7DS^9?M.SFFN)^+[CF1N"C(
MQ, Q($&=E;&#K6.-@Y[$01&"3F0E /*Y$39X-'AH2H@D909J.&[Z_-9J*-'%
MK J9>_S(OIVG2;Y7_HAU5UD.NS!2NUMR;^N+G^[4_BH3S1^4W^C&'?W\_P#E
M]2?/W7?1XM% ?6GHMF<(<'NFVL<,&@)E32.O,F9.-LXP_D:-T8N(661CZ$V2
M<0_$V];IJLA3F4-78%F^<(.RC5PS151S\F8H_22_?O>X?Q4I^FVYW^@6"_\
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M#!:J:_([8I%U>5NU"E5"B@% * 4 H"=;@Z)=H]74V[-$ZK=:<Z;2.U+S+L*
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M:JZ_(W8@*54 H!0"@% * FL%\Z-S]90KW/:HJKJ;S>E2)K=S^A"E5"B@% *
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M:ST%3+/GR3Y_?@X/G.\]""@)KM?S7%=96F/?#!:J:_([8I%U>5NU"E5"B@%
M* 4 H"=;@Z)=H]74V[-$ZK=:<Z;2.U+S+L* A_ 1]4G_ "8U"G+0"@% * 4
MH":Z@Z/ 'K#?: K577Y&[$!2J@% * 4 H!0$U@OG1N?K*%>Y[5%5=3>;TJ1-
M;N?T(4JH44 H!0"@% 30;TQ3/JTUEVIVU5XDYUV-)QKS)M<4NH44 H!0"@%
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MM2\R["@(?P$?5)_R8U"G+0"@% * 4 H":Z@Z/ 'K#?: K577Y&[$!2J@% *
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MKF[).#/-.ZM<..UA0"@% * FNU_-<5UE:8]\,%JIK\CMBD75Y6[4*54** 4
MH!0"@)UN#HEVCU=3;LT3JMUISIM([4O,NPH"'\!'U2?\F-0IRT H!0"@% *
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M:1VI>9=A0$/X"/JD_P"3&H4Y: 4 H!0"@% 374'1X ]8;[0%:JZ_(W8@*54
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M@*U5U^1NQ 4JH!0"@% * 4!-8+YT;GZRA7N>U1574WF]*D36[G]"%*J%% *
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7N#HEVCU=3;LT3JMUISIM([4O,NP__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g428534g00a02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g428534g00a02.jpg
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MU+U7:Z[$UKPP)>+S8A8+)#D_J7JNUUV)K7A@2\7FQ"P62')_4O5=KKL36O#
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ML.Z;_*'57NWHWTQ%C8I7OO?B;]&Y=R\"2!"@
M
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M4.JO=O1OIB+&Q2O?>_$WZ-R[EX$D"%
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MIVV=;?AMNNFZV/05\1"MZOU_7&Z=AO)&DU
M         %:\9!CE@C3?Y0ZJ]V]&^F(L;%*]][\3?HW+N7@20(4
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M#)*R^7LWM.V80@92P+3*LG85YA.3R6QYO_RQ6'>:9\ZY_>Q=OV[MYO-&DU@
M                    5KQD&.6"--_E#JKW;T;Z8BQL4KWWOQ-^C<NY>!)
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MZJ]V]&^F(L;%*]][\3?HW+N7@20(4
M
M                         "M>,@QRP1IO\H=5>[>C?3$6-BE>^]^)OT;E
MW+P)($*
M
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MS6V=[PKI]220ZE5_W=7?C=9^>IG]3G0W^B'17^[>H_\ :ZJ1Z,0_2
M             %L/_IU_R=XCO>74?I9T.;/)7[WZU^.:'YAGCK_":?TW\F']
MU==?[OHBQ:.5#S)                           K7C(,<L$:;_*'57NWH
MWTQ%C8I7OO?B;]&Y=R\"2!"@                                !\\C
M;7YJ[-]X-S^HY(>B^I_>G5?R=4OHVB.J->]VUSXU6/GJ9'P^B8H
M          !9\\@5^5?$)[P*A]./AU:]D%[[='?DZN?2:!S-Y+O<6MOC57^9
MIF_P=?#E(   /FH[<_-;9WO"NGU))#J57_=U=^-UGYZF?U.=#?Z(=%?[MZC_
M -KJI'HQ#](                    6P_\ IU_R=XCO>74?I9T.;/)7[WZU
M^.:'YAGCK_":?TW\F']U==?[OHBQ:.5#S)
M K7C(,<L$:;_ "AU5[MZ-],18V*5[[WXF_1N7<O D@0H
M                 ?/(VU^:NS?>#<_J.2'HOJ?WIU7\G5+Z-HCJC7O=M<^-
M5CYZF1\/HF*                    6?/(%?E7Q">\"H?3CX=6O9!>^W1WY
M.KGTF@<S>2[W%K;XU5_F:9O\'7PY2   #YJ.W/S6V=[PKI]220ZE5_W=7?C=
M9^>IG]3G0W^B'17^[>H_]KJI'HQ#](                    6P_P#IU_R=
MXCO>74?I9T.;/)7[WZU^.:'YAGCK_":?TW\F']U==?[OHBQ:.5#S)
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MC&3%3RNH3!\EQG&38+G.<8SC.?\ N /0]IZUTA@_BS#O  >T]:Z0P?Q9AW@
M/:>M=(8/XLP[P 'M/6ND,'\68=X #VGK72&#^+,.\ ![3UKI#!_%F'>  ]IZ
MUTA@_BS#O  >T]:Z0P?Q9AW@ /:>M=(8/XLP[P 'M/6ND,'\68=X #VGK72&
M#^+,.\ ![3UKI#!_%F'>  ]IZUTA@_BS#O  >T]:Z0P?Q9AW@ /:>M=(8/XL
MP[P /GQ;8,4^T]EG(8IR'O\ <C$.7.#%,4UBDLE,4V,YP8IL9QG&<9SC.,XS
MC/F'HOJ?WIU7\G5+Z-HCJC7O=M<^-5CYZF= 'T3%
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MC&,8QC ZDU_W=7?C=9^>IG]3O0W^B'17^[>H_P#:ZJ1^,0_2
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MS5V;[P;G]1R0]%]3^].J_DZI?1M$=4:][MKGQJL?/4R/A]$Q0
M        "SYY K\J^(3W@5#Z<?#JU[(+WVZ._)U<^DT#F;R7>XM;?&JO\S3-
M_@Z^'*0   ?-1VY^:VSO>%=/J22'4JO^[J[\;K/SU,_J<Z&_T0Z*_P!V]1_[
M752/1B'Z0                    MA_].O^3O$=[RZC]+.AS9Y*_>_6OQS0
M_,,\=?X33^F_DP_NKKK_ '?1%BT<J'F2                          !6
MO&08Y8(TW^4.JO=O1OIB+&Q2O?>_$WZ-R[EX$D"%
M             #YY&VOS5V;[P;G]1R0]%]3^].J_DZI?1M$=4:][MKGQJL?/
M4R/A]$Q0                   "SYY K\J^(3W@5#Z<?#JU[(+WVZ._)U<^
MDT#F;R7>XM;?&JO\S3-_@Z^'*0   ?-1VY^:VSO>%=/J22'4JO\ NZN_&ZS\
M]3/ZG.AO]$.BO]V]1_[752/1B'Z0                    MA_].O\ D[Q'
M>\NH_2SH<V>2OWOUK\<T/S#/'7^$T_IOY,/[JZZ_W?1%BT<J'F2
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M[H:[=<=;KE"M+3+2T-5:J6@6C5'J/1O1Z7K3UNO1^]-CX_5G5\
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M7C(,<L$:;_*'57NWHWTQ%C8I7OO?B;]&Y=R\"2!"@
M             !\\C;7YJ[-]X-S^HY(>B^I_>G5?R=4OHVB.J->]VUSXU6/G
MJ9'P^B8H                   !9\\@5^5?$)[P*A]./AU:]D%[[='?DZN?
M2:!S-Y+O<6MOC57^9IF_P=?#E(
M                      "M>,@QRP1IO\H=5>[>C?3$6-BE>^]^)OT;EW+P
M)($*                                 'SR-M?FKLWW@W/ZCDAZ+ZG]
MZ=5_)U2^C:(ZHU[W;7/C58^>ID?#Z)B@                   %GSR!7Y5\
M0GO J'TX^'5KV07OMT=^3JY])H',WDN]Q:V^-5?YFF;_  =?#E(
M                                               "M>,@QRP1IO\
M*'57NWHWTQ%C8I7OO?B;]&Y=R\"2!"@
M   !\\C;7YJ[-]X-S^HY(>B^I_>G5?R=4OHVB.J->]VUSXU6/GJ9'P^B8H
M                 !9\\@5^5?$)[P*A]./AU:]D%[[='?DZN?2:!S-Y+O<6
MMOC57^9IF_P=?#E(
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M\1^+_P"FMOWM'\!YG:X#S^SQ'XO_ *:V_>T?P'F=K@//[/$?B_\ IK;][1_
M>9VN \_L\1^+_P"FMOWM'\!YG:X#S^SQ'XO_ *:V_>T?P'F=K@//[/$?B_\
MIK;][1_ >9VN \_L\1^+_P"FMOWM'\!YG:X#S^SQ'XO_ *:V_>T?P'F=K@//
M[/$?B_\ IK;][1_ >9VN \_L\1^+_P"FMOWM'\!YG:X#S^SQ'XO_ *:V_>T?
MP'F=K@//[/$?B_\ IK;][1_ >9VN \_L\1^+_P"FMOWM'\!YG:X#S^SQ'XO_
M *:V_>T?P'F=K@//[/$H&[5];S0V1]H]7Z_V]N'KO4^EZKUOM#(^L]5Z?^_U
M?I^EZ'I_[O1\WI?W\X]%=3^].J_DZI?1M$=4Z][MKGQJL?/4SH0^B8H
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M/,[7 >?V>(_%_P#36W[VC^ \SM<!Y_9XC\7_ --;?O:/X#S.UP'G]GB/Q?\
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M.QBCV'8NU6,O:GZ\I97[55PBJHBM/2+E5Y*^@;!'SC*:C@IS((Y3"%@=V
M                         ?/(VU^:NS?>#<_J.2'HOJ?WIU7\G5+Z-HCJ
MC7O=M<^-5CYZF1\/HF*                    6?/(%?E7Q">\"H?3CX=6O
M9!>^W1WY.KGTF@<S>2[W%K;XU5_F:9O\'7PY2
M                                  K7C(,<L$:;_*'57NWHWTQ%C8I7
MOO?B;]&Y=R\"2!"@                                !\\C;7YJ[-]X
M-S^HY(>B^I_>G5?R=4OHVB.J->]VUSXU6/GJ9'P^B8H
M  !9\\@5^5?$)[P*A]./AU:]D%[[='?DZN?2:!S-Y+O<6MOC57^9IF_P=?#E
M(                                                        "M>
M,@QRP1IO\H=5>[>C?3$6-BE>^]^)OT;EW+P)($*
M            'SR-M?FKLWW@W/ZCDAZ+ZG]Z=5_)U2^C:(ZHU[W;7/C58^>I
MD?#Z)B@                   %GSR!7Y5\0GO J'TX^'5KV07OMT=^3JY])
MH',WDN]Q:V^-5?YFF;_!U\.4@
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M:QS-I'L4$FK)@V09LVJ)<$1;-6J1$&Z"1,?V(DBB0B:9<?V*4N,8_P"P%/9
M                         'SR-M?FKLWW@W/ZCDAZ+ZG]Z=5_)U2^C:(Z
MHU[W;7/C58^>ID?#Z)B@                   %GSR!7Y5\0GO J'TX^'5K
MV07OMT=^3JY])H',WDN]Q:V^-5?YFF;_  =?#E(
M                                   "M>,@QRP1IO\ *'57NWHWTQ%C
M8I7OO?B;]&Y=R\"2!"@                                !\\C;7YJ[
M-]X-S^HY(>B^I_>G5?R=4OHVB.J->]VUSXU6/GJ9'P^B8H
M     !9\\@5^5?$)[P*A]./AU:]D%[[='?DZN?2:!S-Y+O<6MOC57^9IF_P=
M?#E(
M"M>,@QRP1IO\H=5>[>C?3$6-BE>^]^)OT;EW+P)($*
M               'SR-M?FKLWW@W/ZCDAZ+ZG]Z=5_)U2^C:(ZHU[W;7/C58
M^>ID?#Z)B@                   %GSR!7Y5\0GO J'TX^'5KV07OMT=^3J
MY])H',WDN]Q:V^-5?YFF;_!U\.4@
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MG&<9SC(]%M3^].J_DZI?1M$=4J][MKGQJL?/4SH(^B8H
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M8QC&,8QC&/-C^P]%]3^].J_DZI?1M$=4:][MKGQJL?/4SH ^B8H
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MXA/>!4/IQ\.K7L@O?;H[\G5SZ30.9O)=[BUM\:J_S-,W^#KX<I
M                                               5KQD&.6"--_E#
MJKW;T;Z8BQL4KWWOQ-^C<NY>!) A0
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MJQWFV<<1'[H
M       "M>,@QRP1IO\ *'57NWHWTQ%C8I7OO?B;]&Y=R\"2!"D=)[<U@KL
MNJR7NL&V*HU>NT:?][-<3:Z4:W;O))-LTR?&7+R-8NVDA(QZ!E'[".=-I!VV
M19KI+G$E3&TY"!V/1;/*O(2OVJ&EI1DG)KJ-&CLAS+MH26/ 3CN.4SZ*,JR@
MI],\!./(M1XUAITAX:36:R9<M<"G$Q.Y]23Z\8U@MET>:=S<@C%PK2(LT1).
MYEZX:+R"*42U9.UW$DFK&M74H1RR37;9BFCN3]=]@:KN$T-7J"2G=;L]?7?<
M26!0
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M(1WYOZV2*(4 "M>,@QRP1IO\H=5>[>C?3$6-BE>^]^)OT;EW+P)($*
M
M                                                  !6O&08Y8(T
MW^4.JO=O1OIB+&Q2O?>_$WZ-R[EX$D"%
M
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M6=RZG&#*(3DF^7$E(U@WHVB+B39-A"6E:N;'HV:+C574A7C?VF6S+(A3OH
M                                            K7C(,<L$:;_*'57N
MWHWTQ%C8I7OO?B;]&Y=R\"2!"@
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MI#1T\+?'^MI:3C+Q0)ZHMT6"TE799"Q0$A9V^7<*J^9X6K:LPB)BVR=_HO\
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MF'L[GF?F+V _4EG\9(QL._7CE'B]L5;5M9;OW6+Q]%W-;]N/A;MROEQL$$*
M                                            5KQD&.6"--_E#JKW
M;T;Z8BQL4KWWOQ-^C<NY>!) A0
M
M                      *UXR#'+!&F_P H=5>[>C?3$6-BE>^]^)OT;EW+
MP)($*
M
M !6O&08Y(-5VUM5G6*XT:;,V"U:M8&';MFS>YV-!NW;H1[=)%!!%*2*FBBBF
M4J:2292D3(4I"%P7&,8D+!9(LO%YLY[G'MWK4V/VXLWB@0L%DA+Q>;'./;O6
MIL?MQ9O% A8+)"7B\V.<>W>M38_;BS>*!"P62$O%YL<X]N]:FQ^W%F\4"%@L
MD)>+S8YQ[=ZU-C]N+-XH$+!9(2\7FQSCV[UJ;'[<6;Q0(6"R0EXO-CG'MWK4
MV/VXLWB@0L%DA+Q>;'./;O6IL?MQ9O% A8+)"7B\V.<>W>M38_;BS>*!"P62
M$O%YL<X]N]:FQ^W%F\4"%@LD)>+S8YQ[=ZU-C]N+-XH$+!9(2\7FQSCV[UJ;
M'[<6;Q0(6"R0EXO-CG'MWK4V/VXLWB@0L%DA+Q>;'./;O6IL?MQ9O% A8+)"
M7B\V.<>W>M38_;BS>*!"P62$O%YL<X]N]:FQ^W%F\4"%@LD)>+S8YQ[=ZU-C
M]N+-XH$+!9(2\7FQSCV[UJ;'[<6;Q0(6"R0EXO-CG'MWK4V/VXLWB@0L%DA+
MQ>;'./;O6IL?MQ9O% A8+)"7B\V.<>W>M38_;BS>*!"P62$O%YL<X]N]:FQ^
MW%F\4"%@LD)>+S8YQ[=ZU-C]N+-XH$+!9(2\7FQSCV[UJ;'[<6;Q0(6"R0EX
MO-CG'MWK4V/VXLWB@0L%DA+Q>;'./;O6IL?MQ9O% A8+)"7B\V.<>W>M38_;
MBS>*!"P62$O%YL<X]N]:FQ^W%F\4"%@LD)>+S8YQ[=ZU-C]N+-XH$+!9(2\7
MFQSCV[UJ;'[<6;Q0(6"R0EXO-CG'MWK4V/VXLWB@0L%DA+Q>;'./;O6IL?MQ
M9O% A8+)"7B\V.<>W>M38_;BS>*!"P62$O%YL<X]N]:FQ^W%F\4"%@LD)>+S
M8YQ[=ZU-C]N+-XH$+!9(2\7FQSCV[UJ;'[<6;Q0(6"R0EXO-CG'MWK4V/VXL
MWB@0L%DA+Q>;'./;O6IL?MQ9O% A8+)"7B\V.<>W>M38_;BS>*!"P62$O%YL
M<X]N]:FQ^W%F\4"%@LD)>+S8YQ[=ZU-C]N+-XH$+!9(2\7FQSCV[UJ;'[<6;
MQ0(6"R0EXO-CG'MWK4V/VXLWB@0L%DA+Q>;'./;O6IL?MQ9O% A8+)"7B\V.
M<>W>M38_;BS>*!"P62$O%YL<X]N]:FQ^W%F\4"%@LD)>+S8YQ[=ZU-C]N+-X
MH$+!9(2\7FQSCV[UJ;'[<6;Q0(6"R0EXO-CG'MWK4V/VXLWB@0L%DA+Q>;'.
M/;O6IL?MQ9O% A8+)"7B\V.<>W>M38_;BS>*!"P62$O%YL<X]N]:FQ^W%F\4
M"%@LD)>+S8YQ[=ZU-C]N+-XH$+!9(2\7FQSCV[UJ;'[<6;Q0(6"R0EXO-CG'
MMWK4V/VXLWB@0L%DA+Q>;'./;O6IL?MQ9O% A8+)"7B\V.<>W>M38_;BS>*!
M"P62$O%YL<X]N]:FQ^W%F\4"%@LD)>+S8YQ[=ZU-C]N+-XH$+!9(2\7FQSCV
M[UJ;'[<6;Q0(6"R0EXO-CG'MWK4V/VXLWB@0L%DA+Q>;'./;O6IL?MQ9O% A
M8+)"7B\V.<>W>M38_;BS>*!"P62$O%YL<X]N]:FQ^W%F\4"%@LD)>+S8YQ[=
MZU-C]N+-XH$+!9(2\7FQSCV[UJ;'[<6;Q0(6"R0EXO-CG'MWK4V/VXLWB@0L
M%DA+Q>;'./;O6IL?MQ9O% A8+)"7B\V.<>W>M38_;BS>*!"P62$O%YL<X]N]
M:FQ^W%F\4"%@LD)>+S8YQ[=ZU-C]N+-XH$+!9(2\7FS W[]F_P#]S*_$7?\
%_84A_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g428534g00a03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g428534g00a03.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[2604&AO=&]S:&]P(#,N,  X0DE-! 0
M    )72^E8@X0DE-! 0      !X< 5H  QLE1QP"   "   < E  "E-T97!H
M96X@36$X0DE-!"4      ! B)R.S>.0!+UE6301,F3\].$))300Z      #E
M    $     $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!
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M;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
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M;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M  !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M     !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL
M;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I
M9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M !  E,S,  $  @"4S,P  0 ".$))300F       .             #^    X
M0DE- _(       H  /_______P  .$))300-       $    6CA"24T$&0
M    !    !XX0DE- _,       D           $ .$))32<0       *  $
M         CA"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"A
MF9H !@       0 R     0!:    !@       0 U     0 M    !@
M 3A"24T#^       <   _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@     _____________________________P/H   X0DE-! @
M !     !   "0    D      .$))301$       0     @   D    )
M #A"24T$'@      !      X0DE-!!H      T$    &              ',
M   "N@    8 9P P #  80 P #,    !                          $
M             KH   ',                      $
M        $     $       !N=6QL     @    9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   ',     %)G:'1L;VYG   "N@    9S;&EC97-6;$QS
M     4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG
M      =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/
M<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54
M>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   !
MS     !29VAT;&]N9P   KH    #=7)L5$585     $       !N=6QL5$58
M5     $       !-<V=E5$585     $       9A;'1486=415A4     0
M    #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0
M    "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U
M;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F
M875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4
M    3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N
M9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L
M;VYG       X0DE-!"@       P    "/_         X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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M[B27&MA))]SCNV_G*K7G-?:RO]E7UASFMW/KK#6R=I<\L>_VUM_=6C]GQ_\
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M-D?TB[_C'_\ 5%#117BNB])?4,_-&_T;!52YUA<
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M          #_XO__24-#7U!23T9)3$4  0F^S/[^'@ (@'!!1$)% A   '!R
M=')#35E+3&%B( ?0  < &@ % "D -6%C<W!!4%!,     $%$0D4
M           !  #VU@ !     -,M041"10
M                                    "F1E<V,   #\    =&-P<G0
M  %P    *W=T<'0   &<    %$$R0C    &P  "B!D$R0C(   &P  "B!D$R
M0C$  *.X  "B!D(R03   47   (XM$(R03$  WYT  (XM$(R03( !;<H  (X
MM&=A;70 !^_<  "0D61E<V,         &E4N4RX@5V5B($-O871E9" H4U=/
M4"D@=C(
M                                                    =&5X=
M  !#;W!Y<FEG:'0@,C P,"!!9&]B92!3>7-T96US+"!);F,N  !865H@
M    M5H  +QG  "2,&UF=#(     ! ,)   !                     0
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MCJ%\HFJC5Z1%I3.F(*<.I_RHZJG7JL6KLZRAK8^N?:]KL%FQ1[(VLR2T$K4
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MGPR3#8(.< ]?$$P1-Q(A$PD3\!36%;L6GQ>#&($9?1IT&V8<51U!'BP?%R
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M3>69YN?H-NF&ZMCL*^V [M?P,?&0\N_T3?6J]P3X6OFK^O;\.OU[_KO___\
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ME*)\"B?SD_-\_02JDW]_IKNSI.*#E*DJH5J"G)85G@J!T()@FOV!/FW;F#J
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MN;:!I(Y"M,* O7UBL 6 #6OSJXQ_GEFXIV1_<D9LHZY_@S%LH-Y_P1>PH3N
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M+3?/IIV%U2/RI%N&& L7I0>%40  A2F  (<^O J28'BEMQ:08FF$LD&.IEG
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MR1*!V6V7PYZ V%]'OCV #U!.N0M_H$!]M#I_;2]0L$=_=QM]KI)_JP27K$F
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M\P  AW*  *7UES:*0)7"E.J)'X3&DL>(#7+VD,V'#V ;CQ.&04PYC9:%E3;
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MK=Y[! "CI]-]+@  @ "  '*5P>V"VF6 O2:!^%?GN&J!0DFHL]* S#IFKZV
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M><1X(GA">EUXRF&O>O]Y>DG9>Z)Z&B[U?$EZD IK?;%ZJ,=E=BJ Y+2N=N:
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M@@<[=O:$Y+MN@I1JG*HQ@CAL>)?K@?EN*H1Y@=%OOV_\@;EQ35IP@;ARV4.
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MHF<BH)-XY5?OG=)Y/4>PFU1YH#8 F6=Y_B'KF,QZ%0B=F6=ZIP  @ "  ((
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MN3R*NUT>M1R)R5!$L0"(W$*>K0V($#/\J9&'DB.=ISJ'P _FIZN&N   F9"
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M.YE:='5R<(6V=79SF'$.=G-TO5MJ=W%UWT1V>%UVY"HX>05WD ;U>UMX%+O
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M=Q""9YQS=YB")8LW>!:!SWCZ>):!<F6N>2>!)E%:>;R Y3N/>CJ HR'F>F2
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M@0-XP%W @-YY54HX@-=YY#4%@/-Z3QLW@9IZ+   @ !^.I]F@!F )9 S?]V
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ME&=[,01TD<!\3   @ "  '@;G+^![VN(FG*!N5X>F#6!=D_(EA.!+4!HE#2
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M]R<VHA=J&Q(JI']IIP  F--N8@  @ "  &V#K!!I/V&ZJ1MJCU3]ID9KX4=
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MI*&=XU]6H:2<J%*9GIB:]T38FZ*95C8SF1>8SR7\EVJ6YQ*JEZF,G@ +CXJ
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MLO5\TE3IKZQ\OTB^K%U\K3NYJ31\G"V.II5\HAT9I8Y\F0GJI8A]&0  CL&
M    @ "  & NL=J#\53'KH&#ETBCJR2#*CN;I_&"P2UOI4B"@QTEI!""H HG
MH\R".0  C>.     @ "  %_]L/R+%%2UK8V*?4B8JA^)O#N+IN&)""U=I#&(
MMATKHMZ)( IEHDJ&B   C3.     @ "  %_9L%>21E2RK,N1?DB8J4B0=CN%
MI?F/B2U+HT&/91T8H>R.O I\H1^'%P  C)R     @ "  %_!K]V9H%2[K"R8
MO4BCJ)&7@3N'I326A"U2HFV6+1TSH0&33@J2H"*')@  C "     @ "  ,$3
M9Q5?[:[3:3EBM)OM:SYE8(@B;21G[G-I;OAJ:5VW<+ELT4;'<D5O$"S/<R9P
MW0H$=BIQ%+\@9"5JT:U+9HILA9J.:+]N+(;H:M)ORW)&;,]Q8%RH;K%RZT7)
M<$ET4ROH</%U70EM=&AU:[U)895UIZN&9"!V3ID'9GUV\X5S:+-WI7#X:M)X
M7%N!;-!Y$43*;G!YKRL/;MEZ"@CI<MQZ+;MW7TN 7:FX8?6 #Y=#9&Q_R(/N
M9L%_C6^7:0%_:5I2:QA_34//;+Y_*2I";.1^[0AV<;-^AKG,756+!*@@8!>)
MW)6R8J:(M8)I90R'EVY29V*&CEDU:9"%IT+G:SF$S2F):QF$&@@4<EF"/[AQ
M6\"5LZ;47I*3NY1P82V1M8$Q8Z*/MFTM9@.-U%@\:#>,'4(::>.*H"CE:7Z)
ML0?!<N6%/K=<6GF@8Z7,75:=GI-J7_6:NH Q8G"7WFP]9-Z5,5=J9QJ2P$%Q
M:+N0KRA@:!>/R@=\<UF%$+:.67^K#J4%7&*G?)*<7OZCOG]?87:@"&MN8^><
MF5:M9BR9CT#69\F7)R?L9N*5(@=$<[B$ZK8*6-2UK*1^6[6Q/Y(#7D2LI7ZZ
M8+&H(6K/8QVD U8?96"@?D!-9O">'R=N9<B97P<8= .$S+,W;NQ?1Z*9<$]B
M,9$.<:=DZ7YH<O9G=VJT=#]I[57I=8%L33^\=J1N=R8"=UIO_ 0R>PEQ$K'"
M;"QIJZ%[;<]KC)  ;U!M4'UK<+UN_VG#<B!PGU4.<WAR,C[X=*!SFB57=0]T
M> /A>7)UR; Q:;5S])_-:WYTWXY[;2!UN'OV;JUVC&AZ<#!W8%/M<:%X+CW^
M<LEXW"2'<N9Y)@.9>>MZ1JZ29X)^'YXF:69^+8S::R%^+GJ5;,=^*6<X;FE^
M,%+9;^Y^.ST<<1=^/"/2<.%^$ -;>E-^*ZT099^(1YRS9YB'BXML:6F&NGDN
M:R"%X683;-&%%5'7;FR$9SQ+;Y*#QR,P;P:#4P,F>JV!@JO69!B2?9N 9A^0
M_(I!9_J/67@.:;^-KV4%:WJ,&E#V;1:*KSN4;CJ)B"*@;5V)'P+Z>OF" ZK<
M8MR<M9J)9.R:<HE+9LN7_G<?:)65A60E:ER3-5 V:_Z1)CK_;1*/CR(O:^J.
MW +5>S>!ZJHC8>RF[9G,8_ZCZ8B$9=F@J'969Y^=8F-@:6J:84^ :Q27T3IN
M;"&6%B'):JJ3D *W>VJ!UJFM846Q'YE&8U2M6X?H92*I376Q9MRE16+%:**A
MI$[Z:DJ>MCGK:TJ<^B%/:8J6A0*?>Y.!Q:6D=Q5>PY9Z=Z]ANH8T>%QD='2G
M>11F^V'P>=-I9TX&>IMKMSB+>V9MOQ[+?#MNTP  @ !R8*1X='EHC95:=51J
MCH4!=B5L:7.+=O9N)V#N=\MOU4TB>*-Q;#?#>69RQQXH>=AS40  @ !W!:,V
M<A=R4)0"<Q]S;H/D= YT=')H=/AU9E_L=>!V4TQ&=L=W-C<1=X5W[1V==Y)X
M!P  @ ![&*'$;_5[]Y*-<1=\3X)8<A]\C'$9<QY\N5ZX="5\Z4L\=1Y]&#8U
M==5]-ASS=7=] P  @ !^HJ!L;B:%G)$X;UJ%.X$(<'6$MV_4<8.$'UVT<I2#
MD$I5<Y^#%S5\=$V"K1QJ<X6";P  @ "  )]0;*^/5I @;>^./G_X;Q.,]V[-
M<"R+G5R]<46*54F-<DR)-C3;<O*(8QOO<<N(2P  @ "  )YM:X"9$X\\;,B7
M1W\4;>Z5/VWP;PN3)UON<"Z1-$C<<3>/B#19<<6.<1N0<%V-6   @ "  )W$
M:I:BTXZ*:^.@5WY8;06=D6TU;AV:O%LV;T*8*T@P<%*6&3/1<-25'QLZ;S61
M>@  @ "  )U4:?&LEXX(:SVI<GW!;%2E\FR7;5^B:UJE;GV?34>U;XJ= S-6
M;_^;>!K$;D>2&0  @ "  )A0?Y=>6HI)?W!A1GL8?WAC^&J6?YYF=EC8?]=H
MU47&@"YK#3#E@+YLWA:U@CUM-   @ !V7)=3?1MGF(E&?3EII'H!?61KAVF1
M?9QM35?M?>-N_D3[?D%PCS Y?KUQR18V?[-QNP  @ !Z9Y8Y>M=POH@!>R!R
M 7CE>V)S)VAX>[!T-U;Z? AU.D0O?'!V*2^7?-MVV!7%?4AVA0  @ !]\Y4%
M>,1YYX:\>2IZ<G>7>85ZVV=Y>>%[.580>DY[CD-Q>L![W"\)>QM\"A5F>QU[
MI@  @ "  )/3=P>##H6N=W^"\W:$=^J"L&9->%*"4E4?>,>!^T*6>4B!M"Y7
M>9*!=A3I>4V!4P  @ "  )+4=:2,2X2I=B:+AW6$=I>*D658=P:)@U0Z=WZ(
M@T'@=_:'KBW&>#"'+12!=\:&I@  @ "  )('=(*5B8/;=0R4(W2W=7V2?&21
M=>Z0P5-]=FR/*4%!=N*-X2U:=OR-4Q0Y=GZ+%@  @ "  )%J<Z">S(,W=#"<
MRG0+=)Z:>&/G=0B8$U+7=8:5\T"A=@"49BS:=@>3_A/U=7>-?@  @ "  )#]
M<OVH'(*Z<X^EBG-]<_2BDV-5=%&?CU)3=,:<_4 S=3F;:BQL=3.9C!.+=+2-
M-P  @ "  (LLB'Y=\'X1AZU@QV_3AQUC:F!'AKAEVT]TAG%H)STKAF9J.RB\
MANUKN0X&B/YK1P  @ !YTXI1AC1FK7TZA:1HM6[LA2UJFE]SA,YL8DZZA(IN
M#SR/A'QOCRA A-]PCPW7ADEO]0  @ !]6(E>A =O4WP=@Z1PHVWM@T)QVUYW
M@O-R^DW?@KMT"SO8@K%T^B>S@O=UAPV>@^=T[P  @ "  (A/@A1WZ'KZ@<5X
MEVRX@7AY*EV$@3)YJ$T @0UZ'CLC@0=Z@2<L@3)ZJPUF@=%Z70  @ "  (=*
M@%: BWG]@!N HVO"?]^ EER+?Z: ;DQG?WN 23JH?WV +2;<?XZ $ U2?_Y_
MZ   @ "  (9H?P>)3WDV?MB(TVL"?IN((UO"?EZ'5DN-?C>&ESG]?BR&"291
M?B2%V0T-?GJ$HP  @ "  (6Q??.2$7AY?<R1!FI'?8V/MUL-?4Z.4$K<?2F-
M#SEF?1:,+"7U?..,.@SJ?3*(E@  @ "  (4B?1V:U7?G?/N91&FP?+>77UIY
M?&^58DI)?$:3LCC3?#22L26">^:22@S+?">(I@  @ "  (2X?'^CL7=T?&"A
MK&DO?!.?.%GV>[R<L4G6>X>:K#AV>VN9X"4F>PR7(PR*>U^(>@  @ "  'Y#
MD?E=9G':D)%@&F1ICW%BIE6ZCH-E!T6^C<-G.30?C7)I&Q_2CE9J%P9.CIEJ
M%   @ !\RWU[C^AEJ'$JCK!GH&.RC9EI?U49C*1K0T4VB]QLY3.UBWUN11^.
MC"=NX 9JB_9N\   @ !_WGRNC==MT7 ZC,5O(V+DB[QP8E1.BM!QCD2+B@UR
MHS,NB:ESAA\VBB-SS 9WB9]T*P  @ "  'O)B^UUZ6]$BNYVJF'>B?EW5%.%
MB1-W\4/7B%UX>S*CA_9XYQ[=B$9X[09\AY)YOP  @ "  'KIBDI^!6YXB5A^
M1&$9B&M^9%*PAXY^:D-1ALM^;3(VAF=^=QZ=AHQ^8P:,A<9^KP  @ "  'HB
MB/J&1&VYB!:%^V!>ARJ%AU(+AD*$^$*ZA7R$<3'RA/>$(!YNA/F$.P:1A#R"
MVP  @ "  'F#A_2.C&TZAQJ-SE_CAB>,RE%WA3"+IT(9A&F*LC%@@]Z*,AXI
M@Z.*B0:+@O.$;   @ "  'D$ARJ6W6RYAE25L5]=A5F4)U#UA%62?$&:@X.1
M,3#4@OB0R!VX@IN/U@:)@>6$:P  @ "  'BBAI*?36Q2A;Z=RU[JA+B;QE""
M@Z69HD$V@L*8)3"&@B:7MAV!@:^3\P9]@12$8P  @ "  '&OF]A<LF7QF?=?
M0ED[F&!AM$M.EOQC^SP*E=IF!RKBE7UGGA8NEX5GQP  DPUIOP  @ !_2G#W
MF@YDC&5GF$=F;UBTEJ)H0$KAE2-I^#NVD^IK@RJODVYLJQ8PE1=LE  OD+YN
MM@  @ "  '!/F!-L0F2BEFIMCE@.E,MNS$H_DTUO^SLTDA%Q"2I6D8)QRA85
MDMQQA0!SCG!T,P  @ "  &^3EC%SXV/1E)9TK5<KDP=U94F-D8]V$CJ9D%MV
MJ"GEC\%W"17>D-EVK0"BC&MY1   @ "  &[7E)M[D&,7DPQ[XE9QD8)\'4C0
MD E\0SH2CL]\9REUCC%\?!6<CPY\.@##BJI]I@  @ "  &XRDUN#6F)\D=:#
M/E7<D$B"^T@[CLJ"H3F$C8:"5BDPC+Z"-Q5VC62": #@B2> EP  @ "  &VL
MDD^+)V'UD-6*H554CT6)Y$>SC;^)%3D&C':(=BC/BYV(415UB^.(! $#A]^
MKP  @ "  &U"D8N3"F&QD!>2-542CGF1 4=IC-./L3B\BW2.TRAPBIZ/!!49
MBL>,H $:AM& O@  @ "  &SOD/B;#F%?CWV9^%2YC=287T<0C""6L3ARBK&5
MT2@YB<65)Q3\B<F., $GA@. R   @ "  &5BIE=;L%H2I!]>%4WPHB-@94"K
MH%MBC3'RGP5D:"#GGQ-EB@O[H;ME&@  C91MT@  @ "  &2SI,QC)UFFHHYD
M\4V3H&UFL$!LGGMH5C'2G/]IOR#SG-5JB@Q/GOII_0  B_MRS   @ "  &0K
MHNAJ=5D,H+AKN$T9GI1L\3_XG)IN'C%_FQ%O&B#0FL%OE0Q]G&QO!@  BGMW
MH@  @ "  &.=H0=QJUAKGN)R>DQHG,ES/#]UFM%S]3$1F4ATC2"0F-YTPPR.
MFAET50  B11[Y0  @ "  &,.GVYX\%?AG5-Y6$O>FSMYK3[CF3]Y[#"TEZEZ
M)R!-ERUZ,0R.F %Z*@  A]%_G   @ "  &*0GBR 5E=QG!: 84MUF?B 2#Y\
ME_. &C!5EDY_^B EE:)_^ R5EAZ $0  AK2     @ "  &(FG2V'OU<9FQB'
M>4LDF/"&^#XHEMR&9B_ZE3*&#A_FE&V&1 RLE'2%#0  A<Z     @ "  &'5
MG%Z/*U;,FDJ.FTK3F!R-OCW8E?V,VR^NE$2,=A^+DWZ,KPR)DR6(>@  A2&
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MIS22?DP,I'J2(D"GH;J1530NGR.0I"9GG2^0F18FG/:-Y 5JF'"#J0  @8"
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MB>)\\%GNB3!]2TX B&=]>T$)AY]]C3+>AP1]F2+9ALQ]HP\+AQ)]M0  @!N
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MDVN!$TZ6DCZ!.T-,D.J!(S;MCY> ["DNCJ6 SAD@CJF ZP=0C!R X   @ "
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M/   @ "  $['I MHIT2CHEEIWCFDH+9K 2VAGTEL !_ GK]LD0[&H#]L*
MF'=O*P  @ !]_P  @ "  $Y+H@MO<40KH&MP3CDSGL5Q$2TKG4QQI!^,G*5Q
M]@[ G=EQC@ UE@!U"0  @ "     @ "  $W7H&IV8$/*GM-V\#CDG2AW52SK
MFYYWD1]8FM=WG [8FZEW7@!QD]IZ5   @ "     @ "  $USGQ-]54-_G8-]
MHCBKF\]]L"RWFC=]GA\FF5U]C [1F>5]M0"PD@E^S@  @ "     @ "  $TD
MG@.$64-*G'.$<3B!FK:$,BR9F0B#WQ\*F!*#Y ZJF'>#>P"UD)F >P  @ "
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M<!:1AEJ^<2B0ZD[K<>"/VT(3<DN.LS0+<GZ. B0O<B&.-A$1<S^*\   @ "
M    @ "  &"FC&]1F%8'B^U4W$IWBZE7_3V<BY5:Y"\:B]==91X(C2E>^@F
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MB:MS@$:9B6=T7#O2B/UU#2_JB(QUCR)IB&AUUQ'BB1]UB )%AE5X2@  @ "
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M40  @ "  $:;G0U;G3TTG"U=K#+"FV]?CB;;FOEA)!C#F[UAZ@B7F\YB4
MC$-I40  @ !YJ0  @ "  $8'FCQB.CR$F6]CW#'VF+QE5B9 F$=FBQA'F.UG
M!@B F$QG7P  B=YN?   @ !]@   @ "  $5DE[AHZ#O=EPQJ*3%>EEAK0"6H
ME=)L"A?[EDQL2PAUE0]LKP  A\9T+P  @ "     @ "  $3%E9-OOCM*E0IP
MIS#DE%MQ7R5,D[YQTQ>XE !QT B2DBER9   AA!Y9P  @ "     @ "  $0[
MD\)VG#K/DUIW.3""DJYWEB3XD@%WO!=HDAYWF0B"C])XFP  A+)]R@  @ "
M    @ "  $/)DD%]D#IMD?9][3 RD4]]^"3#D(A]VA="D'-]R A2C?!^>
M@T6     @ "     @ "  $. D02$QCHED,Z$]"_QD#*$LR29CUF$91=*CP6$
MAPB%C%F#6   @G&     @ "     @ "  )[[4]5-U8_(5PA2'8 $6B)64&]<
M72Q:8UVE8!E>44J_8K5B$39Q9&-E@1Y?8Y9G] %[?8!K&9S13H58"(X44BY;
M;WZ$5;)>OFX(61%A\EQO7$-E!DFK7P=G]C6 8)AJGQVM8#)L=@&+?61OSYK:
M2:QB/HP[3<!DN7SO49QG(FR*54%I>UL@6*AKODB-6XIMZ#2:7/-OVAT.74IQ
M) &:?4MTXICH13QL9(IK2;-M^7LR3=1OB&L?4;EQ#5G:559RA4=^6$YS\#/(
M685U-!Q_6MIV!@&F?39YBY<*039V>(C+1@IW.'F^2GEW]6F]3H]XJEC84EQY
M7D:<56AZ$#,75F9ZLQP*6--[*@&Q?21]B)5G/:F ?H=K0M2 ;'B;1XN 7&C#
M2]R 2U?O3\: /D7W4MZ 0S*14Z" 6!NK5RF J &Z?12 Y90*.I:*<89*0 ^)
MB'>Q10:(IV@!28F'U%<[39.'%45<4*V&>S(N436&(1MG5<J&D@'"?0B!,)+U
M. :4/X5E/<"2=G;Y0NV0Q&=N1YB/-5:Y2[N-UD3<3M2,MC'#3QB,&QLQ5*^+
MRP'(?/V!-)(S-@^=M(2^._*;!W9Q04*8AF<$1@F62U9L2C^48T2E35F2XS&)
M35Z24!KW4\^/\ '-?/6!.).#6KY-[H5#76%2('9;7_U6.69]8HI:+U6!9/E=
M^T,]9Q=ACR]/:$!DL1:J:75F5   @ !MTI%Y59E7F8/56+M:_G4M6[9>2F5_
M7HUA=E2C83%D>$* 8VIG2BZY9%UIMQ9.9F!JV@  @ !RL(^:4.1A28("5&UC
MUW.95[EF4&0"6L]HKU-67:5J\D%C7_%M$"W18)UNVA6Q8^!OB@  @ !W8HW*
M3)-JZX!'4'-LIW'U5 %N5F*T5U)O\E(I6EEQ>$!J7*]RYRT370IT&!4X8;AT
M<P  @ ![=HP<2*YTAG[%3-MU>W"24*UV8V%@5"QW/%$T5UQX#3^46;MXU"QQ
M6;IY>Q357^=YK   @ !^\XJQ14A^&WV$2;A^36]Z3<1^<F!F479^C%!.5+]^
MJ3[T5QU^U"OU5L!_"12'7F1_6   @ "  (F(0EN'GGQ^1P:'#6Z72T2&;5^>
M3QZ%S4^44GZ%0SY85-2$WRN;5$R$Q!157:*$^@  @ "  (BA/_"0_WNR1,J/
MK6WB23".2E\!32:,\T\#4)6+T#W+4MR*^2LM4D>*QA0J7>N)FP  @ "  (?_
M/A&:'GL<0PR8%FU61XJ5]5Z&2Y*3\DZ@3PJ213V"4461'2KA4*V1$Q/?7FF-
M0   @ "  (@=8>Q.#'K#9 =2'6RQ9B96%UV;:#E9[$U6:BY=D3ND:]I@[R?R
M;)ACJ0Z3<.MD:   @ !QM(8G7/E7&WE(7XM:=VMC8?Y=MEQ[9%%@TTQ99G)C
MPSK,:"EF=2=":(=HE Y#;A%H_P  @ !V:(1N6&)@1G>T6UMBWVHM7AQE8UM<
M8*-GQ4MI8NAJ SH+9*%L#2:Y9))MF0X3:X=MQ0  @ !ZBX*[5#!I:7875WEK
M0FB56G1M"UH473!NNDH_7Z!P2CD4855QM"7Y8,ARO0VX:7ARSP  @ !^(X$R
M4&MRB'2J4_1SJF=!5RETN5C46@]ULDE<7)]VG3A,7DMW<25G78-X"0U^:3%X
M.@  @ "  '_K32%[IW. 4.%\%V8V5$=\;U??5U9\M4A[6?9\^3>R6Y!]0R3V
M6LQ]B0U2:7Q^"0  @ "  '[A2DV$M'*.3CR$>&5;4<J$&5<85/B#L$? 5Z6#
M63<962:#*22F6)&#1 T\::&#$P  @ "  'X31_6-I7'23 J,PV2J3[:+LE9W
M4OB*G$<G5:J)N#:$5PJ)*R0W5L*)8@TE:<B'-@  @ "  'V"1B"69W%(2E.4
M\F0?3A&3-E7S45N1>D:Z5 N0%S8Q54^/42/?55"/9 SA:CR(M0  @ "  'R5
M:7-.$W &:PU1_&*Z;+=5TE1A;EA9@T3&;]U<^S./<2M@$Q_4<:QB.0<S=[9C
M$   @ !UAGJS9+)6D6Z<9K=9W&&#:*E="U-8:GU@%4/B;"%BZC+2;65E:!]$
M;4]G"@<?=.IGOP  @ !YK7D=8$5?*VT78J9AR6!)9-ID3E(W9MIFKT+Q:)EH
MY#(0:<IJSAZZ:4UK]P<-=!5LI0  @ !]4G>27"YGTVN:7MIIOE[D841KEU$[
M8W)M6$(794MNZS%M9F5P11Y89=YQ 0<.=!-QS@  @ "  '8C6(=P>&I>6V]Q
MO5VU7@ER[5 "8%1T 4$M8D%U #":8SMUUAVX8OMV/0;G=%5WA   @ "  '3S
M55-Y(6E"6&EYQURP6RMZ3D\1799ZO$!47XE[(C '8%A[@QU/8(E[NP;6=')\
MZ@  @ "  '/]4I&!N6A@5<^!QEOA6+&!IDY06S*!<S^@72:!3R]U7<2!2QT,
M7GZ!B ;8=&^!:0  @ "  ',]4$.*.6>O4Z.)N5LV5IZ(^$VS62J()S\'6Q:'
MAB[>6WR'01R=7.2'Q0;3='B$G0  @ "  '*S3G"2FF<M4>V1HEJP5/602TTO
M5X*.XCZ866&-TBZ*692->1Q 6YZ-&0:==-.$>0  @ "  '#1<7--XF4&<I-1
MI%AX<\U554K1=098WCO-=BU<("KG=T->V1:=>#!@%@"G?N9B6@  @ !XVF\/
M;.M5W&.[;FI9$U=?;]Q<+DGI<39?(3L-<FIAT"I2<UID Q9#= EDUP#.?J1G
M(0  @ !\A&V6:*==]V)2:GA@D58V;"-C$4C8;9UE:3HF;MUGB"F:;Y]I-Q7'
M<'UIK0#@?H9L*@  @ !_O&PU9+1F%V#X9L1H$E3B:)QI]T?>:C9KO3E&:X1M
M32CP;!%N@A5=;6YNJ0#S?F5QE@  @ "  &KC82-N1E^X8V9OI%.[961P[4;*
M9Q=R%CBC:&YS(BAM:,-SYQ4;:LESV@$3?BYW'@  @ "  &G%7@-V@%[(8'9W
M4%+G8I9W_T7T9%QXD#?-9:-Y$2?99:IY>!2N:)IY9P$2?C![]   @ "  &C<
M6TM^JUWM7>-^]%(;8!]_#$4V8?)_"S<;8RM_$R='8MY_+Q1Q9KM_9@$D?A-_
M^@  @ "  &@E60.&P%U$6[N&CU%Y7@N&%T2@7^.%B3:)80B%*2:T8&&%)A0&
M952%1 $P??Z S@  @ "  &>>5RV.QES%6@".,U#W7%Z--D0B7C*,(C8@7S^+
M:B9G7F&+B1.P9#B)\P$/?C6 N   @ "  &3C>@Q-6EG<>KA0^$X'>XA4@D$#
M?&17W3)T?4Q:VR&4?H!=#0S,@*!=>   @ !EG0  @ ![M&-%=<)4WUBH=L%8
M DS]=[I;!4 J>*1=V#'(>8)@4R$<>F=B$0RT?*QB/0  @ !J2   @ !^]&'Q
M<:=<@U==<NY?%TON=!)AD#\O=0]CUS#Z=>9ET""!=GAG'@Q\>4%G&@  @ !O
M5@  @ "  &"P;=5D,E8;;U%F-$JP<)=H'3XW<:QIWS ><GYK61_5<K-L/PPP
M=EAL(   @ !TT0  @ "  %^$:EQKZ%4#; 1M7TFD;6ENO#TL;HMO\R]X;T]P
M^1]+;QUQB O^<]!Q;@  @ !YL@  @ "  %YV9T9SLE0&:1ETI$B^:IQU=#QJ
M:\=V(B[/;'1VL!\#:]MV_0OT<9EW'P  @ !]TP  @ "  %V89)-[>%-+9I5[
M\T@;:#-\.CO2:5]\8BXS:>A\BQYZ:1U\K O7;\)]/0  @ "     @ "  %SG
M8DJ#,E*D9&V#04=]9B&#!SM#9TR"LRVK9[."BAWL9NJ"MPN*;ER">P  @ "
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M:C^&\D=O; &&Z3S<;4&&>#$Y;<Z%\R01;62%VQ00;J2%N 11>+6"ZP  @ "
M    @ "  $SOC:!*UT-@C6I.-CC5C8-1:2R]C?]41!Y5CU]65PR D=U6]@
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MO@  @ "  $>Z>^)M3#Y-?+!N<#/^?39O:"AQ?7UP(AK[?:9P; L3?H9PAP
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M#0  @ "  #\WE;Q/!#94E8Y1V2PLE9E48B!+ED!69A%NF*%7+P,)E159/P
M@:YD0   @ !U 0  @ "  #Y!DA95>#4ZDAE7X2L>DCY: A\ZDM=;H!"@E,-<
M'P+2D,]>+@  @ !I(P  @ !Y=   @ "  #UOCGU;_310CI]=]BH8CM5?J1YG
MCV1@Z __D-=A*@*JC09C.@  @ !N5@  @ !]6   @ "  #R:BQ1BFC-TBVED
M)BE$BZUE=!V9C")F2P^GC1!F9P*9B<5HAP  @ !T!   @ "     @ "  #O+
MA_)I73*FB(=J@2B0B.5K:QT&B4)K\0\_B:1KU@*FAP-N,   @ !Y.P  @ "
M    @ "  #L5A2EP*3'TA?YP[R?XAG=Q>1R-AK]QM [GAJYQA@*6A,5T4P
M@ !]F   @ "     @ "  #I\@KMW"C%=@\]W?"=VA&5WKAPNA)=WJ ZCA$EW
MD@)N@P)Z*P  @ "     @ "     @ "  #H-@*I^)S#G@?9^3R<+@JQ^,1OC
M@LQ^ 0Z1@EQ^+@*)@8A^_P  @ "     @ "     @ "     __\  /__  #_
M_P  ;69T,@     $ PD   $                    !
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MZM3KY>SU[@3O$O @\2SR./-#]$[U6?9C]VKX;OEO^FS[9/Q6_43^+_\7__\
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MYGU5DE*%*GUU>P>$AGW&8\2#\7XU3(^#>'[I-9*#*(  [#V'?8C+UA2&<(=
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MNI6\842?I)*)4=6:?H]50OF5.(P4-.V/OXC!*&F)]X5NGRZSNJ>PC]:N>J-
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M,N"!6H!)WU&!08U!RL& V8MNM9: @HFXG\6 38@^B;* +H;P<Y2 *86^78^
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M>GYR>(6,HGYY936*V7ZE4A2)#W[G/SN'1W];+2N%=( ,P5F3HHA_KZ*1;X=
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M9Z^SPIF[6QRM-98.3K.FEY*!0K*?UX[Z-WR8RHMY+5B1D(@.)-J*583O@(?
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M9B>!.(;.4N*! X5>/]Z [H/8+9V ]H(>PPZ"I)A L4Z!]I6^GN"!99,VB]N
M\I"P>)6 GHXV94N <8O34CN 48E2/VV 4X:@+6: <8.5P?6!VZ'UL#N!,IZ;
MG=* HILDBMN -)>D=[!_Z90I9(A_P)"N4:E_MXT;/PE_SHDZ+3=__X3DP1*!
M/:N;KUF F*=BG.V !*+VB?E_EYYQ=N=_5YGR8^5_.I5E42Y_,Y"M/K=_7HN=
M+1!_H(8)P&2 QK4JKJ: ); -G"U_BZJAB39_%J4)=C)^V9]X8T=^S)G74+A^
MTI0 /G!_ HW"+/!_48<$O^V =+ZAKAY_U;B8FXI_,;(:B(E^KZM?=99^;Z2O
M8LI^:9WR4%M^?9;\/C)^NX^=+-=_$H?5N7>0KG!&J1*.YG&2E_B-3'+0AAZ+
MU'01<]&*:75N85J)!W;R3QF'I7B;/0.&4'J/*Z:%!WSSN'Z/1'F5J"R-G'GJ
MEP6,%'I#A3>*IWJN<O>)2GLV8)6'_'O=3FR&L'R:/(F%=7V(*WZ$0WZRMWJ-
M^8++IP2,8X(_E?N*X8&VA"R)A8%+<@N(.X#Y7\V'!("^3<R%T(",/!V$KH!J
M*UJ#DX!4MFB,Q8P I=N+.8J=E,.)R(DV@R:(<(?I<1J'/8:V7P:&&H6/332$
M_X1B.[N#^8,L*SJ"^8'7M4Z+S)4FI->*0Y+VD[N(V9#!@A*'CXZ/<"R&9(QH
M7CZ%6XI/3*"$4H@=.V&#7H7(*R""<X,VM%J+#9Y)H^")B9M-DLB(()@Y@2V&
MVY4<;V"%MI(!792$K8[A3"2#MXNI.Q6"V8@T*PF" (1MLY**=J=5HQB(]Z.'
MD?^'C)^,@&J&1IM\;K*%*9=J70F$*9-&2[^#,H[Z.MB"9HIH*O:!H85\LO:*
M K!(HG>(B*NDD52'&::Y?\"%S*&F;A2$L9R17("#P)=G2UV"TI(+.J*""(Q>
M*N>!4H9BLHB)KKDAH?J(.+.?D,*&PJVS?RF%;*>/;8Z$3J%J7!:#89LP2PF"
M@93$.FN!Q(X+*MJ!$X<?JUJ9P&^[G".7*W$*C$Z4QW)1>]*2@7.B:NN00W41
M6=^. G:I21J+MGAF.)J)9'IS*0:' WSLJI.8?WB!FW&6 7CGBX^3IWE8>QJ1
M97G>:CJ/+WJ$64&,_GM+2)2*PGPL.$B(A'U"*0>&-7Z9J<.70X$LFG^4V("^
MBK*2@H!>>CJ03X ::7*.*7_S6)F,"W_E2!*)XW_B-_Z'NG_Y*0B%?X GJ-66
M*XFTF8"3Q8B'B:61>H=E>5N/2(9/:*>--H595_>+*H1K1YZ)%H-]-[^' X*.
M*0F$WX&3I_:5*Y)+F)N2T)!=B+V0CXYQ>'2.9HR$9^^,3XJF5V"*68C51S6(
M6(;R-XB&783Y*0J$58+<IRJ4<IK?E^62&I@QB N/UY5P=[>-L)*I9SR+HX_D
M5M")K8T=1L^'O(I!-U&%U(<X*0J#X(/^IG^3X:-3ES:1CY_CAUJ/29Q)=PZ-
M()B=9J>+&93N5EB)*9$Q1GZ'-8U2-RB%7HD^*0N#?X3WI?>3=*NEEJJ1):=L
MAL>.VZ+R=GV,JYY49B"*IIFR5>6(P93\1B^&TI @-P6$_8L(*0N#+X7*I963
M([/>ECR0UZ[6ADF.AZEJ=?R,3J/*9:^*1)XG58V(8IAS1>N&@9*9-MN$N8R+
M*0N"[X9WG<VC"V];CZ6?M7"C@/F<BW'N<<*9<W-*8C264W3'4I&3(W9P0TJ/
MV'@^-&B,<7I?)J*(X7SDG3:A]'>CCR>>JG@.@'";?7B-<3R88'DG8;.50GGF
M4A^2''K+0N^.W7O,-$&+AGT&)LN("'Z G)F@R7_$CFJ=CG]I?\>:8'\B<(Z7
M3'\ 81F4.G[_4:*1)'\:0I6-]G]&-!V*LG^2)O"'2'_[F^*?LH?&C9V<?H:W
M?NJ96X6X;]6628348'.32(0.42"00X-80CZ-)H*D,_N)]8'[)P^&H8%4FR*>
MSX^TC.&;GHWY?BR8@(Q(;Q25<XJC7]^2:XD$4*N/>(=X0?2,:87>,^")3(0Y
M)RJ&$8*)FH6>")>QC$*:XI5$?8V7QI+.;GZ4MY!47U>1LHW=4$B.N(MH0;6+
MNHCG,\F(M89()T"%F(.7F?R=>9^/B\R:5IQN?1:7,IDI;?^4')747MV1'I*#
M3^F.+H\I07R++(NX,[2(.8@C)U.%,X1^F8R=$:=$BUJ9[Z-I?)^6Q9]0;8N3
MIIL97G.0J);D3XZ-PI*B04&*Q8Y',Z*'U(G$)V*$X85 F3B<Q*[:BO^9GZH\
M?#F6;J5 ;2232* 97AJ01IKU3TJ-897&01"*<9"",XN'CHLA)VZ$H(7?D.ZL
MCF\%@[>H?G!"=AZDC7&.:!N@FG+T6=J<BG1_2YB85W8Y/<J3^7@:,(./97I.
M)(&*F7S;D(6KFW;:@VRGB7=#=<JCAW?+9\F?A7AX68J;<7E02U>71'I2/9V2
M[WMR,(B.:GS0)-")L7YHD!NJ>7YY@N:F<GXI=56B:WWV9TV>;'WS61^:8'X5
M2P6607Y:/6V1^GZR,(N-B'\S)16(YG_3CYJI8(7P@E"E7H3[=*^A7X0=9L2=
M88-D6*:998+/2JR55()-/3N1'8'5,(J,OX%Q)5&(-H$;CP^H=HU8@<*D>8O#
M=!N@?XH_9C&<@XC-6#>8@X=Q2EF4@X8E/0Z06834,(J,#H.&)82'GX(]CHZG
MPY2Y@4>CR9*#<Z2?RY!+9;V;S8X;5]"7S8OR2A:3PHG,/.R/IH>C,(R+<H5L
M):Z'(8,ZCBVG))O[@.*C,)D><SZ?,98K95N;,I,R5WR7-9 Z2=V3+8T\/->/
M!(HS,(^*YX<<)=*&N(01C=>FO:,9@*VBQY^1<P:>N)O291>:HI?[5S>6H)0N
M29V2K)!?/*^.E8R&,)"*?(B8)>Z&8X3%C9.F<JH2@&JB<J75<KZ>6:$_9,Z:
M/9R'5OJ6-Y??27&21),W/):..HZ*,(R*,8G4)@6&'X57A+NV1FZJ>&&Q@V_:
M:\:LR'$F7NFG[W*64>NBWW0Q102=DW7_.*>8#'?U+/22.'H](J*,)WS2A(&U
M;G86>$JPF79X:ZNKOG<(7LVFS7?'4="ALWBX1/6<:WG9.*R6ZWL;+261)WR=
M(Q6+,'Y3A$RT37T[=_JO?7SQ:VBJFGS.7H6EI7SH492@D'TO1-";57V>.*:5
MXGXF+4Z0,W[;(WB*6'^OA .S*(0N=YNN7(--:OFI?H*-7BVDBX'\44J?@X&8
M1**:5H%-.)N4]($1+6^/6X#R(\V)GH#G@ZVR,(L1=T.M:(F>:IRHC8A&7<RC
MFH<&40B>D(7G1':9=(3>.)"4((/8+8R.GH+@)!:(_X'[@UFQ=9'L=O>LJX_F
M:E.GRHWE78:BU(OS4,N=RXH31%.8J8A .(B39(9O+:2-^(2A)%*(>H+H@P^P
MY9B>=KJL%I8 :AJG*Y-074ZB+Y"B4)>=*HX#1#:8#8MH.(>2OXC,+;J-:88O
M)(2(#8.R@MZP:9\>=HRKF)OA:>NFIYA\72"AII4-4&Z<H)&J1!&7D(Y&.'J2
M0HKF+<^,[X>')*V'M(19@JZP'*6"=H6K.Z&@:>"F-9UI70.A&YD94%B<"93K
M1 R6_9#*.(.1SXRU+>*,FXBF),V';83A>1K ,&YE;7VZRV^ 8<ZU2G#'5@JO
M@'(]2D>I7'/F/KBBX77),\J<%W?4*:B4[7HQ(/J-D7S)>0Z_:75O;9>YY'7!
M8>>T,W915B*N1W<>2E^H%'@G/MNAFWEG- &:V'K+*@:3PGQQ(8V,B'X^>1"^
M/GP>;8&XN7O/8=:R_WNU5@RM"7OI2E6FV'Q2/N:@:GSL-"B9M7VC*E62N7Z+
M(@R+HW^.>0.] X*0;5RW@8&Y8:&QR8$/5>>KUX"B2CREL8!M/N6?4H!8-$68
ML(!9*IB1SX!^(GF*WX"Y>.>[]8CM;3^V<X>588"PNH9A5;^JR8512BVDI81K
M/N:>68.F-&"7R8+J*M*1 H)((M:*.(&_>,:[)H]$;2VUF8UG872OV(N95;2I
MY8GC2B*CQ8A'/NR=>8;#-'J6_85+*P604H/E(R.)K(*@>*BZA95L;22TZ9,&
M87"O')"65;"I)8XR2B"C#8OE/O2<RHFF-).63H=Q*S*/O851(V*).H-=>(ZZ
M#9MA;2*T79AJ87.N@9505;&H@Y(V2ARB;H\T/O6<.XP_-*25R8E9*U:/0H:)
M(Y6(W8/Z>'NYM*$F;2>SZIV187RM_IG 5;:G^)7H2B2AXY(O/P6;N(Z)-+25
M68KW*VV.Z(>)([Z(DX1YVJ5Q\&TJQJ9S46[$LBMTI'!7G2!UZG'IA[1W,'.)
M<B9XA75"7+5Y\W<51VU[E'DC,JU]BGN3V+9OVW@9Q1=Q:WB)L,9RXWD%F^1T
M3WF2AI1UOGHT<2)W/7KK6\QXU'NO1JUZGGR4,B5\N7VDUN]N&(,%PUMOOX)1
MKT1Q5(&NFGMRWH$UA5=T;X#7<!)V%("*6NIWT8 ]1?UYOW_T,:U[^W^=U31L
MCXW/P9UN18P-K9)O[(ICF0!QD8C6A ES0X=U;OMU"H8<6@]VZ82V15IX^(,X
M,41[48%ZTZ)K1YA]P!)M")7%K INO9,;EXQP<I"%@LAR.XX%;>UT(8N<63]V
M'HD41,5X2H98,.EZO(,RTEAJ2:,8OL]L#Y]VJLAMR9O(EE1OB)@C@:MQ7Y2,
M;/1S5I#V6(!U;XU'1#]WM8E*,)QZ.X3!T5!I@:V7O<MK2:D-J;]M J18E4UN
MQ9^=@+YPJIKN;"URLI8R5]UTVI%#0\]W-HP$,%MYSX8BT(AH[[?LO09JMK)W
MJ.ML:*RYE'%N)Z;>?^EP%*$-:WAR*YLM5U5T9)4(0V]VSHY[,"=Y=8=3S_YH
MD,(#O'QJ4[N4J$AK][3$D[MMK:W'?SAOF*;-:MYQN)^_5M)S_9AG0P]V=I"B
M+_UY+(A3R\1Z&6PDN9=ZGFWRIKU[*&^HDRQ[MG%4?R)\3',,:NI\\73?5M9]
MJW;00NE^CWD +YI_MWN8RF!X+W:+N'UXX'<\I:UYB'?IDB=Z,'B=?BAZXGED
M:@9[J7I"5@Y\B7LR0DY]EWQ)+SE^YWV3R.AV@H#=MN5W28"!I#EX!X JD,=X
MS'_J?/9YGW^_:0-ZBW^F53I[C7^00;)\O'^#+N-^*W]SQV1U#8L+M5-UX8F\
MHJMVL(APCW!WB8<P>\5X?880: 1YAX3V5'1ZJ8/3029[^8*=+IA]A($UQ?ES
MTY4GL_!TL)+RH4MUCI"VCAYV=XY]>J9W>XQ/9Q1XI(HQ4[UYX8?W0*E[3860
M+EA\\H+2Q,YRW)\YLL=SOYPDH"9TH9CQC01UE)6V>:=VIY)^9CIWW8]#4QAY
M-8OP0#IZNHA5+B%\=81&P]UR&JDRL==S *4ZGS-SX:$+C!9TV)S'>-%U^)B$
M98EW/I0P4HYXHH^N/]YZ/HK@+?1\"X6-PR=QB;,%L1UR;ZXHGFMS2ZCXBTQT
M/Z.?>!!U9IY&9.5VO9C:4A1X,9,Q/X]YV(TJ+<Y[M(:FPJYQ*KREL)9R#+;9
MG<URW+"<BJ%SQJHG=V]T[:.N9%UV3)TA4:)WSI93/SUYA8\D+;%[;H>0O6""
M>VM2K-V"'FT_FXF!W&\+B5Z!KG#(=JV!C'*48\B!>'1_41&!<G:+/H>!C7C=
M++.!V'N;O$F MG4;J\F AW8 FF. 7W;:B$N 1G>V=;* .WBB8NZ 1'FG4%N
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M%HIQ:JV">HC<6;^" X=522.!EH6\..:!2H0$*;F!%H(<JG:$G9?QFSF#P)7
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MSJ@_@R^37J2&=6>0T:!+9T:.19O+62J+X)=)2T2)H9+!/?N'8XXM,6.%0(F
M)C2#)83TB("F;&FG?%&B^&N!;Z.?I6U=8G:<26]'5068RG%01Y65*7.%.J&1
M9G7B+CN-?WB0(R&)@'N3B!*E5W%L>_RAZ')S;T>>@G.-8B.;%G3#5+R7E'8<
M1U^3^W>=.H200WD^+D^,;WL<(WF(A'TQAZ"D"GCR>VN@JGE%;LR=1'FK8:B9
MW7HR5%>69GK91Q>2WGNB.F"/.'R +ER+>GV'(\:'J'ZLAQ:BQ(!*>LV?;(
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M)H^ J8,,DT>%7YZ!AC*$>9OB>&B#@9C3:A^"DY5^6[F!U)(A36Z!1HZ\/[B
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M+&Y[6?^#NG"J2]&#6'+Z/@^# W5L,-""T7@@)-:"PWLAC>F#P'!1@:R#5G'
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M?H+\:KF/OH+/7^F-XX)[5,6+]H(029F*#H&J/J*(+X%5-"N&9($+*G6$KH#
M(C6#%(!W=)N0AHG*:D..U(D+7W>,_8@,5%F+%(;G23V)-H7#/F>'9X2J-"N%
MGX.;*HB$"8*!(F."DH%J=#R/T9!L:@B.*8\H7S^,2HUT5!Z*3XM]20F(;XF2
M/BV&MX>V- .%!H7I*I2#@80+(HB"*((U<_*/29;6:<&-GI4(7O6+N9*:4]F)
MN8_72-.'V(TB/@N&)8I_,_:$AH?L*IN#&852(J:!TX+;;4*B;UZP8WB?I&&
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M(DV!KGUJ> >!(GB=;8Z ^GED8IN QWH65T6 DWJ]2]F ;'MM0%6 ;'PO-7*
M>'S^*T: IWWA(H: [G[,=T9_FW_T;-U_CX >8?M_<( A5KY_38 *2VU_/G_T
M0#-_4'_O-6E_A'_U*U5_W7_\(K6 38 #=J=^:(<B;&%^<X:T88U^6X8 5E!^
M/(4B2P!^081'/]Q^;X-Y-4Q^M8*S*UI_,X'A(MQ_QX$-=BE]<HX7:^A]BXT/
M81A]>HNB5>E]8HGZ2J5]=(A7/XE]NH:]-1U^%84L*U]^IX.+(OQ_6H'L=<A\
MMI3+:XA\UY,O8+A\RI$$59!\M(Z-2F!\RXP;/UM]'8FT-0!]CH=5*U=^.X3N
M(Q5_ X*C<'627EH>9JR0VEUP7&V/<V#*4;..!&0V1KF,>F?$.\^*XVN&,7J)
M36]X)]F'RW/%'YF&<7A:;ZF0-&%@9A2.X&0-6^2-B6;&44R,)&F21G2*KFQ]
M.[&).6^7,8:'R'+9*!2&<'9E( F%/GHC;O:-_FB 956,UVJ26TR+G&RL4,2*
M46[81A2(_7$?.WR'KW.,,8&&9W8;*$*%.WCB(&J$,7O&;CN+\&^"9).*YG$
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MLX!N)DB$%(!I(#>"J8!?8BJ/SX;P68Z.4X:$4)N,CH7!1WV*F(37/FZ(J(0
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M']^"/7R(9<> QW$L7/& XW*@4\* X'0-2E> RG5Z0-^ OG< -W. RWB>+KN
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M?GA.0(!4<#Q3UX!"8:A9IX T4OQ?R8 T1+=F-X \-Q5L^H!3*NASS8!YE^)
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MZ76/)0V ''B['QR!27OG7G!V3VP?5DYWF&X&3>-XP6_S149YW''J/*5[!G0
M-!=\3G8V+$)]HWB!)3!_$7KJ'VN ;GU'7:5SY'++59=U;'0A34=VSG5N1,)X
M(7;!/$%Y?G@H,_IZ]'FN+$5\@7M&)5-^*'SI'ZU_MWYZ7/1QR7E$5/)SCWH(
M3+=U*'JR1$YVJWM9.^IX-7P4,]!YV'SF+%U[A7W*)7E]7WZO'^-_'W^ 7&9P
M G^,5(AR!W_'3&=ST7_&1!EU<W^R.\=W''^[,Z9X['_=+$)ZP8 4)8]\O(!
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M'=""MGO'51%_*6H-3<%_JVPF1CE__FY,/I> ,7""-PJ 87+A+YN I'5?*.B
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M_P  __\  /__  !M9G0Q      ,$(0   0                    $
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M@*Z,Q8"NC,6 KHS%@*Z,Q8"NC,7_J#0J_Z8^/_^Q-TKYOC!2Y\\O5='B+&C
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MY)EGA]R6<9+5DWN<SY"$I,N.C*O(BI"PQ8>4M,.$F+?"@9NYP7^>NL%]HKO
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M&+?V*2NI]S,\G?8\2Y'W1%B&]DUB??!6:G;K7G%NYV1V:N1K>F;B<GUDX'>
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M9W*PK6U^IZ=SB9ZA>I*6G8"9CYJ(GXF7D*2$E)BH?Y.BJGR2K:MZDKJL>Y'
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MJ9]S>Z&:>H2:EH&+E)*(D8Z/D):)C)F:A(JBG8&*K9]_BKN??HK(GG^)R9V
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M2CW_E4L\_YQ,//^?3#S_GTP\_Y],//^?3#S_GTP\_Y],//^?3#S_GTRWO ,
MJ<L" )S; P"2_Q "B?\="(#_*A!U_S$8:_\X'V+_/B1;_T0I5/]*+%#_42],
M_U<R2?]<,T;_8#5$_V4V0O]I-T'_;C@__W,Y/?]W.CS_?#L[_X(\.?^'/3C_
MC#TW_Y,^-O^5/C;_E3XV_Y4^-O^5/C;_E3XV_Y4^-O^5/C;_E3ZJQ   G-(
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M7T/RNU]"\\Q@0?/G8$'SZ&!!\^A@0?/H8$'SZ&!!\^A@0?/H8$'SZ&#>IP(
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MV[PY$<ZW12##LD\PN*Q7/J^G7TJFH655GIUL7I>9<V:0E7ILBI*!<H60B7>
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M23G\XTDY_.-).?SC23G\XTDY_.-).?SC23G\XTG'K0  M[<" *K# @">T 0
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M0T'IND1 ZLU$0.KD1$#H]41 Y_A#0.?X0T#G^$- Y_A#0.?X0T#G^$/-HP
MO:X! +"X 0"DQ ( F= % (_A"@")\1H!@?$H!7CR,@QP\CL3:?)#&6+R2A]<
M\U C5O-7)U+S7BM/\V4M3/1L,$GT<S)&]'LT0_2$-D'UCC<^]9DY/?:D.COV
ML#LZ][\\.?C//#CWZ#PX]^P\./?L/#CW[#PX]^P\./?L/#CW[#R_J@  L;,
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M&B+_JALA_ZT;(?^M&R'_K1LA_ZT;(?^M&R'_K1N:O@  B\H  '[7  !PXP
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M5$RXOU1+N=A42[?M5$JV^55*L_Y62K/^5DJS_E9*L_Y62K/^5DJS_E;ZAP(
MUI@  ,FE P"]KP, L[@! *G"! "AS0@ FM 6 )+0* 2*SS8,@<Y!%7G,2AYR
MRU(F;,I:+6;)83)AR&@W7,=O/%C&=C]5QG]#4<6)14[%E$A+Q:!*2<6N2TC%
MOTM'QMA+1\7M2T;#^4U%PO].1<+_3D7"_TY%PO].1<+_3D7"_T[?D   S)\
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M+S?SYR\V\?,O-O'S+S;Q\R\V\?,O-O'S+S;Q\R^YIP  J[   )^[  "2Q@
MAM ! 'O=!0!T]Q$ ;?<< 6;X)@-?^"\&6ODX"E3Y0 Y0^D<13/I.%$C[519%
M^UL80OMB&D#\:!P]_' =.OUX'SC]@B V_8TB-/Z8(S+^I"0Q_[$E,/^_)B__
MSR8N_^,F+O_C)B[_XR8N_^,F+O_C)B[_XR:MK0  G[<  )+"  "&S0  >=H
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M5X)O_5>";_U7@F_]5X)O_5?_8!4!_VX1 ?][$P#_AA0 ]H\6 .>6& #;G!P
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M5UJ4O5A9E-17693L5UF3^59;D?Y56Y#^55N0_E5;D/Y56Y#^55N0_E7_<PD
M]80$ -B1 P#,G 4 PZ4% +NM! "SLPP J[4< :.T+ 6;LCD.DK!$%XJM32"#
MJU0I?:E<,'>G8C9QI6D\;*1O06BB=T5DH7])7Y^(3%R>DD]8GIY25IVK4U2=
MO%13G=%44YWK4U.<^%-4FO]35)G_4U29_U-4F?]35)G_4U29_U/_> 8 X8D
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M/T2^]D%#O?]"0[S_0T.\_T-#O/]#0[S_0T.\_T/6C0  QIL  +BE  "MK@
MHK8  )B_ @"-R 8 @]$+ '_2&@!YTBH#<M(W"&S10@]FT4L58=!3&ES/6Q]8
MSV(C5,YI)U'.<2I-SGHM2LZ#,$C.CC)%SIHT0\ZH-4+.N#9!S\TU0<[H-4#-
M]3<_R_XY/LO_.3[+_SD^R_\Y/LO_.3[+_SG*E@  O*(  *^J  "CLP  F+P
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M&RO[ZQLK^^L;*_OK&RO[ZQNHJ@  FK0  (V_  " R0  =-,  &?>  !>\@@
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M3VE[OE!H?-50:'SM3VE\^TYI?/]-:GO_3&I[_TQJ>_],:GO_3&I[_TS_9@H
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M2%&7]4A1E_]'49;_1U&6_T=1EO]'49;_1U&6_T?V=P  V(4  ,F1  "_FP$
MM*(  *NH  "AL   FK(1 )2S(@&-LC %A;$\#'ZO1A1XKDX;<JQ6(6VK7"=H
MJ6,L9*AJ,&"G<31<IGDX6*6".U6DC#Y1HYA 3Z.E0DVCM$-,H\A#3*/D0TNA
M]$-+H/]$2Z#_1$N@_T1+H/]$2Z#_1$N@_T3C?0  SXL  ,*6  "WGP  K:8
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M+CS%_RX\Q?\N/,7_+CS%_R[$DP  MI\  *FF  "=K@  DK<  (:_  ![QP,
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M"1S_W0F8L   BKH  'S$  !OS0  8M@  %7>  !)Y   1/L% #__#@ [_Q4
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M3"8"_T\O _]0.07_3D,'_TQ/"_]*6P__2&83_T5Q%OQ#?!GZ0H8;^$&.'/9
MEA[U/YT?\S^C(/(^JB#Q/K$A\#ZY(>X^PR'M/L\AZC[B(>8_[R'C/ODCX3W_
M)=\]_R?>/?\HW#W_*-P]_RC</?\HW#W_*-P]_RC_/R,!_T<@ ?],'@'_420"
M_U4L _]6-03_53\&_U-*"OY05@_Z3F(3]DMM%_-)=QKP1X$<[D:*'NQ%DB#K
M1)DAZ4.@(NA#IR/F0ZXCY4*V).1"P"3B0\PDWT/@)-M#[2760O@HTT+_*M%"
M_RO/0?\KSD'_+,Y!_RS.0?\LSD'_+,Y!_RS_0R !_TH< ?]0&P'_5R$!_ULH
M O]<,@/_6SL&_%E&"?9640[Q5%T3[5%H%^E/<AKF37P=Y$N%(.)*CB'@294C
MWDB<)-Q'HR;:1ZLGV$:S*-5&O"C31L@IT4;<*LU'["K)1O<LQT;_+L1&_R_#
M1O\OPD;_+\%&_R_!1O\OP4;_+\%&_R__1AT!_TX8 ?]6& '_7!X!_V E O]B
M+0/\8C<%]&!!".Y=3 WH6E@2XUAC%]]5;AO;4G<?V%" (M1/B23139 GSTR7
M*,U,GBK+2Z8KR4JM+,=*MRW&2L(NQ$K1+\%+YR^]2O0QNTK_,KA*_S*W2_\S
MMDO_,[9+_S.V2_\SMDO_,[9+_S/_2AH!_U(5 ?]:%@'_81L!_V8A ?YH*0+T
M:#(#[&<\!N5D2 O?8500V5Y>%]);:1S.6'(@RU9[),A4@R?%4HLJPU&2+,%0
MF2Z_3Z$OO4^H,;M.L3*Y3KPSMT[*-+5.X32R3O$UKT_]-JU/_S:L3_\VJT__
M-JM/_S:K3_\VJT__-JM/_S;_31<!_U42 ?]?% #_9A@ _VL= ?AM) 'M;BP"
MY6TV!-UK0PC49T\0S61:%\A@9!W$76TBP5MV)KU9?BF[5X4LN%:-+[95E#&T
M5)PSLE.D-+!2K3:M4K<WK%+%.*I2VCBG4NTYI5/Z.:-3_SFB4_\YH53_.*%4
M_SBA5/\XH53_.*%4_SC_3Q0!_UD0 /]C$@#_:A0 _V\9 /)R'P#F="8!W70Q
M M-Q/PC+;4L/Q6E6%\!F8!V[8VDBMV!Q)[1>>2NQ7( NKEN(,:Q9CS.J6)<U
MIU>?-Z57J#FC5K,ZH5; .Y]6TCR=5ND\FU?X/)I7_SR96/\[F%C_.YA8_SJ8
M6/\ZF%C_.IA8_SK_4A(!_UP. /]F$ #_;1$ ^G,4 .MW& #@>1\ U'DM LMV
M/ ?$<D@.OF]3%KAK7!VS:&4BKV5M)ZQC=2NI87POIE^$,J->BS6A79,WGER;
M.9Q;I#N96J\]EUJ[/I9:S#^46N4_DEOU/I%;_SZ07/\]D%S_/(]<_SR/7/\\
MCUS_/(]<_SS_51$ _U\- /]I#@#_<0X ]7<0 .9[$0#9?1@ SGTJ L5[.0:^
M=T4.MW10%;%P61RM;6(BJ&II)Z5H<2RA9G@OGF2 ,YMBAS:888\XEF"8.Y-?
MH3V17JL_CUZX0(U>R$&+7N%!BE_S0(E?_S^)8/\^B&#_/HA@_SV(8/\]B&#_
M/8A@_SW_5P\ _V(, /]L# #X= P Z7H, -Y^# #2@14 R($G <!_-@:X?$(-
MLGA-%:QU5ANG<E\BHF]F)YYL;BR;:G4PEVA\,Y1GA#:198PYCF25/(QCGCZ)
M8JA AV*U0H5BQ4*$8MY#@V/Q0H)C_4&"9/] @F3_/X)D_S^"9/\_@F3_/X)D
M_S__60X _V0+ /]N"@#J=P@ VWT( -2""@#,A!( PX4D ;N#- 6S@$ ,K7Q+
M%*9Y5!NA=EPAG'-D)IAQ:RN4;W(OD6UY,XYK@3:+:HDYB&B2/(5GFS^"9J9!
M@&:R0WYFP41]9ME$?&?O0WQG_$%\:/] ?&C_0'QH_S]\:/\_?&C_/WQH_S__
M6PP _V<) /=Q!P#>>@4 U( ' ,Z%"0#'AQ$ OH@B ;:',02OA#X+J(%)$Z)]
M4AJ<>EH@EW=A)I-U:"N/<V\OBW%W,XAO?C:%;H8Z@FV//7]KF3]\:Z-">6JP
M0WAJOT1V:M1%=FOM0W9K^T)V:_]!=FS_0'9L_T!V;/] =FS_0'9L_T#_70H
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M0V!]]D)@??]!87W_0&%]_T!A??] 87W_0&%]_T#_9P  XW0  -)_  #'B $
MOH\" +:5 0"NF 8 IIH5 )^:)@*8F3,&D9<_#(N52!2%DU :?Y%8('J/7R5V
MC64J<HML+FZ*<S)JB'LV9H>$.6.&CCQ@A9D_782F05N$M$):A,=#6H3C0EJ#
M]$%;@_] 6X/_0%N#_S];@_\_6X/_/UN#_S__:@  WG@  ,V#  #"C   N9,
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M.4F;_SE)F_\Y29O_.4F;_SG;>@  R(<  +R2  "QF@  IJ   )RF  "1K
MA[$( (&R%@!\LR8!=K(S!'&R/0EKL4<.9K!/$V*O5AA>KET<6JUD(%>L:R-4
MK',F4*M\*4VJABQ*JI(O2*F?,$:IK3)%J;\R1*K:,D2H[S)#I_LS0Z;_,T.E
M_S1#I?\T0Z7_-$.E_S30@0  P8X  +68  "IGP  GJ4  ).L  "(L@  ?+D"
M ':Z$0!RNR$ ;KLN FB[.@9DND,*7[I,#ENY4Q)7N%H65+AA&5&W:1Q.MW$?
M2[9Z(DBVA"5%MI G0[6=*4&UK"I MKXJ/[;8*C^T[BH^L_HL/;+_+3VQ_RT]
ML?\M/;'_+3VQ_RW'B0  N94  *R=  "AI   EJL  (JR  !_N   <[\# &K$
M# !GQ1H 8\4H 5_%-0-;Q3\%5\5("53$4 Q0Q%@/3<1?$DK#9A5(PVX71<-X
M&D+#@AQ PXX>/L.<'SS#JR [P[PA.L/5(3O"[B$YP/DB.+__)#B__R0XO_\D
M.+__)#B__R2]D0  L)L  *2B  "8J@  C+$  ("Y  !UOP  :L8$ %[," !9
MSQ( 5] A %70+@%1T#D"3M!#!$O03 9)T%,(1M!;"T/08PU!T&L//M!U$3S1
M@!,ZT8P4.-&:%C;1J1<UT;L7--+2%S70[!8TS_<8,\[_&C/._QHSSO\:,\[_
M&C/._QJSF0  IJ$  )JI  ".L0  @;D  '7   !JQP  7LT# %34" !,W0T
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M QO^B009_I@$&/^H!!?_MP06_\@$%O_@!!;_Y 06_^0$%O_D!!;_Y 23K@
MA;<  'C   !JR0  7=(  %#9  !$WP  .N0  #7W P R_PP +O\2 "O_&@ H
M_R$ )O\G "/_+0 @_S, 'O\Y 1S_/P$9_T4!%_]- 17_50$3_U\!$?]J A#_
M> (._X<"#O^6 @W_I (,_[ "#/^^ @S_P@(,_\("#/_" @S_P@*'M@  >;\
M &O)  !>TP  4-L  $/@   XY0  +_   "O_   G_P@ )/\. "'_$P >_QD
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M-8E:P3:'6M8VAEOM-H5;^S6%7/\TA%S_,X1<_S.$7/\SA%S_,X1<_S/_4PH
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M.FUK]3AM:_\W;6O_-FUK_S9M:_\V;6O_-FUK_S;_6P  ZV<  -EQ  #,>0
MPWX" +N" P"TA D K848 *:%* &?A#4%F8) "I-_21"-?5(6B7M9&X1Y8!^
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M-5A^_S58?O\U6'[_-5A^_S7I:   U'0  ,9^  "[AP  LHT  *B1  ">E
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M*4"@_RG)?@  NHL  *^4  "CF@  F*   (VE  ""J@  =;   &RS# !IM!@
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M#3++H@XQR[(/,,S'#S#+Y0XOR?4/+LC]$2['_Q(NQ_\2+L?_$B['_Q*NEP
MH9X  )6E  ")K0  ?+0  '"[  !DP0  6<8  $[+ P!%T @ /M4. #W5&@ \
MUB8 .]<Q #G8.P XV44!-ME- 3795@(SVEX",=IH S#;<P0NVW\%+-N-!2K<
MG08IW*T&*-W!!BC=W@8GV^\')MGY"";8_@DFV/X))MC^"2;8_@FDG0  F*4
M (NM  !^M   <;P  &7#  !9R0  3<T  $/3 0 ZV08 ->0- #/D%@ QY"
M,.4J "[F,P MYCP *^=$ "KG3 $HZ%0!)^A= 27I9P(CZ7,"(NJ! B#JD0,?
MZZ$#'>NR QSLQP,<[.$#&^KQ QOI^0,;Z?D#&^GY QOI^0.:I   C:P  '^U
M  !RO0  9<4  %G+  !,T   0=4  #C<   OX0( +?$- "OQ$P H\AP )O(D
M "3S*P B]#( (?0Y !_U00 =]4D &_91 !GW6@$7]V4!%?AR 13Y@0$3^9(!
M$OJB A'ZLP(0^\8"$/O= A#[Z0(0^^D"$/OI A#[Z0*/JP  @;0  '.]  !F
MQ@  6<T  $O3  ! V0  -=X  "SC   F\0  )/X* "'_$  ?_Q8 '/\< !G_
M(@ 7_R@ %?\N !/_-0 2_SP $/]#  [_3  -_U8 "_]B  G_;P (_W\!!_^0
M 07_H $$_ZX!!/^\ 0/_QP$#_\<! __' 0/_QP&#M   =;T  &?&  !:SP
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M(Z%)QB2?2MXDG4KP))M*_2692_\DF4O_))A+_R282_\DF$O_))A+_R3_2 P
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M+GI;]2UZ7/\L>5S_*WI<_RIZ7/\J>ES_*GI<_RK_40  \EL  -YD  #/:@
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M+65K_RQE:_\L96O_+&5K_RST6P  W68  ,MO  # =@  MWL  *]^  "F?@$
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M*4^ _RG;:@  QW4  +I_  "PAP  IHP  )R/  "/D0  AI,% ("4$@![E2$
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M'$"?HAT^G[(>/9_&'CV?XQT]G?0>/9S_'SR;_Q\\F_\@/)O_(#R;_R#"?
MM8@  *F0  ">E@  DYL  (>?  ![I   ;Z@  &.L! !?K1$ 7*T? %JN*P!7
MKC8!5*Y  U&M2 5.K4\'2ZU7"4FM7@M&K&8-1*QN#T&L>!$_JX03/*N1%3JK
MH!8YJ[ 7.*O#%SBJX1<WJ?,8-Z?^&3:F_QHVIO\:-J;_&C:F_QJZA   KH\
M **6  "7FP  BZ$  '^F  !SJP  9Z\  %JT  !3M@P 4;<7 $^W) !-N#
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M B'5T@(@T^L"(-+V Q_1_P0?T?\$']'_!!_1_P2?FP  E*(  (>I  !YL0
M;;@  &"^  !4PP  2<<  #[+   UT $ +=4& "7;"P DWA( (]X< "+?)0 A
MX"X (. W !_A0  >X4H '>)3 !SC7@ ;XVH &N1X !CDB $7Y9H!%N:L 17F
MP $4Y]T!$^7O 1/C^@$3X_H!$^/Z 1/C^@&6H@  B:D  'NQ  !NN0  8<
M %3&  !(R@  /<\  #/3   JV0  (MX" ![K"@ <[!  &^T7 !GM'P 7[B8
M%>XM !3O-0 3\#T $?!& !#Q4  /\EL #O)I  WS>  ,](H "_6<  KUK@ )
M]L( "?;9  CU[0 (]>T "/7M  CU[0"+J0  ?;(  &^Z  !BP@  5<D  $?.
M   [T@  ,=@  "?=   ?X0  &>@  !;X!@ 4^@T $OL2 !#\%P ._!T #?TC
M  S]*0 *_C  "/\X  ;_00 #_TP  /]8  #_9@  _W<  /^)  #_FP  _ZL
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M: 34.'$&T3AZ!\\W@0C--X@)RS:/"LHVE@K(-IT+QC6D#,4UK S#-;4-P37
M#< VSPZ]-N8.N3;T$+<V_Q&U-O\2M#;_$[,V_Q.S-O\3LS;_$[,V_Q/_.1
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M'HU*]AZ+2_\>BTO_'8I+_QV*2_\=BDO_'8I+_QW_10  _TT  .54  #960
MSUL# ,I;!@#$6@\ NUL> +5<+@&O6SL"JEI&!:984 BB5ED+GU5@#IQ3:!&9
M4F\3EU%V%950?1>34(09D$^-&HY.EAR,3I\>BDZJ'XA.MR"'3L@AA4[B(81/
M\R"#3_\@@T__'X)0_Q^"4/\>@E#_'H)0_Q[_1P  \U$  -]8  #170  R6 "
M ,-@! "]7@T M6 : *YA*@"I8#<"I%Y#!)]=30B;6U4+F%E=#I589!&25VL3
MCU9R%HU5>1B+5($:B%.)'(93DAZ$4IP?@E*G(8!2M")_4L0C?5+>(WQ3\2)\
M4_XA>U3_(7M4_R![5/\@>U3_('M4_R#_2@  Z50  -I<  #,80  PV0  +QD
M @"V8PH KV07 *EE)P"C9#0"GF- !)EA2@>57U(+D5Y:#HY=81&+6V@3B5IO
M%H99=AB$6'T:@5B&'']7CQY]5ID@>U:D(GE6L2-W5L$D=E;:)'57[R1U5_TC
M=5C_(G58_R%U6/\A=5C_(758_R'_30  Y5<  --?  #(9   OV<  +=H  "Q
M9P< J6@4 *-I) ">:#(!F6<]!)1E1P>09$\*C&)7#8AA7A"%7V43@UYL%H!=
M<QA]77H:>UR#'7E;C!]V6Y<A=%JB(W):KR1Q6K\E<%K5)6];[25O6_PC;UO_
M(F];_R)O6_\A;UO_(6];_R'Z3P  X5H  ,]B  #$9P  NVL  +-L  "L:@0
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M(EQJ_R+C6P  SF8  ,!N  "V=   K'D  *-[  "8>0  D'H+ (I[%@"%?"0
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M'TU^HB!+?;$A2GW$(DI]X2%+?/0A2WO_($M[_R!+>_\@2WO_($M[_R#09P
MP'(  +1[  "J@@  H(8  )6(  "'B   ?(H  ':,#@!RC1H ;HXG &J.,@%F
MC3P#8XU$!6",3 A<BU,*6HM:#5>*81!4B6@248AQ%4^(>A=,AX4:2H:2'$B&
MH!U&AJ\>187"'D6%WQY%A/(>18/^'D6"_QY%@O\>18+_'D6"_Q[*;0  NG@
M *^!  "EAP  FHL  (^-  "!C@  =)$  &Z3"@!IE!4 9I4B &.5+@%@E3@"
M7)5!!%F42096E% (5)-7"E&37@Q.DF8/3))N$4F1>!1&D(,61)"0&$*/GAE
MCZT:/X_ &C^/W!H_C?$:/XS]&S^+_QL_B_\;/XO_&S^+_QO"<P  M7X  *J'
M  "?C   E)   (B3  ![E0  ;)D  &6;! !@G!  79T= %N>*0!8GC0!59X]
M E*=10-0G4T%39U4!TN<6PE(G&,+1IQK#4.;=0]!FX 1/IJ-$SR:FQ0ZFJL5
M.9J]%3F:V14YF.\6.9?\%CB6_Q<XE?\7.)7_%SB5_Q>[>@  KX4  *2,  "8
MD0  C94  (&:  !UG0  :*   %ND  !6I0P 4Z87 %&G(P!/IR\ 3*<X 4JG
M00%(ITD"1J=0!$.G6 5!IU\&/Z9H"#VF<@HZIGT+.*:*#3:EF0XTI:D/,Z6[
M#S.EU \SI.X/,J+[$#*A_Q$RH?\1,J'_$3*A_Q&T@@  J(P  )V2  "2EP
MAIP  'FA  !MI0  8:D  %6L  !+KP4 1[ 0 $6P' !$L2< 0K$R $&R.P _
MLD,!/;)+ 3NR4P(YLEL#-[)D!#6R;@4SLGD&,;*'!R^QE@@NLJ8(+;*X"2RR
MT @LL.P)*Z_Y"BNN_PLJK?\+*JW_"RJM_PNMBP  H)(  )68  ")G0  ?:,
M '&H  !DK0  6;$  $VT  !"N   .[H* #B[$P WO!X -;PI #2],@ SO3L
M,KU$ #&^3  OOE4!+KY> 2R^: $JOG0"*;Z" B>_D0,FOZ(#)+^T R._RP,C
MON@#([SW!"*[_P4BN_\%(KO_!2*[_P6DD@  F)@  (R>  " I0  <ZL  &>P
M  !;M0  3[D  $2\   ZP   ,,0$ "K'"P HR!, )\D= ";))P ER3  ),HY
M "/*0@ BRTL (<M5 "#,7P ?S&P '<UZ !S-B@ ;S9P &<ZN 1C.Q0 8S>0
M&,ST 1C*_ $8RO\"&,K_ AC*_P*;F0  CY\  (*F  !UK0  :+,  %RY  !0
MO0  1,$  #G$   PR   *,P! "#0!@ 9U0L %M<0 !78&0 5V2( %-DK !/:
M-  3VCT $MM( !'<4P 1W5\ $-UM !#>?@ .WY$ #N"D  W@N  ,X-( "]_M
M  S>]P ,W?L #-W[  S=^P"2GP  A:<  '>N  !JM0  7;P  %#!  !$Q0
M.,D  "[-   ET0  'M4  !;: 0 1W@8 $.<-  [G$@ -Z!D #.@A  OI*0 *
MZC$ ">H[  ?K10 %ZU$ !.M>  /K;@ !ZX   .J4  #JIP  Z[P  .O2  #K
MZ0  [.\  .SO  #L[P"'IP  >:\  &NW  !>O@  4<4  $/)   WS0  +=$
M "/6   ;VP  $]\   [C   ,[@( "O8*  ?V#@ %]A(  _88  #U'@  ]24
M /4N  #U-P  ]D(  /9.  #V70  ]FX  /:!  #VE0  ]Z<  />W  #XQP
M^-   /C0  #XT ![KP  ;;@  &#   !2R   1,T  #?1   KUP  (=P  !C@
M   1Y   #.<   ?O   $^@   ?\#  #_"   _PT  /X0  #^%   _QH  /\A
M  #_*0  _S,  /\^  #_2P  _UL  /]L  #_@   _Y(  /^A  #_K0  _[,
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M >,9U0'?&N@!W!OU M@;_P+5'/\#U!S_ ],<_P32'/\$TAS_!-(<_P3_*1<
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M#*8V^ VE-O\.HS?_#J(W_PZB-_\.HC?_#J(W_P[_-P< _SL" /]  P#R0@4
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M%WU+_Q=]2_\6?4O_%GU+_Q;_0P  YDP  -93  #)6   P%D  +I8 0"T5@D
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M&65:_QGH3P  TUD  ,1A  "Y9@  L&@  *=I  ">90  EV8- )%G&0",:"<
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M&EEFHAM79K <5F;#'59FWQU69O,<5V;_&U=F_QI79O\:5V;_&E=F_QK;60
MQV(  +IJ  "O<   IG,  )IS  "/<   AW$% (%R$0!\<QX >',J '1S-0%P
M<S\#;7)'!6IQ3@=G<54)9'!<"V)O8PY?;VH076YR$EIM?!58;8875FR3&51L
MH!M2:Z\<46O!'%%KW!Q1:_$;4FO^&E)J_QI2:O\94FK_&5)J_QG47   PV8
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M%D" TA9!?^T607[[%D%]_Q9!??\607W_%D%]_Q;":@  M74  *I]  "?@@
MDH,  (6$  !YA0  :HD  &2* P!@C!  78T; %N.)P!8CC( 58X[ 5..0P)0
MCDH#3HU2!4R-609)C& (1XQH"D6+<@Q"BWT.0(J)#SZ*F!$\BJ<2.XJX$CJ*
MSQ([B.L2.X?Z$SN&_Q,[AO\3.X;_$SN&_Q.\<0  KWL  *6#  "9AP  C(@
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M!"6H_P4EI_\%):?_!26G_P6GB0  FX\  )&4  "$F0  >)X  &NB  !?I@
M4ZH  $BM   ]L   -+,# "^U#@ MM18 ++4@ "NV*0 JMC( *;<Z "BW0P G
MMTP )KA5 "2X7P CN&L (KAX 2"XB $?N)D!';FK 1RYP $<N-\!'+;R 1NU
M_ (;M/\"&[3_ ANT_P*?CP  E)4  (B;  ![H0  ;J8  &*K  !6L   2K,
M #^V   UN0  ++P  "2_!@ ?P@T '<(4 !S"'@ ;PR8 &L,O !G$.  8Q$$
M%\1* !;%50 5Q6$ %,9O !/&?P 2QI$ $<>D !#'N0 /Q]0 $,;N !#$^@ 0
MP_\ $,/_ !##_P"7E@  BYP  'ZB  !QJ0  9*\  %BT  !+N   0+L  #6^
M   KP0  (\4  !O) 0 4S 8 $- +  [1$0 -T1D #=$A  S1*@ ,T30 "](^
M  K220 )TU4 "=-B  C3<@ &U(0 !=28  34JP #U<   =7<  '5[0 !U?8
M =7V  '5]@".G0  @*0  '.K  !FL0  6;@  $R]   _P   -,,  "K'   A
MR@  &<X  !+2   -U@$ "=L%  ;<#0 $W!$  ]T8  '>(   WB@  -\Q  #@
M/   X4<  .)4  #C8P  XW0  .2(  #DFP  Y:X  .7!  #EU0  YN<  .;G
M  #FYP"#I   =:P  &BS  !:NP  3<$  $#$   SR   *,P  !_0   7U
M$-D   O=   %X0   .0   #E!P  Y@T  .<1  #H%@  Z1T  .HE  #K+@
M[3D  .]%  #P4P  \60  /%V  #RB@  \YP  /.M  #TNP  ],@  /3(  #T
MR !WK0  :K4  %R]  !/Q   0,D  #/-   GT0  '=8  !3<   .X   ".,
M  'F    Z@   .X   #N    [P0  / *  #Q#@  \Q(  /08  #V(   ^"H
M /HU  #]0P  _E(  /]C  #_=@  _XD  /^:  #_I@  _[   /^P  #_L #_
M%B, _Q4A /\1(0#_#20 _PDK /\&-P#_ T0 _P!1 /\ 70#_ &@ _P!R /\
M>P#_ (, _P"* /\ D0#_ )8 _P"< /\ H0#] *8 ^P"L /D LP#W +L ]0#%
M /, T0#R .0 \0#Q .\ ^@#N /\ [@#_ .T _P#M /\ [0#_ .T _P#_&2
M_Q@= /\5'0#_$!\ _PXI /\,- #_"D$ _P=- /\%60#_!&0 _P1N /\#=P#_
M X  _P.' /\#C0#] I, ^P*9 /D"G@#W J0 ]0*J /,!L #Q ;@ [P'" .T!
MSP#K >, Z@'O .@"^P#G!/\ Y@7_ .8&_P#F!O\ Y@;_ .8&_P#_'!L _QL9
M /\7& #_%1T _Q,E /\1, #_$#T _PY) /\,50#_"V  _PMJ /T+<P#["WP
M^0J# /<*B@#U"I  ] J6 /,*FP#Q"J$ [PFG .T)K@#K";8 Z G  .8)S0#D
M">( X@KP -\+^P#>#/\ W W_ -P-_P#;#?\!VPW_ =L-_P'_'Q< _QX3 /\;
M$@#_'!D _QLB /\8+ #_%3@ _Q-$ /X24 #Y$5L ]1!F /,0;P#P$'< [A!_
M .P0A@#J$(P Z1"2 .@0F #F#YX Y0^E .,/K #A#[0 X ^^ -X/S #:$.$
MU1'P -(2^P#/$O\!SA/_ <T3_P'-$_\!S!/_ <P3_P'_(A( _R(/ /\A#P#_
M(A0 _R(< /\@)P#_'3( ^!L^ /(92P#N&%8 ZA=@ .<6:@#D%G( XA9Z . 6
M@@#>%H@ W!:/ -L6E0#9%IL UA:B -06J0#2%K$ T!>[ ,X7R0#,&-X R!GN
M <4:^P'#&O\"P1O_ L ;_P+ &_\"P!O_ L ;_P+_)@X _R4+ /\H# #_*1
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M"I(W_PJ2-_\*DC?_"I(W_PK_,P  ]CH  .0_  #80@  SD(! ,D^!@#$.P\
MNSX= +4_+ "Q/SH K3]% :D_3P&F/E@"HSU? Z$]9P2?/&T%G3QT!IP[>P::
M.X('F#N*")8[DPF5.IP*DSJF"Y$ZL@N0.\ ,CCO5#(P\[ V*//L-B3S_#8D\
M_PR(//\,B#S_#(@\_PS_-P  ZC\  -Q%  #.20  Q4D  +]& @"Z0PP LT09
M *U%)P"H1C4 I$5! :!%2P*=1%,"FD-; YA#8@660FD&E$%P!Y)!=@B00'X)
MCD"&"HU C@N+0)@,B4"B#8= K@Z%0+P/A$#/#X)!Z0^!0?D/@$'_#X!"_PZ
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M$'%+_Q#L0P  V4P  ,A3  "]5P  M%@  *Q7  "E4@$ GE,/ )A4' "35"D
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M$F-5H11B5:\5857!%F!5VQ9@5O$58%;^%&!6_Q-A5O\285;_$F%6_Q+@30
MRU8  +U=  "R80  J&,  )UA  "570  C5X) (=>$P"#7R  ?U\L 'M?-P%W
M7D "=%Y( W%=3P1O7%8%;%Q<!VI;8PEH6VL+9EIS#61:? ]B6H<18%F3$EY9
MH!1=6:X56UF_%EM9V!9;6>\56UG]%%Q9_Q-<6?\27%G_$EQ9_Q+<4   QUD
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M%$QGSQ1,9NL436;[$TUF_Q).9?\23F7_$DYE_Q+,6@  O&,  +!J  "E;P
MF&X  (QM  " ;   =VT  '%N"P!M;Q0 :7 A &9Q+ !D<38!87$^ 5YQ1@)<
M<$T#67!4!5=P6P95;V((4V]J"E!N<PQ.;GX.3&V*$$IMF!%);*<22&RX$T=L
MS1-';.H32&OZ$DAK_Q)(:O\12&K_$4AJ_Q''7@  N&<  *QN  "A<@  DW(
M (=Q  !Z<0  <7(  &MT!P!F=1$ 8W8= &!W* !>=S, 6W@\ 5EW0P)6=TL#
M5'=2!%)V6050=F '3G5H"$MU<0I)='P,1W2(#D5SE@]#<Z400G.V$4%SRQ%"
M<N@10G+X$4)Q_Q!#</\00W#_$$-P_Q#!8P  LVP  *AS  ";=@  CG4  (%V
M  !U=@  :7@  &-Z @!>? X 7'T9 %E^) !7?R\ 57\X 5-_0 %0?T@"3GY/
M TQ^5@1*?ET%2'UE!D9];@A#?'D*07R&"S][E T^>Z,./'NS#CQ[R X\>N8.
M/'GW#CQX_PX\>/\./7?_#CUW_PZ\:   KW(  *1Y  "6>@  B'H  'QZ  !P
M?   8W\  %R"  !7A L 4X44 %&&( !/ABH 3H<T $R'/ %*AT0!2(=+ D:'
M4P)$AEH#0H9B!$"&; 8^A78'.X6#"#F%D0HXA* +-H2Q"S:$Q@LV@^0+-H+V
M"S:!_PPV@/\,-H#_##: _PRV;P  JG@  )]_  "0?@  @W\  '>   !K@@
M7H<  %6*  !.C 8 2HX0 $B/&@!'CR4 19 O $20. !"D$  0)!' 3^03P$]
MD%8".Y!? CF0: ,WCW,$-8^ !3./C@8QCYX',(ZO!R^.PP<OCN$'+XST""^+
M_P@OBO\(+XK_"2^*_PFP=@  I7\  )B$  "*A   ?84  '"'  !EB@  6HX
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M 1.N_P&:C0  D)(  (27  !UF@  :)\  %NC  !0J   1:P  #NP   QL@
M)[4  ""X   8N@< %+P. !.\%0 2O!X $;TF !&]+@ 0O3< $+Y!  Z^3  .
MOE< #;YE  R_=  +OX8 "KZ9  B^K  'OL( ![[?  B^\  (O?H "+W\  B]
M_ "3E   AYD  'J?  !LI0  8*H  %.O  !'LP  /+8  #&X   GNP  '[X
M !?!   1Q $ #,@(  C)#@ 'R10 !LD<  7))  $RBP  \HV  +*0   RTP
M ,M9  #+:   RWD  ,R,  #+GP  R[,  ,O(  #,X@  S.\  ,SQ  #,\0"*
MF@  ?*$  &^G  !BK0  5;,  $BX   [NP  ,+X  ";!   =Q   %<@   _+
M   *S@  !-("  #3"@  TP\  -04  #5&@  UB(  -<J  #9-   VC\  -Q+
M  #<6@  W6H  -U]  #=D0  W:0  -ZV  #>R   WMX  -[B  #>X@!_H@
M<:D  &2P  !6MP  2;P  #S    OQ   ),<  !O+   3SP  #=(   ?6
MVP   -X   #? P  X D  .$.  #B$@  XQ<  .4>  #F)P  Z#$  .H]  #L
M2P  [%H  .UL  #N@   [I0  .ZE  #NM   [L(  .[&  #NQ@!TJ@  9K(
M %BY  !+P   /<4  "_)   DS0  &=$  !'6   +VP   ]X   #A    Y0
M .@   #I    Z@   .L&  #M"P  [P\  / 3  #R&@  ]",  /<N  #Y.P
M^TH  /Q;  #];0  _8   /Z3  #^H@  _JT  /ZO  #^KP#_$!\ _PX= /\*
M'0#_ 2  _P H /\ -0#_ $$ _P!. /\ 6@#_ &4 _P!N /\ =P#_ '\ _@"&
M /P C #[ )( ^0"7 /@ G #W *( ]@"G /4 K0#S +4 \@"] /$ R0#O -P
M[@#K .T ]P#L /\ ZP#_ .H _P#J /\ Z@#_ .H _P#_$QP _Q$9 /\-&0#_
M!AP _P,E /\ ,0#_ #X _P!* /\ 5@#_ &$ _P!K /T <P#Z 'L ]P"# /4
MB0#T (\ \@"4 /$ F0#P )\ [@"D .T JP#L +( Z@"Z .@ Q@#G -8 Y0#H
M .0 ]0#C /X X@#_ .$ _P#A /\ X0#_ .$ _P#_%1@ _Q,4 /\/% #_#1D
M_PLB /\(+0#_!#D _P%& /\ 40#^ %P ^@!F /8 ;P#R '< [P!^ .T A0#K
M (L Z@"1 .@ E@#G )P Y@"A .0 J #C *\ X0"X -\ PP#= -$ VP#F -D
M\P#7 /T U0+_ -0"_P#4 _\ U /_ -0#_P#_&!, _Q40 /\2#P#_$A4 _Q$=
M /\.* #_##0 _PI! /D(3 #U!E< \09A .T&:@#I!7( Y@5Z .0%@0#B!8<
MX :- -\&D@#=!I@ VP:> -D&I0#7!JT U :U -(&P #0!\\ S@CE ,P)] #*
M"_\ R S_ ,<,_P#'#/\ Q@S_ ,8,_P#_&PX _QD, /\8#0#_&!$ _Q<8 /\4
M(@#[$2X \Q Z .T.1@#H#5( Y0U< .$-90#>#6T VPUU -@-? #5#8( TPV)
M -$-CP#0#94 S@V< ,T.HP#+#JL R0ZT ,@.P #&#L\ PQ#F , 1]0"]$O\
MO!+_ +L2_P"Z$O\!NA+_ ;H2_P'_'PH _QP$ /\?" #_'PT _QT2 /@:&P#N
M%B8 YA0S . 3/P#:$TL U!-6 - 37P#.%&@ RQ1O ,D4=P#'%7T QA6$ ,05
MB@##%9$ P1:8 , 6GP"^%J< O!>P +L7O "Y%\L MQCB +,9\@&Q&O\!KQO_
M :X;_P&N&_\!K1O_ :T;_P'_(@0 _R(  /\E @#\) < ]R$, .P=$@#A&AP
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M!X(W_P?T,@  XSL  -)!  #&1   O4,  +<_  "Q.PD JCL4 *4\(@"@/3
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M"G!$H@MO1*\,;D3 #&U%V0UL1>\,:T7]"VM&_PMK1O\*:T;_"FM&_PKE0
MSTD  ,%/  "U4@  JU(  *%/  ";2@  E$H, (]+%P"+3"0 ATPO (1,.@"!
M3$,!?DM+ 7M+4@)Y2E@#=TI?!'5)9@5S26T&<4EU!V])?@AM2(@):TB3"VI(
MGPQH2*T-9TF]#69)U YE2>T-94K\#&5*_PME2O\+94K_"V5*_PO@1   RTT
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M#U95S ]65>D.5E7Y#595_PU75/\,5U3_#%=4_PS130  P%8  +-<  "G7@
MFET  (]<  "&6   ?UD  'E:#0!T6Q< <5LC &Y;+@!K6S< :%M  65;1P%C
M6DX"85I5 U]:7 1=6F,%7%IK!EI9= A867\*5EF+"U19F U36*8.4EFV#E%9
MR@]16><.45CX#5)8_PU26/\,4EC_#%)8_PS-40  O%D  +!?  "C80  EF
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M#$-F_PM#9?\+0V7_"T-E_PN_7   L60  *9J  "6:0  B6D  'UI  !Q:0
M9VH  &)L 0!=;0T 66X6 %=O(0!5<"L 4W U %%P/0!0<$4!3G!, 4QP4P)*
M<%H#2'!B!$9O:P5$;W4&0F^"!T!NCPD_;IX*/6ZO"CUNP@H\;N */6WT"CUL
M_PH]:_\*/FO_"CYK_PJZ8   K6D  *!N  "1;0  A&T  'AM  !L;@  87
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M!"F$_P2J=   GGL  (YZ  " >@  ='L  &A^  !=@0  4H4  $F)  !!C
M.9 % #61#P SDA< ,I(A #&2*0 PDS( +I,Z "V300 LDTH *Y12 "J47  H
ME&< )Y1S 264@@$DE),!(I.D 2&3MP$@D\\!(9+L 2"0^@(@C_\"((__ B"/
M_P*D?   EX   (=_  ![@   ;H(  &*%  !7B0  38X  $*2   ZE@  ,ID
M "J<"0 HG1$ )IT9 "6=(@ DGBH (YXR "*>.@ AGD( ()Y+ !^?50 >GV
M')]M !N??  :GXT &)^? !>?L@ 6G\D %I[H !:<]P 6F_\!%YO_ 1>;_P&=
M@P  CX8  (*&  !TAP  9XL  %N/  !0DP  1I@  #R<   SH   *Z,  ".F
M   <J L &JD1 !BI&  7J2$ %JHI !6J,0 4JCD $ZI# !.K30 2JU@ $:ME
M !"K=  .JX8 #JN9  VKK  ,J\$ #*K?  RI\@ -J/P #:C_  VH_P"6B@
MB8P  'J-  !LD0  8)4  %2:  !)GP  /Z,  #6G   KJ@  (ZX  !NP   4
MLP$ #[4*  VV$  ,MA8 "[8?  JV)P )MB\ "+8Y  >W0P &MT\ !+=;  .W
M:@ "MWL  +>.  "WH0  MK0  +;+  "VY0  M?$  +7W  "U]P"/D0  @90
M '*7  !EG   6*$  $RF  !!JP  -Z\  "RR   CM0  &K@  !.[   .O0
M"< %  /!#0  P1$  ,$7  #"'@  PB8  ,(O  ##.0  Q$0  ,10  #$7@
MQ6\  ,6!  #%E0  Q:@  ,6\  #$T0  Q.8  ,3N  #$[@"&F   >9X  &NC
M  !=J0  4*X  $2S   WM@  ++D  "*\   9OP  $<(   S%   &R    ,L
M  #,!P  S T  ,T1  #-%@  SAT  ,\D  #0+0  TC@  -1$  #44@  U6$
M -5S  #6AP  UIL  -:M  #7OP  V,X  -C=  #8W0![H   ;J8  &"M  !3
MLP  1;@  #B\   KOP  (<(  !?&   0R0  "LP   +0    U    -<   #8
M    V@4  -L+  #<#@  WA,  -\9  #A(0  XRH  .4V  #G0P  YU,  .AD
M  #I=P  Z8P  .J?  #JK@  ZKH  .K#  #JPP!PJ   8J\  %6V  !'O
M.<   "S$   @R   %LP   [0   'U    -D   #=    X0   .,   #D
MY@   .<!  #I!P  ZPP  .P0  #N%0  \!T  /,G  #V,P  ]T,  /A4  #Y
M9@  ^7H  /J.  #ZG@  ^ZD  /NP  #[L #_"QL _P<9 /\ &0#_ !P _P E
M /\ ,@#_ #\ _P!+ /\ 5P#_ &( _P!K /\ <P#] 'L ^P"" /H B #X (T
M]P"2 /8 F #U )T ] "B /, J0#Q +  [P"X .X PP#L -$ ZP#F .D \P#H
M /X Z #_ .@ _P#H /\ Z #_ .@ _P#_#A@ _PH5 /\!% #_ !@ _P B /\
M+@#_ #L _P!' /\ 4P#] %X ^@!G /< ;P#U '< \P!^ /( A #P (D [P"/
M .X E #L )H ZP"? .D I0#H *P Y@"T .0 OP#C ,P X0#B -\ \ #> /L
MW@#_ -T _P#= /\ W #_ -P _P#_$!, _PT1 /\&$ #_ A4 _P > /\ *0#_
M #8 _P!" /H 3@#T %D \0!B .X :P#L '( Z@!Y .@ ?P#G (4 Y0"+ .0
MD #B )8 X0"< -\ H@#= *D V@"Q -@ NP#5 ,@ T@#= -$ [0#0 /D SP#_
M ,X _P#- /\ S0#_ ,T _P#_$0\ _PX- /\,#0#_"Q( _P<9 /\") #_ #
M]@ \ .\ 20#J %, YP!= .0 9@#A &T WP!T -T >P#; ($ V0"& -8 C #4
M )( T@"8 -  G@#. *8 S "N ,H N #( ,0 Q@#7 ,4 Z@## /< P@#_ ,$!
M_P#  O\ P +_ , "_P#_% L _Q & /\0"0#_$ X _PX4 /\*'@#U!BD ZP0V
M .,#0@#? TX VP17 -8$8 #3!&@ T 1O ,X%=@#,!7P R@6" ,D%B #'!8X
MQ@64 ,0%FP#"!:, P :K +X&M0"]!L( NPC4 +H)Z0"W"_@ M0S_ +0,_P"T
M#/\ M S_ +0,_P#_%P0 _Q0  /\6 P#_% D _Q$. /(.%0#H#"$ W@HN -8+
M.P#0#$< S Q1 ,D,6@#&#6( Q UJ ,(-<0# #7< OPU] +T.@P"\#HH N@Z1
M +D.F "W#J  M@ZI +0/M "R#\$ L1#4 *X1ZP"K$OH J1+_ *@3_P"G$_\
MIQ/_ *<3_P#_&@  _QL  /D;  #K&0  Y10& .40#@#9#A< SQ$F ,@2- #$
M$T  OQ1+ +P45 "Y%5T MQ5D +45:P"T%7$ LA5X +$6?@"O%H4 KA:, *P6
ME "K%YP J1>F *<8L "F&+T I!C/ *(:YP"?&O< G1O_ 9P;_P&<&_\!FQO_
M 9L;_P'_'0  ]R$  .@D  #=)0  U"$! ,\;" #*%Q$ PAH@ +P<+0"W'3H
MLQY% + >3P"M'E< JQY? *D?9@"H'VP IA]S *4?>0"C'X  HA^' * @CP"?
M()@ G2"B )L@K &:(;D!F"'* 98BY &4(_4!DB/_ 9$C_P&0(_\!D"/_ 9 C
M_P'_(@  ZRD  -TN  #/+P  QRT  ,$G P"](@T MB,: + E* "L)C0 J"9
M *4G20"B)U( H"=: )XG80"<)V< FR=M )DG= "8)WL!EB>" 94GBP&3)Y0!
MD2B> 9 HJ0&.*+4"C2G& HLIWP*)*O("ARK_ H8J_P*&*O\"ABK_ H8J_P+T
M*   XS$  -$V  #%.   O#8  +8P  "R*PD JRP4 *8M(@"B+B\ GBXZ )LN
M1 "8+TT EB]5 )0N7 "2+F( D"YI 8\N;P&-+G8!C"Y^ 8HNA@*(+H\"ARZ:
M H4OI0.#+[(#@B_" X$PV@-_,.\#?3'^ WTQ_P-\,?\#?#'_ WPQ_P/M+P
MVS<  ,D]  "^/@  LSP  *PX  "G,P0 HC(1 )TT'0"9-2H E34U )(U0 "/
M-4D C350 (LU5P")-5X!AS5D 84T:P&$-'("@C1Y H T@@)^-(L#?326 WLU
MH01Y-:X$>#6^!7<VU 5V-NT%=#?\!70W_P1T-_\$=#?_!'0W_P3G-0  TCT
M ,-"  "X1   K$(  *0^  "?.0  FC@. )0Z&0"0.B8 C3LQ (H[.P"'.T0
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M"&!$R@A@1.8(7T7X!U]%_P=@1?\&8$3_!F!$_P;600  PTD  +9.  "G3P
MFTT  ))+  ",1P  A4<$ (!'$ !\2!H >$@F '5), !S23H <$E" &Y)20%L
M2% !:DA6 6A(70)F2&0"94AL V-(=01A1W\%8$>*!EY(EP==2*4(6TBT"%M(
MQPE:2.0(6DGV"%I)_P=:2/\&6DC_!EI(_P;110  OTP  +)2  "C40  EU
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M"$Q3_P=,4_\'35/_!DU3_P;%3@  ME8  *=:  "860  BU@  (%7  !W5
M<%4  &I6!@!F5Q  8E<: &!8) !=6"X 6UDW %E9/P!7648 5EE- 5195 %3
M65L"45EC D]8; -.6'8$3%B"!4I8CP9)6)X'2%BN"$=8P A'6-T(1UCR"$=7
M_P=(5_\'2%?_!DA7_P;!40  LED  *-<  "46P  AUL  'U:  !R6   :UD
M &5: P!@6PX 75P7 %I<(0!872L 5ETT %1>/ !37D0 45Y+ 5!>4@%.7ED"
M3%YA DM=:@-)770$1UV !45=C09$79P'0UVL!T)=O@A"7=H(0ESQ!T)<_@=#
M6_\&0UO_!D-;_P:]50  KUT  )]?  "07@  @UX  'A=  !M7   95T  %]?
M  !:8 P 5V$4 %5B'@!28B@ 46,Q $]C.0!.8T$ 3&-( $MC3P%)8U8!1V->
M D5C9P)$8W$#0F-]!$!BBP4_8IH&/F*J!CUBO <\8M8'/6'O!CUA_08^8/\&
M/F#_!CY@_P:Y60  JV$  )IA  "+80  ?V$  '1A  !I80  7V(  %ED  !4
M9@D 46<1 $YG&@!,:"0 2VDM $EI-@!(:3X 1FI% $5J3 !#:E0!0FI< 4!I
M90(^:6\"/&E[ SMIB00Y:9@%.&BH!3=HN@4W:=,%-VCN!3=G_ 4X9O\%.&;_
M!3AF_P6T7@  IV4  )5E  "&9   >F4  &]E  !D9@  66@  %)J  !-; 0
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M ":"?P$E@H\!)(*@ 2."L@$B@LD!(H'G 2)_]P$B?O\"(GW_ B)]_P*E<0
MDW$  (-Q  !V<0  ;'(  &!U  !6>   3'P  $.    [@P  ,X8  "V)"@ J
MBA$ *8L9 ">+(@ FBRH )8PQ "2,.0 CC$( (HU* "&-5  @C5X 'XUK !V-
M>0 <C8H &XV< !F-K@ 8C,0 &(SC !F*]0 9B?\!&8C_ 1F(_P&==P  C'8
M 'UV  !R=P  97D  %I\  !0@   1H0  #R)   TC   +9   "63 @ ?E0P
M'982 !R6&@ ;ER( &I<J !F7,@ 8F#H %YA# !:830 5F%@ %)AD !.8<P 1
MF(0 $)B6 !"8J0 .F+\ #I?=  ^6\@ 0E?P $)3_ !"4_P"5?0  A7P  'A\
M  !K?@  7X$  %2&  !*B@  0(\  #:3   MEP  )IH  !Z=   7H , $J(,
M !"C$@ 0HQD #Z,A  ZD*0 .I#$ #:0Z  RD10 +I%  "J1<  FD:@ 'I'L
M!J..  2CH0 "H[0  Z++  .BY@ #H?,  Z'[  .A^P"-@P  ?X(  '&$  !D
MAP  6(P  $V1  !"E@  .)H  "^>   FH@  'J4  !>H   1JP  #*X'  >O
M#0 #KQ(  J\9  &O(0  KRD  + R  "P/   L$<  +!3  "P80  L'$  +"#
M  "OEP  KZH  *^_  "NV0  KNL  *[T  "N] "'B0  >(H  &J.  !=DP
M49@  $6=   [H@  ,*8  ">J   >K@  %K$  !"T   +M@  !;D#  "Z"@
MN@X  +H3  "[&0  NR$  +PH  "\,0  O3P  +Y(  "^5@  OF4  +YW  "^
MC   OI\  +VS  "^QP  OMX  +WK  "]ZP!_D@  <)4  &*:  !5GP  2:4
M #VK   RKP  *+0  !ZV   5N0  #KP   F_   "P@   ,0   #%!   Q@H
M ,8.  #'$@  R!@  ,D?  #*)P  S#   ,X\  #.20  SUD  ,]J  #/?@
MSY,  ,^F  #/N   S\@  ,_;  #/VP!WG   :*$  %NG  !.K@  0;0  #2W
M   HN@  ';T  !/    -Q   !L<   #*    S@   -    #1    T@(  -,(
M  #5#   UA   -D5  #;'   W20  . O  #B/   XTL  .1<  #D;P  Y8,
M .68  #EJ0  Y;8  .7#  #EPP!LI0  7ZP  %&R  !$N0  -;P  "C    <
MQ   $L@   S+   #SP   -,   #8    W    -\   #?    X0   .,   #D
M P  Y@@  .@-  #I$0  [!@  .XB  #Q+@  \SP  /1-  #U7P  ]G,  />'
M  #WF0  ^*4  /BP  #XL #_ Q< _P 5 /\ %0#_ !@ _P C /\ +P#_ #P
M_P!( /\ 5 #_ %X _P!G /T ;P#[ '8 ^0!] /@ @P#V (@ ]0". /0 DP#R
M )@ \0"> /  I #N *L [0"S .L O0#J ,L Z #A .< \0#F /T Y0#_ .0
M_P#D /\ Y #_ .0 _P#_!Q, _P 1 /\ $0#_ !4 _P ? /\ *P#_ #< _P!$
M /X 3P#Z %H ]P!C /0 :P#R '( \ !Y .\ ?P#M (0 ZP"* .H CP#H )0
MYP": .4 H #D *< X@"O .  N0#> ,8 W #: -H [ #8 /D U@#_ -8 _P#7
M /\ V #_ -@ _P#_"A  _P,. /\ #0#_ !( _P : /\ )@#\ #( ]P _ /0
M2@#Q %4 [0!> .H 9@#H &X Y0!T ., >@#B (  X "% -X BP#< )  VP"6
M -@ G #5 *, TP"K -$ M0#. ,$ S #1 ,L YP#) /4 R #_ ,@ _P#( /\
MR #_ ,@ _P#_# P _P8( /\""@#_  \ _P 5 /P ( #Q "P [  Y .D 10#E
M $\ X0!9 -X 80#; &@ UP!O -0 =0#2 'L T "  ,X A@#, (P RP"2 ,D
MF #' *  Q0"H ,, L0#! +P OP#+ +T XP"\ /( NP#] +L _P"Z /\ N@#_
M +H _P#_#@4 _PD  /\)!0#_!@L _P$0 /  &0#F "4 X0 R -P /P#6 $D
MT0!3 ,X 6P#+ &, R !J ,8 < #% '8 PP![ ,$ @0#  (< O@". +P E "[
M )P N0"D +< K@"U +D LP#( +$ WP"P >\ KP'[ *X"_P"M _\ K0/_ *T#
M_P#_$   _PX  /\-  #V"P, \@<* .(!$0#; AT T@,K ,P#-P#(!$, Q 1-
M ,$$5@"^!5T O 5D +H%:P"X!7$ MP5V +4%? "S!H, L@:) + &D0"O!YD
MK0>A *L'JP"I"+< J G& *8*W0"E"_  HPS] *(-_P"A#?\ H0W_ * -_P#_
M$0  _!(  .P3  #B$P  VP\# -8)"P#."!0 Q@HB , ,, "\#3P N U& +4-
M3P"R#E< L Y? *X.90"M#FL JPYQ *H.> "H#GX IP^% *4/C0"D#Y8 HA"?
M * 0J0"?$+4 G1'% )L1W@"9$O$ EQ/_ )84_P"5%/\ E13_ )04_P#_%0
M[1L  . ?  #2'P  R1L  ,04!0#!$ X NA(; +03*0"P%#4 K!5  *D520"F
M%5( I!99 *(68 "A%F8 GQ9L )X6<@"<%GD FQ>  )D7B "8%Y$ EAB; )08
MI@"3&;( D1G! ) :V "-&^X BQS] (H<_P"*'/\ B1S_ (D<_P#T'0  Y"4
M -,I  #'*@  O"8  +8@  "T&0L KAH5 *@<(P"D'2\ H1XZ )X>1 ";'DP
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M G PR0)O,.4";C'W FTQ_P)M,?\";3'_ FTQ_P+?,@  R3D  +L^  "L/0
MH3H  )HW  "5,P  D#$* (PQ% "',B  A#,K ($S-0!_,SX ?3-& 'LS30!Y
M,U0 =S-: '8S80!T,V<!<C1O 7$T=P%O-($!;C2, FPTF )J-:4":36S V@U
MQ@-G-N(#9C;U V8V_P)F-O\"9C;_ F8V_P+8-P  Q#X  +5"  "F00  FS\
M ),\  "-.   B#8' (0W$0" -QP ?#@G 'HX,0!W.3H =3E" ',Y20!Q.5
M<#E7 &XY70!L.60!:SEK 6DY= %H.7X"9CF) F0YE0-C.J(#8CJQ V$ZPP-@
M.^ $7SOS U\[_P-?._\#7SO_ E\[_P+1.P  P$(  +!%  "A1   E4,  (U
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M!%1#_@-40_\#5$/_ U1#_P/(0@  N$D  *=+  "82@  C4D  (-'  !]0P
M=D,  '%$"@!M1!( :D4= &=%)P!D13  8D4X &!%/P!?14< 745- %M%5 !:
M1EL!649C 5=&; %61G8"5$:! U-&C@-21YP$4$>K!%!'O01/1]8%3T?O!$]'
M_01/1_\#3T?_ U!'_P/$10  M4T  *--  "53   B4L  ']*  !X1@  <4<
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M T)1_P.Z3P  JE0  )A4  ")5   ?5,  '-3  !I40  8E(  %Q3  !85 H
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M 35C@0$S8Y$",F.A C%CLP(Q8\@",6+G C%A^ (Q8?\",F#_ C)@_P*N7
MFUT  (I=  !\70  <%T  &9=  !<7@  4F   $QB  !%90  068* #YG$0 \
M:!H .V@B #EI*P X:3( -VHZ #9J00 U:DD -&I2 #-J6P Q:F4 ,&IP 2YJ
M?@$M:HX!+&J? 2MJL $J:L8!*FGE 2IH]@(K9_\"*V?_ BMG_P*I80  E6
M (1@  !W8   ;&$  &)A  !88P  3F8  $=H  ! :P  .FX% #9O#@ T<!4
M,W > #)Q)@ P<2X +W$U "YR/0 M<D4 +')- "MR5P J<F$ *7)M "=R>P F
M<HL )'*< 2-RK@$C<L,!(W'B 2-P] $C;_\!(V[_ 2-N_P&A90  CF0  ']D
M  !R9   :&4  %YF  !4:0  26P  $)O   [<@  -'4  "YX"@ K>1$ *GD8
M "EZ(0 G>B@ )GHP "5[.  D>T  (WM( ")[4@ A>UP ('MH !]\=@ =?(8
M''N8 !M[J@ :>[\ &GO> !IY\@ ;>/X &W?_ 1MW_P&9:0  B&D  'EI  !M
M:0  8VH  %EL  !/;P  17,  #UW   U>@  +GT  ">! P B@PT ((02 !^$
M&@ =A"( '(4J !N%,0 :A3D &85" !B&3  7AE8 %H9C !6&<0 4AH$ $H:3
M !&&I@ 1A;L $(76 !&#[P 1@OL $H+_ !*!_P"1;@  @6T  '1N  !I;@
M77   %-S  !)=P  0'P  #>    O@P  )X<  "&*   :C08 %8\- !.0$P 2
MD!H $I B !&0*@ 0D3( $)$[  ^11  .D4\ #9%<  R1:@ +D7H "I&-  B0
MGP 'D+, !X_)  >/Y@ 'CO0 "(W\  B-_P")<P  >W,  &]S  !C=0  5W@
M $U]  !#@0  .88  #"*   HC@  (9$  !J5   3EP  #IH(  N<#@ )G!,
M")P:  ><(@ &G"H !)PS  .</0 "G4@  )U4  "=8@  G'(  )R$  "<EP
MFZH  )N_  ":VP  FNP  )KU  "9^ "">0  =GD  &AZ  !<?@  48(  $:'
M   \C   ,I$  "F5   AF0  &9T  !*@   .HP  ":8%  .G#   IQ   *<5
M  "H'   J",  *@K  "I-   J3\  *E+  "I60  J6@  *EZ  "IC@  J:$
M *BU  "HRP  I^0  *?O  "G\P!]@   ;X$  &&$  !5B0  28X  #Z4   T
MF0  *IX  "&B   9I@  $JD   VL   'KP   +(   "S!P  LPP  +,0  "T
M%0  M!L  +4B  "V*P  MS4  +=   "X3@  N%T  +AN  "X@@  N)<  +BJ
M  "WO@  M](  +?F  "WZ@!VB   9XL  %J0  !.E@  0IP  #>B   LIP
M(JL  !FO   1LP  "[8   2Y    O    +X   "^    OP8  , +  #!#P
MPA,  ,,9  #$(   Q2D  ,<T  #(0@  R5$  ,EB  #)=0  R8H  ,F?  #*
ML0  RL$  ,G1  #)V0!NDP  8)@  %.>  !&I   .JL  "^P   DM0  &;@
M !"\   *OP   <$   #$    R    ,H   #*    S    ,T#  #."   T T
M -$0  #3%@  UAX  -HH  #=-   WD,  -]4  #?9P  X'P  ."1  #@I
MX+(  ."^  #@PP!FGP  6:8  $RM   _M   ,K@  "2\   8OP  $,,   C'
M    R@   ,T   #1    U0   -@   #9    VP   -T   #?    X00  .,*
M  #E#@  YQ,  .H<  #M)P  \#4  /%&  #R6   \VL  /.   #TE   ]*,
M /2N  #TL@#_ !, _P 1 /\ $0#_ !4 _P ? /\ + #_ #D _P!% /\ 4 #_
M %H _@!C /L :P#Y '( ]P!X /4 ?@#T (0 \@") /$ C@#P ), [@"9 .T
MGP#L *8 Z@"N .@ N #F ,4 Y0#; ., [0#B /L X@#_ .$ _P#A /\ X0#_
M .$ _P#_ !  _P . /\ #0#_ !( _P ; /\ * #_ #0 _@!! /L 3 #W %8
M] !? /$ 9@#O &T [ !T .H >@#I '\ YP"% .8 B@#E (\ XP"5 .$ FP#@
M *( W@"J -L M #9 ,  U@#0 -, Z #2 /< T0#_ -$ _P#0 /\ T #_ -
M_P#_  T _P ) /\ "@#_  \ _P 6 /L (@#W "\ ]  [ /  1P#M %$ Z0!:
M .4 8@#B &D X !O -X =0#< 'H V@"  -@ A0#5 (L TP"1 -$ EP#/ )X
MS0"F ,L KP#) +H QP#) ,4 X@#$ /( PP#^ ,( _P#! /\ P@#_ ,( _P#_
M P8 _P ! /\ !@#_  P ^0 1 /$ '0#K "D YP V ., 00#? $L VP!4 -4
M7 #2 &, SP!J ,T < #+ '4 R0![ ,@ @ #& (8 Q0", ,, DP#! )H OP"B
M +T JP"[ +8 N0#$ +< V@"V .T M #Z +0 _P"T /\ M #_ +0 _P#_!
M_P   /\   #_  8 [  - .4 %@#> "( UP O -$ .P#- $4 R@!. ,8 5P#$
M %X P0!D +\ :@"] '  O !U +H >P"Y ($ MP"' +4 C@"S )4 L@"> +
MIP"N +( K "_ *H T0"H .@ J #W *< _P"G /\ I@#_ *8 _P#_!@  _P4
M /$#  #H    X0 ' -4 $ #- !L QP G ,, ,P"_ #X O !( +D 40"V %@
MM !? +( 90"P &H KP!P *T =@"L 'P J@"" *D B0"G )$ I0": *, I "A
M *X H "[ )X!S0"= N8 G 3T )L$_P":!?\ F@7_ )D%_P#_"@  \0X  .00
M  #9#P  S@L  ,@#"P#" !, O (? +<#+ "S!#< L 5" *T&2@"J!E( J =9
M *8'7P"E!V4 HP=K *((<0"@"'< GPA^ )T(A0";"8X F@F7 )@*H0"6"JP
ME0NZ ),+S "2#.4 D WV (\._P".#O\ C@[_ (T._P#V$0  YA<  -8;  #'
M&0  OA4  +D0  "W"@T L0L7 *P-) "H#C  I0X[ *(.1 "?#TP G0]3 )L/
M6@":#V  F!!F )<0; "5$'( DQ!Y )(0@0"0$(H CQ&4 (T1GP"+$:H BA*X
M (@2RP"&$^8 A13W (,5_P"#%?\ @A7_ ((5_P#M&@  W"$  ,HE  "[(@
ML1\  *L:  "I% 8 I1(1 * 4'@"<%2H F14U )86/@"4%D< DA9. ) 650".
M%UL C!=A (L79P")%VT B!=T (88? "%&(8 @QF0 ($9FP" &J< ?AJU 'T;
MQP!\'.( >AWU 'D=_P!X'?\ >!W_ '@=_P#E(@  T"D  +\L  "P*@  IR<
M * C  "='P  FAH. )4<& "1'20 CAXO (P>.0")'D$ AQ]) (4?4 "#'U8
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M 5\P_0%?,/\!7S#_ 5\P_P'--   O#L  *DZ  ";.@  D#@  (DU  "#,@
M?S ! 'LO#@!W,!8 =# A '$Q*P!O,30 ;3$\ &LQ0P!J,4H :#)0 &<R5P!E
M,ET 9#)E &(R;0!A,W< 7S." 5XSC@%=-)P!6S2J 5HUNP%:-=(!637M 5DU
M_ %8-?\!6#7_ 5DU_P'(.   MSX  *0^  "6/0  BSP  (,Z  !]-P  >#0
M '0T"P!P-1, ;34= &HU)P!H-C  9C8X &0V/P!C-D8 839- & V4P!>-UH
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M/0X 83X7 %X^(0!</BD 6CXQ %@^.0!7/D  53]& %0_30!3/U4 4D!< %!
M90!/0&\!3D%Z 4U!AP%+098!2D&E DE"M0))0LL"24+H DE"^0))0?\"24'_
M 4E!_P&]0P  JD4  )A%  "*10  ?T4  '9#  !O0   :$   &-! 0!?00T
M7$$4 %E"'0!70B8 54(N %-"-@!10CT 3T)# $]#2P!.0U( 341: $Q$8P!*
M1&T!245X 4A%A0%'190!146C D5&M )$1LD"1$;G D1%^ )$1?\"147_ D5%
M_P&Z1@  ID@  )1(  "&2   >T<  ')&  !J0@  8T,  %Y$  !:10L 5D42
M %1&&P!11B, 3T8K $Y&,P!,1SH 2T=! $I'20!)2%  2$A8 $=(80!&26L
M1$EV 4-)@P%"29(!04FB D!)LP(_2L<"/TKE C])]P) 2?\"0$C_ D!(_P&V
M20  HDH  )%*  "#2@  =TH  &Y)  !E10  7D<  %E(  !520@ 44H0 $]*
M& !,2B$ 2DLI $E+,0!'2S@ 1DP_ $5,1@!$3$X 0TU6 $)-7P!!36@ 0$UT
M 3Y-@0$]39 !/$V@ 3M.L0(Z3L8".D[D CM-]@([3?\!.TS_ 3Q,_P&S30
MGDP  (U,  !_3   =$P  &I,  !@2@  64L  %1,  !0304 3$X. $E/%0!'
M3QX 14\F $10+@!"4#4 05 ] $!11  _44L /E%3 #U27  \4F8 .E)R #E2
M?P$X4HX!-U*> 392KP$U4L0!-5+B 392]0$V4?\!-E#_ 3=0_P&N3P  F4\
M (E/  ![3P  <$\  &9/  !<3@  5$\  $]1  !*4@$ 1E,, $-4$@!!5!L
M0%4C #Y5*P ]5C( /%8Z #M600 Z5DD .5=1 #A76@ V5V, -5=O #17? $S
M5XP!,5>< 3!7K0$P5\(!,%?@ 3!6] $Q5O\!,57_ 3%5_P&H4@  E5(  (12
M  !W4@  ;%(  &)2  !84P  3U0  $E6  !$5P  0%D( #U:$  [6A< .5L@
M #A;)P W7"\ -EPV #5</@ T7$8 ,UU. #%=5P P76$ +UUL "Y=>@ L78D
M*UV: 2I=JP$J7;\!*5W> 2I<\@$J6_X!*UO_ 2M:_P&C50  CU4  ']5  !R
M50  9U8  %Y6  !45P  3%D  $5;   _70  .E\$ #9@#0 T81, ,F(< #%B
M(P P8BL +V,R "YC.@ M8T( +&-* "ID4P I9%T *&1I "=D=@ F9(8 )627
M "1DJ0 C9+T (F3: "-C\0 C8OT!)&'_ 21A_P&<6   B5@  'I9  !N60
M8UD  %I:  !07   2%X  $%@   Z8P  -&8  "]H"@ L:1  *FD7 "EJ'P H
M:B8 )VHN "9K-0 E:ST )&M& "-K3P B;%D (&QE !]L<@ >;(( '6R4 !QL
MI@ ;:[H &FO4 !MJ[@ <:?P '&C_ !QH_P"57   @UP  '5<  !I70  7UT
M %9>  !,80  0V0  #QG   U:@  +VT  "AP!  C<@T (7(2 "!S&@ ?<R$
M'G,H !UT,  <=#@ &W1  !IT2@ 9=%0 %W5@ !9U;@ 5=7X %'60 !-TH@ 2
M=+8 $73/ !)S[  2<OH $W'_ !-Q_P".8   ?6   &]A  !E80  6V(  %%D
M  !(9P  /FL  #=N   P<0  *74  ")X   <>P< %WT. !9]$P 5?1L %'XB
M !-^*@ 2?C$ $7XZ !%^1  0?TX #W]:  Y_:  -?W@ #'^*  M^G0 *?K
M"7W&  I]Y  *?/0 "WO]  MZ_P"&90  =V4  &IE  !A9@  5F@  $QK  !"
M;P  .7,  #%W   J>@  (WX  !R!   5A   $(<(  V)#@ ,B10 #(D;  N)
M(P *B2L "8DS  B)/0 &B4@ !8E4  2)80 "B7$  8F#  ")E@  B*D  (>^
M  "'V@  ANP  (;U  "&^@!^:@  <6H  &=K  !;;   4'   $9T   \>
M,WT  "J!   CA0  '(@  !6,   0CP  #)(&  :3#  "DQ$  )06  "4'0
ME"0  )4L  "5-0  E4   )5,  "660  EFD  )5Z  "5C@  E*$  )2U  "3
MS   DN8  )+R  "2]P!X<   ;7   &!R  !4=0  27D  #]^   U@P  +(@
M ".-   ;D0  %)0   ^7   *F@  !)T#  ">"0  GPX  )\2  "@%P  H!T
M *$E  "B+0  HC<  *-#  "C4   HU\  *-Q  "CA   HID  **M  "AP@
MH=P  *'K  "@\@!S=@  9G<  %E[  !-@   0H4  #B+   ND   ))4  !N:
M   4G@  #J$   FD   "IP   *H   "K!   JPH  *P-  "M$0  K18  *X<
M  "O)   L"T  +$Y  "Q1@  LE4  +)F  "R>0  LHX  +&C  "RMP  L<H
M +'@  "QZ0!L?@  7X(  %*'  !&C0  .Y,  #"9   FG@  '*,  !.G   -
MJP  !ZX   "R    M0   +<   "X    N0(  +D(  "Z#   NQ   +P4  "]
M&P  OR,  ,$M  #".@  PDD  ,-:  ##;   Q((  ,27  #$JP  Q+P  ,3+
M  #$V@!EB0  6(X  $N5   _FP  ,Z(  "BH   =K0  %+$   VV   &N0
M +P   "_    PP   ,0   #%    Q@   ,<   #)!   R@D  ,L-  #-$0
MSQ@  -(A  #5+0  UCP  -A-  #97P  VG,  -J*  #;G@  VZX  -NZ  #<
MPP!>E@  49P  $2C   XJ@  ++$  ""W   5NP  #;X   3"    Q0   ,D
M  #-    T    -(   #2    U0   -8   #9    VP   -X%  #@"@  X@\
M .46  #H(   ["T  .T^  #M40  [F4  .]Z  #OCP  \)\  /"K  #PLP#_
M !  _P . /\ #@#_ !( _P = /\ *0#_ #4 _P!! /\ 30#^ %8 ^P!? /@
M9@#V &T ] !T /( >0#Q '\ \ "$ .X B0#M (\ ZP"5 .H FP#H *( Y@"J
M .4 LP#C ,  X0#2 .  Z@#? /D W0#_ -T _P#= /\ W@#_ -X _P#_  T
M_P * /\ "0#_  \ _P 8 /\ ) #^ #$ ^P ] /@ 2 #T %( \ !: .T 8@#K
M &D Z0!O .< =0#E 'H XP!_ .( A0#@ (H W@"0 -P E@#: )T V "E -4
MKP#2 +H T #* ,X XP#- /0 RP#_ ,L _P#+ /\ RP#_ ,L _P#_  @ _P #
M /\ !0#_  P _  4 /< 'P#R "L [P W .L 0@#G $P Y !5 .  70#= &0
MV@!J -@ < #5 '4 T@!Z -  @ #/ (4 S0"+ ,L D@#) )D QP"A ,4 J@##
M +4 P0## +\ V@"^ .X O0#\ +P _P"\ /\ O #_ +P _P#_    _P   /\
M  #Y  < \0 0 .H &@#D "4 WP Q -L / #7 $< T@!0 ,X 5P#+ %X R0!E
M ,8 :@#% '  PP!U ,$ >@#  (  O@"& +P C0"Z )0 N0"< +< I0"U +
MLP"] +$ SP"O .@ K@#X *X _P"M /\ K0#_ *T _P#_    _P   /T   #N
M  $ XP , -H % #1 !\ S  K ,@ -@#% $  P@!* +\ 4@"\ %D N@!? +@
M90"V &H M !O +, =0"Q 'H L "! *X B "M (\ JP"8 *D H0"G *L I0"X
M *, R "B .( H0#S *  _@"@ /\ H #_ *  _P#_    ]@   .H   #@
MTP & ,D #P#" !@ O0 D +D +P"V #H M !# +$ 3 "N %, K !9 *H 7P"I
M &0 IP!J *8 ;P"D '4 HP![ *$ @@"@ (H G@"3 )P G0": *< F "T )8
MPP"5 -P E #O ), ^P"3 /\ DP#_ )( _P#Y!0  Z@L  -P-  #+"@  P@4
M +P "@"V !$ L0 < *X * "J #, IP ] *0 10"B $T H !3 )X 60"< %\
MFP!D )H :@"8 '  EP!V )4 ?@"3 (8 D@&/ ) !F0". J0 C *Q (L#P ")
M!=8 B ;M (@'^@"'"/\ A@C_ (8(_P#O#P  WA0  ,H5  "\$@  LQ   *X,
M  "K!@T IP,5 *(%( "?!RP G @V )D(/P"7"4< E0E. ),)5 "1"EH D I?
M (X*90"-"FL BPIR (H+>0"("X( APN, (4,EP"##*( @0VP ( -P !_#=@
M?0[O 'P/_0![#_\ >Q#_ 'L0_P#F%P  T1X  +T=  "O'   IAD  *$5  ">
M$ 0 G0T/ )@.&0"4#B4 D0\O (\0.0",$$$ BA!( (@03P"'$%4 A1!; (01
M80""$6< @!%N '\1=0!]$7X ?!*( 'H2E !X$J  =Q.N '43O@!T%-4 <Q7N
M '$6_0!Q%O\ <1;_ ' 6_P#<'P  QB4  +,E  "E(P  G"$  )8>  "2&0
MD10+ (T4% ")%1\ AA8I (,6,P"!%SP @!=# 'X72@!\%U  >A=6 'D87 !W
M&&( =AAI '08<0!S&7H <1F$ &\:D !N&IT ;!NK &L<NP!J'-  :1WL &@>
M^P!H'O\ 9Q[_ &<>_P#1)@  O2H  *LJ  "=*@  DR@  (TE  "((@  AAT&
M (,;$ !_'!H ?!TD 'H=+@!W'C8 =AX^ '0>10!R'TL <1]1 &\?6 !N'UX
M;!]E &L@;0!I('8 :"&! &8AC0!E(IH 8R*H &(CN !A(\T 8"3I & D^@!?
M)/\ 7R3_ %\D_P#*+   MB\  *0O  "6+P  C"T  (4J  " *   ?20  'HB
M#0!V(Q4 <R,@ '$D*0!O)#( ;20Z &LE00!J)4< :"5- &8E5 !E)5H 9"9A
M &(F:0!A)G( 7R=] %XGB@!=*)< 6RFE %HIM0!:*LH 62KG %@J^ !8*O\
M6"K_ %@J_P#%,0  KS,  )XS  "0,P  AC(  '\O  !Y+0  =2H  '(H"@!O
M*!( :RD; &DI)0!G*BT 92HU &,J/0!B*D, 8"I* %\K4 !>*U< 7"M> %LL
M9@!9+&\ 6"UZ %<MAP!6+I4 5"ZC %,OLP!3+\< 4B_E %(O]P!2+_\ 4B__
M %(O_P#!-@  JC8  )DV  "+-@  @34  'DS  !S,0  ;R\  &LN!@!H+1
M9"X8 &(N(0!@+RH 7B\Q %PO.0!;+T  62]& %@O30!7,%, 5C!; %0Q8P!3
M,6P 4C)W %$RA !/,Y( 3C.A $TSL0!--,4!3#3C 4PT]@!,-/\ 3#3_ $PS
M_P"[.0  ICD  )4Y  "'.0  ?#D  '0W  !N-   :3,  &4R @!A,@T 7C(4
M %PS'@!:,R8 6#,N %8S-0!5-#P 4S1# %(T2@!1-%  4#58 $XU8 !--FH
M3#9U $LW@@!*-Y  23B? $@XL %'.,,!1SCA 4<X]0%'./\!1SC_ 4<X_P&W
M.P  HCP  )$\  "#/   >#P  ' Z  !J-P  9#8  & V  !<-@L 63<2 %8W
M&@!4-R, 4C<K % W,@!/.#D 33A  $PX1P!+.$X 2CE5 $DY7@!(.F@ 1SIS
M $8[@ !%.XX 1#R> $,\K@%"/,(!0CW? 4(\\P%"//\!0CS_ 4([_P&S/0
MGCX  (T^  !_/@  =3X  &P]  !F.@  8#D  %LZ  !7.@@ 4SL0 %$[& !.
M.R  3#LH $L[+P!)/#8 1SP] $<\1 !&/4L 13U3 $0^7 !#/F8 0C]Q $$_
M?@! /XT /T"< #Y K0$]0, !/4#= 3U \@$]0/\!/C__ 3X__P&N0   FD
M (E!  !\00  <4$  &A   !A/   6ST  %8^  !2/@4 3C\. $P_%0!)/QT
M1T E $9 + !$0#, 0T Z $)!0@!!04D 0$%1 #]"6@ ^0F, /4-O #Q#?  [
M0XL .D2; #E$JP$Y1+X!.$3; 3E$\0$Y0_X!.4/_ 3E#_P&J0@  ED,  (9#
M  !X0P  ;D,  &5#  !=0   5D   %%"  !-0@( 24,, $9#$@!$1!H 0D0B
M $%$*@ _13$ /D4X #U%/P \1D< .T9/ #I&5P Y1V$ .$=L #='>@ V2(D
M-4B9 #1(J@ T2+T ,TC9 #1(\  T1_T -$?_ #5&_P"F1   DD4  ()&  !U
M1@  :D8  &%%  !91   440  $Q&  !(1P  1$<* $%($  _21@ /4D@ #Q)
M)P Z2BX .4HV #A*/0 W2T0 -DM, #5+50 T3%\ ,TQJ #),=P Q3(8 ,$R7
M "]-J  N3;L +DW5 "Y,[P O3/T +TO_ #!+_P"A1P  CD@  'Y(  !Q2
M9DD  %U(  !52   3$D  $=*  !"2P  /TP& #M-#@ Y3A4 -TX= #9/)  U
M3RL ,T\S #)0.@ Q4$( ,%!* "]14@ N45P +5%G "Q1=0 K480 *E*5 "E2
MI@ I4KD *%+2 "E1[@ I4/P *E#_ "I/_P"<2@  B4H  'I+  !M2P  8TP
M %I,  !13   2$T  $-/   ]4   .5(" #53#  S5!( ,509 #!5(0 N52@
M+54O "Q6-P K5CX *E9& "E63P H5UD )U=D "97<@ E5X$ )%>2 "-7I  B
M5[< (E?/ ")7[  C5OH (U7_ "15_P"630  A$X  '5.  !I3@  7T\  %9/
M  !-4   15(  #]3   Y5@  ,U@  "]:"  K6P\ *EL5 "A<'0 G7"0 )EPK
M "5<,P D73H (UU# ")=3  A758 (%YA !]>;@ >7GX '5Z/ !Q>H0 ;7K0
M&EW, !M=Z0 ;7/D '%O_ !Q;_P"040  ?E$  '!1  !D4@  6U(  %)3  !*
M5   05<  #M9   U6P  +EX  "A@ P D8@P (F,1 "%C&  ?9"  'F0G !UD
M+@ <9#8 &V4^ !IE1P 995$ &&5= !=E:@ 697H %66+ !1EG@ 39;$ $F7(
M !)DYP 38_< %&+_ !1B_P")5   >%4  &M5  !@5@  5U8  $]7  !&60
M/5P  #9?   P8@  *60  "-G   =:@< &6P. !AL$P 6;1H %6TA !1M*0 4
M;3  $VTY !)N0@ 1;DP $&Y8  ]N90 .;G4 #6Z'  UNF@ ,;:T "VW"  ML
MX  ,:_, #6O]  UJ_P""60  <ED  &99  !<6@  5%H  $I<  !!7P  .6,
M #%F   J:0  )&P  !UO   7<@  $G4)  ]W#P .=Q0 #G<;  UW(P ,=RH
M"W<S  IW/  )=T< "'=2  =W7P %=V\ !'>   -WE  !=J<  ':[  %UU0 !
M=.L  G3V  )T_ ![70  ;5T  &)>  !97@  3F   $5C   \9P  ,VL  "MN
M   D<@  'G4  !=Y   2?   #7\&  F!#  %@1$  X$6  *!'0 !@20  ($M
M  ""-@  @D   (),  ""60  @F@  ()Y  ""C0  @:   ("T  " RP  ?^<
M '[R  !^^0!T8@  :&(  %YB  !39   26<  #]K   V<   +70  "5X   >
M?   %X   !&#   -A@  "(D$  *+"@  BPX  (L3  ",&   C!\  (TF  "-
M+P  CCD  (Y$  ".40  CF   (YQ  ".A0  CID  (VM  ",PP  C-\  (ON
M  "+]@!N:   9&<  %AI  !-;   0G$  #AV   O>P  )G\  !Z$   6B
M$(P   R/   &D@   )4   "6!P  EPP  )</  "8$P  F1@  )H?  ";)@
MFS   )P[  "<2   G%<  )QH  "<>P  G)   )NE  ";N@  FM   )KG  ":
M\0!J;0  7F\  %%R  !&=P  .WP  #&"   GAP  'HP  !:1   0E0  "ID
M  2<    H    *(   "C 0  HP8  *0+  "E#@  IA(  *<7  "H'@  JB8
M *LQ  "K/@  K$T  *Q=  "L<   K(4  *R;  "KKP  J\,  *O9  "JZ !D
M=0  5WD  $M^   _A   -(H  "F0   ?E@  %IL  !"?   )HP   :<   "J
M    K@   +    "P    L0   +(#  "T"   M0T  +80  "W%0  N1T  +LF
M  "\,P  O4$  +U2  "]9   OGD  +Z0  "]I   O;<  +W&  "]UP!<?P
M4(4  $2+   XD@  +)D  "&?   7I   $*D   FN    L@   +8   "Y
MO0   +\   "_    P    ,$   ##    Q 4  ,8*  #'#@  R1,  ,L<  #.
M)@  T#4  -%%  #25P  TFL  -."  #3EP  TZD  -*X  #2Q !5C   29,
M #V:   PH@  ):@  !JN   1M   ";D   "]    P0   ,0   #(    RP
M ,T   #-    SP   -    #2    U    -@   #:!@  W0P  . 1  #C&@
MYB<  .<X  #H2@  Z5T  .IR  #KB   ZYL  .RH  #LL@#_  T _P + /\
M"P#_ !  _P : /\ )@#_ #( _P ] /\ 2 #[ %( ^ !: /8 8@#S &D \0!O
M /  =0#N 'H [ !_ .L A #I (H Z "0 .8 E@#D )T X@"E .$ KP#? +L
MW0#+ -L Y@#9 /< V #_ -@ _P#7 /\ UP#_ -0 _P#_  @ _P $ /\ ! #_
M  T _P 5 /X (0#Z "P ]P X /0 0P#P $T [0!5 .H 70#G &0 Y !J .(
M< #@ '4 W@!Z -T ?P#; (4 V0"+ -4 D0#3 )D T0"@ ,\ J@#- +4 RP#$
M ,D W0#( /$ QP#_ ,8 _P#& /\ Q@#_ ,< _P#_    _P   /\   #_  H
M^  1 /$ ' #L "< Z0 R .8 /0#B $< W0!0 -D 6 #5 %\ T@!E -  :@#.
M '  S !U ,H >@#) '\ QP"% ,4 C ## )0 P0"< +\ I0"] +  NP"] +H
MT "X .L MP#[ +8 _P"V /\ M@#_ +8 _P#_    _P   /T   #S  4 Z0 .
M .$ %@#; "$ U0 M -$ -P#. $$ R@!* ,< 4@#$ %D P@!? ,  90"^ &H
MO !O +L = "Y 'H MP"  +8 AP"T (X L@"7 +  H "N *H K0"W *L R "I
M ., J #U *< _P"G /\ IP#_ *8 _P#_    _@   /$   #E    UP * ,T
M$0#' !P P@ F +\ ,0"\ #L N@!$ +< 3 "T %, L@!9 +$ 7P"O &0 K0!I
M *P ;P"J '0 J0!Z *< @0"F (D I "1 *( FP"@ *4 G@"R )T P0"; -H
MF@#O )D _0"8 /\ F #_ )@ _P#]    \    .$   #1    Q@ $ +T #0"W
M !4 LP @ +  *P"M #4 JP ^ *@ 1@"F $T I !4 *, 60"A %\ H !D )X
M:0"= &X FP!U )H >P"8 (, E@", )4 E@"3 *$ D0"M (\ NP"- ,\ C #I
M (L ^ ", /\ C #_ (P _P#S @  X@<  ,P'  "_!   MP   +$ " "K !
MIP 9 *0 ) "@ "X G@ W )P 0 ": $< F !. )8 5 "5 %D DP!> )( 9 "0
M &D CP!O (T =@"+ 'X B@"( (@ D@"& )T A0"I (, N "! ,H @ #E (
M]0!_ /\ ?P#_ '\ _P#H#0  T!   +X0  "Q#@  J T  *,(  "@ @P G  3
M )@ '0"5 "< D@ Q )  .0". 4$ C %( (H"3@") E0 AP)9 (8"7P"$ V0
M@P-K ($#<@" !'H ?@2$ 'T%C@![!9H >0:G '@&M0!V!\@ =0CC '4)] !T
M"O\ <PK_ ',*_P#=%0  Q!<  +$7  "E%@  G!,  )81  "4#00 DP@- (X'
M%0"+"2  B DJ (4*,P"#"SL @0M" ( +20!^"T\ ?0Q4 'L,6@!Z#&  > QG
M '<,;@!U#78 = V  '(-C !P#9D ;PZF &T.M0!L#LD :P_F &H0]P!I$/\
M:1#_ &D0_P#0'0  N1X  *@>  ";'0  DAL  (L9  "(%0  AQ$' (4.$ "!
M#QH ?A D 'L0+0!Y$#8 =Q$] '811 !T$4H <Q%0 '$15@!P$5P ;A)B &T2
M:@!K$G, :1-] &@3B0!F$Y8 912C &,5LP!B%<8 8A;C &$6]@!@%_\ 8!?_
M & 7_P#'(@  L",  )\D  "2(P  B2(  ((@  !^'0  ?!D  'H5#0!W%14
M=!8? '$6* !O%S  ;A<X &P7/P!K%T4 :1A+ &@840!F&%@ 91A> &,99@!B
M&6\ 8!EY %\:A0!=&Y( 7!NA %L<L !:',, 61W@ %@>] !8'O\ 6![_ %@>
M_P"_)P  J2@  )DH  "+*   @B<  'LE  !V(P  <R   '$<"0!N'!$ :QP:
M &D=(P!G'2P 91TS &,>.@!B'D$ 8!Y' %\>30!>'E0 7!]; %L?8@!9(&L
M6"!V %8A@@!5(9  5"*> %,BK@!2(\  42/= %$D\@!1)/\ 423_ %$C_P"Y
M*P  HRP  ),L  "&+0  ?"P  '0J  !O*   :R4  &DB!0!F(0X 8R(6 &$B
M'P!?(R< 72,O %PC-@!:(ST 621# %<D2@!6)%  5217 %,E7P!2)6@ 429S
M $\F?P!.)XT 32B< $PHK !+*;X 2RG: $HI\0!**?\ 2RG_ $LI_P"S+@
MGB\  (XP  "!,   =R\  &\N  !J*P  92H  &,G 0!?)PP 7"<3 %HG&P!8
M*"0 5B@K %4H,@!3*#D 4BE  % I1@!/*4T 3BE4 $TJ7 !,*F4 2BMP $DK
M? !(+(L 1RV: $8MJ@!%+KP 12[6 $4N[P!%+OX 12[_ $4M_P"N,0  FC(
M (DS  !\,P  <C,  &LQ  !E+P  8"T  %TL  !9+ D 5BP0 %0L& !2+"
M4"PH $XM+P!-+38 3"T\ $HM0P!)+4H 2"Y1 $<N60!&+V, 13!M $,P>@!"
M,8D 03&8 $$RJ ! ,KL /S+3 #\R[@! ,OT 0#+_ $ R_P"J,P  EC4  (8U
M  !Y-@  ;C4  &8U  !A,@  7#   %<P  !4, 8 43 . $XP%0!,,1T 2C$E
M $@Q+ !',3( 1C$Y $0Q0 !#,D< 0C)/ $$S5P! ,V  /S1K #XU>  ]-8<
M/#:6 #LVIP [-KD .C;1 #HV[0 [-OP .S;_ #LV_P"F-@  DC<  ((X  !U
M.   :S@  &,W  !=-@  5S,  %,T  !/- , 2S0, $DT$@!&-1H 134B $,U
M*0!!-2\ 0#4V #\V/0 ^-D0 /3=, #PW50 [.%X .CAI #DY=@ X.84 -SJ5
M #<ZI0 V.K@ -3K/ #8Z[  V.OL -CG_ #<Y_P"B.   CCD  'XZ  !R.P
M:#L  %\Z  !9.0  4S8  $XW  !*.   1C@* $0Y$ !!.1< /SD? #XY)@ \
M.2T .SHT #HZ.P Y.T( .#M* #<[4P V/%P -3QG #0]=  S/8, ,SZ3 #(^
MI  Q/K8 ,3[- #$^Z@ Q/OH ,CW_ #(]_P">.P  BSP  'L\  !N/0  9#T
M %P]  !5/   3CH  $D[  !%/   03T' #X]#@ \/14 .CX< #D^(P W/BH
M-C\Q #4_.  T/T  ,T!( #) 4  Q0%H ,$%E "]!<@ N0H$ +4*1 "U"H@ L
M0K4 *T++ "Q"Z0 L0OD +4'_ "U!_P"9/0  ASX  '<_  !K/P  84   %D_
M  !2/P  23X  $0_  ! 0   /$$$ #E"#0 W0A( -4,9 #-#(0 R0R@ ,40O
M #!$-@ O1#T +D5% "U%3@ L15@ *T9C "I&;P I1GX *$:/ "='H0 F1[,
M)D?) "9&YP G1O@ *$7_ "A%_P"50   @D$  '-"  !G0@  7D(  %5"  !.
M0@  14(  #]$   [10  -T8  #1'"@ Q2!  +T@6 "Y)'@ L224 *TDL "I)
M,P I2CH *$I" "=*2P F2U4 )4M@ "1+;0 C2WP (DN- "%,GP A3+$ ($S'
M "!+Y@ A2_< (DK_ ")*_P"00P  ?D0  &]$  !D10  6D4  %)%  !*1@
M04<  #Q(   W20  ,DL  "Y-!P K3@X *4X3 "=/&@ F3R$ )4\H "1/,  C
M4#< (E _ "%02  @4%( 'U%= !Y1:@ =47D '%&* !M1G  :4:\ &5'% !E1
MY  :4/8 &T__ !Q/_P"*1@  >4<  &M'  !@2   5D@  $Y(  !'20  /DL
M #E,   S3@  +E   "A3 @ D5 L (E40 "!5%@ ?5AX 'E8D !U6+  <5C,
M&U<[ !I71  95TX &%=9 !=89@ 56'4 %%B' !18F@ 35ZP $E?" !)7X0 3
M5O0 %%7_ !15_P"$20  =$H  &9+  !<2P  4TL  $M,  !$30  /$\  #51
M   O5   *58  "19   >6P< &ET- !A=$@ 771D %EX@ !5>)P 47BX $UXW
M !)>0  17TH $5]5 !!?8@ /7W$ #E^#  U?E@ -7ZD #%Z^  Q>V@ -7?
M#5S\  Y<_P!^30  ;DX  &).  !83P  3T\  $A0  ! 4@  .%0  #!7   J
M6@  )%T  !]?   98@$ $V4) !%F#P 09A0 #V8;  YG(@ -9RD #6<R  QG
M.P +9T4 "F=0  EG70 '9VP !F=]  5GD  $9J,  F:W  -ESP $9>D !&3U
M  1D_ !W40  :5(  %U2  !44@  3%,  $-5   [6   ,UL  "M>   E80
M'V0  !EG   3:@  #VT&  MP#  (<!$ !W 6  5P'0 $<"0  W L  )P-0
M<#\  '!*  !P5P  <&4  '!V  !PB@  ;YX  &^R  !NR   ;>4  &WR  !M
M^0!P5@  8U8  %E6  #_XO__24-#7U!23T9)3$4 ! E15P  1U@  #Y;   V
M7P  +F(  "9F   ?:@  &6T  !-P   .<P  "W8$  5X"P !> \  'D3  !Y
M&0  >1\  'HF  !Z+P  >CD  'I$  !Z4   >E\  'IP  !Z@P  >I@  'JL
M  !YP@  >-\  'CO  !W]P!J6P  7UL  %9;  !,7   0F   #EC   P:
M*&P  "!P   9=   $W<   Y[   )?@  !($"  """   @PT  (,0  "$%
MA1D  (8@  "&*   AS$  (<\  "'20  AU<  (=H  "'>P  AY   (:E  "%
MN@  A=,  (3J  "$] !E8   7&   %%A  !&9   /&D  #)M   I<@  (7<
M !E[   2@   #8,   B'   "B@   (T   ".!   C@D  (\-  "0$   D10
M )(9  "3(   E"D  )4S  "50   EDX  )9?  "5<@  E8@  )6=  "4L@
ME,@  )/B  "3[@!A90  5F8  $IJ   _;@  -70  "MY   A?P  &80  !&)
M   ,C0  !I$   "4    F    )H   ";    G (  )T'  ">"P  GPX  *$2
M  "B&   HR   *4I  "F-@  ID0  *95  "F:   IGT  *:4  "EJ0  I+T
M *31  "DY !;;   3W   $-U   X>P  +8$  ".'   9C0  $9(   N7   $
MG    *    "C    I@   *@   "I    J@   *P   "M!   K@D  + -  "Q
M$0  LQ<  +4@  "V*P  MSH  +=+  "X7   N'$  +B(  "XG0  N+$  +?"
M  "WT !4=@  2'P  #R"   QB0  )I   !N7   2G0  #*(   .G    JP
M *X   "R    M@   +@   "X    N@   +L   "]    O@   , %  #!"P
MPQ   ,86  #)(   RBX  ,L^  #,4   S&0  ,UZ  #-D0  S:0  ,VT  #-
MP !-@P  08H  #61   IF0  'J   !.F   ,K    [$   "V    N@   +X
M  #"    Q@   ,@   #(    R@   ,L   #-    S@   -    #2 0  U0@
M -D.  #=%0  X2$  .(Q  #D0P  Y58  .9K  #F@@  YY8  .>E  #FL #_
M  D _P % /\ !@#_  X _P 6 /\ (0#_ "T _P X /T 0P#Y $T ]0!5 /(
M70#P &, [@!I .P ;P#J '0 Z0!Z .< ?P#F (4 Y "+ ., D0#A )D WP"A
M -P J@#: +8 UP#& -4 X0#3 /0 T@#_ -$ _P#1 /\ SP#_ ,H _P#_  $
M_P   /\  0#_  P _P 2 /H '0#V "@ \P S /  /@#L $@ Z !0 .4 6 #B
M %X WP!D -T :@#; &\ V0!T -8 >@#4 '\ T@"% -  C #. ), S "< ,D
MI0#' +  Q@"^ ,0 U #" .X P0#^ ,  _P#  /\ OP#_ +X _P#_    _P
M /\   #Z  < \0 / .L & #F ", X@ N .  . #; $( U0!+ -$ 4@#. %D
MRP!? ,D 90#' &H Q@!O ,0 = #" 'H P0"  +\ A@"] (X NP"6 +D H "W
M *H M@"W +0 R@"R .8 L0#X +  _P"O /\ KP#_ +  _P#_    _P   /<
M  #J  ( X0 , -< $P#0 !T S  H ,D ,@#& #P P@!% +\ 30"\ %, N@!9
M +@ 7P"W &0 M0!I +0 ;@"R '0 L0!Z *\ @ "M (@ K "1 *H F@"H *4
MI@"Q *0 P0"C -P H0#R *$ _P"@ /\ H #_ *$ _P#_    ]P   .@   #9
M    RP ( ,, $ "] !@ N0 B +8 + "T #8 L@ _ *\ 1P"L $T JP!4 *D
M60"G %X I@!C *4 : "C &X H@!T *  >@"> (( G "+ )L E0"9 )\ F "L
M )8 N@"4 ,\ DP#K )( ^P"2 /\ D@#_ )$ _P#W    YP   -,   #&
MNP " +, # "M !( J@ < *< )@"D #  HP X *  0 "> $< G !. )H 4P"9
M %@ EP!= )8 8P"5 &@ DP!N )( = "0 'P CP"% (T CP"+ )H B@"G (@
MM0"& ,< A0#D (0 ]0"$ /\ @P#_ (, _P#L    TP   ,$!  "T    K
M *8 !P"@  X G0 6 )H ( "7 "D E0 R ), .@"1 $$ CP!( (T 30", %,
MBP!8 (D 70"( &, AP!I (4 ;P"# '< @@"  (  B@!^ )8 ?0"C 'L L !Z
M ,( >0#= '@ \0!W /T > #_ '@ _P#>"@  Q L  +(,  "F"P  G0@  )D$
M  "5  H D0 1 (X &0"+ ", B0 L (< - "% #L @P!" (( 2 "  $X ?P!3
M 'T 6 !\ %X >P!D 'D :@!X '( =@![ '0 A@!S )( <0"? '  K0!N +X
M;0'6 &T"[0!L _H ; /_ &P#_P#.$   MQ$  *82  ":$0  D1   (L.  ")
M"P, AP4, (0!$P"! 1P ?@(E 'P#+@!Z S8 > 0\ '<$0P!U!4@ = 5. ',%
M5 !Q!5D < 9? &X&9@!M!FX :P=X &H'@P!H")  9PF= &4)K !D";P 8PK4
M &,+[ !B#/H 8@S_ &(,_P##%@  K1<  )T8  "0&   AQ8  ($4  !]$0
M? X& 'P*#@!X"A8 =0L? '(+* !P##  ;PPW &T,/@!L#$0 :PU* &D-3P!H
M#54 9PU< &4-8P!C#FL 8@YU & .@0!?#HX 70^< %P0JP!;$+T 6A#6 %D1
M\ !9$?T 61'_ %D1_P"Y&P  I1T  )0>  "('@  ?AT  '@;  !T&   <14
M '$1"0!O$!$ ;! 9 &D0(@!G$2H 9A$R &01.0!C$3\ 8A%% & 22P!?$E$
M71)8 %P27P!:$V@ 61-R %<4?0!6%(L 5!69 %,5J0!2%KH 41;2 %$7[0!1
M%_T 41?_ %$7_P"R(   GB(  (XB  "!(P  =R(  ' A  !L'@  :1L  &<8
M! !F%0X 8Q85 &$6'@!?%B8 718M %P7- !:%SL 61=! %@81P!6&$T 51A4
M %,87 !2&60 41EN $\:>@!.&X@ 31N7 $L<I@!*'+@ 2AW/ $D=ZP!)'?L
M21W_ $H=_P"L)   F"4  (@F  ![)P  <28  &HE  !F(P  8B$  & >  !>
M' L 6QL2 %D<&@!7'"( 51PI %0<, !3'3< 41T] % =0P!/'4H 31Y1 $P>
M6 !+'V$ 21]K $@@=P!'((4 1B&4 $0BI !$(K8 0R+, $,CZ0!#(_H 0R/_
M $,B_P"F)P  DRD  (,J  !V*@  ;2H  &4I  !@)P  7"4  %DC  !7(0<
M52$/ %(A%@!0(1X 3B$E $TB+ !,(C, 2B(Y $DB0 !((D8 1R-- $4C50!$
M)%X 0R1I $(E=0! )H, /R:2 #XGHP ^)[0 /2?* #THZ  ]*/D /2?_ #XG
M_P"B*@  CBL  '\M  !R+0  :"T  &$L  !<*P  6"@  %0F  !1)@0 3B4-
M $PE$P!*)AH 2"8B $<F*0!%)B\ 1"8V $,G/ !!)T, 0"=+ #\H4P ^*5P
M/2EF #PJ<@ [*H$ .BN0 #DKH0 X++( -RS( #<LY@ X+/@ ."S_ #@L_P"=
M+   BBX  'LO  !O,   93   %TO  !8+@  4RL  % J  !,*@  22H+ $8J
M$0!$*A< 0BH? $$J)0 _*BP /BLS #TK.0 \*T  .RQ( #HL4  Y+5D ."YD
M #<N<  V+W\ -2^/ #0PGP S,+$ ,C#' #(PY0 S,/< ,S#_ #0O_P"9+P
MAS$  '<R  !K,@  8C(  %HR  !4,0  3R\  $LM  !'+@  1"X( $$N#@ _
M+A0 /2X< #LN(@ Y+RD ."\O #<O-@ V,#X -3!& #4Q3@ T,5< ,S)B #(R
M;@ Q,WT ,#.- "\TG@ N-+  +33% "TTXP N-/8 +S/_ "\S_P"5,0  @S,
M '0T  !H-0  7C4  %<T  !1-   2S(  $8Q  !",@  /S(% #PR#0 Y,Q(
M.#,9 #8S(  T,R8 ,S,M #(T-  Q-#L ,#5# # U3  O-E4 +C9@ "TW;  L
M-WL *S>+ "HXG  I.*X *#C# "@XX@ I./4 *C?_ "HW_P"2-   ?S4  '$V
M  !E-P  6S<  %0W  !--@  1S8  $(U   ]-@  .C8" #<W"P T-Q  ,C<6
M #$X'0 O."0 +C@K "TY,@ L.3D *SE! "HZ20 J.E, *3M> "@[:@ G.WD
M)CR) "4\FP D/*T (SS" ",\X  D//0 )3O_ "4[_P"--@  ?#@  &TY  !B
M.0  6#H  %$Y  !*.0  1#D  #TY   Y.@  -3L  #(["  O/ X +3T4 "P]
M&@ J/2$ *3TH "@^+P G/C8 )CX^ "4_1P D/U  (T!; ") :  A0'8 ($"'
M !]!F0 ?0:L 'D'  !Y!W@ ?0/, 'T#^ " __P").0  >#H  &D[  !>/
M53P  $T\  !'/   0#P  #@]   T/@  ,$   "U!!0 J0@P )T(1 "9#&  D
M0QX (T,E ")#+  A1#, ($0[ !]$1  >14X '459 !Q%90 ;170 &D6% !E&
MEP 91JD &$:^ !=%W  81?$ &43] !I$_P"$/   <ST  &8^  !;/P  4C\
M $H_  !$/P  /4   #9!   Q0P  +$0  "=& 0 D1PH (4@/ "!)%  >21L
M'4DB !Q)*0 ;2C  &DHX !E*00 82DL %TM5 !9+8@ 52W$ %$N" !-+E  2
M2Z< $DN\ !%+V0 22O  $TK\ !1)_P!_/P  ;T   &%!  !70@  3D(  $="
M  !!0@  .D,  #)%   M1P  *$D  "-+   >308 &T\- !A0$0 74!< %E >
M !50)0 44"P $U$T !)1/0 144< $5%2 !!17P /4FT #E)^  U1D0 -4:0
M#%&X  Q1T0 -4.P #5#Z  Y/_P!Y0P  :D0  %U$  !310  2T4  $1%   ^
M1@  -D@  "]*   I3   )$\  !]1   :4P  %%8) !%7#@ 06!, $%@9  ]8
M(  .6"@ #5@P  U8.0 ,6$, "UA.  I86@ (6&@ !UAY  98C  %6)\ !%BS
M  17R@ %5^8 !5?S  96_ !S1@  9$<  %E(  !02   2$@  $%)   Z2@
M,DT  "M0   E4@  (%4  !I8   56@  $%T&  Q@#  *8!  "6 5  A@'  '
M8", !6 K  1@-  #8#T  6!)  !@50  8&,  &!S  !@A@  7YH  %^N  !?
MQ   7N(  %[P  !>^ !L2@  7TL  %5+  !,3   14P  #U.   U4   +E,
M "=6   @60  &EP  !5?   08@  #64$  AG"P #9PX  &@3  !H&   :!\
M &DF  !I+@  :3@  &E#  !I3P  :5T  &EM  !I@   :90  &BI  !HOP
M9]P  &;N  !F]P!F3P  6D\  %%/  !*3P  05$  #A4   P5P  *%L  "%>
M   :8@  %&4  !!H   ,:P  !VX#  %P"0  < T  '$0  !Q%   <AH  ',A
M  !S*   <S$  ',\  !T2   <U8  '-F  !S>0  <XX  '.C  !RN0  <=(
M ''K  !P] !A4P  5E,  $]3  !%50  .U@  #)<   J8   (F0  !MH   4
M;   #V\   MR   &=@   'D   !Z!@  >@H  'L.  !\$0  ?14  'X;  !_
M(@  @"H  ( U  " 00  @$\  (!?  " <0  @(8  ("=  !_L@  ?LH  '[E
M  !]\0!<6   5%@  $E:   _70  -6$  "QE   C:@  &V\  !1S   .=P
M"7L   -_    @@   (0   "& 0  A@8  (@*  ")#0  BA   (L5  ",&P
MCB(  (\L  "/.   CT8  (]6  "/:   CWX  (^5  ".JP  C<$  (W<  ",
MZP!970  3E\  $-B   X9@  +FP  "1Q   <=P  %'P   Z!   (A0   (D
M  "-    D    )(   "3    E    )8#  "7"   F P  )H/  ";$P  G1H
M )\C  "@+@  H#P  *!,  "@7@  H'0  )^,  "?H@  G[<  )[+  ">X !3
M9   1V@  #QM   Q<P  )WD  !U_   4A0  #8L   :0    E    )@   "<
M    GP   *$   "B    I    *4   "G    J 0  *H)  "L#0  K1(  + 9
M  "R(P  LC$  +)"  "R5   LFD  +*   "RF   L:P  +*_  "QS@!,;@
M0',  #5Z   J@0  'X@  !6.   .E0  !IH   "?    I    *@   "L
MKP   +$   "Q    LP   +4   "V    N    +H   "\!@  O@P  , 1  ##
M&0  Q28  ,4W  #&20  QET  ,=R  #'B@  R)\  ,BO  #(O !&>@  .8$
M "Z)   BD   %Y@   ^?   'I0   *H   "O    LP   +<   "\    OP
M ,$   #"    Q    ,4   #'    R0   ,L   #-    SP,  -(*  #6$
MW!H  -TJ  #>/   WU   .!E  #A>P  X9$  .*B  #BK0#_  ( _P   /\
M P#_  P _P 3 /\ '0#_ "@ _@ S /L /@#W $@ \P!0 /  5P#M %X ZP!D
M .@ :0#G &\ Y0!T ., >0#B '\ X "% -X C #< ), V0"< -8 I@#3 +$
MT0#  ,\ V@#. /$ S #_ ,L _P#+ /\ Q@#_ ,$ _P#_    _P   /\   #_
M  @ ^P 0 /8 &0#R "0 [P N .T .0#H $( XP!+ .  4@#= %D V0!? -8
M9 #3 &D T0!N ,\ = #. 'D S !_ ,H A@#( (X Q@"6 ,0 H #" *L P "Y
M +X S0"\ .H NP#\ +H _P"Z /\ N@#_ +8 _P#_    _P   /X   #T  0
MZP - .0 % #? !\ VP I -@ ,P#3 #T S@!% ,H 30#' %, Q0!9 ,, 7P#!
M &0 OP!I +T ;@"[ ', N@!Y +@ @ "V (@ M "0 +( F@"Q *4 KP"R *T
MQ "L .$ JP#V *H _P"J /\ J@#_ *H _P#_    _0   .X   #B    U0 *
M ,T $0#' !D Q  C ,$ +0"_ #< NP _ +< 1P"U $X L@!3 +  60"O %X
MK0!C *P : "K &T J0!S *@ >@"F ($ I "* *, E "A )\ GP"L )X NP"<
M -( FP#N )H _P": /\ F0#_ )D _P#^    [@   -X   #+    P0 % +D
M#0"T !0 L0 > *X )P"K #  J@ Y *< 00"D $@ H@!- *$ 4P"? %@ G@!=
M )T 8@"; &< F@!M )@ <P"7 'L E0"$ )0 C@"2 )D D "F (X M "- ,@
MC #F (L ^0"* /\ B@#_ (L _P#P    VP   ,<   "Z    L    *@ "@"D
M !  H  8 )T (0"; "H F@ S )@ .P"6 $$ E !( )( 30"1 %( CP!7 (X
M7 ", &$ BP!G (H ;@"( '4 AP!^ (4 B "# )0 @@"@ (  KP!_ ,  ?@#=
M 'T \@!] /\ ?0#_ 'T _P#@    Q@   +4   "J    H@   )L !0"5  T
MD@ 3 )  ' "- "0 BP M (H - "( #L A@!" (4 1P"# $T @@!2 ($ 5P!_
M %P ?@!B 'T : ![ '  >@!Y '@ @P!V (\ =0"< '0 J@!R +H <0#1 '
M[ !P /L < #_ '  _P#-!   MP8  *<'  ";!@  DP0  (X   "*  @ A@ /
M (0 %@"! !X ?P G 'T +@!\ #8 >@ \ 'D 0@!W $< =@!, '4 4@!S %<
M<@!= '$ 8P!O &L ;@!T &P ?@!K (H :0"8 &@ I@!G +8 9@#+ &4 YP!E
M /< 90#_ &4 _P# #   JPT  )L.  "/#@  A@T  ($+  !^!P$ ? $+ 'D
M$0!W !@ =0 A ', *0!Q #  ;P V &X / !L $( :P!' &H 30!I %( : !8
M &8 7P!E &< 8P!P &(!>@!@ 8< 7P*5 %X"HP!< [, 7 /' %L$Y !;!?0
M6P;^ %L&_P"U$   H1(  )$3  "%$P  ?!(  '81  !S#@  <@P$ '$'#0!N
M!!( ; 0; &D%(P!G!2H 9@8Q &0&-P!C!CT 8@=# &$'20!?!TX 7@A5 %T(
M7 !;"6, 6@EM %@*> !7"H4 5@N3 %0+H@!3"[, 4@S' %(,Y !1#?4 40W_
M %$-_P"M%0  F1<  (D8  !]&0  =!@  &T7  !J%   9Q$  &<.!P!F# X
M8PP5 &$,'0!?#"4 70TL %P-,P!;#3D 6@T_ %@-10!7#4L 5@Y1 %4.60!3
M#F$ 4@YK % /=@!.$(, 31"2 $P0H@!+$+( 2A'( $D1Y0!)$?< 21+_ $D1
M_P"E&0  DAP  (,=  !V'@  ;1T  &8<  !B&@  7Q<  %X4 0!>$0H 6Q 1
M %D1& !7$2  51$G %01+@!3$30 41$[ % 200!/$D< 3A). $P250!+$UX
M21-G $@4<P!&%(  116/ $05GP!#%K  0A;% $(7XP!"%_8 0A?_ $(7_P"?
M'0  C"   'TA  !Q(@  :"(  &$A  !<'P  61P  %<9  !5%@8 5!4. %$5
M% !/%AP 3A8C $P6*@!+%C  2A8W $D7/0!'%T, 1A=* $484@!#&%H 0AED
M $$9<  _&GT /AN- #T;G0 \'*X .QS# #L<X0 ['?4 .QS_ #P<_P":(0
MAR,  '@D  !L)0  8R4  %PD  !7(P  4R   %$>  !/' ( 31L, $L:$0!(
M&Q@ 1QL@ $4;)@!$&RT 0QPS $(<.0! '$  /QU' #X=3P ]'E@ /!YB #H?
M;0 Y'WL .""+ #<AFP V(:T -2'! #4AWP U(?, -B'_ #8A_P"6(P  @R8
M '0G  !H*   7R@  %@G  !3)@  3R0  $PB  !)(   1R ) $0?#P!"'Q4
M0" < #\@(P ^("D /" O #LA-@ Z(3T .2%$ #@B3  W(E4 -B-? #0C:P S
M)'D ,B6) #$EF@ P):L ,":_ "\FW  P)O( ,";_ #$E_P"1)@  ?R@  '$J
M  !E*@  7"H  %4J  !/*0  2R@  $@E  !$)   020% #\D#0 ])!( .R09
M #DD'P W)"8 -B0L #4E,P T)3H ,R9! #(F2@ Q)U, ,"== "\H:0 N*7<
M+2F' "PIF  K*JH *BJ] "HJV@ K*O$ *RK^ "PI_P"-*   ?"H  &TL  !B
M+0  62T  %$M  !,+   1RL  $,H   _*   /"@" #DH"P W*!  -2@6 #,H
M'  R*", ,"@I "\I,  O*C< +BH_ "TK1P L*U$ *RQ; "HL9P I+74 *"V%
M "<MEP F+J@ )2Z\ "4NV  F+O  )B[] "<M_P"**P  >"T  &HN  !?+P
M5B\  $XO  !(+@  0RT  #\L   [+   -RP  #0L"0 R+ X ,"T3 "XM&@ M
M+2  *RTG "HN+0 J+C4 *2\] "@O10 G,$X )C!9 "4Q90 D,7, (S&# "(R
ME0 A,J< (3*[ " RU  A,N\ (C'\ "(Q_P"&+0  =2\  &<P  !<,0  4S$
M $LQ  !%,0  0#   #LP   V,   ,S   # Q!@ M,0T *S$1 "DR%P H,AX
M)S(D "4S*P E,S( )#,Z ",T0P B-$P (357 " U8P ?-7$ 'C:! !TVDP <
M-J4 &S:Y !LVT@ <-NT '3;[ !TU_P"",   <3(  &,S  !9-   4#0  $DT
M  !",P  /3,  #<S   Q-   +C4  "LU @ H-@L )3<0 "0W%0 B-QL (3@B
M " X*  ?.#  'C@W !TY0  <.4D &SI4 !HZ8  9.FX &#I_ !<[D0 7.Z0
M%CNW !4[T  6.NP %SKZ !@Y_P!],@  ;30  & U  !5-@  338  $8V  !
M-@  .C8  #0V   N.   *CD  "8Z   C.P@ (#P. !X]$@ =/1@ '#T? !L^
M)0 :/BT &3XT !<^/0 6/T< %3]1 !0_7@ 4/VP $T!\ !) CP 10*( $4"V
M !! S@ 1/^L $C_Y !(^_P!Y-0  :3<  %PX  !2.0  2CD  $,Y   ].0
M-SD  #$Z   K/   )ST  "(_   >000 &D(+ !A#$  70Q4 %40; !1$(@ 3
M1"D $T0Q !)$.@ 114, $$5. !!%6P .16D #D5Y  U%C  -19\ #$6R  M%
MR0 ,1>4 #43V  U$_P!T.0  93H  %@[  !/.P  1SP  $ \   Z/   -#P
M "X^   H0   (T(  !]$   :1@  %4@( !)*#0 12A( $$H8  ]+'@ .2R4
M#4LM  U+-@ ,2T  "TM*  I+5@ )2V0 "$MT  =+AP %2YH !$NN  1*Q  %
M2N  !4KP  9)^@!N/   8#T  %0^  !+/@  1#X  #T^   W/P  ,4   "I"
M   D10  'T<  !I)   53   $4X%  Y1"P +41  "E$4  E1&P (42( !U$I
M  51,@ $4CL  U)&  %24@  4E\  %)O  !2@0  498  %&I  !1OP  4-P
M %#N  !0]P!H0   6T$  %!!  !(00  04$  #M"   T0P  +44  "9(   @
M2P  &TT  !90   14P  #E4$  I8"@ &6 X  E@2  !9%P  61T  %DE  !9
M+0  638  %E!  !930  6EH  %II  !9?   69   %FE  !8N@  6-4  %?L
M  !7]@!C1   5D4  $U%  !%10  /T4  #='   O20  *$P  ")/   ;4@
M%E4  !%8   -6@  "5T#  1?"0  8 T  & 0  !A%   81D  &(@  !B)P
M8C$  &([  !B1P  8E4  &-D  !B=@  8HL  &*@  !AM@  8<\  &#J  !@
M]0!=2   4DD  $I(  !#2   .DH  #)-   J4   (U,  !Q7   66@  $5T
M  U@   (8P   V8!  !G!@  : L  &D.  !J$0  :Q4  &P;  !M(@  ;2H
M &TT  !M0   ;4X  &U=  !M;P  ;80  &R:  !LL   :\@  &OF  !J\P!8
M30  3DT  $A,   ^3@  -5$  "Q4   D6   '5P  !9@   09   #&<   =K
M   !;@   '    !R P  <@<  ',+  !U#@  =A$  '<6  !X'   >2,  'HM
M  !Z.0  >D<  'I6  !Y:   >GP  'F4  !XJ@  >,$  '??  !W[P!440
M3%$  $)2   X50  +UD  "9>   >8@  %F<  !!K   +;P  !7,   !W
M>@   'P   !^    ?P(  ( &  "!"@  @PT  (01  "&%0  B!P  (DE  "*
M,   BCX  (E-  ")7P  B7,  (B+  "(H@  A[D  (?1  "&Z !25@  1U<
M #Q:   R7P  *&0  !]I   6;P  $'0   IY   "?0   ($   "%    B
M (H   ",    C0   (\   "0!   D@@  ),,  "5$   EQ4  )D=  ";)P
MFS0  )M$  ":5@  FFH  )F"  ":F@  F+   )C'  "7W@!+7   0&   #5E
M   K:@  (7$  !=W   0?0  "8,   &(    C    )$   "5    F    )H
M  ";    G0   )\   "@    H@   *0%  "F"@  J X  *H4  "M'0  K2H
M *TY  "M2P  K5\  *UW  "LD   JZ<  *NZ  "KRP!%9@  .6L  "YQ   C
M>   &7\  !"&   )C0   ),   "8    G0   *$   "E    J    *L   "K
M    K@   *\   "Q    LP   +4   "W 0  N0<  +P-  "_$P  PA\  ,(N
M  #"0   PE0  ,%K  #!@P  P)L  ,&M  #!O  ^<@  ,G@  ">    <B
M$I    J7    G0   *,   "H    K0   +(   "V    N0   +L   "\
MO@   ,    #"    Q    ,8   #(    RP   ,X%  #1#0  UA0  -<C  #8
M-0  V4D  -I>  #;=0  VXP  -R?  #<JP#_    _P   /\   #_  D _P 0
M /\ &0#^ "0 _  O /D .0#T $, \ !+ .T 4@#J %D YP!? .0 9 #B &D
MX !N -X <P#< 'D V@!_ -< A@#4 (X T0"6 ,\ H0#, *P R@"[ ,@ T@#&
M .X Q@#_ ,4 _P#% /\ OP#_ +H _P#_    _P   /\   #^  4 ]P . /(
M%0#N !\ ZP J .D - #C #T W@!% -D 30#4 %, T0!9 ,X 7@#, &, R@!H
M ,D ;0#' ', Q0!Y ,, @ #! (@ OP"0 +T FP"[ *8 N0"T +< R "V .8
MM0#[ +0 _P"T /\ LP#_ *X _P#_    _P   /@   #M    Y0 + -T $0#7
M !H T@ D ,\ +@#+ #< QP!  ,, 1P#  $X O@!3 +P 60"Z %X N !C +8
M: "U &T LP!S +$ >0"O ($ K0"* *L E "I *  J "M *8 O@"E -L I #T
M *0 _P"C /\ HP#_ *( _P#_    ]@   .8   #7    RP & ,0 #@"^ !4
MNP ? +D * "W #$ M  Z +  00"M $@ JP!. *D 4P"G %@ I@!< *0 80"C
M &< H0!L *  <P"> 'H G0"# )L C@"9 )D EP"F )8 M@"5 ,P E #K ),
M_0"3 /\ DP#_ ), _P#W    Y    -    #!    MP " *\ "P"K !$ IP 9
M *4 (@"C "L H@ S )\ .P"< $( FP!( )D 30"7 %( E@!7 )4 6P"3 &$
MD@!F )  ;0"/ '0 C0!] (P AP"* ), B "@ (< KP"% ,( A0#B (0 ]P"$
M /\ A #_ (0 _P#E    S0   +P   "O    I@   )X !P":  X E@ 4 )0
M'0"2 "4 D0 M )  -0"- #P C !" (H 1P"( $P AP!1 (8 5@"$ %L @P!@
M ($ 9P"  &X ?@!W 'T @0![ (T >@": '@ J0!W +H =@#3 '8 [P!V /X
M=0#_ '4 _P#0    NP   *L   "?    EP   )   @"+  L B  0 (8 %P"$
M "  @@ G ($ +P!_ #4 ?0 \ 'P 00![ $8 >0!+ '@ 4 !W %4 =@!; '0
M80!S &D <0!Q '  >P!N (< ;0"5 &L HP!J +0 :@#) &D Z !I /D :0#_
M &D _P#     K    )P"  "0 @  B    (,   !_  8 >P - 'D $@!W !H
M=@ B '0 *0!S #  <0 V '  / !O $$ ;0!& &P 2P!K %  :@!6 &@ 7 !G
M &0 90!L &0 =@!C (( 80"0 &  GP!? *\ 7@## %X X0!> /0 70#_ %T
M_P"T!P  H D  ) +  "$"P  ? H  '<'  !T!   <0 ) &\ #P!M !4 :P <
M &D (P!H "H 9P Q &4 -@!D #P 8P!! &( 1@!@ $P 7P!2 %X 6 != %\
M6P!H %H <@!8 'X 5P", %8 FP!5 *L 5 "^ %0 V@!3 .\ 5 #[ %0 _P"I
M#0  E@X  (<0  !Z$   <A   &P.  !I#   9PD# &8$"P!D !  8@ 7 &
M'@!> "4 70 K %P ,0!: #< 60 \ %@ 0@!7 4< 5@%. %4"5 !3 EP 4@-E
M %$#;P!/!'L 3@2* $T%F0!,!:D 2P6\ $H&U !*!^T 2@?Y $H'_P"A$
MCA(  'X4  !S%   :A0  &03  !@$0  7@\  %T-!0!="0T 6@82 %@'&0!6
M!R  50<G %,'+0!2"#, 40@X % (/@!/"40 3@E* $P)40!+"ED 2@IB $@+
M;0!'"WH 1@R( $0,F !##*D 0@V\ $(-U0!"#>X 0@W[ $(-_P":%   AQ8
M '@8  !L&0  8QD  %T8  !9%@  5A,  %01  !4#@@ 4PT. %$-% !/#1L
M30TB $P-* !+#2X 2@TT $D-.@!'#D$ 1@Y' $4.3P!$#E< 0@]A $$0;  _
M$'D /A"( #T1F  [$:D .Q&\ #H1U@ Z$?  .A+] #L1_P"3&   @1H  ',<
M  !G'0  7AT  %@<  !3&P  4!@  $X6  !,$P, 3!$+ $H0$ !($1< 1A$>
M $41) !$$2H 0A$P $$1-P! $CT /Q)$ #T23  \$U0 .Q-> #D4:0 X%'8
M-Q6% #85E@ T%J< -!:Z #,6TP S%NX -!;\ #06_P".&P  ?!T  &X?  !C
M(   6B   %,@  !.'@  2AT  $@:  !&&   118' $,5#@!!%1, /Q4: #X5
M(  ]%2< .Q4M #H6,P Y%CH .!9! #<720 U%U$ -!A; #,99@ R&7, ,!J#
M "\:E  N&Z4 +1NX "T;T  M&^P +AO[ "X;_P"*'@  >"   &HB  !?(P
M5B,  $\B  !*(0  1B   $,>  !!&P  /QH# #T:#  [&1$ .1D6 #<:'0 V
M&B, -1HI #0:,  S&S8 ,1L^ # <1@ O'$\ +AU9 "T=9  L'G$ *Q^! "H?
MD@ I'Z0 *""W "<@S@ G(.L *"#Z "D?_P"&(   =",  &<D  !<)0  4R4
M $PE  !')   0B,  #\A   ]'P  .AX  #<>"0 U'@X ,QX3 #$>&@ P'B
M+QXF "X?+0 M'S, +" [ "L@0P J(4P *2%6 "@B8@ F(F\ )2-_ "0CD  C
M(Z( (B2U "(DS  B).D (R3Y "0C_P""(P  <24  &,F  !9)P  4"@  $DG
M  !#)P  /R8  #LD   X(@  -2(  #(B!@ P(@T +B(1 "PB%P J(AT *2(C
M "@C*@ G(S$ )B0X "4E00 D)4H (R94 "(F8  A)VT ("=] !\GCP >**$
M'BBT !THR@ =*.@ 'BCX !\G_P!^)0  ;B<  & I  !6*0  32H  $8J  !!
M*0  /"@  #<G   T)@  ,"8  "TF P K)PL *"<0 "<G%  E)QH )"<A ",H
M)P B*"X (2DV " I/@ ?*D@ 'BI2 !TK7@ <*VL &RM[ !HLC0 9+)\ &"RR
M !@LR0 8+.< &2OW !HK_P!Z)P  :BH  %TK  !3+   2BP  $,L   ^*P
M.2L  #0J   P*@  *RH  "DK   F*P@ (RP. "(L$@ @+!@ 'RP> !XM)0 =
M+2P '"TS !LN/  :+D4 &2]0 !@O7  7+VD %C!Y !4PBP 4,)X %#"Q !,P
MQP 3,.4 %##V !4O_P!V*@  9RP  %HM  !0+@  2"X  $$N   [+@  -BT
M #$M   L+0  )R\  "0O   A, 4 'S$, !PQ$  ;,A4 &C(< !DR(@ 8,BD
M%S,Q !8S.0 5,T, %#1- !,T60 2-&< $35W !$UB0 0-9P $#6P  XUQ@ /
M-.0 $#3U ! T_P!R+   8RX  %<P  !-,   13   #XP   X,   ,S   "\P
M   I,0  )#(  "$S   =-0( &C8) !<W#@ 5-Q, %#@9 !,X'P 2."8 $C@N
M !$Y-@ 0.4  $#E+  XY5P ..F0 #3IT  PZA@ ,.ID "SFL  HYP0 *.=X
M"SGQ  PX_ !N+P  7S$  %,R  !*,P  0C,  #LS   V,P  ,3(  "PS   G
M-   (38  !TX   9.0  %3L& !(]#  0/A  $#X5  X^'  ./B, #3XJ  P^
M,P ,/CP "S]'  H_4@ (/V  !S]O  8_@0 %/Y0 !#^H  ,^O  $/M< !3[L
M  4^]P!I,P  6S0  % U  !'-0  /S4  #DU   T-0  +C4  "DW   C.
M'CL  !H\   6/P  $D$$  Y#"@ ,1 X "D03  E$&0 (1"  !T0G  9$+P %
M1#@  T5"  )%3@  15L  $5J  !%?   19   $2D  !$N0  1-$  $3J  !#
M]0!D-@  5S<  $PX  !#.   /#@  #<X   Q.   *SD  "4[   @/0  &D
M !9"   21   #D<$  M)"0 '2@T !$L1  %+%@  2QP  $LC  !+*P  2S0
M $L^  !,20  3%<  $QF  !,=P  2XP  $NA  !+M0  2LX  $KI  !*]0!?
M.@  4CL  $@[  ! .P  .CL  #0[   N/   )SX  ")!   <0P  %D8  !))
M   .2P  "TX#  =0"  "40P  %$0  !2$P  4Q@  %,?  !3)@  4R\  %,Y
M  !310  4U(  %-A  !3<@  4X<  %*<  !2L0  4<H  %'G  !1] !9/@
M3CX  $4^   ^/@  .#X  #!    I0@  (T0  !U'   72@  $DT   Y0   +
M4P  !E4"  !7!P  6 L  %D.  !:$0  6A4  %L:  !<(0  7"H  %PT  !<
M/P  7$T  %Q;  !<;   7($  %N7  !;K0  6L4  %KD  !9\P!40@  2D(
M $)"   \0@  -$,  "Q&   E20  'DP  !=/   24P  #E8   I9   %6P
M %X   !@!   80@  &(,  !C#@  9!$  &46  !F'   9R,  &<M  !G.0
M9T8  &=5  !G9@  9WH  &:1  !EJ   9<   &3>  !D\ !/1@  1T8  $!%
M   W1P  +TH  "9-   ?40  &%4  !)9   -7   "&    )C    9@   &@
M  !J    :P0  &P(  !M#   ;PX  ' 2  !R%P  <QT  '0F  !T,@  =#\
M '1.  !S7P  ='(  '.*  !RH0  <;@  ''4  !P[ !,2@  14H  #M+   R
M3@  *5(  "!6   86P  $E\   UD   ':    &L   !O    <@   '4   !V
M    =P   'D"  !Z!@  ? H  'X.  " $0  @A8  (0>  "$*0  A#8  (1%
M  "$5@  @VH  (.!  ""F0  @;$  (#)  " Y0!*3@  /U   #53   K5P
M(EP  !EB   29P  #&P   5Q    =0   'D   !]    @0   (,   "%
MA@   (@   ")    BP0  (T(  "/#0  DA   )06  "6(   EBP  )8[  "6
M3   E6   )5V  "4D   DZ<  )*]  "2U0!$50  .5D  "]=   D8P  &FD
M !)O   ,=0  !'L   "     A0   (D   "-    D0   ),   "4    E@
M )@   ":    G    )X   "@!@  H@L  *40  "H%P  J2,  *DQ  "I0P
MJ58  *AM  "FAP  IYX  *:S  "EQP ^7@  ,F,  "=J   =<   $W@   Q_
M   #A0   (L   "1    E@   )L   "?    H@   *0   "E    IP   *D
M  "K    K0   +    "R    M0(  +<)  "[$   OA@  +XF  "^.   ODL
M +UA  "\>@  NY0  +JI  "ZN0 W:@  *W   "!X   6@   #8@   6/
ME@   )P   "B    IP   *P   "P    LP   +8   "W    N0   +L   "]
M    OP   ,(   #%    R    ,H   #."   TA   -4;  #5+   U$   -17
M  #3;@  U(8  -2;  #3JP#_    _P   /\   #_  4 _P . /\ %0#\ "
M^0 J /8 - #Q #T [0!& .D 30#F %, Y !9 .$ 7@#> &, W !H -D ;@#5
M ', TP!Y -  @ #. (@ RP"1 ,D G #& *< Q "W ,( S #  .P OP#_ +X
M_P"] /\ MP#_ +( _P#_    _P   /\   #Z  $ \P + .T $@#H !L Y0 E
M .0 +@#? #@ V !  -( 1P#. $X RP!4 ,@ 60#& %X Q !C ,( 9P#  &T
MOP!S +T >@"[ ($ N0"+ +8 E0"T *$ L@"O +  P@"N ., K@#Z *P _P"M
M /\ J0#_ *8 _P#_    _P   /(   #F    W0 ' -( #@#- !8 R@ @ ,@
M*0#% #( P  Z +P 0@"Y $@ MP!. +4 4P"S %@ L0!= +  8@"N &< K !L
M *H <P"I 'L IP"$ *4 C@"C )H H0"H )\ N0"> -( G0#R )P _P"= /\
MG #_ )D _P#\    [@   -T   #,    P0 " +H # "V !( L@ : +  (P"O
M "P K0 T *D / "F $( I !( *( 30"@ %( G@!7 )T 6P"< &  F@!F )D
M; "7 '0 E0!] ), AP"1 ), D "A (X L0"- ,8 C #H (L _0", /\ C #_
M (P _P#M    V    ,4   "W    K    *8 " "A  X GP 5 )T '@"; "8
MF@ N )< -0"5 #P DP!" )$ 1P"0 $P C@!1 (T 50"+ %H B@!@ (D 9@"'
M &T A0!V (0 @ "" (P @ ": '\ J0!] +P ? #< 'P ]0!\ /\ ? #_ 'P
M_P#9    P0   +$   "D    G    )0  P"0  P C0 1 (L & ") "  B0 H
M (< +P"% #8 @P \ (( 00"  $8 ?P!+ 'T 3P!\ %0 >P!: 'D 8 !X &<
M=@!P '4 >@!S (8 <0"3 '  H@!O +0 ;@#, &X [0!N /X ;@#_ &X _P#$
M    KP   *    "4    C    (8   "!  @ ?@ . 'P % ![ !L >0 B '@
M*0!W #  =0 V '0 .P!R $  <0!% '  2@!O $\ ;0!4 &P 6P!K &( :0!J
M &@ = !F (  90". &, G0!B *T 80#" &$ Y !A /@ 80#_ &$ _P"T
MH    )$   "&    ?@   'D   !U  , <0 + &\ $ !M !8 ;  = &L ) !K
M "H :0 P &@ -@!F #L 90!  &0 10!C $H 80!/ &  5@!? %T 70!E %P
M;P!: 'H 60"( %@ F !7 *@ 5@"[ %8 V !6 /$ 5@#_ %8 _P"H 0  E 4
M (4'  !Z!P  <@8  &P$  !I 0  9P ' &0 #0!C !$ 80 8 &  'P!? "4
M7@ K %T , !; #8 6@ [ %D 0 !8 $4 5P!+ %8 40!5 %@ 4P!A %( :@!0
M '8 3P"$ $X DP!- *0 3 "V $P S0!, .L 3 #Z $P _P"="0  BPL  'P-
M  !P#0  : T  &(,  !?"@  708! %P!"0!:  X 6  3 %< &0!6 "  50 F
M %, *P!2 #$ 40 V %  .P!/ $$ 3@!' $T 30!+ %4 2@!= $D 9P!' ',
M1@"  $4 D !$ *$ 0P"R $, R !# .8 0P#U $, _P"5#0  @P\  '00  !I
M$0  8!$  %H0  !6#@  5 T  %,*! !3!@L 40,0 $\!%0!. 1L 3 $A $L!
M)P!* BP 20(R $@"-P!' ST 10-# $0#2@!#!%$ 0@1: $ %9  _!7  /@9^
M #T&C@ \!Y\ .P>Q #H'Q@ Z!^, .@?S #H(_ ".$   ?!(  &X4  !B%0
M6A4  %04  !0$P  31$  $L.  !+#08 2@H, $D($0!'"!8 10@= $0((P!"
M""@ 00DN $ ),P _"3D /@I  #T*1P \"D\ .@M8 #D+8P X#&\ -@Q^ #4,
MC@ T#9\ ,PVQ #(-QP R#>, ,@WT #(-_@"($P  =Q4  &D7  !>&   51@
M $\8  !*%@  1Q4  $43  !#$ ( 0PX( $(-#@! #1( /PT8 #T-'P \#20
M.PTJ #D-,  X#C< -PX] #8.10 U#DT ,P]7 #(/8@ Q$&X +Q!] "X0C@ M
M$:  +!&R "L1R  K$>8 *Q'V "P1_P"#%@  <AD  &0:  !9&P  41L  $L;
M  !&&@  0A@  #\7   ^%   /!($ #L1"@ Z$!  .! 5 #<0&P U$2$ -!$G
M #,1+0 R$3, ,!$Z "\20@ N$DL +1-4 "L37P J%&P *11[ "@4C  G%9X
M)A6P "45Q@ E%>0 )17V "85_P!^&0  ;AL  & =  !6'@  31X  $<>  !"
M'0  /AP  #H:   X&   -Q8  #45!P T% T ,A02 # 4%P O%!T +10C "P5
M*@ K%3  *A4W "D6/P H%D@ )Q=2 "8870 D&&H (QEY "(9B@ A&9P (!FO
M !\9Q  ?&>( (!GT " 9_P!Z&P  :AX  %T?  !3(   2B   $0@   ^'P
M.AX  #<=   T'   ,AD  # 9!  N& L +!@0 "H8%  I&!H )Q@@ "89)@ E
M&2T )!HU ",:/0 B&T8 (1M0 " <6P ?'6@ 'AUW !T=B  <'IL &QZM !H>
MPP :'N  &AWS !L=_P!W'0  9R   %HA  !0(@  2"(  $$B   [(@  -R$
M #,@   P'P  +1T  "L=   H'0@ )AT. "4=$@ C'1< (1T= "$=)  @'BH
M'QXR !X?.@ ='T, '"!- !LA60 :(68 &2%U !@BAP 7(ID %B*L !4BP0 5
M(M\ %2'R !8A_@!S(   9"(  %<C  !-)   124  #XD   Y)   -",  # B
M   L(@  *2$  "8A   D(08 (B$, " A$  >(14 '2(; !LB(0 ;(B@ &B,O
M !DC.  8)$$ %R1+ !8E5P 5)60 %"9S !,FA0 2)I@ $2:K !$FP  0)MT
M$27Q !(E_0!P(@  820  %0F  !*)@  0B<  #PF   V)@  ,24  "TE   I
M)   )B0  "(E   ?)0, '28* !LF#@ 9)Q( &"<8 !<G'P 6)R4 %2@M !0H
M-0 3*3X $BE) !$I50 1*F( $"IQ  \J@P .*I8 #BJI  TJO0 -*M< #2KN
M  XI^P!L)   728  %$H  !(*   0"D  #DH   T*   +R@  "LG   G)P
M(B@  !XI   ;*@  &"L' !8K#0 4+!$ $RP6 !(L'  1+2, $"TJ ! M,@ /
M+CP #BY&  TN4@ -+E\ #"]N  LO?P *+Y( "2^E  DNN0 (+M  "2[I  HN
M]P!H)P  6BD  $XJ  !%*P  /2L  #<K   Q*@  +2H  "DJ   D*@  ("L
M !LM   8+@  %2\$ !(Q"@ 0,@X #S(3  XR&0 -,B  #3(G  PR+P +,S@
M"C-"  DS3@ (,UL !C1J  4T>P $,XX  S.B  (SM@ ",\T  S/G  0R\P!D
M*@  5BP  $LM  !"+0  .BT  #0M   O+   *RP  "8L   B+0  '2\  !DQ
M   5,@  $C0#  \V"0 ,. T "C@1  DX%@ (.!T !S@D  8X+  $.#0  S@^
M  (Y2@  .5<  #EE   Y=P  .8L  #B?   XLP  .,H  #CF   W\@!?+0
M4BX  $@O   _,   ."\  #(O   M+P  *2\  "0P   ?,0  &C,  !4U   2
M-P  #SD#  P["  (/0T !3X0  ,^%   /AH  #XA   ^*   /C$  #\[   _
M1@  /U,  #]A   _<P  /X<  #Z<   ^L   /<<  #WD   ]\@!:,   3C(
M $0R   \,@  -3(  # Q   K,0  )C(  " T   ;-@  %C@  !([   //0
M##\#  A!"  $0PP  $,.  !$$@  118  $4=  !%)   12T  $8V  !&0@
M1DX  $9=  !&;@  18(  $68  !$K0  1,0  $/C  !#\@!5-   2C4  $$U
M   Y-0  ,S0  "XT   H-0  (C<  !TZ   7/   $C\   ]!   ,1   "$8!
M  -(!@  20H  $H-  !+$   3!0  $T9  !.(   3B@  $XR  !-/0  3DH
M $Y8  !-:0  37T  $R4  !,J@  2\$  $OA  !*\@!0.   1C@  #TX   W
M.   ,3<  "HY   D.P  'CT  !A    30P  #T8   M)   '2P   DX   !0
M!   40@  %(+  !3#@  5!$  %45  !6&P  5R,  %<L  !7.   5T0  %=2
M  !68P  5G<  %:.  !5I0  5+T  %/=  !3\ !+/   0CP  #L[   U.P
M+3P  "8_   ?0@  &44  !-(   .2P  "T\   51    5    %<   !8 0
M6@4  %L(  !<#   70X  %\1  !@%@  8AT  &(F  !B,0  8CX  &%,  !A
M70  87   &"(  !@H   7[<  %[4  !=[@!'0   /S\  #H_   Q0   *4,
M "%&   :2@  $TX   Y1   *50  !%@   !;    7@   &$   !C    9 $
M &4$  !G"   : L  &H.  !L$@  ;A<  &\@  !O*@  ;S8  &Y%  !N50
M;F@  &U_  !MF   ;+   &O*  !JZ !$1   /D,  #5$   K1P  (TL  !M/
M   35   #E@   A<   "8    &0   !G    :P   &T   !O    <    '(
M  !T @  =08  '<*  !Y#@  ?!(  'X8  !_(@  ?RX  '\]  !^30  ?6$
M 'UW  !\D   >Z@  'K   !YWP!#1P  .4D  "],   E4   '%4  !1;   .
M8   !V4   !J    ;@   '(   !V    >0   'P   !^    ?P   ($   "#
M    A0   (<#  "*"   C T  (\1  "2&0  DB4  )(S  "21   D5<  )!M
M  "/A@  CI\  (VU  ",S0 ]3@  ,E$  "A6   >7   %6(   YH   ';@
M '0   !Y    ?@   ((   "&    B0   (P   ".    D    )(   "4
ME@   )@   ";    G@8  *$,  "D$0  IAL  *8I  "F.@  I4T  *5B  "D
M>P  HY0  *&K  "AOP V5P  +%P  "%B   7:0  #W    =W    ?@   (0
M  "*    CP   )0   "8    FP   )X   "?    H@   *0   "F    J
M *L   "M    L    +,$  "W#   NQ(  +L?  "[,   NT,  +I8  "Y<
MMXL  +>A  "WLP P8@  )6D  !IP   0>   "8    "(    CP   )8   ";
M    H0   *8   "J    K@   +    "Q    M    +8   "X    NP   +T
M  #     PP   ,<   #+ P  SPP  -,5  #2)0  TC@  -%.  #090  SWX
M ,V6  #,J0#_    _P   /\   #_  , _P + /P $0#Y !L ]P E /, +P#N
M #@ Z0!  .8 2 #B $X WP!4 -P 60#9 %X U0!C -, : #0 &T S@!S ,L
M>@#( (( Q@", ,, EP#  *, O@"R +P R "Z .H N0#_ +@ _P"Q /\ J@#_
M *< _P#_    _P   /L   #V    [0 ' .< #P#B !8 WP @ -X *0#9 #,
MT0 [ ,P 0@#( $@ Q0!. ,( 4P#  %@ O@!= +P 8@"Z &< N0!M +< = "U
M 'L L@"% +  D "N )P K "J *D O0"G -X I@#Y *4 _P"C /\ G0#_ )L
M_P#]    ]@   .L   #?    T0 # ,H # #% !( PP ; ,  ) "^ "P N0 U
M +8 / "S $, L !( *X 3@"L %( JP!7 *D 7 "G &$ I@!G *0 ;0"B '0
MH !] )X B "< )4 F@"C )@ M "6 ,T E0#Q )0 _P"5 /\ D #_ (X _P#S
M    Y@   -$   #"    N    +$ " "M  \ J@ 6 *@ '@"H "< I@ O *(
M-@"? #P G0!" )L 1P"9 $P EP!1 )8 50"4 %H DP!@ )$ 9@"0 &X C@!V
M (P @0"* (T B "; (8 K "% ,$ A #F (, _0"$ /\ @P#_ ($ _P#D
MRP   +H   "L    H@   )P ! "8  P E@ 1 )0 &0"3 "$ D@ H (\ , "-
M #8 BP \ (D 00"( $8 A@!+ (4 3P"$ %0 @@!: ($ 8 !_ &< ?@!O 'P
M>@!Z (8 > "4 '< I !U +< = #4 ', ] !T /\ = #_ '0 _P#+    M@
M *8   ":    D@   (H   "&  @ @P . ($ % "! !L @  C '\ *@!] #
M>P V 'H .P!X $  =P!% '4 20!T $X <P!4 '$ 6@!P &$ ;@!I &T <P!K
M '\ :0"- &@ G0!G *X 9@#' &4 Z@!F /\ 9@#_ &< _P"X    I    )4
M  "*    @0   'P   !V  0 =  , '( $ !Q !8 <  = '  ) !N "H ;0 P
M &L -0!J #H :0 _ &@ 1 !G $D 90!. &0 5 !C %L 80!C &  ;0!> 'D
M70"' %L E@!: *@ 60"] %D WP!9 /@ 6@#_ %H _P"H    E0   (<   ![
M    <P   &X   !J  $ 9P ( &4 #@!D !( 8P 8 &, 'P!B "4 80 J %\
M, !> #4 70 Z %P /@!; $0 60!) %@ 3P!7 %8 5@!> %0 : !3 ', 40"!
M %  D0!/ *( 3@"U $X T !. /  3@#_ $\ _P"<    B0   'L#  !P P
M: ,  &(!  !?    70 $ %L "P!9  \ 6  4 %< &0!7 "  5@ E %4 *@!3
M #  4@ T %$ .0!0 #\ 3P!$ $X 2P!- %( 2P!: $H 8P!) &\ 1P!\ $8
MC !% )T 10"P $0 QP!$ .@ 1 #Z $4 _P"2!   @ <  '$*  !F"@  7@H
M %D)  !5!P  5 0  %( !P!0  P 3P 0 $X %0!- !L 3  @ $L )@!* "L
M20 P $@ -0!' #H 1@!  $4 1@!# $X 0@!6 $$ 7P!  &L /@!X #T B  \
M )D / "K #P P0 [ .  .P#T #L _P")"@  > P  &H.  !?#@  5PX  %$.
M  !-#   2PL  $H( @!)! D 2  - $8 $0!% !8 1  < $, (0!" "8 00 K
M #\ ,0 ^ #8 /0 \ #P 0P [ $H .@!2 #D 7  X &@ -@!U #4 A0 T )8
M- "H #, O  S -@ ,P#O #, ^P""#0  <0\  &00  !9$0  41$  $L1  !'
M$   1 X  $(-  !!"P4 00<+ #\%#@ ^ Q( / (8 #L"'0 Z R( .0,H #@#
M+0 W S( -@0Y #4$/P T!4< ,P50 #$&6@ P!F8 +P=S "X'@P M!Y4 + >G
M "L'N@ K!]( *P?K "L']P!]$   ;!$  %\3  !4%   3!0  $84  !"$P
M/A(  #P0   Z#@$ .@T& #H*#  X"1  -@@4 #4(&0 T"1\ ,@DD #$)*0 P
M"2\ +PHV "X*/0 M"D4 + M. "L+60 I#&4 * QS "<,@P F#94 )0VG "0-
MNP C#=( (PWK ",-]P!X$@  :!0  %L6  !1%P  2!<  $(6   ]%@  .14
M #<3   U$0  ,Q # #,."  R#0T , T1 "\-%@ M#1L + TA "L-)P J#2T
M*0XT "@..P G#D0 )0Y. "0/60 C$&4 (1!S " 0A  ?$)8 'A"I !T0O0 <
M$-@ '1#N !T0^0!S%   9!8  %<8  !-&0  11D  #\9   Z&   -1<  #(6
M   P%0  +A,  "T1!  L$ H *Q . "D0$@ H$!@ )A > "40)  D$"H (Q$Q
M "(1.0 A$4( (!)+ !X25@ =$V, '!-Q !H3@@ 9%)4 &!2G !<4NP 7$]0
M%Q/N !@3^@!P%@  8!D  %0:  !*&P  0AP  #P;   V&P  ,AH  "\9   L
M&   *A8  "@4 0 F$P< )1,, ",3$  B$Q4 (!,: !\3(0 >%"< '10N !P5
M-@ ;%3\ &A9) !D65  8%V$ %A=P !48@0 4&), $QBF !(8N@ 2%]( $A?L
M !,7^@!L&0  71L  %$=  !''0  /QX  #D=   T'0  +QP  "L;   H&@
M)AD  "08   B%P0 (!<* !X7#@ <%Q( &A<7 !D8'@ 9&"0 &!DL !<9-  6
M&CT %1I' !0;4@ 3&U\ $AQN !$<?P 0')( $!RE  \<N0 .'-  #AOJ  \;
M^ !I&P  6AT  $X?  !%'P  /2   #8?   Q'P  +1X  "D=   E'0  (QP
M " ;   =&P$ &QL' !D<#0 7'!  %AP5 !4<&P 4'2( $QTI !(>,0 1'CH
M$1]% ! ?4  /(%T #B!L  T@?  -((\ #""B  L@M0 +(,H "R#E  P?] !E
M'0  5Q\  $PA  !"(0  .B$  #0A   O(0  *B   "8?   C'P  (!X  !T>
M   9(   %B $ !0@"P 2(0X $2$3 !$B&0 0(A\ #R(F  XC+P .(S< #2-!
M  PD30 +)%D "B1G  DD>  ()(L !R2>  <DL0 &),< !B/C  <C\0!B'P
M5"$  $DC  ! (P  .",  #(C   L(P  *"(  "0A   A(0  'B$  !HA   6
M(P  $R0# !$E"  /)@T #B<1  TG%@ ,)QT "R<C  HG*P )*#0 ""@^  <H
M20 &*%4 !2ED  0I=  #*8<  BF;  $HKP  *,4  2CA  $G\ !>(@  420
M $8E   ])0  -24  "\E   J)   )B0  "(C   ?(P  &R0  !@E   4)@
M$2@#  \I"  ,+ P "BP0  @L%  '+!H !BPA  4L*  #+3   BTZ  $M10
M+5(  "Y@   N<0  +80  "V9   MK0  +,(  "S@   L\ !:)   328  $,G
M   Z)P  ,R<  "TG   H)@  )"8  "$F   =)@  &2<  !4I   1*P  #RP#
M  TN!P ), P !C$.  ,Q$@ !,A<  #(>   R)0  ,BT  #(V   S0@  ,TX
M #-=   S;0  ,X$  #*6   RJP  ,<$  #'?   Q\ !6)P  2BD  #\J   W
M*@  ,"H  "LI   G*   (R@  !XI   :*@  %BP  !(N   /,   #3$"  HT
M!P %-0L  C8.   W$   .!0  #@:   X(@  ."H  #DS   Y/@  .4H  #E9
M   Y:0  .7T  #B3   XJ   -[\  #?>   V\ !1*P  1BP  #PL   T+
M+BP  "HK   E*P  ("P  !LM   7+P  $S$  ! S   --0  "3<"  4Z!@ !
M.PH  #P-   ]#P  /A(  #\7  ! '@  0"4  $ O  ! .@  0$8  $!4  !
M90  /W@  #^/   ^I@  /KT  #W<   ]\ !-+@  0B\  #DO   R+P  +2X
M "@N   B+P  '3   !@R   3-0  $#<   PZ   )/   !3X   !!!   0@@
M $,+  !$#0  1A   $<4  !(&0  2"$  $@J  !(-0  2$$  $A/  !(8
M1W,  $>*  !&H@  1;D  $79  !$\ !(,@  /C(  #8R   P,0  *S$  "4R
M   ?-   &38  !,Y   0/   ##\   A"   #1    $8   !( @  2@4  $L(
M  !,"P  3@X  $\1  !1%0  4AP  %(E  !2,   4CP  %%*  !16@  46T
M %"$  !/G0  3K4  $W2  !-[@!#-@  .S8  #0U   O-   )S4  "$X   :
M.P  %#X  !!!   ,1   !T<   )*    30   $\   !1    4P(  %0%  !5
M"   5PL  %D.  !;$0  71<  %T?  !=*@  738  %Q$  !<5   6V<  %M^
M  !:EP  6:\  %C+  !7Z@ _.0  .#D  #,X   K.0  (SP  !P_   50P
M$$<   M*   %3@   %$   !4    5P   %H   !<    70   %\   !@!
M8@<  &0+  !F#@  :!(  &L9  !K(P  :BX  &H\  !J30  :5\  &AU  !G
MCP  9J@  &7"  !DXP ]/0  -SP  "X]   E0   '40  !9)   030  "E$
M  15    6@   %T   !@    8P   &8   !H    :@   &L   !M    ;P(
M '$&  !T"@  =@X  'D3  ![&P  >R<  'HU  !Y10  >%D  'AM  !WA@
M=I\  '6W  !TT@ \00  ,D(  "A%   @2@  %TX  !!4   *60   EX   !C
M    9P   &L   !O    <@   '4   !W    >0   'L   !]    ?P   ((
M  "$ P  APD  (H.  ".$P  CQX  (XK  "..P  C4X  (MC  "*?   BI4
M (BM  "'Q0 V1P  +$L  ")/   950  $%L   IA   !9P   &T   !R
M=P   'L   !_    @P   (8   "(    B@   (T   "/    D0   )0   "7
M    F@$  )T'  "A#0  I10  *0A  "D,0  HT0  *)9  "@<   GXL  )VB
M  "=MP P4   )54  !M;   28@  "VD   %P    =P   'T   "#    B
M (T   "1    E0   )@   ":    G    )\   "A    HP   *8   "I
MK    +    "T!P  N X  +H8  "Z)P  N3D  +A.  "W90  MGX  +66  "S
MJP I6P  'F(  !1I   ,<0   GD   "!    B0   (\   "6    FP   *
M  "D    J    *L   "L    KP   +(   "T    M@   +D   "\    P
M ,0   #(    S0<  -(0  #2'0  T2\  -!$  #/6P  S7,  ,N-  #*H0#_
M    _P   /L   #Z    _  ( /@ #P#U !< ]  @ /$ *@#K #, Y@ [ .(
M0P#> $D V@!/ -8 5 #3 %D T !> ,X 8P#+ &@ R0!N ,8 =0## 'T P0"&
M +X D@"[ )X N0"N +8 PP"T .@ LP#_ *\ _P"E /\ G@#_ )L _P#]
M]P   /(   #P    YP # .$ # #< !( V  ; -8 ) #2 "T S  V ,8 /0#"
M $, OP!) +P 3@"Z %, N !8 +8 70"U &( LP!G +$ ;@"O '8 K !_ *H
MB@"H )< I0"F *, N0"A -D H #Y )X _P"8 /\ D@#_ (\ _P#S    [
M .,   #3    R    ,$ "0"]  \ NP 6 +D 'P"W "< LP O *\ -P"L #T
MJ@!# *@ 2 "F $T I !2 *, 5@"A %L GP!A )X 9P"< &\ F@!X )< @P"5
M )  DP"> )$ L "0 ,@ C@#P (T _P"* /\ A0#_ (( _P#G    W0   ,8
M  "X    K@   *@ ! "E  P H0 2 *$ &0"@ "( GP I )L , "8 #< E@ ]
M ), 0@"2 $< D !+ (\ 4 "- %4 C !: (H 80"( &@ AP!P (4 >P"# (@
M@0"6 '\ IP!] +P ? #C 'P _0!\ /\ > #_ '8 _P#6    P    *\   "C
M    F0   ),   "/  D C0 . (L % "* !P B@ C (@ *@"% #  @P V ((
M.P"  $  ?P!% 'X 2@!\ $\ >P!4 'H 6@!X &$ =@!I '4 <P!S (  <0".
M &\ GP!N +( ;0#/ &P ] !L /\ :P#_ &D _P#     JP   )L   "/
MAP   (    !\  0 >@ , '@ $0!X !< >  > '< ) !U "H <P P '$ -0!P
M #H ;@ _ &T 1 !L $D :P!. &H 5 !H %L 9P!C &4 ;0!D '@ 8@"' &
MEP!? *H 7@#" %X Z0!> /\ 7@#_ %T _P"L    F0   (H   !_    =P
M '$   !M    :@ ( &D #@!H !( 9P 8 &< 'P!G "4 90 J &, +P!B #0
M80 Y &  /@!? $, 7@!( %T 3@!; %4 6@!= %@ 9P!7 '( 50"! %0 D0!3
M *, 4@"X %$ W !1 /D 4@#_ %( _P"=    BP   'P   !Q    :0   &0
M  !@    7@ % %P "P!;  \ 6P 4 %H &0!: !\ 60 E %< *@!6 "\ 50 T
M %0 . !3 #T 4@!# %  20!/ %  3@!8 $T 8@!+ &T 2@!Z $D BP!( )T
M1P"Q $< S !& /  1P#_ $< _P"0    ?@   '    !F    7@   %D   !6
M    4P ! %( " !0  T 3P 0 $\ %0!. !H 3@ @ $T )0!, "H 2@ N $D
M,P!( #@ 1P ^ $8 1 !% $L 1 !3 $, 70!! &@ 0 !U #\ A0 ^ )< /0"K
M #T PP ] .8 /0#[ #X _P"'    =0,  &@&  !=!P  508  % &  !,!
M2@$  $D ! !'  H 1@ . $4 $0!% !8 1  ; $, ( !" "4 00 J $  +P _
M #0 /@ Z #T 0  [ $< .@!/ #D 60 X &0 -P!Q #8 @0 U ), - "F #0
MNP T -T - #U #4 _P!^!@  ;0D  & +  !6#   3@P  $@+  !$"@  0@@
M $ % 0 _ 0< /@ + #T #@ \ !( .P 7 #L '  Z "$ .0 E #< *@ V #
M-0 U #0 /  S $, ,@!, #$ 50 P &  +P!M "X ?0 M (\ + "B "P M@ L
M -  + #N "P _ !W"@  9PP  %H.  !0#@  20X  $,.   ^#0  .PP  #D+
M   X"0, -P4( #8"#0 U 1  -  3 #, &  R !T ,0 B #  )P O "P +@ R
M "T .  L $  *P!) "H 4@ I %T * !K "<!>@ F 8P )0"? "4 L@ E ,H
M)0#H "4 ]P!R#0  8@X  %80  !,$0  1!$  #X1   Y$   -@\  #,.   Q
M#0$ , L% # ("@ O!@T +@41 "P$%  K QD *@,> "D#(P H!"D )P0O "8%
M-0 E!3T ) 5& ",&4  B!EP (0=I " '>0 ?!XL '@>= !X'L  =!L8 '0;C
M !T%\P!M#@  7A$  %(2  !($P  0!,  #H3   U$@  ,1$  "X0   L#P
M*@X# "H-!P I"PL * D. "<)$0 E"!8 ) @; ",)(  B"28 (0DL " *,P ?
M"CL '@M$ !T+3P <#%L &PQI !H,>0 8#(L & R> !<,L  6#,4 %@SA !8+
M\ !I$   6A(  $X4  !%%0  /14  #<5   Q%   +1,  "H2   H$0  )A !
M "00!  C#@@ (PT, "(,#P @#!, 'PP8 !X-'0 =#2, ' TJ !L-,@ :#CH
M& Y$ !<.4  6#UP %0]J !,0>P 2$(T $1"@ !$0LP 0#\D $ _D !$/\@!E
M$@  5Q0  $L6  !"%P  .A<  #07   O%@  *A4  "<4   D$P  (A,  " 2
M P >$08 '1 ) !P0#0 ;#Q  &1 5 !@0&P 7$"$ %A H !41,  4$3D $Q%#
M !(23@ 1$EH $!)I ! 3>0 .$XP #A.>  T3L0 -$L4 #!+A  T2\0!B%
M5!8  $D8   _&0  -QD  #$9   L&   *!<  "06   A%@  'Q4  !P4 @ :
M$P0 &1(& !<2"P 5$@X %!(2 !,3&  2$Q\ $1,F !$4+0 0%#8 #Q5!  X5
M3  .%E< #19E  P7=0 +%X< "A>:  D6K0 (%L$ "!;=  D5[@!?%@  41@
M $8:   ]&@  -1L  "\:   J&@  )1D  "(8   ?&   '!<  !D6 0 7%@,
M%18$ !,6"0 1%@T $!<1  \7%@ .%QP #A@C  T8*@ ,&3, #!D\  L:1P *
M&E, "1IA  <;<0 &&X, !1N7  0:J@ #&K\  QG:  09[ !<&   3AH  $,<
M   Z'   ,QP  "P<   G'   (QL  " :   =&0  &AD  !<8 0 5& ( $AD$
M ! ;!P .&PP #1P0  P<$P +'!D "AP?  D=)P ('2\ !QXY  8>0P $'E
M Q]>  (?;@ !'X   !^5   >J0  'KT  !W8   =[ !8&@  2QP  $$>   X
M'@  ,!X  "H>   E'0  (1P  !X<   ;&P  &!L  !8; 0 3&P( $1P$  X>
M!P ,'PL "B .  @@$@ &(1< !2$=  0A)  "(BP  2(U   B0   (TT  "-:
M   C:P  (WX  ".3   BIP  (KP  "'7   A[0!5'0  2!\  #X@   U(
M+B   "@@   C'P  (!X  !T=   :'0  %AT  !,>   1'P( #B $  TB!P *
M) L !B4-  0E$  ")A0  "8:   F(0  )RD  "<R   G/0  )TD  "A7   H
M9P  )WL  ">0   GI0  )KL  ";6   E[0!1(   12$  #LB   R(@  +"(
M "8A   B(0  'B   !L?   8(   %"   !$B   /(P  #24#  HF!@ &* H
M RD-   K#P  +!(  "P7   L'@  +"8  "TO   M.0  +48  "U4   M9
M+7<  "R-   LI   *[H  "O6   J[@!-(@  020  #@D   P)   *20  "0C
M   A(@  '2(  !DB   5(P  $B0   \F   -*   "BH"  8L!0 "+@D  "\+
M   P#@  ,A   #,5   S&P  ,R(  #,K   S-@  ,T(  #-0   S8   ,W,
M #**   RH0  ,;@  ##6   P[P!))0  /B8  #0G   M)P  *"8  ",E   ?
M)   &R4  !8F   2*   $"H   TL   *+@  !C !  (R!   - <  #4*   W
M#   . X  #H2   Z%P  .A\  #HG   Z,@  .CX  #I,   Z7   .F\  #F&
M   XG@  .+8  #?4   V[P!$*0  .BD  #$I   K*0  )B@  "(G   =*
M&"D  !,K   0+@  #3    DR   %-0   3<    Y @  .P4  #P(   ^"P
M/PT  $$0  !#%   0QL  $,C  !#+@  0SD  $-'  !"5P  0FH  $&!  !
MF@  /[(  #[/   ^[P _+   -BP  "\L   J*P  )2H  !\K   9+0  %"\
M ! R   --0  "#@   0Z    /    #\   !!    0P(  $4%  !&"   2 L
M $H.  !,$0  318  $T>  !-*   330  $Q"  !,40  2V0  $M[  !*E
M2:T  $C*  !'[  [,   ,R\  "TO   H+0  (B\  !LQ   5-   $#<   TZ
M   (/0   D    !#    1@   $@   !*    3    $X!  !/!   40<  %,+
M  !5#@  6!(  %D9  !8(@  6"X  %<\  !72P  5EX  %9S  !5C0  5*<
M %+"  !2Y@ X,P  ,3(  "PQ   E,@  '34  !8X   1/   #$    =$
M1P   $H   !-    4    %,   !5    5P   %D   !:    7 ,  %X'  !A
M"P  9 X  &83  !G'   9B<  &8T  !E1   9%<  &1K  !BA0  89\  &"Y
M  !>W  U-P  ,#4  "@W   @.@  &#T  !%"   ,1@  !DH   !/    4P
M %8   !9    7    %\   !A    9    &4   !G    :0   &P!  !N!@
M<0L  '0/  !W%0  =R   '8M  !V/0  =4\  '1C  !S>P  <I4  '"O  !O
MR0 U.@  *SL  "(_   :0P  $D@   Q-   %4@   %<   !<    8    &0
M  !H    :P   &X   !Q    <P   '4   !W    >@   'P   !_    @@0
M (8*  "*#P  C!<  (LD  "*,P  B44  (=;  "&<@  A8L  (.E  ""O  O
M0   )40  !Q)   33@  #50   1:    80   &8   !K    ;P   '0   !Y
M    ?0   (    "#    A0   (<   "*    C    (\   "2    E@   )D"
M  ">"0  HA   *(:  "A*0  H#L  )]0  "=9P  FH$  )J9  "9KP I20
M'TX  !54   .6P  !6(   !I    <    '<   !]    @@   (8   "+
MCP   ),   "5    EP   )H   "=    H    *,   "F    J@   *X   "R
M    MPH  +L1  "Z'P  N3   +=%  "U7   M'0  +&.  "OI  B5   &%L
M !!B   ':@   ',   ![    @@   (D   "0    E0   )H   "?    HP
M *8   "H    JP   *X   "P    LP   +8   "Z    O0   ,(   #'
MS $  -,+  #4%0  TR8  -$Z  #040  S6@  ,N!  #*E@#\    ]@   /(
M  #Q    \P % /0 # #R !, \  < .T )0#H "X X@ V -X /@#9 $0 U !*
M -$ 3P#. %0 RP!9 ,D 7@#& &, Q !I ,$ < "^ '@ O "! +D C0"V )H
MLP"K +$ P "O .8 K@#_ *4 _P": /\ E #_ (\ _P#T    [    .@   #G
M    WP   -D "0#2 !  SP 7 ,\ ( #, "@ Q@ P ,  -P"\ #X N0!$ +<
M20"U $X LP!3 +$ 5P"O %T K0!B *L :0"I '$ IP!Z *4 A0"B ), H "B
M )T M@"; -0 F0#Y )8 _P"- /\ B #_ (0 _P#H    WP   -D   #)
MOP   +@ ! "U  T LP 2 +$ &@"P "( K0 J *D ,0"F #@ I  ] *( 0P"@
M $@ G@!, )P 40"; %8 F0!< )< 8@"5 &D DP!R )$ ?0"/ (L C0": (L
MK ") ,4 B #N (8 _P!_ /\ >@#_ '@ _P#9    S0   +L   "N    I0
M )\   "<  D F0 / )D %0"9 !T F  D )0 *P"1 #$ C@ W (P / "+ $$
MB0!& (@ 2P"& %  A0!5 (, 6P"" &( @ !K 'X =0!\ (( >@"2 '@ HP!W
M +D =@#@ '4 _P!R /\ ;@#_ &P _P#'    M0   *4   "9    CP   (D
M  "%  0 A  , (( $0"" !< @@ > (  )0!^ "L ?  Q 'H -@!Y #L =P!
M '8 1 !U $D <P!/ '( 50!P %P ;P!D &T ;@!L 'H :@"* &@ FP!G *\
M9@#, &4 ]0!D /\ 80#_ &  _P"T    H    )    "%    ?0   '<   !S
M    <  ( &\ #@!O !( ;P 8 &\ 'P!M "4 :P J &D , !H #0 9P Y &8
M/@!E $, 8P!( &( 3@!A %4 7P!> %X 9P!< ', 6P"" %D DP!8 *8 5P"_
M %< Z@!7 /\ 5@#_ %0 _P"A    C@   '\   !U    ;    &@   !D
M80 $ &  "P!?  \ 7P 3 %\ &0!? !\ 70 E %P *@!; "\ 60 S %@ . !7
M #T 5@!# %4 20!3 %  4@!8 %$ 80!0 &T 3@![ $T C !, )\ 2P"U $H
MW !* /H 2@#_ $H _P"2    @    '(   !G    7P   %H   !7    50 !
M %, !P!2  P 4@ 0 %( % !2 !H 40 ? $\ ) !. "D 30 N $P ,P!+ #@
M2@ ] $D 0P!( $H 1@!2 $4 7 !$ &< 0P!U $( A@!! )@ 0 "N $  RP _
M /( 0 #_ $  _P"%    =    &<   !=    50   $\   !,    2@   $@
M! !'  H 1P - $8 $0!& !4 1@ : $4 'P!$ "0 0P I $( +0!! #, /P X
M #X /@ ] $4 / !. #L 5P Z &( .0!O #@ @  W ), -@"G #8 P  V .@
M-@#^ #8 _P!\    :P   %X"  !4 P  30,  $<#  !# 0  00   #\  0 ^
M  < /0 + #T #@ \ !$ /  6 #P &@ Z !\ .0 D #@ *0 W "X -@ S #4
M.@ T $$ ,P!) #( 4P Q %X , !K "\ >P N (X +0"B "T N  M -T +0#X
M "X _P!S 0  9 4  %<'  !-"   1@@  $ (   [!P  . 4  #<#   V  0
M-0 ( #0 #  T  \ -  2 #, %@ R !L ,0 @ #  )  O "D +@ O "T -@ L
M #T *P!% "H 3P I %H * !G "< =P F (D )@"= "4 LP E ,\ )0#P "8
M_P!M!@  7@D  %(+  !(#   0 P  #H+   V"P  ,@H  # (   N!@( +@,&
M "T "@ L  T +  0 "L $P J !< *0 < "@ (  G "4 )@ K "4 ,@ D #D
M(P!" "( 2P B %< (0!D "  <P ? (4 'P"9 !X K@ > ,< '@#I !\ ^@!H
M"0  60P  $T-  !##@  / X  #8.   Q#0  +0T  "H,   H"P  )PD$ "8&
M"  F! L )0,. "0!$  D 10 (@$8 "$!'0 A "( (  H !\ +@ > 38 '0$_
M !P!20 ; 50 &@%A !H!<  9 8( & "6 !@ J@ 8 ,$ & #A !@ ] !C#
M50X  $D/  ! $   .!   #(0   M#P  *0X  "8.   C#0  (@P# " +!@ @
M"0D 'P<, !X&#@ >!1$ ' 45 !L%&@ :!1\ &@4E !D%*P 8!3, %P8\ !8&
M1@ 6!E( %0=? !0';@ 3!X  $@>4 !(&IP 2!;P $@39 !(#[P!?#@  40\
M $80   \$0  -1$  "\1   J$0  )A   "(0   @#P  '0X" !P-!0 :#0<
M&@L* !D*#0 8"1  %PD2 !8)%P 5"1P % DB !0**0 3"C$ $@HZ !(+10 1
M"U$ $ Q?  \,;@ .#(  #@R4  T+IP -"[H #0K2  T*Z@!<#P  3A$  $,2
M   Z$P  ,A,  "P3   G$@  (Q$  !\1   <$   &A " !@/!  6#@< %0X)
M !0-"P 3# T $@P0 !(,%  1#!H $0T@ ! -*  /#3  #@X[  T.1@ -#E$
M# ]>  L/;0 *#W\ "0^3  D/I@ (#KD " [0  <.Z !8$0  2Q(  $ 3   W
M%   ,!0  "D4   E%   (1,  !T2   :$@  %Q$" !41!0 3$ < $A ) !$/
M"@ 0#@P #@X.  X/$@ -$!@ #1 >  P0)0 ,$"T "Q$V  H100 )$4T "!):
M  <2:@ &$GP !1*0  02I  #$;@  Q'/  (1Z !5$@  210  #X5   U%@
M+18  "<6   B%0  'A0  !L4   8$P  %1(# !,2!0 2$0< $!$)  \1"@ -
M$0L #!(.  L2$0 *$A4 "1,;  D3(@ ($RH !Q0S  44/@ $%4H  Q58  (5
M9P !%7H  !6.   5HP  %+<  !3/   3Z0!2%   1A8  #L7   R%P  *Q<
M "47   A%@  '!8  !D5   6% $ %!,$ !(3!@ 1$@@ #Q((  X3"0 ,% H
M"A4-  @6$  &%A, !189  07'P #%R<  A@P  $8.P  &4<  !E5   99
M&7<  !F,   8H@  &+<  !?/   7Z@!/%@  0Q@  #D9   P&0  *1D  ",9
M   ?&   &Q<  !@6   5%0( $Q4% !$4!@ 0% 8 #A4'  P6"  *%PH !QD,
M  0:#@ "&Q(  1L6   ;'0  '"0  !PM   <.   '40  !U2   =8@  '74
M !V*   <H   '+8  !O0   :ZP!,&   0!H  #8;   M&P  )AL  "$:   =
M&0  &1D  !<8   4%P, $A8$ ! 7!  .%P0 #!D%  H:!P '' D  QT+   ?
M#0  (!   " 4   A&@  (2(  "$J   A-0  (D$  ")/   B7P  (G(  "&(
M   AGP  (+8  !_1   ?[0!(&@  /1P  #,=   K'0  )!T  " <   <&P
M&!H  !89 0 3&0$ $1D!  X: 0 ,' ( "AT#  <?!0 #(0@  "(*   D#
M)@X  "82   F&   )Q\  "<G   G,@  )SX  "=+   G7   )VX  ":%   F
MG0  );0  "31   C[@!$'0  .1\  # ?   H'P  (QX  !X=   ;'   &!L
M !0<   1'   #AT   T?   *(0  !B(!  ,D!   )@8  "@(   J"P  *PT
M "T0   M%0  +1P  "TD   N+@  +CH  "Y(   M6   +6H  "V!   LF@
M*[(  "K0   I[P! (   -B$  "TA   F(0  (2   !T?   :'@  %AX  !(?
M   /(0  #2(   HD   &)@   B@    K @  +00  "\&   P"0  ,@P  #0.
M   U$@  -1@  #4@   U*@  -38  #5#   U4P  -&8  #1\   SE@  ,J\
M #'-   P[P \(P  ,B0  "HD   D(P  ("(  !PA   7(0  $R,  ! E   -
M)P  "2D   4K   !+@   #     R    - $  #8$   X!@  .@D  #P-   ^
M$   /A0  #X<   ^)@  /C$  #X_   ]3@  /6$  #QW   [D0  .JL  #G)
M   X[0 W)P  +R<  "@F   C)0  'R0  !DE   4)@  $"@   TK   )+@
M!3     S    -0   #@    Z    /    #X!  !  P  0@<  $0*  !&#0
M21$  $D7  !((0  2"P  $<Z  !'20  1EL  $5Q  !$BP  0Z4  $+#  !!
MZ  T*@  +"H  "<H   B)P  '"@  !8J   1+0  #3    DS   #-@   #D
M   \    /@   $$   !#    1@   $@   !*    3 ,  $X&  !0"@  4PX
M %03  !4'   4R<  %,T  !30P  4E4  %%J  !0@P  3YX  $VY  !,X  P
M+0  *RP  "8K   ?+   &"X  !(R   --0  "#D   (]    0    $,   !&
M    20   $P   !.    40   %,   !5    5P   %D!  !<!@  7PH  &(.
M  !C%0  8Q\  &(L  !A/   8$X  %]B  !>>P  7)8  %NP  !9SP O,
M*B\  "(P   :,P  $S<   X[   (/P   40   !(    3    $\   !2
M50   %@   !;    70   &    !B    9    &8   !I    ;04  ' +  !T
M$   =!@  ',E  !R-   <D4  '!9  !O<0  ;8L  &NF  !JP  N,P  )34
M !TX   4/   #D$   ='    3    %$   !5    60   %T   !A    90
M &@   !K    ;0   &\   !R    =    '<   !Z    ?@   (($  "&"P
MBA$  (D<  "(*P  ACT  (12  "#9P  @8$  '^;  !^L@ I.@  (#T  !9"
M   /2   "$X   !4    6@   &    !D    :0   &X   !R    =@   'H
M  !]    @    ((   "%    B    (L   ".    D@   )8   "; P  H P
M *(3  "@(0  GS,  )U'  ":7@  F'<  )>/  "5IP C0P  &4@  !%.   )
M50   %P   !C    :@   '$   !V    >P   (    "&    B@   (X   "1
M    DP   )8   "9    G    *    "C    IP   *L   "P    M@0  +P-
M  "Z%P  N2@  +<\  "T4@  LFH  *^%  "MG  <3@  $U0   M<   !9
M &P   !T    ?    (,   ")    CP   )0   ":    GP   *(   "D
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M_/[______________________________________________________P
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MA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:]\ 0%?C
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M@ZB)SH&GC,^ IXW/@*>-SX"GC<^ IXW/@*>-SX"GC<^ IXW/@*>-SX"GC<^
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M@+&,PH"QC,* L8S"@+&,PH"QC,* L8S"@+&,PH"QC,* L8S"@+&,PH"QC,*
ML8S"SLH(!L[1"AS&UPI!K^H.89WF''B0VC*(B]),E(G+7YR(QFZCB,-XJ(7
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M@Z.,U(&CD=2 I)G3@*:AT8"FH=& IJ'1@*:AT8"FH=& IJ'1@*:AT8"FH=&
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MEU]^W)-ND\^2>*7&DH*TQ)*)ML.1CKC!CI"ZP(J2O+^'E+V^A):_OH*9P+V
MF\&]?I[!O'VAPKQ[I,*\>JC#O'FMP[AYK\*X>:_"N'FOPKAYK\*X>:_"N'FO
MPKAYK\*X>:_"N'FOPKAYK\*X>:_"_ZH<!?^J)Q?_IS8O_Z)$2OJ=4F7JEU]^
MW)-ND\^2>*7&DH*TQ)*)ML.1CKC!CI"ZP(J2O+^'E+V^A):_OH*9P+V F\&]
M?I[!O'VAPKQ[I,*\>JC#O'FMP[AYK\*X>:_"N'FOPKAYK\*X>:_"N'FOPKAY
MK\*X>:_"N'FOPKAYK\*X>:_"_ZH<!?^J)Q?_IS8O_Z)$2OJ=4F7JEU]^W)-N
MD\^2>*7&DH*TQ)*)ML.1CKC!CI"ZP(J2O+^'E+V^A):_OH*9P+V F\&]?I[!
MO'VAPKQ[I,*\>JC#O'FMP[AYK\*X>:_"N'FOPKAYK\*X>:_"N'FOPKAYK\*X
M>:_"N'FOPKAYK\*X>:_"_ZH<!?^J)Q?_IS8O_Z)$2OJ=4F7JEU]^W)-ND\^2
M>*7&DH*TQ)*)ML.1CKC!CI"ZP(J2O+^'E+V^A):_OH*9P+V F\&]?I[!O'VA
MPKQ[I,*\>JC#O'FMP[AYK\*X>:_"N'FOPKAYK\*X>:_"N'FOPKAYK\*X>:_"
MN'FOPKAYK\*X>:_"_ZH;!?^J)Q?_IS4O_Z-$2OJ=467IEUY^VY1ME,^2=Z;%
MDH&TQ).(ML.2C;C!CX^ZP(N1O+^(D[Z^A9:_O8*8P;R F\*\?I["O'VAP[M[
MI,2[>JG$NGFMQ+5YKL.U>:[#M7FNP[5YKL.U>:[#M7FNP[5YKL.U>:[#M7FN
MP[5YKL.U>:[#_ZL;!?^K)A?_J#0O_Z1#2OF>4&7IF%U_VI5IE<V4=*C%E'ZT
MQ)6&ML*5C+G!D8Z[OXV0O;Z)DK^]AI3!O(.7P[N!FL2Z?IW%NGVAQKI[I<:Y
M>JK&M7JLQK%ZK<2Q>JW$L7JMQ+%ZK<2Q>JW$L7JMQ+%ZK<2Q>JW$L7JMQ+%Z
MK<2Q>JW$_ZL:!?^K)1?_J30O_Z1"2OF?3V;HF5R VI9FELR5<:G%E7RTQ):#
MM\*7B[K DXR\OH^.O[V+D,&\AY/#NH26Q;F!F<:Y?YW'N'VAR+A\ILFU>JK)
ML'NKQZQ[K<6L>ZW%K'NMQ:Q[K<6L>ZW%K'NMQ:Q[K<6L>ZW%K'NMQ:Q[K<6L
M>ZW%_ZP9!?^L)!;_J3,O_Z5!2OF?3V;HF5N!V9ACELR6;ZK%EGFTPY>!M\&8
MB;J_E8N]OI&-P+R-C\*ZB)+%N865Q[B"F,FW?YW*MGVBR[9\J,NP>ZG*K'RJ
MR*A]K,6H?:S%J'VLQ:A]K,6H?:S%J'VLQ:A]K,6H?:S%J'VLQ:A]K,6H?:S%
M_ZP9!?^L)!;_JC(O_Z5!2_F@3F?GFEF!V9EAE\N7;:O%EW>TPYE_M\&:A[N_
MEXJ^O9.,P;N.CL2YBI#'N(:3R;:"F,NU?YW-M'ZCSK%\ILZL?:C+J'VJR:5^
MK,:E?JS&I7ZLQJ5^K,:E?JS&I7ZLQJ5^K,:E?JS&I7ZLQJ5^K,:E?JS&_ZP9
M!?^M(Q;_JC(O_Z9 2_B@36?GG%>!V9I>E\N8:JS%F72TPYI]M\&;A;N^F8F_
MO)6*PKJ0C,6XC(_(MH>2R[2#E\ZS@)W0LG^DT:Q^I<^H?J?,I'^IR:& K,:A
M@*S&H8"LQJ& K,:A@*S&H8"LQJ& K,:A@*S&H8"LQJ& K,:A@*S&_ZT8!?^M
M(Q;_JS$O_Z8_2_B@36?GG56!V9Q<E\J9:*S%FG*TPYQZN,"<@[N^G(F_NY>)
MP[F3B\>WCHW+M(F0SK*$EM&Q@9W3K("BTZ> I="D@*?-H(&IRIZ!J\:>@:O&
MGH&KQIZ!J\:>@:O&GH&KQIZ!J\:>@:O&GH&KQIZ!J\:>@:O&_ZT8!?^M(A;_
MJS$O_Z<_2_BA3&?GGE.!V9U9E\J;9:S%G&^TPYUXN,">@;R]GHC NYJ(Q+B5
MB<FUD(O-LHN/T;"&E=6NA)[7IX*AU*."I-&?@J?-G(.IRIJ#J\>:@ZO'FH.K
MQYJ#J\>:@ZO'FH.KQYJ#J\>:@ZO'FH.KQYJ#J\>:@ZO'_ZT7!?^N(A;_JS O
M_Z<^2_BA2VCGGU&!V9]6E\J<8JS%G6RTPY]UN,"@?KR]H(?!NIV(QK>8B,NS
MDXG/L(Z-U*V)E-FHAIW:HH6AU9Z%I-&;A:;.F86IRI>%J\>7A:O'EX6KQY>%
MJ\>7A:O'EX6KQY>%J\>7A:O'EX6KQY>%J\>7A:O'_ZX7!/^N(A;_K# O_Z<^
M2_BB2VCHH4^!V:!3E\J>7ZS&GVFTPZ%RN,"B?+R]HH3!N:"'Q[6<A\VREXC2
MKI.+V*J.D]^BBYS<G(F@UIF(H]*7B*;.E8BIRI2(J\>4B*O'E(BKQY2(J\>4
MB*O'E(BKQY2(J\>4B*O'E(BKQY2(J\>4B*O'_ZX7!/^N(1;_K"\O_Z@]2_BB
M2FCHHDV V:)0E\N@7*S&H66SPZ1NM\"E>+R\I8+"N*2'R+2@A\ZPG8C5JYF*
MW:67D^:;D9O=EH^@UY2-H].2C*;/D8NHRY"*J\B0BJO(D(JKR)"*J\B0BJO(
MD(JKR)"*J\B0BJO(D(JKR)"*J\B0BJO(_ZX6!/^O(1;_K2\O_Z@\2_>B26CH
MI$J V:1-ELNB6*O&I&&SQ*=JM\"I=+R\J7["N*B'R+.FA\^LHH?7I)V)W9J:
MC>&5FIO>D96?V(^3HM..D*70CH^HS(V.JLF-CJK)C8ZJR8V.JLF-CJK)C8ZJ
MR8V.JLF-CJK)C8ZJR8V.JLF-CJK)_Z\6!/^O(1;_K2XO_ZD\2_>C26GHIDA_
MVJ=(E<RE4ZK'J%RRQ*QDML&N;KN]KWC MJR$R:ZGA]"FHX;5G:"&V9.=B=V-
MG93=C9V?V(N9H=2+EJ30BI.GS8J1J<F*D:G)BI&IR8J1J<F*D:G)BI&IR8J1
MJ<F*D:G)BI&IR8J1J<F*D:G)_Z\5!/^P(!;_KBXO_ZD[2_>D1VGIJ$1^VZM#
ME,VI3*G(K52PQK-<L\*W9KFWL'?"L*N$R:FGAL^AI(33EZ*$UHZ@A]F(GX_:
MAZ&:V(>@H=2'FZ31AYBFSH>5J<J'E:G*AY6IRH>5J<J'E:G*AY6IRH>5J<J'
ME:G*AY6IRH>5J<J'E:G*_[ 5!/^P(!7_KBTO_ZHZ2_BF1&CJJT!]W*\\DL^O
M0J;*M4FMQKQ2L;FU9[NPL'C#JZR$R:2IA,V<IH/0DZ2$TXNCAM6%HHS6@J*4
MUH.DG=2#HJ31@YZFSH2:J,N$FJC+A)JHRX2:J,N$FJC+A)JHRX2:J,N$FJC+
MA)JHRX2:J,N$FJC+_[ 4!/^Q'Q7_KRPN_ZLY2_BI0&?KKSM[WK8SC]*Z-*',
MPCFJN[I5M;"T:KVJL'G#IZV$QY^JA,N8J(/-D*>$T(FEAM*$I(K3@*20TW^E
ME])_IJ#0?Z6FSH"@J,N H*C+@*"HRX"@J,N H*C+@*"HRX"@J,N H*C+@*"H
MRX"@J,N H*C+_[$3!/^R'A7_L"LN_ZPW3/JL.V7MM31XXK\IB=C,()B^OSVN
ML+A9N*FS;+ZEL'K"HJZ$Q9NL@\B4JH3*CJF$S(BHALZ#IXG/@*>-SWZGD\]\
MJ)K.?*FBS7RGJ,M\IZC+?*>HRWRGJ,M\IZC+?*>HRWRGJ,M\IZC+?*>HRWRG
MJ,M\IZC+_[(2!/^S'17_L2DN_ZTV3/RQ-6+QO2IRYLT?@,C,(9NQO$6RJ+=>
MN:.S;[Z@L7O!GJ^$PY>NA,:1K(3'C*N%R8>JA\J#JHG+@*J,S'VID,Q\JI7+
M>JJ<RGFKI,IYJZ3*>:NDRGFKI,IYJZ3*>:NDRGFKI,IYJZ3*>:NDRGFKI,IY
MJZ3*_[,1!/^T&Q3_LR8N_Z\S3/VY*UWKRA]ITM\1?[G,)YRGO4RQH+=BN9VT
M<;V;LGR_FK&$P92PA,./KX7%BJZ&QH:MA\>#K(G'@*R+R'ZLCLA\K)+(>ZR7
MR'FMGL=YK9['>:V>QWFMGL=YK9['>:V>QWFMGL=YK9['>:V>QWFMGL=YK9['
M_[40 _^V&13_M20M_[0L2?+%'U36W1)BP=\3@:S-+IJ?P$^KFKAEMY>U<KN6
MM'R]E;*#OY&QA<&-L8;"B;"'PX:OB,.#KXG$@:^+Q'^NC<5]KI#%>ZZ4Q7JO
MF<1ZKYG$>J^9Q'JOF<1ZKYG$>J^9Q'JOF<1ZKYG$>J^9Q'JOF<1ZKYG$_[<.
M _^X%A/_MR M^;\?0=S9$43$ZQ)FL=\8@:#0,Y67QE"CD\!CK9&[<;.1N'NX
MD+:"NXZTA;V+LX:_B+*'P(:RB<"$L8K!@K&+P8"QC<%^L8_"?+&2PGNQE<%[
ML97!>[&5P7NQE<%[L97!>[&5P7NQE<%[L97!>[&5P7NQE<%[L97!]+H+ _V[
M$A+^NQLLY= /,LCI#TJT\A5GHN(B?9;6-XV/SD^8C,AAH(K$;J:*P7BJA[]]
MK82^@+"!O(*Q?[N$LWV[A;1[NH>U>KF)M7FYB[9WN8VV=KB/MW2XD[=TN).W
M=+B3MW2XD[=TN).W=+B3MW2XD[=TN).W=+B3MW2XD[=TN).WW+X& OC #A'N
MR XBR]L++K;X$4RE]1UCE^@L=8W?/8&'V%"+@]-@DH+/;)=_S7.;?,MWG7G)
M>J!WR'VA=<=_HW/&@J1RQ82E<,6&I6_$B*9NQ(JG;<.-IVO#D*AKPY"H:\.0
MJ&O#D*AKPY"H:\.0J&O#D*AKPY"H:\.0J&O#D*AKPY"HU\ & =O&" [+TPH5
MN.@,,J;_%4J8^B9<C? W:87I1G1_Y%-[?-]@@7C<:(5TVFV)<-AQBV[6=8UL
MU7B/:M1[D&G3?I%GTX"29M*#DV72A91DT8>48]"*E6+0CI9BT(Z68M".EF+0
MCI9BT(Z68M".EF+0CI9BT(Z68M".EF+0CI9BT(Z6T<(& <W+"06ZV@<9J/X.
M,9G_'4.._R]1A?H_7'[T361Y\%AJ<^Q?;VWJ8W-IYVEV9^5N>67D<GMCXW9]
M8N)Y?F#A?']?X'Z 7M^!@5W?@X)<WH:#6]V)A%K=C85:W8V%6MV-A5K=C85:
MW8V%6MV-A5K=C85:W8V%6MV-A5K=C85:W8V%R\0& +O1!@>IYP8:FO\3*X[_
M)#F%_S9$?O]$37G_455Q^U=;:_==8&7T8F1B\FAG7_!M:EWO<6Q;[75M6NUX
M;UGL>W!8ZWYQ5^J!<E;JA')5Z8=S5.F*=%/HCG53Z(YU4^B.=5/HCG53Z(YU
M4^B.=5/HCG53Z(YU4^B.=5/HCG53Z(YUO,D% *O; 0B:_PL6C_\9(X7_*RU^
M_SDW>/]&0'#_3D=I_U1-8O]:4E[^859:_&996/MK6U7Y<%U4^'1>4O=X7U'W
M>V!0]GYA3_6!8D_UA&-.](=D3?2+94SSD&9,\Y!F3/.09DSSD&9,\Y!F3/.0
M9DSSD&9,\Y!F3/.09DSSD&9,\Y!F_Z 8 _^B+!#_H#LE_YQ)//^75U/XDF1G
M[)!L>>*/=8G9CGZ7T8V'HLR,C:K'BI&QQ(B4ML.%EKC"@YFYPH&;N<%_GKK!
M?:&[P7NDN\!ZI[O >:J\P'BNO,!WM+N\>+2[O'BTN[QXM+N\>+2[O'BTN[QX
MM+N\>+2[O'BTN[QXM+N\>+2[_Z 8 _^B+!#_H#LE_YQ)//^75U/XDF1G[)!L
M>>*/=8G9CGZ7T8V'HLR,C:K'BI&QQ(B4ML.%EKC"@YFYPH&;N<%_GKK!?:&[
MP7NDN\!ZI[O >:J\P'BNO,!WM+N\>+2[O'BTN[QXM+N\>+2[O'BTN[QXM+N\
M>+2[O'BTN[QXM+N\>+2[_Z 8 _^B+!#_H#LE_YQ)//^75U/XDF1G[)!L>>*/
M=8G9CGZ7T8V'HLR,C:K'BI&QQ(B4ML.%EKC"@YFYPH&;N<%_GKK!?:&[P7ND
MN\!ZI[O >:J\P'BNO,!WM+N\>+2[O'BTN[QXM+N\>+2[O'BTN[QXM+N\>+2[
MO'BTN[QXM+N\>+2[_Z 8 _^B+!#_H#LE_YQ)//^75U/XDF1G[)!L>>*/=8G9
MCGZ7T8V'HLR,C:K'BI&QQ(B4ML.%EKC"@YFYPH&;N<%_GKK!?:&[P7NDN\!Z
MI[O >:J\P'BNO,!WM+N\>+2[O'BTN[QXM+N\>+2[O'BTN[QXM+N\>+2[O'BT
MN[QXM+N\>+2[_Z 8 _^B+!#_H#LE_YQ)//^75U/XDF1G[)!L>>*/=8G9CGZ7
MT8V'HLR,C:K'BI&QQ(B4ML.%EKC"@YFYPH&;N<%_GKK!?:&[P7NDN\!ZI[O
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MK:K,<+*KRW"VJ\MOO*O(<,"KQ'' JL1QP*K$<<"JQ'' JL1QP*K$<<"JQ''
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MG%)4^YU58_&=6G/GFU^!WIEIC]:6<IK/DWRERI&%K<60C;3#BY*XP866N[^
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M/4-Z_TE+<_]246S^5U=E^UU;8?EC7E[W:&!;]6UB6/1R9%;S=V95\GMG4_&
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MKTU$[;%43>6S6U7<L&5ASJAL<<.?=("XEGR-KH^&F*6(D:&=@YVGEX"MJY.
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M@5RFWX%<IM^!7*;?@5RFWX%<IM^!_X / ?^.#@'_H@T V[4( ,[!" #&T D
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MAAD?_Y$:'O^<&Q[_I1P=_[ ='?^P'1W_L!T=_[ ='?^P'1W_L!T=_[ =G,
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M4K22;UVLC'=GI(> ;YZ"BG>8?I1]DGN@@8UZK82*><"%B'K<A(=ZW8*&>M^
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M>&V,Y7AMC.5X;8SE>&V,Y7AMC.5X_VX3 ?][$0'_C1  _YT0 /JL$0#:NPL
MU<D+ ,W.&P'"S"\*M\D]&:S%22FAP%(XE[Q:1HVX85&#M6A;>K)P9'*O>6MK
MK(-Q9*N/=E^IGGI;J:]\6:K)?%JGXGM>H.-[89OC>F.7Y'EFE.5W9I+F=V:2
MYG=FDN9W9I+F=V:2YG=FDN9W_W 2 ?^ #@'_D@X \J,+ -FS"0#/O@D R\P)
M ,33%P"ZTBP'L,\[%J7,1B::R% UC\18087!7TU\OF=6<[QO7FNY=V5DN()K
M7K:.<%FUG7-5M:YU5+;(=5.SYW97J^9V6J3F=ER@YW5?G.=T8)KH=&":Z'1@
MFNAT8)KH=&":Z'1@FNAT_W(2 ?^&# #[F D V:D& ,ZU!P#&P0< P,\) +K;
M$P"QVBD%I]@W$IS41"&2T4TPA\Y5/'W+74=TR650;,=M5V7%=EY>Q(%C6<..
M:%3#G6M1PZYL3\3(;4["[6U0N.MO4[#K<%6KZG!8INMP6:/K<%FCZW!9H^MP
M6:/K<%FCZW!9H^MP_W</ ?^-" #>H ( SZX% ,2Y!0"[Q08 M=,* *[A%@&F
MX2D&G> W$9/>0AV)W$PI?]I4-7777#]MU61(9=-L3U_2=E19TH%95-&.75#1
MG6!-TK!B2]/)8DK2[6)+R/)F3;_Q:$^X\&E1LO!I4J_O:5*O[VE2K^]I4J_O
M:5*O[VE2K^]I_W\* .V6  #2I@$ Q+(# +F\ P"PR08 J=@* *'G&0*9YRH)
MD.<W%(?F0A]]Y4HI=.11,VOC63IDXF%!7N)K1UCB=4M3X8!/3^*-4TOBFU5)
MXZQ71^3$5T;CZ5=&W?991]#W7$G(]UY*P?9@2[WV8$N]]F!+O?9@2[WV8$N]
M]F!+O?9@_XD  -F>  #'K $ N;8" *[! P"ES@8 G.0, )7O'0.-[RP+A>\Y
M%7SO01YS[TDG:NY0+V+N5S5<[E\Z5NYH/U+N<4)-[WQ&2>^)24;PEDM#\*9-
M0/&Y3C_RVT\^\/=.0N;[3T/=^U%$U/Q31<_\5$7/_%1%S_Q41<_\5$7/_%1%
MS_Q4X94  ,NF  "[L   KKL! *+( @"8U04 D/@/ 8GX( 2"^"X+>?DW$W#Y
M/QMH^48B8/I-*%KZ5"U4^EPQ3_ME-4O[;3A'_'<[0_R#/3_]D#\\_9]!.OZO
M0SC_QD0W_^I%-OS]13OR_T0^ZO]$/N;_1C[F_T8^YO]&/N;_1C[F_T8^YO]&
MT)\  +VL  "NM0  HL(  )7/  "*W0, A/\2 7O_'@-T_RH);/\S#V3_.Q9=
M_T,;5_]*(%'_421,_U@G2/]@*D3_:"Q _W$N//][,3G_B#(U_Y8T,_^D-C'_
MMC<O_] X+O_O.2W__SDQ__\Y,_S_.3/\_SDS_/\Y,_S_.3/\_SDS_/\YP:@
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M$!/_K1$3_[H1$__#$A/_PQ(3_\,2$__#$A/_PQ(3_\,2E[X  (;,  !WVP
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M:7A\\&EX?/!I>'SP:7A\\&EX?/!I_V 7 ?]N$@'_?A  _XP1 /^9$0#QI!,
MXZX6 -:V' '+M# (P; _%[>K2R6MIE0SI*%=0)R=94J4F&Q3C)5T6X:1?6)_
MCH=H>8R2;72*GG%PB*UT;8C!=&V)Y'-OA^IQ<(3L;W*#[6US@>YK=(#P:72
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MVT=$V/1)0M/_343)_T]%PO]01[O_4D>[_U)'N_]21[O_4D>[_U)'N_]2YHH
M ,^;  "_IP  LK   *>[  "<Q@, D]$& (OJ#@"%Z!\"?N@M!G;H. YNZ$$6
M9N=*'5_G4B-9YULI5>=D+5#G;3%,YW@U2>>$.$;HD3I#Z* \0.FR/C_JRSX^
MZ.\^/>;_/SW@_T(_U_]$0,[_1D#._T9 SO]&0,[_1D#._T9 SO]&UI,  ,2C
M  "TK   I[8  )O!  "0S ( AMD& (#R$@!Y\A\"<?(K!FKR-@QC\S\27?-'
M&%?S3QU2\U<A3?1@)$GT:2A&]',J0O5^+3_UBR\\]IDQ.O:I,SCWOC0V^.$U
M-O7Y-37S_S0W[/\V.>7_.#GE_S@YY?\X.>7_.#GE_S@YY?\XR)X  +:I  "H
ML@  F[T  (_(  "#U   >>@' '/\$@%K_1T"9/TG!%[^,0A8_CL-4_]#$4W_
M2Q5)_U,81?]:&D'_8QT^_VP?._]V(3?_@B,T_Y E,O^?)S#_L"@N_\@I+?_J
M*BS__RHL__\J+_G_*B_Y_RHO^?\J+_G_*B_Y_RHO^?\JN:8  *JN  "<N0
MCL4  ('1  !UW@  ;?H) &7_$0%>_QH"5_\C U+_+ 5,_S0'2/\\"D/_1 P_
M_TP.//]3$#C_6Q(U_V,4,O]L%B__=Q<L_X09*?^3&B?_HAPE_[0=)/_,'B/_
M[1XB__T?(O__'R+__Q\B__\?(O__'R+__Q\B__\?K*L  )VV  "/P@  @,X
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M_W 7 ?]X'0'_?R0"_80N!?.&. KJAD(1XX1+&=M_5R/1>6(ORW1L.,5O=D#
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M68-O_%B#;_Q8@V_\6(-O_%B#;_Q8_U88 ?]D$0'_<@X _WX0 /^($0#UD10
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M/C[+_T! P_]"0;W_0T*Y_T1"N?]$0KG_1$*Y_T1"N?]$W8@  ,>8  "XHP
MJZL  *"T  "5O@  B\@# (#1!P!XX0T =.$= 6[A*P-HX#<(8>!"#ES@3117
MX%894^!?'4_@:2)+X',E1^!^*$3@BRM"X)HM/^&K+S[BP2\^XN4O/-_Z,3G>
M_S0YV?\V.M#_.#O,_SD[S/\Y.\S_.3O,_SD[S/\YS9(  +R@  "MJ   H;$
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M$Q[__Q,>__\3'O__$Q[__Q,>__\3IJD  )BS  "*OP  >\H  &[5  !@WP
M5.<  $[_! !)_PX 0_\4 #__'0$Z_R4"-O\L C+_,P,O_SH#*_]!!"C_2 0E
M_T\%(O]7!2#_8 8=_VP'&O]Y!QC_B@@6_YL(%?^M"13_PPD3_^,)$__X"1/_
M_PH3__\*$___"A/__PH3__\*FK$  (N]  !\R   ;=0  %_@  !1Y@  1_4
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M2)%@_T>18/]'D6#_1Y%@_T>18/]'_TX8 ?]:$0'_9 X _V\0 /]V$P#\?1<
M[X$> >2$)P+;A#0%T(%##\A\3QG!>%HCNW-D++5P;3.Q;'8ZK6I_/ZEGB$.E
M99%'HF.;2I]BI4V<8;%/F6#!4)=@W%"58?-/DV+_3I!C_TR.9/]+C&3_2HMD
M_TB+9/](BV3_2(MD_TB+9/](_U 6 ?]<$ #_: T _W(. /]Z$ #V@1( Z887
M -Z*( '2BC $R89 #L&"31FZ?5<CM'EA+*YU:C2I<G(ZI&][0*!LA$2=:HU(
MF6B73)5GH4^29JU1D&6]4HYEU%.,9O!1BV?_4(AG_TZ':/],AFC_2X5G_TF%
M9_])A6?_285G_TF%9_])_U(4 ?]?#@#_:PL _W4, /E^#0#PA0X XXL0 -:/
M&@#,CBX$PXL]#;N'2ABT@U4BK7Y>*Z=[9S.B=V\ZG71X0)ER@$65;XE)D6V3
M38ULGE"*:JI3AVJY5(5JSU2$:^Y3@VS_48)L_T^!:_]-@&O_3(!K_TJ :_]*
M@&O_2H!K_TJ :_]*_U02 ?]A# #_;@H _7@) .B"" #<B0D V(\+ -"3%P#&
MDRL#OI [#+:,2!>NB%(AIX1<*Z& 9#.<?&TZEWEU0))W?46.=89*BG*03H9Q
MFU&";Z=4?V^V57UORU9\;^M4?'#_4GMP_U![;_].>V__37MN_TM[;O]+>V[_
M2WMN_TM[;O]+_U<1 /]C"@#_< < \'P% -R%!0#4C @ T),) ,J6% #!ERD#
MN90Y"[&01A:IC5 @HHE:*IR%8C*6@FHYD7]R/XQ\>D6'>H-*@WB-3G]VF%%[
M=:14>'2S5G9TR%9U=.A5=77]4W5T_U%U<_]/=G+_379Q_TQV<?],=G'_3'9Q
M_TQV<?],_UD0 /]F!P#_<P0 X7\! -:(! #/D 8 RI8( ,2:$@"\FR8"M)@W
M":R51!2DD4X?G8Y7*):*8#&0AV@XBX1P/X:">$2!?X%)?7V+37A[EE%T>J)4
M<7FQ5F]YQ59N>N95;GK\4V]Y_U%P=_]/<7;_37%U_TQQ=?],<77_3'%U_TQQ
M=?],_UL. /]I! #V=P  W8(  -"+ P#)DP4 Q)D& +Z>$ "VGR0"KITT"*::
M01.?EDP=F)-5)Y&07B^+C64WA8IM/8"(=4-[A7Y(=H.(3'*"DU!N@*!3:W^N
M56A_PE9G?^-5:(#Z4VE^_U%J?/]/:WO_36QY_TQL>?],;'G_3&QY_TQL>?],
M_UX, /]L 0#F>@  UH8  ,N/ @#$EP0 OIT$ +BB#@"QHR$!J:(R!Z&?/Q&9
MG$H;DIE3)8N67"V%DV,U?Y%K.WJ.<T%UC'Q&<(J%2VN(D4]GAYU29(:L5&*&
MOU5AAN%488;Y4F.$_U!E@?]/9G__36=^_TQG?O],9W[_3&=^_TQG?O],_V$*
M /]O  #@?@  T(D  ,:3 0"_FP, N*$" +&F"P"JJ!X!HZ<O!9NE/0^4HD@9
MC)]1(H6<62M_FF$R>9AI.725<3]ODWE$:I*#2&60CDQACYM/7HZJ4EN.O5):
MCMY26XWX4%R+_T]>B/].8(7_3&&#_TMA@_]+88/_2V&#_TMA@_]+_V0% /5T
M  #:@@  RXX  ,&7  "XG@$ L:4  *FK!P"CK1H G*PL!)6K.@R-J$46AJ9/
M'W^D5RAYHE\O<Z!F-6V>;CMHG'= 8YJ!15^9C$E;F)E,5Y>H3E67NT]4E]Q.
M5);V3E64_TU8D/],68W_2UN*_TI;BO]*6XK_2EN*_TI;BO]*_V@  .5Y  #1
MAP  Q9(  +N<  "QH@  J:D  *&Q @";LQ4 E;,H HZR-@F&L$(2?ZY,&WBL
M5"-RJEPJ;*AD,6>G;#9BI74[7:1_0%FCBD-5HI='4:&G24^ANDI.HME)3J#U
M24Z?_TE0F?])4I;_2%22_T=4DO]'5)+_1U22_T=4DO]'_VX  -Y_  #*C0
MOI@  +.@  "JIP  H:X  )>V  "1NA  C+HC 86Y,@9^N#X.=[9)%W&U4AYK
MLUHE9;)B*V"Q:C!;L',U5Z]].5.NB3U/K99 3*VE0DJMN4-)KMA"2*OU0T>J
M_T1)I?]$2Z#_1$V<_T1-G/]$39S_1$V<_T1-G/]$ZG4  -*&  ##DP  MYT
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M*S;*_RTVRO\M-LK_+3;*_RTVRO\MQ9   +:=  "HI0  G*T  (^V  "#O@
M=\<  &S/ @!BU@< 6N0. %CD' !4Y"D!4.0U TSE/P5(Y4D'1>53"D+F7 T_
MYF8//.9Q$CKG?A0WYXP6->><%S/HKADRZ<89,NCJ&3'E_ADOY/\<+N3_'BWB
M_R MXO\@+>+_("WB_R MXO\@NIH  *JC  "=JP  D+0  (.]  !WQ@  :\\
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M!0[__P4.__\%E:\  (:Z  !WQ0  :-   %K;  !,X0  0.<  #?S   R_P
M+O\' "K_#@ F_Q, (_\: !__(  ;_R8 &/\K 17_,@$2_S@!$/]  0[_2 $,
M_U(!"?]= @;_:P($_WT" O^0 @'_HP( _[8" /_- P#_[ , _^P# /_L P#_
M[ , _^P#B+D  'C$  !IT   6]T  $OC   ^Z0  ,NX  "O_   F_P  (?\
M !W_"  :_PT %O\1 !/_%@ 0_QH #O\?  O_)  )_RH !O\P  +_-P$ _T !
M /]* 0#_5@$ _V0! /]U 0#_B $ _YH! /^J 0#_NP$ _[L! /^[ 0#_NP$
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M^V8G ?)F,0/J93T&XV-*"]Q@5Q+576(9T%IM'\Q7=R/(58 GQ52)*\)2DB[
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M1E^!_T1@?_]"87W_06)[_S]C>O\_8WK_/V-Z_S]C>O\__UX  .EM  #6>0
MR(0  +Z,  "VDP  KI<  *:;! "@G1< FITI I.<-PB,FD,0AIA-&("651]Z
ME%TF=9)E+'"0;#%LCG4V9XU^.F.+B3Y?BI5!7(FC1%J)M$58B<M%6(CM1%B(
M_T-9AO]!6X/_0%V!_SY=@/\^78#_/EV _SY=@/\^_V(  .1Q  #/?@  PX@
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M-TB<_S=)FO\W29K_-TF:_S=)FO\WXG0  ,J#  "\CP  L)@  *6>  ";I
MD*L  (6Q  !ZN 0 =KD4 '*Y)0%MN3,$:+@_"&.X20Y>MU(36K9:&%:V8AQ2
MM6L@3K1U)$NT@"=(LXXJ1;.=+$*SKBU!L\4N0;/I+4"P_B\_K_\Q/JW_,D"H
M_S)!IO\R0:;_,D&F_S)!IO\RU7P  ,**  "UE@  J)T  )VC  "2J@  A[$
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M%BC:_Q8HVO\6LY@  *6@  "9IP  B[   'ZX  !QP   9<@  %G.  !.TP
M1-L$ #_I#0 ]Z1< .^HC #GJ+@ VZS@!-.M" 3'L2P(O[54#+>U? RKN:P0H
M[G@%)N^(!B7OF@<C\*X'(O'(!R+P[0<A[/\'(>O_""#K_PH?ZO\+'^K_"Q_J
M_PL?ZO\+J)\  )NF  "-KP  ?[@  ''!  !DR@  6-   $S6  !!W0  ..0
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M8@$ _W,! /^' 0#_G0$ _[(! /_* 0#_Z@$ __,! /_S 0#_\P$ __,!A+<
M '3!  !ES   5M@  $??   YY0  +>H  "/N   <_0  &/\  !7_   1_P0
M#_\+  W_#@ )_Q$ !O\5  /_&@  _R   /\F  #_+@  _S<  /]!  #_30
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M.VUL_CEM;/\W;FS_-6YK_S1N:O\R;FK_,FYJ_S)N:O\R_U,  /1?  #>:@
MS7,  ,-Z  "[?@  M8$  *Z#"0"HA1H HH4K IN$.@>5@D4.D']/%8I]6!N&
M>U\@@7EG)7UW;RIZ=G<N=G2 ,G-SBS5O<I8X;'&C.FEPLCQH<,8\9W#G.V=Q
M_#EH<?\W:'#_-6EO_S1I;O\S:6[_,VEN_S-I;O\S_U8  .MB  #8;@  R78
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M-%A__S-9??\R67W_,EE]_S)9??\R[V   -MN  #'>@  NX,  +*+  "HD
MGY,  )26  "-F0X B9H> (2:+@)^F3H'>9=%#7263A-OE588:I->'6:292%B
MD6TF7H]V*EN.@2U7C8TP5(R:,U&,JC5/C+TU3XS>-4^+]S1/BO\S4(G_,E&&
M_S%2A/\Q4H3_,5*$_S%2A/\QZF4  -)S  #"?P  MH@  *R0  "BE   F)@
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M)CND_R8[I/\FS'H  +N(  "ND@  HID  )>>  ",I   @*H  '6O  !IM
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MD (=Z:0"&^F\ AKJX@(:YOP"&>7_ QGD_P08X_\%&./_!1CC_P48X_\%HYT
M ):D  "(K   >K4  &R]  !?Q   4\H  $?.   \TP  ,MH  "K?   E[@D
M(_ 1 "'Q&0 ?\2( '?(K !OS-  9]#X %_1( !7U4@ 3]E\ $O9N 1'W@ $0
M^)0!#_FJ 0[YQ@$.^>T!#?;_ 0WT_P$-\_\!#?/_ 0WS_P$-\_\!F:,  (NL
M  !\M0  ;;X  %_&  !2S0  1=(  #G8   OW@  )N(  !_J   <^P8 &?\.
M !?_$P 4_QH $O\A !#_*  ._S  #?\Y  O_0P )_TX !O]<  3_;  "_X
M ?^6  #_K0  _\H  /_P  #__P  __\  /__  #__P  __\ C:L  'VU  !N
MOP  8,@  %+0  !#UP  -]T  "OB   BY@  &>H  !7Y   2_P  $/\(  [_
M#@ ,_Q$ "?\6  ;_'  #_R(  /\J  #_,P  _ST  /])  #_5P  _VD  /]^
M  #_E0  _ZP  /_'  #_Z   __H  /_Z  #_^@  __H @+4  '"_  !AR0
M4M,  $/;   UX0  *>8  ![J   5[@  $/@   [_   +_P  "/\   3_!@
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M+7Q:^BQ[6O\J>UO_*'M;_R=[6O\F>EK_)7I:_R5Z6O\E_TD  /M2  #C7
MTF,  ,=H  # :P  NFL" +5K#0"N;1T J&XN :-M/ 6=:T@*F6I1#Y1H6A20
M9F(8C65J'(IC<B"'8GHCA&&#)H%@C"E^7Y<K>UZC+7E>L2]W7<0O=5[B+W5>
M^2UU7_\K=5__*75?_RAU7O\F=5[_)G5>_R9U7O\F_TL  /!5  #>7P  S6<
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M*V1K_REE:O\H96K_*&5J_RAE:O\H_5,  .-?  #.:0  P7$  +=W  "O>P
MIWT  )Y]  "8?A$ DX B (Z ,0*)?SX&A'U(#']\41%[>ED6=WE@&G-W:!YO
M=G A;'5X)6ET@BAF<XXK8W*:+F!QJ"]><;HP77'4,%UQ\BY><?\L7G#_*U]P
M_RE@;_\H8&[_*&!N_RA@;O\H\54  -YB  #*;0  O74  +-[  "K@   HH(
M )B!  "1@P\ C84? (B%+@*#A#L%?H-%"GJ!3@]U@%84<7]>&&Y]9AQJ?&T@
M9WMV(V-Z@"=@>8LJ77B8+%IWIBY8=[@O5W?1+U=W\2Y8=O\L6';_*EEU_RE:
M=/\H6G3_)UIT_R=:=/\G[5D  -=F  #%<0  N7H  *^   "FA   G88  )&'
M  "*B0P AHH; (*+*P%]BC@$>(E""'2(3 UOAU02;(5;%FB$8QID@VL>88)T
M(5V!?21:@(DH5W^6*E5^I"Q2?K8M47[.+5%][RQ2??\K4GS_*5-[_RA4>O\G
M5'K_)U1Z_R=4>O\GZ%X  -!K  # =@  M'X  *N%  "AB0  EXL  (F-  "#
MCP@ ?I 7 'N1)P%VD30#<I _!FV/20MICE$/98U9$V*,8!=>BV@;6XIQ'E>)
M>R%4B(8D48>4)T^&HBE-AK0J2X;,*DN%[BE,A/\I3(/_*$R#_R=-@?\F3H'_
M)DZ!_R9.@?\FX6,  ,EP  "[>P  L(0  *:*  ";C@  D9$  (23  !ZE0(
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MF@\SLZT0,K/%$#*RZ1 QL/X2,*[_%"^M_Q4OK/\6+ZS_%B^L_Q8OK/\6NX$
M *Z.  "AE0  EIH  (F@  !]I@  <:L  &6O  !9M   3K<  $.\!0! O1$
M/[T> #Z^*P \OC8 .[]! #F_2P$WOU0"-<!? C/ :@0QP'<%+\"&!BW EP<K
MP*H(*L'"""K YP<IO?T**+S_#">Z_PTGN?\.)[G_#B>Y_PXGN?\.LHP  *64
M  "9F@  C:$  '^G  !RK0  9K,  %JX  !/NP  1+\  #K$ @ PR0@ +LH1
M "W*'0 LRRD *\LU "O,0  JS4H *,U6 "?.80 FSF\!),Y_ 2//D0(ASZ4"
M(-"] B#/Y (?S?H#'LO_!![*_P4=R?\&'<G_!AW)_P8=R?\&J)0  )R:  "0
MH0  @J@  '2O  !GM@  6[P  $[   !#PP  .<<  "_,   GT 0 ']8* !O:
M$  ;VQH &MLF !K<,0 9W3P &-U( !C>50 7WV( %N!R !7@A0 4X9H $^*Q
M !+CSP 2X/0 $M[_ 1'=_P$1V_\"$=O_ A';_P(1V_\"GIH  )*A  "$J0
M=K$  &BX  !;OP  3L0  $+(   WS   +=   "35   <VP  %=\% !3I#@ 2
MZA0 $>L= !#K)@ .[#  #NTZ  WN1@ +[E, "N]B  GP=  (\8D !_*@  7R
MN@ $\>0  O']  +O_P #[?\  ^W_  /M_P #[?\ E:$  (:I  !XL@  :;H
M %O"  !-R   0,P  #31   JU@  (=L  !G@   2Y   #_ !  WY"@ +^@\
M"?L5  ?['  $_"0  ?PL  #\-P  _$(  /Q0  #\80  _74  /R,  #\I
M_,$  /SK  #\_P  _?\  /W_  #]_P  _?\ B:D  'FR  !JNP  7,0  $[,
M   _T0  ,M<  "?=   =X0  %>4   [H   *\0  "/T   7_ P !_PD  /\.
M  #_$@  _Q<  /\?  #_)P  _S$  /\^  #_30  _U\  /]U  #_C0  _Z8
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M *\ _P"V /\ O@#_ ,@ _P#7 /\ YP#_ /, _P#] /\ _P#_ /\ _P#_ /\
M_P#_ /\ _P#_ /\ _P#_ /\ _QLI /\=)@#_'"4 _QDG /\3+ #_#C0 _PM
M ?\(3@'_!5L!_P-H ?\"= '_ G\!_P*( ?\"D0'_ I@!_P*? ?\!I0#_ :P
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M&Y%'^1N/1_\:CD?_&8Y'_QB-1_\8C4?_%XU'_Q>-1_\7_SX" /]#  #K2P
MW5$  -%4  #*5 $ QE(% ,%1$0"Y4R( LU4S :Y400*J5$P%IE-6"*)17PR?
M4&</G4]O$9I.=Q283G\6EDV(&)-,D1F13)L;CTNF'8U+LQZ+2\4>B4OB'H=,
M]QZ&3/\=A4S_'(5-_QJ%3/\9A4S_&85,_QF%3/\9_T   /Q'  #E4   U58
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M('!:_QYP6O\=<%K_''!:_QQP6O\<_T@  .=2  #36P  Q6(  +MF  "S:
MK&@  *5F!0"?9Q0 FFDE )5I- *0:$ $C&=*"(AF4PR$95L0@61B$WYC:A9[
M8G(9>&%Z''9@A!YS7XXA<%Z:(VY>J"5L7;@E:E[.)FE>[B1I7O\B:E[_(&I>
M_Q]J7O\>:E[_'6I>_QUJ7O\=^4H  .-5  #/7P  P64  +=J  "O;   IVP
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M'EMJ_QY;:O\>ZU,  --@  #":0  MG$  *QV  "C>0  F7D  (UW  "'>0L
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MF1I#BJH;0HJ_&T&*X1M!B/D;08;_&T&%_QM"A?\:0H3_&D*$_QI"A/\:S6<
M +QT  "O?@  I88  )J*  ".C   @HT  '60  !GE   894( %Z7% !<ER,
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M"2RLV0@LJO4**ZC_"RJF_PPJI?\-*J7_#2JE_PTJI?\-M8   *B+  "<D0
MD98  (6<  !XH   :Z4  %^H  !3K   2*\  #VR   VM0L -+45 #.V(0 R
MMBP ,;<W #"W00 ON$L +KA5 "RX8 $JN&T!*;E[ B>YC0(EN9\#)+FT R.Y
MT@,CM_0$(K7_!2&T_P8AL_\'(;+_!R&R_P<ALO\'K8H  *"1  "5EP  B)T
M 'NC  !NJ   8:T  %6Q  !*M   /[<  #2[   KO@, ),(, "+"%  BPQ\
M(<,J "#$-  ?Q#\ 'L5* !W&5@ <QF, &\=S !K'A0 9QYD &,BN !?(RP 7
MQO$!%\3_ 1;#_P(6P?\#%L'_ Q;!_P,6P?\#HY$  )B8  "+G@  ?:4  '"K
M  !BL0  5K8  $JY   ^O0  -,   "K$   BR   &<P$ !/0"@ 1TA$ $-(:
M !#3)0 /TS  #M0\  [42  -U58 #=5E  S6>  ,UHT "]BD  K8O@ )V>8
M"M;^  O4_P +TO\ "]+_ 0O2_P$+TO\!FI@  (Z?  " I@  <JT  &2T  !7
MN@  2;\  #W"   RQ@  *,D  !_-   7T0  $=8   S;!0 (W@L !M\1  7?
M&@ $X"0  N$N  'B.@  XT<  .16  #D9P  Y7L  .:2  #FJ@  Y\@  .?P
M  #H_P  Z/\  .C_  #H_P  Z/\ D9\  (*G  !TKP  9;<  %>^  !)PP
M/,<  ##+   ESP  '-0  !39   .W0  ">$   +E    Z08  .D-  #I$0
MZA@  .LA  #M*P  [S<  /%%  #R5@  \V@  /-^  #TEP  ];   /;0  #W
M\P  ]_\  /?_  #W_P  ]_\ A:<  ':P  !FN   6,$  $K(   [S   +M$
M "/6   9W   $>    SC   $YP   .H   #U    ]    /4%  #U"P  ]@\
M /84  #X'0  ^B<  /PT  #_0P  _U4  /]I  #_@0  _YH  /^R  #_SP
M_^T  /_Y  #_^0  __D >+   &BZ  !9PP  2\L  #O1   MV   (=T  !;B
M   .Y@  ".H   #M    \    /@   #_    _P   /\   #_    _P8  /\,
M  #_$   _Q@  /\B  #_,   _T   /]3  #_:0  _X$  /^9  #_KP  _\,
M /_5  #_U0  _]4 _Q,H /\3)0#_$24 _PTG /\&+0#_ #4 _P!! /\ 3P#_
M %P _P!I /\ = #_ 'X _P"( /\ D #_ )< _P"= /\ I #_ *H _P"P /\
MMP#_ ,  _P#, /\ WP#_ .P _P#X /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_
M /\ _P#_ /\ _Q8E /\6(@#_%"$ _Q C /\** #_ #  _P ] /\ 2P#_ %@
M_P!D /\ < #_ 'H _P"$ /\ C #_ ), _P": /\ H #_ *8 _P"M /\ M #_
M +P _@#( /T V0#[ .D ^@#V /D _P#X /\ ^ #_ /@ _P#X /\ ^0#_ /D
M_P#Y /\ _QHB /\:'@#_&!T _Q,> /\.(@#_"BP _P<Y /\#1@#_ %, _P!@
M /\ :P#_ '8 _P!_ /\ B #_ (\ _P"6 /\ G0#_ *, _@"I /P L #Z +D
M]P#$ /4 T@#S .8 \@#T /$ _P#P /\ [P#_ .\ _P#O /\ \ #_ /  _P#P
M /\ _QX= /\>&0#_'!< _Q<8 /\3'@#_$2@ _PXT /\,00#_"DX _PA; /\'
M9@#_!G$ _P9Z /\&@P#^!HL _ :2 /H&F0#X!I\ ]@:F /0&K0#R!K4 \ 7
M .T%S@#K!>0 Z0;S .8(_P#E"O\ Y O_ .0+_P'D"_\!Y O_ >0+_P'D"_\!
M_R$8 /\A$P#_(!$ _QL2 /\<&@#_&B0 _Q8O /\3/ #_$4D _Q!5 /P.80#Y
M#FL ]@YU /0.?@#R#H8 \ Z. .X.E0#M#IL ZPZB .H.J@#H#K, Y@^] .4/
MS #A#^, W1#S -D1_P'6$O\!U!/_ =,3_P+2$_\"TA/_ M(3_P+2$_\"_R43
M /\E$ #_) T _R,. /\C% #_(AX _Q\I /\<-0#Y&4, ]!A/ .\76P#L%V8
MZ1=P .87>0#D%X$ XA>) . 7D0#?%Y@ W1>? -L7IP#9&+$ UAB[ -09R@#0
M&N$!S!OS <D<_P+&'/\"Q!S_ \,<_P/#'/\#PQS_ \,<_P/#'/\#_R@0 /\I
M"P#_* 8 _RL+ /\K$ #_*1< _28B /0C+@#L(3L YB!) .(@50#>(&  VB%J
M -8A= #3(7P!T"&$ <\BC '-(I,!RR*; <DBHP'((ZP"QB.V L0CQ +")-L"
MOB7N [LE_@2X)?\%MB7_!;4E_P:U)?\&M27_!;4E_P6U)?\%_RP- /\M!0#_
M+@$ _S$% /\Q"P#]+Q  \2L8 .<I)0#?*#, V"A" -$J3P#-*UH R2ME <<K
M;@'$+'8"PBQ^ L LA@.^+(X#O2R6 [LLG@2Y+*<$N"RQ!;8LOP6U+=$%L2WJ
M!JXN^P>K+O\(J2[_"*@N_PBH+?\(J"W_"*@M_PBH+?\(_R\( /\Q  #_-0
M]C<  .HV @#G,P@ Y"\/ -DN&P#/,2P R3,\ ,0T20# -54!O#5? KHU: *W
M-7 #M31X!+,T@ 6Q-(@&L#20!JXTF0>L-*((JS2L":DTN0FG-,H*I37E"J$U
M^ N?-?\,G37_#)TU_PN<-?\+G#7_"YPU_PN<-?\+_S," /\U  #V.@  Y3X
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MB$+_$8A"_Q"'0O\0AT+_#X="_P^'0O\/_S@  /,]  #C1P  TDP  ,A.  #
M30  NTH" +9'#@"P21T JTLM *9,.P&B3$<"GDM1!)M+6@:92F((EDEJ"I1)
M<0R22'D.CTB"#XU'BQ&+1Y42B4:@%(=&K!6%1KL6A$;1%H)'[A: 1_\5?T?_
M%']'_Q)_1_\1?T?_$7]'_Q%_1_\1_SL  .Y#  #<3   S%$  ,%4  "Y5
MM%$  *Y-"P"H3QD HU$I )Y2-P&:4D,"EU%.!)115@:14%X)CD]F"XQ.;0V)
M3G4/ATU^$85-AQ."3)$5@$R<%GY+J1=\2[@8>TO-&'E,ZQAX3/X7=TS_%7=,
M_Q1W3/\3=TS_$G=,_Q)W3/\2_SX  .A'  #54   QE8  +Q8  "T60  K58
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M%&59_Q1E6?\4[T8  -I2  #&6P  NF$  +!E  "F9@  G6,  )5A  "/8@X
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MF1E1;:@:3VV[&TYMV1I.;/093VO_&$]K_Q=0:O\64&K_%5!J_Q50:O\5W54
M ,5A  "W:@  K'$  *)U  "4=   B70  'QS  !V=0  <7<0 &]X'0!L>2L
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M$SR$SQ,\@O 2/('_$CV _Q(]?_\2/7[_$3U^_Q$]?O\1Q68  +5Q  "J>P
MGX(  )*"  "%@@  >8,  &V&  !?B@  6(T! %2.#P!2CQL 4(\G $^0,P!-
MD#T!2Y!% DF03@-&D%8$1(]?!4*/: <_CW,)/8Z "SJ.CPPXCJ --XZS#C:.
MS XVC>\.-8O_#C6)_P\UB/\/-H?_#S:'_P\VA_\/OFT  +!Y  "E@@  F8<
M (R(  !_B   <HH  &:-  !:D0  4)4  $F7"0!'F!, 19@@ $29*P!#F38
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M AJM_P(:K/\#&JO_ QJK_P,:J_\#J(@  )N/  "1E   A)H  ':?  !HH@
M6Z4  $^I  !$K0  .;   "^S   FM@  'KD% !B[#@ 7NQ8 %[P@ !:\*@ 5
MO34 %+U  !.^2P 2OE@ $KYG !&_>  0OXP $,"B  [ N@ .P.$ #[W[  ^\
M_P 0NO\!$+K_ 1"Z_P$0NO\!GX\  )25  "'FP  >:$  &NG  !>K   4K$
M $6T   ZM@  +[D  "6\   =OP  %<,   _&!0 +R@T "<H4  C*'0 'RB<
M!\HR  ;+/@ %RTL !,Q:  /,:@ "S'X  <R4  #,JP  S<@  ,SM  #,_P
MR_\  <K_  '*_P !RO\ EY8  (J<  !\HP  ;JH  &"P  !2M@  1;D  #F\
M   NOP  (\,  !O&   3R@  #<T   C1   !U D  -0.  #5%0  UAX  -@G
M  #9,0  VSX  -Q+  #=6P  WFX  -Z$  #?FP  W[0  -[9  #?]P  W_\
M -__  #?_P  W_\ C9T  '^E  !PK   8;,  %.Z  !%OP  .,(  "S&   A
MR0  &,T  !#1   +U0  !-H   #>    X $  .$)  #B#@  Y!,  .4;  #G
M)   Z2\  .L\  #M2P  [ET  .YQ  #OB0  \*(  /"\  #PXP  [_D  /#_
M  #P_P  \/\ @:4  '*M  !CM0  5+T  $;$   WR   *LP  !_0   5U0
M#MH   ?>    X@   .8   #I    Z@   .P   #N!0  [PP  /$0  #S%P
M]2   /@K  #[.0  _4H  /Y>  #_=   _XT  /^F  #_P   _^$  /_U  #_
M]0  __4 =*X  &6W  !6P   1\@  #C-   JT@  '=@  !/=   ,X@   ^8
M  #I    [    /    #S    ]    /8   #X    ^@   /T'  #_#0  _Q(
M /\;  #_*   _S<  /]*  #_7@  _W8  /^/  #_I@  _[H  /_1  #_T0
M_]$ _P\D /\.(@#_"R$ _P,D /\ *0#_ #( _P ^ /\ 3 #_ %D _P!E /\
M< #_ 'H _P"$ /\ C #_ )( _P"9 /\ GP#_ *4 _P"K /\ L@#_ +H _P#%
M /\ TP#_ .< _P#T /\ _P#^ /\ _P#_ /X _P#^ /\ _@#_ /X _P#^ /\
M_Q$A /\0'@#_#1T _P<? /\ (P#_ "T _P Z /\ 2 #_ %4 _P!A /\ ; #_
M '8 _P!_ /\ AP#_ (X _P"5 /\ FP#_ *$ _P"G /X K@#] +8 _ #  /L
MS0#Y .( ^ #P /< _ #V /\ ]0#_ /4 _P#U /\ ]0#_ /4 _P#U /\ _Q4=
M /\3&@#_$!D _PL9 /\ '0#_ "D _P V /\ 0P#_ %  _P!< /\ 9P#_ '$
M_P!Z /X @P#\ (H ^@"1 /D EP#X )T ]P"C /4 J@#T +( \@"[ /$ R #O
M -P [@#L .T ^@#K /\ Z@#_ .H _P#J /\ Z@#_ .H _P#J /\ _Q@9 /\6
M%0#_$Q, _PX3 /\+&@#_!R0 _P(P /\ /@#_ $L _P!7 /\ 8@#\ &P ^ !U
M /4 ?@#R (4 \0", .\ DP#N )D [ "@ .L I@#I *X YP"W .8 PP#D -0
MX@#I .$ ]P#? /\ W0#_ -T _P#= /\ W0#_ -T _P#= /\ _QL3 /\:$ #_
M%@X _Q(. /\2%0#_#Q\ _PPK /\). #_!D4 ^P-1 /<"7 #R F8 [@)P .H"
M> #G H  Y@.' .0#C@#B Y4 X0.< -\$HP#=!*L VP2T -@%P #6!=  TP;G
M - (^ #."O\ S O_ ,L,_P#+#/\ RPO_ ,L+_P#+"_\ _Q\0 /\>"P#_&@<
M_QD+ /\8$0#_%AD _Q(D /H0, #S#CX [@U* .D,5@#E#&$ X@QJ -X-<P#;
M#7L V0V# -8-B@#4#9$ T@V9 - .H #/#JD S0ZS ,L.OP#*#]  QA'I ,(2
M^0"_$_\ O1/_ ;P3_P&\$_\!O!/_ ;L3_P&[$_\!_R(, /\A! #_(   _R$%
M /\?# #_'!$ ]A@< .P5* #E$S8 WQ)# -D33P#3%%H T!5D ,T6;0#+%G4
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M!I8O_P:5+O\%E2[_!94N_P65+O\%_RP  /\N  #J-0  W3D  -$Y  #*-@
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M"W%&_PMQ1O\+\SD  .!$  #,3   OE$  +13  "J4@  HDX  )U* 0"72Q$
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MF!)<6*<46UBX%%E9T!196/ 365C_$5I8_Q!:6/\.6E?_#5I7_PU:5_\-XT@
M ,M3  "[6P  L&$  *1B  "780  CE\  (5<  !_7@< >U\3 'AA(0!U8BX
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M$DEGR1))9^L226;_$$IF_P]*9?\.2V7_#4MD_PU+9/\-T50  +Y>  "Q9P
MIFT  )=L  "*:P  ?VL  '-K  !M;0  :&X, &5P%P!B<20 8'$P %YQ.@%<
M<4,"67%+ U=Q4P15<%H&4G!B!U!P:PE.;W4+2V^"#4ENCP]';I\016ZP$41N
MQQ%#;>H01&S_#T1K_PY%:_\-16K_#45J_PU%:O\-RU@  +IC  "M;   H7$
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M"#"#_P@P@O\(,('_"#"!_P@P@?\(MVL  *IV  "@?P  D'X  ()^  !V?P
M:H   %Z#  !3AP  2HL  $&. @ ]D X .Y 8 #J1(P YD2T .)(W #>20  V
MDDD -)-2 #.37 $QDV<!+Y-T BV2@P,KDI0#*I*G RB2O00HDN$#)Y#Z!">.
M_P4GC?\%)XS_!2>,_P4GC/\%L70  *5^  "9A0  BH0  'V$  !OA0  8X@
M %B+  !-CP  0Y,  #J7   RF@< +IL0 "V;&@ LG"0 *YPN "J=.  IG4$
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M  FR_P )LO\ FHT  )"3  "$F   =)P  &6@  !7I   2Z@  $"L   UL
M*K,  "&U   8N   $;L   R^ @ &P L  L 1  '!&0  P2(  ,(K  #"-@
MPT(  ,-0  #$7P  Q'$  ,2'  #$G0  Q+4  ,3:  #$]@  P_\  ,/_  ##
M_P  P_\ DY0  (>:  !XH   :J8  %RL  !/L0  0;4  #6W   IN@  '[T
M !;    0PP  "L8   /*    S 4  ,P,  #-$0  SA@  ,XA  #0*@  T34
M --#  #44@  U&,  -5X  #5CP  U:<  -;"  #6Z0  UOT  -;_  #6_P
MUO\ BIL  'NB  !LJ0  7K   %"V  !"N@  -+T  "C!   =Q   %,<   W+
M   &S@   -(   #7    V0   -H%  #<"P  W1   -\5  #A'0  XR<  .4S
M  #G0@  Z%0  .AG  #I?@  Z9<  .JO  #JS@  Z^\  .O^  #K_P  Z_\
M?:,  &ZK  !?L@  4;H  $+    TPP  )\<  !O+   2SP  "],   +8
MW0   .$   #D    Y0   .<   #I    ZP<  .T-  #O$0  \1D  /0D  #W
M,0  ^4$  /I5  #Z:@  ^X0  /N=  #\M@  _-(  /WM  #]]   _?0 <:P
M &&U  !2O0  1,0  #3)   FS0  &M(  !#8   (W0   .$   #E    Z
M .P   #O    \0   /,   #U    ]P   /D!  #["   _@X  /\5  #_(0
M_R\  /]!  #_5@  _VT  /^'  #_H   _[8  /_*  #_U   _]0 _PL@ /\'
M'@#_ !T _P @ /\ )0#_ "X _P [ /\ 20#_ %8 _P!B /\ ;0#_ '8 _P!_
M /\ AP#_ (X _P"4 /\ F@#_ *  _P"F /\ K0#_ +4 _P"^ /\ RP#_ .$
M_P#P /X _0#] /\ _0#_ /T _P#] /\ _ #_ /D _P#Y /\ _PT= /\+&@#_
M!!D _P : /\ 'P#_ "H _P W /\ 10#_ %$ _P!> /\ : #_ '( _P!Z /\
M@@#_ (D _P"0 /\ E@#_ )P _@"B /P J0#[ +  ^0"Y /@ Q@#V -D ]0#K
M /0 ^0#S /\ \@#_ /, _P#S /\ \P#_ /, _P#S /\ _Q 9 /\.%0#_"!0
M_P 4 /\ &0#_ "4 _P R /\ 0 #_ $P _P!9 /\ 8P#^ &T _ !U /H ?0#Y
M (0 ]P"+ /8 D0#T )< \P"> /( I #P *P [@"T .T P #K ,\ Z0#F .@
M]0#F /\ YP#_ .8 _P#E /\ Y0#_ .4 _P#E /\ _Q(4 /\0$ #_# \ _P,0
M /\ %0#_ "  _P L /\ .@#_ $< ^@!3 /< 7@#T &< \0!P .\ > #M '\
MZP"& .H C #H ), YP"9 .4 H #C *< X0"P -\ N@#= ,D VP#@ -@ \ #7
M /X U0#_ -0 _P#3 /\ TP#_ -, _P#3 /\ _Q40 /\2# #_#@D _PL, /\)
M$@#_ QH _P F /T ,P#T $  [P!- .L 6 #H &$ Y0!J .( <@#@ 'H W@"
M -P AP#: (X V "5 -0 G #2 *, T "L ,X M@#, ,0 R@#9 ,@ [0#' /L
MQ0#_ ,0!_P## ?\ Q '_ ,0!_P#$ ?\ _Q@+ /\5!0#_$   _Q & /\/#0#_
M#!0 _ <? /$#*P#G #D X@!& -X!40#: EL U0)D -(#; #/ W0 S01[ ,L$
M@@#*!(D R 60 ,8%F #$!:  P@:I ,$&M "_!L$ O0C5 +L)[ "X"_T M@S_
M +4-_P"T#?\ M W_ +0-_P"T#?\ _QL% /\8  #_%P  _Q8  /L3!@#Z$ X
M[@P6 .,)(@#:"3  TPH^ ,X+2@#*#%4 QPU> ,4-9P#"#F\ P0YV +\.?@"]
M#X4 O ^- +H0E0"X$)T MQ"G +41L@"S$<  LA'5 *X3[@"K%/X J17_ *<5
M_P"G%?\ IA3_ :84_P&F%/\!_Q\  /\<  #Z'@  ZQX  .,<  #?%04 W@X-
M -,.& #+$2@ Q1,W , 41 "\%D\ N1=9 +<780"T&&D LQEQ +$9> "O&H
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M X,O_P.#+_\#^RD  .LQ  #9.   R3P  +\\  "V.0  L#(  *PM"P"G+Q<
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MF II1J8+9T:V"V9&S ME1NP+9$?_"61&_PAD1O\'9$;_!F1%_P9D1?\&Z#L
M -!&  "_30  LU$  *51  ":3@  DDL  (U'  "'2 L @TH6 ']+) !]3#$
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M#513Q0U34^8,4U/\"U-3_PE44O\(5%+_"%12_P=44O\'VD8  ,-0  "U6
MJ%L  )E:  "-6   A%<  'M4  !V5@$ <5</ &Y9&P!L6B@ :5HS &=;/0%E
M6T4!8UM- F%:50-?6EP$75ID!5M9; 98678(5EF""518CPM26)X,4%BN#4]8
MPPU.6.0,3EC["T]7_PE/5_\(3U;_"%!6_P=05O\'TTH  ,!4  "R7   HUX
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M1&'Y"D1@_PE$8/\(15__!T5?_P=%7_\'R%(  +A<  "K9   FV0  (QC  "
M8P  =F,  &IB  !C9   7V8& %MG$0!9:!T 5VDI %9J,P!4:CP 4FI% 5!J
M3 %.:E0"3&I< TIJ901(:6\%1FEZ!T1IB A":)@)0&BI"C]HO0H^:-X)/F?W
M"3YF_P@_9?\'/V7_!S]D_P<_9/\'PU<  +-A  "G:0  EF@  (=G  ![9P
M<6<  &5H  !<:@  6&P! %1N#@!2;Q@ 4&\D $YP+@!-<#@ 2W%! $IQ20%(
M<5$!1G%9 D1P8@-"<&P$0'!X!3YPA@8\;Y4'.F^F"#AONP@X;]L'.&[V!SAM
M_P<X;/\&.6O_!CEJ_P8Y:O\&O5P  *]F  "B;0  D6P  ()K  !W:P  ;&P
M &%N  !7<   4',  $QU"@!)=A, 1W<? $9W*0!%>#, 0W@\ $)X1 !!>$T!
M/WA5 3UX7@([>&@".7AT S=X@@0U>),%,W>D!3)WN04Q>-<%,7;U!3%T_P4Q
M<_\%,7+_!3)R_P4R<O\%MV,  *IM  "<<0  BW   'UP  !R<   9W$  %QS
M  !1=P  2GH  $)] P _?@X /7\8 #Q_(P [@"T .H V #F!/P X@4@ -H%0
M #6!6@$S@60!,8%P 2^!?P(M@8\#+(&A RJ!M@,I@=(#*7_S RE]_P,I?/\#
M*7O_ RE[_P,I>_\#L6H  *5T  "5=@  A74  'AU  !M=0  87<  %=Z  !,
M?@  0X$  #N%   UB D ,HD1 #&)&P PB24 +XHO "Z*.  MBT$ +(M* "J+
M5  IBU\ *(MK ":+>@$DBXL!(XN> 2*+LP$AC,X!(8KQ 2"(_P(@AO\"((7_
M B&%_P(AA?\"JW(  *%\  "/>P  @'H  '-Z  !F?   6W\  %""  !&A@
M/(H  #2-   LD0  )I,, "24$P CE!P (I4F "&5+P @E3@ 'Y9" !Z63  =
MEE@ ')9D !J7=  9EX8 &)>9 !>7K@ 5E\D %I7N !:3_P$6DO\!%I'_ 1:0
M_P$6D/\!I7L  )F#  ")@0  >X   &R"  !?A   5(@  $F+   _D   -90
M "V7   EF@  '9X! !:@#  4H1( %*$; !.A)0 2H2X $:(X !&B0P 0HD\
M#Z)<  ZC:P -HWT #:.2  RCIP *HL  "Z+F  R@_@ -G_\ #9[_  V=_P -
MG?\ GH0  )*)  "#B   <X@  &6+  !8C@  3)(  $&7   WFP  +IX  "2B
M   <I0  %:@   ^K!  *K@P !ZT2  :M&P %K20 !*XN  *N.0 !KD4  *Y2
M  "N80  KG,  *Z'  "NG0  KK0  *[5  "M]   K?\  *S_  "K_P  J_\
MEHL  (R0  ![D   :Y(  %V6  !0F@  1)\  #FC   OIP  ):L  !RN   4
ML0  #K0   FW   !N D  +@.  "Y%   N1P  +HE  "Z+P  NSH  +Q'  "\
M5@  O&<  +Q[  "\D0  O*D  +S$  "\ZP  N_X  +O_  "[_P  N_\ D)(
M (.8  !SFP  8Y\  %6C  !'J   .ZT  #"Q   EM   &[<  !*Z   ,O0
M!;\   ##    Q (  ,4*  #%#@  QA0  ,<;  #()   RBX  ,PZ  #-20
MS5D  ,UL  #.@P  SIL  ,VU  #.V@  SO8  ,W_  #-_P  S?\ AID  '>@
M  !II@  6JP  $RR   ^M@  ,+D  "2\   9OP  $<(   K%   "R0   ,P
M  #0    T0   -(!  #3"   U0T  -<1  #:&   W"$  -\L  #A.@  XDH
M .-=  #D<@  Y(L  .6E  #EP   Y>8  .7X  #E_P  Y?\ >J$  &NI  !<
MKP  3;8  #^\   POP  (\,  !?'   /R@  !\X   #1    U@   -P   #?
M    X    .(   #D    Y@,  .@)  #I#@  [!4  .X>  #Q*P  ]#H  /5-
M  #V80  ]WD  /B3  #XK0  ^<8  /GD  #Y\P  ^?, ;:H  %ZR  !/N@
M0,$  #'%   BR0  %LX   W2   $V    -T   #A    Y    .@   #K
M[0   .\   #Q    \P   /8   #X P  ^@L  /T1  #_&P  _RD  /\[  #_
M3P  _V8  /]_  #_F0  _Z\  /_#  #_U@  _]8 _P0< /\ &0#_ !D _P <
M /\ (@#_ "L _P X /\ 1@#_ %, _P!> /\ :0#_ '( _P!Z /\ @@#_ (D
M_P"/ /\ E0#_ )L _P"A /\ J #_ *\ _P"Y /\ Q0#_ -D _@#L /T ^P#[
M /\ ^P#_ /L _P#Z /\ ] #_ /  _P#P /\ _P<8 /\!%0#_ !0 _P 6 /\
M&P#_ "8 _P T /\ 0@#_ $X _P!: /\ 9 #_ &T _P!U /\ ?0#_ (0 _P"*
M /T D #\ )8 ^@"= /D HP#X *L ]P"T /4 OP#T ,X \P#F /$ ]@#P /\
M[P#_ .\ _P#N /\ [@#_ .H _P#J /\ _PL4 /\&$0#_ !  _P 0 /\ %@#_
M "( _P N /\ / #_ $D _P!4 /X 7P#[ &@ ^0!P /< > #U '\ \P"% /(
MBP#P )( [P"8 .T GP#L *8 Z@"N .@ N0#G ,< Y0#> ., \ #B /X X #_
M .  _P#A /\ X0#_ .$ _P#A /\ _PT0 /\)#0#_ 0P _P , /\ $@#_ !P
M_P H /P -@#Y $, ]@!. /( 60#O &( [ !K .H <@#H 'D Y@"  .0 A@#B
M (P X0"3 -\ F@#= *$ VP"J -@ M #5 ,  T@#3 -  Z@#. /H S0#_ ,T
M_P#- /\ S #_ ,P _P#, /\ _Q , /\,!P#_ P( _P ( /\ #@#_ !8 ]@ B
M /  +P#L #P Z0!( .4 4P#A %P W@!E -L ; #7 ', U !Z -( @ #0 (<
MS@". ,P E0#* )T R "E ,8 KP#$ +L P@#+ ,  Y0"^ /4 O0#_ +P _P"\
M /\ O #_ +P _P"\ /\ _Q$% /\.  #_"@  _P@! /\$"@#X !  Z0 : .,
M* #> #4 V0!! -, 3 #/ %8 RP!? ,D 9@#& &X Q !T ,( >P#! (( OP")
M +T D "\ )@ N@"A +@ JP"V +< M #' +( X "Q ?( KP+_ *X#_P"M!/\
MK03_ *T$_P"M!/\ _Q0  /\0  #_#P  \@T  .H*  #I PD W0 2 -0 'P#-
M 2T R (Z ,0#10#  U  O019 +L%80"Y!6@ MP9O +4&=@"T!WT L@>$ +$(
MC "O")4 K0F> *L)J "J"K4 J K% *8+WP"D#?0 H@[_ * ._P"?#O\ GP[_
M )\._P"?#O\ _Q<  /\3  #O&   Y!D  -L6  #2$ ( SPD+ ,@(%@#!"B0
MO PR +<-/@"T#DD L0Y3 *\06P"M$&, JQ!J *D1<0"H$7@ IA&  *41B "C
M$I$ H1*; * 3I@">$[, G!/# )L4W@"7%O0 E1;_ )07_P"3%_\ DA?_ )(6
M_P"2%O\ _QH  /0=  #E(P  U24  ,HD  #"'0  OA8$ +L0$ "T$QT KQ4K
M *L6. "G&$, I1E- *(95@"@&ET GAME )T;; ";'', FAQ[ )@<@P"7'8T
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MF@)[+Z<">B^W G@OS )V,.H"=3#^ G,P_P)S,/\"<R__ G,O_P)S+_\"\"H
M -PU  #'.P  NC\  *P\  "B.   G#,  )@O  "5+A  D# < (PR*0"),S4
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M!F!!P@9>0>(&7D'Y!5U!_P1=0/\#74#_ UU _P-=0/\#WSD  ,A#  "Y2@
MJ4L  )M)  "01P  B$0  (-!  !^008 >D(1 '9#'@!T12H <44U &]&/P!M
M1D< :T9/ 6I&5@%H1ET"9D9E F1&;0-B1G8$8$:"!%Y&C@5<19P&6T6L!EE&
MOP=81M\&6$;W!5=%_P171?\$5T3_ UA$_P-81/\#VCT  ,1'  "U3@  I$X
M )9,  "+2P  @TD  'U%  !X1@( =$<0 '!(&P!N22< :THR &I+/ !H2T0
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M!DA2_P5(4?\$25'_!$E0_P-)4/\#RD@  +E2  "J5P  F%8  (I5  !_5
M=E,  &Q1  !G4P  8E0( %]6$@!=5QX 6U<I %E8,P!86#P 5EE$ %593 %3
M65,!45E; D]89 )-6&T#2UAX!$E8A@5'5Y4&15>E!D17N 9#6-(&0U?R!D-6
M_P5#5?\$1%7_!$14_P-$5/\#QDP  +56  "E6@  E%D  (98  ![6   <5<
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M S)D_P,R9/\#MUL  *ED  "69   AF,  'AC  !M8P  9&0  %EE  !0:
M26L  $-M! ! ;@X /F\8 #UO(@ \<"L .G T #EQ/0 X<44 -W%. #9Q5P T
M<6$!,G%M 3%Q>@$O<8H"+7&< BMQKP(J<<@"*G#K BIO_P(J;?\"*FS_ BML
M_P(K;/\"L6$  *1I  "0:   @&<  '1G  !I9P  7V@  %5K  !+;@  0W$
M #QT   W=@H -'<2 #-X'  R>"4 ,7DN #!Y-P O>3\ +GE( "QZ4@ K>EP
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M:@ 1CWL $(^/  ^/I  .C[L #8_@  Z-^@ /B_\ $(K_ !")_P 0B?\ H7H
M (YY  !^=P  <G<  &1X  !8>P  37X  $*"   YA@  +XH  ">.   @D0
M&)4  !*8!0 .F@X #9H4  R:'0 +FB8 "YHP  J:.P )FD8 ")I3  :;80 %
MFG( !)J&  *:FP  FK$  9G/  *9\  "F/\ !)?_  66_P %EO\ F8$  (=_
M  !Z?@  :WX  %V!  !0A0  18D  #N-   QD@  *)8  !^9   8G0  $:
M  RC @ &I0H  :40  "E%@  IA\  *8H  "F,@  IST  *=*  "G6   IV@
M *=\  "GD0  IJ@  *;#  "EZ0  I?P  *7_  "D_P  I/\ D8<  (*&  !R
MA@  8X@  %6,  !)D0  /98  #*:   HG@  'Z(  !>F   0J0  "ZP   2O
M    L08  +$,  "R$0  LA<  +,?  "S*   M#(  +4_  "U30  M5T  +5P
M  "UA@  M9T  +6V  "UW   M/<  +3_  "T_P  M/\ BX\  'J.  !JD0
M6Y4  $V:  ! GP  -:0  "JH   @K   %K    ^T   )MP   ;D   "]
MO@   +X&  "_#   P!   ,$6  #"'0  PR<  ,4R  #&0   QE$  ,=C  #'
M>   QY$  ,>I  #'QP  Q^P  ,?^  #'_P  Q_\ @Y<  '&:  !AG@  4J,
M $6I   XK@  ++,  ""W   6N@  #KT   ;     PP   ,<   #)    R@
M ,P   #- P  S@D  - .  #2$P  U!L  -@E  #;,@  W4(  -U4  #>:0
MWH$  -Z<  #?M0  W]D  -_S  #?_P  W_\ =Y\  &BF  !9K0  2K,  #NX
M   MNP  '[\  !3"   ,Q@   \D   #,    T    -4   #9    V@   -P
M  #>    X    .(%  #D"P  YQ   .H8  #M)   \#(  /%$  #R6   \V\
M /2*  #TI   ]+\  /3?  #T\P  ]/0 :J@  %NO  !,MP  /;T  "W!   ?
MQ@  $\H   O.    T@   -<   #<    X    .4   #G    Z0   .L   #M
M    [P   /$   #S    ]@<  /D.  #\%@  _R(  /\S  #_1P  _UT  /]V
M  #_D0  _ZD  /^^  #_V   _]L _P 8 /\ %@#_ !4 _P 8 /\ '@#_ "<
M_P V /\ 0P#_ $\ _P!: /\ 9 #_ &T _P!U /\ ?0#_ (0 _P"* /\ D #_
M )8 _P"< /\ HP#_ *L _P"T /X OP#] ,\ ^P#G /H ^ #Y /\ ^0#_ /D
M_P#U /\ [@#_ .D _P#G /\ _P 4 /\ $0#_ !$ _P 2 /\ %P#_ ", _P Q
M /\ /@#_ $H _P!6 /\ 8 #_ &@ _P!P /\ > #] 'X _ "% /H BP#Y )$
M^ "8 /< G@#U *8 ] "N /( N0#Q ,< [P#@ .X \@#L /\ [ #_ .P _P#K
M /\ Y0#_ .  _P#> /\ _P,0 /\ #@#_  T _P - /\ $P#_ !X _P K /\
M. #_ $4 _@!0 /L 6@#X &, ]0!K /, <@#Q 'D [P!_ .X A@#L (P Z@"2
M .D F0#G *  Y@"I .0 LP#A ,  X #3 -X ZP#< /L VP#_ -H _P#: /\
MV0#_ -0 _P#2 /\ _P<- /\ "0#_  8 _P ) /\ #P#_ !@ ^P E /@ ,@#U
M #\ \@!* .T 5 #J %T YP!E .0 ; #B ', X !Z -X @ #< (8 V@"- -<
ME #4 )L T@"D ,\ K0#- +D RP#) ,D Y #( /8 Q@#_ ,4 _P#& /\ QP#_
M ,< _P#' /\ _PH& /\!  #_    _P $ /\ "P#T !( [P ? .H + #E #@
MX@!# -T 3@#9 %< U !? -$ 9P#. &T S !T ,H >@#( (  Q@"' ,4 C@##
M )8 P0"> +\ J "] +, N@#" +D VP"W /  M0#_ +8 _P"U /\ M0#_ +4
M_P"U /\ _PP  /\$  #_    _@   /8  P#H  T X  7 -D ) #1 #$ S0 \
M ,H 1P#& %$ PP!9 ,  8 "^ &< O !N +H = "Y 'L MP"" +4 B0"S )$
ML@": +  I "N *\ K "] *H T "H .L IP#[ *8 _P"F /\ I0#_ *4 _P"E
M /\ _PT  /\'  #T"0  Z@D  .($  #:  < SP 1 ,@ ' #" "D O@ U +L
M0 "W $H M !3 +( 6P"P &( K@!H *P ;P"K '4 J0!] *@ A "F (T I "6
M *, H "A *L GP&Y )T#S "<!.@ F@;Y )D'_P"8"/\ EPC_ )<(_P"7"/\
M_Q   /<0  #H%   W!4  ,X1  #&#0  P@0+ +P % "W 2$ L@,N *X%.@"K
M!D0 J A- *8(50"D"5P H@IC * *:@"?"W$ G0MX )P+@ ":#(D F0R3 )<,
MG@"5#:H E VX )(-S "0#NH CA#\ (P0_P"+$/\ BQ#_ (L0_P"*$/\ ^Q,
M .T:  #=(   S"$  +\=  "W%P  LQ$  +(+#0"K#1D IPXF *,/,P"?$#X
MG1%' )H14 "8$E< EA)> )4390"3$VP DA-S ) 4? "/%(4 C16/ (L5F@"*
M%:< B!:U (86R0"$%^< @AC[ ( 9_P!_&?\ ?QG_ '\8_P!_&/\ ]1H  .0C
M  #/*0  P"H  +,F  "J(@  I1P  *05" "@%!, FQ8A )<8+0"4&3@ D1I"
M (\;2P"-'%( BQQ9 (D=8 "('6< AAYO (4>=P"#'X  @A^+ ( ?EP!^(*,
M?2"R 'L@Q0!Y(>0 =R+Y '8B_P!U(O\ ="'_ '0A_P!T(?\ [R$  -LK  #'
M,0  MC$  *DN  "@*@  FR8  )@A 0"5'A  D" ; (TA* ")(S, AR0] (4D
M1@"#)4X @295 '\F7 !^)F, ?"=K 'LG<P!Y)WP >"B' '8HDP!T** !<BBO
M 7$IP0%O*> !;2GW 6PI_P%K*?\!:RG_ 6LH_P%K*/\!Z"@  - R  # .
MKC<  *$U  "8,@  DBT  (XI  "+)PP AR@7 (,J(P" *R\ ?BPY 'PL0@!Z
M+4H >"Y1 '<N6 !U+F  <R]G '(O;P!P+WD!;R^# 6TOD %K+YT!:2^L 6@P
MO@%G,-L!93#U 60P_P%C,/\!8R__ 6,O_P%C+_\!XBX  ,HX  "Z/0  J#P
M )HZ  "1-P  BC,  (8P  "#+@D ?R\3 'LP'P!X,BL =C,U '0S/@!R-$8
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M0   ?CX  'D[  !T.@  <3H. &T\& !K/20 :3XO &<_. !E/T  9$!( &)
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M TA)LP-'2<H#1DGL T9(_P)&2/\"1T?_ D=&_P)'1O\"QD,  +9,  "B3
MD4P  (1+  !Y2@  <$D  &E&  !D1P  7TD& %Q*$ !:2QL 6$PE %9,+P!5
M33@ 4TU  %)-2 !13D\ 3TY7 $Y.7P%,3FD!2DYS DA-@ )&38\#14V? T--
ML0-"3<@#04WJ T%,_P)!3/\"0DO_ D)*_P)"2O\"PD<  +-/  ">3P  C4X
M (!.  !U30  ;$P  &-*  !>3   6DT" %9.#@!43Q@ 4E B %%1+ !/434
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M C%;_ (Q6O\",5G_ C)9_P$R6/\!ME0  *19  "06   @%@  '-7  !I5P
M8%@  %19  !.6P  2%T  $-?! ! 8 X /F$7 #UA(  [8BD .F(R #EB.@ X
M8T( -V-+ #9C5  T8UT ,V-H #%C=@$O8X4!+F.6 2QCJ0$K8[\!*F/C 2IB
M^P$J8/\!*U__ 2M?_P$K7O\!L5D  )Y<  "+7   >UL  &];  !E6P  7%P
M %%>  !)8   0V(  #QE   X9PH -6@2 #1H&P S:20 ,FDM #%I-0 O:CT
M+FI& "UJ3P L:ED *VME "EK<@ H:X( )FN3 "1KIP C:[T (FK@ "-I^0$C
M9_\!(V;_ 2-F_P$D9?\!K&   )A@  "%8   =E\  &I?  !A8   5V   $UC
M  !$9@  /6@  #9K   P;@0 +' . "IQ%0 I<1X *'$F "=R+P F<C< )7)
M "1R2@ B<E0 (7-@ "!S;0 ><WT '7.0 !MSHP :<[D &7/< !IQ]P :</\
M&V__ !MN_P$;;?\!IF8  )%E  !_9   <60  &9D  !=9   4F8  $AI   _
M;   -V\  #!S   I=@  (GD( !][$  >>Q< ''L? !M[*  :>S  &7PY !A\
M0P 7?$X %GQ: !5\9P 4?7@ $GV+ !%]GP 0?;4 #WW5 !![]0 1>?\ $7C_
M !)W_P 2=_\ GFL  (IJ  !Z:0  ;6D  &)I  !7:@  3&T  $-P   Y=
M,7@  "E[   B?P  &X(  !2%"0 1AA  $887 !"''P 0AR@ #H<Q  Z'.P -
MAT8 #(=3  N'80 *AW$ "8>$  >'F  &AJX !8;)  :%[  'A/\ "(/_  F"
M_P )@O\ E7$  (-O  !T;@  :6X  %QO  !0<@  1G4  #QY   R?0  *H$
M "*%   ;B0  %(P   ^/ P *D@L !I(1  22&  "DB   9(I  "2,P  DSX
M )-+  "360  DVD  )-[  "2D   DJ8  )&_  "1Y0  D/H  (__  "/_P
MC_\ C7<  'UU  !P=   8G4  %5X  !)?   /X   #2$   KB0  (HT  !J1
M   3E   #I<   F;   !G0@  )T.  "=$P  GAH  )XB  "?*P  GS4  *!"
M  "@4   H%\  *!Q  "@AP  GYT  )^U  ">V@  G?8  )W_  "<_P  G/\
MAGT  'A\  !I?   6W\  $Z#  !!B   -HP  "R1   CE@  &IH  !*>   -
MH0  !J0   "G    J0,  *D*  "J#@  JQ,  *P9  "M(@  KBL  *\W  "O
M10  KU0  *]F  "O>P  KI0  *ZK  "NR0  KN\  *W_  "M_P  K?\ @80
M '&$  !AAP  4XL  $:0   YE@  +IL  ".@   :I   $J@   RL   $KP
M +(   "V    MP   +<"  "X"   N0T  +H2  "[&   O2$  +XK  # .
MP$@  ,!:  #!;@  P88  ,&@  #!N@  P>,  ,#Y  # _P  P/\ >8T  &B0
M  !9E   2YH  #V@   QI0  ):L  !JO   1LP  "[@   *[    O@   ,$
M  #$    Q0   ,8   #'    R 4  ,H+  #,#P  SA4  - ?  #3*P  U3H
M -5,  #68   V'<  -B2  #8K   V<D  -GL  #9^P  V/\ <)D  &">  !1
MI   0ZH  #6P   HM@  '+H  !&^   )P0   ,4   #(    RP   ,\   #2
M    TP   -8   #8    VP   -T   #?!P  X@T  .43  #H'0  ["H  .T\
M  #M40  [F<  .^!  #OG   \+<  /#3  #P[   \/0 9Z8  %BM  !)M
M.KH  "J^   <P@  $,8   ?*    S@   -(   #6    W    .    #C
MY    .8   #H    ZP   .T   #O    \@(  /4*  #X$0  _!P  /\L  #_
M/P  _U4  /]N  #_B@  _Z0  /^Z  #_T0  _^$ _P 4 /\ $@#_ !( _P 4
M /\ &0#_ "4 _P R /\ /P#_ $L _P!6 /\ 8 #_ &@ _P!P /\ > #_ '\
M_P"% /\ BP#_ )$ _P"8 /\ G@#^ *8 _0"N /P N0#Z ,@ ^0#B /@ ] #W
M /\ ]@#_ /8 _P#O /\ YP#_ .( _P#> /\ _P 1 /\ #@#_  X _P / /\
M% #_ "  _P M /\ .@#_ $8 _P!1 /\ 6P#_ &, _@!K /P <P#Z 'D ^0"
M /< A@#V (P ]0"2 /, F0#R *  \ "I .X LP#M ,$ ZP#6 .H [@#I /X
MYP#_ .< _P#E /\ W0#_ -4 _P#1 /\ _P - /\ "@#_  @ _P ) /\ $ #_
M !L _P H /\ -0#_ $  ^@!+ /8 50#S %X \0!F .X ;0#L '0 ZP!Z .D
M@ #G (8 Y@"- .0 DP#B )L X "C -X K0#< +D V@#* -< Y@#4 /@ T@#_
M -( _P#2 /\ S@#_ ,D _P#& /\ _P ( /\  P#_    _P # /\ #0#\ !8
M]P B /, +@#O #H [ !% .@ 3P#D %@ X0!@ -X 9P#; &T V0!T -4 >@#3
M (  T0"' ,\ C@#- )4 RP"> ,D IP#' +, Q0#" ,, W #! /$ OP#_ +\
M_P"^ /\ O@#_ +T _P"[ /\ _P   /\   #_    _P   /8 " #N !$ YP ;
M .$ )P#= #, V0 ^ -, 20#/ %( RP!9 ,@ 80#& &< Q !M ,( <P#  'H
MOP"  +T B "[ )  N0"8 +@ H@"U *T LP"[ +$ S@"P .H KP#\ *T _P"M
M /\ K@#_ *X _P"N /\ _P(  /\   #]    \@   .@   #>  P TP 5 ,P
M(0#( "P Q  X ,$ 0@"] $L N@!3 +@ 6@"V &$ M !G +( ;0"P '0 KP!Z
M *T @@"L (H J@"3 *@ G0"F *@ I "U *( Q@"A ., GP#V )X _P"> /\
MG@#_ )X _P"> /\ _P8  /L   #N!0  X@0  -4   #+  8 PP / +T &0"X
M "4 M  Q +$ .P"N $4 K !- *D 50"G %L I0!B *0 : "B &X H0!U )\
M? "> (4 G ". )H F "8 *0 E@"P )4 P0"3 -P D@#R )$ _P"0 /\ D #_
M (\ _P"/ /\ _0H  / .  #A$0  SA   ,(-  "[!P  MP * +$ $@"L !X
MJ  I *4 - "B #X GP!' )T 3P"; %8 F0%< )<!8P"6 FD E )P ),#> "1
M X  D 2* (X$E0",!:$ B@6N (D&O@"'"-@ A@GP (0*_P"#"_\ @PO_ (,+
M_P"#"_\ ]A   .87  #2'   P!H  +,6  "L$@  J T  *8'#0"B!18 G0<B
M )D)+@"6"C@ E M! )(,2@"0#%$ C@U8 (P-7@"+#64 B0UL (@.= "&#GT
MA0Z' (,.DP"!#Y\ @!"M 'X0O@!]$-L >A'T '@2_P!W$O\ =Q+_ '<2_P!W
M$O\ [Q<  -LA  #&)   M",  *@@  "@'   FQ<  )D1! "8#A  DQ ; (\1
M)P",$C( B1,\ (<31 "%%$P @Q13 ($56@" %6  ?A9H 'T6;P![%G@ >1>#
M '@7CP!V&)P =!BJ ',9NP!R&=0 ;QKQ &X;_P!M&_\ ;1K_ &T:_P!M&O\
MYR   - I  "\*P  JRH  )XH  "6)   D"   (T<  ",%PP B!@6 (0:(@"!
M&RT ?APW 'P=0 !Z'4@ >1Y/ '<>50!V'UP =!]C ',?:P!Q('0 <"!_ &XA
MBP!L(9@ :R&G &DBN !H(L\ 9B+N &4C_P!D(_\ 9"+_ &0B_P!D(?\ X"8
M ,@O  "T,0  HS   )8N  "-*P  AR@  (0D  ""( @ ?B 2 'LB'@!X(RD
M=20S ',E/ !Q)4, <"9+ &XF4@!M)UD :R=@ &HG: !I*'$ 9RA[ &4HB !D
M*94 8BFD & IM0!?*<L 7BKL %PJ_P!<*?\ 7"G_ %PI_P!<*/\ V"P  ,,U
M  "M-0  G30  ) S  "&,0  @"T  'PK  !Y* , =B<0 '(I&@!P*B4 ;2LO
M &LL. !J+$  :"U' &<M3@!E+E4 9"Y= &,N90!A+VX 7R]X %XOA !<+Y(
M6B^A 5DOL@%8,,@!5C#I 54P_@%5+_\ 52__ %4N_P!5+O\ T#$  +TZ  "H
M.0  ES@  (HW  " -@  >C(  '4P  !R+@  ;BX- &LO%@!I,"$ 9C$K &0R
M- !C,CT 83-$ & S2P!?-%( 731: %PT8@!:-&L 635U %<U@@!5-9 !5#6?
M 5(UL %1-<8!4#7G 4\U_0%/-?\!3S3_ 4\T_P%/,_\!RS8  +@]  "C/
MDCP  (4[  ![.@  =#<  &\U  !L,P  :#0* &4U$P!B-AX 8#<H %XW,0!=
M.#H 6SA! %HY2 !9.5  5SE7 %8Z7P!4.F@ 4SIS %$Z?P%/.HT!3CJ= 4PZ
MK@%+.L,!2CKE 4DZ_ %).?\!23G_ 4DX_P%*./\!QSH  +-   ">/P  CC\
M ($^  !W/0  <#L  &HX  !F.   8CD' %\Z$0!<.QL 6CLE %D\+@!7/3<
M5CT^ %0^1@!3/DT 4CY5 %$^70!//V8 33]P $P_?0%*/XL!2#^; 4<_K %%
M/\$!1#_C 40^^P%$/O\!1#W_ 40]_P%%//\!PSX  *]#  ":0@  BD(  'U!
M  !S0   :S\  &4\  !@/   7#X$ %D^#P!7/Q@ 54 B %-!*P!2030 4$(\
M $]"0P!.0DL 34-2 $M#6@!*0V0 2$-N $=#>P%%0XD!0T.9 4)#JP% 0\ !
M/T/A 3]#^0$_0O\!/T'_ 4!!_P% 0/\!OT$  *I%  "610  AD4  'E$  !O
M1   9T(  & _  !;00  5T(  %1##0!11!4 3T4? $Y%* !,1C$ 2T8Y $I'
M00!)1T@ 2$=0 $9'6 !%1V$ 0TAL $)(> % 2(<!/DB7 3Q(J0$[2+X!.DC?
M 3I'^ $Z1O\!.D7_ 3M%_P$[1/\!NT4  *9(  "21P  @D<  '9'  !K1P
M8T8  %M#  !610  4D<  $Y("@!,21( 2DD< $A*)0!'2BX 1DLV $5+/@!#
M2T8 0DQ- $%,5@! 3%\ /DQJ #Q,=@ [3(4!.4R5 3=,IP$V3+P!-4S= 35+
M]P$U2_\!-4K_ 39)_P$V2?\!N$D  *)+  ".2@  ?DH  ')*  !H2@  7TD
M %5(  !02@  3$L  $E,!P!&31  1$X9 $)/(@!!3RL 0% S #]0.P ^4$,
M/%%* #M14P Z45P .%%G #=1<P U48( ,U&3 3)1I0$P4;H!+U': 2]0]@$O
M3_\!,$[_ 3!._P$P3?\!M$T  )U-  "*30  >DT  &Y-  !D30  6TT  %%-
M  !+3P  1E   $)2 P _4PT /505 #Q4'@ Z52< .54O #A5-P W5C\ -E9'
M #564  S5ED ,E=D #!7<0 O5X  +5>1 "M7HP J5[@ *5?6 "E6]0 I5?\
M*E3_ 2I3_P$J4O\!KU$  )A1  "%40  =E   &I0  !@4   6%$  $Y2  !'
M4P  054  #M8   X60H -5H1 #1:&@ S6R( ,ELK #%;,P O7#L +EQ# "U<
M3  L7%8 *UU@ "E=;0 H77P )EV. "1=H0 C7;4 (EW2 ")<\P B6_\ (UK_
M "-9_P D6/\ J%4  ))4  " 5   <50  &94  !<5   5%4  $I6  !#6
M/%L  #9=   P8 4 +6$. "MA%0 J8AT *6(E "AB+@ G8S8 )F,^ "5C1P C
M8U$ (F1< "%D:0 ?9'D 'F2* !QDG@ ;9+, &63. !IC\0 ;8?\ &V#_ !Q@
M_P <7_\ H5D  (Q8  ![6   ;5@  &)8  !96   4%D  $=;   ^7@  -V
M #%C   J9@  )&D) "%J$  @:A< 'VH@ !YK*  =:S  '&LY !MK0@ :;$P
M&6Q8 !=L90 6;'0 %&R& !-LF@ 2;*\ $6S* !%K[P 2:?\ $VC_ !-H_P 3
M9_\ F5T  (5=  !U7   :%P  %Y<  !57   2UX  $)A   Y9   ,F<  "MJ
M   D;0  'G ! !=S"P 5=!$ %'08 !-T(0 2=2D $74R !%U.P 0=48 #W52
M  YU7P -=6X #'6!  MUE0 *=:H "'3#  ETYP *<_T "W'_  QQ_P ,</\
MD6(  ']A  !P80  9&$  %IA  !/8@  164  #QH   S;   *V\  "1R   =
M=@  %WD  !%\!  -?PP "W\2  I_&0 )?R( "'\J  9_-  %?S\ !']+  )_
M6  !?V<  ']Y  !_C@  ?Z,  'Z[  !]X   ??<  'S_  ![_P  >_\ B6<
M 'AG  !K9@  868  %1G  !):0  /VT  #5Q   L=0  )'D  !U\   6@
M$(,   R& @ &B0H  8D/  ")%   BAL  (HC  "++   BS<  (M#  "+4
MBU\  (MQ  "+A@  BYP  (JS  ")TP  B/,  (C_  "'_P  A_\ @FT  '-L
M  !H;   6FT  $YO  !"<P  .'<  "Y[   E@   '80  !6(   0C   "X\
M  22    E 8  )4,  "5$   EA4  )<<  "8)   F"X  )DY  "91P  F58
M )EH  "9?0  F90  )BK  "7R   ENX  );_  "5_P  E?\ >W0  &]S  !A
M<P  4W8  $9Z   [?P  ,(0  ":(   =C0  %)(   Z6   )F0   9P   "@
M    H0   *(&  "B#   I!   *44  "E'   IR0  *@O  "H/0  J4P  *E>
M  "I<@  J(D  *BB  "HO   I^4  *;[  "F_P  I?\ =WL  &A[  !9?@
M2X(  #Z'   RC0  )Y(  !V7   4G   #J    >D    J    *L   "N
MKP   +    "Q!   LPH  +0.  "U$P  MAL  +@D  "Z,0  ND   +I2  "[
M90  NWT  +J7  "ZL0  NM(  +KS  "Y_P  N?\ ;X,  %^&  !1BP  0Y
M #:7   JG0  'Z(  !6G   -K   !;    "T    MP   +L   "^    OP
M ,    #!    PP$  ,0'  #%#0  QQ$  ,H9  #-)   SC,  ,]$  #06
MT&X  -&(  #0I   T,$  -'F  #1^   T?\ 9X\  %>4  !)F@  .Z$  "ZG
M   AK0  %K,   ZX   &O    ,    ##    Q@   ,L   #-    S@   -
M  #1    U    -8   #: @  W D  -\/  #C%P  YB0  .<V  #H20  Z5\
M .IX  #KE   ZZ\  .O,  #LZ   [/8 7YX  %"D  !"JP  -+(  ":Y   9
MO@  #L(   3%    R@   ,T   #1    V    -L   #?    X    .(   #D
M    Y@   .D   #K    [@   /$%  #U#0  ^18  /PE  #].0  _D\  /]G
M  #_@@  _YT  /^U  #_RP  _^0 _P 1 /\ #P#_  \ _P 1 /\ %@#_ "(
M_P O /\ .P#_ $< _P!2 /\ 6P#_ &0 _P!L /\ <P#_ 'H _P"  /\ A@#_
M (P _@"3 /T F0#[ *$ ^@"I /@ M #W ,( ]@#: /4 \0#T /\ \P#_ /,
M_P#I /\ X #_ -@ _P#3 /\ _P . /\ "P#_  H _P + /\ $0#_ !T _P J
M /\ -@#_ $$ _P!, /\ 5@#^ %\ ^P!F /D ;0#W '0 ]0!Z /0 @ #R (8
M\ "- .\ E #M )L [ "D .H K@#I +H YP#- .4 Z0#D /L XP#_ .( _P#>
M /\ T0#_ ,P _P#( /\ _P ) /\ ! #_  $ _P $ /\ #@#_ !@ _P D /T
M, #[ #L ]P!& /, 4 #O %D [ !@ .H 9P#G &X Y@!T .0 >@#B (  X "'
M -X C@#< )4 V@"> -8 J #4 +, T0## ,\ WP#. /0 S #_ ,L _P#+ /\
MQ0#_ +\ _P"\ /\ _P " /\   #_    _P   /T "P#W !, \0 > .T *@#J
M #4 YP!  .( 2@#= %( V0!: -4 80#2 &< T !M ,X <P#, 'H R@"  ,@
MAP#& (\ Q "8 ,( H0#  *T O@"[ +P T "Z .T N0#^ +@ _P"X /\ MP#_
M +, _P"P /\ _P   /\   #_    ^0   .X !0#E  X W@ 8 -@ (P#2 "X
MSP Y ,L 0P#' $P Q !4 ,$ 6P"_ &$ O !G +L ;0"Y ', MP!Z +4 @0"T
M (D L@"2 +  FP"O *< K "T *L Q@"I .0 IP#X *8 _P"F /\ I0#_ *4
M_P"D /\ _P   /\   #U    Z@   -X   #0  H R  2 ,( '0"^ "@ NP S
M +D /0"U $8 L@!- +  50"M %L K !A *H 9P"H &T IP!S *4 >@"D ((
MH@", *  E@"? *$ G0"N )L O@"9 -@ EP#Q )8 _P"6 /\ EP#_ )< _P"7
M /\ _P   /4   #G 0  U    ,D   #   0 N  . +, %@"O "$ JP L *@
M-@"F #\ HP!' *$ 3P"? %4 G0!; )L 80": &< F !N )< =0"5 'T E "&
M )( D0"0 )P C@"I (P N "+ ,T B0#K (@ _0"( /\ B #_ (@ _P"( /\
M^08  .D,  #4#@  PPP  +<)  "P @  JP ) *8 $ "B !H G@ E )L , "8
M #D E@!! )0 20"2 %  D !6 (X 7 "- &( BP!I (H < "( '@ AP"! (4
MC "$ )@ @@"E (  M !^ ,@ ?0'G 'P"^0![ _\ >P3_ 'L$_P![!/\ \0X
M -X5  #%%0  M!0  *D1  "A#@  G@H  )L## "7 !, DP > ) !*0"- C,
MB@,\ (@$0P"&!4L A091 (,&5P""!UX @ =D '\(; !]"'0 ? A^ 'H)B0!X
M"98 =PJC '4*LP!S"\< <@SF ' -^P!P#?\ ;PW_ &\-_P!O#?\ Z!8  - >
M  "Y'0  J1P  )T:  "5%@  D!,  (\. P"."@X B0L7 (8,(P"##2T @ TV
M 'X./@!\#D8 >PY- 'D/4P!X$%H =A!A '40: !S$'$ <1%[ ' 1AP!N$90
M;!&B &L2L@!I$L< :!/G &83_0!E%/\ 913_ &43_P!E$_\ WQX  ,8D  "P
M)   H",  )0A  "+'P  AAL  (,7  ""$@@ ?Q$2 'P2'0!Y%"@ =A0Q '05
M.@!R%D$ <19( &\73P!N%U8 ;!== &L89 !I&&T :!EW &89@P!D&9  8QJ?
M &$:KP!@&L0 7AOD %T<^P!<'/\ 7!O_ %P;_P!<&_\ U24  +TJ  "H*0
MF"D  (PH  "#)0  ?2(  'D?  !X&P, =AD/ '(:& !O'", ;1TM &L=-0!I
M'CT :!Y$ &8?2P!E'U( 8R!9 &(@80!A(&D 7R%S %TA?P!<(8T 6B*< %DB
MK !7(L  5B/A %4C^0!4(_\ 5"+_ %0B_P!4(O\ S2L  +8N  "B+@  DBX
M (4M  !\*P  =B@  '(F  !O(P  ;2$, &HB%0!G(Q\ 920I &,D,0!B)3D
M8"9! %\F2 !=)D\ 7"=6 %LG70!9)V8 6"AP %8H? !4*(H 4RF9 %$IJ@!0
M*;X 3RG> $XI]P!-*?\ 32G_ $TH_P!.*/\ R#   + R  "<,@  C#(  ( Q
M  !V,   <"T  &LK  !H*0  9B@) &,H$0!@*1P 7BHE %PK+@!;*S8 62P]
M %@L1 !7+4P 52U3 %0M6P!3+6, 42YN % N>@!.+H@ 3"^7 $LOJ !)+[L
M2"_; $@O]@!'+_\ 1R[_ $<M_P!(+?\ Q#0  *LU  "7-0  AS4  'LU  !R
M-   :S(  &8O  !B+@  7RT% %PN$ !:+Q@ 6# B %8P*P!5,3, 4S$Z %(R
M0@!1,DD 4#)0 $XS6 !-,V$ 2S-K $HS=P!(-(4 1S25 $4TI@!#-+D 0C36
M $(T] !"-/\ 0C/_ $(R_P!",O\ P#@  *<X  "3.   @S@  '<X  !M-P
M9C8  &$S  !=,@  63(" %<S#0!4-!4 4C4? %$U* !/-C  3C8X $PW/P!+
M-T8 2C=. $DX5@!'.%\ 1CAI $0X=0!#.(, 03F3 $ YI  ^.;@ /3G3 #PY
M\P \./\ /3?_ #TW_P ]-O\ NSL  *([  "/.P  ?SL  ',[  !J.@  8CD
M %TW  !8-@  5#<  %$X"P!/.1, 33D< $LZ)0!*.BT 2#LU $<[/ !&/$0
M13Q+ $0\4P!"/%P 03UG #\]<P ^/8$ /#V1 #H]HP Y/;8 .#W1 #<]\@ W
M//\ .#O_ #@[_P X.O\ MCT  )X^  "+/@  ?#X  &\^  !F/0  7CT  %@[
M  !3.@  3SL  $P\" !)/1$ 1SX9 $8_(@!$/RH 0S\R $) .@!!0$$ 0$!)
M #Y!40 ]05H /$%D #I!<  X07\ -T&/ #5"H0 T0K0 ,D+. #)!\  R0/\
M,T#_ #,__P T/O\ L4   )I   "'0   >$$  &Q!  !B0   6T   %0_  !.
M/P  2D   $9!!0!$0@X 0D,6 $!#'P _1"< /D0O #Q$-P [13X .D5& #E%
M3@ X1E@ -D9B #5&;@ S1GP ,4:- #!&GP N1K, +4;, "U&[P M1?\ +D3_
M "Y#_P N0_\ K$,  )9#  "#0P  =$,  &A#  !?0P  5T,  %!#  !(0P
M1$4  $%& 0 ^1PP /$@3 #I('  Y220 .$DL #9)-  U2CL -$I# #-*3  R
M2E4 ,$M? "]+:P M2WH +$N+ "I+G0 H2[$ )TO* "=+[0 G2O\ *$G_ "A(
M_P I1_\ IT8  )%&  !_1@  <$8  &5&  !;1@  5$8  $Q'  !$2   /TH
M #M+   W3 D -4T0 #-.&  R3B  ,4\H #!/,  O3S@ +D]  "Q02  K4%(
M*E!< "A0:  G4'< )5"( "10FP B4*\ (5#( "!0ZP A3_\ (D[_ ")-_P C
M3?\ H4D  (Q)  !Z20  ;$H  &%*  !82@  4$H  $E+  ! 3   .TX  #50
M   Q4@0 +5,- "Q4%  J5!P *54D "A5+  G53, )E4\ "5610 D5DX (E99
M "%690 ?5G0 'E:% !Q6F  ;5JP &5;% !E6Z0 :5?\ &U3_ !M3_P <4O\
MFTT  (9-  !U30  :$T  %U-  !430  34X  $5/   \40  -E,  #%5   K
M6   )EH) "-;$  B6Q< (5P? "!<)P ?7"X '5PW !Q=0  ;74H &EU5 !A=
M80 777  %5V! !1=E0 37:H $5W" !%=YP 26_X $UK_ !-:_P 46?\ E%$
M (!1  !P40  9%$  %E1  !140  25(  $%3   X5@  ,ED  "M;   E7@
M'V$# !IC#  89!$ %V09 !9D(0 59"D %&4Q !-E.@ 2940 $650 !!E70 /
M96L #F5]  UED0 ,9:4 "F2\  IDX  +8_D #&+_  UA_P -8?\ C54  'I5
M  !K50  7U4  %95  !.50  1%<  #Q9   T7   +%\  "9B   ?90  &6@
M !-K!0 0;0T #FX2  UN&@ ,;B( #&XK  MN-  *;CX "&Y*  =N5P &;F4
M!&YV  )NB@  ;9\  &VV  !LU@  ;/,  6O_  )J_P #:O\ A5H  '1:  !F
M6@  7%D  %-9  !(6@  /UT  #9@   N8P  )F<  !]J   9;0  $W$   YT
M P *=PH !7<0  %W%0  =QP  '<D  !X+0  >#<  'A#  !X4   >%X  'AO
M  !XA   >)D  '>P  !VS0  =?   '7_  !T_P  =/\ ?E\  &Y?  !B7@
M65X  $U?  !"8@  .64  #!H   G;   'W   !AT   2=P  #7L   A^   "
M@ @  ($-  "!$0  @A<  (,>  "#)@  A#   (0[  "$2   A%<  (1H  "$
M?   A),  (.J  ""Q0  @>L  ('^  " _P  @/\ =V4  &ED  !?8P  4F0
M $=G   \:P  ,6\  "AS   @=P  &'P  !%_   ,@P  !H<   "*    C ,
M (P)  "-#@  CA$  (\7  "0'@  D2<  )(R  "2/P  DDX  ))?  "2<P
MDHL  )&B  "1O   D.4  (_\  "._P  CO\ <6L  &9J  !8:P  2VT  #]Q
M   T=@  *GL  ""    7A0  $(D   N-   $D0   )4   "8    F0   )H#
M  ";"   G T  )X1  "?%@  H!X  *(H  "B-0  HT0  *-5  "C:0  HH
M **:  "ALP  H-@  *#V  "?_P  G_\ ;G$  %]R  !1=0  1'D  #=^   L
MA   (8H  !>/   0E   "ID   &=    H    *0   "G    J    *D   "J
M    K 8  *T+  "O$   L!4  +(>  "T*0  M#D  +1*  "U70  M7,  +6.
M  "UJ   M,8  +/M  "R_P  LO\ 9GH  %=]  !)@@  /(<  "^.   CE
M&)H  !"?   )I    *D   "M    L    +0   "W    N    +D   "[
MO    +X"  # "   P@X  ,04  #''@  R"P  ,D]  #*4   RF8  ,I_  #*
MFP  RK@  ,K=  #*]0  RO\ 7H8  $^+  !!D0  ,Y@  ">?   ;I0  $:L
M  FP    M0   +D   "]    P0   ,8   #(    R0   ,L   #,    S@
M -    #2    U 4  -D,  #=$@  X1X  .(N  #C0@  Y%<  .5O  #FC
MYJ@  .7%  #EYP  YO8 5I0  $B;   ZH@  +*D  !^P   3M@  "[P   #!
M    Q0   ,D   #-    T@   -8   #:    VP   -X   #@    X@   .0
M  #G    Z0   .T   #P"@  ]!$  /@?  #Y,@  ^D@  /M?  #\>@  _9<
M /VO  #]QP  _>0 _P . /\ #0#_  P _P . /\ $P#_ !X _P J /\ -@#_
M $( _P!- /\ 5P#_ %\ _P!G /\ ;@#_ '0 _P!Z /\ @0#] (< _ "- /H
ME #Y )P ]P"E /4 KP#T +P \P#/ /$ [ #P /X [P#_ .\ _P#C /\ UP#_
M ,X _P#* /\ _P * /\ !@#_  0 _P ( /\ $ #_ !D _P E /\ ,0#_ #T
M_P!' /X 40#[ %D ^0!A /8 : #T &X \P!T /$ >@#O ($ [@"' .P C@#J
M )8 Z "? .8 J0#C +4 X@#& .  XP#? /@ W0#_ -T _P#4 /\ R0#_ ,(
M_P"^ /\ _P # /\   #_    _P ! /\ #0#_ !0 _0 @ /H *P#W #8 \P!!
M .\ 2P#L %0 Z !; .8 8@#C &@ X0!N -\ = #< 'H V@"! -@ B #4 )
MT@"8 ,\ H@#- *X RP"\ ,D TP#' /  Q@#_ ,0 _P#$ /\ NP#_ +8 _P"S
M /\ _P   /\   #_    _P   /< " #P !  ZP : .< )0#D #  X0 [ -P
M10#5 $T T0!5 ,X 6P#+ &( R0!G ,< ;0#% ', PP!Z ,$ @0"_ (D O0"2
M +L G "Y *< MP"U +4 R "S .8 L@#[ +$ _P"P /\ K@#_ *H _P"G /\
M_P   /\   #^    \0   .4  @#<  T TP 4 ,T 'P#* "H QP T ,0 /@#
M $< O !. +H 50"W %L M0!A +, 9P"R &T L !S *X >@"L (( J@"+ *@
ME0"G *  I0"M *, O@"A -L H #T )\ _P"> /\ GP#_ )T _P"; /\ _P
M /P   #N    X    -    #%  @ O@ 0 +D &0"U ", LP N +  -P"M $
MJ@!( *@ 3P"E %4 HP!; *( 8 "@ &8 GP!L )T <P"; 'L F@"$ )@ C@"6
M )H E0"G ), MP"1 ,P D #L (\ _P". /\ C@#_ (X _P"/ /\ _    .\
M  #;    R0   +T   "U  ( K@ , *D $P"E !T H@ G *  ,0"= #H F@!"
M )@ 20"6 $\ E !5 ), 6P"1 &  D !G (X ;0"- '4 BP!^ (D B0"( )4
MA@"B (4 L0"# ,0 @0#D (  ^0!_ /\ @ #_ (  _P"  /\ ] (  . )  #'
M"   MP<  *P#  "F    H  ' )L #P"8 !< E0 A )( *@"/ #, C0 \ (L
M0P") $D AP!0 (8 50"$ %L @P!A ($ : "  '  ?@!Y 'P A ![ )  >0"=
M '@ K !V +X =0#= ', ] !S /\ <P#_ ', _P!S /\ Z0T  ,\0  "Y$
MJ1   )X.  "7"P  DP8  )  "P", !$ B0 : (8 ) "# "X @0 V '\ /@!]
M $0 ? !+ 'H 40!Y %< =P!= '8 9 !T &P <P%U '$!@ !O HT ;@*: &P#
MJ@!K [L :036 &@&\0!H!_\ 9P?_ &<'_P!G!_\ WQ0  ,,7  "N%P  GA8
M ),5  "+$@  AA   (0, @"#!@T @ ,4 'P%'@!Y!R@ =P@P '4(. !S"4
M<@E& ' *3 !O"E, ;0M9 &P+80!J"VD :0QR &<,?@!F#(L 9 V9 &(-J0!A
M#;L 8 W8 %X.\P!=#O\ 70[_ %T._P!=#O\ U!P  +D=  "D'@  E1T  (D<
M  "!&@  >Q<  '@3  !X$ 8 =PT/ ',.& !P#B( ;@\K &P0,P!J$#L :1!"
M &<120!F$4\ 9!%6 &,270!A$F8 8!)O %X2>P!<$X@ 6Q.7 %D3IP!7%+H
M5A35 %45\P!4%?\ 5!7_ %05_P!4%/\ RB(  + B  "=(P  C2,  ($B  !Y
M(0  <QX  &\;  !N%P  ;1,, &H4% !G%1X 918G &,6+P!A%S< 8!<^ %X8
M10!=&$L 7!E2 %H96@!9&6( 5QIL %8:=P!4&H4 4AN4 %$;I !/&[< 3AO0
M $T<\0!,'/\ 3!S_ $T<_P!-&_\ PR8  *HG  "6)P  AR@  'LG  !R)@
M;"0  &@A  !F'@  9!L( &(;$0!?'!H 71TC %L>*P!:'C, 6!\Z %<?00!6
M($@ 5"!/ %,@5P!1(5\ 4"%I $XA= !-(8( 2R*1 $DBH@!((K0 1R+- $8C
M[P!%(_\ 12+_ $8B_P!&(?\ O"H  *0K  "1*P  @BP  '8K  !M*@  9BD
M &(F  !?)   72($ %LA#@!8(A8 5B,? %0D* !3)#  4B4W % E/@!/)D4
M3B9, $PF5 !+)UP 22=F $@G<0!&)W\ 12B/ $,HH !!*+( 0"C+ #\H[0 _
M*/\ /RC_ $ G_P! )_\ MRT  )\N  ",+P  ?2\  '$O  !H+@  82T  %TK
M  !:*   5R<  %0G# !2*!, 4"D< $XI)0!-*BP 2RHT $HK.P!)*T( 2"Q)
M $8L40!%+%H 1"QD $(M;P! +7T /RV- #TMG@ \+;  .BW( #HMZP Z+?\
M.BW_ #HL_P Z+/\ LC   )LQ  "(,@  >3(  &TR  !D,@  73$  %@O  !5
M+   42P  $\M"0!,+1$ 2BX9 $DO(@!'+RH 1C Q $4P. !#,#\ 0C%' $$Q
M3P! ,5< /C%A #TR;0 [,GL .3*+ #@RG  V,J\ -3+' #0RZ0 T,O\ -3'_
M #4Q_P U,/\ K3,  )8T  "$-0  =34  &DU  !@-0  630  %0S  !0,
M3#$  $DQ!@!',@\ 13,6 $,S'P!"-"< 0#0N #\U-@ ^-3T /35$ #PV3  Z
M-E4 .39? #<V:P V-G@ -#>) #(WF@ Q-ZT +S?% "\WZ  O-OX ,#7_ # U
M_P P-/\ J38  )(V  " -P  <C@  &8X  !=-P  5C<  % V  !+-   1S4
M $0V P!!-PT /S@4 #XX'  \.20 .SDL #HY,P Y.CH .#I" #8Z2@ U.E,
M-#M= #([:  P.W8 +SN' "T[F0 L.ZP *CO# "D[Y@ J.OT *CK_ "LY_P L
M./\ I#@  (XY  !\.@  ;CH  &,Z  !:.@  4SH  $TZ  !&.   0CH  #\[
M   \/ L .CP1 #@]&0 W/2$ -CXI #0^,  S/C< ,C\_ #$_1P P/U  +C]:
M "U 9@ K0'0 *4"$ "A EP F0*H )4#! "1 Y0 D/_P )3[_ "8]_P F/?\
MGSL  (H\  !X/0  :CT  %\]  !6/0  3ST  $D]  !"/0  /#X  #D_   V
M00@ -$$/ #)"%@ Q0AX +T,E "Y#+0 M0S0 +$0\ "M$1  J1$T *$18 "=%
M8P E17$ (T6" ")%E0 @1:@ 'T6_ !Y$XP ?1/L 'T/_ "!"_P A0?\ FCX
M (4_  !T0   9T   %Q   !30   3$   $9    ^00  .$,  #1%   P1@,
M+4<- "M($@ J2!H *4@B "A)*0 G23$ )4DY "1)00 C2DH (DI5 "!*80 ?
M2F\ '4I_ !M*D@ :2J8 &$J] !=*X  82?H &4C_ !I'_P :1_\ E4(  (!"
M  !P0P  8T,  %A#  !00P  24,  $)$   [10  -4<  #!)   K2P  )DT)
M "1.$  B3A8 (4\= "!/)0 ?3RP 'D\U !U//0 <4$< &E!1 !E070 74&L
M%E!\ !10CP 34*0 $5"Z !%0W@ 13_@ $D[_ !--_P 43?\ CT4  'M&  !K
M1@  7T<  %5'  !-1P  1D<  #]'   W2@  ,4P  "M.   F4   (%,# !Q5
M#  :5A$ &588 !=6(  65B< %58P !16.0 35T( $E=- !%760 05V@ #U=Y
M  Y7C  -5Z  "U>V  M6U  +5O0 #%7_  U4_P .4_\ B$D  '9*  !G2@
M6TH  %%*  !*2@  0TH  #M,   S3@  +%$  "94   A5@  &UD  !5<!P 1
M7@T $%X3 !!>&@ .7B( #EXJ  U>,P ,7CT "UY(  I>5  (7F( !UYS  5>
MA@ #7IL  EZQ  )=S  "7>X  US_  1;_P %6_\ @4X  '!.  !B3@  5TX
M $Y.  !'3@  /D\  #91   N5   )U<  "%:   ;70  %6   !!C P ,9@L
M"&<0  9G%0 %9QP !&<D  )G+0 !9S<  &="  !G3@  9UP  &=M  !G@
M9I4  &:L  !EQP  9>L  &3\  !D_P  8_\ >E(  &I3  !=4@  5%(  $M2
M  !"4P  .54  #!8   H6P  (5\  !IB   490  $&@   QK 0 &;@D  &\.
M  !O$@  ;Q@  ' ?  !P)P  <3   '$[  !Q2   <58  '%F  !Q>0  <8\
M '"G  !OP0  ;^<  &[\  !M_P  ;?\ <U@  &57  !:5P  458  $97   \
M6@  ,ET  "IA   B9   &F@  !1L   .;P  "G(   1V    > 4  '@+  !Y
M#@  >A,  'L9  !\(   ?2D  'TS  !]0   ?4X  'U>  !]<@  ?8@  'RA
M  !\N@  >^(  'KZ  !Y_P  >/\ ;5T  &!<  !77   2UT  $!?   U8P
M*V<  "-K   :;P  $W,   YW   (>P   GX   ""    @P$  (0&  "%"P
MA@\  (@3  ")&0  BB$  (LK  "+-P  C$8  (M6  "+:0  BX   (N9  "*
MLP  B=@  (CW  "(_P  A_\ :&,  %YB  !18@  1&4  #AI   N;@  )',
M !IX   3?0  #8$   :%    B0   (T   "0    D@   )(   "4!0  E0H
M )<.  "8$@  FA@  )LA  "<+0  G3P  )U,  "<7P  G'8  )N1  ";JP
MFLD  )KP  "9_P  F/\ 96D  %=I  !);   /7$  #!V   E?   &X$  !*'
M   ,C   !)$   "5    F0   )T   "@    H0   *(   "D    I0$  *<'
M  "I#   JA$  *T8  "O(@  KS   *]!  "O5   KVL  *Z%  "NH0  KKX
M *WF  "L_   K/\ 7G$  $]T  !">0  -7\  "B%   =C   $Y(   R8   #
MG0   *(   "F    J@   *X   "P    L0   +,   "T    M@   +@   "Z
M!   O H  +X0  #!%P  PR0  ,,U  #$20  Q%X  ,5W  #%DP  Q:\  ,71
M  ##\@  P_\ 5GP  $>"   ZB   +(\  ""6   4G0  #:,   .I    K@
M +(   "W    NP   +\   #"    P@   ,4   #&    R    ,H   #-
MSP   -((  #5#@  VQ@  -TG  #>.@  WU   .!H  #@A   X:$  .&]  #A
MX@  X/0 3HL  $"2   RF0  ):$  !BH   .KP  !;4   "Z    OP   ,0
M  #(    S@   -$   #4    U0   -@   #:    W0   -\   #B    Y
M .<   #K!0  [PX  /09  #U*P  ]D$  /=8  #X<@  ^9   /FK  #XQ
M^.$ _P + /\ " #_  D _P , /\ $@#_ !H _P F /\ ,@#_ #X _P!( /\
M4@#_ %H _P!B /\ :0#_ &\ _P!U /X >P#\ ($ ^P"( /D CP#W )< ]0"@
M /, J@#R +< [P#) .T Y@#L /L ZP#_ .L _P#= /\ S@#_ ,8 _P#" /\
M_P $ /\   #_    _P % /\ #0#_ !4 _P A /\ + #_ #@ _P!# /T 3 #Y
M %0 ]P!< /0 8P#R &D \ !O .X =0#L 'L Z@"" .@ B0#G )$ Y ": .(
MI #@ +  W0#  -H W #8 /0 U0#_ -, _P#+ /\ P0#_ +L _P"W /\ _P
M /\   #_    _P   /\ "@#] !$ ^0 ; /8 )P#T #( \  \ .P 1@#H $X
MY !6 .$ 7 #> &, W !H -D ;@#5 '0 T@![ -  @@#- (H RP"3 ,@ G0#&
M *@ Q "W ,$ S #  .L O@#_ +T _P"] /\ M #_ *X _P"K /\ _P   /\
M  #_    ^@   /( !0#J  X Y0 6 .  (0#= "L VP V -, /P#. $@ R@!/
M ,< 5@#$ %P P@!A ,  9P"^ &T O !S +H >@"X (( M@"+ +0 E@"R *$
ML "O *X P0"M .  JP#W *H _P"I /\ I@#_ *$ _P"? /\ _P   /\   #W
M    Z    -P   #0  H R@ 1 ,4 &P#" "4 OP O +P . "X $$ M0!( +(
M3P"P %4 K@!; *P 80"J &8 J !L *< <P"E 'L HP"$ *$ C@"? )H G0"G
M )L N ": -  F0#O )@ _P"7 /\ E@#_ )0 _P"2 /\ _P   /8   #D
MT@   ,4   "[  4 M0 . +  %0"L !\ J@ I *@ ,@"E #H H@!" *  20">
M $\ G !5 )H 6@"8 &  E@!F )4 ; "3 '0 D@!] )  AP". ), C "A (L
ML "* ,4 B #F (< ^P"& /\ AP#_ (< _P"& /\ ^    .4   #-    O0
M +,   "J    HP * )\ $0"; !D F0 C )< + "5 #0 D@ \ )  0P". $D
MC !/ (H 5 ") %H AP!@ (8 9@"$ &X @P!W ($ @0!_ (T ?@"; 'P J@![
M +P >@#; '@ ]0!X /\ > #_ '@ _P!X /\ [0   -$"  "[ @  K $  *(
M  ";    E@ % )$ #0"- !0 BP = (@ )@"& "X A  V (( /0"  $, ?@!)
M 'T 3P!\ %4 >@!; 'D 80!W &D =0!Q '0 ? !R (@ <0"6 &\ I0!N +8
M;0#. &P [@!K /\ :P#_ &L _P!K /\ WPL  ,(,  "N#   G@P  ),+  ",
M!P  B (  (4 "0"! !  ?P 7 'P ( !Z "@ >  P '8 . !T #X <P!$ '$
M2@!P %  ;@!6 &T 70!L &0 :@!M &@ =P!G (0 90"2 &0 H0!C +( 80#)
M &  Z0!@ /P 8 #_ &  _P!@ /\ T!   +81  "B$@  DQ(  (@1  " #P
M? T  'D) 0!X PL =0 1 ', &@!P ", ;@$K &P!,P!J CD :0-  &<#1@!F
M!$P 9012 &,%60!B!6$ 8 5J %\&= !=!H$ 7 >/ %H'GP!9![  5P?& %8)
MYP!6"OL 50K_ %4*_P!6"O\ QA4  *T7  "9&   BA@  '\7  !V%@  <1,
M &X0  !M#04 ;0D- &H)% !G"AT 90HF &,++@!B##4 8 P\ %\,0@!>#4@
M7 U/ %L-5@!9#5X 6 YH %8.<P!5#H  4PZ/ %$.GP!0#K$ 3@[( $T0Z@!-
M$/T 31#_ $T0_P!-$/\ O!L  *4<  "2'0  @QX  '<=  !O'   :1H  &87
M  !D%   9! ( &(/$ !?$!@ 71 A %L1*0!:$3$ 6!(X %<2/@!6$D4 5!),
M %,34P!1$UL 4!-E $X4< !,%'T 2Q2, $D4G !'%:X 1A7% $45Z !%%OX
M11;_ $45_P!%%?\ M1\  )XA  "+(@  ?"(  '$B  !H(0  8A\  %\=  !<
M&@  6Q<" %H5#0!7%A0 518= %07)0!2&"T 41@T $\8.P!.&4( 31E( $L:
M4 !*&E@ 2!IB $<:;0!%&WH 0QN) $(;F@! &ZP /QO" #X<Y0 ]'/P /AS_
M #X;_P ^&_\ KR,  )@D  "&)0  =R8  &PF  !C)0  720  %DB  !6'P
M5!T  %,<"P!1'!( 3AT: $T=(@!+'BD 2AXQ $D?-P!''SX 1B!% $4@30!#
M(%4 0B!? $ A:@ _(7< /2&' #LAF  Y(:H ."+  #<BXP W(OL -R+_ #@A
M_P X(?\ JB8  )0G  "!*0  <RD  &<I  !?*0  6"@  %0F  !1(P  3R(
M $PB!P!*(A  2"(7 $<C'P!%)"8 1"0N $(D- !!)3L 0"5# #\E2@ ])E,
M/"9< #HF9P Y)G4 -R>$ #4GE@ T)Z@ ,B>^ #$GX0 Q)_D ,B;_ #(F_P S
M)?\ I2D  (\J  !]+   ;RP  &0M  !;+   52L  % J  !,*   2B8  $<G
M! !$)PT 0B@4 $$H'  _*2, /BDK #TI,@ \*CD .RI  #DJ2  X*U  -BM:
M #4K90 S*W( ,2N" # LE  N+*< +"R\ "LLW@ L+/@ +"O_ "TJ_P M*O\
MH2P  (LM  !Y+@  :R\  & O  !8+P  42X  $PN  !(+   12L  $$K   _
M+ L /2P1 #LM&0 Z+B$ .2XH #<N+P V+S8 -2\^ #0O10 S+TX ,3!8 # P
M8P N,'  +#"  "HPD@ I,*4 )S"Z "8PW  F,/< )R__ "@O_P H+O\ G"X
M (<P  !V,0  :#(  %TR  !5,@  3C$  $@Q  !$,   0"\  #PP   Z,0D
M-S$0 #8R%@ U,AX ,S,E #(S+  Q,S, ,#0[ "\T0P M-$P +#16 "HU80 I
M-6X )S5^ "4UD  C-:, (C6Y "$UV0 A-/8 (C3_ ",S_P C,O\ F#$  (,S
M  !R-   930  %HU  !1-0  2S0  $4T  ! -   .C,  #<T   T-08 ,C8.
M # W$P O-QL +C<B "TX*0 K.#$ *C@X "DY0  H.4D )CE3 "4Y7P C.6P
M(3I\ " ZC@ >.J( '#JW !LYU0 <.?4 '3C_ !TX_P >-_\ DS0  '\V  !N
M-P  83<  %<W  !.-P  2#<  $(W   \-P  -3@  #(Y   O.@( +#L+ "H\
M$0 I/!@ *#T? "8])@ E/2X )#TU ",^/0 B/D8 (#Y0 !\^7  =/VD &S]Y
M !H_C  8/Z  %C^U !4^T@ 6/O, %SW_ !@\_P 8//\ CC<  'HX  !J.0
M7CH  %,Z  !+.@  13H  #\Z   Y.@  ,CP  "X^   I0   )D$( "1"#@ B
M0A0 (4(; "!#(P ?0RH 'D,R !Q#.@ ;1$, &D1- !A$60 71&< %41W !-$
MB@ 21)X $42S !!$T  00_( $4+_ !)"_P 30?\ B3L  '8\  !F/0  6CT
M % ]  !(/0  0CT  #P]   V/@  +T   "I"   E1   (48# !U(#  ;21$
M&4D7 !A)'@ 7228 %DDN !5*-@ 42D  $TI* !%*5@ 02F0 #TIT  Y*AP -
M2IL #$JP  I*R@ +2>P #$C_  U'_P -1_\ @SX  '$_  !B0   5D   $U
M  !%0   /T   #E!   R0@  *T4  "9'   A20  '$L  !9.!P 34 X $E 3
M !%0&0 04"$ #U I  Y0,0 -4#L #5%&  M140 *45\ "5%O  =0@0 %4)8
M U"K  )0Q0 #3^@  T_[  5._P &3?\ ?4(  &M#  !=1   4D0  $I$  !#
M0P  /$0  #5%   N1P  )TH  "%,   <3P  %U$  !)4 P .5PH "U@0  I8
M%0 (6!P !U@D  98+  %6#8  UA   %83   6%H  %AI  !8?   6)$  %>G
M  !7P   5N4  %;Y  !5_P  5?\ =D<  &9'  !92   3T<  $='  ! 1P
M.$@  #!*   I30  (E   !Q3   650  $5@   U; @ )7@D !%\.  !?$@
M7Q@  & ?  !@)P  8#   & [  !@1P  8%0  &!C  !@=@  8(L  %^B  !?
MNP  7^(  %[Y  !=_P  7?\ ;TL  &%,  !53   3$L  $1+   [3   ,DX
M "M1   C5   '%<  !9;   17@  #6    AC   "9@<  &<,  !G#P  :!,
M &D9  !J(0  :BD  &HT  !J0   :DT  &I=  !J;P  :H4  &J=  !IM@
M:-T  &CW  !G_P  9O\ :5$  %Q0  !24   2D\  #]0   U4P  +58  "19
M   =70  %F   !!D   ,9P  !FH   !N    ;P,  ' (  !Q#0  <A   '04
M  !U&P  =B,  '<L  !W.   =D8  '96  !V:   =GX  ':7  !UL0  =-,
M '/U  !S_P  <O\ 8U8  %A5  !05   1%4  #E8   O6P  )E\  !UC   5
M9P  $&P   IP   $<P   '8   !Z    ?    'P#  !^"   ?PP  ($0  ""
M%   A!L  (4D  "&+P  ACT  (9-  "%7P  A74  (6/  "$J0  @\D  (+Q
M  "!_P  @/\ 7UL  %9:  !)6P  /5X  #)A   G9@  'FL  !5P   .=0
M"7D   %^    @0   (4   "(    B@   (L   "- 0  C@8  ) +  "1#P
MDQ0  )4;  "7)@  ES0  )=$  "75@  EFP  )6&  "5H@  E,$  )/J  "2
M_P  DO\ 76$  $]A  !"9   -FD  "IN   ?=   %7D   Y_   'A    (D
M  ".    D@   )8   "8    F@   )L   "=    GP   *$#  "C"   I0T
M *<3  "I'   JB@  *HY  "J2P  JF$  *EZ  "HF0  J+4  *?=  "G^
MIO\ 5F@  $AL   Z<   +G8  ")]   7A   #HH   >0    E@   )H   "?
M    HP   *<   "J    JP   *T   "O    L0   +,   "U    N 4  +H,
M  "]$@  P!P  , M  # 0   OU4  +]N  "^BP  OJ@  +[)  "][P  O/X
M3G0  $!Y   R?P  )8<  !F.   0E0  !YP   "B    IP   *P   "P
MM0   +D   "\    O0   +\   #!    PP   ,8   #(    R@   ,T"  #0
M"P  U1(  -8A  #7-   V$D  -E@  #:?   VIH  -NU  #;V0  V_( 1H(
M #B)   KD   '9@  !*@   *IP   *X   "T    N0   +X   #"    R
M ,L   #.    SP   -(   #4    U@   -H   #=    WP   .(   #F
MZ@H  .\3  #P)0  \CH  /-1  #T:P  ](D  /6E  #UOP  ]=T _P & /\
M P#_  4 _P + /\ $ #_ !< _P B /\ +0#_ #D _P!$ /\ 30#_ %4 _P!=
M /\ 9 #_ &H _P!P /T =@#[ 'P ^0"# /< B@#U )( \P"; /  I@#N +,
MZP#$ .D Y #G /D Y@#_ .4 _P#3 /\ QP#_ +\ _P"[ /\ _P   /\   #_
M    _P " /\ "P#_ !( _P = /\ * #_ #, _P ^ /P 1P#X $\ ] !7 /$
M70#N &, [ !I .H ;P#H '4 Y@!\ .0 @P#B (L WP"5 -P GP#9 *L U0"[
M -( U #/ /( S0#_ ,P _P#% /\ N@#_ +0 _P"P /\ _P   /\   #_
M_P   /\ !@#Y  \ ]0 7 /, (@#Q "T [0 W .< 0 #B $D WP!0 -L 5P#7
M %T U !C -$ : #/ &X S !U ,H ? #( (0 Q0"- ,( F #  *0 O0"R +L
MQ@"Y .@ N #] +< _P"V /\ K0#_ *< _P"C /\ _P   /\   #_    ]0
M .L  0#D  P W@ 3 -D ' #3 "8 T0 P ,P .@#( $( Q !* ,  4 "] %8
MNP!< +D 80"W &< M0!M +, = "Q 'P KP"% *T D "J )P J "J *8 NP"E
M -H HP#U *, _P"B /\ G@#_ )H _P"7 /\ _P   /X   #O    WP   -
M  #'  < P0 / +P %P"Y "  MP J +4 ,P"P #L K0!# *L 20"H $\ I@!5
M *0 6@"C &  H0!F )\ ;0"= '0 G !] )H B "8 )0 E@"B )0 L@"2 ,D
MD0#K )$ _P"0 /\ D #_ (P _P"* /\ _    .P   #9    QP   +H   "Q
M  ( JP , *< $@"D !L H0 D *  + "> #4 FP \ )@ 0P"6 $D E !/ )(
M5 "0 %H CP!? (T 9@"+ &T B0!V (@ @ "& (P A ": (( J@"! +X @ #@
M (  ^0!_ /\ ?P#_ '\ _P!^ /\ \0   -@   #"    LP   *@   "@
MF0 ' )4 #@"2 !4 D  > (X )@"- "X B@ V (< /0"% $, A !) (( 3@"!
M %0 ?P!9 'X 8 !\ &< >@!O 'D >@!W (8 =0"4 '0 HP!R +4 <@#/ '$
M\0!P /\ < #_ '  _P!Q /\ X0   ,0   "P    H@   )<   "1    BP "
M (8 "P"# !$ @0 8 '\ (0!] "D ?  P 'D -P!X #T =@!# '0 20!S $X
M<@!4 '  6@!O &( ;0!J &L = !J (  : ". &< G0!E *\ 90#& &0 Z !D
M /T 8P#_ &, _P!D /\ SP4  +8'  "C"   E @  (D'  "" P  ?@   'L
M!@!W  X =0 3 '( &P!Q ", ;P K &T ,@!L #@ :@ ^ &D 1 !G $D 9@!/
M &4 5@!C %T 8@!E &  ;P!? 'L 70") %P F0!; *H 60"_ %D X0!8 /@
M6 #_ %@ _P!9 /\ P@P  *H-  "7#@  B0X  'T.  !V#0  <0H  &\&  !M
M  H :P 0 &D %@!G !X 90 F &, +0!A #, 8  Y %\ /P!= $4 7 !+ %L
M4@!: %D 6 !B %< ; !5 '@ 4P"& %( E@!1 *< 4 "[ $\!VP!. O0 3@/_
M $X$_P!. _\ N!   *$2  ".$P  ?Q,  '03  !L$@  9Q   &4.  !C"P,
M8P8, &$$$0!> QD 7 0A %L%* !9!B\ 6 8U %8'.P!5!T( 5 =( %,(3P!1
M"%8 4 E? $X):0!-"78 2PJ$ $D*E !("J8 1PJZ $8*V !%"_, 10S_ $4,
M_P!%#/\ L!0  )D6  "'&   >!D  &T8  !E%P  7Q8  %P3  !:$0  6@X&
M %H,#0!7#!0 50P< %,-) !2#2L 4 TQ $\.. !.#CX 30Y% $L.30!*#E4
M2 ]> $</: !%#W4 0Q"$ $$0E0! $*8 /A"[ #T0W  ]$?8 /1'_ #T0_P ^
M$/\ J1D  )(;  "!'   <AT  &<=  !?'   61L  %49  !3%@  4A,  %(1
M"@!0$!  3A$8 $P1( !*$B< 21(N $@3- !'$SL 11-" $0320!#%%( 011;
M #\490 ^%7( /!6! #H5D@ X%:0 -Q6Y #45V  U%O4 -A;_ #86_P W%?\
MHQP  (T>  ![(   ;2$  &(A  !:(0  5!\  % >  !-&P  3!D  $L6!@!)
M%@X 1Q<5 $47' !$&"0 0A@J $$8,0! &3@ /QD_ #T91@ \&D\ .AI8 #D:
M8P W&V\ -1M^ #,;D  R&Z( ,!NW "\;TP O'/, +QO_ # ;_P P&_\ G1\
M (@B  !W(P  :20  %XD  !6)   4",  $LB  !((   1AT  $4< @!#' P
M01P2 #\=&0 ^'2$ /!XG #L>+@ Z'S4 .1\\ #<?1  V'TP -"!6 #,@8  Q
M(&T +R!\ "TAC@ L(:  *B&U "DAT  I(?( *2'_ "H@_P K(/\ F2(  (0E
M  !S)@  92<  %LG  !3)P  3"8  $<E  !$)   0B$  #\A   ](0D .R$0
M #DB%@ X(AX -B,E #4C*P T)#( ,R0Y #(D00 P)$H +R53 "TE7@ K)6L
M*B5Z "@EC  F)9\ )"6S ",ES@ C)?  )"7_ "4D_P E)/\ E"4  ( G  !O
M*0  8BH  %<J  !/*@  22D  $0H  ! )P  /28  #HE   W)@8 -28. #0G
M%  R)QL ,2@B # H*0 O*#  +2DW "PI/P K*4< *2E1 "@J7  F*FD )"IX
M ",JB@ A*IT 'RJR !XJS  >*N\ 'RG_ " I_P A*/\ D"@  'PJ  !L*P
M7RP  %0L  !,+   1BP  $$K   \*P  ."H  #4J   R*P, ,"L, "XL$0 M
M+!@ +"P? "HM)@ I+2T *"TT "<N/  F+D4 )"Y/ ",N6@ A+V< 'R]V !TO
MB  <+YL &B^P !@OR@ 8+NT &2[_ !LM_P ;+?\ C"L  '@M  !H+@  6R\
M %$O  !)+P  0R\  #XN   Y+@  -"X  # N   M+P  *S * "DQ$  G,14
M)C$< "4R(P D,BH (S(Q "$S.0 @,T( 'S-, !TS5P ;,V0 &C1T !@TA@ 6
M-)H %#.N !,SR  3,^P %#/_ !4R_P 6,?\ ARX  '0O  !E,0  6#$  $XR
M  !&,@  0#$  #LQ   V,0  ,3$  "LS   H-   )34& ",V#0 A-A( (#<9
M !\W(  >-R< '3@N !LX-@ :.#\ &3A) !<Y50 5.6( %#EQ !(YA  1.9@
M$#FM  XXQP ...L $#C_ ! W_P 1-O\ @S$  ' R  !A-   530  $LT  !$
M-   /30  #@T   S-   +34  "@W   D.0  (#H" !T["P ;/!  &3T5 !@]
M'  7/2, %CTK !4^,P 4/CP $CY& !$^4@ 0/E\ #SYO  X^@0 ,/I4 "SZI
M  H^P0 */>0 "SW[  P\_P -._\ ?30  &LV  !=-P  43<  $@W  !!-P
M.S<  #4W   P-P  *CD  "4[   @/0  '#\  !=!!@ 40PT $D,2 !%#&  1
M0Q\ $$0G  ]$+P .1#D #41#  Q$3@ +1%L "41J  =$?  &1)  !$.E  )#
MO0 #0^   T/V  1"_P &0?\ >#@  &<Y  !9.@  3CH  $4Z   ^.@  .#H
M #,Z   M.P  )ST  "%    <0@  %T0  !-& P /20H #4H/  Q*%  +2AL
M"4HC  A**P '2C0 !4H^  1*20 "2E8  $IE  !*=P  2HL  $JA  !)N0
M2=T  $GU  !(_P  2/\ <CP  &(]  !5/@  2CX  $(]   \/0  -CT  "\^
M   I0   (T(  !U%   71P  $TH   ], @ +3PD !U -  -1$0  41<  %$>
M  !1)@  42\  %$Y  !11   4E$  %)@  !1<@  48<  %&=  !1M0  4-@
M %#U  !/_P  3_\ ;$   %U!  !100  1T$  $!    Y0   ,D$  "I#   D
M1@  'D@  !=+   23@  #E$   M3 0 &5@<  %<,  !8$   6!,  %D9  !:
M(0  6BD  %HS  !:/P  6DP  %I:  !:;   6H$  %F9  !9L0  6-$  %CT
M  !7_P  5_\ 944  %A%  !-10  140  #Y$   U10  +4<  "5*   >30
M&%   !)3   .5@  "ED   1<    7@0  %\)  !@#0  81   &(5  !C&P
M9",  &0M  !D.   9$4  &14  !D9@  9'L  &.3  !CK0  8LP  &'R  !A
M_P  8/\ 7TH  %-*  !*20  0T@  #E)   O3   )T\  !]2   850  $ED
M  U=   (8    F,   !F    : $  &D%  !J"@  :PT  &T1  !N%@  <!T
M '$F  !Q,0  <#X  '!.  !P7P  <',  &^-  !OIP  ;L8  &WO  !L_P
M;/\ 6D\  %!.  !(30  /4X  #-1   I5   (%@  !A<   18   #&0   9H
M    :P   &\   !R    =    '4   !W!   > D  'H-  !\$   ?18  '\>
M  " *   @#4  (!%  !_5@  ?VL  '^$  !^H   ?;X  'SI  ![_P  >O\
M5E0  $Y3  !"5   -U8  "Q:   B7P  &&,  !%H   +;0   W(   !V
M>@   'T   "     @P   (0   "&    AP(  (D'  "+#   C1   ) 6  "2
M'P  DBP  )([  "230  D6(  )%Z  "/EP  C[0  ([A  ",^P  C/\ 55D
M $A:   [70  +V$  "1F   9;   $7(   IW   "?0   ((   "&    BP
M (X   "1    DP   )4   "7    F0   )L   "=!   GPH  *(/  "D%@
MIB$  *8Q  "F0P  I5<  *1P  "CC@  HZL  *'0  "@]0  G_\ 3F$  $!D
M   S:0  )VX  !MU   1?   "X,   ")    C@   ),   "8    G0   *$
M  "D    I0   *<   "I    JP   *T   "P    L@   +4(  "X#@  O!8
M +PE  "\-P  NTP  +ID  "Y@0  MZ(  +?   "WZ@  M_P 1FL  #EP   K
M=P  'W\  !.&   +C@   94   ";    H0   *8   "K    L    +,   "W
M    MP   +H   "\    OP   ,$   #$    QP   ,H   #-!0  T0X  -09
M  #4*P  U$   --8  #3=   TY(  -*P  #2TP  TO( /GD  #&    CB
M%Y$   V9   #H    *<   "N    LP   +@   "]    P@   ,8   #*
MR@   ,T   #/    T@   -4   #9    W0   -\   #C    YP4  .L/  #L
M'P  [3,  .Y+  #O9   [X(  /"?  #QN0  \=@ _P   /\   #_  0 _P )
M /\ #@#_ !4 _P > /\ *0#_ #0 _P _ /\ 2 #_ %  _P!8 /\ 7@#_ &4
M_0!K /L <0#Y '< ^ !^ /8 A0#S (T \0"7 .X H@#K *\ Z #  .8 X #C
M /@ X@#_ -L _P#+ /\ P0#_ +D _P"T /\ _P   /\   #_    _P   /\
M"0#_ !  _P 9 /\ (P#_ "X _0 Y /D 0@#U $H \@!2 .X 6 #K %X Z0!D
M .8 :@#D '  X@!V -\ ?0#= (8 V0"/ -4 F@#1 *< S@"V ,L S@#) /
MQP#_ ,4 _P"[ /\ M #_ *T _P"I /\ _P   /\   #_    _P   /L  @#V
M  T \0 3 .T '@#L "@ Z0 R ., .P#= $0 V !+ -, 40#0 %@ S0!= ,L
M8P#) &@ Q@!O ,0 =@#" 'X OP"' +P D@"Z )\ MP"M +4 P0"R .0 L0#]
M *\ _P"L /\ I0#_ *  _P"< /\ _P   /\   #[    [@   .0   #<  @
MTP 0 ,\ & #+ "( R0 K ,8 - #! #T O0!$ +H 2P"W %$ M0!6 +( 7 "P
M &$ K@!G *P ;@"J '8 J !_ *8 B@"C )8 H0"E )\ M@"= -$ G #S )L
M_P"< /\ E@#_ ), _P"0 /\ _P   /8   #G    TP   ,8   "]  , N  -
M +, $P"Q !P KP E *X +@"I #8 I@ ] *, 1 "A $H GP!/ )T 50"; %H
MF@!@ )@ 9@"6 &X E !W )( @0"0 (X C@"< (P K0"* ,, B0#H (@ _P")
M /\ AP#_ (4 _P"" /\ \P   .,   #,    O    +    "G    H0 ( )X
M#P"; !8 F0 ? )@ )P"6 "\ DP W )$ /0". $, C !) (L 3@") %0 AP!9
M (4 8 "$ &< @@!O (  >@!^ (8 ? "4 'H I !Y +@ > #8 '< ]P!X /\
M> #_ '< _P!U /\ Y@   ,L   "W    J    )X   "6    CP $ (L # "(
M !( AP 9 (4 (0"$ "D @@ P '\ -P!] #T ? !# 'H 2 !Y $T =P!3 '8
M60!T &$ <@!I '$ <P!O '\ ;0"- &P G0!J *\ :0#( &@ [0!I /\ :0#_
M &D _P!I /\ T@   +@   "E    EP   (T   "&    @0   'P " !Y  X
M=P 4 '8 ' !T ", <P K '$ ,0!O #< ;@ ] &P 0P!K $@ :@!. &@ 5 !G
M %L 90!C &, ;0!B '@ 8 "' %\ E@!= *@ 70"^ %P Y !< /L 7 #_ %P
M_P!< /\ P@   *H!  "8 P  B00  '\"  !X    =    '  ! !M  P :P 1
M &D %P!H !X 9@ E &4 + !C #( 8@ X &  /0!? $, 7@!) %P 3P!; %8
M6@!> %@ : !7 ', 50"! %0 D0!2 *, 40"W %$ U@!1 /4 40#_ %$ _P!2
M /\ M@<  )\)  "-"P  ?@P  ',+  !L"@  : <  &4#  !C  < 80 - %\
M$P!= !H 7  A %L )P!9 "T 6  S %8 .0!5 #\ 5 !% %, 2P!1 %( 4 !:
M $\ 9 !- &\ 3 !] $H C0!) )\ 2 "R $< S !' .\ 1@#_ $< _P!' /\
MK P  )4.  "#$   =1   &L0  !C#P  7@X  %L,  !:"0( 600* %< #P!5
M !4 4P < %( (P!1 "D 3P O $X -0!- 3L 3 %! $H"2 !) D\ 2 )7 $8#
M80!% VT 0P-Z $(#BP!  YP /P.O #X#R  ]!.H /07\ #T&_P ^!O\ I!
M (X2  !\$P  ;A0  &04  !<$P  5A(  %,1  !1#@  4 P% % )# !/!Q$
M30<7 $L('P!)""4 2 DK $<),0!&"3@ 1 H^ $,*10!""DT 0 M5 #\+7P ]
M"VL / MY #H,B@ X#)P -PRO #4,QP U#.D -0W] #4-_P V#/\ G1,  (<5
M  !V%P  :1@  %X8  !6&   4!<  $T5  !*$P  21$  $D.!P!(#0X 1@T3
M $0-&@!##B$ 0@XH $ .+@ _#C4 /@\\ #T/0P [$$L .A!4 #@07@ V$&L
M-!!Y #(0B@ Q$)P +Q"P "T0R0 M$>P +1'_ "X1_P O$/\ EQ8  ((9  !Q
M&P  9!P  %D<  !1'   3!L  $<:  !$&   0Q4  $(3 @!!$@L 0!$0 #X2
M%P \$AX .Q,E #H3*P X$S( -Q,Y #840  T%$@ ,Q11 #$47  P%6@ +A5W
M "P5B  J%9H *!6N "<5QP F%>H )Q7_ "@5_P I%?\ D1H  'T<  !M'@
M8!\  %8?  !.'P  2!X  $,=  ! '   /AH  #T8   [%P< .18. #@7%  V
M%QL -1@B #,8*  R&"\ ,1DV # 9/0 N&48 +1I/ "L:60 J&F8 *!IT "8:
MA@ D&ID (AJM "$:Q0 @&N@ (1K^ "(:_P C&O\ C1T  'D?  !I(0  7"(
M %(B  !*(@  1"$  #\A   \(   .1X  #@;   U' 0 -!P- #(<$@ P'1@
M+QT? "X=)0 M'BP *QXS "H>.P I'T, )Q]- "8?5P D'V0 (A]R " ?A  ?
M'Y< '1^K !L?PP ;'^< &Q_] !T?_P >'O\ B2   '4B  !E(P  620  $\E
M  !')0  020  #PC   X(P  -2(  #,@   P( $ +B$* "PA$  K(14 *B(<
M "@B(P G(BD )B,P "4C.  C(T$ (B1* "$D50 ?)&$ '21P !LD@@ 9))4
M%R2J !8DP0 5).4 %B3\ !<C_P 9(_\ A2(  '$D  !B)@  5B<  $PG  !$
M)P  /B<  #DF   U)@  ,24  "XD   K)0  *24' "<F#@ E)A, )"<9 ",G
M(  B)R< (2@N " H-@ >*#X '2A( !LI4P 9*5\ &"EN !8I@  4*90 $BFH
M !$IP  1*.0 $2C[ !,H_P 4)_\ @"4  &XG  !?*   4RD  $DJ  !"*0
M.RD  #8I   R*   +B@  "HH   F*0  )"H$ "(K#  @*Q$ 'RP6 !TL'0 <
M+"0 &RTK !HM,P 8+3P %RU% !8N4  4+ET $BYL !$N?@ 0+I( #BZG  TM
MO0 -+=\ #2WY  XL_P 0+/\ ?"@  &HJ  !;*P  4"P  $8L   _+   .2P
M #0K   O*P  *RL  "8L   B+@  'R\  !PP"0 :,0X &3$3 !<Q&@ 6,B$
M%3(H !0R,  3,CD $C-# !$S3@ 0,UL #C-I  TS>@ ,,XX "C.B  @RN0 (
M,MD "#+T  HQ_P +,?\ =RL  &8M  !8+@  32\  $,O   \+@  -BX  #$N
M   M+@  *2X  ",P   ?,@  &S,  !<U!0 4-@P $C<1 !$W%@ 1-QT $#@D
M  \X+  ..#4 #3@_  PX2@ +.%< "3AE  <X=@ %.(H  SB?  $WM0 !-],
M C?Q  ,V_P %-O\ <RX  &(P  !4,0  23$  $$Q   Y,0  -#$  "\P   K
M,   )3(  " S   ;-@  %S@  !,Z @ 0/ D #3T.  P]$P +/1D "CTA  D]
M*0 (/3$ !CX[  4^1@ #/E(  3YA   ^<@  /H8  #V<   ]L@  /=   #SP
M   \_P  //\ ;3(  %TS  !0-   1C0  #XT   W-   ,C,  "TS   G-
M(C8  !TX   8.@  %#T  ! _ @ -00@ "4,-  9$$0 #1!8  D0=  !$)
M1"T  $0V  !$00  1$X  $1<  !$;0  1($  $28  !#KP  0\T  $+P  !"
M_P  0O\ :#8  %@W  !,.   0S@  #LW   U-@  ,#8  "DW   C.0  'CL
M !@]   30   $$(   U% 0 (1P<  TD,  !)#P  2A,  $L9  !+(   2R@
M $LR  !+/0  3$D  $Q7  !+:   2WT  $N4  !*K   2LH  $GO  !)_P
M2?\ 8CH  %0[  !).P  0#L  #DZ   S.0  +#H  "4\   ?/P  &4$  !-$
M   01P  #$D   A,   "3P4  % *  !0#0  41   %(5  !4&P  5",  %0L
M  !4-P  5$0  %12  !48P  5'<  %2/  !3J   4L8  %+M  !1_P  4?\
M7#\  $\_  !%/P  /CX  #<]   O/@  )T   "!#   91@  $TD   ],   +
M3P  !E(   !4    5P(  %@'  !9"P  6@X  %L1  !=%@  7AT  %\F  !?
M,0  7CT  %Y,  !>70  7G$  %V)  !=HP  7,$  %OK  !:_P  6O\ 5D0
M $M#  !#0@  /$$  #)"   I10  (4@  !I+   33@  #E(   I5   #60
M %L   !>    8    &("  !C!@  90H  &8.  !H$0  :A<  &L?  !K*0
M:S8  &M%  !K5@  :FH  &J"  !IG0  :+L  &?G  !F_P  9?\ 44@  $A(
M  !!1@  -T<  "Q*   C30  &U$  !-5   .60  "%T   %A    9    &<
M  !J    ;    &X   !P    <@4  ',)  !U#0  =Q$  'H8  ![(0  >RX
M 'H]  !Z3@  >6(  'EY  !XE@  =[,  '7@  !T_   <_\ 3DT  $=,   [
M30  ,$\  "93   <6   $UP   UA   &9@   &H   !O    <@   '8   !Y
M    ?    'T   !_    @0   (,"  "&!P  B P  (L1  ".&   CB0  (XS
M  "-1   C%@  (MO  "*C   B:H  (C/  "&]P  A?\ 35$  $%3   T50
M*5H  !Y?   490  #6H   5P    =@   'L   !_    @P   (<   "*
MC0   (X   "1    DP   )4   "8    F@4  )T,  "@$0  HQH  *,H  "B
M.@  H4X  *!E  "@@0  GJ   )W!  ";[@  FO\ 1ED  #E<   M80  (6<
M !9N   .=0  !7L   "!    AP   (T   "2    E@   )H   "=    GP
M *$   "D    I@   *@   "K    K@   +$#  "T"P  N!$  +D>  "Y+P
MN$,  +=:  "U=@  M)<  +2U  "QX@  L/P /V0  #%I   E;P  &'<   ]_
M   &AP   (X   "4    F@   *    "E    J@   *X   "Q    L@   +4
M  "W    N@   +P   "_    PP   ,8   #)    S@H  -(3  #2(P  T3<
M -!/  #.:@  S8H  ,JK  #+RP  R^\ -W$  "EX   =@   $8D   B1
MF@   *$   "G    K0   +,   "Y    O@   ,(   #%    Q@   ,D   #,
M    S@   -(   #5    V@   -X   #A    Y0   .H+  #K%P  ZBL  .I#
M  #J7@  ZGH  .N9  #KM0  Z]4 _P   /\   #_  $ _P ' /\ #0#_ !(
M_P ; /\ )0#_ "\ _P Z /\ 0P#_ $L _P!3 /\ 6@#] &  ^P!F /H :P#X
M '( ]@!X /0 @ #Q (D [P"2 .P G0#I *H Y@"\ ., W #? /< W0#_ ,P
M_P"^ /\ M0#_ +  _P"M /\ _P   /\   #_    _P   /\ !@#_  T _P 4
M /\ 'P#_ "D ^P S /< /0#S $4 [P!- .P 4P#H %D Y0!? ., 90#@ &H
MW0!Q -H > #6 (  T@"* ,\ E0#, *( R "R ,4 R0#" .T P #_ +L _P"P
M /\ J #_ *0 _P"A /\ _P   /\   #]    ^@   /@   #P  D [  1 .@
M&0#G ", Y0 M -X -@#6 #X T0!& ,T 3 #* %( R !8 ,4 70## &, P !I
M +X < "\ '@ N0"! +< C0"T )H L0"I *X O "L .$ J@#\ *@ _P"@ /\
MF0#_ )8 _P"4 /\ _P   /D   #R    YP   -L   #1  0 R@ - ,< % #$
M !T P@ F +\ +P"[ #< MP _ +0 10"Q $L K@!1 *P 5@"J %P J !A *8
M: "C '  H0!Y )\ A "= )$ F@"@ )@ L0"6 ,P E0#Q )0 _P"1 /\ BP#_
M (@ _P"& /\ ]P   .P   #>    R0   +P   "T    KP * *L $ "I !<
MJ  @ *< * "B #  GP X )P /@": $0 F !* )8 3P"4 %4 DP!: )$ 80"/
M &@ C0!Q (L >P") (@ AP"7 (4 J "# +X @0#D (  _P"  /\ ? #_ 'L
M_P!Y /\ Z0   -<   #!    L0   *8   "=    EP % )0 #0"2 !( D  :
M (\ (@". "H BP Q (D . "' #X A0!# (, 2 "! $X ?P!4 'X 6@!\ &$
M>@!I '@ <P!V '\ =0". ', GP!Q +, < #0 &\ ]@!O /\ ;P#_ &T _P!L
M /\ V@   +\   "L    G@   ),   ",    A0   (( "0!_  \ ?@ 5 'T
M' !\ "0 >@ K '< ,0!U #< =  ] '( 0@!Q $@ ;P!- &X 4P!L %H :P!B
M &D ; !G '@ 9@"& &0 EP!B *H 80#" &  ZP!A /\ 80#_ &$ _P!@ /\
MQ0   *T   ";    C0   (,   !\    =P   '( !0!P  P ;@ 1 &P %P!L
M !X :P E &D + !G #$ 9@ W &0 /0!C $( 8@!( &  3@!? %4 70!= %P
M9@!: '( 60"  %< D !6 *, 50"Y %0 W@!4 /L 5 #_ %4 _P!5 /\ M@
M )\   "-    ?P   '4   !N    :0   &8  0!C  D 80 . &  $P!? !D
M7@ @ %T )@!; "P 6@ R %@ -P!7 #T 5@!# %4 20!3 %  4@!8 %$ 80!/
M &P 3@!Z $P B@!+ )P 2@"Q $D S@!) /, 20#_ $D _P!* /\ J@$  )0%
M  ""!P  = @  &H(  !C!@  7@0  %L   !9  4 5P , %8 $ !4 !4 4P ;
M %( (@!1 "@ 4  M $X ,P!- #@ 3  ^ $L 10!* $P 2 !4 $< 70!& &@
M1 !U $, A0!! )@ 0 "K $  Q0 _ .H /P#_ $  _P!  /\ H @  (H+  !Y
M#0  ; T  &$-  !:#0  50L  %()  !0!@  3P(( $X #0!, !( 2P 7 $H
M'@!) ", 1P I $8 +P!% #0 1  Z $( 00!! $@ 0 !0 #X 6@ ] &0 / !R
M #H @@ Y )0 . "G #< O@ V ., -@#Y #8 _P W /\ F T  (,.  !R$
M91$  %L1  !3$   3A   $H.  !(#0  1PH# $<'"@!%! X 1 (3 $("&@!!
M B  0 ,E #X#*P ]!#$ / 0W #L$/@ Z!44 .05. #<%5P V!6( - 9P #(&
M@  Q!I( , :E "\%NP N!=T +@;U "T'_P N!_\ D1   'T1  !L$P  7Q0
M %44  !.%   2!,  $02  !!$   0 X  $ -!@! "@P /@D0 #P)%@ ["AP
M.0HB #@**  W"RX -@LU #4+.P S"T, ,@Q, # ,5@ O#&$ +0QO "L,?P J
M#)( * RE "<,NP E#-T )0WU "8-_P G#?\ BQ(  '<4  !G%@  6Q<  %$8
M  !)%P  0Q<  #\5   \%   .A(  #D1 0 Y#P@ . X- #<.$@ U#A@ - X?
M #(.)0 Q#RP , \R "\0.@ M$$( +!!+ "H050 H$&$ )A!O "00@  C$),
M(1"G !\0O0 >$.  'A'W !\0_P @$/\ AA0  ',7  !C&0  5QH  $T;  !%
M&@  0!H  #L9   X&   -18  #04   S$@0 ,A(+ #$2$  O$A4 +1(< "P3
M(@ K$RD *A,P "@3-P G%#\ )A1( "044P B%%\ (!5M !\5?@ =%9$ &Q6E
M !D5NP 8%=X &!7X !D4_P :%/\ @A<  &\:  !?'   4QT  $H=  !"'0
M/!T  #<<   T&P  ,1H  "\9   N%@  +!<( "L6#@ I%Q, *!<9 "<8(  E
M&"8 )!@M ",8-  B&3T (!E& !X940 =&5T &QIK !D:?  7&H\ %1JC !09
MN@ 2&=L $QGV !09_P 5&/\ ?1H  &L=  !<'P  4"   $<@   _(   .1\
M #0?   Q'@  +1T  "L<   I&P  )QL% "4;#  D'!$ (AP6 "$<'0 @'2,
M'QTJ !X=,@ <'CH &QY$ !D>3@ 7'EL %AYI !0?>@ 2'HT $1ZB ! >N  .
M'M@ #Q[U ! =_P 1'?\ >AT  &<?  !9(0  32(  $0B   \(@  -B(  #(A
M   N(0  *B   "<@   D'P  (B " " @"@ >(0\ '2$4 !PA&@ ;(B$ &2(G
M !@B+P 7(C@ %2-! !0C3  2(U@ $2-G ! C>  .(XL #2.?  PCM  +(]
M"R+P  PB_P -(?\ =A\  &0B  !6(P  2R0  $$D   Z)   -"0  "\C   K
M(P  *",  "0C   @(P  '20  !LE!P 9)@T %R81 !8F%P 5)QX %"<E !,G
M+  2)S4 $2@_ ! H2@ .*%8 #2AD  PH=  **(< "2B;  <GL0 %)\P !B?L
M  <F_@ ()O\ <2(  & D  !3)@  2"<  #\G   W)@  ,28  "TF   I)0
M)24  "(E   =)P  &2@  !8J!  4*PL $BP0 !$L%  0+!L $"PB  XL*0 .
M+3( #2T[  LM1@ *+5( ""U@  8M<  $+8,  BV8   LK@  +,D  "SK  $K
M_  "*_\ ;24  %TG  !/*   12D  #PI   U*0  +R@  "LH   G)P  (R<
M !\H   ;*@  %RP  !,N @ 0, @ #C$-  TQ$@ ,,1< "S$>  HQ)@ (,BX
M!S(W  4R0@ #,DX  3)<   R;   ,G\  #*5   QK   ,<<  ##J   P_
M,/\ :"D  %@J  !,*P  02P  #DL   R*P  +2L  "DJ   E*@  ("L  !PL
M   7+@  $S   ! R @ .- < "C<,  <W$  %-Q0  S<;  (W(@  -RH  #@S
M   X/@  .$H  #A8   X:   .'P  #>2   WJ0  -L4  #;J   V_0  -?\
M8RP  %0N  !(+P  /B\  #8N   P+@  *RT  "<M   B+0  '2\  !@Q   4
M,P  $#4   XW 0 *.@< !CL+  (\#@  /1(  #X7   ^'@  /B8  #XO   ^
M.@  /D8  #Y4   ^9   /G<  #Z/   ]IP  /<,  #SI   \_0  ._\ 7C
M % Q  !$,@  .S(  #0Q   N,   *2\  "0P   >,@  &30  !0V   0.0
M#3L   H]   %0 4  $$*  !"#0  0Q   $04  !%&@  1B(  $8K  !&-0
M1D$  $9/  !&7P  1G,  $6*  !%I   1,   $/H  !#_@  0O\ 6#0  $LU
M  !!-0  .34  #(T   M,P  )C0  " U   :.   %#H  ! ]   -0   "4(
M  1%    1P,  $@'  !*"P  2PX  $P1  !.%0  3QP  $\E  !/+P  3SP
M $]*  !/6@  3FT  $Z%  !-H   3+P  $OG  !+_@  2O\ 4SD  $<Y   ^
M.0  -S@  #$W   I-P  (3D  !L\   5/P  $$(   Q%   '2    DH   !-
M    3P   %$$  !2!P  5 L  %4.  !7$0  61<  %H?  !9*0  638  %E$
M  !95   6&<  %A_  !7F@  5K<  %7C  !4_0  5/\ 3CT  $,]   \/
M-3L  "P\   D/@  '$$  !5$   02   "TL   5.    40   %0   !7
M60   %L   != @  7@8  & +  !B#@  9!(  &<8  !G(@  9BX  &8\  !F
M30  96   &5W  !DDP  8[$  &'=  !@_   7_\ 24(  $%!   Z/P  ,$
M "9#   >1@  %4H  !!.   *4@   U8   !:    70   &    !C    90
M &<   !I    :P$  &T%  !O"@  <@X  '42  !W&P  =B8  '8U  !U1@
M=%D  '1O  !SBP  <JD  '#-  !O]P  ;O\ 1D8  $!%   U1@  *D@  "!,
M   740  $%8   E:   !7P   &,   !H    :P   &\   !R    =0   '<
M  !Y    >P   'T   "  P  @P@  (8-  ")$P  BAT  (HK  ")/   B$\
M (9F  "%@0  A*   (+"  "!\   ?_\ 1DL  #I,   N3P  (U,  !A8   0
M7@  "60   !I    ;P   '0   !X    ?    ($   "$    AP   (@   "+
M    C@   )    "3    E@   )D'  "=#0  H10  * A  "@,0  GD0  )U;
M  "<=@  F98  )FU  "6Y0  E?X /U(  #)5   F6@  &V   !%G   );0
M '0   ![    @0   (8   "+    D    )0   "7    F0   )P   "?
MH0   *0   "G    J@   *T   "Q!@  M0T  +@6  "W)@  MCD  +50  "T
M:@  LHD  +"J  "NSP  K?4 -UP  "MA   >:   $W    MX    @    (<
M  ".    E0   )H   "?    I    *@   "L    K0   +    "S    M0
M +@   "[    OP   ,,   #'    RP4  -$.  #1&P  T"X  ,]%  #-7P
MRWX  ,F>  #(O@  Q>D +VD  "-P   6>0  #8$   &+    DP   )L   "B
M    J    *X   "T    N    +T   #     P@   ,4   #(    RP   ,X
M  #1    U@   -L   #?    Y    .@&  #K$0  ZB,  .HZ  #I5   YW(
M .63  #CLP  X]0 _P   /\   #_    _P $ /\ "P#_ !  _P 7 /\ (0#_
M "L _P U /\ /@#_ $< _P!. /\ 50#\ %L ^@!A /@ 9@#V &T ] !S /(
M>P#O (0 [0". .H F0#F *< XP"Y -\ U0#; /< U@#_ ,  _P"R /\ J@#_
M *4 _P"B /\ _P   /\   #^    _    /P  P#^  L _P 1 /\ &@#] "0
M^0 N /0 . #P $  [ !( .D 3@#F %0 X@!: -\ 7P#< &4 V !K -0 <@#0
M 'L S0"% ,H D0#' )X PP"N ,  Q0"] .L NP#_ +  _P"D /\ G #_ )@
M_P"5 /\ _P   /H   #T    \0   /(   #J  4 YP . .( %0#A !X X0 H
M -@ ,0#0 #D RP!  ,@ 1P#% $T P@!3 +\ 6 "] %X NP!D +D :P"V ',
MM !\ +$ B "N )4 JP"D *@ N "F -P HP#[ )\ _P"5 /\ CP#_ (L _P")
M /\ ^0   .\   #G    WP   ,\   #(    P0 * +\ $0"\ !@ NP A +D
M*@"T #( L0 Z *X 0 "K $8 J !, *8 40"C %8 H0!< )\ 8P"= &H FP!S
M )D ?@"6 (P E "; )( K0"0 ,< C@#P (T _P"& /\ @ #_ 'T _P!\ /\
M[0   .    #1    OP   +,   "J    I@ % *( #0"A !, H  ; )\ (P";
M "L F  R )4 .0"3 #\ D0!$ (\ 2@". $\ C !5 (H 6P"( &, A@!K (0
M=@"" (( @ "2 'X HP!\ +H >@#A 'D _P!W /\ <@#_ '  _P!O /\ W0
M ,L   "V    IP   )T   "4    C@ ! (L "@") !  B  5 (< '0"' "4
MA  L (( ,@!_ #@ ?0 ] 'L 0P!Y $@ > !. '8 5 !U %L <P!C '$ ;@!O
M 'H ;0") &P F@!J *X :0#, &@ ]@!G /\ 90#_ &0 _P!C /\ R@   +0
M  "A    DP   (D   ""    >P   '@ !0!V  P =0 1 '0 & !S !\ <@ E
M '  + !N #( ;  W &H / !I $( : !( &8 3@!E %4 8P!= &( 9@!@ '(
M7@"  %T D@!; *4 6@"^ %D Z0!9 /\ 60#_ %@ _P!8 /\ N0   *(   "0
M    @P   'D   !Q    ;0   &D  0!F  D 90 . &0 $P!C !D 8P @ &$
M)@!@ "P 7@ Q %P -P!; #P 6@!" %@ 2 !7 $\ 5@!7 %0 8 !3 &P 40!Y
M %  B@!/ )X 3@"T $T V@!- /L 30#_ $T _P!- /\ J@   )0   ""
M=0   &L   !D    8    %T   !:  4 6  , %< $ !6 !4 5@ ; %4 (0!3
M "< 4@ L %$ ,0!/ #< 3@ ] $T 0P!, $H 2@!2 $D 6P!( &8 1@!S $4
MA !$ )< 0P"L $( R0!" /$ 0@#_ $, _P!# /\ G@   (D   !X P  :@0
M &$$  !: P  50$  %(   !0  ( 3@ ) $T #0!, !$ 2P 7 $H ' !) "(
M2  G $< +0!% #( 1  X $, /@!" $4 00!- #\ 5@ ^ &$ /0!N #L ?@ Z
M )$ .0"F #@ OP X .@ . #_ #D _P Y /\ E0,  ( '  !O"0  8@H  %@+
M  !1"@  3 @  $D&  !' P  1@ & $0 "P!#  \ 0@ 3 $$ & !! !X /P C
M #X *0 ] "X .P T #H .@ Y $$ . !) #< 4@ V %T - !J #, >@ R (P
M,0"A #  N  O -X +P#Y "\ _P P /\ C D  '@,  !H#0  7 X  %(.  !+
M#@  10T  $$,   _"@  /@@" #T$"  \ 0T .P 0 #H %0 Y !H .  @ #8
M)0 U "L -  P #, -P R #X ,0!& "\ 4  N %H +0!G "L =P J (D *0"=
M "@ LP G -$ )P#R "< _P G /\ A@P  '(.  !C$   5A$  $T1  !%$0
M0!   #P/   Y#@  -PT  #8+!  V" H -08. #0%$@ R!!< ,04< # %(@ O
M!2@ +@8N "T&-  K!CP *@9$ "D'3@ G!UD )@=E "0'=0 C!X< (@>; " &
ML  @!LL 'P7M !\&_@ ?!_\ @ X  &T1  !>$@  4A,  $@3  !!$P  .Q,
M #<2   T$0  ,A   # / 0 P#08 , L+ "\*$  M"A0 + L9 "H+'P I"R4
M* PK "<,,@ F##H ) Q# ",,30 A#5@ ( UE !X-=0 <#8@ &@V< !D-L0 8
M#,H %PSK !<-_  8#/\ >Q$  &D3  !:%0  3A8  $46   ]%@  .!4  #,5
M   P%   +1,  "L2   J$ , *@\( "D.#0 H#A$ )@X6 "4/'0 D#R, (P\I
M "$0,0 @$#D 'A!" !T03  ;$%@ &1!F !<0=@ 5$(D %!"> !(0LP 1$,X
M$1#N !(0_@ 2$/\ =Q,  &45  !7%P  2Q@  $(9   Z&0  -!@  # 7   L
M%P  *18  "<5   F% $ )1($ ",2"P B$@\ (1(4 " 2&@ >$R  '1,G !P3
M+@ :$S8 &11  !<42@ 6%%8 %!1D !(4=  1%(< $!2<  X4L0 -%,H #13K
M  X3_@ .$_\ <Q4  &$8  !3&@  2!L  #\;   W&P  ,AH  "T:   I&0
M)A@  "08   B%P  (!8! !X6"  =%@T &Q<2 !H7%P 9%QT &!@D !88*P 5
M&#0 %!@] !(92  1&50 $!EB  X9<@ -&80 #!F8  H9K0 )&,8 "1CG  D8
M^@ *%_\ ;Q@  %X:  !0'   11T  #P=   U'0  +QT  "H<   F&P  (QL
M "$:   >&@  '!H  !H;!0 8&PP %AP0 !4<%0 4'!L $QPB !(=*0 1'3$
M$!T[  X=10 -'E$ #!Y>  H>;0 )'H  !QZ4  4=J@ #'<(  QWF  0<^  %
M'/\ :QH  %L=  !-'@  0A\  #H?   R'P  +1\  "@>   D'@  (1T  !X=
M   <'0  &!X  !4? @ 3( D $B$. ! A$@ 0(1@ #B$?  XB)@ -(BX #"(W
M  HB00 )(DT !R):  4B:0 #(GP  2*1   BJ   (<   "'E   @^   (/\
M9QT  %<?  !*(0  0"$  #<B   P(0  *B$  "8@   B(   'Q\  !P?   9
M(   %B$  !(C @ 0) < #B8,  PF$  +)A4 "B8<  DF(@ ()BH !B<S  0G
M/0 #)TD  2=6   G9@  )WD  ">/   FI@  )K\  "7D   E^0  )/\ 8R
M %0B  !'(P  /20  #0D   N(P  *",  "0B   A(@  'B$  !HB   7(P
M$R0  ! F @ .* < "RH+  @K#@ &*Q, !"L8  (K'P !+"<  "PP   L.@
M+$4  "Q3   L8P  +'8  "R,   KI   *[X  "KD   J^@  *?\ 7R,  % E
M  !$)@  .B8  #(F   K)@  )B4  ",D   ?)   &R0  !<E   4)P  $2D
M  XK @ ++08 !R\+  0P#@  ,!$  #$5   Q'   ,2,  #(L   R-@  ,D(
M #)/   R7P  ,G(  #&)   QH@  ,+P  ##D   O^P  +_\ 6B<  $PH  !
M*0  -RD  "\I   I*   )2<  "$F   <)P  &"@  !0J   1+   #BX   LP
M 0 ',@4  S0)   U#   -@\  #<2   X&   ."   #@H   X,@  .3T  #E+
M   Y6P  .&X  #B%   WGP  -[H  #;D   U_   -?\ 52H  $@L   ]+
M-"P  "TK   H*@  )"D  !XJ   9*P  %"T  !$O   -,0  "C0   <V   "
M. 0  #H'   ["@  /0T  #X0  ! %   0!L  $ D  ! +@  0#D  $!'  !
M5@  0&D  $"    _FP  /K<  #WC   \_   //\ 4"\  $,O   Y+P  ,B\
M "PM   G+   ("T  !HO   5,0  $3,   TV   ).   !3L    ]    0 $
M $$$  !#!P  10L  $8.  !($0  2A8  $H>  !**   2C0  $E"  !)40
M260  $A[  !(EP  1[0  $;@  !%_   1/\ 2C,  #\S   V,P  ,#$  "HP
M   C,0  '#,  !8U   1.   #3L   @^   #00   $,   !&    2    $H
M  !,!   3@<  $\+  !1#@  5!(  %49  !5(@  5"X  %0\  !42P  4UX
M %-T  !2D   4:X  %#7  !/^P  3O\ 13<  #PW   U-@  +S0  "8U   >
M-P  %SH  !$]   ,00  !T0   !(    2@   $T   !0    4P   %4   !7
M    6 (  %L&  !="P  7PX  &(3  !B&P  8B<  &(T  !A10  8%<  &!M
M  !?B0  7:<  %S,  !:^   6?\ 03P  #H[   T.0  *CH  "$\   80
M$4,   Q'   &2P   $\   !3    5@   %D   !<    7P   &$   !C
M90   &<!  !J!0  ;0H  ' .  !S%0  <B   '(M  !Q/0  <$\  &]E  !N
M@   ;9\  &O!  !I\0  :/\ /T   #D^   N/P  )$(  !I&   22@  #$\
M  14    6    %T   !A    90   &@   !K    ;@   '$   !S    =0
M '@   ![    ?@,  ($*  "%#P  AQ<  (8D  "%-   A$8  ()=  "!=@
M?Y8  'ZV  !\YP  >O\ /T0  #-%   H2   '4P  !-2   ,5P   UT   !C
M    :    &T   !Q    =@   'H   !^    @0   (,   "&    B0   (L
M  ".    D@   )4!  "9"0  GA   )X:  "=*0  G#P  )I2  "8;   EHL
M )2J  "2U   D/H .$L  "Q.   @4P  %5D   U@   #9P   &X   !T
M>@   (    "$    B@   (X   "2    E0   )<   ":    G0   *    "C
M    IP   *L   "O    M D  +@0  "W'@  M3   +-&  "Q8   KWX  *R@
M  "KP0  J>X ,54  "1;   880  #FD   5Q    >0   ($   "(    CP
M )0   ":    GP   *0   "H    J0   *P   "O    LP   +4   "Y
MO0   ,$   #&    RP   -$*  #3%   T24  - [  #-5   RG$  ,B2  #%
MLP  P]X *6(  !QI   1<0  !WL   "$    C0   )4   "=    HP   *D
M  "O    M    +D   "\    O@   ,(   #%    R    ,P   #0    U
M -H   #?    Y    .H   #N#   [1H  .PO  #J20  Z&4  .:&  #DI0
MXL8 _P   /\   #_    _  ! /P " #^  X _P 4 /\ '0#_ "8 _P P /\
M.@#_ $( _P!) /X 4 #[ %8 ^0!< /8 8@#T &@ \@!O /  =@#M '\ Z@")
M .< E0#D *, X "U -L T #5 /8 R@#_ +8 _P"H /\ GP#_ )H _P"6 /\
M_P   /L   #V    \P   /,   #V  D ^@ . /T %@#[ "  ]P J /( ,P#M
M #L Z0!# .8 20#B $\ W@!5 -L 6P#6 &  T@!G ,\ ;@#, '8 R0"  ,8
MC #" )H OP"J +L P0"X .D M@#_ *< _P": /\ D@#_ (T _P"* /\ ^@
M /$   #J    YP   .<   #D  $ X  + -L $0#: !H VP C -$ + #* #0
MQ@ [ ,( 0@"_ $@ O !. +H 4P"X %D M@!? +, 9@"Q &X K@!W *P @P"I
M )$ I@"A *, M0"@ -@ G@#[ )4 _P"+ /\ A0#_ (  _P!^ /\ [P   .,
M  #:    TP   ,8   "_    N0 & +< #@"T !0 M  = +, )0"N "T JP T
M *< .P"D $$ H0!& )\ 3 "= %$ FP!7 )D 7@"7 &4 E0!N ), >0"0 (<
MC@"7 (P J0") ,0 B #O (4 _P!\ /\ =@#_ ', _P!R /\ X    -    #&
M    M@   *D   "A    G0 ! )D "@"8 !  F  6 )< '@"4 "8 D0 M (\
M- ", #H B@ _ (@ 10"' $H A0!0 (, 5@"! %X @ !F 'X <0!\ 'T >0"-
M '< H !U +8 <P#? '( _P!N /\ :0#_ &< _P!E /\ S    +X   "K
MG0   ),   "*    A0   (( !0"   T ?P 1 '\ & "  "  ?0 F 'H +0!W
M #, =0 X '0 /@!R $, < !) &\ 3P!M %8 ; !> &H : !H '4 9P"$ &4
ME@!D *L 8@#) &$ ]@!@ /\ 7 #_ %L _P!: /\ O0   *D   "7    B0
M 'X   !X    <P   &\  0!M  D ;  . &L $P!K !D :@ @ &@ )@!F "P
M90 R &, -P!B #P 8 !" %\ 2 != $\ 7 !7 %H 80!9 &T 5P![ %8 C@!5
M *( 4P"[ %( Z0!2 /\ 4 #_ $\ _P!/ /\ K0   )@   "&    >    &X
M  !G    8P   &    !=  4 7  + %L $ !; !4 6P ; %H (0!8 "8 5@ L
M %0 ,0!3 #8 4@ \ %$ 0@!/ $D 3@!1 $T 6P!+ &8 2@!T $D A0!( )D
M1P"Q $8 V !& /P 10#_ $4 _P!% /\ GP   (D   !X    ;    &(   !;
M    5@   %,   !1  ( 3P ( $\ #0!. !$ 3@ 6 $T ' !, "$ 2@ F $D
M+ !( #$ 1P W $4 /0!$ $0 0P!, $( 50!  &  /P!N #X ?@ ] )( / "I
M #L QP [ /, .P#_ #L _P \ /\ DP   'X   !N    80   %@   !1
M3    $D   !'    10 % $0 "P!#  X 0P 2 $, %P!" !T 0  B #\ )P ^
M "P /0 R #L .  Z #\ .0!' #@ 4  W %L -0!H #0 >  S (P ,@"B #$
MO  Q .< ,0#_ #( _P S /\ B0   '8#  !F!0  60<  % '  !)!@  0P4
M $ #   ^ 0  /  # #L "  Z  T .@ 0 #D %  Y !D -P > #8 (P U "@
M-  N #, -  R #L , !# "\ 3  N %< +0!D "P <P K (< *@"< "D M0 I
M -P *0#[ "D _P J /\ @00  &X(  !?"@  4PL  $H+  !""P  /0H  #D)
M   V"   -04  #0"!@ S  H ,@ . #$ $0 Q !4 ,  : "\ 'P N "0 +  J
M "L ,  J #< *0 _ "@ 20 G %0 )@!@ "0 ;P C (( (@"7 "$ K@ A ,P
M(0#S "$ _P B /\ >PD  &@,  !:#0  3@X  $4.   ]#@  . T  #,-   P
M#   +@L  "T) P M!@@ + 0, "L"#P J 1( *0$7 "@!'  G "$ )@ G "4
M+0 D #0 (P$] "(!1@ A 5$ 'P%= !X!;  < 7\ &P"4 !H J@ : ,4 &@#K
M !D _P : /\ =0P  &0.  !5#P  2A   $ 0   Y$   ,Q   "\/   L#@
M*0X  "<- 0 G# 4 )PH* "8(#0 E!Q  ) 84 "(&&0 A!A\ ( <D !\'*P >
M!S( '0<Z !P(1  :"$\ &0A< !<(:P 6"'T %0>1 !0'IP 3!K\ $@7D !(%
M^@ 2!?\ <0X  %\0  !1$0  1A(  #T2   V$@  ,!(  "L1   H$0  )1
M ",0   B#@0 (0T' "$,"P @"PX 'PL2 !T+%P <#!P &PPB !H,*0 9##$
M& PY !8-0P 5#4\ $PU< !(-:P 0#7X #PV2  X-IP -#+X #0S@  T,]0 -
M#/\ ;1   %P1  !.$P  0Q0  #H4   R%   +10  "@3   E$P  (A(  " 1
M   >$0, '! % !P/"  ;#PP &@X0 !D/%  7#QH %@\A !40*  4$#  $A Y
M !$01  0$%  #A!=  T0:P ,$'P "Q"0  D0I0 ($+P !Q#?  <0]  '#_\
M:1$  %@4  !+%0  0!8  #<6   P%@  *A8  "85   B%0  'Q0  !T3   :
M$P( &1($ !<2!@ 6$@H %1(. !02$@ 2$A@ $1,> !$3)0 0$RX #A,W  T4
M0  ,%$L "Q18  D49P '%'@ !A2-  04HP #$[L  A/=  $2]  "$O\ 91,
M %46  !(%P  /1@  #08   M&   *!@  ",7   @%P  '18  !H5   8%0(
M%A4$ !05!0 2%@@ $18- ! 7$  .%Q4 #A<;  T7(@ ,%RD "Q@R  D8/  '
M&$< !1A4  088P "&'4  1B+   7H0  %[D  !?=   6]0  %O\ 818  %(8
M  !%&@  .QH  #(:   K&@  )1H  "$9   >&   &Q@  !@7   6%P( %!<#
M !(8!0 0&0< #AL+  P;#P +&Q, "AL8  @<'P ''"8 !1PO  0<.  "'$0
M !U1   =8   '7(  !R(   <H   &[D  !O>   :]@  &O\ 7A@  $\:  !"
M'   .!P  "\=   I'   (QP  !\;   <&@  &1D  !<9 0 4&0( $AH# ! ;
M!  .'0< #!X+  D?#@ &(!$ !2 6  ,@'  !(2,  "$K   A-0  (4   "%.
M   A70  (6\  "&&   @G@  (+@  !_>   >^   'O\ 6AL  $L=   _'@
M-1\  "T?   G'@  (AT  !X=   ;'   &!L  !4;   2'   $!T"  X?!  ,
M(08 "2(*  4C#0 ")!   "43   E&0  )B   "8H   F,@  )CT  "9*   F
M6@  )FP  ":#   EG   );<  "3?   C^0  (_\ 51X  $<@   \(0  ,B$
M "LA   E(   (!\  !T>   :'0  %AX  !,>   0(   #B$   PC @ ()04
M!2<)   H"P  *@X  "L1   L%@  +!T  "PE   L+@  +#H  "Q'   L5@
M+&D  "R    KF@  *K4  "G?   I^P  */\ 42(  $0C   X)   +R0  "@C
M   C(@  'R$  !P@   7(   $R$  ! C   .)   "R8   @H   $*@0  "P'
M   N"0  , P  #$/   S$P  ,QD  #,A   S*@  ,S4  #-#   S4@  ,V4
M #)[   REP  ,;,  ##>   O^P  +O\ 3"4  #\F   U)P  +28  "<E   B
M)   'B,  !DC   4)   $28   XH   +*@  !RP   ,O    ,0(  #,$   U
M!P  -PH  #D-   Z$   .Q4  #L=   [)@  .S$  #L^   [3@  .V   #IW
M   YD@  .+   #?;   V_   -?\ 1RD  #LJ   R*@  *RD  "4G   A)@
M&R<  !4H   1*@  #BP   HO   &,0   30    V    .    #L!   ]!
M/P<  $$*  !##@  11$  $48  !%(0  12P  $0Y  !$2   1%L  $-Q  !"
MC0  0:L  $#2   _^@  /O\ 0BT  #@N   O+0  *2L  "0J   =*@  %RP
M !$N   -,0  "30   0W    .@   #P    _    00   $0   !&    2 ,
M $H'  !,"P  3@X  % 3  !0'   4"<  $\T  !/0P  3U4  $YJ  !-A@
M3*0  $K*  !)^   2/\ /C(  #4Q   N+P  *2X  " N   9,0  $C,   XW
M   ).@   CT   !     1    $<   !)    3    $\   !1    4P   %4!
M  !8!@  6@L  %T.  !?%0  7B   %XL  !=/   7$X  %MC  !:?@  6)T
M %?   !5\@  5/\ .C8  #,T   M,@  )#,  !LV   3.0  #CT   A!
M10   $D   !,    4    %,   !6    60   %L   !=    8    &(   !E
M    : 4  &L+  !O$   ;Q@  &XE  !M-   ;48  &M;  !J=0  :)0  &:V
M  !DZ0  8O\ .#D  #(W   H.0  'CL  !4_   .1   !TD   !-    4@
M %8   !:    7@   &(   !E    :    &L   !M    <    ',   !V
M>0   'T$  "!"P  A1$  (0=  ""+   @#X  'Y4  !^:P  >XH  'JJ  !W
MU@  =?T .#T  "P^   B00  %T8   ]+   '40   %<   !<    8@   &8
M  !K    ;P   '0   !X    >P   'X   "     @P   (8   "*    C0
M )$   "6 P  FPP  )T3  ";(0  FC,  )=)  "48@  DW\  )"@  ".Q0
MC/, ,40  "5(   :30  $%,   A:    80   &@   !N    =    'D   !_
M    A    (D   "-    D0   ),   "6    F0   )T   "@    I    *@
M  "L    L@,  +<-  "W%P  M2@  +(^  "P5@  K',  *J4  "IM   I>4
M*D\  !Y4   26P  "F(   !J    <P   'L   ""    B0   (X   "4
MF@   )\   "D    I@   *D   "M    L    +,   "W    NP   ,    #%
M    RP   -$$  #5#@  TQT  - R  #-2P  RF8  ,:'  #"J0  P<L (EL
M !9B   ,:P   70   !]    AP   )    "7    G@   *0   "K    L0
M +8   "Z    O    ,    #$    R    ,L   #/    U    -H   #@
MY@   .L   #Q!@  \!,  .XG  #L/P  ZEL  .=Z  #DFP  X+L _P   /L
M  #V    \P   /0 !0#V  P ^@ 1 /\ &0#_ "( _P L /\ -0#_ #T _P!%
M /P 3 #Z %( ]P!8 /4 7@#S &0 \0!J .X <@#L 'H Z0"% .4 D0#A *
MW0"R -@ S@#2 /8 P0#_ *T _P"> /\ E@#_ )  _P", /\ ^@   /(   #L
M    Z0   .D   #L  4 \@ , /@ $@#W !L ]0 E /  +@#K #< Y@ ^ .(
M10#= $L V !0 -, 5@#0 %P S0!B ,H :@#( '( Q0!\ ,( B "^ )8 N@"H
M +< OP"T .@ K@#_ )T _P"0 /\ B #_ (, _P"  /\ \    .4   #>
MV@   -L   #<    V  ' -$ #@#1 !4 T@ > ,L )P#% "\ P  W +T /0"Z
M $0 MP!) +4 3P"R %4 L !; *X 80"L &D J0!S *< ?P"D (T H0"> )X
ML@"; -4 F0#\ (P _P"" /\ >P#_ '8 _P!T /\ X@   -,   #*    QP
M +P   "V    L  ! *\ "P"L !$ K0 8 *T ( "H "@ I  O *  -@"= #P
MFP!" )D 1P"7 $T E0!3 ), 60"1 &$ CP!J (P =0"* (, B "4 (8 IP"#
M ,( @@#P 'P _P!S /\ ;0#_ &H _P!H /\ SP   ,$   "Y    K0   *
M  "8    E    )$ !@"0  T D  2 (\ &0". "$ BP H (@ +P"& #4 A  Z
M (( 0 "  $4 ?@!+ 'P 4@!Z %D > !B '8 ; !T 'D <@") '$ G0!O +0
M;0#? &P _P!E /\ 8 #_ %X _P!< /\ O@   +$   "@    D@   (D   ""
M    ?    'H  0!X  D =P . '@ % !W !H =  A '( )P!P "T ;@ S &P
M. !K #X :0!$ &@ 2@!F %$ 9 !: &, 9 !A '  7P!_ %X DP!= *D 7 #(
M %L ]P!7 /\ 5 #_ %( _P!1 /\ L    )\   "-    ?P   '0   !N
M:@   &8   !E  0 8P + &, $ !C !4 8P ; &$ (0!? "< 70 L %P ,@!:
M #< 60 ] %< 0P!6 $L 50!3 %, 7 !2 &@ 4 !W $\ B0!. )\ 30"Z $P
MZ0!+ /\ 20#_ $< _P!' /\ H@   (T   !\    ;@   &4   !>    60
M %<   !5  $ 5  ' %, #0!3 !$ 5  6 %( &P!1 "$ 3P F $X *P!, #$
M2P W $H /0!) $0 1P!, $8 5@!$ &$ 0P!P $( @0!! )< 0 "O #\ UP _
M /\ /@#_ #T _P ^ /\ E    '\   !O    8P   %D   !1    30   $H
M  !(    1P $ $< "@!&  X 1@ 1 $< %@!% !P 1  A $( )@!! "L 0  Q
M #X -P ] #X / !' #H 4  Y %L . !I #< >@ V (\ -0"G #4 Q@ T /4
M- #_ #0 _P U /\ B    '0   !E    6    $\   !(    0P   #\    ]
M    /  " #P !P [  P .P / #L $@ Z !< .0 < #< (0 V "8 -0 L #0
M,@ S #D ,0!! #  2P O %8 +@!C "T <P L (@ + "@ "L NP K .H *P#_
M "L _P L /\ ?P   &P   != 0  40(  $@#  !  P  .P(  #<    T
M,P   #( !0 R  D ,@ - #$ $  Q !, ,  8 "\ '0 M "( +  H "L +@ J
M #4 *0 ] "@ 1@ G %$ )@!> "4 ;@ D (( (P"9 ", LP B -X (@#_ ",
M_P D /\ =P   &4$  !6!@  2P<  $((   Z"   -0<  # &   M!0  + ,
M "L  P J  < *0 + "D #@ I !$ *  5 "< &0 F !X )0 D "0 *@ C #$
M(@ Y "$ 0P @ $X 'P!: !X :0 = 'P ' "3 !L K  ; ,T &P#V !L _P <
M /\ < 4  %\(  !1"@  1@L  #T+   U"P  , L  "L*   H"0  )0@  "0'
M @ C! 8 (P() "(!#  B  \ (0 2 "  %@ ? !L '@ @ !T )@ < "X &P V
M !H /P 9 $H & !7 !< 9@ 6 '@ %0"/ !4 I@ 4 ,, % #N !0 _P 5 /\
M:P@  %L+  !-#   0@T  #D-   Q#0  + T  "<-   C#   (0P  !\+ 0 >
M"@4 '0@( !T&"P <!0T ' 00 !L$%  9!!@ &00> !@$(P 7!"L %@0S !4$
M/  4!$< $P-4 !(#8P 1 W4 $ ** ! !H@ / +P #P#E  \ _@ 0 /\ 9PL
M %<-  !)#@  /@\  #4/   N#P  * \  "0.   @#@  '0X  !L- 0 9#00
M& P' !@+"0 7"0P %PD. !8)$@ 5"18 % D; !,)(0 2"2@ $@DP !$).@ 0
M"44 #PE2  X)80 -"7, # B(  L(GP *![< "@;;  H%]@ *!/\ 8PT  %,.
M  !&$   .Q$  #(1   K$0  )1   "$0   =$   &@\  !@/ 0 6#@0 %0X'
M !0-"0 3#0L $PP- !(,$  1#!0 $ P9 ! ,'P /#"< #@TO  T-.0 ,#44
M"PU1  D-8  (#7$ !@V&  4-G0 $#+0  PS2  (,\0 ""_\ 7PX  % 0  !#
M$0  .!(  "\2   H$@  (Q(  !X1   ;$0  &!$  !40 @ 4$ 4 $A ' !$/
M"0 0#PH $ X,  X.#@ .#Q( #0\7  P0'0 ,$"0 "A L  D0-@ ($$$ !A!.
M  4070 #$&\  1"$   0G   #[0   [4   .\P  #O\ 7!   $T2  ! $P
M-A0  "T4   F%   (1,  !P3   9$@  %A(  !01 P 2$08 $1$( ! 0"@ .
M$ L #1$+  P1#0 +$A$ "A(5  D2&@ ($B$ !A,I  43,P #$SX  A-+   3
M6@  $VP  !."   2FP  $K0  !'7   1]0  $?\ 6!(  $D4   ]%0  ,Q8
M "L6   D%0  'Q4  !H4   7%   %!,! !,2!  1$@< $!()  X2"0 -$@D
M"Q,*  D4#0 '%0\ !A83  06&  #%A\  A8G   7,   %SL  !=(   76
M%VH  !:    6F0  %;0  !79   4]P  $_\ 510  $86   Z%P  ,!@  "@8
M   B%P  '18  !D6   6%0  $Q0# !(3!@ 0$P< #Q,'  T4!P +%0@ "18)
M  88#  #&@X  1H1   :%@  &QP  !LD   ;+0  &S@  !M&   <50  &V<
M !M]   ;EP  &K,  !G;   8^0  %_\ 418  $,8   W&0  +AH  "8:   @
M&0  &Q@  !@7   5%@$ $Q4% !$5!  /%00 #18$  L7!0 )&08 !AH(  (<
M"@  '@T  " 0   @$P  (!D  " A   A*@  (34  "%"   A4@  (&0  "!Z
M   ?E0  '[$  ![;   =^@  '/\ 31D  #\;   T'   *QP  "0<   >&P
M&AH  !<8   4%P( $A<" ! 8 0 -&0$ "QH"  @< P %'00  A\&   A"
M(PL  "4.   F$0  )A8  "8>   G)P  )S(  "<_   F3@  )F   "9W   E
MD@  )*\  "/:   B^P  (?\ 2!T  #P>   Q'P  *!X  "(>   ='   &1L
M !8:   2&@  $!L   T<   +'0  "!\   0A   !(P(  "4$   G!@  *0D
M "P,   N#P  +A,  "X:   N(P  +BX  "X[   N2@  +5P  "UR   LC@
M*ZP  "K4   I^P  */\ 1"   #@A   N(0  )B$  " @   <'@  &!T  !0=
M   0'@  #A\   LA   '(P   R4    G    *0   "P!   N P  , 8  #,*
M   U#0  -A$  #87   V'P  -BD  #8V   V10  -5<  #5M   TB0  ,J@
M #'/   P^@  +_\ /R0  #0D   K)   )",  !\A   ;(   %B   !$A   .
M(P  "B4   8H   "*@   "T    O    ,@   #0    W    .0,  #L&   ^
M"@  0 X  $$2  !!&@  0"4  $ Q  ! 0   /U(  #YG   ]@@  /*(  #K'
M   Y^   ./\ .B@  # H   I)P  (R4  !\C   8)   $B4   XH   **@
M!2T    P    ,P   #8    X    .P   #X   !     0@   $4"  !'!@
M2@H  $T.  !-%0  3!\  $PK  !+.@  2DP  $EA  !(?   1YL  $6_  !#
M\P  0O\ -BP  "TK   G*0  (R<  !LH   4*@  #BT   HP   $,P   #<
M   Z    /0   $    !#    1@   $@   !+    30   %    !3 0  5@8
M %D+  !;$   6QD  %HE  !9-   6$8  %=:  !5=   5),  %*U  !0Z@
M3_\ ,S   "PN   G+   'BT  !8O   0,@  "C8   ,Z    /P   $(   !&
M    20   $P   !/    4@   %4   !8    6@   %T   !@    8P   &<&
M  !K#   ;!(  &L>  !K+   :3T  &=2  !F:@  9(D  &&K  !?W   7?\
M,3,  "PQ   B,@  &34  !$Y   */0   D(   !'    3    %    !4
M6    %L   !?    8@   &4   !H    :P   &X   !Q    =0   'D   !]
M!@  @@T  ((6  " )   ?C4  'Q)  ![80  >'\  ':?  !SQ@  </< ,38
M "8X   <.P  $D    M%   "2P   %$   !6    6P   &    !E    :0
M &X   !R    =@   'D   !\    ?@   ((   "%    B0   (X   "3
MF 8  )P.  ";&@  F"L  )9   "260  D7,  (V5  "+M0  B.@ *SX  "!!
M   51P  #4T   )4    6P   &$   !H    ;@   ',   !Y    ?@   (,
M  "(    C    (\   "2    E0   )D   "=    H0   *4   "J    L
M +<'  "X$0  M2$  +(U  "O30  JFD  *B(  "FJ   HM$ (T@  !A.   .
M5   !%P   !D    ;0   '4   !\    @P   (D   "/    E0   )L   "@
M    HP   *8   "I    K0   +$   "U    N0   +X   #$    R@   -(
M  #:"@  UA8  -(I  #.00  REP  ,5\  #"G0  P;T '%4  !%<   '90
M &X   !W    ?P   (@   "0    F    )\   "E    K0   +,   "X
MN@   +X   #"    Q@   ,H   #.    TP   -H   #@    YP   .T   #S
M    ] X  /(>  #O-@  [%$  .AN  #DD   W[$
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M[>[O\/'R\_3U]O?X^?K[_/W^_VUF=#$      P0A   !
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M/E+_DSY2_Y,^4O^3/E+_DSY2_Y,^4O^3/E+_DSY2_Y,^4O^3/KW%!0"PUP4
MH_\0 YG_(@F+_RD/?O\P%7/_.!II_T ?8O])(UO_4297_UHH5?]B*E+_:2M1
M_V\L4/]S+4__=RY._WHN3O]]+TW_@"],_X0P2_^(,$O_BS!+_XLP2_^+,$O_
MBS!+_XLP2_^+,$O_BS!+_XLP2_^+,$O_BS!+_XLP2_^+,/^+' 3_B"@(_X0T
M#O^/.A3_ET(<_YY+)_^>5S3_G6)"_YEM3_^3>%SXC8)G\HB+<>R"DWGH?)F
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M+4/_FBU#_YHM0_^:+4/_FBU#_YHM0_^:+4/_FBU#_YHM0_^:+;'" 0"CT@
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M<<N;I'/0DZ)TU(ZB=-2.HG34CJ)TU(ZB=-2.HG34CJ)TU(ZB=-2.HG34CO^
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M4$__PU%/_\-13__#44__PU%/_\-13__#44__PU%/_\-13__#4=JO @#&O 4
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M6?%?Y5GQ7^59\5_E6?%?Y5GQ7_]P'@/_;"D&_VDS"?]R-PW_>3X2_WU'&?^
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MB(V1FH65EI:"GIJ2@*>=CW^SGHV PIZ+@,R:BX'2DHJ V(F)@-N&B8#;AHF
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M>$_6Y75/T^=T3]/G=$_3YW1/T^=T3]/G=$_3YW1/T^=T3]/G=/^/#P'_I X
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ML4,<Y;1+*=JO53K-J%Y*PJ!F6+F:;62QDW5NJHY\=J.*@WV>AHN"F8*3AY2
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M7$KC\UQ*X_-<2N/S7$KC\UQ*X_-<2N/S7/F9 P#4K ( Q;<$ +G#!0"PT@@
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M9U>O\6=7K_%G5Z_Q9U>O\6=7K_%G5Z_Q9_]_#@'_DPL X:4% -*S!P#)O@<
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M% &<Z2@&D^DT#HGH/1A_YT0B=^9.*F_F5S)IY5\X8^5G/5_D;T):Y'=%5N2
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M8&B2]U]HDO=?:)+W7VB2]U]HDO=?:)+W7_]O$0'_@0X _Y$. /*@# #:K0D
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M55"Z_E50NOY54+K^5?^% @#=F   S:8" ,&Q P"WN@, KL8& *?3"@"@W14
MF=TH!)#;-PZ&V4(9?=9+)'745"UMTEPU9]%C/&'0:T%<SW)&6,][253.A$U0
MSH]03<Z;4DO.J5-)SKE42,_/5$C.ZU-)SOA02LO_3DK*_TU*RO]-2LK_34K*
M_TU*RO]-2LK_3>>/  #1GP  PZL! +>T @"MOP, H\L& )O9"@"4Y1H!C>4K
M!H3D-0U[XS\6<^)('FSA4B9FX5HL8.!B,EO@:C97X'(Z4]][/5#?A4!-WX]#
M2N";14C@J$9&X+A'1>',1T7@Z$=%W_9&1=[_1$7>_T1%WO]$1=[_1$7>_T1%
MWO]$1=[_1-F7  #'I@  N+   *RY 0"BQ0( F-$& (_K#0")[A\"@.XK!GCM
M- QP[3T3:.U&&6+M3AY=[5<C6>U@)U7M:"I2[7$M3^UY+TSM@S)*[HTT1^Z8
M-47NI3=#[[,X0O#$.$'PWSE![^\X0.W].$#L_SA [/\X0.S_.$#L_SA [/\X
M0.S_.,N@  "ZJP  K;0  *'   "6S $ B]D% (3X$0%\^!\"=/@I!FSX,@ID
M^#L/7OE#$UCY2Q=3^5,:4/E;'4WZ9!]*^FPA2/IT(T;Z?B5$^X@F0?N3*$#[
MGBD^_*LJ/?RY*SO]RRL[_>(K.OST*SK\]RLZ_/<K.OSW*SK\]RLZ_/<K.OSW
M*[VH  "NL   H;P  )7(  ")U   ?N@% '?_$@%O_QP"9_\F!6#_+PA9_S<+
M5/\_#D__1Q%+_TX31_]6%43_719"_V080/]L&3W_=1H[_WX;.?^)'#?_E!TV
M_Z >-?^L'S/_N1\S_\@?,O_B(#+_YR R_^<@,O_G(#+_YR R_^<@,O_G(+"M
M  "BMP  E<0  (?0  ![W0  <OT) &K_$0%A_QD"6O\B U3_*@5._S('2?\Z
M"47_00M!_T@,/O].#CO_50\X_UL0-O]B$33_:1$R_W(2+_][$RW_AA0K_Y(5
M*O^>%2G_J18H_[,6)__"%B?_QQ8G_\<6)__'%B?_QQ8G_\<6)__'%J2T  "6
MP   A\P  'K:  !MZP  9/\% %S_#@%4_Q0!3?\< DC_) 1"_RP%/O\S!CK_
M.0<V_T (,_]%"##_2PDN_U$**_]7"BG_70LG_V0+)/]L#"+_=@T@_X -'O^,
M#AW_EPX<_Z$.&_^L#QO_K@\;_ZX/&_^N#QO_K@\;_ZX/&_^N#Y>\  "(R0
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M5GF!_U%Y@?]1>8'_47F!_U%Y@?]1>8'_4?]E$P'_=0X _X,. /^0#@#UFPX
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M4F&8_U)AF/]289C_4O]R"P#_@P4 WY,! -&?! #)J@8 P;(% +N]! "TOQ@
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M3KG_2>^%  #4E0  QZ,  +JL 0"PM   I[\# )[)!@"5U L D-4= 8G4+@:
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M(C?YR"(V^>,B-OCS(C;W_"(V]_PB-O?\(C;W_"(V]_PB-O?\(K>F  "IK@
MG+D  )#$  "#SP  =]L  &_V"@!G_Q,!8/\= EK_)P-4_S %3_\X"$K_0 I&
M_T@,0_]/#D#_5@\]_UX0._]E$CC_;A,V_W<4-/^"%3+_CQ8P_YL7+_^I%R[_
MMQ@M_\@8+/_A&"S_[Q@L_^\8+/_O&"S_[Q@L_^\8+/_O&*NK  ">M0  D,$
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M_QG_/?\9_SW_&?\]_QG_/?\9_SW_&?] *@+_02X#_T<N _]*,03_3#<&_TM
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M28ET_T2(=/]#B'3_0XAT_T.(=/]#B'3_0_]=$@'_:PX _W@. /^##P#]C!
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M1W*$_T=RA/]'<H3_1_]F#0#_=0< ]H,% -R/ P#2F 8 S*$' ,BH" "_J1H
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M/$/%WSQ$Q/,[1,/_.47"_S=%P?\W1<'_-T7!_S=%P?\W1<'_-]6+  #%F@
MMZ0  *NL  "@M   EKX  (O'! "!T @ >-D. '79( %OV"\$:=@\"6/61A!>
MUE 56=58&E748!]1U&@B3M1Q)DO3>RE(TX4K1=.2+D+4GR]!U*\P/]7",3_5
MX3 _T_(P/]+]+S_1_RX_T/\N/]#_+C_0_RX_T/\N/]#_+LJ4  "[H0  K:D
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M$2;_\A$F__81)O_V$2;_]A$F__81)O_V$:>I  "9LP  B[X  '[)  !PTP
M9-X  %CG  !2_PD 3?\1 $?_&0%#_R(!/O\J CK_,@,W_SD#,_\_!##_1@4M
M_TT%*_]4!BC_6P<F_V,'(_]M""'_>0D?_X<)'O^5"AW_HPH<_[$*&__ "QK_
MU@L:_]\+&O_?"QK_WPL:_]\+&O_?"YNQ  "-O   ?L<  '#2  !CW@  5>0
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M.9ME_S:;9?\SFV7_,YME_S.;9?\SFV7_,_]5$P'_8 X _VL. /]T$ #_>Q(
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M.H!U_SJ =?\Z@'7_.O]=#@#_:@8 _W8& .2  P#9B08 TH\( ,^4"@#%EAL
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M1U";T4=1F^Y$4YO\0%6;_SQ6F_\Z5IO_.E:;_SI6F_\Z5IO_.O%T  #9@P
MR)   +Z:  "SH0  JJ<  *&N  "7M08 DK88 (RU*@.%M#<)?K)"$7>P3!AQ
MKE0?;*U;)6>K8BIBJFDO7JEQ,UJH>C=6IX,Z4Z:./5"FFT!-I:E!2Z6Z0DNF
MT4)+I>T_3:7\/$ZD_SE/I/\W3Z3_-T^D_S=/I/\W3Z3_-^1Z  #/B0  PI4
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M)3O+_R4[RO\E.\K_)3O*_R4[RO\E.\K_)<.3  "UG@  J*8  )VN  "1M@
MA;\  'G'  !OS@0 9-8) %[>$0!;WB  5]XM E/?.@10WT0&3-]."4G?5PQ&
MWU\/0]]H$4'?<1,^WWP5/-^)%SK@EADXX*4:-^"W&C;AS1HVW^P:-=[Y&C3=
M_QLTW/\;--S_&S3<_QLTW/\;--S_&[F<  "JI   GJL  )*U  "%O@  ><<
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M!A/_Z083_^D&$__I!I>O  "(N@  >L4  &S/  !>V@  4.   $3F   \]0
M-_\$ #/_#0 O_Q, *_\: "C_(0 E_R<!(?\M 1[_,@$;_S@!&?\_ 1;_1@(4
M_TT"$?]6 A#_8 (._VP"#/][ PO_BP,*_YH#"O^H PG_M0,(_\(#"/_" PC_
MP@,(_\(#"/_" XJX  ![PP  ;,X  %[;  !/X@  0N<  #;L   Q_P  +/\
M "?_!P C_PX (/\2 !S_&  8_QT %?\A !+_)@ 0_RP!#O\Q 0W_-P$*_SX!
M"/]& 07_3P$!_UD! /]F 0#_= $ _X(" /^0 @#_G ( _Z8" /^F @#_I@(
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M0XP7]$*4&/-!G!GQ0:,;[T"J&^Y LASM/[L=ZS_&'ND_U1[E/^@?XD#T'M]
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M)[-2_R2R4O\BLE+_(K)2_R*R4O\BLE+_(O]*%0'_4Q$ _UL/ /]B$@#_:!<
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M+(YE_RR.9?\LCF7_+/]5#@#_7P8 _VD& /1R!@#B> 8 VWP) -E_# #-@1T
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M1%]^ST1@?^Q 8H#\.F2 _S9E@?\S9H'_,F:!_S)F@?\R9H'_,O]D  #E<@
MTWX  ,>'  "^CP  MI4  *Z9  "FFPP H)P> )F;+@22F3L*BY9&$H643QE_
MD5<?>H]>)76.92IQC&PN;8IS,FF)>S9FB(0Y8H://5^%FC]<A:A!6H6W0EF%
MS$):A>H_7(;[.EZ&_S9?A_\R7X?_,E^'_S)?A_\R7X?_,OUH  #@=@  S8(
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M,DJ?_S!+G_\N2Y__+4N?_RU+G_\M2Y__+=UY  #)A@  O)(  +&:  "FH
MG*8  )&L  "&L@  ?;8- 'FV'0!UMBP";[4Y!FJT0PMELTP18+)4%ERQ6QI8
ML&,>5:]K(5&O<R5.KGTH2ZV(*DBME2U%K:,N1*VS+T.MR"]"K.<O0ZOY+42K
M_RM$JO\I1*K_*42J_RE$JO\I1*K_*=&   #!C0  M9@  *F?  ">I0  DZP
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M$R_4_Q,OU/\3+]3_$[.:  "FH0  FJD  (VQ  " N@  =,$  &C)  !<SP
M4M4# $C<" !%Y1( 0^4> $'F*@ ^YC4!.^<^ 3GG1P(WYU #-.A9!#+H8@4P
MZ&T&+NEY!RSIAP@KZI8)*>JG"BCJN@HGZ]8*)^GP"B?G_0DFYO\*)N;_"B;F
M_PHFYO\*)N;_"JB@  "<IP  C[   (*Y  !TP@  :,H  %O1  !/UP  1=T
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M 8:W  !WP0  :,P  %K7  !+W@  /N0  #+I   G[0  (_\  !__   ;_P4
M%_\, !3_$  1_Q0 #_\8  W_'0 +_R( "/\H  7_+@ "_S4  /\]  #_1P
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M+O\+[B[_"^TN_POL+O\*["[_"NPN_PKL+O\*["[_"O\U(@'_.QX!_S\= ?]
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M':)2_QVB4O\=HE+_'?]*#P#_4@H _UH) /]@"P#_90X ]6<1 .AH& #=9R0
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M.FUJSCIM:^LW;VW\,7!N_RUQ;O\J<6__*'%O_RAQ;_\H<6__*/]9  #K90
MVW   ,UX  #$?@  O((! +:$ 0"NA0X IX8@ *"%, .:@CT(DX!(#XY]416)
M>UD:A'E@'X!W9R-\=6XG>71U*G9S?2YS<H8Q<'&0-&UPG#=J;Z@Y:&^W.F=O
MRSIG<.DW:7'Z,FMR_RUL<_\J;'/_*&QS_RAL<_\H;'/_*/]<  #G:   U7,
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M,5F!_RU;@O\J6X+_*5N"_RE;@O\I6X+_*>QF  #8<P  QWX  +R'  "SC@
MJ9(  *"5  "6F $ D)D3 (J9) &%F#($?Y8^"7F42 YTDU 4;Y%7&6N07AUH
MCF4A9(UM)6",=2A=BWXK6HJ(+E>)E#%4B:$S4HBP-%&(PS50B.(T4HCV,%.(
M_RQ4B/\I58C_*%6(_RA5B/\H58C_*.9K  #0>   PH,  +>,  "MD@  HY8
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M($"D_R! I/\@0*3_(,I^  "[BP  KY4  *2;  "9H0  CJ8  (*L  !WL0
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M!:2>  "8I0  BZX  'VV  !PO@  8\8  %;+  !+T   0-4  #;<   OY0<
M+>T0 "ON&  I[B( )^\K "7O-  C\#P (?!% !_Q3@ =\E@!&_)D 1GS<0$8
M\X$!%_22 A7TI0(4];H"$_76 A/T[P(2\OP"$O#_ A+P_P(2\/\"$O#_ IJD
M  "-K0  ?[8  '&_  !CQP  5LX  $G3   ]V@  ,]\  "KC   F] 4 )/L-
M "'\$P >_1L '/TB !G^*0 7_C$ %?\Y !/_00 1_TH $/]5  [_80 ,_V\!
M#/^  0K_DP$)_Z8!"/^Z 0?_U $'_^L!!O_V 0;_]@$&__8!!O_V 8^L  "
MM@  <K\  &/)  !6T0  2-@  #O=   PX@  )N8  !_P   <_P  &?\) !;_
M#@ 4_Q, $?\9  __'@ -_R0 "_\K  G_,@ &_SL  _]$  #_3P  _UP  /]K
M  #_?0  _Y   /^C  #_M   _\8  /_6  #_U@  _]8  /_6 (*U  !SOP
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M+/\(W2S_"-TL_PC=+/\(W2S_"/\U&@#_.A8 _ST4 /\_%P#_01\ _T$I ?]
M- '_/4$"_SI- _PX6@7X-F4&]#5Q!_$T>PCO,X0)[3.-">LRE KI,IL*Z#*B
M"^8RJ@OD,K(,XS*[#.$RR S?,MP,VC+L#=4S^ W2,_\-T#/_#,XS_PS--/\+
MS#3_"\PT_PO,-/\+S#3_"_\Y%@#_/A( _T$0 /]%$P#_2!L _T@D /]'+P'^
M1#L"]T)' _$_5 7L/F &Z#QK".4[=@GB.W\+X#J(#-TYD W;.9<.V3B>#]8X
MIA#4.*X1TCBW$= XPQ+..-,2RCCH$L<Y]Q+$.?\1PCK_$,$Z_P_ .O\.OSK_
M#K\Z_PZ_.O\.OSK_#O\]$P#_0@\ _T8- /]+$ #_3A8 _T\? /U.*0'T3#0!
M[$A! N9'3@3@15L&VT1F"=9"< S207D.ST""$,U BA'*/Y$3R3^9%,<^H!7%
M/J@6PSZQ%\$^O!? /LL8O3[B&+H^\A>W/_\6M4#_%+1 _Q.S0?\1LT'_$+-!
M_Q"S0?\0LT'_$/] $ #_1@P _TL* /]1#0#_4Q$ _U08 /-4(@#I4BT!X5 [
M =I/20/2354'S$M@"\A):@[%2',1PD=[$[]&@Q6]18L7NT63&+E$FAFW0Z(:
MM4.K&[1#MARR0\0=L$/9'JU#[1VK1?P:J47_&*A&_Q:H1O\5IT?_$Z='_Q.G
M1_\3IT?_$_]$#@#_2@@ _U & /]5"@#_6 T ]UD1 .I8& #?5R0 U%<U <Q5
M1 3&5% (P5);#+U091"Y3FT3MDUV%K1,?1BQ2X4:KTJ-&ZU)E1VK29T>J4BF
M(*=(L"&E2+TBI$C/(J%(Z"*@2?@>GTO_&YY+_QF=3/\7G4S_%IU,_Q:=3/\6
MG4S_%O]'"P#_30( _U0" /=:! #K70< YUT+ .%<$ #371X RETP <-</P2]
M6DP(MUA7#+-68!&O5&D4K%-Q%ZE1>!JG4( <I$^''J)/CR"@3I@AGDVA(YQ-
MJR2:3;@EF4S()I9,XB:53O4BE$__'Y10_QR44?\:E%'_&)11_QB44?\8E%'_
M&/])" #_4   ^U@  .5>  #=8@, UF,' -1A"@#*8AD PF,L ;MB.P.T8$@(
MKUU3#*I;7!&F6F05HUAL&*!7=!N=57L=FU2#()E4BR*64Y,DE%*=)9)1IR>0
M4;,HCE'#*8U1W2J,4O(FBU3_(HM5_QZ+5O\<BU;_&HM6_QJ+5O\:BU;_&O],
M! #_4P  [%P  -]B  #49@$ SF@% ,MG" #"9Q8 NF@H ;-G. .M944'J&-0
M#*-A61&?7V$5FUUH&)A<<!N56G<>DUE_(9!8AR..5X\EC%>9)XE6HRF'5J\J
MA56_*X16U2R#5^\I@UC^)(-9_R"$6O\>A%K_'(1:_QR$6O\<A%K_'/]. 0#_
M5P  Y5\  -AF  #.:@  QVP# ,-K!0"\;!( M&TE *UL-0.G:D('H6=-#)QE
M5A&88UX5E&)E&)%@;!N.7W0>C%Y[(8E=@R2&7(PFA%N5*(%:H"I_6JPL?5J[
M+7Q:SRY[6^PK?%S\)GQ=_R)]7O\??5[_'7U>_QU]7O\=?5[_'?]0  #U60
MX6,  -)J  #);@  PG ! +UP P"V<!  KG$B *AP,@*A;C\&G&Q*"Y=J4Q"2
M:%L4CF9B&(ME:1N(8W >A6)X(8)A@"2 8(DF?5^2*7M>G2MX7JDM=EZX+G5>
MS"]T7NDM=6#Z)W9A_R-W8O\@=V+_'G=B_QYW8O\>=V+_'O]2  #L7   W&8
M ,YM  #$<@  O70  +=T 0"P= X J74? *)T+P*<<CT%EW!'"I%N40^-;%D4
MB6I@%X5I9QN":&X>?V9U(7UE?21Z9(8G=V.0*75CFRQR8J<N<&*V+V]BR2]N
M8N8N;V3Y*'!E_R1Q9O\A<6;_'W%F_Q]Q9O\?<6;_'_]4  #H7P  UVD  ,IP
M  # =0  N7@  +)X  "K> T I'D= )YX+0&7=SH%DG5%"HQR3@Z(<%83A&]>
M%X!M9!I];&L=>FMS('=J>R-T:8,F<FB-*6]GF2QL9J4N:F:S+VEFQC!H9N0O
M:FCW*6MI_R5L:?\B;&K_(&QJ_R!L:O\@;&K_(/]7  #D8@  TFP  ,9S  "]
M>   M7L  *U\  "E? H GWT: )E\*@&3>S@$C7E#"8AW3 Z#=502?W-;%GMR
M8AEX<&D==6]P(')N>"-O;8$F;&R+*6ILERQG:Z,N96NR+V1KQ#!B:^$O9&SV
M*F9M_R9F;?\C9V[_(&=N_R!G;O\@9V[_(/99  #@90  SF\  ,)V  "Y?
ML7\  *F   "@@ < F8$7 )2!* &.@#4#B'Y!"(-\2@U^>E(1>GA9%79W8!ES
M=F<<<'1N'VUS=B-J<G\F9W&)*61QE2MB<*$M8'"P+UYPPB]=<-\O7W'U*F!Q
M_R9A<O\C8G+_(&)R_R!B<O\@8G+_(.]<  #<:0  RG(  +YZ  "U@   K80
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M'U"#_Q]0@_\?4(/_']YI  #)=0  O(   +*(  "HC0  G9$  ).3  "%E@
M?I<+ 'F7&0!UER@!<9<U VR6/P9HE4@*9)10#6&35Q%=DEX56I%F&%>0;AM4
MCW<>48Z!($Z.C2-+C9HE28VI)DB-NR='C=0G1XSP)$B,_R))B_\@2HO_'DJ+
M_QY*B_\>2HO_'M5N  ##>P  MX4  *R-  "BD@  EY8  (R9  !_G   =9X%
M '"?$P!MGR, :9\P 66>.P1AGD4'79U-"EJ<5 U7FUP15)IC%%&::Q=.F709
M2YA_'$B8BQY%EYD@0Y>H(4*7NB)!E],B09;O($*5_AY"E?\=0Y3_'$.4_QQ#
ME/\<0Y3_',QU  "\@0  L8P  *:2  ";EP  D9L  (6?  !YHP  :J<  &6G
M#@!CJ!P 8*@K 5VH-@)9IT $5J=)!E.F40E0IED,3:5@#DJE:1%'I'(41*1]
M%D*CB1@_HY<:/:.G&SRCN1P[H](;.Z+O&SN@_AH[G_\9/)__&#R?_Q@\G_\8
M/)__&,1\  "VB0  JI(  )^7  "5G   B:$  'VF  !QJ@  9*X  %JQ" !7
ML10 5;(C %.R, %0LCL"3;)$ TNQ305(L54'1;%="4.Q90M L&\-/K!Z#SNP
MAQ$YKY83-Z^F%#:ON!0UL-$4-:[O%#2M_A0TK/\4-*O_%#2K_Q0TJ_\4-*O_
M%+N%  "OD   HY<  )B=  ",HP  @*@  '2M  !HL@  7+8  %"Z 0!)O T
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M 1K?K $9W\0!&-[G 1C<^ $8V_\"%]K_ A?:_P(7VO\"%]K_ J"<  "4HP
MAZL  'FS  !LN@  7\$  %+&  !&R@  .\X  #'3   IV0  (=X% ![H#@ =
MZ!4 &^D> !GI)P 8ZC  %NHY !7K0P 4[$X $NQ: !'M9P 0[G< $.Z*  [O
MG@ .\+, #?#-  SO[  ,[?P #.O_  SK_P ,Z_\ #.O_ )>C  ")JP  >[0
M &V\  !?Q   4LH  $7.   YTP  +]@  "7=   =X0  &.P" !;W"P 4]Q$
M$?@7 !#X'@ .^24 #?DM  OZ-0 )^S\ !_M*  3\5P #_68  OYW  #]BP
M_9\  /RU  #\T0  _.T  /S\  #\_0  _/T  /S] (NK  !]M   ;KT  &#&
M  !2S0  1-(  #?8   LW0  (N$  !GE   3Z@  $/H   [_!@ -_PP "O\0
M  ?_%  $_QH  ?\@  #_)P  _S   /\Z  #_10  _U,  /]B  #_=0  _XH
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M'9)(V!V02>\;CTK^&(]+_Q:.2_\4CDS_$HY,_Q*.3/\2CDS_$O]%  #_2P
MZ5,  -Y8  #36P  S5L$ ,I8!P#"6!4 NEHG +-:-P&N6$0$J5=/!Z156 JA
M5& -GE-H$)M1;Q.84'85EE!^%Y1/AAF23HX:CTZ8'(U-HAV+3:X?BDV\((A-
MT""'3>L?AD_\&X90_QB&4/\6AE#_%(91_Q2&4?\4AE'_%/]'  #X3P  Y%<
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M('%<_QQQ7?\:<5W_&'%=_Q=Q7?\7<5W_%_U/  #E60  TV(  ,=H  "];
MMFT  *]L  "G:PL H&P9 )ML*@&5:S<"D&E#!8MH3 F'9E0,@V5;$(!C8A-]
M8FD5>F%P&'AA>!IU8($=<U^+'W!>EB)N7J(D;%ZP)6M>P29I7MXF:E_T(6M@
M_QUK8?\;;&'_&6QA_QAL8?\8;&'_&/51  #B7   SV4  ,-K  "Y;P  L7$
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M&EUM_QE=;?\976W_&>A:  #29@  PV\  +AV  "O>P  IGX  )U^  "1?
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M%\UM  "]>   L8(  *>*  "<C@  DI   (:3  !YE0  ;)<  &:7#@!CF!L
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M##&JL PPJL<,,*GG#"^G^@TOIO\-+Z7_#2^E_PTOI?\-+Z7_#;:$  "JC@
MGI0  )29  "'G@  >Z,  &^H  !CK   5Z\  $NR  !!M08 /K81 #VV'@ [
MMBD .K<T #FW/@ WMT< -K=0 32W6@$RMV0",+=O RZW? 0LMXL%*K><!2FW
MK@8HN,4%*+?F!2>U^0<FL_\')K+_"":R_P@FLO\()K+_"*^-  "BE   EYH
M (N@  !^I@  <:L  &6P  !9M   3;<  $*[   XO@$ +\() "W#$@ LPQX
M*\,I "K$,P IQ#T *,5' "?%40 FQ5P )<9H "/&=@$BQH8!(,:8 1_&JP$>
MQ\$!'L;D 1W$^ (<PO\#','_ QS!_P0<P?\$','_!*64  ":F@  CJ$  (&G
M  !SK@  9[0  %JY  !.O0  0L   #C#   OQP  )LL$ ![0"@ ;T1$ &M(:
M !G2)0 8TR\ &-,Z !?41  6U%  %=5= !35:P 3UGP $M>/ !'8I  0V;L
M$-G> !#5\P 0T_\ $-+_ 1#1_P$0T?\!$-'_ 9R:  "1H0  @Z@  '6P  !H
MMP  6[T  $[!  !"Q0  -\@  "W,   DT   '-4  !7:!0 0X@L $.,1  [D
M&@ .Y", #>4M  SE-P +YD( "N9/  GG70 (YVT !N:   7FE0 $YJL  N;$
M  'FY@  Y_D  .?_  #F_P  YO\  .;_ ).A  "%J0  =[$  &FY  !;P
M3L8  $'*   US@  *M(  "'6   9VP  $M\   WC   +\0@ "?,.  ?S$P $
M\AH  O(B  #R*@  \C0  /(_  #R3   \EP  /)M  #R@@  \I@  /.M  #S
MQ@  ].4  /3V  #T^P  ]/L  /3[ (>I  !YL@  :KH  %S"  !.R0  0,X
M #/3   HV   'MT  !7A   /Y   "N@   7S   #_0$  /P(  #[#0  ^Q$
M /L6  #\'@  _"8  /PP  #]/   _DD  /Y:  #^;0  _X(  /^8  #_K
M_\   /_8  #_Y   _^0  /_D 'NR  !LNP  7<0  $_-  ! T@  ,MD  ";>
M   ;X@  $N8   SJ   %[0   /0   #_    _P   /\   #_!   _PD  /\.
M  #_$@  _Q@  /\A  #_*P  _S<  /]&  #_6   _VL  /^   #_E0  _Z8
M /^S  #_NP  _[L  /^[ /\;)@#_'"0 _QHD /\5)P#_$"T _PHV /\%0P#_
M 5 !_P!> ?\ :P'_ '8!_P"! /\ B@#_ )( _P": /\ H #_ *8 _P"L /\
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M ?\,8@'_"VX!_PMY ?\+@@'_"XL!_PN2 ?\*F0'_"I\ _PJE /\*JP#_"K(
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M";$RY0FM,_4)JS/_":HS_PBH,_\'J#/_!Z<S_P>G,_\'IS/_!_\W!P#_.@
M_SX  /I! 0#Q008 \3\- .8\$@#;.A\ T#LQ ,H\0 #$/$T!P#Q8 KP[80.Y
M.VH%MCIR!K0Z>@>R.8$(L#F(":\YD JM.)@*JSBA"ZDXJ@RH.+8-ICC%#:0X
MW@ZA.?$-GSK_#)XZ_PN=.O\*G#K_"9PZ_PF<.O\)G#K_"?\[ @#_/@  ]T0
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M%8!*_Q* 2_\0@$O_#X!+_PZ 2_\.@$O_#O]#  #L2P  W5,  ,Y8  #$6@
MO5H  +A7 0"Q5 X JE8> *56+@"?5CL!FU5& Y=44 634U@(D%)?"HU19@R+
M4&T.B$]T$(9/?!*$3H43@DZ.%8!-F1=^3:08?$VR&7I-PQIY3=\:>$[T%WA/
M_Q1X3_\2>%#_$'A0_P]X4/\/>%#_#_U&  #G3P  UE<  ,A<  "_7P  MU\
M +%<  "J60P I%H: )Y;*@"96S@!E%I# Y!93 6,6%4(B5=<"H968PR#56H.
M@51Q$']3>1)]4X$4>E*+%GA2E1AV4:$9=%&O&W-1P!MQ4=L<<5+R&7%3_Q5Q
M5/\3<E3_$7)4_Q!R5/\0<E3_$/-(  #C4P  T%L  ,1@  "Z8P  LV,  *QA
M  "D7@D G5\7 )A?)P"37S4!CEY  XI=2@6&7%('@UM9"H!:8 Q]66<.>UAN
M$'A8=1)V5WX4=%:(%W)6DQAO5I\:;E6L&VQ5O1QK5M4=:U;P&FM7_Q=K6/\4
M;%C_$FQ8_Q%L6/\1;%C_$?%+  #?5@  S%X  ,!D  "W9P  KF@  *=F  "?
M8@8 F&,4 ))D) "-8S(!B6(] H1A1P2!8$\'?5]6"7I>70MW760-=5QK$'-<
M<Q)P6WL4;EN%%VQ:D!EJ6IP;:%FJ'&9:NAUE6M$=95KN&V5;_A=F6_\59ES_
M$V=<_Q)G7/\29US_$NU.  #:60  R&$  +QG  "S:@  JVP  *)J  "99P(
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M$]Q<  #'9P  N6\  *]V  "E>P  G'P  )%\  "">   >GD' '5Y% !R>B,
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M%$""KA4_@\(5/H+B%3^!]Q,_@?\20(#_$4" _Q! @/\00(#_$,9K  "W=@
MK'\  **%  "7B0  C(L  (&-  !SC@  98\  %V/"0!:D!0 6) A %:1+0!3
MD#@!49!! DZ020-,D% $2H]8!4>/8 =%CFD)0HYS"T"-?PT^C8T//(V<$#J-
MK!$YC<$1.(WA$#B+]A XBO\/.8G_#SF)_PXYB?\..8G_#K]R  "R?0  IX8
M )R*  "1C@  AI$  'J3  !ME0  7Y<  %29 0!/F0\ 3IH: $R:)P!*FC(
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M B&O\P,@KO\#(*W_!!^L_P0?K/\$'ZS_!*J+  "=D0  DY<  (><  !ZH@
M;:<  &"K  !5KP  2;$  #ZT   SMP  *KH# "2\#0 BO14 (;T@ "&]*@ @
MO3, '[X] !Z^1P =OE( '+]> !J_;  9OWP &+^. !? H0 6P+8 %,#3 !6^
M\0 5O/\!%;O_ 12Z_P(4NO\"%+K_ J&2  "6F   BIX  'VD  !OJ@  8J\
M %:T  !*MP  /KH  #.]   JP   (<0  !G'!0 3RPL $<P2 !',&P 0S"4
M#\TO  [-.@ .S48 #<U2  W.8  ,SG  "\Z#  K.EP )SJP ",[&  C.Z  (
MS?L "<O_  G+_P )R_\ "<O_ )B8  "-G@  ?Z4  '&L  !DLP  5[D  $J]
M   ^P   ,L,  "C&   ?R@  %\T  !'1   ,U@4 "-D,  ;9$@ %VAL !-HD
M  /;+@ !VSD  -Q%  #=4@  WF(  -YS  #>B   WYT  -^S  #?S@  X.X
M -_Z  #?_P  W_\  -__ (^?  "!I@  <ZX  &6U  !8O0  2L(  #W%   Q
MR0  )LP  !W0   4U   #MD   G=   #X0   .,'  #C#0  Y!(  .49  #F
M(@  YRL  .DV  #K0P  [%(  .QB  #M=@  [HP  .ZA  #OMP  []$  ._K
M  #P]@  \/8  /#V (2G  !UKP  9[<  %F_  !+Q@  /,H  "_.   DT@
M&M@  !+<   ,X   !>,   #G    ZP   .L   #M!0  [@L  / 0  #Q%0
M\QX  /0G  #W,P  ^4   /I1  #[8P  _'<  /V-  #]HP  _K8  /[)  #_
MWP  _]\  /_? '>P  !HN0  6L$  $S*   \SP  +M0  "+:   7W@  $.(
M  GF    Z0   .P   #P    ]@   /8   #W    ^    /H'  #[#0  _1$
M /\9  #_(P  _R\  /\^  #_3P  _V(  /]W  #_C0  _Y\  /^N  #_N@
M_[H  /^Z /\6(P#_%2$ _Q(A /\.) #_!BH _P S /\ 00#_ $X _P!< /\
M: #_ '0 _P!^ /\ AP#_ (\ _P"6 /\ G #_ *( _P"H /\ K@#_ +4 _P"]
M /\ QP#_ -8 _P#G /X \P#^ /X _0#_ /P _P#[ /\ ^P#_ /L _P#[ /\
M^P#_ /\:( #_&1X _Q8> /\0( #_"B4 _P0P /\ /0#_ $L _P!8 /\ 9 #_
M '  _P!Z /\ @P#_ (L _P"2 /\ F #_ )X _P"D /\ J@#_ +$ _0"Y /L
MPP#Z -  ^ #C /< \0#V /P ] #_ /0 _P#S /\ \P#_ /, _P#S /\ \P#_
M /\=' #_'!D _QD9 /\4&P#_#B$ _PPL /\).0#_!48 _P)3 /\ 7P#_ &L
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M -P,_P#<#/\ W S_ /\C$@#_(Q  _R$. /\>$ #_'A@ _QPC /\8+P#_%#L
M_Q)) /P050#X#V  ] ]J /$/= #O#GP [0Z$ .L.BP#I#I( YPZ9 .8.H #D
M#J< X@ZO . .N #>#L4 W [: -80[ #2$?H SQ+_ ,T2_P',$O\!RQ/_ <H3
M_P'*$O\!RA+_ ?\G#P#_)PP _R4) /\F#0#_)1, _R,< /\@* #['#4 ]1I"
M .\83P#J%UH YA9E .,6;@#@%G< WA9_ -P6AP#9%HX UA:5 -06G #2%Z,
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M!/\R  #_,P  ^3@  .DY  #B.0  WC4' -XN#0#1+QL R3$L ,,S.P"],T@
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M#8@^Q Z&/^ .A#_T#8- _PN#0/\*@D#_"8)!_PB"0?\(@D'_"/\\  #K0P
MW$H  ,Q/  ##4   O$X  +=) 0"Q1@X JD@< *1)+ "@23H FTE% 9A(3@*4
M1U<#DD=>!8]&90:-1FP'BT5S"8E%>PJ'1(,+A42-#(-$EPZ!0Z(/?T.O$'Y#
MP!!\1-H1>T3Q#WI%_PUZ1O\+>D;_"GI&_PEZ1O\)>D;_"?4^  #F2   TT\
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M%&52^Q%F4_\/9E/_#693_PQF4_\,9E/_#.I)  #54P  Q5H  +I?  "P8@
MJ&(  )]?  "66@  CUH0 (I;'@"%6RP @5LX 7U;00)Z6DH#=UE1!'186 9Q
M6%\';U=F"6U7;0MK5G8-:59_#V=5BA%E59<38U6D%&%5M!5@5<@67U7G%6!6
M^A)@5O\/85?_#F%7_PUA5_\,85?_#.=,  #15@  P5X  +9C  "M9@  I&8
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M#E)B_PU28O\-4F+_#=E6  #$8   MV@  *QN  "C<0  FG,  (]Q  !_:P
M>&L% ')K$@!N;!\ :VPL &AL-P%F;$ "8VM( V!K3P1>:E8&7&I=!UEI90E7
M:6T+56EW#5-H@@]0:(\13F>=$TUGK!1+:, 42VC>%$MG]1),9_\/3&?_#DUG
M_PU-9_\-36?_#=):  # 9   LVP  *ER  "@=@  EG<  (IV  !Y<0  <7$
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M"\!I  "R=   IWP  )V!  "2A   AX8  'N'  !NAP  8(<  %6' 0!0B X
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M B:>H0(DGK4"(Y[. B.=[@,CF_X#(IK_!"*9_P0BF?\$(IG_!*R!  "@B
ME8X  (N2  !_E@  <IH  &6=  !9H   3J,  $*D   WI@  +J@% "FI#P H
MJ1@ )ZHB ":J+  EJC4 )*H_ ".J2  BJU, (:M> ""K:@ >JWD ':N+ !NK
MG0 :J[$ &:O* !FJ[ $9J/T!&*?_ ABF_P(8IO\"&*;_ J6)  "9CP  CY0
M (.9  !UG@  :*(  %RF  !0J0  1*P  #FN   OL   )K,  !ZU!@ 9MP\
M&+<7 !>W(0 6MRH %;<T !2X/@ 3N$D $KA4 !*Y8@ 1N7$ $+F#  ^YEP .
MN:P #;G$  VXYP .MOL #K7_  ZT_P .M/\ #K3_ )R0  "2E0  AIL  'F@
M  !KI@  7JL  %*O  !&L@  .K4  "^W   EN@  ';T  !7    0PP8 "\8.
M  K%%0 )Q1X ",4H  ?%,@ &QCT !<9)  7&5P #QF8  L9W  '&BP  QJ
M ,6V  #&T@  Q>\  ,7\  #%_P  Q?\  ,7_ )66  ")G   >Z,  &VI  !@
MKP  4[0  $:X   ZNP  +KX  "3!   ;Q   $\<   [*   (S@$  = *  #0
M$   T!8  -$>  #2)P  TS$  -0\  #520  UE@  -9I  #6?   UI(  -:G
M  #6OP  UN   -;S  #6_@  UO\  -;_ (R=  !^I   ;ZL  &&R  !4N0
M1KT  #G!   MQ   (L<  !G+   1S@  #-(   75    VP   -P#  #="@
MW@\  -\4  #A'   XB0  .0N  #F.@  YTD  .A9  #H:P  Z8$  .F8  #I
MK0  Z<4  .GB  #I\@  Z?4  .GU ("E  !QK0  8[4  %6\  !'P@  .<8
M "S*   @S@  %M(   _6   (VP   -\   #C    Y0   .<   #H 0  Z@<
M .L-  #M$0  [Q@  /$A  #S*P  ]C@  /=(  #X6@  ^6T  /J$  #ZFP
M^J\  /K"  #ZV@  ^M\  /K? '2N  !EM@  5KX  $C&   YRP  *]   !_4
M   4V@  #=\   7C    Y@   .D   #M    [P   /$   #S    ]0   /8"
M  #X"0  ^@X  /T3  #_'   _R@  /\V  #_1P  _UH  /]N  #_A0  _YH
M /^K  #_N0  _[P  /^\ /\1( #_$!X _PP> /\$(0#_ "< _P P /\ /@#_
M $P _P!9 /\ 90#_ '  _P!Z /\ @P#_ (L _P"2 /\ F #_ )X _P"D /\
MJ@#_ +  _P"X /\ P@#_ ,X _P#B /X \ #] /L ^P#_ /L _P#[ /\ ^@#_
M /H _P#Z /\ ^@#_ /\4' #_$AH _PX: /\(' #_ "$ _P M /\ .@#_ $@
M_P!5 /\ 80#_ &P _P!V /\ ?P#_ (< _P". /\ E #_ )H _@"@ /T I@#\
M *P ^P"T /D O0#X ,D ]P#< /4 [ #S /@ \P#_ /( _P#Q /\ \ #_ /
M_P#P /\ \ #_ /\7& #_%18 _Q$5 /\,%P#_!1T _P H /\ -@#_ $, _P!0
M /\ 7 #_ &< _P!Q /\ >@#\ (( ^@") /@ D #W )8 ]0"< /0 H@#S *@
M\0"P /  N #N ,, [ #3 .H YP#I /4 YP#_ .8 _P#E /\ Y0#_ .4 _P#E
M /\ Y0#_ /\:$P#_&!$ _Q00 /\/$0#_#1D _PHD /\%, #_ 3X _P!+ /\
M5P#^ &( ^@!L /4 =0#R 'T \ "$ .X BP#L )$ ZP"7 .D G@#G *0 Y@"L
M .0 M #B +\ X #- -X XP#< /( V@#] -@ _P#6 /\ U0'_ -4!_P#5 O\
MU0+_ /\>$ #_' T _Q<+ /\5#@#_%!4 _Q$? /\.*@#_"S@ _0A% /@&40#T
M!%P [@1F .H$;P#F W< Y 1_ .($A@#@!(P W@23 -T%F@#;!:  V 6H -4%
ML0#2!;L T ;) ,X'X #,"/$ R0K_ ,<+_P#&#/\ Q0S_ ,4,_P#%#/\ Q0S_
M /\A# #_( 8 _QP# /\="@#_&Q  _Q@8 /\4(P#V$3  [PX^ .H.2@#E#58
MX0U@ -T-:0#9#7$ U0UY -,-@0#1#8@ SPV/ ,T.E@#+#IT R@ZE ,@.K@#&
M#[D Q!#( ,(0WP"^$?( NQ+_ +D3_P"W$_\!MA/_ ;83_P&V$_\!MA/_ ?\E
M!@#_(P  _R,  /\D P#_(0H _1T1 /$:&P#H%B< X10U -H30P#3%$\ SA59
M ,L58P#(%FL Q19S ,,7>P#!%X( P!B) +X8D "\&)@ NQF@ +D9J0"W&;0
MM1K" +0:U@"P&^T!K1S\ :L=_P&I'?\!J1W_ :@=_P&H'?\!J!W_ ?\H  #_
M)P  _BH  .\J  #G)P$ YR() .0=$ #9&QT SQTM ,D>/ #$($D OR!3 +PA
M70"Y(64 MR)M +4B= "S(GP L2*# ; BB@&N(I(!K".; :LCI &I(Z\!IR.\
M :8DS@&C).@"H"7Y IXE_P*=)?\"G"7_ ILE_P*;)?\"FR7_ O\L  #_+0
M[3(  .(T  #:,P  TRX# -(E"@#))1< P2<G +LI-@"V*D, LBM. *\K5P"L
M*V  JBMG :@K;P&F*W8!I"M] :,KA *A*XT"GRN5 IXKGP*<*ZH#FBNV YDL
MQP.7+.(#E"WU!)(M_P.1+?\#D"[_ Y M_P.0+?\#D"W_ _\P  #R,P  Y#H
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M2P  M4D  *]#  "I/@L HC\7 )U )@"8030 E$$_ )%!20&.05$!BT!9 HE
M8 .'0&<#A3]M!(,_=06!/WT&?SZ'!WT^D0A[/IP)>CZI"7@^N IW/\T*=3_J
M"G1 _ AT0/\'=$#_!G- _P9S0/\&<T#_!O$[  #?10  S$P  +]/  "V4
MKD\  *=*  "@1 < FD44 )5&(@"01C  C$<\ (E&10&&1DX!@T95 H%%7 -^
M16,$?$1J!'I$<05Y1'D&=T2""'5#C0ES0YD*<4.F"W!#M0QN1,D,;43G#&U%
M^@IL1?\(;$7_!VQ%_P=L1?\';$7_!^P_  #820  QU   +M4  "Q50  J50
M *%0  "92@( DDD1 (U*'P")2RP A4PX ()+0@%_2TH!?$I2 GE*6 -W2E\$
M=4EF!7-);09Q278';TA_"&U(B@EL2)8+:DBC#&A(L@UG2,4-9DGD#69)^ MF
M2?\)9DK_"&9)_P=F2?\'9DG_!^A#  #230  PE,  +=8  "M60  I%@  )Q5
M  "33@  C$X. (=/&P""3RD ?U U 'M0/P%X3T<!=D]/ G-.50-Q3EP$;TUC
M!6U-:@9K37(':4U\"&=,APIE3),+8TR@#6),KPYA3<(.8$WA#F!-]@Q@3O\*
M8$[_"6!._PA@3O\(8$[_".-'  #-4   OE<  +-;  "J70  H5T  )A:  "-
M4P  AE(, (!3& !\4R4 >50Q '54/ !S4T0!<%-, FU24P)K4ED#:5)@!&=1
M: 9E47 '8U%Y"&%1A I@4)$,7E">#5Q0K0Y;4< .6E'>#UI1]0Q:4O\*6U+_
M"5M1_PA;4?\(6U'_"-]*  #)4P  NUH  +!?  "F80  G6$  )1>  "(5P
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M",I8  "Z8@  KFD  *-N  ":<0  D'(  (1Q  !T:P  :6D  &-I"P!?:14
M7&HA %IJ+0!8:S8 5FL_ 55K1P%3:DX"46I5 T]J701-:F4%2FEN!DAI>0=&
M:88)1&F5"D-HI0M!:;<,0&G/#$!H[@M!:/\*06?_"4%G_PA"9_\(0F?_",5=
M  "V9@  JFT  *!S  "6=@  BW<  (!V  !P<@  97$  %QP!P!8<!$ 5G =
M %1Q* !2<3, 4'$\ $]R1 %-<4L!2W%3 DEQ6@-'<6($17!L!4-P=P9!<(0'
M/W"3"#UOHPD[<+4*.W#-"CIO[ D[;OX(.V[_"#MM_P<[;?\'.VW_![]B  "Q
M:P  IG,  )UY  "2>P  AWP  'M\  !M>@  8'@  %9W 0!0=PX 3G@8 $QX
M) !+>2X 27DW $AY0 !&>4@!1'E/ 4)Y5P)!>6 "/WAI SQX= 0Z>((%.'B1
M!C=XH0<U>+,'-'C+!S1WZP<T=OT'-'7_!S5U_P8U=/\&-73_!KEH  "M<0
MHGD  )A^  "-@   @H$  ':"  !I@0  6X$  %&!  !(@ H 18$3 $.!'@!"
M@BD 08(R $"".P ^@D, /8)+ #N"4P$Y@EP!-X)F C6"<0,S@G\#,8&.!#"!
MGP0N@;$%+8'(!2V!Z00M?_P%+7[_!2U]_P4M??\%+7W_!;-N  "H>   G7\
M )*#  "(A@  ?8<  '"(  !CB0  58H  $N*  !!B@( .XL. #F+%P XC"(
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M !"DX@ 1HO@ $:'_ !&@_P$1H/\!$:#_ :"&  "5C   C)$  '^5  !QF@
M9)X  %BA  !,I   0*8  #6G   JJ0  (JP  !FN   2L D $+$0 !"Q&  .
ML2( #K$K  VQ-0 -L4  #+%+  NQ6  *L6< "+%X  >QBP %L:  !+"U  2P
MT  $L.\ !:_^  :N_P &KO\ !J[_ )B.  "/DP  @I@  '6=  !GH@  6J<
M $ZK  !!K0  -:\  "NQ   AM   &+8  !&Y   -O , ![X,  .]$@ !O1D
M +XB  "^*P  OC8  +Y!  "_3@  OUP  +]M  "_@   OI4  +ZJ  "^P@
MO>0  +WV  "]_P  O?\  +W_ )*4  "%F@  >*   &JF  !<JP  3[   $*S
M   UM@  *K@  ""[   7O@  $,$   O$   $QP   ,D'  #)#0  R1(  ,H9
M  #+(@  RRL  ,TU  #.00  SE   ,]@  #/<@  SX<  ,^=  #/LP  S\X
M ,_K  #.^   SOX  ,[^ (B;  !ZH@  ;*@  %ZO  !0M0  0KD  #6\   I
MOP  'L(  !7&   .R0  ",P   #0    TP   -4   #6!@  V P  -D1  #;
M%@  W!\  -XH  #@-   XD$  .)1  #C8P  XW<  .2.  #DI   Y+H  .74
M  #EZ@  Y?,  .7S 'RC  !NJ@  8+(  %&Y  !#O@  -<(  "C&   <R0
M$\T   S1   $U0   -H   #>    X0   .(   #D    Y0,  .<)  #I#@
MZQ(  .T:  #O)   \C$  /1!  #T4P  ]68  /5\  #VDP  ]JD  />\  #W
MS@  ]]\  /?? '"L  !AM   4[L  $7#   VQP  )\P  !O0   1U0  "ML
M  #?    X@   .4   #I    [    .T   #P    \0   /,   #U!   ]PH
M /H0  #\%@  _R$  /\N  #_0   _U,  /]H  #_@   _Y8  /^H  #_M@
M_[\  /^_ /\-' #_"AL _P(; /\ '@#_ "0 _P N /\ / #_ $H _P!6 /\
M8P#_ &T _P!W /\ ?P#_ (< _P". /\ E #_ )H _P"@ /\ I@#_ *P _P"T
M /\ O0#_ ,D _@#= /T [0#\ /H ^P#_ /H _P#Y /\ ^@#_ /H _P#Z /\
M^@#_ /\0&0#_#1< _P86 /\ & #_ !X _P J /\ -P#_ $4 _P!2 /\ 7@#_
M &D _P!R /\ >P#_ (( _P") /\ D #^ )8 _0"< /P H0#[ *@ ^0"O /@
MN #V ,, ] #2 /, YP#R /8 \ #_ .\ _P#P /\ [P#_ .\ _P#N /\ [@#_
M /\2% #_#Q( _PL2 /\ $@#_ !H _P E /\ ,P#_ $  _P!- /\ 60#_ &0
M_0!M /L =@#Y 'T ]P"$ /4 BP#T )$ \P"7 /$ G0#P *, [@"J .P LP#J
M +T Z #+ .< X0#E /$ XP#] ., _P#B /\ X0#_ .$ _P#@ /\ X #_ /\4
M$ #_$0X _PT- /\'#P#_ A4 _P @ /\ +0#_ #H _P!' /D 4P#U %X \@!H
M /  < #M '@ ZP!_ .D A0#H (P Y@"2 .4 F #C )\ X0"F -\ K@#< +@
MV@#% -8 V0#4 .P T@#Y -$ _P#/ /\ S@#_ ,X _P#. /\ S@#_ /\7# #_
M% @ _P\% /\."P#_#!$ _P<: /\!)@#\ #0 ] !! .T 30#I %@ Y@!B .,
M:@#@ '( W@!Y -L @ #9 (8 U@"- -, DP#1 )H SP"A ,T J@#+ +, R0"_
M ,8 T #% .@ PP#V ,$ _P#  O\ OP/_ +\#_P"_ _\ OP/_ /\;!@#_%P
M_Q0  /\3!0#_$0T _PX4 /D*'P#P!BP Y@,Y . #1@#< U$ U@1; -($9 #/
M!6P S 5S ,H%>@#(!8$ Q@6' ,4&C@##!I8 P0:= +\&I@"]!K  NP>\ +D(
MS0"X"N4 M0OW +,-_P"Q#?\ L W_ + ._P"O#O\ KP[_ /\>  #_&P  _QL
M /H:  #U%@4 ]A$- .L.%0#B"R( V LQ - ,/@#+#4H QPU5 ,0.7@#!#F8
MOPYM +T.= "[#WL N0^" +<0B@"V$)$ M!": +(0HP"P$:T KQ&Z *T1R@"J
M$N4 IQ3W *45_P"C%?\ HA7_ *(5_P"B%?\ HA7_ /\B  #_(   \",  .8D
M  #@(0  W!D% -L0# #0$1D R!,I ,(5-P"]%D0 N1=. +475P"S&&  L!AG
M *X8;@"L&74 JQE\ *D9A "H&HP IAJ4 *0:G@"C&Z@ H1NT )\<Q0">'-\
MFAWS 9@>_P&7'O\!EA__ 94?_P&5'_\!E1__ ?\F  #T)P  YBT  -HO  #/
M+0  RB<  ,<?" #!'!, NAXB +0?,0"O(#T JR%( *@B4@"F(EH HR-B *$C
M:0"@(V\ GB-W )PC?@";(X8 F22/ 9<DF0&6)*,!E"2P 9(EOP&1)=8!CB;O
M 8PG_P*+)_\"BB?_ HDG_P*))_\!B2?_ ?HI  #L,   W38  ,TX  #$-P
MOC(  +HK @"U)0X KB<= *@I*P"D*C@ H"I# )TK3 ":*U4 F"M< )8K8P"4
M*VH!DBMQ 9 L> &/+($!C2R* 8LLE **+)\"B"RK H8LN@*%+<X#@R[J X$N
M_ . +O\"?R[_ G\N_P)^+O\"?B[_ O0N  #D-P  TCT  ,4_  "[/P  M#P
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M!&9 _P1F/_\$9C__!.4]  #/1@  OTP  +1/  "J4   HD\  )E*  "11
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M!=!+  "_5   LEH  *=>  "=8   E&   (E=  !\5P  <E0  &Q3#@!H5!D
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M!D->H =!7K$'0%[(!T!>Z = 7?P&05W_!4%=_P5!7/\%05S_!<-6  "T7P
MJ&8  )YJ  "5;0  BFT  ']L  !O9P  9&0  %MB!0!68A  5&(; %)C)0!0
M8R\ 3F0X $UD0 !+9$@ 2F1/ 4AD5P%&9%\"161H D-D<P-!8W\$/V..!3UC
MG@8\8[ &.V3&!CMDY@8[8_H%.V+_!3MB_P4\8?\$/&'_!+Y;  "P8P  I6H
M )MO  "1<@  AG(  'MQ  !L;0  8&L  %5I  !/: T 36D7 $MI(0!):BL
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M B9[X0(F>O<")GC_ B9X_P(G=_\")W?_ JYL  "C=@  F7P  (Y_  "$@@
M>(,  &R$  !?A   480  $>$   \A   ,X0) #"$$0 OA!H +80D "R%+0 K
MA34 *H4^ "F%1P HAE  )X9: ":&9@ DAG, (X:# "&&E0 @AJ<!'H:\ 1Z&
MW@ >A/4!'H+_ 1Z"_P$>@?\!'H'_ :AT  ">?0  DX(  (F%  !^B   <8H
M &6+  !8C   3(T  $".   VC@  +(\  "60#  CD!, (I < "&0)0 @D2X
M'Y$V !Z10  =D4D ')%4 !J18  9D6X &)%^ !:2D  5DJ0 %)&Y !.1V  3
MC_0 %([_ !2-_P 4C/\!%(S_ :-]  "8@P  CH@  (2,  !WCP  :9$  %V3
M  !0E0  19<  #F8   NF0  )9H  !V; @ 6G0P %9T3 !2=&P 3G20 $ITM
M !&>-P 1GD$ $)Y,  ^>6  .GF< #9YW  R>B@ +G9X "IVR  F=S  )G.P
M"IO^  N:_P +F?\ "YG_ )R$  "1B@  B(X  'N2  !ME@  8)D  %2<  !(
MGP  /*   #"A   FHP  ':4  !6G   0J04 "ZL-  BJ$P 'JAL !JHD  6J
M+@ $JC@  JI$  &J4   JEX  *IN  "J@0  JI4  *FJ  "IP0  J.0  *CV
M  "G_P  I_\  *?_ )6+  ",D   ?Y4  '&:  !CG@  5J(  $JF   ]J
M,:H  ":K   =K0  %+    ZR   )M0$  K8*  "V#P  MA4  +<=  "W)0
MMR\  +@Y  "X1@  N%0  +AD  "X=@  N(L  +>@  "WM@  M],  +;O  "V
M_   MO\  +;_ (^2  ""EP  =)T  &:B  !8IP  2ZP  #ZO   QL0  )K,
M !RV   3N   #;L   :^    P0   ,($  #""P  PQ   ,05  #$'   Q20
M ,8N  #(.@  R4<  ,E7  #):0  R7T  ,F4  #(J@  R,,  ,CD  #(]
MR/T  ,C] (69  !WGP  :*8  %JK  !-L0  /[4  #&X   EN@  &KT  !'
M   +PP   \<   #*    S0   ,X   #/ P  T D  -$.  #3$@  U1D  -<B
M  #:+0  W3D  -Y)  #>6@  WVX  -^%  #?G   W[(  -[+  #>Y@  W_0
M -_T 'FA  !KJ   7*\  $ZU  ! NP  ,;X  "3!   9Q0  $,@   G,
MSP   -,   #9    W    -T   #?    X0   .(%  #D"P  YA   .@6  #J
M(   [2L  / Z  #Q2P  \5X  /)S  #SBP  \Z(  /.V  #SR0  \^$  //A
M &VJ  !>L0  4+D  $&_   RQ   ),@  !?,   .T   !M4   #:    W@
M .(   #F    Z0   .H   #L    [@   /    #R    ] 8  /8,  #Y$@
M_!P  /\I  #_.@  _TT  /]B  #_>   _Y   /^C  #_LP  _\$  /_! /\'
M&0#_ 1< _P 7 /\ &@#_ "$ _P K /\ .0#_ $< _P!4 /\ 7P#_ &H _P!S
M /\ >P#_ (, _P"* /\ D #_ )8 _P"; /\ H0#_ *@ _P"O /\ N #_ ,0
M_@#5 /P Z@#[ /@ ^@#_ /D _P#X /\ ^ #_ /8 _P#S /\ \0#_ /\+%0#_
M!1, _P 3 /\ % #_ !H _P G /\ - #_ $( _P!/ /\ 6P#_ &4 _P!N /\
M=@#_ 'X _P"% /X BP#] )$ ^P"7 /H G0#X *, ]P"K /8 LP#T +X \P#,
M /$ XP#O /, [@#_ .T _P#L /\ ZP#_ .P _P#L /\ ZP#_ /\-$0#_"1
M_P / /\ $ #_ !8 _P B /\ +P#_ #T _P!* /\ 50#] &  ^@!I /@ <0#V
M 'D ] !_ /, A@#Q (P [P"2 .X F #L )\ ZP"F .D K@#G +@ Y0#% .,
MV@#A .T WP#[ -X _P#= /\ W0#_ -T _P#= /\ W0#_ /\/#0#_# L _P,)
M /\ # #_ !( _P = /\ *0#[ #< ^ !$ /4 4 #R %H [@!C .P :P#I ',
MYP!Z .4 @ #C (8 X0", -\ DP#= )D VP"A -D J0#5 +( T@"^ -  S@#.
M .8 S #V ,H _P#* /\ R0#_ ,@ _P#( /\ R #_ /\1" #_#0( _P<  /\%
M" #_  X _P 6 /< (@#O #  ZP ] .@ 20#D %0 X != -T 90#9 &T U0!S
M -( >@#0 (  S@"' ,P C0#* )0 R "; ,8 I #$ *T P@"X ,  QP"] -\
MO #Q +L _@"Y /\ N #_ +@ _P"X /\ N #_ /\4  #_#P  _PT  /\,  #_
M!PD ^ $0 .@ &@#C "@ W0 V -@ 0@#2 $T S@!7 ,H 7P#' &8 Q0!M ,,
M= #! 'H OP"! +T B "[ (\ N0"7 +< GP"U *@ LP"S +$ P@"O -@ K@+M
M *P#^P"K!?\ J@;_ *D&_P"I!O\ J0;_ /\6  #_$@  ]Q(  .P1  #F#@
MY08( -T#$@#4 R  S00M ,@$.@##!48 OP50 +P&6 "Y!F  MP=G +4';@"S
M!W4 L0A[ *\(@@"N"8H K F2 *H)FP"H"J4 I@JP *4+OP"C#-0 H0WM )\.
M_@"=#O\ G __ )L/_P";#_\ FP__ /\:  #W&0  ZAX  -\>  #5&@  T!,"
M ,X,"P#'"Q8 P TE +H.,@"V#C\ L@]) *\04@"L$%H JA!A *@1: "F$6\
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M 7@H_P%X*/\!>"C_ >\K  #=,P  RCD  +X[  "T.@  K38  *8O  "A* <
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M M8_  ##1P  M4P  *I0  "@4   ET\  (Y+  "$10  >D & '4_$0!Q0!P
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M TQ+GP1+2[ $2DO%!$E+Y@1)2_H$24O_ TI+_P-*2_\#2DO_ \A)  "X40
MK%<  *%;  "87   CEP  (-9  !V4P  :TX  &1-"@!?3!, 7$T> %I-* !8
M33$ 5DTZ %1-00!33D@ 4DY/ %!.5P%/3E\!34YH 4Q.<P)*3W\"24^- T=/
MG01&3ZX$14_#!$10Y 1$3_D$14__ T5/_P-%3O\#14[_ \1,  "U50  J5L
M )]>  "58   BV   (!>  !R5P  9U,  %Y1!P!941$ 5U$; %11)0!24B\
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M S1?W0,T7O4#-5W_ C5=_P(U7/\"-5S_ KA9  "J80  H&<  )9L  ",;@
M@6X  '9L  !G:0  7&8  %%D  !(8@D 1&(1 $)B&P!!8R0 /V,M #YC-0 ]
M9#T /&1% #MD30 Y9%4 .&1? #9D:0$U9'8!,V2% 3%EE0(P9:<"+V6[ BYE
MV@(N9/0"+F/_ B]C_P(O8O\"+V+_ K->  "G9@  G&T  )-Q  "(<P  ?7,
M ')R  !D<   6&X  $UL  !":@, /&D. #IJ%@ Y:B  .&HH #9K,0 U:SD
M-&M! #-L20 R;%( ,6Q< "]L9@ N;', +&R" 2ILDP$I;*4!*&RY 2=MU@$G
M:_(!)VK_ 2=J_P$H:?\"*&G_ JYD  "C;   F7,  (YV  "$>   >7D  &UX
M  !@=P  4W8  $AU   ^<P  -'(* #%S$0 P<QH +W,C "YS*P M=#0 +'0\
M "MT1  I=$T *'57 "=U8P E=6\ )'5_ ")UD  A=:( ('6W !]UT@ ?=/$
M'W/_ 1]R_P$@<?\!(''_ :EK  "><P  E'D  (I\  " ?@  ='\  &=_  !:
M?P  37X  $-^   X?0  +WT" "A]#0 F?10 )'T< "-^)0 B?BT (7XV "%^
M/P ??T@ 'G]2 !U_7@ <?VL &G]Z !E_C  7?Y\ %G^S !5_S@ 5?N\ %GS_
M !9[_P 6>_\ %WO_ *1R  ":>@  CW\  (6"  ![A   ;88  &"'  !4AP
M2(@  #R(   RB   *(@  ""(!0 :B0X &8D5 !B)'0 7BB8 %HHN !6*-P 4
MBD$ $XI, !*+6  1BV4 $(MU  ^+AP .BIL #8JO  R*R  ,B>H #8?\  Z'
M_P .AO\ #H;_ )][  "4@0  BH4  ("(  !SBP  98T  %F/  !,D   09(
M #22   JD@  (9,  !F4   2E@8 #I<.  V7%0 ,EQT #)<F  N7+P *ESD
M"9=$  B74  &EUX !9=N  .6@  !EI0  )6H  "5O@  E.   )3T  "3_P !
MDO\  9+_ )B"  ".B   A8P  '>/  !JD@  794  %"8  !$F@  .)L  "R<
M   BG0  &9X  !*@   -H@( !Z,+  &C$   HQ<  *,?  "C)P  HS$  *0\
M  "D2   I%8  *1E  "C=P  HXL  *.@  "BM@  H=(  *'P  "@^P  H/\
M *#_ )&*  ")C@  >Y(  &V7  !@FP  4YX  $:A   YHP  +:0  ".F   9
MJ   $:H   RL   %K@   *\'  "O#0  KQ$  + 8  "P(   L2@  +$R  "R
M/@  LDP  +);  "R;   LH$  +&7  "QK   L,8  +#H  "O]P  K_\  *__
M (R0  !_E0  <9H  &.?  !5I   1Z@  #JJ   MK   (JX  !BP   0LP
M"K4   *X    NP   +L   "\!P  O T  +T1  "^%@  OQX  , G  #!,@
MPD   ,-/  ##8   PW0  ,.+  ##H0  P[@  ,+7  #"[P  POH  ,'^ (&7
M  !SG0  9:,  %>H  !)K0  .[$  "VS   AM@  %KD   Z[   'O@   ,$
M  #%    QP   ,@   #)    R@4  ,L+  #-#P  SA0  - <  #3)@  UC(
M -A!  #84P  V68  -E\  #9E   V:L  -G#  #9X0  V?   -GT ':?  !G
MI@  6:P  $NR   \MP  +KH  "&]   5P   #<0   7'    R@   ,X   #2
M    U0   -8   #9    VP   -T   #?!P  X0P  .,1  #F&0  Z20  .PR
M  #M0P  [E8  .]K  #OA   [YP  .^R  #OQ@  []T  ._D &JH  !;KP
M3+8  #Z\   OP   (,0  !3(   ,S    M    #4    V0   -X   #B
MY0   .8   #H    Z0   .P   #N    \ (  /()  #U#P  ^!<  /PC  #_
M,P  _T8  /]:  #_<0  _XD  /^?  #_L0  _\   /_& /\ %0#_ !0 _P 4
M /\ %P#_ !T _P H /\ -P#_ $0 _P!1 /\ 7 #_ &8 _P!O /\ =P#_ 'X
M_P"% /\ BP#_ )$ _P"7 /\ G0#_ *0 _P"K /\ M #^ +\ _0#. /L Y@#Y
M /8 ^ #_ /< _P#W /\ ]P#_ /  _P#L /\ Z0#_ /\#$@#_ !  _P 0 /\
M$0#_ !< _P D /\ ,@#_ #\ _P!, /\ 5P#_ &$ _P!J /\ <@#_ 'D _0"
M /P A@#Z (P ^0"2 /@ F #V )\ ]0"F /0 K@#R +D \ #& .X W@#M /
MZP#^ .H _P#I /\ Z0#_ .< _P#C /\ X #_ /\'#@#_  T _P + /\ # #_
M !, _P ? /\ + #_ #H _P!& /X 4@#[ %P ^ !E /4 ; #S '0 \0!Z .\
M@0#N (< [ "- .H DP#I )H YP"A .8 J0#C +, X0"_ -\ T #= .D V@#Y
M -D _P#7 /\ U0#_ -4 _P#5 /\ U #_ /\)"@#_ 04 _P # /\ "0#_ !
M_P 9 /L )@#W #0 ] !  /( 3 #N %8 Z@!? .< 9P#D &X X@!T .  >P#>
M ($ W "' -H C0#6 )0 U "; -$ HP#/ *T S "X ,H QP#( .  Q@#S ,4
M_P## /\ PP#_ ,, _P## /\ PP#_ /\+ 0#_ P  _P   /\  P#_  L \P 2
M .X 'P#J "T Y@ Z .( 10#> $\ V0!8 -0 8 #1 &@ S@!N ,P = #* 'L
MR "! ,8 AP#$ (X P@"6 ,  G@"^ *< NP"R +D P "W -0 M0#L +, ^P"S
M /\ L@#_ +( _P"Q /\ L0#_ /\-  #_!@  _P,  /<   #T  , YP - .
M& #: "4 TP R ,X /@#* $D Q@!2 ,, 6@#  &$ O@!H +P ;@"Z '0 N ![
M +8 @0"T (@ L@"0 +  F0"N *( K "M *H N@"H ,L I@#F *4 ]P"D /\
MHP#_ *( _P"B /\ H@#_ /\0  #[#   [PX  .8-  #?"0  V@ & -  $0#)
M !T Q  J +\ -P"[ $( MP!+ +0 5 "R %L KP!B *T : "K &X J0!U *@
M>P"F (, I "+ *( E "@ )X G@&H )P"M0"; \8 F07B )@&] "6"/\ E0G_
M )0)_P"4"?\ E G_ /P1  #Q%0  XQD  -89  #,%0  QQ   ,0'"@"] Q0
MMP0A +(&+@"N"#H J@E$ *<)30"D"E4 H@I< * *8@">"VD G MO )L+=@"9
M#'X EPR& )8,D "4#)H D@VF )$-LP"/#<4 C0[B (L0]@")$/\ B!'_ (<1
M_P"'$?\ AQ'_ /89  #G(   UB0  ,@E  "_(@  N1P  +04 0"Q#0X J@X9
M *4/)P"A$#, G1$^ )H11P"8$D\ E1)6 ),27 "1$F, D!-I (X3< ",$W@
MBQ.! (D4BP"'%)8 AA6B (05L "#%L$ @1?= '\8] !]&?\ ?!G_ 'P9_P![
M&?\ >QG_ .\A  #=*0  RBT  +XO  "U+   KB<  *@@  "C%P@ GA83 )D7
M(0"4&2T D1HX (X:00"+&TD B1M0 (<;5P"%'%X A!QD ((<:P" '', ?QU\
M 'T=A@!\'I$ >AZ> '@?JP!W'[P =B#4 '0A\ !R(?\ <2+_ '$A_P!Q(?\
M<2'_ .@H  #2,   PC4  +<W  "M-0  I3$  )XK  "8(P( DAX0 (T@&P")
M(2< AB(R (,C/ "!(T0 ?B-+ 'PD4@![)%D >21? '<D9@!V)6X ="5W ',E
M@0!Q)HT ;R:9 &XFIP!M)[@ ;"?. 6HH[0%I*?\!:"G_ 6@I_P%H*/\!:"C_
M >$N  #+-@  O#L  +$]  "G/0  GSD  )<S  "/+0  B"<, (,G%@!_*"(
M?"DM 'DJ-P!W*C\ =2I' ',K3@!Q*U0 <"M; &XK8@!L*VH :RQR &DL?0!H
M+(D 9BV6 64MI %D+K0!8R[* 6$OZ0%@+_T!8"__ 6 O_P%@+_\!8"[_ =HT
M  #%/   MT$  *Q#  "B0P  F4   ) Z  "(-   @"X( 'HM$@!W+AX <R\I
M '$P,P!O,#L ;3!# &LQ2@!I,5$ 9S%7 &8Q7@!D,68 8S)O &$R>0!@,H4!
M7S*2 5TSH0%<,[$!6S3& 5HTY@%9-?L!637_ 5DT_P%9-/\!633_ =(X  #
M0   LT4  *A(  ">2   E48  (M   "".P  >34$ ',S$ !O-!H ;#0E &DU
M+P!G-3< 938_ &,V1@!B-DT 8#94 %\V6P!=-V, 7#=K %LW=@%9-X(!6#B/
M 58XG@%5.*\"5#G# E,YY )3.OD!4SG_ 5(Y_P%3.?\!4SG_ <T\  "\1
MKTD  *1,  ":3   D4L  (=&  !]0   <SL  &PX#0!H.1< 93DB &,Z*P!@
M.C0 7CH\ %TZ0P!;.DH 6CM0 %@[6 !7.V  5CMH %4\<P%3/'\!4CR- 5 ]
MG %//:P"3C[! DT^X0)-/O@"33[_ 4T^_P%-/?\!33W_ <E   "X2   K$T
M *%0  "740  CD\  (1+  !Y10  ;D   &8]"P!B/10 7ST> %P^* !:/C$
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M CY+V (^2O,"/DK_ CY)_P$_2?\!/TG_ ;U*  "O4@  HU@  )E;  "070
MAEP  'M9  !M4P  8D\  %=, 0!12@T 3DH5 $Q+'P!*2R@ 24LP $=+. !&
M3#\ 14Q& $1,3@!#358 0DU? $!-:@ _378!/4Z$ 3Q.E $[3J4!.4^Y CE/
MU (Y3_(!.4[_ 3E._P$Y3?\!.DW_ ;I.  "L5@  H5L  )=?  "-80  @V$
M 'A>  !I6   7U8  %12  !,3PL 24\2 $=0' !%4"4 0U M $)0-0!!43P
M0%%$ #]13  ^4E0 /%)= #M29P Z4G, .%." 3=3D@$U4Z0!-%.W 3-4T0$S
M4_$!-%/_ 312_P$T4O\!-%+_ ;92  "I6@  GF   )1D  "+9@  @&4  '1C
M  !F7@  7%P  %%8  !'50< 0E40 $!5&  _5B$ /58J #Q6,@ [5CD .E=!
M #E720 X5U$ -UA: #5890 T6'$ ,EB  3%8D $O6:(!+EFU 2U9SP$M6>\!
M+EC_ 2Y7_P$N5_\!+E;_ ;)7  "E7P  FV4  )%I  "':@  ?&H  '%H  !C
M90  6&(  $U?  !#70( /%L- #I<%  X7!T -UPF #5=+@ T738 ,UT^ #)=
M1@ Q7DX ,%Y7 "]>8@ M7FX +%]] "I?C@ I7Z  *%^S 2=?S  G7^T!)U[_
M 2==_P$H7?\!*%S_ :U<  "B9   F&H  (YN  "#;P  >6\  &YN  !@:P
M5&D  $EG   _90  -6,) #)C$0 P8QD +V0A "YD*0 M9#$ +&0Y "ME0@ J
M94H *&54 "=E7P F9FL )&9Z "-FBP B9IT (&:Q !]FR0 ?9NL (&7^ "!D
M_P @8_\!(6/_ :EB  ">:@  E7   (IS  " =0  =74  &ET  !<<@  3W$
M $1O   Z;@  ,&T# "EL#0 G;!0 )FP< "5M)  D;2P (VTT ")M/0 A;D8
M(&Y0 !YN6P =;F< '&YV !INAP 9;YH &&^N !9OQ@ 6;ND %VW\ !AL_P 8
M:_\ &&O_ *1I  ":<0  D'8  (9Y  !\>P  <7L  &1[  !7>@  2GD  #]X
M   U>   *W<  ")V!P ==@\ ''<6 !MW'@ :=R8 &7<N !AW-P 7>$  %7A*
M !1X5@ 3>&, $GAR !%X@P 0>)< #WBK  YXPP .=^8 #G;Z  ]U_P 0=?\
M$'3_ )]Q  "5>   BWP  ()_  !W@0  :H(  %V"  !0@@  1((  #B"   N
M@@  )((  !R"   4@@D $8,0 !"#%@ 0@QX #H,G  Z#,  -@SD #8-$  R#
M4  +@UT "8-L  B#?@ &@Y$ !8*E  ."NP $@=L !('R  6 _P &?_\ !G__
M )IY  "0?@  AH,  'V%  !OAP  8HD  %6*  !)BP  /8P  #&,   FC
M'8T  !6.   /CP, "I ,  :0$0 $CQ@  X\@  &/*0  CS(  ) ]  "020
MCU8  (]E  "/=@  CXH  (Z?  ".M   C<\  (SN  ",^P  B_\  (O_ )2
M  "+A0  @HD  '2,  !FCP  69$  $R3  ! E0  -)8  "B6   >EP  %9@
M  ^:   *FP   IP)  "<#@  G!,  )P:  "<(@  G2L  )TU  "=0   G4X
M )U<  "=;@  G($  )R7  "<K   F\8  )KH  "9^0  F?\  )C_ (Z(  "&
MC   >)   &J4  !<EP  3YH  $*=   VG@  *9\  !^A   5H@  #J0   BF
M    J    *D$  "I"@  J0X  *D3  "J&@  JB(  *LK  "L-@  K$0  *Q3
M  "L8P  K'<  *N.  "KI   J[P  *K>  "I]   J?T  *G_ (F.  ![DP
M;9<  %^<  !1H   1*0  #:F   JJ   'JD  !2K   -K@  !K    "R
MM0   +4   "U P  M@D  +<.  "X$@  N!D  +HA  "[*P  O#@  +U'  "]
M6   O6L  +V!  "]F0  O;   +W,  "\Z@  O/<  +O^ 'Z5  !PFP  8J
M %.E  !&J@  .*T  "JO   >L0  $[0   RW   #N0   +P   "_    P@
M ,(   ##    Q    ,8&  #'#   R!   ,H6  #,(   SRL  - Z  #12P
MT5X  -)S  #2BP  TJ0  -.[  #3V   T^T  -/V '.=  !DHP  5JD  $>O
M   YLP  *K8  !VY   2O   "K\   ##    Q@   ,D   #-    SP   -
M  #2    U    -8   #9 @  VP@  -X.  #A$P  Y!T  .@J  #H/   Z4\
M .ED  #J?   ZY4  .NL  #KP@  [-4  .SE &:F  !8K   2;,  #NY   K
MO   '<   !'$   )R    ,P   #/    TP   -D   #=    X    .$   #C
M    Y0   .<   #J    [    .X$  #Q"P  ]1(  /@<  #[*P  _3X  /Y3
M  #^:@  _X,  /^;  #_K@  _[X  /_* /\ $@#_ !  _P 1 /\ $P#_ !D
M_P F /\ - #_ $$ _P!- /\ 6 #_ &( _P!K /\ <P#_ 'H _P"! /\ AP#_
M (T _P"3 /\ F0#_ *  _P"G /X KP#\ +H ^@#) /D X0#X /, ]P#_ /8
M_P#U /\ \0#_ .D _P#D /\ X0#_ /\ #P#_  T _P - /\ #@#_ !0 _P A
M /\ +@#_ #P _P!( /\ 4P#_ %T _P!F /X ;0#\ '4 ^P![ /D @@#X (@
M]P". /8 E #T )L \P"B /$ J@#O +0 [0#! .L U0#J .P Z #\ .< _P#E
M /\ Y@#_ .  _P#9 /\ U #_ /\ "P#_  @ _P & /\ "0#_ !  _P < /\
M*0#_ #8 _P!" /L 3@#W %< ] !@ /( : #O &\ [0!V .P ? #J (( Z "(
M .< C@#E )4 XP"< .$ I #? *X W0"Y -H R@#7 .0 U #V -$ _P#0 /\
MT #_ ,\ _P#+ /\ QP#_ /\  P#_    _P   /\ ! #_  T ^@ 6 /8 (P#S
M #  \  \ .T 1P#I %$ Y0!: .( 8@#? &D W0!O -H =@#8 'P U "" -(
MB #0 (\ S0"6 ,L G@#) *@ QP"S ,4 P0#" -@ P #O +\ _@"^ /\ O0#_
M +P _P"\ /\ O #_ /\"  #_    _P   /\   #T  < [0 1 .@ ' #C "D
MWP U -L 00#6 $L T0!4 ,T 7 #* &, R !I ,8 ;P## '4 P0![ +\ @@"^
M (@ O "0 +H F "X *( M0"L +, N0"Q ,L KP#G *X ^ "L /\ JP#_ *P
M_P"L /\ JP#_ /\$  #_    ]@   .X   #G    WP , -8 %0#/ "( R@ N
M ,< .@## $0 P !- +P 50"Y %P MP!C +4 :0"S &\ L0!U *\ >P"M ((
MJP"* *D D@"G )P I0"F *, LP"A ,, GP#> )X \@"= /\ G #_ )P _P";
M /\ FP#_ /\'  #V"0  Z0L  -\*  #5!   S@ % ,8 $ #  !H NP G +<
M,@"S #T L !& *T 3P"J %8 J !< *8 8P"D &@ H@!O *$ =0"? 'P G0"$
M )L C0"9 )< EP"B )4 K@"3 +T D0#3 )  [0"/ /P C@#_ (T!_P"- ?\
MC0'_ /D.  #J$@  W!4  ,T5  #$$0  O@P  +H""@"T !( K@ > *H *@"F
M #4 H@ _ *  2 "= 5  FP)6 )D"7 "7 V, E0-I ),#;P"1!'8 D 1_ (X%
MB ",!9( B@:> (@&J@"&![H A0C/ (0*ZP"""_P @0S_ ( ,_P" #/\ @ S_
M /$5  #@'0  S2   ,$A  "X'0  L1<  *P0  "H"0T H@<6 )T)(P"9"BX
ME0LX ),,00"0#$D C@U0 (P-5P"*#5T B UC (<-:@"%#G$ @PYZ ((.A "
M#H\ ?@^; 'P/J ![$+@ >A#. '@1[ !V$O\ =1+_ '03_P!T$_\ =!/_ .@>
M  #3)@  PRH  +@J  "N*   IR,  * <  ";$P, E@\0 ) 0&P",$2< B1(R
M (83.P"$$T, @A1+ ( 440!^%%< ?!1> 'L590!Y%6P =Q5T '86?@!T%HH
M<A>6 '$7I !O&+0 ;AC) &T9Z !K&OP :AO_ &H;_P!J&_\ :AO_ . F  #*
M+0  O#$  + S  "G,0  GRP  )<F  "0'P  BA<, (48%@"!&2( ?AHL 'L;
M-@!Y&SX =QQ% '4<3 !S'%, <1U9 ' =8 !N'6< ;1YP &L>>@!J'H4 :!^2
M &<?H !E(+  9"'% &,AY !B(OH 82+_ &$B_P!A(O\ 82+_ -<L  ##-
MMC@  *HY  "A.   F#4  ) O  "(*   @"$( 'L@$@!W(1T ="(G '$B,0!O
M(SD ;2-! &LC2 !I(TX :"15 &8D6P!E)&, 8R5K &(E=0!A)8$ 7R:. %XF
MG0!=)ZT 6RC! %LHX !:*?< 62G_ %DI_P!9*?\ 62C_ ,\R  "^.0  L3T
M *8_  "</P  DSP  (HV  "!,   >2H# '(F#P!N)QD :R@C &DH+ !F*34
M92D\ &,I0P!A*DH 8"I1 %XJ5P!=*E\ 7"MH %HK<@!9+'T 6"R+ %8MF@!5
M+:H 5"Z] %,NW !2+_4 4B__ %(N_P!2+O\ 4B[_ ,HV  "Z/0  K4(  *)$
M  "81   CT$  (4\  ![-P  <C$  &LL# !G+14 9"T? &$N* !?+C$ 72XY
M %PO0 !:+T8 6"]- %<O5 !6,%P 53!D %,Q;@!2,7H 43&( % REP!.,J@
M33.[ $TTV !,-/, 3#3_ $PT_P!,,_\ 3#/_ ,8Z  "V0@  J48  )Y)  "5
M20  BT<  (%"  !W/0  ;3<  &0R"0!@,A( 73(< %HR)0!8,RT 5C,U %4S
M/ !3-$, 4C1* %$T40!0-%D 3S5A $TU; !,-G< 2S:% $HWE0!(-Z8 1SBX
M 4<XTP%&./$!1CC_ 48X_P!&./\ 1C?_ ,$^  "R10  IDH  )Q-  "230
MB$L  'Y'  !S0@  :3T  %\W!@!:-A  5S<8 %0W(@!2-RH 4#<R $\X.0!-
M.$  3#A' $LX3@!*.58 23E? $@Z:0!'.G4 13N# $0[DP!#/*0!0CRV 4$]
MT %!/? !03W_ 4$\_P%!//\!03S_ +Y"  "O20  HTX  )E0  "/40  A5
M 'M,  !O1@  94(  %H] @!4.PX 43L5 $\['P!-.R< 2SLO $D\-@!'/#T
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M #)(_P R2/\ ,TC_ +1,  "G5   G%D  ))<  "(70  ?ET  '-:  !E50
M6U(  %!.  !&2@4 0$D. #Y)%@ ]21X .THF #I*+@ Y2C4 .$L] #=+1  V
M2TT -$Q6 #-,8  R3&P ,4UZ #!-BP N39P +4ZO "Q.QP L3ND +$W] "U-
M_P M3/\ +4S_ +!0  "D6   F5T  (]A  "&8@  >V$  '!?  !B6P  6%@
M $Y5  !#40$ .T\, #A/$P V3QL -4\C #10*P S4#( ,E Z #%00@ P44H
M+E%3 "U270 L4FD *U)X "E2B  H4YH )U.M "93Q0 F4^< )E/\ "=2_P G
M4?\ )U'_ *Q5  "@7   EF(  (UF  "#9P  >&8  &UE  !@80  55X  $I;
M   _6   -58( #%5$  P5A< +E8? "U6)P L5B\ *U<V "I7/@ I5T< *%=0
M "986@ E6&< )%AU "-9A@ A69@ (%FK !]9P@ ?6>4 'UCZ "!8_P @5_\
M(5?_ *A:  "=8@  DV<  (IK  !_;   =6P  &IK  !=:   464  $9C   [
M8   ,5X# "I=#0 H71, )ET; "5>(P D7BH (UXR ")>.@ A7D, (%], !]?
M5P >7V, '&!Q !M@@@ 98)4 &&"I !=@P  68.( %U_Y !A>_P 97O\ &5W_
M *1@  "9:   D&X  (9P  !\<@  <G(  &9Q  !8;@  3&P  $%K   V:0
M+6<  "-F"  ?9@\ '685 !QF'0 ;9B4 &F8M !EG-0 89SX %V=( !9G4P 5
M:%\ $VAN !)H?P 1:)( $&BF  ]HO0 .:.  $&?W !!F_P 19?\ $67_ )]G
M  "6;P  C',  ()V  !X>   ;7@  &!W  !3=@  1G0  #MS   Q<@  )W$
M !YQ   6< H $W 0 !-P%P 2<!\ $7$G !!Q+P 0<3@ #G%"  YQ3@ -<5L
M#'%I  MQ>@ *<8T "'&A  9QM@ &<-( !W#O  AO_P );O\ "6[_ )MO  "1
M=0  AWD  'Y\  !T?@  9GX  %E^  !-?@  0'T  #5]   J?   (7P  !A\
M   1? 0 #'P,  I\$0 )?!D "'PA  =\*0 &?#( !'P]  -\2  !?%4  'QC
M  !\=   ?(<  'N<  ![L0  >LL  'GK  !Y^@  >?\  'C_ )9W  ",?
M@X   'F#  !LA   7H4  %&&  !%AP  .8<  "V'   CAP  &H<  !*'   -
MB $ !HD*  &)#P  B10  (@;  "((P  B2P  (DV  ")0@  B$X  (A=  "(
M;0  B($  (>5  "'JP  AL0  (7F  "$^   A/\  (3_ )!^  "'@P  ?H<
M '&)  !CBP  5HT  $F/   \D0  ,)$  "21   :D@  $I,   V4   &E0
M )8&  "6#   E1   )85  "6'0  EB0  )8N  "6.0  ED8  )95  "690
MEG@  )6.  "5I   E+P  )/?  "3]0  DO\  )+_ (N&  "#B@  =8T  &>0
M  !9E   3)<  #^9   RF@  )IL  !N<   2G0  #)\   2@    H@   *,!
M  "C!P  HPP  *,0  "D%0  I!P  *4E  "F+P  ICP  *9+  "F6P  IFX
M *6$  "EFP  I+,  */0  "C[P  HOP  *+_ (:-  !XD0  :I4  %R9  !.
MG0  0:   #.B   FHP  &Z4  !&G   *J0   :L   "M    KP   +    "P
M    L 4  +$+  "R#P  LQ0  +0;  "U)   MS   +<_  "W4   MV(  +=X
M  "WD   MJD  +;"  "VY   MO4  +7^ 'N3  !MF   7YT  %"B  !"I@
M-*D  ":K   :K0  $*\   FR    M    +<   "Z    O    +T   "^
MO@   , "  #!"   P@T  ,02  #&&0  R20  ,HR  #+0P  RU4  ,QJ  #,
M@P  S)P  ,NU  #,S@  S.D  ,SV '";  !AH0  4J8  $2K   VL   )[(
M !JU   0N   ![L   "^    P0   ,0   #(    RP   ,L   #-    S@
M -    #2    U0,  -@*  #;$   WA@  .(D  #C-0  Y$@  .5<  #F<P
MYHT  .:E  #FO   YM,  .?G &.D  !5J@  1K   #BU   HN0  &KP   _
M   %Q    ,<   #+    SP   -0   #8    W    -T   #?    X0   .,
M  #E    Z    .H   #M!@  \0X  /46  #X)0  ^3@  /E-  #Z8P  ^WP
M /R5  #\J@  _+L  /W+ /\ #P#_  X _P . /\ $ #_ !8 _P C /\ , #_
M #T _P!) /\ 5 #_ %X _P!F /\ ;@#_ '8 _P!\ /\ @@#_ (D _P"/ /\
ME0#^ )L _0"C /L JP#Z +4 ^0## /< VP#V /  ] #_ /, _P#R /\ [ #_
M .( _P#< /\ U@#_ /\ # #_  D _P ( /\ "@#_ !( _P > /\ *P#_ #@
M_P!$ /\ 3P#_ %D _@!A /P :0#Z '  ^ !W /< ?0#V (, ] ") /( CP#Q
M )8 [P"= .T I0#L *\ Z@"\ .@ S0#F .@ Y #Z ., _P#B /\ X #_ -4
M_P#. /\ RP#_ /\ !@#_  $ _P   /\ ! #_  X _P 9 /\ )0#] #( ^P ^
M /< 20#S %, \ !< .X 8P#L &H Z@!Q .@ =P#F 'T Y "# .( B0#@ )
MW@"7 -P GP#9 *D U@"T -, Q #0 -X S@#S ,P _P#+ /\ R@#_ ,@ _P#"
M /\ O@#_ /\   #_    _P   /\   #[  L ]@ 3 /$ ( #M "P Z@ X .<
M0P#C $T X !6 -P 70#9 &0 U0!K -( <0#0 '8 S@!\ ,P @P#* (D R "1
M ,8 F0#$ *, P0"M +\ NP"] ,\ NP#K +D _ "W /\ MP#_ +8 _P"T /\
ML0#_ /\   #_    _P   /8   #N  4 YP / .$ &0#; "4 U0 Q -( / #.
M $8 R@!/ ,< 5P#$ %X P0!D +\ :@"] '  NP!V +D ? "X (, M@"* +,
MDP"Q )P KP"G *T LP"K ,4 J0#A *< ]0"F /\ I0#_ *0 _P"D /\ I #_
M /\   #\    \0   .@   #@    U  + ,P $P#' !\ P@ J +\ -0"\ #\
MN !( +4 4 "S %< L !> *X 9 "L &D JP!O *D =0"G 'P I0"$ *, C "A
M )8 GP"A )T K0": +P F #2 )< [@"5 /X E #_ )4 _P"5 /\ E0#_ /P!
M  #P!0  XP<  -4%  #,    Q0 $ +X #@"X !< LP C *\ +@"K #@ J0!!
M *8 2@"C %$ H0!7 )\ 70"= &, FP!I )H ;P"8 '8 E@!] )0 A@"2 )
MD "; (X IP", +8 B@#) (@ YP"' /D AP#_ (8 _P"& /\ A@#_ /0,  #D
M$   T1(  ,41  "]#@  M@@  +$ " "K !$ I@ ; *$ )@"> #$ F@ Z )@
M0P"5 $H DP!1 )$ 5P"/ %T C@!C (P :0"* '  B !W (8 @ "$ (L @@"6
M (  HP!^ +$ ?0#$ 'L"X0!Z _4 >@7_ 'D%_P!X!O\ > ;_ .H3  #6&@
MQAT  +H<  "Q&0  JA,  *0-  "?!0P F0 4 )4 'P"1 BD C0,S (L$/ "(
M!40 A@9+ (0&40""!U< @0== '\'8P!]"&H >PAR 'H(? !X"88 =@F2 '0*
MH !S"J\ <0O! ' ,WP!O#?8 ;@[_ &T._P!M#O\ ;0[_ .$<  #+(P  O"8
M +$F  "H)   H!X  )D8  "3$ ( C@L. (@+%P"$#"( @0TL 'X--0!\#CT
M>@Y% '@.2P!W#E$ =0]8 ',/7@!Q$&4 <!!N &X0=P!L$(( :Q"/ &D1G0!H
M$:T 9A+  &42WP!D$_8 8Q3_ &,4_P!B%/\ 8A3_ -8D  ##*@  M2X  *HO
M  "@+0  F"@  ) B  ")&P  @A,( 'T1$@!Y$AP =A,G ',4, !Q%#@ ;Q4_
M &T51@!L%4P :A93 &@660!G%F$ 919I &07<@!B%WX 81B+ %\8F0!>&:D
M7!F\ %P:V !:&_, 6AS_ %D<_P!9'/\ 61S_ ,TJ  "],0  KS4  *0V  ";
M-   DC$  (DK  "!)0  >1T# ',8#@!O&1@ ;!HB &D;*P!G&S, 91P[ &0<
M00!B'4@ 8!U. %\=50!='5P 7!YD %L>;@!9'WD 6!^' %8@E@!5(*8 5"&X
M %,AT@!2(O$ 4B/_ %(C_P!2(O\ 4B+_ ,@O  "X-@  JSH  * \  "6.P
MC3@  (,R  !Z+0  <B8  &H@# !F(!, 8R$= &$A)@!?(B\ 72(V %LB/0!:
M(T0 6"-* %<C40!5(U@ 5"1A %,D:@!1)78 4"6# $\FDP!.)Z, 3">U $PH
MS@!+*.X 2RG_ $LH_P!+*/\ 2RC_ ,,T  "S.P  IS\  )Q!  "20   B3X
M '\Y  !U,P  ;"T  &,G" !>)A$ 7"89 %DG(@!7)RL 52@R %0H.0!2*$
M42A& % I30!.*54 32E= $PJ9P!+*G, 22N  $@KD !'+*$ 1BVS $4MRP!%
M+NP 1"[_ $0N_P!%+?\ 12W_ +XX  "P/P  I$,  )E%  "/10  A4,  'L^
M  !Q.0  9S0  %XN! !8*PX 52L6 %(L'P!0+"< 3RPO $TM-@!,+3P 2BU#
M $DM2@!(+E( 1RY: $8O9 !%+W  0S!^ $(PC0!!,9X 0#*Q #\RR  _,^H
M/S/^ #\R_P _,O\ /S+_ +L\  "M0P  H4<  )9)  ",20  @T@  'A$  !M
M/@  8SD  %HT  !2, P 3S 3 $PP' !*,"0 23$K $<Q,@!&,3D 1#%  $,R
M1P!",D\ 03-8 $ S8@ _-&T /C1[ #TUBP \-IP .S:O #HWQ@ Y-^@ .3?\
M #HW_P Z-O\ .C;_ +=   "J1@  GDL  )1-  "*3@  @$P  '5(  !J0P
M8#X  %8Y  !--0D 2301 $<U&0!%-2$ 0S4H $$U+P! -38 /S8] #XV10 ]
M-TT /#=5 #LX8  Z.&L .3EY #@YB0 W.IL -3JM #4[Q  T.^8 -#O[ #4[
M_P U.O\ -3K_ +1#  "G2@  G$X  ))1  "(4@  ?E   '--  !G2   7$0
M %(_  !(.@8 1#D/ $$Y%@ _.1X /CDF #PY+0 [.C0 .CH[ #D[0@ X.TH
M-SQ3 #8\70 U/6D -#UW #,^AP Q/ID ,#^K "\_P@ O/^0 +S_Z # __P P
M/O\ ,#[_ +%'  "D30  F5(  (]5  "&5@  ?%4  '%2  !D3   64D  $]%
M  !%0 , /SX- #P^$P Z/AL .3XC #<^*@ V/S$ -3\X #0_0  S0$@ ,D!1
M #%!6P P06< +D)U "U"A0 L0Y< *T.J "I#P  I1.( *D/Y "I#_P K0O\
M*T+_ *Y*  "A40  EU8  (U9  "#6@  >5H  &Y7  !A4@  5TX  $U+  !#
M1P  .D,* #9#$0 T0Q@ ,T,@ #)$)P Q1"\ ,$0V "]%/0 M148 +$5/ "M&
M60 J1F0 *4=R "A'@P F1Y4 )4BH "1(O@ C2.  )$CW "5'_P E1_\ )D?_
M *I/  "?50  E%H  (M>  "!7P  =UX  &M<  !?6   554  $M1  ! 30
M-4H' #!)#@ N214 +4D= "Q))  K2BL *DHS "A*.P G2T, )DM, "5+5@ D
M3&( (TQP "%,@  @39, 'TVF !Y-NP =3MT 'DWV !Y,_P ?3/\ ($O_ *=3
M  "<6@  DE\  (AC  !^9   =&,  &EA  !<7@  4EL  $=8   \50  ,E("
M "I0#  G3Q( )E 9 "50(  D4"@ (U O ")1-P A44  (%%) !Y24P =4E\
M'%)M !I3?0 94Y  &%.D !93N0 54]D %E/T !=2_P 84?\ &5'_ *-9  "8
M8   CV4  (5H  ![:0  <6D  &9G  !99   36$  $)?   X7   +EH  "58
M"  @5PX 'E<4 !U7'  <6", &U@K !I8,P 96#P &%A% !994  565L %%EI
M !-:>@ 26HT $5JA !!:MP .6M4 $%GS !!9_P 16/\ $5C_ )]?  "59@
MC&L  ()M  !X;@  ;F\  &)M  !5:@  2&@  #YF   S90  *6,  "!A 0 8
M8 L %6 0 !1@%P 38!X $F F !)@+@ 183< $&%   ]A2P .85@ #6%F  QB
M=@ +8HD "F&=  EAL@ (8<L "&'K  E@_0 *7_\ "U__ )MF  "2;0  B'$
M 'YS  !U=0  :G0  %QS  !/<@  0W   #AO   M;@  )&P  !MK   3:P0
M#FH,  UJ$@ ,:AD "VHA  IJ*0 ):C( "&H\  =K1P %:U, !&MA  )K<0
M:H0  &J8  !JK0  :<8  &GG  !I^   :/\  &C_ )=M  "-<P  A'<  'MZ
M  !P>P  8WL  %9Z  !)>@  /7D  #%X   G=P  '78  !5V   /=@( "78*
M  1V#P  =A4  '8<  !V)   =2P  '4V  !U00  =4X  '5<  !U;   =7X
M '23  !TJ   <\   '/C  !R]P  <O\  ''_ ))U  ")>@  @'X  ':   !I
M@0  6X(  $Z"  !!@@  -8,  "F"   ?@0  %H$  !""   *@@   H,'  ""
M#0  @A$  ((7  ""'@  @B8  ((O  "".P  @D<  ()5  "!90  @7@  (&-
M  " H@  ?[H  '_=  !^]   ??\  'W_ (U\  "$@0  >X0  &Z&  !@B
M4HH  $6+   YC   +(P  "&,   7C   $(T   F.   "CP   ) #  "/"0
MCPX  (\2  "0&   D!\  ) H  "0,@  D#\  )!-  "070  CW   (^%  ".
MG   CK,  (W0  ",\   B_X  (O_ (B$  " B   <HL  &2-  !6D   2),
M #N5   NE@  (I8  !>7   /F   ")D   ";    G0   )T   "= P  G0D
M )T-  ">$0  GA<  )\?  "?*0  H#4  *!#  "@5   H&8  )][  ">DP
MGJL  )W&  "=Z0  G/D  )S_ (.+  !UC@  9Y(  %F6  !+F0  /9P  #">
M   CGP  %Z    ZB   'I    *8   "H    J@   *H   "J    JP$  *L'
M  "L#   K1   *X6  "O'@  L2D  +$X  "Q2   L5H  +%O  "QB   L:
M +"Z  "OW0  K_(  *_] 'B1  !JE@  7)H  $V?   _HP  ,:8  ".G   7
MJ0  #JL   6N    L    +(   "U    MP   +<   "X    N0   +H   "\
M P  O0D  +X.  # %   PQX  ,4K  #%/   QDX  ,9B  #&>@  QI0  ,:M
M  #&R   Q>4  ,7S &R9  !>G@  3Z0  $&H   RK   )*\  !:Q   -M
M [<   "Z    O0   ,    #$    Q@   ,8   #(    R0   ,L   #,
MS@   - &  #3#0  V!,  -P>  #>+0  WT   .!4  #A:P  X84  .&?  #A
MMP  X<\  .'F &"A  !2IP  0ZT  #2R   EM0  %[D   V\   !OP   ,,
M  #'    R@   ,\   #3    U@   -<   #:    W    -\   #A    XP
M .8   #I 0  [ L  / 2  #S'P  ]#$  /9&  #W7   ^'0  /B/  #YI@
M^;@  /C) /\ #0#_  L _P + /\ #@#_ !, _P ? /\ + #_ #D _P!% /\
M4 #_ %D _P!B /\ :@#_ '$ _P!W /\ ?@#_ (0 _@"* /T D #\ )< ^@">
M /D IP#W +$ ]@"^ /4 T@#S .P \0#^ /  _P#P /\ Y@#_ -P _P#2 /\
MS0#_ /\ !P#_  0 _P " /\ !@#_ !  _P ; /\ )P#_ #, _P _ /\ 2@#^
M %0 ^P!= /D 9 #W &L ]0!R /, > #R 'X \ "$ .\ B@#M )$ [ "9 .H
MH0#H *L Y@"V .0 QP#B ., X #W -X _P#= /\ V0#_ ,P _P#% /\ P0#_
M /\   #_    _P   /\  0#_  T _P 6 /P (@#Y "X ]@ Y /, 10#O $X
M[ !7 .D 7@#F &4 Y !L .( <@#@ '< WP!^ -T A #; (L V "2 -4 FP#2
M *0 SP"O ,T O@#+ -4 R0#O ,< _P#% /\ Q #_ +X _P"X /\ M0#_ /\
M  #_    _P   /X   #W  D \0 1 .L ' #G "@ Y  S .$ /@#= $@ V !1
M -, 6 #0 %\ S@!E ,P :P#* '$ R !W ,8 ?0#$ (0 P@", ,  E "^ )X
MNP"H +D M@"W ,@ M0#F +, ^@"Q /\ L #_ +  _P"L /\ J0#_ /\   #_
M    ^@   /$   #H  , X  - -@ %@#1 "( S0 M ,H -P#& $$ P@!* +\
M4@"] %D N@!? +@ 90"W &H M0!P +, =@"Q 'T KP"% *T C0"K )< J0"A
M *< K@"E +X H@#8 *  \@"? /\ G@#_ )X _P"> /\ G #_ /\   #W
MZP   .$   #6    RP ) ,4 $0"_ !L NP F +< ,0"T #H L0!# *X 2P"K
M %( J0!8 *< 7@"F &0 I !I *( < "@ '8 G@!^ )P A@": )  F "; )8
MIP"4 +8 D@#* )  Z0"/ /P C@#_ (T _P", /\ C0#_ /@   #I @  VP,
M ,P!  #$    O0 " +8 #0"P !4 JP @ *< *@"D #0 H0 \ )X 1 "< $L
MF@!2 )@ 6 "6 %T E0!C ), :0"1 '  CP!W (T @ "+ (H B0"5 (< H0"%
M *\ @P#! ($ X "  /4 ?P#_ '\ _P!_ /\ ?P#_ .X*  #<#@  RA   +X.
M  "U"P  KP,  *D !P"C !  G@ 8 )D (P"6 "P DP U )  /@". $4 C !+
M (H 40"( %< A@!= (4 8P"# &H @0!Q '\ >@!] (0 >P"/ 'D G !W *H
M=0"[ '0 U !R /  <@#_ '( _P!Q /\ <0#_ .,1  #-%P  OQD  +,9  "J
M%0  HQ   )T*  "7 0H D0 2 (T &P") "4 A0 O (, -P"  #X ?@!% 'T
M2P![ %$ >0!7 '@ 70!V &0 = %K '(!= !P G\ ;@*+ &P#F !K Z8 :02W
M &@%S@!G!^P 9@C] &8)_P!E"?\ 90G_ -8:  #$(   MB,  *LC  "A(
MF1L  )(4  ",#@$ A@<- ( $% !\!AX >0<H '8(, !T"#@ <@D_ ' )10!O
M"DP ;0I2 &P*6 !J"U\ : MG &<+< !E#'H 8PR' &(,E0!@#:0 7PVV %X-
MS@!<#NT 7 __ %L0_P!;$/\ 6Q#_ ,TA  "\*   KRL  *0K  ":*0  DB0
M (D?  ""&   >Q$% '4-#P!Q#1< ;@XA &L.*@!I#S( 9Q Y &400 !D$$8
M8Q!- &$04P!?$5H 7A%B %P1:P!;$78 61*# %@2D@!6$Z( 51.T %03RP!3
M%.P 4A7_ %(6_P!2%?\ 4A7_ ,8H  "V+@  J3(  )\R  "5,0  C"T  (,G
M  !Z(0  <AH  &L3"P!G$Q, 9!0< &$4)0!?%2T 714T %P5.P!;%D( 619(
M %@63P!6%U8 51=> %,79P!2&'( 4!A_ $\9C@!.&I\ 3!JP $L;QP!+&^D
M2AS] $H<_P!*'/\ 2AS_ ,$M  "Q-   I3<  )HX  "0-P  AS0  'TO  !T
M*0  ;",  &0<!P!>&1  6QH8 %D;(0!7&RD 51LP %0<-P!2'#T 41Q$ $\=
M2P!.'5( 31U: $L>8P!*'FX 21]\ $<?BP!&()P 12&N $0AQ !#(N8 0R+\
M $,B_P!#(O\ 0R+_ +PR  "M.   H3P  )<^  "-/0  @SH  'DU  !O,
M9BH  %XD @!7( T 5" 4 %$@'0!/(24 3B$L $PA,P!+(CH 22)  $@B1P!'
M(DX 1B-7 $0C8 !#)&L 0B1Y $$EB  _)ID /B:K #TGP0 ])^, /2CZ #TH
M_P ])_\ /2?_ +@V  "J/0  GD   )1"  "*0@  @#\  '8[  !L-@  8C
M %DJ  !1)0L 3241 $LE&0!))2$ 1R8H $4F+P!$)C8 0R8] $(G1 !!)TL
M/RA4 #XH70 ]*6D /"EV #LJA@ Y*Y< ."NI #<LOP W+.  -RSX #<L_P W
M+/\ ."S_ +4Z  "G0   G$0  )%&  "'1@  ?40  '-   !H.P  7S8  %4Q
M  !,*P< 1RD/ $4J%@!#*AX 02HE #\J+  ^*S, /2LY #PK00 [+$@ .BQ1
M #DM6P X+F8 -BYS #4O@P T+Y4 ,S"G #(PO0 Q,=X ,3'W #(Q_P R,/\
M,S#_ +$^  "D1   F4@  (]*  "%2@  >TD  '!%  !E0   6SL  %(V  !(
M,00 0BX- #\N$P ]+AL .RXB #DO*0 X+R\ -R\V #8P/@ U,$8 -#%/ #,Q
M60 R,F0 ,3)Q # S@0 O-), +C2F "PUNP L-=L +#7U "TU_P M-/\ +C3_
M *Y!  "B2   ETP  (U.  "#3@  >4T  &Y*  !B10  6$   $X\  !%-P
M/3,+ #DS$0 W,Q@ -C,? #0S)@ S,RT ,C0T #$T/  P-40 +S5, "XV5@ M
M-F( +#=O "LW?P J.)$ *#BD "<YN0 F.=@ )SGT "@Y_P H./\ *3C_ *M%
M  "?2P  E$\  (M2  "!4P  =U(  &Q/  !?20  5D8  $Q"  !"/0  .#@(
M #0X#P R.!4 ,3@= "\X)  N."L +3DR "PY.0 K.D$ *CI* "D[5  H.U\
M)SQM "4\?0 D/8\ (SVB "(]MP A/M0 (3[S "(]_P C/?\ (SS_ *A)  "=
M3P  DE,  (E6  !_5P  =58  &I3  !=3P  4TP  $I(  ! 1   -D % "\]
M#0 M/1, *ST: "H^(0 I/B@ *#XO "<^-P F/S\ )#]( "- 4@ B0%T (4%J
M "!!>@ >08T '4*@ !Q"M0 ;0M$ &T+Q !Q"_P =0?\ 'D'_ *5-  ":4P
MD%@  (9;  !]7   <EL  &=8  !;5   45(  $A.   ]2@  ,T<  "I#"P F
M0Q  )4,6 "1#'@ C1"4 (D0L "%$-  @13P 'D5% !U%3P <1EH &T9H !E&
M>  81XH %T>> !9'LP 42,X %4?O !9'_P 71O\ %T;_ *)2  "76   C5T
M (1@  !Z80  <&   &5>  !96@  3U@  $14   Y40  +TX  "9+!@ @2@X
M'DH3 !U*&@ <2B$ &TLH !I+,  92S@ %TM" !9,3  53%< %$QE !--=0 2
M38@ $4V< !!-L0 .3LP #TWN !!-_P 13/\ $4S_ )Y7  "470  BV(  (%E
M  !W9@  ;68  &-D  !680  2EX  #];   U6   *U8  ")4 0 :4@H %E(0
M !52%@ 44AT $U(D !)2+  14C0 $5(^ !!32  /4U0 #E-B  U4<@ ,5(0
M"U28  E4K0 (5,4 "53G  I3^P +4O\ "U+_ )M=  "19   B&@  'YK  !T
M;   :VP  %]J  !29P  160  #IB   P8   )EX  !U=   56P4 $%H,  Y:
M$0 .6A@ #5L@  Q;)P +6S  "ELZ  E;10 '6U$ !EM>  1;;0 #6X   5N4
M  !;J   6\   %KB  !:]@ !6O\  EG_ )=D  ".:P  A&X  'MP  !R<@
M9W$  %EP  !,;@  0&P  #5K   J:0  (6<  !AF   19@$ #&4*  =E#P $
M910  V0;  )D(P  9"P  &0U  !D0   9$P  &1:  !D:0  9'L  &2/  !C
MI   8[L  &+=  !B]   8O\  &'_ )-L  ")<0  @'4  'AW  !M>   8'<
M %)V  !&=0  .70  "YT   C<@  &G$  !)Q   -<0  !G$(  !P#0  <!(
M ' 7  !O'P  ;R8  &\P  !O.P  ;T<  &]4  !O9   ;W4  &Z*  !MH
M;;8  &S6  !K\@  :_\  &O_ (YS  "%>   ?7L  '-]  !E?@  6'X  $M^
M   ^?@  ,GX  "9]   <?   $WP   U\   &?0   'T%  !\"P  ? \  'P3
M  !\&0  ?"$  'PI  !\-   >T   'M.  ![7@  >V\  'J$  !ZF@  >;$
M 'C.  !W[P  =OX  ';_ (EZ  "!?P  >((  &N#  !=A0  3X8  $*'   U
MB   *8<  !V'   4AP  #8@   :)    B@   (H   ")!@  B0P  (D/  ")
M$P  B1H  (HB  "*+   BC@  (I&  ")5@  B6@  (E\  "(E   AZL  (;&
M  "%Z@  A?L  (3_ (6"  !]A@  ;X@  &&+  !3C0  18\  #B1   KD0
M'Y(  !22   -DP  !)0   "6    EP   )@   "7    EP4  )<+  "8#@
MF!,  )D:  "9(@  FBX  )H]  "930  F5X  )ES  "8BP  F*,  )>\  "6
MX@  EO<  )7_ (")  !RC   9(\  %:3  !(E@  .ID  "R:   ?FP  %)P
M  R>   #GP   *$   "C    I0   *4   "E    I0   *8"  "G"   IPT
M *@1  "I&0  JR,  *LQ  "K00  K%,  *QG  "K@   JIH  *JS  "JT
MJ>\  *G[ '6/  !GE   69@  $J<   \GP  +:(  ""C   3I0  "Z<   &I
M    JP   *X   "Q    L@   +(   "S    M    +4   "V    N 0  +D+
M  "[$   O1@  +\D  "_-0  P$<  ,!;  # <@  P(T  ,&F  # P0  O^,
M +[S &J7  !;G   3:$  #ZE   OJ0  (:L  !.M   +L    +,   "U
MN    +P   "_    P0   ,$   ##    Q    ,8   #'    R0   ,L   #.
M"   T0\  -48  #8)P  V3D  -I-  #;9   VWX  -R9  #<L   W,D  -SC
M %V?  !/I0  0*H  #*O   BL@  %+4   JX    NP   +\   ##    Q@
M ,L   #.    T0   -$   #4    U@   -D   #;    W@   .    #D
MYP8  .L.  #O&0  \"H  /(_  #S50  ]&T  /2(  #TH0  ]+8  /3' /\
M"0#_  8 _P ' /\ # #_ !$ _P < /\ * #_ #0 _P!! /\ 3 #_ %4 _P!=
M /\ 90#_ &P _P!R /X > #\ 'X ^P"$ /H BP#Y )( ]P"9 /8 H@#T *P
M\P"Y /$ RP#P .@ [@#[ .T _P#L /\ X0#_ -( _P#) /\ Q #_ /\  0#_
M    _P   /\ ! #_  X _P 7 /\ (P#_ "\ _P [ /T 1@#Z %  ]P!8 /0
M7P#R &8 \ !L .\ <@#M '@ [ !^ .H A0#I (P YP"3 .4 G #C *8 X0"Q
M -\ P0#= -T VP#T -D _P#6 /\ SP#_ ,0 _P"] /\ N0#_ /\   #_
M_P   /\   #_  L _  3 /< '@#T "H \@ U .X 0 #I $H Y@!2 ., 60#@
M &  W@!F -P ; #: '( UP!X -0 ?@#2 (4 T "- ,X E0#, )\ R0"J ,<
MN #% ,T PP#K ,  _@"_ /\ O@#_ +8 _P"P /\ K0#_ /\   #_    _P
M /D   #R  8 ZP / .8 &0#A "0 W@ O -H .0#3 $, SP!, ,P 4P#) %H
MQP!@ ,4 9@## &L P0!Q +\ =P"] 'X NP"& +D C@"W )@ M0"C +, L "Q
M ,( K@#@ *P ]P"K /\ J@#_ *@ _P"C /\ H #_ /\   #_    ]0   .L
M  #A    U@ , ,\ $P#* !X Q@ I ,( ,P"_ #T NP!% +@ 30"V %0 LP!:
M +$ 7P"P &4 K@!J *P < "K '< J0!_ *< AP"E )$ HP"< *  J0"> +@
MG #. )H [@"9 /\ EP#_ )8 _P"6 /\ DP#_ /T   #Q    Y0   -D   #-
M    Q  & +T #P"W !@ LP B +  + "M #8 J0 ^ *< 1@"D $T H@!3 *
M60"? %X G0!D )L :@": '  F !W )8 @ "4 (H D0"5 (\ H@"- +  BP##
M (D XP"( /D A@#_ (8 _P"& /\ A@#_ /,   #C    T0   ,4   "]
MM@   *X "P"H !( I  < *  )@"< "\ F@ W )< /P"5 $8 D@!, )$ 4@"/
M %@ C0!= (L 8P"* &H B !Q (8 >0"$ (, @@"/ '\ FP!^ *D ? "[ 'H
MU0!X /( > #_ '< _P!W /\ =P#_ .<'  #1#   PPT  +@,  "N"   J
M *( !0";  X E@ 5 )( 'P". "@ BP Q (@ .0"& $  A !& (( 3 "  %(
M?P!7 'T 70![ &, >@!K '@ <P!V 'T = "( '$ E0!P *0 ;@"T &P R@!K
M .H :@#\ &H _P!J /\ :@#_ -H0  #&%   N!8  *T5  "D$@  G X  )8'
M  "0  D B@ 0 (4 & "! "$ ?@ J 'L ,@!Y #D =P!  '4 1@!S $P <@!1
M '  5P!N %X ;0!E &L ;@!I '< 9P"# &4 D0!C )\ 8@"O &  Q !? .0
M7P'X %X"_P!> O\ 7@+_ ,X8  "]'0  L"   *4?  ";'   DQ<  (L1  "$
M#   ?@0+ 'D $@!U !L <@ C &\ *P!M 3, :P$Z &D"0 !G T8 9@-, &0$
M4@!C!%D 801@ %\%:0!>!7, 7 9_ %H&C0!9!YP 5PBM %8(P0!5">$ 5 OV
M %0+_P!4"_\ 5 O_ ,8?  "V)0  J2@  )XH  "4)0  BR$  (,;  ![%
M= X# &X)#0!I"!0 9@D= &0*)0!B"BT 8 LT %X+.@!="T  6PQ' %H,30!8
M#%0 5PU< %4-9 !4#6\ 4@U[ % .B@!/#IH 3@ZL $P/P@!,$., 2Q#Y $L0
M_P!+$?\ 2Q#_ +\F  "P*P  I"\  )DO  "/+0  ABD  'TD  !T'@  ;!<
M &41!P!?#A  7 \7 %H0'P!8$"< 5A N %00-0!3$#L 4A%" % 12 !/$5
M3A%7 $P28 !+$FL 21)X $@3AP!&$Y< 112I $04O@!#%=\ 0Q;X $,6_P!#
M%O\ 0Q;_ +HK  "K,0  H#0  )4U  "+-   @3$  '@K  !O)@  9B   %X9
M 0!7% T 5!03 %$4&P!/%2, 3A4J $P5,0!+%C< 218^ $@61 !'%TP 11=4
M $0770!#&&< 01AT $ 9@P _&I0 /1JF #P;NP [&]L .QSV #P<_P \'/\
M/!S_ +4P  "H-@  G#D  )$[  "'.@  ?C<  ',R  !J+0  82<  %DA  !1
M&PD 3!D0 $H:%P!(&A\ 1AHF $4;+0!#&S, 0ALZ $$<00! '$@ /AQ0 #T=
M60 \'F0 .QYQ #D?@  X'Y( -R"D #8@N  U(=8 -2'T #4B_P U(?\ -B'_
M +(T  "D.@  F3X  (\_  "%/P  >SP  ' X  !G,@  72T  %0H  !,(@4
M1A\. $,?% !!'QL /Q\B #X@*0 ](#  .R V #HA/0 Y(44 .")- #<B5P V
M(V( -"-N #,D?@ R)(\ ,26B "\EM@ O)M( +R;R "\F_P P)O\ ,";_ *\X
M  "B/@  ED(  (Q#  ""0P  >$$  &X]  !C.   6C,  %$N  !(* $ 0"0,
M #TC$0 [)!@ .20? #@D)@ V)"P -24S #0E.@ S)D( ,B9* #$G5  P)U\
M+RAL "XH>P L*8T *RJ@ "HJM  I*L\ *2OP "HK_P J*O\ *RK_ *P\  "?
M0@  E$8  (I'  " 1P  =D4  &Q"  !A/0  5S@  $XS  !$+@  /"D) #<H
M$  U*!4 ,R@< #(H(P P*"D +RDP "\J-P N*C\ +2M( "PK4@ K+%T *BQJ
M "@M>0 G+8L )BZ> "4NLP D+\T )"_N "4O_P E+_\ )B[_ *D_  "=10
MDDD  (A+  !^3   =$H  &I'  !>0@  5#T  $LY  !!-   ."\& #(M#0 P
M+1, +BT9 "TM(  K+2< *BXN "DN-0 I+ST *"]& "<P3P E,%L )#%H ",Q
M=P B,HD (3*= !\SL0 >,\L 'C/M !\S_P @,_\ (3+_ *9#  ":20  D$T
M (9/  !\4   <T\  &A,  !<1@  4D,  $D_   _.P  -C8" "XR#  K,A$
M*3(7 "@R'@ F,B0 )3,K "0S,@ C-#H (C1# "$U30 @-5@ 'S9E !XV=0 <
M-X< &S>; !HWKP 9.,@ &3CK !HX_P ;-_\ &S?_ *-'  "830  CE$  (13
M  ![5   <5,  &90  !:3   4$D  $=%   ]00  ,ST  "HY"0 E-PX (S<4
M "(X&P A."( (#@H !\X,  >.3@ '3E! !PZ2P :.E8 &3MC !@[<@ 6.X4
M%3R9 !0\K0 3/<8 $SWI !0\_0 5//\ %CO_ *!+  "540  BU4  ()8  !Y
M60  ;E@  &16  !840  3D\  $5+   Z1P  ,$,  "= !0 @/@T '3X1 !P^
M%P ;/AX &CXE !D^+0 8/S4 %C\^ !4_2  40%, $T!@ !)!<  108( $$&7
M  ]!K  .0L0 #D+G  ]!_  00?\ $$#_ )U0  "35@  B5H  (!=  !V7@
M;%T  &);  !65P  3%4  $%1   V3@  +$L  "-(   ;10D %T0/ !5$%  4
M11L $T4B !)%*0 113$ $44[ !!&10 /1E  #D=>  U';0 ,1W\ "T>3  E'
MIP (1[X "$?@  E']@ *1O\ "T;_ )I5  "06P  AV   'UB  !S8P  :F(
M &!A  !37@  1UH  #Q7   R50  *%(  !]0   73@0 $4P,  ],$0 .3!<
M#DP>  U-)0 ,32X "TTW  I-0@ )34T !TY:  9.:0 $3GL  DZ/  %.I
M3;H  $W;  %-\@ !3?\  DS_ )9;  "-8@  A&8  'IH  !Q:0  :&D  %QG
M  !/9   0F$  #=?   M7   (UH  !I8   25P$ #58)  E5#@ '51, !E4:
M  15(@ #52H  E4T  !5/@  54H  %97  !690  57<  %6+  !5H   5;8
M %34  !4\0  4_T  %/_ )-B  "*:   @&P  '=N  !O;P  8VX  %9L  !)
M:@  /6@  #)F   G90  '6,  !5B   .80  "6 (  -@#0  7Q$  %\7  !?
M'@  7R8  %\O  !?.@  7T4  %]3  !?80  7G(  %Z'  !=G   7;(  %S/
M  !<[P  6_T  %O_ )!J  "&;P  ?7(  '5T  !J=0  770  $]S  !"<@
M-G   "MO   @;@  %VT  !!L   *;    FL&  !K"P  :@\  &H4  !J&@
M:B$  &DJ  !I-   :4   &E.  !I7   :6T  &B"  !HF   9ZX  &;*  !E
M[0  9?P  &3_ (MQ  ""=@  >GD  '![  !B>P  57L  $AZ   [>@  +WH
M "-Y   9>   $7<   IW   #=P   '<"  !W"   =@T  '80  !V%0  =AL
M '8C  !V+@  =3H  '5'  !U5@  =6@  '1\  !TD@  <ZH  '+$  !QZ0
M</L  '#_ (9Y  !_?0  =G\  &B!  !:@@  3((  #^#   RA   )8,  !J#
M   1@P  "H,   *#    A    (4   "$ P  @P@  (,-  "#$   @Q4  (0<
M  "$)@  A#(  (0_  "#3P  @V   ()U  ""C   @:0  ("]  !_XP  ?OD
M '[_ (*   !ZA   ;(8  %Z(  !0B@  0HL  #6-   GC0  &XT  !&.   *
MC@   (\   "1    D@   )(   "2    D@$  )('  "2#   DA   ),5  "3
M'0  E"@  )0V  "410  DU<  )-K  "3@@  DIP  )&V  "0V   C_,  (__
M 'Z'  !PB@  88T  %.0  !%DP  -Y4  "F6   <EP  $9@   F9    FP
M )P   ">    H    *    "@    H    *$   "A!   H@D  *,.  "D%
MI1T  *8J  "F.@  IDP  *5@  "E>   I9(  *2L  "DR0  H^L  *+Z '..
M  !DD0  5I4  $>9   YG   *IX  !V@   1H0  "*,   "E    IP   *D
M  "L    K@   *X   "N    KP   +    "Q    L@   +,&  "U#0  MQ,
M +D>  "Y+@  ND   +I4  "[:@  NH4  +FA  "YNP  NMX  +GR &>5  !8
MF0  2IX  #NB   LI@  ':@  !&J   'K    *\   "Q    M    +@   "[
M    O    +P   "^    OP   ,    #"    Q    ,8   #( P  RPL  ,\2
M  #1(   T3(  -)&  #370  U'8  -22  #5JP  U<0  -3B %N=  !,H@
M/:<  "^L   ?KP  $;$   >U    N    +L   "^    P@   ,<   #*
MS    ,P   #.    T    -(   #5    V    -L   #?    X@   .8+  #K
M$P  ["0  .TX  #N3@  [V<  /""  #PG   \+(  /'% /\  P#_  $ _P $
M /\ "0#_  \ _P 8 /\ ) #_ #  _P \ /\ 1P#_ %$ _P!9 /\ 8 #] &<
M_ !M /H <P#Y 'D ^ !_ /8 A0#U (P \P"4 /( G0#P *< [@"S .P Q #K
M .$ Z@#X .D _P#G /\ V0#_ ,L _P#" /\ O0#_ /\   #_    _P   /\
M  #_  P _P 4 /\ ( #_ "L _@ W /H 0@#V $L \@!3 /  6P#N &$ [ !G
M .H ;0#H ', YP!Y .4 ?P#C (8 X0". -\ E@#= *  VP"L -@ NP#4 -$
MTP#P -  _P#. /\ R #_ +T _P"V /\ L@#_ /\   #_    _P   /\   #]
M  @ ]P 0 /, &@#O "8 [0 Q .@ .P#C $4 X !- -P 50#9 %L U@!A -,
M9P#1 &P SP!R ,T > #+ '\ R0"' ,< D #% )H PP"E ,  L@"^ ,4 O #E
M +H ^P"X /\ MP#_ +  _P"I /\ I0#_ /\   #_    _@   /4   #L  ,
MY0 - -\ %0#: "  U  J -  -0#+ #X R !' ,4 3@#" %4 P !; +X 80"\
M &8 N@!L +@ <@"V '@ M0"  +, B "Q )( K@"> *P J@"I +L J #5 *8
M\P"D /\ HP#_ *$ _P"; /\ F #_ /\   #[    \    .4   #8    S@ )
M ,< $0#" !H O@ D +L +@"W #@ M !  +$ 2 "N $X K !4 *H 6@"I %\
MIP!E *4 :P"D '$ H@!X *  @0"> (L G "6 )D HP"7 +( E@#' ), Z "2
M /X D0#_ )  _P"- /\ BP#_ /D   #K    W0   ,\   #&    O  $ +4
M#0"P !4 K  > *@ * "E #$ H@ Y )\ 00"= $@ FP!. )D 4P"7 %D E@!>
M )0 9 "2 &H D !Q (X >@", (, B@"/ (@ G "& *H A "\ (( W "! /8
M@ #_ '\ _P!_ /\ ?@#_ .P   #:    R0   +X   "V    K@   *< "0"A
M !  G  8 )@ (@"5 "H D@ R )  .@"- $$ BP!' (D 30"' %( A@!8 (0
M70"" &0 @0!K '\ <P!] 'T >P"( '@ E0!V *, =0"T ', S !Q .T < #_
M '  _P!P /\ < #_ -\%  #*"@  O L  +$)  "H!   H0   )L  P"4  P
MCP 3 (H &P"' "0 A  L ($ ,P!_ #H ?0!! 'L 1P!Y $P =P!2 '8 5P!T
M %T <@!D '  ;0!O '8 ; "" &H CP!I )T 9P"N &4 PP!D .0 8P#Z &,
M_P!B /\ 8P#_ - .  "_$@  LA,  *<2  "=$   E0L  (\#  ")  < @@ .
M 'X %0!Z !X =@ E '0 +0!Q #0 ;P Z &X 0 !L $8 :@!, &D 4@!G %@
M9@!? &0 9P!B '$ 8 !\ %X B0!< )@ 6P"I %D O !8 -P 6 #T %@ _P!7
M /\ 5P#_ ,86  "V&@  JAT  )\<  "5&0  C10  (4/  !^"0  =P$* '(
M$ !N !< :@ ? &@ )P!E "X 9  T &( .P!@ $  7P!& %T 3 !< %, 6@!:
M %@ 8@!7 &P 50!W %, A0!2 )0 4 &E $\!N !. M( 303P $T%_P!-!?\
M307_ +\=  "P(@  HR4  )DE  "/(@  A1T  'T8  !U$@  ;@T" &<&# !C
M Q$ 7P(9 %T#(0!;!"@ 600O %<%-0!6!3L 5 9! %,&1P!1!DX 4 =5 $X'
M7@!-"&< 2PAS $D)@0!("9( 1PJC $4*M@!$"]  1 SO $,-_P!##?\ 1 W_
M +DD  "J*0  GBP  )0L  "**@  @"8  '<A  !N&P  9A0  %\/!0!9"PT
M50H3 %,+&P!1"R( 3PPI $T,+P!,##8 2PT\ $D-0@!(#4D 1@U1 $4.6@!$
M#F0 0@YP $ .?P _#Y  /A"B #P0M@ [$-$ .Q'Q #L1_P [$?\ /!'_ +0I
M  "F+P  FC(  ) R  "&,0  ?"T  '(H  !I(P  81T  %D6  !1$0@ 3 \0
M $H0%@!($!T 1A D $40*P!#$3$ 0A$W $$1/@! $44 /A)- #T25@ \$F$
M.A-M #D3?  W%(T -A2? #45LP T%<T ,Q;N #06_P T%O\ -!;_ *\N  "B
M-   ES<  (PX  ""-@  >#0  &XN  !E*@  7"0  %0>  !,& 0 1A0- $(4
M$@! %!D /Q0@ #T5)P \%2T .Q4T #D6.@ X%D( -Q9* #874P U%UX ,QAJ
M #(9>0 P&8H +QJ= "X:L0 M&\H +1OL "T<_P N&_\ +AO_ *PR  "?.
ME#L  (H\  " /   =CD  &LT  !B+P  62H  % E  !''P  0!H* #P9$  Z
M&18 .!D= #8:(P U&BD -!HP #,:-P R&SX ,1M' "\<4  N'5L +1UG "P>
M=@ J'H@ *1^; "@?K@ G(,< )B#J "<@_@ H(/\ *"#_ *DV  "=/   DC\
M (=!  !]0   =#X  &DZ  !?-0  5C   $TK  !$)0  .R ' #8>#@ S'A,
M,AX9 # >(  O'B8 +A\M "T?-  L(#L *R!$ "HA3@ I(5@ )R)E "8B=  E
M(X4 (R.9 "(DK0 A),4 (27H "(E_0 B)/\ (R3_ *8Z  ":/P  CT,  (5%
M  ![1   <D,  &<_  !=.@  4S8  $HQ  !!+   ."8# #$C#  N(A$ +"(6
M "HB'0 I(B, *",J "<C,0 F)#D )25! "0E2P C)E8 (B9C "$G<@ ?)X,
M'BB7 !THJP ;*<, &RGF !PI^P =*?\ 'BC_ *,^  "80P  C4<  (-)  !Z
M20  <$<  &9$  !:/P  43L  $<W   ^,@  -2T  "PH"0 H)P\ )R<4 "4G
M&@ D)R$ (R@G "(H+@ A*38 ("D_ !\J20 >*E0 '2M@ !LK;P :+($ &2R5
M !<MJ0 6+<$ %BWD !<M^@ 8+?\ &2W_ *%!  "51P  BTL  ()-  !X30
M;DP  &1)  !81   3T   $8]   ].   ,S0  "HO!@ D+ T (2P2 " L&  ?
M+1X 'BTE !TM+  <+C0 &RX\ !HO1@ 8+U$ %S!> !8P;0 5,7\ $S&3 !(Q
MJ  1,K\ $3+B !(R^0 3,?\ $S'_ )Y%  "32P  B4\  (!1  !V4@  ;5
M &).  !620  348  $1#   [/P  ,3H  "<V P ?,@L '#(0 !LR%0 9,AL
M&#(B !<S*0 6,S$ %30Z !0T1  3-$\ $C5< !$U:P 0-GT #S:1  XVI@ -
M-[P #3?=  TV]@ .-O\ #S;_ )M)  "13P  AU,  'Y6  !U5@  :E4  &!3
M  !53P  3$P  $))   X10  +D$  "0]   <.@@ %C@. !4X$@ 4.!@ $SD?
M !(Y)@ 1.2X $#DW  \Z00 ..DP #3M9  T[:  +.WH "CN-  D\H@ '/+@
M!SS5  @\\  )._\ "CO_ )A.  ".5   A5@  'Q;  !R6P  :%H  %Y8  !3
M50  25(  #Y.   T2P  *D<  "%$   80@, $D + ! _$  ./Q4 #C\<  U
M(P ,0"L "T T  I /@ )04H !T%6  9!90 $078  T&*  %!GP  0;0  $'0
M  %![@ !0?P  D#_ )54  ",60  @UX  'E@  !P8   9F   %U>  !16P
M15<  #I4   O40  )4\  !Q,   42@  #D@(  M'#@ (1Q( !T<9  9'(  %
M2"@  T@Q  )(.P  2$<  $A3  !(8@  2',  $B&  !(FP  2+$  $?,  !'
M[0  1_L  $?_ )):  ")8   @&,  '=E  !N9@  968  %ED  !,8   0%T
M #5;   J60  (%<  !=5   04P  "U('  51#0 !4!$  % 6  !0'0  4"4
M % N  !0.   4$,  %!0  !07@  4&\  %"#  !/F   3ZX  $[)  !.ZP
M3?L  $W_ (]A  "&9@  ?6D  '1L  !L;0  86L  %-I  !&9P  .F0  "]C
M   D80  &E\  !)>   ,7   !EP&  !;"P  6@\  %H3  !:&0  62$  %DI
M  !9,P  63\  %E,  !96@  66L  %A^  !8E   5ZL  %?%  !6Z0  5?L
M %7_ (QH  "";0  >G   ')R  !G<@  6G$  $QP   _;@  ,VT  "AK   =
M:@  %&@   UG   '9P   &8#  !F"0  90T  &41  !D%0  9!P  &0D  !D
M+@  9#H  &-'  !C50  8V8  &-Z  !BD   8:<  &#!  !?Y@  7_H  %[_
M (=O  !_=   >'<  &YX  !@>   4G<  $5W   X=@  *W8  "!T   6<P
M#G,   =R    <@   '(   !Q!0  <0H  '$.  !P$0  <!<  ' >  !P)P
M<#,  &]   !O4   ;V   &YT  !NBP  ;:(  &R\  !KX@  :O@  &G_ (-W
M  !\>P  <WT  &5^  !7?P  27\  #Q_   O@   (G\  !=^   /?@  !WX
M  !_    ?P   '\   !^    ?@4  'X*  !^#0  ?A$  'X7  !^(   ?BL
M 'TY  !]2   ?5D  'QM  !\A   >YP  'JV  !YV@  >/4  '?_ (!_  !W
M@@  :8,  %N%  !-A@  /X@  #*)   DB0  &(D   ^)   'B@   (L   ",
M    C0   (T   ",    C    (P#  ","   C0T  (T1  "-%P  CB(  (XO
M  "./P  C5   (UD  ",>P  C)4  (NN  "*S0  B>\  (G_ 'N%  !MB
M7HH  %"-  !"CP  -)$  ":2   9DP  #I0   :5    E@   )@   ":
MFP   )L   ";    FP   )L   "<    G04  )T+  ">$   GQ<  * D  "@
M-   H$8  *!9  "?<   GXH  )ZE  ">P@  G>@  )SY '",  !ACP  4Y(
M $26   VF0  )YL  !F<   /G0  !9\   "A    HP   *4   "H    J0
M *D   "I    J@   *L   "L    K0   *X!  "P"0  L@\  +,8  "T)P
MM#D  +5-  "T9   M'X  +.:  "SM   L]4  +/P &23  !5EP  1YL  #B?
M   IH@  &J0   ZF   $J    *L   "M    L    +0   "V    N    +@
M  "Y    N@   +P   "]    OP   ,    ##    Q0<  ,D/  #*&@  RRP
M ,Q   #-5@  SF\  ,V+  #,J   S,(  ,SB %B;  !)H   .J4  "RI   <
MJP  #ZX   2Q    M    +<   "Z    O@   ,,   #&    R    ,@   #*
M    RP   ,T   #/    T@   -4   #9    W0   .$%  #F#P  YQX  .@R
M  #I2   ZF   .M[  #KEP  [*X  .S" /\   #_    _P   /\ !@#_  T
M_P 5 /\ (0#_ "P _P X /\ 0P#_ $P _@!4 /L 6P#Z &( ^ !H /8 ;@#U
M '0 ] !Z /( @ #Q (< [P"/ .T EP#K *$ Z0"M .< O0#E -@ Y #S .(
M_P#@ /\ T #_ ,0 _P"\ /\ M@#_ /\   #_    _P   /\   #_  D _P 1
M /\ ' #] "< ^0 R /4 /0#Q $8 [0!/ .L 5@#H %P Y@!B .0 : #C &X
MX0!S -\ >0#= (  V@"( -@ D0#4 )L T@"F ,\ M #, ,D R0#I ,@ _P#'
M /\ P0#_ +< _P"O /\ JP#_ /\   #_    _P   /\   #X  4 \@ . .X
M%P#J "( Y@ L .$ -P#= $  V !) -, 4 #0 %8 S@!< ,P 8@#* &< R !M
M ,8 <P#$ 'D P@"! ,  B@"^ )0 O "? +D K "V +X M #= +, ]P"Q /\
ML #_ *@ _P"B /\ G@#_ /\   #_    ^0   .\   #F    WP + -8 $@#0
M !P S  F ,@ , #$ #H P !" +T 2@"[ %  N !6 +8 6P"U &$ LP!F +$
M; "P '( K@!Z *P @@"I (P IP"8 *4 I0"C +0 H #+ )\ [@"= /\ G #_
M )D _P"4 /\ D0#_ /\   #V    Z@   -T   #/    QP & ,  #P"[ !<
MMP @ +, *@"P #, K0 [ *H 0P"G $D I0!/ *, 50"B %H H !? )X 90"=
M &L FP!R )D >P"7 (4 E "0 )( G0"0 *P C@"_ (P X@"+ /H B0#_ (D
M_P"& /\ @P#_ /0   #D    U    ,@   "_    M0 ! *X "P"I !( I0 ;
M *$ (P"> "P FP T )@ / "6 $, E !) )( 3@"0 %, C@!9 (T 7@"+ &0
MB0!K (< <P"% 'T @P"( ($ E0!_ *0 ?0"U 'L SP!Y /$ > #_ '< _P!W
M /\ =0#_ .4   #1    PP   +@   "O    J    *  !@":  X E0 5 )$
M'@". "8 BP M (@ -0"& #P A !" (( 1P"  $T ?P!2 'T 6 ![ %X >0!E
M '@ ;0!V '8 <P"! '$ C@!O )T ;0"N &P Q !J .< :0#] &@ _P!H /\
M:0#_ -4#  ##!P  M@@  *L&  "B    FP   )0   "-  H B  0 (, & !_
M "  ?  G 'H +@!W #4 =0 [ '0 00!R $< < !, &\ 4@!M %@ :P!? &D
M9@!G '  90![ &, B !B )< 8 "G %X NP!= -P 7 #V %P _P!; /\ 6P#_
M ,D-  "Y$   K!$  *$0  "7#0  CP@  (@   ""  4 >P - '< $@!S !H
M;P A &P * !J "\ :  U &< .P!E $$ 8P!& &( 3 !@ %( 7P!9 %T 80!;
M &H 60!U %< @@!5 )$ 5 "B %, M0!1 ,\ 4 #O %  _P!0 /\ 4 #_ +\4
M  "P&   I!H  )D9  "/%@  AQ$  '\-  !W!@  <0 ( &L #@!G !0 9  ;
M &$ (@!> "D 70 O %L -0!9 #L 6 !! %8 1@!5 $T 4P!4 %( 7 !0 &4
M3@!P $P ?0!+ (T 20"> $@ L !' ,< 1@#I $8 ^P!& /\ 10#_ +@;  "J
M(   GB(  ),B  ")'P  @!H  '<5  !O$   : L  &$$"@!= !  60 6 %8
M'0!4 ", 4@ J %  , !/ #4 3@ [ $P 00!+ $@ 20!/ $<!5P!& 6$ 1 )L
M $,">0!! XD 0 .: #X$K0 ]!,0 / 7E #P'^  \!_\ / ?_ +(B  "E)P
MF2D  (XI  "$)P  >R,  '$>  !I&   81(  %H- P!3" P 3P41 $P%%P!*
M!AX 2 8D $<&*@!%!S  1 <V $,(/0!!"$, 0 A+ #X)4P ]"5T .PIH #H*
M=@ X"X< -PN9 #4+K  T#,( ,PSD #,-^0 S#?\ - W_ *TG  "@+   E2\
M (LO  " +@  =RH  &TE  !D(   7!H  %04  !,#P8 1@P- $,,$@!!#!@
M/PP? #X,)0 \#2L .PTR #H-.  X#3\ -PY' #8.4  T#EH ,PYF #$/=  P
M#X4 +A"8 "T0JP L$,, *Q'E "P1^@ L$?\ +1'_ *HL  "=,0  DC0  (<U
M  !]-   =#$  &HK  !@)P  6"$  $\;  !'%@  0!$) #L0#P Y$!0 -Q ;
M #80(0 T$"< ,Q$M #(1-  Q$3L ,!%# "X230 M$E< +!)C "H3<0 I$X(
M)Q25 "84J0 E%<  )!7C "46^@ F%O\ )A7_ *8Q  ":-@  CSD  (4Z  ![
M.0  <38  &<Q  !=+0  5"@  $PB  !#'0  .Q<% #44#0 R$Q$ ,107 "\4
M'0 N%"0 +!0J "L5,0 J%3@ *19  "@62@ G%U0 )A=@ "08;P C&(  (1F3
M " 9IP ?&;X 'AK@ !\:^  @&O\ (!K_ *,T  "8.@  C3T  (,^  !Y/0
M;SL  &4W  !;,@  4BT  $DH  ! (P  .!X! # 9"@ L& \ *A@4 "D8&@ G
M&"  )ADG "49+0 D&C4 (QH^ "(;1P A&U( (!Q> !\=;  ='7X '!V1 !H>
MI0 9'KP &!_= !D?]@ :'_\ &Q[_ *$X  "5/0  BT$  (%"  !W0@  ;4
M &,\  !9-P  3S,  $8N   ]*0  -20  "T@!P G'0T )1T2 ",=%P A'1T
M(1TD " >*P ?'C( 'A\[ !T?10 <($\ &B%< !DA:@ 8(GL %B*/ !4BHP 4
M([H $R/: !0C]0 5(_\ %B/_ )X\  "300  B40  ']&  !U1@  ;$0  &)!
M  !7/   33@  $0T   \,   ,RL  "HF P C(@L ("$0 !XA%0 <(AL &R(A
M !HB*  :(S  &2,X !@D0@ 6)4T %259 !0F:  3)GD $B:- !$GH@ 0)[@
M#B?6 ! H]  1)_\ $2?_ )Q   "110  AT@  'U*  !T2@  :DD  &!&  !5
M00  3#X  $,Z   Z-@  ,3(  "@M   @*0D &R<. !DG$@ 8)Q@ %B<? !4H
M)0 4*"T $R@V !(I0  2*4L $2I7 ! J9@ .*W< #BN+  TLGP ,++4 "RS/
M  PL[P -+/\ #2O_ )E$  "/20  A4P  'Q.  !S3P  :4X  %Y+  !31P
M2D0  $)    Y/0  +S@  "4T   =, 4 %BT, !0L$  3+14 $BT< !$M(P 0
M+2H #RXS  XN/0 -+T@ #2]5  PP8P *,'0 "3"(  @QG  &,;$ !C'+  8Q
MZP ',/P "##_ )=(  "-30  @U$  'I3  !Q5   9U(  %U0  !23   24H
M $!&   U0@  *SX  "(Z   :-P$ $C0)  \S#@ .,Q, #3,9  TS(  ,-"@
M"S0Q  HU.P (-48 !S52  4V8  $-G$  C:$   VF0  -J\  #;(   VZ
M-OD  37_ )1-  "*4@  @58  'A8  !O60  95@  %M5  !14@  1T\  #Q,
M   Q2   )T0  !Y!   6/P  $#P'  LZ#0 ).A$ "#L7  8['@ %.R8 !#LN
M  ([.  !/$,  #Q/   \7@  /&X  #R!   \EP  /*P  #O%   [YP  ._@
M #O_ )%2  "(6   ?UP  '9=  !M7@  8UT  %I<  !.6   0E0  #=1   M
M3@  (TL  !I)   21@  #40&  =##  #0Q   $,5  !#&P  0R,  $,K  !#
M-0  0T   $--  !#6P  0VL  $-^  !#E   0JH  $+#  !!Y@  0?D  $'_
M (Y8  "&7@  ?6$  '-C  !K9   8F,  %=A  !)70  /5H  #)8   G50
M'E,  !51   .3P  "4T%  )-"P  3 X  $P3  !+&   2Q\  $LH  !+,@
M2ST  $M)  !+5P  2V<  $I[  !*D   2:<  $G   !(Y   2/@  $?_ (M?
M  "#9   >F<  '%I  !I:@  7FD  %!F  !#9   -V$  "Q?   A70  &%L
M !!9   *6    U<#  !7"0  5@T  %40  !5%0  5!L  %0C  !4+0  5#D
M %1%  !44P  5&0  %-W  !3C0  4J0  %&]  !0X@  4/@  $__ (AG  !_
M:P  =VX  &]P  !E<   5VX  $IL   ]:P  ,&D  "5H   :9@  $60   MC
M   $8@   &(!  !A!@  8 L  & .  !?$@  7Q<  %\>  !>*   7C,  %Y
M  !>3P  7E\  %UR  !=B   7*   %NY  !:WP  6?<  %C_ (1N  !\<@
M=74  &MV  !==0  3W0  $)S   U<P  *'(  !UP   3;P  #&X   1N
M;@   &X   !L @  ; <  &L+  !K#@  :Q(  &H9  !J(@  :BT  &HZ  !I
M20  :5H  &EL  !H@P  9YL  &:U  !EV   9/4  &3_ (!U  !Z>0  <'L
M &)[  !4?   1GP  #E\   L?   'WL  !1Z   ->@  !'H   !Z    >@
M 'H   !Y    >0$  '@&  !X"P  > X  '@3  !X&@  >"4  '@R  !W00
M=U(  '=E  !V?   =94  '2O  !SS@  <O$  ''_ 'Y]  !U@   9X$  %B"
M  !*@P  /(0  "Z%   AA0  %84   V%   #A0   (8   "'    B    (@
M  "'    AP   (<   "'!   APD  (<.  "($P  B!P  (@I  "(.   ATH
M (==  "&<P  AHT  (6G  "$Q0  @^P  (+^ 'B$  !JA@  7(@  $V*   _
MC   ,8X  "./   6CP  #9    *1    D@   ),   "5    E@   )8   "6
M    E@   )8   "7    EP   )<'  "8#0  F1,  )H?  ":+0  FC\  )I2
M  "::   F8,  )F?  "8N@  E^(  );X &V*  !?C0  4)   $&3   SE@
M))<  !:8   -F0   9L   "=    GP   *$   "D    I0   *0   "E
MI0   *8   "G    J    *D   "J!   K P  *X3  "N(0  KC,  *Y'  "N
M70  KG8  *Z3  "NK@  K<T  *SO &&1  !3E0  1)@  #6<   FGP  %Z$
M  VC    I0   *<   "J    K    +    "R    M    +,   "T    M0
M +<   "X    N0   +L   "]    OP$  ,,+  #%%0  Q24  ,8Y  #'3P
MQV@  ,:%  #&H@  QKP  ,;> %69  !'G0  .*(  "FF   9J   #:L   "M
M    L0   +0   "W    N@   +\   #!    Q    ,,   #%    Q@   ,@
M  #*    S0   ,\   #2    U@   -L   #@#   X1@  .,K  #D00  Y5H
M .9T  #FD0  Y:P  .7$ /\   #_    _P   /\  0#_  H _P 2 /\ '0#_
M "@ _P T /\ /@#] $@ ^@!0 /< 5P#U %T ] !C /( :0#P &\ [P!T .T
M>P#K ($ Z0") .@ D@#F )P Y "H .( MP#? ,T W #N -D _P#9 /\ R@#_
M +X _P"U /\ L #_ /\   #_    _P   /\   #_  8 _P / /P & #X ",
M]  N /  . #K $( Z !* .4 40#B %@ X != -X 8P#< &@ V0!N -8 = #4
M 'L T0"" ,\ BP#- )4 R@"A ,@ KP#% ,$ P@#C ,  ^P#  /\ NP#_ +
M_P"H /\ I #_ /\   #_    _P   /L   #S  $ [0 , .@ $P#C !X X  H
M -H ,@#3 #P SP!$ ,P 2P#) %$ Q@!7 ,0 70#" &( P0!G +\ ;0"] '0
MNP![ +D A "W (X M "9 +( IP"O +< K0#0 *L \@"J /\ J0#_ *$ _P";
M /\ EP#_ /\   #_    ]    .D   #@    U0 ( ,X $ #) !@ Q0 B ,$
M*P"\ #4 N0 ] +8 10"S $L L0!1 *\ 5@"N %L K !A *H 9@"I &T I@!T
M *0 ? "B (8 H "2 )X GP"< *X F0## )< YP"6 /\ E0#_ )( _P"- /\
MB@#_ /P   #P    XP   -0   #(    OP # +D #0"S !, KP < *P )0"I
M "X I0 V *, /@"@ $0 G@!* )T 4 "; %4 F0!: )< 7P"6 &8 E !L )(
M=0"0 'X C@"* (L EP") *8 AP"X (4 U@"$ /8 @@#_ ($ _P!^ /\ ? #_
M .T   #=    S    ,$   "X    K@   *< "0"B !  G@ 7 )H 'P"7 "<
ME  O )$ -P"/ #T C0!# (L 20") $X B !3 (8 60"$ %\ @@!E (  ;0!^
M '< ? "" 'H CP!X )X =0"O ', QP!R .P <0#_ '  _P!P /\ ;@#_ -T
M  #)    O    +$   "I    H0   )D  P"3  P C@ 2 (H &0"' "$ A  I
M ($ , !_ #< ?0 ] 'L 0@!Y $@ > !- '8 4@!T %@ <@!? '$ 9P!O '
M; ![ &H B !H )< 9@"H &4 O !C .$ 8@#Z &$ _P!A /\ 80#_ ,T!  "\
M!0  KP4  *4"  "<    E    (T   "&  @ @0 . 'P % !X !L =0 C '(
M*0!P #  ;@ V &T / !K $$ :0!' &@ 3 !F %( 9 !9 &, 8 !A &D 7P!T
M %T @0!; )  60"A %< M !6 -  50#R %4 _P!4 /\ 50#_ ,$,  "R#@
MI@\  )L.  "2"P  B04  ((   ![  ( =0 + '  $ !L !8 :  = &8 (P!C
M "H 80 P &  -@!> #L 70!! %L 1@!: $P 6 !3 %8 6P!4 &0 4@!N %$
M>P!/ (H 30"; $P K@!+ ,8 2@#J $D _@!) /\ 20#_ +D2  "J%@  GA<
M )06  "*$P  @1   'D+  !Q P  :P & &4 #0!A !$ 70 8 %H '@!8 "0
M5@ J %0 , !3 #8 40 [ %  00!. $< 30!. $L 5@!) %\ 1P!I $8 =@!$
M (4 0P"7 $$ J0!  +\ /P#B #\ ^  ^ /\ /P#_ +(9  "D'@  F!\  (X?
M  "$'   >A@  '(2  !J#@  8@@  %P!" !7  X 4P 3 %  &0!. !\ 3  E
M $H *P!( #  1P V $8 / !$ $( 0P!) $$ 40 _ %H /@!E #P <@ Z ($
M.0"3 #@ I0 V +H -@#; #4 ]  U /\ -0#_ *P@  "?)   E"8  (DF  !_
M)   =2   &P;  !D%0  7!   %0, 0!.!@H 2@(/ $< % !$ !H 0@ @ $
M)0 _ "L /@$Q #P!-P [ CX .0)% #@#30 V U8 -01A #,$;@ Q!7X , 60
M "\%HP M!K@ + ;4 "P'\  L"/\ + C_ *@E  ";*@  D"P  (8M  ![*P
M<B<  &@B  !?'0  5Q<  $\2  !(#@0 00H+ #X'$  [!A4 .0<; #@'(0 V
M""8 -0@L #,(,@ R"3D ,0E! "\)20 N"E, + I> "L+;  I"WP * R/ "8,
MH@ E#+< ) S3 ",-\  D#?\ )0W_ *0J  "8+P  C3(  (,R  !Y,0  ;RX
M &4I  !<)   4Q\  $L9  !#$P  /! & #4-#  S#!$ ,0P6 "\,'  N#2(
M+0TH "L-+@ J#34 *0T] "<.1@ F#E  ) Y< ",/:@ B#WL (!". !\0H@ =
M$+< '!#4 !T1\@ =$?\ 'A'_ *$O  "5,P  BC8  ( W  !V-@  ;3,  &,O
M  !9*@  4"4  $@@   _&@  .!4  # 1"  L$ X *A 2 "@0&  G$!X )1 D
M "00*@ C$3( (A$Z "$10P @$DX 'A): !T3:  ;$W@ &A.+ !@4H  7%+4
M%A31 !85\0 7%?\ &!3_ )XS  "3-P  B#H  'X[  !T.P  :S@  &$T  !7
M+P  3BL  $4F   ](0  -!P  "T7!0 F$PP (Q,0 "(3%0 @$QH 'Q,A !X4
M)P =%"\ '!4W !L500 :%DL &197 !<790 6%W8 %!B) !,8G@ 2&+, $1G.
M !$9[P 2&?\ $QG_ )PV  "1.P  ACX  'P_  !S/P  :3T  %\Y  !5-0
M3#   $,L   Z)P  ,B(  "H> 0 B&0D 'A<. !P7$@ :%Q< &1@> !D8)  8
M&2P %QDT !8:/@ 5&DD $QM5 !(;8P 1''0 $!R'  \=G  .';$ #1W+  T=
M[  .'?\ #QW_ )DZ  "//P  A$(  'M$  !Q0P  :$(  %X^  !3.@  2C8
M $$R   Y+0  ,2D  "@E   @( 8 &AT, !<<$  5'!4 %!T; !0=(@ 3'2D
M$AXR !$?/  0'T8 $"!3  X@80 -(7$ #"&%  LBF0 *(JX "2+'  DBYP *
M(OL "R'_ )<^  ",0P  @T8  'E(  !P2   9T8  %Q$  !2/P  23L  $ X
M   X-   +S   "<L   >)P, %B,* !(A#@ 1(1, $"(9 ! B(  /(B< #B,O
M  TD.0 ,)$0 "R50  HE7@ ))F\ !R:"  8FE@ $)JP  R;$  0FY0 $)O<
M!B;_ )5"  "*1P  @4H  'A,  !O3   94L  %M(  !01   1T$  #\^   W
M.P  +38  "0Q   ;+0  $RH'  \H#0 -)Q$ #2@6  PH'0 +*"4 "BDM  DI
M-P '*D( !BI.  0K7  #*VP  2M_   KE   *ZD  "O!   KXP  *_8  "K_
M ))&  "(2P  ?T\  '91  !M40  8U   %I-  !/2@  1T<  #Y$   S0
M*3P  " X   7-   $3$%  PO#  )+A  !RX5  8O&P %+R,  R\K  (P-0
M,#\  #!,   Q60  ,6D  #%\   QD0  ,:<  #"_   PX0  ,/4  "__ )!+
M  "&4   ?50  '56  !K5@  8E4  %A3  !.4   14T  #I)   O10  )4(
M !P^   4.P  #CD%  DW"P $-@\  383   V&0  -B   #8I   V,@  -ST
M #=)   W5P  -V<  #=Y   WCP  -J4  #:]   VX   -?4  #7_ (U0  "$
M5@  ?%H  ');  !I6P  8%L  %=9  !,5@  0%(  #5.   J2P  ($@  !=&
M   00P  "T$$  1 "@  /PX  #X1   ^%@  /AT  #XF   ^+P  /CH  #Y&
M   ^5   /F0  #YV   ]C   /:,  #R[   \W@  ._4  #O_ (I7  ""7
M>5\  '!A  !H80  7V$  %1>  !'6P  .E<  "]5   E4@  &U   !)-   ,
M2P  !DH#  !)"0  2 T  $<0  !'%   1AH  $8B  !&+   1C<  $9#  !&
M40  1F   $5S  !%B0  1*   $2X  !#W   0O4  $+_ (A=  !_8@  =V4
M &YG  !G:   6V8  $YC  !!80  -%X  "E<   ?6@  %5<   Y6   '5
M %,!  !2!@  40L  %$.  !0$0  3Q8  $\>  !/)P  3S(  $\_  !/30
M3ET  $YO  !.A0  39T  $RU  !+V   2O4  $K_ (5E  !\:0  =&P  &UN
M  !B;0  5&L  $=I   Z9P  +64  ")D   88@  $&    E?    7@   %X
M  != P  7 @  %L,  !:#P  6A,  %D9  !9(@  62T  %DZ  !92   6%@
M %AK  !7@0  5YD  %:R  !5T@  5/0  %/_ (%L  !Y<   <W,  &AS  !:
M<@  3'$  #]P   R;P  )6X  !IL   1:P  "6H   !J    :0   &D   !H
M    9P,  &8(  !F#   9@\  &44  !E'   92<  &0T  !D0P  9%,  &1E
M  !C>P  8I0  &&M  !@S0  7_$  %[_ 'UT  !W=P  ;GD  %]Y  !1>0
M0WD  #9X   I>   ''<  !%V   *=0   '4   !U    =@   '4   !T
M=    ',"  !S!P  <PP  '(0  !R%0  <B   '(L  !R.P  <4P  '%?  !Q
M=   <(X  &^H  !NQ@  ;.T  &O_ 'M[  !R?@  9'X  %5_  !'@   .8$
M "N"   >@0  $H$   J!    @0   ((   "#    @P   (,   ""    @@
M ((   ""    @@4  ((*  ""#P  @A<  ((C  "",@  @D,  (%6  "!;
M@(8  '^A  !^O0  ?>8  'S\ ':"  !H@P  684  $N'   \B0  +HH  ""+
M   3BP  "HL   ",    C0   (\   "1    D@   )$   "1    D0   )$
M  "1    D@   )("  "3"0  E \  )09  "4)P  E#@  )1,  "38@  DWP
M ).8  "2LP  D=@  )#V &J(  !<B@  38T  #^0   PD@  (90  !25   *
ME@   )<   "9    FP   )T   "?    H    *    "@    H    *$   "B
M    HP   *0   "E    I@<  *@0  "H'   J"T  *E   "I5@  J6\  *F+
M  "HJ   I\<  *;L %^/  !0D@  098  #.9   CG   %)T   J?    H0
M *,   "F    J    *P   "N    KP   *\   "P    L    +(   "S
MM    +8   "W    N@   +T'  "_$   OQ\  , S  # 20  P&(  ,!^  #
MFP  P+<  +_8 %.7  !$FP  -9\  ":C   6I0  "Z<   "J    K0   +
M  "S    M@   +L   "]    P    +\   #!    P@   ,0   #&    R
M ,H   #,    SP   -,   #:!P  VQ,  -TE  #>.P  WU,  .!N  #?C
MW:D  -W" /\   #_    _P   /\   #_  < _P 0 /\ &0#_ "0 _P O /P
M.@#Y $, ]0!+ /, 4@#Q %D [P!> .T 9 #K &D Z0!O .< =0#F 'P Y "$
M .( C0#@ )< W0"B -H L0#5 ,4 T@#H -  _P#/ /\ Q #_ +@ _P"O /\
MJ0#_ /\   #_    _P   /\   #_  ( ^P - /< %0#S !\ [P I .H - #F
M #T X@!% -X 3 #; %, V !8 -0 7@#2 &, T !I ,X ;@#, '4 R@!] ,@
MA0#& )  P@"; ,  J0"^ +H NP#9 +D ]P"X /\ M #_ *D _P"B /\ G0#_
M /\   #_    _P   /8   #N    YP * .$ $0#< !H UP C -  +@#+ #<
MQP _ ,0 1@#! $T OP!2 +T 6 "[ %T N0!B +@ : "V &X M !U +$ ?@"O
M (@ K0"3 *H H0"H +$ I@#( *0 [0"B /\ H@#_ )L _P"5 /\ D0#_ /\
M  #\    [@   .,   #8    S0 % ,8 #@#! !4 O0 > +D )P"U #  L@ X
M *\ 0 "L $8 J@!, *@ 40"G %8 I0!; *, 80"A &< GP!N )X =@"; (
MF0", )< F0"4 *@ D@"\ )  WP". /L C@#_ (L _P"& /\ @P#_ /@   #I
M    W    ,P   #!    N    +( "@"L !$ J  8 *4 (0"B "D G@ R )P
M.0"9 #\ EP!% )4 2@"4 %  D@!5 )  6@"/ &  C0!G (L ;P") '@ A@"$
M (0 D0"" *  @ "R 'T S !\ /$ >P#_ 'H _P!W /\ =0#_ .8   #3
MQ@   +L   "Q    IP   *$ !0";  T EP 3 ), &P"0 ", C  K (H ,@"(
M #@ A@ ^ (0 1 "" $D @0!. '\ 4P!] %D >P!@ 'D : !W '$ =0!\ ',
MB0!P )@ ;P"I &T OP!K .8 :@#_ &D _P!I /\ 9P#_ -,   ##    M0
M *L   "C    FP   )(   ",  H AP 0 (, %@!_ !T ?0 D 'H *P!X #(
M=@ X '0 /0!R $( <0!( &\ 30!M %, ; !9 &H 80!H &H 9@!T &0 @0!A
M )$ 7P"B %X M@!< -4 6P#W %L _P!: /\ 6@#_ ,4   "V @  J0(  )\
M  "6    C@   (<   "   4 >@ , '4 $0!Q !@ ;@ > &L )0!I "L 9P Q
M &8 -P!D #P 8P!! &$ 1P!? $T 7@!3 %P 6P!: &0 6 !N %8 >P!4 (H
M4@"; %$ K@!0 ,@ 3P#N $X _P!. /\ 30#_ +L*  "L#0  H T  )4,  ",
M"   @P(  'P   !U    ;@ ( &D #@!E !, 8@ 9 %\ 'P!= "4 6P K %D
M,0!8 #8 5@ [ %4 00!3 $< 40!. %  50!. %X 3 !H $H =0!( (0 1P"5
M $4 J !$ +\ 0P#D $( _ !" /\ 0@#_ +(1  "E%   F14  (X3  "$$0
M>PT  ',(  !L    90 # %\ "P!;  \ 5P 4 %0 &@!1 !\ 3P E $X *P!,
M #  2P V $D / !( $( 1@!( $4 4 !# %D 00!C #\ ;P ^ 'X / "0 #L
MHP Z +@ .0#9 #@ ]0 X /\ . #_ *P7  "?&P  DQT  (D<  !_&0  =14
M &P0  !D#   708  %8 !@!1  P 30 0 $H %0!' !H 10 @ $0 )@!" "L
M00 Q #\ -@ ^ #T / !$ #L 2P Y %0 -P!? #8 :P T 'H ,@", #$ G@ P
M +, +P#. "\ [P N /\ +@#_ *<>  ":(@  CR0  (0D  !Z(0  <1T  &<8
M  !?$P  5PX  % *  !) P@ 10 - $$ $0 ^ !8 /  ; #H (0 Y "8 -P L
M #8 ,@ T #@ ,P _ #$ 1P P %  +@!; "T 9P K '8 *@"( "@ G  G +
M)@#) "4 Z@ E ?L )0'_ *(C  "6*   BRH  ($J  !W*   ;24  &0@  !;
M&P  4A4  $L0  !## ( /0<) #D##@ V 1( ,P$7 #$!'  P 2( +P(G "T"
M+0 L S0 *@,[ "D$0P H!$T )@58 "4%90 C!G0 (@:& " &F@ ?!ZX '@?&
M !T'YP ="/@ '0G_ )\H  "3+0  B"\  'XO  !T+@  :BL  &$F  !8(0
M3QP  $<7   _$@  . X$ #$+"@ N" X *P<2 "D'%P H"!T )P@C "4(*0 D
M"3  (PDW "$*0  @"DH 'PM5 !T+8@ ;#'( &@R% !@,F0 7#*T %@S& !4-
MY@ 5#?D %@W_ )PM  "0,0  AC0  'PT  !R,P  :#$  %\L  !5)P  3",
M $0=   \&   -!,  "T0!@ F#0L ) P/ "(,$P A#!D 'PP? !X-)0 =#2P
M&PTT !H./0 9#D< %PY3 !8.80 4#W$ $Q"$ !(0F  1$*X $!#& ! 0Z  0
M$/L $1#_ )DQ  ".-0  A#@  'HY  !P.   9S8  %TR  !3+0  2B@  $(D
M   Y'P  ,1H  "H5 0 C$0< '1 - !L/$  9#Q4 &! ; !<0(0 6$"D %1 Q
M !01.@ 3$44 $A)1 !$27P 0$F\ #A."  X3E@ -$ZL "Q/"  L4XP ,%/H
M#1/_ )<U  ",.0  @CP  '@]  !O/0  93H  %LW  !2,@  22X  $ J   W
M)0  +R$  "@<   @& , &10* !42#@ 4$A( $Q,8 !(3'P 1%"8 $10N ! 4
M.  /%4( #A9/  T67  ,%VP "Q=_  D8DP (&*@ !AB_  <8X  '&/4 "1C_
M )4X  "*/0  @$   '=!  !M00  9#\  %H\  !0.   1S,  #XP   V*P
M+B<  "<C   ?'P  %QH( !(7#0 0%Q$ #Q<6  X8'  .&", #1DL  P:-0 +
M&D  "AM,  D;6@ ''&D !1Q\  0=D0 "':8  1V\  (<W0 "'/(  QS_ ),\
M  "(00  ?T0  '5%  !L10  8T0  %E!  !//0  1CD  #XV   U,@  +BX
M "4J   =)0  %"$$  \="P -'1  #!T4  L=&@ *'B( "!XJ  <?,P &(#X
M!"!*  ,A5P !(6<  "%Y   AC@  (:0  "&Z   AVP  (?(  "#^ )!   "&
M10  ?4@  '1*  !K2@  8DD  %A&  !.0@  13\  #T\   U.0  *S0  "(O
M   9*P  $B@$  TD"@ )(PX !B,2  4C&0 $)"   B0H  $E,0  )3P  "5(
M   F50  )F4  "9W   FC   )J(  ":Y   FV0  )?(  "7^ (Y%  "$20
M>TT  '-/  !J3P  8$X  %=+  !-2   1$4  #Q"   Q/0  )SD  !XU   5
M,@  #RX#  HL"@ %*PX  2H1   J%@  *AX  "HF   K+P  *SD  "M%   L
M4P  +&(  "QU   LB@  *Z   "NW   KU@  *O(  "K_ (Q)  ""3@  >E(
M '%4  !H5   7U,  %91  !,3@  0TL  #='   M0P  (S\  !H\   2.
M##8#  8S"0  ,@T  #(0   Q%   ,1L  #$C   Q+   ,C<  #)#   R4
M,F   #)R   RAP  ,9X  #&U   PU   ,/(  "__ (E/  " 5   >%<  &]9
M  !F60  7ED  %57  !)4P  /D\  #),   H2   'D4  !5"   .0   "#T"
M  $\"   .PP  #H/   Y$@  .1@  #D@   Y*0  .30  #E    Y3@  .5T
M #EO   XA0  .)P  #>S   WT@  -O(  #7_ (=5  !_6@  =ET  &U?  !E
M7P  75\  %)<  !$6   .%4  "U2   B3P  &$P  !!*   *2    T8!  !%
M!@  1 H  $,-  !"$   014  $$=  !!)@  03$  $$]  !!2@  05H  $%L
M  ! @0  /YD  #^Q   ^T   /?(  #S_ (1<  !\8   <V,  &QE  !D9@
M660  $MA   ^7@  ,EL  "99   <5@  $E0   Q2   $40   $\   !. P
M30@  $P,  !+#@  2Q(  $H9  !*(@  2BP  $HY  !*1P  2E8  $EH  !)
M?@  2)8  $>O  !&S0  1?$  $3_ (%C  !Y9P  <FH  &ML  !@:P  4FD
M $1F   W9   *F(  !]@   57@  #5T   9;    6@   %D   !8    5P0
M %8(  !6#   51   %04  !4'0  5"<  %0T  !40@  4U(  %-D  !2>0
M4I(  %&K  !0R@  3^\  $[_ 'YJ  !W;@  <'$  &9Q  !8<   2F\  #QM
M   O;   (FH  !=I   .9P  !F8   !E    90   &4   !C    8@   &($
M  !A"   80T  & 0  !@%P  8"$  %\N  !?/   7TT  %Y>  !>=   78T
M %RG  !;Q0  6NT  %G_ 'MR  !U=@  :W<  %UV  !/=@  074  #-U   F
M=   &7,  !!R   '<0   '$   !Q    <0   '$   !O    ;P   &X   !N
M @  ;@@  &T,  !M$0  ;1H  &TF  !L-0  ;$8  &M8  !K;0  :H8  &FA
M  !HO@  9^@  &;^ 'EZ  !P?   87P  %-]  !$?0  -GX  "A^   ;?0
M$'T   =]    ?0   'T   !^    ?P   'X   !]    ?0   'P   !\
M?    'P&  !\#   ?!(  'P=  !\+   ?#P  'Q/  ![90  >WX  'J:  !Y
MM@  >-\  '?Z '.   !E@0  5H,  $B$   YA@  *X<  !V'   1AP  !X@
M  "(    B0   (H   ",    C0   (T   ",    C    (P   ",    C
M (T   "-!   C@P  (X3  "/(0  CC(  (Y&  ".6P  C70  (V0  ",K0
MB\X  (KS &B&  !:B   2XL  #R-   MCP  'I   !&1   'D@   ),   "5
M    EP   )D   ";    G    )L   ";    G    )P   "=    G@   )X
M  "?    H0,  *(,  "B%@  HR8  *,Z  "C3P  HV@  **&  "BH@  HL
M *'H %R-  !-D   /Y,  #"6   AF0  $IH   >;    G0   *    "B
MI    *@   "J    JP   *H   "K    K    *T   "N    KP   +$   "R
M    M    +<!  "Y#0  N1H  +HM  "Z0P  NEL  +IW  "[E   N[$  +G2
M %"5  !!F   ,IP  ".@   3H@  "*0   "G    J@   *P   "O    L@
M +<   "Y    NP   +H   "\    O0   +\   #     P@   ,0   #&
MR0   ,T   #2 0  U \  -4?  #7-0  V$T  -AI  #7A@  UZ,  -:] /\
M  #_    _P   /\   #_  , _P - /\ %0#_ "  _  K /@ -0#T #\ \ !'
M .X 3@#K %0 Z0!: .< 7P#E &0 XP!J .$ < #? '8 W0!^ -L AP#8 )$
MTP"= ,\ JP#- +T RP#@ ,D ^P#' /\ O0#_ +$ _P"I /\ HP#_ /\   #_
M    _P   /\   #\    ]@ + /$ $0#M !L Z0 E .0 , #? #D V@!! -4
M2 #1 $X SP!4 ,T 60#+ %X R0!C ,< :0#% &\ PP!W ,  ?P"^ (H NP"5
M +@ HP"V +0 M #- +( \@"P /\ K #_ *, _P"< /\ EP#_ /\   #_
M^@   /$   #H    X  & -D #@#2 !8 S@ ? ,@ *0#$ #( P  Z +T 00"Z
M $@ N !- +8 4P"T %@ L@!= +  8@"N &D K !O *H > "H (( I@". *0
MFP"A *L GP#  )T Y@"; /\ F@#_ )0 _P". /\ B@#_ /\   #V    Z
M -P   #.    Q@ ! +\ "P"Z !$ M@ : +( (@"N "L J@ T *@ .P"E $$
MHP!' *$ 3 "? %$ G@!6 )P 7 ": &( F0!H )< < "5 'H D@"& )  DP"-
M *( BP"U (D TP"' /< A@#_ (0 _P!_ /\ ? #_ /(   #C    T@   ,4
M  "Z    L0   *L !P"E  X H0 4 )X ' ": "4 EP M )0 - "2 #H D !
M (X 10"- $H BP!0 (D 50"( %L A@!A (0 :0"" '( ?P!] 'T BP![ )H
M> "K '8 Q !T .L <P#_ ', _P!P /\ ;@#_ -\   #,    OP   +0   "K
M    H0   )H  @"4  L D  0 (P %P"( !X A0 F (, +0"! #, ?P Y 'T
M/P![ $0 >0!) '@ 3@!V %0 = !: ', 8@!P &L ;@!U &P @P!J )( : "C
M &8 N !D -X 8P#[ &( _P!B /\ 8 #_ ,P   "\    KP   *4   "=
ME    (P   "&  < @0 - 'P $@!X !D =0 ? ', )@!Q "T ;P R &T . !K
M #T :@!" &@ 2 !G $X 90!4 &, 6P!A &0 7P!N %T >P!; (H 60"; %<
MKP!6 ,L 50#R %0 _P!4 /\ 5 #_ +X   "P    I    )D   "0    B
M ($   !Y  ( <P * &\ #P!K !0 9P : &4 ( !C "8 80 L %\ ,@!> #<
M7  \ %L 0@!9 $< 5P!. %8 50!4 %X 4@!H %  = !. (, 3 "5 $H J !)
M ,  2 #H $< _P!' /\ 1P#_ +0)  "F"P  FPP  ) *  "&!0  ?@   '8
M  !O    :  % &, # !? !  6P 5 %@ &@!6 "$ 5  F %, + !1 #$ 4  V
M $X / !- $( 2P!( $D 4 !( %@ 1@!B $0 ;@!" 'T 0 ". #\ H@ ] +@
M/0#= #P ^  \ /\ / #_ *P0  "?$@  E!(  (D1  !_#P  =@P  &X%  !F
M    8  ! %D " !5  T 40 1 $X %@!+ !L 20 A $@ )@!& "L 10 Q $,
M-@!" #P 0 !# #X 2P ] %, .P!= #D :0 W '@ -@") #0 G  S +$ ,@#.
M #( \0 Q /\ ,0#_ *86  ":&0  CAH  (0:  !Z%@  <!(  &@.  !?"@
M6 ,  %$ ! !,  H 2  . $0 $@!! !8 /P ; #T (0 \ "8 .@ L #D ,0 W
M #< -@ ^ #0 1@ S $\ ,0!9 "\ 90 N ', + "% "L F  J *T *0#& "@
MZ@ H /X * #_ *$<  "5(   BB$  '\A  !U'P  ;!H  &,6  !:$0  4@T
M $L'  !$  8 0  + #P #P X !( -@ 7 #0 '  S "$ ,0 G #  +  N #,
M+0 Z "L 0@ J $L * !5 "8 80 E '  ) "! "( E0 A *D ( #! "  Y  ?
M /D 'P#_ )TB  "1)@  AB@  'PG  !R)0  :2(  %\=  !7&   3A,  $8.
M   _"P  . 4' #0 #  Q !  +@ 3 "P &  J !T *0 B "< *  F "X )  V
M ", /@ B $< ( !2 !\ 7@ = &T ' !^ !H D@ 9 *< & "] !< WP 7 ?4
M%P+_ )HG  ".*P  A"T  'DM  !P*P  9B@  %TD  !4'P  2QH  $,4   [
M$   - T" "T)"0 I!0T )@,0 "0!$P B AD (0(> " ")  > RH '0,R !L$
M.@ :!40 &05/ !<&7  6!FH % =\ !,'D  2!Z4 $0>[ ! 'VP 0"/( $ G_
M )<K  ",+P  @3$  '<R  !N,0  9"X  %LJ  !1)0  22   $ ;   X%@
M,1(  "D.!  C# D 'PD- !T'$  ;!Q4 &0@: !@((  7"2< %@DN !4*-P 3
M"D$ $@M- !$+6@ 0"VD #@Q[  X,D  -#*4 # V[  L-V0 +#?$ # W_ )4O
M  "*,P  ?S8  '8V  !L-0  8S,  %DO  !0*P  1R8  #XA   V'0  +A@
M "<3   @$ 4 &0X* !4,#@ 4#!$ $PP6 !(,'  1#2, $ TK  \--  .#C\
M#0Y*  P/6  +#V< "A!Y  @0C0 '$*( !A"X  40U  %$.\ !A#_ )(S  "(
M-P  ?CH  '0[  !K.@  83@  %@U  !.,   12P  #TG   U(P  +1\  "8:
M   >%@$ %Q,& !$0"P .#@X #@\3  T0&0 -$"  #! H  L1,@ *$3P "!)(
M  <250 &$V4 !!-V  ,3BP !%*   !.V   3T0  $^X  !/[ ) V  "&.P
M?#X  ',_  !J/P  8#T  %<Y  !--@  1#$  #PN   T*@  +"8  "4B   >
M'@  %AH" ! 5"0 ,$PX "A,2  D4%P (%!\ !Q4F  85+P $%CH  Q9&  $7
M4P  %V(  !AT   8B0  &)\  !BU   7T   %^T  !?[ (XZ  "$/P  >T(
M ')#  !H0P  7T(  %8_  !,.P  0S<  #LT   S,   +"P  "0I   ;)
M$Q\"  T;"0 )&0T !AD1  09%@ "&1T  1HD   :+0  &S@  !M$   <40
M'&   !UR   =AP  ')T  !RS   <S@  &^T  !O\ (P^  ""0P  >48  '!(
M  !H2   7D8  %5$  !+0   0ST  #LZ   S-P  *C(  " M   7*0  $"4"
M  LB"0 %( T  1\0   ?%   'QL  " B   @*P  (38  "%!   A3P  (5X
M ")P   BA0  (9L  "&R   AS0  (.T  !_\ (I#  " 2   >$L  &],  !F
M30  74L  %1)  !*1@  0D,  #I    O.P  )3<  !PS   3+P  #2P"  <I
M"  !)PP  "8.   E$@  )AD  "8A   F*0  )C,  "<_   G30  )UP  "=M
M   G@@  )YD  ":P   ES   )>X  "3] (A(  !_3   =E   &Y1  !E4@
M7%$  %-/  !*3   04D  #5$   K0   (3P  !<Y   0-@  "C(!  ,P!P
M+PL  "X.   M$0  +18  "T>   M)P  +3$  "T]   M2@  +5D  "UK   M
M@   +)<  "RO   KRP  *NX  "K^ (5-  !]4@  =54  &Q7  !C5P  6U8
M %-5  !'40  .TT  #!)   E1@  '$,  !,_   -/0  !CH    X!0  -PD
M #8-   U#P  -!0  #0;   T)   -"X  #0Z   T1P  -%<  #1H   T?0
M,Y4  #*M   QR@  ,>X  ##_ (-3  ![6   <UL  &I=  !B70  6UT  $]:
M  !"5@  -E(  "I/   @3   %DD   Y'   (1    $(   !! P  /P<  #X+
M   ]#@  /1$  #P8   \(0  /"L  #PW   \1   /%,  #QE   [>@  .I(
M #JK   YR   ..T  #?_ (%:  !Y7@  <6$  &EC  !B9   5V(  $E>   \
M6P  +U@  "15   94P  $%$   I/   !30   $P   !*    200  $@(  !'
M#   1@\  $84  !%'   12<  $4S  !%0   15   $1A  !$=@  0X\  $*H
M  !!Q@  0.P  #__ 'YA  !V90  ;V@  &AJ  !=:0  3V8  $)D   T80
M*%\  !U=   26P  "UD   )8    5@   %8   !4    4P   %($  !1"0
M4 T  % 0  !/&   3R(  $\N  !//   3TL  $Y=  !.<@  38L  $RE  !+
MP@  2>H  $C_ 'MI  !T;   ;F\  &1O  !5;0  1VP  #EJ   L:0  (&<
M !1E   -9    V(   !B    80   &    !?    7@   %T   !<!   7 D
M %L-  !;$@  6QP  %HH  !:-@  6D8  %E8  !9;0  6(4  %>@  !6O0
M5>@  %/^ 'EP  !S=   :74  %MT  !,<P  /G,  #!R   C<0  %F\   UN
M   $;0   &T   !M    ;0   &P   !K    :@   &D   !I    :0,  &@)
M  !H#@  :!4  &<A  !G+P  9S\  &92  !F9@  97\  &2:  !CMP  8N$
M &'\ '=X  !M>@  7WH  %!Z  !">@  ,WL  "5[   8>@  #GD   1Y
M>0   'D   !Z    >@   'H   !X    >    '<   !W    =P   '<!  !W
M"   =PX  '<8  !W)@  =C8  '9)  !U7P  =7<  '23  !SKP  <M,  ''W
M '%^  !C?P  5(   $6"   V@P  *(0  !J$   .@P  !(0   "$    A0
M (8   "(    B0   (@   "'    AP   (<   "'    AP   (@   "(
MB <  (D0  ")'   B2P  (@_  "(50  B&T  (>)  "&IP  A<<  (3O &:$
M  !7A@  2(@  #F*   JC   &XT   ^-   $C@   )    "1    DP   )4
M  "7    F    )8   "7    EP   )<   "8    F    )D   ":    FP
M )T'  "=$0  G2$  )TS  "=20  G&(  )Q_  "<G   G+D  )OB %J+  !+
MC@  /)$  "V3   >E0  $)8   28    F@   )P   ">    H0   *0   "F
M    IP   *8   "G    IP   *@   "I    J@   *P   "M    KP   +$
M  "S"0  LQ4  +0G  "T/0  M54  +5P  "TC@  M*P  +3, $V2   _E@
M+YH  ""=   1GP  !:$   "C    I@   *D   "L    KP   +,   "U
MMP   +8   "W    N    +H   "[    O0   +\   #!    Q    ,<   #+
M    S0P  ,X:  #/+P  ST@  -!B  #0@   T)T  -"X
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MZ>KK[.WN[_#Q\O/T]?;W^/GZ^_S]_O]M9G0Q      ,!(0   0
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M____________SW0U"P    I2I_______________________________EC0
M      !/I______________________________V:1T   D,!@E2L?______
M_______________________+.PX3-4Q;34Q>P_______________________
M______^I8#9@AI^VK*FXV?_____________________________@EXV^Y?__
M____________________________________[?G_____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________________________________^O9RKS'____
M_______________________________/FH%M6D:(ZO__________________
M_____________\1\/B80  !4L/______________________________X(,\
M       NA^W_____________________________K%,0       7;=;_____
M_______________________[@#$        )8<S_____________________
M_______26@(         7<S___________________________^H-0
M    7-/___________________________]]#0          5-;_________
M_________________^Y]10          1-3_________________________
M__RJ9"\"   $(C=)6,[____________________________II&M!*#]C?Y6G
MNMK______________________________]6RK++,Y/K_________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________^6[EW=BR/_________________________________;
MGF<V"@ "C/_______________________________\A_/P4     7L______
M________________________V8$Y        /*K_____________________
M________GDP         (Y#____________________________<;QH
M    $'WY__________________________^O2            &_N________
M__________________^$$P           &3F________________________
M_^Q1             %?>_________________________[@5
M $C6_________________________W04             #C/____________
M____________^:):$P           "/%_________________________]^;
M7"P           VZ___________________________OL7U5.2(1!P$"$2*R
M_______________________________?OZ69F)J@K+W:________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________________COIV ?/O_____
M___________________________RMX17, X ':S_____________________
M_________]**3!4      '+S____________________________UG\V
M     $O)___________________________ZD3X          "^K________
M___________________ 6@           !J5________________________
M__^-)             B$_________________________^=>
M  !W_________________________[0E              !J____________
M_____________WT               !;]/_______________________2L
M              !,Z_______________________I0                 \
MX?______________________, P                MV?______________
M______^9BF$G               GU_______________________[;Z)52<
M           EW/_________________________^RIUV74H\,BTL,#E'WO__
M_____________________________>;=UM+0T]GD____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________^_4N];_________________________________Y[B/
M:DLO%6_______________________________^2A9S0'     #S)________
M____________________UH([         !*7________________________
M___MA3$           !O__________________________^F0@
M  !0X?_______________________^QI               WR?__________
M_____________[,O               BMO_______________________WD
M               0I_______________________\C0
MF?______________________J0                  C/______________
M________1@                  ?______________________?
M            =/____________________^7                    :O__
M___________________.                    8___________________
M____*2(!                8?______________________N:. 5S<7
M        :/__________________________^M.NE(9\=7%P<G>!E/______
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________;NIV":6G3________________________
M_______(DV4]&0   !V>____________________________VXY,$P
M  !N___________________________;?"P           !%U___________
M______________^+*@             BM/_______________________\)$
M               #E________________________WT!
M?_______________________YS8                 :O______________
M________G0                  6/______________________1@
M            1_C____________________I                    ->G_
M__________________^6                    )=O_________________
M__^\                    &,[____________________K
M        #\+_____________________                    "KG_____
M________________)P                  "K7_____________________
M<                   #;G_____________________X)R,<%5",R8;% \-
M#A(:)K_____________________________YY-C2SLS+S,_6X/S_________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________________________K
MT[SC________________________________TJF%94@L$@&%____________
M________________\:MQ/ \       !/X/_________________________5
M?S4            ?LO_______________________^-U'0
MB?_______________________Y C                9_______________
M________U4,                 2/;_____________________B@
M            +MW_____________________.                   %\C_
M__________________^^                    !+;_________________
M__^<                     *7___________________^Z
M         )/____________________<                     (+_____
M________________                     '3_____________________
M$P                   &C_____________________0@
M     &#_____________________>@                   %W_________
M____________T0                   &'______________________R0
M                 &;______________________\FLF8E]=G%L:6=F9VMP
M>HS_________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______BQ:J1>6%W_____________________________]VF=U L#      Q
MQ/_________________________@DDX3            C_______________
M_________])P'0              8/______________________[F\/
M            -^+_____________________EAP                 %,#_
M____________________0                    */_________________
M__^N                     (G___________________^>
M         '+___________________^\                     %______
M_______________:                     $W____________________Z
M                     #O_____________________#@
M     "KY____________________,P                   !OI________
M____________7@                    _;____________________CP
M                  ;0____________________T
M  #*_____________________RL                   #(____________
M_________X                    #+______________________<6 04%
M P$       $&#1C+_______________________\Z^'8S\S-S]#2U-?<XNK_
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________\=K&________________
M_______________QQJ.$:$TR&  5J___________________________N7Q&
M&           <?_______________________]=\+P              .^/_
M____________________WV0)                #+7_________________
M____= ,                  (W____________________%%0
M         &K___________________^9                     $O_____
M______________^V                     ##]___________________7
M                     !GG___________________V
M      73____________________#@                    #!________
M____________+P                    "O____________________4@
M                  ">____________________>0
M  ".____________________I0                    " ____________
M________V                     !T_____________________S8
M              !M_____________________WP                   !I
M_____________________]<-                  !H________________
M______]P                  !A________________________4#Q&3E19
M76%D:&QP=GZ)________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________________OU;NCBW-:E?__
M________________________^+^.9$$A!0      4OS_________________
M______>=5A@             %\'_____________________Y6P6
M         (W_____________________8P                   %[_____
M______________^=                     #7\__________________^A
M                     !'9___________________*
M      "[___________________N                      "A________
M____________#                     "*____________________+0
M                  !V____________________30
M  !D____________________;P                    !2____________
M________E                     ! ____________________O
M               P____________________Z@X                    B
M_____________________T0                    5________________
M_____X$                    +]?___________________\@+
M           "[/____________________]>                    Y?__
M___________________)'                   VO__________________
M____G0$             !PX7Q?_______________________]6YO,''SM7;
MX>;M]/O_____________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M______________________C?S______________________________LQJ6(
M;50[(0< ,M[________________________7DEDI             *#_____
M_________________XDV                 &?_____________________
M9@                   #+V__________________^5
M      /(__________________^G                      "@________
M___________7                      !\____________________
M                  !>____________________)0
M  !#____________________2                      L____________
M________:@                     8____________________BP
M               %\___________________KP
MX?__________________U0                      S_______________
M_____R0                     OO___________________U0
M            KO___________________XL                     G___
M_________________\L.                    DO__________________
M__]7                    AO____________________^J"@
M        >?______________________;0                  9O______
M________________]U4                 1?______________________
M__]J(RLU/TI58&IU?H>1G/______________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________Z,^VG8-I3KG_____________________
M____[+*#7#H= @       'O______________________\5M*0
M     $#_____________________@QL                   ?+________
M__________^2                      "8__________________^D
M                  !J___________________=
M  !!____________________#@                     =____________
M________.0                      Z/__________________8
M                SO__________________A0
MM___________________J                       H_______________
M____RP                      D/__________________[Q8
M            ??___________________SX                     ;/__
M_________________VD                     6O__________________
M_YD                     2?___________________](6
M        .?____________________]8                    *?______
M______________^B                    &?_____________________U
M5@                  !/______________________NR\
M     /C______________________ZLI                 ,__________
M_______________)1P     '$R N/E)HA.W_________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___TU<G____________________________ZTK"2=UU"* P  $K_________
M_______________%?447             !'8____________________Q%
M                  "?__________________^B#
M  !H__________________^4                       V____________
M_______:                       '[/__________________%0
M                Q/__________________2
MHO__________________=0                      @_______________
M____G0                      :?__________________PP
M            4O__________________YP\                     /O__
M_________________S,                     *___________________
M_U@                     &/___________________X$
M        !?___________________ZP                      /______
M_____________]XB                     /+___________________]<
M                     -____________________^?
M     ,S____________________H2@                   +?_________
M____________H!8                  )S______________________WH"
M                 '?_______________________]Z"P
M!4S_________________________HE=H=("-G*N\T.?_________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________[>/__________________________]*C>E@Z*2,<%@X&
M  "?_____________________ZQ2#@                !I____________
M_______D0P                     T__________________]Y
M                X__________________-
MLO__________________$P                      A?______________
M____3P                      7?__________________@P
M            .O__________________L@                      '/__
M________________VP,                      O__________________
M_RH                      /O__________________T\
M         .?__________________W0                      -3_____
M_____________YL                      ,#__________________\0'
M                     *W___________________ S
M     )K___________________]G                     (;_________
M__________^C                     '+____________________C1
M                 %S_____________________D08
M $'_____________________ZU\                  !W_____________
M_________\I+                  #________________________+5P
M#!@D,3].8'2+I\?__________________________]?G\O______________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________________________________________^O4
MS<?"OKJWL["MJ:BE____________________W7Y3/S C&1$) @
MV_________________]V                        I_______________
M__^Z                        =?__________________!P
M            1O__________________3@                      &O__
M________________C                        /W_________________
MP0                       -O_________________\1D
M         +[__________________T0                      *3_____
M_____________VL                      (W__________________Y$
M                     'G__________________[<
M     &;__________________]XA                     %/_________
M__________]*                     #____________________]W
M                 "O___________________^L"@
M !;____________________G10                    #_____________
M________B@                    #_____________________UDT
M              #]_____________________Z<N                  #5
M______________________^8*@          !A@M16#@________________
M________J&-T@8^<J[O-XOK_____________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________________________________^?+MZF=E8Z)
MA(!\>'1P;&AED/________________^\:D@M&0H                 ,?__
M________________                         ___________________
M0@                       -S_________________C@
M         ++_________________S@                       (W_____
M_____________RD                      &O__________________UH
M                     $[__________________X8
M     #3__________________ZX                      ![_________
M_________]07                      K___________________H]
M                  #___________________]E
M  #___________________^.                      #_____________
M______^\&0                    #O___________________Q3@
M              #8____________________BP                    "_
M____________________S$,                   "A________________
M_____Y$9                  !Z______________________)T"@
M         !%?_______________________H=!,?+#A%4V)RA9NTTO7_____
M_____________________]?H]/__________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________^_?S\>[LZ^OL\?__________________V;*9AWEM9%U644M&
M03PX,BTH(\3_________________2R4+                     )+_____
M____________B                        &;_________________UP
M                     #W__________________S,
M     !C__________________VP                       #_________
M_________YT                       #__________________\D,
M                  #V__________________$U
M  #?__________________];                      #+____________
M______^"                      "W__________________^I!@
M              "C___________________3+P                    "-
M____________________7@                    !W________________
M____DP<                   !>____________________S4,
M          ! _____________________X<0                   <____
M_________________]A>                    ____________________
M__^_3@      #APL/E)JAJ7(________________________PGR,FJ>VQ=;H
M_?__________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M[N'7S\G#OKJVL:VIIZ:FIZ[_________________OH9M6TQ -R\H(AP6$ L$
M     !3_________________UP4                       #_________
M_________S0                       #V_________________W8
M                  #2_________________[
M  "R_________________^$D                      "6____________
M______]1                      !\__________________]Y
M              !F__________________^@                      !1
M___________________'(P                     \________________
M___N2P                     G____________________=
M           0____________________HQ8                     ____
M________________V$P                     ____________________
M_X@/                    _____________________\M3
M        ______________________^E.           "1TT3FN,________
M________________F3E#45]N?8Z@M<OE____________________________
M_^OY________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________________________^O,N:RA
MF9&+AH%\>'1P:VAF9FCQ_________________V%%,B,8#@8
M  ">_________________WX                       !U____________
M_____\,                       !2__________________LW
M               R__________________]J                       6
M__________________^6                        ________________
M__^_&P                      ___________________F0@
M            ____________________:0                      ____
M________________D (                     ____________________
MN2P                     ]/__________________Z%P
M        V?___________________Y$8                    O/______
M_____________\I3                    G?____________________^8
M+@             0*49FQ/_____________________N?QT,&B@W1E=I?I6O
MS.[_________________________YZ"JN<C8Z?S_____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________]]?#KYN+?V]C4TM'0TM?@_________________\Z>BGQQ:6%;
M5E%,2$,^.C8R+RXQ_________________](E$0,
M__________________]"                        ________________
M__]]                        __________________^P"P
M            ]O_________________=.0                      W/__
M________________8@                      Q?__________________
MB0                      K___________________KR(
M        F?__________________UD@                     @O______
M_____________W(                     :?___________________Z$H
M                    3O___________________]-<
M    ,_____________________^6+@              %3)2=___________
M___________@<A,   $/'R]"6'"+J,CL________________________RF]N
M?HZ>L,/8[___________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___YX-+(P+JUL*RHI:*?G9N;G*"G__________________^"9%9+0SPV,"LG
M(AT8$PX)!   U/________________^2                        K?__
M_______________,'@                      B__________________[
M4@                      ;?__________________@
M        4?__________________J1L                     .O______
M____________T$(                     (___________________]6@
M                    #/___________________X\4
M     /___________________[@^                     /__________
M_________^5M P                   /____________________^?-P
M            $"]0=/_____________________=<A0     !A<J05IUE+;:
M________________________O%A$5&1UAIJOR./_____________________
M_________]+-X?'_____________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M______________________________S[^OO]_______________________N
MN:B=EH^*AH)_>WAV=')S=7A_D/_________________K3SHP*"$;%1 +!P(
M        (___________________:0                       /______
M____________FPH                      /__________________R#D
M                     /__________________\&,
M     /___________________XH.                     /__________
M_________[ T                     /___________________]5;
M                 /____________________^%&@
M ^S___________________^Q20              &#E=@?______________
M_______E>QX       PA.%)OC[/9________________________NU@I.4E:
M;("7L,WM_____________________________[.>M,77Z_______________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M______________KOY^'<V=;4TM#0T-'3V>#K]___________________N(I^
M=W%L:&1A7EM96%=765YE<?__________________OS$?%A *!0
M     /__________________[58                      .C_________
M_________X($                     ,S__________________ZLO
M                 +/__________________])7
M )O___________________=\$                    (7_____________
M______^B-P                 %*Y3____________________+80(
M       ,+%!VGM'____________________UC3        TC.U=VF;[E____
M____________________PV,8*CM,7W2-I\;G________________________
M_____ZA_EJB[T.?____________________________________]________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________]W.Q;^\N;:TL[&RLK6YP,G5X____________________Y=L9%Y9
M55%/3$I(1T9(2U!99J'__________________Z<F#@<"
M %;__________________\Y0                     #K_____________
M______1Y"P                   "'___________________^?,@
M              [____________________$6                 @Q6H3_
M___________________I?Q\           8G2W&:PNG_________________
M____ITD      A<O2FB*KM7\________________________TW4>)CA*7G6/
MJ\OO_____________________________ZYRA9BLPMOV________________
M___________________?[_______________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M______^_LJJFHZ&@GY^AHZ:LM,#-W>S___________________^*6E-/2TA&
M1$-"04)#1TY9:7W___________________^>+@8                   #_
M___________________#5@                  %4'_________________
M___G>QH             "31@B[3_____________________GS\
M!"5*<9G"Z_______________________QF8/    $RI$8H.GS?7_________
M________________ZXXU*SY1:(&=O-[_____________________________
M_[YV?Y2IP=SY___________________________________2V//_________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M______________________;R\._O[_'S^/W_________________________
M___XL)^:EY:6EIB;GZ2LML+1X>[____________________^CE!*1T5$1$1%
M1D=+45IH@ZG_____________________ID$!           '-F./NN'_____
M________________QF4*       $)TQSG,3L________________________
MY8@O   3*D1B@J;,]/___________________________ZM0-DIA>Y:TUOK_
M_____________________________]*'?)BQR^G_____________________
M_______________4SNW_________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________^WEX^/DYNCM\?G_____________________________
M_;&4DI*5F9VCJ;*\T.W__________________________YU31TE-459@<XJO
MUOS__________________________[)6 !HU4&V+KM+W________________
M_____________\UO/E][F;?7^?_______________________________^Z?
M@Z;"X?_____________________________________CSNO_____________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M______________________________________\
M
M
M                             /______________________________
M____________________________________________________________
M____________________________________________________________
M____________________     /_A0+=H='1P.B\O;G,N861O8F4N8V]M+WAA
M<"\Q+C O #P_>'!A8VME="!B96=I;CTB[[N_(B!I9#TB5S5-,$UP0V5H:4AZ
M<F53>DY48WIK8SED(C\^"CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#<N,BUC,# P(#<Y+C%B
M-C5A-SDL(#(P,C(O,#8O,3,M,3<Z-#8Z,30@(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.G!D9CTB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]P9&8O,2XS+R(*(" @(" @(" @(" @>&UL;G,Z>&UP/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O(@H@(" @(" @(" @("!X;6QN<SIX;7!-
M33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+VUM+R(*(" @(" @(" @
M(" @>&UL;G,Z<W1%=G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S
M5'EP92]297-O=7)C945V96YT(R(*(" @(" @(" @(" @>&UL;G,Z<W12968]
M(FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E
M9B,B"B @(" @(" @(" @('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O9&,O
M96QE;65N=',O,2XQ+R(*(" @(" @(" @(" @>&UL;G,Z<&AO=&]S:&]P/2)H
M='1P.B\O;G,N861O8F4N8V]M+W!H;W1O<VAO<"\Q+C O(@H@(" @(" @(" @
M("!X;6QN<SIT:69F/2)H='1P.B\O;G,N861O8F4N8V]M+W1I9F8O,2XP+R(*
M(" @(" @(" @(" @>&UL;G,Z97AI9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]E
M>&EF+S$N,"\B/@H@(" @(" @(" \<&1F.E!R;V1U8V5R/DUI8W)O<V]F=,*N
M(%=O<F0@,C Q.3PO<&1F.E!R;V1U8V5R/@H@(" @(" @(" \>&UP.D-R96%T
M;W)4;V]L/DUI8W)O<V]F=,*N(%=O<F0@,C Q.3PO>&UP.D-R96%T;W)4;V]L
M/@H@(" @(" @(" \>&UP.D-R96%T941A=&4^,C R,BTQ,2TR-E0P,CHP,CHR
M-"LP-3HS,#PO>&UP.D-R96%T941A=&4^"B @(" @(" @(#QX;7 Z36]D:69Y
M1&%T93XR,#(S+3 Q+3 X5#$Q.C4U.C(Q*S U.C,P/"]X;7 Z36]D:69Y1&%T
M93X*(" @(" @(" @/'AM<#I-971A9&%T841A=&4^,C R,RTP,2TP.%0Q,3HU
M-3HR,2LP-3HS,#PO>&UP.DUE=&%D871A1&%T93X*(" @(" @(" @/'AM<$U-
M.D1O8W5M96YT240^861O8F4Z9&]C:60Z<&AO=&]S:&]P.C0U9#9B9C$Y+3<P
M-C4M934T9BUA930S+6(U,#-C8V%E-64Y,3PO>&UP34TZ1&]C=6UE;G1)1#X*
M(" @(" @(" @/'AM<$U-.DEN<W1A;F-E240^>&UP+FEI9#HW.3(Y9C=B82TV
M8V0T+3,Y-#8M.6(U9BUC96$Q.&8Q.&1F,V(\+WAM<$U-.DEN<W1A;F-E240^
M"B @(" @(" @(#QX;7!-33I/<FEG:6YA;$1O8W5M96YT240^=75I9#I!.4$V
M,#)%1"TX13,Y+30Q1D8M03!!,"TV1#0P1C8U-$9!-38\+WAM<$U-.D]R:6=I
M;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.DAI<W1O<GD^"B @(" @
M(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.F%C93@Y-3(Y+6,P,S<M-CDT
M-"TY961A+39B,S-C,F-E9&(Y93PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @
M(" @(" @(" @(" @/'-T179T.G=H96X^,C R,BTQ,2TR-E0P,SHS.3HQ-2LP
M-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O
M9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P(#(S+C4@*%=I;F1O=W,I/"]S
M=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D
M9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V
M960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN
M<W1A;F-E240^>&UP+FEI9#ID968U-38R.2UE,V8S+3,U-#@M8F1B8RUF,F5D
M8V$U8S,S-C<\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IW:&5N/C(P,C,M,#$M,#A4,3$Z-34Z,C$K,#4Z,S \+W-T179T
M.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT
M/D%D;V)E(%!H;W1O<VAO<" R,RXU("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A
M<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO
M<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @
M(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/F-O;G9E<G1E9#PO<W1%
M=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE=&5R
M<SYF<F]M(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W @=&\@:6UA
M9V4O97!S9CPO<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @/"]R
M9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB
M4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/F1E
M<FEV960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.G!A<F%M971E<G,^8V]N=F5R=&5D(&9R;VT@87!P;&EC871I;VXO=FYD+F%D
M;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]E<'-F/"]S=$5V=#IP87)A;65T97)S
M/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D
M9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @
M(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HW.3(Y9C=B
M82TV8V0T+3,Y-#8M.6(U9BUC96$Q.&8Q.&1F,V(\+W-T179T.FEN<W1A;F-E
M240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C,M,#$M,#A4
M,3$Z-34Z,C$K,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<" R,RXU("A7
M:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @
M(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @
M(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @
M(" @/"]X;7!-33I(:7-T;W)Y/@H@(" @(" @(" \>&UP34TZ1&5R:79E9$9R
M;VT@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" \<W12
M968Z:6YS=&%N8V5)1#YX;7 N:6ED.F1E9C4U-C(Y+64S9C,M,S4T."UB9&)C
M+68R961C835C,S,V-SPO<W12968Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @
M/'-T4F5F.F1O8W5M96YT240^=75I9#I!.4$V,#)%1"TX13,Y+30Q1D8M03!!
M,"TV1#0P1C8U-$9!-38\+W-T4F5F.F1O8W5M96YT240^"B @(" @(" @(" @
M(#QS=%)E9CIO<FEG:6YA;$1O8W5M96YT240^=75I9#I!.4$V,#)%1"TX13,Y
M+30Q1D8M03!!,"TV1#0P1C8U-$9!-38\+W-T4F5F.F]R:6=I;F%L1&]C=6UE
M;G1)1#X*(" @(" @(" @/"]X;7!-33I$97)I=F5D1G)O;3X*(" @(" @(" @
M/&1C.F-R96%T;W(^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @
M(" @(" \<F1F.FQI/E-T97!H96X@36$\+W)D9CIL:3X*(" @(" @(" @(" @
M/"]R9&8Z4V5Q/@H@(" @(" @(" \+V1C.F-R96%T;W(^"B @(" @(" @(#QD
M8SIF;W)M870^:6UA9V4O97!S9CPO9&,Z9F]R;6%T/@H@(" @(" @(" \<&AO
M=&]S:&]P.D-O;&]R36]D93XT/"]P:&]T;W-H;W Z0V]L;W)-;V1E/@H@(" @
M(" @(" \<&AO=&]S:&]P.DE#0U!R;V9I;&4^52Y3+B!796(@0V]A=&5D("A3
M5T]0*2!V,CPO<&AO=&]S:&]P.DE#0U!R;V9I;&4^"B @(" @(" @(#QT:69F
M.D]R:65N=&%T:6]N/C$\+W1I9F8Z3W)I96YT871I;VX^"B @(" @(" @(#QT
M:69F.EA297-O;'5T:6]N/C$Q,#(Q,3 O,3 P,# \+W1I9F8Z6%)E<V]L=71I
M;VX^"B @(" @(" @(#QT:69F.EE297-O;'5T:6]N/C$Q,#(Q,3 O,3 P,# \
M+W1I9F8Z65)E<V]L=71I;VX^"B @(" @(" @(#QT:69F.E)E<V]L=71I;VY5
M;FET/C(\+W1I9F8Z4F5S;VQU=&EO;E5N:70^"B @(" @(" @(#QE>&EF.D-O
M;&]R4W!A8V4^-C4U,S4\+V5X:68Z0V]L;W)3<&%C93X*(" @(" @(" @/&5X
M:68Z4&EX96Q81&EM96YS:6]N/C8Y.#PO97AI9CI0:7AE;%A$:6UE;G-I;VX^
M"B @(" @(" @(#QE>&EF.E!I>&5L641I;65N<VEO;CXT-C \+V5X:68Z4&EX
M96Q91&EM96YS:6]N/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @/"]R
M9&8Z4D1&/@H\+W@Z>&UP;65T83X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,  0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( 9$"8 ,!$0 "
M$0$#$0'_Q  >   !! ,! 0$             !08'" $$"0(#"O_$ %L0   &
M 0,"!0($ P0$!@T("P$" P0%!@< "!$2(0D3%#%!%5$6(F%Q%X&1(R0RH1BQ
MP? E-#9"T>$F,S4X149255=B993Q&2A$5')TE;35)T=6=7>"I+6WLO_$ !T!
M 0 " P$! 0$            !! (#!08'" G_Q !7$0 " @$"! ,%!08$ P0&
M A," P$$!0 1!A(3(10Q00<B46'P%7&!D:$((S*QP=$6).'Q)3-"-#9#4A<U
M-V)RM"8G1&-U=K5&4U56=%1D969S@H:2IO_:  P# 0 "$0,1 #\ _?QIIHTT
MT:::---&FFC331IIHTTT:::---&FFC331IIHTTT:::---&FFC331IIHTTT::
M:---&FFC331IIJE.[7=4VV\2%"KC&TXZ87?([>>;4.E7>$R&^?Y LS%>'8P]
M>@9FH,5X&OJ2,O,Q\2J_MSV.CT%I-HZ.X39-GRR7D^)>(QPC*: LT0MWA<-.
MI;3>,[M@)4"D);5 DHEC6@N3LF #+!*2@!.8^]>QCV/-]IM;B/*6,1Q/8P'"
M[,<WB+/8"_PS7K<-XJPN[8O9/(T<W95D<D%6E1LW0K86O:LL75<D5$]M<#K1
M";D_%7=S,2UF?#_I$9$.9-@WE9%/,]+<*,(U9TDF^>D03NZAUCM&QE5RI)D4
M.H9,"%(81 H\%.>]HQ-4+>"ZBU$P!:<96K,@N2B#.(BW,S(CO,1$3,[;;3KZ
MMD/97^QZFC==0_:1S]N\JI994K%P+G5A9M+295T298 (6+FP"Y,B&!@IF9&(
MWTL7W<5XH$->+G$T;8C3+72HJUV*.I]G<Y@I\<YLE68S#QK7YYQ'N;HV<,%I
MB)2:2*K-=LW6:G<&050243,F7;<SGM!5<MJI\'U+%1=EZZM@LG5 GUP:8H<0
M%;$@EJH$Y&1&1DMIB)C;5'ASV8?LE7N'\%=X@_:(SF&SUS#8RUF\2K@C-VE8
MK+V*2'9+'+LJP35V HW#=5!ZVL!PJA@,,2@I?>6\Y>(36H[&"^*MG55R!(6"
MA-)G)3-]D^KPI*1>57[Q%U5&:KVUL2R[9LQ2:.PDFAWC90S@R97)C$$A;F3R
M_&M<,?.-X7K73=2!M\3R%=45+DF4%6"3LA#1$8$NH$F,\VW-KSO!7L^_9IRM
MGBU?&/MPS'#5?&\1OH\*N1PEE[T\0</!70:,R\$8>Q-)K;!/3-5PH:,+$Y5
ME$DU$=P?B8FQC(SZVQRG)Y)0OD+#Q])#+E1,S>4=U7YY[,6H\L%Q%HDYC9YG
M!Q"<<9X1PNE*J.4VRB;=15.M&:X^G'L?/"-6+XW5*"I]IUN0Z9(<;;/4\5RP
M2W E4!)\Q0V2@9@9F.PSV:?LI1Q;5QJ_V@<V7"K.'+]ZSGYX+S4/1Q G)XZO
M1PXT_L.'&JWCGY"Z5F$2I1TA43A)H 3NPAG#Q!K;-VEIFC9Y5<8PT=1;++UF
M2CLG5BP*SMV8- 4KE660C[7(G9MIIUR@K(KIHMVI?SJN40'J"UB,OQK9;9'+
M<,5L>I=-[:[%Y"NZ76P'=%<A"RR1%I=I.8$1]2C7%]H'L_\ V:\+0P[N!/;?
MF.++UKB'%4LM4L\)Y;'#CL!8=(Y3+@VSAZPO;05LP*P$QKIGE6IDQMJ*(7<I
MXJ[N9B6LSX?](C8AS)L&\K(IYGI:ZC"-6=I)/GJ:!+PH=8[5J95P5(B9SJ"0
M"%(<Q@*/-3GO:,35"W@NHM1, 6G&5JS(+DH@SB(MS,R([S$1$S.VVTZ]E?\
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MX2JUB54:VI Y*L?B+8\O2KERVBY!9N6YERB.W<HWUCQ%[-OV5:+.'QX?]O\
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M!VTG7>HA@WM(W(DD!U^U\[U^B-&FFC331IIHTTT:::P(\ (\"/ "/ =Q'CX
M/D1^-)[1,_#X>>D=YV^/Q\OQU5G'C[ >1+MEO(M=QN];7FJKO<>9%M,Y2WL7
M*RPL&8KO:VDNZ QIUNU9G05,U0(HD0CYJ*9>MUP/6MA?IX2BMEH"Q&5AF2KT
MTN%HG*V=(K3$#',!RX&)$B]XC0T([+UXO$-X;S7%.=O5<0]7$>"FO@LEE;F/
M;6,@97BPJBBVR>2RD*KDV2 (D 5;2R>[IUY+(;=:)'X1@TZ,G"1F1+D@^Q=&
M_@]ZFC$W-S&+R2#IPV72ZZO("Q27 HN"-P2,4Z'20P](V1#,W+]]<6^K<QN(
MMG9;XH)DL6F5JM*4Z)V>,P\((!(B,9F=YB)VK2[@[$XW ;8F:N/XAXAH3C*\
M8UP0K.V!-U*S8KF,%0."K[ PQ 5,Y!V&2C4S5O$N-*?89&V5>D5V"LLN$B63
MFXV/2;2+XLO)GF9,KEP0 .J5[+*J2"X&Y [M11;@#G,(\HKULJJZ)6&S34-8
M5UY*>D U%$BK AY1T$F2E^HKF0CW>VO4(PF(K9!V5KXZHG)62MF^Z"A&PTKS
M5/N2;(]Z9LN0EKO_ #L6)S[W?6M)Q] Q4VMN14:P5DZ?%;N+*]K<&YDYV7Y>
M="/+*/26>O3$=/5%S)H)#TBHNX.7L<^I25FW-'%B[]VVTBO56U@KKJ=9)599
ML8<P"5C$+$VL* 4H=RD0&=87 Q>&5EN(CI[-K8RQ:OOJ5CL7WT\<JQ>-"4I$
MGV6_\XD5DB3'/.  2,HC4F:J:[$=XB?CJ+<PY?J6#J4ZO]W2GSUMB[9,WR]?
MA'D\Z:&?K%;-EEV;$#+D;'<G2;F7Z1*159(IO\?(6Z%-V1NUL?6E?B;9RM$-
M8*@-FVXKYR]V#/:8")_BF-M<C/9JGP[B;N:R 6CI8]<.M33KG:>M/,(FV$+]
M\@7S<["B)Y B2GM&MW%V4ZAF"L#;*6Z>+QR,M)P+]M),'$7*Q4W#+@WDXJ4C
M712N&3YHH)/,15#GH434*(D.41RO4+&/8I;^F4/KJM(:E@M2^NZ)E;5-'W3"
M9$AF8\C AG8AF-8X//4.(*KK="7C%:Y8Q]NO:0=:W3NU9'KU;5=GOJ: FL^4
MOXEL68S(G$RA,,8X2F[?)Y"C*=39*XQLRX9REB9L&RSY"PQJ1$G17)TP\D9A
MHFL5%9<Q#.TC&%(ZH'*8I7CK]:A%476 H6$N8%>)GIN0;& V%A/FIK5,&1'8
M&3$]I@MYU3@N';F8/+%C\>[,T7H4V[TQFPBRNLAZ):0]O$*K6$&##@FK681!
M#RQ$0_C_ !AM*SY1S35>Q-5Y6J-;G=61H^;JRL9Z*W1LC(UFX')%.NCTJRKM
M.08N5$4R).D3J](&25'GH6+>;QI4B.\V)L8C'MJ,6^&\^*LK3<HASQS3*^4$
M,%93,A(!$Q$A&W HX7@;B9.4E."I.73XES-;(*?2)')Q%CK%K'95T*GEB'=8
M[2RL+B(;#6%$SSE,R@;;1@(T;)0XXFI?TF9BXJ%EHTL2F5E(Q4$LU<0[%ZV*
M8$G",<JQ9F:@J4QDO3(E W0F4H59S.5EBW3?LRU5P\@IDLF37>8)B=H"GN+B
MAAS)Q,3)%)?Q3OKK1P7PI%=M6,!C1K/QH8=R!KB*FXM<A*Z#5QL)U@Z8"*RB
M8$!$(V".76Z\V\X0D)%[+O<85%U*R$A7Y5Y(K1:9WJ\E54%FM<?&<B/FE<PS
M9PNW8JD,4Z*"RJ0")%#E'%>6R287"KKUPEEQJX ^6 /(<OCBB(\_%<@=>)WA
MD@,S&XQMML<)<-6I>5G"T'E97BTO)J(,F+PI$6)&2G<H^SY(_"D,P2H,X&=C
M*)F,A"ID(F0H$(0I2$*4."E*4 *4H!\     'P :Y\S,S,S,S,S,S,^<S/>9
MGYS.O0Q$#$",1$#$1$1Y1$1M$1\HCMJMV?)K"T1*XY:9;HDA<7EJFGM.IIVM
M2>6=LA)V!BHS?1[HS<119)R<:+E-8SH@I*M$W'(@4A@'IXA-VRZXBA8779%(
MK-F6O! LJTVC9G8C_BE#06V!'8H/IS'?;7E>*[6"I*Q3L[C;&1!F452H17HL
MO2B]D$NJ#+ 7/[M;TM=7(V1*R$R HG?2;*8/PDK99JJ5JLR./+=;:K&.)ZUT
M6%1C5Y:H03EK&)U21FI"*EH-9BY9E")<0+AJ9<T.JY!IZ8>'!,XR6197-MAT
M7J52\;VT+;)8JS<R"[3#?*!8M[3DQ-Q/4P278"O)''N#.D^'.'J^0%6-ILPF
M8OXNJM67Q-84V*^-P=C'A7I19:A]-2H7"J@T7I,'4CM@*MI8<9H56VUY]A%+
MW"8\A)ELQ44QDLYL-:58R;9+&-B211@%&SX 6(SK]@A4%V <>65PS2<(F$2E
M,.=FQEZ,I,[AQ&3%'$2S4Z&"\\E4<"[I3&_[YU.V]1[^]TW, HV*8UJQN/X.
MXB79FMB*SAP9W^!VA8IDJ:R<'?0-G%+$XC>FB]0K,5(;KDZZF+G<8G3C4VI[
M<%G\5)J88H1I"#*Q+$.OH:!58XL9(JR\<5H)> 1*QE%E7[4I  $'2AUDP*<1
M'6M6>S*9DE9*V!$4$4BV=Y**T4^:9]9\(,5IGU3'3G<=XU9L<!\'6B65CAS%
M-E02M?-6'W +(3E9&(C:.7[2GQT1MVL_O8V/OIYF88^N=]<G?5@'UPQDO%JM
M)N5@W22;%>68KNV:L#*N$B-9 R#=RX(N=F=86#A91(XI+', U$LLUZI.0Z5)
MO%:JL &0+&0F5 ^&KB><5LB%B)S$"X!VB2&)C77?7QF0O@BU3&Q:Q,T\@ACJ
MY2I+6Q9&LRNXHZ1N3RNF1&2)!&!S D03J3M5-=;5;6.ZO%+O+$CAE<;9$7*,
ML+>JN#S55DXV!/.OXA6?B6#>=6+Z%969AD5)&*Z3\/&X )! P].NNC"W;&,7
MEDS7968JTX0%X>)Y*+5)O1-?^.#IL>H; ^:Y./.(G;QS..,*GB-W"[PR2,@A
M]*N;VX]X8[J9)=EN-@;TQT2'(#2M14+?9I(,(F"VB96R#"8[LT4QK>28ZOR\
M5.RK:/C8NP)(+)/ID4UG#5%@17^T]>"2"ZR1FYBK$(DH<#%*41USZI6%OAU0
MFA8KK8^&)F88I(<HM9,CWA4<X">_N3) )1,S$:]%DZ^-N5"IY955].VQ=>46
MX E.<R9E2P$_XGS(D2^G^]'E(PF( BB&;=6MMM.LV&<8SV/(9"3M,]8D\7IM
M*RJLS8ST=#KSDX<\NV #1CAU&M5E3J.UN'XI@F<5# 4-=*J_+7CRMI-LR93Q
M(LR$FV (\8RTJE"Q"?=: V+*XE8CNOJRR(C<IUYG(X[A#%1PUA[>'0*LAG6*
MP@*J$Q5?-+HVLC+6/'WJS&U*=F1:P]G=$E3OL(Z7XS:AMMAF\RUBL+4!@WL#
M1NQF4V\$W($@U:R9)EJBN(?F$&\L0L@@8@E.D[Y6(8IS&$=9YS,,A$'D;116
ML+M5XZLQT;"JYU%M#;;E(:K65XV[=$I7,2/;5A7 G!R"N$KAS%++(5GT[LC6
M'_,U;5U61>EL>1 R^E5R>T3%D(<,P>\RN*;=\'K,;+&K8PJ2K"XNX-_:FRL:
M51.P/:R4"0#J5ZS&%VO$D "LE%1,9$I2@ \%#C7&7R0E3,;KQ+'V+-JC,'MX
M6Q<F)M.3$1L#'S$2PHCWIC?5H^$.&6*RB&86@:LU5Q]++ 2MXR%7%+E6.1:W
MG=JZ:RD$"4^X,[=XB-GK4L>4>AGF#TRKP]:-8)!25F@B&A&A9&25  5>N")\
M$,X5X 55"E**AOSGZC=]5W7+5A2$O>QJJPR" ,N:%!,R4@&_>!WF=AWV&.PQ
M$=M=*EB,9CG6[%"C7J.OL!MQB%PN;# & %C-NTGRQ$$6T2<^\4D7?3RU6UT=
M1Y;<L8\HKF:9VVT,H5S7:#/Y0FD7*+Y0S"A5<%!G[(KZ9JN!V<:"2GG(HBH]
M/TCY+97D.;E>A<M0HJZ":+K:J*IB1B#MOVZ28YBC8CWC:9V&/4HUQ<CQ%A<2
M=I>1OJJLI8>YG[0F+2E.'Q^_C+Q=-9Q*D<L\PCNR=O< M5L@/$6V56B:B:[
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M"0>+K.WKUTLJY=.555UU#JG,8<5Y[.)6M2LSE%*4 K4M=^T"UK 8$  !; B
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MG4RB@1DZM7!8RO7R"%G)K3>2JJ"[2EF1&"WBP1(I(8B9F=)4/M0VN5V5CYV
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ML@_;L&*#UX@@1PZ19M4UU#D;HE)G&=S8M)XYC)PXP%9MB_:AIK"2D )D-YB
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MW+YEZAU7$ X>OS#'LS=L[T#'$S+OZ9$78HP-O/(-79FT?,+MVZ#UHH@BX;K
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M*,GC7Q 2V!UY\FL# U\MONS.<&9_.4ED$#.(R/#;.%H>6T3M=H9(.*%C6ZT
M:G8^X/,<<O+9[&N]%&X;[KWMS+DC%4Y4V%7FX2O5&'FX%7)T-D/&XUE:XR=H
MB&THK,,H>RA995C!-G<6W;I&I#IVW<KIRR(:PP;PRU'-6Q$V<E@;^,8A9E7K
M8BMD\CP[?J7'CSI.VS(4Z&8H') ;\5EAV7_DVE-S* 6/L8=),E4DL:.0385(
MMNY&_CD\08_(8\QF5?9B,4<8^U)2+/MHVU8"81!3TEUNTU0[=WP%CJ C\0CT
M0#G@/^/AW']OT[_RYTUB43/E\]Y_I^/S[>7>)VU43@.1#N'(C[!P'?V ?V[^
MW;CO]]-8[SM$]IVB/.=Y[><Q]_;S[[]OAH#GC@ #GD0$??V[A\?/?CG[?TGS
MWF?K]-NWX=O+2?/>=]MMX^6_:=^^\_/;UG>?F<B(@(\? \@/L >_MSV'G[_O
MV#4?7UYZ;1MM'SC:?69\N\[=XVCT^[O.L<"(_?CCOV'W#M[]NX<<]A'MSWU/
M;_3^WG^NWXZ;Q$>6V^\?#R\]_+UWVVVCOM.V@ #D![>_QSQ^G<??OV[<]O<=
M/.?P^'R^7I'KZ[=_/29G:?/\9WGO_+>/2=N\[1&L\" <<AQ\<]OD._\ +X[\
M_I\:1^7G_+Z[>OEIVGO$3,]MXB-X]>W?X^L[3MZ:Q[#P''L''?GO[=OWY'L/
M'W'C3\?EZ^7]HVTF-XWG>>\]MHC://UVG\=Y]8W[]S@!'CD ^1^1^XAR <=N
M.W'[?(ZCZ^M^^IWG;?:=_+OVB/2/7UWC?>?GZ1K/MP'/8/D!XY$>![_R^W/W
M^X:GS[]H^7]OJ/QUC'GY;S/QC>8VWC]9V^'???;M.L#V'M]NX=^>_OS]P^>1
MX$.?N !IMWB(\_7[_P!-91Y=_+?M/;:-O7MOW^41M/;XS,Y'CV]A[B8.1'WX
MX]O?X_;[#I]>>W\]1&_GY]H@9VC?MOOZ_?'S^,:JEO:>O8W;7?7L:[=,GK=S
M3A1=LW"K1RD(W:NE$47")DU4Q$@G#J(<!Z1$.>!XU['@$ 9Q3CA8(D,A>W$A
M@AWBA9D=XF)B>\;^7;;>/E\3_:(>ZO[(^*&H:RNT78*08EA*8._$&+$MC H(
M=QGE+:8WB9C:>^F]LX%_;?#0S//65S>K E3-U58L\@X@K#<R6!C6(-AAYU9%
MTEJO)(3[B-:0:TLY?QS8[A)9J+DYFBIA[;_:J->IQAP7<.5U:M2_A67&S^[K
M*JOR-ZK8.T,;*-$K=RMEPDL!F&%R\G,/COV6&Y/)^ROCVNMMF[D+63S:*<&V
M6VC<O!8*RE=5KCDP=SK(E"HP,CF0#>3D2G7,.\9? UUNN<=L;FDV"B9ELAH!
MO9<IM\RV6K3P8JPFYN#\V-F;>Y0C%FE(64[*F.Y)C'F8/K(^,W!19Y$N&SCY
M[0*U2;8Q^2@54\AF.(N**X%(Q?9B07P1BP)+CEOA:MK,LXOLU$O5RD!IOU5'
MCGUNI^I@J(R-ZM:KW%K55P_!?#9L*9*K0R>1XCXN#+,O(W29VL9P]_A&_>(F
M0<4JLH<Q5H[#5_:Y>*=?*VKF25I\1AQJK%MHBV1MQLT3D^0J3V&:X%CLGL*-
M)HLK:U03NEBEW$I5H.P,'<!"(^B.J^KLK)(BW5WI!@6K-*5% HXJXBQQ3O(S
ME?"9; 86JR@3.>*]A-&RVU=61646BP=V::J?B6MKXXU:[V5Q-5Y2HLQC>$4=
M48G;$6<I>SM>[]H#WZU:M:53E4+37L+'.5%V[+(57ZRQ:O%%W(4FS9>JCO$U
M%NMDHE?R9-5BJ5.HWF*GIYM!P6/+72Y8',]>3P3Z/-7KA/N)IL61AB3 4R0>
MLIFMM55BL:CK)!3M2/+%FI=Q^/N6"$/"X\Y]HN2X,R]ZS7?9J;UJN)3B^(@2
M>1JC73D5A:O>&+Q@:ZQC8C!-Y/W>8PK,JE?49S6[,<$1Q)7QM1J*MI@MN9A-
MS"J8%*ZT97$!4L65RIO4'9GFV[[A=O\ 4,HY#K4)5K3-KS+=['UV4K,I$.6\
M?)+M6$JU_"60<IPT8,FR(@Z<0B-_M"L0Y.JR5EG@I N?MW:P5HI\NXG8H5K+
ME29MA#VP4,6MYUJD6%;C#%M!$!R,@()A 1E2HVCLS>@HCDK7W54L@063E+!1
MBQB L6I0R"8:B6QL,+IPXE(ZL)"TVJ.KVC337/+>+N_N&W/*&!:;4(:-M:>1
M)])"VUES2)A]*FJZLO&PJ\W!7T<A52O0;V/>R;5(88]6O<I("Y2<&8Q<:@YD
M"<L[[UW[M=5)N174P]FY**LRBU%WP&9MXU &0V2N?:;\25$%5Z0JJN,"O9"M
M-FDJQNL+%6+BWU00X\C3K ;N9E>:[+M%%]K1 5^'&C4MLO&YEF38M!C7IV96
M^5<.K)O+R-9\]UC+@9$J5"R!+WC%]Q2I;]OF]KCNBM6N(<WM+71LD5%]:XI:
M>E:A--:A5L@/8A6L1,C:6\<_:PD*Y53;FZ O^Q<?F+%%E7B!U/%\6W^>L)S4
MXB*</PI?HS@4L)UFE&5<G)5,0+VW2K6 M-.&M&SCUV[,+R XVF278T6Y:IAY
M"Q JR=& XM74",N2AFFYZ4.*\U=1DK;4LC6&VZK%7*6;N5+Q5MR60K7:HZ%P
MKC*E5)EB.JW2$MV19^$BV*,M,QU#?/YE.,>YBK]YN=?%S8K3!L(=O0:5'(S]
M89QC[)_5+NU86S8!:/\ $9FZ03B,ZVO4Y 79LOQ",A:5'.A-B%%9R6*73RM"
MZZUCD^'N&88V[-=2KW+HGXD.%AG=MC-8BPRX" (%*S*\9D72E;+$B2:M#*T(
MH9)"5Y:XM5CQ$E7BLR#5K/XE.4H2;L UR"Q8W?RC?"JSG(%GI66"U6FPMKQA
M?;BH6[52+O4@\,M-W* B\>U.5@I.,BVDA;HUW,O+"*<6TEN8+G#9R*5U2Z=;
M)\0D SUA;F[..Q7"K\7P[1EZ5'0S^41D<NZ"M5R4(<+9*M&*C(M, R3TF$AC
M6RTWXG&R)*5"9IK/B?.8K*9BRHK#A?A\0L,7=>NLPK$AG:369 <6)7:L@[:?
M$>R_E7<9#XGR;6L64R'G[<XIK:J,86]L<D1CQ7"U7R>TEW\M+V!Y .8UC8Y&
M8H3Q(E?9+/Y$K)0JT0[9/(UWV:B%62< F39^R^)KP$J &*MCA[BK&8A5&Y',
MV#L9+#9)V46"6!"(PUMX,N5[0C2HVK3T#1;*14EC>&DV2:1&3HX@QO$3HL58
M 0A"!NX:G");-DFIR@H9TVH"Q:9WBLVO(M?W.^'XPIEDND)#S&1'*-G9UF8G
M8V,E&H9!Q2B",\WBG*#5\W]*X>I 20(JF#==T3CRU%2F^+>T:S?3Q!P6%1]M
M2FW2BP%9KEK8/C<=&SA44"8\I'&QQ,<LE'E,Z_HO^QWA^&,E[)OVD[.=Q>!O
MW:/#*F8E^6HX^U:J.GAKC!DGCVW%,;79UE(.2K$!]1:BWY@"8Z86/9?M?MLE
M;Y>QX@@)5_?(RRQ%J47?6 J,HRN;QP_MH%9HS"3./=61PZ7^MR$8W92$DW.#
M-TZ59D30+]7&L@*QU 7RUS94;*Q(HY2HO5:JBLX+G4I5I*[<I40)9:'Q+5F\
MB9/\_P";=F;"+<M+Q-?:5-B!$H(:(8U;"Y8B&N30 *E=S8-M=(P"#7$:B&\>
M&?M-M5>MT=!4-S1+-:Z_-P'XZ@[':).=B26"LM*=(OFC.S3DS!NWB]:8,8DZ
MDE&.^INS:'[.&K==*;*F/B.2PU!3E:>7:2^69=8J\35.+3$N89Y M9FFNRXD
M2IP21>'8F>68TJZ2PZ)I!M?PI4Q04S"P3&/MXVO B,\NU2M>L@A9B:8%K5L4
M:G.!F_0?#LVZ5F%:,KO#S&89UM"6*M?BC(-AL3YX%>M+AH[F85K&MYA*(8,E
MWD>P?)>F:%<M)!DT?LW#=VU;*H[VPI@O 4PJ+*\>%D@-G5:6*NCD<<R'\T-4
MRE>&;%0TFMB"8X0/D<T3TB!=1;&,EO0?9?668+Z*)NX\L7<"%0/(U=NB1)M+
M?#%OB1(PDP AL#+;<L-SV*4,(S=04EL8-U6"Z=9D;+;G@F4C)%*68"O-KSQ[
M$Z*WD$$7!2.9=8AO+*DH4Z(>7H^9LV:5M\0=C'6*]JDSE$.A8J!(5W0 0(&Q
M43,B3!.>ILV=V1!Q*5@A-NNJ.5-Y-I%I<S)PU-V"&TK<Y*5@T2(>54A #/*O
MECMJ()/8?M[*RLD?2ZFUH#>^J-&F2@B$2S?X[K#>PO;6O4Y)*V&G6T;&/+'(
MO98[B%;L)!LZ>OCLW+<7SKS=:0!(TZ_*)4*5BI<70F-DS;Q@N^RGP8S#E'CF
M.EB82Q<&(*0WGKI4L-DS,]4XF>NQ624+RDCE0YI%"IF)A13*3/)5,;318-@&
M4RD7#,/YF$[;YLQVS9,D;'*77%D?*N[A"Q5?M@-IZVP3*RQ<(W9LXE*=BZ]/
MQ,7*.6#*.8,F\@\9*R*;)DT9 Z]*W11($ !AL&-B9DEYB8F2(!RBG*LA>4LI
M($V/$I59)B1"3LA%@^9VYRWGHHKSL2JU%F,4)",[8YHO!E(BF.9E4ALV1Z#)
M-8Q8?RB/69S658,6L8Q91K%,464<T;,6:(J*K"DU:(D;MTQ57.JLJ*:29"BH
MLHHJ?CJ4.<XB8=[6FYK'-GF8UAM84"(P1L*3.>48$1W*9GE$8&/*(B-HUI0E
M==*:Z1D$H4M*ADB.16H( !DS(C*8$8CF,B(MMR*9F9UMZUZVZ---5IRWL^VX
MYVN+&_99QHUN-KC:ZK4FLF[L5P8)A6'#TDB\@%XR&L,=$/(F1>I(+RC%XP70
ME!;-22)'*;5N1+4A":[K3U*#J7F5&W.H,.79.@!A2ER70Q1C4AKIKKD.FHWV
M&@,,L.,]IN:Q:%$PX"MU_#\A2LT39VAYJ8N08#&Q B;!*&2 @'-R@,1$U;V\
M;#).QR^::E6J,M,TNVM8Z7L4!<;.C&UVVXC3/"-(E>#86-.!9.:(F]48)1)8
M@K:**\5(#4GJ5!4VU+?16C(5;$DO,V+>3KVNI-@;]C,6)P]NX!MEG5.W84.,
M,^_*59%2.0:J%KIN57CQ5)H@J<74KXNX@/\ +E4IT$(SJ*;H5*R!::YIRG),
M[L6XK)\\6&DQS9>Q/0\-;;-XECQ!!+5"?R#C3-^3)^3A)BP*O96_R=!L3U2T
M,S.9-V:-EW#P$7":D*5B!%DVYD$R&11Z.-G(.CPGD\?4YZZ,;A\U-%*I*"JL
M<BS9;*CB9;!LMFRR4\\E-EK7[]5K#+Z5[)%4\C[8_9I8R*JUM>2X_P#9_5R7
MBEJ96N4$9S#T03;2R/#-0./6%0X:N1.JL$LDE (Q#&RC&%6W!;!]N3?/$/(W
MZ0)7[ ^.^L\Q8T[(B^7M=HCSNPG6\FRL"#M6,$&!G!7Y%C1ZAVG7Z94Z9^)P
M.KQ7"V"LW88^WX*RDVV#8;6);>EC4/DRF7)<56M+4NYUMA*Q8!#&VOH/[4];
M&X_V_>TFAAJV/IXJMG,<ZE4QM>JBA7:'#=-,-J)K -=)A%VY F@1D&/8P9AN
MQQ-%G\/S9Y<)J'L$]A.'6EJ_%5V$A5V%BNT&C&Q=2*[+6FK9C!6:-8$^C"_?
M'8KBU%PDL]=K^<*SE8Y_9$ DRRTHW.VU[GS._*3+./G$O( _@5#,7,XXA2*P
M\#,U8&$S(:_/( "T(K@ PJL @D>49*!&_P#:@R;"B6-(<EMD!-IF<7(BS!=8
M8.(AC/"\P%#Y)D+=&RUY8T21A6$ KAMC8I-C3!B8^ODK1(UQ(-'J-FDHYQ%@
MJBZ:RTL_.H5=1,CA)$B":4+".G;5;F;P62L2(N]P$@\>2%BM'364(& E!2,,
M%BDN(C8$D6;"*/LWPA%1G&N6]95RF2-H7GY&2@F2<JAERPQK05(K+F,8 18<
M3:''6U/ &)+*UMV-\>-JC/-(./KI745/6L&SF+BHY&(CBR<4XG5XF8?M(ILU
MC4IB58O9@&+1HU%^*#5 B=KQ+_\ .?O)F+[SLVA*!(3>PP8UJP*)&N3FA#G^
M&A4.<3'-@VM:9ZB4LY21 /,B.59QV9RP32$6,'8W"$O;"Q<3(4!0"X$! 1:E
MWV-[4\D7&Q9 O&'XBQW"UR"4I/SCZ<MP.'[Y"#3K:2WDM["@T:E+!HI1WD,F
M[9N9%),QDA5(50*E1*J,1%4!3RWCR6\>\4WCO5,G-@B/F(SB]0HV @Y(%%3J
MBL06A0#LL;6NIXB!;U:8X]D$(['2!-BN-8AB(B5]&W;7,;;D-NUS3,V'2:HG
MM/Q7+?Q4'(<:CDA7+BD UL:\W'1T0X0KM,<.EZ+ L'E9;P\@D>GG=J*1-A,\
M-9@=$1?*2HO$B+! I7X:N@XYFJRC,VVV,RE]C,-2JJ5^>A*P2?A$+J]-(@J4
M2U1B8.8)3)%U)F)CH#CXQ=>J8@Y2,?(P3ZL2X38Y=BQ!6SBP;86^1),+Y V=
MV,-N6&<-3\_:<<4WZ!8K3%0D)8IE:PVJ>D)B,KA%4X1L^<62<ESK#')K*IH+
MB(.13.)%%CE  "R+3%+JXS I?<+(-6(C G<-"JQO[1'*9)0I90.PS 1,CS;S
M.! )&EA1)'70=9!%)3*J['%8-(;S.P$\S;R^4&13&V\ZF[6O66C335;=Q=!V
MVY20QU0]Q2,%(%FKNW5QG"S%HG:P\D[['QSYTT"OK5^9A7KN;:1Q'SILD1P=
M1)--5PD0#I]9=:TK=D$RF)+(UJ=VTF%F</72 5KO/$!*/W8 U8.9M,B#.69@
M3*)V$]B*5J#* HVCK5+?.(2IIF\654')1/<WJ$UA$QS&N)VF1C2039)M:1C:
M1$M<1Q+!CCJ>D[342QLY;8QQ'6>9240EK([?1]@;/IR?DD5EDGLQ/N921<)J
MJD4<F*H<#&*4TA,EB/)B+6"4"HA*DXBZ)C;I(2GIJ0NQU")I) &DR8;U.K G
M&F!& 8$QSP[(5\JZ63+3;?J$)5K#&,DV'-?E$4K(I2M<=(5PO<-.B$VL8#KD
MIB:;A,>M&$K@N)EX+%+Y.;LYUJ?#3X$"9C6HK3:I9!I(^6D+E&9+(E.9!N8.
M#-T1)9%S0L6+(%R.MX^IBK!"(B#<?1& IUI5$0J K#&R2$!8&Y2)Q)%,Q*PF
MO%68YD1D'96!*9(OM&PV7OM]4IELM<TB-LR?*R3."&1,HF?S% Y3$,')3%$I
M@ 1 1 P" AR @(=A]P$!#W 0'6@A@Q("C<2&1*-YC>"B8F-XF)CM/G$Q,>DZ
MV1,C,%'G$Q,>4]XG>.T]I_'MKA%4CT&,)8\)+.KFQSG2=YU]RDC5K!:,NR"\
M;CN&?/YUA<IE9*R-TUL5JTPK=LW:GFDJZ^542BVA"3:Q2EY*+EA&&X2R]$>N
MWACA+B).9ERC8JKDE83-*"GE0*1EMNWQ$K#!1ZW4L-(EOJ<U.+!SG?ID>0RE
M*V136S_$7#LX\:S 4ZWC;>0QYE&.*(]V*=)V4*]THB*XHLC:B34"X95*\5#)
M-T'&[6\P6&K-//[/BN>_"N/H3*4'-"C;*_>E'-8C_J-Y?IA<*_9*K%'7<2R;
M^!6C[C%13R!!VW+,/>BYY5AN6DUVVVT$<6 H$%RS:\)P-@.*,383N#8\-<MY
M3+\,M_=L=8N8AMRD59L'0'40G%DZ[275J.LXE:[#N8PJI9QUF.%LDVV8PKGF
MM4I8W*P*H1%;QA*=-E$K=*\IXI.X+\/3=G;1N!7L5',(YPNI'T3+;T];G[;C
M?(MNKM"L;<UY:2)K+7[72FM&GE@CXHL_(/%3QT; +J(,T]&2LMH4++T0&196
MGB&K5L5XD:F>M8/'<'YQ-K'##'%6J93&<0Y!*J['W&UVT5WCM-0+JDXT29<R
MF/I.0S&C:M\/3D46B@[7#]#.WLQB&#?,84M]G&WL?3L/L+6BNY%SPH)64!=.
MP>S_ ,07,^X_<M.XJLV'8*HXV;8^AK1!VHDG76,S*.WM7JTZ$U'14AE-]=YR
MK3CN<DX]@H3$\,PA%(44W%MG7#A=-CZ :0\O$Q,.0^R,_DL;1#F$V'4JYS)8
MVG-L$18 3OXNI1SE>XYN.BPC)K2C&DI07;/+JWK3ZO##F(!3LIAJ5O++F'!"
M,B_%UK5VO3ZX)VC%Y0KV&N5H*\U3Z<L.R)2RNKKGKFZZ^C33439UR%_"C$5_
MR)]0;11JG7GDJG(O*I-WAHT62Z2(+.JK79> F)EL590GGMFDY$=*76LM),FZ
M:KA.AD;+:M:&(@2<;ZM=($ F+&V+"T@N99:I)5U). A]BTBNDIACCA8E$VZ-
M>+5D5%$R/3>TX%D++D0ACBD9Z3R(HA<S"EI:UTQTE!+#'7Y]LS[_ '(.;\7X
M>:9,85_$C'\1,IVYRS*/R=6WUQ-$9@O^-IQK19*F7^QP]785ZM5F*L]UCI^S
MWUD+*\POT>?.U02FG7+XG59)36TO%)>OAJM9I5*S6%>'(\0^SK)Y!S6FRO71
M9QU;B4QX=H -=.0C,XVQU1245@M1CR/P\G)(9(\3&D[$JY4KHX3B[ABUC)*N
M;#<JSE^&[Q9@F,=-4\>NQ'A7K-XTVMB/Q3-RN*=K^%:56J)2\U72O43"T8]M
M4J[<1";1*7Q0VF%JYE*PY5S'CN,97EY9F+F!D[J:V+&9.W!5T\<6)\FHP6][
ME6+N\6.#IJ"@_B7(UGOIRE%6[1\3@GURPL$;&+<.-RUYB5A6R8Y"QB#@5XY%
MAAT>-2@AJ9"2;R$-<[5'J+L6FUH9E>(Z=BW<!8@-JE6L8VB$JAV*&NO(@HK[
M6*KQ=MU:?$;RM'6*O?4*3C6[SD9?,N-(.D4=C<5WZKV"PM=;118**OD-D6;J
M=GLC^1;L*M9&S^NM4?7V9HE&UZ/?MHJ3?>4.VQ5=K4P#[0<+Y*PVWT;(T%VZ
MN;X7&W;"KR-LVL$C%7,GEI97+[695X;NL$*K;#L6CJ5Q!YX\+4301;SG#U.R
M)M5:FG7RBLRF.M:7"%*R'VI2I4Q28Q36S( $6+R(5?9&:_BT;A8JW143*1>W
MQS42U2QVQ6\-:5EV,C+_ /0++BAB6N45&2O!W<--O6E\M-?,,XA*D;6*@RLF
M@WD&(N(=EUZ0)=<E+V?NUYKAG&\JB$6W<;FN(,S@;7$%4YABU8ZO6J8SB()F
M+,+H6XIL:R+"<JKF6'VHQOBD5X"TQ&5>27]61QMBAPJ/$)86X$+2=G)5+(-Q
M=MB3K*9+5O%-9]=M!OZ$F#Q"18LY!J<JK9\U;O&ZA#=1%$'*)%DCD-P'44R9
MRF*;@.0$!X#VU@Q9*8Q1Q(FLS68S&TB0%(E$QZ3$Q,3'QU:2T7*4X)B0:L&A
M,3O$BP8(9B=HWB8F-IVC?X:BW+&!L1YQ:,&.5*6QMS>+!T2/]2]EXY=JD^!(
MK]!)W"R$:[],_3130?M3+F;O6P&:NDE6ZBB1JI5JYV!M&E9N!4HYC&# T2Y-
MB4.46ZGHE]=#92X&+EB@*1F1C6Z3.5PKFF %LO#:>4UOZ#JW64P=F*="+#EB
MU9 80PI$H+:8@RV^'ELVO-G>7*S80AWMB?Q["*<OFMEO,.D,;%UPU1CF2,;"
MVB.BVK=G63JPJ";5DB5-@NX2 /[PL*F1H4V+HM6+HR+K]B]#OWL6VY0D%D2?
MU.;GB[%:L%D)]QJ:U=!#*4J6)92D*()@5#C$U*^/A0BN:BJ!O92A)! D)5&6
M;!UV;]11O:0'$L*9BF%\+W ,;=[K-/Y2[S>.KM"'K3["SFPR3*B$KIZG'4P8
M!TI%O6<W-Q)82+:(E1FY!\Z%1(@JO%$R%2#<!&2K0W3*^^S<.]XFQ,BQ5F<R
MK.*> JZ:XL(NH3*K$##)$62V6L>]AX1'0;AV8^2QHX5?3IJIE(" ^%O5>42+
MF-2A'(VF*2HA57;*2KBKP]>%VUQWMMPIB>T2-QQU2$JK/R\<A%R;B/G+,=B_
M;-D&K9-9U".YIS!JR9D&+1-Q,FCAF'0(E%T^6,)A-LAS8795!;*MVCN.#8>7
MQ#&-<PU1M_EQ-KVM-5?I))C".5R4[ZPE*N9!=,8*NJ$J(8Y9A8@*Q$Y';J\B
MQ%8$WG(%B(!(B(Q$=R>Q7:C,6^0O\CA^)=W.4L$M:GE@6G;>=ZK/SB\(ZE'_
M $C8?3)@\=UN =*,TD", <1#!8C4BC<A@K55#14M5*!K0@U-1( )RMZ,@W*U
MW[-@X8VODGONJ)O/(/?8F-H>Z#RL@%PGE:&'3: 5V.;M#0&DW'<LP/+$1-!Q
MU"Y=I-'366XI3"U-':-B26@,@0V2(E+);O)U\8Y$N,]*M&M:F']C@X:)K=8>
M-7=*)7EXMS6X"#CHV.D(Y9M)&!-PX<NUG#MP<\BI85\=7 9",:^[=2Q;&*,L
MCDW.=D[Q=(@@67B>2WJ"(05<5HE<K"(UL(I.Q:>7*46*M;'BMBUM%.+I,:ZC
MCX)@$;4T[%BS80QY,>#[+3%HQR"$AXPP+B;#,A<);&U2)7)2_NX:0N<@,S8I
MEY8GU?@V5:AWLBXGY>555=,8&-CXM-P4Q%5&C-NFL=7RB"&Z&&*)JC,#7F]D
M,ETA$1"+V4=%B^^(B(Y2LNB&&([+&8B  !B(UKD!DUL+<F)IHH*,B(I"G6-K
M$5ADIG92F/>T8_\ RKWLF9-S"*7]8:RT:::CW*>*J!FRB3V,LH5U&V46SHH-
MY^O.7LI'MI-NV=(/4D'#B'?1S\$0<MT5%$DW:9%BD\I8JB1CD-I:A3Y3+0YI
MKO5:3/,0].PF9E38Y9C<EE/,'-O G G$<PC,;T67U3)E=DJ,E.21#$;])ZR4
MT8F8GEYUF0\P[%$3,C,3WU4U[M$V%1SQ+!S^A4UG/V'TN6_PPZNEO0ND^WH3
ME&)86QY-JVDMKF(JGO)=LU8 ]EW,9!.7S<6S=LJJD8=D$-LY@9%AX)PWSA7*
M$TK6?)J%WGPOEYK>2+'-2NVZ#L,\*:P9$!,:T0'A5&R1Z:<LJ,/),CF781C@
M&]..3U.85)KKVLG61TUR/,PQ*.>=2G6MK^V0K"BQ=:I#!9G@V]S]BI)4+1<'
M:].O<T*CZQ/ >N+"L\>/G_UA5=\A*N)!JH5^IRCT*F <TMV?3R*)$6UL98P5
M-RP$07BT/G'V,>"H&%2E+\?-61)<DHZL )#TXVTL6ERKU%D02WY"KD[R8*8D
M\AT$WZMHY&8(6FBTFU$B0PR+'5.")A3-H=1K=JAV[KC\24_GXA'W_P"?+_D'
MO_U<Z:Q+?;M]?Z_#^^VJB  B(AR/OQSR/?C^G(_Y '/Z:GM]>O\ ;_?[M8S.
MT1VCRWVVCMOM]_;?>?C,[1\=8 !#D0X^_ ?F'Y#]?GD?Y_/'&GU_+^WUZ)VW
MVG?[Y]WUWG?M'QC[Y^&^\Y'L #W >_Q[?''P <\<B''OSVU&D=YF.TQVWW\Y
MCSW]9[;QM._E^<'?CL//MU (]P]Q]Q'M]A[?RU,[?R\I_7O&_?\ 3\M1'G&\
M;>>W;S\MO+SV\_.?OUCVXYYYY$.!^WW#[<^W/?Y$/;4:RW\^\?'>/CW[3_YM
MH[^GEWC:= @(=A]N>??_ *N?T]N.?COJ?[;>7^O:9]=O]XB8\X[EZ^?K^43$
M=YVGOM'G&W8+V[@'/?L ]AXX'^H_U]AT_'U_GY_#X?=\_B+OVGMO'>?3>)C:
M)\]H[[[]O.-_AKT//'/L8 ^/MSWY#OV#_P"/'MJ-1&W-MYC,^OQV[=^W>?\
M;?SUY'@?<1XX]_UXY'YX[_8/D/YC._R^_P"'Y1MMK*-XWVV\_+UVWF-]]MYV
MGOO,;;?'T/DW<>. '[B(=OV^![]A^?YNVWE\8W_T]=HF/6(_7>._;RC:9[?"
M9W^_MO$_/X3&\;' ?OQR <?( /?D?_ZO?V[?KI]3Y?IMZ:F-_NWB//TF8VCM
M/GW'U[]_OU4K?,/_ ,V'(0!_]8IO >_(?C>NA^GZA[=Q]AU[+V?_ />O&_\
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M3%;57<E6.CPQP./NWO'""X*1LW[CWX\K KB)8Q[+%)])I",R!TR0V \/ A+
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M/,(2'8H\XWWC?7AO:/Q73X)X/RG$M_&QF*E J MQ^Z8AY7,C4I!.[@-?[H[
M-W()G89VF"VG5J,#W3%'B;;;[21"FV/"E:KV98-$4*@[J:$PI8J&G2[Y'2J:
MCJLR\$HV=*O64:^0>PKI99HW6(DL@H9NLCGQ?PT>'RN-5<NG?-*3NA,\X@Q5
MM&0Q3ZKN>2;TFUGV!*4,2T),6*<M@04<SV/>T:A[0.&LWD\3@@P->;MWA]];
M]P4D14,?9*XJ:ZU+%PQ95"^H#!YD1#08N>2<XS\)_ >&W;64QC?\L4Z=CK,I
M/QE@C(G;T>71CW$?+Q+ZGS"SW ;I"]5A[&33YF8V2&URLK$AP5B+)&N3++J\
MBK894&DL.0E54V:STD, C)(LC@XY+J$]%2W)/AS#N5>QP8_(R=-0/MN2(J'Z
M/8JILR\F#,L:0-2Z3,WTGBZ\XFU7-)C9%LY*Z#*=HK..Z;S$*83,S.O>?"KQ
M_?96VR3_ '+[GXE"Z7.S7B8AX1/:^G&%D[38ZC:7S%F:3VQ2LHE$-I2C5H&#
M9637<)-6)V[AXZ*Z<F5Y^-JKQCL/841N=A.]-E@H*387$F1XL:VP*H2#&.S>
M5NV3Y16 +8-=(*2L BPZ!=.0*0$)R:;*+73DXB56^$T\$/%<$10OFX<KKIQR
MQ'(V"MCM:*6RJ1?A9X?8R*DA(9DW!V(DG=TK[;8V7E,.-HV[S$=EESG"O-["
MA7<+0*C6/K.37:]@BB59>MO72)Q@[ ^FX  B];ZT335077*5EC*-6KCVS &R
MK<HX:_@:.:"&"2BR53&9%R5K:MF)-BT6'XMSU=0LKYGD777V2W;D*A8RX8"(
M=?#NJ8^A<Q!# R,5+M'&HJV'# Y$ -[*MZM8;+H^A/# Q8U8,VX9:SC8#-W<
M!-3D;8Y?&#:%R//T6^R&4L<NKV%5Q'7Y)BC3;X_-*,_X=/*,O)LR$BK&>>CB
M^D-5"L-12O J3UJ%"NC$KL&V:]/(4N$W\%U,KS!,N.W&!=%1HN*Q0EBE7HQW
MC@ZY920M=9-Q, +[LD%WH0KJ'B<UE_MC*89?6!@12?99:%;6">22FY84K(A$
MJE4#8H\-S+D'B^T8FR1+XQD:YD#)51N%E>5Z;C&EBK;FJ2$C+GO=2LM+VX8@
MGIVTRQ_I,"E6LB2-E4B(P))\ODJ?,N>(=7:RZZZO"E1@%"^''S?DAB"DVHJ4
M: XGHJFI3L4,Q6C)KRU^*E*PM5D:\4+ZSYJ]:SUIL<1V:D"#LTFSCUF]D-#P
M%RQ9>#V@ZO9LJN8<W0RFD;]FM:=R-2>&:B6V.S[!BTBV+*-8($;,8]JW9,VZ
M10*F@U:I$001(4.  B:1"D* !V  UDQAM8QK)DF-,F&4^9&9213/SDIF=9+
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M%,"+25S"N2F(@IB9F(U[?V9KS#O:1[/E<.V*53B!O&_"B\':R*V-Q];,'GJ
MXRQ?4H3:VDF[*&6EK F&@6" D4Q$T&Q!E2#B]L&RRA;5TK+C:GYQL-EK=:GK
MTC"VBWT.FUAMD"ZVI<B:Y96LR-OEG%>=1E<&4;RD0Q3DQDWL;*?3!C'7#X0;
M2LXC&IQ$7*6*I\-YOB6%NA+KEA&)R6.QZ\:3BARDC:R.;K.MO!;7?9M>U5JS
M5MV47Z7L/VCU\58[VN<<IX]OXG)\;6^)L%@+>0P-9R,'.2R.#"_XY-6QX6P"
M:N!Q5I:!,>6<U-$K*;%&;"F1G@KQ,YZ!PRK*YSH.1KI,4BQ-V]ZR>U+BR'B0
MH%ERY>,;5[)$C&PTC7&C6)@WE6(RM23&O1[QN41F$8HS$RBB?LA<JQ5X>L=*
M*4Y6G@J;X,RE<<0Y/@[#<15*X[L=(#Q!8R44L9'/(*OL34L37AJBGXM9+I97
MB*H D88T\KD*RQB?_55#)7:EE824\Y'C%5)<XFS)NK;M6QQK; [&7_$KG(N\
MXMD*=1<EPM6J-GL37-]0<J8@64LS=7;S=LS1=1:A*/WED8V*-CH* GF<U#2T
M!7E2/GT+*/)%T*2#317:*[-E]R&>"'#YT$U^6)9.4P_$'"^%OO&%;- \1?R[
ML=82]LIM09OKH; (?/2165:KW*RV"%U;<!85:$MUHJY/,S3JC8$N<'5<WC5W
M;B"K*.R@T4S)Z%S:4R<@\3''[><@HN7Q-DR'8OV&-W-@F'+NC*I5![F&+G)S
M&<;*QR%J/*O36.'@U7CF1AVC^*@E'*+.7>MG:+Q)M+V179F%,&99B+N;Q4PO
M8XMYCAWAO&<4YC'H*)V":V,R]*%6K'1JVK!,4AI0N3GE(85A--H*,9MT:&7E
M9[":</DL]>X<J9 ^\P<ED<;<AM-,LN)0M;6)@7IYX@<>,70(N)@9B>VT;D(E
M&W6U2L4QLG6X68D+:C'0C*?L,W!1L/+O9!ZPK[-^BW=E(UZG<BD[:1IG8-CK
M#8J!XN]C<?O*;.0ZAD#!+:G4#)4<0-^S,1N%0[]\ YR@#"NFQ:,!4$26+["U
M5[EE.]E=9(DOI<HS:MLK7KBL<@C(5G=;5H&T1$S5$V*:R;#'[!)&*]QF6F=W
MH/XLNCV]4W(NYS-N $(N5J-9C9V%)"(RUMH$TF^J<%6RI-X>)B']:FB2D>Y4
M<('BG;IP,JF^>/J6!8VY7Q:+<K;9N<,<3Y(K0STY\7P=QMD.&G,,0_R[9S%
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MU[FVR96#NR3#A^[(R,X3; W4>/%7%6K$5 ):>RQI!C::IVZ6,Q\.\2^EC%1
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M)#*RI\UH8@R2:@V62B)<C(S,:16>T[";B#OU:OE/@,O0.2'D.-CA,GTW'<U
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MEF4R0#,.$FS/:*G#FKQ-KVWXD"85S&A2X?H!8LPN8/\ ##@3, @ :F\^M_\
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M12-AJ<0U@U'J))-PD6+!1%F(_P!JH04IU=3J*'MT(J&^Q!TU&Y=NT?/\_O\
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M59L9)07)U/2R$@7DJH)E#K,F/ CP4P<B$]OK\/\ 7_32)F?.-OU^.JQ;N_\
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M .GZ=^W_ *.L:_;_ 'Y[_.NO[4O_ %[2_P#N2K\?\Y>[^G^VT:\9^R1_[/\
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M*JF=,P@8H@&\UL7TY8!!#4IL*YAD>HBPL7(<&_\ $IRC!BCC<3 A(9D9B=:
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MXZJAO>;+O-M-_;-&ZSEPHYII4T&R1UUE.+M71'RTTBG.H(%#JX*41 "B(@
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M;!MDJY1*%8V,"BO9&J]HUFL0_-5TW*ZRI5G5Y;E!%*Z[:ZRZ>[E[#-5';CN
MM=;DG,/8JQA+*MA@)=F8I'<5-0M$GI**DFISE.0KEB^;(.D#&*8I54BB8H@
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M8&+!K>$<XF*E/B8BQ#J\%W+>W?:AL8ON:I=QANO[F:/BW(F2F>-Y$9.0A[S
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MN;Z,_KV-)3ZHO6)#!EGD;C)).\8#C&1K,/ENP;@K!98BEMF9$IBK0-B87AS
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M%J*TUAE5ALVK0UAE"C<*2(#/J6""?W-<87L3C]V"(![20[J0<\B ?80 1#W
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M[3.\:9;PG*[BZ0[PU#3;"NR5WF*NP:S4HW<.V3 [6S1,D91PW:B#A0IRLC)
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MC5NO _L=ALVV/);VQSTQ8'B&>)QHB[FI1]*N4FI,?8Y5*W27?KN%4T"JK*J
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M%6!HSA+S7*],22+"3;.8_P!?',74>Y>-G#=JY7514*66ST:-?($)E7MT?M%
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MS7,D2UOS([K=/'#%KA9&)ME2F7..X%&4EH?SHE--Y(LXPW2S2ZU1U>KGBLK
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M7%RCH7-JMD@N5Q0U#\;?Q-U3F,4P$VRKV$VZQ IHM;7M54R=9G1!Z38,64'
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M.>WQJ/KZ[3J!CMZ;SWC;TB=H]>_;>?C'GYSMK(\CV^_(_';[>P]QX#M[<_J
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MM;'UN>&5:MQ65\-0>,V):^J[Q*J@S$QQKMF:5>BTH4UUFX=1R5,*028<09#
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M:;N'+N>KJKX^L9 =QU^OA L;D5=-<\C60+;,JL,7T,VEY[DMR^"JGF"7H_\
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M"=9'CCD1YY'\H]Q$>.>W'80_4?U^^H[^GU&GK';;;SCM$1,[=]YWCU[1Y]M
MB/Z=^W?C@!  $>X^_N(=_P!=3Z?U^[T_7^6D1'S[?#?>8F9B.W;;RB>WG&L<
M<_IR(\?/[@'Q[#_4 [A\1J?+UWVVW]-M_+?U\_QVF=]_4$/S?'<3<?(=OO\
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MA0;7"]4&!*Y9EPXF.FG,)MC%.<:[(L4I4JJDKGFEM6IPV%]S OW&4VW9K*7
M6ZU?C6A5S-M27PQE?$MX2/+MQDQ(W8R%;'*<YC8N#8EBG6;Q.#U(9"TO,T*2
M36;I:JL*;'>VR,N$Q-O8D&&0JU'2K.GRE/B\1P4Z[)+U*P2<"M=I1FR,UDK6
M*"2ZKW&1 KN.!+6S1=>R%9;;(@NQ]DM#"G2RO$4 $+1E*4CG%13Q44ZMDVU7
M&ED(BK:U6/%2.2F)16-=6NR/"B=M07U6<[,U<-#9ZKZ=RLOA\K5C(>+<F&9"
MO7"L^PJSCF(WNOBNC>8>K/@W -83\78LB)6VML:;5'\0:%1R[?8O*,OZHE-2
M.5@[Q(M2)EFY1CDUR3K+S8MJV24E(M[&+F'SCO&Q*8-T>-ZW[O97^ WQ&\KY
MNG)<>UT%,B)2-*TWW9J]%:+F3):J^6FB$L= YR<=([ME<,S_  ^["],")<.;
M7P;LY4*'$2V"E96(;= ;3+B[+)3?H[RWG1ENS<@I0&2WIL7MC5ZI-&Y3,[)+
MHMI2#L%2J-8!]&S544A5I&*G7=ED64VV>.FLHR8O"PS''$23.'5-R0P.;.Q3
M)H;2LT2=6Q]IUN02Z+J2;@5IQC@5%@$FX+ER^9*:NOD()>=Z5$S9B!1DHAIP
M!0\1L8Z,2TI$.HF[-<LC]HQ+?#V#FO-6CCXKM&P_M_%BW20&*(\=I,1D"0R>
MYE7"K=W2FV*G\>S2CF"\@FTM\=D^GV\KR$FU4 B4R5E.$F"OG+836&':BJ\2
MT+-PYS!08$6*B_3/,P<#-=N-^T:2\@G9?2N#:B@RTZL:+=8!E12779"D,MDM
M;,7EX%HKOE3:K&%&\.5>:BP-6R,LAE24(MQ7FV%BO9YD$4K7O!%%'F.2_$_0
MD<PD9US.<ZE(O\AA06]OQIMTB(ZI5EM?*K^'7=.?045&.)VVDH#ZYFK#"_&G
M8J4DH>OHV%)9PL_<R&%<7S3I*ML:,"_'3DKRA0>6FG_BG.5WQ6JRK[-*T_AD
M>'K&0GPG3K/=D'44B20IE3&;'CBGD1"CKY3PB2EA4HR$\&XVQBQO-!B[B\>/
M&092H4J>#O!&CK62!@6$7MV"UR^U3"L[$9'KE\KUB5R[E.=3/D>)ID):)Z&L
M=K>S$+8)&.Q^"-2:O)./=(KR"$-'1#1%^+E-**9%*");51/AL)@:Q!60ZM1M
MIL5*K7N55<6:REGIK.P;62HE65L3NYT"LH 3D1C6N.:<MGW?OS5;R%6RBP\4
MB3P^Q,369.R04/,NS5>HMU"4P(D1,(I857O$/KN[F^W*!J6+H#)K[&D8\PO<
MZROC&NX>FFBMYK66F$Q<).]R&2(R2GHEQ4ZY'Q$K2&E9,SBY9<\XA96\^W\B
M-2HU9O1DV6H(TV*-VS.+:0H\-7IVN#LW4"\@Y C9DBXAMIH6T6X?3#$,ARJD
M/([B.QU$!6Z'()IOX?/5<A,$9.;:<*45*#E20@K'-HG:LA;KR-S[377"'I4K
MH7:_PEX\5^5GH:OV ^Y2N12TM74IVT1V*-H[X4X9+#]J;VQ1@9U2GC--TXRU
M'5A]$'<1#LA4)=Z!FBD$9",8[6E8;2R#06(61H\6OHU"'W&V68/A"SPO5=)D
MS>%9V>*J1ASC)T3@+KG/75N*Y]%9+-,7'=>"7PPHRF0$1L)XTXDK\2O+H+2<
M*L\%LX>N!M,1&2K;TAKP=RM8:)<_^)?CFJ3][R$TW!5RLUG'U>"20M&'=K,?
M2Z[+-L13I;M;W3R"B8:53:QV3&$%)1S8TH6%Z9.2248'@1:,(W++601&1-;U
MUZ]K-Y%6/LV&0LZ.,MJX1C"*$V@]</C+6N)L:#;J+LKQJ:C[86[8C896J*R4
M,HB:(O$FKBF7D5QYVW;*,CQ+]MBL%0DH!F&#AVR,(E9,NS8"J=98M4=I-LU[
MS!N)\/3<T_O>797/%\M=&S5 UZ3=1>(H6 8H2N-7[. K-;LV,*C0:?9FI7CH
MPR5BD&Y%6<DX<1SU=JE'&.?/BNE$\+VJU=)E;L83-@QKA969:?9"T=,06XX1
M%5-%]*NFZGE3>8-BX4HEDTJ?NO8]E4XSVQ\#Y+)VP5C,3[0/9]D&"E960Q]"
MIE\4[(-;%=+;C+K+%:_;90V<ZO3+'I2IAGXBW)NSF:@,"[6=D6',TUEPWO&0
M).R4.K-R1T/:XN+N;=Q?KTDW?S4:\D(^.,XKD-(N6C]FLY2,LW%J=5)80)KS
M7 %%Z\#C,2Y0JR%3 9/)O R60^ K9&O5N #ED8&7-E:<$D2F&+:7GR%$?2OV
MH<[BN(O;7[2>*,-<F[@KW$."KU;$HM53>=O$4*E<_!W$5[*P"Q6:!$Y*R#W3
M@9$X*>C9*I5DTDD4ZU $10<)O$4B0T<5)%VD7I2=))E; 1-PD41*FN0 5(4>
M"F ->LB9@A.)F"#F@"B9@@@XB#@9\QYH$8+:8YH&(G?:-?!)B)@QF(D6;0R)
MC>#B)F8@X\BVF9F.;?:9F?.9TW@'&<E;YNH>CJ;VYM(>$M5@B#1<>O*IP\K(
M2K* EY+J:F$R3N1@I9*/474,KYT<Y.F!03ZM0L8E9FJ(Z=>U"C(-H%5PJXOY
M)V["_P -8!D[>_"G@4["T>;8U9B-=K1GEMC:57(]IERZ<T_% .\R7345JI!0
M40!$0P/,2S@%TU/J1R+IFJU<,FZ7*Z<IFA(PQ'+D@& CA<@M1*LN4#F JR@&
M4*!C !@Y'F-HV$=HY0DI =NP2<1!R,>0R<1$%,;241$3O$:P]9GUF!&9]9$)
MY@&9]8&8B1B>PS&\;3I;0:-6K9)DU;-VS-%($$6B"*:+9) I>DJ*2"92I)I%
M+^4$RD @%[ '';4G^\YNI[_/$P?/[W-$QM,%S;\T3':8G?>.TZ#[LQ(^[,3O
M$CVF)WWWC;RG?OOY[]])"%4JS46AFU:@&XL%%5F(H0T<B+-9?CSE6@IMBBW4
M6X#S5$>@RG =8CQI\?FN4S\TSS;JG_[7/,6X?PSS%V[SJ-HG?>([G#)[>;!V
MY63\3'E'8OXHVC:>T:4V$='Q38K.,8LXYH0QSD:L&J#-L4ZAA,H8J#<B:13'
M,(F.8"@)C"(F$1[ZG>9@8F9F!&!&-^PC'D(QZ#'I$;1'I&I_ZB+_ *C*3,O^
MHS+^(RGS(B]2G>9]9UH/*S6Y%T9[(5^$?/#%*4SMY%,'3HQ2$.F0IG"[<ZHE
M(FHHF4!/P4BAR@ %,8!Q@1C?:(C?FF=HB-Y.!@IG;SYH$8+?^*!&)WVC:9F9
MY=YF>28D-YF>21F2B1_\LP4R43&VTS,QWUE*MUU!=DZ1@(5%S&I"C'.$HIBF
MNP1$1$462Q$ 4:I")A$4T#)D$1$1#D1UE$R)$43,$8P!E$[$8#'*(%,=R&([
M0,S,1':(VUC,1,0,Q$P)RR(F(F(84\TG$3V@Y+WI*/>F>\SOK=?QL=*(@VDV
M#*1;@H14&[]J@\1!5,>4U02<)J)@H01$2' O441Y*(:QD1G:9B)F-]IF(G;F
MB1+;?RW&9&?C$S$]IG643,;Q$S$3VG:9C>(F)B)^.TQ$]_6(GSC2:E5*L@KY
MR%:@$5A,U.*J4-')JB=D4I&1_,(V*;J:$(4K4W/+<I2E2$@%  RB9B9F)F)D
MF',QYR;H*&G,^?,V"*&%YG!%!3.\[X[1MMM&W+ [;=N49@A';RY1(1F(\HD8
MF(WB-#6J59BY3>LJU ,WB*JJZ3MK#QS=RDNN42KK)KHMB*D56*(E54*<#J%$
M0.)@$=!F0B!"9$8#IQ ^[$+WB>G$1M')O$3R_P .\1.V\:DO>F2+WBDN:9+O
M,E'D4S/>2CXSWTNG'I(8PE$P%*81*4.3&X 1Z2@/ "(^P (AR(\:P,H$"*8D
MH$2*1B-Y*(B9F(CUF?*(]9[:F(WF(WB-YB-YG:(WGSF?2(\YG4(X=MV*LRU4
ME_I%4;LV*-CLT$8)JIQ\-,M)VL3KF(F@.@":QTS!*QZBB;E-<WJ0(DX W(EX
ME,B=3'74$,ULEC:F0ID'NSX.TLV) AVB5D$,:)JGL!DR._-,SJEHM?D*Q\Q-
MH9&WC[<'&\3;J$*7D,S,PP2@ @&_]:X#TB(A\69+'E5K<O+6IC5HBKM5/JTT
MYDHV/)& X.JFF#YXF9L9-9VHL=-,BQDU'"BIR$()CF* XD:U^& I@?WZ*U0=
MO*Q;<%="D#$>Z;G- !@(CN6\S$;S&V9F(LNG?8:[[%H^\SX:JEEA[&S'<@2A
M3&%OOL(SM'II4)5*@NB4Q*S75$5G"<F7_@2-$BCL2\IOA*+7NZZ3?E<"'G
M\=8:V3$K,8VD321P&W8E%,QS\DQW"2D8YN7;>1C??:-81(,"9C8P<L(GMN+%
MP,PL2B?X@@"F!&=X@9F(B(F8UNM*_ L'J\DQA(AE(NNOU+]I&LVSUQYA@,IY
M[I%$BZOF& #'\Q0W48 $W(@ Z@8@!Y CD#M[@^Z/:9F/=C:.TS,QV[3,SZSK
M(O?*#+WBB)B"+N41,1$Q!3O,1,",3M/>(B/2-?5Y"P\BY;/)")C'SMD"@,W3
MQ@U<N6@*EZ50;+KI'50!4HB50$C$ZR]C<AVU'*.Y3M&YA*SG:-R7,%$@4_\
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MB !IM&\3M&XB0#.W<0,I(QB?03*9(ACL13,S$S.^H])CT*1DH]"D!Y F8]9
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MB;J\;D\?D&UUVUTKE>R=9L#(/%+19*R@Q,)YH':.<##?;G QW&>4N&?#"LE
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MVCYE=S-RL.;S)=D6;Z:K6 ^T#+C.N6M.MVJ';NPYLE0["/\ P(^]O_OP>_\
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M[*6B7S.3BY)J@^CI&/<HO&+YDZ3*LV=LW;<ZB#ELX1.15%=$YTE4S%.0QBB
MCDQ;%&:F@:V+*0-;!D# AG8A(2B"$HGM,3$3$^>MRFJ>L')8#5,&#6U9B:S
MHW@@,9D2&8[Q,3,3KB9E3Q2;[3<UY)Q; HX,2A*QE*I8_@KED)6QTUF@:3O"
ME'N36?8N+:,XH\I2PI3B\TM!UB#FH0OU* +*0CMM.AR\7;/(TJ]DB0B7WLLH
M6GS"IE"KA.(LG4R$)YR.N,7\&O#VZ]EX7!N7% ZK0-E9;]^7!F->0*K6+8JH
M8:RU21(VC8R-WAU;4"\5]%D%B\V[*K8@'+JIHVEO-S:5T$Q\P\0.Q[@,W[)&
MRDI5<=0Q\L4M6RHP-PN[/^(9K=CS*\9*C$ T?MZ?8L9,;;%0$1Z6T!*R#:UO
M8)N0S205;IO.MA BWECL&BR@;'#&5.IBK43XRF;\'P]FUEE$&(IFU)6K];'.
MKJ4[GPN9A?-";05];;(#A\TB84;Z]RM'C.4H4<8SVA4L7UL6]),;$EA%,O91
M-DAJ_9N9J-.9!E1CN_YS=!#F HG$I3& I>.HW2 CTEY$ Y'C@.1 .1[CJNPI
M!9G D<@!% #MS'(C,P([S$<Q;;1O,1O,=]91&\Q&\1O,1O/E&\^<_*/.=?G?
M>^(9DF,W*7S(R"M)B(YC1ZM3Y[%5FG<G)_@6&:;@'-'F9ZZ5AU)MJW#Y#KT5
M*1UGEY:!CFR0TF6C!F^63B#DW/-Q%A\5<L]AIL)R<\#W(<LB;4IV;6#]I!M1
MCFMCQ*Y/(TN&\%FD\JZQY6*BDK'(L8J)SE<J^4QZ@ZBYQN-]HZ5KYN7[5;CK
M7LWOXYCQ7RJ<NYC3XJMX%D"QPH5DV"^Q4KV!6\8KQ1\B9 HF0K,Z:[>6U8Q_
M1,$W.U%;6R\QLF1WD>[3U3M-8"0C;(P<0DE4E:\VL*RCIP11"'G(UG+,1*N9
MROU1@!FHY[ 2AO%^-X=!IE @*[W#'#7$2LH9D0J*LBWE,OB& 4$I]K#6PY@*
MK95K-L3%MU2E(N8O \8Y(I(883?L/-9G#TU(1 R<#D*E;'V8?!=13+@'7F8=
M6,$J.\8#("M/O$GZ3;5,3K!.P&HZ,%=W#>-<-J[FN4Q>B_LCZV72OUYHVM=<
M:,;M6GDU=J;7U&+HAW=H*W=-%E*!VK'V?C'C6D;UV.$G/K,):EUXXBX<RV4O
MTN=[*PC=PF4Q48Z[#&"2IM@B*K;RUU[4&*@R=Y 3)8RL.:"L[F:U[V8RS@55
MF%-:M:DEV*^:EL@FNZ?\MXAKJU(WVJG8/:ODVX9DP%C?)E]5QDI;K="?4YQ#
M#]G:72@1SXSI=%6)AK3'S5ACIM2+,D+"2>QTR_8'DD'9&CA1$A##WLC553>M
M*B:R)J4G$UBVJ!K+%53S;5%Z*SSI&3)FFYJ%,L5^F^5AU( >?3L'9![#"%"-
MRVI*R))/"NEYJ1-R*[[2%7&+ 76*Z;#UUC9X>'.E4M/G]G_Q$,TXNW/9&P9"
M8IQ_!TNE8VEK:SR;E2Y5J :RCYE3WUJ:R<9539%B,EW.LG?QXU&0)C[&]E/%
M23Y"2?32"#5RP-YVK<?9Q_$%SIJ!V)NJJU*9%)6+C)S.!QZ:IK1-AE9F<1E;
M/V1?O!0H!>KUJY3=&U))ZME JL89"RB0OQSV[3IZ%5"6T<LR7*L/%-9A8FW4
MHMRE8++GSC677#%9J4B^$3>+-G,[G$#!AB#%,@[NTK9F=^>N+Y6J;6L>OH">
MCH=U0EK)DS)]%93]^B8MZ:XNF-))=G,[!J,R0L$5NL>9);)I3=L(5RE47A R
M:+C!,#N,=9X@0WPU%<NOO#!MQ%;'YA"*SI\;:)D6ZB&48N<\6E%&;)P)/^T)
MJ^%7S!()"A@[=9K[%F$4ZR^((REFQAK%NS7)=2H0LIV[*KJJDNX\\0S--X@\
M(24LRVUT,F6J/,W].7NEEN<%4YMO#S)ZY*4&D6 ZSAN[R/7U6;RURT1)&2%Q
M7GT6RCT!60E9AHR1G3?F4C .C&<-XW-K2)R-S(CF*N>NKL8Y8S'BJ.)7C<?2
MR9)*'>*R:K$E22=4+.75G=4P,2NQQ'E\(#^>9KTRQ%W$4E5<DZ D:^0SDW[[
M,6.TK$L/<K$NRSW@8D+XG5_B,.1]QK^/\?WI8^"/QS"46@VN5OUO1M\4[2:W
M)*X+RER-)U"KUIP]\XSF\GBVR[2/>$<W6.5.FBUV7&-4_(I&%R-:UPH%:Y+*
MPTJN(SF/PQ>.REAMBK6!T6[=Q*5-LTB970BY++4.LDBY"I/($LS5(S;XQ\0L
M9,+E^WBLCGBHHQ%!27/:O(U<?3:$X^MD %F46BM22JN@+/1'9MN:7W&XDJEB
MNZ6/ZKEB3CYB7FL?T[)&.[^"5=96>4@86VM%\>7[(\2E#V%NQ;NP01M<X$1(
M+N81U)N'C)4QNC;K+4-<T$9[T,6^\$BPHHW[U,7NIDXD(%R^J%@J5D5B%NH(
M/"-^H(<VO8)AV09 P(7KE>HV.08MUZ_1.60J'.-3:\65UKBFR# L@9]):FIB
M4S?5N9L&UG#B%\I[&OS5QDK 2$K59LD9).F%I?I1$M.KP*$LA8:I#5R3?,(=
MV6+D;'/M&+I\"$3'M)><D(R)>>?NY J=JH I\0N57+MQ(3(6(QU"$%>MH.>?
MGFBE_BGU:U;(9%U9;F4L?9BO8E?8K5@>FTQADJ%>%4ML1S@-FY:75K+:N-IY
M;#F"@'-;5J)<Q17+E=4\T\X(?Q>+VZLMRB7U:PE+QP0V2E*8VJEALCNP1KRE
MN,4J,YN\M"/G:JE5/ Y#L$_*&KS4DD6*QU9I%@*B39PFSZUA A5N =A(O7E,
M=1*WS%%"KCKG&61X2M9*Z2SARDU5IHY&7 Y:EC9*&M6N5OCGUS,Z57(D$S)4
M<59;BAC;)V;F2X*O<4S0H@4$!.J9+&EPZ\&*,OM'*XI,B+RE+[Z>&Y?G>0]O
M,E,R%VCK[(-LPYA8+S,19++:(I-N2]R[F+:0\C<9*5LQ((D2Y8K0#65>**(P
MJ[#TP^C,W$<P608?ADR6\"9P[C>H5H1BRQZ!96L%9, "&V1>ABK!E$MZRSAT
MRWGF="WR[)<0"3%'*LW:B!1,PE:FJKV$"I>\PI1(<MJP'9<@R#7'(0ZB[Q4-
MPMGP_AM>G5U9I5#9%JEZ4')<K,7:N-X*0J\2G*1=>K,[0GD?+L\@V!V)#UM)
MT^;QKE)@_2=$=IB=L?BE:B<[B:;3FNBO;P.6:<% LNJ5Q7@Z5RFF&3X=BJ]"
MW9OY5=D&K^RD6#E< +'HZ9 P,9>L(25A[D9/'*@0A@4V.P.6LHMV(@9,(;9J
MIH46*);1RENG ')R '4BZ^+1DC%"UQJC^-P:X<TE.93K+ZR3MK8.+Q -:AB6
MX4.8*\6E!2=N+G#W:QQR;UB+E"3F:TZD(I%9FW?-"=I<':NTDLA*;%G.IQ.3
MKKW7&/</M&O<&Y4H6<R25U,-]F\5B+HGPV*<;;,S78EX\:RUE3$C9I*?>B>&
M"S%!O*5CQSPX.?G*Z%ROEFT5G,U&X((2?49<,$1,68E9./('B6Y0Q5:K]5W,
MKM16MT'>KI%33Q]=+VC7G4+5\)AE&N.XI@_MCH[!W++HA2E 9E:1\G.NVCM!
M ')SM5>)&08BA:L%3L6/LZIQ/;N54 ?C+V4X>SV!PK<=C@9U36[+A=NAC:;2
M<5>YB[<0MT#9&.BM8NR=, G:IEK7#*:]V&2VK4QF<QG$%V,A;</)6)&,91QY
M6[BEI7:1E:@F22=59$\;>?$"R+G_ '=?P=B6> &&(D:FM/&DBY%AE\LS,D:H
M05B:Q=5I)KTG;I9!LK*OEYZ<6QFSJ;&*BNJ*M$\Y=./IGHJE,B'B6;11,XFY
M8KX\:FSBL5TY@L?&0NPN; TJ?0BMM-QE*VZYDJ@*I^&@'VJ+;>U3A-XP"G9Z
MC3M74V# (J6'8RS<L8Y/.:F.OJ?7:$5DA:E5:E?;<.LU/0U;C>SN!N.V+;W:
MLNT3'RF2;%#25:C&T&+B.9QK!"?GF,.[LL^^F)^IQ#&O5QL\4EIE[+6FN1C5
MBV57?SD8U(J[2X%^XZL[&)4"O^(9 :;+%AJDUJHS7L/$GN<Y"U^):A=%!$S_
M +5:1 K>4BEG=Q]15J;DM88Q4Q]NZ"4@QMBTRLJ3&M76E+VFTY[P()8<B)0(
M[]XYK-_%0S<RDX5.PX^P>*<OC2.N"-<J%S5O]E6ORE+M-D#"K27H%IM]&?VZ
MU)0;.R5"=A+#-U8*XLZB)9\E9585.7NWF>&^VHKB=HL>.0.D,+8GQP5IX7FQ
MRS<&IM/"R\^1\3,9%>I9 Z)X6T^4<0+PG+01-^S(/9<6+ A?:73E=>H=K*TZ
M-U<5W6B,<]:Q5BKC:RXL6J#%.9EU5U%2\;\,>^*=N%N=;J\LMB'$!9V4I^;;
M@I3(*^U^\6FR,<4QD).,$*S'XCR;E=G&RTJVE74-(UF6EGMICI.)7=C#?WIM
M$#G=GPC&"1@*4X7'9*Y;Y6NJ8_QO&%OA<K]BT +K/Q*: U^)WNIN>%:C4R]*
M;;VU9MAI6RPY]52TQ/C<Q./K*,A19,(X<K9KP9JM'7*ME6WPO8:JN\-1+V6,
M5:9X:&6$#(Z&_P R K)1)CV/:#9[!,8<N%WIUCJV7[%&4%92/M]4BRMK"C99
M^)C6$@VBIAPJ^@)1R27;S,5],2L42247!EC8ZE9V75"SY\=4P%FTR"4]+J5K
M(YH+-BC).2EZW4J-2W3<EJQ#QC0:S()JJ.QMJ$-VUAN86BC)/SR:R179"_7M
M(P./OT*>0K=,34\[S+52V#ZYL56K%;150[Q"!V\(>)Q<LA;B6>.[[CNE8XPN
MEC0USFLLVV[T6AJD.2K-; G8X.LW#*2-VL5#=2"CJ ">@*%,5QJH@C+_ (U=
MQCGS$K-40=]N$^9JC1?1KT5-DPMDZ_9Q%6G5R%(TC<H6LD66 Z2LE7Q3Q>K[
M,.LV^P5ZTL><?9 HB+<W;%]-AJUDM$KH+S[+5BHUIPFP-*<* V H/RL,1:+(
M=6O2K,,NQ2;A%9N1T@JFLW51*X171,"R2J*A 4352,F)@534(('(9,3 <H@)
M1$!#6EVZ(;U(("3!\XD!R02N)YH(!B3DAF)B0B).9C:(W[:LK,' MBC%BVB!
MK,"$@,#B" P.)D9$AF)$HF1F)B8G;7!.[^+5DF!NF0ZI"M=OJ,;6LE5^M5BV
M7QS9J@QGJQ,L,IIRJZ\,>XO9UC-4^QXY2B)D)QI65U_JA%@KK!FXB)&2YB,@
MPL30R+*Y&UL<5'8J(F#<VOA>%L#Q-AK=00ERP7G#R5K#(23[#!R7A*["3?7=
MQJK=FN2,J^D(LFN#,!7Z\@<"BU?XBMX7,I>V0 &#B:48_-G84N$3CGS9@VU'
MUK<N6A;Y97<'NSVRH&FZS0JX1\NP&IQMNN"$Q>BW#"+.XDLZ[$L@A1++CMQ8
MWRU;I[H[.2F$K)5YE 'Z#TKZ,;=_&58G)YXC%A\N+XAK5JQ1,G27BL_CJ]1F
M02<$"\CE:$?;V-?7%,MX?O(:OQ"IL-5RO']?!U()4)LFWAN]:80D'[^R^ZB_
M7H.7N1U<6P#Q.:1<,>AEHE#DJ-=([G<W535S5#MW8_\ 9'3P]O\ @5]R/R']
M_ .WQ["/Q^OQV?7U]?SUB7Y]O+S^<;[1OYQ'K$=OSJ&81X$..0#C@WZ?O^O;
MD0_VAI]?7Z:Q';???:9WW'?\^WIMWVC_ %UD.P=A^?S#Q[<AQ[>P@ _;^@Z?
M7U]>ND]YVF/3M&_GM/YQO'W3VVWT#SVX'W#J]OD._/ !_P#'CYU/W_/ZGOV^
MO/2/7MY3R^?:(^$3/^FV_;;1SP7V .KG]/D?CC[?//\ UHVW\]N_GY_C_:-O
MOU&V\[=YV]-_N[3._P ?/;X=OE@. XXY]^!$/;D?C]?;O_UAQ&LIF9WWV\MX
MB?/:/7Y?+UW^Z=9 1#@ #CN/OVYYY$![_8 ^_P#/4_7UV]/7[NVL9VG>9G>=
MO28[;=OUF>W;M\//6/D1X_Q![<"/VY'CD.P_ \^X?RU'U^&IV^<;1/W?&(B9
M[]XB.\;>6CN( (CP'QV[\_[@/ \\_P!=/K^?U^>G:)F(B-_7OM$1/\]]^\>7
MEM$S&@>0'GG@?GCVXYX[AS[A[?(?'.FD;;;;;QZ;[[[S\/E,=]^WK.T1Y ]C
M!^ON >_?X$ '[<?O[]]3O\/3O\?KTTCN,_+RF?A$?&8^._W;[=M'WX'V[<B'
M'Z< (B(\\? <?RU&I^^//OM$[_/>8B(C;?UG?\=,/)63Z=AJK*9*O]0)?JA5
MIFL.YFI*-8M\28;N+)%,DT#-IE-6-6%)PY2<@1RF8H"ER4>L"B';X>Q]K*9:
MM1I6O!V7#8E=GF8'3A==K"V)4PR.<!(.WQVF=IG7A?:1Q)B.$N#LIG\[B8S>
M+I,Q\6<9*JS8LE9R-2HF>E<$D%"7O4[=D3MT^81@X&=7\V2;HL(YZP_;,CXZ
MQ_$X+IL!D%W59:.?HU.M,'<XE7ZQ(C+JGA2LHOK=-)F.CB*N1]6H9F1'J,F5
M H6N*<1>PN1JT\CD/M"Q9K+8@Y8YA3#'/6" Z\RPCYE&< &^_-,Q&^^N1[(N
M-.'^/.'LAE>&N'HX=I4\N^B^F%>DB&6%4:%D[<C0 %;2FTE4F<<\0K:9Y8'9
M^Q>3\%;KJAG/&5OBE4*W4+A;\29*J=VG:_$'FV-?9PSV0L#)Q3KI*+FHDU'S
MC!9A*N9"(>J)'7;2L9&KIJ-A\@(ULAB\9E3[5WML6@6PC4_'7L+Q%E<$2KG(
M4*793E\%;)$J<]#0!#U-.2Y0^K*L-1DLC05!>(I'6I$R !B;J\MP[BLZ!4X*
M"-R3Q6=K Z&)4Y;NNLE0("PYDA+=B2IP-:K\/=J3&P3.%C&%7:GN,4N16%:E
M3BHL&+I[*KN9%#E%-FBZ%PZ.X6+T&657$W/0>YUJVXG%++CVPUH\L0TFVIEH
M%*@@>67[R:X$(@XG<(D=5D)13JJ4F(54K*-2YDR(%JIP(-B6F13,5HY1<1G,
MKF8ZDQ,]UL^1,?I\>9>J<3EM(/ Z[-"%Y:1)E"2KH.I\'+:,.BJ607#^R9&2
M4*Y,F)# %>#"1@X,9"5H;!P42,JLF*ZS8+?:5V&& (/?E:9"*Y(BB)L2)1,C
M,3!0TT2,Q,3#EA+6)F/.&K5$L-<^^ 1)E$#$SI&)E['8OY!HM<*HU9Q_I4QF
ME[G2_ICE\X1<NEHM$B-B5ED'[%HV%VZ3D8M@B=LH19DN[(FY%N&>:2B1D"AI
MJ6)2,R_I0J'&J (_=2UHUVBSIN!W:5<AK8>'-$R,#[XDE+I8,C(#%@V"@"WF
M#DG OK*,1)+%E'(TF"Q:_M'RN+J[8';)C/T^.M-X=MYMPQ-88T)RR.%FB+5D
M]0:.'YGSU(S)J@BS]*D9N""12MR@4!UFL9VFHN"GPI/DTCN1H-A%8?+![F$[
MG+#ZG<1V\@@8B3/> L,/W&@H%-(ME$ ?NU"F9GIP/-O$0O:#81E/,PR*9$U&
MIT:::---&FFF6ZR3CMBL[;/;]2V;B/>!'/T'5I@VZS*0,BLX*Q=I*OR';/#(
M-G"X-EBD6%%!94"="1S%Q$P.!D"$H/J\DB4%!=&0AW+,3,%TI8$-VWZ<F'/M
MS1O)1(ERE$B4=/<2B8*.M,PGM/?][,3"^WOS$P.\Q.F)8\_4>NY5Q5B,2/IJ
M<RVC95825@)"HOX:$&N0)K(0ME:J6AM:VR-ABD'ZM?DXFL3,,NK&N4)&2C%5
MH\KZ:\S9O7Z B2W4,0[,-)D?NF)K9/$XJU6 E]0U7:[LYC'$FV%8&UK$LK->
M:+"U8/($5:MLC$@N9)&,2 ;RR66*>2NA8]Z!6=6 Q5E+&*8Q@/E02KD,F!RZ
M\42SXQ@MRFPME><8N+U-RV0'"-3FD;I+U@E3>!?<7I"\5C8Y!5O.@9VNQ=^G
M>F33 &!D 'H=*"'RCVA6,>G/<'!<QY7&LNE%9PVVU_#%XS'QS2L!D7>](%RG
M,1[G+Y%.OWU^R/B>+<A[*_VBK'#O%JN'J%+AM9YF@S TLL691/#O%IPD+5I@
M-Q\PE=A'40)EO8AFW,H8E(RA@7Q&Z_9]R2NVF5L%1:6Z^WRZ1KF8NN/Y&G6^
M*N$[3Y",+BNM_BB!L=8R/&Q#2U,9Y]>I6@0;EXM%H1=C4;C]78_0<:FY6P^,
MH6.K"J62R(VD+E;;Y(O<:\7Y[Q.-9XFK7#&GC\SB?%5GWJUTK*[H#4,%KFW^
M!["]\K?MUYKP5X*ME+BZBJHG4X)X8X=BKE1\-9<RY&0PEQM%M6I:JIJNJL<\
M6FY*+ 6:C[Y2;7MMI8V?R?9LWT^Y@GFB/C9C%.-;K<:#*PEV@E0D2+96R!CI
M6:KSV2I\X*K/+4FNX+#.I)JX=RR@0JW1S\..S/V7RE%CA/+XV6UV0NM7XE?P
MO(8O,L4^O48A8<2(6RP%.K:BG%I@UT7*BY;K+&0M=/)1;EA/7FL3DL<+QAC3
MH5>-<5?R>)@UM8#46.$YS..K#;97\1(T@MOJ-DWC <G3?%/>XBEV-7')<1EB
M4PCCME)RU]NV%'$?#7^$M5%0OD=CMA3,ON6L[9;/3VEZ=M+%9I/&,:SE746D
M-H_X04/7MV1@67,G-0V#BV<4XNZ@%I#[3/".I9&+U.B!VJU:M5Q]\L0;A?D$
M/N)7D%HKOV4RXJ0 6%&Z2E@8WB6LD&E!8L;1RUG#]N^X5-NF^&2M1"K%7EP@
MY8XTE6&K:UZIB+Q#W^4]MDEFN'R7DVM8XOF+K&YFVEIP73(:,@65=LL9=7F2
M<=CF6ZR,MDN/L<I'/6<G3+M=(EY4TW(MY,\V0\'([:X5_MZM>8 +A$YY;;!D
M3Z8+R'!5G#8UN)2JO7LU"/(6[L9L'UCY7/5-*;M.>M1Y^04Y^$961+"(GX>R
M-0N5=PK.+X[JYFR-FQ+VU[5-F ITPQ,S94WQJ71=JT9(7/DO=AB'Q%7FXF0G
M]M=XN#K#<[%4"8<QZV5:Q6VE>FA<6^F9"JT# RS8KA!J$%+T_)L3*+ ^;A,U
M>4ATRJ.91LD2AC4'U;%;(6'A5G,6)3;B18TL1FZ>*(XB0_>+/AG(X;)&C]W+
MK%?BBO71U54;9)ZM^5%558ID0WPQ]J)IPH(J_:.*-;L8QS#*":OB$+K<?D5#
M(!2'$AD!8+K,(?6 V&?$AQ7;<FAB:@[F)&*M><I:VJR+;+^U)*#LL"TL>*2I
M6Q9K/YIB)U.8NE8K-W1FTGL6Q=NBRL6@]8Q:IE/0;>'R.O\ X?KY!"TXNM9X
MANWJ4[,FI.<]HW'7$JJ2(2; FNO"<28WQJUM8,95#1K->I0N=1M5RAV9<EP,
M==JTDJM"3>LYU#V7<,\+UK3S<M?[]/%&")ZF<@Q]D<C#7XAS*H2=B3%'B0P6
MX&BR:45=,3;>%,ZYEO5LI0+8/N+J3ALAYEO=U44OAH?<E%I1\=)U:RP8,'E6
MB,H6"%FXV01-6VS;RG$EOPD=&<>K)L@ZM/@O$8I58H+H(O4L3<KO5UEA8:-U
M>3&E80U-4ZEFKNAN0K<[A79XB=-R6OQ:VA9;<P,O?,KEK%T,9PIBK)K0;4+.
MJ5?%Y=1PZVMJUOKVDX^S: 41W5UCK'1IIHTTT:::@_<XZBV.VS<(]G(LTY"L
M\'Y8=2\*1ZM&GF(MO0I]60BR2+<IW$>:0:$6:%>H%,LT%8%TBB=,H#R.("6&
M!S9N7+E#B,D350<KEJQINDUPP=R"3&)'GB)D=^:.\:^@>R9-RQ[5/9HC'W(Q
M]]_M X-31OE7"V-&XSB/&A6N%5;(KLQ6<0.FNPA!T!TSF!*9U3S9SGC'% VD
M;*V\=0+/6ZOFN?E,;4]A&2T;98ZE3"KG(UG34M<W8YR%G%HAXWJ<V<K^+BYM
MTW=K-F[AF@T'U9.9P"=>YP_B$5$>!1&$R^6"'/EJ4U\4_FLI)Y;NEQPZ6JDU
M"CE!@M>J87#/??M/8_-4?;7[43S64#B')8O,</KRF1111C&7/M57#N'JVE8]
M)364M%G)X^N]2G$Z0F7J2W9L!:R8W/8LA<IX^Q:XDR.39*KMVG:[?F,[2'&/
M4W5!>UME-U>1E?Q:2;;V=8UKB%8UFA773!VF==,TFB[2],;U=82M-N) 9$ZE
M6A<#G_\ LY60LV:JXHP'.3C2RL9/@Q5$+("23IAD+^#.2::47RY20.47B;,#
M.S*-AV/OY*NRV+.2 KO1C+H :R:8.4(O6D&I8:]D[.]*QA!*SKDKVX)L;;4*
MC.QM)?U61F*TZNDVT@8R2GF,M98,6L8W=O45GI$%'4N+0%%8^)D#IF2UJ!H'
M:Q=:)]W*Y(<2FUV*JFXQ;36%DPDF")M *W[E3R4YZC>"JT.L)K6FC4IY"XS>
M8QM LDVN.WB6U0,!,T <@LI$")L2UJ@,%,%9FWIJ.(,@1NUS$CK*&[-2 BY^
MX5IL[F;@\K%T8.).4F:U!-VWIFT!8[U!8_+=T8**:,61WYXJ84;,VS0CP.E%
M,=86 QE<)K <IR-D@5"I!LF60M;6V5"<>X))SV/NA2*)."<4J89$)7ET3S-^
MG2:2XLHFLI'B)-0HDC8%*+'2"9B#<PU5V60(!84>^ A)!.$CFW&T#3*+>[78
MV=0@LC+U1C5QLB[9BZ>2US205@H<R:3ARA]17]04BI$'#A!(Q%#^H,B3S1O6
M4S6R@8<C!EYUJU40M4D77;44][Y5S"!2 IKM.",0W]T=H,Q&>6JVMN,++R+%
MTE5JUNPPQB9K)M/1743NF3 '9UE0&0F8#$DR2E8$</\ BK'7IU1^C"3T-,K1
M3@S.42BI1C(*1KLO/4U?D:+K&9N"\#U(. 35#@>2]AUI'WEBX?>4<S -'NLY
M';F@3C<2D=XWVF=MXWU:GW62HO=:(B4KGLR!.-P*0GWH$H[C,QL4>4SI+3O]
M#63E54;M454H))1>;43LD,=.'116.W66E3E>B6/22<)G044=BB0BQ#I&$#E$
MH8\X=(7<X]$Y4(-YHZ1D[;HB+-^4I;S#THB9EF\<F^\:F!*6=*!F6_O/W<1,
ML_=;=7W/XOW6\=3M[F\<VVD&'S'C"P9 >XM@[M7Y>]L*;$9 <U^-D$'KHM/G
M9*1B8J<(HW.HW6:.WT4^2(**ISE*F18Y"HKH'4V@LV+M- 2(*5H*=J=O^1:8
MA=H$MCS R0U;(B8B.4Q[[E$:DPE:J;RD(7?*X-0H,)ETT9KQ9D1@I*!";*Q$
MIB!80O%<E-=\+WINV8TDAG*=.6^HF<!'/$[! +VF,:23:,].)GQW[5.10D6+
M<C8PG77." ))&ZS*%*/5JN4)>EA'TVUUE'6*9@DC(M$.5T[R'++>51 SW2*>
MD8SS2,Y#U%,7 \ZVGW3MN+"F0DXE7D4ER01B0=XB),9CEWA(J^4\2/[63$U0
MN%6?V>'I<3;DJO!R31ZHUI;YTO%1$JB#155$6#E=BX1:F(H85"('4 !3#K'<
M+"M-R4Q)L9CG4UY&9&8Z#\BI]BJMDS$1!L37-LA'=2S01P V$<]79-0<>B(%
M0757IH",>XU>+;51=A<QN,=!MM*Y&9@B+JP,%T'<B\.2\< LX;CD"D@NT551
M=(C:X+SFRR#LC!=%PGZ_K151?*)LE4U"E.F[4(V. +'*0<5S#H7*IAL-Z/2E
M<P<,\1S>'Z<CO!]?D/H\N_5Y"Y.;EG;:R85S]685TX83.I/)TQ3',V3YMN6%
M1W9);0$=RVC3?G\Y8AK$C3XF9R)4V\A?;I_#NJM4IIB[4E;H$9)3!Z^3TBRX
M(/TX^)?+*IN11\HR::!Q*NN@FI*/\RU2$3#6NJ6;R1"8*6U*A)&P]4QO#%J.
MP@2()F.9H1YSK=*3%-VP40"L?%:;A,(5RGQEA5:N)"<B4FUCA(0B)+HBU\Q"
M4L,95$> $0 1$ $> XY'] Y$ Y'V#D0#[B :B9F(F8B2F(F8&-MRF(\HYI$=
MY\HYBB-_.8COK5^GU\M5ZH>Y:AWZL3LZR8S$%-0=AO\ 5R8]LTE1(^]3LMCF
M2>Q<RG7F+:ZOX21;O'+(PQ;HT^@@*2R)I0\6?SB(U;%Q:,.C-"++-=V#3Q!-
M>O %<30:MC9AZF&H <H4NAD0TDE*RA+G1M,[5*AN0?CNHM1(RQ8:;+88%1EH
M22/,HX7+35,O5MND7>]',D9D=UO%VX'&65<:5G*45/L*_!V5A%.S1UJFZNRF
MJ^]ET2+-H"QDBY^8B6,\7S"IG8MI=\14_ M'#E(Q%#]*PB:[P1#%/EIPNNQ$
MF2[)R ,D$<X+89B)CSKZ<,"9V((U30\7J-L":X4)FX6Q FE0,8KK-B"* 41*
M.084P,C'G$Q,1&TG9,";HX6_X]R;77<?&8[S(OCEU%76PQU5<RMWKT9#S\3-
MTJ8I=V6?KM)&)L<>_A5$I.+G_*<K-I*%CW*:S4M,*Z[M;!Y+EF&W(RUFE7YS
M&[5;B<ME^&LFIZTG*S)5O&7@.4MM53KDML-GGV"SXLJ[LK2!O[M"L:F\Z(CP
MCU9.AC<Y5"#9$%,"-NI!PQ:IBVDH5U %;F.?&V3,61.3)O;%0H%]&.<=4J,M
MZCUD\KDG5SLIJ9D(]S'B]:VN6MI;2VDVRSJ<+:X..<.S/4WR4A)J+.#IV@>W
M*(OY&2B0I7Z^-.9$ %LLIR]+*D5X*MX58*96E<$EJ')("K N5,97(546TJ.Y
MRRS3;:7!&UIJ578NO 6#L%UI,@)1(F):N:\"(M'DA8O2N9UP];'UBC8+(U2=
MOZK='F/)MJ>;8-%FUT8)H*NJZD1VL@9W(I$<I *#0%S&.)B%ZCD.4NM42Y55
MZ8ZJ[H/;4)<P?B%UFFEYJ@9F3%3%D)E$3 [;S.TQ.K5E1U&&NQ$*-:*UED$0
M[*3; F5R:43,+E@"10)R)1$=XC3ZF[75ZR+4+)9("OB^%8&03<Q'10O!;@0R
MX-0?N6XN!0!1,5@1Z_+!0@GZ0,7G&)@CZ8S$LF!F B=SF#.%A/+'O;$PA6,[
M>\90,;E,1K"8F )LQ,+"8@V3$P S(D401S[HS(@91$S$R(%/D,S#9N>7,8X^
MB;%-7&]U:"8U.!5L]A!Y-,"O(R!2)UC*.(\BYGP-% X*@J5N8KA0Q$T/,4.4
MHZV.4H9)AP(C;K43+O,+MVW+KUZ[)C?IL8UJQ@3Y9B"YBV&)F$1,Q$Q$SS(=
M9#;O+$5U,>YJXCNP%J4PR(.:($"GTG2Z:[4]*ML+BZL\"QJLHR92#&P2,JQC
MXAPSD42.&2Y'[Q=!KTN4E"'2Y5 3=7 !SVUO>,U7%7L;)>#33*F3 GU0F8,(
MB9W(AD9W@=^T;^7?6"3&RH7HGJJ-8M%@1)#TRB)@YF-]AF)CO.W?M/?48VW*
M>W_'K.RYCLUZHL<C"TQ.2G;.%B8R#A"F(.!5;+-FS5XZ54CW3U0A&PQS4PR3
MTZ""8N%_)(&N"%3 K\T+/(Y3$X^ *>6&9+)-31Q:3DIV43RMKY).06*F%99,
M*$VQ+&;I)QD1)I5<E;F1DB!=>@MEC)N@!W@RK+K,ZY0),7TR5O'<)D^4NU-@
MVS![-6VLP[.504<Q;J5GHJ/;2+9)OZM5=@N[=(INT4VH@Y45;F4(1#^V,8$_
MS:R+W&$D_<:'\:B]U@>_"]R"=B&.I,+WF(]^8'^*=M2&[5PU<2:BY=F![P3)
MQ,A$&.XS)1$R.T]XB9C?6K_$3'_")OQU3NER[3CVX_B:%X</UFY7:+) ?7<*
MO%6IBN4FR?4LHW,58A!3$#"+W)Y2W$N1Q\LQ,%R5NU@^7SY43V=.VRI['RSJ
M9B8&3F)@(Y)DYCW8AO-TYDO*.IR%R;S[_*7+ORSM\<>Y)HV5JZ6VX\LT5;*X
M:2EH@LO#N2.F8R,)(+Q<HU!0G;S&KULLB;X-T@H03)G(8V*RAM>I:""Z%ZLJ
MY5.1D>K6?',IL041,041/:8B8VF)B)C;6,S OMUB[/HVG4K2I_B391,0Q1Q\
M8WB8F-X(2$AF1*)EJW_-5;QO?,5T.PQ5@%7+4A9HR%LS0*\6KP3RK5Q[:7I+
M0XD;#'S#))U%1SPS)U&0DNU!9 4Y!9@4Z2ARB%MFS7F85X7%MRIN<0@@DIMU
M:9I H(CBQSVUL&&+6B5B?[_JP"CL>';--MT!ZJTVZ-1JE[RX9OL)*'0!0(FF
M'0*F0LR>), A22X8:T(-R>,QRU XD"0 SRU4QY<ZO=$YJF+T2PI1TZVK[^O1
M4DWM2TVXLS5\\:&,Q&O$9KHK@#61<.$G#='.N)V2O@($!T(H'*V1$':5D M&
MI],0DR8I44VP\F0J1W$EBQ<D8ZGCT*U:V1 :+%RS1,P*/\G9KH59A=OGY(7X
MA3=T=.6[D!"V%22NHHY SY2,?NJ,V4(_MA;ME:M8?5<TU]5)-*FV>U>L)%NK
MFB_LT4^8Q17#3TCL(EI-S+99P@H,,9H#ARWTJ<MMS'4X.!C**S)T[9>]38S!
MX7(9^W7EJ^H4.9C\5?)!=.:_61T;#ZY,5)Z;;(IU+=MD$44GX5-BN&WB1'/9
MS&</TWPMDK'HA?R]*7[G#8KF;4*?($&H-OB^U+;7%Y(W;L:ZSG)ALXD)2R.Z
M3<8Z8EI>7,F6/GU:Y!6R_P -2$[.A$J.E)5*,6C9]Y%-WK- CYPHFP<Y5)BH
M%'&U!(4Y>U5J(@=FQ"LCDZ\$X39)V/LP+S46K84^J$2 .BLPU+@;PTFYB^H3
MY#N4Q,$]4I2*WC58I-<^6!4%JPO>E69;@($G\AO2DVLBR]ER[CNF$H V^TQ=
M87R?-Q];H[.9=(M74]/R<:O+-XEHGYARG=E8-7+A?I.9%$B)Q,KP)1-L9$+R
M XN2$KAQD"!0;SS*Q==MFZ[>8CE2I29_>' 03#2F-W.6!<Y=@#QL9:8,*4CC
MB-IC_P J<K9K4Z0,@9*(-EBTE<P,D(1)L(H4LS%WQ-BK\^@Z=04[#335BY69
MO7,3)LI%!F[;@ KM72S-=9-NY0 0%9!4Q%4@$!.4H"&L9F(4+YF(282P'3,0
MHECOS&+/X" =IW*)D8VG>>VM_P#XA)_\4)$35_X@$7<1(/XADH[C$Q$SZ:1D
M\BX^68/I5*]TU6,C 1&2DD[/"'81X.3"1N+YX5\+=H"YP$B(N%$P5, E)U"
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M B(:G_7Z_7_;STCU*/+X;^4>6\?">TQ'W[1/;;6#<?'OR;GC]N_N =NW^8\
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M+J8R*U15>7<S%LSUB;"PE1S;SW#.9X6L&L)8T*]953*5LB%-/(LLSB:-Z2$
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MTK5G'RA^!21UV6;R75K=RLF*9M\3&&1F;[,Z>Y"&9O4KP@V8;""JY>]DF5K
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M<1]P#OW[_P ^>-1]?S_O_/XZ;]^T=XVGO$3VCUVCRF>V\;?#RB-] =//Q[
MCR  /Z\=AYY#_;]M-)YO/OOO,QVF9CY;]XVV_MH'CGVY[\?8.?T'X'GW^_OS
MWU/UY;?R_'X=ORTC?;SV[;_A\XGSC;M&WEY;=NV> #N/ \B'/8> ]_O^O <_
M;W]^1;>7SC?X^6_]8W^4:C>=MHGX[=XWGRVC:/A$^7Q\O+:,=A#\O/["/' C
M[#W_ *\ /<>-1J>\3[VWW[;Q.WG$[?#RWF.T;ZB3.>(Y'.V.)3%,18:]5I&W
MRM59-IZUN5V<!'G;VF'D!5DG+5!RNDD<C044S)MU!%51,!#@1$/0\+9->'S=
M3(-0^R"!LQ*:T03BZM9R8Y!(AB8&601>]$P$%/GKYM[6.%;'&O 6:X:JWJ&,
M?D#QA!=R;&*HJBGEJ5PH:Q:VF,L%!+#8)B6F SRQ,SK[0&U'(.TO8_,Q;6[4
M:[6VN[L,:YBC;CCZ%N&2(6GQ#9[CJ"FWTM68!6LVB>+'0T9+.9N$AGS5=["/
M?*3>)&6.9++C?B <IQ1PUEZM9U#PB[M BR-4W1$W,5G$+@TUW 4IM6K56L+"
M8(J>0,/W%SO1]@7L_L\ <$\8\.Y#)8G/LRI9>^C[&N3"2;]FXH:B/$6JVR[:
MK..&T$0HIVZ7)/-,[9RIONWR.:XTJ=8IK.#N-FVZWBP3+R,VTY93/6[N:JWZ
M4Q];:=9W>6':"J-N_#,>9+'<M4%IFER4HS:2]QE7BK=DOY/G8QN3$_\ AXT6
M8"6 Z/$'0MFGA&_G\2TDD,9JO4JYG*B.7HQC%L+'V*B4'9JM=/V;&DH#H/;*
M;)_:MX4K-115S6+#.Y;$8J_ ,*/LR711I7+5"RR^3*EU+2)%9_5"N]<W7;B,
M+2&ZA)NU@\AIY)8*6):.L>UW<8\:67(;+:KCF66D(YHRNH-VE2N]R8S]4E*J
M#U>3"Q/'4@-K!5!6/=W'$E5-V/4L!IU.+.(3JJ*9:Q-!O'N*I7X-L" N!E*Y
MD,GC&+  J!6ZDADDD91GCA2[*</Y-MEE1[>'>$DY&R!0!C9FUQJY+MB I"]A
M*0\/1?-D%%VNQ"0#'L$8"PM9\3C<85QF\[FNX]<5.I4G,TKB(QMN.XFC)D4Q
M]2ZE9:4[MLU/VR38S,7+/9F=K"\7$L*Q(RKJK+.8MTS5?)QR-6X]T47NDX^T
M79+%5DN((:HOM3VD6^$>U*75V6K5K"-PV=K)B_5!;,A"WN\/U'5N14D5NP@&
MCHX[[+5.40LOWU>Y7X-5G;:DOZ<IIUJV1K9*C$-1;F%*6KK$\(*UTMV'YIRS
MG;#+FZ9GF\;2ES+:YB,-'XVQ_<,<-8&,:BD,='V&!N=^R*^"Q*('!T\483ZL
M65-9%-J9;I,L;J64H56Q[%23&/0P[+1:#*\NA[!A*!A2V+)"H4-@721=<C@(
MZ4 ;-59U@[>12^%+%#:\5DP)0^$,JJ9UWG+" Q>Z737A:UR* 'J<S"(0NMJE
MJ]HTTT:::---&FFC331IIKB3XHN&<F9,W*;"K%1JLXGX:BY </[6^1?1+4D0
MS-?<7/BK*I2,@S<.0%I&/ENEDDY4X;B42]9TR'^3>T+%9#(9[@Y].L3TT[A'
M9.#4,*#QF//>8,Q(O=6<[!!3[NVV\Q$_OG]D;COA/A3V5_M%8OB#,*QU_B#A
MM=?#UV5[KBNNCASBVOR =:L]2IZUJNO=YJ']Y$[\L$0V[<;3]G.YJ>G<H$-D
M*W3T/D.:CY2>BLZ[AZJXKU[J2TW"RT0P8QU_@"P2<*I/3#5*+BF32&33>E58
M(&1*T5)],12IMQZGJ7#:&<QMP181FR,CC;H.P]U5B6%+6K/PEFF]%F.HIX6>
M< L$TB_!I7F3=<F37%S#6*%1RQ2D)J6:94,[2C8%PLF%#,?<)P<_BT&D7,<D
MN36A_HM;$MOMJQ&\D(A:OSZ4M2\7XRC;%DS+=LCGMJ/696C4'ZA7IFV3T)(W
M!.J+2E3KMXMD>O.MHHYX9I8$TC)-QOL?]I7LG5:86K_$=?-^.4< 1V5LQ2KG
M$4IWB J6,ABL2-W+^%E%G*JJ.M6?$G#CGFRFMCZ-:=YK4L8[%"HH8R.7J9L5
MX1#]BEMJE6SN00O&(L=:GC[C:@U@KRJO *U7\//9!6XK(.,ZYAMLTB[E1*Q3
M+O$'LN1W)'U1B9ES.UA!"5D;$N9G(Q\NW!TVF(1^WL+;Z=$I+/B-XV*2;ZV[
MVZI5V&TDHR>+N08L8FPK)X6O6+&V%V5DNU#:ZX4^6K;ROLNLV'DVU9M&RX;I
M+(1:;,,N%4S4;L"&K*GQ):?.942B$JTKOO%H-00>XH5K6M=<4CI4)X=>U4C.
MRL@K&1Q1MU7I-,GSFW Y_,Z>US'=D<VZH1Z;T<FB[9&BK"]?/SO&"[9](^N>
MM91R]9NW#=3*?>)9;S$JS5'B$.62"!S&-I*Q].Y$!,1S*JHK!*MN@TZE-[5&
M^I78O7TPZ71F.94XW+8F0+WHFAF[$6LBF>;>9-CMY0^9FQ261II-KJ,P*'\G
M>%;@V>J\VUQ),7/&MXF'<LN:T6[*&XS+$ 9"T7-C?+FT=T]?<!37!#6JR1S2
M1>RU=M59GVCI!)6.EFQ2BF:F=8H&DJN2E5ZA84#0:F,AE/AZ<J6&JK8NQ7;7
M'''FLE-8A,P%5NS78EB'&N;?66T[+;2I>YZ\ETVB8J)-C*U<72MV)"%FE\,K
MX?'P5=RS1UJX6A$+7,XKQ8'Q<\PQBJJ8V?V^5O3JMMWB2EAEUYY=18'LB[D"
M,(\;59[M:$8*'(Z+%0#2QW.VS;2'9LVTE9)ATFH]5[%ZT-MXM!<K$:]9$<Y*
M-S/#5UHE]AB455-L/E<M<T:ZNHPI(HDY(RYU5$UU2$]*)(S80H&P%<2.=RZ*
MK5NZY0F6[35XDD UC!J*JU(141+VJ>K.C331IIJ"\][;L0;FJS&T_,M>E;'7
MXF35EV+.)N=UI*Q'KB->Q"XKOZ/8:Y(/&JT=(.VZK!XZ78J>:"AFXK)I*$T'
M64=FO;F#BQ4%PUV"Q@2OK]*3*! X C@DJ8IA"1H8L6I);(YM;1>P:]FK$C*+
MD)&PLEK.&17>%A4;F)$$0Q8\\!(PP))3.99D$UAB?"KV508Q!XZCY.36KZ\N
M[@'+C<MN6?.X)_/V52WS4G#.GV6W#B+E9.Q++23R38J(/ECKKH&<>E640-LE
M8$!!(["=&IC#B)F.ICJ%:_2JT&3$Q)U%4\G?J>'+=1UK34,$E%RZK-4MT;,
M2B'V+,=HCEL6@QXL</+$<C!G%8]J"'::UBL%BOTGD;"EK(.#:WC'9-ES V'(
M:72@(K;]EBG4.NRMKL5K?H_4J/8VL3"IV.\3DQ,*-RNGB;-@22F3MH]MY+5$
M[9DW3(G3XI9;R>%S(EL^RS!6J2N4%+)O2QAU*PG(B FT@!8F]LRUI[M<PS(C
MGZ%[);E+$^UCV=YB^Z*U.O[2^%L[E+)0PQ4,\54<ED[<K6+#B)*;%DUH7,D9
M'*UR1;3SY@<I9[V:>&GMP;TFI@MF!DTL\>:ER6*+)F!A*GCW]ZMAJZ^=T+)-
M)"EKS+-HBA'6M9Y:FR#U=%@C5I>0=(-=>8X'&WC\9PABKE>05RR>87.P&C&A
MFJ:LA83>$GI78IT+K[JZO@[;+8H/D@(0V#^D?M+9;!\5^W+VF9S$Y('8W*9K
M$5\3E16WHQ8LX2A52U^/L!4LLJS;KS7<QC\>JN1 ;K"U'U!MSBC<CE>]AN,:
MV9G74AHM02M-#7B<19(:031M)Q4NX:0MADYRUI/<@SZ"C%!>7B:W"TQ5L@Z(
MS14<*+).P]-DS?6X5S%^(2W)8_(9W';=-CJEH:0P=648]9Q<>F5F*76@MB%E
M_4A*4B'O?GC%F5K+XI+HA-2_C\/<E0LD+E5MH0FW-BRU<5D;F7-71*6&D%EU
MG-/> @+:GGW<3<5<RVNR25=KM2B-JN'[SC?'B>W_ "G 1$+=G$9?E[:XC_J]
M]%])-6MA9H,9RF$;(VMVW<5]-*;9)1H+2NS*OLX[!<86E+*Q?QN>7&'ATQ8@
M,8[A#AR[3I&FN*VWE.N,N4DNKLKQ3O4LFZR!Q>14H5<-$6<OP_2?'AJUO%/^
MTH4,I2S(5>+,]0N6*YNZ@T&)QXXNZ]=EEL+M>_2\'T9J7+-RO6'/$]W1V6V5
MF/O]:I*T"_7J:$X2G[5MS45-('M&.IZ>ERQREDN#I@97'ULKQ8^23<E EH3L
MD=$-5Z\YCAF)BRQD1%_D4Z(6?$JJCX@'QR8OA_A[.8S)G7@D%8K7KV8R/#/@
M@=7>ZY@K.37:4M\8Y&(MMR6/@DK&'?X8FWU9E, S)<39["9>ISB5B*[*N+HX
M?/\ B"&PJBG+#58N_P LV5R-1-Y^_2[P%8G8NMXI7:6+,LOA5$9G;EE2DS!Q
MLE=@;3C'*2U;E]Q$D+"J,H]_+L[O7DIR7?F=17*4[7GPNX=GNJI<UV%KV>E6
M9E:66:\A<+U8VUPQQ3DZN578,($F!F^%Z=6W@S6OH5LK<1U;.2H.%H[RL*C[
M98$-8O&GCVUEFLJ[KM;+89 (4/,+(%V.XJ*Q2R)B!G.,2RP%-1)ZCIGW@[PM
MP6WK-^/*A48^FV"ANZQ1YZ[MU<$YEML_+.I/*M5I5ICZS<*;<C5NK';U*;F;
M@T"<@+*O%I0!B.D95!T95MHQC1N9N]2;$Q4&YBZ=%8[IL1.4H9Q@L?=<)5'C
M6NT<:#96BL'3LL6QE<V*:-QU<EXFK8AJXO30XCL/*1YZ[+.%QM:]0KJJ@SQ"
M)S-J7XI'/8?*GO19B7!68BQ6MYO)WU9$G*W%L(JO8YKC7/\ A%K=IMCMYS"M
M(4"N3.5)2O3^*;9Z_(C0EZ4-%,*].3F2:5]$K2D#+/(UU"L&RQY ,<'+K%S@
MIN1B.E?L9&OD@7,5ZMVS9]E_$>9FITG0YV+G#<2UU</)LW&-39SC<3EAF$5'
MX6_0SC/#TN(9H$<NJ!6=2&()CZ].MQYPWC8R\L@85?K9?AJ[D,N>+0A5^MCZ
M>0IPX+3ZV1IV7WT[AMSN.Y*]47";N$;NGN'I^<J#B'PID#(ULC+7"1KJ5?S,
MM.QMYK=<BXDZ(,XV&A6L).RCN26*)I))1=)HGS9;8LMRE4F^&74M85\6D@T8
M1C'9C 4;BFG,R5J]95?R35C5%$5*M'Q!%9W<*.W5KI\3AH:2>C=B[6LBYD]1
MMDZ.8.JVN 0 5D4WTJ4NFP]AW)NL (IC3!MVN5,WF;CT;1-4=U%8L8M7V3WD
M+;<TS.V+<;&5:],(_'>*EX6#?P,?>+'-PUJMS61NT2WR0+^Q5:-5HC>/>U0S
MF0*8O99X6[,)<J*^-Y>+IM8P(GFO+K<7Y:DZ<6Z0Z5"9PC<;GYIW$VBR<Y8E
M4[2AK625Q:<VE4^>2:6237X0E-AG(95%Y#A9F0?<O!!**[T>(:K,(2ZYU6TH
M/Q-@62*E69E\*7-5RM=:N.&['692GUS&#NT.<>LYC'608E[9ZU/Y5OS\EF"\
MVIS'QHMVHKI0#3'Q*FUEX:,CXRQGL,I'6-K'1,XM;W\*X*[=-DY)&(X6Q5VN
MZ 2^JREPEB%,-\2QY9)EVPM[&7E33&G<1>Q;ZCV5UY"S@R!KY?(5Z\#X.QF.
M,+ZVC!FMA6>+,C9KUT;BKP:*F-M4G)$XLAD*N1J-KMJE3MU(Z_ZQU;T:::P8
M> $?L CV#D>P<^P=Q_8/?VUB9<H$7>>42+:(DI[1,]AB8DI[=HB8F9[;ZF.\
MQ'S^.WZ^GWZXECO\W/+V?-48PKM:3K5#OU!1I\]8-L>:(2<L%/FGN2HJW5B-
MJC;+,RA:K?%2M-@D8^U'LM(B1BIY2;5I[E/Z2SE<<21V\;@[EL9AUO-VZ-U"
M @'/Q[L;P]8P]Q5=C#G%"5S*9160-KLO*HQ8I\.ECGLJ;;ZQKY#/5%D0KI<.
MSD,>[E&TI>4HY1J<JA[P.O&11]F,QMB@JLJBU]F[RB]BEME+WWVY^SW2KBVK
MF&F45$STOM@F[Q"W8^#LCW>TU.RHY!IK24B$Y2 MT;!%9S%56EY U3.DA96S
MFMJNFTNZ!PW00@%L;E<E4BR-=%',\"K8\ (P?B[^<RB,NI[))<6U5XJXYLLJ
MRGI5[KH>N08+%9J@'8*BXX8;KZN)9BM+(0Q=ROPC8M8JRA<P94K47W32 K$O
M VVE0,1-9HV$W>=O<W)[<;9BR"Q^THEOB;!B2%MEA<2.WG.]H=35L-=J;77S
M")D:/=EF51;R%<G+!:$HV?:SDI"I5U1-=Q,>H$$\EF5KB?)XH>2I1"_AZU5A
MB33I)RKLI7LVK%B.C5R*L9**=DPK^!ZJX:@F(\2JS6JH5,<,X_(FZ'Y J67:
MX('I#;=C<%]ITEJJF;+%,LI?3&'#K,LRM^118]^*;466/CSQ ]U%\O>'*$VK
M]:(\M&1\D8PO\^XVI9QAJFV9QDW?*]CC+L+,3>8V:\-!3+F%J,E+T)]'6$YH
MZ=.)<CPR:Z#MLHB_)K3*171.[P6.74-PH.,=Q(-*Q;*@_8JYWZEB*-L@5 8R
MQ5W37)]IY+%^=PZU!EZ&,*T%'-8<4^'$HG*X7(V>&T7DJ/D8-+(8D\Y:0=V8
MO)MEB;%L<8BK+?#6-H^XK=LYVZ;G,H9"B\91-VPO 7&O5)E"8DR"]B;+DO'C
M>7&<GTJZQRS/6"R46QO4X9"MU^%DHZP($4> YG7K@2H-J.2NFGAFAFJ:9\?D
M9H/7CF[V>B!6Z>,N8XR1"B.Q8R:\HFIDME(K5BIV[-!RTMZ^^HI3LQ8Q9MZB
MZ)6TV;JH!*FDQ3;]!Z!<9$OPF,=2^TJ;HDW7@LJJ6A4:6#5E+Q%MVSZ@03V-
MIU&=68EEMK"=MG^C=N%+4I5['4VG6BD8UBZ4M=6UHKTY>)"?L-<2R4_L$[5(
M=[4UU7E=,K(I,6_0L\Z[RUUDG8KC&5"O7DQ78X@?0XK##"-&WRE7PX_83$\0
M1&03;\6#H16.!4]JN15L.;4LG:&*=@"P!,.08Y>(IY/A>[E+]ZU7"(9E8J<1
MTAX>FK2?5:J;86&D4*"+=CL(YNW7'P'NNON29.KL\F5'-EO8T*OVO$U^91-&
MJ"*-=5BF+UC$7%X^R3&A'.U7<.K4W=:07<@LU?2AW"SE\WJV"\#@<"U;YO6V
M7,D&3MRH^=XCQ#DE>&30DP8BP"%B%1SK7A(IOHP*B"F9W>@ DW-9(9"%5&8K
MAJY3I]0AA-BYPOBW7"F]R/'HCDC?7L5@IS9'(T\C9*5KR->KCJMM-V^ZXV6F
M4[=&$+;J+:;1M/"LXXD]L&88)Y$-+=2K0ZMMKJ]@1RC88JJR#6[HF0>+62,G
M1C&;J&1EU$$F)'#J0;81]MJ"HR[<JYWC4\8J6!7M>&K>SWA;.\/8R;)+E'2M
MW;5S$OV&8G,5\V8.'QM>AC<53+F-*+!4Z9<.8LGL-<OJ6K0>T'/X7+&M 2-B
M>EB:F.R0?O2BS3=C+2:JQ7:.[$^4-XNXLUCVUYTEZE R^08R3R#'S$%1\!;A
M6[O"U>GJI'$M,!DZH2LN!,J2>-9I%T=DYJEUIK3))8Q5Q#,ZHX<-VQ[](:=7
M.  W(L4LKA54['$ 56!0N4W9[!EC[B<8QDV\18M,.U2L)L6LD>$KNG+N\>FI
M:QY8WR8[%9*9JF#</GZ-VEA#L+/(]>GCN*ZF25&32LJ-U#T^ M5#KUT+N/Z.
M/Z@^)1D _2!%.ROXR-?D6*Y(]8,W97!6B[ JY7+=-8JQ6+HZCID54#@<&CE0
MZ[<# BL<RA#&$]<J>Y4C(2IK%R$L!LA(&0\LM7$+;([;=0(@#VYAB!F(UJJM
MZ]:N[GAG60EO4%3$"SJ+$^>$-(VI@]^:%,(F+B>0R(AF9W]:M;]&FFJ ;[=R
M^6=NK'%B^(X$EFE[3<V#&;@W>';IDAB_JR4C&(V'ILU2OU1)C^281+MW*,)&
M3A+LG(F9':(0)C=:I=--O6XCQF,=[N/L)8R\WD)!( K-:FEZKQ2Y/.M]E74H
MS2-C4D=CQ-=5=DSO8M8XG(6NITK*5O*D4Q#P.Q7H7,A%9M,92TAMC3FNNR-M
M(I>Q0=.PQJTFSXO<WF:P8,WC6"6BZJ^N6(*M:I6B)LL*90&CR@JUN=F*_5G3
M![=DK1E5\1-O%QE@5K"="5<.GIB-(MEZA$J?(RSK$<#+R4TU7LDXG8^Y1Y63
M6RS5_9BK2*5*)FW4J6FW+F.J7++[(S*AO.0  ZE%K$J!G%BZ+K8T\;+JK4V@
MG:UBDR^TN;5VP<17>Y*JZ<H5:NI<!!MQR[#R4&0?&6'=P.X@] W@9&>3,"W8
MT;!N.[Y@BA/< Y3:Q-:>FPBUL*D:2.->VTS=(K\7)NX-[5X-* M":R!&ZTDD
MN5(H]GBRS:Q.(XJN4XG,97'\<<1U\<QN[&9;%S9Q;L)6(*^QD[*U+0J5E0*:
MM6ZZS=?4-,%01YO@Z)R%SAJG?3.(IV>$>'3R-=<=-&-RHA=J9R:Y/&>@C$VJ
ML\^/<Q[;%=25HMCSC:; >,/$VW*SEFC&=UA:@YK\G#Y (Z5I.TS<NG.0DK X
M::9(A)@C:QWINRG6#>UA)8_<UOU$&]LS]NFXC;#!KB#%6+ARJ<^JN+)BE3S;
M\5>( :FP>+XLPN)QY.J=6N;EYO!9._E5 NW6.D&#L/85D+0HK6J3++RX=EU8
M5>/R7#M7*I-O2*NG+<.9BU?@'P#QJGC>(J6)QK'M3:3RYF%$$14F\Z4<4[PM
M]%])@YV\K.+$8[,=TO6)5!<X!R=5)BK6ZGS2-@C[]-P\SGM_Z:A6;$L9:WY8
ME!Z_=1%L9P[;\52K>2,S0Z"JI'=15;()&Q@*'$A%#A<NJG&WJ^/XMPKF@L2+
M).?=I?X>M^'74YG/7;2X:]=V0P&R1T[U@1*3IY1N.!;%&EEA62Q]E_#U\$D9
M'T4W/!HS:EDYP5R;9 :RQLG0>&Z#>SN-P=NO2Q?4JO5+?BQO3<.32D>3".8Y
M:W3]BOMGOU<M,'%Y.KUK<4.')7VD%4[$*DA4WQXUK/>BD@6(L23:<NDUM@.(
M9E4O?2O6:6(JKWJDZ?\ "3LW6)[GPQ=F!R:!I,97BNMXW5H J]JH4V^RVJD4
MX<YN+K39I9>SDF,7-@%%C<KP_5J=%2F Q/VM5R>9Z*6D]E=F 98DK";8*5$^
M.]W&]W+-_P *-I-.K4VBKY:HK>_S\3MSS)#(M?Q-4K>YLF$+#&V3)1GYY:BS
M<9%,7F5V*Q:3-.IN*>_AJ/*Q7CG5VFH9RU(6MFW1-'$]:N],13K\0!5P.'R.
M/SU=3XL,PH#=M9+'KQEYEMSG8]AJN&;I2CAWK#QH2P$'4N2[#LM52*+3<'+L
MU;Q[Z=ERA!.95;K#7<%BDND5;8FN'P[%&<I;V]R.ZRG3F3Z#AN1A(A*.B<?S
M-<F83!&2<BSD#%C?Z-'7R1LUBCK[6HA7KKT[*N6$!7(!:3^FQ<BJG/I/3E/'
M<O'F^[>2NRY=>O4XVX;JV' IHHG#6V#,5[,&SJ6C;>3$9%B)K55XTYKG)189
M93V+"(%3P#EF;7!?&%BNOK0-T\W4PF4L8\J9"/1J3+:ZJU$GS99.4LUK)))5
M>*5Z*H?>%GN5L5CQQ)U[%D!5G>0\DQ%PO$CMPW$Q5>R[%QE@:PLG"UMM'6BU
M/*'<5Z,=:=C;1._C:JVN1;-8ANRA&ZKB29:XE62PK)NH;6H%P]F&,Q >_?:+
M'\3*"[1L$L$0M5FOC+%K#OK#<L)R%ER+BIZ ,D9.O9(ZSQ;=3D* A?Z<#54,
M8? WJL64=;K$&2LV\C4"TEY?9 4@AU7(NABYGCPFLTWC)&$'='O%;EJ>?$R,
M%7*S!SE!O5>E'58<)R"\=8G5OMSI%K:C2Y"%+])CZY NZ@9H:-DU)@RZ#TOI
M'0RQB\1D;+.>_9ITT9%<P*CJVZF)QBG5VJZCCL,EO5L%DA8M-OK<@U4,KMEO
M H!%5]FBH2BHMMY]4R@BZXV,UE3YPF8#PZDJZ%9=(P,PA7BALM1:4JOU:US]
M=71IIHTTU0[=WQ^(ZCS[#"/@_7_CP#V_I_7C36)>FV^_W_='IW]?RWU43@H!
M]^_ \?/8?8.?OQ_3D-3'X]O+;[X^OOVUC,E,[=HWC?:?3]/OWCX3.^@P '/
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M&Z<>V*N9<SL"&%P)S<_A'QD\.8KQ]2*%SH,Z]2*<4(046';#X. 7"-PY3D8
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MY1MM^6WX?=K'^CUC?Z&6O>CE?II94\P!/JJ_G>N49D8F-YW3U>6+=,H>7_A
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M8XBD)ALS:2I4IR-&)?@>67.8S,7C-^)4C"7E(_J&+<>LO?I Q?8W.F_U^?\
M?4<D?6W]N_X[_EOKW7\ 8ZK,U&S\4TE22,4X!TT.M*++)%5*4Q0$Z1B@4Y>#
M#^41XTT@8CRW^M_EK0D-MV,9)\[D'328%R]<KNEQ)+KD(*SE0ZJHE(!! I1.
M<W!0[ ' ![:;_P!/T\M(&(C;SW^.MV8V^XXG5VKA^TE3*,XR-B$?*E5TB@SB
MFB3%F4Q0*(&4*@B0%#^YS )A#D=3OOWGZ_+4<D?&?EW\ONUO+X.H+FKL*@JU
MDAA8V2<RS5,))8'!7CL@IK&.X O6=,2C^5,0X*/<-1_74\L;1'?:/]?[Z3HS
M;UC>(2ED6;26*G-12D,^!2674$S)5ZR?F*F(E#RU?4,&X@H'<" <G'!QT^OS
MTD8G\]_TV_+7N!V^XYK<U'3\6TE22$4Z3>-#+2JZR15TN>@QTC% #E#D>2B/
M Z;_ -OS_P!](&(V\^T[^GRGX?*/G\])B^V?%CE95=5E,BHLJHL<0F7 !UJG
M%0X@'3P =1AX#V .WP&FIVV]9[[?#T]/+?\ K\_/2Q.X#QY8C19I)K*'&'@X
MNNLO)E%D@)&PZ(MV1% *4?,6*F/"BQOS*#W'C33:-XGX?A_+_;0XP'CQU7XV
MM*M908J*D)"2:)EE%BK ZDTVZ;H5%@+U*$$K5+H(/8@@(@/?3^FFT;1\O*?7
MT_#TU\8O;YCB'3F$F325*2=B585^"DJNIU,5GC)\H5+DH>6J+B/;#Y@<F H'
M+[''34<O;;>?+;?U\]_/;68';[CFMS4=/Q;25)(Q3I-XS.M*KK)%73_PB=(Q
M0*<OW*/OI]?GI Q&T;SV^[TG?X;ZU)/;CC*6D'LF\:2YG3]TN\<F3EUTR&6<
M*&54$I )P4O681*4.Q>> U._]/T[:F!B/+Z\_+X=IVUL2VWK&\THR4?,Y4QV
M$5&PS84Y59/I8Q34C-F4W!1ZE"HIE Z@]SFY,/<=1J.7OOO/Y_=\O7;OH6V]
M8W7B&,(HTEA81SMZ];%"67!0%WY$".!44Z>HY1*V2Z2CV*(#Q[Z;^GUZ_P!]
M.6/KT[[]OA]>LSNHPV#J% Q-DA8YM)$8VIHU92Y5))950Z#-155 $%#%Y0,!
MUC]1B@(F#@/C34[1MMYQ\_OW_GI,AMN^-8&38R\>TEBO8]P1TV,K++JI@JGW
M*)TQ* '*'_DCV'321B9B>_;\M:"NV;%BRBBIV4P)E3F4/Q,. #J.83&$ Z>W
M(F'^7&FHY?+O/;Y_IY>7;RTX;3@V@W&4++S;:34>E9LV(&;R:S=/T[%$$&Y1
M3(40$P)@'6;W,/<=-)&)F9^,;?Z_?K17V^XY<0S&!4:ROT^.>/'S8I95<JH.
M'Q$4W G5 O4<HE;I]!1#@H@(A[Z:<L?7X?VV^[6[#8,H$#%V.'CVLF1E:63=
MA+%5DUE5%&[98ZZ0(J&+U(G!10W4<O(F#@!]M-3M]\_I\/AM\-)L3MVQI"R;
M"68LY8KR-=(NVIE)9=0A5D#@HF)R&+P<H&*')1["'8=-1R]]]Y\]_/X^?IK2
M5VSXM6657.RF>M90ZJG$RX !.H83F$ Z>P")A[!V . T\])&)V\^WEY>7P\O
M33BM6#Z%<I-.7FVTDH]28M(XAF\DLW3!LR(*:!13(42B<"C^8_N8>XZ:2,3O
MWGOM\/3M\-)RNWO&Z\*R@5&DJ,<P?O))N0)5<%0=/T6J#@QU0+U'(9-FB!2"
M'!1 PAW,.F\_'3EC^?P]?3R^4;>L;=IT--O>-V,9+1+=I*E9S0,@?%-*KF4,
M$>N=PV\M02\I\*',)^.>L. 'L&IWG???O']=_P"\Z<D>N_I\/3T[1&MFL8&Q
M[49QG885K*)23$CPB!EY-9=$"OF+F.7ZT3% IA%L[6 @CQTG$IP[E#4:F(V^
M?PWV[;^?IZZ1E]M&+7*ZKA1G,>:LJHLH)9A<H"HJ<3G$  G8!,(]@]@[::CE
MCO'?OV[]]OAM]VE&<V^XYL,DO*R366,\<%0(H9&561()6Z";=, (4H@']FD3
MJ$.YC!U#WTW\OEY:<L??]_?\?KM'I&MV0P90).NP-7=-9,8FMG?GBR$DUB+D
M-)/%WSKS5P*)U0,NX4$@&XZ""!0[%#34[?U^'KY[QMM^FM-EM]QPPC9>*;LY
M0&<V1FF_*>46.<Q6"QW#<$E!+REPH<PFZ?\ $'Y1[:;_ -OTV_EJ.6._>>_?
MS]?C_OK:JN"<?TV?866$:R:<I&^J],=Q)K.$0]8R<1ZPG1,4"GY;.EBEYXZ3
M"!@[E#34Q&WU'Y>6_P#M&DMUMRQD\D7$HLSEQ=N7RL@J8LNN4@N5G!G*ABDZ
M1 I15,80('8"CTAVTCMJ.6-]^_EMMZ;;;;:4[/@G']OEUIR9:R:C]=!FV4.W
MDUD$_+8-$63?I3*40 Q4$$P,;W,;DP]Q'33E\N\]HVV]-OGV]?77T<8-H+JK
M1].5;28PD9*.)AJF$DL#@'KE,Z2IE''3UG3$BA@!,0 "CP(>VFIVC:8^/?[O
MN^[3EHN.:SCMM(-:TB[11DUT7#H';M1V8RC=,Z:8D,H "0 *<W(![CP/QI]?
M7Y:B!@=]M^_QU4G=UP%CJ B(_P#<1][?;UY0$?8>/?XX'W#YTT+>=HB(_'\]
MO/OY>4Q,>7PU4/GN(\!_01X_7XX[_/O^FG;^_I_?\_TU&T[1'?[]X[Q\/G.W
MIOM\]9[<#P/(B(<^X '/Z_ =Q]^?V'34=]XWC:(B=O*9G;Y>L]H\MO7O&O(_
M8![!V$?OWY^_L'W /]>I[=M_G^'S^_U_+O\ "8B>\[;3YQ^$>7EZ^7>?GMV[
M^A'VXY >W8/8?;CGN'N';_X:?=W^OY_=O]^HB.T[[3'QGSCX[=I\IW^'?OZZ
M\\\]^>1#O_(/MVX#]>0_;Y#41J?*)[;1^?GY[[3O/PC:?O\ *-9$3?/'8.?\
M^/U#WX'M_P!(:GM/E$[_ ']OC/\ MW^_MWB-H\IF8F=OAWV[1^NV_;[O*8/@
M0XYY$1  ^/Z<\#_,0X_S?/[H^,_V^Z-]/6-IVVCO,]M_OWF)F)GSG;S[^L;9
M$HC^H\^_// ?T#V_V^WVC2"B/E&WEMM]_E,_4;;Z XY[ASP !Q[#W'GV'W[\
M<]P#]PU/>?Q^Z/7;Z^7RTGR[3MWF=_/T[]X^6_I,SYSM.^O0" ? !QQS\C[?
M(_;]>_Z\:>O;O\/GK&=YC>9GOO,;S$1VGOM_;M^.O//')0'].>P<>P#]O8 ]
M_?X_73[_ )^7Z?+;?4[3.Q;?/;O._G]\[_+R]9]8U4G?.(_Z,60N1'_C--]P
M$/\ QXKO \@ ]^/;@?ZZ]G[/_P#O7CN__1>^_P#[!9_#;T\_PU\/_:-B/_0_
MQ3M$?\W 3'??_P#&'$_C&T^LQ^7K:[P)! =K64! ..<_SO\ 7^'6->==;VH_
M^O:7_P!R4_\ SEW7C?V2/_9_G^VW_P!,;GX_\$P7?7;37S77ZGT:::---&FF
MC331IIHTTT:::---&FFC337%+Q/ZSB*<W([#WN1<K3] GXF_N%J7!1&,E;RU
MN#W\>8P6,RD9I.XULM43*]0CF?JSQTV IR"KOR !B*#GY1[0:^,=G>#SO9)U
M)ZKI352O'E<&T?C,?/(;8LHBM'/ !S2#>QR6WN;%^]/V2LMQKCO9;^T.CAC@
MW'<2XVYPXL,]D;O%@</.P:/\.\6A#ZU \)E)S!S79:?T1LT)@JP)ZDS8ABKW
M63>OB>BVG-D!D6*N6/H;!503O%FO=E;5=2K2\ H]/& K!LZ_:YR[-':TD4&D
M2QN%/JCFT%42?U%.?BU"/A^E3?1&/MWRAD%5RE+#C1@>I>MW<E+1QRJ@)EE=
MC+A*D8KLLJN588D\A6IJ:!S^%9J-BY4IC*CFW0L9+Q$- :]>M34M]P[$ME;H
M752SG?92EU)9K=6FU-Q+:XRQC;.55R#C&L95E&3W%\%;E3$A6&29NA,I14BK
MIPA&'57JMRMM>3<3*"'KF,4$\>;;HJ VEXR+E$7<>VZ=M)4B6JR:5N*J-IJ8
M:!S7_<>(>HW!)5G355$F^Q2?:H\@RU-MR8ZFN=4>-X'.KK<2%--8N)1KAJQ,
M%#8A+(&S76QQPD5WD5+4,CD967)!SNT<HXS"-?3(Y%HH0\85F:2EAMU?"-CR
MR/3]/,^??4/2M"O^HOHQ<*I@ZZB^0)^0YT',+@9.8""=-<9/W8)XA#20,SMN
MX5S#)7&YP$P<CRSOK>'[PI%?[PH5+I$/>*$P1!+9@=YA4&!A+)CE@@(=]QF(
M9[S<+B-C;HJI.+M6DQEJ:M>$+*I9JNWJA(D90(J,0^KNIM 7C^>5;3CJ)2BV
MS]N9E6)Y=\Z8BW:$>@F3;;3(FME2*,S#!D9L%=&V<A6C:985)=>NR]$P'0#*
M8LHEGBXY)*"$*K.627;;=0HPCG 74/ ]=;2CW5L*<@@4+*8-Y!9Z0E%5\K6+
M?F_#]"B)R<MN2Z3"Q]<KA[?,BXL<4=VSK)2>8$V,<@Z5?JQRQ1*#9RBV43<G
M,0B!E#G*4<&N6CFZIP'):K46;[_NK=MRD5T-B(F5,8UZA@6<NT'!%L/O:@=S
M$3#WQ-#K*R#WH:BNMKGM5,;]4%K2TRD.;:%GZC,:C[)6ZS$F-J_5[,K+$N$3
M9+3CZMN%:;.4ITO5FF2WC5E6K=:6LY;(!PPJ9C/FB[MZS3D9$K18'+2*>)D4
M$F<[ADJN,;'1.S;R./*RPA\)4O8S'7<DZI;8$F:W-5C["DB"F1#^07DA12V-
M#;"PQ[<B&[U@FA86A,<UBU7R&2IXM;ZH%R@Q2GWDFZ98,PJ&2H6M&%%8>/D8
M^78M)2*?,Y.,D&Z3MA(Q[I!ZQ>M5R HBY:.VQU6[ENL0P'2614.FH00,0P@(
M#K,P-92!B0&,[$)C(D,_"1F(F)^^-;A(2C<2@HW*-QF)C<9D2C>/42B1*/.)
MB8GO$ZW-8ZG35O-I"CTVT7$T',V4E7@I.>5@:\>%).2R,4T5>K,HHUCF:]!
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MJL;2(?)00E"E:@O<7]!EG$:F:UL82U6BJ)FC(IE)%E),'3YJ\(U:.VK-J]F
M;Q;BU:6RED48VR$K>S/XCARP<$!HQ]_.9.OA\>RZQ9'(567[=9<N0+RZ38L+
M6Q FP<<?*LDD;%9ZNBW&Y'*5C/JCXM&-QUG)N57$5D9V&(JL6H"$ %\B-AB
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MY+JJ=G =YSL@?0+6.K.J@Y6VJ*9%<W^S1N0!KN1;'=\476FVE_52V*-I)L.
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MNV,-#*5'4[D?\N978Q"\!:?7)7(5'(6\,I>.N92C-;)VZP\MFVV9F9VD]QV
MMF<G9'(EE9>R(-KKIYD.(B*T9Q,VZY9X S$T;4NH_:(Q;\-UO?TWS^%[LD-
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MHK<4IE.:O5=G6J3RV2T6R+7HN4<O'3,&$=3EGD;*?35QABBG.RC&0;'*=8C
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M!>*0Y]=U?EF6@ZM%27*D8C?G"+].8B-Y.'A*^:-YAC2&]JI#E+'E2J8XZO5
MN=SFZ;.WJN9*EG$_17$;A>P9ICI&7I'\-C1SUG,0M<>(H RO0'(R=QLLAZT7
M"\<TR7$B_(IO"5,<?A>),L3^4G+EO"_$O#7#F2QSHF$L194[B-;6\H.Z+*C*
M_(P6A8C0;TE7H.J'%IF1R.!IH2,B'-6S^+S>3J7P/F/F68X@ 0$B$/"R32:B
M:\+>BN?$0P4VRW1:D>W4 <39#H5SGX#,/XTDT3IWNCWFF4N5Q[+4YU2FZ$6*
MREWC736?<7 %2N6KR/>P#,@M'[F:0E:=D:QQ"K"(X7;BE@4-',5N)1XI$#6S
M=<(?4L<*VE>'&+(V1LH(7J>)UM97&!5"HSWS$F9Q62D@D(QI8=6$>'-$=0WC
M;5F.>2Y4P@:TG'76V35KS&_BH1%\;P9C8G<X[?U7,$TWRNCER>"$B+!B.]TJ
MC/:E<(T<1=<"\>N[Q&^N>,)&P!"R;=S%@TE$!0E5=58BL*:R>DN"K<*V<>4L
M*59(>)LKE\: UVRL9@E1C%G3YES%^S9.JSP(H&S8N7Z_A*CK8$3!IY!F.R"G
M!"&TF#PK9XF6\X6=F#K<M"XM[(F#51FEDE+LLLNQ]-PTSQ&]GMS?VN'1S+6X
MB:ID[>("8CY<LDR%POCAR#*WR$*JO'I?58B->E61(Y(FB[7(B+CT":2R!E,Z
MTQ<IUK]>&2BW'.H6AT[ J;G'X&BQR8(^G]HVEUV58@SW5>J"V5O)B5U#ZB;-
MBH\(6ZMX2#,3@ZS)M8"EQ%,H?,!SKKT;DBXV G9M2U(B20!IW;:.F[YJV>M%
M2K-7C=%TV6*!@*JW<)E615*!@*8"J)G*< ,4#  ]P >0UF8$LS6<<IK(@,9V
MW$AF1*)VWCM,3':9C4*8#EK<HH-;0!BSC?8@,8("C?:=B&8F-XB>^MC6.L]&
MFFC337$/Q2L/Y.R/N6V#V&BTR8LT+2<@N'UKD(U%)1M!M#7_ !:]!=\919,Q
M$Q:1KY<.@IQZ&J@_  /R7VAXO(7\]P:^G4;854ND=EBXB12/C<>?,<S,;1RK
M,O7L,Z_?O[(?&_"7"WLJ_:-QG$.=H8F_GN&E5\-5MF8-R#XX;XOK].O @4$7
M7M5U;%(Q!-'X[Q?VZ;4IZW)7)DCNEW(5^'O'UH\O"-)V@S<8U5F5SF,E!IVW
M'U@6A8ADQ44BVU;8+)5Y1H<5'D8Z> 5R7Z@JMRU4U'-.V"!J<C+0(:UC*SDV
M&LLETH&W-QJ?WZK ,0M3&5ZJJZ)A<?@@7<EN;@! -W= BICE*6LT645Q4M;!
M%3*?76Y-H-K;;%6NZV^P?5EO.$WAA[DXJ)QK%QN5\:6A_1\TY7R'#VVQJ*U:
M9H+:\YG1R'$V",B*+B1C6\FF/76YHVRX>LS"GTT9V27>0=T9,8R-0+NQ<,K9
M3A>Y:A8KQ.(PV/RIIZMIEY-'(7K>6Q70N,@;",M5N>&H9MUE&2X>N0.633R5
MA()*KG%Q?H\1U:9'_P 5BM%!-B%5E5G5>$<)@:%V7U%&RO\ 960QAO;C5)L5
M.(\0"<5D64HL6W38+,6P_*2(S-DVC6;'6WJZR&3VL_U0;BP04?(U61CW?XNE
MY*5C:W-/6UQF[,K#6&4AVD0K"V."JC7'SF=AHRPRDXT8L"Q]S!B4P6(J/<%V
MD$>ZB@+$LHU:J2CER5=0KM!8H7+%%+[>13D^O!8#'4K%JQ-5Z\DUZ9M7K%2F
M56P7+4;.2"U5C(-;:7XAE4K&+79QU2^A+FT0L6#72)MZXT^J+!)T@Q9HO7!7
M;U%HW2=NBI@B5RZ31(1PX*D B"15E0.H"8"($ P%Y'CG5AQ+-K34$J43#):Y
M+GE:R*9 )*8B2D!F!YIB.;;?;OJG7!JZZ >V'/!*@<Z Z<-:(##&P&\\D,."
M. WGEB=MYVWUM:UZW:---5*W14FV2\O@3(]8KTA=&V(,J&L=EID6=/ZC(P%@
MJL]3G,Y%M% YD9*J+3:$N#%N8'ZT824&,2>21&K!W56N0S";!<TINX/-\.26
MY0JK9S+<4^G=MD$&U5&&XN:-JRE3CJ!>&TQ45$VG*QMQU,6\!8T&T\AC,T*4
MK@V9%>,\6NQC8YG)"")5Z<D@3ED/MXNM5!4O>EB^5K?P\=]+&SU"S,7V"$7]
M,FF#Z#?%W5[@2*QS1AN<-F#@L<KMJ<Q\BNYQ6ZD,3"A) JW;MW1E1.ZCQ!JG
M<P!?9SL6V[$D2:'#6/R+$2-HC#'<(Y;AS,M2JT"E/.[:N4\@J'=&7E4@K!I<
M(&5_,/K9!N1Z-?=%AG%K:HM_RY0[-T<6K"6&P@CE)83+8\\["5,8)/L%44Q:
MX*PRPFY'99NOO^8:;D:CWBD9"<U.C$@X>[94RQ+8CNU5GG67Z7?G8Q4!A/;.
M_JMB@8VL5F1K<>6?=(/I529,,P )I'<+4*E=R+EUT.BL5FUP<,Y!,%8N6*/#
MR.,%Y2;=)A5Z46<L/%45@37-=:LNG-H2ZK12KFY%4W*ZA!L@88[BVM%(EC%:
MO9XB'A?P1UKPS-[HXU_#462EH$ZPRT$<RQJQ#H7<>&ON[<I3\PKDK&I[.VL=
M)EH]L;,6;1A<K2$5;;I(VR]WUT:BF5QQ8Y:CVQK14ZM48>[0D@VA2/WTVT%6
M.:0FLJCAH^'KL%<MJ7,>-22.*V("SPE?P5G(T+<PRU=LY;-LQ'$EJC8545CK
M&%4JI=LMM6;9](;4%>\2WF@>2RYK@!1.N,/-X++8O%/1 I0JIP_6QF5Q=7)K
M,G9!/$#VNQ5,:05;2[8/#^WF3^,82IQF0\=T2[)8.KF-[;>F&<<F7-2POZDI
M' SA*_'SN!HK\&PME;HR1+%<'[B[O"^O5 ] F55/4I7<E!7,GE;BQVI7\KAL
MN>,EHK\8^O3QU:_7=;\*\*-.M-,V4D+HWHO/*;1_9)V;"HY5!1UZF/2UD^.I
MU<M17D1)K1IJLW,FVM9"E+*\W[=I%FG%LRO8XJ<J&NMN1512RU="*PIDG''A
MT9!PA9G3^W9$8;>\S5ANF-Z+DUV]D)FK6X(.$8W0^+<)_6T&X2#.(BC+8XK)
MVK1)JQ43<^G%\OKXQ.,AALHNF#&LGA<<>,DF%/M6JN""@;71XFU#K5IRI8^U
MU%S<>P[15ZI.)"_>^QA];!>U/V>9+)6%U,?5]J/#F;MO-ILKTZ1\7T\G:9&Z
M0*O60!.8%08<%-(Q62YJU!.H1PCDJ_;,?#-PM99S&;"5L%)A7K:TU:WW1S02
MQK=[=;&NFW2DHFF9%>NK%)E=,V=<B2P"44]DWK8D_9*K$@[FFGD>"_$8W!<(
M8RY6))W; 8Y_,Q86$MLWS!05TM)59SY!I62B[>QE%=2M98_(J:-=%CZ9^T[E
M<5Q1[=/:AGL#D*^1QEB_3M4L@J2C'FE&!QJVVK3]IL)HI:@D-93I9*]+V)%&
M->J7NK] L@;A</XEK-7M&5;[5J SMJU::0Z$_.QB+ET\M,A%Q3%-JF5R)GK1
MO(2[-*1E&A58V/;G,_>.4&)#KE]VT 7D&8T7+98!KEP,STID4Q8+JF#>0T@P
M:KN270$DP>C'[V8#7Y\Q\.R%%=X$RM98]F08)L7,+6BGXZPH6B4J>Y2=^5:"
M,G%RPD3E@032W"9SM^*<8IY5Q?CFO9HKC%LI/61R.46%*9-:BW],*K^KOV]7
MNI;=89 K@0K\&1O#P\DHW63D+9"B=F+NC9>RG<IJM5G!2:Y2+EA8RRY69:MT
MZE4:^.*%S;(BM'8?SVJ@IJ57&LK%@D57;%P-BI8;48%BR"VLK)@HBNT*]2Y<
ML,?;#JRA814&L'1KW',MVZPR@*HV[=6M%(\1%2T9'R_CZ?PG)X]_ ,Y4(FES
M]RN"T-%W-M85YH)=]9'<G28Z)HOX>BH8MI.2/F+VR=U>=K3MU)Q,O)K0;&Y4
M&+%.M8:Q:+#<UDL8^M!045JN/,%^,ZK9KF^Q+F*JV*"T;+N6J=>G<R,O,TZV
M&(&N1%CT,Q%+(C*%R=GKW<=B<@JN22D*XUC+*.JIN%=ADMP/$1V:51-&H>1M
M#FK<C4\,N*0R?ILI)>WDEIQT]7F0C*_6<?52/+-7:^R\NC&RZAHN"AQ!5FU:
M1ZRLR_79LBK,4%EG[6FRVA%MU>TP*J*5-F0REIY0N*%6;"\?4DE%,2QMO*V:
ME* YU@@&-LO: (@&Y\C65DMJ@-JQ;M(IT*JV#SW7&!6;'1*=^8*M!-BX7(!F
MR%@H W;S@AEWP[2#UPEN#/V.BUP\ZA6PE%)@R2(3#EFC(HMCIJ($<)HGCW"#
M\7ZB)8XC%4CP[LK<?,U=Z+/$U*< 4VKUAU2JB(W8VTBPJHVORQ_RW!:>BOTF
M<ARYR5C$DT(+4#5L2^P!P:*U.KD','N(TKR&VJE@=N[%V*Z7.5TX.2!+9V_=
MGR[D]NFQ](8IS'D3"\U4\ORF'8.SR$O74+,^KT:>7JI'QI&OR=E;5BSJ0SHJ
MD:\;F51K\P=%=,@*-/*4!8O+OWXIX@<V"IL4)\*Z6"4KZE)KE19=6Y@F'/35
M)SD5SE"[%E0U'VJ4&RPBQ4%5N^6.AX#:&&A(1$'R/$#Z .V*.FIC^F#&CU#6
M@YL*38Y04R*\J[]\98^IWU:&<U*R7F$98WLM_P ;REQE:O+5*AWF7K\1*VEF
M_2HUB+8SUE:QL!*P18QS.45.FW<S,(HNB)NC<)-3*+J=678\.+:G">0R2P]Z
MA8R+\A3Q]@J9%$LA]R@8$HK"8&N%QZ76&U(JV.6FZ;L&&4A$!=L\+OXGQ^,-
MO:ZFI6HW+E8+<+GDE*+JXAL5CF7'6!B$KL$Y+[GMZVWPD&BI1<I8YNMSL5,L
M=NQW3U+6M"A=!@&TL;T!Y5O!SSB"]4^A9".%1Q"/'Z:S-[Z>)>JLUD H9*V=
M&CE;:D>,9B,9]KV:X-@)*E%.,CS@R :!&6/GQ:P&"GHDIK94AD.CKU%IL6J=
M=U@:P7,L.$AQ#S=/(%=#'2DUR:RB0NL"L<S(QU9E82;(@)V<#;G#Y=G&=5L]
M%#'MDGL74_,-/;H6I"VQEJI%D91Z,NX9O_HM<>M).H6ETI 2[!Y#ID7:K0LV
MS=*$E5V$7UV("&9="V&3\)D$T[RF*A>U7)>.=@<@DQ8T&)R=7'7!<F2"QC\E
M1OU#!],<=E,GQ*&1.W7Q-EE<4JS..9=ID#B= NI^$7E*+^9".FZHZ[6.NP8-
M5ZC838 E60OT*%K=5M=31IIH_P _]_UTGRGMO\OC\M-51PUN4D\EY<SYBNR4
M>#I(X3"INRS3/(:5I5E(ZTC9.$K+%+U2L)U2;BT:\F_?-X:5O5:^GS,:!+?]
M62E(B.PIF%G"3EVL6DE9C(XFPJ)DZRXHT\;;&R%Q@UR(3\>RLT'5*XKLTK,5
MFW41UXSN!X;*KQJR\1#\;7R"&0#5N9#K#J\C""62B61+ JY)M.M2)Q-^ECH;
M1F[)E"S_ (:RI,7"NXVR13;O8J-*K0L_"5ZQQ#^02?HP\-.&%LDD\-ZQAZ.?
MC$C2S858M-\HX8*.R/&3Q%&.9K,?]HU4,M*-=PDB$B$M.G?NXPED3)$$2Z[0
M>NN;Y!;E2JTLBK.4T]?.L;15&L%#0:I1]6"C8F5D7-PB!DG=.O8 VPF#)9"Q
M11#%F T)R;XB>6,1O;-7K=M&>N[96LBXXK3AC3\L/;?7CU#);*3D(F77LD7B
M(56F0&*44NSD,?C"+UXDDNR*GDX\0[1FABFY5EN*4PH5%G-Y# Y5X>]6H6J%
M3 WF7*+7^$G(8L:N?59?9O!A+%>MC\H<TS:BNFUC?(Z:,E86AUD:V!^W:%<(
M5XZR//F%15R%=;7!CV-=B?#UVU'Y==BQ=K*7OR623?;&.9JYE%O;9.'5BT8:
MO2BS>/<$GF;Z4EH-!L10MI>0:*1'D!#R:Y7?X?.^.H>;C&R<TVZ6#UH95U(7
MCQR-CE2F0<\XWDO#5@7#E>+/E$47&5IBVZC[[*E=U<;!A;*Q5JY;[W&5%R)R
M$+$#@QF7NYS59A C)0RO6L#X3Q,'LRVJTJ%B* :^!Z1OWP!8%(Q&X76IXV=7
M&19J8TBK!9/.F+E3YR6=0=/N;ANG%-X^O,+G),7)*^U<2CXRR)V0.739\\+'
MIJK(LJJ[[+N6*RK;:,S,LJ+M4!R]-#S,5Q%]F),+CZ8C)5YDZXF]J7<BSS56
M6Y:!!4JVKM$;3(D.O:Q-H<=FH%.Q$%?'9*9IE8,HAD1%DUIKL2;'L3>SM/4,
M@1+/% 64=VYU0FJ:,HHLHZN+.+6FUJ\V32;G.XD!B&[B1031*<CMH@LLU.L1
M,XEVU=[LTHJ1+YR->S;I0N)F;%>FRJNTT(G:8%!7:DLYH&1782W;I'!ZR9'1
M*R+)@)ILJ*M<TQL@[S7(J09;\L0^Q7=7643(S84:)F'#(:1K9N_I.-,R9-QW
ME@(&@4:@8MQ3DYEE!Y9)%^A+M\G63(E7"(EZXE4FP5H\,^QX[<%D26"=:/V4
MB@LX+$';JI&A$BRO8-Q@BPOB2.'JM;>3BV1X>CE5OEQ0H4N(K3:TU9 PB$K<
M-LR?*$[W56@C%6T1-BMDJN=<PA@A;6;@G8,7!"1AGB$6$<046)<)K=#@LH*I
MR+58>U\8[\\/VVVYHI%^LN/L<V'$URGH]BD2^N+ RN..HVETV_QV1VKZ1J50
M)'@[KEVC%):NH)S(P[Q%PFUFYMD+>06Q2P#PU7*MF4._XPK+4IB3+%V\/QIG
M^"24+(V9<3;R&")M5T5J[)BXBNRLMT1SU#,?M)U)6[$2&*.A</90W@R7#>-X
MB9,A,DNOX5=]B)DK!BT*IV8)?,:4M"[>(/7(6:^K8_J<!EO"T=BR8R_9\G57
M(IFLQ!T^FV\*GD=PC1Y&E$;2+NC]8S+Z-/<X^4>L(^:;-V))9FPCY?;6&#<8
MWI\%6.]PY1J71Y;"63Q.3Z^-M6O>3X:E]H BI8>F;LUPL3;>"DUK/2O#499I
MK=C^:]=98R5%>,!;!M/R./JU;Z\?5@1;+K60I.;X$3!(NN31KB70O>-K]#&;
MML_:-7S-8CAF];H.VCA(>I-=LY2*L@LF;_G$52.0Y!^2F =2Q9I8Q30(&*,E
ML HV(# I$P*/0A*)B8])C7/2Y5A*K"#%J7J6Y+ F)!BFC!K,9CM(F!00S':8
MF)UL:PUMT:::@_/>6)O#=5KUJB*E%6]M(Y"HE-FVLC;'=47BXNZ61A6SSD69
MM4K6G-OXMQ(H.2P3L8%N_1*J49YD<I.O!12S*8?'E$"K*6WTRL1/,RNP,==N
MH(:\P(O!K*D(;,V$$@&R\!L$N$'7OV(I8O(Y"!EIT5U6C7F>F#A?D*=)L2_8
MY42@M2Y<0AL.)?1(DP?6#X57+\W.Y^RCA63I\5%QU$IE"NL!;F%M=R[VRL;F
MYL#!RTF*PXJ$,A5W<0_KS@B LK-:T91HNBY44C%@.S+KI/&VO+<T2I^*R=6D
M2QV8IU>[1*Y7LPZ>F:W;J<I]64$"X%3%VW=0P5:MA-9F(@9ABLI1R=F3G]VQ
M%C%W*=9U>%QU!:EBLA6<JSU5,ED/2=4!6M[E&K[A\(73(5AQ55<HTB>R!5TV
MRDQ6(RQQ3R22]2FZ4%-NB@Z.+Y=F5DY"3;L_/6BC)"20(V.)0&PF/$UO&5YA
M];SZRBA@<FR2AVX3/[@O$*@'_P#*,C$0.9G;65E95/#19Y4E<EPH S"&&=<B
M!JI7,\X-&0.84<"P@6;!&0 BBFV9O$6)CJ=W$P%&PG.906P+0,<7%"0;6=Q#
M1MU?7K(TCCR78M0BZ;<):-K]#6C7$K8K.SB;"X51:R39A75S,?4.**K9.HA>
M%!@IG%=7AL9=) $5[&,1DHRQD"V$*WDV:&.KROEN73J0ZU2KV2L(LG4!=A-4
M[ ]5F#S>88(C$RIN(3+58[WC&#LVXD.;:8\,+!F L,V5-D\ ;EHK/)&YVL"W
MJ2QZ96+ YA)FR-SVQ"P2C7U-F@4JR>-8OW,13EEF<2]MG4BW>3IWT66,:*1R
MJBG7?7!3+\*=UU5+QUE-$0F751 >G><"FNBG%A\/0A#3,G16982QE8T-=RQ=
MO%86!(-<MA&4?]EE@E[B:3FPE]PY1$7'S-2O%:M9HP?-:;<JT&(UWZ8$8SLZ
MTOUPK>-J\%DGJQCZ<M$VLF]R.O29<M;OTW'0R$09")K%?LSAI!LI5[,K.)=8
M'[Y6.BHM"/>RW/H/7?32E9A%S(H1DJ=$3$V%@LDT*V#R;CW %,R]D;4*I##9
MK5_LXK%@+M]F/H[K'-7L7 *!*K1EE9]P3@@^U*55M_,X\%C!%OAZ?1\4TY R
MMAD4!7Z./BU:><EO:VG1$C-Q,CGK'K>1KLVC6YAK]6,L=I.KE=BC%E,@@J1T
MZ.HQ>-@(S.X 'K5=@)@>IF0#96*+D59JSU_&M:FI 1,S8-*V-/IQM$D/24UH
M,VZ;5+8U1F $49%'(9+*1$Q2AY1)#[J;+ZM9)E.^PP3[M1)04Q*V64BR DQW
M]6_<]7Z!E5Q3[FRB(/'2.'BY;#)Y[!).5DVX6)M *Q;ZGH5(3MFX^N9NVLLV
ML3]98%%4%XAF"(+JXBP%QEO&$-6<;<Q=)43,L\2S)!<*884"$5B0=,@B(ZX-
M$I,FIY>0MW0-E;%VJO\ F%Y$\B)1M*R2-&K5N U<3S==;D6"D^::YI)8B(/A
MDRN-*-O_ ,*6?+MOQC-VO'];C$(RIV'%5R3O2\FQRM6K+3W=P<22+9[5(%C7
M'<0RC9,58T)R?]6U9J/$G::A5V;?9N*Z=Q]MBZUC'MR!7*O/!BK&TJ]6W&3A
M_N=53*UH'M!:B%"HAL-<J>I&MPP'V4Q)B^KEURNNZ-P,<H&9M8-N,-.Q<K/'
MUHKI83!EMEGAI2MT"+/C<=\L&>0QXM@>O57<!4;O%9:<NYVOY(4KLK$S&)8B
M)L4I LH)Y2)1A*.)"!=2JR"TA9:Z=&28QK$K5TTF%)6+IMM^&LV5VD-751PR
M7%06E<C)9C:?%'#?#F8YTL)'2;1#B:K?2$,85KPEZFX:+%H:_2PI(: 5"2^U
M=XE5PQ*&-E )NW>%N)^(\8V7@NQSHMGPTRBTX6(("\B\H[8+:B+D46Y0F1*9
M5KW7%5%X&W04988E19,4E_12C1)V@1=(1$4G"15?*73$1\M8AR<CQSKI6$S7
M<Q,F#("?=:N9E;5E$$MRYF(F5M60L7,Q$R!#,Q$]M85W#82#1B1YN:""2 I6
MP");5$2R-9$I@FLB69K*1F0,AF"EUZTZW:---4.W=B/XCJ !\PCX/_[\. _3
MY_WYTUC,1VF?3OZ_C/;\/N^?EKE.:9R&ZSC8JRWMUD;TZ$:UR84\EGCH(>.+
M(-9-TO&21GU8-9G;224CTF315E+-G#)1RHJM(G$$$C>K0G&#PXJXVC49>99N
MU0EAY/K6.G-2%RF$7!JK<H;3&%+$D!BH!A!3U"U\IMW.)G>T2UB*^;S%?!U\
M7BLHT4HX6\!CRL_:L,5<\;AVY>S4M,QZ$A%:ZIZ3>TSN+"4@,*RN9LVNUBJL
MI-2'96"YY BV9&L!39->O16.(V4>N$V7U"20+*A,@D@=X$HH1TW/&.0CGA"2
M""2781A<$M"Y>,/96PU#).DGW51;;E;5.L"V0I9="*DL9*B3_'XI'6 _#NEG
MB;_&?'SKMF*;2Q]:_P 9YCAZH(4<';9BJO#6,RV1<U,V+@1=++C70+UVY@JT
M4;TU7(*]3&O+;O/XJ4Z:4B8^RO9"NTV)EINUMXNO 6,D96(;S#8%H5W*(MCK
MKLUO/3*B<\89<%&:;HRJ(E#FQPX,9! M950BSEV4J]4FV2ZX(M+KO$7BJ6"(
MF?),E$/Y-VB$C$;^KGVCD7#]QE6KEKMVAPJG,Y#)JJXU?@'7,8^_3EU)UP*Q
ML:E!,$5FRC+H&J;X8<Q"B_W.UB.<6)DE7+7+C5I"'AWS]LR;(,'4E).HIBN@
MDY<+I-$EF;F6;F4146*HLF58[0JI$NH=">%K+PJ-\140-^;)(4;"E@J3%N09
M(Q$F0,BFV(D1+DF0ZG+S1M9M^U;$T3RZ)QV7O'@4XV+UI%5:T'9O#B>:N+38
M" >D<O5,ERP89 V(1+.E,$N0F?XJS'@FU;J5CEI&79RKUU'HGBD%8@D3*O8)
M0'BKE^DW6(K+,S-?.9*.$T"K(N%S$2-U:T/X==5&RRQ;KK37"H8-Y7%#_&50
MNK$!A<D)17.2Y60',8RL)(NVNG1]H=3)NQ]6AB<E9NW79=#ZL'3!F/C$90\/
M::\SL MR_' (<U8V\B2A[(%/O0_,>7X,A1BDPA 24&W34.V,22<1JJZ<BV67
M;R$<LBQ=.3(NH]= 4G *=)!,<HIF.'/%')XV,:0!-E5F6B+5DH'!!H:H&)>$
ML 8);(+:(_BB1*)@?/7>X;XC+B)#7QC+>."N;*SPN.IL8J]7L.K7*3!K/=(-
MJFN)(M^F8,62S.)G:0@'CCCX[\=O<1XX^1[ASV]PX^??7+GU]?2/3RV]/N^/
M\XUZ7;?S]?7X1M,_*.Q=]X[3OZ1.VL\=N. YY]A'COQ[@/SS\? #S]N-1]?7
MU_73?OOO,Q\8C?:/A/PV]?68V\M!A^.X\\>X\<"'(?' !\\_'/?V#3]/K?08
M[;_"9CM&^\3M.W?O/\_.//RP4!Y#L/Z#_7[_  /?]?MI^/U'KJ2VF)\M]N_E
M\OAWWC:/E_3T(!QR/'?@/T .W;L(!VXYY^?YZ:QB9WVC?MO/;SF?+?O$SWWV
MV]/PU4[>\Z<M-M.0'+-PNU<INJ<*:S=91%9(WXWKH"*:B0D4((@(AR4P=A$H
M]A$->RX!&"XJQPF,$,A=W$HB8G:C9GRF)CS[_?W\XU\2_:*-B?9#Q0:F&I@M
MP/*U1$!QOQ#BXG8@*)CM.TQO$S$S$]IG>0?"WP^\W*[%LJX]F,L9-QT1?<J6
M64M= -0)"TA^'*CB^<8QQ#Y5H.3:\2//)-FZ[DI*^#LWE"FB\1357*KT/:E7
MY>)\!:2XZY8M%3)*6D*_2=9KVK\UI?#$,.02V0L"*C3)L4L'2Q$L0SQW[*3/
M&^S7BRI>B;J[_$E^@TK#K,M6AF(X?)L),'!(D8B:IYH,1!K"6(.Y&A=QSX5>
M(I9Y(REFS5N%M,Q:+#DZV9'EI64P\R=9*L64:97*#)R<^C7<,P<?73U^M56'
M;5EKC1E0V#=P@=[+M9ERH937S@$@A"*U2)J(J8YU&D"IELT[-GBM?&EG,*9;
MFPUN1?Q"BI;-=IEC%@NJNJG&JK-M*L?J!P39>RS;*;+VVJ;6FP%A#,?2PM[A
M]6%-: 2HL<>-R=Y3G2O[7,[$LC*"2J_1^[SPML822\+(2F>=R,E.,LC1.5K)
M,NYK$ C?KS75*:G6)RT0"6&$J>S>UR(HL)7HUY3*W4WRD.I*A).Y"1E'<@I:
MK-\)D,9D%+5OBBR3J]8A*:YV\U9REK-W63!1:!V59E[@VE5K->F"N@NI5K#6
MKPO781%JA>Q[&,@+M>C2AX<@V:V/Q=>58V@H^65OKTK$SD%%?5<L,NS)6'NK
M3-;4FW+8%C:VU_+-9;Y,S54H?,61BY"L;"M6&GGCX]%TDI^):!"PUDHEB@PQ
MW=9!U)SUI@9F,F7;R?E7DJRE8]R1D9GR&8NN[%4\,TVLHTHS0 !=*#:G,1D.
MDEQBH9F,$>1<SAYJNE9QA*K +VI2*M= ;;0OV\FN!7=MU\4J; <\&AV(;CB3
M=1,G/+8LIQ5&E?6R&4K=%;*[*G+9LRZ(JQX6-,J,U7)B%W2[JFY:NM'.8F.2
M=[=&:*+B*PY)X,8."RD;MT8V5NX;T:8?^6X8SK1<DTHG*$4(H@BF3JVV,N,S
M#FL,7YM'%:;;E3"C7/&.0Q.6RK:_+&RVKRF"Q-ZGSPQ:SIQ7:M]*Q:JOYRZM
M9(45I2"EX]_#KJZXDV#R<-1DDTJS(>;>=#\?EKF,M[_OCJD#D.KY!8WM;$5X
M4V%XR'B857+N?I1NW<WE.S.'TOBE!WD&MY(E*98+G3K:I$8BBTDH:;LE"KT^
MXE*HC6+F1\F];H6I**D'4<IDEL(LUW*2@$UEXH0H"$C2)V RN8S'#]F5@0M
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M5,68T532(I0J@H1NYE':!#U^+,5-W.$!.9<IE%L($6E4BE(_4+P=V4O2N*@
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M1\N_G,S'GZ_&)U4;?,/_ ,V+(8\!V<TWX["(7BN>X_//O[CSSSS\:]E[/_\
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MF\;B'89%/+-Q95WM2TVL72I6R>)(  B""XM<"43.ZYF9VF(BU0'W"_0C"*5
M_$'U8G2 "^]!]&]&IUB/]H)Q>>M\OI[@3R>KGOP.O.:^F>]_;]?/O'EVCM,^
M6^VE"M&SD)I?\5)T@I/HST87Z6+SD9SRA] #WS#C_<15X\_HX/T<\" Z=O7Z
MCUT][;\)_&?3UG;Y_P!N^D)D?<GZUGZY+'/H/4M_6B@+_P _TGFD]2*/*HE\
MWR>OR^KD.OCGMIJ8WV[_ *?[>?X;?+7TDS[COJ4C]*2QV,5ZYW],%T+_ -4+
M#U"GHO4]*@%\\6WE^=T@!?,ZN XTTG?T_7\>\?/R\^VEBQFSF!(3\,)T@3C$
M(#/?4Q><!->:OZ@&/EJ!_<O)]/Y?6(GZ_,Y'CC3[M1'-Z]Y_U^[X>?;X;>NM
M$#[@_H!Q%*@?B/ZND! Y??3OHOHEO.$W]H*GK?7>0!._1Y'F<ASQIJ>_KMY_
M'T_*/+6]6C9S$TK^*4Z0!?H[X8?Z6+SGZWY)OIX//,4-_<A6Z?4"3@_1ST\#
MIJ/>W\^W?X;_ "](CZ[S.D%H?<KZMMZU+''H_4(^K\D9#S@;>87SQ2ZE!+YG
ME=71R''5QSVTU/?TCT]=O/YQ'\X[?*=?>3/N.^I2'TE+'?TKUSOZ:+H7_JA8
M>>IZ,7/2H!?/]/Y7G 4.GS.OC@.--._Z_=V_7S^/QV[;;Z6;$;.((P7X93I)
MEQB$OQ!]2%V"837F*><##RU 'T?E>6).OD_5U<CIJ/>[?P_/S^O+]=:!#[@O
MH"PG3H/XC^KMO( /6_3OHOHG?JQ/_:^9ZWUWHP2X$">1YW(=7&FGO?+\9[^7
MRC;?R^,>?IMKD'X@4O!1^X39RGN2ILW9+F[M#U+"KK%]LCJY!PUK&[8W*D\O
M36:AIAS,0Y94\(H=I&N(]P9HB^3!<#JIG3^6\>MPB\YPB.4J7[%D[A1194M)
M0I+/%T(WL@Q+2:/4E9; 2YY1.-]RB8_=/[*=+VEVO9A^T"S@C.\)XG#(X=47
M%%7B#"9#*W\A4_P_Q44+P]FGD:*:#_"A=7++*+(2YU<X&!48'UK:GW*^I;>K
M1QQZ7ST?5>4+_P WR/,+YWE<J<=?E]71SVZN.=?4OOU^%O>[^7KM\OAOOZ_=
MV^.^MF6/N+"4D@ADL>C$?4'OTH7@O@=_3?4J>A%T!%.D7/I?*\_IX+YO5T\!
MQPT][Y3'Z_CY;?A$_CZJMA-G,$(+\,IT@7 Q*8V#ZD+SRPF?-4\T(_RU 'T?
MD^5T^9R;KZN_&G;?Y?KMI[VWEZ3VB8\^_P =X^'K\?/RTGE/N&^A+"9+'_XA
M^K-O( !??3_HWHW?JA/_ &GF>L]=Z/RN!Z/(%;D.>--3W^$[>D=OG_IZ_II1
MJQLY"Y?_ (N3I!6@13WZ=])%YYHS'E_W ''FG$/2"I_V_IX-T_X1Y]I[>N_G
M'Y>OX_#43S>GEM/>=NT^D_C/^T>J/&'W'#)1_P!52QV$7ZYI]2%J+[U01_J$
M_6^FZE.GU -_-%$3!T^9T@8..=1J8W]?KZ^'?_XMNVO<P?<4$M*A")8]&&"2
M??2!>B^!X,7ZE7Z>+OH4Z/5"T\KU'0 %\WKZ> XTTG??MMM^O\X[?K\M?-Z?
M<=TL?0)8[$_H4O7^>+_CZAYJWF@WZ5?^+^5Y/1U<FZNOG]&D[_[;;_KV^'Z]
M_+?)C[C?IK?H2QW]5]<\]3R+_P!+]/\ (8^A%/\ M.KU'J/J/G\CT^6#?IX'
MJ'3Z^OTU$\W;;\=_P^[Y_#U[>6O4>?<7YCKZDECT$_I[WTGIA?=7U+R#^@!7
MJ4$/3"XZ//XX-Y?5T]^X-/>^6_IY[?W_ $]/S\1Q]Q_U!B$FECL(WUC7Z@+8
M7WJ09>>3U?IP,H)?.]/YGE=7(>9T\AQII[WR_#?R_&?/]/GJ']T:V8D<)[BE
M9MG4GF,DL69=4F&T>X<-+.ZHA*E8#/T&+I8%VC:?6KX+)MG"K=9LC('(J=!1
M,@IFY6>E X/,E:!C*T8K(S86DQ!IHBHZ6@HR$A!A+YH R$A$IB9&8C:?>^RQ
M>4;[3_9RO"V*=3,,X\X0#$6L@AEJC6R9\0XX:%B[62:&V*B;4J980IRF-2)K
M!H$0F,8[*GUR?;5\+.]O$#'0&'UZU(FJ$/DF8+.W5@@%IL!'R<U+1#2+CGJI
MY(KM9!1LP;%(U412,4QTS'/S."RI'POB"QRK"*4H;-=5IH.> ^)?$PQJP6!S
MS\TQ(@.PS$3O,3,^U_:41Q-6]N'M!1Q??Q.3XD7E*492_A*5C'8JPV<+C"4=
M.E:LVK%=8UY2!"RPTB8)GO$%$#<9P;.?X5CA;)TC\7_4W0295!>?2 BNC^Z"
MVX/YOJ^O_MO4;HZ?8->H^HU\.[^GS\_T\O3]?+YZT8P^X/T\S]62H'J0C!&"
M](+[RQE?6M. ?=2@CZ7T/K>>C@WG@C\<Z?7U^FH][]/EMOV\N^_Q\]H\M>ZZ
M?/XS<:%F2H18#U)?JHQHO1?@UZ3=7I?,4$GF]73QU (<<]M-3'-Z[?A_7S^7
ME\^_QT'Y]R'KWGTY+'0QX.5_0BX%_P"H%IYI_3BOTJ 4%?*Z/,Z0XZ^K@ #C
M3Z_OJ/>^6_Z3_6=OO'\=;DT?<&#AI]"2H(MOI<9ZSUPO05^K^C2^J@CT* 'I
M >^:#7D.OR>CJ$1YT^[4]]OGVWC^>W?^NW\];[@V<OPHP%LG2!N/U-T$B507
MGT@(GH'T@M^%/-]7YG'F]1A+T\\!SI]1IW[;;1\?]/Y_SV\M)\8?<+Y4Q]62
MH *_25/HGI1?=(S/K6/E@]ZE?^)^A^H=71P?S_3]P#JY?7]M1[W;O&_K\/P[
M3]?IZKQ]P0S<:%E2H(0(NT_J@QHO?7@S[^8+4%%!(*W''3U!Q[]AT^O[:GOV
M\O3?^OUM/X>>M22/N.^H/0BTL=C&^I7]"+H7_J!:>8;R// J@%\WRNGKX[=7
M/ :?7]]1[WR\_+Y?.>_G\H_&/+6S,'W" LR^B)4 R'TB*%]ZT7P'^M"Q1^L
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M5V9CP[7$R>6:RF\K+0\K#96%H+4YA"H^ABBIADJ1Y&(*@-E170D3*3JP42\
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MS(.2Q; F1*)UIKO"ROJ + D6/0U3@E3Z]FJYE:U5L*+WE6*ME3:]A1>\MRS
MNXSIWZU:WZ---4:WP8TR]G2K5'"6.ZC 2%3NLN_<9/N5ZBH>TX^@:[%1+Q1E
M!S]+1RSB^]6!S8Y99HDP/6%WC6+5;>OE5$TTDT%^5>JV+CBY&%672QU^W6<
M =EV6-#*V/#&MZX11R5%C)R%:Y<45&'+2IA1)DQ/2I6@HJFR$RRW-[&K6@1B
M1&LNVNW:L6I:'(5*(K ERJ["NLZL"I#%]61@/;5BC=.7).U>Y9MJ&1:L.*L
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M%$Q/Z3I':8GX:X^._"4KRCZS/FF3:JD)'R+_ !RS?8292$<U53RTPS )<WM
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MJ/;'$DVZY365_*<HD3 0]UDP[ZF-MHWGOOW^[X^7U\-1$E/I'K\8[]]O/O\
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MIB8^.V\QO\M?6H6C<2\LD,UM5-BF%?6>%)+/$$6Q56[02G$RA#$GG)@,!ND
MZ4%1_P#4^=/KZ_EI$S,_+YQ/S]=MO3?O\=M)4M;=S:,G(IQE(AEXU-ZZ(P6.
MW;"HJS(L<K90PC84Q$QT0(8>4R"(C_@*/Y0GMO'P[;_UTWGRVG?OWV[?+U_V
MTHV.T[C&SIB2OTR)=ME(.%7>'51;&%*97CT%)=L7JGT!!-N^,LDF  <H%*
MJJ'YS)V]/KO_ &VTWF-M]OPB9[??]_II4=V//1*+%/VM3C%+HM-/$)*-,BW]
M.A#D3$6C@A1FRI@HHIP4P@[4$0]TB^^D;=]_AV^_3<MHG:/GVGM^'G]?#23"
MVG<<NA/FEZ7$-EV\"LX@RD0; #J;"1C4DFJO3/J@*1H]616$#"B7K1)_; (
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MJ/G_ +_7W>6LX\HG:=HWVB(G:8CY;^?KW_#>=IUD1'V$>X!W[#P _?D._/\
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M=8 %)!@+A=,'BRH&**:;?S#G P"4H@(:G:>K"=OWQ<W*K_Q9Y/X]E_Q3R?\
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MI9;7X642&6*R7,07^%^-"YDFP")<\P#.X3$[C$^8QMU(F< 6Z4W;UK<6E;J
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M[>(P3ZI^T["%G2RU5Z,G'#N+Z"\2NG;79HE7C!0HFON,J6!=->6 %<@%HB9
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M7Q@Z6<K,F1D6RCA5RNHJ=,5#JJG,)QWHRG 8I4+^&;S'BH!:P<C:$3; C!G
MQ>&(@B@BY8&(B)VB(VU1O\)?M!MOW&T/:K@:M!EJP=*L?#6)8Q%4VF5=!L/
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BC331IIHTTT:::---&FFC331IIHTTT:::---&FFC337__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g428534g0110085822104.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g428534g0110085822104.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  J ) # 2(  A$! Q$!_\0
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M_:6G?$?2M;MM%OM1MH;"2%_LJ D,S''4U.T5Z_J:W3K22?V;?A8]!HKE-/\
M%]_?:A!:R>$=:M4E;:9YHU"1^YP>E=76J:>QQSIR@[2"BBBF0%%%% !1110
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MSJ6D^-8-#;67U:UGMWE?S@#);D=,D>OOZUW':N.^'-I;0Z!Y\5O$DTC8>14
M9OJ>]=C0!R/PV_Y$^/\ Z^)O_0S4OQ&_Y$34OHG_ *&M7O"D,4&A(D,:1IYL
MAVHH ^\:=XJBCG\.7<<L:2(0N5=<@_,.U &E;?\ 'A#_ -<E_E7 ^&_#\/B'
MX<P0,YANHKB62VN%^]%('."/;UKT&$ 6T8 XV#C\*R/"D,4&@QI#&D:"1SM1
M0!]XT <4FM7.I>+/#-CJ<1AU:PN)8[I<?*^4&UU]CBNF^(=K-<>$Y)(8S)]F
MFCN'C Y9%;)_3G\*EU6UMV\8:3<-;Q&8*P$A0;AU[]>YKI>M &.]Y;^(-!\W
M2]7^S+*H9;F(J6CY!((/ /8YKF_">J7,_C+4-._MR;5;."V!$KJH!DW '&T<
M@=,_6N2\6V%G!XQ$,-I!'$[C<B1@*WU ZUZ9I]G:VNMP_9[:&'&G*H\N,+@;
M\XX[9H S?$XT/4=>L-(U>.:"=XVEM;U)/+VG."@;/7OCZ5E:Y#J'@^VAOM/\
M2W=W^]1%L+QA+YP)QA3US72^,;2VNO#MQ]HMXIO+&Y/,0-M/J,]*X/X:6EM-
3K4DLMO"\D0)C9D!*'V/:@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g428534g03v30.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g428534g03v30.jpg
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M P$1  (1 0,1 ?_$ !X  0 " P$! 0$!           '" 4&"00# 0(*_\0
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M%UEIVEIF9]7'L6LIJK1VG+DJV)P8*\@90M:GEK8AGQ=D@[1;3VBT_P"=*O6
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M*V0(QI1]W LN/DL&HA&JFUBK ,.06(1V"('27"\>XM/&E/\ FVZT 2KYDH[
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M E )7E)HRE0-L![\UL)* 5EJQ75]NE4NY +,R$44'E6:K6KO%>8=K)VRAY\
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MEJ]63:(<NEWR/8@.O=N[#' #4$,!E6(=IA0ABT,04RS;DV&Q+DFHF:^<(#F
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M0F?^I'594O:<&MB:'LVQ727;;[1)-(#CJ>D^)MFN@(ZVG1!-\M=A5=0J743
MFS@IL,],&F!9. B+-R2E,CUHX"QP3,2W1#6C7J6VLDG9<1*]TLZXB0854AGX
M; R +"0HS&2$^*/!%YJ9](F-[0&C6P^>NY0F2S&()BJP,8URMD<'3!D;E:Q.
MSE:])G)CK5:_4**X4%FO8"PR]<2(7VKJ+OEMH^MR*-;2*XSM2SXF@];(MLAF
M-7EV.,%*6)YPLZ\\RVW&8"@RBH^7,Y9?+*&0'<=IJ>^OAZM>U=@]UC/0!PEN
MO79Y&8,B#"S#9F=WDY2C:6W.(^LFWR'71UOE\EB<&=L%.C'4.0ZZI@FR,X#I
M/>'5L792L2G*,6A"K4L/#B=XSLO7#+_%9?"I=1-+NVOM-7>OQRQ21O,<U(IU
M9$X&+.)FL5V?8;+!G++SA0D>Y36112">>)38S+)>(V(:3()SH,&3-C#V:MO)
M53..#8N;M9.3C87"YH!#.+#B0DVLN0<Q-",G<<G([M",Y1IC=;8K+872^6I0
MLV)ZN!&>+H5^H>VQ8437KX3/9-6K!EC(5[ KDCE'&-D35HM.P409U%U[U6;(
M&LT6TWF+;[R ?T5U+["N==K@+744_%>U#O8%5QY]:I!&J#4NA:5-(#R0H6>>
M07EHCO#19$CW><]#<P-*;V@595ZI6RN$IUC&+<D&39'%%/,3<,+$W8MF$)P)
M,3..+R:<X0^*WS;#=(><KQQ%_+#R67ISTAKK-Y2E1J80=R$]-ZMIT W'E,V-
MKM*KBC&">N"W*-DD1R!7,?><K9YZF]:.VP'4AF3)Q\S9*U4WB09D1+C@C=NJ
M@VY@&SH91EFY1QLL*< 9D6"'5Y]>%S#<.&6*P78Y3V=P/@2ZU<MB;#$P@FL-
M KDBY15[$ZQG$7JWK2G$@C;!D>!B1%*0QS9Q\?T9]>X*62J8T#VK<[5ZCCI'
MJQK%'4MY+' RE.-NJ]J.4@ M6W3>=T6/-2KEMB'9L!E"QU.MRNI"I6JB4F^U
M>9=1=5L^R]+UD?8PHZAFD$WMB;"%U!BMEXTTV56$947E,UK8$%V,.V!2FR?I
MF1D,JQC+&:.&L5[=FH>-8AP4LF:82SMB>#4Z9+#G'* AL5V'%SU)M*=2T\.%
MYR'+GHEUSCLAB,5F,>7*U\=?SVEJ ;U4&(M-8GF\W7QD*-D9K5AZD7LDC0S(
MI#!F<5$_'  K$&>&U8ZCZ,N4 RR,M#X&VWJYZRJ=P:BA/@U8;_1EVB.5K,-Q
M9]!>$]-)4FW" 98V'%5PL2!K:C&?0EJ\^8U_@:TT3;D QJ]6M=L5GD7KPU+3
M D,TFZGJY-&%JN0HQ$(8<"[R'N,S#Z+:XQ+DI\-?(3J9++Y3 8[)Q%5[#=S.
M)?(0L4!2>XUD4BGQ62K5+-NM7HV;%1XCM<-FE.S\].]2%0W3+#Q 5;NM=^$N
MJ:7N>K/VV#7XK-CH=W4^U GP$@[+8),28-EL)AEAYN.)D)<DQ9 S!,>]ZZF<
MCAK&-B2135C=3?LXT[5Y&DX;=79YPFY0!C*,XOQ#D*1&VC*).KFW"JZ8USC-
M5$JCIT<K2[?IW%ZIQ\\D*D.-[#Y9YQ"8+5+]V8B@)!A60VX5IM(@Y@:P&76M
MIFN;O>]\7+>[HJ[D]<TW4FTR^E:X-K@6I$"YZP54!7B=JMEIFV^OV9&83A>P
M)%5P(#9"*:&BI!(G/(O&8C8G9N5:N*K8IB587+.0HCR9IF+8@,03F,,%<$:Y
M0/Q,,+D,4KEWF1H#A!AR<G+P>6R^K\IJ^5?+6,'B]-ZALZ5HUZ-7&GLW+F/I
M4K&0R61-DZ5]NJE9NL"C4J0J/$%>1[!CRM#A6S3V_!^L:H2B;-DD[8;T_6:"
MC?=^J8<5&JU;,6 9$>(6":+DF(!9@=B(M-Q*P*\)-+ 5LE$?4VYC&6DXFQ4[
MUB$J,85Q9 ]M\34L$)(YAAG)H!@1AS&\^)NS#F8@F*:$FW9^;[4M8@P&..//
MDL9&WIFAAFUCF<=6KCQ]&U<KCF>Z:O.R&S ##=LG8#2K6GIT3CF[29GBW[*Z
MI*Q'LJZPS0-F3G\;:+Z/9)1(5*P+D[)&4EW8$8*RN7>8L],0W767'1AV0/8!
M1Y:?5#I$*YG')C@CN%CO;HQC\'CRCPE*SQQI3M-4D5^&K*+R$9V:8HRD5XOQ
M"@5MU).D"A"_+'QPV>--M26=)Q.,6*:N3. Q4LR.K!R9<9F%:HQ>0+<P0J#(
MW57#59+'-=6M8(Q:RJMZSVU;"]HH^S[U%K0$=0\G(433=Y"Z[V0#G8*[!%"E
MV*O6<]"B(B#"I*":3AW%?)%9&8\>1=]/GA(_77<?7&"U1JR.6=OJIRR54MRD
M6'5TR$ZDP!2EQ3'"8N770''BE'!'I(QYQT'HX'4>1LY#$Y_+CH5 8A[8A:7R
MU3"9VH9K&:KUWNTK]T(V&"P<-IN+L1[,WA">Q"^I_7)N1K;(N';) 3;3E49H
M5J>#1QH"P/72A3=B@\#<EB, P18R#B-0R9 6(G# E@GQ0AB;"FM$4P,),'=$
MUWK) 8N/:P]L#$E,H6K6XTR\?5PD*#];)Y0A,D)E%"1!QE%X<>[7U_@[<\$]
M<61)4U(^.CA\C*K %.[+*X<V;J=1VDX;)X/4%$1S5ZQ@5;AAU;)1%B=@ZR*Z
MOZ*5!0+!BG7T9#/MG'::T>=UN"D7=%4FFA=M^#V2FQHL5I=:*"(XZ>W89()<
MU^PUUT"DQ#GNRHN8FG;0RR#VBH20G$UEPM=*U5SQ&2OUW!2>3]>,DIP<,2M%
M@F8O5RBT9:-?I+Q%BH&ZV,S%<5R-N6+C<E@ZD\LV/+:!D>Q=HS@QQ>C8K0 9
MKI*;EG=I2IM9$:1!ZIM[J?Q)U.2L^GDVILL.=T22)F)( %%9JL+;%KJ6&*]:
M@EP?:+13S]1.XDDQ<$'-(@?:@MZ4[$=<[)SX["<-^ <CV=QS;*P&-C%D]B>/
MKV-R@)69X.)K MH3F6$"]61HM)FY\W4NOV)IP^0TPV0:R!](V+%F=.H...%J
M+(X[@I9&IDYQLCN3QMOK+%<-0IZ?: 2)(4GY7<YYE?5TX10 ;T,V8W,K=Z=@
MVV+9H=-Q1:P+<A5(I7J4%E2VR%A>JT$G793T(O;IL> NR&),J:0FQ!0L4P_%
M%1$PE]865ZO&_!G8Z\@2L]J.1I6(&LEC%X!8\QFBTAUXRFP1QC&$9$(1VD27
M$WC;>CXV=4OJQLUDAWQ8ML10KR#C+%+%52$8UV6.%8HDF&SDRP"]^U,I3E'7
MKUXS'7$PG_BXZ"1>:MKRN']D7B9*U[M,'MYBR.M519@]9JY:9EM$0C#7P;2(
M9KT6=,S!0,"#1+C8B+"@QI<?#&7')K99ZI[AA4JL8W*!<>X6>PPQ ,"-<DAO
MU_6.:4(\3S+,C.24IO%]]FC*:.CE\?A:-S.98I,+J&GJ6%Z4<<]JY?HY$N2K
M!M1["U:-(9B]4U>J"M*-88@C+#@>4OOL?08C9-ALM@(VFQ"G+1I2XZ+FPA;(
M3,6/6;Q+BS#!B&J<*F24V)IR&PB _(?D"F&L+P^(DK5Z3%:>6)2" , !(P,G
M6RD9$<O%(]6,HC'+@)&/4NTG>;1:)'?N)%N2OG-'UL[=OW#Y&]7?(:6R>DBB
MKQJ.,=#+$&6S:$YJQ2->C(46#.<YUH1WXZQ'?=1\9Z0:\5;L,.-LK8@(3<T:
MBE704(325L'K)I5RK-U*UH<,T\P\(+S!=-K8>Q,#5LB2<,*-4R.A/-RW)NX/
M41AN&<J5,I*SY&-8A.U,X@Y-C]HKNPK(V(.,[)R!>>Y!R+/><F>+1XMKHTI6
M8W10SN;IU\HVFB92O6;%/"Y?TK+'MC<DTK6,LSK625\71K78 >%:P*J!X@%*
M)'+O0;ISIX6?"2T4.RJJ(VT?W>#I<M8Y8</L.S/G21:7%DM#VB:@GPFLIVY#
MP;TM;0^T$G9#,C(F,,#0-4F9LDC)W@*)R8\6++9CQL0E,$1#'&47F\.MZ@ J
MTRM%N,$&9X]8\RSZU70^,JF$T;%LF/K:DN:LJ8LC@>M6S=^=L]DHYQ#$[U>W
MW[F4#4D1XAR%B<XD>N.O6#D;AI--IVS6-PPK[;*K9*G1+9KT7&"0ZC+&^Q;H
M8K!LY*?:L5:-N.%,S*>#]2>RYZI%;9?0N$_B2YWI6R;@QY\;*K7."Q;KW"2+
M*Q&?6UAG$*+.$PF8?#8+QMMQ2=VVFVS+/D]*-D-1X_4XLQD<=?QN(R6%KCJ"
MQI =ERMG'6[A)QNT;<I6'+BZG53XNK'&,V<4^.3K2Y/2G5HRPAVIWB_4_9(F
M\V'8)#:L)^KF+=;SMO"1:S:V;A#L58*5(D(+U\<$&Q \&M"QU;:K5:35XP>.
M'9C+V6S]B3%%8K5+%(E4-.%"3''7KBK%<]=Z\@G'8@099EG(DC$F9S&<\B.1
MW7,GT>8\<JMS'97,8S.U\O=S1M0BG0LY+)6\G4'0R,<D*[0L8T]:Q2!4KBK"
MHUP48T*#8^%:%:$'^EVZ7 5Z5L-9:_7KT^R]4TK4A^;YZW(GH#TFTVRWQ#41
MZ4 =CM'BA:[V%)+&8B@3$)Z#""@Q# ]A&5;.EJ]C8=2IM2OV<@*&QHP<EH%>
MO(4FB9G<,!U0\'QNN>33F4I)3=U.5Z/ZF7?-2LYC+\>=T[BM-W#;T9F:MB<A
MDLF*V.1*<H1N6+.6NL=NK[' 4@BJ5*T 09_9/Z9J[.O)C96;598UUF[-KFV
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M,!N"+,SJ4W"T#!&.O/4AR+L>-JJOPV94>?[/=F6(3'?*#HD0]&>'!&C _+[
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M];FF2Y(ELG9!&&8QU!1'Q$I=,6VV%ZCWH,NZ!\%\U#-AE-B)8P8W49A$M-F
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M@UL!ZT*VJ"H(;7)T-1QQL*>*Z0JNVW:F%FAS>1!&"/I[Q6ZF#-EL:I$2>\9
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MQ'XX^"C&HRNCUZ5\1*9KO(>'5Z<'FTCIX<<H52&EAQ,8!%36+S&EG4B(XJ$
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M\</TH^U.+Z,O8GXVEC^IQUB?<?5?ZY>.'Z4?:G%]&7L3\;2Q_4XZQ/N/JO\
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MF.&<PQ88T2U*EH(<4*GD1S:,.TFOU[%@Q1!L=; HF=\2)0\'0&::Z>^OF8V
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MC!4Q*KQ8/@N1;DN)_P _0SMW;>K_ *[ILWOW?EN^_?X*:A(H:"%# 8:#&&"
MP^&*%#8;26(@\:.C-Q(,&*RC&$,QHD5EIAAI.,);:;2A.,8QCD*5SFZ+WWW>
MK_Q96W7G76XW59H]J,VXXM:([2^ACIA?4TPE6<I:;4^\\\I#>$IRZZXYG&5K
M4K-GE*31C*4G:#/&#.[NT(O)Y.T6=]HL\I2D[-LSRD[][NZJPA#>4QC'"9W8
MAIPA&,C$C%@QF6469R3B(8Q1E-WDPQP@S\,(LW2GE590YL#IWT+M;TRMDZ:U
MC=Y#W?*B%DI%=*%D*5\KL<Q)'K*17OE_9XTQE['?/9>.^>=*IF,M0V[%DKU9
MF_R!M&@-V\G&T^KDWHE%V]"\QFM$Z/U%Q/G=+X#+3GWFOXFC8L,_SH62 >P.
M?E,98R;P=0U^)!K 'C&=57W?^CLX]Z8NL=W7C%?2O'[12:5>I]XHJ$MX[)0R
MBLHCI3W3AK&%+\W1_B>\7?M]7$Y3?_->Q=7K?3_>:L*MKGYN=W\G9>7_ +)\
M!4YZ=S&LM);=P\!JS+M29_\ *[8K+FRV(9H\F:,:#0V;;AV=V?\ /P5]9%0_
M9*7U2T_8\9G\E@)OG2(E<IYG'N2AVXZ>/ZW<;>2G&$^LO5(BM:\^F>0[E*FW
M9[?INR^UK V*3OWEQ.4)LS^;5LB*ZSMW_%:Q#R9V[VC^'>D_&?&Q72%C,X./
M*%36&DZTB2CX-+*:8N8)XS9N762QAW=_C2B[L[2_?PI]9%0_8[GTN4S9$9G\
MM\UH?=POUMUK'O4IJG;AK^N5-O)3C*O5F;@06M6?0LK=SA*W([!INQSK9VS2
MD_)A97&$X6??9M[..-<W;N^,]:'F[,G\0]*&,^+E.C[%YT<><[6C]65^ME'Q
M>.,U/2P?#-FY]7')FW?XL92?9W_/QWM9@_=M;7_4!H[..Z52MF:2NRJ^E:?V
MZ576A0;U1D);QW4M]RRHCI3V5EW&%H\T_P ,7B_[A;Q&4[GX:64JL;9]W;^[
M6YU;6[[;;,%WWY;*6Z6,#4Y:BPNL])/W.3/:3RSTFEXL^6PX<OB&V[WE*_&&
MVS\7-M\3LGQ&^C76E"1L&5O*E7$>_.C#80'71L5<KC,F2%)RXWFLC9WM :W"
MCY7,GR3:1<:,RA+67E394&)*R4M&ZDO6^QQQ=FO-H2G(MP1*U:,6;D_7SAP3
M>3[1A$?'*3ONS<+2E'5SW3CT78'#-FB:NQ63!,PP"IX2W7RF3*6;MO'L%<W7
M 84-RFG::O <(\+R<LQ#)<*L6>OW2N [=4R\&P5FRBH)L";&/IDCRHHE';E0
M9T1]'N<9D1W4.)SG&%)[^5:4K2I./.' :L8M>P.83A)(113;AF,D'>,HR9^Y
MV=G;\6Y+Z=0OTLI1J9+'60W*%^N&W3M@FTPV*QX1($PYMWPG"32;N=M]G9G9
MV6=YB6VG")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G"+@
MSX^G[@FD/M>F_P!C#7,P/EO]5_>RI/N;U_DZZ1>'U\R;IB^R&J?U/F.?RY?6
ME[W5H]S>IO<KB<JI3A$X1<Q/"!&CB_A8]& TM ADQTS1H1F7 (1F9D.2TJ<2
M\S4B-(0XR\WGZ4.(4G/YN:MVC2R54]'(U*M^E:&XK-.Z 5JK8&_>,U<\)B+!
MW9G>,X2;=F?;DMD-JS2M0M4[!ZED!7(&Q6*0!PS9WVF(HI1(.3>$HR9_2KG*
MUG8J7G,G45E]E0D9RM6OK8N89I#V.^<J:#R?2.'J>I65+4CV9(FB&U93CV$I
M..?,GT%FM*NY^C7/?!U2+O-]%ZCE:RNDR-ONX\8?CGF-,O)WG*+8\UK&PD\?
M^R'BVR]HVJ\9G=A:TQ7;#NW"VI,-$%'/P\IW1<,<=F]F:+.]L8+DH[_]H,[K
MW"]NCH\^, V((FZUL<ES#$1L\\R_6#3^>_9%=N4?"0Q%:\>7R09BA9GS+PA0
MO"L9YMX_I+I N PVML;:T'G#S858>8*(V RI7YLV$U0%HXN[*3/'AJ694,GQ
M2:$J#29:]O1=DE8N2TU=!JG%BBY#3Q\)CRU$?GD\&7>]6:/QN*P!K=%FB\FM
MNSLI?QG&<8SC.,XSCOC./?C.,_)G&?IQGGTQG9VW9]V?FSMW.WFO%=W>G")P
MBUNSTRGW: H5<ZI6K<+5A6%#;."%GX"L+QC"L*AE8LN/G"L8QA7=O\K&,8SW
MYG!9LU9]96L'KD_[P!2!GR[OC#E&7+UK1OXO&94+ULICJ.2KOON"_4KW OOR
M?<5@9(<VY/\ %YKEWU;>$AH;?@ZJKU,+J_3Y91%H;E')]/K+3%?-58CZ%H]$
MS4AD@6(8.QTQXTP'/BHA-9=9?@$?21I;4@?[G3W2#E<1.QV^9\N$E=XBA9.[
MF$>&[AEVB<2$<3[O$L)/)]GC.&THNT_S[TD_[-FCM9@Q[Z<KX_1=ZMD(EMFQ
M>/C"G;QY^"-P3XT$Z]6%N$80+4,.(H\<9A/Q#*TPV J'0F#H%6KU0I74GU<U
MD160X\*+BC]RM2X,:*.BMQ64Q QZKF@8]C"6\*;'#AL49%3G#$.$Q&0VRGD6
M-4EMG-8LX73QR'),LY3QKQD\IR>3\1 G$2;\^<YSD27?*3N[NO:8SHBJ8;'4
ML9BM==)-&M0J@J5QAU1$HAC .(X,.M<Q]JJ"&T6X0  .N-OB"% ;-%MC_%IW
M,,_^&.N/J)BIQ^U1:ZQT\75/;_NK5.TM ?6GZ._ITN]O_F>;\KF'X:QLV_GZ
M7P\G\7 ?,5G]D<G.+>S;[.2WOX$U17_W#I:UN-O!LC0T1E6^URZ4#-V_\;/X
M[[\T_ YU?P__ ';UGB)_;/Y.+?TS4@IYL8^3#N:I<:)YLY]WFRWAKZ?+A/N[
M/A+3LOEZ:)#_ -WS=H?L[16M\O7N_I3^&.DL7^!THUC;=WPGH/$V-_K?!V3Q
M&[^?#P,_@S)\&^O<7^1$VUTJVQM/_&=TAM&K2G,8^3NZ%W<;C,Y5].<07NV<
M^[&>WO==I,G.6/SU?S864H'BWGR+BQ2?EW?&9.P],-?D/4G1YDHMXV])ZAQQ
M)>N575EP<?3L*7H[N;!+K_@=U.4_I!LZ4>_*8NP=R4U]W&/H;1)UQ=&&UY^C
M#DK*<?2O/;WN#24^ZSJ$&_C*GC;+-]V[6=_+DS>:ES],@>;XSHTR#-WM#-:G
MQ4Y-X[-/!9:+/Y;SV\W3\*G6@/\ R272-KHSY/<I^H]4,-W+OY\M1+7J&KX1
MW^A+L['T8RK'R\=@TU/Y&H;@_)K&"DWME7R-C\(J/XAZ4@\K'1M@[.W?/&=(
M Y\7U1Y'3..V]#2+ZW9/QA>H<?CSG^AG;OHD_MWJCM/IYM/R?+Z*-+V=7)[O
MN]Z>\1O*ODSA.?=PV'P\^0M4XYG\&LT<P#VRC1/!O3\9_7Y/XUUJ#G<Z)-2O
M%N^6,U#HG(-_X8&U!0-+T?RF]+,J 5[Q<+<0ZR3&C3/39LT;18D6;7454?59
MECWX+MPB.\4FGB=4KL\H-F@'HJ%1U"0<@DI@6F-:HA\C&>6-7ZTW1]7AIH>5
M'FJ,[4I0,YYV(AQ)*Y),.(H6#0'.!FD[2:98PWGQ D*$F:;?&:/^TGDC]*-K
M2%K0F?!B!B+2;'AQY+VL:^3K0E8+<L8ZD:Q7+2F-G&]>H0[P P\@.Z<<WKO?
M_/7/I"#[K6%WY0G,9[91=.F+J$$H3GZ?22F-;38+:<8]_I')26\X]^%YQG&<
M^2_A;*3V>N7$VV?_ .K9S$$?[KW8S=_0T=_1R?;[-_:YI,7+(U=8X>7BV5T!
MK6LS>LD<$4+,WB[D:/I7WC=?71P^ZEB3U!4($^O/;#%NDD:4]C/O]RVK</".
M-YQVSW](E/;MGOV[9Y$M):D9MXXBV9O.M&%IO;6F5G[_  5X=,?1A*;#+K3#
M4IOW0R9#8F7VQR8:CQ].[-MXJ3@?4WTW6;R8KG4%I(\ISMA" ^U:*1<SG/R)
M]'$.NN87[^V493A>,^[.,9]W-$N$S0=^NQ&3%MONY*%J#<N]]Y"9MO3W+OU-
M>Z&O[=AUGI2YQ;;-6U#B#N[OR9N$=R3[[\MMM]^6REL6="'&O3A3(HPSVPKT
MPLC$(->7/R*])$>>1VS]&>_;/.>011/L49!OY$A*#^R3,O25[E2W'CJVJ]F'
M?Q5SB-';SXARDWXK*\QK83A%_*U)0E2UJ2A"$Y4M:\X2E*4XSE2E*SG&$I3C
M&<YSG.,8QC.<Y[<=_<H=V9G=W9F9G=W=]F9FYN[N_)F9N;N_<O,/(0"T&&4%
MS8A(81BQYP\B/DLS(,^%*:2_%F0Y<=;D>5%DL+0]'D,.+:>:6EQM:D*QG-IP
MF.<ADC*$X2>,X3B\9PE%]I1E&3,\91=G9V=F=G;9VW6,)@V0BL5RB. XX& <
M)(E"81(M,91%@\H$&2#M*$X2>,HNTHN[.SKU\JLJ<(G")PB<(G")PB<(J=V'
MY_>IOT2=\_WN]/?+-\B7UH^Z:CQ;U/[XJXG*J53OP^_F5]-OV7@_Z9')EWOZ
MW]Z*XG(1.$3A%Q6Z<>JOI>T]UL^*V VWU(Z$U:>+=4VF9PH)L;<.O*07)PAW
M11TU@2$P>-LUB&3)L6"=%DPLR1&9<:BEATX<^M$R)(9;*[L[M#9G?XK^'TY+
MH;"ZV>C,EV]G=7'3&0\W;R^I;[U5*\W?Y.WH+6YW[_1V^7Z.%79_)_8ZV^%U
M+].)+M[.Z@-)3_-V\OJ6UJ)*[]_D[>@/.=^_T=OEX39_)UM\':^K2?;V;LJ@
M$._;MZC<:[+[]_D[>@(N=^_T=OEX4+;89<20QC, H.G85^US#FQI.,_^&675
M]_\ TX19'A$X148ZP^@#2G6,(KS-K872K77K#$*-7VHC!35FG!77V4V*MD7G
MV/1$(QB"WV@2R")C@$NU$*1V94;!(45]3IS5V3TV0SUY-9KF#(;U+$R.")&9
M^I-!F?>$A2?XT8/%BC>0Y.S\$Q_(^D[H:TITH5J4,E"6+R-*Z.Q',8T%>%\M
M64X->HGG.'"8=H,=A$,Q7IV8BL#B2#'KV/:#\.[I(K0<:% :[L(..+AQX;$B
MO[;W'6)SN([>$9E2959OP=;LV0O"I$F1C"5/2'''<XQE7;%2ZPU <DRFN!+(
MDI2=C8_''@W$^_#&)ZA&:+-LT6Y[,S-X+-4Z$^C>A5KU*>$NU!U@P#"=+4FI
MZ!I-"+,Y)DH9BJ\BS=N,D^3RF[R?FZROXD^O(?NK>UNJJHMX]Z& 75/O!^*C
MM^U[1+#<CT5S"?HP\R[CM[LXSC.<9Q_Q/<GS/0P-A_&1<#BVD_\ X@UA2Y^.
MSLMANBG""_W'472'C6;DT*G2'JT@F;P;JKV4N#?;PXH2V3\4NQ0_R@76%U?"
M%I][:95ZUU:V$YQ\F'$735-A?>3^?"I.%9[8[K^7N_B ,O\ %T[IXC>/#5N5
MW?[:U\+-]C*?[.+H^=3I,Z2ZKM\EIY?!Y&#.W=Q1RVG;TI-YMQL[^+I^ /J6
M@_DANN78KS:?^S:MVF-!6#&,?1AU\-1JC->_-G.9259]^<93G/'PMA)_XNEJ
M;._>]?)98/L8MJS%ONNH;1VNP\JO2WG)Q;Y,<GI?1MW[)3J8C&%EZ?CL_+D[
M)^#3K:&X\X[JIU%8?+^UCV[I?EQ_2=OD]+-JN[PN,=_D5Z* C\Z<)^3CMNF)
M[L3 Y$6_C7SD7V]4;&++R]<W?UH^!Z5@<Z_2'IJYMW0R?1^6+OY<1<=JVFWK
MX0-Z&;N3,7Q 87N2;Z/++A/R976-TTI;F,?][*+;?4M*5].4H<2G/?LG..V.
M&EI*7>+40/4?&6MO;7J;[>OGYLG5],HO_6^C*_MW.^/U3BGEZ]LEF&B[^.S.
MWDR_?A=UX"??/T=TRVY./?VK/4'L.MO+QC\S=CT).9:5GZ$YDNIQ\F5_3QV?
M2I-^#*9NN_AU^'IF9O6X<M%W^ZR?"73!6?<NDM!9*+?_ %'6F;HS?_PW='&A
M%W\NLDS>;KFKN+K<\0NJ=;NI=5PNG5 X#+@LS,Z<JQH?=VMI@"B$1[!8\;6E
MAZ] %_!5U#RH<IR)6Q-7F1LNW#U\;-2M?M<;I?1]C2^1ORS+S-"3Q;(G%*J]
M L'>00]@B4TR=H9V:46D8AXRVK\$X\OA&J.ECIKQW2SIK3H=$1#2*&!7TQC[
M8,JVH:9V:%Z]_$1:M(-;X.DTG$20Z-:@0?%D^N 5G?I3^-1?1N/):>B[JK%.
MISV<<!#--WN$CM\N4O5+<1":]C&?D]".7YL>_'T8SXKX!J3?^[ZEP!&VY=:3
M)5)/Z-K&.A%OMFR^[MTAY@'+(=%G2)6DWRI5 :7RXF[M]I8S4]@LN_\ R@=W
MVY-OR3'6OK^%[[3J?JII36,]G))_I>W/,A-_][S3JI4[+"7A/_%EE]W';WX[
MX]_'\,VY[]1D,#9?PB'.XV,W]4;%@$O:S(_2KA0_^D-.=(>+C_F);Z/]4F%'
MSW-C<;?$_KC.3)CK]Z2&L]BNVVZOG_BQ=Z1LBA^C_@>^&=/!>ASCZ<.^3M\N
M>V./X3U [;CQ_7^/]UM4K6_J[-9+O]F_EWI_;)T;Q_WC4D<?X/\ "V*SF'X?
MK?"F,I\&WCQ;;>*W4)UB])EC\B0W4QH>8ZYV\D7\*]'CS5=_D_Z#+-L3,?\
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M>7_R>QK)!\G\'D\O;Z.$XI>;\O3^_P#3P7Y\3WX=B/\ 9- SQ?;]K[$W9U!
MO+_Y/8VUH/D_@\GE[?1VX3B?S_!OT3XH;H21_L=(W<*SC'9.0G6CUK!/)_Y,
M"NH6(E';Z/*G';MC\V.$XI>CR[F?EY=R?%-]*T?_ -S6[K,KO;]I@)X@W7 Q
MZ/\ -A'K6_9G;M]'?O\ P]^$XG\H_<A_2GQ6VJ&/_=74]XCX1/;LEL?XB75F
MZTG&/DQAHILXDVK"?HPM*\8_-PG$_BT7_P#"S>YF7[\66":_V#K?\3"!VQV3
M_P"VKL8OY>WR?_$C!OS9_A<\_?Z>_"<7HC[&3XMTLS_L'B)^)? ^3M_[0]*+
M^7M\G_Q'IPWA7\/I//C/T]^$XOHQ\^Y_R=O9W+\^+RV;'[Y&^*+XDT-6/>G$
MJZ=+!IO&<?)A23/29-<6G\^,N]\^[NK/O[DXF^9'_P W]7NV;T=R_?Q&.IV'
MW]C>+%ULL=L]T>VZ'T26+M^;S^M=*4;TG\/?MC/YN$XF^9'_ ,_]2_/Q/>N>
M/[H/BV;\=1C/Y*#?2_T0$O=^9;D#0P1]?\.<.IS^;MPF\?F-]CR]'F[^GVKY
M*Z3O$&:D-2X_BF%Y4EAI^.Q(.=%?3;-D-QY*X[DAC#P=BNN)9D.1(KDAMI32
M'EQHZUIRIEO*9W?9X[OPN[.[;OL[LSLSNW<[LTI,S][,[[=[JCQ$\XD<4')&
M,X1)M\>,"2A*<(R?>483<8WG%GVD\(.^[PCM]OQ;_$Q8QCU7Q-M?2<X^3)OH
M%H\SS?F\_L;>E<[_ ,/D]'W^CMR.?[;P]OX_@K[Q^;^+K\_ ;XJT/WQ?$(Z8
M"_;Y&S?A[GXOF_-E;H;K+C_+[L9\K*<8]^<8^C!-X_-E]DF_.+IG7GB\PO=&
MZI^@,[C'N_ZZZ,]ZB\KQ_P#B]D=9+N$^;Z>R<XQ]&,\)\3RE]YG_  X6W]JT
MHWIKQ1S^%XLA#PF[MA??SX.=,/4/&]-G/RY<S.WU:\8RK_B[I<]_Y\>[FR*[
M<!MU%NR';NZHY1[>K@FRY5O!8*_Q=NPV,N\7?VO'T[&_IEUP)[[_ &^M0\;Z
M,>M0WY\E^FCP6#KJ^_GE-:EW?4IKF<_+E4X>,-S$9SGOG&?3N93G/?'?/?.>
MB+4FH0\AYO*Q;YKW[4H;?4D64>[T<UYBWT7=&E[=[6@M(DF^^Y&T[B1E??Q<
MH:HB[_\ CY>#K4,]#G6S!SW$],OAL"\I]Z,T;JMZ]=293_\ 833M<OHC^_WI
MPW^2GMCW9[<V/XLU _\ B7HG_P#>J="WOY;]IJEW].^_>_>N:W0YT;0_W;3Y
M<?XQ^"<UG\1P>B'P7EZC0;;NX6BS/W1Y,L!:^DGQ/I]8L58%4?48>$>"DPV6
M*GXK76U*%LMDH3\-2G >R.E^RCYL=.'O^D0I.<M2V?/%=<]$XI7,]?5=L1PG
M-C<#9D$HR;SPF.#-WA-IML6M7#*$N7*3?)?:3,[LM+)=#V$MX^]CZ6JND;%"
MN5+%7A#KK4EVO")Q3%\:IE,G=$8;-+XPI;,2&XY29I.Z@CI\Z%/%+Z4W[8QK
M^I BD&U(!/R7-;]; #4T=<T:S,2^DI6KYT9;O&&5L.2U-###$ROS,Q/3-2H>
M,/I;C^BU/KNCF35>JP5&T&N+=R96!Y'8A8P<@Q/3M5W@*$FVWD0C%DS3:$&9
MN+YCT4?[/F>T/1RW;>D34&(NY&YLU;2!,=#'SJU)F'4LVXYS$Y*)K=@<V)PB
MKUWJ#DX)&LN^X[+_ /[ZD;C_ *'K.Y+PG.>V,=8?1];/=C/?'Y5AZ%ZDISZ<
M?EJ:SGW=_+CW<\O\,XN7^)I;$]__  K>:%[&;)R9O8^R^MOH75@O]UZ7M9Q;
MP:WAM"7'\^;RTJ)W\N_\.;/AMXW4+M_^P^Z3^WR]MI]!YG*NW_\ I-=87A7_
M .1G_P O?W/A3 O\K2X6_P#99?)Q^W^:0W=]J-I+I!@_\OI:N$;_ /JM%Z7)
MW?\ NM>EW^/=Z%^?AG\;@?[U]*]V(83^9'0F8RK./X6>L^AJ5C/_ -IG/YO+
M\F(?(:;EWZ=MQ](L[-MO4Q<>;]O[)_AOI/A_A])V'(_AVOH\"3P[G>KJ6GON
M_BT6Y>"_<=67C*!O]OZ%+T5PGOYO+KOIAGY5V^C'P>\2UK&>^<?*C'O[^[O[
ML<GM.E)?*Q.;%_[/,TR;?_$Q#;^W\.2CX*Z7A?X>L] V]N[M6A<[7W]?9M:2
MV^QG3/7]XJ@_W$_#;V[+4GY<PM/Z[;;SV^7\H3UZVUS&._R90R[G./?Y?S1Q
M:2?_ (.HA_\ YG&&_#L@/?\ ZSU'3+#_ /B'1A9;Q_[*U72W]3/F+SM]K/MW
M\_'\^,M\1R#_ +?X86ZW^V.ZO+K>TQ\Y_@Q\'+7?TXSCZ?(IW\R<JY/#I)_^
M-J,?_P"5QA?_ /K#ZO!0Y.F6#NW8NC"SMW?]K:KI;MZWPEYHOW^?ES5>>H;Q
M'?$FN@:JPZGTC;RZ8D";C6Y)"S2]6[)E_#0Q+*QXU6I,6;:*,*'>IE3&&XI&
MNQVR$NUKECP^'<PG9XXC['1^)T1>->:Q<LV9PID>-?*A!0B,/!)[%D4@6[$"
M%!!N)IN0<J\>(S0D\6(/XATUZOZ?-/T=/OC<+B<:$^9K1+D='7K^HRV;O7"C
MC<5<#?PV,-5JW[$NKD.-6P/(3ZNE.P-IRK6^HG3SXC:]DMZLI6T^E?K5UGMJ
MXOA*[97B/1AU+"M1@K.0DI@.SYFR#^O88&O57+N4399>P$&1@..ZXU),SHT3
MVK*^;Y"%(5ZT/'F+8HP/.-4Y1]60H6?XDI0\-V[I.T'DS-*0Q.[CC^HM.&SE
MK 8FUJ2E4QN>/0KERV/I6>U5JMR4&<PA%DS;M%W;B&TS1#-Y!A9M1&UDM4/'
MT_<$TA]KTW^QAKF$'RW^J_O9=:?<WK_)UTB\/KYDW3%]D-4_J?,<_ER^M+WN
MK1[F]3>Y7$Y52G")PBYH^#A_NONB?[$07]>)\*T_ER^M+WNNEW"JG")PBQA@
M*(L Z2(.C(!@7,1EN4/)1&)L-]'T8<CR$.-*RG/Y2593YD*QA2,X5C&<:&3Q
M6,S5(^-R^/IY3'V8\%BE?K"MU31\&($\)CD[/SB[QXHR9I1=I,SK:I7KN-LB
MNX^W8HVP2X@V:IB ..7G HI1FV_<[,^SMNSL[.[*)/P>W"C?L^J;)AT0W^5G
M75YDS2E?PWCO^P5VQ=Y-@K&<8[X8C.*-!T+SC"1T=O'?'S7^"M3:1_F]'6=Z
MW&#Y_P #ZNL6\AA8C;;<.#SG]XS> =HL[! 666Q<)R9HT0P;=O:?Q+A-0?$U
MABWA=GR_B?3X:]3)O)]OYF4QG\G&9?GS(6+4+TF9WE:+)]GRP3;89\E'K=R'
M$-=6Z0KT<<+:,L(@%W<=L*^#-FCK6"L+>59QAMJ+*:)Y_P#G#&,XRG'1Q/25
MBS7P8+5-&YH?4IWZL&*U X8T\D1MF?X SX92P^;@\I,T!U[ [_/^;0"[/%M*
M_HR\.J7*8.S6U/AA1XRWL1UDK%*#\V^%L41HY'&29OE3,&=3_N[9&YJ6.?2%
MXY.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3.,9]V<=\?FSPBQ<P(%(XRD@(%SD
MYQVSB8/B2L9Q^;.'V5XSC^#/"+49VH]4D_-[2UCKTAYN_F]>I=;E^;O\OF].
M-<[]_I[\(M1F],?383\WM+I[T<0\W?S>NZGH4OS=_E\WIP#G?O\ 3W[]^%.[
M^;^7?X>2T^=T1=%Q/O[2Z0^E\AYO>KU[06J9?FSGY<Y]/4W._P#Z\)N_F_M=
M:A.\.#P\2??)#H.Z,YN5>]2I73!I)Y6>_P"=3E(4K/\ ZYX4\4F[I2;[76H3
M?"E\,N?W]/T ]'[??OW]2Z>]7C?E_-[.K47R_P 'E[=OH[<)QS^=+[S_ *K5
MI'@[>%S(5Y_Q%>G2*OOG/F&4 >(5C.?I3D7F'E.?S93V[?1VX3CE\YW]?/WK
MS_$Z^&DC_9.E"E"_HQ[$L.PP/EQ]&$>QKC \G;Z/)Y>WT=N$XY>;^'X>7E]B
M\D[P</#H(178,C0YY$)_",/0X6_^I09%<PTXAYKS1QVX(C6?1/-MNM_D?L;B
M$K1V4G&<7&0@9Q((DQ$COPS'.4)QW9XOPRB[.V\7=GV?FS[/R6"R"O=!.M<K
M@MUB</65[(!6 $X)1G#C$6$QRX9QC./%%^&<8R;:3,[>KXHKH@:]X^O]0X97
M_"H)UR]<8OR9Q\F4(B=1;;2>W;';'H_+CMV[=N46?CEZ/NQ\MO+R4S&([<3K
MRT]%9])Z&-TA;TCM>E==D.^C9VUT\MH](^^MQ]YSRIQYW7G%NN*[K<6I:LJS
M9OD2^M'W35/%O4_OBKE<JI5._#[^97TV_9>#_ID<F7>_K?WHK26"V5:IQVI5
MJLH"M17\OX8DGS X.P]ZJRJ3)]$\1D1VW/5HR%R)'D5GT#"%O.^1M*E8A%\Y
MURJ R>,%DK57!Y,TF*L..FG!D6<51.E-P8*QL1^4V_.1,FO,PXBHS;J9,MUJ
M.SE;SB$9(MDX1<T>BOYX7BU_I8:-_P"1+I=X5I=T/JO_ ,\ETNX54X1.$3A$
MX1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1?F
M<8S[LXQG'?&??CO[\9QG&?\ QQG&,XS]&<8SCW\)^_9W+]X1<&?'T_<$TA]K
MTW^QAKF8'RW^J_O94GW-Z_R==(O#Z^9-TQ?9#5/ZGS'/Y<OK2][JT>YO4WN6
M@=3NWKEKO9CHUDR5'T\A1-?+'W*OR9[@70-N(;$L0V7?]Y!1L=[,_7%\$H@"
M*[,+LD@L8K0K-!GQZX*)&KD),V_AOS[O/EW-ZOS]3/#O^3OZ&9]W]/-FVV;\
MUXYNYKVW!.;208))=$]<]>Z>X]12^OV&YK:9M"M:)F#\A^WJ[Q25-,S=GQSR
MT>WL$LPQ:"B:JU@,J=F[O.+RW]+,[^7HVV[OM3GW[^.WHVY;^/AXOYL[=RG7
MJ(ZIJQTVNU)JQZHZF-FYN+9QR&OIZZ<ML[\:#8 J$I?3;'-85JPHJSA#)AG(
M1!K,11I,,LH?A_ J;Z&BR-'??G%MO-V;V;JM'@V+PYX771(YA*TX<T< 7A+B
M%-N)PJ:25A*VUXPI"\=^RD*QA25=TYQC.,\)/Y4OK/[W73'A53A$X1.$3A%B
M3@$)91L@/81(\T*E)\L@>3B,38KO;OY599?0M&'$9SYFW4XPXTO&%MJ2O&%8
MYN6P^*SU ^+S6.I97'68\)Z5^L*U7)W[2<1HSBTX._$,D68@Y;3'*,F9VW*&
M1OXJT*]C;EFA<"^XK-0Q &AYLTQRC+AEW3@[O&<=XR9XN[+G?U(WLGHYZ%0=
M9WVQLI*QV"DZO$)2#::=$C38\@6V#.S_ $IR T15%=;<"2YA",@:E66TQ6)C
M*'?Q)TZ:PO\ 1(6IHW06L<X*.0"'(6\)<LME6TO6KVPGQX\3F+;DR],5Z5<@
MYXFS:N@C0C)X-7#9%$GZ:Z+=.5.D"%C4>J].8LG9"$J5\E6"]!\X<H""MSR&
M.KM#'V)U6+&<;X 52RM.S2<Q DE"Q&M^H,]>*D.M6=36F>/>R[#F3Z>3K)]+
M).%G#4UMX-+,!SL3&5]I+3&8,ISU5^.MMR0EQ#B_MVA>FG,:MTW2U$_1OJ&[
M2*\ZMFYIC(8',L*_5>([8RXNSD\9EZV\G8XP]DL3[.8,X3-&<22^9:IZ-<=I
M_,VL.VLL16M":)PULW4RV.<E4[/,$AW@TKN.-\7<4B=H"SF&6,H">+Q;>\;W
MUY&SA%ADV"EO]\86U=*A:*VVWWSC&,J($!+8G*<YSV\[9!:,X_*PKRYPK/KV
MZ8-$@=H9JQFM*FWVD/56F=08&$/2]V[CH8UX]_QH791Y;[\.SOYU^CS4Q?C8
MT6-SH^?#/ YK$Y64MMWV:M5N3N,^S?)E6C+PVWY+?0=TI]F2E5<M=</85CNG
M <V-)*^3OVRB')>4G./^)*L84GMG&<8SC//8XG56F,^T7P>HL'F.)MV;&9:C
M>EW;\XUCEDSLS\V=F=O%F7G<A@LWB7=LIA\ICG9W9^W4+55N3[;LYQ09VW[G
M9W9_!WW6S<[ZY2<(G")PB<(G")PB<(G")PBK5U<;,O>H='&+WKP/.*EH%VT\
M'L$L8#D68C3M9V[<-$J.W]F0J]%BSG3$K5>JSEQV*Q#<'DH7I:PAXF-(BV9D
M)\I;;Q?;D_MV?9OM?9E0_476#M?>?4U;.E&J7QJ*'J1SJH* ^H,;6ZJ1F; J
M6I*5T5%*7%B090-=*GI@6_K-GA;.:KX&"P8B:;'Y&/PW+04DI*VS,S/MX-RW
M\]_?MOXLV_-837O7;OW8^E*;U'G PS4E4L>C]$7>L"2E6DR-:6^P['U%-N6R
M+-8-G&%,PQM(J=YGB:B#&AK$*L])K=5NFY=B#[-KA24@RAV9G=N_F_K[]F9N
M7V]WHY/W]0M-[$!W;686P-6LK9<!P82-9+?:*28UA,,3_@F#L4BSS*I8P]?>
M 1#HHQ LK<9$!F"/BDTP\9:<AR&&"AVV^WR??]50OI^\1BK66=U@S=PVVAQZ
MGI2F#NJN@EJ//C''OQ/[/4"$P:NRCQ4HC+_"K2K'0KM%V)6FENSA<BP4N*W&
M0DT,0^4O%^7)^;[>7/T;^AV[_2M%V+U?=1=>ZBS-1@!;2, P]\]&-1@:JDP-
M/3+).K.ZM>[S-W8!&L6"C@AF00+4:NYS.)7&-(!DQAJ,,+/ I$240)MR;T\7
MGX=V_?X^7@K%UGQ$-;W&'3':MJ;?MG*'4T=RZURIZ]3<3>I6+QM^[Z.:EWA%
M2+&QSL*M7?6]YFVJ56R)UD;2*P3N451 ?F"U-*-O2WH]/+?E]CMW[=Z_M[K<
MU_> E8.TR7?Q8Q'4[JW0QZ17(^JS)0?<;7L0G09NOMFUFPV&19->*C$X,-5U
M'N!!^P H&R5DQ7&I&9T_(PFS_AO]FV_?W>CUK%V_Q*M,4O7\7:A&E[/(4&SZ
M@VYO#5YX+ ILM.T:/I68(3<E5^-*ND!P.9DU\W!O=9$VY0!T[3,3)#:X]E&D
MJO$)MS9N6[NS>K?S_/R\5:32V\!FYG]MBV:A;:+9=*;4?U'>JU<55=^?$L*M
M?:]VJ)F09].LMK D!1B@[3I1EAZ.75(B29\P5.C1YHY].2.VWIW_ .GCZE-W
M"A4[L/S^]3?HD[Y_O=Z>^6;Y$OK1]TU'BWJ?WQ5Q.54JG?A]_,KZ;?LO!_TR
M.3+O?UO[T6K]7,6T2;OJ_.O+F-UKL./KO>RQUPN<B&QK@Y55M:WQ:M6'')L:
M0B!9;9*17;96+%%P[,JT/7=C-+$V(4P5"3);N?=MVW;DW?X_OT^CO57[V[FY
M/W^7CZ/WXMNRJ\77)GZ9ZJXL.L&:2>V;TS=-B.G:A&)#ZK8+8EZJ6%UW2@ST
MS*9TX_2]S2RL>6EG"IHPY/CE)R(RRL=UZS=\?1)^+P\=WW];*/!^?>S.WGS;
M9N3-NS[^7V>*Z9;>9WJO6TYK0,_5$3;V%AL"YNY!EN*Z[]$F;%^$&20^CE0E
MC6^Z-Q-P)S$(,M-$%1ERT.QDNM*QJZY\>&P"W@.W'XCM@Z@5:XF7V[=3.N#3
MAS4$"SC=8G8('I@TOK[$FI1;B2,61IH:0I9  :P2)25*L@@P]#R@:["1CB87
M46&U$V3EAKX;\</EKF#R+A=W:MDZ'5]JJR=V;>0^MA\:.\)-+>,G;FNIE,1D
M<1V!LC5)5?(8ZODZ;%VW-2MR*X#MMW-/@E\5V:4=OC,RZQ<[:Y:<(G")PB<(
MG")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(N?'6'U!;"U#
M=!@*!85:LU_+Z;>HK90_;$JL0[$!G[RUN]KMW7.K#THH+*"QH\Y7#-[LSU>;
MR%MM^;KRXE+L@EVMFV"12S;^GFW+?;OY>_;\U6G6O7ON'8>OA'41/%HJ-=QU
MA='?2^3TD\)'NJ:$=1]2Z;0UJ.DS$J#\*F+C5-J=2+Q,?B&4C@ET?7XR!, .
M%#)<KPIV;N]#OOZM_+?OV^QW[_!2!2NJ?=,<GHR'NHX1UQ9]LO5&QW35ZM/%
MY5IIITBB_6"1H#7PF*(G6^TD$CPP@&3N\H!9 =LKNO.H7;%,N=4KU!D00I-N
M_;WMX^/AM]OB[-LNI8<N//B!1X1(];%&QL$N,E>B?C^LCR45J9"D>@E-,R6?
M31GFG/12&6GV_-Y'6FW$J1@JK)<(N#/CZ?N":0^UZ;_8PUS,#Y;_ %7][*D^
MYO7^3KI%X?7S)NF+[(:I_4^8Y_+E]:7O=6CW-ZF]RF>Z:2I%\(6B>;;*(;OM
M,@:[V$-@SDL#+W2!DL_+@5RP1W8\AQN,Q\*[3$S-"/!RT@?8"$"41?BXB-18
MW?EZ'=V];[<_P;V([;_GZ6\E_;FE*&[8G+"J',]&_>HFT9%>Q+QBMR-D0 S
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M1$&P7%)SG"7D9SG//G4^BG#8^4C:,R^H-!6'DY&#IW(//!S*[N[.?3&6AD<
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M*[ S4\W>FG$RW,17Y.71,3I<ASQ\Z5"?D0,UJ 2'-2G&&74X>S;@?[>_;O\
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M];Z6.5WV:N^;QX;6_D]2P<5EGWY;.)G9^7>M"YHG6&/9Y6],YP0VY]=\&6R
MV\VL"%,+MZ6(^ZD%B0Q*:2_&?9D,KQW0\PXAYI>/SI<;4I"L?PXSGGM F#8'
M$H#".*3;Q($D"CDWG&<'E%V]+.Z\T09!3<91S%./*4"0E"<7\GC)F=OM9?;F
M543A$X1.$3A%P9\?3]P32'VO3?[&&N9@?+?ZK^]E2?<WK_)UTB\/KYDW3%]D
M-4_J?,<_ER^M+WNK1[F]3>Y7$Y52G")PBYH^#A_NONB?[$07]>)\*T_ER^M+
MWNNEW"JL6<&NF I<1'+$P+Y460&LG BX;9D,[.B/16RPAPA#(P&R8Y;J9D!<
MX?.AIE,M*DPY3.%L+N*;#*,CC@5ASA-Q%:3C(T9-)QD:$H3>$V;AFT)PEPN_
M#*+[.VO;!*U5LUH6;%.=BN8$+=5Q1M59%'(<;-9SB.%K 'DQ0N8)A,2,7((D
M-X/5'\52Z?73ZO/X]T9^H?G?^'JW_P!VM/\ _P +)_\ S1?._P"SS*?_ (I]
M)7_ZO27_ .SURK(>%=U,O]></:Z>H2YOZ_7,3=G-^K.BV]QP<0T-#4:_P.;A
M(%*.O05)%QB+0!- 55<2%/@\*;^!<CWL->X1M)SQSX>LUQH]E;$L(GP;/B=Y
MO<XWDY&$T]R2@YNU]HVV+L_:8_G8W^SQKV?3$+4C:URL\*Y/A66L7N5XZH"P
MFB!L*P8AC6>U,3]G&>-)L-\'-/CI[Q^#"=5/Q5+I]=/J\_CW1GZA^>"^'JW_
M -VM/_\ PLG_ /-%^B?[/,I_^*?25_\ J])?_L]9G;6N[S9Q.M-4KCV2]ZI8
M@Q<;JL$@M46[[LR%5XL%H-2S+4B33@ZA5]*8?+[/(C61\6>(B2ZB.!(&V\B\
M%X121*8Q8B&!B$(2(1--A!:<GDPQ-.1)M ;/P#:<YR:+-Q3E)MW^@TZTZE.G
M4G:M7IU:U>N2]=D&5R[( HBE:MR &N"5FQ*+FL2!7 )RSEU01P=H1T4[J;8I
M^[V*V_ $8*5:+KTO65"HYP"[*&!M0;/6<L LBM#S.5D6ZN-&2FV1ZYHQZ>^P
M.ASGVXSDEFF[;,WEQ>?BW+9;6WO;;U-SV]K>GO6E3])[Y(B' 9D7BSP9)FKE
MZSDS=V7Y%%(U?JNM^V"\\A+F2YTJ=BWZH)4:N0GQKA6; G4IROSV& Q',];=
MO5RV?EW[Q9OP=OQW4<_+?EY[-OOW[-W;MS?T<E/.J-<[/KUP!&K855G JL[4
M!7F8T77-A[0.6+8E>/ZVM[<#+BUP9%5J8^RC9+$^,.<"+M.*N"]JUP5#EL0[
MMSV;RV]')]V_??X\U+-W>C=O7Z>__IOLK/\ (4IPB<(G")PB<(G")PB<(G")
MPB<(G")PB<(G")PB<(G")PB<(G"*G=A^?WJ;]$G?/][O3WRS?(E]:/NFH\6]
M3^^*N)RJE4[\/OYE?3;]EX/^F1R9=[^M_>BN)R$3A$X1<T>BOYX7BU_I8:-_
MY$NEWA6EW0^J_P#SR72[A53A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$
MX1.$3A$X18"T5<#<PDRN6: DH$(>AQ-@+D2XS4G$=]N2REU<-^.\I"'VFG?)
MZ7"%+;3E2<]L<XNH-/8?5.)M8//4VR&)N]5VJG(]D$#L$T#BB2=4P"O")AC)
MP=8T92A'B9V;9=+$Y?(X*^#*8JR]2_6XWKV8C"68G(.0IO")QE@TI#G.'%P<
M3-)]G;=1##Z7]&#B,$N/HR8!(9,C$($R'8K9'=BS8;Z),60UALZE&'&7VT.(
MSE&<=TX[XSC';GS6K_L_]$5&]4R5+2,:=ZA:!=IV:V<U($E>U5+$]<P^#,1B
MTQ%A&<=XNV\6W9VY+VI^EKI!M5;%*UJ&5BK: 6M8 ;&88D# ,.0BCGQ8YY/&
M<)2B_-GY[[[\U/O/LB^<+!EJO6CR5(.5T$:2K'922PF 12K'R=E8F1WL9QV^
MC..W.1D<!@<PSQR^$Q&4B[;.V1QM.\SMMML[60E9VVY;/X+H4\ME,<[2Q^2R
M%&3/NST[EBJ[/YLX"0=G]+*/G]#:B=<6]&I T*^O/?+]8D$JF]C/T92Y69HE
M2<X_X?+G&,?1CGBS=#W1H0DC TG0Q1I/NY=/FO:;(SL^[/&> MXV479^[9V7
MI!](FM(0B,N?MWQQ;9AY<=7,PV\6>&6!=B^_CNSKX_@=1$_]P[+VT!PGWM-)
MN;EBC-]O?A&(]R@V1.6L?)Z/"D]\>[OC/OYC_LQA6YX?7G21AVCNXQQU3/-U
MQO\ Y6ZG5-3.LXV?_)Q-NW+=N6U_XWD;_P!(Z5T9D=^4YRP4<867=N[DP5C%
M/QOM\IV?;RVY)\$-P#\=QFWX!;"/VC%OUX*E9<QCY$NRZL4JBD_1C*TQ5*S[
M\]N_(_AGI.I\Z'2;3R+1^2'4VB,;8XV;NB2SI_(:<E'EMO.().[MOLSONT_#
M6B;+[6]$V:?$_P :>$U-<#P[][P#EZF99_1%S19N[?9/7=]C<>9\!JRU-I_;
M)&6&S5*6Y_"VP1"6:*COC_A60]V?^+M[\3VOIBHOQ&PW1YJ$<>^-#-Y_3EJ;
M><!7L3GZT7]$[K-OLW%MN[1V?HZM<AY+5^(D_<]O&8G-!CZ)$JY#$EDWIC6[
MO!WY*$]S=35MU=!%0BFN5@+(6FPY4/T]EK]@&20HZ?%6<2GV<^@FPY+C9R.A
MO3!D-OSR7I+#BWH"V>?)^E+I\U)T?4\=5R&AYX;.Y&Y6L5F-GL+FJ!\51N@G
MEFCV \<@&=H#O1JEM8^K!I6"V DD6G(3^^T+T48;5]BX>GJ>.1Q=.N<1^KQ6
M2QML5ZS7-''N_:ARJ$B$K-:.,%LTN$4 DC&%AIM;@ <&V8&(L0=_$H6;'1"D
M!_';&7(LUA#[7G3WSZ-U*5X0ZTK/F:=2MM>,*3G&/TIA<O0S^(QN;Q9FL8_+
M4:V0IF;9GG7M"B8?%'=^ D8S:)!N_$,C2A)FE%V;XODL?:Q.0NXR\)PW*%DU
M2R-]_BF 20Y\+[-Q0=X[PFWQ9P>,X[QDSKAAX^G[@FD/M>F_V,-<[(/EO]5_
M>RY\^YO7^3KI%X?7S)NF+[(:I_4^8Y_+E]:7O=6CW-ZF]RFR^;QU=K(R'!7F
MT>P9IJ2)B,2' EBFA!KQ\ED. ^$]D&")M=IK)TJEP<%DVTH$C%IK3\8>[(=8
M>2B&9W[OWZO/[$=V;O\ WOY^7K687M.@MV;-078F4G$GV*FMOU,GD:U;)0!-
MIC55X_B%D S9GZZMDRU7W2:##D"3$D)AY3+C>E;/W_OU^KT]RG?]^O\ ?[W4
M@<A%S1\'#_=?=$_V(@OZ\3X5I_+E]:7O==+N%5.$3A$X1.$3A$X1.$3A$X1.
M$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X14[L/S^]3?HD[
MY_O=Z>^6;Y$OK1]TU'BWJ?WQ5Q.54JG?A]_,KZ;?LO!_TR.3+O?UO[T5@=B$
M]F0AS+&K*U4SI]]N;)7(O-C)UNL0682&,MQ7Y(0%9"\@B5?D(9A-M#6H,:*P
M2(3)^'H<(47-MX[MZFW_ #9.?A[]OR=5C"=7A&X4DA<JQK_++U.Z;*=U(WVM
MERN53VH5VC6R<#H5<(18S<.46G#:#;R,:R366QJV4U;N+PQ9)4P!/#S9G?D[
MNV^WERW]7^JC?O\ 0S/MO[_!OWZU<BOG!MG A+*&?]:#V$0-."I.4Y1F0-+0
MF9\%_*%?E(]+%D-.>57O3YNV??CE>Y2N='17\\+Q:_TL-&_\B72[PK2[H?5?
M_GDNEW"JOA*DLPHLF9)4I$>(P])?6EMQY2&6&U.NJ2TRAQYU24(5G#;3:W%Y
MQA*$*5G"<X;!Q5:Y[1Y/ %8)3FE&$R2B(,)$))ABC,A'C"+NT!PG.3MPPC*3
MLSY B(<H@"9I%,2 AQ>48,Y"2:$&><Y1A!GD[,\IRC&+<Y29F=U$WX>=7?OZ
M4^YEW_\ ^<Y\W_MBZ/?_ +8R'_\ JVK?_D:]G_9UJ_\ ^SJG_P#G<!_\T4:V
M7JOUZ%O%,KD69(E!S&"?PE*.@[#%DA59CI2 PP.E#&)\[)"?AQE[$6(_EMOR
M+1YE9RG'A,[_ +1VB<5JW2V#KVC6,9D^W_#V0)B<W7/B7ZF+89A4;% -VWVV
MYQB*U>J;@'PRCQ2=XMZG%]#>IK^G\[E"@&&]1>I\%TX9#&&%?;K)/DG):#;)
M6K]FK\!(=:8?'+BC+A;:3R1^'K6.?VI6PK_^WK[8CG_Z>CJJN_\ Z?P_FSSW
M?]L6@'[LCF9;_,T9K6?_ "Z>=>6?H[U8W?4QL?K:ETS'T_YLPRT_8.VB,@WH
M.J4.:Z'C;NNUF!2;@2!28Y &%IE(MUQ)QPX2S0(Z$VDX]6$C!&3HN5!C#,F#
MOLPJF#&CR/>X;+T,]C:^6QL[!*-J)'!*U1O8T\F$<E>;DI9*M3O V**;18]<
M3D@T2CXA$A.7E,CC[6*NFQ]V(H6@<'6L"U5NB9R#&:'#9I&LU2;C)'BZLT^"
M6XY\)(RC'6F-_P"*L<V%2,?#;;]PJ]HM+4, .J<*#9$"*A2=164X$C. 8+ 4
M^8RG:E7)@R+D.NA9B+@-!E2PJ:'*R&NEMOL^S-W-W^;OS\=NY:6[-R[WY_AL
M^WL?DO2]U8U>$<("2E2LPZ,U.O@8.34L;-P<.T+9>NM62Q[0\9*FD(K9FQ[3
MJ.0DEUE;CL9194Z)!<@Q4$6WNW_#?W)O[]OR]_[V7CM74K.AAKG$5K78U=*U
MC5E]V)8".,5&-.K@2KR+F&C&P0RV3(SAR04F5B*;K$8T!@LRPIL1+.CX4A),
M)&EF[N;<W9F;GS[O9W\T=WWVV\._QY[^#\O!3-3=E_#4FZP$KQ*97(4XV (6
MQ<X.VU#LM=9$*G#I@=<E@EZ"2^1F0(4Z%'D^DG@RBI,* *>"E"T;;?A^/[_'
MUJ?W^_W^6^K:7NEELT[>K=D*K*M4K=]BH]98]4$0%104"M4XM @8<BQH"9<M
MR?893"94]Y;KJ?5&UN84EQUT_AZ6_-V_)0WCZ'_)G_-0K%ZF9E@I&G3-1D%W
M&9QSIU9V$?LT6N,%E#MM!H1]\=/#B(3@W!9ZOS89(S*K:1\ :0*CXU?5/CM%
M61D[=^_E+;[/W^";\F=O'A]CNRDD)U/UT^4H "'72;)S;M7J=SU:Q,FPVA]D
M 6^N7*W1<$R3"9/L$P'KU%,$#HWU4FPWB2)9"D#KTB:@=&WCX,^SNWV?KR3?
MVNV^S_GY+P7CJ2C5\7:X!.K7"J&AVM;M:E)A2Z*=L8 K5-95S8A4:Y%CESM1
M9-"H-GQ#@L&2KT8D: 3W_9TRGSZ_83[;U/S;SY[N_J\O1[4WY[;/^'HY\_6O
MX+]655K)6T0[#5K/#"4XC8012RX<"2DRC%<T76NH%YF&+BS\3'&9M'L"F69+
MK<1*3T3$!4=#$K$J.9G?\/Q?;WH[[?\ 5O+?QV]/YJ>Z+;9MO'$I9"K'*I*%
MG)H940U%DQDDFHS463'-!\SHHXA(#3H\QM++Q 6+EHF,3HKD/"8R'WX4K=>$
M3A$X1.$3A$X1.$3A$X1.$3A$X1.$50=L=)L;;5QGW QL,S$?DLQX<(>@/#DP
MQ0^(C*6(43S3&7,M^D6]*=4K.,NRY,A[.$^D\J?S-TD?[. .DG4]S4^3UME*
MICB!6J4HXNM8JXZE6APAJ5^*T*;PXY%L%D[LY+-@Y=H\?"WVS1O3*71>#KX2
MCIFB88ID/8LRO'$>Y9-+<AS; G%I<$1A@S-M (APY\.[S1IS6LO4]-:ICUH>
MM,&#.ER!,B2,2->'PYJDONCO*B=.2^RB:J5*:<SEI2,RW&O+EM#?E^J=%^A+
M/1QI<>E2Z@+J&I4N6CXTYZ$:!:56U)C3H\,;EN)1QMRL6!SW&\7LS'PO",-O
M":XU4'66<GG88@>(L6*X!71BMO:'9."+BA:WE7KN.;UXA#./QVDP8SW:4I;\
M;_'T_<$TA]KTW^QAKGTL'RW^J_O9>+GW-Z_R==(O#Z^9-TQ?9#5/ZGS'/Y<O
MK2][JT>YO4WN7KZC+C0I"LZ?MM=V4^#M7L*QW<E2]'[>V'!+B!1B%)C55LYK
M^AV8.T8L*P,<65<($(TP-6,NN,+ASI@69&AM^]MN7F[>7I_?XH_/E^/J_']]
MZ@N3K^\/"C>MO89UJY%.O^K[IADECI:H;6LX^U*IN:19E&VFW1/LX72!4_7;
MBLD%-YL\1JJ8\[TR&S(MNW)_*#M]NSLW=Z>?^B;>_?\ '?\ ';\?%^;V3ZB-
M>]4UZ=J2NFWJ4H'3XT,;.)N+=WZ<\;[5;')BA.0*QKF=PZJ^"R0B8IA,M'D.
M>V<EHRO,-]E]IU%=GBV^\7?RV?;;\'5:/!LPM/A==$B7%X<<3HX!AQQ*/1I6
MO$TEA2\(\RO)A2NZL(\RO+C/;S9[=\DG\J7UG][KICPJIPB<(M8@7"OD[38*
M;"G(>/UB"'GF(>.V,QF3B93D).,YSW6YAJ,EZ0E*>S#4R"I2N\E.,<"GJ?#7
M]0YG2U6W$F9P%3%W<G5;9G '+QL3J,V[[SFP@1*9FCL(=JH\I;GBS=:QA,E5
MQ&-SAZ\H8W+6+U:B=^;%)CW#&P^VVT8\97&-W?<DP6&9MA.[[/SOKDJ&KCL$
M]7]Q:<U[!CB' NQ1^QYIB5+C3'"D)5'& Y\5 UUD@Q$2F>LQEN1F5#DY:3'P
MIOS9=[-RS;L[^6WXHOL1VT#$7\[19A%$@TQ#H" 5:A@R;9P@6NS>Q9<5J,2G
M2XX,VQ)&:\/DLHA+@MU^#6C\PX0PSEK,-M_U]GZHH^UIU-5:ST2F6.V.H$%#
MC5$B65T>/GXKU6L.RR[H.BABS\IU^4-DV4IZG!BM/9DX'R2@C!M\:T9$NS)>
M.SO^'IV;=_9_T56EOZ//T<]FW[N]>>!U05EV[6$=,]&S2UZ[T[===E5L8'E+
MN_M&3NV0EH=DD38@.07:WJ3X0B/7?8D],=XDT0C)=1#0[&W+[79_1MMS_%3O
M[F=O3OO^BV!/5%JAU"9$1VXS1_I-;1G"D:@7'V>P0V]+I4+78J0Z^&8<:*6-
MZ_5[#4)3/I8.5SF2F(4F!(82V?W^+>&^_N=&=G_#\=G_ #6UT'=M'V.4R&K^
M3C!'(LP5;CF@4\3Z=NLVF92+9%8<DMX;=F5:V0G 9EM"\M8E.,O#WY\)S$K!
MV=O^OHW;VHS[^?L]+M^V4N\A2G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(
MG")PB<(G"*G=A^?WJ;]$G?/][O3WRS?(E]:/NFH\6]3^^*N)RJE4[\/OYE?3
M;]EX/^F1R9=[^M_>BF3<H3:%D 0@>MO@-Z$A,=:N+-W(6(>R1KF8KJ' @]ZN
M#ITIG)9]QMDI+RMAU EN5#AY;E$&R XVWCOZ-O-0_P!GIW]W[]BA<MH#8A1.
MRRK1:A!K)N_1HG3%\:#QS,>N5%5:F["CU2STN"]%D23:@]:V88&RPA1VNQBL
ML"#?9F"(\F:PRW;T\GW;V?AS9O/;T[<VW/??PV_U_%2QL+IPTQMK3430&T:0
M/O>IX@VJBLU,Z_.Q%DQZ6H>[7527QLH?+4] D"X4E*FWVDK>9QE:%(SE&8[U
M+<NY<^/#.U!K70N_O%)U-J&I#J+KJI=5NH$5RJBG)KH\4@ST6=-UA)ICN$)4
MV8K$PT6(D'/327>STMS"/(WA"$E:3N[0W??XOC]:2Z[\*J<(G"*N%WZ7-=;
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MH=)B8@O1VWQS<+*6T-E/$_F[>IW6)KWA^=-E;MUMM4*NV=;=H':^'Q@2]A[
M;'5?\'(^X"1$FM2X]G9,P'9(NZ%1TII1-V,U PF' 8B1GYC4@F[^CQ\&\=N]
MN[P4[]/NE*KTX:1U9HBD2C,^JZGH]>HX4A82#I,X2B@!S,')(I+=SY,S2+K;
MDU^/":B"X2W\PQ, >,8B0F".^[N_FIAX4)PBIW8?G]ZF_1)WS_>[T]\LWR)?
M6C[IJ/%O4_OBKB<JI5._#[^97TV_9>#_ *9')EWOZW]Z*XG(1.$3A%S1Z*_G
MA>+7^EAHW_D2Z7>%:7=#ZK_\\ETNX54X1.$3A$X1.$3A$X1.$3A$X1.$3A$X
M1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$4<SMPZF&;'"Z=);-H,#;-C'2R]?UG
M-MP"-?38R#%D3IDX34WIZ#I"-&@0YL]UV+!=2B#!G3,Y]6A2G6B;/W[<O-;4
M+LU<.$K('#'@Y8M3BD4';1HXC$FSJR9G Q-FA"3T6.ZX^))2ZX>!GH\*<AB2
M\',#"3;:H<Z*\Z19SA$X1<&?'T_<$TA]KTW^QAKF8'RW^J_O94GW-Z_R==(O
M#Z^9-TQ?9#5/ZGS'/Y<OK2][JT>YO4WN5Q.54J$9^_J0./DA#S!M0H)LFL:A
M-W)J.-S51.Q[A#!R -9DO+*H,O.RIEIJ@%TC!"2Q$2Q60>&DD&Y<4VD3.WXL
M[_8W_1_9Z6WC?]/;^V]OK4W<A2N:/@X?[K[HG^Q$%_7B?"M/Y<OK2][KI=PJ
MIPB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<
M(G")PB<(G"*G=A^?WJ;]$G?/][O3WRS?(E]:/NFH\6]3^^*N)RJE4[\/OYE?
M3;]EX/\ ID<F7>_K?WHKB<A%3/:V_+C7B'4Y+J;0U([I:U-6MCD1<Z)AYR^&
M" 6W7@[79$Q3B5B!K-)K$&$%GC\(E(LM@<GD/6Q@3V06EF[O3^'@S^W?_3O4
M._?Z.;]WL_/P\%8NU[4U[0=:D]P7ZV!:/K8%6F[?8+A:I\<,#K]=7&9EJ*&9
M\IQ$:!%89?;R^Z\YA#6<]LJ^GD*6Y]S.[OX;<_8N%/2;XG7AYU+JD\3*TV;K
M-Z=@5<V;U*:?LNO3939]:B#;E7P_1QT[4TJ8KLIV:EHF/'VNNG:]*E1E+:9+
M"9\):L/1G$I+(\);0^++Y+MW/\Z3\_L=E?[XWKPO/K[=+7\K]2_U#A5X)_-E
M]U_T3XWKPO/K[=+7\K]2_P!0X3@G\V7W7_1/C>O"\^OMTM?ROU+_ %#A."?S
M9?=?]$^-Z\+SZ^W2U_*_4O\ 4.$X)_-E]U_T3XWKPO/K[=+7\K]2_P!0X3@G
M\V7W7_1/C>O"\^OMTM?ROU+_ %#A."?S9?=?]$^-Z\+SZ^W2U_*_4O\ 4.$X
M)_-E]U_T3XWKPO/K[=+7\K]2_P!0X3@G\V7W7_1/C>O"\^OMTM?ROU+_ %#A
M."?S9?=?]$^-Z\+SZ^W2U_*_4O\ 4.$X)_-E]U_T3XWKPO/K[=+7\K]2_P!0
MX3@G\V7W7_1/C>O"\^OMTM?ROU+_ %#A."?S9?=?]$^-Z\+SZ^W2U_*_4O\
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M'PBC>5N/44*5/@S=I:ZB311&FB"<.5=:W'E#BNQ3"Z]KX9.CNDD.Q"%Z/MN
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ME&D-AV<7#EC4RK45O[@G\V7W7_11Q-YM[6]/ZJ+$6CI4(Y%DYW6+I 44&(Z
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,4F[.W)V?GY^M?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g428534g04a04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g428534g04a04.jpg
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MG4^AXMAM;.57#L1A3A4JV_M=6,+BA*%2%6VN::2JT9Q]I"C7C5H4MJAP)]#
M
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MT9NM2I5Y4:JHU)PC"HZ<U!O5>6='B/;
M                                                   *XV=[ALOE
M='ZD_&X;WW?-&)[EW_)F8H?O3B?B>_:+P2?O/P^"+#W5X_%DO&30
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MM2C2QFC:4KUO-92L*UW3DGG&<D>K=Z#:2VU&=W;V,<8P^&UXC@%S;XY9J/\
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MBE"M0JTZ]&I'6IU:,XU*52+W2A4@Y1E'MBVCZQD\@
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MW4+G^@/VW;@G^D<*W&"WY<^?_P 'XQYRY?)ET?=+^KH]+F/DWV>3W8]HZ_\
M>,X^4[:+YG[,_:1->_T?=)<,M_\ S:H5?_(Q2MGX9C'&)&%QS<<.7&"VY>?&
M>'>W/,_\(P[[G_Z>8?9V;]W&='9?[XMX?^8H?KO0_:907OZ$=)</_!6(U?\
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MV8R^U@[SGES[.ES^#]@?:"GUZ/Z.O_\ !74?R7T1^SBY7N=(_27#_?F%5/\
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MR;'6FS<AE?(5L6S>ZD1%(N3Y2\'/.26.-;EQC/2-'6=LFB3F8J.<%R4W2YZ
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M.XT9
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M !,_K6X(/XG)7^7'?8U'=/\ "OSQ(]\>_P"3-P!DH
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MFFLTUM33W-/K3.'::;3636QI[T^#.10
M      ?S_<<>ZMGZL)^5.M=[EMP4.Y:FU?KW9OY/NY5R#V6XH9V%5TY'6!9O
M!RE7CG5%=3TKQ'M;75MRP5K.FYGZ'+4^OV]M(4%:$(!N*3U-VUM2[-O?PVKM
M3WY,CFP>(+<LWPE_E1N,R4G+)3=V<)F]7\1J&MM+#-L:_KR#X<==:/M\A0.K
MR3TL7)1>V[3.W_V2<RC)XXN4!<(N&D%%F%5J*<."2SBNJ2V][SV]>67EM?6S
M9V_6#=<-;]^[)VEG;D;*XW54X/AXKT9LFYZRU"PTT37-6Q2(A!>M3\=6K+;-
MJ[6FKJAN6P6*/G9G5E-83%RFT*Y4]64QY+B<,N#;V;>WDMWJ;?<%>S:?<M/4
M:)J,ELVVQ*E)C;U [;V4V?HJ[TA[?,S;I]MFM%GK'/W!G6;;8"R,Y7(RX-H!
MVVJDQ6SUZ-6JJD4XP(][W+;N74:*_E-N,26T7=ZA=:/NBLU6/X+)[7.]-[:=
M4ML!'6?B!HFQI"6H-VU]"P+J10E)J0U?HZ2O>XRP.&;HC^U2.HI-BBI(1S?)
M!J*SS66;>Q/;L?5S>S/J69Z!6_B+93VRZ5H?4<1"[&M.R]&6;?)I=SL.5U_5
MHW4C:5K%2A)B/N%7K5OL"LY>)RXMBU(\'&-DFD5!V6PN;#&/HZOQMB&<MC[&
MEEU[<_0\.N#3>_$57V/!5?*T6=WE9G?Y'3:&T[?3=M<0E[K%5L5AJF\M3+N+
M;*S3FN;:*XV&\8.'D WL6*2YE)G$ET)^Q-(YOA4HTTLWU;8K8N*?5\?F>D;C
M\IHM:J+"730_#GL7=SW.BN''?UJH=::WIS<VE>XCH#KG"TZIGJ6K+S4)C8->
MHR:MC=QEVMFLX"84=PL5%6111Y,.ZZ)J[]JV-KJYO-[N[/K+MK/&,RV)Q [:
MX9X"LUAC?=9O)!G)TZY;*E=?[2E*B[UZQM%8VU!4EU0SN9?4MFLC_-$Z[TFQ
MV5W694K=S)QB,GY1@X83++)]3Z]_'MW[-SR91G"3QFL-DZHX4M:\/>HLEM%Y
MX*:_Q,1U+VUO6W2*%$UCY2B*)1:Y/[?EJ7L>\W^W6*=4?,59V3@EC-V%;FYJ
M;E%7RL+%SA;4GQ*UDWF^O>EOZ\\MG%9YM;]F>TC4=^5)LNQ(:K2FD^')C95[
M)P?[FXJW,=LK<A];.*V^X?=H1>I-J:DFC06J]F$/88RX.92+@[#%YD829=1.
M3NBP\8Z+*)"ZF6]_Q);%GO6>:SR^1Z<:=V3%;FU'JS<$$R>QL)M;7-(V3#QT
MCE+,@PBKU68RT1[)_E QT<O6K2410=91.=+PZ:G@S&)RSD8>QM<"Q@    5Q
ML[W#9?*Z/U)^-PWON^:,3W+O^3,Q0_>G$_$]^T7@D_>?A\$6'NKQ^+)>,F@
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M>;^]'BVN21E[UM>_=LX/LS/208-
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MZL4O8GL!2X)C7852:<0<1 1+B1Q&1S5-TX8PT<BX5(9;Q8ASFY@WFV^+S+)
M@   5QL[W#9?*Z/U)^-PWON^:,3W+O\ DS,4/WIQ/Q/?M%X)/WGX?!%A[J\?
MBR7C)H           #3_ (F?UK<$'\3DK_+COL:CNG^%?GB1[X]_R9N ,E
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MM:M6&WJ^\=6O<-Q'#:GL<1L+W#ZVU>RO;6O:U,UO6I7ITY;.O9L,N.3/2
M                                        "N-G>X;+Y71^I/QN&]]W
MS1B>Y=_R9F*'[TXGXGOVB\$G[S\/@BP]U>/Q9+QDT           !I_Q,_K6
MX(/XG)7^7'?8U'=/\*_/$CWQ[_DS< 9*
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M:W!!_$Y*_P N.^QJ.Z?X5^>)'OCW_)FX R4
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M?UK<$'\3DK_+COL:CNG^%?GB1[X]_P F;@#)0
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MM8C@V+X1/V6*X7B&&U,VM2^L[BTDVOY57IT];BG'--;4VB0#FCC0
M           "N-G>X;+Y71^I/QN&]]WS1B>Y=_R9F*'[TXGXGOVB\$G[S\/@
MBP]U>/Q9+QDT           !I_Q,_K6X(/XG)7^7'?8U'=/\*_/$CWQ[_DS<
M 9*
M                         \_G %>SVIM:V5;QN8I->7?]+IXE6\>E&S)#
M?]).9C,,Y1,V,]N#)NRYP;\[&<9[1TG&.C?0/'JOTC$]$\$K7FLY+$*%E3L<
M3C)YYRABE@K7$*<MN>M"YBT]J>>T[+AVF6E.%4_8V./8E3MLLG9U;F=U8R6[
M*5C=^WLYK+8U*@TUL>S81[V)GL5^=3=G;%K70_H6#^80N\,F3_JO$KLTFWQ$
ML8["E:RK7)<9ST38-R-CA?V;76'?>T6T_P!.,!U=E*SN\3H:687"/^C^BZ5V
MN+7:II9)1H8C;RBO=E%[3DOME0O-F.:*:,8KK?O+BWLJF 7TG_.J^ U["W=1
M[W*M9UE)Y:T6LTW@][0?Z#C7&P&J?;R<(SFOYE8OPERJ@>XQ!UO@QGQ9@EGM
MSG!>PHNITOX3[M;0;3.WI[<JU+%M#,5JQ_E]I1EI/ADZO"7L+.F][4=R.71[
MB&^EI1HW5GGFZ=3#])+&F^IZE18'>QI\?ZVYFMF6MM;>RI-Q7,MPU/L&$P7E
MD[^!9Q]\B<$_UE,*55Z\FBD+VFSX>!0/@F.D8A<_FA^T/%L.^[I-T<::X5DL
MYW>#VMEICAJBO>FJFCMW=8JH16<G[;!J,E%9N*>P?9&PN]N":8Z-7^>R-OB%
M>YT=O')[HN.,6]"PUGL2U,2J)R>2;63>7A]R:NG'&&+.[0;>1SG&/),RX/79
MCI9\Q?)%@3C)+I_!DOBO2QGSXP.2PSI0Z/L6K?1;72S"*-[FE]78I7E@F)YO
M^'ZLQF%A?ZRW-?1\T]C29Z=[H/I;84G<5\ Q"I:K;],L:2Q.QRX_3<.E=6N3
MZG[;)]191#D4(51,Y3D.7!B'(;!B'*;',IBF+G.#%SCMQG&<XSCMQD=[C*,X
MQG"49PDE*,HM2C*+6:E&2;336U--IK:CJLHRBW&2<91;4HR3336QII[4T]C3
MVH[#1            *XV=[ALOE='ZD_&X;WW?-&)[EW_ "9F*'[TXGXGOVB\
M$G[S\/@BP]U>/Q9+QDT8Z7\K^37>('R=B7.EX-@I+>,FC4%E#%)XT\19Y(Z=
M)-"&,YRQ179G?F2*RQ(1N'&7[8#3NVZ7K.+&=]>^*3B5:6C+9"9=KP6T9"BU
M"OLGCETVCW+VM4N#BZ! 0:[MB]8PJER:.SRIHYV@XDYM^UD'!M9\(K+<EEGY
M[V_UD1KBVNO-/+^[+]<<]HJ3#VJ C5(:SVD]V*R.F6(M4BSCXZRR3 R?]':&
ML''QE><2S50N<9EX*-AF4D@JD4\"P<M%G4E'EW?K]?K=29B C!+G5E;.O3&T
MTT>VEFV0>2<''Y5D7T*T=I*+,75@38IN"UYO))I*YBUILS!.4,DH2/,Y4(8N
M&7Z].(_7ZY&.@=E4.SRQH. M41*2G@I9PV;-7&3%DVU?DDX6PNH1P8I6L\UK
MTRLA#V!S"K/T(.670C)51H^620/<G^OUL[.),\R<"%-/^)G]:W!!_$Y*_P N
M.^QJ.Z?X5^>)'OCW_)FX R4
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MZY,G*X02:X5:&46+M9:LLL\]59YY9>]$SMSCGEO?7GU/L1Z1C!H
M
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M/^)G]:W!!_$Y*_RX[[&H[I_A7YXD>^/?\F;@#)0
M
M                  !G&,XSC.,9QG'+.,]N,XSY\9Q\.,@TFFFLT]C3W-<&
M-VXQ)(""3Y>#A8E/EYNA&LR\OBZ*..0XV&#8/3]S"L-A^"QM8_"DCW)8CB$_
M>O[R7XKJN_C-F4(F1(A4TR$33(7!2$(7!"$+CLP4I2XP4I<8[,8QC&,? .0A
M"%.,84X1A""48PA%1C&*W*,8I))=2221ZDI2G)RE)RE)MRE)N4I-[VV\VV^M
MMYG8:(5QL[W#9?*Z/U)^-PWON^:,3W+O^3,Q0_>G$_$]^T7@D_>?A\$6'NKQ
M^+)>,F@ -6K7Q1MX&WVFH5K0_$/M(U-E$(*?L6NJ36W=7;SJL/%SJL0VD;1=
MJHXD73*/F8X[Q:/8N8])9QEL1ZJNBNFE<MVU+/CGW<"9[]C>7#+U\M_-9[ T
MVP+6RH56U.(26K*]FK<'8%ZW/(D;SE?6F8QK(J0DTW3.=-"6BCN3,)%$ASD2
M>-UB%.8I<9S"DD      &G_$S^M;@@_B<E?Y<=]C4=T_PK\\2/?'O^3-P!DH
M
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MX]_R9N ,E
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MQWV-1W3_  K\\2/?'O\ DS< 9*
M
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M=/\ "OSQ(]\>_P"3-P!DH
M
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MB<E?Y<=]C4=T_P *_/$CWQ[_ ),W &2@
M
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M^M-=3XGI(,&@
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M\>_Y,W &2@
M                                                        5QL[
MW#9?*Z/U)^-PWON^:,3W+O\ DS,4/WIQ/Q/?M%X)/WGX?!%A[J\?BR7C)HP%
MJBI>;KDU$0%F?TR:D(YRUB[5%L(:5?P#Y4F<-Y-K&V%A*0KY1LIR/XK),'+9
M8O2(8A<Y*H0#S8CN%3&LK_0]F[;IMAXE[%69V6D;-O.;EY;:5K\CJU:P-&>(
M[24J@JA2$&%B?1#N.@M-QUN>9PS,\RF@9LW;C;EGN^[_ &4LESZ_'Y&<LMZU
MNU[7V?I=?5M9Z-T.8@+%1J98*JS5CJO.52NS%;CW$:I#KL8"3AV;V'9K1"R:
M2T4JUCEVZ"D:JDFHQ.0S51,ADLEQA[WGOZS7D2L      :?\3/ZUN"#^)R5_
MEQWV-1W3_"OSQ(]\>_Y,W &2@
M
M           5QL[W#9?*Z/U)^-PWON^:,3W+O^3,Q0_>G$_$]^T7@D_>?A\$
M6'NKQ^+)>,F@   XQC&,8QC&,8QC&,8QCEC&,=F,8QCLQC&.S&,>8 <@
M #3_ (F?UK<$'\3DK_+COL:CNG^%?GB1[X]_R9N ,E
M
M                             KC9WN&R^5T?J3\;AO?=\T8GN7?\F9BA
M^].)^)[]HO!)^\_#X(L/=7C\62\9-            :?\3/ZUN"#^)R5_EQWV
M-1W3_"OSQ(]\>_Y,W &2@
M
M       5QL[W#9?*Z/U)^-PWON^:,3W+O^3,Q0_>G$_$]^T7@D_>?A\$6'NK
MQ^+)>,F@           -/^)G]:W!!_$Y*_RX[[&H[I_A7YXD>^/?\F;@#)0
M
M                                             *XV=[ALOE='ZD_&
MX;WW?-&)[EW_ "9F*'[TXGXGOVB\$G[S\/@BP]U>/Q9+QDT           !I
M_P 3/ZUN"#^)R5_EQWV-1W3_  K\\2/?'O\ DS< 9*
M
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M,Z02PV?+)-5<D6.4F=I-1DVFDXK)M/)_>CUF6UFEGMS?P9Z*#!H
M
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MR4
M                                                "N-G>X;+Y71^
MI/QN&]]WS1B>Y=_R9F*'[TXGXGOVB\$G[S\/@BP]U>/Q9+QDT
M!I_Q,_K6X(/XG)7^7'?8U'=/\*_/$CWQ[_DS< 9*
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MH_4GXW#>^[YHQ/<N_P"3,Q0_>G$_$]^T7@D_>?A\$6'NKQ^+)>,F@
M    -/\ B9_6MP0?Q.2O\N.^QJ.Z?X5^>)'OCW_)FX R4
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MMP0?Q.2O\N.^QJ.Z?X5^>)'OCW_)FX R4
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M:CNG^%?GB1[X]_R9N ,E
M
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M)R5_EQWV-1W3_"OSQ(]\>_Y,W &2@
M
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M^%?GB1[X]_R9N ,E
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MY!C#2C?*7C$+*2S1)6)8SS<JR*KB!<O4YE!!5-PJQ(@<JF61,T2D"@
M               86P6*#JL8I,V&3:Q4:FX9,_&71\X\.^DWJ$;%QK-$F#N'
MTI+23II&Q48S27?R<DZ:L&#9P[<(HG _*M6FO6^./*UN5;2K)%\^BW1D?")N
M(^6BW!V<I$2C%P1%]%3$8[34:R45)-VLBP<D.@[;(JER3 &?
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M]GK$\DUI**CG,9I992XY9Y]62>[+BWD1[UPSX9]WSV]3R9NB,E
M            U\XLK+<J;PQ;_M>O3.DKK7M17V7KCIB4QW\?),JY(+IRC A,
M&.=]$D(>29$*4^3.6J1?!J<^@:QR<HI[FUGW9D>Y]S*(TFK9M'[!X>] 05AC
M+[IZ_: MUJA'3>O1T5+U&9UPXUSXU8#2D2IRFZ[L/V1O''3FPEE;$K:>G(N+
M-(9D7*>:]N;W-/MVYY\FLN[NRVELR2W9=>SAU9<_\$;]#)0
M        -=^(W7-VOT/K*4U^>*<V+5FYZ/M7%<G)%Q#Q=QC*XG,1LQ6EI=!E
M)>37JL;/.)6#=N(]TR)8(F)*]PW;'5>-JGEGVIHC6>78\]OZV=Y6/",M.66W
M\5>TE6;>+IFR-XQZM+9L)/,Q$R!Z)JV@ZYN%GB),C)@UD6<M;:O)QJDBQ148
MO7U?>+,'LI'Y:2KZRV:JZTMO4]K;2:S?KM[ L]K?7U<./Z6SKZS=89*
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M[!"XQ&0#-PNNX904?AM$,UUUEFS))150QKF^+)DD340H
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ME\KH_4GXW#>^[YHQ/<N_Y,S%#]Z<3\3W[1>"3]Y^'P18>ZO'XLEXR:
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MR3A!0O8=)0IL=F1"F1
M  !7&SO<-E\KH_4GXW#>^[YHQ/<N_P"3,Q0_>G$_$]^T7@D_>?A\$6'NKQ^+
M)>,F@
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M))YMM;FVUXL)9)+L_7$NL0H
M      5QL[W#9?*Z/U)^-PWON^:,3W+O^3,Q0_>G$_$]^T7@D_>?A\$6'NKQ
M^+)>,F@
M           #YE6;1=PU=K-6RSIEE;+)RJ@DHX:9<)^"<9:K'+E1OE=+_)+9
M2,3PJ?YA^D7L 'T@     #YUVC1T9L9TU;N3,W!7;0RZ*:QFKLB:J)'3;*A3
M90<%2762*LEDJA4UE28-@JA\9 ^@
M              5QL[W#9?*Z/U)^-PWON^:,3W+O^3,Q0_>G$_$]^T7@D_>?
MA\$6'NKQ^+)>,F@
M
M                *XV=[ALOE='ZD_&X;WW?-&)[EW_)F8H?O3B?B>_:+P2?
MO/P^"+#W5X_%DO&30
M
M                  %<;.]PV7RNC]2?C<-[[OFC$]R[_DS,4/WIQ/Q/?M%X
M)/WGX?!%A[J\?BR7C)H
M
M                    "N-G>X;+Y71^I/QN&]]WS1B>Y=_R9F*'[TXGXGOV
MB\$G[S\/@BP]U>/Q9+QDT
M
M                      !7&SO<-E\KH_4GXW#>^[YHQ/<N_P"3,Q0_>G$_
M$]^T7@D_>?A\$6'NKQ^+)>,F@
M
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77!L8YX*8V.?+.0R2W)+P&;>]M^)__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g428534g05a05.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g428534g05a05.jpg
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M 0$! 0$! 0'_P  1" 'R EX# 1$  A$! Q$!_\0 '@ !  (" P$! 0
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MKBFFFNJ>]'O<)PJ1C.G.,X268SA)2C)<XRBVFOBFT?L(:
M
M                              *PVE[4UWG$_LSPW#B^GU1B?!=?HR7X
MI[FZ7S?'^H,RXOJ_4U'@NB]"0"%   "H]]Z[L]O:5VGJBHM(%%+V9@65X$=Y
M8Q9$^/31LMHYU%*M"KXS\5V>_"8G+?CQ#F0VWG4))R2A!&2JGAI\FGV>2/>F
MN>XB=YIFTGVVB,^@V%0UL/1U??T;"'DS$8]E6-9?C<''\JH9$E#3UC2E.ETF
M,Y'763<2V576%"U!?@V,66^\EG<USQ^#&.#_ #O_ .A7^-\*JL+R;%=J4E]7
MV&V:K8&YL\RV9.B2:S',R;WKW-[Z\5;*,NRL,?KJ%.+X QBEHMN^E,Q,)99L
MH4QZ\G2XU\6=WEN73';/%\>8QY^><OMAXXX_RP75I?5#&I<<R" Y9IN\BS?/
M\VVAFUVW$.OBV679W=OV]BFNKU2):X5/41#K\>I(STN7*13T\$YTN5-5(D.Q
MO/R22^02QZ\,'DI^UXX 8FWL2O>*76C+,39FO<:>G[&JENI8CYQ@6,5[C[]J
MTIU266\GQ"HBN.-<S0=U0155I*<GUU/&D>F; [7K2JL=&U&HEIUQ4_T:O)X5
ME<5);U-OA;5IO,Y-XHU'[QXA.I*/\H_RC?8G/;"TJ[;[,6\I[3Z;:I:II]).
M4]=TZVIXA*A!9<M4L:4?#1A%>*\M8_9H^*O1M:<XU^RY_9DX7CFNX>]N(_"L
M8SK*-EX_%EX7@.6T]5D^.XEA-RPS-AV]K4V<>;5R\KR2(N/*;2\P\K':AQJ*
M2F;6=:1X7[[;;<5[FZ_1NAW=:WM;6H_?WMK5G1J75>.8N-&K2E&:MJ3RO%&2
M5>>9;Z<:<I\?[ _Y/^GZ3I/ZT;?Z-9ZCJ^KVR5AH.KV="\MM(T^LE)5+RSNJ
M=2C+5+N/A<H5*;E84&J+\%S5N(4O3)_@,X23><DU&FZG"I+BC6<C65_F6JWD
M+/Q+:<UQD>+&TI/5T3;Z))Y<B+EU#IBVJV@PHU-1J7,5NQ>T;:_37)_;*-?*
MYI\3W6?L@]G'BE.UV8MM*G)Y<]!O-3V>DI?O1>AWVG^%KR<<8/Q\#R!6>XSB
M.XM\(0C_ *O&B[RM<YA1B+^!MJ%N"KV3'["GQ=A4A2#+G\)](7]8IS_UG1MG
M[I^<I:73M92YMRTZ=E++YYR9_FSHT/\ NO;?VCZ2E_5PI[6W.KTJ:7",:6TM
M#7(>%?NM-<Q^Y/BIINK&>-&?;--_["/M30>L<KYI3_"W)F:_=U',>YEU*>-P
MGCYFHS4?(@_2>@U/Z_9N--OC*PU:^H;_ #:C=K4(K_#C'ED?JK[0[;=8>U*M
M<1C^Q#:'8[0=1REP52IHT]FZDN3EE2\]['0X^J0^29'"/L9IHNHW(VX-1S92
M4_\ :-N1N.&T^X1=9I;)DEG_  H0&=DZO%;06;;\I:=J$8]XZ=)I/YX7FV,>
MV&T6Z?LWUQ1_>AM+LU4J)<\3VGIPFUR3CE\$EO?OFXLJ;JR/@T3>(;_VTG5?
M$)KW(NR)21=-V/"V-5ZD?/GUJ2PIPW?$@E+4?,/T;H%3^IVD]TWPC?Z1>4<<
MDY6<]07SQCC\,OUH]HMK_KWLP5VH_M3V>VST6^\27&4*>MV^S<WGBH-^+?C.
M1X7Z*P^69\,O%QAA-\^V7U:8<V!"8Z/\;ARM/9!L8EL)Y&KLR6R(T%TC2DS)
M(?J\Y_ZMK>S]SG]F*U+[).7)>'4:-GA_#/PRQ_.6J'_>FP?M(TOP_MR>R[UF
MG#'%^\V9O-<4H>?BBGNWX7 ^VN/3A.;<0Q>[99P60M1(-C9^'Y_JQQMPSY&V
MZ>Q<5QAM"DGU&9KZ'5S)1IY&#V4U]INEI[NDM^;&XM+]-<U]CKUVU\C4?:_[
M.DU&[VCCI$V_"X;0:9K.SSC+AX9_IS3M/46GN>7CCAM;RY\5WWHS.NQ]Y.YM
M4Y>;O+L:<8V'B-ZM9GXDDBKMY2^ESZC0:242N:3(C(R'&U])U2US]ITV_M\?
M^?9W%+\9TXK'QX'9]/VPV2U?P_HK:C9W4O'CPJPUK3;MMOR2M[FH\^6,93W-
M9+7(R41*29&DR(R,C(R,C+F1D9=1D9=9&749#CSL:::RGE/>FN#7,Y
M
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MPTTUQ333[,]?A.%2*G"49PDLQE"2E%KFI)M-=&?J(:
M
M"L-I>U-=YQ/[,\-PXOI]48GP77Z,E^*>YNE\WQ_J#,N+ZOU-1X+HO0D A0
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M$OV?VPV^Z.I^SC54N$JVC;2:+4E_B='6=:IQ;YQI86<X>,-W\\<=+[&UX>=
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M5&YMZL9T;BC/$Z56$H/AEV0/B.=
M                    "L-I>U-=YQ/[,\-PXOI]48GP77Z,E^*>YNE\WQ_J
M#,N+ZOU-1X+HO0D A0         "@^*SWKO$E] >XO\ 'F1"QXKJO4DN#Z/T
M,QPZ>]\T3]#>L/[)HPEQ?5^I2Y!
M        1^ZQ+%<E0;>18SC]^VI/1-NZIJVU0:?%T31.C/I-/+X#+D/VI7%>
MB\T:]:D^=*I.F^\)(^*[TW3K]>&^L+*\CC'AN[6A<+'+%:G-8^!2U]PA\*F4
M=-5]PVZ+LGG.?2E/:JPA$[KYF9IGLTC4U!F9F?-#Z3YF9\^8Y*EM#KU#'NM:
MU6"7"*O[KP?[#JN+^:.KWGLV]GFH9=[L-LE<2?&I/9[256^5:-I&JNJFB#^
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MS+K^#KZC,RY=8F/+Q+\?7&"Y?)_A_$>& V1D1\,7&$GG\/[C9*B+^O8[]?\
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M;F2T\,^3P5'RY' X.^)NK4DR^!*J[5<7HF7B]@?5\!\A^BVJVE7_ .<WDO\
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M3WOFB?H;UA_9-&$N+ZOU*7((
M
M      .%)2I)I41*2HC2I*B(TJ29<C(R/J,C+J,CZC+J,"-)III--8:>]-/B
MFO-,Y H %8;2]J:[SB?V9X;AQ?3ZHQ/@NOT9+\4]S=+YOC_4&9<7U?J:CP71
M>A(!"@         %!\5GO7>)+Z ]Q?X\R(6/%=5ZDEP?1^AF.'3WOFB?H;UA
M_9-&$N+ZOU*7((
M
M *PVE[4UWG$_LSPW#B^GU1B?!=?HR7XI[FZ7S?'^H,RXOJ_4U'@NB]"0"%
M        *#XK/>N\27T![B_QYD0L>*ZKU)+@^C]#,<.GO?-$_0WK#^R:,)<7
MU?J4N00
M                                                      5AM+VI
MKO.)_9GAN'%]/JC$^"Z_1DOQ3W-TOF^/]09EQ?5^IJ/!=%Z$@$*
M 4'Q6>]=XDOH#W%_CS(A8\5U7J27!]'Z&8X=/>^:)^AO6']DT82XOJ_4I<@@
M
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M5),ML<F?$
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MJEK.VN(QC4AEQG1N*$UFE<VMQ3<J-U:UH_>I7%"=2E47[,FTTI&.<.+
M
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M-6MH.$K:M+>K'5[1N573+^.5_15G*C<+%2TKW%-MQLP=].J@
M
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M;33RG@Z TXMQDG&46U*+3333PTT]Z:>YI[TSZ&B
M
M                   %8;2]J:[SB?V9X;AQ?3ZHQ/@NOT9+\4]S=+YOC_4&
M9<7U?J:CP71>A(!"@         %!\5GO7>)+Z ]Q?X\R(6/%=5ZDEP?1^AF.
M'3WOFB?H;UA_9-&$N+ZOU*7((  /PE18TZ-(AS8[$N'*9<CRHLIIM^-)8>0;
M;K#[#J5M/,NH4I#C;B5(6DS2I)D9D/QN+>WNZ%:UNZ%&ZM;FE.A<6UQ2A6H5
MZ-6+A4HUJ-2,J=6E4@W"=.<90G%N,DTVC]*-:K;U:=>A5J4*]&<:E*M1G*G5
MI5(-2A4IU(.,X3A)*49Q:E%I---%'KQW*]2K5,P.--RW7Q*-V=KA<@GKS&FC
M/I/2=>S9;A=M0D),W58;8R";YI4BAF15.)@+\EEH>T7LVE*ZV/M[K:38I2=2
M\V&E5=75]"IMMU:^Q-U<3_TBU@LU'LM>55#,7#1KJVE4C9S[_'4]'VRC&AM#
M5M]%VD:4;?:A4_!I^J32Q"EM+0HQ_H:\FE!:Y;4W/>I:C0K*+N(VIBV68_FE
M0U=XW8M6,%Q:V'>B2V94*8R9)DU]E"?2W+KK&*L^A*@S&69+"N1+;(E),_1-
MGMI-%VJTVGJVA7U.]M)SG1J8C.E<6EU2:5>ROK2M&%S8WUO)^"XM+JE2KTI8
M\<$G%OI^KZ-J6A7D[#5+6=K<1C&I#+C.E7HU%FE<VM>FY4;JVK1^]2N*$ZE*
MHM\9O#2D8YPXP
M                                                   *PVE[4UWG
M$_LSPW#B^GU1B?!=?HR7XI[FZ7S?'^H,RXOJ_4U'@NB]"0"%          *#
MXK/>N\27T![B_P >9$+'BNJ]22X/H_0S'#I[WS1/T-ZP_LFC"7%]7ZE+D$
M   !5&5:X?=MGLUU_9,XCGBD-IFR%,*>QS+V8_\ LJ[,ZEE3?;J21TF8MW$-
MF]JTK(X\EYAOM-?G6T.PU:IJ53:O8R_I[-[7N$%=594I5=#VFI45_1V.U&FT
MI05U'PYI6^K6_N]7T^,E*A7JTH*UGW#2-J*<+.&A;26L]:V>C*3H4E4C3U31
M)U7]^ZT*]FI>X;>*E73ZRGI]VXXJTJ=27OX]S#MC,7M@]BN25KV'Y]!8-^;C
M%@\AU$^*D^BJXQ:S2EN/D5&M1'_K40DRH2^;%I#A/D2%?1LQMS1U>]J;.Z[8
M5-F=L[2C[ZZV?O*L:L+RWCE/5-GK^*A1UO2)N,O](MU&YM))T=0M;2JE&7XZ
MWLQ4T^VIZQIEU#6MG+BI[NAJUM!PE;UGO5CJ]HW*KIFH137]#6;HW"_I+.O<
M4\R5ECOIU4
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MH:(
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MHS6:5S:UZ;E1NK:M'[U*XH3J4JBWQF\-*1CG#C
M
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MVC<JNEZA%-?T-9NC<+^DM*]Q3S)66.^'50
M
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M4HM---/#33WII[FGO3/H:(
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MT?O4KBA.I2J+]F;PTI$.<.,
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M[UWB2^@/<7^/,B%CQ75>I)<'T?H9CAT][YHGZ&]8?V31A+B^K]2ER"
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MN%_26=>XIYE&RQWPZJ
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MA8\5U7J27!]'Z&8X=/>^:)^AO6']DT82XOJ_4I<@@
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MII[_ '5Q1=.O2;WN%2.=^42H=B.'
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MIRQF%6#E3FL2A*46F9L<L?
M                                       !6&TO:FN\XG]F>&X<7T^J
M,3X+K]&2_%/<W2^;X_U!F7%]7ZFH\%T7H2 0I"MCX\O,-?YQB#,F+%?R?$,C
MHFG9C\F/$0=M4RJ_I37H*VY[,'I24HF/P7&IK4=;BXCS,DFG$U;FNH-0-?5^
M:3=CZ]KIG#%ISAWQ3!;2:J%E=-GF"Y'=Y"XK&[NL9P_6='AF.5$J!4V2)"IM
MQ/R8Z9T\?K9,5K%>Z$AJ=3W=AXDWGBL->?G^>)-^[=C\K<NO3RZ,WT&2@
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M
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M555H)XJ4X2RB<#MIP
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ME]GOZ5K<IY3HIHL8=X.L
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MVE>VM*DI;H5JBQ)VH/0SJ
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MBVI1::::>&FGO33W-/>F?0T0
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M^C]#,<.GO?-$_0WK#^R:,)<7U?J4N00
M              !U)T"#:1)%?9PHEC EMJ9E0IT=F7$DM*_B:?C/H<9>;5_O
M(<0I)_"0^:[L[34+:M97]K;7MG<0=*XM+NA2N;:O3E^U3K4*T9TJL'YPG"47
MYH_:WN+BTK4[FUKUK:XHR4Z->WJSHUJ4UPG3JTY1G"2\I1DFO)E0KU388LI4
MK4N4R</22E.*PZW;?R+7TI1GTC;9J)$EJRQOLJN1&[C-G CMEUG7/D70/S.7
MLZO=G92N?9OM!7V9BI.I+9?4X5M;V+N'ER=.EIM:O3OM!][)X=30;^TH4UO=
MA6QX'W5;86VKQ5';+2*6MO"BM<LI4],VEI+&%.I?4Z4[75? MZCJUK<U9/<K
MJG^TN6]LR,:<1"VSC4K!5FM+*,JBO+OM>35F9(0LLDCQV7Z$WE$:DQ\IKJ@D
M%[%$J3RZ9ZA[1Z^@SA:^T?0;C9&;E&E#:*VJ3UC8FZG)^"$EKE"A3K:,ZLDY
M1H[0V6FJ"Q&-S7>).3V.I:I&5?8[5:6T$5%SEI%:G'3MI:$4G*4?T75JSIZE
MX%N=32+F]<N,J-+/A4[R'.L3Q?'F<JN;R#'QZ1)K(L>U:?1*B/N6\QB%#6P[
M'-Q+[*G'R>=>:-:&8C3\I9DPPXM/;]:VOV;V?T6EM%JFK6='1:]>PMZ.HTZL
M+BVK3U*ZI6MK*C4H.I&K2E.JJE2K3<H4K>G6N)M4J524>O:9L]K.KZE/1['3
M[BKJ=.E=UJEG*G*E7IQLJ%2XKQJ0JJ$J=11IN$(3493K2IT8IU*D8N6^/Q#L
MAPP                                                      !6&
MTO:FN\XG]F>&X<7T^J,3X+K]&2_%/<W2^;X_U!F7%]7ZFH\%T7H2 0H %;6N
MHM>7&;8_L>1C,"+G&.6"[&)DM6E55:6#BZ2UQ],7(7X!QSR6OCUMS.3"@WI3
MX]=*6W-@(C2VD/%<O#6=S\OGGY?(F%G.-_,LD0I1NUL1VYD.187;:[OM<PZS
M&"MI\NDV!C^37,:7D<E,6+37K*\<R.A6;E'7JN6(<28<B&F7;':&PNRKJB57
MU/&>._D\;NSXD:SCANYK._NN!H/PW:SVYKRKX$]B[,Q^3'@8%IO9>H\GJ:K$
MLIC7V 0,UIM=WF(S,QQV6JSNF9[=O@%S09-:Q8$2O@O7..]LPH$1$Z8G3:^\
MES3WM;\93Q_M;N/#XD2X?!8Y86%QY\.2XYPL&X7"AA.08M0;AR;(:V?2+W!Q
M$[9VU24EM%?K[>MQ2_L8%+BZ[6LDH;E5,^ZI,;A9*_4S6F;&L[MI@VL:):,3
M(C&7Y?!8^>_\/(J\]V-_^6?P*YXZM-7F;:=W-G,#>FY\ K\8T#LDI>O<'ML0
MAX+EO<G%\KN'E91#N<,N[N0=RQ(326_<V^JR=IXT=J(4.6ER8YJ+PTO#%Y:W
MO.5TPT22W-Y?![L[OF;%<.GO?-$_0WK#^R:,9EQ?5^IHN00
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M[SB?V9X;AQ?3ZHQ/@NOT9+\4]S=+YOC_ %!F7%]7ZFH\%T7H2 0H
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MUWG$_LSPW#B^GU1B?!=?HR7XI[FZ7S?'^H,RXOJ_4U'@NB]"0"%
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M5=:3<5+!IN.I6$J6IZ7.*W^*.HZ=4NK/#332E6C+'&*::5BCNYU@
M                                K#:7M37><3^S/#<.+Z?5&)\%U^C)
M?BGN;I?-\?Z@S+B^K]34>"Z+T) (4          H/BL]Z[Q)?0'N+_'F1"QX
MKJO4DN#Z/T,QPZ>]\T3]#>L/[)HPEQ?5^I2Y!
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M;C*+6]2BVFMZ9T^<)TYRIU(2IU(-QG"<7"<9+<XRC)*46GN::31^@V9
M                            "L-I>U-=YQ/[,\-PXOI]48GP77Z,E^*>
MYNE\WQ_J#,N+ZOU-1X+HO0D A0         "@^*SWKO$E] >XO\ 'F1"QXKJ
MO4DN#Z/T,QPZ>]\T3]#>L/[)HPEQ?5^I2Y!
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MPVE[4UWG$_LSPW#B^GU1B?!=?HR7XI[FZ7S?'^H,RXOJ_4U'@NB]"0"%
M      *#XK/>N\27T![B_P >9$+'BNJ]22X/H_0S'#I[WS1/T-ZP_LFC"7%]
M7ZE+D$
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M4DN#Z/T,QPZ>]\T3]#>L/[)HPEQ?5^I2Y!
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M7M37><3^S/#<.+Z?5&)\%U^C)?BGN;I?-\?Z@S+B^K]34>"Z+T) (4
M    H/BL]Z[Q)?0'N+_'F1"QXKJO4DN#Z/T,QPZ>]\T3]#>L/[)HPEQ?5^I2
MY!
M                            1S(\/Q3+XO:>4XY2Y!&(C)MNWK8DXV3/
MKZ<=R0TMR,X1]:78ZVW$*]DE9*(C'!ZYLSL[M-;_ &7:'0]*UJ@DU"&I6-O=
MNDW_ &J$ZU.52A43WQJ494ZD7]Z,D]YRFEZWK&BUO?Z1JE_IM5_M2LKJM;^\
M7[M6-.<8U8-;G"I&<)+<XM;BO?W1R:/V>O-@9CAB4_[*GF32S;%4D?6;::7*
MU3ID-DSZR;IKJI)!&I+9H+H]'I7\VM?2%XMB=L]I]EE'^KTRZN_UKV=BO."T
MK:)WES;4V\/P:9JFG*"RH>%-8[+^N=*_^[M-LWHFNM_M7M"@]!U=O?B3OM'5
MO0K3P\>*^L+SQ-)R4FGD5]N7&N97V&4&?P&^L[/ ;3N%=]B1SZ3CN*99(*$X
M\I/LNQPLN=4I9&EICV24I?ICVHZ#NU?9;1MLK.&/%J&QNH_HC553CNE.ILYM
M'65K4J-?>\%IM+4<I)QA17BC%3]';#:IAZ=KNI;.7$MRM-H[/](6'CEPC'6=
M&I^_C!/=XJ^B026'.IN;.]7;JU_*EM5=Q9R\*NW3Z**3/JV9A\YQ?,B)N*]<
MM1ZRR4HS+H*JK"<VYS+L:U=)//Z['VJ[&7%S3T_4[^YV4U6HU&.E;8V%WLS=
MSF^$+>IJE.A87SEE>%Z=>W<)Y7AD\H_"ZV$VDI49W=E:T=>L(+Q2O]G+JAK=
MO&._,JT+&=6ZM$L/Q*\MK>4</Q16&6HVXAU"'6EH<;<2E;;C:B6A:%$1I6A:
M3-*DJ(R-*DF9&1D9'R'HD)PJ0C4IRC.$XJ4)PDI0G&2S&491;4HR3333::>4
M\'4)1E"4H3C*,XMQE&2<91DGAQE%X::>YII-/<S[&C(           %8;2]J
M:[SB?V9X;AQ?3ZHQ/@NOT9+\4]S=+YOC_4&9<7U?J:CP71>A(!"@
M %!\5GO7>)+Z ]Q?X\R(6/%=5ZDEP?1^AF.'3WOFB?H;UA_9-&$N+ZOU*7((
M
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MVE[4UWG$_LSPW#B^GU1B?!=?HR7XI[FZ7S?'^H,RXOJ_4U'@NB]"0"%
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M31A+B^K]2ER"
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M1/T-ZP_LFC&9<7U?J4N00
M
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M0S'#I[WS1/T-ZP_LFC"7%]7ZE+D$
M
M               %8;2]J:[SB?V9X;AQ?3ZHQ/@NOT9+\4]S=+YOC_4&9<7U
M?J:CP71>A(!"@         %!\5GO7>)+Z ]Q?X\R(6/%=5ZDEP?1^AF.'3WO
MFB?H;UA_9-&$N+ZOU*7((
M
M        *PVE[4UWG$_LSPW#B^GU1B?!=?HR7XI[FZ7S?'^H,RXOJ_4U'@NB
M]"0"%          *#XK/>N\27T![B_QYD0L>*ZKU)+@^C]#,<.GO?-$_0WK#
M^R:,)<7U?J4N00
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M/>N\27T![B_QYD0L>*ZKU)+@^C]#,<.GO?-$_0WK#^R:,)<7U?J4N00
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MYH&JVDDJ1,JJ6SCW+R>[?PRGGO\ #=N\PN/GQY/'#M\?)YX\"O,!+>%-KKA
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MO4DN#Z/T,QPZ>]\T3]#>L/[)HPEQ?5^I2Y!
M                          ?)I2:B6:4FM*5)2LR+I)2LTFM)*Y<R2HT(
M-1$?)1H29\^B7)^?SW9,+*>%E)I/&])X;2?'#:65YX7)'T!0      ..1<^?
M(N?47/EU\BY\BY_-S/E_+F?\S '/(N?/D7,R(C/X3(N?(N?\BYGR_ES/^8
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MMMMI2A"4I21%N'%]/JC$^"Z_1DVQ3W-TOF^/]09EQ?5^IJ/!=%Z$@$*
M     4'Q6>]=XDOH#W%_CS(A8\5U7J27!]'Z&8X=/>^:)^AO6']DT82XOJ_4
MI<@@
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M(6/%=5ZDEP?1^AF.'3WOFB?H;UA_9-&$N+ZOU*7((
M
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M^4^"Z_1DOQ3W-TOF^/\ 4&9<7U?J:CP71>A(!"@         %!\5GO7>)+Z
M]Q?X\R(6/%=5ZDEP?1^AF.'3WOFB?H;UA_9-&$N+ZOU*7((
M
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MSLRH9=CUD@GB[*TY!;>FV#AQS:6V2'52W>V"+LZ2:2XEEN%,B
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M5R[*4VA2D(E63K#DZ2AM1MI?D.);]@22!O+;?%MON5;DER+'$
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MQ?3ZHQ/@NOT9+\4]S=+YOC_4&9<7U?J:CP71>A(!"@
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MEM:D<^DE#BFG4H49$2C;<))F:%<@/L
M                5AM+VIKO.)_9GAN'%]/JC$^"Z_1DOQ3W-TOF^/\ 4&9<
M7U?J:CP71>A(!"@
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M[_'I52[+-EVZCSF-[37D\?#&_CTSU_%7?N^6=W/X>6_#^"-VQDH
M                                   !6&TO:FN\XG]F>&X<7T^J,3X+
MK]&2_%/<W2^;X_U!F7%]7ZFH\%T7H2 0H
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MYW/3U?YW_%]-]]"%
M *PVE[4UWG$_LSPW#B^GU1B?!=?HR7XI[FZ7S?'^H,RXOJ_4U'@NB]"0"%
M
M
MK#:7M37><3^S/#<.+Z?5&)\%U^C)?BGN;I?-\?Z@S+B^K]34>"Z+T) (4
M
M                                                          "L
M-I>U-=YQ/[,\-PXOI]48GP77Z,E^*>YNE\WQ_J#,N+ZOU-1X+HO0D A0
M
M                                                         *PV
ME[4UWG$_LSPW#B^GU1B?!=?HR7XI[FZ7S?'^H,RXOJ_4U'@NB]"0"%
M
M                                                        K#:7
MM37><3^S/#<.+Z?5&)\%U^C)?BGN;I?-\?Z@S+B^K]34>"Z+T) (4
M
M                                                      "L-I>U
M-=YQ/[,\-PXOI]48GP77Z,IMNSLFD);:L)K;:")*&VY;Z$(27B2E*7"2DB^
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IB3+DR$I/I)2^^ZZE*N1ETDDXM1$?(S+F1<^1F082X)+Y#+?%M_,__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g428534g07q47.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g428534g07q47.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[16X4&AO=&]S:&]P(#,N,  X0DE-! 0
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M=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
M  IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8
M   )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I;G1/
M=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP
M %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B
M;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M  !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M         $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M  !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M      !2<VQT56YT1B-0>&Q 6X-D0         IV96-T;W)$871A8F]O; $
M    4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M             %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R
M8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C
M=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R
M;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"
M24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-!"8       X
M    /X   #A"24T#\@      "@  ________   X0DE-! T       0   !:
M.$))3009       $    'CA"24T#\P      "0           0 X0DE-)Q
M      H  0         ".$))30/U      !( "]F9@ ! &QF9@ &       !
M "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4    ! "T
M   &       !.$))30/X      !P  #_____________________________
M ^@     _____________________________P/H     /______________
M______________\#Z     #_____________________________ ^@  #A"
M24T$"       $     $   )    "0      X0DE-!!X       0     .$))
M300:      ,U    !@             !/    KD          0
M               !              *Y   !/                      !
M                         !     !        ;G5L;     (    &8F]U
M;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M3&5F=&QO;F<          $)T;VUL;VYG   !/     !29VAT;&]N9P   KD
M   &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@    =S
M;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N
M=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N
M=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
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M;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M"W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
M.$))3001       ! 0 X0DE-!!0       0    &.$))300,      M"
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MTW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H
M# ,!  (1 Q$ /P#U1SFM$N(:/$F%4&)D3+<
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M:FC0R2 <E$'=CZ*,<GM7R4UQTC2)$JJZ@5M-.=-RPYSO@*60$.EX-A$@ ?\
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M-[U-G*)WXT#IZX())#G@=SGF#ITRP!'S]Y;'I%S@Z6-I:K%J<,!EC&;DY!
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MTZRCE(>1(!$#7VMRPG%U+JN"_P H;F2V:)-12Z78TSR1%OH'5VU^+L3P:F:
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M;#$HJ'24=%*=,PD.7P\#!Y@/C[L@(YY"DCU%3D#N0/OKCZRP_P [)Y;^9?\
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M"BL9 P^R8PD* B9-,=_9#.=*ZU<@%E5DYY#(Y4O&P_B1]"ZE/!P/2K%E=%=
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M[0YSF$QSF1*)C&$=Q$1V\1$?,<X#N!@,0!76!Z"N'<,-]&,_W)/Y9.X_UC3
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MU=Z9=)00,8LH4"N4O:Y]LI@9(94CV5N)[>P0N0R"6TW/;Y" J8,WM-KH(/\
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M>_GW_9^%*Y<I=PWY?B(B "/Z!#W[;>7A[\<?ES\,_9]U0.<^7/'V#^7O!Y%
M(78 '8N_CY /@/E[PW#P'SVV_7CCTS^'/Z^S-/QY_7W_ &XY/EP*D.CARHR
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MGN;BT6-FNK1-RY@ S)"F6&J11]$95AD^AJ@J5@CN6!%O,Y2*4\)(Z@$JI\R
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M,51)0!*8HE,8H@(>("(>_)!([&E>?>K7HG> /65-(+1PXZ>Q[E BZ:4C6JW
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M5S&4'SCZLK*WFF:PNQ$JW73KR]NH5X,#K?FS,D;I@'YLV2:&U'(D<:5QS'-
M]%Q?M,:[7F])NVD4#;:#?JM;*Y8V^D9@"U,:L21!FWNC5&[-U7+LJKH%&[DK
MY8&HNI "I*=H]GN2[,B3':BC:^L^J6=Y$J9AT]1]E^<@'AQ)#L,!E3J#CZ.,
M&L/&BRQ+NNFY:RP22OJFC]F]H!C9L>(2B9=;>'F,'2V>)(KOHTIRK3$)%QNJ
M\:OIX\?Z?V.\QSRCF//NK%IN>P!#A6I4+6"4+%OT;=-E<MU&,@HU4;LC$57
M3@&BWZCLW44CHKV]A)+-TY4&U<;LQCU"[F <31J((M*A(_I2=LBNI;DR6DJ*
MH6ZO()[2\9SN0;$ZJ&:WBPNW+E3XB[Z@5R!I.?6[/*K+3%*ZSP3%:KF*( 8$
MC"41'8 ';P$1#R#)'?[CW^PUVF-:9Y&H9'W_ '5Y_1'!?IM$7%E;$'UD<1K.
MRN;I$:?N[$1;3Z+MCM5LJM.L*[W85%!YLU;HI*$5!0B*8)]4VX<M-NAMX6@P
M)A[-):0/<'<DMK>4+N1V[$ H#HCQ@ #2#@\$?37-W[3++*V]&TCQO=;*[:W3
MQF0H\X).LG7)D$G4#QC%8(CZ.301A#5B'BV\Y%FJ,Y/S4;*H3K7O912S%@R2
ML<[=DATS*QZGJY&F0;E @)&*N8PJ=4.2V"22VGM9TTDVUM;6>E@2D\5F7-N;
M@<;DD>[(-1/(D("C-53RQ7(N!(DI:XGDNPP4:H7FQN"'+$I$X"93ST+EN*V"
MB>'J@,*7,:<J0S"<J$W.R-CDX2<71D&ZTE)I(H.3"F=F5'I=)$I$TSHG,0#'
M#G,!M@SK HM["VPKQ],B@BM"W+QBW!$3ZL?YBZF\0 [\ 5W[0B2WDP65&OWE
M>YPH"OOD&10-7T&(&0<\#GBL/8<(^DD-HS;-!8V)(PT[NJ<J6:8HOFQ'IS3#
M5-F[6:NBQQ445RH)%*@H9JJ*0B(B!@';$L._;6=K([&*Q2)+<AR'41 A"S:3
MDD$ZB ,X';%6VUV;2[N+V")TFN9GGE^;\#.Y!9=(<'0#V75P#R3YX,KP#</S
MA.TH.(11PC;Z#"Z<RQ5Y1FH!(*#[Z!NY9@,1LA+N>_'7;GH@H#CHM/D"=$>?
M5+-<2>VG<"-?]6BZS,R9!2]A,VR8OJ11^T2Z4))&H888.<\!BMUL42*8Q]/Z
M<_2X(W4%#9R"$,C@$!F^83!X Y&GD8Z). +1LCNFR8OK ,U2TW*#>;[^0"1F
M6CD8\PLYA?NP5'*"9XXIT"\X%3%PZ'E'J#MQJ.[+(%33/#!#-#WB?V<RF)V7
MSD3>E&>?IG '.8^9,<<8CE^9EEDC<(-:;VWNID$95]F+(X^@/N^"?H^=$650
M1H4,ZLD+34I.-FE*U'V1NC$.Y:.2=( _<,R1)4#.GB3H2/5Q3,=<J* >'3 !
MY4RQFQ:-E#]-+M8LP++;NVV5(7*Y1#$NE%*]SSSFM$UPMP>H-)%)JZH3[:R(
M%:8'7J!.6.6UMDMJR3G%2)8N&!&[::UVA7'5&].9:N3Z=H8:@U^QJ5^WMIA-
MNFBF9D_,G**MFJ1B"LBD54QB*&W!3<-Q7"+/=6%XJB&:PC"H8V(W6)0R22X7
M),AC0D9XP1J(/'"3Z(;^W*.T-^QUQ[0"Q1>,)%$-1"A [<XP<@A1BN]1N&&N
MTNZNM07-WO5[M*U<<U1E(7ZWFL2D/!OE4UY!G&"K'I*-P?JMF1G'(J!#BQ;<
MR9N0NT2();3J%D8XDBZF($O&1=,LD=J+@6R:QGP1"ZN-(8'&XV O.82;3/9S
MD7#O8R2S6RN-21RSF$ROIU=W,$78@^'!)XQA\;P,:%Q$VO8F,6NG+N*_7ZTJ
MZ&6:#O'5T\JHU, %B2F!T\-+N!DEQ4$'0(,PZ1.A[7;EI59) CH_4;7J;JPR
M&N;/?V!R#\T/:)-2<ELCQ#'->8Q''&$G"Q65S81D* RP7>QN\Y_S%]G3:<8$
M>7\)U5';OT9_#TYKTM52*V1G R+U-XVCV=B:H)0Z29'"8QL:4(<4T61DUREZ
M8)E .@E[([!M3-$;A85G9I3#')%J+>*19-O)D)!U.#&"K>19B%YK4MWHEN)H
MHGC:YE6>0+&-&ZA<AE&K(7+ME<Y[>*IHI_")I719.&E8 K\CJ!LK*VQX.9E)
M5-.8CS&,W.H4L:D)D2B<>8@&*8VX;'+L&7AI!="[\.\!U4#OI ZR;$WP [^/
M]WVVCGP8;.HL,9Y&CDM(+)HYMFWBZ9%'X1J*])6[6SUMGQ%1>3ZS@:LC&G!S
MA4CP5P-A2N$)8M0[4-'M%TE[@>F5R9- 1#E&=Z1'L#84!)(H3C)!%JBDR4.W
M9@@5P^ 6Q@<[$KLD6RBZ5&D,<AZ.ZM:;@#1JT&W[+,8\#3.F'W)%;+AE TZ2
M6[NIA<2WT@$\8ZC"J7!0:9"[[GM1W P^;FU1Z8\';T'+R:AIYRW!;!*P;VK0
M&H=HCJM,W..MLM6Y67&9@T"LR/DW$?!1I2QR,6#U-\":B^[GE(U;E%%0"!M%
MK$MN>FI(BW4'39HYHUG):4R0Z1 PFP=)4:]9"'46!&G!SW+<F0]0D1989NH6
MTUK(4C&R([C_ #BT.L%F)5"GC 7#9SJ&-PE8]910YQ79%YS&,)0<#L41]P?)
MA_N#&AO,@GS.3S^%<"95&!'+C_[?_E7$8U?8 Z[(-@'^T&#P';<1^3]^WCDZ
M3W&.??QSYCCCW<FF^IQ\W*?,>'_Y5R&/5,81ZS'Q\?Z??;;WCNG^?Q^/AC0?
M=WSD$@_R^'IS4F<>22C_ / ?[N_X>XUVG3%8R;'9=J4Q&I YC+B',(;>)?DQ
MW*&_GX;[^6V25)"]N!@\_P N*JCF4-+X)"#(2,*/Q&>":Z8QJP^:[+</^W'<
M1]^X]/\ -_\ YD%#Z\>\D_T%6[X_Y<O^@?G51C5Q#;KL]@\0 7 B(!^8>D @
M'Q'\P?#(","#QQ]OY5&^/J2_9H'G]^>_V58IJBP5E[#ZQ1%>G!BG/;XH\FFF
MZ/&/0Y=GK$RJ)NSN $A!!4@ ;V"["&V-+!MQ&VY0K(DL9TR1AL9T,!E?HK\!
MZ4,R,NAXI7B+!GB9,I)IS@.NKQ#D]_4^M:_5W@\IE;B[O!K7._ST3J/8!LML
M83]R[<WE'2Y79'S11,T8!#1TD1T)7[94JH. 10YS""8 /*0K':6UDBA(;/VL
MP@<.)+P6P>8G3S)&+5-AL QZI>^KCKVMC=RWPWM^4VP9@HTJ+4SF-% ;A<W#
MZESSA>V#G 7OHZ-(I.+:1[RRZB.WS9LX8'L*]Q34G7M><%1*-==OC1'.I$)&
M0%1!N;=-$ZS@>F/5':UB[R22MC5.\\U]C/\ CI;G;,TUSW,DC[0\3Y.2V<YJ
ME)HHM!19%,1MULFT@M9"U,FS';$,-M%,IRJZ0<)VP*SO4?A(J&H4K4U%WZ$=
M7X*C3FGTC%MQ3%^^A)$T-W6K'RH%(2,?0I&$@5)88]X509(#%(AT1*O#AIKF
M^NIW9I;LVLJ;;;8M[NT-T8KA,AR23<MD94C2,.>:NAN/9K2UM(%E2.UEE(5H
M]:S07"Q+<0R#4N0P@BTGR.HE3D8ND'PFUFMUJQ5^/NM](6Z-I5.T3:]N%28G
MY&:30(_GGSPL<0R\T?H =)ZJ511,ZJPCS]3PYND:ZB2W8[5ND,,$<$1*11QP
M!P0BC(4RB11/C_,VHL\(*BWNQ;R"5%D>=':3=D75(,E3&K-KSH@TOLKQHW),
M8U5=J#PM573EMIDA$R4W.+:/UV4K>GZUKFB3'=3.4" ZRRH"Q0%1R@-<CA;*
MHF:@ENX#E'JEZ=\\]U-)?3I(D-W?V<=I).%.5CCW2S!0P.9C*#<9?$NW%DC1
MSG0VVVEO,MQ+;1WK7TB'&IY6"Z<L3C$0#;/ARFY)@^*LAT7T:3T:T\B:&WFF
M\TJQ55>/Y=8.QGD))RBU1=NNS=1V*15A:$.!1<K"&X@)S; (\.(REO#!"D$%
MK:Q6D42-E52'4%QA% X(&G'&.^3Q<;AI)KJYEW));NZFNI66(*-<Q!( UL>"
M#SJYSR/65QCUO#==D(@)O$S@?$1V\PZ8^6WEO[_=E>@^H^S)^[R^VNM\'LDO
M^@'X>+\_LJ@QRP@ "NR$H; 'RX@/Z-^F.V_O^.P9.DYR,?><X/NX';RIOC_E
MR^?\ \_OK.:>@=!)\!U$E.91 =TCB<-P!;?<1*781$?S^0YTHQD<=_7^? KR
M>I.':+"LN%?AA@]QVY-13Q-S,K ::OY.-:3LHGRN&3N&@((9YS($=("8@N$.
M\H\$6B((*$5.(+\PN"@!"[#S\MAIK>%ERMQ*("=.H1M)@++C^(I@Z8_#KR?&
MN.<D(^:N9 RJ\$1G&6TEQ'G5$O!QN94:P?!CZ+9XP/A0K<C6?75HK7+#$1BQ
MH)5H_L=(+1'3]P09HKE)&,).V(CA)J4R!A< _()1<E**( 8##Z,K9ME5F0,L
MTNA%DULRMMYD==*:,E0%'BSXLZ=/BP__ .@LNIE:&/4S)@*P+$!6R=?!.>!I
MX'.KC<7,574Q2F*4Q2F*4Q2F*4Q2F*4Q2F*5HUQ\<+ZW$KI"F2LNCQ>J.G3I
MY:M-)A%L+APA-]F)S1Y#)*(N44I%PTC3+*MU!. LDAZ2I@)R?H/[.?E:OR5Z
MT3=H)ND=31+3JD#-I5K?6?G#D,I,2/+I##'C;E03GY#Y:?)QOE%TL);2;/4K
M"0W?39].HQW*KX1PRL S!-15@?"//&+UP.<3S?BAT89620;A%WVKJMZYJ'!'
M7!5Q'6)-HFHNL9,2$50;NURNR-R+%$^[18!,82CMG_:!\DV^2779+6)][IUV
M&NNF7 72LEJSD*N02K,BE"Q4X\8P*M^1_P HE^4G2$NGCV+VW86W4+8MJ:"Z
M55+JW (!)( 8 ^$UN7GPU?54Q2F*4Q2F*4Q2F*501V 1V$=O<'B/Z@P!D^0^
MVE>7G#KH=P^Z><3^I^IU&X89NA3NH3"J-HVXJZ=1L,1L]2?VEQ:A/(-W J,6
M[T\C *N3D.X,Z[&D*Q2"U2Y[F#!0>,@')X/'&,? Y&!W'NJ221@\_;[NW]?+
M/V\8]0BE*0-BE H;[[ &P;Y423WJ*Y9%*8I3%*8I3%*UFU@K.LEENE#>TZ#J
M:]=ID^SL2KB5MCN-?2BR:I!68BQ1K;]-LFF1!,4W0NW G%90HMR=,!4N5D"D
M$GQ  X!]/M]Y! I6S.4TIBE,4IBE,4IBE1-K+ID\U:ISNFH6Z1J#.2!5"5=1
MC8SE=\P62,DJR$ ?,03*<#"/.8RQ=_\ 5#YYTC:23C/''.,>\4K+J7 S-<@D
M(N=LSJVR"2ACJ3+ML=HLL4Q$BE3,B=](& "F(<^_:3;BH(;!MN,,03D# ]/U
MBE:V\3EWX@ZQ(4YOH=7499F5I8Y.X+.8)Y,F7!D:""$BH\6KUF#5R]!>9%15
M45]N@ARH' #YS 9'N6BVP$58BC2>&.5Y&D#*9<-MB+0NK"2%MP?1T^+;%# ]
MLS/(JS.Y6,E\"%8U\1DCTY<2F1=!UH%VW^EDZ=4=1K_QKA4KBUMK.>BG4KJ'
M7HW3<^D]'DV,TQK9T[ $TO8I,]D$738ICP/*Y0:($ Q5C&0W,0H:K&*WGN>C
MPW$TD;37BO<R*N(8X(S%J6X77X4?<) U8PC9R!FN"8H8^IS%%EABZ?*D4:'7
M<-=RCYI[<G )0(P/A!U.F"/. M19#C7LMRUAFZ\&M\-#3,XC%5RHMI"7@T58
MDBTT9O&Q$NDF\)69+E<$2/-(Q$R"P= _=:?8RD<401D6,(U-+>RRP2@,VVBR
MA7W6U8D.Q&S)N6FD;NI<S1[8U;&-K'<$.8&C@MKF(/&@.IG,6W*REAK9M#F*
M74IC\>%<.='M+I-'W*)TUI,=J%(%E;NSKL:A:)$AUE2NYE-N4'RY5' BLH"B
MW,8#J^V._M!OFSJ;6S7]T;/!M3-)L$((@T>HE"(PSB/PX&@.X7&-1[UXL1+(
MK&-HM0!$3ONM$"/H-+HCW"O8OMIJ[Z14AYAJRF*5\'0@5NL)@ P F81 1V ?
M#R$=AV ??X#^@<>N..#V^P_KW5W'S(@SCQ#G[Z_..STAO[>VZ[=:6U3"K245
M.M[S?TM.U74_9I5ZJN%;;M*^-Q02L3:#33L2PKKV-D<3S!$TT40<*'S!M[UB
M%8K:VP?I1MX476)KRW6\]KN9X=4807(DMMXZG*[:\OP5^XN9"O4A)"L<SF/J
M0D!?2+:TG-H;>&*<*V3%MR[2;:*0S$:1D&XR>G7$,\IM$O=0@9BM62*I\_'R
M%/C*\]A$R5&/3KZR*L>B@]<FC):TJ++)=Q"DZ1*$(G_G-UTN5/69&CNIY;A'
MTW]G9)?PI(9TM&D]J_P\4Q2,R)!E]0:.+9U*</ND)YPC+10BVE4O8W]P]@[Q
M[2WIC$/S\\2N^T7Q'A@\QFU,#HVAKGC6!I-VVK\.3W5'2;4!?1YI7[6VO.G%
M&:&F9J.M"B=)&F.I>/<M8]HK&MFA+<WZ:R:*B1S'*D<Q550+LN#:)UBZEE=K
MEYK6*7IEQ&BF&VOBTQO8Y@7)25LVAMI$;4!'-J0Y&*X3.W24CB58Y([^-+U9
M6Q)<V 1M+)I7E3XQ<(058F+Q @UM)P]QEACY/5Q:7C[#'0LA9XY>HH6,BB;K
MN<IIKV2$-N0HID.V!8$A$@"9/Q\0RLG'3;2.9HVNTZEUEK@IXCHD7IPA;)"E
MD9DF,9..S$#N*KB!]ON619$M6LNF+ '&!K0WNZ, D!U#1A^3Y9-;* ;8W, ;
M#^;RW^.VWE^;[<R>I'N'/<9YX^'?C[*W5R$HE\R^9!$/'?\ 7X^7Z,GT/ICO
MWY\O>!CW5!SQR/I#W<>G/G]E4V*(;@'B >(;C^HP?^8#Y9''(Y'/ISQY=Q]]
M.?T/+\_UBFWOV#<H (!L @(>\1W\_P!GC^;;'&,X]?/MZ9&/AR,X]*D_;CX?
MUJ@B4?(NWG[_ -F_A[O'?X_FVQY?>?Z9^/&/L-*;>&^P@&P>7CXCOL(_ !V'
MPQWP. /7M\<>G]:C)\L'G''&![^_(JH[CS#N7S#?8//S_%\/+X^7NR< 8+=B
M.,=_*@\N3Y]P!G\!_2J>  (;[[^\ \A#R$!'QV'QW\ \L<$\#&>/=DCG ^WM
MSQ_*?U^L\U4P@)A]G8/(-@Y?U[;_ /GXXQC';G^W<D<8_#FHYQQ_+''W^?VU
M0-@V$0W =P#QV\MO?L/QR./+U/P]_P!F/Q-3^NW\OT:J(#R[[  %V_2/-OX_
M9Y#Y>['N['/.>P_7.:@>?.?L\O[_ *Q5!V$ \P, ["&WG\/U_'XX/KQSV (X
MSY'[/T:G([_K_P ^[OFF_D([>'@'AOY>6X#\?']@^&,9Q]Y]"3QP.^3Z?;4'
MR \S\/CQ]WY5WWNP(QX>8=C)L(!M]GP#X>'Z<[/93QPO8]N,?CS]^*JBSJF\
MSN']?;_7S\ZMX_F\0]P[;;_[\Y[\$ 8[^1./+[?ZU=3W^&^WV[9''GGX?W'?
M^GGY1SCW_K[LX^[/NK%;8YNS<(?U,B8&1(H_ L^::FEHA5G$_)\SB+Z,3*=O
M? '5Y6R@LR[E+NO[0\L84OIE9EMS&^\\/,Z\KC90Z0QQK(.M0"%'GQ)9@I,0
M5IPZB-9#B$]]6XXU%0#IX"$D:NV!G1/AKMMGIE8UQBX&CZK24VZU4DE-/":B
M1IT"OBRZ;@L2[D)0JCM0D,!V0=XNT&*W9NHB<B*_5Y2UVPNCT+I<'S45[GJA
MR01LQQIT\1&51R9&+OLQZAN:)?&I4YF4P#J][,YF>S$?3 ^""TCZK\SK 3D8
M"B/4Q[%ER#FM'Y^N:LU[274&F:TZ1ZT3]MLVKJ\A4+G64'%R5K+E=NY1E[DW
M;O6D(KT&2AXE2&02?MQ<_AI3/FO3*8_I 6P'R2BL2;26RFO&GF=0[QVJ?N[1
M%, 8R9;HASG4 OLY 5\X3*9)S/UV>Z3?ANX;81VR.=M[AS>>%&*-HMK88#81
MR=Y1X>S>R59U$?W2H/7FEC +%*UJ8]6G*E_>&K+:5<L$S&>NC/FS6QG,(G.W
MWW;G$P*"83!R@!JKAC+)#=Q)!%;WLKR:8W)$$/A)*+I77PXVQE V#X@1P@4P
MQ26DKS/<6MN@+,N&EF.H ,2Q*DE#K/B*\<9->?.CT=J=4->EK=8J=J0-A:/-
M06NMDRWAUW$%;(Z1>U5334M>74<(J2R$<HQU&,4SP40:DE$1;D/VMP";I36L
M?2KB&1)$CNX>FVZQ7!#7 ZKIO!=7,V<!(P#!O2^)CE,C(%:>J!I+_<AT!H)F
MN;9XG.TG3$;,ULIQDR2':V(QA<))J.,$6G4O0%(S?7"Z-8B[T&"?W*OUNH5^
MOTHEU]86U6];5I*>FZUW[4$5HNPEG8E-%T215 G=[DABK]8ID\,<CVMAT]HX
MUN;B>ZN+N.QF0;<$""W]BMIY<DPR2&2</B!PN@:0V<#N>-;FYN5#F"*WM(UN
M+V-OG9;B<R>TM"F )4@$,;*#*K,9>2F!GTOT.5LCK22AKV^L(4^QFK\=WG6F
MA3HHQ;@6J0G;$;J-VYVH$4%1,6PD,*/3 .H<1'E]3J2Q)=NL,QG7 U.3JP^6
MU*'!^<"\8DPFK).@>?G]/,AMQN1[1#,$7&DM& NERO\  6YRN6TX'B8YQ*._
M@(>'CM[O'P^ ^[\^8/CZ_;WY_7OK;7("E\=S!^K?W>_QVW_,'O\ 'RVQ3.?7
M[P1_.I"H_P#0R'_WVW^Y?+4[??7B=5^G%]C_ /ZU&G$G:64+0SU]8DVJ]N1G
M,.Q2@2E,\Y11!-RJ<#*)[H)"Z;\Y0'VA.7<0 /'B1$EDC21G6&(/>W149!L[
M0I[0&&0"")4X/!/O SC@U*)'33N/IMK<L?$+JXU;&WQ]/,;X(((/:H-X':&I
M5XZ[SD6SD&U)LIZ\M3GDG'$BWDY&-BS9RR;AFDZ>I)G.B\:B)BNE^8RA@$2B
M4!-Z]R9$MDAN%2.Y664O$I)$8&@9P0""YR",$#;')/; PC>Z>2'.UM(-1 R7
M);4F1PPCP,$@$ZSPN,&=]8]8%:E"VYA3%XIU>ZU75[*>-ESF(T+&($<%,N()
M =14X+)%*"6R0'#F^5*(9YA8Z&F4!HH9HHYR,EAN!R%4<#4=#<D\:>Q!K:D7
MBC1P09T<P<@!F71R?^D:USQSGOQ6.ZTZFZD52E4RU5!CRQ[WJO+O,H5<]N&N
MQ":+17MI84)RN@LGRJ.SG.:50Y>@4H$-SB9/9<1Q6W4I+>1B+6)IP[G \4;1
MB-6DR1&'!?+Z),:?H^M-A_B[$2A=5W(+?:B4X+"19=QE&#K*E8P%\(.OEE%;
M%5Z6;3T'%3+-T1\UDF2#QN\32Z";E)8@&*L1$%5^D4X#N!.LKR^7.;SSBYB,
M%Q-"5T&-V0KJUZ2/+450MCUTK]E4PR"6*.53E9$#@XTY##(.,G&1Y9/VUR5F
M 24.F,=*'$AA+SD:D,0VW]8ANL&Y1]PB >'NRL(2,ZE]W?\ +^>*LS[C^OQ/
MW ^ZOGWV7Z,E_P"$)]_D[9^LO_=_MIGW'\/ZG^_J!3OLOT9+_P &7[[&V?K+
M_P!W^VF?<?P_.G?9?HR7_A"??XVS]9?^[_;3/N/X?T-.^R_1DO\ PA/O\;9^
MLO\ W?[:9]Q_#^AJO?9?HR7\]O\ 1"??^7Y_+(VSZKV]_P .W?\ #WTS[C\/
M+U_MW]U4[[+]&2_\(3[_ "=L_67_ +O]M,^X_A_4T[[+]&2_\(3[_(VSZJ?C
M_4"F?<1^/\L_KOY4[[+]&2_\&7[[)VS]9?\ N_VTS[C^'YUXS:YJ.> WBIB.
M)JN1DDGH?KL\"M:T10MP:(P,^UDBR$?96Y$CF;.5G#2:L!44ETT%" S-LZ."
MAN3]U^3SI^T7Y'S_ "4NF4=?^3L?M70YF.HW-O)$8Y;9BV&15>WMBQ4D?.#P
M @9_*.M*?D5\I8OE'"K?N?KC+:]:B7 6WN$DUP7@ R&U+/<AP0#E%PU>R;:R
M-7C=!VT9R;EJY2(LW<(MB'262.&Y%$S M[1#!X@/O#/PQH'1F20:'4E61LAE
M([@@ X(K]6#!@&7Q*1D,,8(]1DBOMWV7Z,E_X0GW^<[9]5_'\JG/N/X?G^O+
M/-.^R_1DO_"$^_QMGZR_]W^VF?<?P_H:=]E^C)?^#+]]C;/UE_[O]M,^X_A^
M=.^R_1DO_"$^_P ;9^LO_=_MIGW'\/Y9S^&?=3OLOT9+_P (3[_&V?K+_P!W
M^VF?<?P_H:=]E^C)?^$)]_D;9]1^/Q[?W]U,^X_R^[G!_I[Z=]E^C)?^$)]_
MD[9^LO\ W?[:9]Q_#\_U\:=]E^C)?^#+]]C;/UE_[O\ ;3)]#^'YT[[+]&2_
M\(3[_&V?K+_W?[:9]Q_#^A_OZ T[[+]&2_\ "$^_QMGZR_\ =_MIGW'\/ZFG
M?9?HR7_A"??XVS]9?^[_ &TS[C^']351FRA_[LE_X0@_[E\C;/JH^W/] :9]
M 3]V/YXJG?9?HR7_ (0GW^3MGU7\?RIGW'\/ZG!^[-.^R_1DO_"$^_QMGU7\
M?RIGW'\/Z' ^_%.^R_1DO_"$^_R-L^H_'X]O[^ZF?<?Y?=S@_P!/?3OLOT9+
M_P (3[_)VS]9?^[_ &TS[C^'Y_KXT[[+]&2_\(3[_(VSZC\?CV_O[J9]Q_E]
MW.#_ $]].^R_1DOX?_*$^_\ ']6-L^J_CQ]O'\LTS[C[O?\ E]^*=]E^C)?^
M#+]]D[9^LO\ W?[:9]Q_#\Z=]E\N[)?^$)_OZ^V1MGU7\?RIGW']>X\_A3OL
MOEW9+_PA/]_7VQMGU7\?RIGW']>X<_A3OLOT9+_P9?OLG;/UE_[O]M,GT/X?
MG3OLOT9+_P (3[_&V?5?Q_*F?<?P_/\ 7GCBG?9?HR7^'^B$^_\ M\L;9]5_
M'X=O[>^F?<?U]_X=_=WIWV7Z,E_A_HA/O_M\L;9]5_'X=O[>^F?<?U]_X=_=
MWKLM)(':HI S?M_9$W.Y0*DGX;>R!@4./,._@&WN'(*$#.0?LS_4"GW$?;C^
MA-7+.*FF*4Q2NL\(95JNF7;F.F8H;^ ;B&V2.3\?Y?KGR[UVA"NA/8,"?LS7
MG+5^,O1>Q3[N#=2%@J3=HM86;*SV^-:Q%5F755/&$L#>%E$I-XHZ4BPF(A1<
MIFB0@G(MS#RB;;*+0"^M?:H" @2VDVW\,ICNQ*8)- U K(890#J'T<8/E]=?
MJ_3KDVUPK:P64O'XXPZG#(6.G#@X.-)XSS75G.-31J$;R:W/:Y=S"J61.8CH
MB':.G\4:JA&#(G>IGE$>@DJ,HB5@KN?KBW=\Q4@2#GK61=@7# Q1F&SF&X-#
MA;T7#0@CQ>,>S2"10?"=.DMG(ED82&+(<[DJ*5.5EV"@=T/&4S(N&(&03D#-
M8=0..K3J[6J;9)(2"%96859]2IEL1)=_-%GE9X'B<LQ$Z)(M5BG'1ARD2?27
M5%ZL7=+H%%?2L,JP]6DF54_=*7=U-I.I'L++3KG0^'4Q+#2A #<DN,<PP4MT
M80N7'5Y%M@'\)BO9#'MPGEM2G4V6\)73]$Y.,MTSXV-!]7KY'Z=4R7G'<])L
M>UL5W<6V;QBRY5DD%8KM*<FNH621.N@*B (&+RJ@//OL K:W>\BNIH,&.SUF
M0G(+I$,R21CG4J@J2<K])>.]4W<BV,T4%QE9)3&N!SH,I81!\X*ERCX.#]%L
M]LC;8!]KV0#?8.7QWV\_#R\3?LVRDC'?/GSW!^SMQ[^:MKY[> CX^ @'EX>.
M_F._AY?#)&<D<#)YY X\P/=Z]_PY5S_%*8 ]PEYAW 0'S\-MO$//QW#.:COZ
M\_9QCR^WXX/GVKYYV.^<8U9Q[O0C[/+M]M2<^0SS\!ZU].41'8H>!MQ*(@&X
MA^G]?Z?C[\Y)[?K]>6>U1YYR?3&1C_S]_P"%<? -AWW'SVVW#\P#X^_QW^&.
M^>?4\G]9-#GR\_0XP/6J[B<-MQ$=]P 0\Q'S\=_S!M^D?+&,>_&/L.>?OS0=
MR3Z\?G]_O_K5!W$2^ ;B&P '\O\ =C[R.X^WMQW^/W4 QV^)\S^O[4,40]VP
M#OL&^^VWN$=@\M\9[<#C'W_;Z]N?MJ:;^(B/B(A^G81^/P'&/>.^._\ ;MVY
MJ#GC'J,_9YU4/+8!W-XE'S'<!VVY?T>._N^S&"./<&^S&1_7M3@XR#WS]A'Z
M^S\*H/D [;>8;^X=MOM#WC[]_P V3C)Y(!//?C[#_P"3C':IJH^&P (B >)1
MVV'<=OS_ )OT_FP%R,Y&//U_+\<5R3W\QD#N./?QSG/EWSVKO/AW1CQ'S[&3
M?_R_\\ENR_9^55Q?2F__ .A_E72*;V@  '8VP&* >?ZOAG/\NPR>V/\ S]E6
MC."#Z\>\>1^WX50=@Y@$/'?8/#;P\=_#W>[;!';GT\^V>P)^.>.*D<>_[:BO
M5C66@Z,QL3(7:17;JV)^>(K,3'H)NI:QS!"IF",B6BJ[8J[M3K(D(GU@W.JF
M B "(AR&9IH;:*-Y[JX#M!!'].18B@<CT5#-'J(R1D<=J$!()KF5UBMK?0)Y
MY#A(]>X4R<')81.1G .G(XS4"P7%?9Y_5V#IRNF)HFASMQ4TT3GG]C-ZT,+L
MBY;)+(O:V%?! L>FB[2.H<L\*@* *?3V]O.K9[>;;5KA-5XO4'Z>8?G4E7I7
MLGM1E8LFWN?O&UV"%?($N0" #7,SI',Z1N/8ATXWRR@1/'^]1>&U$0(<.4_=
M]SO:BF,Q8SDXBB:X^['$2R";?2I@YA;S9[)0]'W07,Z,C.6VHGARR1;,S"IJ
MD@XMV2T5\62S9U+J@8) #(""1!5OMK6XNI+*S"1PWO4[:QOK/<8FV]AZ@9EA
M>:0*&$J&%MQ A&",-FJ[^[M>GM>2/))+;=,DGM[]HT F%S!C4D":R&0@$ZRZ
M$$ 8R:D:J\6%JDI+2:O2NDC*+<W/5"3TDN,BPMYWD95[-&&KY%'$2D>J,S3;
M1WWNY,D*JD.HF6.+N!P<B*$6)M>J"&6TFD]GN>BWO5K=IH@LS>P^RE[5D$A"
M8%W'F0,W).8QP3U>+-TY;I)U1[BTZC9V,R1/\V!?"[T3ARN6.;-_ 4&>"'/(
MK$9;BQXF6%4U0FVG"5//I2E:AMJK4H0+(HD-N@5TI<[FP$5"IJ"R*S/'L"*(
ME0>E4&2(/:"='9:B(L]KTB:1=J:_(6\A)U&S0B+#9(&LMK<!<1XVSRVKPVR@
M)<]1ACR\=I:">WE^B+J?YSYO3@Z -"G.ILZ\X\/BG2L:S:MS&O*FF<GHI*PE
M")1HZQCJ4K*F.W2G7CUVW7KQF PR1>9%!N1P"_>91V,)0;@ \V:XHXV_>PDD
M$8L;R2"S8J2O4(4)T7"8(*!^"J_.:LG+ KBL\DLJQ]+9(BS7L8>[3.#9,1&6
M0G!$FC4P9O!R!QWQLR83 (@.X;[^ COMOMO\/A__ ,S+CC/..WD.?QXK1C/?
MR(Q^O/O]GXT* _C[#L [^'A^GQ]VWZ!WWVQW/VGS_K4G]?K^5/';<2^XH /N
M !W\1_./N\L@_K\NPIGT^_W?W_7VR'2 V1D/CU&X#\/ %_+[=_U9<GT?US7B
M=5^G%]C_ /ZU9-8832^3J+F1U8@(B>K5?ZLF*4NQ0?D;JII"8ZC=)QL3KF33
M$ ]HNX%\3  ;Y!*))$Q ,K-L1<99FF*_-KCGQE%R//2*P1B1UDC1L1X$LH)(
M0+'D!WQGA-9YQQJ/K6-:&LM*V;2<#3#3Y>A-E%6(R2*T U@@?F*#WLAB$:N%
MP7*W SGQ,)>GV@-M^<=MLN]M()'#(&?"ZB2&\&HD'MJ\//NQQVK(IC,C%5\6
MA"7P,%26T@-[O$<>6??4KVFH5B[Q"T!;H*-L4*X,!EXN6:IO&2Q@(<@"H@J!
MB&$"*'* B&X 8P>_,A )!(!*D,N1V8=B/>*O5W35H8KJ4JV#C*GN#[C6(N]$
M])'[!K%O=/*HYCF)6I&;):(:G;-B,2J%:%12$G*0K<JRH)  >R!S;>>7&:0R
M"8L3*&=Q(22P=].IL_6.E<GSP,UR/"I1>$8:2HX!4 @ CT )^)J3DTTT4R))
M$*FFF4"$(0 *4A2AL!2@'@  '@ !E;,SL68EF)R2>Y/J:@ *    !@ <  =@
M!7/(J:8I3%*8I3%*8I3%*8I3%*C#632:J:X:<6C3*YM$G4%:(UU'KBH@1P=H
MHX;JMRO6Y#F* .4"+J=(P&*(<P[&#?/6Z'UF\Z!U2TZK8N4N+25)% 8H'"LK
MF-B ?"Q49&"#CM6#JG3;7J]A<]/O(UDM[F-HW5AG 8%<@<<@$X.?.O.ST=>K
M]JITC>^##6I^)]1M$3,B5.67<',G:J(!GT4DZ:(+EZJ"4:O#$,.SAV13O0@;
MHBF/6_3OVG=%L[V+I_RZZ$@'3.O[AO8@H!M.H';F*.RG2QE6<CE4(V3]+/A^
M%^0G4[NVDOODCU=RW4>B&,6LS$DWG3VW(XIE!Y&DPG5RP\8\1YKU>3625$X)
MG*<2#RG H[\H^/@/P\A_9GXX01W&,U^DU],BE,4IBE,4IBE,4IBE,4IBE,4I
MBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4KYK<_2/TR@8_*/*4
M1V 3>X!$ $0#XCL.WP')!P<^F?Y?K^U2,9&>V><#/'V9'\Z\]-&N JE:23-B
ML[E9Q>['89>=DNT6#V8>';V S%1\QAX50S[LAEE&#873LKX.UE;M"&;I]F*8
M]=G&UAT^+IT)0HD4$4LQ(W)A;JZQY\U0;DAT$L 6/BQW^CZCU:VZEU"2_E$J
MEF+)"H!2,LQ9CG(U,V0,Z5X49SY9!;>!71R[2U[G)RH@$MJ0K!.+1(1\@1FY
M5<5TU@/'+,U CE#ME -9I07!A,J*^[?Q+T1ZG MPD)@4C;-Y+?$:ADW$P42.
M<C'.A<#!QSXC7+=5@=UD8,Q2T2R4&/*BW0DHF-?==1P<C&3QS6*F]')H)ZM$
MJK>IR$?'I!#%2>1\ZFVF$BP2;])@5.0+$B)2\LBX%P'2$%CE1-L3I[#=*9)9
M)'=A\ZLJ2HKA4FCF*F2*5.0\;:5\!X^VH7JD"Q11*7Q"P>)C'EHY ,"5#KRL
M@P,,.1S[L9UIMP6:8:1V<;;0*^Y@I(8Y&-,T1E@[H4204,J5TK'IQR13OE#&
MV5<=7<Y2E 2^&XRADC$ZJ4TW#.\BDC2K28UF,?P!L#U^B,]A5,E]:RM TFZ7
MMU5%?'B=(_H"4DG65R<=L:F]:V(]4Y@-_8;^(;?TAON_/XY7MMSRN/34/N^W
M%6GJ5L?^9Q_TC_=^OOJ@U*7\0 B  .WFJ81\-_?TOS^.!&WGI/IX\8I^\K;_
M -S_ $#TQZ_K[*>J4OX[)M]A^*AA$/T#TP_W8VVXY4X]6'P[]J?O*V_]S_3_
M /*N9JK,&\13;[[ &_4-^O<.G^SX?KR-MAV*C_\ (5'[RMN?\SGT3'_[5P]4
MI?8=R(;B(#OU3?GW_P!7X[[_ !#]>-L_]/G_ !#[OU[ZG]Y6W_N?Z!S]O.?U
MS0*E+AO["'B&W]*;S^/@GY?FR3&QQDKP,?2'Y]Z?O*V_]SOYH.WIPP_K7+U3
MEO9#D0'P]K=4_P"P/DAVV]WF'B/EC:;ZR]N,$=_0]OCS4?O*V[G<]WA_^7?'
M]NYKCZIS ;"!&X"&VP@H;?PW\?Z/]OQ\,&,GG*]^VH<]\^F![N_OJ?WE;<?Y
MG'_2/Q\5/5*8\?90\?,>H;?_ /;]_OP8V( RO';Q"H_>5KQ_F<<_1'^[\>_Q
M.05*7#?V$!W#;^D-X?G_ */!C8_4\NS#W]_>?7W5/[SMO_<_T#_=51J<QR@7
ME0V#QVZIO$?W?[ P8R<_1';'B' _7G3]Y6W_ +G^@?[JKZJ2^Q@!-OL;;_6F
M';;?_LO$?'SR-MO5?]0I^\[;_P!S_0/]U4"IRX#_ $:&P[;AU3;"(;_%(=O/
MP^&3MMZKVP/$./T.*C]Y6WK)_H']6-=MS6)51-F4A4-T6Y4S@*AMN8-MP_H_
M$/\ GW9)0\8*Y QRW;WCW\?#&:K2_MP9"VYXGU#"CM_JX/\ Y&#BNGZI3 CN
M)$!W'<?E3!O^OICG(C89^AVQR1^LU;^\K;_W/](_W4"I2_\ \" CN&WRIMOS
M@(=/QW_2&3ML<#P<>C 9^WW_ )T/4K8_\S[E'^ZK!9])V-SB7,%:X"&L$,[(
MHFO'2J17;8Y%2B13V%41+N8@B41V\A\0'*Y+=90 ZH<?1.H!E/UE/D>W//IV
MXKI.K0QG*-*OJ- (;W,-63W/F.]06CP.:3MK0XM[2 ?,Y59B9DFBTF2HQ[)4
MZG5-+1[0(P2M)KFY0"0*<R@%(0.3V0RX"0;N7U;TDLI+299&GTF<1G'@28I'
MN+X@VTF?HBJOWA:XC4*RI&D,858P%D6WU;&\-6)##N2A,XP)),?2-6=7T?\
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MTSK\:[!7!-I> /!NHA&"9%N!J8,I!B7.K.5_-?V@V$UJEE\K.GNL74.A.[R
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MQN-Z+\*C'.<G[,\?"J!7FH;_ (9)^6WB['[OSR=QO1?@*FJ>KS;YY)_Q?_\
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ME>>XD>::1BTDDA+.[$Y+,QY)).23R:NBBB@C2&%%BBC4*D: *J*. J@<  <
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M_JM\:<^H^']ZKTK#\[8_PH_K_P!=[\C,?U6\_/X?#]"G/N^']Z=*P?.V/O\
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M6^ J%3OT-85;1#K3->G(IVW=5^63;JM$E6;*135$%GY1?M#]G*GOTUR&YO:
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M\,>/"WH:[-O,&1=I]4EPUJ@QR]RFG5"OK(NI<J.1J'K4=7SC2X;J#38:[O\
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MTU)%3\K)=L%)A$N1'E<N2%:%.HD7Q*5R@/\ 6R][=TBM9&X-VUR(8S]-UM1
M9'4>:CVB,9&>3S4-;RA6<*66-5:4J"1%KU8#GR/A;/EQWJ[4?BTX=M0VU;7J
M^J]1>*VT'PUYB>5:IOY08P(T9 K9L5505#,QEXTK@"F'IF>( /XX9#P2H&8K
MQ'91]0D(Y$5G+N;=Q)]6-MI\-V\)YKB2)XY'B899;E[0$<J\Z$ I&>-1Y&.
M3GM7RIG%IH%?8>_6>NZB0#FG:;N&C:RW(7S<*R@=X234(*4F"ADCE32B72JP
MF G(F*9O'F\,^K$8E=6B1IY((S*-&ZT>C+1Y/C1M8TL._I5S6DPE6",":8P1
MW#1PDNT:2:L+(,#2ZZ3J'(!P,YKFEQ><,*\3+3J.N>G"D/!,V,A,21;&S%I&
MLI(KT[!T[5YN5)%V6-?F1.;P.#1<0_HQSME*+K8:5$RVY8D ;SZM$>?KMH;
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MA:V>CRTXUNC+/'SMED8U:S6JY6Q9\SBTE5T7MN)%$[.H!Y%+M36-[M,*9.9
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M_JB4+*!SASJ.*KF6(KU66"-8RT-@]K& 'D]I47_M<<!!71"VJU&L*2VE<J,
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M-,/1Z[86@B\YGCMEN^H30PK':B'<:W@(/ML[LY9M 51(TP0!XL_X==(,DN\
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M!A&9V"'43!.4B,:AU$.T_BEW!HZEFMQ=LT($-O-8W$9B7$BX<Q[,<K (!<*
MX=]/CR/ NDYSZ0T6](O7=*)*3IFIE[]>9;UR;R];DK#/2L7!UR/;0AJJVT[C
M$DF*L3/N5GT\F1<55DSE9LRII *!N;S^NOF]TV+O<6,T=K=W,XXO!=@S[T$+
MC4%A8,AE7Q%R$R!I!-\#]/;<DD5$G$8@MD.D6VI^3/<+CQ,I5-+Y4J"XSSQL
M7:6/&$3@=K<4KZ^637B648-Y22JLE*T:\5QFYB!*+MR(-;2\EGD<\!0SQ,ZD
M6#U51$!5:F3$3V=<,<EW9IT\+&NQ&)KB%@8#>(?I/"H4+;2ZB7!E8PA% ,NO
MP^7TS907KW)9@K2F"&4 NT3?PQRG'SJX&VPCPVICA0N&@IGIUZ3XE&)70U"?
MI3[/3@]H7M3^7L4F^D+Y)(E*O346W*S43:0ZC)-1DZ%\LLN,BN L&PI *U-\
M1+:W4T>$E@94@AM0(I+BUO!)ND8)S>67LT6W( 0/:G\"Y\6ZT>R%Q")HT,,T
MK*SOI_PS6!3V=W4Y$EOU/VN4W"$IM^PQX><2$1=6BT7C]+I%+VC42QZTV2TL
M:@WC:Y2X*V3=!L(N9%JY4D9"545C+<I,V&)481R3!8K-@951^]YNS"(%/?>F
M 0$1:O:Y380[\+!XHU/M0N)C -!4@F$R_/'@(,C -8;7'M11S&+:..ZG^<4!
MY)E,.S;K-G B8%]'S;$$-A3G UN@-2N.BL7W3S0N]W[4D=?92/KYJTN:TS)J
M6>).LJRF7]YKRS4'E@>.'IHD1?DDHXL>DF](9)V:1*9I1E[R2=+$*L\%G(;X
M.-R %2-B2V4%# RG>W929-T&+P1[/CVW$=K;6EK<.N;:;J<NR$(6[:("(Z)7
MPV8L%0L. %)8ASKP,B;:5>DAM6E1Z[JS)ZOW!&9=V>(9PD;*3U9E8Z4<MH=-
MA*75XY;V3UJHQ_PHB$9V*$%L*3\2OEP?B#:ZY%I<P6R;,9F^8>)I=+0K##K]
MICOH=(U7DFN V\^X -NX!A)(Q7:3^SW>]NA(XF N%B7YV9V),;V4^M=J% D@
MN(C')K,D!UKH.K=;CWTIXA]1?4ZJ4&-ND[4WT&Z9]UU&P/H:OL9]/L::[G41
MFA#2R,W$N$UTBQ*8FCCM$V\V7J..V!V?3TRY6+Y3O?S',$=UT^ZMFE8>SK'!
M)=F]32?H7,P>U,4H8Z%20&-L@BFP,=MTJSB)VITAO(+O9P)F>1;4631.2#L1
M%+OVB,K\YN1$.NDZM8&6CO'CJ7/7P;W%70:%+S#5[6ZM>[;-6)[6E!4E.^FD
M0_7K\<@,2Y16B$VJJ4:UZHLCB=(  I2_.26TDL/3D+,S0222;[KHN!%,(="S
M>)\S1&)R>>#(<!<FO4@O+>W:ZTX4R!4=4.8)&CW/%'C3A&UD 8)  Y-;*:%K
M:\:X4OBMCK)9GUMJM91E-(=)'!7KU1A?C,DI8LG:7XJ=I3%^X3/!=-1L+P2E
M<*[JGW( ^KU")IODXCF)/;.KVRND1YDA@MXSLSB0C)/43=.) $4+[%'XY<XC
MSV4T-C\H[(K\U:]/N1/<OP?G;B1-RU*X01_NX6V474VKVMN(\>/434UWZ0+0
M^>U0M%ZO%PC]$8.*9)BA4>^XYH2MB>:4*A2K&J]5:UBQQK-JH#V2")EBJ ZB
MU.R(@T KFVVNH628]6+2S2]2BU2K)LRO*V[J-O(5E)LW/)BP<D(2XP:QK;9B
MAAZ:D,;0]-9DW$WTC6/2&2XC#1:KGE=$FI2@#>!M7$X*ZF:]V;@[T&G85]KG
M+V&ZWYLD]3KEL?QNJ4W4'$7&'11"T$C)!4RJJBZNSLT.NFHX4!7LX<HE/Y_4
MHKZVZET*WE91(_3YFOC IC@%VK6P62:,LQ,:9EU(SYP<:_.M]I[#)#\HIHT4
MQ0WBI8;S+*ZPM[00L3A4\1")A@H[?1[ 1[>:%Z2:RW:(BTPN1H)C230=T*\M
M]@D:/;'3I5,&$K&QO<+4C.:;$;R@2X*.) 5$I"-*"J8)&%;Z;HLO38NM7MS>
MJJVGMB-;1DJZP2Q/(3<6CG2%M90RA(@ 8Q&#N2:_#CU1);6FVQ610KYS\Z8&
M UP7A',EPA5?G/")-3$HFG#;_</6FO$92K),O]0=0KY:X^WU0SV1;6F?D9YE
M5;2W4$S9I4F#A%J6.9JE?/ <HBN*C@&D>7Y/LXB;YV)6'0+NTD=A?I8=&-K=
MXW;HWCQ]27JQ9RR,X4ITXQ(,%&:0LQ#+CBY>-NLV\\4:>Q"^ZN)8%(C@:T#=
M._=F5"L%8CVW6YX(QI&0:T(K52](P&ERK*=?ZW/I ;G,I0+Y*[S\!>^UO&[
M(.3L@&@I8Q:)%F;O1>QZ:AQ>K/@Y'K,&PBXO02.O31K@CN39SI\YX[6.X'LV
M).I'P-+N$_-( AB$=P-<FX=%\K6@NKXX#6PFMV8Q(HDD@S<:X^GIJ*HRC3J?
M6^O5%E4T^+-=*-*?2 6&;BHFY7S5RI1T8^A$]0963U G9%*Q6IJ9T21DM/55
M82++%:>.RJ*F5BUADCFVC^9Z/1$3ZLV36EQ);"6*7V7J;])CNV5Y8[I1:&U7
MJV%7?1B6V441$:+C!.O*TW3QK/;*JQRJ;RW7J$D.$B/3V+ZS9* VW<1X<R$L
MP8- ,)H\<V<!+CC+II[=#\5AKO<75@L\>S@7SR*E#Q\ 9L+XLS)(2DF_<']6
MY 7D<9@@1J@#8(]P8R[CK%!!'[/-;1(GS;&*]N%>90DL4=J+7;M[DY8O<76\
MVP/  8)\!LG3GOR4NV>,H\(>" K;I\V[SF8[T:AL1Q0"+YX^,D31 Z2OBBW4
M:E\>=XXF;J6I2VJ6G>CC]9] .%6M\FUV MCR"G==HHX(U^-:PZP-#/>UM0%\
M#8 C!(_6 PB'E62-(L*W32QQS7UM+.H<;UND6Y[5!'.1XK:;=BVW,2:MHDIX
M0*]&Y>UBBD]G6.:=+%UA9D&V\SX,;21ZO#-&5.HAW)UXR".>C<M%N+Z1NNEE
M7L$AJA>:A 7>$=1$PK<95:*;P]?6Z<I):IM%(1RE8Y:42>QQH9\#N**W*RL(
M'3<=M S;TK"6)Y>DW%Y%"E["O3KF^*H%LT=3*95M8F)9+J,_YCLYU*T8TC'.
M.Y*I:=:AMW8PW,75[.UC! N'6;V86IFE4G7:D+(!$(\*=6';/$CZGZ%\4+_B
M9NC_ $PNNI]5JEK9M)U6=1N$DC3PDV#^3&$A4XQM&))(LVR4E('E&HR"HKIJ
MLBE,B")A4P]*1X>G]=,S1+>1W=[==(BD75'/)<JNWO@E2T:&!0R+G(?Z0/?T
M'FL'GL6G5GA-OTVVN3%I$T<5N;GVT)G4!*XEAV'. I1\H^KPZ>EK?I4%])'4
M&_E-6W>H#NY.SP%BCYFR5Q2 [ V3(<TZ46TPXL%3GEWC<[$I'$*$1W,^ !DQ
ME &.UV^TTG0-7@CA>:2^:9]33VKFTQ:WD6E?\3$$D,4Y=@^[*!"FG+9RL"R=
M1)>-UD$"(BJH$;CVCYZTDU$",@XGB"9X@(DX.90T^X;^-9HQDXM/436ZF$BK
ML@8Z;6_3)&5A:38+EL$PS.$.VW;-0BXP(Y,Q%0; \<\ZYP6*!=<)L9! LQD6
MW"V=HJEP)X[6,S>T2.V#F<AH0DND#*L2IR")OKE#=RR01QS![1[C5* ZF]SF
M&$+P!$,R;RZB9,QXQHRV,2VG/I5275_$-=2KBE7@T^DV,#(-C6-^BHLBLV(U
M[ZF0?-"-KNY(<3)SR;%<R8)+G"/5WV+%C[)+/)'?,JQ3R0//)#IA$,3&08LL
MZ]+1#)FB)\8,/C32-5:-;Q30'0LD*W P'Q(Q5=.LW"X77$XTA!J4+B3EM0(V
M.K.A'%[2=<%)2LZC72>;)Q]M@*Y:]6965OM?;5UN[@C,"V&( 8 '<[)<QE(Z
M2)+MR))LI,H-%^T<R'FV#N9>HFY2&*.4]/0,$S)/!9F^R ^H8G87(R^'U<>
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,IBE,4IBE,4IBE?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g428534g30m75.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g428534g30m75.jpg
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M">%*MZM0'L>.]VPF!R'@$\*5;U:@/8\=[MA,#D/ )X4JWJU >QX[W;"8'(>
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M+F'5?J81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB814"T_<Y,_T!?\
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M.$;*& !,( "LA(K #&)9 =X\4  226N39796Z;776*UVR/722JJG@^3T5-O
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M5=(  P!@#0 < .2_60B81,(F$3")A%_#%*8HE, &*8!*8I@ 2F*(=! 0'T"
MAZ! ?0(>@<<."* G(7LT.)/(A-Z^F==-*#<G153EO.L"-*C,F=*=XPN92-:M
M5:S8%5%>Z9PXFX1Y(G3**:$@V$PG#(6SO2?MALX61P7)]PHF8!H+H7UD(8,
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M-+F/#F.<T\07)WC??^*VWK%J38+<#NXPQ7U?GVR*B45;ZL\56+$6:(%03_\
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M-#=>+J5Q;'V?,GQ  ECW+=SF#%DA,(F$3")A$PB81,(F$3")A$PB81,(F$5
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MGN"WV9P/?]P*?.<2K3")A$PB81>#K[&<?@%OT9L(J?7_ +0PGS1&_J2.%#>
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M-$_BLI?^"-,/\]WPG>TJ&>:/7[2I Y2JDPB81,(F$3"+6/ROK'"CD;<7&O\
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M1K0QV+IH>U=8;3;RCS66QJ+L1I!O@C)IS1K; VQ"(DC$%4L?*+03]^FP>F3
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MT=/OP-MTYCI9ZN:2.GI8I*29L\+(75$L8>VD;3.W"XAPQD;4   #H = #T
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M4A)1T0S6D)5^RC&#<"BX?2#I!DS0 YRI$%9RY4212 ZAR)E$YR]XYRD#J8P
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MWR3Y*VVFK(K7=G4VY'U#[E1U3XNJB+'-,46Y6ZGH#5%)FZW8J_7'I)6F0\W
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M=S;(OEREB0ZK0D7*M!2B;'&Q4W&SL1YDN]8,9&.<.E4"BP*J1P<XD'0XY]@
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M@C[O%;%MM\'N9T?VG6^>9^I]8Z[OE"Y5=GZ]XRRT1:]O-*#+:<O[UM23*N;
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MG>Q>W@[UE1$:_P  >.##5.[8IGMJ)>2SZ>D-:FUP[/2?.8.-:31(9!!I-O\
MSU>*;+N5W4/%/9%!HA-/R!PW7CZ8@C3D<Z^SBL\]MGK'5_,/1,EQBH6VZ37N
M<FGK1H[DEH6M?#J"-ZKLW*;;@]1UJ<.Q:%5E64/:9&YN:NP>"4C-M9WE8E9
M"-F;9?"ACMTY(RT@M/ISV9\/4MQNI]>1VIM:476L6\<RC6E5B(@%)I^5,LG8
M7[%HF25LTP9( (M.664%Y/3CKTG>2TB]=*F.JL<YBH6F:;X ;XXH=I_L7M'>
M(E8K.Y:'R:HBM)Y-<<9:XQ^N[M'V$[FKOT]GZALUA;^"IAT[DJBQDYJL7&:K
M'1[+6?S":62GF?A<J]X%@:=,'+2.&O81XZC)]"E9R2T)OOM .-W(G0>TH"O<
M:M>;;U!.T>HP3R;8;*V@38+B1B)RL7N\R5/?%HM:K-7E8)%JM1:K/7Y[;V,J
M\?/+A5E8]M$/"@$-((UP0>0[N?K^):^:%V8_(_9=^[&MMN^&K>M*;V3&N)*,
MM<Y#W&,M8[TV1"PVKZQ0%-8MHHI92,HH!J6%M5FE-AQM.L)0E'-78U1YT-/(
MOO\ O^_55;X^::>>? $DD=FO#P4K]7]F:YUIVM6_.<T//)L-+[>UI0;:IK5B
M[\W0><JXYA<M;S%]?1*28E4;PFKIJR.F;M=8I9"T[EM;T&XN8E)P!0798&]H
M)U]&AQZ=<GU!0?X\]ECO3B_RGYD1"_%'AQRRX\\I-URN[=7[KWL\KCRT<?G-
MKE)>1L-<MNOYW7-HLU^;182;7X,@Z?8:PPL3NO-5WMMJJMMD'=1??]_QJ2\.
M#=2"UN"!P..&-<#TZ:=F>"EAQPX;\DM:]LMS@YM6RF5EMH7DQK37^N:4^C;Q
M%/K;#N]85#6-=2FK'50;(^;0]I7U_(K1R4=)R4I&DE(=.3CT0-)J1A02-QH[
M079]?_P%!GG%V>7:?\K[7VF-2N4/JK<&L]QURC,^#TW:MW/:M6=%P50LR%EF
M(*M:90J$I#+;;OL<TB*M/;-LSRLNX\(V2,TNSVN3*L =]_W_ '^W26N:W<(S
MIJ[0:G.FN>SEP]:P'NV#Y5:NY)\)]=:_X0.=\[MXT=E=2=-[S<\6.1T'1-SU
MA.X_"&M$JML.]VRC6.G/=:NH2I3%CHD,THJ-O9W2QSUCJ6Q6C*JG&?*<AP<2
M[ +R0""1GCQ&N<'N\=/)/A5*<R="\,;WPPX6PG'^^=DORHV7JW97 ?E!;&L]
M6-G-K&&J=G[(B3;7EHFP15KDK"1]$N#V"T1#1JY4LUD5$HIUZLLYHIWL%P<X
MD/ (>WCH2 <9&@UR!R73WQ/UY)4'7TFI+\=M$<7)"UV%2Q+:DT.G#/8R' T5
M&1_G5TMM>J-#@KA=7JK)95Z_B*JTCXN-&,@$)2Q?!AYU\7$>\G3M_P#DZ**O
M;(5-.R<%+Y*F3*HK1;?KJV-^H=3)J+VEE355$_1Z#%9VYT!Q]'1(5.H].H9E
M;H7K#2[>V^$$@5]'<J-W(AM(^M:#Z"^C9C]D!VJR.D& 3;,U4F,FEJ*2<:9(
M)G;3DCE[VH=D\L]BXVLW26OJ81=+?8$64SBH\E*>=4>[$V/6]E01$P].]88R
MV1;M4A>O3J 5AF14P  ]!2 1$.[TUB]T'2[M9LQ6 :S4USI7.Q^AY:25@)__
M &GD#O68>BV8F"\4Y.D<M',!Z965#''_ /Q;GU+H5S71973")A$PB81:MNV7
M_B^=O_/NK?\ ,VJY??1M]%]N^I5_VC4+7CW5'Y26U/UWL[_:&V+9E7_M#"?-
M$;^I(Y9$WSV7ZH_^<5GZB_&=)];0?T3%5\XUV4PB814R:8*2L3(QJ4E)0RKU
MFNV3E8=5NC*1RBJ9BD>1ZKML]:D=MS""B(N6;I#OE %FZJ8F(8BTU<+=U[ZV
M_P!BE'\CKUNNYRW("T<=]U[,4VN6-HC*:B+;4U[Z-;<Q$"PIS6D)1\6%9BDQ
MC'=7>-7Z970217:CM90T Y /,953L!QP- 1ID\--,\=5*/8?-RG\<9*5U#8*
M)R(W7?M8<9VG)6WRU2K^N)!Y,ZGC9"0@[/=%I6:NVN:XK-Q<C#2[I_5&C>*F
MI)-OY"F5^:669,%6>_AGA]^OH48SKD#)QKGEGTZ=GMYJW.4/,FN27''>ZO'U
MU?+7=XGAROR1:6O7<52%OWL*AL&G6Z:T]<+&ALR1CX]=Y:O"%CEHRIQL%;K,
M:(K4FY>UMMY[7QEI0#49X$XP>WAD?&L>P?:<:9T;Q>TE;-\6B;MMSB^*''+=
M&]Y6#?:]^'*S&;.I3!RM=I>M6"Z4^PVU=^[B[19I6N:HKMWM<=#,BOUJN@G-
MU9";*=TDD#F1Z/0,G3Q4H*WS9H5VWW9^/U&UKNNYSE%G-?1-[O5?J,$MK"GQ
MVTM?S&R*+;I:S/;<R>NJE.0<05HG)0,),NFTM+0K=Y'H-'IGR!1C3/AZ=<:*
M96%"81,(F$6A']T!_%TTG^.H_P"PUGS+/1%^3-T_:P?;4"TS]VK] NR?[K#_
M %/<%/7LTOBGU/\ K+=OVA=YBN;SSW!;DLX'O^X%/G.)5IA$PB_)A,!3"4O?
M,!1$I.H%[Q@ 1 O>'T!WAZ!U'T!UZCZ,(M>FL.>LUN:(W[+ZTXF;XM'T.FY]
MIZ$NL8WL>A&<M,;$U$2/4LK*G-)+<#(LPQ?%E&(5]V\6BC2*BX)+(,U2F(!5
M%N,:C4 ]O;W@>M3U8R 2\ TE0:/8\).';R ,)) 6TBR!ZR(Y!H_;"8PMWK;R
MOD72 F,*2Y%$^\/=ZX5*MG7UTJ=L8RT56K#%3DCKZ0BJ7=F<:[3=+5BV*4VJ
MW(M>F"I"(-)7PM<*Q.&:''RI&$VP4.!16[H% X#N"O["E,(F$3")A$PBP/RD
M^+;OG\4>P/V8DLJ9Y[?A-]H4.X'N/L7S<4?BT:)_%92_\$:8?Y[OA.]I4,\T
M>OVE2!RE5)A$PB81,(M?G/MR8M?UPTZ_4KS-@<B7Y3-64<D4?_M!X8/_ +L^
M:?\ U(JIS-F^BRB!]Y47S:6J<.;J.@M4+3ZA7/'K6Q?N>8@;EM--C6.AMT0/
M(33U+R.>IA'AKV+65GR;6TJ81;D>&K0&^B8)8"@ OYFR.Q'_ ,0DEEV/>'Y1
M &0%]/WB@'UNF?<_W"U$*7W.^SLX: ;E?=J:UQ P7&.\U%NWCS(;0!N>30.Q
M:4=-DQEV_N#,D^3T5LA Y!U''48'HS.3WDJ4^;@K$R81,(F$3")A$PB81,(F
M$6()CC[HJP[>K?(">TYK*9WE3X-:LU7;TG2*X^V17:^X,],I#PUR<QRD]'QX
M#)RH)-VSY-- DM+$0!,DF_*X*<G&,G''&=,\\++^%"81,(F$3")A$PB818:O
M/'?16R[4QOE[U-0[+>XV&&ML;Q(5R.\9MZV9V=^:MDM:"*,^-<,_44?&@3R)
MH@STYG9F8N#"H)3D\,G''&>WFK]IU(IFNX!M5:!4JU2*RR6>.6E>J4'&5V%;
MN9%TL_D'*,9$-FC(CF0?.'#U\X*B"SQXNLZ<G57544,4*Z,(H1]I#&$EN#?)
M%J<@*%2U^>3 HAU #PLU$S"9_P#U248%4 ?O"0!R^NC.4P[>;,O!QFX"+U3P
M30$>L2$'T%6WM>P2;-7AI&<4N_ZXY8Y ?46@^I<->;W+6M,(N@+L"WYT]C<B
MHP/^[>4FBOS_ "=^.G9QNG_R_P!V55Z?^_3[^:\^Z"C!MNS<O:RNKXQW2T\#
MC\<(64^BYY%9=F=CJ:F>>]DL@'Q/*Z;LU=694PB81,(F$6K;ME_XOG;_ ,^Z
MM_S-JN7WT;?1?;OJ5?\ :-0M>/=4?E);4_7>SO\ :&V+9E7_ +0PGS1&_J2.
M61-\]E^J/_G%9^HOQG2?6T']$Q5?.-=E,(F$3Z_U\(M5ND.$^]-&<9I?@E W
M;54GQN%KLRDU#9KQI;FVYZQIG9U@LTN]I#RD(HJ4N>N];AK;*56M[-+=8B)+
MYG"V29UA+K-9"#E2J+LNWNWCZQ]__*O_ ';Q"V+L?>^ZMJ5NPT:,@=F<#;'P
MZA(>6//!(PTU.6>SV9&]2!F46NU<0[(;+\'&KK91-XN2.!X$RB+WS-F4 C3T
M'/JTS[%&$_9X\@=9TG8D5K7:^J!CMX<$=0\2MZ1-TKMPDD(RV:'UI;=7T_<.
MKI"(D(Q86T_6;>];677UA9MTV[MC%R;*V.CMW3-] & .X#P4EPQDC@XNT/'/
M$'NP,<.WO62-.\(>5_&FVUB9TGO[2LA#VCCKQZTAO",V1J.[/6K>V<<JD\H5
M5V_J6-@=HLU6SN=IKQM$6>B6J=5CGK^ BYII8F15W$2E*$@\1VD^HZX\>WTG
M0J3>A^.M]U7R8Y8;IL5F@+'7>0Z&C$X9%)5X%OB%]*Z]-KX[VS"E!15?D'5S
M354L3KX%0B6E?=E&);,Y5LN5^T*"<@#EGXU,["A,(F$3"+0C^Z _BZ:3_'4?
M]AK/F6>B+\F;I^U@^VH%IG[M7Z!=D_W6'^I[@IZ]FE\4^I_UENW[0N\Q7-YY
M[@MR6<#W_<"GSG$JTPB81?DYBD*8YS%(0A1,<YQ I2E* B8QC"( 4I0 1$1$
M   $1'IA%H%X!Z!A]VF[0\SW8^Y:&ZDNU.WYLNOQU9NMKJU9MM%0N&N+54K5
MX-5590MTU]L-6O2,*K8&Z#F%M\&A(L&<HN5H8R, >TGX\JMQ\W0>:.SO^_DL
M&[E.[K"G,_5:M)V,IL=MVSO#_D72(&MZJV+8W*.AIF>X,)V79-2D*Q5I..&J
M2 UW:,78%(-\95>11LT1)M1?/739Q*G(T]$;@<\\/Q]S'JQV*AWW7L57]!]K
M;%0&II5AM>.Y[:+Y!,3UK4L^-K7T@R)P0M\_>*_,0E8.YEX1PC [>G%6<&^>
M2$JO&[!<HQ[MPC8!".&=/^?#_P"5#>$?+=QKC4^^'#N('#EZ%]?*B3:7NO=K
M/:*-#[)0J>Q[[V;=DU388:E[0I+2[J-Y:CM=D2^OY-*%@5YQ[\"DL4C9SP2J
M[YS7B/+.\(M!&)+''T<Q[1GXE(T+0<:;V>!Q]_Q+,?(?3_'ZL\@[UQQVDWW#
MJ+B9N+CA69;B]8] :L':-;:[KM^R]W6/D&[H5@#3>\)S6_(:7>6S4]XHLW2Q
MKTG*,XJ'5K:KAY7FK,LJ 3@'0D'7)UQ@ =NH&#G0@#CH5OLUXT=L*!1F,@XM
MKM^SI]9:/75_<1+N]N7;>%9(N7%U=0!$H)S;5EB'4LCB%33B5IDSU2-(5F9$
MH%0KPPB81,(L#\I/BV[Y_%'L#]F)+*F>>WX3?:%#N![C[%\W%'XM&B?Q64O_
M  1IA_GN^$[VE0SS1Z_:5('*54F$3")A$PBUY<_2&&+U@I_PE?VL@_)WE&\"
M8O\ ^$S?_G/F/_U)6.-JZ(Y1G<9<-LV.Y;TE-LTYN?3B)^/1E;(>YX</*]JF
M]II[0X=S9;@#KWN;]X6M3/E.MH$PBW.\/U"GT'42@("*3VSIF /^$PV:55 !
M_P"?=4*;_P!#!GW=]Q#(U_N;]B6M<"8J_:V-X'%KCM9>90T^G<D:[N<%I%TS
MM(Z0[R2,!T%J</2!:Z-N1ZVD=X*DWFV:Q8F$3")A$PB81,(F$3")A$PB81,(
MF$3")A$PB81,(F$3")A%#'M$'1&?"/DJJH/0I]8R[4!]'^^^6:,DP]/_ (E'
M!"_+Z?1Z>F7MT<,+]NMF .(ND+_5&U[SX!I5O;6$-V;O!/Z"D'K<6M'QE<+N
M;Y+6A,(M^_8'-SFVKR"=AU\FAKZI-S?)WW5C>JI_^_=9J=/_ 'S7SW0+@+3L
MZSM=<:QP[F4S ?C>%E'HO'XNNKNP4D _?3.(_FE=/.:M+,Z81,(F$3"+5MVR
M_P#%\[?^?=6_YFU7+[Z-OHOMWU*O^T:A:\>ZH_*2VI^N]G?[0VQ;,J_]H83Y
MHC?U)'+(F^>R_5'_ ,XK/U%^,Z3ZV@_HF*KYQKLJ,G(_E'4..RNK*PO7K)L;
M;N^;JMKS2&GJ3\$A;-@65C#N['8GHO)V1B8.MTJBUA@]M-_N<W(-XRMP3;O$
M3DIE_#0DH4@9R>P:D\M<>T_>,E?+5]Y;8)N:H:;VIH!>F#=J)=KK#[-IFQ8_
M8VKTG=*D*>T<4.3D']9H-QC;R^9VPTRT:NJ22N/(V#F#P]FF%V#Y!F3&F<^K
MM[=>[[\*3*,@P<$<*(/F:Z;1PHT=*(N45"-G2(E*JV<&(<Q47"1C%*HBH)5"
M"8H&* B'4H7N59$QBE*LD8QR>4(4JA!,=/\ \PH (B8G_P"\ $O_ #PB\F[Y
MD[;E=M7C5RT,8Y"NF[A%9N8Z:ID%"%63.9,3$6*9$Y0-U*J4R9@ X" $5N6J
M4C KCT1D6/20:NF[ ?.V_1ZNF0XG1:?PG_:52 DH)TT>^<H)G$2@!#="AW ]
MQ]BN51VT2<-VBKINDZ=@L9HV463(X=%;E*=P+=$Q@46! ABF6%,I@2*8IC]T
M! 1*44>-$G+=FJZ;INW15CM6JBZ1'+DC<"F<';H&,"JQ4 .05C)E,"0'*)Q*
M!@ZD7HLLDW2577530013.JLLL<J:22291.HHJH<2D33(0!,<YQ I2@)C"  (
MX1?A)TU7;HNT'*"S5P5([=RDLFHW7(X$H('16(84U2K"<@)&(8P*"<H$$W>#
MJ1?I!=!TBDX;+).&ZZ9%4%T%"*HK)*% Q%$E4Q,11,Y1 Q#D,)3%$! 1 <(O
M7"+0C^Z _BZ:3_'4?]AK/F6>B+\F;I^U@^VH%IG[M7Z!=D_W6'^I[@IZ]FE\
M4^I_UENW[0N\Q7-YY[@MR6<#W_<"GSG$JU8%LVQJRART/ WG9= IDY81 ("&
MMERKM=EIP14%$ AXZ8DF;R3$52F2 &2*XBH42!]4 AA%>;"082K1)_%OF<DQ
M7[_D'K!RB\:+>24.BIY)RW.HBIY-9-1(_<.;N*$.0W0Q3 !%]F$3"*WVUCKT
MTK9HN'GH:6DZJZ"'L\=&2C%^^KDLZB&4VVBYYHU75<0\BXA92,ET&4@FW<K1
M<BP?II&:/&ZJA%3ZC8Z]*-RP,;/0LC.5V'KQK!#,91B[EH(LJP.I%FF8YNNH
M\BPDDV;L[ 7J* /"-7)F_E"H*B4H'FM[@KPPI3"*C6"QUZI1#NP6J>AJS L!
M;%?3=@E&,+$,S/7:#!F5W)22[9FW%V^=-F38%EB"N[<H-DN^LLF0Q%6<(F$3
M"+ _*3XMN^?Q1[ _9B2RIGGM^$WVA0[@>X^Q?-Q1^+1HG\5E+_P1IA_GN^$[
MVE0SS1Z_:5('*54F$3")A$PB@EST8&5H5)DP*(E9VY9B)NGH*,C#/5P 1^]W
MO@L>GR]/_3/G;_U&K<Z7HYV!NX:2VAVUGMQ=V--TL5?4@'X7R(./@K/_ +GR
MH#-H;Y2$C,]F94 =I\EK8(SCN\K^-:M,^0*VQ3"+;SPCD0>:74:]1[T3;YQB
M(#]X%F\9)E$ _P#"(R!@^3O%-]_KGVR]P!=&U_01-1@^^LFW&T%N<T\0)Z2T
M7=I ^E/R3(!X%S7CB#C37IVIC!MPV;LK+-03Y]+)*JE([P*8'N(4O\W>6&4P
MB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(M;_:TV8E;X%;J)Y4
M$G5B4H=99 (]!5/(["K"SY(/2 B(P[.3,(!U]!!ZAW0',E]$-*:GI L9QEE,
M*^JDTS@1VZJ:P^CYL^(9YGFK0V[F$.R]Q&<.F-+"WTEU7 7#_P!MKUQ7YNZM
M=DPBZ.NP$@3 3E!:%$Q AC:F@6:W3ZDQB!L&1DDP-];J4%(HQ@#KT Y1'IU#
MKK5[H2HUV5I0> N]0]O;K\CHXR1ZI0.X\>S+G1;$?_&IB-/Q#$T^G\5O>/C8
M3ZN:Z-LUL67$PB81,(F$6K;ME_XOG;_S[JW_ #-JN7WT;?1?;OJ5?]HU"UX]
MU1^4EM3]=[._VAMBV95_[0PGS1&_J2.61-\]E^J/_G%9^HOQG2?6T']$Q5?.
M-=E:E^>>O=A5/F%V>?..O4BX[.UGQED^1.O-XU77M>EKO?JM2N1M"@*S&[;J
M]$K[5_9;8PHUBJS!.]1%1BYVVJ5>6/(0\%()13X$RK:='-[3@@DX&0>!SS!.
MN1J%D7F!LR]<B>'7)NC\+D]C2FX)_1=Z3HUJ956X:XCDIU6,!-*KP5WN<?42
M(7VS,3R4) C6'#V4J4VJUDK XJH%8/U2AN,C.,9'ITYGB-.T%8!-Q]USR0Y%
M:S7UGIV4HG%S8/!;=>G.85'FM;3&K8.;1MLGJ=MQ^U?.U.<@85-7;FL$R[H=
M&72C7$]K"*548R+V)3M]>;2Q3G /TP<""#DCCDY&0<Z=O=G51Y-J?E;'<![E
M,6/5=NEM[<6F6JN(<2THU9@WNRMW\8..G)NI.N0-\U5'OHY^VE1Y3Z%K#=LG
M0I2$D6=@D*H>,;0K]&RILG#[_OXIID#.AR<CL)&@//=/$]ZM?=^F],V71$]>
M-#47E'>8#;_.'L\=D6IM>N/%NUHP9OM>[PUVPVK9=;Z2A-&ZELE.2BM-5\ZV
MY=B,*(QK5B(S9MDK-,V*+M:#$I!.]K@8:X Y!XAV-<G.ITU/@OSVA="J-!A.
M5.F>/_%N[ZZ\)<,M:6+2=CU1I/:5SJ%K>MMY;3V_/5W33.EP$EJ+0TOK&W+D
MN]\E"L8[8^PI*ZU!G"!%!2JVYE2@'):7$$%V#DZXT&2>)&.&N!KS*^KF&YTA
ML+D9R2I6X;)86]'VZGP6O4#>[SQCY)3TMH5/53]GL"Q5F@S4!I*X4YE&7*I.
M"+V2#OMQU1*T6S;"O9+K6;- 2#V.<D' 8XC>X$=NG#.I&IR,Y&!V:7TZHE8V
M#R7W9K_>-;Y0HW%AR8U'N[A;9=&:982>L;1J*I4;5;K49->\EHG2=HBM05RG
M3<%:*QL^I3NW-?U$8R9L$B9A(-MBSAI0AP ",<"'9X@YP<C.O$$8&1ZE/[GW
M$WY>6X<6=A5YV^:)HO*R G^3U(KL'(6ET]UV]UMLFM4NW3E2BFDA)6JEZQW)
M.Z[V#9HII&R@Q@0$==',>+"HNWS$H;CWP.AW=#PUR,CUC(X^C7*U;;NT'*N+
M_-/HW5EKE>+-R[6OAOL74M&8:TM\I#PE)C=;UUKRRV3&56-K[EY3-&W;8AWK
MJQ.Y-C#4NUS#6VV\B+^N6YE,SA3G./0T@G/'C@:\M,8^XNB?7VOJ+JFEUS76
MLZE7Z)0JE')Q-6I]5BVL)7:_%)G.JE'Q$2Q21:,&:9U5#)MFZ2:1!.;ND#KT
MPJ%>.$6A']T!_%TTG^.H_P"PUGS+/1%^3-T_:P?;4"TS]VK] NR?[K#_ %/<
M%/7LTOBGU/\ K+=OVA=YBN;SSW!;DLX'O^X%/G.)5K2UV+L5![OX63G('<E?
MA+CR'Y*;>Y%J<IW]OBV,Y.*3M9W7?Z!#ZBG$)A!TO'TG7M KU9KM8UZJ5.NP
MT0)G,=%-R3+@R\#/;]_QGVJI^AQV #'=@:^OB3S6<Z+.2VMMRS/9W<51I&JJ
MYQVXO5#;U?D+_5)6\L#!MK96TZYKJA5^!A;9054->Z[)KN4;6)T1^[F7T7-5
M:"C)6)DXF5EI.4[-XZY)''70 DZYXY]OJB_K?M#N4O)#]Z)+6$;I73ZVRN .
M[^3LTC?*%=MFN:IMK1>YZAIVP5J-6A]I:Y;6.@SLO+2[F"?K-HB50B2L9596
M3.L$>4I(:,YR2"!I@:$$\CKIW=ZO9#M*+V%$X:;2V!#UO1VK^57&#CYM:.W#
M/T>VWK2L/OC;/P?)V'2&R[G 6./<Z2AW5?DXM#5E^N;12O62Q2[L)&7!2F.Z
MQ:R;NK@,DM)SP&@[0-2=>([!ZR/6P<S[-J;9W-REMJ'IF/N33G-PYXM:ZMD%
M2I*M)6JQ\J-2Z(E([8>]E&]I<R5[FM;UZ^*1* Q\K65[;%4.MU!BYJH2J+^(
M*,9QQ/O23ZB=!X<>96 :?NNX<8.7'/1ZHUKMZV'MC8799Z6I:L-6&=8C%YW;
M5,OL,UDYV&F-@P\;*34=%I2RC9NK>ZFSM\^A!0HR59+*G>LR  M;C(P#QUX
M'3 X8U.FFI4E=A\H^>>JX;7,/=J'IJHV?97.W6''.EV&V0GPOXCT;MJ#?OHC
M8LM1M;[XLJ=1OM2L$)8J])0JMXDH.[-8I"5BE*<:26;0Q &GGHTD]XY:<#IW
M9[<:^^Y.7_)?CPD[0ND]Q_V;-:VOO!K7VP(W6--OK0\F')/=%.U+L>S7()6X
M2<9I!ZDC>HB:TU2%++L6R32,>XL$\S>U6:(K7"  YXC1QUQV D#T\-3@?<.
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M:-K5.=U]6M;J4>&K,]5(F!E'LJN_B'[Z6CK >0<ND&")_@QT%=(W,RC6:?\
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MR;Q3]?5L'C6.&P7BS0M3@PD'QC%9,?A:>>L&'GCPQ#E:M?./+N#$,"1#B40
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M5BR/:W )0$2R;-C$>  _T-TQZN//^_52UC>7>X%^3>C==HVFCW*B;VY*\OM
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M"@!2E      #/GR27$N<27$DDDDDDG)))U))U).I*VC       P -  .  [
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MH6).2<K/3OO\5.20!RX:#/CQQZ,X4*^('"'<&KK!09^ZP,YJBWTYXG([!LU
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MH>-U_>32JI[75Y<R+44"JWCKKQ&#H-0,8SW8&#Q"^N%X#<5Z[$Z_@(:A65C
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MCCC8"Y[WN(:UK07.<0 "2J7O9$Q\DCVQQQM<][WN#6,8T%SG.<2 UK0"220
M 23A<GO:;]I@YY%/)#1VD))VPT9%O2DL5B2!=D^VO),%P42,*9P3<-:.Q=)$
M<1D<N1->:=I(R\FDF1&.9M-N.B[HP;LVR._7V)DE^EC)IJ8[KX[1%(W!&1EK
MZ^1I+996DM@870Q.)=+(_!FV>V)NSGVRVO<VV,<.NF&6NKGL.0<'#FTS7 %C
M#@R. D>!AC6Z8,S8L>)A%)7B;QENO++=%;U/3R*-6SHX2EQLQD#+,J?3F2Z!
M9B>=@'0AUB%628Q#(YTOA*:>1[#RJ!%U'"-L;7;44.R%DJ;O6D/<P=514N\&
MOK:U[7&&G9Q(!W2^9X#NJA9))AVZ&GV+%9JF^W&&@I\M#COU$V,MIZ=I'62N
MYD9#8VY&_(YC,C>)'=!K'6U/T_K^I:QH,4E"U"E0K2"A&"?=,<K9J414=.U@
M*07<E(N3KR,J_5#R\A).G3UP8R[A0PZ&W2YUEYN-9=+A,9ZRNG?//(<X+G'1
MC 2=R*)@;%#&#NQQ,9&W#6@+9:BHZ>WTE/14K!'3TT;8HVC&<-XN<0!O/>XE
M\CB,O>YSCJ2K[SH+M)A$PB81,(F$3")A$PB81,(F$3")A$PBH%I^YR9_H"_]
MW"AW ]Q]BK^%*81,(F$3")A$PB81,(F$3")A$PB\'7V,X_ +?HS814^O_:&$
M^:(W]21PH;P'</8JOA2F$3")A$PB81,(F$3")A$PB81,(F$3")A%#[FOQ!IG
M,?3S^A3AFT1<887,SK6ZF0\HXJUF\@! (X%,HKKUV;(FDPL<<3O X:E;OD$_
MA2+C%V]Y;#[8UNQ=YCN%/O344^Y#<Z$.PVKI0[.6Y.ZVI@)=)32'&ZXNC<>J
MEE:ZW]H[!3[06]U++NQU$>])1U.,N@FQC!QJ89<!LS.!&'@;[&$<2&T]77G2
M]_LVLMD0+JMW&I2*D;+QCH.H=XH%4;/63@O\"_BY)J=%_%234RC208.&[MLH
M=%8AAWEM-UH+W;Z6Z6RH94T59$)896'U.CD;YT<T3PZ.:)X#XY&N8\!S2%KC
M6T53;JJ:BK(G0U$#RR1CO%KFG@YCVD/8]N6O8YKFD@A8_P ]%=5,(MA7!SM#
M]J\-ITD03SB]:8EGPN+)K5^],D5DLN8H.)^EOEBK%@)X  #ND 3-$3I"^0E&
MQ716,K&XZV[Z.+3MI3F8[M!>X8]VEN<;,E[6^;3US&EIJ*?L8[/74Y.]$[<,
MD4MU[-;65VSTHC&:FW2.S-1N=C=).LM.X@]5+VD?.Y>$C=[=>SKLX]<E].<H
M*2A>=/VUI/,@(@6:A%Q39VFIOUR&-\%VB!,JHZBW8&(J1%;JO&R)45',1(2#
M+N.3Z>;1;,7K96N=07FC?3OR[J)VY?25<;2/FM)4;H9*P@M);[V6+>#9HXGY
M8,\VF\V^]4PJ:"=LK<#K(CAL\#R,[DT62YCN.#JQ^"8W/;JL]9;Z]1,(F$3"
M)A$PB81,(F$3")A$PBQ1N;>.J^/U)?[!VY<8JG5IB!B)KOU1._EGH)F42B8"
M);E5DIR7<%(8R,=&-G+D4R*.%")MD5UD_7LMBNVT5=';K/135M5)J6QC$<,>
M0#-43.Q%!"W(WI)7-;DAH)>YK3T;C<J&U4SJNOJ(Z>%N@+SETCL$B.*,9?+(
M0#AC&N=@$D!H)')7SU[378O+=V[HE.2DM=:&:N^\A5BNBEG[P9LJ!VDI?7;-
M0R!T2'(1VRJC)9>'CG/DUG;F;?M&4@VV\Z/^BZV['L9<*UT5RO[F8=5%GXGH
M-X$/BM['C>#B"6/JWALTK<AC((WOB=@G:C;*KOSG4U.'TEK:[2#>Q+4[IRV2
MJ<TX(T#FP-)C8X DR/:UXU=9E566F$5Y:]U]<MJW2N:\U_ /K/<;9)H1,%"1
MR8'<.W:W4QC'.<2(M6;5 BKR0?NE$64<P0<OGJZ#1NLL3I7&XT5IH:FXW&HC
MI:*DB=+//*<-8P:  #+GO>XAD<; Y\DCFQL:Y[F@]BEI:BNJ8:2EB=-43O$<
M43!ESG'7MP&M: 7/>XAK&!SW$-:2.U_@APOJ?#/42%9;BRF=EVDC*6VC<T$A
M_P!K3221_-X2*45(1PG5ZV#APTAT5"I'=*JOIEPW;NY19NCH]M]MM5[:WAU4
M[K(+72%\-JHG'YS 2-Z>8-)::JI+6OF<"0P".!KG,B#G;&;,;.P;/4 A&[)6
MSAKZVH ^>2 '$<9(!$$.2V,8&\2Z1P#GD";^6*KD3")A$PB81,(F$3")A$PB
M81,(F$3")A$PBH%I^YR9_H"_]W"AW ]Q]BK^%*81,(F$3")A$PB81,(F$3")
MA$PB\'7V,X_ +?HS814^O_:&$^:(W]21PH;P'</8JOA2F$3")A$PB81,(F$3
M")A$PB81,(F$3")A$PBUV=H#P!IO,RDED8TT?5MWU-@L2CW95$2-I-L457 4
MVWF;IG<.JZ\<J**,GI4W#VM2"ZLC'I.&SF6BI7)'1YTA5NQ5=U4O65=BJY&F
MOH007Q/.&^6T0<0UE2QH DC);'51M$<A:]L,L-I;5;+4^T--OLW(+E PBFJ2
M,!XU/D]00"70N)):[!="\E[ 6ND9)QM[*UI>M07:?UULFM253N59>F8R\+*)
M FLB<  Z+ENL0QVS^.>H&3=QLFQ6<,)%DLB\9.%VRR:IMT;9<Z"\T-/<K951
M5E%5,#X9XG9:X<'-<T@.CD8[+)8I&MDB>',D:U[2!K[64=305,M)60O@J(7;
MLD;Q@@]A!&6O8X8<Q[26/:0YKBT@JQL[ZZR819&U7MW9>D;A'W[5%SFZ/;(W
MJ5&5A'7DA<-C'(HK'R;-4JT?,13DR:8NXF5:O8UV!" Y:J@4H!YMVL]LOM%)
M;[M105U'+JZ&=N=UV"!)$\$20RM!.Y-$]DC"26N"[=#7UEMJ&55#424T[.#X
MW8R.)8]IRR1AP-Z-[7,=VM*Z,.*7;>4NR)1M1Y5P'@>= J+4NT*BQ>2-/D5
M " YL59;@\G*XNIT*99S#!/1JRZBBOF4$R("9-;=K>@NMIC+6;)5'E]/ESS:
MJQ[(ZR(9SN4U4[<@J6C.&MG\GD:UH'65#SDY;L?213S!E/?(O)I<!OEM.USZ
M=YX9FA:'2PD]KH^M822=V)H6\ZDWRD[)KS&VZ^ME=NM8DB=]E/5B88S<6X'N
ME,=,KR/771*NEW@*NV4,1PW4ZIKI)J )0P-76^NME3)1W&CJ:&JB.)*>JAD@
ME;R)9(UKMTXRUP!:X:M)&JR7355-61-GI)X:F%_FRP2,E8?1O,)&1V@Z@Z$
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MDY0Z'*@TJL0"AN\0[D@'*=/#M[Z!MGJPOELEPK;/(XDB"8"XT;?V+&R/AJV
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MH(6DG<AA8R-I)(;DDG,E!;J*UT[*6@IXZ:!FNZP:N=@ OD><OED( S)(YSR
M 3@ #)V>6NZF$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(J!:?N<F?Z
MO_=PH=P/<?8J_A2F$3")A$PB81,(F$3")A$PB81,(O!U]C./P"WZ,V$5/K_V
MAA/FB-_4D<*&\!W#V*KX4IA$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"
M)A$PBBSR+X8<<^4K Z6V]>1S^?(W\VC[W""$!?(HI2"1 &UD8D*X>MFW43H1
M4XG+PA5!$YXPYO3EU[-[;;2;*2!UGN,L=.7;TE!/^*+?,<Y=O4TA+8W/X.F@
M,,Y&@E 7B7?9VT7MOXOI&.E W6547S*J8!H,3,U>UN3ADHDC!UW,K0=R$[#7
M;]24>S7'>ZQ.U8,HJK(5*UJLZA>T$_2*31M)+*%I\\H4H#Y5XY>U(3',4B,:
M;TF#8'9SIWL]8&0;24,UIG. ZLI ^LH''3+WQ-'EE.">#&1U@ !+I1P6+[KT
M:U\&])::F.NC&2*><MIZH<FM>3Y/*>;G.I]<89Q(TY;-TQMG3$P,#M?7-QU_
M*"<Y$$;3 R$4B^!/_>5BWSA K"6;??*[C'+MJH'I36,'IS-%KO=HO<(J+3<J
M*XQ8!+J6HCE<S.N[+&UW61/YLE:QX.A:"L?5EOKK=)U5=25%+)D@">)\8=CB
M6.(W9&\G,+FGL)6,\]1=-,(F$3")A$PB81,(K[U_J[9&UYM.N:RH=MOTXH9,
M/@VI0$G.N42J"(%6=ECFRY638O0QE';LR#9%,AU%5B)D.8OGW&ZVRT0&INEP
MH[? ,_-:RHBIVN(_,LZQS2]W8&,#G$D  D@+M4M%65T@AHZ6>JD./>01/E<,
M]KMQIW1H27.P  22 "MOW'OL0M]7Q1E,[XLD+I:NG%-96!8*,[G?W*(]#BB+
M>,>>%X3RZ0@4KES.R;UFJ(@Y@3&(9,<.;1=.FS] 'PV"FGO=2,M;42!]#;V.
MX;V]*SRJ?=.NXR")D@\VH (<K]M71O=*HMDNDT=NAT)B:6U-4X<<88[J(\C\
MTZ5[FGSHCC"W[\:^"G&KBLV;KZRH39Q;R("@[V/;3)6*^/.^GY)<4IAPW20@
MD71.A7+"KL8..< !17:**=3CKYM-M[M/M8YS;I<'-HR[>9;:0&FH&8.6YA:X
MNG+2,MDJI)Y&GS7@:+*5GV9L]D -%2M-0!AU9/B:J=G0XD( B#AHYD#(F.P,
MM)U4P,LU>^F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"*@6G[G)
MG^@+_P!W"AW ]Q]BK^%*81,(F$3")A$PB81,(F$3")A$PB\'7V,X_ +?HS81
M4^O_ &AA/FB-_4D<*&\!W#V*KX4IA$PB81,(F$3")A$PB81,(F$3")A$PB81
M,(F$3")A$PB81,(J//5Z M,6Z@[/!P]CA7I/)O8>>C&4O%NR>GZAU'R"#AHX
M)Z1^I51.'I'T9S4]344DK)Z6>:FGC.634\KX96'FR2-S7M/I#@N.6**=CHIH
MHYHW:.CE8V1CAR<QX+3ZP5 7:/95<(-HF=.EM0-J%+.1./PMJ^6D:9YN)^HB
M+>O-%7%,)T,/>+WJR?NB'=#H01*.0K5TL[=6D,8V\.N$+,#J;K#'6[V,>=4.
M#:TZ#&E4.?'56M6[#[-UI<XT I9'9^:44CZ?&<\(074PU/YSZ.&B@5>NP.H#
MPZJNL^0EPKQ $QDF5YIT-<!.'I[J9Y*!DJ1Y+IZ.JP12_H ?X'J/4+_H/=!7
M%@ NFSM%4G3>DH*V>B YD15$5?GNZYO?IK;%3T74KLFCNU1%R;4T\=1GT%\3
MZ;'?U9[E%RQ]@]R29J*#5MLZ5GFY.HIC,NKO6WBH!UZ #=M4;&U(<?1Z#R $
M#T]3^CJ-U4W3]LR\#RNT7NG<<9ZEM#5,;S.\ZLIGD#T1Y]"\2;HQO#3\PKK=
M*/\ U'5,+O!M/,/Y2Q8\[$_FPU$00;ZHD0 >@&9WY0@&#K]</A""8FZ??])0
M'I][KZ,]=G3CL._SG7>/X=O!QW]742?%E=)W1SM&W@VA?\&J(S^_B9\>%^&G
M8H\V7"A2+,]5L"C]=5W?A.F7_P#D#&%>*_\ ]4S8?TX;#-&0^[2'DRWX)_?S
ML'B5#>CK:,G!;1-'-U5I_)C<?B62Z]V$7)Y\<IK)L[2$ @80[P1\I=I]Z0/O
MB+<U*B&@B'W@+(CU^^)?KYYE3T^;+1Y%-:[[4.' R14-.P_]WETSQZXPN[%T
M97IQ^;5MMB'["2IE</5Y-&W^6I.4?L"ZLW.@MLGD7/RR8B47,;1Z+'5XY0_X
MB(3<].V<JG7_ (55(!+I]](<M:O]T%5N#FVS9NGA.NY+75\E2/0704]/2X](
M%0>]>S3=%T (-9=Y9!^:934K(2.8$LLLX/>8AW*=VK^R3X0:S.@[6UF^V3*-
MQ**<EM"Q/[&F;N^D?+UY@$)3W0'$ $P.:XL =.Z3N$,8IK!NO2_MU= YC;I'
M;(G9S%:J:.F.OTM1)U]8S'9N5+?3E7-1;";-T9#C1OK'C@^MF=,/7$SJJ=W_
M '0E;":M4*G1X=O7J55Z]4(!H'1I"5>%C8"(;!T O1O&Q39HS1^I*4O\&B7T
M% /K &8ZJZRKKYG5%=55-94/\^>KGEJ)G_"EF<][O6XJZX*>"FC$--#%3Q-\
MV*&-D48[F,#6CU!7%G67,F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(
MF$3")A$PBH%I^YR9_H"_]W"AW ]Q]BK^%*81,(F$3")A$PB81,(F$3")A$PB
M\'7V,X_ +?HS814^O_:&$^:(W]21PH;P'</8JOA2F$3")A$PB81,(F$3")A$
MPB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$
M3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$5 M/W.3/] 7_NX4.X'N/L
M5?PI3")A$PB81,(F$3")A$PB81,(F$7@Z^QG'X!;]&;"*GU_[0PGS1&_J2.%
M#> [A[%5\*4PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"
M)A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,
M(F$3")A$PBH%I^YR9_H"_P#=PH=P/<?8J_A2F$3")A$PB81,(F$3")A$PB81
M,(O!U]C./P"WZ,V$4*V5GLJ;-HFG89PA"-D"$(26?E(0A4B%*4I2N  I2@
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4D\SXE31R%SIA$PB81,(F$3"+_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g428534g42x62.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g428534g42x62.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1/X4&AO=&]S:&]P(#,N,  X0DE-! 0
M    $]R^4(0X0DE-! 0      !X< 5H  QLE1QP"   "   < E  "E-T97!H
M96X@36$X0DE-!"4      ! B)R.S>.0!+UE6301,F3\].$))300Z      #E
M    $     $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!
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M;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
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M;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M  !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M     !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL
M;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I
M9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M !  E,S,  $  @"4S,P  0 ".$))300F       .             #^    X
M0DE-! T       0   !:.$))3009       $    'CA"24T#\P      "0
M         0 X0DE-)Q        H  0         ".$))30/U      !( "]F
M9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &
M       ! #4    ! "T    &       !.$))30/X      !P  #_________
M____________________ ^@     _____________________________P/H
M     /____________________________\#Z     #_________________
M____________ ^@  #A"24T$"       $     $   )    "0      X0DE-
M!$0      !     "   "0    D      .$))300>       $     #A"24T$
M&@     #00    8              48   *[    !@!G #0 ,@!X #8 ,@
M  $                          0             "NP   48
M             0                         0     0       &YU;&P
M   "    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO
M;F<          $QE9G1L;VYG          !"=&]M;&]N9P   48     4F=H
M=&QO;F<   *[    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC
M90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M  9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D
M     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/
M8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,969T
M;&]N9P          0G1O;6QO;F<   %&     %)G:'1L;VYG   "NP    -U
M<FQ415A4     0       &YU;&Q415A4     0       $US9V5415A4
M 0      !F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L
M 0    AC96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%
M4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M
M#T53;&EC959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU
M;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO
M;F<         "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L
M;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #
M  (_\        #A"24T$%       !     ,X0DE-! P     "80    !
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M(R054L%B,S1R@M%#!R624_#A\6-S-1:BLH,F
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M     /_B__])0T-?4%)/1DE,10 !";[,_OX>  B <$%$0D4"$   <')T<D--
M64M,86(@!]  !P :  4 *0 U86-S<$%04$P     041"10
M      $  /;6  $     TRU!1$)%
M                               *9&5S8P   /P   !T8W!R=    7
M   K=W1P=    9P    403)",    ;   *(&03)",@   ;   *(&03)",0
MH[@  *(&0C)!,  !1<   CBT0C)!,0 #?G0  CBT0C)!,@ %MR@  CBT9V%M
M=  '[]P  )"19&5S8P         :52Y3+B!796(@0V]A=&5D("A35T]0*2!V
M,@
M                                              !T97AT     $-O
M<'ER:6=H=" R,# P($%D;V)E(%-Y<W1E;7,L($EN8RX  %A96B        "U
M6@  O&<  )(P;69T,@     $ PD   $                    !
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MY^@VZ8;JV.PK[8#NU_ Q\9#R[_1-]:KW!/A:^:OZ]OPZ_7O^N____P"  (
MY;1_S7]4S#]_I7[#LHQ_E'YIF']_GGY,?>-_P7YC8D%__GZ21&& ?W\%'V2!
M_H <_+A^=(MYY ]^5XFRRMM^3X@4L3Y^7(:TER]^@H6;?)-^OH2Z8.E_#X/T
M0P!_EH-X':* Y(/?^J-])9<(XDA]')0QR5A])9%ZK\Y]2X\>E=9]AHT->TY]
MUXL\7[1^-XF)0<M^P(@M' 1_SX@1^+]\%Z*PX()\%Y[)Q[)\*YL4KD5\6Y>C
ME'-\JY2F>@Y]#)'F7I5]=X]/0+9]_XTM&HQ^Q(O)]PE[1ZYUWMI[1*EZQAM[
M7:3$K-)[EJ!FDQ![ZIQ:>-I\6YB[78A\SY5-/[E]4I*+&3Q]QH[P]85ZJKI=
MW5EZG[1(Q*=ZLZZ+JWQZ\*D]D>)[3*1.=[)[P)^Z7(M\/9N//M-\O)AV&!=\
MVY!)]#AZ+\9RW UZ&[\[PV)Z)[ASJDUZ9+(VD-]ZR:QQ=M)[1*<06ZY[P*(P
M/@Q\.Y\/%QQ\!X^@\QUYT=+(VO%YM,IAPDEYN,*-J3]Y\+MAC^=Z6;3.=@9Z
MW:[&6P9[7JF'/6-[T*33%DE[4H\1\BIYC-^$V?UY9M73P55Y8,SNJ%9YE,3B
MCQ-Y_KV2=4MZAK<'6FE[#+'</-I[>JDE%9YZR(Z=[>V)$WXKUGZ( 'VQOLV'
M!7U7IK6&,'TSCAJ%A'U(=-"$_'V,6FN$FWWH/8Z$GWZ+&(N&>H !Z\F'KHD(
MU0"&HX=]O8V%N88AI7Z$^(4#C-"$9(0J<WV#](.(60^#J(,'/#F#N(+@%OF%
M=X0#Z?N&<)/XTU.%=Y%UO!"$G(\9I!2#]8T3BXF#=8M6<E6#%XG55_^"V(A\
M.RR"ZX>4%8B$>X>HZ%*%<Y[XT;*$@YN!NG^#LI@[HJ&##I4ZBCB"H)*A<2F"
M4)!#5O>"&XX<.C2"+HR6%#B#B8K)YLB$JJH8T#*#NZ6MN0:"\:&"H3^"59VD
MB.Z!XYH2< N!HY;G5@*!=9/_.5.!AI(,$Q6"FHSGY6.$#+5BSM:#'; #M[6"
M4JKJH 6!N:8NA]6!3J'&;OV!"9V\51^ XYHS.(F \Y@X$A^!O(Q!Y"^#B\#:
MS:R"G+J"MI*!SK1ZGO2!-J[?ANB TZFP;C& DZ3M5%R 9:#8-]V =)Y8$52!
M XNWXRF#),R5S*^"-L4[M9B!9;Y#G@. RK?+A@F :;'=;7> ,ZR-4\: "*A6
M-TV "J-<$*Z ;(M'XDZ"T-B[R]J!YM!.M,2!$\AAG36 =,$4A4Z $KIZ;-5_
MW[3-4SQ_NK!(-M%_O*40$"I_](KNW3R287R8QVN0>GQ#L5:.LGP0FL>-&GP1
M@Y>+MWQ):YZ*@GRQ4G6)B'TR-HZ))WX!$3*+UG_>VT:1+8;+Q@6/0H6$L"J-
M@X1OF;*+_(.0@H.*K8+R:HR)C8*(45Z(HX) -7J(28)@$ 2*F(.&V;.0 )$D
MQ)V.(H[MKOV,8XS?F("*\8LF@56)LXFR:6J(IHA\4$J'RX=V-':'>8<%#OJ)
M5H:[V$>/")N2PRZ-,IA[K8&+AI67EQZ*$Y+]@!>(Z)"^:%.'YHZ\3UN'$XS_
M,YV&PHP=#A2(*(F$UNF.2J85P=&,>*(FK"2*U)YSE=*):)L*?N:(,I?J9TN'
M/I4M3GV&;Y+,,MF&')'!#4Z')8C_U:>-L;#'P)N+XJP JO:*/J=WE+2(UJ-!
M?>*'I)]<9EB&IYO:3;6%W9CY,BR%BI?R#*B&2XB/U)"-,[NEOY*+9[8%J?*)
MPK"FD[Z(6ZND?0J',*<(99Z&-J+G30R%7Y^O,9V%"YT_#!Z%EX@QTZ.,R\;'
MOK.+ \!)J1:)7KH4DN>']+1)?$*&S*\$9/:%W*IW3(>%!:=E,22$HJ$Z"ZZ%
M!(?FTN",<M)7O?N*L,KQJ%V)#</ADC&'H[U3>YV&>K=\9&F%B[+'3 V$O:YG
M,+>$7*#P"U6$CH>IS/N;\GM;N).91WLAH_:6N'L)CMZ48'LF>16217MX8FF0
M97OY2G*.VGR3+V..-7U^"GZ0'W_ RSJ:XH3]MV:8(X/GHP&5F8+\C?J338)+
M>"N10X'887R/=8&:27Z-]X&!+GF-5X'C"<^.FX,(R=.9WXZMMAR7)8S"H>64
MF(KXC.&26XF)=R&07HA48(..GH=>2)B-*H:@+:>,C(:="36-1X7HR*B8YYB.
MM..6/97.H*>3O9,TB[N1<I#M=@./AH[_7W^-THU21[&,9HO[+-Z+S(O-"*^,
M'X7?QWR8+**&L\:5A)[ZGWN3"YNLBH20TIBJ=.R.V97T7H^-,9.@1NZ+Q9'$
M+#N+)Y&^"#R+(861QE^7FZRELK*4]:A9GFR2?J1*B8202J"-= &.4YTC7;B,
MG9HG1D&+-)?W*ZZ*E)<[!]N*3(50Q6:7)K;LL<F4@+'>G8F2"*T.B*J/U:B:
M<T"-Y:2/71.,,*$31;&*M)[3*SJ*$IO(!XN)FX4:Q)*6P\%XL0>4'KNEG,F1
MI[86A^Z/<K#N<H^-A:Q57'V+VJB913Z*7*9!*MF)J)SY!TJ)"X3NP^*6;LQY
ML&>3RL78G"B15K^%ATZ/([FS<?Z--K2J7 .+C;$31-6*&JQ"*GR):9RZ!Q:(
MF83+O3^ET'IZJARB:'I-EM&?''I%@Q2<"'IR;IV9.'K462R6LGMD0E.4HGP*
M)_.3\WS]!*J3?W^FN[.DXH.4J2JA6H*<EA6>"H'0@F":_8$^;=N8.H#K6&.5
MPH#.08*3O(#;)S23"X%U!&B2 X*:NHBCZXS"J!>@:(L!E22=%8EN@6N:%X@I
M;/&778<G5XJ4[X9F0+R2[H7H)HZ2.(9;!"^0M(+4N7RC&Y7UIOV?HY-ZD_^<
M69$Y@%^93H\S:_66G8V15JV4-(PQ0 *2-(LY)?F1=XO9 _V/DH*RN):B59]H
MI@J>Z9PSDOZ;JID_?U:8II:+:P25V)0N5=F3?)(_/U*1?I#L)6Z0OY%6 ]..
MF8*6MZ.AR*D"I36>5:45DBZ;$:%K?H*8$9X9:CF55ILB52*2ZYBL/L.0[)<_
M)0&0)Y8+ Z^-R()]MLNA5[*]I&V=X:X>D6R:G:G&?<J7H*71:9:4ZZ)25):2
M@)^#/D^0;)Y4)*R/H)C, Y&-&H)IM@^@_KRVH\:=@K=AD,J:/;)<?2R7/ZW,
M:0&4CJG@5!>2+:<-/>^0$J3#)&6/,)B; WF,C8)9M7&@K\<LHSR=+<$7D$&9
MZKM??*66\+8_:(B40+(24[.1X*]'/9N/TJFH)!^.])AL V6,'8),KAZO_GGD
MG"FKWGFVBA"GWGFR=XJD%WGF9$>@F'I03_F=<WKF.A^:]GN-("F:F'QQ  "5
MTW_*K,ZO*(*#FVBJY(&9B7ZFVH#@=ONC$X!C8ZB?FX F3U.<?X C.72:!8!,
M'Z&9EH$7  "4CH  J]^N/8LNFHJI_HF-B+VE[8@:=C&B,(;[8N2>O(8@3I^;
MIH6..-69+(5+'RZ8JX9&  "3<(  JQ*M:I/GF:JI-Y&:A\RE,(^$=5"A:(V]
M8A*=_(Q13>B:Z(LX.$&8:HJB'LJ7UXNS  "2>(  JD&LRIRTF-JHF)G"AO.D
ME)<7='6@SY3 84V=2Y*P34*:/9$H-[^7N)!K'G67%)!A  N1DH 'J9"L+*7,
MF"^G_*(QADBC^9[B<\J@-9OO8*J<LIE<3*^9CY=K-TV7"I;E'BB67Y18 !N0
MQ( 2J.*KN:\#EZ*G?:JXA<*C<J;#<T"?K*-#8"F<-J!/3$&9')X[-O:6@)U]
M'?.5R)1  "B0&8 ;J$*K8;ATEQFG&[-[A4.C#:[G<LB?2*KD7[N;UJ>I2^&8
MQ:7C-K"6(Z+K'<R53Y0F #./CX BI[FK%<)>EJ:FQ+RKA-:BMK=Q<F*>]K+Z
M7V.;AJ^Z2YR8=:T?-GN5W:36':>5"90- #R/(( HG["ZA'ETCM6UJWDZ?=&P
M_'DR;&2LBWEG6CBH9'G41N^DKGIJ,>NAYGL'%_"B<GN^  "1*(  GJ:YMH&D
MCD*TPH"]?6*P!8 -:_.KC'^>6;BG9']R1FRCKG^#,6R@WG_!%["A.X"Z  "0
M;H  G?>XRXG5C9JSWHA)?,^O&H;N:U6JHX7M61ZF>H4T1>&BQH3,,/J?[(3$
M%X&@'(8$  "/RX  G6BW\Y(0C/BS#X_G?!JN4HW[:JJISHQC6'VEJXLM15FA
M]HI7,)6?$XHL%UR?'(JP  "//H  G-6W1IIIC&*R89>F>WNMII4T:@:I)),8
M5^VD\)%=1.&A/Y U,#Z>4I J%SZ>-HZX  ".Q(  G#NVOZ+NB]FQT9^2>OJM
M#YR/:8NHCYGX5WFD6I?61'V@DI9P+_B=GI:D%R>=9X^H  ".7H  F\BV-JN@
MBW"Q1*>E>IBL@J03:2^H!*$%5R6CU)Z71#F@")U)+\2<\)PG%Q6<J(^;  ".
M"H  FTJUU[2,BR*PU*_;>E>L ZNK:.FG>:@Q5M^C2Z6P0_R?E:2>+YR<AJ Q
M%Q6<%X^;  "-Q8  FMFUAKWKBLNP=+B#>@ZKH;.V:*RG&Z_C5K*B[ZV@0]^?
M.*JG+Y&<+Z I%Q^;MH^B  "-CH  D?/%8WD8@A^_TGC+<A:Z?'BY8:.U:7CJ
M4'&PIWE3/@NL<WGD*::IEGIJ#V:K67L+  "-0X  D3?$BX#F@;:^\W_X<<*Y
MD']*84JT;7[B4 VOGG[$/:VK7W[E*5VH9G\R#X6IPX!$  ",_H  D,W#DHBH
M@4>^"(<G<5ZXGH7<8-NS=83S3Z&NGX19/5*J6H09*2.G2H1.#Z^H3X3N  ",
MP8  D('"J9!K@.B](XY?<.FWO(R58&NRAHLF3SJMLHHE/0"I:HF3*/:F2(GC
M#]JG!(D"  ",C(  D"S!Z)A/@)2\6Y6U<)*V\)-T8 NQNY&53NBLUI F/,.H
MDH]I*->E8Y ;$ 2EX8K4  ",7H  C\?!4*!B@$*[M9TW<$VV0)IS7\^Q"9@L
M3JZL)I9Q/)6GT)6R*,*DEI6\$"NDXXKN  ",.(  CV; U:B4?_R[*J30<!:U
MJJ&'7Z*P;Y[?3HFKDYT'/'VG.IRL*+BCX)IN$$ZD!HL&  ",&8  CR; 4;#U
M?\RZH:R3;_:U'ZC+7XVOXZ783G>K":0:/&^FO*+_*+.C4YN%$&RC1(L;  "+
M_X  CM2_\+G)?ZZZ+;2;;^VTF[ M7X>O4:SZ3GNJ<*M</("F(*?U*-RBR)N@
M$+"BN(M(  "+ZX  A+30GWCS==?*67B#9J[$;WA;5Q&^UGA]1K.YDWC:-0>U
M"'E8(/:R=WFN!^NRV7M%  ")^8  A&+/GX!N=9O)?G]G9G##C'ZM5LZ]UGY$
M1G&X='XI--FSS'Y0(/:P_GZ?"&>PZG_G  "*%H  A$K.A8?%=6_(?(9!9D/"
MA83Z5IF\O80A1C^W2X.>-+ZRD8.!(0NOE8/X".:O*(/^  "*+X  A$;-?(\6
M=5_';(T99B#!<HMG5G:[FXH:1B2V*(E(-+6Q9HC^(2RN28GD"5VMFX95  "*
M18  A#G,F):%=5C&>)0'9AW <)'P5FJZEY!)1B&U%8\D-,2P58[?(5JM((][
M"<RL0H:@  "*6(  A!W+U)XA=5#%I)L:9BB_CIB05H.YKY:91CBT+Y5+-..O
M795*(9*L&)1 "C2K&X;F  "*:(  @_[++*7/=4K$[Z(Y9C>^S)\[5J&XZ9S]
M1ERS;INY-0ZNFINM(<VK,I;;"I&J'X<E  "*=8  @]S*FJVF=47$5*EV9DJ^
M**8!5L*X/:..1H2RPJ*A-3VM^*#I(@JJ@I<$"N>I3X=?  "*@(  @[[*$K7%
M=47#Q;#J9F2]DZSR5O*WHZIF1L*R):C?-8BM5J0R(F6IVY=!"T>HL(>@  "*
MB(  \H9[1GF*VO=[G'FEPOU[]GG1JGU\6'H<D7!\PWJ*=[M].WL67/9]PWNJ
M/]9^>'Q<&Q9_T7T/\%QYD(3OV3IZ!X/HP7%Z@(,$J15Z_H).D!U[A8'(=GE\
M%X%D6[I\LH$*/I=]9X#4&75^7X#;[FIX)I!TUVAXK(Y1O]=Y-XQ1IY)YS(J?
MCKQZ:8DE=3=[$8?56I%[NH:5/79\:X6)%_9\[X48[)AV^)P&U9]WA9C3OB!X
M&I71I@%XO),-C5)Y;Y"F<_5Z)XYK675ZVXQ-/&Q[A8J"%II[B(C?ZO!V!:>C
MU !VDZ-LO(IW+9]OI(5WUYNYB^]XD9A&<KYY6I4L6&=Z%Y(Y.W5ZMX_5%61Z
M5XP4Z8)U2[-2TIEUU:XBNREV;*DHHS5W&:1^BKUWVJ B<9AXIYP35VQY:YAF
M.I9Z I6N%%9Y9XW Z%!TN;\=T6UU/;CTN?YUSK+_HA-V>JUDB;EW0Z@L<+-X
M%J-.5I%XV)[K.=9Y9IPJ$W)XIHTFYU=T3,L+T'ETRL/JN09U4KT H1EU^;9V
MB,QVQ+!H;^AWGJKA5>=X9*8<.3-XXZ'1$KEX"(RHYI%T ]<IS[AT><\,N#IT
M]L<QH$5UE+_(A_]V7+CW;R]W.++H549X *XM.*9X=Z9-$B5WBXQ$X>.$+G?E
MS#.#HW@[M?*#+GB8GOZ"T7D,AUJ"BWF=;O""77I+56""3WL".2:"F7O3$]^$
MG7R.X!^"H(*]RO>"*8'WM-V!Q8%-G=^!>8#,AB.!0X!T;;.!*8! 5!Z!,( >
M-^Z!@X L$GB#(("FWH2!2HVKR4Z X8O>LU& AXHOG&> 48C#A-2 ,H>,;(:
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MACN;:[$I=B*8>*U&94&5JJFN4[23*J<.02^1$J4Z+0Z/?9YV% *0#(V'  "
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M?#2G38T-;1ZCP8NT74&@8HJ!3(F=3(F).HV:P8CL)I29,8C_#3^:7(<]  "
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M<>&UP&YI8[&QO6]Q5*NMZ7" 1)FJ8'&-,P&GDW)X'KNFT7+!!;VG/W-M  "
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M<$^PK9) 8@BL<9"74P*H8H\F0R6DJHX2,?ZAG8VU'H&@(XW@!R&>HX32  "
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M9<._L72+6#J[!'352?&VAG5 .I:R=G6_*8VO?W8A%16OQ'6[  ^IZ7CG  "
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M93^Z8I;@5ZZU?Y4*26.PSY.-.C^LD)+"*;:I.),'%F"H+8\A D>AM(&*  "
M (  <A.^TZ!@93VYS)X:5[&TU9ON262P%IHZ.CJKTIFV*;>H?9AY%H6G38\Z
M HV@LX&Z  "  (  <?Z^=J@V94.Y4*6B5[NT0Z,H26NO=Z%K.D6K*:!1*="G
MRIQ%%JBFCX]2 KJ?\X'8  "  (  V;5Q@6RJQ0YRUVXWK[]T&V^WF9MU27$M
M@JQV:W*C:NMWBG0;4@5XH'6"-GIYH'; $@)Z>7:MU[=O5W?>PW!PW'A'KDER
M07BWF$MSCWDT@71TTGF^:<=V#GI14.MW-'K6-6AX(7L^$,YXPGJMU>)MA(,=
MP:1O&X)GK+5PF8'"ELQR (%)@!QS7H#J:)-TLH"<3]EUY8!*-&QVO'_O#\!W
M07\BU!EKZHY*O]5MCHR0JNYO&8KPE3IPEXEU?K!R#H@Q9U=S=H<$3LQTM(7B
M,X!U<H3;#M9U\X,PTGIJE)EOOCML0);,J51MUI0_DZYO7I'5?5)PXH^49B5R
M7HV13<YSI(NH,J5T1XH8#@YTU(:HT29IBJ2=O.MK.*$CJ )LSYVJDF%N7)I1
M?!QOZ)<J90IQ:)0_3.-RMI&F,>!S/X_.#65SXXD.T!5HN:_4N]UJ9ZN*INMK
M^:<KD4EMA:+G>QAO&)[F9"9PGYLS3!EQZ)?O,3IR6I84#-ES&XBPST=H'[L5
MNQ!IR[8!I@QK4[##D%YLUJN8>B]N:J;&8U=O^*)M2W!Q0Y[(,*IQEYN0#&=R
M>8ABSKEGO,9@NH!I8<!]I6%JVKICCYQL3;1@>6UMVJ[/8J=O:*GO2LYPKJ90
M,!IPZY_N# QQ]X@EREIYY&N+MWUZ9&U+H\%ZYF[KCP)[:'!T>55[[G'Z8K5\
M?'-_2M)]%73N+^%]T'8>"SE_9'8WR.EWZ'8\ME=XD7;DHJ1Y+7>#C>QYQ'@B
M>$)Z77C*8:]Z_WEZ2=E[HGH:+O5\27J0"FM]L7JHQV5V*H#DM*YVYH"'H1QW
ME8 LC'-X0W_H=O)X]7^Y8(5YK7^82,]Z6G]S+@=ZY7] ";9\,W[6Q=-TI8MZ
MLPMU:XHSGWAV)XCRBP-VY(?$=:)WKH:_7U]X>(701]5Y+83O+3!YG(0T"1EZ
MZ()WQ%MS7983L9=T*I/VG@1T\)'9B9=UMX_-=&5VB8WA7DAW9HPM1NUX((J=
M+&QX<HF*")-YS(63PR1R6Z#"L&)S+)W7G,YS\IK>B&ATOI?T<TIUEY4S74MV
M=)*N1AMW-)"+*[UW:X]Z"")XW86 PBMQCZM^KV9R8:?,F\US(Z/YAVAS[J S
M<EUTSYRL7'UUL9EV16IV:9;1*RQVAY57!\1X%X5 P6YP^+9-KJ1QQ['9FOIR
M@:TQAHYS1*B3<8=T)J1-6[UU$:",1,YUR9W *JYUQYHC!WAW=H4-P/!PE,$V
MKA=Q7KP#FE)R";:)A=9ROK$><-5SF:PK6QYTA*@(1#MU.Z40*BIU(YR"!SMV
M]H3DNVZ"E&J<JC&".&QXE^N!^6XJA'F!T6^_;_R!N7%-6G"!N'+90X"!W71'
M*02"@753!3R#NW:-NDR O72SJ1" C76-EK. 9796@T^ 2W<7;N6 0G?=67"
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MEY:#^I=^AH&#,)5<=&^"@),S88R!\9$P3:J!AH]X.$6!18Y2'K6!6(W=  "
M((  IN*$'*,RELB#1:"(A:V"=IVL<YF!PIK*8,2!-Y@F30" S97R-\> =I2Z
M'E& ;))7  "  (  IDJ#CZT(EB."OJFZA/B!YZ8F<N&!)J*,8!* EY]63%.
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MBH>,6ITP>GF*S9JU:7J)7I@]5ZV((98*1-6'')1;,%Z&5Y/T%O^&LH^-  "
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M@769NGH2<GV7;7I-8F"54WJ543V3:GKI/LN1X7M *EF1''MQ$ :3+WLE  "
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M?B*54J)#;P"3 Y^37O:0S9SQ3AV.W)K4/":-3YG<*&N,.)@:#TN,K(I7  "
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M=)"B.H  9E^?3G^V5TZ<C'^"1QR:&']I-8N8*7]?(:&7=7]8"*Z7BW^3  "
M (  @62D)8A'<_"A)(=X9;6>/(:M5I^;>87Q1I:8^H5<-1N7#X4"(5J60H44
M"+R5WX/1  "  (  @-BC2Y!?<VB@3H\992Z=88W+5A6:F(R/1A.8$HN(-,B6
M!XKQ(2N5)(MB",R48(7S  "  (  @&VBD)B'<O>?F9;.9+B<J)4"59V9VI--
M1::749'R-'>5/)%;(164'I#H".*3#H8"  "  (  @!2B%*#3<L.?&YZY9'Z<
M%YQM55&9+)HX15"6E9BF-!>4CIAA(,:3;Y5_".B2 (8&  "  (  ?]&AO*E<
M<GV>MZ;L9"Z;IJ0R5/J8K:&E10*6#: M,]F3_)Y\()F2V)8*"..1.X8"  "
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M:'^K6(4N6P6GSX2'3+>D;8/S/7*A9(./+)"?,H-K&-F>]X._ NV:.X'[  "
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M7<Z[0&@.4..WEFEP0R.T!6K&-"JPZ&OT(Q^O/FRB#B&Q2&OC  "?!'.P  "
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M71ZU'(G)4$2Q (C<0IZM#8@0,_RID8>2(YVG.H? #^:GJX:X  "9D(    "
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M6G0[-<""?74X&\B#;W5F  "  'JYH(N!V7;5D6:!B'>+@5V!.W@K<!*! WC
M7<" WGE52CB UWGD-06 \WI/&S>!FGHL  "  'XZGV: &8 ED#-_W8 B@!=_
MIX #;Q-_>7_>7-M_9'_"28!_9G^M-'A_?G^4&LI_X7]7  "  (  GCM^L(E]
MCR1^?8C/?P=^4(?_;>1^*X<=6]9^'H9*2)%^,H69,[)^0H4-&CE^684,  "
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MAO*-G67Q=_",>6@@9Y^+B6HG5AN*NVP50SV**FWA+G:**6]'$\B,FV\4  "
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M@E2&2HZR<T.%8(UW8R*$A8PG4B2#S(KP/_*#1(H *]*"_8F>$A^#9X@Z  "
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M><^5'VT":YF3:6YG7$61VV^_2[R0>W$&.;Z/@7(G)7B/=G+("RZ1&')%  "
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M=?&.W9/P9[R-.Y)B6(:+J)#%2&N*38]H-Q2)0HZ8(YZ(LH[&"L:('8=)  "
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M;.Z=0G,A7YV:]'/F42&8T72L08*6\G5H,$25L77^'#:6!77[!%*3Q7=-  "
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M:DN8!IB#7-V5KI;+3G.3894,/QZ199/6+F./^Y/2&S"/C)$]!-6,'(-%  "
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M8*^F WA34_VC+'B<1FJ@>GCO-XF>,WE!)MV<W'EL$I>>,GCU  "4,'QC  "
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M7U:AI)RH4IF>F)KW1-B;HIE6-C.9%YC/)?R7:I;G$JJ7J8R>  N/BH (  "
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M5.FOK'R_2+ZL77RM.[FI-'R<+8ZFE7RB'1FECGR9">JEB'T9  ".P8    "
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ME )S'W-N@^1T#G1T<FAT^'5F7^QUX'933$9VQW<V-Q%WA7?M'9UWDG@'  "
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MCHIKXZ!7?EAM!9V1;35N'9J\6S9O0I@K2#!P4I89,]%PU)4?&SIO-9%Z  "
M (  G51I\:R7C@AK/:ER?<%L5*7R;)=M7Z)K6J5N?9]-1[5OBIT#,U9O_YMX
M&L1N1Y(9  "  (  F%!_EUY:BDE_<&%&>QA_>&/X:I9_GF9V6-A_UVC51<:
M+FL-,.6 OFS>%K6"/6TT  "  '9<EU-]&V>8B49].6FD>@%]9&N':9%]G&U-
M5^U]XV[^1/M^07"/,#E^O7')%C9_LW&[  "  'IGECEZUW"^B %[('(!>.5[
M8G,G:'A[L'0W5OI\"'4Z1"]\<'8I+Y=\VW;8%<5]2':%  "  'WSE05XQ'GG
MAKQY*GIR=Y=YA7K;9WEYX7LY5A!Z3GN.0W%ZP'O<+PE[&WP*%69['7NF  "
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M@KISCZ6*<WUS]**38U5T49^/4E-TQIS]0#-U.9MJ+&QU,YF,$XMTM(TW  "
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M>?V &X"C:\)_WX"67(M_IH!N3&=_>X!).JA_?8 M)MQ_CH 0#5)__G_H  "
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M<=J0D6 :9&F/<6*F5;J.@V4'1;Z-PV<Y-!^-<FD;']*.5FH7!DZ.F6H4  "
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M;;F(%H7[8%Z'*H6'4@N&0H3X0KJ%?(1Q,?*$]X0@'FZ$^80[!I&$/(+;  "
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M96>81V9O6+26HFA 2N&5(VGX.[:3ZFN#*J^3;FRK%C"5%VR4 "^0OFZV  "
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M8?60U8JA552/18GD1[.-OXD5.0:,=HAV*,^+G8A1%76+XX@$ 0.'WX"O  "
M (  ;4*1BY,*8;&0%Y(U51*.>9$!1VF,TX^Q.+R+=([3*'"*GH\$%1F*QXR@
M 1J&T8"^  "  (  ;.^0^)L.85^/?9GX5+F-U)A?1Q",():Q.'**L971*#F)
MQ94G%/R)R8XP 2>& X#(  "  (  96*F5UNP6A*D'UX53?"B(V!E0*N@6V*-
M,?*?!61H(.>?$V6*"_NANV4:  "-E&W2  "  (  9+.DS&,G6::BCF3Q39.@
M;6:P0&R>>VA6,=*<_VF_(/.<U6J*#$^>^FG]  "+^W+,  "  (  9"NBZ&IU
M60R@N&NX31F>E&SQ/_B<FFX>,7^;$6\:(-":P6^5#'V<;&\&  "*>W>B  "
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M5LR:2HZ;2M.8'(V^/=B5_8S;+ZZ41(QV'XN3?HRO#(F3)8AZ  "%(8    "
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M3-^J)F_]05>GJ'"Y-.>E57%M)M^CO''L%@JD3G&K!(2A7'+\  "%07Z*  "
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M3 RD>I(B0*>ANI%5-"Z?(Y"D)F>=+Y"9%B:<]HWD!6J8<(.I  "!@(    "
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MBZ-N[F4/?#%P06=I:Z-QC&FA6>5RT6N^1N9T!VVZ,CAT]6]@&-)TR6_<  "
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MA65D9I#8=D9F-H]F9B%G[8WB50UIDHQ]0M9J](M6+Q5K:HJL%IUK(XG'  "
M (  DMYA+IN)A+)C.YFA=8YE#I=U96YFPY4Z5%YH;9,]0B]ITI&R+I-J+I$E
M%E9J%8WE  "  (  DF9@3:3SA"YB7:)G=/MD*9^$9-EEUIR<4]AG>IH70<%H
MV9A3+B)I&)=@%>5I3([.  "  (  CGQXYUBQ@2=Y4EP)<K=YX5\H8OYZA&(3
M4@%[,634/YU[[V=>*SQ\Q6E;$-Y^4&E@  "  '8)C5)UX6&Z@!!VF61 <9QW
M4F:;8?UX#VC341]XSVKK/MUYE6S3*I]Z1VY $(A[A6WV  "  'H?C!US&VJU
M?KUT"6QY<'MTXVX=8.5UNV^B4#)VCW$2/AIW77)=*@MW[7-%$#UY$'++  "
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M><UK6)9$:Y5L?)2!7%UMB9*I3"-NCI$/.JIO6X_V)X!O)X_L#P!Q4(HE  "
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M<@YZ#7+W9)9Z:'0%5BYZNW3W1EM[('73-1=[AW:((71[U';0"+)]<'<+  "
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M;E=S)YK]8/-SFYD04I-S\I<.0S5T296!,G1T>I42'X%SMI+6""QW"H6&  "
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M9;F!'7B160Z ZGDB2UV MWF8/)F DWG\*^B J7I"&$B _WH3 FZ!1'O   "
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M7="32%GW4:Z255S%1%&1E5]B-7F1)6&P)'*1HF-5#T^4C&,G  "("6F:  "
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M6>Z),'U+3@"(9WU[00F'GWV-,MZ'!'V9(MF&S'VC#PN'$GVU  " &X    "
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M4:R;65]51C>9]&%Y.968P&-R*U&8%&4,&E"9$66T!M^8W67C  ""$'(Q  "
M (  6U^:A61#4/69&V7\19^7O6>B.066A&DF*NJ5Q6I6&B:6AVJU!Q>5G&KD
M  " EW<4  "  (  6K:80&M:4#B6YVR>1-&5EVW..&J486[C*FJ3GV^Q&=V4
M,V_.!RZ2L7 C  "  'ME  "  (  6@R63'*!3Y*5!'-;1#"3MW0<-\:2?'2W
M*@*1JW4M&922''4A!S&0*G7>  "  '\N  "  (  67.4MWG(3P:3?7I#0[&2
M+GJ5-U&0Z7K#*9B0!'K?&7&0+7K,!SN-^'O1  "  (    "  (  6/"3:X$3
M3I:2/H$[0TR0ZH$C-NV/EX#L*2Z.I8#.&2".J8#K!U",'(#@  "  (    "
M (  6(B27(A@3B^1.H@[0N>/YH?$-I".AH<V*-R-?H<&&+>-<X='!RN*HX39
M  "  (    "  (  6#>1CH_E3@F0<H^C0L./%8[.-F^-D(W;*.*,5XW"&/F,
M"(RA!W*)5(4)  "  (    "  (  4*:J851-1F*HF%;2.TVG#5D]+NREY%MI
M((:EV5SW#I>HHUT(  "@"&!\  "  '$N  "  (  3\:HE%LJ1<2FS%TW.K^E
M'E\R+H6CP6#W(%NC;6(K#L>ELF('  "=;&45  "  '7X  "  (  3SVF4V'O
M12VDEF...D&BZV48+A&A?F9Y(!.A!V=6#M&BX6<*  ":WFGN  "  'H\  "
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M0TJ<<X1Q.(&:MH0R+)F9"(/?'PJ8$H/D#JJ8=X-[ +60F8![  "  (    "
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MB'5777M?>4E::GN]:1Y=/GP*6 )?ZGQ618YB*'RD,:UC&WSE&;!C1'SN  "
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M@YYK3%<O=/-L\%K,91MND%XW5!!P(V%X0:QQF&2 +75RI6<)$]%SQF?'  "
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M?-)<:H(';J)>\H'?7V5A1H&@3R=C9X%D/9UE"X$[*DUE)($L$>9H]X$[  "
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M=S=O,%\#:8%PA&'.6J5QS61S2H)S!F;M..%T(FDD)0MTR&JV"XUW]VJJ  "
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M<5YB6H?*9 ]D3(<T5:YF#8:&1CUGF(7K-7!HDX6"(J1GI(6*"LMNSX1#  "
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M:K!T%V747?QU"6?S3_QUZFGK0+EVOVNX+\5W?6TU'!!WRVW6!)Q[Q6ZY  "
M '_O=41P!6O?:7-Q.FU]7+IR3V[^3Q!S17!@/^)T+G&:+R%TWW*6&Z9TNG+B
M!)]YL70H  "  (  =!-M5W0W:$MNL'4Z6Z)OWG8=3@5PYW;>/SQQUG>,+IER
M>W@2&UAQ[G@B!*UX&7FS  "  (  <PYK&'R>9V]LCWT36MIMSWU:33)NXGU^
M/FIOSGV<+@!P4GV]&N%OB'W"!)AX/'Z"  "  (  <CII,X3Y9J%JOH3D6A9L
M"H213'AM)80B/;IN$(/$+6YN=8.7&IAMB(/>!)IX.(*#  "  (  <9)GIXU&
M9@!I0XRQ67AJEHO-2^1KL(K./2ALDXH&+-QLWXFZ&BMK]HG,!)EX.H,<  "
M (  <15F<96-981H&I2.6/=I<),B2V5J@Y&>/+UK6)" +(IKA9!?&=!JM(Z(
M!&QXAX+]  "  (  ;,6"V5)[88*"S57G54B"]%DL1\N#.5P].-:#H5\!)]F$
M>&$L$O2&NV&5  "#.F6N  "  'P#:Y9_A%I.8)!_P5TA5&: !U_01Q" 56)3
M.$. N620)W2!:V9$$M>"^V9?  "!"6IB  "  '\V:H1\4V(C7V]\RV1>4W9]
M,F9\1BY]D&AN-XM]^&HG)NI^BFMG$I1_B6L_  "  &]Z  "  (  :6UY9FGX
M7DYZ!&NA4E%ZA6TM14MZ]VZ8-K][:&_.)DQ[VW"A$CE\CW!(  "  '3^  "
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M6KYQ*)#J3NMQX(_;0A-R2XZS- MR?HX")"]R(8XV$1%S/XKP  "  (    "
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M4DZ!$G!Q1O2!''&%.HN!%7)O+,"!)W,M'&>!CG-C"6&!XW.*  "  'RL  "
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M2HR5\5-5/XF53U9*,R:5 ECZ),^5=UL6$N^84ENH 8*4I5V-  "  &T4  "
M (  4YZ3_5<_2;R31%G@/L62IUQ=,HB21%Z;)&>2B&!/$MB4YV"9 =21"F)I
M  "  ''X  "  (  4LN1#%X_2-R0>6!G/@J/[&)M,=B/AV0Y(^2/KV6'$IN1
MI&6. @:-RV=G  "  ';D  "  (  4@".0F5 2 :-R&;Q/2B-2VB!,2^,Z6GA
M(U2- 6K0$DJ.DVJ= A^*\&RD  "  'L\  "  (  43F+R&Q51T2+:6V6/&N*
M]VZU,'2*CV^>(N.*BG ]$?Z+OF_F BV(>'):  "  '\&  "  (  4(*)JW.
M1IF)9W1<.]*(_74-+^J(C'6/(FF(:'77$>*)'W6( D6&57A*  "  (    "
M (  3^*'XGJI1@R'N'LM.UB'5'MU+X"&U7N7(@2&DWNF$:B&Y7N+ G"$@GU7
M  "  (    "  (  3V"&8X'$18B&4H'P.MB%]H'7+PR%<(&G(9N%$8&F$2^%
M&('# F&#$8%U  "  (    "  (  3OB%-(DS15J%1HE .KF$\XB]+Q"$.(@4
M(>V#@X@:$>2#'8<D M>!M('L  "  (    "  (  2%BB<4Y?/M^A/%%"-&F@
M9U/V*%F@*%9.&<.A<U>_"*.C&UAE  "1E%_D  "  '!Z  "  (  1T>?YE3^
M/?B>[%=W,WB>&EG%)X^=KUN\&46>H5S8"*>?<UU9  ".W&1^  "  '51  "
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M.L^36G<Y,(*2KG>6)/B2 7>\%VB2'G>9"(*/TGB;  "$LGW*  "  (    "
M (  0\F207V0.FV1]GWM,#*13WWX),.0B'W:%T*0<WW("%*-\'YX  "#18
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M@$=0<VRG<?54 6Y68K174F_R4BE:67%X0&I<KW+G+1-="G08%3AAN'1S  "
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M>QQ##)@6;59'BI7U7H9+DI/R3J!/"I)%/8)119$=*N%0K9$3$]]>:8U   "
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M=*I3]'.J9T%7*72Y6-1:#W6R25Q<GW:=.$Q>2W=Q)6==@W@)#7YI,7@Z  "
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M< 9K#5'\8KILMU725&%N6%F#1,9OW5S[,X]Q*V 3']1QK&(Y!S-WMF,0  "
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M:4)8:7G'7+!;*WI.3Q%=EGJ\0%1?B7LB, =@6'N#'4]@B7N[!M9T<GSJ  "
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M8[MN:ED35U]OW%PN2>EQ-E\A.PUR:F'0*E)S6F0#%D-T"637 ,Y^I&<A  "
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M7>U=XW[T4AM@'W\,139A\G\+-QMC*W\3)T=BWG\O%'%FNW]F 21^$W_Z  "
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M5UUR[E\72^YT$F&0/R]U#V/7,/IUYF70((%V>&<>#'QY06<:  "  &]6  "
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M4J1D;8-!1WUF(8,'.T-G3(*S+:MGLX**'>QFZH*W"XIN7()[  "  (    "
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M2S%XDF/]0%9Y567D-%AY]V>:)HAZ?VCF%=-Z^&DO!'-]W&IO  "  '@@  "
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M1V]L 8;I/-QM089X,3EMSH7S)!%M9(7;%!!NI(6X!%%XM8+K  "  (    "
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M/R=_CV?.-,)__FDW*1Z 3VI7&Y6 P6KX"SN!8&K]  "  '!Y  "  'Z^  "
M (  1[I[XFU,/DU\L&YP,_Y]-F]H*'%]?7 B&OM]IG!L"Q-^AG"'  "  '95
M  "  (    "  (  1OAY,71=/95Z+74=,UQZRW6G)^9[!78#&G)ZYW83"M1\
M-G9L  "  'M'  "  (    "  (  1D]VT'ML/.MX WO0,KUXO'OX)UUX[7P
M&?IXA'O["FUZ;WRM  "  ']X  "  (    "  (  1=-TVX*\/(=V1(+@,F]W
M((*?)SIW.8)+&B1V<H);"LYXM8(&  "  (    "  (    "  (  0)F914BK
M-[*8K4OE+:.8E$[4(:J945$[$GF<,E)3 U*9OE1@  "$LE^*  "  ' -  "
M (  /S>5O$\$-E25CE'9+"R5F51B($N60%9F$6Z8H5<O PF5%5D_  "!KF1
M  "  '4!  "  (  /D&2%E5X-3J2&5?A*QZ2/EH"'SJ2UUN@$*"4PUP? M*0
MSUXN  "  &DC  "  'ET  "  (  /6^.?5O]-%".GUWV*AB.U5^I'F>/9&#H
M#_^0UV$J JJ-!F,Z  "  &Y6  "  'U8  "  (  /)J+%&*:,W2+:60F*42+
MK65T'9F,(F9+#Z>-$&9G IF)Q6B'  "  '0$  "  (    "  (  .\N'\FE=
M,J:(AVJ!*)"(Y6MK'0:)0FOQ#S^)I&O6 J:' VXP  "  'D[  "  (    "
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MA:''[);8JF"T_I0BI=>AKI&2H7"."X\YG3%Z3(T)F0)FEXKXE,Y3-HCPD'1
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MB!K*"H9UQ<VW X4\OL"C6800MWV/68,2L"5[8H)1J-1GC8' H6A4!H$_F;!
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M?LO%LX3AA,JT (0MA *AHH.!@T*.6H+U@IYZQ8)Y@AIG&X(7@:Q3GX'*@41
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MD/98@'5OC4=$/W>UB4HPG'H[A,'14&F!K9>]RVM)J0VIOVT"I%B536[%GYV
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M@M+$SG+<GSFRQW._G"2@)G2AF/&-!'64E;9YIW:GDGYF.G?=CT-3&'DUB_!
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M28]@>\6#AHVC>_YT 8O_?$5D*(ID?*-4/(C5?1A$JH=$?9PUC(7 ?CPGEX1
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MB]0Q\)(GB.4I?8R$AA<BC8<<@YO.H6T89OJ[Z&[L:3VHM7"M:W&4ZG)>;9R
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MAE7$&F'WN>NQ]&1@M%*?&6:?KE>+V&CHJ"UXD6MKH@=E;6XIF]!2IW$5E5Q
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MC7_/=P$K"("Z>E6QQ'L,;TNB:GMI<,^2&WO'<CZ!$WPR<Z=OA'RM=1U=RGU
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M_GX)AN(H:W['@X:?2GPTHLB1!GPDG[N"%'P&G$-RHGO\F(QC WPDE,A3<WR
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MGHT!F#ANX8LQE85ANHE>DI%4A8>OCYI'?(8GC*$[&82BB:4O78-"AHDD_8(
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M7(>I@% C$H3U@#M]?9E^B-UR-);QB!)F>)1/AR)::)&@AA].38[PA1Y"98Q
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M@LW"SV@.8."Q2FI.8[^?46QY9HR,PFZ9:4UYPW##;!-FEG,(;O!3GW5R<?)
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M<R%G/(*-=(%938([=?%+2X']=WD]NH'/>1HPMH'$>N4E 8':?-R,[8'O>'"
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MA'EFI')U@]A8_W07@S1+4W7N@I@^('?U@?\Q?WHZ@5XF.7RC@+.,6FS.C7R
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M9(T*=(XV,HK5=H<MJHBD>)HEW(:1>M@?8X2R?1MC<Y-7=#-:L)&B=4E1FH_
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MPDZ.ER2%(5--E()UXE@0D=IF1%T3CS=6GV)EC(U'A&?[B<\X^6WFANLKO70
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M?!\NMW_<?14FX8!%?A8@:8"\?PUD=GUD?GU;NWW+?M)2LGX!?OM);7XA?Q%
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M;5MF>DM3?6$_>SQ%$V=;?#\W1&W3?6HJXW1J?KV9*D+N@':,&4BO@&5^>$Y
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M_P  __\  &UF=#$      P0A   !                     0
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M'!T>'A\@("$B(B,D)"4F)B<H*2DJ*RPM+2XO,#$R,C,T-38W.#DZ.SP]/C]
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MYO^F.3+_HD9*_:!-8/&D3'+FITR$VJA0EL^F6:;'I62QQ*=OML&G>+N]IX'
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MTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3K7^BT_^C.2K_GT9
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MV8R;GMF,FY[9C)N>V8R;GMF,FY[9C)N>V8R;GMF,FY[9C)N>V?^D."K_H45
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M_YI12O^=4EGWGU1I[:!7>..?7(?:G&>5TIEPH<R6>ZO&E(2SQ).+ML*/C[K
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MW)9QDM63>YS/D(2DRXZ,J\B*D+#%AY2TPX28M\*!F[G!?YZZP7VBN\![IKS
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MCCX=_XY++O^543K_F%1'_YA84_Z87E_VE61J[Y)L=>F.=G[DBH"'WX6'CMN
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MESP>_Z(Z)O^J.2[_LSHT^;T\..[(0SGCU5 WU]I22,C265RZRU]MK<5E?*'
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MH9IZA)J6@8N4DHB1CH^0EHF,F9J$BJ*=@8JMGW^*NY]^BLB>?XG)G8"(RIR
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M2SS_G$P\_Y],//^?3#S_GTP\_Y],//^?3#S_GTP\_Y],//^?3+>\ P"IRP(
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M7T+SS&!!\^=@0?/H8$'SZ&!!\^A@0?/H8$'SZ&!!\^A@0?/H8-ZG @#+M@4
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M;4_"Y&Q/O>QN4+GL;U"Y[&]0N>QO4+GL;U"Y[&]0N>QO4+GL;_^)$ '_G0X
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M23G\XTDY_.-).?SC23G\XTDY_.-).?SC2<>M  "WMP( JL," )[0! "3XPD
MC/T8 H3^)P=[_S$/<O\X%FG_0!QB_T8B7/]-)E;_4RI2_UDM3O]?,$K_93)'
M_VLT1/]Q-4'_>3<__X$X//^*.CK_DSLX_YT\-O^G/37_L3XT_[X^,__*/S/_
MRC\S_\H_,__*/S/_RC\S_\H_,__*/[BR  "JO0  G<H  )'8 @"(^PT!?_\9
M G;_) 9N_RT,9O\U$E__/!=8_T,;4_])'D[_3R%*_U4D1O];)D/_8"= _V8I
M/O]K*CO_<BLY_WDM-O^!+C3_BB\Q_Y0P,/^<,2[_I3(M_Z\S+/^W,RS_MS,L
M_[<S+/^W,RS_MS,L_[<S+/^W,ZNX  ">Q0  D-(  (/@  !]_P\!<O\6 FC_
M'@1A_R<(6O\O#%3_-Q!._SX32?]$%D7_2AA!_T\9/O]5&SO_61PY_U\=-O]D
M'C3_:1\R_W @+_]W(2W_?R(K_X<C*/^0)"?_F24F_Z$F)?^G)B7_IR8E_Z<F
M)?^G)B7_IR8E_Z<F)?^G)I_   "1S0  @]L  'CV @!O_PT!9/\2 ES_&0-4
M_R $3O\G!DC_+PA#_S8*/_\\##S_0@XX_T</-?],$#/_41$P_U82+O]:$RS_
M7Q0J_V44*/]K%2;_<18C_WD7(O^!&"#_B1@>_Y$9'?^7&1W_EQD=_Y<9'?^7
M&1W_EQD=_Y<9'?^7&?]6)P3_43(%_U8U!_]?/0[_9$46_V9.'_]D6"?_86(O
M_UYN-?]:>3O_5X0__U2/0_]1F$;_3Z!(_TZG2O]-KDO_3+5,_TN\3?]*Q$[_
M2<Y/_TG>3_](Z5#_2/)0_$GV4/=+^5#Q3/I/ZT[[4.I/^U#J3_M0ZD_[4.I/
M^U#J3_M0ZD_[4/]6)P3_43(%_U@T!_]B.P[_9T06_VE-'_]G5B?_8V O_V!K
M-?]<=SO_6() _U6-1/]3ED?_4)])_T^F2_].K4W_3;1._TR\3_]+Q5#_2L]1
M_TG@4?])ZU'^2?)2^4OW4O--^5'M3_I1YE#Z4N50^E+E4/I2Y5#Z4N50^E+E
M4/I2Y5#Z4O]7)P/_4C$%_UHR!_]D.@[_:D(6_VQ+'_]J5"?_9UXO_V)H-O]>
M=#S_6H!!_U>+1?]4E4C_4IU*_U"E3/]/K4[_3K1/_TV\4?],Q5'_2]%2_TKB
M4_])[5/[2_-3]4SW4^Y/^%/H4/E3X5+Z5.!2^E7@4OI5X%+Z5>!2^E7@4OI5
MX%+Z5?]8)@/_5# %_UTQ!_]G. [_;4 6_V])'O]N4B?_:EPO_V5F-O]A<3S_
M77U!_UF(1O]6DDG_5)Q,_U*D3O]0JU#_3[-1_TZ[4O]-Q%/_3<]4_DS@5?M,
MZU7X3/15\$_W5>E1^%7B4OA6VU3Y5]E4^5?95/E7V53Y5]E4^5?95/E7V53Y
M5_]9)@/_5RX%_V O!_]J-@W_<3X5_W-('O]R42;_;UHN_VIC-O]E;CS_87I"
M_UV%1_]:CTK_5YA-_U6@4/]4J%+^4J]3_5&W5?Q0P%;Z3\M6^$_<5_5/Z5?R
M3_-7ZE+V5^%3]UC:5?A9T5;X6L]6^%K/5OA:SU;X6L]6^%K/5OA:SU;X6O]9
M)@/_6BP%_V0M!_]N,PW_=3T5_WA&'?]W3R7_=%@M_W!@-?]J:CS_9G9"_V*!
M1_Y>BTO[6Y1/^5F=4OA7I%3V5JQ6]52T5_-3O%CR4\=9\%+56NQ2YEKI4_)9
MX53U6]=6]ES/5_==R%GX7<=9^%W'6?A=QUGX7<=9^%W'6?A=QUGX7?]:)0/_
M72H%_V<J!O]R,@S_>3L4_WQ%'/]\323_>E4L_W5>-/]O9SS\:G)"^69]2/9C
MATSS7Y!0\5V94^];H5;M6:A8ZUBP6NI7N5OH5L-<YE;17.-6Y%S?5O!=U5?U
M7\Q9]F#&6O9@P%OV8;Y<]F&^7/9AOESV8;Y<]F&^7/9AOESV8?];)0/_8"@%
M_VLH!O]W, O_?CH3_X%#&O^"2R+_?U,J_WM;,_EV9#KU<&Y!\6QY2.UH@TWJ
M9(Q1YV&55>5?G5CC7:5:X5NM7-Y:ME[<6<!?VEG.8-59XF#16>]AREKT8L)<
M]&.\7?1DMU[S9+9?\V2V7_-DME_S9+9?\V2V7_-DME_S9/]<) /_8R8$_V\F
M!?][+PO_@CD1_X9!&/^'22#_A5$H^()9,/)]8#CM=VI Z')U1^1N?TWA:8A2
MW6:15]ECF5K58*%=TE^H8,]=L6+-7+MCRUS'9,E<VV7%7>MEOUWR9KA?\6>S
M8/%GKV'Q9ZYB\6>N8O%GKF+Q9ZYB\6>N8O%GKF+Q9_]=) /_9B0$_W(D!?]^
M+@K_AS<0_XL_%O^,1QWYBT\E\HA6+>R#73;F?F<^X'AQ1MMS>TW5;H-3T&J,
M6,QGE%W)99Q@QF.C8\-AK&7!8+5GOU_!:+U?T&FZ8.9IM6'O:J]B[VJK8^]J
MIV3O::9E\&FF9?!IIF7P::9E\&FF9?!IIF7P:?]>(P/_:2($_W8C!/^"+ G_
MBS8._X\^%/V111OTD4PB[8Y3*N:*6C+?A64[UWYM1=!X=DW+=']4QG"'6L)L
MCUZ_:9=BNV>?9;AEIVBV9+!JLV.[:[%CRFRO8^%LJV3M;:9F[6RC9^ULH&CN
M:Y]H[FN?:.YKGVCN:Y]H[FN?:.YKGVCN:_]?(P/_:R #_WDB!/^%*PC_CC0,
M_Y,\$OB60QCOEDH>YY50)N"16"[7BF$ZSH1J1<A^<TW">7M5OG6#6[EQBV"U
M;I)DLFR:9Z]JHVJL:*QLJ6>V;J=GQ&^E9]IOHFCK;YYI[&^;:NQNF6OM;9AK
M[6V8:^UMF&OM;9AK[6V8:^UMF&OM;?]?(P/_;AX#_WLA!/^(*@?_D3(+_Y<Z
M#_2:017KFT<:XYM-(=J652W/CUXYR(EG1,&#;TV[?G=5MGE_6[%VAV"M<X]E
MJ7"6:*9NGVRC;*ANH&NR<)UKP'&<:])RFFSI<9=MZG"4;>MPDF[L;Y)N[&Z2
M;NQNDF[L;I)N[&Z2;NQNDF[L;O]A(0/_<!T#_WX@ _^+*0;_E3$)^YLX#?">
M/A'GH$06WZ!*'=.:4BO*DUPXPHUD0[N';4VT@G14KWY\6ZIZA&&F=XMEHG23
M:9YRFVV:<*1PEV^O<I5OO'.3;\USDG#F<Y!PZ7*.<>IQC7'K<(QQZW",<>MP
MC''K<(QQZW",<>MPC''K</]C( /_<AL#_X ? _^.)P7_ER\(^)XV"^VB.P[D
MI4 2VJ1&',Z>42K%EUHWO9%B0K6,:DROAW)4J8)Y6Z1_@&"??(AEFWF0:I=W
MF&V3=:%PD'.L<XUSN'2+<\EUBG3B=(ETZ'.(=>ERAW7J<8=UZG"'=>IPAW7J
M<(=UZG"'=>IPAW7J</]E'P/_=!H"_X,> O^0)@3_FBT&]*$T">FF-PO@JCT.
MU*=$&\FA3RG FU@VN)5@0K"0:$NIBV]3HX=V6IZ#?F"9@(5EE'V-:I![EFZ,
M>9]QB7BI<X9WM76$=\5V@WC?=8-XZ'2">.ES@GCJ<8)XZG&">.IQ@GCJ<8)X
MZG&">.IQ@GCJ<?]G'0/_=QD"_X4< O^3) /_G2L%\:0P!N:J,PC<KC<,SZI#
M&L6E3BB\GU<ULYE?0:N49DJDD&U3GHMT6IB(>V"3A8-ECH*+:HJ DVZ&?IQQ
M@GVG=']\LW5]?,-V?'W;=GQ]Z'1]?.AS?7SI<GU\ZG%]?.IQ?7SJ<7U\ZG%]
M?.IQ?7SJ<?]I' +_>1@"_X<; O^5(P/[H"D$[J@L!..O+P77LC0+RZU!&<&H
M3">WHU4TKYU=0*>99$F?E&M2F9!R69.->5^.BH!DB8>(:82%D6V @YIQ?(*D
M='F!L79W@<!V=H'6=G:!YW1W@>AS>(#I<GA_ZG%X?^IQ>'_J<7A_ZG%X?^IQ
M>'_J<?]K&P+_>Q<"_XH: ?^8(0+XHR8#ZJPG ]^T*0/2M3(*Q[! &+RL2R:S
MIU,SJJ);/J*=8TB:F6E1E)5P6(Z2=UZ(CWYD@XV&:7Z*CFUZB9AQ=H>B<W.&
MKG5QAKUV;X?2=G"'Z'1QA>AS<H3I<G.$ZG%SA.IQ<X3J<7.$ZG%SA.IQ<X3J
M<?]M&0+_?A8!_XT8 ?^;'@'TIR("YK @ =JZ(0'-N#$)PK0^%[BP222NJU(Q
MI:9:/9VB84>5GFA/CIMN5XB8=5V"E7QC?9.$:'B0C&QTCY5P<(V@<FV,K'1J
MC+MU:8W.=6F-Z'1KB^ES;8GJ<6V(ZG%MB.IQ;8CJ<6V(ZG%MB.IQ;8CJ<?]P
M%P+_@14!_Y 6 ?^>&@'PJQL!XK86 -.]'0'(NR\(O;@\%;.T1R.IL% PH*M8
M.YBH7T60I&9.B:%L58*><UM]G'IA=YF!9G*7BFINEI-N:I2><6:4JG-DD[AS
M8Y3+<V.4YG)EDNIQ9X_J<&>.ZG!GCNIP9X[J<&>.ZG!GCNIP9X[J</]S%0+_
MA1,!_Y04 /RC%0#JL!( V;X, ,W!&P'"P"T'N+TZ$ZZY1B&DM4\MFK%6.9*N
M7D.*JV1,@ZAJ4WRE<5EVHWA?<:%_8VR?AVAHGI%K9)V<;F"<J'!>G+9Q79S)
M<5V<Y'!>FNMP8);K;V&5[&]AE>QO897L;V&5[&]AE>QO897L;_]W$@'_B1$!
M_YD1 /.H#@#7M0H S\$* ,;%& "\Q"H%LL(X$:>_1!Z>NTTKE+A5-HNU7$"$
MLF))?*]I4':M;U9PJW9;:ZI]8&:HAF1BIX]G7J:::ENEIFQ8I;5M5Z;';5>F
MXFQ7I.UL6I_M;%J>[6Q:GNUL6I[M;%J>[6Q:GNUL6I[M;/]\$ '_CA  ]IX-
M -BM"0#-N D Q\0( +[*% "URB<$J\@V#Z'%01N7PDLHC;]3,X6]6CQ]NF%%
M=KAG2W"W;5%JM7169;1\6V"RA%]<L8YB6+&9956PI693L+-G4K'&9U*QX6=1
MK_%H4ZKP:%2I\&A4J?!H5*GP:%2I\&A4J?!H5*GP:/^"#@#_E P VZ4& ,ZQ
M!P#%NP< O<<' +70$ "LT",#H\\S#)G-/QB/RD@DALA1+GW&6#AVQ%\_;\)F
M1FG!;$MDP'-07[][5%N^A%A7O8U;5+V875&\I%]/O+-@3;W%8$W_XO__24-#
M7U!23T9)3$4  PF]X%],O/!A3;?U8DVV]6)-MO5B3;;U8DVV]6)-MO5B3;;U
M8O^)"P#AG , T*H% ,6U!0"[OP0 LLL( *O8#0"CV2 "FM@O"9#6/!2'U$8?
M?M)/*7;05C)OSUXY:,UD/V/,:T1>S'-)6LMZ3%;*@T]2RHU23\J85$W*I59+
MRK-72LO%5TG+X%9)R?!81\?Z64C%^UI(Q?M:2,7[6DC%^UI(Q?M:2,7[6O>1
M! #4H@( QZ\$ +JY P"PQ 4 I] ) )_A$ "8X2$#C^ P"8;@.Q)]WT0;==Y-
M)&[=52MGW%PR8MMD-UW;:SM9VG(_5=IZ0U+:@T5.VHU(3-J82DG:I4M(V[-,
M1]S$3$;<WDQ&VNU,1-CY3T/8^T]#V/M/0]C[3T/8^T]#V/M/0]C[3]N:  #*
MJ0( N[," +"] P"ER04 F]8) )3H% &,Z24$A.@S"WOH/!1SZ$0;:^A+(F3G
M4BA>YUDM6>=@,E7G:#52YV\X3^=W.TSG@#U)YXD_1^B4043HGT)"Z:Q#0>FZ
M1$#JS41 ZN1$0.CU1$#G^$- Y_A#0.?X0T#G^$- Y_A#0.?X0\VC  "]K@$
ML+@! *3$ @"9T 4 C^$* (GQ&@&!\2@%>/(R#'#R.Q-I\D,98O)*'USS4"-6
M\U<G4O->*T_S92U,]&PP2?1S,D;T>S1#](0V0?6.-S[UF3D]]J0Z._:P.SKW
MOSPY^,\\./?H/#CW[#PX]^P\./?L/#CW[#PX]^P\./?L/+^J  "QLP  I+\
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M&R'_K1LA_ZT;(?^M&R'_K1LA_ZT;(?^M&YJ^  "+R@  ?M<  '#C  !G_P0
M7O\- %;_$@%/_QD"2?\@ T/_)P0__RX%.O\T!C?_.@<S_S\',/]$""[_20DL
M_TX)*?]3"B?_6 HE_UX+(_]D"R'_; P?_W0-'?]]#AO_APX9_X\/&/^9#QC_
MFQ 8_YL0&/^;$!C_FQ 8_YL0&/^;$/],*@/_2#,%_T\T!O]4-PC_6D$._UQ*
M%O]:5!W_5V D_U1K*O]0>"__380S_TJ/-O]'F3G_1J$[_T6I//]$L#[_0[<_
M_T+ /_]"R4#_0=5!_T'D0?]![D+_0?9"_T']0O]"_T'Y1/]!]$;_0N]'_T+O
M1_]"[T?_0N]'_T+O1_]"[T?_0O]-*0/_2C($_U$R!O]7-@C_7#\._UY)%O]=
M4QW_6EXD_U=I*O]3=2__4($T_TV--_]*ESK_2)\\_T>G/?]&KC__1;5 _T2]
M0?]$QD+_0]%"_T/B0_]#[$/_0_5#_T/\0_Q$_T/U1_]#[TC_1.M)_T3K2?]$
MZTG_1.M)_T3K2?]$ZTG_1/]-*0/_3# $_U0Q!?]9- C_7ST._V%'%O]@4AW_
M75PD_UIG*_]6<S#_4W\T_T^*./]-E#O_2YT]_TJD/_](K$#_2+-!_T>[0O]&
MPT/_1LY$_T7?1/]%ZD7]1?-%^T7[1?=&_T3P2?]%ZDK_1N5+_T?E2_]'Y4O_
M1^5+_T?E2_]'Y4O_1_].*0/_3RX$_U<N!?]=,@?_8SL._V5&%O]E4!W_85DD
M_UUD*_]:<##_5GPU_U.'.?]0D3S_3IH__TVB0/]+J4+_2K!#_TJW1/])P$7_
M2,I&_4C;1OI(YT?X2/)']4CZ1O%)_T?J2_](XTS_2=Y-_TK>3?]*WDW_2MY-
M_TK>3?]*WDW_2O]/* /_4BP$_UHL!?]A+P?_9SH._VI$%?]J3AS_9U<D_V)A
M*_]>;3'_6W@V_U>#.O]4C3W_4I9 _U">0OY/I43\3JU%^TVT1_I,O$CY3,=(
M]DO42?-+Y4GP2_!)[4SY2.E,_TKA3O]+VD__3--0_TW34/]-TU#_3=-0_TW3
M4/]-TU#_3?]0* /_52H$_UTI!?]E+0?_;#@-_V]"%/]O2QS_;%4C_VA>*O]C
M:3'_7W0V_5Q_._M9B3_Y5I)"]U2:1/53HD;T4JE(\E&Q2?%0N4KO3\-+[D_/
M2^M/XDOG3^Y+Y$_X3=]/_D[54?]/SE+_4,E3_U#)4_]0R5/_4,E3_U#)4_]0
MR5/_4/]1)P/_6"<$_V$G!/]J+ ;_<38,_W1 $_]T21K_<E(B_VY;*?UH9##Y
M97 V]F%[._->A4#P6XY#[EF61NQ7GDCJ5:9*Z%2M3.=3M4WE4[].XU/,3N%3
MWT[=4^U/V%+W4=%3_5+*5/Y3Q%;_4[]7_U._5_]3OU?_4[]7_U._5_]3OU?_
M4_]2)P/_6R4#_V4D!/]N*@;_=C0+_WH]$?]Z1AC_>$\@^W18*/9O82_Q:VPV
M[6=V/.EC@$#F8(I%Y%V22.%;FDK?6:)-W5BJ3]I7LE#85KQ1U57(4M)5VU/.
M5NM3RU;V5<96_5:_6/U6NEG]5[9:_5>V6OU7MEK]5[9:_5>V6OU7MEK]5_]3
M)@/_7R(#_VDA _]S* 7_>S(*_W\[$/^ 1!;[?DP>]'M4)>YV72WI<6@TY&UR
M.^!I?$'<985&V&*.2M1?EDW179U0SERE4LQ:K53)6;96QUG"5\99T%?"6>98
MOUGS6;M:^UFU6_M:L%W[6JU=^UFM7?M9K5W[6:U=^UFM7?M9K5W[6?]6) /_
M8B #_VT@ _]W)@3_?S (_X0Y#?V&013UA4D;[H)1(N=]6BKA>&0RW'-N.M1N
M=T'0:H!'S&:)3,ADD5#%8IA3PV"@5<!>J%B^7;%9NUV\6[E<R5RW7.!<M%WO
M7+!>^5VK7_E=J&#Y7*5A^5RE8?E<I6'Y7*5A^5RE8?E<I6'Y7/]8(@/_91X#
M_W$? _][) /_A"X'_XDV"_B+/A'OBT87Z(A.'N&$5R;9?F$QT7AJ.LMS<T+&
M;WQ(PFR$3;YIC%&[9I-5N&2;6+5CHUJS8:Q<L&"W7JY@Q%^L8-A?J6'K7Z=A
M]U^B8_=?GV3W7YUD^%Z=9/A>G63X7IUD^%Z=9/A>G63X7O];( +_:!P"_W0=
M O]^(P/_B"L%_8TT"?.0.P[JD$,4XH]*&MJ*5"70@UTPR7YG.L-X;T*^='A(
MN7& 3K5NB%*R:X]6KVF76JQGGURI9:A?IF2R8:1DOV*B9-!BH&3G8IYE]6*:
M9O5AF&?V8)9H]F"6:/9@EFCV8)9H]F"6:/9@EFCV8/]='P+_:AH"_W<< O^"
M(0+_BRD$^9$Q!^^5. OFEC\0W91'%]*.423*B%LOPH-D.;Q^;$&W>71(LG5\
M3JYRA%.J;XM7IFV36Z-KFUZ@:J1@G6BN8YMHNF29:,MEEVCC9)5I\V23:O1C
MD6OU8I!K]6&0:_5AD&OU89!K]6&0:_5AD&OU8?]?'0+_;1@"_WH; O^%'P+_
MCB<#]94N!>N9-0CAG#L,UIA#%LR33R+$C5@NO8=A.+:":4&P?G%(JWIY3J=W
M@%.C=(A8GW&06YMOF%^8;J%BE6VK9))LMV:0;,9FCVS?9HYM\66,;O-DBV[T
M8XIN]&**;O1BBF[T8HIN]&**;O1BBF[T8O]A' +_;Q8"_WP: ?^('@'_D20"
M\IDK!.>>,07=H#8)T9Q!%<>732&_D58MMXQ?-[&'9T"K@FY(I7YV3J![?5.<
M>(58F':-7)1TE5^1<IYBCG&H98MPM&>)<,-HAW#;9X9Q[F:&<O)EA7+S9(1R
M]&.$<O1CA'+T8X1R]&.$<O1CA'+T8_]C&@+_<14!_W\8 ?^*' '\E"$"[IPG
M N.B+ /8I#((S)] %,.:2R"ZE54LLY!=-ZR+93^EAVQ'H(-S39N >U.6?8)7
MDGJ*7(YXDF"*=IMCAW6E9H1TL6>"=,!H@'35:(!U[&=_=O)F?W7S97]U\V1_
M=?-D?W7S9']U\V1_=?-D?W7S9/]E&0+_=!0!_X$7 ?^-&@'YEQX!ZZ C =^F
M)@+2IS 'R*,^$[^>21^VF5,KKI1;-J>/8S^@BVI&FX=Q396$>%*0@7]7C'^'
M7(A]D&"$>YEC@'JC9GYYKVA[>;UI>GG1:7EZZFAZ>O)F>GGR97IY\V1Z>?-D
M>GGS9'IY\V1Z>?-D>GGS9/]G%P+_=A0!_X06 ?^0%P'UFQH!YZ0= =NK'P'.
MJB\&Q*8]$KJA2!ZRG5$JJIA9-**483Z<D&A%EHQO3)")=E*+AGU7AH2%6X*"
MC5]^@)=C>G^A9G=^K&AU?;MI<W[.:7-^Z&AT?O%F='WR975\\V1U?/-D=7SS
M9'5\\V1U?/-D=7SS9/]I%@'_>!,!_X<4 /^3%0#QGA4 XZ@6 -6N&P'*K2T&
MP*D[$;:E1AVMH5 II9Q8,YZ87SR7E&9$D)%M2XN.=%&&C'M6@8F#6WR'BU]X
MAI1B=(2?97&#JF=O@[AI;8/+:6V#YFAN@_)F;X+R97"!\V1P@?-D<('S9'"!
M\V1P@?-D<('S9/]K% '_>Q(!_XH2 /^6$@#MHA  WJT. -"Q&0#%L"L%NZTY
M#[*I1!NII4XGH*%6,IF=7CN2FF1#BY=K2H:4<E" DGE5>X^ 6G>-B5YRC))A
M;HJ<9&N)J&=IB;9H9XG(:&>)XV=HB?)F:8?S96J&\V1JAO-D:H;S9&J&\V1J
MAO-D:H;S9/]N$@'_?A  _XT0 />:#@#;IPH T[ + ,JT%@# M"D$MK$W#JVN
M0QJDJDPEFZ95,).C7#F,H&-!AIUI2(":<$Y[F'=3=I9^6'&4AEQLDI!@:)&:
M8V60IF5CD+1F89#&9F&0X69AD/)E8X[S9&2,]&-DC/1C9(ST8V2,]&-DC/1C
M9(ST8_]Q$ '_@@\ _Y$- -Z?"0#3J@D S+,) ,2X$P"ZN"8#L;8U#*>S01B>
MKTHCEJQ3+HZI6C>'IF$_@*1G1GJA;DQUGW51<)U\56N<A%IFFHY=8YF88%^8
MI&)=F+)D6YC#9%N8WF-;F/!C7)7U8EZ3]6)>D_5B7I/U8EZ3]6)>D_5B7I/U
M8O]U#@#_A@T ZY8( -6C!P#,K0@ Q;8' +V\$0"TO2,"J[LR"J&Y/Q68MD@@
MD+-1*XBP6#2 KE\\>JMF0W2I;$AOJ'-.:J9Z4F6E@E9AHXQ:7:*67%JBHE]7
MH;!@5J'!8%6BW&!5H>]@5I_W7U><]U]7G/=?5YSW7U><]U]7G/=?5YSW7_]Z
M# #]BPD VIL$ ,ZG!@#$L 8 O+D$ +7!#@"LPB !I,$P")J_/!.1O48=B;I/
M)X&X5C!ZMETX<[1D/VZR:D1HL7%)9+!Y35^N@5%;K8I46*V55U2LH5E2K*];
M4*S 6U"LVEI/J^Y;3ZKZ6U&F^EM1IOI;4:;Z6U&F^EM1IOI;4:;Z6_^ "0#A
MD@$ T: $ ,:K!0"\M 0 L[T# *O'"P"DR1P!G,@L!I/'.0^*Q409@<--(WK!
M5"QSOULS;;YB.6>\:3YBNW!#7KIW1UJY@$M6N8E.4[B44%"XH%)-N*Y43+B_
M5$NYV%1+M^U42K;Y54JS_E9*L_Y62K/^5DJS_E9*L_Y62K/^5OJ' @#6F
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M+S;Q\R\V\?,O-O'S+S;Q\R\V\?,O-O'S+[FG  "KL   G[L  )+&  "&T $
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MFDP?H)=4*9F37#&3D&,XC8UJ/XB*<42#B'A)?H9_37J$B%%V@I%5<X&;6&^
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M6%F4U%=9E.Q769/Y5EN1_E5;D/Y56Y#^55N0_E5;D/Y56Y#^5?]S"0#UA 0
MV)$# ,R<!0##I04 NZT$ +.S# "KM1P!H[0L!9NR.0Z2L$07BJU-((.K5"E]
MJ5PP=Z=B-G&E:3QLI&]!:*)W162A?TE?GXA,7)Z23UB>GE)6G:M35)V\5%.=
MT513G>M34YSX4U2:_U-4F?]35)G_4U29_U-4F?]35)G_4_]X!@#AB0  T)8"
M ,:A P"\J0, L[ ! *NX" "DNA@ G+HI Y2Y-@N,MT$4A+5*'7RS4B5VL5HL
M<*]@,FNN9SAFK6X\8JMU0%ZJ?41:J89(5JB12E.HG4U1IZI.3ZBZ3TZHST].
MI^E/3:;W3TVE_T].I/]/3J3_3TZD_T].I/]/3J3_3_I_  #8C@  R9L! +ZE
M @"TK0$ J[4  *&_! ";P10 E,$E HS ,PB$OSX1?+U(&76\4"%ONE@G:KE?
M+66X93)@MVPV7+9T.EBU?#Y5M(5!4;201$ZSG$9,LZE(2K.Y2$FTSDA)L^E(
M2+'V24BP_TI(L/]*2+#_2DBP_TI(L/]*2+#_2N*&  #.E   PJ$  +:I  "K
ML0  H;H! )C#!0"0R1  BLD@ 8/)+P5[R#L-=,=%%&[&3AMHQ58A8\1=)U[#
M9"M:PFLO5L%R,U/!>S9/P(0Y3,"//$K FSY'P*@_1L"X0$7 S4!%P.@_1+[V
M04.]_T)#O/]#0[S_0T.\_T-#O/]#0[S_0]:-  #&FP  N*4  *VN  "BM@
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M&RO[ZQLK^^L;*_OK&ZBJ  ":M   C;\  (#)  !TTP  9]X  %[R" !9_A$
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M4&A\U5!H?.U/:7S[3FE\_TUJ>_],:GO_3&I[_TQJ>_],:GO_3/]F"@#_=0@
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M2%&7_T=1EO]'49;_1U&6_T=1EO]'49;_1_9W  #8A0  R9$  +^; 0"TH@
MJZ@  *&P  ":LA$ E+,B 8VR, 6%L3P,?J]&%'BN3AMRK%8A;:M<)VBI8RQD
MJ&HP8*=Q-%RF>3A8I8([5:2,/E&CF$!/HZ5"3:.T0TRCR$-,H^1#2Z'T0TN@
M_T1+H/]$2Z#_1$N@_T1+H/]$2Z#_1.-]  #/BP  PI8  +>?  "MI@  HZT
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M+CS%_RX\Q?\N/,7_+L23  "VGP  J:8  )VN  "2MP  AK\  'O' P!PSP<
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M"9BP  "*N@  ?,0  &_-  !BV   5=X  $GD  !$^P4 /_\. #O_%0 X_QP
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M1'9JU$5V:^U#=FO[0G9K_T%V;/] =FS_0'9L_T!V;/] =FS_0/]="@#_:0<
M['0# -I\! #0@P8 R8@' ,.*#P"ZBR !LHHO!*N(/ JDA4<2G8%0&9A^6!^3
M?%\ECGEF*HIW;2Z&=70R@G1\-G]RA#E\<8T]>7"60'9OH4)T;JY$<FZ]17!N
MT45P;^M$<&_Z0W%O_T%Q;_] <7#_0'%P_T!Q</] <7#_0/]?" #_:P0 X78
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M0F!]_T%A??] 87W_0&%]_T!A??] 87W_0/]G  #C=   TG\  ,>( 0"^CP(
MMI4! *Z8!@"FFA4 GYHF IB9,P:1ES\,BY5(%(634!I_D5@@>H]?)7:-92IR
MBVPN;HIS,FJ(>S9FAX0Y8X:./&"%F3]=A*9!6X2T0EJ$QT-:A.-"6H/T05N#
M_T!;@_] 6X/_/UN#_S];@_\_6X/_/_]J  #>>   S8,  ,*,  "YDP  L)@
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M.4F;_SE)F_\Y29O_.=MZ  #(AP  O)(  +&:  "FH   G*8  )&L  "'L0@
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M&K.9  "FH0  FJD  (ZQ  "!N0  =<   &K'  !>S0, 5-0( $S=#0!*W1@
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M!!G^F 08_Z@$%_^W!!;_R 06_^ $%O_D!!;_Y 06_^0$%O_D!).N  "%MP
M>,   &K)  !=T@  4-D  $3?   ZY   -?<# #+_#  N_Q( *_\: "C_(0 F
M_R< (_\M "#_,P >_SD!'/\_ 1G_10$7_TT!%?]5 1/_7P$1_VH"$/]X @[_
MAP(._Y8"#?^D @S_L (,_[X"#/_" @S_P@(,_\("#/_" H>V  !YOP  :\D
M %[3  !0VP  0^   #CE   O\   *_\  "?_"  D_PX (?\3 ![_&0 ;_QX
M&/\C !7_*  3_RT $?\R !#_.  ._S\ #/]& 0K_3P$'_UD!!/]E 0'_<@$
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M-H=:UC:&6^TVA5O[-85<_S2$7/\SA%S_,X1<_S.$7/\SA%S_,_]3"@#_708
M]68$ -]M P#5<@8 T'4) ,EV$0# =R( N'8Q [%T/@>K<4D.IFY2%*%L6QF=
M:6(=F6=J(I9F<2639'@HD&-_*XUAARZ*8) PB%^9,X5?HS6#7J\V@5Z^.(!>
MT3A_7^HW?E_Z-GY@_S5^8/\T?F#_-'Y@_S1^8/\T?F#_-/]5" #_8 0 Z&D
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M.&UK_S=M:_\V;6O_-FUK_S9M:_\V;6O_-O];  #K9P  V7$  ,QY  ##?@(
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M-5A^_S58?O\U6'[_->EH  #4=   QGX  +N'  "RC0  J)$  )Z4  "6E@X
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M8;0S EZT/01:M$8'5K-."E.S50U0LUP03;)C$TJR:Q9'L7081;%^&D*PBAU
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M#C'+L@\PS,</,,OE#B_)]0\NR/T1+L?_$B['_Q(NQ_\2+L?_$JZ7  "AG@
ME:4  (FM  !\M   <+L  &3!  !9Q@  3LL# $70"  ^U0X /=4: #S6)@ [
MUS$ .=@[ #C910$VV4T!-=E6 C/:7@(QVF@#,-MS!"[;?P4LVXT%*MR=!BG<
MK08HW<$&*-W>!B?;[P<FV?D()MC^"2;8_@DFV/X))MC^":2=  "8I0  BZT
M 'ZT  !QO   9<,  %G)  !-S0  0],! #K9!@ UY T ,^06 #'D(  PY2H
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M 03_K@$$_[P! __' 0/_QP$#_\<! __' 8.T  !UO0  9\8  %K/  !+U0
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M))]*WB2=2O DFTK])9E+_R292_\DF$O_))A+_R282_\DF$O_)/](# #_3P@
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M+7I<_RQY7/\K>ES_*GI<_RIZ7/\J>ES_*O]1  #R6P  WF0  ,]J  #';@(
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M+&5K_RQE:_\L96O_+/1;  #=9@  RV\  ,!V  "W>P  KWX  *9^ 0"??Q
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M'3Z?LAX]G\8>/9_C'3V=]!X]G/\?/)O_'SR;_R \F_\@/)O_(,)\  "UB
MJ9   )Z6  "3FP  AY\  'ND  !OJ   8ZP$ %^M$0!<K1\ 6JXK %>N-@%4
MKD #4:U(!4ZM3P=+K5<)2:U>"T:L9@U$K&X/0:QX$3^KA!,\JY$5.JN@%CFK
ML!<XJ\,7.*KA%S>I\Q@WI_X9-J;_&C:F_QHVIO\:-J;_&KJ$  "NCP  HI8
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M B#3ZP(@TO8#']'_!!_1_P0?T?\$']'_!)^;  "4H@  AZD  'FQ  !MN
M8+X  %3#  !)QP  /LL  #70 0 MU08 )=L+ "3>$@ CWAP (M\E "'@+@ @
MX#< '^%  ![A2@ =XE, '.-> !OC:@ :Y'@ &.2( 1?EF@$6YJP!%>;  13G
MW0$3Y>\!$^/Z 1/C^@$3X_H!$^/Z 9:B  ")J0  >[$  &ZY  !AP   5,8
M $C*   ]SP  ,],  "K9   BW@( 'NL* !SL$  ;[1< &>T? !?N)@ 5[BT
M%.\U !/P/0 1\$8 $/%0  _R6P .\FD #?-X  STB@ +]9P "O6N  GVP@ )
M]MD "/7M  CU[0 (]>T "/7M (NI  !]L@  ;[H  &+"  !5R0  1\X  #O2
M   QV   )]T  !_A   9Z   %O@& !3Z#0 2^Q( $/P7  [\'0 -_2, #/TI
M  K^,  (_S@ !O]!  /_3   _U@  /]F  #_=P  _XD  /^;  #_JP  _[L
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M#KTVY@ZY-O00MS;_$;4V_Q*T-O\3LS;_$[,V_Q.S-O\3LS;_$_\Y$ #_/0L
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M'HM+_QZ+2_\=BDO_'8I+_QV*2_\=BDO_'?]%  #_30  Y50  -E9  #/6P,
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M(F];_R%O6_\A;UO_(?I/  #A6@  SV(  ,1G  "[:P  LVP  *QJ! "D:Q(
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M($M]L2%*?<0B2GWA(4M\]"%+>_\@2WO_($M[_R!+>_\@2WO_(-!G  # <@
MM'L  *J"  "@A@  E8@  (>(  !\B@  =HP. '*-&@!NCB< :HXR 6:-/ -C
MC40%8(Q,"%R+4PI:BUH-5XIA$%2):!)1B'$53XAZ%TR'A1I*AI(<2(:@'4:&
MKQY%A<(>187?'D6$\AY%@_X>18+_'D6"_QY%@O\>18+_'LIM  "Z>   KX$
M *6'  ":BP  CXT  (&.  !TD0  ;I,* &F4%0!FE2( 8Y4N 6"5. )<E4$$
M691)!E:44 A4DU<*49->#$Z29@],DFX129%X%$:0@Q9$D) 80H^>&4"/K1H_
MC\ :/X_<&C^-\1H_C/T;/XO_&S^+_QL_B_\;/XO_&\)S  "U?@  JH<  )^,
M  "4D   B),  'N5  !LF0  99L$ &"<$ !=G1T 6YXI %B>- %5GCT"4IU%
M U"=305-G50'2YQ;"4B<8PM&G&L-0YMU#T&;@!$^FHT3/)J;%#J:JQ4YFKT5
M.9K9%3F8[Q8YE_P6.);_%SB5_Q<XE?\7.)7_%[MZ  "OA0  I(P  )B1  "-
ME0  @9H  '6=  !HH   6Z0  %:E# !3IA< 4:<C $^G+P!,IS@!2J=! 4BG
M20)&IU $0Z=8!4&G7P8_IF@(/:9R"CJF?0LXIHH--J69#C2EJ0\SI;L/,Z74
M#S.D[@\RHOL0,J'_$3*A_Q$RH?\1,J'_$;2"  "HC   G9(  )*7  "&G
M>:$  &VE  !AJ0  5:P  $NO!0!'L!  1; < $2Q)P!"L3( 0;([ #^R0P$]
MLDL!.[)3 CFR6P,WLF0$-;)N!3.R>08QLH<'+[&6""ZRI@@MLK@)+++0""RP
M[ DKK_D**Z[_"RJM_PLJK?\+*JW_"ZV+  "@D@  E9@  (F=  !]HP  <:@
M &2M  !9L0  3;0  $*X   [N@H .+L3 #>\'@ UO"D -+TR #.].P RO40
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M  S=^P ,W?L #-W[ )*?  "%IP  =ZX  &JU  !=O   4,$  $3%   XR0
M+LT  "71   >U0  %MH! !'>!@ 0YPT #N<2  WH&0 ,Z"$ "^DI  KJ,0 )
MZCL !^M%  7K40 $ZUX  ^MN  'K@   ZI0  .JG  #KO   Z](  .OI  #L
M[P  [.\  .SO (>G  !YKP  :[<  %Z^  !1Q0  0\D  #?-   MT0  (]8
M !O;   3WP  #N,   SN @ *]@H !_8.  7V$@ #]A@  /4>  #U)0  ]2X
M /4W  #V0@  ]DX  /9=  #V;@  ]H$  /:5  #WIP  ][<  /C'  #XT
M^-   /C0 'NO  !MN   8,   %+(  !$S0  -]$  "O7   AW   &.   !'D
M   ,YP  !^\   3Z   !_P,  /\(  #_#0  _A   /X4  #_&@  _R$  /\I
M  #_,P  _SX  /]+  #_6P  _VP  /^   #_D@  _Z$  /^M  #_LP  _[,
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M =\:Z '<&_4"V!O_ M4<_P/4'/\#TQS_!-(<_P32'/\$TAS_!/\I%P#_*A,
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M#:4V_PZC-_\.HC?_#J(W_PZB-_\.HC?_#O\W!P#_.P( _T # /)"!0#I0@D
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M%WU+_Q9]2_\6?4O_%O]#  #F3   UE,  ,E8  # 60  NE@! +16"0"L5Q8
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M&U=FL!Q69L,=5F;?'59F\QQ79O\;5V;_&E=F_QI79O\:5V;_&MM9  #'8@
MNFH  *]P  "F<P  FG,  (]P  "'<04 @7(1 'QS'@!X<RH =',U 7!S/P-M
M<D<%:G%.!V=Q50ED<%P+8F]C#E]O:A!=;G(26FU\%5AMAA=6;),95&R@&U)K
MKQQ1:\$<46O<'%%K\1M2:_X:4FK_&E)J_QE2:O\94FK_&=1<  ##9@  MFX
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M%D%_[19!?OL607W_%D%]_Q9!??\607W_%L)J  "U=0  JGT  )^"  "2@P
MA80  'F%  !JB0  9(H# &",$ !=C1L 6XXG %B.,@!5CCL!4XY# E".2@-.
MC5(%3(U9!DF,8 A'C&@*18MR#$*+?0Y BHD//HJ8$3R*IQ([BK@2.HK/$CN(
MZQ([A_H3.X;_$SN&_Q,[AO\3.X;_$[QQ  "O>P  I8,  )F'  ",B   ?XD
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M!26G_P4EI_\%):?_!:>)  ";CP  D90  (29  !XG@  :Z(  %^F  !3J@
M2*T  #VP   TLP, +[4. "VU%@ LM2  *[8I "JV,@ IMSH *+=# ">W3  F
MN%4 )+A? ".X:P BN'@!(+B( 1^XF0$=N:L!'+G  1RXWP$<MO(!&[7\ ANT
M_P(;M/\"&[3_ I^/  "4E0  B)L  'NA  !NI@  8JL  %:P  !*LP  /[8
M #6Y   LO   )+\& !_"#0 =PA0 ',(> !O#)@ :PR\ &<0X !C$00 7Q$H
M%L55 !7%80 4QF\ $\9_ !+&D0 1QZ0 $,>Y  _'U  0QNX $,3Z !##_P 0
MP_\ $,/_ )>6  "+G   ?J(  '&I  !DKP  6+0  $NX  ! NP  -;X  "O!
M   CQ0  &\D! !3,!@ 0T L #M$1  W1&0 -T2$ #-$J  S1-  +TCX "M))
M  G350 )TV( "--R  ;4A  %U)@ !-2K  /5P  !U=P  =7M  '5]@ !U?8
M =7V (Z=  " I   <ZL  &:Q  !9N   3+T  #_    TPP  *L<  "'*   9
MS@  $M(   W6 0 )VP4 !MP-  3<$0 #W1@  =X@  #>*   WS$  . \  #A
M1P  XE0  .-C  #C=   Y(@  .2;  #EK@  Y<$  .75  #FYP  YN<  .;G
M (.D  !UK   :+,  %J[  !-P0  0,0  #/(   HS   ']   !?4   0V0
M"]T   7A    Y    .4'  #F#0  YQ$  .@6  #I'0  ZB4  .LN  #M.0
M[T4  /!3  #Q9   \78  /**  #SG   \ZT  /2[  #TR   ],@  /3( '>M
M  !JM0  7+T  $_$  ! R0  ,\T  "?1   =U@  %-P   [@   (XP   >8
M  #J    [@   .X   #O!   \ H  /$.  #S$@  ]!@  /8@  #X*@  ^C4
M /U#  #^4@  _V,  /]V  #_B0  _YH  /^F  #_L   _[   /^P /\6(P#_
M%2$ _Q$A /\-) #_"2L _P8W /\#1 #_ %$ _P!= /\ : #_ '( _P![ /\
M@P#_ (H _P"1 /\ E@#_ )P _P"A /T I@#[ *P ^0"S /< NP#U ,4 \P#1
M /( Y #Q /$ [P#Z .X _P#N /\ [0#_ .T _P#M /\ [0#_ /\9( #_&!T
M_Q4= /\0'P#_#BD _PPT /\*00#_!TT _P59 /\$9 #_!&X _P-W /\#@ #_
M X< _P.- /T"DP#[ ID ^0*> /<"I #U JH \P&P /$!N #O <( [0'/ .L!
MXP#J >\ Z +[ .<$_P#F!?\ Y@;_ .8&_P#F!O\ Y@;_ /\<&P#_&QD _Q<8
M /\5'0#_$R4 _Q$P /\0/0#_#DD _PQ5 /\+8 #_"VH _0MS /L+? #Y"H,
M]PJ* /4*D #T"I8 \PJ; /$*H0#O":< [0FN .L)M@#H"<  Y@G- .0)X@#B
M"O  WPO[ -X,_P#<#?\ W W_ -L-_P';#?\!VPW_ ?\?%P#_'A, _QL2 /\<
M&0#_&R( _Q@L /\5. #_$T0 _A)0 /D16P#U$&8 \Q!O / 0=P#N$'\ [!"&
M .H0C #I$)( Z!"8 .8/G@#E#Z4 XP^L .$/M #@#[X W@_, -H0X0#5$?
MTA+[ ,\2_P'.$_\!S1/_ <T3_P',$_\!S!/_ ?\B$@#_(@\ _R$/ /\B% #_
M(AP _R G /\=,@#X&SX \AE+ .X85@#J%V  YQ9J .06<@#B%GH X!:" -X6
MB #<%H\ VQ:5 -D6FP#6%J( U!:I -(6L0#0%[L SA?) ,P8W@#(&>X!Q1K[
M <,:_P+!&_\"P!O_ L ;_P+ &_\"P!O_ O\F#@#_)0L _R@, /\I$ #_*!8
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M"I(W_PJ2-_\*DC?_"O\S  #V.@  Y#\  -A"  #.0@$ R3X& ,0[#P"[/AT
MM3\L +$_.@"M/T4!J3]/ :8^6 *C/5\#H3UG!)\\;06=/'0&G#M[!IH[@@>8
M.XH(ECN3"94ZG J3.J8+D3JR"Y [P R..]4,C#SL#8H\^PV)//\-B3S_#(@\
M_PR(//\,B#S_#/\W  #J/P  W$4  ,Y)  #%20  OT8" +I## "S1!D K44G
M *A&-0"D14$!H$5+ IU$4P*:0UL#F$-B!99":0:407 'DD%V")! ?@F.0(8*
MC4"."XM F R)0*(-AT"N#H5 O ^$0,\/@D'I#X%!^0^ 0?\/@$+_#H!"_PZ
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M$.Q#  #93   R%,  +U7  "T6   K%<  *52 0">4P\ F%0< )-4*0"/5#4
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M%&)5KQ5A5<$68%7;%F!6\15@5OX48%;_$V%6_Q)A5O\285;_$N!-  #+5@
MO5T  +)A  "H8P  G6$  )5=  "-7@D AUX3 (-?( !_7RP >U\W 7=>0 )T
M7D@#<5U/!&]<5@5L7%P':EMC"6A;:PMF6G,-9%I\#V):AQ%@69,27EF@%%U9
MKA5;6;\66UG8%EM9[Q5;6?T47%G_$UQ9_Q)<6?\27%G_$MQ0  #'60  NF
M *]D  "D90  F60  )!@  "(808 @F(1 'YC'0!Z8RH =F,T 7-B/0%O8D8"
M;&%-!&IA5 5G8%H'96!A"&-?:0IA7W$,7UYZ#EU>A1!;7I$265V>%%A=K!57
M7;T65EW5%E9=[A577?P45UW_$U==_Q)77?\25UW_$M93  #$7   MV,  *QH
M  "@:   E6<  (IC  "#90( ?68/ 'AF&@!T9R< <6<R &YG.P%K9D,":&9+
M V5E4@5C95D&861?"%YD9PI<8V\,6F-X#EAC@Q!68H\25&*<$U-BJA528KL5
M46+2%5%A[1528?L44F'_$U-A_Q)38?\24V'_$M%6  # 7P  LV8  *EK  "<
M:P  D&H  (5G  !]:0  =VH- '-K%P!O:R0 ;&PO &EL. %F:T$"8VM) V%K
M4 1>:E<&7&I=!UII90E8:6T+56AV#5-H@0]19XT13V>:$DYGJ11-9[D43&?/
M%$QFZQ1-9OL336;_$DYE_Q).9?\23F7_$LQ:  "\8P  L&H  *5O  "8;@
MC&T  (!L  !W;0  <6X+ &UO% !I<"$ 9G$L &1Q-@%A<3X!7G%& EQP30-9
M<%0%5W!;!E5O8@A3;VH*4&YS#$YN?@Y,;8H02FV8$4ELIQ)(;+@31VS-$T=L
MZA-(:_H22&O_$DAJ_Q%(:O\12&K_$<=>  "X9P  K&X  *%R  "3<@  AW$
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M##: _PPV@/\,-H#_#+9O  "J>   GW\  )!^  "#?P  =X   &N"  !>AP
M58H  $Z,!@!*CA  2(\: $>/)0!%D"\ 1) X $*00 ! D$<!/Y!/ 3V05@([
MD%\".9!H S>/<P0UCX %,X^.!C&/G@<PCJ\'+X[#!R^.X0<OC/0(+XO_""^*
M_P@OBO\)+XK_";!V  "E?P  F(0  (J$  !]A0  <(<  &6*  !:C@  3Y(
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M 9J-  "0D@  A)<  '6:  !HGP  6Z,  %"H  !%K   .[   #&R   GM0
M(+@  !BZ!P 4O X $[P5 !*\'@ 1O28 $;TN !"]-P 0OD$ #KY,  Z^5P -
MOF4 #+]T  N_A@ *OID "+ZL  >^P@ 'OM\ "+[P  B]^@ (O?P "+W\ ).4
M  "'F0  >I\  &RE  !@J@  4Z\  $>S   \M@  ,;@  ">[   ?O@  %\$
M !'$ 0 ,R @ ",D.  ?)%  &R1P !<DD  3*+  #RC8  LI   #+3   RUD
M ,MH  #+>0  S(P  ,N?  #+LP  R\@  ,SB  #,[P  S/$  ,SQ (J:  !\
MH0  ;Z<  &*M  !5LP  2+@  #N[   PO@  )L$  !W$   5R   #\L   K.
M   $T@(  -,*  #3#P  U!0  -4:  #6(@  URH  -DT  #:/P  W$L  -Q:
M  #=:@  W7T  -V1  #=I   WK8  -[(  #>W@  WN(  -[B '^B  !QJ0
M9+   %:W  !)O   /,   "_$   DQP  &\L  !//   -T@  !]8   #;
MW@   -\#  #@"0  X0X  .(2  #C%P  Y1X  .8G  #H,0  ZCT  .Q+  #L
M6@  [6P  .Z   #NE   [J4  .ZT  #NP@  [L8  .[& '2J  !FL@  6+D
M $O    ]Q0  +\D  "3-   9T0  $=8   O;   #W@   .$   #E    Z
M .D   #J    ZP8  .T+  #O#P  \!,  /(:  #T(P  ]RX  /D[  #[2@
M_%L  /UM  #]@   _I,  /ZB  #^K0  _J\  /ZO /\0'P#_#AT _PH= /\!
M( #_ "@ _P U /\ 00#_ $X _P!: /\ 90#_ &X _P!W /\ ?P#^ (8 _ ",
M /L D@#Y )< ^ "< /< H@#V *< ]0"M /, M0#R +T \0#) .\ W #N .L
M[0#W .P _P#K /\ Z@#_ .H _P#J /\ Z@#_ /\3' #_$1D _PT9 /\&' #_
M R4 _P Q /\ /@#_ $H _P!6 /\ 80#_ &L _0!S /H >P#W (, ]0") /0
MCP#R )0 \0"9 /  GP#N *0 [0"K .P L@#J +H Z #& .< U@#E .@ Y #U
M ., _@#B /\ X0#_ .$ _P#A /\ X0#_ /\5& #_$Q0 _P\4 /\-&0#_"R(
M_P@M /\$.0#_ 48 _P!1 /X 7 #Z &8 ]@!O /( =P#O 'X [0"% .L BP#J
M )$ Z "6 .< G #F *$ Y "H ., KP#A +@ WP## -T T0#; .8 V0#S -<
M_0#5 O\ U +_ -0#_P#4 _\ U /_ /\8$P#_%1  _Q(/ /\2%0#_$1T _PXH
M /\,- #_"D$ ^0A, /4&5P#Q!F$ [09J .D%<@#F!7H Y 6! .(%AP#@!HT
MWP:2 -T&F #;!IX V0:E -<&K0#4!K4 T@;  - 'SP#.".4 S GT ,H+_P#(
M#/\ QPS_ ,<,_P#&#/\ Q@S_ /\;#@#_&0P _Q@- /\8$0#_%Q@ _Q0B /L1
M+@#S$#H [0Y& .@-4@#E#5P X0UE -X-;0#;#74 V U\ -4-@@#3#8D T0V/
M - -E0#.#9P S0ZC ,L.JP#)#K0 R [  ,8.SP##$.8 P!'U +T2_P"\$O\
MNQ+_ +H2_P&Z$O\!NA+_ ?\?"@#_' 0 _Q\( /\?#0#_'1( ^!H; .X6)@#F
M%#, X!,_ -H32P#4$U8 T!-? ,X4: #+%&\ R11W ,<5?0#&%80 Q!6* ,,5
MD0#!%I@ P!:? +X6IP"\%[  NQ>\ +D7RP"W&.( LQGR ;$:_P&O&_\!KAO_
M :X;_P&M&_\!K1O_ ?\B! #_(@  _R4" /PD!P#W(0P [!T2 .$:' #8&BH
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M!_0R  #C.P  TD$  ,9$  "]0P  MS\  +$["0"J.Q0 I3PB * ], "=/3L
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M"V]$KPQN1, ,;479#6Q%[PQK1?T+:T;_"VM&_PIK1O\*:T;_"N5   #/20
MP4\  +52  "K4@  H4\  )M*  "42@P CTL7 (M,) "'3"\ A$PZ (%,0P%^
M2TL!>TM2 GE*6 -W2E\$=4EF!7-);09Q274';TE^"&U(B EK2),+:DB?#&A(
MK0UG2;T-9DG4#F5)[0UE2OP,94K_"V5*_PME2O\+94K_"^!$  #+30  O5(
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M#U95Z0Y65?D-5E7_#5=4_PQ75/\,5U3_#-%-  # 5@  LUP  *=>  ":70
MCUP  (98  !_60  >5H- '1;%P!Q6R, ;ELN &M;-P!H6T !95M' 6-:3@)A
M6E4#7UI<!%U:8P5<6FL&6EET"%A9?PI668L+5%F8#5-8I@Y26;8.45G*#U%9
MYPY16/@-4EC_#5)8_PQ26/\,4EC_#,U1  "\60  L%\  *-A  "68   BU\
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M"T-E_PM#9?\+0V7_"[]<  "Q9   IFH  )9I  "):0  ?6D  '%I  !G:@
M8FP! %UM#0!9;A8 5V\A %5P*P!3<#4 47 ] %!P10%.<$P!3'!3 DIP6@-(
M<&($1F]K!41O=09";X('0&Z/"3]NG@H];J\*/6[""CQNX H];?0*/6S_"CUK
M_PH^:_\*/FO_"KI@  "M:0  H&X  )%M  "$;0  >&T  &QN  !A<   6W(
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M!*IT  ">>P  CGH  (!Z  !T>P  :'X  %V!  !2A0  28D  $&,   YD 4
M-9$/ #.2%P RDB$ ,9(I #"3,@ NDSH +9-! "R32@ KE%( *I1< "B49P G
ME',!)92" 224DP$BDZ0!(9.W 2"3SP$ADNP!()#Z B"/_P(@C_\"((__ J1\
M  "7@   AW\  'N   !N@@  8H4  %>)  !-C@  0I(  #J6   RF0  *IP)
M "B=$0 FG1D )9TB "2>*@ CGC( (IXZ "&>0@ @GDL 'Y]5 !Z?8  <GVT
M&Y]\ !J?C0 8GY\ %Y^R !:?R0 6GN@ %ISW !:;_P$7F_\!%YO_ 9V#  "/
MA@  @H8  '2'  !GBP  6X\  %"3  !&F   /)P  #.@   KHP  (Z8  !RH
M"P :J1$ &*D8 !>I(0 6JBD %:HQ !2J.0 3JD, $ZM- !*K6  1JV4 $*MT
M  ZKA@ .JYD #:NL  RKP0 ,JM\ #*GR  VH_  -J/\ #:C_ ):*  ")C
M>HT  &R1  !@E0  5)H  $F?   _HP  -:<  "NJ   CK@  &[   !2S 0 /
MM0H #;80  RV%@ +MA\ "K8G  FV+P (MCD ![=#  :W3P $MUL  [=J  *W
M>P  MXX  +>A  "VM   MLL  +;E  "U\0  M?<  +7W (^1  "!E   <I<
M &6<  !8H0  3*8  $&K   WKP  ++(  ".U   :N   $[L   Z]   )P 4
M \$-  #!$0  P1<  ,(>  #")@  PB\  ,,Y  #$1   Q%   ,1>  #%;P
MQ8$  ,65  #%J   Q;P  ,31  #$Y@  Q.X  ,3N (:8  !YG@  :Z,  %VI
M  !0K@  1+,  #>V   LN0  (KP  !F_   1P@  #,4   ;(    RP   ,P'
M  #,#0  S1$  ,T6  #.'0  SR0  - M  #2.   U$0  -12  #580  U7,
M -:'  #6FP  UJT  ->_  #8S@  V-T  -C= 'N@  !NI@  8*T  %.S  !%
MN   .+P  "N_   AP@  %\8  !#)   *S    M    #4    UP   -@   #:
M!0  VPL  -P.  #>$P  WQD  .$A  #C*@  Y38  .=#  #G4P  Z&0  .EW
M  #IC   ZI\  .JN  #JN@  ZL,  .K# '"H  !BKP  5;8  $>\   YP
M+,0  "#(   6S   #M    ?4    V0   -T   #A    XP   .0   #F
MYP$  .D'  #K#   [!   .X5  #P'0  \R<  /8S  #W0P  ^%0  /EF  #Y
M>@  ^HX  /J>  #[J0  ^[   /NP /\+&P#_!QD _P 9 /\ ' #_ "4 _P R
M /\ /P#_ $L _P!7 /\ 8@#_ &L _P!S /T >P#[ (( ^@"( /@ C0#W )(
M]@"8 /4 G0#T *( \P"I /$ L #O +@ [@## .P T0#K .8 Z0#S .@ _@#H
M /\ Z #_ .@ _P#H /\ Z #_ /\.& #_"A4 _P$4 /\ & #_ "( _P N /\
M.P#_ $< _P!3 /T 7@#Z &< ]P!O /4 =P#S 'X \@"$ /  B0#O (\ [@"4
M .P F@#K )\ Z0"E .@ K #F +0 Y "_ ., S #A .( WP#P -X ^P#> /\
MW0#_ -T _P#< /\ W #_ /\0$P#_#1$ _P80 /\"%0#_ !X _P I /\ -@#_
M $( ^@!. /0 60#Q &( [@!K .P <@#J 'D Z !_ .< A0#E (L Y "0 .(
ME@#A )P WP"B -T J0#: +$ V "[ -4 R #2 -T T0#M -  ^0#/ /\ S@#_
M ,T _P#- /\ S0#_ /\1#P#_#@T _PP- /\+$@#_!QD _P(D /\ , #V #P
M[P!) .H 4P#G %T Y !F .$ ;0#? '0 W0![ -L @0#9 (8 U@", -0 D@#2
M )@ T "> ,X I@#, *X R@"X ,@ Q #& -< Q0#J ,, ]P#" /\ P0'_ , "
M_P#  O\ P +_ /\4"P#_$ 8 _Q ) /\0#@#_#A0 _PH> /4&*0#K!#8 XP-"
M -\#3@#;!%< U@1@ -,$: #0!&\ S@5V ,P%? #*!8( R06( ,<%C@#&!90
MQ 6; ,(%HP# !JL O@:U +T&P@"["-0 N@GI +<+^ "U#/\ M S_ +0,_P"T
M#/\ M S_ /\7! #_%   _Q8# /\4"0#_$0X \@X5 .@,(0#>"BX U@L[ - ,
M1P#,#%$ R0Q: ,8-8@#$#6H P@UQ , -=P"_#7T O0Z# +P.B@"Z#I$ N0Z8
M +<.H "V#JD M ^T +(/P0"Q$-0 KA'K *L2^@"I$O\ J!/_ *<3_P"G$_\
MIQ/_ /\:  #_&P  ^1L  .L9  #E% 8 Y1 . -D.%P#/$28 R!(T ,030 "_
M%$L O!14 +D570"W%60 M15K +05<0"R%7@ L19^ *\6A0"N%HP K!:4 *L7
MG "I%Z8 IQBP *88O0"D&,\ HAKG )\:]P"=&_\!G!O_ 9P;_P&;&_\!FQO_
M ?\=  #W(0  Z"0  -TE  #4(0$ SQL( ,H7$0#"&B  O!PM +<=.@"S'D4
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M X,OL@."+\(#@3#: W\P[P-],?X#?3'_ WPQ_P-\,?\#?#'_ ^TO  #;-P
MR3T  +X^  "S/   K#@  *<S! "B,A$ G30= )DU*@"5-34 DC5  (\U20"-
M-5  BS57 (DU7@&'-60!A31K 80T<@*"-'D"@#2" GXTBP-]-)8#>S6A!'DU
MK@1X-;X%=S;4!78V[05T-_P%=#?_!'0W_P1T-_\$=#?_!.<U  #2/0  PT(
M +A$  "L0@  I#X  )\Y  ":. X E#H9 ) Z)@"-.S$ BCL[ (<[1 "$.TP
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M"&!$Y@A?1?@'7T7_!V!%_P9@1/\&8$3_!M9!  ##20  MDX  *=/  ";30
MDDL  (Q'  "%1P0 @$<0 'Q(&@!X2"8 =4DP '-).@!P24( ;DE) 6Q(4 %J
M2%8!:$A= F9(9 )E2&P#8TAU!&%'?P5@1XH&7DB7!UU(I0A;2+0(6TC'"5I(
MY A:2?8(6DG_!UI(_P9:2/\&6DC_!M%%  "_3   LE(  *-1  "74   C4X
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M!TQ3_P=-4_\&35/_!L5.  "V5@  IUH  )A9  "+6   @5<  '=4  !P50
M:E8& &97$ !B5QH 8%@D %U8+@!;63< 65D_ %=91@!664T!5%E4 5-96P)1
M66,"3UAL TY8=@1,6((%2EB/!DE8G@=(6*X(1UC "$=8W0A'6/((1U?_!TA7
M_P=(5_\&2%?_!L%1  "R60  HUP  )1;  "'6P  ?5H  ')8  !K60  95H#
M &!;#@!=7!< 6EPA %A=*P!6730 5%X\ %->1 !17DL!4%Y2 4Y>60),7F$"
M2UUJ TE== 1'78 %15V-!D1=G =#7:P'0EV^"$)=V@A"7/$'0ES^!T-;_P9#
M6_\&0UO_!KU5  "O70  GU\  )!>  "#7@  >%T  &U<  !E70  7U\  %I@
M# !7810 56(> %)B* !18S$ 3V,Y $YC00!,8T@ 2V-/ 4EC5@%'8UX"16-G
M D1C<0-"8WT$0&*+!3]BF@8^8JH&/6*\!SQBU@<]8>\&/6']!CY@_P8^8/\&
M/F#_!KE9  "K80  FF$  (MA  !_80  =&$  &EA  !?8@  660  %1F"0!1
M9Q$ 3F<: $QH) !+:2T 26DV $AI/@!&:D4 16I, $-J5 %":EP!0&EE CYI
M;P(\:7L#.VF)!#EIF 4X:*@%-VBZ!3=ITP4W:.X%-V?\!3AF_P4X9O\%.&;_
M!;1>  "G90  E64  (9D  !Z90  ;V4  &1F  !9:   4FH  $UL! !);@X
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M;0  B6P  'QM  !P;0  9FX  %MQ  !0=0  2'@  $%[   Z?@4 -G\. #2
M%@ S@2  ,H$H #"!,  O@C@ +H)  "V"2  L@E  *X): "J"9  H@G  )H)_
M 26"CP$D@J !(X*R 2*"R0$B@><!(G_W 2)^_P(B??\"(GW_ J5Q  "3<0
M@W$  '9Q  !L<@  8'4  %9X  !,?   0X   #N#   SA@  +8D* "J*$0 I
MBQD )XLB ":+*@ EC#$ )(PY ".,0@ BC4H (8U4 ""-7@ ?C6L '8UY !R-
MB@ ;C9P &8VN !B,Q  8C., &8KU !F)_P$9B/\!&8C_ 9UW  ",=@  ?78
M ')W  !E>0  6GP  %"   !&A   /(D  #2,   MD   )9," !^5#  =EA(
M')8: !N7(@ :ERH &9<R !B8.@ 7F$, %IA- !686  4F&0 $YAS !&8A  0
MF)8 $)BI  Z8OP .E]T #Y;R !"5_  0E/\ $)3_ )5]  "%?   >'P  &M^
M  !?@0  5(8  $J*  ! CP  -I,  "V7   FF@  'IT  !>@ P 2H@P $*,2
M !"C&0 /HR$ #J0I  ZD,0 -I#H #*1%  ND4  *I%P ":1J  >D>P &HXX
M!*.A  *CM  #HLL  Z+F  .A\P #H?L  Z'[ (V#  !_@@  <80  &2'  !8
MC   39$  $*6   XF@  +YX  ":B   >I0  %Z@  !&K   ,K@< !Z\-  .O
M$@ "KQD  :\A  "O*0  L#(  + \  "P1P  L%,  +!A  "P<0  L(,  *^7
M  "OJ@  K[\  *[9  "NZP  KO0  *[T (>)  !XB@  :HX  %V3  !1F
M19T  #NB   PI@  )ZH  !ZN   6L0  $+0   NV   %N0,  +H*  "Z#@
MNA,  +L9  "[(0  O"@  +PQ  "]/   OD@  +Y6  "^90  OG<  +Z,  "^
MGP  O;,  +['  "^W@  O>L  +WK '^2  !PE0  8IH  %6?  !)I0  /:L
M #*O   HM   'K8  !6Y   .O   ";\   +"    Q    ,4$  #&"@  Q@X
M ,<2  #(&   R1\  ,HG  #,,   SCP  ,Y)  #/60  SVH  ,]^  #/DP
MSZ8  ,^X  #/R   S]L  ,_; '><  !HH0  6Z<  $ZN  !!M   -+<  "BZ
M   =O0  $\    W$   &QP   ,H   #.    T    -$   #2 @  TP@  -4,
M  #6$   V14  -L<  #=)   X"\  .(\  #C2P  Y%P  .1O  #E@P  Y9@
M .6I  #EM@  Y<,  .7# &RE  !?K   4;(  $2Y   UO   *,   !S$   2
MR   #,L   //    TP   -@   #<    WP   -\   #A    XP   .0#  #F
M"   Z T  .D1  #L&   [B(  /$N  #S/   ]$T  /5?  #V<P  ]X<  />9
M  #XI0  ^+   /BP /\#%P#_ !4 _P 5 /\ & #_ ", _P O /\ / #_ $@
M_P!4 /\ 7@#_ &< _0!O /L =@#Y 'T ^ "# /8 B #U (X ] "3 /( F #Q
M )X \ "D .X JP#M +, ZP"] .H RP#H .$ YP#Q .8 _0#E /\ Y #_ .0
M_P#D /\ Y #_ /\'$P#_ !$ _P 1 /\ %0#_ !\ _P K /\ -P#_ $0 _@!/
M /H 6@#W &, ] !K /( <@#P 'D [P!_ .T A #K (H Z@"/ .@ E #G )H
MY0"@ .0 IP#B *\ X "Y -X Q@#< -H V@#L -@ ^0#6 /\ U@#_ -< _P#8
M /\ V #_ /\*$ #_ PX _P - /\ $@#_ !H _P F /P ,@#W #\ ] !* /$
M50#M %X Z@!F .@ ;@#E '0 XP!Z .( @ #@ (4 W@"+ -P D #; )8 V "<
M -4 HP#3 *L T0"U ,X P0#, -$ RP#G ,D ]0#( /\ R #_ ,@ _P#( /\
MR #_ /\,# #_!@@ _P(* /\ #P#_ !4 _  @ /$ + #L #D Z0!% .4 3P#A
M %D W@!A -L : #7 &\ U !U -( >P#0 (  S@"& ,P C #+ )( R0"8 ,<
MH #% *@ PP"Q ,$ O "_ ,L O0#C +P \@"[ /T NP#_ +H _P"Z /\ N@#_
M /\.!0#_"0  _PD% /\&"P#_ 1  \  9 .8 )0#A #( W  _ -8 20#1 %,
MS@!; ,L 8P#( &H Q@!P ,4 =@## 'L P0"! ,  AP"^ (X O "4 +L G "Y
M *0 MP"N +4 N0"S ,@ L0#? + ![P"O ?L K@+_ *T#_P"M _\ K0/_ /\0
M  #_#@  _PT  /8+ P#R!PH X@$1 -L"'0#2 RL S ,W ,@$0P#$!$T P016
M +X%70"\!60 N@5K +@%<0"W!78 M05\ +,&@P"R!HD L :1 *\'F0"M!Z$
MJP>K *D(MP"H"<8 I@K= *4+\ "C#/T H@W_ *$-_P"A#?\ H W_ /\1  #\
M$@  [!,  .(3  #;#P, U@D+ ,X(% #&"B( P PP +P-/ "X#48 M0U/ +(.
M5P"P#E\ K@YE *T.:P"K#G$ J@YX *@.?@"G#X4 I0^- *0/E@"B$)\ H!"I
M )\0M0"=$<4 FQ'> )D2\0"7$_\ EA3_ )44_P"5%/\ E!3_ /\5  #M&P
MX!\  -(?  #)&P  Q!0% ,$0#@"Z$AL M!,I + 4-0"L%4  J15) *854@"D
M%ED HA9@ *$69@"?%FP GA9R )P6>0";%X  F1>( )@7D0"6&)L E!BF ),9
ML@"1&<$ D!K8 (T;[@"+'/T BAS_ (H<_P")'/\ B1S_ /0=  #D)0  TRD
M ,<J  "\)@  MB   +09"P"N&A4 J!PC *0=+P"A'CH GAY$ )L>3 "9'E0
MEQ]; )4?80"4'V< DA]M )$?= "/('P CB"$ (P@C0"*()< B2&B (<AK@"&
M(KT A2+1 8(CZP&!)/L!@"3_ 7\D_P%_)/\!?R3_ >PE  #;+0  R3$  +PQ
M  "Q+@  JRD  *<D!0"C(Q$ GB0= )HE*@"6)C4 DR8_ )$F1P"/)D\ C296
M (LG7 "))V( B"=I (8G;P"%)W< @R=_ ($GB0& *),!?BB> 7TIJP%[*;D!
M>BG- 7@JZ %W*_D!=BO_ 78K_P%U*_\!=2K_ >4L  #0-   P3@  +,X  "H
M-0  HC$  )TM  "9*@X E"L8 ) L) "-+3  BBTZ (<M0P"%+4H @RU1 ($N
M6 " +EX ?BYD 'TN:P![+G,!>2Y[ 7@NA0%V+H\!="^; 7,OJ )Q+[8"<##)
M F\PY0)N,?<";3'_ FTQ_P)M,?\";3'_ M\R  #).0  NSX  *P]  "A.@
MFC<  )4S  "0,0H C#$4 (<R( "$,RL @3,U '\S/@!],T8 >S-- 'DS5 !W
M,UH =C-A '0S9P%R-&\!<31W 6\T@0%N-(P";#28 FHUI0)I-;,#:#7& V<V
MX@-F-O4#9C;_ F8V_P)F-O\"9C;_ M@W  #$/@  M4(  *9!  ";/P  DSP
M (TX  "(-@< A#<1 ( W' !\."< >C@Q '<Y.@!U.4( <SE) '$Y4 !P.5<
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M U1#_P-40_\#5$/_ \A"  "X20  ITL  )A*  "-20  @T<  'U#  !V0P
M<40* &U$$@!J11T 9T4G &1%, !B13@ 8$4_ %]%1P!=14T 6T54 %I&6P%9
M1F,!5T9L 59&=@)41H$#4T:. U)'G 101ZL$4$>]!$]'U@5/1^\$3T?]!$]'
M_P-/1_\#4$?_ \1%  "U30  HTT  )5,  ")2P  ?TH  'A&  !Q1P  ;$<'
M &A($ !D2!H 84DD %])+0!=234 6TD] %E)1 !724H 5DE1 %5*60%42F$!
M4DII 5%*= )/2G\#3DJ, TU*FP1,2ZH$2TN\!$I+TP5*2^X$2TO]!$M*_P-+
M2O\#2TK_ \%(  "R4   H$\  )%/  "%3@  >TT  '-)  !L2@  9TL$ &),
M#@!?3!< 7$TA %I-*@!833( 5DTZ %1-00!33D@ 4DY/ %!.5P%/3E\!3DYG
M 4Q.<@)+3GT"24Z+ TA.F01'3Z@$1D^Z!$9/T01&3^T$1D[\!$9._P-'3O\#
M1T[_ [U,  "N4@  G%$  (U1  "!40  =U   &Y,  !G3@  8D\  %U0#0!:
M4!0 5U$> %51)P!343  45(X %!2/P!.4D8 35)- $Q350!*4UT!25-E 4A3
M;P)&4WL"15.) T-3EP-"4Z<$05.X!$%3SP1!4^P$05+[ T)2_P-"4O\#0E'_
M [I/  "J5   F%0  (E4  !]4P  <U,  &E1  !B4@  7%,  %A4"@!451(
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M 3-CD0(R8Z$",6.S C%CR (Q8N<",6'X C%A_P(R8/\",F#_ JY<  ";70
MBET  'Q=  !P70  9ET  %Q>  !28   3&(  $5E  !!9@H /F<1 #QH&@ [
M:"( .6DK #AI,@ W:CH -FI! #5J20 T:E( ,VI; #%J90 P:G !+FI^ 2UJ
MC@$L:I\!*VJP 2IJQ@$J:>4!*FCV BMG_P(K9_\"*V?_ JEA  "58   A&
M '=@  !L80  8F$  %AC  !.9@  1V@  $!K   Z;@4 -F\. #1P%0 S<!X
M,G$F #!Q+@ O<34 +G(] "UR10 L<DT *W)7 "IR80 I<FT )W)[ "9RBP D
M<IP!(W*N 2-RPP$C<>(!(W#T 2-O_P$C;O\!(V[_ :%E  ".9   ?V0  ')D
M  !H90  7F8  %1I  !);   0F\  #MR   T=0  +G@* "MY$0 J>1@ *7HA
M "=Z*  F>C  )7LX "1[0  C>T@ (GM2 "%[7  @>V@ 'WQV !U\A@ <>Y@
M&WNJ !I[OP :>]X &GGR !MX_@ ;=_\!&W?_ 9EI  "(:0  >6D  &UI  !C
M:@  66P  $]O  !%<P  /7<  #5Z   N?0  )X$# "*##0 @A!( 'X0: !V$
M(@ <A2H &X4Q !J%.0 9A4( &(9, !>&5@ 6AF, %89Q !2&@0 2AI, $8:F
M !&%NP 0A=8 $8/O !&"^P 2@O\ $H'_ )%N  "!;0  =&X  &EN  !=<
M4W,  $EW  ! ?   -X   "^#   GAP  (8H  !J-!@ 5CPT $Y 3 !*0&@ 2
MD"( $9 J !"1,@ 0D3L #Y%$  Z13P -D5P #)%J  N1>@ *D8T ")"?  >0
MLP 'C\D !X_F  >.]  (C?P "(W_ (ES  ![<P  ;W,  &-U  !7>   37T
M $.!   YA@  ,(H  "B.   AD0  &I4  !.7   .F@@ "YP.  F<$P (G!H
M!YPB  :<*@ $G#,  YP]  *=2   G50  )UB  "<<@  G(0  )R7  ";J@
MF[\  )K;  ":[   FO4  )GX ()Y  !V>0  :'H  %Q^  !1@@  1H<  #R,
M   RD0  *94  "&9   9G0  $J    ZC   )I@4  Z<,  "G$   IQ4  *@<
M  "H(P  J"L  *DT  "I/P  J4L  *E9  "I:   J7H  *F.  "IH0  J+4
M *C+  "GY   I^\  *?S 'V   !O@0  880  %6)  !)C@  /I0  #29   J
MG@  (:(  !FF   2J0  #:P   >O    L@   +,'  "S#   LQ   +05  "T
M&P  M2(  +8K  "W-0  MT   +A.  "X70  N&X  +B"  "XEP  N*H  +>^
M  "WT@  M^8  +?J ':(  !GBP  6I   $Z6  !"G   -Z(  "RG   BJP
M&:\  !&S   +M@  !+D   "\    O@   +X   "_!@  P L  ,$/  #"$P
MPQD  ,0@  #%*0  QS0  ,A"  #)40  R6(  ,EU  #)B@  R9\  ,JQ  #*
MP0  R=$  ,G9 &Z3  !@F   4YX  $:D   ZJP  +[   "2U   9N   $+P
M  J_   !P0   ,0   #(    R@   ,H   #,    S0,  ,X(  #0#0  T1
M -,6  #6'@  VB@  -TT  #>0P  WU0  -]G  #@?   X)$  ."D  #@L@
MX+X  .## &:?  !9I@  3*T  #^T   RN   )+P  !B_   0PP  ",<   #*
M    S0   -$   #5    V    -D   #;    W0   -\   #A!   XPH  .4.
M  #G$P  ZAP  .TG  #P-0  \48  /)8  #S:P  \X   /24  #THP  ]*X
M /2R /\ $P#_ !$ _P 1 /\ %0#_ !\ _P L /\ .0#_ $4 _P!0 /\ 6@#^
M &, ^P!K /D <@#W '@ ]0!^ /0 A #R (D \0". /  DP#N )D [0"? .P
MI@#J *X Z "X .8 Q0#E -L XP#M .( ^P#B /\ X0#_ .$ _P#A /\ X0#_
M /\ $ #_  X _P - /\ $@#_ !L _P H /\ - #^ $$ ^P!, /< 5@#T %\
M\0!F .\ ;0#L '0 Z@!Z .D ?P#G (4 Y@"* .4 CP#C )4 X0"; .  H@#>
M *H VP"T -D P #6 -  TP#H -( ]P#1 /\ T0#_ -  _P#0 /\ T #_ /\
M#0#_  D _P * /\ #P#_ !8 ^P B /< +P#T #L \ !' .T 40#I %H Y0!B
M .( :0#@ &\ W@!U -P >@#: (  V "% -4 BP#3 )$ T0"7 ,\ G@#- *8
MRP"O ,D N@#' ,D Q0#B ,0 \@## /X P@#_ ,$ _P#" /\ P@#_ /\#!@#_
M  $ _P & /\ # #Y !$ \0 = .L *0#G #8 XP!! -\ 2P#; %0 U0!< -(
M8P#/ &H S0!P ,L =0#) 'L R "  ,8 A@#% (P PP"3 ,$ F@"_ *( O0"K
M +L M@"Y ,0 MP#: +8 [0"T /H M #_ +0 _P"T /\ M #_ /\$  #_
M_P   /\ !@#L  T Y0 6 -X (@#7 "\ T0 [ ,T 10#* $X Q@!7 ,0 7@#!
M &0 OP!J +T < "\ '4 N@![ +D @0"W (< M0". +, E0"R )X L "G *X
ML@"L +\ J@#1 *@ Z "H /< IP#_ *< _P"F /\ I@#_ /\&  #_!0  \0,
M .@   #A  < U0 0 ,T &P#' "< PP S +\ /@"\ $@ N0!1 +8 6 "T %\
ML@!E +  :@"O '  K0!V *P ? "J (( J0") *< D0"E )H HP"D *$ K@"@
M +L G@'- )T"Y@"<!/0 FP3_ )H%_P":!?\ F07_ /\*  #Q#@  Y!   -D/
M  #."P  R ,+ ,( $P"\ A\ MP,L +,$-P"P!4( K09* *H&4@"H!UD I@=?
M *4'90"C!VL H@AQ * (=P"?"'X G0B% )L)C@":"9< F JA )8*K "5"[H
MDPO, )(,Y0"0#?8 CP[_ (X._P".#O\ C0[_ /81  #F%P  UAL  ,<9  "^
M%0  N1   +<*#0"Q"Q< K TD *@., "E#CL H@Y$ )\/3 "=#U, FP]: )H/
M8 "8$&8 EQ!L )40<@"3$'D DA"! ) 0B@"/$90 C1&? (L1J@"*$K@ B!++
M (83Y@"%%/< @Q7_ (,5_P""%?\ @A7_ .T:  #<(0  RB4  +LB  "Q'P
MJQH  *D4!@"E$A$ H!0> )P5*@"9%34 EA8^ )061P"2%DX D!95 (X76P",
M%V$ BQ=G (D7;0"(%W0 AAA\ (48A@"#&9  @1F; ( :IP!^&K4 ?1O' 'P<
MX@!Z'?4 >1W_ '@=_P!X'?\ >!W_ .4B  #0*0  ORP  + J  "G)P  H",
M )T?  ":&@X E1P8 )$=) ".'B\ C!XY (D>00"''TD A1]0 (,?5@""'UP
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M 5\P_P%?,/\!7S#_ <TT  "\.P  J3H  )LZ  "0.   B34  (,R  !_, $
M>R\. '<P%@!T,"$ <3$K &\Q- !M,3P :S%# &HQ2@!H,E  9S)7 &4R70!D
M,F4 8C)M &$S=P!?,X(!7C.. 5TTG %;-*H!6C6[ 5HUT@%9->T!637\ 5@U
M_P%8-?\!637_ <@X  "W/@  I#X  )8]  "+/   @SH  'TW  !X-   =#0+
M ' U$P!M-1T :C4G &@V, !F-C@ 9#8_ &,V1@!A-DT 8#93 %XW6@!=-V(
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M/A< 7CXA %P^*0!:/C$ 6#XY %<^0 !5/T8 5#]- %,_50!20%P 4$!E $]
M;P%.07H!34&' 4M!E@%*0:4"24*U DE"RP))0N@"24+Y DE!_P))0?\!24'_
M ;U#  "J10  F$4  (I%  !_10  =D,  &]   !H0   8T$! %]!#0!<010
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M 3U-D $\3: !.TZQ CI.Q@(Z3N0".TWV CM-_P$[3/\!/$S_ ;--  ">3
MC4P  '],  !T3   :DP  &!*  !92P  5$P  %!-!0!,3@X 24\5 $=/'@!%
M3R8 1% N $)0-0!!4#T 0%%$ #]12P ^45, /5)< #Q29@ Z4G( .5)_ 3A2
MC@$W4IX!-E*O 352Q $U4N(!-E+U 391_P$V4/\!-U#_ :Y/  "93P  B4\
M 'M/  !P3P  9D\  %Q.  !43P  3U$  $I2 0!&4PP 0U02 $%4&P! 52,
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M "-DO0 B9-H (V/Q "-B_0$D8?\!)&'_ 9Q8  ")6   >ED  &Y9  !C60
M6EH  %!<  !(7@  06   #IC   T9@  +V@* "QI$  J:1< *6H? "AJ)@ G
M:BX )FLU "5K/0 D:T8 (VM/ ")L60 @;&4 'VQR !YL@@ =;)0 '&RF !MK
MN@ ::]0 &VKN !QI_  <:/\ '&C_ )5<  "#7   =5P  &E=  !?70  5EX
M $QA  !#9   /&<  #5J   O;0  *' $ "-R#0 A<A( (',: !]S(0 ><R@
M'70P !QT.  ;=$  &G1* !ET5  7=6  %G5N !5U?@ 4=9  $W2B !)TM@ 1
M=,\ $G/L !)R^@ 3<?\ $W'_ (Y@  !]8   ;V$  &5A  !;8@  460  $AG
M   ^:P  -VX  #!Q   I=0  (G@  !Q[!P 7?0X %GT3 !5]&P 4?B( $WXJ
M !)^,0 1?CH $7Y$ !!_3@ /?UH #G]H  U_>  ,?XH "WZ=  I^L  )?<8
M"GWD  I\]  +>_T "WK_ (9E  !W90  :F4  &%F  !6:   3&L  $)O   Y
M<P  ,7<  "IZ   C?@  '($  !6$   0AP@ #8D.  R)%  ,B1L "XDC  J)
M*P )B3, "(D]  :)2  %B50 !(EA  *)<0 !B8,  (F6  "(J0  A[X  (?:
M  "&[   AO4  (;Z 'YJ  !Q:@  9VL  %ML  !0<   1G0  #QX   S?0
M*H$  ".%   <B   %8P  !"/   ,D@8 !I,,  *3$0  E!8  )0=  "4)
ME2P  )4U  "50   E4P  )99  "6:0  E7H  )6.  "4H0  E+4  )/,  "2
MY@  DO(  )+W 'AP  !M<   8'(  %1U  !)>0  /WX  #6#   LB   (XT
M !N1   4E   #Y<   J:   $G0,  )X)  "?#@  GQ(  * 7  "@'0  H24
M *(M  "B-P  HT,  *-0  "C7P  HW$  *.$  "BF0  HJT  *'"  "AW
MH>L  *#R '-V  !F=P  67L  $V   !"A0  .(L  "Z0   DE0  &YH  !2>
M   .H0  ":0   *G    J@   *L$  "K"@  K T  *T1  "M%@  KAP  *\D
M  "P+0  L3D  +%&  "R50  LF8  +)Y  "RC@  L:,  +*W  "QR@  L>
M +'I &Q^  !?@@  4H<  $:-   [DP  ,)D  ":>   <HP  $Z<   VK   '
MK@   +(   "U    MP   +@   "Y @  N0@  +H,  "[$   O!0  +T;  "_
M(P  P2T  ,(Z  #"20  PUH  ,-L  #$@@  Q)<  ,2K  #$O   Q,L  ,3:
M &6)  !8C@  2Y4  #^;   SH@  **@  !VM   4L0  #;8   :Y    O
M +\   ##    Q    ,4   #&    QP   ,D$  #*"0  RPT  ,T1  #/&
MTB$  -4M  #6/   V$T  -E?  #:<P  VHH  -N>  #;K@  V[H  -S# %Z6
M  !1G   1*,  #BJ   LL0  (+<  !6[   -O@  !,(   #%    R0   ,T
M  #0    T@   -(   #5    U@   -D   #;    W@4  . *  #B#P  Y18
M .@@  #L+0  [3X  .U1  #N90  [WH  .^/  #PGP  \*L  /"S /\ $ #_
M  X _P . /\ $@#_ !T _P I /\ -0#_ $$ _P!- /X 5@#[ %\ ^ !F /8
M;0#T '0 \@!Y /$ ?P#P (0 [@") .T CP#K )4 Z@"; .@ H@#F *H Y0"S
M ., P #A -( X #J -\ ^0#= /\ W0#_ -T _P#> /\ W@#_ /\ #0#_  H
M_P ) /\ #P#_ !@ _P D /X ,0#[ #T ^ !( /0 4@#P %H [0!B .L :0#I
M &\ YP!U .4 >@#C '\ X@"% .  B@#> )  W "6 -H G0#8 *4 U0"O -(
MN@#0 ,H S@#C ,T ] #+ /\ RP#_ ,L _P#+ /\ RP#_ /\ " #_  , _P %
M /\ # #\ !0 ]P ? /( *P#O #< ZP!" .< 3 #D %4 X != -T 9 #: &H
MV !P -4 =0#2 'H T "  ,\ A0#- (L RP"2 ,D F0#' *$ Q0"J ,, M0#!
M ,, OP#: +X [@"] /P O #_ +P _P"\ /\ O #_ /\   #_    _P   /D
M!P#Q !  Z@ : .0 )0#? #$ VP \ -< 1P#2 %  S@!7 ,L 7@#) &4 Q@!J
M ,4 < ## '4 P0!Z ,  @ "^ (8 O "- +H E "Y )P MP"E +4 L "S +T
ML0#/ *\ Z "N /@ K@#_ *T _P"M /\ K0#_ /\   #_    _0   .X  0#C
M  P V@ 4 -$ 'P#, "L R  V ,4 0 #" $H OP!2 +P 60"Z %\ N !E +8
M:@"T &\ LP!U +$ >@"P ($ K@"( *T CP"K )@ J0"A *< JP"E +@ HP#(
M *( X@"A /, H #^ *  _P"@ /\ H #_ /\   #V    Z@   .    #3  8
MR0 / ,( & "] "0 N0 O +8 .@"T $, L0!, *X 4P"L %D J@!? *D 9 "G
M &H I@!O *0 =0"C 'L H0"" *  B@"> ), G "= )H IP"8 +0 E@## )4
MW "4 .\ DP#[ ), _P"3 /\ D@#_ /D%  #J"P  W T  ,L*  #"!0  O  *
M +8 $0"Q !P K@ H *H ,P"G #T I !% *( 30"@ %, G@!9 )P 7P"; &0
MF@!J )@ < "7 '8 E0!^ ), A@"2 8\ D &9 (X"I ", K$ BP/  (D%U@"(
M!NT B ?Z (<(_P"&"/\ A@C_ .\/  #>%   RA4  +P2  "S$   K@P  *L&
M#0"G Q4 H@4@ )\'+ "<"#8 F0@_ )<)1P"5"4X DPE4 )$*6@"0"E\ C@IE
M (T*:P"+"G( B@MY (@+@@"'"XP A0R7 (,,H@"!#;  @ W  '\-V !]#N\
M? _] 'L/_P![$/\ >Q#_ .87  #1'@  O1T  *\<  "F&0  H14  )X0! "=
M#0\ F X9 )0.)0"1#R\ CQ Y (P000"*$$@ B!!/ (<050"%$%L A!%A ((1
M9P" $6X ?Q%U 'T1?@!\$H@ >A*4 '@2H !W$ZX =1.^ '04U0!S%>X <1;]
M '$6_P!Q%O\ <!;_ -P?  #&)0  LR4  *4C  "<(0  EAX  )(9  "1% L
MC104 (D5'P"&%BD @Q8S ($7/ " %T, ?A=* 'P74 !Z%U8 >1A< '<88@!V
M&&D =!AQ ',9>@!Q&80 ;QJ0 &X:G0!L&ZL :QR[ &H<T !I'>P :![[ &@>
M_P!G'O\ 9Q[_ -$F  "]*@  JRH  )TJ  "3*   C24  (@B  "&'08 @QL0
M '\<&@!\'20 >ATN '<>-@!V'CX =!Y% '(?2P!Q'U$ ;Q]8 &X?7@!L'V4
M:R!M &D@=@!H(8$ 9B&- &4BF@!C(J@ 8B.X &$CS0!@).D 8"3Z %\D_P!?
M)/\ 7R3_ ,HL  "V+P  I"\  )8O  ",+0  A2H  ( H  !])   >B(- '8C
M%0!S(R  <20I &\D,@!M)#H :R5! &HE1P!H)4T 9B54 &4E6@!D)F$ 8B9I
M &$F<@!?)WT 7B>* %THEP!;*:4 6BFU %HJR@!9*N< 6"KX %@J_P!8*O\
M6"K_ ,4Q  "O,P  GC,  ) S  "&,@  ?R\  'DM  !U*@  <B@* &\H$@!K
M*1L :2DE &<J+0!E*C4 8RH] &(J0P!@*DH 7RM0 %XK5P!<*UX 6RQF %DL
M;P!8+7H 5RV' %8NE0!4+J, 4R^S %,OQP!2+^4 4B_W %(O_P!2+_\ 4B__
M ,$V  "J-@  F38  (LV  "!-0  >3,  ',Q  !O+P  :RX& &@M$ !D+A@
M8BXA & O*@!>+S$ 7"\Y %LO0 !9+T8 6"]- %<P4P!6,%L 5#%C %,Q; !2
M,G< 43*$ $\SD@!.,Z$ 33.Q $TTQ0%,-.,!3#3V $PT_P!,-/\ 3#/_ +LY
M  "F.0  E3D  (<Y  !\.0  =#<  &XT  !I,P  93(" &$R#0!>,A0 7#,>
M %HS)@!8,RX 5C,U %4T/ !3-$, 4C1* %$T4 !0-5@ 3C5@ $TV:@!,-G4
M2S>" $HWD !).)\ 2#BP 4<XPP%'..$!1SCU 4<X_P%'./\!1SC_ ;<[  "B
M/   D3P  (,\  !X/   <#H  &HW  !D-@  8#8  %PV"P!9-Q( 5C<: %0W
M(P!2-RL 4#<R $\X.0!-.$  3#A' $LX3@!*.54 23E> $@Z: !'.G, 1CN
M $4[C@!$/)X 0SRN 4(\P@%"/=\!0CSS 4(\_P%"//\!0CO_ ;,]  ">/@
MC3X  '\^  !U/@  ;#T  &8Z  !@.0  6SH  %<Z" !3.Q  43L8 $X[( !,
M.R@ 2SLO $D\-@!'/#T 1SQ$ $8]2P!%/5, 1#Y< $,^9@!"/W$ 03]^ $ _
MC0 _0)P /D"M 3U P $]0-T!/4#R 3U _P$^/_\!/C__ :Y   ":0   B4$
M 'Q!  !Q00  :$   &$\  !;/0  5CX  %(^!0!./PX 3#\5 $D_'0!'0"4
M1D L $1 ,P!#0#H 0D%" $%!20! 05$ /T): #Y"8P ]0V\ /$-\ #M#BP Z
M1)L .42K 3E$O@$X1-L!.43Q 3E#_@$Y0_\!.4/_ :I"  "60P  AD,  'A#
M  !N0P  94,  %U   !60   44(  $U" @!)0PP 1D,2 $1$&@!"1"( 040J
M #]%,0 ^13@ /44_ #Q&1P [1D\ .D97 #E'80 X1VP -T=Z #9(B0 U2)D
M-$BJ #1(O0 S2-D -$CP #1'_0 T1_\ -4;_ *9$  "210  @D8  '5&  !J
M1@  844  %E$  !11   3$8  $A'  !$1PH 04@0 #])&  ]22  /$DG #I*
M+@ Y2C8 .$H] #=+1  V2TP -4M5 #1,7P S3&H ,DQW #%,A@ P3)< +TVH
M "Y-NP N3=4 +DSO "],_0 O2_\ ,$O_ *%'  ".2   ?D@  '%(  !F20
M74@  %5(  !,20  1TH  $)+   _3 8 .TT. #E.%0 W3AT -D\D #5/*P S
M3S, ,E Z #%00@ P4$H +U%2 "Y17  M46< +%%U "M1A  J4I4 *5*F "E2
MN0 H4M( *5'N "E0_  J4/\ *D__ )Q*  ")2@  >DL  &U+  !C3   6DP
M %%,  !(30  0T\  #U0   Y4@( -5,, #-4$@ Q5!D ,%4A "Y5*  M52\
M+%8W "M6/@ J5D8 *59/ "A760 G5V0 )E=R "57@0 D5Y( (U>D ")7MP B
M5\\ (E?L "-6^@ C5?\ )%7_ )9-  "$3@  =4X  &E.  !?3P  5D\  $U0
M  !%4@  /U,  #E6   S6   +UH( "M;#P J6Q4 *%P= "=<)  F7"L )5PS
M "1=.@ C74, (EU, "%=5@ @7F$ 'UYN !Y>?@ =7H\ '%ZA !M>M  :7<P
M&UWI !M<^0 <6_\ '%O_ )!1  !^40  <%$  &12  !;4@  4E,  $I4  !!
M5P  .UD  #5;   N7@  *& # "1B#  B8Q$ (6,8 !]D(  >9"< '60N !QD
M-@ ;93X &F5' !EE40 895T %V5J !9E>@ 598L %&6> !-EL0 29<@ $F3G
M !-C]P 48O\ %&+_ (E4  !X50  :U4  &!6  !75@  3U<  $99   ]7
M-E\  #!B   I9   (V<  !UJ!P 9; X &&P3 !9M&@ 5;2$ %&TI !1M,  3
M;3D $FY" !%N3  0;E@ #VYE  YN=0 -;H< #6Z:  QMK0 +;<( "VS@  QK
M\P -:_T #6K_ ()9  !R60  9ED  %Q:  !46@  2EP  $%?   Y8P  ,68
M "II   D;   '6\  !=R   2=0D #W</  YW%  .=QL #7<C  QW*@ +=S,
M"G<\  EW1P (=U( !W=?  5W;P $=X   W>4  %VIP  =KL  775  %TZP "
M=/8  G3\ 'M=  !M70  8EX  %E>  !.8   16,  #QG   S:P  *VX  "1R
M   >=0  %WD  !)\   -?P8 "8$,  6!$0 #@18  H$=  &!)   @2T  ((V
M  ""0   @DP  ()9  "":   @GD  (*-  "!H   @+0  (#+  !_YP  ?O(
M '[Y '1B  !H8@  7F(  %-D  !)9P  /VL  #9P   M=   )7@  !Y\   7
M@   $8,   V&   (B00  HL*  "+#@  BQ,  (P8  ",'P  C28  (TO  ".
M.0  CD0  (Y1  ".8   CG$  (Z%  ".F0  C:T  (S#  ",WP  B^X  (OV
M &YH  !D9P  6&D  $UL  !"<0  .'8  "][   F?P  'H0  !:(   0C
M#(\   :2    E0   )8'  "7#   EP\  )@3  "9&   FA\  )LF  ";,
MG#L  )Q(  "<5P  G&@  )Q[  "<D   FZ4  )NZ  ":T   FN<  )KQ &IM
M  !>;P  47(  $9W   [?   ,8(  ">'   >C   %I$  !"5   *F0  !)P
M  "@    H@   *,!  "C!@  I L  *4.  "F$@  IQ<  *@>  "J)@  JS$
M *L^  "L30  K%T  *QP  "LA0  K)L  *NO  "KPP  J]D  *KH &1U  !7
M>0  2WX  #^$   TB@  *9   !^6   6FP  $)\   FC   !IP   *H   "N
M    L    +    "Q    L@,  +0(  "U#0  MA   +<5  "Y'0  NR8  +PS
M  "]00  O5(  +UD  "^>0  OI   +VD  "]MP  O<8  +W7 %Q_  !0A0
M1(L  #B2   LF0  (9\  !>D   0J0  ":X   "R    M@   +D   "]
MOP   +\   #     P0   ,,   #$!0  Q@H  ,<.  #)$P  RQP  ,XF  #0
M-0  T44  -)7  #2:P  TX(  -.7  #3J0  TK@  -+$ %6,  !)DP  /9H
M #"B   EJ   &JX  !&T   )N0   +T   #!    Q    ,@   #+    S0
M ,T   #/    T    -(   #4    V    -H&  #=#   X!$  .,:  #F)P
MYS@  .A*  #I70  ZG(  .N(  #KFP  [*@  .RR /\ #0#_  L _P + /\
M$ #_ !H _P F /\ ,@#_ #T _P!( /L 4@#X %H ]@!B /, :0#Q &\ \ !U
M .X >@#L '\ ZP"$ .D B@#H )  Y@"6 .0 G0#B *4 X0"O -\ NP#= ,L
MVP#F -D ]P#8 /\ V #_ -< _P#7 /\ U #_ /\ " #_  0 _P $ /\ #0#_
M !4 _@ A /H + #W #@ ] !# /  30#M %4 Z@!= .< 9 #D &H X@!P .
M=0#> 'H W0!_ -L A0#9 (L U0"1 -, F0#1 *  SP"J ,T M0#+ ,0 R0#=
M ,@ \0#' /\ Q@#_ ,8 _P#& /\ QP#_ /\   #_    _P   /\ "@#X !$
M\0 < .P )P#I #( Y@ ] .( 1P#= %  V0!8 -4 7P#2 &4 T !J ,X < #,
M '4 R@!Z ,D ?P#' (4 Q0", ,, E #! )P OP"E +T L "[ +T N@#0 +@
MZP"W /L M@#_ +8 _P"V /\ M@#_ /\   #_    _0   /, !0#I  X X0 6
M -L (0#5 "T T0 W ,X 00#* $H QP!2 ,0 60#" %\ P !E +X :@"\ &\
MNP!T +D >@"W (  M@"' +0 C@"R )< L "@ *X J@"M +< JP#( *D XP"H
M /4 IP#_ *< _P"G /\ I@#_ /\   #^    \0   .4   #7  H S0 1 ,<
M' #" "8 OP Q +P .P"Z $0 MP!, +0 4P"R %D L0!? *\ 9 "M &D K !O
M *H = "I 'H IP"! *8 B0"D )$ H@"; *  I0"> +( G0#! )L V@": .\
MF0#] )@ _P"8 /\ F #_ /T   #P    X0   -$   #&  0 O0 - +< %0"S
M "  L  K *T -0"K #X J !& *8 30"D %0 HP!9 *$ 7P"@ &0 G@!I )T
M;@"; '4 F@![ )@ @P"6 (P E0"6 ), H0"1 *T CP"[ (T SP", .D BP#X
M (P _P", /\ C #_ /,"  #B!P  S <  +\$  "W    L0 ( *L $ "G !D
MI  D *  +@"> #< G !  )H 1P"8 $X E@!4 )4 60"3 %X D@!D )  :0"/
M &\ C0!V (L ?@"* (@ B "2 (8 G0"% *D @P"X ($ R@"  .4 @ #U '\
M_P!_ /\ ?P#_ .@-  #0$   OA   +$.  "H#0  HP@  * "# "< !, F  =
M )4 )P"2 #$ D  Y (X!00", 4@ B@). (D"5 "' ED A@)? (0#9 "# VL
M@0-R ( $>@!^!(0 ?06. 'L%F@!Y!J< > :U '8'R !U"., =0GT '0*_P!S
M"O\ <PK_ -T5  #$%P  L1<  *46  "<$P  EA$  )0-! "3" T C@<5 (L)
M( "("2H A0HS (,+.P"!"T( @ M) 'X+3P!]#%0 >PQ: 'H,8 !X#&< =PQN
M '4-=@!T#8  <@V, ' -F0!O#J8 ;0ZU &P.R0!K#^8 :A#W &D0_P!I$/\
M:1#_ - =  "Y'@  J!X  )L=  "2&P  BQD  (@5  "'$0< A0X0 ($/&@!^
M$"0 >Q M 'D0-@!W$3T =A%$ '012@!S$5  <1%6 ' 17 !N$F( ;1)J &L2
M<P!I$WT :!.) &83E@!E%*, 8Q6S &(5Q@!B%N, 81;V & 7_P!@%_\ 8!?_
M ,<B  "P(P  GR0  )(C  ")(@  @B   'X=  !\&0  >A4- '<5%0!T%A\
M<18H &\7, !N%S@ ;!<_ &L710!I&$L :!A1 &886 !E&%X 8QEF &(9;P!@
M&7D 7QJ% %T;D@!<&Z$ 6QRP %H<PP!9'>  6![T %@>_P!8'O\ 6![_ +\G
M  "I*   F2@  (LH  "")P  >R4  '8C  !S(   <1P) &X<$0!K'!H :1TC
M &<=+ !E'3, 8QXZ &(>00!@'D< 7QY- %X>5 !<'UL 6Q]B %D@:P!8('8
M5B&" %4AD !4(IX 4R*N %(CP !1(]T 423R %$D_P!1)/\ 42/_ +DK  "C
M+   DRP  (8M  !\+   ="H  &\H  !K)0  :2(% &8A#@!C(A8 82(? %\C
M)P!=(R\ 7",V %HC/0!9)$, 5R1* %8D4 !5)%< 4R5? %(E: !1)G, 3R9_
M $XGC0!-*)P 3"BL $LIO@!+*=H 2BGQ $HI_P!+*?\ 2RG_ +,N  ">+P
MCC   ($P  !W+P  ;RX  &HK  !E*@  8R<! %\G# !<)Q, 6B<; %@H) !6
M*"L 52@R %,H.0!2*4  4"E& $\I30!.*50 32I< $PJ90!**W  22M\ $@L
MBP!'+9H 1BVJ $4NO !%+M8 12[O $4N_@!%+O\ 12W_ *XQ  ":,@  B3,
M 'PS  !R,P  :S$  &4O  !@+0  72P  %DL"0!6+!  5"P8 %(L( !0+"@
M3BTO $TM-@!,+3P 2BU# $DM2@!(+E$ 1RY9 $8O8P!%,&T 0S!Z $(QB0!!
M,9@ 03*H $ RNP _,M, /S+N $ R_0! ,O\ 0#+_ *HS  "6-0  AC4  'DV
M  !N-0  9C4  &$R  !<,   5S   %0P!@!1, X 3C 5 $PQ'0!*,24 2#$L
M $<Q,@!&,3D 1#%  $,R1P!",D\ 03-7 $ S8  _-&L /C5X #TUAP \-I8
M.S:G #LVN0 Z-M$ .C;M #LV_  [-O\ .S;_ *8V  "2-P  @C@  '4X  !K
M.   8S<  %TV  !7,P  4S0  $\T P!+- P 2302 $8U&@!%-2( 0S4I $$U
M+P! -38 /S8] #XV1  ]-TP /#=5 #LX7@ Z.&D .3EV #@YA0 W.I4 -SJE
M #8ZN  U.L\ -CKL #8Z^P V.?\ -SG_ *(X  "..0  ?CH  '([  !H.P
M7SH  %DY  !3-@  3C<  $HX  !&. H 1#D0 $$Y%P _.1\ /CDF #PY+0 [
M.C0 .CH[ #D[0@ X.TH -SM3 #8\7  U/&< -#UT #,]@P S/I, ,CZD #$^
MM@ Q/LT ,3[J #$^^@ R/?\ ,CW_ )X[  "+/   >SP  &X]  !D/0  7#T
M %4\  !..@  23L  $4\  !!/0< /CT. #P]%0 Z/AP .3XC #<^*@ V/S$
M-3\X #0_0  S0$@ ,D!0 #% 6@ P064 +T%R "Y"@0 M0I$ +4*B "Q"M0 K
M0LL +$+I "Q"^0 M0?\ +4'_ )D]  "'/@  =S\  &L_  !A0   63\  %(_
M  !)/@  1#\  $!    \000 .4(- #="$@ U0QD ,T,A #)#*  Q1"\ ,$0V
M "]$/0 N144 +45. "Q%6  K1F, *D9O "E&?@ H1H\ )T>A "9'LP F1\D
M)D;G "=&^  H1?\ *$7_ )5   ""00  <T(  &="  !>0@  54(  $Y"  !%
M0@  /T0  #M%   W1@  -$<* #%($  O2!8 +DD> "Q))0 K22P *DDS "E*
M.@ H2D( )TI+ "9+50 E2V  )$MM "-+?  B2XT (4R? "%,L0 @3,< ($OF
M "%+]P B2O\ (DK_ )!#  !^1   ;T0  &1%  !:10  4D4  $I&  !!1P
M/$@  #=)   R2P  +DT' "M.#@ I3A, )T\: "9/(0 E3R@ )$\P "-0-P B
M4#\ (5!( "!04@ ?45T 'E%J !U1>0 <48H &U&< !I1KP 94<4 &5'D !I0
M]@ ;3_\ '$__ (I&  !Y1P  :T<  &!(  !62   3D@  $=)   ^2P  .4P
M #-.   N4   *%," "14"P B51  (%46 !]6'@ >5B0 '58L !Q6,P ;5SL
M&E=$ !E73@ 85UD %UAF !58=0 46(< %%B: !-7K  25\( $E?A !-6]  4
M5?\ %%7_ (1)  !T2@  9DL  %Q+  !32P  2TP  $1-   \3P  -5$  "]4
M   I5@  )%D  !Y;!P :70T &%T2 !==&0 67B  %5XG !1>+@ 37C< $EY
M !%?2@ 17U4 $%]B  ]?<0 .7X, #5^6  U?J0 ,7KX #%[:  U=\  -7/P
M#ES_ 'Y-  !N3@  8DX  %A/  !/3P  2%   $!2   X5   ,%<  "I:   D
M70  'U\  !EB 0 390D $68/ !!F%  /9AL #F<B  UG*0 -9S( #&<[  MG
M10 *9U  "6==  =G;  &9WT !6>0  1FHP "9K<  V7/  1EZ0 $9/4 !&3\
M '=1  !I4@  75(  %12  !,4P  0U4  #M8   S6P  *UX  "5A   ?9
M&6<  !-J   /;08 "W ,  AP$0 '<!8 !7 =  1P)  #<"P  G U  !P/P
M<$H  '!7  !P90  <'8  '"*  !OG@  ;[(  &[(  !MY0  ;?(  &WY '!6
M  !C5@  658  /_B__])0T-?4%)/1DE,10 $"5%7  !'6   /EL  #9?   N
M8@  )F8  !]J   9;0  $W    YS   +=@0 !7@+  %X#P  >1,  'D9  !Y
M'P  >B8  'HO  !Z.0  >D0  'I0  !Z7P  >G   'J#  !ZF   >JP  'G"
M  !XWP  >.\  '?W &I;  !?6P  5EL  $Q<  !"8   .6,  #!H   H;
M('   !ET   3=P  #GL   E^   $@0(  (((  "##0  @Q   (04  "%&0
MAB   (8H  "',0  ASP  (=)  "'5P  AV@  (=[  "'D   AJ4  (6Z  "%
MTP  A.H  (3T &5@  !<8   46$  $9D   \:0  ,FT  "ER   A=P  &7L
M !*    -@P  "(<   **    C0   (X$  "."0  CPT  ) 0  "1%   DAD
M ),@  "4*0  E3,  )5   "63@  EE\  )5R  "5B   E9T  )2R  "4R
MD^(  )/N &%E  !69@  2FH  #]N   U=   *WD  "%_   9A   $8D   R-
M   &D0   )0   "8    F@   )L   "< @  G0<  )X+  "?#@  H1(  *(8
M  "C(   I2D  *8V  "F1   IE4  *9H  "F?0  II0  *6I  "DO0  I-$
M *3D %ML  !/<   0W4  #A[   M@0  (X<  !F-   1D@  "Y<   2<
MH    *,   "F    J    *D   "J    K    *T$  "N"0  L T  +$1  "S
M%P  M2   +8K  "W.@  MTL  +A<  "X<0  N(@  +B=  "XL0  M\(  +?0
M %1V  !(?   /((  #&)   FD   &Y<  !*=   ,H@   Z<   "K    K@
M +(   "V    N    +@   "Z    NP   +T   "^    P 4  ,$+  ##$
MQA8  ,D@  #*+@  RSX  ,Q0  #,9   S7H  ,V1  #-I   S;0  ,W  $V#
M  !!B@  -9$  "F9   >H   $Z8   RL   #L0   +8   "Z    O@   ,(
M  #&    R    ,@   #*    RP   ,T   #.    T    -(!  #5"   V0X
M -T5  #A(0  XC$  .1#  #E5@  YFL  .:"  #GE@  YZ4  .:P /\ "0#_
M  4 _P & /\ #@#_ !8 _P A /\ +0#_ #@ _0!# /D 30#U %4 \@!= /
M8P#N &D [ !O .H = #I 'H YP!_ .8 A0#D (L XP"1 .$ F0#? *$ W "J
M -H M@#7 ,8 U0#A -, ] #2 /\ T0#_ -$ _P#/ /\ R@#_ /\  0#_
M_P ! /\ # #_ !( ^@ = /8 * #S #, \  ^ .P 2 #H %  Y0!8 .( 7@#?
M &0 W0!J -L ;P#9 '0 U@!Z -0 ?P#2 (4 T ", ,X DP#, )P R0"E ,<
ML #& +X Q #4 ,( [@#! /X P #_ ,  _P"_ /\ O@#_ /\   #_    _P
M /H !P#Q  \ ZP 8 .8 (P#B "X X  X -L 0@#5 $L T0!2 ,X 60#+ %\
MR0!E ,< :@#& &\ Q !T ,( >@#! (  OP"& +T C@"[ )8 N0"@ +< J@"V
M +< M #* +( Y@"Q /@ L #_ *\ _P"O /\ L #_ /\   #_    ]P   .H
M @#A  P UP 3 -  '0#, "@ R0 R ,8 / #" $4 OP!- +P 4P"Z %D N !?
M +< 9 "U &D M !N +( = "Q 'H KP"  *T B "L )$ J@": *@ I0"F +$
MI #! *, W "A /( H0#_ *  _P"@ /\ H0#_ /\   #W    Z    -D   #+
M  @ PP 0 +T & "Y "( M@ L +0 -@"R #\ KP!' *P 30"K %0 J0!9 *<
M7@"F &, I0!H *, ;@"B '0 H !Z )X @@"< (L FP"5 )D GP"8 *P E@"Z
M )0 SP"3 .L D@#[ )( _P"2 /\ D0#_ /<   #G    TP   ,8   "[  (
MLP , *T $@"J !P IP F *0 , "C #@ H !  )X 1P"< $X F@!3 )D 6 "7
M %T E@!C )4 : "3 &X D@!T )  ? "/ (4 C0"/ (L F@"* *< B "U (8
MQP"% .0 A #U (0 _P"# /\ @P#_ .P   #3    P0$  +0   "L    I@ '
M *  #@"= !8 F@ @ )< *0"5 #( DP Z )$ 00"/ $@ C0!- (P 4P"+ %@
MB0!= (@ 8P"' &D A0!O (, =P"" (  @ "* 'X E@!] *, >P"P 'H P@!Y
M -T > #Q '< _0!X /\ > #_ -X*  #$"P  L@P  *8+  "="   F00  )4
M"@"1 !$ C@ 9 (L (P") "P AP T (4 .P"# $( @@!( (  3@!_ %, ?0!8
M 'P 7@![ &0 >0!J '@ <@!V 'L = "& ', D@!Q )\ < "M &X O@!M =8
M;0+M &P#^@!L _\ ; /_ ,X0  "W$0  IA(  )H1  "1$   BPX  (D+ P"'
M!0P A $3 ($!' !^ B4 ? ,N 'H#-@!X!#P =P1# '4%2 !T!4X <P54 '$%
M60!P!E\ ;@9F &T&;@!K!W@ :@># &@(D !G"9T 90FL &0)O !C"M0 8POL
M &(,^@!B#/\ 8@S_ ,,6  "M%P  G1@  ) 8  "'%@  @10  'T1  !\#@8
M? H. '@*%@!U"Q\ <@LH ' ,, !O##< ;0P^ &P,1 !K#4H :0U/ &@-50!G
M#5P 90UC &,.:P!B#G4 8 Z! %\.C@!=#YP 7!"K %L0O0!:$-8 61'P %D1
M_0!9$?\ 61'_ +D;  "E'0  E!X  (@>  !^'0  >!L  '08  !Q%0  <1$)
M &\0$0!L$!D :1 B &<1*@!F$3( 9!$Y &,1/P!B$44 8!)+ %\240!=$E@
M7!)? %H3: !9$W( 5Q1] %84BP!4%9D 4Q6I %(6N@!1%M( 41?M %$7_0!1
M%_\ 41?_ +(@  ">(@  CB(  ($C  !W(@  <"$  &P>  !I&P  9Q@$ &85
M#@!C%A4 818> %\6)@!=%BT 7!<T %H7.P!9%T$ 6!A' %8830!5&%0 4QA<
M %(99 !1&6X 3QIZ $X;B !-&Y< 2QRF $H<N !*'<\ 21WK $D=^P!)'?\
M2AW_ *PD  "8)0  B"8  'LG  !Q)@  :B4  &8C  !B(0  8!X  %X<"P!;
M&Q( 61P: %<<(@!5'"D 5!PP %,=-P!1'3T 4!U# $\=2@!-'E$ 3!Y8 $L?
M80!)'VL 2"!W $<@A0!&(90 1"*D $0BM@!#(LP 0R/I $,C^@!#(_\ 0R+_
M *8G  "3*0  @RH  '8J  !M*@  92D  & G  !<)0  62,  %<A!P!5(0\
M4B$6 % A'@!.(24 32(L $PB,P!*(CD 22)  $@B1@!'(TT 12-5 $0D7@!#
M)&D 0B5U $ F@P _)I( /B>C #XGM  ])\H /2CH #TH^0 ])_\ /B?_ *(J
M  ".*P  ?RT  '(M  !H+0  82P  %PK  !8*   5"8  %$F! !.)0T 3"43
M $HF&@!()B( 1R8I $4F+P!$)C8 0R<\ $$G0P! )TL /RA3 #XI7  ]*68
M/"IR #LJ@0 Z*Y  .2NA #@LL@ W+,@ -RSF #@L^  X+/\ ."S_ )TL  "*
M+@  >R\  &\P  !E,   72\  %@N  !3*P  4"H  $PJ  !)*@L 1BH1 $0J
M%P!"*A\ 02HE #\J+  ^*S, /2LY #PK0  [+$@ .BQ0 #DM60 X+F0 -RYP
M #8O?P U+X\ -#"? #,PL0 R,,< ,C#E #,P]P S,/\ -"__ )DO  "',0
M=S(  &LR  !B,@  6C(  %0Q  !/+P  2RT  $<N  !$+@@ 02X. #\N%  ]
M+AP .RXB #DO*0 X+R\ -R\V #8P/@ U,$8 -3%. #0Q5P S,F( ,C)N #$S
M?0 P,XT +S2> "XTL  M-,4 +33C "XT]@ O,_\ +S/_ )4Q  "#,P  =#0
M &@U  !>-0  5S0  %$T  !+,@  1C$  $(R   _,@4 /#(- #DS$@ X,QD
M-C,@ #0S)@ S,RT ,C0T #$T.P P-4, ,#5, "\V50 N-F  +3=L "PW>P K
M-XL *CB< "DXK@ H.,, *#CB "DX]0 J-_\ *C?_ )(T  !_-0  <38  &4W
M  !;-P  5#<  $TV  !'-@  0C4  #TV   Z-@( -S<+ #0W$  R-Q8 ,3@=
M "\X)  N."L +3DR "PY.0 K.4$ *CI) "HZ4P I.UX *#MJ "<[>0 F/(D
M)3R; "0\K0 C/,( (SS@ "0\]  E._\ )3O_ (TV  !\.   ;3D  &(Y  !8
M.@  43D  $HY  !$.0  /3D  #DZ   U.P  ,CL( "\\#@ M/10 +#T: "H]
M(0 I/2@ *#XO "<^-@ F/CX )3]' "0_4  C0%L (D!H "% =@ @0(< 'T&9
M !]!JP >0<  'D'> !] \P ?0/X (#__ (DY  !X.@  :3L  %X\  !5/
M33P  $<\  ! /   .#T  #0^   P0   +4$% "I"#  G0A$ )D,8 "1#'@ C
M0R4 (D,L "%$,P @1#L 'T1$ !Y%3@ =15D '$5E !M%=  :184 &4:7 !E&
MJ0 81KX %T7< !A%\0 91/T &D3_ (0\  !S/0  9CX  %L_  !2/P  2C\
M $0_   ]0   -D$  #%#   L1   )T8! "1'"@ A2 \ ($D4 !Y)&P =22(
M'$DI !M*,  :2C@ &4I! !A*2P 72U4 %DMB !5+<0 42X( $TN4 !)+IP 2
M2[P $4O9 !)*\  32OP %$G_ '\_  !O0   84$  %="  !.0@  1T(  $%"
M   Z0P  ,D4  "U'   H20  (TL  !Y-!@ ;3PT &% 1 !=0%P 64!X %5 E
M !10+  3430 $E$] !%11P 145( $%%?  ]2;0 .4GX #5&1  U1I  ,4;@
M#%'1  U0[  -4/H #D__ 'E#  !J1   740  %-%  !+10  1$4  #Y&   V
M2   +TH  "E,   D3P  'U$  !I3   45@D $5<. !!8$P 06!D #U@@  Y8
M*  -6#  #5@Y  Q80P +6$X "EA:  A8:  '6'D !EB,  58GP $6+, !%?*
M  57Y@ %5_, !E;\ '-&  !D1P  64@  %!(  !(2   04D  #I*   R30
M*U   "52   @50  &E@  !5:   0708 #& ,  I@$  )8!4 "& <  =@(P %
M8"L !& T  -@/0 !8$D  &!5  !@8P  8',  &"&  !?F@  7ZX  %_$  !>
MX@  7O   %[X &Q*  !?2P  54L  $Q,  !%3   /4X  #50   N4P  )U8
M "!9   :7   %5\  !!B   -900 "&<+  -G#@  :!,  &@8  !H'P  :28
M &DN  !I.   :4,  &E/  !I70  :6T  &F   !IE   :*D  &B_  !GW
M9NX  &;W &9/  !:3P  44\  $I/  !!40  .%0  #!7   H6P  (5X  !IB
M   490  $&@   QK   ';@,  7 )  !P#0  <1   '$4  !R&@  <R$  ',H
M  !S,0  <SP  '1(  !S5@  <V8  '-Y  !SC@  <Z,  '*Y  !QT@  <>L
M '#T &%3  !64P  3U,  $55   [6   ,EP  "I@   B9   &V@  !1L   /
M;P  "W(   9V    >0   'H&  !Z"@  >PX  'P1  !]%0  ?AL  '\B  "
M*@  @#4  (!!  " 3P  @%\  (!Q  " A@  @)T  '^R  !^R@  ?N4  'WQ
M %Q8  !46   25H  #]=   U80  +&4  "-J   ;;P  %',   YW   )>P
M W\   ""    A    (8!  "&!@  B H  (D-  "*$   BQ4  (P;  ".(@
MCRP  (\X  "/1@  CU8  (]H  "/?@  CY4  (ZK  "-P0  C=P  (SK %E=
M  !.7P  0V(  #AF   N;   )'$  !QW   4?   #H$   B%    B0   (T
M  "0    D@   ),   "4    E@,  )<(  "8#   F@\  )L3  "=&@  GR,
M * N  "@/   H$P  *!>  "@=   GXP  )^B  "?MP  GLL  )[@ %-D  !'
M:   /&T  #%S   G>0  '7\  !2%   -BP  !I    "4    F    )P   "?
M    H0   *(   "D    I0   *<   "H!   J@D  *P-  "M$@  L!D  +(C
M  "R,0  LD(  +)4  "R:0  LH   +*8  "QK   LK\  +'. $QN  ! <P
M-7H  "J!   ?B   %8X   Z5   &F@   )\   "D    J    *P   "O
ML0   +$   "S    M0   +8   "X    N@   +P&  "^#   P!$  ,,9  #%
M)@  Q3<  ,9)  #&70  QW(  ,>*  #(GP  R*\  ,B\ $9Z   Y@0  +HD
M "*0   7F   #Y\   >E    J@   *\   "S    MP   +P   "_    P0
M ,(   #$    Q0   ,<   #)    RP   ,T   #/ P  T@H  -80  #<&@
MW2H  -X\  #?4   X&4  .%[  #AD0  XJ(  .*M /\  @#_    _P # /\
M# #_ !, _P = /\ * #^ #, ^P ^ /< 2 #S %  \ !7 .T 7@#K &0 Z !I
M .< ;P#E '0 XP!Y .( ?P#@ (4 W@", -P DP#9 )P U@"F -, L0#1 ,
MSP#: ,X \0#, /\ RP#_ ,L _P#& /\ P0#_ /\   #_    _P   /\ " #[
M !  ]@ 9 /( ) #O "X [0 Y .@ 0@#C $L X !2 -T 60#9 %\ U@!D -,
M:0#1 &X SP!T ,X >0#, '\ R@"& ,@ C@#& )8 Q "@ ,( JP#  +D O@#-
M +P Z@"[ /P N@#_ +H _P"Z /\ M@#_ /\   #_    _@   /0 ! #K  T
MY  4 -\ 'P#; "D V  S -, /0#. $4 R@!- ,< 4P#% %D PP!? ,$ 9 "_
M &D O0!N +L <P"Z 'D N "  +8 B "T )  L@": +$ I0"O +( K0#$ *P
MX0"K /8 J@#_ *H _P"J /\ J@#_ /\   #]    [@   .(   #5  H S0 1
M ,< &0#$ ", P0 M +\ -P"[ #\ MP!' +4 3@"R %, L !9 *\ 7@"M &,
MK !H *L ;0"I ', J !Z *8 @0"D (H HP"4 *$ GP"? *P G@"[ )P T@";
M .X F@#_ )H _P"9 /\ F0#_ /X   #N    W@   ,L   #!  4 N0 - +0
M% "Q !X K@ G *L , "J #D IP!! *0 2 "B $T H0!3 )\ 6 "> %T G0!B
M )L 9P": &T F !S )< >P"5 (0 E ". )( F0"0 *8 C@"T (T R ", .8
MBP#Y (H _P"* /\ BP#_ /    #;    QP   +H   "P    J  * *0 $ "@
M !@ G0 A )L *@": #, F  [ )8 00"4 $@ D@!- )$ 4@"/ %< C@!< (P
M80"+ &< B@!N (@ =0"' 'X A0"( (, E "" *  @ "O '\ P !^ -T ?0#R
M 'T _P!] /\ ?0#_ .    #&    M0   *H   "B    FP % )4 #0"2 !,
MD  < (T ) "+ "T B@ T (@ .P"& $( A0!' (, 30"" %( @0!7 '\ 7 !^
M &( ?0!H 'L < !Z 'D > "# '8 CP!U )P = "J '( N@!Q -$ < #L '
M^P!P /\ < #_ ,T$  "W!@  IP<  )L&  "3!   C@   (H " "&  \ A  6
M ($ '@!_ "< ?0 N 'P -@!Z #P >0!" '< 1P!V $P =0!2 ', 5P!R %T
M<0!C &\ :P!N '0 ; !^ &L B@!I )@ : "F &< M@!F ,L 90#G &4 ]P!E
M /\ 90#_ , ,  "K#0  FPX  (\.  "&#0  @0L  'X' 0!\ 0L >0 1 '<
M& !U "$ <P I '$ , !O #8 ;@ \ &P 0@!K $< :@!- &D 4@!H %@ 9@!?
M &4 9P!C '  8@%Z & !AP!? I4 7@*C %P#LP!< \< 6P3D %L%] !;!OX
M6P;_ +40  "A$@  D1,  (43  !\$@  =A$  ',.  !R# 0 <0<- &X$$@!L
M!!L :04C &<%*@!F!C$ 9 8W &,&/0!B!T, 80=) %\'3@!>"%4 70A< %L)
M8P!:"6T 6 IX %<*A0!6"Y, 5 NB %,+LP!2#,< 4@SD %$-]0!1#?\ 40W_
M *T5  "9%P  B1@  'T9  !T&   ;1<  &H4  !G$0  9PX' &8,#@!C#!4
M80P= %\,)0!=#2P 7 TS %L-.0!:#3\ 6 U% %<-2P!6#E$ 50Y9 %,.80!2
M#FL 4 ]V $X0@P!-$)( 3!"B $L0L@!*$<@ 21'E $D1]P!)$O\ 21'_ *49
M  "2'   @QT  '8>  !M'0  9AP  &(:  !?%P  7A0! %X1"@!;$!$ 61$8
M %<1( !5$2< 5!$N %,1- !1$3L 4!)! $\21P!.$DX 3!)5 $L37@!)$V<
M2!1S $84@ !%%8\ 1!6? $,6L !"%L4 0A?C $(7]@!"%_\ 0A?_ )\=  ",
M(   ?2$  '$B  !H(@  82$  %P?  !9'   5QD  %46!@!4%0X 4144 $\6
M' !.%B, 3!8J $L6, !*%C< 21<] $<70P!&%TH 11A2 $,86@!"&60 01EP
M #\:?0 ^&XT /1N= #P<K@ [',, .QSA #L=]0 ['/\ /!S_ )HA  "'(P
M>"0  &PE  !C)0  7"0  %<C  !3(   41X  $\< @!-&PP 2QH1 $@;& !'
M&R  11LF $0;+0!#'#, 0APY $ <0  _'4< /AU/ #T>6  \'F( .A]M #D?
M>P X((L -R&; #8AK0 U(<$ -2'? #4A\P V(?\ -B'_ )8C  "#)@  ="<
M &@H  !?*   6"<  %,F  !/)   3"(  $D@  !'( D 1!\/ $(?%0! (!P
M/R C #X@*0 \("\ .R$V #HA/0 Y(40 ."), #<B50 V(U\ -"-K #,D>0 R
M)8D ,26: # EJP P)K\ +R;< # F\@ P)O\ ,27_ )$F  !_*   <2H  &4J
M  !<*@  52H  $\I  !+*   2"4  $0D  !!) 4 /R0- #TD$@ [)!D .20?
M #<D)@ V)"P -24S #0E.@ S)D$ ,B9* #$G4P P)UT +RAI "XI=P M*8<
M+"F8 "LJJ@ J*KT *BK: "LJ\0 K*OX +"G_ (TH  !\*@  ;2P  &(M  !9
M+0  42T  $PL  !'*P  0R@  #\H   \* ( .2@+ #<H$  U*!8 ,R@< #(H
M(P P*"D +RDP "\J-P N*C\ +2M' "PK40 K+%L *BQG "DM=0 H+84 )RV7
M "8NJ  E+KP )2[8 "8N\  F+OT )RW_ (HK  !X+0  :BX  %\O  !6+P
M3B\  $@N  !#+0  /RP  #LL   W+   -"P) #(L#@ P+1, +BT: "TM(  K
M+2< *BXM "HN-0 I+ST *"]% "<P3@ F,%D )3%E "0Q<P C,8, (C*5 "$R
MIP A,KL (#+4 "$R[P B,?P (C'_ (8M  !U+P  9S   %PQ  !3,0  2S$
M $4Q  ! ,   .S   #8P   S,   ,#$& "TQ#0 K,1$ *3(7 "@R'@ G,B0
M)3,K "4S,@ D,SH (S1# "(T3  A-5< (#5C !\U<0 >-H$ '3:3 !PVI0 ;
M-KD &S;2 !PV[0 =-OL '37_ ((P  !Q,@  8S,  %DT  !0-   230  $(S
M   ],P  -S,  #$T   N-0  *S4" "@V"P E-Q  )#<5 "(W&P A."( (#@H
M !\X,  >.#< '3E  !PY20 ;.E0 &CI@ !DZ;@ 8.G\ %SN1 !<[I  6.[<
M%3O0 !8Z[  7.OH &#G_ 'TR  !M-   8#4  %4V  !--@  1C8  $ V   Z
M-@  -#8  "XX   J.0  )CH  ",["  @/ X 'CT2 !T]&  </1\ &SXE !H^
M+0 9/C0 %SX] !8_1P 5/U$ %#]> !0_;  30'P $D"/ !% H@ 10+8 $$#.
M !$_ZP 2/_D $C[_ 'DU  !I-P  7#@  %(Y  !*.0  0SD  #TY   W.0
M,3H  "L\   G/0  (C\  !Y!!  :0@L &$,0 !=#%0 51!L %$0B !-$*0 3
M1#$ $D0Z !%%0P 014X $$5;  Y%:0 .17D #46,  U%GP ,1;( "T7)  Q%
MY0 -1/8 #43_ '0Y  !E.@  6#L  $\[  !'/   0#P  #H\   T/   +CX
M "A    C0@  'T0  !I&   52 @ $DH- !%*$@ 02A@ #TL>  Y+)0 -2RT
M#4LV  Q+0  +2TH "DM6  E+9  (2W0 !TN'  5+F@ $2ZX !$K$  5*X  %
M2O  !DGZ &X\  !@/0  5#X  $L^  !$/@  /3X  #<_   Q0   *D(  "1%
M   ?1P  &DD  !5,   13@4 #E$+  M1$  *410 "5$;  A1(@ '42D !5$R
M  12.P #4D8  5)2  !27P  4F\  %*!  !1E@  4:D  %&_  !0W   4.X
M %#W &A   !;00  4$$  $A!  !!00  .T(  #1#   M10  )D@  "!+   ;
M30  %E   !%3   .500 "E@*  98#@ "6!(  %D7  !9'0  624  %DM  !9
M-@  64$  %E-  !:6@  6FD  %E\  !9D   6:4  %BZ  !8U0  5^P  %?V
M &-$  !610  344  $5%   _10  -T<  "])   H3   (D\  !M2   650
M$5@   U:   )70, !%\)  !@#0  8!   &$4  !A&0  8B   &(G  !B,0
M8CL  &)'  !B50  8V0  &)V  !BBP  8J   &&V  !ASP  8.H  &#U %U(
M  !220  2D@  $-(   Z2@  ,DT  "I0   C4P  '%<  !9:   170  #6
M  AC   #9@$  &<&  !H"P  :0X  &H1  !K%0  ;!L  &TB  !M*@  ;30
M &U   !M3@  ;5T  &UO  !MA   ;)H  &RP  !KR   :^8  &KS %A-  !.
M30  2$P  #Y.   U40  +%0  "18   =7   %F   !!D   ,9P  !VL   %N
M    <    '(#  !R!P  <PL  '4.  !V$0  =Q8  '@<  !Y(P  >BT  'HY
M  !Z1P  >E8  'EH  !Z?   >90  'BJ  !XP0  =]\  '?O %11  !,40
M0E(  #A5   O60  )EX  !YB   69P  $&L   MO   %<P   '<   !Z
M?    'X   !_ @  @ 8  ($*  "##0  A!$  (85  "('   B24  (HP  "*
M/@  B4T  (E?  ")<P  B(L  (BB  "'N0  A]$  (;H %)6  !'5P  /%H
M #)?   H9   'VD  !9O   0=   "GD   )]    @0   (4   "(    B@
M (P   "-    CP   ) $  "2"   DPP  )40  "7%0  F1T  )LG  ";-
MFT0  )I6  "::@  F8(  )J:  "8L   F,<  )?> $M<  ! 8   -64  "MJ
M   A<0  %W<  !!]   )@P   8@   ",    D0   )4   "8    F@   )L
M  "=    GP   *    "B    I 4  *8*  "H#@  JA0  *T=  "M*@  K3D
M *U+  "M7P  K7<  *R0  "KIP  J[H  *O+ $5F   Y:P  +G$  "-X   9
M?P  $(8   F-    DP   )@   "=    H0   *4   "H    JP   *L   "N
M    KP   +$   "S    M0   +<!  "Y!P  O T  +\3  #"'P  PBX  ,)
M  #"5   P6L  ,&#  # FP  P:T  ,&\ #YR   R>   )X   !R(   2D
M"I<   "=    HP   *@   "M    L@   +8   "Y    NP   +P   "^
MP    ,(   #$    Q@   ,@   #+    S@4  -$-  #6%   UR,  -@U  #9
M20  VEX  -MU  #;C   W)\  -RK /\   #_    _P   /\ "0#_ !  _P 9
M /X ) #\ "\ ^0 Y /0 0P#P $L [0!2 .H 60#G %\ Y !D .( :0#@ &X
MW@!S -P >0#: '\ UP"& -0 C@#1 )8 SP"A ,P K #* +L R #2 ,8 [@#&
M /\ Q0#_ ,4 _P"_ /\ N@#_ /\   #_    _P   /X !0#W  X \@ 5 .X
M'P#K "H Z0 T ., /0#> $4 V0!- -0 4P#1 %D S@!> ,P 8P#* &@ R0!M
M ,< <P#% 'D PP"  ,$ B "_ )  O0"; +L I@"Y +0 MP#( +8 Y@"U /L
MM #_ +0 _P"S /\ K@#_ /\   #_    ^    .T   #E  L W0 1 -< &@#2
M "0 SP N ,L -P#' $  PP!' ,  3@"^ %, O !9 +H 7@"X &, M@!H +4
M;0"S ', L0!Y *\ @0"M (H JP"4 *D H "H *T I@"^ *4 VP"D /0 I #_
M *, _P"C /\ H@#_ /\   #V    Y@   -<   #+  8 Q  . +X %0"[ !\
MN0 H +< ,0"T #H L !! *T 2 "K $X J0!3 *< 6 "F %P I !A *, 9P"A
M &P H !S )X >@"= (, FP". )D F0"7 *8 E@"V )4 S "4 .L DP#] ),
M_P"3 /\ DP#_ /<   #D    T    ,$   "W  ( KP + *L $0"G !D I0 B
M *, *P"B #, GP [ )P 0@"; $@ F0!- )< 4@"6 %< E0!; ), 80"2 &8
MD !M (\ = "- 'T C "' (H DP"( *  AP"O (4 P@"% .( A #W (0 _P"$
M /\ A #_ .4   #-    O    *\   "F    G@ ' )H #@"6 !0 E  = )(
M)0"1 "T D  U (T / ", $( B@!' (@ 3 "' %$ A@!6 (0 6P"# &  @0!G
M (  ;@!^ '< ?0"! 'L C0!Z )H > "I '< N@!V -, =@#O '8 _@!U /\
M=0#_ -    "[    JP   )\   "7    D  " (L "P"( !  A@ 7 (0 ( ""
M "< @0 O '\ -0!] #P ? !! 'L 1@!Y $L > !0 '< 50!V %L = !A ',
M:0!Q '$ < ![ &X AP!M )4 :P"C &H M !J ,D :0#H &D ^0!I /\ :0#_
M ,    "L    G (  ) "  "(    @P   '\ !@![  T >0 2 '< &@!V "(
M=  I ', , !Q #8 <  \ &\ 00!M $8 ; !+ &L 4 !J %8 : !< &< 9 !E
M &P 9 !V &, @@!A )  8 "? %\ KP!> ,, 7@#A %X ] != /\ 70#_ +0'
M  "@"0  D L  (0+  !\"@  =P<  '0$  !Q  D ;P / &T %0!K !P :0 C
M &@ *@!G #$ 90 V &0 / !C $$ 8@!& &  3 !? %( 7@!8 %T 7P!; &@
M6@!R %@ ?@!7 (P 5@"; %4 JP!4 +X 5 #: %, [P!4 /L 5 #_ *D-  "6
M#@  AQ   'H0  !R$   ; X  &D,  !G"0, 9@0+ &0 $ !B !< 8  > %X
M)0!= "L 7  Q %H -P!9 #P 6 !" %<!1P!6 4X 50)4 %,"7 !2 V4 40-O
M $\$>P!.!(H 3069 $P%J0!+!;P 2@;4 $H'[0!*!_D 2@?_ *$0  ".$@
M?A0  ',4  !J%   9!,  & 1  !>#P  70T% %T)#0!:!A( 6 <9 %8'( !5
M!R< 4P<M %((,P!1"#@ 4 @^ $\)1 !."4H 3 E1 $L*60!*"F( 2 MM $<+
M>@!&#(@ 1 R8 $,,J0!"#;P 0@W5 $(-[@!"#?L 0@W_ )H4  "'%@  >!@
M &P9  !C&0  71@  %D6  !6$P  5!$  %0." !3#0X 40T4 $\-&P!-#2(
M3 TH $L-+@!*#30 20TZ $<.00!&#D< 10Y/ $0.5P!"#V$ 01!L #\0>0 ^
M$(@ /1&8 #L1J0 [$;P .A'6 #H1\  Z$OT .Q'_ ),8  "!&@  <QP  &<=
M  !>'0  6!P  %,;  !0&   3A8  $P3 P!,$0L 2A 0 $@1%P!&$1X 11$D
M $01*@!"$3  01$W $ 2/0 _$D0 /1), #P35  [$UX .11I #@4=@ W%84
M-A66 #06IP T%KH ,Q;3 #,6[@ T%OP -!;_ (X;  !\'0  ;A\  &,@  !:
M(   4R   $X>  !*'0  2!H  $88  !%%@< 0Q4. $$5$P _%1H /A4@ #T5
M)P [%2T .A8S #D6.@ X%D$ -Q=) #4740 T&%L ,QEF #(9<P P&H, +QJ4
M "X;I0 M&[@ +1O0 "T;[  N&_L +AO_ (H>  !X(   :B(  %\C  !6(P
M3R(  $HA  !&(   0QX  $$;   _&@, /1H, #L9$0 Y&18 -QH= #8:(P U
M&BD -!HP #,;-@ Q&SX ,!Q& "\<3P N'5D +1UD "P><0 K'X$ *A^2 "D?
MI  H(+< )R#. "<@ZP H(/H *1__ (8@  !T(P  9R0  %PE  !3)0  3"4
M $<D  !"(P  /R$  #T?   Z'@  -QX) #4>#@ S'A, ,1X: # >(  O'B8
M+A\M "T?,P L(#L *R!# "HA3  I(58 *")B "8B;P E(W\ )".0 ",CH@ B
M)+4 (B3, "(DZ0 C)/D )"/_ ((C  !Q)0  8R8  %DG  !0*   22<  $,G
M   _)@  .R0  #@B   U(@  ,B(& # B#0 N(A$ +"(7 "HB'0 I(B, *",J
M "<C,0 F)#@ )25! "0E2@ C)E0 (B9@ "$G;0 @)WT 'R>/ !XHH0 >*+0
M'2C* !THZ  >*/@ 'R?_ 'XE  !N)P  8"D  %8I  !-*@  1BH  $$I   \
M*   -R<  #0F   P)@  +28# "LG"P H)Q  )R<4 "4G&@ D)R$ (R@G "(H
M+@ A*38 ("D^ !\J2  >*E( '2M> !PK:P ;*WL &BR- !DLGP 8++( &"S)
M !@LYP 9*_< &BO_ 'HG  !J*@  72L  %,L  !*+   0RP  #XK   Y*P
M-"H  # J   K*@  *2L  "8K"  C+ X (BP2 " L&  ?+!X 'BTE !TM+  <
M+3, &RX\ !HN10 9+U  &"]< !<O:0 6,'D %3"+ !0PG@ 4,+$ $S#' !,P
MY0 4,/8 %2__ '8J  !G+   6BT  % N  !(+@  02X  #LN   V+0  ,2T
M "PM   G+P  )"\  "$P!0 ?,0P '#$0 !LR%0 :,AP &3(B !@R*0 7,S$
M%C,Y !4S0P 4-$T $S19 !(T9P 1-7< $36) ! UG  0-;  #C7&  \TY  0
M-/4 $#3_ '(L  !C+@  5S   $TP  !%,   /C   #@P   S,   +S   "DQ
M   D,@  (3,  !TU @ :-@D %S<. !4W$P 4.!D $S@? !(X)@ 2."X $3DV
M ! Y0  0.4L #CE7  XZ9  -.G0 ##J&  PZF0 +.:P "CG!  HYW@ +.?$
M##C\ &XO  !?,0  4S(  $HS  !",P  .S,  #8S   Q,@  +#,  "<T   A
M-@  '3@  !DY   5.P8 $CT, ! ^$  0/A4 #CX<  X^(P -/BH ##XS  P^
M/  +/T< "C]2  @_8  '/V\ !C^!  4_E  $/Z@  SZ\  0^UP %/NP !3[W
M &DS  !;-   4#4  $<U   _-0  .34  #0U   N-0  *3<  ",X   >.P
M&CP  !8_   2000 #D,*  Q$#@ *1!, "409  A$(  '1"< !D0O  5$.  #
M14(  D5.  !%6P  16H  $5\  !%D   1*0  $2Y  !$T0  1.H  $/U &0V
M  !7-P  3#@  $,X   \.   -S@  #$X   K.0  )3L  " ]   :0   %D(
M !)$   .1P0 "TD)  =*#0 $2Q$  4L6  !+'   2R,  $LK  !+-   2SX
M $Q)  !,5P  3&8  $QW  !+C   2Z$  $NU  !*S@  2ND  $KU %\Z  !2
M.P  2#L  $ [   Z.P  -#L  "X\   G/@  (D$  !Q#   61@  $DD   Y+
M   +3@, !U (  )1#   41   %(3  !3&   4Q\  %,F  !3+P  4SD  %-%
M  !34@  4V$  %-R  !3AP  4IP  %*Q  !1R@  4><  %'T %D^  !./@
M13X  #X^   X/@  ,$   "E"   C1   '4<  !=*   230  #E    M3   &
M50(  %<'  !8"P  60X  %H1  !:%0  6QH  %PA  !<*@  7#0  %P_  !<
M30  7%L  %QL  !<@0  6Y<  %NM  !:Q0  6N0  %GS %1"  !*0@  0D(
M #Q"   T0P  +$8  "5)   >3   %T\  !)3   .5@  "ED   5;    7@
M & $  !A"   8@P  &,.  !D$0  918  &8<  !G(P  9RT  &<Y  !G1@
M9U4  &=F  !G>@  9I$  &6H  !EP   9-X  &3P $]&  !'1@  0$4  #='
M   O2@  )DT  !]1   850  $ED   U<   (8    F,   !F    :    &H
M  !K!   ; @  &T,  !O#@  <!(  '(7  !S'0  ="8  '0R  !T/P  =$X
M '-?  !T<@  <XH  '*A  !QN   <=0  '#L $Q*  !%2@  .TL  #).   I
M4@  (%8  !A;   27P  #60   =H    :P   &\   !R    =0   '8   !W
M    >0(  'H&  !\"@  ?@X  ( 1  ""%@  A!X  (0I  "$-@  A$4  (16
M  "#:@  @X$  (*9  "!L0  @,D  (#E $I.   _4   -5,  "M7   B7
M&6(  !)G   ,;   !7$   !U    >0   'T   "!    @P   (4   "&
MB    (D   "+!   C0@  (\-  "2$   E!8  )8@  "6+   ECL  )9,  "5
M8   E78  )20  "3IP  DKT  )+5 $15   Y60  +UT  "1C   ::0  $F\
M  QU   $>P   (    "%    B0   (T   "1    DP   )0   "6    F
M )H   "<    G@   * &  "B"P  I1   *@7  "I(P  J3$  *E#  "I5@
MJ&T  *:'  "GG@  IK,  *7' #Y>   R8P  )VH  !UP   3>   #'\   .%
M    BP   )$   "6    FP   )\   "B    I    *4   "G    J0   *L
M  "M    L    +(   "U @  MPD  +L0  "^&   OB8  +XX  "^2P  O6$
M +QZ  "[E   NJD  +JY #=J   K<   ('@  !:    -B   !8\   "6
MG    *(   "G    K    +    "S    M@   +<   "Y    NP   +T   "_
M    P@   ,4   #(    R@   ,X(  #2$   U1L  -4L  #40   U%<  --N
M  #4A@  U)L  -.K /\   #_    _P   /\ !0#_  X _P 5 /P ( #Y "H
M]@ T /$ /0#M $8 Z0!- .8 4P#D %D X0!> -X 8P#< &@ V0!N -4 <P#3
M 'D T "  ,X B #+ )$ R0"< ,8 IP#$ +< P@#, ,  [ "_ /\ O@#_ +T
M_P"W /\ L@#_ /\   #_    _P   /H  0#S  L [0 2 .@ &P#E "4 Y  N
M -\ . #8 $  T@!' ,X 3@#+ %0 R !9 ,8 7@#$ &, P@!G ,  ;0"_ ',
MO0!Z +L @0"Y (L M@"5 +0 H0"R *\ L #" *X XP"N /H K #_ *T _P"I
M /\ I@#_ /\   #_    \@   .8   #=  < T@ . ,T %@#* "  R  I ,4
M,@#  #H O !" +D 2 "W $X M0!3 +, 6 "Q %T L !B *X 9P"L &P J@!S
M *D >P"G (0 I0". *, F@"A *@ GP"Y )X T@"= /( G #_ )T _P"< /\
MF0#_ /P   #N    W0   ,P   #!  ( N@ , +8 $@"R !H L  C *\ + "M
M #0 J0 \ *8 0@"D $@ H@!- *  4@"> %< G0!; )P 8 ": &8 F0!L )<
M= "5 'T DP"' )$ DP"0 *$ C@"Q (T Q@", .@ BP#] (P _P", /\ C #_
M .T   #8    Q0   +<   "L    I@ ( *$ #@"? !4 G0 > )L )@": "X
MEP U )4 / "3 $( D0!' )  3 ". %$ C0!5 (L 6@"* &  B0!F (< ;0"%
M '8 A "  (( C "  )H ?P"I 'T O !\ -P ? #U 'P _P!\ /\ ? #_ -D
M  #!    L0   *0   "<    E  # )  # "- !$ BP 8 (D ( ") "@ AP O
M (4 -@"# #P @@!! (  1@!_ $L ?0!/ 'P 5 ![ %H >0!@ '@ 9P!V '
M=0!Z ', A@!Q ), < "B &\ M !N ,P ;@#M &X _@!N /\ ;@#_ ,0   "O
M    H    )0   ",    A@   ($ " !^  X ?  4 'L &P!Y "( >  I '<
M, !U #8 =  [ '( 0 !Q $4 < !* &\ 3P!M %0 ; !; &L 8@!I &H : !T
M &8 @ !E (X 8P"= &( K0!A ,( 80#D &$ ^ !A /\ 80#_ +0   "@
MD0   (8   !^    >0   '4  P!Q  L ;P 0 &T %@!L !T :P D &L *@!I
M #  :  V &8 .P!E $  9 !% &, 2@!A $\ 8 !6 %\ 70!= &4 7 !O %H
M>@!9 (@ 6 "8 %< J !6 +L 5@#8 %8 \0!6 /\ 5@#_ *@!  "4!0  A0<
M 'H'  !R!@  ; 0  &D!  !G  < 9  - &, $0!A !@ 8  ? %\ )0!> "L
M70 P %L -@!: #L 60!  %@ 10!7 $L 5@!1 %4 6 !3 &$ 4@!J %  =@!/
M (0 3@"3 $T I !, +8 3 #- $P ZP!, /H 3 #_ )T)  "+"P  ? T  ' -
M  !H#0  8@P  %\*  !=!@$ 7 $) %H #@!8 !, 5P 9 %8 ( !5 "8 4P K
M %( ,0!1 #8 4  [ $\ 00!. $< 30!- $L 50!* %T 20!G $< <P!& (
M10"0 $0 H0!# +( 0P#( $, Y@!# /4 0P#_ )4-  "##P  =!   &D1  !@
M$0  6A   %8.  !4#0  4PH$ %,&"P!1 Q  3P$5 $X!&P!, 2$ 2P$G $H"
M+ !) C( 2 (W $<#/0!% T, 1 -* $,$40!"!%H 0 5D #\%<  ^!GX /0:.
M #P'GP [![$ .@?& #H'XP Z!_, .@C\ (X0  !\$@  ;A0  &(5  !:%0
M5!0  % 3  !-$0  2PX  $L-!@!*"@P 20@1 $<(%@!%"!T 1 @C $((* !!
M"2X 0 DS #\).0 ^"D  /0I' #P*3P Z"U@ .0MC #@,;P V#'X -0R. #0-
MGP S#;$ ,@W' #(-XP R#?0 ,@W^ (@3  !W%0  :1<  %X8  !5&   3Q@
M $H6  !'%0  11,  $,0 @!##@@ 0@T. $ -$@ _#1@ /0T? #P-)  [#2H
M.0TP #@.-P W#CT -@Y% #4.30 S#U< ,@]B #$0;@ O$'T +A". "T1H  L
M$;( *Q'( "L1Y@ K$?8 +!'_ (,6  !R&0  9!H  %D;  !1&P  2QL  $8:
M  !"&   /Q<  #X4   \$@0 .Q$* #H0$  X$!4 -Q ; #41(0 T$2< ,Q$M
M #(1,P P$3H +Q)" "X22P M$U0 *Q-? "H4;  I%'L *!2, "<5G@ F%;
M)17& "45Y  E%?8 )A7_ 'X9  !N&P  8!T  %8>  !-'@  1QX  $(=   ^
M'   .AH  #@8   W%@  -14' #04#0 R%!( ,!07 "\4'0 M%", +!4J "L5
M,  J%3< *18_ "@62  G%U( )AA= "08:@ C&7D (AF* "$9G  @&:\ 'QG$
M !\9X@ @&?0 (!G_ 'H;  !J'@  71\  %,@  !*(   1"   #X?   Z'@
M-QT  #0<   R&0  ,!D$ "X8"P L&!  *A@4 "D8&@ G&"  )ADF "49+0 D
M&C4 (QH] "(;1@ A&U  (!Q; !\=:  >'7< '1V( !P>FP ;'JT &A[# !H>
MX  :'?, &QW_ '<=  !G(   6B$  % B  !((@  02(  #LB   W(0  ,R
M # ?   M'0  *QT  "@="  F'0X )1T2 ",=%P A'1T (1TD " >*@ ?'C(
M'A\Z !T?0P <($T &R%9 !HA9@ 9(74 &"*' !<BF0 6(JP %2+! !4BWP 5
M(?( %B'^ ',@  !D(@  5R,  $TD  !%)0  /B0  #DD   T(P  ,"(  "PB
M   I(0  )B$  "0A!@ B(0P ("$0 !XA%0 =(AL &R(A !LB*  :(R\ &2,X
M !@D00 7)$L %B57 !4E9  4)G, $R:% !(FF  1)JL $2;  ! FW0 1)?$
M$B7] ' B  !A)   5"8  $HF  !")P  /"8  #8F   Q)0  +24  "DD   F
M)   (B4  !\E P =)@H &R8. !DG$@ 8)Q@ %R<? !8G)0 5*"T %"@U !,I
M/@ 2*4D $2E5 !$J8@ 0*G$ #RJ#  XJE@ .*JD #2J]  TJUP -*NX #BG[
M &PD  !=)@  42@  $@H  ! *0  .2@  #0H   O*   *R<  "<G   B*
M'BD  !LJ   8*P< %BL- !0L$0 3+!8 $BP< !$M(P 0+2H $"TR  \N/  .
M+D8 #2Y2  TN7P ,+VX "R]_  HOD@ )+Z4 "2ZY  @NT  )+ND "B[W &@G
M  !:*0  3BH  $4K   ]*P  -RL  #$J   M*@  *2H  "0J   @*P  &RT
M !@N   5+P0 $C$* ! R#@ /,A, #C(9  TR(  -,B< ##(O  LS.  *,T(
M"3-.  @S6P &-&H !31[  0SC@ #,Z(  C.V  (SS0 #,^< !#+S &0J  !6
M+   2RT  $(M   Z+0  -"T  "\L   K+   )BP  "(M   =+P  &3$  !4R
M   2- , #S8)  PX#0 *.!$ "3@6  @X'0 '."0 !C@L  0X-  #.#X  CE*
M   Y5P  .64  #EW   YBP  .)\  #BS   XR@  ..8  #?R %\M  !2+@
M2"\  #\P   X+P  ,B\  "TO   I+P  )#   !\Q   :,P  %34  !(W   /
M.0, ##L(  @]#0 %/A   SX4   ^&@  /B$  #XH   ^,0  /SL  #]&   _
M4P  /V$  #]S   _AP  /IP  #ZP   ]QP  />0  #WR %HP  !.,@  1#(
M #PR   U,@  ,#$  "LQ   F,@  (#0  !LV   6.   $CL   \]   ,/P,
M"$$(  1##   0PX  $02  !%%@  11T  $4D  !%+0  1C8  $9"  !&3@
M1ET  $9N  !%@@  19@  $2M  !$Q   0^,  $/R %4T  !*-0  034  #DU
M   S-   +C0  "@U   B-P  '3H  !<\   2/P  #T$   Q$   (1@$  T@&
M  !)"@  2@T  $L0  !,%   31D  $X@  !.*   3C(  $T]  !.2@  3E@
M $UI  !-?0  3)0  $RJ  !+P0  2^$  $KR % X  !&.   /3@  #<X   Q
M-P  *CD  "0[   >/0  &$   !-#   /1@  "TD   =+   "3@   % $  !1
M"   4@L  %,.  !4$0  514  %8;  !7(P  5RP  %<X  !71   5U(  %9C
M  !6=P  5HX  %6E  !4O0  4]T  %/P $L\  !"/   .SL  #4[   M/
M)C\  !]"   910  $T@   Y+   +3P  !5$   !4    5P   %@!  !:!0
M6P@  %P,  !=#@  7Q$  & 6  !B'0  8B8  &(Q  !B/@  84P  &%=  !A
M<   8(@  &"@  !?MP  7M0  %WN $=    _/P  .C\  #%    I0P  (48
M !I*   33@  #E$   I5   $6    %L   !>    80   &,   !D 0  900
M &<(  !H"P  :@X  &P2  !N%P  ;R   &\J  !O-@  ;D4  &Y5  !N:
M;7\  &V8  !LL   :\H  &KH $1$   ^0P  -40  "M'   C2P  &T\  !-4
M   .6   "%P   )@    9    &<   !K    ;0   &\   !P    <@   '0"
M  !U!@  =PH  'D.  !\$@  ?A@  '\B  !_+@  ?ST  'Y-  !]80  ?7<
M 'R0  ![J   >L   'G? $-'   Y20  +TP  "50   <50  %%L   Y@   '
M90   &H   !N    <@   '8   !Y    ?    'X   !_    @0   (,   "%
M    AP,  (H(  ",#0  CQ$  )(9  "2)0  DC,  ))$  "15P  D&T  (^&
M  ".GP  C;4  (S- #U.   R40  *%8  !Y<   58@  #F@   =N    =
M 'D   !^    @@   (8   ")    C    (X   "0    D@   )0   "6
MF    )L   ">!@  H0P  *01  "F&P  IBD  *8Z  "E30  I6(  *1[  "C
ME   H:L  *&_ #97   L7   (6(  !=I   /<   !W<   !^    A    (H
M  "/    E    )@   ";    G@   )\   "B    I    *8   "H    JP
M *T   "P    LP0  +<,  "[$@  NQ\  +LP  "[0P  NE@  +EP  "WBP
MMZ$  +>S #!B   E:0  &G   !!X   )@    (@   "/    E@   )L   "A
M    I@   *H   "N    L    +$   "T    M@   +@   "[    O0   ,
M  ##    QP   ,L#  #/#   TQ4  -(E  #2.   T4X  -!E  #/?@  S98
M ,RI /\   #_    _P   /\  P#_  L _  1 /D &P#W "4 \P O .X . #I
M $  Y@!( .( 3@#? %0 W !9 -D 7@#5 &, TP!H -  ;0#. ', RP!Z ,@
M@@#& (P PP"7 ,  HP"^ +( O #( +H Z@"Y /\ N #_ +$ _P"J /\ IP#_
M /\   #_    ^P   /8   #M  < YP / .( %@#? "  W@ I -D ,P#1 #L
MS !" ,@ 2 #% $X P@!3 ,  6 "^ %T O !B +H 9P"Y &T MP!T +4 >P"R
M (4 L "0 *X G "L *H J0"] *< W@"F /D I0#_ *, _P"= /\ FP#_ /T
M  #V    ZP   -\   #1  , R@ , ,4 $@## !L P  D +X + "Y #4 M@ \
M +, 0P"P $@ K@!. *P 4@"K %< J0!< *< 80"F &< I !M *( = "@ 'T
MG@"( )P E0": *, F "T )8 S0"5 /$ E #_ )4 _P"0 /\ C@#_ /,   #F
M    T0   ,(   "X    L0 ( *T #P"J !8 J  > *@ )P"F "\ H@ V )\
M/ "= $( FP!' )D 3 "7 %$ E@!5 )0 6@"3 &  D0!F )  ;@". '8 C "!
M (H C0"( )L A@"L (4 P0"$ .8 @P#] (0 _P"# /\ @0#_ .0   #+
MN@   *P   "B    G  $ )@ # "6 !$ E  9 ), (0"2 "@ CP P (T -@"+
M #P B0!! (@ 1@"& $L A0!/ (0 5 "" %H @0!@ '\ 9P!^ &\ ? !Z 'H
MA@!X )0 =P"D '4 MP!T -0 <P#T '0 _P!T /\ = #_ ,L   "V    I@
M )H   "2    B@   (8 " "#  X @0 4 ($ &P"  ", ?P J 'T , ![ #8
M>@ [ '@ 0 !W $4 =0!) '0 3@!S %0 <0!: '  80!N &D ;0!S &L ?P!I
M (T : "= &< K@!F ,< 90#J &8 _P!F /\ 9P#_ +@   "D    E0   (H
M  "!    ?    '8 ! !T  P <@ 0 '$ %@!P !T <  D &X *@!M #  :P U
M &H .@!I #\ : !$ &< 20!E $X 9 !4 &, 6P!A &, 8 !M %X >0!= (<
M6P"6 %H J !9 +T 60#? %D ^ !: /\ 6@#_ *@   "5    AP   'L   !S
M    ;@   &H  0!G  @ 90 . &0 $@!C !@ 8P ? &( )0!A "H 7P P %X
M-0!= #H 7  ^ %L 1 !9 $D 6 !/ %< 5@!6 %X 5 !H %, <P!1 ($ 4 "1
M $\ H@!. +4 3@#0 $X \ !. /\ 3P#_ )P   ")    >P,  ' #  !H P
M8@$  %\   !=  0 6P + %D #P!8 !0 5P 9 %< ( !6 "4 50 J %, , !2
M #0 40 Y %  /P!/ $0 3@!+ $T 4@!+ %H 2@!C $D ;P!' 'P 1@", $4
MG0!% +  1 #' $0 Z !$ /H 10#_ )($  " !P  <0H  &8*  !>"@  60D
M %4'  !4!   4@ ' %  # !/ !  3@ 5 $T &P!, "  2P F $H *P!) #
M2  U $< .@!& $  10!& $, 3@!" %8 00!? $  :P ^ '@ /0"( #P F0 \
M *L / #! #L X  [ /0 .P#_ (D*  !X#   :@X  %\.  !7#@  40X  $T,
M  !+"P  2@@" $D$"0!(  T 1@ 1 $4 %@!$ !P 0P A $( )@!! "L /P Q
M #X -@ ] #P / !# #L 2@ Z %( .0!< #@ :  V '4 -0"% #0 E@ T *@
M,P"\ #, V  S .\ ,P#[ ((-  !Q#P  9!   %D1  !1$0  2Q$  $<0  !$
M#@  0@T  $$+!0!!!PL /P4. #X#$@ \ A@ .P(= #H#(@ Y R@ . ,M #<#
M,@ V!#D -00_ #0%1P S!5  ,09: # &9@ O!W, +@># "T'E0 L!Z< *P>Z
M "L'T@ K!^L *P?W 'T0  !L$0  7Q,  %04  !,%   1A0  $(3   ^$@
M/!   #H. 0 Z#08 .@H, #@)$  V"!0 -0@9 #0)'P R"20 ,0DI # )+P O
M"C8 +@H] "T*10 L"TX *PM9 "D,90 H#', )PR# "8-E0 E#:< ) V[ ",-
MT@ C#>L (PWW '@2  !H%   6Q8  %$7  !(%P  0A8  #T6   Y%0  -Q,
M #41   S$ , ,PX( #(-#0 P#1$ +PT6 "T-&P L#2$ *PTG "H-+0 I#C0
M* X[ "<.1  E#DX ) ]9 ",090 A$', (!"$ !\0E@ >$*D '1"] !P0V  =
M$.X '1#Y ',4  !D%@  5Q@  $T9  !%&0  /QD  #H8   U%P  ,A8  # 5
M   N$P  +1$$ "P0"@ K$ X *1 2 "@0&  F$!X )1 D "00*@ C$3$ (A$Y
M "$10@ @$DL 'A)6 !T38P <$W$ &A." !D4E0 8%*< %Q2[ !<3U  7$^X
M&!/Z ' 6  !@&0  5!H  $H;  !"'   /!L  #8;   R&@  +QD  "P8   J
M%@  *!0! "83!P E$PP (Q,0 "(3%0 @$QH 'Q,A !X4)P =%"X '!4V !L5
M/P :%DD &194 !@780 6%W  %1B! !08DP 3&*8 $ABZ !(7T@ 2%^P $Q?Z
M &P9  !=&P  41T  $<=   _'@  .1T  #0=   O'   *QL  "@:   F&0
M)!@  "(7!  @%PH 'A<. !P7$@ :%Q< &1@> !D8)  8&2P %QDT !8:/0 5
M&D< %!M2 !,;7P 2'&X $1Q_ ! <D@ 0'*4 #QRY  X<T  .&^H #QOX &D;
M  !:'0  3A\  $4?   ](   -A\  #$?   M'@  *1T  "4=   C'   (!L
M !T; 0 ;&P< &1P- !<<$  6'!4 %1P; !0=(@ 3'2D $AXQ !$>.@ 1'T4
M$!]0  \@70 .(&P #2!\  T@CP ,(*( "R"U  L@R@ +(.4 #!_T &4=  !7
M'P  3"$  $(A   Z(0  -"$  "\A   J(   )A\  ",?   @'@  '1X  !D@
M   6( 0 %" + !(A#@ 1(1, $2(9 ! B'P /(B8 #B,O  XC-P -(T$ #"1-
M  LD60 *)&< "21X  @DBP '))X !R2Q  8DQP &(^, !R/Q &(?  !4(0
M22,  $ C   X(P  ,B,  "PC   H(@  )"$  "$A   >(0  &B$  !8C   3
M) , $24(  \F#0 .)Q$ #2<6  PG'0 +)R, "B<K  DH-  (*#X !RA)  8H
M50 %*60 !"ET  ,IAP "*9L  2BO   HQ0 !*.$  2?P %XB  !1)   1B4
M #TE   U)0  +R4  "HD   F)   (B,  !\C   ;)   &"4  !0F   1* ,
M#RD(  PL#  *+!  ""P4  <L&@ &+"$ !2PH  ,M,  "+3H  2U%   M4@
M+F   "YQ   MA   +9D  "VM   LP@  +.   "SP %HD  !-)@  0R<  #HG
M   S)P  +2<  "@F   D)@  (28  !TF   9)P  %2D  !$K   /+ , #2X'
M  DP#  &,0X  S$2  $R%P  ,AX  #(E   R+0  ,C8  #-"   S3@  ,UT
M #-M   S@0  ,I8  #*K   QP0  ,=\  #'P %8G  !**0  /RH  #<J   P
M*@  *RD  "<H   C*   'BD  !HJ   6+   $BX   \P   -,0( "C0'  4U
M"P "-@X  #<0   X%   .!H  #@B   X*@  .3,  #D^   Y2@  .5D  #EI
M   Y?0  .),  #BH   WOP  -]X  #;P %$K  !&+   /"P  #0L   N+
M*BL  "4K   @+   &RT  !<O   3,0  $#,   TU   )-P( !3H&  $["@
M/ T  #T/   ^$@  /Q<  $ >  ! )0  0"\  $ Z  ! 1@  0%0  $!E   _
M>   /X\  #ZF   ^O0  /=P  #WP $TN  !"+P  .2\  #(O   M+@  *"X
M "(O   =,   &#(  !,U   0-P  ##H   D\   %/@   $$$  !""   0PL
M $0-  !&$   1Q0  $@9  !((0  2"H  $@U  !(00  2$\  $A@  !'<P
M1XH  $:B  !%N0  1=D  $3P $@R   ^,@  -C(  # Q   K,0  )3(  !\T
M   9-@  $SD  ! \   ,/P  "$(   -$    1@   $@"  !*!0  2P@  $P+
M  !.#@  3Q$  %$5  !2'   4B4  %(P  !2/   44H  %%:  !1;0  4(0
M $^=  !.M0  3=(  $WN $,V   [-@  -#4  "\T   G-0  (3@  !H[   4
M/@  $$$   Q$   '1P   DH   !-    3P   %$   !3 @  5 4  %4(  !7
M"P  60X  %L1  !=%P  71\  %TJ  !=-@  7$0  %Q4  !;9P  6WX  %J7
M  !9KP  6,L  %?J #\Y   X.0  ,S@  "LY   C/   '#\  !5#   01P
M"TH   5.    40   %0   !7    6@   %P   !=    7P   & $  !B!P
M9 L  &8.  !H$@  :QD  &LC  !J+@  :CP  &I-  !I7P  :'4  &>/  !F
MJ   9<(  &3C #T]   W/   +CT  "5    =1   %DD  !!-   *40  !%4
M  !:    70   &    !C    9@   &@   !J    :P   &T   !O @  <08
M '0*  !V#@  >1,  'L;  ![)P  >C4  'E%  !X60  >&T  '>&  !VGP
M=;<  '32 #Q!   R0@  *$4  "!*   73@  $%0   I9   "7@   &,   !G
M    :P   &\   !R    =0   '<   !Y    >P   'T   !_    @@   (0#
M  "'"0  B@X  (X3  "/'@  CBL  (X[  "-3@  BV,  (I\  "*E0  B*T
M (?% #9'   L2P  (D\  !E5   06P  "F$   %G    ;0   '(   !W
M>P   '\   "#    A@   (@   "*    C0   (\   "1    E    )<   ":
M 0  G0<  *$-  "E%   I"$  *0Q  "C1   HED  *!P  "?BP  G:(  )VW
M #!0   E50  &UL  !)B   +:0   7    !W    ?0   (,   "(    C0
M )$   "5    F    )H   "<    GP   *$   "C    I@   *D   "L
ML    +0'  "X#@  NA@  +HG  "Y.0  N$X  +=E  "V?@  M98  +.K "E;
M   >8@  %&D   QQ   ">0   ($   ")    CP   )8   ";    H    *0
M  "H    JP   *P   "O    L@   +0   "V    N0   +P   #     Q
M ,@   #-!P  TA   -(=  #1+P  T$0  ,];  #-<P  RXT  ,JA /\   #_
M    ^P   /H   #\  @ ^  / /4 %P#T "  \0 J .L ,P#F #L X@!# -X
M20#: $\ U@!4 -, 60#0 %X S@!C ,L : #) &X Q@!U ,, ?0#! (8 O@"2
M +L G@"Y *X M@## +0 Z "S /\ KP#_ *4 _P"> /\ FP#_ /T   #W
M\@   /    #G  , X0 , -P $@#8 !L U@ D -( +0#, #8 Q@ ] ,( 0P"_
M $D O !. +H 4P"X %@ M@!= +4 8@"S &< L0!N *\ =@"L '\ J@"* *@
MEP"E *8 HP"Y *$ V0"@ /D G@#_ )@ _P"2 /\ CP#_ /,   #L    XP
M -,   #(    P0 ) +T #P"[ !8 N0 ? +< )P"S "\ KP W *P /0"J $,
MJ !( *8 30"D %( HP!6 *$ 6P"? &$ G@!G )P ;P": '@ EP"# )4 D "3
M )X D0"P )  R ". /  C0#_ (H _P"% /\ @@#_ .<   #=    Q@   +@
M  "N    J  $ *4 # "A !( H0 9 *  (@"? "D FP P )@ -P"6 #T DP!"
M )( 1P"0 $L CP!0 (T 50", %H B@!A (@ : "' '  A0![ (, B "! )8
M?P"G 'T O !\ ., ? #] 'P _P!X /\ =@#_ -8   #     KP   *,   "9
M    DP   (\ "0"-  X BP 4 (H ' "* ", B  J (4 , "# #8 @@ [ (
M0 !_ $4 ?@!* 'P 3P![ %0 >@!: '@ 80!V &D =0!S ', @ !Q (X ;P"?
M &X L@!M ,\ ; #T &P _P!K /\ :0#_ ,    "K    FP   (\   "'
M@    'P ! !Z  P >  1 '@ %P!X !X =P D '4 *@!S #  <0 U '  .@!N
M #\ ;0!$ &P 20!K $X :@!4 &@ 6P!G &, 90!M &0 > !B (< 8 "7 %\
MJ@!> ,( 7@#I %X _P!> /\ 70#_ *P   "9    B@   '\   !W    <0
M &T   !J  @ :0 . &@ $@!G !@ 9P ? &< )0!E "H 8P O &( - !A #D
M8  ^ %\ 0P!> $@ 70!. %L 50!: %T 6 !G %< <@!5 ($ 5 "1 %, HP!2
M +@ 40#< %$ ^0!2 /\ 4@#_ )T   "+    ?    '$   !I    9    &
M  !>  4 7  + %L #P!; !0 6@ 9 %H 'P!9 "4 5P J %8 +P!5 #0 5  X
M %, /0!2 $, 4 !) $\ 4 !. %@ 30!B $L ;0!* 'H 20"+ $@ G0!' +$
M1P#, $8 \ !' /\ 1P#_ )    !^    <    &8   !>    60   %8   !3
M  $ 4@ ( %  #0!/ !  3P 5 $X &@!. "  30 E $P *@!* "X 20 S $@
M. !' #X 1@!$ $4 2P!$ %, 0P!= $$ : !  '4 /P"% #X EP ] *L /0##
M #T Y@ ] /L /@#_ (<   !U P  : 8  %T'  !5!@  4 8  $P$  !* 0
M20 $ $< "@!&  X 10 1 $4 %@!$ !L 0P @ $( )0!! "H 0  O #\ -  ^
M #H /0!  #L 1P Z $\ .0!9 #@ 9  W '$ -@"! #4 DP T *8 - "[ #0
MW0 T /4 -0#_ 'X&  !M"0  8 L  %8,  !.#   2 L  $0*  !""   0 4!
M #\!!P ^  L /0 . #P $@ [ !< .P < #H (0 Y "4 -P J #8 ,  U #4
M-  \ #, 0P R $P ,0!5 #  8  O &T +@!] "T CP L *( + "V "P T  L
M .X + #\ '<*  !G#   6@X  % .  !)#@  0PX  #X-   [#   .0L  #@)
M P W!0@ -@(- #4!$  T !, ,P 8 #( '0 Q "( ,  G "\ +  N #( +0 X
M "P 0  K $D *@!2 "D 70 H &L )P%Z "8!C  E )\ )0"R "4 R@ E .@
M)0#W '(-  !B#@  5A   $P1  !$$0  /A$  #D0   V#P  ,PX  #$- 0 P
M"P4 , @* "\&#0 N!1$ + 04 "L#&0 J QX *0,C "@$*0 G!"\ )@4U "4%
M/0 D!48 (P90 "(&7  A!VD ( =Y !\'BP >!YT '@>P !T&Q@ =!N, '07S
M &T.  !>$0  4A(  $@3  ! $P  .A,  #42   Q$0  +A   "P/   J#@,
M*@T' "D+"P H"0X )PD1 "4(%@ D"!L (PD@ "())@ A"2P ( HS !\*.P >
M"T0 '0M/ !P,6P ;#&D &@QY !@,BP 8#)X %PRP !8,Q0 6#.$ %@OP &D0
M  !:$@  3A0  $45   ]%0  -Q4  #$4   M$P  *A(  "@1   F$ $ )! $
M ",."  C#0P (@P/ " ,$P ?#!@ '@T= !T-(P <#2H &PTR !H..@ 8#D0
M%PY0 !8/7  5#VH $Q![ !(0C0 1$*  $1"S ! /R0 0#^0 $0_R &42  !7
M%   2Q8  $(7   Z%P  -!<  "\6   J%0  )Q0  "03   B$P  (!(# !X1
M!@ =$ D '! - !L/$  9$!4 &! ; !<0(0 6$"@ %1$P !01.0 3$4, $A).
M !$26@ 0$FD $!-Y  X3C  .$YX #1.Q  T2Q0 ,$N$ #1+Q &(4  !4%@
M21@  #\9   W&0  ,1D  "P8   H%P  )!8  "$6   ?%0  '!0" !H3!  9
M$@8 %Q(+ !42#@ 4$A( $Q,8 !(3'P 1$R8 $10M ! 4-@ /%4$ #A5,  X6
M5P -%F4 #!=U  L7AP *%YH "1:M  @6P0 (%MT "17N %\6  !1&   1AH
M #T:   U&P  +QH  "H:   E&0  (A@  !\8   <%P  &18! !<6 P 5%@0
M$Q8) !$6#0 0%Q$ #Q<6  X7'  .&", #1@J  P9,P ,&3P "QI'  H:4P )
M&F$ !QMQ  8;@P %&Y< !!JJ  ,:OP #&=H !!GL %P8  !.&@  0QP  #H<
M   S'   +!P  "<<   C&P  (!H  !T9   :&0  %Q@! !48 @ 2&00 $!L'
M  X;#  -'!  #!P3  L<&0 *'!\ "1TG  @=+P ''CD !AY#  0>4  #'UX
M A]N  $?@   'Y4  !ZI   >O0  '=@  !WL %@:  !+'   01X  #@>   P
M'@  *AX  "4=   A'   'AP  !L;   8&P  %AL! !,; @ 1' 0 #AX'  P?
M"P *( X "" 2  8A%P %(1T !"$D  (B+  !(C4  ")    C30  (UH  "-K
M   C?@  (Y,  "*G   BO   (=<  "'M %4=  !('P  /B   #4@   N(
M*"   ",?   @'@  '1T  !H=   6'0  $QX  !$? @ .( 0 #2('  HD"P &
M)0T !"40  (F%   )AH  "8A   G*0  )S(  "<]   G20  *%<  "AG   G
M>P  )Y   ">E   FNP  )M8  "7M %$@  !%(0  .R(  #(B   L(@  )B$
M "(A   >(   &Q\  !@@   4(   $2(   \C   -)0, "B8&  8H"@ #*0T
M "L/   L$@  +!<  "P>   L)@  +2\  "TY   M1@  +50  "UD   M=P
M+(T  "RD   KN@  *]8  "KN $TB  !!)   ."0  # D   I)   )",  "$B
M   =(@  &2(  !4C   2)   #R8   TH   **@( !BP%  (N"0  +PL  # .
M   R$   ,Q4  #,;   S(@  ,RL  #,V   S0@  ,U   #-@   S<P  ,HH
M #*A   QN   ,-8  ##O $DE   ^)@  -"<  "TG   H)@  (R4  !\D   ;
M)0  %B8  !(H   0*@  #2P   HN   &, $  C($   T!P  -0H  #<,   X
M#@  .A(  #H7   Z'P  .B<  #HR   Z/@  .DP  #I<   Z;P  .88  #B>
M   XM@  -]0  #;O $0I   Z*0  ,2D  "LI   F*   (B<  !TH   8*0
M$RL  ! N   -,   "3(   4U   !-P   #D"   [!0  / @  #X+   _#0
M01   $,4  !#&P  0R,  $,N  !#.0  0T<  $)7  !":@  08$  $":   _
ML@  /L\  #[O #\L   V+   +RP  "HK   E*@  'RL  !DM   4+P  $#(
M  TU   (.   !#H    \    /P   $$   !# @  104  $8(  !("P  2@X
M $P1  !-%@  31X  $TH  !--   3$(  $Q1  !+9   2WL  $J4  !)K0
M2,H  $?L #LP   S+P  +2\  "@M   B+P  &S$  !4T   0-P  #3H   @]
M   "0    $,   !&    2    $H   !,    3@$  $\$  !1!P  4PL  %4.
M  !8$@  61D  %@B  !8+@  5SP  %=+  !67@  5G,  %6-  !4IP  4L(
M %+F #@S   Q,@  +#$  "4R   =-0  %C@  !$\   ,0   !T0   !'
M2@   $T   !0    4P   %4   !7    60   %H   !< P  7@<  &$+  !D
M#@  9A,  &<<  !F)P  9C0  &5$  !D5P  9&L  &*%  !AGP  8+D  %[<
M #4W   P-0  *#<  " Z   8/0  $4(   Q&   &2@   $\   !3    5@
M %D   !<    7P   &$   !D    90   &<   !I    ; $  &X&  !Q"P
M= \  '<5  !W(   =BT  '8]  !U3P  =&,  '-[  !RE0  <*\  &_) #4Z
M   K.P  (C\  !I#   22   #$T   52    5P   %P   !@    9    &@
M  !K    ;@   '$   !S    =0   '<   !Z    ?    '\   ""!   A@H
M (H/  ",%P  BR0  (HS  ")10  AUL  (9R  "%BP  @Z4  (*\ "]    E
M1   '$D  !-.   -5   !%H   !A    9@   &L   !O    =    'D   !]
M    @    (,   "%    AP   (H   ",    CP   )(   "6    F0(  )X)
M  "B$   HAH  *$I  "@.P  GU   )UG  ":@0  FID  )FO "E)   ?3@
M%50   Y;   %8@   &D   !P    =P   'T   ""    A@   (L   "/
MDP   )4   "7    F@   )T   "@    HP   *8   "J    K@   +(   "W
M"@  NQ$  +H?  "Y,   MT4  +5<  "T=   L8X  *^D ")4   86P  $&(
M  =J    <P   'L   ""    B0   )    "5    F@   )\   "C    I@
M *@   "K    K@   +    "S    M@   +H   "]    P@   ,<   #, 0
MTPL  -05  #3)@  T3H  -!1  #-:   RX$  ,J6 /P   #V    \@   /$
M  #S  4 ]  , /( $P#P !P [0 E .@ +@#B #8 W@ ^ -D 1 #4 $H T0!/
M ,X 5 #+ %D R0!> ,8 8P#$ &D P0!P +X > "\ ($ N0"- +8 F@"S *L
ML0#  *\ Y@"N /\ I0#_ )H _P"4 /\ CP#_ /0   #L    Z    .<   #?
M    V0 ) -( $ #/ !< SP @ ,P * #& #  P  W +P /@"Y $0 MP!) +4
M3@"S %, L0!7 *\ 70"M &( JP!I *D <0"G 'H I0"% *( DP"@ *( G0"V
M )L U "9 /D E@#_ (T _P"( /\ A #_ .@   #?    V0   ,D   "_
MN  $ +4 #0"S !( L0 : +  (@"M "H J0 Q *8 . "D #T H@!# *  2 ">
M $P G !1 )L 5@"9 %P EP!B )4 :0"3 '( D0!] (\ BP"- )H BP"L (D
MQ0"( .X A@#_ '\ _P!Z /\ > #_ -D   #-    NP   *X   "E    GP
M )P "0"9  \ F0 5 )D '0"8 "0 E  K )$ ,0". #< C  \ (L 00") $8
MB !+ (8 4 "% %4 @P!; (( 8@"  &L ?@!U 'P @@!Z )( > "C '< N0!V
M .  =0#_ '( _P!N /\ ; #_ ,<   "U    I0   )D   "/    B0   (4
M! "$  P @@ 1 (( %P"" !X @  E 'X *P!\ #$ >@ V 'D .P!W $  =@!$
M '4 20!S $\ <@!5 '  7 !O &0 ;0!N &P >@!J (H : "; &< KP!F ,P
M90#U &0 _P!A /\ 8 #_ +0   "@    D    (4   !]    =P   ',   !P
M  @ ;P . &\ $@!O !@ ;P ? &T )0!K "H :0 P &@ - !G #D 9@ ^ &4
M0P!C $@ 8@!. &$ 50!? %X 7@!G %P <P!; (( 60"3 %@ I@!7 +\ 5P#J
M %< _P!6 /\ 5 #_ *$   ".    ?P   '4   !L    :    &0   !A  0
M8  + %\ #P!? !, 7P 9 %\ 'P!= "4 7  J %L +P!9 #, 6  X %< /0!6
M $, 50!) %, 4 !2 %@ 40!A %  ;0!. 'L 30", $P GP!+ +4 2@#< $H
M^@!* /\ 2@#_ )(   "     <@   &<   !?    6@   %<   !5  $ 4P '
M %( # !2 !  4@ 4 %( &@!1 !\ 3P D $X *0!- "X 3  S $L . !* #T
M20!# $@ 2@!& %( 10!< $0 9P!# '4 0@"& $$ F !  *X 0 #+ #\ \@!
M /\ 0 #_ (4   !T    9P   %T   !5    3P   $P   !*    2  $ $<
M"@!'  T 1@ 1 $8 %0!& !H 10 ? $0 ) !# "D 0@ M $$ ,P _ #@ /@ ^
M #T 10 \ $X .P!7 #H 8@ Y &\ . "  #< DP V *< -@#  #8 Z  V /X
M-@#_ 'P   !K    7@(  %0#  !- P  1P,  $,!  !!    /P ! #X !P ]
M  L /0 . #P $0 \ !8 /  : #H 'P Y "0 .  I #< +@ V #, -0 Z #0
M00 S $D ,@!3 #$ 7@ P &L +P![ "X C@ M *( +0"X "T W0 M /@ +@#_
M ',!  !D!0  5P<  $T(  !&"   0 @  #L'   X!0  -P,  #8 !  U  @
M-  , #0 #P T !( ,P 6 #( &P Q "  ,  D "\ *0 N "\ +0 V "P /0 K
M $4 *@!/ "D 6@ H &< )P!W "8 B0 F )T )0"S "4 SP E /  )@#_ &T&
M  !>"0  4@L  $@,  ! #   .@L  #8+   R"@  , @  "X& @ N P8 +0 *
M "P #0 L !  *P 3 "H %P I !P *  @ "< )0 F "L )0 R "0 .0 C $(
M(@!+ "( 5P A &0 ( !S !\ A0 ? )D '@"N !X QP > .D 'P#Z &@)  !9
M#   30T  $,.   \#@  -@X  #$-   M#0  *@P  "@+   G"00 )@8( "8$
M"P E PX ) $0 "0!%  B 1@ (0$= "$ (@ @ "@ 'P N !X!-@ = 3\ ' %)
M !L!5  : 6$ &@%P !D!@@ 8 )8 & "J !@ P0 8 .$ & #T &,,  !5#@
M20\  $ 0   X$   ,A   "T/   I#@  )@X  ",-   B# , ( L& " )"0 ?
M!PP '@8. !X%$0 <!14 &P4: !H%'P :!24 &04K !@%,P 7!CP %@9& !8&
M4@ 5!U\ % =N !,'@  2!Y0 $@:G !(%O  2!-D $@/O %\.  !1#P  1A
M #P1   U$0  +Q$  "H1   F$   (A   " /   =#@( ' T% !H-!P :"PH
M&0H- !@)$  7"1( %@D7 !4)'  4"2( % HI !,*,0 2"CH $@M% !$+40 0
M#%\ #PQN  X,@  .#)0 #0NG  T+N@ -"M( #0KJ %P/  !.$0  0Q(  #H3
M   R$P  +!,  "<2   C$0  'Q$  !P0   :$ ( & \$ !8.!P 5#@D % T+
M !,,#0 2#!  $@P4 !$,&@ 1#2  $ TH  \-,  .#CL #0Y&  T.40 ,#UX
M"P]M  H/?P )#Y, "0^F  @.N0 (#M  !P[H %@1  !+$@  0!,  #<4   P
M%   *10  "44   A$P  '1(  !H2   7$0( %1$% !,0!P 2$ D $0\* ! .
M#  .#@X #@\2  T0&  -$!X #! E  P0+0 +$38 "A%!  D130 ($EH !Q)J
M  82?  %$I  !!*D  ,1N  #$<\  A'H %42  !)%   /A4  #46   M%@
M)Q8  "(5   >%   &Q0  !@3   5$@, $Q(% !(1!P 0$0D #Q$*  T1"P ,
M$@X "Q(1  H2%0 )$QL "1,B  @3*@ '%#, !10^  052@ #%5@  A5G  $5
M>@  %8X  !6C   4MP  %,\  !/I %(4  !&%@  .Q<  #(7   K%P  )1<
M "$6   <%@  &14  !84 0 4$P0 $A,& !$2"  /$@@ #A,)  P4"@ *%0T
M"!80  86$P %%AD !!<?  ,7)P "&#   1@[   91P  &54  !ED   9=P
M&8P  !BB   8MP  %\\  !?J $\6  !#&   .1D  # 9   I&0  (QD  !\8
M   ;%P  &!8  !45 @ 3%04 $10& ! 4!@ .%0< #!8(  H7"@ '&0P !!H.
M  (;$@ !&Q8  !L=   <)   '"T  !PX   =1   '5(  !UB   ==0  '8H
M !R@   <M@  &]   !KK $P8  ! &@  -AL  "T;   F&P  (1H  !T9   9
M&0  %Q@  !07 P 2%@0 $!<$  X7!  ,&04 "AH'  <<"0 #'0L  !\-   @
M$   (!0  "$:   A(@  (2H  "$U   B00  (D\  ")?   B<@  (8@  "&?
M   @M@  ']$  !_M $@:   ]'   ,QT  "L=   D'0  (!P  !P;   8&@
M%AD! !,9 0 1&0$ #AH!  P< @ *'0, !Q\%  ,A"   (@H  "0,   F#@
M)A(  "88   G'P  )R<  "<R   G/@  )TL  "=<   G;@  )H4  ":=   E
MM   )-$  "/N $0=   Y'P  ,!\  "@?   C'@  'AT  !L<   8&P  %!P
M !$<   .'0  #1\   HA   &(@$  R0$   F!@  * @  "H+   K#0  +1
M "T5   M'   +20  "XN   N.@  +D@  "U8   M:@  +8$  "R:   KL@
M*M   "GO $ @   V(0  +2$  "8A   A(   '1\  !H>   6'@  $A\   \A
M   -(@  "B0   8F   "*    "L"   M!   +P8  # )   R#   - X  #42
M   U&   -2   #4J   U-@  -4,  #53   T9@  -'P  #.6   RKP  ,<T
M ##O #PC   R)   *B0  "0C   @(@  '"$  !<A   3(P  $"4   TG   )
M*0  !2L   $N    ,    #(    T 0  -@0  #@&   Z"0  / T  #X0   ^
M%   /AP  #XF   ^,0  /C\  #U.   ]80  /'<  #N1   ZJP  .<D  #CM
M #<G   O)P  *"8  ",E   ?)   &24  !0F   0*   #2L   DN   %,
M #,    U    .    #H    \    /@$  $ #  !"!P  1 H  $8-  !)$0
M21<  $@A  !(+   1SH  $=)  !&6P  17$  $2+  !#I0  0L,  $'H #0J
M   L*@  )R@  "(G   <*   %BH  !$M   -,   "3,   ,V    .0   #P
M   ^    00   $,   !&    2    $H   !, P  3@8  % *  !3#@  5!,
M %0<  !3)P  4S0  %-#  !250  46H  %"#  !/G@  3;D  $S@ # M   K
M+   )BL  !\L   8+@  $C(   TU   (.0   CT   !     0P   $8   !)
M    3    $X   !1    4P   %4   !7    60$  %P&  !?"@  8@X  &,5
M  !C'P  8BP  &$\  !@3@  7V(  %Y[  !<E@  6[   %G/ "\P   J+P
M(C   !HS   3-P  #CL   @_   !1    $@   !,    3P   %(   !5
M6    %L   !=    8    &(   !D    9@   &D   !M!0  < L  '00  !T
M&   <R4  '(T  !R10  <%D  &]Q  !MBP  :Z8  &K  "XS   E-0  '3@
M !0\   .00  !T<   !,    40   %4   !9    70   &$   !E    :
M &L   !M    ;P   '(   !T    =P   'H   !^    @@0  (8+  "*$0
MB1P  (@K  "&/0  A%(  (-G  "!@0  ?YL  'ZR "DZ   @/0  %D(   ](
M   (3@   %0   !:    8    &0   !I    ;@   '(   !V    >@   'T
M  "     @@   (4   "(    BP   (X   "2    E@   )L#  "@#   HA,
M * A  "?,P  G4<  )I>  "8=P  EX\  )6G "-#   92   $4X   E5
M7    &,   !J    <0   '8   ![    @    (8   "*    C@   )$   "3
M    E@   )D   "<    H    *,   "G    JP   +    "V!   O T  +H7
M  "Y*   MSP  +12  "R:@  KX4  *V< !Q.   35   "UP   %D    ;
M '0   !\    @P   (D   "/    E    )H   "?    H@   *0   "G
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M____________________________________________________
M              $#! 4&" D*"PT.#Q$2$Q06%Q@:&QP='R A(B0E)B@I*BLM
M+B\P,C,T-C<X.3L\/3Y 04)$149'24I+34Y/4%)35%576%E;7%U>8&%B8V5F
M9VEJ:VQN;W!Q<W1U=WAY>GQ]?H"!@H.%AH>(BHN,CH^0D9.4E9:8F9J<G9Z?
MH:*CI*:GJ*JKK*VOL+&SM+6VN+FZN[V^O\'"P\3&Q\C)R\S-S]#1TM35UM?9
MVMO=WM_@XN/DYN?HZ>OL[>[P\?+T]?;W^?K[_/[_____________________
M_________________________________P ! @,$!08'" D*"PP-#@\0$1(3
M%!46%Q@9&AL<'1X?("$B(R0E)B<H*2HK+"TN+S Q,C,T-38W.#DZ.SP]/C]
M04)#1$5&1TA)2DM,34Y/4%%24U155E=865I;7%U>7V!A8F-D969G:&EJ:VQM
M;F]P<7)S='5V=WAY>GM\?7Y_@(&"@X2%AH>(B8J+C(V.CY"1DI.4E9:7F)F:
MFYR=GI^@H:*CI*6FIZBIJJNLK:ZOL+&RL[2UMK>XN;J[O+V^O\#!PL/$Q<;'
MR,G*R\S-SL_0T=+3U-76U]C9VMO<W=[?X.'BX^3EYN?HZ>KK[.WN[_#Q\O/T
M]?;W^/GZ^_S]_O]M9G0Q      ,$(0   0                    $
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MI9>2YJ67DN:EEY+FI9>2YJ67DN;:RPD;Z,T..NG,$&#<R Z2R[HRK,:W4+3
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M@:>,SX"GC<^ IXW/@*>-SX"GC<^ IXW/@*>-SX"GC<^ IXW/@*>-SX"GC<^
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ME7*PQ95]M<.7A;C!EXN[OY.,O;Z/CL"\C(_"NXF2Q+J&E,6Y@Y;&N8&9Q[B
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MKWRHRZ]\J,O_LA<)_[(A'O^O+SK_JCQ9[*1)>MB;6IG&EG&RQ)AXM<*9@;G
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M@:.1U("DF=. IJ'1@*:AT8"FH=& IJ'1@*:AT8"FH=& IJ'1@*:AT8"FH=&
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M9>J77W[<DVZ3SY)XI<:2@K3$DHFVPY&.N,&.D+K BI*\OX>4O;Z$EK^^@IG
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M&RSET \RR.D/2K3R%6>BXB)]EM8WC8_.3YB,R&&@BL1NIHK!>*J'OWVMA+Z
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MS(R-JL>*D;'$B)2VPX66N,*#F;G"@9NYP7^>NL%]H;O!>Z2[P'JGN\!YJKS
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MLJO+<+:KRV^\J\APP*O$<<"JQ'' JL1QP*K$<<"JQ'' JL1QP*K$<<"JQ''
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MA]_&6X[6R&N4QKUQIK6S>+6EJ('#E)^-S8F<HM*'E*?,B)&KQXF/KL.)CK#
MB8VROHJ,L[R*B[2ZBHNTNHJ+M+J*B[2ZBHNTNHJ+M+J*B[2ZBHNTNHJ+M+K_
MG! !_Z$F"O^@-AS_GD(Q_Z5 /O^K0$S_L4!9^K=!9/.]1&_NQ4EWY<Y2?-W6
M8G_,SFB2O,5NI*N[=K2:L7_!BJJ*RW^GG<^ GZC,@IFKQX.5K<2$DZ_!A9&Q
MOX:/L[V'CK2[AXZTNX>.M+N'CK2[AXZTNX>.M+N'CK2[AXZTNX>.M+O_G1 !
M_Z(F"O^@-1S_H#\P_Z<]/?^N/$K_M3Q5^KT]8/#&0F?FT4ILWMY.=LW:5X>^
MT&*6KL5NI:&\>;*5M(.]AJV(QGNJE,IXJZC)>Z*KQWZ<K<2 F:_"@9:PP(*4
MLKZ#DK.\@Y*SO(.2L[R#DK.\@Y*SO(.2L[R#DK.\@Y*SO(.2L[S_GA !_Z(F
M"O^A-!S_HCPN_ZHZ._^R.$?\NS=1\L4Z6.;105S;WD)IS>)&?+[748RNS%^;
MH<-MJ)B\>;*1M82[A;&)PGRND<5XKI_%=:VLQ7BEKL1ZH*_"?)RPP'Z9L;Y_
MEK*]?Y:RO7^6LKU_EK*]?Y:RO7^6LKU_EK*]?Y:RO7^6LKW_GA !_Z,E"?^B
M-!S_I3DM_ZXU./^X,T+TPS-*Y] X3MG>.5K+YCUNON!"@*[44)"ARU^=F,-M
MJ)&]>;&+N(.X@[2(O7VQD,%YL9K!=;&EP7*OK\)UJ*_!=Z.PP'F?L;][G+*]
M>YRRO7N<LKU[G+*]>YRRO7N<LKU[G+*]>YRRO7N<LKW_H! !_Z0D"?^C,AS_
MJ#0K_[,O-/F_+3SIS2] V=XO2LKG-%^]ZCISK]Y!@Z'349&7RV"=D,1NIHR_
M>JV&NX&S?[B'N'JVC;MWM96\=;6?O'*TJ+UNL[*^<:RROG2GLKYVH[*]=J.R
MO7:CLKUVH[*]=J.RO7:CLKUVH[*]=J.RO7:CLKW_H1 !_Z4C"?^D,1S_K2XG
M_[DI+^[()C/:W"8WRN<L3[WR,F.OZ#EUH=U"A);44Y"/S6*:BL=PHH;#>JB
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MA! !_X,: _^+*@S_G#$2_Z4T&O^L-B'^LSHH\[M +>G#2#'ARU$WTL=62\7
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M*2C_HBHG_ZTK)O^Y+";_R2TF_\DM)O_)+2;_R2TF_\DM)O_)+2;_R2VJMP
MFL4  (O3  !]X@  =?\% &G_# %?_Q$"5_\7 U#_'P5)_R8'1/\N"3__-@L[
M_ST--_]##S/_21$P_T\2+O]5$RS_6Q0J_V(5)_]I%B7_<A<C_WL8(?^&&1__
MD1H>_YP;'O^E'!W_L!T=_[ ='?^P'1W_L!T=_[ ='?^P'1W_L!V<P   C,X
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M^5;<4_E6W%/Y5MQ3^5;<4_E6W%/Y5MQ3^5;_7AL"_UHE _]4,0;_6#<(_V%
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MDWINCX^#=HB+CGR"B)F!?(:GA7F&N89WA]>%>(7=@WJ#WH%Z@N!_>X'A?7R
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M>&V,Y7AMC.5X;8SE>&V,Y7C_;A,!_WL1 ?^-$ #_G1  ^JP1 -J["P#5R0L
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M1#?_ZD4V_/U%._+_1#[J_T0^YO]&/N;_1C[F_T8^YO]&/N;_1C[F_T;0GP
MO:P  *ZU  "BP@  E<\  (K= P"$_Q(!>_\> W3_*@EL_S,/9/\[%EW_0QM7
M_TH@4?]1)$S_6"=(_V J1/]H+$#_<2X\_WLQ.?^(,C7_EC0S_Z0V,?^V-R__
MT#@N_^\Y+?__.3'__SDS_/\Y,_S_.3/\_SDS_/\Y,_S_.3/\_SG!J   K[$
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M$1/_NA$3_\,2$__#$A/_PQ(3_\,2$__#$A/_PQ*7O@  ALP  '?;  !IYP
M7/T  %3_  !+_P4 0_\, 3W_$0(W_Q<",O\> R[_) ,J_RH$)?\O!"+_-04?
M_SH%'?\_!1K_1088_TL&%O]2!A3_6@<2_V('$/]L!P__=P@-_X0(#/^0" S_
MG @,_Z((#/^B" S_H@@,_Z((#/^B" S_H@C_4" "_TLJ _]$-@7_1SH&_TH_
M"/].20__3U07_T]@'O]-;"3_2GDJ_TB%+O]&D#+_1)HT_T.B-_]"JCC_0;$Z
M_T"Y._] P3S_/\L]_S[</O\^Z#[_/?,^_SW[/_\^_S[_0/\^^D/_/?1$_S[N
M1O\_[D;_/^Y&_S_N1O\_[D;_/^Y&_S__4" "_TLJ _]%-07_2C@&_TT]"/]1
M2 __4E(7_U%>'O]/:B7_37<K_TJ#+_](CC/_1I@V_T2A./]#J3K_0K \_T*X
M/?]!P3[_0,L__T#<0/\_Z4#_/_1 _S[]0?] _T#]0O] ]D7_0/!&_T'I2/]!
MZ4C_0>E(_T'I2/]!Z4C_0>E(_T'_41\"_TPI _]'- 7_338&_U$["/]51A#_
M5E 8_U5<'_]2:";_4'0L_TV ,?]*C#7_2)<X_T:@._]%J#S_1+ ^_T.X/_]#
MP4'_0LQ!_T'>0O]!ZT/_0/5#_T#]0_]#_T/X1O]"\$C_0^I)_T3C2O]%XTK_
M1>-*_T7C2O]%XTK_1>-*_T7_4A\"_TTI _]*,@3_4#,&_U4Y"/]90Q#_6DT8
M_UE8(/]69"?_4W$M_U!],_]-B3?_2Y0Z_TF>/?]'IC__1JY!_T6W0O]$P43_
M1,Q%_T/?1?]"[4;_0O=&_T/]1OE&_T;P2?]&Z4O_1^),_TC;3?](VTW_2-M-
M_TC;3?](VTW_2-M-_TC_4QX"_TXH _].+P3_5# &_UHV"/]>0!#_8$H8_UY5
M(/];8"C_6&TO_U1Y-/]1A3G_3I$]_TR;0/]*I$+_2:U$_TBV1O]'P4?_1LU(
M_T7A2?]$[TK_1?A*^T?]2O%*_TGH3?]+WT[_3-=/_TS/4?],SU'_3,]1_TS/
M4?],SU'_3,]1_TS_5!T"_U G _]2+ 3_62T%_U\R"/]D/!#_9D<8_V12(/]A
M7"C_76@P_UIU-O]6@3O_4HT__T^80_]-HD7_3*M(_TJU2?])OTO_2,Q,_TCA
M3?]([DW\2/E.\DO\3>=._4_=4/U0TE+^4,Q3_U'&5/]1QE3_4<94_U'&5/]1
MQE3_4<94_U'_51T"_U$G _]6*03_7BH%_V0O"/]J.@__;$47_VQ/(/]H62C_
M9&,P_V!P-_]<?#W_6(A"_U631O]3G4G_4:9+_T^P3?].ND_]3<90^DW94?9,
MZE'R3?=1YU#Z4MM2^U3.5/Q5QU;]5<%7_E6\6/Y5O%C^5;Q8_E6\6/Y5O%C^
M5;Q8_E7_5QP"_U(F _]:)@3_8B8$_VHL!_]Q-P[_<T(6_W-,'_]P5BC_:V P
M_V9K./]C=S[^7X-$^UN.2/E8F$SW5J%/]56K4?-3M5/Q4L%4[U'05>M1YU7F
M4O96VE3Y6,Q6^EG#6/M:O%K[6K=;^UFS7/M9LUS[6;-<^UFS7/M9LUS[6;-<
M^UG_6!L"_U,E _]>(P/_9R,$_W J!O]W-0W_>D 5_WI*'?]X4R;_<UPO_&YF
M-_AI<C_T97Y%\6&)2NY>DT[K7)U2Z%FF5>98L%?D5[Q8XE;,6=Y6Y%G85O1;
MRECW7<!:^%ZX7/A>LUWX7JY>^%VK7_E<JU_Y7*M?^5RK7_E<JU_Y7*M?^5S_
M61L"_U8C _]B( /_;" #_W4H!?]],PO_@#T3_X%'&_]_4"3Y>UDM]'9B-NYQ
M;3[J;'E%YFB$2^)DCE'>89A5VUZB6=9<K%O36[A>T%K&7\U:WV#(6O)AOESU
M8K5>]&*N8/5BJF'U8:9B]F&C8_=?HV/W7Z-C]U^C8_=?HV/W7Z-C]U__6AH"
M_UDA O]F'0+_<!X#_WHF!/^",0G_ACL0_XA$&?F&32'R@U8KZWY>-.5Y:3W@
M='1%VF]_3--JB5//9I)8RV.<7<=AIF#$7[%CP5Z_9+Y>TF6Z7^QFLF#R9JMB
M\F:E9/)EH67S9)]E]&.<9O5BG&;U8IQF]6*<9O5BG&;U8IQF]6+_6QH"_UP?
M O]I&P+_=1P"_WXD _^'+@C_C#@.^XY"%O*.2A[KBU(GY(=;,-V!9CK3>G!%
MS75Z3LAP@U7#;(U;OFF68+IFH&2W9*MGM&.X:;%BRFJN8^9JJ&3O:J)F[VF=
M9_!HFFCQ9YAI\F:6:?-DEFGS9)9I\V26:?-DEFGS9)9I\V3_6QD"_U\< O]L
M& +_>1L"_X,A _^,+ ;_D38+]90_$NR51QGDDT\BW(Y8+=*'8CK*@6Q%PWMU
M3KYV?U:X<HA=M&Z18J]KFV:K::9JJ&>S;*5GPVZB9^!NGFGM;9EJ[FR6:^]J
MDVSP:9)L\6>0;/)FD&SR9I!L\F:0;/)FD&SR9I!L\F;_7!D!_V(: O]P%@+_
M?!D"_X8? O^0*03ZEC,)\)H\#N>;1!7?FDL=TY15+,J-7SG"AVE%NX%Q3[5\
M>U>O>(1>JG2-8Z5QEVBA;J)LG6RN;YILOG"8;-EQE6WK;Y%N[&Z/;^ULC6_O
M:HQO\&F+;_%GBV_Q9XMO\6>+;_%GBV_Q9XMO\6?_71D!_V09 O]R% '_?Q@!
M_XH= ?^4)@/VFS &ZY\X"N*B/Q#8GT<<S9E2*\2273F[C&9$M(=N3JV"=U>G
M?8!>HGF)9)UVDVF8<YYME'&J<9!QNG*.<=%SC'+J<8ISZV^(<^UMAW/N:X=S
M[VJ&<O!HAG+P:(9R\&B&<O!HAG+P:(9R\&C_7A@!_V<7 ?]U$P'_@Q8!_XX:
M ?Z8(P+QGRP$YZ4S!]VH.0S1HT4;QYU0*KZ76CBUDF-$K8QL3J:'=%>@@WQ>
MFG^&9)5\CVJ0>9INBW>F<HAVMG2%=LQTA'?I<H-WZG""=^QN@G;M;()V[VJ!
M=O!I@7;P:8%V\&F!=O!I@7;P:8%V\&G_7A@!_VD5 ?]X$@'_AA0!_Y$8 ?J<
M'P'MI"<"XJHL!-:L- O+IT,:P:).*;B<6#:OEV%#IY%I3:"-<5:9B'E>DX6"
M9(V!C&J(?Y=O@WVD<G]\LW1]?,AU?'WH<WQ\ZG%\>^QO?7KM;7UY[FM]>?!I
M?7GP:7UY\&E]>?!I?7GP:7UY\&G_7Q@!_VL3 ?][$0'_B1, _Y45 /6@&@'H
MJ2 !W; D ="P,@K&K$$8O*9,)[.A5C6JG%]!HI=G3)J2;U63CG==C(N 9(:(
MBFF!A95N?(.A<G>"L'1U@L5U=(/G<W6!ZG%V?^MO=W[M;7A][FMX?/!I>'SP
M:7A\\&EX?/!I>'SP:7A\\&G_8!<!_VX2 ?]^$ #_C!$ _YD1 /&D$P#CKA8
MUK8< <NT, C!L#\7MZM+):VF5#.DH5U G)UE2I28;%.,E71;AI%]8G^.AVAY
MC))M=(J><7"(K71MB,%T;8GD<V^'ZG%PA.QO<H/M;7.![FMT@/!I=(#P:72
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M4T?(]U5(P/Q82KC[64RR^UI.K?I:3JWZ6DZM^EI.K?I:3JWZ6DZM^EK_?P
MW),  ,JB  "\K $ L;4  *C  P"?RP8 EMD+ )'@&P&*WRP&@M\Y#GG>0Q=Q
MW4T@:MQ6*&/;7R]=VF<U6-EQ.E/9>SY/V8A"2]F614C9ID=&VKI(1=O;1T38
M]$E"T_]-1,G_3T7"_U!'N_]21[O_4D>[_U)'N_]21[O_4D>[_U+FB@  SYL
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M*BS__RHO^?\J+_G_*B_Y_RHO^?\J+_G_*B_Y_RJYI@  JJX  )RY  ".Q0
M@=$  '7>  !M^@D 9?\1 5[_&@)7_R,#4O\L!4S_- =(_SP*0_]$##__3 X\
M_U,0./];$C7_8Q0R_VP6+_]W%RS_A!DI_Y,:)_^B'"7_M!TD_\P>(__M'B+_
M_1\B__\?(O__'R+__Q\B__\?(O__'R+__Q^LJP  G;8  (_"  " S@  <]P
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M&P+_9QL"_VXB _]S*@3_=S4)_WA $/EW2ACR<U0@[&]>*.=K:C#B9W4VWF.
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M6(-O_%B#;_Q8@V_\6(-O_%C_5A@!_V01 ?]R#@#_?A  _X@1 /61% #HF!D
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M75:=ZUQ7FOI;6I7Z6ER1^UE>COQ87XW\5U^-_%=?C?Q77XW\5U^-_%?_:@H
M_WP  -R,  #-F   PZ,# +JJ @"SLP$ K+P* *:]'0&>O"\&EKH\$8VX1QR%
MM5 G?;-9,':Q8#AOKV@_::UP16.K>4I>JH1/6JF04E6HGE52IZ]74:C&5U"G
MZE=0I?Q74Y_]5U6:_597EOY66)7^55B5_E58E?Y56)7^55B5_E7_;P0 YH(
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M0$##_T)!O?]#0KG_1$*Y_T1"N?]$0KG_1$*Y_T3=B   QY@  +BC  "KJP
MH+0  )6^  "+R , @-$' 'CA#0!TX1T!;N$K VC@-PAAX$(.7.!-%%?@5AE3
MX%\=3^!I(DO@<R5'X'XH1."+*T+@FBT_X:LO/N+!+S[BY2\\W_HQ.=[_-#G9
M_S8ZT/\X.\S_.3O,_SD[S/\Y.\S_.3O,_SG-D@  O*   *VH  "AL0  E;L
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M$Q[__Q,>__\3'O__$Q[__Q.FJ0  F+,  (J_  ![R@  ;M4  &#?  !4YP
M3O\$ $G_#@!#_Q0 /_\= 3K_)0(V_RP",O\S R__.@,K_T$$*/](!"7_3P4B
M_U<%(/]@!AW_; <:_WD'&/^*"!;_FP@5_ZT)%/_#"1/_XPD3__@)$___"A/_
M_PH3__\*$___"A/__PJ:L0  B[T  'S(  !MU   7^   %'F  !']0  0?\
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M5F=_XU5H@/I3:7[_46I\_T]K>_]-;'G_3&QY_TQL>?],;'G_3&QY_TS_7@P
M_VP! .9Z  #6A@  RX\" ,27! "^G00 N*(. +&C(0&IHC('H9\_$9F<2AN2
MF5,EBY9<+8638S5_D6L[>HYS076,?$9PBH5+:XB13V>'G5)DAJQ48H:_56&&
MX51AAOE28X3_4&6!_T]F?_]-9W[_3&=^_TQG?O],9W[_3&=^_TS_80H _V\
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M25"9_TE2EO](5)+_1U22_T=4DO]'5)+_1U22_T?_;@  WG\  ,J-  "^F
MLZ   *JG  "AK@  E[8  )&Z$ ",NB,!A;DR!GZX/@YWMDD7<;52'FNS6B5E
MLF(K8+%J,%NP<S57KWTY4ZZ)/4^MED!,K:5"2JVY0TFNV$)(J_5#1ZK_1$FE
M_T1+H/]$39S_1$V<_T1-G/]$39S_1$V<_T3J=0  TH8  ,.3  "WG0  K*0
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M+3;*_RTVRO\M-LK_+3;*_RW%D   MIT  *BE  "<K0  C[8  (.^  !WQP
M;,\" &+6!P!:Y X 6.0< %3D*0%0Y#4#3.4_!4CE20=%Y5,*0N9<#3_F9@\\
MYG$2.N=^%#?GC!8UYYP7,^BN&3+IQADRZ.H9,>7^&2_D_QPNY/\>+>+_("WB
M_R MXO\@+>+_("WB_R"ZF@  JJ,  )VK  "0M   @[T  '?&  !KSP  7]8
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M!0[__P65KP  AKH  '?%  !HT   6ML  $SA  ! YP  -_,  #+_   N_P<
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M4@X _UT# /UI  #A<@  UGH" ,Y_!0#*@P@ Q882 +R')@&UAC8&KH-##Z>
M3ABA?%@@FWE@)Y9W:2V2=' SCG)Y-XIP@3R&;HL_@VV50W]LH45\:ZY'>FN_
M2'AKW4AX;/9&>&S_1'=L_T)W:_] =VK_/W=J_SYW:O\^=VK_/G=J_S[_5 P
M_U\  /)L  #==@  T'T" ,F#! #$AP8 OXH0 +>,(P&PBC0%J8A!#J*%3!><
M@54?EG]>)I%\9BV,>6XRB'=V-X1U?SN =(@_?'*20WAQGD9U<*Q(<V^]27%P
MV4EQ</1'<7'_1')P_T)R;_]!<F[_/W)N_SYR;O\^<F[_/G)N_S[_5@H _V(
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M1&!__T)A??]!8GO_/V-Z_S]C>O\_8WK_/V-Z_S__7@  Z6T  -9Y  #(A
MOHP  +:3  "NEP  IIL$ *"=%P":G2D"DYPW"(R:0Q"&F$T8@)95'WJ4729U
MDF4L<)!L,6R.=39GC7XZ8XN)/E^*E4%<B:-$6HFT15B)RT58B.U$6(C_0UF&
M_T%;@_] 78'_/EV _SY=@/\^78#_/EV _S[_8@  Y'$  ,]^  ##B   N9$
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M-TF:_S=)FO\W29K_-TF:_S?B=   RH,  +R/  "PF   I9X  )ND  "0JP
MA;$  'JX! !VN10 <KDE 6VY,P1HN#\(8[A)#EZW4A-:MEH85K9B'%*U:R!.
MM'4D2[2 )TBSCBI%LYTL0K.N+4&SQ2Y!L^DM0+#^+S^O_S$^K?\R0*C_,D&F
M_S)!IO\R0:;_,D&F_S+5?   PHH  +66  "HG0  G:,  )*J  "'L0  ?+<
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M%BC:_Q:SF   I:   )FG  "+L   ?K@  ''   !ER   6<X  $[3  !$VP0
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M 0O_B@(*_Y\""?^U @C_U0('__0"!___ @?__P('__\"!___ @?__P*1K0
M@K@  '/"  !DS   5M4  $C=   [X@  ,.<  "?N   C_P  (/\$ !S_#  9
M_Q$ %O\6 !/_&P 1_R$ #O\G  W_+@ *_S8 !_\^  3_2   _U0  /]B 0#_
M<P$ _X<! /^= 0#_L@$ _\H! /_J 0#_\P$ __,! /_S 0#_\P&$MP  =,$
M &7,  !6V   1]\  #GE   MZ@  (^X  !S]   8_P  %?\  !'_!  /_PL
M#?\.  G_$0 &_Q4  _\:  #_(   _R8  /\N  #_-P  _T$  /]-  #_7
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M4A&L9EP8J&1E':1B;2*A8'4FGEY^*9M=ABV87(\OE5J9,I-9I#206; VCEG
M-HQ9VS>*6?,VB5K_-(A;_S.'6_\QAEO_,(5;_R^%6_\OA5O_+X5;_R__2PP
M_U0  /M>  #B90  V&L! ,]N!0#,< @ QG(2 +YS)@&W<S8$L7!$"JMN3Q&F
M:UD8H6EA'9UG:B*997(GEF-Z*I-B@RZ08(PQC5^5-(I>H#:'7JTXA5V\.8-=
MU#F"7O X@5__-H!?_S2 7_\S?U__,7Y?_S!^7_\P?E__,'Y?_S#_30D _U8
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M.6UL_S=N;/\U;FO_-&YJ_S)N:O\R;FK_,FYJ_S+_4P  ]%\  -YJ  #-<P
MPWH  +M^  "U@0  KH,) *B%&@"BA2L"FX0Z!Y6"10Z0?T\5BGU8&X9[7R"!
M>6<E?7=O*GIV=RYV=( R<W.+-6]RECAL<:,Z:7"R/&APQCQG<.<[9W'\.6AQ
M_S=H</\U:6__-&EN_S-I;O\S:6[_,VEN_S/_5@  ZV(  -AN  #)=@  OWT
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M,UE]_S)9??\R67W_,EE]_S+O8   VVX  ,=Z  "[@P  LHL  *B0  "?DP
ME)8  (V9#@")FAX A)HN GZ9.@=YET4-=)9.$V^55AAJDUX=9I)E(6*1;29>
MCW8J6XZ!+5>-C3!4C)HS48RJ-4^,O35/C-XU3XOW-$^*_S-0B?\R48;_,5*$
M_S%2A/\Q4H3_,5*$_S'J90  TG,  ,)_  "VB   K)   **4  "8F   C)P
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M)CND_R;,>@  NX@  *Z2  "BF0  EYX  (RD  " J@  =:\  &FT  !>N08
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M!2C9L08GVLT&)]?O!B;4_PDETO\+)-'_#"/0_PTCT/\-(]#_#2/0_PVNE@
MH)T  )2D  "&K   >;0  &R[  !@P@  5,8  $C+   ^T   -=4$ "W="@ L
MX1, *^(? "GC*@ HY#4 )^0_ ";E2@ DYE4 (^9A 2'G;@$@YWX"'NB0 AWI
MI (;Z;P"&NKB AKF_ (9Y?\#&>3_!!CC_P48X_\%&./_!1CC_P6CG0  EJ0
M (BL  !ZM0  ;+T  %_$  !3R@  1\X  #S3   RV@  *M\  "7N"0 C\!$
M(?$9 !_Q(@ =\BL &_,T !GT/@ 7]$@ %?52 !/V7P 2]FX!$?>  1#XE $/
M^:H!#OG& 0[Y[0$-]O\!#?3_ 0WS_P$-\_\!#?/_ 0WS_P&9HP  BZP  'RU
M  !MO@  7\8  %+-  !%T@  .=@  "_>   FX@  '^H  !S[!@ 9_PX %_\3
M !3_&@ 2_R$ $/\H  [_,  -_SD "_]#  G_3@ &_UP !/]L  +_@  !_Y8
M /^M  #_R@  __   /__  #__P  __\  /__  #__P"-JP  ?;4  &Z_  !@
MR   4M   $/7   WW0  *^(  "+F   9Z@  %?D  !+_   0_P@ #O\.  S_
M$0 )_Q8 !O\<  /_(@  _RH  /\S  #_/0  _TD  /]7  #_:0  _WX  /^5
M  #_K   _\<  /_H  #_^@  __H  /_Z  #_^@" M0  <+\  &')  !2TP
M0]L  #7A   IY@  'NH  !7N   0^   #O\   O_   (_P  !/\&  #_"@
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M'Z=&X""D1O0@H4;_(9]'_R">1_\@GD?_'YM'_QZ:1_\>FD?_'II'_Q[_0 T
M_T8$ /],  #X4@( Z%4$ .%5" #B50T U549 ,Q7+ #%5SP"OU9*!KI550JV
M4U\.LE)H$J]0<16L3WD8JDZ!&JA-BAVE3)(?HTR<(*%+IB*?2[$CG4O ))M+
MV"692_ EEDS_))5,_R243/\CDTS_(I%-_R&13?\AD4W_(9%-_R'_0@H _TD
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M+'M:_RI[6_\H>UO_)WM:_R9Z6O\E>EK_)7I:_R7_20  ^U(  .-<  #28P
MQV@  ,!K  "Z:P( M6L- *YM'0"H;BX!HVT\!9UK2 J9:E$/E&A:%)!F8AB-
M96H<BF-R((=B>B.$88,F@6",*7Y?ERM[7J,M>5ZQ+W==Q"]U7N(O=5[Y+75?
M_RMU7_\I=5__*'5>_R9U7O\F=5[_)G5>_R;_2P  \%4  -Y?  #-9P  PVP
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M*65J_RAE:O\H96K_*&5J_RC]4P  XU\  ,YI  #!<0  MW<  *][  "G?0
MGGT  )A^$0"3@"( CH Q HE_/@:$?4@,?WQ1$7MZ619W>6 :<W=H'F]V<"%L
M=7@E:72"*&9SCBMC<IHN8'&H+UYQNC!=<=0P77'R+EYQ_RQ></\K7W#_*6!O
M_RA@;O\H8&[_*&!N_RCQ50  WF(  ,IM  "]=0  LWL  *N   "B@@  F($
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M)DZ!_R;A8P  R7   +M[  "PA   IHH  )N.  "1D0  A),  'J5 @!UEQ(
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M%SJFKQ@YIL<8.:7J&#BC_QHWH?\;-Z#_'#>?_QPWG_\<-Y__'#>?_QS$>
MM84  *F/  "=E0  DIH  (:?  !ZHP  ;J@  &*L  !5L   4+(. $ZR&P!-
MLR@ 2[,U $FS/P%&LTD"1+-2!$&S6P8_LV0(/+-O"CJS>PPWLXH.-;*:#S.S
MK1 RL\40,K+I$#&P_A(PKO\4+ZW_%2^L_Q8OK/\6+ZS_%B^L_Q:[@0  KHX
M *&5  "6F@  B:   'VF  !QJP  9:\  %FT  !.MP  0[P% $"]$0 _O1X
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M !+@]  2WO\!$=W_ 1';_P(1V_\"$=O_ A';_P*>F@  DJ$  (2I  !VL0
M:+@  %N_  !.Q   0L@  #?,   MT   )-4  !S;   5WP4 %.D. !+J%  1
MZQT $.LF  [L,  .[3H #>Y&  ON4P *[V( "?!T  CQB0 '\J  !?*Z  3Q
MY  "\?T  N__  /M_P #[?\  ^W_  /M_P"5H0  AJD  'BR  !IN@  6\(
M $W(  ! S   --$  "K6   AVP  &>   !+D   /\ $ #?D*  OZ#P )^Q4
M!_L<  3\)  !_"P  /PW  #\0@  _%   /QA  #]=0  _(P  /RD  #\P0
M_.L  /S_  #]_P  _?\  /W_  #]_P")J0  >;(  &J[  !<Q   3LP  #_1
M   RUP  )]T  !WA   5Y0  #N@   KQ   (_0  !?\#  '_"0  _PX  /\2
M  #_%P  _Q\  /\G  #_,0  _SX  /]-  #_7P  _W4  /^-  #_I@  _\(
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M +8 _P"^ /\ R #_ -< _P#G /\ \P#_ /T _P#_ /\ _P#_ /\ _P#_ /\
M_P#_ /\ _P#_ /\ _P#_&RD _QTF /\<)0#_&2< _Q,L /\.- #_"T !_PA.
M ?\%6P'_ V@!_P)T ?\"?P'_ H@!_P*1 ?\"F '_ I\!_P&E /\!K #_ ;(
M_P&Z /\!Q #_ =$ _P#D /\ \0#_ /P _ '_ /P"_P#\ _\ _ 3_ ?P%_P'\
M!?\!_ 7_ ?P%_P'_'R8 _R$B /\@(0#_'B, _Q@G /\3, #_$3P!_PY* ?\-
M5P'_"V,!_PIO ?\*>@'_"H0!_PJ- ?\*E '_"IL!_PJB ?\*J '_"J\!_PJW
M ?\*P #_"LP _PK@ /L*[P#W"OH ]0O_ ?4,_P'T#?\!] W_ O0-_P+T#?\"
M] W_ O0-_P+_(B( _R0= /\D' #_(AT _QXB /\<+ #_&3@ _Q9% ?\34@'_
M$EX!_Q!J ?\0=0'_$'\!_Q"( ?\0D '_$)<!_Q"> ?\0I0']$*P!_!"S ?H0
MO0'Y$<D!]1'= ?$1[0'N$?D![!+_ NL3_P+J$_\#Z1/_ ^D3_P/I$_\#Z1/_
M ^D3_P/_)AT _R@8 /\H%@#_)A8 _R8= /\F* #_(S0 _R!  /\=30'_&UD!
M_QEE ?X9< '\&'H!^1B# ?<8C 'V&),!]!B: ?,8H0'Q&:@!\!FP NX9N@+M
M&<8"ZAK9 N8:ZP'B&_D"X!O_ ]X<_P3='/\%W!S_!=P<_P7;'/\%VQS_!=L<
M_P7_*AD _RT3 /\M$0#_+1$ _RX9 /\M(@#_+"X _RDZ /\F1P'Z)%0!]B-@
M ?(B:P'O(G4"[2)^ NLBAP+I(H\"YR*6 N4BG@+D(J4"XB*M N$CMP+?(\,"
MW2/6 M@DZ@/2)/D%SR7_!LTE_P?+)?\(RB7_",HD_PC*)/\(RB3_",HD_PC_
M+A0 _S$0 /\R#0#_- X _S44 /\U' #_,R< ^C$T /,O00#N+4X!Z2Q: >4L
M90+B+' "WRMY MTK@@/:*XL#V"N2!-4KF@33*Z($T2NJ!<\KLP7-*[\&S"S/
M!L@MYP?$+?<)P2W_"K\M_PN]+?\,O"W_#+PL_PR[+/\,NRS_#+LL_PS_,1$
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M&X]'_QJ.1_\9CD?_&(U'_QB-1_\7C4?_%XU'_Q?_/@( _T,  .M+  #=40
MT50  ,I4 0#&4@4 P5$1 +E3(@"S53,!KE1! JI43 6F4U8(HE%?#)]09P^=
M3V\1FDYW%)A.?Q:638@8DTR1&9%,FQN/2Z8=C4NS'HM+Q1Z)2^(>ATSW'H9,
M_QV%3/\<A4W_&H5,_QF%3/\9A4S_&85,_QG_0   _$<  .50  #55@  RED
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M'G!:_QUP6O\<<%K_''!:_QS_2   YU(  --;  #%8@  NV8  +-H  "L:
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M'EMJ_Q[K4P  TV   ,)I  "V<0  K'8  *-Y  "9>0  C7<  (=Y"P"#>Q@
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M'DF!K!](@,$@1X#C'T=_^AY(?O\>2'W_'4E\_QQ)?/\<27S_'$E\_QS680
MPFX  +1X  "J@   GX4  )2'  "(AP  >XD  '",  !KC@T :(\: &:/*0!B
MD#4!7X\_ UR/2 59CE (5HY8"U.-8 Y0C&@038QR$TJ+?19(BHH818J9&D.*
MJAM"BK\;08KA&T&(^1M!AO\;087_&T*%_QI"A/\:0H3_&D*$_QK-9P  O'0
M *]^  "EA@  FHH  (Z,  ""C0  =9   &>4  !AE0@ 7I<4 %R7(P!:F"\
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M""RJ]0HKJ/\+*J;_#"JE_PTJI?\-*J7_#2JE_PVU@   J(L  )R1  "1E@
MA9P  'B@  !KI0  7Z@  %.L  !(KP  /;(  #:U"P TM14 ,[8A #*V+  Q
MMS< ,+=! "^X2P NN%4 ++A@ 2JX;0$IN7L")[F- B6YGP,DN;0#([G2 R.W
M] 0BM?\%(;3_!B&S_P<ALO\'(;+_!R&R_P>MB@  H)$  )67  "(G0  >Z,
M &ZH  !AK0  5;$  $JT   _MP  -+L  "N^ P DP@P (L(4 "+#'P APRH
M(,0T !_$/P >Q4H '<96 !S&8P ;QW, &L>% !G'F0 8R*X %\C+ !?&\0$7
MQ/\!%L/_ A;!_P,6P?\#%L'_ Q;!_P.CD0  F)@  (N>  !]I0  <*L  &*Q
M  !6M@  2KD  #Z]   TP   *L0  "+(   9S 0 $] * !'2$0 0TAH $-,E
M  _3,  .U#P #M1(  W55@ -U64 #-9X  S6C0 +V*0 "MB^  G9Y@ *UOX
M"]3_  O2_P +TO\!"]+_ 0O2_P&:F   CI\  ("F  !RK0  9+0  %>Z  !)
MOP  /<(  #+&   HR0  '\T  !?1   1U@  #-L%  C>"P &WQ$ !=\:  3@
M)  "X2X  >(Z  #C1P  Y%8  .1G  #E>P  YI(  .:J  #GR   Y_   .C_
M  #H_P  Z/\  .C_  #H_P"1GP  @J<  '2O  !EMP  5[X  $G#   \QP
M,,L  "7/   <U   %-D   [=   )X0   N4   #I!@  Z0T  .D1  #J&
MZR$  .TK  #O-P  \44  /)6  #S:   \WX  /27  #UL   ]M   /?S  #W
M_P  ]_\  /?_  #W_P"%IP  =K   &:X  !8P0  2L@  #O,   NT0  (]8
M !G<   1X   #.,   3G    Z@   /4   #T    ]04  /4+  #V#P  ]A0
M /@=  #Z)P  _#0  /]#  #_50  _VD  /^!  #_F@  _[(  /_/  #_[0
M__D  /_Y  #_^0!XL   :+H  %G#  !+RP  .]$  "W8   AW0  %N(   [F
M   (Z@   .T   #P    ^    /\   #_    _P   /\   #_!@  _PP  /\0
M  #_&   _R(  /\P  #_0   _U,  /]I  #_@0  _YD  /^O  #_PP  _]4
M /_5  #_U0#_$R@ _Q,E /\1)0#_#2< _P8M /\ -0#_ $$ _P!/ /\ 7 #_
M &D _P!T /\ ?@#_ (@ _P"0 /\ EP#_ )T _P"D /\ J@#_ +  _P"W /\
MP #_ ,P _P#? /\ [ #_ /@ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_
M /\ _P#_%B4 _Q8B /\4(0#_$", _PHH /\ , #_ #T _P!+ /\ 6 #_ &0
M_P!P /\ >@#_ (0 _P", /\ DP#_ )H _P"@ /\ I@#_ *T _P"T /\ O #^
M ,@ _0#9 /L Z0#Z /8 ^0#_ /@ _P#X /\ ^ #_ /@ _P#Y /\ ^0#_ /D
M_P#_&B( _QH> /\8'0#_$QX _PXB /\*+ #_!SD _P-& /\ 4P#_ &  _P!K
M /\ =@#_ '\ _P"( /\ CP#_ )8 _P"= /\ HP#^ *D _ "P /H N0#W ,0
M]0#2 /, Y@#R /0 \0#_ /  _P#O /\ [P#_ .\ _P#P /\ \ #_ /  _P#_
M'AT _QX9 /\<%P#_%Q@ _Q,> /\1* #_#C0 _PQ! /\*3@#_"%L _P=F /\&
M<0#_!GH _P:# /X&BP#\!I( ^@:9 /@&GP#V!J8 ] :M /(&M0#P!<  [07.
M .L%Y #I!O, Y@C_ .4*_P#D"_\ Y O_ >0+_P'D"_\!Y O_ >0+_P'_(1@
M_R$3 /\@$0#_&Q( _QP: /\:) #_%B\ _Q,\ /\120#_$%4 _ YA /D.:P#V
M#G4 ] Y^ /(.A@#P#HX [@Z5 .T.FP#K#J( Z@ZJ .@.LP#F#[T Y0_, .$/
MXP#=$/, V1'_ =82_P'4$_\!TQ/_ M(3_P+2$_\"TA/_ M(3_P+_)1, _R40
M /\D#0#_(PX _R,4 /\B'@#_'RD _QPU /D90P#T&$\ [Q=; .P79@#I%W
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M!ZLN_PBI+O\(J"[_"*@M_PBH+?\(J"W_"*@M_PC_+P@ _S$  /\U  #V-P
MZC8" .<S" #D+P\ V2X; ,\Q+ #),SP Q#1) , U50&\-5\"NC5H K<U< .U
M-'@$LS2 !;$TB :P-) &KC29!ZPTH@BK-*P)J32Y":<TR@JE->4*H37X"Y\U
M_PR=-?\,G37_"YPU_PN<-?\+G#7_"YPU_PO_,P( _S4  /8Z  #E/@  W$
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M$G]'_Q%_1_\1?T?_$7]'_Q'_.P  [D,  -Q,  #,40  P50  +E4  "T40
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M$@"66R( DEPQ 8Y</0**7$<$AUM0!H-:6 F!66 ,?EEG#GM8;Q!Y5W<3=E:
M%716BQ=R5989;U6C&FU4LAML5,8;:E7F&VI5^QEJ5?\7:E7_%FI5_Q5K5?\4
M:U7_%&M5_Q3R0P  WT\  ,M8  "]70  LV$  *MB  "B8   FUP  )5>$ "0
M8!\ C&$N (AA.@*$8$4$@6!.!GY?5@E[7ET+>%UE#G9<;!!S7'03<%M]%6Y:
MB!=K6I09:5FA&V=9L!QE6<,<9%GC'&19^AID6?\89%G_%V59_Q5E6?\495G_
M%&59_Q3O1@  VE(  ,9;  "Z80  L&4  *9F  "=8P  E6$  (]B#@"+9!P
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M&E9GJAM59[T<5&?<'%1G]AI49O\856;_%U5E_Q969?\55F7_%59E_Q7B40
MRET  +MF  "O;   IG$  )EP  ".;P  @VX  'UP!0!X<A( =7,A ')S+P%O
M<SH";'-$!&ER3 9F<E0(8W%;"V!P8PU=<&L06V]T$UAN?Q55;HL74VV9&5%M
MJ!I/;;L;3FW9&DYL]!E/:_\83VO_%U!J_Q90:O\54&K_%5!J_Q7=50  Q6$
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M$SR"\!(\@?\2/8#_$CU__Q(]?O\1/7[_$3U^_Q'%9@  M7$  *I[  "?@@
MDH(  (6"  !Y@P  ;88  %^*  !8C0$ 5(X/ %*/&P!0CR< 3Y S $V0/0%+
MD$4"29!. T:05@1$CU\%0H]H!S^/<PD]CH +.HZ/##B.H TWCK,.-H[,#C:-
M[PXUB_\.-8G_#S6(_P\VA_\/-H?_#S:'_P^^;0  L'D  *6"  "9AP  C(@
M '^(  !RB@  9HT  %J1  !0E0  29<) $>8$P!%F"  1)DK $.9-@!!FD
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M AJL_P,:J_\#&JO_ QJK_P.HB   FX\  )&4  "$F@  =I\  &BB  !;I0
M3ZD  $2M   YL   +[,  ":V   >N04 &+L. !>[%@ 7O"  %KPJ !6]-0 4
MO4  $[Y+ !*^6  2OF< $;]X !"_C  0P*( #L"Z  [ X0 /O?L #[S_ !"Z
M_P$0NO\!$+K_ 1"Z_P&?CP  E)4  (>;  !YH0  :Z<  %ZL  !2L0  1;0
M #JV   ON0  );P  !V_   5PP  #\8%  O*#0 )RA0 ",H=  ?*)P 'RC(
M!LL^  7+2P $S%H  \QJ  +,?@ !S)0  ,RK  #-R   S.T  ,S_  #+_P !
MRO\  <K_  '*_P"7E@  BIP  'RC  !NJ@  8+   %*V  !%N0  .;P  "Z_
M   CPP  &\8  !/*   -S0  "-$   '4"0  U X  -45  #6'@  V"<  -DQ
M  #;/@  W$L  -U;  #>;@  WH0  -^;  #?M   WMD  -_W  #?_P  W_\
M -__  #?_P"-G0  ?Z4  '"L  !ALP  4[H  $6_   XP@  +,8  "')   8
MS0  $-$   O5   $V@   -X   #@ 0  X0D  .(.  #D$P  Y1L  .<D  #I
M+P  ZSP  .U+  #N70  [G$  .^)  #PH@  \+P  /#C  #O^0  \/\  /#_
M  #P_P"!I0  <JT  &.U  !4O0  1L0  #?(   JS   ']   !75   .V@
M!]X   #B    Y@   .D   #J    [    .X%  #O#   \1   /,7  #U(
M^"L  /LY  #]2@  _EX  /]T  #_C0  _Z8  /_   #_X0  __4  /_U  #_
M]0!TK@  9;<  %;   !'R   .,T  "K2   =V   $]T   SB   #Y@   .D
M  #L    \    /,   #T    ]@   /@   #Z    _0<  /\-  #_$@  _QL
M /\H  #_-P  _TH  /]>  #_=@  _X\  /^F  #_N@  _]$  /_1  #_T0#_
M#R0 _PXB /\+(0#_ R0 _P I /\ ,@#_ #X _P!, /\ 60#_ &4 _P!P /\
M>@#_ (0 _P", /\ D@#_ )D _P"? /\ I0#_ *L _P"R /\ N@#_ ,4 _P#3
M /\ YP#_ /0 _P#_ /X _P#_ /\ _@#_ /X _P#^ /\ _@#_ /X _P#_$2$
M_Q > /\-'0#_!Q\ _P C /\ +0#_ #H _P!( /\ 50#_ &$ _P!L /\ =@#_
M '\ _P"' /\ C@#_ )4 _P"; /\ H0#_ *< _@"N /T M@#\ ,  ^P#- /D
MX@#X /  ]P#\ /8 _P#U /\ ]0#_ /4 _P#U /\ ]0#_ /4 _P#_%1T _Q,:
M /\0&0#_"QD _P = /\ *0#_ #8 _P!# /\ 4 #_ %P _P!G /\ <0#_ 'H
M_@"# /P B@#Z )$ ^0"7 /@ G0#W *, ]0"J /0 L@#R +L \0#( .\ W #N
M .P [0#Z .L _P#J /\ Z@#_ .H _P#J /\ Z@#_ .H _P#_&!D _Q85 /\3
M$P#_#A, _PL: /\') #_ C  _P ^ /\ 2P#_ %< _P!B /P ; #X '4 ]0!^
M /( A0#Q (P [P"3 .X F0#L *  ZP"F .D K@#G +< Y@## .0 U #B .D
MX0#W -\ _P#= /\ W0#_ -T _P#= /\ W0#_ -T _P#_&Q, _QH0 /\6#@#_
M$@X _Q(5 /\/'P#_#"L _PDX /\&10#[ U$ ]P)< /("9@#N G  Z@)X .<"
M@ #F X< Y .. .(#E0#A YP WP2C -T$JP#;!+0 V 7  -8%T #3!N< T CX
M ,X*_P#,"_\ RPS_ ,L,_P#+"_\ RPO_ ,L+_P#_'Q  _QX+ /\:!P#_&0L
M_Q@1 /\6&0#_$B0 ^A P /,./@#N#4H Z0Q6 .4,80#B#&H W@US -L->P#9
M#8, U@V* -0-D0#2#9D T Z@ ,\.J0#-#K, RPZ_ ,H/T #&$>D PA+Y +\3
M_P"]$_\!O!/_ ;P3_P&\$_\!NQ/_ ;L3_P'_(@P _R$$ /\@  #_(04 _Q\,
M /\<$0#V&!P [!4H .43-@#?$D, V1-/ -,46@#0%60 S19M ,L6=0#)%WT
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M!I4N_P65+O\%E2[_!94N_P7_+   _RX  .HU  #=.0  T3D  ,HV  #'+P8
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M//\(@3S_"($\_PC_,P  [#H  -I#  #*1P  OTD  +='  "Q0@  K3X* *9
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M"W%&_POS.0  X$0  ,Q,  "^40  M%,  *I2  "B3@  G4H! )=+$0"332
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M$F)4J1-@5+H47U33%%Y4\A->5/\17U3_#U]4_PY?4_\-7U/_#5]3_PWG1
MSU   +]8  "S70  J%\  )Q=  "26P  BU@  (5:"@"!6Q8 ?5PD 'I=,0!W
M73P!=%U& G%=3@1O7%4%;%Q=!VI<9 EH6VP+95IU#6-:?P]A68L17EF8$EQ8
MIQ1;6+@465G0%%E8\!-96/\16EC_$%I8_PY:5_\-6E?_#5I7_PWC2   RU,
M +M;  "P80  I&(  )=A  ".7P  A5P  ']>!P![7Q, >&$A '5B+@!R8CD!
M;V)# FQA2P-J85,%9V%:!V5@8@EC8&H+8%]S#5Y>?0];7HD165V6$E==I1-5
M7;845%W.%%1=[A-47?\155S_$%5<_PY56_\.5EO_#59;_PW>3   QU8  +A?
M  "M9   H&4  )-D  ")8P  ?V$  'EB P!U9!$ <F4> &]F*P!L9S<!:F=
M F=F20-E9E$$8F58!F!E8 A=9&<*6V1P#%EC>PY68X805&*4$E)BHQ-08K03
M3V+,$T]B[1)/8?\13V'_$%!@_PY08/\.4&#_#5!@_PW93P  PUH  +1C  "I
M:0  FV@  (]G  "$9P  >64  '-G  !O:0X ;&H; &EK* !G;#0 9&P] 6)L
M1@)?:TX$76M6!5IJ70=8:F4)5FEN"U-I> U1:(0/3FB2$$QGH1)+9[(226?)
M$DEGZQ))9O\02F;_#TIE_PY+9?\-2V3_#4MD_PW15   OEX  +%G  "F;0
MEVP  (IK  !_:P  <VL  &UM  !H;@P 97 7 &)Q) !@<3  7G$Z 5QQ0P)9
M<4L#5W%3!%5P6@92<&('4'!K"4YO=0M+;X(-26Z/#T=NGQ!%;K 11&['$4-M
MZA!$;/\/1&O_#D5K_PU%:O\-16K_#45J_PW+6   NF,  *UL  "A<0  DG
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M"#""_P@P@?\(,('_"#"!_PBW:P  JG8  *!_  "0?@  @GX  '9_  !J@
M7H,  %.'  !*BP  08X" #V0#@ [D!@ .I$C #F1+0 XDC< -Y)  #:220 T
MDU( ,Y-< 3&39P$ODW0"+9*# RN2E ,JDJ<#*)*]!"B2X0,GD/H$)X[_!2>-
M_P4GC/\%)XS_!2>,_P6Q=   I7X  )F%  "*A   ?80  &^%  !CB   6(L
M $V/  !#DP  .I<  #*:!P NFQ  +9L: "R<)  KG"X *ITX "F=00 HG4L
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M  FR_P":C0  D),  (28  !TG   9:   %>D  !+J   0*P  #6P   JLP
M(;4  !BX   1NP  #+X"  ; "P "P!$  <$9  #!(@  PBL  ,(V  ##0@
MPU   ,1?  #$<0  Q(<  ,2=  #$M0  Q-H  ,3V  ##_P  P_\  ,/_  ##
M_P"3E   AYH  'B@  !JI@  7*P  $^Q  !!M0  -;<  "FZ   ?O0  %L
M !##   *Q@   \H   #,!0  S P  ,T1  #.&   SB$  - J  #1-0  TT,
M -12  #48P  U7@  -6/  #5IP  UL(  -;I  #6_0  UO\  -;_  #6_P"*
MFP  >Z(  &RI  !>L   4+8  $*Z   TO0  *,$  !W$   4QP  #<L   ;.
M    T@   -<   #9    V@4  -P+  #=$   WQ4  .$=  #C)P  Y3,  .="
M  #H5   Z&<  .E^  #IEP  ZJ\  .K.  #K[P  Z_X  .O_  #K_P!]HP
M;JL  %^R  !1N@  0L   #3#   GQP  &\L  !+/   +TP   M@   #=
MX0   .0   #E    YP   .D   #K!P  [0T  .\1  #Q&0  ]"0  /<Q  #Y
M00  ^E4  /IJ  #[A   ^YT  /RV  #\T@  _>T  /WT  #]] !QK   8;4
M %*]  !$Q   -,D  ";-   :T@  $-@   C=    X0   .4   #H    [
M .\   #Q    \P   /4   #W    ^0$  /L(  #^#@  _Q4  /\A  #_+P
M_T$  /]6  #_;0  _X<  /^@  #_M@  _\H  /_4  #_U #_"R  _P<> /\
M'0#_ "  _P E /\ +@#_ #L _P!) /\ 5@#_ &( _P!M /\ =@#_ '\ _P"'
M /\ C@#_ )0 _P": /\ H #_ *8 _P"M /\ M0#_ +X _P#+ /\ X0#_ /
M_@#] /T _P#] /\ _0#_ /T _P#\ /\ ^0#_ /D _P#_#1T _PL: /\$&0#_
M !H _P ? /\ *@#_ #< _P!% /\ 40#_ %X _P!H /\ <@#_ 'H _P"" /\
MB0#_ )  _P"6 /\ G #^ *( _ "I /L L #Y +D ^ #& /8 V0#U .L ] #Y
M /, _P#R /\ \P#_ /, _P#S /\ \P#_ /, _P#_$!D _PX5 /\(% #_ !0
M_P 9 /\ )0#_ #( _P!  /\ 3 #_ %D _P!C /X ;0#\ '4 ^@!] /D A #W
M (L ]@"1 /0 EP#S )X \@"D /  K #N +0 [0#  .L SP#I .8 Z #U .8
M_P#G /\ Y@#_ .4 _P#E /\ Y0#_ .4 _P#_$A0 _Q 0 /\,#P#_ Q  _P 5
M /\ ( #_ "P _P Z /\ 1P#Z %, ]P!> /0 9P#Q '  [P!X .T ?P#K (8
MZ@", .@ DP#G )D Y0"@ ., IP#A +  WP"Z -T R0#; .  V #P -< _@#5
M /\ U #_ -, _P#3 /\ TP#_ -, _P#_%1  _Q(, /\."0#_"PP _PD2 /\#
M&@#_ "8 _0 S /0 0 #O $T ZP!8 .@ 80#E &H X@!R .  >@#> (  W "'
M -H C@#8 )4 U "< -( HP#0 *P S@"V ,P Q #* -D R #M ,< ^P#% /\
MQ '_ ,,!_P#$ ?\ Q '_ ,0!_P#_& L _Q4% /\0  #_$ 8 _P\- /\,% #\
M!Q\ \0,K .< .0#B $8 W@%1 -H"6P#5 F0 T@-L ,\#= #-!'L RP2" ,H$
MB0#(!9  Q@68 ,0%H #"!JD P0:T +\&P0"]"-4 NPGL +@+_0"V#/\ M0W_
M +0-_P"T#?\ M W_ +0-_P#_&P4 _Q@  /\7  #_%@  ^Q,& /H0#@#N#!8
MXPDB -H), #3"CX S@M* ,H,50#'#5X Q0UG ,(.;P#!#G8 OPY^ +T/A0"\
M#XT NA"5 +@0G0"W$*< M1&R +,1P "R$=4 KA/N *L4_@"I%?\ IQ7_ *<5
M_P"F%/\!IA3_ :84_P'_'P  _QP  /H>  #K'@  XQP  -\5!0#>#@T TPX8
M ,L1* #%$S< P!1$ +P63P"Y%UD MQ=A +08:0"S&7$ L1EX *\:@ "N&H@
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M X,O_P/[*0  ZS$  -DX  #)/   OSP  +8Y  "P,@  K"T+ *<O%P"B,28
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M"'!!J0EO0;D*;4'0"FQ![@EK0O\(:D+_!VI!_P9J0?\&:D'_!6I!_P7M-P
MUD(  ,1)  "W30  JTT  *!*  "81P  DT(  (Y##0")11H AD8H (-'- "
M2#\ ?DA( 7M(4 )Y2%<"=TA? W5(9@1S1VX%<4=V!F]'@ =M1HP):T:8"FE&
MI@MG1K8+9D;,"V5&[ MD1_\)9$;_"&1&_P=D1O\&9$7_!F1%_P;H.P  T$8
M +]-  "S40  I5$  )I.  "22P  C4<  (=("P"#2A8 ?TLD 'U,,0!Z33P
M=TU% 75-30)S354"<4U< V]-8P1M3&L%:TQS!VE+?0AF2XD)9$N6"F)+I MA
M2[0,7TO*#%Y+Z@M>2_X*7DO_"5Y*_PA>2O\'7DK_!UY*_P?C/P  RTD  +Q1
M  "P50  H50  )92  "-4   ATP  (%-" !]3Q, >E A '=1+@!T4CD <E)"
M 6]22P%M4E(":U%9 VE1801G46@&95!Q!V-0>PAA4(8*7T^3"UU/H0Q;3[(-
M64_'#5E/Z Q83_T+6$__"5E/_PA93O\'64[_!UE._P??0P  QTT  +A4  "L
M60  G5<  )%5  "(5   @5   'M2! !W4Q$ =%0> '%5*P!O5C8 ;%9  6I6
M2 %H5E "9E97 V167@1B568%8%5O!UU5> A;5(0*6521"U=4H Q54[ -5%/%
M#5-3Y@Q34_P+4U/_"512_PA44O\(5%+_!U12_P?:1@  PU   +58  "H6P
MF5H  (U8  "$5P  >U0  '96 0!Q5P\ ;ED; &Q:* !I6C, 9UL] 65;10%C
M6TT"85I5 U]:7 1=6F0%6UEL!EA9=@A668()5%B/"U)8G@Q06*X-3UC##4Y8
MY Q.6/L+3U?_"4]7_PA/5O\(4%;_!U!6_P?32@  P%0  +)<  "C7@  E5T
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M"#]E_P<_9?\'/V3_!S]D_P?#5P  LV$  *=I  "6:   AV<  'MG  !Q9P
M96@  %QJ  !8; $ 5&X. %)O& !0;R0 3G N $UP. !+<4$ 2G%) 4AQ40%&
M<5D"1'!B T)P; 1 <'@%/G"&!CQOE0<Z;Z8(.&^["#AOVP<X;O8'.&W_!SAL
M_P8Y:_\&.6K_!CEJ_P:]7   KV8  *)M  "1;   @FL  '=K  !L;   86X
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M B&%_P*K<@  H7P  (][  " >@  <WH  &9\  !;?P  4((  $:&   \B@
M-(T  "R1   FDPP ))03 ".4'  BE28 (94O ""5.  ?ED( 'I9, !V66  <
MEF0 &I=T !F7A@ 8EYD %Y>N !67R0 6E>X %I/_ 1:2_P$6D?\!%I#_ 1:0
M_P&E>P  F8,  (F!  ![@   ;((  %^$  !4B   28L  #^0   UE   +9<
M "6:   =G@$ %J , !2A$@ 4H1L $Z$E !*A+@ 1HC@ $:)# !"B3P /HEP
M#J-K  VC?0 -HY( #*.G  JBP  +HN8 #*#^  V?_P -GO\ #9W_  V=_P">
MA   DHD  (.(  !SB   98L  %B.  !,D@  09<  #>;   NG@  )*(  !RE
M   5J   #ZL$  JN#  'K1( !JT;  6M)  $KBX  JXY  &N10  KE(  *YA
M  "N<P  KH<  *Z=  "NM   KM4  *WT  "M_P  K/\  *O_  "K_P"6BP
MC)   'N0  !KD@  798  %":  !$GP  .:,  "^G   EJP  '*X  !2Q   .
MM   ";<   &X"0  N X  +D4  "Y'   NB4  +HO  "[.@  O$<  +Q6  "\
M9P  O'L  +R1  "\J0  O,0  +SK  "[_@  N_\  +O_  "[_P"0D@  @Y@
M '.;  !CGP  5:,  $>H   [K0  ,+$  "6T   ;MP  $KH   R]   %OP
M ,,   #$ @  Q0H  ,4.  #&%   QQL  ,@D  #*+@  S#H  ,U)  #-60
MS6P  ,Z#  #.FP  S;4  ,[:  #.]@  S?\  ,W_  #-_P"&F0  =Z   &FF
M  !:K   3+(  #ZV   PN0  )+P  !F_   1P@  "L4   +)    S    -
M  #1    T@$  -,(  #5#0  UQ$  -H8  #<(0  WRP  .$Z  #B2@  XUT
M .1R  #DBP  Y:4  .7   #EY@  Y?@  .7_  #E_P!ZH0  :ZD  %RO  !-
MM@  /[P  #"_   CPP  %\<   _*   'S@   -$   #6    W    -\   #@
M    X@   .0   #F P  Z D  .D.  #L%0  [AX  /$K  #T.@  ]4T  /9A
M  #W>0  ^),  /BM  #YQ@  ^>0  /GS  #Y\P!MJ@  7K(  $^Z  ! P0
M,<4  "+)   6S@  #=(   38    W0   .$   #D    Z    .L   #M
M[P   /$   #S    ]@   /@#  #Z"P  _1$  /\;  #_*0  _SL  /]/  #_
M9@  _W\  /^9  #_KP  _\,  /_6  #_U@#_!!P _P 9 /\ &0#_ !P _P B
M /\ *P#_ #@ _P!& /\ 4P#_ %X _P!I /\ <@#_ 'H _P"" /\ B0#_ (\
M_P"5 /\ FP#_ *$ _P"H /\ KP#_ +D _P#% /\ V0#^ .P _0#[ /L _P#[
M /\ ^P#_ /H _P#T /\ \ #_ /  _P#_!Q@ _P$5 /\ % #_ !8 _P ; /\
M)@#_ #0 _P!" /\ 3@#_ %H _P!D /\ ;0#_ '4 _P!] /\ A #_ (H _0"0
M /P E@#Z )T ^0"C /@ JP#W +0 ]0"_ /0 S@#S .8 \0#V /  _P#O /\
M[P#_ .X _P#N /\ Z@#_ .H _P#_"Q0 _P81 /\ $ #_ !  _P 6 /\ (@#_
M "X _P \ /\ 20#_ %0 _@!? /L : #Y '  ]P!X /4 ?P#S (4 \@"+ /
MD@#O )@ [0"? .P I@#J *X Z "Y .< QP#E -X XP#P .( _@#@ /\ X #_
M .$ _P#A /\ X0#_ .$ _P#_#1  _PD- /\!# #_  P _P 2 /\ ' #_ "@
M_  V /D 0P#V $X \@!9 .\ 8@#L &L Z@!R .@ >0#F (  Y "& .( C #A
M ), WP": -T H0#; *H V "T -4 P #2 -, T #J ,X ^@#- /\ S0#_ ,T
M_P#, /\ S #_ ,P _P#_$ P _PP' /\# @#_  @ _P . /\ %@#V "( \  O
M .P / #I $@ Y0!3 .$ 7 #> &4 VP!L -< <P#4 'H T@"  -  AP#. (X
MS "5 ,H G0#( *4 Q@"O ,0 NP#" ,L P #E +X ]0"] /\ O #_ +P _P"\
M /\ O #_ +P _P#_$04 _PX  /\*  #_" $ _P0* /@ $ #I !H XP H -X
M-0#9 $$ TP!, ,\ 5@#+ %\ R0!F ,8 ;@#$ '0 P@![ ,$ @@"_ (D O0"0
M +P F "Z *$ N "K +8 MP"T ,< L@#@ +$!\@"O O\ K@/_ *T$_P"M!/\
MK03_ *T$_P#_%   _Q   /\/  #R#0  Z@H  .D#"0#= !( U  ? ,T!+0#(
M CH Q -% , #4 "]!%D NP5A +D%: "W!F\ M09V +0'?0"R!X0 L0B, *\(
ME0"M"9X JPFH *H*M0"H"L4 I@O? *0-] "B#O\ H [_ )\._P"?#O\ GP[_
M )\._P#_%P  _Q,  .\8  #D&0  VQ8  -(0 @#/"0L R @6 ,$*) "\##(
MMPT^ +0.20"Q#E, KQ!; *T08P"K$&H J1%Q *@1> "F$8  I1&( *,2D0"A
M$IL H!.F )X3LP"<$\, FQ3> )<6] "5%O\ E!?_ ),7_P"2%_\ DA;_ )(6
M_P#_&@  ]!T  .4C  #5)0  RB0  ,(=  "^%@0 NQ 0 +03'0"O%2L JQ8X
M *<80P"E&4T HAE6 * :70">&V4 G1ML )L<<P":''L F!R# )<=C0"5'9<
MDQZB )(>KP"0'K\ CQ_8 (P@\0&)(/\!B"#_ 8<@_P&'(/\!AB#_ 88@_P'Z
M'@  ZR8  -HM  #*,   OBX  +4H  "P(@  KAL, *@=%P"C'R8 GR$S )PB
M/@"9(T@ ER11 )4D60"3)6  DB5G ) F;@".)G8 C29_ (LFB &*)Y,!B">>
M 88GJP&$)[L!@RC1 8 H[@%^*?\!?2G_ 7PH_P%\*/\!?"C_ 7PH_P'U)
MXRX  ,\U  #!.   M#8  *LQ  "E+   HB8& )XF$P"9*"$ E2HN )(K.0"/
M+$0 C2U, (LM5 ")+EP ARYC (8N:@&$+G(!@BYZ 8$OA %_+X\"?2^: GLO
MIP)Z+[<">"_, G8PZ@)U,/X"<S#_ G,P_P)S+_\"<R__ G,O_P+P*@  W#4
M ,<[  "Z/P  K#P  *(X  "<,P  F"\  )4N$ "0,!P C#(I (DS-0"&-#\
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M!EY!X@9>0?D%74'_!%U _P-=0/\#74#_ UU _P/?.0  R$,  +E*  "I2P
MFTD  )!'  "(1   @T$  'Y!!@!Z0A$ =D,> '1%*@!Q134 ;T8_ &U&1P!K
M1D\!:D96 6A&70)F1F4"9$9M V)&=@1@1H($7D:.!5Q%G 9;1:P&64:_!UA&
MWP981O<%5T7_!%=%_P171/\#6$3_ UA$_P/:/0  Q$<  +5.  "D3@  EDP
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M!4A1_P1)4?\$25#_ TE0_P/*2   N5(  *I7  "85@  BE4  ']4  !V4P
M;%$  &=3  !B5 @ 7U82 %U7'@!;5RD 65@S %A8/ !6640 55E, 5-94P%1
M65L"3UAD DU8;0-+6'@$25B&!4=7E09%5Z4&1%>X!D-8T@9#5_(&0U;_!4-5
M_P1$5?\$1%3_ T14_P/&3   M58  *5:  "460  AE@  'M8  !Q5P  9E8
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M S)D_P.W6P  J60  )9D  "&8P  >&,  &UC  !D9   664  %!H  !):P
M0VT$ $!N#@ ^;Q@ /6\B #QP*P Z<#0 .7$] #AQ10 W<4X -G%7 #1Q80$R
M<6T!,7%Z 2]QB@(M<9P"*W&O BIQR (J<.L"*F__ BIM_P(J;/\"*VS_ BML
M_P*Q80  I&D  )!H  " 9P  =&<  &EG  !?:   56L  $MN  !#<0  /'0
M #=V"@ T=Q( ,W@< #)X)0 Q>2X ,'DW "]Y/P N>4@ +'I2 "MZ7  J>F@
M*'IV "9ZAP$E>ID!(WJL 2)ZQ0$B>>D!(G?_ 2)V_P$B=?\"(G3_ B-T_P*L
M:   G6X  (IM  ![;   ;VP  &5L  !:;@  4'$  $5U   ]>   -GP  "Y_
M @ I@0T )X(4 ":"'@ E@B< )((O ".#.  B@T( (8-+ ""$5@ ?A&( 'H1Q
M !R$@@ ;A)4 &H2I !B$P0 8@^8 &('] !F _P$9?_\!&7[_ 1E^_P&F<
ME7,  (1R  !V<0  :W$  %YS  !4=@  27D  #]]   W@0  +X0  ">(   @
MBP4 &XT. !J-%0 9C1X &(XG !>.,  6CCD %8Y# !2/3P 3CUL $H]J !&/
M>P 0CX\ #X^D  Z/NP -C^  #HWZ  ^+_P 0BO\ $(G_ !")_P"A>@  CGD
M 'YW  !R=P  9'@  %A[  !-?@  0H(  #F&   OB@  )XX  ""1   8E0
M$I@%  Z:#@ -FA0 #)H=  N:)@ +FC  "IH[  F:1@ (FE, !IMA  6:<@ $
MFH8  IJ;  ":L0 !F<\  IGP  *8_P $E_\ !9;_  66_P"9@0  AW\  'I^
M  !K?@  78$  %"%  !%B0  .XT  #&2   HE@  'YD  !B=   1H   #*,"
M  :E"@ !I1   *46  "F'P  IB@  *8R  "G/0  ITH  *=8  "G:   IWP
M *>1  "FJ   IL,  *7I  "E_   I?\  *3_  "D_P"1AP  @H8  '*&  !C
MB   58P  $F1   ]E@  ,IH  "B>   ?H@  %Z8  !"I   +K   !*\   "Q
M!@  L0P  +(1  "R%P  LQ\  +,H  "T,@  M3\  +5-  "U70  M7   +6&
M  "UG0  M;8  +7<  "T]P  M/\  +3_  "T_P"+CP  >HX  &J1  !;E0
M39H  $"?   UI   *J@  ""L   6L   #[0   FW   !N0   +T   "^
MO@8  +\,  # $   P18  ,(=  ##)P  Q3(  ,9   #&40  QV,  ,=X  #'
MD0  QZD  ,?'  #'[   Q_X  ,?_  #'_P"#EP  <9H  &&>  !2HP  1:D
M #BN   LLP  (+<  !:Z   .O0  !L    ##    QP   ,D   #*    S
M ,T#  #."0  T X  -(3  #4&P  V"4  -LR  #=0@  W50  -YI  #>@0
MWIP  -^U  #?V0  W_,  -__  #?_P!WGP  :*8  %FM  !*LP  .[@  "V[
M   ?OP  %,(   S&   #R0   ,P   #0    U0   -D   #:    W    -X
M  #@    X@4  .0+  #G$   ZA@  .TD  #P,@  \40  /)8  #S;P  ](H
M /2D  #TOP  ]-\  /3S  #T] !JJ   6Z\  $RW   ]O0  +<$  !_&   3
MR@  "\X   #2    UP   -P   #@    Y0   .<   #I    ZP   .T   #O
M    \0   /,   #V!P  ^0X  /P6  #_(@  _S,  /]'  #_70  _W8  /^1
M  #_J0  _[X  /_8  #_VP#_ !@ _P 6 /\ %0#_ !@ _P > /\ )P#_ #8
M_P!# /\ 3P#_ %H _P!D /\ ;0#_ '4 _P!] /\ A #_ (H _P"0 /\ E@#_
M )P _P"C /\ JP#_ +0 _@"_ /T SP#[ .< ^@#X /D _P#Y /\ ^0#_ /4
M_P#N /\ Z0#_ .< _P#_ !0 _P 1 /\ $0#_ !( _P 7 /\ (P#_ #$ _P ^
M /\ 2@#_ %8 _P!@ /\ : #_ '  _P!X /T ?@#\ (4 ^@"+ /D D0#X )@
M]P"> /4 I@#T *X \@"Y /$ QP#O .  [@#R .P _P#L /\ [ #_ .L _P#E
M /\ X #_ -X _P#_ Q  _P . /\ #0#_  T _P 3 /\ '@#_ "L _P X /\
M10#^ %  ^P!: /@ 8P#U &L \P!R /$ >0#O '\ [@"& .P C #J )( Z0"9
M .< H #F *D Y "S .$ P #@ -, W@#K -P ^P#; /\ V@#_ -H _P#9 /\
MU #_ -( _P#_!PT _P ) /\ !@#_  D _P / /\ & #[ "4 ^  R /4 /P#R
M $H [0!4 .H 70#G &4 Y !L .( <P#@ 'H W@"  -P A@#: (T UP"4 -0
MFP#2 *0 SP"M ,T N0#+ ,D R0#D ,@ ]@#& /\ Q0#_ ,8 _P#' /\ QP#_
M ,< _P#_"@8 _P$  /\   #_  0 _P + /0 $@#O !\ Z@ L .4 . #B $,
MW0!. -D 5P#4 %\ T0!G ,X ;0#, '0 R@!Z ,@ @ #& (< Q0". ,, E@#!
M )X OP"H +T LP"Z ,( N0#; +< \ "U /\ M@#_ +4 _P"U /\ M0#_ +4
M_P#_#   _P0  /\   #^    ]@ # .@ #0#@ !< V0 D -$ ,0#- #P R@!'
M ,8 40## %D P !@ +X 9P"\ &X N@!T +D >P"W (( M0") +, D0"R )H
ML "D *X KP"L +T J@#0 *@ ZP"G /L I@#_ *8 _P"E /\ I0#_ *4 _P#_
M#0  _P<  /0)  #J"0  X@0  -H !P#/ !$ R  < ,( *0"^ #4 NP!  +<
M2@"T %, L@!; +  8@"N &@ K !O *L =0"I 'T J "$ *8 C0"D )8 HP"@
M *$ JP"? ;D G0/, )P$Z ":!OD F0?_ )@(_P"7"/\ EPC_ )<(_P#_$
M]Q   .@4  #<%0  SA$  ,8-  #"! L O  4 +<!(0"R RX K@4Z *L&1 "H
M"$T I@A5 *0)7 "B"F, H IJ )\+<0"="W@ G N  )H,B0"9#), EPR> )4-
MJ@"4#;@ D@W, ) .Z@".$/P C!#_ (L0_P"+$/\ BQ#_ (H0_P#[$P  [1H
M -T@  #,(0  OQT  +<7  "S$0  L@L- *L-&0"G#B8 HP\S )\0/@"=$4<
MFA%0 )@25P"6$EX E1-E ),3; "2$W, D!1\ (\4A0"-%8\ BQ6: (H5IP"(
M%K4 AA;) (07YP""&/L @!G_ '\9_P!_&?\ ?QC_ '\8_P#U&@  Y",  ,\I
M  # *@  LR8  *HB  "E'   I!4( * 4$P";%B$ EQ@M )09. "1&D( CQM+
M (T<4@"+'%D B1U@ (@=9P"&'F\ A1YW (,?@ ""'XL @!^7 'X@HP!](+(
M>R#% 'DAY !W(OD =B+_ '4B_P!T(?\ ="'_ '0A_P#O(0  VRL  ,<Q  "V
M,0  J2X  * J  ";)@  F"$! )4>$ "0(!L C2$H (DC,P"')#T A21& (,E
M3@"!)E4 ?R9< 'XF8P!\)VL >R=S 'DG? !X*(< =BB3 '0HH %R**\!<2G!
M 6\IX %M*?<!;"G_ 6LI_P%K*?\!:RC_ 6LH_P'H*   T#(  , X  "N-P
MH34  )@R  "2+0  CBD  (LG# "'*!< @RHC ( K+P!^+#D ?"Q" 'HM2@!X
M+E$ =RY8 '4N8 !S+V< <B]O ' O>0%O+X,!;2^0 6LOG0%I+ZP!:#"^ 6<P
MVP%E,/4!9##_ 6,P_P%C+_\!8R__ 6,O_P'B+@  RC@  +H]  "H/   FCH
M )$W  "*,P  AC   (,N"0!_+Q, >S ? '@R*P!V,S4 =#,^ '(T1@!P-$X
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M/@  >3L  '0Z  !Q.@X ;3P8 &L]) !I/B\ 9S\X &4_0 !D0$@ 8D!/ &%
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M T=)R@-&2>P#1DC_ D9(_P)'1_\"1T;_ D=&_P+&0P  MDP  *),  "13
MA$L  'E*  !P20  :48  &1'  !?208 7$H0 %I+&P!83"4 5DPO %5-. !3
M34  4DU( %%.3P!/3E< 3DY? 4Q.:0%*3G,"2$V  D9-CP-%39\#0TVQ T)-
MR -!3>H#04S_ D%,_P)"2_\"0DK_ D)*_P+"1P  LT\  )Y/  "-3@  @$X
M '5-  !L3   8TH  %Y,  !:30( 5DX. %1/& !24"( 45$L $]1-0!.4CT
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M C%:_P(Q6?\",EG_ 3)8_P&V5   I%D  )!8  " 6   <U<  &E7  !@6
M5%D  $Y;  !(70  0U\$ $!@#@ ^81< /6$@ #MB*0 Z8C( .6(Z #AC0@ W
M8TL -F-4 #1C70 S8V@ ,6-V 2]CA0$N8Y8!+&.I 2MCOP$J8^,!*F+[ 2I@
M_P$K7_\!*U__ 2M>_P&Q60  GEP  (M<  ![6P  ;UL  &5;  !<7   45X
M $E@  !#8@  /&4  #AG"@ U:!( -&@; #-I)  R:2T ,6DU "]J/0 N:D8
M+6I/ "QJ60 K:V4 *6MR "AK@@ F:Y, )&NG "-KO0 B:N  (VGY 2-G_P$C
M9O\!(V;_ 21E_P&L8   F&   (5@  !V7P  :E\  &%@  !78   36,  $1F
M   ]:   -FL  #!N!  L< X *G$5 "EQ'@ H<28 )W(O "9R-P E<D  )')*
M ")R5  A<V  ('-M !YS?0 =<Y  &W.C !ISN0 9<]P &G'W !IP_P ;;_\
M&V[_ 1MM_P&F9@  D64  ']D  !Q9   9F0  %UD  !29@  2&D  #]L   W
M;P  ,',  "EV   B>0@ 'WL0 !Y[%P <>Q\ &WLH !I[,  9?#D &'Q# !=\
M3@ 6?%H %7QG !1]>  2?8L $7V? !!]M0 /?=4 $'OU !%Y_P 1>/\ $G?_
M !)W_P">:P  BFH  'II  !M:0  8FD  %=J  !,;0  0W   #ET   Q>
M*7L  ")_   ;@@  %(4) !&&$  1AA< $(<? !"'*  .AS$ #H<[  V'1@ ,
MAU, "X=A  J'<0 )AX0 !X>8  :&K@ %ALD !H7L  >$_P (@_\ "8+_  F"
M_P"5<0  @V\  '1N  !I;@  7&\  %!R  !&=0  /'D  #)]   J@0  (H4
M !N)   4C   #X\#  J2"P &DA$ !)(8  *2(  !DBD  )(S  "3/@  DTL
M )-9  "3:0  DWL  )*0  "2I@  D;\  )'E  "0^@  C_\  (__  "/_P"-
M=P  ?74  '!T  !B=0  57@  $E\   _@   -(0  "N)   BC0  &I$  !.4
M   .EP  "9L   &="   G0X  )T3  ">&@  GB(  )\K  "?-0  H$(  *!0
M  "@7P  H'$  *"'  "?G0  G[4  )[:  "=]@  G?\  )S_  "<_P"&?0
M>'P  &E\  !;?P  3H,  $&(   VC   +)$  ".6   :F@  $IX   VA   &
MI    *<   "I P  J0H  *H.  "K$P  K!D  *TB  "N*P  KS<  *]%  "O
M5   KV8  *][  "NE   KJL  *[)  "N[P  K?\  *W_  "M_P"!A   <80
M &&'  !3BP  1I   #F6   NFP  (Z   !JD   2J   #*P   2O    L@
M +8   "W    MP(  +@(  "Y#0  NA(  +L8  "](0  OBL  , X  # 2
MP%H  ,%N  #!A@  P:   ,&Z  #!XP  P/D  ,#_  # _P!YC0  :)   %F4
M  !+F@  /:   #&E   EJP  &J\  !&S   +N    KL   "^    P0   ,0
M  #%    Q@   ,<   #(!0  R@L  ,P/  #.%0  T!\  -,K  #5.@  U4P
M -9@  #8=P  V)(  -BL  #9R0  V>P  -G[  #8_P!PF0  8)X  %&D  !#
MJ@  -;   "BV   <N@  $;X   G!    Q0   ,@   #+    SP   -(   #3
M    U@   -@   #;    W0   -\'  #B#0  Y1,  .@=  #L*@  [3P  .U1
M  #N9P  [X$  .^<  #PMP  \-,  /#L  #P] !GI@  6*T  $FT   ZN@
M*KX  !S"   0Q@  !\H   #.    T@   -8   #<    X    .,   #D
MY@   .@   #K    [0   .\   #R @  ]0H  /@1  #\'   _RP  /\_  #_
M50  _VX  /^*  #_I   _[H  /_1  #_X0#_ !0 _P 2 /\ $@#_ !0 _P 9
M /\ )0#_ #( _P _ /\ 2P#_ %8 _P!@ /\ : #_ '  _P!X /\ ?P#_ (4
M_P"+ /\ D0#_ )@ _P"> /X I@#] *X _ "Y /H R #Y .( ^ #T /< _P#V
M /\ ]@#_ .\ _P#G /\ X@#_ -X _P#_ !$ _P . /\ #@#_  \ _P 4 /\
M( #_ "T _P Z /\ 1@#_ %$ _P!; /\ 8P#^ &L _ !S /H >0#Y (  ]P"&
M /8 C #U )( \P"9 /( H #P *D [@"S .T P0#K -8 Z@#N .D _@#G /\
MYP#_ .4 _P#= /\ U0#_ -$ _P#_  T _P * /\ " #_  D _P 0 /\ &P#_
M "@ _P U /\ 0 #Z $L ]@!5 /, 7@#Q &8 [@!M .P = #K 'H Z0"  .<
MA@#F (T Y "3 .( FP#@ *, W@"M -P N0#: ,H UP#F -0 ^ #2 /\ T@#_
M -( _P#. /\ R0#_ ,8 _P#_  @ _P # /\   #_  , _P - /P %@#W "(
M\P N .\ .@#L $4 Z !/ .0 6 #A &  W@!G -L ;0#9 '0 U0!Z -, @ #1
M (< SP". ,T E0#+ )X R0"G ,< LP#% ,( PP#< ,$ \0"_ /\ OP#_ +X
M_P"^ /\ O0#_ +L _P#_    _P   /\   #_    ]@ ( .X $0#G !L X0 G
M -T ,P#9 #X TP!) ,\ 4@#+ %D R !A ,8 9P#$ &T P@!S ,  >@"_ (
MO0"( +L D "Y )@ N "B +4 K0"S +L L0#. +  Z@"O /P K0#_ *T _P"N
M /\ K@#_ *X _P#_ @  _P   /T   #R    Z    -X # #3 !4 S  A ,@
M+ #$ #@ P0!" +T 2P"Z %, N !: +8 80"T &< L@!M +  = "O 'H K0""
M *P B@"J ), J "= *8 J "D +4 H@#& *$ XP"? /8 G@#_ )X _P"> /\
MG@#_ )X _P#_!@  ^P   .X%  #B!   U0   ,L !@##  \ O0 9 +@ )0"T
M #$ L0 [ *X 10"L $T J0!5 *< 6P"E &( I !H *( ;@"A '4 GP!\ )X
MA0"< (X F@"8 )@ I "6 +  E0#! ), W "2 /( D0#_ )  _P"0 /\ CP#_
M (\ _P#]"@  \ X  .$1  #.$   P@T  +L'  "W  H L0 2 *P '@"H "D
MI0 T *( /@"? $< G0!/ )L 5@"9 5P EP%C )8":0"4 G  DP-X )$#@ "0
M!(H C@25 (P%H0"*!:X B0:^ (<(V "&"?  A K_ (,+_P"#"_\ @PO_ (,+
M_P#V$   YA<  -(<  # &@  LQ8  *P2  "H#0  I@<- *(%%@"=!R( F0DN
M )8*. "4"T$ D@Q* ) ,40".#5@ C U> (L-90")#6P B YT (8.?0"%#H<
M@PZ3 ($/GP" $*T ?A"^ 'T0VP!Z$?0 >!+_ '<2_P!W$O\ =Q+_ '<2_P#O
M%P  VR$  ,8D  "T(P  J"   * <  ";%P  F1$$ )@.$ "3$!L CQ$G (P2
M,@")$SP AQ-$ (443 "#%%, @15: ( 58 !^%F@ ?19O 'L6> !Y%X, >!>/
M '88G !T&*H <QF[ '(9U !O&O$ ;AO_ &T;_P!M&O\ ;1K_ &T:_P#G(
MT"D  +PK  "K*@  GB@  )8D  "0(   C1P  (P7# "(&!8 A!HB ($;+0!^
M'#< ?!U  'H=2 !Y'D\ =QY5 '8?7 !T'V, <Q]K '$@= !P('\ ;B&+ &PA
MF !K(:< :2*X &@BSP!F(NX 92/_ &0C_P!D(O\ 9"+_ &0A_P#@)@  R"\
M +0Q  "C,   EBX  (TK  "'*   A"0  ((@" !^(!( >R(> '@C*0!U)#,
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M 5$UQ@%0-><!3S7] 4\U_P%/-/\!3S3_ 4\S_P'+-@  N#T  *,\  "2/
MA3L  'LZ  !T-P  ;S4  &PS  !H- H 9343 &(V'@!@-R@ 7C<Q %TX.@!;
M.$$ 6CE( %DY4 !7.5< 5CI? %0Z: !3.G, 43I_ 4\ZC0%..IT!3#JN 4LZ
MPP%*.N4!23K\ 4DY_P%).?\!23C_ 4HX_P''.@  LT   )X_  "./P  @3X
M '<]  !P.P  :C@  &8X  !B.0< 7SH1 %P[&P!:.R4 63PN %<]-P!6/3X
M5#Y& %,^30!2/E4 43Y= $\_9@!-/W  3#]] 4H_BP%(/YL!1S^L 44_P0%$
M/^,!1#[[ 40^_P%$/?\!1#W_ 44\_P'#/@  KT,  )I"  "*0@  ?4$  '-
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M 3I&_P$Z1?\!.T7_ 3M$_P&[10  ID@  ))'  ""1P  =D<  &M'  !C1@
M6T,  %9%  !21P  3D@* $Q)$@!*21P 2$HE $=*+@!&2S8 14L^ $-+1@!"
M3$T 04Q6 $!,7P ^3&H /$QV #M,A0$Y3)4!-TRG 39,O $U3-T!-4OW 35+
M_P$U2O\!-DG_ 39)_P&X20  HDL  (Y*  !^2@  <DH  &A*  !?20  54@
M %!*  !,2P  24P' $9-$ !$3AD 0D\B $%/*P! 4#, /U [ #Y00P \44H
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M "18_P"H50  DE0  (!4  !Q5   9E0  %Q4  !450  2E8  $-8   \6P
M-ET  #!@!0 M80X *V$5 "IB'0 I8B4 *&(N "=C-@ F8SX )6-' "-C40 B
M9%P (61I !]D>0 >9(H '&2> !MDLP 99,X &F/Q !MA_P ;8/\ '&#_ !Q?
M_P"A60  C%@  'M8  !M6   8E@  %E8  !060  1UL  #Y>   W8   ,6,
M "IF   D:0D (6H0 "!J%P ?:B  'FLH !UK,  <:SD &VM" !IL3  9;%@
M%VQE !9L=  4;(8 $VR: !)LKP 1;,H $6OO !)I_P 3:/\ $VC_ !-G_P"9
M70  A5T  '5<  !H7   7EP  %5<  !+7@  0F$  #ED   R9P  *VH  "1M
M   >< $ %W,+ !5T$0 4=!@ $W0A !)U*0 1=3( $74[ !!U1@ /=5( #G5?
M  UU;@ ,=8$ "W65  IUJ@ (=,, "73G  IS_0 +<?\ #''_  QP_P"18@
M?V$  '!A  !D80  6F$  $]B  !%90  /&@  #-L   K;P  )'(  !UV   7
M>0  $7P$  U_#  +?Q( "G\9  E_(@ (?RH !G\T  5_/P $?TL  G]8  %_
M9P  ?WD  '^.  !_HP  ?KL  'W@  !]]P  ?/\  'O_  ![_P")9P  >&<
M &MF  !A9@  5&<  $EI   _;0  -7$  "QU   D>0  '7P  !:    0@P
M#(8"  :)"@ !B0\  (D4  "*&P  BB,  (LL  "+-P  BT,  (M0  "+7P
MBW$  (N&  "+G   BK,  (G3  "(\P  B/\  (?_  "'_P"";0  <VP  &AL
M  !:;0  3F\  $)S   X=P  +GL  "6    =A   %8@  !",   +CP  !)(
M  "4!@  E0P  )40  "6%0  EQP  )@D  "8+@  F3D  )E'  "95@  F6@
M )E]  "9E   F*L  )?(  "6[@  EO\  )7_  "5_P![=   ;W,  &%S  !3
M=@  1GH  #M_   PA   )H@  !V-   4D@  #I8   F9   !G    *    "A
M    H@8  *(,  "D$   I10  *4<  "G)   J"\  *@]  "I3   J5X  *ER
M  "HB0  J*(  *B\  "GY0  IOL  *;_  "E_P!W>P  :'L  %E^  !+@@
M/H<  #*-   GD@  '9<  !2<   .H   !Z0   "H    JP   *X   "O
ML    +$$  "S"@  M X  +43  "V&P  N"0  +HQ  "Z0   NE(  +ME  "[
M?0  NI<  +JQ  "ZT@  NO,  +G_  "Y_P!O@P  7X8  %&+  !#D   -I<
M "J=   ?H@  %:<   VL   %L    +0   "W    NP   +X   "_    P
M ,$   ## 0  Q <  ,4-  #'$0  RAD  ,TD  #.,P  ST0  -!8  #0;@
MT8@  -"D  #0P0  T>8  -'X  #1_P!GCP  5Y0  $F:   [H0  +J<  "&M
M   6LP  #K@   :\    P    ,,   #&    RP   ,T   #.    T    -$
M  #4    U@   -H"  #<"0  WP\  .,7  #F)   YS8  .A)  #I7P  ZG@
M .N4  #KKP  Z\P  .SH  #L]@!?G@  4*0  $*K   TL@  )KD  !F^   .
MP@  !,4   #*    S0   -$   #8    VP   -\   #@    X@   .0   #F
M    Z0   .L   #N    \04  /4-  #Y%@  _"4  /TY  #^3P  _V<  /^"
M  #_G0  _[4  /_+  #_Y #_ !$ _P / /\ #P#_ !$ _P 6 /\ (@#_ "\
M_P [ /\ 1P#_ %( _P!; /\ 9 #_ &P _P!S /\ >@#_ (  _P"& /\ C #^
M ), _0"9 /L H0#Z *D ^ "T /< P@#V -H ]0#Q /0 _P#S /\ \P#_ .D
M_P#@ /\ V #_ -, _P#_  X _P + /\ "@#_  L _P 1 /\ '0#_ "H _P V
M /\ 00#_ $P _P!6 /X 7P#[ &8 ^0!M /< = #U 'H ] "  /( A@#P (T
M[P"4 .T FP#L *0 Z@"N .D N@#G ,T Y0#I .0 ^P#C /\ X@#_ -X _P#1
M /\ S #_ ,@ _P#_  D _P $ /\  0#_  0 _P . /\ & #_ "0 _0 P /L
M.P#W $8 \P!0 .\ 60#L &  Z@!G .< ;@#F '0 Y !Z .( @ #@ (< W@".
M -P E0#: )X U@"H -0 LP#1 ,, SP#? ,X ] #, /\ RP#_ ,L _P#% /\
MOP#_ +P _P#_  ( _P   /\   #_    _0 + /< $P#Q !X [0 J .H -0#G
M $  X@!* -T 4@#9 %H U0!A -( 9P#0 &T S@!S ,P >@#* (  R "' ,8
MCP#$ )@ P@"A ,  K0"^ +L O #0 +H [0"Y /X N #_ +@ _P"W /\ LP#_
M +  _P#_    _P   /\   #Y    [@ % .4 #@#> !@ V  C -( +@#/ #D
MRP!# ,< 3 #$ %0 P0!; +\ 80"\ &< NP!M +D <P"W 'H M0"! +0 B0"R
M )( L "; *\ IP"L +0 JP#& *D Y "G /@ I@#_ *8 _P"E /\ I0#_ *0
M_P#_    _P   /4   #J    W@   -  "@#( !( P@ = +X * "[ #, N0 ]
M +4 1@"R $T L !5 *T 6P"L &$ J@!G *@ ;0"G ', I0!Z *0 @@"B (P
MH "6 )\ H0"= *X FP"^ )D V "7 /$ E@#_ )8 _P"7 /\ EP#_ )< _P#_
M    ]0   .<!  #4    R0   ,  ! "X  X LP 6 *\ (0"K "P J  V *8
M/P"C $< H0!/ )\ 50"= %L FP!A )H 9P"8 &X EP!U )4 ?0"4 (8 D@"1
M )  G ". *D C "X (L S0") .L B #] (@ _P"( /\ B #_ (@ _P#Y!@
MZ0P  -0.  ###   MPD  + "  "K  D I@ 0 *( &@"> "4 FP P )@ .0"6
M $$ E !) )( 4 "0 %8 C@!< (T 8@"+ &D B@!P (@ > "' ($ A0", (0
MF "" *4 @ "T 'X R !] >< ? +Y 'L#_P![!/\ >P3_ 'L$_P#Q#@  WA4
M ,45  "T%   J1$  *$.  ">"@  FP,, )< $P"3 !X D $I (T",P"* SP
MB 1# (8%2P"%!E$ @P97 (('7@" !V0 ?PAL 'T(= !\"'X >@F) '@)E@!W
M"J, =0JS ',+QP!R#.8 < W[ ' -_P!O#?\ ;PW_ &\-_P#H%@  T!X  +D=
M  "I'   G1H  )46  "0$P  CPX# (X*#@")"Q< A@PC (,-+0" #38 ?@X^
M 'P.1@![#DT >0]3 '@06@!V$&$ =1!H ',0<0!Q$7L <!&' &X1E !L$:(
M:Q*R &D2QP!H$^< 9A/] &44_P!E%/\ 91/_ &43_P#?'@  QB0  + D  "@
M(P  E"$  (L?  "&&P  @Q<  ((2" !_$1( ?!(= 'D4* !V%#$ =!4Z '(6
M00!Q%D@ ;Q=/ &X75@!L%UT :QAD &D8;0!H&7< 9AF# &09D !C&I\ 81JO
M & :Q !>&^0 71S[ %P<_P!<&_\ 7!O_ %P;_P#5)0  O2H  *@I  "8*0
MC"@  (,E  !](@  >1\  '@; P!V&0\ <AH8 &\<(P!M'2T :QTU &D>/0!H
M'D0 9A]+ &4?4@!C(%D 8B!A &$@:0!?(7, 72%_ %PAC0!:(IP 62*L %<B
MP !6(^$ 52/Y %0C_P!4(O\ 5"+_ %0B_P#-*P  MBX  *(N  "2+@  A2T
M 'PK  !V*   <B8  &\C  !M(0P :B(5 &<C'P!E)"D 8R0Q &(E.0!@)D$
M7R9( %TF3P!<)U8 6R== %DG9@!8*'  5BA\ %0HB@!3*9D 42FJ % IO@!/
M*=X 3BGW $TI_P!-*?\ 32C_ $XH_P#(,   L#(  )PR  ",,@  @#$  '8P
M  !P+0  :RL  &@I  !F* D 8R@1 & I' !>*B4 7"LN %LK-@!9+#T 6"Q$
M %<M3 !5+5, 5"U; %,M8P!1+FX 4"YZ $XNB !,+Y< 2R^H $DONP!(+]L
M2"_V $<O_P!'+O\ 1RW_ $@M_P#$-   JS4  )<U  "'-0  >S4  '(T  !K
M,@  9B\  &(N  !?+04 7"X0 %HO& !8,"( 5C K %4Q,P!3,3H 4C)" %$R
M20!0,E  3C-8 $TS80!+,VL 2C-W $@TA0!'-)4 132F $,TN0!"--8 0C3T
M $(T_P!",_\ 0C+_ $(R_P# .   IS@  ),X  "#.   =S@  &TW  !F-@
M83,  %TR  !9,@( 5S,- %0T%0!2-1\ 434H $\V, !.-C@ 3#<_ $LW1@!*
M-TX 23A6 $<X7P!&.&D 1#AU $,X@P!!.9, 0#FD #XYN  ].=, /#GS #PX
M_P ]-_\ /3?_ #TV_P"[.P  HCL  (\[  !_.P  <SL  &HZ  !B.0  73<
M %@V  !4-P  43@+ $\Y$P!-.1P 2SHE $HZ+0!(.S4 1SL\ $8\1 !%/$L
M1#Q3 $(\7 !!/6< /SUS #X]@0 \/9$ .CVC #D]M@ X/=$ -SWR #<\_P X
M._\ .#O_ #@Z_P"V/0  GCX  (L^  !\/@  ;SX  &8]  !>/0  6#L  %,Z
M  !/.P  3#P( $D]$0!'/AD 1C\B $0_*@!#/S( 0D Z $% 00! 0$D /D%1
M #U!6@ \060 .D%P #A!?P W08\ -4*A #1"M  R0LX ,D'P #) _P S0/\
M,S__ #0^_P"Q0   FD   (=   !X00  ;$$  &)   !;0   5#\  $X_  !*
M0   1D$% $1"#@!"0Q8 0$,? #]$)P ^1"\ /$0W #M%/@ Z148 .45. #A&
M6  V1F( -49N #-&?  Q1HT ,$:? "Y&LP M1LP +4;O "U%_P N1/\ +D/_
M "Y#_P"L0P  ED,  (-#  !T0P  :$,  %]#  !70P  4$,  $A#  !$10
M048! #Y'#  \2!, .D@< #E))  X22P -DDT #5*.P T2D, ,TI, #)*50 P
M2U\ +TMK "U+>@ L2XL *DN= "A+L0 G2\H )TOM "=*_P H2?\ *$C_ "E'
M_P"G1@  D48  ']&  !P1@  948  %M&  !41@  3$<  $1(   _2@  .TL
M #=,"0 U31  ,TX8 #).(  Q3R@ ,$\P "]/.  N3T  +%!( "M04@ J4%P
M*%!H "=0=P E4(@ )%"; ")0KP A4,@ (%#K "%/_P B3O\ (DW_ "--_P"A
M20  C$D  'I)  !L2@  84H  %A*  !02@  24L  $!,   [3@  -5   #%2
M!  M4PT +%04 "I4'  I520 *%4L "=5,P F53P )59% "163@ B5ED (59E
M !]6=  >5H4 '%:8 !M6K  95L4 &5;I !I5_P ;5/\ &U/_ !Q2_P";30
MADT  '5-  !H30  74T  %1-  !-3@  14\  #Q1   V4P  ,54  "M8   F
M6@D (UL0 ");%P A7!\ (%PG !]<+@ =7#< '%U  !M=2@ :754 &%UA !==
M<  578$ %%V5 !-=J@ 17<( $5WG !);_@ 36O\ $UK_ !19_P"440  @%$
M '!1  !D40  65$  %%1  !)4@  05,  #A6   R60  *UL  "5>   ?80,
M&F,, !AD$0 79!D %F0A !5D*0 493$ $V4Z !)E1  195  $&5=  ]E:P .
M97T #661  QEI0 *9+P "F3@  MC^0 ,8O\ #6'_  UA_P"-50  >E4  &M5
M  !?50  5E4  $Y5  !$5P  /%D  #1<   L7P  )F(  !]E   9:   $VL%
M !!M#0 .;A( #6X:  QN(@ ,;BL "VXT  IN/@ (;DH !VY7  9N90 $;G8
M FZ*  !MGP  ;;8  &S6  !L\P !:_\  FK_  -J_P"%6@  =%H  &9:  !<
M60  4UD  $A:   _70  -F   "YC   F9P  'VH  !EM   3<0  #G0#  IW
M"@ %=Q   7<5  !W'   =R0  '@M  !X-P  >$,  'A0  !X7@  >&\  'B$
M  !XF0  =[   ';-  !U\   =?\  '3_  !T_P!^7P  ;E\  &)>  !97@
M35\  $)B   Y90  ,&@  "=L   ?<   &'0  !)W   ->P  "'X   * "
M@0T  ($1  ""%P  @QX  (,F  "$,   A#L  (1(  "$5P  A&@  (1\  "$
MDP  @ZH  (+%  "!ZP  @?X  (#_  " _P!W90  :60  %]C  !29   1V<
M #QK   Q;P  *',  "!W   8?   $7\   R#   &AP   (H   ", P  C D
M (T.  ".$0  CQ<  ) >  "1)P  DC(  )(_  "23@  DE\  ))S  "2BP
MD:(  )&\  "0Y0  C_P  ([_  "._P!Q:P  9FH  %AK  !+;0  /W$  #1V
M   J>P  ((   !>%   0B0  "XT   21    E0   )@   "9    F@,  )L(
M  "<#0  GA$  )\6  "@'@  HB@  *(U  "C1   HU4  *-I  "B@   HIH
M *&S  "@V   H/8  )__  "?_P!N<0  7W(  %%U  !$>0  -WX  "R$   A
MB@  %X\  !"4   *F0   9T   "@    I    *<   "H    J0   *H   "L
M!@  K0L  *\0  "P%0  LAX  +0I  "T.0  M$H  +5=  "U<P  M8X  +6H
M  "TQ@  L^T  ++_  "R_P!F>@  5WT  $F"   \AP  +XX  ".4   8F@
M$)\   FD    J0   *T   "P    M    +<   "X    N0   +L   "\
MO@(  , (  #"#@  Q!0  ,<>  #(+   R3T  ,I0  #*9@  RG\  ,J;  #*
MN   RMT  ,KU  #*_P!>A@  3XL  $&1   SF   )Y\  !NE   1JP  ";
M  "U    N0   +T   #!    Q@   ,@   #)    RP   ,P   #.    T
M -(   #4!0  V0P  -T2  #A'@  XBX  .-"  #D5P  Y6\  .:,  #FJ
MY<4  .7G  #F]@!6E   2)L  #JB   LJ0  '[   !.V   +O    ,$   #%
M    R0   ,T   #2    U@   -H   #;    W@   .    #B    Y    .<
M  #I    [0   / *  #T$0  ^!\  /DR  #Z2   ^U\  /QZ  #]EP  _:\
M /W'  #]Y #_  X _P - /\ # #_  X _P 3 /\ '@#_ "H _P V /\ 0@#_
M $T _P!7 /\ 7P#_ &< _P!N /\ = #_ 'H _P"! /T AP#\ (T ^@"4 /D
MG #W *4 ]0"O /0 O #S ,\ \0#L /  _@#O /\ [P#_ ., _P#7 /\ S@#_
M ,H _P#_  H _P & /\ ! #_  @ _P 0 /\ &0#_ "4 _P Q /\ /0#_ $<
M_@!1 /L 60#Y &$ ]@!H /0 ;@#S '0 \0!Z .\ @0#N (< [ ". .H E@#H
M )\ Y@"I ., M0#B ,8 X #C -\ ^ #= /\ W0#_ -0 _P#) /\ P@#_ +X
M_P#_  , _P   /\   #_  $ _P - /\ % #] "  ^@ K /< -@#S $$ [P!+
M .P 5 #H %L Y@!B ., : #A &X WP!T -P >@#: ($ V "( -0 D #2 )@
MSP"B ,T K@#+ +P R0#3 ,< \ #& /\ Q #_ ,0 _P"[ /\ M@#_ +, _P#_
M    _P   /\   #_    ]P ( /  $ #K !H YP E .0 , #A #L W !% -4
M30#1 %4 S@!; ,L 8@#) &< QP!M ,4 <P## 'H P0"! +\ B0"] )( NP"<
M +D IP"W +4 M0#( +, Y@"R /L L0#_ +  _P"N /\ J@#_ *< _P#_
M_P   /X   #Q    Y0 " -P #0#3 !0 S0 ? ,H *@#' #0 Q  ^ ,  1P"\
M $X N@!5 +< 6P"U &$ LP!G +( ;0"P ', K@!Z *P @@"J (L J "5 *<
MH "E *T HP"^ *$ VP"@ /0 GP#_ )X _P"? /\ G0#_ )L _P#_    _
M .X   #@    T    ,4 " "^ !  N0 9 +4 (P"S "X L  W *T 0 "J $@
MJ !/ *4 50"C %L H@!@ *  9@"? &P G0!S )L >P": (0 F ". )8 F@"5
M *< DP"W )$ S "0 .P CP#_ (X _P". /\ C@#_ (\ _P#\    [P   -L
M  #)    O0   +4  @"N  P J0 3 *4 '0"B "< H  Q )T .@": $( F !)
M )8 3P"4 %4 DP!; )$ 8 "0 &< C@!M (T =0"+ 'X B0") (@ E0"& *(
MA0"Q (, Q "! .0 @ #Y '\ _P"  /\ @ #_ (  _P#T @  X D  ,<(  "W
M!P  K ,  *8   "@  < FP / )@ %P"5 "$ D@ J (\ ,P"- #P BP!# (D
M20"' %  A@!5 (0 6P"# &$ @0!H (  < !^ 'D ? "$ 'L D !Y )T > "L
M '8 O@!U -T <P#T ', _P!S /\ <P#_ ', _P#I#0  SQ   +D0  "I$
MG@X  )<+  "3!@  D  + (P $0") !H A@ D (, +@"! #8 ?P ^ 'T 1 !\
M $L >@!1 'D 5P!W %T =@!D '0 ; !S 74 <0&  &\"C0!N IH ; .J &L#
MNP!I!-8 : ;Q &@'_P!G!_\ 9P?_ &<'_P#?%   PQ<  *X7  ">%@  DQ4
M (L2  "&$   A P" (,&#0"  Q0 ? 4> 'D'* !W"#  =0@X ',)0 !R"48
M< I, &\*4P!M"UD ; MA &H+:0!I#'( 9PQ^ &8,BP!D#9D 8@VI &$-NP!@
M#=@ 7@[S %T._P!=#O\ 70[_ %T._P#4'   N1T  *0>  "5'0  B1P  ($:
M  ![%P  >!,  '@0!@!W#0\ <PX8 ' .(@!N#RL ;! S &H0.P!I$$( 9Q%)
M &813P!D$58 8Q)= &$29@!@$F\ 7A)[ %P3B !;$Y< 61.G %<4N@!6%-4
M517S %05_P!4%?\ 5!7_ %04_P#*(@  L"(  )TC  "-(P  @2(  'DA  !S
M'@  ;QL  &X7  !M$PP :A04 &<5'@!E%B< 8Q8O &$7-P!@%SX 7AA% %T8
M2P!<&5( 6AE: %D98@!7&FP 5AIW %0:A0!2&Y0 41ND $\;MP!.&]  31SQ
M $P<_P!,'/\ 31S_ $T;_P##)@  JB<  )8G  "'*   >R<  '(F  !L)
M:"$  &8>  !D&P@ 8AL1 %\<&@!='2, 6QXK %H>,P!8'SH 5Q]! %8@2 !4
M($\ 4R!7 %$A7P!0(6D 3B%T $TA@@!+(I$ 22*B $@BM !'(LT 1B/O $4C
M_P!%(O\ 1B+_ $8A_P"\*@  I"L  )$K  ""+   =BL  &TJ  !F*0  8B8
M %\D  !=(@0 6R$. %@B%@!6(Q\ 5"0H %,D, !2)3< 4"4^ $\F10!.)DP
M3"94 $LG7 !))V8 2"=Q $8G?P!%*(\ 0RB@ $$HL@! *,L /RCM #\H_P _
M*/\ 0"?_ $ G_P"W+0  GRX  (PO  !]+P  <2\  &@N  !A+0  72L  %HH
M  !7)P  5"<, %(H$P!0*1P 3BDE $TJ+ !+*C0 2BL[ $DK0@!(+$D 1BQ1
M $4L6@!$+&0 0BUO $ M?0 _+8T /2V> #PML  Z+<@ .BWK #HM_P Z+?\
M.BS_ #HL_P"R,   FS$  (@R  !Y,@  ;3(  &0R  !=,0  6"\  %4L  !1
M+   3RT) $PM$0!*+AD 22\B $<O*@!&,#$ 13 X $,P/P!",4< 03%/ $ Q
M5P ^,6$ /3)M #LR>P Y,HL .#*< #8RKP U,L< -#+I #0R_P U,?\ -3'_
M #4P_P"M,P  EC0  (0U  !U-0  :34  & U  !9-   5#,  % P  !,,0
M23$& $<R#P!%,Q8 0S,? $(T)P! -"X /S4V #XU/0 ]-40 /#9, #HV50 Y
M-E\ -S9K #8V>  T-XD ,C>: #$WK0 O-\4 +S?H "\V_@ P-?\ ,#7_ # T
M_P"I-@  DC8  ( W  !R.   9C@  %TW  !6-P  4#8  $LT  !'-0  1#8#
M $$W#0 _.!0 /C@< #PY)  [.2P .CDS #DZ.@ X.D( -CI* #4Z4P T.UT
M,CMH # [=@ O.X< +3N9 "P[K  J.\, *3OF "HZ_0 J.O\ *SG_ "PX_P"D
M.   CCD  'PZ  !N.@  8SH  %HZ  !3.@  33H  $8X  !".@  /SL  #P\
M"P Z/!$ .#T9 #<](0 V/BD -#XP #,^-P R/S\ ,3]' # _4  N/UH +4!F
M "M =  I0(0 *$"7 "9 J@ E0,$ )$#E "0__  E/O\ )CW_ "8]_P"?.P
MBCP  '@]  !J/0  7ST  %8]  !//0  23T  $(]   \/@  .3\  #9!"  T
M00\ ,D(6 #%"'@ O0R4 +D,M "U#-  L1#P *T1$ "I$30 H1%@ )T5C "5%
M<0 C18( (D65 "!%J  ?1;\ 'D3C !]$^P ?0_\ ($+_ "%!_P":/@  A3\
M '1   !G0   7$   %-   !,0   1D   #Y!   X0P  -$4  #!& P M1PT
M*T@2 "I(&@ I2"( *$DI "=),0 E23D )$E! "-*2@ B2E4 ($IA !]*;P =
M2G\ &TJ2 !I*I@ 82KT %TK@ !A)^@ 92/\ &D?_ !I'_P"50@  @$(  '!#
M  !C0P  6$,  %!#  !)0P  0D0  #M%   U1P  ,$D  "M+   F30D )$X0
M ").%@ A3QT ($\E !]/+  >3S4 '4\] !Q01P :4%$ &5!= !=0:P 64'P
M%%"/ !-0I  14+H $5#> !%/^  23O\ $TW_ !1-_P"/10  >T8  &M&  !?
M1P  54<  $U'  !&1P  /T<  #=*   Q3   *TX  "90   @4P, '%4, !I6
M$0 95A@ %U8@ !96)P 55C  %%8Y !-70@ 25TT $5=9 !!7:  /5WD #E>,
M  U7H  +5[8 "U;4  M6]  ,5?\ #53_  Y3_P"(20  =DH  &=*  !;2@
M44H  $I*  !#2@  .TP  #-.   L40  )E0  "%6   ;60  %5P' !%>#0 0
M7A, $%X:  Y>(@ .7BH #5XS  Q>/0 +7D@ "EY4  A>8@ '7G, !5Z&  ->
MFP "7K$  EW,  )=[@ #7/\ !%O_  5;_P"!3@  <$X  &).  !73@  3DX
M $=.   ^3P  -E$  "Y4   G5P  (5H  !M=   58   $&,#  QF"P (9Q
M!F<5  5G'  $9R0  F<M  %G-P  9T(  &=.  !G7   9VT  &>   !FE0
M9JP  &7'  !EZP  9/P  &3_  !C_P!Z4@  :E,  %U2  !44@  2U(  $)3
M   Y50  ,%@  "A;   A7P  &F(  !1E   0:   #&L!  9N"0  ;PX  &\2
M  !O&   <!\  ' G  !Q,   <3L  '%(  !Q5@  <68  '%Y  !QCP  <*<
M &_!  !OYP  ;OP  &W_  !M_P!S6   95<  %I7  !15@  1E<  #Q:   R
M70  *F$  ")D   ::   %&P   YO   *<@  !'8   !X!0  > L  'D.  !Z
M$P  >QD  'P@  !]*0  ?3,  'U   !]3@  ?5X  'UR  !]B   ?*$  'RZ
M  ![X@  >OH  'G_  !X_P!M70  8%P  %=<  !+70  0%\  #5C   K9P
M(VL  !IO   3<P  #G<   A[   "?@   ((   "# 0  A 8  (4+  "&#P
MB!,  (D9  "*(0  BRL  (LW  ",1@  BU8  (MI  "+@   BYD  (JS  ")
MV   B/<  (C_  "'_P!H8P  7F(  %%B  !$90  .&D  "YN   D<P  &G@
M !-]   -@0  !H4   ")    C0   )    "2    D@   )0%  "5"@  EPX
M )@2  ":&   FR$  )PM  "=/   G4P  )Q?  "<=@  FY$  )NK  ":R0
MFO   )G_  "8_P!E:0  5VD  $EL   ]<0  ,'8  "5\   ;@0  $H<   R,
M   $D0   )4   "9    G0   *    "A    H@   *0   "E 0  IP<  *D,
M  "J$0  K1@  *\B  "O,   KT$  *]4  "O:P  KH4  *ZA  "NO@  K>8
M *S\  "L_P!><0  3W0  $)Y   U?P  *(4  !V,   3D@  #)@   .=
MH@   *8   "J    K@   +    "Q    LP   +0   "V    N    +H$  "\
M"@  OA   ,$7  ##)   PS4  ,1)  #$7@  Q7<  ,63  #%KP  Q=$  ,/R
M  ##_P!6?   1X(  #J(   LCP  ()8  !2=   -HP   ZD   "N    L@
M +<   "[    OP   ,(   #"    Q0   ,8   #(    R@   ,T   #/
MT@@  -4.  #;&   W2<  -XZ  #?4   X&@  ."$  #AH0  X;T  .'B  #@
M] !.BP  0)(  #*9   EH0  &*@   ZO   %M0   +H   "_    Q    ,@
M  #.    T0   -0   #5    V    -H   #=    WP   .(   #D    YP
M .L%  #O#@  ]!D  /4K  #V00  ]U@  /AR  #YD   ^:L  /C$  #XX0#_
M  L _P ( /\ "0#_  P _P 2 /\ &@#_ "8 _P R /\ /@#_ $@ _P!2 /\
M6@#_ &( _P!I /\ ;P#_ '4 _@![ /P @0#[ (@ ^0"/ /< EP#U *  \P"J
M /( MP#O ,D [0#F .P ^P#K /\ ZP#_ -T _P#. /\ Q@#_ ,( _P#_  0
M_P   /\   #_  4 _P - /\ %0#_ "$ _P L /\ . #_ $, _0!, /D 5 #W
M %P ] !C /( :0#P &\ [@!U .P >P#J (( Z ") .< D0#D )H X@"D .
ML #= ,  V@#< -@ ] #5 /\ TP#_ ,L _P#! /\ NP#_ +< _P#_    _P
M /\   #_    _P * /T $0#Y !L ]@ G /0 ,@#P #P [ !& .@ 3@#D %8
MX0!< -X 8P#< &@ V0!N -4 = #2 'L T "" ,T B@#+ ), R "= ,8 J #$
M +< P0#, ,  ZP"^ /\ O0#_ +T _P"T /\ K@#_ *L _P#_    _P   /\
M  #Z    \@ % .H #@#E !8 X  A -T *P#; #8 TP _ ,X 2 #* $\ QP!6
M ,0 7 #" &$ P !G +X ;0"\ ', N@!Z +@ @@"V (L M "6 +( H0"P *\
MK@#! *T X "K /< J@#_ *D _P"F /\ H0#_ )\ _P#_    _P   /<   #H
M    W    -  "@#* !$ Q0 ; ,( )0"_ "\ O  X +@ 00"U $@ L@!/ +
M50"N %L K !A *H 9@"H &P IP!S *4 >P"C (0 H0". )\ F@"= *< FP"X
M )H T "9 .\ F #_ )< _P"6 /\ E #_ )( _P#_    ]@   .0   #2
MQ0   +L !0"U  X L  5 *P 'P"J "D J  R *4 .@"B $( H !) )X 3P"<
M %4 F@!: )@ 8 "6 &8 E0!L ), = "2 'T D "' (X DP", *$ BP"P (H
MQ0"( .8 AP#[ (8 _P"' /\ AP#_ (8 _P#X    Y0   ,T   "]    LP
M *H   "C  H GP 1 )L &0"9 ", EP L )4 - "2 #P D !# (X 20", $\
MB@!4 (D 6@"' &  A@!F (0 ;@"# '< @0"! '\ C0!^ )L ? "J 'L O !Z
M -L > #U '@ _P!X /\ > #_ '@ _P#M    T0(  +L"  "L 0  H@   )L
M  "6  4 D0 - (T % "+ !T B  F (8 +@"$ #8 @@ ] (  0P!^ $D ?0!/
M 'P 50!Z %L >0!A '< :0!U '$ = !\ '( B !Q )8 ;P"E &X M@!M ,X
M; #N &L _P!K /\ :P#_ &L _P#?"P  P@P  *X,  ">#   DPL  (P'  "(
M @  A0 ) ($ $ !_ !< ?  @ 'H * !X #  =@ X '0 /@!S $0 <0!* '
M4 !N %8 ;0!= &P 9 !J &T : !W &< A !E )( 9 "A &, L@!A ,D 8 #I
M &  _ !@ /\ 8 #_ &  _P#0$   MA$  *(2  "3$@  B!$  ( /  !\#0
M>0D! '@#"P!U !$ <P : '  (P!N 2L ; $S &H".0!I T  9P-& &8$3 !E
M!%( 8P59 &(%80!@!6H 7P9T %T&@0!<!X\ 6@>? %D'L !7!\8 5@GG %8*
M^P!5"O\ 50K_ %8*_P#&%0  K1<  )D8  "*&   ?Q<  '86  !Q$P  ;A
M &T-!0!M"0T :@D4 &<*'0!E"B8 8PLN &(,-0!@##P 7PQ" %X-2 !<#4\
M6PU6 %D-7@!8#F@ 5@YS %4.@ !3#H\ 40Z? % .L0!.#L@ 31#J $T0_0!-
M$/\ 31#_ $T0_P"\&P  I1P  )(=  "#'@  =QT  &\<  !I&@  9A<  &04
M  !D$ @ 8@\0 %\0& !=$"$ 6Q$I %H1,0!8$C@ 5Q(^ %8210!4$DP 4Q-3
M %$36P!0$V4 3A1P $P4?0!+%(P 212< $<5K@!&%<4 117H $46_@!%%O\
M117_ $45_P"U'P  GB$  (LB  !\(@  <2(  &@A  !B'P  7QT  %P:  !;
M%P( 6A4- %<6% !5%AT 5!<E %(8+0!1&#0 3Q@[ $X90@!-&4@ 2QI0 $H:
M6 !(&F( 1QIM $4;>@!#&XD 0AN: $ ;K  _&\( /ASE #T<_  ^'/\ /AO_
M #X;_P"O(P  F"0  (8E  !W)@  ;"8  &,E  !=)   62(  %8?  !4'0
M4QP+ %$<$@!.'1H 31TB $L>*0!*'C$ 21\W $<?/@!&($4 12!- $,@50!"
M(%\ 0"%J #\A=P ](8< .R&8 #DAJ@ X(L  -R+C #<B^P W(O\ ."'_ #@A
M_P"J)@  E"<  ($I  !S*0  9RD  %\I  !8*   5"8  %$C  !/(@  3"('
M $HB$ !((A< 1R,? $4D)@!$)"X 0B0T $$E.P! )4, /R5* #TF4P \)EP
M.B9G #DF=0 W)X0 -2>6 #0GJ  R)[X ,2?A #$G^0 R)O\ ,B;_ #,E_P"E
M*0  CRH  'TL  !O+   9"T  %LL  !5*P  4"H  $PH  !*)@  1R<$ $0G
M#0!"*!0 02@< #\I(P ^*2L /2DR #PJ.0 [*D  .2I( #@K4  V*UH -2ME
M #,K<@ Q*X( ,"R4 "XLIP L++P *RS> "PL^  L*_\ +2K_ "TJ_P"A+
MBRT  'DN  !K+P  8"\  %@O  !1+@  3"X  $@L  !%*P  02L  #\L"P ]
M+!$ .RT9 #HN(0 Y+B@ -RXO #8O-@ U+SX -"]% #,O3@ Q,%@ ,#!C "XP
M<  L,(  *C"2 "DPI0 G,+H )C#< "8P]P G+_\ *"__ "@N_P"<+@  AS
M '8Q  !H,@  73(  %4R  !.,0  2#$  $0P  ! +P  /#   #HQ"0 W,1
M-C(6 #4R'@ S,R4 ,C,L #$S,P P-#L +S1# "TT3  L-%8 *C5A "DU;@ G
M-7X )360 ",UHP B-;D (379 "$T]@ B-/\ (S/_ ",R_P"8,0  @S,  '(T
M  !E-   6C4  %$U  !+-   130  $ T   Z,P  -S0  #0U!@ R-@X ,#<3
M "\W&P N-R( +3@I "LX,0 J.#@ *3E  "@Y20 F.5, )3E? ",Y;  A.GP
M(#J. !XZH@ <.K< &SG5 !PY]0 =./\ '3C_ !XW_P"3-   ?S8  &XW  !A
M-P  5S<  $XW  !(-P  0C<  #PW   U.   ,CD  "\Z @ L.PL *CP1 "D\
M&  H/1\ )CTF "4]+@ D/34 (SX] "(^1@ @/E  'SY< !T_:0 ;/WD &C^,
M !@_H  6/[4 %3[2 !8^\P 7/?\ &#S_ !@\_P".-P  >C@  &HY  !>.@
M4SH  $LZ  !%.@  /SH  #DZ   R/   +CX  "E    F00@ )$(. ")"%  A
M0AL ($,C !]#*@ >0S( '$,Z !M$0P :1$T &$19 !=$9P 51'< $T2* !)$
MG@ 11+, $$30 !!#\@ 10O\ $D+_ !-!_P").P  =CP  &8]  !:/0  4#T
M $@]  !"/0  /#T  #8^   O0   *D(  "5$   A1@, '4@, !M)$0 921<
M&$D> !=))@ 622X %4HV !1*0  32DH $4I6 !!*9  /2G0 #DJ'  U*FP ,
M2K  "DK*  M)[  ,2/\ #4?_  U'_P"#/@  <3\  &)   !60   34   $5
M   _0   .4$  #)"   K10  )D<  "%)   <2P  %DX' !-0#@ 24!, $5 9
M !!0(0 /4"D #E Q  U0.P -448 "U%1  I17P )46\ !U"!  50E@ #4*L
M E#%  -/Z  #3_L !4[_  9-_P!]0@  :T,  %U$  !21   2D0  $-#   \
M1   -44  "Y'   G2@  (4P  !Q/   740  $E0#  Y7"@ +6!  "E@5  A8
M'  '6"0 !E@L  58-@ #6$   5A,  !86@  6&D  %A\  !8D0  5Z<  %?
M  !6Y0  5OD  %7_  !5_P!V1P  9D<  %E(  !/1P  1T<  $!'   X2
M,$H  "E-   B4   '%,  !95   16   #5L"  E>"0 $7PX  %\2  !?&
M8!\  & G  !@,   8#L  &!'  !@5   8&,  &!V  !@BP  7Z(  %^[  !?
MX@  7OD  %W_  !=_P!O2P  84P  %5,  !,2P  1$L  #M,   R3@  *U$
M "-4   <5P  %EL  !%>   -8   "&,   )F!P  9PP  &</  !H$P  :1D
M &HA  !J*0  :C0  &I   !J30  :ET  &IO  !JA0  :IT  &FV  !HW0
M:/<  &?_  !F_P!I40  7%   %)0  !*3P  /U   #53   M5@  )%D  !U=
M   68   $&0   QG   &:@   &X   !O P  < @  '$-  !R$   =!0  '4;
M  !V(P  =RP  '<X  !V1@  =E8  '9H  !V?@  =I<  '6Q  !TTP  <_4
M '/_  !R_P!C5@  6%4  %!4  !$50  .5@  "];   F7P  '6,  !5G   0
M;   "G    1S    =@   'H   !\    ? ,  'X(  !_#   @1   ((4  "$
M&P  A20  (8O  "&/0  ADT  (5?  "%=0  A8\  (2I  "#R0  @O$  ('_
M  " _P!?6P  5EH  $E;   ]7@  ,F$  "=F   >:P  %7    YU   )>0
M 7X   "!    A0   (@   "*    BP   (T!  ".!@  D L  )$/  "3%
ME1L  )<F  "7-   ET0  )=6  "6;   E88  )6B  "4P0  D^H  )+_  "2
M_P!=80  3V$  $)D   V:0  *FX  !]T   5>0  #G\   >$    B0   (X
M  "2    E@   )@   ":    FP   )T   "?    H0,  *,(  "E#0  IQ,
M *D<  "J*   JCD  *I+  "J80  J7H  *B9  "HM0  I]T  *?X  "F_P!6
M:   2&P  #IP   N=@  (GT  !>$   .B@  !Y    "6    F@   )\   "C
M    IP   *H   "K    K0   *\   "Q    LP   +4   "X!0  N@P  +T2
M  # '   P"T  ,!   "_50  OVX  +Z+  "^J   OLD  +WO  "\_@!.=
M0'D  #)_   EAP  &8X  !"5   'G    *(   "G    K    +    "U
MN0   +P   "]    OP   ,$   ##    Q@   ,@   #*    S0(  - +  #5
M$@  UB$  -<T  #820  V6   -I\  #:F@  V[4  -O9  #;\@!&@@  .(D
M "N0   =F   $J    JG    K@   +0   "Y    O@   ,(   #(    RP
M ,X   #/    T@   -0   #6    V@   -T   #?    X@   .8   #J"@
M[Q,  / E  #R.@  \U$  /1K  #TB0  ]:4  /6_  #UW0#_  8 _P # /\
M!0#_  L _P 0 /\ %P#_ "( _P M /\ .0#_ $0 _P!- /\ 50#_ %T _P!D
M /\ :@#_ '  _0!V /L ? #Y (, ]P"* /4 D@#S )L \ "F .X LP#K ,0
MZ0#D .< ^0#F /\ Y0#_ -, _P#' /\ OP#_ +L _P#_    _P   /\   #_
M  ( _P + /\ $@#_ !T _P H /\ ,P#_ #X _ !' /@ 3P#T %< \0!= .X
M8P#L &D Z@!O .@ =0#F 'P Y "# .( BP#? )4 W "? -D JP#5 +L T@#4
M ,\ \@#- /\ S #_ ,4 _P"Z /\ M #_ +  _P#_    _P   /\   #_
M_P & /D #P#U !< \P B /$ +0#M #< YP!  .( 20#? %  VP!7 -< 70#4
M &, T0!H ,\ ;@#, '4 R@!\ ,@ A #% (T P@"8 ,  I "] +( NP#& +D
MZ "X /T MP#_ +8 _P"M /\ IP#_ *, _P#_    _P   /\   #U    ZP !
M .0 # #> !, V0 < -, )@#1 #  S  Z ,@ 0@#$ $H P !0 +T 5@"[ %P
MN0!A +< 9P"U &T LP!T +$ ? "O (4 K0"0 *H G "H *H I@"[ *4 V@"C
M /4 HP#_ *( _P"> /\ F@#_ )< _P#_    _@   .\   #?    T    ,<
M!P#!  \ O  7 +D ( "W "H M0 S +  .P"M $, JP!) *@ 3P"F %4 I !:
M *, 8 "A &8 GP!M )T = "< 'T F@"( )@ E "6 *( E "R )( R0"1 .L
MD0#_ )  _P"0 /\ C #_ (H _P#\    [    -D   #'    N@   +$  @"K
M  P IP 2 *0 &P"A "0 H  L )X -0"; #P F !# )8 20"4 $\ D@!4 )
M6@"/ %\ C0!F (L ;0") '8 B "  (8 C "$ )H @@"J ($ O@"  .  @ #Y
M '\ _P!_ /\ ?P#_ 'X _P#Q    V    ,(   "S    J    *    "9  <
ME0 . )( %0"0 !X C@ F (T +@"* #8 AP ] (4 0P"$ $D @@!. ($ 5 !_
M %D ?@!@ 'P 9P!Z &\ >0!Z '< A@!U )0 = "C '( M0!R ,\ <0#Q '
M_P!P /\ < #_ '$ _P#A    Q    +    "B    EP   )$   "+  ( A@ +
M (, $0"! !@ ?P A 'T *0!\ #  >0 W '@ /0!V $, = !) ', 3@!R %0
M< !: &\ 8@!M &H :P!T &H @ !H (X 9P"= &4 KP!E ,8 9 #H &0 _0!C
M /\ 8P#_ &0 _P#/!0  M@<  *,(  "4"   B0<  ((#  !^    >P & '<
M#@!U !, <@ ; '$ (P!O "L ;0 R &P . !J #X :0!$ &< 20!F $\ 90!6
M &, 70!B &4 8 !O %\ >P!= (D 7 "9 %L J@!9 +\ 60#A %@ ^ !8 /\
M6 #_ %D _P#"#   J@T  )<.  ")#@  ?0X  '8-  !Q"@  ;P8  &T "@!K
M !  :0 6 &< '@!E "8 8P M &$ ,P!@ #D 7P _ %T 10!< $L 6P!2 %H
M60!8 &( 5P!L %4 > !3 (8 4@"6 %$ IP!0 +L 3P'; $X"] !. _\ 3@3_
M $X#_P"X$   H1(  (X3  !_$P  =!,  &P2  !G$   90X  &,+ P!C!@P
M8001 %X#&0!<!"$ 6P4H %D&+P!8!C4 5@<[ %4'0@!4!T@ 4PA/ %$(5@!0
M"5\ 3@EI $T)=@!+"H0 20J4 $@*I@!'"KH 1@K8 $4+\P!%#/\ 10S_ $4,
M_P"P%   F18  (<8  !X&0  ;1@  &47  !?%@  7!,  %H1  !:#@8 6@P-
M %<,% !5#!P 4PTD %(-*P!0#3$ 3PXX $X./@!-#D4 2PY- $H.50!(#UX
M1P]H $4/=0!#$(0 01"5 $ 0I@ ^$+L /1#< #T1]@ ]$?\ /1#_ #X0_P"I
M&0  DAL  ($<  !R'0  9QT  %\<  !9&P  51D  %,6  !2$P  4A$* % 0
M$ !.$1@ 3!$@ $H2)P!)$BX 2!,T $<3.P!%$T( 1!-) $,44@!!%%L /Q1E
M #X5<@ \%8$ .A62 #@5I  W%;D -178 #46]0 V%O\ -A;_ #<5_P"C'
MC1X  'L@  !M(0  8B$  %HA  !4'P  4!X  $T;  !,&0  2Q8& $D6#@!'
M%Q4 11<< $08) !"&"H 01@Q $ 9.  _&3\ /1E& #P:3P Z&E@ .1IC #<;
M;P U&WX ,QN0 #(;H@ P&[< +QO3 "\<\P O&_\ ,!O_ # ;_P"='P  B"(
M '<C  !I)   7B0  %8D  !0(P  2R(  $@@  !&'0  11P" $,<# !!'!(
M/QT9 #X=(0 \'B< .QXN #H?-0 Y'SP -Q]$ #8?3  T(%8 ,R!@ #$@;0 O
M('P +2&. "PAH  J(;4 *2'0 "DA\@ I(?\ *B#_ "L@_P"9(@  A"4  ',F
M  !E)P  6R<  %,G  !,)@  1R4  $0D  !"(0  /R$  #TA"0 [(1  .2(6
M #@B'@ V(R4 -2,K #0D,@ S)#D ,B1! # D2@ O)5, +25> "LE:P J)7H
M*"6, "8EGP D);, (R7. ",E\  D)?\ )23_ "4D_P"4)0  @"<  &\I  !B
M*@  5RH  $\J  !)*0  1"@  $ G   ])@  .B4  #<F!@ U)@X -"<4 #(G
M&P Q*"( ,"@I "\H,  M*3< +"D_ "LI1P I*5$ *"I< "8J:0 D*G@ (RJ*
M "$JG0 ?*K( 'BK, !XJ[P ?*?\ ("G_ "$H_P"0*   ?"H  &PK  !?+
M5"P  $PL  !&+   02L  #PK   X*@  -2H  #(K P P*PP +BP1 "TL&  L
M+!\ *BTF "DM+0 H+30 )RX\ "8N10 D+D\ (RY: "$O9P ?+W8 '2^( !PO
MFP :+[  &"_* !@N[0 9+O\ &RW_ !LM_P",*P  >"T  &@N  !;+P  42\
M $DO  !#+P  /BX  #DN   T+@  ,"X  "TO   K, H *3$0 "<Q%0 F,1P
M)3(C "0R*@ C,C$ (3,Y " S0@ ?,TP '3-7 !LS9  :-'0 &#2& !8TF@ 4
M,ZX $S/( !,S[  4,_\ %3+_ !8Q_P"'+@  ="\  &4Q  !8,0  3C(  $8R
M  ! ,0  .S$  #8Q   Q,0  *S,  "@T   E-08 (S8- "$V$@ @-QD 'S<@
M !XW)P =."X &S@V !HX/P 9.$D %SE5 !4Y8@ 4.7$ $CF$ !$YF  0.:T
M#CC'  XXZP 0./\ $#?_ !$V_P"#,0  <#(  &$T  !5-   2S0  $0T   ]
M-   .#0  #,T   M-0  *#<  "0Y   @.@( '3L+ !L\$  9/14 &#T< !<]
M(P 6/2L %3XS !0^/  2/D8 $3Y2 ! ^7P //F\ #CZ!  P^E0 +/JD "C[!
M  H]Y  +/?L ##S_  T[_P!]-   :S8  %TW  !1-P  2#<  $$W   [-P
M-3<  # W   J.0  )3L  " ]   </P  %T$& !1##0 20Q( $4,8 !%#'P 0
M1"< #T0O  Y$.0 -1$, #$1.  M$6P )1&H !T1\  9$D  $0Z4  D.]  -#
MX  #0_8 !$+_  9!_P!X.   9SD  %DZ  !..@  13H  #XZ   X.@  ,SH
M "T[   G/0  (4   !Q"   71   $T8#  ])"@ -2@\ #$H4  M*&P )2B,
M"$HK  =*-  %2CX !$I)  )*5@  2F4  $IW  !*BP  2J$  $FY  !)W0
M2?4  $C_  !(_P!R/   8CT  %4^  !*/@  0CT  #P]   V/0  +SX  "E
M   C0@  '44  !='   32@  #TP"  M/"0 '4 T  U$1  !1%P  41X  %$F
M  !1+P  43D  %%$  !240  4F   %%R  !1AP  49T  %&U  !0V   4/4
M $__  !/_P!L0   74$  %%!  !'00  0$   #E    R00  *D,  "1&   >
M2   %TL  !).   .40  "U,!  96!P  5PP  %@0  !8$P  61D  %HA  !:
M*0  6C,  %H_  !:3   6EH  %IL  !:@0  69D  %FQ  !8T0  6/0  %?_
M  !7_P!E10  6$4  $U%  !%1   /D0  #5%   M1P  )4H  !Y-   84
M$E,   Y6   *60  !%P   !>!   7PD  & -  !A$   8A4  &,;  !D(P
M9"T  &0X  !D10  9%0  &1F  !D>P  8Y,  &.M  !BS   8?(  &'_  !@
M_P!?2@  4TH  $I)  !#2   .4D  "],   G3P  'U(  !A5   260  #5T
M  A@   "8P   &8   !H 0  :04  &H*  !K#0  ;1$  &X6  !P'0  <28
M '$Q  !P/@  <$X  '!?  !P<P  ;XT  &^G  !NQ@  ;>\  &S_  !L_P!:
M3P  4$X  $A-   ]3@  ,U$  "E4   @6   &%P  !%@   ,9   !F@   !K
M    ;P   '(   !T    =0   '<$  !X"0  >@T  'P0  !]%@  ?QX  ( H
M  " -0  @$4  ']6  !_:P  ?X0  'Z@  !]O@  ?.D  'O_  !Z_P!65
M3E,  $)4   W5@  +%H  ")?   88P  $6@   MM   #<@   '8   !Z
M?0   (    "#    A    (8   "' @  B0<  (L,  "-$   D!8  )(?  "2
M+   DCL  ))-  "18@  D7H  (^7  "/M   CN$  (S[  ",_P!560  2%H
M #M=   O80  )&8  !EL   1<@  "G<   )]    @@   (8   "+    C@
M )$   "3    E0   )<   "9    FP   )T$  "?"@  H@\  *06  "F(0
MIC$  *9#  "E5P  I'   *..  "CJP  H=   *#U  "?_P!.80  0&0  #-I
M   G;@  &W4  !%\   +@P   (D   ".    DP   )@   "=    H0   *0
M  "E    IP   *D   "K    K0   +    "R    M0@  +@.  "\%@  O"4
M +PW  "[3   NF0  +F!  "WH@  M\   +?J  "W_ !&:P  .7   "MW   ?
M?P  $X8   N.   !E0   )L   "A    I@   *L   "P    LP   +<   "W
M    N@   +P   "_    P0   ,0   #'    R@   ,T%  #1#@  U!D  -0K
M  #40   TU@  --T  #3D@  TK   -+3  #2\@ ^>0  ,8   ".(   7D0
M#9D   .@    IP   *X   "S    N    +T   #"    Q@   ,H   #*
MS0   ,\   #2    U0   -D   #=    WP   .,   #G!0  ZP\  .P?  #M
M,P  [DL  .]D  #O@@  \)\  /&Y  #QV #_    _P   /\ ! #_  D _P .
M /\ %0#_ !X _P I /\ - #_ #\ _P!( /\ 4 #_ %@ _P!> /\ 90#] &L
M^P!Q /D =P#X 'X ]@"% /, C0#Q )< [@"B .L KP#H ,  Y@#@ ., ^ #B
M /\ VP#_ ,L _P#! /\ N0#_ +0 _P#_    _P   /\   #_    _P ) /\
M$ #_ !D _P C /\ +@#] #D ^0!" /4 2@#R %( [@!8 .L 7@#I &0 Y@!J
M .0 < #B '8 WP!] -T A@#9 (\ U0": -$ IP#. +8 RP#. ,D \ #' /\
MQ0#_ +L _P"T /\ K0#_ *D _P#_    _P   /\   #_    ^P " /8 #0#Q
M !, [0 > .P * #I #( XP [ -T 1 #8 $L TP!1 -  6 #- %T RP!C ,D
M: #& &\ Q !V ,( ?@"_ (< O "2 +H GP"W *T M0#! +( Y "Q /T KP#_
M *P _P"E /\ H #_ )P _P#_    _P   /L   #N    Y    -P " #3 !
MSP 8 ,L (@#) "L Q@ T ,$ /0"] $0 N@!+ +< 40"U %8 L@!< +  80"N
M &< K !N *H =@"H '\ I@"* *, E@"A *4 GP"V )T T0"< /, FP#_ )P
M_P"6 /\ DP#_ )  _P#_    ]@   .<   #3    Q@   +T  P"X  T LP 3
M +$ ' "O "4 K@ N *D -@"F #T HP!$ *$ 2@"? $\ G0!5 )L 6@": &
MF !F )8 ;@"4 '< D@"! )  C@". )P C "M (H PP") .@ B #_ (D _P"'
M /\ A0#_ (( _P#S    XP   ,P   "\    L    *<   "A  @ G@ / )L
M%@"9 !\ F  G )8 +P"3 #< D0 ] (X 0P", $D BP!. (D 5 "' %D A0!@
M (0 9P"" &\ @ !Z 'X A@!\ )0 >@"D 'D N !X -@ =P#W '@ _P!X /\
M=P#_ '4 _P#F    RP   +<   "H    G@   )8   "/  0 BP , (@ $@"'
M !D A0 A (0 *0"" #  ?P W 'T /0!\ $, >@!( 'D 30!W %, =@!9 '0
M80!R &D <0!S &\ ?P!M (T ; "= &H KP!I ,@ : #M &D _P!I /\ :0#_
M &D _P#2    N    *4   "7    C0   (8   "!    ?  ( 'D #@!W !0
M=@ < '0 (P!S "L <0 Q &\ -P!N #T ; !# &L 2 !J $X : !4 &< 6P!E
M &, 8P!M &( > !@ (< 7P"6 %T J != +X 7 #D %P ^P!< /\ 7 #_ %P
M_P#"    J@$  )@#  ")!   ?P(  '@   !T    <  $ &T # !K !$ :0 7
M &@ '@!F "4 90 L &, ,@!B #@ 8  ] %\ 0P!> $D 7 !/ %L 5@!: %X
M6 !H %< <P!5 ($ 5 "1 %( HP!1 +< 40#6 %$ ]0!1 /\ 40#_ %( _P"V
M!P  GPD  (T+  !^#   <PL  &P*  !H!P  90,  &, !P!A  T 7P 3 %T
M&@!< "$ 6P G %D +0!8 #, 5@ Y %4 /P!4 $4 4P!+ %$ 4@!0 %H 3P!D
M $T ;P!, 'T 2@"- $D GP!( +( 1P#, $< [P!& /\ 1P#_ $< _P"L#
ME0X  (,0  !U$   :Q   &,/  !>#@  6PP  %H) @!9! H 5P / %4 %0!3
M !P 4@ C %$ *0!/ "\ 3@ U $T!.P!, 4$ 2@)( $D"3P!( E< 1@-A $4#
M;0!# WH 0@.+ $ #G  _ Z\ /@/( #T$Z@ ]!?P /0;_ #X&_P"D$   CA(
M 'P3  !N%   9!0  %P3  !6$@  4Q$  %$.  !0# 4 4 D, $\'$0!-!Q<
M2P@? $D()0!("2L 1PDQ $8). !$"CX 0PI% $(*30! "U4 /PM? #T+:P \
M"WD .@R* #@,G  W#*\ -0S' #4,Z0 U#?T -0W_ #8,_P"=$P  AQ4  '87
M  !I&   7A@  %88  !0%P  314  $H3  !)$0  20X' $@-#@!&#1, 1 T:
M $,.(0!"#B@ 0 XN #\.-0 ^#SP /0]# #L02P Z$%0 .!!> #80:P T$'D
M,A"* #$0G  O$+  +1#) "T1[  M$?\ +A'_ "\0_P"7%@  @AD  '$;  !D
M'   61P  %$<  !,&P  1QH  $08  !#%0  0A," $$2"P! $1  /A(7 #P2
M'@ [$R4 .A,K #@3,@ W$SD -A1  #042  S%%$ ,11< # 5:  N%7< +!6(
M "H5F@ H%:X )Q7' "85Z@ G%?\ *!7_ "D5_P"1&@  ?1P  &T>  !@'P
M5A\  $X?  !('@  0QT  $ <   ^&@  /1@  #L7!P Y%@X .!<4 #87&P U
M&"( ,Q@H #(8+P Q&38 ,!D] "X91@ M&D\ *QI9 "H:9@ H&G0 )AJ& "0:
MF0 B&JT (1K% " :Z  A&OX (AK_ ",:_P"-'0  >1\  &DA  !<(@  4B(
M $HB  !$(0  /R$  #P@   Y'@  .!L  #4<!  T' T ,AP2 # =&  O'1\
M+ATE "T>+  K'C, *AX[ "D?0P G'TT )A]7 "0?9  B'W( (!^$ !\?EP =
M'ZL &Q_# !L?YP ;'_T '1__ !X>_P")(   =2(  &4C  !9)   3R4  $<E
M  !!)   /",  #@C   U(@  ,R   # @ 0 N(0H +"$0 "LA%0 J(AP *"(C
M "<B*0 F(S  )2,X ",C00 B)$H (215 !\D80 =)'  &R2" !DDE0 7)*H
M%B3! !4DY0 6)/P %R/_ !DC_P"%(@  <20  &(F  !6)P  3"<  $0G   ^
M)P  .28  #4F   Q)0  +B0  "LE   I)0< )R8. "4F$P D)QD (R<@ "(G
M)P A*"X ("@V !XH/@ =*$@ &RE3 !DI7P 8*6X %BF  !0IE  2*:@ $2G
M !$HY  1*/L $RC_ !0G_P" )0  ;B<  %\H  !3*0  22H  $(I   [*0
M-BD  #(H   N*   *B@  "8I   D*@0 (BL, " K$0 ?+!8 '2P= !PL)  ;
M+2L &BTS !@M/  7+44 %BY0 !0N70 2+FP $2Y^ ! ND@ .+J< #2V]  TM
MWP -+?D #BS_ ! L_P!\*   :BH  %LK  !0+   1BP  #\L   Y+   -"L
M "\K   K*P  )BP  "(N   ?+P  '# ) !HQ#@ 9,1, %S$: !8R(0 5,B@
M%#(P !,R.0 2,T, $3-. ! S6P .,VD #3-Z  PSC@ *,Z( "#*Y  @RV0 (
M,O0 "C'_  LQ_P!W*P  9BT  %@N  !-+P  0R\  #PN   V+@  ,2X  "TN
M   I+@  (S   !\R   ;,P  %S4% !0V#  2-Q$ $3<6 !$W'0 0."0 #S@L
M  XX-0 -.#\ ##A*  LX5P ).&4 !SAV  4XB@ #.)\  3>U  $WTP "-_$
M S;_  4V_P!S+@  8C   %0Q  !),0  03$  #DQ   T,0  +S   "LP   E
M,@  (#,  !LV   7.   $SH" ! \"0 -/0X ##T3  L]&0 */2$ "3TI  @]
M,0 &/CL !3Y&  ,^4@ !/F$  #YR   ^A@  /9P  #VR   ]T   //   #S_
M   \_P!M,@  73,  % T  !&-   /C0  #<T   R,P  +3,  "<T   B-@
M'3@  !@Z   4/0  $#\"  U!"  )0PT !D01  -$%@ "1!T  $0D  !$+0
M1#8  $1!  !$3@  1%P  $1M  !$@0  1)@  $.O  !#S0  0O   $+_  !"
M_P!H-@  6#<  $PX  !#.   .S<  #4V   P-@  *3<  ",Y   >.P  &#T
M !-    00@  #44!  A'!P #20P  $D/  !*$P  2QD  $L@  !+*   2S(
M $L]  !,20  3%<  $MH  !+?0  2Y0  $JL  !*R@  2>\  $G_  !)_P!B
M.@  5#L  $D[  ! .P  .3H  #,Y   L.@  )3P  !\_   900  $T0  !!'
M   ,20  "$P   )/!0  4 H  % -  !1$   4A4  %0;  !4(P  5"P  %0W
M  !41   5%(  %1C  !4=P  5(\  %.H  !2Q@  4NT  %'_  !1_P!</P
M3S\  $4_   ^/@  -ST  "\^   G0   ($,  !E&   320  #TP   M/   &
M4@   %0   !7 @  6 <  %D+  !:#@  6Q$  %T6  !>'0  7R8  %\Q  !>
M/0  7DP  %Y=  !><0  78D  %VC  !<P0  6^L  %K_  !:_P!61   2T,
M $-"   \00  ,D(  "E%   A2   &DL  !-.   .4@  "E4   -9    6P
M %X   !@    8@(  &,&  !E"@  9@X  &@1  !J%P  :Q\  &LI  !K-@
M:T4  &M6  !J:@  :H(  &F=  !HNP  9^<  &;_  !E_P!12   2$@  $%&
M   W1P  +$H  "--   ;40  $U4   Y9   (70   6$   !D    9P   &H
M  !L    ;@   '    !R!0  <PD  '4-  !W$0  >A@  'LA  ![+@  >CT
M 'I.  !Y8@  >7D  'B6  !WLP  =>   '3\  !S_P!.30  1TP  #M-   P
M3P  )E,  !Q8   37   #6$   9F    :@   &\   !R    =@   'D   !\
M    ?0   '\   "!    @P(  (8'  "(#   BQ$  (X8  ".)   CC,  (U$
M  ",6   BV\  (J,  ")J@  B,\  (;W  "%_P!-40  05,  #15   I6@
M'E\  !1E   -:@  !7    !V    >P   '\   "#    AP   (H   "-
MC@   )$   "3    E0   )@   ":!0  G0P  * 1  "C&@  HR@  *(Z  "A
M3@  H&4  *"!  ">H   G<$  )ON  ":_P!&60  .5P  "UA   A9P  %FX
M  YU   %>P   ($   "'    C0   )(   "6    F@   )T   "?    H0
M *0   "F    J    *L   "N    L0,  +0+  "X$0  N1X  +DO  "X0P
MMUH  +5V  "TEP  M+4  +'B  "P_  _9   ,6D  "5O   8=P  #W\   :'
M    C@   )0   ":    H    *4   "J    K@   +$   "R    M0   +<
M  "Z    O    +\   ##    Q@   ,D   #."@  TA,  -(C  #1-P  T$\
M ,YJ  #-B@  RJL  ,O+  #+[P W<0  *7@  !V    1B0  ")$   ":
MH0   *<   "M    LP   +D   "^    P@   ,4   #&    R0   ,P   #.
M    T@   -4   #:    W@   .$   #E    Z@L  .L7  #J*P  ZD,  .I>
M  #J>@  ZYD  .NU  #KU0#_    _P   /\  0#_  < _P - /\ $@#_ !L
M_P E /\ +P#_ #H _P!# /\ 2P#_ %, _P!: /T 8 #[ &8 ^@!K /@ <@#V
M '@ ] "  /$ B0#O )( [ "= .D J@#F +P XP#< -\ ]P#= /\ S #_ +X
M_P"U /\ L #_ *T _P#_    _P   /\   #_    _P & /\ #0#_ !0 _P ?
M /\ *0#[ #, ]P ] /, 10#O $T [ !3 .@ 60#E %\ XP!E .  :@#= '$
MV@!X -8 @ #2 (H SP"5 ,P H@#( +( Q0#) ,( [0#  /\ NP#_ +  _P"H
M /\ I #_ *$ _P#_    _P   /T   #Z    ^    /  "0#L !$ Z  9 .<
M(P#E "T W@ V -8 /@#1 $8 S0!, ,H 4@#( %@ Q0!= ,, 8P#  &D O@!P
M +P > "Y ($ MP"- +0 F@"Q *D K@"\ *P X0"J /P J #_ *  _P"9 /\
ME@#_ )0 _P#_    ^0   /(   #G    VP   -$ ! #*  T QP 4 ,0 '0#"
M "8 OP O +L -P"W #\ M !% +$ 2P"N %$ K !6 *H 7 "H &$ I@!H *,
M< "A 'D GP"$ )T D0": *  F "Q )8 S "5 /$ E #_ )$ _P"+ /\ B #_
M (8 _P#W    [    -X   #)    O    +0   "O  H JP 0 *D %P"H "
MIP H *( , "? #@ G  ^ )H 1 "8 $H E@!/ )0 50"3 %H D0!A (\ : "-
M '$ BP![ (D B "' )< A0"H (, O@"! .0 @ #_ (  _P!\ /\ >P#_ 'D
M_P#I    UP   ,$   "Q    I@   )T   "7  4 E  - )( $@"0 !H CP B
M (X *@"+ #$ B0 X (< /@"% $, @P!( ($ 3@!_ %0 ?@!: 'P 80!Z &D
M> !S '8 ?P!U (X <P"? '$ LP!P -  ;P#V &\ _P!O /\ ;0#_ &P _P#:
M    OP   *P   ">    DP   (P   "%    @@ ) '\ #P!^ !4 ?0 < 'P
M) !Z "L =P Q '4 -P!T #T <@!" '$ 2 !O $T ;@!3 &P 6@!K &( :0!L
M &< > !F (8 9 "7 &( J@!A ,( 8 #K &$ _P!A /\ 80#_ &  _P#%
MK0   )L   "-    @P   'P   !W    <@ % '  # !N !$ ;  7 &P '@!K
M "4 :0 L &< ,0!F #< 9  ] &, 0@!B $@ 8 !. %\ 50!= %T 7 !F %H
M<@!9 (  5P"0 %8 HP!5 +D 5 #> %0 ^P!4 /\ 50#_ %4 _P"V    GP
M (T   !_    =0   &X   !I    9@ ! &, "0!A  X 8  3 %\ &0!> "
M70 F %L + !: #( 6  W %< /0!6 $, 50!) %, 4 !2 %@ 40!A $\ ; !.
M 'H 3 "* $L G !* +$ 20#. $D \P!) /\ 20#_ $H _P"J 0  E 4  (('
M  !T"   :@@  &,&  !>!   6P   %D !0!7  P 5@ 0 %0 %0!3 !L 4@ B
M %$ * !0 "T 3@ S $T . !, #X 2P!% $H 3 !( %0 1P!= $8 : !$ '4
M0P"% $$ F !  *L 0 #% #\ Z@ _ /\ 0 #_ $  _P"@"   B@L  'D-  !L
M#0  80T  %H-  !5"P  4@D  % &  !/ @@ 3@ - $P $@!+ !< 2@ > $D
M(P!' "D 1@ O $4 - !$ #H 0@!! $$ 2 !  %  /@!: #T 9  \ '( .@""
M #D E  X *< -P"^ #8 XP V /D -@#_ #< _P"8#0  @PX  '(0  !E$0
M6Q$  %,0  !.$   2@X  $@-  !'"@, 1P<* $4$#@!$ A, 0@(: $$"( !
M R4 /@,K #T$,0 \!#< .P0^ #H%10 Y!4X -P57 #8%8@ T!G  ,@:  #$&
MD@ P!J4 +P6[ "X%W0 N!O4 +0?_ "X'_P"1$   ?1$  &P3  !?%   510
M $X4  !($P  1!(  $$0  ! #@  0 T& $ *#  ^"1  / D6 #L*'  Y"B(
M. HH #<++@ V"S4 -0L[ #,+0P R#$P , Q6 "\,80 M#&\ *PQ_ "H,D@ H
M#*4 )PR[ "4,W0 E#?4 )@W_ "<-_P"+$@  =Q0  &<6  !;%P  41@  $D7
M  !#%P  /Q4  #P4   Z$@  .1$! #D/"  X#@T -PX2 #4.&  T#A\ ,@XE
M #$/+  P#S( +Q Z "T00@ L$$L *A!5 "@080 F$&\ )!"  ",0DP A$*<
M'Q"] !X0X  >$?< 'Q#_ " 0_P"&%   <Q<  &,9  !7&@  31L  $4:  !
M&@  .QD  #@8   U%@  -!0  #,2!  R$@L ,1(0 "\2%0 M$AP +!,B "L3
M*0 J$S  *!,W "<4/P F%$@ )!13 "(47P @%6T 'Q5^ !T5D0 ;%:4 &16[
M !@5W@ 8%?@ &13_ !H4_P""%P  ;QH  %\<  !3'0  2AT  $(=   \'0
M-QP  #0;   Q&@  +QD  "X6   L%P@ *Q8. "D7$P H%QD )Q@@ "48)@ D
M&"T (Q@T "(9/0 @&48 'AE1 !T970 ;&FL &1I\ !<:CP 5&J, %!FZ !(9
MVP 3&?8 %!G_ !48_P!]&@  :QT  %P?  !0(   1R   #\@   Y'P  -!\
M #$>   M'0  *QP  "D;   G&P4 )1L, "0<$0 B'!8 (1P= " =(P ?'2H
M'ATR !P>.@ ;'D0 &1Y. !<>6P 6'FD %!]Z !(>C0 1'J( $!ZX  X>V  /
M'O4 $!W_ !$=_P!Z'0  9Q\  %DA  !-(@  1"(  #PB   V(@  ,B$  "XA
M   J(   )R   "0?   B( ( (" * !XA#P =(10 '"$: !LB(0 9(B< &"(O
M !<B.  5(T$ %"-, !(C6  1(V< $"-X  XCBP -(Y\ #".T  LCT  +(O
M#"+_  TA_P!V'P  9"(  %8C  !+)   020  #HD   T)   +R,  "LC   H
M(P  )",  " C   =)   &R4' !DF#0 7)A$ %B87 !4G'@ 4)R4 $R<L !(G
M-0 1*#\ $"A*  XH5@ -*&0 #"AT  HHAP )*)L !R>Q  4GS  &)^P !R;^
M  @F_P!Q(@  8"0  %,F  !()P  /R<  #<F   Q)@  +28  "DE   E)0
M(B4  !TG   9*   %BH$ !0K"P 2+!  $2P4 ! L&P 0+"( #BPI  XM,@ -
M+3L "RU&  HM4@ (+6  !BUP  0M@P "+9@  "RN   LR0  +.L  2O\  (K
M_P!M)0  72<  $\H  !%*0  /"D  #4I   O*   *R@  "<G   C)P  'R@
M !LJ   7+   $RX" ! P"  .,0T #3$2  PQ%P +,1X "C$F  @R+@ ',C<
M!3)"  ,R3@ !,EP  #)L   R?P  ,I4  #&L   QQP  ,.H  ##\   P_P!H
M*0  6"H  $PK  !!+   .2P  #(K   M*P  *2H  "4J   @*P  '"P  !<N
M   3,   $#("  XT!P *-PP !S<0  4W%  #-QL  C<B   W*@  .#,  #@^
M   X2@  .%@  #AH   X?   -Y(  #>I   VQ0  -NH  #;]   U_P!C+
M5"X  $@O   ^+P  -BX  # N   K+0  )RT  "(M   =+P  &#$  !0S   0
M-0  #C<!  HZ!P &.PL  CP.   ]$@  /A<  #X>   ^)@  /B\  #XZ   ^
M1@  /E0  #YD   ^=P  /H\  #VG   ]PP  /.D  #S]   [_P!>,   4#$
M $0R   [,@  -#$  "XP   I+P  )#   !XR   9-   %#8  ! Y   -.P
M"CT   5 !0  00H  $(-  !#$   1!0  $4:  !&(@  1BL  $8U  !&00
M1D\  $9?  !&<P  18H  $6D  !$P   0^@  $/^  !"_P!8-   2S4  $$U
M   Y-0  ,C0  "TS   F-   (#4  !HX   4.@  $#T   U    )0@  !$4
M  !' P  2 <  $H+  !+#@  3!$  $X5  !/'   3R4  $\O  !//   3TH
M $]:  !.;0  3H4  $V@  !,O   2^<  $O^  !*_P!3.0  1SD  #XY   W
M.   ,3<  "DW   A.0  &SP  !4_   00@  #$4   =(   "2@   $T   !/
M    400  %('  !4"P  50X  %<1  !9%P  6A\  %DI  !9-@  640  %E4
M  !89P  6'\  %>:  !6MP  5>,  %3]  !4_P!./0  0ST  #P\   U.P
M+#P  "0^   <00  %40  !!(   +2P  !4X   !1    5    %<   !9
M6P   %T"  !>!@  8 L  &(.  !D$@  9Q@  &<B  !F+@  9CP  &9-  !E
M8   97<  &23  !CL0  8=T  &#\  !?_P!)0@  04$  #H_   P0   )D,
M !Y&   52@  $$X   I2   #5@   %H   !=    8    &,   !E    9P
M &D   !K 0  ;04  &\*  !R#@  =1(  '<;  !V)@  =C4  '5&  !T60
M=&\  '.+  !RJ0  <,T  &_W  !N_P!&1@  0$4  #5&   J2   ($P  !=1
M   05@  "5H   %?    8P   &@   !K    ;P   '(   !U    =P   'D
M  ![    ?0   ( #  "#"   A@T  (D3  "*'0  BBL  (D\  "(3P  AF8
M (6!  "$H   @L(  ('P  !__P!&2P  .DP  "Y/   C4P  &%@  !!>   )
M9    &D   !O    =    '@   !\    @0   (0   "'    B    (L   ".
M    D    ),   "6    F0<  )T-  "A%   H"$  * Q  ">1   G5L  )QV
M  "9E@  F;4  );E  "5_@ _4@  ,E4  "9:   ;8   $6<   EM    =
M 'L   "!    A@   (L   "0    E    )<   "9    G    )\   "A
MI    *<   "J    K0   +$&  "U#0  N!8  +<F  "V.0  M5   +1J  "R
MB0  L*H  *[/  "M]0 W7   *V$  !YH   3<   "W@   "     AP   (X
M  "5    F@   )\   "D    J    *P   "M    L    +,   "U    N
M +L   "_    PP   ,<   #+!0  T0X  -$;  #0+@  ST4  ,U?  #+?@
MR9X  ,B^  #%Z0 O:0  (W   !9Y   -@0   8L   "3    FP   *(   "H
M    K@   +0   "X    O0   ,    #"    Q0   ,@   #+    S@   -$
M  #6    VP   -\   #D    Z 8  .L1  #J(P  ZCH  .E4  #G<@  Y9,
M ..S  #CU #_    _P   /\   #_  0 _P + /\ $ #_ !< _P A /\ *P#_
M #4 _P ^ /\ 1P#_ $X _P!5 /P 6P#Z &$ ^ !F /8 ;0#T ', \@![ .\
MA #M (X Z@"9 .8 IP#C +D WP#5 -L ]P#6 /\ P #_ +( _P"J /\ I0#_
M *( _P#_    _P   /X   #\    _  # /X "P#_ !$ _P : /T ) #Y "X
M]  X /  0 #L $@ Z0!. .8 5 #B %H WP!? -P 90#8 &L U !R -  >P#-
M (4 R@"1 ,< G@## *X P #% +T ZP"[ /\ L #_ *0 _P"< /\ F #_ )4
M_P#_    ^@   /0   #Q    \@   .H !0#G  X X@ 5 .$ '@#A "@ V  Q
M -  .0#+ $  R !' ,4 30#" %, OP!8 +T 7@"[ &0 N0!K +8 <P"T 'P
ML0"( *X E0"K *0 J "X *8 W "C /L GP#_ )4 _P"/ /\ BP#_ (D _P#Y
M    [P   .<   #?    SP   ,@   #!  H OP 1 +P & "[ "$ N0 J +0
M,@"Q #H K@!  *L 1@"H $P I@!1 *, 5@"A %P GP!C )T :@"; ', F0!^
M )8 C "4 )L D@"M )  QP". /  C0#_ (8 _P"  /\ ?0#_ 'P _P#M
MX    -$   "_    LP   *H   "F  4 H@ - *$ $P"@ !L GP C )L *P"8
M #( E0 Y ), /P"1 $0 CP!* (X 3P", %4 B@!; (@ 8P"& &L A !V ((
M@@"  )( ?@"C 'P N@!Z .$ >0#_ '< _P!R /\ < #_ &\ _P#=    RP
M +8   "G    G0   )0   ".  $ BP * (D $ "( !4 AP = (< )0"$ "P
M@@ R '\ . !] #T >P!# 'D 2 !X $X =@!4 '4 6P!S &, <0!N &\ >@!M
M (D ; ": &H K@!I ,P : #V &< _P!E /\ 9 #_ &, _P#*    M    *$
M  "3    B0   ((   ![    >  % '8 # !U !$ =  8 ', 'P!R "4 <  L
M &X ,@!L #< :@ \ &D 0@!H $@ 9@!. &4 50!C %T 8@!F &  <@!> (
M70"2 %L I0!: +X 60#I %D _P!9 /\ 6 #_ %@ _P"Y    H@   )    "#
M    >0   '$   !M    :0 ! &8 "0!E  X 9  3 &, &0!C "  80 F &
M+ !> #$ 7  W %L / !: $( 6 !( %< 3P!6 %< 5 !@ %, ; !1 'D 4 "*
M $\ G@!. +0 30#: $T ^P!- /\ 30#_ $T _P"J    E    ((   !U
M:P   &0   !@    70   %H !0!8  P 5P 0 %8 %0!6 !L 50 A %, )P!2
M "P 40 Q $\ -P!. #T 30!# $P 2@!* %( 20!; $@ 9@!& ', 10"$ $0
MEP!# *P 0@#) $( \0!" /\ 0P#_ $, _P">    B0   '@#  !J!   800
M %H#  !5 0  4@   %   @!.  D 30 - $P $0!+ !< 2@ < $D (@!( "<
M1P M $4 ,@!$ #@ 0P ^ $( 10!! $T /P!6 #X 80 ] &X .P!^ #H D0 Y
M *8 . "_ #@ Z  X /\ .0#_ #D _P"5 P  @ <  &\)  !B"@  6 L  %$*
M  !,"   208  $<#  !&  8 1  + $, #P!" !, 00 8 $$ '@ _ ", /@ I
M #T +@ [ #0 .@ Z #D 00 X $D -P!2 #8 70 T &H ,P!Z #( C  Q *$
M, "X "\ W@ O /D +P#_ #  _P","0  > P  &@-  !<#@  4@X  $L.  !%
M#0  00P  #\*   ^" ( /00( #P!#0 [ !  .@ 5 #D &@ X "  -@ E #4
M*P T #  ,P W #( /@ Q $8 +P!0 "X 6@ M &< *P!W "H B0 I )T * "S
M "< T0 G /( )P#_ "< _P"&#   <@X  &,0  !6$0  31$  $41  ! $
M/ \  #D.   W#0  -@L$ #8("@ U!@X - 42 #($%P Q!1P , 4B "\%*  N
M!BX +08T "L&/  J!D0 *0=. "<'60 F!V4 ) =U ",'AP B!YL ( :P " &
MRP ?!>T 'P;^ !\'_P" #@  ;1$  %X2  !2$P  2!,  $$3   [$P  -Q(
M #01   R$   , \! # -!@ P"PL +PH0 "T*%  L"QD *@L? "D+)0 H#"L
M)PPR "8,.@ D#$, (PQ- "$-6  @#64 '@UU !P-B  :#9P &0VQ !@,R@ 7
M#.L %PW\ !@,_P![$0  :1,  %H5  !.%@  118  #T6   X%0  ,Q4  # 4
M   M$P  *Q(  "H0 P J#P@ *0X- "@.$0 F#A8 )0\= "0/(P C#RD (1 Q
M " 0.0 >$$( '1!, !L06  9$&8 %Q!V !40B0 4$)X $A"S !$0S@ 1$.X
M$A#^ !(0_P!W$P  914  %<7  !+&   0AD  #H9   T&   ,!<  "P7   I
M%@  )Q4  "84 0 E$@0 (Q(+ "(2#P A$A0 (!(: !X3(  =$R< '!,N !H3
M-@ 9%$  %Q1* !845@ 4%&0 $A1T !$4AP 0%)P #A2Q  T4R@ -%.L #A/^
M  X3_P!S%0  81@  %,:  !(&P  /QL  #<;   R&@  +1H  "D9   F&
M)!@  "(7   @%@$ 'A8( !T6#0 ;%Q( &A<7 !D7'0 8&"0 %A@K !48-  4
M&#T $AE( !$95  0&6( #AER  T9A  ,&9@ "AFM  D8Q@ )&.< "1CZ  H7
M_P!O&   7AH  % <  !%'0  /!T  #4=   O'0  *AP  "8;   C&P  (1H
M !X:   <&@  &AL% !@;#  6'!  %1P5 !0<&P 3'"( $ATI !$=,0 0'3L
M#AU%  T>40 ,'EX "AYM  D>@  ''I0 !1VJ  ,=P@ #'>8 !!SX  4<_P!K
M&@  6QT  $T>  !"'P  .A\  #(?   M'P  *!X  "0>   A'0  'AT  !P=
M   8'@  %1\" !,@"0 2(0X $"$2 ! A&  .(1\ #B(F  TB+@ ,(C< "B)!
M  DB30 '(EH !2)I  ,B?  !(I$  "*H   AP   (>4  "#X   @_P!G'0
M5Q\  $HA  ! (0  -R(  # A   J(0  )B   "(@   ?'P  '!\  !D@   6
M(0  $B," ! D!P .)@P #"80  LF%0 *)AP "28B  @F*@ &)S, !"<]  ,G
M20 !)U8  "=F   G>0  )X\  ":F   FOP  )>0  "7Y   D_P!C(   5"(
M $<C   ])   -"0  "XC   H(P  )"(  "$B   >(0  &B(  !<C   3)
M$"8"  XH!P +*@L ""L.  8K$P $*Q@  BL?  $L)P  +#   "PZ   L10
M+%,  "QC   L=@  +(P  "ND   KO@  *N0  "KZ   I_P!?(P  4"4  $0F
M   Z)@  ,B8  "LF   F)0  (R0  !\D   ;)   %R4  !0G   1*0  #BL"
M  LM!@ '+PL !# .   P$0  ,14  #$<   Q(P  ,BP  #(V   R0@  ,D\
M #)?   R<@  ,8D  #&B   PO   ,.0  "_[   O_P!:)P  3"@  $ I   W
M*0  +RD  "DH   E)P  (28  !PG   8*   %"H  !$L   .+@  "S !  <R
M!0 #- D  #4,   V#P  -Q(  #@8   X(   ."@  #@R   Y/0  .4L  #E;
M   X;@  .(4  #>?   WN@  -N0  #7\   U_P!5*@  2"P  #TL   T+
M+2L  "@J   D*0  'BH  !DK   4+0  $2\   TQ   *-   !S8   (X!
M.@<  #L*   ]#0  /A   $ 4  ! &P  0"0  $ N  ! .0  0$<  $!6  !
M:0  0(   #^;   ^MP  />,  #S\   \_P!0+P  0R\  #DO   R+P  +"T
M "<L   @+0  &B\  !4Q   1,P  #38   DX   %.P   #T   !  0  000
M $,'  !%"P  1@X  $@1  !*%@  2AX  $HH  !*-   24(  $E1  !)9
M2'L  $B7  !'M   1N   $7\  !$_P!*,P  /S,  #8S   P,0  *C   ",Q
M   <,P  %C4  !$X   -.P  "#X   -!    0P   $8   !(    2@   $P$
M  !.!P  3PL  %$.  !4$@  51D  %4B  !4+@  5#P  %1+  !37@  4W0
M %*0  !1K@  4-<  $_[  !._P!%-P  /#<  #4V   O-   )C4  !XW   7
M.@  $3T   Q!   '1    $@   !*    30   %    !3    50   %<   !8
M @  6P8  %T+  !?#@  8A,  &(;  !B)P  8C0  &%%  !@5P  8&T  %^)
M  !=IP  7,P  %KX  !9_P!!/   .CL  #0Y   J.@  (3P  !A    10P
M#$<   9+    3P   %,   !6    60   %P   !?    80   &,   !E
M9P$  &H%  !M"@  < X  ',5  !R(   <BT  '$]  !P3P  ;V4  &Z   !M
MGP  :\$  &GQ  !H_P _0   .3X  "X_   D0@  &D8  !)*   ,3P  !%0
M  !8    70   &$   !E    :    &L   !N    <0   ',   !U    >
M 'L   !^ P  @0H  (4/  "'%P  AB0  (4T  "$1@  @ET  (%V  !_E@
M?K8  'SG  !Z_P _1   ,T4  "A(   =3   $U(   Q7   #70   &,   !H
M    ;0   '$   !V    >@   'X   "!    @P   (8   ")    BP   (X
M  "2    E0$  )D)  ">$   GAH  )TI  "</   FE(  )AL  "6BP  E*H
M )+4  "0^@ X2P  +$X  "!3   560  #6    -G    ;@   '0   !Z
M@    (0   "*    C@   )(   "5    EP   )H   "=    H    *,   "G
M    JP   *\   "T"0  N!   +<>  "U,   LT8  +%@  "O?@  K*   *O!
M  "I[@ Q50  )%L  !AA   .:0  !7$   !Y    @0   (@   "/    E
M )H   "?    I    *@   "I    K    *\   "S    M0   +D   "]
MP0   ,8   #+    T0H  -,4  #1)0  T#L  ,U4  #*<0  R)(  ,6S  ##
MW@ I8@  '&D  !%Q   '>P   (0   "-    E0   )T   "C    J0   *\
M  "T    N0   +P   "^    P@   ,4   #(    S    -    #4    V@
M -\   #D    Z@   .X,  #M&@  ["\  .I)  #H90  YH8  .2E  #BQ@#_
M    _P   /\   #\  $ _  ( /X #@#_ !0 _P = /\ )@#_ #  _P Z /\
M0@#_ $D _@!0 /L 5@#Y %P ]@!B /0 : #R &\ \ !V .T ?P#J (D YP"5
M .0 HP#@ +4 VP#0 -4 ]@#* /\ M@#_ *@ _P"? /\ F@#_ )8 _P#_
M^P   /8   #S    \P   /8 "0#Z  X _0 6 /L ( #W "H \@ S .T .P#I
M $, Y@!) .( 3P#> %4 VP!; -8 8 #2 &< SP!N ,P =@#) (  Q@", ,(
MF@"_ *H NP#! +@ Z0"V /\ IP#_ )H _P"2 /\ C0#_ (H _P#Z    \0
M .H   #G    YP   .0  0#@  L VP 1 -H &@#; ", T0 L ,H - #& #L
MP@!" +\ 2 "\ $X N@!3 +@ 60"V %\ LP!F +$ ;@"N '< K "# *D D0"F
M *$ HP"U *  V "> /L E0#_ (L _P"% /\ @ #_ 'X _P#O    XP   -H
M  #3    Q@   +\   "Y  8 MP . +0 % "T !T LP E *X +0"K #0 IP [
M *0 00"A $8 GP!, )T 40"; %< F0!> )< 90"5 &X DP!Y )  AP". )<
MC "I (D Q "( .\ A0#_ 'P _P!V /\ <P#_ '( _P#@    T    ,8   "V
M    J0   *$   "=  $ F0 * )@ $ "8 !8 EP > )0 )@"1 "T CP T (P
M.@"* #\ B !% (< 2@"% %  @P!6 ($ 7@"  &8 ?@!Q 'P ?0!Y (T =P"@
M '4 M@!S -\ <@#_ &X _P!I /\ 9P#_ &4 _P#,    O@   *L   "=
MDP   (H   "%    @@ % (  #0!_ !$ ?P 8 (  ( !] "8 >@ M '< ,P!U
M #@ =  ^ '( 0P!P $D ;P!/ &T 5@!L %X :@!H &@ =0!G (0 90"6 &0
MJP!B ,D 80#V &  _P!< /\ 6P#_ %H _P"]    J0   )<   ")    ?@
M '@   !S    ;P ! &T "0!L  X :P 3 &L &0!J "  :  F &8 + !E #(
M8P W &( / !@ $( 7P!( %T 3P!< %< 6@!A %D ;0!7 'L 5@". %4 H@!3
M +L 4@#I %( _P!0 /\ 3P#_ $\ _P"M    F    (8   !X    ;@   &<
M  !C    8    %T !0!<  L 6P 0 %L %0!; !L 6@ A %@ )@!6 "P 5  Q
M %, -@!2 #P 40!" $\ 20!. %$ 30!; $L 9@!* '0 20"% $@ F0!' +$
M1@#8 $8 _ !% /\ 10#_ $4 _P"?    B0   '@   !L    8@   %L   !6
M    4P   %$  @!/  @ 3P - $X $0!. !8 30 < $P (0!* "8 20 L $@
M,0!' #< 10 ] $0 1 !# $P 0@!5 $  8  _ &X /@!^ #T D@ \ *D .P#'
M #L \P [ /\ .P#_ #P _P"3    ?@   &X   !A    6    %$   !,
M20   $<   !%  4 1  + $, #@!# !( 0P 7 $( '0!  "( /P G #X +  ]
M #( .P X #H /P Y $< . !0 #< 6P U &@ - !X #, C  R *( ,0"\ #$
MYP Q /\ ,@#_ #, _P")    =@,  &8%  !9!P  4 <  $D&  !#!0  0 ,
M #X!   \  , .P ( #H #0 Z !  .0 4 #D &0 W !X -@ C #4 *  T "X
M,P T #( .P P $, +P!, "X 5P M &0 + !S "L AP J )P *0"U "D W  I
M /L *0#_ "H _P"!!   ;@@  %\*  !3"P  2@L  $(+   ]"@  .0D  #8(
M   U!0  - (& #, "@ R  X ,0 1 #$ %0 P !H +P ? "X )  L "H *P P
M "H -P I #\ * !) "< 5  F &  ) !O ", @@ B )< (0"N "$ S  A /,
M(0#_ "( _P!["0  : P  %H-  !.#@  10X  #T.   X#0  ,PT  # ,   N
M"P  +0D# "T&"  L! P *P(/ "H!$@ I 1< * $< "< (0 F "< )0 M "0
M-  C 3T (@%& "$!40 ? 5T '@%L !P!?P ; )0 &@"J !H Q0 : .L &0#_
M !H _P!U#   9 X  %4/  !*$   0!   #D0   S$   +P\  "P.   I#@
M)PT! "<,!0 G"@H )@@- "4'$  D!A0 (@89 "$&'P @!R0 'P<K !X',@ =
M!SH ' A$ !H(3P 9"%P %PAK !8(?0 5!Y$ % >G !,&OP 2!>0 $@7Z !(%
M_P!Q#@  7Q   %$1  !&$@  /1(  #82   P$@  *Q$  "@1   E$   (Q
M "(.!  A#0< (0P+ " +#@ ?"Q( '0L7 !P,'  ;#"( &@PI !D,,0 8##D
M%@U# !4-3P 3#5P $@UK ! -?@ /#9( #@VG  T,O@ -#.  #0SU  T,_P!M
M$   7!$  $X3  !#%   .A0  #(4   M%   *!,  "43   B$@  (!$  !X1
M P <$ 4 ' \( !L/#  :#A  &0\4 !</&@ 6#R$ %1 H !00,  2$#D $1!$
M ! 04  .$%T #1!K  P0?  +$)  "1"E  @0O  '$-\ !Q#T  </_P!I$0
M6!0  $L5  ! %@  -Q8  # 6   J%@  )A4  "(5   ?%   '1,  !H3 @ 9
M$@0 %Q(& !82"@ 5$@X %!(2 !(2&  1$QX $1,E ! 3+@ .$S< #11   P4
M2P +%%@ "11G  <4>  &%(T !!2C  ,3NP "$]T  1+T  (2_P!E$P  518
M $@7   ]&   -!@  "T8   H&   (Q<  " 7   =%@  &A4  !@5 @ 6%00
M%!4% !(6"  1%@T $!<0  X7%0 .%QL #1<B  P7*0 +&#( "1@\  <81P %
M&%0 !!AC  (8=0 !&(L  !>A   7N0  %]T  !;U   6_P!A%@  4A@  $4:
M   [&@  ,AH  "L:   E&@  (1D  !X8   ;&   &!<  !87 @ 4%P, $A@%
M ! 9!P .&PL #!L/  L;$P *&Q@ "!P?  <<)@ %'"\ !!PX  (<1   '5$
M !U@   =<@  '(@  !R@   ;N0  &]X  !KV   :_P!>&   3QH  $(<   X
M'   +QT  "D<   C'   'QL  !P:   9&0  %QD! !09 @ 2&@, $!L$  X=
M!P ,'@L "1\.  8@$0 %(!8  R <  $A(P  (2L  "$U   A0   (4X  "%=
M   A;P  (88  "">   @N   ']X  ![X   >_P!:&P  2QT  #\>   U'P
M+1\  "<>   B'0  'AT  !L<   8&P  %1L  !(<   0'0( #A\$  PA!@ )
M(@H !2,-  (D$   )1,  "49   F(   )B@  "8R   F/0  )DH  "9:   F
M;   )H,  "6<   EMP  )-\  "/Y   C_P!5'@  1R   #PA   R(0  *R$
M "4@   @'P  '1X  !H=   6'@  $QX  ! @   .(0  #","  @E!0 %)PD
M "@+   J#@  *Q$  "P6   L'0  +"4  "PN   L.@  +$<  "Q6   L:0
M+(   "N:   JM0  *=\  "G[   H_P!1(@  1",  #@D   O)   *",  ",B
M   ?(0  '"   !<@   3(0  $",   XD   +)@  ""@   0J!   + <  "X)
M   P#   ,0\  #,3   S&0  ,R$  #,J   S-0  ,T,  #-2   S90  ,GL
M #*7   QLP  ,-X  "_[   N_P!,)0  /R8  #4G   M)@  )R4  "(D   >
M(P  &2,  !0D   1)@  #B@   LJ   '+    R\    Q @  ,P0  #4'   W
M"@  .0T  #H0   [%0  .QT  #LF   [,0  .SX  #M.   [8   .G<  #F2
M   XL   -]L  #;\   U_P!'*0  .RH  #(J   K*0  )2<  "$F   ;)P
M%2@  !$J   .+   "B\   8Q   !-    #8    X    .P$  #T$   _!P
M00H  $,.  !%$0  11@  $4A  !%+   1#D  $1(  !$6P  0W$  $*-  !!
MJP  0-(  #_Z   ^_P!"+0  ."X  "\M   I*P  )"H  !TJ   7+   $2X
M  TQ   )-   !#<    Z    /    #\   !!    1    $8   !( P  2@<
M $P+  !.#@  4!,  % <  !0)P  3S0  $]#  !/50  3FH  $V&  !,I
M2LH  $GX  !(_P ^,@  -3$  "XO   I+@  ("X  !DQ   2,P  #C<   DZ
M   "/0   $    !$    1P   $D   !,    3P   %$   !3    50$  %@&
M  !:"P  70X  %\5  !>(   7BP  %T\  !<3@  6V,  %I^  !8G0  5\
M %7R  !4_P Z-@  ,S0  "TR   D,P  &S8  !,Y   ./0  "$$   !%
M20   $P   !0    4P   %8   !9    6P   %T   !@    8@   &4   !H
M!0  :PL  &\0  !O&   ;B4  &TT  !M1@  :UL  &IU  !HE   9K8  &3I
M  !B_P X.0  ,C<  "@Y   >.P  %3\   Y$   '20   $T   !2    5@
M %H   !>    8@   &4   !H    :P   &T   !P    <P   '8   !Y
M?00  ($+  "%$0  A!T  ((L  " /@  ?E0  'YK  ![B@  >JH  '?6  !U
M_0 X/0  +#X  ")!   71@  #TL   =1    5P   %P   !B    9@   &L
M  !O    =    '@   ![    ?@   (    "#    A@   (H   "-    D0
M )8#  ";#   G1,  )LA  ":,P  ETD  )1B  "3?P  D*   ([%  ",\P Q
M1   )4@  !I-   04P  "%H   !A    :    &X   !T    >0   '\   "$
M    B0   (T   "1    DP   )8   "9    G0   *    "D    J    *P
M  "R P  MPT  +<7  "U*   LCX  +!6  "L<P  JI0  *FT  "EY0 J3P
M'E0  !);   *8@   &H   !S    >P   ((   ")    C@   )0   ":
MGP   *0   "F    J0   *T   "P    LP   +<   "[    P    ,4   #+
M    T00  -4.  #3'0  T#(  ,U+  #*9@  QH<  ,*I  #!RP B6P  %F(
M  QK   !=    'T   "'    D    )<   ">    I    *L   "Q    M@
M +H   "\    P    ,0   #(    RP   ,\   #4    V@   .    #F
MZP   /$&  #P$P  [B<  .P_  #J6P  YWH  .2;  #@NP#_    ^P   /8
M  #S    ]  % /8 # #Z !$ _P 9 /\ (@#_ "P _P U /\ /0#_ $4 _ !,
M /H 4@#W %@ ]0!> /, 9 #Q &H [@!R .P >@#I (4 Y0"1 .$ H #= +(
MV #. -( ]@#! /\ K0#_ )X _P"6 /\ D #_ (P _P#Z    \@   .P   #I
M    Z0   .P !0#R  P ^  2 /< &P#U "4 \  N .L -P#F #X X@!% -T
M2P#8 %  TP!6 -  7 #- &( R@!J ,@ <@#% 'P P@"( +X E@"Z *@ MP"_
M +0 Z "N /\ G0#_ )  _P"( /\ @P#_ (  _P#P    Y0   -X   #:
MVP   -P   #8  < T0 . -$ %0#2 !X RP G ,4 +P#  #< O0 ] +H 1 "W
M $D M0!/ +( 50"P %L K@!A *P :0"I ', IP!_ *0 C0"A )X G@"R )L
MU0"9 /P C #_ (( _P![ /\ =@#_ '0 _P#B    TP   ,H   #'    O
M +8   "P  $ KP + *P $0"M !@ K0 @ *@ * "D "\ H  V )T / "; $(
MF0!' )< 30"5 %, DP!9 )$ 80"/ &H C !U (H @P"( )0 A@"G (, P@""
M /  ? #_ ', _P!M /\ :@#_ &@ _P#/    P0   +D   "M    H    )@
M  "4    D0 & )  #0"0 !( CP 9 (X (0"+ "@ B  O (8 -0"$ #H @@!
M (  10!^ $L ? !2 'H 60!X &( =@!L '0 >0!R (D <0"= &\ M !M -\
M; #_ &4 _P!@ /\ 7@#_ %P _P"^    L0   *    "2    B0   ((   !\
M    >@ ! '@ "0!W  X >  4 '< &@!T "$ <@ G '  +0!N #, ;  X &L
M/@!I $0 : !* &8 40!D %H 8P!D &$ < !? '\ 7@"3 %T J0!< ,@ 6P#W
M %< _P!4 /\ 4@#_ %$ _P"P    GP   (T   !_    =    &X   !J
M9@   &4 ! !C  L 8P 0 &, %0!C !L 80 A %\ )P!= "P 7  R %H -P!9
M #T 5P!# %8 2P!5 %, 4P!< %( : !0 '< 3P") $X GP!- +H 3 #I $L
M_P!) /\ 1P#_ $< _P"B    C0   'P   !N    90   %X   !9    5P
M %4  0!4  < 4P - %, $0!4 !8 4@ ; %$ (0!/ "8 3@ K $P ,0!+ #<
M2@ ] $D 1 !' $P 1@!6 $0 80!# '  0@"! $$ EP!  *\ /P#7 #\ _P ^
M /\ /0#_ #X _P"4    ?P   &\   !C    60   %$   !-    2@   $@
M  !'  0 1P * $8 #@!& !$ 1P 6 $4 ' !$ "$ 0@ F $$ *P!  #$ /@ W
M #T /@ \ $< .@!0 #D 6P X &D -P!Z #8 CP U *< -0#& #0 ]0 T /\
M- #_ #4 _P"(    =    &4   !8    3P   $@   !#    /P   #T    \
M  ( /  ' #L #  [  \ .P 2 #H %P Y !P -P A #8 )@ U "P -  R #,
M.0 Q $$ , !+ "\ 5@ N &, +0!S "P B  L *  *P"[ "L Z@ K /\ *P#_
M "P _P!_    ;    %T!  !1 @  2 ,  $ #   [ @  -P   #0    S
M,@ % #( "0 R  T ,0 0 #$ $P P !@ +P = "T (@ L "@ *P N "H -0 I
M #T * !& "< 40 F %X )0!N "0 @@ C )D (P"S "( W@ B /\ (P#_ "0
M_P!W    900  %8&  !+!P  0@@  #H(   U!P  , 8  "T%   L P  *P #
M "H !P I  L *0 . "D $0 H !4 )P 9 "8 '@ E "0 )  J ", ,0 B #D
M(0!# "  3@ ? %H '@!I !T ?  < ), &P"L !L S0 ; /8 &P#_ !P _P!P
M!0  7P@  %$*  !&"P  /0L  #4+   P"P  *PH  "@)   E"   ) <" ",$
M!@ C @D (@$, "( #P A !( (  6 !\ &P > "  '0 F !P +@ ; #8 &@ _
M !D 2@ 8 %< %P!F !8 >  5 (\ %0"F !0 PP 4 .X % #_ !4 _P!K"
M6PL  $T,  !"#0  .0T  #$-   L#0  )PT  ",,   A#   'PL! !X*!0 =
M" @ '08+ !P%#0 <!!  &P04 !D$&  9!!X & 0C !<$*P 6!#, %00\ !0$
M1P 3 U0 $@-C !$#=0 0 HH $ &B  \ O  / .4 #P#^ !  _P!G"P  5PT
M $D.   ^#P  -0\  "X/   H#P  ) X  " .   =#@  &PT! !D-!  8# <
M& L) !<)#  7"0X %@D2 !4)%@ 4"1L $PDA !()*  2"3  $0DZ ! )10 /
M"5( #@EA  T)<P ,"(@ "PB?  H'MP *!ML "@7V  H$_P!C#0  4PX  $80
M   [$0  ,A$  "L1   E$   (1   !T0   :#P  & \! !8.!  5#@< % T)
M !,-"P 3# T $@P0 !$,%  0#!D $ P?  \,)P .#2\ #0TY  P-10 +#5$
M"0U@  @-<0 &#88 !0V=  0,M  ##-(  @SQ  (+_P!?#@  4!   $,1   X
M$@  +Q(  "@2   C$@  'A$  !L1   8$0  %1 " !00!0 2$ < $0\) ! /
M"@ 0#@P #@X.  X/$@ -#Q< #! =  P0)  *$"P "1 V  @000 &$$X !1!=
M  ,0;P !$(0  !"<   /M   #M0   [S   ._P!<$   31(  $ 3   V%
M+10  "84   A$P  '!,  !D2   6$@  %!$# !(1!@ 1$0@ $! *  X0"P -
M$0L #!$-  L2$0 *$A4 "1(:  @2(0 &$RD !1,S  ,3/@ "$TL  !-:   3
M;   $X(  !*;   2M   $=<  !'U   1_P!8$@  210  #T5   S%@  *Q8
M "05   ?%0  &A0  !<4   4$P$ $Q($ !$2!P 0$@D #A()  T2"0 +$PH
M"10-  <5#P &%A, !!88  ,6'P "%B<  !<P   7.P  %T@  !=8   7:@
M%H   !:9   5M   %=D  !3W   3_P!5%   1A8  #H7   P&   *!@  "(7
M   =%@  &18  !85   3% , $A,& ! 3!P /$P< #10'  L5"  )%@D !A@,
M  ,:#@ !&A$  !H6   ;'   &R0  !LM   ;.   &T8  !Q5   ;9P  &WT
M !N7   :LP  &=L  !CY   7_P!1%@  0Q@  #<9   N&@  )AH  " 9   ;
M&   &!<  !46 0 3%04 $14$  \5!  -%@0 "Q<%  D9!@ &&@@  AP*   >
M#0  (!   " 3   @&0  ("$  "$J   A-0  (4(  "%2   @9   ('H  !^5
M   ?L0  'ML  !WZ   <_P!-&0  /QL  #0<   K'   )!P  !X;   :&@
M%Q@  !07 @ 2%P( $!@!  T9 0 +&@( "!P#  4=!  "'P8  "$(   C"P
M)0X  "81   F%@  )AX  "<G   G,@  )S\  "9.   F8   )G<  "62   D
MKP  (]H  "+[   A_P!('0  /!X  #$?   H'@  (AX  !T<   9&P  %AH
M !(:   0&P  #1P   L=   ('P  !"$   $C @  )00  "<&   I"0  + P
M "X/   N$P  +AH  "XC   N+@  +CL  "Y*   M7   +7(  "R.   KK
M*M0  "G[   H_P!$(   ."$  "XA   F(0  ("   !P>   8'0  %!T  ! >
M   .'P  "R$   <C   #)0   "<    I    + $  "X#   P!@  ,PH  #4-
M   V$0  -A<  #8?   V*0  -C8  #9%   U5P  -6T  #2)   RJ   ,<\
M ##Z   O_P _)   -"0  "LD   D(P  'R$  !L@   6(   $2$   XC   *
M)0  !B@   (J    +0   "\    R    -    #<    Y P  .P8  #X*  !
M#@  01(  $$:  ! )0  0#$  $!    _4@  /F<  #V"   \H@  .L<  #GX
M   X_P Z*   ,"@  "DG   C)0  'R,  !@D   2)0  #B@   HJ   %+0
M #     S    -@   #@    [    /@   $    !"    10(  $<&  !*"@
M30X  $T5  !,'P  3"L  $LZ  !*3   26$  $A\  !'FP  1;\  $/S  !"
M_P V+   +2L  "<I   C)P  &R@  !0J   .+0  "C    0S    -P   #H
M   ]    0    $,   !&    2    $L   !-    4    %,!  !6!@  60L
M %L0  !;&0  6B4  %DT  !81@  5UH  %5T  !4DP  4K4  %#J  !/_P S
M,   +"X  "<L   >+0  %B\  ! R   *-@   SH    _    0@   $8   !)
M    3    $\   !2    50   %@   !:    70   &    !C    9P8  &L,
M  !L$@  :QX  &LL  !I/0  9U(  &9J  !DB0  8:L  %_<  !=_P Q,P
M+#$  "(R   9-0  $3D   H]   "0@   $<   !,    4    %0   !8
M6P   %\   !B    90   &@   !K    ;@   '$   !U    >0   'T&  ""
M#0  @A8  ( D  !^-0  ?$D  'MA  !X?P  =I\  '/&  !P]P Q-@  )C@
M !P[   20   "T4   )+    40   %8   !;    8    &4   !I    ;@
M '(   !V    >0   'P   !^    @@   (4   ")    C@   ),   "8!@
MG X  )L:  "8*P  ED   ))9  "1<P  C94  (NU  "(Z  K/@  ($$  !5'
M   -30   E0   !;    80   &@   !N    <P   'D   !^    @P   (@
M  ",    CP   )(   "5    F0   )T   "A    I0   *H   "P    MP<
M +@1  "U(0  LC4  *]-  "J:0  J(@  *:H  "BT0 C2   &$X   Y4   $
M7    &0   !M    =0   'P   "#    B0   (\   "5    FP   *    "C
M    I@   *D   "M    L0   +4   "Y    O@   ,0   #*    T@   -H*
M  #6%@  TBD  ,Y!  #*7   Q7P  ,*=  #!O0 <50  $5P   =E    ;@
M '<   !_    B    )    "8    GP   *4   "M    LP   +@   "Z
MO@   ,(   #&    R@   ,X   #3    V@   .    #G    [0   /,   #T
M#@  \AX  .\V  #L40  Z&X  .20  #?L0                       0,$
M!08("0H+#0X/$1(3%!87&!H;'!T?("$B)"4F*"DJ*RTN+S R,S0V-S@Y.SP]
M/D!!0D1%1D=)2DM-3D]04E-455=865M<75Y@86)C969G:6IK;&YO<'%S='5W
M>'EZ?'U^@(&"@X6&AXB*BXR.CY"1DY25EIB9FIR=GI^AHJ.DIJ>HJJNLK:^P
ML;.TM;:XN;J[O;Z_P<+#Q,;'R,G+S,W/T-'2U-76U]G:V]W>W^#BX^3FY^CI
MZ^SM[O#Q\O3U]O?Y^OO\_O______________________________________
M________________                      $#! 4&" D*"PT.#Q$2$Q06
M%Q@:&QP='R A(B0E)B@I*BLM+B\P,C,T-C<X.3L\/3Y 04)$149'24I+34Y/
M4%)35%576%E;7%U>8&%B8V5F9VEJ:VQN;W!Q<W1U=WAY>GQ]?H"!@H.%AH>(
MBHN,CH^0D9.4E9:8F9J<G9Z?H:*CI*:GJ*JKK*VOL+&SM+6VN+FZN[V^O\'"
MP\3&Q\C)R\S-S]#1TM35UM?9VMO=WM_@XN/DYN?HZ>OL[>[P\?+T]?;W^?K[
M_/[______________________________________________________P
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M8F'VC&)A]HQB\\0/ ,[:"P"]\QT'L?\R%*/_.A^5_S\JB?]&,X#_3SIX_UM
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MC340_Y@[%_^@1"'_IDXM_Z=9//^E9$S_H6Y;]YMX:NZ5@7?GCHF"X8:/B]R
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M_XLI0_^+*4/_BRE#_XLI0_^+*4/_BRE#_XLI0_^+*4/_BRE#_XLI_X,< _^
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M.!'_N4 9^,)')N[+337DT%1&U<M;6\?#8FZZNVA^KK1NBZ.N<Y::J7J?DJ6
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M44__PU%/_\-13__#44__PU%/_\-13__#44__PU%/_\-1VJ\" ,:\!0"YR04
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M?R<'_XHL"O^3-0[_F3T6_YY&'_^A3BO[H%DX]9QC1N^8;53HD'=BXHA_;]J
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MA966EH*>FI* IYV/?[.>C8#"GHN S)J+@=*2BH#8B8F VX:)@-N&B8#;AHF
MVX:)@-N&B8#;AHF VX:)@-N&_WD: O][(03_BR(%_Y@H!_^C, K_JS@0^;)
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M=4_3YW1/T^=T3]/G=$_3YW1/T^=T3]/G=$_3YW1/T^=T_X\/ ?^D#@#;N @
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M?UZGY7A>I^5X7J?E>%ZGY7A>I^5X7J?E>%ZGY7A>I^5X_WH5 O^.$@'_GQ,
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M9U>O\6=7K_%G5Z_Q9U>O\6=7K_%G_W\. ?^3"P#AI04 TK,' ,F^!P#"RP@
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MAA(E_Y 3)/^9$R/_HQ0B_ZL4(O^K%"+_JQ0B_ZL4(O^K%"+_JQ0B_ZL4G+X
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M7VB2]U]HDO=?:)+W7VB2]U]HDO=?_V\1 ?^!#@#_D0X \J , -JM"0#3N H
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MTRL&F= Z$H_.11^%RTXJ?<E6-'7'73UNQ65$:,1L26/"<TY>P7M36<&$5E7
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MJRH]_+DK._W+*SO]XBLZ_/0K.OSW*SK\]RLZ_/<K.OSW*SK\]RLZ_/<KO:@
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M#AS_H0X;_ZP/&_^N#QO_K@\;_ZX/&_^N#QO_K@\;_ZX/E[P  (C)  !YU@
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M47F!_U%Y@?]1>8'_47F!_U%Y@?]1_V43 ?]U#@#_@PX _Y . /6;#@#HI@X
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MLTA&RLA(1LKF1T?)]T5'R/]#2,?_0DC'_T)(Q_]"2,?_0DC'_T)(Q_]"WHT
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M(C;YXR(V^/,B-O?\(C;W_"(V]_PB-O?\(C;W_"(V]_PBMZ8  *FN  "<N0
MD,0  (//  !WVP  ;_8* &?_$P%@_QT"6O\G U3_, 5/_S@(2O] "D;_2 Q#
M_T\.0/]6#SW_7A [_V42./]N$S;_=Q0T_X(5,O^/%C#_FQ<O_ZD7+O^W&"W_
MR!@L_^$8+/_O&"S_[Q@L_^\8+/_O&"S_[Q@L_^\8JZL  )ZU  "0P0  @LP
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MX&%Y,]Q>@CC87(L\TUJ4/]!8G$+.5Z-$RU6L1LE5M4?'5,!)Q5302<)3YDG
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M1(AT_T.(=/]#B'3_0XAT_T.(=/]#_UT2 ?]K#@#_> X _X,/ /V,$ #ME!(
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MKE-3G\!34I_=4E6?\TY7H/]*6:#_1EF?_T59G_]%69__15F?_T59G_]%_W4
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M/$3$\SM$P_\Y1<+_-T7!_S=%P?\W1<'_-T7!_S=%P?\WU8L  ,6:  "WI
MJZP  *"T  "6O@  B\<$ ('0" !XV0X ==D@ 6_8+P1IV#P)8]9&$%[64!59
MU5@:5=1@'U'4:").U'$F2]-[*4C3A2M%TY(N0M2?+T'4KS _U<(Q/]7A,#_3
M\C _TOTO/]'_+C_0_RX_T/\N/]#_+C_0_RX_T/\NRI0  +NA  "MJ0  HK$
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M$2;_]A$F__81)O_V$2;_]A$F__81IZD  )FS  "+O@  ?LD  '#3  !DW@
M6.<  %+_"0!-_Q$ 1_\9 4/_(@$^_RH".O\R S?_.0,S_S\$,/]&!2W_304K
M_U0&*/];!R;_8P<C_VT((?]Y"1__APD>_Y4*'?^C"AS_L0H;_\ +&O_6"QK_
MWPL:_]\+&O_?"QK_WPL:_]\+F[$  (V\  !^QP  <-(  &/>  !5Y   2_4
M $;_!0! _PX ._\4 #?_&P$S_R,!+_\I BO_, (H_S4")?\[ R+_00,?_T<#
M'?]. QK_5008_UX$%?]H!1/_= 41_X(%$/^0!A#_G08/_ZD&#O^U!@[_N@8.
M_[H&#O^Z!@[_N@8._[H&CKH  '_%  !PT0  8MX  %3E  !&ZP  /_X  #G_
M   T_PD +_\. "O_%  G_QH!(_\A 1__)0$<_RH!&?\O 1;_- (4_SH"$?]
M A#_1@(._TX"#/]6 @G_8 ,'_VP#!/]X P/_A@,"_Y$# ?^= P'_H0,!_Z$#
M ?^A P'_H0,!_Z$#_S8M O\Y+@+_/BX#_T R _] . 3_/D$&_SQ,"/\Z6@K_
M.&@,_S9V#O\U@P__-(\0_S.9$?\SH1'_,ZD2_S*P$O\RMQ+_,K\2_S+($_\R
MTQ/_,N,3_S+M$_\R]A+_,_X2_S/_$O\S_Q+_,_\1_S/_$?\S_Q#_,_\0_S/_
M$/\S_Q#_,_\0_S8M O\[+ +_0"P#_T,O _]#-03_0CX&_T!*"/\^5PO_/&4-
M_SIS#_\X@!#_-XP1_S>6$O\VGQ/_-J<3_S:N%/\VM13_-KP4_S7%%?\UT!7_
M-> 5_S;K%?\V]!7_-OT4_S;_%/\V_Q3^-_\3_C;_$_TV_Q+]-O\2_3;_$OTV
M_Q+]-O\2_S<L O\^*@+_0RH"_T8M _]',@3_1CP&_T5("/]#50O_06(-_S]P
M$/\]?1'_/(D3_SN3%/\[G!7_.J06_SJK%O\ZLA?_.KD7_SG"%_\YS!?_.=T8
M_SGI&/\Y\QC_.OL8_#K_%_HZ_Q?Y.O\6^#K_%O@Z_Q7X.O\5^#K_%?@Z_Q7X
M.O\5_SDK O]!)P+_1B<"_THI _]++P3_3#D&_TM%"/](40O_1EX._T1L$?]"
M>1/_0845_T"/%_] F!C_/Z 8_S^G&?\^KAK_/K8:_SZ^&_\^R!O_/=8<_CWF
M'/L^\1SX/OH<]3[_'/,^_QKR/_\9\3__&?$__QCQ/_\8\3__&/$__QCQ/_\8
M_STH O]%) +_2B,"_TXE _]1+ 3_4C8&_U%!"/]/30S_3%H/_TIG$O](=!7_
M1X 7_T:+&?]%E!O_1)P<_T.D'?Y#JQ[]0K(?_$*Z(/I"Q"#Y0M A]D'B(?)"
M[B+O0ODB[4+_(.M#_Q_J0_\=Z43_'.A$_QOH1/\;Z$3_&^A$_QOH1/\;_T E
M O]((0+_3R "_U,A O]7*0/_63,%_U@^"/]620S_4E40_U%C%/]/;Q?^37L:
M^TN&'?E*CQ_W29@A]DB?(O1'IB3S1ZXE\4:V)O!&OR?O1<LH[$7>*>A%["GE
M1O@HXD?_)N%(_R3?2?\BWDG_(-U)_Q_=2?\?W4G_']U)_Q_=2?\?_T,B O],
M'@'_4QP"_UD> O]=)@/_7S $_U\Z!_]=10O_6E 0_5A>%?A5:AGU4W8=\E&
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M-IME_S.;9?\SFV7_,YME_S.;9?\S_U43 ?]@#@#_:PX _W00 /][$@#U@1<
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M1U&;[D13F_Q 59O_/%:;_SI6F_\Z5IO_.E:;_SI6F_\Z\70  -F#  #(D
MOIH  +.A  "JIP  H:X  )>U!@"2MA@ C+4J X6T-PE^LD(1=[!,&'&N5!]L
MK5LE9ZMB*F*J:2]>J7$S6JAZ-U:G@SI3IHX]4*:;0$VEJ4%+I;I"2Z;10DNE
M[3]-I?P\3J3_.4^D_S=/I/\W3Z3_-T^D_S=/I/\WY'H  ,^)  #"E0  MI\
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M)3O*_R4[RO\E.\K_)3O*_R4[RO\EPY,  +6>  "HI@  G:X  )&V  "%OP
M><<  &_.! !DU@D 7MX1 %O>( !7WBT"4]\Z!%#?1 9,WTX)2=]7#$;?7P]#
MWV@10=]Q$S[??!4\WXD7.N"6&3C@I1HWX+<:-N'-&C;?[!HUWOD:--W_&S3<
M_QLTW/\;--S_&S3<_QLTW/\;N9P  *JD  ">JP  DK4  (6^  !YQP  ;<\
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M!A/_Z083_^D&EZ\  (BZ  !ZQ0  ;,\  %[:  !0X   1.8  #SU   W_P0
M,_\- "__$P K_QH */\A "7_)P$A_RT!'O\R 1O_. $9_S\!%O]& A3_30(1
M_U8"$/]@ @[_; (,_WL#"_^+ PK_F@,*_Z@#"?^U PC_P@,(_\(#"/_" PC_
MP@,(_\(#BK@  'O#  !LS@  7ML  $_B  !"YP  -NP  #'_   L_P  )_\'
M "/_#@ @_Q( '/\8 !C_'0 5_R$ $O\F !#_+ $._S$!#?\W 0K_/@$(_T8!
M!?]/ 0'_60$ _V8! /]T 0#_@@( _Y " /^< @#_I@( _Z8" /^F @#_I@(
M_Z8"_RXO O\S+ +_-RT"_S@P O\W-@/_-#\$_S%+!O\O6 ?_+&8(_RIT"?\I
M@0K_*(T+_RB7"_\HGPO_**8,_R>M#/\GM S_)[L,_R?$#/\GS@S_*-X+_RCI
M"_\H\PO_*/L+_RC_"O\I_PK_*?\*_RG_"O\H_PK_*/\*_RC_"O\H_PK_*/\*
M_S M O\V*@+_.2H"_SLN O\Z- /_.#P$_S9)!O\S5@?_,6,)_R]Q"O\M?@O_
M+8H,_RR4#/\LG W_+*0-_RRK#?\LL0W_++D-_RO!#?\LRPW_+-H-_RSG#?\L
M\0W_+/H-_RS_#/XM_PS]+?\,_2W_#/TL_PO]+/\+_2S_"_TL_PO]+/\+_S(K
M ?\Y* +_/2@"_S\J O\^, /_/3H$_SQ&!O\Y4PC_-V )_S5M"_\S>@S_,H8-
M_S&0#O\QF0[_,:$/_S&H#_\PK@__,+4/_S"]$/\PQQ#_,-00_S#D$/\Q[Q#^
M,?D/^S'_#_DQ_P_X,?\.]S'_#O<Q_P[V,?\.]C'_#O8Q_P[V,?\._S4H ?\\
M)0'_0"0"_T,G O]#+ /_1#<$_T)#!O] 3PC_/5P*_SMI#/\Y=@W_.((/_S>,
M$/\WE1'_-IT1_S:D$O\VJQ+_-K(3_S6Z$_\UPQ/_-<\3_#7A$_DV[1/V-O<3
M\S;_$_$V_Q+P-O\2\#?_$>\W_Q'O-_\0[S?_$.\W_Q#O-_\0_SDE ?] (0'_
M12 !_T<B O])*0+_2C0$_TD_!?]&2PC_1%@*_T)E#?] <0__/GT1_SV'$O\]
MD13^/)D5_3R@%?P[IQ;Z.ZX7^3NV%_@[OQ?V.\H8]#O<&/ [ZACM._88ZCO_
M%^@\_Q?G//\6YCW_%>4]_Q3E/?\4Y3W_%.4]_Q3E/?\4_STB ?]$'@'_21P!
M_TT> ?]0)@+_43 #_U [!?].1@C_2U,+_TA@#O]&;!'[17@3^$2"%?9#C!?T
M0I08\T&<&?%!HQOO0*H;[D"R'.T_NQWK/\8>Z3_5'N4_Z!_B0/0>WT#^'=U!
M_QO;0O\:V4+_&-A"_Q?80O\7V$+_%]A"_Q?80O\7_T ? ?](&@'_3A@!_U(;
M ?]6(P+_6"P#_U<W!/]50@?_4DT+^5!:#O5-9Q+Q3'(6[DI]&.M(AAOI1X\=
MYT:7'^5%GB#C1*8BX42N(^!#MR3>0\(EW$/0)M=#Y2;31/,DT$7^(LU&_R#,
M1_\>RD?_',E(_QO)2/\;R4C_&\E(_QO)2/\;_T0; ?],%@'_4A0!_U@8 ?]=
M'P'_7R@"_UXR _U=/0;V6DD*\%=5#^I58A/F4FT8XE!W'-].@1_<3(HBV4N2
M)-5*FB;32:$HT4FI*<](LBK-2+PKRTC)+,A(WRS%2.\KPDK\*,!+_R6_3/\B
MODW_(+U-_Q^]3?\>O4W_'KU-_QZ]3?\>_T<8 ?]/$P'_5A$ _UX5 /]B' '_
M920!_F4M O1D. 7M84,)YE]1#N!<713:6&@:U%9R'M!4>R+,4H0FRE",*,=/
ME"K%3ILLPTZC+L%-K"^_3+8PO4S",;M,TS*X3.DQMD[X+;10_RJS4?\GLU+_
M)+)2_R*R4O\BLE+_(K)2_R*R4O\B_TH5 ?]3$0#_6P\ _V(2 /]H%P#_:A\!
M]FLH >QK,@/D:3X'W&9,#=-B6!3-7V,;R%QM(,1:=B3!6'XHOE:&*[M5CBZY
M4Y8PME*>,K12IC.R4; UL%&\-JY0RS>L4.,WJE+T,ZE4_RZH5O\KJ%?_**A7
M_R6H5_\EJ%?_):A7_R6H5_\E_TT3 /]6#@#_7PT _V<0 /]L$P#[<!D [W$B
M >1Q+ +;<#H%T6Q(#,EH5!3#95\;OF)H(;I?<2:V77DJLUN!+;!:B3"N6)$S
MJU>9-:E6H3>G5JLXI56V.J-5Q3NA5=T[GU;P-Y]8_C*?6O\NGEO_*YY<_RB>
M7/\HGES_*)Y<_RB>7/\H_U 1 /]9# #_8PP _VL- /]P$ #U=!, Z'8: -UW
M)0'1=C8$R')$#,%N4!2[:UL;MF=D(;%E;2>M8G4KJF!\+Z=?A#*D78PTHER4
M-Y];G3F=6J8[FEFQ/9A9OSZ76=,^E5KL.Y5=^S667O\QEE__+99@_RJ68/\J
MEF#_*I9@_RJ68/\J_U(/ /]<"@#_9@D _VX* /9T# #O> X X7L2 -1\( #*
M>S,$P7=!"[IT31.T<%@;KFQA(:EJ:2>F9W$KHF5X+Y]D@#.<8H@VF6&0.)9?
MF3N47J(]D5ZM/X]=NT"-7<U!C%[H/XUA^3B-8O\SCF3_,(YD_RR.9?\LCF7_
M+(YE_RR.9?\L_U4. /]?!@#_:08 ]'(& .)X!@#;? D V7\, ,V!'0#$?S #
MNWP_"K1X2Q*M=54:J'%>(:-N9B:?;&XKFVIU+YAH?3.59X0VDF6,.8]DE3R,
M8Y\^B6*J0(=AMT*%8<E"A&+D085D]SN&9O\UAV?_,8=H_RZ':?\MAVG_+8=I
M_RV':?\M_U<, /]A! #^; , Y'4! -M[!0#3@ @ T(,* ,>%&@"^A"T#MH$\
M":]]2!*H>5(9HG9;()US8R:9<&LKE6YR+Y%M>3..:X$VBVF).HAHDCR%9YP_
M@F:G08!FM$-^9L5$?&;A0WYH]3Q_:O\W@&O_,X%L_R^!;/\O@6S_+X%L_R^!
M;/\O_UD+ /]C 0#T;P  WW@  -1_! #.@P8 RH<( ,*(& "YARL"L84Z"*J!
M1A&C?E 8G7I9'YAW8263=6@JCW-O+XMQ=S.(;WXVA6Z&.H)LCSU_:YE ?&JE
M0GEJL41W:L)$=FK=1'AL\SYY;O\X>F__-'MP_S!\</\P?'#_,'QP_S!\</\P
M_UL( /]F  #G<@  VGL  ,^" P#)AP4 Q(H& +R,%0"TBR@"K(DX!Z6%1!">
M@DX8F']7'I-\7R2.>68JBG=M+H9U=#*"='PV?W*$.7QQC3UY<)= =F^B0G-N
MKT1Q;L!%<&[917)P\3]S<O\Y=7/_-79T_S%V=/\Q=G3_,79T_S%V=/\Q_UT&
M /]I  #B=   U'T  ,N% @#$B@0 OXT% +>/$P"PCR8!J(TU!Z"*0@Z:ADP6
MDX-5'8Z!722)?F0IA7QK+8%Z<C)]>'DU>G>".79VBSQS=95 <'2@0FUSK41K
M<[U%:G/516QT[T!N=OXZ;W?_-G%X_S)Q>/\Q<7C_,7%X_S%Q>/\Q_U\" /=L
M  #>=P  T($  ,>( 0# C0, N9$# +*3$0"KDR,!HY$S!IR.0 V5BTH5CXA3
M'(F&6R*$@V(H@(%I+7Q_<#%X?G<U='R .'%[B3QN>I,_:WF>0FAXJT1F>+M%
M9'C1169Y[D!H>_TZ:GO_-FM\_S)K?/\R:WS_,FM\_S)K?/\R_V$  .IO  #9
M>@  S(0  ,.+  "[D0$ M)4! *R7#@"EER$!GI8Q!9>3/@R0D$@4BHY1&X2+
M62%_B6 G>X=G*W>%;C!SA'4T;X)]-VN!ASMH@)$^97^<06)^J4-@?KE$7W[/
M1&!_[$!B@/PZ9(#_-F6!_S-F@?\R9H'_,F:!_S)F@?\R_V0  .5R  #3?@
MQX<  +Z/  "VE0  KID  *:;# "@G!X F9LN!)*9.PJ+ED82A91/&7^15Q]Z
MCUXE=8YE*G&,;"YMBG,R:8E[-F:(A#EBAH\]7X6:/UR%J$%:A;="687,0EJ%
MZC]<AOLZ7H;_-E^'_S)?A_\R7X?_,E^'_S)?A_\R_6@  .!V  #-@@  PHP
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M,$N?_RY+G_\M2Y__+4N?_RU+G_\MW7D  ,F&  "\D@  L9H  *:@  "<I@
MD:P  (:R  !]M@T >;8= '6V+ )OM3D&:K1#"V6S3!%@LE067+%;&EBP8QY5
MKVLA4:]S)4ZN?2A+K8@J2*V5+46MHRY$K;,O0ZW(+T*LYR]#J_DM1*O_*T2J
M_RE$JO\I1*K_*42J_RE$JO\IT8   ,&-  "UF   J9\  )ZE  "3K   B+(
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M$R_4_Q,OU/\3LYH  *:A  ":J0  C;$  ("Z  !TP0  :,D  %S/  !2U0,
M2-P( $7E$@!#Y1X 0>8J #[F-0$[YSX!.>=' C?G4 ,TZ%D$,NAB!3#H;08N
MZ7D'+.F'""OJE@DIZJ<**.JZ"B?KU@HGZ? *)^?]"2;F_PHFYO\*)N;_"B;F
M_PHFYO\*J*   )RG  "/L   @KD  '3"  !HR@  6]$  $_7  !%W0  /NX)
M #SR$0 Y\QL -O,E #3T+@ Q]#<!+O4_ 2SU1P$I]D\")_97 B7W80,C]VP#
M(?AZ!!_XB00>^9H%'/FK!1OZP 4:^MX%&OGR!1KW_049]O\%&?;_!1GV_P49
M]O\%GJ8  )&O  "#N0  =<(  &?+  !:TP  3=H  $+?   XY0  -?L' #'_
M#P N_Q8 *_\? "G_)@ E_RT (_\T "#_.P$>_T,!&_]+ 1G_4P$6_UT"%/]J
M A+_> (1_X@"$/^: A#_JP,._[X##O_5 P[_[0,.__ ##O_P P[_\ ,.__ #
MDZX  (2X  !VP@  9\P  %K5  !,W   /^$  #7F   M]   *O\" ";_"P C
M_Q$ (/\7 !W_'0 9_R, %O\I !3_+P 2_S4 $/\]  [_10$,_TX!"O]8 0?_
M90$%_W0! _^% 0+_E@$!_Z8! /^U 0#_Q@$ _\H! /_* 0#_R@$ _\H!AK<
M '?!  !HS   6M<  $O>   ^Y   ,ND  "?M   C_P  '_\  !O_!0 7_PP
M%/\0 !'_%  /_Q@ #?\=  O_(@ (_R@ !?\N  +_-0  _ST  /]'  #_4@
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M_Q^95_\?_TT- /]5!@#_704 ^V0' .]I"0#I:PP X6P0 --M'@#);#$"PFI
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M.FUKZS=O;?PQ<&[_+7%N_RIQ;_\H<6__*'%O_RAQ;_\H_UD  .ME  #;<
MS7@  ,1^  "\@@$ MH0! *Z%#@"GAB  H(4P YJ"/0B3@$@/CGU1%8E[61J$
M>6 ?@'=G(WQU;B=Y='4J=G-]+G-RAC%P<9 T;7"<-VIOJ#EH;[<Z9V_+.F=P
MZ3=I<?HR:W+_+6QS_RIL<_\H;'/_*&QS_RAL<_\H_UP  .=H  #5<P  R7L
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M+5N"_RI;@O\I6X+_*5N"_RE;@O\I[&8  -AS  #'?@  O(<  +..  "ID@
MH)4  ):8 0"0F1, BIDD 868,@1_ECX)>91(#G234!1OD5<9:Y!>'6B.92%D
MC6TE8(QU*%V+?BM:BH@N5XF4,52)H3-2B+ T48C#-5"(XC12B/8P4XC_+%2(
M_RE5B/\H58C_*%6(_RA5B/\HYFL  -!X  #"@P  MXP  *V2  "CE@  FIH
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M($"D_R! I/\@RGX  +N+  "OE0  I)L  )FA  ".I@  @JP  '>Q  !JM@
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MCP,CY:$$(N6T!"'ES00@Y.P$(.+[!!_A_P4?X/\%'^#_!1_@_P4?X/\%I)X
M )BE  "+K@  ?;8  '"^  !CQ@  5LL  $O0  ! U0  -MP  "_E!P M[1
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M  #_D   _Z,  /^T  #_Q@  _]8  /_6  #_U@  _]8 @K4  '._  !DR0
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M+GM;["M\7/PF?%W_(GU>_Q]]7O\=?5[_'7U>_QU]7O\=_U   /59  #A8P
MTFH  ,EN  #"< $ O7 # +9P$ "N<2( J' R J%N/P:<;$H+EVI3$))H6Q2.
M9F(8BV5I&XAC<!Z%8G@A@F& )(!@B29]7Y(I>UZ=*WA>J2UV7K@N=5[,+W1>
MZ2UU8/HG=F'_(W=B_R!W8O\>=V+_'G=B_QYW8O\>_U(  .Q<  #<9@  SFT
M ,1R  "]=   MW0! +!T#@"I=1\ HG0O IQR/067<$<*D6Y1#XUL612):F 7
MA6EG&X)H;AY_9G4A?65])'IDAB=W8Y I=6.;+')BIRYP8K8O;V+)+VYBYBYO
M9/DH<&7_)'%F_R%Q9O\?<6;_'W%F_Q]Q9O\?_U0  .A?  #7:0  RG   ,!U
M  "Y>   LG@  *MX#0"D>1T GG@M 9=W.@62=44*C').#HAP5A.$;UX7@&UD
M&GUL:QUZ:W,@=VI[(W1I@R9R:(TI;V>9+&QFI2YJ9K,O:6;&,&AFY"]J:/<I
M:VG_)6QI_R)L:O\@;&K_(&QJ_R!L:O\@_U<  .1B  #2;   QG,  +UX  "U
M>P  K7P  *5\"@"??1H F7PJ 9-[. 2->4,)B'=,#H-U5!)_<UL6>W)B&7AP
M:1UU;W @<FYX(V]M@29L;(LI:FR7+&=KHRYE:[(O9&O$,&)KX2]D;/8J9FW_
M)F9M_R-G;O\@9V[_(&=N_R!G;O\@]ED  .!E  #.;P  PG8  +E\  "Q?P
MJ8   *" !P"9@1< E($H 8Z -0.(?D$(@WQ*#7YZ4A%Z>%D5=G=@&7-V9QQP
M=&X?;7-V(VIR?R9G<8DI9'&5*V)PH2U@<+ O7G#"+UUPWR]?<?4J8''_)F%R
M_R-B<O\@8G+_(&)R_R!B<O\@[UP  -QI  #*<@  OGH  +6   "MA   I(4
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M'U"#_Q]0@_\?WFD  ,EU  "\@   LH@  *B-  "=D0  DY,  (66  !^EPL
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MEA,WKZ84-J^X%#6PT10UKN\4-*W^%#2L_Q0TJ_\4-*O_%#2K_Q0TJ_\4NX4
M *^0  "CEP  F)T  (RC  " J   =*T  &BR  !<M@  4+H! $F\#0!(O!D
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M 1G?Q $8WN<!&-SX 1C;_P(7VO\"%]K_ A?:_P(7VO\"H)P  )2C  "'JP
M>;,  &RZ  !?P0  4L8  $;*   [S@  ,=,  "G9   AW@4 'N@. !WH%0 ;
MZ1X &>DG !CJ,  6ZCD %>M# !3L3@ 2[%H $>UG !#N=P 0[HH #N^>  [P
MLP -\,T #._L  SM_  ,Z_\ #.O_  SK_P ,Z_\ EZ,  (FK  ![M   ;;P
M %_$  !2R@  1<X  #G3   OV   )=T  !WA   8[ ( %O<+ !3W$0 1^!<
M$/@>  [Y)0 -^2T "_HU  G[/P '^TH !/Q7  /]9@ "_G<  /V+  #]GP
M_+4  /S1  #\[0  _/P  /S]  #\_0  _/T BZL  'VT  !NO0  8,8  %+-
M  !$T@  -]@  "S=   BX0  &>4  !/J   0^@  #O\&  W_#  *_Q  !_\4
M  3_&@ !_R   /\G  #_,   _SH  /]%  #_4P  _V(  /]U  #_B@  _Y\
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M'9!)[QN/2OX8CTO_%HY+_Q2.3/\2CDS_$HY,_Q*.3/\2_T4  /]+  #I4P
MWE@  --;  #-6P0 RE@' ,)8%0"Z6B< LUHW :Y81 2I5T\'I%58"J%48 V>
M4V@0FU%O$YA0=A664'X7E$^&&9).CAJ/3I@<C4VB'8M-KA^*3;P@B$W0((=-
MZQ^&3_P;AE#_&(90_Q:&4/\4AE'_%(91_Q2&4?\4_T<  /A/  #D5P  U5T
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M''%=_QIQ7?\8<5W_%W%=_Q=Q7?\7_4\  .59  #38@  QV@  +UL  "V;0
MKVP  *=K"P"@;!D FVPJ 95K-P*0:4,%BVA,"8=F5 R#95L0@&-B$WUB:15Z
M87 8>&%X&G5@@1US7XL?<%Z6(FY>HB1L7K E:U[!)FE>WB9J7_0A:V#_'6MA
M_QML8?\9;&'_&&QA_QAL8?\8]5$  .)<  #/90  PVL  +EO  "Q<0  JG$
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M&5UM_QE=;?\9Z%H  -)F  ##;P  N'8  *][  "F?@  G7X  )%\  "*? \
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ME1M&B*,=1(BT'4.(RAU#A^H<1(;[&D2&_QA%AO\7187_%T6%_Q=%A?\7S6T
M +UX  "Q@@  IXH  )R.  "2D   AI,  'F5  !LEP  9I<. &.8&P!AF"D
M7I@U 5J7/@-7ET<%599/!U*65@E/E5X,3)1F#DJ4;Q!'DWD31).%%4*2DQ=
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M##"JQPPPJ><,+Z?Z#2^F_PTOI?\-+Z7_#2^E_PTOI?\-MH0  *J.  ">E
ME)D  (>>  ![HP  ;Z@  &.L  !7KP  2[(  $&U!@ ^MA$ /;8> #NV*0 Z
MMS0 .;<^ #>W1P VMU !-+=: 3*W9 (PMV\#+K=\!"RWBP4JMYP%*;>N!BBX
MQ04HM^8%)[7Y!R:S_P<FLO\()K+_"":R_P@FLO\(KXT  **4  "7F@  BZ
M 'ZF  !QJP  9;   %FT  !-MP  0KL  #B^ 0 OP@D +<,2 "S#'@ KPRD
M*L0S "G$/0 HQ4< )\51 ";%7  EQF@ (\9V 2+&A@$@QI@!'\:K 1['P0$>
MQN0!'<3X AS"_P,<P?\#','_!!S!_P0<P?\$I90  )J:  ".H0  @:<  '.N
M  !GM   6KD  $Z]  !"P   .,,  "_'   FRP0 'M * !O1$0 :TAH &=(E
M !C3+P 8TSH %]1$ !;44  5U5T %-5K !/6?  2UX\ $=BD !#9NP 0V=X
M$-7S !#3_P 0TO\!$-'_ 1#1_P$0T?\!G)H  )&A  "#J   =;   &BW  !;
MO0  3L$  $+%   WR   +<P  "30   <U0  %=H% !#B"P 0XQ$ #N0:  [D
M(P -Y2T #.4W  OF0@ *YD\ ">==  CG;0 &YH  !>:5  3FJP "YL0  >;F
M  #G^0  Y_\  .;_  #F_P  YO\ DZ$  (6I  !WL0  :;D  %O   !.Q@
M0<H  #7.   JT@  (=8  !G;   2WP  #>,   OQ"  )\PX !_,3  3R&@ "
M\B(  /(J  #R-   \C\  /),  #R7   \FT  /*"  #RF   \ZT  //&  #T
MY0  ]/8  /3[  #T^P  ]/L AZD  'FR  !JN@  7,(  $[)  ! S@  ,],
M "C8   >W0  %>$   _D   *Z   !?,   /] 0  _ @  /L-  #[$0  ^Q8
M /P>  #\)@  _#   /T\  #^20  _EH  /YM  #_@@  _Y@  /^L  #_P
M_]@  /_D  #_Y   _^0 >[(  &R[  !=Q   3\T  $#2   RV0  )MX  !OB
M   2Y@  #.H   7M    ]    /\   #_    _P   /\$  #_"0  _PX  /\2
M  #_&   _R$  /\K  #_-P  _T8  /]8  #_:P  _X   /^5  #_I@  _[,
M /^[  #_NP  _[L _QLF /\<) #_&B0 _Q4G /\0+0#_"C8 _P5# /\!4 '_
M %X!_P!K ?\ =@'_ ($ _P"* /\ D@#_ )H _P"@ /\ I@#_ *P _P"R /\
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M ?\+;@'_"WD!_PN" ?\+BP'_"Y(!_PJ9 ?\*GP#_"J4 _PJK /\*L@#_"KL
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M":TS]0FK,_\)JC/_"*@S_P>H,_\'IS/_!Z<S_P>G,_\'_S<' /\Z  #_/@
M^D$! /%!!@#Q/PT YCP2 -LZ'P#0.S$ RCQ  ,0\30' /%@"O#MA [D[:@6V
M.G(&M#IZ![(Y@0BP.8@)KSF0"JTXF JK.*$+J3BJ#*@XM@VF.,4-I#C>#J$Y
M\0V?.O\,GCK_"YTZ_PJ<.O\)G#K_"9PZ_PF<.O\)_SL" /\^  #W1   YD<
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M$H!+_Q" 2_\/@$O_#H!+_PZ 2_\._T,  .Q+  #=4P  SE@  ,1:  "]6@
MN%<! +%4#@"J5AX I58N )]6.P&;548#EU10!9-36 B04E\*C5%F#(M0;0Z(
M3W00AD]\$H1.A1."3HX5@$V9%WY-I!A\3;(9>DW#&GE-WQIX3O07>$__%'A/
M_Q)X4/\0>%#_#WA0_P]X4/\/_48  .=/  #65P  R%P  +]?  "W7P  L5P
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M$F=<_Q)G7/\2[4X  -I9  #(80  O&<  +-J  "K;   HFH  )EG @"29Q$
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ME!E3;*,;46RS'%!LR!Q/;.<;46SZ&%%L_Q52;/\44FS_$U)L_Q-2;/\3W%P
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M%3^#PA4^@N(5/X'W$S^!_Q) @/\10(#_$$" _Q! @/\0QFL  +=V  "L?P
MHH4  )>)  ",BP  @8T  '..  !ECP  78\) %J0% !8D"$ 5I$M %.0. %1
MD$$"3I!) TR04 1*CU@%1X]@!T6.:0E"CG,+0(U_#3Z-C0\\C9P0.HVL$3F-
MP1$XC>$0.(OV$#B*_P\YB?\/.8G_#CF)_PXYB?\.OW(  +)]  "GA@  G(H
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M R"N_P,@K?\$'ZS_!!^L_P0?K/\$JHL  )V1  "3EP  AYP  'JB  !MIP
M8*L  %6O  !)L0  /K0  #.W   JN@, )+P- "*]%0 AO2  (;TJ ""],P ?
MOCT 'KY' !V^4@ <OUX &K]L !F_?  8OXX %\"A !; M@ 4P-, %;[Q !6\
M_P$5N_\!%+K_ A2Z_P(4NO\"H9(  ):8  "*G@  ?:0  &^J  !BKP  5K0
M $JW   ^N@  ,[T  "K    AQ   &<<% !/+"P 1S!( $<P; !#,)0 /S2\
M#LTZ  [-1@ -S5( #<Y@  S.<  +SH, "LZ7  G.K  (SL8 ",[H  C-^P )
MR_\ "<O_  G+_P )R_\ F)@  (V>  !_I0  <:P  &2S  !7N0  2KT  #[
M   RPP  *,8  !_*   7S0  $=$   S6!0 (V0P !MD2  7:&P $VB0  ]LN
M  ';.0  W$4  -U2  #>8@  WG,  -Z(  #?G0  W[,  -_.  #@[@  W_H
M -__  #?_P  W_\ CY\  (&F  !SK@  9;4  %B]  !*P@  /<4  #')   F
MS   '=   !34   .V0  "=T   /A    XP<  .,-  #D$@  Y1D  .8B  #G
M*P  Z38  .M#  #L4@  [&(  .UV  #NC   [J$  .^W  #OT0  [^L  /#V
M  #P]@  \/8 A*<  '6O  !GMP  6;\  $O&   \R@  +\X  "32   :V
M$MP   S@   %XP   .<   #K    ZP   .T%  #N"P  \!   /$5  #S'@
M]"<  /<S  #Y0   ^E$  /MC  #\=P  _8T  /VC  #^M@  _LD  /_?  #_
MWP  _]\ =[   &BY  !:P0  3,H  #S/   NU   (MH  !?>   0X@  ">8
M  #I    [    /    #V    ]@   /<   #X    ^@<  /L-  #]$0  _QD
M /\C  #_+P  _SX  /]/  #_8@  _W<  /^-  #_GP  _ZX  /^Z  #_N@
M_[H _Q8C /\5(0#_$B$ _PXD /\&*@#_ #, _P!! /\ 3@#_ %P _P!H /\
M= #_ 'X _P"' /\ CP#_ )8 _P"< /\ H@#_ *@ _P"N /\ M0#_ +T _P#'
M /\ U@#_ .< _@#S /X _@#] /\ _ #_ /L _P#[ /\ ^P#_ /L _P#[ /\
M_QH@ /\9'@#_%AX _Q @ /\*)0#_!#  _P ] /\ 2P#_ %@ _P!D /\ < #_
M 'H _P"# /\ BP#_ )( _P"8 /\ G@#_ *0 _P"J /\ L0#] +D ^P## /H
MT #X ., ]P#Q /8 _ #T /\ ] #_ /, _P#S /\ \P#_ /, _P#S /\ _QT<
M /\<&0#_&1D _Q0; /\.(0#_#"P _PDY /\%1@#_ E, _P!? /\ :P#_ '4
M_P!^ /\ A@#_ (X _P"4 /X FP#\ *$ ^@"G /@ K@#U +4 \P"_ /$ RP#P
M -\ [@#N .P ^0#K /\ Z@#_ .H!_P#I ?\ Z0'_ .D!_P#I ?\ _R 7 /\?
M% #_'!, _Q<5 /\6'0#_$R@ _Q T /\-00#_#$X _PE: /\(9@#_"'  _@=Y
M /P'@0#Z!XD ^ >0 /8&E@#S!IT \0:C .\&J@#M!K( _^+__TE#0U]04D]&
M24Q%  @)Z@:[ .@&R #F!MP Y ;L .((^@#@"O\ W@O_ -T+_P#=#/\ W S_
M -P,_P#<#/\ _R,2 /\C$ #_(0X _QX0 /\>& #_'", _Q@O /\4.P#_$DD
M_!!5 /@/8 #T#VH \0]T .\.? #M#H0 ZPZ+ .D.D@#G#ID Y@Z@ .0.IP#B
M#J\ X ZX -X.Q0#<#MH UA#L -(1^@#/$O\ S1+_ <P2_P'+$_\!RA/_ <H2
M_P'*$O\!_R</ /\G# #_)0D _R8- /\E$P#_(QP _R H /L<-0#U&D( [QA/
M .H76@#F%F4 XQ9N . 6=P#>%G\ W!:' -D6C@#6%I4 U!:< -(7HP#0%ZL
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MM02N*\0$K"O;!*@L[P2F+/X%I"S_!*,M_P2B+?\$HBS_!*(L_P2B+/\$_S(
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M#H8_X Z$/_0-@T#_"X- _PJ"0/\)@D'_"()!_PB"0?\(_SP  .M#  #<2@
MS$\  ,-0  "\3@  MTD! +%&#@"J2!P I$DL *!).@";244!F$A. I1'5P.2
M1UX%CT9E!HU&; >+17,)B45["H=$@PN%1(T,@T27#H%#H@]_0Z\0?D/ $'Q$
MVA%[1/$/>D7_#7I&_PMZ1O\*>D;_"7I&_PEZ1O\)]3X  .9(  #33P  QU0
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M$693_P]F4_\-9E/_#&93_PQF4_\,ZDD  -53  #%6@  NE\  +!B  "H8@
MGU\  )9:  "/6A  BEL> (5;+ "!6S@!?5M! GI:2@-W65$$=%A8!G%87P=O
M5V8);5=M"VM6=@UI5G\/9U6*$655EQ-C5:04856T%6!5R!9?5><58%;Z$F!6
M_P]A5_\.85?_#6%7_PQA5_\,YTP  -%6  #!7@  MF,  *UF  "D9@  FV0
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M#5)B_PU28O\-V58  ,1@  "W:   K&X  *-Q  ":<P  CW$  ']K  !X:P4
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MB L]?9<,/'VG#3I]N@XZ?M8-.GSQ#3I[_PPZ>_\+.GK_"SIZ_PLZ>O\+P&D
M +)T  "G?   G8$  )*$  "'A@  >X<  &Z'  !@AP  58<! %"(#@!.B!H
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M B2>M0(CGLX"(YWN R.;_@,BFO\$(IG_!"*9_P0BF?\$K($  *"(  "5C@
MBY(  '^6  !RF@  99T  %F@  !.HP  0J0  #>F   NJ 4 *:D/ "BI&  G
MJB( )JHL "6J-0 DJC\ (ZI( "*K4P AJUX (*MJ !ZK>0 =JXL &ZN= !JK
ML0 9J\H &:KL 1FH_0$8I_\"&*;_ ABF_P(8IO\"I8D  )F/  "/E   @YD
M '6>  !HH@  7*8  %"I  !$K   .:X  "^P   FLP  'K4& !FW#P 8MQ<
M%[<A !:W*@ 5MS0 %+@^ !.X20 2N%0 $KEB !&Y<0 0N8, #[F7  ZYK  -
MN<0 #;CG  ZV^P .M?\ #K3_  ZT_P .M/\ G)   )*5  "&FP  >:   &NF
M  !>JP  4J\  $:R   ZM0  +[<  "6Z   =O0  %<   !##!@ +Q@X "L45
M  G%'@ (Q2@ !\4R  ;&/0 %QDD !<97  /&9@ "QG<  <:+  #&H   Q;8
M ,;2  #%[P  Q?P  ,7_  #%_P  Q?\ E98  (F<  ![HP  ;:D  &"O  !3
MM   1K@  #J[   NO@  ),$  !O$   3QP  #LH   C. 0 !T H  - 0  #0
M%@  T1X  -(G  #3,0  U#P  -5)  #66   UFD  -9\  #6D@  UJ<  -:_
M  #6X   UO,  -;^  #6_P  UO\ C)T  'ZD  !OJP  8;(  %2Y  !&O0
M.<$  "W$   BQP  &<L  !'.   ,T@  !=4   #;    W ,  -T*  #>#P
MWQ0  .$<  #B)   Y"X  .8Z  #G20  Z%D  .AK  #I@0  Z9@  .FM  #I
MQ0  Z>(  .GR  #I]0  Z?4 @*4  '&M  !CM0  5;P  $?"   YQ@  +,H
M "#.   6T@  #]8   C;    WP   .,   #E    YP   .@!  #J!P  ZPT
M .T1  #O&   \2$  /,K  #V.   ]T@  /A:  #Y;0  ^H0  /J;  #ZKP
M^L(  /K:  #ZWP  ^M\ =*X  &6V  !6O@  2,8  #G+   KT   ']0  !3:
M   -WP  !>,   #F    Z0   .T   #O    \0   /,   #U    ]@(  /@)
M  #Z#@  _1,  /\<  #_*   _S8  /]'  #_6@  _VX  /^%  #_F@  _ZL
M /^Y  #_O   _[P _Q$@ /\0'@#_#!X _P0A /\ )P#_ #  _P ^ /\ 3 #_
M %D _P!E /\ < #_ 'H _P"# /\ BP#_ )( _P"8 /\ G@#_ *0 _P"J /\
ML #_ +@ _P#" /\ S@#_ .( _@#P /T ^P#[ /\ ^P#_ /L _P#Z /\ ^@#_
M /H _P#Z /\ _Q0< /\2&@#_#AH _P@< /\ (0#_ "T _P Z /\ 2 #_ %4
M_P!A /\ ; #_ '8 _P!_ /\ AP#_ (X _P"4 /\ F@#^ *  _0"F /P K #[
M +0 ^0"] /@ R0#W -P ]0#L /, ^ #S /\ \@#_ /$ _P#P /\ \ #_ /
M_P#P /\ _Q<8 /\5%@#_$14 _PP7 /\%'0#_ "@ _P V /\ 0P#_ %  _P!<
M /\ 9P#_ '$ _P!Z /P @@#Z (D ^ "0 /< E@#U )P ] "B /, J #Q +
M\ "X .X PP#L -, Z@#G .D ]0#G /\ Y@#_ .4 _P#E /\ Y0#_ .4 _P#E
M /\ _QH3 /\8$0#_%!  _P\1 /\-&0#_"B0 _P4P /\!/@#_ $L _P!7 /X
M8@#Z &P ]0!U /( ?0#P (0 [@"+ .P D0#K )< Z0"> .< I #F *P Y "T
M .( OP#@ ,T W@#C -P \@#: /T V #_ -8 _P#5 ?\ U0'_ -4"_P#5 O\
M_QX0 /\<#0#_%PL _Q4. /\4%0#_$1\ _PXJ /\+. #]"$4 ^ 91 /0$7 #N
M!&8 Z@1O .8#=P#D!'\ X@2& . $C #>!), W06: -L%H #8!:@ U06Q -(%
MNP#0!LD S@?@ ,P(\0#)"O\ QPO_ ,8,_P#%#/\ Q0S_ ,4,_P#%#/\ _R$,
M /\@!@#_' , _QT* /\;$ #_&!@ _Q0C /81, #O#CX Z@Y* .4-5@#A#6
MW0UI -D-<0#5#7D TPV! -$-B #/#8\ S0Z6 ,L.G0#*#J4 R ZN ,8/N0#$
M$,@ PA#? +X1\@"[$O\ N1/_ +<3_P&V$_\!MA/_ ;83_P&V$_\!_R4& /\C
M  #_(P  _R0# /\A"@#]'1$ \1H; .@6)P#A%#4 VA-# -,43P#.%5D RQ5C
M ,@6:P#%%G, PQ=[ ,$7@@# &(D OAB0 +P8F "[&:  N1FI +<9M "U&L(
MM!K6 + ;[0&M'/P!JQW_ :D=_P&I'?\!J!W_ :@=_P&H'?\!_R@  /\G  #^
M*@  [RH  .<G 0#G(@D Y!T0 -D;'0#/'2T R1X\ ,0@20"_(%, O"%= +DA
M90"W(FT M2)T +,B? "Q(H,!L"** :XBD@&L(YL!JR.D :DCKP&G([P!IB3.
M :,DZ *@)?D"GB7_ ITE_P*<)?\"FR7_ ILE_P*;)?\"_RP  /\M  #M,@
MXC0  -HS  #3+@, TB4* ,DE%P#!)R< NRDV +8J0P"R*TX KRM7 *PK8 "J
M*V<!J"MO :8K=@&D*WT!HRN$ J$KC0*?*Y4"GBN? IPKJ@.:*[8#F2S' Y<L
MX@.4+?4$DBW_ Y$M_P.0+O\#D"W_ Y M_P.0+?\#_S   /(S  #D.@  UCT
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M20  KT,  *D^"P"B/Q< G4 F )A!- "403\ D4%) 8Y!40&+0%D"B4!@ X=
M9P.%/VT$@S]U!8$_?09_/H<'?3Z1"'L^G EZ/JD)>#ZX"G<_S0IU/^H*=$#\
M"'1 _P=T0/\&<T#_!G- _P9S0/\&\3L  -]%  #,3   OT\  +90  "N3P
MITH  *!$!P":110 E48B )!&, ",1SP B49% 89&3@&#1E4"@45< WY%8P1\
M1&H$>D1Q!7E$>09W1(((=4.-"7-#F0IQ0Z8+<$.U#&Y$R0QM1.<,;47Z"FQ%
M_PAL1?\';$7_!VQ%_P=L1?\'[#\  -A)  #'4   NU0  +%5  "I5   H5
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M"%M1_PA;4?\(WTH  ,E3  "[6@  L%\  *9A  "=80  E%X  (A7  " 5@H
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MB I*8Y<+2&.F#$=CN U&8]$-1F/O#$9B_PI'8O\)1V+_"4=B_PA'8O\(RE@
M +IB  "N:0  HVX  )IQ  "0<@  A'$  '1K  !I:0  8VD+ %]I%0!<:B$
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M!S5XLP<T>,L'-'?K!S1V_0<T=?\'-77_!C5T_P8U=/\&N6@  *UQ  "B>0
MF'X  (V   ""@0  =H(  &F!  !;@0  48$  $B "@!%@1, 0X$> $*"*0!!
M@C( 0(([ #Z"0P ]@DL .X)3 3F"7 $W@F8"-8)Q S."?P,Q@8X$,(&?!"Z!
ML04M@<@%+8'I!"U__ 4M?O\%+7W_!2U]_P4M??\%LVX  *AX  "=?P  DH,
M (B&  !]AP  <(@  &.)  !5B@  2XH  $&* @ [BPX .8L7 #B,(@ WC"P
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M !&B^  1H?\ $:#_ 1&@_P$1H/\!H(8  )6,  ",D0  ?Y4  '&:  !DG@
M6*$  $RD  ! I@  -:<  "JI   BK   &:X  !*P"0 0L1  $+$8  ZQ(@ .
ML2L #;$U  VQ0  ,L4L "[%8  JQ9P (L7@ ![&+  6QH  $L+4 !+#0  2P
M[P %K_X !J[_  :N_P &KO\ F(X  (^3  ""F   =9T  &>B  !:IP  3JL
M $&M   UKP  *[$  "&T   8M@  $;D   V\ P 'O@P  [T2  &]&0  OB(
M +XK  "^-@  OD$  +].  "_7   OVT  +^   "^E0  OJH  +["  "]Y
MO?8  +W_  "]_P  O?\ DI0  (6:  !XH   :J8  %RK  !/L   0K,  #6V
M   JN   (+L  !>^   0P0  "\0   3'    R0<  ,D-  #)$@  RAD  ,LB
M  #+*P  S34  ,Y!  #.4   SV   ,]R  #/AP  SYT  ,^S  #/S@  S^L
M ,[X  #._@  SOX B)L  'JB  !LJ   7J\  %"U  !"N0  -;P  "F_   >
MP@  %<8   [)   (S    -    #3    U0   -8&  #8#   V1$  -L6  #<
M'P  WB@  . T  #B00  XE$  .-C  #C=P  Y(X  .2D  #DN@  Y=0  .7J
M  #E\P  Y?, ?*,  &ZJ  !@L@  4;D  $.^   UP@  *,8  !S)   3S0
M#-$   35    V@   -X   #A    X@   .0   #E P  YPD  .D.  #K$@
M[1H  .\D  #R,0  ]$$  /13  #U9@  ]7P  /:3  #VJ0  ][P  /?.  #W
MWP  ]]\ <*P  &&T  !3NP  1<,  #;'   GS   &]   !'5   *VP   -\
M  #B    Y0   .D   #L    [0   /    #Q    \P   /4$  #W"@  ^A
M /P6  #_(0  _RX  /]   #_4P  _V@  /^   #_E@  _Z@  /^V  #_OP
M_[\ _PT< /\*&P#_ AL _P > /\ ) #_ "X _P \ /\ 2@#_ %8 _P!C /\
M;0#_ '< _P!_ /\ AP#_ (X _P"4 /\ F@#_ *  _P"F /\ K #_ +0 _P"]
M /\ R0#^ -T _0#M /P ^@#[ /\ ^@#_ /D _P#Z /\ ^@#_ /H _P#Z /\
M_Q 9 /\-%P#_!A8 _P 8 /\ '@#_ "H _P W /\ 10#_ %( _P!> /\ :0#_
M '( _P![ /\ @@#_ (D _P"0 /X E@#] )P _ "A /L J #Y *\ ^ "X /8
MPP#T -( \P#G /( ]@#P /\ [P#_ /  _P#O /\ [P#_ .X _P#N /\ _Q(4
M /\/$@#_"Q( _P 2 /\ &@#_ "4 _P S /\ 0 #_ $T _P!9 /\ 9 #] &T
M^P!V /D ?0#W (0 ]0"+ /0 D0#S )< \0"= /  HP#N *H [ "S .H O0#H
M ,L YP#A .4 \0#C /T XP#_ .( _P#A /\ X0#_ .  _P#@ /\ _Q00 /\1
M#@#_#0T _P</ /\"%0#_ "  _P M /\ .@#_ $< ^0!3 /4 7@#R &@ \ !P
M .T > #K '\ Z0"% .@ C #F )( Y0"8 ., GP#A *8 WP"N -P N #: ,4
MU@#9 -0 [ #2 /D T0#_ ,\ _P#. /\ S@#_ ,X _P#. /\ _Q<, /\4" #_
M#P4 _PX+ /\,$0#_!QH _P$F /P - #T $$ [0!- .D 6 #F &( XP!J .
M<@#> 'D VP"  -D A@#6 (T TP"3 -$ F@#/ *$ S0"J ,L LP#) +\ Q@#0
M ,4 Z ## /8 P0#_ , "_P"_ _\ OP/_ +\#_P"_ _\ _QL& /\7  #_%
M_Q,% /\1#0#_#A0 ^0H? / &+ #F SD X -& -P#40#6!%L T@1D ,\%; #,
M!7, R@5Z ,@%@0#&!8< Q0:. ,,&E@#!!IT OP:F +T&L "[![P N0C- +@*
MY0"U"_< LPW_ +$-_P"P#?\ L [_ *\._P"O#O\ _QX  /\;  #_&P  ^AH
M /46!0#V$0T ZPX5 .(+(@#8"S$ T P^ ,L-2@#'#54 Q Y> ,$.9@"_#FT
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M HLG_P**)_\"B2?_ HDG_P&))_\!^BD  .PP  #=-@  S3@  ,0W  "^,@
MNBL" +4E#@"N)QT J"DK *0J. "@*D, G2M, )HK50"8*UP EBMC )0K:@&2
M*W$!D"QX 8\L@0&-+(H!BRR4 HHLGP*(+*L"ABRZ H4MS@.#+NH#@2[\ X N
M_P)_+O\"?R[_ GXN_P)^+O\"]"X  .0W  #2/0  Q3\  +L_  "T/   KS4
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M!&8__P1F/_\$Y3T  ,]&  "_3   M$\  *I0  "B3P  F4H  )%$  "*00T
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MB 934)8'4E"E"%!0MPE04,X)3U#M"%!0_P=04/\&4%#_!5!0_P504/\%T$L
M +]4  "R6@  IUX  )U@  "48   B5T  'Q7  !R5   ;%,. &A4&0!E5"0
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M!T%>L0= 7L@'0%[H!T!=_ 9!7?\%05W_!4%<_P5!7/\%PU8  +1?  "H9@
MGFH  )5M  "*;0  ?VP  &]G  !D9   6V(% %9B$ !48AL 4F,E %!C+P!.
M9#@ 361  $MD2 !*9$\!2&17 49D7P)%9&@"0V1S T%C?P0_8XX%/6.>!CQC
ML 8[9,8&.V3F!CMC^@4[8O\%.V+_!3QA_P0\8?\$OEL  +!C  "E:@  FV\
M )%R  "&<@  >W$  &QM  !@:P  56D  $]H#0!-:1< 2VDA $EJ*P!(:C0
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M B9Z]P(F>/\")GC_ B=W_P(G=_\"KFP  *-V  "9?   CG\  (2"  !X@P
M;(0  %^$  !1A   1X0  #R$   SA D ,(01 "^$&@ MA"0 +(4M "N%-0 J
MA3X *85' "B&4  GAEH )H9F "2&<P CAH, (8:5 ""&IP$>AKP!'H;> !Z$
M]0$>@O\!'H+_ 1Z!_P$>@?\!J'0  )Y]  "3@@  B84  'Z(  !QB@  98L
M %B,  !,C0  0(X  #:.   LCP  )9 , ".0$P BD!P (9 E ""1+@ ?D38
M'I%  !V120 <D50 &I%@ !F1;@ 8D7X %I*0 !62I  4D;D $Y'8 !./]  4
MCO\ %(W_ !2,_P$4C/\!HWT  )B#  ".B   A(P  '>/  !ID0  79,  %"5
M  !%EP  .9@  "Z9   EF@  '9L" !:=#  5G1, %)T; !.=)  2G2T $9XW
M !&>00 0GDP #YY8  Z>9P -GG< #)Z*  N=G@ *G;( "9W,  F<[  *F_X
M"YK_  N9_P +F?\ G(0  )&*  "(C@  >Y(  &V6  !@F0  5)P  $B?   \
MH   ,*$  ":C   =I0  %:<  !"I!0 +JPT "*H3  >J&P &JB0 !:HN  2J
M.  "JD0  :I0  "J7@  JFX  *J!  "JE0  J:H  *G!  "HY   J/8  *?_
M  "G_P  I_\ E8L  (R0  !_E0  <9H  &.>  !6H@  2J8  #VH   QJ@
M)JL  !VM   4L   #K(   FU 0 "M@H  +8/  "V%0  MQT  +<E  "W+P
MN#D  +A&  "X5   N&0  +AV  "XBP  MZ   +>V  "WTP  MN\  +;\  "V
M_P  MO\ CY(  (*7  !TG0  9J(  %BG  !+K   /J\  #&Q   FLP  '+8
M !.X   -NP  !KX   #!    P@0  ,(+  ##$   Q!4  ,0<  #%)   QBX
M ,@Z  #)1P  R5<  ,EI  #)?0  R90  ,BJ  #(PP  R.0  ,CT  #(_0
MR/T A9D  '>?  !HI@  6JL  $VQ   _M0  ,;@  "6Z   :O0  $<    O#
M   #QP   ,H   #-    S@   ,\#  #0"0  T0X  -,2  #5&0  UR(  -HM
M  #=.0  WDD  -Y:  #?;@  WX4  -^<  #?L@  WLL  -[F  #?]   W_0
M>:$  &NH  !<KP  3K4  $"[   QO@  ),$  !G%   0R   "<P   #/
MTP   -D   #<    W0   -\   #A    X@4  .0+  #F$   Z!8  .H@  #M
M*P  \#H  /%+  #Q7@  \G,  /.+  #SH@  \[8  //)  #SX0  \^$ ;:H
M %ZQ  !0N0  0;\  #+$   DR   %\P   [0   &U0   -H   #>    X@
M .8   #I    Z@   .P   #N    \    /(   #T!@  ]@P  /D2  #\'
M_RD  /\Z  #_30  _V(  /]X  #_D   _Z,  /^S  #_P0  _\$ _P<9 /\!
M%P#_ !< _P : /\ (0#_ "L _P Y /\ 1P#_ %0 _P!? /\ :@#_ ', _P![
M /\ @P#_ (H _P"0 /\ E@#_ )L _P"A /\ J #_ *\ _P"X /\ Q #^ -4
M_ #J /L ^ #Z /\ ^0#_ /@ _P#X /\ ]@#_ /, _P#Q /\ _PL5 /\%$P#_
M !, _P 4 /\ &@#_ "< _P T /\ 0@#_ $\ _P!; /\ 90#_ &X _P!V /\
M?@#_ (4 _@"+ /T D0#[ )< ^@"= /@ HP#W *L ]@"S /0 O@#S ,P \0#C
M .\ \P#N /\ [0#_ .P _P#K /\ [ #_ .P _P#K /\ _PT1 /\)$ #_  \
M_P 0 /\ %@#_ "( _P O /\ /0#_ $H _P!5 /T 8 #Z &D ^ !Q /8 >0#T
M '\ \P"& /$ C #O )( [@"8 .P GP#K *8 Z0"N .< N #E ,4 XP#: .$
M[0#? /L W@#_ -T _P#= /\ W0#_ -T _P#= /\ _P\- /\,"P#_ PD _P ,
M /\ $@#_ !T _P I /L -P#X $0 ]0!0 /( 6@#N &, [ !K .D <P#G 'H
MY0"  ., A@#A (P WP"3 -T F0#; *$ V0"I -4 L@#2 +X T #. ,X Y@#,
M /8 R@#_ ,H _P#) /\ R #_ ,@ _P#( /\ _Q$( /\- @#_!P  _P4( /\
M#@#_ !8 ]P B .\ , #K #T Z !) .0 5 #@ %T W0!E -D ;0#5 ', T@!Z
M -  @ #. (< S "- ,H E #( )L Q@"D ,0 K0#" +@ P #' +T WP"\ /$
MNP#^ +D _P"X /\ N #_ +@ _P"X /\ _Q0  /\/  #_#0  _PP  /\'"0#X
M 1  Z  : ., * #= #8 V !" -( 30#. %< R@!? ,< 9@#% &T PP!T ,$
M>@"_ ($ O0"( +L CP"Y )< MP"? +4 J "S +, L0#" *\ V "N NT K /[
M *L%_P"J!O\ J0;_ *D&_P"I!O\ _Q8  /\2  #W$@  [!$  .8.  #E!@@
MW0,2 -0#( #-!"T R 0Z ,,%1@"_!5  O 98 +D&8 "W!V< M0=N +,'=0"Q
M"'L KPB" *X)B@"L"9( J@F; *@*I0"F"K  I0N_ *,,U "A#>T GP[^ )T.
M_P"<#_\ FP__ )L/_P";#_\ _QH  /<9  #J'@  WQX  -4:  #0$P( S@P+
M ,<+%@# #24 N@XR +8./P"R#TD KQ!2 *P06@"J$&$ J!%H *81;P"D$78
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M 7@H_P%X*/\![RL  -TS  #*.0  OCL  +0Z  "M-@  IB\  *$H!P";)Q,
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M) !\-R\ >3<Y '<X0@!T.$D <CA0 '$X5P!O.%X ;3AE 6PX;0%J.'4!:#B
M F<XC )E.)D#9#FH V(YN0-A.M #8#KN V Z_P-?.O\"7SK_ E\Z_P)?.O\"
MW3L  ,=#  "Y20  KDL  *1,  ";2@  DD4  (D_  "!.@D >SH4 '<[( !T
M/"L <CPU &\]/@!M/48 :SU- &D]4P!H/5H 9CUA 60]:0%C/7(!83U] F ]
MB0)>/98#73ZE UL^M@1:/LP$6C_L!%D__@-9/_\#63__ ED__P)9/O\"UC\
M ,-'  "U3   JE   *!0  "73P  CDL  (1%  !Z0 8 =3\1 '% ' !M0"@
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M!$M+L 1*2\4$24OF!$E+^@1)2_\#2DO_ TI+_P-*2_\#R$D  +A1  "L5P
MH5L  )A<  ".7   @UD  '93  !K3@  9$T* %],$P!<31X 6DTH %A-,0!6
M33H 5$U! %-.2 !23D\ 4$Y7 4].7P%-3F@!3$YS DI/?P))3XT#1T^=!$9/
MK@1%3\,$1%#D!$1/^01%3_\#14__ T5._P-%3O\#Q$P  +55  "I6P  GUX
M )5@  "+8   @%X  ')7  !G4P  7E$' %E1$0!741L 5%$E %)2+P!14C<
M3U(_ $Y21@!-4TT 3%-5 $I370%)4V8!1U-P D53?0)$4XL#0E.; T%4K 1
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M S1>]0,U7?\"-5W_ C5<_P(U7/\"N%D  *IA  "@9P  EFP  (QN  "!;@
M=FP  &=I  !<9@  460  $AB"0!$8A$ 0F(; $%C)  _8RT /F,U #UD/0 \
M9$4 .V1- #ED50 X9%\ -F1I 35D=@$S9(4!,665 C!EIP(O9;L"+F7: BYD
M] (N8_\"+V/_ B]B_P(O8O\"LUX  *=F  "<;0  DW$  (AS  !]<P  <G(
M &1P  !8;@  36P  $)J P \:0X .FH6 #EJ(  X:B@ -FLQ #5K.0 T:T$
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M !9[_P 7>_\ I'(  )IZ  "/?P  A8(  'N$  !MA@  8(<  %2'  !(B
M/(@  #*(   HB   ((@% !J)#@ 9B14 &(D= !>*)@ 6BBX %8HW !2*00 3
MBDP $HM8 !&+90 0BW4 #XN'  Z*FP -BJ\ #(K(  R)Z@ -A_P #H?_  Z&
M_P .AO\ GWL  )2!  "*A0  @(@  '.+  !EC0  68\  $R0  !!D@  -)(
M "J2   ADP  &90  !*6!@ .EPX #9<5  R7'0 ,ER8 "Y<O  J7.0 )ET0
M")=0  :77@ %EVX  Y:   &6E   E:@  )6^  "4X   E/0  )/_  &2_P !
MDO\ F((  (Z(  "%C   =X\  &J2  !=E0  4)@  $2:   XFP  +)P  "*=
M   9G@  $J    VB @ 'HPL  :,0  "C%P  HQ\  *,G  "C,0  I#P  *1(
M  "D5@  I&4  *-W  "CBP  HZ   **V  "AT@  H?   *#[  "@_P  H/\
MD8H  (F.  ![D@  ;9<  &";  !3G@  1J$  #FC   MI   (Z8  !FH   1
MJ@  #*P   6N    KP<  *\-  "O$0  L!@  + @  "Q*   L3(  +(^  "R
M3   LEL  +)L  "R@0  L9<  +&L  "PQ@  L.@  *_W  "O_P  K_\ C)
M '^5  !QF@  8Y\  %6D  !'J   .JH  "VL   BK@  &+   !"S   *M0
M K@   "[    NP   +P'  "\#0  O1$  +X6  "_'@  P"<  ,$R  #"0
MPT\  ,-@  ##=   PXL  ,.A  ##N   PM<  ,+O  #"^@  P?X @9<  '.=
M  !EHP  5Z@  $FM   [L0  +;,  "&V   6N0  #KL   >^    P0   ,4
M  #'    R    ,D   #*!0  RPL  ,T/  #.%   T!P  -,F  #6,@  V$$
M -A3  #99@  V7P  -F4  #9JP  V<,  -GA  #9\   V?0 =I\  &>F  !9
MK   2[(  #RW   NN@  (;T  !7    -Q   !<<   #*    S@   -(   #5
M    U@   -D   #;    W0   -\'  #A#   XQ$  .89  #I)   [#(  .U#
M  #N5@  [VL  .^$  #OG   [[(  ._&  #OW0  [^0 :J@  %NO  !,M@
M/KP  "_    @Q   %,@   S,   "T    -0   #9    W@   .(   #E
MY@   .@   #I    [    .X   #P @  \@D  /4/  #X%P  _",  /\S  #_
M1@  _UH  /]Q  #_B0  _Y\  /^Q  #_P   _\8 _P 5 /\ % #_ !0 _P 7
M /\ '0#_ "@ _P W /\ 1 #_ %$ _P!< /\ 9@#_ &\ _P!W /\ ?@#_ (4
M_P"+ /\ D0#_ )< _P"= /\ I #_ *L _P"T /X OP#] ,X ^P#F /D ]@#X
M /\ ]P#_ /< _P#W /\ \ #_ .P _P#I /\ _P,2 /\ $ #_ !  _P 1 /\
M%P#_ "0 _P R /\ /P#_ $P _P!7 /\ 80#_ &H _P!R /\ >0#] (  _ "&
M /H C #Y )( ^ "8 /8 GP#U *8 ] "N /( N0#P ,8 [@#> .T \ #K /X
MZ@#_ .D _P#I /\ YP#_ ., _P#@ /\ _P<. /\ #0#_  L _P , /\ $P#_
M !\ _P L /\ .@#_ $8 _@!2 /L 7 #X &4 ]0!L /, = #Q 'H [P"! .X
MAP#L (T Z@"3 .D F@#G *$ Y@"I ., LP#A +\ WP#0 -T Z0#: /D V0#_
M -< _P#5 /\ U0#_ -4 _P#4 /\ _PD* /\!!0#_  , _P ) /\ $ #_ !D
M^P F /< - #T $  \@!, .X 5@#J %\ YP!G .0 ;@#B '0 X ![ -X @0#<
M (< V@"- -8 E #4 )L T0"C ,\ K0#, +@ R@#' ,@ X #& /, Q0#_ ,,
M_P## /\ PP#_ ,, _P## /\ _PL! /\#  #_    _P # /\ "P#S !( [@ ?
M .H +0#F #H X@!% -X 3P#9 %@ U !@ -$ : #. &X S !T ,H >P#( ($
MQ@"' ,0 C@#" )8 P "> +X IP"[ +( N0#  +< U "U .P LP#[ +, _P"R
M /\ L@#_ +$ _P"Q /\ _PT  /\&  #_ P  ]P   /0  P#G  T X  8 -H
M)0#3 #( S@ ^ ,H 20#& %( PP!: ,  80"^ &@ O !N +H = "X 'L M@"!
M +0 B "R )  L "9 *X H@"L *T J@"Z *@ RP"F .8 I0#W *0 _P"C /\
MH@#_ *( _P"B /\ _Q   /L,  #O#@  Y@T  -\)  #:  8 T  1 ,D '0#$
M "H OP W +L 0@"W $L M !4 +( 6P"O &( K0!H *L ;@"I '4 J ![ *8
M@P"D (L H@"4 *  G@"> :@ G *U )L#Q@"9!>( F ;T )8(_P"5"?\ E G_
M )0)_P"4"?\ _!$  /$5  #C&0  UAD  ,P5  #'$   Q <* +T#% "W!"$
ML@8N *X(.@"J"40 IPE- *0*50"B"EP H IB )X+:0"<"V\ FPMV )D,?@"7
M#(8 E@R0 )0,F@"2#:8 D0VS (\-Q0"-#N( BQ#V (D0_P"($?\ AQ'_ (<1
M_P"'$?\ ]AD  .<@  #6)   R"4  +\B  "Y'   M!0! +$-#@"J#AD I0\G
M *$0,P"=$3X FA%' )@23P"5$E8 DQ)< )$28P"0$VD CA-P (P3> "+$X$
MB12+ (<4E@"&%:( A!6P (,6P0"!%]T ?QCT 'T9_P!\&?\ ?!G_ 'L9_P![
M&?\ [R$  -TI  #*+0  OB\  +4L  "N)P  J"   *,7" ">%A, F1<A )09
M+0"1&C@ CAI! (L;20")&U  AQM7 (4<7@"$'&0 @AQK ( <<P!_'7P ?1V&
M 'P>D0!Z'IX >!^K '<?O !V(-0 ="'P '(A_P!Q(O\ <2'_ '$A_P!Q(?\
MZ"@  -(P  #"-0  MS<  *TU  "E,0  GBL  )@C @"2'A  C2 ; (DA)P"&
M(C( @R,\ ($C1 !^(TL ?"12 'LD60!Y)%\ =R1F '8E;@!T)7< <R6! '$F
MC0!O)ID ;B:G &TGN !L)\X!:BCM 6DI_P%H*?\!:"G_ 6@H_P%H*/\!X2X
M ,LV  "\.P  L3T  *<]  "?.0  ES,  (\M  "()PP @R<6 '\H(@!\*2T
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M 54XKP)4.<,"4SGD E,Z^0%3.?\!4CG_ 5,Y_P%3.?\!S3P  +Q$  "O20
MI$P  )I,  "12P  AT8  'U   !S.P  ;#@- &@Y%P!E.2( 8SHK & Z- !>
M.CP 73I# %LZ2@!:.U  6#M8 %<[8 !6.V@ 53QS 5,\?P%2/(T!4#V< 4\]
MK )./L$"33[A DT^^ )-/O\!33[_ 4T]_P%-/?\!R4   +A(  "L30  H5
M )=1  ".3P  A$L  'E%  !N0   9CT+ &(]% !?/1X 7#XH %H^,0!8/C@
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M CY*\P(^2O\"/DG_ 3])_P$_2?\!O4H  *]2  "C6   F5L  )!=  "&7
M>UD  &U3  !B3P  5TP! %%*#0!.2A4 3$L? $I+* !)2S  1TLX $9,/P!%
M3$8 1$Q. $--5@!"35\ 0$UJ #]-=@$]3H0!/$Z4 3M.I0$Y3[D".4_4 CE/
M\@$Y3O\!.4[_ 3E-_P$Z3?\!NDX  *Q6  "A6P  EU\  (UA  "#80  >%X
M &E8  !?5@  5%(  $Q/"P!)3Q( 1U < $50)0!#4"T 0E U $%1/ ! 440
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M 2A=_P$H7/\!K5P  *)D  "8:@  CFX  (-O  !Y;P  ;FX  &!K  !4:0
M26<  #]E   U8PD ,F,1 #!C&0 O9"$ +F0I "UD,0 L9#D *V5" "IE2@ H
M950 )V5? "9F:P D9GH (V:+ ")FG0 @9K$ 'V;) !]FZP @9?X (&3_ "!C
M_P$A8_\!J6(  )YJ  "5<   BG,  (!U  !U=0  :70  %QR  !/<0  1&\
M #IN   P;0, *6P- "=L%  F;!P )6TD "1M+  C;30 (FT] "%N1@ @;E
M'FY; !UN9P <;G8 &FZ' !EOF@ 8;ZX %F_& !9NZ0 7;?P &&S_ !AK_P 8
M:_\ I&D  )IQ  "0=@  AGD  'Q[  !Q>P  9'L  %=Z  !*>0  /W@  #5X
M   K=P  (G8' !UV#P <=Q8 &W<> !IW)@ 9=RX &'<W !=X0  5>$H %'A6
M !-X8P 2>'( $7B# !!XEP />*L #GC#  YWY@ .=OH #W7_ !!U_P 0=/\
MGW$  )5X  "+?   @G\  '>!  !J@@  78(  %""  !$@@  .((  "Z"   D
M@@  '((  !2""0 1@Q  $(,6 !"#'@ .@R< #H,P  V#.0 -@T0 #(-0  N#
M70 )@VP "(-^  :#D0 %@J4  X*[  2!VP $@?( !8#_  9__P &?_\ FGD
M )!^  "&@P  ?84  &^'  !BB0  58H  $F+   ]C   ,8P  ":,   =C0
M%8X   ^/ P *D P !I 1  2/&  #CR   8\I  "/,@  D#T  )!)  "/5@
MCV4  (]V  "/B@  CI\  (ZT  "-SP  C.X  (S[  "+_P  B_\ E(   (N%
M  ""B0  =(P  &:/  !9D0  3),  $"5   TE@  *)8  !Z7   5F   #YH
M  J;   "G D  )P.  "<$P  G!H  )PB  "=*P  G34  )U   "=3@  G5P
M )UN  "<@0  G)<  )RL  ";Q@  FN@  )GY  "9_P  F/\ CH@  (:,  !X
MD   :I0  %R7  !/F@  0IT  #:>   IGP  'Z$  !6B   .I   "*8   "H
M    J00  *D*  "I#@  J1,  *H:  "J(@  JRL  *PV  "L1   K%,  *QC
M  "L=P  JXX  *ND  "KO   JMX  *GT  "I_0  J?\ B8X  'N3  !MEP
M7YP  %&@  !$I   -J8  "JH   >J0  %*L   VN   &L    +(   "U
MM0   +4#  "V"0  MPX  +@2  "X&0  NB$  +LK  "\.   O4<  +U8  "]
M:P  O8$  +V9  "]L   O<P  +SJ  "\]P  N_X ?I4  '";  !BH   4Z4
M $:J   XK0  *J\  !ZQ   3M   #+<   .Y    O    +\   #"    P@
M ,,   #$    Q@8  ,<,  #($   RA8  ,P@  #/*P  T#H  -%+  #17@
MTG,  -*+  #2I   T[L  -/8  #3[0  T_8 <YT  &2C  !6J0  1Z\  #FS
M   JM@  ';D  !*\   *OP   ,,   #&    R0   ,T   #/    T    -(
M  #4    U@   -D"  #;"   W@X  .$3  #D'0  Z"H  .@\  #I3P  Z60
M .I\  #KE0  ZZP  .O"  #LU0  [.4 9J8  %BL  !)LP  .[D  "N\   =
MP   $<0   G(    S    ,\   #3    V0   -T   #@    X0   .,   #E
M    YP   .H   #L    [@0  /$+  #U$@  ^!P  /LK  #]/@  _E,  /YJ
M  #_@P  _YL  /^N  #_O@  _\H _P 2 /\ $ #_ !$ _P 3 /\ &0#_ "8
M_P T /\ 00#_ $T _P!8 /\ 8@#_ &L _P!S /\ >@#_ ($ _P"' /\ C0#_
M ), _P"9 /\ H #_ *< _@"O /P N@#Z ,D ^0#A /@ \P#W /\ ]@#_ /4
M_P#Q /\ Z0#_ .0 _P#A /\ _P / /\ #0#_  T _P . /\ % #_ "$ _P N
M /\ / #_ $@ _P!3 /\ 70#_ &8 _@!M /P =0#[ 'L ^0"" /@ B #W (X
M]@"4 /0 FP#S *( \0"J .\ M #M ,$ ZP#5 .H [ #H /P YP#_ .4 _P#F
M /\ X #_ -D _P#4 /\ _P + /\ " #_  8 _P ) /\ $ #_ !P _P I /\
M-@#_ $( ^P!. /< 5P#T &  \@!H .\ ;P#M '8 [ !\ .H @@#H (@ YP".
M .4 E0#C )P X0"D -\ K@#= +D V@#* -< Y #4 /8 T0#_ -  _P#0 /\
MSP#_ ,L _P#' /\ _P # /\   #_    _P $ /\ #0#Z !8 ]@ C /, , #P
M #P [0!' .D 40#E %H X@!B -\ :0#= &\ V@!V -@ ? #4 (( T@"( -
MCP#- )8 RP"> ,D J #' +, Q0#! ,( V #  .\ OP#^ +X _P"] /\ O #_
M +P _P"\ /\ _P(  /\   #_    _P   /0 !P#M !$ Z  < ., *0#? #4
MVP!! -8 2P#1 %0 S0!< ,H 8P#( &D Q@!O ,, =0#! 'L OP"" +X B "\
M )  N@"8 +@ H@"U *P LP"Y +$ RP"O .< K@#X *P _P"K /\ K #_ *P
M_P"K /\ _P0  /\   #V    [@   .<   #?  P U@ 5 ,\ (@#* "X QP Z
M ,, 1 #  $T O !5 +D 7 "W &, M0!I +, ;P"Q '4 KP![ *T @@"K (H
MJ0"2 *< G "E *8 HP"S *$ PP"? -X G@#R )T _P"< /\ G #_ )L _P";
M /\ _P<  /8)  #I"P  WPH  -4$  #.  4 Q@ 0 ,  &@"[ "< MP R +,
M/0"P $8 K0!/ *H 5@"H %P I@!C *0 : "B &\ H0!U )\ ? "= (0 FP"-
M )D EP"7 *( E0"N ), O0"1 -, D #M (\ _ ". /\ C0'_ (T!_P"- ?\
M^0X  .H2  #<%0  S14  ,01  "^#   N@(* +0 $@"N !X J@ J *8 -0"B
M #\ H !( )T!4 "; E8 F0)< )<#8P"5 VD DP-O )$$=@"0!'\ C@6( (P%
MD@"*!IX B :J (8'N@"%",\ A KK ((+_ "!#/\ @ S_ ( ,_P" #/\ \14
M . =  #-(   P2$  +@=  "Q%P  K!   *@)#0"B!Q8 G0DC )D*+@"5"S@
MDPQ! ) ,20".#5  C U7 (H-70"(#6, APUJ (4.<0"##GH @@Z$ ( .CP!^
M#YL ? ^H 'L0N !Z$,X >!'L '82_P!U$O\ =!/_ '03_P!T$_\ Z!X  -,F
M  ##*@  N"H  *XH  "G(P  H!P  )L3 P"6#Q  D! ; (P1)P")$C( AA,[
M (030P""%$L @!11 'X45P!\%%X >Q5E 'D5; !W%70 =A9^ '06B@!R%Y8
M<1>D &\8M !N&,D ;1GH &L:_ !J&_\ :AO_ &H;_P!J&_\ X"8  ,HM  "\
M,0  L#,  *<Q  "?+   ER8  ) ?  "*%PP A1@6 ($9(@!^&BP >QLV 'D;
M/@!W'$4 =1Q, ',<4P!Q'5D <!U@ &X=9P!M'G  :QYZ &H>A0!H'Y( 9Q^@
M &4@L !D(<4 8R'D &(B^@!A(O\ 82+_ &$B_P!A(O\ URP  ,,T  "V.
MJCD  *$X  "8-0  D"\  (@H  " (0@ >R 2 '<A'0!T(B< <2(Q &\C.0!M
M(T$ :R-( &DC3@!H)%4 9B1; &4D8P!C)6L 8B5U &$E@0!?)HX 7B:= %TG
MK0!;*,$ 6RC@ %HI]P!9*?\ 62G_ %DI_P!9*/\ SS(  +XY  "Q/0  IC\
M )P_  "3/   BC8  ($P  !Y*@, <B8/ &XG&0!K*", :2@L &8I-0!E*3P
M8RE# &$J2@!@*E$ 7BI7 %TJ7P!<*V@ 6BMR %DL?0!8+(L 5BV: %4MJ@!4
M+KT 4R[< %(O]0!2+_\ 4B[_ %(N_P!2+O\ RC8  +H]  "M0@  HD0  )A$
M  "/00  A3P  'LW  !R,0  :RP, &<M%0!D+1\ 82XH %\N,0!=+CD 7"]
M %HO1@!8+TT 5R]4 %8P7 !5,&0 4S%N %(Q>@!1,8@ 4#*7 $XRJ !-,[L
M3338 $PT\P!,-/\ 3#3_ $PS_P!,,_\ QCH  +9"  "I1@  GDD  )5)  "+
M1P  @4(  '<]  !M-P  9#() & R$@!=,AP 6C(E %@S+0!6,S4 53,\ %,T
M0P!2-$H 4311 % T60!/-6$ 335L $PV=P!+-H4 2C>5 $@WI@!'.+@!1SC3
M 48X\0%&./\!1CC_ $8X_P!&-_\ P3X  +)%  "F2@  G$T  ))-  "(2P
M?D<  '-"  !I/0  7S<& %HV$ !7-Q@ 5#<B %(W*@!0-S( 3S@Y $TX0 !,
M.$< 2SA. $HY5@!).5\ 2#II $<Z=0!%.X, 1#N3 $,\I %"/+8!03W0 4$]
M\ %!/?\!03S_ 4$\_P%!//\ OD(  *])  "C3@  F5   (]1  "%4   >TP
M &]&  !E0@  6CT" %0[#@!1.Q4 3SL? $T[)P!+.R\ 23PV $<\/0!'/$0
M1CU+ $4]5 !$/EP 0SYG $(_<P! /X$ /S^1 #Y H@ ]0+4!/$'. 3Q![@$\
M0?\!/$#_ 3Q _P$]/_\!ND4  *Q,  "A40  EU0  (U5  "#5   >%$  &Q+
M  !A1P  5D(  $] # !,/Q, 24 < $= ) !&0"P 1$ S $- .@!"04( 04%)
M $!"40 _0EH /D-E #U#<0 [0W\ .D2/ #E$H  X1;,!-T7+ 3=%[ $W1?\!
M-T3_ 3A$_P$X0_\ MTD  *E0  ">50  E%@  (M9  " 6   =E8  &A0  !=
M3   4T@  $I%"0!&1!$ 1$09 $)$(@!!12D /T4Q #Y%.  ]13\ /$9' #M&
M3P Z1U@ .4=B #A(;@ V2'P -4B- #1)G@ S2;$ ,DG) #%)ZP R2?X ,DC_
M #)(_P S2/\ M$P  *=4  "<60  DEP  (A=  !^70  <UH  &55  !;4@
M4$X  $9*!0! 20X /DD6 #U)'@ [2B8 .DHN #E*-0 X2ST -TM$ #9+30 T
M3%8 ,TQ@ #),;  Q37H ,$V+ "Y-G  M3J\ +$[' "Q.Z0 L3?T +4W_ "U,
M_P M3/\ L%   *18  "970  CV$  (9B  ![80  <%\  &);  !86   3E4
M $-1 0 [3PP .$\3 #9/&P U3R, -% K #-0,@ R4#H ,5!" #!12@ N45,
M+5)= "Q2:0 K4G@ *5*( "A3F@ G4ZT )E/% "93YP F4_P )U+_ "=1_P G
M4?\ K%4  *!<  "68@  C68  (-G  !X9@  ;64  &!A  !57@  2EL  #]8
M   U5@@ ,540 #!6%P N5A\ +58G "Q6+P K5S8 *E<^ "E71P H5U  )EA:
M "589P D6'4 (UF& "%9F  @6:L 'UG" !]9Y0 ?6/H (%C_ "!7_P A5_\
MJ%H  )UB  "39P  BFL  ']L  !U;   :FL  %UH  !190  1F,  #M@   Q
M7@, *ET- "A=$P F71L )5XC "1>*@ C7C( (EXZ "%>0P @7TP 'U]7 !Y?
M8P <8'$ &V"" !E@E0 88*D %V#  !9@X@ 77_D &%[_ !E>_P 97?\ I&
M )EH  "0;@  AG   'QR  !R<@  9G$  %AN  !,;   06L  #9I   M9P
M(V8( !]F#P =9A4 '&8= !MF)0 :9BT &6<U !AG/@ 79T@ %F=3 !5H7P 3
M:&X $FA_ !%HD@ 0:*8 #VB]  YHX  09_< $&;_ !%E_P 19?\ GV<  )9O
M  ",<P  @G8  'AX  !M>   8'<  %-V  !&=   .W,  #%R   G<0  'G$
M !9P"@ 3<!  $W 7 !)P'P 1<2< $'$O !!Q.  .<4( #G%.  UQ6P ,<6D
M"W%Z  IQC0 (<:$ !G&V  9PT@ '<.\ "&__  EN_P );O\ FV\  )%U  "'
M>0  ?GP  '1^  !F?@  67X  $U^  ! ?0  -7T  "I\   A?   &'P  !%\
M!  ,? P "GP1  E\&0 (?"$ !WPI  9\,@ $?#T  WQ(  %\50  ?&,  'QT
M  !\AP  >YP  'NQ  !ZRP  >>L  'GZ  !Y_P  >/\ EG<  (Q\  "#@
M>8,  &R$  !>A0  488  $6'   YAP  +8<  ".'   :AP  $H<   V( 0 &
MB0H  8D/  ")%   B!L  (@C  ")+   B38  (E"  "(3@  B%T  (AM  "(
M@0  AY4  (>K  "&Q   A>8  (3X  "$_P  A/\ D'X  (>#  !^AP  <8D
M &.+  !6C0  28\  #R1   PD0  ))$  !J2   2DP  #90   :5    E@8
M )8,  "5$   EA4  )8=  "6)   EBX  )8Y  "61@  EE4  )9E  "6>
ME8X  )6D  "4O   D]\  )/U  "2_P  DO\ BX8  (.*  !UC0  9Y   %F4
M  !,EP  /YD  #*:   FFP  &YP  !*=   ,GP  !*    "B    HP$  *,'
M  "C#   HQ   *05  "D'   I24  *8O  "F/   IDL  *9;  "F;@  I80
M *6;  "DLP  H]   */O  "B_   HO\ AHT  'B1  !JE0  7)D  $Z=  !!
MH   ,Z(  ":C   ;I0  $:<   JI   !JP   *T   "O    L    +    "P
M!0  L0L  +(/  "S%   M!L  +4D  "W,   MS\  +=0  "W8@  MW@  +>0
M  "VJ0  ML(  +;D  "V]0  M?X >Y,  &V8  !?G0  4*(  $*F   TJ0
M)JL  !JM   0KP  ";(   "T    MP   +H   "\    O0   +X   "^
MP (  ,$(  #"#0  Q!(  ,89  #))   RC(  ,M#  #+50  S&H  ,R#  #,
MG   R[4  ,S.  #,Z0  S/8 <)L  &&A  !2I@  1*L  #:P   GL@  &K4
M !"X   'NP   +X   #!    Q    ,@   #+    RP   ,T   #.    T
M -(   #5 P  V H  -L0  #>&   XB0  .,U  #D2   Y5P  .9S  #FC0
MYJ4  .:\  #FTP  Y^< 8Z0  %6J  !&L   .+4  "BY   :O   #\    7$
M    QP   ,L   #/    U    -@   #<    W0   -\   #A    XP   .4
M  #H    Z@   .T&  #Q#@  ]18  /@E  #Y.   ^4T  /IC  #[?   _)4
M /RJ  #\NP  _<L _P / /\ #@#_  X _P 0 /\ %@#_ ", _P P /\ /0#_
M $D _P!4 /\ 7@#_ &8 _P!N /\ =@#_ 'P _P"" /\ B0#_ (\ _P"5 /X
MFP#] *, ^P"K /H M0#Y ,, ]P#; /8 \ #T /\ \P#_ /( _P#L /\ X@#_
M -P _P#6 /\ _P , /\ "0#_  @ _P * /\ $@#_ !X _P K /\ . #_ $0
M_P!/ /\ 60#^ &$ _ !I /H < #X '< ]P!] /8 @P#T (D \@"/ /$ E@#O
M )T [0"E .P KP#J +P Z #- .8 Z #D /H XP#_ .( _P#@ /\ U0#_ ,X
M_P#+ /\ _P & /\  0#_    _P $ /\ #@#_ !D _P E /T ,@#[ #X ]P!)
M /, 4P#P %P [@!C .P :@#J '$ Z !W .8 ?0#D (, X@") .  D #> )<
MW "? -D J0#6 +0 TP#$ -  W@#. /, S #_ ,L _P#* /\ R #_ ,( _P"^
M /\ _P   /\   #_    _P   /L "P#V !, \0 @ .T + #J #@ YP!# .,
M30#@ %8 W != -D 9 #5 &L T@!Q -  =@#. 'P S "# ,H B0#( )$ Q@"9
M ,0 HP#! *T OP"[ +T SP"[ .L N0#\ +< _P"W /\ M@#_ +0 _P"Q /\
M_P   /\   #_    ]@   .X !0#G  \ X0 9 -L )0#5 #$ T@ \ ,X 1@#*
M $\ QP!7 ,0 7@#! &0 OP!J +T < "[ '8 N0!\ +@ @P"V (H LP"3 +$
MG "O *< K0"S *L Q0"I .$ IP#U *8 _P"E /\ I #_ *0 _P"D /\ _P
M /P   #Q    Z    .    #4  L S  3 ,< 'P#" "H OP U +P /P"X $@
MM0!0 +, 5P"P %X K@!D *P :0"K &\ J0!U *< ? "E (0 HP", *$ E@"?
M *$ G0"M )H O "8 -( EP#N )4 _@"4 /\ E0#_ )4 _P"5 /\ _ $  / %
M  #C!P  U04  ,P   #%  0 O@ . +@ %P"S ", KP N *L . "I $$ I@!*
M *, 40"A %< GP!= )T 8P"; &D F@!O )@ =@"6 'T E "& )( D "0 )L
MC@"G (P M@"* ,D B #G (< ^0"' /\ A@#_ (8 _P"& /\ ] P  .00  #1
M$@  Q1$  +T.  "V"   L0 ( *L $0"F !L H0 F )X ,0": #H F !# )4
M2@"3 %$ D0!7 (\ 70". &, C !I (H < "( '< A@"  (0 BP"" )8 @ "C
M 'X L0!] ,0 >P+A 'H#]0!Z!?\ >07_ '@&_P!X!O\ ZA,  -8:  #&'0
MNAP  +$9  "J$P  I T  )\%# "9 !0 E0 ? )$"*0"- S, BP0\ (@%1 "&
M!DL A 91 (('5P"!!UT ?P=C 'T(:@!["'( >@A\ '@)A@!V"9( = J@ ',*
MKP!Q"\$ < S? &\-]@!N#O\ ;0[_ &T._P!M#O\ X1P  ,LC  "\)@  L28
M *@D  "@'@  F1@  ),0 @"."PX B L7 (0,(@"!#2P ?@TU 'P./0!Z#D4
M> Y+ '<.40!U#U@ <P]> '$090!P$&X ;A!W &P0@@!K$(\ :1&= &@1K0!F
M$L  91+? &03]@!C%/\ 8Q3_ &(4_P!B%/\ UB0  ,,J  "U+@  JB\  * M
M  "8*   D"(  (D;  ""$P@ ?1$2 'D2' !V$R< <Q0P '$4. !O%3\ ;15&
M &P53 !J%E, :!99 &<680!E%FD 9!=R &(7?@!A&(L 7QB9 %X9J0!<&;P
M7!K8 %H;\P!:'/\ 61S_ %D<_P!9'/\ S2H  +TQ  "O-0  I#8  )LT  "2
M,0  B2L  ($E  !Y'0, <Q@. &\9& !L&B( :1LK &<;,P!E'#L 9!Q! &(=
M2 !@'4X 7QU5 %T=7 !<'F0 6QYN %D?>0!8'X< 5B"6 %4@I@!4(;@ 4R'2
M %(B\0!2(_\ 4B/_ %(B_P!2(O\ R"\  +@V  "K.@  H#P  )8[  "-.
M@S(  'HM  !R)@  :B , &8@$P!C(1T 82$F %\B+P!=(C8 6R(] %HC1 !8
M(TH 5R-1 %4C6 !4)&$ 4R1J %$E=@!0)8, 3R:3 $XGHP!,)[4 3"C. $LH
M[@!+*?\ 2RC_ $LH_P!+*/\ PS0  +,[  "G/P  G$$  ))   ")/@  ?SD
M '4S  !L+0  8R<( %XF$0!<)AD 62<B %<G*P!5*#( 5"@Y %(H0 !1*$8
M4"E- $XI50!-*5T 3"IG $LJ<P!)*X  2"N0 $<LH0!&+;, 12W+ $4N[ !$
M+O\ 1"[_ $4M_P!%+?\ OC@  + _  "D0P  F44  (]%  "%0P  >SX  '$Y
M  !G-   7BX$ %@K#@!5*Q8 4BP? % L)P!/+"\ 32TV $PM/ !*+4, 22U*
M $@N4@!'+EH 1B]D $4O< !#,'X 0C"- $$QG@! ,K$ /S+( #\SZ@ _,_X
M/S+_ #\R_P _,O\ NSP  *U#  "A1P  EDD  (Q)  "#2   >$0  &T^  !C
M.0  6C0  %(P# !/,!, 3# < $HP) !),2L 1S$R $8Q.0!$,4  0S)' $(R
M3P!!,U@ 0#-B #\T;0 ^-'L /36+ #PVG  [-J\ .C?& #DWZ  Y-_P .C?_
M #HV_P Z-O\ MT   *I&  ">2P  E$T  (I.  " 3   =4@  &I#  !@/@
M5CD  $TU"0!)-!$ 1S49 $4U(0!#-2@ 034O $ U-@ _-CT /C9% #TW30 \
M-U4 .SA@ #HX:P Y.7D .#F) #<ZFP U.JT -3O$ #0[Y@ T._L -3O_ #4Z
M_P U.O\ M$,  *=*  "<3@  DE$  (A2  !^4   <TT  &=(  !<1   4C\
M $@Z!@!$.0\ 03D6 #\Y'@ ^.28 /#DM #LZ-  Z.CL .3M" #@[2@ W/%,
M-CQ= #4]:0 T/7< ,SZ' #$^F0 P/ZL +S_" "\_Y  O/_H ,#__ # ^_P P
M/O\ L4<  *1-  "94@  CU4  (96  !\50  <5(  &1,  !920  3T4  $5
M P _/@T /#X3 #H^&P Y/B, -SXJ #8_,0 U/S@ -#]  #- 2  R0%$ ,4%;
M #!!9P N0G4 +4*% "Q#EP K0ZH *D/  "E$X@ J0_D *D/_ "M"_P K0O\
MKDH  *%1  "75@  C5D  (-:  !Y6@  ;E<  &%2  !73@  34L  $-'   Z
M0PH -D,1 #1#&  S0R  ,D0G #%$+P P1#8 +T4] "U%1@ L14\ *T99 "I&
M9  I1W( *$># "9'E0 E2*@ )$B^ "-(X  D2/< )4?_ "5'_P F1_\ JD\
M )]5  "46@  BUX  (%?  !W7@  :UP  %]8  !550  2U$  $!-   U2@<
M,$D. "Y)%0 M21T +$DD "M**P J2C, *$H[ "=+0P F2TP )4M6 "1,8@ C
M3'  (4R  "!-DP ?3:8 'DV[ !U.W0 >3?8 'DS_ !],_P @2_\ IU,  )Q:
M  "27P  B&,  'YD  !T8P  :6$  %Q>  !26P  1U@  #Q5   R4@( *E ,
M "=/$@ F4!D )5 @ "10*  C4"\ (E$W "%10  @44D 'E)3 !U27P <4FT
M&E-] !E3D  84Z0 %E.Y !53V0 64_0 %U+_ !A1_P 94?\ HUD  )A@  "/
M90  A6@  'MI  !Q:0  9F<  %ED  !-80  0E\  #A<   N6@  )5@( "!7
M#@ >5Q0 '5<< !Q8(P ;6"L &E@S !E8/  86$4 %EE0 !596P 466D $UIZ
M !):C0 16J$ $%JW  Y:U0 06?, $%G_ !%8_P 16/\ GU\  )5F  ",:P
M@FT  'AN  !N;P  8FT  %5J  !(:   /F8  #-E   I8P  (&$! !A@"P 5
M8!  %& 7 !-@'@ 28"8 $F N !%A-P 084  #V%+  YA6  -868 #&)V  MB
MB0 *89T "6&R  AARP (8>L "6#]  I?_P +7_\ FV8  ))M  "(<0  ?G,
M '5U  !J=   7',  $]R  !#<   .&\  "UN   D;   &VL  !-K!  .:@P
M#6H2  QJ&0 +:B$ "FHI  EJ,@ (:CP !VM'  5K4P $:V$  FMQ  !JA
M:I@  &JM  !IQ@  :><  &GX  !H_P  :/\ EVT  (US  "$=P  >WH  '![
M  !C>P  5GH  $EZ   ]>0  ,7@  "=W   ==@  %78   ]V @ )=@H !'8/
M  !V%0  =AP  '8D  !U+   =38  '5!  !U3@  =5P  '5L  !U?@  =),
M '2H  !SP   <^,  '+W  !R_P  <?\ DG4  (EZ  " ?@  =H   &F!  !;
M@@  3H(  $&"   U@P  *8(  !^!   6@0  $((   J"   "@P<  ((-  ""
M$0  @A<  ((>  "")@  @B\  (([  ""1P  @E4  (%E  "!>   @8T  ("B
M  !_N@  ?]T  '[T  !]_P  ??\ C7P  (2!  ![A   ;H8  &"(  !2B@
M18L  #F,   LC   (8P  !>,   0C0  "8X   */    D ,  (\)  "/#@
MCQ(  ) 8  "0'P  D"@  ) R  "0/P  D$T  )!=  "/<   CX4  (Z<  ".
MLP  C=   (SP  "+_@  B_\ B(0  ("(  !RBP  9(T  %:0  !(DP  .Y4
M "Z6   BE@  %Y<   ^8   (F0   )L   "=    G0   )T#  "="0  G0T
M )X1  ">%P  GQ\  )\I  "@-0  H$,  *!4  "@9@  GWL  )Z3  ">JP
MG<8  )WI  "<^0  G/\ @XL  '6.  !GD@  698  $N9   ]G   ,)X  ".?
M   7H   #J(   >D    I@   *@   "J    J@   *H   "K 0  JP<  *P,
M  "M$   KA8  *\>  "Q*0  L3@  +%(  "Q6@  L6\  +&(  "QH   L+H
M *_=  "O\@  K_T >)$  &J6  !<F@  39\  #^C   QI@  (Z<  !>I   .
MJP  !:X   "P    L@   +4   "W    MP   +@   "Y    N@   +P#  "]
M"0  O@X  , 4  ##'@  Q2L  ,4\  #&3@  QF(  ,9Z  #&E   QJT  ,;(
M  #%Y0  Q?, ;)D  %Z>  !/I   0:@  #*L   DKP  %K$   VT   #MP
M +H   "]    P    ,0   #&    Q@   ,@   #)    RP   ,P   #.
MT 8  -,-  #8$P  W!X  -XM  #?0   X%0  .%K  #AA0  X9\  .&W  #A
MSP  X>8 8*$  %*G  !#K0  -+(  "6U   7N0  #;P   &_    PP   ,<
M  #*    SP   -,   #6    UP   -H   #<    WP   .$   #C    Y@
M .D!  #L"P  \!(  /,?  #T,0  ]D8  /=<  #X=   ^(\  /FF  #YN
M^,D _P - /\ "P#_  L _P . /\ $P#_ !\ _P L /\ .0#_ $4 _P!0 /\
M60#_ &( _P!J /\ <0#_ '< _P!^ /\ A #^ (H _0"0 /P EP#Z )X ^0"G
M /< L0#V +X ]0#2 /, [ #Q /X \ #_ /  _P#F /\ W #_ -( _P#- /\
M_P ' /\ ! #_  ( _P & /\ $ #_ !L _P G /\ ,P#_ #\ _P!* /X 5 #[
M %T ^0!D /< :P#U '( \P!X /( ?@#P (0 [P"* .T D0#L )D Z@"A .@
MJP#F +8 Y #' .( XP#@ /< W@#_ -T _P#9 /\ S #_ ,4 _P#! /\ _P
M /\   #_    _P ! /\ #0#_ !8 _  B /D +@#V #D \P!% .\ 3@#L %<
MZ0!> .8 90#D &P X@!R .  =P#? 'X W0"$ -L BP#8 )( U0"; -( I #/
M *\ S0"^ ,L U0#) .\ QP#_ ,4 _P#$ /\ O@#_ +@ _P"U /\ _P   /\
M  #_    _@   /< "0#Q !$ ZP < .< * #D #, X0 ^ -T 2 #8 %$ TP!8
M -  7P#. &4 S !K ,H <0#( '< Q@!] ,0 A #" (P P "4 +X G@"[ *@
MN0"V +< R "U .8 LP#Z +$ _P"P /\ L #_ *P _P"I /\ _P   /\   #Z
M    \0   .@  P#@  T V  6 -$ (@#- "T R@ W ,8 00#" $H OP!2 +T
M60"Z %\ N !E +< :@"U '  LP!V +$ ?0"O (4 K0"- *L EP"I *$ IP"N
M *4 O@"B -@ H #R )\ _P"> /\ G@#_ )X _P"< /\ _P   /<   #K
MX0   -8   #+  D Q0 1 +\ &P"[ "8 MP Q +0 .@"Q $, K@!+ *L 4@"I
M %@ IP!> *8 9 "D &D H@!P *  =@"> 'X G "& )H D "8 )L E@"G )0
MM@"2 ,H D #I (\ _ ". /\ C0#_ (P _P"- /\ ^    .D"  #; P  S $
M ,0   "]  ( M@ - +  %0"K "  IP J *0 - "A #P G@!$ )P 2P": %(
MF !8 )8 70"5 &, DP!I )$ < "/ '< C0"  (L B@") )4 AP"A (4 KP"#
M ,$ @0#@ (  ]0!_ /\ ?P#_ '\ _P!_ /\ [@H  -P.  #*$   O@X  +4+
M  "O P  J0 ' *, $ "> !@ F0 C )8 + "3 #4 D  ^ (X 10", $L B@!1
M (@ 5P"& %T A0!C (, :@"! '$ ?P!Z 'T A ![ (\ >0"< '< J@!U +L
M= #4 '( \ !R /\ <@#_ '$ _P!Q /\ XQ$  ,T7  "_&0  LQD  *H5  "C
M$   G0H  )<!"@"1 !( C0 ; (D )0"% "\ @P W (  /@!^ $4 ?0!+ 'L
M40!Y %< > != '8 9 !T 6L <@%T ' "?P!N HL ; .8 &L#I@!I!+< : 7.
M &<'[ !F"/T 9@G_ &4)_P!E"?\ UAH  ,0@  "V(P  JR,  *$@  "9&P
MDA0  (P. 0"&!PT @ 04 'P&'@!Y!R@ =@@P '0(. !R"3\ < E% &\*3 !M
M"E( ; I8 &H+7P!H"V< 9PMP &4,>@!C#(< 8@R5 & -I !?#;8 7@W. %P.
M[0!<#_\ 6Q#_ %L0_P!;$/\ S2$  +PH  "O*P  I"L  )HI  "2)   B1\
M ((8  ![$04 =0T/ '$-%P!N#B$ :PXJ &D/,@!G$#D 91!  &001@!C$$T
M81!3 %\16@!>$6( 7!%K %L1=@!9$H, 6!*2 %83H@!5$[0 5!/+ %,4[ !2
M%?\ 4A;_ %(5_P!2%?\ QB@  +8N  "I,@  GS(  )4Q  ",+0  @R<  'HA
M  !R&@  :Q,+ &<3$P!D%!P 810E %\5+0!=%30 7!4[ %L60@!9%D@ 6!9/
M %875@!5%UX 4Q=G %(8<@!0&'\ 3QF. $X:GP!,&K  2QO' $L;Z0!*'/T
M2AS_ $H<_P!*'/\ P2T  +$T  "E-P  FC@  ) W  "'-   ?2\  '0I  !L
M(P  9!P' %X9$ !;&A@ 61LA %<;*0!5&S  5!PW %(</0!1'$0 3QU+ $X=
M4@!-'5H 2QYC $H>;@!)'WP 1Q^+ $8@G !%(:X 1"'$ $,BY@!#(OP 0R+_
M $,B_P!#(O\ O#(  *TX  "A/   ESX  (T]  "#.@  >34  &\P  !F*@
M7B0" %<@#0!4(!0 42 = $\A)0!.(2P 3"$S $LB.@!)(D  2")' $<B3@!&
M(U< 1"-@ $,D:P!")'D 026( #\FF0 ^)JL /2?! #TGXP ]*/H /2C_ #TG
M_P ])_\ N#8  *H]  ">0   E$(  (I"  " /P  =CL  &PV  !B,   62H
M %$E"P!-)1$ 2R49 $DE(0!')B@ 128O $0F-@!#)CT 0B=$ $$G2P _*%0
M/BA= #TI:0 \*78 .RJ& #DKEP X*ZD -RR_ #<LX  W+/@ -RS_ #<L_P X
M+/\ M3H  *=   "<1   D48  (=&  !]1   <T   &@[  !?-@  53$  $PK
M!P!'*0\ 12H6 $,J'@!!*B4 /RHL #XK,P ]*SD /"M! #LL2  Z+%$ .2U;
M #@N9@ V+G, -2^# #0OE0 S,*< ,C"] #$QW@ Q,?< ,C'_ #(P_P S,/\
ML3X  *1$  "92   CTH  (5*  ![20  <$4  &5   !;.P  4C8  $@Q! !"
M+@T /RX3 #TN&P [+B( .2\I #@O+P W+S8 -C ^ #4P1@ T,4\ ,S%9 #(R
M9  Q,G$ ,#.! "\TDP N-*8 +#6[ "PUVP L-?4 +37_ "TT_P N-/\ KD$
M *)(  "73   C4X  (-.  !Y30  ;DH  &)%  !80   3CP  $4W   ],PL
M.3,1 #<S&  V,Q\ -#,F #,S+0 R-#0 ,30\ # U1  O-4P +C96 "TV8@ L
M-V\ *S=_ "HXD0 H.*0 )SFY "8YV  G.?0 *#G_ "@X_P I./\ JT4  )]+
M  "43P  BU(  (%3  !W4@  ;$\  %])  !61@  3$(  $(]   X. @ -#@/
M #(X%0 Q.!T +S@D "XX*P M.3( +#DY "LZ00 J.DH *3M4 "@[7P G/&T
M)3Q] "0]CP C/:( (CVW "$^U  A/O, (CW_ ",]_P C//\ J$D  )U/  "2
M4P  B58  ']7  !U5@  :E,  %U/  !33   2D@  $!$   V0 4 +ST- "T]
M$P K/1H *CXA "D^*  H/B\ )SXW "8_/P D/T@ (T!2 ") 70 A06H ($%Z
M !Y!C0 =0J  '$*U !M"T0 ;0O$ '$+_ !U!_P >0?\ I4T  )I3  "06
MAEL  'U<  !R6P  9U@  %M4  !14@  2$X  #U*   S1P  *D,+ "9#$  E
M0Q8 )$,> "-$)0 B1"P (40T "!%/  >144 '45/ !Q&6@ ;1F@ &49X !A'
MB@ 71YX %D>S !1(S@ 51^\ %D?_ !=&_P 71O\ HE(  )=8  "-70  A&
M 'IA  !P8   95X  %E:  !/6   1%0  #E1   O3@  )DL& "!*#@ >2A,
M'4H: !Q*(0 ;2R@ &DLP !E+.  72T( %DQ, !5,5P 43&4 $TUU !)-B  1
M39P $$VQ  Y.S  /3>X $$W_ !%,_P 13/\ GE<  )1=  "+8@  @64  '=F
M  !M9@  8V0  %9A  !*7@  /UL  #58   K5@  (E0! !I2"@ 64A  %5(6
M !12'0 34B0 $E(L !%2-  14CX $%-(  ]35  .4V( #51R  Q4A  +5)@
M"52M  A4Q0 )5.< "E/[  M2_P +4O\ FUT  )%D  "(:   ?FL  '1L  !K
M;   7VH  %)G  !%9   .F(  #!@   F7@  '5T  !5;!0 06@P #EH1  Y:
M&  -6R  #%LG  M;,  *6SH "5M%  =;40 &6UX !%MM  -;@  !6Y0  %NH
M  !;P   6N(  %KV  %:_P "6?\ EV0  (YK  "$;@  >W   ')R  !G<0
M67   $QN  ! ;   -6L  "II   A9P  &&8  !%F 0 ,90H !V4/  1E%  #
M9!L  F0C  !D+   9#4  &1   !D3   9%H  &1I  !D>P  9(\  &.D  !C
MNP  8MT  &+T  !B_P  8?\ DVP  (EQ  " =0  >'<  &UX  !@=P  4G8
M $9U   Y=   +G0  "-R   :<0  $G$   UQ   &<0@  ' -  !P$@  <!<
M &\?  !O)@  ;S   &\[  !O1P  ;U0  &]D  !O=0  ;HH  &V@  !MM@
M;-8  &OR  !K_P  :_\ CG,  (5X  !]>P  <WT  &5^  !8?@  2WX  #Y^
M   R?@  )GT  !Q\   3?   #7P   9]    ?04  'P+  !\#P  ?!,  'P9
M  !\(0  ?"D  'PT  ![0   >TX  'M>  ![;P  >H0  'J:  !YL0  >,X
M '?O  !V_@  =O\ B7H  (%_  !X@@  :X,  %V%  !/A@  0H<  #6(   I
MAP  '8<  !2'   -B   !HD   "*    B@   (D&  ")#   B0\  (D3  ")
M&@  BB(  (HL  "*.   BD8  (E6  "):   B7P  (B4  "'JP  AL8  (7J
M  "%^P  A/\ A8(  'V&  !OB   88L  %.-  !%CP  .)$  "N1   ?D@
M%)(   V3   $E    )8   "7    F    )<   "7!0  EPL  )@.  "8$P
MF1H  )DB  ":+@  FCT  )E-  "97@  F7,  )B+  "8HP  E[P  );B  "6
M]P  E?\ @(D  '*,  !DCP  5I,  $B6   ZF0  +)H  !^;   4G   #)X
M  .?    H0   *,   "E    I0   *4   "E    I@(  *<(  "G#0  J!$
M *D9  "K(P  JS$  *M!  "L4P  K&<  *N   "JF@  JK,  *K0  "I[P
MJ?L =8\  &>4  !9F   2IP  #R?   MH@  (*,  !.E   +IP   :D   "K
M    K@   +$   "R    L@   +,   "T    M0   +8   "X!   N0L  +L0
M  "]&   OR0  +\U  # 1P  P%L  ,!R  # C0  P:8  ,#!  "_XP  OO,
M:I<  %N<  !-H0  /J4  "^I   AJP  $ZT   NP    LP   +4   "X
MO    +\   #!    P0   ,,   #$    Q@   ,<   #)    RP   ,X(  #1
M#P  U1@  -@G  #9.0  VDT  -MD  #;?@  W)D  -RP  #<R0  W., 79\
M $^E  ! J@  ,J\  "*R   4M0  "K@   "[    OP   ,,   #&    RP
M ,X   #1    T0   -0   #6    V0   -L   #>    X    .0   #G!@
MZPX  .\9  #P*@  \C\  /-5  #T;0  ](@  /2A  #TM@  ],< _P ) /\
M!@#_  < _P , /\ $0#_ !P _P H /\ - #_ $$ _P!, /\ 50#_ %T _P!E
M /\ ; #_ '( _@!X /P ?@#[ (0 ^@"+ /D D@#W )D ]@"B /0 K #S +D
M\0#+ /  Z #N /L [0#_ .P _P#A /\ T@#_ ,D _P#$ /\ _P ! /\   #_
M    _P $ /\ #@#_ !< _P C /\ +P#_ #L _0!& /H 4 #W %@ ] !? /(
M9@#P &P [P!R .T > #L 'X Z@"% .D C #G ), Y0"< ., I@#A +$ WP#!
M -T W0#; /0 V0#_ -8 _P#/ /\ Q #_ +T _P"Y /\ _P   /\   #_
M_P   /\ "P#\ !, ]P > /0 *@#R #4 [@!  .D 2@#F %( XP!9 .  8 #>
M &8 W !L -H <@#7 '@ U !^ -( A0#0 (T S@"5 ,P GP#) *H QP"X ,4
MS0## .L P #^ +\ _P"^ /\ M@#_ +  _P"M /\ _P   /\   #_    ^0
M /( !@#K  \ Y@ 9 .$ ) #> "\ V@ Y -, 0P#/ $P S !3 ,D 6@#' &
MQ0!F ,, :P#! '$ OP!W +T ?@"[ (8 N0". +< F "U *, LP"P +$ P@"N
M .  K #W *L _P"J /\ J #_ *, _P"@ /\ _P   /\   #U    ZP   .$
M  #6  P SP 3 ,H '@#& "D P@ S +\ /0"[ $4 N !- +8 5 "S %H L0!?
M +  90"N &H K !P *L =P"I '\ IP"' *4 D0"C )P H "I )X N "< ,X
MF@#N )D _P"7 /\ E@#_ )8 _P"3 /\ _0   /$   #E    V0   ,T   #$
M  8 O0 / +< & "S "( L  L *T -@"I #X IP!& *0 30"B %, H !9 )\
M7@"= &0 FP!J )H < "8 '< E@"  )0 B@"1 )4 CP"B (T L "+ ,, B0#C
M (@ ^0"& /\ A@#_ (8 _P"& /\ \P   .,   #1    Q0   +T   "V
MK@ + *@ $@"D !P H  F )P +P": #< EP _ )4 1@"2 $P D0!2 (\ 6 "-
M %T BP!C (H :@"( '$ A@!Y (0 @P"" (\ ?P"; 'X J0!\ +L >@#5 '@
M\@!X /\ =P#_ '< _P!W /\ YP<  -$,  ###0  N P  *X(  "H    H@ %
M )L #@"6 !4 D@ ? (X * "+ #$ B  Y (8 0 "$ $8 @@!, (  4@!_ %<
M?0!= 'L 8P!Z &L > !S '8 ?0!T (@ <0"5 '  I !N +0 ; #* &L Z@!J
M /P :@#_ &H _P!J /\ VA   ,84  "X%@  K14  *02  "<#@  E@<  )
M"0"* !  A0 8 ($ (0!^ "H >P R 'D .0!W $  =0!& ', 3 !R %$ < !7
M &X 7@!M &4 :P!N &D =P!G (, 90"1 &, GP!B *\ 8 #$ %\ Y !? ?@
M7@+_ %X"_P!> O\ SA@  +T=  "P(   I1\  )L<  "3%P  BQ$  (0,  !^
M! L >0 2 '4 &P!R ", ;P K &T!,P!K 3H :0)  &<#1@!F TP 9 12 &,$
M60!A!&  7P5I %X%<P!<!G\ 6@:- %D'G !7"*T 5@C! %4)X0!4"_8 5 O_
M %0+_P!4"_\ QA\  +8E  "I*   GB@  )0E  "+(0  @QL  'L4  !T#@,
M;@D- &D(% !F"1T 9 HE &(*+0!@"S0 7@LZ %T+0 !;#$< 6@Q- %@,5 !7
M#5P 50UD %0-;P!2#7L 4 Z* $\.F@!.#JP 3 _" $P0XP!+$/D 2Q#_ $L1
M_P!+$/\ OR8  + K  "D+P  F2\  (\M  "&*0  ?20  '0>  !L%P  91$'
M %\.$ !<#Q< 6A ? %@0)P!6$"X 5! U %,0.P!2$4( 4!%( $\14 !.$5<
M3!)@ $L2:P!)$G@ 2!.' $83EP!%%*D 1!2^ $,5WP!#%O@ 0Q;_ $,6_P!#
M%O\ NBL  *LQ  "@-   E34  (LT  "!,0  >"L  &\F  !F(   7AD! %<4
M#0!4%!, 410; $\5(P!.%2H 3!4Q $L6-P!)%CX 2!9$ $<73 !%%U0 1!==
M $,89P!!&'0 0!F# #\:E  ]&J8 /!N[ #L;VP ['/8 /!S_ #P<_P \'/\
MM3   *@V  "<.0  D3L  (<Z  !^-P  <S(  &HM  !A)P  62$  %$;"0!,
M&1  2AH7 $@:'P!&&B8 11LM $,;,P!"&SH 01Q! $ <2  ^'%  /1U9 #P>
M9  ['G$ .1^  #@?D@ W(*0 -B"X #4AU@ U(?0 -2+_ #4A_P V(?\ LC0
M *0Z  "9/@  CS\  (4_  ![/   <#@  &<R  !=+0  5"@  $PB!0!&'PX
M0Q\4 $$?&P _'R( /B I #T@,  [(#8 .B$] #DA10 X(DT -R)7 #8C8@ T
M(VX ,R1^ #(DCP Q):( +R6V "\FT@ O)O( +R;_ # F_P P)O\ KS@  *(^
M  "60@  C$,  ()#  !X00  ;CT  &,X  !:,P  42X  $@H 0! ) P /2,1
M #LD&  Y)!\ ."0F #8D+  U)3, -"4Z #,F0@ R)DH ,2=4 # G7P O*&P
M+BA[ "PIC0 K*J  *BJT "DJSP I*_  *BO_ "HJ_P K*O\ K#P  )]"  "4
M1@  BD<  (!'  !V10  ;$(  &$]  !7.   3C,  $0N   \*0D -R@0 #4H
M%0 S*!P ,B@C # H*0 O*3  +RHW "XJ/P M*T@ +"M2 "LL70 J+&H *"UY
M "<MBP F+IX )2ZS "0OS0 D+^X )2__ "4O_P F+O\ J3\  )U%  "220
MB$L  'Y,  !T2@  :D<  %Y"  !4/0  2SD  $$T   X+P8 ,BT- # M$P N
M+1D +2T@ "LM)P J+BX *2XU "DO/0 H+T8 )S!/ "4P6P D,6@ (S%W "(R
MB0 A,IT 'S.Q !XSRP >,^T 'S/_ " S_P A,O\ ID,  )I)  "030  AD\
M 'Q0  !S3P  :$P  %Q&  !20P  23\  #\[   V-@( +C(, "LR$0 I,A<
M*#(> "8R)  E,RL )#,R ",T.@ B-$, (35- " U6  ?-F4 'C9U !PWAP ;
M-YL &C>O !DXR  9..L &CC_ !LW_P ;-_\ HT<  )A-  ".40  A%,  'M4
M  !Q4P  9E   %I,  !020  1T4  #U!   S/0  *CD) "4W#@ C-Q0 (C@;
M "$X(@ @."@ 'S@P !XY.  =.4$ '#I+ !HZ5@ 9.V, &#MR !8[A0 5/)D
M%#RM !,]Q@ 3/>D %#S] !4\_P 6._\ H$L  )51  "+50  @E@  'E9  !N
M6   9%8  %A1  !.3P  14L  #I'   P0P  )T % " ^#0 =/A$ '#X7 !L^
M'@ :/B4 &3XM !@_-0 6/SX %3]( !1 4P 30&  $D%P !%!@@ 009< #T&L
M  Y"Q  .0N< #T'\ !!!_P 00/\ G5   )-6  ")6@  @%T  '9>  !L70
M8EL  %97  !,50  05$  #9.   L2P  (T@  !M%"0 71 \ %404 !1%&P 3
M12( $D4I !%%,0 113L $$9%  ]&4  .1UX #4=M  Q'?P +1Y, "4>G  A'
MO@ (1^  "4?V  I&_P +1O\ FE4  )!;  "'8   ?6(  '-C  !J8@  8&$
M %->  !'6@  /%<  #)5   H4@  'U   !=.!  13 P #TP1  Y,%P .3!X
M#4TE  Q-+@ +33< "DU"  E-30 '3EH !DYI  1.>P "3H\  4ZD  !-N@
M3=L  4WR  %-_P "3/\ EEL  (UB  "$9@  >F@  '%I  !H:0  7&<  $]D
M  !"80  -U\  "U<   C6@  &E@  !)7 0 -5@D "54.  =5$P &51H !%4B
M  -5*@ "530  %4^  !52@  5E<  %9E  !5=P  58L  %6@  !5M@  5-0
M %3Q  !3_0  4_\ DV(  (IH  " ;   =VX  &]O  !C;@  5FP  $EJ   ]
M:   ,F8  "=E   =8P  %6(   YA   )8 @  V -  !?$0  7Q<  %\>  !?
M)@  7R\  %\Z  !?10  7U,  %]A  !><@  7H<  %V<  !=L@  7,\  %SO
M  !;_0  6_\ D&H  (9O  !]<@  =70  &IU  !==   3W,  $)R   V<
M*V\  "!N   7;0  $&P   IL   ":P8  &L+  !J#P  :A0  &H:  !J(0
M:2H  &DT  !I0   :4X  &E<  !I;0  :((  &B8  !GK@  9LH  &7M  !E
M_   9/\ BW$  ()V  !Z>0  <'L  &)[  !5>P  2'H  #MZ   O>@  (WD
M !EX   1=P  "G<   -W    =P(  '<(  !V#0  =A   '85  !V&P  =B,
M '8N  !U.@  =4<  '56  !U:   ='P  '22  !SJ@  <L0  ''I  !P^P
M</\ AGD  ']]  !V?P  :($  %J"  !,@@  /X,  #*$   E@P  &H,  !&#
M   *@P   H,   "$    A0   (0#  "#"   @PT  (,0  "#%0  A!P  (0F
M  "$,@  A#\  (-/  "#8   @G4  (*,  "!I   @+T  '_C  !^^0  ?O\
M@H   'J$  !LA@  7H@  %"*  !"BP  -8T  ">-   ;C0  $8X   J.
MCP   )$   "2    D@   )(   "2 0  D@<  )(,  "2$   DQ4  ),=  "4
M*   E#8  )1%  "35P  DVL  )."  "2G   D;8  )#8  "/\P  C_\ ?H<
M '"*  !AC0  4Y   $63   WE0  *98  !R7   1F   "9D   ";    G
M )X   "@    H    *    "@    H0   *$$  "B"0  HPX  *04  "E'0
MIBH  *8Z  "F3   I6   *5X  "ED@  I*P  *3)  "CZP  HOH <XX  &21
M  !6E0  1YD  #F<   JG@  ':   !&A   (HP   *4   "G    J0   *P
M  "N    K@   *X   "O    L    +$   "R    LP8  +4-  "W$P  N1X
M +DN  "Z0   NE0  +MJ  "ZA0  N:$  +F[  "ZW@  N?( 9Y4  %B9  !*
MG@  .Z(  "RF   =J   $:H   >L    KP   +$   "T    N    +L   "\
M    O    +X   "_    P    ,(   #$    Q@   ,@#  #+"P  SQ(  -$@
M  #1,@  TD8  --=  #4=@  U)(  -6K  #5Q   U.( 6YT  $RB   ]IP
M+ZP  !^O   1L0  ![4   "X    NP   +X   #"    QP   ,H   #,
MS    ,X   #0    T@   -4   #8    VP   -\   #B    Y@L  .L3  #L
M)   [3@  .Y.  #O9P  \((  /"<  #PL@  \<4 _P # /\  0#_  0 _P )
M /\ #P#_ !@ _P D /\ , #_ #P _P!' /\ 40#_ %D _P!@ /T 9P#\ &T
M^@!S /D >0#X '\ ]@"% /4 C #S )0 \@"= /  IP#N +, [ #$ .L X0#J
M /@ Z0#_ .< _P#9 /\ RP#_ ,( _P"] /\ _P   /\   #_    _P   /\
M# #_ !0 _P @ /\ *P#^ #< ^@!" /8 2P#R %, \ !; .X 80#L &< Z@!M
M .@ <P#G 'D Y0!_ ., A@#A (X WP"6 -T H #; *P V "[ -0 T0#3 /
MT #_ ,X _P#( /\ O0#_ +8 _P"R /\ _P   /\   #_    _P   /T " #W
M !  \P : .\ )@#M #$ Z  [ ., 10#@ $T W !5 -D 6P#6 &$ TP!G -$
M; #/ '( S0!X ,L ?P#) (< QP"0 ,4 F@## *4 P "R +X Q0"\ .4 N@#[
M +@ _P"W /\ L #_ *D _P"E /\ _P   /\   #^    ]0   .P  P#E  T
MWP 5 -H ( #4 "H T  U ,L /@#( $< Q0!. ,( 50#  %L O@!A +P 9@"Z
M &P N !R +8 > "U (  LP"( +$ D@"N )X K "J *D NP"H -4 I@#S *0
M_P"C /\ H0#_ )L _P"8 /\ _P   /L   #P    Y0   -@   #.  D QP 1
M ,( &@"^ "0 NP N +< . "T $  L0!( *X 3@"L %0 J@!: *D 7P"G &4
MI0!K *0 <0"B '@ H "! )X BP"< )8 F0"C )< L@"6 ,< DP#H )( _@"1
M /\ D #_ (T _P"+ /\ ^0   .L   #=    SP   ,8   "\  0 M0 - +
M%0"L !X J  H *4 ,0"B #D GP!! )T 2 "; $X F0!3 )< 60"6 %X E !D
M )( :@"0 '$ C@!Z (P @P"* (\ B "< (8 J@"$ +P @@#< ($ ]@"  /\
M?P#_ '\ _P!^ /\ [    -H   #)    O@   +8   "N    IP ) *$ $ "<
M !@ F  B )4 *@"2 #( D  Z (T 00"+ $< B0!- (< 4@"& %@ A != ((
M9 "! &L ?P!S 'T ?0![ (@ > "5 '8 HP!U +0 <P#, '$ [0!P /\ < #_
M '  _P!P /\ WP4  ,H*  "\"P  L0D  *@$  "A    FP # )0 # "/ !,
MB@ ; (< ) "$ "P @0 S '\ .@!] $$ >P!' 'D 3 !W %( =@!7 '0 70!R
M &0 < !M &\ =@!L (( :@"/ &D G0!G *X 90## &0 Y !C /H 8P#_ &(
M_P!C /\ T X  +\2  "R$P  IQ(  )T0  "5"P  CP,  (D !P""  X ?@ 5
M 'H '@!V "4 =  M '$ - !O #H ;@!  &P 1@!J $P :0!2 &< 6 !F %\
M9 !G &( <0!@ 'P 7@") %P F !; *D 60"\ %@ W !8 /0 6 #_ %< _P!7
M /\ QA8  +8:  "J'0  GQP  )49  "-%   A0\  'X)  !W 0H <@ 0 &X
M%P!J !\ :  G &4 +@!D #0 8@ [ &  0 !? $8 70!, %P 4P!: %H 6 !B
M %< ; !5 '< 4P"% %( E !0 :4 3P&X $X"T@!-!/  307_ $T%_P!-!?\
MOQT  + B  "C)0  F24  (\B  "%'0  ?1@  '42  !N#0( 9P8, &,#$0!?
M AD 70,A %L$* !9!"\ 5P4U %8%.P!4!D$ 4P9' %$&3@!0!U4 3@=> $T(
M9P!+"', 20F! $@)D@!'"J, 10JV $0+T !$#.\ 0PW_ $,-_P!$#?\ N20
M *HI  ">+   E"P  (HJ  " )@  =R$  &X;  !F%   7P\% %D+#0!5"A,
M4PL; %$+(@!/#"D 30PO $P,-@!+#3P 20U" $@-20!&#5$ 10Y: $0.9 !"
M#G  0 Y_ #\/D  ^$*( /!"V #L0T0 [$?$ .Q'_ #L1_P \$?\ M"D  *8O
M  ":,@  D#(  (8Q  !\+0  <B@  &DC  !A'0  618  %$1" !,#Q  2A 6
M $@0'0!&$"0 11 K $,1,0!"$3< 01$^ $ 110 ^$DT /1)6 #P280 Z$VT
M.1-\ #<4C0 V%)\ -16S #05S0 S%NX -!;_ #06_P T%O\ KRX  *(T  "7
M-P  C#@  ((V  !X-   ;BX  &4J  !<)   5!X  $P8! !&% T 0A02 $ 4
M&0 _%"  /14G #P5+0 [%30 .18Z #@60@ W%DH -A=3 #477@ S&&H ,AEY
M # 9B@ O&IT +AJQ "T;R@ M&^P +1S_ "X;_P N&_\ K#(  )\X  "4.P
MBCP  ( \  !V.0  :S0  &(O  !9*@  4"4  $<?  ! &@H /!D0 #H9%@ X
M&1T -AHC #4:*0 T&C  ,QHW #(;/@ Q&T< +QQ0 "X=6P M'6< +!YV "H>
MB  I'YL *!^N "<@QP F(.H )R#^ "@@_P H(/\ J38  )T\  "2/P  AT$
M 'U   !T/@  :3H  %\U  !6,   32L  $0E   [( < -AX. #,>$P R'AD
M,!X@ "\>)@ N'RT +1\T "P@.P K($0 *B%. "DA6  G(F4 )B)T "4CA0 C
M(YD (B2M "$DQ0 A)>@ (B7] "(D_P C)/\ ICH  )H_  "/0P  A44  'M$
M  !R0P  9S\  %TZ  !3-@  2C$  $$L   X)@, ,2,, "XB$0 L(A8 *B(=
M "DB(P H(RH )R,Q "8D.0 E)4$ )"5+ ",F5@ B)F, (2=R !\G@P >*)<
M'2BK !LIPP ;*>8 '"G[ !TI_P >*/\ HSX  )A#  "-1P  @TD  'I)  !P
M1P  9D0  %H_  !1.P  1S<  #XR   U+0  +"@) "@G#P G)Q0 )2<: "0G
M(0 C*"< (B@N "$I-@ @*3\ 'RI) !XJ5  =*V  &RMO !HL@0 9+)4 %RVI
M !8MP0 6+>0 %RWZ !@M_P 9+?\ H4$  )5'  "+2P  @DT  'A-  !N3
M9$D  %A$  !/0   1CT  #TX   S-   *B\& "0L#0 A+!( ("P8 !\M'@ >
M+24 '2TL !PN-  ;+CP &B]& !@O40 7,%X %C!M !4Q?P 3,9, $C&H !$R
MOP 1,N( $C+Y !,Q_P 3,?\ GD4  )-+  ")3P  @%$  '92  !M4   8DX
M %9)  !-1@  1$,  #L_   Q.@  )S8# !\R"P <,A  &S(5 !DR&P 8,B(
M%S,I !8S,0 5-#H %#1$ !,T3P 2-5P $35K ! V?0 /-I$ #C:F  TWO  -
M-]T #3;V  XV_P /-O\ FTD  )%/  "'4P  ?E8  '56  !J50  8%,  %5/
M  !,3   0DD  #A%   N00  )#T  !PZ"  6. X %3@2 !0X&  3.1\ $CDF
M !$Y+@ 0.3< #SI!  XZ3  -.UD #3MH  L[>@ *.XT "3RB  <\N  '/-4
M"#SP  D[_P *._\ F$X  (Y4  "%6   ?%L  ');  !H6@  7E@  %-5  !)
M4@  /DX  #1+   J1P  (40  !A" P 20 L $#\0  X_%0 ./QP #4 C  Q
M*P +0#0 "D ^  E!2@ '058 !D%E  1!=@ #08H  4&?  !!M   0=   4'N
M  %!_  "0/\ E50  (Q9  "#7@  >6   '!@  !F8   75X  %%;  !%5P
M.E0  "]1   E3P  '$P  !1*   .2 @ "T<.  A'$@ '1QD !D<@  5(*  #
M2#$  D@[  !(1P  2%,  $AB  !(<P  2(8  $B;  !(L0  1\P  $?M  !'
M^P  1_\ DEH  (E@  " 8P  =V4  &YF  !E9@  660  $Q@  ! 70  -5L
M "I9   @5P  %U4  !!3   +4@< !5$-  %0$0  4!8  % =  !0)0  4"X
M % X  !00P  4%   %!>  !0;P  4(,  $^8  !/K@  3LD  $[K  !-^P
M3?\ CV$  (9F  !]:0  =&P  &QM  !A:P  4VD  $9G   Z9   +V,  "1A
M   :7P  $EX   Q<   &7 8  %L+  !:#P  6A,  %H9  !9(0  62D  %DS
M  !9/P  64P  %E:  !9:P  6'X  %B4  !7JP  5\4  %;I  !5^P  5?\
MC&@  ()M  !Z<   <G(  &=R  !:<0  3'   #]N   S;0  *&L  !UJ   4
M:   #6<   =G    9@,  &8)  !E#0  91$  &05  !D'   9"0  &0N  !D
M.@  8T<  &-5  !C9@  8WH  &*0  !AIP  8,$  %_F  !?^@  7O\ AV\
M ']T  !X=P  ;G@  &!X  !2=P  17<  #AV   K=@  ('0  !9S   .<P
M!W(   !R    <@   '$%  !Q"@  <0X  ' 1  !P%P  <!X  ' G  !P,P
M;T   &]0  !O8   ;G0  &Z+  !MH@  ;+P  &OB  !J^   :?\ @W<  'Q[
M  !S?0  97X  %=_  !)?P  /'\  "^    B?P  %WX   ]^   '?@   '\
M  !_    ?P   'X   !^!0  ?@H  'X-  !^$0  ?A<  'X@  !^*P  ?3D
M 'U(  !]60  ?&T  'R$  ![G   >K8  'G:  !X]0  =_\ @'\  '>"  !I
M@P  6X4  $V&   _B   ,HD  "2)   8B0  #XD   >*    BP   (P   "-
M    C0   (P   ",    C ,  (P(  "-#0  C1$  (T7  ".(@  CB\  (X_
M  "-4   C60  (Q[  ",E0  BZX  (K-  ")[P  B?\ >X4  &V(  !>B@
M4(T  $*/   TD0  )I(  !F3   .E   !I4   "6    F    )H   ";
MFP   )L   ";    FP   )P   "=!0  G0L  )X0  "?%P  H"0  * T  "@
M1@  H%D  )]P  "?B@  GJ4  )["  "=Z   G/D <(P  &&/  !3D@  1)8
M #:9   GFP  &9P   ^=   %GP   *$   "C    I0   *@   "I    J0
M *D   "J    JP   *P   "M    K@$  + )  "R#P  LQ@  +0G  "T.0
MM4T  +1D  "T?@  LYH  +.T  "SU0  L_  9),  %67  !'FP  .)\  "FB
M   :I   #J8   2H    JP   *T   "P    M    +8   "X    N    +D
M  "Z    O    +T   "_    P    ,,   #%!P  R0\  ,H:  #++   S$
M ,U6  #.;P  S8L  ,RH  #,P@  S.( 6)L  $F@   ZI0  +*D  !RK   /
MK@  !+$   "T    MP   +H   "^    PP   ,8   #(    R    ,H   #+
M    S0   ,\   #2    U0   -D   #=    X04  .8/  #G'@  Z#(  .E(
M  #J8   ZWL  .N7  #LK@  [,( _P   /\   #_    _P & /\ #0#_ !4
M_P A /\ + #_ #@ _P!# /\ 3 #^ %0 ^P!; /H 8@#X &@ ]@!N /4 = #T
M 'H \@"  /$ AP#O (\ [0"7 .L H0#I *T YP"] .4 V #D /, X@#_ .
M_P#0 /\ Q #_ +P _P"V /\ _P   /\   #_    _P   /\ "0#_ !$ _P <
M /T )P#Y #( ]0 ] /$ 1@#M $\ ZP!6 .@ 7 #F &( Y !H ., ;@#A ',
MWP!Y -T @ #: (@ V "1 -0 FP#2 *8 SP"T ,P R0#) .D R #_ ,< _P#!
M /\ MP#_ *\ _P"K /\ _P   /\   #_    _P   /@ !0#R  X [@ 7 .H
M(@#F "P X0 W -T 0 #8 $D TP!0 -  5@#. %P S !B ,H 9P#( &T Q@!S
M ,0 >0#" ($ P "* +X E "\ )\ N0"L +8 O@"T -T LP#W +$ _P"P /\
MJ #_ *( _P"> /\ _P   /\   #Y    [P   .8   #?  L U@ 2 -  ' #,
M "8 R  P ,0 .@#  $( O0!* +L 4 "X %8 M@!; +4 80"S &8 L0!L +
M<@"N 'H K "" *D C "G )@ I0"E *, M "@ ,L GP#N )T _P"< /\ F0#_
M )0 _P"1 /\ _P   /8   #J    W0   ,\   #'  8 P  / +L %P"W "
MLP J +  ,P"M #L J@!# *< 20"E $\ HP!5 *( 6@"@ %\ G@!E )T :P";
M '( F0![ )< A0"4 )  D@"= )  K ". +\ C #B (L ^@") /\ B0#_ (8
M_P"# /\ ]    .0   #4    R    +\   "U  $ K@ + *D $@"E !L H0 C
M )X + "; #0 F  \ )8 0P"4 $D D@!. )  4P". %D C0!> (L 9 ") &L
MAP!S (4 ?0"# (@ @0"5 '\ I !] +4 >P#/ 'D \0!X /\ =P#_ '< _P!U
M /\ Y0   -$   ##    N    *\   "H    H  & )H #@"5 !4 D0 > (X
M)@"+ "T B  U (8 / "$ $( @@!' (  30!_ %( ?0!8 'L 7@!Y &4 > !M
M '8 =@!S ($ <0". &\ G0!M *X ; #$ &H YP!I /T : #_ &@ _P!I /\
MU0,  ,,'  "V"   JP8  *(   ";    E    (T "@"( !  @P 8 '\ ( !\
M "< >@ N '< -0!U #L = !! '( 1P!P $P ;P!2 &T 6 !K %\ :0!F &<
M< !E 'L 8P"( &( EP!@ *< 7@"[ %T W !< /8 7 #_ %L _P!; /\ R0T
M +D0  "L$0  H1   )<-  "/"   B    (( !0![  T =P 2 ', &@!O "$
M;  H &H +P!H #4 9P [ &4 00!C $8 8@!, &  4@!? %D 70!A %L :@!9
M '4 5P"" %4 D0!4 *( 4P"U %$ SP!0 .\ 4 #_ %  _P!0 /\ OQ0  + 8
M  "D&@  F1D  (\6  "'$0  ?PT  '<&  !Q  @ :P . &< % !D !L 80 B
M %X *0!= "\ 6P U %D .P!8 $$ 5@!& %4 30!3 %0 4@!< %  90!. '
M3 !] $L C0!) )X 2 "P $< QP!& .D 1@#[ $8 _P!% /\ N!L  *H@  ">
M(@  DR(  (D?  " &@  =Q4  &\0  !H"P  800* %T $ !9 !8 5@ = %0
M(P!2 "H 4  P $\ -0!. #L 3 !! $L 2 !) $\ 1P%7 $8!80!$ FP 0P)Y
M $$#B0!  YH /@2M #T$Q  \!>4 / ?X #P'_P \!_\ LB(  *4G  "9*0
MCBD  (0G  ![(P  <1X  &D8  !A$@  6@T# %,(# !/!1$ 3 47 $H&'@!(
M!B0 1P8J $4', !$!S8 0P@] $$(0P! "$L /@E3 #T)70 ["F@ .@IV #@+
MAP W"YD -0NL #0,P@ S#.0 ,PWY #,-_P T#?\ K2<  * L  "5+P  BR\
M ( N  !W*@  ;24  &0@  !<&@  5!0  $P/!@!&# T 0PP2 $$,&  _#!\
M/@PE #P-*P [#3( .@TX #@-/P W#D< -@Y0 #0.6@ S#F8 ,0]T # /A0 N
M$)@ +1"K "P0PP K$>4 +!'Z "P1_P M$?\ JBP  )TQ  "2-   AS4  'TT
M  !T,0  :BL  & G  !8(0  3QL  $<6  ! $0D .Q / #D0%  W$!L -A A
M #00)P S$2T ,A$T #$1.P P$4, +A)- "T25P L$F, *A-Q "D3@@ G%)4
M)A2I "45P  D%>, )1;Z "86_P F%?\ IC$  )HV  "/.0  A3H  'LY  !Q
M-@  9S$  %TM  !4*   3"(  $,=   [%P4 -10- #(3$0 Q%!< +Q0= "X4
M)  L%"H *Q4Q "H5.  I%D  *!9* "<75  F%V  )!AO ",8@  A&9, (!FG
M !\9O@ >&N  'QKX " :_P @&O\ HS0  )@Z  "-/0  @SX  'D]  !O.P
M93<  %LR  !2+0  22@  $ C   X'@$ ,!D* "P8#P J&!0 *1@: "<8(  F
M&2< )1DM "0:-0 C&CX (AM' "$;4@ @'%X 'QUL !T=?@ <'9$ &AZE !D>
MO  8']T &1_V !H?_P ;'O\ H3@  )4]  "+00  @4(  '="  !M0   8SP
M %DW  !/,P  1BX  #TI   U)   +2 ' "<=#0 E'1( (QT7 "$='0 A'20
M(!XK !\>,@ >'SL '1]% !P@3P :(5P &2%J !@B>P 6(H\ %2*C !0CN@ 3
M(]H %"/U !4C_P 6(_\ GCP  )-!  ")1   ?T8  '5&  !L1   8D$  %<\
M  !-.   1#0  #PP   S*P  *B8# ",B"P @(1  'B$5 !PB&P ;(B$ &B(H
M !HC,  9(S@ &"1" !8E30 5)5D %"9H !,F>0 2)HT $2>B ! GN  .)]8
M$"CT !$G_P 1)_\ G$   )%%  "'2   ?4H  '1*  !J20  8$8  %5!  !,
M/@  0SH  #HV   Q,@  *"T  " I"0 ;)PX &2<2 !@G&  6)Q\ %2@E !0H
M+0 3*#8 $BE  !(I2P 1*E< $"IF  XK=P .*XL #2R?  PLM0 ++,\ #"SO
M  TL_P -*_\ F40  (])  "%3   ?$X  '-/  !I3@  7DL  %-'  !*1
M0D   #D]   O.   )30  !TP!0 6+0P %"P0 !,M%0 2+1P $2TC ! M*@ /
M+C, #BX]  TO2  -+U4 ##!C  HP=  ),(@ "#&<  8QL0 &,<L !C'K  <P
M_  (,/\ ET@  (U-  "#40  >E,  '%4  !G4@  75   %),  !)2@  0$8
M #5"   K/@  (CH  !HW 0 2- D #S,.  XS$P -,QD #3,@  PT*  +-#$
M"C4[  @U1@ '-5( !39@  0V<0 "-H0  #:9   VKP  -L@  #;H   V^0 !
M-?\ E$T  (I2  "!5@  >%@  &]9  !E6   6U4  %%2  !'3P  /$P  #%(
M   G1   'D$  !8_   0/ < "SH-  DZ$0 (.Q< !CL>  4[)@ $.RX  CLX
M  $\0P  /$\  #Q>   \;@  /($  #R7   \K   .\4  #OG   [^   ._\
MD5(  (A8  !_7   =ET  &U>  !C70  6EP  $Y8  !"5   -U$  "U.   C
M2P  &DD  !)&   -1 8 !T,,  -#$   0Q4  $,;  !#(P  0RL  $,U  !#
M0   0TT  $-;  !#:P  0WX  $.4  !"J@  0L,  $'F  !!^0  0?\ CE@
M (9>  !]80  <V,  &MD  !B8P  5V$  $E=   ]6@  ,E@  "=5   >4P
M%5$   Y/   )304  DT+  !,#@  3!,  $L8  !+'P  2R@  $LR  !+/0
M2TD  $M7  !+9P  2GL  $J0  !)IP  2<   $CD  !(^   1_\ BU\  (-D
M  !Z9P  <6D  &EJ  !>:0  4&8  $-D   W80  +%\  "%=   86P  $%D
M  I8   #5P,  %<)  !6#0  51   %45  !4&P  5",  %0M  !4.0  5$4
M %13  !49   4W<  %.-  !2I   4;T  %#B  !0^   3_\ B&<  ']K  !W
M;@  ;W   &5P  !7;@  2FP  #UK   P:0  )6@  !IF   19   "V,   1B
M    8@$  &$&  !@"P  8 X  %\2  !?%P  7QX  %XH  !>,P  7D   %Y/
M  !>7P  77(  %V(  !<H   6[D  %K?  !9]P  6/\ A&X  'QR  !U=0
M:W8  %UU  !/=   0G,  #5S   H<@  '7   !-O   ,;@  !&X   !N
M;@   &P"  !L!P  :PL  &L.  !K$@  :AD  &HB  !J+0  :CH  &E)  !I
M6@  :6P  &B#  !GFP  9K4  &78  !D]0  9/\ @'4  'IY  !P>P  8GL
M %1\  !&?   .7P  "Q\   ?>P  %'H   UZ   $>@   'H   !Z    >@
M 'D   !Y 0  > 8  '@+  !X#@  >!,  '@:  !X)0  >#(  '=!  !W4@
M=V4  '9\  !UE0  =*\  '/.  !R\0  <?\ ?GT  '6   !G@0  6((  $J#
M   \A   +H4  "&%   5A0  #84   .%    A@   (<   "(    B    (<
M  "'    AP   (<$  "'"0  APX  (@3  "('   B"D  (@X  "'2@  AUT
M (9S  "&C0  A:<  (3%  "#[   @OX >(0  &J&  !<B   38H  #^,   Q
MC@  (X\  !:/   -D    I$   "2    DP   )4   "6    E@   )8   "6
M    E@   )<   "7    EP<  )@-  "9$P  FA\  )HM  ":/P  FE(  )IH
M  "9@P  F9\  )BZ  "7X@  EO@ ;8H  %^-  !0D   09,  #.6   DEP
M%I@   V9   !FP   )T   "?    H0   *0   "E    I    *4   "E
MI@   *<   "H    J0   *H$  "L#   KA,  *XA  "N,P  KD<  *Y=  "N
M=@  KI,  *ZN  "MS0  K.\ 89$  %.5  !$F   -9P  ":?   7H0  #:,
M  "E    IP   *H   "L    L    +(   "T    LP   +0   "U    MP
M +@   "Y    NP   +T   "_ 0  PPL  ,45  #%)0  QCD  ,=/  #':
MQH4  ,:B  #&O   QMX 59D  $>=   XH@  *:8  !FH   -JP   *T   "Q
M    M    +<   "Z    OP   ,$   #$    PP   ,4   #&    R    ,H
M  #-    SP   -(   #6    VP   . ,  #A&   XRL  .1!  #E6@  YG0
M .:1  #EK   Y<0 _P   /\   #_    _P ! /\ "@#_ !( _P = /\ * #_
M #0 _P ^ /T 2 #Z %  ]P!7 /4 70#T &, \@!I /  ;P#O '0 [0![ .L
M@0#I (D Z "2 .8 G #D *@ X@"W -\ S0#< .X V0#_ -D _P#* /\ O@#_
M +4 _P"P /\ _P   /\   #_    _P   /\ !@#_  \ _  8 /@ (P#T "X
M\  X .L 0@#H $H Y0!1 .( 6 #@ %T W@!C -P : #9 &X U@!T -0 >P#1
M (( SP"+ ,T E0#* *$ R "O ,4 P0#" ., P #[ ,  _P"[ /\ L #_ *@
M_P"D /\ _P   /\   #_    ^P   /,  0#M  P Z  3 ., '@#@ "@ V@ R
M -, / #/ $0 S !+ ,D 40#& %< Q != ,( 8@#! &< OP!M +T = "[ 'L
MN0"$ +< C@"T )D L@"G *\ MP"M -  JP#R *H _P"I /\ H0#_ )L _P"7
M /\ _P   /\   #T    Z0   .    #5  @ S@ 0 ,D & #% "( P0 K +P
M-0"Y #T M@!% +, 2P"Q %$ KP!6 *X 6P"L &$ J@!F *D ;0"F '0 I !\
M *( A@"@ )( G@"? )P K@"9 ,, EP#G )8 _P"5 /\ D@#_ (T _P"* /\
M_    /    #C    U    ,@   "_  , N0 - +, $P"O !P K  E *D +@"E
M #8 HP ^ *  1 "> $H G0!0 )L 50"9 %H EP!? )8 9@"4 &P D@!U )
M?@". (H BP"7 (D I@"' +@ A0#6 (0 ]@"" /\ @0#_ 'X _P!\ /\ [0
M -T   #,    P0   +@   "N    IP ) *( $ "> !< F@ ? )< )P"4 "\
MD0 W (\ /0"- $, BP!) (D 3@"( %, A@!9 (0 7P"" &4 @ !M 'X =P!\
M (( >@"/ '@ G@!U *\ <P#' '( [ !Q /\ < #_ '  _P!N /\ W0   ,D
M  "\    L0   *D   "A    F0 # ), # ". !( B@ 9 (< (0"$ "D @0 P
M '\ -P!] #T >P!" 'D 2 !X $T =@!2 '0 6 !R %\ <0!G &\ < !L 'L
M:@"( &@ EP!F *@ 90"\ &, X0!B /H 80#_ &$ _P!A /\ S0$  +P%  "O
M!0  I0(  )P   "4    C0   (8 " "!  X ?  4 '@ &P!U ", <@ I '
M, !N #8 ;0 \ &L 00!I $< : !, &8 4@!D %D 8P!@ &$ :0!? '0 70"!
M %L D !9 *$ 5P"T %8 T !5 /( 50#_ %0 _P!5 /\ P0P  +(.  "F#P
MFPX  )(+  ")!0  @@   'L  @!U  L <  0 &P %@!H !T 9@ C &, *@!A
M #  8  V %X .P!= $$ 6P!& %H 3 !8 %, 5@!; %0 9 !2 &X 40![ $\
MB@!- )L 3 "N $L Q@!* .H 20#^ $D _P!) /\ N1(  *H6  ">%P  E!8
M (H3  "!$   >0L  '$#  !K  8 90 - &$ $0!= !@ 6@ > %@ ) !6 "H
M5  P %, -@!1 #L 4 !! $X 1P!- $X 2P!6 $D 7P!' &D 1@!V $0 A0!#
M )< 00"I $  OP _ .( /P#X #X _P _ /\ LAD  *0>  "8'P  CA\  (0<
M  !Z&   <A(  &H.  !B"   7 $( %< #@!3 !, 4  9 $X 'P!, "4 2@ K
M $@ , !' #8 1@ \ $0 0@!# $D 00!1 #\ 6@ ^ &4 / !R #H @0 Y ),
M. "E #8 N@ V -L -0#T #4 _P U /\ K"   )\D  "4)@  B28  '\D  !U
M(   ;!L  &05  !<$   5 P! $X&"@!* @\ 1P 4 $0 &@!" "  0  E #\
M*P ^ 3$ / $W #L"/@ Y D4 . -- #8#5@ U!&$ ,P1N #$%?@ P!9  +P6C
M "T&N  L!M0 + ?P "P(_P L"/\ J"4  )LJ  "0+   ABT  'LK  !R)P
M:"(  %\=  !7%P  3Q(  $@.! !!"@L /@<0 #L&%0 Y!QL . <A #8()@ U
M""P ,P@R #().0 Q"4$ +PE) "X*4P L"EX *PML "D+?  H#(\ )@RB "4,
MMP D#-, (PWP "0-_P E#?\ I"H  )@O  "-,@  @S(  'DQ  !O+@  92D
M %PD  !3'P  2QD  $,3   \$ 8 -0T, #,,$0 Q#!8 +PP< "X-(@ M#2@
M*PTN "H--0 I#3T )PY& "8.4  D#EP (P]J "(/>P @$(X 'Q"B !T0MP <
M$-0 '1'R !T1_P >$?\ H2\  )4S  "*-@  @#<  '8V  !M,P  8R\  %DJ
M  !0)0  2"   #\:   X%0  ,!$( "P0#@ J$!( *! 8 "<0'@ E$"0 )! J
M ",1,@ B$3H (1%# " 23@ >$EH '1-H !L3>  :$XL &!2@ !<4M0 6%-$
M%A7Q !<5_P 8%/\ GC,  ),W  "(.@  ?CL  '0[  !K.   830  %<O  !.
M*P  128  #TA   T'   +1<% "83#  C$Q  (A,5 " 3&@ ?$R$ 'A0G !T4
M+P <%3< &Q5! !H62P 9%E< %Q=E !87=@ 4&(D $QB> !(8LP 1&<X $1GO
M !(9_P 3&?\ G#8  )$[  "&/@  ?#\  ',_  !I/0  7SD  %4U  !,,
M0RP  #HG   R(@  *AX! "(9"0 >%PX '!<2 !H7%P 9&!X &1@D !@9+  7
M&30 %AH^ !4:20 3&U4 $AMC !$<=  0'(< #QV<  X=L0 -'<L #1WL  X=
M_P /'?\ F3H  (\_  "$0@  >T0  '%#  !H0@  7CX  %,Z  !*-@  03(
M #DM   Q*0  *"4  " @!@ :'0P %QP0 !4<%0 4'1L %!TB !,=*0 2'C(
M$1\\ ! ?1@ 0(%, #B!A  TA<0 ,(84 "R*9  HBK@ )(L< "2+G  HB^P +
M(?\ ESX  (Q#  "#1@  >4@  '!(  !G1@  7$0  %(_  !).P  0#@  #@T
M   O,   )RP  !XG P 6(PH $B$. !$A$P 0(AD $"(@  \B)P .(R\ #20Y
M  PD1  +)5  "B5>  DF;P ')H( !B:6  0FK  #)L0 !";E  0F]P &)O\
ME4(  (I'  "!2@  >$P  &],  !E2P  6T@  %!$  !'00  /SX  #<[   M
M-@  )#$  !LM   3*@< #R@-  TG$0 -*!8 #"@=  LH)0 **2T "2DW  <J
M0@ &*DX !"M<  ,K;  !*W\  "N4   KJ0  *\$  "OC   K]@  *O\ DD8
M (A+  !_3P  =E$  &U1  !C4   6DT  $]*  !'1P  /D0  #-    I/
M(#@  !<T   1,04 #"\,  DN$  '+A4 !B\;  4O(P #+RL  C U   P/P
M,$P  #%9   Q:0  ,7P  #&1   QIP  ,+\  ##A   P]0  +_\ D$L  (90
M  !]5   =58  &M6  !B50  6%,  $Y0  !%30  .DD  "]%   E0@  '#X
M !0[   ..04 "3<+  0V#P !-A,  #89   V(   -BD  #8R   W/0  -TD
M #=7   W9P  -WD  #>/   VI0  -KT  #;@   U]0  -?\ C5   (16  !\
M6@  <EL  &E;  !@6P  5UD  $Q6  ! 4@  -4X  "I+   @2   %T8  !!#
M   +000 !$ *   _#@  /A$  #X6   ^'0  /B8  #XO   ^.@  /D8  #Y4
M   ^9   /G8  #V,   ]HP  /+L  #S>   []0  ._\ BE<  ()<  !Y7P
M<&$  &AA  !?80  5%X  $=;   Z5P  +U4  "52   ;4   $DT   Q+   &
M2@,  $D)  !(#0  1Q   $<4  !&&@  1B(  $8L  !&-P  1D,  $91  !&
M8   17,  $6)  !$H   1+@  $/<  !"]0  0O\ B%T  ']B  !W90  ;F<
M &=H  !;9@  3F,  $%A   T7@  *5P  !]:   55P  #E8   =4    4P$
M %(&  !1"P  40X  % 1  !/%@  3QX  $\G  !/,@  3S\  $]-  !.70
M3F\  $Z%  !-G0  3+4  $O8  !*]0  2O\ A64  'QI  !T;   ;6X  &)M
M  !4:P  1VD  #IG   M90  (F0  !AB   08   "5\   !>    7@   %T#
M  !<"   6PP  %H/  !:$P  61D  %DB  !9+0  63H  %E(  !86   6&L
M %>!  !7F0  5K(  %72  !4]   4_\ @6P  'EP  !S<P  :',  %IR  !,
M<0  /W   #)O   E;@  &FP  !%K   ):@   &H   !I    :0   &@   !G
M P  9@@  &8,  !F#P  910  &4<  !E)P  9#0  &1#  !D4P  9&4  &-[
M  !BE   8:T  &#-  !?\0  7O\ ?70  '=W  !N>0  7WD  %%Y  !#>0
M-G@  "EX   <=P  $78   IU    =0   '4   !V    =0   '0   !T
M<P(  ','  !S#   <A   '(5  !R(   <BP  '([  !Q3   <5\  '%T  !P
MC@  ;Z@  &[&  !L[0  :_\ >WL  ')^  !D?@  57\  $>    Y@0  *X(
M !Z!   2@0  "H$   "!    @@   (,   "#    @P   ((   ""    @@
M ((   ""!0  @@H  ((/  ""%P  @B,  ((R  ""0P  @58  (%L  " A@
M?Z$  'Z]  !]Y@  ?/P =H(  &B#  !9A0  2X<  #R)   NB@  ((L  !.+
M   *BP   (P   "-    CP   )$   "2    D0   )$   "1    D0   )$
M  "2    D@(  ),)  "4#P  E!D  )0G  "4.   E$P  )-B  "3?   DY@
M )*S  "1V   D/8 :H@  %R*  !-C0  /Y   #"2   AE   %)4   J6
MEP   )D   ";    G0   )\   "@    H    *    "@    H0   *(   "C
M    I    *4   "F!P  J!   *@<  "H+0  J4   *E6  "I;P  J8L  *BH
M  "GQP  INP 7X\  %"2  !!E@  ,YD  ".<   4G0  "I\   "A    HP
M *8   "H    K    *X   "O    KP   +    "P    L@   +,   "T
MM@   +<   "Z    O0<  +\0  "_'P  P#,  ,!)  # 8@  P'X  ,";  #
MMP  O]@ 4Y<  $2;   UGP  )J,  !:E   +IP   *H   "M    L    +,
M  "V    NP   +T   #     OP   ,$   #"    Q    ,8   #(    R@
M ,P   #/    TP   -H'  #;$P  W24  -X[  #?4P  X&X  -^,  #=J0
MW<( _P   /\   #_    _P   /\ !P#_ !  _P 9 /\ ) #_ "\ _  Z /D
M0P#U $L \P!2 /$ 60#O %X [0!D .L :0#I &\ YP!U .8 ? #D (0 X@"-
M .  EP#= *( V@"Q -4 Q0#2 .@ T #_ ,\ _P#$ /\ N #_ *\ _P"I /\
M_P   /\   #_    _P   /\  @#[  T ]P 5 /, 'P#O "D Z@ T .8 /0#B
M $4 W@!, -L 4P#8 %@ U !> -( 8P#0 &D S@!N ,P =0#* 'T R "% ,8
MD #" )L P "I +X N@"[ -D N0#W +@ _P"T /\ J0#_ *( _P"= /\ _P
M /\   #_    ]@   .X   #G  H X0 1 -P &@#7 ", T  N ,L -P#' #\
MQ !& ,$ 30"_ %( O0!8 +L 70"Y &( N !H +8 ;@"T '4 L0!^ *\ B "M
M ), J@"A *@ L0"F ,@ I #M *( _P"B /\ FP#_ )4 _P"1 /\ _P   /P
M  #N    XP   -@   #-  4 Q@ . ,$ %0"] !X N0 G +4 , "R #@ KP!
M *P 1@"J $P J !1 *< 5@"E %L HP!A *$ 9P"? &X G@!V )L @ "9 (P
MEP"9 )0 J "2 +P D #? (X ^P". /\ BP#_ (8 _P"# /\ ^    .D   #<
M    S    ,$   "X    L@ * *P $0"H !@ I0 A *( *0"> #( G  Y )D
M/P"7 $4 E0!* )0 4 "2 %4 D !: (\ 8 "- &< BP!O (D > "& (0 A "1
M (( H "  +( ?0#, 'P \0![ /\ >@#_ '< _P!U /\ Y@   -,   #&
MNP   +$   "G    H0 % )L #0"7 !, DP ; )  (P", "L B@ R (@ . "&
M #X A !$ (( 20"! $X ?P!3 'T 60![ &  >0!H '< <0!U 'P <P") '
MF !O *D ;0"_ &L Y@!J /\ :0#_ &D _P!G /\ TP   ,,   "U    JP
M *,   ";    D@   (P "@"' !  @P 6 '\ '0!] "0 >@ K '@ ,@!V #@
M=  ] '( 0@!Q $@ ;P!- &T 4P!L %D :@!A &@ :@!F '0 9 "! &$ D0!?
M *( 7@"V %P U0!; /< 6P#_ %H _P!: /\ Q0   +8"  "I @  GP   )8
M  ".    AP   (  !0!Z  P =0 1 '$ & !N !X :P E &D *P!G #$ 9@ W
M &0 / !C $$ 80!' %\ 30!> %, 7 !; %H 9 !8 &X 5@![ %0 B@!2 )L
M40"N %  R !/ .X 3@#_ $X _P!- /\ NPH  *P-  "@#0  E0P  (P(  "#
M @  ?    '4   !N  @ :0 . &4 $P!B !D 7P ? %T )0!; "L 60 Q %@
M-@!6 #L 50!! %, 1P!1 $X 4 !5 $X 7@!, &@ 2@!U $@ A !' )4 10"H
M $0 OP!# .0 0@#\ $( _P!" /\ LA$  *44  "9%0  CA,  (01  ![#0
M<P@  &P   !E  , 7P + %L #P!7 !0 5  : %$ 'P!/ "4 3@ K $P , !+
M #8 20 \ $@ 0@!& $@ 10!0 $, 60!! &, /P!O #X ?@ \ )  .P"C #H
MN  Y -D . #U #@ _P X /\ K!<  )\;  "3'0  B1P  '\9  !U%0  ;!
M &0,  !=!@  5@ & %$ # !- !  2@ 5 $< &@!% "  1  F $( *P!! #$
M/P V #X /0 \ $0 .P!+ #D 5  W %\ -@!K #0 >@ R (P ,0"> #  LP O
M ,X +P#O "X _P N /\ IQX  )HB  "/)   A"0  'HA  !Q'0  9Q@  %\3
M  !7#@  4 H  $D#" !%  T 00 1 #X %@ \ !L .@ A #D )@ W "P -@ R
M #0 .  S #\ ,0!' #  4  N %L +0!G "L =@ J (@ * "< "< L  F ,D
M)0#J "4!^P E ?\ HB,  )8H  "+*@  @2H  '<H  !M)0  9"   %L;  !2
M%0  2Q   $,, @ ]!PD .0,. #8!$@ S 1< ,0$< # !(@ O B< +0(M "P#
M-  J SL *01# "@$30 F!5@ )05E ",&=  B!H8 ( :: !\'K@ >!\8 '0?G
M !T(^  ="?\ GR@  ),M  "(+P  ?B\  '0N  !J*P  828  %@A  !/'
M1Q<  #\2   X#@0 ,0L* "X(#@ K!Q( *0<7 "@('0 G"", )0@I "0),  C
M"3< (0I  " *2@ ?"U4 '0MB !L,<@ :#(4 & R9 !<,K0 6#,8 %0WF !4-
M^0 6#?\ G"T  ) Q  "&-   ?#0  '(S  !H,0  7RP  %4G  !,(P  1!T
M #P8   T$P  +1 & "8-"P D# \ (@P3 "$,&0 ?#!\ '@TE !T-+  ;#30
M&@X] !D.1P 7#E, %@YA !0/<0 3$(0 $A"8 !$0K@ 0$,8 $!#H ! 0^P 1
M$/\ F3$  (XU  "$.   >CD  ' X  !G-@  73(  %,M  !**   0B0  #D?
M   Q&@  *A4! ",1!P =$ T &P\0 !D/%0 8$!L %Q A !80*0 5$#$ %!$Z
M !,110 2$E$ $1)? ! 2;P .$X( #A.6  T3JP +$\( "Q3C  P4^@ -$_\
MES4  (PY  ""/   >#T  &\]  !E.@  6S<  %(R  !)+@  0"H  #<E   O
M(0  *!P  " 8 P 9% H %1(. !02$@ 3$Q@ $A,? !$4)@ 1%"X $!0X  \5
M0@ .%D\ #19<  P7;  +%W\ "1B3  @8J  &&+\ !QC@  <8]0 )&/\ E3@
M (H]  " 0   =T$  &U!  !D/P  6CP  % X  !',P  /C   #8K   N)P
M)R,  !\?   7&@@ $A<- ! 7$0 /%Q8 #A@<  X8(P -&2P #!HU  L:0  *
M&TP "1M:  <<:0 %''P !!V1  (=I@ !';P  AS=  (<\@ #'/\ DSP  (A!
M  !_1   =44  &Q%  !C1   64$  $\]  !&.0  /C8  #4R   N+@  )2H
M !TE   4(00 #QT+  T=$  ,'10 "QT:  H>(@ ('BH !Q\S  8@/@ $($H
M R%7  $A9P  (7D  "&.   AI   (;H  "';   A\@  (/X D$   (9%  !]
M2   =$H  &M*  !B20  6$8  $Y"  !%/P  /3P  #4Y   K-   (B\  !DK
M   2* 0 #20*  DC#@ &(Q( !2,9  0D(  ")"@  24Q   E/   )4@  "95
M   F90  )G<  ":,   FH@  )KD  ";9   E\@  )?X CD4  (1)  ![30
M<T\  &I/  !@3@  5TL  $U(  !$10  /$(  #$]   G.0  'C4  !4R   /
M+@, "BP*  4K#@ !*A$  "H6   J'@  *B8  "LO   K.0  *T4  "Q3   L
M8@  +'4  "R*   KH   *[<  "O6   J\@  *O\ C$D  ().  !Z4@  <50
M &A4  !?4P  5E$  $Q.  !#2P  -T<  "U#   C/P  &CP  !(X   ,-@,
M!C,)   R#0  ,A   #$4   Q&P  ,2,  #$L   R-P  ,D,  #)0   R8
M,G(  #*'   QG@  ,;4  ##4   P\@  +_\ B4\  (!4  !X5P  ;UD  &99
M  !>60  55<  $E3   ^3P  ,DP  "A(   >10  %4(   Y    (/0(  3P(
M   [#   .@\  #D2   Y&   .2   #DI   Y-   .4   #E.   Y70  .6\
M #B%   XG   -[,  #?2   V\@  -?\ AU4  ']:  !V70  ;5\  &5?  !=
M7P  4EP  $18   X50  +5(  ")/   83   $$H   I(   #1@$  $4&  !$
M"@  0PT  $(0  !!%0  01T  $$F  !!,0  03T  $%*  !!6@  06P  $"!
M   _F0  /[$  #[0   ]\@  //\ A%P  'Q@  !S8P  ;&4  &1F  !99
M2V$  #Y>   R6P  )ED  !Q6   25   #%(   11    3P   $X#  !-"
M3 P  $L.  !+$@  2AD  $HB  !*+   2CD  $I'  !*5@  26@  $E^  !(
ME@  1Z\  $;-  !%\0  1/\ @6,  'EG  !R:@  :VP  &!K  !2:0  1&8
M #=D   J8@  'V   !5>   -70  !EL   !:    60   %@   !7!   5@@
M %8,  !5$   5!0  %0=  !4)P  5#0  %1"  !34@  4V0  %)Y  !2D@
M4:L  %#*  !/[P  3O\ ?FH  '=N  !P<0  9G$  %AP  !*;P  /&T  "]L
M   B:@  %VD   YG   &9@   &4   !E    90   &,   !B    8@0  &$(
M  !A#0  8!   & 7  !@(0  7RX  %\\  !?30  7EX  %YT  !=C0  7*<
M %O%  !:[0  6?\ >W(  '5V  !K=P  778  $]V  !!=0  ,W4  "9T   9
M<P  $'(   =Q    <0   '$   !Q    <0   &\   !O    ;@   &X"  !N
M"   ;0P  &T1  !M&@  ;28  &PU  !L1@  :U@  &MM  !JA@  ::$  &B^
M  !GZ   9OX >7H  '!\  !A?   4WT  $1]   V?@  *'X  !M]   0?0
M!WT   !]    ?0   'X   !_    ?@   'T   !]    ?    'P   !\
M? 8  'P,  !\$@  ?!T  'PL  !\/   ?$\  'ME  ![?@  >IH  'FV  !X
MWP  =_H <X   &6!  !6@P  2(0  #F&   KAP  '8<  !&'   'B    (@
M  ")    B@   (P   "-    C0   (P   ",    C    (P   ",    C0
M (T$  ".#   CA,  (\A  ".,@  CD8  (Y;  "-=   C9   (RM  "+S@
MBO, :(8  %J(  !+BP  /(T  "V/   >D   $9$   >2    DP   )4   "7
M    F0   )L   "<    FP   )L   "<    G    )T   ">    G@   )\
M  "A P  H@P  *(6  "C)@  HSH  *-/  "C:   HH8  **B  "BP   H>@
M7(T  $V0   _DP  ,)8  "&9   2F@  !YL   "=    H    *(   "D
MJ    *H   "K    J@   *L   "L    K0   *X   "O    L0   +(   "T
M    MP$  +D-  "Y&@  NBT  +I#  "Z6P  NG<  +N4  "[L0  N=( 4)4
M $&8   RG   (Z   !.B   (I    *<   "J    K    *\   "R    MP
M +D   "[    N@   +P   "]    OP   ,    #"    Q    ,8   #)
MS0   -(!  #4#P  U1\  -<U  #830  V&D  ->&  #7HP  UKT _P   /\
M  #_    _P   /\  P#_  T _P 5 /\ ( #\ "L ^  U /0 /P#P $< [@!.
M .L 5 #I %H YP!? .4 9 #C &H X0!P -\ =@#= 'X VP"' -@ D0#3 )T
MSP"K ,T O0#+ .  R0#[ ,< _P"] /\ L0#_ *D _P"C /\ _P   /\   #_
M    _P   /P   #V  L \0 1 .T &P#I "4 Y  P -\ .0#: $$ U0!( -$
M3@#/ %0 S0!9 ,L 7@#) &, QP!I ,4 ;P## '< P !_ +X B@"[ )4 N "C
M +8 M "T ,T L@#R +  _P"L /\ HP#_ )P _P"7 /\ _P   /\   #Z
M\0   .@   #@  8 V0 . -( %@#. !\ R  I ,0 ,@#  #H O0!! +H 2 "X
M $T M@!3 +0 6 "R %T L !B *X :0"L &\ J@!X *@ @@"F (X I "; *$
MJP"? ,  G0#F )L _P": /\ E #_ (X _P"* /\ _P   /8   #H    W
M ,X   #&  $ OP + +H $0"V !H L@ B *X *P"J #0 J  [ *4 00"C $<
MH0!, )\ 40"> %8 G !< )H 8@"9 &@ EP!P )4 >@"2 (8 D "3 (T H@"+
M +4 B0#3 (< ]P"& /\ A #_ '\ _P!\ /\ \@   .,   #2    Q0   +H
M  "Q    JP ' *4 #@"A !0 G@ < )H )0"7 "T E  T )( .@"0 $  C@!%
M (T 2@"+ %  B0!5 (@ 6P"& &$ A !I (( <@!_ 'T ?0"+ 'L F@!X *L
M=@#$ '0 ZP!S /\ <P#_ '  _P!N /\ WP   ,P   "_    M    *L   "A
M    F@ " )0 "P"0 !  C  7 (@ '@"% "8 @P M ($ ,P!_ #D ?0 _ 'L
M1 !Y $D > !. '8 5 !T %H <P!B '  :P!N '4 ; "# &H D@!H *, 9@"X
M &0 W@!C /L 8@#_ &( _P!@ /\ S    +P   "O    I0   )T   "4
MC    (8 !P"!  T ?  2 '@ &0!U !\ <P F '$ +0!O #( ;0 X &L /0!J
M $( : !( &< 3@!E %0 8P!; &$ 9 !? &X 70![ %L B@!9 )L 5P"O %8
MRP!5 /( 5 #_ %0 _P!4 /\ O@   +    "D    F0   )    "(    @0
M 'D  @!S  H ;P / &L % !G !H 90 @ &, )@!A "P 7P R %X -P!< #P
M6P!" %D 1P!7 $X 5@!5 %0 7@!2 &@ 4 !T $X @P!, )4 2@"H $D P !(
M .@ 1P#_ $< _P!' /\ M D  *8+  ";#   D H  (8%  !^    =@   &\
M  !H  4 8P , %\ $ !; !4 6  : %8 (0!4 "8 4P L %$ ,0!0 #8 3@ \
M $T 0@!+ $@ 20!0 $@ 6 !& &( 1 !N $( ?0!  (X /P"B #T N  ] -T
M/ #X #P _P \ /\ K!   )\2  "4$@  B1$  '\/  !V#   ;@4  &8   !@
M  $ 60 ( %4 #0!1 !$ 3@ 6 $L &P!) "$ 2  F $8 *P!% #$ 0P V $(
M/ !  $, /@!+ #T 4P [ %T .0!I #< >  V (D - "< #, L0 R ,X ,@#Q
M #$ _P Q /\ IA8  )H9  ".&@  A!H  'H6  !P$@  : X  %\*  !8 P
M40 $ $P "@!(  X 1  2 $$ %@ _ !L /0 A #P )@ Z "P .0 Q #< -P V
M #X - !& #, 3P Q %D +P!E "X <P L (4 *P"8 "H K0 I ,8 * #J "@
M_@ H /\ H1P  )4@  "*(0  ?R$  '4?  !L&@  8Q8  %H1  !2#0  2P<
M $0 !@!   L /  / #@ $@ V !< -  < #, (0 Q "< ,  L "X ,P M #H
M*P!" "H 2P H %4 )@!A "4 <  D ($ (@"5 "$ J0 @ ,$ ( #D !\ ^0 ?
M /\ G2(  )$F  "&*   ?"<  '(E  !I(@  7QT  %<8  !.$P  1@X  #\+
M   X!0< -  , #$ $  N !, +  8 "H '0 I "( )P H "8 +@ D #8 (P ^
M "( 1P @ %( 'P!> !T ;0 < 'X &@"2 !D IP 8 +T %P#? !<!]0 7 O\
MFB<  (XK  "$+0  >2T  ' K  !F*   720  %0?  !+&@  0Q0  #L0   T
M#0( +0D) "D%#0 F Q  ) $3 "("&0 A AX ( (D !X#*@ = S( &P0Z !H%
M1  9!4\ %P9< !8&:@ 4!WP $P>0 !('I0 1![L $ ?; ! (\@ 0"?\ ERL
M (PO  "!,0  =S(  &XQ  !D+@  6RH  %$E  !)(   0!L  #@6   Q$@
M*0X$ ",,"0 ?"0T '0<0 !L'%0 9"!H & @@ !<))P 6"2X %0HW !,*00 2
M"TT $0M: ! +:0 .#'L #@R0  T,I0 ,#;L "PW9  L-\0 ,#?\ E2\  (HS
M  !_-@  =C8  &PU  !C,P  62\  % K  !')@  /B$  #8=   N&   )Q,
M " 0!0 9#@H %0P. !0,$0 3#!8 $@P< !$-(P 0#2L #PTT  X./P -#DH
M# ]8  L/9P *$'D "!"-  <0H@ &$+@ !1#4  40[P &$/\ DC,  (@W  !^
M.@  =#L  &LZ  !A.   6#4  $XP  !%+   /2<  #4C   M'P  )AH  !X6
M 0 7$P8 $1 +  X.#@ .#Q, #1 9  T0(  ,$"@ "Q$R  H1/  ($D@ !Q)5
M  8390 $$W8  Q.+  $4H   $[8  !/1   3[@  $_L D#8  (8[  !\/@
M<S\  &H_  !@/0  5SD  $TV  !$,0  /"X  #0J   L)@  )2(  !X>   6
M&@( $!4)  P3#@ *$Q( "107  @4'P '%28 !A4O  06.@ #%D8  1=3   7
M8@  &'0  !B)   8GP  &+4  !?0   7[0  %_L CCH  (0_  ![0@  <D,
M &A#  !?0@  5C\  $P[  !#-P  .S0  #,P   L+   )"D  !LD   3'P(
M#1L)  D9#0 &&1$ !!D6  (9'0 !&B0  !HM   ;.   &T0  !Q1   <8
M'7(  !V'   <G0  '+,  !S.   ;[0  &_P C#X  ()#  !Y1@  <$@  &A(
M  !>1@  540  $M   !#/0  .SH  #,W   J,@  ("T  !<I   0)0( "R()
M  4@#0 !'Q   !\4   ?&P  ("(  " K   A-@  (4$  "%/   A7@  (G
M "*%   AFP  (;(  "'-   @[0  '_P BD,  (!(  !X2P  ;TP  &9-  !=
M2P  5$D  $I&  !"0P  .D   "\[   E-P  '#,  !,O   -+ ( !RD(  $G
M#   )@X  "42   F&0  )B$  "8I   F,P  )S\  "=-   G7   )VT  ">"
M   GF0  )K   "7,   E[@  )/T B$@  '],  !V4   ;E$  &52  !<40
M4T\  $I,  !!20  -40  "M    A/   %SD  ! V   *,@$  S '   O"P
M+@X  "T1   M%@  +1X  "TG   M,0  +3T  "U*   M60  +6L  "V    L
MEP  +*\  "O+   J[@  *OX A4T  'U2  !U50  ;%<  &-7  !;5@  4U4
M $=1   [30  ,$D  "5&   <0P  $S\   T]   &.@   #@%   W"0  -@T
M #4/   T%   -!L  #0D   T+@  -#H  #1'   T5P  -&@  #1]   SE0
M,JT  #'*   Q[@  ,/\ @U,  'M8  !S6P  :ET  &)=  !;70  3UH  $)6
M   V4@  *D\  "!,   620  #D<   A$    0@   $$#   _!P  /@L  #T.
M   ]$0  /!@  #PA   \*P  /#<  #Q$   \4P  /&4  #MZ   ZD@  .JL
M #G(   X[0  -_\ @5H  'E>  !Q80  :6,  &)D  !78@  25X  #Q;   O
M6   )%4  !E3   040  "D\   %-    3    $H   !)!   2 @  $<,  !&
M#P  1A0  $4<  !%)P  13,  $5   !%4   1&$  $1V  !#CP  0J@  $'&
M  ! [   /_\ ?F$  '9E  !O:   :&H  %UI  !/9@  0F0  #1A   H7P
M'5T  !);   +60   E@   !6    5@   %0   !3    4@0  %$)  !0#0
M4!   $\8  !/(@  3RX  $\\  !/2P  3ET  $YR  !-BP  3*4  $O"  !)
MZ@  2/\ >VD  '1L  !N;P  9&\  %5M  !';   .6H  "QI   @9P  %&4
M  UD   #8@   &(   !A    8    %\   !>    70   %P$  !<"0  6PT
M %L2  !;'   6B@  %HV  !:1@  65@  %EM  !8A0  5Z   %:]  !5Z
M4_X >7   '-T  !I=0  6W0  $QS   ^<P  ,'(  "-Q   6;P  #6X   1M
M    ;0   &T   !M    ;    &L   !J    :0   &D   !I P  : D  &@.
M  !H%0  9R$  &<O  !G/P  9E(  &9F  !E?P  9)H  &.W  !BX0  8?P
M=W@  &UZ  !?>@  4'H  $)Z   S>P  )7L  !AZ   .>0  !'D   !Y
M>0   'H   !Z    >@   '@   !X    =P   '<   !W    =P$  '<(  !W
M#@  =Q@  '<F  !V-@  =DD  '5?  !U=P  =),  '.O  !RTP  <?< <7X
M &-_  !4@   18(  #:#   HA   &H0   Z#   $A    (0   "%    A@
M (@   ")    B    (<   "'    AP   (<   "'    B    (@   "(!P
MB1   (D<  ")+   B#\  (A5  "(;0  AXD  (:G  "%QP  A.\ 9H0  %>&
M  !(B   .8H  "J,   ;C0  #XT   2.    D    )$   "3    E0   )<
M  "8    E@   )<   "7    EP   )@   "8    F0   )H   ";    G0<
M )T1  "=(0  G3,  )U)  "<8@  G'\  )R<  "<N0  F^( 6HL  $N.   \
MD0  +9,  !Z5   0E@  !)@   ":    G    )X   "A    I    *8   "G
M    I@   *<   "G    J    *D   "J    K    *T   "O    L0   +,)
M  "S%0  M"<  +0]  "U50  M7   +2.  "TK   M,P 39(  #^6   OF@
M()T  !&?   %H0   *,   "F    J0   *P   "O    LP   +4   "W
MM@   +<   "X    N@   +L   "]    OP   ,$   #$    QP   ,L   #-
M#   SAH  ,\O  #/2   T&(  -"   #0G0  T+@
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M[>[O\/'R\_3U]O?X^?K[_/W^_VUF=#$      P$A   !
M     0                    $    ! @,$!08'" @)"@L,#0X/$!$2$Q05
M%A<8&1H:&QP='A\@(2(C)"4F)R@I*BLL+2XO,#$Q,C,T-38W.#DZ.SP]/C]
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M_______/=#4+    "E*G______________________________^6-
M $^G______________________________9I'0  "0P&"5*Q____________
M_________________\L[#A,U3%M-3%[#____________________________
M_ZE@-F"&G[:LJ;C9_____________________________^"7C;[E________
M_______________________________M^?__________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________Z]G*O,?_________
M_________________________\^:@6U:1HCJ________________________
M________Q'P^)A   %2P_______________________________@@SP
M "Z'[?____________________________^L4Q       !=MUO__________
M__________________N ,0        EAS/__________________________
M_]): @        !=S/___________________________Z@U          !<
MT____________________________WT-          !4UO______________
M____________[GU%          !$U/___________________________*ID
M+P(   0B-TE8SO___________________________^FD:T$H/V-_E:>ZVO__
M____________________________U;*LLLSD^O______________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________Y;N7=V+(_________________________________]N>9S8*
M  *,________________________________R'\_!0    !>S___________
M___________________9@3D        \JO__________________________
M__^>3          CD/___________________________]QO&@         0
M??G__________________________Z](            ;^[_____________
M_____________X03            9.;_________________________[%$
M            5][_________________________N!4             2-;_
M________________________=!0             .,__________________
M_______YHEH3            (\7_________________________WYM<+
M        #;K__________________________^^Q?54Y(A$' 0(1(K+_____
M_________________________]^_I9F8FJ"LO=K_____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________________________^.^G8!\^___________
M______________________*WA%<P#@ =K/__________________________
M____THI,%0      <O/____________________________6?S8
M2\G___________________________J1/@          +ZO_____________
M_____________\!:            &I7__________________________XTD
M            "(3_________________________YUX              '?_
M________________________M"4              &K_________________
M________?0               %OT_______________________]*P
M         $SK______________________^E                 #SA____
M__________________\P#                "W9____________________
M_YF*82<              "?7_______________________MOHE5)P
M     "7<__________________________[*G79=2CPR+2PP.4?>________
M_______________________]YMW6TM#3V>3_________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________[]2[UO_________________________________GN(]J2R\5
M;_______________________________Y*%G- <     /,G_____________
M_______________6@CL         $I?__________________________^V%
M,0           &___________________________Z9"             %#A
M________________________[&D              #?)________________
M________LR\              "*V________________________>0
M         !"G_______________________R-                 "9____
M__________________^I                  ",____________________
M__]&                  !______________________]\
M      !T_____________________Y<                   !J________
M_____________\X                   !C______________________\I
M(@$               !A______________________^YHX!7-Q<
M  !H___________________________ZTZZ4AGQU<7!R=X&4____________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________]NZG8)I:=/_____________________________
M_\B393T9    '9[____________________________;CDP3         &[_
M_________________________]M\+            $77________________
M_________XLJ             "*T________________________PD0
M          .7________________________?0$               !_____
M___________________G-@                !J____________________
M__^=                  !8______________________]&
M      !'^/___________________^D                    UZ?______
M_____________Y8                    EV____________________[P
M                   8SO___________________^L
M   /PO____________________\                    *N?__________
M__________\G                   *M?____________________]P
M               -N?_____________________@G(QP54(S)AL4#PT.$AHF
MO_____________________________GDV-+.S,O,S];@_/______________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________________________^O3O./_
M_______________________________2J85E2"P2 87_________________
M___________QJW$\#P       $_@_________________________]5_-0
M         !^R________________________XW4=              ")____
M____________________D",               !G____________________
M___50P                !(]O____________________^*
M       NW?____________________\X                   7R/______
M_____________[X                    $MO___________________YP
M                    I?___________________[H
M    D____________________]P                     @O__________
M__________\                     =/____________________\3
M                :/____________________]"
M8/____________________]Z                    7?______________
M_______1                    8?______________________)
M            9O______________________R:R9B7UV<6QI9V9G:W!ZC/__
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_^+%JI%Y87?_____________________________W:9W4"P,     #'$____
M_____________________^"23A,           "/____________________
M____TG =              !@_______________________N;P\
M       WXO____________________^6'                  4P/______
M______________]                     H____________________ZX
M                    B?___________________YX
M    <O___________________[P                     7___________
M_________]H                     3?____________________H
M                ._____________________\.
M*OG___________________\S                    &^G_____________
M______]>                    #]O___________________^/
M            !M#____________________0                     ,K_
M____________________*P                   ,C_________________
M____@                    ,O_____________________]Q8!!04# 0
M     08-&,O_______________________SKX=C/S,W/T-+4U]SBZO______
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________QVL;_____________________
M__________'&HX1H33(8 !6K__________________________^Y?$88
M      !Q________________________UWPO               [X_______
M_______________?9 D                ,M?____________________]T
M P                  C?___________________\45
M    :O___________________YD                     2___________
M_________[8                     ,/W__________________]<
M                &>?___________________8
M!=/___________________\.                     ,'_____________
M______\O                     *____________________]2
M             )[___________________]Y                     ([_
M__________________^E                     (#_________________
M___8                     '3_____________________-@
M         &W_____________________?                    &G_____
M________________UPT                  &C_____________________
M_W                   &'_______________________]0/$9.5%E=861H
M;'!V?HG_____________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________________________^_5NZ.+<UJ5________
M___________________XOXYD02$%      !2_/______________________
M]YU6&              7P?_____________________E;!8
M    C?____________________]C                    7O__________
M_________YT                     -?S__________________Z$
M                $=G__________________\H
M +O__________________^X                      *'_____________
M______\,                     (K___________________\M
M             ';___________________]-                     &3_
M__________________]O                     %+_________________
M__^4                     $#___________________^\
M         ##____________________J#@                   "+_____
M________________1                    !7_____________________
M@0                    OU____________________R L
M      +L_____________________UX                   #E________
M_____________\D<                  #:______________________^=
M 0             '#A?%________________________U;F\P<?.U=OAYNWT
M^___________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________^-_/_____________________________^S&I8AM5#LA
M!P RWO_______________________]>262D             H/__________
M____________B38                 9_____________________]F
M                ,O;__________________Y4
M \C__________________Z<                      *#_____________
M_____]<                      'S___________________\
M             %[___________________\E                     $/_
M__________________](                     "S_________________
M__]J                     !C___________________^+
M          7S__________________^O                      #A____
M_______________5                      #/____________________
M)                     "^____________________5
M      "N____________________BP                    "?________
M____________RPX                   "2_____________________U<
M                  "&_____________________ZH*
M  !Y______________________]M                  !F____________
M___________W50                !%_________________________VHC
M*S4_2E5@:G5^AY&<____________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________HS[:=@VE.N?_________________________L
MLH-<.AT"        >_______________________Q6TI
M0/____________________^#&P                  !\O_____________
M_____Y(                      )C__________________Z0
M             &K__________________]T                      $'_
M__________________\.                     !W_________________
M__\Y                      #H__________________]@
M          #.__________________^%                      "W____
M______________^H                      "C___________________+
M                      "0___________________O%@
M      !]____________________/@                    !L________
M____________:0                    !:____________________F0
M                  !)____________________TA8
M   Y_____________________U@                    I____________
M_________Z(                    9______________________56
M               $______________________^[+P
M^/______________________JRD                 S_______________
M_________\E'      <3("X^4FB$[?______________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________________________________35
MR?____________________________K2L))W74(H#   2O______________
M_________\5]11<             $=C____________________$4
M             )___________________Z(,                     &C_
M_________________Y0                      #;_________________
M_]H                       ?L__________________\5
M          #$__________________](                      "B____
M______________]U                      "#__________________^=
M                      !I___________________#
M      !2___________________G#P                     ^________
M____________,P                     K____________________6
M                   8____________________@0
M   %____________________K                       ____________
M________WB(                     \O___________________UP
M                W____________________Y\
MS/___________________^A*                    M_______________
M______^@%@                  G/______________________>@(
M            =________________________WH+               %3/__
M______________________^B5VAT@(V<J[S0Y_______________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________MX___________________________TJ-Z6#HI(QP6#@8  )__
M____________________K%(.                 &G_________________
M_^1#                     #3__________________WD
M          #C_________________\T                       "R____
M______________\3                      "%__________________]/
M                      !=__________________^#
M       Z__________________^R                       <________
M___________; P                     "____________________*@
M                    ^___________________3P
M    Y___________________=                       U/__________
M________FP                      P/__________________Q <
M                K?__________________\#,
MFO___________________V<                     AO______________
M_____Z,                     <O___________________^-$
M            7/____________________^1!@                  0?__
M___________________K7P                  '?__________________
M____RDL                  /_______________________\M7   ,&"0Q
M/TY@=(NGQ___________________________U^?R____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________Z]3-Q\*^
MNK>SL*VIJ*7____________________=?E,_,",9$0D"          #;____
M_____________W8                       "G_________________[H
M                      !U__________________\'
M      !&__________________].                       :________
M__________^,                        _?_________________!
M                    V__________________Q&0
M    OO__________________1                       I/__________
M________:P                      C?__________________D0
M                >?__________________MP
M9O__________________WB$                     4_______________
M_____TH                     /____________________W<
M            *____________________ZP*                    %O__
M_________________^=%                     /__________________
M__^*                     /_____________________630
M         /W_____________________IRX                  -7_____
M_________________Y@J           &&"U%8.#_____________________
M__^H8W2!CYRKN\WB^O__________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________Y\NWJ9V5CHF$@'QX
M='!L:&60_________________[QJ2"T9"@                 Q________
M__________\                        #__________________]"
M                    W/________________^.
M    LO_________________.                        C?__________
M________*0                      :___________________6@
M                3O__________________A@
M-/__________________K@                      'O______________
M____U!<                     "O__________________^CT
M             /___________________V4                      /__
M_________________XX                      /__________________
M_[P9                     .____________________%.
M         -C___________________^+                     +______
M_______________,0P                   *'_____________________
MD1D                  'K_____________________\G0*
M    $5_______________________^AT$Q\L.$538G*%F[32]?__________
M________________U^CT________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______[]_/Q[NSKZ^SQ___________________9LIF'>6UD75912T9!/#@R
M+2@CQ/________________]+)0L                     DO__________
M______^(                        9O_________________7
M                /?__________________,P
M&/__________________;                        /______________
M____G0                       /__________________R0P
M             /;_________________\34                      -__
M_________________UL                      ,O_________________
M_X(                      +?__________________ZD&
M         */__________________],O                     (W_____
M______________]>                     '?___________________^3
M!P                   %[____________________-0P
M     $#_____________________AQ                   !S_________
M____________V%X                   #______________________[].
M       .'"P^4FJ&I<C________________________"?(R:I[;%UNC]____
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________________________NX=?/
MR<.^NK:QK:FGIJ:GKO________________^^AFU;3$ W+R@B'!80"P0
M%/_________________7!0                       /______________
M____-                        /;_________________=@
M             -+_________________L                        ++_
M________________X20                      );_________________
M_U$                      'S__________________WD
M         &;__________________Z                       %'_____
M_____________\<C                     #S__________________^Y+
M                     "?___________________]T
M     !#___________________^C%@                    #_________
M___________83                     #_____________________B \
M                  #_____________________RU,
M  #______________________Z4X           )'31.:XS_____________
M__________^9.4-17VY]CJ"UR^7_____________________________Z_G_
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________________Z\RYK*&9D8N&
M@7QX='!K:&9F:/'_________________844R(Q@.!@               )[_
M________________?@                       '7_________________
MPP                       %+_________________^S<
M         #+__________________VH                      !;_____
M_____________Y8                       #__________________[\;
M                      #__________________^9"
M      #___________________]I                      #_________
M__________^0 @                    #___________________^Y+
M                  #T___________________H7
M  #9____________________D1@                   "\____________
M________RE,                   "=_____________________Y@N
M         ! I1F;$_____________________^Y_'0P:*#=&5VE^E:_,[O__
M_______________________GH*JYR-CI_/__________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M______WU\.OFXM_;V-32T=#2U^#_________________SIZ*?'%I85M644Q(
M0SXZ-C(O+C'_________________TB41 P                    #_____
M_____________T(                       #__________________WT
M                      #__________________[ +
M      #V_________________]TY                      #<________
M__________]B                      #%__________________^)
M                  "O__________________^O(@
M  "9___________________62                     ""____________
M________<@                    !I____________________H2@
M              !.____________________TUP                    S
M_____________________Y8N               5,E)W________________
M_____^!R$P   0\?+T)8<(NHR.S________________________*;VY^CIZP
MP]CO________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________________________________G@
MTLC NK6PK*BEHI^=FYN<H*?__________________X)D5DM#/#8P*R<B'1@3
M#@D$  #4_________________Y(                       "M________
M_________\P>                      "+__________________M2
M                  !M__________________^
M  !1__________________^I&P                     Z____________
M_______00@                     C___________________U:
M               ,____________________CQ0
M____________________N#X                     ________________
M____Y6T#                    _____________________Y\W
M       0+U!T_____________________]UR%      &%RI!6G64MMK_____
M__________________^\6$149'6&FJ_(X___________________________
M____TLWA\?__________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________/OZ^_W______________________^ZYJ)V6
MCXJ&@G][>'9T<G-U>'^0_________________^M/.C H(1L5$ L' @
M   C__________________]I                        ____________
M______^;"@                      ___________________(.0
M                ___________________P8P
M____________________B@X                     ________________
M____L#0                     ____________________U5L
M            _____________________X4:                   #[/__
M_________________[%)               8.5V!____________________
M_^5['@      #"$X4F^/L]G_______________________^[6"DY25IL@)>P
MS>W_____________________________LYZTQ=?K____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________^N_GX=S9UM32T-#0T=/9X.OW__________________^XBGYW<6QH
M9&%>6UE85U=97F5Q__________________^_,1\6$ H%
M___________________M5@                      Z/______________
M____@@0                     S/__________________JR\
M            L___________________TE<                     F___
M________________]WP0                    A?__________________
M_Z(W                  4KE/___________________\MA @
M  PL4':>T?____________________6-,       #2,[5W:9ON7_________
M_______________#8Q@J.TQ?=(VGQN?_____________________________
MJ'^6J+O0Y_____________________________________W_____________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____W<[%O[RYMK2SL;*RM;G R=7C____________________EVQD7EE544],
M2DA'1DA+4%EFH?__________________IR8.!P(                 5O__
M________________SE                      .O__________________
M]'D+                    (?___________________Y\R
M        #O___________________\18                "#%:A/______
M_____________^E_'P          !B=+<9K"Z?____________________^G
M20     "%R]*:(JNU?S________________________3=1XF.$I>=8^KR^__
M____________________________KG*%F*S"V_;_____________________
M_____________]_O____________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_[^RJJ:CH:"?GZ&CIJRTP,W=[/___________________XI:4T]+2$9$0T)!
M0D-'3EEI??___________________YXN!@                   /______
M_____________\-6                   50?___________________^=[
M&@             )-&"+M/____________________^?/P         $)4IQ
MF<+K_______________________&9@\    3*D1B@Z?-]?______________
M___________KCC4K/E%H@9V\WO______________________________OG9_
ME*G!W/G__________________________________]+8\_______________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________]O+P[^_O\?/X_?____________________________BP
MGYJ7EI:6F)N?I*RVPM'A[O____________________Z.4$I'141$1$5&1TM1
M6FB#J?____________________^F00$           <V8X^ZX?__________
M___________&90H       0G3'.<Q.S________________________EB"\
M !,J1&*"ILST____________________________JU V2F%[EK36^O______
M________________________TH=\F+'+Z?__________________________
M_________]3.[?______________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________[>7CX^3FZ.WQ^?_____________________________]L922
MDI69G:.ILKS0[?__________________________G5-'24U15F!SBJ_6_/__
M________________________LE8 &C50;8NNTO?_____________________
M________S6\^7WN9M]?Y________________________________[I^#IL+A
M_____________________________________^/.Z___________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________________P
M
M
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MD]?A\1@T1$9'8V:#P?_$ !L! 0 " P$!               $!0$" P8'_\0
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MI&G2,K.,'BLC#7=:#E8*'1\+R;1%JHF)@SZG7C4KSM9MY/?5QU.)70FO3;Q
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M_P!=&?R5WU]'(T5H,J[^'XGB%8$VG.G#T+5FO'EX"QV=1:Z-XH>R@Z7YGM2
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M1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1(&4\K5GT@_\
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M&B@'73?N:I=B4^9<%%<"H:73UQAP<EB8LKUJW8O CV8.F30"@U:. ;I@LV;
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MQ,9BL^3/7W?4?M+(:Q;[=6+D+D;[#C7<+N/JS'=4X/U51S6[UKS=>#6$7/\
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M+<Q>5# BS54JMY,[$D4YZSV _BI!!"JH_())^?!%@IX3@LX=E(*8K;'3P5%
M1K]-O0/@68$$,SN>@" O435E4ZS5PX/:'J[-BO')F=7>Y&24;.5W;A873-*=
M28.W!E'JX$=N6JKI%($$4%DTFK<B6G^CG&&VJ]SR-MM-#YT-G,<L:S78]KO[
ME"[5SVV%KGZMLJ:U%"*CJM=878^JN6\+:ZUXNA+KZ]+"K@^&5ULJ2FM!5<V!
MM%586A"U-=JU6.;'L1WML9JDNK]>=,J2U.@7J98U:'$LHP2ENK%.%%UEX]P,
MF#LSEHNHY7.L@X%4BHJGZ@& >&=3Z?X1E*6<7BO0Y[,C+IH34'S6ES;19]0+
M?<JL]Q_<1_)7\B&!$Y'U1ZB\BZ<SR%#'2FT'+H?)XZZU1*]%8RFD575K6BI9
M6%90H"D2?95:LQ@(EC:[!1Y6[8K-N5E$1[0$&A>/*U1!!NF"38O$>5 G*D'$
M>!0XY-JX_!G""C%DI"5BI!5FIK"5#\5H$10M8_1!TH_02!?RG)Z2YT\COT&R
MPW6&_7HM-EI_-KFRQO.P_J[=L?YR=         .  'B  #X@ /S &2Y _/YC
M$1B(Q$8B,1&(C$1B(Q$8B0,EY9KGTB2]F+XB3V(D E\J'_H")\?_ +1FO[_[
M<1)_$1B)J[V>%.C:-[Q??$#@SVC+J$C2- 15CP>++OU#'=@D4'Q'RCT713BL
ML+<QSM_R0$Z80>F7G.4\KJW6[%PMU=*TBMZE7&]#,]@4>][C4]J2S&L+X_ G
M?)XMZ;XWQJL4Y^8]39GM:XV)8S<@FM4KK+M[(K&DEE"J'9RWR>YM%DZ<(Q$8
MB,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1(&4\K
M5GT@_P#8LCB)/8B>??NDD]N2*[.T]$ZOU)=MQ5NZQUMH^V*YJEG7G^W6=.M%
M*GXAE+Z[3MD[$UMG*QUD=1+Q[+RD9<DX^/;K 2FRXN3*LJ_74=5^?#>NI<6L
M>#ZL1J73DVU[,%N.WSN#UI3[::RW=1\[EHK^HQAS>+3C;AD8;JFS';BUX;Z<
M^T6-DT9%N;]H5NE+566VM5[==58TYU"VVW,UHI]FS"WN94!LZL4';\#L-/M[
MI-6"-<0K"/;REM12=H:1J$'*-C,=>ET\R;0;6K-"(-R.$I%961[^)@!)%L1$
M5/0WW>_A2VULSZGY3D'NL'N'?:KYN.L%FMW_ ';5-:]WT_M^7WB\NY8^*>;H
MJ]G8U=:7U9DXS"E-2^ X^LI?O4IG4 6#2M8J&CRZ0T?1A$4AR?5^,\FQ_#XN
MXM.'_N$\KI82+D/E)7?HL]_5QV9_0_WC_K_]YJ?XE_WO\I<68FT8B:IPS9/_
M  ?=H>K,8]:1=4/:M_GF,6DY[BL^F)A2&W]'(MW9T%"("[F+DD5-R")TDEQ.
M4QC'25/D7UC79=PEN@9SLM'#4[<V9+5I>^_A21DI6TJXJ=[N,J1793X]JQ '
M76O_ &:W9LGJ&["ERXJ*?5?(<?LT/0UM=%7JA4W[]!I\J_>04^HKK'5''D?-
M02X(FU"*J;A%)=(P&263(JF8. @9-0H'(8! 1 0$I@$. B'C\0Y(5E=5=3VK
MJ&4C\%6'8/\ B#W.CHU;O6XZ9&9&!_(925(/]Q!$[,VFL8B,1&(C$1B(Q$8B
M,1&(D7+343!-R.IB19QJ"JR;9 [QPDAWATKQZ+5L50Q3.'2PE$$FZ('64$!
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M=]C];LH"2<82W0X(,62,9<II=!)J\*XXMIH4)TSMT05UE&:[I_(OU#MUNEP
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ME+7K6+65"Q$[C'6O?EL9G0)<I#I;;2RN._;/O45VWU+Y^/G9359:B>35HS@
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M4=&GAL58CI!59)=\D+J*EQ1(NF1.<A'B\1,H=)RBW<)BC),G).59!(_  ,!
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M:4(^GVA^*;GG2((K]UB5>[MRBL0QG2W3;%3!1450325,0_/85\?%.0N\[AG
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MR"0?@R^6<5%QX 5A&L&(!\0,V;=L ?! GB!%,@!\ I2^+_T0 OQ  9&9W?\
MB=F_^)B?\R99)557\5UUH!^/!%7KXZ_U0/T^/[I7YK.D8B,1&(C$1B(Q$8B,
M1&(C$1B(Q$8B,1&(C$2!DO+-<^D27LQ?$2>Q$@4OE0_] Q/M&:Q$GL1&(FIE
MK1=(=JZG/A\)#'A4*NH1-BKP:F?C_AH@G"LPB!%#"Q(A8F IF_)%-(I1XBJ
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MJN9O<6HHUR5CP9Q8?))]&.V6J9$3VVEM$@8.4W*;6B3*S@TH8%@:/&[QS?\
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M?:Y(4JBW;?XG?,HXK1Z!+1,3",P1,]0;NDD7<E%'9QO5*Z7?L'!6DN14'Z;
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M</ZOY3-&0)?QB(Q$8B,1.)C%(4QSF*0A"B8YS"!2E*4!$QC&$0 I2@ B(B(
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M](/_ &+(XF9/8B,1(Z7\DRGHY[_9E<1.<9Y-C_H+3^H3Q$BY#Y25WZ+/>/\
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M?)Z>X_/:NK1[_*;PH!W\I8->C_5+>TO@F;(C.BV&G%GS9U<>5=2?$R\
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M8B1TOY)E/1SW^S*XB<XSR;'_ $%I_4)XB14A\I*Y]$GO^2._/_?_ (9G]/\
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MDE:LH7*/!QHW9[!77;.U;3\7&2S:W7*5?;%OS<H]WL]B31*WAA.!@4)5:\W
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M$$$@CJ<FS9NS01:M$$6K5NF1%NV;I$10013*!4TD44RE333(4 *0A"E*4
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M@\4BGD"*2$N[:2C(PFCG?> ,#%NJ^SJ$K]WPL9:ZSQSW%S8A%.T\'?R-5)8
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>(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g428534g43v59.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g428534g43v59.jpg
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M;IB.L3B)]&+1GV;UO[D3-*SSY>LS0\U>WYLD9E"PP!@# & , 8 P!@# & ,
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M(B.?DH$A!;VG:KY!9G]AE$24JCO_ #JK-REPD[ #2_%M_I>RW\&W\>[]._\
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M,T/-7M^;)&90L, 8 P!@# & , UL=D9] G5GVB\I/YL=X8+3\Y^SY(V3X*C
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M8]Z]:^9$NY^I_(XSLWS =8G$3Z,6C/LWK?W(F:5GGR]9FAYJ]OS9(S*%A@#
M& , 8 P!@&MCLC/H$ZL^T7E)_-CO#!:?G/V?)&R?!48 P!@# & , 8 P!@#
M& , 8 P!@$,^;=&F[=K%E*11F)&E*D'MDFC/'(MS^;TXQ=MW&9024\H=*+*I
MIIHB*8&,8/CAF6EI3Z^E;+UMKZ%)]WJ?U,/]GJD9%;; *B5-91"B*%;*=XC@
M4#$M*R;D$SE#O-U4W"1DU"B8# <IAZ%42,>]_P#I_P#>_LB*_3[/[FRS-<R#
M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M?LUB_P!E9J\0(X;JA\OJ414(</6/J',18]F , 8 P!@# & , 8 P!@# & ,
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M]M.6,E"J<;.3$\A/R4H3%]/.]_\ PN6+WM+_ ,L9Z?\ ^L7:_P#_ &>]<_\
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MD$>^\6,<2]MH_P#IZ^OFEW^S;V$ ^S\DK?%<->)&U)<VC*1;+'Q-M4S4=V;
MVE?[C8[YL]I2VMC:K[=IY6-!7G:JE3HB\W*ZKI7FV2L:>MM';&:B5DA6EA,W
MU:?CU739;>#]#\>GBNIE6'[0C<UMHFK(N-BM)4#?FT(3DZL^J^W LE/I^JMF
M<;GFM8AYHC8*L[<:Y-EN-@3OZ^POV@8BD<NLH"2LE7I%R@2(6ET'+Z]DTOU>
M^_5?IT^/>7@UYM[<:VJX.;C*:*J&MF?+BI\2X>;7KUN=M*M+7C1>H]Z5Z^72
M\O=CPD/(Q+U>XSFFH>&0J]3-8KU8];3@3<*W7DZF^$;=.F_=O[.9K]?T]74_
MLOR/W-5=E;&4AJ=I_;VR8GC7Q@MAWVJ7\PBC?F-EY.[FU[9H2AL[ULZ#JDS)
M,:M#V*R:ZJZ\]7)&P7Z83H[^_P ZQ"#?8&R>W?MN_9T75[+?9>G]%T14=2<Z
MKMN[8U6KU!<:;+6H21T:SV8UOR=JUEL"V06WM8M+*K=]84ZQ3BUIKX,[U*J4
MR)I-HJ5B5<RNO]A0$I<XR1:I/X\0UM\?8T^J?LZFTO!!CW9EKM5.K99>G4-]
ML26&1:M#0+"22BUDF:Z;@RTD9=1H].HDW4210,@@V45,9T14>X@DLH6T4F]G
M+E7CMO["'OMT6[(\+[_WWX*W_P!UFR(_NE/WO[7 /A?$']YT_98.O<_M=.H?
M)\N7Y(?_ $J_;_R5WGX+^>TU\U[DGO<\_!D"]66<$TQ&%\R>5-DO/'>>H!YK
M\4&:@I^<.ODGB 0XD\;O 0W3H.=UPV?1+H^OA^OL*<\O'?V(V%^G_??_ (5;
M)[W!_P K9@Y(?_2K]O\ R7WGX+^>TCYVC]FM$SV?TY;):J&HUQ';?%LK>O2M
MA,U/'+R7+G3M769.++&QZCN/86>OR;Z(EU$(I9<]>GY.*>1D@V<NF+O&TDVD
M]UX]VYDCOZ>CV?=ZGW$<+UOZ\<?^<'*.Z6^LZNJ,J7COV;=.BT@V#.6;5-(]
M-O*3D[JN;V3;9R2IFLE:\"K&/J$5/KDBFK-RA5M?M9JT)12"1H2"VV\5_P"J
M?AW*,7_/@F^AEZP<^-GZ_>:\K=SL7&&PW-S>>.E=OT;K.5LLO"+U/D+S<?<7
MX*\P=AL5D@&<>1K36<C/OH"N!MES7=F4Z]U2S/X^JQ4/;)\1MX)[>AOQ2W:?
M]NO=U_0EOP4V?>]P<=(.\[+MD%;[F\O6X8J5?0$,E (1R5;VU=*[&0;J+1EY
M<K=S%Q<6S12*95LN6.%@F[1<.TUY.0$/H_YU_7V]Y,'!!"SE)R(Y#Z5GJM&:
M8XA6GD;%340\?S%A@KNTK3:OR#=YY.E#+,2UFR/5UU6W=?"[6*Q:F35(BU,Z
M52> VY+H>CZ1J=5\]1XAQ]&LJLC"NF[%E>[H..[L4_+T124OP\J<Y;IN7*G'
MFZL[0>-N->%<O3Z.%NS74..,?+QK;LK-P]6KP(85T+>2.+.I8&=;.<X-6^4D
MJJVI*-;LE&SDB5*\^N>#6,D7*/9?[";*MF#Q=)PKLES*I-U$6ZBA%E(QCK9L
M]DDTC% YV#-P@Z>%*+=NLDLH0Y?OU\)\+2LA%\<8<E*<4XK"C6Y)R2:5D\Z4
M8-KHIRC*,?.DFDT=;Y';'VOUT7V1[ -:A*%-DXSEKT\B,)1A*2G*BK0H6WJ+
M6[IJG"RQ+DA*,I)J&/#'M+N>MR9[*(?C?/\ +!%M:3282=?=FH9M?+S:CMRK
M4#O6]7GV#Z)1\(#P44X22F89NFX3<OW[)5DDQY)Q)P5PKC2PFM9IT!RH\GR7
M1^]K+52C%9"C+(IG"Q[[6V)NNR334(24G/J[LN[>.V'5*==4N!<SM%C7J+O^
M\85CT=Z+/+E;9+3'9#3\RF['AR[X>/.,<K%KC.-EUU4JHU3A2YX\ZSJI$-V7
M.Q0*=0A3#Z6DB="F, "/?5UD1(O0!$>\H<B9?E.8I0$0XN^%>%TF_P#'.%T3
M?_R>_P"V<W[DWX)G;,>U_M=<HI_9^UM)R2;_ ,216R;2;WEH,8KURDHKTM+J
M7YR[J>]'N\-(;>XUS+N,WIJW3.V+P_T=(V=*.I/(JG,[;IAE8]*WWN++Q#29
M78SLT;56QS)*IT39!8MZX<K5&3M$?(<!DDI249*<5)I22:4DGLI)-)I-==FD
MUOLUN>D:9RG37.RMTV3A7*=4I0G.F4H[RK<X.4).N3Y92A)PDUO%M-,PCIOF
M.]4UF9725=AZ&A;=5<\^7+17?E6MD:^7?ZDY,S53<:BF81.R5J0J,O06LFSK
MUZ%9Y+I:\B6=6BX.OOH5ND5"IE:7I?Y5OZ%NN_N[NG3N[BY&7-SDW8H#8NPH
M^#U!2ZY4>6/#7C.UUY<M?WQ_?H\>6S3@+-K2MHL#/:\'&(3FL8_EE>8*0A6U
M203L,W5*X^\IK[8DM%OPY5TZ_P"F3[]_-YOT]/+[F4HG:"[HJ;-U)[*D>/["
M(\G[0^IHS@U#95;B(J]<*N0D3I:J6J:%K?-AR[BJ[':R!GTI0X>&<V*)F56#
M*+NDDBN<2"-O#?\ T^OJMW[GZ>GZEPZYW[9MV\KN-3N<%C$R-4O/:$ZCFV%:
M?G;0T\SU>ZULQK4E*P;*V7&+)*MV#LH+E+8IY!"3-)NXQVS;/QCVPEI)/T](
MM>_KL7KKQ.)W)S7YW4CD2J:2'4P:3;Z"H=@F7T;!P&A+1I^#G)K<U(BTWS!!
M*S3NZW.TJI.;8BT4[17%*'#51G88Q"(13<B.Y+;T[M]W>GW>K;9^'7]#PU;D
M_<*:FTU_K="$N-!TWR:XZ\*V[*SK6"W;<O5,V%I[4,O"\@RW9*T(,)UHT3V0
ME>Y0#5R50M6O*)<[%^U\?*O7!:X&V_7HMTW^BZM;?IW=/U:]9AS57:2;GFXW
M2'I'C=-L'/(?5G""]UJQ0E;M\)6-82O**Z;;I]A879.8V1-K6B-3=ZTC8Z@N
MF4I25'%ON</5Y09 #)2K@''9M=^SDO9'V>OJ1Y;\DMH:BT7M^:ID[2YO8](T
M+_Z1!M:H[(<,[+.OJI9.+_/6,&IP,-"2%]EH!6E2\1<*V>*@; TGI*KL*=5&
MD7.O:Z[E8F4%MES)=R;KWZ]-G%=>Y=>_K^I.-?E';*-R$N.NT(S73N2O>ZN*
MFHW&VFL1;3UZ+=[,TAM&X>?[?75=B2#,Y'LYK*-U12&,'.5A,UMV%6BS+J>>
M(F0DA3;?QZ)M>_T>.W5OV]%MN8DLO:'<D(IG=WB56T['$U%3=SVBV#)5:[OF
MVR0T1S*DN-$J\H;Q'8\7^R$)LNKQI[57W,PVNZE(L)U(IP.P(M D@Y$\OKZ[
M[?MYEU]NW=UZD\-)\A[=?-W[:T]?JZVJ<E375PDZ,5C".GL%?=>0.R)BF1UU
MK.RHZU6"NSKMFFC%P&RZ+,0=!N^M]AI246K"S]7>P5G>B&MMO^WH73;^_<U[
M245K^:UE^H)C\.<Y,>]>M?,K+N?J?R.,[-\P'6)Q$^C%HS[-ZW]R)FE9Y\O6
M9H>:O;\V2,RA88!IJYJ;2F=:\LS!'\F-O\:VDWQWUL*[O1G!B^<LYR\N(W96
MZ01;W^PQ&F]Q5ZHQ532D%E*!#,&,#,OW=HV"^L#J08DJZ3062W7H[WWR27H[
MMVO;[#8'Q%L2MLX]T.Q+[$MFV%I5Q=7"NQ+UK1?3ENM1R[ M2)I">U>Z@JPZ
MI+\@I^1G@G5;K[EL1L0SB$BUE#L4!#Z-^CU=?CZ?7W/T="26"!@# & :V.R,
M^@3JS[1>4G\V.\,%I^<_9\D;)\%1@# & , 8 P!@# & , 8 P!@# & 0XUG_
M %DY;;UL@?O&]4K=<IK8P_&!!1VE&*NB /R <SV D>G3H(%,H7^)NN672N"\
M6Y?3?W_/VT764GX=/Y[F3'S$7(9:-_J%R WSJL_[IA,NVNR:VC_81*VDCIJ2
M:;8/4!@3\\Q[("@'>*6)5_M%(8P99_BA"7A^!^SN]ZW]3*)I-Q_7=>Y="9N8
MBXP!@# & , MYO4JHSFG%D:5FOM;$[*<KJ?;PT<A-.2J!W5 7E$VQ7RP*%Z%
M."BYN^  !NH  9\2CAKAW&U6[7<;0-%Q];R5)9&L4Z7@U:K>IK::NU"%$<NW
MG72?/=+F6RENDCZ5NLZQ=@5:5=JNI6Z92XNG3K<[*LP*G%[Q=>).UX\'%MN+
MC6N5MM;;LN'/MGS2W+#3ZE;BQI+95JY9R0T@E+1!;#"1DT6*E4.H(2<:62:N
M08R"("()/6H).4^H]Q0O7 /%/Z\H%J<N7MHHU/LCQ[$?L^\=S]9A9AR[@?+4
MY+S(Y7D63E5>(\XI)/\ S:J<[+RU)-UX/CD*H %GTK3<75G>QGU@L]DV@[V0
M\=-7Y]@,:,=K!:]3>V%Y6M/P<53Z94(=;75++;+*S@D[,PL=P?-)IZ2V6^RG
M!LHW$M^SW^_JWU?I+N1UUKYNO&N4*)34',,SEX^'<(UB$27BF%@.JK/,8U4C
M$JC%G-J+K*2[9J9)&2.LJ=X18RAQ$04HVG-1'A82M'U7K@U<K2$TUKD :CUD
MT+ -;(T=,+$VA(H8L6,4A/,7SUE-(L$$$Y1H\=-WQ5T7"I#@5V*HE(@FDTPA
M*;58=C9!.:Q,HJO1$>TGC*,RQZAIILT9HHR@G8%*Q.+XBXF9E*V-U1 "8!:4
M;H?1T.HHM$:9U1%+*M562JL;KNH,5%6:YTU%FBBC6'2,=JLHDD=5N8124.FF
M8Y!,0H@)W?B_>5N3U9K":,Y/,ZXH<L=Y8V-P>'DZA7GYG5NC$0;QMI<F=1RH
MKV..;@"#&;5$TFT1 $F[I,@=W!&[\?T]G@?=WK77+^-M,.^H%)>1%Y=F?W6*
M=U6"<1MP?',F8[RTL5F!VM@=F,BD8SB62=K&,DF(G$2%Z ?ESK/6[U8[AYK^
MD.USQ45 G7<U2!76/!P3M!_"0QU%6!SFBH9\U;/8J.$PLX]VV0<-$45D4SE
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M,F)#$,(&S);U:DNZ44_;Z?[;E(=S73H]B8&8RXP!@# & , 8 P!@# & , 8
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MDE.5^[SIJI*$$Q%$U"& Y#D,)3E$#%$0$!P6GYS]GR1LKP5& , 8 P!@# &
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M);M=5W/T]WI12'277INOY\C;%FL91@# & , 8 P!@# & , 8 P!@# & , 8
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M41*8H@("(" YA+G[P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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MW2[UX2Z[^_\ G>4BVGROT=WZK^?SH3!S$7& , 8 P!@# & , 8 P!@# & ,
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MB\?TW]!1;Q>[73NW\.[P-HU'V'3-D1!)NES["<8B! 7!LH)'C%4Y>\#>28+
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M%^FH<5?>^_V]_M)=X(& , 8!K8[(SZ!.K/M%Y2?S8[PP6GYS]GR1LGP5& ,
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M%"X=CWP2M)E%H[6MAHCQ0PG\MI6P+<W,FIUZE4096&3L<2V$@]!(1".32 0
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M]9TB ID2!3I1+,I7;L" 0\C)KB*\E(JAZS=YX\.JH0AC&\!#P6Q#>$B0 V.
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MZB<L?',(EBTC(MFVCHY@W2:,F+)!-LT:-D" FB@W02*1-)),A0*0A"@4H!T
M,Q%^XAKVA'(8>-'%/9=\CGOD=RF6 4+7?</W'0W2WI.(]B^9?]MS78TLK:RI
MCU!1.!43Z&$P%'DG"6DK6==P\:U)XM,GF9KEYBQ<;:=D;&^BA;+DH;>VWE4]
MUMNNK.V?C.7 W9YKNK8UCAJN74M&T-0_\V6K:HI4464I=968=/WC4%'KS+$<
M=FVDXK]E)QA]&6JH6]6)B*<NLU=A&E7)^\&;EOC6F7[P@'>.SZEJ3)<O0QD(
M^2*H4W>3./FGAFR7:QVO<<=NF?S7:-7EY'!O9A"Q-UU\.:-*S3\C6\6,M_)Q
MU2U9=M7++\%^H:S!KEE4UW=POPS'L8[$. ^QK'A&C7K<*GC'M*G#976<4Z]"
MO49:3E2CTLGI-4L3!E)K\>/IFES3YE9OM^SO(^(, 8 P!@# & 6U:Z=5[S$+
MP-MA&$[%+@(F;/D0.*2@E$H.&BY1(Y9.R (@D[9K(.4NH^&J7J.?!XCX7X?X
MNTRW1^)-)P]8TZ[=NC,J4W5/9Q5V-=%QOQ,B*;4,G%MIOKW?)9'=GU='US5N
M'\VO4=&S\G3LRKNNQY\O/'=-UW5R4JLBF32YZ;X653V7/!D37&J-P:(<+2VC
MIM:ZTD%#N7VK+.OX[ANF8XJ+C7W8G1*97NBH8GDIV+TYRI X;SROQ!\X7=G'
M:9V/W6ZEV2:M;Q5PFK)7YG9YQ!;Y6^F$I.=ST7)<JHN>SG**QYX>7*2J5U.L
MV?A.Y*^,>">T.NO"[0,"&@Z_RJK'XPTBM5UVR24:UJ="4VHMJ*;MCD413FZ[
M-.ANS*^M.1U"V =6(?K*T:YL?$3E*C;#%C7S=PW*8SHC)RZ*V1?E0 BACI]Q
MM(I)IG5=1S=,.\/8W 7;EP=QI.S3,RRSA'BG#YX:APUQ'*.#ETW4Q;R(XM^0
MJ*LR-7+-S@XT9M<(3LOPJ*US/AW%79?Q%PW&&;C0AQ!H61RRP];T9/*Q[:[&
ME5*^JEVSQG/>*4N:W&E.4859-LGL9X:NVCYNF[9.6[QJL F1<M5DW#=4H")1
M,FLB8Z9P P"41*80 0$/E <[AQ\G'S*:\G$R*<K'M3E5?CVUWTV13<6Z[:I2
MA-)IIN,FMTUWHZ\NINQ[)TY%5M%T'M.JZN55D&TFE.$U&47LT]FET:9Z,S&(
M8 P!@# /@Y<MF;=9V\<(-&K9,ZSARY530;H(IE$RBJRRIB)I)D* F.H<Q2E*
M B80 ,Q7WT8M-N3DW58^/17*V^^^R%---4$Y3LMML<85UPBG*4YR48I-MI(R
M556WV5TT5V776SC7555"5EEDY/:,*ZX)RG.3:48Q3;;V2;(%[^Y@1\0R& TW
M,(24X#P$I6UIQZ3^&C6X)JB#>*6>D.QD7[A4@"5T#5[&D:I+^"==<P';>.NV
M;[36'IF(]&[+]3JSM765&O4.(Z\*O,TO I4;&J-.LRX3Q,[,OG#ID?=\K!CC
MPN=,[;I*='HKLW[$LG.O_J7'.#9BZ>Z'/#T>>3/&SLNQR@G;F0QY1R,7&JA)
MIU>6HRG=.OGC76FK;8TWLSE;N6+DSUFRT5LA7EFC)[,62&!HX?.7B;A<H(A%
MPKYBLLW22*+@J;-H5,JS4PD.*ICY\#LNX]^T7VI:=GST'7N$,>K1;<;$R]4U
MW2ECW95^3"ZZ*J6GZ5EXEME%=<?+1ABXRA&W'<HR=DIGUN.>%.QW@7,Q8ZKI
M7$-UFI5W9&/@Z7G>6KHJIE76W-YF=CY$(6SE+R3E?<Y2KM2<5!1,R!0.7SWU
M/MX4Z-*;^T2*JL<X[O\ >!5'%69K#T_AU4 1_P!G4<[0_P &?::RNF5VM<+X
M,7WQT[A[!NV_2,[N'<:WI_\ >+]3@W^).Q2C_P"+]G^N9;7<\S6<JK?]7&K5
MKH+V1:V] ]!O(%]ZY/DY+MNO]H(NJII?[P*9O,QG=_V"!0_W!U]3_I'VT9G_
M ,H=OVIX^_G+3N'H5]_?RRHU33^7KW-16WH2'_4#LVQ__BG9-A6[=SS-9G/W
MJS!RM_4Y>/5^G'>TN+FV9.FR)66Y[ILB235;. J<\^=,(B4315 YRHI/)]['
MD?(&!-PT!UX:(G2$H*IJF3,'">T+[/G:/J'"V='%[4^*>.L^N>/>N'-9R[\/
M3=0A58I35=>3K&5AQRZ7RWXWWAPK<JW%6PLE"1R?A#M<X-Q-=Q97\":%POBR
MA;4]9T['JR<[#E.#C%SG3IU&3+'L3=5[IYK.6:;A."DC&.FHW<_&4TI<;/K&
M<DJ7/(I,[ UC)!BYE(@D:J95O-J1K-P\[I$B.':13O2M&YDS*@L]9%.B=;@'
M9;@=J?8&]0XGX@X U?.X5UBJO&UK'T_-Q,C4-,C@V2LIU:S!Q;LKEA5"[)KC
M++6-2ZY3\KEXL95RMY9QWE\"]JZP]$TCBS3\77M.G9?IMN7C9%.'FRRH1A9I
M\<J^JC>4Y543:H=UBE&/)1?*,XU["]>;7H>TH[SA39]K(G33*=[%JCY+-1HF
MZ!W7\6L)7*)0.(IE<D*HR7.4WDSE8H=[/:W!/:-P=VA87WWA;6<?.E7",\K3
M[']WU3 <MERYFGV\M]45-\D;XQLQ;9)^0R+8KF/-'$W!W$7".5]VUW3KL52D
MXT9<5Y7!RDMWOC9<-ZK'R_B=3<;ZTUY6JMO8R+G.#C!$+FAP]H/,K4SNA6@4
M82U19U977U\18-W4I4I_PA* ")RE<.J]+ 5)M8H9-RW+(-DT'"2J$E'QSQKR
M'AOB++X<U".71O;18E7EXKFXPR*M]_1TC=7UE38XMP;E%IPG.,NM.U+LRT?M
M0X<MT?4.7$U#'<LC1=8C3"S(TW,Y=O2E.S"R=HUYN+&R"NA&$XRA?3197I'X
MW:OY=]DW8I[9^RM02VV=)W.)/%W\FH;DO.!1RP\TL+.Y2=9%J@U<NR1K91TQ
MD))JUC6L-,GCWUF@)-P^CD^S=9SN'N/J:L'"U&O U/'L5F)_4,95?>?*5+FQ
MH7[MJ+G)1E"$I3E;4IQHMKC&;\I<"\/=I7V<\W,U_7>&<GB3A75,9X^LKAK5
M)Y?])6-E2\EJE^GNN%=MBH@YU770KHKQ<ITW9^'?.VA;H:3L3B7S\I 2U+L4
M-;G+)H07**!RP6S:*HN/0$I.*<E++QZ(.!.1,SEN_K,HND=1FM))$*MG56JZ
M+JV@W^1U#%LHW;5=J_'C7I==ZKH[USZ;-QW5L$TIPA+H>P^#.T#A#M P/O\
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M[^FWP]!)[! P!@# -;'9&?0)U9]HO*3^;'>&"T_.?L^2-D^"HP!@# & , 8
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MR+[5O:!PAP379A=FNAPR=0Y956\7:[7Y;+LW3C*>%CSC7.$9)IKFCA4<T?\
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MH6\LG3)]'97=!MS=->ZYG+>=,6G8YU;7R\V=G7:QJ<=8?9KVJXT-#X\Q%&K
MSYJ%6E\5T]8496%<E#'69D*+<(5*-&9-3CCQHRHV8%4FZ]=+KQ;FV-"VJY>6
M?3\@X!E2=CD157<UTH]?!AIY,GBJ%;MT@]383**MFZ9UHDSQ@B=A'\):5F\H
M])>F/YOU7Z^/CT[F^OH--QV3ZKT/P_3^=WJ1.1F\:2+1L_CW3=\Q>H).F;QH
MLFX:NFRY 41<-UTC'26153,4Z:B9C$.0P&*(@(#F$N>G & , 8 P!@# & ,
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M ![E'AO)T 525GZ(^>',9)NDHL=) 6KI8W=()SH1K]8W>,,;)K":1Z_V5O\
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M..RN\E9.Z*L24;<FW+OCS5SH<94YZ(.H!@# & , 8 P!@# & , 8 P!@# &
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MNO&HBN2C%I3[J<>I1KCZ9-.R>]DYR=YYRD^$, 8 P!@# & , 8 P!@# & ,
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M:LBN$Y1IK2P>><WG2MF;GJ4Z+& , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M/JY2DVWZ%W)))(]^;AKC & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M:JQZ(;5U5IOEBES.4G*4KJSD)\@8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M[QD0<,_5,S+LR+*\F56GZ=Y'&Q<G+U?:YGQ3N@8 P!@# & , 8 P!@# & ,
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M;'W @9O/UTTF,1,(&01,E(,W"8I)B42 )?(FTE)[-K?F77]?,])E7S9VP/\
MC7LV/^&'*#_J[@KT\'[U]!YL[8'_ !KV;'_##E!_U=P.G@_>OH4:QJ]L'7Z]
M/3Q;-V<4H:$AI27+&,=7<H#O9$T:Q7>@Q9D#;9A.Z=BCY.W*!3"990@ 4>O0
M0_#X/WKZ%D:0N_;#;FTMJ';ZR_9\4!;:NL*#LA6B6W5/*)K:J4I>*K%692I6
M5L?;"!F]@KAI08>90,@B9*19N4Q23$HD 2^5-I;O9M;[KK^O=Z3*'FSM@?\
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MA*'3_<-Q-_\ OU_^&"/P?[O@?WR;M@_]=]FO[K\H/^;\#\'^[X%(L+WM@X&
MG)T'W9PR7F6'DY;S<PJG*!1\_P#-S)=YY$S3_:\?$=NO!\!N3H/>64(7IZ\#
M\'^[X%CZ1V!VPNYM,ZEV^>-[/J@FVIK2B[&-1KC3>4+&VTPUVK$79!JMH9#;
M2"TL->&2&)FFPD(*$BT<I"4O=Z ):@FU^)[-K?IZ#)_DW;!_Z[[-?W7Y0?\
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MX29$^]W"%  /;@# /PHFFJF=)4A%4E2&3434*4Z:B9RB4Y#D, E.0Y1$IBF
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MR3)D5(&<A=Y%K,7J1AV7>&/@I&]S#%E,WI_"M6#RZ3#-I*V=:5D&R+D@&2\
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M.(GT8M&?9O6_N1,TK//EZS-#S5[?FR1F4+# & , 8 P!@# & , 8 P!@# &
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M1QG9OF ZQ.(GT8M&?9O6_N1,TK//EZS-#S5[?FR1F4+# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ! ! 0$
M$!#H(#ZP$!^4!#^(#@# & , 8 Z!UZ] ZB  (_Q$ Z] Z_W!U'I_=U'^_ &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P"@6OYK67Z@F
M/PYSDQ[UZU\R)=S]3^1QG9OF ZQ.(GT8M&?9O6_N1,TK//EZS-#S5[?FR1F4
M+# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P
M!@# & , 8 P!@% M?S6LOU!,?ASG)CWKUKYD2[GZG\CC.S?,!?D?M/9\2R:Q
MD5L>^1D<Q1(V91\?;["R9,VZ8=U-!JT;2*:#=%,OJ(DDF0A0]12@&1LO!>Y
M]GIDV][5=D>_-G_5,;+P7N0'IDV][5=D>_-G_5,;+P7N0'IDV][5=D>_-G_5
M,;+P7N0'IDV][5=D>_-G_5,;+P7N0'IDV][5=D>_-G_5,;+P7N0'IDV][5=D
M>_-G_5,;+P7N0'IDV][5=D>_-G_5,;+P7N0'IDV][5=D>_-G_5,;+P7N0'ID
MV][5=D>_-G_5,;+P7N0'IDV][5=D>_-G_5,;+P7N0'IDV][5=D>_-G_5,;+P
M7N0'IDV][5=D>_-G_5,;+P7N0'IDV][5=D>_-G_5,;+P7N0'IDV][5=D>_-G
M_5,;+P7N0'IDV][5=D>_-G_5,;+P7N0'IDV][5=D>_-G_5,;+P7N0'IDV][5
M=D>_-G_5,;+P7N0'IDV][5=D>_-G_5,;+P7N0'IDV][5=D>_-G_5,;+P7N0'
MIDV][5=D>_-G_5,;+P7N0'IDV][5=D>_-G_5,;+P7N0'IDV][5=D>_-G_5,;
M+P7N0'IDV][5=D>_-G_5,;+P7N0'IDV][5=D>_-G_5,;+P7N0'IDV][5=D>_
M-G_5,;+P7N0'IDV][5=D>_-G_5,;+P7N0'IDV][5=D>_-G_5,;+P7N0'IDV]
M[5=D>_-G_5,;+P7N0'IDV][5=D>_-G_5,;+P7N0'IDV][5=D>_-G_5,;+P7N
M0'IDV][5=D>_-G_5,;+P7N0'IDV][5=D>_-G_5,;+P7N0'IDV][5=D>_-G_5
M,;+P7N0'IDV][5=D>_-G_5,;+P7N0'IDV][5=D>_-G_5,;+P7N0'IDV][5=D
M>_-G_5,;+P7N0'IDV][5=D>_-G_5,;+P7N0'IDV][5=D>_-G_5,;+P7N0'ID
MV][5=D>_-G_5,;+P7N0'IDV][5=D>_-G_5,;+P7N0'IDV][5=D>_-G_5,;+P
M7N0'IDV][5=D>_-G_5,;+P7N0'IDV][5=D>_-G_5,;+P7N0'IDV][5=D>_-G
M_5,;+P7N0'IDV][5=D>_-G_5,;+P7N0'IDV][5=D>_-G_5,;+P7N0'IDV][5
M=D>_-G_5,;+P7N0'IDV][5=D>_-G_5,;+P7N0'IDV][5=D>_-G_5,;+P7N0'
MIDV][5=D>_-G_5,;+P7N0'IDV][5=D>_-G_5,;+P7N0'IDV][5=D>_-G_5,;
M+P7N0'IDV][5=D>_-G_5,;+P7N0'IDV][5=D>_-G_5,;+P7N0'IDV][5=D>_
M-G_5,;+P7N0'IDV][5=D>_-G_5,;+P7N0'IDV][5=D>_-G_5,;+P7N0'IDV]
M[5=D>_-G_5,;+P7N0'IDV][5=D>_-G_5,;+P7N0'IDV][5=D>_-G_5,;+P7N
M0'IDV][5=D>_-G_5,;+P7N0'IDV][5=D>_-G_5,;+P7N0'IDV][5=D>_-G_5
M,;+P7N0'IDV][5=D>_-G_5,;+P7N0'IDV][5=D>_-G_5,;+P7N0'IDV][5=D
M>_-G_5,;+P7N0'IDV][5=D>_-G_5,;+P7N0'IDV][5=D>_-G_5,;+P7N0'ID
MV][5=D>_-G_5,;+P7N0'IDV][5=D>_-G_5,;+P7N0'IDV][5=D>_-G_5,;+P
M7N0'IDV][5=D>_-G_5,;+P7N0'IDV][5=D>_-G_5,;+P7N0/PIN#;:I#I*[2
LV*HDH0R:B:EWLQR*$. E.0Y#28E,0Q1$IBF 0, B @(#C9>"]R!CK)!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g428534g47j55.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g428534g47j55.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1<(4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %NR^6&@X0DE-! 0      !X< 5H  QLE1QP"   "   < E  "E-T97!H
M96X@36$X0DE-!"4      ! B)R.S>.0!+UE6301,F3\].$))300Z      #E
M    $     $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!
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M;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
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M;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M  !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M     !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL
M;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I
M9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M !  E,S,  $  @"4S,P  0 ".$))300F       .             #^    X
M0DE-! T       0   !:.$))3009       $    'CA"24T#\P      "0
M         0 X0DE-)Q        H  0         ".$))30/U      !( "]F
M9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &
M       ! #4    ! "T    &       !.$))30/X      !P  #_________
M____________________ ^@     _____________________________P/H
M     /____________________________\#Z     #_________________
M____________ ^@  #A"24T$"       $     $   )    "0      X0DE-
M!$0      !     "   "0    D      .$))300>       $     #A"24T$
M&@     #00    8              7<   (O    !@!G #0 -P!J #4 -0
M  $                          0             "+P   7<
M             0                         0     0       &YU;&P
M   "    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO
M;F<          $QE9G1L;VYG          !"=&]M;&]N9P   7<     4F=H
M=&QO;F<   (O    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC
M90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M  9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D
M     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/
M8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,969T
M;&]N9P          0G1O;6QO;F<   %W     %)G:'1L;VYG   "+P    -U
M<FQ415A4     0       &YU;&Q415A4     0       $US9V5415A4
M 0      !F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L
M 0    AC96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%
M4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M
M#T53;&EC959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU
M;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO
M;F<         "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L
M;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #
M  (_\        #A"24T$%       !     ,X0DE-! P     #)0    !
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M1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_V@ , P$
M A$#$0 _ /4FM!$F>3W/BGV#S^\I,X^9_*A?:OU[[)M_P?J[Y'[VS;L24OD6
M"BL/VN?+FM@$S[G!G_?D+$RVY+7N-;ZPP F2=9'YOW?]M[%;4+?YM_\ 5/Y$
ME*T_==]_^U+3P=]_^U368[]IY3<W[-8QC"YU>,73J6CT[)VC<QOK!S-__7$V
M1(H &1/E_P!TD5U-.AIX.^__ &J!MI;])T?%WGZ?[W[_ +$"O"R',:,G)<YP
M W"OVM)CW?3]1_\ F[$
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                              #_XO__24-#7U!23T9)3$4  0F^S/[^
M'@ (@'!!1$)% A   '!R=')#35E+3&%B( ?0  < &@ % "D -6%C<W!!4%!,
M     $%$0D4                    !  #VU@ !     -,M041"10
M                                                        "F1E
M<V,   #\    =&-P<G0   %P    *W=T<'0   &<    %$$R0C    &P  "B
M!D$R0C(   &P  "B!D$R0C$  *.X  "B!D(R03   47   (XM$(R03$  WYT
M  (XM$(R03( !;<H  (XM&=A;70 !^_<  "0D61E<V,         &E4N4RX@
M5V5B($-O871E9" H4U=/4"D@=C(
M
M            =&5X=     !#;W!Y<FEG:'0@,C P,"!!9&]B92!3>7-T96US
M+"!);F,N  !865H@        M5H  +QG  "2,&UF=#(     ! ,)   !
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MJ&ZI>*J"JXZLG*VKKKNOS+#?L?.S";0@M3BV4;=LN(>YI+K"N^&] ;XAOT/
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MG7-ZYCH?FO9[C2 IFIA\<0  E=-_RJS.KRB"@YMHJN2!F8E^IMJ X';[HQ.
M8V.HGYN )D]3G'^ (SETF@6 3!^AF9:!%P  E(Z  *O?KCV++IJ*J?Z)C8B]
MI>V(&G8QHC"&^V+DGKR&($Z?FZ:%CCC5F2R%2Q\NF*N&1@  DW"  *L2K6J3
MYYFJJ3>1FH?,I3"/A'50H6B-O6(2G?R,44WHFNB+.#A!F&J*HA[*E]>+LP
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M:8QBLF&7IGM[K::5-&H&J223&%?MI/"1743AH3^0-3 ^GE*0*A<^GC:.N
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M&((?O])XRW(6NGQXN6&CM6EXZE!QL*=Y4SX+K'-YY"FFJ99Z:@]FJUE["P
MC4.  )$WQ(N YH&VOO-_^''"N9!_2F%*M&U^XE -KYY^Q#VMJU]^Y2E=J&9_
M,@^%J<. 1   C/Z  )#-PY*(J(%'O@B')W%>N)Z%W&#;LW6$\T^AKI^$63U2
MJEJ$&2DCITJ$3@^OJ$^$[@  C,&  )"!PJF0:X#HO2..7W#IM[R,E6!KLH:+
M)D\ZK;**)3T J6J)DRCVIDB)XP_:IP2) @  C(R  ) LP>B83X"4O%N5M7"2
MMO"3=& +L;N1E4[HK-:0)CS#J)*/:2C7I6.0&Q $I>&*U   C%Z  (_'P5"@
M8H!"N[6=-W!-MD":<U_/L0F8+$ZNK":6<3R5I]"5LBC"I):5O! KI..*[@
MC#B  (]FP-6HE'_\NRJDT' 6M:JAAU^BL&^>WTZ)JY.=!SQ]ISJ<K"BXH^":
M;A!.I :+!@  C!F  (\FP%&P]7_,NJ&LDV_VM1^HRU^-K^.EV$YWJPFD&CQO
MIKRB_RBSHU.;A1!LHT2+&P  B_^  ([4O_"YR7^NNBVTFV_MM)NP+5^'KU&L
M^DY[JG"K7#R IB"G]2C<HLB;H!"PHKB+2   B^N  (2TT)]X\W77REEX@V:N
MQ&]X6U<1OM9X?4:SN9-XVC4'M0AY6"#VLG=YK@?KLME[10  B?F  (1BSY^
M;G6;R7Y_9V9PPXQ^K5;.O=9^1$9QN'1^*339L\Q^4"#VL/Y^GPAGL.I_YP
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MSW5*Q.^B.68WOLR?.U:AN.F<_49<LVZ;N34.KIJ;K2'-JS*6VPJ1JA^')0
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M@EUZ2U5@@D][ CDF@IE[TQ/?A)U\CN ?@J""O<KW@BF!][3=@<6!39W?@7F
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MB)(_I.2$A8%LH6:#I&^RGC&"_ET?FSR"B$EYF*."1#0LEK*"*QIMEQF"Q@
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M-([FH:2N$'WTGB.J%6Q(FMJF>EGUE^"CE$:^E4RB#C(1DRZ?=!DFDQ"1 0
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M4X3LK<^*PG3[J:2)8&19I;&(/U+6HAB':$ ]GO*&V"O2G+J&P1(KG@:&R@
MAY.  ).[L5.4DH14K022<'19J-R0B&.RI.F.WU)*H4"-A#_(GA^,H2N!F]N,
MJ!(;G.Z*X@  AQF  ),JL+><^8/+K&::2W/4J#B7U6,OI$&5K5'.H)23Y3]F
MG5F2PRM FPN3$Q(0F_*,-@  AK.  )*^L"6EA8-@J]6B2W-HIZ6?2F+&HZV<
MIU%NH &:CC\;G+^9>BL0FD:8E!()FPR,,@  AEZ  ))3K\6N18,;JVRJ>',F
MIRRFXV)XHQ^CR5$=GVVAC3[.G#V@NBK:F<J<^1('FEV,,0  AAF  )'[KWJW
M;(+*JQ>S$7+5IM"N\6(JHK^K?%#<GPFI<SZ>F]2FS2J\F62<Y1(&F>:,,
MA>*  (AVO^5S47GANO5SK6K9MD-T*ULGL<ITS$J*K9YUASB3JA1V1B12J"MV
MMPI8J@=W%P  A@R  (@>OP5[+GFYN@AZU&JNM3QZK%KTL*MZMDI/K&YZ[CA?
MJ-5[0R0TIL=[@0J?J"Y\8@  A;:  (?>O?*"Z7EBN/V!]&I>M":!+EJ6KX^
MM4GVJTR =#@:IZR ;"03I8& E K?IH.!)@  A6N  (>7O.>*F'D!M_6)&VGG
MLR*'U%HLKH&&UTF4JD&&+3?/IIV%U2/RI%N&& L7I0>%40  A2F  (<^O J2
M8'BEMQ:08FF$LD&.IEG K9Z-,TD_J4Z,'#>/I:R+EB/7HU:,/@M*H[F'H@
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M_6V9Q;9S-U]8P']SFE!SNX)T)T">MM]TRR]%LR%U9!L&L?AU:P-OL$UWB0
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MY&U4P)J5D%[WNQ^3CE #M=61]D!/L.Z0["]AK-*1 1P5JJ:0"P7DI^&#^P
M@QV  'L7Q82?=6U'O^J<LU[WNF":1U *M0R89D!;L"6772]YK "7>1Q+J:.3
M(08[ILZ$-P  @QV  'KVQ0:G,&T_OUNC_5[\N<&A+% 6M&&?%$!GKW6>62^-
MJU:<TQQXJ."30 :'I>N$:@  @QR  'K<Q)VO/FT^ON&KDU\)N3BH6U JL\RF
M,T"%KM>DSB^YJK"@11RSJ#&39P;(I4:$E@  @QR  .8?=G!S&- ;=TMS\;F
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M")B.F'-P08>EECQQ:76PE#QRC&*UDFASMTZ2D-5TYSC4C\)U]!ZCD(9VA
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MQI0-DR^:48,*D0Z7WG$DCQJ5AEYWC5J3:$K*B]^1KC68BL60QQPCBO*/D0
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M+HJTH*1WA7K#G<%WZ6GDFQ%X7E?\F)MXYT3=EH)Y>B_JE2IY[16FEM1YW
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MCX<8G"B?SW<5F42=#68YEHJ:=%2=E!6804'_D?R6R2VTD&V6A11AD3B-R
M@4N  )7.GK&KEX:=F[VH3G:2F-*D^66VE@ZAUU0>DY6?44&'D8*>$"U8C^F;
MX!0YD(2-K   @."  )5UGF*T\(8[FVNQ*78BF'BM1F5!E:JIKE.TDRJG#D$O
MD1*E.BT.CWV>=A0"D R-AP  @(N  (R<KS1N 'Y7JWMO%V]=J -P+U]YI,!Q
M2TZ,H;MR:#Q!GS=S=R?-G?=T) TOH+ASQ0  @G^  (PLKCEV07X&JGIVCF\
MINUV\E\:HY5W;$XKH(-W^SOHG?1XC">$G)EXY TZGN)XT0  @<6  (NZK0U^
M77USJ5A]_VY\I<)]NUZ+HFE]HDVGGU9]J#MYG,=]QB<SFU=]W@T_G39^.P
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MIWL%I8JDO6OGH>2ASEOXGF*?(TM*FSF=.3F*F)F<K"7SELN9<@U*ESF(_
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MDG$%LG&#L&+&KCV"\5/*JCB"9D/)II:"%#)RHZ2!\!ZDHF*"%@:VH7^!Y
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M1V_0KRNI5F&$JL&F75)DIH*CZT*0HJVBPS&4GX^?\QYVG<F4F0>@F\6%*
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M"V5?O >(R%? MT6'MDEULJB&VCI1KG.&42F>JT>&217MJJ^&D &1I%6!#P
M@ "  ')1O_F1:&5*NQ^/RU>RMDZ.5$EGL:B-(CI!K6R,7BFHJB&,A18GJ5B+
M@P'QHNJ!4   @ "  '(POU"8TV4_NF*6X%>NM7^5"DECL,^3C3H_K)"2PBFV
MJ3B3!Q9@J"V/(0)'H;2!B@  @ "  '(3OM.@8&4]N<R>&E>QM-6;[DEDL!::
M.CHZJ]*9MBFWJ'V8>1:%ITV/.@*-H+.!N@  @ "  ''^OG:H-F5#N5"EHE>[
MM$.C*$EKKW>A:SI%JRF@42G0I\J<11:HIH^/4@*ZG_.!V   @ "  -FU<8%L
MJL4.<M=N-Z^_=!MOMYF;=4EQ+8*L=FMRHVKK=XIT&U(%>*!U@C9Z>:!VP!("
M>GEVK=>W;U=WWL-P<-QX1ZY)<D%XMYA+<X]Y-(%T=-)YOFG'=@YZ45#K=S1Z
MUC5H>"%[/A#.>,)ZK=7B;82#'<&D;QN"9ZRU<)F!PI;,<@"!28 <<UZ ZFB3
M=+* G$_9=>6 2C1L=KQ_[P_ =T%_(M09:^J.2K_5;8Z,D*KN;QF*\)4Z<)>)
M=7ZP<@Z(,6=7<W:'!$[,=+2%XC. =7*$VP[6=?.#,-)Z:I29;[X[;$"6S*E4
M;=:4/Y.N;UZ1U7U2<.*/E&8E<EZ-D4W.<Z2+J#*E=$>*& X.=-2&J-$F:8JD
MG;SK:SBA(Z@";,^=JI)A;ER:47P<;^B7*F4*<6B4/TSC<K:1IC'@<S^/S@UE
M<^.)#M 5:+FOU+O=:F>KBJ;K:_FG*Y%);86BYWL8;QB>YF0F<)^;,TP9<>B7
M[S$Z<EJ6% S9<QN(L,]':!^[%;L0:<NV :8,:U.PPY!>;-:KF'HO;FJFQF-7
M;_BB;4MP<4.>R#"J<9>;D QG<GF(8LZY9[S&8+J :6' ?:5A:MJZ8X^<;$VT
M8'EM;=JNSV*G;VBI[TK.<*ZF4# :<.N?[@P,<?>()<I:>>1KB[=]>F1M2Z/!
M>N9NZX\">VAP='E5>^YQ^F*U?'QS?TK2?15T[B_A?=!V'@LY?V1V-\CI=^AV
M/+97>)%VY**D>2UW@XWL><1X(GA">EUXRF&O>O]Y>DG9>Z)Z&B[U?$EZD IK
M?;%ZJ,=E=BJ Y+2N=N: AZ$<=Y6 +(QS>$-_Z';R>/5_N6"%>:U_F$C/>EI_
M<RX'>N5_0 FV?#-^UL73=*6+>K,+=6N*,Y]X=B>(\HL#=N2'Q'6B=ZZ&OU]?
M>'B%T$?5>2V$[RTP>9R$- D9>NB"=\1;<UV6$[&7="J3]IX$=/"1V8F7=;>/
MS71E=HF-X5Y(=V:,+4;M>""*G2QL>'*)B@B3><R%D\,D<EN@PK!B<RR=UYS.
M<_*:WHAH=+Z7]'-*=9>5,UU+=G22KD8;=S20BRN]=VN/>@@B>-V%@,(K<8^K
M?J]F<F&GS)O-<R.C^8=H<^Z@,W)==,^<K%Q]=;&9=D5J=FF6T2LL=H>55P?$
M>!>%0,%N</BV3:ZD<<>QV9KZ<H&M,8:.<T2HDW&'=":D35N]=1&@C$3.=<F=
MP"JN=<>:(P=X=W:%#<#P<)3!-JX7<5Z\ YI2<@FVB876<KZQ'G#5<YFL*UL>
M=(2H"$0[=3NE$"HJ=2.<@@<[=O:$Y+MN@I1JG*HQ@CAL>)?K@?EN*H1Y@=%O
MOV_\@;EQ35IP@;ARV4. @=UT1RD$@H%U4P4\@[MVC;I,@+UTLZD0@(UUC9:S
M@&5V5H-/@$MW%V[E@$)WW5EP@%!XID*3@'AY6B@N@/QYR 3(@@QZTKD<?PY^
MS:?"?OE^MY68?M]^G((D?MA^AFW/?MQ^@UAY?OA^C4&Z?R=^DB=N?XY^? 1B
M@)%^DK>\?92(U:9<?8:'[I0.?7R&_H#)?8&&%6R0?9^%3%=A?<R$F$#,??^#
M]B:H?D2#A 0)?TB!U+9M?%F2X:4+?%"1.)*_?%"/?W^$?%V-R&MW?(",+59H
M?+Z*QS_^?/2)D"7_?1B)!@.^?B^"B+55>V*=#*/S>UZ:HY&H>UZ8'GYU>VZ5
MFVIY>Y63/%6*>\^1'C]&? F/=25H? ^/  -^?4&"7+1U>IZG2:,->IVD)I"\
M>IF@U7V*>J>=B&F@>M2:=53.>Q*7OSZL>SZ5QB3L>RJ4( -)?'V".;/,>@NQ
MH*)8>@RMQH_X>?^IKWS">@2EF6C<>C&AW50:>GF>NCX9>J.<Y"1_>FJ84@,>
M>]V"'+-<>:>\(*'2>:>WF(]6>8VROGP4>8.MZ6@Y>:BIEU.,>>ZF03V7>AJC
M?"0+><V87P+\>UZ"!*S8B[UIVISYBH!KNXO]B7YM<'G B*EO"&9IA_%PF%'L
MAV)R)#OHAR!SA2&QA_5T3@  AX%W)*OSB@)S99P'B/AT58KNB QU,GBYAS]V
M"&5QAHUVXE$'A@9WO#L1A<!X>"#VAFIXQP  A95[%:KPB&I\VYK5AWM\^8G9
MAIA]"W>=A=I](61QA31]1E IA+A]=3I1A')]F2!5A/1]D   @^9^BJG1AO:&
M6IFDA@^%MXB0A3Z% ':+A(:$4V-Y@^V#PT]<@WF#23FF@SB"XQ_&@YB"N
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M&I6D@F"S,X1>@7RNZW(\@*FJH%]\@!"F[TO7?Z^D>C;-?UBA>1V>?PV4!P
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M+(P C>*,$'OXC%Z*Z6L(BO:)OUDMB;6(LD8<B+Z'W#%9B!>'4!>PB,:'6
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MS(+7G$QJC7/?F@)L-&/$E^]MQ5*'E@MO23_LE(9PL2M*D^AQLQ!LEMYQ+P
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M1W\7EGB1RW !E#R00& *DA^.ND\SD#.-8#TECI^,:BDBC;:,70^+CL")D0
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M9W7>I-9Q1V>MH>=R+%B!GR=S%D@PG*MS_C9GFL-TRR(KFD=U'@B FW1U,0
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MAW+WGYF6SF2XG*B5 E6=F=J3346FEU&1\C1WE3R16R$5E!Z0Z CBDPZ& @
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MZ&E@K=AW&UP"JD=W8$V@INMWPSXHH^QX+2T0H<=XA!CNH>EX5 )>G?EZ6
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M F>QJ2V;.UHRI8:95DO8H@:7HSR4GNR6M2OKG).6=AB[F\:0N0.)EE."9
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M:UUAMV9\'E"'LUU[Z4+RKW=[WC0MK!1[\".3J?)[^ ]GJN)[V   FVA_H0
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MZUTCLQ.?25!1KK6=?$*6JIN<)3/IIPN;;B.QI)28(A!6I(.+#   E[*
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M8*T$=8)GOIIL=G%I[X:^=UIK_7(/>$)M^UQ:>2QO[D53>@]QNRL#>M]S&0>
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MT5^XA MLRDOQ@_)NK#:!A"!P2!QEA6%PY@  @$QVNJ&8@[AM@Y*G@T5O"8*
M@NAP;7$U@I]QOE[#@FMS!$L7@EIT.S7 @GUU.!O(@V]U9@  @ !ZN:"+@=EV
MU9%F@8AWBX%=@3MX*W 2@0-XP%W @-YY54HX@-=YY#4%@/-Z3QLW@9IZ+
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M\XRV>]RC57R.>Z>@:VMW>WF=<EF)>W&:R4:/>X.8PS(?>VV7^1D@>L20_0
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M^X0+B+)^)'3RA\%^-63JAN)^.U.IABY^1T$NA:E^52S+A79^5!*YAJ!^!@
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M]X"7A&6H5W%C@V*E16$_@F*B(5!8@9>?F#Y6@0J>92J;@(Z;-1%Q@$6+RP
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M67<JD+&$!VCXCQB#H5G&C9J#,4FHC$&"R3@%BU&"AR0XBOZ"9PKMBO&![@
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M<&X3H"9DE6"KG>YFH%(@F^=HBD)8FAYJ3C#BF/YKPQR!F<%L/P/?F*%LO@
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MWVKZF7.).%V3ES"(=4\ZE0F'K3_BDR*'!R\9D;F&L1N/D9V'%@2HCG:#)@
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M/V&ZJ1MJCU3]ID9KX4= HZ!M*C@WH6!N4R<_H#%O&Q)QHBUNB@  ERUS:0
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M?5^1HM*-KU+?G^>,LD4ZG1Z+NS:&FKR+&R8[F26+2A*EF:B)H0  D-N
M@ "  &LDI0^6$%]4HB:4]5*<GS.3GT3SG%^2639 F?21LR7IF&&1O!*"F*V,
M@P  D">     @ "  &KPI*&=XU]6H:2<J%*9GIB:]T38FZ*95C8SF1>8SR7\
MEVJ6YQ*JEZF,G@ +CXJ "   @ "  &&SN'Q@B57TM7QB4DFALI!D&#QAK\-E
MPRV[K8QG)1R2K41GN A<KJ1G:P  DUARV   @ "  &$PMY%GVU7'M$]I DF2
ML15J.#QOK@MK9BWEJY]L9!SPJPILN@CQK EL:0  DA=W;@  @ "  &#JM@MN
M[%5WLK]ODDE=KW)P13Q#K%%Q!RW6J<YQIQT4J05QR0E<J:5QG0  D.%[@
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M1E2RK,N1?DB8J4B0=CN%I?F/B2U+HT&/91T8H>R.O I\H1^'%P  C)R
M@ "  %_!K]V9H%2[K"R8O4BCJ)&7@3N'I326A"U2HFV6+1TSH0&33@J2H"*'
M)@  C "     @ "  ,$39Q5?[:[3:3EBM)OM:SYE8(@B;21G[G-I;OAJ:5VW
M<+ELT4;'<D5O$"S/<R9PW0H$=BIQ%+\@9"5JT:U+9HILA9J.:+]N+(;H:M)O
MRW)&;,]Q8%RH;K%RZT7)<$ET4ROH</%U70EM=&AU:[U)895UIZN&9"!V3ID'
M9GUV\X5S:+-WI7#X:M)X7%N!;-!Y$43*;G!YKRL/;MEZ"@CI<MQZ+;MW7TN
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MPY9Z=Z]ANH8T>%QD='2G>11F^V'P>=-I9TX&>IMKMSB+>V9MOQ[+?#MNTP
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M5I @;>^./G_X;Q.,]V[-<"R+G5R]<46*54F-<DR)-C3;<O*(8QOO<<N(2P
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MF(E&?3EII'H!?61KAVF1?9QM35?M?>-N_D3[?D%PCS Y?KUQR18V?[-QNP
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MB8/;=0R4(W2W=7V2?&21=>Z0P5-]=FR/*4%!=N*-X2U:=OR-4Q0Y=GZ+%@
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M4WP=@Z1PHVWM@T)QVUYW@O-R^DW?@KMT"SO8@K%T^B>S@O=UAPV>@^=T[P
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MU7?G?/N91&FP?+>77UIY?&^58DI)?$:3LCC3?#22L26">^:22@S+?">(I@
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MZ6]$BNYVJF'>B?EW5%.%B1-W\4/7B%UX>S*CA_9XYQ[=B$9X[09\AY)YOP
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M36Q2A;Z=RU[JA+B;QE""@Z69HD$V@L*8)3"&@B:7MAV!@:^3\P9]@12$8P
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MD&,7DPQ[XE9QD8)\'4C0D E\0SH2CL]\9REUCC%\?!6<CPY\.@##BJI]I@
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ML%H2I!]>%4WPHB-@94"KH%MBC3'RGP5D:"#GGQ-EB@O[H;ME&@  C91MT@
M@ "  &2SI,QC)UFFHHYD\4V3H&UFL$!LGGMH5C'2G/]IOR#SG-5JB@Q/GOII
M_0  B_MRS   @ "  &0KHNAJ=5D,H+AKN$T9GI1L\3_XG)IN'C%_FQ%O&B#0
MFL%OE0Q]G&QO!@  BGMWH@  @ "  &.=H0=QJUAKGN)R>DQHG,ES/#]UFM%S
M]3$1F4ATC2"0F-YTPPR.FAET50  B11[Y0  @ "  &,.GVYX\%?AG5-Y6$O>
MFSMYK3[CF3]Y[#"TEZEZ)R!-ERUZ,0R.F %Z*@  A]%_G   @ "  &*0GBR
M5E=QG!: 84MUF?B 2#Y\E_. &C!5EDY_^B EE:)_^ R5EAZ $0  AK2
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M?4VZK>)C&T(CJVIDN35_J2YF.B<ZI[UG8!7JJ,]G< /2IK]H40  AZ!VL@
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M+4PIIA*$%D"YHW6#QS1!H0*#;"9TGS2#1Q8=GRV#AP4^FR&">@  @JV
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M?E1\9J&H77^!?9)@8!F!78(M8GR!)G#^9+B XE[H9N& I$N7:-2 =S;H:@.
M2QYK:'2 '0#J?G5_U*!C6Y"+>Y$K7D**EH$)8+B)DF_I8PF(@UWF94"'@DK)
M9S6&HS9#:%B%^!WN9JN%V@#9?I& DY]?6?F5=) R7+R3S( :7SZ1^V\&89N0
M)%T18^*.;TH39=R,\S6_9N6+X1V/93.+C #,?JB BIZ=6+N?88]S6XB<]W]9
M7@V:6VY*8&R7OUQ:8KB584EH9+F3:34W9;*2-QTZ9 20-@#!?KJ @IX=5]BI
M-H[J6J6F#'[#72.BIVVR7WN?3EO08<2<6$CU8\*:!S3#9**8Y1S+8PV3> "X
M?LF ?)LV<+)8]XS5<<Q<8'UG<O%?D&R\=!MBC%KA=41E9$?!=F=H$S+R=VAJ
M8!E>=\UK6@  @ !R'9GA;8=BC8NC;NYE#WPQ<$%G:6NC<8QIH5GE<M%KOD;F
M= =MNC(X=/5O8!C2=,EOW   @ !VR)B%:J%L((H_;$!MQWL1;;UO56J%;R9P
MQECN<(-R*$88<<ES=#&9<J5T?!AC<B9TDP  @ !ZXI<$: 5UF8C!:<MV?GF#
M:V=W1FDZ;.QW^5>^;FQXHT46;\)Y03#'<(EYMQ?*;^QYC   @ !^<96@9<9_
M#H=G9Z9_/'@S:5Y_1F?X:OE_.5;&;(A_+$0Y;>U_*# :;IY_'A=2;@9^\
M@ "  )1[8^J(DH9,9=^("G<F9Z:'5F;W:5.&C%76:NV%S$-_;$Z%*R^(;.>$
MOQ;I;'*$P   @ "  )./8F*2$H5E9&:0V'9&9C:/9F8A9^V-XE4-:9*,?4+6
M:O2+5B\5:VJ*K!:=:R.)QP  @ "  )+>82Z;B82R8SN9H76.90Z7=65N9L.5
M.E1>:&V3/4(O:=*1LBZ3:BZ1)196:A6-Y0  @ "  ))F8$VD\X0N8EVB9W3[
M9"F?A&399=:<G%/89WJ:%T'!:-F84RXB:1B78!7E:4R.S@  @ "  (Y\>.=8
ML8$G>5)<"7*W>>%?*&+^>H1B$U(!>S%DU#^=>^]G7BL\?,5I6Q#>?E!I8
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MMGM';>.%>FT.;O^%#%W'< F$@DU_<0>#_SOC<=N#F2A;<?^#90]:<Z&"^@
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MXG1H?LIC7V;4?NUEM5@7?QYGYT@+?V!I\C9P?\IKN2)G@(1LR0C?@>ELF@
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M:F]F=1"*WF(,=8F*$%.E=?&)*$0T=EB(73-<=J"'V2!*=CN(#PAR>-B%50
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MYV>LA3YILUL+A.EK9DTCA*%L^3WXA'AN9"T'A*%O?1D A9EOH ).A1-Q-@
M@ "  ')P@S]OWV:A@PAQ&5GV@L=R.$Q*@HQS/CTT@G!T(RQM@HYTRAB<@S9T
ML@)=@PIVS0  @ "  '%]@4)WX&6Y@1UXD5D.@.IY(DM=@+=YF#R9@)-Y_"OH
M@*EZ0AA(@/]Z$P)N@41[P   @ "  '"F?Y!_\F3O?W^ (UA2?U6 )TJU?R&
M##P'?OA_\"NS?NE_Y1@S?O-_Z *-?[U_^   @ "  &_V?CF("V1A?CJ'QE?/
M?@V'/4HK?<J&E#MR?9N&"RLI?7V%U!?W?2J&'0*6?G:!P   @ "  &]I?2:0
M)&/7?2^/<E=%?0".9TFJ?+6-/#KU?'R,8"JD?%&,/!>0>[2+6P*??6J!Q@
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MO%M>C)YN_T]BB\EP*D)EBP5Q/#/LBH!R("-OBIARG0\WB\]R#@  @KQXF@
M@ "  &6OBWUU3%J6BKQV%4Z;B?%VPD&>B2YW4#-FB)]WR",#B*)W_0\,B5-W
ME   @4Y\Y0  @ "  &3WB>)\\%GNB3!]2TX B&=]>T$)AY]]C3+>AP1]F2+9
MALQ]HP\+AQ)]M0  @!N     @ "  &1:B(B$BUE2A^:$=TUHAR"$+T!VAE2#
MT#):A;"#BB* A5B#B0\SA2&#1P  @ "     @ "  &/>AX",15D-AN^+Y4TO
MAA^+)$ _A2R*.S(OA&>)L"(VA :* 0[E@Z"'\@  @ "     @ "  &-\AK&4
M&5BMAB&3?$S+A4V24S_AA$^1!C'C@W.0;B("@NV0*@[;@EV*"P  @ "
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M@4^2E01S6T0PD[=T'#?&DGQTMRH"D:MU+1F4DAQU(0<QD"IUW@  @ !_+@
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M349BJ)A6TCM-IPU9/2[LI>1;:2"&I=E<]PZ7J*-="   H A@?   @ !Q+@
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M8$/*GM-V\#CDG2AW52SKFYYWD1]8FM=WG [8FZEW7@!QD]IZ5   @ "
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M68N>74-I9GQ/7_5K7&O,8GYM/%H\9.)O"4=W9OMPO#,K:"UR+AJZ9Y%RSP
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M&H5[46V61':(5,6426:15]N24E6=6K>0DT.,7/J/+3 L77B.?!BY7SF,[0
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M;G]386APUW#^8ZMR)6&A9<9S6%#^9\-T>#\;:6-U@"MQ:>MV11*2;$=V#
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MF7JJ5[V;GVR"6F>95EU>7-*7"$U%7P.5%COZ8(^3TRD)7^^3:!$D9>^+EP
M@ "  (4P<9)30'AJ<I96\VJE<[-:>%NE=-A=R4M>=?=@YSF7=PYCNR69=_EE
MUPNZ>L1F @  @ !UPH/';=)<#G<W;S!? VF!<(1ASEJE<<UD<TJ"<P9F[3CA
M=")I)"4+=,AJM@N-=_=JJ@  @ !YX8)P:EUDW772; %G%VA8;8-I,EF-;NYK
M*4F8<$!L_S@C<5YNGB2"<;QOL@ME=8)OB@  @ !]@($.9S-ML'1P:0QO-V<
M:K9PH5B5;$!Q\DB];:YS(C=];LQT*R07;N%TRPM.<UYTLP  @ "  '^Z9')V
M@'-(9G-W8V7<:#YX(E=@:=UXP4?/:UIY5#:D;'AYTR-M;#EZ%0L*<9MZ90
M@ "  'Z@8AU_67(W9#E_FF3<9AM_K59P9]!_HT;T:51_F#8&:E]_F"+W:<I_
MHPK?<!A_QP  @ "  'V\8"B()G%>8EJ'RF0/9$R'-%6N9@V&AD8]9YB%ZS5P
M:).%@B*D9Z2%B@K+;L^$0P  @ "  'T*7I&0Y7"S8-2/]F-D8M".NU4,9)2-
M:T6?9AZ,4#349PJ+I2(N9=B+Z0JS;>J'/   @ "  'R+75>9DG R7ZB8(&+;
M8:662E2$8V24844I9.62UC1X9;Z2&R')9&*140IK;F2'"P  @ "  'C]>>Y2
M_FT$>F)6CV ->P!9]E'7>[!=*4)'?&A@'S#_?4%BKASB?FQD(P2$@.ED[0
M@ !Y('>S=F!;2&OU=RA>+U\.=_)@[U#_>+ACA4&4>7UEYC!T>D=GZAR(>P5H
M\02;?BEIL@  @ !\P'9]<PUCEVJP=!=EU%W\=0EG\T_\=>IIZT"Y=K]KN"_%
M=WUM-1P0=\MMU@2<>\5NN0  @ !_[W5$< 5KWVES<3IM?5RZ<D]N_D\0<T5P
M8#_B="YQFB\A=-]REANF=+IRX@2?>;%T*   @ "  '03;5=T-VA+;K!U.ENB
M;]YV'4X%<.=VWC\\<=9WC"Z9<GMX$AM8<>YX(@2M>!EYLP  @ "  ',.:QA\
MGF=O;(]]$UK:;<]]6DTR;N)]?CYJ;\Y]G"X <%)]O1KA;XA]P@28>#Q^@@
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M3F"0?\%=(51F@ =?T$<0@%5B4SA#@+EDD"=T@6MF1!+7@OMF7P  @0EJ8@
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MLUO+<[V!VT_V=&N!Q4,+=..!C#3I=3F!8R3W=2^!9!&I==J!B0  @ "
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M8U0MAC%BF$C7AA=DKSPOA@1FEBX%AB1H*1UBAO5H_0FCAU%HZP  @ !S9
M@ "  %VP@VAGR5,R@W=I>D?5@W%K#3MG@VIL>BU5@XEMG!SCA"1N& F&A&=N
M#   @ !X6P  @ "  %S&@.AO/5).@1)P<4;T@1QQA3J+@15R;RS @2=S+1QG
M@8YS8PEA@>-SB@  @ !\K   @ "  %OT?L=VQ%&(?PIWA48]?Q]X'#G=?Q=X
MCBPC?Q1XXAPE?RAX\0E:?[1YF0  @ "     @ "  %L\?/!^/5#7?4]^DD69
M?6]^M#E'?61^MRN;?4]^NAO1?21^Q F-?=)_,P  @ "     @ "  %JL>WF%
MRU!T>_F%SD5&?!N%>#D&>_&$_2MO>[:$PQN->UJ%&PE2?%R#WP  @ "
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M0$@&C<AF\3THC4MH@3$OC.EIX2-4C0%JT!)*CI-JG0(?BO!LI   @ ![/
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M,T5:A4:)0#JYA/.(O2\0A#B(%"'M@X.(&A'D@QV') +7@;2![   @ "
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MZ#O=EPQJ*3%>EEAK0"6HE=)L"A?[EDQL2PAUE0]LKP  A\9T+P  @ "
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M2GEW]6F]3H]XJEC84EQY7D:<56AZ$#,75F9ZLQP*6--[*@&Q?21]B)5G/:F
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MF8/56+M:_G4M6[9>2F5_7HUA=E2C83%D>$* 8VIG2BZY9%UIMQ9.9F!JV@
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MGGQ^1P:'#6Z72T2&;5^>3QZ%S4^44GZ%0SY85-2$WRN;5$R$Q!157:*$^@
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M1G>T6UMBWVHM7AQE8UM<8*-GQ4MI8NAJ SH+9*%L#2:Y9))MF0X3:X=MQ0
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MI7'23 J,PV2J3[:+LE9W4OB*G$<G5:J)N#:$5PJ)*R0W5L*)8@TE:<B'-@
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MTVN:7MIIOE[D841KEU$[8W)M6$(794MNZS%M9F5P11Y89=YQ 0<.=!-QS@
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MFF<M4>V1HEJP5/602TTO5X*.XCZ866&-TBZ*692->1Q 6YZ-&0:==-.$>0
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M1E^X8V9OI%.[961P[4;*9Q=R%CBC:&YS(BAM:,-SYQ4;:LESV@$3?BYW'@
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M6EG<>KA0^$X'>XA4@D$#?&17W3)T?4Q:VR&4?H!=#0S,@*!=>   @ !EG0
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MLE0&:1ETI$B^:IQU=#QJ:\=V(B[/;'1VL!\#:]MV_0OT<9EW'P  @ !]TP
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M?$V$?]56BD)Y@&!9<38L@/%<&R@3@;%>21;Q@S-?0P2-A A@;@  @ !M\0
M@ "  %9(>UI:LTQ4?!]=0$%[?,E?JC4^?5]AUR=3?@)CD19K?OMD+P2*@+9E
M5@  @ !S)   @ "  %4K=Z)A]4LQ>))C_4!6>55EY#18>?=GFB:(>G]HYA73
M>OAI+P1S?=QJ;P  @ !X(   @ "  %0:=#EI1THI=5)JSC]5=B]L-C-B=M!M
M;"7B=S=N6!5'=X1N7@1:>VEOXP  @ !\<@  @ "  %,F<2QPJTE#<F]QNSZ$
M<V1RIC*A= 9S9R4W=#USZQ4%=(=STP1B>4-UWP  @ "     @ "  %)1;G=X
M"DAS;^=XJ3W$</9Y&C'U<99Y:R2A<9MYGQ2B<B9Y@ 20>$I[<P  @ "
M@ "  %&F;"=_=$?O;<Q_N#U8;O=_L3&H;XE_C21E;U)_B11"<#I_L 1<>**
M)P  @ "     @ "  %$E:C^&\D=O; &&Z3S<;4&&>#$Y;<Z%\R01;62%VQ00
M;J2%N 11>+6"ZP  @ "     @ "  $SOC:!*UT-@C6I.-CC5C8-1:2R]C?]4
M1!Y5CU]65PR D=U6]@  B8I<-   @ !LK0  @ "  $N3B<M1E$(XB>94BS>U
MBA=74"O%BG]9OAV9BYA;; PYC15;U@  ADY@WP  @ !QC@  @ "  $J%A?I8
M9T$<ADM:Z3:\AI1=/"K7AO-?.QS<A]1@A ODB)Y@OP  @U1EN@  @ !VB
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M;#SK> -[T#*]>+Q[^"==>.U\ !GZ>(1[^PIM>F]\K0  @ !_>   @ "
M@ "  $73=-N"O#R'=D2"X#)O=R""GR<Z=SF"2QHD=G*"6PK.>+6"!@  @ "
M    @ "     @ "  $"9F45(JS>RF*U+Y2VCF)1.U"&JF5%1.Q)YG#)24P-2
MF;Y48   A+)?B@  @ !P#0  @ "  #\WE;Q/!#94E8Y1V2PLE9E48B!+ED!6
M9A%NF*%7+P,)E159/P  @:YD0   @ !U 0  @ "  #Y!DA95>#4ZDAE7X2L>
MDCY: A\ZDM=;H!"@E,-<'P+2D,]>+@  @ !I(P  @ !Y=   @ "  #UOCGU;
M_310CI]=]BH8CM5?J1YGCV1@Z __D-=A*@*JC09C.@  @ !N5@  @ !]6
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M)S#G@?9^3R<+@JQ^,1OC@LQ^ 0Z1@EQ^+@*)@8A^_P  @ "     @ "
M@ "     __\  /__  #__P  ;69T,@     $ PD   $
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MN____P"  (  YD]_SG]8S9E_J'[-M-I_F7YYG!1_HWYE@TQ_QGZ%:H5__G[
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MT!N#!*VZN<V".JA8HS*!HZ,MC'N!-IX@=<B [ID47TJ OI/;2.2 KXXZ,KF
MP8?/Y-6#<[WXSOJ"A[=6N+6!O+#BHB^!)JJHBY^ Q*2*=1& @YY57J> 5)?1
M2&F 4Y#9,F" <HC[X]:##LBES@6"),#BM\:!5[E3H4J O['ZBM" 8:J[=&N
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M68L\C0R!W(FG>9^!?X@V9B>!.(;.4N*! X5>/]Z [H/8+9V ]H(>PPZ"I)A
ML4Z!]I6^GN"!99,VB]N \I"P>)6 GHXV94N <8O34CN 48E2/VV 4X:@+6:
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M.*2 MH9O*:Z F(-?J;:#ZJ#'FG:#%9W-BGN"2)J*>>Z!EY<9:3F!#I.C6)B
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ME$A_WX @A5-_KH #==Q_AW_B9=I_>G_+5<=_AG^^1@5_IG^U-J9_\7^L*&N
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MBH7#J(=WB& &FBYX,&,;BOAX[V8#>N)YPFC1:C]ZIFNG66U[HVZ>2.5\O7'
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M,+:!Q'KE)0&!VGS<C.V![WAP@**!GGDN<\&!4'G89FJ!"'IY6)B VGLE2L:
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M<\&%JY*0: *$I9"%6]2#EXXT3YR"LXOF0XN" 8F>.""!7H=>+5F [H4!(^^
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MUX0J++R+VX,^)>"($8)7($2$J(%_8%FB&(ZD5].>KXV'3N*:_XOA1=.7%XH
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M]GPC31YNQGS%/'ERZ7V"+0!W8WY;L$%7JX/$H)=;18-$D&!>O(+!?Y]B+X)
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MSWA!A?E^T&*X>JE^Z&5I;H=_#F@+8<E_06JN5)]_@FUC1V9_VG ].J: 2G-
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MB6;&44R,)&F21G2*KFQ].[&).6^7,8:'R'+9*!2&<'9E( F%/GHC;O:-_FB
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M8IJ%[(G$6+Z% 8BJ3I2#](=51'6#!H83.HJ"283G,4N!GH/2*,.!*H*K(9F
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M?8+&C']8?)J5@%E;^9@W<Y!?695V9DIBTI*&6-!FDH^;2V1JHHRR/HIN[(G
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M6[M]RW[24K)^ 7[[26U^(7\10"1^4'\P-RA^F']?+M!^]'^?)P1_B7_<()V
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MV'O2,]5U2WS8*I!XYGWR(K5\8'\/<%-@:W[29L5CG'\97,=FN7\U4F5IX']
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M3)1[N'> 14)\>WAT/=E]#'EN-GM]EWJ#+VM^,GNR*0A^UGSN(T1_JGXA'K"
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M"7H^3'B+$6'01>J*?&2D/S&)KV>/.'N(K&J?,<F'B6W@*V6&;W%&):^%:G3
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M(9J GH ;'@6 Q(!4  #__P  __\  /__  !M9G0Q      ,$(0   0
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ML[MMLZNU>+NEL8#!GZZ$QIBKA,J0J(3.B*:&T8*DC-. I)+3@*22TX"DDM.
MI)+3@*22TX"DDM. I)+3@*22TX"DDM. I)+3@*22TX"DDM. I)+3@*22TX"D
MDM/_I3<J_Z%$0?^E15'^K$)?];0_;.V\/GCGQT"!X-9&A\G-49JXPF"JK+IM
MM:6U>+R@L8#!FZZ$Q96LA,B.JH3+AZB&SH*GB\]_IH_0?Z:/T'^FC]!_IH_0
M?Z:/T'^FC]!_IH_0?Z:/T'^FC]!_IH_0?Z:/T'^FC]!_IH_0?Z:/T'^FC]#_
MI38J_Z)#0?^G0U#_KC]=][<\:?#".W/FT#]YT]D_BK[+49VOP&&LI;ENMJ"U
M>;R<LH' F*^$PY*NA,:,K(7(AZJ'RH*IBLQ_J8[-?ZF.S7^ICLU_J8[-?ZF.
MS7^ICLU_J8[-?ZF.S7^ICLU_J8[-?ZF.S7^ICLU_J8[-?ZF.S7^ICLW_IC8J
M_Z)"0?^I0$__LCM;^;TX9>S+.&W<W#5XQ]8^CK/)4J"GP&.MG[EPMIJU>KR8
MLH&_E+&%PH^OA<2+KH;%AJV'QX*LBLA_JXW)?ZN-R7^KC<E_JXW)?ZN-R7^K
MC<E_JXW)?ZN-R7^KC<E_JXW)?ZN-R7^KC<E_JXW)?ZN-R7^KC<G_IS4J_Z-"
M0?^L/$W_MS97\L4S7^'6-F/-XS%\NM,_D:G(5*&?P&6MF;IRM9:V>[J4LX*^
MDK*%P(VQAL&)L(?#AJ^(Q(*NBL6 KHS%@*Z,Q8"NC,6 KHS%@*Z,Q8"NC,6
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M-6R,Y41ZA-Y3@X#98HI\U6R/>-)QDW70=95SSWB7<<YZF'#-?)EOS7Z:;LR
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M047_KSU0_K@[6?/$/&'FT4-DV=]#<\C<2H6WT%>5JL=EHJ# <*R9NGFTE+:
MNI&SA;Z+L8;!A;"(PX&NB\5]K9#&>JV7QGJMFL9ZK9K&>JV:QGJMFL9ZK9K&
M>JV:QGJMFL9ZK9K&>JV:QGJMFL9ZK9K&>JV:QGJMFL;_I#0B_Z%!-_^I/4/_
MLSE-^;XW5>K,.EG;W3MBR^4_=[O92(FKSE>8H,9EI)C <:R3NWJSD+B!N(RU
MA+N(LX:^A;*)P(&QB\%^L(_">["4PWJPEL-ZL);#>K"6PWJPEL-ZL);#>K"6
MPWJPEL-ZL);#>K"6PWJPEL-ZL);#>K"6PWJPEL/_I#0B_Z,^-O^M.4'_N#1(
M\,8S3=_9-E#-Y39GON0[>ZW72(R@S5B9E\9GI)+!<JN.O7NPC+J!M(BX@[>$
MMX6Y@K6(NW^TBKU\LXV^>K.1OWJSD[]ZLY._>K.3OWJSD[]ZLY._>K.3OWJS
MD[]ZLY._>K.3OWJSD[]ZLY._>K.3OWJSD[__IC(B_Z8Z-/^R,SWWP"Y"Y-(O
M0<_D+E6_[S-KK^$[?J#62HV6SEN9D,AIH8S#<ZB)P'NLAKY_KX*\@;* NX2S
M?;J&M7NYB+9YN(NW=[>/N'>WD+EWMY"Y=[>0N7>WD+EWMY"Y=[>0N7>WD+EW
MMY"Y=[>0N7>WD+EWMY"Y=[>0N7>WD+G_IS$B_ZPS,?^Y*S;JS"8VTN$F0<'O
M+%JP[3-NH>$]?Y7738R-T%Z6B<MKG8;'=**#Q'JF?\-]J7S!@*MZP(*L>;^$
MK7>^AJ]UOHFP<[V,L7.]C;%SO8VQ<[V-L7.]C;%SO8VQ<[V-L7.]C;%SO8VQ
M<[V-L7.]C;%SO8VQ<[V-L7.]C;'_J2XA_[,J*_+%(BS6WAPMP^TC1[+Y*UVB
M[#9OE>)"?8O:4HB%U&"0@M!LEG[,<YM[RG>>>,E[H';(?J)TQX"C<\:"I''%
MA*5PQ(>F;L2*IV[#BZ=NPXNG;L.+IV[#BZ=NPXNG;L.+IV[#BZ=NPXNG;L.+
MIV[#BZ=NPXNG;L.+IV[#BZ?_K"H@^KT?(MS9$AO%ZQHSM/HC2J/Y+EZ5[CQM
MBN5)>8/?5H)^VF2)>M9LCG;3<9%STG64<=!YE6_/>Y=MSGZ8;,Z F6O-@IIJ
MS82;:<R'G&C,B)QHS(B<:,R(G&C,B)QHS(B<:,R(G&C,B)QHS(B<:,R(G&C,
MB)QHS(B<:,R(G&C,B)S_MAX8Y- .$\CI$2"U^1LWI?\F2Y?Z-%R+\4)H@NI/
M<GSE6WIWX61_<MYJ@V[<<(9LVW2(:MEWB6C9>8MGV'R+9M=^C&76@(UDUH*.
M8]6%CV+5A8]BU86/8M6%CV+5A8]BU86/8M6%CV+5A8]BU86/8M6%CV+5A8]B
MU86/8M6%CV+5A8_IQPT,RMH+#[?W$B2G_QTYF/\K28S^.E>#]DEA?/!5:77L
M7F]NZ6-T:N=I=V?E;GEEY')[8^-U?&+B=WUAXGE^8.%[?U_A?7]?X'^ 7N""
M@5W?@X%=WX.!7=^#@5W?@X%=WX.!7=^#@5W?@X%=WX.!7=^#@5W?@X%=WX.!
M7=^#@5W?@X'+T D#NN(+$ZC_%"::_R$WC?\Q183_0%!\_$Y8=/A77VWT761G
M\F)G8_!H:F'N;&Q?[7!M7>UR;USL=6];['=P6NMY<5KK>G%9ZGQR6.I_<ECJ
M?W-8ZG]S6.I_<UCJ?W-8ZG]S6.I_<UCJ?W-8ZG]S6.I_<UCJ?W-8ZG]S6.I_
M<UCJ?W/_G#@:_YI&+?^744'_FE-/_IQ57O6<6FSLFU]ZY)EGA]R6<9+5DWN<
MSY"$I,N.C*O(BI"PQ8>4M,.$F+?"@9NYP7^>NL%]HKO >Z:\P'FKO;]XLKV[
M>+.]NWBSO;MXL[V[>+.]NWBSO;MXL[V[>+.]NWBSO;MXL[V[>+.]NWBSO;MX
ML[W_G#@:_YI&+?^744'_FE-/_IQ57O6<6FSLFU]ZY)EGA]R6<9+5DWN<SY"$
MI,N.C*O(BI"PQ8>4M,.$F+?"@9NYP7^>NL%]HKO >Z:\P'FKO;]XLKV[>+.]
MNWBSO;MXL[V[>+.]NWBSO;MXL[V[>+.]NWBSO;MXL[V[>+.]NWBSO;MXL[W_
MG#@:_YI&+?^744'_FE-/_IQ57O6<6FSLFU]ZY)EGA]R6<9+5DWN<SY"$I,N.
MC*O(BI"PQ8>4M,.$F+?"@9NYP7^>NL%]HKO >Z:\P'FKO;]XLKV[>+.]NWBS
MO;MXL[V[>+.]NWBSO;MXL[V[>+.]NWBSO;MXL[V[>+.]NWBSO;MXL[W_G#@:
M_YI&+?^744'_FE-/_IQ57O6<6FSLFU]ZY)EGA]R6<9+5DWN<SY"$I,N.C*O(
MBI"PQ8>4M,.$F+?"@9NYP7^>NL%]HKO >Z:\P'FKO;]XLKV[>+.]NWBSO;MX
ML[V[>+.]NWBSO;MXL[V[>+.]NWBSO;MXL[V[>+.]NWBSO;MXL[W_G#@:_YI&
M+?^744'_FE-/_IQ57O6<6FSLFU]ZY)EGA]R6<9+5DWN<SY"$I,N.C*O(BI"P
MQ8>4M,.$F+?"@9NYP7^>NL%]HKO >Z:\P'FKO;]XLKV[>+.]NWBSO;MXL[V[
M>+.]NWBSO;MXL[V[>+.]NWBSO;MXL[V[>+.]NWBSO;MXL[W_G#@:_YI&+?^7
M44'_FE-/_IQ57O6<6FSLFU]ZY)EGA]R6<9+5DWN<SY"$I,N.C*O(BI"PQ8>4
MM,.$F+?"@9NYP7^>NL%]HKO >Z:\P'FKO;]XLKV[>+.]NWBSO;MXL[V[>+.]
MNWBSO;MXL[V[>+.]NWBSO;MXL[V[>+.]NWBSO;MXL[W_G#@:_YI&+?^744'_
MFE-/_IQ57O6<6FSLFU]ZY)EGA]R6<9+5DWN<SY"$I,N.C*O(BI"PQ8>4M,.$
MF+?"@9NYP7^>NL%]HKO >Z:\P'FKO;]XLKV[>+.]NWBSO;MXL[V[>+.]NWBS
MO;MXL[V[>+.]NWBSO;MXL[V[>+.]NWBSO;MXL[W_G#@:_YI&+?^744'_FE-/
M_IQ57O6<6FSLFU]ZY)EGA]R6<9+5DWN<SY"$I,N.C*O(BI"PQ8>4M,.$F+?"
M@9NYP7^>NL%]HKO >Z:\P'FKO;]XLKV[>+.]NWBSO;MXL[V[>+.]NWBSO;MX
ML[V[>+.]NWBSO;MXL[V[>+.]NWBSO;MXL[W_G3@:_YI%+O^74$'_FU%/_YU4
M7?6>6&OLG5UYY)MDAMR8;I+5E7B<T)*!I,N/B:O'C8^QQ8F3M<.%E[C"@IJZ
MP7^>N\!]HKV_>Z>^OWFMOKMXL;ZV>;*^MGFROK9YLKZV>;*^MGFROK9YLKZV
M>;*^MGFROK9YLKZV>;*^MGFROK9YLK[_G3@:_YI%+O^83T#_G5!._Y]27/:@
M56KMH%IXY9]@A=V<:I'6F'.;T)5]I,N2A:O'CXVQQ(R1ML*'E;G!@YF[OW^=
MOKY]HK^]>JC O'FOP;1YL,&P>K# L'JPP+!ZL,"P>K# L'JPP+!ZL,"P>K#
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M9UU:^&M?6/=N8%?W<6%6]G1A5?9V8E3U=V-3]7EC4_1\9%+T?F11](!E4?2
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MM'R5N;1\E;FT?)6YM'R5N;3_E2P._Y4]'O^@/2?_J#LP_[ \-_VX/SSQP41
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M8_\Z)%S_0BA6_TDL4?]/+T[_53%+_UHS2/]>-4;_8C9$_V8W0_]I.$'_;#A
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M/#;_ISTU_[$^-/^^/C/_RC\S_\H_,__*/S/_RC\S_\H_,__*/S/_RC^XL@
MJKT  )W*  "1V ( B/L- 7__&0)V_R0&;O\M#&;_-1)?_SP76/]#&U/_21Y.
M_T\A2O]5)$;_6R9#_V G0/]F*3[_:RH[_W(K.?]Y+3;_@2XT_XHO,?^4,##_
MG#$N_Z4R+?^O,RS_MS,L_[<S+/^W,RS_MS,L_[<S+/^W,RS_MS.KN   GL4
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M6S/Y=F0Z]7!N0?%L>4CM:(--ZF2,4>=AE57E7YU8XUVE6N%;K5S>6K9>W%G
M7]I9SF#56>)@T5GO8<I:]&+"7/1CO%WT9+=>\V2V7_-DME_S9+9?\V2V7_-D
MME_S9+9?\V3_7"0#_V,F!/]O)@7_>R\+_X(Y$?^&01C_ATD@_X51*/B"63#R
M?6 X[7=J0.AR=4?D;G]-X6F(4MUFD5?98YE:U6"A7=)?J&#/7;%BS5R[8\M<
MQV3)7-MEQ5WK9;]=\F:X7_%GLV#Q9Z]A\6>N8O%GKF+Q9ZYB\6>N8O%GKF+Q
M9ZYB\6?_720#_V8D!/]R) 7_?BX*_X<W$/^+/Q;_C$<=^8M/)?*(5BWL@UTV
MYGYG/N!X<4;;<WM-U6Z#4]!JC%C,9Y1=R66<8,9CHV/#8:QEP6"U9[]?P6B]
M7]!INF#F:;5A[VJO8N]JJV/O:J=D[VFF9?!IIF7P::9E\&FF9?!IIF7P::9E
M\&G_7B,#_VDB!/]V(P3_@BP)_XLV#O^//A3]D44;])%,(NV.4RKFBEHRWX5E
M.]=^;470>'9-RW1_5,9PAUK";(]>OVF78KMGGV6X9:=HMF2P:K-CNVNQ8\IL
MKV/A;*MD[6VF9NULHV?M;*!H[FN?:.YKGVCN:Y]H[FN?:.YKGVCN:Y]H[FO_
M7R,#_VL@ _]Y(@3_A2L(_XXT#/^3/!+XED,8[Y9*'N>54";@D5@NUXIA.LZ$
M:D7(?G--PGE[5;YU@UNY<8M@M6Z29+)LFF>O:J-JK&BL;*EGMFZG9\1OI6?:
M;Z)HZV^>:>QOFVKL;IEK[6V8:^UMF&OM;9AK[6V8:^UMF&OM;9AK[6W_7R,#
M_VX> _][(03_B"H'_Y$R"_^7.@_TFD$5ZYM'&N.;32':EE4MSX]>.<B)9T3!
M@V]-NWYW5;9Y?UNQ=H=@K7./9:EPEFBF;I]LHVRH;J!KLG"=:\!QG&O2<IIL
MZ7&7;>IPE&WK<))N[&^2;NQNDF[L;I)N[&Z2;NQNDF[L;I)N[&[_82$#_W =
M _]^( /_BRD&_Y4Q"?N;. WPGCX1YZ!$%M^@2AW3FE(KRI-<.,*-9$.[AVU-
MM()T5*]^?%NJ>H1AIG>+9:)TDVF><IMMFG"D<)=OKW*5;[QSDV_-<Y)PYG.0
M<.ERCG'J<8UQZW",<>MPC''K<(QQZW",<>MPC''K<(QQZW#_8R #_W(; _^
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M6DC%^UI(Q?M:2,7[6DC%^UKWD00 U*(" ,>O! "ZN0, L,0% *?0"0"?X1
MF.$A X_@, F&X#L2?=]$&W7>321NW54K9]Q<,F+;9#==VVL[6=IR/U7:>D-2
MVH-%3MJ-2$S:F$I)VJ5+2-NS3$?<Q$Q&W-Y,1MKM3$38^4]#V/M/0]C[3T/8
M^T]#V/M/0]C[3T/8^T_;F@  RJD" +NS @"PO0, I<D% )O6"0"4Z!0!C.DE
M!(3H,PM[Z#P4<^A$&VOH2R)DYU(H7N=9+5GG8#)5YV@U4N=O.$_G=SM,YX ]
M2>>)/T?HE$%$Z)]"0NFL0T'IND1 ZLU$0.KD1$#H]41 Y_A#0.?X0T#G^$-
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M9F^"\F5P@?-D<('S9'"!\V1P@?-D<('S9'"!\V3_:Q0!_WL2 ?^*$@#_EA(
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M7U><]U]7G/=?5YSW7U><]U__>@P _8L) -J;! #.IP8 Q+ & +RY! "UP0X
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M1<+_3D7"_T[?D   S)\  +^J 0"SLP$ J;T" )_'!0"6T@D CMH2 (C;) *
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M(S+^I"0Q_[$E,/^_)B__SR8N_^,F+O_C)B[_XR8N_^,F+O_C)B[_XR:MK0
MG[<  )+"  "&S0  >=H  '#R" !H_Q$ 8?\: 5K_(P-4_RL$3_\S!DK_.PA&
M_T(+0_])#4#_3PX]_U40.O];$3C_81,U_V@4,_]O%3#_>!8N_X(7+/^-&2K_
MF1HI_Z0:*/^O&R?_NAPF_\<<)O_''";_QQPF_\<<)O_''";_QQRAM   D[\
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MX4^[0.!/QT#>3]A!V4_H0=1/]$/03OY%SD[_1LA0_T;"4?]'P%'_1\!1_T?
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M6GQR_%E\<OQ7?'+]5WQR_5=\<OU7?'+]5WQR_5?_8A0!_W$1 ?]]$0#_B!(
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M5V>#_%=G@_Q79X/\5V>#_%?_; X _WL, /*)"0#9E08 SYX( ,FF" #!JQ
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M-4+.N#9!S\TU0<[H-4#-]3<_R_XY/LO_.3[+_SD^R_\Y/LO_.3[+_SG*E@
MO*(  *^J  "CLP  F+P  (W& P""SP< >-D+ '/>& !NWB8":-XS!6+>/@I=
MWD@/6=Y0%%7>6!=1WF ;3MYG'DO=;R!(WG@C1MZ!)4/>C"=!WI@I/]ZF*C[?
MM2H]X,@J/=_C*CS=\2L[W/LM.MS]+CK<_2XZW/TN.MS]+CK<_2[ GP  L:<
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M+?N^&BS[SQLK^^<;*_OK&RO[ZQLK^^L;*_OK&RO[ZQNHJ@  FK0  (V_  "
MR0  =-,  &?>  !>\@@ 6?X1 %/_&@%._R,"2?\K T7_,P1!_SH%/O]!!CO_
M1P<X_TX(-?]4"3/_6@DQ_V$*+_]I"RS_<@PJ_WT-*/^(#B;_E0\E_Z$0)/^N
M$2/_NA(B_\H2(O_0$B+_T!(B_] 2(O_0$B+_T!*<L@  CKP  (''  !ST0
M9]T  %GC  !3_08 3?\. $C_%@!#_QX!/_\F CK_+0(W_S,#,_\Y S#_/P0N
M_T0$*_]*!2G_4 4G_U8&)/]=!B+_90<@_VX''?]Y"!O_A0@:_Y()&?^>"1C_
MJ D7_[,)%_^W"1?_MPD7_[<)%_^W"1?_MPF0N@  @L4  '30  !GW   6.,
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M2XUC_TJ,9/])BV3_28MD_TF+9/])BV3_28MD_TG_6A,!_V80 /]Q$0#_>A(
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M3'1S_TQT<_],='/_3'1S_TS_8@X _V\, /Q["@#>A@8 U8X( ,^4"0#'F!$
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M0DVCM$-,H\A#3*/D0TNA]$-+H/]$2Z#_1$N@_T1+H/]$2Z#_1$N@_T3C?0
MSXL  ,*6  "WGP  K:8  *.M  "9M0  D+D. (NZ'@&$NBT#?;DY"7>X0Q!Q
MMDP7:[53'6:T6B)BLV$F7K)H*UJQ;RY6L'<R4["!-4^OBSA,KY<Z2JZD/$BN
MLSU'KL<]1Z[C/$:M\SU&J_X^1:O_/T6K_S]%J_\_1:O_/T6K_S_:@P  QY$
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M(#G7[R XU?DB-]3_(S?4_R,WU/\C-]3_(S?4_R.YG   JZ0  )^L  "3M0
MA[X  'O&  !PS@, 9=8' %WC#@!:XQL 5N,G 5+D,@).Y#P$2N1$!D?E30A%
MY54*0N5<#$#E9 X^YFP0.^9V$CGF@!0WYXP5->>9%C3GJ!<RZ+@8,NC,&#'H
MY1@QYO08,>7\&#'E_!@QY?P8,>7\&#'E_!BNH@  H:H  )2S  "(O0  >\8
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M!1'_O 41_[P%$?^\!1'_O 6,N   ?<(  &_,  !BV   5-\  $?E   ^\0
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M.:-3_SFB4_\YH53_.*%4_SBA5/\XH53_.*%4_SC_3Q0!_UD0 /]C$@#_:A0
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M$0#9?1@ SGTJ L5[.0:^=T4.MW10%;%P61RM;6(BJ&II)Z5H<2RA9G@OGF2
M,YMBAS:888\XEF"8.Y-?H3V17JL_CUZX0(U>R$&+7N%!BE_S0(E?_S^)8/\^
MB&#_/HA@_SV(8/\]B&#_/8A@_SW_5P\ _V(, /]L# #X= P Z7H, -Y^# #2
M@14 R($G <!_-@:X?$(-LGA-%:QU5ANG<E\BHF]F)YYL;BR;:G4PEVA\,Y1G
MA#:198PYCF25/(QCGCZ)8JA AV*U0H5BQ4*$8MY#@V/Q0H)C_4&"9/] @F3_
M/X)D_S^"9/\_@F3_/X)D_S__60X _V0+ /]N"@#J=P@ VWT( -2""@#,A!(
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M/7EPED!V;Z%"=&ZN1')NO45P;M%%<&_K1'!O^D-Q;_]!<6__0'%P_T!Q</]
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M05N$M$):A,=#6H3C0EJ#]$%;@_] 6X/_0%N#_S];@_\_6X/_/UN#_S__:@
MWG@  ,V#  #"C   N9,  +"8  "GG0( H)\2 )F?(P&3GC$%C)T\"X6;1A)_
MF4X8>I=6'G6672-PE&,H;))J+&B1<3!ED'DT88Z"-UZ-C#I:C)<]6(RD/U:+
MLD!4B\5 5(OA0%2*\S]5BOX_58G_/E6)_SY5B?\^58G_/E6)_S[O;P  UGP
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M,D2H[S)#I_LS0Z;_,T.E_S1#I?\T0Z7_-$.E_S30@0  P8X  +68  "IGP
MGJ4  ).L  "(L@  ?+D" ':Z$0!RNR$ ;KLN FB[.@9DND,*7[I,#ENY4Q)7
MN%H65+AA&5&W:1Q.MW$?2[9Z(DBVA"5%MI G0[6=*4&UK"I MKXJ/[;8*C^T
M[BH^L_HL/;+_+3VQ_RT]L?\M/;'_+3VQ_RW'B0  N94  *R=  "AI   EJL
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M#RS?_1 LW_T0+-_]$"S?_1"HH   G*<  (^P  "#N   =L$  &K)  !>SP
M4]4! $G<!@!%Z0\ 0ND9 $#J)  ]ZBX .NLV 3CL/@$V[$8",^U- S'M50,O
M[ET$+>YE!2ON< 4I[WL&*.^)!R;PEP<E\*<()/&X""/QS @B\N4((O#S""+O
M]0@B[_4((N_U""+O]0B>I@  D:\  (2X  !WP0  :LD  %W0  !1UP  1MT
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M(\!!_R2^0?\DO4'_);U!_R6]0?\EO4'_);U!_R7_0A@!_TD3 /]0% #_5AD
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M,)14_S"45/\PE%3_,)14_S#_3PX _U@+ /]@"P#[9@P \&L- .1M#@#6;A8
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M.&EOM3IH;\<Z9V_B.F=O]#AH;_\W:&__-FAO_S9H;_\V:&__-FAO_S;_7@
MY&H  --T  #(?   OX$! +>% 0"OAP< J(D5 *&))0&;B#,$E(8^"8Z$1P^)
M@5 5A']7&G]^7AY[?&4B>'IL)G1Y<RIQ>'LM;G>$,&MVCC-H=9DV9G2E.&1S
MLSEB<\0Z8G/@.F)S\SAC<_\W8W/_-F-S_S9C<_\V8W/_-F-S_S;_80  X&T
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M-5&&[C52A?LT4H7_-%*%_S-2A?\S4H7_,U*%_S/C;   SGD  ,&#  "VBP
MK)$  **5  "7F0  CYL+ (J=& "$G2<!?IPT!'F;/@ASFD<-;YE/$FJ85A=F
MEUT;8Y5C'E^4:B)<DW(E69)[*%61A2M2D9 N4)"=,$Z0JS%,D+PR3)#3,DR/
M[3),COHR3(W_,4R,_S%,C/\Q3(S_,4R,_S'<<0  R'X  +N(  "QD0  II8
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M(CJL_R,ZK/\C.JS_(SJL_R/ A@  LY(  *>9  "<GP  D*8  (2L  !YL0
M;;<  &&\!0!=O1( 6KX@ %B^+0%4OC@"4;Y"!$Z^2@9,OE((2;Y9"D:^8 Q$
MOF@.0;UQ$3^]?!,\O8@5.KV5%CB]I!<WO;48-KW*&#>\YQ<UN_89-;K_&C2Y
M_QLTN?\;-+G_&S2Y_QNXCP  JI@  )^?  "3I@  AZP  'NS  !ON0  8[X
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M QOI^0.:I   C:P  '^U  !RO0  9<4  %G+  !,T   0=4  #C<   OX0(
M+?$- "OQ$P H\AP )O(D "3S*P B]#( (?0Y !_U00 =]4D &_91 !GW6@$7
M]V4!%?AR 13Y@0$3^9(!$OJB A'ZLP(0^\8"$/O= A#[Z0(0^^D"$/OI A#[
MZ0*/JP  @;0  '.]  !FQ@  6<T  $O3  ! V0  -=X  "SC   F\0  )/X*
M "'_$  ?_Q8 '/\< !G_(@ 7_R@ %?\N !/_-0 2_SP $/]#  [_3  -_U8
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M'JQ!_QZL0?\>K$'_'JQ!_Q[_0A$ _T<- /]/#@#_4Q$ _U85 /-7' #H5B4
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M+79>M2YU7L8O=%[A+W1?\RYT7_\L=&#_*W1@_RMT8/\K=&#_*W1@_RO_4P
MZ%X  -EG  #+;0  PW$! +MS @"U<PD K747 *=U)P&A=#0#FW(_!Y5P20N1
M;E(0C&Q9%(EJ8!B%:6<;@FAN'G]F=2%]97TD>F2%)G=DCREU8YHK<F*E+7!B
MLR]O8L0O;F+>+VYC\BYN8_XM;F/_+&YC_RMN8_\K;F/_*VYC_RO_50  Y6
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M8VO8,&-K[R]D:_PM9&O_+65K_RQE:_\L96O_+&5K_RST6P  W68  ,MO  #
M=@  MWL  *]^  "F?@$ GW\0 )F 'P"3@"T"C7\Y!8A]0PF#>TL-?GI3$GIX
M6A9V=V$9<W5G''!T;A]M<W8B:G)_)FAQB2AE<)0K8G"@+6!OK2]?;[TO7F_4
M+UYO[2]?;_LM7V__+&!O_RQ@;_\L8&__+&!O_RSK7@  V&D  ,=R  "\>0
MLW\  *N"  "A@@  F8,. )2$'0".A"L!B(,V!(."0 A^@$D,>7]1$'5]6!1R
M?%\8;GME&VMZ;!YH>70B97A])6)WAR=@=I(J776>+%MUJRY:=+LO6771+UET
M["Y9=/HM6G3_+%IT_RM:=/\K6G3_*UIT_ROF80  T6T  ,-V  "Y?0  KX,
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M)TF'_R=)A_\G28?_)TF'_R?1;P  P7L  +6$  "KC   H)   )64  ")EP
M?IH  '>;#@!SG!P ;YTI 6N<-0)FG#\%8IM'"%^:3PM<FE8/6)E<$E688Q53
MF&L74)=S&DV6?1U*E8D?1Y65(465I"-$E+,C0Y3((T.4Y2-#DO4D0Y'_)$.0
M_R1#D/\D0Y#_)$.0_R3*=0  NX$  +"+  "DD0  FI4  (^9  "#G0  =*(
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M$S"S_Q.RC@  I94  )J;  ".H@  @J@  '6M  !ILP  7K<  %.[  !'P 4
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M !CDB $7Y9H!%N:L 17FP $4Y]T!$^7O 1/C^@$3X_H!$^/Z 1/C^@&6H@
MB:D  'NQ  !NN0  8<   %3&  !(R@  /<\  #/3   JV0  (MX" ![K"@ <
M[!  &^T7 !GM'P 7[B8 %>XM !3O-0 3\#T $?!& !#Q4  /\EL #O)I  WS
M>  ,](H "_6<  KUK@ )]L( "?;9  CU[0 (]>T "/7M  CU[0"+J0  ?;(
M &^Z  !BP@  5<D  $?.   [T@  ,=@  "?=   ?X0  &>@  !;X!@ 4^@T
M$OL2 !#\%P ._!T #?TC  S]*0 *_C  "/\X  ;_00 #_TP  /]8  #_9@
M_W<  /^)  #_FP  _ZL  /^[  #_S@  _\\  /_/  #_SP!_L@  <;H  &/#
M  !6RP  2-$  #K6   OW0  )>$  !SE   4Z0  $?<   __ 0 -_PD "_\-
M  C_$  &_Q0  _\8  #_'@  _R,  /\J  #_,@  _SP  /]'  #_5   _V,
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M2D@"Q$A3!,!'70>\1F8)ND1N"[=#=@VU0WT.LT*$$+%!BQ&P09(2KD":$ZQ
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M'XA.MR"'3L@AA4[B(81/\R"#3_\@@T__'X)0_Q^"4/\>@E#_'H)0_Q[_1P
M\U$  -]8  #170  R6 " ,-@! "]7@T M6 : *YA*@"I8#<"I%Y#!)]=30B;
M6U4+F%E=#I589!&25VL3CU9R%HU5>1B+5($:B%.)'(93DAZ$4IP?@E*G(8!2
MM")_4L0C?5+>(WQ3\2)\4_XA>U3_(7M4_R![5/\@>U3_('M4_R#_2@  Z50
M -I<  #,80  PV0  +QD @"V8PH KV07 *EE)P"C9#0"GF- !)EA2@>57U(+
MD5Y:#HY=81&+6V@3B5IO%H99=AB$6'T:@5B&'']7CQY]5ID@>U:D(GE6L2-W
M5L$D=E;:)'57[R1U5_TC=5C_(G58_R%U6/\A=5C_(758_R'_30  Y5<  --?
M  #(9   OV<  +=H  "Q9P< J6@4 *-I) ">:#(!F6<]!)1E1P>09$\*C&)7
M#8AA7A"%7V43@UYL%H!=<QA]77H:>UR#'7E;C!]V6Y<A=%JB(W):KR1Q6K\E
M<%K5)6];[25O6_PC;UO_(F];_R)O6_\A;UO_(6];_R'Z3P  X5H  ,]B  #$
M9P  NVL  +-L  "L:@0 I&L2 )YL(0"9;"\!E&LZ X]I1 :*:$T)AF95#8-E
M7!" 9&(3?6)I%7IB<!AX87@:=6" '7-?BA]P7Y0A;EZ@(VQ>K25K7KPF:E[1
M)FE>["5J7_LD:E__(VI?_R)J7_\B:E__(FI?_R+P4@  W5T  ,ME  # :P
MMVX  *]O  "G;@$ H&\0 )IP'P"4<"P!CV\X XIM0@:&;$L)@FI2#'YI60][
M:& 2=V9F%'5F;A=R974:<&1^'6UCB!]K8Y(B:6*>)&=BJR5E8KHF9&+/)F1B
MZB9E8OHD96/_(V5C_R)E8_\B96/_(F5C_R+K50  V&   ,AH  "\;@  LW$
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M(U9O_R)7;_\B5V__(E=O_R+?7P  RFD  +QR  "R>   J7T  )]_  "2?@
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M&S^+_QO"<P  M7X  *J'  "?C   E)   (B3  ![E0  ;)D  &6;! !@G!
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M!R^QE@@NLJ8(+;*X"2RRT @LL.P)*Z_Y"BNN_PLJK?\+*JW_"RJM_PNMBP
MH)(  )68  ")G0  ?:,  '&H  !DK0  6;$  $VT  !"N   .[H* #B[$P W
MO!X -;PI #2],@ SO3L ,KU$ #&^3  OOE4!+KY> 2R^: $JOG0"*;Z" B>_
MD0,FOZ(#)+^T R._RP,CON@#([SW!"*[_P4BN_\%(KO_!2*[_P6DD@  F)@
M (R>  " I0  <ZL  &>P  !;M0  3[D  $2\   ZP   ,,0$ "K'"P HR!,
M)\D= ";))P ER3  ),HY "/*0@ BRTL (<M5 "#,7P ?S&P '<UZ !S-B@ ;
MS9P &<ZN 1C.Q0 8S>0 &,ST 1C*_ $8RO\"&,K_ AC*_P*;F0  CY\  (*F
M  !UK0  :+,  %RY  !0O0  1,$  #G$   PR   *,P! "#0!@ 9U0L %M<0
M !78&0 5V2( %-DK !/:-  3VCT $MM( !'<4P 1W5\ $-UM !#>?@ .WY$
M#N"D  W@N  ,X-( "]_M  S>]P ,W?L #-W[  S=^P"2GP  A:<  '>N  !J
MM0  7;P  %#!  !$Q0  .,D  "[-   ET0  'M4  !;: 0 1W@8 $.<-  [G
M$@ -Z!D #.@A  OI*0 *ZC$ ">H[  ?K10 %ZU$ !.M>  /K;@ !ZX   .J4
M  #JIP  Z[P  .O2  #KZ0  [.\  .SO  #L[P"'IP  >:\  &NW  !>O@
M4<4  $/)   WS0  +=$  "/6   ;VP  $]\   [C   ,[@( "O8*  ?V#@ %
M]A(  _88  #U'@  ]24  /4N  #U-P  ]D(  /9.  #V70  ]FX  /:!  #V
ME0  ]Z<  />W  #XQP  ^-   /C0  #XT ![KP  ;;@  &#   !2R   1,T
M #?1   KUP  (=P  !C@   1Y   #.<   ?O   $^@   ?\#  #_"   _PT
M /X0  #^%   _QH  /\A  #_*0  _S,  /\^  #_2P  _UL  /]L  #_@
M_Y(  /^A  #_K0  _[,  /^S  #_LP#_'"8 _QPD /\:)0#_%2< _Q$N /\0
M.@#_#D<!_PU3 ?\+7P'_"FL!_PIU ?\*?P'_"H<!_PJ. ?\*E0'_"IL!_PF@
M ?\)I0#_":L _PFQ /\)N #_"<$ _@G, /P)W@#Y">L ]0GV /,)_P#R"O\
M\0K_ ?$+_P'Q"_\!\0O_ ?$+_P'_'R, _Q\A /\>(0#_&20 _Q<L /\5-P#_
M$T0 _Q%0 ?\07 '_#F<!_PYR ?\.>P'_#H0!_PZ+ ?\.D@'_#I@!_PZ= ?\.
MHP'^#J@!_ ZN ?L.M0#Z#KX ^ [) /4.VP#R#NH [@[U .P._P'K#_\!Z@__
M >H0_P'I$/\!Z1#_ >D0_P'_(A\ _R(< /\A' #_'R  _Q\I /\<- #_&D
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M";DJ_PG_, \ _S(+ /\V#0#_.!  _SD5 /DW'@#O-2@ YS,U . R0@#;,D\
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M-P< _SL" /]  P#R0@4 Z4() .4_#@#8/A8 SD G ,=!-@#"040!O4%/ KE
M60.V/V$$M#YI!K$]<0>O/7@(KCQ_":P\A@JJ.XT+J3N5#*<[G0VE.Z8-HSJP
M#J([O ^@.\T/GCOF$)L\]1&://\1F3S_$9@\_Q&8//\1F#S_$9@\_Q'_.@$
M_T   .]%  #A2   V4@% --&"0#,11( Q$<B +U(,0"X2#\!LT=* K!&5 2L
M15T%JD1D!Z=#; BE0G,*HT)Z"Z%!@0R@08@-GD"0#YQ F!":0*$1F$"L$I=
MN!*50,@3DT#A$Y%!\Q200?\4CT'_%(Y"_Q..0O\3CD+_$XY"_Q/_/   ^40
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M&G=.ZQIW3_H9=D__&79/_QAV3_\7=D__%W9/_Q?X1@  XE   -!7  #$7
MNUX  +1=  "N6@8 IEL3 *!<(@";7"\ EUL[ I):10./64T&BUA5"(A77 J&
M5F,,@U5J#H%4<1!^5'@2?%. %'I2B19X4I08=E*?&712JQIR4KH;<5+-''!2
MZ!MP4_D:<%/_&G!3_QEP4_\8<%/_&'!3_QCO20  W5,  ,M:  # 7P  MV(
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M&V!>_QIA7O\:85[_&F%>_QKD4@  SUP  ,!D  "V:0  K&P  *-L  "9:0
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M&4UO_QG.8   OFH  +)R  "H>   G7L  )!Z  "$>@  >GL  '1\# !O?A<
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M#SZ*F!$\BJ<2.XJX$CJ*SQ([B.L2.X?Z$SN&_Q,[AO\3.X;_$SN&_Q.\<0
MKWL  *6#  "9AP  C(@  '^)  !SC   99   %R3  !7E0P 5)86 %*6(@!0
MERT 39<V $N7/P%)ET<"1Y=. T66501#EET%099E!CZ5;P@\E7H).I6'"SB5
ME0PVE*4--92V#C24S TTD^D--)+X#C20_P\TD/\/-)#_#S20_P^U>   JH(
M )Z(  "3C0  AHX  'F0  !MDP  89<  %6;  !-G@8 29\0 $>?&P!&H"8
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M 1RYP $<N-\!'+;R 1NU_ (;M/\"&[3_ ANT_P*?CP  E)4  (B;  ![H0
M;J8  &*K  !6L   2K,  #^V   UN0  ++P  "2_!@ ?P@T '<(4 !S"'@ ;
MPR8 &L,O !G$.  8Q$$ %\1* !;%50 5Q6$ %,9O !/&?P 2QI$ $<>D !#'
MN0 /Q]0 $,;N !#$^@ 0P_\ $,/_ !##_P"7E@  BYP  'ZB  !QJ0  9*\
M %BT  !+N   0+L  #6^   KP0  (\4  !O) 0 4S 8 $- +  [1$0 -T1D
M#=$A  S1*@ ,T30 "](^  K220 )TU4 "=-B  C3<@ &U(0 !=28  34JP #
MU<   =7<  '5[0 !U?8  =7V  '5]@".G0  @*0  '.K  !FL0  6;@  $R]
M   _P   -,,  "K'   AR@  &<X  !+2   -U@$ "=L%  ;<#0 $W!$  ]T8
M  '>(   WB@  -\Q  #@/   X4<  .)4  #C8P  XW0  .2(  #DFP  Y:X
M .7!  #EU0  YN<  .;G  #FYP"#I   =:P  &BS  !:NP  3<$  $#$   S
MR   *,P  !_0   7U   $-D   O=   %X0   .0   #E!P  Y@T  .<1  #H
M%@  Z1T  .HE  #K+@  [3D  .]%  #P4P  \60  /%V  #RB@  \YP  /.M
M  #TNP  ],@  /3(  #TR !WK0  :K4  %R]  !/Q   0,D  #/-   GT0
M'=8  !3<   .X   ".,   'F    Z@   .X   #N    [P0  / *  #Q#@
M\Q(  /08  #V(   ^"H  /HU  #]0P  _E(  /]C  #_=@  _XD  /^:  #_
MI@  _[   /^P  #_L #_%B, _Q4A /\1(0#_#20 _PDK /\&-P#_ T0 _P!1
M /\ 70#_ &@ _P!R /\ >P#_ (, _P"* /\ D0#_ )8 _P"< /\ H0#] *8
M^P"L /D LP#W +L ]0#% /, T0#R .0 \0#Q .\ ^@#N /\ [@#_ .T _P#M
M /\ [0#_ .T _P#_&2  _Q@= /\5'0#_$!\ _PXI /\,- #_"D$ _P=- /\%
M60#_!&0 _P1N /\#=P#_ X  _P.' /\#C0#] I, ^P*9 /D"G@#W J0 ]0*J
M /,!L #Q ;@ [P'" .T!SP#K >, Z@'O .@"^P#G!/\ Y@7_ .8&_P#F!O\
MY@;_ .8&_P#_'!L _QL9 /\7& #_%1T _Q,E /\1, #_$#T _PY) /\,50#_
M"V  _PMJ /T+<P#["WP ^0J# /<*B@#U"I  ] J6 /,*FP#Q"J$ [PFG .T)
MK@#K";8 Z G  .8)S0#D">( X@KP -\+^P#>#/\ W W_ -P-_P#;#?\!VPW_
M =L-_P'_'Q< _QX3 /\;$@#_'!D _QLB /\8+ #_%3@ _Q-$ /X24 #Y$5L
M]1!F /,0;P#P$'< [A!_ .P0A@#J$(P Z1"2 .@0F #F#YX Y0^E .,/K #A
M#[0 X ^^ -X/S #:$.$ U1'P -(2^P#/$O\!SA/_ <T3_P'-$_\!S!/_ <P3
M_P'_(A( _R(/ /\A#P#_(A0 _R(< /\@)P#_'3( ^!L^ /(92P#N&%8 ZA=@
M .<6:@#D%G( XA9Z . 6@@#>%H@ W!:/ -L6E0#9%IL UA:B -06J0#2%K$
MT!>[ ,X7R0#,&-X R!GN <4:^P'#&O\"P1O_ L ;_P+ &_\"P!O_ L ;_P+_
M)@X _R4+ /\H# #_*1  _R@6 /XF( #T)"L ["$X .8@1 #A'U  W1]; -D>
M90#5'FT TA]U - ??0#.'X, S!^* <L?D ')'Y<!R!^> <8?I0'%(*T!PR"W
M <$@Q ' (=8!O"+J KDB^ .V(O\#M2/_ [0C_P2S(_\$LR/_!+,C_P3_*0L
M_RH% /\N" #_+PP _RT0 /,K%P#H*"( X"8O -DF/0#2)TH S2=5 ,HH7P#'
M*&@!Q2AO <,G=P'!)WX!OR>$ ;XGBP*\)Y("NR>9 KDGH *W)ZD#MBBS [0H
MOP.S*,\#L"GF!*TI]@2K*O\%J2K_!J@J_P:H*O\&J"K_!J@J_P;_+04 _S
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M#(P\[ V*//L-B3S_#8D\_PR(//\,B#S_#(@\_PS_-P  ZC\  -Q%  #.20
MQ4D  +]& @"Z0PP LT09 *U%)P"H1C4 I$5! :!%2P*=1%,"FD-; YA#8@66
M0FD&E$%P!Y)!=@B00'X)CD"&"HU C@N+0)@,B4"B#8= K@Z%0+P/A$#/#X)!
MZ0^!0?D/@$'_#X!"_PZ 0O\.@$+_#H!"_P[Z.P  Y40  --+  #'3@  OD\
M +A,  "R20D JTD5 *5+(P"@2S$ G$L] 9A*1P*524\#DDE7!)!(7@6.1V4&
MBT=K!XE&<@F(1GD*AD6""X1%B@V"190.@$2?#WY$JQ!\1;D1>T7+$7I%YA%Y
M1O<1>$;_$'A&_Q!X1O\/>$;_#WA&_P_P/P  WTD  ,U/  #!4P  N%0  +%2
M  "K3@4 I$X1 )Y/( "94"T E5 Y 9)/0P&.3DP#BTU3!(E-6@6&3&$&A$MH
M"()+;@F 2G8+?DI^#'Q)APYZ29$/>$F<$'9)J!)T2;82<TG($W)*XQ-Q2O42
M<4K_$7%+_Q%Q2_\0<4O_$'%+_Q#L0P  V4P  ,A3  "]5P  M%@  *Q7  "E
M4@$ GE,/ )A4' "35"D CU0U (M30 &(4T@"A5)0!()15P5_4%X&?5!D"'M/
M:PEY3W(+=TY[#75.A YS38X0<4V9$6]-I1-M3;,4;$W%%&M.X11K3O03:T[_
M$FM._Q)K3O\1:T[_$6M._Q'H1@  TU   ,16  "Y6@  L%P  *9:  "?5@
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M$E==_Q+64P  Q%P  +=C  "L:   H&@  )5G  "*8P  @V4" 'UF#P!X9AH
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M$$IMF!%);*<22&RX$T=LS1-';.H32&OZ$DAK_Q)(:O\12&K_$4AJ_Q''7@
MN&<  *QN  "A<@  DW(  (=Q  !Z<0  <7(  &MT!P!F=1$ 8W8= &!W* !>
M=S, 6W@\ 5EW0P)6=TL#5'=2!%)V6050=F '3G5H"$MU<0I)='P,1W2(#D5S
ME@]#<Z400G.V$4%SRQ%"<N@10G+X$4)Q_Q!#</\00W#_$$-P_Q#!8P  LVP
M *AS  ";=@  CG4  (%V  !U=@  :7@  &-Z @!>? X 7'T9 %E^) !7?R\
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M!R^.PP<OCN$'+XST""^+_P@OBO\(+XK_"2^*_PFP=@  I7\  )B$  "*A
M?84  '"'  !EB@  6HX  $^2  !&E0  09@, #Z8%  ]F1\ .YDH #J:,0 Y
MFCH -YI" #::2@ UFE(!,YI: 3&:9 $OFF\"+9I[ BR:B@,JFIH#*9JL!"B:
MP 0GF=X#)Y?R!">6_04GE?\%)Y7_!2>5_P6I?@  GH4  )*)  "$B@  =HP
M &J/  !>DP  5)<  $F;  ! GP  -Z($ #*C#@ QHQ< ,*0A "ZD*@ MI#(
M+*4Z "NE0P JI4L *:54 "BE7@ FI6D ):5V 2.EA0$BI98!(*:H 1^ENP$>
MI=<!'J3O 1ZB^P(>H?\"'J'_ AZA_P*BA@  EXP  (N/  !]D0  ;Y0  &.8
M  !7G0  3:$  $.E   XJ   ,*L  "BN!P DKQ  (Z\7 "&O(0 @L"D '[ Q
M !ZP.@ =L4( '+%, !NQ5@ :L6$ &;)O !BR?@ 6LI  %;*B !2RM@ 3LLX
M$['K !.O^0 3KO\!$Z[_ 1.N_P&:C0  D)(  (27  !UF@  :)\  %NC  !0
MJ   1:P  #NP   QL@  )[4  ""X   8N@< %+P. !.\%0 2O!X $;TF !&]
M+@ 0O3< $+Y!  Z^3  .OE< #;YE  R_=  +OX8 "KZ9  B^K  'OL( ![[?
M  B^\  (O?H "+W\  B]_ "3E   AYD  'J?  !LI0  8*H  %.O  !'LP
M/+8  #&X   GNP  '[X  !?!   1Q $ #,@(  C)#@ 'R10 !LD<  7))  $
MRBP  \HV  +*0   RTP  ,M9  #+:   RWD  ,R,  #+GP  R[,  ,O(  #,
MX@  S.\  ,SQ  #,\0"*F@  ?*$  &^G  !BK0  5;,  $BX   [NP  ,+X
M ";!   =Q   %<@   _+   *S@  !-("  #3"@  TP\  -04  #5&@  UB(
M -<J  #9-   VC\  -Q+  #<6@  W6H  -U]  #=D0  W:0  -ZV  #>R
MWMX  -[B  #>X@!_H@  <:D  &2P  !6MP  2;P  #S    OQ   ),<  !O+
M   3SP  #=(   ?6    VP   -X   #? P  X D  .$.  #B$@  XQ<  .4>
M  #F)P  Z#$  .H]  #L2P  [%H  .UL  #N@   [I0  .ZE  #NM   [L(
M .[&  #NQ@!TJ@  9K(  %BY  !+P   /<4  "_)   DS0  &=$  !'6   +
MVP   ]X   #A    Y0   .@   #I    Z@   .L&  #M"P  [P\  / 3  #R
M&@  ]",  /<N  #Y.P  ^TH  /Q;  #];0  _8   /Z3  #^H@  _JT  /ZO
M  #^KP#_$!\ _PX= /\*'0#_ 2  _P H /\ -0#_ $$ _P!. /\ 6@#_ &4
M_P!N /\ =P#_ '\ _@"& /P C #[ )( ^0"7 /@ G #W *( ]@"G /4 K0#S
M +4 \@"] /$ R0#O -P [@#K .T ]P#L /\ ZP#_ .H _P#J /\ Z@#_ .H
M_P#_$QP _Q$9 /\-&0#_!AP _P,E /\ ,0#_ #X _P!* /\ 5@#_ &$ _P!K
M /T <P#Z 'L ]P"# /4 B0#T (\ \@"4 /$ F0#P )\ [@"D .T JP#L +(
MZ@"Z .@ Q@#G -8 Y0#H .0 ]0#C /X X@#_ .$ _P#A /\ X0#_ .$ _P#_
M%1@ _Q,4 /\/% #_#1D _PLB /\(+0#_!#D _P%& /\ 40#^ %P ^@!F /8
M;P#R '< [P!^ .T A0#K (L Z@"1 .@ E@#G )P Y@"A .0 J #C *\ X0"X
M -\ PP#= -$ VP#F -D \P#7 /T U0+_ -0"_P#4 _\ U /_ -0#_P#_&!,
M_Q40 /\2#P#_$A4 _Q$= /\.* #_##0 _PI! /D(3 #U!E< \09A .T&:@#I
M!7( Y@5Z .0%@0#B!8< X :- -\&D@#=!I@ VP:> -D&I0#7!JT U :U -(&
MP #0!\\ S@CE ,P)] #*"_\ R S_ ,<,_P#'#/\ Q@S_ ,8,_P#_&PX _QD,
M /\8#0#_&!$ _Q<8 /\4(@#[$2X \Q Z .T.1@#H#5( Y0U< .$-90#>#6T
MVPUU -@-? #5#8( TPV) -$-CP#0#94 S@V< ,T.HP#+#JL R0ZT ,@.P #&
M#L\ PQ#F , 1]0"]$O\ O!+_ +L2_P"Z$O\!NA+_ ;H2_P'_'PH _QP$ /\?
M" #_'PT _QT2 /@:&P#N%B8 YA0S . 3/P#:$TL U!-6 - 37P#.%&@ RQ1O
M ,D4=P#'%7T QA6$ ,05B@##%9$ P1:8 , 6GP"^%J< O!>P +L7O "Y%\L
MMQCB +,9\@&Q&O\!KQO_ :X;_P&N&_\!K1O_ :T;_P'_(@0 _R(  /\E @#\
M) < ]R$, .P=$@#A&AP V!HJ - ;. #+'44 QQU0 ,,>6@# 'F( OAYJ +P?
M<0"Z'W@ N1]^ +<?A0"V'XP M!^3 +,?F@&Q(*,!L""L :X@MP&L(<8!JR'=
M :<B[P*E(OT"HR/_ J(C_P*B(_\"H2/_ J$C_P+_)0  _R@  /(J  #E*P
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M"7H\_PAZ//\(>CS_"'H\_PCN-P  W4$  ,M&  "_20  MDD  *Y&  "I000
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M"V!-_PO<1P  QU   +E6  "N60  HE@  )A6  "040  B5(& (-3$0!_4QT
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M"U19F U36*8.4EFV#E%9R@]16><.45CX#5)8_PU26/\,4EC_#%)8_PS-40
MO%D  +!?  "C80  EF   (M?  "!6P  >5T  '-># !O7A4 :U\@ &A?*P!F
M8#4 8V ] 6%?10%?7TP"75]3 UM?6@197F$%5UYI!E5><@A37GT)45V)"U!=
ME@Q.7:0-35VT#DQ=R Y,7>8.35WW#4U<_PQ-7/\,3ES_#$Y<_PS)5   N5P
M *UC  "?8P  DF,  (=B  !\8   =&$  &YB"0!I8Q( 9F,= &-D* !A9#(
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M"CUNP@H\;N */6WT"CUL_PH]:_\*/FO_"CYK_PJZ8   K6D  *!N  "1;0
MA&T  'AM  !L;@  87   %MR  !6= H 4G42 %!V'0!.=R< 3'<Q $MX.0!)
M>$$ 2'A) 49X4 %$=U<"0G=? T!W: ,^=W,$/'9_!CIVC0<Y=IP(-W6M"#=U
MP @V==X(-W3R"#=S_@@W<O\(-W+_"#=R_PBU9@  J6\  )IQ  "+<0  ?G$
M '-R  !H<P  7'8  %1Y  !.>P4 2GT/ $A^& !&?R, 17\L $. -0!"@#T
M08!% #^ 3 $]@%0!/(!< CI_90(X?V\#-G]\!#1_B@0R?YH%,7ZJ!C!^O08P
M?MH&,'WP!C![_08P>_\&,'K_!C!Z_P:P;   I'4  )1U  "&=0  >78  &YW
M  !C>0  5WT  $^!  !'A   0H8, #^'$P ]B!T /(@G #N),  ZB3@ .(E
M #>)2  VB4\ -(E8 3.)80$QB6P!+XEX BV)AP(LB9<#*HBG RF(N@,IB-0#
M*8;N RF%_ 0IA/\$*83_!"F$_P2J=   GGL  (YZ  " >@  ='L  &A^  !=
M@0  4H4  $F)  !!C   .9 % #61#P SDA< ,I(A #&2*0 PDS( +I,Z "V3
M00 LDTH *Y12 "J47  HE&< )Y1S 264@@$DE),!(I.D 2&3MP$@D\\!(9+L
M 2"0^@(@C_\"((__ B"/_P*D?   EX   (=_  ![@   ;H(  &*%  !7B0
M38X  $*2   ZE@  ,ID  "J<"0 HG1$ )IT9 "6=(@ DGBH (YXR "*>.@ A
MGD( ()Y+ !^?50 >GV  ')]M !N??  :GXT &)^? !>?L@ 6G\D %I[H !:<
M]P 6F_\!%YO_ 1>;_P&=@P  CX8  (*&  !TAP  9XL  %N/  !0DP  1I@
M #R<   SH   *Z,  ".F   <J L &JD1 !BI&  7J2$ %JHI !6J,0 4JCD
M$ZI# !.K30 2JU@ $:ME !"K=  .JX8 #JN9  VKK  ,J\$ #*K?  RI\@ -
MJ/P #:C_  VH_P"6B@  B8P  'J-  !LD0  8)4  %2:  !)GP  /Z,  #6G
M   KJ@  (ZX  !NP   4LP$ #[4*  VV$  ,MA8 "[8?  JV)P )MB\ "+8Y
M  >W0P &MT\ !+=;  .W:@ "MWL  +>.  "WH0  MK0  +;+  "VY0  M?$
M +7W  "U]P"/D0  @90  '*7  !EG   6*$  $RF  !!JP  -Z\  "RR   C
MM0  &K@  !.[   .O0  "< %  /!#0  P1$  ,$7  #"'@  PB8  ,(O  ##
M.0  Q$0  ,10  #$7@  Q6\  ,6!  #%E0  Q:@  ,6\  #$T0  Q.8  ,3N
M  #$[@"&F   >9X  &NC  !=J0  4*X  $2S   WM@  ++D  "*\   9OP
M$<(   S%   &R    ,L   #,!P  S T  ,T1  #-%@  SAT  ,\D  #0+0
MTC@  -1$  #44@  U6$  -5S  #6AP  UIL  -:M  #7OP  V,X  -C=  #8
MW0![H   ;J8  &"M  !3LP  1;@  #B\   KOP  (<(  !?&   0R0  "LP
M  +0    U    -<   #8    V@4  -L+  #<#@  WA,  -\9  #A(0  XRH
M .4V  #G0P  YU,  .AD  #I=P  Z8P  .J?  #JK@  ZKH  .K#  #JPP!P
MJ   8J\  %6V  !'O   .<   "S$   @R   %LP   [0   'U    -D   #=
M    X0   .,   #D    Y@   .<!  #I!P  ZPP  .P0  #N%0  \!T  /,G
M  #V,P  ]T,  /A4  #Y9@  ^7H  /J.  #ZG@  ^ZD  /NP  #[L #_"QL
M_P<9 /\ &0#_ !P _P E /\ ,@#_ #\ _P!+ /\ 5P#_ &( _P!K /\ <P#]
M 'L ^P"" /H B #X (T ]P"2 /8 F #U )T ] "B /, J0#Q +  [P"X .X
MPP#L -$ ZP#F .D \P#H /X Z #_ .@ _P#H /\ Z #_ .@ _P#_#A@ _PH5
M /\!% #_ !@ _P B /\ +@#_ #L _P!' /\ 4P#] %X ^@!G /< ;P#U '<
M\P!^ /( A #P (D [P"/ .X E #L )H ZP"? .D I0#H *P Y@"T .0 OP#C
M ,P X0#B -\ \ #> /L W@#_ -T _P#= /\ W #_ -P _P#_$!, _PT1 /\&
M$ #_ A4 _P > /\ *0#_ #8 _P!" /H 3@#T %D \0!B .X :P#L '( Z@!Y
M .@ ?P#G (4 Y0"+ .0 D #B )8 X0"< -\ H@#= *D V@"Q -@ NP#5 ,@
MT@#= -$ [0#0 /D SP#_ ,X _P#- /\ S0#_ ,T _P#_$0\ _PX- /\,#0#_
M"Q( _P<9 /\") #_ #  ]@ \ .\ 20#J %, YP!= .0 9@#A &T WP!T -T
M>P#; ($ V0"& -8 C #4 )( T@"8 -  G@#. *8 S "N ,H N #( ,0 Q@#7
M ,4 Z@## /< P@#_ ,$!_P#  O\ P +_ , "_P#_% L _Q & /\0"0#_$ X
M_PX4 /\*'@#U!BD ZP0V .,#0@#? TX VP17 -8$8 #3!&@ T 1O ,X%=@#,
M!7P R@6" ,D%B #'!8X Q@64 ,0%FP#"!:, P :K +X&M0"]!L( NPC4 +H)
MZ0"W"_@ M0S_ +0,_P"T#/\ M S_ +0,_P#_%P0 _Q0  /\6 P#_% D _Q$.
M /(.%0#H#"$ W@HN -8+.P#0#$< S Q1 ,D,6@#&#6( Q UJ ,(-<0# #7<
MOPU] +T.@P"\#HH N@Z1 +D.F "W#J  M@ZI +0/M "R#\$ L1#4 *X1ZP"K
M$OH J1+_ *@3_P"G$_\ IQ/_ *<3_P#_&@  _QL  /D;  #K&0  Y10& .40
M#@#9#A< SQ$F ,@2- #$$T  OQ1+ +P45 "Y%5T MQ5D +45:P"T%7$ LA5X
M +$6?@"O%H4 KA:, *P6E "K%YP J1>F *<8L "F&+T I!C/ *(:YP"?&O<
MG1O_ 9P;_P&<&_\!FQO_ 9L;_P'_'0  ]R$  .@D  #=)0  U"$! ,\;" #*
M%Q$ PAH@ +P<+0"W'3H LQY% + >3P"M'E< JQY? *D?9@"H'VP IA]S *4?
M>0"C'X  HA^' * @CP"?()@ G2"B )L@K &:(;D!F"'* 98BY &4(_4!DB/_
M 9$C_P&0(_\!D"/_ 9 C_P'_(@  ZRD  -TN  #/+P  QRT  ,$G P"](@T
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M!6P\_P7B.0  S$(  +Y'  "Q2   I48  )U#  "7/P  DCX+ (T_%0")/R$
MA4 M () -P!_0$  ?4!( 'M 3P%Y0%8!=S]= 74_8P)S/VH"<3]R W _>@-N
M/X0$;#^0!6L_G 9I/ZD&:#^X!V= S =F0.@'9D#Y!F5 _P9E0/\&94#_!65
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M!EY(EP==2*4(6TBT"%M(QPE:2.0(6DGV"%I)_P=:2/\&6DC_!EI(_P;110
MOTP  +)2  "C40  EU   (U.  "&2@  @$H! 'I+#@!V3!< <DPC &],+0!M
M338 :DP_ &A,1@!F3$T!9$Q3 6),6@)A3&$"7TQI UY,<@1<3'P%6DR(!EE,
ME0=73*,(5DRR"%5,Q@E53.()54SU"%5,_P=53/\'5DS_!E9,_P;,2   O%
M *]5  "@5   DU,  (E1  "!30  >DX  '5/# !P3Q4 ;5 @ &I0*@!G4#,
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M"$=8P A'6-T(1UCR"$=7_P=(5_\'2%?_!DA7_P;!40  LED  *-<  "46P
MAUL  'U:  !R6   :UD  &5: P!@6PX 75P7 %I<(0!872L 5ETT %1>/ !3
M7D0 45Y+ 5!>4@%.7ED"3%YA DM=:@-)770$1UV !45=C09$79P'0UVL!T)=
MO@A"7=H(0ESQ!T)<_@=#6_\&0UO_!D-;_P:]50  KUT  )]?  "07@  @UX
M 'A=  !M7   95T  %]?  !:8 P 5V$4 %5B'@!28B@ 46,Q $]C.0!.8T$
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M!#%N^P0Q;?\$,6S_!#%L_P2O9   H6D  (]H  "!:   =6D  &MI  !@:P
M56X  $UQ  !&<P  0G4+ #]V$@ ]=QP /'<E #IX+0 Y>#4 .'D] #=Y10 V
M>4T -7E5 #-Y7@ Q>6@!,'ET 2YY@P(M>9("*WBC BIXM0(J>,P"*G?J BIV
M^0,J=?\#*G3_ RIT_P.J:@  FFT  (EL  !\;0  <&T  &9N  !;<0  4'4
M $AX  !!>P  .GX% #9_#@ T@!8 ,X$@ #*!*  P@3  +X(X "Z"0  M@D@
M+()0 "N"6@ J@F0 *()P ":"?P$E@H\!)(*@ 2."L@$B@LD!(H'G 2)_]P$B
M?O\"(GW_ B)]_P*E<0  DW$  (-Q  !V<0  ;'(  &!U  !6>   3'P  $.
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M !"4_P"5?0  A7P  'A\  !K?@  7X$  %2&  !*B@  0(\  #:3   MEP
M)IH  !Z=   7H , $J(, !"C$@ 0HQD #Z,A  ZD*0 .I#$ #:0Z  RD10 +
MI%  "J1<  FD:@ 'I'L !J..  2CH0 "H[0  Z++  .BY@ #H?,  Z'[  .A
M^P"-@P  ?X(  '&$  !DAP  6(P  $V1  !"E@  .)H  "^>   FH@  'J4
M !>H   1JP  #*X'  >O#0 #KQ(  J\9  &O(0  KRD  + R  "P/   L$<
M +!3  "P80  L'$  +"#  "OEP  KZH  *^_  "NV0  KNL  *[T  "N] "'
MB0  >(H  &J.  !=DP  49@  $6=   [H@  ,*8  ">J   >K@  %K$  !"T
M   +M@  !;D#  "Z"@  N@X  +H3  "[&0  NR$  +PH  "\,0  O3P  +Y(
M  "^5@  OF4  +YW  "^C   OI\  +VS  "^QP  OMX  +WK  "]ZP!_D@
M<)4  &*:  !5GP  2:4  #VK   RKP  *+0  !ZV   5N0  #KP   F_   "
MP@   ,0   #%!   Q@H  ,8.  #'$@  R!@  ,D?  #*)P  S#   ,X\  #.
M20  SUD  ,]J  #/?@  SY,  ,^F  #/N   S\@  ,_;  #/VP!WG   :*$
M %NG  !.K@  0;0  #2W   HN@  ';T  !/    -Q   !L<   #*    S@
M -    #1    T@(  -,(  #5#   UA   -D5  #;'   W20  . O  #B/
MXTL  .1<  #D;P  Y8,  .68  #EJ0  Y;8  .7#  #EPP!LI0  7ZP  %&R
M  !$N0  -;P  "C    <Q   $L@   S+   #SP   -,   #8    W    -\
M  #?    X0   .,   #D P  Y@@  .@-  #I$0  [!@  .XB  #Q+@  \SP
M /1-  #U7P  ]G,  />'  #WF0  ^*4  /BP  #XL #_ Q< _P 5 /\ %0#_
M !@ _P C /\ +P#_ #P _P!( /\ 5 #_ %X _P!G /T ;P#[ '8 ^0!] /@
M@P#V (@ ]0". /0 DP#R )@ \0"> /  I #N *L [0"S .L O0#J ,L Z #A
M .< \0#F /T Y0#_ .0 _P#D /\ Y #_ .0 _P#_!Q, _P 1 /\ $0#_ !4
M_P ? /\ *P#_ #< _P!$ /X 3P#Z %H ]P!C /0 :P#R '( \ !Y .\ ?P#M
M (0 ZP"* .H CP#H )0 YP": .4 H #D *< X@"O .  N0#> ,8 W #: -H
M[ #8 /D U@#_ -8 _P#7 /\ V #_ -@ _P#_"A  _P,. /\ #0#_ !( _P :
M /\ )@#\ #( ]P _ /0 2@#Q %4 [0!> .H 9@#H &X Y0!T ., >@#B (
MX "% -X BP#< )  VP"6 -@ G #5 *, TP"K -$ M0#. ,$ S #1 ,L YP#)
M /4 R #_ ,@ _P#( /\ R #_ ,@ _P#_# P _P8( /\""@#_  \ _P 5 /P
M( #Q "P [  Y .D 10#E $\ X0!9 -X 80#; &@ UP!O -0 =0#2 'L T "
M ,X A@#, (P RP"2 ,D F #' *  Q0"H ,, L0#! +P OP#+ +T XP"\ /(
MNP#] +L _P"Z /\ N@#_ +H _P#_#@4 _PD  /\)!0#_!@L _P$0 /  &0#F
M "4 X0 R -P /P#6 $D T0!3 ,X 6P#+ &, R !J ,8 < #% '8 PP![ ,$
M@0#  (< O@". +P E "[ )P N0"D +< K@"U +D LP#( +$ WP"P >\ KP'[
M *X"_P"M _\ K0/_ *T#_P#_$   _PX  /\-  #V"P, \@<* .(!$0#; AT
MT@,K ,P#-P#(!$, Q 1- ,$$5@"^!5T O 5D +H%:P"X!7$ MP5V +4%? "S
M!H, L@:) + &D0"O!YD K0>A *L'JP"I"+< J G& *8*W0"E"_  HPS] *(-
M_P"A#?\ H0W_ * -_P#_$0  _!(  .P3  #B$P  VP\# -8)"P#."!0 Q@HB
M , ,, "\#3P N U& +4-3P"R#E< L Y? *X.90"M#FL JPYQ *H.> "H#GX
MIP^% *4/C0"D#Y8 HA"? * 0J0"?$+4 G1'% )L1W@"9$O$ EQ/_ )84_P"5
M%/\ E13_ )04_P#_%0  [1L  . ?  #2'P  R1L  ,04!0#!$ X NA(; +03
M*0"P%#4 K!5  *D520"F%5( I!99 *(68 "A%F8 GQ9L )X6<@"<%GD FQ>
M )D7B "8%Y$ EAB; )08I@"3&;( D1G! ) :V "-&^X BQS] (H<_P"*'/\
MB1S_ (D<_P#T'0  Y"4  -,I  #'*@  O"8  +8@  "T&0L KAH5 *@<(P"D
M'2\ H1XZ )X>1 ";'DP F1Y4 )<?6P"5'V$ E!]G )(?;0"1'W0 CR!\ (X@
MA ",((T BB"7 (DAH@"'(:X AB*] (4BT0&"(^L!@23[ 8 D_P%_)/\!?R3_
M 7\D_P'L)0  VRT  ,DQ  "\,0  L2X  *LI  "G) 4 HR,1 )XD'0":)2H
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M FPTF )J-:4":36S V@UQ@-G-N(#9C;U V8V_P)F-O\"9C;_ F8V_P+8-P
MQ#X  +5"  "F00  FS\  ),\  "-.   B#8' (0W$0" -QP ?#@G 'HX,0!W
M.3H =3E" ',Y20!Q.5  <#E7 &XY70!L.60!:SEK 6DY= %H.7X"9CF) F0Y
ME0-C.J(#8CJQ V$ZPP-@.^ $7SOS U\[_P-?._\#7SO_ E\[_P+1.P  P$(
M +!%  "A1   E4,  (U   "'/0  @CL" 'T[#@!Y/!@ =3TC ',]+0!P/38
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M!%!'O01/1]8%3T?O!$]'_01/1_\#3T?_ U!'_P/$10  M4T  *--  "53
MB4L  ']*  !X1@  <4<  &Q'!P!H2!  9$@: &%)) !?22T 74DU %M)/0!9
M240 5TE* %9)40!52ED!5$IA 5)*:0%12G0"3TI_ TY*C --2IL$3$NJ!$M+
MO 1*2],%2DON!$M+_01+2O\#2TK_ TM*_P/!2   LE   *!/  "13P  A4X
M 'M-  !S20  ;$H  &=+! !B3 X 7TP7 %Q-(0!:32H 6$TR %9-.@!434$
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M SQ7^@,]5O\#/5;_ SU6_P.V4P  I5<  )17  "%5@  >58  &]6  !E50
M7%8  %=8  !260< 3EH0 $Q:& !*6R$ 2%PJ $=<,@!%7#H 1%U! $-=2 !"
M75  0%U8 #]=80$]76L!/%UV CI=A (Y79,".%VC S==M0,V7<L#-ESH S=<
M^0,W6_\#.%O_ SA:_P.R5P  H%H  (]9  "!60  =5D  &M9  !@6@  5EL
M %%=  !,7@( 2& - $5@% !$81X 0F(F $!B+@ _8C8 /F,^ #UC10 \8TT
M.V-5 #EC7@ X8V@!-F-T 35C@0$S8Y$",F.A C%CLP(Q8\@",6+G C%A^ (Q
M8?\",F#_ C)@_P*N7   FUT  (I=  !\70  <%T  &9=  !<7@  4F   $QB
M  !%90  068* #YG$0 \:!H .V@B #EI*P X:3( -VHZ #9J00 U:DD -&I2
M #-J6P Q:F4 ,&IP 2YJ?@$M:HX!+&J? 2MJL $J:L8!*FGE 2IH]@(K9_\"
M*V?_ BMG_P*I80  E6   (1@  !W8   ;&$  &)A  !88P  3F8  $=H  !
M:P  .FX% #9O#@ T<!4 ,W > #)Q)@ P<2X +W$U "YR/0 M<D4 +')- "MR
M5P J<F$ *7)M "=R>P F<HL )'*< 2-RK@$C<L,!(W'B 2-P] $C;_\!(V[_
M 2-N_P&A90  CF0  ']D  !R9   :&4  %YF  !4:0  26P  $)O   [<@
M-'4  "YX"@ K>1$ *GD8 "EZ(0 G>B@ )GHP "5[.  D>T  (WM( ")[4@ A
M>UP ('MH !]\=@ =?(8 ''N8 !M[J@ :>[\ &GO> !IY\@ ;>/X &W?_ 1MW
M_P&9:0  B&D  'EI  !M:0  8VH  %EL  !/;P  17,  #UW   U>@  +GT
M ">! P B@PT ((02 !^$&@ =A"( '(4J !N%,0 :A3D &85" !B&3  7AE8
M%H9C !6&<0 4AH$ $H:3 !&&I@ 1A;L $(76 !&#[P 1@OL $H+_ !*!_P"1
M;@  @6T  '1N  !I;@  77   %-S  !)=P  0'P  #>    O@P  )X<  "&*
M   :C08 %8\- !.0$P 2D!H $I B !&0*@ 0D3( $)$[  ^11  .D4\ #9%<
M  R1:@ +D7H "I&-  B0GP 'D+, !X_)  >/Y@ 'CO0 "(W\  B-_P")<P
M>W,  &]S  !C=0  5W@  $U]  !#@0  .88  #"*   HC@  (9$  !J5   3
MEP  #IH(  N<#@ )G!, ")P:  ><(@ &G"H !)PS  .</0 "G4@  )U4  "=
M8@  G'(  )R$  "<EP  FZH  )N_  ":VP  FNP  )KU  "9^ "">0  =GD
M &AZ  !<?@  48(  $:'   \C   ,I$  "F5   AF0  &9T  !*@   .HP
M":8%  .G#   IQ   *<5  "H'   J",  *@K  "I-   J3\  *E+  "I60
MJ6@  *EZ  "IC@  J:$  *BU  "HRP  I^0  *?O  "G\P!]@   ;X$  &&$
M  !5B0  28X  #Z4   TF0  *IX  "&B   9I@  $JD   VL   'KP   +(
M  "S!P  LPP  +,0  "T%0  M!L  +4B  "V*P  MS4  +=   "X3@  N%T
M +AN  "X@@  N)<  +BJ  "WO@  M](  +?F  "WZ@!VB   9XL  %J0  !.
ME@  0IP  #>B   LIP  (JL  !FO   1LP  "[8   2Y    O    +X   "^
M    OP8  , +  #!#P  PA,  ,,9  #$(   Q2D  ,<T  #(0@  R5$  ,EB
M  #)=0  R8H  ,F?  #*L0  RL$  ,G1  #)V0!NDP  8)@  %.>  !&I
M.JL  "^P   DM0  &;@  !"\   *OP   <$   #$    R    ,H   #*
MS    ,T#  #."   T T  -$0  #3%@  UAX  -HH  #=-   WD,  -]4  #?
M9P  X'P  ."1  #@I   X+(  ."^  #@PP!FGP  6:8  $RM   _M   ,K@
M "2\   8OP  $,,   C'    R@   ,T   #1    U0   -@   #9    VP
M -T   #?    X00  .,*  #E#@  YQ,  .H<  #M)P  \#4  /%&  #R6
M\VL  /.   #TE   ]*,  /2N  #TL@#_ !, _P 1 /\ $0#_ !4 _P ? /\
M+ #_ #D _P!% /\ 4 #_ %H _@!C /L :P#Y '( ]P!X /4 ?@#T (0 \@")
M /$ C@#P ), [@"9 .T GP#L *8 Z@"N .@ N #F ,4 Y0#; ., [0#B /L
MX@#_ .$ _P#A /\ X0#_ .$ _P#_ !  _P . /\ #0#_ !( _P ; /\ * #_
M #0 _@!! /L 3 #W %8 ] !? /$ 9@#O &T [ !T .H >@#I '\ YP"% .8
MB@#E (\ XP"5 .$ FP#@ *( W@"J -L M #9 ,  U@#0 -, Z #2 /< T0#_
M -$ _P#0 /\ T #_ -  _P#_  T _P ) /\ "@#_  \ _P 6 /L (@#W "\
M]  [ /  1P#M %$ Z0!: .4 8@#B &D X !O -X =0#< 'H V@"  -@ A0#5
M (L TP"1 -$ EP#/ )X S0"F ,L KP#) +H QP#) ,4 X@#$ /( PP#^ ,(
M_P#! /\ P@#_ ,( _P#_ P8 _P ! /\ !@#_  P ^0 1 /$ '0#K "D YP V
M ., 00#? $L VP!4 -4 7 #2 &, SP!J ,T < #+ '4 R0![ ,@ @ #& (8
MQ0", ,, DP#! )H OP"B +T JP"[ +8 N0#$ +< V@"V .T M #Z +0 _P"T
M /\ M #_ +0 _P#_!   _P   /\   #_  8 [  - .4 %@#> "( UP O -$
M.P#- $4 R@!. ,8 5P#$ %X P0!D +\ :@"] '  O !U +H >P"Y ($ MP"'
M +4 C@"S )4 L@"> +  IP"N +( K "_ *H T0"H .@ J #W *< _P"G /\
MI@#_ *8 _P#_!@  _P4  /$#  #H    X0 ' -4 $ #- !L QP G ,, ,P"_
M #X O !( +D 40"V %@ M !? +( 90"P &H KP!P *T =@"L 'P J@"" *D
MB0"G )$ I0": *, I "A *X H "[ )X!S0"= N8 G 3T )L$_P":!?\ F@7_
M )D%_P#_"@  \0X  .00  #9#P  S@L  ,@#"P#" !, O (? +<#+ "S!#<
ML 5" *T&2@"J!E( J =9 *8'7P"E!V4 HP=K *((<0"@"'< GPA^ )T(A0";
M"8X F@F7 )@*H0"6"JP E0NZ ),+S "2#.4 D WV (\._P".#O\ C@[_ (T.
M_P#V$0  YA<  -8;  #'&0  OA4  +D0  "W"@T L0L7 *P-) "H#C  I0X[
M *(.1 "?#TP G0]3 )L/6@":#V  F!!F )<0; "5$'( DQ!Y )(0@0"0$(H
MCQ&4 (T1GP"+$:H BA*X (@2RP"&$^8 A13W (,5_P"#%?\ @A7_ ((5_P#M
M&@  W"$  ,HE  "[(@  L1\  *L:  "I% 8 I1(1 * 4'@"<%2H F14U )86
M/@"4%D< DA9. ) 650".%UL C!=A (L79P")%VT B!=T (88? "%&(8 @QF0
M ($9FP" &J< ?AJU 'T;QP!\'.( >AWU 'D=_P!X'?\ >!W_ '@=_P#E(@
MT"D  +\L  "P*@  IR<  * C  "='P  FAH. )4<& "1'20 CAXO (P>.0")
M'D$ AQ]) (4?4 "#'U8 @A]< ( ?8@!_'VD ?2!P 'P@> !Z(($ >2&, '<A
MEP!U(J0 ="*R ',CPP!R(]\ <"3S &\D_P!O)/\ ;B3_ &XD_P#=*0  R#
M +<R  "H,   GBX  )<J  "3)P  D",* (PC$P"()!\ A"4J ((E- " )CT
M?29$ 'PF2P!Z)E( >"98 '<F7@!U)F4 ="=L '(G= !Q)WT ;RB( &XHE !L
M**$ :RFO 6HIP %I*ML!9RKQ 6<K_P%F*_\!9BK_ 68J_P'4+P  PC8  *\V
M  "A-0  EC0  ) P  "*+0  ARH& (,I$ !_*AH ?"LE 'DK+P!W+#@ =2Q
M ',L1P!Q+$T <"Q4 &XL6@!M+&$ :RUH &HM< !H+7H 9RZ% &4ND0%D+IX!
M8B^L 6$OO0%A,-4!8##O 5\P_0%?,/\!7S#_ 5\P_P'--   O#L  *DZ  ";
M.@  D#@  (DU  "#,@  ?S ! 'LO#@!W,!8 =# A '$Q*P!O,30 ;3$\ &LQ
M0P!J,4H :#)0 &<R5P!E,ET 9#)E &(R;0!A,W< 7S." 5XSC@%=-)P!6S2J
M 5HUNP%:-=(!637M 5DU_ %8-?\!6#7_ 5DU_P'(.   MSX  *0^  "6/0
MBSP  (,Z  !]-P  >#0  '0T"P!P-1, ;34= &HU)P!H-C  9C8X &0V/P!C
M-D8 839- & V4P!>-UH 73=B %PW:@!:.'0!63A_ 5<XC %6.9D!53FH E0Y
MN0)3.L\"4SKK E,Z^P%3.O\!4SG_ 5,Y_P'$/   LD$  *!   "20   AC\
M 'X]  !X.@  <S@  &XY" !J.1$ 9SD: &0Z) !B.BP 8#HT %XZ/ !=.T,
M6SM* %H[4 !8.U< 5SM? %8\9P!4/'$!4SQ\ 5(]B0%1/9<!3SVF DX^MP).
M/LT"3C[I DT^^@)./O\!3CW_ 4X]_P' /P  KD,  )Q#  ".0P  @D(  'I
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M D1%^ )$1?\"147_ D5%_P&Z1@  ID@  )1(  "&2   >T<  ')&  !J0@
M8T,  %Y$  !:10L 5D42 %1&&P!11B, 3T8K $Y&,P!,1SH 2T=! $I'20!)
M2%  2$A8 $=(80!&26L 1$EV 4-)@P%"29(!04FB D!)LP(_2L<"/TKE C])
M]P) 2?\"0$C_ D!(_P&V20  HDH  )%*  "#2@  =TH  &Y)  !E10  7D<
M %E(  !520@ 44H0 $]*& !,2B$ 2DLI $E+,0!'2S@ 1DP_ $5,1@!$3$X
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M 3%5_P&H4@  E5(  (12  !W4@  ;%(  &)2  !84P  3U0  $E6  !$5P
M0%D( #U:$  [6A< .5L@ #A;)P W7"\ -EPV #5</@ T7$8 ,UU. #%=5P P
M76$ +UUL "Y=>@ L78D *UV: 2I=JP$J7;\!*5W> 2I<\@$J6_X!*UO_ 2M:
M_P&C50  CU4  ']5  !R50  9U8  %Y6  !45P  3%D  $5;   _70  .E\$
M #9@#0 T81, ,F(< #%B(P P8BL +V,R "YC.@ M8T( +&-* "ID4P I9%T
M*&1I "=D=@ F9(8 )627 "1DJ0 C9+T (F3: "-C\0 C8OT!)&'_ 21A_P&<
M6   B5@  'I9  !N60  8UD  %I:  !07   2%X  $%@   Z8P  -&8  "]H
M"@ L:1  *FD7 "EJ'P H:B8 )VHN "9K-0 E:ST )&M& "-K3P B;%D (&QE
M !]L<@ >;(( '6R4 !QLI@ ;:[H &FO4 !MJ[@ <:?P '&C_ !QH_P"57
M@UP  '5<  !I70  7UT  %9>  !,80  0V0  #QG   U:@  +VT  "AP!  C
M<@T (7(2 "!S&@ ?<R$ 'G,H !UT,  <=#@ &W1  !IT2@ 9=%0 %W5@ !9U
M;@ 5=7X %'60 !-TH@ 2=+8 $73/ !)S[  2<OH $W'_ !-Q_P".8   ?6
M &]A  !E80  6V(  %%D  !(9P  /FL  #=N   P<0  *74  ")X   <>P<
M%WT. !9]$P 5?1L %'XB !-^*@ 2?C$ $7XZ !%^1  0?TX #W]:  Y_:  -
M?W@ #'^*  M^G0 *?K  "7W&  I]Y  *?/0 "WO]  MZ_P"&90  =V4  &IE
M  !A9@  5F@  $QK  !";P  .7,  #%W   J>@  (WX  !R!   5A   $(<(
M  V)#@ ,B10 #(D;  N)(P *B2L "8DS  B)/0 &B4@ !8E4  2)80 "B7$
M 8F#  ")E@  B*D  (>^  "'V@  ANP  (;U  "&^@!^:@  <6H  &=K  !;
M;   4'   $9T   \>   ,WT  "J!   CA0  '(@  !6,   0CP  #)(&  :3
M#  "DQ$  )06  "4'0  E"0  )4L  "5-0  E4   )5,  "660  EFD  )5Z
M  "5C@  E*$  )2U  "3S   DN8  )+R  "2]P!X<   ;7   &!R  !4=0
M27D  #]^   U@P  +(@  ".-   ;D0  %)0   ^7   *F@  !)T#  ">"0
MGPX  )\2  "@%P  H!T  *$E  "B+0  HC<  *-#  "C4   HU\  *-Q  "C
MA   HID  **M  "AP@  H=P  *'K  "@\@!S=@  9G<  %E[  !-@   0H4
M #B+   ND   ))4  !N:   4G@  #J$   FD   "IP   *H   "K!   JPH
M *P-  "M$0  K18  *X<  "O)   L"T  +$Y  "Q1@  LE4  +)F  "R>0
MLHX  +&C  "RMP  L<H  +'@  "QZ0!L?@  7X(  %*'  !&C0  .Y,  #"9
M   FG@  '*,  !.G   -JP  !ZX   "R    M0   +<   "X    N0(  +D(
M  "Z#   NQ   +P4  "]&P  OR,  ,$M  #".@  PDD  ,-:  ##;   Q((
M ,27  #$JP  Q+P  ,3+  #$V@!EB0  6(X  $N5   _FP  ,Z(  "BH   =
MK0  %+$   VV   &N0   +P   "_    PP   ,0   #%    Q@   ,<   #)
M!   R@D  ,L-  #-$0  SQ@  -(A  #5+0  UCP  -A-  #97P  VG,  -J*
M  #;G@  VZX  -NZ  #<PP!>E@  49P  $2C   XJ@  ++$  ""W   5NP
M#;X   3"    Q0   ,D   #-    T    -(   #2    U0   -8   #9
MVP   -X%  #@"@  X@\  .46  #H(   ["T  .T^  #M40  [F4  .]Z  #O
MCP  \)\  /"K  #PLP#_ !  _P . /\ #@#_ !( _P = /\ *0#_ #4 _P!!
M /\ 30#^ %8 ^P!? /@ 9@#V &T ] !T /( >0#Q '\ \ "$ .X B0#M (\
MZP"5 .H FP#H *( Y@"J .4 LP#C ,  X0#2 .  Z@#? /D W0#_ -T _P#=
M /\ W@#_ -X _P#_  T _P * /\ "0#_  \ _P 8 /\ ) #^ #$ ^P ] /@
M2 #T %( \ !: .T 8@#K &D Z0!O .< =0#E 'H XP!_ .( A0#@ (H W@"0
M -P E@#: )T V "E -4 KP#2 +H T #* ,X XP#- /0 RP#_ ,L _P#+ /\
MRP#_ ,L _P#_  @ _P # /\ !0#_  P _  4 /< 'P#R "L [P W .L 0@#G
M $P Y !5 .  70#= &0 V@!J -@ < #5 '4 T@!Z -  @ #/ (4 S0"+ ,L
MD@#) )D QP"A ,4 J@## +4 P0## +\ V@"^ .X O0#\ +P _P"\ /\ O #_
M +P _P#_    _P   /\   #Y  < \0 0 .H &@#D "4 WP Q -L / #7 $<
MT@!0 ,X 5P#+ %X R0!E ,8 :@#% '  PP!U ,$ >@#  (  O@"& +P C0"Z
M )0 N0"< +< I0"U +  LP"] +$ SP"O .@ K@#X *X _P"M /\ K0#_ *T
M_P#_    _P   /T   #N  $ XP , -H % #1 !\ S  K ,@ -@#% $  P@!*
M +\ 4@"\ %D N@!? +@ 90"V &H M !O +, =0"Q 'H L "! *X B "M (\
MJP"8 *D H0"G *L I0"X *, R "B .( H0#S *  _@"@ /\ H #_ *  _P#_
M    ]@   .H   #@    TP & ,D #P#" !@ O0 D +D +P"V #H M !# +$
M3 "N %, K !9 *H 7P"I &0 IP!J *8 ;P"D '4 HP![ *$ @@"@ (H G@"3
M )P G0": *< F "T )8 PP"5 -P E #O ), ^P"3 /\ DP#_ )( _P#Y!0
MZ@L  -P-  #+"@  P@4  +P "@"V !$ L0 < *X * "J #, IP ] *0 10"B
M $T H !3 )X 60"< %\ FP!D )H :@"8 '  EP!V )4 ?@"3 (8 D@&/ ) !
MF0". J0 C *Q (L#P ")!=8 B ;M (@'^@"'"/\ A@C_ (8(_P#O#P  WA0
M ,H5  "\$@  LQ   *X,  "K!@T IP,5 *(%( "?!RP G @V )D(/P"7"4<
ME0E. ),)5 "1"EH D I? (X*90"-"FL BPIR (H+>0"("X( APN, (4,EP"#
M#*( @0VP ( -P !_#=@ ?0[O 'P/_0![#_\ >Q#_ 'L0_P#F%P  T1X  +T=
M  "O'   IAD  *$5  ">$ 0 G0T/ )@.&0"4#B4 D0\O (\0.0",$$$ BA!(
M (@03P"'$%4 A1!; (0180""$6< @!%N '\1=0!]$7X ?!*( 'H2E !X$J
M=Q.N '43O@!T%-4 <Q7N '$6_0!Q%O\ <1;_ ' 6_P#<'P  QB4  +,E  "E
M(P  G"$  )8>  "2&0  D10+ (T4% ")%1\ AA8I (,6,P"!%SP @!=# 'X7
M2@!\%U  >A=6 'D87 !W&&( =AAI '08<0!S&7H <1F$ &\:D !N&IT ;!NK
M &L<NP!J'-  :1WL &@>^P!H'O\ 9Q[_ &<>_P#1)@  O2H  *LJ  "=*@
MDR@  (TE  "((@  AAT& (,;$ !_'!H ?!TD 'H=+@!W'C8 =AX^ '0>10!R
M'TL <1]1 &\?6 !N'UX ;!]E &L@;0!I('8 :"&! &8AC0!E(IH 8R*H &(C
MN !A(\T 8"3I & D^@!?)/\ 7R3_ %\D_P#*+   MB\  *0O  "6+P  C"T
M (4J  " *   ?20  'HB#0!V(Q4 <R,@ '$D*0!O)#( ;20Z &LE00!J)4<
M:"5- &8E5 !E)5H 9"9A &(F:0!A)G( 7R=] %XGB@!=*)< 6RFE %HIM0!:
M*LH 62KG %@J^ !8*O\ 6"K_ %@J_P#%,0  KS,  )XS  "0,P  AC(  '\O
M  !Y+0  =2H  '(H"@!O*!( :RD; &DI)0!G*BT 92HU &,J/0!B*D, 8"I*
M %\K4 !>*U< 7"M> %LL9@!9+&\ 6"UZ %<MAP!6+I4 5"ZC %,OLP!3+\<
M4B_E %(O]P!2+_\ 4B__ %(O_P#!-@  JC8  )DV  "+-@  @34  'DS  !S
M,0  ;R\  &LN!@!H+1  9"X8 &(N(0!@+RH 7B\Q %PO.0!;+T  62]& %@O
M30!7,%, 5C!; %0Q8P!3,6P 4C)W %$RA !/,Y( 3C.A $TSL0!--,4!3#3C
M 4PT]@!,-/\ 3#3_ $PS_P"[.0  ICD  )4Y  "'.0  ?#D  '0W  !N-
M:3,  &4R @!A,@T 7C(4 %PS'@!:,R8 6#,N %8S-0!5-#P 4S1# %(T2@!1
M-%  4#58 $XU8 !--FH 3#9U $LW@@!*-Y  23B? $@XL %'.,,!1SCA 4<X
M]0%'./\!1SC_ 4<X_P&W.P  HCP  )$\  "#/   >#P  ' Z  !J-P  9#8
M & V  !<-@L 63<2 %8W&@!4-R, 4C<K % W,@!/.#D 33A  $PX1P!+.$X
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M 3E#_P&J0@  ED,  (9#  !X0P  ;D,  &5#  !=0   5D   %%"  !-0@(
M24,, $9#$@!$1!H 0D0B $%$*@ _13$ /D4X #U%/P \1D< .T9/ #I&5P Y
M1V$ .$=L #='>@ V2(D -4B9 #1(J@ T2+T ,TC9 #1(\  T1_T -$?_ #5&
M_P"F1   DD4  ()&  !U1@  :D8  &%%  !91   440  $Q&  !(1P  1$<*
M $%($  _21@ /4D@ #Q))P Z2BX .4HV #A*/0 W2T0 -DM, #5+50 T3%\
M,TQJ #),=P Q3(8 ,$R7 "]-J  N3;L +DW5 "Y,[P O3/T +TO_ #!+_P"A
M1P  CD@  'Y(  !Q2   9DD  %U(  !52   3$D  $=*  !"2P  /TP& #M-
M#@ Y3A4 -TX= #9/)  U3RL ,T\S #)0.@ Q4$( ,%!* "]14@ N45P +5%G
M "Q1=0 K480 *E*5 "E2I@ I4KD *%+2 "E1[@ I4/P *E#_ "I/_P"<2@
MB4H  'I+  !M2P  8TP  %I,  !13   2$T  $-/   ]4   .5(" #53#  S
M5!( ,509 #!5(0 N52@ +54O "Q6-P K5CX *E9& "E63P H5UD )U=D "97
M<@ E5X$ )%>2 "-7I  B5[< (E?/ ")7[  C5OH (U7_ "15_P"630  A$X
M '5.  !I3@  7T\  %9/  !-4   15(  #]3   Y5@  ,U@  "]:"  K6P\
M*EL5 "A<'0 G7"0 )EPK "5<,P D73H (UU# ")=3  A758 (%YA !]>;@ >
M7GX '5Z/ !Q>H0 ;7K0 &EW, !M=Z0 ;7/D '%O_ !Q;_P"040  ?E$  '!1
M  !D4@  6U(  %)3  !*5   05<  #M9   U6P  +EX  "A@ P D8@P (F,1
M "%C&  ?9"  'F0G !UD+@ <9#8 &V4^ !IE1P 995$ &&5= !=E:@ 697H
M%66+ !1EG@ 39;$ $F7( !)DYP 38_< %&+_ !1B_P")5   >%4  &M5  !@
M5@  5U8  $]7  !&60  /5P  #9?   P8@  *60  "-G   =:@< &6P. !AL
M$P 6;1H %6TA !1M*0 4;3  $VTY !)N0@ 1;DP $&Y8  ]N90 .;G4 #6Z'
M  UNF@ ,;:T "VW"  MLX  ,:_, #6O]  UJ_P""60  <ED  &99  !<6@
M5%H  $I<  !!7P  .6,  #%F   J:0  )&P  !UO   7<@  $G4)  ]W#P .
M=Q0 #G<;  UW(P ,=RH "W<S  IW/  )=T< "'=2  =W7P %=V\ !'>   -W
ME  !=J<  ':[  %UU0 !=.L  G3V  )T_ ![70  ;5T  &)>  !97@  3F
M $5C   \9P  ,VL  "MN   D<@  'G4  !=Y   2?   #7\&  F!#  %@1$
M X$6  *!'0 !@20  ($M  ""-@  @D   (),  ""60  @F@  ()Y  ""C0
M@:   ("T  " RP  ?^<  '[R  !^^0!T8@  :&(  %YB  !39   26<  #]K
M   V<   +70  "5X   >?   %X   !&#   -A@  "(D$  *+"@  BPX  (L3
M  ",&   C!\  (TF  "-+P  CCD  (Y$  ".40  CF   (YQ  ".A0  CID
M (VM  ",PP  C-\  (ON  "+]@!N:   9&<  %AI  !-;   0G$  #AV   O
M>P  )G\  !Z$   6B   $(P   R/   &D@   )4   "6!P  EPP  )</  "8
M$P  F1@  )H?  ";)@  FS   )P[  "<2   G%<  )QH  "<>P  G)   )NE
M  ";N@  FM   )KG  ":\0!J;0  7F\  %%R  !&=P  .WP  #&"   GAP
M'HP  !:1   0E0  "ID   2<    H    *(   "C 0  HP8  *0+  "E#@
MIA(  *<7  "H'@  JB8  *LQ  "K/@  K$T  *Q=  "L<   K(4  *R;  "K
MKP  J\,  *O9  "JZ !D=0  5WD  $M^   _A   -(H  "F0   ?E@  %IL
M !"?   )HP   :<   "J    K@   +    "P    L0   +(#  "T"   M0T
M +80  "W%0  N1T  +LF  "\,P  O4$  +U2  "]9   OGD  +Z0  "]I
MO;<  +W&  "]UP!<?P  4(4  $2+   XD@  +)D  "&?   7I   $*D   FN
M    L@   +8   "Y    O0   +\   "_    P    ,$   ##    Q 4  ,8*
M  #'#@  R1,  ,L<  #.)@  T#4  -%%  #25P  TFL  -."  #3EP  TZD
M -*X  #2Q !5C   29,  #V:   PH@  ):@  !JN   1M   ";D   "]
MP0   ,0   #(    RP   ,T   #-    SP   -    #2    U    -@   #:
M!@  W0P  . 1  #C&@  YB<  .<X  #H2@  Z5T  .IR  #KB   ZYL  .RH
M  #LL@#_  T _P + /\ "P#_ !  _P : /\ )@#_ #( _P ] /\ 2 #[ %(
M^ !: /8 8@#S &D \0!O /  =0#N 'H [ !_ .L A #I (H Z "0 .8 E@#D
M )T X@"E .$ KP#? +L W0#+ -L Y@#9 /< V #_ -@ _P#7 /\ UP#_ -0
M_P#_  @ _P $ /\ ! #_  T _P 5 /X (0#Z "P ]P X /0 0P#P $T [0!5
M .H 70#G &0 Y !J .( < #@ '4 W@!Z -T ?P#; (4 V0"+ -4 D0#3 )D
MT0"@ ,\ J@#- +4 RP#$ ,D W0#( /$ QP#_ ,8 _P#& /\ Q@#_ ,< _P#_
M    _P   /\   #_  H ^  1 /$ ' #L "< Z0 R .8 /0#B $< W0!0 -D
M6 #5 %\ T@!E -  :@#. '  S !U ,H >@#) '\ QP"% ,4 C ## )0 P0"<
M +\ I0"] +  NP"] +H T "X .L MP#[ +8 _P"V /\ M@#_ +8 _P#_
M_P   /T   #S  4 Z0 . .$ %@#; "$ U0 M -$ -P#. $$ R@!* ,< 4@#$
M %D P@!? ,  90"^ &H O !O +L = "Y 'H MP"  +8 AP"T (X L@"7 +
MH "N *H K0"W *L R "I ., J #U *< _P"G /\ IP#_ *8 _P#_    _@
M /$   #E    UP * ,T $0#' !P P@ F +\ ,0"\ #L N@!$ +< 3 "T %,
ML@!9 +$ 7P"O &0 K0!I *P ;P"J '0 J0!Z *< @0"F (D I "1 *( FP"@
M *4 G@"R )T P0"; -H F@#O )D _0"8 /\ F #_ )@ _P#]    \    .$
M  #1    Q@ $ +T #0"W !4 LP @ +  *P"M #4 JP ^ *@ 1@"F $T I !4
M *, 60"A %\ H !D )X :0"= &X FP!U )H >P"8 (, E@", )4 E@"3 *$
MD0"M (\ NP"- ,\ C #I (L ^ ", /\ C #_ (P _P#S @  X@<  ,P'  "_
M!   MP   +$ " "K !  IP 9 *0 ) "@ "X G@ W )P 0 ": $< F !. )8
M5 "5 %D DP!> )( 9 "0 &D CP!O (T =@"+ 'X B@"( (@ D@"& )T A0"I
M (, N "! ,H @ #E (  ]0!_ /\ ?P#_ '\ _P#H#0  T!   +X0  "Q#@
MJ T  *,(  "@ @P G  3 )@ '0"5 "< D@ Q )  .0". 4$ C %( (H"3@")
M E0 AP)9 (8"7P"$ V0 @P-K ($#<@" !'H ?@2$ 'T%C@![!9H >0:G '@&
MM0!V!\@ =0CC '4)] !T"O\ <PK_ ',*_P#=%0  Q!<  +$7  "E%@  G!,
M )81  "4#00 DP@- (X'%0"+"2  B DJ (4*,P"#"SL @0M" ( +20!^"T\
M?0Q4 'L,6@!Z#&  > QG '<,;@!U#78 = V  '(-C !P#9D ;PZF &T.M0!L
M#LD :P_F &H0]P!I$/\ :1#_ &D0_P#0'0  N1X  *@>  ";'0  DAL  (L9
M  "(%0  AQ$' (4.$ "!#QH ?A D 'L0+0!Y$#8 =Q$] '811 !T$4H <Q%0
M '$15@!P$5P ;A)B &T2:@!K$G, :1-] &@3B0!F$Y8 912C &,5LP!B%<8
M8A;C &$6]@!@%_\ 8!?_ & 7_P#'(@  L",  )\D  "2(P  B2(  ((@  !^
M'0  ?!D  'H5#0!W%14 =!8? '$6* !O%S  ;A<X &P7/P!K%T4 :1A+ &@8
M40!F&%@ 91A> &,99@!B&6\ 8!EY %\:A0!=&Y( 7!NA %L<L !:',, 61W@
M %@>] !8'O\ 6![_ %@>_P"_)P  J2@  )DH  "+*   @B<  'LE  !V(P
M<R   '$<"0!N'!$ :QP: &D=(P!G'2P 91TS &,>.@!B'D$ 8!Y' %\>30!>
M'E0 7!]; %L?8@!9(&L 6"!V %8A@@!5(9  5"*> %,BK@!2(\  42/= %$D
M\@!1)/\ 423_ %$C_P"Y*P  HRP  ),L  "&+0  ?"P  '0J  !O*   :R4
M &DB!0!F(0X 8R(6 &$B'P!?(R< 72,O %PC-@!:(ST 621# %<D2@!6)%
M5217 %,E7P!2)6@ 429S $\F?P!.)XT 32B< $PHK !+*;X 2RG: $HI\0!*
M*?\ 2RG_ $LI_P"S+@  GB\  (XP  "!,   =R\  &\N  !J*P  92H  &,G
M 0!?)PP 7"<3 %HG&P!8*"0 5B@K %4H,@!3*#D 4BE  % I1@!/*4T 3BE4
M $TJ7 !,*F4 2BMP $DK? !(+(L 1RV: $8MJ@!%+KP 12[6 $4N[P!%+OX
M12[_ $4M_P"N,0  FC(  (DS  !\,P  <C,  &LQ  !E+P  8"T  %TL  !9
M+ D 5BP0 %0L& !2+"  4"PH $XM+P!-+38 3"T\ $HM0P!)+4H 2"Y1 $<N
M60!&+V, 13!M $,P>@!",8D 03&8 $$RJ ! ,KL /S+3 #\R[@! ,OT 0#+_
M $ R_P"J,P  EC4  (8U  !Y-@  ;C4  &8U  !A,@  7#   %<P  !4, 8
M43 . $XP%0!,,1T 2C$E $@Q+ !',3( 1C$Y $0Q0 !#,D< 0C)/ $$S5P!
M,V  /S1K #XU>  ]-8< /#:6 #LVIP [-KD .C;1 #HV[0 [-OP .S;_ #LV
M_P"F-@  DC<  ((X  !U.   :S@  &,W  !=-@  5S,  %,T  !/- , 2S0,
M $DT$@!&-1H 134B $,U*0!!-2\ 0#4V #\V/0 ^-D0 /3=, #PW50 [.%X
M.CAI #DY=@ X.84 -SJ5 #<ZI0 V.K@ -3K/ #8Z[  V.OL -CG_ #<Y_P"B
M.   CCD  'XZ  !R.P  :#L  %\Z  !9.0  4S8  $XW  !*.   1C@* $0Y
M$ !!.1< /SD? #XY)@ \.2T .SHT #HZ.P Y.T( .#M* #<[4P V/%P -3QG
M #0]=  S/8, ,SZ3 #(^I  Q/K8 ,3[- #$^Z@ Q/OH ,CW_ #(]_P">.P
MBSP  'L\  !N/0  9#T  %P]  !5/   3CH  $D[  !%/   03T' #X]#@ \
M/14 .CX< #D^(P W/BH -C\Q #4_.  T/T  ,T!( #) 4  Q0%H ,$%E "]!
M<@ N0H$ +4*1 "U"H@ L0K4 *T++ "Q"Z0 L0OD +4'_ "U!_P"9/0  ASX
M '<_  !K/P  84   %D_  !2/P  23X  $0_  ! 0   /$$$ #E"#0 W0A(
M-4,9 #-#(0 R0R@ ,40O #!$-@ O1#T +D5% "U%3@ L15@ *T9C "I&;P I
M1GX *$:/ "='H0 F1[, )D?) "9&YP G1O@ *$7_ "A%_P"50   @D$  '-"
M  !G0@  7D(  %5"  !.0@  14(  #]$   [10  -T8  #1'"@ Q2!  +T@6
M "Y)'@ L224 *TDL "I),P I2CH *$I" "=*2P F2U4 )4M@ "1+;0 C2WP
M(DN- "%,GP A3+$ ($S' "!+Y@ A2_< (DK_ ")*_P"00P  ?D0  &]$  !D
M10  6D4  %)%  !*1@  04<  #Q(   W20  ,DL  "Y-!P K3@X *4X3 "=/
M&@ F3R$ )4\H "1/,  C4#< (E _ "%02  @4%( 'U%= !Y1:@ =47D '%&*
M !M1G  :4:\ &5'% !E1Y  :4/8 &T__ !Q/_P"*1@  >4<  &M'  !@2
M5D@  $Y(  !'20  /DL  #E,   S3@  +E   "A3 @ D5 L (E40 "!5%@ ?
M5AX 'E8D !U6+  <5C, &U<[ !I71  95TX &%=9 !=89@ 56'4 %%B' !18
MF@ 35ZP $E?" !)7X0 35O0 %%7_ !15_P"$20  =$H  &9+  !<2P  4TL
M $M,  !$30  /$\  #51   O5   *58  "19   >6P< &ET- !A=$@ 771D
M%EX@ !5>)P 47BX $UXW !)>0  17TH $5]5 !!?8@ /7W$ #E^#  U?E@ -
M7ZD #%Z^  Q>V@ -7?  #5S\  Y<_P!^30  ;DX  &).  !83P  3T\  $A0
M  ! 4@  .%0  #!7   J6@  )%T  !]?   98@$ $V4) !%F#P 09A0 #V8;
M  YG(@ -9RD #6<R  QG.P +9T4 "F=0  EG70 '9VP !F=]  5GD  $9J,
M F:W  -ESP $9>D !&3U  1D_ !W40  :5(  %U2  !44@  3%,  $-5   [
M6   ,UL  "M>   E80  'V0  !EG   3:@  #VT&  MP#  (<!$ !W 6  5P
M'0 $<"0  W L  )P-0  <#\  '!*  !P5P  <&4  '!V  !PB@  ;YX  &^R
M  !NR   ;>4  &WR  !M^0!P5@  8U8  %E6  #_XO__24-#7U!23T9)3$4
M! E15P  1U@  #Y;   V7P  +F(  "9F   ?:@  &6T  !-P   .<P  "W8$
M  5X"P !> \  'D3  !Y&0  >1\  'HF  !Z+P  >CD  'I$  !Z4   >E\
M 'IP  !Z@P  >I@  'JL  !YP@  >-\  'CO  !W]P!J6P  7UL  %9;  !,
M7   0F   #EC   P:   *&P  "!P   9=   $W<   Y[   )?@  !($"  ""
M"   @PT  (,0  "$%   A1D  (8@  "&*   AS$  (<\  "'20  AU<  (=H
M  "'>P  AY   (:E  "%N@  A=,  (3J  "$] !E8   7&   %%A  !&9
M/&D  #)M   I<@  (7<  !E[   2@   #8,   B'   "B@   (T   ".!
MC@D  (\-  "0$   D10  )(9  "3(   E"D  )4S  "50   EDX  )9?  "5
M<@  E8@  )6=  "4L@  E,@  )/B  "3[@!A90  5F8  $IJ   _;@  -70
M "MY   A?P  &80  !&)   ,C0  !I$   "4    F    )H   ";    G (
M )T'  ">"P  GPX  *$2  "B&   HR   *4I  "F-@  ID0  *95  "F:
MIGT  *:4  "EJ0  I+T  *31  "DY !;;   3W   $-U   X>P  +8$  ".'
M   9C0  $9(   N7   $G    *    "C    I@   *@   "I    J@   *P
M  "M!   K@D  + -  "Q$0  LQ<  +4@  "V*P  MSH  +=+  "X7   N'$
M +B(  "XG0  N+$  +?"  "WT !4=@  2'P  #R"   QB0  )I   !N7   2
MG0  #*(   .G    JP   *X   "R    M@   +@   "X    N@   +L   "]
M    O@   , %  #!"P  PQ   ,86  #)(   RBX  ,L^  #,4   S&0  ,UZ
M  #-D0  S:0  ,VT  #-P !-@P  08H  #61   IF0  'J   !.F   ,K
M [$   "V    N@   +X   #"    Q@   ,@   #(    R@   ,L   #-
MS@   -    #2 0  U0@  -D.  #=%0  X2$  .(Q  #D0P  Y58  .9K  #F
M@@  YY8  .>E  #FL #_  D _P % /\ !@#_  X _P 6 /\ (0#_ "T _P X
M /T 0P#Y $T ]0!5 /( 70#P &, [@!I .P ;P#J '0 Z0!Z .< ?P#F (4
MY "+ ., D0#A )D WP"A -P J@#: +8 UP#& -4 X0#3 /0 T@#_ -$ _P#1
M /\ SP#_ ,H _P#_  $ _P   /\  0#_  P _P 2 /H '0#V "@ \P S /
M/@#L $@ Z !0 .4 6 #B %X WP!D -T :@#; &\ V0!T -8 >@#4 '\ T@"%
M -  C #. ), S "< ,D I0#' +  Q@"^ ,0 U #" .X P0#^ ,  _P#  /\
MOP#_ +X _P#_    _P   /\   #Z  < \0 / .L & #F ", X@ N .  . #;
M $( U0!+ -$ 4@#. %D RP!? ,D 90#' &H Q@!O ,0 = #" 'H P0"  +\
MA@"] (X NP"6 +D H "W *H M@"W +0 R@"R .8 L0#X +  _P"O /\ KP#_
M +  _P#_    _P   /<   #J  ( X0 , -< $P#0 !T S  H ,D ,@#& #P
MP@!% +\ 30"\ %, N@!9 +@ 7P"W &0 M0!I +0 ;@"R '0 L0!Z *\ @ "M
M (@ K "1 *H F@"H *4 I@"Q *0 P0"C -P H0#R *$ _P"@ /\ H #_ *$
M_P#_    ]P   .@   #9    RP ( ,, $ "] !@ N0 B +8 + "T #8 L@ _
M *\ 1P"L $T JP!4 *D 60"G %X I@!C *4 : "C &X H@!T *  >@"> ((
MG "+ )L E0"9 )\ F "L )8 N@"4 ,\ DP#K )( ^P"2 /\ D@#_ )$ _P#W
M    YP   -,   #&    NP " +, # "M !( J@ < *< )@"D #  HP X *
M0 "> $< G !. )H 4P"9 %@ EP!= )8 8P"5 &@ DP!N )( = "0 'P CP"%
M (T CP"+ )H B@"G (@ M0"& ,< A0#D (0 ]0"$ /\ @P#_ (, _P#L
MTP   ,$!  "T    K    *8 !P"@  X G0 6 )H ( "7 "D E0 R ), .@"1
M $$ CP!( (T 30", %, BP!8 (D 70"( &, AP!I (4 ;P"# '< @@"  (
MB@!^ )8 ?0"C 'L L !Z ,( >0#= '@ \0!W /T > #_ '@ _P#>"@  Q L
M +(,  "F"P  G0@  )D$  "5  H D0 1 (X &0"+ ", B0 L (< - "% #L
M@P!" (( 2 "  $X ?P!3 'T 6 !\ %X >P!D 'D :@!X '( =@![ '0 A@!S
M )( <0"? '  K0!N +X ;0'6 &T"[0!L _H ; /_ &P#_P#.$   MQ$  *82
M  ":$0  D1   (L.  ")"P, AP4, (0!$P"! 1P ?@(E 'P#+@!Z S8 > 0\
M '<$0P!U!4@ = 5. ',%5 !Q!5D < 9? &X&9@!M!FX :P=X &H'@P!H")
M9PF= &4)K !D";P 8PK4 &,+[ !B#/H 8@S_ &(,_P##%@  K1<  )T8  "0
M&   AQ8  ($4  !]$0  ? X& 'P*#@!X"A8 =0L? '(+* !P##  ;PPW &T,
M/@!L#$0 :PU* &D-3P!H#54 9PU< &4-8P!C#FL 8@YU & .@0!?#HX 70^<
M %P0JP!;$+T 6A#6 %D1\ !9$?T 61'_ %D1_P"Y&P  I1T  )0>  "('@
M?AT  '@;  !T&   <14  '$1"0!O$!$ ;! 9 &D0(@!G$2H 9A$R &01.0!C
M$3\ 8A%% & 22P!?$E$ 71)8 %P27P!:$V@ 61-R %<4?0!6%(L 5!69 %,5
MJ0!2%KH 41;2 %$7[0!1%_T 41?_ %$7_P"R(   GB(  (XB  "!(P  =R(
M ' A  !L'@  :1L  &<8! !F%0X 8Q85 &$6'@!?%B8 718M %P7- !:%SL
M61=! %@81P!6&$T 51A4 %,87 !2&60 41EN $\:>@!.&X@ 31N7 $L<I@!*
M'+@ 2AW/ $D=ZP!)'?L 21W_ $H=_P"L)   F"4  (@F  ![)P  <28  &HE
M  !F(P  8B$  & >  !>' L 6QL2 %D<&@!7'"( 51PI %0<, !3'3< 41T]
M % =0P!/'4H 31Y1 $P>6 !+'V$ 21]K $@@=P!'((4 1B&4 $0BI !$(K8
M0R+, $,CZ0!#(_H 0R/_ $,B_P"F)P  DRD  (,J  !V*@  ;2H  &4I  !@
M)P  7"4  %DC  !7(0< 52$/ %(A%@!0(1X 3B$E $TB+ !,(C, 2B(Y $DB
M0 !((D8 1R-- $4C50!$)%X 0R1I $(E=0! )H, /R:2 #XGHP ^)[0 /2?*
M #THZ  ]*/D /2?_ #XG_P"B*@  CBL  '\M  !R+0  :"T  &$L  !<*P
M6"@  %0F  !1)@0 3B4- $PE$P!*)AH 2"8B $<F*0!%)B\ 1"8V $,G/ !!
M)T, 0"=+ #\H4P ^*5P /2EF #PJ<@ [*H$ .BN0 #DKH0 X++( -RS( #<L
MY@ X+/@ ."S_ #@L_P"=+   BBX  'LO  !O,   93   %TO  !8+@  4RL
M % J  !,*@  22H+ $8J$0!$*A< 0BH? $$J)0 _*BP /BLS #TK.0 \*T
M.RQ( #HL4  Y+5D ."YD #<N<  V+W\ -2^/ #0PGP S,+$ ,C#' #(PY0 S
M,/< ,S#_ #0O_P"9+P  AS$  '<R  !K,@  8C(  %HR  !4,0  3R\  $LM
M  !'+@  1"X( $$N#@ _+A0 /2X< #LN(@ Y+RD ."\O #<O-@ V,#X -3!&
M #4Q3@ T,5< ,S)B #(R;@ Q,WT ,#.- "\TG@ N-+  +33% "TTXP N-/8
M+S/_ "\S_P"5,0  @S,  '0T  !H-0  7C4  %<T  !1-   2S(  $8Q  !"
M,@  /S(% #PR#0 Y,Q( .#,9 #8S(  T,R8 ,S,M #(T-  Q-#L ,#5# # U
M3  O-E4 +C9@ "TW;  L-WL *S>+ "HXG  I.*X *#C# "@XX@ I./4 *C?_
M "HW_P"2-   ?S4  '$V  !E-P  6S<  %0W  !--@  1S8  $(U   ]-@
M.C8" #<W"P T-Q  ,C<6 #$X'0 O."0 +C@K "TY,@ L.3D *SE! "HZ20 J
M.E, *3M> "@[:@ G.WD )CR) "4\FP D/*T (SS" ",\X  D//0 )3O_ "4[
M_P"--@  ?#@  &TY  !B.0  6#H  %$Y  !*.0  1#D  #TY   Y.@  -3L
M #(["  O/ X +3T4 "P]&@ J/2$ *3TH "@^+P G/C8 )CX^ "4_1P D/U
M(T!; ") :  A0'8 ($"' !]!F0 ?0:L 'D'  !Y!W@ ?0/, 'T#^ " __P")
M.0  >#H  &D[  !>/   53P  $T\  !'/   0#P  #@]   T/@  ,$   "U!
M!0 J0@P )T(1 "9#&  D0QX (T,E ")#+  A1#, ($0[ !]$1  >14X '459
M !Q%90 ;170 &D6% !E&EP 91JD &$:^ !=%W  81?$ &43] !I$_P"$/
M<ST  &8^  !;/P  4C\  $H_  !$/P  /4   #9!   Q0P  +$0  "=& 0 D
M1PH (4@/ "!)%  >21L '4DB !Q)*0 ;2C  &DHX !E*00 82DL %TM5 !9+
M8@ 52W$ %$N" !-+E  22Z< $DN\ !%+V0 22O  $TK\ !1)_P!_/P  ;T
M &%!  !70@  3D(  $="  !!0@  .D,  #)%   M1P  *$D  "-+   >308
M&T\- !A0$0 74!< %E > !50)0 44"P $U$T !)1/0 144< $5%2 !!17P /
M4FT #E)^  U1D0 -4:0 #%&X  Q1T0 -4.P #5#Z  Y/_P!Y0P  :D0  %U$
M  !310  2T4  $1%   ^1@  -D@  "]*   I3   )$\  !]1   :4P  %%8)
M !%7#@ 06!, $%@9  ]8(  .6"@ #5@P  U8.0 ,6$, "UA.  I86@ (6&@
M!UAY  98C  %6)\ !%BS  17R@ %5^8 !5?S  96_ !S1@  9$<  %E(  !0
M2   2$@  $%)   Z2@  ,DT  "M0   E4@  (%4  !I8   56@  $%T&  Q@
M#  *8!  "6 5  A@'  '8", !6 K  1@-  #8#T  6!)  !@50  8&,  &!S
M  !@A@  7YH  %^N  !?Q   7N(  %[P  !>^ !L2@  7TL  %5+  !,3
M14P  #U.   U4   +E,  "=6   @60  &EP  !5?   08@  #64$  AG"P #
M9PX  &@3  !H&   :!\  &DF  !I+@  :3@  &E#  !I3P  :5T  &EM  !I
M@   :90  &BI  !HOP  9]P  &;N  !F]P!F3P  6D\  %%/  !*3P  05$
M #A4   P5P  *%L  "%>   :8@  %&4  !!H   ,:P  !VX#  %P"0  < T
M '$0  !Q%   <AH  ',A  !S*   <S$  ',\  !T2   <U8  '-F  !S>0
M<XX  '.C  !RN0  <=(  ''K  !P] !A4P  5E,  $]3  !%50  .U@  #)<
M   J8   (F0  !MH   4;   #V\   MR   &=@   'D   !Z!@  >@H  'L.
M  !\$0  ?14  'X;  !_(@  @"H  ( U  " 00  @$\  (!?  " <0  @(8
M ("=  !_L@  ?LH  '[E  !]\0!<6   5%@  $E:   _70  -6$  "QE   C
M:@  &V\  !1S   .=P  "7L   -_    @@   (0   "& 0  A@8  (@*  ")
M#0  BA   (L5  ",&P  CB(  (\L  "/.   CT8  (]6  "/:   CWX  (^5
M  ".JP  C<$  (W<  ",ZP!970  3E\  $-B   X9@  +FP  "1Q   <=P
M%'P   Z!   (A0   (D   "-    D    )(   "3    E    )8#  "7"
MF P  )H/  ";$P  G1H  )\C  "@+@  H#P  *!,  "@7@  H'0  )^,  "?
MH@  G[<  )[+  ">X !39   1V@  #QM   Q<P  )WD  !U_   4A0  #8L
M  :0    E    )@   "<    GP   *$   "B    I    *4   "G    J 0
M *H)  "L#0  K1(  + 9  "R(P  LC$  +)"  "R5   LFD  +*   "RF
ML:P  +*_  "QS@!,;@  0',  #5Z   J@0  'X@  !6.   .E0  !IH   "?
M    I    *@   "L    KP   +$   "Q    LP   +4   "V    N    +H
M  "\!@  O@P  , 1  ##&0  Q28  ,4W  #&20  QET  ,=R  #'B@  R)\
M ,BO  #(O !&>@  .8$  "Z)   BD   %Y@   ^?   'I0   *H   "O
MLP   +<   "\    OP   ,$   #"    Q    ,4   #'    R0   ,L   #-
M    SP,  -(*  #6$   W!H  -TJ  #>/   WU   .!E  #A>P  X9$  .*B
M  #BK0#_  ( _P   /\  P#_  P _P 3 /\ '0#_ "@ _@ S /L /@#W $@
M\P!0 /  5P#M %X ZP!D .@ :0#G &\ Y0!T ., >0#B '\ X "% -X C #<
M ), V0"< -8 I@#3 +$ T0#  ,\ V@#. /$ S #_ ,L _P#+ /\ Q@#_ ,$
M_P#_    _P   /\   #_  @ ^P 0 /8 &0#R "0 [P N .T .0#H $( XP!+
M .  4@#= %D V0!? -8 9 #3 &D T0!N ,\ = #. 'D S !_ ,H A@#( (X
MQ@"6 ,0 H #" *L P "Y +X S0"\ .H NP#\ +H _P"Z /\ N@#_ +8 _P#_
M    _P   /X   #T  0 ZP - .0 % #? !\ VP I -@ ,P#3 #T S@!% ,H
M30#' %, Q0!9 ,, 7P#! &0 OP!I +T ;@"[ ', N@!Y +@ @ "V (@ M "0
M +( F@"Q *4 KP"R *T Q "L .$ JP#V *H _P"J /\ J@#_ *H _P#_
M_0   .X   #B    U0 * ,T $0#' !D Q  C ,$ +0"_ #< NP _ +< 1P"U
M $X L@!3 +  60"O %X K0!C *P : "K &T J0!S *@ >@"F ($ I "* *,
ME "A )\ GP"L )X NP"< -( FP#N )H _P": /\ F0#_ )D _P#^    [@
M -X   #+    P0 % +D #0"T !0 L0 > *X )P"K #  J@ Y *< 00"D $@
MH@!- *$ 4P"? %@ G@!= )T 8@"; &< F@!M )@ <P"7 'L E0"$ )0 C@"2
M )D D "F (X M "- ,@ C #F (L ^0"* /\ B@#_ (L _P#P    VP   ,<
M  "Z    L    *@ "@"D !  H  8 )T (0"; "H F@ S )@ .P"6 $$ E !(
M )( 30"1 %( CP!7 (X 7 ", &$ BP!G (H ;@"( '4 AP!^ (4 B "# )0
M@@"@ (  KP!_ ,  ?@#= 'T \@!] /\ ?0#_ 'T _P#@    Q@   +4   "J
M    H@   )L !0"5  T D@ 3 )  ' "- "0 BP M (H - "( #L A@!" (4
M1P"# $T @@!2 ($ 5P!_ %P ?@!B 'T : ![ '  >@!Y '@ @P!V (\ =0"<
M '0 J@!R +H <0#1 '  [ !P /L < #_ '  _P#-!   MP8  *<'  ";!@
MDP0  (X   "*  @ A@ / (0 %@"! !X ?P G 'T +@!\ #8 >@ \ 'D 0@!W
M $< =@!, '4 4@!S %< <@!= '$ 8P!O &L ;@!T &P ?@!K (H :0"8 &@
MI@!G +8 9@#+ &4 YP!E /< 90#_ &4 _P# #   JPT  )L.  "/#@  A@T
M ($+  !^!P$ ? $+ 'D $0!W !@ =0 A ', *0!Q #  ;P V &X / !L $(
M:P!' &H 30!I %( : !8 &8 7P!E &< 8P!P &(!>@!@ 8< 7P*5 %X"HP!<
M [, 7 /' %L$Y !;!?0 6P;^ %L&_P"U$   H1(  )$3  "%$P  ?!(  '81
M  !S#@  <@P$ '$'#0!N!!( ; 0; &D%(P!G!2H 9@8Q &0&-P!C!CT 8@=#
M &$'20!?!TX 7@A5 %T(7 !;"6, 6@EM %@*> !7"H4 5@N3 %0+H@!3"[,
M4@S' %(,Y !1#?4 40W_ %$-_P"M%0  F1<  (D8  !]&0  =!@  &T7  !J
M%   9Q$  &<.!P!F# X 8PP5 &$,'0!?#"4 70TL %P-,P!;#3D 6@T_ %@-
M10!7#4L 5@Y1 %4.60!3#F$ 4@YK % /=@!.$(, 31"2 $P0H@!+$+( 2A'(
M $D1Y0!)$?< 21+_ $D1_P"E&0  DAP  (,=  !V'@  ;1T  &8<  !B&@
M7Q<  %X4 0!>$0H 6Q 1 %D1& !7$2  51$G %01+@!3$30 41$[ % 200!/
M$D< 3A). $P250!+$UX 21-G $@4<P!&%(  116/ $05GP!#%K  0A;% $(7
MXP!"%_8 0A?_ $(7_P"?'0  C"   'TA  !Q(@  :"(  &$A  !<'P  61P
M %<9  !5%@8 5!4. %$5% !/%AP 3A8C $P6*@!+%C  2A8W $D7/0!'%T,
M1A=* $484@!#&%H 0AED $$9<  _&GT /AN- #T;G0 \'*X .QS# #L<X0 [
M'?4 .QS_ #P<_P":(0  AR,  '@D  !L)0  8R4  %PD  !7(P  4R   %$>
M  !/' ( 31L, $L:$0!(&Q@ 1QL@ $4;)@!$&RT 0QPS $(<.0! '$  /QU'
M #X=3P ]'E@ /!YB #H?;0 Y'WL .""+ #<AFP V(:T -2'! #4AWP U(?,
M-B'_ #8A_P"6(P  @R8  '0G  !H*   7R@  %@G  !3)@  3R0  $PB  !)
M(   1R ) $0?#P!"'Q4 0" < #\@(P ^("D /" O #LA-@ Z(3T .2%$ #@B
M3  W(E4 -B-? #0C:P S)'D ,B6) #$EF@ P):L ,":_ "\FW  P)O( ,";_
M #$E_P"1)@  ?R@  '$J  !E*@  7"H  %4J  !/*0  2R@  $@E  !$)
M020% #\D#0 ])!( .R09 #DD'P W)"8 -B0L #4E,P T)3H ,R9! #(F2@ Q
M)U, ,"== "\H:0 N*7< +2F' "PIF  K*JH *BJ] "HJV@ K*O$ *RK^ "PI
M_P"-*   ?"H  &TL  !B+0  62T  %$M  !,+   1RL  $,H   _*   /"@"
M #DH"P W*!  -2@6 #,H'  R*", ,"@I "\I,  O*C< +BH_ "TK1P L*U$
M*RQ; "HL9P I+74 *"V% "<MEP F+J@ )2Z\ "4NV  F+O  )B[] "<M_P"*
M*P  >"T  &HN  !?+P  5B\  $XO  !(+@  0RT  #\L   [+   -RP  #0L
M"0 R+ X ,"T3 "XM&@ M+2  *RTG "HN+0 J+C4 *2\] "@O10 G,$X )C!9
M "4Q90 D,7, (S&# "(RE0 A,J< (3*[ " RU  A,N\ (C'\ "(Q_P"&+0
M=2\  &<P  !<,0  4S$  $LQ  !%,0  0#   #LP   V,   ,S   # Q!@ M
M,0T *S$1 "DR%P H,AX )S(D "4S*P E,S( )#,Z ",T0P B-$P (357 " U
M8P ?-7$ 'C:! !TVDP <-J4 &S:Y !LVT@ <-NT '3;[ !TU_P"",   <3(
M &,S  !9-   4#0  $DT  !",P  /3,  #<S   Q-   +C4  "LU @ H-@L
M)3<0 "0W%0 B-QL (3@B " X*  ?.#  'C@W !TY0  <.4D &SI4 !HZ8  9
M.FX &#I_ !<[D0 7.Z0 %CNW !4[T  6.NP %SKZ !@Y_P!],@  ;30  & U
M  !5-@  338  $8V  ! -@  .C8  #0V   N.   *CD  "8Z   C.P@ (#P.
M !X]$@ =/1@ '#T? !L^)0 :/BT &3XT !<^/0 6/T< %3]1 !0_7@ 4/VP
M$T!\ !) CP 10*( $4"V !! S@ 1/^L $C_Y !(^_P!Y-0  :3<  %PX  !2
M.0  2CD  $,Y   ].0  -SD  #$Z   K/   )ST  "(_   >000 &D(+ !A#
M$  70Q4 %40; !1$(@ 31"D $T0Q !)$.@ 114, $$5. !!%6P .16D #D5Y
M  U%C  -19\ #$6R  M%R0 ,1>4 #43V  U$_P!T.0  93H  %@[  !/.P
M1SP  $ \   Z/   -#P  "X^   H0   (T(  !]$   :1@  %4@( !)*#0 1
M2A( $$H8  ]+'@ .2R4 #4LM  U+-@ ,2T  "TM*  I+5@ )2V0 "$MT  =+
MAP %2YH !$NN  1*Q  %2N  !4KP  9)^@!N/   8#T  %0^  !+/@  1#X
M #T^   W/P  ,4   "I"   D10  'T<  !I)   53   $4X%  Y1"P +41
M"E$4  E1&P (42( !U$I  51,@ $4CL  U)&  %24@  4E\  %)O  !2@0
M498  %&I  !1OP  4-P  %#N  !0]P!H0   6T$  %!!  !(00  04$  #M"
M   T0P  +44  "9(   @2P  &TT  !90   14P  #E4$  I8"@ &6 X  E@2
M  !9%P  61T  %DE  !9+0  638  %E!  !930  6EH  %II  !9?   69
M %FE  !8N@  6-4  %?L  !7]@!C1   5D4  $U%  !%10  /T4  #='   O
M20  *$P  ")/   ;4@  %E4  !%8   -6@  "5T#  1?"0  8 T  & 0  !A
M%   81D  &(@  !B)P  8C$  &([  !B1P  8E4  &-D  !B=@  8HL  &*@
M  !AM@  8<\  &#J  !@]0!=2   4DD  $I(  !#2   .DH  #)-   J4
M(U,  !Q7   66@  $5T   U@   (8P   V8!  !G!@  : L  &D.  !J$0
M:Q4  &P;  !M(@  ;2H  &TT  !M0   ;4X  &U=  !M;P  ;80  &R:  !L
ML   :\@  &OF  !J\P!830  3DT  $A,   ^3@  -5$  "Q4   D6   '5P
M !9@   09   #&<   =K   !;@   '    !R P  <@<  ',+  !U#@  =A$
M '<6  !X'   >2,  'HM  !Z.0  >D<  'I6  !Y:   >GP  'F4  !XJ@
M>,$  '??  !W[P!440  3%$  $)2   X50  +UD  "9>   >8@  %F<  !!K
M   +;P  !7,   !W    >@   'P   !^    ?P(  ( &  "!"@  @PT  (01
M  "&%0  B!P  (DE  "*,   BCX  (E-  ")7P  B7,  (B+  "(H@  A[D
M (?1  "&Z !25@  1U<  #Q:   R7P  *&0  !]I   6;P  $'0   IY   "
M?0   ($   "%    B    (H   ",    C0   (\   "0!   D@@  ),,  "5
M$   EQ4  )D=  ";)P  FS0  )M$  ":5@  FFH  )F"  ":F@  F+   )C'
M  "7W@!+7   0&   #5E   K:@  (7$  !=W   0?0  "8,   &(    C
M )$   "5    F    )H   ";    G0   )\   "@    H@   *0%  "F"@
MJ X  *H4  "M'0  K2H  *TY  "M2P  K5\  *UW  "LD   JZ<  *NZ  "K
MRP!%9@  .6L  "YQ   C>   &7\  !"&   )C0   ),   "8    G0   *$
M  "E    J    *L   "K    K@   *\   "Q    LP   +4   "W 0  N0<
M +P-  "_$P  PA\  ,(N  #"0   PE0  ,%K  #!@P  P)L  ,&M  #!O  ^
M<@  ,G@  ">    <B   $I    J7    G0   *,   "H    K0   +(   "V
M    N0   +L   "\    O@   ,    #"    Q    ,8   #(    RP   ,X%
M  #1#0  UA0  -<C  #8-0  V4D  -I>  #;=0  VXP  -R?  #<JP#_
M_P   /\   #_  D _P 0 /\ &0#^ "0 _  O /D .0#T $, \ !+ .T 4@#J
M %D YP!? .0 9 #B &D X !N -X <P#< 'D V@!_ -< A@#4 (X T0"6 ,\
MH0#, *P R@"[ ,@ T@#& .X Q@#_ ,4 _P#% /\ OP#_ +H _P#_    _P
M /\   #^  4 ]P . /( %0#N !\ ZP J .D - #C #T W@!% -D 30#4 %,
MT0!9 ,X 7@#, &, R@!H ,D ;0#' ', Q0!Y ,, @ #! (@ OP"0 +T FP"[
M *8 N0"T +< R "V .8 M0#[ +0 _P"T /\ LP#_ *X _P#_    _P   /@
M  #M    Y0 + -T $0#7 !H T@ D ,\ +@#+ #< QP!  ,, 1P#  $X O@!3
M +P 60"Z %X N !C +8 : "U &T LP!S +$ >0"O ($ K0"* *L E "I *
MJ "M *8 O@"E -L I #T *0 _P"C /\ HP#_ *( _P#_    ]@   .8   #7
M    RP & ,0 #@"^ !4 NP ? +D * "W #$ M  Z +  00"M $@ JP!. *D
M4P"G %@ I@!< *0 80"C &< H0!L *  <P"> 'H G0"# )L C@"9 )D EP"F
M )8 M@"5 ,P E #K ), _0"3 /\ DP#_ ), _P#W    Y    -    #!
MMP " *\ "P"K !$ IP 9 *4 (@"C "L H@ S )\ .P"< $( FP!( )D 30"7
M %( E@!7 )4 6P"3 &$ D@!F )  ;0"/ '0 C0!] (P AP"* ), B "@ (<
MKP"% ,( A0#B (0 ]P"$ /\ A #_ (0 _P#E    S0   +P   "O    I@
M )X !P":  X E@ 4 )0 '0"2 "4 D0 M )  -0"- #P C !" (H 1P"( $P
MAP!1 (8 5@"$ %L @P!@ ($ 9P"  &X ?@!W 'T @0![ (T >@": '@ J0!W
M +H =@#3 '8 [P!V /X =0#_ '4 _P#0    NP   *L   "?    EP   )
M @"+  L B  0 (8 %P"$ "  @@ G ($ +P!_ #4 ?0 \ 'P 00![ $8 >0!+
M '@ 4 !W %4 =@!; '0 80!S &D <0!Q '  >P!N (< ;0"5 &L HP!J +0
M:@#) &D Z !I /D :0#_ &D _P#     K    )P"  "0 @  B    (,   !_
M  8 >P - 'D $@!W !H =@ B '0 *0!S #  <0 V '  / !O $$ ;0!& &P
M2P!K %  :@!6 &@ 7 !G &0 90!L &0 =@!C (( 80"0 &  GP!? *\ 7@##
M %X X0!> /0 70#_ %T _P"T!P  H D  ) +  "$"P  ? H  '<'  !T!
M<0 ) &\ #P!M !4 :P < &D (P!H "H 9P Q &4 -@!D #P 8P!! &( 1@!@
M $P 7P!2 %X 6 != %\ 6P!H %H <@!8 'X 5P", %8 FP!5 *L 5 "^ %0
MV@!3 .\ 5 #[ %0 _P"I#0  E@X  (<0  !Z$   <A   &P.  !I#   9PD#
M &8$"P!D !  8@ 7 &  '@!> "4 70 K %P ,0!: #< 60 \ %@ 0@!7 4<
M5@%. %4"5 !3 EP 4@-E %$#;P!/!'L 3@2* $T%F0!,!:D 2P6\ $H&U !*
M!^T 2@?Y $H'_P"A$   CA(  'X4  !S%   :A0  &03  !@$0  7@\  %T-
M!0!="0T 6@82 %@'&0!6!R  50<G %,'+0!2"#, 40@X % (/@!/"40 3@E*
M $P)40!+"ED 2@IB $@+;0!'"WH 1@R( $0,F !##*D 0@V\ $(-U0!"#>X
M0@W[ $(-_P":%   AQ8  '@8  !L&0  8QD  %T8  !9%@  5A,  %01  !4
M#@@ 4PT. %$-% !/#1L 30TB $P-* !+#2X 2@TT $D-.@!'#D$ 1@Y' $4.
M3P!$#E< 0@]A $$0;  _$'D /A"( #T1F  [$:D .Q&\ #H1U@ Z$?  .A+]
M #L1_P"3&   @1H  ',<  !G'0  7AT  %@<  !3&P  4!@  $X6  !,$P,
M3!$+ $H0$ !($1< 1A$> $41) !$$2H 0A$P $$1-P! $CT /Q)$ #T23  \
M$U0 .Q-> #D4:0 X%'8 -Q6% #85E@ T%J< -!:Z #,6TP S%NX -!;\ #06
M_P".&P  ?!T  &X?  !C(   6B   %,@  !.'@  2AT  $@:  !&&   118'
M $,5#@!!%1, /Q4: #X5(  ]%2< .Q4M #H6,P Y%CH .!9! #<720 U%U$
M-!A; #,99@ R&7, ,!J# "\:E  N&Z4 +1NX "T;T  M&^P +AO[ "X;_P"*
M'@  >"   &HB  !?(P  5B,  $\B  !*(0  1B   $,>  !!&P  /QH# #T:
M#  [&1$ .1D6 #<:'0 V&B, -1HI #0:,  S&S8 ,1L^ # <1@ O'$\ +AU9
M "T=9  L'G$ *Q^! "H?D@ I'Z0 *""W "<@S@ G(.L *"#Z "D?_P"&(
M=",  &<D  !<)0  4R4  $PE  !')   0B,  #\A   ]'P  .AX  #<>"0 U
M'@X ,QX3 #$>&@ P'B  +QXF "X?+0 M'S, +" [ "L@0P J(4P *2%6 "@B
M8@ F(F\ )2-_ "0CD  C(Z( (B2U "(DS  B).D (R3Y "0C_P""(P  <24
M &,F  !9)P  4"@  $DG  !#)P  /R8  #LD   X(@  -2(  #(B!@ P(@T
M+B(1 "PB%P J(AT *2(C "@C*@ G(S$ )B0X "4E00 D)4H (R94 "(F8  A
M)VT ("=] !\GCP >**$ 'BBT !THR@ =*.@ 'BCX !\G_P!^)0  ;B<  & I
M  !6*0  32H  $8J  !!*0  /"@  #<G   T)@  ,"8  "TF P K)PL *"<0
M "<G%  E)QH )"<A ",H)P B*"X (2DV " I/@ ?*D@ 'BI2 !TK7@ <*VL
M&RM[ !HLC0 9+)\ &"RR !@LR0 8+.< &2OW !HK_P!Z)P  :BH  %TK  !3
M+   2BP  $,L   ^*P  .2L  #0J   P*@  *RH  "DK   F*P@ (RP. "(L
M$@ @+!@ 'RP> !XM)0 =+2P '"TS !LN/  :+D4 &2]0 !@O7  7+VD %C!Y
M !4PBP 4,)X %#"Q !,PQP 3,.4 %##V !4O_P!V*@  9RP  %HM  !0+@
M2"X  $$N   [+@  -BT  #$M   L+0  )R\  "0O   A, 4 'S$, !PQ$  ;
M,A4 &C(< !DR(@ 8,BD %S,Q !8S.0 5,T, %#1- !,T60 2-&< $35W !$U
MB0 0-9P $#6P  XUQ@ /-.0 $#3U ! T_P!R+   8RX  %<P  !-,   13
M #XP   X,   ,S   "\P   I,0  )#(  "$S   =-0( &C8) !<W#@ 5-Q,
M%#@9 !,X'P 2."8 $C@N !$Y-@ 0.4  $#E+  XY5P ..F0 #3IT  PZA@ ,
M.ID "SFL  HYP0 *.=X "SGQ  PX_ !N+P  7S$  %,R  !*,P  0C,  #LS
M   V,P  ,3(  "PS   G-   (38  !TX   9.0  %3L& !(]#  0/A  $#X5
M  X^'  ./B, #3XJ  P^,P ,/CP "S]'  H_4@ (/V  !S]O  8_@0 %/Y0
M!#^H  ,^O  $/M< !3[L  4^]P!I,P  6S0  % U  !'-0  /S4  #DU   T
M-0  +C4  "DW   C.   'CL  !H\   6/P  $D$$  Y#"@ ,1 X "D03  E$
M&0 (1"  !T0G  9$+P %1#@  T5"  )%3@  15L  $5J  !%?   19   $2D
M  !$N0  1-$  $3J  !#]0!D-@  5S<  $PX  !#.   /#@  #<X   Q.
M*SD  "4[   @/0  &D   !9"   21   #D<$  M)"0 '2@T !$L1  %+%@
M2QP  $LC  !+*P  2S0  $L^  !,20  3%<  $QF  !,=P  2XP  $NA  !+
MM0  2LX  $KI  !*]0!?.@  4CL  $@[  ! .P  .CL  #0[   N/   )SX
M ")!   <0P  %D8  !))   .2P  "TX#  =0"  "40P  %$0  !2$P  4Q@
M %,?  !3)@  4R\  %,Y  !310  4U(  %-A  !3<@  4X<  %*<  !2L0
M4<H  %'G  !1] !9/@  3CX  $4^   ^/@  .#X  #!    I0@  (T0  !U'
M   72@  $DT   Y0   +4P  !E4"  !7!P  6 L  %D.  !:$0  6A4  %L:
M  !<(0  7"H  %PT  !</P  7$T  %Q;  !<;   7($  %N7  !;K0  6L4
M %KD  !9\P!40@  2D(  $)"   \0@  -$,  "Q&   E20  'DP  !=/   2
M4P  #E8   I9   %6P   %X   !@!   80@  &(,  !C#@  9!$  &46  !F
M'   9R,  &<M  !G.0  9T8  &=5  !G9@  9WH  &:1  !EJ   9<   &3>
M  !D\ !/1@  1T8  $!%   W1P  +TH  "9-   ?40  &%4  !)9   -7
M"&    )C    9@   &@   !J    :P0  &P(  !M#   ;PX  ' 2  !R%P
M<QT  '0F  !T,@  =#\  '1.  !S7P  ='(  '.*  !RH0  <;@  ''4  !P
M[ !,2@  14H  #M+   R3@  *5(  "!6   86P  $E\   UD   ':    &L
M  !O    <@   '4   !V    =P   'D"  !Z!@  ? H  'X.  " $0  @A8
M (0>  "$*0  A#8  (1%  "$5@  @VH  (.!  ""F0  @;$  (#)  " Y0!*
M3@  /U   #53   K5P  (EP  !EB   29P  #&P   5Q    =0   'D   !]
M    @0   (,   "%    A@   (@   ")    BP0  (T(  "/#0  DA   )06
M  "6(   EBP  )8[  "63   E6   )5V  "4D   DZ<  )*]  "2U0!$50
M.5D  "]=   D8P  &FD  !)O   ,=0  !'L   "     A0   (D   "-
MD0   ),   "4    E@   )@   ":    G    )X   "@!@  H@L  *40  "H
M%P  J2,  *DQ  "I0P  J58  *AM  "FAP  IYX  *:S  "EQP ^7@  ,F,
M "=J   =<   $W@   Q_   #A0   (L   "1    E@   )L   "?    H@
M *0   "E    IP   *D   "K    K0   +    "R    M0(  +<)  "[$
MOA@  +XF  "^.   ODL  +UA  "\>@  NY0  +JI  "ZN0 W:@  *W   "!X
M   6@   #8@   6/    E@   )P   "B    IP   *P   "P    LP   +8
M  "W    N0   +L   "]    OP   ,(   #%    R    ,H   #."   TA
M -4;  #5+   U$   -17  #3;@  U(8  -2;  #3JP#_    _P   /\   #_
M  4 _P . /\ %0#\ "  ^0 J /8 - #Q #T [0!& .D 30#F %, Y !9 .$
M7@#> &, W !H -D ;@#5 ', TP!Y -  @ #. (@ RP"1 ,D G #& *< Q "W
M ,( S #  .P OP#_ +X _P"] /\ MP#_ +( _P#_    _P   /\   #Z  $
M\P + .T $@#H !L Y0 E .0 +@#? #@ V !  -( 1P#. $X RP!4 ,@ 60#&
M %X Q !C ,( 9P#  &T OP!S +T >@"[ ($ N0"+ +8 E0"T *$ L@"O +
MP@"N ., K@#Z *P _P"M /\ J0#_ *8 _P#_    _P   /(   #F    W0 '
M -( #@#- !8 R@ @ ,@ *0#% #( P  Z +P 0@"Y $@ MP!. +4 4P"S %@
ML0!= +  8@"N &< K !L *H <P"I 'L IP"$ *4 C@"C )H H0"H )\ N0">
M -( G0#R )P _P"= /\ G #_ )D _P#\    [@   -T   #,    P0 " +H
M# "V !( L@ : +  (P"O "P K0 T *D / "F $( I !( *( 30"@ %( G@!7
M )T 6P"< &  F@!F )D ; "7 '0 E0!] ), AP"1 ), D "A (X L0"- ,8
MC #H (L _0", /\ C #_ (P _P#M    V    ,4   "W    K    *8 " "A
M  X GP 5 )T '@"; "8 F@ N )< -0"5 #P DP!" )$ 1P"0 $P C@!1 (T
M50"+ %H B@!@ (D 9@"' &T A0!V (0 @ "" (P @ ": '\ J0!] +P ? #<
M 'P ]0!\ /\ ? #_ 'P _P#9    P0   +$   "D    G    )0  P"0  P
MC0 1 (L & ") "  B0 H (< +P"% #8 @P \ (( 00"  $8 ?P!+ 'T 3P!\
M %0 >P!: 'D 8 !X &< =@!P '4 >@!S (8 <0"3 '  H@!O +0 ;@#, &X
M[0!N /X ;@#_ &X _P#$    KP   *    "4    C    (8   "!  @ ?@ .
M 'P % ![ !L >0 B '@ *0!W #  =0 V '0 .P!R $  <0!% '  2@!O $\
M;0!4 &P 6P!K &( :0!J &@ = !F (  90". &, G0!B *T 80#" &$ Y !A
M /@ 80#_ &$ _P"T    H    )$   "&    ?@   'D   !U  , <0 + &\
M$ !M !8 ;  = &L ) !K "H :0 P &@ -@!F #L 90!  &0 10!C $H 80!/
M &  5@!? %T 70!E %P ;P!: 'H 60"( %@ F !7 *@ 5@"[ %8 V !6 /$
M5@#_ %8 _P"H 0  E 4  (4'  !Z!P  <@8  &P$  !I 0  9P ' &0 #0!C
M !$ 80 8 &  'P!? "4 7@ K %T , !; #8 6@ [ %D 0 !8 $4 5P!+ %8
M40!5 %@ 4P!A %( :@!0 '8 3P"$ $X DP!- *0 3 "V $P S0!, .L 3 #Z
M $P _P"="0  BPL  'P-  !P#0  : T  &(,  !?"@  708! %P!"0!:  X
M6  3 %< &0!6 "  50 F %, *P!2 #$ 40 V %  .P!/ $$ 3@!' $T 30!+
M %4 2@!= $D 9P!' ', 1@"  $4 D !$ *$ 0P"R $, R !# .8 0P#U $,
M_P"5#0  @P\  '00  !I$0  8!$  %H0  !6#@  5 T  %,*! !3!@L 40,0
M $\!%0!. 1L 3 $A $L!)P!* BP 20(R $@"-P!' ST 10-# $0#2@!#!%$
M0@1: $ %9  _!7  /@9^ #T&C@ \!Y\ .P>Q #H'Q@ Z!^, .@?S #H(_ ".
M$   ?!(  &X4  !B%0  6A4  %04  !0$P  31$  $L.  !+#08 2@H, $D(
M$0!'"!8 10@= $0((P!"""@ 00DN $ ),P _"3D /@I  #T*1P \"D\ .@M8
M #D+8P X#&\ -@Q^ #4,C@ T#9\ ,PVQ #(-QP R#>, ,@WT #(-_@"($P
M=Q4  &D7  !>&   51@  $\8  !*%@  1Q4  $43  !#$ ( 0PX( $(-#@!
M#1( /PT8 #T-'P \#20 .PTJ #D-,  X#C< -PX] #8.10 U#DT ,P]7 #(/
M8@ Q$&X +Q!] "X0C@ M$:  +!&R "L1R  K$>8 *Q'V "P1_P"#%@  <AD
M &0:  !9&P  41L  $L;  !&&@  0A@  #\7   ^%   /!($ #L1"@ Z$!
M.! 5 #<0&P U$2$ -!$G #,1+0 R$3, ,!$Z "\20@ N$DL +1-4 "L37P J
M%&P *11[ "@4C  G%9X )A6P "45Q@ E%>0 )17V "85_P!^&0  ;AL  & =
M  !6'@  31X  $<>  !"'0  /AP  #H:   X&   -Q8  #45!P T% T ,A02
M # 4%P O%!T +10C "P5*@ K%3  *A4W "D6/P H%D@ )Q=2 "8870 D&&H
M(QEY "(9B@ A&9P (!FO !\9Q  ?&>( (!GT " 9_P!Z&P  :AX  %T?  !3
M(   2B   $0@   ^'P  .AX  #<=   T'   ,AD  # 9!  N& L +!@0 "H8
M%  I&!H )Q@@ "89)@ E&2T )!HU ",:/0 B&T8 (1M0 " <6P ?'6@ 'AUW
M !T=B  <'IL &QZM !H>PP :'N  &AWS !L=_P!W'0  9R   %HA  !0(@
M2"(  $$B   [(@  -R$  #,@   P'P  +1T  "L=   H'0@ )AT. "4=$@ C
M'1< (1T= "$=)  @'BH 'QXR !X?.@ ='T, '"!- !LA60 :(68 &2%U !@B
MAP 7(ID %B*L !4BP0 5(M\ %2'R !8A_@!S(   9"(  %<C  !-)   124
M #XD   Y)   -",  # B   L(@  *2$  "8A   D(08 (B$, " A$  >(14
M'2(; !LB(0 ;(B@ &B,O !DC.  8)$$ %R1+ !8E5P 5)60 %"9S !,FA0 2
M)I@ $2:K !$FP  0)MT $27Q !(E_0!P(@  820  %0F  !*)@  0B<  #PF
M   V)@  ,24  "TE   I)   )B0  "(E   ?)0, '28* !LF#@ 9)Q( &"<8
M !<G'P 6)R4 %2@M !0H-0 3*3X $BE) !$I50 1*F( $"IQ  \J@P .*I8
M#BJI  TJO0 -*M< #2KN  XI^P!L)   728  %$H  !(*   0"D  #DH   T
M*   +R@  "LG   G)P  (B@  !XI   ;*@  &"L' !8K#0 4+!$ $RP6 !(L
M'  1+2, $"TJ ! M,@ /+CP #BY&  TN4@ -+E\ #"]N  LO?P *+Y( "2^E
M  DNN0 (+M  "2[I  HN]P!H)P  6BD  $XJ  !%*P  /2L  #<K   Q*@
M+2H  "DJ   D*@  ("L  !LM   8+@  %2\$ !(Q"@ 0,@X #S(3  XR&0 -
M,B  #3(G  PR+P +,S@ "C-"  DS3@ (,UL !C1J  4T>P $,XX  S.B  (S
MM@ ",\T  S/G  0R\P!D*@  5BP  $LM  !"+0  .BT  #0M   O+   *RP
M "8L   B+0  '2\  !DQ   5,@  $C0#  \V"0 ,. T "C@1  DX%@ (.!T
M!S@D  8X+  $.#0  S@^  (Y2@  .5<  #EE   Y=P  .8L  #B?   XLP
M.,H  #CF   W\@!?+0  4BX  $@O   _,   ."\  #(O   M+P  *2\  "0P
M   ?,0  &C,  !4U   2-P  #SD#  P["  (/0T !3X0  ,^%   /AH  #XA
M   ^*   /C$  #\[   _1@  /U,  #]A   _<P  /X<  #Z<   ^L   /<<
M #WD   ]\@!:,   3C(  $0R   \,@  -3(  # Q   K,0  )C(  " T   ;
M-@  %C@  !([   //0  ##\#  A!"  $0PP  $,.  !$$@  118  $4=  !%
M)   12T  $8V  !&0@  1DX  $9=  !&;@  18(  $68  !$K0  1,0  $/C
M  !#\@!5-   2C4  $$U   Y-0  ,S0  "XT   H-0  (C<  !TZ   7/
M$C\   ]!   ,1   "$8!  -(!@  20H  $H-  !+$   3!0  $T9  !.(
M3B@  $XR  !-/0  3DH  $Y8  !-:0  37T  $R4  !,J@  2\$  $OA  !*
M\@!0.   1C@  #TX   W.   ,3<  "HY   D.P  'CT  !A    30P  #T8
M  M)   '2P   DX   !0!   40@  %(+  !3#@  5!$  %45  !6&P  5R,
M %<L  !7.   5T0  %=2  !68P  5G<  %:.  !5I0  5+T  %/=  !3\ !+
M/   0CP  #L[   U.P  +3P  "8_   ?0@  &44  !-(   .2P  "T\   51
M    5    %<   !8 0  6@4  %L(  !<#   70X  %\1  !@%@  8AT  &(F
M  !B,0  8CX  &%,  !A70  87   &"(  !@H   7[<  %[4  !=[@!'0
M/S\  #H_   Q0   *4,  "%&   :2@  $TX   Y1   *50  !%@   !;
M7@   &$   !C    9 $  &4$  !G"   : L  &H.  !L$@  ;A<  &\@  !O
M*@  ;S8  &Y%  !N50  ;F@  &U_  !MF   ;+   &O*  !JZ !$1   /D,
M #5$   K1P  (TL  !M/   35   #E@   A<   "8    &0   !G    :P
M &T   !O    <    '(   !T @  =08  '<*  !Y#@  ?!(  'X8  !_(@
M?RX  '\]  !^30  ?6$  'UW  !\D   >Z@  'K   !YWP!#1P  .4D  "],
M   E4   '%4  !1;   .8   !V4   !J    ;@   '(   !V    >0   'P
M  !^    ?P   ($   "#    A0   (<#  "*"   C T  (\1  "2&0  DB4
M )(S  "21   D5<  )!M  "/A@  CI\  (VU  ",S0 ]3@  ,E$  "A6   >
M7   %6(   YH   ';@   '0   !Y    ?@   ((   "&    B0   (P   ".
M    D    )(   "4    E@   )@   ";    G@8  *$,  "D$0  IAL  *8I
M  "F.@  I4T  *5B  "D>P  HY0  *&K  "AOP V5P  +%P  "%B   7:0
M#W    =W    ?@   (0   "*    CP   )0   "8    FP   )X   "?
MH@   *0   "F    J    *L   "M    L    +,$  "W#   NQ(  +L?  "[
M,   NT,  +I8  "Y<   MXL  +>A  "WLP P8@  )6D  !IP   0>   "8
M  "(    CP   )8   ";    H0   *8   "J    K@   +    "Q    M
M +8   "X    NP   +T   #     PP   ,<   #+ P  SPP  -,5  #2)0
MTC@  -%.  #090  SWX  ,V6  #,J0#_    _P   /\   #_  , _P + /P
M$0#Y !L ]P E /, +P#N #@ Z0!  .8 2 #B $X WP!4 -P 60#9 %X U0!C
M -, : #0 &T S@!S ,L >@#( (( Q@", ,, EP#  *, O@"R +P R "Z .H
MN0#_ +@ _P"Q /\ J@#_ *< _P#_    _P   /L   #V    [0 ' .< #P#B
M !8 WP @ -X *0#9 #, T0 [ ,P 0@#( $@ Q0!. ,( 4P#  %@ O@!= +P
M8@"Z &< N0!M +< = "U 'L L@"% +  D "N )P K "J *D O0"G -X I@#Y
M *4 _P"C /\ G0#_ )L _P#]    ]@   .L   #?    T0 # ,H # #% !(
MPP ; ,  ) "^ "P N0 U +8 / "S $, L !( *X 3@"L %( JP!7 *D 7 "G
M &$ I@!G *0 ;0"B '0 H !] )X B "< )4 F@"C )@ M "6 ,T E0#Q )0
M_P"5 /\ D #_ (X _P#S    Y@   -$   #"    N    +$ " "M  \ J@ 6
M *@ '@"H "< I@ O *( -@"? #P G0!" )L 1P"9 $P EP!1 )8 50"4 %H
MDP!@ )$ 9@"0 &X C@!V (P @0"* (T B "; (8 K "% ,$ A #F (, _0"$
M /\ @P#_ ($ _P#D    RP   +H   "L    H@   )P ! "8  P E@ 1 )0
M&0"3 "$ D@ H (\ , "- #8 BP \ (D 00"( $8 A@!+ (4 3P"$ %0 @@!:
M ($ 8 !_ &< ?@!O 'P >@!Z (8 > "4 '< I !U +< = #4 ', ] !T /\
M= #_ '0 _P#+    M@   *8   ":    D@   (H   "&  @ @P . ($ % "!
M !L @  C '\ *@!] #  >P V 'H .P!X $  =P!% '4 20!T $X <P!4 '$
M6@!P &$ ;@!I &T <P!K '\ :0"- &@ G0!G *X 9@#' &4 Z@!F /\ 9@#_
M &< _P"X    I    )4   "*    @0   'P   !V  0 =  , '( $ !Q !8
M<  = '  ) !N "H ;0 P &L -0!J #H :0 _ &@ 1 !G $D 90!. &0 5 !C
M %L 80!C &  ;0!> 'D 70"' %L E@!: *@ 60"] %D WP!9 /@ 6@#_ %H
M_P"H    E0   (<   ![    <P   &X   !J  $ 9P ( &4 #@!D !( 8P 8
M &, 'P!B "4 80 J %\ , !> #4 70 Z %P /@!; $0 60!) %@ 3P!7 %8
M5@!> %0 : !3 ', 40"! %  D0!/ *( 3@"U $X T !. /  3@#_ $\ _P"<
M    B0   'L#  !P P  : ,  &(!  !?    70 $ %L "P!9  \ 6  4 %<
M&0!7 "  5@ E %4 *@!3 #  4@ T %$ .0!0 #\ 3P!$ $X 2P!- %( 2P!:
M $H 8P!) &\ 1P!\ $8 C !% )T 10"P $0 QP!$ .@ 1 #Z $4 _P"2!
M@ <  '$*  !F"@  7@H  %D)  !5!P  5 0  %( !P!0  P 3P 0 $X %0!-
M !L 3  @ $L )@!* "L 20 P $@ -0!' #H 1@!  $4 1@!# $X 0@!6 $$
M7P!  &L /@!X #T B  \ )D / "K #P P0 [ .  .P#T #L _P")"@  > P
M &H.  !?#@  5PX  %$.  !-#   2PL  $H( @!)! D 2  - $8 $0!% !8
M1  < $, (0!" "8 00 K #\ ,0 ^ #8 /0 \ #P 0P [ $H .@!2 #D 7  X
M &@ -@!U #4 A0 T )8 - "H #, O  S -@ ,P#O #, ^P""#0  <0\  &00
M  !9$0  41$  $L1  !'$   1 X  $(-  !!"P4 00<+ #\%#@ ^ Q( / (8
M #L"'0 Z R( .0,H #@#+0 W S( -@0Y #4$/P T!4< ,P50 #$&6@ P!F8
M+P=S "X'@P M!Y4 + >G "L'N@ K!]( *P?K "L']P!]$   ;!$  %\3  !4
M%   3!0  $84  !"$P  /A(  #P0   Z#@$ .@T& #H*#  X"1  -@@4 #4(
M&0 T"1\ ,@DD #$)*0 P"2\ +PHV "X*/0 M"D4 + M. "L+60 I#&4 * QS
M "<,@P F#94 )0VG "0-NP C#=( (PWK ",-]P!X$@  :!0  %L6  !1%P
M2!<  $(6   ]%@  .14  #<3   U$0  ,Q # #,."  R#0T , T1 "\-%@ M
M#1L + TA "L-)P J#2T *0XT "@..P G#D0 )0Y. "0/60 C$&4 (1!S " 0
MA  ?$)8 'A"I !T0O0 <$-@ '1#N !T0^0!S%   9!8  %<8  !-&0  11D
M #\9   Z&   -1<  #(6   P%0  +A,  "T1!  L$ H *Q . "D0$@ H$!@
M)A > "40)  D$"H (Q$Q "(1.0 A$4( (!)+ !X25@ =$V, '!-Q !H3@@ 9
M%)4 &!2G !<4NP 7$]0 %Q/N !@3^@!P%@  8!D  %0:  !*&P  0AP  #P;
M   V&P  ,AH  "\9   L&   *A8  "@4 0 F$P< )1,, ",3$  B$Q4 (!,:
M !\3(0 >%"< '10N !P5-@ ;%3\ &A9) !D65  8%V$ %A=P !48@0 4&),
M$QBF !(8N@ 2%]( $A?L !,7^@!L&0  71L  %$=  !''0  /QX  #D=   T
M'0  +QP  "L;   H&@  )AD  "08   B%P0 (!<* !X7#@ <%Q( &A<7 !D8
M'@ 9&"0 &!DL !<9-  6&CT %1I' !0;4@ 3&U\ $AQN !$<?P 0')( $!RE
M  \<N0 .'-  #AOJ  \;^ !I&P  6AT  $X?  !%'P  /2   #8?   Q'P
M+1X  "D=   E'0  (QP  " ;   =&P$ &QL' !D<#0 7'!  %AP5 !4<&P 4
M'2( $QTI !(>,0 1'CH $1]% ! ?4  /(%T #B!L  T@?  -((\ #""B  L@
MM0 +(,H "R#E  P?] !E'0  5Q\  $PA  !"(0  .B$  #0A   O(0  *B
M "8?   C'P  (!X  !T>   9(   %B $ !0@"P 2(0X $2$3 !$B&0 0(A\
M#R(F  XC+P .(S< #2-!  PD30 +)%D "B1G  DD>  ()(L !R2>  <DL0 &
M),< !B/C  <C\0!B'P  5"$  $DC  ! (P  .",  #(C   L(P  *"(  "0A
M   A(0  'B$  !HA   6(P  $R0# !$E"  /)@T #B<1  TG%@ ,)QT "R<C
M  HG*P )*#0 ""@^  <H20 &*%4 !2ED  0I=  #*8<  BF;  $HKP  *,4
M 2CA  $G\ !>(@  420  $8E   ])0  -24  "\E   J)   )B0  "(C   ?
M(P  &R0  !@E   4)@  $2@#  \I"  ,+ P "BP0  @L%  '+!H !BPA  4L
M*  #+3   BTZ  $M10  +5(  "Y@   N<0  +80  "V9   MK0  +,(  "S@
M   L\ !:)   328  $,G   Z)P  ,R<  "TG   H)@  )"8  "$F   =)@
M&2<  !4I   1*P  #RP#  TN!P ), P !C$.  ,Q$@ !,A<  #(>   R)0
M,BT  #(V   S0@  ,TX  #-=   S;0  ,X$  #*6   RJP  ,<$  #'?   Q
M\ !6)P  2BD  #\J   W*@  ,"H  "LI   G*   (R@  !XI   :*@  %BP
M !(N   /,   #3$"  HT!P %-0L  C8.   W$   .!0  #@:   X(@  ."H
M #DS   Y/@  .4H  #E9   Y:0  .7T  #B3   XJ   -[\  #?>   V\ !1
M*P  1BP  #PL   T+   +BP  "HK   E*P  ("P  !LM   7+P  $S$  ! S
M   --0  "3<"  4Z!@ !.PH  #P-   ]#P  /A(  #\7  ! '@  0"4  $ O
M  ! .@  0$8  $!4  ! 90  /W@  #^/   ^I@  /KT  #W<   ]\ !-+@
M0B\  #DO   R+P  +2X  "@N   B+P  '3   !@R   3-0  $#<   PZ   )
M/   !3X   !!!   0@@  $,+  !$#0  1A   $<4  !(&0  2"$  $@J  !(
M-0  2$$  $A/  !(8   1W,  $>*  !&H@  1;D  $79  !$\ !(,@  /C(
M #8R   P,0  *S$  "4R   ?-   &38  !,Y   0/   ##\   A"   #1
M $8   !( @  2@4  $L(  !,"P  3@X  $\1  !1%0  4AP  %(E  !2,
M4CP  %%*  !16@  46T  %"$  !/G0  3K4  $W2  !-[@!#-@  .S8  #0U
M   O-   )S4  "$X   :.P  %#X  !!!   ,1   !T<   )*    30   $\
M  !1    4P(  %0%  !5"   5PL  %D.  !;$0  71<  %T?  !=*@  738
M %Q$  !<5   6V<  %M^  !:EP  6:\  %C+  !7Z@ _.0  .#D  #,X   K
M.0  (SP  !P_   50P  $$<   M*   %3@   %$   !4    5P   %H   !<
M    70   %\   !@!   8@<  &0+  !F#@  :!(  &L9  !K(P  :BX  &H\
M  !J30  :5\  &AU  !GCP  9J@  &7"  !DXP ]/0  -SP  "X]   E0
M'40  !9)   030  "E$   15    6@   %T   !@    8P   &8   !H
M:@   &L   !M    ;P(  '$&  !T"@  =@X  'D3  ![&P  >R<  'HU  !Y
M10  >%D  'AM  !WA@  =I\  '6W  !TT@ \00  ,D(  "A%   @2@  %TX
M !!4   *60   EX   !C    9P   &L   !O    <@   '4   !W    >0
M 'L   !]    ?P   ((   "$ P  APD  (H.  ".$P  CQX  (XK  "..P
MC4X  (MC  "*?   BI4  (BM  "'Q0 V1P  +$L  ")/   950  $%L   IA
M   !9P   &T   !R    =P   'L   !_    @P   (8   "(    B@   (T
M  "/    D0   )0   "7    F@$  )T'  "A#0  I10  *0A  "D,0  HT0
M *)9  "@<   GXL  )VB  "=MP P4   )54  !M;   28@  "VD   %P
M=P   'T   "#    B    (T   "1    E0   )@   ":    G    )\   "A
M    HP   *8   "I    K    +    "T!P  N X  +H8  "Z)P  N3D  +A.
M  "W90  MGX  +66  "SJP I6P  'F(  !1I   ,<0   GD   "!    B0
M (\   "6    FP   *    "D    J    *L   "L    KP   +(   "T
MM@   +D   "\    P    ,0   #(    S0<  -(0  #2'0  T2\  -!$  #/
M6P  S7,  ,N-  #*H0#_    _P   /L   #Z    _  ( /@ #P#U !< ]  @
M /$ *@#K #, Y@ [ .( 0P#> $D V@!/ -8 5 #3 %D T !> ,X 8P#+ &@
MR0!N ,8 =0## 'T P0"& +X D@"[ )X N0"N +8 PP"T .@ LP#_ *\ _P"E
M /\ G@#_ )L _P#]    ]P   /(   #P    YP # .$ # #< !( V  ; -8
M) #2 "T S  V ,8 /0#" $, OP!) +P 3@"Z %, N !8 +8 70"U &( LP!G
M +$ ;@"O '8 K !_ *H B@"H )< I0"F *, N0"A -D H #Y )X _P"8 /\
MD@#_ (\ _P#S    [    .,   #3    R    ,$ "0"]  \ NP 6 +D 'P"W
M "< LP O *\ -P"L #T J@!# *@ 2 "F $T I !2 *, 5@"A %L GP!A )X
M9P"< &\ F@!X )< @P"5 )  DP"> )$ L "0 ,@ C@#P (T _P"* /\ A0#_
M (( _P#G    W0   ,8   "X    K@   *@ ! "E  P H0 2 *$ &0"@ "(
MGP I )L , "8 #< E@ ] ), 0@"2 $< D !+ (\ 4 "- %4 C !: (H 80"(
M &@ AP!P (4 >P"# (@ @0"6 '\ IP!] +P ? #C 'P _0!\ /\ > #_ '8
M_P#6    P    *\   "C    F0   ),   "/  D C0 . (L % "* !P B@ C
M (@ *@"% #  @P V (( .P"  $  ?P!% 'X 2@!\ $\ >P!4 'H 6@!X &$
M=@!I '4 <P!S (  <0". &\ GP!N +( ;0#/ &P ] !L /\ :P#_ &D _P#
M    JP   )L   "/    AP   (    !\  0 >@ , '@ $0!X !< >  > '<
M) !U "H <P P '$ -0!P #H ;@ _ &T 1 !L $D :P!. &H 5 !H %L 9P!C
M &4 ;0!D '@ 8@"' &  EP!? *H 7@#" %X Z0!> /\ 7@#_ %T _P"L
MF0   (H   !_    =P   '$   !M    :@ ( &D #@!H !( 9P 8 &< 'P!G
M "4 90 J &, +P!B #0 80 Y &  /@!? $, 7@!( %T 3@!; %4 6@!= %@
M9P!7 '( 50"! %0 D0!3 *, 4@"X %$ W !1 /D 4@#_ %( _P"=    BP
M 'P   !Q    :0   &0   !@    7@ % %P "P!;  \ 6P 4 %H &0!: !\
M60 E %< *@!6 "\ 50 T %0 . !3 #T 4@!# %  20!/ %  3@!8 $T 8@!+
M &T 2@!Z $D BP!( )T 1P"Q $< S !& /  1P#_ $< _P"0    ?@   '
M  !F    7@   %D   !6    4P ! %( " !0  T 3P 0 $\ %0!. !H 3@ @
M $T )0!, "H 2@ N $D ,P!( #@ 1P ^ $8 1 !% $L 1 !3 $, 70!! &@
M0 !U #\ A0 ^ )< /0"K #T PP ] .8 /0#[ #X _P"'    =0,  &@&  !=
M!P  508  % &  !,!   2@$  $D ! !'  H 1@ . $4 $0!% !8 1  ; $,
M( !" "4 00 J $  +P _ #0 /@ Z #T 0  [ $< .@!/ #D 60 X &0 -P!Q
M #8 @0 U ), - "F #0 NP T -T - #U #4 _P!^!@  ;0D  & +  !6#
M3@P  $@+  !$"@  0@@  $ % 0 _ 0< /@ + #T #@ \ !( .P 7 #L '  Z
M "$ .0 E #< *@ V #  -0 U #0 /  S $, ,@!, #$ 50 P &  +P!M "X
M?0 M (\ + "B "P M@ L -  + #N "P _ !W"@  9PP  %H.  !0#@  20X
M $,.   ^#0  .PP  #D+   X"0, -P4( #8"#0 U 1  -  3 #, &  R !T
M,0 B #  )P O "P +@ R "T .  L $  *P!) "H 4@ I %T * !K "<!>@ F
M 8P )0"? "4 L@ E ,H )0#H "4 ]P!R#0  8@X  %80  !,$0  1!$  #X1
M   Y$   -@\  #,.   Q#0$ , L% # ("@ O!@T +@41 "P$%  K QD *@,>
M "D#(P H!"D )P0O "8%-0 E!3T ) 5& ",&4  B!EP (0=I " '>0 ?!XL
M'@>= !X'L  =!L8 '0;C !T%\P!M#@  7A$  %(2  !($P  0!,  #H3   U
M$@  ,1$  "X0   L#P  *@X# "H-!P I"PL * D. "<)$0 E"!8 ) @; ",)
M(  B"28 (0DL " *,P ?"CL '@M$ !T+3P <#%L &PQI !H,>0 8#(L & R>
M !<,L  6#,4 %@SA !8+\ !I$   6A(  $X4  !%%0  /14  #<5   Q%
M+1,  "H2   H$0  )A ! "00!  C#@@ (PT, "(,#P @#!, 'PP8 !X-'0 =
M#2, ' TJ !L-,@ :#CH & Y$ !<.4  6#UP %0]J !,0>P 2$(T $1"@ !$0
MLP 0#\D $ _D !$/\@!E$@  5Q0  $L6  !"%P  .A<  #07   O%@  *A4
M "<4   D$P  (A,  " 2 P >$08 '1 ) !P0#0 ;#Q  &1 5 !@0&P 7$"$
M%A H !41,  4$3D $Q%# !(23@ 1$EH $!)I ! 3>0 .$XP #A.>  T3L0 -
M$L4 #!+A  T2\0!B%   5!8  $D8   _&0  -QD  #$9   L&   *!<  "06
M   A%@  'Q4  !P4 @ :$P0 &1(& !<2"P 5$@X %!(2 !,3&  2$Q\ $1,F
M !$4+0 0%#8 #Q5!  X53  .%E< #19E  P7=0 +%X< "A>:  D6K0 (%L$
M"!;=  D5[@!?%@  41@  $8:   ]&@  -1L  "\:   J&@  )1D  "(8   ?
M&   '!<  !D6 0 7%@, %18$ !,6"0 1%@T $!<1  \7%@ .%QP #A@C  T8
M*@ ,&3, #!D\  L:1P *&E, "1IA  <;<0 &&X, !1N7  0:J@ #&K\  QG:
M  09[ !<&   3AH  $,<   Z'   ,QP  "P<   G'   (QL  " :   =&0
M&AD  !<8 0 5& ( $AD$ ! ;!P .&PP #1P0  P<$P +'!D "AP?  D=)P (
M'2\ !QXY  8>0P $'E   Q]>  (?;@ !'X   !^5   >J0  'KT  !W8   =
M[ !8&@  2QP  $$>   X'@  ,!X  "H>   E'0  (1P  !X<   ;&P  &!L
M !8; 0 3&P( $1P$  X>!P ,'PL "B .  @@$@ &(1< !2$=  0A)  "(BP
M 2(U   B0   (TT  "-:   C:P  (WX  ".3   BIP  (KP  "'7   A[0!5
M'0  2!\  #X@   U(   +B   "@@   C'P  (!X  !T=   :'0  %AT  !,>
M   1'P( #B $  TB!P *) L !B4-  0E$  ")A0  "8:   F(0  )RD  "<R
M   G/0  )TD  "A7   H9P  )WL  ">0   GI0  )KL  ";6   E[0!1(
M12$  #LB   R(@  +"(  "8A   B(0  'B   !L?   8(   %"   !$B   /
M(P  #24#  HF!@ &* H  RD-   K#P  +!(  "P7   L'@  +"8  "TO   M
M.0  +48  "U4   M9   +7<  "R-   LI   *[H  "O6   J[@!-(@  020
M #@D   P)   *20  "0C   A(@  '2(  !DB   5(P  $B0   \F   -*
M"BH"  8L!0 "+@D  "\+   P#@  ,A   #,5   S&P  ,R(  #,K   S-@
M,T(  #-0   S8   ,W,  #**   RH0  ,;@  ##6   P[P!))0  /B8  #0G
M   M)P  *"8  ",E   ?)   &R4  !8F   2*   $"H   TL   *+@  !C !
M  (R!   - <  #4*   W#   . X  #H2   Z%P  .A\  #HG   Z,@  .CX
M #I,   Z7   .F\  #F&   XG@  .+8  #?4   V[P!$*0  .BD  #$I   K
M*0  )B@  "(G   =*   &"D  !,K   0+@  #3    DR   %-0   3<    Y
M @  .P4  #P(   ^"P  /PT  $$0  !#%   0QL  $,C  !#+@  0SD  $-'
M  !"5P  0FH  $&!  ! F@  /[(  #[/   ^[P _+   -BP  "\L   J*P
M)2H  !\K   9+0  %"\  ! R   --0  "#@   0Z    /    #\   !!
M0P(  $4%  !&"   2 L  $H.  !,$0  318  $T>  !-*   330  $Q"  !,
M40  2V0  $M[  !*E   2:T  $C*  !'[  [,   ,R\  "TO   H+0  (B\
M !LQ   5-   $#<   TZ   (/0   D    !#    1@   $@   !*    3
M $X!  !/!   40<  %,+  !5#@  6!(  %D9  !8(@  6"X  %<\  !72P
M5EX  %9S  !5C0  5*<  %+"  !2Y@ X,P  ,3(  "PQ   E,@  '34  !8X
M   1/   #$    =$    1P   $H   !-    4    %,   !5    5P   %D
M  !:    7 ,  %X'  !A"P  9 X  &83  !G'   9B<  &8T  !E1   9%<
M &1K  !BA0  89\  &"Y  !>W  U-P  ,#4  "@W   @.@  &#T  !%"   ,
M1@  !DH   !/    4P   %8   !9    7    %\   !A    9    &4   !G
M    :0   &P!  !N!@  <0L  '0/  !W%0  =R   '8M  !V/0  =4\  '1C
M  !S>P  <I4  '"O  !OR0 U.@  *SL  "(_   :0P  $D@   Q-   %4@
M %<   !<    8    &0   !H    :P   &X   !Q    <P   '4   !W
M>@   'P   !_    @@0  (8*  "*#P  C!<  (LD  "*,P  B44  (=;  "&
M<@  A8L  (.E  ""O  O0   )40  !Q)   33@  #50   1:    80   &8
M  !K    ;P   '0   !Y    ?0   (    "#    A0   (<   "*    C
M (\   "2    E@   )D"  ">"0  HA   *(:  "A*0  H#L  )]0  "=9P
MFH$  )J9  "9KP I20  'TX  !54   .6P  !6(   !I    <    '<   !]
M    @@   (8   "+    CP   ),   "5    EP   )H   "=    H    *,
M  "F    J@   *X   "R    MPH  +L1  "Z'P  N3   +=%  "U7   M'0
M +&.  "OI  B5   &%L  !!B   ':@   ',   ![    @@   (D   "0
ME0   )H   "?    HP   *8   "H    JP   *X   "P    LP   +8   "Z
M    O0   ,(   #'    S $  -,+  #4%0  TR8  -$Z  #040  S6@  ,N!
M  #*E@#\    ]@   /(   #Q    \P % /0 # #R !, \  < .T )0#H "X
MX@ V -X /@#9 $0 U !* -$ 3P#. %0 RP!9 ,D 7@#& &, Q !I ,$ < "^
M '@ O "! +D C0"V )H LP"K +$ P "O .8 K@#_ *4 _P": /\ E #_ (\
M_P#T    [    .@   #G    WP   -D "0#2 !  SP 7 ,\ ( #, "@ Q@ P
M ,  -P"\ #X N0!$ +< 20"U $X LP!3 +$ 5P"O %T K0!B *L :0"I '$
MIP!Z *4 A0"B ), H "B )T M@"; -0 F0#Y )8 _P"- /\ B #_ (0 _P#H
M    WP   -D   #)    OP   +@ ! "U  T LP 2 +$ &@"P "( K0 J *D
M,0"F #@ I  ] *( 0P"@ $@ G@!, )P 40"; %8 F0!< )< 8@"5 &D DP!R
M )$ ?0"/ (L C0": (L K ") ,4 B #N (8 _P!_ /\ >@#_ '@ _P#9
MS0   +L   "N    I0   )\   "<  D F0 / )D %0"9 !T F  D )0 *P"1
M #$ C@ W (P / "+ $$ B0!& (@ 2P"& %  A0!5 (, 6P"" &( @ !K 'X
M=0!\ (( >@"2 '@ HP!W +D =@#@ '4 _P!R /\ ;@#_ &P _P#'    M0
M *4   "9    CP   (D   "%  0 A  , (( $0"" !< @@ > (  )0!^ "L
M?  Q 'H -@!Y #L =P!  '8 1 !U $D <P!/ '( 50!P %P ;P!D &T ;@!L
M 'H :@"* &@ FP!G *\ 9@#, &4 ]0!D /\ 80#_ &  _P"T    H    )
M  "%    ?0   '<   !S    <  ( &\ #@!O !( ;P 8 &\ 'P!M "4 :P J
M &D , !H #0 9P Y &8 /@!E $, 8P!( &( 3@!A %4 7P!> %X 9P!< ',
M6P"" %D DP!8 *8 5P"_ %< Z@!7 /\ 5@#_ %0 _P"A    C@   '\   !U
M    ;    &@   !D    80 $ &  "P!?  \ 7P 3 %\ &0!? !\ 70 E %P
M*@!; "\ 60 S %@ . !7 #T 5@!# %4 20!3 %  4@!8 %$ 80!0 &T 3@![
M $T C !, )\ 2P"U $H W !* /H 2@#_ $H _P"2    @    '(   !G
M7P   %H   !7    50 ! %, !P!2  P 4@ 0 %( % !2 !H 40 ? $\ ) !.
M "D 30 N $P ,P!+ #@ 2@ ] $D 0P!( $H 1@!2 $4 7 !$ &< 0P!U $(
MA@!! )@ 0 "N $  RP _ /( 0 #_ $  _P"%    =    &<   !=    50
M $\   !,    2@   $@ ! !'  H 1P - $8 $0!& !4 1@ : $4 'P!$ "0
M0P I $( +0!! #, /P X #X /@ ] $4 / !. #L 5P Z &( .0!O #@ @  W
M ), -@"G #8 P  V .@ -@#^ #8 _P!\    :P   %X"  !4 P  30,  $<#
M  !# 0  00   #\  0 ^  < /0 + #T #@ \ !$ /  6 #P &@ Z !\ .0 D
M #@ *0 W "X -@ S #4 .@ T $$ ,P!) #( 4P Q %X , !K "\ >P N (X
M+0"B "T N  M -T +0#X "X _P!S 0  9 4  %<'  !-"   1@@  $ (   [
M!P  . 4  #<#   V  0 -0 ( #0 #  T  \ -  2 #, %@ R !L ,0 @ #
M)  O "D +@ O "T -@ L #T *P!% "H 3P I %H * !G "< =P F (D )@"=
M "4 LP E ,\ )0#P "8 _P!M!@  7@D  %(+  !(#   0 P  #H+   V"P
M,@H  # (   N!@( +@,& "T "@ L  T +  0 "L $P J !< *0 < "@ (  G
M "4 )@ K "4 ,@ D #D (P!" "( 2P B %< (0!D "  <P ? (4 'P"9 !X
MK@ > ,< '@#I !\ ^@!H"0  60P  $T-  !##@  / X  #8.   Q#0  +0T
M "H,   H"P  )PD$ "8&"  F! L )0,. "0!$  D 10 (@$8 "$!'0 A "(
M(  H !\ +@ > 38 '0$_ !P!20 ; 50 &@%A !H!<  9 8( & "6 !@ J@ 8
M ,$ & #A !@ ] !C#   50X  $D/  ! $   .!   #(0   M#P  *0X  "8.
M   C#0  (@P# " +!@ @"0D 'P<, !X&#@ >!1$ ' 45 !L%&@ :!1\ &@4E
M !D%*P 8!3, %P8\ !8&1@ 6!E( %0=? !0';@ 3!X  $@>4 !(&IP 2!;P
M$@39 !(#[P!?#@  40\  $80   \$0  -1$  "\1   J$0  )A   "(0   @
M#P  '0X" !P-!0 :#0< &@L* !D*#0 8"1  %PD2 !8)%P 5"1P % DB !0*
M*0 3"C$ $@HZ !(+10 1"U$ $ Q?  \,;@ .#(  #@R4  T+IP -"[H #0K2
M  T*Z@!<#P  3A$  $,2   Z$P  ,A,  "P3   G$@  (Q$  !\1   <$
M&A " !@/!  6#@< %0X) !0-"P 3# T $@P0 !(,%  1#!H $0T@ ! -*  /
M#3  #@X[  T.1@ -#E$ # ]>  L/;0 *#W\ "0^3  D/I@ (#KD " [0  <.
MZ !8$0  2Q(  $ 3   W%   ,!0  "D4   E%   (1,  !T2   :$@  %Q$"
M !41!0 3$ < $A ) !$/"@ 0#@P #@X.  X/$@ -$!@ #1 >  P0)0 ,$"T
M"Q$V  H100 )$4T "!):  <2:@ &$GP !1*0  02I  #$;@  Q'/  (1Z !5
M$@  210  #X5   U%@  +18  "<6   B%0  'A0  !L4   8$P  %1(# !,2
M!0 2$0< $!$)  \1"@ -$0L #!(.  L2$0 *$A4 "1,;  D3(@ ($RH !Q0S
M  44/@ $%4H  Q58  (59P !%7H  !6.   5HP  %+<  !3/   3Z0!2%
M1A8  #L7   R%P  *Q<  "47   A%@  '!8  !D5   6% $ %!,$ !(3!@ 1
M$@@ #Q((  X3"0 ,% H "A4-  @6$  &%A, !189  07'P #%R<  A@P  $8
M.P  &4<  !E5   99   &7<  !F,   8H@  &+<  !?/   7Z@!/%@  0Q@
M #D9   P&0  *1D  ",9   ?&   &Q<  !@6   5%0( $Q4% !$4!@ 0% 8
M#A4'  P6"  *%PH !QD,  0:#@ "&Q(  1L6   ;'0  '"0  !PM   <.
M'40  !U2   =8@  '74  !V*   <H   '+8  !O0   :ZP!,&   0!H  #8;
M   M&P  )AL  "$:   =&0  &1D  !<8   4%P, $A8$ ! 7!  .%P0 #!D%
M  H:!P '' D  QT+   ?#0  (!   " 4   A&@  (2(  "$J   A-0  (D$
M ")/   B7P  (G(  "&(   AGP  (+8  !_1   ?[0!(&@  /1P  #,=   K
M'0  )!T  " <   <&P  &!H  !89 0 3&0$ $1D!  X: 0 ,' ( "AT#  <?
M!0 #(0@  "(*   D#   )@X  "82   F&   )Q\  "<G   G,@  )SX  "=+
M   G7   )VX  ":%   FG0  );0  "31   C[@!$'0  .1\  # ?   H'P
M(QX  !X=   ;'   &!L  !0<   1'   #AT   T?   *(0  !B(!  ,D!
M)@8  "@(   J"P  *PT  "T0   M%0  +1P  "TD   N+@  +CH  "Y(   M
M6   +6H  "V!   LF@  *[(  "K0   I[P! (   -B$  "TA   F(0  (2
M !T?   :'@  %AX  !(?   /(0  #2(   HD   &)@   B@    K @  +00
M "\&   P"0  ,@P  #0.   U$@  -1@  #4@   U*@  -38  #5#   U4P
M-&8  #1\   SE@  ,J\  #'-   P[P \(P  ,B0  "HD   D(P  ("(  !PA
M   7(0  $R,  ! E   -)P  "2D   4K   !+@   #     R    - $  #8$
M   X!@  .@D  #P-   ^$   /A0  #X<   ^)@  /C$  #X_   ]3@  /6$
M #QW   [D0  .JL  #G)   X[0 W)P  +R<  "@F   C)0  'R0  !DE   4
M)@  $"@   TK   )+@  !3     S    -0   #@    Z    /    #X!  !
M P  0@<  $0*  !&#0  21$  $D7  !((0  2"P  $<Z  !'20  1EL  $5Q
M  !$BP  0Z4  $+#  !!Z  T*@  +"H  "<H   B)P  '"@  !8J   1+0
M#3    DS   #-@   #D    \    /@   $$   !#    1@   $@   !*
M3 ,  $X&  !0"@  4PX  %03  !4'   4R<  %,T  !30P  4E4  %%J  !0
M@P  3YX  $VY  !,X  P+0  *RP  "8K   ?+   &"X  !(R   --0  "#D
M  (]    0    $,   !&    20   $P   !.    40   %,   !5    5P
M %D!  !<!@  7PH  &(.  !C%0  8Q\  &(L  !A/   8$X  %]B  !>>P
M7)8  %NP  !9SP O,   *B\  "(P   :,P  $S<   X[   (/P   40   !(
M    3    $\   !2    50   %@   !;    70   &    !B    9    &8
M  !I    ;04  ' +  !T$   =!@  ',E  !R-   <D4  '!9  !O<0  ;8L
M &NF  !JP  N,P  )34  !TX   4/   #D$   ='    3    %$   !5
M60   %T   !A    90   &@   !K    ;0   &\   !R    =    '<   !Z
M    ?@   (($  "&"P  BA$  (D<  "(*P  ACT  (12  "#9P  @8$  '^;
M  !^L@ I.@  (#T  !9"   /2   "$X   !4    6@   &    !D    :0
M &X   !R    =@   'H   !]    @    ((   "%    B    (L   ".
MD@   )8   "; P  H P  *(3  "@(0  GS,  )U'  ":7@  F'<  )>/  "5
MIP C0P  &4@  !%.   )50   %P   !C    :@   '$   !V    >P   (
M  "&    B@   (X   "1    DP   )8   "9    G    *    "C    IP
M *L   "P    M@0  +P-  "Z%P  N2@  +<\  "T4@  LFH  *^%  "MG  <
M3@  $U0   M<   !9    &P   !T    ?    (,   ")    CP   )0   ":
M    GP   *(   "D    IP   *H   "N    L0   +0   "X    O    ,$
M  #'    S0   -0%  #8$   U1X  -,Q  #02   S5\  ,MV  #(C@
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M^_S^______________________________________________________\
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MXN/DY>;GZ.GJZ^SM[N_P\?+S]/7V]_CY^OO\_?[_;69T,0     #!"$   $
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M@K&+PH"PC,* L(S"@+",PH"PC,* L(S"@+",PH"PC,* L(S"@+",PH"PC,*
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MA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:]\ 0%?C
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MP(JL<<"+K'' BZQQP(NL<<"+K'' BZQQP(NL<<"+K'' BZQQP(NL<<"+K''
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ML'ZDT;!^I-&P?J31_[@4#O^X'B?_M"I&]Z\V:=ZG0H_'FV*QQ)MRML*;?[G
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MB9#.LX>2T+*$E=*Q@IG3L8&>U*Z HM2L@*/2K("CTJR H]*L@*/2K("CTJR
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MUI.2H-:3DJ#6_;L1#?V\&2;^N21&]K0N:MRK.I+'H%RQQ*%HML&E<;J^IWK
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MB:N&RH>KALJ%JHC*@ZJ)RX&JB\N JHS+@*J,RX"JC,N JHS+@*J,RX"JC,N
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M"?^Q(Q[_KC$Z_ZD^6>VB2WG9FER7R)5RL,65?;7#EX6XP9>+N[^3C+V^CX[
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MQ+%ZK<2Q>JW$L7JMQ+%ZK<2Q>JW$_ZL:!?^K)1?_J30O_Z1"2OF?3V;HF5R
MVI9FELR5<:G%E7RTQ):#M\*7B[K DXR\OH^.O[V+D,&\AY/#NH26Q;F!F<:Y
M?YW'N'VAR+A\ILFU>JK)L'NKQZQ[K<6L>ZW%K'NMQ:Q[K<6L>ZW%K'NMQ:Q[
MK<6L>ZW%K'NMQ:Q[K<6L>ZW%_ZP9!?^L)!;_J3,O_Z5!2OF?3V;HF5N!V9AC
MELR6;ZK%EGFTPY>!M\&8B;J_E8N]OI&-P+R-C\*ZB)+%N865Q[B"F,FW?YW*
MMGVBR[9\J,NP>ZG*K'RJR*A]K,6H?:S%J'VLQ:A]K,6H?:S%J'VLQ:A]K,6H
M?:S%J'VLQ:A]K,6H?:S%_ZP9!?^L)!;_JC(O_Z5!2_F@3F?GFEF!V9EAE\N7
M;:O%EW>TPYE_M\&:A[N_EXJ^O9.,P;N.CL2YBI#'N(:3R;:"F,NU?YW-M'ZC
MSK%\ILZL?:C+J'VJR:5^K,:E?JS&I7ZLQJ5^K,:E?JS&I7ZLQJ5^K,:E?JS&
MI7ZLQJ5^K,:E?JS&_ZP9!?^M(Q;_JC(O_Z9 2_B@36?GG%>!V9I>E\N8:JS%
MF72TPYI]M\&;A;N^F8F_O)6*PKJ0C,6XC(_(MH>2R[2#E\ZS@)W0LG^DT:Q^
MI<^H?J?,I'^IR:& K,:A@*S&H8"LQJ& K,:A@*S&H8"LQJ& K,:A@*S&H8"L
MQJ& K,:A@*S&_ZT8!?^M(Q;_JS$O_Z8_2_B@36?GG56!V9Q<E\J9:*S%FG*T
MPYQZN,"<@[N^G(F_NY>)P[F3B\>WCHW+M(F0SK*$EM&Q@9W3K("BTZ> I="D
M@*?-H(&IRIZ!J\:>@:O&GH&KQIZ!J\:>@:O&GH&KQIZ!J\:>@:O&GH&KQIZ!
MJ\:>@:O&_ZT8!?^M(A;_JS$O_Z<_2_BA3&?GGE.!V9U9E\J;9:S%G&^TPYUX
MN,">@;R]GHC NYJ(Q+B5B<FUD(O-LHN/T;"&E=6NA)[7IX*AU*."I-&?@J?-
MG(.IRIJ#J\>:@ZO'FH.KQYJ#J\>:@ZO'FH.KQYJ#J\>:@ZO'FH.KQYJ#J\>:
M@ZO'_ZT7!?^N(A;_JS O_Z<^2_BA2VCGGU&!V9]6E\J<8JS%G6RTPY]UN,"@
M?KR]H(?!NIV(QK>8B,NSDXG/L(Z-U*V)E-FHAIW:HH6AU9Z%I-&;A:;.F86I
MRI>%J\>7A:O'EX6KQY>%J\>7A:O'EX6KQY>%J\>7A:O'EX6KQY>%J\>7A:O'
M_ZX7!/^N(A;_K# O_Z<^2_BB2VCHH4^!V:!3E\J>7ZS&GVFTPZ%RN,"B?+R]
MHH3!N:"'Q[6<A\VREXC2KI.+V*J.D]^BBYS<G(F@UIF(H]*7B*;.E8BIRI2(
MJ\>4B*O'E(BKQY2(J\>4B*O'E(BKQY2(J\>4B*O'E(BKQY2(J\>4B*O'_ZX7
M!/^N(1;_K"\O_Z@]2_BB2FCHHDV V:)0E\N@7*S&H66SPZ1NM\"E>+R\I8+"
MN*2'R+2@A\ZPG8C5JYF*W:67D^:;D9O=EH^@UY2-H].2C*;/D8NHRY"*J\B0
MBJO(D(JKR)"*J\B0BJO(D(JKR)"*J\B0BJO(D(JKR)"*J\B0BJO(_ZX6!/^O
M(1;_K2\O_Z@\2_>B26CHI$J V:1-ELNB6*O&I&&SQ*=JM\"I=+R\J7["N*B'
MR+.FA\^LHH?7I)V)W9J:C>&5FIO>D96?V(^3HM..D*70CH^HS(V.JLF-CJK)
MC8ZJR8V.JLF-CJK)C8ZJR8V.JLF-CJK)C8ZJR8V.JLF-CJK)_Z\6!/^O(1;_
MK2XO_ZD\2_>C26GHIDA_VJ=(E<RE4ZK'J%RRQ*QDML&N;KN]KWC MJR$R:ZG
MA]"FHX;5G:"&V9.=B=V-G93=C9V?V(N9H=2+EJ30BI.GS8J1J<F*D:G)BI&I
MR8J1J<F*D:G)BI&IR8J1J<F*D:G)BI&IR8J1J<F*D:G)_Z\5!/^P(!;_KBXO
M_ZD[2_>D1VGIJ$1^VZM#E,VI3*G(K52PQK-<L\*W9KFWL'?"L*N$R:FGAL^A
MI(33EZ*$UHZ@A]F(GX_:AZ&:V(>@H=2'FZ31AYBFSH>5J<J'E:G*AY6IRH>5
MJ<J'E:G*AY6IRH>5J<J'E:G*AY6IRH>5J<J'E:G*_[ 5!/^P(!7_KBTO_ZHZ
M2_BF1&CJJT!]W*\\DL^O0J;*M4FMQKQ2L;FU9[NPL'C#JZR$R:2IA,V<IH/0
MDZ2$TXNCAM6%HHS6@J*4UH.DG=2#HJ31@YZFSH2:J,N$FJC+A)JHRX2:J,N$
MFJC+A)JHRX2:J,N$FJC+A)JHRX2:J,N$FJC+_[ 4!/^Q'Q7_KRPN_ZLY2_BI
M0&?KKSM[WK8SC]*Z-*',PCFJN[I5M;"T:KVJL'G#IZV$QY^JA,N8J(/-D*>$
MT(FEAM*$I(K3@*20TW^EE])_IJ#0?Z6FSH"@J,N H*C+@*"HRX"@J,N H*C+
M@*"HRX"@J,N H*C+@*"HRX"@J,N H*C+_[$3!/^R'A7_L"LN_ZPW3/JL.V7M
MM31XXK\IB=C,()B^OSVNL+A9N*FS;+ZEL'K"HJZ$Q9NL@\B4JH3*CJF$S(BH
MALZ#IXG/@*>-SWZGD\]\J)K.?*FBS7RGJ,M\IZC+?*>HRWRGJ,M\IZC+?*>H
MRWRGJ,M\IZC+?*>HRWRGJ,M\IZC+_[(2!/^S'17_L2DN_ZTV3/RQ-6+QO2IR
MYLT?@,C,(9NQO$6RJ+=>N:.S;[Z@L7O!GJ^$PY>NA,:1K(3'C*N%R8>JA\J#
MJHG+@*J,S'VID,Q\JI7+>JJ<RGFKI,IYJZ3*>:NDRGFKI,IYJZ3*>:NDRGFK
MI,IYJZ3*>:NDRGFKI,IYJZ3*_[,1!/^T&Q3_LR8N_Z\S3/VY*UWKRA]ITM\1
M?[G,)YRGO4RQH+=BN9VT<;V;LGR_FK&$P92PA,./KX7%BJZ&QH:MA\>#K(G'
M@*R+R'ZLCLA\K)+(>ZR7R'FMGL=YK9['>:V>QWFMGL=YK9['>:V>QWFMGL=Y
MK9['>:V>QWFMGL=YK9['_[40 _^V&13_M20M_[0L2?+%'U36W1)BP=\3@:S-
M+IJ?P$^KFKAEMY>U<KN6M'R]E;*#OY&QA<&-L8;"B;"'PX:OB,.#KXG$@:^+
MQ'^NC<5]KI#%>ZZ4Q7JOF<1ZKYG$>J^9Q'JOF<1ZKYG$>J^9Q'JOF<1ZKYG$
M>J^9Q'JOF<1ZKYG$_[<. _^X%A/_MR M^;\?0=S9$43$ZQ)FL=\8@:#0,Y67
MQE"CD\!CK9&[<;.1N'NXD+:"NXZTA;V+LX:_B+*'P(:RB<"$L8K!@K&+P8"Q
MC<%^L8_"?+&2PGNQE<%[L97!>[&5P7NQE<%[L97!>[&5P7NQE<%[L97!>[&5
MP7NQE<%[L97!]+H+ _V[$A+^NQLLY= /,LCI#TJT\A5GHN(B?9;6-XV/SD^8
MC,AAH(K$;J:*P7BJA[]]K82^@+"!O(*Q?[N$LWV[A;1[NH>U>KF)M7FYB[9W
MN8VV=KB/MW2XD[=TN).W=+B3MW2XD[=TN).W=+B3MW2XD[=TN).W=+B3MW2X
MD[=TN).WW+X& OC #A'NR XBR]L++K;X$4RE]1UCE^@L=8W?/8&'V%"+@]-@
MDH+/;)=_S7.;?,MWG7G)>J!WR'VA=<=_HW/&@J1RQ82E<,6&I6_$B*9NQ(JG
M;<.-IVO#D*AKPY"H:\.0J&O#D*AKPY"H:\.0J&O#D*AKPY"H:\.0J&O#D*AK
MPY"HU\ & =O&" [+TPH5N.@,,J;_%4J8^B9<C? W:87I1G1_Y%-[?-]@@7C<
M:(5TVFV)<-AQBV[6=8ULU7B/:M1[D&G3?I%GTX"29M*#DV72A91DT8>48]"*
ME6+0CI9BT(Z68M".EF+0CI9BT(Z68M".EF+0CI9BT(Z68M".EF+0CI9BT(Z6
MT<(& <W+"06ZV@<9J/X.,9G_'4.._R]1A?H_7'[T361Y\%AJ<^Q?;VWJ8W-I
MYVEV9^5N>67D<GMCXW9]8N)Y?F#A?']?X'Z 7M^!@5W?@X)<WH:#6]V)A%K=
MC85:W8V%6MV-A5K=C85:W8V%6MV-A5K=C85:W8V%6MV-A5K=C85:W8V%R\0&
M +O1!@>IYP8:FO\3*X[_)#F%_S9$?O]$37G_455Q^U=;:_==8&7T8F1B\FAG
M7_!M:EWO<6Q;[75M6NUX;UGL>W!8ZWYQ5^J!<E;JA')5Z8=S5.F*=%/HCG53
MZ(YU4^B.=5/HCG53Z(YU4^B.=5/HCG53Z(YU4^B.=5/HCG53Z(YUO,D% *O;
M 0B:_PL6C_\9(X7_*RU^_SDW>/]&0'#_3D=I_U1-8O]:4E[^859:_&996/MK
M6U7Y<%U4^'1>4O=X7U'W>V!0]GYA3_6!8D_UA&-.](=D3?2+94SSD&9,\Y!F
M3/.09DSSD&9,\Y!F3/.09DSSD&9,\Y!F3/.09DSSD&9,\Y!F_Z 8 _^B+!#_
MH#LE_YQ)//^75U/XDF1G[)!L>>*/=8G9CGZ7T8V'HLR,C:K'BI&QQ(B4ML.%
MEKC"@YFYPH&;N<%_GKK!?:&[P7NDN\!ZI[O >:J\P'BNO,!WM+N\>+2[O'BT
MN[QXM+N\>+2[O'BTN[QXM+N\>+2[O'BTN[QXM+N\>+2[_Z 8 _^B+!#_H#LE
M_YQ)//^75U/XDF1G[)!L>>*/=8G9CGZ7T8V'HLR,C:K'BI&QQ(B4ML.%EKC"
M@YFYPH&;N<%_GKK!?:&[P7NDN\!ZI[O >:J\P'BNO,!WM+N\>+2[O'BTN[QX
MM+N\>+2[O'BTN[QXM+N\>+2[O'BTN[QXM+N\>+2[_Z 8 _^B+!#_H#LE_YQ)
M//^75U/XDF1G[)!L>>*/=8G9CGZ7T8V'HLR,C:K'BI&QQ(B4ML.%EKC"@YFY
MPH&;N<%_GKK!?:&[P7NDN\!ZI[O >:J\P'BNO,!WM+N\>+2[O'BTN[QXM+N\
M>+2[O'BTN[QXM+N\>+2[O'BTN[QXM+N\>+2[_Z 8 _^B+!#_H#LE_YQ)//^7
M5U/XDF1G[)!L>>*/=8G9CGZ7T8V'HLR,C:K'BI&QQ(B4ML.%EKC"@YFYPH&;
MN<%_GKK!?:&[P7NDN\!ZI[O >:J\P'BNO,!WM+N\>+2[O'BTN[QXM+N\>+2[
MO'BTN[QXM+N\>+2[O'BTN[QXM+N\>+2[_Z 8 _^B+!#_H#LE_YQ)//^75U/X
MDF1G[)!L>>*/=8G9CGZ7T8V'HLR,C:K'BI&QQ(B4ML.%EKC"@YFYPH&;N<%_
MGKK!?:&[P7NDN\!ZI[O >:J\P'BNO,!WM+N\>+2[O'BTN[QXM+N\>+2[O'BT
MN[QXM+N\>+2[O'BTN[QXM+N\>+2[_Z$8 _^C*Q#_H#HE_YQ(//^75E/XDV-H
M[))I>N&1<XK8CWR8T(Z$I,J.C*W&C9"TQ(J3M\.&E;C"A)BYP8&;NL%_G;O
M?:"\P'NDO,!ZI[W >:R]P'BPO;UXL[RX>+.\N'BSO+AXL[RX>+.\N'BSO+AX
ML[RX>+.\N'BSO+AXL[RX>+.\_Z$8 _^C*A#_H3DE_YU(/?^8553WE&%IZY1F
M>^"2;XS6D7B:SI""ILB/B;#$CX^VPXN1M\*(E+G!A)>ZP(*:O,!_G;V_?:"^
MOWNDOKYZJ+^^>*V_O7BQOKAXLKZT>;.]M'FSO;1YL[VT>;.]M'FSO;1YL[VT
M>;.]M'FSO;1YL[VT>;.]_Z(8 _^D*1#_H3@E_YU'/?^9553WEEYIZY5C>^"4
M;(W5DG6<S9%_J,>1A[+$D8ZVPXV0N,&)D[K AI:\OX*9O;]_G+Z^?:"_O7NE
MP+UYJL"]>+# N'FPP+1YL;^O>K*]KWJRO:]ZLKVO>K*]KWJRO:]ZLKVO>K*]
MKWJRO:]ZLKVO>K*]_Z,8 _^D*1#_HC@E_YY&/?^95%7WEUQIZY=@?-^6:8W5
MDW*=S))\JL62A;3$DHRVPH^/N<&+DKO AY6]OH.8O[V G,"]?:#!O'NEPKQY
MJ\*Y>:_"M'FOP;!ZL,"L>[*^K'NROJQ[LKZL>[*^K'NROJQ[LKZL>[*^K'NR
MOJQ[LKZL>[*^_Z,8 O^E*!#_HC<E_Y]&/?^:4U7WF5IIZYE>?-^798[4E6^=
MRY1YJ\63@K3$E(JWPI&.N<",D+R_B).^O827P+R F\*[?:##NWNFQ+IZK<6T
M>J[$KWJOPJQ[L,"H?+&_J'RQOZA\L;^H?+&_J'RQOZA\L;^H?+&_J'RQOZA\
ML;^H?+&__Z08 O^E*!#_HS8E_Y]%/?^:4U7WFE=IZYM;?-^98H[4EVN>RY5V
MK,64@+3#E8BWP9.-NL".C[V^B9+ O(65PKN!FL2Y?:#&N7NHQ[1ZJ\>O>ZW%
MJWNNPZ=\K\&D?;&_I'VQOZ1]L;^D?;&_I'VQOZ1]L;^D?;&_I'VQOZ1]L;^D
M?;&__Z08 O^F)Q#_HS8E_Z!$/?^;4E;WG%5IZYQ8?-^;7H[4F6>>RI=SK,66
M?+3#EX6WP9:+N[^1C;Z]BY#!NX:4Q+F!F<>W?J#)MGRIRJY[JLBJ?*S&IGVM
MQ*-^K\&@?K&_H'ZQOZ!^L;^@?K&_H'ZQOZ!^L;^@?K&_H'ZQOZ!^L;^@?K&_
M_Z48 O^F)@__I#4E_Z!$/?^<45;WGE-IZYY5>]^>6HW4FV2>RIEOK,68>;3#
MF8*XP9F*N[Z4C+^\CH[#N8B2Q[>"F,NU?J'-KWRGS:E]J<JE?JO'HG^MQ)]_
MK\*=@+&_G8"QOYV L;^=@+&_G8"QOYV L;^=@+&_G8"QOYV L;^=@+&__Z88
M O^G)@__I#4E_Z!#/O^=4%7WGU%HZZ!3>^"@5XW4GE^>RIMKK,6;=;3#FWZX
MP)N'O+V7BL"ZD8S%MXJ0RK2$E\^R@*/2J'^ESZ. J,N@@*O'G8&MQ9N!K\*9
M@K&_F8*QOYF"L;^9@K&_F8*QOYF"L;^9@K&_F8*QOYF"L;^9@K&__Z88 O^G
M)0__I30E_Z%#/O^>3E7XH4YH[*)0>N"C4HS5H5N=RYYFK,:=<;3#GGJXP)Z$
MO+R;B,*YE8K'M8V-SK"&EM2I@J#6H8*DT)V"J,N:@ZK(F8.MQ9>$K\*6A+#
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M\[8Y<.J_-WWCRC6'U-$WE;["2ZFPN6"UJ+1PO:.P?L*=K83'DJJ$RXBGALZ
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MHJ;-=*:HS7*IJ<QQK:K,<+*KRW"VJ\MOO*O(<,"KQ'' JL1QP*K$<<"JQ''
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MM+J*B[2ZBHNTNHJ+M+J*B[2Z_YP0 ?^A)@K_H#8<_YY",?^E0#[_JT!,_[%
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M;,R:_X82 ?^((0;_B#44_X9&)?^'4S7_BUM#_XQB4?Z*:E[VAW%J\(1Z=.J
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M2CO_HTL[_Z-+._^C2SO_HTL[_Z-+._^C2SO_HTL[_Z-+MKH" *;*  "8W
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M9T7NYV=&Z^AG1NOH9T;KZ&=&Z^AG1NOH9T;KZ&=&Z^AG[J(  ,VT @"\O@0
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M2X#48%=VT6AA;<]P:67->G!>S(9U6,R5>53,IGM1S;Q\4,SB?%/!X']5M]^
M6+'>@5JKWH%<IM^!7*;?@5RFWX%<IM^!7*;?@5RFWX%<IM^!_X / ?^.#@'_
MH@T V[4( ,[!" #&T D OND2 K3I)0JJZ#,7H.8^)9;E1S*+XTX_@.%527;@
M75-MWF9;9=UO85[=>F=8W(9K4]R5;U#=IG%-WKMR3=_A<4[1YW10QN9W4K[D
M>%.XY'E5LN-Z5;+C>E6RXWI5LN-Z5;+C>E6RXWI5LN-Z_X,. ?^6"P#=JP0
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MYW68;N=UF&[G=9ANYW68;N=U_V<6 ?]D( /_<!X#_WXB!?^++ G_DS<0_YA
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M@(#;A8" W8. ?]Z!@'[@?X!]X7V ?>-[@'SD>H!\Y'J ?.1Z@'SD>H!\Y'J
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M>F.7Y'EFE.5W9I+F=V:2YG=FDN9W9I+F=V:2YG=FDN9W_W 2 ?^ #@'_D@X
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M8$N]]F!+O?9@2[WV8$N]]F!+O?9@_XD  -F>  #'K $ N;8" *[! P"ES@8
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M;W*#[6US@>YK=(#P:72 \&ET@/!I=(#P:72 \&ET@/!I_V$7 ?]Q$ '_@@X
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M9%R7\V1<E_-D7)?S9%R7\V1<E_-D_W - /^$! #=E@  SJ,# ,2N! "[MP0
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MD@\;_Z(0&O^R$1G_R!(8_^43%__Z%!?_^A07__H4%__Z%!?_^A07__H4G[,
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M8']S^%Y^<_E<?G+Z6GYR^UE^<OM9?G+[67YR^UE^<OM9_U@7 ?]G$ '_=0X
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M6FN!^UIK@?M::X'[6FN!^UIK@?M:_V(0 /]R!P#X@@, VX\" ,^:!0#)HP8
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M45&>_U%1GO]1_W8  -V)  #*EP  OJ(  +.J  "ILP  H+P" )C&!@"1S!(
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MMB8U\=(F-._S)C3L_R8RZ_\H,N?_*S/D_RPSY/\L,^3_+#/D_RPSY/\LP9P
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M"13_PPD3_^,)$__X"1/__PH3__\*$___"A/__PH3__\*FK$  (N]  !\R
M;=0  %_@  !1Y@  1_4  $'_   \_PD -_\0 #+_%0$N_QT!*O\C 2;_*0$B
M_R\"'_\U AS_.P(9_T(#%O]) Q/_40,1_UH##_]F! W_= 0+_X4$"O^6!0G_
MJ 4(_[D%!__0!0?_XP4'_^,%!__C!0?_XP4'_^,%C;H  'W'  !MTP  7^
M %#G  !"[0  .O\  #7_   O_P( *O\* ";_#P B_Q0 'O\: 1K_'P$6_R,!
M$_\H 1#_+0$._S,!#/\Y @K_00('_TD" _]3 @#_7@( _VP" /]\ P#_C0,
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M3I!C_TR.9/]+C&3_2HMD_TB+9/](BV3_2(MD_TB+9/](_U 6 ?]<$ #_: T
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M379Q_TQV<?],=G'_3'9Q_TQV<?],_UD0 /]F!P#_<P0 X7\! -:(! #/D 8
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M2V&#_TMA@_]+_V0% /5T  #:@@  RXX  ,&7  "XG@$ L:4  *FK!P"CK1H
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MN#I$NM<Y0[CU.T*V_SU"L_\^1*[_/D6I_SY%J?\^1:G_/D6I_SY%J?\^X'T
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M&3'E_ADOY/\<+N3_'BWB_R MXO\@+>+_("WB_R MXO\@NIH  *JC  "=JP
MD+0  (.]  !WQ@  :\\  %_6  !4W@0 4? 0 $WP&P!*\"8!1O$P D+R.@,^
M\D,$._-+!3CS5 <V]%T(,_1H"3#U= LN]8$,+/:1#BKVH@\H][<0)_C6$2?V
M]!$F\_\1)O'_$27Q_Q,E\?\3)?'_$R7Q_Q,E\?\3K:$  *"I  "2LP  A+P
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M P#_[ , _^P# /_L P#_[ , _^P#B+D  'C$  !IT   6]T  $OC   ^Z0
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M.*Q0_SBG4?\WHU+_-J!3_S6?4_\UGU/_-9]3_S6?4_\U_T87 ?]0$0#_6 T
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M/H)C_SV"8_\\@F/_/()C_SR"8_\\_U / /];!P#_9@, [&\" -QV P#4? <
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M/VUR_S]M<O\__UD' /]E  #B<@  T7P  ,>$  # B@( N8\" +.2# "LE!T
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MLD%2DLE"4I'K05*0_T!2C_\_58O_/E:(_SU7A_\]5X?_/5>'_SU7A_\]^6<
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M+4"P_B\_K_\Q/JW_,D"H_S)!IO\R0:;_,D&F_S)!IO\RU7P  ,**  "UE@
MJ)T  )VC  "2J@  A[$  'RW  !PO@, :,(. &;#'0!CPRT!7L,Y!%K#1 A6
MPDX,4L)7$$_!7Q1+P6D72,%S&D7 ?AU"P(P@/\";(CW K2,\P<0C/,#I(SJ^
M_B8XO/\H-[O_*3BX_RHXMO\K.+;_*SBV_RLXMO\KR84  +F3  "LG   H*(
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M""#K_PH?ZO\+'^K_"Q_J_PL?ZO\+J)\  )NF  "-KP  ?[@  ''!  !DR@
M6-   $S6  !!W0  ..0  #7V#  S]Q0 ,/<> "[X)P K^3  */DX 2;Z0 $C
M^TD!(?M2 1[\70(<_6D"&OUY QC^BP,7_YX#%?^S!!3_TP04_O0$$_S_ Q/Z
M_P,3^?\#$_G_ Q/Y_P,3^?\#G:4  (^N  " N   <L(  &3+  !6TP  2=H
M #[?   TY   +O0  "O_"@ H_Q  )?\7 "+_'P ?_R8 '/\M !G_-  7_SP
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M',TZ_Q[+.O\>RCK_'\0[_Q_ //\>P#S_'L \_Q[ //\>_SD; ?] %0#_11$
M_TH3 /].&0#_4"(!_U L ?U.-P+V2T,$\$E0!^M(70KG1FD-XT5T$.!$?A/=
M0X<5VT*0%]A!F!C50* 9TT"I&]% LAS/0+T=S4#,'<I!Y![&0/0@PD#_(K]
M_R.]0/\CNT#_([9!_R.S0O\BLT+_(K-"_R*S0O\B_ST7 /]$$0#_2@X _U 0
M /]4%0#_5AT _58F ?-5,0'K4ST#Y5)+!M]06 K:3F,.U$QN$]!*>!;-28$9
MRTB*&\A'DAW&1YH?Q$:C(<)&K"+ 1;<COD7%)+Q%W"2X1O EM4;_)[)&_R>P
M1O\GKD;_)ZI'_R:G2/\FITC_)J=(_R:G2/\F_T 4 /](#@#_3@L _U4. /]9
M$0#_7!8 ]%T? .I<*@'B6S<"VEI&!=)74PO,55X0R%-H%<11<AG!4'L<OD^$
M'[Q-C"*Y394DMTR=)K5+IR>S2[$IL4J_*J]*T2JL2^LKJ4O\+*9+_RRE3/\K
MHTS_*I]-_RJ=3?\IG4W_*9U-_RF=3?\I_T,1 /]+# #_4P@ _UH+ /]>#0#Y
M8!  ZV$6 .%B(0#68C$!SF%!!<=?3@O"7%D1O5ID%[E8;1NV5G8?LU5^(K!3
MAR6N4H\HJU&8*JE0HBRG4*PMI4^Y+Z-/RR^@4.8OGE#Y,)Q0_R^:4?\NF%'_
M+992_RR44O\KE%+_*Y12_RN44O\K_T80 /]."0#_5@4 _EX& .]B!P#G90H
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M,7EB_S%Y8O\Q_T\' /]9  #F9   UVP  ,QS  #$=P( OWD$ +EZ#@"R?"
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ML#MA=L0\87;E.V%V^SEB=O\W8W7_-6-S_S1D<O\S9'+_,V1R_S-D<O\S_U@
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M-4^+]S1/BO\S4(G_,E&&_S%2A/\Q4H3_,5*$_S%2A/\QZF4  -)S  #"?P
MMH@  *R0  "BE   F)@  (R<  "$GPH @* 9 'RA*0%WH#8%<I]!"FV>2P]H
MG5,49)Q;&6";8QU<FFLA6)ET)568?BE1EXHL3I:8+DN6J#!*EKPQ29;<,$F4
M]C!)D_\P29+_,$J0_R]+C?\O2XW_+TN-_R]+C?\OXFL  ,IY  "\A0  L8\
M *:4  ";F0  D9T  (:B  !ZI@, =J<3 '.H) !NJ#(#:J@]!F6G1PMAIE /
M7:58%%FD8!A5HV@<4J-Q'TZB?"-+H8@F2*&6*$6@IBI$H;HK0Z':*D.?]2M"
MG?\K0IS_+$*;_RQ$E_\K1)?_*T27_RM$E_\KUW(  ,.   "VC   JI0  )^9
M  "4G@  B:,  'ZH  !PK@  :K . &BQ'0!EL2P!8;$X UVP0P99L$P*5:]4
M#E*O71%.KF452ZYO&$BM>1M%K88>0JR5(#^LI2(^K;DC/:W8(CVK]2,\J?\E
M.Z?_)CNF_R8[I/\F.Z3_)CND_R8[I/\FS'H  +N(  "ND@  HID  )>>  ",
MI   @*H  '6O  !IM   7KD& %NZ% !9NR0 5KLQ 5.[/0-0NT<%3;M0!TJZ
M60I'NF(-1+IL$$&Z=Q,^N805/+F3%SFYHQ@XN;<9-[K6&3>X]!HUMO\<-+3_
M'C.S_Q\SLO\@,[+_(#.R_R SLO\@P8,  +21  "FF   FYX  (^E  ""JP
M=K$  &NV  !?O   5,$# $S%#0!+Q1D 2<8H $C&-0!%QT !0\=* T#'4P0^
MQUT&.\=G"#G'<PHWQX ,-,>0#3+'H0XQR+4/,,C3#S#&]! NQ/\3+<+_%2S!
M_Q8KP/\7*\#_%RO _Q<KP/\7N(T  *J7  ">G@  D:4  (2L  !XL@  :[D
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M 0WS_P$-\_\!F:,  (NL  !\M0  ;;X  %_&  !2S0  1=(  #G8   OW@
M)N(  !_J   <^P8 &?\. !?_$P 4_QH $O\A !#_*  ._S  #?\Y  O_0P )
M_TX !O]<  3_;  "_X   ?^6  #_K0  _\H  /_P  #__P  __\  /__  #_
M_P  __\ C:L  'VU  !NOP  8,@  %+0  !#UP  -]T  "OB   BY@  &>H
M !7Y   2_P  $/\(  [_#@ ,_Q$ "?\6  ;_'  #_R(  /\J  #_,P  _ST
M /])  #_5P  _VD  /]^  #_E0  _ZP  /_'  #_Z   __H  /_Z  #_^@
M__H @+4  '"_  !AR0  4M,  $/;   UX0  *>8  ![J   5[@  $/@   [_
M   +_P  "/\   3_!@  _PH  /\.  #_$0  _Q4  /\;  #_(P  _RL  /\V
M  #_0P  _U,  /]E  #_>@  _Y$  /^F  #_N   _\\  /_/  #_SP  _\\
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M!?$<_P;P'/\'[QW_".\=_PGO'/\)[AS_">X<_PGN'/\)_RHB ?\N'0#_,!L
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M&;4Z_QBR._\8L3O_&+$[_QBQ._\8_SD2 /\_#0#_0PD _T@, /]+$ #_3!4
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M(XA2_R.(4O\C_T4' /]+  #P50  WUL  --@  #,80, R&$& ,-A$0"[9"0
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MKR]P8L$P;V+?,&YC]RYO8_\L;V/_*F]C_RAO8O\G;V+_)V]B_R=O8O\G_TT
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M,%UQ\BY><?\L7G#_*U]P_RE@;_\H8&[_*&!N_RA@;O\H\54  -YB  #*;0
MO74  +-[  "K@   HH(  )B!  "1@P\ C84? (B%+@*#A#L%?H-%"GJ!3@]U
M@%84<7]>&&Y]9AQJ?&T@9WMV(V-Z@"=@>8LJ77B8+%IWIBY8=[@O5W?1+U=W
M\2Y8=O\L6';_*EEU_RE:=/\H6G3_)UIT_R=:=/\G[5D  -=F  #%<0  N7H
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M)4:+_R1&BO\D1HK_)$:*_R1&BO\DV&D  ,-V  "U@0  JXH  )^/  "5DP
MBI8  'Z:  !PG0  :Y\. &B?' !FH"H!8J W E^?005;GTH(6)Y2"U2>6@Y1
MG6(23IQK%4N<=1A(FX$:19N/'4*:GQ] FK @/YK((#^9ZQ\_F/\@/I;_(3Z5
M_R$_E/\A/Y3_(3^4_R$_E/\AS7   +Q]  "PB   I(\  )F4  ".F   @YT
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MM   3K<  $.\!0! O1$ /[T> #Z^*P \OC8 .[]! #F_2P$WOU0"-<!? C/
M:@0QP'<%+\"&!BW EP<KP*H(*L'"""K YP<IO?T**+S_#">Z_PTGN?\.)[G_
M#B>Y_PXGN?\.LHP  *64  "9F@  C:$  '^G  !RK0  9K,  %JX  !/NP
M1+\  #K$ @ PR0@ +LH1 "W*'0 LRRD *\LU "O,0  JS4H *,U6 "?.80 F
MSF\!),Y_ 2//D0(ASZ4"(-"] B#/Y (?S?H#'LO_!![*_P4=R?\&'<G_!AW)
M_P8=R?\&J)0  )R:  "0H0  @J@  '2O  !GM@  6[P  $[   !#PP  .<<
M "_,   GT 0 ']8* !O:$  ;VQH &MLF !K<,0 9W3P &-U( !C>50 7WV(
M%N!R !7@A0 4X9H $^*Q !+CSP 2X/0 $M[_ 1'=_P$1V_\"$=O_ A';_P(1
MV_\"GIH  )*A  "$J0  =K$  &BX  !;OP  3L0  $+(   WS   +=   "35
M   <VP  %=\% !3I#@ 2ZA0 $>L= !#K)@ .[#  #NTZ  WN1@ +[E, "N]B
M  GP=  (\8D !_*@  7RN@ $\>0  O']  +O_P #[?\  ^W_  /M_P #[?\
ME:$  (:I  !XL@  :;H  %O"  !-R   0,P  #31   JU@  (=L  !G@   2
MY   #_ !  WY"@ +^@\ "?L5  ?['  $_"0  ?PL  #\-P  _$(  /Q0  #\
M80  _74  /R,  #\I   _,$  /SK  #\_P  _?\  /W_  #]_P  _?\ B:D
M 'FR  !JNP  7,0  $[,   _T0  ,M<  "?=   =X0  %>4   [H   *\0
M"/T   7_ P !_PD  /\.  #_$@  _Q<  /\?  #_)P  _S$  /\^  #_30
M_U\  /]U  #_C0  _Z8  /_"  #_YP  __P  /__  #__P  __\ ?+,  &R\
M  !=Q@  3L\  #_6   QW0  )>(  !KF   1Z@  #.X   7R    _P   /\
M  #_    _P   /\%  #_"@  _PX  /\2  #_&   _R$  /\K  #_.0  _TH
M /]=  #_<P  _XP  /^D  #_N0  _]0  /_>  #_W@  _]X _Q@L /\9*0#_
M&2@ _Q4K /\0, #_"S@!_P-$ ?\ 40'_ %X!_P!L ?\ > '_ ((!_P", ?\
ME '_ )P _P"B /\ J #_ *\ _P"V /\ O@#_ ,@ _P#7 /\ YP#_ /, _P#]
M /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _QLI /\=)@#_'"4
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M!=P<_P7<'/\%VQS_!=L<_P7;'/\%_RH9 /\M$P#_+1$ _RT1 /\N&0#_+2(
M_RPN /\I.@#_)D<!^B14 ?8C8 'R(FL![R)U NTB?@+K(H<"Z2*/ N<BE@+E
M(IX"Y"*E N(BK0+A([<"WR/# MTCU@+8).H#TB3Y!<\E_P;-)?\'RR7_",HE
M_PC*)/\(RB3_",HD_PC*)/\(_RX4 /\Q$ #_,@T _S0. /\U% #_-1P _S,G
M /HQ- #S+T$ [BU. >DL6@'E+&4"XBQP M\K>0+=*X(#VBN+ ]@KD@35*YH$
MTRNB!-$KJ@7/*[,%S2N_!LPLSP;(+><'Q"WW"<$M_PJ_+?\+O2W_#+PM_PR\
M+/\,NRS_#+LL_PR[+/\,_S$1 /\U# #_-@< _SH+ /\\$ #_.Q4 ^#D? .\W
M*P#G-CD X35' -PU5 '5-6 "T35J \XT<P3,-'P%RC2%!L@TC0?&,Y0(Q#.<
M"<(SI0G!,ZX*OS.Y"[TSR N[-.$+MS3S#;0T_P^Q-/\/L#3_$*\T_Q"N-/\/
MKC3_#ZXT_P^N-/\/_S4. /\X!P#_/ ( _T & /]!"P#Z00\ [3\6 .,\(@#:
M/3$ TCY! ,P^3P+(/EH#Q#UD!<$];@>_/'8(O#Q^"KH[APNX.X\,MSN7#;4Z
MGPZS.JD/L3JT$*\ZPA&N.MD1JCOO$J<[_Q.E._\4I#O_$Z,[_Q.B._\3HCO_
M$J([_Q*B._\2_S@* /\\  #_00  ]44  .9& @#A10< XT(- -5#&0#,12P
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ML"""4,$A@%#=(7Y1]"!]4?\??5'_'7U1_QQ]4?\;?5'_&GU1_QI]4?\:_T(
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M)FE>[B1I7O\B:E[_(&I>_Q]J7O\>:E[_'6I>_QUJ7O\=^4H  .-5  #/7P
MP64  +=J  "O;   IVP  )]J 0"9:Q$ E&TB )!N,0&+;3T$AVQ'!X-K4 M_
M:E@/?&A@$WAG9Q9V9V\9<V9X''!E@1YM9(PA:F.8(VABIB5F8K8F9&+,)F1B
M["5D8O\C9&+_(65B_Q]E8O\>96+_'65B_QUE8O\=\DP  -]8  #*8@  O6D
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M(%1P_Q]5</\>56__'55O_QU5;_\=Y5<  ,UD  "^;0  LG4  *A[  "??@
MDWT  (=]  " ?P< ?( 5 'B!) !U@C(!<8$]!&V 1@=I@$\*9G]6#6-^7A%@
M?68477QN%UI[=QI7>H(=5'J/'U%YG2%/>:XB3GG#(DUXY2)-=_LA3G?_'TYV
M_QY/=?\=3W7_'4]U_QU/=?\=WUP  ,AH  "Y<@  KGH  *6   ":@@  CH(
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M%SJ._Q<ZCO\7Q6X  +9[  "JA0  GHL  )2/  "(D@  >Y0  &Z7  !BFP
M5YX  %*@#@!1H!L 3Z$H $VA- !+H3X!2:%' D>A4 -$H5@%0J%A!S^@:PD]
MH'<+.J"%#3B@E XVH*8/-:"[$#2@W0\TG?<0,YS_$C.:_Q(SF?\3,YG_$S.9
M_Q,SF?\3O7<  *^#  "CBP  F)$  (V5  "!F0  <YP  &>?  !;H@  3Z8
M $>I" !$JA( 0ZH? $&K*P! JS< /ZQ! #VL2@$[K%,".:Q< S>L9P0UK',%
M,JR!!C"LD0<NK*,(+:RX"2RLV0@LJO4**ZC_"RJF_PPJI?\-*J7_#2JE_PTJ
MI?\-M8   *B+  "<D0  D98  (6<  !XH   :Z4  %^H  !3K   2*\  #VR
M   VM0L -+45 #.V(0 RMBP ,;<W #"W00 ON$L +KA5 "RX8 $JN&T!*;E[
M B>YC0(EN9\#)+FT R.YT@,CM_0$(K7_!2&T_P8AL_\'(;+_!R&R_P<ALO\'
MK8H  *"1  "5EP  B)T  'NC  !NJ   8:T  %6Q  !*M   /[<  #2[   K
MO@, ),(, "+"%  BPQ\ (<,J "#$-  ?Q#\ 'L5* !W&5@ <QF, &\=S !K'
MA0 9QYD &,BN !?(RP 7QO$!%\3_ 1;#_P(6P?\#%L'_ Q;!_P,6P?\#HY$
M )B8  "+G@  ?:4  '"K  !BL0  5K8  $JY   ^O0  -,   "K$   BR
M&<P$ !/0"@ 1TA$ $-(: !#3)0 /TS  #M0\  [42  -U58 #=5E  S6>  ,
MUHT "]BD  K8O@ )V>8 "M;^  O4_P +TO\ "]+_ 0O2_P$+TO\!FI@  (Z?
M  " I@  <JT  &2T  !7N@  2;\  #W"   RQ@  *,D  !_-   7T0  $=8
M  S;!0 (W@L !M\1  7?&@ $X"0  N$N  'B.@  XT<  .16  #D9P  Y7L
M .:2  #FJ@  Y\@  .?P  #H_P  Z/\  .C_  #H_P  Z/\ D9\  (*G  !T
MKP  9;<  %>^  !)PP  /,<  ##+   ESP  '-0  !39   .W0  ">$   +E
M    Z08  .D-  #I$0  ZA@  .LA  #M*P  [S<  /%%  #R5@  \V@  /-^
M  #TEP  ];   /;0  #W\P  ]_\  /?_  #W_P  ]_\ A:<  ':P  !FN
M6,$  $K(   [S   +M$  "/6   9W   $>    SC   $YP   .H   #U
M]    /4%  #U"P  ]@\  /84  #X'0  ^B<  /PT  #_0P  _U4  /]I  #_
M@0  _YH  /^R  #_SP  _^T  /_Y  #_^0  __D >+   &BZ  !9PP  2\L
M #O1   MV   (=T  !;B   .Y@  ".H   #M    \    /@   #_    _P
M /\   #_    _P8  /\,  #_$   _Q@  /\B  #_,   _T   /]3  #_:0
M_X$  /^9  #_KP  _\,  /_5  #_U0  _]4 _Q,H /\3)0#_$24 _PTG /\&
M+0#_ #4 _P!! /\ 3P#_ %P _P!I /\ = #_ 'X _P"( /\ D #_ )< _P"=
M /\ I #_ *H _P"P /\ MP#_ ,  _P#, /\ WP#_ .P _P#X /\ _P#_ /\
M_P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _Q8E /\6(@#_%"$ _Q C /\** #_
M #  _P ] /\ 2P#_ %@ _P!D /\ < #_ 'H _P"$ /\ C #_ ), _P": /\
MH #_ *8 _P"M /\ M #_ +P _@#( /T V0#[ .D ^@#V /D _P#X /\ ^ #_
M /@ _P#X /\ ^0#_ /D _P#Y /\ _QHB /\:'@#_&!T _Q,> /\.(@#_"BP
M_P<Y /\#1@#_ %, _P!@ /\ :P#_ '8 _P!_ /\ B #_ (\ _P"6 /\ G0#_
M *, _@"I /P L #Z +D ]P#$ /4 T@#S .8 \@#T /$ _P#P /\ [P#_ .\
M_P#O /\ \ #_ /  _P#P /\ _QX= /\>&0#_'!< _Q<8 /\3'@#_$2@ _PXT
M /\,00#_"DX _PA; /\'9@#_!G$ _P9Z /\&@P#^!HL _ :2 /H&F0#X!I\
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M \,<_P/#'/\#_R@0 /\I"P#_* 8 _RL+ /\K$ #_*1< _28B /0C+@#L(3L
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MM Z;.\4.F3O@#I8[] ^4//\/DCS_#Y(\_PZ1//\-D3S_#9$\_PV1//\-_S4
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M&'E,ZQAX3/X7=TS_%7=,_Q1W3/\3=TS_$G=,_Q)W3/\2_SX  .A'  #54
MQE8  +Q8  "T60  K58  *=3!P"A5!4 G%8E )A7- &45T "D%=*!(U64P:*
M55L)AU1C"X14:@Z"4W(0@%)Z$GU2@Q1[48X6>%"9&'90IAET4+4:<U#)&G%0
MZ!IP4?P8<%'_%W!1_Q5P4?\4<5#_$W%0_Q-Q4/\3]4   .1+  #/5   P5H
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M&%]=_Q=@7?\68%W_%6!=_Q5@7?\5ZTH  -16  ##7@  MF4  *QI  "B:0
MF&<  (]E  ")9@P A6@9 (%I* !^:C4!>FD_ W9I205S:%$(<&=9"FUG8 UK
M9F<0:&5P$F5D>15C9(,78&./&5YBG1M<8JP<6F*_'%EBWQQ98O<:6F+_&5IA
M_Q=;8?\66V'_%5MA_Q5;8?\5YTT  ,]9  "_8@  LV@  *EM  ">;0  DVL
M (EI  "#:PD ?VT5 'QN)0!X;C(!=6X] G%N1@1N;4\':VQ6"6AL7@QE:V4/
M8VIM$6!I=A1=:8$66VB-&%AGFQI69ZH;56>]'%1GW!Q49_8:5&;_&%5F_Q=5
M9?\65F7_%59E_Q569?\5XE$  ,I=  "[9@  KVP  *9Q  "9<   CF\  (-N
M  !]< 4 >'(2 '5S(0!R<R\!;W,Z FQS1 1I<DP&9G)4"&-Q6PM@<&,-77!K
M$%MO=!-8;G\556Z+%U-MF1E1;:@:3VV[&TYMV1I.;/093VO_&$]K_Q=0:O\6
M4&K_%5!J_Q50:O\5W54  ,5A  "W:@  K'$  *)U  "4=   B70  'QS  !V
M=0  <7<0 &]X'0!L>2L :7DW 69Y0 -C>4D%8'A1!UUW6 E;=V ,6'9H#E5U
M<1%2=7P34'2(%DUTEQ=+<Z8827.Y&4ASU1E)<O,827'_%TIQ_Q9*</\52W#_
M%$MP_Q1+</\4U%H  ,!F  "S;P  J'8  )UY  "/>   A'@  '=Y  !O?
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M#P!2CQL 4(\G $^0,P!-D#T!2Y!% DF03@-&D%8$1(]?!4*/: <_CW,)/8Z
M"SJ.CPPXCJ --XZS#C:.S XVC>\.-8O_#C6)_P\UB/\/-H?_#S:'_P\VA_\/
MOFT  +!Y  "E@@  F8<  (R(  !_B   <HH  &:-  !:D0  4)4  $F7"0!'
MF!, 19@@ $29*P!#F38 09I  $":2 $^FE$"/)I: CJ:9 ,WFF\%-9E]!C.9
MC <QF9T(+YFP""Z9R@@NF.T(+I;_"BV4_PHMD_\++9+_"RV2_PLMDO\+MG4
M *J!  ">B   DXT  (:.  !XCP  :Y(  %^5  !4F0  29T  $"@   ZH@T
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M  [ N@ .P.$ #[W[  ^\_P 0NO\!$+K_ 1"Z_P$0NO\!GX\  )25  "'FP
M>:$  &NG  !>K   4K$  $6T   ZM@  +[D  "6\   =OP  %<,   _&!0 +
MR@T "<H4  C*'0 'RB< !\HR  ;+/@ %RTL !,Q:  /,:@ "S'X  <R4  #,
MJP  S<@  ,SM  #,_P  R_\  <K_  '*_P !RO\ EY8  (J<  !\HP  ;JH
M &"P  !2M@  1;D  #F\   NOP  (\,  !O&   3R@  #<T   C1   !U D
M -0.  #5%0  UAX  -@G  #9,0  VSX  -Q+  #=6P  WFX  -Z$  #?FP
MW[0  -[9  #?]P  W_\  -__  #?_P  W_\ C9T  '^E  !PK   8;,  %.Z
M  !%OP  .,(  "S&   AR0  &,T  !#1   +U0  !-H   #>    X $  .$)
M  #B#@  Y!,  .4;  #G)   Z2\  .L\  #M2P  [ET  .YQ  #OB0  \*(
M /"\  #PXP  [_D  /#_  #P_P  \/\ @:4  '*M  !CM0  5+T  $;$   W
MR   *LP  !_0   5U0  #MH   ?>    X@   .8   #I    Z@   .P   #N
M!0  [PP  /$0  #S%P  ]2   /@K  #[.0  _4H  /Y>  #_=   _XT  /^F
M  #_P   _^$  /_U  #_]0  __4 =*X  &6W  !6P   1\@  #C-   JT@
M'=@  !/=   ,X@   ^8   #I    [    /    #S    ]    /8   #X
M^@   /T'  #_#0  _Q(  /\;  #_*   _S<  /]*  #_7@  _W8  /^/  #_
MI@  _[H  /_1  #_T0  _]$ _P\D /\.(@#_"R$ _P,D /\ *0#_ #( _P ^
M /\ 3 #_ %D _P!E /\ < #_ 'H _P"$ /\ C #_ )( _P"9 /\ GP#_ *4
M_P"K /\ L@#_ +H _P#% /\ TP#_ .< _P#T /\ _P#^ /\ _P#_ /X _P#^
M /\ _@#_ /X _P#^ /\ _Q$A /\0'@#_#1T _P<? /\ (P#_ "T _P Z /\
M2 #_ %4 _P!A /\ ; #_ '8 _P!_ /\ AP#_ (X _P"5 /\ FP#_ *$ _P"G
M /X K@#] +8 _ #  /L S0#Y .( ^ #P /< _ #V /\ ]0#_ /4 _P#U /\
M]0#_ /4 _P#U /\ _Q4= /\3&@#_$!D _PL9 /\ '0#_ "D _P V /\ 0P#_
M %  _P!< /\ 9P#_ '$ _P!Z /X @P#\ (H ^@"1 /D EP#X )T ]P"C /4
MJ@#T +( \@"[ /$ R #O -P [@#L .T ^@#K /\ Z@#_ .H _P#J /\ Z@#_
M .H _P#J /\ _Q@9 /\6%0#_$Q, _PX3 /\+&@#_!R0 _P(P /\ /@#_ $L
M_P!7 /\ 8@#\ &P ^ !U /4 ?@#R (4 \0", .\ DP#N )D [ "@ .L I@#I
M *X YP"W .8 PP#D -0 X@#I .$ ]P#? /\ W0#_ -T _P#= /\ W0#_ -T
M_P#= /\ _QL3 /\:$ #_%@X _Q(. /\2%0#_#Q\ _PPK /\). #_!D4 ^P-1
M /<"7 #R F8 [@)P .H"> #G H  Y@.' .0#C@#B Y4 X0.< -\$HP#=!*L
MVP2T -@%P #6!=  TP;G - (^ #."O\ S O_ ,L,_P#+#/\ RPO_ ,L+_P#+
M"_\ _Q\0 /\>"P#_&@< _QD+ /\8$0#_%AD _Q(D /H0, #S#CX [@U* .D,
M5@#E#&$ X@QJ -X-<P#;#7L V0V# -8-B@#4#9$ T@V9 - .H #/#JD S0ZS
M ,L.OP#*#]  QA'I ,(2^0"_$_\ O1/_ ;P3_P&\$_\!O!/_ ;L3_P&[$_\!
M_R(, /\A! #_(   _R$% /\?# #_'!$ ]A@< .P5* #E$S8 WQ)# -D33P#3
M%%H T!5D ,T6;0#+%G4 R1=] ,<7A0#%&(P Q!B4 ,(9G # &:4 OAFO +T:
MNP"[&LL N!OE ;0<]@&R'?\"L!W_ J\=_P*N'?\"KAW_ JX=_P*N'?\"_R8&
M /\E  #_)@  ^R<  /$E P#P(0L Z!P2 -X9'0#4&RT S1T\ ,@?20#%(%4
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M") U[ B.-OX(C#;_"(LV_PB+-O\'BC7_!XHU_P>*-?\'_R\  /(T  #B/
MTD$  ,="  # 0   NSH! +8V#@"P.1P JCLL *8\.@"C/48 GSU0 9T]60*:
M/6$#F#UH!)8\< 64/'<&DCR !Y$\B >/.Y((C3N="8L[J0J).[<+B#O*"X4\
MZ N#//L+@CS_"H$\_PJ!//\)@3S_"($\_PB!//\(_S,  .PZ  #:0P  RD<
M +])  "W1P  L4(  *T^"@"F0!< HD(G )Y#-0":1$(!ET1, 91$50*10UT#
MCT-D!8U#:P:+0G,'B4)["(="A J%08X+@T&9#(%!I0U_0;,.?D'&#GQ!Y YZ
M0OD->4+_#'A"_PMX0O\+>$+_"GA!_PIX0?\*]C8  .9   #12   PTT  +E.
M  "Q30  J4D  *1%!@"?1A, FD@C )9),@"22CX!CTI( HQ*40.*25D$ATE@
M!85): >#2&\(@4AW"G]'@ M]1XH->D>5#GA&H@]V1K 0=4;"$'-&X!!R1_</
M<4?_#G%'_PUQ1_\,<4?_"W%&_PMQ1O\+\SD  .!$  #,3   OE$  +13  "J
M4@  HDX  )U* 0"72Q$ DTT@ (]/+@",3SH!B$]% H5/3@.#3U8$@$Y=!GY.
M9 =\36P)>4UT"W=,?0QU3(<.<TR2#W%+GQ%O2ZT2;4N_$FQ+W!)K3/41:DS_
M#VI,_PYJ2_\-:DO_#&I+_PQJ2_\,\#T  -M(  #'4   NE4  +!8  "E5@
MG%,  )=/  "14 X C%(< (E4*P"%5#< @E1" 7]42P-\5%,$>E-:!GA38@AU
M4FD)<U)Q"W%1>@UN480/;%"0$&I0G!)H4*L39E"\$V50V!-D4/,29%#_$&10
M_P]D4/\.94__#65/_PQE3_\,[$$  -1,  ##5   MED  *Q<  "@6@  EU<
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M#E9;_PU66_\-WDP  ,=6  "X7P  K60  *!E  "39   B6,  ']A  !Y8@,
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MC0Q!=9T./W6N#CYUQ0X]=>@./G/]#3YR_PT^<?\,/W'_##]P_PP_</\,Q5X
M +5I  "I<0  G'4  (UT  " =   =70  &EV  !>>0  6'P! %1]#@!2?AH
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M RB2O00HDN$#)Y#Z!">._P4GC?\%)XS_!2>,_P4GC/\%L70  *5^  "9A0
MBH0  'V$  !OA0  8X@  %B+  !-CP  0Y,  #J7   RF@< +IL0 "V;&@ L
MG"0 *YPN "J=.  IG4$ *)U+ ">>50 FGF$ )9YN ".>?@$BGI !()ZC 1^>
MN0$>GMT!'ISX AZ:_P(>F?\#'I?_ QZ7_P,>E_\#JGT  )Z%  "3BP  A8H
M '6+  !HC@  6Y$  %"5  !&F0  .YT  #*@   JHP  (J8) !^G$0 >IQH
M':@D !RH+0 ;J#< &JE! !FI3  8J5@ %ZIF !:J=@ 5JHD %*J> !.KM  2
MJ], $JCU !.G_P$3I?\!$Z7_ 1.D_P$3I/\!HX8  )>,  "-D0  ?9(  &V5
M  !@F   5)P  $B@   ^I   -*<  "JK   AK@  &;$  !*S!P /M1  #K47
M  ZU(0 -M2L #;4V  RV00 +MDX "K9<  FV;  (MG\ ![:4  :VJ@ %ML4
M!K;J  >U_P (M/\ "+/_  FR_P )LO\ FHT  )"3  "$F   =)P  &6@  !7
MI   2Z@  $"L   UL   *K,  "&U   8N   $;L   R^ @ &P L  L 1  '!
M&0  P2(  ,(K  #"-@  PT(  ,-0  #$7P  Q'$  ,2'  #$G0  Q+4  ,3:
M  #$]@  P_\  ,/_  ##_P  P_\ DY0  (>:  !XH   :J8  %RL  !/L0
M0;4  #6W   IN@  '[T  !;    0PP  "L8   /*    S 4  ,P,  #-$0
MSA@  ,XA  #0*@  T34  --#  #44@  U&,  -5X  #5CP  U:<  -;"  #6
MZ0  UOT  -;_  #6_P  UO\ BIL  'NB  !LJ0  7K   %"V  !"N@  -+T
M "C!   =Q   %,<   W+   &S@   -(   #7    V0   -H%  #<"P  W1
M -\5  #A'0  XR<  .4S  #G0@  Z%0  .AG  #I?@  Z9<  .JO  #JS@
MZ^\  .O^  #K_P  Z_\ ?:,  &ZK  !?L@  4;H  $+    TPP  )\<  !O+
M   2SP  "],   +8    W0   .$   #D    Y0   .<   #I    ZP<  .T-
M  #O$0  \1D  /0D  #W,0  ^4$  /I5  #Z:@  ^X0  /N=  #\M@  _-(
M /WM  #]]   _?0 <:P  &&U  !2O0  1,0  #3)   FS0  &M(  !#8   (
MW0   .$   #E    Z    .P   #O    \0   /,   #U    ]P   /D!  #[
M"   _@X  /\5  #_(0  _R\  /]!  #_5@  _VT  /^'  #_H   _[8  /_*
M  #_U   _]0 _PL@ /\''@#_ !T _P @ /\ )0#_ "X _P [ /\ 20#_ %8
M_P!B /\ ;0#_ '8 _P!_ /\ AP#_ (X _P"4 /\ F@#_ *  _P"F /\ K0#_
M +4 _P"^ /\ RP#_ .$ _P#P /X _0#] /\ _0#_ /T _P#] /\ _ #_ /D
M_P#Y /\ _PT= /\+&@#_!!D _P : /\ 'P#_ "H _P W /\ 10#_ %$ _P!>
M /\ : #_ '( _P!Z /\ @@#_ (D _P"0 /\ E@#_ )P _@"B /P J0#[ +
M^0"Y /@ Q@#V -D ]0#K /0 ^0#S /\ \@#_ /, _P#S /\ \P#_ /, _P#S
M /\ _Q 9 /\.%0#_"!0 _P 4 /\ &0#_ "4 _P R /\ 0 #_ $P _P!9 /\
M8P#^ &T _ !U /H ?0#Y (0 ]P"+ /8 D0#T )< \P"> /( I #P *P [@"T
M .T P #K ,\ Z0#F .@ ]0#F /\ YP#_ .8 _P#E /\ Y0#_ .4 _P#E /\
M_Q(4 /\0$ #_# \ _P,0 /\ %0#_ "  _P L /\ .@#_ $< ^@!3 /< 7@#T
M &< \0!P .\ > #M '\ ZP"& .H C #H ), YP"9 .4 H #C *< X0"P -\
MN@#= ,D VP#@ -@ \ #7 /X U0#_ -0 _P#3 /\ TP#_ -, _P#3 /\ _Q40
M /\2# #_#@D _PL, /\)$@#_ QH _P F /T ,P#T $  [P!- .L 6 #H &$
MY0!J .( <@#@ 'H W@"  -P AP#: (X V "5 -0 G #2 *, T "L ,X M@#,
M ,0 R@#9 ,@ [0#' /L Q0#_ ,0!_P## ?\ Q '_ ,0!_P#$ ?\ _Q@+ /\5
M!0#_$   _Q & /\/#0#_#!0 _ <? /$#*P#G #D X@!& -X!40#: EL U0)D
M -(#; #/ W0 S01[ ,L$@@#*!(D R 60 ,8%F #$!:  P@:I ,$&M "_!L$
MO0C5 +L)[ "X"_T M@S_ +4-_P"T#?\ M W_ +0-_P"T#?\ _QL% /\8  #_
M%P  _Q8  /L3!@#Z$ X [@P6 .,)(@#:"3  TPH^ ,X+2@#*#%4 QPU> ,4-
M9P#"#F\ P0YV +\.?@"]#X4 O ^- +H0E0"X$)T MQ"G +41L@"S$<  LA'5
M *X3[@"K%/X J17_ *<5_P"G%?\ IA3_ :84_P&F%/\!_Q\  /\<  #Z'@
MZQX  .,<  #?%04 W@X- -,.& #+$2@ Q1,W , 41 "\%D\ N1=9 +<780"T
M&&D LQEQ +$9> "O&H  KAJ( *P;D "K&YD J1NC *<<K@"F'+P I!W/ *$>
MZ@&>'OP!G!__ 9L?_P&:'_\!FA[_ 9D>_P&9'O\!_R(  /\A  #L)P  X"H
M -0I  #-)   RAP( ,09$@"]'"( MQXQ +,@/@"O(4D K2)3 *HC7 "H)&0
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M!7LV_P5Z-O\$>C;_!'HU_P1Z-?\$]2T  .0W  #0/P  PD,  +=$  "M0
MISH  *,V!@"=-Q, F3DB )4Z+P"2/#L CSQ& (P\3P&*/%<!B#Q> H8\90*$
M/&T#@CQU!( \?01_/(<%?3R2!GL[G@=Y.ZP'=SN\"'8\U0AT//$(<SS_!W(\
M_P9R//\%<CS_!7([_P5R._\%\3(  -X]  #)1   O$@  +!)  "F1@  GT$
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M!UY*_P=>2O\'XS\  ,M)  "\40  L%4  *%4  "64@  C5   (=,  "!30@
M?4\3 'I0(0!W42X =%(Y ')20@%O4DL!;5)2 FM160-I46$$9U%H!F50<0=C
M4'L(85"&"E]/DPM=3Z$,6T^R#5E/QPU93^@,6$_]"UA/_PE93_\(64[_!UE.
M_P=93O\'WT,  ,=-  "X5   K%D  )U7  "150  B%0  (%0  ![4@0 =U,1
M '14'@!Q52L ;U8V &Q60 %J5D@!:%90 F965P-D5EX$8E5F!6!5;P==57@(
M6U2$"EE4D0M75* ,55.P#513Q0U34^8,4U/\"U-3_PE44O\(5%+_"%12_P=4
M4O\'VD8  ,-0  "U6   J%L  )E:  "-6   A%<  'M4  !V5@$ <5</ &Y9
M&P!L6B@ :5HS &=;/0%E6T4!8UM- F%:50-?6EP$75ID!5M9; 98678(5EF"
M"518CPM26)X,4%BN#4]8PPU.6.0,3EC["T]7_PE/5_\(3U;_"%!6_P=05O\'
MTTH  ,!4  "R7   HUX  )5=  ")7   ?UL  '99  !P6@  :UP- &A=& !F
M7B0 9%\P &)?.@!@7T,!7E]+ EQ?4@):7UH#6%]A!55>:@937G0'45U_"4]=
MC0I-79P+2UVL#$I=P0Q)7>,,25SZ"DE;_PE*6_\(2EK_"$I:_P=*6O\'SDX
M +Q8  "N8   GV$  )%@  "%7P  >U\  '!=  !J7P  96$* &)B% !@8R$
M7F0M %QD-P!:9$ !6&1( 59D4 )49%<#4F1?!%!D9P5.8W$&3&-]"$EBBPE'
M8IH*1F*J"T1BOPM$8N$+1&'Y"D1@_PE$8/\(15__!T5?_P=%7_\'R%(  +A<
M  "K9   FV0  (QC  " 8P  =F,  &IB  !C9   7V8& %MG$0!9:!T 5VDI
M %9J,P!4:CP 4FI% 5!J3 %.:E0"3&I< TIJ901(:6\%1FEZ!T1IB A":)@)
M0&BI"C]HO0H^:-X)/F?W"3YF_P@_9?\'/V7_!S]D_P<_9/\'PU<  +-A  "G
M:0  EF@  (=G  ![9P  <6<  &5H  !<:@  6&P! %1N#@!2;Q@ 4&\D $YP
M+@!-<#@ 2W%! $IQ20%(<5$!1G%9 D1P8@-"<&P$0'!X!3YPA@8\;Y4'.F^F
M"#AONP@X;]L'.&[V!SAM_P<X;/\&.6O_!CEJ_P8Y:O\&O5P  *]F  "B;0
MD6P  ()K  !W:P  ;&P  &%N  !7<   4',  $QU"@!)=A, 1W<? $9W*0!%
M>#, 0W@\ $)X1 !!>$T!/WA5 3UX7@([>&@".7AT S=X@@0U>),%,W>D!3)W
MN04Q>-<%,7;U!3%T_P4Q<_\%,7+_!3)R_P4R<O\%MV,  *IM  "<<0  BW
M 'UP  !R<   9W$  %QS  !1=P  2GH  $)] P _?@X /7\8 #Q_(P [@"T
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M !:3_P$6DO\!%I'_ 1:0_P$6D/\!I7L  )F#  ")@0  >X   &R"  !?A
M5(@  $F+   _D   -90  "V7   EF@  '9X! !:@#  4H1( %*$; !.A)0 2
MH2X $:(X !&B0P 0HD\ #Z)<  ZC:P -HWT #:.2  RCIP *HL  "Z+F  R@
M_@ -G_\ #9[_  V=_P -G?\ GH0  )*)  "#B   <X@  &6+  !8C@  3)(
M $&7   WFP  +IX  "2B   <I0  %:@   ^K!  *K@P !ZT2  :M&P %K20
M!*XN  *N.0 !KD4  *Y2  "N80  KG,  *Z'  "NG0  KK0  *[5  "M]
MK?\  *S_  "K_P  J_\ EHL  (R0  ![D   :Y(  %V6  !0F@  1)\  #FC
M   OIP  ):L  !RN   4L0  #K0   FW   !N D  +@.  "Y%   N1P  +HE
M  "Z+P  NSH  +Q'  "\5@  O&<  +Q[  "\D0  O*D  +S$  "\ZP  N_X
M +O_  "[_P  N_\ D)(  (.8  !SFP  8Y\  %6C  !'J   .ZT  #"Q   E
MM   &[<  !*Z   ,O0  !;\   ##    Q (  ,4*  #%#@  QA0  ,<;  #(
M)   RBX  ,PZ  #-20  S5D  ,UL  #.@P  SIL  ,VU  #.V@  SO8  ,W_
M  #-_P  S?\ AID  '>@  !II@  6JP  $RR   ^M@  ,+D  "2\   9OP
M$<(   K%   "R0   ,P   #0    T0   -(!  #3"   U0T  -<1  #:&
MW"$  -\L  #A.@  XDH  .-=  #D<@  Y(L  .6E  #EP   Y>8  .7X  #E
M_P  Y?\ >J$  &NI  !<KP  3;8  #^\   POP  (\,  !?'   /R@  !\X
M  #1    U@   -P   #?    X    .(   #D    Y@,  .@)  #I#@  [!4
M .X>  #Q*P  ]#H  /5-  #V80  ]WD  /B3  #XK0  ^<8  /GD  #Y\P
M^?, ;:H  %ZR  !/N@  0,$  #'%   BR0  %LX   W2   $V    -T   #A
M    Y    .@   #K    [0   .\   #Q    \P   /8   #X P  ^@L  /T1
M  #_&P  _RD  /\[  #_3P  _V8  /]_  #_F0  _Z\  /_#  #_U@  _]8
M_P0< /\ &0#_ !D _P < /\ (@#_ "L _P X /\ 1@#_ %, _P!> /\ :0#_
M '( _P!Z /\ @@#_ (D _P"/ /\ E0#_ )L _P"A /\ J #_ *\ _P"Y /\
MQ0#_ -D _@#L /T ^P#[ /\ ^P#_ /L _P#Z /\ ] #_ /  _P#P /\ _P<8
M /\!%0#_ !0 _P 6 /\ &P#_ "8 _P T /\ 0@#_ $X _P!: /\ 9 #_ &T
M_P!U /\ ?0#_ (0 _P"* /T D #\ )8 ^@"= /D HP#X *L ]P"T /4 OP#T
M ,X \P#F /$ ]@#P /\ [P#_ .\ _P#N /\ [@#_ .H _P#J /\ _PL4 /\&
M$0#_ !  _P 0 /\ %@#_ "( _P N /\ / #_ $D _P!4 /X 7P#[ &@ ^0!P
M /< > #U '\ \P"% /( BP#P )( [P"8 .T GP#L *8 Z@"N .@ N0#G ,<
MY0#> ., \ #B /X X #_ .  _P#A /\ X0#_ .$ _P#A /\ _PT0 /\)#0#_
M 0P _P , /\ $@#_ !P _P H /P -@#Y $, ]@!. /( 60#O &( [ !K .H
M<@#H 'D Y@"  .0 A@#B (P X0"3 -\ F@#= *$ VP"J -@ M #5 ,  T@#3
M -  Z@#. /H S0#_ ,T _P#- /\ S #_ ,P _P#, /\ _Q , /\,!P#_ P(
M_P ( /\ #@#_ !8 ]@ B /  +P#L #P Z0!( .4 4P#A %P W@!E -L ; #7
M ', U !Z -( @ #0 (< S@". ,P E0#* )T R "E ,8 KP#$ +L P@#+ ,
MY0"^ /4 O0#_ +P _P"\ /\ O #_ +P _P"\ /\ _Q$% /\.  #_"@  _P@!
M /\$"@#X !  Z0 : ., * #> #4 V0!! -, 3 #/ %8 RP!? ,D 9@#& &X
MQ !T ,( >P#! (( OP") +T D "\ )@ N@"A +@ JP"V +< M #' +( X "Q
M ?( KP+_ *X#_P"M!/\ K03_ *T$_P"M!/\ _Q0  /\0  #_#P  \@T  .H*
M  #I PD W0 2 -0 'P#- 2T R (Z ,0#10#  U  O019 +L%80"Y!6@ MP9O
M +4&=@"T!WT L@>$ +$(C "O")4 K0F> *L)J "J"K4 J K% *8+WP"D#?0
MH@[_ * ._P"?#O\ GP[_ )\._P"?#O\ _Q<  /\3  #O&   Y!D  -L6  #2
M$ ( SPD+ ,@(%@#!"B0 O PR +<-/@"T#DD L0Y3 *\06P"M$&, JQ!J *D1
M<0"H$7@ IA&  *41B "C$I$ H1*; * 3I@">$[, G!/# )L4W@"7%O0 E1;_
M )07_P"3%_\ DA?_ )(6_P"2%O\ _QH  /0=  #E(P  U24  ,HD  #"'0
MOA8$ +L0$ "T$QT KQ4K *L6. "G&$, I1E- *(95@"@&ET GAME )T;; ";
M'', FAQ[ )@<@P"7'8T E1V7 ),>H@"2'J\ D!Z_ (\?V ",(/$!B2#_ 8@@
M_P&'(/\!AR#_ 88@_P&&(/\!^AX  .LF  #:+0  RC   +XN  "U*   L"(
M *X;# "H'1< HQ\F )\A,P"<(CX F2-( )<D40"5)%D DR5@ )(E9P"0)FX
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M FHU_P)J-?\"ZC   -,Z  #"00  LT,  *5!  ";/@  E3H  ) V  ",-0T
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MC 572IH&54JJ!U1*O0=32MP'4DKV!E)*_P522?\$4DG_ U)(_P-32/\#U$$
M ,!+  "R40  H%   ))/  "'3@  ?DP  'A(  !R2@  ;DL- &M-& !H3B0
M9DXO &1/.0!B3T( 85!) 5]040%=4%@"6T]@ EE/: -73W($54]]!5-/B@52
M3I@&4$ZH!TY.NP=-3MD'34[U!DU._P5-3?\$34W_!$Y,_P-.3/\#SD0  +Q.
M  "N5   G%,  (Y2  "#40  >E   ')-  !L3P  :% + &51%0!C4B$ 85,L
M %]3-@!=5#\ 6U1' %I43@%85%8!5E1= E149@-24V\#4%-[!$Y3B 5,4Y<&
M2U.G!TE3N@=(4]4'2%+S!DA2_P5(4?\$25'_!$E0_P-)4/\#RD@  +E2  "J
M5P  F%8  (I5  !_5   =E,  &Q1  !G4P  8E0( %]6$@!=5QX 6U<I %E8
M,P!86#P 5EE$ %593 %365,!45E; D]89 )-6&T#2UAX!$E8A@5'5Y4&15>E
M!D17N 9#6-(&0U?R!D-6_P5#5?\$1%7_!$14_P-$5/\#QDP  +56  "E6@
ME%D  (98  ![6   <5<  &96  !A6   75D$ %E:$ !76QL 55PF %-=, !2
M73D 45Y! $]>20!-7E$!3%Y8 4I>80)(76L#1EUV T1=@P1"79(%0%VC!C]=
MM@8^7= &/5SQ!3Y;_P0^6O\$/EK_ SY9_P,_6?\#P5   +%:  "A70  D%P
M ();  !V6P  ;5L  &%;  !;70  5EX  %)@#0!081< 3F(B $UB+ !,8S4
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M BIO_P(J;?\"*FS_ BML_P(K;/\"L6$  *1I  "0:   @&<  '1G  !I9P
M7V@  %5K  !+;@  0W$  #QT   W=@H -'<2 #-X'  R>"4 ,7DN #!Y-P O
M>3\ +GE( "QZ4@ K>EP *GIH "AZ=@ F>H<!)7J9 2-ZK $B>L4!(GGI 2)W
M_P$B=O\!(G7_ B)T_P(C=/\"K&@  )UN  "*;0  >VP  &]L  !E;   6FX
M %!Q  !%=0  /7@  #9\   N?P( *8$- ">"%  F@AX )8(G "2"+P C@S@
M(H-" "&#2P @A%8 'X1B !Z$<0 <A(( &X25 !J$J0 8A,$ &(/F !B!_0 9
M@/\!&7__ 1E^_P$9?O\!IG   )5S  "$<@  =G$  &MQ  !><P  5'8  $EY
M   _?0  -X$  "^$   GB   ((L% !N-#@ :C14 &8T> !B.)P 7CC  %HXY
M !6.0P 4CT\ $X]; !*/:@ 1CWL $(^/  ^/I  .C[L #8_@  Z-^@ /B_\
M$(K_ !")_P 0B?\ H7H  (YY  !^=P  <G<  &1X  !8>P  37X  $*"   Y
MA@  +XH  ">.   @D0  &)4  !*8!0 .F@X #9H4  R:'0 +FB8 "YHP  J:
M.P )FD8 ")I3  :;80 %FG( !)J&  *:FP  FK$  9G/  *9\  "F/\ !)?_
M  66_P %EO\ F8$  (=_  !Z?@  :WX  %V!  !0A0  18D  #N-   QD@
M*)8  !^9   8G0  $:    RC @ &I0H  :40  "E%@  IA\  *8H  "F,@
MIST  *=*  "G6   IV@  *=\  "GD0  IJ@  *;#  "EZ0  I?P  *7_  "D
M_P  I/\ D8<  (*&  !RA@  8X@  %6,  !)D0  /98  #*:   HG@  'Z(
M !>F   0J0  "ZP   2O    L08  +$,  "R$0  LA<  +,?  "S*   M#(
M +4_  "U30  M5T  +5P  "UA@  M9T  +6V  "UW   M/<  +3_  "T_P
MM/\ BX\  'J.  !JD0  6Y4  $V:  ! GP  -:0  "JH   @K   %K    ^T
M   )MP   ;D   "]    O@   +X&  "_#   P!   ,$6  #"'0  PR<  ,4R
M  #&0   QE$  ,=C  #'>   QY$  ,>I  #'QP  Q^P  ,?^  #'_P  Q_\
M@Y<  '&:  !AG@  4J,  $6I   XK@  ++,  ""W   6N@  #KT   ;
MPP   ,<   #)    R@   ,P   #- P  S@D  - .  #2$P  U!L  -@E  #;
M,@  W4(  -U4  #>:0  WH$  -Z<  #?M0  W]D  -_S  #?_P  W_\ =Y\
M &BF  !9K0  2K,  #NX   MNP  '[\  !3"   ,Q@   \D   #,    T
M -4   #9    V@   -P   #>    X    .(%  #D"P  YQ   .H8  #M)
M\#(  /%$  #R6   \V\  /2*  #TI   ]+\  /3?  #T\P  ]/0 :J@  %NO
M  !,MP  /;T  "W!   ?Q@  $\H   O.    T@   -<   #<    X    .4
M  #G    Z0   .L   #M    [P   /$   #S    ]@<  /D.  #\%@  _R(
M /\S  #_1P  _UT  /]V  #_D0  _ZD  /^^  #_V   _]L _P 8 /\ %@#_
M !4 _P 8 /\ '@#_ "< _P V /\ 0P#_ $\ _P!: /\ 9 #_ &T _P!U /\
M?0#_ (0 _P"* /\ D #_ )8 _P"< /\ HP#_ *L _P"T /X OP#] ,\ ^P#G
M /H ^ #Y /\ ^0#_ /D _P#U /\ [@#_ .D _P#G /\ _P 4 /\ $0#_ !$
M_P 2 /\ %P#_ ", _P Q /\ /@#_ $H _P!6 /\ 8 #_ &@ _P!P /\ > #]
M 'X _ "% /H BP#Y )$ ^ "8 /< G@#U *8 ] "N /( N0#Q ,< [P#@ .X
M\@#L /\ [ #_ .P _P#K /\ Y0#_ .  _P#> /\ _P,0 /\ #@#_  T _P -
M /\ $P#_ !X _P K /\ . #_ $4 _@!0 /L 6@#X &, ]0!K /, <@#Q 'D
M[P!_ .X A@#L (P Z@"2 .D F0#G *  Y@"I .0 LP#A ,  X #3 -X ZP#<
M /L VP#_ -H _P#: /\ V0#_ -0 _P#2 /\ _P<- /\ "0#_  8 _P ) /\
M#P#_ !@ ^P E /@ ,@#U #\ \@!* .T 5 #J %T YP!E .0 ; #B ', X !Z
M -X @ #< (8 V@"- -< E #4 )L T@"D ,\ K0#- +D RP#) ,D Y #( /8
MQ@#_ ,4 _P#& /\ QP#_ ,< _P#' /\ _PH& /\!  #_    _P $ /\ "P#T
M !( [P ? .H + #E #@ X@!# -T 3@#9 %< U !? -$ 9P#. &T S !T ,H
M>@#( (  Q@"' ,4 C@## )8 P0"> +\ J "] +, N@#" +D VP"W /  M0#_
M +8 _P"U /\ M0#_ +4 _P"U /\ _PP  /\$  #_    _@   /8  P#H  T
MX  7 -D ) #1 #$ S0 \ ,H 1P#& %$ PP!9 ,  8 "^ &< O !N +H = "Y
M 'L MP"" +4 B0"S )$ L@": +  I "N *\ K "] *H T "H .L IP#[ *8
M_P"F /\ I0#_ *4 _P"E /\ _PT  /\'  #T"0  Z@D  .($  #:  < SP 1
M ,@ ' #" "D O@ U +L 0 "W $H M !3 +( 6P"P &( K@!H *P ;P"K '4
MJ0!] *@ A "F (T I "6 *, H "A *L GP&Y )T#S "<!.@ F@;Y )D'_P"8
M"/\ EPC_ )<(_P"7"/\ _Q   /<0  #H%   W!4  ,X1  #&#0  P@0+ +P
M% "W 2$ L@,N *X%.@"K!D0 J A- *8(50"D"5P H@IC * *:@"?"W$ G0MX
M )P+@ ":#(D F0R3 )<,G@"5#:H E VX )(-S "0#NH CA#\ (P0_P"+$/\
MBQ#_ (L0_P"*$/\ ^Q,  .T:  #=(   S"$  +\=  "W%P  LQ$  +(+#0"K
M#1D IPXF *,/,P"?$#X G1%' )H14 "8$E< EA)> )4390"3$VP DA-S ) 4
M? "/%(4 C16/ (L5F@"*%:< B!:U (86R0"$%^< @AC[ ( 9_P!_&?\ ?QG_
M '\8_P!_&/\ ]1H  .0C  #/*0  P"H  +,F  "J(@  I1P  *05" "@%!,
MFQ8A )<8+0"4&3@ D1I" (\;2P"-'%( BQQ9 (D=8 "('6< AAYO (4>=P"#
M'X  @A^+ ( ?EP!^(*, ?2"R 'L@Q0!Y(>0 =R+Y '8B_P!U(O\ ="'_ '0A
M_P!T(?\ [R$  -LK  #',0  MC$  *DN  "@*@  FR8  )@A 0"5'A  D" ;
M (TA* ")(S, AR0] (4D1@"#)4X @295 '\F7 !^)F, ?"=K 'LG<P!Y)WP
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MC %C-9H"83:I F VNP)?-M8"73;S ETV_P)<-O\!7#7_ 5PU_P%<-/\!W#,
M ,4\  "T00  HD   )4^  "+/   A#D  '\V  ![- 0 =S40 '0W' !Q."<
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M E$^_P%1/O\!SSL  +U%  "J1P  F48  (M%  "!1   >4(  '0^  !O/P
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M?@)!4HT"/U*= SY2KP,]4L8#/%+I CQ1_@(\4/\"/4__ CU/_P(]3O\"ODL
M *Y3  ":4@  B5$  'Q1  !Q4   :%   %Y.  !840  5%(  %%3# !.5!0
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M 2QCJ0$K8[\!*F/C 2IB^P$J8/\!*U__ 2M?_P$K7O\!L5D  )Y<  "+7
M>UL  &];  !E6P  7%P  %%>  !)8   0V(  #QE   X9PH -6@2 #1H&P S
M:20 ,FDM #%I-0 O:CT +FI& "UJ3P L:ED *VME "EK<@ H:X( )FN3 "1K
MIP C:[T (FK@ "-I^0$C9_\!(V;_ 2-F_P$D9?\!K&   )A@  "%8   =E\
M &I?  !A8   5V   $UC  !$9@  /6@  #9K   P;@0 +' . "IQ%0 I<1X
M*'$F "=R+P F<C< )7)  "1R2@ B<E0 (7-@ "!S;0 ><WT '7.0 !MSHP :
M<[D &7/< !IQ]P :</\ &V__ !MN_P$;;?\!IF8  )%E  !_9   <60  &9D
M  !=9   4F8  $AI   _;   -V\  #!S   I=@  (GD( !][$  >>Q< ''L?
M !M[*  :>S  &7PY !A\0P 7?$X %GQ: !5\9P 4?7@ $GV+ !%]GP 0?;4
M#WW5 !![]0 1>?\ $7C_ !)W_P 2=_\ GFL  (IJ  !Z:0  ;6D  &)I  !7
M:@  3&T  $-P   Y=   ,7@  "E[   B?P  &X(  !2%"0 1AA  $887 !"'
M'P 0AR@ #H<Q  Z'.P -AT8 #(=3  N'80 *AW$ "8>$  >'F  &AJX !8;)
M  :%[  'A/\ "(/_  F"_P )@O\ E7$  (-O  !T;@  :6X  %QO  !0<@
M1G4  #QY   R?0  *H$  "*%   ;B0  %(P   ^/ P *D@L !I(1  22&  "
MDB   9(I  "2,P  DSX  )-+  "360  DVD  )-[  "2D   DJ8  )&_  "1
MY0  D/H  (__  "/_P  C_\ C7<  'UU  !P=   8G4  %5X  !)?   /X
M #2$   KB0  (HT  !J1   3E   #I<   F;   !G0@  )T.  "=$P  GAH
M )XB  "?*P  GS4  *!"  "@4   H%\  *!Q  "@AP  GYT  )^U  ">V@
MG?8  )W_  "<_P  G/\ AGT  'A\  !I?   6W\  $Z#  !!B   -HP  "R1
M   CE@  &IH  !*>   -H0  !J0   "G    J0,  *D*  "J#@  JQ,  *P9
M  "M(@  KBL  *\W  "O10  KU0  *]F  "O>P  KI0  *ZK  "NR0  KN\
M *W_  "M_P  K?\ @80  '&$  !AAP  4XL  $:0   YE@  +IL  ".@   :
MI   $J@   RL   $KP   +(   "V    MP   +<"  "X"   N0T  +H2  "[
M&   O2$  +XK  # .   P$@  ,!:  #!;@  P88  ,&@  #!N@  P>,  ,#Y
M  # _P  P/\ >8T  &B0  !9E   2YH  #V@   QI0  ):L  !JO   1LP
M"[@   *[    O@   ,$   #$    Q0   ,8   #'    R 4  ,H+  #,#P
MSA4  - ?  #3*P  U3H  -5,  #68   V'<  -B2  #8K   V<D  -GL  #9
M^P  V/\ <)D  &">  !1I   0ZH  #6P   HM@  '+H  !&^   )P0   ,4
M  #(    RP   ,\   #2    TP   -8   #8    VP   -T   #?!P  X@T
M .43  #H'0  ["H  .T\  #M40  [F<  .^!  #OG   \+<  /#3  #P[
M\/0 9Z8  %BM  !)M   .KH  "J^   <P@  $,8   ?*    S@   -(   #6
M    W    .    #C    Y    .8   #H    ZP   .T   #O    \@(  /4*
M  #X$0  _!P  /\L  #_/P  _U4  /]N  #_B@  _Z0  /^Z  #_T0  _^$
M_P 4 /\ $@#_ !( _P 4 /\ &0#_ "4 _P R /\ /P#_ $L _P!6 /\ 8 #_
M &@ _P!P /\ > #_ '\ _P"% /\ BP#_ )$ _P"8 /\ G@#^ *8 _0"N /P
MN0#Z ,@ ^0#B /@ ] #W /\ ]@#_ /8 _P#O /\ YP#_ .( _P#> /\ _P 1
M /\ #@#_  X _P / /\ % #_ "  _P M /\ .@#_ $8 _P!1 /\ 6P#_ &,
M_@!K /P <P#Z 'D ^0"  /< A@#V (P ]0"2 /, F0#R *  \ "I .X LP#M
M ,$ ZP#6 .H [@#I /X YP#_ .< _P#E /\ W0#_ -4 _P#1 /\ _P - /\
M"@#_  @ _P ) /\ $ #_ !L _P H /\ -0#_ $  ^@!+ /8 50#S %X \0!F
M .X ;0#L '0 ZP!Z .D @ #G (8 Y@"- .0 DP#B )L X "C -X K0#< +D
MV@#* -< Y@#4 /@ T@#_ -( _P#2 /\ S@#_ ,D _P#& /\ _P ( /\  P#_
M    _P # /\ #0#\ !8 ]P B /, +@#O #H [ !% .@ 3P#D %@ X0!@ -X
M9P#; &T V0!T -4 >@#3 (  T0"' ,\ C@#- )4 RP"> ,D IP#' +, Q0#"
M ,, W #! /$ OP#_ +\ _P"^ /\ O@#_ +T _P"[ /\ _P   /\   #_
M_P   /8 " #N !$ YP ; .$ )P#= #, V0 ^ -, 20#/ %( RP!9 ,@ 80#&
M &< Q !M ,( <P#  'H OP"  +T B "[ )  N0"8 +@ H@"U *T LP"[ +$
MS@"P .H KP#\ *T _P"M /\ K@#_ *X _P"N /\ _P(  /\   #]    \@
M .@   #>  P TP 5 ,P (0#( "P Q  X ,$ 0@"] $L N@!3 +@ 6@"V &$
MM !G +( ;0"P '0 KP!Z *T @@"L (H J@"3 *@ G0"F *@ I "U *( Q@"A
M ., GP#V )X _P"> /\ G@#_ )X _P"> /\ _P8  /L   #N!0  X@0  -4
M  #+  8 PP / +T &0"X "4 M  Q +$ .P"N $4 K !- *D 50"G %L I0!B
M *0 : "B &X H0!U )\ ? "> (4 G ". )H F "8 *0 E@"P )4 P0"3 -P
MD@#R )$ _P"0 /\ D #_ (\ _P"/ /\ _0H  / .  #A$0  SA   ,(-  "[
M!P  MP * +$ $@"L !X J  I *4 - "B #X GP!' )T 3P"; %8 F0%< )<!
M8P"6 FD E )P ),#> "1 X  D 2* (X$E0",!:$ B@6N (D&O@"'"-@ A@GP
M (0*_P"#"_\ @PO_ (,+_P"#"_\ ]A   .87  #2'   P!H  +,6  "L$@
MJ T  *8'#0"B!18 G0<B )D)+@"6"C@ E M! )(,2@"0#%$ C@U8 (P-7@"+
M#64 B0UL (@.= "&#GT A0Z' (,.DP"!#Y\ @!"M 'X0O@!]$-L >A'T '@2
M_P!W$O\ =Q+_ '<2_P!W$O\ [Q<  -LA  #&)   M",  *@@  "@'   FQ<
M )D1! "8#A  DQ ; (\1)P",$C( B1,\ (<31 "%%$P @Q13 ($56@" %6
M?A9H 'T6;P![%G@ >1># '@7CP!V&)P =!BJ ',9NP!R&=0 ;QKQ &X;_P!M
M&_\ ;1K_ &T:_P!M&O\ YR   - I  "\*P  JRH  )XH  "6)   D"   (T<
M  ",%PP B!@6 (0:(@"!&RT ?APW 'P=0 !Z'4@ >1Y/ '<>50!V'UP =!]C
M ',?:P!Q('0 <"!_ &XABP!L(9@ :R&G &DBN !H(L\ 9B+N &4C_P!D(_\
M9"+_ &0B_P!D(?\ X"8  ,@O  "T,0  HS   )8N  "-*P  AR@  (0D  ""
M( @ ?B 2 'LB'@!X(RD =20S ',E/ !Q)4, <"9+ &XF4@!M)UD :R=@ &HG
M: !I*'$ 9RA[ &4HB !D*94 8BFD & IM0!?*<L 7BKL %PJ_P!<*?\ 7"G_
M %PI_P!<*/\ V"P  ,,U  "M-0  G30  ) S  "&,0  @"T  'PK  !Y* ,
M=B<0 '(I&@!P*B4 ;2LO &LL. !J+$  :"U' &<M3@!E+E4 9"Y= &,N90!A
M+VX 7R]X %XOA !<+Y( 6B^A 5DOL@%8,,@!5C#I 54P_@%5+_\ 52__ %4N
M_P!5+O\ T#$  +TZ  "H.0  ES@  (HW  " -@  >C(  '4P  !R+@  ;BX-
M &LO%@!I,"$ 9C$K &0R- !C,CT 83-$ & S2P!?-%( 731: %PT8@!:-&L
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M?0%*/XL!2#^; 4<_K %%/\$!1#_C 40^^P%$/O\!1#W_ 40]_P%%//\!PSX
M *]#  ":0@  BD(  'U!  !S0   :S\  &4\  !@/   7#X$ %D^#P!7/Q@
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M 3=,IP$V3+P!-4S= 35+]P$U2_\!-4K_ 39)_P$V2?\!N$D  *)+  ".2@
M?DH  ')*  !H2@  7TD  %5(  !02@  3$L  $E,!P!&31  1$X9 $)/(@!!
M3RL 0% S #]0.P ^4$, /%%* #M14P Z45P .%%G #=1<P U48( ,U&3 3)1
MI0$P4;H!+U': 2]0]@$O3_\!,$[_ 3!._P$P3?\!M$T  )U-  "*30  >DT
M &Y-  !D30  6TT  %%-  !+3P  1E   $)2 P _4PT /505 #Q4'@ Z52<
M.54O #A5-P W5C\ -E9' #564  S5ED ,E=D #!7<0 O5X  +5>1 "M7HP J
M5[@ *5?6 "E6]0 I5?\ *E3_ 2I3_P$J4O\!KU$  )A1  "%40  =E   &I0
M  !@4   6%$  $Y2  !'4P  054  #M8   X60H -5H1 #1:&@ S6R( ,ELK
M #%;,P O7#L +EQ# "U<3  L7%8 *UU@ "E=;0 H77P )EV. "1=H0 C7;4
M(EW2 ")<\P B6_\ (UK_ "-9_P D6/\ J%4  ))4  " 5   <50  &94  !<
M5   5%4  $I6  !#6   /%L  #9=   P8 4 +6$. "MA%0 J8AT *6(E "AB
M+@ G8S8 )F,^ "5C1P C8U$ (F1< "%D:0 ?9'D 'F2* !QDG@ ;9+, &63.
M !IC\0 ;8?\ &V#_ !Q@_P <7_\ H5D  (Q8  ![6   ;5@  &)8  !96
M4%D  $=;   ^7@  -V   #%C   J9@  )&D) "%J$  @:A< 'VH@ !YK*  =
M:S  '&LY !MK0@ :;$P &6Q8 !=L90 6;'0 %&R& !-LF@ 2;*\ $6S* !%K
M[P 2:?\ $VC_ !-H_P 39_\ F5T  (5=  !U7   :%P  %Y<  !57   2UX
M $)A   Y9   ,F<  "MJ   D;0  'G ! !=S"P 5=!$ %'08 !-T(0 2=2D
M$74R !%U.P 0=48 #W52  YU7P -=6X #'6!  MUE0 *=:H "'3#  ETYP *
M<_T "W'_  QQ_P ,</\ D6(  ']A  !P80  9&$  %IA  !/8@  164  #QH
M   S;   *V\  "1R   ==@  %WD  !%\!  -?PP "W\2  I_&0 )?R( "'\J
M  9_-  %?S\ !']+  )_6  !?V<  ']Y  !_C@  ?Z,  'Z[  !]X   ??<
M 'S_  ![_P  >_\ B6<  'AG  !K9@  868  %1G  !):0  /VT  #5Q   L
M=0  )'D  !U\   6@   $(,   R& @ &B0H  8D/  ")%   BAL  (HC  "+
M+   BS<  (M#  "+4   BU\  (MQ  "+A@  BYP  (JS  ")TP  B/,  (C_
M  "'_P  A_\ @FT  '-L  !H;   6FT  $YO  !"<P  .'<  "Y[   E@
M'80  !6(   0C   "X\   22    E 8  )4,  "5$   EA4  )<<  "8)
MF"X  )DY  "91P  F58  )EH  "9?0  F90  )BK  "7R   ENX  );_  "5
M_P  E?\ >W0  &]S  !A<P  4W8  $9Z   [?P  ,(0  ":(   =C0  %)(
M  Z6   )F0   9P   "@    H0   *(&  "B#   I!   *44  "E'   IR0
M *@O  "H/0  J4P  *E>  "I<@  J(D  *BB  "HO   I^4  *;[  "F_P
MI?\ =WL  &A[  !9?@  2X(  #Z'   RC0  )Y(  !V7   4G   #J    >D
M    J    *L   "N    KP   +    "Q!   LPH  +0.  "U$P  MAL  +@D
M  "Z,0  ND   +I2  "[90  NWT  +J7  "ZL0  NM(  +KS  "Y_P  N?\
M;X,  %^&  !1BP  0Y   #:7   JG0  'Z(  !6G   -K   !;    "T
MMP   +L   "^    OP   ,    #!    PP$  ,0'  #%#0  QQ$  ,H9  #-
M)   SC,  ,]$  #06   T&X  -&(  #0I   T,$  -'F  #1^   T?\ 9X\
M %>4  !)F@  .Z$  "ZG   AK0  %K,   ZX   &O    ,    ##    Q@
M ,L   #-    S@   -    #1    U    -8   #: @  W D  -\/  #C%P
MYB0  .<V  #H20  Z5\  .IX  #KE   ZZ\  .O,  #LZ   [/8 7YX  %"D
M  !"JP  -+(  ":Y   9O@  #L(   3%    R@   ,T   #1    V    -L
M  #?    X    .(   #D    Y@   .D   #K    [@   /$%  #U#0  ^18
M /PE  #].0  _D\  /]G  #_@@  _YT  /^U  #_RP  _^0 _P 1 /\ #P#_
M  \ _P 1 /\ %@#_ "( _P O /\ .P#_ $< _P!2 /\ 6P#_ &0 _P!L /\
M<P#_ 'H _P"  /\ A@#_ (P _@"3 /T F0#[ *$ ^@"I /@ M #W ,( ]@#:
M /4 \0#T /\ \P#_ /, _P#I /\ X #_ -@ _P#3 /\ _P . /\ "P#_  H
M_P + /\ $0#_ !T _P J /\ -@#_ $$ _P!, /\ 5@#^ %\ ^P!F /D ;0#W
M '0 ]0!Z /0 @ #R (8 \ "- .\ E #M )L [ "D .H K@#I +H YP#- .4
MZ0#D /L XP#_ .( _P#> /\ T0#_ ,P _P#( /\ _P ) /\ ! #_  $ _P $
M /\ #@#_ !@ _P D /T , #[ #L ]P!& /, 4 #O %D [ !@ .H 9P#G &X
MY@!T .0 >@#B (  X "' -X C@#< )4 V@"> -8 J #4 +, T0## ,\ WP#.
M /0 S #_ ,L _P#+ /\ Q0#_ +\ _P"\ /\ _P " /\   #_    _P   /T
M"P#W !, \0 > .T *@#J #4 YP!  .( 2@#= %( V0!: -4 80#2 &< T !M
M ,X <P#, 'H R@"  ,@ AP#& (\ Q "8 ,( H0#  *T O@"[ +P T "Z .T
MN0#^ +@ _P"X /\ MP#_ +, _P"P /\ _P   /\   #_    ^0   .X !0#E
M  X W@ 8 -@ (P#2 "X SP Y ,L 0P#' $P Q !4 ,$ 6P"_ &$ O !G +L
M;0"Y ', MP!Z +4 @0"T (D L@"2 +  FP"O *< K "T *L Q@"I .0 IP#X
M *8 _P"F /\ I0#_ *4 _P"D /\ _P   /\   #U    Z@   -X   #0  H
MR  2 ,( '0"^ "@ NP S +D /0"U $8 L@!- +  50"M %L K !A *H 9P"H
M &T IP!S *4 >@"D (( H@", *  E@"? *$ G0"N )L O@"9 -@ EP#Q )8
M_P"6 /\ EP#_ )< _P"7 /\ _P   /4   #G 0  U    ,D   #   0 N  .
M +, %@"O "$ JP L *@ -@"F #\ HP!' *$ 3P"? %4 G0!; )L 80": &<
MF !N )< =0"5 'T E "& )( D0"0 )P C@"I (P N "+ ,T B0#K (@ _0"(
M /\ B #_ (@ _P"( /\ ^08  .D,  #4#@  PPP  +<)  "P @  JP ) *8
M$ "B !H G@ E )L , "8 #D E@!! )0 20"2 %  D !6 (X 7 "- &( BP!I
M (H < "( '@ AP"! (4 C "$ )@ @@"E (  M !^ ,@ ?0'G 'P"^0![ _\
M>P3_ 'L$_P![!/\ \0X  -X5  #%%0  M!0  *D1  "A#@  G@H  )L## "7
M !, DP > ) !*0"- C, B@,\ (@$0P"&!4L A091 (,&5P""!UX @ =D '\(
M; !]"'0 ? A^ 'H)B0!X"98 =PJC '4*LP!S"\< <@SF ' -^P!P#?\ ;PW_
M &\-_P!O#?\ Z!8  - >  "Y'0  J1P  )T:  "5%@  D!,  (\. P"."@X
MB0L7 (8,(P"##2T @ TV 'X./@!\#D8 >PY- 'D/4P!X$%H =A!A '40: !S
M$'$ <1%[ ' 1AP!N$90 ;!&B &L2L@!I$L< :!/G &83_0!E%/\ 913_ &43
M_P!E$_\ WQX  ,8D  "P)   H",  )0A  "+'P  AAL  (,7  ""$@@ ?Q$2
M 'P2'0!Y%"@ =A0Q '05.@!R%D$ <19( &\73P!N%U8 ;!== &L89 !I&&T
M:!EW &89@P!D&9  8QJ? &$:KP!@&L0 7AOD %T<^P!<'/\ 7!O_ %P;_P!<
M&_\ U24  +TJ  "H*0  F"D  (PH  "#)0  ?2(  'D?  !X&P, =AD/ '(:
M& !O'", ;1TM &L=-0!I'CT :!Y$ &8?2P!E'U( 8R!9 &(@80!A(&D 7R%S
M %TA?P!<(8T 6B*< %DBK !7(L  5B/A %4C^0!4(_\ 5"+_ %0B_P!4(O\
MS2L  +8N  "B+@  DBX  (4M  !\*P  =B@  '(F  !O(P  ;2$, &HB%0!G
M(Q\ 920I &,D,0!B)3D 8"9! %\F2 !=)D\ 7"=6 %LG70!9)V8 6"AP %8H
M? !4*(H 4RF9 %$IJ@!0*;X 3RG> $XI]P!-*?\ 32G_ $TH_P!.*/\ R#
M + R  "<,@  C#(  ( Q  !V,   <"T  &LK  !H*0  9B@) &,H$0!@*1P
M7BHE %PK+@!;*S8 62P] %@L1 !7+4P 52U3 %0M6P!3+6, 42YN % N>@!.
M+H@ 3"^7 $LOJ !)+[L 2"_; $@O]@!'+_\ 1R[_ $<M_P!(+?\ Q#0  *LU
M  "7-0  AS4  'LU  !R-   :S(  &8O  !B+@  7RT% %PN$ !:+Q@ 6# B
M %8P*P!5,3, 4S$Z %(R0@!1,DD 4#)0 $XS6 !-,V$ 2S-K $HS=P!(-(4
M1S25 $4TI@!#-+D 0C36 $(T] !"-/\ 0C/_ $(R_P!",O\ P#@  *<X  "3
M.   @S@  '<X  !M-P  9C8  &$S  !=,@  63(" %<S#0!4-!4 4C4? %$U
M* !/-C  3C8X $PW/P!+-T8 2C=. $DX5@!'.%\ 1CAI $0X=0!#.(, 03F3
M $ YI  ^.;@ /3G3 #PY\P \./\ /3?_ #TW_P ]-O\ NSL  *([  "/.P
M?SL  ',[  !J.@  8CD  %TW  !8-@  5#<  %$X"P!/.1, 33D< $LZ)0!*
M.BT 2#LU $<[/ !&/$0 13Q+ $0\4P!"/%P 03UG #\]<P ^/8$ /#V1 #H]
MHP Y/;8 .#W1 #<]\@ W//\ .#O_ #@[_P X.O\ MCT  )X^  "+/@  ?#X
M &\^  !F/0  7CT  %@[  !3.@  3SL  $P\" !)/1$ 1SX9 $8_(@!$/RH
M0S\R $) .@!!0$$ 0$!) #Y!40 ]05H /$%D #I!<  X07\ -T&/ #5"H0 T
M0K0 ,D+. #)!\  R0/\ ,T#_ #,__P T/O\ L4   )I   "'0   >$$  &Q!
M  !B0   6T   %0_  !./P  2D   $9!!0!$0@X 0D,6 $!#'P _1"< /D0O
M #Q$-P [13X .D5& #E%3@ X1E@ -D9B #5&;@ S1GP ,4:- #!&GP N1K,
M+4;, "U&[P M1?\ +D3_ "Y#_P N0_\ K$,  )9#  "#0P  =$,  &A#  !?
M0P  5T,  %!#  !(0P  1$4  $%& 0 ^1PP /$@3 #I('  Y220 .$DL #9)
M-  U2CL -$I# #-*3  R2E4 ,$M? "]+:P M2WH +$N+ "I+G0 H2[$ )TO*
M "=+[0 G2O\ *$G_ "A(_P I1_\ IT8  )%&  !_1@  <$8  &5&  !;1@
M5$8  $Q'  !$2   /TH  #M+   W3 D -4T0 #-.&  R3B  ,4\H #!/,  O
M3S@ +D]  "Q02  K4%( *E!< "A0:  G4'< )5"( "10FP B4*\ (5#( "!0
MZP A3_\ (D[_ ")-_P C3?\ H4D  (Q)  !Z20  ;$H  &%*  !82@  4$H
M $E+  ! 3   .TX  #50   Q4@0 +5,- "Q4%  J5!P *54D "A5+  G53,
M)E4\ "5610 D5DX (E99 "%690 ?5G0 'E:% !Q6F  ;5JP &5;% !E6Z0 :
M5?\ &U3_ !M3_P <4O\ FTT  (9-  !U30  :$T  %U-  !430  34X  $5/
M   \40  -E,  #%5   K6   )EH) "-;$  B6Q< (5P? "!<)P ?7"X '5PW
M !Q=0  ;74H &EU5 !A=80 777  %5V! !1=E0 37:H $5W" !%=YP 26_X
M$UK_ !-:_P 46?\ E%$  (!1  !P40  9%$  %E1  !140  25(  $%3   X
M5@  ,ED  "M;   E7@  'V$# !IC#  89!$ %V09 !9D(0 59"D %&4Q !-E
M.@ 2940 $650 !!E70 /96L #F5]  UED0 ,9:4 "F2\  IDX  +8_D #&+_
M  UA_P -8?\ C54  'I5  !K50  7U4  %95  !.50  1%<  #Q9   T7
M+%\  "9B   ?90  &6@  !-K!0 0;0T #FX2  UN&@ ,;B( #&XK  MN-  *
M;CX "&Y*  =N5P &;F4 !&YV  )NB@  ;9\  &VV  !LU@  ;/,  6O_  )J
M_P #:O\ A5H  '1:  !F6@  7%D  %-9  !(6@  /UT  #9@   N8P  )F<
M !]J   9;0  $W$   YT P *=PH !7<0  %W%0  =QP  '<D  !X+0  >#<
M 'A#  !X4   >%X  'AO  !XA   >)D  '>P  !VS0  =?   '7_  !T_P
M=/\ ?E\  &Y?  !B7@  65X  $U?  !"8@  .64  #!H   G;   'W   !AT
M   2=P  #7L   A^   "@ @  ($-  "!$0  @A<  (,>  "#)@  A#   (0[
M  "$2   A%<  (1H  "$?   A),  (.J  ""Q0  @>L  ('^  " _P  @/\
M=V4  &ED  !?8P  4F0  $=G   \:P  ,6\  "AS   @=P  &'P  !%_   ,
M@P  !H<   "*    C ,  (P)  "-#@  CA$  (\7  "0'@  D2<  )(R  "2
M/P  DDX  ))?  "2<P  DHL  )&B  "1O   D.4  (_\  "._P  CO\ <6L
M &9J  !8:P  2VT  #]Q   T=@  *GL  ""    7A0  $(D   N-   $D0
M )4   "8    F0   )H#  ";"   G T  )X1  "?%@  H!X  *(H  "B-0
MHT0  *-5  "C:0  HH   **:  "ALP  H-@  *#V  "?_P  G_\ ;G$  %]R
M  !1=0  1'D  #=^   LA   (8H  !>/   0E   "ID   &=    H    *0
M  "G    J    *D   "J    K 8  *T+  "O$   L!4  +(>  "T*0  M#D
M +1*  "U70  M7,  +6.  "UJ   M,8  +/M  "R_P  LO\ 9GH  %=]  !)
M@@  /(<  "^.   CE   &)H  !"?   )I    *D   "M    L    +0   "W
M    N    +D   "[    O    +X"  # "   P@X  ,04  #''@  R"P  ,D]
M  #*4   RF8  ,I_  #*FP  RK@  ,K=  #*]0  RO\ 7H8  $^+  !!D0
M,Y@  ">?   ;I0  $:L   FP    M0   +D   "]    P0   ,8   #(
MR0   ,L   #,    S@   -    #2    U 4  -D,  #=$@  X1X  .(N  #C
M0@  Y%<  .5O  #FC   YJ@  .7%  #EYP  YO8 5I0  $B;   ZH@  +*D
M !^P   3M@  "[P   #!    Q0   ,D   #-    T@   -8   #:    VP
M -X   #@    X@   .0   #G    Z0   .T   #P"@  ]!$  /@?  #Y,@
M^D@  /M?  #\>@  _9<  /VO  #]QP  _>0 _P . /\ #0#_  P _P . /\
M$P#_ !X _P J /\ -@#_ $( _P!- /\ 5P#_ %\ _P!G /\ ;@#_ '0 _P!Z
M /\ @0#] (< _ "- /H E #Y )P ]P"E /4 KP#T +P \P#/ /$ [ #P /X
M[P#_ .\ _P#C /\ UP#_ ,X _P#* /\ _P * /\ !@#_  0 _P ( /\ $ #_
M !D _P E /\ ,0#_ #T _P!' /X 40#[ %D ^0!A /8 : #T &X \P!T /$
M>@#O ($ [@"' .P C@#J )8 Z "? .8 J0#C +4 X@#& .  XP#? /@ W0#_
M -T _P#4 /\ R0#_ ,( _P"^ /\ _P # /\   #_    _P ! /\ #0#_ !0
M_0 @ /H *P#W #8 \P!! .\ 2P#L %0 Z !; .8 8@#C &@ X0!N -\ = #<
M 'H V@"! -@ B #4 )  T@"8 ,\ H@#- *X RP"\ ,D TP#' /  Q@#_ ,0
M_P#$ /\ NP#_ +8 _P"S /\ _P   /\   #_    _P   /< " #P !  ZP :
M .< )0#D #  X0 [ -P 10#5 $T T0!5 ,X 6P#+ &( R0!G ,< ;0#% ',
MPP!Z ,$ @0"_ (D O0"2 +L G "Y *< MP"U +4 R "S .8 L@#[ +$ _P"P
M /\ K@#_ *H _P"G /\ _P   /\   #^    \0   .4  @#<  T TP 4 ,T
M'P#* "H QP T ,0 /@#  $< O !. +H 50"W %L M0!A +, 9P"R &T L !S
M *X >@"L (( J@"+ *@ E0"G *  I0"M *, O@"A -L H #T )\ _P"> /\
MGP#_ )T _P"; /\ _P   /P   #N    X    -    #%  @ O@ 0 +D &0"U
M ", LP N +  -P"M $  J@!( *@ 3P"E %4 HP!; *( 8 "@ &8 GP!L )T
M<P"; 'L F@"$ )@ C@"6 )H E0"G ), MP"1 ,P D #L (\ _P". /\ C@#_
M (X _P"/ /\ _    .\   #;    R0   +T   "U  ( K@ , *D $P"E !T
MH@ G *  ,0"= #H F@!" )@ 20"6 $\ E !5 ), 6P"1 &  D !G (X ;0"-
M '4 BP!^ (D B0"( )4 A@"B (4 L0"# ,0 @0#D (  ^0!_ /\ @ #_ (
M_P"  /\ ] (  . )  #'"   MP<  *P#  "F    H  ' )L #P"8 !< E0 A
M )( *@"/ #, C0 \ (L 0P") $D AP!0 (8 50"$ %L @P!A ($ : "  '
M?@!Y 'P A ![ )  >0"= '@ K !V +X =0#= ', ] !S /\ <P#_ ', _P!S
M /\ Z0T  ,\0  "Y$   J1   )X.  "7"P  DP8  )  "P", !$ B0 : (8
M) "# "X @0 V '\ /@!] $0 ? !+ 'H 40!Y %< =P!= '8 9 !T &P <P%U
M '$!@ !O HT ;@*: &P#J@!K [L :036 &@&\0!H!_\ 9P?_ &<'_P!G!_\
MWQ0  ,,7  "N%P  GA8  ),5  "+$@  AA   (0, @"#!@T @ ,4 'P%'@!Y
M!R@ =P@P '4(. !S"4  <@E& ' *3 !O"E, ;0M9 &P+80!J"VD :0QR &<,
M?@!F#(L 9 V9 &(-J0!A#;L 8 W8 %X.\P!=#O\ 70[_ %T._P!=#O\ U!P
M +D=  "D'@  E1T  (D<  "!&@  >Q<  '@3  !X$ 8 =PT/ ',.& !P#B(
M;@\K &P0,P!J$#L :1!" &<120!F$4\ 9!%6 &,270!A$F8 8!)O %X2>P!<
M$X@ 6Q.7 %D3IP!7%+H 5A35 %45\P!4%?\ 5!7_ %05_P!4%/\ RB(  + B
M  "=(P  C2,  ($B  !Y(0  <QX  &\;  !N%P  ;1,, &H4% !G%1X 918G
M &,6+P!A%S< 8!<^ %X810!=&$L 7!E2 %H96@!9&6( 5QIL %8:=P!4&H4
M4AN4 %$;I !/&[< 3AO0 $T<\0!,'/\ 3!S_ $T<_P!-&_\ PR8  *HG  "6
M)P  AR@  'LG  !R)@  ;"0  &@A  !F'@  9!L( &(;$0!?'!H 71TC %L>
M*P!:'C, 6!\Z %<?00!6($@ 5"!/ %,@5P!1(5\ 4"%I $XA= !-(8( 2R*1
M $DBH@!((K0 1R+- $8C[P!%(_\ 12+_ $8B_P!&(?\ O"H  *0K  "1*P
M@BP  '8K  !M*@  9BD  &(F  !?)   72($ %LA#@!8(A8 5B,? %0D* !3
M)#  4B4W % E/@!/)D4 3B9, $PF5 !+)UP 22=F $@G<0!&)W\ 12B/ $,H
MH !!*+( 0"C+ #\H[0 _*/\ /RC_ $ G_P! )_\ MRT  )\N  ",+P  ?2\
M '$O  !H+@  82T  %TK  !:*   5R<  %0G# !2*!, 4"D< $XI)0!-*BP
M2RHT $HK.P!)*T( 2"Q) $8L40!%+%H 1"QD $(M;P! +7T /RV- #TMG@ \
M+;  .BW( #HMZP Z+?\ .BW_ #HL_P Z+/\ LC   )LQ  "(,@  >3(  &TR
M  !D,@  73$  %@O  !5+   42P  $\M"0!,+1$ 2BX9 $DO(@!'+RH 1C Q
M $4P. !#,#\ 0C%' $$Q3P! ,5< /C%A #TR;0 [,GL .3*+ #@RG  V,J\
M-3+' #0RZ0 T,O\ -3'_ #4Q_P U,/\ K3,  )8T  "$-0  =34  &DU  !@
M-0  630  %0S  !0,   3#$  $DQ!@!',@\ 13,6 $,S'P!"-"< 0#0N #\U
M-@ ^-3T /35$ #PV3  Z-E4 .39? #<V:P V-G@ -#>) #(WF@ Q-ZT +S?%
M "\WZ  O-OX ,#7_ # U_P P-/\ J38  )(V  " -P  <C@  &8X  !=-P
M5C<  % V  !+-   1S4  $0V P!!-PT /S@4 #XX'  \.20 .SDL #HY,P Y
M.CH .#I" #8Z2@ U.E, -#M= #([:  P.W8 +SN' "T[F0 L.ZP *CO# "D[
MY@ J.OT *CK_ "LY_P L./\ I#@  (XY  !\.@  ;CH  &,Z  !:.@  4SH
M $TZ  !&.   0CH  #\[   \/ L .CP1 #@]&0 W/2$ -CXI #0^,  S/C<
M,C\_ #$_1P P/U  +C]: "U 9@ K0'0 *4"$ "A EP F0*H )4#! "1 Y0 D
M/_P )3[_ "8]_P F/?\ GSL  (H\  !X/0  :CT  %\]  !6/0  3ST  $D]
M  !"/0  /#X  #D_   V00@ -$$/ #)"%@ Q0AX +T,E "Y#+0 M0S0 +$0\
M "M$1  J1$T *$18 "=%8P E17$ (T6" ")%E0 @1:@ 'T6_ !Y$XP ?1/L
M'T/_ "!"_P A0?\ FCX  (4_  !T0   9T   %Q   !30   3$   $9    ^
M00  .$,  #1%   P1@, +4<- "M($@ J2!H *4@B "A)*0 G23$ )4DY "1)
M00 C2DH (DI5 "!*80 ?2F\ '4I_ !M*D@ :2J8 &$J] !=*X  82?H &4C_
M !I'_P :1_\ E4(  (!"  !P0P  8T,  %A#  !00P  24,  $)$   [10
M-4<  #!)   K2P  )DT) "1.$  B3A8 (4\= "!/)0 ?3RP 'D\U !U//0 <
M4$< &E!1 !E070 74&L %E!\ !10CP 34*0 $5"Z !%0W@ 13_@ $D[_ !--
M_P 43?\ CT4  'M&  !K1@  7T<  %5'  !-1P  1D<  #]'   W2@  ,4P
M "M.   F4   (%,# !Q5#  :5A$ &588 !=6(  65B< %58P !16.0 35T(
M$E=- !%760 05V@ #U=Y  Y7C  -5Z  "U>V  M6U  +5O0 #%7_  U4_P .
M4_\ B$D  '9*  !G2@  6TH  %%*  !*2@  0TH  #M,   S3@  +%$  "94
M   A5@  &UD  !5<!P 17@T $%X3 !!>&@ .7B( #EXJ  U>,P ,7CT "UY(
M  I>5  (7F( !UYS  5>A@ #7IL  EZQ  )=S  "7>X  US_  1;_P %6_\
M@4X  '!.  !B3@  5TX  $Y.  !'3@  /D\  #91   N5   )U<  "%:   ;
M70  %6   !!C P ,9@L "&<0  9G%0 %9QP !&<D  )G+0 !9S<  &="  !G
M3@  9UP  &=M  !G@   9I4  &:L  !EQP  9>L  &3\  !D_P  8_\ >E(
M &I3  !=4@  5%(  $M2  !"4P  .54  #!8   H6P  (5\  !IB   490
M$&@   QK 0 &;@D  &\.  !O$@  ;Q@  ' ?  !P)P  <3   '$[  !Q2
M<58  '%F  !Q>0  <8\  '"G  !OP0  ;^<  &[\  !M_P  ;?\ <U@  &57
M  !:5P  458  $97   \6@  ,ET  "IA   B9   &F@  !1L   .;P  "G(
M  1V    > 4  '@+  !Y#@  >A,  'L9  !\(   ?2D  'TS  !]0   ?4X
M 'U>  !]<@  ?8@  'RA  !\N@  >^(  'KZ  !Y_P  >/\ ;5T  &!<  !7
M7   2UT  $!?   U8P  *V<  "-K   :;P  $W,   YW   (>P   GX   ""
M    @P$  (0&  "%"P  A@\  (@3  ")&0  BB$  (LK  "+-P  C$8  (M6
M  "+:0  BX   (N9  "*LP  B=@  (CW  "(_P  A_\ :&,  %YB  !18@
M1&4  #AI   N;@  )',  !IX   3?0  #8$   :%    B0   (T   "0
MD@   )(   "4!0  E0H  )<.  "8$@  FA@  )LA  "<+0  G3P  )U,  "<
M7P  G'8  )N1  ";JP  FLD  )KP  "9_P  F/\ 96D  %=I  !);   /7$
M #!V   E?   &X$  !*'   ,C   !)$   "5    F0   )T   "@    H0
M *(   "D    I0$  *<'  "I#   JA$  *T8  "O(@  KS   *]!  "O5
MKVL  *Z%  "NH0  KKX  *WF  "L_   K/\ 7G$  $]T  !">0  -7\  "B%
M   =C   $Y(   R8   #G0   *(   "F    J@   *X   "P    L0   +,
M  "T    M@   +@   "Z!   O H  +X0  #!%P  PR0  ,,U  #$20  Q%X
M ,5W  #%DP  Q:\  ,71  ##\@  P_\ 5GP  $>"   ZB   +(\  ""6   4
MG0  #:,   .I    K@   +(   "W    NP   +\   #"    P@   ,4   #&
M    R    ,H   #-    SP   -((  #5#@  VQ@  -TG  #>.@  WU   .!H
M  #@A   X:$  .&]  #AX@  X/0 3HL  $"2   RF0  ):$  !BH   .KP
M!;4   "Z    OP   ,0   #(    S@   -$   #4    U0   -@   #:
MW0   -\   #B    Y    .<   #K!0  [PX  /09  #U*P  ]D$  /=8  #X
M<@  ^9   /FK  #XQ   ^.$ _P + /\ " #_  D _P , /\ $@#_ !H _P F
M /\ ,@#_ #X _P!( /\ 4@#_ %H _P!B /\ :0#_ &\ _P!U /X >P#\ ($
M^P"( /D CP#W )< ]0"@ /, J@#R +< [P#) .T Y@#L /L ZP#_ .L _P#=
M /\ S@#_ ,8 _P#" /\ _P $ /\   #_    _P % /\ #0#_ !4 _P A /\
M+ #_ #@ _P!# /T 3 #Y %0 ]P!< /0 8P#R &D \ !O .X =0#L 'L Z@""
M .@ B0#G )$ Y ": .( I #@ +  W0#  -H W #8 /0 U0#_ -, _P#+ /\
MP0#_ +L _P"W /\ _P   /\   #_    _P   /\ "@#] !$ ^0 ; /8 )P#T
M #( \  \ .P 1@#H $X Y !6 .$ 7 #> &, W !H -D ;@#5 '0 T@![ -
M@@#- (H RP"3 ,@ G0#& *@ Q "W ,$ S #  .L O@#_ +T _P"] /\ M #_
M *X _P"K /\ _P   /\   #_    ^@   /( !0#J  X Y0 6 .  (0#= "L
MVP V -, /P#. $@ R@!/ ,< 5@#$ %P P@!A ,  9P"^ &T O !S +H >@"X
M (( M@"+ +0 E@"R *$ L "O *X P0"M .  JP#W *H _P"I /\ I@#_ *$
M_P"? /\ _P   /\   #W    Z    -P   #0  H R@ 1 ,4 &P#" "4 OP O
M +P . "X $$ M0!( +( 3P"P %4 K@!; *P 80"J &8 J !L *< <P"E 'L
MHP"$ *$ C@"? )H G0"G )L N ": -  F0#O )@ _P"7 /\ E@#_ )0 _P"2
M /\ _P   /8   #D    T@   ,4   "[  4 M0 . +  %0"L !\ J@ I *@
M,@"E #H H@!" *  20"> $\ G !5 )H 6@"8 &  E@!F )4 ; "3 '0 D@!]
M )  AP". ), C "A (L L "* ,4 B #F (< ^P"& /\ AP#_ (< _P"& /\
M^    .4   #-    O0   +,   "J    HP * )\ $0"; !D F0 C )< + "5
M #0 D@ \ )  0P". $D C !/ (H 5 ") %H AP!@ (8 9@"$ &X @P!W ($
M@0!_ (T ?@"; 'P J@![ +P >@#; '@ ]0!X /\ > #_ '@ _P!X /\ [0
M -$"  "[ @  K $  *(   ";    E@ % )$ #0"- !0 BP = (@ )@"& "X
MA  V (( /0"  $, ?@!) 'T 3P!\ %4 >@!; 'D 80!W &D =0!Q '0 ? !R
M (@ <0"6 &\ I0!N +8 ;0#. &P [@!K /\ :P#_ &L _P!K /\ WPL  ,(,
M  "N#   G@P  ),+  ",!P  B (  (4 "0"! !  ?P 7 'P ( !Z "@ >  P
M '8 . !T #X <P!$ '$ 2@!P %  ;@!6 &T 70!L &0 :@!M &@ =P!G (0
M90"2 &0 H0!C +( 80#) &  Z0!@ /P 8 #_ &  _P!@ /\ T!   +81  "B
M$@  DQ(  (@1  " #P  ? T  'D) 0!X PL =0 1 ', &@!P ", ;@$K &P!
M,P!J CD :0-  &<#1@!F!$P 9012 &,%60!B!6$ 8 5J %\&= !=!H$ 7 >/
M %H'GP!9![  5P?& %8)YP!6"OL 50K_ %4*_P!6"O\ QA4  *T7  "9&
MBA@  '\7  !V%@  <1,  &X0  !M#04 ;0D- &H)% !G"AT 90HF &,++@!B
M##4 8 P\ %\,0@!>#4@ 7 U/ %L-5@!9#5X 6 YH %8.<P!5#H  4PZ/ %$.
MGP!0#K$ 3@[( $T0Z@!-$/T 31#_ $T0_P!-$/\ O!L  *4<  "2'0  @QX
M '<=  !O'   :1H  &87  !D%   9! ( &(/$ !?$!@ 71 A %L1*0!:$3$
M6!(X %<2/@!6$D4 5!), %,34P!1$UL 4!-E $X4< !,%'T 2Q2, $D4G !'
M%:X 1A7% $45Z !%%OX 11;_ $45_P!%%?\ M1\  )XA  "+(@  ?"(  '$B
M  !H(0  8A\  %\=  !<&@  6Q<" %H5#0!7%A0 518= %07)0!2&"T 41@T
M $\8.P!.&4( 31E( $L:4 !*&E@ 2!IB $<:;0!%&WH 0QN) $(;F@! &ZP
M/QO" #X<Y0 ]'/P /AS_ #X;_P ^&_\ KR,  )@D  "&)0  =R8  &PF  !C
M)0  720  %DB  !6'P  5!T  %,<"P!1'!( 3AT: $T=(@!+'BD 2AXQ $D?
M-P!''SX 1B!% $4@30!#(%4 0B!? $ A:@ _(7< /2&' #LAF  Y(:H ."+
M #<BXP W(OL -R+_ #@A_P X(?\ JB8  )0G  "!*0  <RD  &<I  !?*0
M6"@  %0F  !1(P  3R(  $PB!P!*(A  2"(7 $<C'P!%)"8 1"0N $(D- !!
M)3L 0"5# #\E2@ ])E, /"9< #HF9P Y)G4 -R>$ #4GE@ T)Z@ ,B>^ #$G
MX0 Q)_D ,B;_ #(F_P S)?\ I2D  (\J  !]+   ;RP  &0M  !;+   52L
M % J  !,*   2B8  $<G! !$)PT 0B@4 $$H'  _*2, /BDK #TI,@ \*CD
M.RI  #DJ2  X*U  -BM: #4K90 S*W( ,2N" # LE  N+*< +"R\ "LLW@ L
M+/@ +"O_ "TJ_P M*O\ H2P  (LM  !Y+@  :R\  & O  !8+P  42X  $PN
M  !(+   12L  $$K   _+ L /2P1 #LM&0 Z+B$ .2XH #<N+P V+S8 -2\^
M #0O10 S+TX ,3!8 # P8P N,'  +#"  "HPD@ I,*4 )S"Z "8PW  F,/<
M)R__ "@O_P H+O\ G"X  (<P  !V,0  :#(  %TR  !5,@  3C$  $@Q  !$
M,   0"\  #PP   Z,0D -S$0 #8R%@ U,AX ,S,E #(S+  Q,S, ,#0[ "\T
M0P M-$P +#16 "HU80 I-6X )S5^ "4UD  C-:, (C6Y "$UV0 A-/8 (C3_
M ",S_P C,O\ F#$  (,S  !R-   930  %HU  !1-0  2S0  $4T  ! -
M.C,  #<T   T-08 ,C8. # W$P O-QL +C<B "TX*0 K.#$ *C@X "DY0  H
M.4D )CE3 "4Y7P C.6P (3I\ " ZC@ >.J( '#JW !LYU0 <.?4 '3C_ !TX
M_P >-_\ DS0  '\V  !N-P  83<  %<W  !.-P  2#<  $(W   \-P  -3@
M #(Y   O.@( +#L+ "H\$0 I/!@ *#T? "8])@ E/2X )#TU ",^/0 B/D8
M(#Y0 !\^7  =/VD &S]Y !H_C  8/Z  %C^U !4^T@ 6/O, %SW_ !@\_P 8
M//\ CC<  'HX  !J.0  7CH  %,Z  !+.@  13H  #\Z   Y.@  ,CP  "X^
M   I0   )D$( "1"#@ B0A0 (4(; "!#(P ?0RH 'D,R !Q#.@ ;1$, &D1-
M !A$60 71&< %41W !-$B@ 21)X $42S !!$T  00_( $4+_ !)"_P 30?\
MB3L  '8\  !F/0  6CT  % ]  !(/0  0CT  #P]   V/@  +T   "I"   E
M1   (48# !U(#  ;21$ &4D7 !A)'@ 7228 %DDN !5*-@ 42D  $TI* !%*
M5@ 02F0 #TIT  Y*AP -2IL #$JP  I*R@ +2>P #$C_  U'_P -1_\ @SX
M '$_  !B0   5D   $U   !%0   /T   #E!   R0@  *T4  "9'   A20
M'$L  !9.!P 34 X $E 3 !%0&0 04"$ #U I  Y0,0 -4#L #5%&  M140 *
M45\ "5%O  =0@0 %4)8  U"K  )0Q0 #3^@  T_[  5._P &3?\ ?4(  &M#
M  !=1   4D0  $I$  !#0P  /$0  #5%   N1P  )TH  "%,   <3P  %U$
M !)4 P .5PH "U@0  I8%0 (6!P !U@D  98+  %6#8  UA   %83   6%H
M %AI  !8?   6)$  %>G  !7P   5N4  %;Y  !5_P  5?\ =D<  &9'  !9
M2   3T<  $='  ! 1P  .$@  #!*   I30  (E   !Q3   650  $5@   U;
M @ )7@D !%\.  !?$@  7Q@  & ?  !@)P  8#   & [  !@1P  8%0  &!C
M  !@=@  8(L  %^B  !?NP  7^(  %[Y  !=_P  7?\ ;TL  &%,  !53
M3$L  $1+   [3   ,DX  "M1   C5   '%<  !9;   17@  #6    AC   "
M9@<  &<,  !G#P  :!,  &D9  !J(0  :BD  &HT  !J0   :DT  &I=  !J
M;P  :H4  &J=  !IM@  :-T  &CW  !G_P  9O\ :5$  %Q0  !24   2D\
M #]0   U4P  +58  "19   =70  %F   !!D   ,9P  !FH   !N    ;P,
M ' (  !Q#0  <A   '04  !U&P  =B,  '<L  !W.   =D8  '96  !V:
M=GX  ':7  !UL0  =-,  '/U  !S_P  <O\ 8U8  %A5  !05   1%4  #E8
M   O6P  )E\  !UC   59P  $&P   IP   $<P   '8   !Z    ?    'P#
M  !^"   ?PP  ($0  ""%   A!L  (4D  "&+P  ACT  (9-  "%7P  A74
M (6/  "$J0  @\D  (+Q  "!_P  @/\ 7UL  %9:  !)6P  /5X  #)A   G
M9@  'FL  !5P   .=0  "7D   %^    @0   (4   "(    B@   (L   "-
M 0  C@8  ) +  "1#P  DQ0  )4;  "7)@  ES0  )=$  "75@  EFP  )6&
M  "5H@  E,$  )/J  "2_P  DO\ 76$  $]A  !"9   -FD  "IN   ?=
M%7D   Y_   'A    (D   ".    D@   )8   "8    F@   )L   "=
MGP   *$#  "C"   I0T  *<3  "I'   JB@  *HY  "J2P  JF$  *EZ  "H
MF0  J+4  *?=  "G^   IO\ 5F@  $AL   Z<   +G8  ")]   7A   #HH
M  >0    E@   )H   "?    HP   *<   "J    JP   *T   "O    L0
M +,   "U    N 4  +H,  "]$@  P!P  , M  # 0   OU4  +]N  "^BP
MOJ@  +[)  "][P  O/X 3G0  $!Y   R?P  )8<  !F.   0E0  !YP   "B
M    IP   *P   "P    M0   +D   "\    O0   +\   #!    PP   ,8
M  #(    R@   ,T"  #0"P  U1(  -8A  #7-   V$D  -E@  #:?   VIH
M -NU  #;V0  V_( 1H(  #B)   KD   '9@  !*@   *IP   *X   "T
MN0   +X   #"    R    ,L   #.    SP   -(   #4    U@   -H   #=
M    WP   .(   #F    Z@H  .\3  #P)0  \CH  /-1  #T:P  ](D  /6E
M  #UOP  ]=T _P & /\  P#_  4 _P + /\ $ #_ !< _P B /\ +0#_ #D
M_P!$ /\ 30#_ %4 _P!= /\ 9 #_ &H _P!P /T =@#[ 'P ^0"# /< B@#U
M )( \P"; /  I@#N +, ZP#$ .D Y #G /D Y@#_ .4 _P#3 /\ QP#_ +\
M_P"[ /\ _P   /\   #_    _P " /\ "P#_ !( _P = /\ * #_ #, _P ^
M /P 1P#X $\ ] !7 /$ 70#N &, [ !I .H ;P#H '4 Y@!\ .0 @P#B (L
MWP"5 -P GP#9 *L U0"[ -( U #/ /( S0#_ ,P _P#% /\ N@#_ +0 _P"P
M /\ _P   /\   #_    _P   /\ !@#Y  \ ]0 7 /, (@#Q "T [0 W .<
M0 #B $D WP!0 -L 5P#7 %T U !C -$ : #/ &X S !U ,H ? #( (0 Q0"-
M ,( F #  *0 O0"R +L Q@"Y .@ N #] +< _P"V /\ K0#_ *< _P"C /\
M_P   /\   #_    ]0   .L  0#D  P W@ 3 -D ' #3 "8 T0 P ,P .@#(
M $( Q !* ,  4 "] %8 NP!< +D 80"W &< M0!M +, = "Q 'P KP"% *T
MD "J )P J "J *8 NP"E -H HP#U *, _P"B /\ G@#_ )H _P"7 /\ _P
M /X   #O    WP   -    #'  < P0 / +P %P"Y "  MP J +4 ,P"P #L
MK0!# *L 20"H $\ I@!5 *0 6@"C &  H0!F )\ ;0"= '0 G !] )H B "8
M )0 E@"B )0 L@"2 ,D D0#K )$ _P"0 /\ D #_ (P _P"* /\ _    .P
M  #9    QP   +H   "Q  ( JP , *< $@"D !L H0 D *  + "> #4 FP \
M )@ 0P"6 $D E !/ )( 5 "0 %H CP!? (T 9@"+ &T B0!V (@ @ "& (P
MA ": (( J@"! +X @ #@ (  ^0!_ /\ ?P#_ '\ _P!^ /\ \0   -@   #"
M    LP   *@   "@    F0 ' )4 #@"2 !4 D  > (X )@"- "X B@ V (<
M/0"% $, A !) (( 3@"! %0 ?P!9 'X 8 !\ &< >@!O 'D >@!W (8 =0"4
M '0 HP!R +4 <@#/ '$ \0!P /\ < #_ '  _P!Q /\ X0   ,0   "P
MH@   )<   "1    BP " (8 "P"# !$ @0 8 '\ (0!] "D ?  P 'D -P!X
M #T =@!# '0 20!S $X <@!4 '  6@!O &( ;0!J &L = !J (  : ". &<
MG0!E *\ 90#& &0 Z !D /T 8P#_ &, _P!D /\ SP4  +8'  "C"   E @
M (D'  "" P  ?@   'L !@!W  X =0 3 '( &P!Q ", ;P K &T ,@!L #@
M:@ ^ &D 1 !G $D 9@!/ &4 5@!C %T 8@!E &  ;P!? 'L 70") %P F0!;
M *H 60"_ %D X0!8 /@ 6 #_ %@ _P!9 /\ P@P  *H-  "7#@  B0X  'T.
M  !V#0  <0H  &\&  !M  H :P 0 &D %@!G !X 90 F &, +0!A #, 8  Y
M %\ /P!= $4 7 !+ %L 4@!: %D 6 !B %< ; !5 '@ 4P"& %( E@!1 *<
M4 "[ $\!VP!. O0 3@/_ $X$_P!. _\ N!   *$2  ".$P  ?Q,  '03  !L
M$@  9Q   &4.  !C"P, 8P8, &$$$0!> QD 7 0A %L%* !9!B\ 6 8U %8'
M.P!5!T( 5 =( %,(3P!1"%8 4 E? $X):0!-"78 2PJ$ $D*E !("J8 1PJZ
M $8*V !%"_, 10S_ $4,_P!%#/\ L!0  )D6  "'&   >!D  &T8  !E%P
M7Q8  %P3  !:$0  6@X& %H,#0!7#!0 50P< %,-) !2#2L 4 TQ $\.. !.
M#CX 30Y% $L.30!*#E4 2 ]> $</: !%#W4 0Q"$ $$0E0! $*8 /A"[ #T0
MW  ]$?8 /1'_ #T0_P ^$/\ J1D  )(;  "!'   <AT  &<=  !?'   61L
M %49  !3%@  4A,  %(1"@!0$!  3A$8 $P1( !*$B< 21(N $@3- !'$SL
M11-" $0320!#%%( 011; #\490 ^%7( /!6! #H5D@ X%:0 -Q6Y #45V  U
M%O4 -A;_ #86_P W%?\ HQP  (T>  ![(   ;2$  &(A  !:(0  5!\  % >
M  !-&P  3!D  $L6!@!)%@X 1Q<5 $47' !$&"0 0A@J $$8,0! &3@ /QD_
M #T91@ \&D\ .AI8 #D:8P W&V\ -1M^ #,;D  R&Z( ,!NW "\;TP O'/,
M+QO_ # ;_P P&_\ G1\  (@B  !W(P  :20  %XD  !6)   4",  $LB  !(
M(   1AT  $4< @!#' P 01P2 #\=&0 ^'2$ /!XG #L>+@ Z'S4 .1\\ #<?
M1  V'TP -"!6 #,@8  Q(&T +R!\ "TAC@ L(:  *B&U "DAT  I(?( *2'_
M "H@_P K(/\ F2(  (0E  !S)@  92<  %LG  !3)P  3"8  $<E  !$)
M0B$  #\A   ](0D .R$0 #DB%@ X(AX -B,E #4C*P T)#( ,R0Y #(D00 P
M)$H +R53 "TE7@ K)6L *B5Z "@EC  F)9\ )"6S ",ES@ C)?  )"7_ "4D
M_P E)/\ E"4  ( G  !O*0  8BH  %<J  !/*@  22D  $0H  ! )P  /28
M #HE   W)@8 -28. #0G%  R)QL ,2@B # H*0 O*#  +2DW "PI/P K*4<
M*2E1 "@J7  F*FD )"IX ",JB@ A*IT 'RJR !XJS  >*N\ 'RG_ " I_P A
M*/\ D"@  'PJ  !L*P  7RP  %0L  !,+   1BP  $$K   \*P  ."H  #4J
M   R*P, ,"L, "XL$0 M+!@ +"P? "HM)@ I+2T *"TT "<N/  F+D4 )"Y/
M ",N6@ A+V< 'R]V !TOB  <+YL &B^P !@OR@ 8+NT &2[_ !LM_P ;+?\
MC"L  '@M  !H+@  6R\  %$O  !)+P  0R\  #XN   Y+@  -"X  # N   M
M+P  *S * "DQ$  G,14 )C$< "4R(P D,BH (S(Q "$S.0 @,T( 'S-, !TS
M5P ;,V0 &C1T !@TA@ 6-)H %#.N !,SR  3,^P %#/_ !4R_P 6,?\ ARX
M '0O  !E,0  6#$  $XR  !&,@  0#$  #LQ   V,0  ,3$  "LS   H-
M)34& ",V#0 A-A( (#<9 !\W(  >-R< '3@N !LX-@ :.#\ &3A) !<Y50 5
M.6( %#EQ !(YA  1.9@ $#FM  XXQP ...L $#C_ ! W_P 1-O\ @S$  ' R
M  !A-   530  $LT  !$-   /30  #@T   S-   +34  "@W   D.0  (#H"
M !T["P ;/!  &3T5 !@]'  7/2, %CTK !4^,P 4/CP $CY& !$^4@ 0/E\
M#SYO  X^@0 ,/I4 "SZI  H^P0 */>0 "SW[  P\_P -._\ ?30  &LV  !=
M-P  43<  $@W  !!-P  .S<  #4W   P-P  *CD  "4[   @/0  '#\  !=!
M!@ 40PT $D,2 !%#&  10Q\ $$0G  ]$+P .1#D #41#  Q$3@ +1%L "41J
M  =$?  &1)  !$.E  )#O0 #0^   T/V  1"_P &0?\ >#@  &<Y  !9.@
M3CH  $4Z   ^.@  .#H  #,Z   M.P  )ST  "%    <0@  %T0  !-& P /
M20H #4H/  Q*%  +2AL "4HC  A**P '2C0 !4H^  1*20 "2E8  $IE  !*
M=P  2HL  $JA  !)N0  2=T  $GU  !(_P  2/\ <CP  &(]  !5/@  2CX
M $(]   \/0  -CT  "\^   I0   (T(  !U%   71P  $TH   ], @ +3PD
M!U -  -1$0  41<  %$>  !1)@  42\  %$Y  !11   4E$  %)@  !1<@
M48<  %&=  !1M0  4-@  %#U  !/_P  3_\ ;$   %U!  !100  1T$  $!
M   Y0   ,D$  "I#   D1@  'D@  !=+   23@  #E$   M3 0 &5@<  %<,
M  !8$   6!,  %D9  !:(0  6BD  %HS  !:/P  6DP  %I:  !:;   6H$
M %F9  !9L0  6-$  %CT  !7_P  5_\ 944  %A%  !-10  140  #Y$   U
M10  +4<  "5*   >30  &%   !)3   .5@  "ED   1<    7@0  %\)  !@
M#0  81   &(5  !C&P  9",  &0M  !D.   9$4  &14  !D9@  9'L  &.3
M  !CK0  8LP  &'R  !A_P  8/\ 7TH  %-*  !*20  0T@  #E)   O3
M)T\  !]2   850  $ED   U=   (8    F,   !F    : $  &D%  !J"@
M:PT  &T1  !N%@  <!T  '$F  !Q,0  <#X  '!.  !P7P  <',  &^-  !O
MIP  ;L8  &WO  !L_P  ;/\ 6D\  %!.  !(30  /4X  #-1   I5   (%@
M !A<   18   #&0   9H    :P   &\   !R    =    '4   !W!   > D
M 'H-  !\$   ?18  '\>  " *   @#4  (!%  !_5@  ?VL  '^$  !^H
M?;X  'SI  ![_P  >O\ 5E0  $Y3  !"5   -U8  "Q:   B7P  &&,  !%H
M   +;0   W(   !V    >@   'T   "     @P   (0   "&    AP(  (D'
M  "+#   C1   ) 6  "2'P  DBP  )([  "230  D6(  )%Z  "/EP  C[0
M ([A  ",^P  C/\ 55D  $A:   [70  +V$  "1F   9;   $7(   IW   "
M?0   ((   "&    BP   (X   "1    DP   )4   "7    F0   )L   "=
M!   GPH  *(/  "D%@  IB$  *8Q  "F0P  I5<  *1P  "CC@  HZL  *'0
M  "@]0  G_\ 3F$  $!D   S:0  )VX  !MU   1?   "X,   ")    C@
M ),   "8    G0   *$   "D    I0   *<   "I    JP   *T   "P
ML@   +4(  "X#@  O!8  +PE  "\-P  NTP  +ID  "Y@0  MZ(  +?   "W
MZ@  M_P 1FL  #EP   K=P  'W\  !.&   +C@   94   ";    H0   *8
M  "K    L    +,   "W    MP   +H   "\    OP   ,$   #$    QP
M ,H   #-!0  T0X  -09  #4*P  U$   --8  #3=   TY(  -*P  #2TP
MTO( /GD  #&    CB   %Y$   V9   #H    *<   "N    LP   +@   "]
M    P@   ,8   #*    R@   ,T   #/    T@   -4   #9    W0   -\
M  #C    YP4  .L/  #L'P  [3,  .Y+  #O9   [X(  /"?  #QN0  \=@
M_P   /\   #_  0 _P ) /\ #@#_ !4 _P > /\ *0#_ #0 _P _ /\ 2 #_
M %  _P!8 /\ 7@#_ &4 _0!K /L <0#Y '< ^ !^ /8 A0#S (T \0"7 .X
MH@#K *\ Z #  .8 X #C /@ X@#_ -L _P#+ /\ P0#_ +D _P"T /\ _P
M /\   #_    _P   /\ "0#_ !  _P 9 /\ (P#_ "X _0 Y /D 0@#U $H
M\@!2 .X 6 #K %X Z0!D .8 :@#D '  X@!V -\ ?0#= (8 V0"/ -4 F@#1
M *< S@"V ,L S@#) /  QP#_ ,4 _P"[ /\ M #_ *T _P"I /\ _P   /\
M  #_    _P   /L  @#V  T \0 3 .T '@#L "@ Z0 R ., .P#= $0 V !+
M -, 40#0 %@ S0!= ,L 8P#) &@ Q@!O ,0 =@#" 'X OP"' +P D@"Z )\
MMP"M +4 P0"R .0 L0#] *\ _P"L /\ I0#_ *  _P"< /\ _P   /\   #[
M    [@   .0   #<  @ TP 0 ,\ & #+ "( R0 K ,8 - #! #T O0!$ +H
M2P"W %$ M0!6 +( 7 "P &$ K@!G *P ;@"J '8 J !_ *8 B@"C )8 H0"E
M )\ M@"= -$ G #S )L _P"< /\ E@#_ ), _P"0 /\ _P   /8   #G
MTP   ,8   "]  , N  - +, $P"Q !P KP E *X +@"I #8 I@ ] *, 1 "A
M $H GP!/ )T 50"; %H F@!@ )@ 9@"6 &X E !W )( @0"0 (X C@"< (P
MK0"* ,, B0#H (@ _P") /\ AP#_ (4 _P"" /\ \P   .,   #,    O
M +    "G    H0 ( )X #P"; !8 F0 ? )@ )P"6 "\ DP W )$ /0". $,
MC !) (L 3@") %0 AP!9 (4 8 "$ &< @@!O (  >@!^ (8 ? "4 'H I !Y
M +@ > #8 '< ]P!X /\ > #_ '< _P!U /\ Y@   ,L   "W    J    )X
M  "6    CP $ (L # "( !( AP 9 (4 (0"$ "D @@ P '\ -P!] #T ? !#
M 'H 2 !Y $T =P!3 '8 60!T &$ <@!I '$ <P!O '\ ;0"- &P G0!J *\
M:0#( &@ [0!I /\ :0#_ &D _P!I /\ T@   +@   "E    EP   (T   "&
M    @0   'P " !Y  X =P 4 '8 ' !T ", <P K '$ ,0!O #< ;@ ] &P
M0P!K $@ :@!. &@ 5 !G %L 90!C &, ;0!B '@ 8 "' %\ E@!= *@ 70"^
M %P Y !< /L 7 #_ %P _P!< /\ P@   *H!  "8 P  B00  '\"  !X
M=    '  ! !M  P :P 1 &D %P!H !X 9@ E &4 + !C #( 8@ X &  /0!?
M $, 7@!) %P 3P!; %8 6@!> %@ : !7 ', 50"! %0 D0!2 *, 40"W %$
MU@!1 /4 40#_ %$ _P!2 /\ M@<  )\)  "-"P  ?@P  ',+  !L"@  : <
M &4#  !C  < 80 - %\ $P!= !H 7  A %L )P!9 "T 6  S %8 .0!5 #\
M5 !% %, 2P!1 %( 4 !: $\ 9 !- &\ 3 !] $H C0!) )\ 2 "R $< S !'
M .\ 1@#_ $< _P!' /\ K P  )4.  "#$   =1   &L0  !C#P  7@X  %L,
M  !:"0( 600* %< #P!5 !4 4P < %( (P!1 "D 3P O $X -0!- 3L 3 %!
M $H"2 !) D\ 2 )7 $8#80!% VT 0P-Z $(#BP!  YP /P.O #X#R  ]!.H
M/07\ #T&_P ^!O\ I!   (X2  !\$P  ;A0  &04  !<$P  5A(  %,1  !1
M#@  4 P% % )# !/!Q$ 30<7 $L('P!)""4 2 DK $<),0!&"3@ 1 H^ $,*
M10!""DT 0 M5 #\+7P ]"VL / MY #H,B@ X#)P -PRO #4,QP U#.D -0W]
M #4-_P V#/\ G1,  (<5  !V%P  :1@  %X8  !6&   4!<  $T5  !*$P
M21$  $D.!P!(#0X 1@T3 $0-&@!##B$ 0@XH $ .+@ _#C4 /@\\ #T/0P [
M$$L .A!4 #@07@ V$&L -!!Y #(0B@ Q$)P +Q"P "T0R0 M$>P +1'_ "X1
M_P O$/\ EQ8  ((9  !Q&P  9!P  %D<  !1'   3!L  $<:  !$&   0Q4
M $(3 @!!$@L 0!$0 #X2%P \$AX .Q,E #H3*P X$S( -Q,Y #840  T%$@
M,Q11 #$47  P%6@ +A5W "P5B  J%9H *!6N "<5QP F%>H )Q7_ "@5_P I
M%?\ D1H  'T<  !M'@  8!\  %8?  !.'P  2!X  $,=  ! '   /AH  #T8
M   [%P< .18. #@7%  V%QL -1@B #,8*  R&"\ ,1DV # 9/0 N&48 +1I/
M "L:60 J&F8 *!IT "8:A@ D&ID (AJM "$:Q0 @&N@ (1K^ "(:_P C&O\
MC1T  'D?  !I(0  7"(  %(B  !*(@  1"$  #\A   \(   .1X  #@;   U
M' 0 -!P- #(<$@ P'1@ +QT? "X=)0 M'BP *QXS "H>.P I'T, )Q]- "8?
M5P D'V0 (A]R " ?A  ?'Y< '1^K !L?PP ;'^< &Q_] !T?_P >'O\ B2
M '4B  !E(P  620  $\E  !')0  020  #PC   X(P  -2(  #,@   P( $
M+B$* "PA$  K(14 *B(< "@B(P G(BD )B,P "4C.  C(T$ (B1* "$D50 ?
M)&$ '21P !LD@@ 9))4 %R2J !8DP0 5).4 %B3\ !<C_P 9(_\ A2(  '$D
M  !B)@  5B<  $PG  !$)P  /B<  #DF   U)@  ,24  "XD   K)0  *24'
M "<F#@ E)A, )"<9 ",G(  B)R< (2@N " H-@ >*#X '2A( !LI4P 9*5\
M&"EN !8I@  4*90 $BFH !$IP  1*.0 $2C[ !,H_P 4)_\ @"4  &XG  !?
M*   4RD  $DJ  !"*0  .RD  #8I   R*   +B@  "HH   F*0  )"H$ "(K
M#  @*Q$ 'RP6 !TL'0 <+"0 &RTK !HM,P 8+3P %RU% !8N4  4+ET $BYL
M !$N?@ 0+I( #BZG  TMO0 -+=\ #2WY  XL_P 0+/\ ?"@  &HJ  !;*P
M4"P  $8L   _+   .2P  #0K   O*P  *RL  "8L   B+@  'R\  !PP"0 :
M,0X &3$3 !<Q&@ 6,B$ %3(H !0R,  3,CD $C-# !$S3@ 0,UL #C-I  TS
M>@ ,,XX "C.B  @RN0 (,MD "#+T  HQ_P +,?\ =RL  &8M  !8+@  32\
M $,O   \+@  -BX  #$N   M+@  *2X  ",P   ?,@  &S,  !<U!0 4-@P
M$C<1 !$W%@ 1-QT $#@D  \X+  ..#4 #3@_  PX2@ +.%< "3AE  <X=@ %
M.(H  SB?  $WM0 !-],  C?Q  ,V_P %-O\ <RX  &(P  !4,0  23$  $$Q
M   Y,0  -#$  "\P   K,   )3(  " S   ;-@  %S@  !,Z @ 0/ D #3T.
M  P]$P +/1D "CTA  D]*0 (/3$ !CX[  4^1@ #/E(  3YA   ^<@  /H8
M #V<   ]L@  /=   #SP   \_P  //\ ;3(  %TS  !0-   1C0  #XT   W
M-   ,C,  "TS   G-   (C8  !TX   8.@  %#T  ! _ @ -00@ "4,-  9$
M$0 #1!8  D0=  !$)   1"T  $0V  !$00  1$X  $1<  !$;0  1($  $28
M  !#KP  0\T  $+P  !"_P  0O\ :#8  %@W  !,.   0S@  #LW   U-@
M,#8  "DW   C.0  'CL  !@]   30   $$(   U% 0 (1P<  TD,  !)#P
M2A,  $L9  !+(   2R@  $LR  !+/0  3$D  $Q7  !+:   2WT  $N4  !*
MK   2LH  $GO  !)_P  2?\ 8CH  %0[  !).P  0#L  #DZ   S.0  +#H
M "4\   ?/P  &4$  !-$   01P  #$D   A,   "3P4  % *  !0#0  41
M %(5  !4&P  5",  %0L  !4-P  5$0  %12  !48P  5'<  %2/  !3J
M4L8  %+M  !1_P  4?\ 7#\  $\_  !%/P  /CX  #<]   O/@  )T   "!#
M   91@  $TD   ],   +3P  !E(   !4    5P(  %@'  !9"P  6@X  %L1
M  !=%@  7AT  %\F  !?,0  7CT  %Y,  !>70  7G$  %V)  !=HP  7,$
M %OK  !:_P  6O\ 5D0  $M#  !#0@  /$$  #)"   I10  (4@  !I+   3
M3@  #E(   I5   #60   %L   !>    8    &("  !C!@  90H  &8.  !H
M$0  :A<  &L?  !K*0  :S8  &M%  !K5@  :FH  &J"  !IG0  :+L  &?G
M  !F_P  9?\ 44@  $A(  !!1@  -T<  "Q*   C30  &U$  !-5   .60
M"%T   %A    9    &<   !J    ;    &X   !P    <@4  ',)  !U#0
M=Q$  'H8  ![(0  >RX  'H]  !Z3@  >6(  'EY  !XE@  =[,  '7@  !T
M_   <_\ 3DT  $=,   [30  ,$\  "93   <6   $UP   UA   &9@   &H
M  !O    <@   '8   !Y    ?    'T   !_    @0   (,"  "&!P  B P
M (L1  ".&   CB0  (XS  "-1   C%@  (MO  "*C   B:H  (C/  "&]P
MA?\ 35$  $%3   T50  *5H  !Y?   490  #6H   5P    =@   'L   !_
M    @P   (<   "*    C0   (X   "1    DP   )4   "8    F@4  )T,
M  "@$0  HQH  *,H  "B.@  H4X  *!E  "@@0  GJ   )W!  ";[@  FO\
M1ED  #E<   M80  (6<  !9N   .=0  !7L   "!    AP   (T   "2
ME@   )H   "=    GP   *$   "D    I@   *@   "K    K@   +$#  "T
M"P  N!$  +D>  "Y+P  N$,  +=:  "U=@  M)<  +2U  "QX@  L/P /V0
M #%I   E;P  &'<   ]_   &AP   (X   "4    F@   *    "E    J@
M *X   "Q    L@   +4   "W    N@   +P   "_    PP   ,8   #)
MS@H  -(3  #2(P  T3<  -!/  #.:@  S8H  ,JK  #+RP  R^\ -W$  "EX
M   =@   $8D   B1    F@   *$   "G    K0   +,   "Y    O@   ,(
M  #%    Q@   ,D   #,    S@   -(   #5    V@   -X   #A    Y0
M .H+  #K%P  ZBL  .I#  #J7@  ZGH  .N9  #KM0  Z]4 _P   /\   #_
M  $ _P ' /\ #0#_ !( _P ; /\ )0#_ "\ _P Z /\ 0P#_ $L _P!3 /\
M6@#] &  ^P!F /H :P#X '( ]@!X /0 @ #Q (D [P"2 .P G0#I *H Y@"\
M ., W #? /< W0#_ ,P _P"^ /\ M0#_ +  _P"M /\ _P   /\   #_
M_P   /\ !@#_  T _P 4 /\ 'P#_ "D ^P S /< /0#S $4 [P!- .P 4P#H
M %D Y0!? ., 90#@ &H W0!Q -H > #6 (  T@"* ,\ E0#, *( R "R ,4
MR0#" .T P #_ +L _P"P /\ J #_ *0 _P"A /\ _P   /\   #]    ^@
M /@   #P  D [  1 .@ &0#G ", Y0 M -X -@#6 #X T0!& ,T 3 #* %(
MR !8 ,4 70## &, P !I +X < "\ '@ N0"! +< C0"T )H L0"I *X O "L
M .$ J@#\ *@ _P"@ /\ F0#_ )8 _P"4 /\ _P   /D   #R    YP   -L
M  #1  0 R@ - ,< % #$ !T P@ F +\ +P"[ #< MP _ +0 10"Q $L K@!1
M *P 5@"J %P J !A *8 : "C '  H0!Y )\ A "= )$ F@"@ )@ L0"6 ,P
ME0#Q )0 _P"1 /\ BP#_ (@ _P"& /\ ]P   .P   #>    R0   +P   "T
M    KP * *L $ "I !< J  @ *< * "B #  GP X )P /@": $0 F !* )8
M3P"4 %4 DP!: )$ 80"/ &@ C0!Q (L >P") (@ AP"7 (4 J "# +X @0#D
M (  _P"  /\ ? #_ 'L _P!Y /\ Z0   -<   #!    L0   *8   "=
MEP % )0 #0"2 !( D  : (\ (@". "H BP Q (D . "' #X A0!# (, 2 "!
M $X ?P!4 'X 6@!\ &$ >@!I '@ <P!V '\ =0". ', GP!Q +, < #0 &\
M]@!O /\ ;P#_ &T _P!L /\ V@   +\   "L    G@   ),   ",    A0
M (( "0!_  \ ?@ 5 'T ' !\ "0 >@ K '< ,0!U #< =  ] '( 0@!Q $@
M;P!- &X 4P!L %H :P!B &D ; !G '@ 9@"& &0 EP!B *H 80#" &  ZP!A
M /\ 80#_ &$ _P!@ /\ Q0   *T   ";    C0   (,   !\    =P   '(
M!0!P  P ;@ 1 &P %P!L !X :P E &D + !G #$ 9@ W &0 /0!C $( 8@!(
M &  3@!? %4 70!= %P 9@!: '( 60"  %< D !6 *, 50"Y %0 W@!4 /L
M5 #_ %4 _P!5 /\ M@   )\   "-    ?P   '4   !N    :0   &8  0!C
M  D 80 . &  $P!? !D 7@ @ %T )@!; "P 6@ R %@ -P!7 #T 5@!# %4
M20!3 %  4@!8 %$ 80!/ &P 3@!Z $P B@!+ )P 2@"Q $D S@!) /, 20#_
M $D _P!* /\ J@$  )0%  ""!P  = @  &H(  !C!@  7@0  %L   !9  4
M5P , %8 $ !4 !4 4P ; %( (@!1 "@ 4  M $X ,P!- #@ 3  ^ $L 10!*
M $P 2 !4 $< 70!& &@ 1 !U $, A0!! )@ 0 "K $  Q0 _ .H /P#_ $
M_P!  /\ H @  (H+  !Y#0  ; T  &$-  !:#0  50L  %()  !0!@  3P((
M $X #0!, !( 2P 7 $H '@!) ", 1P I $8 +P!% #0 1  Z $( 00!! $@
M0 !0 #X 6@ ] &0 / !R #H @@ Y )0 . "G #< O@ V ., -@#Y #8 _P W
M /\ F T  (,.  !R$   91$  %L1  !3$   3A   $H.  !(#0  1PH# $<'
M"@!%! X 1 (3 $("&@!! B  0 ,E #X#*P ]!#$ / 0W #L$/@ Z!44 .05.
M #<%5P V!6( - 9P #(&@  Q!I( , :E "\%NP N!=T +@;U "T'_P N!_\
MD1   'T1  !L$P  7Q0  %44  !.%   2!,  $02  !!$   0 X  $ -!@!
M"@P /@D0 #P)%@ ["AP .0HB #@**  W"RX -@LU #4+.P S"T, ,@Q, # ,
M5@ O#&$ +0QO "L,?P J#)( * RE "<,NP E#-T )0WU "8-_P G#?\ BQ(
M '<4  !G%@  6Q<  %$8  !)%P  0Q<  #\5   \%   .A(  #D1 0 Y#P@
M. X- #<.$@ U#A@ - X? #(.)0 Q#RP , \R "\0.@ M$$( +!!+ "H050 H
M$&$ )A!O "00@  C$), (1"G !\0O0 >$.  'A'W !\0_P @$/\ AA0  ',7
M  !C&0  5QH  $T;  !%&@  0!H  #L9   X&   -18  #04   S$@0 ,A(+
M #$2$  O$A4 +1(< "P3(@ K$RD *A,P "@3-P G%#\ )A1( "044P B%%\
M(!5M !\5?@ =%9$ &Q6E !D5NP 8%=X &!7X !D4_P :%/\ @A<  &\:  !?
M'   4QT  $H=  !"'0  /!T  #<<   T&P  ,1H  "\9   N%@  +!<( "L6
M#@ I%Q, *!<9 "<8(  E&"8 )!@M ",8-  B&3T (!E& !X940 =&5T &QIK
M !D:?  7&H\ %1JC !09N@ 2&=L $QGV !09_P 5&/\ ?1H  &L=  !<'P
M4"   $<@   _(   .1\  #0?   Q'@  +1T  "L<   I&P  )QL% "4;#  D
M'!$ (AP6 "$<'0 @'2, 'QTJ !X=,@ <'CH &QY$ !D>3@ 7'EL %AYI !0?
M>@ 2'HT $1ZB ! >N  .'M@ #Q[U ! =_P 1'?\ >AT  &<?  !9(0  32(
M $0B   \(@  -B(  #(A   N(0  *B   "<@   D'P  (B " " @"@ >(0\
M'2$4 !PA&@ ;(B$ &2(G !@B+P 7(C@ %2-! !0C3  2(U@ $2-G ! C>  .
M(XL #2.?  PCM  +(]  "R+P  PB_P -(?\ =A\  &0B  !6(P  2R0  $$D
M   Z)   -"0  "\C   K(P  *",  "0C   @(P  '20  !LE!P 9)@T %R81
M !8F%P 5)QX %"<E !,G+  2)S4 $2@_ ! H2@ .*%8 #2AD  PH=  **(<
M"2B;  <GL0 %)\P !B?L  <F_@ ()O\ <2(  & D  !3)@  2"<  #\G   W
M)@  ,28  "TF   I)0  )24  "(E   =)P  &2@  !8J!  4*PL $BP0 !$L
M%  0+!L $"PB  XL*0 .+3( #2T[  LM1@ *+5( ""U@  8M<  $+8,  BV8
M   LK@  +,D  "SK  $K_  "*_\ ;24  %TG  !/*   12D  #PI   U*0
M+R@  "LH   G)P  (R<  !\H   ;*@  %RP  !,N @ 0, @ #C$-  TQ$@ ,
M,1< "S$>  HQ)@ (,BX !S(W  4R0@ #,DX  3)<   R;   ,G\  #*5   Q
MK   ,<<  ##J   P_   ,/\ :"D  %@J  !,*P  02P  #DL   R*P  +2L
M "DJ   E*@  ("L  !PL   7+@  $S   ! R @ .- < "C<,  <W$  %-Q0
M S<;  (W(@  -RH  #@S   X/@  .$H  #A8   X:   .'P  #>2   WJ0
M-L4  #;J   V_0  -?\ 8RP  %0N  !(+P  /B\  #8N   P+@  *RT  "<M
M   B+0  '2\  !@Q   4,P  $#4   XW 0 *.@< !CL+  (\#@  /1(  #X7
M   ^'@  /B8  #XO   ^.@  /D8  #Y4   ^9   /G<  #Z/   ]IP  /<,
M #SI   \_0  ._\ 7C   % Q  !$,@  .S(  #0Q   N,   *2\  "0P   >
M,@  &30  !0V   0.0  #3L   H]   %0 4  $$*  !"#0  0Q   $04  !%
M&@  1B(  $8K  !&-0  1D$  $9/  !&7P  1G,  $6*  !%I   1,   $/H
M  !#_@  0O\ 6#0  $LU  !!-0  .34  #(T   M,P  )C0  " U   :.
M%#H  ! ]   -0   "4(   1%    1P,  $@'  !*"P  2PX  $P1  !.%0
M3QP  $\E  !/+P  3SP  $]*  !/6@  3FT  $Z%  !-H   3+P  $OG  !+
M_@  2O\ 4SD  $<Y   ^.0  -S@  #$W   I-P  (3D  !L\   5/P  $$(
M  Q%   '2    DH   !-    3P   %$$  !2!P  5 L  %4.  !7$0  61<
M %H?  !9*0  638  %E$  !95   6&<  %A_  !7F@  5K<  %7C  !4_0
M5/\ 3CT  $,]   \/   -3L  "P\   D/@  '$$  !5$   02   "TL   5.
M    40   %0   !7    60   %L   != @  7@8  & +  !B#@  9!(  &<8
M  !G(@  9BX  &8\  !F30  96   &5W  !DDP  8[$  &'=  !@_   7_\
M24(  $%!   Z/P  ,$   "9#   >1@  %4H  !!.   *4@   U8   !:
M70   &    !C    90   &<   !I    :P$  &T%  !O"@  <@X  '42  !W
M&P  =B8  '8U  !U1@  =%D  '1O  !SBP  <JD  '#-  !O]P  ;O\ 1D8
M $!%   U1@  *D@  "!,   740  $%8   E:   !7P   &,   !H    :P
M &\   !R    =0   '<   !Y    >P   'T   "  P  @P@  (8-  ")$P
MBAT  (HK  ")/   B$\  (9F  "%@0  A*   (+"  "!\   ?_\ 1DL  #I,
M   N3P  (U,  !A8   07@  "60   !I    ;P   '0   !X    ?    ($
M  "$    AP   (@   "+    C@   )    "3    E@   )D'  "=#0  H10
M * A  "@,0  GD0  )U;  "<=@  F98  )FU  "6Y0  E?X /U(  #)5   F
M6@  &V   !%G   );0   '0   ![    @0   (8   "+    D    )0   "7
M    F0   )P   "?    H0   *0   "G    J@   *T   "Q!@  M0T  +@6
M  "W)@  MCD  +50  "T:@  LHD  +"J  "NSP  K?4 -UP  "MA   >:
M$W    MX    @    (<   ".    E0   )H   "?    I    *@   "L
MK0   +    "S    M0   +@   "[    OP   ,,   #'    RP4  -$.  #1
M&P  T"X  ,]%  #-7P  RWX  ,F>  #(O@  Q>D +VD  "-P   6>0  #8$
M  &+    DP   )L   "B    J    *X   "T    N    +T   #     P@
M ,4   #(    RP   ,X   #1    U@   -L   #?    Y    .@&  #K$0
MZB,  .HZ  #I5   YW(  .63  #CLP  X]0 _P   /\   #_    _P $ /\
M"P#_ !  _P 7 /\ (0#_ "L _P U /\ /@#_ $< _P!. /\ 50#\ %L ^@!A
M /@ 9@#V &T ] !S /( >P#O (0 [0". .H F0#F *< XP"Y -\ U0#; /<
MU@#_ ,  _P"R /\ J@#_ *4 _P"B /\ _P   /\   #^    _    /P  P#^
M  L _P 1 /\ &@#] "0 ^0 N /0 . #P $  [ !( .D 3@#F %0 X@!: -\
M7P#< &4 V !K -0 <@#0 'L S0"% ,H D0#' )X PP"N ,  Q0"] .L NP#_
M +  _P"D /\ G #_ )@ _P"5 /\ _P   /H   #T    \0   /(   #J  4
MYP . .( %0#A !X X0 H -@ ,0#0 #D RP!  ,@ 1P#% $T P@!3 +\ 6 "]
M %X NP!D +D :P"V ', M !\ +$ B "N )4 JP"D *@ N "F -P HP#[ )\
M_P"5 /\ CP#_ (L _P") /\ ^0   .\   #G    WP   ,\   #(    P0 *
M +\ $0"\ !@ NP A +D *@"T #( L0 Z *X 0 "K $8 J !, *8 40"C %8
MH0!< )\ 8P"= &H FP!S )D ?@"6 (P E "; )( K0"0 ,< C@#P (T _P"&
M /\ @ #_ 'T _P!\ /\ [0   .    #1    OP   +,   "J    I@ % *(
M#0"A !, H  ; )\ (P"; "L F  R )4 .0"3 #\ D0!$ (\ 2@". $\ C !5
M (H 6P"( &, A@!K (0 =@"" (( @ "2 'X HP!\ +H >@#A 'D _P!W /\
M<@#_ '  _P!O /\ W0   ,L   "V    IP   )T   "4    C@ ! (L "@")
M !  B  5 (< '0"' "4 A  L (( ,@!_ #@ ?0 ] 'L 0P!Y $@ > !. '8
M5 !U %L <P!C '$ ;@!O 'H ;0") &P F@!J *X :0#, &@ ]@!G /\ 90#_
M &0 _P!C /\ R@   +0   "A    DP   (D   ""    >P   '@ !0!V  P
M=0 1 '0 & !S !\ <@ E '  + !N #( ;  W &H / !I $( : !( &8 3@!E
M %4 8P!= &( 9@!@ '( 7@"  %T D@!; *4 6@"^ %D Z0!9 /\ 60#_ %@
M_P!8 /\ N0   *(   "0    @P   'D   !Q    ;0   &D  0!F  D 90 .
M &0 $P!C !D 8P @ &$ )@!@ "P 7@ Q %P -P!; #P 6@!" %@ 2 !7 $\
M5@!7 %0 8 !3 &P 40!Y %  B@!/ )X 3@"T $T V@!- /L 30#_ $T _P!-
M /\ J@   )0   ""    =0   &L   !D    8    %T   !:  4 6  , %<
M$ !6 !4 5@ ; %4 (0!3 "< 4@ L %$ ,0!/ #< 3@ ] $T 0P!, $H 2@!2
M $D 6P!( &8 1@!S $4 A !$ )< 0P"L $( R0!" /$ 0@#_ $, _P!# /\
MG@   (D   !X P  :@0  &$$  !: P  50$  %(   !0  ( 3@ ) $T #0!,
M !$ 2P 7 $H ' !) "( 2  G $< +0!% #( 1  X $, /@!" $4 00!- #\
M5@ ^ &$ /0!N #L ?@ Z )$ .0"F #@ OP X .@ . #_ #D _P Y /\ E0,
M ( '  !O"0  8@H  %@+  !1"@  3 @  $D&  !' P  1@ & $0 "P!#  \
M0@ 3 $$ & !! !X /P C #X *0 ] "X .P T #H .@ Y $$ . !) #< 4@ V
M %T - !J #, >@ R (P ,0"A #  N  O -X +P#Y "\ _P P /\ C D  '@,
M  !H#0  7 X  %(.  !+#@  10T  $$,   _"@  /@@" #T$"  \ 0T .P 0
M #H %0 Y !H .  @ #8 )0 U "L -  P #, -P R #X ,0!& "\ 4  N %H
M+0!G "L =P J (D *0"= "@ LP G -$ )P#R "< _P G /\ A@P  '(.  !C
M$   5A$  $T1  !%$0  0!   #P/   Y#@  -PT  #8+!  V" H -08. #0%
M$@ R!!< ,04< # %(@ O!2@ +@8N "T&-  K!CP *@9$ "D'3@ G!UD )@=E
M "0'=0 C!X< (@>; " &L  @!LL 'P7M !\&_@ ?!_\ @ X  &T1  !>$@
M4A,  $@3  !!$P  .Q,  #<2   T$0  ,A   # / 0 P#08 , L+ "\*$  M
M"A0 + L9 "H+'P I"R4 * PK "<,,@ F##H ) Q# ",,30 A#5@ ( UE !X-
M=0 <#8@ &@V< !D-L0 8#,H %PSK !<-_  8#/\ >Q$  &D3  !:%0  3A8
M $46   ]%@  .!4  #,5   P%   +1,  "L2   J$ , *@\( "D.#0 H#A$
M)@X6 "4/'0 D#R, (P\I "$0,0 @$#D 'A!" !T03  ;$%@ &1!F !<0=@ 5
M$(D %!"> !(0LP 1$,X $1#N !(0_@ 2$/\ =Q,  &45  !7%P  2Q@  $(9
M   Z&0  -!@  # 7   L%P  *18  "<5   F% $ )1($ ",2"P B$@\ (1(4
M " 2&@ >$R  '1,G !P3+@ :$S8 &11  !<42@ 6%%8 %!1D !(4=  1%(<
M$!2<  X4L0 -%,H #13K  X3_@ .$_\ <Q4  &$8  !3&@  2!L  #\;   W
M&P  ,AH  "T:   I&0  )A@  "08   B%P  (!8! !X6"  =%@T &Q<2 !H7
M%P 9%QT &!@D !88*P 5&#0 %!@] !(92  1&50 $!EB  X9<@ -&80 #!F8
M  H9K0 )&,8 "1CG  D8^@ *%_\ ;Q@  %X:  !0'   11T  #P=   U'0
M+QT  "H<   F&P  (QL  "$:   >&@  '!H  !H;!0 8&PP %AP0 !4<%0 4
M'!L $QPB !(=*0 1'3$ $!T[  X=10 -'E$ #!Y>  H>;0 )'H  !QZ4  4=
MJ@ #'<(  QWF  0<^  %'/\ :QH  %L=  !-'@  0A\  #H?   R'P  +1\
M "@>   D'@  (1T  !X=   <'0  &!X  !4? @ 3( D $B$. ! A$@ 0(1@
M#B$?  XB)@ -(BX #"(W  HB00 )(DT !R):  4B:0 #(GP  2*1   BJ
M(<   "'E   @^   (/\ 9QT  %<?  !*(0  0"$  #<B   P(0  *B$  "8@
M   B(   'Q\  !P?   9(   %B$  !(C @ 0) < #B8,  PF$  +)A4 "B8<
M  DF(@ ()BH !B<S  0G/0 #)TD  2=6   G9@  )WD  ">/   FI@  )K\
M "7D   E^0  )/\ 8R   %0B  !'(P  /20  #0D   N(P  *",  "0B   A
M(@  'B$  !HB   7(P  $R0  ! F @ .* < "RH+  @K#@ &*Q, !"L8  (K
M'P !+"<  "PP   L.@  +$4  "Q3   L8P  +'8  "R,   KI   *[X  "KD
M   J^@  *?\ 7R,  % E  !$)@  .B8  #(F   K)@  )B4  ",D   ?)
M&R0  !<E   4)P  $2D   XK @ ++08 !R\+  0P#@  ,!$  #$5   Q'
M,2,  #(L   R-@  ,D(  #)/   R7P  ,G(  #&)   QH@  ,+P  ##D   O
M^P  +_\ 6B<  $PH  ! *0  -RD  "\I   I*   )2<  "$F   <)P  &"@
M !0J   1+   #BX   LP 0 ',@4  S0)   U#   -@\  #<2   X&   ."
M #@H   X,@  .3T  #E+   Y6P  .&X  #B%   WGP  -[H  #;D   U_
M-?\ 52H  $@L   ]+   -"P  "TK   H*@  )"D  !XJ   9*P  %"T  !$O
M   -,0  "C0   <V   ". 0  #H'   ["@  /0T  #X0  ! %   0!L  $ D
M  ! +@  0#D  $!'  ! 5@  0&D  $"    _FP  /K<  #WC   \_   //\
M4"\  $,O   Y+P  ,B\  "PM   G+   ("T  !HO   5,0  $3,   TV   )
M.   !3L    ]    0 $  $$$  !#!P  10L  $8.  !($0  2A8  $H>  !*
M*   2C0  $E"  !)40  260  $A[  !(EP  1[0  $;@  !%_   1/\ 2C,
M #\S   V,P  ,#$  "HP   C,0  '#,  !8U   1.   #3L   @^   #00
M $,   !&    2    $H   !,!   3@<  $\+  !1#@  5!(  %49  !5(@
M5"X  %0\  !42P  4UX  %-T  !2D   4:X  %#7  !/^P  3O\ 13<  #PW
M   U-@  +S0  "8U   >-P  %SH  !$]   ,00  !T0   !(    2@   $T
M  !0    4P   %4   !7    6 (  %L&  !="P  7PX  &(3  !B&P  8B<
M &(T  !A10  8%<  &!M  !?B0  7:<  %S,  !:^   6?\ 03P  #H[   T
M.0  *CH  "$\   80   $4,   Q'   &2P   $\   !3    5@   %D   !<
M    7P   &$   !C    90   &<!  !J!0  ;0H  ' .  !S%0  <B   '(M
M  !Q/0  <$\  &]E  !N@   ;9\  &O!  !I\0  :/\ /T   #D^   N/P
M)$(  !I&   22@  #$\   14    6    %T   !A    90   &@   !K
M;@   '$   !S    =0   '@   ![    ?@,  ($*  "%#P  AQ<  (8D  "%
M-   A$8  ()=  "!=@  ?Y8  'ZV  !\YP  >O\ /T0  #-%   H2   '4P
M !-2   ,5P   UT   !C    :    &T   !Q    =@   'H   !^    @0
M (,   "&    B0   (L   ".    D@   )4!  "9"0  GA   )X:  "=*0
MG#P  )I2  "8;   EHL  )2J  "2U   D/H .$L  "Q.   @4P  %5D   U@
M   #9P   &X   !T    >@   (    "$    B@   (X   "2    E0   )<
M  ":    G0   *    "C    IP   *L   "O    M D  +@0  "W'@  M3
M +-&  "Q8   KWX  *R@  "KP0  J>X ,54  "1;   880  #FD   5Q
M>0   ($   "(    CP   )0   ":    GP   *0   "H    J0   *P   "O
M    LP   +4   "Y    O0   ,$   #&    RP   -$*  #3%   T24  - [
M  #-5   RG$  ,B2  #%LP  P]X *6(  !QI   1<0  !WL   "$    C0
M )4   "=    HP   *D   "O    M    +D   "\    O@   ,(   #%
MR    ,P   #0    U    -H   #?    Y    .H   #N#   [1H  .PO  #J
M20  Z&4  .:&  #DI0  XL8 _P   /\   #_    _  ! /P " #^  X _P 4
M /\ '0#_ "8 _P P /\ .@#_ $( _P!) /X 4 #[ %8 ^0!< /8 8@#T &@
M\@!O /  =@#M '\ Z@") .< E0#D *, X "U -L T #5 /8 R@#_ +8 _P"H
M /\ GP#_ )H _P"6 /\ _P   /L   #V    \P   /,   #V  D ^@ . /T
M%@#[ "  ]P J /( ,P#M #L Z0!# .8 20#B $\ W@!5 -L 6P#6 &  T@!G
M ,\ ;@#, '8 R0"  ,8 C #" )H OP"J +L P0"X .D M@#_ *< _P": /\
MD@#_ (T _P"* /\ ^@   /$   #J    YP   .<   #D  $ X  + -L $0#:
M !H VP C -$ + #* #0 Q@ [ ,( 0@"_ $@ O !. +H 4P"X %D M@!? +,
M9@"Q &X K@!W *P @P"I )$ I@"A *, M0"@ -@ G@#[ )4 _P"+ /\ A0#_
M (  _P!^ /\ [P   .,   #:    TP   ,8   "_    N0 & +< #@"T !0
MM  = +, )0"N "T JP T *< .P"D $$ H0!& )\ 3 "= %$ FP!7 )D 7@"7
M &4 E0!N ), >0"0 (< C@"7 (P J0") ,0 B #O (4 _P!\ /\ =@#_ ',
M_P!R /\ X    -    #&    M@   *D   "A    G0 ! )D "@"8 !  F  6
M )< '@"4 "8 D0 M (\ - ", #H B@ _ (@ 10"' $H A0!0 (, 5@"! %X
M@ !F 'X <0!\ 'T >0"- '< H !U +8 <P#? '( _P!N /\ :0#_ &< _P!E
M /\ S    +X   "K    G0   ),   "*    A0   (( !0"   T ?P 1 '\
M& "  "  ?0 F 'H +0!W #, =0 X '0 /@!R $, < !) &\ 3P!M %8 ; !>
M &H : !H '4 9P"$ &4 E@!D *L 8@#) &$ ]@!@ /\ 7 #_ %L _P!: /\
MO0   *D   "7    B0   'X   !X    <P   &\  0!M  D ;  . &L $P!K
M !D :@ @ &@ )@!F "P 90 R &, -P!B #P 8 !" %\ 2 != $\ 7 !7 %H
M80!9 &T 5P![ %8 C@!5 *( 4P"[ %( Z0!2 /\ 4 #_ $\ _P!/ /\ K0
M )@   "&    >    &X   !G    8P   &    !=  4 7  + %L $ !; !4
M6P ; %H (0!8 "8 5@ L %0 ,0!3 #8 4@ \ %$ 0@!/ $D 3@!1 $T 6P!+
M &8 2@!T $D A0!( )D 1P"Q $8 V !& /P 10#_ $4 _P!% /\ GP   (D
M  !X    ;    &(   !;    5@   %,   !1  ( 3P ( $\ #0!. !$ 3@ 6
M $T ' !, "$ 2@ F $D + !( #$ 1P W $4 /0!$ $0 0P!, $( 50!  &
M/P!N #X ?@ ] )( / "I #L QP [ /, .P#_ #L _P \ /\ DP   'X   !N
M    80   %@   !1    3    $D   !'    10 % $0 "P!#  X 0P 2 $,
M%P!" !T 0  B #\ )P ^ "P /0 R #L .  Z #\ .0!' #@ 4  W %L -0!H
M #0 >  S (P ,@"B #$ O  Q .< ,0#_ #( _P S /\ B0   '8#  !F!0
M60<  % '  !)!@  0P4  $ #   ^ 0  /  # #L "  Z  T .@ 0 #D %  Y
M !D -P > #8 (P U "@ -  N #, -  R #L , !# "\ 3  N %< +0!D "P
M<P K (< *@"< "D M0 I -P *0#[ "D _P J /\ @00  &X(  !?"@  4PL
M $H+  !""P  /0H  #D)   V"   -04  #0"!@ S  H ,@ . #$ $0 Q !4
M,  : "\ 'P N "0 +  J "L ,  J #< *0 _ "@ 20 G %0 )@!@ "0 ;P C
M (( (@"7 "$ K@ A ,P (0#S "$ _P B /\ >PD  &@,  !:#0  3@X  $4.
M   ]#@  . T  #,-   P#   +@L  "T) P M!@@ + 0, "L"#P J 1( *0$7
M "@!'  G "$ )@ G "4 +0 D #0 (P$] "(!1@ A 5$ 'P%= !X!;  < 7\
M&P"4 !H J@ : ,4 &@#K !D _P : /\ =0P  &0.  !5#P  2A   $ 0   Y
M$   ,Q   "\/   L#@  *0X  "<- 0 G# 4 )PH* "8(#0 E!Q  ) 84 "(&
M&0 A!A\ ( <D !\'*P >!S( '0<Z !P(1  :"$\ &0A< !<(:P 6"'T %0>1
M !0'IP 3!K\ $@7D !(%^@ 2!?\ <0X  %\0  !1$0  1A(  #T2   V$@
M,!(  "L1   H$0  )1   ",0   B#@0 (0T' "$,"P @"PX 'PL2 !T+%P <
M#!P &PPB !H,*0 9##$ & PY !8-0P 5#4\ $PU< !(-:P 0#7X #PV2  X-
MIP -#+X #0S@  T,]0 -#/\ ;1   %P1  !.$P  0Q0  #H4   R%   +10
M "@3   E$P  (A(  " 1   >$0, '! % !P/"  ;#PP &@X0 !D/%  7#QH
M%@\A !40*  4$#  $A Y !$01  0$%  #A!=  T0:P ,$'P "Q"0  D0I0 (
M$+P !Q#?  <0]  '#_\ :1$  %@4  !+%0  0!8  #<6   P%@  *A8  "85
M   B%0  'Q0  !T3   :$P( &1($ !<2!@ 6$@H %1(. !02$@ 2$A@ $1,>
M !$3)0 0$RX #A,W  T40  ,%$L "Q18  D49P '%'@ !A2-  04HP #$[L
M A/=  $2]  "$O\ 91,  %46  !(%P  /1@  #08   M&   *!@  ",7   @
M%P  '18  !H5   8%0( %A4$ !05!0 2%@@ $18- ! 7$  .%Q4 #A<;  T7
M(@ ,%RD "Q@R  D8/  '&$< !1A4  088P "&'4  1B+   7H0  %[D  !?=
M   6]0  %O\ 818  %(8  !%&@  .QH  #(:   K&@  )1H  "$9   >&
M&Q@  !@7   6%P( %!<# !(8!0 0&0< #AL+  P;#P +&Q, "AL8  @<'P '
M'"8 !1PO  0<.  "'$0  !U1   =8   '7(  !R(   <H   &[D  !O>   :
M]@  &O\ 7A@  $\:  !"'   .!P  "\=   I'   (QP  !\;   <&@  &1D
M !<9 0 4&0( $AH# ! ;!  .'0< #!X+  D?#@ &(!$ !2 6  ,@'  !(2,
M "$K   A-0  (4   "%.   A70  (6\  "&&   @G@  (+@  !_>   >^
M'O\ 6AL  $L=   _'@  -1\  "T?   G'@  (AT  !X=   ;'   &!L  !4;
M   2'   $!T"  X?!  ,(08 "2(*  4C#0 ")!   "43   E&0  )B   "8H
M   F,@  )CT  "9*   F6@  )FP  ":#   EG   );<  "3?   C^0  (_\
M51X  $<@   \(0  ,B$  "LA   E(   (!\  !T>   :'0  %AX  !,>   0
M(   #B$   PC @ ()04 !2<)   H"P  *@X  "L1   L%@  +!T  "PE   L
M+@  +#H  "Q'   L5@  +&D  "R    KF@  *K4  "G?   I^P  */\ 42(
M $0C   X)   +R0  "@C   C(@  'R$  !P@   7(   $R$  ! C   .)
M"R8   @H   $*@0  "P'   N"0  , P  #$/   S$P  ,QD  #,A   S*@
M,S4  #-#   S4@  ,V4  #)[   REP  ,;,  ##>   O^P  +O\ 3"4  #\F
M   U)P  +28  "<E   B)   'B,  !DC   4)   $28   XH   +*@  !RP
M  ,O    ,0(  #,$   U!P  -PH  #D-   Z$   .Q4  #L=   [)@  .S$
M #L^   [3@  .V   #IW   YD@  .+   #?;   V_   -?\ 1RD  #LJ   R
M*@  *RD  "4G   A)@  &R<  !4H   1*@  #BP   HO   &,0   30    V
M    .    #L!   ]!   /P<  $$*  !##@  11$  $48  !%(0  12P  $0Y
M  !$2   1%L  $-Q  !"C0  0:L  $#2   _^@  /O\ 0BT  #@N   O+0
M*2L  "0J   =*@  %RP  !$N   -,0  "30   0W    .@   #P    _
M00   $0   !&    2 ,  $H'  !,"P  3@X  % 3  !0'   4"<  $\T  !/
M0P  3U4  $YJ  !-A@  3*0  $K*  !)^   2/\ /C(  #4Q   N+P  *2X
M " N   9,0  $C,   XW   ).@   CT   !     1    $<   !)    3
M $\   !1    4P   %4!  !8!@  6@L  %T.  !?%0  7B   %XL  !=/
M7$X  %MC  !:?@  6)T  %?   !5\@  5/\ .C8  #,T   M,@  )#,  !LV
M   3.0  #CT   A!    10   $D   !,    4    %,   !6    60   %L
M  !=    8    &(   !E    : 4  &L+  !O$   ;Q@  &XE  !M-   ;48
M &M;  !J=0  :)0  &:V  !DZ0  8O\ .#D  #(W   H.0  'CL  !4_   .
M1   !TD   !-    4@   %8   !:    7@   &(   !E    :    &L   !M
M    <    ',   !V    >0   'T$  "!"P  A1$  (0=  ""+   @#X  'Y4
M  !^:P  >XH  'JJ  !WU@  =?T .#T  "P^   B00  %T8   ]+   '40
M %<   !<    8@   &8   !K    ;P   '0   !X    >P   'X   "
M@P   (8   "*    C0   )$   "6 P  FPP  )T3  ";(0  FC,  )=)  "4
M8@  DW\  )"@  ".Q0  C/, ,40  "5(   :30  $%,   A:    80   &@
M  !N    =    'D   !_    A    (D   "-    D0   ),   "6    F0
M )T   "@    I    *@   "L    L@,  +<-  "W%P  M2@  +(^  "P5@
MK',  *J4  "IM   I>4 *D\  !Y4   26P  "F(   !J    <P   'L   ""
M    B0   (X   "4    F@   )\   "D    I@   *D   "M    L    +,
M  "W    NP   ,    #%    RP   -$$  #5#@  TQT  - R  #-2P  RF8
M ,:'  #"J0  P<L (EL  !9B   ,:P   70   !]    AP   )    "7
MG@   *0   "K    L0   +8   "Z    O    ,    #$    R    ,L   #/
M    U    -H   #@    Y@   .L   #Q!@  \!,  .XG  #L/P  ZEL  .=Z
M  #DFP  X+L _P   /L   #V    \P   /0 !0#V  P ^@ 1 /\ &0#_ "(
M_P L /\ -0#_ #T _P!% /P 3 #Z %( ]P!8 /4 7@#S &0 \0!J .X <@#L
M 'H Z0"% .4 D0#A *  W0"R -@ S@#2 /8 P0#_ *T _P"> /\ E@#_ )
M_P", /\ ^@   /(   #L    Z0   .D   #L  4 \@ , /@ $@#W !L ]0 E
M /  +@#K #< Y@ ^ .( 10#= $L V !0 -, 5@#0 %P S0!B ,H :@#( '(
MQ0!\ ,( B "^ )8 N@"H +< OP"T .@ K@#_ )T _P"0 /\ B #_ (, _P"
M /\ \    .4   #>    V@   -L   #<    V  ' -$ #@#1 !4 T@ > ,L
M)P#% "\ P  W +T /0"Z $0 MP!) +4 3P"R %4 L !; *X 80"L &D J0!S
M *< ?P"D (T H0"> )X L@"; -4 F0#\ (P _P"" /\ >P#_ '8 _P!T /\
MX@   -,   #*    QP   +P   "V    L  ! *\ "P"L !$ K0 8 *T ( "H
M "@ I  O *  -@"= #P FP!" )D 1P"7 $T E0!3 ), 60"1 &$ CP!J (P
M=0"* (, B "4 (8 IP"# ,( @@#P 'P _P!S /\ ;0#_ &H _P!H /\ SP
M ,$   "Y    K0   *    "8    E    )$ !@"0  T D  2 (\ &0". "$
MBP H (@ +P"& #4 A  Z (( 0 "  $4 ?@!+ 'P 4@!Z %D > !B '8 ; !T
M 'D <@") '$ G0!O +0 ;0#? &P _P!E /\ 8 #_ %X _P!< /\ O@   +$
M  "@    D@   (D   ""    ?    'H  0!X  D =P . '@ % !W !H =  A
M '( )P!P "T ;@ S &P . !K #X :0!$ &@ 2@!F %$ 9 !: &, 9 !A '
M7P!_ %X DP!= *D 7 #( %L ]P!7 /\ 5 #_ %( _P!1 /\ L    )\   "-
M    ?P   '0   !N    :@   &8   !E  0 8P + &, $ !C !4 8P ; &$
M(0!? "< 70 L %P ,@!: #< 60 ] %< 0P!6 $L 50!3 %, 7 !2 &@ 4 !W
M $\ B0!. )\ 30"Z $P Z0!+ /\ 20#_ $< _P!' /\ H@   (T   !\
M;@   &4   !>    60   %<   !5  $ 5  ' %, #0!3 !$ 5  6 %( &P!1
M "$ 3P F $X *P!, #$ 2P W $H /0!) $0 1P!, $8 5@!$ &$ 0P!P $(
M@0!! )< 0 "O #\ UP _ /\ /@#_ #T _P ^ /\ E    '\   !O    8P
M %D   !1    30   $H   !(    1P $ $< "@!&  X 1@ 1 $< %@!% !P
M1  A $( )@!! "L 0  Q #X -P ] #X / !' #H 4  Y %L . !I #< >@ V
M (\ -0"G #4 Q@ T /4 - #_ #0 _P U /\ B    '0   !E    6    $\
M  !(    0P   #\    ]    /  " #P !P [  P .P / #L $@ Z !< .0 <
M #< (0 V "8 -0 L #0 ,@ S #D ,0!! #  2P O %8 +@!C "T <P L (@
M+ "@ "L NP K .H *P#_ "L _P L /\ ?P   &P   != 0  40(  $@#  !
M P  .P(  #<    T    ,P   #( !0 R  D ,@ - #$ $  Q !, ,  8 "\
M'0 M "( +  H "L +@ J #4 *0 ] "@ 1@ G %$ )@!> "4 ;@ D (( (P"9
M ", LP B -X (@#_ ", _P D /\ =P   &4$  !6!@  2P<  $((   Z"
M-0<  # &   M!0  + ,  "L  P J  < *0 + "D #@ I !$ *  5 "< &0 F
M !X )0 D "0 *@ C #$ (@ Y "$ 0P @ $X 'P!: !X :0 = 'P ' "3 !L
MK  ; ,T &P#V !L _P < /\ < 4  %\(  !1"@  1@L  #T+   U"P  , L
M "L*   H"0  )0@  "0' @ C! 8 (P() "(!#  B  \ (0 2 "  %@ ? !L
M'@ @ !T )@ < "X &P V !H /P 9 $H & !7 !< 9@ 6 '@ %0"/ !4 I@ 4
M ,, % #N !0 _P 5 /\ :P@  %L+  !-#   0@T  #D-   Q#0  + T  "<-
M   C#   (0P  !\+ 0 >"@4 '0@( !T&"P <!0T ' 00 !L$%  9!!@ &00>
M !@$(P 7!"L %@0S !4$/  4!$< $P-4 !(#8P 1 W4 $ ** ! !H@ / +P
M#P#E  \ _@ 0 /\ 9PL  %<-  !)#@  /@\  #4/   N#P  * \  "0.   @
M#@  '0X  !L- 0 9#00 & P' !@+"0 7"0P %PD. !8)$@ 5"18 % D; !,)
M(0 2"2@ $@DP !$).@ 0"44 #PE2  X)80 -"7, # B(  L(GP *![< "@;;
M  H%]@ *!/\ 8PT  %,.  !&$   .Q$  #(1   K$0  )1   "$0   =$
M&@\  !@/ 0 6#@0 %0X' !0-"0 3#0L $PP- !(,$  1#!0 $ P9 ! ,'P /
M#"< #@TO  T-.0 ,#44 "PU1  D-8  (#7$ !@V&  4-G0 $#+0  PS2  (,
M\0 ""_\ 7PX  % 0  !#$0  .!(  "\2   H$@  (Q(  !X1   ;$0  &!$
M !40 @ 4$ 4 $A ' !$/"0 0#PH $ X,  X.#@ .#Q( #0\7  P0'0 ,$"0
M"A L  D0-@ ($$$ !A!.  4070 #$&\  1"$   0G   #[0   [4   .\P
M#O\ 7!   $T2  ! $P  -A0  "T4   F%   (1,  !P3   9$@  %A(  !01
M P 2$08 $1$( ! 0"@ .$ L #1$+  P1#0 +$A$ "A(5  D2&@ ($B$ !A,I
M  43,P #$SX  A-+   36@  $VP  !."   2FP  $K0  !'7   1]0  $?\
M6!(  $D4   ]%0  ,Q8  "L6   D%0  'Q4  !H4   7%   %!,! !,2!  1
M$@< $!()  X2"0 -$@D "Q,*  D4#0 '%0\ !A83  06&  #%A\  A8G   7
M,   %SL  !=(   76   %VH  !:    6F0  %;0  !79   4]P  $_\ 510
M $86   Z%P  ,!@  "@8   B%P  '18  !D6   6%0  $Q0# !(3!@ 0$P<
M#Q,'  T4!P +%0@ "18)  88#  #&@X  1H1   :%@  &QP  !LD   ;+0
M&S@  !M&   <50  &V<  !M]   ;EP  &K,  !G;   8^0  %_\ 418  $,8
M   W&0  +AH  "8:   @&0  &Q@  !@7   5%@$ $Q4% !$5!  /%00 #18$
M  L7!0 )&08 !AH(  (<"@  '@T  " 0   @$P  (!D  " A   A*@  (34
M "%"   A4@  (&0  "!Z   ?E0  '[$  ![;   =^@  '/\ 31D  #\;   T
M'   *QP  "0<   >&P  &AH  !<8   4%P( $A<" ! 8 0 -&0$ "QH"  @<
M P %'00  A\&   A"   (PL  "4.   F$0  )A8  "8>   G)P  )S(  "<_
M   F3@  )F   "9W   ED@  )*\  "/:   B^P  (?\ 2!T  #P>   Q'P
M*!X  "(>   ='   &1L  !8:   2&@  $!L   T<   +'0  "!\   0A   !
M(P(  "4$   G!@  *0D  "P,   N#P  +A,  "X:   N(P  +BX  "X[   N
M2@  +5P  "UR   LC@  *ZP  "K4   I^P  */\ 1"   #@A   N(0  )B$
M " @   <'@  &!T  !0=   0'@  #A\   LA   '(P   R4    G    *0
M "P!   N P  , 8  #,*   U#0  -A$  #87   V'P  -BD  #8V   V10
M-5<  #5M   TB0  ,J@  #'/   P^@  +_\ /R0  #0D   K)   )",  !\A
M   ;(   %B   !$A   .(P  "B4   8H   "*@   "T    O    ,@   #0
M   W    .0,  #L&   ^"@  0 X  $$2  !!&@  0"4  $ Q  ! 0   /U(
M #YG   ]@@  /*(  #K'   Y^   ./\ .B@  # H   I)P  (R4  !\C   8
M)   $B4   XH   **@  !2T    P    ,P   #8    X    .P   #X   !
M    0@   $4"  !'!@  2@H  $T.  !-%0  3!\  $PK  !+.@  2DP  $EA
M  !(?   1YL  $6_  !#\P  0O\ -BP  "TK   G*0  (R<  !LH   4*@
M#BT   HP   $,P   #<    Z    /0   $    !#    1@   $@   !+
M30   %    !3 0  5@8  %D+  !;$   6QD  %HE  !9-   6$8  %=:  !5
M=   5),  %*U  !0Z@  3_\ ,S   "PN   G+   'BT  !8O   0,@  "C8
M  ,Z    /P   $(   !&    20   $P   !/    4@   %4   !8    6@
M %T   !@    8P   &<&  !K#   ;!(  &L>  !K+   :3T  &=2  !F:@
M9(D  &&K  !?W   7?\ ,3,  "PQ   B,@  &34  !$Y   */0   D(   !'
M    3    %    !4    6    %L   !?    8@   &4   !H    :P   &X
M  !Q    =0   'D   !]!@  @@T  ((6  " )   ?C4  'Q)  ![80  >'\
M ':?  !SQ@  </< ,38  "8X   <.P  $D    M%   "2P   %$   !6
M6P   &    !E    :0   &X   !R    =@   'D   !\    ?@   ((   "%
M    B0   (X   "3    F 8  )P.  ";&@  F"L  )9   "260  D7,  (V5
M  "+M0  B.@ *SX  "!!   51P  #4T   )4    6P   &$   !H    ;@
M ',   !Y    ?@   (,   "(    C    (\   "2    E0   )D   "=
MH0   *4   "J    L    +<'  "X$0  M2$  +(U  "O30  JFD  *B(  "F
MJ   HM$ (T@  !A.   .5   !%P   !D    ;0   '4   !\    @P   (D
M  "/    E0   )L   "@    HP   *8   "I    K0   +$   "U    N0
M +X   #$    R@   -(   #:"@  UA8  -(I  #.00  REP  ,5\  #"G0
MP;T '%4  !%<   '90   &X   !W    ?P   (@   "0    F    )\   "E
M    K0   +,   "X    N@   +X   #"    Q@   ,H   #.    TP   -H
M  #@    YP   .T   #S    ] X  /(>  #O-@  [%$  .AN  #DD   W[$
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M_________________________________________P
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M[8Z(>.>'CX'B@)6*W7N:D-IWH);6=*::U'&LGM)OLJ'0;;FCSVS#IL5GPZ;
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MBI6[IH>=OJ*%I<"?A*_!EGZPP91_MKB3@+NRDX"[LI. N[*3@+NRDX"[LI.
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M-1EQ_ST>:?]%(V+_329;_U8I6/]?+%;_:"U4_VXO4_]S,%+_>#%1_WPQ4/^
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MC"(&_YTG!_^J+@G_MC8.]\$^%NW,1B#DV$LNV=Q01,G46%B[S5YKKL9E>J+
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M*3S_L"H\_[0J//^T*CS_M"H\_[0J//^T*CS_M"H\_[0J//^T*K.X 0"EQ@
ME]4  (OO! &$_Q,"=_\:!&W_(@=D_RH+7/\R#E7_.1%0_T$32_](%4C_3Q=%
M_U880O]<&4#_81H^_V<://]M&SO_<QPY_WD<./^ '3;_B!TU_X\>-/^7'C+_
MH!\R_Z0?,O^D'S+_I!\R_Z0?,O^D'S+_I!\R_Z0?,O^D'Z;   "7S@  B=X
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M34GXX$U(]_--2/?T34CW]$U(]_1-2/?T34CW]$U(]_1-2/?T3=JC  #'L0(
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M:D_%[6A0P/-D4;WU85&]]6%1O?5A4;WU85&]]6%1O?5A4;WU8?^&"@#PF@0
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M-3__[S4__^\U/__O-3__[S4__^\U/__O-<2J  "SLP  I[\  )K+  "/V@(
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M<%^?ZVMAG?)E8IKV8&*9]UYBF?=>8IGW7F*9]UYBF?=>8IGW7O]S$ '_A0P
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M3DK*_TU*RO]-2LK_34K*_TU*RO]-2LK_3>>/  #1GP  PZL! +>T @"MOP,
MH\L& )O9"@"4Y1H!C>4K!H3D-0U[XS\6<^)('FSA4B9FX5HL8.!B,EO@:C97
MX'(Z4]][/5#?A4!-WX]#2N";14C@J$9&X+A'1>',1T7@Z$=%W_9&1=[_1$7>
M_T1%WO]$1=[_1$7>_T1%WO]$1=[_1-F7  #'I@  N+   *RY 0"BQ0( F-$&
M (_K#0")[A\"@.XK!GCM- QP[3T3:.U&&6+M3AY=[5<C6>U@)U7M:"I2[7$M
M3^UY+TSM@S)*[HTT1^Z8-47NI3=#[[,X0O#$.$'PWSE![^\X0.W].$#L_SA
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M:6^&ZV-RA_E<<X;]5G.%_U)SA?]2<X7_4G.%_U)SA?]2<X7_4O]H$0'_> T
M_X8- /:3# #>H D UJD* -*R#0#'LB("O:\S"K.K01>JITPDH:)5,)F>73J2
MFF1"BY=K2864<E" DGE5>X^!6G:-B5YRC))B;HJ=96N)J6=HB;AH9XG+:&F+
MZ6-LC?E<;8S]5VV*_U)MBO]2;8K_4FV*_U)MBO]2;8K_4O]K$ '_>PL _XH*
M .*8!@#6HP@ T*P) ,NU"P#!MA\!N+0Q":ZP/Q:DK$HBG*A3+I2D6SB,H&)
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M5%NA_U!;H?]06Z'_4%NA_U!;H?]06Z'_4/]W!P#PB0  UI@  ,ND P#!K00
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M.4/8_SE#V/\Y0]C_.="6  #!HP  LJP  *>U  "<P   D<H# (?6!P" Z1$
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M7']S[%:!=OM/@WC_2H-X_T6">/]$@GC_1()X_T2">/]$@GC_1/]?$0'_;0P
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M36R*_TALB?]';(G_1VR)_T=LB?]';(G_1_]I"P#_> 0 Y8<  -:2 P#-G 4
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M0E*I_T)2J?]"4JG_0O)\  #7C   R)D  +VC  "RJP  J;(  *"[ @"7Q D
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M"AW_HPH<_[$*&__ "QK_U@L:_]\+&O_?"QK_WPL:_]\+&O_?"YNQ  "-O
M?L<  '#2  !CW@  5>0  $OU  !&_P4 0/\. #O_%  W_QL!,_\C 2__*0(K
M_S "*/\U B7_.P,B_T$#'_]' QW_3@,:_U4$&/]>!!7_: 43_W0%$?^"!1#_
MD 80_YT&#_^I!@[_M08._[H&#O^Z!@[_N@8._[H&#O^Z!HZZ  !_Q0  <-$
M &+>  !4Y0  1NL  #_^   Y_P  -/\) "__#@ K_Q0 )_\: 2/_(0$?_R4!
M'/\J 1G_+P$6_S0"%/\Z A'_0 (0_T8"#O]. @S_5@()_V #!_]L P3_> ,#
M_X8# O^1 P'_G0,!_Z$# ?^A P'_H0,!_Z$# ?^A _\V+0+_.2X"_SXN _]
M,@/_0#@$_SY!!O\\3 C_.EH*_SAH#/\V=@[_-8,/_S2/$/\SF1'_,Z$1_S.I
M$O\RL!+_,K<2_S*_$O\RR!/_,M,3_S+C$_\R[1/_,O82_S/^$O\S_Q+_,_\2
M_S/_$?\S_Q'_,_\0_S/_$/\S_Q#_,_\0_S/_$/\V+0+_.RP"_T L _]#+P/_
M0S4$_T(^!O] 2@C_/E<+_SQE#?\Z<P__.( 0_S>,$?\WEA+_-I\3_S:G$_\V
MKA3_-K44_S:\%/\UQ17_-= 5_S7@%?\VZQ7_-O05_S;]%/\V_Q3_-O\4_C?_
M$_XV_Q/]-O\2_3;_$OTV_Q+]-O\2_3;_$O\W+ +_/BH"_T,J O]&+0/_1S($
M_T8\!O]%2 C_0U4+_T%B#?\_<!#_/7T1_SR)$_\[DQ3_.YP5_SJD%O\ZJQ;_
M.K(7_SJY%_\YPA?_.<P7_SG=&/\YZ1C_.?,8_SK[&/PZ_Q?Z.O\7^3K_%O@Z
M_Q;X.O\5^#K_%?@Z_Q7X.O\5^#K_%?\Y*P+_02<"_T8G O]**0/_2R\$_TPY
M!O]+10C_2%$+_T9>#O]$;!'_0GD3_T&%%?] CQ?_0)@8_S^@&/\_IQG_/JX:
M_SZV&O\^OAO_/L@;_SW6'/X]YAS[/O$<^#[Z'/4^_QSS/O\:\C__&?$__QGQ
M/_\8\3__&/$__QCQ/_\8\3__&/\]* +_120"_THC O].)0/_42P$_U(V!O]1
M00C_3TT,_TQ:#_]*9Q+_2'05_T> %_]&BQG_190;_T2<'/]#I!W^0ZL>_4*R
M'_Q"NB#Z0L0@^4+0(?9!XB'R0NXB[T+Y(NU"_R#K0_\?ZD/_'>E$_QSH1/\;
MZ$3_&^A$_QOH1/\;Z$3_&_] )0+_2"$"_T\@ O]3(0+_5RD#_UDS!?]8/@C_
M5DD,_U)5$/]18Q3_3V\7_DU[&OM+AAWY2H\?]TF8(?9(GR+T1Z8D\T>N)?%&
MMB;P1K\G[T7+*.Q%WBGH1>PIY4;X*.)'_R;A2/\DWTG_(MY)_R#=2?\?W4G_
M']U)_Q_=2?\?W4G_'_]#(@+_3!X!_U,< O]9'@+_728#_U\P!/]?.@?_744+
M_UI0$/U87A7X56H9]5-V'?)1@"'O3XHD[4V3)NM,FBGI2Z(KYTJI+.5)L2[D
M2+LOXDC',>!(V3'<2.HQV$GV+M1+_RO23/\IT$W_)L]._R7.3O\CSD[_(\Y.
M_R/.3O\CSD[_(_]''P'_4!H!_U<8 ?]>' '_8R,"_V8L!/]F-@;_9$$*^F),
M#_1?617O7&4;ZUEP(.=6>R7D5(0IX5&-+=Y0E3#<3YTRV4ZE,]9-K3733;<V
MT4S"-\],T3C,3.8XR4WT-<=/_S'%4?\NQ%+_*\-3_RG"4_\GPE/_)\)3_R?"
M4_\GPE/_)_]*' '_5!<!_UP5 ?]C&0'_:2 "_VPI _]M,@7Y;#T)\FE'#NMF
M5!7E8V <X%]K(MM<=2C667\MTE>(,,]5D#/,5)@VRE.@.,=2ISK%4; [PU"[
M/,%0R3V_4-\]O%'P.[I3_#>Y5?\SN%?_+[=8_RVW6/\KMUC_*[=8_RNW6/\K
MMUC_*_]-&@'_5Q0!_V 2 ?]H%P'_;AT!_W(E OMS+@/R<S@'Z7%##>)N4!3;
M:5P<TV5F),YB<"K)7WHOQER",\-;BC; 69(YO5B:.[M6HCZX5:L_ME6U0;14
MPD*R5-1"L%7J0:Y7^3RN6?\WK5O_,ZU<_S"M7?\NK5W_+JU=_RZM7?\NK5W_
M+O]0%P'_6A(!_V00 /]M% #_<QH!_W<A ?1Y*0+J>C,%XG@_"MET3!//<%@<
MR6MB),1H;"N_974PNV)]-;A@A3BU7HT\LER5/J];G4&M6J9#JUFO1*E9O$6G
M6,Q&I%CE1J1;]D"C7O\[HU__-Z-@_S.C8?\QHV'_,:-A_S&C8?\QHV'_,?]3
M%0'_71  _V@/ /]P$@#_=Q8 ^WP< >Y_) 'D@"T#VG\[",]Z21+'=50;P7%?
M)+MM:"NV:G QLF=Y-J]E@#JK8X@]J&&00*9@F$.C7J%%H%ZK1YY=MTB<7<9)
MFES?29I?\D2:8O\^FF/_.9ME_S:;9?\SFV7_,YME_S.;9?\SFV7_,_]5$P'_
M8 X _VL. /]T$ #_>Q( ]8$7 .B$'@#>AR<!T80W!\A_1A' >U$;N79;([1R
M92NO;VTQJFQU-J=J?#JC:(0^H&:,09UDE$2:8YU'EV*G295ALDN38<%,D6'8
M3)%C[T>29?U!DF?_/)-I_SB3:O\UDVK_-9-J_S63:O\UDVK_-?]7$0'_8PT
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M0GIX_SY[>?\Z>WG_.GMY_SI[>?\Z>WG_.O]?# #_; 0 ]7D" -Z# @#3BP4
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M/&.,_SQCC/\\8XS_//]J  #F>@  U88  ,F1  # F0$ N)\! +"E  "HJ0X
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M&C;AS1HVW^P:-=[Y&C3=_QLTW/\;--S_&S3<_QLTW/\;--S_&[F<  "JI
MGJL  )*U  "%O@  ><<  &W/  !BU@, 6.$( %7J$P!1ZR  3>LK 4GK-0)%
M[#X$0NQ'!3_L3P<][5@).NU@"CCM:@PV[G0-,^Z #C+NC@\P[YT0+N^M$2WP
MP!$M\-X1+.[Q$2SL_A$LZ_\0+.O_$"SK_Q LZ_\0+.O_$*VB  "@J0  D[,
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M PG_M0,(_\(#"/_" PC_P@,(_\(#"/_" XJX  ![PP  ;,X  %[;  !/X@
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M-ZI2]#.I5/\NJ%;_*ZA7_RBH5_\EJ%?_):A7_R6H5_\EJ%?_)?]-$P#_5@X
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M-8=G_S&':/\NAVG_+8=I_RV':?\MAVG_+?]7# #_800 _FP# .1U 0#;>P4
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M,7%X_S%Q>/\Q<7C_,?]? @#W;   WG<  -"!  #'B $ P(T# +F1 P"RDQ$
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M+T.MR"]"K.<O0ZOY+42K_RM$JO\I1*K_*42J_RE$JO\I1*K_*=&   #!C0
MM9@  *F?  ">I0  DZP  (BR  !]N   <;X& &Z_%0!JOR8!9K\S V&^/P==
MOD@+6;U1#U6]61-1O& 73KQH&DN[<1U(NWL?1;J'(D*ZE"1 NJ(F/KJS)CVZ
MR"8]NN@F/;CY)3VW_R0]MO\C/;;_(SVV_R,]MO\C/;;_(\>(  "YE0  K)T
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M,-CV$C#6_Q,OU/\3+]3_$R_4_Q,OU/\3+]3_$[.:  "FH0  FJD  (VQ  "
MN@  =,$  &C)  !<SP  4M4# $C<" !%Y1( 0^4> $'F*@ ^YC4!.^<^ 3GG
M1P(WYU #-.A9!#+H8@4PZ&T&+NEY!RSIAP@KZI8)*>JG"BCJN@HGZ]8*)^GP
M"B?G_0DFYO\*)N;_"B;F_PHFYO\*)N;_"JB@  "<IP  C[   (*Y  !TP@
M:,H  %O1  !/UP  1=T  #[N"0 \\A$ .?,; #;S)0 T]"X ,?0W 2[U/P$L
M]4<!*?9/ B?V5P(E]V$#(_=L R'X>@0?^(D$'OF:!1SYJP4;^L %&OK>!1KY
M\@4:]_T%&?;_!1GV_P49]O\%&?;_!9ZF  "1KP  @[D  '7"  !GRP  6M,
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M&\L_^QK)0/\8QT#_%\9!_Q7%0?\4Q$'_%,1!_Q3$0?\4Q$'_%/]!%P#_1Q(
M_TP0 /]2% #_5AL _U<D ?]6+@+X5#D#\5%%!NM/4@GF35X,X4MI$-U)=!/9
M2'T6U4:&&-)%CAK0198<SD2='<Q$I1[*0ZT?R$.V(,9#PR'%0],AP4/I(;Y$
M]Q^\1?\=ND;_&[E'_QFX1_\8N$?_%[A'_Q>X1_\7N$?_%_]$% #_2Q  _U$.
M /]7$0#_6Q8 _UT> /E=* 'O6S,"YUD_!.!730C:5%D-TU)D$LY0;A;*3G<9
MQTR ',5+B!["2I @P$J7(;Y)GR.\2*<DNDBP);A(O":W2,LGM$?C)[))\R6P
M2O\BKDO_'ZY,_QVM3/\;K4W_&JU-_QJM3?\:K4W_&O]'$0#_3PT _U8, /]<
M#@#_8!( _6(8 /!C(0#F8BP!WF Z ]1>2 ?-6U0-QUA?$\-6:1>_5'(;O%)Z
M'KE1@B&V4(HCM$^1);).F2>P3:(HKDVK*JQ,MBNJ3,0LJ$S;+*9-[RJD3_TF
MI%#_(Z-1_R"C4O\>HE+_':)2_QVB4O\=HE+_'?]*#P#_4@H _UH) /]@"P#_
M90X ]6<1 .AH& #=9R0 TF8U LID1 ?#85 -O5Y;$[E<9!BU6FT<L5AU(*Y7
M?2.L580EJ52,**=3E"JE4ITLHU*F+:%1L2^?4;XPG5'1,)M1ZB^:4_HJFE7_
M)IE6_R.95O\AF5?_'YE7_Q^95_\?F5?_'_]-#0#_508 _UT% /MD!P#O:0D
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M"0#$=A< O'8J ;1T.@6N<48,IVY1$J)K6AB>:6(=FF=I(99E<2639'@HD&*
M*XUAB"Z+8)$QB%^:,X9>I36#7K(W@E["-X!>W#B 7_(S@6'_+8)B_RF"8_\F
M@F3_)8)D_R6"9/\E@F3_)?]3!@#_70  YV<  -MO  #0= ( RG@% ,9Y!P"^
M>A4 MGHH :]X-P6H=D0+HG-.$IQP5QB8;5\=E&MG(9!J;B6-:'4HBF=]*X=E
MA2Z$9(XQ@6.7-']BHC9\8J\X>F*^.7EBU3EY8^\T>F7^+WMF_RM\9_\H?&?_
M)GQG_R9\9_\F?&?_)O]5 P#_8   XVH  -5R  #,> $ Q7L# ,!]!0"Y?A(
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M-%&(PS50B.(T4HCV,%.(_RQ4B/\I58C_*%6(_RA5B/\H58C_*.9K  #0>
MPH,  +>,  "MD@  HY8  )J:  ".G@  AY\0 (.?( !^GR\">)T[!W.<10QN
MFTT1:9E5%F687!IAEV,>7I9J(5N5<B57E'PH5).&*U&2DBY.DJ P3)*O,4N2
MPC%*D> Q3)'U+4V1_RI.D/\H3I#_)DZ0_R9.D/\F3I#_)MYP  #)?0  O(D
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M'#FR_QPYL?\;.;#_&SFP_QLYL/\;.;#_&\&&  "TDP  IYH  )R@  "1IP
MA:T  'FS  !MN   8KT! %;"!P!3PQ0 4L,C %#$, %-Q#L"2L1% T?$3@5%
MQ%<'0L-?"4##: L]PW(-.\-^#SC#C!$VPYL2-<.K$S/#P!,SP^ 3,\'U$S+
M_Q0RO_\4,;[_%#&^_Q0QOO\4,;[_%+B0  "KF0  GZ   ).G  "'K@  >[0
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M A+P_P(2\/\"$O#_ IJD  "-K0  ?[8  '&_  !CQP  5LX  $G3   ]V@
M,]\  "KC   F] 4 )/L- "'\$P >_1L '/TB !G^*0 7_C$ %?\Y !/_00 1
M_TH $/]5  [_80 ,_V\!#/^  0K_DP$)_Z8!"/^Z 0?_U $'_^L!!O_V 0;_
M]@$&__8!!O_V 8^L  " M@  <K\  &/)  !6T0  2-@  #O=   PX@  )N8
M !_P   <_P  &?\) !;_#@ 4_Q, $?\9  __'@ -_R0 "_\K  G_,@ &_SL
M _]$  #_3P  _UP  /]K  #_?0  _Y   /^C  #_M   _\8  /_6  #_U@
M_]8  /_6 (*U  !SOP  9,D  %;3  !'VP  .N   "[E   CZ0  &NT  !7]
M   2_P  $/\"  [_"0 +_PT "/\0  3_$P !_Q@  /\>  #_)   _RL  /\S
M  #_/0  _TD  /]6  #_9@  _W@  /^*  #_FP  _Z@  /^Q  #_L0  _[$
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M)@'_+B,!_R\B ?\O)0'_+"L!_RHU O\G00+_)$X#_R); _\@: 3_'G0$_QV
M!/\=B@3_'9(%_QV:!?\=H07_':<%_QVM!?\=M 3_';T$_QW'!/\=U 3^'>8$
M^QWR!/<>^P/U'O\$]![_!/,>_P3S'O\$\A[_!/(>_P3R'O\$\A[_!/\N(@'_
M,A\!_S0> ?\S( '_,B8!_S(R ?\O/@+_+$H#_RI7 _\G9 3_)G %_R5[!?\D
MA07_)(X&_R26!O\DG0;_)*,&_R2J!OTDL0;\)+D&^R3#!ODDSP;V).,&\B3P
M!>XE^@7M)?\&ZR7_!NHE_P;I)?\&Z27_!NDE_P;I)?\&Z27_!O\R'@'_-AL
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M3A8 _T\? /U.*0'T3#0![$A! N9'3@3@15L&VT1F"=9"< S207D.ST""$,U
MBA'*/Y$3R3^9%,<^H!7%/J@6PSZQ%\$^O!? /LL8O3[B&+H^\A>W/_\6M4#_
M%+1 _Q.S0?\1LT'_$+-!_Q"S0?\0LT'_$/] $ #_1@P _TL* /]1#0#_4Q$
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M&HM6_QJ+5O\:BU;_&O],! #_4P  [%P  -]B  #49@$ SF@% ,MG" #"9Q8
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M+UYPPB]=<-\O7W'U*F!Q_R9A<O\C8G+_(&)R_R!B<O\@8G+_(.]<  #<:0
MRG(  +YZ  "U@   K80  *2%  ":A0, E(44 (Z&)0&)A#,#@X,^!WZ!2 MY
M?U 0=7Y7%'%]7AAN>V4;:WIL'FAY=")E>'TE8G>'*%]VDRI<=I\L6G6N+EEU
MP"Y8==TN67;S*EMV_R9<=_\C7'?_(%QW_R!<=_\@7'?_(.I@  #5;   Q78
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M)$B,_R))B_\@2HO_'DJ+_QY*B_\>2HO_'M5N  ##>P  MX4  *R-  "BD@
MEY8  (R9  !_G   =9X% '"?$P!MGR, :9\P 66>.P1AGD4'79U-"EJ<5 U7
MFUP15)IC%%&::Q=.F7092YA_'$B8BQY%EYD@0Y>H(4*7NB)!E],B09;O($*5
M_AY"E?\=0Y3_'$.4_QQ#E/\<0Y3_',QU  "\@0  L8P  *:2  ";EP  D9L
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M#BRX_PXLN/\.++C_#K./  "FEP  FYT  (^C  "#J@  =K   &JU  !>N@
M4KX  $?" 0 ]QP8 .,D0 #?)&P VRB< -<HS #3+/0 SRT< ,<M1 3#+6P$N
MS&4"+,QQ BK,?P,IS) $)\RA!";-M 0ES<X$)<ON!"3)_ 8CR/\'(\?_!R/'
M_P<CQ_\'(\?_!ZF6  ">G0  DJ,  (6K  !XL@  :[@  %^^  !2P@  1\8
M #W*   TSP0 *]0) ";9#P EV1D )=HE "3:,  CVSL (]M% "+<4  AW5L
M(-UH ![>=@ =WH<!'-^9 1K?K $9W\0!&-[G 1C<^ $8V_\"%]K_ A?:_P(7
MVO\"%]K_ J"<  "4HP  AZL  'FS  !LN@  7\$  %+&  !&R@  .\X  #'3
M   IV0  (=X% ![H#@ =Z!4 &^D> !GI)P 8ZC  %NHY !7K0P 4[$X $NQ:
M !'M9P 0[G< $.Z*  [OG@ .\+, #?#-  SO[  ,[?P #.O_  SK_P ,Z_\
M#.O_ )>C  ")JP  >[0  &V\  !?Q   4LH  $7.   YTP  +]@  "7=   =
MX0  &.P" !;W"P 4]Q$ $?@7 !#X'@ .^24 #?DM  OZ-0 )^S\ !_M*  3\
M5P #_68  OYW  #]BP  _9\  /RU  #\T0  _.T  /S\  #\_0  _/T  /S]
M (NK  !]M   ;KT  &#&  !2S0  1-(  #?8   LW0  (N$  !GE   3Z@
M$/H   [_!@ -_PP "O\0  ?_%  $_QH  ?\@  #_)P  _S   /\Z  #_10
M_U,  /]B  #_=0  _XH  /^?  #_LP  _\<  /_E  #_Y0  _^4  /_E '^T
M  !PO0  8<<  %/0  !#U@  -MT  "KB   ?Y@  %NH  !#M   ,^@  "?\
M  ;_   "_P0  /\)  #_#0  _Q   /\4  #_&@  _R$  /\I  #_-   _T
M /].  #_7@  _W(  /^'  #_F@  _ZH  /^Y  #_N0  _[D  /^Y /\@*0'_
M(B<!_R(G ?\?*@'_&3 !_Q(Y ?\010'_#5,!_PQ@ ?\*;0+_"7D"_PF$ O\)
MC@'_"98!_PF= ?\)HP'_":D!_PFP ?\(MP'_"+X!_PC( ?\(U@'_".8!_PCQ
M ?\(^P#_"/\ _PC_ /\)_P'_"?\!_PG_ ?\)_P'_"?\!_PG_ ?\C)@'_)20
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M!-DD_P38)/\$UR3_!-8D_P36)/\$UB3_!/\Q%@#_-!( _S81 /\W$P#_.1L
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M#J)!_PZB0?\.HD'_#O\_"0#_1   _TH  /=. @#L4 8 ZD\+ .-,$ #63!X
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M)6M>P29I7MXF:E_T(6M@_QUK8?\;;&'_&6QA_QAL8?\8;&'_&/51  #B7
MSV4  ,-K  "Y;P  L7$  *IQ  "B;P@ FV\7 )9P)P"0;S4"BVY !89L20B"
M:E(,?FE9#WMH8!)W9F84=69N%W)E=AIP9'X=;6.('VMCDR)I8J D9F*N)65B
MOR9D8MHF9&/R(F5D_QYF9/\;9V3_&6=E_QAG9?\89V7_&/!3  #=7P  RV@
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M(E9Q_AY7<?\<5W'_&EAQ_QE8<?\96''_&>->  #-:0  OW,  +1Z  "K?P
MHH(  )B#  "+@0  A($- '^"&@![@BD!=H$V G*!0 5N?TD(:GY0"V=]5PYD
M?%X187MF%%YZ;1=;>G8967F '%9XBQ]3>)@A47>F(E!WMR-/=\XC3W?L(5!W
M_1Y1=_\;4G?_&5)W_QE2=_\94G?_&=YB  #(;@  NW<  +!_  "GA   G8<
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M%3Z/_Q4^C_\5/H__%<5S  "W?P  K(D  *&/  "6DP  BY8  '^9  !SG
M9)\  %R@"0!9H!0 5Z$B %6A+P!2H3D!4*%# DV@2P1*H%,%2*!:!T6?8PE#
MGVP+0)YV#CZ>@Q [GI$1.9V@$CB=LA,WGL@3-YWH$C:;^A(VFO\2-IG_$3>9
M_Q$WF?\1-YG_$;Y[  "QAP  I8\  )N4  "0F   A)P  '>@  !KI   7Z<
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M!*64  ":F@  CJ$  (&G  !SK@  9[0  %JY  !.O0  0L   #C#   OQP
M)LL$ ![0"@ ;T1$ &M(: !G2)0 8TR\ &-,Z !?41  6U%  %=5= !35:P 3
MUGP $M>/ !'8I  0V;L $-G> !#5\P 0T_\ $-+_ 1#1_P$0T?\!$-'_ 9R:
M  "1H0  @Z@  '6P  !HMP  6[T  $[!  !"Q0  -\@  "W,   DT   '-4
M !7:!0 0X@L $.,1  [D&@ .Y", #>4M  SE-P +YD( "N9/  GG70 (YVT
M!N:   7FE0 $YJL  N;$  'FY@  Y_D  .?_  #F_P  YO\  .;_ ).A  "%
MJ0  =[$  &FY  !;P   3L8  $'*   US@  *M(  "'6   9VP  $M\   WC
M   +\0@ "?,.  ?S$P $\AH  O(B  #R*@  \C0  /(_  #R3   \EP  /)M
M  #R@@  \I@  /.M  #SQ@  ].4  /3V  #T^P  ]/L  /3[ (>I  !YL@
M:KH  %S"  !.R0  0,X  #/3   HV   'MT  !7A   /Y   "N@   7S   #
M_0$  /P(  #[#0  ^Q$  /L6  #\'@  _"8  /PP  #]/   _DD  /Y:  #^
M;0  _X(  /^8  #_K   _\   /_8  #_Y   _^0  /_D 'NR  !LNP  7<0
M $_-  ! T@  ,MD  ";>   ;X@  $N8   SJ   %[0   /0   #_    _P
M /\   #_!   _PD  /\.  #_$@  _Q@  /\A  #_*P  _S<  /]&  #_6
M_VL  /^   #_E0  _Z8  /^S  #_NP  _[L  /^[ /\;)@#_'"0 _QHD /\5
M)P#_$"T _PHV /\%0P#_ 5 !_P!> ?\ :P'_ '8!_P"! /\ B@#_ )( _P":
M /\ H #_ *8 _P"L /\ L@#_ +D _P#" /\ S0#_ -\ _P#L /\ ^ #_ /\
M_0#_ /T _P#] /\ _0#_ /T _P#] /\ _0#_ /\?(P#_'R$ _QXA /\9(P#_
M$RD _PXR /\,0 #_"4T!_P=: ?\$9P'_ W,!_P-] ?\#AP'_ X\ _P*6 /\"
MG #_ J( _P*H /\"KP#_ ;8 _P&^ /\!R0#_ =L _P#J /P ]@#X /\ ]P+_
M /<#_P#V!/\ ]@3_ /8%_P#V!?\ ]@7_ /\B'P#_(AP _R$< /\>'P#_&"0
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M \$D_P/!)/\#P23_ _\P#P#_,@L _S,( /\V#0#_-A( _S4: /TR)0#T,#(
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M0ZP4CT.Z%8U#S16+1.@5BD7Z$HE&_Q")1O\.B$;_#8A&_PV(1O\-B$;_#?]
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M&7I-PQIY3=\:>$[T%WA/_Q1X3_\2>%#_$'A0_P]X4/\/>%#_#_U&  #G3P
MUE<  ,A<  "_7P  MU\  +%<  "J60P I%H: )Y;*@"96S@!E%I# Y!93 6,
M6%4(B5=<"H968PR#56H.@51Q$']3>1)]4X$4>E*+%GA2E1AV4:$9=%&O&W-1
MP!MQ4=L<<5+R&7%3_Q5Q5/\3<E3_$7)4_Q!R5/\0<E3_$/-(  #C4P  T%L
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M&V!?_1AA7_\585__$V)?_Q)B7_\28E__$NI1  #47   Q&0  +EJ  "P;@
MIW   )YN  "4:P  C6H0 (=K'@"#:RP ?FLX GIJ0@-V:4H&<VA2"'!G60IM
M9F -:V5G#VAD;A%F9'<49&.!%F%CC!A?8I@:76*F'%MBMAU:8LP=6F+J'%MC
M_!A<8_\67&/_%%UC_Q-=8_\376/_$^95  #/7P  P6@  +9N  "L<@  I'0
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M$TUR_Q)-<O\237+_$M1@  #":P  M70  *M[  "B?P  EX$  (R!  !Z?@
M<W\" &Y_$0!K@!X :( L &6 -P%B@$ #7W](!%Q^4 99?E<(5WU>"U1\9@U1
M?&X/3WMX$4Q[@Q1*>I$62'J?%T9ZKQA%>L081'KD&$5Y^!9&>?\41GC_$D=X
M_Q%'>/\11WC_$<UE  "]<   L7D  *>   "<A   DH8  (:&  !WA@  :X8
M &:'#0!CAQD 8(@G %Z(,P%;B#P"6(=% U:'3013AE0&4(9;"$Z%8PI+A&P,
M281V#T:#@1%$@X\30H.=%$""KA4_@\(5/H+B%3^!]Q,_@?\20(#_$4" _Q!
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M"[AZ  "LA0  H8L  ):0  "+E   ?Y<  '*;  !FG0  6J   $ZB  !%I D
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M !? H0 6P+8 %,#3 !6^\0 5O/\!%;O_ 12Z_P(4NO\"%+K_ J&2  "6F
MBIX  'VD  !OJ@  8J\  %:T  !*MP  /KH  #.]   JP   (<0  !G'!0 3
MRPL $<P2 !',&P 0S"4 #\TO  [-.@ .S48 #<U2  W.8  ,SG  "\Z#  K.
MEP )SJP ",[&  C.Z  (S?L "<O_  G+_P )R_\ "<O_ )B8  "-G@  ?Z4
M '&L  !DLP  5[D  $J]   ^P   ,L,  "C&   ?R@  %\T  !'1   ,U@4
M"-D,  ;9$@ %VAL !-HD  /;+@ !VSD  -Q%  #=4@  WF(  -YS  #>B
MWYT  -^S  #?S@  X.X  -_Z  #?_P  W_\  -__ (^?  "!I@  <ZX  &6U
M  !8O0  2L(  #W%   QR0  )LP  !W0   4U   #MD   G=   #X0   .,'
M  #C#0  Y!(  .49  #F(@  YRL  .DV  #K0P  [%(  .QB  #M=@  [HP
M .ZA  #OMP  []$  ._K  #P]@  \/8  /#V (2G  !UKP  9[<  %F_  !+
MQ@  /,H  "_.   DT@  &M@  !+<   ,X   !>,   #G    ZP   .L   #M
M!0  [@L  / 0  #Q%0  \QX  /0G  #W,P  ^4   /I1  #[8P  _'<  /V-
M  #]HP  _K8  /[)  #_WP  _]\  /_? '>P  !HN0  6L$  $S*   \SP
M+M0  "+:   7W@  $.(   GF    Z0   .P   #P    ]@   /8   #W
M^    /H'  #[#0  _1$  /\9  #_(P  _R\  /\^  #_3P  _V(  /]W  #_
MC0  _Y\  /^N  #_N@  _[H  /^Z /\6(P#_%2$ _Q(A /\.) #_!BH _P S
M /\ 00#_ $X _P!< /\ : #_ '0 _P!^ /\ AP#_ (\ _P"6 /\ G #_ *(
M_P"H /\ K@#_ +4 _P"] /\ QP#_ -8 _P#G /X \P#^ /X _0#_ /P _P#[
M /\ ^P#_ /L _P#[ /\ ^P#_ /\:( #_&1X _Q8> /\0( #_"B4 _P0P /\
M/0#_ $L _P!8 /\ 9 #_ '  _P!Z /\ @P#_ (L _P"2 /\ F #_ )X _P"D
M /\ J@#_ +$ _0"Y /L PP#Z -  ^ #C /< \0#V /P ] #_ /0 _P#S /\
M\P#_ /, _P#S /\ \P#_ /\=' #_'!D _QD9 /\4&P#_#B$ _PPL /\).0#_
M!48 _P)3 /\ 7P#_ &L _P!U /\ ?@#_ (8 _P". /\ E #^ )L _ "A /H
MIP#X *X ]0"U /, OP#Q ,L \ #? .X [@#L /D ZP#_ .H _P#J ?\ Z0'_
M .D!_P#I ?\ Z0'_ /\@%P#_'Q0 _QP3 /\7%0#_%AT _Q,H /\0- #_#4$
M_PQ. /\)6@#_"&8 _PAP /X'>0#\!X$ ^@>) /@'D #V!I8 \P:= /$&HP#O
M!JH [0:R /_B__])0T-?4%)/1DE,10 (">H&NP#H!L@ Y@;< .0&[ #B"/H
MX K_ -X+_P#="_\ W0S_ -P,_P#<#/\ W S_ /\C$@#_(Q  _R$. /\>$ #_
M'A@ _QPC /\8+P#_%#L _Q)) /P050#X#V  ] ]J /$/= #O#GP [0Z$ .L.
MBP#I#I( YPZ9 .8.H #D#J< X@ZO . .N #>#L4 W [: -80[ #2$?H SQ+_
M ,T2_P',$O\!RQ/_ <H3_P'*$O\!RA+_ ?\G#P#_)PP _R4) /\F#0#_)1,
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M!I8T_P66-/\%EC3_!?\U  #_.   ZCX  -]"  #50@  SS\# ,TX" #%.!4
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M"O)"  #@3   SE,  ,%8  "X6@  L%D  *E6  "B4@< FU(5 )93) "14S(
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M%&%5M!5@5<@67U7G%6!6^A)@5O\/85?_#F%7_PUA5_\,85?_#.=,  #15@
MP5X  +9C  "M9@  I&8  )MD  "07@  B5X. (1?&P" 7RD ?%\U 7A?/P)T
M7D<#<5U/!&]<5@5L7%P':EMC"6A;:PMF6G,-9%I]#V):B!%?69037EFB%%Q9
MLA5;6<866EGE%5M:^1);6O\07%K_#EQ:_PU<6O\-7%K_#>-/  #-60  OF$
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M%$MG]1),9_\/3&?_#DUG_PU-9_\-36?_#=):  # 9   LVP  *ER  "@=@
MEG<  (IV  !Y<0  <7$  &MQ#P!H<1P 9G(H &-R- !@<CT!7G)% EMQ30-9
M<50%5W!;!E1P8PA2;VL*4&]T#$UN@ Y+;HT026Z;$4=MJQ)&;KX316[<$D9M
M]!%&;?\/1VW_#D=L_PU';/\-1VS_#<Q?  "\:0  L'$  *5W  "<>P  D7P
M (9[  !U>   :W<  &5W# !A>!< 7W@D %UY, !:>3H!6'E" E9X2@)3>%$$
M47=8!4]W8 =,=F@(2G9R"DAU?0Q%=8H.0W69#T)UJ1! =;P00'79$$!T\P]
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M"3.#_PDS@_\),X/_";EP  "M>@  HH(  )>'  "-B@  @8P  '6.  !HCP
M6I   $^1  !'D@H 1)(3 $.3'P!!DRH 0),T #^3/0 ]DT4 .Y-- 3J35@$X
MDU\"-I-I S23=0,RDH,$,)*3!2Z2I 8MDK<&+)+1!BR1[P8KC_\&*X[_!BN-
M_P<KC?\'*XW_![-X  "G@@  G(@  )&,  "'D   >I,  &V5  !AEP  59D
M $F;   _G $ .9T. #>=%P VGB( -)XL #.>-0 RGCX ,9Y' #"?4  NGUH
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M )R0  "2E0  AIL  'F@  !KI@  7JL  %*O  !&L@  .K4  "^W   EN@
M';T  !7    0PP8 "\8.  K%%0 )Q1X ",4H  ?%,@ &QCT !<9)  7&5P #
MQF8  L9W  '&BP  QJ   ,6V  #&T@  Q>\  ,7\  #%_P  Q?\  ,7_ )66
M  ")G   >Z,  &VI  !@KP  4[0  $:X   ZNP  +KX  "3!   ;Q   $\<
M  [*   (S@$  = *  #0$   T!8  -$>  #2)P  TS$  -0\  #520  UE@
M -9I  #6?   UI(  -:G  #6OP  UN   -;S  #6_@  UO\  -;_ (R=  !^
MI   ;ZL  &&R  !4N0  1KT  #G!   MQ   (L<  !G+   1S@  #-(   75
M    VP   -P#  #="@  W@\  -\4  #A'   XB0  .0N  #F.@  YTD  .A9
M  #H:P  Z8$  .F8  #IK0  Z<4  .GB  #I\@  Z?4  .GU ("E  !QK0
M8[4  %6\  !'P@  .<8  "S*   @S@  %M(   _6   (VP   -\   #C
MY0   .<   #H 0  Z@<  .L-  #M$0  [Q@  /$A  #S*P  ]C@  /=(  #X
M6@  ^6T  /J$  #ZFP  ^J\  /K"  #ZV@  ^M\  /K? '2N  !EM@  5KX
M $C&   YRP  *]   !_4   4V@  #=\   7C    Y@   .D   #M    [P
M /$   #S    ]0   /8"  #X"0  ^@X  /T3  #_'   _R@  /\V  #_1P
M_UH  /]N  #_A0  _YH  /^K  #_N0  _[P  /^\ /\1( #_$!X _PP> /\$
M(0#_ "< _P P /\ /@#_ $P _P!9 /\ 90#_ '  _P!Z /\ @P#_ (L _P"2
M /\ F #_ )X _P"D /\ J@#_ +  _P"X /\ P@#_ ,X _P#B /X \ #] /L
M^P#_ /L _P#[ /\ ^@#_ /H _P#Z /\ ^@#_ /\4' #_$AH _PX: /\(' #_
M "$ _P M /\ .@#_ $@ _P!5 /\ 80#_ &P _P!V /\ ?P#_ (< _P". /\
ME #_ )H _@"@ /T I@#\ *P ^P"T /D O0#X ,D ]P#< /4 [ #S /@ \P#_
M /( _P#Q /\ \ #_ /  _P#P /\ \ #_ /\7& #_%18 _Q$5 /\,%P#_!1T
M_P H /\ -@#_ $, _P!0 /\ 7 #_ &< _P!Q /\ >@#\ (( ^@") /@ D #W
M )8 ]0"< /0 H@#S *@ \0"P /  N #N ,, [ #3 .H YP#I /4 YP#_ .8
M_P#E /\ Y0#_ .4 _P#E /\ Y0#_ /\:$P#_&!$ _Q00 /\/$0#_#1D _PHD
M /\%, #_ 3X _P!+ /\ 5P#^ &( ^@!L /4 =0#R 'T \ "$ .X BP#L )$
MZP"7 .D G@#G *0 Y@"L .0 M #B +\ X #- -X XP#< /( V@#] -@ _P#6
M /\ U0'_ -4!_P#5 O\ U0+_ /\>$ #_' T _Q<+ /\5#@#_%!4 _Q$? /\.
M*@#_"S@ _0A% /@&40#T!%P [@1F .H$;P#F W< Y 1_ .($A@#@!(P W@23
M -T%F@#;!:  V 6H -4%L0#2!;L T ;) ,X'X #,"/$ R0K_ ,<+_P#&#/\
MQ0S_ ,4,_P#%#/\ Q0S_ /\A# #_( 8 _QP# /\="@#_&Q  _Q@8 /\4(P#V
M$3  [PX^ .H.2@#E#58 X0U@ -T-:0#9#7$ U0UY -,-@0#1#8@ SPV/ ,T.
ME@#+#IT R@ZE ,@.K@#&#[D Q!#( ,(0WP"^$?( NQ+_ +D3_P"W$_\!MA/_
M ;83_P&V$_\!MA/_ ?\E!@#_(P  _R,  /\D P#_(0H _1T1 /$:&P#H%B<
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M!/PS  #K.@  W$$  ,U$  ##1   O4$  +@[ 0"R-PX JS@< *4Y*P"A.C@
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M"W!#M0QN1,D,;43G#&U%^@IL1?\(;$7_!VQ%_P=L1?\';$7_!^P_  #820
MQU   +M4  "Q50  J50  *%0  "92@( DDD1 (U*'P")2RP A4PX ()+0@%_
M2TH!?$I2 GE*6 -W2E\$=4EF!7-);09Q278';TA_"&U(B@EL2)8+:DBC#&A(
ML@UG2,4-9DGD#69)^ MF2?\)9DK_"&9)_P=F2?\'9DG_!^A#  #230  PE,
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M#U55\PU55?\+5E7_"595_PE65?\(5E7_"-M-  #%5P  N%X  *UB  "C90
MFF4  )!C  "#7   >UL& '5;$@!Q6Q\ ;EPK &M<-@!H6S\!95M' 6-;3@)A
M6E4#7UI<!%U:8P5;6FL&65EU"%=9@ I568P+5%F:#5)9J@Y16;P.4%G8#E!9
M\@U16?\+45G_"E%9_PE16?\(45G_"-11  #"6@  M&$  *IF  "@:   EVD
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M"4%G_PA"9_\(0F?_",5=  "V9@  JFT  *!S  "6=@  BW<  (!V  !P<@
M97$  %QP!P!8<!$ 5G = %1Q* !2<3, 4'$\ $]R1 %-<4L!2W%3 DEQ6@-'
M<6($17!L!4-P=P9!<(0'/W"3"#UOHPD[<+4*.W#-"CIO[ D[;OX(.V[_"#MM
M_P<[;?\'.VW_![]B  "Q:P  IG,  )UY  "2>P  AWP  'M\  !M>@  8'@
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M ZUV  "C@   EX4  (V)  ""C   =HX  &F0  !<D@  4),  $24   ZE0
M,98( "V7$0 LEQH *Y<D "J7+0 IES8 *)@_ ">82  FF%( )9A< ".8:  B
MF'< ()B' !^8F0$=F*P!')C# 1R7Y0$<E?H!&Y3_ 1N3_P(;D_\"&Y/_ J=_
M  "<A@  D8L  (>/  !ZD@  ;94  &&8  !5FP  29T  #V>   SGP  *J$
M "&C"@ ?HQ$ 'J,: !VD)  <I"T &Z0V !JD/P 9I$H &*15 !:E80 5I7
M%*6! !.EE  2I:@ $:6_ !"DX@ 1HO@ $:'_ !&@_P$1H/\!$:#_ :"&  "5
MC   C)$  '^5  !QF@  9)X  %BA  !,I   0*8  #6G   JJ0  (JP  !FN
M   2L D $+$0 !"Q&  .L2( #K$K  VQ-0 -L4  #+%+  NQ6  *L6< "+%X
M  >QBP %L:  !+"U  2PT  $L.\ !:_^  :N_P &KO\ !J[_ )B.  "/DP
M@I@  '6=  !GH@  6J<  $ZK  !!K0  -:\  "NQ   AM   &+8  !&Y   -
MO , ![X,  .]$@ !O1D  +XB  "^*P  OC8  +Y!  "_3@  OUP  +]M  "_
M@   OI4  +ZJ  "^P@  O>0  +WV  "]_P  O?\  +W_ )*4  "%F@  >*
M &JF  !<JP  3[   $*S   UM@  *K@  ""[   7O@  $,$   O$   $QP
M ,D'  #)#0  R1(  ,H9  #+(@  RRL  ,TU  #.00  SE   ,]@  #/<@
MSX<  ,^=  #/LP  S\X  ,_K  #.^   SOX  ,[^ (B;  !ZH@  ;*@  %ZO
M  !0M0  0KD  #6\   IOP  'L(  !7&   .R0  ",P   #0    TP   -4
M  #6!@  V P  -D1  #;%@  W!\  -XH  #@-   XD$  .)1  #C8P  XW<
M .2.  #DI   Y+H  .74  #EZ@  Y?,  .7S 'RC  !NJ@  8+(  %&Y  !#
MO@  -<(  "C&   <R0  $\T   S1   $U0   -H   #>    X0   .(   #D
M    Y0,  .<)  #I#@  ZQ(  .T:  #O)   \C$  /1!  #T4P  ]68  /5\
M  #VDP  ]JD  />\  #WS@  ]]\  /?? '"L  !AM   4[L  $7#   VQP
M)\P  !O0   1U0  "ML   #?    X@   .4   #I    [    .T   #P
M\0   /,   #U!   ]PH  /H0  #\%@  _R$  /\N  #_0   _U,  /]H  #_
M@   _Y8  /^H  #_M@  _[\  /^_ /\-' #_"AL _P(; /\ '@#_ "0 _P N
M /\ / #_ $H _P!6 /\ 8P#_ &T _P!W /\ ?P#_ (< _P". /\ E #_ )H
M_P"@ /\ I@#_ *P _P"T /\ O0#_ ,D _@#= /T [0#\ /H ^P#_ /H _P#Y
M /\ ^@#_ /H _P#Z /\ ^@#_ /\0&0#_#1< _P86 /\ & #_ !X _P J /\
M-P#_ $4 _P!2 /\ 7@#_ &D _P!R /\ >P#_ (( _P") /\ D #^ )8 _0"<
M /P H0#[ *@ ^0"O /@ N #V ,, ] #2 /, YP#R /8 \ #_ .\ _P#P /\
M[P#_ .\ _P#N /\ [@#_ /\2% #_#Q( _PL2 /\ $@#_ !H _P E /\ ,P#_
M $  _P!- /\ 60#_ &0 _0!M /L =@#Y 'T ]P"$ /4 BP#T )$ \P"7 /$
MG0#P *, [@"J .P LP#J +T Z #+ .< X0#E /$ XP#] ., _P#B /\ X0#_
M .$ _P#@ /\ X #_ /\4$ #_$0X _PT- /\'#P#_ A4 _P @ /\ +0#_ #H
M_P!' /D 4P#U %X \@!H /  < #M '@ ZP!_ .D A0#H (P Y@"2 .4 F #C
M )\ X0"F -\ K@#< +@ V@#% -8 V0#4 .P T@#Y -$ _P#/ /\ S@#_ ,X
M_P#. /\ S@#_ /\7# #_% @ _P\% /\."P#_#!$ _P<: /\!)@#\ #0 ] !!
M .T 30#I %@ Y@!B ., :@#@ '( W@!Y -L @ #9 (8 U@"- -, DP#1 )H
MSP"A ,T J@#+ +, R0"_ ,8 T #% .@ PP#V ,$ _P#  O\ OP/_ +\#_P"_
M _\ OP/_ /\;!@#_%P  _Q0  /\3!0#_$0T _PX4 /D*'P#P!BP Y@,Y . #
M1@#< U$ U@1; -($9 #/!6P S 5S ,H%>@#(!8$ Q@6' ,4&C@##!I8 P0:=
M +\&I@"]!K  NP>\ +D(S0"X"N4 M0OW +,-_P"Q#?\ L W_ + ._P"O#O\
MKP[_ /\>  #_&P  _QL  /H:  #U%@4 ]A$- .L.%0#B"R( V LQ - ,/@#+
M#4H QPU5 ,0.7@#!#F8 OPYM +T.= "[#WL N0^" +<0B@"V$)$ M!": +(0
MHP"P$:T KQ&Z *T1R@"J$N4 IQ3W *45_P"C%?\ HA7_ *(5_P"B%?\ HA7_
M /\B  #_(   \",  .8D  #@(0  W!D% -L0# #0$1D R!,I ,(5-P"]%D0
MN1=. +475P"S&&  L!AG *X8;@"L&74 JQE\ *D9A "H&HP IAJ4 *0:G@"C
M&Z@ H1NT )\<Q0">'-\ FAWS 9@>_P&7'O\!EA__ 94?_P&5'_\!E1__ ?\F
M  #T)P  YBT  -HO  #/+0  RB<  ,<?" #!'!, NAXB +0?,0"O(#T JR%(
M *@B4@"F(EH HR-B *$C:0"@(V\ GB-W )PC?@";(X8 F22/ 9<DF0&6)*,!
ME"2P 9(EOP&1)=8!CB;O 8PG_P*+)_\"BB?_ HDG_P*))_\!B2?_ ?HI  #L
M,   W38  ,TX  #$-P  OC(  +HK @"U)0X KB<= *@I*P"D*C@ H"I# )TK
M3 ":*U4 F"M< )8K8P"4*VH!DBMQ 9 L> &/+($!C2R* 8LLE **+)\"B"RK
M H8LN@*%+<X#@R[J X$N_ . +O\"?R[_ G\N_P)^+O\"?B[_ O0N  #D-P
MTCT  ,4_  "[/P  M#P  *\U  "I+PL HR\7 )XQ)@"9,C, EC(^ )(S2 "0
M,U  C3-8 (LS7@&),V4!AS-L 88S<P&$,WP"@C.% H SCP-_,YH#?3.G WPS
MM01Z,\D$>33F!'<U^01V-?\#=37_ W4U_P-U-?\#=37_ _ S  #=/0  RD,
M +Y%  "U1@  K4,  *8]  "@-@8 F383 )0X(0"0.2X C#DY (DY0P"'.4P
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M"&!$\P=@1/\&7T3_!5]$_P1@1/\$8$3_!.!!  #*2@  NU   +!3  "G50
MGE,  )5/  "+20  @T<+ 'U'%0!Y1R( =D@N '-(. !Q2$$ ;DA) 6Q(4 %J
M2%8!:$A= F9'9 )E1VP#8T=V!&%'@ 5@1XT&7D>:!UQ'J0A;2+L(6DC4"%I(
M\0=:2?\&6DG_!5I(_P5:2/\$6DC_!-M$  #&30  N%,  *U7  "C60  FE@
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M!DM4_P5+5/\%2U3_!<Q.  "[5P  KEX  *1B  ":9   D60  (9B  !W6P
M;5@  &98# !B6!8 7U@B %U9+ !;638 65D^ %=91@!664T!5%E4 5)96P)1
M66,#3UEL TU9=P1+6(0%25B2!TA8H@='6;,(1EG*"$59Z@A&6?T&1EC_!D98
M_P5'6/\%1UC_!<=2  "X6P  JV$  *%F  "8:   CFD  (-G  !R8   :%X
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M!+E@  "L:0  H7   )AU  "-=P  @G<  '=W  !I=   7',  %%Q  !(< H
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M "&&E0 @AJ<!'H:\ 1Z&W@ >A/4!'H+_ 1Z"_P$>@?\!'H'_ :AT  ">?0
MDX(  (F%  !^B   <8H  &6+  !8C   3(T  $".   VC@  +(\  "60#  C
MD!, (I < "&0)0 @D2X 'Y$V !Z10  =D4D ')%4 !J18  9D6X &)%^ !:2
MD  5DJ0 %)&Y !.1V  3C_0 %([_ !2-_P 4C/\!%(S_ :-]  "8@P  CH@
M (2,  !WCP  :9$  %V3  !0E0  19<  #F8   NF0  )9H  !V; @ 6G0P
M%9T3 !2=&P 3G20 $ITM !&>-P 1GD$ $)Y,  ^>6  .GF< #9YW  R>B@ +
MG9X "IVR  F=S  )G.P "IO^  N:_P +F?\ "YG_ )R$  "1B@  B(X  'N2
M  !ME@  8)D  %2<  !(GP  /*   #"A   FHP  ':4  !6G   0J04 "ZL-
M  BJ$P 'JAL !JHD  6J+@ $JC@  JI$  &J4   JEX  *IN  "J@0  JI4
M *FJ  "IP0  J.0  *CV  "G_P  I_\  *?_ )6+  ",D   ?Y4  '&:  !C
MG@  5J(  $JF   ]J   ,:H  ":K   =K0  %+    ZR   )M0$  K8*  "V
M#P  MA4  +<=  "W)0  MR\  +@Y  "X1@  N%0  +AD  "X=@  N(L  +>@
M  "WM@  M],  +;O  "V_   MO\  +;_ (^2  ""EP  =)T  &:B  !8IP
M2ZP  #ZO   QL0  )K,  !RV   3N   #;L   :^    P0   ,($  #""P
MPQ   ,05  #$'   Q20  ,8N  #(.@  R4<  ,E7  #):0  R7T  ,F4  #(
MJ@  R,,  ,CD  #(]   R/T  ,C] (69  !WGP  :*8  %JK  !-L0  /[4
M #&X   EN@  &KT  !'    +PP   \<   #*    S0   ,X   #/ P  T D
M -$.  #3$@  U1D  -<B  #:+0  W3D  -Y)  #>6@  WVX  -^%  #?G
MW[(  -[+  #>Y@  W_0  -_T 'FA  !KJ   7*\  $ZU  ! NP  ,;X  "3!
M   9Q0  $,@   G,    SP   -,   #9    W    -T   #?    X0   .(%
M  #D"P  YA   .@6  #J(   [2L  / Z  #Q2P  \5X  /)S  #SBP  \Z(
M /.V  #SR0  \^$  //A &VJ  !>L0  4+D  $&_   RQ   ),@  !?,   .
MT   !M4   #:    W@   .(   #F    Z0   .H   #L    [@   /    #R
M    ] 8  /8,  #Y$@  _!P  /\I  #_.@  _TT  /]B  #_>   _Y   /^C
M  #_LP  _\$  /_! /\'&0#_ 1< _P 7 /\ &@#_ "$ _P K /\ .0#_ $<
M_P!4 /\ 7P#_ &H _P!S /\ >P#_ (, _P"* /\ D #_ )8 _P"; /\ H0#_
M *@ _P"O /\ N #_ ,0 _@#5 /P Z@#[ /@ ^@#_ /D _P#X /\ ^ #_ /8
M_P#S /\ \0#_ /\+%0#_!1, _P 3 /\ % #_ !H _P G /\ - #_ $( _P!/
M /\ 6P#_ &4 _P!N /\ =@#_ 'X _P"% /X BP#] )$ ^P"7 /H G0#X *,
M]P"K /8 LP#T +X \P#, /$ XP#O /, [@#_ .T _P#L /\ ZP#_ .P _P#L
M /\ ZP#_ /\-$0#_"1  _P / /\ $ #_ !8 _P B /\ +P#_ #T _P!* /\
M50#] &  ^@!I /@ <0#V 'D ] !_ /, A@#Q (P [P"2 .X F #L )\ ZP"F
M .D K@#G +@ Y0#% ., V@#A .T WP#[ -X _P#= /\ W0#_ -T _P#= /\
MW0#_ /\/#0#_# L _P,) /\ # #_ !( _P = /\ *0#[ #< ^ !$ /4 4 #R
M %H [@!C .P :P#I ', YP!Z .4 @ #C (8 X0", -\ DP#= )D VP"A -D
MJ0#5 +( T@"^ -  S@#. .8 S #V ,H _P#* /\ R0#_ ,@ _P#( /\ R #_
M /\1" #_#0( _P<  /\%" #_  X _P 6 /< (@#O #  ZP ] .@ 20#D %0
MX != -T 90#9 &T U0!S -( >@#0 (  S@"' ,P C0#* )0 R "; ,8 I #$
M *T P@"X ,  QP"] -\ O #Q +L _@"Y /\ N #_ +@ _P"X /\ N #_ /\4
M  #_#P  _PT  /\,  #_!PD ^ $0 .@ &@#C "@ W0 V -@ 0@#2 $T S@!7
M ,H 7P#' &8 Q0!M ,, = #! 'H OP"! +T B "[ (\ N0"7 +< GP"U *@
MLP"S +$ P@"O -@ K@+M *P#^P"K!?\ J@;_ *D&_P"I!O\ J0;_ /\6  #_
M$@  ]Q(  .P1  #F#@  Y08( -T#$@#4 R  S00M ,@$.@##!48 OP50 +P&
M6 "Y!F  MP=G +4';@"S!W4 L0A[ *\(@@"N"8H K F2 *H)FP"H"J4 I@JP
M *4+OP"C#-0 H0WM )\._@"=#O\ G __ )L/_P";#_\ FP__ /\:  #W&0
MZAX  -\>  #5&@  T!," ,X,"P#'"Q8 P TE +H.,@"V#C\ L@]) *\04@"L
M$%H JA!A *@1: "F$6\ I!%V *(1?0"A$84 GQ*. )T2EP"<$J( FA.M )@3
MO "7%-  E!7L )(6_0"0%_\ CQ?_ (X7_P".%_\ CA?_ /H=  #N(P  WR@
M - J  #')P  P2$  +T9!0"Y$A  LA4> *T6+ "H%S@ I!A# *$93 "?&50
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M G$N] )P+_\";R__ F\O_P%N+_\!;B__ >@Q  #3.@  PS\  +=!  "N00
MICX  )XX  "7,0$ D2X0 (PO' "(,"@ A#$S ($R/0!_,D8 ?3)- 'LR5 !Y
M,EL =S)A '4R:0%T,G !<C)Y 7 SA %O,Y ";3.= FPSJP)J-+P":335 V@U
M\0)G-?\"9S7_ F8U_P)F-?\"9C3_ N(V  #,/P  O40  +)'  "H1P  H$0
M )@_  "0.0  B#0- (,U%P!_-B0 ?#<O 'DW.0!W.$( =#A) '(X4 !Q.%<
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M U1#_P-40_\"5$/_ M!"  "_2@  LE   *=3  "=5   E%,  (I0  !_2@
M=44" &Y##@!K1!D 9T4D &5%+@!B13< 844_ %]%1@!=14T 6T54 %I&6P%9
M1F,!5T9L E9&=P)41H,#4T:1 U%&H0101[$$3T?'!$Y'YP1.1_L$3D?_ TY'
M_P-/1_\#3T?_ \Q&  "[3@  KU0  *17  ":6   D5<  (94  ![3@  <$H
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M \!0  "R6   IEX  )QB  "290  B&4  'UB  !N7   8UD  %E6 P!45@X
M4588 $]6(@!-5RP 3%<T $I7/ !)6$0 2%A+ $=84P!%6%L!1%AD 4)8;@%
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M 3%EE0(P9:<"+V6[ BYEV@(N9/0"+F/_ B]C_P(O8O\"+V+_ K->  "G9@
MG&T  )-Q  "(<P  ?7,  ')R  !D<   6&X  $UL  !":@, /&D. #IJ%@ Y
M:B  .&HH #9K,0 U:SD -&M! #-L20 R;%( ,6Q< "]L9@ N;', +&R" 2IL
MDP$I;*4!*&RY 2=MU@$G:_(!)VK_ 2=J_P$H:?\"*&G_ JYD  "C;   F7,
M (YV  "$>   >7D  &UX  !@=P  4W8  $AU   ^<P  -'(* #%S$0 P<QH
M+W,C "YS*P M=#0 +'0\ "MT1  I=$T *'57 "=U8P E=6\ )'5_ ")UD  A
M=:( ('6W !]UT@ ?=/$ 'W/_ 1]R_P$@<?\!(''_ :EK  "><P  E'D  (I\
M  " ?@  ='\  &=_  !:?P  37X  $-^   X?0  +WT" "A]#0 F?10 )'T<
M "-^)0 B?BT (7XV "%^/P ??T@ 'G]2 !U_7@ <?VL &G]Z !E_C  7?Y\
M%G^S !5_S@ 5?N\ %GS_ !9[_P 6>_\ %WO_ *1R  ":>@  CW\  (6"  ![
MA   ;88  &"'  !4AP  2(@  #R(   RB   *(@  ""(!0 :B0X &8D5 !B)
M'0 7BB8 %HHN !6*-P 4BD$ $XI, !*+6  1BV4 $(MU  ^+AP .BIL #8JO
M  R*R  ,B>H #8?\  Z'_P .AO\ #H;_ )][  "4@0  BH4  ("(  !SBP
M98T  %F/  !,D   09(  #22   JD@  (9,  !F4   2E@8 #I<.  V7%0 ,
MEQT #)<F  N7+P *ESD "9=$  B74  &EUX !9=N  .6@  !EI0  )6H  "5
MO@  E.   )3T  "3_P !DO\  9+_ )B"  ".B   A8P  '>/  !JD@  794
M %"8  !$F@  .)L  "R<   BG0  &9X  !*@   -H@( !Z,+  &C$   HQ<
M *,?  "C)P  HS$  *0\  "D2   I%8  *1E  "C=P  HXL  *.@  "BM@
MH=(  *'P  "@^P  H/\  *#_ )&*  ")C@  >Y(  &V7  !@FP  4YX  $:A
M   YHP  +:0  ".F   9J   $:H   RL   %K@   *\'  "O#0  KQ$  + 8
M  "P(   L2@  +$R  "R/@  LDP  +);  "R;   LH$  +&7  "QK   L,8
M +#H  "O]P  K_\  *__ (R0  !_E0  <9H  &.?  !5I   1Z@  #JJ   M
MK   (JX  !BP   0LP  "K4   *X    NP   +L   "\!P  O T  +T1  "^
M%@  OQX  , G  #!,@  PD   ,-/  ##8   PW0  ,.+  ##H0  P[@  ,+7
M  #"[P  POH  ,'^ (&7  !SG0  9:,  %>H  !)K0  .[$  "VS   AM@
M%KD   Z[   'O@   ,$   #%    QP   ,@   #)    R@4  ,L+  #-#P
MSA0  - <  #3)@  UC(  -A!  #84P  V68  -E\  #9E   V:L  -G#  #9
MX0  V?   -GT ':?  !GI@  6:P  $NR   \MP  +KH  "&]   5P   #<0
M  7'    R@   ,X   #2    U0   -8   #9    VP   -T   #?!P  X0P
M .,1  #F&0  Z20  .PR  #M0P  [E8  .]K  #OA   [YP  .^R  #OQ@
M[]T  ._D &JH  !;KP  3+8  #Z\   OP   (,0  !3(   ,S    M    #4
M    V0   -X   #B    Y0   .8   #H    Z0   .P   #N    \ (  /()
M  #U#P  ^!<  /PC  #_,P  _T8  /]:  #_<0  _XD  /^?  #_L0  _\
M /_& /\ %0#_ !0 _P 4 /\ %P#_ !T _P H /\ -P#_ $0 _P!1 /\ 7 #_
M &8 _P!O /\ =P#_ 'X _P"% /\ BP#_ )$ _P"7 /\ G0#_ *0 _P"K /\
MM #^ +\ _0#. /L Y@#Y /8 ^ #_ /< _P#W /\ ]P#_ /  _P#L /\ Z0#_
M /\#$@#_ !  _P 0 /\ $0#_ !< _P D /\ ,@#_ #\ _P!, /\ 5P#_ &$
M_P!J /\ <@#_ 'D _0"  /P A@#Z (P ^0"2 /@ F #V )\ ]0"F /0 K@#R
M +D \ #& .X W@#M /  ZP#^ .H _P#I /\ Z0#_ .< _P#C /\ X #_ /\'
M#@#_  T _P + /\ # #_ !, _P ? /\ + #_ #H _P!& /X 4@#[ %P ^ !E
M /4 ; #S '0 \0!Z .\ @0#N (< [ "- .H DP#I )H YP"A .8 J0#C +,
MX0"_ -\ T #= .D V@#Y -D _P#7 /\ U0#_ -4 _P#5 /\ U #_ /\)"@#_
M 04 _P # /\ "0#_ !  _P 9 /L )@#W #0 ] !  /( 3 #N %8 Z@!? .<
M9P#D &X X@!T .  >P#> ($ W "' -H C0#6 )0 U "; -$ HP#/ *T S "X
M ,H QP#( .  Q@#S ,4 _P## /\ PP#_ ,, _P## /\ PP#_ /\+ 0#_ P
M_P   /\  P#_  L \P 2 .X 'P#J "T Y@ Z .( 10#> $\ V0!8 -0 8 #1
M &@ S@!N ,P = #* 'L R "! ,8 AP#$ (X P@"6 ,  G@"^ *< NP"R +D
MP "W -0 M0#L +, ^P"S /\ L@#_ +( _P"Q /\ L0#_ /\-  #_!@  _P,
M /<   #T  , YP - .  & #: "4 TP R ,X /@#* $D Q@!2 ,, 6@#  &$
MO@!H +P ;@"Z '0 N ![ +8 @0"T (@ L@"0 +  F0"N *( K "M *H N@"H
M ,L I@#F *4 ]P"D /\ HP#_ *( _P"B /\ H@#_ /\0  #[#   [PX  .8-
M  #?"0  V@ & -  $0#) !T Q  J +\ -P"[ $( MP!+ +0 5 "R %L KP!B
M *T : "K &X J0!U *@ >P"F (, I "+ *( E "@ )X G@&H )P"M0"; \8
MF07B )@&] "6"/\ E0G_ )0)_P"4"?\ E G_ /P1  #Q%0  XQD  -89  #,
M%0  QQ   ,0'"@"] Q0 MP0A +(&+@"N"#H J@E$ *<)30"D"E4 H@I< * *
M8@">"VD G MO )L+=@"9#'X EPR& )8,D "4#)H D@VF )$-LP"/#<4 C0[B
M (L0]@")$/\ B!'_ (<1_P"'$?\ AQ'_ /89  #G(   UB0  ,@E  "_(@
MN1P  +04 0"Q#0X J@X9 *4/)P"A$#, G1$^ )H11P"8$D\ E1)6 ),27 "1
M$F, D!-I (X3< ",$W@ BQ.! (D4BP"'%)8 AA6B (05L "#%L$ @1?= '\8
M] !]&?\ ?!G_ 'P9_P![&?\ >QG_ .\A  #=*0  RBT  +XO  "U+   KB<
M *@@  "C%P@ GA83 )D7(0"4&2T D1HX (X:00"+&TD B1M0 (<;5P"%'%X
MA!QD ((<:P" '', ?QU\ 'T=A@!\'I$ >AZ> '@?JP!W'[P =B#4 '0A\ !R
M(?\ <2+_ '$A_P!Q(?\ <2'_ .@H  #2,   PC4  +<W  "M-0  I3$  )XK
M  "8(P( DAX0 (T@&P")(2< AB(R (,C/ "!(T0 ?B-+ 'PD4@![)%D >21?
M '<D9@!V)6X ="5W ',E@0!Q)HT ;R:9 &XFIP!M)[@ ;"?. 6HH[0%I*?\!
M:"G_ 6@I_P%H*/\!:"C_ >$N  #+-@  O#L  +$]  "G/0  GSD  )<S  "/
M+0  B"<, (,G%@!_*"( ?"DM 'DJ-P!W*C\ =2I' ',K3@!Q*U0 <"M; &XK
M8@!L*VH :RQR &DL?0!H+(D 9BV6 64MI %D+K0!8R[* 6$OZ0%@+_T!8"__
M 6 O_P%@+_\!8"[_ =HT  #%/   MT$  *Q#  "B0P  F4   ) Z  "(-
M@"X( 'HM$@!W+AX <R\I '$P,P!O,#L ;3!# &LQ2@!I,5$ 9S%7 &8Q7@!D
M,68 8S)O &$R>0!@,H4!7S*2 5TSH0%<,[$!6S3& 5HTY@%9-?L!637_ 5DT
M_P%9-/\!633_ =(X  # 0   LT4  *A(  ">2   E48  (M   "".P  >34$
M ',S$ !O-!H ;#0E &DU+P!G-3< 938_ &,V1@!B-DT 8#94 %\V6P!=-V,
M7#=K %LW=@%9-X(!6#B/ 58XG@%5.*\"5#G# E,YY )3.OD!4SG_ 5(Y_P%3
M.?\!4SG_ <T\  "\1   KTD  *1,  ":3   D4L  (=&  !]0   <SL  &PX
M#0!H.1< 93DB &,Z*P!@.C0 7CH\ %TZ0P!;.DH 6CM0 %@[6 !7.V  5CMH
M %4\<P%3/'\!4CR- 5 ]G %//:P"3C[! DT^X0)-/O@"33[_ 4T^_P%-/?\!
M33W_ <E   "X2   K$T  *%0  "740  CD\  (1+  !Y10  ;D   &8]"P!B
M/10 7ST> %P^* !:/C$ 6#XX %<^0 !5/T8 5#]- %,_50!20%T 4$!F $]
M< %.0'P!3$&* 4M!F@)*0:L"24*^ DA"W@)(0O8"2$+_ DA"_P%(0?\!2$'_
M <5$  "U2P  J5   )Y4  "55   BU,  (!0  !U2@  :D8  &%"" !<01$
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M 3Q.E $[3J4!.4^Y CE/U (Y3_(!.4[_ 3E._P$Y3?\!.DW_ ;I.  "L5@
MH5L  )=?  "-80  @V$  'A>  !I6   7U8  %12  !,3PL 24\2 $=0' !%
M4"4 0U M $)0-0!!43P 0%%$ #]13  ^4E0 /%)= #M29P Z4G, .%." 3=3
MD@$U4Z0!-%.W 3-4T0$S4_$!-%/_ 312_P$T4O\!-%+_ ;92  "I6@  GF
M )1D  "+9@  @&4  '1C  !F7@  7%P  %%8  !'50< 0E40 $!5&  _5B$
M/58J #Q6,@ [5CD .E=! #E720 X5U$ -UA: #5890 T6'$ ,EB  3%8D $O
M6:(!+EFU 2U9SP$M6>\!+EC_ 2Y7_P$N5_\!+E;_ ;)7  "E7P  FV4  )%I
M  "':@  ?&H  '%H  !C90  6&(  $U?  !#70( /%L- #I<%  X7!T -UPF
M #5=+@ T738 ,UT^ #)=1@ Q7DX ,%Y7 "]>8@ M7FX +%]] "I?C@ I7Z
M*%^S 2=?S  G7^T!)U[_ 2==_P$H7?\!*%S_ :U<  "B9   F&H  (YN  "#
M;P  >6\  &YN  !@:P  5&D  $EG   _90  -6,) #)C$0 P8QD +V0A "YD
M*0 M9#$ +&0Y "ME0@ J94H *&54 "=E7P F9FL )&9Z "-FBP B9IT (&:Q
M !]FR0 ?9NL (&7^ "!D_P @8_\!(6/_ :EB  ">:@  E7   (IS  " =0
M=74  &ET  !<<@  3W$  $1O   Z;@  ,&T# "EL#0 G;!0 )FP< "5M)  D
M;2P (VTT ")M/0 A;D8 (&Y0 !YN6P =;F< '&YV !INAP 9;YH &&^N !9O
MQ@ 6;ND %VW\ !AL_P 8:_\ &&O_ *1I  ":<0  D'8  (9Y  !\>P  <7L
M &1[  !7>@  2GD  #]X   U>   *W<  ")V!P ==@\ ''<6 !MW'@ :=R8
M&7<N !AW-P 7>$  %7A* !1X5@ 3>&, $GAR !%X@P 0>)< #WBK  YXPP .
M=^8 #G;Z  ]U_P 0=?\ $'3_ )]Q  "5>   BWP  ()_  !W@0  :H(  %V"
M  !0@@  1((  #B"   N@@  )((  !R"   4@@D $8,0 !"#%@ 0@QX #H,G
M  Z#,  -@SD #8-$  R#4  +@UT "8-L  B#?@ &@Y$ !8*E  ."NP $@=L
M!('R  6 _P &?_\ !G__ )IY  "0?@  AH,  'V%  !OAP  8HD  %6*  !)
MBP  /8P  #&,   FC   '8T  !6.   /CP, "I ,  :0$0 $CQ@  X\@  &/
M*0  CS(  ) ]  "020  CU8  (]E  "/=@  CXH  (Z?  ".M   C<\  (SN
M  ",^P  B_\  (O_ )2   "+A0  @HD  '2,  !FCP  69$  $R3  ! E0
M-)8  "B6   >EP  %9@   ^:   *FP   IP)  "<#@  G!,  )P:  "<(@
MG2L  )TU  "=0   G4X  )U<  "=;@  G($  )R7  "<K   F\8  )KH  "9
M^0  F?\  )C_ (Z(  "&C   >)   &J4  !<EP  3YH  $*=   VG@  *9\
M !^A   5H@  #J0   BF    J    *D$  "I"@  J0X  *D3  "J&@  JB(
M *LK  "L-@  K$0  *Q3  "L8P  K'<  *N.  "KI   J[P  *K>  "I]
MJ?T  *G_ (F.  ![DP  ;9<  %^<  !1H   1*0  #:F   JJ   'JD  !2K
M   -K@  !K    "R    M0   +4   "U P  M@D  +<.  "X$@  N!D  +HA
M  "[*P  O#@  +U'  "]6   O6L  +V!  "]F0  O;   +W,  "\Z@  O/<
M +O^ 'Z5  !PFP  8J   %.E  !&J@  .*T  "JO   >L0  $[0   RW   #
MN0   +P   "_    P@   ,(   ##    Q    ,8&  #'#   R!   ,H6  #,
M(   SRL  - Z  #12P  T5X  -)S  #2BP  TJ0  -.[  #3V   T^T  -/V
M '.=  !DHP  5JD  $>O   YLP  *K8  !VY   2O   "K\   ##    Q@
M ,D   #-    SP   -    #2    U    -8   #9 @  VP@  -X.  #A$P
MY!T  .@J  #H/   Z4\  .ED  #J?   ZY4  .NL  #KP@  [-4  .SE &:F
M  !8K   2;,  #NY   KO   '<   !'$   )R    ,P   #/    TP   -D
M  #=    X    .$   #C    Y0   .<   #J    [    .X$  #Q"P  ]1(
M /@<  #[*P  _3X  /Y3  #^:@  _X,  /^;  #_K@  _[X  /_* /\ $@#_
M !  _P 1 /\ $P#_ !D _P F /\ - #_ $$ _P!- /\ 6 #_ &( _P!K /\
M<P#_ 'H _P"! /\ AP#_ (T _P"3 /\ F0#_ *  _P"G /X KP#\ +H ^@#)
M /D X0#X /, ]P#_ /8 _P#U /\ \0#_ .D _P#D /\ X0#_ /\ #P#_  T
M_P - /\ #@#_ !0 _P A /\ +@#_ #P _P!( /\ 4P#_ %T _P!F /X ;0#\
M '4 ^P![ /D @@#X (@ ]P". /8 E #T )L \P"B /$ J@#O +0 [0#! .L
MU0#J .P Z #\ .< _P#E /\ Y@#_ .  _P#9 /\ U #_ /\ "P#_  @ _P &
M /\ "0#_ !  _P < /\ *0#_ #8 _P!" /L 3@#W %< ] !@ /( : #O &\
M[0!V .P ? #J (( Z "( .< C@#E )4 XP"< .$ I #? *X W0"Y -H R@#7
M .0 U #V -$ _P#0 /\ T #_ ,\ _P#+ /\ QP#_ /\  P#_    _P   /\
M! #_  T ^@ 6 /8 (P#S #  \  \ .T 1P#I %$ Y0!: .( 8@#? &D W0!O
M -H =@#8 'P U "" -( B #0 (\ S0"6 ,L G@#) *@ QP"S ,4 P0#" -@
MP #O +\ _@"^ /\ O0#_ +P _P"\ /\ O #_ /\"  #_    _P   /\   #T
M  < [0 1 .@ ' #C "D WP U -L 00#6 $L T0!4 ,T 7 #* &, R !I ,8
M;P## '4 P0![ +\ @@"^ (@ O "0 +H F "X *( M0"L +, N0"Q ,L KP#G
M *X ^ "L /\ JP#_ *P _P"L /\ JP#_ /\$  #_    ]@   .X   #G
MWP , -8 %0#/ "( R@ N ,< .@## $0 P !- +P 50"Y %P MP!C +4 :0"S
M &\ L0!U *\ >P"M (( JP"* *D D@"G )P I0"F *, LP"A ,, GP#> )X
M\@"= /\ G #_ )P _P"; /\ FP#_ /\'  #V"0  Z0L  -\*  #5!   S@ %
M ,8 $ #  !H NP G +< ,@"S #T L !& *T 3P"J %8 J !< *8 8P"D &@
MH@!O *$ =0"? 'P G0"$ )L C0"9 )< EP"B )4 K@"3 +T D0#3 )  [0"/
M /P C@#_ (T!_P"- ?\ C0'_ /D.  #J$@  W!4  ,T5  #$$0  O@P  +H"
M"@"T !( K@ > *H *@"F #4 H@ _ *  2 "= 5  FP)6 )D"7 "7 V, E0-I
M ),#;P"1!'8 D 1_ (X%B ",!9( B@:> (@&J@"&![H A0C/ (0*ZP"""_P
M@0S_ ( ,_P" #/\ @ S_ /$5  #@'0  S2   ,$A  "X'0  L1<  *P0  "H
M"0T H@<6 )T)(P"9"BX E0LX ),,00"0#$D C@U0 (P-5P"*#5T B UC (<-
M:@"%#G$ @PYZ ((.A " #H\ ?@^; 'P/J ![$+@ >A#. '@1[ !V$O\ =1+_
M '03_P!T$_\ =!/_ .@>  #3)@  PRH  +@J  "N*   IR,  * <  ";$P,
ME@\0 ) 0&P",$2< B1(R (83.P"$$T, @A1+ ( 440!^%%< ?!1> 'L590!Y
M%6P =Q5T '86?@!T%HH <A>6 '$7I !O&+0 ;AC) &T9Z !K&OP :AO_ &H;
M_P!J&_\ :AO_ . F  #*+0  O#$  + S  "G,0  GRP  )<F  "0'P  BA<,
M (48%@"!&2( ?AHL 'L;-@!Y&SX =QQ% '4<3 !S'%, <1U9 ' =8 !N'6<
M;1YP &L>>@!J'H4 :!^2 &<?H !E(+  9"'% &,AY !B(OH 82+_ &$B_P!A
M(O\ 82+_ -<L  ##-   MC@  *HY  "A.   F#4  ) O  "(*   @"$( 'L@
M$@!W(1T ="(G '$B,0!O(SD ;2-! &LC2 !I(TX :"15 &8D6P!E)&, 8R5K
M &(E=0!A)8$ 7R:. %XFG0!=)ZT 6RC! %LHX !:*?< 62G_ %DI_P!9*?\
M62C_ ,\R  "^.0  L3T  *8_  "</P  DSP  (HV  "!,   >2H# '(F#P!N
M)QD :R@C &DH+ !F*34 92D\ &,I0P!A*DH 8"I1 %XJ5P!=*E\ 7"MH %HK
M<@!9+'T 6"R+ %8MF@!5+:H 5"Z] %,NW !2+_4 4B__ %(N_P!2+O\ 4B[_
M ,HV  "Z/0  K4(  *)$  "81   CT$  (4\  ![-P  <C$  &LL# !G+14
M9"T? &$N* !?+C$ 72XY %PO0 !:+T8 6"]- %<O5 !6,%P 53!D %,Q;@!2
M,7H 43&( % REP!.,J@ 33.[ $TTV !,-/, 3#3_ $PT_P!,,_\ 3#/_ ,8Z
M  "V0@  J48  )Y)  "520  BT<  (%"  !W/0  ;3<  &0R"0!@,A( 73(<
M %HR)0!8,RT 5C,U %4S/ !3-$, 4C1* %$T40!0-%D 3S5A $TU; !,-G<
M2S:% $HWE0!(-Z8 1SBX 4<XTP%&./$!1CC_ 48X_P!&./\ 1C?_ ,$^  "R
M10  IDH  )Q-  "230  B$L  'Y'  !S0@  :3T  %\W!@!:-A  5S<8 %0W
M(@!2-RH 4#<R $\X.0!-.$  3#A' $LX3@!*.58 23E? $@Z:0!'.G4 13N#
M $0[DP!#/*0!0CRV 4$]T %!/? !03W_ 4$\_P%!//\!03S_ +Y"  "O20
MHTX  )E0  "/40  A5   'M,  !O1@  94(  %H] @!4.PX 43L5 $\['P!-
M.R< 2SLO $D\-@!'/#T 1SQ$ $8]2P!%/50 1#Y< $,^9P!"/W, 0#^! #\_
MD0 ^0*( /4"U 3Q!S@$\0>X!/$'_ 3Q _P$\0/\!/3__ ;I%  "L3   H5$
M )=4  "-50  @U0  'A1  !L2P  84<  %9"  !/0 P 3#\3 $E ' !'0"0
M1D L $1 ,P!#0#H 0D%" $%!20! 0E$ /T): #Y#90 ]0W$ .T-_ #I$CP Y
M1*  .$6S 3=%RP$W1>P!-T7_ 3=$_P$X1/\!.$/_ +=)  "I4   GE4  )18
M  "+60  @%@  '96  !H4   74P  %-(  !*10D 1D01 $1$&0!"1"( 044I
M #]%,0 ^13@ /44_ #Q&1P [1D\ .D=8 #E'8@ X2&X -DA\ #5(C0 T29X
M,TFQ #))R0 Q2>L ,DG^ #)(_P R2/\ ,TC_ +1,  "G5   G%D  ))<  "(
M70  ?ET  '-:  !E50  6U(  %!.  !&2@4 0$D. #Y)%@ ]21X .THF #I*
M+@ Y2C4 .$L] #=+1  V2TT -$Q6 #-,8  R3&P ,4UZ #!-BP N39P +4ZO
M "Q.QP L3ND +$W] "U-_P M3/\ +4S_ +!0  "D6   F5T  (]A  "&8@
M>V$  '!?  !B6P  6%@  $Y5  !#40$ .T\, #A/$P V3QL -4\C #10*P S
M4#( ,E Z #%00@ P44H +E%3 "U270 L4FD *U)X "E2B  H4YH )U.M "93
MQ0 F4^< )E/\ "=2_P G4?\ )U'_ *Q5  "@7   EF(  (UF  "#9P  >&8
M &UE  !@80  55X  $I;   _6   -58( #%5$  P5A< +E8? "U6)P L5B\
M*U<V "I7/@ I5T< *%=0 "986@ E6&< )%AU "-9A@ A69@ (%FK !]9P@ ?
M6>4 'UCZ "!8_P @5_\ (5?_ *A:  "=8@  DV<  (IK  !_;   =6P  &IK
M  !=:   464  $9C   [8   ,5X# "I=#0 H71, )ET; "5>(P D7BH (UXR
M ")>.@ A7D, (%], !]?5P >7V, '&!Q !M@@@ 98)4 &&"I !=@P  68.(
M%U_Y !A>_P 97O\ &5W_ *1@  "9:   D&X  (9P  !\<@  <G(  &9Q  !8
M;@  3&P  $%K   V:0  +6<  "-F"  ?9@\ '685 !QF'0 ;9B4 &F8M !EG
M-0 89SX %V=( !9G4P 5:%\ $VAN !)H?P 1:)( $&BF  ]HO0 .:.  $&?W
M !!F_P 19?\ $67_ )]G  "6;P  C',  ()V  !X>   ;7@  &!W  !3=@
M1G0  #MS   Q<@  )W$  !YQ   6< H $W 0 !-P%P 2<!\ $7$G !!Q+P 0
M<3@ #G%"  YQ3@ -<5L #'%I  MQ>@ *<8T "'&A  9QM@ &<-( !W#O  AO
M_P );O\ "6[_ )MO  "1=0  AWD  'Y\  !T?@  9GX  %E^  !-?@  0'T
M #5]   J?   (7P  !A\   1? 0 #'P,  I\$0 )?!D "'PA  =\*0 &?#(
M!'P]  -\2  !?%4  'QC  !\=   ?(<  'N<  ![L0  >LL  'GK  !Y^@
M>?\  'C_ )9W  ",?   @X   'F#  !LA   7H4  %&&  !%AP  .8<  "V'
M   CAP  &H<  !*'   -B $ !HD*  &)#P  B10  (@;  "((P  B2P  (DV
M  ")0@  B$X  (A=  "(;0  B($  (>5  "'JP  AL0  (7F  "$^   A/\
M (3_ )!^  "'@P  ?H<  '&)  !CBP  5HT  $F/   \D0  ,)$  "21   :
MD@  $I,   V4   &E0   )8&  "6#   E1   )85  "6'0  EB0  )8N  "6
M.0  ED8  )95  "690  EG@  )6.  "5I   E+P  )/?  "3]0  DO\  )+_
M (N&  "#B@  =8T  &>0  !9E   3)<  #^9   RF@  )IL  !N<   2G0
M#)\   2@    H@   *,!  "C!P  HPP  *,0  "D%0  I!P  *4E  "F+P
MICP  *9+  "F6P  IFX  *6$  "EFP  I+,  */0  "C[P  HOP  *+_ (:-
M  !XD0  :I4  %R9  !.G0  0:   #.B   FHP  &Z4  !&G   *J0   :L
M  "M    KP   +    "P    L 4  +$+  "R#P  LQ0  +0;  "U)   MS
M +<_  "W4   MV(  +=X  "WD   MJD  +;"  "VY   MO4  +7^ 'N3  !M
MF   7YT  %"B  !"I@  -*D  ":K   :K0  $*\   FR    M    +<   "Z
M    O    +T   "^    O@   , "  #!"   P@T  ,02  #&&0  R20  ,HR
M  #+0P  RU4  ,QJ  #,@P  S)P  ,NU  #,S@  S.D  ,SV '";  !AH0
M4J8  $2K   VL   )[(  !JU   0N   ![L   "^    P0   ,0   #(
MRP   ,L   #-    S@   -    #2    U0,  -@*  #;$   WA@  .(D  #C
M-0  Y$@  .5<  #F<P  YHT  .:E  #FO   YM,  .?G &.D  !5J@  1K
M #BU   HN0  &KP   _    %Q    ,<   #+    SP   -0   #8    W
M -T   #?    X0   .,   #E    Z    .H   #M!@  \0X  /46  #X)0
M^3@  /E-  #Z8P  ^WP  /R5  #\J@  _+L  /W+ /\ #P#_  X _P . /\
M$ #_ !8 _P C /\ , #_ #T _P!) /\ 5 #_ %X _P!F /\ ;@#_ '8 _P!\
M /\ @@#_ (D _P"/ /\ E0#^ )L _0"C /L JP#Z +4 ^0## /< VP#V /
M] #_ /, _P#R /\ [ #_ .( _P#< /\ U@#_ /\ # #_  D _P ( /\ "@#_
M !( _P > /\ *P#_ #@ _P!$ /\ 3P#_ %D _@!A /P :0#Z '  ^ !W /<
M?0#V (, ] ") /( CP#Q )8 [P"= .T I0#L *\ Z@"\ .@ S0#F .@ Y #Z
M ., _P#B /\ X #_ -4 _P#. /\ RP#_ /\ !@#_  $ _P   /\ ! #_  X
M_P 9 /\ )0#] #( ^P ^ /< 20#S %, \ !< .X 8P#L &H Z@!Q .@ =P#F
M 'T Y "# .( B0#@ )  W@"7 -P GP#9 *D U@"T -, Q #0 -X S@#S ,P
M_P#+ /\ R@#_ ,@ _P#" /\ O@#_ /\   #_    _P   /\   #[  L ]@ 3
M /$ ( #M "P Z@ X .< 0P#C $T X !6 -P 70#9 &0 U0!K -( <0#0 '8
MS@!\ ,P @P#* (D R "1 ,8 F0#$ *, P0"M +\ NP"] ,\ NP#K +D _ "W
M /\ MP#_ +8 _P"T /\ L0#_ /\   #_    _P   /8   #N  4 YP / .$
M&0#; "4 U0 Q -( / #. $8 R@!/ ,< 5P#$ %X P0!D +\ :@"] '  NP!V
M +D ? "X (, M@"* +, DP"Q )P KP"G *T LP"K ,4 J0#A *< ]0"F /\
MI0#_ *0 _P"D /\ I #_ /\   #\    \0   .@   #@    U  + ,P $P#'
M !\ P@ J +\ -0"\ #\ N !( +4 4 "S %< L !> *X 9 "L &D JP!O *D
M=0"G 'P I0"$ *, C "A )8 GP"A )T K0": +P F #2 )< [@"5 /X E #_
M )4 _P"5 /\ E0#_ /P!  #P!0  XP<  -4%  #,    Q0 $ +X #@"X !<
MLP C *\ +@"K #@ J0!! *8 2@"C %$ H0!7 )\ 70"= &, FP!I )H ;P"8
M '8 E@!] )0 A@"2 )  D "; (X IP", +8 B@#) (@ YP"' /D AP#_ (8
M_P"& /\ A@#_ /0,  #D$   T1(  ,41  "]#@  M@@  +$ " "K !$ I@ ;
M *$ )@"> #$ F@ Z )@ 0P"5 $H DP!1 )$ 5P"/ %T C@!C (P :0"* '
MB !W (8 @ "$ (L @@"6 (  HP!^ +$ ?0#$ 'L"X0!Z _4 >@7_ 'D%_P!X
M!O\ > ;_ .H3  #6&@  QAT  +H<  "Q&0  JA,  *0-  "?!0P F0 4 )4
M'P"1 BD C0,S (L$/ "(!40 A@9+ (0&40""!U< @0== '\'8P!]"&H >PAR
M 'H(? !X"88 =@F2 '0*H !S"J\ <0O! ' ,WP!O#?8 ;@[_ &T._P!M#O\
M;0[_ .$<  #+(P  O"8  +$F  "H)   H!X  )D8  "3$ ( C@L. (@+%P"$
M#"( @0TL 'X--0!\#CT >@Y% '@.2P!W#E$ =0]8 ',/7@!Q$&4 <!!N &X0
M=P!L$(( :Q"/ &D1G0!H$:T 9A+  &42WP!D$_8 8Q3_ &,4_P!B%/\ 8A3_
M -8D  ##*@  M2X  *HO  "@+0  F"@  ) B  ")&P  @A,( 'T1$@!Y$AP
M=A,G ',4, !Q%#@ ;Q4_ &T51@!L%4P :A93 &@660!G%F$ 919I &07<@!B
M%WX 81B+ %\8F0!>&:D 7!F\ %P:V !:&_, 6AS_ %D<_P!9'/\ 61S_ ,TJ
M  "],0  KS4  *0V  ";-   DC$  (DK  "!)0  >1T# ',8#@!O&1@ ;!HB
M &D;*P!G&S, 91P[ &0<00!B'4@ 8!U. %\=50!='5P 7!YD %L>;@!9'WD
M6!^' %8@E@!5(*8 5"&X %,AT@!2(O$ 4B/_ %(C_P!2(O\ 4B+_ ,@O  "X
M-@  JSH  * \  "6.P  C3@  (,R  !Z+0  <B8  &H@# !F(!, 8R$= &$A
M)@!?(B\ 72(V %LB/0!:(T0 6"-* %<C40!5(U@ 5"1A %,D:@!1)78 4"6#
M $\FDP!.)Z, 3">U $PHS@!+*.X 2RG_ $LH_P!+*/\ 2RC_ ,,T  "S.P
MIS\  )Q!  "20   B3X  '\Y  !U,P  ;"T  &,G" !>)A$ 7"89 %DG(@!7
M)RL 52@R %0H.0!2*$  42A& % I30!.*54 32E= $PJ9P!+*G, 22N  $@K
MD !'+*$ 1BVS $4MRP!%+NP 1"[_ $0N_P!%+?\ 12W_ +XX  "P/P  I$,
M )E%  "/10  A4,  'L^  !Q.0  9S0  %XN! !8*PX 52L6 %(L'P!0+"<
M3RPO $TM-@!,+3P 2BU# $DM2@!(+E( 1RY: $8O9 !%+W  0S!^ $(PC0!!
M,9X 0#*Q #\RR  _,^H /S/^ #\R_P _,O\ /S+_ +L\  "M0P  H4<  )9)
M  ",20  @T@  'A$  !M/@  8SD  %HT  !2, P 3S 3 $PP' !*,"0 23$K
M $<Q,@!&,3D 1#%  $,R1P!",D\ 03-8 $ S8@ _-&T /C1[ #TUBP \-IP
M.S:O #HWQ@ Y-^@ .3?\ #HW_P Z-O\ .C;_ +=   "J1@  GDL  )1-  "*
M3@  @$P  '5(  !J0P  8#X  %8Y  !--0D 2301 $<U&0!%-2$ 0S4H $$U
M+P! -38 /S8] #XV10 ]-TT /#=5 #LX8  Z.&L .3EY #@YB0 W.IL -3JM
M #4[Q  T.^8 -#O[ #4[_P U.O\ -3K_ +1#  "G2@  G$X  ))1  "(4@
M?E   '--  !G2   7$0  %(_  !(.@8 1#D/ $$Y%@ _.1X /CDF #PY+0 [
M.C0 .CH[ #D[0@ X.TH -SQ3 #8\70 U/6D -#UW #,^AP Q/ID ,#^K "\_
MP@ O/^0 +S_Z # __P P/O\ ,#[_ +%'  "D30  F5(  (]5  "&5@  ?%4
M '%2  !D3   64D  $]%  !%0 , /SX- #P^$P Z/AL .3XC #<^*@ V/S$
M-3\X #0_0  S0$@ ,D!1 #%!6P P06< +D)U "U"A0 L0Y< *T.J "I#P  I
M1.( *D/Y "I#_P K0O\ *T+_ *Y*  "A40  EU8  (U9  "#6@  >5H  &Y7
M  !A4@  5TX  $U+  !#1P  .D,* #9#$0 T0Q@ ,T,@ #)$)P Q1"\ ,$0V
M "]%/0 M148 +$5/ "M&60 J1F0 *4=R "A'@P F1Y4 )4BH "1(O@ C2.
M)$CW "5'_P E1_\ )D?_ *I/  "?50  E%H  (M>  "!7P  =UX  &M<  !?
M6   554  $M1  ! 30  -4H' #!)#@ N214 +4D= "Q))  K2BL *DHS "A*
M.P G2T, )DM, "5+5@ D3&( (TQP "%,@  @39, 'TVF !Y-NP =3MT 'DWV
M !Y,_P ?3/\ ($O_ *=3  "<6@  DE\  (AC  !^9   =&,  &EA  !<7@
M4EL  $=8   \50  ,E(" "I0#  G3Q( )E 9 "50(  D4"@ (U O ")1-P A
M44  (%%) !Y24P =4E\ '%)M !I3?0 94Y  &%.D !93N0 54]D %E/T !=2
M_P 84?\ &5'_ *-9  "88   CV4  (5H  ![:0  <6D  &9G  !99   36$
M $)?   X7   +EH  "58"  @5PX 'E<4 !U7'  <6", &U@K !I8,P 96#P
M&%A% !994  565L %%EI !-:>@ 26HT $5JA !!:MP .6M4 $%GS !!9_P 1
M6/\ $5C_ )]?  "59@  C&L  ()M  !X;@  ;F\  &)M  !5:@  2&@  #YF
M   S90  *6,  "!A 0 88 L %6 0 !1@%P 38!X $F F !)@+@ 183< $&%
M  ]A2P .85@ #6%F  QB=@ +8HD "F&=  EAL@ (8<L "&'K  E@_0 *7_\
M"U__ )MF  "2;0  B'$  'YS  !U=0  :G0  %QS  !/<@  0W   #AO   M
M;@  )&P  !MK   3:P0 #FH,  UJ$@ ,:AD "VHA  IJ*0 ):C( "&H\  =K
M1P %:U, !&MA  )K<0  :H0  &J8  !JK0  :<8  &GG  !I^   :/\  &C_
M )=M  "-<P  A'<  'MZ  !P>P  8WL  %9Z  !)>@  /7D  #%X   G=P
M'78  !5V   /=@( "78*  1V#P  =A4  '8<  !V)   =2P  '4V  !U00
M=4X  '5<  !U;   =7X  '23  !TJ   <\   '/C  !R]P  <O\  ''_ ))U
M  ")>@  @'X  ':   !I@0  6X(  $Z"  !!@@  -8,  "F"   ?@0  %H$
M !""   *@@   H,'  ""#0  @A$  ((7  ""'@  @B8  ((O  "".P  @D<
M ()5  "!90  @7@  (&-  " H@  ?[H  '_=  !^]   ??\  'W_ (U\  "$
M@0  >X0  &Z&  !@B   4HH  $6+   YC   +(P  "&,   7C   $(T   F.
M   "CP   ) #  "/"0  CPX  (\2  "0&   D!\  ) H  "0,@  D#\  )!-
M  "070  CW   (^%  ".G   CK,  (W0  ",\   B_X  (O_ (B$  " B
M<HL  &2-  !6D   2),  #N5   NE@  (I8  !>7   /F   ")D   ";
MG0   )T   "= P  G0D  )T-  ">$0  GA<  )\?  "?*0  H#4  *!#  "@
M5   H&8  )][  ">DP  GJL  )W&  "=Z0  G/D  )S_ (.+  !UC@  9Y(
M %F6  !+F0  /9P  #">   CGP  %Z    ZB   'I    *8   "H    J@
M *H   "J    JP$  *L'  "L#   K1   *X6  "O'@  L2D  +$X  "Q2
ML5H  +%O  "QB   L:   +"Z  "OW0  K_(  *_] 'B1  !JE@  7)H  $V?
M   _HP  ,:8  ".G   7J0  #JL   6N    L    +(   "U    MP   +<
M  "X    N0   +H   "\ P  O0D  +X.  # %   PQX  ,4K  #%/   QDX
M ,9B  #&>@  QI0  ,:M  #&R   Q>4  ,7S &R9  !>G@  3Z0  $&H   R
MK   )*\  !:Q   -M    [<   "Z    O0   ,    #$    Q@   ,8   #(
M    R0   ,L   #,    S@   - &  #3#0  V!,  -P>  #>+0  WT   .!4
M  #A:P  X84  .&?  #AMP  X<\  .'F &"A  !2IP  0ZT  #2R   EM0
M%[D   V\   !OP   ,,   #'    R@   ,\   #3    U@   -<   #:
MW    -\   #A    XP   .8   #I 0  [ L  / 2  #S'P  ]#$  /9&  #W
M7   ^'0  /B/  #YI@  ^;@  /C) /\ #0#_  L _P + /\ #@#_ !, _P ?
M /\ + #_ #D _P!% /\ 4 #_ %D _P!B /\ :@#_ '$ _P!W /\ ?@#_ (0
M_@"* /T D #\ )< ^@"> /D IP#W +$ ]@"^ /4 T@#S .P \0#^ /  _P#P
M /\ Y@#_ -P _P#2 /\ S0#_ /\ !P#_  0 _P " /\ !@#_ !  _P ; /\
M)P#_ #, _P _ /\ 2@#^ %0 ^P!= /D 9 #W &L ]0!R /, > #R 'X \ "$
M .\ B@#M )$ [ "9 .H H0#H *L Y@"V .0 QP#B ., X #W -X _P#= /\
MV0#_ ,P _P#% /\ P0#_ /\   #_    _P   /\  0#_  T _P 6 /P (@#Y
M "X ]@ Y /, 10#O $X [ !7 .D 7@#F &4 Y !L .( <@#@ '< WP!^ -T
MA #; (L V "2 -4 FP#2 *0 SP"O ,T O@#+ -4 R0#O ,< _P#% /\ Q #_
M +X _P"X /\ M0#_ /\   #_    _P   /X   #W  D \0 1 .L ' #G "@
MY  S .$ /@#= $@ V !1 -, 6 #0 %\ S@!E ,P :P#* '$ R !W ,8 ?0#$
M (0 P@", ,  E "^ )X NP"H +D M@"W ,@ M0#F +, ^@"Q /\ L #_ +
M_P"L /\ J0#_ /\   #_    ^@   /$   #H  , X  - -@ %@#1 "( S0 M
M ,H -P#& $$ P@!* +\ 4@"] %D N@!? +@ 90"W &H M0!P +, =@"Q 'T
MKP"% *T C0"K )< J0"A *< K@"E +X H@#8 *  \@"? /\ G@#_ )X _P">
M /\ G #_ /\   #W    ZP   .$   #6    RP ) ,4 $0"_ !L NP F +<
M,0"T #H L0!# *X 2P"K %( J0!8 *< 7@"F &0 I !I *( < "@ '8 G@!^
M )P A@": )  F "; )8 IP"4 +8 D@#* )  Z0"/ /P C@#_ (T _P", /\
MC0#_ /@   #I @  VP,  ,P!  #$    O0 " +8 #0"P !4 JP @ *< *@"D
M #0 H0 \ )X 1 "< $L F@!2 )@ 6 "6 %T E0!C ), :0"1 '  CP!W (T
M@ "+ (H B0"5 (< H0"% *\ @P#! ($ X "  /4 ?P#_ '\ _P!_ /\ ?P#_
M .X*  #<#@  RA   +X.  "U"P  KP,  *D !P"C !  G@ 8 )D (P"6 "P
MDP U )  /@". $4 C !+ (H 40"( %< A@!= (4 8P"# &H @0!Q '\ >@!]
M (0 >P"/ 'D G !W *H =0"[ '0 U !R /  <@#_ '( _P!Q /\ <0#_ .,1
M  #-%P  OQD  +,9  "J%0  HQ   )T*  "7 0H D0 2 (T &P") "4 A0 O
M (, -P"  #X ?@!% 'T 2P![ %$ >0!7 '@ 70!V &0 = %K '(!= !P G\
M;@*+ &P#F !K Z8 :02W &@%S@!G!^P 9@C] &8)_P!E"?\ 90G_ -8:  #$
M(   MB,  *LC  "A(   F1L  )(4  ",#@$ A@<- ( $% !\!AX >0<H '8(
M, !T"#@ <@D_ ' )10!O"DP ;0I2 &P*6 !J"U\ : MG &<+< !E#'H 8PR'
M &(,E0!@#:0 7PVV %X-S@!<#NT 7 __ %L0_P!;$/\ 6Q#_ ,TA  "\*
MKRL  *0K  ":*0  DB0  (D?  ""&   >Q$% '4-#P!Q#1< ;@XA &L.*@!I
M#S( 9Q Y &400 !D$$8 8Q!- &$04P!?$5H 7A%B %P1:P!;$78 61*# %@2
MD@!6$Z( 51.T %03RP!3%.P 4A7_ %(6_P!2%?\ 4A7_ ,8H  "V+@  J3(
M )\R  "5,0  C"T  (,G  !Z(0  <AH  &L3"P!G$Q, 9!0< &$4)0!?%2T
M714T %P5.P!;%D( 619( %@63P!6%U8 51=> %,79P!2&'( 4!A_ $\9C@!.
M&I\ 3!JP $L;QP!+&^D 2AS] $H<_P!*'/\ 2AS_ ,$M  "Q-   I3<  )HX
M  "0-P  AS0  'TO  !T*0  ;",  &0<!P!>&1  6QH8 %D;(0!7&RD 51LP
M %0<-P!2'#T 41Q$ $\=2P!.'5( 31U: $L>8P!*'FX 21]\ $<?BP!&()P
M12&N $0AQ !#(N8 0R+\ $,B_P!#(O\ 0R+_ +PR  "M.   H3P  )<^  "-
M/0  @SH  'DU  !O,   9BH  %XD @!7( T 5" 4 %$@'0!/(24 3B$L $PA
M,P!+(CH 22)  $@B1P!'(DX 1B-7 $0C8 !#)&L 0B1Y $$EB  _)ID /B:K
M #TGP0 ])^, /2CZ #TH_P ])_\ /2?_ +@V  "J/0  GD   )1"  "*0@
M@#\  '8[  !L-@  8C   %DJ  !1)0L 3241 $LE&0!))2$ 1R8H $4F+P!$
M)C8 0R8] $(G1 !!)TL /RA4 #XH70 ]*6D /"EV #LJA@ Y*Y< ."NI #<L
MOP W+.  -RSX #<L_P W+/\ ."S_ +4Z  "G0   G$0  )%&  "'1@  ?40
M '-   !H.P  7S8  %4Q  !,*P< 1RD/ $4J%@!#*AX 02HE #\J+  ^*S,
M/2LY #PK00 [+$@ .BQ1 #DM6P X+F8 -BYS #4O@P T+Y4 ,S"G #(PO0 Q
M,=X ,3'W #(Q_P R,/\ ,S#_ +$^  "D1   F4@  (]*  "%2@  >TD  '!%
M  !E0   6SL  %(V  !(,00 0BX- #\N$P ]+AL .RXB #DO*0 X+R\ -R\V
M #8P/@ U,$8 -#%/ #,Q60 R,F0 ,3)Q # S@0 O-), +C2F "PUNP L-=L
M+#7U "TU_P M-/\ +C3_ *Y!  "B2   ETP  (U.  "#3@  >4T  &Y*  !B
M10  6$   $X\  !%-P  /3,+ #DS$0 W,Q@ -C,? #0S)@ S,RT ,C0T #$T
M/  P-40 +S5, "XV5@ M-F( +#=O "LW?P J.)$ *#BD "<YN0 F.=@ )SGT
M "@Y_P H./\ *3C_ *M%  "?2P  E$\  (M2  "!4P  =U(  &Q/  !?20
M5D8  $Q"  !"/0  .#@( #0X#P R.!4 ,3@= "\X)  N."L +3DR "PY.0 K
M.D$ *CI* "D[5  H.U\ )SQM "4\?0 D/8\ (SVB "(]MP A/M0 (3[S "(]
M_P C/?\ (SS_ *A)  "=3P  DE,  (E6  !_5P  =58  &I3  !=3P  4TP
M $I(  ! 1   -D % "\]#0 M/1, *ST: "H^(0 I/B@ *#XO "<^-P F/S\
M)#]( "- 4@ B0%T (4%J "!!>@ >08T '4*@ !Q"M0 ;0M$ &T+Q !Q"_P =
M0?\ 'D'_ *5-  ":4P  D%@  (9;  !]7   <EL  &=8  !;5   45(  $A.
M   ]2@  ,T<  "I#"P F0Q  )4,6 "1#'@ C1"4 (D0L "%$-  @13P 'D5%
M !U%3P <1EH &T9H !E&>  81XH %T>> !9'LP 42,X %4?O !9'_P 71O\
M%T;_ *)2  "76   C5T  (1@  !Z80  <&   &5>  !96@  3U@  $14   Y
M40  +TX  "9+!@ @2@X 'DH3 !U*&@ <2B$ &TLH !I+,  92S@ %TM" !9,
M3  53%< %$QE !--=0 238@ $4V< !!-L0 .3LP #TWN !!-_P 13/\ $4S_
M )Y7  "470  BV(  (%E  !W9@  ;68  &-D  !680  2EX  #];   U6
M*U8  ")4 0 :4@H %E(0 !52%@ 44AT $U(D !)2+  14C0 $5(^ !!32  /
M4U0 #E-B  U4<@ ,5(0 "U28  E4K0 (5,4 "53G  I3^P +4O\ "U+_ )M=
M  "19   B&@  'YK  !T;   :VP  %]J  !29P  160  #IB   P8   )EX
M !U=   56P4 $%H,  Y:$0 .6A@ #5L@  Q;)P +6S  "ELZ  E;10 '6U$
M!EM>  1;;0 #6X   5N4  !;J   6\   %KB  !:]@ !6O\  EG_ )=D  ".
M:P  A&X  'MP  !R<@  9W$  %EP  !,;@  0&P  #5K   J:0  (6<  !AF
M   19@$ #&4*  =E#P $910  V0;  )D(P  9"P  &0U  !D0   9$P  &1:
M  !D:0  9'L  &2/  !CI   8[L  &+=  !B]   8O\  &'_ )-L  ")<0
M@'4  'AW  !M>   8'<  %)V  !&=0  .70  "YT   C<@  &G$  !)Q   -
M<0  !G$(  !P#0  <!(  ' 7  !O'P  ;R8  &\P  !O.P  ;T<  &]4  !O
M9   ;W4  &Z*  !MH   ;;8  &S6  !K\@  :_\  &O_ (YS  "%>   ?7L
M '-]  !E?@  6'X  $M^   ^?@  ,GX  "9]   <?   $WP   U\   &?0
M 'T%  !\"P  ? \  'P3  !\&0  ?"$  'PI  !\-   >T   'M.  ![7@
M>V\  'J$  !ZF@  >;$  'C.  !W[P  =OX  ';_ (EZ  "!?P  >((  &N#
M  !=A0  3X8  $*'   UB   *8<  !V'   4AP  #8@   :)    B@   (H
M  ")!@  B0P  (D/  ")$P  B1H  (HB  "*+   BC@  (I&  ")5@  B6@
M (E\  "(E   AZL  (;&  "%Z@  A?L  (3_ (6"  !]A@  ;X@  &&+  !3
MC0  18\  #B1   KD0  'Y(  !22   -DP  !)0   "6    EP   )@   "7
M    EP4  )<+  "8#@  F!,  )D:  "9(@  FBX  )H]  "930  F5X  )ES
M  "8BP  F*,  )>\  "6X@  EO<  )7_ (")  !RC   9(\  %:3  !(E@
M.ID  "R:   ?FP  %)P   R>   #GP   *$   "C    I0   *4   "E
MI0   *8"  "G"   IPT  *@1  "I&0  JR,  *LQ  "K00  K%,  *QG  "K
M@   JIH  *JS  "JT   J>\  *G[ '6/  !GE   69@  $J<   \GP  +:(
M ""C   3I0  "Z<   &I    JP   *X   "Q    L@   +(   "S    M
M +4   "V    N 0  +D+  "[$   O1@  +\D  "_-0  P$<  ,!;  # <@
MP(T  ,&F  # P0  O^,  +[S &J7  !;G   3:$  #ZE   OJ0  (:L  !.M
M   +L    +,   "U    N    +P   "_    P0   ,$   ##    Q    ,8
M  #'    R0   ,L   #."   T0\  -48  #8)P  V3D  -I-  #;9   VWX
M -R9  #<L   W,D  -SC %V?  !/I0  0*H  #*O   BL@  %+4   JX
MNP   +\   ##    Q@   ,L   #.    T0   -$   #4    U@   -D   #;
M    W@   .    #D    YP8  .L.  #O&0  \"H  /(_  #S50  ]&T  /2(
M  #TH0  ]+8  /3' /\ "0#_  8 _P ' /\ # #_ !$ _P < /\ * #_ #0
M_P!! /\ 3 #_ %4 _P!= /\ 90#_ &P _P!R /X > #\ 'X ^P"$ /H BP#Y
M )( ]P"9 /8 H@#T *P \P"Y /$ RP#P .@ [@#[ .T _P#L /\ X0#_ -(
M_P#) /\ Q #_ /\  0#_    _P   /\ ! #_  X _P 7 /\ (P#_ "\ _P [
M /T 1@#Z %  ]P!8 /0 7P#R &8 \ !L .\ <@#M '@ [ !^ .H A0#I (P
MYP"3 .4 G #C *8 X0"Q -\ P0#= -T VP#T -D _P#6 /\ SP#_ ,0 _P"]
M /\ N0#_ /\   #_    _P   /\   #_  L _  3 /< '@#T "H \@ U .X
M0 #I $H Y@!2 ., 60#@ &  W@!F -P ; #: '( UP!X -0 ?@#2 (4 T "-
M ,X E0#, )\ R0"J ,< N #% ,T PP#K ,  _@"_ /\ O@#_ +8 _P"P /\
MK0#_ /\   #_    _P   /D   #R  8 ZP / .8 &0#A "0 W@ O -H .0#3
M $, SP!, ,P 4P#) %H QP!@ ,4 9@## &L P0!Q +\ =P"] 'X NP"& +D
MC@"W )@ M0"C +, L "Q ,( K@#@ *P ]P"K /\ J@#_ *@ _P"C /\ H #_
M /\   #_    ]0   .L   #A    U@ , ,\ $P#* !X Q@ I ,( ,P"_ #T
MNP!% +@ 30"V %0 LP!: +$ 7P"P &4 K@!J *P < "K '< J0!_ *< AP"E
M )$ HP"< *  J0"> +@ G #. )H [@"9 /\ EP#_ )8 _P"6 /\ DP#_ /T
M  #Q    Y0   -D   #-    Q  & +T #P"W !@ LP B +  + "M #8 J0 ^
M *< 1@"D $T H@!3 *  60"? %X G0!D )L :@": '  F !W )8 @ "4 (H
MD0"5 (\ H@"- +  BP## (D XP"( /D A@#_ (8 _P"& /\ A@#_ /,   #C
M    T0   ,4   "]    M@   *X "P"H !( I  < *  )@"< "\ F@ W )<
M/P"5 $8 D@!, )$ 4@"/ %@ C0!= (L 8P"* &H B !Q (8 >0"$ (, @@"/
M '\ FP!^ *D ? "[ 'H U0!X /( > #_ '< _P!W /\ =P#_ .<'  #1#
MPPT  +@,  "N"   J    *( !0";  X E@ 5 )( 'P". "@ BP Q (@ .0"&
M $  A !& (( 3 "  %( ?P!7 'T 70![ &, >@!K '@ <P!V 'T = "( '$
ME0!P *0 ;@"T &P R@!K .H :@#\ &H _P!J /\ :@#_ -H0  #&%   N!8
M *T5  "D$@  G X  )8'  "0  D B@ 0 (4 & "! "$ ?@ J 'L ,@!Y #D
M=P!  '4 1@!S $P <@!1 '  5P!N %X ;0!E &L ;@!I '< 9P"# &4 D0!C
M )\ 8@"O &  Q !? .0 7P'X %X"_P!> O\ 7@+_ ,X8  "]'0  L"   *4?
M  ";'   DQ<  (L1  "$#   ?@0+ 'D $@!U !L <@ C &\ *P!M 3, :P$Z
M &D"0 !G T8 9@-, &0$4@!C!%D 801@ %\%:0!>!7, 7 9_ %H&C0!9!YP
M5PBM %8(P0!5">$ 5 OV %0+_P!4"_\ 5 O_ ,8?  "V)0  J2@  )XH  "4
M)0  BR$  (,;  ![%   = X# &X)#0!I"!0 9@D= &0*)0!B"BT 8 LT %X+
M.@!="T  6PQ' %H,30!8#%0 5PU< %4-9 !4#6\ 4@U[ % .B@!/#IH 3@ZL
M $P/P@!,$., 2Q#Y $L0_P!+$?\ 2Q#_ +\F  "P*P  I"\  )DO  "/+0
MABD  'TD  !T'@  ;!<  &41!P!?#A  7 \7 %H0'P!8$"< 5A N %00-0!3
M$#L 4A%" % 12 !/$5  3A%7 $P28 !+$FL 21)X $@3AP!&$Y< 112I $04
MO@!#%=\ 0Q;X $,6_P!#%O\ 0Q;_ +HK  "K,0  H#0  )4U  "+-   @3$
M '@K  !O)@  9B   %X9 0!7% T 5!03 %$4&P!/%2, 3A4J $P5,0!+%C<
M218^ $@61 !'%TP 11=4 $0770!#&&< 01AT $ 9@P _&I0 /1JF #P;NP [
M&]L .QSV #P<_P \'/\ /!S_ +4P  "H-@  G#D  )$[  "'.@  ?C<  ',R
M  !J+0  82<  %DA  !1&PD 3!D0 $H:%P!(&A\ 1AHF $4;+0!#&S, 0ALZ
M $$<00! '$@ /AQ0 #T=60 \'F0 .QYQ #D?@  X'Y( -R"D #8@N  U(=8
M-2'T #4B_P U(?\ -B'_ +(T  "D.@  F3X  (\_  "%/P  >SP  ' X  !G
M,@  72T  %0H  !,(@4 1A\. $,?% !!'QL /Q\B #X@*0 ](#  .R V #HA
M/0 Y(44 .")- #<B5P V(V( -"-N #,D?@ R)(\ ,26B "\EM@ O)M( +R;R
M "\F_P P)O\ ,";_ *\X  "B/@  ED(  (Q#  ""0P  >$$  &X]  !C.
M6C,  %$N  !(* $ 0"0, #TC$0 [)!@ .20? #@D)@ V)"P -24S #0E.@ S
M)D( ,B9* #$G5  P)U\ +RAL "XH>P L*8T *RJ@ "HJM  I*L\ *2OP "HK
M_P J*O\ *RK_ *P\  "?0@  E$8  (I'  " 1P  =D4  &Q"  !A/0  5S@
M $XS  !$+@  /"D) #<H$  U*!4 ,R@< #(H(P P*"D +RDP "\J-P N*C\
M+2M( "PK4@ K+%T *BQJ "@M>0 G+8L )BZ> "4NLP D+\T )"_N "4O_P E
M+_\ )B[_ *D_  "=10  DDD  (A+  !^3   =$H  &I'  !>0@  5#T  $LY
M  !!-   ."\& #(M#0 P+1, +BT9 "TM(  K+2< *BXN "DN-0 I+ST *"]&
M "<P3P E,%L )#%H ",Q=P B,HD (3*= !\SL0 >,\L 'C/M !\S_P @,_\
M(3+_ *9#  ":20  D$T  (9/  !\4   <T\  &A,  !<1@  4D,  $D_   _
M.P  -C8" "XR#  K,A$ *3(7 "@R'@ F,B0 )3,K "0S,@ C-#H (C1# "$U
M30 @-5@ 'S9E !XV=0 <-X< &S>; !HWKP 9.,@ &3CK !HX_P ;-_\ &S?_
M *-'  "830  CE$  (13  ![5   <5,  &90  !:3   4$D  $=%   ]00
M,ST  "HY"0 E-PX (S<4 "(X&P A."( (#@H !\X,  >.3@ '3E! !PZ2P :
M.E8 &3MC !@[<@ 6.X4 %3R9 !0\K0 3/<8 $SWI !0\_0 5//\ %CO_ *!+
M  "540  BU4  ()8  !Y60  ;E@  &16  !840  3D\  $5+   Z1P  ,$,
M "= !0 @/@T '3X1 !P^%P ;/AX &CXE !D^+0 8/S4 %C\^ !4_2  40%,
M$T!@ !)!<  108( $$&7  ]!K  .0L0 #D+G  ]!_  00?\ $$#_ )U0  "3
M5@  B5H  (!=  !V7@  ;%T  &);  !65P  3%4  $%1   V3@  +$L  "-(
M   ;10D %T0/ !5$%  411L $T4B !)%*0 113$ $44[ !!&10 /1E  #D=>
M  U';0 ,1W\ "T>3  E'IP (1[X "$?@  E']@ *1O\ "T;_ )I5  "06P
MAV   'UB  !S8P  :F(  &!A  !37@  1UH  #Q7   R50  *%(  !]0   7
M3@0 $4P,  ],$0 .3!< #DP>  U-)0 ,32X "TTW  I-0@ )34T !TY:  9.
M:0 $3GL  DZ/  %.I   3;H  $W;  %-\@ !3?\  DS_ )9;  "-8@  A&8
M 'IH  !Q:0  :&D  %QG  !/9   0F$  #=?   M7   (UH  !I8   25P$
M#58)  E5#@ '51, !E4:  15(@ #52H  E4T  !5/@  54H  %97  !690
M57<  %6+  !5H   5;8  %34  !4\0  4_T  %/_ )-B  "*:   @&P  '=N
M  !O;P  8VX  %9L  !):@  /6@  #)F   G90  '6,  !5B   .80  "6 (
M  -@#0  7Q$  %\7  !?'@  7R8  %\O  !?.@  7T4  %]3  !?80  7G(
M %Z'  !=G   7;(  %S/  !<[P  6_T  %O_ )!J  "&;P  ?7(  '5T  !J
M=0  770  $]S  !"<@  -G   "MO   @;@  %VT  !!L   *;    FL&  !K
M"P  :@\  &H4  !J&@  :B$  &DJ  !I-   :4   &E.  !I7   :6T  &B"
M  !HF   9ZX  &;*  !E[0  9?P  &3_ (MQ  ""=@  >GD  '![  !B>P
M57L  $AZ   [>@  +WH  "-Y   9>   $7<   IW   #=P   '<"  !W"
M=@T  '80  !V%0  =AL  '8C  !V+@  =3H  '5'  !U5@  =6@  '1\  !T
MD@  <ZH  '+$  !QZ0  </L  '#_ (9Y  !_?0  =G\  &B!  !:@@  3((
M #^#   RA   )8,  !J#   1@P  "H,   *#    A    (4   "$ P  @P@
M (,-  "#$   @Q4  (0<  "$)@  A#(  (0_  "#3P  @V   ()U  ""C
M@:0  ("]  !_XP  ?OD  '[_ (*   !ZA   ;(8  %Z(  !0B@  0HL  #6-
M   GC0  &XT  !&.   *C@   (\   "1    D@   )(   "2    D@$  )('
M  "2#   DA   ),5  "3'0  E"@  )0V  "410  DU<  )-K  "3@@  DIP
M )&V  "0V   C_,  (__ 'Z'  !PB@  88T  %.0  !%DP  -Y4  "F6   <
MEP  $9@   F9    FP   )P   ">    H    *    "@    H    *$   "A
M!   H@D  *,.  "D%   I1T  *8J  "F.@  IDP  *5@  "E>   I9(  *2L
M  "DR0  H^L  *+Z '..  !DD0  5I4  $>9   YG   *IX  !V@   1H0
M"*,   "E    IP   *D   "L    K@   *X   "N    KP   +    "Q
ML@   +,&  "U#0  MQ,  +D>  "Y+@  ND   +I4  "[:@  NH4  +FA  "Y
MNP  NMX  +GR &>5  !8F0  2IX  #NB   LI@  ':@  !&J   'K    *\
M  "Q    M    +@   "[    O    +P   "^    OP   ,    #"    Q
M ,8   #( P  RPL  ,\2  #1(   T3(  -)&  #370  U'8  -22  #5JP
MU<0  -3B %N=  !,H@  /:<  "^L   ?KP  $;$   >U    N    +L   "^
M    P@   ,<   #*    S    ,P   #.    T    -(   #5    V    -L
M  #?    X@   .8+  #K$P  ["0  .TX  #N3@  [V<  /""  #PG   \+(
M /'% /\  P#_  $ _P $ /\ "0#_  \ _P 8 /\ ) #_ #  _P \ /\ 1P#_
M %$ _P!9 /\ 8 #] &< _ !M /H <P#Y 'D ^ !_ /8 A0#U (P \P"4 /(
MG0#P *< [@"S .P Q #K .$ Z@#X .D _P#G /\ V0#_ ,L _P#" /\ O0#_
M /\   #_    _P   /\   #_  P _P 4 /\ ( #_ "L _@ W /H 0@#V $L
M\@!3 /  6P#N &$ [ !G .H ;0#H ', YP!Y .4 ?P#C (8 X0". -\ E@#=
M *  VP"L -@ NP#4 -$ TP#P -  _P#. /\ R #_ +T _P"V /\ L@#_ /\
M  #_    _P   /\   #]  @ ]P 0 /, &@#O "8 [0 Q .@ .P#C $4 X !-
M -P 50#9 %L U@!A -, 9P#1 &P SP!R ,T > #+ '\ R0"' ,< D #% )H
MPP"E ,  L@"^ ,4 O #E +H ^P"X /\ MP#_ +  _P"I /\ I0#_ /\   #_
M    _@   /4   #L  , Y0 - -\ %0#: "  U  J -  -0#+ #X R !' ,4
M3@#" %4 P !; +X 80"\ &8 N@!L +@ <@"V '@ M0"  +, B "Q )( K@">
M *P J@"I +L J #5 *8 \P"D /\ HP#_ *$ _P"; /\ F #_ /\   #[
M\    .4   #8    S@ ) ,< $0#" !H O@ D +L +@"W #@ M !  +$ 2 "N
M $X K !4 *H 6@"I %\ IP!E *4 :P"D '$ H@!X *  @0"> (L G "6 )D
MHP"7 +( E@#' ), Z "2 /X D0#_ )  _P"- /\ BP#_ /D   #K    W0
M ,\   #&    O  $ +4 #0"P !4 K  > *@ * "E #$ H@ Y )\ 00"= $@
MFP!. )D 4P"7 %D E@!> )0 9 "2 &H D !Q (X >@", (, B@"/ (@ G "&
M *H A "\ (( W "! /8 @ #_ '\ _P!_ /\ ?@#_ .P   #:    R0   +X
M  "V    K@   *< "0"A !  G  8 )@ (@"5 "H D@ R )  .@"- $$ BP!'
M (D 30"' %( A@!8 (0 70"" &0 @0!K '\ <P!] 'T >P"( '@ E0!V *,
M=0"T ', S !Q .T < #_ '  _P!P /\ < #_ -\%  #*"@  O L  +$)  "H
M!   H0   )L  P"4  P CP 3 (H &P"' "0 A  L ($ ,P!_ #H ?0!! 'L
M1P!Y $P =P!2 '8 5P!T %T <@!D '  ;0!O '8 ; "" &H CP!I )T 9P"N
M &4 PP!D .0 8P#Z &, _P!B /\ 8P#_ - .  "_$@  LA,  *<2  "=$
ME0L  (\#  ")  < @@ . 'X %0!Z !X =@ E '0 +0!Q #0 ;P Z &X 0 !L
M $8 :@!, &D 4@!G %@ 9@!? &0 9P!B '$ 8 !\ %X B0!< )@ 6P"I %D
MO !8 -P 6 #T %@ _P!7 /\ 5P#_ ,86  "V&@  JAT  )\<  "5&0  C10
M (4/  !^"0  =P$* '( $ !N !< :@ ? &@ )P!E "X 9  T &( .P!@ $
M7P!& %T 3 !< %, 6@!: %@ 8@!7 &P 50!W %, A0!2 )0 4 &E $\!N !.
M M( 303P $T%_P!-!?\ 307_ +\=  "P(@  HR4  )DE  "/(@  A1T  'T8
M  !U$@  ;@T" &<&# !C Q$ 7P(9 %T#(0!;!"@ 600O %<%-0!6!3L 5 9!
M %,&1P!1!DX 4 =5 $X'7@!-"&< 2PAS $D)@0!("9( 1PJC $4*M@!$"]
M1 SO $,-_P!##?\ 1 W_ +DD  "J*0  GBP  )0L  "**@  @"8  '<A  !N
M&P  9A0  %\/!0!9"PT 50H3 %,+&P!1"R( 3PPI $T,+P!,##8 2PT\ $D-
M0@!(#4D 1@U1 $4.6@!$#F0 0@YP $ .?P _#Y  /A"B #P0M@ [$-$ .Q'Q
M #L1_P [$?\ /!'_ +0I  "F+P  FC(  ) R  "&,0  ?"T  '(H  !I(P
M81T  %D6  !1$0@ 3 \0 $H0%@!($!T 1A D $40*P!#$3$ 0A$W $$1/@!
M$44 /A)- #T25@ \$F$ .A-M #D3?  W%(T -A2? #45LP T%<T ,Q;N #06
M_P T%O\ -!;_ *\N  "B-   ES<  (PX  ""-@  >#0  &XN  !E*@  7"0
M %0>  !,& 0 1A0- $(4$@! %!D /Q0@ #T5)P \%2T .Q4T #D6.@ X%D(
M-Q9* #874P U%UX ,QAJ #(9>0 P&8H +QJ= "X:L0 M&\H +1OL "T<_P N
M&_\ +AO_ *PR  "?.   E#L  (H\  " /   =CD  &LT  !B+P  62H  % E
M  !''P  0!H* #P9$  Z&18 .!D= #8:(P U&BD -!HP #,:-P R&SX ,1M'
M "\<4  N'5L +1UG "P>=@ J'H@ *1^; "@?K@ G(,< )B#J "<@_@ H(/\
M*"#_ *DV  "=/   DC\  (=!  !]0   =#X  &DZ  !?-0  5C   $TK  !$
M)0  .R ' #8>#@ S'A, ,AX9 # >(  O'B8 +A\M "T?-  L(#L *R!$ "HA
M3@ I(5@ )R)E "8B=  E(X4 (R.9 "(DK0 A),4 (27H "(E_0 B)/\ (R3_
M *8Z  ":/P  CT,  (5%  ![1   <D,  &<_  !=.@  4S8  $HQ  !!+
M."8# #$C#  N(A$ +"(6 "HB'0 I(B, *",J "<C,0 F)#D )25! "0E2P C
M)E8 (B9C "$G<@ ?)X, 'BB7 !THJP ;*<, &RGF !PI^P =*?\ 'BC_ *,^
M  "80P  C4<  (-)  !Z20  <$<  &9$  !:/P  43L  $<W   ^,@  -2T
M "PH"0 H)P\ )R<4 "4G&@ D)R$ (R@G "(H+@ A*38 ("D_ !\J20 >*E0
M'2M@ !LK;P :+($ &2R5 !<MJ0 6+<$ %BWD !<M^@ 8+?\ &2W_ *%!  "5
M1P  BTL  ()-  !X30  ;DP  &1)  !81   3T   $8]   ].   ,S0  "HO
M!@ D+ T (2P2 " L&  ?+1X 'BTE !TM+  <+C0 &RX\ !HO1@ 8+U$ %S!>
M !8P;0 5,7\ $S&3 !(QJ  1,K\ $3+B !(R^0 3,?\ $S'_ )Y%  "32P
MB4\  (!1  !V4@  ;5   &).  !620  348  $1#   [/P  ,3H  "<V P ?
M,@L '#(0 !LR%0 9,AL &#(B !<S*0 6,S$ %30Z !0T1  3-$\ $C5< !$U
M:P 0-GT #S:1  XVI@ --[P #3?=  TV]@ .-O\ #S;_ )M)  "13P  AU,
M 'Y6  !U5@  :E4  &!3  !53P  3$P  $))   X10  +D$  "0]   <.@@
M%C@. !4X$@ 4.!@ $SD? !(Y)@ 1.2X $#DW  \Z00 ..DP #3M9  T[:  +
M.WH "CN-  D\H@ '/+@ !SS5  @\\  )._\ "CO_ )A.  ".5   A5@  'Q;
M  !R6P  :%H  %Y8  !350  25(  #Y.   T2P  *D<  "%$   80@, $D +
M ! _$  ./Q4 #C\<  U (P ,0"L "T T  I /@ )04H !T%6  9!90 $078
M T&*  %!GP  0;0  $'0  %![@ !0?P  D#_ )54  ",60  @UX  'E@  !P
M8   9F   %U>  !16P  15<  #I4   O40  )4\  !Q,   42@  #D@(  M'
M#@ (1Q( !T<9  9'(  %2"@  T@Q  )(.P  2$<  $A3  !(8@  2',  $B&
M  !(FP  2+$  $?,  !'[0  1_L  $?_ )):  ")8   @&,  '=E  !N9@
M968  %ED  !,8   0%T  #5;   J60  (%<  !=5   04P  "U('  51#0 !
M4!$  % 6  !0'0  4"4  % N  !0.   4$,  %!0  !07@  4&\  %"#  !/
MF   3ZX  $[)  !.ZP  3?L  $W_ (]A  "&9@  ?6D  '1L  !L;0  86L
M %-I  !&9P  .F0  "]C   D80  &E\  !)>   ,7   !EP&  !;"P  6@\
M %H3  !:&0  62$  %DI  !9,P  63\  %E,  !96@  66L  %A^  !8E
M5ZL  %?%  !6Z0  5?L  %7_ (QH  "";0  >G   ')R  !G<@  6G$  $QP
M   _;@  ,VT  "AK   =:@  %&@   UG   '9P   &8#  !F"0  90T  &41
M  !D%0  9!P  &0D  !D+@  9#H  &-'  !C50  8V8  &-Z  !BD   8:<
M &#!  !?Y@  7_H  %[_ (=O  !_=   >'<  &YX  !@>   4G<  $5W   X
M=@  *W8  "!T   6<P  #G,   =R    <@   '(   !Q!0  <0H  '$.  !P
M$0  <!<  ' >  !P)P  <#,  &]   !O4   ;V   &YT  !NBP  ;:(  &R\
M  !KX@  :O@  &G_ (-W  !\>P  <WT  &5^  !7?P  27\  #Q_   O@
M(G\  !=^   /?@  !WX   !_    ?P   '\   !^    ?@4  'X*  !^#0
M?A$  'X7  !^(   ?BL  'TY  !]2   ?5D  'QM  !\A   >YP  'JV  !Y
MV@  >/4  '?_ (!_  !W@@  :8,  %N%  !-A@  /X@  #*)   DB0  &(D
M  ^)   'B@   (L   ",    C0   (T   ",    C    (P#  ","   C0T
M (T1  "-%P  CB(  (XO  "./P  C5   (UD  ",>P  C)4  (NN  "*S0
MB>\  (G_ 'N%  !MB   7HH  %"-  !"CP  -)$  ":2   9DP  #I0   :5
M    E@   )@   ":    FP   )L   ";    FP   )L   "<    G04  )T+
M  ">$   GQ<  * D  "@-   H$8  *!9  "?<   GXH  )ZE  ">P@  G>@
M )SY '",  !ACP  4Y(  $26   VF0  )YL  !F<   /G0  !9\   "A
MHP   *4   "H    J0   *D   "I    J@   *L   "L    K0   *X!  "P
M"0  L@\  +,8  "T)P  M#D  +5-  "T9   M'X  +.:  "SM   L]4  +/P
M &23  !5EP  1YL  #B?   IH@  &J0   ZF   $J    *L   "M    L
M +0   "V    N    +@   "Y    N@   +P   "]    OP   ,    ##
MQ0<  ,D/  #*&@  RRP  ,Q   #-5@  SF\  ,V+  #,J   S,(  ,SB %B;
M  !)H   .J4  "RI   <JP  #ZX   2Q    M    +<   "Z    O@   ,,
M  #&    R    ,@   #*    RP   ,T   #/    T@   -4   #9    W0
M .$%  #F#P  YQX  .@R  #I2   ZF   .M[  #KEP  [*X  .S" /\   #_
M    _P   /\ !@#_  T _P 5 /\ (0#_ "P _P X /\ 0P#_ $P _@!4 /L
M6P#Z &( ^ !H /8 ;@#U '0 ] !Z /( @ #Q (< [P"/ .T EP#K *$ Z0"M
M .< O0#E -@ Y #S .( _P#@ /\ T #_ ,0 _P"\ /\ M@#_ /\   #_
M_P   /\   #_  D _P 1 /\ ' #] "< ^0 R /4 /0#Q $8 [0!/ .L 5@#H
M %P Y@!B .0 : #C &X X0!S -\ >0#= (  V@"( -@ D0#4 )L T@"F ,\
MM #, ,D R0#I ,@ _P#' /\ P0#_ +< _P"O /\ JP#_ /\   #_    _P
M /\   #X  4 \@ . .X %P#J "( Y@ L .$ -P#= $  V !) -, 4 #0 %8
MS@!< ,P 8@#* &< R !M ,8 <P#$ 'D P@"! ,  B@"^ )0 O "? +D K "V
M +X M #= +, ]P"Q /\ L #_ *@ _P"B /\ G@#_ /\   #_    ^0   .\
M  #F    WP + -8 $@#0 !P S  F ,@ , #$ #H P !" +T 2@"[ %  N !6
M +8 6P"U &$ LP!F +$ ; "P '( K@!Z *P @@"I (P IP"8 *4 I0"C +0
MH #+ )\ [@"= /\ G #_ )D _P"4 /\ D0#_ /\   #V    Z@   -T   #/
M    QP & ,  #P"[ !< MP @ +, *@"P #, K0 [ *H 0P"G $D I0!/ *,
M50"B %H H !? )X 90"= &L FP!R )D >P"7 (4 E "0 )( G0"0 *P C@"_
M (P X@"+ /H B0#_ (D _P"& /\ @P#_ /0   #D    U    ,@   "_
MM0 ! *X "P"I !( I0 ; *$ (P"> "P FP T )@ / "6 $, E !) )( 3@"0
M %, C@!9 (T 7@"+ &0 B0!K (< <P"% 'T @P"( ($ E0!_ *0 ?0"U 'L
MSP!Y /$ > #_ '< _P!W /\ =0#_ .4   #1    PP   +@   "O    J
M *  !@":  X E0 5 )$ '@". "8 BP M (@ -0"& #P A !" (( 1P"  $T
M?P!2 'T 6 ![ %X >0!E '@ ;0!V '8 <P"! '$ C@!O )T ;0"N &P Q !J
M .< :0#] &@ _P!H /\ :0#_ -4#  ##!P  M@@  *L&  "B    FP   )0
M  "-  H B  0 (, & !_ "  ?  G 'H +@!W #4 =0 [ '0 00!R $< < !,
M &\ 4@!M %@ :P!? &D 9@!G '  90![ &, B !B )< 8 "G %X NP!= -P
M7 #V %P _P!; /\ 6P#_ ,D-  "Y$   K!$  *$0  "7#0  CP@  (@   ""
M  4 >P - '< $@!S !H ;P A &P * !J "\ :  U &< .P!E $$ 8P!& &(
M3 !@ %( 7P!9 %T 80!; &H 60!U %< @@!5 )$ 5 "B %, M0!1 ,\ 4 #O
M %  _P!0 /\ 4 #_ +\4  "P&   I!H  )D9  "/%@  AQ$  '\-  !W!@
M<0 ( &L #@!G !0 9  ; &$ (@!> "D 70 O %L -0!9 #L 6 !! %8 1@!5
M $T 4P!4 %( 7 !0 &4 3@!P $P ?0!+ (T 20"> $@ L !' ,< 1@#I $8
M^P!& /\ 10#_ +@;  "J(   GB(  ),B  ")'P  @!H  '<5  !O$   : L
M &$$"@!= !  60 6 %8 '0!4 ", 4@ J %  , !/ #4 3@ [ $P 00!+ $@
M20!/ $<!5P!& 6$ 1 )L $,">0!! XD 0 .: #X$K0 ]!,0 / 7E #P'^  \
M!_\ / ?_ +(B  "E)P  F2D  (XI  "$)P  >R,  '$>  !I&   81(  %H-
M P!3" P 3P41 $P%%P!*!AX 2 8D $<&*@!%!S  1 <V $,(/0!!"$, 0 A+
M #X)4P ]"5T .PIH #H*=@ X"X< -PN9 #4+K  T#,( ,PSD #,-^0 S#?\
M- W_ *TG  "@+   E2\  (LO  " +@  =RH  &TE  !D(   7!H  %04  !,
M#P8 1@P- $,,$@!!#!@ /PP? #X,)0 \#2L .PTR #H-.  X#3\ -PY' #8.
M4  T#EH ,PYF #$/=  P#X4 +A"8 "T0JP L$,, *Q'E "P1^@ L$?\ +1'_
M *HL  "=,0  DC0  (<U  !]-   =#$  &HK  !@)P  6"$  $\;  !'%@
M0!$) #L0#P Y$!0 -Q ; #80(0 T$"< ,Q$M #(1-  Q$3L ,!%# "X230 M
M$E< +!)C "H3<0 I$X( )Q25 "84J0 E%<  )!7C "46^@ F%O\ )A7_ *8Q
M  ":-@  CSD  (4Z  ![.0  <38  &<Q  !=+0  5"@  $PB  !#'0  .Q<%
M #44#0 R$Q$ ,107 "\4'0 N%"0 +!0J "L5,0 J%3@ *19  "@62@ G%U0
M)A=@ "08;P C&(  (1F3 " 9IP ?&;X 'AK@ !\:^  @&O\ (!K_ *,T  "8
M.@  C3T  (,^  !Y/0  ;SL  &4W  !;,@  4BT  $DH  ! (P  .!X! # 9
M"@ L& \ *A@4 "D8&@ G&"  )ADG "49+0 D&C4 (QH^ "(;1P A&U( (!Q>
M !\=;  ='7X '!V1 !H>I0 9'KP &!_= !D?]@ :'_\ &Q[_ *$X  "5/0
MBT$  (%"  !W0@  ;4   &,\  !9-P  3S,  $8N   ]*0  -20  "T@!P G
M'0T )1T2 ",=%P A'1T (1TD " >*P ?'C( 'A\[ !T?10 <($\ &B%< !DA
M:@ 8(GL %B*/ !4BHP 4([H $R/: !0C]0 5(_\ %B/_ )X\  "300  B40
M ']&  !U1@  ;$0  &)!  !7/   33@  $0T   \,   ,RL  "HF P C(@L
M("$0 !XA%0 <(AL &R(A !HB*  :(S  &2,X !@D0@ 6)4T %259 !0F:  3
M)GD $B:- !$GH@ 0)[@ #B?6 ! H]  1)_\ $2?_ )Q   "110  AT@  'U*
M  !T2@  :DD  &!&  !500  3#X  $,Z   Z-@  ,3(  "@M   @*0D &R<.
M !DG$@ 8)Q@ %B<? !4H)0 4*"T $R@V !(I0  2*4L $2I7 ! J9@ .*W<
M#BN+  TLGP ,++4 "RS/  PL[P -+/\ #2O_ )E$  "/20  A4P  'Q.  !S
M3P  :4X  %Y+  !31P  2D0  $)    Y/0  +S@  "4T   =, 4 %BT, !0L
M$  3+14 $BT< !$M(P 0+2H #RXS  XN/0 -+T@ #2]5  PP8P *,'0 "3"(
M  @QG  &,;$ !C'+  8QZP ',/P "##_ )=(  "-30  @U$  'I3  !Q5
M9U(  %U0  !23   24H  $!&   U0@  *SX  "(Z   :-P$ $C0)  \S#@ .
M,Q, #3,9  TS(  ,-"@ "S0Q  HU.P (-48 !S52  4V8  $-G$  C:$   V
MF0  -J\  #;(   VZ   -OD  37_ )1-  "*4@  @58  'A8  !O60  95@
M %M5  !14@  1T\  #Q,   Q2   )T0  !Y!   6/P  $#P'  LZ#0 ).A$
M"#L7  8['@ %.R8 !#LN  ([.  !/$,  #Q/   \7@  /&X  #R!   \EP
M/*P  #O%   [YP  ._@  #O_ )%2  "(6   ?UP  '9=  !M7@  8UT  %I<
M  !.6   0E0  #=1   M3@  (TL  !I)   21@  #40&  =##  #0Q   $,5
M  !#&P  0R,  $,K  !#-0  0T   $--  !#6P  0VL  $-^  !#E   0JH
M $+#  !!Y@  0?D  $'_ (Y8  "&7@  ?6$  '-C  !K9   8F,  %=A  !)
M70  /5H  #)8   G50  'E,  !51   .3P  "4T%  )-"P  3 X  $P3  !+
M&   2Q\  $LH  !+,@  2ST  $M)  !+5P  2V<  $I[  !*D   2:<  $G
M  !(Y   2/@  $?_ (M?  "#9   >F<  '%I  !I:@  7FD  %!F  !#9
M-V$  "Q?   A70  &%L  !!9   *6    U<#  !7"0  5@T  %40  !5%0
M5!L  %0C  !4+0  5#D  %1%  !44P  5&0  %-W  !3C0  4J0  %&]  !0
MX@  4/@  $__ (AG  !_:P  =VX  &]P  !E<   5VX  $IL   ]:P  ,&D
M "5H   :9@  $60   MC   $8@   &(!  !A!@  8 L  & .  !?$@  7Q<
M %\>  !>*   7C,  %Y   !>3P  7E\  %UR  !=B   7*   %NY  !:WP
M6?<  %C_ (1N  !\<@  =74  &MV  !==0  3W0  $)S   U<P  *'(  !UP
M   3;P  #&X   1N    ;@   &X   !L @  ; <  &L+  !K#@  :Q(  &H9
M  !J(@  :BT  &HZ  !I20  :5H  &EL  !H@P  9YL  &:U  !EV   9/4
M &3_ (!U  !Z>0  <'L  &)[  !4?   1GP  #E\   L?   'WL  !1Z   -
M>@  !'H   !Z    >@   'H   !Y    >0$  '@&  !X"P  > X  '@3  !X
M&@  >"4  '@R  !W00  =U(  '=E  !V?   =94  '2O  !SS@  <O$  ''_
M 'Y]  !U@   9X$  %B"  !*@P  /(0  "Z%   AA0  %84   V%   #A0
M (8   "'    B    (@   "'    AP   (<   "'!   APD  (<.  "($P
MB!P  (@I  "(.   ATH  (==  "&<P  AHT  (6G  "$Q0  @^P  (+^ 'B$
M  !JA@  7(@  $V*   _C   ,8X  "./   6CP  #9    *1    D@   ),
M  "5    E@   )8   "6    E@   )8   "7    EP   )<'  "8#0  F1,
M )H?  ":+0  FC\  )I2  "::   F8,  )F?  "8N@  E^(  );X &V*  !?
MC0  4)   $&3   SE@  ))<  !:8   -F0   9L   "=    GP   *$   "D
M    I0   *0   "E    I0   *8   "G    J    *D   "J!   K P  *X3
M  "N(0  KC,  *Y'  "N70  KG8  *Z3  "NK@  K<T  *SO &&1  !3E0
M1)@  #6<   FGP  %Z$   VC    I0   *<   "J    K    +    "R
MM    +,   "T    M0   +<   "X    N0   +L   "]    OP$  ,,+  #%
M%0  Q24  ,8Y  #'3P  QV@  ,:%  #&H@  QKP  ,;> %69  !'G0  .*(
M "FF   9J   #:L   "M    L0   +0   "W    N@   +\   #!    Q
M ,,   #%    Q@   ,@   #*    S0   ,\   #2    U@   -L   #@#
MX1@  .,K  #D00  Y5H  .9T  #FD0  Y:P  .7$ /\   #_    _P   /\
M 0#_  H _P 2 /\ '0#_ "@ _P T /\ /@#] $@ ^@!0 /< 5P#U %T ] !C
M /( :0#P &\ [P!T .T >P#K ($ Z0") .@ D@#F )P Y "H .( MP#? ,T
MW #N -D _P#9 /\ R@#_ +X _P"U /\ L #_ /\   #_    _P   /\   #_
M  8 _P / /P & #X ", ]  N /  . #K $( Z !* .4 40#B %@ X != -X
M8P#< &@ V0!N -8 = #4 'L T0"" ,\ BP#- )4 R@"A ,@ KP#% ,$ P@#C
M ,  ^P#  /\ NP#_ +  _P"H /\ I #_ /\   #_    _P   /L   #S  $
M[0 , .@ $P#C !X X  H -H ,@#3 #P SP!$ ,P 2P#) %$ Q@!7 ,0 70#"
M &( P0!G +\ ;0"] '0 NP![ +D A "W (X M "9 +( IP"O +< K0#0 *L
M\@"J /\ J0#_ *$ _P"; /\ EP#_ /\   #_    ]    .D   #@    U0 (
M ,X $ #) !@ Q0 B ,$ *P"\ #4 N0 ] +8 10"S $L L0!1 *\ 5@"N %L
MK !A *H 9@"I &T I@!T *0 ? "B (8 H "2 )X GP"< *X F0## )< YP"6
M /\ E0#_ )( _P"- /\ B@#_ /P   #P    XP   -0   #(    OP # +D
M#0"S !, KP < *P )0"I "X I0 V *, /@"@ $0 G@!* )T 4 "; %4 F0!:
M )< 7P"6 &8 E !L )( =0"0 'X C@"* (L EP") *8 AP"X (4 U@"$ /8
M@@#_ ($ _P!^ /\ ? #_ .T   #=    S    ,$   "X    K@   *< "0"B
M !  G@ 7 )H 'P"7 "< E  O )$ -P"/ #T C0!# (L 20") $X B !3 (8
M60"$ %\ @@!E (  ;0!^ '< ? "" 'H CP!X )X =0"O ', QP!R .P <0#_
M '  _P!P /\ ;@#_ -T   #)    O    +$   "I    H0   )D  P"3  P
MC@ 2 (H &0"' "$ A  I ($ , !_ #< ?0 ] 'L 0@!Y $@ > !- '8 4@!T
M %@ <@!? '$ 9P!O '  ; ![ &H B !H )< 9@"H &4 O !C .$ 8@#Z &$
M_P!A /\ 80#_ ,T!  "\!0  KP4  *4"  "<    E    (T   "&  @ @0 .
M 'P % !X !L =0 C '( *0!P #  ;@ V &T / !K $$ :0!' &@ 3 !F %(
M9 !9 &, 8 !A &D 7P!T %T @0!; )  60"A %< M !6 -  50#R %4 _P!4
M /\ 50#_ ,$,  "R#@  I@\  )L.  "2"P  B04  ((   ![  ( =0 + '
M$ !L !8 :  = &8 (P!C "H 80 P &  -@!> #L 70!! %L 1@!: $P 6 !3
M %8 6P!4 &0 4@!N %$ >P!/ (H 30"; $P K@!+ ,8 2@#J $D _@!) /\
M20#_ +D2  "J%@  GA<  )06  "*$P  @1   'D+  !Q P  :P & &4 #0!A
M !$ 70 8 %H '@!8 "0 5@ J %0 , !3 #8 40 [ %  00!. $< 30!. $L
M5@!) %\ 1P!I $8 =@!$ (4 0P"7 $$ J0!  +\ /P#B #\ ^  ^ /\ /P#_
M +(9  "D'@  F!\  (X?  "$'   >A@  '(2  !J#@  8@@  %P!" !7  X
M4P 3 %  &0!. !\ 3  E $H *P!( #  1P V $8 / !$ $( 0P!) $$ 40 _
M %H /@!E #P <@ Z ($ .0"3 #@ I0 V +H -@#; #4 ]  U /\ -0#_ *P@
M  "?)   E"8  (DF  !_)   =2   &P;  !D%0  7!   %0, 0!.!@H 2@(/
M $< % !$ !H 0@ @ $  )0 _ "L /@$Q #P!-P [ CX .0)% #@#30 V U8
M-01A #,$;@ Q!7X , 60 "\%HP M!K@ + ;4 "P'\  L"/\ + C_ *@E  ";
M*@  D"P  (8M  ![*P  <B<  &@B  !?'0  5Q<  $\2  !(#@0 00H+ #X'
M$  [!A4 .0<; #@'(0 V""8 -0@L #,(,@ R"3D ,0E! "\)20 N"E, + I>
M "L+;  I"WP * R/ "8,H@ E#+< ) S3 ",-\  D#?\ )0W_ *0J  "8+P
MC3(  (,R  !Y,0  ;RX  &4I  !<)   4Q\  $L9  !#$P  /! & #4-#  S
M#!$ ,0P6 "\,'  N#2( +0TH "L-+@ J#34 *0T] "<.1@ F#E  ) Y< ",/
M:@ B#WL (!". !\0H@ =$+< '!#4 !T1\@ =$?\ 'A'_ *$O  "5,P  BC8
M ( W  !V-@  ;3,  &,O  !9*@  4"4  $@@   _&@  .!4  # 1"  L$ X
M*A 2 "@0&  G$!X )1 D "00*@ C$3( (A$Z "$10P @$DX 'A): !T3:  ;
M$W@ &A.+ !@4H  7%+4 %A31 !85\0 7%?\ &!3_ )XS  "3-P  B#H  'X[
M  !T.P  :S@  &$T  !7+P  3BL  $4F   ](0  -!P  "T7!0 F$PP (Q,0
M "(3%0 @$QH 'Q,A !X4)P =%"\ '!4W !L500 :%DL &197 !<790 6%W8
M%!B) !,8G@ 2&+, $1G. !$9[P 2&?\ $QG_ )PV  "1.P  ACX  'P_  !S
M/P  :3T  %\Y  !5-0  3#   $,L   Z)P  ,B(  "H> 0 B&0D 'A<. !P7
M$@ :%Q< &1@> !D8)  8&2P %QDT !8:/@ 5&DD $QM5 !(;8P 1''0 $!R'
M  \=G  .';$ #1W+  T=[  .'?\ #QW_ )DZ  "//P  A$(  'M$  !Q0P
M:$(  %X^  !3.@  2C8  $$R   Y+0  ,2D  "@E   @( 8 &AT, !<<$  5
M'!4 %!T; !0=(@ 3'2D $AXR !$?/  0'T8 $"!3  X@80 -(7$ #"&%  LB
MF0 *(JX "2+'  DBYP *(OL "R'_ )<^  ",0P  @T8  'E(  !P2   9T8
M %Q$  !2/P  23L  $ X   X-   +S   "<L   >)P, %B,* !(A#@ 1(1,
M$"(9 ! B(  /(B< #B,O  TD.0 ,)$0 "R50  HE7@ ))F\ !R:"  8FE@ $
M)JP  R;$  0FY0 $)O< !B;_ )5"  "*1P  @4H  'A,  !O3   94L  %M(
M  !01   1T$  #\^   W.P  +38  "0Q   ;+0  $RH'  \H#0 -)Q$ #2@6
M  PH'0 +*"4 "BDM  DI-P '*D( !BI.  0K7  #*VP  2M_   KE   *ZD
M "O!   KXP  *_8  "K_ ))&  "(2P  ?T\  '91  !M40  8U   %I-  !/
M2@  1T<  #Y$   S0   *3P  " X   7-   $3$%  PO#  )+A  !RX5  8O
M&P %+R,  R\K  (P-0  ,#\  #!,   Q60  ,6D  #%\   QD0  ,:<  #"_
M   PX0  ,/4  "__ )!+  "&4   ?50  '56  !K5@  8E4  %A3  !.4
M14T  #I)   O10  )4(  !P^   4.P  #CD%  DW"P $-@\  383   V&0
M-B   #8I   V,@  -ST  #=)   W5P  -V<  #=Y   WCP  -J4  #:]   V
MX   -?4  #7_ (U0  "$5@  ?%H  ');  !I6P  8%L  %=9  !,5@  0%(
M #5.   J2P  ($@  !=&   00P  "T$$  1 "@  /PX  #X1   ^%@  /AT
M #XF   ^+P  /CH  #Y&   ^5   /F0  #YV   ]C   /:,  #R[   \W@
M._4  #O_ (I7  ""7   >5\  '!A  !H80  7V$  %1>  !'6P  .E<  "]5
M   E4@  &U   !)-   ,2P  !DH#  !)"0  2 T  $<0  !'%   1AH  $8B
M  !&+   1C<  $9#  !&40  1F   $5S  !%B0  1*   $2X  !#W   0O4
M $+_ (A=  !_8@  =V4  &YG  !G:   6V8  $YC  !!80  -%X  "E<   ?
M6@  %5<   Y6   '5    %,!  !2!@  40L  %$.  !0$0  3Q8  $\>  !/
M)P  3S(  $\_  !/30  3ET  $YO  !.A0  39T  $RU  !+V   2O4  $K_
M (5E  !\:0  =&P  &UN  !B;0  5&L  $=I   Z9P  +64  ")D   88@
M$&    E?    7@   %X   != P  7 @  %L,  !:#P  6A,  %D9  !9(@
M62T  %DZ  !92   6%@  %AK  !7@0  5YD  %:R  !5T@  5/0  %/_ (%L
M  !Y<   <W,  &AS  !:<@  3'$  #]P   R;P  )6X  !IL   1:P  "6H
M  !J    :0   &D   !H    9P,  &8(  !F#   9@\  &44  !E'   92<
M &0T  !D0P  9%,  &1E  !C>P  8I0  &&M  !@S0  7_$  %[_ 'UT  !W
M=P  ;GD  %]Y  !1>0  0WD  #9X   I>   ''<  !%V   *=0   '4   !U
M    =@   '4   !T    =    ',"  !S!P  <PP  '(0  !R%0  <B   '(L
M  !R.P  <4P  '%?  !Q=   <(X  &^H  !NQ@  ;.T  &O_ 'M[  !R?@
M9'X  %5_  !'@   .8$  "N"   >@0  $H$   J!    @0   ((   "#
M@P   (,   ""    @@   ((   ""    @@4  ((*  ""#P  @A<  ((C  ""
M,@  @D,  (%6  "!;   @(8  '^A  !^O0  ?>8  'S\ ':"  !H@P  684
M $N'   \B0  +HH  ""+   3BP  "HL   ",    C0   (\   "1    D@
M )$   "1    D0   )$   "1    D@   )("  "3"0  E \  )09  "4)P
ME#@  )1,  "38@  DWP  ).8  "2LP  D=@  )#V &J(  !<B@  38T  #^0
M   PD@  (90  !25   *E@   )<   "9    FP   )T   "?    H    *
M  "@    H    *$   "B    HP   *0   "E    I@<  *@0  "H'   J"T
M *E   "I5@  J6\  *F+  "HJ   I\<  *;L %^/  !0D@  098  #.9   C
MG   %)T   J?    H0   *,   "F    J    *P   "N    KP   *\   "P
M    L    +(   "S    M    +8   "W    N@   +T'  "_$   OQ\  , S
M  # 20  P&(  ,!^  # FP  P+<  +_8 %.7  !$FP  -9\  ":C   6I0
M"Z<   "J    K0   +    "S    M@   +L   "]    P    +\   #!
MP@   ,0   #&    R    ,H   #,    SP   -,   #:!P  VQ,  -TE  #>
M.P  WU,  .!N  #?C   W:D  -W" /\   #_    _P   /\   #_  < _P 0
M /\ &0#_ "0 _P O /P .@#Y $, ]0!+ /, 4@#Q %D [P!> .T 9 #K &D
MZ0!O .< =0#F 'P Y "$ .( C0#@ )< W0"B -H L0#5 ,4 T@#H -  _P#/
M /\ Q #_ +@ _P"O /\ J0#_ /\   #_    _P   /\   #_  ( ^P - /<
M%0#S !\ [P I .H - #F #T X@!% -X 3 #; %, V !8 -0 7@#2 &, T !I
M ,X ;@#, '4 R@!] ,@ A0#& )  P@"; ,  J0"^ +H NP#9 +D ]P"X /\
MM #_ *D _P"B /\ G0#_ /\   #_    _P   /8   #N    YP * .$ $0#<
M !H UP C -  +@#+ #< QP _ ,0 1@#! $T OP!2 +T 6 "[ %T N0!B +@
M: "V &X M !U +$ ?@"O (@ K0"3 *H H0"H +$ I@#( *0 [0"B /\ H@#_
M )L _P"5 /\ D0#_ /\   #\    [@   .,   #8    S0 % ,8 #@#! !4
MO0 > +D )P"U #  L@ X *\ 0 "L $8 J@!, *@ 40"G %8 I0!; *, 80"A
M &< GP!N )X =@"; (  F0", )< F0"4 *@ D@"\ )  WP". /L C@#_ (L
M_P"& /\ @P#_ /@   #I    W    ,P   #!    N    +( "@"L !$ J  8
M *4 (0"B "D G@ R )P .0"9 #\ EP!% )4 2@"4 %  D@!5 )  6@"/ &
MC0!G (L ;P") '@ A@"$ (0 D0"" *  @ "R 'T S !\ /$ >P#_ 'H _P!W
M /\ =0#_ .8   #3    Q@   +L   "Q    IP   *$ !0";  T EP 3 ),
M&P"0 ", C  K (H ,@"( #@ A@ ^ (0 1 "" $D @0!. '\ 4P!] %D >P!@
M 'D : !W '$ =0!\ ', B0!P )@ ;P"I &T OP!K .8 :@#_ &D _P!I /\
M9P#_ -,   ##    M0   *L   "C    FP   )(   ",  H AP 0 (, %@!_
M !T ?0 D 'H *P!X #( =@ X '0 /0!R $( <0!( &\ 30!M %, ; !9 &H
M80!H &H 9@!T &0 @0!A )$ 7P"B %X M@!< -4 6P#W %L _P!: /\ 6@#_
M ,4   "V @  J0(  )\   "6    C@   (<   "   4 >@ , '4 $0!Q !@
M;@ > &L )0!I "L 9P Q &8 -P!D #P 8P!! &$ 1P!? $T 7@!3 %P 6P!:
M &0 6 !N %8 >P!4 (H 4@"; %$ K@!0 ,@ 3P#N $X _P!. /\ 30#_ +L*
M  "L#0  H T  )4,  ","   @P(  'P   !U    ;@ ( &D #@!E !, 8@ 9
M %\ 'P!= "4 6P K %D ,0!8 #8 5@ [ %4 00!3 $< 40!. %  50!. %X
M3 !H $H =0!( (0 1P"5 $4 J !$ +\ 0P#D $( _ !" /\ 0@#_ +(1  "E
M%   F14  (X3  "$$0  >PT  ',(  !L    90 # %\ "P!;  \ 5P 4 %0
M&@!1 !\ 3P E $X *P!, #  2P V $D / !( $( 1@!( $4 4 !# %D 00!C
M #\ ;P ^ 'X / "0 #L HP Z +@ .0#9 #@ ]0 X /\ . #_ *P7  "?&P
MDQT  (D<  !_&0  =14  &P0  !D#   708  %8 !@!1  P 30 0 $H %0!'
M !H 10 @ $0 )@!" "L 00 Q #\ -@ ^ #T / !$ #L 2P Y %0 -P!? #8
M:P T 'H ,@", #$ G@ P +, +P#. "\ [P N /\ +@#_ *<>  ":(@  CR0
M (0D  !Z(0  <1T  &<8  !?$P  5PX  % *  !) P@ 10 - $$ $0 ^ !8
M/  ; #H (0 Y "8 -P L #8 ,@ T #@ ,P _ #$ 1P P %  +@!; "T 9P K
M '8 *@"( "@ G  G +  )@#) "4 Z@ E ?L )0'_ *(C  "6*   BRH  ($J
M  !W*   ;24  &0@  !;&P  4A4  $L0  !## ( /0<) #D##@ V 1( ,P$7
M #$!'  P 2( +P(G "T"+0 L S0 *@,[ "D$0P H!$T )@58 "4%90 C!G0
M(@:& " &F@ ?!ZX '@?& !T'YP ="/@ '0G_ )\H  "3+0  B"\  'XO  !T
M+@  :BL  &$F  !8(0  3QP  $<7   _$@  . X$ #$+"@ N" X *P<2 "D'
M%P H"!T )P@C "4(*0 D"3  (PDW "$*0  @"DH 'PM5 !T+8@ ;#'( &@R%
M !@,F0 7#*T %@S& !4-Y@ 5#?D %@W_ )PM  "0,0  AC0  'PT  !R,P
M:#$  %\L  !5)P  3",  $0=   \&   -!,  "T0!@ F#0L ) P/ "(,$P A
M#!D 'PP? !X-)0 =#2P &PTT !H./0 9#D< %PY3 !8.80 4#W$ $Q"$ !(0
MF  1$*X $!#& ! 0Z  0$/L $1#_ )DQ  ".-0  A#@  'HY  !P.   9S8
M %TR  !3+0  2B@  $(D   Y'P  ,1H  "H5 0 C$0< '1 - !L/$  9#Q4
M&! ; !<0(0 6$"D %1 Q !01.@ 3$44 $A)1 !$27P 0$F\ #A."  X3E@ -
M$ZL "Q/"  L4XP ,%/H #1/_ )<U  ",.0  @CP  '@]  !O/0  93H  %LW
M  !2,@  22X  $ J   W)0  +R$  "@<   @& , &10* !42#@ 4$A( $Q,8
M !(3'P 1%"8 $10N ! 4.  /%4( #A9/  T67  ,%VP "Q=_  D8DP (&*@
M!AB_  <8X  '&/4 "1C_ )4X  "*/0  @$   '=!  !M00  9#\  %H\  !0
M.   1S,  #XP   V*P  +B<  "<C   ?'P  %QH( !(7#0 0%Q$ #Q<6  X8
M'  .&", #1DL  P:-0 +&D  "AM,  D;6@ ''&D !1Q\  0=D0 "':8  1V\
M  (<W0 "'/(  QS_ ),\  "(00  ?T0  '5%  !L10  8T0  %E!  !//0
M1CD  #XV   U,@  +BX  "4J   =)0  %"$$  \="P -'1  #!T4  L=&@ *
M'B( "!XJ  <?,P &(#X !"!*  ,A5P !(6<  "%Y   AC@  (:0  "&Z   A
MVP  (?(  "#^ )!   "&10  ?4@  '1*  !K2@  8DD  %A&  !.0@  13\
M #T\   U.0  *S0  "(O   9*P  $B@$  TD"@ )(PX !B,2  4C&0 $)"
M B0H  $E,0  )3P  "5(   F50  )F4  "9W   FC   )J(  ":Y   FV0
M)?(  "7^ (Y%  "$20  >TT  '-/  !J3P  8$X  %=+  !-2   1$4  #Q"
M   Q/0  )SD  !XU   5,@  #RX#  HL"@ %*PX  2H1   J%@  *AX  "HF
M   K+P  *SD  "M%   L4P  +&(  "QU   LB@  *Z   "NW   KU@  *O(
M "K_ (Q)  ""3@  >E(  '%4  !H5   7U,  %91  !,3@  0TL  #='   M
M0P  (S\  !H\   2.   ##8#  8S"0  ,@T  #(0   Q%   ,1L  #$C   Q
M+   ,C<  #)#   R4   ,F   #)R   RAP  ,9X  #&U   PU   ,/(  "__
M (E/  " 5   >%<  &]9  !F60  7ED  %57  !)4P  /D\  #),   H2
M'D4  !5"   .0   "#T"  $\"   .PP  #H/   Y$@  .1@  #D@   Y*0
M.30  #E    Y3@  .5T  #EO   XA0  .)P  #>S   WT@  -O(  #7_ (=5
M  !_6@  =ET  &U?  !E7P  75\  %)<  !$6   .%4  "U2   B3P  &$P
M !!*   *2    T8!  !%!@  1 H  $,-  !"$   014  $$=  !!)@  03$
M $$]  !!2@  05H  $%L  ! @0  /YD  #^Q   ^T   /?(  #S_ (1<  !\
M8   <V,  &QE  !D9@  660  $MA   ^7@  ,EL  "99   <5@  $E0   Q2
M   $40   $\   !. P  30@  $P,  !+#@  2Q(  $H9  !*(@  2BP  $HY
M  !*1P  2E8  $EH  !)?@  2)8  $>O  !&S0  1?$  $3_ (%C  !Y9P
M<FH  &ML  !@:P  4FD  $1F   W9   *F(  !]@   57@  #5T   9;
M6@   %D   !8    5P0  %8(  !6#   51   %04  !4'0  5"<  %0T  !4
M0@  4U(  %-D  !2>0  4I(  %&K  !0R@  3^\  $[_ 'YJ  !W;@  <'$
M &9Q  !8<   2F\  #QM   O;   (FH  !=I   .9P  !F8   !E    90
M &4   !C    8@   &($  !A"   80T  & 0  !@%P  8"$  %\N  !?/
M7TT  %Y>  !>=   78T  %RG  !;Q0  6NT  %G_ 'MR  !U=@  :W<  %UV
M  !/=@  074  #-U   F=   &7,  !!R   '<0   '$   !Q    <0   '$
M  !O    ;P   &X   !N @  ;@@  &T,  !M$0  ;1H  &TF  !L-0  ;$8
M &M8  !K;0  :H8  &FA  !HO@  9^@  &;^ 'EZ  !P?   87P  %-]  !$
M?0  -GX  "A^   ;?0  $'T   =]    ?0   'T   !^    ?P   'X   !]
M    ?0   'P   !\    ?    'P&  !\#   ?!(  'P=  !\+   ?#P  'Q/
M  ![90  >WX  'J:  !YM@  >-\  '?Z '.   !E@0  5H,  $B$   YA@
M*X<  !V'   1AP  !X@   "(    B0   (H   ",    C0   (T   ",
MC    (P   ",    C    (T   "-!   C@P  (X3  "/(0  CC(  (Y&  ".
M6P  C70  (V0  ",K0  B\X  (KS &B&  !:B   2XL  #R-   MCP  'I
M !&1   'D@   ),   "5    EP   )D   ";    G    )L   ";    G
M )P   "=    G@   )X   "?    H0,  *(,  "B%@  HR8  *,Z  "C3P
MHV@  **&  "BH@  HL   *'H %R-  !-D   /Y,  #"6   AF0  $IH   >;
M    G0   *    "B    I    *@   "J    JP   *H   "K    K    *T
M  "N    KP   +$   "R    M    +<!  "Y#0  N1H  +HM  "Z0P  NEL
M +IW  "[E   N[$  +G2 %"5  !!F   ,IP  ".@   3H@  "*0   "G
MJ@   *P   "O    L@   +<   "Y    NP   +H   "\    O0   +\   #
M    P@   ,0   #&    R0   ,T   #2 0  U \  -4?  #7-0  V$T  -AI
M  #7A@  UZ,  -:] /\   #_    _P   /\   #_  , _P - /\ %0#_ "
M_  K /@ -0#T #\ \ !' .X 3@#K %0 Z0!: .< 7P#E &0 XP!J .$ < #?
M '8 W0!^ -L AP#8 )$ TP"= ,\ JP#- +T RP#@ ,D ^P#' /\ O0#_ +$
M_P"I /\ HP#_ /\   #_    _P   /\   #\    ]@ + /$ $0#M !L Z0 E
M .0 , #? #D V@!! -4 2 #1 $X SP!4 ,T 60#+ %X R0!C ,< :0#% &\
MPP!W ,  ?P"^ (H NP"5 +@ HP"V +0 M #- +( \@"P /\ K #_ *, _P"<
M /\ EP#_ /\   #_    ^@   /$   #H    X  & -D #@#2 !8 S@ ? ,@
M*0#$ #( P  Z +T 00"Z $@ N !- +8 4P"T %@ L@!= +  8@"N &D K !O
M *H > "H (( I@". *0 FP"A *L GP#  )T Y@"; /\ F@#_ )0 _P". /\
MB@#_ /\   #V    Z    -P   #.    Q@ ! +\ "P"Z !$ M@ : +( (@"N
M "L J@ T *@ .P"E $$ HP!' *$ 3 "? %$ G@!6 )P 7 ": &( F0!H )<
M< "5 'H D@"& )  DP"- *( BP"U (D TP"' /< A@#_ (0 _P!_ /\ ? #_
M /(   #C    T@   ,4   "Z    L0   *L !P"E  X H0 4 )X ' ": "4
MEP M )0 - "2 #H D !  (X 10"- $H BP!0 (D 50"( %L A@!A (0 :0""
M '( ?P!] 'T BP![ )H > "K '8 Q !T .L <P#_ ', _P!P /\ ;@#_ -\
M  #,    OP   +0   "K    H0   )H  @"4  L D  0 (P %P"( !X A0 F
M (, +0"! #, ?P Y 'T /P![ $0 >0!) '@ 3@!V %0 = !: ', 8@!P &L
M;@!U &P @P!J )( : "C &8 N !D -X 8P#[ &( _P!B /\ 8 #_ ,P   "\
M    KP   *4   "=    E    (P   "&  < @0 - 'P $@!X !D =0 ? ',
M)@!Q "T ;P R &T . !K #T :@!" &@ 2 !G $X 90!4 &, 6P!A &0 7P!N
M %T >P!; (H 60"; %< KP!6 ,L 50#R %0 _P!4 /\ 5 #_ +X   "P
MI    )D   "0    B    ($   !Y  ( <P * &\ #P!K !0 9P : &4 ( !C
M "8 80 L %\ ,@!> #< 7  \ %L 0@!9 $< 5P!. %8 50!4 %X 4@!H %
M= !. (, 3 "5 $H J !) ,  2 #H $< _P!' /\ 1P#_ +0)  "F"P  FPP
M ) *  "&!0  ?@   '8   !O    :  % &, # !? !  6P 5 %@ &@!6 "$
M5  F %, + !1 #$ 4  V $X / !- $( 2P!( $D 4 !( %@ 1@!B $0 ;@!"
M 'T 0 ". #\ H@ ] +@ /0#= #P ^  \ /\ / #_ *P0  "?$@  E!(  (D1
M  !_#P  =@P  &X%  !F    8  ! %D " !5  T 40 1 $X %@!+ !L 20 A
M $@ )@!& "L 10 Q $, -@!" #P 0 !# #X 2P ] %, .P!= #D :0 W '@
M-@") #0 G  S +$ ,@#. #( \0 Q /\ ,0#_ *86  ":&0  CAH  (0:  !Z
M%@  <!(  &@.  !?"@  6 ,  %$ ! !,  H 2  . $0 $@!! !8 /P ; #T
M(0 \ "8 .@ L #D ,0 W #< -@ ^ #0 1@ S $\ ,0!9 "\ 90 N ', + "%
M "L F  J *T *0#& "@ Z@ H /X * #_ *$<  "5(   BB$  '\A  !U'P
M;!H  &,6  !:$0  4@T  $L'  !$  8 0  + #P #P X !( -@ 7 #0 '  S
M "$ ,0 G #  +  N #, +0 Z "L 0@ J $L * !5 "8 80 E '  ) "! "(
ME0 A *D ( #! "  Y  ? /D 'P#_ )TB  "1)@  AB@  'PG  !R)0  :2(
M %\=  !7&   3A,  $8.   _"P  . 4' #0 #  Q !  +@ 3 "P &  J !T
M*0 B "< *  F "X )  V ", /@ B $< ( !2 !\ 7@ = &T ' !^ !H D@ 9
M *< & "] !< WP 7 ?4 %P+_ )HG  ".*P  A"T  'DM  !P*P  9B@  %TD
M  !4'P  2QH  $,4   [$   - T" "T)"0 I!0T )@,0 "0!$P B AD (0(>
M " ")  > RH '0,R !L$.@ :!40 &05/ !<&7  6!FH % =\ !,'D  2!Z4
M$0>[ ! 'VP 0"/( $ G_ )<K  ",+P  @3$  '<R  !N,0  9"X  %LJ  !1
M)0  22   $ ;   X%@  ,1(  "D.!  C# D 'PD- !T'$  ;!Q4 &0@: !@(
M(  7"2< %@DN !4*-P 3"D$ $@M- !$+6@ 0"VD #@Q[  X,D  -#*4 # V[
M  L-V0 +#?$ # W_ )4O  "*,P  ?S8  '8V  !L-0  8S,  %DO  !0*P
M1R8  #XA   V'0  +A@  "<3   @$ 4 &0X* !4,#@ 4#!$ $PP6 !(,'  1
M#2, $ TK  \--  .#C\ #0Y*  P/6  +#V< "A!Y  @0C0 '$*( !A"X  40
MU  %$.\ !A#_ )(S  "(-P  ?CH  '0[  !K.@  83@  %@U  !.,   12P
M #TG   U(P  +1\  "8:   >%@$ %Q,& !$0"P .#@X #@\3  T0&0 -$"
M#! H  L1,@ *$3P "!)(  <250 &$V4 !!-V  ,3BP !%*   !.V   3T0
M$^X  !/[ ) V  "&.P  ?#X  ',_  !J/P  8#T  %<Y  !--@  1#$  #PN
M   T*@  +"8  "4B   >'@  %AH" ! 5"0 ,$PX "A,2  D4%P (%!\ !Q4F
M  85+P $%CH  Q9&  $74P  %V(  !AT   8B0  &)\  !BU   7T   %^T
M !?[ (XZ  "$/P  >T(  ')#  !H0P  7T(  %8_  !,.P  0S<  #LT   S
M,   +"P  "0I   ;)   $Q\"  T;"0 )&0T !AD1  09%@ "&1T  1HD   :
M+0  &S@  !M$   <40  '&   !UR   =AP  ')T  !RS   <S@  &^T  !O\
M (P^  ""0P  >48  '!(  !H2   7D8  %5$  !+0   0ST  #LZ   S-P
M*C(  " M   7*0  $"4"  LB"0 %( T  1\0   ?%   'QL  " B   @*P
M(38  "%!   A3P  (5X  ")P   BA0  (9L  "&R   AS0  (.T  !_\ (I#
M  " 2   >$L  &],  !F30  74L  %1)  !*1@  0D,  #I    O.P  )3<
M !PS   3+P  #2P"  <I"  !)PP  "8.   E$@  )AD  "8A   F*0  )C,
M "<_   G30  )UP  "=M   G@@  )YD  ":P   ES   )>X  "3] (A(  !_
M3   =E   &Y1  !E4@  7%$  %-/  !*3   04D  #5$   K0   (3P  !<Y
M   0-@  "C(!  ,P!P  +PL  "X.   M$0  +18  "T>   M)P  +3$  "T]
M   M2@  +5D  "UK   M@   +)<  "RO   KRP  *NX  "K^ (5-  !]4@
M=54  &Q7  !C5P  6U8  %-5  !'40  .TT  #!)   E1@  '$,  !,_   -
M/0  !CH    X!0  -PD  #8-   U#P  -!0  #0;   T)   -"X  #0Z   T
M1P  -%<  #1H   T?0  ,Y4  #*M   QR@  ,>X  ##_ (-3  ![6   <UL
M &I=  !B70  6UT  $]:  !"5@  -E(  "I/   @3   %DD   Y'   (1
M $(   !! P  /P<  #X+   ]#@  /1$  #P8   \(0  /"L  #PW   \1
M/%,  #QE   [>@  .I(  #JK   YR   ..T  #?_ (%:  !Y7@  <6$  &EC
M  !B9   5V(  $E>   \6P  +U@  "15   94P  $%$   I/   !30   $P
M  !*    200  $@(  !'#   1@\  $84  !%'   12<  $4S  !%0   15
M $1A  !$=@  0X\  $*H  !!Q@  0.P  #__ 'YA  !V90  ;V@  &AJ  !=
M:0  3V8  $)D   T80  *%\  !U=   26P  "UD   )8    5@   %8   !4
M    4P   %($  !1"0  4 T  % 0  !/&   3R(  $\N  !//   3TL  $Y=
M  !.<@  38L  $RE  !+P@  2>H  $C_ 'MI  !T;   ;F\  &1O  !5;0
M1VP  #EJ   L:0  (&<  !1E   -9    V(   !B    80   &    !?
M7@   %T   !<!   7 D  %L-  !;$@  6QP  %HH  !:-@  6D8  %E8  !9
M;0  6(4  %>@  !6O0  5>@  %/^ 'EP  !S=   :74  %MT  !,<P  /G,
M #!R   C<0  %F\   UN   $;0   &T   !M    ;0   &P   !K    :@
M &D   !I    :0,  &@)  !H#@  :!4  &<A  !G+P  9S\  &92  !F9@
M97\  &2:  !CMP  8N$  &'\ '=X  !M>@  7WH  %!Z  !">@  ,WL  "5[
M   8>@  #GD   1Y    >0   'D   !Z    >@   'H   !X    >    '<
M  !W    =P   '<!  !W"   =PX  '<8  !W)@  =C8  '9)  !U7P  =7<
M '23  !SKP  <M,  ''W '%^  !C?P  5(   $6"   V@P  *(0  !J$   .
M@P  !(0   "$    A0   (8   "(    B0   (@   "'    AP   (<   "'
M    AP   (@   "(    B <  (D0  ")'   B2P  (@_  "(50  B&T  (>)
M  "&IP  A<<  (3O &:$  !7A@  2(@  #F*   JC   &XT   ^-   $C@
M )    "1    DP   )4   "7    F    )8   "7    EP   )<   "8
MF    )D   ":    FP   )T'  "=$0  G2$  )TS  "=20  G&(  )Q_  "<
MG   G+D  )OB %J+  !+C@  /)$  "V3   >E0  $)8   28    F@   )P
M  ">    H0   *0   "F    IP   *8   "G    IP   *@   "I    J@
M *P   "M    KP   +$   "S"0  LQ4  +0G  "T/0  M54  +5P  "TC@
MM*P  +3, $V2   _E@  +YH  ""=   1GP  !:$   "C    I@   *D   "L
M    KP   +,   "U    MP   +8   "W    N    +H   "[    O0   +\
M  #!    Q    ,<   #+    S0P  ,X:  #/+P  ST@  -!B  #0@   T)T
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M______________________________________________\
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MVMO<W=[?X.'BX^3EYN?HZ>KK[.WN[_#Q\O/T]?;W^/GZ^_S]_O]M9G0Q
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M__________^H-0          7-/___________________________]]#0
M        5-;__________________________^Y]10          1-3_____
M______________________RJ9"\"   $(C=)6,[_____________________
M_______II&M!*#]C?Y6GNMK______________________________]6RK++,
MY/K_________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________^6[EW=BR/______________
M___________________;GF<V"@ "C/______________________________
M_\A_/P4     7L______________________________V8$Y        /*K_
M____________________________GDP         (Y#_________________
M___________<;QH         $'WY__________________________^O2
M         &_N__________________________^$$P           &3F____
M_____________________^Q1             %?>____________________
M_____[@5             $C6_________________________W04
M     #C/________________________^:):$P           "/%________
M_________________]^;7"P           VZ________________________
M___OL7U5.2(1!P$"$2*R_______________________________?OZ69F)J@
MK+W:________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______COIV ?/O________________________________RMX17, X ':S_
M_____________________________]**3!4      '+S________________
M____________UG\V         $O)___________________________ZD3X
M         "^K___________________________ 6@           !J5____
M______________________^-)             B$____________________
M_____^=>              !W_________________________[0E
M      !J_________________________WT               !;]/______
M_________________2L               !,Z_______________________
MI0                 \X?______________________, P
M   MV?____________________^9BF$G               GU___________
M____________[;Z)52<            EW/_________________________^
MRIUV74H\,BTL,#E'WO_______________________________>;=UM+0T]GD
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________^_4N];_________________
M________________Y[B/:DLO%6_______________________________^2A
M9S0'     #S)____________________________UH([         !*7____
M_______________________MA3$           !O____________________
M______^F0@            !0X?_______________________^QI
M       WR?_______________________[,O               BMO______
M_________________WD                0I_______________________
M\C0                 F?______________________J0
M    C/______________________1@                  ?___________
M___________?                    =/____________________^7
M                :O_____________________.
M8_______________________*2(!                8?______________
M________N:. 5S<7            :/__________________________^M.N
ME(9\=7%P<G>!E/______________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________________;NIV":6G3____
M___________________________(DV4]&0   !V>____________________
M________VXY,$P        !N___________________________;?"P
M      !%U_________________________^+*@             BM/______
M_________________\)$               #E_______________________
M_WT!                ?_______________________YS8
M    :O______________________G0                  6/__________
M____________1@                  1_C____________________I
M                ->G___________________^6
M)=O___________________^\                    &,[_____________
M_______K                    #\+_____________________
M            "KG_____________________)P                  "K7_
M____________________<                   #;G_________________
M____X)R,<%5",R8;% \-#A(:)K_____________________________YY-C2
MSLS+S,_6X/S_________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________KT[SC________________________________TJF%
M94@L$@&%____________________________\:MQ/ \       !/X/______
M___________________5?S4            ?LO______________________
M_^-U'0              B?_______________________Y C
M    9_______________________U4,                 2/;_________
M____________B@                  +MW_____________________.
M                %\C___________________^^
M!+;___________________^<                     *7_____________
M______^Z                     )/____________________<
M             (+_____________________                     '3_
M____________________$P                   &C_________________
M____0@                   &#_____________________>@
M         %W_____________________T0                   &'_____
M_________________R0                  &;_____________________
M_\FLF8E]=G%L:6=F9VMP>HS_____________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________BQ:J1>6%W________________________
M_____]VF=U L#      QQ/_________________________@DDX3
M    C________________________])P'0              8/__________
M____________[F\/                -^+_____________________EAP
M                %,#_____________________0
M */___________________^N                     (G_____________
M______^>                     '+___________________^\
M             %_____________________:                     $W_
M___________________Z                     #O_________________
M____#@                   "KY____________________,P
M         !OI____________________7@                    _;____
M________________CP                    ;0____________________
MT                     #*_____________________RL
M      #(_____________________X                    #+________
M______________<6 04% P$       $&#1C+_______________________\
MZ^'8S\S-S]#2U-?<XNK_________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M\=K&_______________________________QQJ.$:$TR&  5J___________
M________________N7Q&&           <?_______________________]=\
M+P              .^/_____________________WV0)
M#+7_____________________= ,                  (W_____________
M_______%%0                   &K___________________^9
M             $O___________________^V                     ##]
M___________________7                     !GG________________
M___V                      73____________________#@
M          #!____________________+P                    "O____
M________________4@                    ">____________________
M>0                    ".____________________I0
M      " ____________________V                     !T________
M_____________S8                   !M_____________________WP
M                  !I_____________________]<-
M  !H______________________]P                  !A____________
M____________4#Q&3E1976%D:&QP=GZ)____________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______OU;NCBW-:E?__________________________^+^.9$$A!0
M4OS_______________________>=5A@             %\'_____________
M________Y6P6                 (W_____________________8P
M             %[___________________^=                     #7\
M__________________^A                     !'9________________
M___*                      "[___________________N
M          "A____________________#                     "*____
M________________+0                    !V____________________
M30                    !D____________________;P
M      !2____________________E                     ! ________
M____________O                      P____________________Z@X
M                   B_____________________T0
M   5_____________________X$                    +]?__________
M_________\@+                   "[/____________________]>
M                Y?_____________________)'
MVO______________________G0$             !PX7Q?______________
M_________]6YO,''SM7;X>;M]/O_________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________________C?S_______________
M_______________LQJ6(;50[(0< ,M[________________________7DEDI
M             *#______________________XDV                 &?_
M____________________9@                   #+V________________
M__^5                      /(__________________^G
M          "@___________________7                      !\____
M________________                      !>____________________
M)0                    !#____________________2
M       L____________________:@                     8________
M____________BP                     %\___________________KP
M                    X?__________________U0
M    S____________________R0                     OO__________
M_________U0                     KO___________________XL
M                G____________________\L.
MDO____________________]7                    AO______________
M______^J"@                  >?______________________;0
M            9O______________________]U4                 1?__
M______________________]J(RLU/TI58&IU?H>1G/__________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________________Z,^VG8-I3KG_
M________________________[+*#7#H= @       'O_________________
M_____\5M*0               $#_____________________@QL
M          ?+__________________^2                      "8____
M______________^D                      !J___________________=
M                      !!____________________#@
M       =____________________.0                      Z/______
M____________8                       SO__________________A0
M                    M___________________J
M    H___________________RP                      D/__________
M________[Q8                     ??___________________SX
M                ;/___________________VD
M6O___________________YD                     2?______________
M_____](6                    .?____________________]8
M            *?____________________^B                    &?__
M___________________U5@                  !/__________________
M____NR\                  /C______________________ZLI
M         ,_________________________)1P     '$R N/E)HA.W_____
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________TU<G____________________________ZTK"2
M=UU"* P  $K________________________%?447             !'8____
M________________Q%                    "?__________________^B
M#                     !H__________________^4
M       V___________________:                       '[/______
M____________%0                      Q/__________________2
M                    HO__________________=0
M    @___________________G0                      :?__________
M________PP                      4O__________________YP\
M                /O___________________S,
M*____________________U@                     &/______________
M_____X$                     !?___________________ZP
M             /___________________]XB                     /+_
M__________________]<                     -__________________
M__^?                     ,S____________________H2@
M         +?_____________________H!8                  )S_____
M_________________WH"                 '?_____________________
M__]Z"P              !4S_________________________HE=H=("-G*N\
MT.?_________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________[>/_____________________
M_____]*C>E@Z*2,<%@X&  "?_____________________ZQ2#@
M      !I___________________D0P                     T________
M__________]Y                        X__________________-
M                    LO__________________$P
M    A?__________________3P                      7?__________
M________@P                      .O__________________L@
M                '/__________________VP,
M O___________________RH                      /O_____________
M_____T\                      .?__________________W0
M             -3__________________YL                      ,#_
M_________________\0'                     *W_________________
M__ S                     )K___________________]G
M         (;___________________^C                     '+_____
M_______________C1                    %S_____________________
MD08                  $'_____________________ZU\
M     !W______________________\I+                  #_________
M_______________+5P  #!@D,3].8'2+I\?_________________________
M_]?G\O______________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________^O4S<?"OKJWL["MJ:BE____________________W7Y3
M/S C&1$) @          V_________________]V
M    I_________________^Z                        =?__________
M________!P                      1O__________________3@
M                &O__________________C
M /W_________________P0                       -O_____________
M____\1D                      +[__________________T0
M             *3__________________VL                      (W_
M_________________Y$                      'G_________________
M_[<                      &;__________________]XA
M         %/___________________]*                     #______
M______________]W                     "O___________________^L
M"@                   !;____________________G10
M      #_____________________B@                    #_________
M____________UDT                   #]_____________________Z<N
M                  #5______________________^8*@          !A@M
M16#@________________________J&-T@8^<J[O-XOK_________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________^?+MZF=E8Z)A(!\>'1P;&AED/________________^\:D@M&0H
M                ,?__________________
M ___________________0@                       -S_____________
M____C@                       ++_________________S@
M             (W__________________RD                      &O_
M_________________UH                      $[_________________
M_X8                      #3__________________ZX
M         ![__________________]07                      K_____
M______________H]                      #___________________]E
M                      #___________________^.
M      #___________________^\&0                    #O________
M___________Q3@                    #8____________________BP
M                  "_____________________S$,
M  "A_____________________Y$9                  !Z____________
M__________)T"@               !%?_______________________H=!,?
M+#A%4V)RA9NTTO7__________________________]?H]/______________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________^_?S\>[LZ^OL\?______________
M____V;*9AWEM9%U644M&03PX,BTH(\3_________________2R4+
M             )+_________________B                        &;_
M________________UP                       #W_________________
M_S,                      !C__________________VP
M          #__________________YT                       #_____
M_____________\D,                      #V__________________$U
M                      #?__________________];
M      #+__________________^"                      "W________
M__________^I!@                    "C___________________3+P
M                  "-____________________7@
M  !W____________________DP<                   !>____________
M________S4,                   ! _____________________X<0
M               <_____________________]A>
M______________________^_3@      #APL/E)JAJ7(________________
M________PGR,FJ>VQ=;H_?______________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________[N'7S\G#OKJVL:VIIZ:FIZ[_________________
MOH9M6TQ -R\H(AP6$ L$     !3_________________UP4
M          #__________________S0                       #V____
M_____________W8                       #2_________________[
M                      "R_________________^$D
M      "6__________________]1                      !\________
M__________]Y                      !F__________________^@
M                  !1___________________'(P
M   \___________________N2P                     G____________
M________=                      0____________________HQ8
M                ____________________V$P
M_____________________X@/                    ________________
M_____\M3                    ______________________^E.
M    "1TT3FN,________________________F3E#45]N?8Z@M<OE________
M_____________________^OY____________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________^O,N:RAF9&+AH%\>'1P:VAF9FCQ_________________V%%
M,B,8#@8               ">_________________WX
M      !U_________________\,                       !2________
M__________LW                       R__________________]J
M                   6__________________^6
M    __________________^_&P                      ____________
M_______F0@                      ____________________:0
M                ____________________D (
M____________________N2P                     ]/______________
M____Z%P                     V?___________________Y$8
M            O/___________________\I3                    G?__
M__________________^8+@             0*49FQ/__________________
M___N?QT,&B@W1E=I?I6OS.[_________________________YZ"JN<C8Z?S_
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________]]?#KYN+?V]C4TM'0TM?@________
M_________\Z>BGQQ:6%;5E%,2$,^.C8R+RXQ_________________](E$0,
M                    __________________]"
M    __________________]]                        ____________
M______^P"P                      ]O_________________=.0
M                W/__________________8@
MQ?__________________B0                      K_______________
M____KR(                     F?__________________UD@
M            @O___________________W(                     :?__
M_________________Z$H                    3O__________________
M_]-<                    ,_____________________^6+@
M    %3)2=______________________@<A,   $/'R]"6'"+J,CL________
M________________RF]N?HZ>L,/8[_______________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________YX-+(P+JUL*RHI:*?G9N;G*"G____________
M______^"9%9+0SPV,"LG(AT8$PX)!   U/________________^2
M                K?_________________,'@
MB__________________[4@                      ;?______________
M____@                       4?__________________J1L
M            .O__________________T$(                     (___
M________________]6@                     #/__________________
M_X\4                     /___________________[@^
M         /___________________^5M P                   /______
M______________^?-P              $"]0=/_____________________=
M<A0     !A<J05IUE+;:________________________O%A$5&1UAIJOR./_
M_____________________________]+-X?'_________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________________________S[^OO]____
M___________________NN:B=EH^*AH)_>WAV=')S=7A_D/______________
M___K3SHP*"$;%1 +!P(         (___________________:0
M             /__________________FPH                      /__
M________________R#D                      /__________________
M\&,                      /___________________XH.
M         /___________________[ T                     /______
M_____________]5;                     /____________________^%
M&@                   ^S___________________^Q20
M&#E=@?_____________________E>QX       PA.%)OC[/9____________
M____________NU@I.4E:;("7L,WM_____________________________[.>
MM,77Z_______________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________KOY^'<V=;4TM#0T-'3V>#K]___
M________________N(I^=W%L:&1A7EM96%=765YE<?__________________
MOS$?%A *!0               /__________________[58
M         .C__________________X($                     ,S_____
M_____________ZLO                     +/__________________])7
M                     )O___________________=\$
M     (7___________________^B-P                 %*Y3_________
M___________+80(            ,+%!VGM'____________________UC3
M      TC.U=VF;[E________________________PV,8*CM,7W2-I\;G____
M_________________________ZA_EJB[T.?_________________________
M___________]________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________]W.Q;^\N;:TL[&RLK6YP,G5X_______
M_____________Y=L9%Y955%/3$I(1T9(2U!99J'__________________Z<F
M#@<"                 %;__________________\Y0
M     #K___________________1Y"P                   "'_________
M__________^?,@                    [____________________$6
M              @Q6H3____________________I?Q\           8G2W&:
MPNG_____________________ITD      A<O2FB*KM7\________________
M________TW4>)CA*7G6/J\OO_____________________________ZYRA9BL
MPMOV___________________________________?[___________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________^_LJJFHZ&@GY^AHZ:LM,#-W>S_________
M__________^*6E-/2TA&1$-"04)#1TY9:7W___________________^>+@8
M                  #____________________#5@
M%4'____________________G>QH             "31@B[3_____________
M________GS\         !"5*<9G"Z_______________________QF8/
M$RI$8H.GS?7_________________________ZXXU*SY1:(&=O-[_________
M_____________________[YV?Y2IP=SY____________________________
M_______2V//_________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________________;R\._O[_'S^/W_____
M_______________________XL)^:EY:6EIB;GZ2LML+1X>[_____________
M_______^CE!*1T5$1$1%1D=+45IH@ZG_____________________ID$!
M       '-F./NN'_____________________QF4*       $)TQSG,3L____
M____________________Y8@O   3*D1B@J;,]/______________________
M_____ZM0-DIA>Y:TUOK______________________________]*'?)BQR^G_
M___________________________________4SNW_____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________^WEX^/DYNCM\?G_________
M_____________________;&4DI*5F9VCJ;*\T.W_____________________
M_____YU31TE-459@<XJOUOS__________________________[)6 !HU4&V+
MKM+W_____________________________\UO/E][F;?7^?______________
M_________________^Z?@Z;"X?__________________________________
M___CSNO_____________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________________________________\
M
M
M                                                 /__________
M____________________________________________________________
M____________________________________________________________
M________________________________________     /_A0,9H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O #P_>'!A8VME="!B96=I;CTB[[N_(B!I
M9#TB5S5-,$UP0V5H:4AZ<F53>DY48WIK8SED(C\^"CQX.GAM<&UE=&$@>&UL
M;G,Z>#TB861O8F4Z;G,Z;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E
M(#DN,"UC,# P(#<Y+C$W,6,R-V8L(#(P,C(O,#@O,38M,3@Z,#(Z-#,@(" @
M(" @("(^"B @(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO
M<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S
M8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.G!D9CTB
M:'1T<#HO+VYS+F%D;V)E+F-O;2]P9&8O,2XS+R(*(" @(" @(" @(" @>&UL
M;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O(@H@(" @(" @
M(" @("!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP
M+VUM+R(*(" @(" @(" @(" @>&UL;G,Z<W1%=G0](FAT=' Z+R]N<RYA9&]B
M92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C945V96YT(R(*(" @(" @(" @
M(" @>&UL;G,Z<W12968](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S
M5'EP92]297-O=7)C95)E9B,B"B @(" @(" @(" @('AM;&YS.F1C/2)H='1P
M.B\O<'5R;"YO<F<O9&,O96QE;65N=',O,2XQ+R(*(" @(" @(" @(" @>&UL
M;G,Z<&AO=&]S:&]P/2)H='1P.B\O;G,N861O8F4N8V]M+W!H;W1O<VAO<"\Q
M+C O(@H@(" @(" @(" @("!X;6QN<SIT:69F/2)H='1P.B\O;G,N861O8F4N
M8V]M+W1I9F8O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z97AI9CTB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]E>&EF+S$N,"\B/@H@(" @(" @(" \<&1F.E!R;V1U
M8V5R/DUI8W)O<V]F=,*N(%=O<F0@,C Q.3PO<&1F.E!R;V1U8V5R/@H@(" @
M(" @(" \>&UP.D-R96%T;W)4;V]L/DUI8W)O<V]F=,*N(%=O<F0@,C Q.3PO
M>&UP.D-R96%T;W)4;V]L/@H@(" @(" @(" \>&UP.D-R96%T941A=&4^,C R
M,BTQ,2TR-E0P,CHP,CHR-"LP-3HS,#PO>&UP.D-R96%T941A=&4^"B @(" @
M(" @(#QX;7 Z36]D:69Y1&%T93XR,#(S+3 Q+3 X5#$S.C0S.C4P*S U.C,P
M/"]X;7 Z36]D:69Y1&%T93X*(" @(" @(" @/'AM<#I-971A9&%T841A=&4^
M,C R,RTP,2TP.%0Q,SHT,SHU,"LP-3HS,#PO>&UP.DUE=&%D871A1&%T93X*
M(" @(" @(" @/'AM<$U-.D1O8W5M96YT240^861O8F4Z9&]C:60Z<&AO=&]S
M:&]P.F0Y-3-F865F+34W9#4M-C,T8BUB.3(R+6%B,64V-S8X,3(W,3PO>&UP
M34TZ1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.DEN<W1A;F-E240^>&UP
M+FEI9#ID8S)E.&(V.2TS.#<U+6(P-#(M8C T."UE-&0R8V%E8V%F,3 \+WAM
M<$U-.DEN<W1A;F-E240^"B @(" @(" @(#QX;7!-33I/<FEG:6YA;$1O8W5M
M96YT240^=75I9#I!.4$V,#)%1"TX13,Y+30Q1D8M03!!,"TV1#0P1C8U-$9!
M-38\+WAM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-
M.DAI<W1O<GD^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @
M(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @
M(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C)E
M83<U.#<T+68U-F8M9C,T,RTY.30V+3!E,C%B.6(S-V(Y-3PO<W1%=G0Z:6YS
M=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R,BTQ
M,2TR-E0P-#HQ,#HU,RLP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P(#(S
M+C4@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @
M(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HS,&0U93@U."TP,S T
M+64Q-#@M.3 W.2TR8C(X,C4R968S-3 \+W-T179T.FEN<W1A;F-E240^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C,M,#$M,#A4,3,Z-#,Z
M-3 K,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<" R-"XQ("A7:6YD;W=S
M*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T
M179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @
M/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP
M93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N
M/F-O;G9E<G1E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z<&%R86UE=&5R<SYF<F]M(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP
M:&]T;W-H;W @=&\@:6UA9V4O97!S9CPO<W1%=G0Z<&%R86UE=&5R<SX*(" @
M(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z86-T:6]N/F1E<FEV960\+W-T179T.F%C=&EO;CX*(" @(" @(" @
M(" @(" @(" @/'-T179T.G!A<F%M971E<G,^8V]N=F5R=&5D(&9R;VT@87!P
M;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]E<'-F/"]S
M=$5V=#IP87)A;65T97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T
M.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^
M>&UP+FEI9#ID8S)E.&(V.2TS.#<U+6(P-#(M8C T."UE-&0R8V%E8V%F,3 \
M+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW
M:&5N/C(P,C,M,#$M,#A4,3,Z-#,Z-3 K,#4Z,S \+W-T179T.G=H96X^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H
M;W1O<VAO<" R-"XQ("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*
M(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA
M;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO
M<F1F.E-E<3X*(" @(" @(" @/"]X;7!-33I(:7-T;W)Y/@H@(" @(" @(" \
M>&UP34TZ1&5R:79E9$9R;VT@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" \<W12968Z:6YS=&%N8V5)1#YX;7 N:6ED.C,P9#5E.#4X
M+3 S,#0M93$T."TY,#<Y+3)B,C@R-3)E9C,U,#PO<W12968Z:6YS=&%N8V5)
M1#X*(" @(" @(" @(" @/'-T4F5F.F1O8W5M96YT240^861O8F4Z9&]C:60Z
M<&AO=&]S:&]P.F-F,#(W-V8R+6$U-V,M-6$T8BUB-S$W+3(R96$U-F5E-31F
M93PO<W12968Z9&]C=6UE;G1)1#X*(" @(" @(" @(" @/'-T4F5F.F]R:6=I
M;F%L1&]C=6UE;G1)1#YU=6ED.D$Y038P,D5$+3A%,SDM-#%&1BU!,$$P+39$
M-#!&-C4T1D$U-CPO<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/@H@(" @(" @
M(" \+WAM<$U-.D1E<FEV961&<F]M/@H@(" @(" @(" \9&,Z8W)E871O<CX*
M(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D^
M4W1E<&AE;B!-83PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @
M(" @(" @(#PO9&,Z8W)E871O<CX*(" @(" @(" @/&1C.F9O<FUA=#YI;6%G
M92]E<'-F/"]D8SIF;W)M870^"B @(" @(" @(#QP:&]T;W-H;W Z0V]L;W)-
M;V1E/C0\+W!H;W1O<VAO<#I#;VQO<DUO9&4^"B @(" @(" @(#QP:&]T;W-H
M;W Z24-#4')O9FEL93Y5+E,N(%=E8B!#;V%T960@*%-73U I('8R/"]P:&]T
M;W-H;W Z24-#4')O9FEL93X*(" @(" @(" @/'1I9F8Z3W)I96YT871I;VX^
M,3PO=&EF9CI/<FEE;G1A=&EO;CX*(" @(" @(" @/'1I9F8Z6%)E<V]L=71I
M;VX^.38P,C,P+S$P,# P/"]T:69F.EA297-O;'5T:6]N/@H@(" @(" @(" \
M=&EF9CI94F5S;VQU=&EO;CXY-C R,S O,3 P,# \+W1I9F8Z65)E<V]L=71I
M;VX^"B @(" @(" @(#QT:69F.E)E<V]L=71I;VY5;FET/C(\+W1I9F8Z4F5S
M;VQU=&EO;E5N:70^"B @(" @(" @(#QE>&EF.D-O;&]R4W!A8V4^-C4U,S4\
M+V5X:68Z0V]L;W)3<&%C93X*(" @(" @(" @/&5X:68Z4&EX96Q81&EM96YS
M:6]N/C4U.3PO97AI9CI0:7AE;%A$:6UE;G-I;VX^"B @(" @(" @(#QE>&EF
M.E!I>&5L641I;65N<VEO;CXS-S4\+V5X:68Z4&EX96Q91&EM96YS:6]N/@H@
M(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @/"]R9&8Z4D1&/@H\+W@Z>&UP
M;65T83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" */#]X<&%C
M:V5T(&5N9#TB=R(_/O_; $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! ?_  !$( 7<"+P,!$0 "$0$#$0'_Q  >  $  @,!
M 0$! 0          !@@!!PD%! ,""O_$ %@0   & @ !!P8("@8'!@4%   "
M P0%!@$'"!$2%!465M8357:4E98A,34V4521U DB06&!M;:WU? 7(W&AP>$D
M)C)$A;'Q&"4S-&;10D928L93A*:TQ?_$ !T! 0 !!0$! 0             $
M @,%!@<!" G_Q !#$0 " @(! P,# 00(! 0%!0$" P$$  4&$1(3!Q0A%2(Q
M(R0R,T$(%E%A<G2RM"4T0G$70U*11%1DDJ%3@;'1TO#_V@ , P$  A$#$0 _
M /\ >W)R<@WD6$9&L&3Q=ZSDGQSOI)>-211C5XIN8I3-XJ4.JHJ>53R4N4T2
ME*D?.3FR;& QGY=)MGF2N^]$EX0#&.DVSS)7?>B2\(!C'2;9YDKOO1)>$ QC
MI-L\R5WWHDO" 8QTFV>9*[[T27A ,8Z3;/,M=]Z)+]'_ ,H?S^<,9GI-L\RU
MWWGDO" 8S'2;9YDKOO1)>$ QCI-L\R5WWHDO" 8QTFV>9*[[T27A ,8Z3;/,
MM=]Z)+P@&,=)MGF2N^]$EX0#&.DVSS)7?>B2\(!C,Y<VS\D+7?TV>2Q_^(9#
M&8Z3;/,M=]Z)+P@&,=)MGF2N^]$EX0#&.DVSS)7?>B2\(!C'2;9YEKO)Z427
M_+LA_B&,=)MGF2N^]$EX0#&9Z3;/,M=^/O/)?%[H?'^;^\,8Z3;/RPM=]YY+
M/_XA@,9CI-L\R5WWHDO" 8QTFV>9*[[T27A ,8Z3;/,E=]Z)+P@&,STFV>9:
M][SR7A$,9CI-L\R5WWHDO" 8QTFV>9:[[T27A ,8Z3;/,E=]Z)+P@&,=)MGF
M2N^]$EX0#&.DVSS)7?>B2\(!C'2;9YDKOO1)>$ QCI-L\R5WWHDO" 8QTFV>
M9:[[T27A#Z?_ '_,&,=)MGF6N^]$EX0#&.DVSS)7?>B2\(!C'2;9YEKOO1)?
M'[H?W_W!C'2;9YDKOO1)>$ QF>DVSS+7?>>2\(!C,=)MGF2N^]$EX0#&.DVS
MS)7?>B2\(!C'2;9YDKOO1)>$ QCI-L\R5WWHDO" 8QTFV?DA:[[T27A#(8QT
MFV>9:[[T27A ,8Z3;/,M=]Z)+P@&,=)MGF2N^]$EX0#&.DVSS)7?>B2\(!C,
M])MGF6O>\\EX1#&8Z3;/,E=]Z)+P@&,=)MGF2N^]$EX0#&.DVSS)7?>B2\(!
MC'2;9YDKOO1)>$ QCI-L\RUWWHDOT_\ RA_U_,&,=)MGF2N^]$EX0#&.DVSS
M)7?>B2\(!C'2;9YDKOO1)>$ QCI-L\R5WWHDO" 8QTFV>9*[[T27A ,9GI-L
M\RUWWGDO" 8QTFV>9:[[SR7A ,9CI-L\R5WWHDO" 8QTFV>9:[^?_6B2\(?#
M_<&,=)MGF6N^]$EX0#&9Z3;/,M=]YY+P@&,=)MGF6N_G_P!9Y+PA\/\ <&,Q
MTFV>9*[[T27A ,9GI-L\RU[WGDO"/]O\_$QF.DVSS)7?>B2\(!C/IAY)V_S*
M(OF;9DZBY$K!4C1\K(-U?*1D;)D537681JF.5.2(D=,S;'-.D;.#G*;&<,9\
M[GYV0OT]G;/^LJA_D&,D(8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,
M!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8
MP&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,C
ML)\I6_TB;?LG5PQAS\[(3Z>SMH_650_R#&2(,8#& Q@,8#& Q@,8#&4-X\8"
M.>PG#[85SR99*#XGM*-(_#><FV<89"8N<:5]B1@F<BA!S2O(Q;Y9.)F.?N(L
MV%5(M5F=PY,K7JY\?*= 8].YZ^1U6240R(2/$>0V>BA9W"@R<I4L<B%N8 "E
MC"3U7-Y\=_'N3++]U>MKVAZ?:4.7M=?6&9,>AD'AMO&4D4I(R!I+EJ4FN&;L
M@ZULS>7$'#;1PW<P&H.&2O6_6R#]14A*I/SKF^NYW9M?-A4IXRV1#FMPD>PL
M\;Y"4B$6V4&CMOTQQA?$N>ZEH>6;RDPE[K7;I%/76E]/<4DTN/Z[;ZZLB>DS
M"MQMKMP+B)B5;1=%=*T%A""5$Q2%V-OQ#5. 'ZW:U]@[8TFC!HV+7;>MJ7!9
M#]UHZ_7=(KB<$=0]R^PHE&]1Y7I@_7W/2-U[ W<[RK==2\(>GKEKEU(Y,WD*
M-9IO7D[=IC:-9P0R9H:UR%OCVK%Q-Q:+9TLA"H0QE#M.D-%<WOX^D3R78ZD8
M3M*WJ&_5TR7'<RO6H5N-'K-"OO[YBALK&UNC;I',HV,6"79!P*"%XW2 &Q=Q
M/4W^MG3W./A8M2\^Y>RF[O-QK;VS>?Q,V=?J=7KK->X)0[6G<9<K,KN?+BZX
M:OEI>>UIKR<L&#EGIFCU25F\*)E24Q+2$"P=R.%$BE(5,^'BRW.3P0N"&Y2X
M+CDY,2MRA%7<;6M6B(KU]E>0B(F9B$JLM6J(DIF9B $8B9F9GIUF9_.8S2/=
M9TVILV"DWOUM%SCF(B3:VJHV',1$1$D124Q$1$=?B(C/<LDRK!197Z#1-\NK
M*U^)1;+.C,DC*S\_&02:JKDC5Z=--L>2PY/@C54RA4<I%P7)\'+!4OR%(]>W
MHMS.O3K_  E&WITZQ^]V=O7^77KTGITG*1'6>GX^"G_VB9__ #TZ?W?GY_&?
MQTFU^9:][SR7A$6\\QTFU^9:][S27A(,8Z3:_,M>]YY+PD&,=)M?F6O>\\EX
M1#&9Z3:O,U?]YI+PD&,QTFU^9:][S27A+^W^?B8QTFU^9:][SR7A$,8Z3:_,
MM>]YY+PD&,=)M?F6O>\\EX1#&.DVOS+7O>:2^+W2_N_O#&.DVOS+7O>>2\(A
MC,])M7F:O^\TEX2#&?BE(65?RGD8NLK>15,BKY*UOU/)+$Y,G14YE3SS%28,
M7)DS<AR\N.7&.7 MK:IO?XFK;XV$IGC,3\;0Z22S[9GL8,3$D!="CK'6(ZQE
M9K-?;W@8=X0P.\9'O NO:8]8CN ND]"CK$])Z3\9\;2PRK][)QC)"GNY*%.V
M2EX]M<G2[V+4>(=):$D&J=5,NSRZ;_US;#A,GETL&.ESBE-G$6MM-;<MWZ%3
M84K5[5&A>SIU[276M>=I,6*PW:ZS)M6;")AR(< >5?4U]PQ,Q?=2N5T5;3ZE
ME-:\+3I6&I8M%L4,\3BK-(86^$M_3;*R+QG,"?29CKYC6\JO;1)4MJ6JKV>'
MCVLK)0Y+-+]):1[PY2(.#FS3L(&P8RB.3IIK'61*X:G733(Z;F5@5^3:&UR"
M_P 6K[.NWD&LHU]C?U8^3W%:E:* 0\YD(5,%)+D@!A-4+JYM  LH)DIVEVJ-
M35WKJ3EZF[9;3JWB[?$ZRB))BQB"ED=($^TB 09*VBLB)+8"1Y=VG!L$ZGKO
M.SC)L%S:)'!LE+DN#&P7LERYP7)BXSG'+C&3%QG/PXY<YUCK ]8[IB9@>L=9
M@9B"F(_,Q$D,3/XB2CK^8S&=)Z3/2>D3$3/3XB9ZS$3/XB9B)F(_GTGI^)S\
MSR%D3511/%UDBR_/\@D>U/RJK>2+@ZOD4\U/!U?)E_&/S,9YA>0QN3&1035
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MLUMAE96O.E6[AW6K6:"G8S-UK+UPU0<OJY;^O(1ZY)EPZ8++**'-ZOHNTRX
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M@,9'83Y2M_I$V_9.K_S\/_(,9ES\[(7T=L_ZRJ'Y?Y_N#&2$,8#& Q@,8#&
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MU&,!_>$B2R 6^14!+0E5)(&FT)LR=>K>M+52#R7+;*M*Q9"C47UZ'9ODJ*2
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MB5\$X@!<>XL5:# "4G:)JV^12J([89NSGN,I)A]#!F<S> Q@,8#& Q@,8#&
MQ@,8#& Q@,8#& Q@,8#& Q@,8#& QF.3'T8^S \Z1_9'_M&,9QRXSC&>3.<9
MQC./CQR_E_0$QUB8_MCIB/S'\\Y[2_ DYF):4EW6W%%',K(O9)PHM2/*KG</
MG*KI8ZJQ;<D514ZBIC**%22PH?.383)C."8^*=G_ $/W[79;#9V/4LV6-C>M
MWWF[B?D:;K;V6&DUD<E7#&$;"DSA8013)0 Q/;'TM1_I#JH4JE%/"@!-.JBJ
MH%\@D%BNNH% (!.D.0"!"($9,Y&(B)(NG69PRX?MN:DCV3W26T\RCENBDI-T
M6^MC8J%@=EP3ICB&5:9>.*RJ\RF=8Z!R/W+QTH5$UCB69>4G:=#Z1[3AFFUJ
M.&<YV>MVU&HM=U.SK3M.';^T'666+G'6V2M:5ULNT77-%M4- !\K47K)-8[E
M>Y]0%\@V=VQON+Z[9ZRU8(ZX57QK.3:A!=!A5'>JK^UVBZXP1II;K6L6QIRL
M;]&M"P5^U6XPX)C/M:%O6ISNE+\LD<R+.PMC*P4OA#F%<.8*7:'=M)9DB=5(
MCA_ N[!",E#^2>3B:F,E&</GNWXL/;ZE\:?H*8L\(\TT).Y#P:P<](65F[70
M.UXXRS,SX:G(==4GM$RFR0CW3AJNGTO)'Q6X9O N;8E%8+AO( 5HN9*4OM\Y
M5*;G'K>1UZDF 6-AQS8;"K##6 _><#EOHV3CIADWDHE^RE(YVGA5J^CW2#QF
MX3-\.%$'+<ZB*I,_D,0YL?G'1Z-^CLZJ;VMN5=A2L!#*]NE85:K."?P:GH,U
M,&?[1*8S7K52U1>RK=K/J64E(-KV4L0]11^18IHB83_<0Q.?<)>1\!C 8P&,
M!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8R/0ORE;O2%M^R=
M8_G\G^.6,.?G9"^CMG_650_GXO\ -C)"&,!C 8RNO%I!IV/AUVI$**5!/I->
M(=+-^EE(2F*.&LDQ=M6]DD4S8PC%.7""3=TDL55JZ(KEH[07;KJI'AVQF6:L
MA76:2M]H&BFX,G7=(;BE^DQ4"<O@XF1]N"V-?U\5<?<&HADUBB!O1)6@$]/O
M%&RG(!96#M/>4;%-9, @EB<G[DY@:T#+RGM7.4JX<(Y&+XDHBJ+Z\_!]U"SU
MB$E):<)PSH3,=LYC&S%;<88$?=:4NJM7T$[+(1Z\I'-I"3D69W<+(.HI%JH1
M^CFJ<]Z]RT#N>-%9VM;XIB:GO5[C4&RO:B"CN\'MGA#EI-2+BCJ,L(>?MWX>
MS$B>EDQIE[AXVTL;!0V:YZS9"MU&?N@7O[H(%L9!OUTVWJ!RP)J^KX@Y/P&,
M!C 8P&,!C 8R%WWY"9>F6N?WA5<2*O\ $+_+V_\ :.RH?S/^$_\ 06301\IP
M&,!C.>GX02U34A4*-H:F/CL[KO"WP]1CEFZRB+E@E*ODHPDMCR9<F.2OI.).
M\*8)RF*VH[PYLDP7!L\ZY&E?)N=^G_"6"3M76O/]1^8*&"()X[PDE6=92N!(
MRLZN\Y6[3Z^09/0I6<?$]L%D+]^SQOT_YGR"BX:V^W2:OIMPUWD%3U\CYO)T
M;FRHEU@_=<<XT&XWAPN)*$5C/I( P@O13ZK"T6IUFE5MH5A7ZC 1%:@V1.3F
MM(F#8-XV/;XSC!<9\DU;)$R;FXR;.,FSCESD=*>]EE[K#B[VO:QS2G_J8TY,
MY_\ W(IG,%K=?5U6OHZNDN$T]=3K4:JHZ?IUZJ00D/CI$R*P&)F/S/SDC%K)
MN Q@,8#& Q@,8#& Q@,8#& Q@,8#& Q@,8#& Q@,8#& Q@,8#& Q@,9#[UK^
MD;-KCRI;!JT);ZX^,DHO$SK!!\VPX;F\HU>MO*ERHRD62V,+L)%FH@^8.2D<
MLW""Y"*%NI>ZN<FEA+*0-9=/P:V#(L4P9ZBQ3!F08I@DM@3(F)#,QD'8ZRAM
MJWM-C43;1Y%N &CUE5A)0Q%E#(Z,KVJ[(%M>RDUO0T1:E@,$2BA-CX5-X:1>
MKVKA&V4^D(W"F73_ $WLZ?<K-WB:*:N4VE:OSIG*K+*\N2$2:['C;0NOG/DB
M7& ;YRH30+GICQ=UI^TXI>V/I9R&P4M;L>'I0WC&SLS/VLY%P2U,:6V,=Q]7
M:B-1:&"[NK2&!F:'*N=Z9"ZMB*/JIQU PL>/\YMN1RC7U@"8\7&?42NMNV6R
M>@EX.4*WH6#B!*_3 I,?1UQQZ,TK8CJO?U#LVIMG$3,;,-,1"K)])-R+.D,2
M4/%HNI5G;8PY6#ER>6UO/W=DFD7)W2,9DBJ",&WN^?<'3[CGW&%[SC2R[9]1
M?3@+>[TJAF!*#W_&2 N3<=-:Y&;33K7*GG. K&2Y@LR&FVW .;7_ */QK=7.
M*\R(2./3?U("MH=^_MET3/'MX#F<9Y2AGA8Q$ZO8&Y=8>^Y"6]RXOM7+37+?
M&I2]7FXV=C5L%R5U&.TG1"&-CE\DN5,V5&S@O)G"C9P1)PD?!B*ID.4Q<;?H
M^0Z+DU%>SX_MJ&XHMB)&S0LKL ,S'7QM@"DT.'Y@T/%;EE$B8"43$5;34;32
MVCI;:A:UUH)F)3;2:2F(GIW+DH@6KGXD6K(UG$P0E,3$S[XS.8[ 8P&,!C 8
MP&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C(["?*5O](FW[)U?X_P"?
MBY QAU\[83T=M'ZSJ 8R1!C 8P&,TWQ .*LSU';GEP=61G$,DHIZ@XIT:2:M
MA; SG(QU4R5J%59R+::G5K0E$(Q<0^8/(Z3>'192#95FNN3,:R; FL://-J+
MM7V8UE YI62<(A$K;$KE/;)S9,Y#PUH<\7(-0O7*J1)'8&?%X3U^T7<EQDM0
MZYFMM!L3(PB6#V42L'!+$V00Q(+870"Y_P#"Y::G);6UU6*W1^)5CSYG=FP;
M7>-S4"L5(MQVBH1:OVB9F96-64,^?Q!)1]56M?ARQS2N%2;,UHQX5/#J)RU1
M8"IO@]NBG2XE4IZVMYC,BU^PW6GV3K:Y/N=<M;.TFOL+%]K#60RV(E,N2#L7
M=DN]#; V6W+?)D,LV/# K D<;WE>C2GYA=*G4I+,*E-*HELS#X.!!_FZR"%D
MK 8P&,!C 8P&,!C(7??D)EZ9:Y_>%5Q(J_Q"_P O;_VCLJ'\S_A/_06301\I
MP&,!C.;VMR_T[\<E[V*<W2Z9PZU[LS6CX6*LT6O=M2>PR:[?FE,3R\'4VEJD
ML8YQ3=!VHP5QRXS@<]].O^+6N?\ J"<]X\FWH\+XRR>AB/#^!L:B_9J.B>A5
M-[S"QL'=(B8F=./S^8R1S2)GD/#.&CUBMP3CQ\OWP"0=I\XY\J5ZRO95(RQ=
M[CG"ZLB424=5<H67;T[9SI".A9'P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C
M 8P&,!C 8P&,!C 8P&,!C 8P&,!C-<;0U!K'=-:6J.U*17KQ7U<F4393K!-R
MHQ<9+DF'T2_+Y.0A9),N<X0DXETRD&^<\J+E//PB92V%W6NBQ1LNJMCXDE'(
MP8_^E@3U!H3_ #!@D$_S&<PN]XYHN3TBUV_U5/:TRGK"K:1,E'_)M=L='5GC
M_P!+Z[%."?D3C.?%DX1=[Z.DW5KX:[U(;(@2*&<?T;W^V.:]LN/;E,9;JVF[
MF.D^965H=3#=JUK^XH2=:-8UMT5&SMC*Y.-2WGIUZ?\ *[Q[H$7O3?F;(GKS
M3T_D=5-UA%!]W(-$D8UNW49Q!69;78U\1V= CYB'K=YZK\ K10T>SI^JG"5E
MW1P'U+>R[L:".A1*>+<R;)WJ1B)>.HG8D:JPB';9ZQTF9:AXWG$K.?T?;"K\
MPUV"P3QF7HD_!EU_N=@0F3IY>(Z[DW1XG8,:N=-1RVFM6S\T@>+PF\6BFISY
M;DUG81ZM^GJXL<ET=?U.XB/[O-_3](AMDJCI$GM^(DPO(V"+]6-39%@ ,R&O
M9/6(VWC?,?2OU$M?2M3L[OIESGI^MZ?>H<S5DF3,_&HWLC"[54H&90Y@O6T9
M$F6E1/2+TT_85-OC=1>K3S*25;8Y'\=SC-IB+/@^4S)2L.[*C)1RA52F2SAV
MU2P8Y383,?&.7.=XQS;BW,4,=Q[<5;[$=8N4>I5]IKS$NPE[#5V13?HF+(D.
MEFNN"*/L(QZ3.6W?&MYQUHKV^NL5 ;/[/:Z0VC;'IW0=2\F65+0R$P?5+CF!
MF.Z!GXR9C:LP6 Q@,8#& Q@,8#& Q@,8#& Q@,8#& Q@,8#& Q@,8#& QD=A
M/E*W^D3;]DZN&,.OG9">CMH_650#&2(,8#& QE0.(A]OJ?=36MJ9P[U+:FN)
MJLQRLC89O<[G6T@65<O7_E&4:DSJLE(,9*"5CHZ58S4?*MW;1RX9.V:J#I#E
M2C>(K$.BP/@%%Q)TVI>8O+P*JV5VX(( D$NW+DPON,6 CJSN4\E9)$Q1"F*.
M&DU-E-I+4B2O&T65W5V <F#Z]JH[L/N@>Z#>J0B %C*_Z UEM!/?%4O=FTVT
MJ5?A8J:@UY"+XHK#N2$BITU6-%.)P]-=QT8R:W.RMV#!A9K:[<OGDB8N5'K!
M24D599++5F!'U=Q&(_4:5AE;MK#*Q]SOM9L;.OH-@H&G0?9FSM&54K(66D=P
M.0 FBQBK2R(M4D0D_8W5E:DG2#9E&GV5"I=NATZV[-2NT-55EDC->D^% !*K
M(&OT_$+)F Q@,8#& Q@,8#&0N^_(3+TRUS^\*KB15_B%_E[?^T=E0_F?\)_Z
M"R:"/E. QFH][;";:MU-=KHN[38JQD*Y3CW*I\)E0DGI<M&;G.<Y+G*;!17K
M%SS<X,5HT<*8SC!,YQH_J-OK?'N'[>WJQ)F\N C2<=0OI+G\AWMA6ITX)"9B
M6$%ZVJP8#/=*4MF/W>N;)Q+75-EOJ0;)BT:BE#]MN[+I[45]+J$,V.S:XYB1
M6OVE9B^\OM@V!U_.:>X'=<.J#H"O2LRT79VW:KY[MNU(/4RIR#-S<4VJM<A)
M N$DSE>U6BLZI5'*:F5C$7A%,86.7DR-MU>CJ<4TFAXC0(&4^*::CH5N7)D%
MNQ27UV>PB3GK,[3;,O[(YZ!U*W,^,/W8T'3W[>_/<\RV2W*V7.MYL.6V4604
M%BG5V9B.AU3Q2,##-'QNOI]*4232ZZ^9)K2F3*WHEYFL!C 8P&,!C 8P&,!C
M 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C-3;>T7J;?%=
M[,;7I$-;HY(QEHUR[2.VG(%YG),XD:U8V"C6=KDF3*9,E?PL@Q=<A?)F4,ED
MQ#3]?M+^J=YZ%IM<YCH8C,$IH_/V/2<$IP3UG[&@8_SZ=?G-=Y'Q/CW+:?L>
M0:JKL5#,FAC!D+=-OQT?1NI)=ND^.D='57*9TCMDI&9B:+7/AUX@=0.6LS1)
M1YQ04:*-CH\';9YM2.)ZF,4D\$)V'W<PZMCMAHM$S*Y1@]G,C/LH(-V32=76
M5YY,#R;@/IKZB/"]NM47$>6*Z%3YEQ9C]7=4^!@!8UM(@MJ[1B( ).W1B9(R
MH_$9C-)OO6+TK7-;C6XGU-X3/Q9X5S$ZUG:)K1/<2]?L;8Q1V?SU+LV"JU\A
M$$KV924S$\TYQ4N[/)O*G$2;R[6B#1,M8=/;)AB:EXEZDW1+DZV5JK*82@;Z
MS:-2%74F*XYRV<F5+_WDLHJ0HT39:/UE]-PBPU=/U:XC';XMC295UG*T('I$
MP+E1&DWS%KB2A;XTNRLN@A[&&43'1.-<^](O4RPS757W?33FBAF;G&MY7L^V
M!O0B(CI6)G:4$R7[UFB>XU:%]LPX(B8RX%/VM2KHY4BXZ14C;(VYV']0L396
M"M<>=/&#*$<0K_";A4J93%,=PQR[9XP;'(XSGEQC)<9]1>*\J>S74KS*&]K]
MT7.,[NNS4<BI& P1B[57(!S! 9@B?4FS5Z3'1\_/3,;OA^]T2AMV:P6M6WI-
M?=:QP;'3V1*>T97?K2:@DBB8A5CP/ZQ/54?'78PWC-8P&,!C 8P&,!C 8P&,
M!C 8P&,!C 8P&,!C 8P&,!C(["?*5O\ 2)M^R=7_ )_)_B&,.OG9">CMH_65
M0#&2(,8#& QE?N*JO6FU\/6U:]2X^=F++*5=PWC86MRQ8.9G,](;J.H1I*94
M0RT++LR.(YT<CALJ=HY732<H*'*J6'<7#9U\'5]\@=UHSN4I9"EVZ0;>G-Q#
MV%(BNN=;R>X890"E0;60P%DHY51OB*R<6/9MC6[8:UL4S895MGJ[@4[*$1$R
MVRBT26U5QT[K J'N#KW#0BAUC<6G[=5;+IC\&W+ZR08-)2.N3&O<0VFB)W:*
M7BU&T7'S+8]O,TD',9,';S;>=DDGLPW,R58M5RH3$@896++1*]!.EE6Q2,%U
M?' J7L8O:]Z+X* 9%!JI5[U(AKC$O'8?J3,5E06*FL,JI3 0%FK;6TGRPF-.
MI-&^BQ3*P<PYRFVWTK4@^25)T@;V0T0(>FD9?$X_6,5L/9J+77.2U:.G[>RF
MG9$4*H[<,D%Y",=NE<XP=5@Z5,QQS<&.Y7*4B!#J*ID-:V$UJ;W JQ[E 6(1
M6>M3.^Y)LA5>$5Q$GFVR9 *:P ;S,Q4($R>DRZXNL=(E,J;T:1J)JCA )[S8
M3+ %[>5)4!,;9@XKPL"=WPF.[*V&XZM>8ELMT]0<4[BJX4YIMEH<.>QCT+"&
M#<W+WIF8PL]EEC&<*>7+73<J6<'*7.,XY:5CUCK9(-?/\HOE".O]G=,>0%1/
M2>LN)<!TGR=D1/3QA1$1->8O=>G7V4^:(ZS$3$%/8+.G6/E1,@^L>.3[AZVY
MJ]IKMU@8RT5.883]?F&Y74;+1JY7#1TCDQB&R4Y>0Q%4E"G1<(*E37;+IJ(.
M$DEDSIEK<EB#E;1[2[0..DB0FMH"Q35F$D#5-60,2U9$MJS%BR("$IH6T&C)
M!,S$$:R@A(#6Q1DMJFK.!8IRF"2VJ8(L4P26P1,9&/>%K+F4NXL9&VP%SX4I
MBN7ZY5N/E>(VETJR5:"DFL=7K9#3[:6?."60J+#KI_AN>%20;L23"$,JW>/<
M2,8^5,V5;5ZF(+DM9#8\Z+&@Y6WP-^4I?KM#?L)L+6/:)NEKEGW6/.*3JUVU
M1KN%C&TWXF='L#7,I;5N<<=#E=(<P+/*^/Z]M<V%!$%<J]JQ!C7\!NAI+L,<
MB83&M=S3]VMMXXJ73+8-OHK+AHU+6+#KYC6+1+5N.<W>2KUBN[ZSW!A&N6C&
MYPAT8F+KV:]:4I>OI,DI15)BD_>9=HX_W1T=1>Y (C8LHY06L34?$NJ3K=73
MT%BU1*K,PHW[ANYL!-OL]]7 :D4;%<PDV9!=95[:Z31'Y%5]CJUV[=A!>&W[
MG;;G:Z>HVO:&(8J-2&G*T".XJMA]N??HM(%:1O/KBQN[CKRB6Y^@1L^M--K%
MB>-DRF(FW=34*RDG")"&,8Q")*N3D*4QC&*4N,9SG..49W;55T=KLZ2BDE4]
MA<JJ(I@B)=>PQ024Q$1)2(1W3$1$SUZ1&8'46F7M5K;KH&&VZ%.RV B8"&/K
MK:?;$S,P/<4]L3,S$=(F9_.?GL,YDJZW4(BHX.G;M>'(@CE+"JYB; K!BHI9
M7510PHIG&"$RLLDE@QL9453)RGQ'J_Q"_P O;_VCLR0_F?\ "?\ H+/6Z[D>
MZ-B]8JWB;^>3^P1\IS^%; ]02477JT\BBBF=5995W4TTDDDRY.HHHH>SE(1-
M,F,F.<V<%*7&39SR8SD,\F8B)F9B(B)F9F>D1$?,S,S\1$1^9SCWO+9W_:'O
MB55FIE_%Z<DK;46+V!=+H%9NZI&S+=&R'>(KK(QS=Y:H%W8(UP[=J='CV<NB
MB]7<-HTBV?@77>NE?D'](/C]_<6KI<"U/(15QW6K?!TE;NI1V.LXYR:PG]-<
ME&\OAM&-']6M4E(=[YHJDOISD?I#85Z([[3ZY=-7)MUJ%#R*Z]4B]W'+>QUU
MWE7'E'T,HFSQRI;U:A.)4=MALD5#89$=A23+\A"D)4+"4A"E*0I5ZK@N"EQC
M!<%QBS<F,8QC&,8QCDQCD^+ ^^NO7Y_/7YZ_V]<^8XB!B(B.D1$1$1\1$1'2
M(Z1\?C/[Z[D>Z5B]8JWB4,]S'7<CW1L7K%6^'_\ DW_,,8Z[D>Z-B]8JWV_.
M;_/\P8QUW(]T;%ZQ5?$P8QUW(]T;%ZQ5O$P8QUW(]T;%ZQ5?$P8QUW(]T;%Z
MQ5O$WZ?\_@#&.NY'NC8O6*KXF#&.NY'NC8O6*KXF#&.NY'NC8O6*MXF#&.NY
M'NC8O6*KXF#&.NY'NC8O6*MXF_)_T#&.NY'NC8O6*KXF#&9Z[D>Z5B]8JWB4
M,9CKN1[HV+UBJ^)@QCKN1[HV+UBJ^)@QCKN1[HV+UBJ^)@QCKN1[HV+UBJ^)
M@QCKN1[HV+UBJ^)@QCKN1[HV+UBJ^)@QCKN1[HV+UBK>)@QCKN1[HV+UBJ^)
M@QCKN1[HV+UBJ^)@QCKN1[HV+UBK?9\YO\OSAC'7<CW1L7K%5\3!C'7<CW1L
M7K%5\3!C'7<CW1L7K%5\3!C'7<CW1L7K%5\3!C'7<CW1L7K%6\3!C'7<CW1L
M7K%5\3!C'7<CW1L7K%5\3!C-)[CTCK#?+%DWV5J"5E9.'/A>M6Z/?0$!>:D\
M*H5=)[5KG"6QC8X-9)R1)R9-E($:.ED$L/6SI(OD\Y+7;?8:HR*E8)8,^'5S
M@6U; ])B1?6;!I;$C,CU()*(F>TAGYS5^3<,XWRY2@WFM78?6GNH[%!LI[77
M,B>X6T-G5--VJ0G L[5.%9D(^4#&.F5*G]=\3&LN<TFZA(<96G8WD6C>ULE5
M:GQ3T9@@;!\)05WAI=.*V@HU)Y=V;,DI5+1)N#D:$?.?@*?&\HX9Z:^I2%)Y
M-HZFMVBYCVVP2+@KH;$R8MJ7JK%;C1E+)CYHV3KC'4C7(S,3B=#OO63TG:]N
M@W%CGO&8&99KKK4(Y8JO$=I).'I+1\K[5Q)3]252O-GHL'F4#UF^EN(=W>UW
MS#2]GD]CJU]51*TZ;W0>)HV[J/E#)2KM'R4A(HV0N4UE"MDW=CKKN./S>:WG
M'1N4XYC?X1ZN^G,@S2;97/N-S$$C5<KM".UE$1)0K2<WI);5OM/K @O?US)8
M"/DN04D4]6XUZF>DGJ?#D, ^)\CKS(7XU=1U8ZC^L09;OA>Q).PH N9^YNJ+
MPL,I\:R&(B+.0V]Z_(S"58DZ]:*M;5,$P6N6=."A';HY\\W&(AS)3K1E.)G-
MC/DC1:[E10N.=E$GPXQ>T7JCQK:7U:/:Q=XCRAGQ'&^55_I=YY=W9$ZVP9%K
MMNMA1,I/6W+)L".XE!,2,9K:\&W-"H>THE5Y!HQ^9W&B;[ZLJ.G=,74B(W->
M81T\D7*Z@$IZ0P_B9V=UW(]T;%ZQ5?$PZ1FFXZ[D>Z-B]8JOB8,9GKN1[I6+
MUBK>)0QF.NY'NC8O6*MXF_1_E\(8S/7<CW2L7K%6\2AC,==R/=&Q>L57Q,&,
MSUW(]TK%ZQ5O$H8S'7<CW1L7K%5\3!C'7<CW1L7K%5\3!C'7<CW1L7K%6^WY
MS?Y_F#&.NY'NC8O6*KXF#&.NY'NC8O6*KXF#&.NY'NC8O6*KXF#&.NY'NC8O
M6*MXF_1_E\(8SVFBZCENFLLT<,%#\_G-79FIW"7-.8F/*&9.7C7/E"EPJ3R3
ME3D(<N#\Q3!TR,9] 8R.PGRE;_2)M^R=7#&'/SLA/H[.VC]95#D_Q#&2(,8#
M& QFK]SV^P4365LM=7:1CJ<BF*!F*DYTGJ&*Z6^:L7%AL&&1TWAZ_6FKE>?G
M"-%$G!XN-=E261/G"I(]DR 4C#TU1=:J5V6['RFJI]A:F/*)(!DA$I%7E8NN
M+B65EJJPN8$FJL6&WN6U_BJ7K(5D=WGN.J4GV44D]BW'+KKE!55"DN;)M&%)
M:R1651=$\6;[86QM0:V;W"E;7E+7K*V6':;ZA)M%66NIZJ/FK.(E7#F)?2#1
MA%WC*SE)M 2JZTJU6)'O&SO+)WE-3)UE#;C:.%#ZU6KI>-;2NY\3';L-LFL%
M_1-.0 '6Z\FVY'B%;:OM[J+"V1*XIXMKB1[438IKW\BY!J?$F)D7:S7/VS*N
MZ7'<3$U^RM1IP;28B_%^LVNQ;:[IO6<WK6=HV>N5Y+4:VMT+3%6Z-F<K[1@Y
MJPUULS:,I)/IC>-A)J$64EV;U=FX8*N%G*+8Q%'*3?#U%JNC CS#;JM"5BL
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M8O4DS*JND7.''E6Q$E<U65,IO+]NQE>IK#8DA?VHI-+;:9 L\$1($34L<@9
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M8#& Q@,8#& Q@,8#& Q@,8#& Q@,8#& Q@,8#& Q@,8#& Q@,8#& Q@,8#&
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MP/1(A*"$I$AF)$AF8(9B>L3$QTF)B?F)CYB<H8M;5FIH Q3!(&+8,&!@42)
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M<':J$98=$QBON*X1\S!TY*8M0$2(RZD;H,I_AAUZ0K>I+M*]&M]2=*SB-MK
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MWUNI>*8Z+\7&MYZ&\(WW-J7-;53M<MDV=KJ1 "UF[NK\?M;-U)=1'MD)*ZD
ME.RF!]T$]UKW70M!!%LBDW;I)-VZ"9$4$$4RI(HHIEP1-)),F"D333)C!2$(
M7!2EQ@I<8QC&!J,S,S,S,S,S,S,SUF9GYF9F?F9F?F9G\YV,1$!$ $0 !@0
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MXU''5-@IZE6U+=30$(.>IS'?I+JB4)2F! AZ!,2N.H0W+,K@,8#& Q@,8#&
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MR@ODV$CQK4!(HAQV0J>[J>_*G#)M11BPN;4)E(D\>Y4$+CK@RVNO+F4UG;%
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M<=K:KWE@/;$?]X#&.UM5[RP'MB/^\!C':ZJ]Y8#VQ'_> QCM;5>\L![8C_O
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M!B(B(B(C)Z-QS7<!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C
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MHS5(^00,FZ(= ^,*ER3!42^L-Q$>:H?A[+2OU*Y>X6;4=KAZK+S+6QBNA3Y
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MC$T[V%-U6NJ %S74&_2*<B)1.R+C2-MIZ+:TB(+M5[ENIKKFOGR@F\A]3O:
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MVB8:::U()(S2@NR3L2*A]S$K%C!DD[FUK>.*#8M0C;/#?T((M%S.&1TK"QV
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MU8I6=E=;3ILU+-DO3F5)J"!RWP*C>VLBP\&6G6='Q38NJ+7/?4+96=FC=6$
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M^W 8QRX^G'VX#&.7'TX^W 8QRX^G'VX#&.7'TX^W 8QRX^G'VX#&.7'TX^W
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M>,K<.*=MC&Y+R.PGRE;_ $B;?LG5PQAS\[(3/_IVT?K*H?\ L&,D08P&,!C
M8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,
M!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8
MP&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,CL)\I6_TB;?LG5_Y_+_@&,.?G9">C
MMH^'_B50_G] 8R1!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C 8P&,!C
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M-L)EB$5$69&LY[V+6JR:T,(6L "]")8=E<1(,J6*]1P.B:Y^ZM5UVZM=0O\
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M9E-6'1*I)I*-2>C7:5R*,#'N"+5@$R:XK,9NVDG3K5=DHI-9LC _9 NP1V
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M&,!C 8P&,CL)\I6_TB;?LG5PQAS\[(3T=M'ZRJ'Z/Y_M#&2(,8#& Q@,8#&
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(YSFR;X&,_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g428534g47l56.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g428534g47l56.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1K24&AO=&]S:&]P(#,N,  X0DE-! 0
M    &K:^:#@X0DE-! 0      !X< 5H  QLE1QP"   "   < E  "E-T97!H
M96X@36$X0DE-!"4      ! B)R.S>.0!+UE6301,F3\].$))300Z      #E
M    $     $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!
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M;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B
M:F,    !        4D="0P    ,     4F0@(&1O=6) ;^            !'
M<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D5%5N
M=$8C4FQT                0FQD(%5N=$8C4FQT                4G-L
M=%5N=$8C4'AL0%C\F\         *=F5C=&]R1&%T86)O;VP!     %!G4'-E
M;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M  !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M     !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL
M;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I
M9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M !  E,S,  $  @"4S,P  0 ".$))300F       .             #^    X
M0DE-! T       0   !:.$))3009       $    'CA"24T#\P      "0
M         0 X0DE-)Q        H  0         ".$))30/U      !( "]F
M9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &
M       ! #4    ! "T    &       !.$))30/X      !P  #_________
M____________________ ^@     _____________________________P/H
M     /____________________________\#Z     #_________________
M____________ ^@  #A"24T$"       $     $   )    "0      X0DE-
M!$0      !     "   "0    D      .$))300>       $     #A"24T$
M&@     #00    8              5(   )Y    !@!G #0 -P!L #4 -@
M  $                          0             ">0   5(
M             0                         0     0       &YU;&P
M   "    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO
M;F<          $QE9G1L;VYG          !"=&]M;&]N9P   5(     4F=H
M=&QO;F<   )Y    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC
M90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M  9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D
M     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/
M8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,969T
M;&]N9P          0G1O;6QO;F<   %2     %)G:'1L;VYG   ">0    -U
M<FQ415A4     0       &YU;&Q415A4     0       $US9V5415A4
M 0      !F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L
M 0    AC96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%
M4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M
M#T53;&EC959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU
M;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO
M;F<         "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L
M;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #
M  (_\        #A"24T$%       !     ,X0DE-! P     $%T    !
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M1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_V@ , P$
M A$#$0 _ /0W,LZE9D4OMLQF46;:S0XUV$;?=ZGT_9N_FOWT3&J<Z_,'K6^V
M\;?=( -5#]K0_=M9N=]%5:\?%S,CJF/:YWIBZO<6VN!!%;'QO:[V;7_X)6L2
MEGVC-U=_2 ?IN[TX_P#*240V/1M[7O\ F&?^DTMF2.+6G^LR?^I>Q2]!GB__
M #W_ /DDO09XO_SW?^2213&,L<.K=_9<W_OSU&VS.;637378\1#386@Z^[W>
MD_\ -1/09XO_ ,]__DDO09XO_P ]W_DDK57B6.[*_P!&S_//_I)+=E?Z.O\
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M:TO_
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M    _^+__TE#0U]04D]&24Q%  $)OLS^_AX "(!P041"10(0  !P<G1R0TU9
M2TQA8B 'T  ' !H !0 I #5A8W-P05!03     !!1$)%
M     0  ]M8  0    #3+4%$0D4
M                              ID97-C    _    '1C<')T   !<
M "MW='!T   !G    !1!,D(P   !L   H@9!,D(R   !L   H@9!,D(Q  "C
MN   H@9",D$P  %%P  ".+1",D$Q  -^=  ".+1",D$R  6W*  ".+1G86UT
M  ?OW   D)%D97-C         !I5+E,N(%=E8B!#;V%T960@*%-73U I('8R
M
M                                             '1E>'0     0V]P
M>7)I9VAT(#(P,# @061O8F4@4WES=&5M<RP@26YC+@  6%E:(        +5:
M  "\9P  DC!M9G0R      0#"0   0                    $
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M 9 GE@L#KXW(@GVVRZ%7LKVD;9WAKAZ1;)J=J<9]RI>@I=%IEI3KHE)4EI*
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MVGX@JB2N[7W5I;V82WVQH8^!%7VPG:EI,GW+FAM0.'WYEPLT7GXRE5\.>WZ
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M:)IMCF",;I>TC+9YMY4PBS-F$Y+ZB?I1?I$%B/,[;H]XB#DAE8]*B+, ^HQ
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M'YL\@HA)>9BC@D0T+):R@BL:;9<9@L8  (M@@ "AL*>5CB^18Z/VC(. ?:"
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MI \CPJ!@F"T+\: =B!,  (1A@ ![;LLQ<OUMF<6V<S=?6,!_<YI0<[N"="=
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MBJP;WZO0BS %@:DD@[D  (,>@ ![.<8EE^1M5,":E9!>][L?DXY0 [75D?9
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MX;7 ;FECL;&];W%4JZWI<(!$F:I@<8TS :>3<G@>NZ;1<L$%O:<_<VT  (
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M3["MDD!B"*QQD)=3 JABCR9#):2JCA(Q_J&=C;4>@: CC> '(9ZCA-(  (
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MP[^Q=(M8.KL$=-5)\;:&=4 ZEK)V=;\IC:]_=B$5%:_$=;L #ZGI>.<  (
M@ !RH\,Z>[AEJKYR>T58)KFU>OU)UK4D>O<ZB+$#>Q(IGJWR>S@5;JW>>P0
MHZ?3?2X  (  @ !RE<'M@MIE@+TF@?A7Y[AJ@4))J+/2@,PZ9J^M@)8IG*R*
M@) 5KZPP@,P!(:7X@,0  (  @ !R=L#2B@ME7[P'B,A7P+=%A[9)=;*HAMHZ
M4:YSAE$IGJM'ADD5[:JOAI !D:15@0\  (  @ !R4;_YD6AE2KL?C\M7LK9.
MCE1)9[&HC2(Z0:ULC%XIJ*HAC(46)ZE8BX,!\:+J@5   (  @ !R,+]0F--E
M/[IBEN!7KK5_E0I)8[#/DXTZ/ZR0DL(IMJDXDP<68*@MCR$"1Z&T@8H  (
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MAXQ:G3!Z>8K-FK5I>HE>F#U7K8@AE@I$U8<<E%LP7H97D_06_X:RCXT  (
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M=9FZ>A)R?9=M>DUB8)53>I51/9-J>ND^RY'A>T J69$<>W$0!I,O>R4  (
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M(I52HD-O ),#GY->]I#-G/%.'8[<FM0\)HU/F=PH:XPXF!H/2XRLBE<  (
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MD*(Z@ !F7Y].?[973IR,?X)'')H8?VDUBY@I?U\AH9=U?U@(KI>+?Y,  (
M@ "!9*0EB$=S\*$DAWAEM9X\AJU6GYMYA?%&EICZA5PU&Y</A0(A6I9"A10(
MO)7?@]$  (  @ " V*-+D%]S:*!.CQEE+IUAC<M6%9J8C(]&$Y@2BX@TR)8'
MBO$A*Y4DBV((S)1@A?,  (  @ " ;:*0F(=R]Y^9ELYDN)RHE0)5G9G:DTU%
MII=1D?(T=Y4\D5LA%90>D.@(XI,.A@(  (  @ " %*(4H--RPY\;GKED?IP7
MG&U549DLFCA%4):5F*8T%Y2.F&$@QI-OE7\(Z)( A@8  (  @ !_T:&\J5QR
M?9ZWINQD+INFI#)4^IBMH:5% I8-H"TSV9/\GGP@F9+8E@H(XY$[A@(  (
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M?ZM8A2Y;!:?/A(=,MZ1M@_,]<J%D@X\LD)\R@VL8V9[W@[\"[9H[@?L  (
M@ !TY*X3C8IH**IUC'):KZ;CBUA,7Z-YBE@]'J!HB9HL7YX8B6@8TIVVB8,#
M(YBV@A\  (  @ !TE*UEE3UGYJG!D\I:;J8CDD-,&**MD-X\U)^:C^XL,)T[
MD <8VIR5CED#5I=J@D(  (  @ !T7:S7G0)GL:DMFSM:,J6&F59+V*(&EZ,\
ME)[LEK4KZYR3EG88NYO&D+D#B993@F0  (  @ !T+JQ^I1=GM*B^HQE:+J3\
MH-!+N*%=GLD\>YXIG?,KZYN^FY,8T9KRD,@#K)6,@GP  (  @ !J,K\#9K1=
MSKM : Y0X[>6:7!#([0%:L8T*K#H:_0C'Z\^;*(.(;%(:^,  )\$<[   (
M@ !I[;X];C)=S[HY;MA0];9";YQ#1;)W<&XT6Z\N<3$C<ZU*<9P.M:[H<.8
M )W >"D  (  @ !IS;SG=61=G;C:=8!0U;3/=;A#)K#M=ADT4:V0=GPCD:N(
M=JX/'*S(=B8  )R)?"(  (  @ !IJ+MR?&M=8;=F?!Y0A[-=>^E"\J]W>]XT
M+:P4>_ CDZGR>_@/9ZKB>]@  )MH?Z$  (  @ !I>KHQ@W]=-;8C@MI05K(5
M@DM"M*XK@=<T%*JW@9HCE*B%@9X/J:DP@:X  )IL@    (  @ !I3KD\BKM=
M'K4<B<E01+$ B-Q"GJT-B! S_*F1AY(CG:<ZA\ /YJ>KAK@  )F0@    (
M@ !I*;A_D?Y=%+1'D,A0/[ 8CX)"E*P;CFPS\:B;C>$CIZ8RCD40(J99BND
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M)'Y]B,]_!WY0A_]MY'XKAQU;UGX>ADI(D7XRA9DSLGY"A0T:.7Y9A0P  (
M@ "=1'V0DNZ.)'UED95^"GTZD ]L\GT9CG=:]7T.C/A'UWT9B[$S''TDBMT9
MQWS[BF8  (  @ "<?7RJG&>-67R&FFE]/7Q7F"YL)GPTE>1:-'PND\E'-'PX
MD@HRI7PKD289<7O'CMD  (  @ ";Y7O[I?.,MGO<HU5\CGNGH&MK=WMYG7)9
MB7MQFLE&CWN#F,,R'WMME_D9('K$D/T  (  @ ";?7M_KY^,.7MBK&Y[_'LA
MJ-EJWGKDI3Q8_GK2HAU&&7K@H!HQKWK&G9\8N'GRD+<  (  @ "4T8\,8Y*&
M\HV=9?%W\(QY:"!GGXN):B=6&XJ[;!5#/8HJ;>$N=HHI;T<3R(R;;Q0  (
M>D"4$(TM;'J&*XOW;?YW#HKE;VAFRXGT<,!568DE<@M"D8B3<S\MWXA]=!X3
M8HI]<ZP  (  ?;:3,8M?=4>%'(I-=@YV&(E(=L1EU(AD=W!4?8>?>!I!UX<3
M>+DM28;N>1\3 XA_>)H  (  @ "2+(FX??N$"XBR?B1T\H?!?C5DZH;B?CM3
MJ88N?D=!+H6I?E4LRX5V?E02N8:@?@8  (  @ "1,(A,ALR##X=3AE=S_(9K
MA<-C]862A1U2]839A(% G(1<A PL6X0@@[\2=X3H@X8  (  @ "05X<[C[Z"
M5(9*CK)S0X5@C7=C(H2%C"=2)(/,BO _\H-$B@ KTH+]B9X2'X-GB#H  (
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MSY4?;0)KF9-I;F=<19';;[]+O)![<08YOH^!<B<E>(]V<L@++I$8<D4  (
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M\8[=D_!GO(T[DF)8AHNHD,5(:XI-CV@W%(E"CI@CGHBRCL8*QH@=ATD  (
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M[IU"<R%?G9KT<^91(9C1=*Q!@I;R=6@P1)6Q=?X<-I8%=?L$4I/%=TT  (
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M2Y@&F(-<W96NELM.<Y-AE0P_'I%ED]8N8X_[D](;,(^,D3T$U8P<@T4  (
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MKZ8#>%-3_:,L>)Q&:J!Z>.\WB9XS>4$FW9S<>6P2EYXR>/4  )0P?&,  (
M@ !L**>0?VQ@.*2O?U!3@:'9?RM%XY\F?P0W,9S0?O0FG9MP?O(2DIR&?N,
M )+H@    (  @ !KO::'AO)?V:.EAG=3):#'A>1%A9X+A5 VV)NKA.4F;YHH
MA-42DIL#A+@  )'&@    (  @ !K9*6WCGU?D:+2C:]2WY_GC+)%.IT>B[LV
MAIJ\BQLF.YDEBTH2I9FHB:$  )#;@    (  @ !K)*4/EA!?5*(FE/52G)\S
MDY]$\YQ?DEDV0)GTD;,EZ9AAD;P2@IBMC(,  ) G@    (  @ !J\*2AG>-?
M5J&DG*A2F9Z8FO=$V)NBF58V,YD7F,\E_)=JEN<2JI>IC)X "X^*@ @  (
M@ !AL[A\8(E5]+5\8E))H;*09!@\8:_#9<,MNZV,9R4<DJU$9[@(7*ZD9VL
M )-8<M@  (  @ !A,+>19]M5Q[1/:0))DK$5:C@\;ZX+:V8MY:N?;&0<\*L*
M;+H(\:P);&D  )(7=VX  (  @ !@ZK8+;NQ5=[*_;Y))7:]R<$4\0ZQ1<0<M
MUJG.<:<=%*D%<<D)7*FE<9T  )#A>X   (  @ !@JK1D==A5);$:=AE(_:W0
M=F$\!*JK=KHMJJ@@=PL=%Z<R=P8)J*=Z=S@  (^_?Q8  (  @ !@:++U?-)4
MZ:^L?+](OJQ=?*T[N:DT?)PMCJ:5?*(=&:6.?)D)ZJ6(?1D  ([!@    (
M@ !@+K':@_%4QZZ!@Y=(HZLD@RH[FZ?Q@L$M;Z5(@H,=):00@J *)Z/,@CD
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M G,?<VZ#Y'0.='1R:'3X=69?['7@=E-,1G;'=S8W$7>%=^T=G7>2> <  (
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MBFOCH%=^6&T%G9%M-6X=FKQ;-F]"F"M(,'!2EADST7#4E1\;.F\UD7H  (
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MO'DJ>G)WEWF%>MMG>7GA>SE6$'I.>XY#<7K >]PO"7L;? H59GL=>Z8  (
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MNG./I8IS?7/THI-C5711GX]24W3&G/U ,W4YFVHL;'4SF8P3BW2TC3<  (
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M_8 ;@*-KPG_?@)9<BW^F@&Y,9W][@$DZJ']]@"TFW'^.@! -4G_^?^@  (
M@ "&:'\'B4]Y-G[8B--K GZ;B"-;PGY>AU9+C7XWAI<Y_7XLA@DF47XDA=D-
M#7YZA*,  (  @ "%L7WSDA%X>7W,D09J1WV-C[=;#7U.CE!*W'TIC0\Y9GT6
MC"PE]7SCC#H,ZGTRB)8  (  @ "%(GT=FM5WYWS[F41IL'RWEU]:>7QOE6)*
M27Q&D[(XTWPTDK$E@GOFDDH,RWPGB*8  (  @ "$N'Q_H[%W='Q@H:QI+WP3
MGSA9]GN\G+%)UGN'FJPX=GMKF> E)GL,ER,,BGM?B'H  (  @ !^0Y'Y769Q
MVI"18!ID:8]Q8J95NHZ#90=%OHW#9SDT'XUR:1L?THY6:A<&3HZ9:A0  (
M?,M]>X_H9:AQ*HZP9Z!CLHV9:7]5&8RD:T-%-HO<;.4SM8M];D4?CHPG;N &
M:HOV;O   (  ?]Y\KHW7;=%P.HS%;R-BY(N\<&)43HK0<8Y$BXH-<J,S+HFI
M<X8?-HHC<\P&=XF?="L  (  @ ![R8OM=>EO1(KN=JIAWHGY=U13A8D3=_%#
MUXA=>'LRHX?V>.<>W8A&>.T&?(>2>;\  (  @ !ZZ8I*?@5N>(E8?D1A&8AK
M?F12L(>.?FI#48;+?FTR-H9G?G<>G8:,?F,&C(7&?J\  (  @ !Z(HCZAD1M
MN8@6A?M@7H<JA8=2"X9"A/A"NH5\A'$Q\H3WA" >;H3YA#L&D80\@ML  (
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M9YA'9F]8M):B:$!*X94C:?@[MI/J:X,JKY-N;*L6,)47;)0 +Y"^;K8  (
M@ !P3Y@3;$)DHI9J;8Y8#I3+;LQ*/Y--;_L[-)(1<0DJ5I&"<<H6%9+<<84
M<XYP=#,  (  @ !ODY8Q<^-CT926=*U7*Y,'=65)C9&/=A(ZF9!;=J@IY8_!
M=PD5WI#9=JT HHQK>40  (  @ !NUY2;>Y!C%Y,,>^)6<9&"?!U(T) )?$,Z
M$H[/?&<I=8XQ?'P5G(\.?#H PXJJ?:8  (  @ !N,I-;@UIB?)'6@SY5W)!(
M@OM(.X[*@J$YA(V&@E8I,(R^@C<5=HUD@F@ X(DG@)<  (  @ !MK))/BR=A
M]9#5BJ%55(]%B>1'LXV_B14Y!HQVB'8HSXN=B%$5=8OCB 0! X??@*\  (
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M#*"X:[A-&9Z4;/$_^)R:;AXQ?YL1;QH@T)K!;Y4,?9QL;P8  (I[=Z(  (
M@ !CG:$'<:M8:Y[B<GI,:)S)<SP_=9K1<_4Q$9E(=(T@D)C>=,,,CIH9=%4
M (D4>^4  (  @ !C#I]N>/!7X9U3>5A+WIL[>:T^XYD_>>PPM)>I>B<@39<M
M>C$,CI@!>BH  (?1?YP  (  @ !BD)XL@%97<9P6@&%+=9GX@$@^?)?S@!HP
M599.?_H@)96B?_@,E98>@!$  (:T@    (  @ !B)ITMA[]7&9L8AWE+))CP
MAO@^*);<AF8O^I4RA@X?YI1MAD0,K)1TA0T  (7.@    (  @ !AU9Q>CRM6
MS)I*CIM*TY@<C;X]V)7]C-LOKI1$C'8?BY-^C*\,B9,EB'H  (4A@    (
M@ !AE9O+ELU6OYFNEB1*Q9=LE.\]O94HDZPOJY-*DV<?L9);D>\,OY'LB)\
M (2<@    (  @ !9([&M6F1.&J]27(U"9*T97JHUG*L88)XG+*GC8B,5DZMA
M8F@#1:FV8UH  (CG<?T  (  @ !8<+!G87U-NJWB8QM"(ZMJ9+DU?ZDN9CHG
M.J>]9V 5ZJC/9W #TJ:_:%$  (>@=K(  (  @ !8"*Z2:&A-2JP+:9!!T*F)
M:K0U.*<X:\XG&*6L;)H6"J9S;'P$.:/S;7@  (9G>MT  (  @ !7KJRG;SI,
MWZHF;_U!5Z>H<+DTYZ55<6TFWZ.\<>P6"J1.<:L$A*%<<OP  (5!?HH  (
M@ !74JK]=AQ,BJB"=HI!!*7_=NHTBJ.F=S,FNJ'U=VT6":)==RD$PI\&>.$
M (0^@    (  @ !6_ZFM?2-,4*<J?4I U:2=?4XT7J(W?3\FDJ!T?3,6&Z"7
M?18$_YSO?A8  (->@    (  @ !6NJB@A"U,*:82A!9 N:-U@\<T0:$"@VPF
M=)\T@T<6'9\M@X<%/ILA@GH  (*M@    (  @ !6A:?2BT-,$Z4RBOU JJ*#
MBF<T,I_^B<\F79XAB<H5_YX1B38%39FK@Y8  ((6@    (  @ !68J<TDGY,
M#*1ZDB) IZ&ZD54T+I\CD*0F9YTOD)D6)ISVC>0%:IAP@ZD  (& @    (
M@ "U)F%36;*C_F/170.2-F8O8#=_AFAQ8TQKWFJ?9D97*&RN:25!*FYB:\\G
MZV[:;=T&N72C;L6S*EW.9&&B<6":9JR0U&,V:.9^2V6N:Q!JNF@-;2A6'FI
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MHV[N90]\,7!!9VEKHW&,::%9Y7+1:[Y&YG0';;HR.'3U;V 8TG3);]P  (
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M961FD-AV1F8VCV9F(6?MC>)5#6F2C'U"UFKTBU8O%6MJBJP6G6LCB<<  (
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MO70);'EP>W3C;AU@Y76[;Z)0,G:/<1(^&G==<ETJ"W?M<T40/7D0<LL  (
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MS6M8ED1KE6Q\E(%<76V)DJE,(VZ.D0\ZJF];C_8G@&\GC^P/ '%0BB4  (
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M#GH-<O=DEGIH= 56+GJ[=/=&6WL@==,U%WN'=H@A='O4=M (LGUP=PL  (
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M5W,GFOU@\W.;F1!2DW/REPY#-71)E8$R='1ZE1(?@7.VDM8(+'<*A88  (
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MN8$=>)%9#H#J>2)+78"W>9@\F8"3>?PKZ("I>D(82(#_>A,";H%$>\   (
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MT)-(6?=1KI)57,5$49&57V(U>9$E8; D<I&B8U4/3Y2,8R<  (@):9H  (
M?M1H'9(C7JA='Y$48/U1"9 A8SA#S(]194XU%X[,9Q\D/H\<:%L/:9%M9_H
M (8B;F0  (  @ !G48^V9C=<0([,9_U04(WG::U#'(T;:STTC8R1;)4CXHS"
M;6X/7HZ";.D  (1><Z<  (  @ !F?HUQ;;Q;7HR>;O]/8HO)<"I"98L%<3PS
M[(J <B C;XJ8<IT/-XO/<@X  (*\>)H  (  @ !EKXM]=4Q:EHJ\=A5.FXGQ
M=L)!GHDN=U S9HB?=\@C XBB=_T/#(E3=Y0  (%.?.4  (  @ !D]XGB?/!9
M[HDP?4M. (AG?7M!"8>??8TRWH<$?9DBV8;,?:,/"X<2?;4  ( ;@    (
M@ !D6HB(A(M94H?FA'=-:(<@A"] =H94@] R6H6P@XHB@(58@XD/,X4A@T<
M (  @    (  @ !CWH> C$59#8;OB^5-+X8?BR1 /X4LBCLR+X1GB; B-H0&
MB@$.Y8.@A_(  (  @    (  @ !C?(:QE!E8K88ADWQ,RX5-DE,_X81/D08Q
MXX-SD&XB H+MD"H.VX)=B@L  (  @    (  @ !<X)[Q5=]20IU96)]&P)P(
M6T4Y^9K[7;@KB9I]7[X:29O-8+@&A)Q*800  (.C;4D  (  @ !<!IS=71U1
MK)M97U5&-YGT87DYE9C 8W(K49@490P:4)D19;0&WYC=9>,  ((0<C$  (
M@ !;7YJ%9$-0]9D;9?Q%GY>]9Z(Y!9:$:28JZI7%:E8:)I:':K4'%Y6<:N0
M ("7=Q0  (  @ !:MIA :UI0.);G;)Y$T967;<XX:I1A;N,J:I.?;[$9W90S
M;\X'+I*Q<",  (  >V4  (  @ !:#)9,<H%/DI4$<UM$,).W=!PWQI)\=+<J
M I&K=2T9E)(<=2$',9 J==X  (  ?RX  (  @ !9<Y2W><A/!I-]>D-#L9(N
M>I4W49#I>L,IF) $>M\9<9 M>LP'.XWX>]$  (  @    (  @ !8\)-K@1-.
MEI(^@3M#3)#J@2,V[8^7@.PI+HZE@,X9((ZI@.L'4(P<@.   (  @    (
M@ !8B))<B&!.+Y$ZB#M"YX_FA\0VD(Z&AS8HW(U^AP88MXUSAT<'*XJCA-D
M (  @    (  @ !8-Y&.C^5."9!RCZ-"PX\5CLXV;XV0C=LHXHQ7C<(8^8P(
MC*$'<HE4A0D  (  @    (  @ !0IJIA5$U&8JB85M([3:<-63TN[*7D6VD@
MAJ797/<.EZBC70@  * (8'P  (  <2X  (  @ !/QJB46RI%Q*;,73<ZOZ4>
M7S(NA:/!8/<@6Z-M8BL.QZ6R8@<  )UL914  (  =?@  (  @ !//:938>]%
M+:268XXZ0:+K91@N$:%^9GD@$Z$'9U8.T:+A9PH  )K>:>X  (  >CP  (
M@ !.QZ0+:*=$HZ)9:=XYI*"V:P$MH9]);  ?P)Z_;)$.QJ _;"@  )AW;RL
M (  ??\  (  @ !.2Z(+;W%$*Z!K<$XY,Y[%<1$M*YU,<:0?C)RE<?8.P)W9
M<8X -98 =0D  (  @    (  @ !-UZ!J=F!#RI[3=O XY)TH=U4LZYN>=Y$?
M6)K7=YP.V)NI=UX <9/:>E0  (  @    (  @ !-<Y\3?55#?YV#?:(XJYO/
M?; LMYHW?9X?)IE=?8P.T9GE?;4 L)()?LX  (  @    (  @ !-))X#A%E#
M2IQSA'$X@9JVA#(LF9D(@]\?"I@2@^0.JIAW@WL M9"9@'L  (  @    (
M@ !,\9TIBX]#*)N4BX8X9)G0BP@LAI@0BHX?$Y;SBJ\.V9<>B$0 W8]G@)8
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M=5==>U]Y25IJ>[UI'ET^? I8 E_J?%9%CF(H?*0QK6,;?.49L&-$?.X  (
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MGFM,5R]T\VSP6LQE&VZ07C=4$' C87A!K'&89( M=7*E9PD3T7/&9\<  (
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MTEQJ@@=NHE[R@=]?96%&@:!/)V-G@60]G64+@3LJ364D@2P1YFCW@3L  (
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M-V\P7P-I@7"$8<Y:I7'-9'-*@G,&9NTXX70B:20E"W3(:K8+C7?W:JH  (
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M7F):A\ID#V1,AS15KF8-AH9&/6>8A>LU<&B3A8(BI&>DA8H*RV[/A$,  (
M@ !]"EZ1D.5PLV#4C_9C9&+0CKM5#&24C6M%GV8>C% TU&<*BZ4B+F78B^D*
MLVWJASP  (  @ !\BUU7F9)P,E^HF"!BVV&EEDI4A&-DE&%%*63EDM8T>&6^
MDALAR61BD5$*:VYDAPL  (  @ !X_7GN4OYM!'IB5H]@#7L 6?91UWNP72E"
M1WQH8!\P_WU!8JX<XGYL9",$A(#I9.T  (  >2!WLW9@6TAK]7<H7B]?#G?R
M8.]0_WBX8X5!E'E]9>8P='I'9^H<B'L%:/$$FWXI:;(  (  ?,!V?7,-8Y=J
ML'079=1=_'4)9_-/_'7J:>M N7:_:[@OQ7=];34<$'?+;=8$G'O%;KD  (
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M &E#C+%9>&J6B\U+Y&NPBLX]*&R3B@8LW&S?B;H:*VOVB<P$F7@Z@QP  (
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M3GH$:Z%247J%;2U%2WKW;I@VOWMH;\XF3'O;<*$2.7R/<$@  (  =/X  (
M@ !H8W;5<=-=5'>0<O5177@E<_5$47BB=-$V(WD+=8TER'E@=@,1]7GX=9X
M (  >>(  (  @ !G<W2@><5<<'5X>F)0B'8>>M5#FG:=>R4U?W;_>V0E?7<?
M>Y(1UW>Y>V   (  ?@D  (  @ !FKG+(@;-;RW.]@=M/]G1K@<5#"W3C@8PT
MZ74Y@6,D]W4O@601J77:@8D  (  @    (  @ !F$G%)B9I;-')-B55/8G,!
MB+U"@G-TB 4T9W.[AXLD<G.)AYL12W1JAL$  (  @    (  @ !EF' 6D89:
MOG$HD.I.ZW'@C]M"$W)+CK,T"W)^C@(D+W(ACC81$7,_BO   (  @    (
M@ !@IHQO49A6!XOM5-Q*=XNI5_T]G(N56N0O&HO7764>"(TI7OH)@(YJ7RD
M (  :6D  (  ?G!?CXE26/Y5*XD16[M)JHC>7E4\]8C$8+PNH8CN8L8=R8GY
M8_@)I(JH8_T  (  ;BD  (  @ !>GX9!8&-4+88Q8IA(UX879*\\+X8$9I8N
M!88D:"D=8H;U:/T)HX=1:.L  (  <V0  (  @ !=L(-H9\E3,H-W:7I'U8-Q
M:PT[9X-J;'HM58.);9P<XX0D;A@)AH1G;@P  (  >%L  (  @ !<QH#H;SU2
M3H$2<'%&]($<<84ZBX$5<F\LP($G<RT<9X&.<V,)88'C<XH  (  ?*P  (
M@ !;]'['=L11B'\*=X5&/7\?>!PYW7\7>(XL(W\4>.(<)7\H>/$)6G^T>9D
M (  @    (  @ !;/'SP?CU0UWU/?I)%F7UO?K0Y1WUD?K<KFWU/?KH;T7TD
M?L0)C7W2?S,  (  @    (  @ !:K'MYA<M0='OYA<Y%1GP;A7@Y!GOQA/TK
M;WNVA,,;C7M:A1L)4GQ<@]\  (  @    (  @ !:.WI*C6Q0!7K7C2M$V7K_
MC&TXIWK-BY(K)WIUBT@;8GG9BS()3'LJADD  (  @    (  @ !4I9;<4#U*
MC)7Q4U4_B95/5DHS)I4"6/HDSY5W6Q82[YA26Z@!@I2E78T  (  ;10  (
M@ !3GI/]5S])O)-$6> ^Q9*G7%TRB))$7ILD9Y*(8$\2V)3G8)D!U)$*8FD
M (  <?@  (  @ !2RY$,7C](W)!Y8&<^"H_L8FTQV(^'9#DCY(^O98<2FY&D
M98X"!HW+9V<  (  =N0  (  @ !2 (Y"94!(!HW(9O$]*(U+:($Q+XSI:>$C
M5(T!:M 22HZ3:IT"'XKP;*0  (  >SP  (  @ !1.8O(;%5'1(MI;98\:XKW
M;K4P=(J/;YXBXXJ*<#T1_HN^;^8"+8AX<EH  (  ?P8  (  @ !0@HFK<X!&
MF8EG=%P[THC]=0TOZHB,=8\B:8AH==<1XHD?=8@"1895>$H  (  @    (
M@ !/XH?B>JE&#(>X>RT[6(=4>W4O@(;5>Y<B!(:3>Z81J(;E>XL"<(2"?5<
M (  @    (  @ !/8(9C@<1%B(92@? ZV(7V@=<O#(5P@:<AFX41@:81+X48
M@<,"88,1@74  (  @    (  @ !.^(4TB3-%6H5&B4 ZN83SB+TO$(0XB!0A
M[8.#B!H1Y(,=AR0"UX&T@>P  (  @    (  @ !(6*)Q3E\^WZ$\44(T::!G
M4_8H6: H5DX9PZ%S5[\(HZ,;6&4  )&47^0  (  <'H  (  @ !'1Y_F5/X]
M^)[L5W<S>)X:6<4GCYVO6[P919ZA7-@(IY]S75D  ([<9'X  (  =5$  (
M@ !&FYT-6YT]-)PM7:PRPIMO7XXFVYKY8208PYN]8>H(EYO.8E   (Q#:5$
M (  >:D  (  @ !&!YH\8CH\A)EO8]PQ]IB\958F0)A'9HL81YCM9P8(@)A,
M9U\  (G>;GP  (  ?8   (  @ !%9)>X:.@[W9<,:BDQ7I98:T EJ)72; H7
M^Y9,;$L(=94/;*\  (?&="\  (  @    (  @ !$Q963;[X[2I4*<*<PY)1;
M<5\E3).^<=,7N)0 <= (DI(I<F0  (80>6<  (  @    (  @ !$.Y/"=IPZ
MSY-:=SDP@I*N=Y8D^)(!=[P7:)(>=YD(@H_2>)L  (2R?<H  (  @    (
M@ !#R9)!?9 Z;9'V?>TP,I%/??@DPY"(?=H70I!S?<@(4HWP?G@  (-%@
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M9E!D EK/:*]35EVE:O)!8U_Q;1 MT6"=;MH5L6/@;XH  (  =V*-RDR3:NN
M1U!S;*=Q]50!;E9BM%=2;_)2*5I9<7A :ERO<N<M$UT*=!@5.&&X=',  (
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M'$,,F!9M5D>*E?5>ADN2D_).H$\*DD4]@E%%D1TJX5"MD1,3WUYIC4   (
M@ "('6'L3@QZPV0'4AULL68F5A==FV@Y6>Q-5FHN79$[I&O:8.\G\FR88ZD.
MDW#K9&@  (  <;2&)USY5QMY2%^+6G=K8V'^7;9<>V118--,669R8\,ZS&@I
M9G4G0FB':)0.0VX1:/\  (  =FB$;EAB8$9WM%M;8M]J+5X<96-;7&"C9\5+
M:6+H:@,Z"V2A; TFN622;9D.$VN';<4  (  >HN"NU0P:6EV%U=Y:T)HE5IT
M;0M:%%TP;KI*/U^@<$HY%&%5<;0E^6#(<KT-N&EX<L\  (  ?B.!,E!K<HAT
MJE/T<ZIG05<I=+E8U%H/=;))7%R?=ITX3%Y+=W$E9UV#> D-?FDQ>#H  (
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M!FL-4?QBNFRW5=)486Y868-$QF_=7/LSCW$K8!,?U'&L8CD',W>V8Q   (
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M0EAI><=<L%LK>DY/$5V6>KQ 5%^)>R(P!V!8>X,=3V")>[L&UG1R?.H  (
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MNVYJ61-77V_<7"Y)Z7$V7R$[#7)J8= J4G-:9 ,60W0)9-< SGZD9R$  (
M?(1MEFBG7?=B4FIX8)%6-FPC8Q%(V&V=96DZ)F[=9X@IFF^?:3<5QW!]::T
MX'Z&;"H  (  ?[QL-62T9A=@^&;$:!)4XFB<:?='WFHV:[TY1FN$;4TH\&P1
M;H(576UN;JD \WYE<98  (  @ !JXV$C;D9?N&-F;Z13NV5D<.U&RF<7<A8X
MHVAN<R(H;6C#<^<5&VK)<]H!$WXN=QX  (  @ !IQ5X#=H!>R&!V=U!2YV*6
M=_]%]&1<>) WS66C>1$GV66J>7@4KFB:>6<!$GXP>_0  (  @ !HW%M+?JM=
M[5WC?O12&V ??PQ%-F'R?PLW&V,K?Q,G1V+>?R\4<6:[?V8!)'X3?_H  (
M@ !H)5D#AL!=1%N[AH]1>5X+AA=$H%_CA8DVB6$(A2DFM&!AA284!F54A40!
M,'W^@,X  (  @ !GGE<MCL9<Q5H CC-0]UQ>C39$(EXRC"(V(%\_BVHF9UYA
MBXD3L&0XB?,!#WXU@+@  (  @ !DXWH,35I9W'JX4/A.!WN(5()! WQD5]TR
M='U,6MLAE'Z 70T,S("@77@  (  99T  (  >[1C177"5-]8J';!6 ),_7>Z
M6P5 *GBD7=@QR'F"8%,A''IG8A$,M'RL8CT  (  :D@  (  ?O1A\7&G7(-7
M77+N7Q=+[G0289 _+W4/8]<P^G7F9= @@79X9QX,?'E!9QH  (  ;U8  (
M@ !@L&W59#)6&V]19C1*L'"7:!T^-W&L:=\P'G)^:UD?U7*S;#\,,'98;"
M (  =-$  (  @ !?A&I<:^A5 VP$;5])I&UI;KP]+&Z+;_,O>&]/</D?2V\=
M<8@+_G/0<6X  (  >;(  (  @ !>=F=&<[)4!FD9=*1(OFJ<=70\:FO'=B(N
MSVQT=K ? VO;=OT+]'&9=Q\  (  ?=,  (  @ !=F&23>WA32V:5>_-(&V@S
M?#H[TFE??&(N,VGH?(L>>FD=?*P+UV_"?3T  (  @    (  @ !<YV)*@S)2
MI&1M@T%'?68A@P<[0V=,@K,MJV>S@HH=[&;J@K<+BFY<@GL  (  @    (
M@ !<8F!MBNQ2)F*JBJ5&_V1NB?4ZS&65B2TM2V78B,P=J&4FB2H+66T^AJH
M (  @    (  @ !8\X-<3&!.JX.63]U#A(0$4SXW"H2:5F$HO(6 60(75H>)
M6EP$<8?56Z(  (  :34  (  ?AI7>'].4WQ-A'_55HI">8!@67$V+(#Q7!LH
M$X&Q7DD6\8,S7T,$C80(8&X  (  ;?$  (  @ !62'M:6K-,5'P?74!!>WS)
M7ZHU/GU?8=<G4WX"8Y$6:W[[9"\$BH"V958  (  <R0  (  @ !5*W>B8?5+
M,7B28_U 5GE59>0T6'GW9YHFB'I_:.85TWKX:2\$<WW<:F\  (  >"   (
M@ !4&G0Y:4=**752:LX_578O;#8S8G;0;6PEXG<W;E@51W>$;EX$6GMI;^,
M (  ?'(  (  @ !3)G$L<*M)0W)O<;L^A'-D<J8RH70&<V<E-W0]<^L5!72'
M<],$8GE#==\  (  @    (  @ !246YW> I(<V_G>*D]Q'#V>1HQ]7&6>6LD
MH7&;>9\4HG(F>8 $D'A*>W,  (  @    (  @ !1IFPG?W1'[VW,?[@]6&[W
M?[$QJ&^)?XTD96]2?XD40G Z?[ $7'BB@"<  (  @    (  @ !1)6H_AO)'
M;VP!AND\W&U!AG@Q.6W.A?,D$6UDA=L4$&ZDA;@$47BU@NL  (  @    (
M@ !,[XV@2M=#8(UJ3C8XU8V#46DLO8W_5$0>58]?5E<,@)'=5O8  (F*7#0
M (  ;*T  (  @ !+DXG+491".(GF5(LWM8H75U KQ8I_6;X=F8N86VP,.8T5
M6]8  (9.8-\  (  <8X  (  @ !*A87Z6&=!'(9+6NDVO(:473PJUX;S7SL<
MW(?48(0+Y(B>8+\  (-49;H  (  =H@  (  @ !)C8)47T= %X+(84\UJX,C
M8RLJ 8.!9+\<((0Q9:L+B(2W9<(  ("J:MX  (  >NL  (  @ !(FW[Q9CP_
M)W^/9\XTPG_^:3<I'H!/:E<;E8#!:O@+.X%@:OT  (  <'D  (  ?KX  (
M@ !'NGOB;4P^37RP;G S_GTV;V@H<7U]<"(:^WVF<&P+$WZ&<(<  (  =E4
M (  @    (  @ !&^'DQ=%T]E7HM=1TS7'K+=:<GYGL%=@,:<GKG=A,*U'PV
M=FP  (  >T<  (  @    (  @ !&3W;0>VP\ZW@#>] RO7B\>_@G77CM?  9
M^GB$>_L*;7IO?*T  (  ?W@  (  @    (  @ !%TW3;@KP\AW9$@N R;W<@
M@I\G.G<Y@DL:)'9R@EL*SGBU@@8  (  @    (  @    (  @ ! F9E%2*LW
MLIBM2^4MHYB43M0AJIE143L2>9PR4E,#4IF^5&   (2R7XH  (  < T  (
M@  _-Y6\3P0V5)6.4=DL+)695&(@2Y9 5F81;IBA5R\#"94563\  (&N9$
M (  =0$  (  @  ^09(657@U.I(95^$K'I(^6@(?.I+76Z 0H)3#7!\"TI#/
M7BX  (  :2,  (  >70  (  @  ];XY]6_TT4(Z?7?8J&([57ZD>9X]D8.@/
M_Y#782H"JHT&8SH  (  ;E8  (  ?5@  (  @  \FHL48IHS=(MI9"8I1(NM
M970=F8PB9DL/IXT09F<"F8G%:(<  (  = 0  (  @    (  @  [RX?R:5TR
MIHB':H$HD(CE:VL=!HE":_$//XFD:]8"IH<#;C   (  >3L  (  @    (
M@  [%84I<"DQ](7^<.\G^(9W<7D<C8:_<;0.YX:N<88"EH3%=%,  (  ?9@
M (  @    (  @  Z?(*[=PHQ78//=WPG=H1E=ZX<+H27=Z@.HX1)=Y(";H,"
M>BL  (  @    (  @    (  @  Z#8"J?B<PYX'V?D\G"X*L?C$;XX+,?@$.
MD8)<?BX"B8&(?O\  (  @    (  @    (  @    /__  #__P  __\  &UF
M=#(     ! ,)   !                     0                    $
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MO]/@U0/6)]=,V'/9F]K$V^_=&MY&WW/@H>'/XP+D3>69YN?H-NF&ZMCL*^V
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MHWUZK%._GDA[@T1&F-]\AC5*DQQ]YR=_C-E_MJ'DMRV!C9)WL>B L(+6K+R
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M@A>!YK<2@;.!/Z$H@66 P8KI@2N :W2@@0F .5YS@/Z &4AU@16 'S+@@5J
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MM/^!QW&IKX2!#&/IJ@* FE8FI&. 74B4GIR 33N8F)6 5"]PDC^ C"3-BYV
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MJ]Q[7D*+I-Q\'3;CG8=] "P:E<E^*B+7C<!_AX$0Q&"!L'2'OCN P6?PM^R
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MC&."/Y7[BN&!MH0LB86!2W(+B#N ^5_-AP2 ODW,A=" C#P=A*Z :BM:@Y.
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MCR]ZA%E!C/Y[2TB4BL)\+#A(B(1]0BD'AC5^F:G#ET.!+)I_E-B OHJRDH*
M7GHZD$^ &FERCBE_\UB9C M_Y4@2B>-_XC?^A[I_^2D(A7^ )ZC5EBN)M)F
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MEJZ!M7@-E"V!4VGKD;6 _UMPCTJ P$T#C-V D3\-BF& :#&UA^" 3"6YA52
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M<(*#_IGI<=V#7H?;<SV"P750=+J".V*P=E.!O%!0> N!/#Y!>?N MBT=?#"
M&+J[;9^.>ZGX;QN-!)B-<(N+>H:-<@")Z'0_<Y.(7F',=5&&XD^F=RN%5#W4
M>3Z#J"SO>Y.!PKF2;'684ZC4;?R6 )=O;W63AH5[</J0^7-'<J".;&$!='&+
MW4\0=FN)/SUT>)V&:BS)>PV#0+BF:XBB"Z?H;1:>W):";I*;;(26<!^7W7)X
M<=B436!7<[R0KTZ3=<B,[STF>!6(\2RI>IV$C[?W:M>KF*<T;&>GB)7!;>&C
M'(/4;VV>@G&_<3"9Y5^Y<RJ5.4X@=4F07SSB=Z6+-BR/>D"%K[>&:F&TZ*:S
M:^VO[94I;5RJ?(,R;N"DSW$I<*6?(%\\<JJ98$VV=-J3;#R5=TJ-*2QZ>?6&
MGK+5?2%EI*-U?41H+),Y?8%JB8(<?=!LSW!P?BYO'UZ2?IUQCDSP?R%T(CN-
M?\]W 2L(@+IZ5;'$>PQO2Z)J>VEPSY(;>\=R/H$3?#)SIV^$?*UU'5W*?4!V
MK$Q/?>IX5#LB?L)Z+2KF?]5\3+"<>2AXX:$J>:MY<I$->B1Y^8 ">JMZ?FZ5
M>T1[%%T%>_I[O$NZ?,M\<CK#?<U]/RK(?PE^):]&=WJ"2Y_0>!&"!X^A>*6!
MKG[/>42!46V%>@.! EPG>MV O$L5>]* =SI>?/B ,"JN?E1_VZX$=A6+H9Z/
M=KJ*CHYF=V")7'VD>!*(%VR5>.2&U5M>>>&%G$J#>O6$5CH'?#R"]BJ7?;>!
M:ZSZ=/B4\)V(=:B3#HUF=E:0^'RP=Q:.QFNX=_B,CEJP>06*4DH$>C>(!SF\
M>YN%C"J$?3&"T*PF=!2>'YRQ=,R;:XR/=7V8;'OA=D2516K^=S>2%EH:>%6.
MV$F=>92+?#F >Q.'YRIU?,&$!ZN'<VBG))P)="2CF8O==-.?JWLR=9F;A6I9
M=I:75EF+=\F3%4DW>1F.KCE+>J2* 2IH?&6%$*L?<O*O\9N.<ZZKB8M-=%2F
MHGJ<=1&A=6G2=@^</ED>=TN6]DC;>*V1@CD+>DR+S"I>?!R%[*6+A7QE.Y=_
MA,AGR(B-A$1J+'BV@]YL>VA1@X-NV%>]@S-Q5T=R@O!S_C=R@LQV]"AJ@M1Z
M7*2O@XAN4Y:5@Q)O[X>,@J]Q='?&@EQR]F=^@AATB%<-@>5V-$;J@<%W_#<C
M@<!Y^2AK@>A\/J.P@<!W195H@7!X"89_@2-XNW; @.EY;V:?@+]Z+U9:@*U[
M T9H@*I[YC;;@,U\Y"AK@19^ :*;@!B (Y1(?]^ ((53?ZZ  W7<?X=_XF7:
M?WI_RU7'?X9_OD8%?Z9_M3:F?_%_K"AK@%Y_H*%_?L*([Y-+?I:(+X19?G.'
M273,?EV&2F3Z?F2%354)?I*$6$5]?L^#639??S6"1RAK?[^!&*"6?;*1LY)<
M?9&0,8-Q?76.=G/T?6J,EV0Y?7Z*L51V?;>(QT46?@^&T38H?I.$L2AK?SB"
M99_9?-F:4I&>?,*8#(*U?*>5=G,^?*"2L6.5?,*/X%/U?0J- 43%?6N*"S7^
M?@F&XBAK?L>#AI]*?#2BR)$&?"2?NX(4? :<0W*B>_R8C&,#?"24R%-S?("0
M\D1J?/&- #78?9B(U"AK?FN$>Y[H>\"K#)"1>[.G-(&.>XVBT7(:>WF>'F*-
M>Z&97U,7? 24CD0>?(>/GC6G?4**>2AK?B&%19B=CC%DZ8NIC*YG;'W=BVAI
MT&\ZBD%L*& =B1QND5#>A_EQ($'ZAM=SV3-RA<EVYB7_A-5Z89?HC&IM>8KP
MBR%O&GT0B?)PKFY_B--R15]ZA[QS[U!9AJ]UN4&8A:AWH3-&A+AYQ28A@^!\
M,)<7BK1UWXGUB9)VN7PQB'1WBFVFAVMX7U[#AFMY1D_+A7IZ1$$VA)%[53,=
M@\%\AR8^@P=]W98BB2-^&HCYB!!^1WLFAPQ^7VS9AA!^<5X2A2Y^CT]*A%M^
MN$#F@Y%^ZC+]@N-_)298@DE_9I4UA\N&5X@0ALB%TGI'A=*%*VP"A.6$;EU\
MA R#L4[;@U:# T">@JN"4#+@@A^!DR9N@:: R)1KALF.CX=CA=&-6GF@A-Z+
M[&M)@_:*5ES/@RF(O$Y:@GR'*4!'@>J%CC*Y@7F#U": @1R" )/'A?N6GX:W
MA0V4MGCUA!F2>FJF@S.0"EPW@G&-DTWC@="+&$ (@4.(D#*@@.R%W2:/@*F#
M#)-'A5^>@88RA'F;XGAH@X&8TVH?@I.5?ENY@=22(4UN@4:.O#^X@,:+2C**
M@'B'J2:<@$N#[Y+LA.^F.H7)A ZBY7?O@PV>]VFE@A.:KUM3@4^69$TC@,>2
M%#^#@%F-M3)M@!Z)+2:F@ "$J8PHEP-DK8 >E-!G('-9DM1I@V7?D.AKXU@$
MCNMN5TH9C.%P]CR@BLUSP"^<B+QVWR/,AK=Z8XN.E7ALPG^1DVYN8'+!D7=O
M_659CX=QIE>2C8]S9TG"BY=U3#QGB9AW4R^5AZ%YF20.A;5\(8KFD]ITI'[$
MD?!UB7(0D 9V;V2LCB5W85<%C$!X:TE:BF%YD#PIB'UZS2^-AJ-\,B1(A--]
MNXH>DE=\77WID'Q\GG$GCJ=\U6/VC-1]$E9IBPM]7DCJB49]O#OGAWY^)B^
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MG73KJ5!CZ&I/I>-F/5]@HG)HH50?GM!K'DBYFNYMOCUOEMEPD#*^DI]SC"C
MCDAVV2 BB?AZ8G1UJ#5K(VH0I+ALNE\MH21N;E/_G6IP1$BIF8-R0CUTE7ET
M;C+=D4]VO2D'C0YY3"">B-M\ W05IKQR%&F?HTES#5[9G[5T'%.QF_UU4TAT
MF"-VK3U?E"YX,#+KD!IYSBE"B_9[FR$*A^)]?G.LI3QXT6DGH=1Y/UY7GDQY
MN5-6FJ)Z3T@MEMQ[!3TZDOY[UC+NCP1\O"EPBOU]P2%GAPM^TW- H_9_?&C
MH)=_9UWPG19_3U+MF7)_.D?NE;9_03T4D>]_7C+LC@Y_A2F6BB1_OB&UAE5_
M_W+AHON&'FANGZ"%A5VCG!V$SU*CF'F$#D>OE,*#6CSXD/^"N#+LC3."("FT
MB6B!CB'WA;R!!'*2HC>,CV@OGMN+=5UJFU**'%)HEZJ(ID=VD_J'.CS9D$&%
MV3+TC':$@RG2B,:#*B(MA3V!X7)9H9F2Q6?[GCR1(ETRFJ^/)%(QEP*,]D=$
MDU2*SSRICZN(KS+EB^2&H2GPB#^$D")9A->"F7(KH3"8U6?]G<B6O5TOFB:4
M!%(<EF"0_$<[DJ:.##RTCP.+-#+VBUZ(=2H$A]J%N2)\A(6#+VH)LM=C:E_\
MKNAEJ57AJKEH#4NPIB1JFT& H2MM6#>)F^AP32X]EG1S:R6]D-EVTQZ@BUQZ
M8&F8L?)J0%_7K=)KRU76J6EMB4NZI+%O>$&<GZYQFS>YFG1S\RZ%E0]V<"8H
MCXUY*!\VBC![]6E;L(1PPE^3K&#_XO__24-#7U!23T9)3$4  @EQNU6LI_)R
MVTN9HS5T-T&2GCQUP3?+F15W>BZXD\=Y42:"CF-[5A^WB2M]9&DDKOEW"%]/
MJMMW@U5?IG9X&DMKH<AXWT%VG.%YT#?-E])ZXR[=DI]\#B;,C5Q]6R GB$M^
MJFCJK:)].5\<J8M]054MI2E]5$LTH(%]=T%DFZA]Q#?.EK!^+B[\D9=^IR<+
MC'9_-B"%AXU_RFBWK)F#8U\ J'J"^547I!6">TL>GV^!_D%/FI^!ES?4E;"!
M3"\9D+"!$R=!B[" YB#3ANZ PFB.J\J)6U[QIYZ(?E4.HS"':DL2GHN&14%#
MF<2%,3?7E.*$,2\WC^F#1"=RBPF"8B$4AFN!DVANJR^/&U[OIO"-R54/HG6,
M&TL-G<J*14$XF0B(@3?-E#F&T"]!CT^%-R>8BG^#JR%(A@&"06A:JKZ4H5[V
MIF*2V547H=B0B$L/G2>-_4$\F&>+@S?;DZ.))"],CLV&WR>JBA2$MB%RA:V"
MS<+/: Y@X+%*:DYCOY]1;'EFC(S";IEI37G#<,-L$V:6<PAN\%.?=7)Q\D#H
M>"!U/"\(>RQY L#N945K?Z_39\AM19X&:BIO!XN?;(!PS'B\;N-RFF6N<61T
M?U+8= IV?$!5=O5XL2[!>CU[.;\I8MAV!*XB989VMYR5:!AW;(I%:IMX-G>/
M;3!Y$&2Q;^9Y_%(1<L1Z]S_,=>=\$2Z!>65]4[UI8+" 6:QJ8X. #IKJ9C9_
MS(C=:.-_EG92:ZE_>6.N;I!_9U%.<:%_63]+=/A_4RY*>*5_3+O/7MF*C*KF
M8<F)69EQ9)N()8=V9V:&]'4O:D^%SF*\;6:$NU";<*6#G3[9="B";RX:=_Z!
M'+J!75Z4JZFI8&.2EYA#8TB0;(969BN..W0I:3",#V'H;&2)YT_^;\R'M3YT
M<W>%6RWR=VZ"O[EW7"V>IJBN7T&;KI=-8C"8B85K92.54W-3:$&2(6$W:Y&.
MYT]\;Q2+DCXC<N&("RW0=O:$,+BQ6T2H;J?P7F&DC):+85.@:(2J9$R<)7*;
M9WN7YV"8:N63GT\';H*/+3W<<F:*=BVU=I*%;;@S6J2QZJ=P7<*M"Y7[8*ZG
MW(028Z2BC7(-9MB=0V @:E*7ZTZ?;@*28CV1<?Z,CBV?=D*&=[5^;ZY@7J6C
M<29C8Y46<IUF0H/'=!AI"W'U=:-KVE_T=TENQ4XQ>1%QV#RX>Q9U."PM?7!Y
M%[08;1-J>:24;LYL<)09<'1N4H+><AAP+W$?<\]R%5\[=:AT%$V>=Z=V,CQ4
M>>EXB2P$?'Y[-K*9:K]T;J+\;*9U9I*M;G1V5(&)<$5W1F_\<BMX1EY*=#AY
M6DSB=FMZ?SO;>.![Q2O@>Z9]-K$,:*]^-*%L:K9^1I$H;*9^3(!&;IE^46[?
M<+!^95UE<NI^ADPZ=4U^K3MS=_1^WRO >N9_%*^;9NJ'X: -:0R'&H_2:QF&
M/'[_;2J%4FW>;U^$;ER/<<>#F$N@=%6"NCL7=R:!SRNE>D" R:YO97Z1?Y[J
M9[*/X(Z\:=&.&'WX:_F,.FSP;DB*6UO5<,J(?DL9<X"&F3K&=G>$CRN.>;*"
M4:V!9%B:^9X!9IJ8?XW7:,*5QWT?:OF2\&PL;6&0%ELW;_Z--$JL<LJ*.CJ&
M=>.'$RM[>3N#J*S08WBD0)U/9<"@YXT=9^R=.7QH:BB98&N ;*"5A5JA;UB1
MGTI"<CV-F#I.=6F)5"MK>-F$SJQ?8MZM/YS092:H_HR-9TJD4GO2:8.?<FKX
M; *:DUHT;L>5ITGC<<*0E#H*=0>+02M?>(J%PZB'=XA@!IHN>#!C&XKX>.]F
M WKB><)HT6H_>J9KIUEM>Z-NGDCE?+UQP#BP?@UU-2E]?Z1Y*:=J=1%IA)D?
M=?YKGHG<=NAMGGGA=]]OE&E>>.QQE5BS>A9SLDA6>V!U[3A:?.1X92ER?JU[
M,:8X<M-R[9?;<_%T'(C4=0)U.WC;=AUV4VA_=TYW>5@!>*5XM4?8>A]Z!3@2
M>]=[>"EH?=)]&:3:<--\*I9]<A%\B(=F<T-\SG>M='Y]"F=T==]]45<K=V-]
MI$<]>0I^ 3>[>NY^:BE@?1!^W:.2;R.%3I4]<'B$XH8Q<<6$4W:)<QN#KF:4
M=):#"U9R=D6"<D:[>!2!UC=T>B&!,"E9?&F >**%;<>.9Y0W;RV-+X4V<(F+
MPW6=<?6*-F7 <XB(I572=4V'$T9+=T"%?#<W>7*#Q2E3>]J!YJ&O;*V76Y-A
M;B"5581E;X63!737</Z0C&4.<JB."U5%=(6+@47P=HR(Y#<(>-Z&'BE.>V.#
M):$/:]2@'9*[;4^=1(.X;K>:"W0P<#26G&1Q<>V3)52\<^2/HT62=@*,!C;=
M>&2(-2E*>P&$-J"E:SRHG))";+FD[8,M;AN@PW.C;Y6<5V/U<5.7YE1;<U>3
M:$4^=8J.RS:C> 2)_"E'>K.%%YOH?YU?T8[#?WIBXX"^?X-ES'':?ZEHGV)M
M?]YK?E+6@"1N@4.7@']QL32Y@09U-R;X@<1Y-YKZ?4=HOXW3?6MJZ7^_?9]L
M^G#S?>)O!6&F?CAQ'E(W?J5S5$,C?RIUJS2 ?]YX02<,@,9[*IGP>R9QAXRD
M>WMRX'Z\>\YT)F_Z?#)U9V#9?*MVM%&8?4%X%D*X??%YCS1.?M)[+B<=?^5\
M^YC/>39Z/XMW>:UZTWV,>B%[3&\8>I][P6 4>S]\.5$%>_Q\P$):?-5]4C0E
M?>-]]2<L?Q]^II>O=YB"W8I\>"6"NGR2>+&";FX0>4B""5]*>@"!IE!=>N:!
M3$'F>^6 \3/N?1> DB<Y?G6 *9:_=DZ+;XF+=NJ*C7NJ=X.)<6TY>"N(,EZ*
M>/B&[$_2>?&%IT&(>Q&$7C/!?&:"_"=#?>2!@)7_=4&3V(C,=>J2-7KQ=HJ0
M16R*=SZ.)EWM>!Z+_4]8>2R)S$%">ER'C3.C>]"%*R=,?6R"J95L='&<#X@U
M=2.9J7I5=<66WFOV=GN3UUUC=VB0Q4[>>(^-ID#P>=**=C.%>U6'&R=3?0F#
MI94&<]JD!H?!=)*@WGG4=3"=,6MV=>*9.ESV=M*5.$Z+> 21*D"I>5R-!C-7
M>O>(O2=9?+J$=8^7A^]?J8-WAQ%BKW:(AFEEEFC-A=MH;UJ8A5)K6$Q%A,]N
M:3Y;A%=QIC#E@_UU/"2E@\MY0H[+A<EH$(*RA2YJ0'6XA*9L7F@6A"QN>UG_
M@[IPJDO1@UAR^CX/@P-U;##0@M%X("36@L-[(8WI@\!P48&L@U9QP'35@NMS
M(6<\@HUT@5E-@CMU\4M+@?UW>3VZ@<]Y&C"V@<1ZY24!@=I\W(SM@>]X<("B
M@9YY+G/!@5!YV&9J@0AZ>5B8@-I[)4K&@,%[WCUI@+A\IC"<@-1]@R4G@0Y^
M<HOZ@%" @7^[@!F E'+E?^* A665?[. 7E@<?Y2 .TIM?Z" (3TY?[R "C"3
M?_]_]25&@%]_WXLH?QF(CW\&?O*']7(Z?L.'(V3I?IN&*U=L?I&%+DGP?JZ$
M.#SF?NB#0#!S?TR"-B5A?\N!((I_?AJ0;GY:??^/)7&4?=2-BV1.?;6+P5;=
M?;N)[DF#?>F(%SRP?C&&.3!C?K*$/R5W?U""-8GZ?528%GW5?4*6''$.?1B3
MN&/0?/B1$E9H?0B.8DD9?4R+JCQM?:2(ZC!5?C2&"26)?NR#'HF8?,.?A'UL
M?+:<W'"<?(B9I6-@?&.6'%8,?'.2B$C6?,&.[CPW?2V+2# W?=2'BB67?IR#
MWH.ED)Q?<WA:CPIB8VQGC:ME1E_+C%IH*5+0BOUK(47(B9IN1#D[B#=QE"T\
MAN5U/B*)A:]Y2X+MCJUG6'>\C4]IA&O'C %KK5]%BKAMWU)EB6MP)T5_B"1R
ME#D7AM]U)BU*A;!W_2+6A)M[%X(QC+YO%7;EBXMPD&L3BE1R"5Z;B2%SB5'@
MA^]U'D4BALAVSSCHA:9XG2U0A)MZFB,:@ZA\OX%@BO9VKG8(B=MWB&HOB+YX
M5EWTAZ!Y)U%4AH]Z D3$A8IZ\3BYA(Q[\BU3@Z9]$"-5@M5^08"3B7%^,'51
MB&A^<FF#AUQ^F5U"AE)^KE#MA4U^QT1ZA&M^\CB7@XY_(BU:@LQ_7".'@B!_
MF7_>B#F%K72FAT.%3&CAAC^$O5RZA3B$#5!YA$*#6$1+@VB"M3A_@JR"&"U=
M@@^!<B.P@8B QW],AT:-!70UAEZ,"FAWA5J*OUP_A$^)0$_]@V>'P4/I@J&&
M3CA:@>^$WRU:@7&#5R/3@0J!RG[8AHR4)W/!A:N2D&@"A*60A5O4@Y>.-$^<
M@K.+YD.+@@&)GC@@@5Z'7BU9@.Z% 2/O@*."HWY_A@&;%'-EA2*8Y&>?A!>6
M$EMU@P.2YD]/@AR/P4-7@7&,I3@#@.")CRU3@(B&9B0%@%&#57@SF69?*6V_
MES)B"&+!E2%DZ5<ZDP5GUDMOD,1JWC^OCFQN%S1]C AQ?2GIB:IU/2"JAVAY
M4'>.E[AFGVU&E:5HQ6).DY!J]U;BD6UM/$LRCS-OGS^0C/%R+#1^BJ=TWRH7
MB&EWVB$2AD9[#7;WE>%MX6R9D^]O96'"D>MP\%9@C]9RD4K3C;-T2C]8BXYV
M*#1RB65X(RH\ATIZ4R%MA4A\I'9.E"!T^6OBDD%UZ6$"D%1VV%72CE9WTTIA
MC%%XX#\2BDMZ!S19B$1[0RI5ADQ\HR&[A&U^$W6FDJ=\ &M D-E\86!ECOE\
MLU4[C0=\_4G_BQ1]5S[-B2]]Q#0\AT9^/2IFA6Y^R"'^@[%_6G43D7Z"_&JY
MC[Z"SU_IC>.">U3%B_:"$$F9B@Z!JCZBB"^!530KAF2!"RIUA*Z P"(U@Q2
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MD--[[CE^C=I\I3 YBM5]:B>]A]Y^12"IA1-_(FK*FM: 2V$]F$R 4E=8E9*
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M[S5I?X1_]2M5?]U__"*U@$V  W:G?FB'(FQA?G.&M&&-?EN& %90?CR%(DL
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ME\]^)TC\E1U^44#9DB%^<3C?CPQ^J3%"B_I^^RI<B/A_8"0BACY_PA\F@]F
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M9UY_I&S,:<)_MV!D;#=_LE/#;ME_KD<<<;=_MSKV=,I_RR]P>!M_Y25/>WV
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M;9.$16-\;UJ#V5@J<2R#2TRO<RF"P$%/=5R"0#:-=[*!R"QB>DB!3".>?.&
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M6V9Z2U-]83][/$439UM\/S=$;=-]:BKC=&I^O9DJ0NZ =HP92*^ 97YX3D"
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M=@A^A22">F]_8WI(6 Z!CF_E6_"!D&4#7\*!:%FI8ZB!+4X<9\" ^T*B;!:
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M<@=_QTQG<]%_QD09=7-_LCO'=QQ_NS.F>.Q_W2Q">L& %"6/?+R 0" /?J2
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M>/:"%T2@>A^!OSUQ>NV!6#95>Z.!&B]H?'R ^"DG?6. Z".*?GZ SA\(?YB
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M  #__P  ;69T,0     #!"$   $                    !
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M_Z,X*O^@14#_H$Q4^Z1+8_&H2W/FJTR#W:U0D=2L6)[,JF*IQZILL<2J=K;
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M14#_H4I3^Z9(8O*K2''HKTB W[-*CM:U49K0MEJDS+AEJ\J]<:[!N7NVM[*
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MD*B$SHBFAM&"I(S3@*22TX"DDM. I)+3@*22TX"DDM. I)+3@*22TX"DDM.
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M@*Z,Q8"NC,6 KHS%@*Z,Q8"NC,6 KHS%@*Z,Q8"NC,6 KHS%@*Z,Q8"NC,6
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MP+!ZL,"P>K# L'JPP+!ZL,"P>K# L'JPP+!ZL,"P>K# L'JPP+!ZL,"P>K#
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M=F)4]7=C4_5Y8U/T?&12]'YD4?2 95'T@&51](!E4?2 95'T@&51](!E4?2
M95'T@&51](!E4?2 95'T@&51](!E_Y8S%/^50R7_DE$W_Y=31?^95U/]F5M@
M]9AA;>V5:'GEDG*$WX]\CMJ,A9;5AXN<T8.0H<^ E:;-?9JIRWN>J\IYH:W)
M=Z6OR'6IL,=TKK''<[.RQG.ZLL%UN[+!=;NRP76[LL%UN[+!=;NRP76[LL%U
MN[+!=;NRP76[LL%UN[+!=;NR_Y8S%/^50R7_DE$W_Y=31?^95U/]F5M@]9AA
M;>V5:'GEDG*$WX]\CMJ,A9;5AXN<T8.0H<^ E:;-?9JIRWN>J\IYH:W)=Z6O
MR'6IL,=TKK''<[.RQG.ZLL%UN[+!=;NRP76[LL%UN[+!=;NRP76[LL%UN[+!
M=;NRP76[LL%UN[+!=;NR_Y8S%/^50R7_DE$W_Y=31?^95U/]F5M@]9AA;>V5
M:'GEDG*$WX]\CMJ,A9;5AXN<T8.0H<^ E:;-?9JIRWN>J\IYH:W)=Z6OR'6I
ML,=TKK''<[.RQG.ZLL%UN[+!=;NRP76[LL%UN[+!=;NRP76[LL%UN[+!=;NR
MP76[LL%UN[+!=;NR_Y8S%/^50R7_DE$W_Y=31?^95U/]F5M@]9AA;>V5:'GE
MDG*$WX]\CMJ,A9;5AXN<T8.0H<^ E:;-?9JIRWN>J\IYH:W)=Z6OR'6IL,=T
MKK''<[.RQG.ZLL%UN[+!=;NRP76[LL%UN[+!=;NRP76[LL%UN[+!=;NRP76[
MLL%UN[+!=;NR_Y8S%/^50R7_DE$W_Y=31?^95U/]F5M@]9AA;>V5:'GEDG*$
MWX]\CMJ,A9;5AXN<T8.0H<^ E:;-?9JIRWN>J\IYH:W)=Z6OR'6IL,=TKK''
M<[.RQG.ZLL%UN[+!=;NRP76[LL%UN[+!=;NRP76[LL%UN[+!=;NRP76[LL%U
MN[+!=;NR_Y8S%/^50R7_DE$W_Y=31?^95U/]F5M@]9AA;>V5:'GEDG*$WX]\
MCMJ,A9;5AXN<T8.0H<^ E:;-?9JIRWN>J\IYH:W)=Z6OR'6IL,=TKK''<[.R
MQG.ZLL%UN[+!=;NRP76[LL%UN[+!=;NRP76[LL%UN[+!=;NRP76[LL%UN[+!
M=;NR_Y8S%/^50R7_DU$W_Y=31?^95E+]F5M@]9A@;>V69WGEDW&$WY![CMJ-
MA);5B(J<T820HL^ E:;,?9FIRWN=K,EYH:[(=Z6OR':JL<=TKK+'<[2RQ'2Z
MLK]UNK*_=;JROW6ZLK]UNK*_=;JROW6ZLK]UNK*_=;JROW6ZLK]UNK*_=;JR
M_Y8S%/^60R7_E5 W_YE11/^;5%+^G%A?]9M=;.V99'CFEFR#WY-VC=J/@);4
MC(B=T8>.H\V#DZC+@)BKR7V<KLAZH;'&>*6RQG>JM,5UL+7%=+BUO7>XM;AW
MN+6X=[BUN'>XM;AWN+6X=[BUN'>XM;AWN+6X=[BUN'>XM;AWN+6X=[BU_Y<S
M%/^60R7_EDXW_YI/1/^=4E'^GE5>]IY::NZ<8';GFF>"X)9RC-J2>Y74CH2=
MT(J+H\V&D:G*@I:MR'Z;L,9[H+/%>::UQ'>LML-VL[>^=[>WMWBVN+)YMKBR
M>;:XLGFVN+)YMKBR>;:XLGFVN+)YMKBR>;:XLGFVN+)YMKBR>;:X_Y@S%/^7
M0R7_ETTW_YM-0_^?4%#_H%-=]Z!8:>^?777HG62 X9INB]N6=Y35D8"<T(Z)
MH\R)CZG)A)6NQX":LL5]H+7#>J>WPGBNN<!WM;FX>+6YL7FUN:QZM;FL>K6Y
MK'JUN:QZM;FL>K6YK'JUN:QZM;FL>K6YK'JUN:QZM;FL>K6Y_Y@S%/^80R7_
MF$PV_YQ,0_^@3D__HE%<^*-5:/"B6W3IH6%_XIYJB=R:<Y/6E7R;T9&%H\R,
MC*G)AY.OQH*9L\-^H+?">JBYP7BQN[EXL[RQ>;.[JWJTNZ=[M;JG>[6ZIWNU
MNJ=[M;JG>[6ZIWNUNJ=[M;JG>[6ZIWNUNJ=[M;JG>[6Z_YDS%/^80R7_F4LV
M_YY+0O^A3$[_I$];^:539O&E6'+JI%Y]XZ)FA]V><)'7F7B9TI6!H<V/B:G)
MBI&OQ8.8M,)_G[B]?*>[NGJPO;)ZLKZK>[*]IGRSO*-]M+JC?;2ZHWVTNJ-]
MM+JC?;2ZHWVTNJ-]M+JC?;2ZHWVTNJ-]M+JC?;2Z_YDS%/^80R;_F4HV_Y]*
M0O^C2T[_IDY9^JA19?*H5G#KJ%Q[Y:=BA=^C;([9GW67TYI^G\V3AJC%C8VO
MOX>4M;F#G+FU?Z.\L7VLOJQ\L;^E?+&_H7ZSO9Y^M+N>?K2[GGZTNYY^M+N>
M?K2[GGZTNYY^M+N>?K2[GGZTNYY^M+N>?K2[_YDS%/^90R;_FDDU_Z!(0?^D
M24W_ITQ8^JI09/.K5&[MK%IYYJQ@@N"J:8O:IG.4SY]\G<:7@ZB^D(JPN(N1
MMK*&F+JM@Z"]J8&HOZ6 L,"??[# G("RO9J!L[N:@;.[FH&SNYJ!L[N:@;.[
MFH&SNYJ!L[N:@;.[FH&SNYJ!L[N:@;.[_YHS%/^90R;_FT@U_Z%'0?^E2$S_
MJ4I7^ZQ.8O6O4FSNL%AVZ+%>?]^P:(C5K'20RJ-ZG<";@:BXE(>PL8^.MJN*
ME;NFAYV^HH6EP)^$K\&9@:_!EX*ROI6#L[R5@[.\E8.SO)6#L[R5@[.\E8.S
MO)6#L[R5@[.\E8.SO)6#L[R5@[.\_YHS%/^90R;_G$<U_Z)&0/^G1TO_JTE6
M_:],8/:R46KNM%=SY;=>?-VV:H//KW*0Q:9XG;N>?J>RF(6PJY.+MJ6.D[N?
MBYJ^FXFBP9B(K,*3A:_"DH:QOY&&L[R1AK.\D8:SO)&&L[R1AK.\D8:SO)&&
ML[R1AK.\D8:SO)&&L[R1AK.\_YHS%/^90B;_G$8T_Z-%0/^H14K_K4=5_K%*
M7_6U4&CKN59PX[U>=]F[:H#+LG"0P*EVG;:B?*>MG(*OI9>)MIZ3D+N9CYB^
ME(V@P9&,J<*-BJ["C8FQOXV)LKV-B;*]C8FRO8V)LKV-B;*]C8FRO8V)LKV-
MB;*]C8FRO8V)LKV-B;*]_YLS%/^:0B;_G44T_Z1$/_^J1$G_KT53_+1)7?*Y
M3V7IOE9LX<-@<M.^:8#&M6Z/NZUTG+"F>J>GH("OGYN&M9B7CKN3E96^CI*=
MP8J2I\*(D*["B(ZPP(B-LKV(C;*]B(VRO8B-LKV(C;*]B(VRO8B-LKV(C;*]
MB(VRO8B-LKV(C;*]_YLS%/^:0B;_GD0S_Z5"/O^K0DC_L412^K=(6O"]3F'F
MQ%9GWLEB;<[!9W_!N6V.MK%RFZNJ>*:BI7ZNF:"$M9*=B[J,FI.^AYB;P(27
MI,*"EJ_"@Y.PP(21LKZ$D;*^A)&ROH21LKZ$D;*^A)&ROH21LKZ$D;*^A)&R
MOH21LKZ$D;*^_YLS%/^:02;_GT(S_Z9 /?^M0$?_M$)/][M'5^W#35WDS%A@
MV<U@;,G%9GZ\O6N-L+5QFJ6O=J6<JGRMDZ:"M(RBB;F&H)"]@9Z9OWV>HL%[
MGJ_!?9FPP'^6LKY_EK*^?Y:ROG^6LKY_EK*^?Y:ROG^6LKY_EK*^?Y:ROG^6
MLKY_EK*^_YPS%/^:02;_H$$R_Z@_//^P/D7_MT%-],!%4^K)3E;BU5I7TM%>
M:\3)9'VVP6J,JKMOF9^U=*26L'JLC:R LH:IA[=_IXZ[>J:6OG>EH+]TIJV_
M=Z&QOWJ=LKYZG;*^>IVROGJ=LKYZG;*^>IVROGJ=LKYZG;*^>IVROGJ=LKYZ
MG;*^_YTS%/^;02;_HC\Q_ZH\.O^S/$+[NSY)\,9$3>;23TW<W%=6S-5=:K[-
M8WNPQVB+I,%MEYF\<Z*/N'BJAK1^L'^RA;5YL(RX=*^5NW&NG[QNKZN]<:JS
MO'2EL[QTI;.\=*6SO'2EL[QTI;.\=*6SO'2EL[QTI;.\=*6SO'2EL[QTI;.\
M_YTS%/^;0";_I#PP_ZTY./^V.3_UP3Q#Z<Y$1-[=34?2X%-8Q=M<:+?387JI
MS6:)G,AKE9'$<9^(P':G?[U]K7B[A+%SNHNT;[B4MVRWG;AJMZBY:;:VN&VO
MM;EMK[6Y;:^UN6VOM;EMK[6Y;:^UN6VOM;EMK[6Y;:^UN6VOM;EMK[6Y_YXR
M%/^=/B7_ISDN_[$V-?N\-CKMR3H\X-I$.M+B1TS'XDU>N=Y4;JS96WR?U&*(
ME-!HDXK,;YN"QW>B?,-^J'; A*QROHJO;[R1L6V\F+)KNZ&S:KNMLF>ZMK1G
MNK:T9[JVM&>ZMK1GNK:T9[JVM&>ZMK1GNK:T9[JVM&>ZMK1GNK:T_Y\R%/^@
M.B3_JC0L_[4R,?/#,C/CU#@PT^$\/\;H0E*YY4ACK.)-<I_?5'^3V5V*B=)G
MDX/-<)I]R7>?>,9]I'3$@Z=PPHBI;L&.JVS E*QJOYNM:;^EK6B_KJUHOZZM
M:+^NK6B_KJUHOZZM:+^NK6B_KJUHOZZM:+^NK6B_KJUHOZZM_Z P%/^C-B+_
MKS H^[PM*^C-+"C5X# PQ^DX1+GL/E>LZ45GGN=+=9+@4X")V5Z)@M1HD7S0
M<99XS'>;=,I]GG#(@J%NQX>C:\6+I6G$D*9HQ):G9L.>J&7#I:AEPZ6H9<.E
MJ&7#I:AEPZ6H9<.EJ&7#I:AEPZ6H9<.EJ&7#I:AEPZ6H_Z$O%/^H+Q__M2HB
M\,8D(=C=(R#(Z2TUNO(U2:SQ/%J>\$-IDNA,=8CA57^!VV&'>]=JC7;3<9%R
MT7>5;\]\EVS-@)IJS(6;:,N)G6;*C9YER9*?8\F8H&+(GJ%BR)ZA8LB>H6+(
MGJ%BR)ZA8LB>H6+(GJ%BR)ZA8LB>H6+(GJ%BR)ZA_Z,M%/^N*1KXOR :WM88
M$\GH(B6Z]"LZK/@T39[W/%R2\49IB.E0<W_C67MZWV2"=-QKAG#9<8IMUG:-
M:M5[CVC3?Y%FTH.29-&'E&/1BI5AT(^68,^4EU[/F9A>SYF87L^9F%[/F9A>
MSYF87L^9F%[/F9A>SYF87L^9F%[/F9A>SYF8_Z<H$O^W'Q+FSA$-R^85%KOT
M(2JL_BL^GO\T3I+Z/UR(\DIF?^Q5;WGH7G5RY&1[;N%K?FK?<(%HWG6$9=QY
MA6/;?8=BVH&(8-J$B5_9AXI=V(N+7->0C%O6E(U;UI2-6]:4C5O6E(U;UI2-
M6]:4C5O6E(U;UI2-6]:4C5O6E(U;UI2-_[ >"^W&#@C-VPL(N_,5&JS_(2Z>
M_RP_DO\W38?]1%A_]D]A>/%9:''M7VUJZV1Q9^AJ=&3G;W=BY71Y8.1X>E_C
M>WM=XWY\7.*!?5OAA'Y:X8A_6>",@%C@CX%8X(^!6."/@5C@CX%8X(^!6."/
M@5C@CX%8X(^!6."/@5C@CX%8X(^!\[T-!,S/"0&]Y0P,K/\7'I[_)"^2_R\]
MA_\]27__25)X_%1:</A:7VGT7V1D\F5G8?!J:5[O;FM<[G)M6^UV;EKL>6]8
M['QP5^M^<%;K@7%5ZH1R5.J(<U/IBW13Z8MT4^F+=%/IBW13Z8MT4^F+=%/I
MBW13Z8MT4^F+=%/IBW13Z8MTS,8( +W4" .M]0X/G_\:'Y/_)RV(_S0Y?O]"
M0W?_34IN_U-09_]956+\7EA>^V1;6_EH75GX;%Y7]W!@5O=S857V=F)4]7AB
M4_5[8U+T?611](!D4/.#94_SAF9/\X9F3_.&9D_SAF9/\X9F3_.&9D_SAF9/
M\X9F3_.&9D_SAF9/\X9FO<L& *[;!@2?_Q 0D_\='8C_*BA^_S@R=O]$.FW_
M2T%E_U%&7_]725O_74Q8_V).5?]F4%/_:E%2_VU24/]P4T__<E1._W543?]W
M54W_>55,_GM62_Y^5TK]@5=*_8%72OV!5TK]@5=*_8%72OV!5TK]@5=*_8%7
M2OV!5TK]@5=*_8%7_XTM#O^,/AW_BDPN_Y)3._^45TC_E5Q4_9-B8/61:FOO
MC7)VZ8E\?^2%A(;@@(N-W'R1DMIYEY;8=IR9U7.@F]1QI9W3;ZF?TFZNH-)M
MLZ'1;+FBT6O H\ULQ:/(;L:BR&[&HLANQJ+(;L:BR&[&HLANQJ+(;L:BR&[&
MHLANQJ+(;L:B_XTM#O^,/AW_BDPN_Y)3._^45TC_E5Q4_9-B8/61:FOOC7)V
MZ8E\?^2%A(;@@(N-W'R1DMIYEY;8=IR9U7.@F]1QI9W3;ZF?TFZNH-)MLZ'1
M;+FBT6O H\ULQ:/(;L:BR&[&HLANQJ+(;L:BR&[&HLANQJ+(;L:BR&[&HLAN
MQJ+(;L:B_XTM#O^,/AW_BDPN_Y)3._^45TC_E5Q4_9-B8/61:FOOC7)VZ8E\
M?^2%A(;@@(N-W'R1DMIYEY;8=IR9U7.@F]1QI9W3;ZF?TFZNH-)MLZ'1;+FB
MT6O H\ULQ:/(;L:BR&[&HLANQJ+(;L:BR&[&HLANQJ+(;L:BR&[&HLANQJ+(
M;L:B_XTM#O^,/AW_BDPN_Y)3._^45TC_E5Q4_9-B8/61:FOOC7)VZ8E\?^2%
MA(;@@(N-W'R1DMIYEY;8=IR9U7.@F]1QI9W3;ZF?TFZNH-)MLZ'1;+FBT6O
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MDIK4>YB>TG>>H=!TI*3.<JJFS7"QJ,UON:G+;\&IPW'!J;QRP*JW<\"JMW/
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M0$A]_TM1=?U46&WY6EUG]F!B8_-F95_R:V=<\'!I6N]T:UCN>&Q7[7QN5>R
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M/C;_E3XV_Y4^-O^5/C;_E3XV_Y4^-O^5/C;_E3XV_Y4^JL0  )S2  "/YP(
MAO\1 GS_&P5Q_R0+:/\K$5__,A=7_SD;4?\_'DS_1B%(_TTC1?]2)4+_5R=
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M,:#,4C^5R5E,B\5@5X+#9F!ZP&QG<[YS;6R\>G-GNX)W8KJ*>UZYE'Y:N)^
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M5CS^S58\_LY6//[.5CS^SE8\_LY6//[.5CS^SE8\_LY6SK " +VZ! "QQP0
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MC(*6?(B GX"$?ZJ"@7^W@X!_R(1_@-V#?W_>@7]_WX" ?N!_@'[@?X!^X'^
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M8DK.\F5+R/)F2\CR9DO(\F9+R/)F2\CR9DO(\F9+R/)F_Y(- -ZF! #.M 8
MPK\& +G," "PW0P I^4= Y[E+0N4Y3D6BN1"(('C2BIWXE S;^%8.VG@7T%C
MX&9&7M]N2EK?=4Y6WWU14M^&4T_?D%9-WYM72^"G6$G@M5E(X<992.'?64??
M\%E&W/5;1MSU6T;<]5M&W/5;1MSU6T;<]5M&W/5;[9P$ -&M! #"N 4 M\,%
M *W1" "D[1 !F^T@!9+M+@Z)[#H8@.Q#(7;L2BIN[% Q9NM6-V#K7#Q;ZV1
M5^MK0U/K<D90ZWI)3>R#2TKLC$U([)9.1>VA4$/MKE%"[KQ10>_,4D'OY5)
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M;%>D[6Q:G^UL6I[M;%J>[6Q:GNUL6I[M;%J>[6Q:GNUL_WP0 ?^.$ #VG@T
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M/#GXSSPX]^@\./?L/#CW[#PX]^P\./?L/#CW[#PX]^P\OZH  +&S  "DOP
MF,H! (S8! "$^@X ?/L; G3[)@5L_# *9?PX$%[]0!58_D<94_Y-'4__5"!+
M_UHB2/]A)47_9R9"_VTH0/]U*CW_?2LZ_X8M./^1+C;_FR\T_Z8P,_^R,3+_
MOC(Q_] R,?_6,C'_UC(Q_]8R,?_6,C'_UC(Q_]8RLJ\  *6Z  "8Q@  B](
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M)P/UE2X%ZYDU".&<.PS6F$,6S)-/(L2-6"Z]AV$XMH)I0;!^<4BK>GE.IW>
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M=7SS9'5\\V1U?/-D_VD6 ?]X$P'_AQ0 _Y,5 /&>%0#CJ!8 U:X; <JM+0;
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M2T?%[4M&P_E-1<+_3D7"_TY%PO].1<+_3D7"_TY%PO].WY   ,R?  "_J@$
ML[,! *F] @"?QP4 EM() ([:$@"(VR0"@-HR"'C9/A!QV$@8:M=0'V366"5?
MU5\J6]1G+U?4;C-3TW8V4--_.4S3B#M*TY0^1].@/T74KD!$U+]!0]780$33
M[$!"TO9"0='^1$'1_D1!T?Y$0='^1$'1_D1!T?Y$T9@  ,.E  "UK@  J;@
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M)B[_XR8N_^,F+O_C)B[_XR8N_^,FK:T  )^W  "2P@  ALT  'G:  !P\@@
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M O]X* /_?#$'^'XZ"_!]0Q'I>DP8XG97']QR82C4;6LOSVET-LME?3O'8H5
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M5%.=ZU-3G/A35)K_4U29_U-4F?]35)G_4U29_U-4F?]3_W@& .&)  #0E@(
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M.3[+_SD^R_\Y/LO_.3[+_SD^R_\YRI8  +RB  "OJ@  H[,  )B\  "-Q@,
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M$B+_T!(B_] 2G+(  (Z\  "!QP  <]$  &?=  !9XP  4_T& $W_#@!(_Q8
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M3V*!ZTYC@?E-8X'_3&2 _TMD@/]+9(#_2V2 _TMD@/]+_VD( /MX! #<A $
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M1$N@_T1+H/]$2Z#_1$N@_T1+H/]$XWT  ,^+  #"E@  MY\  *VF  "CK0
MF;4  )"Y#@"+NAX!A+HM WVY.0EWN$,0<;9,%VNU4QUFM%HB8K-A)EZR:"M:
ML6\N5K!W,E.P@35/KXLX3*^7.DJNI#Q(KK,]1Z['/4>NXSQ&K?,]1JO^/D6K
M_S]%J_\_1:O_/T6K_S]%J_\_VH,  ,>1  "[G   KZ0  *6K  ":L@  D+H!
M (;!"0"!PA@ >\(H G7"-09OP4 ,:<!)$F2_41=?OE@<6[Y?(%>]9B14O&XG
M4;QV*DV[?RU*NXHP2+N6,D6[HS1#N[(T0KO%-4.[XC1"N?,U0;C]-T"W_S=
MM_\W0+?_-T"W_S= M_\WSHL  +^8  "RH0  IZD  )RP  "1N   AL " 'O(
M!P!TRQ( <,PB 6O+, -FRSP'8<M%#%S*3A%8RE855,I=&5')9!Q.R6P?2\ET
M(DC(?B1%R(@G0\B5*$'(HBH_R+$K/LG$*S[)X2H^Q_(K/<;\+3S%_RX\Q?\N
M/,7_+CS%_RX\Q?\NQ),  +:?  "II@  G:X  )*W  "&OP  >\<# '#/!P!G
MU@T 9-<: &#8*@%<V#8#6-A!!E382@I0V%(-3=A:$$K78A-'UVD61==R&$+7
M?!I V(<</=B3'CS8H1\ZV; @.=G#(#G9WR YU^\@.-7Y(C?4_R,WU/\C-]3_
M(S?4_R,WU/\CN9P  *ND  "?K   D[4  (>^  ![Q@  <,X# &76!P!=XPX
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M<@05_W\$%/^,!1/_F@42_Z8%$?^R!1'_O 41_[P%$?^\!1'_O 41_[P%C+@
M 'W"  !OS   8M@  %3?  !'Y0  /O$  #G_ 0 T_PL ,/\0 "S_%@ I_QP
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M17!OZT1P;_I#<6__07%O_T!Q</] <7#_0'%P_T!Q</] _U\( /]K! #A=@
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M0%N#_T!;@_\_6X/_/UN#_S];@_\__VH  -YX  #-@P  PHP  +F3  "PF
MIYT" *"?$@"9GR,!DYXQ!8R=/ N%FT82?YE.&'J75AYUEETC<)1C*&R2:BQH
MD7$P99!Y-&&.@C=>C8PZ6HR7/5B,I#]6B[) 5(O%0%2+X4!4BO,_58K^/U6)
M_SY5B?\^58G_/E6)_SY5B?\^[V\  -9\  #(AP  O9$  +28  "JG   H*(
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M-$.E_S1#I?\TT($  ,&.  "UF   J9\  )ZE  "3K   B+(  'RY @!VNA$
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ME TPXJ,.+N*S#B[CQPXMX^,.+>#R#BS?^P\LW_T0+-_]$"S?_1 LW_T0J*
M )RG  "/L   @[@  ';!  !JR0  7L\  %/5 0!)W 8 1>D/ $+I&0! ZB0
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M @[_E@(-_Z0"#/^P @S_O@(,_\("#/_" @S_P@(,_\("A[8  'F_  !KR0
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M_QKC,O\:XS+_&N,R_QKC,O\:_S@C ?\]( '_01\!_T4C ?]'+ +_1S8#_T9
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M.']?ZC=^7_HV?F#_-7Y@_S1^8/\T?F#_-'Y@_S1^8/\T_U4( /]@! #H:0
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M-VAO_S9H;_\V:&__-FAO_S9H;_\V_UX  .1J  #3=   R'P  +^! 0"WA0$
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M,U*%_S-2A?\SXVP  ,YY  #!@P  MHL  *R1  "BE0  EYD  (^;"P"*G1@
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MEQX^L*8@/+"W(#RPS" \K^@@.Z[W(3JM_R(ZK/\C.JS_(SJL_R,ZK/\CP(8
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M!BC=P08HW=X&)]OO!R;9^0@FV/X))MC^"2;8_@DFV/X)I)T  )BE  "+K0
M?K0  '&\  !EPP  6<D  $W-  !#TP$ .MD& #7D#0 SY!8 ,>0@ ##E*@ N
MYC, +>8\ "OG1  JYTP!*.A4 2?H70$EZ6<"(^ES B+J@0(@ZI$#'^NA QWK
ML@,<[,<#'.SA QOJ\0,;Z?D#&^GY QOI^0,;Z?D#FJ0  (VL  !_M0  <KT
M &7%  !9RP  3-   $'5   XW   +^$" "WQ#0 K\1, */(< ";R)  D\RL
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M1V8+SD9P#LM%>!#(1( 2QD.'%,1"CA7#0I46P4&<%[]!I!B]0*P9O$"V&KI
MPAJX0-(;M4'H&[)!]AVP0?\>KD'_'JU!_QZL0?\>K$'_'JQ!_QZL0?\>_T(1
M /]'#0#_3PX _U,1 /]6%0#S5QP Z%8E .!5,0'74S\"SU),!<I05PG&3F$-
MPTQJ$,!*<A*]27H5NTB"%KE'B1BW1Y 9M4:7&[-&GQRQ1:<=L$6Q'JY%O!^L
M1<P?JD7C(*=&\R&E1O\AHT;_(J)&_R&B1O\AHD;_(:)&_R&B1O\A_T4. /]+
M"@#_4PP _U<- /E:$ #K6Q0 WUH< -1:*P#,6CL"QEA(!<%64PF\5%P-N5)E
M$;50;12S3W47L$Y\&:Y-A!JL3(L<JDN2'JA*FA^F2J,AI$FL(J-)N".A2<8D
MGTK>))U*\"2;2OTEF4O_))E+_R282_\DF$O_))A+_R282_\D_T@, /]/" #_
M5@@ ]5L) .E>"@#D7@T U5\5 ,M@)P#$7S8"OEY#!;A;3@FT65@.L%=A$JQ5
M:16J5' 8IU-X&J52?QRB488>H%".()Y/EB*<3I\CFDZH)9A.LR:73L(GE4[6
M)Y-.[">13_LGD$__)Y!0_R:/4/\FCU#_)H]0_R:/4/\F_TH) /]3!0#X6@0
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M>ES_+'E<_RMZ7/\J>ES_*GI<_RIZ7/\J_U$  /);  #>9   SVH  ,=N @#
M< 0 NG , +)Q&@"K<2D!I7 W Y]N0@>:;$L,EFI4$9)H7!6.9F,8BV5I&XAC
M<!Z%8G@A@F%_)(!@B"9]7Y$I>U^<*WA>IRUV7K4N=5[&+W1>X2]T7_,N=%__
M+'1@_RMT8/\K=&#_*W1@_RMT8/\K_U,  .A>  #99P  RVT  ,-Q 0"[<P(
MM7,) *UU%P"G=2<!H70T YMR/P>5<$D+D6Y2$(QL612):F 8A6EG&X)H;AY_
M9G4A?65])'IDA29W9(\I=6.:*W)BI2UP8K,O;V+$+VYBWB]N8_(N;F/^+6YC
M_RQN8_\K;F/_*VYC_RMN8_\K_U4  .5@  #3:0  R'   +]T  "W=P$ L'<'
M *AX%0"B>20 G'@R I9V/0:1=$<+C')/#XAP5Q.$;UX7@&UD&GUL:QUZ:W,@
M=VIZ(W1I@R9R:(TI;V>7+&UGHRYK9K$O:6;!,&EFVS!I9_ O:6?]+6EG_RQJ
M9_\K:F?_*VIG_RMJ9_\K_E@  .%C  #/;   Q',  +MX  "S>@  JWH$ *1[
M$@">?"( F'PO I)Z.P6,>$4*AW=-#H-U51)_<UP6>W)B&GAP:1UU;W @<FYX
M(V]M@29M;(LI:FR6*VAKH2YF:Z\O9&J_,&-KV#!C:^\O9&O\+61K_RUE:_\L
M96O_+&5K_RQE:_\L]%L  -UF  #+;P  P'8  +=[  "O?@  IGX! )]_$ "9
M@!\ DX M HU_.06(?4,)@WM+#7YZ4Q)Z>%H6=G=A&7-U9QQP=&X?;7-V(FIR
M?R9H<8DH97"4*V)PH"U@;ZTO7V^]+UYOU"]>;^TO7V_[+5]O_RQ@;_\L8&__
M+&!O_RQ@;_\LZUX  -AI  #'<@  O'D  +-_  "K@@  H8(  )F##@"4A!T
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MF"5+BZ4G28NU*$B+RBA(BN<G28GW*$F(_R=)A_\G28?_)TF'_R=)A_\GT6\
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M%SBKPQ<XJN$7-ZGS&#>G_ADVIO\:-J;_&C:F_QHVIO\:NH0  *Z/  "BE@
MEYL  (NA  !_I@  <ZL  &>O  !:M   4[8, %&W%P!/MR0 3;@P $JX.@%(
MN$,"1KA+ T2X4@1!N%H&/[AB!SVX:PDZN'4+.+>!##:WC@XTMYT/,[>M#S*W
MP0\QM]X/,;;R$#"T_!$PL_\2,+/_$S"S_Q,PL_\3LHX  *65  ":FP  CJ(
M (*H  !UK0  :;,  %ZW  !3NP  1\ % $/"$ !"PAL 0,,G #_#,@ ^Q#P
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M 1/E[P$3X_H!$^/Z 1/C^@$3X_H!EJ(  (FI  ![L0  ;KD  &'   !4Q@
M2,H  #W/   STP  *MD  "+> @ >ZPH '.P0 !OM%P 9[1\ %^XF !7N+0 4
M[S4 $_ ] !'P1@ 0\5  #_);  [R:0 -\W@ #/2*  OUG  *]:X "?;"  GV
MV0 (]>T "/7M  CU[0 (]>T BZD  'VR  !ON@  8L(  %7)  !'S@  .](
M #'8   GW0  '^$  !GH   6^ 8 %/H- !+[$@ 0_!< #OP=  W](P ,_2D
M"OXP  C_.  &_T$  _],  #_6   _V8  /]W  #_B0  _YL  /^K  #_NP
M_\X  /_/  #_SP  _\\ ?[(  '&Z  !CPP  5LL  $C1   ZU@  +]T  "7A
M   <Y0  %.D  !'W   /_P$ #?\)  O_#0 (_Q  !O\4  /_&   _QX  /\C
M  #_*@  _S(  /\\  #_1P  _U0  /]C  #_<P  _X4  /^7  #_I   _[(
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M$ZX\\12K//T5J3S_%J@\_Q:H//\6ISS_%J<\_Q:G//\6_ST- /]"" #_2 H
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M((-/_Q^"4/\?@E#_'H)0_QZ"4/\>_T<  /-1  #?6   T5T  ,E@ @##8 0
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M(FI?_R)J7_\B\%(  -U=  #+90  P&L  +=N  "O;P  IVX! *!O$ ":<!\
ME' L 8]O. .*;4(&AFQ+"8)J4@Q^:5D/>VA@$G=F9A1U9FX7<F5U&G!D?AUM
M8X@?:V.2(FEBGB1G8JLE96*Z)F1BSR9D8NHF96+Z)&5C_R-E8_\B96/_(F5C
M_R)E8_\BZU4  -A@  #(:   O&X  +-Q  "K<P  HG$  )MR#@"5<QP D'0J
M 8IS-@*%<D %@7!("'UO4 MY;5<.=FQ>$7-K9!1P:FP7;6ES&FMI?!QH:(8?
M9F>0(61GG"-B9JDE8&:Y)E]FS29?9N@F8&;Y)&!F_R-@9O\C86;_(F%F_R)A
M9O\BZ%@  --C  #$:P  N7$  +!U  "G=P  GG4  )9V#0"0=QD BW@G (9W
M,P*!=CT$?'5&!WAS3@MU<E4.<7%<$6YP8Q1K;VH6:6YQ&69N>AQC;8,>86R.
M(5]KFB-=:Z<E6VNW)EIKRB9::^<E6VOW)%MJ_R-<:O\B7&K_(EQJ_R)<:O\B
MXUL  ,YF  # ;@  MG0  *QY  "C>P  F'D  )!Z"P"*>Q8 A7PD (%\,0%\
M>SL$=WI$!G-Y3 IP>%,-;'=:$&EV81-G=6@69'1O&&%S>!M><H$=7'&,(%IQ
MF")8<*8D5G"U)55PR"55<.4E57#V)%9O_R-6;_\B5V__(E=O_R)7;_\BWU\
M ,II  "\<@  LG@  *E]  "??P  DGX  (I_!P"$@!, @($A 'N!+@%W@#D#
M<H!"!6Y_2@AK?E$+:'U8#F1\7Q%B>V847WIM%UQY=1E9>'\<5WB*'E1WEB%2
M=J0B47:S(U!VQB10=N,C4'7U(U%U_R)1=/\A473_(5%T_R%1=/\AV&,  ,5M
M  "X=@  KGT  *6"  ":@P  C8,  (2$ P!]A1  >88> '6'*P%QAS8";88_
M!&F%1P=EA$\*8H-6#5^#7 ]<@F,26H%K%5> <QA4?WT:47^('$]^E!]-?J(@
M2WVQ(4I]Q")*?>$A2WST(4M[_R!+>_\@2WO_($M[_R!+>_\@T&<  ,!R  "T
M>P  JH(  *"&  "5B   AX@  'R*  !VC X <HT: &Z.)P!JCC(!9HT\ V.-
M1 5@C$P(7(M3"EJ+6@U7BF$05(EH$E&(<15/B'H73(>%&DJ&DAQ(AJ =1H:O
M'D6%PAY%A=\>183R'D6#_AY%@O\>18+_'D6"_QY%@O\>RFT  +IX  "O@0
MI8<  )J+  "/C0  @8X  '21  !NDPH :905 &:5(@!CE2X!8)4X ER50019
ME$D&5I10"%235PI1DUX,3I)F#TR2;A%)D7@41I"#%D20D!A"CYX90(^M&C^/
MP!H_C]P:/XWQ&C^,_1L_B_\;/XO_&S^+_QL_B_\;PG,  +5^  "JAP  GXP
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M"2NO^0HKKO\+*JW_"RJM_PLJK?\+K8L  *"2  "5F   B9T  'VC  !QJ
M9*T  %FQ  !-M   0K@  #NZ"@ XNQ, -[P> #6\*0 TO3( ,[T[ #*]1  Q
MODP +[Y5 2Z^7@$LOF@!*KYT BF^@@(GOY$#)K^B R2_M ,CO\L#([[H R.\
M]P0BN_\%(KO_!2*[_P4BN_\%I)(  )B8  ",G@  @*4  '.K  !GL   6[4
M $^Y  !$O   .L   ##$!  JQPL *,@3 "?)'0 FR2< )<DP "3*.0 CRD(
M(LM+ "'+50 @S%\ '\QL !W->@ <S8H &\V< !G.K@$8SL4 &,WD !C,] $8
MROP!&,K_ AC*_P(8RO\"FYD  (^?  ""I@  =:T  &BS  !<N0  4+T  $3!
M   YQ   ,,@  "C, 0 @T 8 &=4+ !;7$  5V!D %=DB !39*P 3VC0 $]H]
M !+;2  1W%, $=U? !#=;0 0WGX #M^1  [@I  -X+@ #.#2  O?[0 ,WO<
M#-W[  S=^P ,W?L DI\  (6G  !WK@  :K4  %V\  !0P0  1,4  #C)   N
MS0  )=$  ![5   6V@$ $=X& !#G#0 .YQ( #>@9  SH(0 +Z2D "NHQ  GJ
M.P 'ZT4 !>M1  3K7@ #ZVX  >N   #JE   ZJ<  .N\  #KT@  Z^D  .SO
M  #L[P  [.\ AZ<  'FO  !KMP  7KX  %'%  !#R0  -\T  "W1   CU@
M&]L  !/?   .XP  #.X"  KV"@ ']@X !?82  /V&   ]1X  /4E  #U+@
M]3<  /9"  #V3@  ]ET  /9N  #V@0  ]I4  />G  #WMP  ^,<  /C0  #X
MT   ^-  >Z\  &VX  !@P   4L@  $3-   WT0  *]<  "'<   8X   $>0
M  SG   '[P  !/H   '_ P  _P@  /\-  #^$   _A0  /\:  #_(0  _RD
M /\S  #_/@  _TL  /];  #_;   _X   /^2  #_H0  _ZT  /^S  #_LP
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M LTB] /*(_\$R"/_!<<C_P;&(_\&QB/_!L8C_P;&(_\&_RP2 /\N#P#_,!
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M$9D\_Q&8//\1F#S_$9@\_Q&8//\1_SH! /]   #O10  X4@  -E(!0#31@D
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M%W9/_Q=V3_\7^$8  .)0  #05P  Q%P  +M>  "T70  KEH& *9;$P"@7"(
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MF!IC7J4<85ZT'6!>QQU@7N,=8%[U'&!>_QM@7O\:85[_&F%>_QIA7O\:Y%(
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M'%%KP1Q1:]P<46OQ&U)K_AI2:O\:4FK_&5)J_QE2:O\9U%P  ,-F  "V;@
MK'0  *)W  "6=@  B74  (%V 0!Z=P\ =G@; ')Y)P!O>3(!:W@\ FAX1 1E
M=TP&8G=3"%]V6@I==6$,6G5H#UAT<!%5<WD34W.$%E%RD!A/<IX937&M&DQQ
MOQM+<=D;3''P&DQP_1I-</\936__&4UO_QE-;_\9SF   +YJ  "R<@  J'@
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M$CN'^A,[AO\3.X;_$SN&_Q,[AO\3O'$  *][  "E@P  F8<  (R(  !_B0
M<XP  &60  !<DP  5Y4, %26%@!2EB( 4)<M $V7-@!+ES\!29=' D>73@-%
MEE4$0Y9=!4&6908^E6\(/)5Z"3J5APLXE94,-I2E#364M@XTE,P--)/I#322
M^ XTD/\/-)#_#S20_P\TD/\/M7@  *J"  ">B   DXT  (:.  !YD   ;9,
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M ANT_P(;M/\"GX\  )25  "(FP  >Z$  &ZF  !BJP  5K   $JS   _M@
M-;D  "R\   DOP8 '\(- !W"%  <PAX &\,F !K#+P 9Q#@ &,1! !?$2@ 6
MQ54 %<5A !3&;P 3QG\ $L:1 !''I  0Q[D #\?4 !#&[@ 0Q/H $,/_ !##
M_P 0P_\ EY8  (N<  !^H@  <:D  &2O  !8M   2[@  $"[   UO@  *\$
M "/%   ;R0$ %,P& !#0"P .T1$ #=$9  W1(0 ,T2H #-$T  O2/@ *TDD
M"=-5  G38@ (TW( !M2$  74F  $U*L  ]7   '5W  !U>T  =7V  '5]@ !
MU?8 CIT  ("D  !SJP  9K$  %FX  !,O0  /\   #3#   JQP  (<H  !G.
M   2T@  #=8!  G;!0 &W T !-P1  /=&  !WB   -XH  #?,0  X#P  .%'
M  #B5   XV,  .-T  #DB   Y)L  .6N  #EP0  Y=4  .;G  #FYP  YN<
M@Z0  '6L  !HLP  6KL  $W!  ! Q   ,\@  "C,   ?T   %]0  !#9   +
MW0  !>$   #D    Y0<  .8-  #G$0  Z!8  .D=  #J)0  ZRX  .TY  #O
M10  \%,  /%D  #Q=@  \HH  /.<  #SK0  ]+L  /3(  #TR   ],@ =ZT
M &JU  !<O0  3\0  $#)   SS0  )]$  !W6   4W   #N    CC   !Y@
M .H   #N    [@   .\$  #P"@  \0X  /,2  #T&   ]B   /@J  #Z-0
M_4,  /Y2  #_8P  _W8  /^)  #_F@  _Z8  /^P  #_L   _[  _Q8C /\5
M(0#_$2$ _PTD /\)*P#_!C< _P-$ /\ 40#_ %T _P!H /\ <@#_ 'L _P"#
M /\ B@#_ )$ _P"6 /\ G #_ *$ _0"F /L K #Y +, ]P"[ /4 Q0#S -$
M\@#D /$ \0#O /H [@#_ .X _P#M /\ [0#_ .T _P#M /\ _QD@ /\8'0#_
M%1T _Q ? /\.*0#_##0 _PI! /\'30#_!5D _P1D /\$;@#_ W< _P.  /\#
MAP#_ XT _0*3 /L"F0#Y IX ]P*D /4"J@#S ;  \0&X .\!P@#M <\ ZP'C
M .H![P#H OL YP3_ .8%_P#F!O\ Y@;_ .8&_P#F!O\ _QP; /\;&0#_%Q@
M_Q4= /\3)0#_$3  _Q ] /\.20#_#%4 _PM@ /\+:@#]"W, ^PM\ /D*@P#W
M"HH ]0J0 /0*E@#S"IL \0JA .\)IP#M":X ZPFV .@)P #F"<T Y GB .(*
M\ #?"_L W@S_ -P-_P#<#?\ VPW_ =L-_P';#?\!_Q\7 /\>$P#_&Q( _QP9
M /\;(@#_&"P _Q4X /\31 #^$E  ^1%; /409@#S$&\ \!!W .X0?P#L$(8
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M [4C_P.T(_\$LR/_!+,C_P2S(_\$_RD+ /\J!0#_+@@ _R\, /\M$ #S*Q<
MZ"@B . F+P#9)CT TB=* ,TG50#**%\ QRAH <4H;P'#)W<!P2=^ ;\GA &^
M)XL"O">2 KLGF0*Y)Z "MR>I [8HLP.T*+\#LRC/ [ IY@2M*?8$JRK_!:DJ
M_P:H*O\&J"K_!J@J_P:H*O\&_RT% /\P  #_,P( ]C0& .\R"@#H+A  W"P8
M -$N* #++S< QC!$ ,$P3P"^,%D!NS!B ;@P:@*V+W$"M2]X K,O?P.Q+X8#
ML"^- ZXNE 2M+IP$JRZD!:DOK@6H+[H%IB_*!J0PX@:A,/,'GS#_")XQ_PB=
M,?\(G#'_")PQ_PB<,?\(_S   /\U  #O.   XCH  -LY! #6-0D SC03 ,8V
M(@"_.#$ NC@_ +8X2@&S.%0!L#== JTW9 *K-FP#J39S!*@V>02F-8 %I#6'
M!:,UCP:A-9<'GS6@!YXUJ@B<-;8(FS7%"9DUW0F6-N\*E#;]"I,W_PJ2-_\*
MDC?_"I(W_PJ2-_\*_S,  /8Z  #D/P  V$(  ,Y" 0#)/@8 Q#L/ +L^'0"U
M/RP L3\Z *T_10&I/T\!ICY8 J,]7P.A/6<$GSQM!9T\= :<.WL&FCN"!Y@[
MB@B6.Y,)E3J<"I,ZI@N1.K(+D#O #(X[U0R,/.P-BCS[#8D\_PV)//\,B#S_
M#(@\_PR(//\,_S<  .H_  #<10  SDD  ,5)  "_1@( ND,, +-$&0"M12<
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MF1%O3:43;4VS%&Q-Q11K3N$4:T[T$VM._Q)K3O\2:T[_$6M._Q%K3O\1Z$8
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M%5M9OQ9;6=@66UGO%5M9_11<6?\37%G_$EQ9_Q)<6?\2W%   ,=9  "Z8
MKV0  *1E  "99   D&   (AA!@""8A$ ?F,= 'IC*@!V8S0!<V(] 6]B1@)L
M84T$:F%4!6=@6@=E8&$(8U]I"F%?<0Q?7GH.75Z%$%M>D1)979X46%VL%5==
MO1967=465EWN%5==_!177?\35UW_$E==_Q)77?\2UE,  ,1<  "W8P  K&@
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M$TAK^A)(:_\22&K_$4AJ_Q%(:O\1QUX  +AG  "L;@  H7(  )-R  "'<0
M>G$  '%R  !K= < 9G41 &-V'0!@=R@ 7G<S %MX/ %9=T,"5G=+ U1W4@12
M=ED%4'9@!TYU: A+=7$*271\#$=TB Y%<Y8/0W.E$$)SMA%!<\L10G+H$4)R
M^!%"<?\00W#_$$-P_Q!#</\0P6,  +-L  "H<P  FW8  (YU  "!=@  =78
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M""^*_PDOBO\)L'8  *5_  "8A   BH0  'V%  !PAP  98H  %J.  !/D@
M1I4  $&8#  ^F!0 /9D? #N9*  ZFC$ .9HZ #>:0@ VFDH -9I2 3.:6@$Q
MFF0!+YIO BV:>P(LFHH#*IJ: RF:K 0HFL $)YG> R>7\@0GEOT%)Y7_!2>5
M_P4GE?\%J7X  )Z%  "2B0  A(H  ':,  !JCP  7I,  %27  !)FP  0)\
M #>B!  RHPX ,:,7 #"D(0 NI"H +:0R "RE.@ KI4, *J5+ "FE5  HI5X
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M90 ,OW0 "[^&  J^F0 (OJP ![["  >^WP (OO  "+WZ  B]_  (O?P DY0
M (>9  !ZGP  ;*4  &"J  !3KP  1[,  #RV   QN   )[L  !^^   7P0
M$<0!  S("  (R0X !\D4  ;)'  %R20 !,HL  /*-@ "RD   ,M,  #+60
MRV@  ,MY  #,C   RY\  ,NS  #+R   S.(  ,SO  #,\0  S/$ BIH  'RA
M  !OIP  8JT  %6S  !(N   .[L  #"^   FP0  '<0  !7(   /RP  "LX
M  32 @  TPH  -,/  #4%   U1H  -8B  #7*@  V30  -H_  #<2P  W%H
M -UJ  #=?0  W9$  -VD  #>M@  WL@  -[>  #>X@  WN( ?Z(  '&I  !D
ML   5K<  $F\   \P   +\0  "3'   ;RP  $\\   W2   'U@   -L   #>
M    WP,  . )  #A#@  XA(  .,7  #E'@  YB<  .@Q  #J/0  [$L  .Q:
M  #M;   [H   .Z4  #NI0  [K0  .["  #NQ@  [L8 =*H  &:R  !8N0
M2\   #W%   OR0  ),T  !G1   1U@  "]L   />    X0   .4   #H
MZ0   .H   #K!@  [0L  .\/  #P$P  \AH  /0C  #W+@  ^3L  /M*  #\
M6P  _6T  /V   #^DP  _J(  /ZM  #^KP  _J\ _Q ? /\.'0#_"AT _P$@
M /\ * #_ #4 _P!! /\ 3@#_ %H _P!E /\ ;@#_ '< _P!_ /X A@#\ (P
M^P"2 /D EP#X )P ]P"B /8 IP#U *T \P"U /( O0#Q ,D [P#< .X ZP#M
M /< [ #_ .L _P#J /\ Z@#_ .H _P#J /\ _Q,< /\1&0#_#1D _P8< /\#
M)0#_ #$ _P ^ /\ 2@#_ %8 _P!A /\ :P#] ', ^@![ /< @P#U (D ] "/
M /( E #Q )D \ "? .X I #M *L [ "R .H N@#H ,8 YP#6 .4 Z #D /4
MXP#^ .( _P#A /\ X0#_ .$ _P#A /\ _Q48 /\3% #_#Q0 _PT9 /\+(@#_
M""T _P0Y /\!1@#_ %$ _@!< /H 9@#V &\ \@!W .\ ?@#M (4 ZP"+ .H
MD0#H )8 YP"< .8 H0#D *@ XP"O .$ N #? ,, W0#1 -L Y@#9 /, UP#]
M -4"_P#4 O\ U /_ -0#_P#4 _\ _Q@3 /\5$ #_$@\ _Q(5 /\1'0#_#B@
M_PPT /\*00#Y"$P ]097 /$&80#M!FH Z05R .8%>@#D!8$ X@6' . &C0#?
M!I( W0:8 -L&G@#9!J4 UP:M -0&M0#2!L  T ?/ ,X(Y0#,"?0 R@O_ ,@,
M_P#'#/\ QPS_ ,8,_P#&#/\ _QL. /\9# #_& T _Q@1 /\7& #_%"( ^Q$N
M /,0.@#M#D8 Z U2 .4-7 #A#64 W@UM -L-=0#8#7P U0V" -,-B0#1#8\
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M J$C_P*A(_\"_R4  /\H  #R*@  Y2L  -\H!0#<(0L TB$4 ,DD) ##)3(
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MG >!.J@(@#JU"7X[Q@E].^$)>SSS"7L\_PEZ//\(>CS_"'H\_PAZ//\([C<
M -U!  #+1@  OTD  +9)  "N1@  J4$$ *-!$0"=0AX F$,K )5#-P"10T$
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M#6=)O0UF2=0.94GM#65*_ QE2O\+94K_"V5*_PME2O\+X$0  ,M-  "]4@
MLE8  *95  "<4@  E4X  (Y."0")3Q0 A5 @ (%0+ !^4#< >U!  7A02 %U
M3T\"<TY5 W%.7 1O3F,%;4UJ!FM-<@=I37L(9TV%"F5-D0MD3)T,8DVK#6%-
MNPY@3=$.8$WL#F!-^PU@3?\,8$W_"V!-_PM@3?\+W$<  ,=0  "Y5@  KED
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M#E%8^ U26/\-4EC_#%)8_PQ26/\,S5$  +Q9  "P7P  HV$  )9@  "+7P
M@5L  'E=  !S7@P ;UX5 &M?( !H7RL 9F U &-@/0%A7T4!7U], EU?4P-;
M7UH$65YA!5=>:0957G((4UY]"5%=B0M0798,3EVD#4U=M Y,7<@.3%WF#DU=
M]PU-7/\,35S_#$Y<_PQ.7/\,R50  +E<  "M8P  GV,  ))C  "'8@  ?&
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M"CYK_PH^:_\*NF   *UI  "@;@  D6T  (1M  !X;0  ;&X  &%P  !;<@
M5G0* %)U$@!0=AT 3G<G $QW,0!+>#D 27A! $AX20%&>% !1'=7 D)W7P-
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M<P$EE((!))23 2*3I $AD[<!()// 2&2[ $@D/H"((__ B"/_P(@C_\"I'P
M )>   "'?P  >X   &Z"  !BA0  5XD  $V.  !"D@  .I8  #*9   JG D
M*)T1 ":=&0 EG2( ))XJ ".>,@ BGCH (9Y" "">2P ?GU4 'I]@ !R?;0 ;
MGWP &I^- !B?GP 7G[( %I_) !:>Z  6G/< %IO_ 1>;_P$7F_\!G8,  (^&
M  ""A@  =(<  &>+  !;CP  4),  $:8   \G   ,Z   "NC   CI@  '*@+
M !JI$0 8J1@ %ZDA !:J*0 5JC$ %*HY !.J0P 3JTT $JM8 !&K90 0JW0
M#JN&  ZKF0 -JZP #*O!  RJWP ,J?( #:C\  VH_P -J/\ EHH  (F,  !Z
MC0  ;)$  &"5  !4F@  29\  #^C   UIP  *ZH  ".N   ;L   %+,!  ^U
M"@ -MA  #+86  NV'P *MB< ";8O  BV.0 'MT, !K=/  2W6P #MVH  K=[
M  "WC@  MZ$  +:T  "VRP  MN4  +7Q  "U]P  M?< CY$  (&4  !REP
M99P  %BA  !,I@  0:L  #>O   LL@  ([4  !JX   3NP  #KT   G !0 #
MP0T  ,$1  #!%P  PAX  ,(F  #"+P  PSD  ,1$  #$4   Q%X  ,5O  #%
M@0  Q94  ,6H  #%O   Q-$  ,3F  #$[@  Q.X AI@  'F>  !KHP  7:D
M %"N  !$LP  -[8  "RY   BO   &;\  !'"   ,Q0  !L@   #+    S <
M ,P-  #-$0  S18  ,X=  #/)   T"T  -(X  #41   U%(  -5A  #5<P
MUH<  -:;  #6K0  U[\  -C.  #8W0  V-T >Z   &ZF  !@K0  4[,  $6X
M   XO   *[\  "'"   7Q@  $,D   K,   "T    -0   #7    V    -H%
M  #;"P  W X  -X3  #?&0  X2$  .,J  #E-@  YT,  .=3  #H9   Z7<
M .F,  #JGP  ZJX  .JZ  #JPP  ZL, <*@  &*O  !5M@  1[P  #G    L
MQ   (,@  !;,   .T   !]0   #9    W0   .$   #C    Y    .8   #G
M 0  Z0<  .L,  #L$   [A4  / =  #S)P  ]C,  /=#  #X5   ^68  /EZ
M  #ZC@  ^IX  /NI  #[L   ^[  _PL; /\'&0#_ !D _P < /\ )0#_ #(
M_P _ /\ 2P#_ %< _P!B /\ :P#_ ', _0![ /L @@#Z (@ ^ "- /< D@#V
M )@ ]0"= /0 H@#S *D \0"P .\ N #N ,, [ #1 .L Y@#I /, Z #^ .@
M_P#H /\ Z #_ .@ _P#H /\ _PX8 /\*%0#_ 10 _P 8 /\ (@#_ "X _P [
M /\ 1P#_ %, _0!> /H 9P#W &\ ]0!W /, ?@#R (0 \ ") .\ CP#N )0
M[ ": .L GP#I *4 Z "L .8 M #D +\ XP#, .$ X@#? /  W@#[ -X _P#=
M /\ W0#_ -P _P#< /\ _Q 3 /\-$0#_!A  _P(5 /\ '@#_ "D _P V /\
M0@#Z $X ] !9 /$ 8@#N &L [ !R .H >0#H '\ YP"% .4 BP#D )  X@"6
M .$ G #? *( W0"I -H L0#8 +L U0#( -( W0#1 .T T #Y ,\ _P#. /\
MS0#_ ,T _P#- /\ _Q$/ /\.#0#_# T _PL2 /\'&0#_ B0 _P P /8 / #O
M $D Z@!3 .< 70#D &8 X0!M -\ = #= 'L VP"! -D A@#6 (P U "2 -(
MF #0 )X S@"F ,P K@#* +@ R #$ ,8 UP#% .H PP#W ,( _P#! ?\ P +_
M , "_P#  O\ _Q0+ /\0!@#_$ D _Q . /\.% #_"AX ]08I .L$-@#C T(
MWP-. -L$5P#6!&  TP1H - $;P#.!78 S 5\ ,H%@@#)!8@ QP6. ,8%E #$
M!9L P@6C , &JP"^!K4 O0;" +L(U "Z">D MPOX +4,_P"T#/\ M S_ +0,
M_P"T#/\ _Q<$ /\4  #_%@, _Q0) /\1#@#R#A4 Z PA -X*+@#6"SL T Q'
M ,P,40#)#%H Q@UB ,0-:@#"#7$ P UW +\-?0"]#H, O Z* +H.D0"Y#I@
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MH@";(*P!FB&Y 9@AR@&6(N0!E"/U 9(C_P&1(_\!D"/_ 9 C_P&0(_\!_R(
M .LI  #=+@  SR\  ,<M  #!)P, O2(- +8C&@"P)2@ K"8T *@F0 "E)TD
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M!'@UO@5W-M0%=C;M!70W_ 5T-_\$=#?_!'0W_P1T-_\$YS4  -(]  ##0@
MN$0  *Q"  "D/@  GSD  )HX#@"4.AD D#HF (T[,0"*.SL ASM$ (0[3 ""
M.U,!@#I: 7XZ8 %].F<">SIN GDZ=0)W.GX#=CJ(!'0ZDP1R.IX%<3JK!6\[
MNP9N.\\&;3OJ!FT\^@9L//\%;#S_!6P\_P5L//\%XCD  ,Q"  "^1P  L4@
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M"%I)]@A:2?\'6DC_!EI(_P9:2/\&T44  +],  "R4@  HU$  )=0  "-3@
MADH  (!* 0!Z2PX =DP7 '),(P!O3"T ;4TV &I,/P!H3$8 9DQ- 61,4P%B
M3%H"84QA E],:0->3'($7$Q\!5I,B 993)4'5TRC"%9,L@A53,8)54SB"55,
M]0A53/\'54S_!U9,_P963/\&S$@  +Q0  "O50  H%0  )-3  ")40  @4T
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M!TA7_P9(5_\&P5$  +)9  "C7   E%L  (=;  !]6@  <E@  &M9  !E6@,
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M> (U<(8#,W"5 S)PI@0Q<+@$,'#0!#%O[ 0Q;OL$,6W_!#%L_P0Q;/\$KV0
M *%I  "/:   @6@  '5I  !K:0  8&L  %5N  !-<0  1G,  $)U"P _=A(
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M !N-G  9C:X &(S$ !B,XP 9BO4 &8G_ 1F(_P$9B/\!G7<  (QV  !]=@
M<G<  &5Y  !:?   4(   $:$   \B0  -(P  "V0   EDP( 'Y4, !V6$@ <
MEAH &Y<B !J7*@ 9ES( &)@Z !>80P 6F$T %9A8 !289  3F', $9B$ !"8
ME@ 0F*D #IB_  Z7W0 /EO( $)7\ !"4_P 0E/\ E7T  (5\  !X?   :WX
M %^!  !4A@  2HH  $"/   VDP  +9<  "::   >G0  %Z # !*B#  0HQ(
M$*,9  ^C(0 .I"D #J0Q  VD.@ ,I$4 "Z10  JD7  )I&H !Z1[  :CC@ $
MHZ$  J.T  .BRP #HN8  Z'S  .A^P #H?L C8,  '^"  !QA   9(<  %B,
M  !-D0  0I8  #B:   OG@  )J(  !ZE   7J   $:L   RN!P 'KPT  Z\2
M  *O&0 !KR$  *\I  "P,@  L#P  +!'  "P4P  L&$  +!Q  "P@P  KY<
M *^J  "OOP  KMD  *[K  "N]   KO0 AXD  'B*  !JC@  79,  %&8  !%
MG0  .Z(  #"F   GJ@  'JX  !:Q   0M   "[8   6Y P  N@H  +H.  "Z
M$P  NQD  +LA  "\*   O#$  +T\  "^2   OE8  +YE  "^=P  OHP  +Z?
M  "]LP  OL<  +[>  "]ZP  O>L ?Y(  '"5  !BF@  59\  $FE   ]JP
M,J\  "BT   >M@  %;D   Z\   )OP   L(   #$    Q00  ,8*  #&#@
MQQ(  ,@8  #)'P  RB<  ,PP  #./   SDD  ,]9  #/:@  SWX  ,^3  #/
MI@  S[@  ,_(  #/VP  S]L =YP  &BA  !;IP  3JX  $&T   TMP  *+H
M !V]   3P   #<0   ;'    R@   ,X   #0    T0   -("  #3"   U0P
M -80  #9%0  VQP  -TD  #@+P  XCP  .-+  #D7   Y&\  .6#  #EF
MY:D  .6V  #EPP  Y<, ;*4  %^L  !1L@  1+D  #6\   HP   ',0  !+(
M   ,RP   \\   #3    V    -P   #?    WP   .$   #C    Y ,  .8(
M  #H#0  Z1$  .P8  #N(@  \2X  /,\  #T30  ]5\  /9S  #WAP  ]YD
M /BE  #XL   ^+  _P,7 /\ %0#_ !4 _P 8 /\ (P#_ "\ _P \ /\ 2 #_
M %0 _P!> /\ 9P#] &\ ^P!V /D ?0#X (, ]@"( /4 C@#T ), \@"8 /$
MG@#P *0 [@"K .T LP#K +T Z@#+ .@ X0#G /$ Y@#] .4 _P#D /\ Y #_
M .0 _P#D /\ _P<3 /\ $0#_ !$ _P 5 /\ 'P#_ "L _P W /\ 1 #^ $\
M^@!: /< 8P#T &L \@!R /  >0#O '\ [0"$ .L B@#J (\ Z "4 .< F@#E
M *  Y "G .( KP#@ +D W@#& -P V@#: .P V #Y -8 _P#6 /\ UP#_ -@
M_P#8 /\ _PH0 /\##@#_  T _P 2 /\ &@#_ "8 _  R /< /P#T $H \0!5
M .T 7@#J &8 Z !N .4 = #C 'H X@"  .  A0#> (L W "0 -L E@#8 )P
MU0"C -, JP#1 +4 S@#! ,P T0#+ .< R0#U ,@ _P#( /\ R #_ ,@ _P#(
M /\ _PP, /\&" #_ @H _P / /\ %0#\ "  \0 L .P .0#I $4 Y0!/ .$
M60#> &$ VP!H -< ;P#4 '4 T@![ -  @ #. (8 S ", ,L D@#) )@ QP"@
M ,4 J ## +$ P0"\ +\ RP"] ., O #R +L _0"[ /\ N@#_ +H _P"Z /\
M_PX% /\)  #_"04 _P8+ /\!$ #P !D Y@ E .$ ,@#< #\ U@!) -$ 4P#.
M %L RP!C ,@ :@#& '  Q0!V ,, >P#! ($ P "' +X C@"\ )0 NP"< +D
MI "W *X M0"Y +, R "Q -\ L 'O *\!^P"N O\ K0/_ *T#_P"M _\ _Q
M /\.  #_#0  ]@L# /('"@#B 1$ VP(= -(#*P#, S< R 1# ,0$30#!!%8
MO@5= +P%9 "Z!6L N 5Q +<%=@"U!7P LP:# +(&B0"P!I$ KP>9 *T'H0"K
M!ZL J0BW *@)Q@"F"MT I0OP *,,_0"B#?\ H0W_ *$-_P"@#?\ _Q$  /P2
M  #L$P  XA,  -L/ P#6"0L S@@4 ,8*(@# ##  O T\ +@-1@"U#4\ L@Y7
M + .7P"N#F4 K0YK *L.<0"J#G@ J Y^ *</A0"E#XT I ^6 *(0GP"@$*D
MGQ"U )T1Q0";$=X F1+Q )<3_P"6%/\ E13_ )44_P"4%/\ _Q4  .T;  #@
M'P  TA\  ,D;  #$% 4 P1 . +H2&P"T$RD L!0U *P50 "I%4D IA52 *06
M60"B%F  H19F )\6; ">%G( G!9Y )L7@ "9%X@ F!>1 )88FP"4&*8 DQFR
M )$9P0"0&M@ C1ON (L<_0"*'/\ BAS_ (D<_P")'/\ ]!T  .0E  #3*0
MQRH  +PF  "V(   M!D+ *X:%0"H'", I!TO *$>.@">'D0 FQY, )D>5 "7
M'UL E1]A )0?9P"2'VT D1]T (\@? ".((0 C""- (H@EP")(:( AR&N (8B
MO0"%(M$!@B/K 8$D^P& )/\!?R3_ 7\D_P%_)/\!["4  -LM  #),0  O#$
M +$N  "K*0  IR0% *,C$0">)!T FB4J )8F-0"3)C\ D29' (\F3P"-)E8
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M V8V]0-F-O\"9C;_ F8V_P)F-O\"V#<  ,0^  "U0@  ID$  )L_  "3/
MC3@  (@V!P"$-Q$ @#<< 'PX)P!Z.#$ =SDZ '4Y0@!S.4D <3E0 ' Y5P!N
M.5T ;#ED 6LY:P%I.70!:#E^ F8YB0)D.94#8SJB V(ZL0-A.L,#8#O@!%\[
M\P-?._\#7SO_ U\[_P)?._\"T3L  ,!"  "P10  H40  )5#  "-0   AST
M (([ @!].PX >3P8 '4](P!S/2T <#TV &X]/P!L/48 :SU- &D]4P!G/5H
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M T]'_P-01_\#Q$4  +5-  "C30  E4P  (E+  !_2@  >$8  '%'  !L1P<
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M>0) 6(8"/EB5 SU8I0,\6+<$/%C-!#Q7Z@,\5_H#/5;_ SU6_P,]5O\#ME,
M *57  "45P  A58  'E6  !O5@  954  %Q6  !76   4ED' $Y:$ !,6A@
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M 2QJGP$K:K !*FK& 2IIY0$J:/8"*V?_ BMG_P(K9_\"J6$  )5@  "$8
M=V   &QA  !B80  6&,  $YF  !':   0&L  #IN!0 V;PX -' 5 #-P'@ R
M<28 ,'$N "]Q-0 N<CT +7)% "QR30 K<E< *G)A "ER;0 G<GL )G*+ "1R
MG $C<JX!(W+# 2-QX@$C</0!(V__ 2-N_P$C;O\!H64  (YD  !_9   <F0
M &AE  !>9@  5&D  $EL  !";P  .W(  #1U   N> H *WD1 "IY&  I>B$
M)WHH "9Z,  E>S@ )'M  "-[2  B>U( (7M< "![:  ??'8 '7R& !Q[F  ;
M>ZH &GN_ !I[W@ :>?( &WC^ !MW_P$;=_\!F6D  (AI  !Y:0  ;6D  &-J
M  !9;   3V\  $5S   ]=P  -7H  "Y]   G@0, (H,- ""$$@ ?A!H '80B
M !R%*@ ;A3$ &H4Y !F%0@ 8ADP %X96 !:&8P 5AG$ %(:! !*&DP 1AJ8
M$86[ !"%U@ 1@^\ $8+[ !*"_P 2@?\ D6X  (%M  !T;@  :6X  %UP  !3
M<P  27<  $!\   W@   +X,  ">'   AB@  &HT& !6/#0 3D!, $I : !*0
M(@ 1D"H $)$R !"1.P /D40 #I%/  V17  ,D6H "Y%Z  J1C0 (D)\ !Y"S
M  >/R0 'C^8 !X[T  B-_  (C?\ B7,  'MS  !O<P  8W4  %=X  !-?0
M0X$  #F&   PB@  *(X  "&1   :E0  $Y<   Z:"  +G X "9P3  B<&@ '
MG"( !IPJ  2<,P #G#T  IU(  "=5   G6(  )QR  "<A   G)<  )NJ  ";
MOP  FML  )KL  ":]0  F?@ @GD  '9Y  !H>@  7'X  %&"  !&AP  /(P
M #*1   IE0  (9D  !F=   2H   #J,   FF!0 #IPP  *<0  "G%0  J!P
M *@C  "H*P  J30  *D_  "I2P  J5D  *EH  "I>@  J8X  *FA  "HM0
MJ,L  *?D  "G[P  I_, ?8   &^!  !AA   58D  $F.   ^E   -)D  "J>
M   AH@  &:8  !*I   -K   !Z\   "R    LP<  +,,  "S$   M!4  +0;
M  "U(@  MBL  +<U  "W0   N$X  +A=  "X;@  N((  +B7  "XJ@  M[X
M +?2  "WY@  M^H =H@  &>+  !:D   3I8  $*<   WH@  +*<  "*K   9
MKP  $;,   NV   $N0   +P   "^    O@   +\&  # "P  P0\  ,(3  ##
M&0  Q"   ,4I  #'-   R$(  ,E1  #)8@  R74  ,F*  #)GP  RK$  ,K!
M  #)T0  R=D ;I,  &"8  !3G@  1J0  #JK   OL   )+4  !FX   0O
M"K\   '!    Q    ,@   #*    R@   ,P   #- P  S@@  - -  #1$
MTQ8  -8>  #:*   W30  -Y#  #?5   WV<  .!\  #@D0  X*0  ."R  #@
MO@  X,, 9I\  %FF  !,K0  /[0  #*X   DO   &+\  !##   (QP   ,H
M  #-    T0   -4   #8    V0   -L   #=    WP   .$$  #C"@  Y0X
M .<3  #J'   [2<  / U  #Q1@  \E@  /-K  #S@   ])0  /2C  #TK@
M]+( _P 3 /\ $0#_ !$ _P 5 /\ 'P#_ "P _P Y /\ 10#_ %  _P!: /X
M8P#[ &L ^0!R /< > #U 'X ] "$ /( B0#Q (X \ "3 .X F0#M )\ [ "F
M .H K@#H +@ Y@#% .4 VP#C .T X@#[ .( _P#A /\ X0#_ .$ _P#A /\
M_P 0 /\ #@#_  T _P 2 /\ &P#_ "@ _P T /X 00#[ $P ]P!6 /0 7P#Q
M &8 [P!M .P = #J 'H Z0!_ .< A0#F (H Y0"/ ., E0#A )L X "B -X
MJ@#; +0 V0#  -8 T #3 .@ T@#W -$ _P#1 /\ T #_ -  _P#0 /\ _P -
M /\ "0#_  H _P / /\ %@#[ "( ]P O /0 .P#P $< [0!1 .D 6@#E &(
MX@!I .  ;P#> '4 W !Z -H @ #8 (4 U0"+ -, D0#1 )< SP"> ,T I@#+
M *\ R0"Z ,< R0#% .( Q #R ,, _@#" /\ P0#_ ,( _P#" /\ _P,& /\
M 0#_  8 _P , /D $0#Q !T ZP I .< -@#C $$ WP!+ -L 5 #5 %P T@!C
M ,\ :@#- '  RP!U ,D >P#( (  Q@"& ,4 C ## ), P0": +\ H@"] *L
MNP"V +D Q "W -H M@#M +0 ^@"T /\ M #_ +0 _P"T /\ _P0  /\   #_
M    _P & .P #0#E !8 W@ B -< +P#1 #L S0!% ,H 3@#& %< Q !> ,$
M9 "_ &H O0!P +P =0"Z 'L N0"! +< AP"U (X LP"5 +( G@"P *< K@"R
M *P OP"J -$ J #H *@ ]P"G /\ IP#_ *8 _P"F /\ _P8  /\%  #Q P
MZ    .$ !P#5 !  S0 ; ,< )P## #, OP ^ +P 2 "Y %$ M@!8 +0 7P"R
M &4 L !J *\ < "M '8 K !\ *H @@"I (D IP"1 *4 F@"C *0 H0"N *
MNP"> <T G0+F )P$] ";!/\ F@7_ )H%_P"9!?\ _PH  /$.  #D$   V0\
M ,X+  #( PL P@ 3 +P"'P"W RP LP0W + %0@"M!DH J@92 *@'60"F!U\
MI0=E *,':P"B"'$ H AW )\(?@"="(4 FPF. )H)EP"8"J$ E@JL )4+N@"3
M"\P D@SE ) -]@"/#O\ C@[_ (X._P"-#O\ ]A$  .87  #6&P  QQD  +X5
M  "Y$   MPH- +$+%P"L#20 J XP *4..P"B#D0 GP], )T/4P";#UH F@]@
M )@09@"7$&P E1!R ),0>0"2$($ D!"* (\1E "-$9\ BQ&J (H2N "($LL
MAA/F (44]P"#%?\ @Q7_ ((5_P""%?\ [1H  -PA  #*)0  NR(  +$?  "K
M&@  J10& *42$0"@%!X G!4J )D5-0"6%CX E!9' )(63@"0%E4 CA=; (P7
M80"+%V< B1=M (@7= "&&'P A1B& (,9D "!&9L @!JG 'X:M0!]&\< ?!SB
M 'H=]0!Y'?\ >!W_ '@=_P!X'?\ Y2(  - I  "_+   L"H  *<G  "@(P
MG1\  )H:#@"5'!@ D1TD (X>+P",'CD B1Y! (<?20"%'U  @Q]6 ((?7 "
M'V( ?Q]I 'T@< !\('@ >B"! 'DAC !W(9< =2*D '0BL@!S(\, <B/? ' D
M\P!O)/\ ;R3_ &XD_P!N)/\ W2D  ,@P  "W,@  J#   )XN  "7*@  DR<
M ) C"@",(Q, B"0? (0E*@"")30 @"8] 'TF1 !\)DL >B92 '@F6 !W)EX
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M 5@U_P%9-?\!R#@  +<^  "D/@  ECT  (L\  "#.@  ?3<  '@T  !T- L
M<#43 &TU'0!J-2< :#8P &8V. !D-C\ 8S9& &$V30!@-E, 7C=: %TW8@!<
M-VH 6CAT 5DX?P%7.(P!5CF9 54YJ )4.;D"4SK/ E,ZZP)3.OL!4SK_ 5,Y
M_P%3.?\!Q#P  +)!  "@0   DD   (8_  !^/0  >#H  ',X  !N.0@ :CD1
M &<Y&@!D.B0 8CHL & Z- !>.CP 73M# %L[2@!:.U  6#M7 %<[7P!6/&<
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M> %(184!1T64 45%HP)%1K0"1$;) D1&YP)$1?@"1$7_ D5%_P)%1?\!ND8
M *9(  "42   AD@  'M'  !R1@  :D(  &-#  !>1   6D4+ %9%$@!41AL
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M 3=2G@$V4J\!-5+$ 352X@$V4O4!-E'_ 390_P$W4/\!KD\  )E/  ")3P
M>T\  '!/  !F3P  7$X  %1/  !/40  2E(! $93# !#5!( 050; $!5(P ^
M52L /58R #Q6.@ [5D$ .E9) #E740 X5UH -E=C #57;P T5WP!,U>, 3%7
MG $P5ZT!,%?" 3!7X $P5O0!,5;_ 3%5_P$Q5?\!J%(  )52  "$4@  =U(
M &Q2  !B4@  6%,  $]4  !)5@  1%<  $!9"  ]6A  .UH7 #E;(  X6R<
M-UPO #9<-@ U7#X -%Q& #-=3@ Q75< ,%UA "]=;  N77H +%V) "M=F@$J
M7:L!*EV_ 2E=W@$J7/(!*EO^ 2M;_P$K6O\!HU4  (]5  !_50  <E4  &=6
M  !>5@  5%<  $Q9  !%6P  /UT  #I?!  V8 T -&$3 #)B'  Q8B, ,&(K
M "]C,@ N8SH +6-" "QC2@ J9%, *61= "AD:0 G9'8 )F2& "5DEP D9*D
M(V2] ")DV@ C8_$ (V+] 21A_P$D8?\!G%@  (E8  !Z60  ;ED  &-9  !:
M6@  4%P  $A>  !!8   .F,  #1F   O: H +&D0 "II%P I:A\ *&HF "=J
M+@ F:S4 )6L] "1K1@ C:T\ (FQ9 "!L90 ?;'( 'FR" !ULE  <;*8 &VNZ
M !IKU  ;:NX '&G\ !QH_P <:/\ E5P  (-<  !U7   :5T  %]=  !67@
M3&$  $-D   \9P  -6H  "]M   H< 0 (W(- "%R$@ @<QH 'W,A !YS*  =
M=#  ''0X !MT0  :=$H &714 !=U8  6=6X %75^ !1UD  3=*( $G2V !%T
MSP 2<^P $G+Z !-Q_P 3<?\ CF   'U@  !O80  96$  %MB  !19   2&<
M #YK   W;@  ,'$  "EU   B>   ''L' !=]#@ 6?1, %7T; !1^(@ 3?BH
M$GXQ !%^.@ 1?D0 $'].  ]_6@ .?V@ #7]X  Q_B@ +?IT "GZP  E]Q@ *
M?>0 "GST  M[_0 +>O\ AF4  '=E  !J90  868  %9H  !,:P  0F\  #ES
M   Q=P  *GH  "-^   <@0  %80  !"'"  -B0X #(D4  R)&P +B2, "HDK
M  F),P (B3T !HE(  6)5  $B6$  HEQ  &)@P  B98  (BI  "'O@  A]H
M (;L  "&]0  AOH ?FH  '%J  !G:P  6VP  %!P  !&=   /'@  #-]   J
M@0  (X4  !R(   5C   $(\   R2!@ &DPP  I,1  "4%@  E!T  )0D  "5
M+   E34  )5   "53   EED  )9I  "5>@  E8X  )2A  "4M0  D\P  )+F
M  "2\@  DO< >'   &UP  !@<@  5'4  $EY   _?@  -8,  "R(   CC0
M&Y$  !24   /EP  "IH   2= P  G@D  )\.  "?$@  H!<  * =  "A)0
MHBT  *(W  "C0P  HU   *-?  "C<0  HX0  **9  "BK0  H<(  *'<  "A
MZP  H/( <W8  &9W  !9>P  38   $*%   XBP  +I   "25   ;F@  %)X
M  ZA   )I    J<   "J    JP0  *L*  "L#0  K1$  *T6  "N'   KR0
M + M  "Q.0  L48  +)5  "R9@  LGD  +*.  "QHP  LK<  +'*  "QX
ML>D ;'X  %^"  !2AP  1HT  #N3   PF0  )IX  !RC   3IP  #:L   >N
M    L@   +4   "W    N    +D"  "Y"   N@P  +L0  "\%   O1L  +\C
M  #!+0  PCH  ,))  ##6@  PVP  ,2"  #$EP  Q*L  ,2\  #$RP  Q-H
M98D  %B.  !+E0  /YL  #.B   HJ   ':T  !2Q   -M@  !KD   "\
MOP   ,,   #$    Q0   ,8   #'    R00  ,H)  #+#0  S1$  ,\8  #2
M(0  U2T  -8\  #830  V5\  -IS  #:B@  VYX  -NN  #;N@  W,, 7I8
M %&<  !$HP  .*H  "RQ   @MP  %;L   V^   $P@   ,4   #)    S0
M -    #2    T@   -4   #6    V0   -L   #>!0  X H  .(/  #E%@
MZ"   .PM  #M/@  [5$  .YE  #O>@  [X\  /"?  #PJP  \+, _P 0 /\
M#@#_  X _P 2 /\ '0#_ "D _P U /\ 00#_ $T _@!6 /L 7P#X &8 ]@!M
M /0 = #R 'D \0!_ /  A #N (D [0"/ .L E0#J )L Z "B .8 J@#E +,
MXP#  .$ T@#@ .H WP#Y -T _P#= /\ W0#_ -X _P#> /\ _P - /\ "@#_
M  D _P / /\ & #_ "0 _@ Q /L /0#X $@ ] !2 /  6@#M &( ZP!I .D
M;P#G '4 Y0!Z ., ?P#B (4 X "* -X D #< )8 V@"= -@ I0#5 *\ T@"Z
M -  R@#. ., S0#T ,L _P#+ /\ RP#_ ,L _P#+ /\ _P ( /\  P#_  4
M_P , /P % #W !\ \@ K .\ -P#K $( YP!, .0 50#@ %T W0!D -H :@#8
M '  U0!U -( >@#0 (  SP"% ,T BP#+ )( R0"9 ,< H0#% *H PP"U ,$
MPP"_ -H O@#N +T _ "\ /\ O #_ +P _P"\ /\ _P   /\   #_    ^0 '
M /$ $ #J !H Y  E -\ ,0#; #P UP!' -( 4 #. %< RP!> ,D 90#& &H
MQ0!P ,, =0#! 'H P "  +X A@"\ (T N@"4 +D G "W *4 M0"P +, O0"Q
M ,\ KP#H *X ^ "N /\ K0#_ *T _P"M /\ _P   /\   #]    [@ ! .,
M# #: !0 T0 ? ,P *P#( #8 Q0!  ,( 2@"_ %( O !9 +H 7P"X &4 M@!J
M +0 ;P"S '4 L0!Z +  @0"N (@ K0"/ *L F "I *$ IP"K *4 N "C ,@
MH@#B *$ \P"@ /X H #_ *  _P"@ /\ _P   /8   #J    X    -, !@#)
M  \ P@ 8 +T ) "Y "\ M@ Z +0 0P"Q $P K@!3 *P 60"J %\ J0!D *<
M:@"F &\ I !U *, >P"A (( H "* )X DP"< )T F@"G )@ M "6 ,, E0#<
M )0 [P"3 /L DP#_ ), _P"2 /\ ^04  .H+  #<#0  RPH  ,(%  "\  H
MM@ 1 +$ ' "N "@ J@ S *< /0"D $4 H@!- *  4P"> %D G !? )L 9 ":
M &H F !P )< =@"5 'X DP"& )(!CP"0 9D C@*D (P"L0"+ \  B076 (@&
M[0"(!_H APC_ (8(_P"&"/\ [P\  -X4  #*%0  O!(  +,0  "N#   JP8-
M *<#%0"B!2  GP<L )P(-@"9"#\ EPE' )4)3@"3"50 D0I: ) *7P"."F4
MC0IK (L*<@"*"WD B N" (<+C "%#)< @PRB ($-L " #<  ?PW8 'T.[P!\
M#_T >P__ 'L0_P![$/\ YA<  -$>  "]'0  KQP  *89  "A%0  GA $ )T-
M#P"8#AD E XE )$/+P"/$#D C!!! (H02 "($$\ AQ!5 (406P"$$6$ @A%G
M ( 1;@!_$74 ?1%^ 'P2B !Z$I0 >!*@ '<3K@!U$[X =!35 ',5[@!Q%OT
M<1;_ '$6_P!P%O\ W!\  ,8E  "S)0  I2,  )PA  "6'@  DAD  )$4"P"-
M%!0 B14? (86*0"#%C, @1<\ ( 70P!^%TH ?!=0 'H75@!Y&%P =QAB '88
M:0!T&'$ <QEZ '$9A !O&I  ;AJ= &P;JP!K'+L :AS0 &D=[ !H'OL :![_
M &<>_P!G'O\ T28  +TJ  "K*@  G2H  ),H  "-)0  B"(  (8=!@"#&Q
M?QP: 'P=) !Z'2X =QXV '8>/@!T'D4 <A]+ '$?40!O'U@ ;A]> &P?90!K
M(&T :2!V &@A@0!F(8T 92*: &,BJ !B([@ 82/- & DZ0!@)/H 7R3_ %\D
M_P!?)/\ RBP  +8O  "D+P  EB\  (PM  "%*@  @"@  'TD  !Z(@T =B,5
M ',C( !Q)"D ;R0R &TD.@!K)4$ :B5' &@E30!F)50 925: &0F80!B)FD
M829R %\G?0!>)XH 72B7 %LII0!:*;4 6BK* %DJYP!8*O@ 6"K_ %@J_P!8
M*O\ Q3$  *\S  ">,P  D#,  (8R  !_+P  >2T  '4J  !R* H ;R@2 &LI
M&P!I*24 9RHM &4J-0!C*CT 8BI# & J2@!?*U  7BM7 %PK7@!;+&8 62QO
M %@M>@!7+8< 5BZ5 %0NHP!3+[, 4R_' %(OY0!2+_< 4B__ %(O_P!2+_\
MP38  *HV  "9-@  BS8  ($U  !Y,P  <S$  &\O  !K+@8 :"T0 &0N& !B
M+B$ 8"\J %XO,0!<+SD 6R]  %DO1@!8+TT 5S!3 %8P6P!4,6, 4S%L %(R
M=P!1,H0 3S.2 $XSH0!-,[$ 333% 4PTXP%,-/8 3#3_ $PT_P!,,_\ NSD
M *8Y  "5.0  ASD  'PY  !T-P  ;C0  &DS  !E,@( 83(- %XR% !<,QX
M6C,F %@S+@!6,S4 530\ %,T0P!2-$H 4310 % U6 !.-6  339J $PV=0!+
M-X( 2C>0 $DXGP!(.+ !1SC# 4<XX0%'./4!1SC_ 4<X_P%'./\!MSL  *(\
M  "1/   @SP  '@\  !P.@  :C<  &0V  !@-@  7#8+ %DW$@!6-QH 5#<C
M %(W*P!0-S( 3S@Y $TX0 !,.$< 2SA. $HY50!).5X 2#IH $<Z<P!&.X
M13N. $0\G@!#/*X!0CS" 4(]WP%"//,!0CS_ 4(\_P%"._\!LST  )X^  "-
M/@  ?SX  '4^  !L/0  9CH  & Y  !;.@  5SH( %,[$ !1.Q@ 3CL@ $P[
M* !+.R\ 23PV $<\/0!'/$0 1CU+ $4]4P!$/EP 0SYF $(_<0!!/WX 0#^-
M #] G  ^0*T!/4#  3U W0$]0/(!/4#_ 3X__P$^/_\!KD   )I   ")00
M?$$  '%!  !H0   83P  %L]  !6/@  4CX% $X_#@!,/Q4 23\= $= )0!&
M0"P 1$ S $- .@!"04( 04%) $!!40 _0EH /D)C #U#;P \0WP .T.+ #I$
MFP Y1*L!.42^ 3A$VP$Y1/$!.4/^ 3E#_P$Y0_\!JD(  )9#  "&0P  >$,
M &Y#  !E0P  74   %9   !10@  34(" $E## !&0Q( 1$0: $)$(@!!1"H
M/T4Q #Y%.  ]13\ /$9' #M&3P Z1E< .4=A #A';  W1WH -DB) #5(F0 T
M2*H -$B] #-(V0 T2/  -$?] #1'_P U1O\ ID0  ))%  ""1@  =48  &I&
M  !A10  640  %%$  !,1@  2$<  $1'"@!!2!  /TD8 #U)(  \22< .DHN
M #E*-@ X2CT -TM$ #9+3  U2U4 -$Q? #-,:@ R3'< ,4R& #!,EP O3:@
M+DV[ "Y-U0 N3.\ +TS] "]+_P P2_\ H4<  (Y(  !^2   <4@  &9)  !=
M2   54@  $Q)  !'2@  0DL  #],!@ [30X .4X5 #=.'0 V3R0 -4\K #-/
M,P R4#H ,5!" #!02@ O45( +E%< "U19P L474 *U&$ "I2E0 I4J8 *5*Y
M "A2T@ I4>X *5#\ "I0_P J3_\ G$H  (E*  !Z2P  ;4L  &-,  !:3
M44P  $A-  !#3P  /5   #E2 @ U4PP ,U02 #%4&0 P52$ +E4H "U5+P L
M5C< *U8^ "I61@ I5D\ *%=9 "=79  F5W( )5>! "17D@ C5Z0 (E>W ")7
MSP B5^P (U;Z "-5_P D5?\ EDT  (1.  !U3@  :4X  %]/  !63P  35
M $52   _4P  .58  #-8   O6@@ *UL/ "I;%0 H7!T )UPD "9<*P E7#,
M)%TZ "-=0P B74P (5U6 "!>80 ?7FX 'EY^ !U>CP <7J$ &UZT !I=S  ;
M7>D &USY !Q;_P <6_\ D%$  'Y1  !P40  9%(  %M2  !24P  2E0  $%7
M   [60  -5L  "Y>   H8 , )&(, ")C$0 A8Q@ 'V0@ !YD)P =9"X '&0V
M !ME/@ :94< &651 !AE70 796H %F5Z !5EBP 499X $V6Q !)ER  29.<
M$V/W !1B_P 48O\ B50  'A5  !K50  8%8  %=6  !/5P  1ED  #U<   V
M7P  ,&(  "ED   C9P  '6H' !EL#@ 8;!, %FT: !5M(0 4;2D %&TP !-M
M.0 2;D( $6Y, !!N6  /;F4 #FYU  UNAP -;IH #&VM  MMP@ +;.  #&OS
M  UK_0 -:O\ @ED  ')9  !F60  7%H  %1:  !*7   05\  #EC   Q9@
M*FD  "1L   =;P  %W(  !)U"0 /=P\ #G<4  YW&P -=R, #'<J  MW,P *
M=SP "7='  AW4@ '=U\ !7=O  1W@  #=Y0  7:G  !VNP !==4  73K  )T
M]@ "=/P >UT  &U=  !B7@  65X  $Y@  !%8P  /&<  #-K   K;@  )'(
M !YU   7>0  $GP   U_!@ )@0P !8$1  .!%@ "@1T  8$D  "!+0  @C8
M ()   ""3   @ED  ()H  "">0  @HT  (&@  " M   @,L  '_G  !^\@
M?OD =&(  &AB  !>8@  4V0  $EG   _:P  -G   "UT   E>   'GP  !>
M   1@P  #88   B)!  "BPH  (L.  "+$P  C!@  (P?  "-)@  C2\  (XY
M  ".1   CE$  (Y@  ".<0  CH4  (Z9  "-K0  C,,  (S?  "+[@  B_8
M;F@  &1G  !8:0  36P  $)Q   X=@  +WL  "9_   >A   %H@  !",   ,
MCP  !I(   "5    E@<  )<,  "7#P  F!,  )D8  ":'P  FR8  )LP  "<
M.P  G$@  )Q7  "<:   G'L  )R0  ";I0  F[H  )K0  ":YP  FO$ :FT
M %YO  !1<@  1G<  #M\   Q@@  )X<  !Z,   6D0  $)4   J9   $G
M *    "B    HP$  *,&  "D"P  I0X  *82  "G%P  J!X  *HF  "K,0
MJSX  *Q-  "L70  K'   *R%  "LFP  JZ\  *O#  "KV0  JN@ 9'4  %=Y
M  !+?@  /X0  #2*   ID   'Y8  !:;   0GP  ":,   &G    J@   *X
M  "P    L    +$   "R P  M @  +4-  "V$   MQ4  +D=  "[)@  O#,
M +U!  "]4@  O60  +YY  "^D   O:0  +VW  "]Q@  O=< 7'\  %"%  !$
MBP  .)(  "R9   AGP  %Z0  !"I   )K@   +(   "V    N0   +T   "_
M    OP   ,    #!    PP   ,0%  #&"@  QPX  ,D3  #+'   SB8  - U
M  #110  TE<  -)K  #3@@  TY<  -.I  #2N   TL0 58P  $F3   ]F@
M,*(  "6H   :K@  $;0   FY    O0   ,$   #$    R    ,L   #-
MS0   ,\   #0    T@   -0   #8    V@8  -T,  #@$0  XQH  .8G  #G
M.   Z$H  .E=  #J<@  ZX@  .N;  #LJ   [+( _P - /\ "P#_  L _P 0
M /\ &@#_ "8 _P R /\ /0#_ $@ ^P!2 /@ 6@#V &( \P!I /$ ;P#P '4
M[@!Z .P ?P#K (0 Z0"* .@ D #F )8 Y "= .( I0#A *\ WP"[ -T RP#;
M .8 V0#W -@ _P#8 /\ UP#_ -< _P#4 /\ _P ( /\ ! #_  0 _P - /\
M%0#^ "$ ^@ L /< . #T $, \ !- .T 50#J %T YP!D .0 :@#B '  X !U
M -X >@#= '\ VP"% -D BP#5 )$ TP"9 -$ H #/ *H S0"U ,L Q #) -T
MR #Q ,< _P#& /\ Q@#_ ,8 _P#' /\ _P   /\   #_    _P * /@ $0#Q
M !P [  G .D ,@#F #T X@!' -T 4 #9 %@ U0!? -( 90#0 &H S@!P ,P
M=0#* 'H R0!_ ,< A0#% (P PP"4 ,$ G "_ *4 O0"P +L O0"Z -  N #K
M +< ^P"V /\ M@#_ +8 _P"V /\ _P   /\   #]    \P % .D #@#A !8
MVP A -4 +0#1 #< S@!! ,H 2@#' %( Q !9 ,( 7P#  &4 O@!J +P ;P"[
M '0 N0!Z +< @ "V (< M ". +( EP"P *  K@"J *T MP"K ,@ J0#C *@
M]0"G /\ IP#_ *< _P"F /\ _P   /X   #Q    Y0   -< "@#- !$ QP <
M ,( )@"_ #$ O  [ +H 1 "W $P M !3 +( 60"Q %\ KP!D *T :0"L &\
MJ@!T *D >@"G ($ I@") *0 D0"B )L H "E )X L@"= ,$ FP#: )H [P"9
M /T F #_ )@ _P"8 /\ _0   /    #A    T0   ,8 ! "]  T MP 5 +,
M( "P "L K0 U *L /@"H $8 I@!- *0 5 "C %D H0!? *  9 "> &D G0!N
M )L =0": 'L F "# )8 C "5 )8 DP"A )$ K0"/ +L C0#/ (P Z0"+ /@
MC #_ (P _P", /\ \P(  .('  #,!P  OP0  +<   "Q  @ JP 0 *< &0"D
M "0 H  N )X -P"< $  F@!' )@ 3@"6 %0 E0!9 ), 7@"2 &0 D !I (\
M;P"- '8 BP!^ (H B "( )( A@"= (4 J0"# +@ @0#* (  Y0"  /4 ?P#_
M '\ _P!_ /\ Z T  - 0  "^$   L0X  *@-  "C"   H (, )P $P"8 !T
ME0 G )( ,0"0 #D C@%! (P!2 "* DX B0)4 (<"60"& E\ A -D (,#:P"!
M W( @ 1Z 'X$A !]!8X >P6: 'D&IP!X!K4 =@?( '4(XP!U"?0 = K_ ',*
M_P!S"O\ W14  ,07  "Q%P  I18  )P3  "6$0  E T$ ),(#0".!Q4 BPD@
M (@)*@"%"C, @PL[ ($+0@" "TD ?@M/ 'T,5 ![#%H >@Q@ '@,9P!W#&X
M=0UV '0-@ !R#8P < V9 &\.I@!M#K4 ; [) &L/Y@!J$/< :1#_ &D0_P!I
M$/\ T!T  +D>  "H'@  FQT  )(;  "+&0  B!4  (<1!P"%#A  @0\: 'X0
M) ![$"T >1 V '<1/0!V$40 =!%* ',14 !Q$58 <!%< &X28@!M$FH :Q)S
M &D3?0!H$XD 9A.6 &44HP!C%;, 8A7& &(6XP!A%O8 8!?_ & 7_P!@%_\
MQR(  + C  "?)   DB,  (DB  ""(   ?AT  'P9  !Z%0T =Q45 '06'P!Q
M%B@ ;Q<P &X7. !L%S\ :Q=% &D82P!H&%$ 9AA8 &487@!C&68 8AEO & 9
M>0!?&H4 71N2 %P;H0!;'+  6AS# %D=X !8'O0 6![_ %@>_P!8'O\ OR<
M *DH  "9*   BR@  ((G  ![)0  =B,  ',@  !Q' D ;AP1 &L<&@!I'2,
M9QTL &4=,P!C'CH 8AY! & >1P!?'DT 7AY4 %P?6P!;'V( 62!K %@@=@!6
M(8( 52&0 %0BG@!3(JX 4B/  %$CW0!1)/( 423_ %$D_P!1(_\ N2L  *,L
M  "3+   ABT  'PL  !T*@  ;R@  &LE  !I(@4 9B$. &,B%@!A(A\ 7R,G
M %TC+P!<(S8 6B,] %DD0P!7)$H 5B10 %4D5P!3)5\ 4B5H %$F<P!/)G\
M3B>- $THG !,**P 2RF^ $LIV@!**?$ 2BG_ $LI_P!+*?\ LRX  )XO  ".
M,   @3   '<O  !O+@  :BL  &4J  !C)P$ 7R<, %PG$P!:)QL 6"@D %8H
M*P!5*#( 4R@Y %(I0 !0*48 3RE- $XI5 !-*EP 3"IE $HK< !)*WP 2"R+
M $<MF@!&+:H 12Z\ $4NU@!%+N\ 12[^ $4N_P!%+?\ KC$  )HR  "),P
M?#,  '(S  !K,0  92\  & M  !=+   62P) %8L$ !4+!@ 4BP@ % L* !.
M+2\ 32TV $PM/ !*+4, 22U* $@N40!'+ED 1B]C $4P;0!#,'H 0C&) $$Q
MF !!,J@ 0#*[ #\RTP _,NX 0#+] $ R_P! ,O\ JC,  )8U  "&-0  >38
M &XU  !F-0  83(  %PP  !7,   5# & %$P#@!.,!4 3#$= $HQ)0!(,2P
M1S$R $8Q.0!$,4  0S)' $(R3P!!,U< 0#-@ #\T:P ^-7@ /36' #PVE@ [
M-J< .S:Y #HVT0 Z-NT .S;\ #LV_P [-O\ IC8  )(W  "".   =3@  &LX
M  !C-P  738  %<S  !3-   3S0# $LT# !)-!( 1C4: $4U(@!#-2D 034O
M $ U-@ _-CT /C9$ #TW3  \-U4 .SA> #HX:0 Y.78 .#F% #<ZE0 W.J4
M-CJX #4ZSP V.NP -CK[ #8Y_P W.?\ HC@  (XY  !^.@  <CL  &@[  !?
M.@  63D  %,V  !.-P  2C@  $8X"@!$.1  03D7 #\Y'P ^.28 /#DM #LZ
M-  Z.CL .3M" #@[2@ W.U, -CQ< #4\9P T/70 ,SV# #,^DP R/J0 ,3ZV
M #$^S0 Q/NH ,3[Z #(]_P R/?\ GCL  (L\  ![/   ;CT  &0]  !</0
M53P  $XZ  !).P  13P  $$]!P ^/0X /#T5 #H^'  Y/B, -SXJ #8_,0 U
M/S@ -#]  #- 2  R0%  ,4!: #!!90 O07( +D*! "U"D0 M0J( +$*U "M"
MRP L0ND +$+Y "U!_P M0?\ F3T  (<^  !W/P  :S\  &%   !9/P  4C\
M $D^  !$/P  0$   #Q!!  Y0@T -T(2 #5#&0 S0R$ ,D,H #%$+P P1#8
M+T0] "Y%10 M14X +$58 "M&8P J1F\ *49^ "A&CP G1Z$ )D>S "9'R0 F
M1N< )T;X "A%_P H1?\ E4   ()!  !S0@  9T(  %Y"  !50@  3D(  $5"
M   _1   .T4  #=&   T1PH ,4@0 "](%@ N21X +$DE "M)+  J23, *4HZ
M "A*0@ G2DL )DM5 "5+8  D2VT (TM\ ")+C0 A3)\ (4RQ "!,QP @2^8
M(4OW ")*_P B2O\ D$,  'Y$  !O1   9$4  %I%  !210  2D8  $%'   \
M2   -TD  #)+   N30< *TX. "E.$P G3QH )D\A "5/*  D3S  (U W ")0
M/P A4$@ (%!2 !]170 >46H '5%Y !Q1B@ ;49P &E&O !E1Q0 94>0 &E#V
M !M/_P <3_\ BD8  'E'  !K1P  8$@  %9(  !.2   1TD  #Y+   Y3
M,TX  "Y0   H4P( )%0+ ")5$  @518 'U8> !Y6)  =5BP '%8S !M7.P :
M5T0 &5=. !A760 76&8 %5AU !18AP 46)H $U>L !)7P@ 25^$ $U;T !15
M_P 45?\ A$D  '1*  !F2P  7$L  %-+  !+3   1$T  #Q/   U40  +U0
M "E6   D60  'EL' !I=#0 871( %UT9 !9>(  57B< %%XN !->-P 27D
M$5]* !%?50 07V( #U]Q  Y?@P -7Y8 #5^I  Q>O@ ,7MH #5WP  U<_  .
M7/\ ?DT  &Y.  !B3@  6$\  $]/  !(4   0%(  #A4   P5P  *EH  "1=
M   ?7P  &6(! !-E"0 19@\ $&84  ]F&P .9R( #6<I  UG,@ ,9SL "V=%
M  IG4  )9UT !V=L  9G?0 %9Y  !&:C  )FMP #9<\ !&7I  1D]0 $9/P
M=U$  &E2  !=4@  5%(  $Q3  !#50  .U@  #-;   K7@  )6$  !]D   9
M9P  $VH   ]M!@ +< P "' 1  =P%@ %<!T !' D  -P+  "<#4  ' _  !P
M2@  <%<  '!E  !P=@  <(H  &^>  !OL@  ;L@  &WE  !M\@  ;?D <%8
M &-6  !95@  _^+__TE#0U]04D]&24Q%  0)45<  $=8   ^6P  -E\  "YB
M   F9@  'VH  !EM   3<   #G,   MV!  %> L  7@/  !Y$P  >1D  'D?
M  !Z)@  >B\  'HY  !Z1   >E   'I?  !Z<   >H,  'J8  !ZK   ><(
M 'C?  !X[P  =_< :EL  %];  !66P  3%P  $)@   Y8P  ,&@  "AL   @
M<   &70  !-W   .>P  "7X   2! @  @@@  (,-  "#$   A!0  (49  "&
M(   AB@  (<Q  "'/   ATD  (=7  "':   AWL  (>0  "&I0  A;H  (73
M  "$Z@  A/0 96   %Q@  !180  1F0  #QI   R;0  *7(  "%W   9>P
M$H    V#   (AP   HH   "-    C@0  (X)  "/#0  D!   )$4  "2&0
MDR   )0I  "5,P  E4   )9.  "67P  E7(  )6(  "5G0  E+(  )3(  "3
MX@  D^X 864  %9F  !*:@  /VX  #5T   K>0  (7\  !F$   1B0  #(T
M  :1    E    )@   ":    FP   )P"  "=!P  G@L  )\.  "A$@  HA@
M *,@  "E*0  IC8  *9$  "F50  IF@  *9]  "FE   I:D  *2]  "DT0
MI.0 6VP  $]P  !#=0  .'L  "V!   CAP  &8T  !&2   +EP  !)P   "@
M    HP   *8   "H    J0   *H   "L    K00  *X)  "P#0  L1$  +,7
M  "U(   MBL  +<Z  "W2P  N%P  +AQ  "XB   N)T  +BQ  "WP@  M]
M5'8  $A\   \@@  ,8D  ":0   ;EP  $IT   RB   #IP   *L   "N
ML@   +8   "X    N    +H   "[    O0   +X   # !0  P0L  ,,0  #&
M%@  R2   ,HN  #+/@  S%   ,QD  #->@  S9$  ,VD  #-M   S<  38,
M $&*   UD0  *9D  !Z@   3I@  #*P   .Q    M@   +H   "^    P@
M ,8   #(    R    ,H   #+    S0   ,X   #0    T@$  -4(  #9#@
MW14  .$A  #B,0  Y$,  .56  #F:P  YH(  .>6  #GI0  YK  _P ) /\
M!0#_  8 _P . /\ %@#_ "$ _P M /\ . #] $, ^0!- /4 50#R %T \ !C
M .X :0#L &\ Z@!T .D >@#G '\ Y@"% .0 BP#C )$ X0"9 -\ H0#< *H
MV@"V -< Q@#5 .$ TP#T -( _P#1 /\ T0#_ ,\ _P#* /\ _P ! /\   #_
M  $ _P , /\ $@#Z !T ]@ H /, ,P#P #X [ !( .@ 4 #E %@ X@!> -\
M9 #= &H VP!O -D = #6 'H U !_ -( A0#0 (P S@"3 ,P G #) *4 QP"P
M ,8 O@#$ -0 P@#N ,$ _@#  /\ P #_ +\ _P"^ /\ _P   /\   #_
M^@ ' /$ #P#K !@ Y@ C .( +@#@ #@ VP!" -4 2P#1 %( S@!9 ,L 7P#)
M &4 QP!J ,8 ;P#$ '0 P@!Z ,$ @ "_ (8 O0". +L E@"Y *  MP"J +8
MMP"T ,H L@#F +$ ^ "P /\ KP#_ *\ _P"P /\ _P   /\   #W    Z@ "
M .$ # #7 !, T  = ,P * #) #( Q@ \ ,( 10"_ $T O !3 +H 60"X %\
MMP!D +4 :0"T &X L@!T +$ >@"O (  K0"( *P D0"J )H J "E *8 L0"D
M ,$ HP#< *$ \@"A /\ H #_ *  _P"A /\ _P   /<   #H    V0   ,L
M" ## !  O0 8 +D (@"V "P M  V +( /P"O $< K !- *L 5 "I %D IP!>
M *8 8P"E &@ HP!N *( = "@ 'H G@"" )P BP"; )4 F0"? )@ K "6 +H
ME #/ ), ZP"2 /L D@#_ )( _P"1 /\ ]P   .<   #3    Q@   +L  @"S
M  P K0 2 *H ' "G "8 I  P *, . "@ $  G@!' )P 3@": %, F0!8 )<
M70"6 &, E0!H ), ;@"2 '0 D !\ (\ A0"- (\ BP": (H IP"( +4 A@#'
M (4 Y "$ /4 A #_ (, _P"# /\ [    -,   #! 0  M    *P   "F  <
MH  . )T %@": "  EP I )4 ,@"3 #H D0!! (\ 2 "- $T C !3 (L 6 ")
M %T B !C (< :0"% &\ @P!W (( @ "  (H ?@"6 'T HP![ +  >@#" 'D
MW0!X /$ =P#] '@ _P!X /\ W@H  ,0+  "R#   I@L  )T(  "9!   E0 *
M )$ $0". !D BP C (D + "' #0 A0 [ (, 0@"" $@ @ !. '\ 4P!] %@
M? !> 'L 9 !Y &H > !R '8 >P!T (8 <P"2 '$ GP!P *T ;@"^ &T!U@!M
M NT ; /Z &P#_P!L _\ SA   +<1  "F$@  FA$  )$0  "+#@  B0L# (<%
M# "$ 1, @0$< 'X")0!\ RX >@,V '@$/ !W!$, =05( '0%3@!S!50 <059
M ' &7P!N!F8 ;09N &L'> !J!X, : B0 &<)G0!E":P 9 F\ &,*U !C"^P
M8@SZ &(,_P!B#/\ PQ8  *T7  "=&   D!@  (<6  "!%   ?1$  'P.!@!\
M"@X > H6 '4+'P!R"R@ < PP &\,-P!M##X ; Q$ &L-2@!I#4\ : U5 &<-
M7 !E#6, 8PYK &(.=0!@#H$ 7PZ. %T/G !<$*L 6Q"] %H0U@!9$?  61']
M %D1_P!9$?\ N1L  *4=  "4'@  B!X  'X=  !X&P  =!@  '$5  !Q$0D
M;Q 1 &P0&0!I$"( 9Q$J &81,@!D$3D 8Q$_ &(110!@$DL 7Q)1 %T26 !<
M$E\ 6A-H %D3<@!7%'T 5A2+ %05F0!3%:D 4A:Z %$6T@!1%^T 41?] %$7
M_P!1%_\ LB   )XB  ".(@  @2,  '<B  !P(0  ;!X  &D;  !G& 0 9A4.
M &,6%0!A%AX 7Q8F %T6+0!<%S0 6A<[ %D700!8&$< 5AA- %485 !3&%P
M4AED %$9;@!/&GH 3AN( $T;EP!+'*8 2ARX $H=SP!)'>L 21W[ $D=_P!*
M'?\ K"0  )@E  "()@  >R<  '$F  !J)0  9B,  &(A  !@'@  7AP+ %L;
M$@!9'!H 5QPB %4<*0!4'#  4QTW %$=/0!0'4, 3QU* $T>40!,'E@ 2Q]A
M $D?:P!(('< 1R"% $8AE !$(J0 1"*V $,BS !#(^D 0R/Z $,C_P!#(O\
MIB<  ),I  "#*@  =BH  &TJ  !E*0  8"<  %PE  !9(P  5R$' %4A#P!2
M(18 4"$> $XA)0!-(BP 3"(S $HB.0!)(D  2")& $<C30!%(U4 1"1> $,D
M:0!")74 0":# #\FD@ ^)Z, /B>T #TGR@ ]*.@ /2CY #TG_P ^)_\ HBH
M (XK  !_+0  <BT  &@M  !A+   7"L  %@H  !4)@  428$ $XE#0!,)1,
M2B8: $@F(@!')BD 128O $0F-@!#)SP 02=# $ G2P _*%, /BE< #TI9@ \
M*G( .RJ! #HKD  Y*Z$ ."RR #<LR  W+.8 ."SX #@L_P X+/\ G2P  (HN
M  ![+P  ;S   &4P  !=+P  6"X  %,K  !0*@  3"H  $DJ"P!&*A$ 1"H7
M $(J'P!!*B4 /RHL #XK,P ]*SD /"M  #LL2  Z+%  .2U9 #@N9  W+G
M-B]_ #4OCP T,)\ ,S"Q #(PQP R,.4 ,S#W #,P_P T+_\ F2\  (<Q  !W
M,@  :S(  &(R  !:,@  5#$  $\O  !++0  1RX  $0N" !!+@X /RX4 #TN
M'  [+B( .2\I #@O+P W+S8 -C ^ #4P1@ U,4X -#%7 #,R8@ R,FX ,3-]
M # SC0 O-)X +C2P "TTQ0 M-., +C3V "\S_P O,_\ E3$  (,S  !T-
M:#4  %XU  !7-   430  $LR  !&,0  0C(  #\R!0 \,@T .3,2 #@S&0 V
M,R  -#,F #,S+0 R-#0 ,30[ # U0P P-4P +S95 "XV8  M-VP +#=[ "LW
MBP J.)P *3BN "@XPP H..( *3CU "HW_P J-_\ DC0  '\U  !Q-@  93<
M %LW  !4-P  338  $<V  !"-0  /38  #HV @ W-PL -#<0 #(W%@ Q.!T
M+S@D "XX*P M.3( +#DY "LY00 J.DD *CI3 "D[7@ H.VH )SMY "8\B0 E
M/)L )#RM ",\P@ C/.  )#ST "4[_P E._\ C38  'PX  !M.0  8CD  %@Z
M  !1.0  2CD  $0Y   ].0  .3H  #4[   R.P@ +SP. "T]%  L/1H *CTA
M "D]*  H/B\ )SXV "8^/@ E/T< )#]0 "- 6P B0&@ (4!V "! AP ?09D
M'T&K !Y!P  >0=X 'T#S !] _@ @/_\ B3D  '@Z  !I.P  7CP  %4\  !-
M/   1SP  $ \   X/0  -#X  #!    M004 *D(, "="$0 F0Q@ )$,> "-#
M)0 B0RP (40S "!$.P ?1$0 'D5. !U%60 <164 &T5T !I%A0 91I< &4:I
M !A&O@ 71=P &$7Q !E$_0 :1/\ A#P  ',]  !F/@  6S\  %(_  !*/P
M1#\  #U    V00  ,4,  "Q$   G1@$ )$<* "%(#P @210 'DD; !U)(@ <
M22D &THP !I*.  92D$ &$I+ !=+50 62V( %4MQ !1+@@ 32Y0 $DNG !)+
MO  12]D $DKP !-*_  42?\ ?S\  &]   !A00  5T(  $Y"  !'0@  04(
M #I#   R10  +4<  "A)   C2P  'DT& !M/#0 84!$ %U 7 !90'@ 54"4
M%% L !-1-  243T $5%' !%14@ 045\ #U)M  Y2?@ -49$ #5&D  Q1N  ,
M4=$ #5#L  U0^@ .3_\ >4,  &I$  !=1   4T4  $M%  !$10  /D8  #9(
M   O2@  *4P  "1/   ?40  &E,  !16"0 15PX $%@3 !!8&0 /6"  #E@H
M  U8,  -6#D #%A#  M83@ *6%H "%AH  =8>0 &6(P !5B?  18LP $5\H
M!5?F  57\P &5OP <T8  &1'  !92   4$@  $A(  !!20  .DH  #)-   K
M4   )5(  "!5   :6   %5H  !!=!@ ,8 P "F 0  E@%0 (8!P !V C  5@
M*P $8#0  V ]  %@20  8%4  &!C  !@<P  8(8  %^:  !?K@  7\0  %[B
M  !>\   7O@ ;$H  %]+  !52P  3$P  $5,   ]3@  -5   "Y3   G5@
M(%D  !I<   57P  $&(   UE!  (9PL  V<.  !H$P  :!@  &@?  !I)@
M:2X  &DX  !I0P  :4\  &E=  !I;0  :8   &F4  !HJ0  :+\  &?<  !F
M[@  9O< 9D\  %I/  !13P  2D\  $%1   X5   ,%<  "A;   A7@  &F(
M !1E   0:   #&L   =N P !< D  ' -  !Q$   <10  '(:  !S(0  <R@
M ',Q  !S/   =$@  '-6  !S9@  <WD  '..  !SHP  <KD  ''2  !QZP
M</0 85,  %93  !/4P  154  #M8   R7   *F   ")D   ;:   %&P   ]O
M   +<@  !G8   !Y    >@8  'H*  ![#@  ?!$  'T5  !^&P  ?R(  ( J
M  " -0  @$$  (!/  " 7P  @'$  ("&  " G0  ?[(  '[*  !^Y0  ??$
M7%@  %18  !)6@  /UT  #5A   L90  (VH  !MO   4<P  #G<   E[   #
M?P   ((   "$    A@$  (8&  "("@  B0T  (H0  "+%0  C!L  (XB  "/
M+   CS@  (]&  "/5@  CV@  (]^  "/E0  CJL  (W!  "-W   C.L 65T
M $Y?  !#8@  .&8  "YL   D<0  ''<  !1\   .@0  "(4   ")    C0
M )    "2    DP   )0   "6 P  EP@  )@,  ":#P  FQ,  )T:  "?(P
MH"X  * \  "@3   H%X  *!T  "?C   GZ(  )^W  ">RP  GN  4V0  $=H
M   \;0  ,7,  "=Y   =?P  %(4   V+   &D    )0   "8    G    )\
M  "A    H@   *0   "E    IP   *@$  "J"0  K T  *T2  "P&0  LB,
M +(Q  "R0@  LE0  +)I  "R@   LI@  +&L  "ROP  L<X 3&X  $!S   U
M>@  *H$  !^(   5C@  #I4   ::    GP   *0   "H    K    *\   "Q
M    L0   +,   "U    M@   +@   "Z    O 8  +X,  # $0  PQD  ,4F
M  #%-P  QDD  ,9=  #'<@  QXH  ,B?  #(KP  R+P 1GH  #F!   NB0
M(I   !>8   /GP  !Z4   "J    KP   +,   "W    O    +\   #!
MP@   ,0   #%    QP   ,D   #+    S0   ,\#  #2"@  UA   -P:  #=
M*@  WCP  -]0  #@90  X7L  .&1  #BH@  XJT _P " /\   #_  , _P ,
M /\ $P#_ !T _P H /X ,P#[ #X ]P!( /, 4 #P %< [0!> .L 9 #H &D
MYP!O .4 = #C 'D X@!_ .  A0#> (P W "3 -D G #6 *8 TP"Q -$ P #/
M -H S@#Q ,P _P#+ /\ RP#_ ,8 _P#! /\ _P   /\   #_    _P ( /L
M$ #V !D \@ D .\ +@#M #D Z !" ., 2P#@ %( W0!9 -D 7P#6 &0 TP!I
M -$ ;@#/ '0 S@!Y ,P ?P#* (8 R ". ,8 E@#$ *  P@"K ,  N0"^ ,T
MO #J +L _ "Z /\ N@#_ +H _P"V /\ _P   /\   #^    ]  $ .L #0#D
M !0 WP ? -L *0#8 #, TP ] ,X 10#* $T QP!3 ,4 60## %\ P0!D +\
M:0"] &X NP!S +H >0"X (  M@"( +0 D "R )H L0"E *\ L@"M ,0 K #A
M *L ]@"J /\ J@#_ *H _P"J /\ _P   /T   #N    X@   -4 "@#- !$
MQP 9 ,0 (P#! "T OP W +L /P"W $< M0!. +( 4P"P %D KP!> *T 8P"L
M &@ JP!M *D <P"H 'H I@"! *0 B@"C )0 H0"? )\ K "> +L G #2 )L
M[@": /\ F@#_ )D _P"9 /\ _@   .X   #>    RP   ,$ !0"Y  T M  4
M +$ '@"N "< JP P *H .0"G $$ I !( *( 30"A %, GP!8 )X 70"= &(
MFP!G )H ;0"8 ', EP![ )4 A "4 (X D@"9 )  I@". +0 C0#( (P Y@"+
M /D B@#_ (H _P"+ /\ \    -L   #'    N@   +    "H  H I  0 *
M& "= "$ FP J )H ,P"8 #L E@!! )0 2 "2 $T D0!2 (\ 5P". %P C !A
M (L 9P"* &X B !U (< ?@"% (@ @P"4 (( H "  *\ ?P#  'X W0!] /(
M?0#_ 'T _P!] /\ X    ,8   "U    J@   *(   ";  4 E0 - )( $P"0
M !P C0 D (L +0"* #0 B  [ (8 0@"% $< @P!- (( 4@"! %< ?P!< 'X
M8@!] &@ >P!P 'H >0!X (, =@"/ '4 G !T *H <@"Z '$ T0!P .P < #[
M '  _P!P /\ S00  +<&  "G!P  FP8  ),$  ".    B@ ( (8 #P"$ !8
M@0 > '\ )P!] "X ?  V 'H / !Y $( =P!' '8 3 !U %( <P!7 '( 70!Q
M &, ;P!K &X = !L 'X :P"* &D F !H *8 9P"V &8 RP!E .< 90#W &4
M_P!E /\ P P  *L-  ";#@  CPX  (8-  "!"P  ?@<! 'P!"P!Y !$ =P 8
M '4 (0!S "D <0 P &\ -@!N #P ; !" &L 1P!J $T :0!2 &@ 6 !F %\
M90!G &, < !B 7H 8 &' %\"E0!> J, 7 .S %P#QP!;!.0 6P7T %L&_@!;
M!O\ M1   *$2  "1$P  A1,  'P2  !V$0  <PX  '(,! !Q!PT ;@02 &P$
M&P!I!2, 9P4J &8&,0!D!C< 8P8] &('0P!A!TD 7P=. %X(50!="%P 6PEC
M %H);0!8"G@ 5PJ% %8+DP!4"Z( 4PNS %(,QP!2#.0 40WU %$-_P!1#?\
MK14  )D7  ")&   ?1D  '08  !M%P  :A0  &<1  !G#@< 9@P. &,,%0!A
M#!T 7PPE %T-+ !<#3, 6PTY %H-/P!8#44 5PU+ %8.40!5#ED 4PYA %(.
M:P!0#W8 3A"# $T0D@!,$*( 2Q"R $H1R !)$>4 21'W $D2_P!)$?\ I1D
M )(<  "#'0  =AX  &T=  !F'   8AH  %\7  !>% $ 7A$* %L0$0!9$1@
M5Q$@ %41)P!4$2X 4Q$T %$1.P!0$D$ 3Q)' $X23@!,$E4 2Q-> $D39P!(
M%', 1A2  $45CP!$%9\ 0Q:P $(6Q0!"%^, 0A?V $(7_P!"%_\ GQT  (P@
M  !](0  <2(  &@B  !A(0  7!\  %D<  !7&0  518& %05#@!1%10 3Q8<
M $X6(P!,%BH 2Q8P $H6-P!)%ST 1Q=# $872@!%&%( 0QA: $(99 !!&7
M/QI] #X;C0 ]&YT /!RN #L<PP ['.$ .QWU #L<_P \'/\ FB$  (<C  !X
M)   ;"4  &,E  !<)   5R,  %,@  !1'@  3QP" $T;# !+&A$ 2!L8 $<;
M( !%&R8 1!LM $,<,P!"'#D 0!Q  #\=1P ^'4\ /1Y8 #P>8@ Z'VT .1][
M #@@BP W(9L -B&M #4AP0 U(=\ -2'S #8A_P V(?\ EB,  (,F  !T)P
M:"@  %\H  !8)P  4R8  $\D  !,(@  22   $<@"0!$'P\ 0A\5 $ @'  _
M(", /B I #P@+P [(38 .B$] #DA1  X(DP -R)5 #8C7P T(VL ,R1Y #(E
MB0 Q)9H ,"6K # FOP O)MP ,";R # F_P Q)?\ D28  '\H  !Q*@  92H
M %PJ  !5*@  3RD  $LH  !()0  1"0  $$D!0 _) T /202 #LD&0 Y)!\
M-R0F #8D+  U)3, -"4Z #,F00 R)DH ,2=3 # G70 O*&D +BEW "TIAP L
M*9@ *RJJ "HJO0 J*MH *RKQ "LJ_@ L*?\ C2@  'PJ  !M+   8BT  %DM
M  !1+0  3"P  $<K  !#*   /R@  #PH @ Y* L -R@0 #4H%@ S*!P ,B@C
M # H*0 O*3  +RHW "XJ/P M*T< +"M1 "LL6P J+&< *2UU "@MA0 G+9<
M)BZH "4NO  E+M@ )B[P "8N_0 G+?\ BBL  '@M  !J+@  7R\  %8O  !.
M+P  2"X  $,M   _+   .RP  #<L   T+ D ,BP. # M$P N+1H +2T@ "LM
M)P J+BT *BXU "DO/0 H+T4 )S!. "8P60 E,64 )#%S ",Q@P B,I4 (3*G
M "$RNP @,M0 (3+O "(Q_  B,?\ ABT  '4O  !G,   7#$  %,Q  !+,0
M13$  $ P   [,   -C   #,P   P,08 +3$- "LQ$0 I,A< *#(> "<R)  E
M,RL )3,R "0S.@ C-$, (C1, "$U5P @-6, 'S5Q !XV@0 =-I, '#:E !LV
MN0 ;-M( '#;M !TV^P =-?\ @C   '$R  !C,P  630  % T  !)-   0C,
M #TS   W,P  ,30  "XU   K-0( *#8+ "4W$  D-Q4 (C<; "$X(@ @."@
M'S@P !XX-P =.4  '#E) !LZ5  :.F  &3IN !@Z?P 7.Y$ %SND !8[MP 5
M.]  %CKL !<Z^@ 8.?\ ?3(  &TT  !@-0  538  $TV  !&-@  0#8  #HV
M   T-@  +C@  "HY   F.@  (SL( " \#@ >/1( '3T8 !P]'P ;/B4 &CXM
M !D^-  7/CT %C]' !4_40 4/UX %#]L !- ?  20(\ $4"B !% M@ 00,X
M$3_K !(_^0 2/O\ >34  &DW  !<.   4CD  $HY  !#.0  /3D  #<Y   Q
M.@  *SP  "<]   B/P  'D$$ !I""P 80Q  %T,5 !5$&P 41"( $T0I !-$
M,0 21#H $45# !!%3@ 015L #D5I  Y%>0 -18P #46?  Q%L@ +1<D #$7E
M  U$]@ -1/\ =#D  &4Z  !8.P  3SL  $<\  ! /   .CP  #0\   N/@
M*$   "-"   ?1   &D8  !5("  22@T $4H2 !!*&  /2QX #DLE  U++0 -
M2S8 #$M   M+2@ *2U8 "4MD  A+=  '2X< !4N:  1+K@ $2L0 !4K@  5*
M\  &2?H ;CP  & ]  !4/@  2SX  $0^   ]/@  -S\  #%    J0@  )$4
M !]'   :20  %4P  !%.!0 .40L "U$0  I1%  )41L "%$B  =1*0 %43(
M!%([  -21@ !4E(  %)?  !2;P  4H$  %&6  !1J0  4;\  %#<  !0[@
M4/< :$   %M!  !000  2$$  $%!   [0@  -$,  "U%   F2   ($L  !M-
M   64   $5,   Y5!  *6 H !E@.  )8$@  61<  %D=  !9)0  62T  %DV
M  !900  64T  %I:  !::0  67P  %F0  !9I0  6+H  %C5  !7[   5_8
M8T0  %9%  !-10  144  #]%   W1P  +TD  "A,   B3P  &U(  !95   1
M6   #5H   E= P $7PD  & -  !@$   810  &$9  !B(   8B<  &(Q  !B
M.P  8D<  &)5  !C9   8G8  &*+  !BH   8;8  &'/  !@Z@  8/4 74@
M %))  !*2   0T@  #I*   R30  *E   "-3   <5P  %EH  !%=   -8
M"&,   -F 0  9P8  &@+  !I#@  :A$  &L5  !L&P  ;2(  &TJ  !M-
M;4   &U.  !M70  ;6\  &V$  !LF@  ;+   &O(  !KY@  :O, 6$T  $Y-
M  !(3   /DX  #51   L5   )%@  !U<   68   $&0   QG   ':P   6X
M  !P    <@,  '('  !S"P  =0X  '81  !W%@  >!P  'DC  !Z+0  >CD
M 'I'  !Z5@  >6@  'I\  !YE   >*H  'C!  !WWP  =^\ 5%$  $Q1  !"
M4@  .%4  "]9   F7@  'F(  !9G   0:P  "V\   5S    =P   'H   !\
M    ?@   '\"  " !@  @0H  (,-  "$$0  AA4  (@<  "))0  BC   (H^
M  ")30  B5\  (ES  "(BP  B*(  (>Y  "'T0  AN@ 4E8  $=7   \6@
M,E\  "AD   ?:0  %F\  !!T   *>0   GT   "!    A0   (@   "*
MC    (T   "/    D 0  )((  "3#   E1   )<5  "9'0  FR<  )LT  ";
M1   FE8  )IJ  "9@@  FIH  )BP  "8QP  E]X 2UP  $!@   U90  *VH
M "%Q   7=P  $'T   F#   !B    (P   "1    E0   )@   ":    FP
M )T   "?    H    *(   "D!0  I@H  *@.  "J%   K1T  *TJ  "M.0
MK4L  *U?  "M=P  K)   *NG  "KN@  J\L 168  #EK   N<0  (W@  !E_
M   0A@  "8T   "3    F    )T   "A    I0   *@   "K    JP   *X
M  "O    L0   +,   "U    MP$  +D'  "\#0  OQ,  ,(?  #"+@  PD
M ,)4  #!:P  P8,  ,";  #!K0  P;P /G(  #)X   G@   '(@  !*0   *
MEP   )T   "C    J    *T   "R    M@   +D   "[    O    +X   #
M    P@   ,0   #&    R    ,L   #.!0  T0T  -84  #7(P  V#4  -E)
M  #:7@  VW4  -N,  #<GP  W*L _P   /\   #_    _P ) /\ $ #_ !D
M_@ D /P +P#Y #D ] !# /  2P#M %( Z@!9 .< 7P#D &0 X@!I .  ;@#>
M ', W !Y -H ?P#7 (8 U ". -$ E@#/ *$ S "L ,H NP#( -( Q@#N ,8
M_P#% /\ Q0#_ +\ _P"Z /\ _P   /\   #_    _@ % /< #@#R !4 [@ ?
M .L *@#I #0 XP ] -X 10#9 $T U !3 -$ 60#. %X S !C ,H : #) &T
MQP!S ,4 >0## (  P0"( +\ D "] )L NP"F +D M "W ,@ M@#F +4 ^P"T
M /\ M #_ +, _P"N /\ _P   /\   #X    [0   .4 "P#= !$ UP : -(
M) #/ "X RP W ,< 0 ## $< P !. +X 4P"\ %D N@!> +@ 8P"V &@ M0!M
M +, <P"Q 'D KP"! *T B@"K )0 J0"@ *@ K0"F +X I0#; *0 ] "D /\
MHP#_ *, _P"B /\ _P   /8   #F    UP   ,L !@#$  X O@ 5 +L 'P"Y
M "@ MP Q +0 .@"P $$ K0!( *L 3@"I %, IP!8 *8 7 "D &$ HP!G *$
M; "@ ', G@!Z )T @P"; (X F0"9 )< I@"6 +8 E0#, )0 ZP"3 /T DP#_
M ), _P"3 /\ ]P   .0   #0    P0   +<  @"O  L JP 1 *< &0"E "(
MHP K *( ,P"? #L G !" )L 2 "9 $T EP!2 )8 5P"5 %L DP!A )( 9@"0
M &T CP!T (T ?0", (< B@"3 (@ H "' *\ A0#" (4 X@"$ /< A #_ (0
M_P"$ /\ Y0   ,T   "\    KP   *8   ">  < F@ . )8 % "4 !T D@ E
M )$ +0"0 #4 C0 \ (P 0@"* $< B !, (< 40"& %8 A !; (, 8 "! &<
M@ !N 'X =P!] ($ >P"- 'H F@!X *D =P"Z '8 TP!V .\ =@#^ '4 _P!U
M /\ T    +L   "K    GP   )<   "0  ( BP + (@ $ "& !< A  @ ((
M)P"! "\ ?P U 'T / !\ $$ >P!& 'D 2P!X %  =P!5 '8 6P!T &$ <P!I
M '$ <0!P 'L ;@"' &T E0!K *, :@"T &H R0!I .@ :0#Y &D _P!I /\
MP    *P   "< @  D (  (@   "#    ?P & 'L #0!Y !( =P : '8 (@!T
M "D <P P '$ -@!P #P ;P!! &T 1@!L $L :P!0 &H 5@!H %P 9P!D &4
M; !D '8 8P"" &$ D !@ )\ 7P"O %X PP!> .$ 7@#T %T _P!= /\ M <
M * )  "0"P  A L  'P*  !W!P  = 0  '$ "0!O  \ ;0 5 &L ' !I ",
M:  J &< ,0!E #8 9  \ &, 00!B $8 8 !, %\ 4@!> %@ 70!? %L : !:
M '( 6 !^ %< C !6 )L 50"K %0 O@!4 -H 4P#O %0 ^P!4 /\ J0T  )8.
M  "'$   >A   '(0  !L#@  :0P  &<) P!F! L 9  0 &( %P!@ !X 7@ E
M %T *P!< #$ 6@ W %D / !8 $( 5P%' %8!3@!5 E0 4P)< %(#90!1 V\
M3P1[ $X$B@!-!9D 3 6I $L%O !*!M0 2@?M $H'^0!*!_\ H1   (X2  !^
M%   <Q0  &H4  !D$P  8!$  %X/  !=#04 70D- %H&$@!8!QD 5@<@ %4'
M)P!3!RT 4@@S %$(. !0"#X 3PE$ $X)2@!,"5$ 2PI9 $H*8@!("VT 1PMZ
M $8,B !$#)@ 0PRI $(-O !"#=4 0@WN $(-^P!"#?\ FA0  (<6  !X&
M;!D  &,9  !=&   618  %83  !4$0  5 X( %,-#@!1#10 3PT; $T-(@!,
M#2@ 2PTN $H-- !)#3H 1PY! $8.1P!%#D\ 1 Y7 $(/80!!$&P /Q!Y #X0
MB  ]$9@ .Q&I #L1O  Z$=8 .A'P #H2_0 [$?\ DQ@  ($:  !S'   9QT
M %X=  !8'   4QL  % 8  !.%@  3!,# $P1"P!*$!  2!$7 $81'@!%$20
M1!$J $(1, !!$3< 0!(] #\21  ]$DP /!-4 #L37@ Y%&D .!1V #<5A0 V
M%98 -!:G #06N@ S%M, ,Q;N #06_  T%O\ CAL  'P=  !N'P  8R   %H@
M  !3(   3AX  $H=  !(&@  1A@  $46!P!#%0X 0143 #\5&@ ^%2  /14G
M #L5+0 Z%C, .18Z #@600 W%TD -1=1 #086P S&68 ,AES # :@P O&I0
M+ANE "T;N  M&]  +1OL "X;^P N&_\ BAX  '@@  !J(@  7R,  %8C  !/
M(@  2B$  $8@  !#'@  01L  #\: P ]&@P .QD1 #D9%@ W&AT -AHC #4:
M*0 T&C  ,QLV #$;/@ P'$8 +QQ/ "X=60 M'60 +!YQ "L?@0 J'Y( *1^D
M "@@MP G(,X )R#K "@@^@ I'_\ AB   '0C  !G)   7"4  %,E  !,)0
M1R0  $(C   _(0  /1\  #H>   W'@D -1X. #,>$P Q'AH ,!X@ "\>)@ N
M'RT +1\S "P@.P K($, *B%, "DA5@ H(F( )B)O "4C?P D(Y  (R.B "(D
MM0 B),P (B3I ",D^0 D(_\ @B,  '$E  !C)@  62<  % H  !))P  0R<
M #\F   [)   ."(  #4B   R(@8 ,"(- "XB$0 L(A< *B(= "DB(P H(RH
M)R,Q "8D.  E)4$ )"5* ",F5  B)F  (2=M " G?0 ?)X\ 'BBA !XHM  =
M*,H '2CH !XH^  ?)_\ ?B4  &XG  !@*0  5BD  $TJ  !&*@  02D  #PH
M   W)P  -"8  # F   M)@, *R<+ "@G$  G)Q0 )2<: "0G(0 C*"< (B@N
M "$I-@ @*3X 'RI( !XJ4@ =*UX '"MK !LK>P :+(T &2R? !@LL@ 8+,D
M&"SG !DK]P :*_\ >B<  &HJ  !=*P  4RP  $HL  !#+   /BL  #DK   T
M*@  ,"H  "LJ   I*P  )BL( ",L#@ B+!( ("P8 !\L'@ >+24 '2TL !PM
M,P ;+CP &BY% !DO4  8+UP %R]I !8P>0 5,(L %#"> !0PL0 3,,< $S#E
M !0P]@ 5+_\ =BH  &<L  !:+0  4"X  $@N  !!+@  .RX  #8M   Q+0
M+"T  "<O   D+P  (3 % !\Q#  <,1  &S(5 !HR'  9,B( &#(I !<S,0 6
M,SD %3-# !0T30 3-%D $C1G !$U=P 1-8D $#6< ! UL  .-<8 #S3D ! T
M]0 0-/\ <BP  &,N  !7,   33   $4P   ^,   .#   #,P   O,   *3$
M "0R   A,P  '34" !HV"0 7-PX %3<3 !0X&0 3.!\ $C@F !(X+@ 1.38
M$#E  ! Y2P ..5< #CID  TZ=  ,.H8 ##J9  LYK  *.<$ "CG>  LY\0 ,
M./P ;B\  %\Q  !3,@  2C,  $(S   [,P  -C,  #$R   L,P  )S0  "$V
M   =.   &3D  !4[!@ 2/0P $#X0 ! ^%0 ./AP #CXC  T^*@ ,/C, ##X\
M  L_1P */U( "#]@  <_;P &/X$ !3^4  0_J  #/KP !#[7  4^[  %/O<
M:3,  %LT  !0-0  1S4  #\U   Y-0  -#4  "XU   I-P  (S@  !X[   :
M/   %C\  !)!!  .0PH #$0.  I$$P )1!D "$0@  =$)P &1"\ !40X  -%
M0@ "14X  $5;  !%:@  17P  $60  !$I   1+D  $31  !$Z@  0_4 9#8
M %<W  !,.   0S@  #PX   W.   ,3@  "LY   E.P  (#T  !I    60@
M$D0   Y'!  +20D !TH-  1+$0 !2Q8  $L<  !+(P  2RL  $LT  !+/@
M3$D  $Q7  !,9@  3'<  $N,  !+H0  2[4  $K.  !*Z0  2O4 7SH  %([
M  !(.P  0#L  #H[   T.P  +CP  "<^   B00  '$,  !9&   220  #DL
M  M. P '4 @  E$,  !1$   4A,  %,8  !3'P  4R8  %,O  !3.0  4T4
M %-2  !380  4W(  %.'  !2G   4K$  %'*  !1YP  4?0 63X  $X^  !%
M/@  /CX  #@^   P0   *4(  "-$   =1P  %TH  !)-   .4   "U,   95
M @  5P<  %@+  !9#@  6A$  %H5  !;&@  7"$  %PJ  !<-   7#\  %Q-
M  !<6P  7&P  %R!  !;EP  6ZT  %K%  !:Y   6?, 5$(  $I"  !"0@
M/$(  #1#   L1@  )4D  !Y,   73P  $E,   Y6   *60  !5L   !>
M8 0  &$(  !B#   8PX  &01  !E%@  9AP  &<C  !G+0  9SD  &=&  !G
M50  9V8  &=Z  !FD0  9:@  &7   !DW@  9/  3T8  $=&  ! 10  -T<
M "]*   F30  'U$  !A5   260  #5P   A@   "8P   &8   !H    :@
M &L$  !L"   ;0P  &\.  !P$@  <A<  ',=  !T)@  =#(  '0_  !T3@
M<U\  '1R  !SB@  <J$  '&X  !QU   <.P 3$H  $5*   [2P  ,DX  "E2
M   @5@  &%L  !)?   -9   !V@   !K    ;P   '(   !U    =@   '<
M  !Y @  >@8  'P*  !^#@  @!$  ((6  "$'@  A"D  (0V  "$10  A%8
M (-J  "#@0  @ID  (&Q  " R0  @.4 2DX  #]0   U4P  *U<  ")<   9
M8@  $F<   QL   %<0   '4   !Y    ?0   ($   "#    A0   (8   "(
M    B0   (L$  "-"   CPT  )(0  "4%@  EB   )8L  "6.P  EDP  )5@
M  "5=@  E)   ).G  "2O0  DM4 1%4  #E9   O70  )&,  !II   2;P
M#'4   1[    @    (4   ")    C0   )$   "3    E    )8   "8
MF@   )P   ">    H 8  *(+  "E$   J!<  *DC  "I,0  J4,  *E6  "H
M;0  IH<  *>>  "FLP  I<< /EX  #)C   G:@  '7   !-X   ,?P   X4
M  "+    D0   )8   ";    GP   *(   "D    I0   *<   "I    JP
M *T   "P    L@   +4"  "W"0  NQ   +X8  "^)@  OC@  +Y+  "]80
MO'H  +N4  "ZJ0  NKD -VH  "MP   @>   %H    V(   %CP   )8   "<
M    H@   *<   "L    L    +,   "V    MP   +D   "[    O0   +\
M  #"    Q0   ,@   #*    S@@  -(0  #5&P  U2P  -1   #45P  TVX
M -2&  #4FP  TZL _P   /\   #_    _P % /\ #@#_ !4 _  @ /D *@#V
M #0 \0 ] .T 1@#I $T Y@!3 .0 60#A %X W@!C -P : #9 &X U0!S -,
M>0#0 (  S@"( ,L D0#) )P Q@"G ,0 MP#" ,P P #L +\ _P"^ /\ O0#_
M +< _P"R /\ _P   /\   #_    ^@ ! /, "P#M !( Z  ; .4 )0#D "X
MWP X -@ 0 #2 $< S@!. ,L 5 #( %D Q@!> ,0 8P#" &< P !M +\ <P"]
M 'H NP"! +D BP"V )4 M "A +( KP"P ,( K@#C *X ^@"L /\ K0#_ *D
M_P"F /\ _P   /\   #R    Y@   -T !P#2  X S0 6 ,H ( #( "D Q0 R
M ,  .@"\ $( N0!( +< 3@"U %, LP!8 +$ 70"P &( K@!G *P ; "J ',
MJ0![ *< A "E (X HP": *$ J "? +D G@#2 )T \@"< /\ G0#_ )P _P"9
M /\ _    .X   #=    S    ,$  @"Z  P M@ 2 +( &@"P ", KP L *T
M- "I #P I@!" *0 2 "B $T H !2 )X 5P"= %L G !@ )H 9@"9 &P EP!T
M )4 ?0"3 (< D0"3 )  H0". +$ C0#& (P Z "+ /T C #_ (P _P", /\
M[0   -@   #%    MP   *P   "F  @ H0 . )\ %0"= !X FP F )H +@"7
M #4 E0 \ ), 0@"1 $< D !, (X 40"- %4 BP!: (H 8 ") &8 AP!M (4
M=@"$ (  @@", (  F@!_ *D ?0"\ 'P W !\ /4 ? #_ 'P _P!\ /\ V0
M ,$   "Q    I    )P   "4  , D  , (T $0"+ !@ B0 @ (D * "' "\
MA0 V (, / "" $$ @ !& '\ 2P!] $\ ? !4 'L 6@!Y &  > !G '8 < !U
M 'H <P"& '$ DP!P *( ;P"T &X S !N .T ;@#^ &X _P!N /\ Q    *\
M  "@    E    (P   "&    @0 ( 'X #@!\ !0 >P ; 'D (@!X "D =P P
M '4 -@!T #L <@!  '$ 10!P $H ;P!/ &T 5 !L %L :P!B &D :@!H '0
M9@"  &4 C@!C )T 8@"M &$ P@!A .0 80#X &$ _P!A /\ M    *    "1
M    A@   'X   !Y    =0 # '$ "P!O !  ;0 6 &P '0!K "0 :P J &D
M, !H #8 9@ [ &4 0 !D $4 8P!* &$ 3P!@ %8 7P!= %T 90!< &\ 6@!Z
M %D B !8 )@ 5P"H %8 NP!6 -@ 5@#Q %8 _P!6 /\ J $  )0%  "%!P
M>@<  '(&  !L!   :0$  &< !P!D  T 8P 1 &$ & !@ !\ 7P E %X *P!=
M #  6P V %H .P!9 $  6 !% %< 2P!6 %$ 50!8 %, 80!2 &H 4 !V $\
MA !. ), 30"D $P M@!, ,T 3 #K $P ^@!, /\ G0D  (L+  !\#0  < T
M &@-  !B#   7PH  %T& 0!< 0D 6@ . %@ $P!7 !D 5@ @ %4 )@!3 "L
M4@ Q %$ -@!0 #L 3P!! $X 1P!- $T 2P!5 $H 70!) &< 1P!S $8 @ !%
M )  1 "A $, L@!# ,@ 0P#F $, ]0!# /\ E0T  (,/  !T$   :1$  & 1
M  !:$   5@X  %0-  !3"@0 4P8+ %$#$ !/ 14 3@$; $P!(0!+ 2< 2@(L
M $D",@!( C< 1P,] $4#0P!$ TH 0P11 $($6@! !60 /P5P #X&?@ ]!HX
M/ >? #L'L0 Z!\8 .@?C #H'\P Z"/P CA   'P2  !N%   8A4  %H5  !4
M%   4!,  $T1  !+#@  2PT& $H*# !)"!$ 1P@6 $4('0!$"", 0@@H $$)
M+@! "3, /PDY #X*0  ]"D< / I/ #H+6  Y"V, . QO #8,?@ U#(X - V?
M #,-L0 R#<< ,@WC #(-]  R#?X B!,  '<5  !I%P  7A@  %48  !/&
M2A8  $<5  !%$P  0Q " $,." !"#0X 0 T2 #\-&  ]#1\ / TD #L-*@ Y
M#3  . XW #<./0 V#D4 -0Y- #,/5P R#V( ,1!N "\0?0 N$(X +1&@ "P1
ML@ K$<@ *Q'F "L1]@ L$?\ @Q8  '(9  !D&@  61L  %$;  !+&P  1AH
M $(8   _%P  /A0  #P2!  [$0H .A 0 #@0%0 W$!L -1$A #01)P S$2T
M,A$S # 1.@ O$D( +A)+ "T35  K$U\ *A1L "D4>P H%(P )Q6> "85L  E
M%<8 )17D "45]@ F%?\ ?AD  &X;  !@'0  5AX  $T>  !''@  0AT  #X<
M   Z&@  .!@  #<6   U%0< -!0- #(4$@ P%!< +Q0= "T4(P L%2H *Q4P
M "H5-P I%C\ *!9( "<74@ F&%T )!AJ ",9>0 B&8H (1F< " 9KP ?&<0
M'QGB " 9]  @&?\ >AL  &H>  !='P  4R   $H@  !$(   /A\  #H>   W
M'0  -!P  #(9   P&00 +A@+ "P8$  J&!0 *1@: "<8(  F&28 )1DM "0:
M-0 C&CT (AM& "$;4  @'%L 'QUH !X==P ='8@ '!Z; !L>K0 :'L, &A[@
M !H=\P ;'?\ =QT  &<@  !:(0  4"(  $@B  !!(@  .R(  #<A   S(
M,!\  "T=   K'0  *!T( "8=#@ E'1( (QT7 "$='0 A'20 (!XJ !\>,@ >
M'SH '1]# !P@30 ;(5D &B%F !DA=0 8(H< %R*9 !8BK  5(L$ %2+? !4A
M\@ 6(?X <R   &0B  !7(P  320  $4E   ^)   .20  #0C   P(@  +"(
M "DA   F(0  )"$& "(A#  @(1  'B$5 !TB&P ;(B$ &R(H !HC+P 9(S@
M&"1! !<D2P 6)5< %25D !0F<P 3)H4 $B:8 !$FJP 1)L  $";= !$E\0 2
M)?T <"(  &$D  !4)@  2B8  $(G   \)@  -B8  #$E   M)0  *20  "8D
M   B)0  'R4# !TF"@ ;)@X &2<2 !@G&  7)Q\ %B<E !4H+0 4*#4 $RD^
M !(I20 1*54 $2IB ! J<0 /*H, #BJ6  XJJ0 -*KT #2K7  TJ[@ .*?L
M;"0  %TF  !1*   2"@  $ I   Y*   -"@  "\H   K)P  )R<  "(H   >
M*0  &RH  !@K!P 6*PT %"P1 !,L%@ 2+!P $2TC ! M*@ 0+3( #RX\  XN
M1@ -+E( #2Y?  PO;@ ++W\ "B^2  DOI0 )+KD ""[0  DNZ0 *+O< :"<
M %HI  !.*@  12L  #TK   W*P  ,2H  "TJ   I*@  )"H  " K   ;+0
M&"X  !4O!  2,0H $#(.  \R$P .,AD #3(@  TR)P ,,B\ "S,X  HS0@ )
M,TX "#-;  8T:@ %-'L !#..  ,SH@ ",[8  C/-  ,SYP $,O, 9"H  %8L
M  !++0  0BT  #HM   T+0  +RP  "LL   F+   (BT  !TO   9,0  %3(
M !(T P /-@D ##@-  HX$0 ).!8 "#@=  <X)  &."P !#@T  ,X/@ ".4H
M #E7   Y90  .7<  #F+   XGP  .+,  #C*   XY@  -_( 7RT  %(N  !(
M+P  /S   #@O   R+P  +2\  "DO   D,   'S$  !HS   5-0  $C<   \Y
M P ,.P@ "#T-  4^$  #/A0  #X:   ^(0  /B@  #XQ   _.P  /T8  #]3
M   _80  /W,  #^'   ^G   /K   #W'   ]Y   /?( 6C   $XR  !$,@
M/#(  #4R   P,0  *S$  "8R   @-   &S8  !8X   2.P  #ST   P_ P (
M00@ !$,,  !##@  1!(  $46  !%'0  120  $4M  !&-@  1D(  $9.  !&
M70  1FX  $6"  !%F   1*T  $3$  !#XP  0_( 530  $HU  !!-0  .34
M #,T   N-   *#4  "(W   =.@  %SP  !(_   /00  #$0   A& 0 #2 8
M $D*  !*#0  2Q   $P4  !-&0  3B   $XH  !.,@  33T  $Y*  !.6
M36D  $U]  !,E   3*H  $O!  !+X0  2O( 4#@  $8X   ].   -S@  #$W
M   J.0  )#L  !X]   80   $T,   ]&   +20  !TL   ).    4 0  %$(
M  !2"P  4PX  %01  !5%0  5AL  %<C  !7+   5S@  %=$  !74@  5F,
M %9W  !6C@  5:4  %2]  !3W0  4_  2SP  $(\   [.P  -3L  "T\   F
M/P  'T(  !E%   32   #DL   M/   %40   %0   !7    6 $  %H%  !;
M"   7 P  %T.  !?$0  8!8  &(=  !B)@  8C$  &(^  !A3   85T  &%P
M  !@B   8*   %^W  !>U   7>X 1T   #\_   Z/P  ,4   "E#   A1@
M&DH  !-.   .40  "E4   18    6P   %X   !A    8P   &0!  !E!
M9P@  &@+  !J#@  ;!(  &X7  !O(   ;RH  &\V  !N10  ;E4  &YH  !M
M?P  ;9@  &RP  !KR@  :N@ 1$0  #Y#   U1   *T<  "-+   ;3P  $U0
M  Y8   (7    F    !D    9P   &L   !M    ;P   '    !R    = (
M '4&  !W"@  >0X  'P2  !^&   ?R(  '\N  !_/0  ?DT  'UA  !]=P
M?)   'NH  !ZP   >=\ 0T<  #E)   O3   )5   !Q5   46P  #F    =E
M    :@   &X   !R    =@   'D   !\    ?@   '\   "!    @P   (4
M  "' P  B@@  (P-  "/$0  DAD  )(E  "2,P  DD0  )%7  "0;0  CX8
M (Z?  "-M0  C,T /4X  #)1   H5@  'EP  !5B   .:   !VX   !T
M>0   'X   ""    A@   (D   ",    C@   )    "2    E    )8   "8
M    FP   )X&  "A#   I!$  *8;  "F*0  ICH  *5-  "E8@  I'L  *.4
M  "AJP  H;\ -E<  "Q<   A8@  %VD   ]P   '=P   'X   "$    B@
M (\   "4    F    )L   ">    GP   *(   "D    I@   *@   "K
MK0   +    "S!   MPP  +L2  "['P  NS   +M#  "Z6   N7   +>+  "W
MH0  M[, ,&(  "5I   :<   $'@   F     B    (\   "6    FP   *$
M  "F    J@   *X   "P    L0   +0   "V    N    +L   "]    P
M ,,   #'    RP,  ,\,  #3%0  TB4  -(X  #13@  T&4  ,]^  #-E@
MS*D _P   /\   #_    _P # /\ "P#\ !$ ^0 ; /< )0#S "\ [@ X .D
M0 #F $@ X@!. -\ 5 #< %D V0!> -4 8P#3 &@ T !M ,X <P#+ 'H R ""
M ,8 C ## )< P "C +X L@"\ ,@ N@#J +D _P"X /\ L0#_ *H _P"G /\
M_P   /\   #[    ]@   .T !P#G  \ X@ 6 -\ ( #> "D V0 S -$ .P#,
M $( R !( ,4 3@#" %, P !8 +X 70"\ &( N@!G +D ;0"W '0 M0![ +(
MA0"P )  K@"< *P J@"I +T IP#> *8 ^0"E /\ HP#_ )T _P"; /\ _0
M /8   #K    WP   -$  P#*  P Q0 2 ,, &P#  "0 O@ L +D -0"V #P
MLP!# +  2 "N $X K !2 *L 5P"I %P IP!A *8 9P"D &T H@!T *  ?0">
M (@ G "5 )H HP"8 +0 E@#- )4 \0"4 /\ E0#_ )  _P". /\ \P   .8
M  #1    P@   +@   "Q  @ K0 / *H %@"H !X J  G *8 +P"B #8 GP \
M )T 0@"; $< F0!, )< 40"6 %4 E !: ), 8 "1 &8 D !N (X =@", ($
MB@"- (@ FP"& *P A0#! (0 Y@"# /T A #_ (, _P"! /\ Y    ,L   "Z
M    K    *(   "<  0 F  , )8 $0"4 !D DP A )( * "/ #  C0 V (L
M/ ") $$ B !& (8 2P"% $\ A !4 (( 6@"! &  ?P!G 'X ;P!\ 'H >@"&
M '@ E !W *0 =0"W '0 U !S /0 = #_ '0 _P!T /\ RP   +8   "F
MF@   )(   "*    A@ ( (, #@"! !0 @0 ; (  (P!_ "H ?0 P 'L -@!Z
M #L > !  '< 10!U $D = !. ', 5 !Q %H < !A &X :0!M ', :P!_ &D
MC0!H )T 9P"N &8 QP!E .H 9@#_ &8 _P!G /\ N    *0   "5    B@
M ($   !\    =@ $ '0 # !R !  <0 6 '  '0!P "0 ;@ J &T , !K #4
M:@ Z &D /P!H $0 9P!) &4 3@!D %0 8P!; &$ 8P!@ &T 7@!Y %T AP!;
M )8 6@"H %D O0!9 -\ 60#X %H _P!: /\ J    )4   "'    >P   ',
M  !N    :@ ! &< " !E  X 9  2 &, & !C !\ 8@ E &$ *@!? #  7@ U
M %T .@!< #X 6P!$ %D 20!8 $\ 5P!6 %8 7@!4 &@ 4P!S %$ @0!0 )$
M3P"B $X M0!. -  3@#P $X _P!/ /\ G    (D   ![ P  < ,  &@#  !B
M 0  7P   %T ! !;  L 60 / %@ % !7 !D 5P @ %8 )0!5 "H 4P P %(
M- !1 #D 4  _ $\ 1 !. $L 30!2 $L 6@!* &, 20!O $< ? !& (P 10"=
M $4 L !$ ,< 1 #H $0 ^@!% /\ D@0  ( '  !Q"@  9@H  %X*  !9"0
M50<  %0$  !2  < 4  , $\ $ !. !4 30 ; $P ( !+ "8 2@ K $D , !(
M #4 1P Z $8 0 !% $8 0P!. $( 5@!! %\ 0 !K #X >  ] (@ / "9 #P
MJP \ ,$ .P#@ #L ]  [ /\ B0H  '@,  !J#@  7PX  %<.  !1#@  30P
M $L+  !*" ( 200) $@ #0!& !$ 10 6 $0 ' !# "$ 0@ F $$ *P _ #$
M/@ V #T /  \ $, .P!* #H 4@ Y %P . !H #8 =0 U (4 - "6 #0 J  S
M +P ,P#8 #, [P S /L @@T  '$/  !D$   61$  %$1  !+$0  1Q   $0.
M  !"#0  00L% $$'"P _!0X /@,2 #P"&  [ AT .@,B #D#*  X RT -P,R
M #8$.0 U!#\ - 5' #,%4  Q!EH , 9F "\'<P N!X, +0>5 "P'IP K![H
M*P?2 "L'ZP K!_< ?1   &P1  !?$P  5!0  $P4  !&%   0A,  #X2   \
M$   .@X! #H-!@ Z"@P . D0 #8(%  U"!D - D? #())  Q"2D , DO "\*
M-@ N"CT +0I% "P+3@ K"UD *0QE "@,<P G#(, )@V5 "4-IP D#;L (PW2
M ",-ZP C#?< >!(  &@4  !;%@  41<  $@7  !"%@  /18  #D5   W$P
M-1$  #,0 P S#@@ ,@T- # -$0 O#18 +0T; "P-(0 K#2< *@TM "D.-  H
M#CL )PY$ "4.3@ D#UD (Q!E "$0<P @$(0 'Q"6 !X0J0 =$+T '!#8 !T0
M[@ =$/D <Q0  &06  !7&   31D  $49   _&0  .A@  #47   R%@  ,!4
M "X3   M$00 +! * "L0#@ I$!( *! 8 "80'@ E$"0 )! J ",1,0 B$3D
M(1%" " 22P >$E8 '1-C !P3<0 :$X( &125 !@4IP 7%+L %Q/4 !<3[@ 8
M$_H <!8  & 9  !4&@  2AL  $(<   \&P  -AL  #(:   O&0  +!@  "H6
M   H% $ )A,' "43#  C$Q  (A,5 " 3&@ ?$R$ 'A0G !T4+@ <%38 &Q4_
M !H620 9%E0 &!=A !87<  5&($ %!B3 !,8I@ 2&+H $A?2 !(7[  3%_H
M;!D  %T;  !1'0  1QT  #\>   Y'0  -!T  "\<   K&P  *!H  "89   D
M&   (A<$ " 7"@ >%PX '!<2 !H7%P 9&!X &1@D !@9+  7&30 %AH] !4:
M1P 4&U( $QM? !(<;@ 1''\ $!R2 ! <I0 /'+D #AS0  X;Z@ /&_@ :1L
M %H=  !.'P  11\  #T@   V'P  ,1\  "T>   I'0  )1T  ",<   @&P
M'1L! !L;!P 9' T %QP0 !8<%0 5'!L %!TB !,=*0 2'C$ $1XZ !$?10 0
M'U  #R!=  X@;  -('P #2"/  P@H@ +(+4 "R#*  L@Y0 ,'_0 91T  %<?
M  !,(0  0B$  #HA   T(0  +R$  "H@   F'P  (Q\  " >   ='@  &2
M !8@!  4( L $B$. !$A$P 1(AD $"(?  \B)@ .(R\ #B,W  TC00 ,)$T
M"R19  HD9P ))'@ ""2+  <DG@ ')+$ !B3'  8CXP '(_$ 8A\  %0A  !)
M(P  0",  #@C   R(P  +",  "@B   D(0  (2$  !XA   :(0  %B,  !,D
M P 1)0@ #R8-  XG$0 -)Q8 #"<=  LG(P *)RL "2@T  @H/@ '*$D !BA5
M  4I9  $*70  RF'  (IFP !**\  "C%  $HX0 !)_  7B(  %$D  !&)0
M/24  #4E   O)0  *B0  "8D   B(P  'R,  !LD   8)0  %"8  !$H P /
M*0@ #"P,  HL$  (+!0 !RP:  8L(0 %+"@  RTP  (M.@ !+44  "U2   N
M8   +G$  "V$   MF0  +:T  "S"   LX   +/  6B0  $TF  !#)P  .B<
M #,G   M)P  *"8  "0F   A)@  '28  !DG   5*0  $2L   \L P -+@<
M"3 ,  8Q#@ #,1(  3(7   R'@  ,B4  #(M   R-@  ,T(  #-.   S70
M,VT  #.!   RE@  ,JL  #'!   QWP  ,?  5B<  $HI   _*@  -RH  # J
M   K*0  )R@  ",H   >*0  &BH  !8L   2+@  #S    TQ @ *- < !34+
M  (V#@  -Q   #@4   X&@  ."(  #@J   Y,P  .3X  #E*   Y60  .6D
M #E]   XDP  .*@  #>_   WW@  -O  42L  $8L   \+   -"P  "XL   J
M*P  )2L  " L   ;+0  %R\  !,Q   0,P  #34   DW @ %.@8  3L*   \
M#0  /0\  #X2   _%P  0!X  $ E  ! +P  0#H  $!&  ! 5   0&4  #]X
M   _CP  /J8  #Z]   ]W   /?  32X  $(O   Y+P  ,B\  "TN   H+@
M(B\  !TP   8,@  $S4  ! W   ,.@  "3P   4^    000  $((  !#"P
M1 T  $80  !'%   2!D  $@A  !(*@  2#4  $A!  !(3P  2&   $=S  !'
MB@  1J(  $6Y  !%V0  1/  2#(  #XR   V,@  ,#$  "LQ   E,@  'S0
M !DV   3.0  $#P   P_   (0@   T0   !&    2 (  $H%  !+"   3 L
M $X.  !/$0  414  %(<  !2)0  4C   %(\  !12@  45H  %%M  !0A
M3YT  $ZU  !-T@  3>X 0S8  #LV   T-0  +S0  "<U   A.   &CL  !0^
M   000  #$0   ='   "2@   $T   !/    40   %,"  !4!0  50@  %<+
M  !9#@  6Q$  %T7  !='P  72H  %TV  !<1   7%0  %MG  !;?@  6I<
M %FO  !8RP  5^H /SD  #@Y   S.   *SD  ",\   </P  %4,  !!'   +
M2@  !4X   !1    5    %<   !:    7    %T   !?    8 0  &('  !D
M"P  9@X  &@2  !K&0  :R,  &HN  !J/   :DT  &E?  !H=0  9X\  &:H
M  !EP@  9., /3T  #<\   N/0  )4   !U$   620  $$T   I1   $50
M %H   !=    8    &,   !F    :    &H   !K    ;0   &\"  !Q!@
M= H  '8.  !Y$P  >QL  'LG  !Z-0  >44  'A9  !X;0  =X8  ':?  !U
MMP  =-( /$$  #)"   H10  ($H  !=.   05   "ED   )>    8P   &<
M  !K    ;P   '(   !U    =P   'D   ![    ?0   '\   ""    A ,
M (<)  "*#@  CA,  (\>  ".*P  CCL  (U.  "+8P  BGP  (J5  "(K0
MA\4 -D<  "Q+   B3P  &54  !!;   *80   6<   !M    <@   '<   ![
M    ?P   (,   "&    B    (H   "-    CP   )$   "4    EP   )H!
M  "=!P  H0T  *44  "D(0  I#$  *-$  "B60  H'   )^+  "=H@  G;<
M,%   "55   ;6P  $F(   MI   !<    '<   !]    @P   (@   "-
MD0   )4   "8    F@   )P   "?    H0   *,   "F    J0   *P   "P
M    M <  +@.  "Z&   NB<  +DY  "X3@  MV4  +9^  "UE@  LZL *5L
M !YB   4:0  #'$   )Y    @0   (D   "/    E@   )L   "@    I
M *@   "K    K    *\   "R    M    +8   "Y    O    ,    #$
MR    ,T'  #2$   TAT  -$O  #01   SUL  ,US  #+C0  RJ$ _P   /\
M  #[    ^@   /P " #X  \ ]0 7 /0 ( #Q "H ZP S .8 .P#B $, W@!)
M -H 3P#6 %0 TP!9 -  7@#. &, RP!H ,D ;@#& '4 PP!] ,$ A@"^ )(
MNP"> +D K@"V ,, M #H +, _P"O /\ I0#_ )X _P"; /\ _0   /<   #R
M    \    .<  P#A  P W  2 -@ &P#6 "0 T@ M ,P -@#& #T P@!# +\
M20"\ $X N@!3 +@ 6 "V %T M0!B +, 9P"Q &X KP!V *P ?P"J (H J "7
M *4 I@"C +D H0#9 *  ^0"> /\ F #_ )( _P"/ /\ \P   .P   #C
MTP   ,@   #!  D O0 / +L %@"Y !\ MP G +, +P"O #< K  ] *H 0P"H
M $@ I@!- *0 4@"C %8 H0!; )\ 80"> &< G !O )H > "7 (, E0"0 ),
MG@"1 +  D #( (X \ "- /\ B@#_ (4 _P"" /\ YP   -T   #&    N
M *X   "H  0 I0 , *$ $@"A !D H  B )\ *0"; #  F  W )8 /0"3 $(
MD@!' )  2P"/ %  C0!5 (P 6@"* &$ B !H (< < "% 'L @P"( ($ E@!_
M *< ?0"\ 'P XP!\ /T ? #_ '@ _P!V /\ U@   ,    "O    HP   )D
M  "3    CP ) (T #@"+ !0 B@ < (H (P"( "H A0 P (, -@"" #L @ !
M '\ 10!^ $H ? !/ 'L 5 !Z %H > !A '8 :0!U ', <P"  '$ C@!O )\
M;@"R &T SP!L /0 ; #_ &L _P!I /\ P    *L   ";    CP   (<   "
M    ?  $ 'H # !X !$ >  7 '@ '@!W "0 =0 J ', , !Q #4 <  Z &X
M/P!M $0 ; !) &L 3@!J %0 : !; &< 8P!E &T 9 !X &( AP!@ )< 7P"J
M %X P@!> .D 7@#_ %X _P!= /\ K    )D   "*    ?P   '<   !Q
M;0   &H " !I  X :  2 &< & !G !\ 9P E &4 *@!C "\ 8@ T &$ .0!@
M #X 7P!# %X 2 != $X 6P!5 %H 70!8 &< 5P!R %4 @0!4 )$ 4P"C %(
MN !1 -P 40#Y %( _P!2 /\ G0   (L   !\    <0   &D   !D    8
M %X !0!<  L 6P / %L % !: !D 6@ ? %D )0!7 "H 5@ O %4 - !4 #@
M4P ] %( 0P!0 $D 3P!0 $X 6 !- &( 2P!M $H >@!) (L 2 "= $< L0!'
M ,P 1@#P $< _P!' /\ D    'X   !P    9@   %X   !9    5@   %,
M 0!2  @ 4  - $\ $ !/ !4 3@ : $X ( !- "4 3  J $H +@!) #, 2  X
M $< /@!& $0 10!+ $0 4P!# %T 00!H $  =0 _ (4 /@"7 #T JP ] ,,
M/0#F #T ^P ^ /\ AP   '4#  !H!@  70<  %4&  !0!@  3 0  $H!  !)
M  0 1P * $8 #@!% !$ 10 6 $0 &P!# "  0@ E $$ *@!  "\ /P T #X
M.@ ] $  .P!' #H 3P Y %D . !D #< <0 V ($ -0"3 #0 I@ T +L - #=
M #0 ]0 U /\ ?@8  &T)  !@"P  5@P  $X,  !("P  1 H  $((  ! !0$
M/P$' #X "P ]  X /  2 #L %P [ !P .@ A #D )0 W "H -@ P #4 -0 T
M #P ,P!# #( 3  Q %4 , !@ "\ ;0 N 'T +0"/ "P H@ L +8 + #0 "P
M[@ L /P =PH  &<,  !:#@  4 X  $D.  !##@  /@T  #L,   Y"P  . D#
M #<%"  V @T -0$0 #0 $P S !@ ,@ = #$ (@ P "< +P L "X ,@ M #@
M+ !  "L 20 J %( *0!= "@ :P G 7H )@&, "4 GP E +( )0#* "4 Z  E
M /< <@T  &(.  !6$   3!$  $01   ^$0  .1   #8/   S#@  ,0T! # +
M!0 P" H +P8- "X%$0 L!!0 *P,9 "H#'@ I R, * 0I "<$+P F!34 )04]
M "0%1@ C!E  (@9< "$':0 @!WD 'P>+ !X'G0 >![  '0;& !T&XP =!?,
M;0X  %X1  !2$@  2!,  $ 3   Z$P  -1(  #$1   N$   + \  "H. P J
M#0< *0L+ "@)#@ G"1$ )0@6 "0(&P C"2  (@DF "$)+  @"C, 'PH[ !X+
M1  ="T\ ' Q; !L,:0 :#'D & R+ !@,G@ 7#+  %@S% !8,X0 6"_  :1
M %H2  !.%   114  #T5   W%0  ,10  "T3   J$@  *!$  "80 0 D$ 0
M(PX( ",-#  B# \ ( P3 !\,&  >#1T '0TC !P-*@ ;#3( &@XZ !@.1  7
M#E  %@]< !4/:@ 3$'L $A"- !$0H  1$+, $ _) ! /Y  1#_( 91(  %<4
M  !+%@  0A<  #H7   T%P  +Q8  "H5   G%   )!,  "(3   @$@, 'A$&
M !T0"0 <$ T &P\0 !D0%0 8$!L %Q A !80*  5$3  %!$Y !,10P 2$DX
M$1): ! 2:0 0$WD #A.,  X3G@ -$[$ #1+%  P2X0 -$O$ 8A0  %06  !)
M&   /QD  #<9   Q&0  +!@  "@7   D%@  (18  !\5   <% ( &A,$ !D2
M!@ 7$@L %1(. !02$@ 3$Q@ $A,? !$3)@ 1%"T $!0V  \500 .%4P #A97
M  T690 ,%W4 "Q>'  H7F@ )%JT "!;!  @6W0 )%>X 7Q8  %$8  !&&@
M/1H  #4;   O&@  *AH  "49   B&   'Q@  !P7   9%@$ %Q8# !46!  3
M%@D $18- ! 7$0 /%Q8 #A<<  X8(P -&"H #!DS  P9/  +&D< "AI3  D:
M80 '&W$ !AN#  4;EP $&JH  QJ_  ,9V@ $&>P 7!@  $X:  !#'   .AP
M #,<   L'   )QP  ",;   @&@  '1D  !H9   7& $ %1@" !(9!  0&P<
M#AL,  T<$  ,'!, "QP9  H<'P )'2< "!TO  <>.0 &'D, !!Y0  ,?7@ "
M'VX  1^    ?E0  'JD  !Z]   =V   '>P 6!H  $L<  !!'@  .!X  # >
M   J'@  )1T  "$<   >'   &QL  !@;   6&P$ $QL" !$<!  .'@< #!\+
M  H@#@ ((!( !B$7  4A'0 $(20  B(L  $B-0  (D   "--   C6@  (VL
M "-^   CDP  (J<  "*\   AUP  (>T 51T  $@?   ^(   -2   "X@   H
M(   (Q\  " >   ='0  &AT  !8=   3'@  $1\"  X@!  -(@< "B0+  8E
M#0 $)1   B84   F&@  )B$  "<I   G,@  )ST  "=)   H5P  *&<  "=[
M   GD   )Z4  ":[   FU@  )>T 42   $4A   [(@  ,B(  "PB   F(0
M(B$  !X@   ;'P  &"   !0@   1(@  #R,   TE P *)@8 !B@*  ,I#0
M*P\  "P2   L%P  +!X  "PF   M+P  +3D  "U&   M5   +60  "UW   L
MC0  +*0  "NZ   KU@  *NX 32(  $$D   X)   ,"0  "DD   D(P  (2(
M !TB   9(@  %2,  !(D   /)@  #2@   HJ @ &+ 4  BX)   O"P  , X
M #(0   S%0  ,QL  #,B   S*P  ,S8  #-"   S4   ,V   #-S   RB@
M,J$  #&X   PU@  ,.\ 224  #XF   T)P  +2<  "@F   C)0  'R0  !LE
M   6)@  $B@  ! J   -+   "BX   8P 0 ",@0  #0'   U"@  -PP  #@.
M   Z$@  .A<  #H?   Z)P  .C(  #H^   Z3   .EP  #IO   YA@  .)X
M #BV   WU   -N\ 1"D  #HI   Q*0  *RD  "8H   B)P  '2@  !@I   3
M*P  $"X   TP   ),@  !34   $W    .0(  #L%   \"   /@L  #\-  !!
M$   0Q0  $,;  !#(P  0RX  $,Y  !#1P  0E<  $)J  !!@0  0)H  #^R
M   ^SP  /N\ /RP  #8L   O+   *BL  "4J   ?*P  &2T  !0O   0,@
M#34   @X   $.@   #P    _    00   $,"  !%!0  1@@  $@+  !*#@
M3!$  $T6  !-'@  32@  $TT  !,0@  3%$  $MD  !+>P  2I0  $FM  !(
MR@  1^P .S   #,O   M+P  *"T  "(O   ;,0  %30  ! W   -.@  "#T
M  )     0P   $8   !(    2@   $P   !. 0  3P0  %$'  !3"P  50X
M %@2  !9&0  6"(  %@N  !7/   5TL  %9>  !6<P  58T  %2G  !2P@
M4N8 .#,  #$R   L,0  )3(  !TU   6.   $3P   Q    '1    $<   !*
M    30   %    !3    50   %<   !9    6@   %P#  !>!P  80L  &0.
M  !F$P  9QP  &8G  !F-   940  &17  !D:P  8H4  &&?  !@N0  7MP
M-3<  # U   H-P  (#H  !@]   10@  #$8   9*    3P   %,   !6
M60   %P   !?    80   &0   !E    9P   &D   !L 0  ;@8  '$+  !T
M#P  =Q4  '<@  !V+0  =CT  '5/  !T8P  <WL  '*5  !PKP  ;\D -3H
M "L[   B/P  &D,  !)(   ,30  !5(   !7    7    &    !D    :
M &L   !N    <0   ',   !U    =P   'H   !\    ?P   (($  "&"@
MB@\  (P7  "+)   BC,  (E%  "'6P  AG(  (6+  "#I0  @KP +T   "5$
M   <20  $TX   U4   $6@   &$   !F    :P   &\   !T    >0   'T
M  "     @P   (4   "'    B@   (P   "/    D@   )8   "9 @  G@D
M *(0  "B&@  H2D  * [  "?4   G6<  )J!  ":F0  F:\ *4D  !].   5
M5   #EL   5B    :0   '    !W    ?0   ((   "&    BP   (\   "3
M    E0   )<   ":    G0   *    "C    I@   *H   "N    L@   +<*
M  "[$0  NA\  +DP  "W10  M5P  +1T  "QC@  KZ0 (E0  !A;   08@
M!VH   !S    >P   ((   ")    D    )4   ":    GP   *,   "F
MJ    *L   "N    L    +,   "V    N@   +T   #"    QP   ,P!  #3
M"P  U!4  -,F  #1.@  T%$  ,UH  #+@0  RI8 _    /8   #R    \0
M /, !0#T  P \@ 3 /  ' #M "4 Z  N .( -@#> #X V0!$ -0 2@#1 $\
MS@!4 ,L 60#) %X Q@!C ,0 :0#! '  O@!X +P @0"Y (T M@": +, JP"Q
M ,  KP#F *X _P"E /\ F@#_ )0 _P"/ /\ ]    .P   #H    YP   -\
M  #9  D T@ 0 ,\ %P#/ "  S  H ,8 , #  #< O  ^ +D 1 "W $D M0!.
M +, 4P"Q %< KP!= *T 8@"K &D J0!Q *< >@"E (4 H@"3 *  H@"= +8
MFP#4 )D ^0"6 /\ C0#_ (@ _P"$ /\ Z    -\   #9    R0   +\   "X
M  0 M0 - +, $@"Q !H L  B *T *@"I #$ I@ X *0 /0"B $, H !( )X
M3 "< %$ FP!6 )D 7 "7 &( E0!I ), <@"1 'T CP"+ (T F@"+ *P B0#%
M (@ [@"& /\ ?P#_ 'H _P!X /\ V0   ,T   "[    K@   *4   "?
MG  ) )D #P"9 !4 F0 = )@ ) "4 "L D0 Q (X -P", #P BP!! (D 1@"(
M $L A@!0 (4 50"# %L @@!B (  :P!^ '4 ? "" 'H D@!X *, =P"Y '8
MX !U /\ <@#_ &X _P!L /\ QP   +4   "E    F0   (\   ")    A0 $
M (0 # "" !$ @@ 7 (( '@"  "4 ?@ K 'P ,0!Z #8 >0 [ '< 0 !V $0
M=0!) ', 3P!R %4 < !< &\ 9 !M &X ; !Z &H B@!H )L 9P"O &8 S !E
M /4 9 #_ &$ _P!@ /\ M    *    "0    A0   'T   !W    <P   '
M" !O  X ;P 2 &\ & !O !\ ;0 E &L *@!I #  :  T &< .0!F #X 90!#
M &, 2 !B $X 80!5 %\ 7@!> &< 7 !S %L @@!9 ), 6 "F %< OP!7 .H
M5P#_ %8 _P!4 /\ H0   (X   !_    =0   &P   !H    9    &$ ! !@
M  L 7P / %\ $P!? !D 7P ? %T )0!< "H 6P O %D ,P!8 #@ 5P ] %8
M0P!5 $D 4P!0 %( 6 !1 &$ 4 !M $X >P!- (P 3 "? $L M0!* -P 2@#Z
M $H _P!* /\ D@   (    !R    9P   %\   !:    5P   %4  0!3  <
M4@ , %( $ !2 !0 4@ : %$ 'P!/ "0 3@ I $T +@!, #, 2P X $H /0!)
M $, 2 !* $8 4@!% %P 1 !G $, =0!" (8 00"8 $  K@!  ,L /P#R $
M_P!  /\ A0   '0   !G    70   %4   !/    3    $H   !(  0 1P *
M $< #0!& !$ 1@ 5 $8 &@!% !\ 1  D $, *0!" "T 00 S #\ .  ^ #X
M/0!% #P 3@ [ %< .@!B #D ;P X (  -P"3 #8 IP V ,  -@#H #8 _@ V
M /\ ?    &L   !> @  5 ,  $T#  !' P  0P$  $$    _  $ /@ ' #T
M"P ]  X /  1 #P %@ \ !H .@ ? #D )  X "D -P N #8 ,P U #H - !!
M #, 20 R %, ,0!> #  :P O 'L +@". "T H@ M +@ +0#= "T ^  N /\
M<P$  &0%  !7!P  30@  $8(  ! "   .P<  #@%   W P  -@ $ #4 "  T
M  P -  / #0 $@ S !8 ,@ ; #$ (  P "0 +P I "X +P M #8 +  ] "L
M10 J $\ *0!: "@ 9P G '< )@") "8 G0 E +, )0#/ "4 \  F /\ ;08
M %X)  !2"P  2 P  $ ,   Z"P  -@L  #(*   P"   +@8" "X#!@ M  H
M+  - "P $  K !, *@ 7 "D '  H "  )P E "8 *P E #( )  Y ", 0@ B
M $L (@!7 "$ 9  @ ', 'P"% !\ F0 > *X '@#' !X Z0 ? /H : D  %D,
M  !-#0  0PX  #P.   V#@  ,0T  "T-   J#   * L  "<)!  F!@@ )@0+
M "4##@ D 1  ) $4 "(!&  A 1T (0 B "  *  ? "X '@$V !T!/P < 4D
M&P%4 !H!80 : 7  &0&" !@ E@ 8 *H & #! !@ X0 8 /0 8PP  %4.  !)
M#P  0!   #@0   R$   +0\  "D.   F#@  (PT  "(, P @"P8 ( D) !\'
M#  >!@X '@41 !P%%0 ;!1H &@4? !H%)0 9!2L & 4S !<&/  6!D8 %@92
M !4'7P 4!VX $P>  !('E  2!J< $@6\ !($V0 2 ^\ 7PX  %$/  !&$
M/!$  #41   O$0  *A$  "80   B$   ( \  !T. @ <#04 &@T' !H+"@ 9
M"@T & D0 !<)$@ 6"1< %0D< !0)(@ 4"BD $PHQ !(*.@ 2"T4 $0M1 ! ,
M7P /#&X #@R   X,E  -"Z< #0NZ  T*T@ -"NH 7 \  $X1  !#$@  .A,
M #(3   L$P  )Q(  ",1   ?$0  '!   !H0 @ 8#P0 %@X' !4."0 4#0L
M$PP- !(,$  2#!0 $0P: !$-(  0#2@ #PTP  X..P -#D8 #0Y1  P/7@ +
M#VT "@]_  D/DP )#Z8 " ZY  @.T  '#N@ 6!$  $L2  ! $P  -Q0  # 4
M   I%   )10  "$3   =$@  &A(  !<1 @ 5$04 $Q ' !(0"0 1#PH $ X,
M  X.#@ .#Q( #1 8  T0'@ ,$"4 #! M  L1-@ *$4$ "1%-  @26@ '$FH
M!A)\  42D  $$J0  Q&X  ,1SP "$>@ 51(  $D4   ^%0  -18  "T6   G
M%@  (A4  !X4   ;%   &!,  !42 P 3$@4 $A$' ! 1"0 /$0H #1$+  P2
M#@ +$A$ "A(5  D3&P )$R( "!,J  <4,P %%#X !!5*  ,56  "%6<  15Z
M   5C@  %:,  !2W   4SP  $^D 4A0  $86   [%P  ,A<  "L7   E%P
M(18  !P6   9%0  %A0! !03!  2$P8 $1((  \2"  .$PD #!0*  H5#0 (
M%A  !A83  46&0 $%Q\  Q<G  (8,  !&#L  !E'   950  &60  !EW   9
MC   &*(  !BW   7SP  %^H 3Q8  $,8   Y&0  ,!D  "D9   C&0  'Q@
M !L7   8%@  %14" !,5!0 1% 8 $!0&  X5!P ,%@@ "A<*  <9#  $&@X
M AL2  $;%@  &QT  !PD   <+0  '#@  !U$   =4@  '6(  !UU   =B@
M'*   !RV   ;T   &NL 3!@  $ :   V&P  +1L  "8;   A&@  '1D  !D9
M   7&   %!<# !(6!  0%P0 #A<$  P9!0 *&@< !QP)  ,="P  'PT  " 0
M   @%   (1H  "$B   A*@  (34  ")!   B3P  (E\  ")R   AB   (9\
M ""V   ?T0  '^T 2!H  #T<   S'0  *QT  "0=   @'   '!L  !@:   6
M&0$ $QD! !$9 0 .&@$ #!P"  H= P ''P4  R$(   B"@  ) P  "8.   F
M$@  )A@  "<?   G)P  )S(  "<^   G2P  )UP  "=N   FA0  )IT  "6T
M   DT0  (^X 1!T  #D?   P'P  *!\  ",>   >'0  &QP  !@;   4'
M$1P   X=   -'P  "B$   8B 0 #) 0  "8&   H"   *@L  "L-   M$
M+14  "T<   M)   +BX  "XZ   N2   +5@  "UJ   M@0  +)H  "NR   J
MT   *>\ 0"   #8A   M(0  )B$  "$@   ='P  &AX  !8>   2'P  #R$
M  TB   *)   !B8   (H    *P(  "T$   O!@  , D  #(,   T#@  -1(
M #48   U(   -2H  #4V   U0P  -5,  #1F   T?   ,Y8  #*O   QS0
M,.\ /",  #(D   J)   )",  " B   <(0  %R$  !,C   0)0  #2<   DI
M   %*P   2X    P    ,@   #0!   V!   . 8  #H)   \#0  /A   #X4
M   ^'   /B8  #XQ   ^/P  /4X  #UA   \=P  .Y$  #JK   YR0  ..T
M-R<  "\G   H)@  (R4  !\D   9)0  %"8  ! H   -*P  "2X   4P
M,P   #4    X    .@   #P    ^ 0  0 ,  $('  !$"@  1@T  $D1  !)
M%P  2"$  $@L  !'.@  1TD  $9;  !%<0  1(L  $.E  !"PP  0>@ -"H
M "PJ   G*   (B<  !PH   6*@  $2T   TP   ),P   S8    Y    /
M #X   !!    0P   $8   !(    2@   $P#  !.!@  4 H  %,.  !4$P
M5!P  %,G  !3-   4T,  %)5  !1:@  4(,  $^>  !-N0  3.  ,"T  "LL
M   F*P  'RP  !@N   2,@  #34   @Y   "/0   $    !#    1@   $D
M  !,    3@   %$   !3    50   %<   !9 0  7 8  %\*  !B#@  8Q4
M &,?  !B+   83P  &!.  !?8@  7GL  %R6  !;L   6<\ +S   "HO   B
M,   &C,  !,W   ..P  "#\   %$    2    $P   !/    4@   %4   !8
M    6P   %T   !@    8@   &0   !F    :0   &T%  !P"P  =!   '08
M  !S)0  <C0  ')%  !P60  ;W$  &V+  !KI@  :L  +C,  "4U   =.
M%#P   Y!   '1P   $P   !1    50   %D   !=    80   &4   !H
M:P   &T   !O    <@   '0   !W    >@   'X   ""!   A@L  (H1  ")
M'   B"L  (8]  "$4@  @V<  (&!  !_FP  ?K( *3H  " ]   60@  #T@
M  A.    5    %H   !@    9    &D   !N    <@   '8   !Z    ?0
M (    ""    A0   (@   "+    C@   )(   "6    FP,  * ,  "B$P
MH"$  )\S  "=1P  FEX  )AW  "7CP  E:< (T,  !E(   13@  "54   !<
M    8P   &H   !Q    =@   'L   "     A@   (H   ".    D0   ),
M  "6    F0   )P   "@    HP   *<   "K    L    +8$  "\#0  NA<
M +DH  "W/   M%(  +)J  "OA0  K9P '$X  !-4   +7    60   !L
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M__________________________________________________\
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M]O?X^?K[_/W^_VUF=#$      P0A   !                     0
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MT]35UM?8V=K;W-W>W^#AXN/DY>;GZ.GJZ^SM[N_Q\O/T]?;W^/GZ^_S]_O\
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M@+",PH"PC,* L(S"@+",PH"PC,* L(S"@+",PH"PC,* L(S"@+",PH"PC,*
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MA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VO?
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MGH_<BYZ/W(N>C]R+GH_<BYZ/W(N>C]R+GH_<BYZ/W.;%"Q/QQA$O\L074NK
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MFW^YP)N(O;Z9B<"\E8K#NI&+QKB-C<BWBH_*MHB1S+6%D\VT@Y;/LX&9T+.
MG=&R?Z/1L'ZDT;!^I-&P?J31L'ZDT;!^I-&P?J31L'ZDT;!^I-&P?J31L'ZD
MT;!^I-&P?J31L'ZDT?^X% [_N!TG_[4I1O>P-6G>J$&0QYQAL<2<<;;"FWZY
MOYV&O;V:B<&[EXG$N9.*Q[>/C,JUC([,M(F0SK.'DM"RA)72L8*9T[&!GM2N
M@*+4K("CTJR H]*L@*/2K("CTJR H]*L@*/2K("CTJR H]*L@*/2K("CTJR
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M@*J,RX"JC,N JHS+@*J,RX"JC,N JHS+@*J,RX"JC,N JHS+@*J,RX"JC,N
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MCK.&OHRRAK^*LH? B+*(P(:QB,&%L8G!A+&*P8*QB\&!L8S"@+&,PH"QC,*
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MRO&]# ;YOA(:^KX;-_RZ)5KGSA-HR-D+B:W#,J>AN%:XG;5HNYNS=;Z9LG_
MF+&$P9.PA<*/KX7#C*^&Q(FNAL6&KH?%A*Z(QH.MBL:!K8O&?ZV.QWVMD,=]
MK9#'?:V0QWVMD,=]K9#'?:V0QWVMD,=]K9#'?:V0QWVMD,=]K9#'?:V0Q]_
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MD(S%N(R/R+:'DLNT@Y?.LX"=T+)_I-&L?J7/J'ZGS*1_J<FA@*S&H8"LQJ&
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MV8Y^E]&-AZ+,C(VJQXJ1L<2(E+;#A9:XPH.9N<*!F[G!?YZZP7VAN\%[I+O
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M@IC+M7ZAS:]\I\VI?:G*I7ZKQZ)_K<2??Z_"G8"QOYV L;^=@+&_G8"QOYV
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MUJ&"I-"=@JC+FH.JR)F#K<67A*_"EH2PP):$L,"6A+# EH2PP):$L,"6A+#
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ML+E@M:BT<+VCL'["G:V$QY*JA,N(IX;.@*:-T'VGF-!]J*3.?J2HRW^?JLF
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M)#'JRQHUT.(70[_P'5ZOZ"5UH-LQAY;12)20RER>C<5JI8O!=JJ)OGVOA;R
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MMJO+;[RKR'# J\1QP*K$<<"JQ'' JL1QP*K$<<"JQ'' JL1QP*K$<<"JQ''
MJO^1$@'_E2<+_Y4['/^32R__CUE#_XQD5/N,:V/RBG)QZHA\?>.&A(?>@HJ/
MVG^/EM9]E)O3>IB?T7B<HM!WGZ3.=:*FS72FJ,URJ:G,<:VJS'"RJ\MPMJO+
M;[RKR'# J\1QP*K$<<"JQ'' JL1QP*K$<<"JQ'' JL1QP*K$<<"JQ'' JO^1
M$@'_E2<+_Y4['/^32R__CUE#_XQD5/N,:V/RBG)QZHA\?>.&A(?>@HJ/VG^/
MEM9]E)O3>IB?T7B<HM!WGZ3.=:*FS72FJ,URJ:G,<:VJS'"RJ\MPMJO+;[RK
MR'# J\1QP*K$<<"JQ'' JL1QP*K$<<"JQ'' JL1QP*K$<<"JQ'' JO^2$@'_
MEB<*_Y8['/^42S#_D%E#_X]C5/J.:63QC7!RZ8MZ?N*)@HG<A8F2V(*.F=1_
MDY[1?9>BSWN;ILUYGJC,=Z*JRW:EK,ITJ:W)<ZVNR7*RK\EQMZ_(<;ROPG.]
MKKYTO:^^=+VOOG2]K[YTO:^^=+VOOG2]K[YTO:^^=+VOOG2]K_^3$@'_ER<*
M_Y@['/^52S#_D5E$_Y%@5?J09F3PCVUSZ(UW@.&,@(O;B(>4U86-G-*"D:'/
M?Y:FS'V9J<M[G:S)>:&NR'>EL,=VJ;'&=:VRQG2RL\9SN;/"=;JSO'6ZL[AV
MNK.X=KJSN':ZL[AVNK.X=KJSN':ZL[AVNK.X=KJSN':ZL_^4$0'_F"<*_YD[
M'/^62S#_DEE$_Y)>5?J29&7PD6ITYX]S@>".?8S9BX66U(B+GM"%D*3-@I2I
MRG^8K<A]G+#'>Z"RQGFDM,5XJ+7$=JZVQ'6TML%VM[:\=[>VMW>WMK-XM[:S
M>+>VLWBWMK-XM[:S>+>VLWBWMK-XM[:S>+>VLWBWMO^5$0'_F2<*_YD['/^7
M2C#_DUA$_Y1<5?J4867PDV=TYY%P@M^/>H[8C8.8THN*H,Z'CZ?+A).LR(&7
ML,9_F[/$?9^UPWNDM\)YJ;G"=Z^YPG:UN;QXMKBX>+:XLWBVM[!YM[>P>;>W
ML'FWM[!YM[>P>;>WL'FWM[!YM[>P>;>WL'FWM_^6$0'_FB<*_YH['/^72C'_
ME%5$_Y995?J67F7PE61TYY-L@MZ1=H[8CW^9T8V(HLV*CJG)AY*NQH26L\2!
MFK;"?I^YPGNDNL%YJKK!=[&ZO7BUNK=XM;FS>;6YKWFVN*QZMK>L>K:WK'JV
MMZQZMK>L>K:WK'JVMZQZMK>L>K:WK'JVM_^7$0'_FR8*_YL['/^823'_EE-$
M_YA75?J86V7PEV%TYY9H@MZ3<H_6D7N:T(^$H\N-C*O'BI&QQ(:5ML.#F;C!
M?YZZP7NDN\!YJ[R_=[.\N'BSN[)YM+NN>;6ZJWJUN:A[MKBH>[:XJ'NVN*A[
MMKBH>[:XJ'NVN*A[MKBH>[:XJ'NVN/^7$0'_FR8*_YPZ'/^823'_F%%$_YI4
M5/J;6&3PFEUTYYAC@MZ6;8_6DW>:T)& I,J/B:S&C8^SPXF4M\*$F+K ?YZ\
MOWNEOK]YKKZY>+*^LGFRO:UZL[RI>[2ZIGNUN:1\MKBD?+:XI'RVN*1\MKBD
M?+:XI'RVN*1\MKBD?+:XI'RVN/^8$0'_G"8*_YPY'/^92#'_F4]$_YQ25/N=
M56/QG5ISYYM?@=Z9:8_6EG*:SY-\I<J1A:W%D(VTPXN2N,&%EKN_@)V^O7NE
MP;MYK\&R>K# K'NQOJA[L[VE?+2[HGVUN:!]MKB@?;:XH'VVN*!]MKB@?;:X
MH'VVN*!]MKB@?;:XH'VVN/^9$0'_G28*_YTY'/^91S'_FTU#_YY/4_N?4F/Q
MH%9RZ)];@-^=9([7FFV:T)=WI,J4@:W%DHJUPHZ0N;^'E;V]@)S!NWNGQ+-Z
MK<2K>Z_"IGRQOZ-]LKV@?K2[GG^UN9Q_MKB<?[:XG'^VN)Q_MKB<?[:XG'^V
MN)Q_MKB<?[:XG'^VN/^9$0'_GB8*_YTX'/^:1S'_G$M"_Z!-4ORB4&+RHU-Q
MZ:-7?^"A7HS8GF>8T)MQH\J8>ZW%E86TPI*-NKZ*DK^Z@9O%MWRIR:M\J\>D
M?:[#H'ZPP)U_LKV;@+.[F8&UNIB!MKB8@;:XF(&VN)B!MKB8@;:XF(&VN)B!
MMKB8@;:XF(&VN/^:$0'_GB8*_YXX'/^:1C+_GDE"_Z)*4?VD36#SIE!OZJ=4
M?>&F6(K:I&*6TJ%KH<N==:O&FH"SPIB*NKR.C\*V@YG+K'VFSJ)_JLF=@*W$
MFH&PP)B"LKZ7@[.\E8.UNI2#MKB4@[:XE(.VN)2#MKB4@[:XE(.VN)2#MKB4
M@[:XE(.VN/^:$0'_GR8*_YXW'/^;1C+_GT=!_Z1(4/ZG2E_TJ4QMZZM0>^.L
M5(?<JUR3U*EEG<ZF;Z?(HWJPPY^$N+N6B\2PC)G.H(.DT9F$J<J6A:W%E(6O
MP9.%L;Z2A;.\D86TNI&%M;F1A;6YD86UN9&%M;F1A;6YD86UN9&%M;F1A;6Y
MD86UN?^;$0'_GR8*_Y\W'/^;13+_H45 _Z9&3_^J1UWVK4EK[;!,>.:S3X/?
MM%6.V;5?E].U::#.M7:GP:M\MK"?A<2AE9+.E(ZCTI"+J,N/BJS&CHJOPHZ)
ML;^.B;*]CHBTNXZ(M;F.B+6YCHBUN8Z(M;F.B+6YCHBUN8Z(M;F.B+6YCHBU
MN?^;$0'_H"8*_Y\V'/^<1#'_HT,__ZA#3O^M1%OXL45H\+9(=.F[3'[CP%&'
MW\9;CM;(:Y3&O7&FM;-XM:6H@<.4GXW-B9RBTH>4I\R(D:O'B8^NPXF.L,")
MC;*^BHRSO(J+M+J*B[2ZBHNTNHJ+M+J*B[2ZBHNTNHJ+M+J*B[2ZBHNTNO^<
M$ '_H28*_Z V'/^>0C'_I4 ^_ZM 3/^Q0%GZMT%D\[U$;^[%27?ESE)\W=9B
M?\S.:)*\Q6ZDJ[MVM)JQ?\&*JHK+?Z>=SX"?J,R"F:O'@Y6MQ(23K\&%D;&_
MAH^SO8>.M+N'CK2[AXZTNX>.M+N'CK2[AXZTNX>.M+N'CK2[AXZTN_^=$ '_
MHB8*_Z U'/^@/S#_IST]_ZX\2O^U/%7ZO3U@\,9"9^;12FS>WDYVS=I7A[[0
M8I:NQ6ZEH;QYLI6T@[V&K8C&>ZJ4RGBKJ,E[HJO'?IRMQ("9K\*!EK# @I2R
MOH.2L[R#DK.\@Y*SO(.2L[R#DK.\@Y*SO(.2L[R#DK.\@Y*SO/^>$ '_HB8*
M_Z$T'/^B/"[_JCH[_[(X1_R[-U'RQ3I8YM%!7-O>0FG-XD9\OM=1C*[,7YNA
MPVVHF+QYLI&UA+N%L8G"?*Z1Q7BNG\5UK:S%>*6NQ'J@K\)\G+# ?IFQOG^6
MLKU_EK*]?Y:RO7^6LKU_EK*]?Y:RO7^6LKU_EK*]?Y:RO?^>$ '_HR4)_Z(T
M'/^E.2W_KC4X_[@S0O3#,TKGT#A.V=XY6LOF/6Z^X$* KM10D*'+7YV8PVVH
MD;UYL8NX@[B#M(B]?;&0P7FQFL%UL:7!<J^OPG6HK\%WH[# >9^QOWN<LKU[
MG+*]>YRRO7N<LKU[G+*]>YRRO7N<LKU[G+*]>YRRO?^@$ '_I"0)_Z,R'/^H
M-"O_LR\T^;\M/.G-+T#9WB]*RN<T7[WJ.G.OWD&#H=-1D9?+8)V0Q&ZFC+]Z
MK8:[@;-_N(>X>K:-NW>UE;QUM9^\<K2HO6ZSLKYQK+*^=*>ROG:CLKUVH[*]
M=J.RO7:CLKUVH[*]=J.RO7:CLKUVH[*]=J.RO?^A$ '_I2,)_Z0Q'/^M+B?_
MN2DO[L@F,]K<)C?*YRQ/O?(R8Z_H.76AW4*$EM13D(_-8IJ*QW"BAL-ZJ("_
M@*U[O86Q=KN+M'.YDK5QN9JV<+FCM6VYJ[9JN+2X:[*VN&ZLMKANK+:X;JRV
MN&ZLMKANK+:X;JRVN&ZLMKANK+:X;JRVN/^C$ '_IR()_Z4O&_^S)R+TPB$F
MW=@=),OG(SR]\BI3K_,R9J'G.W:5WD:#C=96C8?09):$RW&<?\AXH7K%?J5V
MPH.I<L&)JV^_CZULOY:N:[Z=KFJ_IJYHOZZN9;VXL&6YN[!EN;NP9;F[L&6Y
MN[!EN;NP9;F[L&6YN[!EN;NP9;F[L/^E$ '_J" (_ZPF%_R['1KCT1,9S.49
M*;WR(D&O_2I5H?,T9I;I/W2,X4M_A=M9B(#59H]\T6^4=\YVF7/+?)QPR8&?
M;<B'H6K'C*-HQI*D9L69I63%H*5DQ:BE8\:RI&#$NZ9@Q+NF8,2[IF#$NZ9@
MQ+NF8,2[IF#$NZ9@Q+NF8,2[IO^H$ #_JAX(_[,=$>S)#@_.XPX5OO(8+:_^
M(D.A_RU5EO0Y9(SL16^$Y5%Y?N!<@'G<9X9TV6Z*<-9TCFS3>9%ITG^39]"$
ME63/BI=BSH^88,V5F5_-G)I>S:*;7<VKFUS-M)I<S;2:7,VTFES-M)I<S;2:
M7,VTFES-M)I<S;2:7,VTFO^K#P#_K1H'\L -",[3"@:^\ X:K_X9,*'_)$.5
M_S)2B_@_7H/Q2VA][%9P=^A?=G'D97ILX6Q^:=]R@6;=>(1CW'V&8=N"B%_:
MAXE=V8R+6]B2C%G7F(U8UIZ-5]:ECE;5K(Y6U:R.5M6LCE;5K(Y6U:R.5M6L
MCE;5K(Y6U:R.5M6LCO^O#0#_MPX#S<D( ;[8"0FN_1 <H?\<+Y7_*3^+_S=,
M@OY%5GSY4%YU]%ED;O%?:6CN9&UDZVIP8>IP<U_H=75=YWIW6^9_>%GEA'E8
MY(E[5N..?%7BDWU4XIA^4N&>?E'AI7]1X:5_4>&E?U'AI7]1X:5_4>&E?U'A
MI7]1X:5_4>&E?_&T" #.P 8 O<X' :[@!PN@_Q(<E/\@*XK_+SB!_SU#>O])
M2W/_4E%L_E=79?M=6V'Y8UY>]VA@6_5M8ECT<F16\W=F5?)[9U/Q@&A1\(1I
M4/"):D_OCFM.[I-L3.Z9;4OMGVY+[9]N2^V?;DOMGVY+[9]N2^V?;DOMGVY+
M[9]N2^V?;M&Y P"\Q04 K=8# 9_X"PN3_Q88B?\D)(#_-"]Y_T$W</](/FC_
M3T-B_U5'7?]:2UG_8$U6_V504_]J45'_;E-/_W)43O]V54S^>U9+_7]72?V$
M6$C\B%E'^XU:1ON36T7ZF%Q%^IA<1?J87$7ZF%Q%^IA<1?J87$7ZF%Q%^IA<
M1?J87+V] P"MS0$ GM\  9+_#0B'_QD2?O\I&W7_-2-L_SPJ9/]#+U[_2C18
M_U W5/]6.E'_6SQ._V ^2_]D0$K_:$%(_VQ"1O]P0T7_=$1$_WA%0O]]1D'_
M@4= _X9(/_^,23W_D4H]_Y%*/?^12CW_D4H]_Y%*/?^12CW_D4H]_Y%*/?^1
M2J[%  ">UP  C_4  8;_#P1\_QL+<?\D$6?_+!=?_S4<6?\](53_129/_TLI
M3/]2+$C_5R]&_UTP1/]A,D+_9C- _VHU/_]N-CW_<S<\_W<X._]\.3K_@3HX
M_X8Z-_^,.S;_DCPV_Y(\-O^2/#;_DCPV_Y(\-O^2/#;_DCPV_Y(\-O^2//^#
M$P'_A"(&_X4U%/^#1B3_?U4T_X%>0O^!9E#_?VY<^7QW9O-Z@&_N=XAWZG6/
M?>=RE8+D<)J%XVZ>B.%LHHO@:Z>-WVFKCMYHKY#=9[21W6:ZD=QEP9+<9<F2
MVV70DM)GTI'.:-*1SFC2D<YHTI'.:-*1SFC2D<YHTI'.:-*1SFC2D?^#$P'_
MA"(&_X4U%/^#1B3_?U4T_X%>0O^!9E#_?VY<^7QW9O-Z@&_N=XAWZG6/?>=R
ME8+D<)J%XVZ>B.%LHHO@:Z>-WVFKCMYHKY#=9[21W6:ZD=QEP9+<9<F2VV70
MDM)GTI'.:-*1SFC2D<YHTI'.:-*1SFC2D<YHTI'.:-*1SFC2D?^#$P'_A"(&
M_X4U%/^#1B3_?U4T_X%>0O^!9E#_?VY<^7QW9O-Z@&_N=XAWZG6/?>=RE8+D
M<)J%XVZ>B.%LHHO@:Z>-WVFKCMYHKY#=9[21W6:ZD=QEP9+<9<F2VV70DM)G
MTI'.:-*1SFC2D<YHTI'.:-*1SFC2D<YHTI'.:-*1SFC2D?^$$P'_A2(&_X8U
M%/^$1B3_@%4T_X1=0_^%95#_@VU=^(!U:/)]?G'L>H9YZ'>-?^5UDX7B<IB)
MX'"=C-]NHH[=;*:0W&NKDMMIKY3::+65VF>[E=IFPY;:9LR6TVC/ELQISY7(
M:L^6R&K/ELAJSY;(:L^6R&K/ELAJSY;(:L^6R&K/EO^%$@'_AR(&_X<U%/^%
M1B3_A%0U_XA<0_^(9%'^AVM>]X-R:?& ?'/K?85[YWJ,@N-WDH?@=)>,WG*<
MC]QPH9+;;J:4V6RJEMEJL)C8:;:9UVB]F==HQIK3:,R:S&K,F<9KS)K";,R:
MPFS,FL)LS)K";,R:PFS,FL)LS)K";,R:PFS,FO^&$@'_B"$&_X@U%/^&1B7_
MAU,U_XM;0_^,8E'^BFI>]H=Q:O"$>G3J@(-]Y7V*A.)ZD(K>=I:/W'2;DMIQ
MH)78;Z68UFVKFM5KL)O5:K><U&F_G=1IR9W,:\J=QFS)G<!MR9V];LF=O6[)
MG;UNR9V];LF=O6[)G;UNR9V];LF=O6[)G?^'$@'_B2$&_XHU%/^(1B7_BE(U
M_XY:0_^/85'^CFA>]HMO:N^'>'7IA(%^Y("(AN!\CXS=>921VG::E=ASGYG5
M<*6;U&ZJGM-ML9_2:[B@TFO"H<ULQZ'&;L>AP&['H;MOQZ&X<,>AN'#'H;AP
MQZ&X<,>AN'#'H;APQZ&X<,>AN'#'H?^($0'_BB$&_XLU%/^)1B7_C5$U_Y)8
M0_^27E'^D&5>]HYL:^^+=7;HAWZ XX2&B-Y_C8_;>Y.4V'B9F=5UGIS3<J2?
MT7"JHM!NLJ/0;;JDSFS$I<9OQ*2_<,2ENG'$I;5QQ*6R<L2DLG+$I+)RQ*2R
M<L2DLG+$I+)RQ*2R<L2DLG+$I/^)$0'_BR$&_XPT%/^*1B7_D$\T_Y160_^4
M6U'^DV%>]I%H:^Z.<';HBWN XH>#B=V#BI'9?I&7U7J7G--WG:#0=*2CSW&J
MILYOLZ?-;KVHQW#"J+YQP:FX<L&IM'/!J:]TPJBM=,*GK73"IZUTPJ>M=,*G
MK73"IZUTPJ>M=,*GK73"I_^*$0'_C"$&_XTT%/^+1B;_DTXT_Y930O^76%#^
MEEY>]I1D:NZ2;';GCW:!X8R BMR'B)+8@H^9TWV5G]!YG*/.=:.GS'*KJLMP
MM*O(<+^LOW.^K+=TOJVR=;ZLKG:_K*IVOZNH=\"JJ'? JJAWP*JH=\"JJ'?
MJJAWP*JH=\"JJ'? JO^+$0'_C2 &_XXT%/^-12;_EDTS_YE00?^:54__FEI=
M]YA@:>^5:'7HDG" X8][BMR+A)/6AHR:TH"3H<Y[FJ;,=Z*JRG2KKLARN*_
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M:_-KDW#P:9ES[F>?=^QEI7GK9*I[ZF*O?>EAM7[H8+U_Z%_%@.A>T('B7]J
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MZZ%G1^RS:4;MT&E(YNAI2]GK:DS/[&U.Q^MO3\#J<$_ ZG!/P.IP3\#J<$_
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M&A[_G!L>_Z4<'?^P'1W_L!T=_[ ='?^P'1W_L!T=_[ ='?^P'9S   ",S@
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MA^1Y<H?D>7*'Y'ERA^1Y<H?D>?]M$P'_=A,!_X@2 ?^8$P#_IQD![[,6 >+
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M=V:2YG=FDN9W9I+F=_]P$@'_@ X!_Y(. /*C"P#9LPD S[X) ,O,"0#$TQ<
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M."[_[SDM__\Y,?__.3/\_SDS_/\Y,_S_.3/\_SDS_/\Y,_S_.<&H  "OL0
MHKT  )3*  "'V   ??,' ';_$@%M_QH#9?\D!5[_+0I8_S8/4O\]$TS_119(
M_TP90_]3&S__6AX\_V$@./]I(37_<B,Q_WTE+O^*)BO_F2@I_Z<I)_^Y*R;_
MTBPE_^\L)/__+23__RTD__\M)/__+23__RTD__\M)/__+;&N  "CN0  E,8
M (;3  !YX0  <?\( &?_#P%?_Q4"5_\> U'_)@5+_RX'1O\V"D'_/0P]_T0.
M.?]+$#;_41(R_U@3+_]?%2S_9Q8I_W$7)O]\&"/_B1H@_Y@;'_^F'!W_MQT<
M_\H>'/_F'QO_\!\;__ ?&__P'QO_\!\;__ ?&__P'Z2U  "5P@  AL\  '?>
M  !K]   8O\# %G_"P%1_Q$!2O\7 D3_'P,__R8$.O\M!3;_- 8R_SH'+O]
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M:72 \&ET@/!I=(#P:?]A%P'_<1 !_X(. /^0#@#UG0T XZD, -FU# #/N1H
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M24+3_TU$R?]/1<+_4$>[_U)'N_]21[O_4D>[_U)'N_]21[O_4N:*  #/FP
MOZ<  +*P  "GNP  G,8# )/1!@"+Z@X A>@? G[H+09VZ#@.;NA!%F;G2AU?
MYU(C6>=;*57G9"U0YVTQ3.=X-4GGA#A&Z)$Z0^B@/$#ILCX_ZLL^/NCO/CWF
M_S\]X/]"/]?_1$#._T9 SO]&0,[_1D#._T9 SO]&0,[_1M:3  #$HP  M*P
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M'R+__Q\B__\?(O__'R+__Q\B__\?(O__'ZRK  "=M@  C\(  (#.  !SW
M9^D  %__!@!8_PX 4?\5 4O_'0)&_R8#0?\M!#S_-04X_SP&-/]"!S'_20@N
M_U )*_]7"BC_7PHE_VD,(_]T#2#_@@X=_Y(/&_^B$!K_LA$9_\@2&/_E$Q?_
M^A07__H4%__Z%!?_^A07__H4%__Z%)^S  "0OP  @,P  '+:  !DY   6/4
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M67YR^UE^<OM9?G+[6?]8%P'_9Q !_W4. /^!#@#_C X \940 ..=$0#6HQL
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M5U"E_%=3G_U759K]5E>6_E98E?Y56)7^55B5_E58E?Y56)7^5?]O! #F@@
MTI$  ,:=  "[I@$ LJX  *JW 0"BP@4 G,08 )7#*@2-PCD-A<!$&'V^3B%U
MO%8J;KI>,FBY9CABMVX^7;9X0UBU@D=4M(]+4+2=3DVSKE!+M,502[/J4$JQ
M_U%,J_]23J7_4E"A_U)1GO]149[_45&>_U%1GO]149[_4?]V  #=B0  RI<
M +ZB  "SJ@  J;,  *"\ @"8Q@8 D<P2 (O,)0*$RS0)?,E $G7(2AMMQU,C
M9\5<*F'$9#!<PVTV5\)V.E/"@3]/P8Y"2\&=14C!KD9'P<5&1\'J1D2^_TE%
MN?]*1[/_2TFM_TQ*J_],2JO_3$JK_TQ*J_],2JO_3.E_  #1D   PIX  +6G
M  "JKP  H+@  );! @",RP< A-4- (#5'@%YU2X%<M0\#&S31Q1ETE ;7]%9
M(5K18B=5T&LL4=!U,$W/@31)SXXW1L^=.430KCM"T,8[0]#J.D#-_3X^R_]
M0,/_0D&]_T-"N?]$0KG_1$*Y_T1"N?]$0KG_1-V(  #'F   N*,  *NK  "@
MM   E;X  (O( P" T0< >.$- '3A'0%NX2L#:. W"&'@0@Y<X$T45^!6&5/@
M7QU/X&DB2^!S)4?@?BA$X(LK0N":+3_AJR\^XL$O/N+E+SS?^C$YWO\T.=G_
M-CK0_S@[S/\Y.\S_.3O,_SD[S/\Y.\S_.<V2  "\H   K:@  *&Q  "5NP
MB<4  '[/ @!TV@8 ;NL1 &CK'@%BZRH#7>PU!E?L/PM2[$@/3>Q1$TKM6A9&
M[6,90^UM'$#M>!X][H4A.NZ3(SCOHR0V\+8F-?'2)C3O\R8T[/\F,NO_*#+G
M_RLSY/\L,^3_+#/D_RPSY/\L,^3_+,&<  "PI@  HZX  ):X  ")PP  ?<T
M ''8  !GY@8 8O81 %SW'0%7]R<"4O<Q!$WX.@9(^4()1/E+"T'Z5 X^^EP0
M._ME$CC[;Q0U^WL6,OR)&##]F!DN_:H;+/Z_'"O_XQTJ_/H=*OK_'2KW_QPJ
M]_\=*O?_'2KW_QTJ]_\=*O?_';.C  "DJP  E[8  (G!  ![RP  ;]8  &/?
M  !;]08 5?\0 %#_&0%+_R,"1O\L T+_- 0^_SP%.O]#!C?_2P<T_U,(,?];
M"2[_9 HK_V\,*/]\#2;_BPXD_YP0(O^N$2'_Q1(@_^D3'__\$Q[__Q,>__\3
M'O__$Q[__Q,>__\3'O__$Z:I  "8LP  BK\  'O*  !NU0  8-\  %3G  !.
M_P0 2?\. $/_%  __QT!.O\E C;_+ (R_S,#+_\Z RO_000H_T@$)?]/!2+_
M5P4@_V &'?]L!QK_>0<8_XH(%O^;"!7_K0D4_\,)$__C"1/_^ D3__\*$___
M"A/__PH3__\*$___"IJQ  "+O0  ?,@  &W4  !?X   4>8  $?U  !!_P
M//\) #?_$  R_Q4!+O\= 2K_(P$F_RD!(O\O A__-0(<_SL"&?]" Q;_20,3
M_U$#$?]: P__9@0-_W0$"_^%! K_E@4)_Z@%"/^Y!0?_T 4'_^,%!__C!0?_
MXP4'_^,%!__C!8VZ  !]QP  ;=,  %_@  !0YP  0NT  #K_   U_P  +_\"
M "K_"@ F_P\ (O\4 ![_&@$:_Q\!%O\C 1/_* $0_RT!#O\S 0S_.0(*_T$"
M!_]) @/_4P( _UX" /]L @#_? , _XT# /^= P#_K , _[4# /^U P#_M0,
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MBFJJ4X=JN52%:L]4A&ON4X-L_U&";/]/@6O_38!K_TR :_]*@&O_2H!K_TJ
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M5&&&^5)CA/]098'_3V9__TUG?O],9W[_3&=^_TQG?O],9W[_3/]A"@#_;P
MX'X  -")  #&DP$ OYL# +BA @"QI@L JJ@> :.G+P6;I3T/E*)(&8R?42*%
MG%DK?YIA,GF8:3ETE7$_;Y-Y1&J2@TAED(Y,88^;3UZ.JE);CKU26H[>4EN-
M^%!<B_]/7HC_3F"%_TQA@_]+88/_2V&#_TMA@_]+88/_2_]D!0#U=   VH(
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M1$N@_T1-G/]$39S_1$V<_T1-G/]$39S_1.IU  #2A@  PY,  +>=  "LI
MHJL  )BS  ".NP$ A<$, ('"'0![PBT#=<$Z"6_ 11%IOT\88[Y7'EZ]7R-9
MO&@H5;MQ+5&[>S!-NH<T2KJ5-T>ZI3E%NK@Z1+K7.4.X]3M"MO\]0K/_/D2N
M_SY%J?\^1:G_/D6I_SY%J?\^1:G_/N!]  #)C0  NYH  *ZB  "CJ0  F+$
M (ZY  "$P0( ><D' '3+% !PS"8!:\LU!67+0 I@RDL06\I4%E?)71I2R64?
M3LAO(TO(>B9'R(8I1,B4+$+(I"Y R+@O/\G7+S_']3 ]Q/\S.\/_-3R^_S8]
MN/\W/;C_-SVX_S<]N/\W/;C_-]&&  # E0  LI\  *6G  ":KP  CK<  (._
M  !XQP, ;L\' &77#0!CV!T 8-@M EO8.@17V$8)4]A0#4_861%+UV(51]=L
M&$37=QM!UX0>/MB3(#S8HR$[V;<B.MK5(CK6\B,WU/\G-M+_*331_RLVRO\M
M-LK_+3;*_RTVRO\M-LK_+<60  "VG0  J*4  )RM  "/M@  @[X  '?'  !L
MSP( 8M8' %KD#@!8Y!P 5.0I 5#D-0-,Y3\%2.5)!T7E4PI"YEP-/^9F#SSF
M<1(ZYWX4-^>,%C7GG!<SZ*X9,NG&&3+HZADQY?X9+^3_'"[D_QXMXO\@+>+_
M("WB_R MXO\@+>+_(+J:  "JHP  G:L  )"T  "#O0  =\8  &O/  !?U@
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M XBY  !XQ   :=   %O=  !+XP  /ND  #+N   K_P  )O\  "'_   =_P@
M&O\- !;_$0 3_Q8 $/\:  [_'P +_R0 "?\J  ;_,  "_S<! /]  0#_2@$
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M+?\:^2W_'/,O_QSM,?\=ZC+_'>HR_QWJ,O\=ZC+_'?\S*0'_."8!_STD ?]
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M27%P]$=Q<?]$<G#_0G)O_T%R;O\_<F[_/G)N_SYR;O\^<F[_/O]6"@#_8@
MYF\  -=Y  #,@0$ Q8<# +^+! "YC@X LI @ :N/,06DC#\-G8I*%I:'4QZ1
MA%PEBX%D+(9_:S&"?7,V?GM\.WIYAC]V=Y!"<G:<16]UJ4AL=;I):W7426MU
M\D=K=?]%;'7_0VUS_T%M<O\_;7+_/VUR_S]M<O\_;7+_/_]9!P#_90  XG(
M -%\  #'A   P(H" +F/ @"SD@P K)0= *:3+P2>D3P+F(](%)&,41R+B5HD
MAH=B*H&%:3!\@G$U>(%Z.G1_@SYP?8Y";'R:16E[IT=F>KA(9'O02&1[\$=E
M>_]$9GK_0V=X_T%H=O\_:';_/VAV_S]H=O\_:';_/_];! #W:0  W78  ,V
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M05N#_T!=@?\^78#_/EV _SY=@/\^78#_/O]B  #D<0  SWX  ,.(  "YD0
ML)<  *>;  ">H0  F*,3 ).C)0&-HC0&AJ% #8"?2A5YG5,<=)M:(V^98BAJ
MF&HN9I9R,F&5?#==E(8Z69*3/E:2H4!3D;)!4I+)0E*1ZT%2D/] 4H__/U6+
M_SY6B/\]5X?_/5>'_SU7A_\]5X?_/?EG  #==@  R8,  +V-  "SE0  J9L
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M,D&F_S)!IO\R0:;_,M5\  #"B@  M98  *B=  "=HP  DJH  (>Q  !\MP
M<+X# &C"#@!FPQT 8\,M 5[#.01:PT0(5L).#%+"5Q!/P5\42\%I%TC!<QI%
MP'X=0L",(#_ FR(]P*TC/,'$(SS Z2,ZOOXF.+S_*#>[_RDXN/\J.+;_*SBV
M_RLXMO\K.+;_*\F%  "YDP  K)P  *"B  "4J@  B+$  'RX  !QO@  9L4#
M %O+" !7S1, 5LXC %/.,@%0SCX#3<](!4G/4@A&SUL+0\]E#D#/;Q ^SWL3
M.\^)%3G/F1<WSZL8-M##&#;/Z!@TS?L;,LO_'3'*_Q\PR?\A+\C_(2_(_R$O
MR/\A+\C_(;Z/  "OF@  HJ$  ):I  "*L   ?;@  '&_  !FQ@  6\P" %#2
M!P!'V@P 1MP8 $7<)P!$W34!0=U  C_>2P,]WE4$.M]?!CC?:0<UWW8),^"$
M"S'@E POX:8-+N&\#BWBX XMWO@/*]W_$BK<_Q0IVO\6*-K_%BC:_Q8HVO\6
M*-K_%K.8  "EH   F:<  (NP  !^N   <<   &7(  !9S@  3M,  $3;!  _
MZ0T />D7 #OJ(P YZBX -NLX 33K0@$Q[$L"+^U5 RWM7P,J[FL$*.YX!2;O
MB 8E[YH'(_"N!R+QR <B\.T'(>S_!R'K_P@@Z_\*'^K_"Q_J_PL?ZO\+'^K_
M"ZB?  ";I@  C:\  '^X  !QP0  9,H  %C0  !,U@  0=T  #CD   U]@P
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M 0#_AP$ _YT! /^R 0#_R@$ _^H! /_S 0#_\P$ __,! /_S 82W  !TP0
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M+?\6X"[_%N N_Q;@+O\6X"[_%O\R(P'_.!T!_SP; ?\^&P'_0"(!_T$K ?]
M-@+_/D(#_SQ/!?\Y7 ;_.&@(_39S"_LU?@SX-8@.]S21#_4TF1#S-* 1\C.H
M$O SL!+O,[D3[C/%$^LTUQ/G-.H2XS3W%.$T_Q?>,_\9W#/_&MLS_QK4-/\:
MSC7_&LXU_QK.-?\:SC7_&O\V'P'_/!D!_T$6 /]$%@#_1QX!_TDG ?](,@+_
M1CT#_T1)!?I"5@?V0&()\C]N#.\]>0_M/(,0ZCR,$N@[E!/G.YP4Y3ND%>,Z
MK17B.K86X#O"%M\[TA;:.^@7U#KV&M Z_QS-.O\>RSK_'LHZ_Q_$._\?P#S_
M'L \_Q[ //\>P#S_'O\Y&P'_0!4 _T41 /]*$P#_3AD _U B ?]0+ ']3C<"
M]DM#!/!)4 ?K2%T*YT9I#>-%=!#@1'X3W4.'%=M"D!?809@8U4"@&=- J1O1
M0+(<ST"]'<U S!W*0>0>QD#T(,) _R*_0/\CO4#_([M _R.V0?\CLT+_(K-"
M_R*S0O\BLT+_(O\]%P#_1!$ _TH. /]0$ #_5!4 _U8= /U6)@'S53$!ZU,]
M ^522P;?4%@*VDYC#M1,;A/02G@6S4F!&<M(BAO(1Y(=QD>:'\1&HR'"1JPB
MP$6W([Y%Q22\1=PDN$;P);5&_R>R1O\GL$;_)ZY&_R>J1_\FITC_)J=(_R:G
M2/\FITC_)O] % #_2 X _TX+ /]5#@#_61$ _UP6 /1='P#J7"H!XELW MI:
M1@725U,+S%5>$,A3:!7$47(9P5!['+Y/A!^\38PBN4V5)+=,G2:U2Z<GLTNQ
M*;%*ORJO2M$JK$OK*ZE+_"RF2_\LI4S_*Z-,_RJ?3?\JG4W_*9U-_RF=3?\I
MG4W_*?]#$0#_2PP _U,( /]:"P#_7@T ^6 0 .MA%@#A8B$ UF(Q <YA007'
M7TX+PEQ9$;U:9!>Y6&T;ME9V'[-5?B*P4X<EKE*/**M1F"JI4*(LIU"L+:5/
MN2^C3\LOH%#F+YY0^3"<4/\OFE'_+IA1_RV64O\LE%+_*Y12_RN44O\KE%+_
M*_]&$ #_3@D _U8% /Y>!@#O8@< YV4* .1F#@#69QD S6@M <5G/06_94H+
MN6-5$K1@7Q>P7FD<K%QQ(:E:>B2F68(HI%B+*Z%6E"V?59TOG%6H,9I4M#.8
M5,4SEE3A-)-5]C.25?\RD5;_,8]6_S"-5O\NC%?_+8Q7_RV,5_\MC%?_+?])
M#@#_404 _UH! .YB  #?9P, V&H& -5K"@#-;14 Q6XI ;YM.02W:T<+L6A2
M$:QF7!BH9&4=I&)M(J%@=2:>7GXIFUV&+9A<CR^56IDRDUFD-)!9L#:.6< V
MC%G;-XI9\S:)6O\TB%O_,X=;_S&&6_\PA5O_+X5;_R^%6_\OA5O_+_]+# #_
M5   ^UX  .)E  #8:P$ SVX% ,QP" #&<A( OG,F ;=S-@2Q<$0*JVY/$:9K
M61BA:6$=G6=J(IEE<B>68WHJDV*#+I!@C#&-7Y4TBEZ@-H=>K3B%7;PY@UW4
M.8)>\#B!7_\V@%__-(!?_S-_7_\Q?E__,'Y?_S!^7_\P?E__,/]-"0#_5@
M[F$  -UI  #1;P  RG,# ,5U!@# =A  N'@C +%X,P.K=D$)I7-,$)]P5A>;
M;E\=EFQG(I-J;R>/:'<KC&=_+XEEB#*%9)(U@F.=-X!BJCE]8KDZ>V+/.WIB
M[CEZ8_\X>F/_-GEC_S1Y8_\R>6+_,7EB_S%Y8O\Q>6+_,?]/!P#_60  YF0
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M-VAP_S5I;_\T:6[_,VEN_S-I;O\S:6[_,_]6  #K8@  V&X  ,EV  "_?0
MMX(  +"%  "HAP8 HHD7 )R**0&6B3<&D(=##(N%31.%@E49@(!='WQ_921X
M?6TI='MU+7!Z?C%M>8@T:7>4-V9VH3IC=K [87;$/&%VY3MA=OLY8G;_-V-U
M_S5C<_\T9'+_,V1R_S-D<O\S9'+_,_]8  #F9@  TG$  ,5Z  "[@0  LH<
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M,5*$_S%2A/\Q4H3_,>IE  #2<P  PG\  +:(  "LD   HI0  )B8  ",G
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M(,&#  "TD0  II@  )N>  "/I0  @JL  ':Q  !KM@  7[P  %3! P!,Q0T
M2\49 $G&* !(QC4 1<=  4/'2@- QU,$/L==!CO'9P@YQW,*-\> ##3'D TR
MQZ$.,<BU#S#(TP\PQO00+L3_$RW"_Q4LP?\6*\#_%RO _Q<KP/\7*\#_%[B-
M  "JEP  GIX  )&E  "$K   >+(  &NY  !@OP  5,,  $K( @! S0< .M(.
M #G2&P XTR@ -],U #;40  TU4L!,]55 3'68 (OUFP#+==Z!"O8BP4JV)T%
M*-FQ!B?:S08GU^\&)M3_"272_PLDT?\,(]#_#2/0_PTCT/\-(]#_#:Z6  "@
MG0  E*0  (:L  !YM   ;+L  &#"  !4Q@  2,L  #[0   UU00 +=T* "SA
M$P KXA\ *>,J "CD-0 GY#\ )N5* "3F50 CYF$!(>=N 2#G?@(>Z) "'>FD
M AOIO (:ZN("&N;\ AGE_P,9Y/\$&./_!1CC_P48X_\%&./_!:.=  "6I
MB*P  'JU  !LO0  7\0  %/*  !'S@  /-,  #+:   JWP  )>X) "/P$0 A
M\1D '_$B !WR*P ;\S0 &?0^ !?T2  5]5( $_9? !+V;@$1]X !$/B4 0_Y
MJ@$.^<8!#OGM 0WV_P$-]/\!#?/_ 0WS_P$-\_\!#?/_ 9FC  "+K   ?+4
M &V^  !?Q@  4LT  $72   YV   +]X  ";B   ?Z@  '/L& !G_#@ 7_Q,
M%/\: !+_(0 0_R@ #O\P  W_.0 +_T, "?].  ;_7  $_VP  O^   '_E@
M_ZT  /_*  #_\   __\  /__  #__P  __\  /__ (VK  !]M0  ;K\  &#(
M  !2T   0]<  #?=   KX@  (N8  !GJ   5^0  $O\  !#_"  ._PX #/\1
M  G_%@ &_QP  _\B  #_*@  _S,  /\]  #_20  _U<  /]I  #_?@  _Y4
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M)9E+\"663/\DE4S_))1,_R.33/\BD4W_(9%-_R&13?\AD4W_(?]""@#_20
M_U$  .97  #=6P$ U5P% -);"0#+7!0 PUXH +Q>. *V748&L5M1"JU96P^I
M6&03IE9L%Z-5=!J@5'T=GE.%'YM2CB*949<DEU"A)I50K2>24+PHD5#0*(Y0
M["B-4?XGBU'_)HM1_R6*4O\DB5+_(XA2_R.(4O\CB%+_(_]%!P#_2P  \%4
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M*W5?_REU7_\H=5[_)G5>_R9U7O\F=5[_)O]+  #P50  WE\  ,UG  ##;
MNV\  +5P  "O;PH J'$: *-R*P&=<CD$F'!%"9-N3PZ/;5@4BVM@&(=I9QR$
M:&\@@6=W(WUF@"9Z9(HI=V.4+'5CH2YR8J\O<&+!,&]BWS!N8_<N;V/_+&]C
M_RIO8_\H;V+_)V]B_R=O8O\G;V+_)_]-  #K6   V6,  ,EJ  "_<   MW,
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M*&!N_RA@;O\H8&[_*/%5  #>8@  RFT  +UU  "S>P  JX   **"  "8@0
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M)-AI  ##=@  M8$  *N*  "?CP  E9,  (J6  !^F@  <)T  &N?#@!HGQP
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M$#*SQ1 RLND0,;#^$C"N_Q0OK?\5+ZS_%B^L_Q8OK/\6+ZS_%KN!  "NC@
MH94  )::  ")H   ?:8  '&K  !EKP  6;0  $ZW  !#O 4 0+T1 #^]'@ ^
MOBL /+XV #N_00 YOTL!-[]4 C7 7P(SP&H$,<!W!2_ A@8MP)<'*\"J""K!
MP@@JP.<'*;W]"BB\_PPGNO\-)[G_#B>Y_PXGN?\.)[G_#K*,  "EE   F9H
M (VA  !_IP  <JT  &:S  !:N   3[L  $2_   ZQ ( ,,D( "[*$0 MRAT
M+,LI "O+-0 KS$  *LU* "C-5@ GSF$ )LYO 23.?P$CSY$"(<^E B#0O0(@
MS^0"'\WZ Q[+_P0>RO\%'<G_!AW)_P8=R?\&'<G_!JB4  "<F@  D*$  (*H
M  !TKP  9[8  %N\  !.P   0\,  #G'   OS   )] $ !_6"@ ;VA  &]L:
M !K;)@ :W#$ &=T\ !C=2  8WE4 %]]B !;@<@ 5X(4 %.&: !/BL0 2X\\
M$N#T !+>_P$1W?\!$=O_ A';_P(1V_\"$=O_ IZ:  "2H0  A*D  ':Q  !H
MN   6[\  $[$  !"R   -\P  "W0   DU0  '-L  !7?!0 4Z0X $NH4 !'K
M'0 0ZR8 #NPP  [M.@ -[D8 "^Y3  KO8@ )\'0 "/&)  ?RH  %\KH !/'D
M  +Q_0 "[_\  ^W_  /M_P #[?\  ^W_ )6A  "&J0  >+(  &FZ  !;P@
M3<@  $#,   TT0  *M8  "';   9X   $N0   _P 0 -^0H "_H/  G[%0 '
M^QP !/PD  '\+   _#<  /Q"  #\4   _&$  /UU  #\C   _*0  /S!  #\
MZP  _/\  /W_  #]_P  _?\  /W_ (FI  !YL@  :KL  %S$  !.S   /]$
M #+7   GW0  '>$  !7E   .Z   "O$   C]   %_P,  ?\)  #_#@  _Q(
M /\7  #_'P  _R<  /\Q  #_/@  _TT  /]?  #_=0  _XT  /^F  #_P@
M_^<  /_\  #__P  __\  /__ 'RS  !LO   7<8  $[/   _U@  ,=T  "7B
M   :Y@  $>H   SN   %\@   /\   #_    _P   /\   #_!0  _PH  /\.
M  #_$@  _Q@  /\A  #_*P  _SD  /]*  #_70  _W,  /^,  #_I   _[D
M /_4  #_W@  _]X  /_> /\8+ #_&2D _QDH /\5*P#_$#  _PLX ?\#1 '_
M %$!_P!> ?\ ; '_ '@!_P"" ?\ C '_ )0!_P"< /\ H@#_ *@ _P"O /\
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M"[<T\PVT-/\/L33_#[ T_Q"O-/\0KC3_#ZXT_P^N-/\/KC3_#_\U#@#_. <
M_SP" /] !@#_00L ^D$/ .T_%@#C/"( VCTQ -(^00#,/D\"R#Y: \0]9 7!
M/6X'OSQV"+P\?@JZ.X<+N#N/#+<[EPVU.I\.LSJI#[$ZM!"O.L(1KCK9$:H[
M[Q*G._\3I3O_%*0[_Q.C._\3HCO_$Z([_Q*B._\2HCO_$O\X"@#_/   _T$
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M'85,_QR%3?\:A4S_&85,_QF%3/\9A4S_&?]   #\1P  Y5   -56  #*60
MPEH  +U8 P"X5PX L5D> *Q:+P&G6CT"HEE)!9Y84PF;5UL,EU9D$)55:Q*2
M5',5CU-[%XU2A!J+48T<B%&7'H90HQ^$4+ @@E#!(8!0W2%^4?0@?5'_'WU1
M_QU]4?\<?5'_&WU1_QI]4?\:?5'_&O]"  #P2@  WU0  ,Y:  #$7@  O%\
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M'FI>_QUJ7O\=:E[_'?E*  #C50  SU\  ,%E  "W:@  KVP  *=L  "?:@$
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M'>57  #-9   OFT  +)U  "H>P  GWX  )-]  "'?0  @'\' 'R %0!X@20
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M&T**OQM!BN$;08CY&T&&_QM!A?\;0H7_&D*$_QI"A/\:0H3_&LUG  "\=
MKWX  *6&  ":B@  CHP  (*-  !UD   9Y0  &&5" !>EQ0 7)<C %J8+P!7
MF#H!5)A$ U*73 5/EU0'3)=<"4F690Q'EF\.1)5Z$4&5B!,_E)<5/92H%CN4
MO18[E-\6.I+X%SJ0_Q<ZC_\7.H[_%SJ._Q<ZCO\7.H[_%\5N  "V>P  JH4
M )Z+  "4CP  B)(  'N4  !NEP  8IL  %>>  !2H X 4: ; $^A* !-H30
M2Z$^ 4FA1P)'H5 #1*%8!4*A80<_H&L)/:!W"SJ@A0TXH)0.-J"F#S6@NQ T
MH-T/-)WW$#.<_Q(SFO\2,YG_$S.9_Q,SF?\3,YG_$[UW  "O@P  HXL  )B1
M  "-E0  @9D  '.<  !GGP  6Z(  $^F  !'J0@ 1*H2 $.J'P!!JRL 0*LW
M #^L00 ]K$H!.ZQ3 CFL7 ,WK&<$-:QS!3*L@08PK)$'+JRC""VLN DLK-D(
M+*KU"BNH_PLJIO\,*J7_#2JE_PTJI?\-*J7_#;6   "HBP  G)$  )&6  "%
MG   >*   &NE  !?J   4ZP  $BO   ]L@  -K4+ #2U%0 SMB$ ,K8L #&W
M-P PMT$ +[A+ "ZX50 LN& !*KAM 2FY>P(GN8T");F? R2YM ,CN=(#([?T
M!"*U_P4AM/\&(;/_!R&R_P<ALO\'(;+_!ZV*  "@D0  E9<  (B=  ![HP
M;J@  &&M  !5L0  2K0  #^W   TNP  *[X# "3"#  BPA0 (L,? "'#*@ @
MQ#0 '\0_ ![%2@ =QE8 ',9C !O'<P :QX4 &<>9 !C(K@ 7R,L %\;Q 1?$
M_P$6P_\"%L'_ Q;!_P,6P?\#%L'_ Z.1  "8F   BYX  'VE  !PJP  8K$
M %:V  !*N0  /KT  #3    JQ   (L@  !G,!  3T H $=(1 !#2&@ 0TR4
M#],P  [4/  .U$@ #=56  W590 ,UG@ #-:-  O8I  *V+X "=GF  K6_@ +
MU/\ "]+_  O2_P$+TO\!"]+_ 9J8  ".GP  @*8  '*M  !DM   5[H  $F_
M   ]P@  ,L8  "C)   ?S0  %]$  !'6   ,VP4 "-X+  ;?$0 %WQH !. D
M  +A+@ !XCH  .-'  #D5@  Y&<  .5[  #FD@  YJH  .?(  #G\   Z/\
M .C_  #H_P  Z/\  .C_ )&?  ""IP  =*\  &6W  !7O@  2<,  #S'   P
MRP  )<\  !S4   4V0  #MT   GA   "Y0   .D&  #I#0  Z1$  .H8  #K
M(0  [2L  .\W  #Q10  \E8  /-H  #S?@  ])<  /6P  #VT   ]_,  /?_
M  #W_P  ]_\  /?_ (6G  !VL   9K@  %C!  !*R   .\P  "[1   CU@
M&=P  !'@   ,XP  !.<   #J    ]0   /0   #U!0  ]0L  /8/  #V%
M^!T  /HG  #\-   _T,  /]5  #_:0  _X$  /^:  #_L@  _\\  /_M  #_
M^0  __D  /_Y 'BP  !HN@  6<,  $O+   [T0  +=@  "'=   6X@  #N8
M  CJ    [0   /    #X    _P   /\   #_    _P   /\&  #_#   _Q
M /\8  #_(@  _S   /]   #_4P  _VD  /^!  #_F0  _Z\  /_#  #_U0
M_]4  /_5 /\3* #_$R4 _Q$E /\-)P#_!BT _P U /\ 00#_ $\ _P!< /\
M:0#_ '0 _P!^ /\ B #_ )  _P"7 /\ G0#_ *0 _P"J /\ L #_ +< _P#
M /\ S #_ -\ _P#L /\ ^ #_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\
M_P#_ /\6)0#_%B( _Q0A /\0(P#_"B@ _P P /\ /0#_ $L _P!8 /\ 9 #_
M '  _P!Z /\ A #_ (P _P"3 /\ F@#_ *  _P"F /\ K0#_ +0 _P"\ /X
MR #] -D ^P#I /H ]@#Y /\ ^ #_ /@ _P#X /\ ^ #_ /D _P#Y /\ ^0#_
M /\:(@#_&AX _Q@= /\3'@#_#B( _PHL /\'.0#_ T8 _P!3 /\ 8 #_ &L
M_P!V /\ ?P#_ (@ _P"/ /\ E@#_ )T _P"C /X J0#\ +  ^@"Y /< Q #U
M -( \P#F /( ] #Q /\ \ #_ .\ _P#O /\ [P#_ /  _P#P /\ \ #_ /\>
M'0#_'AD _QP7 /\7& #_$QX _Q$H /\.- #_#$$ _PI. /\(6P#_!V8 _P9Q
M /\&>@#_!H, _@:+ /P&D@#Z!ID ^ :? /8&I@#T!JT \@:U / %P #M!<X
MZP7D .D&\P#F"/\ Y0K_ .0+_P#D"_\!Y O_ >0+_P'D"_\!Y O_ ?\A& #_
M(1, _R 1 /\;$@#_'!H _QHD /\6+P#_$SP _Q%) /\050#\#F$ ^0YK /8.
M=0#T#GX \@Z& / .C@#N#I4 [0Z; .L.H@#J#JH Z ZS .8/O0#E#\P X0_C
M -T0\P#9$?\!UA+_ =03_P'3$_\"TA/_ M(3_P+2$_\"TA/_ O\E$P#_)1
M_R0- /\C#@#_(Q0 _R(> /\?*0#_'#4 ^1E# /083P#O%UL [!=F .D7< #F
M%WD Y!>! .(7B0#@%Y$ WQ>8 -T7GP#;%Z< V1BQ -88NP#4&<H T!KA <P;
M\P')'/\"QAS_ L0<_P/#'/\#PQS_ \,<_P/#'/\#PQS_ _\H$ #_*0L _R@&
M /\K"P#_*Q  _RD7 /TF(@#T(RX ["$[ .8@20#B(%4 WB!@ -HA:@#6(70
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M#)TU_PR=-?\+G#7_"YPU_PN<-?\+G#7_"_\S @#_-0  ]CH  .4^  #<0
MU#T$ -(W"0#+.!4 PSHF +T]-@"X/D0!M#Y0 ;$]6@.N/6,$K#UK!:D\<P:G
M/'L(ICR#":0[BPJB.Y0+H#N=#)X[J V=.[0.FSO%#ID[X Z6._0/E#S_#Y(\
M_P^2//\.D3S_#9$\_PV1//\-D3S_#?\U  #_.0  ZD$  -U&  #01P  R48
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M$W=,_Q)W3/\2=TS_$O\^  #H1P  U5   ,96  "\6   M%D  *U6  "G4P<
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M%>M*  #45@  PUX  +9E  "L:0  HFD  )AG  "/90  B68, (5H&0"!:2@
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M&D]MNQM.;=D:3FST&4]K_QA/:_\74&K_%E!J_Q50:O\54&K_%=U5  #%80
MMVH  *QQ  "B=0  E'0  (ET  !\<P  =G4  '%W$ !O>!T ;'DK &EY-P%F
M>4 #8WE)!6!X40===U@)6W=@#%AV: Y5=7$14G5\$U!TB!9-=)<72W.F&$ES
MN1E(<]4927+S&$EQ_Q=*<?\62G#_%4MP_Q1+</\42W#_%-1:  # 9@  LV\
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M#C6+_PXUB?\/-8C_#S:'_P\VA_\/-H?_#[YM  "P>0  I8(  )F'  ",B
M?X@  '**  !FC0  6I$  %"5  !)EPD 1Y@3 $68( !$F2L 0YDV $&:0 !
MFD@!/II1 CR:6@(ZFF0#-YIO!369?08SF8P',9F=""^9L @NF<H(+ICM""Z6
M_PHME/\*+9/_"RV2_PLMDO\++9+_"[9U  "J@0  GH@  ).-  "&C@  >(\
M &N2  !?E0  5)D  $F=  ! H   .J(- #BC%P WHR( -J0M #6D-P TI$$
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M 1"Z_P$0NO\!$+K_ 9^/  "4E0  AYL  'FA  !KIP  7JP  %*Q  !%M
M.K8  "^Y   EO   ';\  !7#   /Q@4 "\H-  G*%  (RAT !\HG  ?*,@ &
MRSX !<M+  3,6@ #S&H  LQ^  ',E   S*L  ,W(  #,[0  S/\  ,O_  '*
M_P !RO\  <K_ )>6  "*G   ?*,  &ZJ  !@L   4K8  $6Y   YO   +K\
M "/#   ;Q@  $\H   W-   (T0   =0)  #4#@  U14  -8>  #8)P  V3$
M -L^  #<2P  W5L  -YN  #>A   WYL  -^T  #>V0  W_<  -__  #?_P
MW_\  -__ (V=  !_I0  <*P  &&S  !3N@  1;\  #C"   LQ@  (<D  !C-
M   0T0  "]4   3:    W@   . !  #A"0  X@X  .03  #E&P  YR0  .DO
M  #K/   [4L  .Y=  #N<0  [XD  /"B  #PO   \.,  ._Y  #P_P  \/\
M /#_ (&E  !RK0  8[4  %2]  !&Q   -\@  "K,   ?T   %=4   [:   '
MW@   .(   #F    Z0   .H   #L    [@4  .\,  #Q$   \Q<  /4@  #X
M*P  ^SD  /U*  #^7@  _W0  /^-  #_I@  _\   /_A  #_]0  __4  /_U
M '2N  !EMP  5L   $?(   XS0  *M(  !W8   3W0  #.(   /F    Z0
M .P   #P    \P   /0   #V    ^    /H   #]!P  _PT  /\2  #_&P
M_R@  /\W  #_2@  _UX  /]V  #_CP  _Z8  /^Z  #_T0  _]$  /_1 /\/
M) #_#B( _PLA /\#) #_ "D _P R /\ /@#_ $P _P!9 /\ 90#_ '  _P!Z
M /\ A #_ (P _P"2 /\ F0#_ )\ _P"E /\ JP#_ +( _P"Z /\ Q0#_ -,
M_P#G /\ ] #_ /\ _@#_ /\ _P#^ /\ _@#_ /X _P#^ /\ _@#_ /\1(0#_
M$!X _PT= /\''P#_ ", _P M /\ .@#_ $@ _P!5 /\ 80#_ &P _P!V /\
M?P#_ (< _P". /\ E0#_ )L _P"A /\ IP#^ *X _0"V /P P #[ ,T ^0#B
M /@ \ #W /P ]@#_ /4 _P#U /\ ]0#_ /4 _P#U /\ ]0#_ /\5'0#_$QH
M_Q 9 /\+&0#_ !T _P I /\ -@#_ $, _P!0 /\ 7 #_ &< _P!Q /\ >@#^
M (, _ "* /H D0#Y )< ^ "= /< HP#U *H ] "R /( NP#Q ,@ [P#< .X
M[ #M /H ZP#_ .H _P#J /\ Z@#_ .H _P#J /\ Z@#_ /\8&0#_%A4 _Q,3
M /\.$P#_"QH _P<D /\", #_ #X _P!+ /\ 5P#_ &( _ !L /@ =0#U 'X
M\@"% /$ C #O ), [@"9 .P H #K *8 Z0"N .< MP#F ,, Y #4 .( Z0#A
M /< WP#_ -T _P#= /\ W0#_ -T _P#= /\ W0#_ /\;$P#_&A  _Q8. /\2
M#@#_$A4 _P\? /\,*P#_"3@ _P9% /L#40#W EP \@)F .X"< #J G@ YP*
M .8#AP#D XX X@.5 .$#G #?!*, W02K -L$M #8!<  U@70 -,&YP#0"/@
MS@K_ ,P+_P#+#/\ RPS_ ,L+_P#+"_\ RPO_ /\?$ #_'@L _QH' /\9"P#_
M&!$ _Q89 /\2) #Z$#  \PX^ .X-2@#I#%8 Y0QA .(,:@#>#7, VPU[ -D-
M@P#6#8H U V1 -(-F0#0#J  SPZI ,T.LP#+#K\ R@_0 ,81Z0#"$OD OQ/_
M +T3_P&\$_\!O!/_ ;P3_P&[$_\!NQ/_ ?\B# #_(00 _R   /\A!0#_'PP
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M!XHU_P>*-?\'BC7_!_\O  #R-   XCP  -)!  #'0@  P$   +LZ 0"V-@X
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M#/ ]  #;2   QU   +I5  "P6   I58  )Q3  "73P  D5 . (Q2' ")5"L
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M%%M8N!196= 465CP$UE8_Q%:6/\06EC_#EI7_PU:5_\-6E?_#>-(  #+4P
MNUL  +!A  "D8@  EV$  (Y?  "%7   ?UX' 'M?$P!X82$ =6(N ')B.0%O
M8D,";&%+ VIA4P5G85H'96!B"6-@:@M@7W,-7EY]#UM>B1%979825UVE$U5=
MMA147<X45%WN$U1=_Q%57/\055S_#E5;_PY66_\-5EO_#=Y,  #'5@  N%\
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M$$1L_P]$:_\.16O_#45J_PU%:O\-16K_#<M8  "Z8P  K6P  *%Q  "2<
MA6\  'IO  !N<   97,  &!U!P!==A( 6W<? %EX*P!7>#8 57@_ 5-X2 )1
M>$\#3W=7!$QW7P5*=V@'2'9S"45V?PM#=8T,076=#C]UK@X^=<4./77H#CYS
M_0T^<O\-/G'_##]Q_PP_</\,/W#_#,5>  "U:0  J7$  )QU  "-=   @'0
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M!2>,_P4GC/\%)XS_!;%T  "E?@  F84  (J$  !]A   ;X4  &.(  !8BP
M38\  $.3   ZEP  ,IH' "Z;$  MFQH +)PD "N<+@ JG3@ *9U! "B=2P G
MGE4 )IYA "6>;@ CGGX!(IZ0 2">HP$?GKD!'I[= 1Z<^ (>FO\"'IG_ QZ7
M_P,>E_\#'I?_ ZI]  ">A0  DXL  (6*  !UBP  :(X  %N1  !0E0  1ID
M #N=   RH   *J,  "*F"0 ?IQ$ 'J<: !VH)  <J"T &Z@W !JI00 9J4P
M&*E8 !>J9@ 6JG8 %:J) !2JG@ 3J[0 $JO3 !*H]0 3I_\!$Z7_ 1.E_P$3
MI/\!$Z3_ :.&  "7C   C9$  'V2  !ME0  8)@  %2<  !(H   /J0  #2G
M   JJP  (:X  !FQ   2LP< #[40  ZU%P .M2$ #;4K  VU-@ ,MD$ "[9.
M  JV7  )MFP "+9_  >VE  &MJH !;;%  :VZ@ 'M?\ "+3_  BS_P )LO\
M";+_ )J-  "0DP  A)@  '2<  !EH   5Z0  $NH  ! K   -;   "JS   A
MM0  &+@  !&[   ,O@( !L +  + $0 !P1D  ,$B  #"*P  PC8  ,-"  ##
M4   Q%\  ,1Q  #$AP  Q)T  ,2U  #$V@  Q/8  ,/_  ##_P  P_\  ,/_
M ).4  "'F@  >*   &JF  !<K   3[$  $&U   UMP  *;H  !^]   6P
M$,,   K&   #R@   ,P%  #,#   S1$  ,X8  #.(0  T"H  -$U  #30P
MU%(  -1C  #5>   U8\  -6G  #6P@  UND  -;]  #6_P  UO\  -;_ (J;
M  ![H@  ;*D  %ZP  !0M@  0KH  #2]   HP0  '<0  !3'   -RP  !LX
M  #2    UP   -D   #:!0  W L  -T0  #?%0  X1T  .,G  #E,P  YT(
M .A4  #H9P  Z7X  .F7  #JKP  ZLX  .OO  #K_@  Z_\  .O_ 'VC  !N
MJP  7[(  %&Z  !"P   -,,  "?'   ;RP  $L\   O3   "V    -T   #A
M    Y    .4   #G    Z0   .L'  #M#0  [Q$  /$9  #T)   ]S$  /E!
M  #Z50  ^FH  /N$  #[G0  _+8  /S2  #][0  _?0  /WT '&L  !AM0
M4KT  $3$   TR0  )LT  !K2   0V   "-T   #A    Y0   .@   #L
M[P   /$   #S    ]0   /<   #Y 0  ^P@  /X.  #_%0  _R$  /\O  #_
M00  _U8  /]M  #_AP  _Z   /^V  #_R@  _]0  /_4 /\+( #_!QX _P =
M /\ ( #_ "4 _P N /\ .P#_ $D _P!6 /\ 8@#_ &T _P!V /\ ?P#_ (<
M_P". /\ E #_ )H _P"@ /\ I@#_ *T _P"U /\ O@#_ ,L _P#A /\ \ #^
M /T _0#_ /T _P#] /\ _0#_ /P _P#Y /\ ^0#_ /\-'0#_"QH _P09 /\
M&@#_ !\ _P J /\ -P#_ $4 _P!1 /\ 7@#_ &@ _P!R /\ >@#_ (( _P")
M /\ D #_ )8 _P"< /X H@#\ *D ^P"P /D N0#X ,8 ]@#9 /4 ZP#T /D
M\P#_ /( _P#S /\ \P#_ /, _P#S /\ \P#_ /\0&0#_#A4 _P@4 /\ % #_
M !D _P E /\ ,@#_ $  _P!, /\ 60#_ &, _@!M /P =0#Z 'T ^0"$ /<
MBP#V )$ ] "7 /, G@#R *0 \ "L .X M #M ,  ZP#/ .D Y@#H /4 Y@#_
M .< _P#F /\ Y0#_ .4 _P#E /\ Y0#_ /\2% #_$!  _PP/ /\#$ #_ !4
M_P @ /\ + #_ #H _P!' /H 4P#W %X ] !G /$ < #O '@ [0!_ .L A@#J
M (P Z "3 .< F0#E *  XP"G .$ L #? +H W0#) -L X #8 /  UP#^ -4
M_P#4 /\ TP#_ -, _P#3 /\ TP#_ /\5$ #_$@P _PX) /\+# #_"1( _P,:
M /\ )@#] #, ] !  .\ 30#K %@ Z !A .4 :@#B '( X !Z -X @ #< (<
MV@". -@ E0#4 )P T@"C -  K #. +8 S #$ ,H V0#( .T QP#[ ,4 _P#$
M ?\ PP'_ ,0!_P#$ ?\ Q '_ /\8"P#_%04 _Q   /\0!@#_#PT _PP4 /P'
M'P#Q RL YP Y .( 1@#> 5$ V@); -4"9 #2 VP SP-T ,T$>P#+!(( R@2)
M ,@%D #&!9@ Q 6@ ,(&J0#!!K0 OP;! +T(U0"[">P N O] +8,_P"U#?\
MM W_ +0-_P"T#?\ M W_ /\;!0#_&   _Q<  /\6  #[$P8 ^A . .X,%@#C
M"2( V@DP -,*/@#."TH R@Q5 ,<-7@#%#6< P@YO ,$.=@"_#GX O0^% +P/
MC0"Z$)4 N!"= +<0IP"U$;( LQ'  +(1U0"N$^X JQ3^ *D5_P"G%?\ IQ7_
M *84_P&F%/\!IA3_ ?\?  #_'   ^AX  .L>  #C'   WQ4% -X.#0#3#A@
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M!/4M  #D-P  T#\  ,)#  "W1   K4   *<Z  "C-@8 G3<3 )DY(@"5.B\
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M"V=&M@MF1LP+94;L"V1'_PED1O\(9$;_!V1&_P9D1?\&9$7_!N@[  #01@
MOTT  +-1  "E40  FDX  ))+  "-1P  AT@+ (-*%@!_2R0 ?4PQ 'I-/ !W
M344!=4U- G--50)Q35P#;TUC!&U,:P5K3',':4M]"&9+B0ED2Y8*8DND"V%+
MM Q?2\H,7DOJ"UY+_@I>2_\)7DK_"%Y*_P=>2O\'7DK_!^,_  #+20  O%$
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M#$Y8^PM/5_\)3U?_"$]6_PA05O\'4%;_!]-*  # 5   LEP  *->  "570
MB5P  '];  !V60  <%H  &M<#0!H71@ 9EXD &1?, !B7SH 8%]# 5Y?2P)<
M7U("6E]: UA?80557FH&4UYT!U%=?PE/78T*35V<"TM=K Q*7<$,25WC#$E<
M^@I)6_\)2EO_"$I:_PA*6O\'2EK_!\Y.  "\6   KF   )]A  "18   A5\
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M!CEK_P8Y:O\&.6K_!KU<  "O9@  HFT  )%L  "":P  =VL  &QL  !A;@
M5W   %!S  !,=0H 2783 $=W'P!&=RD 17@S $-X/ !">$0 07A- 3]X50$]
M>%X".WAH CEX= ,W>(($-7B3!3-WI 4R=[D%,7C7!3%V]04Q=/\%,7/_!3%R
M_P4R<O\%,G+_!;=C  "J;0  G'$  (MP  !]<   <G   &=Q  !<<P  47<
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M :5[  "9@P  B8$  'N   !L@@  7X0  %2(  !)BP  /Y   #64   MEP
M)9H  !V> 0 6H P %*$2 !2A&P 3H24 $J$N !&B.  1HD, $*)/  ^B7  .
MHVL #:-]  VCD@ ,HZ< "J+   NBY@ ,H/X #9__  V>_P -G?\ #9W_ )Z$
M  "2B0  @X@  '.(  !EBP  6(X  $R2  !!EP  -YL  "Z>   DH@  '*4
M !6H   /JP0 "JX,  >M$@ &K1L !:TD  2N+@ "KCD  :Y%  "N4@  KF$
M *YS  "NAP  KIT  *ZT  "NU0  K?0  *W_  "L_P  J_\  *O_ ):+  ",
MD   >Y   &N2  !=E@  4)H  $2?   YHP  +Z<  "6K   <K@  %+$   ZT
M   )MP   ;@)  "X#@  N10  +D<  "Z)0  NB\  +LZ  "\1P  O%8  +QG
M  "\>P  O)$  +RI  "\Q   O.L  +O^  "[_P  N_\  +O_ )"2  "#F
M<YL  &.?  !5HP  1Z@  #NM   PL0  );0  !NW   2N@  #+T   6_
MPP   ,0"  #%"@  Q0X  ,84  #'&P  R"0  ,HN  #,.@  S4D  ,U9  #-
M;   SH,  ,Z;  #-M0  SMH  ,[V  #-_P  S?\  ,W_ (:9  !WH   ::8
M %JL  !,L@  /K8  #"Y   DO   &;\  !'"   *Q0   LD   #,    T
M -$   #2 0  TP@  -4-  #7$0  VA@  -PA  #?+   X3H  .)*  #C70
MY'(  .2+  #EI0  Y<   .7F  #E^   Y?\  .7_ 'JA  !KJ0  7*\  $VV
M   _O   ,+\  "/#   7QP  #\H   ?.    T0   -8   #<    WP   .
M  #B    Y    .8#  #H"0  Z0X  .P5  #N'@  \2L  /0Z  #U30  ]F$
M /=Y  #XDP  ^*T  /G&  #YY   ^?,  /GS &VJ  !>L@  3[H  $#!   Q
MQ0  (LD  !;.   -T@  !-@   #=    X0   .0   #H    ZP   .T   #O
M    \0   /,   #V    ^ ,  /H+  #]$0  _QL  /\I  #_.P  _T\  /]F
M  #_?P  _YD  /^O  #_PP  _]8  /_6 /\$' #_ !D _P 9 /\ ' #_ "(
M_P K /\ . #_ $8 _P!3 /\ 7@#_ &D _P!R /\ >@#_ (( _P") /\ CP#_
M )4 _P"; /\ H0#_ *@ _P"O /\ N0#_ ,4 _P#9 /X [ #] /L ^P#_ /L
M_P#[ /\ ^@#_ /0 _P#P /\ \ #_ /\'& #_ 14 _P 4 /\ %@#_ !L _P F
M /\ - #_ $( _P!. /\ 6@#_ &0 _P!M /\ =0#_ 'T _P"$ /\ B@#] )
M_ "6 /H G0#Y *, ^ "K /< M #U +\ ] #. /, Y@#Q /8 \ #_ .\ _P#O
M /\ [@#_ .X _P#J /\ Z@#_ /\+% #_!A$ _P 0 /\ $ #_ !8 _P B /\
M+@#_ #P _P!) /\ 5 #^ %\ ^P!H /D < #W '@ ]0!_ /, A0#R (L \ "2
M .\ F #M )\ [ "F .H K@#H +D YP#' .4 W@#C /  X@#^ .  _P#@ /\
MX0#_ .$ _P#A /\ X0#_ /\-$ #_"0T _P$, /\ # #_ !( _P < /\ * #\
M #8 ^0!# /8 3@#R %D [P!B .P :P#J '( Z !Y .8 @ #D (8 X@", .$
MDP#? )H W0"A -L J@#8 +0 U0#  -( TP#0 .H S@#Z ,T _P#- /\ S0#_
M ,P _P#, /\ S #_ /\0# #_# < _P," /\ " #_  X _P 6 /8 (@#P "\
M[  \ .D 2 #E %, X0!< -X 90#; &P UP!S -0 >@#2 (  T "' ,X C@#,
M )4 R@"= ,@ I0#& *\ Q "[ ,( RP#  .4 O@#U +T _P"\ /\ O #_ +P
M_P"\ /\ O #_ /\1!0#_#@  _PH  /\( 0#_! H ^  0 .D &@#C "@ W@ U
M -D 00#3 $P SP!6 ,L 7P#) &8 Q@!N ,0 = #" 'L P0"" +\ B0"] )
MO "8 +H H0"X *L M@"W +0 QP"R .  L0'R *\"_P"N _\ K03_ *T$_P"M
M!/\ K03_ /\4  #_$   _P\  /(-  #J"@  Z0,) -T $@#4 !\ S0$M ,@"
M.@#$ T4 P -0 +T$60"[!6$ N05H +<&;P"U!G8 M =] +('A "Q"(P KPB5
M *T)G@"K":@ J@JU *@*Q0"F"]\ I WT *(._P"@#O\ GP[_ )\._P"?#O\
MGP[_ /\7  #_$P  [Q@  .09  #;%@  TA " ,\)"P#("!8 P0HD +P,,@"W
M#3X M Y) +$.4P"O$%L K1!C *L0:@"I$7$ J!%X *81@ "E$8@ HQ*1 *$2
MFP"@$Z8 GA.S )P3PP";%-X EQ;T )46_P"4%_\ DQ?_ )(7_P"2%O\ DA;_
M /\:  #T'0  Y2,  -4E  #*)   PAT  +X6! "[$!  M!,= *\5*P"K%C@
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M GHOMP)X+\P"=C#J G4P_@)S,/\"<S#_ G,O_P)S+_\"<R__ O J  #<-0
MQSL  +H_  "L/   HC@  )PS  "8+P  E2X0 ) P' ",,BD B3,U (8T/P"$
M-4D @C51 ( U6 !^-5\!?35F 7LV;@%Y-78">#6  G8UBP-T-9<#<C:D W V
MM 1O-L@$;3;G!&PV_ -K-O\#:S;_ FHV_P)J-?\":C7_ NHP  #3.@  PD$
M +-#  "E00  FSX  )4Z  "0-@  C#4- (@W& "$."4 @3HQ '\[/ !\.T4
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M!EA&]P571?\$5T7_!%=$_P-81/\#6$3_ ]H]  #$1P  M4X  *1.  "63
MBTL  (-)  !]10  >$8" '1'$ !P2!L ;DDG &M*,@!J2SP :$M$ &9+3 %D
M2U,!8DM: F!+8@)?2VH#74MT!%M*?P592HP%5TJ:!E5*J@=42KT'4TK<!U)*
M]@922O\%4DG_!%))_P-22/\#4TC_ ]1!  # 2P  LE$  *!0  "23P  ATX
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M!$15_P1$5/\#1%3_ \9,  "U5@  I5H  )19  "&6   >U@  '%7  !F5@
M85@  %U9! !96A  5UL; %5<)@!373  4ETY %%>00!/7DD 35Y1 4Q>6 %*
M7F$"2%UK T9==@-$78,$0EV2!4!=HP8_7;8&/EW0!CU<\04^6_\$/EK_!#Y:
M_P,^6?\#/UG_ \%0  "Q6@  H5T  )!<  ""6P  =EL  &U;  !A6P  6UT
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M K%A  "D:0  D&@  (!G  !T9P  :6<  %]H  !5:P  2VX  $-Q   \=
M-W8* #1W$@ S>!P ,G@E #%Y+@ P>3< +WD_ "YY2  L>E( *WI< "IZ:  H
M>G8 )GJ' 25ZF0$C>JP!(GK% 2)YZ0$B=_\!(G;_ 2)U_P(B=/\"(W3_ JQH
M  "=;@  BFT  'ML  !O;   96P  %IN  !0<0  174  #UX   V?   +G\"
M "F!#0 G@A0 )H(> "6")P D@B\ (X,X "*#0@ A@TL ((16 !^$8@ >A'$
M'(2" !N$E0 :A*D &(3! !B#Y@ 8@?T &8#_ 1E__P$9?O\!&7[_ :9P  "5
M<P  A'(  '9Q  !K<0  7G,  %1V  !)>0  /WT  #>!   OA   )X@  ""+
M!0 ;C0X &HT5 !F-'@ 8CB< %XXP !:..0 5CD, %(]/ !./6P 2CVH $8][
M !"/CP /CZ0 #H^[  V/X  .C?H #XO_ !"*_P 0B?\ $(G_ *%Z  ".>0
M?G<  ')W  !D>   6'L  $U^  !"@@  .88  "^*   GC@  ()$  !B5   2
MF 4 #IH.  V:%  ,FAT "YHF  N:,  *FCL "9I&  B:4P &FV$ !9IR  2:
MA@ "FIL  )JQ  &9SP "F?   IC_  27_P %EO\ !9;_ )F!  "'?P  >GX
M &M^  !=@0  4(4  $6)   [C0  ,9(  "B6   ?F0  &)T  !&@   ,HP(
M!J4*  &E$   I18  *8?  "F*   IC(  *<]  "G2@  IU@  *=H  "G?
MIY$  *:H  "FPP  I>D  *7\  "E_P  I/\  *3_ )&'  ""A@  <H8  &.(
M  !5C   29$  #V6   RF@  *)X  !^B   7I@  $*D   NL   $KP   +$&
M  "Q#   LA$  +(7  "S'P  LR@  +0R  "U/P  M4T  +5=  "U<   M88
M +6=  "UM@  M=P  +3W  "T_P  M/\  +3_ (N/  !ZC@  :I$  %N5  !-
MF@  0)\  #6D   JJ   (*P  !:P   /M   ";<   &Y    O0   +X   "^
M!@  OPP  , 0  #!%@  PAT  ,,G  #%,@  QD   ,91  #'8P  QW@  ,>1
M  #'J0  Q\<  ,?L  #'_@  Q_\  ,?_ (.7  !QF@  89X  %*C  !%J0
M.*X  "RS   @MP  %KH   Z]   &P    ,,   #'    R0   ,H   #,
MS0,  ,X)  #0#@  TA,  -0;  #8)0  VS(  -U"  #=5   WFD  -Z!  #>
MG   W[4  -_9  #?\P  W_\  -__ '>?  !HI@  6:T  $JS   [N   +;L
M !^_   4P@  #,8   /)    S    -    #5    V0   -H   #<    W@
M .    #B!0  Y L  .<0  #J&   [20  / R  #Q1   \E@  /-O  #TB@
M]*0  /2_  #TWP  ]/,  /3T &JH  !;KP  3+<  #V]   MP0  '\8  !/*
M   +S@   -(   #7    W    .    #E    YP   .D   #K    [0   .\
M  #Q    \P   /8'  #Y#@  _!8  /\B  #_,P  _T<  /]=  #_=@  _Y$
M /^I  #_O@  _]@  /_; /\ & #_ !8 _P 5 /\ & #_ !X _P G /\ -@#_
M $, _P!/ /\ 6@#_ &0 _P!M /\ =0#_ 'T _P"$ /\ B@#_ )  _P"6 /\
MG #_ *, _P"K /\ M #^ +\ _0#/ /L YP#Z /@ ^0#_ /D _P#Y /\ ]0#_
M .X _P#I /\ YP#_ /\ % #_ !$ _P 1 /\ $@#_ !< _P C /\ ,0#_ #X
M_P!* /\ 5@#_ &  _P!H /\ < #_ '@ _0!^ /P A0#Z (L ^0"1 /@ F #W
M )X ]0"F /0 K@#R +D \0#' .\ X #N /( [ #_ .P _P#L /\ ZP#_ .4
M_P#@ /\ W@#_ /\#$ #_  X _P - /\ #0#_ !, _P > /\ *P#_ #@ _P!%
M /X 4 #[ %H ^ !C /4 :P#S '( \0!Y .\ ?P#N (8 [ ", .H D@#I )D
MYP"@ .8 J0#D +, X0#  .  TP#> .L W #[ -L _P#: /\ V@#_ -D _P#4
M /\ T@#_ /\'#0#_  D _P & /\ "0#_  \ _P 8 /L )0#X #( ]0 _ /(
M2@#M %0 Z@!= .< 90#D &P X@!S .  >@#> (  W "& -H C0#7 )0 U ";
M -( I #/ *T S0"Y ,L R0#) .0 R #V ,8 _P#% /\ Q@#_ ,< _P#' /\
MQP#_ /\*!@#_ 0  _P   /\ ! #_  L ]  2 .\ 'P#J "P Y0 X .( 0P#=
M $X V0!7 -0 7P#1 &< S@!M ,P = #* 'H R "  ,8 AP#% (X PP"6 ,$
MG@"_ *@ O0"S +H P@"Y -L MP#P +4 _P"V /\ M0#_ +4 _P"U /\ M0#_
M /\,  #_!   _P   /X   #V  , Z  - .  %P#9 "0 T0 Q ,T / #* $<
MQ@!1 ,, 60#  &  O@!G +P ;@"Z '0 N0![ +< @@"U (D LP"1 +( F@"P
M *0 K@"O *P O0"J -  J #K *< ^P"F /\ I@#_ *4 _P"E /\ I0#_ /\-
M  #_!P  ] D  .H)  #B!   V@ ' ,\ $0#( !P P@ I +X -0"[ $  MP!*
M +0 4P"R %L L !B *X : "L &\ JP!U *D ?0"H (0 I@"- *0 E@"C *
MH0"K )\!N0"= \P G 3H )H&^0"9!_\ F C_ )<(_P"7"/\ EPC_ /\0  #W
M$   Z!0  -P5  #.$0  Q@T  ,($"P"\ !0 MP$A +(#+@"N!3H JP9$ *@(
M30"F"%4 I E< *(*8P"@"FH GPMQ )T+> "<"X  F@R) )D,DP"7#)X E0VJ
M )0-N "2#<P D [J (X0_ ",$/\ BQ#_ (L0_P"+$/\ BA#_ /L3  #M&@
MW2   ,PA  "_'0  MQ<  +,1  "R"PT JPT9 *<.)@"C#S, GQ ^ )T11P":
M$5  F!)7 )827@"5$V4 DQ-L )(3<P"0%'P CQ2% (T5CP"+%9H BA6G (@6
MM0"&%LD A!?G ((8^P" &?\ ?QG_ '\9_P!_&/\ ?QC_ /4:  #D(P  SRD
M , J  "S)@  JB(  *4<  "D%0@ H!03 )L6(0"7&"T E!DX )$:0@"/&TL
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M 64P]0%D,/\!8S#_ 6,O_P%C+_\!8R__ >(N  #*.   NCT  *@\  ":.@
MD3<  (HS  "&,   @RX) '\O$P![,!\ >#(K '8S-0!T,SX <C1& ' T3@!O
M-54 ;35< &PU9 !J-6P!:#5U 6<U@ %E-8P!8S6: F$VJ0)@-KL"7S;6 ETV
M\P)=-O\"7#;_ 5PU_P%<-?\!7#3_ =PS  #%/   M$$  *)   "5/@  BSP
M (0Y  !_-@  >S0$ '<U$ !T-QP <3@G &\Y,@!M.3L :SI# &HZ2P!H.U(
M9SM9 &4[80%C.VD!8CMR 6 [?0%>.XH"7#N7 EL[IP)9.[@#6#O2 U<[\0)6
M._\"5CO_ E8Z_P%6.O\!5CG_ =0W  # 00  KT0  )U#  "00@  A4   'X^
M  !Y.P  =#H  '$Z#@!M/!@ :STD &D^+P!G/S@ 93]  &1 2 !B0$\ 84!7
M %] 7@%=0&8!7$!O 5I >@)80(<"5D"5 E1 I -30+8#4D#/ U% [P-00/_B
M__])0T-?4%)/1DE,10 &"?\"4#__ E __P)1/O\!43[_ <\[  "]10  JD<
M )E&  "+10  @40  'E"  !T/@  ;S\  &M # !G014 94(A &-#*P!A0S4
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M T%-Z@-!3/\"04S_ D)+_P)"2O\"0DK_ L)'  "S3P  GD\  (U.  " 3@
M=4T  &Q,  !C2@  7DP  %I- @!63@X 5$\8 %)0(@!142P 3U$U $Y2/0!-
M4D4 3%)- $I25 !)4ET!1U)F 452<0%#4GX"05*- C]2G0,^4J\#/5+& SQ2
MZ0(\4?X"/%#_ CU/_P(]3_\"/4[_ KY+  "N4P  FE(  (E1  !\40  <5
M &A0  !>3@  6%$  %12  !14PP 3E04 $Q5'P!+5BD 258R $A6.@!'5T(
M1E=* $174@!#5UH 05=D 4!7;@$^5WL"/%>+ CI7FP(X5ZT"-U?$ C=7YP(W
M5OT"-U7_ C=4_P(W4_\".%/_ KI/  "I5@  E54  (54  !X5   ;50  &14
M  !85   4E8  $Y7  !*60D 1UH1 $9:&P!$6R4 0ULN $)<-@!!7#X /UQ&
M #Y=3P ]75< .UUA #I=; $X77D!-EV( 31=F0(S7:L",5W" C%<Y0(Q6_P"
M,5K_ C%9_P(R6?\!,EC_ ;94  "D60  D%@  (!8  !S5P  :5<  &!8  !4
M60  3EL  $A=  !#7P0 0& . #YA%P ]82  .V(I #IB,@ Y8CH .&-" #=C
M2P V8U0 -&-= #-C:  Q8W8!+V.% 2YCE@$L8ZD!*V._ 2ICXP$J8OL!*F#_
M 2M?_P$K7_\!*U[_ ;%9  ">7   BUP  'M;  !O6P  95L  %Q<  !17@
M26   $-B   \90  .&<* #5H$@ T:!L ,VDD #)I+0 Q:34 +VH] "YJ1@ M
M:D\ +&I9 "MK90 I:W( *&N" "9KDP D:Z< (VN] ")JX  C:?D!(V?_ 2-F
M_P$C9O\!)&7_ :Q@  "88   A6   '9?  !J7P  86   %=@  !-8P  1&8
M #UH   V:P  ,&X$ "QP#@ J<14 *7$> "AQ)@ G<B\ )G(W "5R0  D<DH
M(G)4 "%S8  @<VT 'G-] !USD  ;<Z, &G.Y !ESW  :<?< &G#_ !MO_P ;
M;O\!&VW_ :9F  "190  ?V0  '%D  !F9   760  %)F  !(:0  /VP  #=O
M   P<P  *78  ")Y"  ?>Q  'GL7 !Q['P ;>R@ &GLP !E\.0 8?$, %WQ.
M !9\6@ 5?&< %'UX !)]BP 1?9\ $'VU  ]]U0 0>_4 $7G_ !%X_P 2=_\
M$G?_ )YK  "*:@  >FD  &UI  !B:0  5VH  $QM  !#<   .70  #%X   I
M>P  (G\  !N"   4A0D $880 !&&%P 0AQ\ $(<H  Z',0 .ASL #8=&  R'
M4P +AV$ "H=Q  F'A  'AY@ !H:N  6&R0 &A>P !X3_  B#_P )@O\ "8+_
M )5Q  "#;P  =&X  &EN  !<;P  4'(  $9U   \>0  ,GT  "J!   BA0
M&XD  !2,   /CP, "I(+  :2$0 $DA@  I(@  &2*0  DC,  ),^  "32P
MDUD  )-I  "3>P  DI   )*F  "1OP  D>4  )#Z  "/_P  C_\  (__ (UW
M  !]=0  <'0  &)U  !5>   27P  #^    TA   *XD  "*-   :D0  $Y0
M  Z7   )FP   9T(  "=#@  G1,  )X:  ">(@  GRL  )\U  "@0@  H%
M *!?  "@<0  H(<  )^=  "?M0  GMH  )WV  "=_P  G/\  )S_ (9]  !X
M?   :7P  %M_  !.@P  08@  #:,   LD0  (Y8  !J:   2G@  #:$   :D
M    IP   *D#  "I"@  J@X  *L3  "L&0  K2(  *XK  "O-P  KT4  *]4
M  "O9@  KWL  *Z4  "NJP  KLD  *[O  "M_P  K?\  *W_ (&$  !QA
M88<  %.+  !&D   .98  "Z;   CH   &J0  !*H   ,K   !*\   "R
MM@   +<   "W @  N @  +D-  "Z$@  NQ@  +TA  "^*P  P#@  ,!(  #
M6@  P6X  ,&&  #!H   P;H  ,'C  # ^0  P/\  ,#_ 'F-  !HD   690
M $N:   ]H   ,:4  "6K   :KP  $;,   NX   "NP   +X   #!    Q
M ,4   #&    QP   ,@%  #*"P  S \  ,X5  #0'P  TRL  -4Z  #53
MUF   -AW  #8D@  V*P  -G)  #9[   V?L  -C_ '"9  !@G@  4:0  $.J
M   UL   *+8  !RZ   1O@  "<$   #%    R    ,L   #/    T@   -,
M  #6    V    -L   #=    WP<  .(-  #E$P  Z!T  .PJ  #M/   [5$
M .YG  #O@0  [YP  /"W  #PTP  \.P  /#T &>F  !8K0  2;0  #JZ   J
MO@  ',(  !#&   'R@   ,X   #2    U@   -P   #@    XP   .0   #F
M    Z    .L   #M    [P   /("  #U"@  ^!$  /P<  #_+   _S\  /]5
M  #_;@  _XH  /^D  #_N@  _]$  /_A /\ % #_ !( _P 2 /\ % #_ !D
M_P E /\ ,@#_ #\ _P!+ /\ 5@#_ &  _P!H /\ < #_ '@ _P!_ /\ A0#_
M (L _P"1 /\ F #_ )X _@"F /T K@#\ +D ^@#( /D X@#X /0 ]P#_ /8
M_P#V /\ [P#_ .< _P#B /\ W@#_ /\ $0#_  X _P . /\ #P#_ !0 _P @
M /\ +0#_ #H _P!& /\ 40#_ %L _P!C /X :P#\ ', ^@!Y /D @ #W (8
M]@", /4 D@#S )D \@"@ /  J0#N +, [0#! .L U@#J .X Z0#^ .< _P#G
M /\ Y0#_ -T _P#5 /\ T0#_ /\ #0#_  H _P ( /\ "0#_ !  _P ; /\
M* #_ #4 _P!  /H 2P#V %4 \P!> /$ 9@#N &T [ !T .L >@#I (  YP"&
M .8 C0#D ), X@"; .  HP#> *T W "Y -H R@#7 .8 U #X -( _P#2 /\
MT@#_ ,X _P#) /\ Q@#_ /\ " #_  , _P   /\  P#_  T _  6 /< (@#S
M "X [P Z .P 10#H $\ Y !8 .$ 8 #> &< VP!M -D = #5 'H TP"  -$
MAP#/ (X S0"5 ,L G@#) *< QP"S ,4 P@## -P P0#Q +\ _P"_ /\ O@#_
M +X _P"] /\ NP#_ /\   #_    _P   /\   #V  @ [@ 1 .< &P#A "<
MW0 S -D /@#3 $D SP!2 ,L 60#( &$ Q@!G ,0 ;0#" ', P !Z +\ @ "]
M (@ NP"0 +D F "X *( M0"M +, NP"Q ,X L #J *\ _ "M /\ K0#_ *X
M_P"N /\ K@#_ /\"  #_    _0   /(   #H    W@ , -, %0#, "$ R  L
M ,0 . #! $( O0!+ +H 4P"X %H M@!A +0 9P"R &T L !T *\ >@"M ((
MK "* *H DP"H )T I@"H *0 M0"B ,8 H0#C )\ ]@"> /\ G@#_ )X _P">
M /\ G@#_ /\&  #[    [@4  .($  #5    RP & ,, #P"] !D N  E +0
M,0"Q #L K@!% *P 30"I %4 IP!; *4 8@"D &@ H@!N *$ =0"? 'P G@"%
M )P C@": )@ F "D )8 L "5 ,$ DP#< )( \@"1 /\ D #_ )  _P"/ /\
MCP#_ /T*  #P#@  X1$  ,X0  #"#0  NP<  +< "@"Q !( K  > *@ *0"E
M #0 H@ ^ )\ 1P"= $\ FP!6 )D!7 "7 6, E@)I )0"< "3 W@ D0.  ) $
MB@".!)4 C 6A (H%K@")!KX APC8 (8)\ "$"O\ @PO_ (,+_P"#"_\ @PO_
M /80  #F%P  TAP  , :  "S%@  K!(  *@-  "F!PT H@46 )T'(@"9"2X
ME@HX )0+00"2#$H D Q1 (X-6 ",#5X BPUE (D-; "(#G0 A@Y] (4.AP"#
M#I, @0^? ( 0K0!^$+X ?1#; 'H1] !X$O\ =Q+_ '<2_P!W$O\ =Q+_ .\7
M  #;(0  QB0  +0C  "H(   H!P  )L7  "9$00 F X0 ),0&P"/$2< C!(R
M (D3/ "'$T0 A11, (,44P"!%5H @!5@ 'X6: !]%F\ >Q9X 'D7@P!X%X\
M=AB< '08J@!S&;L <AG4 &\:\0!N&_\ ;1O_ &T:_P!M&O\ ;1K_ .<@  #0
M*0  O"L  *LJ  ">*   EB0  ) @  "-'   C!<, (@8%@"$&B( @1LM 'X<
M-P!\'4  >AU( 'D>3P!W'E4 =A]< '0?8P!S'VL <2!T ' @?P!N(8L ;"&8
M &LAIP!I(K@ :"+/ &8B[@!E(_\ 9"/_ &0B_P!D(O\ 9"'_ . F  #(+P
MM#$  *,P  "6+@  C2L  (<H  "$)   @B ( 'X@$@![(AX >",I '4D,P!S
M)3P <25# ' F2P!N)E( ;2=9 &LG8 !J)V@ :2AQ &<H>P!E*(@ 9"F5 &(I
MI !@*;4 7RG+ %XJ[ !<*O\ 7"G_ %PI_P!<*?\ 7"C_ -@L  ##-0  K34
M )TT  "0,P  AC$  ( M  !\*P  >2@# '8G$ !R*1H <"HE &TK+P!K+#@
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M 4HZY0%).OP!23G_ 4DY_P%)./\!2CC_ <<Z  "S0   GC\  (X_  "!/@
M=ST  ' [  !J.   9C@  &(Y!P!?.A$ 7#L; %H[)0!9/"X 5STW %8]/@!4
M/D8 4SY- %(^50!1/ET 3S]F $T_< !,/WT!2C^+ 4@_FP%'/ZP!13_! 40_
MXP%$/OL!1#[_ 40]_P%$/?\!13S_ <,^  "O0P  FD(  (I"  !]00  <T
M &L_  !E/   8#P  %P^! !9/@\ 5S\8 %5 (@!302L 4D$T %!"/ !/0D,
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M 35*_P$V2?\!-DG_ ;A)  "B2P  CDH  'Y*  !R2@  :$H  %])  !52
M4$H  $Q+  !)3 < 1DT0 $1.&0!"3R( 04\K $!0,P _4#L /E!# #Q12@ [
M45, .E%< #A19P W47, -5&" #-1DP$R4:4!,%&Z 2]1V@$O4/8!+T__ 3!.
M_P$P3O\!,$W_ ;1-  "=30  BDT  'I-  !N30  9$T  %M-  !130  2T\
M $90  !"4@, /U,- #U4%0 \5!X .E4G #E5+P X53< -U8_ #961P U5E
M,U99 #)79  P5W$ +U>  "U7D0 K5Z, *E>X "E7U@ I5O4 *57_ "I4_P$J
M4_\!*E+_ :]1  "840  A5$  '90  !J4   8%   %A1  !.4@  1U,  $%5
M   [6   .%D* #5:$0 T6AH ,ULB #);*P Q6S, +UP[ "Y<0P M7$P +%Q6
M "M=8  I76T *%U\ "9=C@ D7:$ (UVU ")=T@ B7/, (EO_ "-:_P C6?\
M)%C_ *A5  "25   @%0  '%4  !F5   7%0  %15  !*5@  0U@  #Q;   V
M70  ,& % "UA#@ K814 *F(= "EB)0 H8BX )V,V "9C/@ E8T< (V-1 ")D
M7  A9&D 'V1Y !YDB@ <9)X &V2S !EDS@ :8_$ &V'_ !M@_P <8/\ '%__
M *%9  ",6   >U@  &U8  !B6   65@  %!9  !'6P  /EX  #=@   Q8P
M*F8  "1I"0 A:A  (&H7 !]J(  >:R@ '6LP !QK.0 ;:T( &FQ, !EL6  7
M;&4 %FQT !1LA@ 3;)H $FRO !%LR@ 1:^\ $FG_ !-H_P 3:/\ $V?_ )E=
M  "%70  =5P  &A<  !>7   55P  $M>  !"80  .60  #)G   K:@  )&T
M !YP 0 7<PL %701 !1T&  3="$ $G4I !%U,@ 1=3L $'5&  ]U4@ .=5\
M#75N  QU@0 +=94 "G6J  ATPP )=.< "G/]  MQ_P ,<?\ #'#_ )%B  !_
M80  <&$  &1A  !:80  3V(  $5E   \:   ,VP  "MO   D<@  '78  !=Y
M   1? 0 #7\,  M_$@ *?QD "7\B  A_*@ &?S0 !7\_  1_2P "?U@  7]G
M  !_>0  ?XX  '^C  !^NP  ?>   'WW  !\_P  >_\  'O_ (EG  !X9P
M:V8  &%F  !49P  26D  #]M   U<0  +'4  "1Y   =?   %H   !"#   ,
MA@( !HD*  &)#P  B10  (H;  "*(P  BRP  (LW  "+0P  BU   (M?  "+
M<0  BX8  (N<  "*LP  B=,  (CS  "(_P  A_\  (?_ ()M  !S;   :&P
M %IM  !.;P  0G,  #AW   N>P  )8   !V$   5B   $(P   N/   $D@
M )0&  "5#   E1   )85  "7'   F"0  )@N  "9.0  F4<  )E6  "9:
MF7T  )F4  "8JP  E\@  );N  "6_P  E?\  )7_ 'MT  !O<P  87,  %-V
M  !&>@  .W\  #"$   FB   '8T  !22   .E@  "9D   &<    H    *$
M  "B!@  H@P  *00  "E%   I1P  *<D  "H+P  J#T  *E,  "I7@  J7(
M *B)  "HH@  J+P  *?E  "F^P  IO\  *7_ '=[  !H>P  67X  $N"   ^
MAP  ,HT  ">2   =EP  %)P   Z@   'I    *@   "K    K@   *\   "P
M    L00  +,*  "T#@  M1,  +8;  "X)   NC$  +I   "Z4@  NV4  +M]
M  "ZEP  NK$  +K2  "Z\P  N?\  +G_ &^#  !?A@  48L  $.0   VEP
M*IT  !^B   5IP  #:P   6P    M    +<   "[    O@   +\   #
MP0   ,,!  #$!P  Q0T  ,<1  #*&0  S20  ,XS  #/1   T%@  -!N  #1
MB   T*0  -#!  #1Y@  T?@  -'_ &>/  !7E   29H  #NA   NIP  (:T
M !:S   .N   !KP   #     PP   ,8   #+    S0   ,X   #0    T0
M -0   #6    V@(  -P)  #?#P  XQ<  .8D  #G-@  Z$D  .E?  #J>
MZY0  .NO  #KS   [.@  .SV %^>  !0I   0JL  #2R   FN0  &;X   ["
M   $Q0   ,H   #-    T0   -@   #;    WP   .    #B    Y    .8
M  #I    ZP   .X   #Q!0  ]0T  /D6  #\)0  _3D  /Y/  #_9P  _X(
M /^=  #_M0  _\L  /_D /\ $0#_  \ _P / /\ $0#_ !8 _P B /\ +P#_
M #L _P!' /\ 4@#_ %L _P!D /\ ; #_ ', _P!Z /\ @ #_ (8 _P", /X
MDP#] )D ^P"A /H J0#X +0 ]P#" /8 V@#U /$ ] #_ /, _P#S /\ Z0#_
M .  _P#8 /\ TP#_ /\ #@#_  L _P * /\ "P#_ !$ _P = /\ *@#_ #8
M_P!! /\ 3 #_ %8 _@!? /L 9@#Y &T ]P!T /4 >@#T (  \@"& /  C0#O
M )0 [0"; .P I #J *X Z0"Z .< S0#E .D Y #[ ., _P#B /\ W@#_ -$
M_P#, /\ R #_ /\ "0#_  0 _P ! /\ ! #_  X _P 8 /\ ) #] #  ^P [
M /< 1@#S %  [P!9 .P 8 #J &< YP!N .8 = #D 'H X@"  .  AP#> (X
MW "5 -H G@#6 *@ U "S -$ PP#/ -\ S@#T ,P _P#+ /\ RP#_ ,4 _P"_
M /\ O #_ /\  @#_    _P   /\   #]  L ]P 3 /$ '@#M "H Z@ U .<
M0 #B $H W0!2 -D 6@#5 &$ T@!G -  ;0#. ', S !Z ,H @ #( (< Q@"/
M ,0 F #" *$ P "M +X NP"\ -  N@#M +D _@"X /\ N #_ +< _P"S /\
ML #_ /\   #_    _P   /D   #N  4 Y0 . -X & #8 ", T@ N ,\ .0#+
M $, QP!, ,0 5 #! %L OP!A +P 9P"[ &T N0!S +< >@"U ($ M ") +(
MD@"P )L KP"G *P M "K ,8 J0#D *< ^ "F /\ I@#_ *4 _P"E /\ I #_
M /\   #_    ]0   .H   #>    T  * ,@ $@#" !T O@ H +L ,P"Y #T
MM0!& +( 30"P %4 K0!; *P 80"J &< J !M *< <P"E 'H I "" *( C "@
M )8 GP"A )T K@"; +X F0#8 )< \0"6 /\ E@#_ )< _P"7 /\ EP#_ /\
M  #U    YP$  -0   #)    P  $ +@ #@"S !8 KP A *L + "H #8 I@ _
M *, 1P"A $\ GP!5 )T 6P"; &$ F@!G )@ ;@"7 '4 E0!] )0 A@"2 )$
MD "< (X J0", +@ BP#- (D ZP"( /T B #_ (@ _P"( /\ B #_ /D&  #I
M#   U X  ,,,  "W"0  L (  *L "0"F !  H@ : )X )0"; #  F  Y )8
M00"4 $D D@!0 )  5@". %P C0!B (L :0"* '  B !X (< @0"% (P A "8
M (( I0"  +0 ?@#( 'T!YP!\ OD >P/_ 'L$_P![!/\ >P3_ /$.  #>%0
MQ14  +04  "I$0  H0X  )X*  "; PP EP 3 ), '@"0 2D C0(S (H#/ "(
M!$, A@5+ (4&40"#!E< @@=> ( '9 !_"&P ?0AT 'P(?@!Z"8D > F6 '<*
MHP!U"K, <PO' '(,Y@!P#?L < W_ &\-_P!O#?\ ;PW_ .@6  #0'@  N1T
M *D<  "=&@  E18  ) 3  "/#@, C@H. (D+%P"&#", @PTM ( --@!^#CX
M? Y& 'L.30!Y#U, >!!: '8080!U$&@ <Q!Q '$1>P!P$8< ;A&4 &P1H@!K
M$K( :1+' &@3YP!F$_T 913_ &44_P!E$_\ 91/_ -\>  #&)   L"0  * C
M  "4(0  BQ\  (8;  "#%P  @A(( '\1$@!\$AT >10H '84,0!T%3H <A9!
M '$62 !O%T\ ;A=6 &P770!K&&0 :1AM &@9=P!F&8, 9!F0 &,:GP!A&J\
M8!K$ %X;Y !='/L 7!S_ %P;_P!<&_\ 7!O_ -4E  "]*@  J"D  )@I  ",
M*   @R4  'TB  !Y'P  >!L# '89#P!R&A@ ;QPC &T=+0!K'34 :1X] &@>
M1 !F'TL 91]2 &,@60!B(&$ 82!I %\A<P!=(7\ 7"&- %HBG !9(JP 5R+
M %8CX0!5(_D 5"/_ %0B_P!4(O\ 5"+_ ,TK  "V+@  HBX  )(N  "%+0
M?"L  '8H  !R)@  ;R,  &TA# !J(A4 9R,? &4D*0!C)#$ 8B4Y & F00!?
M)D@ 729/ %PG5@!;)UT 62=F %@H< !6*'P 5"B* %,IF0!1*:H 4"F^ $\I
MW@!.*?< 32G_ $TI_P!-*/\ 3BC_ ,@P  "P,@  G#(  (PR  " ,0  =C
M ' M  !K*P  :"D  &8H"0!C*!$ 8"D< %XJ)0!<*RX 6RLV %DL/0!8+$0
M5RU, %4M4P!4+5L 4RUC %$N;@!0+GH 3BZ( $POEP!++Z@ 22^[ $@OVP!(
M+_8 1R__ $<N_P!'+?\ 2"W_ ,0T  "K-0  ES4  (<U  ![-0  <C0  &LR
M  !F+P  8BX  %\M!0!<+A  6B\8 %@P(@!6,"L 53$S %,Q.@!2,D( 43))
M % R4 !.,U@ 33-A $LS:P!*,W< 2#2% $<TE0!%-*8 0S2Y $(TU@!"-/0
M0C3_ $(S_P!",O\ 0C+_ , X  "G.   DS@  (,X  !W.   ;3<  &8V  !A
M,P  73(  %DR @!7,PT 5#05 %(U'P!1-2@ 3S8P $XV. !,-S\ 2S=& $HW
M3@!).%8 1SA? $8X:0!$.'4 0SB# $$YDP! .:0 /CFX #TYTP \.?, /#C_
M #TW_P ]-_\ /3;_ +L[  "B.P  CSL  '\[  !S.P  :CH  &(Y  !=-P
M6#8  %0W  !1. L 3SD3 $TY' !+.B4 2CHM $@[-0!'.SP 1CQ$ $4\2P!$
M/%, 0CQ< $$]9P _/7, /CV! #P]D0 Z/:, .3VV #@]T0 W/?( -SS_ #@[
M_P X._\ .#K_ +8]  ">/@  BSX  'P^  !O/@  9CT  %X]  !8.P  4SH
M $\[  !,/ @ 23T1 $<^&0!&/R( 1#\J $,_,@!"0#H 04!! $! 20 ^05$
M/4%: #Q!9  Z07  .$%_ #=!CP U0J$ -$*T #)"S@ R0?  ,D#_ #- _P S
M/_\ -#[_ +%   ":0   AT   'A!  !L00  8D   %M   !4/P  3C\  $I
M  !&004 1$(. $)#%@! 0Q\ /T0G #Y$+P \1#< .T4^ #I%1@ Y14X .$98
M #9&8@ U1FX ,T9\ #%&C0 P1I\ +D:S "U&S  M1N\ +47_ "Y$_P N0_\
M+D/_ *Q#  "60P  @T,  '1#  !H0P  7T,  %=#  !00P  2$,  $1%  !!
M1@$ /D<, #Q($P Z2!P .4DD #A)+  V230 -4H[ #1*0P S2DP ,DI5 #!+
M7P O2VL +4MZ "Q+BP J2YT *$NQ "=+R@ G2^T )TK_ "A)_P H2/\ *4?_
M *=&  "11@  ?T8  '!&  !E1@  6T8  %1&  !,1P  1$@  #]*   [2P
M-TP) #5-$  S3A@ ,DX@ #%/*  P3S  +T\X "Y/0  L4$@ *U!2 "I07  H
M4&@ )U!W "50B  D4)L (E"O "%0R  @4.L (4__ ")._P B3?\ (TW_ *%)
M  ",20  >DD  &Q*  !A2@  6$H  %!*  !)2P  0$P  #M.   U4   ,5($
M "U3#0 L5!0 *E0< "E5)  H52P )U4S "95/  E5D4 )%9. ")660 A5F4
M'U9T !Y6A0 <5I@ &U:L !E6Q0 95ND &E7_ !M4_P ;4_\ '%+_ )M-  "&
M30  =4T  &A-  !=30  5$T  $U.  !%3P  /%$  #93   Q50  *U@  "9:
M"0 C6Q  (EL7 "%<'P @7"< 'UPN !U<-P <74  &UU* !I=50 876$ %UUP
M !5=@0 4794 $UVJ !%=P@ 17>< $EO^ !-:_P 36O\ %%G_ )11  " 40
M<%$  &11  !940  45$  $E2  !!4P  .%8  #)9   K6P  )5X  !]A P :
M8PP &&01 !=D&0 69"$ %60I !1E,0 393H $F5$ !%E4  095T #V5K  YE
M?0 -99$ #&6E  IDO  *9.  "V/Y  QB_P -8?\ #6'_ (U5  !Z50  :U4
M %]5  !650  3E4  $17   \60  -%P  "Q?   F8@  'V4  !EH   3:P4
M$&T-  YN$@ -;AH #&XB  QN*P +;C0 "FX^  AN2@ ';E< !FYE  1N=@ "
M;HH  &V?  !MM@  ;-8  &SS  %K_P ":O\  VK_ (5:  !T6@  9EH  %Q9
M  !360  2%H  #]=   V8   +F,  "9G   ?:@  &6T  !-Q   .= , "G<*
M  5W$  !=Q4  '<<  !W)   >"T  '@W  !X0P  >%   'A>  !X;P  >(0
M 'B9  !WL   =LT  '7P  !U_P  =/\  '3_ 'Y?  !N7P  8EX  %E>  !-
M7P  0F(  #EE   P:   )VP  !]P   8=   $G<   U[   (?@   H (  "!
M#0  @1$  ((7  "#'@  @R8  (0P  "$.P  A$@  (17  "$:   A'P  (23
M  "#J@  @L4  ('K  "!_@  @/\  (#_ '=E  !I9   7V,  %)D  !'9P
M/&L  #%O   H<P  ('<  !A\   1?P  #(,   :'    B@   (P#  ","0
MC0X  (X1  "/%P  D!X  )$G  "2,@  DC\  )).  "27P  DG,  )*+  "1
MH@  D;P  )#E  "/_   CO\  ([_ '%K  !F:@  6&L  $MM   _<0  -'8
M "I[   @@   %X4  !")   +C0  !)$   "5    F    )D   ": P  FP@
M )P-  ">$0  GQ8  * >  "B*   HC4  *-$  "C50  HVD  **   "BF@
MH;,  *#8  "@]@  G_\  )__ &YQ  !?<@  474  $1Y   W?@  +(0  "&*
M   7CP  $)0   J9   !G0   *    "D    IP   *@   "I    J@   *P&
M  "M"P  KQ   + 5  "R'@  M"D  +0Y  "T2@  M5T  +5S  "UC@  M:@
M +3&  "S[0  LO\  ++_ &9Z  !7?0  28(  #R'   OC@  (Y0  !B:   0
MGP  ":0   "I    K0   +    "T    MP   +@   "Y    NP   +P   "^
M @  P @  ,(.  #$%   QQX  ,@L  #)/0  RE   ,IF  #*?P  RIL  ,JX
M  #*W0  RO4  ,K_ %Z&  !/BP  09$  #.8   GGP  &Z4  !&K   )L
M +4   "Y    O0   ,$   #&    R    ,D   #+    S    ,X   #0
MT@   -0%  #9#   W1(  .$>  #B+@  XT(  .17  #E;P  YHP  .:H  #E
MQ0  Y><  .;V %:4  !(FP  .J(  "RI   ?L   $[8   N\    P0   ,4
M  #)    S0   -(   #6    V@   -L   #>    X    .(   #D    YP
M .D   #M    \ H  /01  #X'P  ^3(  /I(  #[7P  _'H  /V7  #]KP
M_<<  /WD /\ #@#_  T _P , /\ #@#_ !, _P > /\ *@#_ #8 _P!" /\
M30#_ %< _P!? /\ 9P#_ &X _P!T /\ >@#_ ($ _0"' /P C0#Z )0 ^0"<
M /< I0#U *\ ] "\ /, SP#Q .P \ #^ .\ _P#O /\ XP#_ -< _P#. /\
MR@#_ /\ "@#_  8 _P $ /\ " #_ !  _P 9 /\ )0#_ #$ _P ] /\ 1P#^
M %$ ^P!9 /D 80#V &@ ] !N /, = #Q 'H [P"! .X AP#L (X Z@"6 .@
MGP#F *D XP"U .( Q@#@ ., WP#X -T _P#= /\ U #_ ,D _P#" /\ O@#_
M /\  P#_    _P   /\  0#_  T _P 4 /T ( #Z "L ]P V /, 00#O $L
M[ !4 .@ 6P#F &( XP!H .$ ;@#? '0 W !Z -H @0#8 (@ U "0 -( F #/
M *( S0"N ,L O #) -, QP#P ,8 _P#$ /\ Q #_ +L _P"V /\ LP#_ /\
M  #_    _P   /\   #W  @ \  0 .L &@#G "4 Y  P .$ .P#< $4 U0!-
M -$ 50#. %L RP!B ,D 9P#' &T Q0!S ,, >@#! ($ OP") +T D@"[ )P
MN0"G +< M0"U ,@ LP#F +( ^P"Q /\ L #_ *X _P"J /\ IP#_ /\   #_
M    _@   /$   #E  ( W  - -, % #- !\ R@ J ,< - #$ #X P !' +P
M3@"Z %4 MP!; +4 80"S &< L@!M +  <P"N 'H K "" *H BP"H )4 IP"@
M *4 K0"C +X H0#; *  ] "? /\ G@#_ )\ _P"= /\ FP#_ /\   #\
M[@   .    #0    Q0 ( +X $ "Y !D M0 C +, +@"P #< K0!  *H 2 "H
M $\ I0!5 *, 6P"B &  H !F )\ ; "= ', FP![ )H A "8 (X E@": )4
MIP"3 +< D0#, )  [ "/ /\ C@#_ (X _P". /\ CP#_ /P   #O    VP
M ,D   "]    M0 " *X # "I !, I0 = *( )P"@ #$ G0 Z )H 0@"8 $D
ME@!/ )0 50"3 %L D0!@ )  9P". &T C0!U (L ?@") (D B "5 (8 H@"%
M +$ @P#$ ($ Y "  /D ?P#_ (  _P"  /\ @ #_ /0"  #@"0  QP@  +<'
M  "L P  I@   *  !P";  \ F  7 )4 (0"2 "H CP S (T / "+ $, B0!)
M (< 4 "& %4 A !; (, 80"! &@ @ !P 'X >0!\ (0 >P"0 'D G0!X *P
M=@"^ '4 W0!S /0 <P#_ ', _P!S /\ <P#_ .D-  #/$   N1   *D0  ">
M#@  EPL  ),&  "0  L C  1 (D &@"& "0 @P N ($ -@!_ #X ?0!$ 'P
M2P!Z %$ >0!7 '< 70!V &0 = !L ',!=0!Q 8  ;P*- &X"F@!L ZH :P.[
M &D$U@!H!O$ : ?_ &<'_P!G!_\ 9P?_ -\4  ##%P  KA<  )X6  "3%0
MBQ(  (80  "$# ( @P8- ( #% !\!1X >0<H '<(, !U"#@ <PE  '()1@!P
M"DP ;PI3 &T+60!L"V$ :@MI &D,<@!G#'X 9@R+ &0-F0!B#:D 80V[ & -
MV !>#O, 70[_ %T._P!=#O\ 70[_ -0<  "Y'0  I!X  )4=  ")'   @1H
M 'L7  !X$P  >! & '<-#P!S#A@ < XB &X/*P!L$#, :A [ &D00@!G$4D
M9A%/ &015@!C$ET 81)F & 2;P!>$GL 7!.( %L3EP!9$Z< 5Q2Z %84U0!5
M%?, 5!7_ %05_P!4%?\ 5!3_ ,HB  "P(@  G2,  (TC  "!(@  >2$  ',>
M  !O&P  ;A<  &T3# !J%!0 9Q4> &46)P!C%B\ 81<W & 7/@!>&$4 71A+
M %P94@!:&5H 61EB %<:; !6&G< 5!J% %(;E !1&Z0 3QNW $X;T !-'/$
M3!S_ $P<_P!-'/\ 31O_ ,,F  "J)P  EB<  (<H  ![)P  <B8  &PD  !H
M(0  9AX  &0;" !B&Q$ 7QP: %T=(P!;'BL 6AXS %@?.@!7'T$ 5B!( %0@
M3P!3(%< 42%? % A:0!.(70 32&" $LBD0!)(J( 2"*T $<BS0!&(^\ 12/_
M $4B_P!&(O\ 1B'_ +PJ  "D*P  D2L  ((L  !V*P  ;2H  &8I  !B)@
M7R0  %TB! !;(0X 6"(6 %8C'P!4)"@ 4R0P %(E-P!0)3X 3R9% $XF3 !,
M)E0 2R=< $DG9@!()W$ 1B=_ $4HCP!#**  02BR $ HRP _*.T /RC_ #\H
M_P! )_\ 0"?_ +<M  "?+@  C"\  'TO  !Q+P  :"X  &$M  !=*P  6B@
M %<G  !4)PP 4B@3 % I' !.*24 32HL $LJ- !**SL 22M" $@L20!&+%$
M12Q: $0L9 !"+6\ 0"U] #\MC0 ]+9X /"VP #HMR  Z+>L .BW_ #HM_P Z
M+/\ .BS_ +(P  ";,0  B#(  'DR  !M,@  9#(  %TQ  !8+P  52P  %$L
M  !/+0D 3"T1 $HN&0!)+R( 1R\J $8P,0!%,#@ 0S _ $(Q1P!!,4\ 0#%7
M #XQ80 ],FT .S)[ #DRBP X,IP -C*O #4RQP T,ND -#+_ #4Q_P U,?\
M-3#_ *TS  "6-   A#4  '4U  !I-0  8#4  %DT  !4,P  4#   $PQ  !)
M,08 1S(/ $4S%@!#,Q\ 0C0G $ T+@ _-38 /C4] #TU1  \-DP .C95 #DV
M7P W-FL -C9X #0WB0 R-YH ,3>M "\WQ0 O-^@ +S;^ # U_P P-?\ ,#3_
M *DV  "2-@  @#<  '(X  !F.   73<  %8W  !0-@  2S0  $<U  !$-@,
M03<- #\X%  ^.!P /#DD #LY+  Z.3, .3HZ #@Z0@ V.DH -3I3 #0[70 R
M.V@ ,#MV "\[AP M.YD +#NL "H[PP I.^8 *CK] "HZ_P K.?\ +#C_ *0X
M  "..0  ?#H  &XZ  !C.@  6CH  %,Z  !-.@  1C@  $(Z   _.P  /#P+
M #H\$0 X/1D -STA #8^*0 T/C  ,SXW #(_/P Q/T< ,#]0 "X_6@ M0&8
M*T!T "E A  H0)< )D"J "5 P0 D0.4 )#_\ "4^_P F/?\ )CW_ )\[  "*
M/   >#T  &H]  !?/0  5CT  $\]  !)/0  0CT  #P^   Y/P  -D$( #1!
M#P R0A8 ,4(> "]#)0 N0RT +4,T "Q$/  K1$0 *D1- "A$6  G16, )45Q
M "-%@@ B194 ($6H !]%OP >1., 'T3[ !]#_P @0O\ (4'_ )H^  "%/P
M=$   &=   !<0   4T   $Q   !&0   /D$  #A#   T10  ,$8# "U'#0 K
M2!( *D@: "E((@ H22D )TDQ "5).0 D24$ (TI* ")*50 @2F$ 'TIO !U*
M?P ;2I( &DJF !A*O0 72N  &$GZ !E(_P :1_\ &D?_ )5"  " 0@  <$,
M &-#  !80P  4$,  $E#  !"1   .T4  #5'   P20  *TL  "9-"0 D3A
M(DX6 "%/'0 @3R4 'T\L !Y/-0 =3ST '%!' !I040 94%T %U!K !90?  4
M4(\ $U"D !%0N@ 14-X $4_X !)._P 33?\ %$W_ (]%  ![1@  :T8  %]'
M  !51P  34<  $9'   _1P  -TH  #%,   K3@  )E   "!3 P <50P &E81
M !E6&  75B  %E8G !56,  45CD $U=" !)730 15UD $%=H  ]7>0 .5XP
M#5>@  M7M@ +5M0 "U;T  Q5_P -5/\ #E/_ (A)  !V2@  9TH  %M*  !1
M2@  2DH  $-*   [3   ,TX  "Q1   F5   (58  !M9   57 < $5X- !!>
M$P 07AH #EXB  Y>*@ -7C, #%X]  M>2  *7E0 "%YB  =><P %7H8  UZ;
M  )>L0 "7<P  EWN  -<_P $6_\ !5O_ (%.  !P3@  8DX  %=.  !.3@
M1TX  #Y/   V40  +E0  "=7   A6@  &UT  !5@   08P, #&8+  AG$  &
M9Q4 !6<<  1G)  "9RT  6<W  !G0@  9TX  &=<  !G;0  9X   &:5  !F
MK   9<<  &7K  !D_   9/\  &/_ 'I2  !J4P  75(  %12  !+4@  0E,
M #E5   P6   *%L  "%?   :8@  %&4  !!H   ,:P$ !FX)  !O#@  ;Q(
M &\8  !P'P  <"<  '$P  !Q.P  <4@  '%6  !Q9@  <7D  '&/  !PIP
M;\$  &_G  !N_   ;?\  &W_ '-8  !E5P  6E<  %%6  !&5P  /%H  #)=
M   J80  (F0  !IH   4;   #F\   IR   $=@   '@%  !X"P  >0X  'H3
M  ![&0  ?"   'TI  !],P  ?4   'U.  !]7@  ?7(  'V(  !\H0  ?+H
M 'OB  !Z^@  >?\  'C_ &U=  !@7   5UP  $M=  ! 7P  -6,  "MG   C
M:P  &F\  !-S   .=P  "'L   )^    @@   (,!  "$!@  A0L  (8/  "(
M$P  B1D  (HA  "+*P  BS<  (Q&  "+5@  BVD  (N   "+F0  BK,  (G8
M  "(]P  B/\  (?_ &AC  !>8@  46(  $1E   X:0  +FX  "1S   :>
M$WT   V!   &A0   (D   "-    D    )(   "2    E 4  )4*  "7#@
MF!(  )H8  ";(0  G"T  )T\  "=3   G%\  )QV  ";D0  FZL  )K)  ":
M\   F?\  )C_ &5I  !7:0  26P  #UQ   P=@  )7P  !N!   2AP  #(P
M  21    E0   )D   "=    H    *$   "B    I    *4!  "G!P  J0P
M *H1  "M&   KR(  *\P  "O00  KU0  *]K  "NA0  KJ$  *Z^  "MY@
MK/P  *S_ %YQ  !/=   0GD  #5_   HA0  '8P  !.2   ,F    YT   "B
M    I@   *H   "N    L    +$   "S    M    +8   "X    N@0  +P*
M  "^$   P1<  ,,D  ##-0  Q$D  ,1>  #%=P  Q9,  ,6O  #%T0  P_(
M ,/_ %9\  !'@@  .H@  "R/   @E@  %)T   VC   #J0   *X   "R
MMP   +L   "_    P@   ,(   #%    Q@   ,@   #*    S0   ,\   #2
M"   U0X  -L8  #=)P  WCH  -]0  #@:   X(0  .&A  #AO0  X>(  .#T
M $Z+  ! D@  ,ID  "6A   8J   #J\   6U    N@   +\   #$    R
M ,X   #1    U    -4   #8    V@   -T   #?    X@   .0   #G
MZP4  .\.  #T&0  ]2L  /9!  #W6   ^'(  /F0  #YJP  ^,0  /CA /\
M"P#_  @ _P ) /\ # #_ !( _P : /\ )@#_ #( _P ^ /\ 2 #_ %( _P!:
M /\ 8@#_ &D _P!O /\ =0#^ 'L _ "! /L B #Y (\ ]P"7 /4 H #S *H
M\@"W .\ R0#M .8 [ #[ .L _P#K /\ W0#_ ,X _P#& /\ P@#_ /\ ! #_
M    _P   /\ !0#_  T _P 5 /\ (0#_ "P _P X /\ 0P#] $P ^0!4 /<
M7 #T &, \@!I /  ;P#N '4 [ ![ .H @@#H (D YP"1 .0 F@#B *0 X "P
M -T P #: -P V #T -4 _P#3 /\ RP#_ ,$ _P"[ /\ MP#_ /\   #_
M_P   /\   #_  H _0 1 /D &P#V "< ]  R /  / #L $8 Z !. .0 5@#A
M %P W@!C -P : #9 &X U0!T -( >P#0 (( S0"* ,L DP#( )T Q@"H ,0
MMP#! ,P P #K +X _P"] /\ O0#_ +0 _P"N /\ JP#_ /\   #_    _P
M /H   #R  4 Z@ . .4 %@#@ "$ W0 K -L -@#3 #\ S@!( ,H 3P#' %8
MQ !< ,( 80#  &< O@!M +P <P"Z 'H N "" +8 BP"T )8 L@"A +  KP"N
M ,$ K0#@ *L ]P"J /\ J0#_ *8 _P"A /\ GP#_ /\   #_    ]P   .@
M  #<    T  * ,H $0#% !L P@ E +\ +P"\ #@ N !! +4 2 "R $\ L !5
M *X 6P"L &$ J@!F *@ ; "G ', I0![ *, A "A (X GP": )T IP"; +@
MF@#0 )D [P"8 /\ EP#_ )8 _P"4 /\ D@#_ /\   #V    Y    -(   #%
M    NP % +4 #@"P !4 K  ? *H *0"H #( I0 Z *( 0@"@ $D G@!/ )P
M50": %H F !@ )8 9@"5 &P DP!T )( ?0"0 (< C@"3 (P H0"+ +  B@#%
M (@ Y@"' /L A@#_ (< _P"' /\ A@#_ /@   #E    S0   +T   "S
MJ@   *, "@"? !$ FP 9 )D (P"7 "P E0 T )( / "0 $, C@!) (P 3P"*
M %0 B0!: (< 8 "& &8 A !N (, =P"! ($ ?P"- 'X FP!\ *H >P"\ 'H
MVP!X /4 > #_ '@ _P!X /\ > #_ .T   #1 @  NP(  *P!  "B    FP
M )8 !0"1  T C0 4 (L '0"( "8 A@ N (0 -@"" #T @ !# 'X 20!] $\
M? !5 'H 6P!Y &$ =P!I '4 <0!T 'P <@"( '$ E@!O *4 ;@"V &T S@!L
M .X :P#_ &L _P!K /\ :P#_ -\+  #"#   K@P  )X,  "3"P  C <  (@"
M  "%  D @0 0 '\ %P!\ "  >@ H '@ , !V #@ =  ^ ', 1 !Q $H < !0
M &X 5@!M %T ; !D &H ;0!H '< 9P"$ &4 D@!D *$ 8P"R &$ R0!@ .D
M8 #\ &  _P!@ /\ 8 #_ - 0  "V$0  HA(  ),2  "($0  @ \  'P-  !Y
M"0$ > ,+ '4 $0!S !H <  C &X!*P!L 3, :@(Y &D#0 !G T8 9@1, &4$
M4@!C!5D 8@5A & %:@!?!G0 70:! %P'CP!:!Y\ 60>P %<'Q@!6">< 5@K[
M %4*_P!5"O\ 5@K_ ,85  "M%P  F1@  (H8  !_%P  =A8  '$3  !N$
M;0T% &T)#0!J"10 9PH= &4*)@!C"RX 8@PU & ,/ !?#$( 7@U( %P-3P!;
M#58 60U> %@.: !6#G, 50Z  %,.CP!1#I\ 4 ZQ $X.R !-$.H 31#] $T0
M_P!-$/\ 31#_ +P;  "E'   DAT  (,>  !W'0  ;QP  &D:  !F%P  9!0
M &00" !B#Q  7Q 8 %T0(0!;$2D 6A$Q %@2. !7$CX 5A)% %023 !3$U,
M41-; % 390!.%'  3!1] $L4C !)%)P 1Q6N $85Q0!%%>@ 11;^ $46_P!%
M%?\ 117_ +4?  ">(0  BR(  'PB  !Q(@  :"$  &(?  !?'0  7!H  %L7
M @!:%0T 5Q84 %46'0!4%R4 4A@M %$8- !/&#L 3AE" $T92 !+&E  2AI8
M $@:8@!'&FT 11MZ $,;B0!"&YH 0!NL #\;P@ ^'.4 /1S\ #X<_P ^&_\
M/AO_ *\C  "8)   AB4  '<F  !L)@  8R4  %TD  !9(@  5A\  %0=  !3
M' L 41P2 $X=&@!-'2( 2QXI $H>,0!)'S< 1Q\^ $8@10!%($T 0R!5 $(@
M7P! (6H /R%W #TAAP [(9@ .2&J #@BP  W(N, -R+[ #<B_P X(?\ ."'_
M *HF  "4)P  @2D  ',I  !G*0  7RD  %@H  !4)@  42,  $\B  !,(@<
M2B(0 $@B%P!'(Q\ 120F $0D+@!")#0 024[ $ E0P _)4H /293 #PF7  Z
M)F< .29U #<GA  U)Y8 -">H #(GO@ Q)^$ ,2?Y #(F_P R)O\ ,R7_ *4I
M  "/*@  ?2P  &\L  !D+0  6RP  %4K  !0*@  3"@  $HF  !')P0 1"<-
M $(H% !!*!P /RDC #XI*P ]*3( /"HY #LJ0  Y*D@ ."M0 #8K6@ U*V4
M,RMR #$K@@ P+)0 +BRG "PLO  K+-X +"SX "PK_P M*O\ +2K_ *$L  "+
M+0  >2X  &LO  !@+P  6"\  %$N  !,+@  2"P  $4K  !!*P  /RP+ #TL
M$0 [+1D .BXA #DN*  W+B\ -B\V #4O/@ T+T4 ,R]. #$P6  P,&, +C!P
M "PP@  J,)( *3"E "<PN@ F,-P )C#W "<O_P H+_\ *"[_ )PN  "',
M=C$  &@R  !=,@  53(  $XQ  !(,0  1#   $ O   \,   .C$) #<Q$  V
M,A8 -3(> #,S)0 R,RP ,3,S # T.P O-$, +31, "PT5@ J-6$ *35N "<U
M?@ E-9  (S6C "(UN0 A-=D (33V "(T_P C,_\ (S+_ )@Q  "#,P  <C0
M &4T  !:-0  434  $LT  !%-   0#0  #HS   W-   -#4& #(V#@ P-Q,
M+S<; "XW(@ M."D *S@Q "HX.  I.4  *#E) "8Y4P E.5\ (SEL "$Z?  @
M.HX 'CJB !PZMP ;.=4 '#GU !TX_P =./\ 'C?_ ),T  !_-@  ;C<  &$W
M  !7-P  3C<  $@W  !"-P  /#<  #4X   R.0  +SH" "P["P J/!$ *3P8
M "@]'P F/28 )3TN "0]-0 C/CT (CY& " ^4  ?/EP '3]I !L_>0 :/XP
M&#^@ !8_M0 5/M( %C[S !<]_P 8//\ &#S_ (XW  !Z.   :CD  %XZ  !3
M.@  2SH  $4Z   _.@  .3H  #(\   N/@  *4   "9!"  D0@X (D(4 "%"
M&P @0R, 'T,J !Y#,@ <0SH &T1# !I$30 81%D %T1G !5$=P 31(H $D2>
M !%$LP 01-  $$/R !%"_P 20O\ $T'_ (D[  !V/   9CT  %H]  !0/0
M2#T  $(]   \/0  -CX  "]    J0@  )40  "%& P =2 P &TD1 !E)%P 8
M21X %TDF !9)+@ 52C8 %$I  !-*2@ 12E8 $$ID  ]*=  .2H< #4J;  Q*
ML  *2LH "TGL  Q(_P -1_\ #4?_ (,^  !Q/P  8D   %9   !-0   14
M #]    Y00  ,D(  "M%   F1P  (4D  !Q+   63@< $U . !)0$P 14!D
M$% A  ]0*0 .4#$ #5 [  U11@ +45$ "E%?  E1;P '4($ !5"6  -0JP "
M4,4  T_H  -/^P %3O\ !DW_ 'U"  !K0P  740  %)$  !*1   0T,  #Q$
M   U10  +D<  "=*   A3   '$\  !=1   25 , #E<*  M8$  *6!4 "%@<
M  =8)  &6"P !5@V  -80  !6$P  %A:  !8:0  6'P  %B1  !7IP  5\
M %;E  !6^0  5?\  %7_ '9'  !F1P  64@  $]'  !'1P  0$<  #A(   P
M2@  *4T  ")0   <4P  %E4  !%8   -6P( "5X)  1?#@  7Q(  %\8  !@
M'P  8"<  & P  !@.P  8$<  &!4  !@8P  8'8  &"+  !?H@  7[L  %_B
M  !>^0  7?\  %W_ &]+  !A3   54P  $Q+  !$2P  .TP  #).   K40
M(U0  !Q7   66P  $5X   U@   (8P   F8'  !G#   9P\  &@3  !I&0
M:B$  &HI  !J-   :D   &I-  !J70  :F\  &J%  !JG0  :;8  &C=  !H
M]P  9_\  &;_ &E1  !<4   4E   $I/   _4   -5,  "U6   D60  '5T
M !9@   09   #&<   9J    ;@   &\#  !P"   <0T  '(0  !T%   =1L
M '8C  !W+   =S@  '9&  !V5@  =F@  '9^  !VEP  =;$  '33  !S]0
M<_\  '+_ &-6  !850  4%0  $15   Y6   +UL  "9?   =8P  %6<  !!L
M   *<   !',   !V    >@   'P   !\ P  ?@@  '\,  "!$   @A0  (0;
M  "%)   AB\  (8]  "&30  A5\  (5U  "%CP  A*D  (/)  ""\0  @?\
M (#_ %];  !66@  25L  #U>   R80  )V8  !YK   5<   #G4   EY   !
M?@   ($   "%    B    (H   "+    C0$  (X&  "0"P  D0\  ),4  "5
M&P  ER8  )<T  "71   EU8  )9L  "5A@  E:(  )3!  "3Z@  DO\  )+_
M %UA  !/80  0F0  #9I   J;@  'W0  !5Y   .?P  !X0   ")    C@
M )(   "6    F    )H   ";    G0   )\   "A P  HP@  *4-  "G$P
MJ1P  *HH  "J.0  JDL  *IA  "I>@  J)D  *BU  "GW0  I_@  *;_ %9H
M  !(;   .G   "YV   B?0  %X0   Z*   'D    )8   ":    GP   *,
M  "G    J@   *L   "M    KP   +$   "S    M0   +@%  "Z#   O1(
M , <  # +0  P$   +]5  "_;@  OHL  +ZH  "^R0  O>\  +S^ $YT  !
M>0  ,G\  "6'   9C@  $)4   ><    H@   *<   "L    L    +4   "Y
M    O    +T   "_    P0   ,,   #&    R    ,H   #- @  T L  -42
M  #6(0  US0  -A)  #98   VGP  -J:  #;M0  V]D  -OR $:"   XB0
M*Y   !V8   2H   "J<   "N    M    +D   "^    P@   ,@   #+
MS@   ,\   #2    U    -8   #:    W0   -\   #B    Y@   .H*  #O
M$P  \"4  /(Z  #S40  ]&L  /2)  #UI0  ];\  /7= /\ !@#_  , _P %
M /\ "P#_ !  _P 7 /\ (@#_ "T _P Y /\ 1 #_ $T _P!5 /\ 70#_ &0
M_P!J /\ < #] '8 ^P!\ /D @P#W (H ]0"2 /, FP#P *8 [@"S .L Q #I
M .0 YP#Y .8 _P#E /\ TP#_ ,< _P"_ /\ NP#_ /\   #_    _P   /\
M @#_  L _P 2 /\ '0#_ "@ _P S /\ /@#\ $< ^ !/ /0 5P#Q %T [@!C
M .P :0#J &\ Z !U .8 ? #D (, X@"+ -\ E0#< )\ V0"K -4 NP#2 -0
MSP#R ,T _P#, /\ Q0#_ +H _P"T /\ L #_ /\   #_    _P   /\   #_
M  8 ^0 / /4 %P#S "( \0 M .T -P#G $  X@!) -\ 4 #; %< UP!= -0
M8P#1 &@ SP!N ,P =0#* 'P R "$ ,4 C0#" )@ P "D +T L@"[ ,8 N0#H
M +@ _0"W /\ M@#_ *T _P"G /\ HP#_ /\   #_    _P   /4   #K  $
MY  , -X $P#9 !P TP F -$ , #, #H R !" ,0 2@#  %  O0!6 +L 7 "Y
M &$ MP!G +4 ;0"S '0 L0!\ *\ A0"M )  J@"< *@ J@"F +L I0#: *,
M]0"C /\ H@#_ )X _P": /\ EP#_ /\   #^    [P   -\   #0    QP '
M ,$ #P"\ !< N0 @ +< *@"U #, L  [ *T 0P"K $D J !/ *8 50"D %H
MHP!@ *$ 9@"? &T G0!T )P ?0": (@ F "4 )8 H@"4 +( D@#) )$ ZP"1
M /\ D #_ )  _P", /\ B@#_ /P   #L    V0   ,<   "Z    L0 " *L
M# "G !( I  ; *$ ) "@ "P G@ U )L / "8 $, E@!) )0 3P"2 %0 D !:
M (\ 7P"- &8 BP!M (D =@"( (  A@", (0 F@"" *H @0"^ (  X "  /D
M?P#_ '\ _P!_ /\ ?@#_ /$   #8    P@   +,   "H    H    )D !P"5
M  X D@ 5 )  '@". "8 C0 N (H -@"' #T A0!# (0 20"" $X @0!4 '\
M60!^ &  ? !G 'H ;P!Y 'H =P"& '4 E !T *, <@"U '( SP!Q /$ < #_
M '  _P!P /\ <0#_ .$   #$    L    *(   "7    D0   (L  @"&  L
M@P 1 ($ & !_ "$ ?0 I 'P , !Y #< >  ] '8 0P!T $D <P!. '( 5 !P
M %H ;P!B &T :@!K '0 :@"  &@ C@!G )T 90"O &4 Q@!D .@ 9 #] &,
M_P!C /\ 9 #_ ,\%  "V!P  HP@  )0(  ")!P  @@,  'X   ![  8 =P .
M '4 $P!R !L <0 C &\ *P!M #( ;  X &H /@!I $0 9P!) &8 3P!E %8
M8P!= &( 90!@ &\ 7P![ %T B0!< )D 6P"J %D OP!9 .$ 6 #X %@ _P!8
M /\ 60#_ ,(,  "J#0  EPX  (D.  !]#@  =@T  '$*  !O!@  ;0 * &L
M$ !I !8 9P > &4 )@!C "T 80 S &  .0!? #\ 70!% %P 2P!; %( 6@!9
M %@ 8@!7 &P 50!X %, A@!2 )8 40"G %  NP!/ =L 3@+T $X#_P!.!/\
M3@/_ +@0  "A$@  CA,  '\3  !T$P  ;!(  &<0  !E#@  8PL# &,&# !A
M!!$ 7@,9 %P$(0!;!2@ 608O %@&-0!6!SL 50=" %0'2 !3"$\ 40A6 % )
M7P!."6D 30EV $L*A !)"I0 2 JF $<*N@!&"M@ 10OS $4,_P!%#/\ 10S_
M + 4  "9%@  AQ@  '@9  !M&   91<  %\6  !<$P  6A$  %H.!@!:# T
M5PP4 %4,' !3#20 4@TK % -,0!/#C@ 3@X^ $T.10!+#DT 2@Y5 $@/7@!'
M#V@ 10]U $,0A !!$)4 0!"F #X0NP ]$-P /1'V #T1_P ]$/\ /A#_ *D9
M  "2&P  @1P  '(=  !G'0  7QP  %D;  !5&0  4Q8  %(3  !2$0H 4! 0
M $X1& !,$2  2A(G $D2+@!($S0 1Q,[ $430@!$$TD 0Q12 $$46P _%&4
M/A5R #P5@0 Z%9( .!6D #<5N0 U%=@ -1;U #86_P V%O\ -Q7_ *,<  "-
M'@  >R   &TA  !B(0  6B$  %0?  !0'@  31L  $P9  !+%@8 218. $<7
M%0!%%QP 1!@D $(8*@!!&#$ 0!DX #\9/P ]&48 /!I/ #H:6  Y&F, -QMO
M #4;?@ S&Y  ,ANB # ;MP O&], +QSS "\;_P P&_\ ,!O_ )T?  "((@
M=R,  &DD  !>)   5B0  % C  !+(@  2"   $8=  !%' ( 0QP, $$<$@ _
M'1D /ATA #P>)P ['BX .A\U #D?/  W'T0 -A], #0@5@ S(&  ,2!M "\@
M?  M(8X +"&@ "HAM0 I(=  *2'R "DA_P J(/\ *R#_ )DB  "$)0  <R8
M &4G  !;)P  4R<  $PF  !')0  1"0  $(A   _(0  /2$) #LA$  Y(A8
M."(> #8C)0 U(RL -"0R #,D.0 R)$$ ,"1* "\E4P M)5X *R5K "HE>@ H
M)8P )B6? "0ELP C)<X (R7P "0E_P E)/\ )23_ )0E  " )P  ;RD  &(J
M  !7*@  3RH  $DI  !$*   0"<  #TF   Z)0  -R8& #4F#@ T)Q0 ,B<;
M #$H(@ P*"D +R@P "TI-P L*3\ *RE' "DI40 H*EP )BII "0J>  C*HH
M(2J= !\JL@ >*LP 'BKO !\I_P @*?\ (2C_ ) H  !\*@  ;"L  %\L  !4
M+   3"P  $8L  !!*P  /"L  #@J   U*@  ,BL# # K#  N+!$ +2P8 "PL
M'P J+28 *2TM "@M-  G+CP )BY% "0N3P C+EH (2]G !\O=@ =+X@ '"^;
M !HOL  8+\H &"[M !DN_P ;+?\ &RW_ (PK  !X+0  :"X  %LO  !1+P
M22\  $,O   ^+@  .2X  #0N   P+@  +2\  "LP"@ I,1  )S$5 "8Q'  E
M,B, )#(J ",R,0 A,SD (#-" !\S3  =,U< &S-D !HT=  8-(8 %C2: !0S
MK@ 3,\@ $S/L !0S_P 5,O\ %C'_ (<N  !T+P  93$  %@Q  !.,@  1C(
M $ Q   [,0  -C$  #$Q   K,P  *#0  "4U!@ C-@T (382 " W&0 ?-R
M'C<G !TX+@ ;.#8 &C@_ !DX20 7.54 %3EB !0Y<0 2.80 $3F8 ! YK0 .
M.,< #CCK ! X_P 0-_\ $3;_ (,Q  !P,@  830  %4T  !+-   1#0  #TT
M   X-   ,S0  "TU   H-P  )#D  " Z @ =.PL &SP0 !D]%0 8/1P %STC
M !8]*P 5/C, %#X\ !(^1@ 1/E( $#Y?  \^;P ./H$ ##Z5  L^J0 */L$
M"CWD  L]^P ,//\ #3O_ 'TT  !K-@  73<  %$W  !(-P  03<  #LW   U
M-P  ,#<  "HY   E.P  (#T  !P_   7008 %$,- !)#$@ 10Q@ $4,? !!$
M)P /1"\ #D0Y  U$0P ,1$X "T1;  E$:@ '1'P !D20  1#I0 "0[T  T/@
M  -#]@ $0O\ !D'_ '@X  !G.0  63H  $XZ  !%.@  /CH  #@Z   S.@
M+3L  "<]   A0   '$(  !=$   31@, #TD*  U*#P ,2A0 "TH;  E*(P (
M2BL !THT  5*/@ $2DD  DI6  !*90  2G<  $J+  !*H0  2;D  $G=  !)
M]0  2/\  $C_ '(\  !B/0  53X  $H^  !"/0  /#T  #8]   O/@  *4
M "-"   =10  %T<  !-*   /3 ( "T\)  =0#0 #41$  %$7  !1'@  428
M %$O  !1.0  440  %)1  !28   47(  %&'  !1G0  4;4  %#8  !0]0
M3_\  $__ &Q   !=00  44$  $=!  ! 0   .4   #)!   J0P  )$8  !Y(
M   72P  $DX   Y1   +4P$ !E8'  !7#   6!   %@3  !9&0  6B$  %HI
M  !:,P  6C\  %I,  !:6@  6FP  %J!  !9F0  6;$  %C1  !8]   5_\
M %?_ &5%  !810  344  $5$   ^1   -44  "U'   E2@  'DT  !A0   2
M4P  #E8   I9   $7    %X$  !?"0  8 T  &$0  !B%0  8QL  &0C  !D
M+0  9#@  &1%  !D5   9&8  &1[  !CDP  8ZT  &+,  !A\@  8?\  &#_
M %]*  !32@  2DD  $-(   Y20  +TP  "=/   ?4@  &%4  !)9   -70
M"&    )C    9@   &@!  !I!0  :@H  &L-  !M$0  ;A8  ' =  !Q)@
M<3$  ' ^  !P3@  <%\  '!S  !OC0  ;Z<  &[&  !M[P  ;/\  &S_ %I/
M  !03@  2$T  #U.   S40  *50  "!8   87   $6    QD   &:    &L
M  !O    <@   '0   !U    =P0  '@)  !Z#0  ?!   'T6  !_'@  @"@
M ( U  " 10  ?U8  ']K  !_A   ?J   'V^  !\Z0  >_\  'K_ %94  !.
M4P  0E0  #=6   L6@  (E\  !AC   1:   "VT   -R    =@   'H   !]
M    @    (,   "$    A@   (<"  ")!P  BPP  (T0  "0%@  DA\  )(L
M  "2.P  DDT  )%B  "1>@  CY<  (^T  ".X0  C/L  (S_ %59  !(6@
M.UT  "]A   D9@  &6P  !%R   *=P   GT   ""    A@   (L   ".
MD0   ),   "5    EP   )D   ";    G00  )\*  "B#P  I!8  *8A  "F
M,0  ID,  *57  "D<   HXX  *.K  "AT   H/4  )__ $YA  ! 9   ,VD
M "=N   ;=0  $7P   N#    B0   (X   "3    F    )T   "A    I
M *4   "G    J0   *L   "M    L    +(   "U"   N X  +P6  "\)0
MO#<  +M,  "Z9   N8$  +>B  "WP   M^H  +?\ $9K   Y<   *W<  !]_
M   3A@  "XX   &5    FP   *$   "F    JP   +    "S    MP   +<
M  "Z    O    +\   #!    Q    ,<   #*    S04  -$.  #4&0  U"L
M -1   #36   TW0  -.2  #2L   TM,  -+R #YY   Q@   (X@  !>1   -
MF0   Z    "G    K@   +,   "X    O0   ,(   #&    R@   ,H   #-
M    SP   -(   #5    V0   -T   #?    XP   .<%  #K#P  [!\  .TS
M  #N2P  [V0  .^"  #PGP  \;D  /'8 /\   #_    _P $ /\ "0#_  X
M_P 5 /\ '@#_ "D _P T /\ /P#_ $@ _P!0 /\ 6 #_ %X _P!E /T :P#[
M '$ ^0!W /@ ?@#V (4 \P"- /$ EP#N *( ZP"O .@ P #F .  XP#X .(
M_P#; /\ RP#_ ,$ _P"Y /\ M #_ /\   #_    _P   /\   #_  D _P 0
M /\ &0#_ ", _P N /T .0#Y $( ]0!* /( 4@#N %@ ZP!> .D 9 #F &H
MY !P .( =@#? 'T W0"& -D CP#5 )H T0"G ,X M@#+ ,X R0#P ,< _P#%
M /\ NP#_ +0 _P"M /\ J0#_ /\   #_    _P   /\   #[  ( ]@ - /$
M$P#M !X [  H .D ,@#C #L W0!$ -@ 2P#3 %$ T !8 ,T 70#+ &, R0!H
M ,8 ;P#$ '8 P@!^ +\ AP"\ )( N@"? +< K0"U ,$ L@#D +$ _0"O /\
MK #_ *4 _P"@ /\ G #_ /\   #_    ^P   .X   #D    W  ( -, $ #/
M !@ RP B ,D *P#& #0 P0 ] +T 1 "Z $L MP!1 +4 5@"R %P L !A *X
M9P"L &X J@!V *@ ?P"F (H HP"6 *$ I0"? +8 G0#1 )P \P"; /\ G #_
M )8 _P"3 /\ D #_ /\   #V    YP   -,   #&    O0 # +@ #0"S !,
ML0 < *\ )0"N "X J0 V *8 /0"C $0 H0!* )\ 3P"= %4 FP!: )H 8 "8
M &8 E@!N )0 =P"2 ($ D ". (X G ", *T B@## (D Z "( /\ B0#_ (<
M_P"% /\ @@#_ /,   #C    S    +P   "P    IP   *$ " ">  \ FP 6
M )D 'P"8 "< E@ O ), -P"1 #T C@!# (P 20"+ $X B0!4 (< 60"% &
MA !G (( ;P"  'H ?@"& 'P E !Z *0 >0"X '@ V !W /< > #_ '@ _P!W
M /\ =0#_ .8   #+    MP   *@   ">    E@   (\ ! "+  P B  2 (<
M&0"% "$ A  I (( , !_ #< ?0 ] 'P 0P!Z $@ >0!- '< 4P!V %D = !A
M '( :0!Q ', ;P!_ &T C0!L )T :@"O &D R !H .T :0#_ &D _P!I /\
M:0#_ -(   "X    I0   )<   "-    A@   ($   !\  @ >0 . '< % !V
M !P =  C ', *P!Q #$ ;P W &X /0!L $, :P!( &H 3@!H %0 9P!; &4
M8P!C &T 8@!X &  AP!? )8 70"H %T O@!< .0 7 #[ %P _P!< /\ 7 #_
M ,(   "J 0  F ,  (D$  !_ @  >    '0   !P  0 ;0 , &L $0!I !<
M:  > &8 )0!E "P 8P R &( . !@ #T 7P!# %X 20!< $\ 6P!6 %H 7@!8
M &@ 5P!S %4 @0!4 )$ 4@"C %$ MP!1 -8 40#U %$ _P!1 /\ 4@#_ +8'
M  "?"0  C0L  'X,  !S"P  ; H  &@'  !E P  8P ' &$ #0!? !, 70 :
M %P (0!; "< 60 M %@ ,P!6 #D 50 _ %0 10!3 $L 40!2 %  6@!/ &0
M30!O $P ?0!* (T 20"? $@ L@!' ,P 1P#O $8 _P!' /\ 1P#_ *P,  "5
M#@  @Q   '40  !K$   8P\  %X.  !;#   6@D" %D$"@!7  \ 50 5 %,
M' !2 ", 40 I $\ +P!. #4 30$[ $P!00!* D@ 20)/ $@"5P!& V$ 10-M
M $,#>@!" XL 0 .< #\#KP ^ \@ /03J #T%_  ]!O\ /@;_ *00  ".$@
M?!,  &X4  !D%   7!,  %82  !3$0  40X  % ,!0!0"0P 3P<1 $T'%P!+
M"!\ 20@E $@)*P!'"3$ 1@DX $0*/@!#"D4 0@I- $ +50 _"U\ /0MK #P+
M>0 Z#(H . R< #<,KP U#,< -0SI #4-_0 U#?\ -@S_ )T3  "'%0  =A<
M &D8  !>&   5A@  % 7  !-%0  2A,  $D1  !)#@< 2 T. $8-$P!$#1H
M0PXA $(.* ! #BX /PXU #X//  ]#T, .Q!+ #H05  X$%X -A!K #00>0 R
M$(H ,1"< "\0L  M$,D +1'L "T1_P N$?\ +Q#_ )<6  ""&0  <1L  &0<
M  !9'   41P  $P;  !'&@  1!@  $,5  !"$P( 01(+ $ 1$  ^$A< /!(>
M #L3)0 Z$RL .!,R #<3.0 V%$  -!1( #,440 Q%%P ,!5H "X5=P L%8@
M*A6: "@5K@ G%<< )A7J "<5_P H%?\ *17_ )$:  !]'   ;1X  & ?  !6
M'P  3A\  $@>  !#'0  0!P  #X:   ]&   .Q<' #D6#@ X%Q0 -A<; #48
M(@ S&"@ ,A@O #$9-@ P&3T +AE& "T:3P K&ED *AIF "@:=  F&H8 )!J9
M "(:K0 A&L4 (!KH "$:_@ B&O\ (QK_ (T=  !Y'P  :2$  %PB  !2(@
M2B(  $0A   _(0  /"   #D>   X&P  -1P$ #0<#0 R'!( ,!T8 "\='P N
M'24 +1XL "L>,P J'CL *1]# "<?30 F'U< )!]D "(?<@ @'X0 'Q^7 !T?
MJP ;'\, &Q_G !L?_0 ='_\ 'A[_ (D@  !U(@  92,  %DD  !/)0  1R4
M $$D   \(P  .",  #4B   S(   ," ! "XA"@ L(1  *R$5 "HB'  H(B,
M)R(I "8C,  E(S@ (R-! "(D2@ A)%4 'R1A !TD<  ;)(( &225 !<DJ@ 6
M),$ %23E !8D_  7(_\ &2/_ (4B  !Q)   8B8  %8G  !,)P  1"<  #XG
M   Y)@  -28  #$E   N)   *R4  "DE!P G)@X )283 "0G&0 C)R  (B<G
M "$H+@ @*#8 'B@^ !TH2  ;*5, &2E? !@I;@ 6*8  %"F4 !(IJ  1*<
M$2CD !$H^P 3*/\ %"?_ ( E  !N)P  7R@  %,I  !)*@  0BD  #LI   V
M*0  ,B@  "XH   J*   )BD  "0J!  B*PP ("L1 !\L%@ =+!T '"PD !LM
M*P :+3, &"T\ !<M10 6+E  %"Y= !(N;  1+GX $"Z2  XNIP -+;T #2W?
M  TM^0 .+/\ $"S_ 'PH  !J*@  6RL  % L  !&+   /RP  #DL   T*P
M+RL  "LK   F+   (BX  !\O   <, D &C$. !DQ$P 7,1H %C(A !4R*  4
M,C  $S(Y !(S0P 1,TX $#-;  XS:0 -,WH ##..  HSH@ (,KD "#+9  @R
M]  *,?\ "S'_ '<K  !F+0  6"X  $TO  !#+P  /"X  #8N   Q+@  +2X
M "DN   C,   'S(  !LS   7-04 %#8, !(W$0 1-Q8 $3<= ! X)  /."P
M#C@U  TX/P ,.$H "SA7  DX90 '.'8 !3B*  ,XGP !-[4  3?3  (W\0 #
M-O\ !3;_ ',N  !B,   5#$  $DQ  !!,0  .3$  #0Q   O,   *S   "4R
M   @,P  &S8  !<X   3.@( $#P)  T]#@ ,/1, "ST9  H](0 )/2D "#TQ
M  8^.P %/D8  SY2  $^80  /G(  #Z&   ]G   /;(  #W0   \\   //\
M #S_ &TR  !=,P  4#0  $8T   ^-   -S0  #(S   M,P  )S0  "(V   =
M.   &#H  !0]   0/P( #4$(  E##0 &1!$  T06  )$'0  1"0  $0M  !$
M-@  1$$  $1.  !$7   1&T  $2!  !$F   0Z\  $/-  !"\   0O\  $+_
M &@V  !8-P  3#@  $,X   [-P  -38  # V   I-P  (SD  !X[   8/0
M$T   !!"   -10$ "$<'  -)#   20\  $H3  !+&0  2R   $LH  !+,@
M2ST  $Q)  !,5P  2V@  $M]  !+E   2JP  $K*  !)[P  2?\  $G_ &(Z
M  !4.P  23L  $ [   Y.@  ,SD  "PZ   E/   'S\  !E!   31   $$<
M  Q)   (3    D\%  !0"@  4 T  %$0  !2%0  5!L  %0C  !4+   5#<
M %1$  !44@  5&,  %1W  !4CP  4Z@  %+&  !2[0  4?\  %'_ %P_  !/
M/P  13\  #X^   W/0  +SX  "=    @0P  &48  !-)   /3   "T\   92
M    5    %<"  !8!P  60L  %H.  !;$0  718  %X=  !?)@  7S$  %X]
M  !>3   7ET  %YQ  !=B0  7:,  %S!  !;ZP  6O\  %K_ %9$  !+0P
M0T(  #Q!   R0@  *44  "%(   :2P  $TX   Y2   *50   UD   !;
M7@   &    !B @  8P8  &4*  !F#@  :!$  &H7  !K'P  :RD  &LV  !K
M10  :U8  &IJ  !J@@  :9T  &B[  !GYP  9O\  &7_ %%(  !(2   048
M #='   L2@  (TT  !M1   350  #ED   A=   !80   &0   !G    :@
M &P   !N    <    '(%  !S"0  =0T  '<1  !Z&   >R$  'LN  !Z/0
M>DX  'EB  !Y>0  >)8  '>S  !UX   =/P  '/_ $Y-  !'3   .TT  #!/
M   F4P  '%@  !-<   -80  !F8   !J    ;P   '(   !V    >0   'P
M  !]    ?P   ($   "# @  A@<  (@,  "+$0  CA@  (XD  ".,P  C40
M (Q8  "+;P  BHP  (FJ  "(SP  AO<  (7_ $U1  !!4P  -%4  "E:   >
M7P  %&4   UJ   %<    '8   ![    ?P   (,   "'    B@   (T   ".
M    D0   ),   "5    F    )H%  "=#   H!$  *,:  "C*   HCH  *%.
M  "@90  H($  )Z@  "=P0  F^X  )K_ $99   Y7   +6$  "%G   6;@
M#G4   5[    @0   (<   "-    D@   )8   ":    G0   )\   "A
MI    *8   "H    JP   *X   "Q P  M L  +@1  "Y'@  N2\  +A#  "W
M6@  M78  +27  "TM0  L>(  +#\ #]D   Q:0  )6\  !AW   /?P  !H<
M  ".    E    )H   "@    I0   *H   "N    L0   +(   "U    MP
M +H   "\    OP   ,,   #&    R0   ,X*  #2$P  TB,  -$W  #03P
MSFH  ,V*  #*JP  R\L  ,OO #=Q   I>   '8   !&)   (D0   )H   "A
M    IP   *T   "S    N0   +X   #"    Q0   ,8   #)    S    ,X
M  #2    U0   -H   #>    X0   .4   #J"P  ZQ<  .HK  #J0P  ZEX
M .IZ  #KF0  Z[4  .O5 /\   #_    _P ! /\ !P#_  T _P 2 /\ &P#_
M "4 _P O /\ .@#_ $, _P!+ /\ 4P#_ %H _0!@ /L 9@#Z &L ^ !R /8
M> #T (  \0") .\ D@#L )T Z0"J .8 O #C -P WP#W -T _P#, /\ O@#_
M +4 _P"P /\ K0#_ /\   #_    _P   /\   #_  8 _P - /\ % #_ !\
M_P I /L ,P#W #T \P!% .\ 30#L %, Z !9 .4 7P#C &4 X !J -T <0#:
M '@ U@"  -( B@#/ )4 S "B ,@ L@#% ,D P@#M ,  _P"[ /\ L #_ *@
M_P"D /\ H0#_ /\   #_    _0   /H   #X    \  ) .P $0#H !D YP C
M .4 +0#> #8 U@ ^ -$ 1@#- $P R@!2 ,@ 6 #% %T PP!C ,  :0"^ '
MO !X +D @0"W (T M ": +$ J0"N +P K #A *H _ "H /\ H #_ )D _P"6
M /\ E #_ /\   #Y    \@   .<   #;    T0 $ ,H #0#' !0 Q  = ,(
M)@"_ "\ NP W +< /P"T $4 L0!+ *X 40"L %8 J@!< *@ 80"F &@ HP!P
M *$ >0"? (0 G0"1 )H H "8 +$ E@#, )4 \0"4 /\ D0#_ (L _P"( /\
MA@#_ /<   #L    W@   ,D   "\    M    *\ "@"K !  J0 7 *@ ( "G
M "@ H@ P )\ . "< #X F@!$ )@ 2@"6 $\ E !5 ), 6@"1 &$ CP!H (T
M<0"+ 'L B0"( (< EP"% *@ @P"^ ($ Y "  /\ @ #_ 'P _P![ /\ >0#_
M .D   #7    P0   +$   "F    G0   )< !0"4  T D@ 2 )  &@"/ "(
MC@ J (L ,0") #@ AP ^ (4 0P"# $@ @0!. '\ 5 !^ %H ? !A 'H :0!X
M ', =@!_ '4 C@!S )\ <0"S '  T !O /8 ;P#_ &\ _P!M /\ ; #_ -H
M  "_    K    )X   "3    C    (4   ""  D ?P / 'X %0!] !P ?  D
M 'H *P!W #$ =0 W '0 /0!R $( <0!( &\ 30!N %, ; !: &L 8@!I &P
M9P!X &8 A@!D )< 8@"J &$ P@!@ .L 80#_ &$ _P!A /\ 8 #_ ,4   "M
M    FP   (T   "#    ?    '<   !R  4 <  , &X $0!L !< ;  > &L
M)0!I "P 9P Q &8 -P!D #T 8P!" &( 2 !@ $X 7P!5 %T 70!< &8 6@!R
M %D @ !7 )  5@"C %4 N0!4 -X 5 #[ %0 _P!5 /\ 50#_ +8   "?
MC0   '\   !U    ;@   &D   !F  $ 8P ) &$ #@!@ !, 7P 9 %X ( !=
M "8 6P L %H ,@!8 #< 5P ] %8 0P!5 $D 4P!0 %( 6 !1 &$ 3P!L $X
M>@!, (H 2P"< $H L0!) ,X 20#S $D _P!) /\ 2@#_ *H!  "4!0  @@<
M '0(  !J"   8P8  %X$  !;    60 % %< # !6 !  5  5 %, &P!2 "(
M40 H %  +0!. #, 30 X $P /@!+ $4 2@!, $@ 5 !' %T 1@!H $0 =0!#
M (4 00"8 $  JP!  ,4 /P#J #\ _P!  /\ 0 #_ * (  "*"P  >0T  &P-
M  !A#0  6@T  %4+  !2"0  4 8  $\"" !.  T 3  2 $L %P!* !X 20 C
M $< *0!& "\ 10 T $0 .@!" $$ 00!( $  4  ^ %H /0!D #P <@ Z ((
M.0"4 #@ IP W +X -@#C #8 ^0 V /\ -P#_ )@-  "##@  <A   &41  !;
M$0  4Q   $X0  !*#@  2 T  $<* P!'!PH 100. $0"$P!" AH 00(@ $ #
M)0 ^ RL /00Q #P$-P [!#X .@5% #D%3@ W!5< -@5B #0&<  R!H  ,0:2
M # &I0 O!;L +@7= "X&]0 M!_\ +@?_ )$0  !]$0  ;!,  %\4  !5%
M3A0  $@3  !$$@  01   $ .  ! #08 0 H, #X)$  \"18 .PH< #D*(@ X
M"B@ -PLN #8+-0 U"SL ,PM# #(,3  P#%8 +PQA "T,;P K#'\ *@R2 "@,
MI0 G#+L )0S= "4-]0 F#?\ )PW_ (L2  !W%   9Q8  %L7  !1&   21<
M $,7   _%0  /!0  #H2   Y$0$ .0\( #@.#0 W#A( -0X8 #0.'P R#B4
M,0\L # /,@ O$#H +1!" "P02P J$%4 *!!A "80;P D$(  (Q"3 "$0IP ?
M$+T 'A#@ !X1]P ?$/\ (!#_ (84  !S%P  8QD  %<:  !-&P  11H  $ :
M   [&0  .!@  #46   T%   ,Q($ #(2"P Q$A  +Q(5 "T2'  L$R( *Q,I
M "H3,  H$S< )Q0_ "842  D%%, (A1? " 5;0 ?%7X '161 !L5I0 9%;L
M&!7> !@5^  9%/\ &A3_ ((7  !O&@  7QP  %,=  !*'0  0AT  #P=   W
M'   -!L  #$:   O&0  +A8  "P7"  K%@X *1<3 "@7&0 G&"  )1@F "08
M+0 C&#0 (AD] " 91@ >&5$ '1E= !L::P 9&GP %QJ/ !4:HP 4&;H $AG;
M !,9]@ 4&?\ %1C_ 'T:  !K'0  7!\  % @  !'(   /R   #D?   T'P
M,1X  "T=   K'   *1L  "<;!0 E&PP )!P1 "(<%@ A'!T (!TC !\=*@ >
M'3( '!XZ !L>1  9'DX %QY; !8>:0 4'WH $AZ- !$>H@ 0'K@ #A[8  \>
M]0 0'?\ $1W_ 'H=  !G'P  62$  $TB  !$(@  /"(  #8B   R(0  +B$
M "H@   G(   )!\  "(@ @ @( H 'B$/ !TA%  <(1H &R(A !DB)P 8(B\
M%R(X !4C00 4(TP $B-8 !$C9P 0(W@ #B.+  TCGP ,([0 "R/0  LB\  ,
M(O\ #2'_ '8?  !D(@  5B,  $LD  !!)   .B0  #0D   O(P  *R,  "@C
M   D(P  (",  !TD   ;)0< &28- !<F$0 6)A< %2<> !0G)0 3)RP $B<U
M !$H/P 0*$H #BA6  TH9  ,*'0 "BB'  DHFP ')[$ !2?,  8G[  ')OX
M"";_ '$B  !@)   4R8  $@G   _)P  -R8  #$F   M)@  *24  "4E   B
M)0  '2<  !DH   6*@0 %"L+ !(L$  1+!0 $"P; ! L(@ .+"D #BTR  TM
M.P ++48 "BU2  @M8  &+7  !"V#  (MF   +*X  "S)   LZP !*_P  BO_
M &TE  !=)P  3R@  $4I   \*0  -2D  "\H   K*   )R<  ",G   ?*
M&RH  !<L   3+@( $# (  XQ#0 -,1( ##$7  LQ'@ *,28 "#(N  <R-P %
M,D(  S).  $R7   ,FP  #)_   RE0  ,:P  #''   PZ@  ,/P  ##_ &@I
M  !8*@  3"L  $$L   Y+   ,BL  "TK   I*@  )2H  " K   <+   %RX
M !,P   0,@( #C0'  HW#  '-Q  !3<4  ,W&P "-R(  #<J   X,P  .#X
M #A*   X6   .&@  #A\   WD@  -ZD  #;%   VZ@  -OT  #7_ &,L  !4
M+@  2"\  #XO   V+@  ,"X  "LM   G+0  (BT  !TO   8,0  %#,  ! U
M   .-P$ "CH'  8["P "/ X  #T2   ^%P  /AX  #XF   ^+P  /CH  #Y&
M   ^5   /F0  #YW   ^CP  /:<  #W#   \Z0  //T  #O_ %XP  !0,0
M1#(  #LR   T,0  +C   "DO   D,   'C(  !DT   4-@  $#D   T[   *
M/0  !4 %  !!"@  0@T  $,0  !$%   11H  $8B  !&*P  1C4  $9!  !&
M3P  1E\  $9S  !%B@  1:0  $3   !#Z   0_X  $+_ %@T  !+-0  034
M #DU   R-   +3,  "8T   @-0  &C@  !0Z   0/0  #4    E"   $10
M $<#  !(!P  2@L  $L.  !,$0  3A4  $\<  !/)0  3R\  $\\  !/2@
M3UH  $YM  !.A0  3:   $R\  !+YP  2_X  $K_ %,Y  !'.0  /CD  #<X
M   Q-P  *3<  "$Y   ;/   %3\  !!"   ,10  !T@   )*    30   $\
M  !1!   4@<  %0+  !5#@  5Q$  %D7  !:'P  62D  %DV  !91   650
M %AG  !8?P  5YH  %:W  !5XP  5/T  %3_ $X]  !#/0  /#P  #4[   L
M/   )#X  !Q!   51   $$@   M+   %3@   %$   !4    5P   %D   !;
M    70(  %X&  !@"P  8@X  &02  !G&   9R(  &8N  !F/   9DT  &5@
M  !E=P  9),  &.Q  !AW0  8/P  %__ $E"  !!00  .C\  #!    F0P
M'D8  !5*   03@  "E(   -6    6@   %T   !@    8P   &4   !G
M:0   &L!  !M!0  ;PH  '(.  !U$@  =QL  '8F  !V-0  =48  '19  !T
M;P  <XL  '*I  !PS0  ;_<  &[_ $9&  ! 10  -48  "I(   @3   %U$
M !!6   )6@   5\   !C    :    &L   !O    <@   '4   !W    >0
M 'L   !]    @ ,  (,(  "&#0  B1,  (H=  "**P  B3P  (A/  "&9@
MA8$  (2@  ""P@  @?   '__ $9+   Z3   +D\  "-3   86   $%X   ED
M    :0   &\   !T    >    'P   "!    A    (<   "(    BP   (X
M  "0    DP   )8   "9!P  G0T  *$4  "@(0  H#$  )Y$  "=6P  G'8
M )F6  "9M0  EN4  )7^ #]2   R50  )EH  !M@   19P  "6T   !T
M>P   ($   "&    BP   )    "4    EP   )D   "<    GP   *$   "D
M    IP   *H   "M    L08  +4-  "X%@  MR8  +8Y  "U4   M&H  +*)
M  "PJ@  KL\  *WU #=<   K80  'F@  !-P   +>    (    "'    C@
M )4   ":    GP   *0   "H    K    *T   "P    LP   +4   "X
MNP   +\   ##    QP   ,L%  #1#@  T1L  - N  #/10  S5\  ,M^  #)
MG@  R+X  ,7I "]I   C<   %GD   V!   !BP   ),   ";    H@   *@
M  "N    M    +@   "]    P    ,(   #%    R    ,L   #.    T0
M -8   #;    WP   .0   #H!@  ZQ$  .HC  #J.@  Z50  .=R  #EDP
MX[,  ./4 /\   #_    _P   /\ ! #_  L _P 0 /\ %P#_ "$ _P K /\
M-0#_ #X _P!' /\ 3@#_ %4 _ !; /H 80#X &8 ]@!M /0 <P#R 'L [P"$
M .T C@#J )D Y@"G ., N0#? -4 VP#W -8 _P#  /\ L@#_ *H _P"E /\
MH@#_ /\   #_    _@   /P   #\  , _@ + /\ $0#_ !H _0 D /D +@#T
M #@ \ !  .P 2 #I $X Y@!4 .( 6@#? %\ W !E -@ :P#4 '( T ![ ,T
MA0#* )$ QP"> ,, K@#  ,4 O0#K +L _P"P /\ I #_ )P _P"8 /\ E0#_
M /\   #Z    ]    /$   #R    Z@ % .< #@#B !4 X0 > .$ * #8 #$
MT  Y ,L 0 #( $< Q0!- ,( 4P"_ %@ O0!> +L 9 "Y &L M@!S +0 ? "Q
M (@ K@"5 *L I "H +@ I@#< *, ^P"? /\ E0#_ (\ _P"+ /\ B0#_ /D
M  #O    YP   -\   #/    R    ,$ "@"_ !$ O  8 +L (0"Y "H M  R
M +$ .@"N $  JP!& *@ 3 "F %$ HP!6 *$ 7 "? &, G0!J )L <P"9 'X
ME@", )0 FP"2 *T D #' (X \ "- /\ A@#_ (  _P!] /\ ? #_ .T   #@
M    T0   +\   "S    J@   *8 !0"B  T H0 3 *  &P"? ", FP K )@
M,@"5 #D DP _ )$ 1 "/ $H C@!/ (P 50"* %L B !C (8 :P"$ '8 @@""
M (  D@!^ *, ? "Z 'H X0!Y /\ =P#_ '( _P!P /\ ;P#_ -T   #+
MM@   *<   "=    E    (X  0"+  H B0 0 (@ %0"' !T AP E (0 + ""
M #( ?P X 'T /0![ $, >0!( '@ 3@!V %0 =0!; ', 8P!Q &X ;P!Z &T
MB0!L )H :@"N &D S !H /8 9P#_ &4 _P!D /\ 8P#_ ,H   "T    H0
M ),   ")    @@   'L   !X  4 =@ , '4 $0!T !@ <P ? '( )0!P "P
M;@ R &P -P!J #P :0!" &@ 2 !F $X 90!5 &, 70!B &8 8 !R %X @ !=
M )( 6P"E %H O@!9 .D 60#_ %D _P!8 /\ 6 #_ +D   "B    D    (,
M  !Y    <0   &T   !I  $ 9@ ) &4 #@!D !, 8P 9 &, ( !A "8 8  L
M %X ,0!< #< 6P \ %H 0@!8 $@ 5P!/ %8 5P!4 &  4P!L %$ >0!0 (H
M3P"> $X M !- -H 30#[ $T _P!- /\ 30#_ *H   "4    @@   '4   !K
M    9    &    !=    6@ % %@ # !7 !  5@ 5 %8 &P!5 "$ 4P G %(
M+ !1 #$ 3P W $X /0!- $, 3 !* $H 4@!) %L 2 !F $8 <P!% (0 1 "7
M $, K !" ,D 0@#Q $( _P!# /\ 0P#_ )X   ")    > ,  &H$  !A!
M6@,  %4!  !2    4  " $X "0!-  T 3  1 $L %P!* !P 20 B $@ )P!'
M "T 10 R $0 . !# #X 0@!% $$ 30 _ %8 /@!A #T ;@ [ 'X .@"1 #D
MI@ X +\ . #H #@ _P Y /\ .0#_ )4#  " !P  ;PD  &(*  !8"P  40H
M $P(  !)!@  1P,  $8 !@!$  L 0P / $( $P!! !@ 00 > #\ (P ^ "D
M/0 N #L -  Z #H .0!! #@ 20 W %( -@!= #0 :@ S 'H ,@", #$ H0 P
M +@ +P#> "\ ^0 O /\ , #_ (P)  !X#   : T  %P.  !2#@  2PX  $4-
M  !!#   /PH  #X( @ ]! @ / $- #L $  Z !4 .0 : #@ (  V "4 -0 K
M #0 ,  S #< ,@ ^ #$ 1@ O %  +@!: "T 9P K '< *@") "D G0 H +,
M)P#1 "< \@ G /\ )P#_ (8,  !R#@  8Q   %81  !-$0  11$  $ 0   \
M#P  .0X  #<-   V"P0 -@@* #4&#@ T!1( ,@07 #$%'  P!2( +P4H "X&
M+@ M!C0 *P8\ "H&1  I!TX )P=9 "8'90 D!W4 (P>' "('FP @!K  ( ;+
M !\%[0 ?!OX 'P?_ ( .  !M$0  7A(  %(3  !($P  01,  #L3   W$@
M-!$  #(0   P#P$ , T& # +"P O"A  +0H4 "P+&0 J"Q\ *0LE "@,*P G
M##( )@PZ "0,0P C#$T (0U8 " -90 >#74 ' V( !H-G  9#;$ & S* !<,
MZP 7#?P & S_ 'L1  !I$P  6A4  $X6  !%%@  /18  #@5   S%0  ,!0
M "T3   K$@  *A # "H/"  I#@T * X1 "8.%@ E#QT ) \C ",/*0 A$#$
M(! Y !X00@ =$$P &Q!8 !D09@ 7$'8 %1") !00G@ 2$+, $1#. !$0[@ 2
M$/X $A#_ '<3  !E%0  5Q<  $L8  !"&0  .AD  #08   P%P  +!<  "D6
M   G%0  )A0! "42!  C$@L (A(/ "$2%  @$AH 'A,@ !T3)P <$RX &A,V
M !D40  7%$H %A16 !049  2%'0 $12' ! 4G  .%+$ #13*  T4ZP .$_X
M#A/_ ',5  !A&   4QH  $@;   _&P  -QL  #(:   M&@  *1D  "88   D
M&   (A<  " 6 0 >%@@ '18- !L7$@ :%Q< &1<= !@8)  6&"L %1@T !08
M/0 2&4@ $1E4 ! 98@ .&7( #1F$  P9F  *&:T "1C&  D8YP )&/H "A?_
M &\8  !>&@  4!P  $4=   \'0  -1T  "\=   J'   )AL  ",;   A&@
M'AH  !P:   :&P4 &!L, !8<$  5'!4 %!P; !,<(@ 2'2D $1TQ ! =.P .
M'44 #1Y1  P>7@ *'FT "1Z   <>E  %':H  QW"  ,=Y@ $'/@ !1S_ &L:
M  !;'0  31X  $(?   Z'P  ,A\  "T?   H'@  )!X  "$=   >'0  '!T
M !@>   5'P( $R ) !(A#@ 0(1( $"$8  XA'P .(B8 #2(N  PB-P *(D$
M"2)-  <B6@ %(FD  R)\  $BD0  (J@  "'    AY0  (/@  "#_ &<=  !7
M'P  2B$  $ A   W(@  ,"$  "HA   F(   (B   !\?   <'P  &2   !8A
M   2(P( $"0'  XF#  ,)A  "R85  HF'  ))B( ""8J  8G,P $)ST  R=)
M  $G5@  )V8  "=Y   GCP  )J8  ":_   EY   )?D  "3_ &,@  !4(@
M1R,  #TD   T)   +B,  "@C   D(@  (2(  !XA   :(@  %R,  !,D   0
M)@( #B@'  LJ"P (*PX !BL3  0K&  "*Q\  2PG   L,   +#H  "Q%   L
M4P  +&,  "QV   LC   *Z0  "N^   JY   *OH  "G_ %\C  !0)0  1"8
M #HF   R)@  *R8  "8E   C)   'R0  !LD   7)0  %"<  !$I   .*P(
M"RT&  <O"P $, X  # 1   Q%0  ,1P  #$C   R+   ,C8  #)"   R3P
M,E\  #)R   QB0  ,:(  #"\   PY   +_L  "__ %HG  !,*   0"D  #<I
M   O*0  *2@  "4G   A)@  '"<  !@H   4*@  $2P   XN   +, $ !S(%
M  ,T"0  -0P  #8/   W$@  .!@  #@@   X*   .#(  #D]   Y2P  .5L
M #AN   XA0  -Y\  #>Z   VY   -?P  #7_ %4J  !(+   /2P  #0L   M
M*P  *"H  "0I   >*@  &2L  !0M   1+P  #3$   HT   '-@   C@$   Z
M!P  .PH  #T-   ^$   0!0  $ ;  ! )   0"X  $ Y  ! 1P  0%8  $!I
M  ! @   /YL  #ZW   ]XP  //P  #S_ % O  !#+P  .2\  #(O   L+0
M)RP  " M   :+P  %3$  !$S   --@  "3@   4[    /0   $ !  !!!
M0P<  $4+  !&#@  2!$  $H6  !*'@  2B@  $HT  !)0@  25$  $ED  !(
M>P  2)<  $>T  !&X   1?P  $3_ $HS   _,P  -C,  # Q   J,   (S$
M !PS   6-0  $3@   T[   (/@   T$   !#    1@   $@   !*    3 0
M $X'  !/"P  40X  %02  !5&0  52(  %0N  !4/   5$L  %->  !3=
M4I   %&N  !0UP  3_L  $[_ $4W   \-P  -38  "\T   F-0  'C<  !<Z
M   1/0  #$$   =$    2    $H   !-    4    %,   !5    5P   %@"
M  !;!@  70L  %\.  !B$P  8AL  &(G  !B-   844  &!7  !@;0  7XD
M %VG  !<S   6O@  %G_ $$\   Z.P  -#D  "HZ   A/   &$   !%#   ,
M1P  !DL   !/    4P   %8   !9    7    %\   !A    8P   &4   !G
M 0  :@4  &T*  !P#@  <Q4  '(@  !R+0  <3T  '!/  !O90  ;H   &V?
M  !KP0  :?$  &C_ #]    Y/@  +C\  "1"   :1@  $DH   Q/   $5
M %@   !=    80   &4   !H    :P   &X   !Q    <P   '4   !X
M>P   'X#  "!"@  A0\  (<7  "&)   A30  (1&  ""70  @78  '^6  !^
MM@  ?.<  'K_ #]$   S10  *$@  !U,   34@  #%<   -=    8P   &@
M  !M    <0   '8   !Z    ?@   ($   "#    A@   (D   "+    C@
M )(   "5 0  F0D  )X0  ">&@  G2D  )P\  ":4@  F&P  ):+  "4J@
MDM0  )#Z #A+   L3@  (%,  !59   -8    V<   !N    =    'H   "
M    A    (H   ".    D@   )4   "7    F@   )T   "@    HP   *<
M  "K    KP   +0)  "X$   MQX  +4P  "S1@  L6   *]^  "LH   J\$
M *GN #%5   D6P  &&$   YI   %<0   'D   "!    B    (\   "4
MF@   )\   "D    J    *D   "L    KP   +,   "U    N0   +T   #!
M    Q@   ,L   #1"@  TQ0  -$E  #0.P  S50  ,IQ  #(D@  Q;,  ,/>
M "EB   <:0  $7$   =[    A    (T   "5    G0   *,   "I    KP
M +0   "Y    O    +X   #"    Q0   ,@   #,    T    -0   #:
MWP   .0   #J    [@P  .T:  #L+P  ZDD  .AE  #FA@  Y*4  .+& /\
M  #_    _P   /P  0#\  @ _@ . /\ % #_ !T _P F /\ , #_ #H _P!"
M /\ 20#^ %  ^P!6 /D 7 #V &( ] !H /( ;P#P '8 [0!_ .H B0#G )4
MY "C .  M0#; -  U0#V ,H _P"V /\ J #_ )\ _P": /\ E@#_ /\   #[
M    ]@   /,   #S    ]@ ) /H #@#] !8 ^P @ /< *@#R #, [0 [ .D
M0P#F $D X@!/ -X 50#; %L U@!@ -( 9P#/ &X S !V ,D @ #& (P P@":
M +\ J@"[ ,$ N #I +8 _P"G /\ F@#_ )( _P"- /\ B@#_ /H   #Q
MZ@   .<   #G    Y  ! .  "P#; !$ V@ : -L (P#1 "P R@ T ,8 .P#"
M $( OP!( +P 3@"Z %, N !9 +8 7P"S &8 L0!N *X =P"L (, J0"1 *8
MH0"C +4 H #8 )X ^P"5 /\ BP#_ (4 _P"  /\ ?@#_ .\   #C    V@
M -,   #&    OP   +D !@"W  X M  4 +0 '0"S "4 K@ M *L - "G #L
MI !! *$ 1@"? $P G0!1 )L 5P"9 %X EP!E )4 ;@"3 'D D "' (X EP",
M *D B0#$ (@ [P"% /\ ? #_ '8 _P!S /\ <@#_ .    #0    Q@   +8
M  "I    H0   )T  0"9  H F  0 )@ %@"7 !X E  F )$ +0"/ #0 C  Z
M (H /P"( $4 AP!* (4 4 "# %8 @0!> (  9@!^ '$ ? !] 'D C0!W *
M=0"V ', WP!R /\ ;@#_ &D _P!G /\ 90#_ ,P   "^    JP   )T   "3
M    B@   (4   ""  4 @  - '\ $0!_ !@ @  @ 'T )@!Z "T =P S '4
M. !T #X <@!# '  20!O $\ ;0!6 &P 7@!J &@ : !U &< A !E )8 9 "K
M &( R0!A /8 8 #_ %P _P!; /\ 6@#_ +T   "I    EP   (D   !^
M>    ',   !O  $ ;0 ) &P #@!K !, :P 9 &H ( !H "8 9@ L &4 ,@!C
M #< 8@ \ &  0@!? $@ 70!/ %P 5P!: &$ 60!M %< >P!6 (X 50"B %,
MNP!2 .D 4@#_ %  _P!/ /\ 3P#_ *T   "8    A@   '@   !N    9P
M &,   !@    70 % %P "P!; !  6P 5 %L &P!: "$ 6  F %8 + !4 #$
M4P V %( / !1 $( 3P!) $X 40!- %L 2P!F $H = !) (4 2 "9 $< L0!&
M -@ 1@#\ $4 _P!% /\ 10#_ )\   ")    >    &P   !B    6P   %8
M  !3    40 " $\ " !/  T 3@ 1 $X %@!- !P 3  A $H )@!) "P 2  Q
M $< -P!% #T 1 !$ $, 3 !" %4 0 !@ #\ ;@ ^ 'X /0"2 #P J0 [ ,<
M.P#S #L _P [ /\ / #_ ),   !^    ;@   &$   !8    40   $P   !)
M    1P   $4 !0!$  L 0P . $, $@!# !< 0@ = $  (@ _ "< /@ L #T
M,@ [ #@ .@ _ #D 1P X %  -P!; #4 :  T '@ ,P", #( H@ Q +P ,0#G
M #$ _P R /\ ,P#_ (D   !V P  9@4  %D'  !0!P  208  $,%  !  P
M/@$  #P  P [  @ .@ - #H $  Y !0 .0 9 #< '@ V ", -0 H #0 +@ S
M #0 ,@ [ #  0P O $P +@!7 "T 9  L ', *P"' "H G  I +4 *0#< "D
M^P I /\ *@#_ ($$  !N"   7PH  %,+  !*"P  0@L  #T*   Y"0  -@@
M #4%   T @8 ,P * #( #@ Q !$ ,0 5 #  &@ O !\ +@ D "P *@ K #
M*@ W "D /P H $D )P!4 "8 8  D &\ (P"" "( EP A *X (0#, "$ \P A
M /\ (@#_ 'L)  !H#   6@T  $X.  !%#@  /0X  #@-   S#0  , P  "X+
M   M"0, +08( "P$#  K @\ *@$2 "D!%P H 1P )P A "8 )P E "T )  T
M ",!/0 B 48 (0%1 !\!70 > 6P ' %_ !L E  : *H &@#% !H ZP 9 /\
M&@#_ '4,  !D#@  50\  $H0  ! $   .1   #,0   O#P  + X  "D.   G
M#0$ )PP% "<*"@ F" T )0<0 "0&%  B!AD (08? " ')  ?!RL '@<R !T'
M.@ <"$0 &@A/ !D(7  7"&L %@A] !4'D0 4!Z< $P:_ !(%Y  2!?H $@7_
M '$.  !?$   41$  $82   ]$@  -A(  # 2   K$0  *!$  "40   C$
M(@X$ "$-!P A# L ( L. !\+$@ ="Q< ' P< !L,(@ :#"D &0PQ !@,.0 6
M#4, %0U/ !,-7  2#6L $ U^  \-D@ .#:< #0R^  T,X  -#/4 #0S_ &T0
M  !<$0  3A,  $,4   Z%   ,A0  "T4   H$P  )1,  "(2   @$0  'A$#
M !P0!0 <#P@ &P\, !H.$  9#Q0 %P\: !8/(0 5$"@ %! P !(0.0 1$$0
M$!!0  X070 -$&L #!!\  L0D  )$*4 "!"\  <0WP '$/0 !P__ &D1  !8
M%   2Q4  $ 6   W%@  ,!8  "H6   F%0  (A4  !\4   =$P  &A," !D2
M!  7$@8 %A(* !42#@ 4$A( $A(8 !$3'@ 1$R4 $!,N  X3-P -%$  #!1+
M  L46  )%&< !Q1X  84C0 $%*,  Q.[  (3W0 !$O0  A+_ &43  !5%@
M2!<  #T8   T&   +1@  "@8   C%P  (!<  !T6   :%0  &!4" !85!  4
M%04 $A8( !$6#0 0%Q  #A<5  X7&P -%R( #!<I  L8,@ )&#P !QA'  48
M5  $&&,  AAU  $8BP  %Z$  !>Y   7W0  %O4  !;_ &$6  !2&   11H
M #L:   R&@  *QH  "4:   A&0  'A@  !L8   8%P  %A<" !07 P 2& 4
M$!D'  X;"P ,&P\ "QL3  H;&  ('!\ !QPF  4<+P $'#@  AQ$   =40
M'6   !UR   <B   '*   !NY   ;W@  &O8  !K_ %X8  !/&@  0AP  #@<
M   O'0  *1P  ",<   ?&P  '!H  !D9   7&0$ %!D" !(: P 0&P0 #AT'
M  P>"P )'PX !B 1  4@%@ #(!P  2$C   A*P  (34  "%    A3@  (5T
M "%O   AA@  ()X  ""X   ?W@  'O@  ![_ %H;  !+'0  /QX  #4?   M
M'P  )QX  "(=   >'0  &QP  !@;   5&P  $AP  ! = @ .'P0 #"$&  DB
M"@ %(PT  B00   E$P  )1D  "8@   F*   )C(  "8]   F2@  )EH  "9L
M   F@P  )9P  "6W   DWP  (_D  "/_ %4>  !'(   /"$  #(A   K(0
M)2   " ?   ='@  &AT  !8>   3'@  $"    XA   ,(P( ""4%  4G"0
M* L  "H.   K$0  +!8  "P=   L)0  +"X  "PZ   L1P  +%8  "QI   L
M@   *YH  "JU   IWP  *?L  "C_ %$B  !$(P  ."0  "\D   H(P  (R(
M !\A   <(   %R   !,A   0(P  #B0   LF   (*   !"H$   L!P  +@D
M # ,   Q#P  ,Q,  #,9   S(0  ,RH  #,U   S0P  ,U(  #-E   R>P
M,I<  #&S   PW@  +_L  "[_ $PE   _)@  -2<  "TF   G)0  (B0  !XC
M   9(P  %"0  !$F   .*   "RH   <L   #+P   #$"   S!   -0<  #<*
M   Y#0  .A   #L5   ['0  .R8  #LQ   [/@  .TX  #M@   Z=P  .9(
M #BP   WVP  -OP  #7_ $<I   [*@  ,BH  "LI   E)P  (28  !LG   5
M*   $2H   XL   *+P  !C$   $T    -@   #@    [ 0  /00  #\'  !!
M"@  0PX  $41  !%&   12$  $4L  !$.0  1$@  $1;  !#<0  0HT  $&K
M  ! T@  /_H  #[_ $(M   X+@  +RT  "DK   D*@  '2H  !<L   1+@
M#3$   DT   $-P   #H    \    /P   $$   !$    1@   $@#  !*!P
M3 L  $X.  !0$P  4!P  % G  !/-   3T,  $]5  !.:@  388  $RD  !*
MR@  2?@  $C_ #XR   U,0  +B\  "DN   @+@  &3$  !(S   .-P  "3H
M  (]    0    $0   !'    20   $P   !/    40   %,   !5 0  6 8
M %H+  !=#@  7Q4  %X@  !>+   73P  %Q.  !;8P  6GX  %B=  !7P
M5?(  %3_ #HV   S-   +3(  "0S   ;-@  $SD   X]   (00   $4   !)
M    3    %    !3    5@   %D   !;    70   &    !B    90   &@%
M  !K"P  ;Q   &\8  !N)0  ;30  &U&  !K6P  :G4  &B4  !FM@  9.D
M &+_ #@Y   R-P  *#D  !X[   5/P  #D0   =)    30   %(   !6
M6@   %X   !B    90   &@   !K    ;0   '    !S    =@   'D   !]
M!   @0L  (41  "$'0  @BP  ( ^  !^5   ?FL  'N*  !ZJ@  =]8  '7]
M #@]   L/@  (D$  !=&   /2P  !U$   !7    7    &(   !F    :P
M &\   !T    >    'L   !^    @    (,   "&    B@   (T   "1
ME@,  )L,  "=$P  FR$  )HS  "720  E&(  )-_  "0H   CL4  (SS #%$
M   E2   &DT  !!3   (6@   &$   !H    ;@   '0   !Y    ?P   (0
M  ")    C0   )$   "3    E@   )D   "=    H    *0   "H    K
M +(#  "W#0  MQ<  +4H  "R/@  L%8  *QS  "JE   J;0  *7E "I/   >
M5   $EL   IB    :@   ',   ![    @@   (D   ".    E    )H   "?
M    I    *8   "I    K0   +    "S    MP   +L   #     Q0   ,L
M  #1!   U0X  -,=  #0,@  S4L  ,IF  #&AP  PJD  ,'+ ");   68@
M#&L   %T    ?0   (<   "0    EP   )X   "D    JP   +$   "V
MN@   +P   #     Q    ,@   #+    SP   -0   #:    X    .8   #K
M    \08  / 3  #N)P  [#\  .I;  #G>@  Y)L  ."[ /\   #[    ]@
M /,   #T  4 ]@ , /H $0#_ !D _P B /\ + #_ #4 _P ] /\ 10#\ $P
M^@!2 /< 6 #U %X \P!D /$ :@#N '( [ !Z .D A0#E )$ X0"@ -T L@#8
M ,X T@#V ,$ _P"M /\ G@#_ )8 _P"0 /\ C #_ /H   #R    [    .D
M  #I    [  % /( # #X !( ]P ; /4 )0#P "X ZP W .8 /@#B $4 W0!+
M -@ 4 #3 %8 T !< ,T 8@#* &H R !R ,4 ? #" (@ O@"6 +H J "W +\
MM #H *X _P"= /\ D #_ (@ _P"# /\ @ #_ /    #E    W@   -H   #;
M    W    -@ !P#1  X T0 5 -( '@#+ "< Q0 O ,  -P"] #T N@!$ +<
M20"U $\ L@!5 +  6P"N &$ K !I *D <P"G '\ I "- *$ G@"> +( FP#5
M )D _ ", /\ @@#_ 'L _P!V /\ = #_ .(   #3    R@   ,<   "\
MM@   +   0"O  L K  1 *T & "M "  J  H *0 +P"@ #8 G0 \ )L 0@"9
M $< EP!- )4 4P"3 %D D0!A (\ :@", '4 B@"# (@ E "& *< @P#" ((
M\ !\ /\ <P#_ &T _P!J /\ : #_ ,\   #!    N0   *T   "@    F
M )0   "1  8 D  - )  $@"/ !D C@ A (L * "( "\ A@ U (0 .@"" $
M@ !% 'X 2P!\ %( >@!9 '@ 8@!V &P = !Y '( B0!Q )T ;P"T &T WP!L
M /\ 90#_ &  _P!> /\ 7 #_ +X   "Q    H    )(   ")    @@   'P
M  !Z  $ >  ) '< #@!X !0 =P : '0 (0!R "< <  M &X ,P!L #@ :P ^
M &D 1 !H $H 9@!1 &0 6@!C &0 80!P %\ ?P!> ), 70"I %P R !; /<
M5P#_ %0 _P!2 /\ 40#_ +    "?    C0   '\   !T    ;@   &H   !F
M    90 $ &, "P!C !  8P 5 &, &P!A "$ 7P G %T + !< #( 6@ W %D
M/0!7 $, 5@!+ %4 4P!3 %P 4@!H %  =P!/ (D 3@"? $T N@!, .D 2P#_
M $D _P!' /\ 1P#_ *(   "-    ?    &X   !E    7@   %D   !7
M50 ! %0 !P!3  T 4P 1 %0 %@!2 !L 40 A $\ )@!. "L 3  Q $L -P!*
M #T 20!$ $< 3 !& %8 1 !A $, < !" ($ 00"7 $  KP _ -< /P#_ #X
M_P ] /\ /@#_ )0   !_    ;P   &,   !9    40   $T   !*    2
M $< ! !'  H 1@ . $8 $0!' !8 10 < $0 (0!" "8 00 K $  ,0 ^ #<
M/0 ^ #P 1P Z %  .0!; #@ :0 W 'H -@"/ #4 IP U ,8 - #U #0 _P T
M /\ -0#_ (@   !T    90   %@   !/    2    $,    _    /0   #P
M @ \  < .P , #L #P [ !( .@ 7 #D '  W "$ -@ F #4 +  T #( ,P Y
M #$ 00 P $L +P!6 "X 8P M ', + "( "P H  K +L *P#J "L _P K /\
M+ #_ '\   !L    70$  %$"  !( P  0 ,  #L"   W    -    #,    R
M  4 ,@ ) #( #0 Q !  ,0 3 #  &  O !T +0 B "P *  K "X *@ U "D
M/0 H $8 )P!1 "8 7@ E &X ) "" ", F0 C +, (@#> "( _P C /\ ) #_
M '<   !E!   5@8  $L'  !""   .@@  #4'   P!@  +04  "P#   K  ,
M*@ ' "D "P I  X *0 1 "@ %0 G !D )@ > "4 )  D "H (P Q "( .0 A
M $, ( !. !\ 6@ > &D '0!\ !P DP ; *P &P#- !L ]@ ; /\ ' #_ ' %
M  !?"   40H  $8+   ]"P  -0L  # +   K"@  * D  "4(   D!P( (P0&
M ",""0 B 0P (@ / "$ $@ @ !8 'P ; !X (  = "8 '  N !L -@ : #\
M&0!* !@ 5P 7 &8 %@!X !4 CP 5 *8 % ## !0 [@ 4 /\ %0#_ &L(  !;
M"P  30P  $(-   Y#0  ,0T  "P-   G#0  (PP  "$,   ?"P$ '@H% !T(
M"  =!@L ' 4- !P$$  ;!!0 &008 !D$'@ 8!", %P0K !8$,P 5!#P % 1'
M !,#5  2 V, $0-U ! "B@ 0 :( #P"\  \ Y0 / /X $ #_ &<+  !7#0
M20X  #X/   U#P  +@\  "@/   D#@  ( X  !T.   ;#0$ &0T$ !@,!P 8
M"PD %PD, !<)#@ 6"1( %0D6 !0)&P 3"2$ $@DH !(),  1"3H $ E%  \)
M4@ ."6$ #0ES  P(B  +")\ "@>W  H&VP *!?8 "@3_ &,-  !3#@  1A
M #L1   R$0  *Q$  "40   A$   '1   !H/   8#P$ %@X$ !4.!P 4#0D
M$PT+ !,,#0 2#!  $0P4 ! ,&0 0#!\ #PPG  X-+P -#3D # U%  L-40 )
M#6  " UQ  8-A@ %#9T ! RT  ,,T@ "#/$  @O_ %\.  !0$   0Q$  #@2
M   O$@  *!(  ",2   >$0  &Q$  !@1   5$ ( %! % !(0!P 1#PD $ \*
M ! .#  .#@X #@\2  T/%P ,$!T #! D  H0+  )$#8 "!!!  803@ %$%T
M Q!O  $0A   $)P   ^T   .U   #O,   [_ %P0  !-$@  0!,  #84   M
M%   )A0  "$3   <$P  &1(  !82   4$0, $A$& !$1"  0$ H #A +  T1
M"P ,$0T "Q(1  H2%0 )$AH "!(A  83*0 %$S,  Q,^  (32P  $UH  !-L
M   3@@  $IL  !*T   1UP  $?4  !'_ %@2  !)%   /14  #,6   K%@
M)!4  !\5   :%   %Q0  !03 0 3$@0 $1(' ! 2"0 .$@D #1()  L3"@ )
M% T !Q4/  86$P $%A@  Q8?  (6)P  %S   !<[   72   %U@  !=J   6
M@   %ID  !6T   5V0  %/<  !/_ %44  !&%@  .A<  # 8   H&   (A<
M !T6   9%@  %A4  !,4 P 2$P8 $!,'  \3!P -% < "Q4(  D6"0 && P
M QH.  $:$0  &A8  !L<   ;)   &RT  !LX   ;1@  '%4  !MG   ;?0
M&Y<  !JS   9VP  &/D  !?_ %$6  !#&   -QD  "X:   F&@  (!D  !L8
M   8%P  %18! !,5!0 1%00 #Q4$  T6!  +%P4 "1D&  8:"  "' H  !X-
M   @$   (!,  " 9   @(0  (2H  "$U   A0@  (5(  "!D   @>@  'Y4
M !^Q   >VP  '?H  !S_ $T9   _&P  -!P  "L<   D'   'AL  !H:   7
M&   %!<" !(7 @ 0& $ #1D!  L: @ (' , !1T$  (?!@  (0@  ",+   E
M#@  )A$  "86   F'@  )R<  "<R   G/P  )DX  "9@   F=P  )9(  "2O
M   CV@  (OL  "'_ $@=   \'@  ,1\  "@>   B'@  '1P  !D;   6&@
M$AH  ! ;   -'   "QT   @?   $(0   2,"   E!   )P8  "D)   L#
M+@\  "X3   N&@  +B,  "XN   N.P  +DH  "U<   M<@  +(X  "NL   J
MU   *?L  "C_ $0@   X(0  +B$  "8A   @(   '!X  !@=   4'0  $!X
M  X?   +(0  !R,   ,E    )P   "D    L 0  +@,  # &   S"@  -0T
M #81   V%P  -A\  #8I   V-@  -D4  #57   U;0  -(D  #*H   QSP
M,/H  "__ #\D   T)   *R0  "0C   ?(0  &R   !8@   1(0  #B,   HE
M   &*    BH    M    +P   #(    T    -P   #D#   [!@  /@H  $ .
M  !!$@  01H  $ E  ! ,0  0$   #]2   ^9P  /8(  #RB   ZQP  .?@
M #C_ #HH   P*   *2<  ",E   ?(P  &"0  !(E   .*   "BH   4M
M,    #,    V    .    #L    ^    0    $(   !% @  1P8  $H*  !-
M#@  314  $P?  !,*P  2SH  $I,  !)80  2'P  $>;  !%OP  0_,  $+_
M #8L   M*P  )RD  ",G   ;*   %"H   XM   *,   !#,    W    .@
M #T   !     0P   $8   !(    2P   $T   !0    4P$  %8&  !9"P
M6Q   %L9  !:)0  630  %A&  !76@  570  %23  !2M0  4.H  $__ #,P
M   L+@  )RP  !XM   6+P  $#(   HV   #.@   #\   !"    1@   $D
M  !,    3P   %(   !5    6    %H   !=    8    &,   !G!@  :PP
M &P2  !K'@  :RP  &D]  !G4@  9FH  &2)  !AJP  7]P  %W_ #$S   L
M,0  (C(  !DU   1.0  "CT   )"    1P   $P   !0    5    %@   !;
M    7P   &(   !E    :    &L   !N    <0   '4   !Y    ?08  ((-
M  ""%@  @"0  'XU  !\20  >V$  'A_  !VGP  <\8  '#W #$V   F.
M'#L  !)    +10   DL   !1    5@   %L   !@    90   &D   !N
M<@   '8   !Y    ?    'X   ""    A0   (D   ".    DP   )@&  "<
M#@  FQH  )@K  "60   DED  )%S  "-E0  B[4  (CH "L^   @00  %4<
M  U-   "5    %L   !A    :    &X   !S    >0   'X   "#    B
M (P   "/    D@   )4   "9    G0   *$   "E    J@   +    "W!P
MN!$  +4A  "R-0  KTT  *II  "HB   IJ@  *+1 "-(   83@  #E0   1<
M    9    &T   !U    ?    (,   ")    CP   )4   ";    H    *,
M  "F    J0   *T   "Q    M0   +D   "^    Q    ,H   #2    V@H
M -86  #2*0  SD$  ,I<  #%?   PIT  ,&] !Q5   17   !V4   !N
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M_O______________________________________________________
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M\O/T]?;W^/GZ^_S]_O]M9G0Q      ,$(0   0                    $
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MH#X:_ZA')O^N433_KUM%_ZUE5_BI;VCMHWAYXYM_A]N2A934BXR>SX61ILN
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MNF.VD;ICMI&Z8[:1NF.VD;K_H!X$_Z$H"/^Q, O[P#D1[,Y"&=_?1RC3Z4Q
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M2%C_D$A8_Y!(6/^02%C_D$A8_Y!(6/^02%C_D$A8_Y!(6/^02%C_D$C$QP<
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MM*Z=A+RFF(K!H)21QIJ1F,F6CZ'+D(NHS(R)K,6,B;# C(FPP(R)L,",B;#
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MK\&"DJ_!@I*OP8*2K\&"DJ_!@I*OP8*2K\'_EQL#_Y4G"/^>+PW_JC@3_[5
M'/^^2"GYR$XZ\\U63>K37&+>SV)XS<=HB[^^;INRMW.HI[!YLIZK?KJ5IX3
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MUG2FFM1QK)[2;[*AT&VYH\]LPZ;%9\.FP&G'H<!IQZ' :<>AP&G'H<!IQZ'
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M?[:XDX"[LI. N[*3@+NRDX"[LI. N[*3@+NRDX"[LI. N[*3@+NRDX"[LI.
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MJZMXIJ*E?JZ9H(2UDIV+NHR:D[Z'F)O A)>EPH"6K\)_DK.\@)&XM8"1N+6
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M-4O_EC5+_Y8U2_^6-4O_EC5+_Y8U2_^6-4O_EC5+_Y8U2_^6-4O_EC6WQ ,
MJ=0" )SY"P*3_QL%A?\C"GG_*0]N_S$49?\Y&%W_01M7_TH>4_]2(%#_62)-
M_V C2_]F)$K_:R5)_V\E2/]S)D?_=R9&_WLG1?]^)T7_@BA$_X<H0_^+*4/_
MBRE#_XLI0_^+*4/_BRE#_XLI0_^+*4/_BRE#_XLI0_^+*4/_BRG_@QP#_X G
M!_][,PW_AC@1_XY &?^322+_E54M_Y-A.?^0;47_BWA/_X:$6?R"CF'W?99H
M]'B=;O%THW/N<:EW[&ZN>NILLWWI:KE_YVC @>9GQX/C9<^%W6/8AM-@VH?3
M8-J'TV#:A]-@VH?38-J'TV#:A]-@VH?38-J'TV#:A]-@VH?_@QP#_X G!_][
M,PW_AC@1_XY &?^322+_E54M_Y-A.?^0;47_BWA/_X:$6?R"CF'W?99H]'B=
M;O%THW/N<:EW[&ZN>NILLWWI:KE_YVC @>9GQX/C9<^%W6/8AM-@VH?38-J'
MTV#:A]-@VH?38-J'TV#:A]-@VH?38-J'TV#:A]-@VH?_@QP#_X G!_][,PW_
MAC@1_XY &?^322+_E54M_Y-A.?^0;47_BWA/_X:$6?R"CF'W?99H]'B=;O%T
MHW/N<:EW[&ZN>NILLWWI:KE_YVC @>9GQX/C9<^%W6/8AM-@VH?38-J'TV#:
MA]-@VH?38-J'TV#:A]-@VH?38-J'TV#:A]-@VH?_@QP#_X G!_][,PW_AC@1
M_XY &?^322+_E54M_Y-A.?^0;47_BWA/_X:$6?R"CF'W?99H]'B=;O%THW/N
M<:EW[&ZN>NILLWWI:KE_YVC @>9GQX/C9<^%W6/8AM-@VH?38-J'TV#:A]-@
MVH?38-J'TV#:A]-@VH?38-J'TV#:A]-@VH?_@QP#_X G!_][,PW_AC@1_XY
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M6E3[L5M4^[%;5/NQ6U3[L5M4^[%;5/NQ6U3[L5M4^[%;5/NQ6U3[L5OPKP@
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MB723V(G_?!@"_X0< _^5'P/_HR4$_Z\L!O>Z,PGLQ#L/XLY"&-/.2"S&QU)
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M:$WHZ&A-Z.AH3>CH:$WHZ&A-Z.AH3>CH:$WHZ&C_F0L W:X$ ,R\!@#!R0<
MN-L* *WX' 2D^"\-F?@Y%X_X/R&%^$8J?/A-,G7W5SEN]V _:?=I0V3X<4=A
M^'E*7?B!3%KXB4]8^))15OF;4E/YI511^J]54/J[5D[ZRE=-^^-73/OI5TS[
MZ5=,^^E73/OI5TS[Z5=,^^E73/OI5TS[Z5?EI0  SK0$ +^_!0"TS@8 JNL-
M :#_'P:7_R\-C/\V%8+_/1UX_T0D</],*FK_5"]E_UXS8?]G-UW_;SE:_W8\
M6/]^/E;_AC]3_XY!4?^70E#_H$-._ZE%3?^S14O_OD9*_]!'2?_<1TG_W$=)
M_]Q'2?_<1TG_W$=)_]Q'2?_<1TG_W$?1K@  O[D# ++% P"GU04 G/T/ I3_
M(@:)_RL,?O\R$G7_.AAL_T(=9?])(E__425:_UHH5_]C*U3_:RU2_W(O4/]Y
M,$__@#%-_X@R2_^0-$K_F#5(_Z$U1_^J-D;_LS=$_[\X1/_%.$3_Q3A$_\4X
M1/_%.$3_Q3A$_\4X1/_%.$3_Q3C!LP  LKX" *7, 0"9W0, D/\2 H;_'P5[
M_R<*<?\N#FC_-A-A_SX76O]&&E7_31U1_U4?3O]=($O_9"))_VLC1_]Q)$;_
M>"5$_W\F0_^&)T'_CBA _Y8H/_^>*3W_IRD\_[ J//^T*CS_M"H\_[0J//^T
M*CS_M"H\_[0J//^T*CS_M"JSN $ I<8  )?5  "+[P0!A/\3 G?_&@1M_R('
M9/\J"US_,@Y5_SD14/]!$TO_2!5(_T\71?]6&$+_7!E _V$:/O]G&CS_;1L[
M_W,<.?]Y'#C_@!TV_X@=-?^/'C3_EQXR_Z ?,O^D'S+_I!\R_Z0?,O^D'S+_
MI!\R_Z0?,O^D'S+_I!^FP   E\X  (G>  !__P<!=/\0 FG_%0-?_QP%5_\D
M"%#_+ I*_S,,1?\[#D'_00\]_T<0.O]-$3C_4A$V_U<2-/]<$S+_81,Q_V84
M+_]K%"[_<14M_W<5+/]]%2K_@Q8I_XL6*?^.%BG_CA8I_XX6*?^.%BG_CA8I
M_XX6*?^.%BG_CA;_9B #_V$J!?]A,PC_:38+_VX]#_]Q1A7_<U$<_W->(_]P
M;2G_;GPP_VN)-?]IECG_9Z$]_V:J0/]DLD+_8[E$_V'"1O]@R$?_7LU(_US4
M2O];WDO[6>1,]UCJ3/17[TWP5O--[%7X3>Q5^$WL5?A-[%7X3>Q5^$WL5?A-
M[%7X3>Q5^$W_9B #_V$J!?]A,PC_:38+_VX]#_]Q1A7_<U$<_W->(_]P;2G_
M;GPP_VN)-?]IECG_9Z$]_V:J0/]DLD+_8[E$_V'"1O]@R$?_7LU(_US42O];
MWDO[6>1,]UCJ3/17[TWP5O--[%7X3>Q5^$WL5?A-[%7X3>Q5^$WL5?A-[%7X
M3>Q5^$W_9B #_V(J!?]C,0C_:S4+_W \#_]S117_=4\<_W9=(_]S;"K_<'HQ
M_VV'-O]KE#O_:9\__VBH0O]FL$7_9+A'_V/ 2?]AQTK_7\Q,_UW33?Q<WD[Y
M6N1/]5GJ4/%8[U'M5_11Z5?Y4.E7^5#I5_E0Z5?Y4.E7^5#I5_E0Z5?Y4.E7
M^5#_9Q\#_V,J!?]E, C_;C,+_W0Z#_]W0Q7_>4X<_WI:)/]W:"O_='8S_W&$
M.?]ND#__;)M#_VJE1_]HK4K_9[9,_V6^3O]CQ5#_8<M2_5_25/E=W57T6^16
M\%KJ5^M8\%CG6/57XUGZ5.-9^E3C6?I4XUGZ5.-9^E3C6?I4XUGZ5.-9^E3_
M:!\#_V,I!?]H+@?_<3(*_W<X#_][0A7_?4P<_WY8)/][9BW_=W,U_W2 //]Q
MC$+_;Y='_VRA2_]JJD__:+)2_V>[5/]EQ%;^8LI8^6#16O5>W%SP7.1=ZEKK
M7N99\5_B6O5;W%OY5]Q;^5?<6_E7W%OY5]Q;^5?<6_E7W%OY5]Q;^5?_:1X#
M_V0I!?]K+0?_=# *_WLW#O]_017_@4H<_X)5)?]_8R[_>W V_WA\/O]UB47_
M<91+_V^>4/]LIE3_:JY8_6BW6_QFP%WZ9,E@]6'08O!>W&/J7.5EY5OL9MY:
M\&/86_1@T5WX6]%=^%O17?A;T5WX6]%=^%O17?A;T5WX6]%=^%O_:1X#_V4H
M!?]N*P?_>"X*_W\V#O^#/Q3_A4@<_X=3)?^$8"__@&PX_WQY0?]XA4G^=)!0
M^W&95OENHEKX:ZI?]FBR8O1FNV7S9,5H\&+0:^I?W6WC7>=NVUOJ;=-<[VC-
M7O-DR%_W7\A?]U_(7_=?R%_W7\A?]U_(7_=?R%_W7\A?]U__:AX#_V8H!?]Q
M*0?_>RP)_X,U#?^'/A3_BD<;_XQ0)?^)72__A6DZ_8%U1/I\@$WW>(M5]'.5
M7/%OG6+O;*5G[6FM:^MFMF_H8\!RYF',=>-@WW?67.1XSE[I<LE?[6W$8/!H
MOV+T8[]B]&._8O1COV+T8[]B]&._8O1COV+T8[]B]&/_:QT#_V<G!?]T)P;_
M?RL(_X<S#?^,/!/_CT4;_Y%.)?^/6C#\BV8[^(9Q1O.!?%'O?(=:[':08NAQ
MF&GE;*!PX6BH==YDL'K;8KI^V&''?]1AVG_+7^%^Q&'E=[]BZ7*[8^UMMF3Q
M9[9D\6>V9/%GMF3Q9[9D\6>V9/%GMF3Q9[9D\6?_;!T#_VHF!?]W)@;_@BH(
M_XHR#/^0.Q+_DT,:_Y9,)/V55S#WD6(\\HQM2>R&>%3G?X%?XGB*:=QRDG+6
M;9IXTFJB?,YGJW_+9K2!R66_@\=DSH3!8]V#NF3B?+9FYG:R9^IQKFCO:JYH
M[VJN:.]JKFCO:JYH[VJN:.]JKFCO:JYH[VK_;1P#_VPD!?]Z) 7_A2D'_XXQ
M"_^4.1'_F$(9_YM*)/B;5##REU\]ZY)J2^6*<UC>@GQDU7R%;L]VC77*<I5Z
MQFZ=?L-LI8*_:J^$O6FYAKIHQX>W:-J'L6C>@:UIXWJI:^ATIFOL;:9L[6VF
M;.UMIFSM;:9L[6VF;.UMIFSM;:9L[6W_;1P#_VXC!/]](@7_B"@'_Y$P"O^8
M.!#_G$ 8^Y])(_2A4B_MG5P]Y99F3-V.;UK3AWAES(&!;L9[B7;!=Y%[O'.9
M@+APH82U;JJ'LFVTB:]LP8JM;-**J&S<A:5MX7ZB;N5WGV_K<)]OZW"?;^MP
MGV_K<)]OZW"?;^MPGV_K<)]OZW#_;AP#_W$B!/]_(07_BR<&_Y0O"?^;-P__
MH#\7^*1'(?"G3R[HHEH]WYMC3=24;%K+C'5EQ(9];[Z A7:X?(U\LWB5@:]U
MG86K<J6)J'&OBZ5PNXRC<,N-H''9B)UQWX&;<N1ZF7/I<IESZ7*9<^ERF7/I
M<IESZ7*9<^ERF7/I<IESZ7+_;QL#_W,@!/^"( 3_CB8&_Y<N"/^?-@[]I#X5
M]*A&(.RL32WCIU@\V:!A3,V8:EG%D7)EO8MZ;K:%@G:P@(E]JWV1@J=YF8:C
M=Z**GW6KC9QTMXZ:=,:/F'76BY9VW8.4=N)\DW;G=))VZ'22=NATDG;H=))V
MZ'22=NATDG;H=))VZ'3_;QL"_W4?!/^$'P3_D"4%_YHM"/^B-0SZJ#T4\:Q%
M'NBP3"O?JU<[TJ1?2\B<:%F_E6]DMX]W;K"*?W:JA89]I(&.@I]^EH>;>YZ+
MEWFHCI1XLX^2>,*0D7K5C8]ZVX6.>N%^C7KF=HUZYG:->N9VC7KF=HUZYG:-
M>N9VC7KF=HUZYG;_<!L"_W8> _^&'@3_DR4%_YTL!_^E- OWJSP2[K%#'.6T
M2RG:KU4ZS:A>2L*@9EBYFFUDL9-U;JJ.?':CBH-]GH:+@IF"DX>4@)N+D'ZE
MCHU]L)"*?;Z1BG_3CXE^VH>(?M]_AW[E=X=^Y7>'?N5WAW[E=X=^Y7>'?N5W
MAW[E=X=^Y7?_<!L"_W@= _^('@/_E20$_Z K!O^H,@KTKSH1Z[5"&N&X2B?4
MLU,YR*M<2;ZD9%>TGFMCK)AR;:23>76>CH%\F(N(@I*'D(>-A9F+B8.BCH:"
MKI&#@KR1@H/.D8.#V8B"@M^!@H+D>8*"Y'B"@N1X@H+D>(*"Y'B"@N1X@H+D
M>(*"Y'C_<1H"_WH< _^*'0/_ER,$_Z(I!?RL,0GQLSD/Z+I %]V\2"7/ME(X
MPZ];2+FH8E:OHFIBIYQP;)^7=W68DWY\DI"&@HR-CH>'BI>+@XB@CG^'JY%\
MA[F1>X?+D7R(V(E]A]Z"?8;D>GV&Y'E]AN1Y?8;D>7V&Y'E]AN1Y?8;D>7V&
MY'G_<1H"_WP: _^-' /_FB(#_Z4H!/FO+P?NN#<,Y+\_%-C 1B3*NE WO[-9
M1[2L856JIFAAH:%N:YF<=722F'Q[C)6#@8:2BX:!D)2+?(Z>CGB-J9!VC+:1
M=(W(D7:.V(IWC-V"=XKC>G>*XWIWBN-Z=XKC>G>*XWIWBN-Z=XKC>G>*XWK_
M<AH"_W\9 O^/&P+_G2 #_ZDF _:S+07JO34)X,8\$-+$1"/%O4\UNK=81J^Q
M7U2EJV9@G*9M:I2B<W.,GGIZAIN!@("8B85ZEI*)=92;C7*3IH]OD[20;93%
MD'"5V(IPDMV#<9#C>W&0XWMQD.-[<9#C>W&0XWMQD.-[<9#C>W&0XWO_<QD"
M_X(7 O^2&@+_H!\"_ZTD O*X*@3FPS$&V\PU#\S(0B' PDTTM+Q61*FV7E*?
ML61>EJQK:(ZI<7&&I7AX?Z)_?GF@AX-TG8^(;YR9BVN;I(UHF[*.9YO"CFF=
MV(IJF=V":Y;C>VN6XWMKEN-[:Y;C>VN6XWMKEN-[:Y;C>VN6XWO_=!D"_X45
M O^6& '_I!P!^[(@ >V_)0+AS"H#U-$R#<?,01^ZQTPQKL%40J.\7%"9MV)<
MD+-I9H>P;VZ K79U>:I]>W.HA(!MIHV%:*67B&6DHXIBI+"+8*3!BV*FV8AC
MHMZ!99[C>F6>XWIEGN-Z99[C>F6>XWIEGN-Z99[C>F6>XWK_=A@"_XD3 ?^:
M%@'_J1@!]K@; >?'&@';V1P!S=8P"\#2/QVTS4HOJ,A2/YW#6DV2OV%8B;MG
M8H"X;6MYMG1Q<K-[=VRQ@WQGL(R 8J^6@UZNH89<KJ^'6J^_AUNPVH1=K.!_
M7J?E>%ZGY7A>I^5X7J?E>%ZGY7A>I^5X7J?E>%ZGY7C_>A4"_XX2 ?^?$P#_
ML!, [\ 0 -G4# #.WQP!Q-TO";G9/1JMTT@LH<]0.Y7+6$F+QU]4@L1E7GG"
M;&9RP')L:[YZ<F:]@G9ANXMZ7+N5?5FZH7]7NJ^ 5;N_@%6\V7]6N.-Z6++G
M=5BRYW18LN=T6++G=%BRYW18LN=T6++G=%BRYW3_@!(!_Y00 /^F#P#CN L
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M, U=_S@05_] $U'_1Q9-_TX82O]6&4?_7!I$_V,<0O]I'4#_<!X__W@>/?^
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M<6J4[6QJE.UL:I3M;&J4[6QJE.UL:I3M;&J4[6S_<18"_X,1 ?^4$P'_HA0
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M85&]]6%1O?5A4;WU85&]]6'_A@H \)H$ -2J! #(M@8 OL$% +?/"0"PXQ$
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M$B7_D!,D_YD3(_^C%"+_JQ0B_ZL4(O^K%"+_JQ0B_ZL4(O^K%"+_JQ2<O@
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M9GJ"]U]Z@OA>>H+X7GJ"^%YZ@OA>>H+X7GJ"^%[_9Q<"_W<1 ?^'$P'_E!4
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M7F*9]UYBF?=>8IGW7F*9]U[_<Q !_X4, /J6"@#;I08 T;$( ,N[" #&QPL
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M*CW\N2L[_<LK._WB*SK\]"LZ_/<K.OSW*SK\]RLZ_/<K.OSW*SK\]RN]J
MKK   *&\  "5R   B=0  '[H!0!W_Q(!;_\< F?_)@5@_R\(6?\W"U3_/PY/
M_T<12_].$T?_5A5$_UT60O]D&$#_;!D]_W4:._]^&SG_B1PW_Y0=-O^@'C7_
MK!\S_[D?,__('S+_XB R_^<@,O_G(#+_YR R_^<@,O_G(#+_YR"PK0  HK<
M )7$  "'T   >]T  '+]"0!J_Q$!8?\9 EK_(@-4_RH%3O\R!TG_.@E%_T$+
M0?](##[_3@X[_U4/./];$#;_8A$T_VD1,O]R$B__>Q,M_X84*_^2%2K_GA4I
M_ZD6*/^S%B?_PA8G_\<6)__'%B?_QQ8G_\<6)__'%B?_QQ:DM   EL   (?,
M  !ZV@  ;>L  &3_!0!<_PX!5/\4 4W_' )(_R0$0O\L!3[_,P8Z_SD'-O]
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M ?]S%0'_?AH!_X<@ O^-)P/TDB\&ZI0X"^&40A/6CTX@S(E9+<6#8S>^?6M
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M6(IV_U*)=O].B7;_3HEV_TZ)=O].B7;_3HEV_T[_7Q<!_VX1 ?][$@'_AQ0
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M4G.%_U)SA?]2<X7_4G.%_U+_:!$!_W@- /^&#0#VDPP WJ ) -:I"@#2L@T
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M2$;*R$A&RN9'1\GW14?(_T-(Q_]"2,?_0DC'_T)(Q_]"2,?_0DC'_T+>C0
MRYP  +VG  "QL   IKH  )S$ P"3SP< BMT, (7?'0%^WRP%=MXW"V_>0Q-H
MW4T:8MQ5(%W;7298VV4J5-IM+E#:=C)-VH U2MJ+-T?:ESE%VJ0[0]NT/$+<
MR#Q"V^4[0MKT.D+9_CI#V/\Y0]C_.4/8_SE#V/\Y0]C_.4/8_SG0E@  P:,
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M&"S_X1@L_^\8+/_O&"S_[Q@L_^\8+/_O&"S_[QBKJP  GK4  )#!  ""S
M==D  &GD  !A_PD 6_\1 %3_&0%._R("2?\K!$3_,@5 _SH&//]!!SG_1P@V
M_TX),_]4"C'_6PLN_V(,+/]K#"G_=0TG_X .)?^-#B3_F@\C_Z80(O^S$"'_
MP1 A_] 0(?_0$"'_T! A_] 0(?_0$"'_T!"?L@  D;X  (/*  !UU@  9^(
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M/\D=_S_6'?\_Y1W_/^\=_S_W'O\__AW_/_\=_S__'?] _QS^0/\;_D#_&_Y
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M1()X_T2">/]$@GC_1()X_T3_7Q$!_VT, /]Z#0#_A0T \H\- .>8#0#;GPX
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M4U.?P%-2G]U259_S3E>@_TI9H/]&69__15F?_T59G_]%69__15F?_T7_=0
MX(8  ,^3  #$GP$ NJ<! +&N  "IM@  H;T- )N]( &4O#$'B[H]$(.W2!I\
MM5 B=;-8*F^R7S!JL&8V9:]M.V"M=3]<K'Y#6*N'1U6JDTI1JI],3ZJN34VJ
MP$U-JMQ-3JKR25"J_D92J?]#4JG_0E*I_T)2J?]"4JG_0E*I_T+R?   UXP
M ,B9  "]HP  LJL  *FR  "@NP( E\0) )+%&P"+Q"P$@\(Z#'O!1!5TOTX=
M;KU6)&B\72ICNV0P7[IL-%JY=#E6N'P\4[>'/T^WDD),MI]$2K:M1DBVP$9(
MM]U%2;;R0TJU_T%+M?\^2[3_/4NT_SU+M/\]2[3_/4NT_SWB@P  S9(  ,&?
M  "TIP  JJ\  *"X  "6P , C,H' (;-% "!S28">LPU"'/+00]LRDH79LE3
M'6'(6R-<QV(H6,9J+%3&<C!0Q7PS3<6&-DK$DCE'Q)\[1<2N/$3%P3Q#Q=\\
M1,3S.T3#_SE%PO\W1<'_-T7!_S=%P?\W1<'_-T7!_S?5BP  Q9H  +>D  "K
MK   H+0  ):^  "+QP0 @= ( 'C9#@!UV2 !;]@O!&G8/ ECUD807M90%5G5
M6!I5U& ?4=1H(D[4<29+TWLI2-.%*T73DBY"U)\O0=2O,#_5PC$_U>$P/]/R
M,#_2_2\_T?\N/]#_+C_0_RX_T/\N/]#_+C_0_R[*E   NZ$  *VI  "BL0
MEKL  (O$  " S0, ==@( &_D$0!JY" !9.0M U[D. =9Y$$+5>1+#U'D5!)-
MY%T62N1E&$?D;AM%Y'<=0N2"'T#DCB$^Y9LC/.6J)#OFO"0ZYM,D.>7N)#GC
M^B,YXO\D.>+_)#GB_R0YXO\D.>+_)#GB_R2_G@  KZ8  *.N  "7N   BL(
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M"QK_WPL:_]\+&O_?"QK_WPN;L0  C;P  '['  !PT@  8]X  %7D  !+]0
M1O\% $#_#@ [_Q0 -_\; 3/_(P$O_RD"*_\P BC_-0(E_SL#(O]! Q__1P,=
M_TX#&O]5!!C_7@05_V@%$_]T!1'_@@40_Y &$/^=!@__J08._[4&#O^Z!@[_
MN@8._[H&#O^Z!@[_N@:.N@  ?\4  '#1  !BW@  5.4  $;K   __@  .?\
M #3_"0 O_PX *_\4 "?_&@$C_R$!'_\E 1S_*@$9_R\!%O\T A3_.@(1_T "
M$/]& @[_3@(,_U8""?]@ P?_; ,$_W@# _^& P+_D0,!_YT# ?^A P'_H0,!
M_Z$# ?^A P'_H0/_-BT"_SDN O\^+@/_0#(#_T X!/\^00;_/$P(_SI:"O\X
M: S_-G8._S6##_\TCQ#_,YD1_S.A$?\SJ1+_,K 2_S*W$O\ROQ+_,L@3_S+3
M$_\RXQ/_,NT3_S+V$O\S_A+_,_\2_S/_$O\S_Q'_,_\1_S/_$/\S_Q#_,_\0
M_S/_$/\S_Q#_-BT"_SLL O] + /_0R\#_T,U!/]"/@;_0$H(_SY7"_\\90W_
M.G,/_SB $/\WC!'_-Y82_S:?$_\VIQ/_-JX4_S:U%/\VO!3_-<45_S70%?\U
MX!7_-NL5_S;T%?\V_13_-O\4_S;_%/XW_Q/^-O\3_3;_$OTV_Q+]-O\2_3;_
M$OTV_Q+_-RP"_SXJ O]#*@+_1BT#_T<R!/]&/ ;_14@(_T-5"_]!8@W_/W 0
M_SU]$?\\B1/_.Y,4_SN<%?\ZI!;_.JL6_SJR%_\ZN1?_.<(7_SG,%_\YW1C_
M.>D8_SGS&/\Z^QC\.O\7^CK_%_DZ_Q;X.O\6^#K_%?@Z_Q7X.O\5^#K_%?@Z
M_Q7_.2L"_T$G O]&)P+_2BD#_TLO!/],.0;_2T4(_TA1"_]&7@[_1&P1_T)Y
M$_]!A17_0(\7_T"8&/\_H!C_/Z<9_SZN&O\^MAK_/KX;_S[(&_\]UAS^/>8<
M^S[Q'/@^^ASU/O\<\S[_&O(__QGQ/_\9\3__&/$__QCQ/_\8\3__&/$__QC_
M/2@"_T4D O]*(P+_3B4#_U$L!/]2-@;_44$(_T]-#/],6@__2F<2_TAT%?]'
M@!?_1HL9_T64&_]$G!S_0Z0=_D.K'OU"LA_\0KH@^D+$(/E"T"'V0>(A\D+N
M(N]"^2+M0O\@ZT/_'^I#_QWI1/\<Z$3_&^A$_QOH1/\;Z$3_&^A$_QO_0"4"
M_T@A O]/( +_4R$"_U<I _]9,P7_6#X(_U9)#/]251#_46,4_T]O%_Y->QK[
M2X8=^4J/'_=)F"'V2)\B]$>F)/-'KB7Q1K8F\$:_)^]%RRCL1=XIZ$7L*>5&
M^"CB1_\FX4C_)-])_R+>2?\@W4G_']U)_Q_=2?\?W4G_']U)_Q__0R("_TP>
M ?]3' +_61X"_UTF _]?, 3_7SH'_UU%"_]:4!#]6%X5^%5J&?53=AWR48 A
M[T^*).U-DR;K3)HIZ4NB*^=*J2SE2;$NY$B[+^)(QS'@2-DQW$CJ,=A)]B[4
M2_\KTDS_*=!-_R;/3O\ESD[_(\Y._R/.3O\CSD[_(\Y._R/_1Q\!_U : ?]7
M& '_7AP!_V,C O]F+ 3_9C8&_V1!"OIB3 _T7UD5[UQE&^M9<"#G5GLEY%2$
M*>%1C2W>4)4PW$^=,ME.I3/63:TUTTVW-M%,PC?/3-$XS$SF.,E-]#7'3_\Q
MQ5'_+L12_RO#4_\IPE/_)\)3_R?"4_\GPE/_)\)3_R?_2AP!_U07 ?]<%0'_
M8QD!_VD@ O]L*0/_;3(%^6P]"?)I1P[K9E05Y6-@'.!?:R+;7'4HUEE_+=)7
MB##/59 SS%28-LI3H#C'4J<ZQ5&P.\-0NSS!4,D]OU#?/;Q1\#NZ4_PWN57_
M,[A7_R^W6/\MMUC_*[=8_RNW6/\KMUC_*[=8_RO_31H!_U<4 ?]@$@'_:!<!
M_VX= ?]R)0+[<RX#\G,X!^EQ0PWB;E 4VVE<'--E9B3.8G JR5]Z+\9<@C/#
M6XHVP%F2.;U8FCN[5J(^N%6K/[95M4&T5,)"LE340K!5ZD&N5_D\KEG_-ZU;
M_S.M7/\PK5W_+JU=_RZM7?\NK5W_+JU=_R[_4!<!_UH2 ?]D$ #_;10 _W,:
M ?]W(0'T>2D"ZGHS!>)X/PK9=$P3SW!8',EK8B3$:&PKOV5U,+MB?36X8(4X
MM5Z-/+)<E3ZO6YU!K5JF0ZM9KT2I6;Q%IUC,1J18Y4:D6_9 HU[_.Z-?_S>C
M8/\SHV'_,:-A_S&C8?\QHV'_,:-A_S'_4Q4!_UT0 /]H#P#_<!( _W<6 /M\
M' 'N?R0!Y( M ]I_.PC/>DD2QW54&\%Q7R2[;6@KMFIP,;)G>3:O98 ZJV.(
M/:AAD$"F8)A#HUZA1:!>JT>>7;=(G%W&29I<WTF:7_)$FF+_/IIC_SF;9?\V
MFV7_,YME_S.;9?\SFV7_,YME_S/_51,!_V . /]K#@#_=!  _WL2 /6!%P#H
MA!X WH<G =&$-P?(?T81P'M1&[EV6R.T<F4KKV]M,:IL=3:G:GPZHVB$/J!F
MC$&=9)1$FF.=1Y=BITF58;)+DV'!3)%AV$R18^]'DF7]09)G_SR3:?\XDVK_
M-9-J_S63:O\UDVK_-9-J_S7_5Q$!_V,- /]N# #_=PX _W\/ /"%$0#CB18
MUHLC <N(-0;"A$,0NH!/&K-[62.M=V(JJ'1J,:-Q<3:?;GD[G&R!/YAJB$*5
M:9%%DF>:2(]FHTJ-9:],BF6]38EET4Z)9^Q*BFG[0XMK_SZ,;?\ZC&[_-XQN
M_S>,;O\WC&[_-XQN_S?_61  _V4+ /]Q"P#_>@L \8(, .B)#0#=C@X SX\@
M <:-,@:]B4$/M81-&:Z 5B*G?%\JHGAG,)UU;S:9<W8ZE7%]/Y)OA4*.;8Y&
MBVR628AJH$N%:JQ-@VFZ3X%IS$^!:NA,@VWY181O_S^%</\[AG'_.(9Q_SB&
M<?\XAG'_.(9Q_SC_6P\ _V<( /]S" #S?0@ WH8' -F,"0#5D0L RI(> ,&0
M, 6XC3\.L(A*&*F$5"&B@%TIG7UE,)AZ;#63=W,ZCW5[/HQS@D*(<HM&A7"4
M28)OGDQ_;JE.?&VW3WMMR5!Z;N9-?''X1GYS_T%_=/\]@'7_.H!U_SJ =?\Z
M@'7_.H!U_SK_70X _VH& /]V!@#D@ , V8D& -*/" #/E H Q98; +R4+@2S
MD3T-JXU(%Z2(4B">A5LHF(%C+Y-^:C6.?'$YBGIX/89X@$*#=HA%?W6127QS
MFTQY<J=.=G*U4'1RQE!T<N-/=G7V1WAW_T)Z>/\^>WG_.GMY_SI[>?\Z>WG_
M.GMY_SK_7PP _VP$ /5Y @#>@P( TXL% ,V2!P#)EP@ P)D9 +>8+ .OE3L,
MIY%'%I^-4!^9B5DGDX9A+HZ#:#2)@6\YA7]V/8%]?D%]>X9%>7J/279XF4QS
M=Z5.<'>R4&YWQ%!M=^!/<'GU2')[_T-T?/\^=7W_.W5]_SMU??\[=7W_.W5]
M_SO_80H _V\" .A\  #9A@$ SXX$ ,B5!@##F@8 NYP6 +.<*@.JF3D+HI5%
M%)N13AV4CE<FCHM?+8F(9C.$AFTX@(1T/7N">T%W@(1%='^-2'!]ETMM?*-.
M:GRP3VA\P5!G?-U0:G[S26V _T-N@?\_;X'_/&^!_SQO@?\\;X'_/&^!_SS_
M9 @ _W(  .%_  #3B0$ RI(# ,.8! "]G@0 MJ 3 *Z@)P*EG38)G9I#$Y:7
M31R/DU4DB9%=*X2.9#%_C&LW>HIR.W:(>4!RAH)$;H6+1VJ#E4IG@J%-9(*N
M3V*"OT]A@MI/9(3R26:%_T-HAO\_:H;_/&J&_SQJAO\\:H;_/&J&_SS_9P0
M]G8  -R"  #.C0  Q94" +Z< P"WH0( KZ01 *BD) *@HC0(F)] $9&<2AJ*
MF5,BA)=;*7Z58C!YDFDU=9!P.G"/=SYLC7]":(R)1F6*DTEAB9]+7HFL35V)
MO4Y<B=9-7HKP2&"+_D-BB_\_8XS_/&.,_SQCC/\\8XS_/&.,_SS_:@  YGH
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M/TVE_#Q.I/\Y3Z3_-T^D_S=/I/\W3Z3_-T^D_S?D>@  SXD  ,*5  "VGP
MK*4  **L  "8LP  CKL" (B]$@"#O24!?+PS!G:[/PUONDD4:KA1&F6W61]@
MMF D7+5G*5BT;RQ4LW@P4;.",TVRC39*LIHX2+&H.D:RN3I%LM$Z1K'M.4>P
M_#9'L/\T2*__,TBO_S-(K_\S2*__,TBO_S/;@@  QY   +N<  "NHP  I*H
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M&S3<_QLTW/\;--S_&S3<_QNYG   JJ0  )ZK  "2M0  A;X  'G'  !MSP
M8M8# %CA" !5ZA, 4>L@ $WK*P%)ZS4"1>P^!$+L1P4_[$\'/>U8"3KM8 HX
M[6H,-NYT#3/N@ XR[HX/,.^=$"[OK1$M\, 1+?#>$2SN\1$L[/X1+.O_$"SK
M_Q LZ_\0+.O_$"SK_Q"MH@  H*D  ).S  "&O0  ><8  &S/  !@V   5=X
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M PC_P@.*N   >\,  &S.  !>VP  3^(  $+G   V[   ,?\  "S_   G_P<
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M1'%NP$5P;ME%<G#Q/W-R_SEU<_\U=G3_,79T_S%V=/\Q=G3_,79T_S'_708
M_VD  .)T  #4?0  RX4" ,2*! "_C04 MX\3 +"/)@&HC34'H(I"#IJ&3!:3
M@U4=CH%=)(E^9"F%?&LM@7IR,GUX>35Z=X(Y=G:+/'-UE4!P=*!";7.M1&MS
MO45J<]5%;'3O0&YV_CIO=_\V<7C_,G%X_S%Q>/\Q<7C_,7%X_S'_7P( ]VP
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M/UR&^SI>AO\V7X?_,E^'_S)?A_\R7X?_,E^'_S+]:   X'8  ,V"  #"C
MN9,  +"9  "HG0  GZ ) )FA&@"3H"L#C)\X"(6=0Q!_FDP7>9A4'7277")P
ME6,G:Y-J+&>2<3!DD7DS8(^"-UR.C3I9C9D]5XVF/U2-MD!3C<M 5(WI/5:-
M^CE7C?\U68[_,EF._S%9CO\Q68[_,5F._S'M;0  V7L  ,B'  "]D   M)@
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M*42J_RE$JO\I1*K_*42J_RG1@   P8T  +68  "IGP  GJ4  ).L  "(L@
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M"B;F_PJHH   G*<  (^P  ""N0  =,(  &C*  !;T0  3]<  $7=   ^[@D
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M 07_= $#_X4! O^6 0'_I@$ _[4! /_& 0#_R@$ _\H! /_* 0#_R@&&MP
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M-X)>PC> 7MPX@%_R,X%A_RV"8O\I@F/_)H)D_R6"9/\E@F3_)8)D_R7_4P8
M_UT  .=G  #;;P  T'0" ,IX!0#&>0< OGH5 +9Z* &O>#<%J'9$"Z)S3A*<
M<%<8F&U?'91K9R&0:FXEC6AU*(IG?2N'984NA&2.,8%CES1_8J(V?&*O.'IB
MOCEY8M4Y>6/O-'IE_B][9O\K?&?_*'QG_R9\9_\F?&?_)GQG_R;_50, _V
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M-VEQ^C)K<O\M;'/_*FQS_RAL<_\H;'/_*&QS_RC_7   YV@  -5S  #)>P
MP((  +B&  "QB   J8D- ***'0"<B2X"E8<[!X^%10Z)@D\4A(!7&7]^7AY[
M?&4B>'ML)G1Y<RIQ>'LM;G>$,&MVCC-H=9HV972F.&-TM3EA=,DZ873G.&-V
M^3)E=O\N9G?_*V=W_REG=_\I9W?_*6=W_RG_7P  XVP  -!V  #%?P  O(4
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M*56(_RA5B/\H58C_*%6(_RCF:P  T'@  ,*#  "WC   K9(  *.6  ":F@
MCIX  (>?$ "#GR  ?I\O GB=.P=SG$4,;IM-$6F9519EF%P:89=C'EZ6:B%;
ME7(E5Y1\*%23ABM1DI(N3I*@,$R2KS%+DL(Q2I'@,4R1]2U-D?\J3I#_*$Z0
M_R9.D/\F3I#_)DZ0_R;><   R7T  +R)  "RD@  IY<  )V;  "3GP  AJ0
M 'ZF# !ZIAL =:8J 7"F-P1LI4$)9Z-*#6.B4A)?H5D66Z%A&5B@:!U4GW @
M49YZ(TZ=A"9+G9$I2)R>*D:<KBQ%G,$L19S?*T6;]"E&FO\G1YK_)4>:_R1'
MFO\D1YK_)$>:_R34=P  PH0  +:/  "KE@  H9P  ):@  "+I0  ?ZH  '2N
M!0!OKQ0 ;*\D &BO,@)DKCT%7ZU&"5NL3PU8K%815*M>%%&J9A=.JFX:2ZEX
M'4BI@R!%J(\B0ZB=)$&HK25 J, E/ZC?)3^F]"- I?\B0*7_(4"D_R! I/\@
M0*3_($"D_R#*?@  NXL  *^5  "DFP  F:$  (ZF  ""K   =[$  &JV  !C
MN X 8;@= %ZX+ %:N#@"5[A"!5.X2PA0MU,+3;=;#DJV8Q!'MFL31+5U%D*U
M@1@_M8X:/;6<'#NUK!PZM< =.;7?'#FS]!PYLO\<.;'_&SFP_QLYL/\;.;#_
M&SFP_QO!A@  M),  *>:  "<H   D:<  (6M  !YLP  ;;@  &*] 0!6P@<
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M R/EH00BY;0$(>7-!"#D[ 0@XOL$'^'_!1_@_P4?X/\%'^#_!1_@_P6DG@
MF*4  (NN  !]M@  <+X  &/&  !6RP  2]   $#5   VW   +^4' "WM$  K
M[A@ *>XB "?O*P E[S0 (_ \ "'P10 ?\4X '?)8 1OR9 $9\W$!&/.! 1?T
MD@(5]*4"%/6Z A/UU@(3].\"$O+\ A+P_P(2\/\"$O#_ A+P_P*:I   C:T
M '^V  !QOP  8\<  %;.  !)TP  /=H  #/?   JXP  )O0% "3[#0 A_!,
M'OT; !S](@ 9_BD %_XQ !7_.0 3_T$ $?]* !#_50 ._V$ #/]O 0S_@ $*
M_Y,!"?^F 0C_N@$'_]0!!__K 0;_]@$&__8!!O_V 0;_]@&/K   @+8  '*_
M  !CR0  5M$  $C8   [W0  ,.(  ";F   ?\   '/\  !G_"0 6_PX %/\3
M !'_&0 /_QX #?\D  O_*P )_S( !O\[  /_1   _T\  /]<  #_:P  _WT
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M)9E,R":63.(FE4[U(I1/_Q^44/\<E%'_&I11_QB44?\8E%'_&)11_QC_20@
M_U   /M8  #E7@  W6(# -9C!P#480H RF(9 ,)C+ &[8CL#M&!("*]=4PRJ
M6UP1IEID%:-8;!B@5W0;G55['9M4@R"95(LBEE.3))12G2624:<GD%&S*(Y1
MPRF-4=TJC%+R)HM4_R*+5?\>BU;_'(M6_QJ+5O\:BU;_&HM6_QK_3 0 _U,
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M+75@^B=V8?\C=V+_('=B_QYW8O\>=V+_'G=B_Q[_4@  [%P  -QF  #.;0
MQ'(  +UT  "W= $ L'0. *EU'P"B="\"G'(]!9=P1PJ1;E$/C6Q9%(EJ8!>%
M:6<;@FAN'G]F=2%]97TD>F2&)W=CD"EU8YLL<F*G+G!BMB]O8LDO;F+F+F]D
M^2AP9?\D<6;_(7%F_Q]Q9O\?<6;_'W%F_Q__5   Z%\  -=I  #*<   P'4
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M(V)R_R!B<O\@8G+_(&)R_R#O7   W&D  ,IR  "^>@  M8   *V$  "DA0
MFH4# )2%% ".AB4!B80S X.#/@=^@4@+>7]0$'5^5Q1Q?5X8;GME&VMZ;!YH
M>70B97A])6)WARA?=I,J7':?+%IUKBY9=< N6'7=+EEV\RI;=O\F7'?_(UQW
M_R!<=_\@7'?_(%QW_R#J8   U6P  ,5V  "Z?@  L80  *B(  "?B0  E(H
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M'DJ+_Q[5;@  PWL  +>%  "LC0  HI(  )>6  ",F0  ?YP  '6>!0!PGQ,
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M$S>OIA0VK[@4-;#1%#6N[Q0TK?X4-*S_%#2K_Q0TJ_\4-*O_%#2K_Q2[A0
MKY   *.7  "8G0  C*,  ("H  !TK0  :+(  %RV  !0N@$ 2;P- $B\&0!&
MO2< 1;TS $.]/0%!O4<!/[U0 CV]6 ,ZO6$%.+UK!C:]=P@TO80),KV3"C"]
MI LOO;<,+K[0"RZ\[@PMNOX-++G_#2RX_PXLN/\.++C_#BRX_PZSCP  II<
M )N=  "/HP  @ZH  ':P  !JM0  7KH  %*^  !'P@$ /<<& #C)$  WR1L
M-LHG #7*,P TRST ,\M' #'+40$PRUL!+LQE BS,<0(JS'\#*<R0!"?,H00F
MS;0$)<W.!"7+[@0DR?P&(\C_!R/'_P<CQ_\'(\?_!R/'_P>IE@  GIT  )*C
M  "%JP  >+(  &NX  !?O@  4L(  $?&   ]R@  -,\$ "O4"0 FV0\ )=D9
M "7:)0 DVC  (]L[ "/;10 BW%  (=U; "#=:  >WG8 '=Z' 1S?F0$:WZP!
M&=_$ 1C>YP$8W/@!&-O_ A?:_P(7VO\"%]K_ A?:_P*@G   E*,  (>K  !Y
MLP  ;+H  %_!  !2Q@  1LH  #O.   QTP  *=D  "'>!0 >Z X '>@5 !OI
M'@ 9Z2< &.HP !;J.0 5ZT, %.Q. !+L6@ 1[6< $.YW !#NB@ .[YX #O"S
M  WPS0 ,[^P #.W\  SK_P ,Z_\ #.O_  SK_P"7HP  B:L  'NT  !MO
M7\0  %+*  !%S@  .=,  "_8   EW0  '>$  !CL @ 6]PL %/<1 !'X%P 0
M^!X #ODE  WY+0 +^C4 "?L_  ?[2@ $_%<  _UF  +^=P  _8L  /V?  #\
MM0  _-$  /SM  #\_   _/T  /S]  #\_0"+JP  ?;0  &Z]  !@Q@  4LT
M $32   WV   +-T  "+A   9Y0  $^H  !#Z   ._P8 #?\,  K_$  '_Q0
M!/\:  '_(   _R<  /\P  #_.@  _T4  /]3  #_8@  _W4  /^*  #_GP
M_[,  /_'  #_Y0  _^4  /_E  #_Y0!_M   <+T  &''  !3T   0]8  #;=
M   JX@  '^8  !;J   0[0  #/H   G_   &_P   O\$  #_"0  _PT  /\0
M  #_%   _QH  /\A  #_*0  _S0  /]   #_3@  _UX  /]R  #_AP  _YH
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M#[DXUQ"U..P0LCG[#[ Z_PZO.O\-KCK_#*TZ_PNM.O\+K3K_"ZTZ_PO_/ T
M_T & /]%! #_20D _TL- /E*$0#M21H XT8F -I&-@#11D4!RT51 \9$7 7"
M0F8(OT)O"KQ!=PNZ0'\-N#^&#K8_CA"T/I41LCZ=$K ^IA.O/K 4K3Z]%*L^
MS16I/N85IC_W$Z1 _Q*C0/\0HD#_#Z) _PZB0?\.HD'_#J)!_P[_/PD _T0
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M'X9/_!N&4/\8AE#_%H90_Q2&4?\4AE'_%(91_Q3_1P  ^$\  .17  #570
MS&   ,5@ @#!7@4 NET1 +-?(P"L7S,!IEY  Z%<2P>=6E0*F5E<#I989!&3
M5FL3D%5R%HY4>AB+5((:B5.*'(=2E!Z%4IX?@U&J(8%1N")_4<LB?E+G(7Y3
M^1U^5/\:?E7_%WY5_Q9^5?\5?E7_%7Y5_Q7_2@  [E(  -Y;  #/80  QF0
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M&VQA_QEL8?\8;&'_&&QA_QCU40  XEP  ,]E  ##:P  N6\  +%Q  "J<0
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M&5AQ_QGC7@  S6D  +]S  "T>@  JW\  **"  "8@P  BX$  (2!#0!_@AH
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M&T:(HQU$B+0=0XC*'4.'ZAQ$AOL:1(;_&$6&_Q=%A?\7187_%T6%_Q?-;0
MO7@  +&"  "GB@  G(X  )*0  "&DP  >94  &R7  !FEPX 8Y@; &&8*0!>
MF#4!6I<^ U>71P55ED\'4I96"4^57@Q,E&8.2I1O$$>3>1-$DX450I*3%T"2
MHA@^DK,9/9+)&3V1Z1@]D/H7/H__%CZ/_Q4^C_\5/H__%3Z/_Q7%<P  MW\
M *R)  "ACP  EI,  (N6  !_F0  <YP  &2?  !<H D 6: 4 %>A(@!5H2\
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M!2BWY@4GM?D')K/_!R:R_P@FLO\()K+_"":R_PBOC0  HI0  )>:  "+H
M?J8  '&K  !EL   6;0  $VW  !"NP  .+X! "_""0 MPQ( +,,> "O#*0 J
MQ#, *<0] "C%1P GQ5$ )L5< "7&:  CQG8!(L:& 2#&F $?QJL!'L?! 1[&
MY $=Q/@"',+_ QS!_P,<P?\$','_!!S!_P2EE   FIH  (ZA  "!IP  <ZX
M &>T  !:N0  3KT  $+    XPP  +\<  ";+!  >T H &]$1 !K2&@ 9TB4
M&-,O !C3.@ 7U$0 %M10 !7570 4U6L $]9\ !+7CP 1V*0 $-F[ !#9W@ 0
MU?, $-/_ !#2_P$0T?\!$-'_ 1#1_P&<F@  D:$  (.H  !UL   :+<  %N]
M  !.P0  0L4  #?(   MS   )-   !S5   5V@4 $.(+ !#C$0 .Y!H #N0C
M  WE+0 ,Y3< "^9"  KF3P )YUT ".=M  ;F@  %YI4 !.:K  +FQ  !YN8
M .?Y  #G_P  YO\  .;_  #F_P"3H0  A:D  '>Q  !IN0  6\   $[&  !!
MR@  -<X  "K2   AU@  &=L  !+?   -XP  "_$(  GS#@ '\Q, !/(:  +R
M(@  \BH  /(T  #R/P  \DP  /)<  #R;0  \H(  /*8  #SK0  \\8  /3E
M  #T]@  ]/L  /3[  #T^P"'J0  >;(  &JZ  !<P@  3LD  $#.   STP
M*-@  ![=   5X0  #^0   KH   %\P   _T!  #\"   ^PT  /L1  #[%@
M_!X  /PF  #\,   _3P  /Y)  #^6@  _FT  /^"  #_F   _ZP  /_   #_
MV   _^0  /_D  #_Y ![L@  ;+L  %W$  !/S0  0-(  #+9   FW@  &^(
M !+F   ,Z@  !>T   #T    _P   /\   #_    _P0  /\)  #_#@  _Q(
M /\8  #_(0  _RL  /\W  #_1@  _U@  /]K  #_@   _Y4  /^F  #_LP
M_[L  /^[  #_NP#_&R8 _QPD /\:) #_%2< _Q M /\*-@#_!4, _P%0 ?\
M7@'_ &L!_P!V ?\ @0#_ (H _P"2 /\ F@#_ *  _P"F /\ K #_ +( _P"Y
M /\ P@#_ ,T _P#? /\ [ #_ /@ _P#_ /T _P#] /\ _0#_ /T _P#] /\
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M ?\1= '_$7T!_Q"& ?T0C@'\$)4!^A"; ?D0H0'W$*@!]A"O ?00MP#S$,(
M\1#0 .T0Y0#H$?( YA'^ >02_P'C$O\!XA+_ >(2_P'A$O\!X1+_ >$2_P'_
M*18 _RH3 /\I$@#_)Q, _R@< /\G)P#_(S, _R _ /\=3 #_&U@!_!ED ?@9
M;@'V&'@!\QB! ?$8B0'O&) ![AB7 >P8G@'J&*0!Z1BL ><8M 'F&+\!Y!C-
M > 9XP'<&O$!V!K^ M0;_P+2&_\"T1O_ M ;_P+0&_\"T!O_ M ;_P+_+1(
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M#9\Z_PR>.O\+G3K_"IPZ_PF<.O\)G#K_"9PZ_PG_.P( _SX  /=$  #F1P
MWT@! -I&!@#90 L S4(9 ,5$*P"^1#L N41( ;5#4P.Q0EP$KD)E!JM!; >I
M0'0)ID!["J0_@PNC/XH-H3Z3#I\^G ^=/J40FSZQ$9H^OQ&8/M02EC_M$90_
M_ ^30/\.DD#_#))!_PN20?\+DD'_"Y)!_PO_/0  _T,  .E)  #>3@  TT\
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M$GA0_Q!X4/\/>%#_#WA0_P_]1@  YT\  -97  #(7   OU\  +=?  "Q7
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M$F)?_Q+J40  U%P  ,1D  "Y:@  L&X  *=P  ">;@  E&L  (UJ$ "':QX
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M&5-LHQM1;+,<4&S('$]LYQM1;/H846S_%5)L_Q12;/\34FS_$U)L_Q/<7
MQV<  +EO  "O=@  I7L  )Q\  "1?   @G@  'IY!P!U>10 <GHC &YZ+P%K
M>3H":'E# V1X2P5A=U((7W=9"EQV8 Q9=6@/5W1P$51T>A-2<X863W.3&$UR
MH1E,<K$:2G+&&DIRY1I+<OD73'+_%4QR_Q--<O\237+_$DUR_Q+48   PFL
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M$3B-X1 XB_80.(K_#SF)_P\YB?\..8G_#CF)_PZ_<@  LGT  *>&  "<B@
MD8X  (:1  !ZDP  ;94  %^7  !4F0$ 3YD/ $Z:&@!,FB< 2IHR $B:/ %&
MFD0!1)I, D*:5 - F5P$/IEF!3N9< <YF'P(-YB*"C68F@LSF*L+,IB_##*8
MWPLQEO4+,97_"S&4_PLQD_\+,9/_"S&3_PNX>@  K(4  *&+  "6D   BY0
M '^7  !RFP  9IT  %J@  !.H@  1:0) $*D$P! I!\ /Z0J #ZE-  \I3X
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M 16[_P$4NO\"%+K_ A2Z_P*AD@  EI@  (J>  !]I   ;ZH  &*O  !6M
M2K<  #ZZ   SO0  *L   "'$   9QP4 $\L+ !',$@ 1S!L $,PE  _-+P .
MS3H #LU&  W-4@ -SF  #,YP  O.@P *SI< "<ZL  C.Q@ (SN@ ",W[  G+
M_P )R_\ "<O_  G+_P"8F   C9X  '^E  !QK   9+,  %>Y  !*O0  /L
M #+#   HQ@  '\H  !?-   1T0  #-8%  C9#  &V1( !=H;  3:)  #VRX
M =LY  #<10  W5(  -YB  #><P  WH@  -^=  #?LP  W\X  .#N  #?^@
MW_\  -__  #?_P"/GP  @:8  '.N  !EM0  6+T  $K"   ]Q0  ,<D  ";,
M   =T   %-0   [9   )W0   ^$   #C!P  XPT  .02  #E&0  YB(  .<K
M  #I-@  ZT,  .Q2  #L8@  [78  .Z,  #NH0  [[<  ._1  #OZP  \/8
M /#V  #P]@"$IP  =:\  &>W  !9OP  2\8  #S*   OS@  )-(  !K8   2
MW   #.    7C    YP   .L   #K    [04  .X+  #P$   \14  /,>  #T
M)P  ]S,  /E   #Z40  ^V,  /QW  #]C0  _:,  /ZV  #^R0  _]\  /_?
M  #_WP!WL   :+D  %K!  !,R@  /,\  "[4   BV@  %]X  !#B   )Y@
M .D   #L    \    /8   #V    ]P   /@   #Z!P  ^PT  /T1  #_&0
M_R,  /\O  #_/@  _T\  /]B  #_=P  _XT  /^?  #_K@  _[H  /^Z  #_
MN@#_%B, _Q4A /\2(0#_#B0 _P8J /\ ,P#_ $$ _P!. /\ 7 #_ &@ _P!T
M /\ ?@#_ (< _P"/ /\ E@#_ )P _P"B /\ J #_ *X _P"U /\ O0#_ ,<
M_P#6 /\ YP#^ /, _@#^ /T _P#\ /\ ^P#_ /L _P#[ /\ ^P#_ /L _P#_
M&B  _QD> /\6'@#_$"  _PHE /\$, #_ #T _P!+ /\ 6 #_ &0 _P!P /\
M>@#_ (, _P"+ /\ D@#_ )@ _P"> /\ I #_ *H _P"Q /T N0#[ ,, ^@#0
M /@ XP#W /$ ]@#\ /0 _P#T /\ \P#_ /, _P#S /\ \P#_ /, _P#_'1P
M_QP9 /\9&0#_%!L _PXA /\,+ #_"3D _P5& /\"4P#_ %\ _P!K /\ =0#_
M 'X _P"& /\ C@#_ )0 _@"; /P H0#Z *< ^ "N /4 M0#S +\ \0#+ /
MWP#N .X [ #Y .L _P#J /\ Z@'_ .D!_P#I ?\ Z0'_ .D!_P#_(!< _Q\4
M /\<$P#_%Q4 _Q8= /\3* #_$#0 _PU! /\,3@#_"5H _PAF /\(< #^!WD
M_ >! /H'B0#X!Y  ]@:6 /,&G0#Q!J, [P:J .T&L@#_XO__24-#7U!23T9)
M3$4 " GJ!KL Z ;( .8&W #D!NP X@CZ . *_P#>"_\ W0O_ -T,_P#<#/\
MW S_ -P,_P#_(Q( _R,0 /\A#@#_'A  _QX8 /\<(P#_&"\ _Q0[ /\220#\
M$%4 ^ ]@ /0/:@#Q#W0 [PY\ .T.A #K#HL Z0Z2 .<.F0#F#J  Y ZG .(.
MKP#@#K@ W@[% -P.V@#6$.P TA'Z ,\2_P#-$O\!S!+_ <L3_P'*$_\!RA+_
M <H2_P'_)P\ _R<, /\E"0#_)@T _R43 /\C' #_("@ ^QPU /4:0@#O&$\
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M!*XKQ 2L*]L$J"SO!*8L_@6D+/\$HRW_!*(M_P2B+/\$HBS_!*(L_P3_,@
M_S,  /DX  #I.0  XCD  -XU!P#>+@T T2\; ,DQ+ ##,SL O3-( +DT4P&V
M,UP!LS-E K S;0*N,W0#K#)[ ZLR@P2I,HH$IS*3!:4RFP:D,J4&HC*P!Z R
MO@>?,M$'G#/J!YHS^P>8-/\'ES3_!I8T_P:6-/\%EC3_!98T_P7_-0  _S@
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M$7M$\0]Z1?\->D;_"WI&_PIZ1O\)>D;_"7I&_PGU/@  YD@  --/  #'5
MO54  +94  "P4   J4P+ *)-& "=3B@ F$XV )1.00&034L"C4U3!(I,6@6'
M2V$&A4MH"(-*;PF 2G<+?DE_#'Q)B0YZ2),/>$B?$'=(K!)U2+P2=$G2$W-)
M[A%R2O\/<DK_#7)*_PMR2O\+<DK_"G)*_PKR0@  X$P  ,Y3  #!6   N%H
M +!9  "I5@  HE(' )M2%0"64R0 D5,R (U3/@&)4D<"AE%0!(-15P6 4%X&
M?D]E"'M/; EY3G,+=TY[#75-A0YS39 0<4V<$F]-J1-N3;D4;$W.%&Q-ZQ-L
M3OT0;$__#FQ/_PQL3_\+;$__"VQ/_PON10  W%   ,E7  "]7   M%X  *Q>
M  "D6P  G%8$ )56$@"05R$ BU@O (=7.P&#5D0"?U9- WQ55 5Z5%L&=U1B
M"'53: ES4W +<5)X#6]2@@]M48T1:U&9$FE1IA1G4;859E'+%652Z11E4OL1
M9E/_#V93_PUF4_\,9E/_#&93_PSJ20  U5,  ,5:  "Z7P  L&(  *AB  "?
M7P  EEH  (]:$ "*6QX A5LL (%;. %]6T$">EI* W=9401T6%@&<5A?!V]7
M9@EM5VT+:U9V#6E6?P]G58H19567$V-5I!1A5;058%7(%E]5YQ5@5OH28%;_
M#V%7_PYA5_\-85?_#&%7_PSG3   T58  ,%>  "V8P  K68  *1F  ";9
MD%X  (E>#@"$7QL @%\I 'Q?-0%X7S\"=%Y' W%=3P1O7%8%;%Q<!VI;8PEH
M6VL+9EIS#61:?0]B6H@17UF4$UY9HA1<6;(56UG&%EI9Y15;6OD26UK_$%Q:
M_PY<6O\-7%K_#5Q:_PWC3P  S5D  +YA  "S9@  J6D  *!J  "7:   BV(
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M#4UG_PW26@  P&0  +-L  "I<@  H'8  )9W  "*=@  >7$  '%Q  !K<0\
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M9   MVX  *MV  "B?   EW\  (R!  "!@0  <H   &5_  !=?P@ 67\3 %>
M( !5@"L 4X$V %& /@%/@$8"38!. DM_50-)?UT%1G]F!D1^< A"?GL)/WZ(
M"SU]EPP\?:<-.GVZ#CI^U@TZ?/$-.GO_##I[_PLZ>O\+.GK_"SIZ_PO :0
MLG0  *=\  "=@0  DH0  (>&  ![AP  ;H<  &"'  !5AP$ 4(@. $Z(&@!-
MB28 2XDP $F).@!(B4(!1HE* 42)4@)"B5H#0(AC!#V(;04[B'@&.8>&"#>'
ME0DUAZ8*-(>Y"C.'TPHSAO ),X7_"3.$_PDS@_\),X/_"3.#_PFY<   K7H
M **"  "7AP  C8H  (&,  !UC@  :(\  %J0  !/D0  1Y(* $22$P!#DQ\
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M !FKR@ 9JNP!&:C] 1BG_P(8IO\"&*;_ ABF_P*EB0  F8\  (^4  "#F0
M=9X  &BB  !<I@  4*D  $2L   YK@  +[   ":S   >M08 &;</ !BW%P 7
MMR$ %K<J !6W-  4N#X $[A) !*X5  2N6( $;EQ !"Y@P /N9< #KFL  VY
MQ  -N.< #K;[  ZU_P .M/\ #K3_  ZT_P"<D   DI4  (:;  !YH   :Z8
M %ZK  !2KP  1K(  #JU   OMP  );H  !V]   5P   $,,&  O&#@ *Q14
M"<4>  C%*  'Q3( !L8]  7&20 %QE<  \9F  +&=P !QHL  ,:@  #%M@
MQM(  ,7O  #%_   Q?\  ,7_  #%_P"5E@  B9P  'NC  !MJ0  8*\  %.T
M  !&N   .KL  "Z^   DP0  &\0  !/'   .R@  ",X!  '0"@  T!   - 6
M  #1'@  TB<  -,Q  #4/   U4D  -98  #6:0  UGP  -:2  #6IP  UK\
M -;@  #6\P  UOX  -;_  #6_P",G0  ?J0  &^K  !AL@  5+D  $:]   Y
MP0  +<0  "+'   9RP  $<X   S2   %U0   -L   #< P  W0H  -X/  #?
M%   X1P  .(D  #D+@  YCH  .=)  #H60  Z&L  .F!  #IF   Z:T  .G%
M  #IX@  Z?(  .GU  #I]0" I0  <:T  &.U  !5O   1\(  #G&   LR@
M(,X  !;2   /U@  "-L   #?    XP   .4   #G    Z $  .H'  #K#0
M[1$  .\8  #Q(0  \RL  /8X  #W2   ^%H  /EM  #ZA   ^IL  /JO  #Z
MP@  ^MH  /K?  #ZWP!TK@  9;8  %:^  !(Q@  .<L  "O0   ?U   %-H
M  W?   %XP   .8   #I    [0   .\   #Q    \P   /4   #V @  ^ D
M /H.  #]$P  _QP  /\H  #_-@  _T<  /]:  #_;@  _X4  /^:  #_JP
M_[D  /^\  #_O #_$2  _Q > /\,'@#_!"$ _P G /\ , #_ #X _P!, /\
M60#_ &4 _P!P /\ >@#_ (, _P"+ /\ D@#_ )@ _P"> /\ I #_ *H _P"P
M /\ N #_ ,( _P#. /\ X@#^ /  _0#[ /L _P#[ /\ ^P#_ /H _P#Z /\
M^@#_ /H _P#_%!P _Q(: /\.&@#_"!P _P A /\ +0#_ #H _P!( /\ 50#_
M &$ _P!L /\ =@#_ '\ _P"' /\ C@#_ )0 _P": /X H #] *8 _ "L /L
MM #Y +T ^ #) /< W #U .P \P#X /, _P#R /\ \0#_ /  _P#P /\ \ #_
M /  _P#_%Q@ _Q46 /\1%0#_#!< _P4= /\ * #_ #8 _P!# /\ 4 #_ %P
M_P!G /\ <0#_ 'H _ "" /H B0#X )  ]P"6 /4 G #T *( \P"H /$ L #P
M +@ [@## .P TP#J .< Z0#U .< _P#F /\ Y0#_ .4 _P#E /\ Y0#_ .4
M_P#_&A, _Q@1 /\4$ #_#Q$ _PT9 /\*) #_!3  _P$^ /\ 2P#_ %< _@!B
M /H ; #U '4 \@!] /  A #N (L [ "1 .L EP#I )X YP"D .8 K #D +0
MX@"_ .  S0#> ., W #R -H _0#8 /\ U@#_ -4!_P#5 ?\ U0+_ -4"_P#_
M'A  _QP- /\7"P#_%0X _Q05 /\1'P#_#BH _PLX /T(10#X!E$ ] 1< .X$
M9@#J!&\ Y@-W .0$?P#B!(8 X 2, -X$DP#=!9H VP6@ -@%J #5!;$ T@6[
M - &R0#.!^  S CQ ,D*_P#'"_\ Q@S_ ,4,_P#%#/\ Q0S_ ,4,_P#_(0P
M_R & /\< P#_'0H _QL0 /\8& #_%", ]A$P .\./@#J#DH Y0U6 .$-8 #=
M#6D V0UQ -4->0#3#8$ T0V( ,\-CP#-#I8 RPZ= ,H.I0#(#JX Q@^Y ,00
MR #"$-\ OA'R +L2_P"Y$_\ MQ/_ ;83_P&V$_\!MA/_ ;83_P'_)08 _R,
M /\C  #_) , _R$* /T=$0#Q&AL Z!8G .$4-0#:$T, TQ1/ ,X560#+%6,
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M Y0M]022+?\#D2W_ Y N_P.0+?\#D"W_ Y M_P/_,   \C,  .0Z  #6/0
MS#P  ,<Y  ##,04 O2X1 +4P(0"P,C  JS,] *<S20"D,U( H3-: 9\S8@&<
M,VD"FC-P IDS=P*7,G\#E3*' Y,RD 22,IH$D#*E!8XRL06-,\(&BS/<!HDT
M\@:'-/\%AC3_!88T_P2%-/\$A33_!(4T_P3\,P  ZSH  -Q!  #-1   PT0
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M"&Q%_P=L1?\';$7_!VQ%_P?L/P  V$D  ,=0  "[5   L54  *E4  "A4
MF4H" )))$0"-2A\ B4LL (5,. ""2T(!?TM* 7Q*4@)Y2E@#=TI?!'5)9@5S
M26T&<4EV!V](?PAM2(H);$B6"VI(HPQH2+(-9TC%#69)Y UF2?@+9DG_"69*
M_PAF2?\'9DG_!V9)_P?H0P  TDT  ,)3  "W6   K5D  *18  "<50  DTX
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M"%95_PC;30  Q5<  +A>  "M8@  HV4  )IE  "08P  @UP  'M;!@!U6Q(
M<5L? &Y<*P!K7#8 :%L_ 65;1P%C6TX"85I5 U]:7 1=6F,%6UIK!EE9=0A7
M68 *55F,"U19F@U26:H.45F\#E!9V Y06?(-45G_"U%9_PI16?\)45G_"%%9
M_PC440  PEH  +1A  "J9@  H&@  )=I  ",9P  ?6   '5? P!O7Q  :U\<
M &A@* !F8#, 8V \ 6%@1 %?7TP"7%]3 UM?6@197V$%5UYI!E5><PA37GX)
M45V*"T]=F0Q-7:@-3%ZZ#DM>U Y+7O$,3%[_"TQ=_PI,7?\)3%W_"$Q=_PC/
M5   OEX  +%E  "G:@  G6T  )1M  ");   >&4  &]D  !I9 X 9609 &)D
M)0!@93  7F4Z %QE0@%:94H"6&11 E9D6 -49%\$4F1G!5!C<0=.8WL)3&.(
M"DICEPM(8Z8,1V.X#49CT0U&8^\,1F+_"D=B_PE'8O\)1V+_"$=B_PC*6
MNF(  *YI  "C;@  FG$  )!R  "$<0  =&L  &EI  !C:0L 7VD5 %QJ(0!:
M:BT 6&LV %9K/P%5:T<!4VI. E%J50-/:ET$36IE!4II;@9(:7D'1FF&"41I
ME0I#:*4+06FW#$!ISPQ :.X+06C_"D%G_PE!9_\(0F?_"$)G_PC%70  MF8
M *IM  "@<P  EG8  (MW  " =@  <'(  &5Q  !<< < 6' 1 %9P'0!4<2@
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M!2V!R 4M@>D$+7_\!2U^_P4M??\%+7W_!2U]_P6S;@  J'@  )U_  "2@P
MB(8  'V'  !PB   8XD  %6*  !+B@  08H" #N+#@ YBQ< .(PB #>,+  V
MC#4 -(P] #.,1@ RC4\ ,8U8 "^-8@$MC&X!*XQ[ 2J,BP(HC)P")HRO B6,
MQ@(EB^@")8K[ R6(_P,EB/\#)8?_ R6'_P.M=@  HX   )>%  "-B0  @HP
M ':.  !ID   7)(  %"3  !$E   .I4  #&6"  MEQ$ +)<: "N7)  JERT
M*9<V "B8/P GF$@ )IA2 "687  CF&@ (IAW ""8AP ?F)D!'9BL 1R8PP$<
ME^4!')7Z 1N4_P$;D_\"&Y/_ AN3_P*G?P  G(8  )&+  "'CP  >I(  &V5
M  !AF   59L  $F=   ]G@  ,Y\  "JA   AHPH 'Z,1 !ZC&@ =I"0 '*0M
M !ND-@ :I#\ &:1* !BD50 6I6$ %:5P !2E@0 3I90 $J6H !&EOP 0I.(
M$:+X !&A_P 1H/\!$:#_ 1&@_P&@A@  E8P  (R1  !_E0  <9H  &2>  !8
MH0  3*0  $"F   UIP  *JD  "*L   9K@  $K ) !"Q$  0L1@ #K$B  ZQ
M*P -L34 #;%   RQ2P +L5@ "K%G  BQ>  'L8L !;&@  2PM0 $L-  !+#O
M  6O_@ &KO\ !J[_  :N_P"8C@  CY,  (*8  !UG0  9Z(  %JG  !.JP
M0:T  #6O   KL0  (;0  !BV   1N0  #;P#  >^#  #O1(  ;T9  "^(@
MOBL  +XV  "^00  OTX  +]<  "_;0  OX   +Z5  "^J@  OL(  +WD  "]
M]@  O?\  +W_  "]_P"2E   A9H  'B@  !JI@  7*L  $^P  !"LP  -;8
M "JX   @NP  %[X  !#!   +Q   !,<   #)!P  R0T  ,D2  #*&0  RR(
M ,LK  #--0  SD$  ,Y0  #/8   SW(  ,^'  #/G0  S[,  ,_.  #/ZP
MSO@  ,[^  #._@"(FP  >J(  &RH  !>KP  4+4  $*Y   UO   *;\  !["
M   5Q@  #LD   C,    T    -,   #5    U@8  -@,  #9$0  VQ8  -P?
M  #>*   X#0  .)!  #B40  XV,  .-W  #DC@  Y*0  .2Z  #EU   Y>H
M .7S  #E\P!\HP  ;JH  &"R  !1N0  0[X  #7"   HQ@  ',D  !/-   ,
MT0  !-4   #:    W@   .$   #B    Y    .4#  #G"0  Z0X  .L2  #M
M&@  [R0  /(Q  #T00  ]%,  /5F  #U?   ]I,  /:I  #WO   ]\X  /??
M  #WWP!PK   8;0  %.[  !%PP  -L<  "?,   ;T   $=4   K;    WP
M .(   #E    Z0   .P   #M    \    /$   #S    ]00  /<*  #Z$
M_!8  /\A  #_+@  _T   /]3  #_:   _X   /^6  #_J   _[8  /^_  #_
MOP#_#1P _PH; /\"&P#_ !X _P D /\ +@#_ #P _P!* /\ 5@#_ &, _P!M
M /\ =P#_ '\ _P"' /\ C@#_ )0 _P": /\ H #_ *8 _P"L /\ M #_ +T
M_P#) /X W0#] .T _ #Z /L _P#Z /\ ^0#_ /H _P#Z /\ ^@#_ /H _P#_
M$!D _PT7 /\&%@#_ !@ _P > /\ *@#_ #< _P!% /\ 4@#_ %X _P!I /\
M<@#_ 'L _P"" /\ B0#_ )  _@"6 /T G #\ *$ ^P"H /D KP#X +@ ]@##
M /0 T@#S .< \@#V /  _P#O /\ \ #_ .\ _P#O /\ [@#_ .X _P#_$A0
M_P\2 /\+$@#_ !( _P : /\ )0#_ #, _P!  /\ 30#_ %D _P!D /T ;0#[
M '8 ^0!] /< A #U (L ] "1 /, EP#Q )T \ "C .X J@#L +, Z@"] .@
MRP#G .$ Y0#Q ., _0#C /\ X@#_ .$ _P#A /\ X #_ .  _P#_%!  _Q$.
M /\-#0#_!P\ _P(5 /\ ( #_ "T _P Z /\ 1P#Y %, ]0!> /( : #P '
M[0!X .L ?P#I (4 Z ", .8 D@#E )@ XP"? .$ I@#? *X W "X -H Q0#6
M -D U #L -( ^0#1 /\ SP#_ ,X _P#. /\ S@#_ ,X _P#_%PP _Q0( /\/
M!0#_#@L _PP1 /\'&@#_ 28 _  T /0 00#M $T Z0!8 .8 8@#C &H X !R
M -X >0#; (  V0"& -8 C0#3 ), T0": ,\ H0#- *H RP"S ,D OP#& -
MQ0#H ,, ]@#! /\ P +_ +\#_P"_ _\ OP/_ +\#_P#_&P8 _Q<  /\4  #_
M$P4 _Q$- /\.% #Y"A\ \ 8L .8#.0#@ T8 W -1 -8$6P#2!&0 SP5L ,P%
M<P#*!7H R 6! ,8%AP#%!HX PP:6 ,$&G0"_!J8 O0:P +L'O "Y",T N KE
M +4+]P"S#?\ L0W_ + -_P"P#O\ KP[_ *\._P#_'@  _QL  /\;  #Z&@
M]18% /81#0#K#A4 X@LB -@+,0#0##X RPU* ,<-50#$#EX P0YF +\.;0"]
M#G0 NP][ +D/@@"W$(H MA"1 +00F@"R$*, L!&M *\1N@"M$<H JA+E *<4
M]P"E%?\ HQ7_ *(5_P"B%?\ HA7_ *(5_P#_(@  _R   / C  #F)   X"$
M -P9!0#;$ P T!$9 ,@3*0#"%3< O19$ +D73@"U%U< LQA@ + 89P"N&&X
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M G\N_P)_+O\"?B[_ GXN_P+T+@  Y#<  -(]  #%/P  NS\  +0\  "O-0
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M!&!$_P3@00  RDH  +M0  "P4P  IU4  )Y3  "53P  BTD  (-'"P!]1Q4
M>4<B '9(+@!S2#@ <4A! &Y(20%L2% !:DA6 6A(70)F1V0"94=L V-'=@1A
M1X %8$>-!EY'F@=<1ZD(6TB["%I(U A:2/$'6DG_!EI)_P5:2/\%6DC_!%I(
M_P3;1   QDT  +A3  "M5P  HUD  )I8  "15   ADX  'U+" !W2Q( <TP?
M '!,*P!M3#4 :TP^ &A,1@!F3$T!9$Q3 6),6@)A3&("7TQJ UY,<P1<2WX%
M6DN*!EA+F =73*<(5DRY"55,T0E43.\(5$W_!E5,_P953/\%54S_!55,_P75
M2   PE$  +57  "J6P  H%P  )=<  "-60  @5,  '=/! !Q3Q  ;E < &I0
M* !H4#( 95 [ &-00P!A4$H!7U!1 5U06 )<4%\"6E!G UA0<0174'L%55"(
M!E-0E@=24*4(4%"W"5!0S@E/4.T(4%#_!U!0_P904/\%4%#_!5!0_P702P
MOU0  +):  "G7@  G6   )1@  ")70  ?%<  ')4  !L4PX :%09 &54) !B
M5"\ 8%0X %Y40 !<5$@!6E1/ 5E45@%75%T"551E U14;@125'D%4%2&!DY4
ME =-5*0(2U2U"$M4S E*5.L(2U3^!TM4_P9+5/\%2U3_!4M4_P7,3@  NU<
M *Y>  "D8@  FF0  )%D  "&8@  =UL  &U8  !F6 P 8E@6 %]8(@!=62P
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M!CMDQ@8[9.8&.V/Z!3MB_P4[8O\%/&'_!#QA_P2^6P  L&,  *5J  ";;P
MD7(  (9R  ![<0  ;&T  &!K  !5:0  3V@- $UI%P!+:2$ 26HK $AJ- !'
M:CT 16M$ $1K3 !":U0!06M< 3]J90(]:G ".VI] SEJC 0W:IP$-FJN!35J
MQ 4U:N4%-6GY!#5I_P0U:/\$-6C_!#5H_P2Y8   K&D  *%P  "8=0  C7<
M ()W  !W=P  :70  %QS  !1<0  2' * $5P$@!#<1T 0G$G $!R,  _<C@
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M 1Z"_P$>@O\!'H'_ 1Z!_P&H=   GGT  )."  ")A0  ?H@  '&*  !EBP
M6(P  $R-  ! C@  -HX  "R/   ED P (Y 3 "*0'  AD"4 ()$N !^1-@ >
MD4  '9%) !R15  :D6  &9%N !B1?@ 6DI  %9*D !21N0 3D=@ $X_T !2.
M_P 4C?\ %(S_ 12,_P&C?0  F(,  (Z(  "$C   =X\  &F1  !=DP  4)4
M $67   YF   +ID  "6:   =FP( %IT, !6=$P 4G1L $YTD !*=+0 1GC<
M$9Y! !">3  /GE@ #IYG  V>=P ,GHH "YV>  J=L@ )G<P "9SL  J;_@ +
MFO\ "YG_  N9_P"<A   D8H  (B.  ![D@  ;98  &"9  !4G   2)\  #R@
M   PH0  )J,  !VE   5IP  $*D%  NK#0 (JA, !ZH;  :J)  %JBX !*HX
M  *J1  !JE   *I>  "J;@  JH$  *J5  "IJ@  J<$  *CD  "H]@  I_\
M *?_  "G_P"5BP  C)   '^5  !QF@  8YX  %:B  !*I@  /:@  #&J   F
MJP  ':T  !2P   .L@  ";4!  *V"@  M@\  +85  "W'0  MR4  +<O  "X
M.0  N$8  +A4  "X9   N'8  +B+  "WH   M[8  +?3  "V[P  MOP  +;_
M  "V_P"/D@  @I<  '2=  !FH@  6*<  $NL   ^KP  ,;$  ":S   <M@
M$[@   V[   &O@   ,$   #"!   P@L  ,,0  #$%0  Q!P  ,4D  #&+@
MR#H  ,E'  #)5P  R6D  ,E]  #)E   R*H  ,C#  #(Y   R/0  ,C]  #(
M_0"%F0  =Y\  &BF  !:JP  3;$  #^U   QN   );H  !J]   1P   "\,
M  /'    R@   ,T   #.    SP,  - )  #1#@  TQ(  -49  #7(@  VBT
M -TY  #>20  WEH  -]N  #?A0  WYP  -^R  #>RP  WN8  -_T  #?] !Y
MH0  :Z@  %RO  !.M0  0+L  #&^   DP0  &<4  !#(   )S    ,\   #3
M    V0   -P   #=    WP   .$   #B!0  Y L  .80  #H%@  ZB   .TK
M  #P.@  \4L  /%>  #R<P  \XL  /.B  #SM@  \\D  //A  #SX0!MJ@
M7K$  %"Y  !!OP  ,L0  "3(   7S   #M    ;5    V@   -X   #B
MY@   .D   #J    [    .X   #P    \@   /0&  #V#   ^1(  /P<  #_
M*0  _SH  /]-  #_8@  _W@  /^0  #_HP  _[,  /_!  #_P0#_!QD _P$7
M /\ %P#_ !H _P A /\ *P#_ #D _P!' /\ 5 #_ %\ _P!J /\ <P#_ 'L
M_P"# /\ B@#_ )  _P"6 /\ FP#_ *$ _P"H /\ KP#_ +@ _P#$ /X U0#\
M .H ^P#X /H _P#Y /\ ^ #_ /@ _P#V /\ \P#_ /$ _P#_"Q4 _P43 /\
M$P#_ !0 _P : /\ )P#_ #0 _P!" /\ 3P#_ %L _P!E /\ ;@#_ '8 _P!^
M /\ A0#^ (L _0"1 /L EP#Z )T ^ "C /< JP#V +, ] "^ /, S #Q .,
M[P#S .X _P#M /\ [ #_ .L _P#L /\ [ #_ .L _P#_#1$ _PD0 /\ #P#_
M !  _P 6 /\ (@#_ "\ _P ] /\ 2@#_ %4 _0!@ /H :0#X '$ ]@!Y /0
M?P#S (8 \0", .\ D@#N )@ [ "? .L I@#I *X YP"X .4 Q0#C -H X0#M
M -\ ^P#> /\ W0#_ -T _P#= /\ W0#_ -T _P#_#PT _PP+ /\#"0#_  P
M_P 2 /\ '0#_ "D ^P W /@ 1 #U %  \@!: .X 8P#L &L Z0!S .< >@#E
M (  XP"& .$ C #? ), W0"9 -L H0#9 *D U0"R -( O@#0 ,X S@#F ,P
M]@#* /\ R@#_ ,D _P#( /\ R #_ ,@ _P#_$0@ _PT" /\'  #_!0@ _P .
M /\ %@#W "( [P P .L /0#H $D Y !4 .  70#= &4 V0!M -4 <P#2 'H
MT "  ,X AP#, (T R@"4 ,@ FP#& *0 Q "M ,( N #  ,< O0#? +P \0"[
M /X N0#_ +@ _P"X /\ N #_ +@ _P#_%   _P\  /\-  #_#   _P<) /@!
M$ #H !H XP H -T -@#8 $( T@!- ,X 5P#* %\ QP!F ,4 ;0## '0 P0!Z
M +\ @0"] (@ NP"/ +D EP"W )\ M0"H +, LP"Q ,( KP#8 *X"[0"L _L
MJP7_ *H&_P"I!O\ J0;_ *D&_P#_%@  _Q(  /<2  #L$0  Y@X  .4&" #=
M Q( U ,@ ,T$+0#(!#H PP5& +\%4 "\!E@ N09@ +<'9P"U!VX LP=U +$(
M>P"O"(( K@F* *P)D@"J"9L J JE *8*L "E"[\ HPS4 *$-[0"?#OX G0[_
M )P/_P";#_\ FP__ )L/_P#_&@  ]QD  .H>  #?'@  U1H  - 3 @#.# L
MQPL6 , -)0"Z#C( M@X_ +(/20"O$%( K!!: *H080"H$6@ IA%O *01=@"B
M$7T H1&% )\2C@"=$I< G!*B )H3K0"8$[P EQ30 )05[ "2%OT D!?_ (\7
M_P".%_\ CA?_ (X7_P#Z'0  [B,  -\H  #0*@  QR<  ,$A  "]&04 N1(0
M +(5'@"M%BP J!<X *080P"A&4P GQE4 )P:7 ":&F( F1II )<;< "5&W<
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M 6XO_P'H,0  TSH  ,,_  "W00  KD$  *8^  ">.   ES$! )$N$ ",+QP
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M EX]E@-=/J4#6SZV!%H^S 1:/^P$63_^ UD__P-9/_\"63__ ED^_P+6/P
MPT<  +5,  "J4   H%   )=/  ".2P  A$4  'I !@!U/Q$ <4 < &U * !K
M03( :4$[ &=!0@!E04D 8T%0 &%!5P!@05X!7D%F 5U";P);0GH"6D*& UA"
ME -70J,$54.S!%1#R0140^D$4T/] U-#_P-40_\#5$/_ E1#_P+00@  OTH
M +)0  "G4P  G50  )13  "*4   ?TH  '5% @!N0PX :T09 &=%) !E12X
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M!$5/PP1$4.0$1$_Y!$5/_P-%3_\#14[_ T5._P/$3   M54  *E;  "?7@
ME6   (M@  " 7@  <E<  &=3  !>40< 65$1 %=1&P!4424 4E(O %%2-P!/
M4C\ 3E)& $U330!,4U4 2E-= 4E39@%'4W "15-] D13BP-"4YL#052L!$!4
MP00_5.($/U3X T!3_P- 4_\#0%/_ T!2_P/ 4   LE@  *9>  "<8@  DF4
M (AE  !]8@  ;EP  &-9  !95@, 5%8. %%6& !/5B( 35<L $Q7- !*5SP
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M BYC_P(O8_\"+V+_ B]B_P*S7@  IV8  )QM  "3<0  B',  'US  !R<@
M9'   %AN  !-;   0FH# #QI#@ Z:A8 .6H@ #AJ*  V:S$ -6LY #1K00 S
M;$D ,FQ2 #%L7  O;&8 +FQS "QL@@$J;),!*6RE 2ALN0$G;=8!)VOR 2=J
M_P$G:O\!*&G_ BAI_P*N9   HVP  )ES  ".=@  A'@  'EY  !M>   8'<
M %-V  !(=0  /G,  #1R"@ Q<Q$ ,',: "]S(P N<RL +70T "QT/  K=$0
M*71- "AU5P G=6, )75O "1U?P B=9  (76B "!UMP ?==( 'W3Q !]S_P$?
M<O\!(''_ 2!Q_P&I:P  GG,  )1Y  "*?   @'X  '1_  !G?P  6G\  $U^
M  !#?@  .'T  "]] @ H?0T )GT4 "1]'  C?B4 (GXM "%^-@ A?C\ 'W](
M !Y_4@ =?UX '']K !I_>@ 9?XP %W^? !9_LP 5?\X %7[O !9\_P 6>_\
M%GO_ !=[_P"D<@  FGH  (]_  "%@@  >X0  &V&  !@AP  5(<  $B(   \
MB   ,H@  "B(   @B 4 &HD. !F)%0 8B1T %XHF !:*+@ 5BC< %(I! !.*
M3  2BU@ $8ME !"+=0 /BX< #HJ;  V*KP ,BL@ #(GJ  V'_  .A_\ #H;_
M  Z&_P"?>P  E($  (J%  " B   <XL  &6-  !9CP  3)   $&2   TD@
M*I(  "&3   9E   $I8&  Z7#@ -EQ4 #)<=  R7)@ +ER\ "I<Y  F71  (
MEU  !I=>  67;@ #EH   9:4  "5J   E;X  )3@  "4]   D_\  9+_  &2
M_P"8@@  CH@  (6,  !WCP  :I(  %V5  !0F   1)H  #B;   LG   (IT
M !F>   2H   #:("  >C"P !HQ   *,7  "C'P  HR<  *,Q  "D/   I$@
M *16  "D90  HW<  *.+  "CH   HK8  *'2  "A\   H/L  *#_  "@_P"1
MB@  B8X  'N2  !MEP  8)L  %.>  !&H0  .:,  "VD   CI@  &:@  !&J
M   ,K   !:X   "O!P  KPT  *\1  "P&   L"   +$H  "Q,@  LCX  +),
M  "R6P  LFP  +*!  "QEP  L:P  +#&  "PZ   K_<  *__  "O_P",D
M?Y4  '&:  !CGP  5:0  $>H   ZJ@  +:P  "*N   8L   $+,   JU   "
MN    +L   "[    O <  +P-  "]$0  OA8  +\>  # )P  P3(  ,)   ##
M3P  PV   ,-T  ##BP  PZ$  ,.X  #"UP  PN\  ,+Z  #!_@"!EP  <YT
M &6C  !7J   2:T  #NQ   MLP  (;8  !:Y   .NP  ![X   #!    Q0
M ,<   #(    R0   ,H%  #+"P  S0\  ,X4  #0'   TR8  -8R  #800
MV%,  -EF  #9?   V90  -FK  #9PP  V>$  -GP  #9] !VGP  9Z8  %FL
M  !+L@  /+<  "ZZ   AO0  %<    W$   %QP   ,H   #.    T@   -4
M  #6    V0   -L   #=    WP<  .$,  #C$0  YAD  .DD  #L,@  [4,
M .Y6  #O:P  [X0  .^<  #OL@  [\8  ._=  #OY !JJ   6Z\  $RV   ^
MO   +\   "#$   4R   #,P   +0    U    -D   #>    X@   .4   #F
M    Z    .D   #L    [@   / "  #R"0  ]0\  /@7  #\(P  _S,  /]&
M  #_6@  _W$  /^)  #_GP  _[$  /_   #_Q@#_ !4 _P 4 /\ % #_ !<
M_P = /\ * #_ #< _P!$ /\ 40#_ %P _P!F /\ ;P#_ '< _P!^ /\ A0#_
M (L _P"1 /\ EP#_ )T _P"D /\ JP#_ +0 _@"_ /T S@#[ .8 ^0#V /@
M_P#W /\ ]P#_ /< _P#P /\ [ #_ .D _P#_ Q( _P 0 /\ $ #_ !$ _P 7
M /\ ) #_ #( _P _ /\ 3 #_ %< _P!A /\ :@#_ '( _P!Y /T @ #\ (8
M^@", /D D@#X )@ ]@"? /4 I@#T *X \@"Y /  Q@#N -X [0#P .L _@#J
M /\ Z0#_ .D _P#G /\ XP#_ .  _P#_!PX _P - /\ "P#_  P _P 3 /\
M'P#_ "P _P Z /\ 1@#^ %( ^P!< /@ 90#U &P \P!T /$ >@#O ($ [@"'
M .P C0#J ), Z0": .< H0#F *D XP"S .$ OP#? -  W0#I -H ^0#9 /\
MUP#_ -4 _P#5 /\ U0#_ -0 _P#_"0H _P$% /\  P#_  D _P 0 /\ &0#[
M "8 ]P T /0 0 #R $P [@!6 .H 7P#G &< Y !N .( = #@ 'L W@"! -P
MAP#: (T U@"4 -0 FP#1 *, SP"M ,P N #* ,< R #@ ,8 \P#% /\ PP#_
M ,, _P## /\ PP#_ ,, _P#_"P$ _P,  /\   #_  , _P + /, $@#N !\
MZ@ M .8 .@#B $4 W@!/ -D 6 #4 &  T0!H ,X ;@#, '0 R@![ ,@ @0#&
M (< Q ". ,( E@#  )X O@"G +L L@"Y ,  MP#4 +4 [ "S /L LP#_ +(
M_P"R /\ L0#_ +$ _P#_#0  _P8  /\#  #W    ]  # .< #0#@ !@ V@ E
M -, ,@#. #X R@!) ,8 4@## %H P !A +X : "\ &X N@!T +@ >P"V ($
MM "( +( D "P )D K@"B *P K0"J +H J #+ *8 Y@"E /< I #_ *, _P"B
M /\ H@#_ *( _P#_$   ^PP  .\.  #F#0  WPD  -H !@#0 !$ R0 = ,0
M*@"_ #< NP!" +< 2P"T %0 L@!; *\ 8@"M &@ JP!N *D =0"H 'L I@"#
M *0 BP"B )0 H "> )X!J "< K4 FP/& )D%X@"8!O0 E@C_ )4)_P"4"?\
ME G_ )0)_P#\$0  \14  .,9  #6&0  S!4  ,<0  #$!PH O0,4 +<$(0"R
M!BX K@@Z *H)1 "G"4T I I5 *(*7 "@"F( G@MI )P+;P";"W8 F0Q^ )<,
MA@"6#)  E R: )(-I@"1#;, CPW% (T.X@"+$/8 B1#_ (@1_P"'$?\ AQ'_
M (<1_P#V&0  YR   -8D  #()0  OR(  +D<  "T% $ L0T. *H.&0"E#R<
MH1 S )T1/@":$4< F!)/ )425@"3$EP D1)C ) 3:0".$W  C!-X (L3@0")
M%(L AQ26 (85H@"$%;  @Q;! ($7W0!_&/0 ?1G_ 'P9_P!\&?\ >QG_ 'L9
M_P#O(0  W2D  ,HM  "^+P  M2P  *XG  "H(   HQ<( )X6$P"9%R$ E!DM
M )$:. ".&D$ BQM) (D;4 "'&U< A1Q> (0<9 ""'&L @!QS '\=? !]'88
M?!Z1 'H>G@!X'ZL =Q^\ '8@U !T(?  <B'_ '$B_P!Q(?\ <2'_ '$A_P#H
M*   TC   ,(U  "W-P  K34  *4Q  ">*P  F"," )(>$ "-(!L B2$G (8B
M,@"#(SP @2-$ 'XC2P!\)%( >R19 'DD7P!W)&8 =B5N '0E=P!S)8$ <2:-
M &\FF0!N)J< ;2>X &PGS@%J*.T!:2G_ 6@I_P%H*?\!:"C_ 6@H_P'A+@
MRS8  +P[  "Q/0  IST  )\Y  "7,P  CRT  (@G# "#)Q8 ?R@B 'PI+0!Y
M*C< =RH_ '4J1P!S*TX <2M4 ' K6P!N*V( ;"MJ &LL<@!I+'T :"R) &8M
ME@%E+:0!9"ZT 6,NR@%A+^D!8"_] 6 O_P%@+_\!8"__ 6 N_P':-   Q3P
M +=!  "L0P  HD,  )E   "0.@  B#0  ( N" !Z+1( =RX> ',O*0!Q,#,
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M DX^P0)-/N$"33[X DT^_P%-/O\!33W_ 4T]_P')0   N$@  *Q-  "A4
MEU$  (Y/  "$2P  >44  &Y   !F/0L 8CT4 %\]'@!</B@ 6CXQ %@^. !7
M/D  53]& %0_30!3/U4 4D!= %! 9@!/0' !3D!\ 4Q!B@%+09H"2D&K DE"
MO@)(0MX"2$+V DA"_P)(0O\!2$'_ 4A!_P'%1   M4L  *E0  ">5   E50
M (M3  " 4   =4H  &I&  !A0@@ 7$$1 %E"&P!70B4 54(N %-"-0!10CT
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M 3E._P$Y3O\!.4W_ 3I-_P&Z3@  K%8  *%;  "77P  C6$  (-A  !X7@
M:5@  %]6  !44@  3$\+ $E/$@!'4!P 15 E $-0+0!"4#4 05$\ $!11  _
M44P /E)4 #Q270 [4F< .E)S #A3@@$W4Y(!-5.D 313MP$S5-$!,U/Q 313
M_P$T4O\!-%+_ 312_P&V4@  J5H  )Y@  "49   BV8  (!E  !T8P  9EX
M %Q<  !16   1U4' $)5$ ! 51@ /U8A #U6*@ \5C( .U8Y #I700 Y5TD
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M 2%C_P&I8@  GFH  )5P  "*<P  @'4  '5U  !I=   7'(  $]Q  !$;P
M.FX  #!M P I; T )VP4 "9L'  E;20 )&TL "-M-  B;3T (6Y& "!N4  >
M;EL '6YG !QN=@ :;H< &6^: !AOK@ 6;\8 %F[I !=M_  8;/\ &&O_ !AK
M_P"D:0  FG$  )!V  "&>0  ?'L  '%[  !D>P  5WH  $IY   _>   -7@
M "MW   B=@< '78/ !QW%@ ;=QX &G<F !EW+@ 8=S< %WA  !5X2@ 4>%8
M$WAC !)X<@ 1>(, $'B7  ]XJP .>,, #G?F  YV^@ /=?\ $'7_ !!T_P"?
M<0  E7@  (M\  ""?P  =X$  &J"  !=@@  4((  $2"   X@@  +H(  "2"
M   <@@  %(() !&#$  0@Q8 $(,>  Z#)P .@S  #8,Y  V#1  ,@U  "X-=
M  F#;  (@WX !H.1  6"I0 #@KL !(';  2!\@ %@/\ !G__  9__P":>0
MD'X  (:#  !]A0  ;X<  &*)  !5B@  28L  #V,   QC   )HP  !V-   5
MC@  #X\#  J0#  &D!$ !(\8  ./(  !CRD  (\R  "0/0  D$D  (]6  "/
M90  CW8  (^*  ".GP  CK0  (W/  ",[@  C/L  (O_  "+_P"4@   BX4
M (*)  !TC   9H\  %F1  !,DP  0)4  #26   HE@  'I<  !68   /F@
M"IL   *<"0  G X  )P3  "<&@  G"(  )TK  "=-0  G4   )U.  "=7
MG6X  )R!  "<EP  G*P  )O&  ":Z   F?D  )G_  "8_P".B   AHP  'B0
M  !JE   7)<  $^:  !"G0  -IX  "F?   ?H0  %:(   ZD   (I@   *@
M  "I!   J0H  *D.  "I$P  JAH  *HB  "K*P  K#8  *Q$  "L4P  K&,
M *QW  "KC@  JZ0  *N\  "JW@  J?0  *G]  "I_P")C@  >Y,  &V7  !?
MG   4:   $2D   VI@  *J@  !ZI   4JP  #:X   :P    L@   +4   "U
M    M0,  +8)  "W#@  N!(  +@9  "Z(0  NRL  +PX  "]1P  O5@  +UK
M  "]@0  O9D  +VP  "]S   O.H  +SW  "[_@!^E0  <)L  &*@  !3I0
M1JH  #BM   JKP  'K$  !.T   ,MP   [D   "\    OP   ,(   #"
MPP   ,0   #&!@  QPP  ,@0  #*%@  S"   ,\K  #0.@  T4L  -%>  #2
M<P  THL  -*D  #3NP  T]@  -/M  #3]@!SG0  9*,  %:I  !'KP  .;,
M "JV   =N0  $KP   J_    PP   ,8   #)    S0   ,\   #0    T@
M -0   #6    V0(  -L(  #>#@  X1,  .0=  #H*@  Z#P  .E/  #I9
MZGP  .N5  #KK   Z\(  .S5  #LY0!FI@  6*P  $FS   [N0  *[P  !W
M   1Q   "<@   #,    SP   -,   #9    W0   .    #A    XP   .4
M  #G    Z@   .P   #N!   \0L  /42  #X'   ^RL  /T^  #^4P  _FH
M /^#  #_FP  _ZX  /^^  #_R@#_ !( _P 0 /\ $0#_ !, _P 9 /\ )@#_
M #0 _P!! /\ 30#_ %@ _P!B /\ :P#_ ', _P!Z /\ @0#_ (< _P"- /\
MDP#_ )D _P"@ /\ IP#^ *\ _ "Z /H R0#Y .$ ^ #S /< _P#V /\ ]0#_
M /$ _P#I /\ Y #_ .$ _P#_  \ _P - /\ #0#_  X _P 4 /\ (0#_ "X
M_P \ /\ 2 #_ %, _P!= /\ 9@#^ &T _ !U /L >P#Y (( ^ "( /< C@#V
M )0 ] "; /, H@#Q *H [P"T .T P0#K -4 Z@#L .@ _ #G /\ Y0#_ .8
M_P#@ /\ V0#_ -0 _P#_  L _P ( /\ !@#_  D _P 0 /\ ' #_ "D _P V
M /\ 0@#[ $X ]P!7 /0 8 #R &@ [P!O .T =@#L 'P Z@"" .@ B #G (X
MY0"5 ., G #A *0 WP"N -T N0#: ,H UP#D -0 ]@#1 /\ T #_ -  _P#/
M /\ RP#_ ,< _P#_  , _P   /\   #_  0 _P - /H %@#V ", \P P /
M/ #M $< Z0!1 .4 6@#B &( WP!I -T ;P#: '8 V !\ -0 @@#2 (@ T "/
M ,T E@#+ )X R0"H ,< LP#% ,$ P@#8 ,  [P"_ /X O@#_ +T _P"\ /\
MO #_ +P _P#_ @  _P   /\   #_    ]  ' .T $0#H !P XP I -\ -0#;
M $$ U@!+ -$ 5 #- %P R@!C ,@ :0#& &\ PP!U ,$ >P"_ (( O@"( +P
MD "Z )@ N "B +4 K "S +D L0#+ *\ YP"N /@ K #_ *L _P"L /\ K #_
M *L _P#_!   _P   /8   #N    YP   -\ # #6 !4 SP B ,H +@#' #H
MPP!$ ,  30"\ %4 N0!< +< 8P"U &D LP!O +$ =0"O 'L K0"" *L B@"I
M )( IP"< *4 I@"C +, H0## )\ W@"> /( G0#_ )P _P"< /\ FP#_ )L
M_P#_!P  ]@D  .D+  #?"@  U00  ,X !0#& !  P  : +L )P"W #( LP ]
M +  1@"M $\ J@!6 *@ 7 "F &, I !H *( ;P"A '4 GP!\ )T A "; (T
MF0"7 )< H@"5 *X DP"] )$ TP"0 .T CP#\ (X _P"- ?\ C0'_ (T!_P#Y
M#@  ZA(  -P5  #-%0  Q!$  +X,  "Z @H M  2 *X '@"J "H I@ U *(
M/P"@ $@ G0%0 )L"5@"9 EP EP-C )4#:0"3 V\ D01V ) $?P".!8@ C 62
M (H&G@"(!JH A@>Z (4(SP"$"NL @@O\ ($,_P" #/\ @ S_ ( ,_P#Q%0
MX!T  ,T@  #!(0  N!T  +$7  "L$   J D- *('%@"="2, F0HN )4+. "3
M#$$ D Q) (X-4 ",#5< B@U= (@-8P"'#6H A0YQ (,.>@""#H0 @ Z/ 'X/
MFP!\#Z@ >Q"X 'H0S@!X$>P =A+_ '42_P!T$_\ =!/_ '03_P#H'@  TR8
M ,,J  "X*@  KB@  *<C  "@'   FQ,# )8/$ "0$!L C!$G (D2,@"&$SL
MA!-# ((42P" %%$ ?A17 'P47@![%64 >15L '<5= !V%GX =!:* '(7E@!Q
M%Z0 ;QBT &X8R0!M&>@ :QK\ &H;_P!J&_\ :AO_ &H;_P#@)@  RBT  +PQ
M  "P,P  IS$  )\L  "7)@  D!\  (H7# "%&!8 @1DB 'X:+ ![&S8 >1L^
M '<<10!U'$P <QQ3 '$=60!P'6  ;AUG &T>< !K'GH :AZ% &@?D@!G'Z
M92"P &0AQ0!C(>0 8B+Z &$B_P!A(O\ 82+_ &$B_P#7+   PS0  +8X  "J
M.0  H3@  )@U  "0+P  B"@  ( A" ![(!( =R$= '0B)P!Q(C$ ;R,Y &TC
M00!K(T@ :2-. &@D50!F)%L 921C &,E:P!B)74 826! %\FC@!>)IT 72>M
M %LHP0!;*.  6BGW %DI_P!9*?\ 62G_ %DH_P#/,@  OCD  +$]  "F/P
MG#\  ),\  "*-@  @3   'DJ P!R)@\ ;B<9 &LH(P!I*"P 9BDU &4I/ !C
M*4, 82I* & J40!>*E< 72I? %PK: !:*W( 62Q] %@LBP!6+9H 52VJ %0N
MO0!3+MP 4B_U %(O_P!2+O\ 4B[_ %(N_P#*-@  NCT  *U"  "B1   F$0
M (]!  "%/   >S<  '(Q  !K+ P 9RT5 &0M'P!A+B@ 7RXQ %TN.0!<+T
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M 4$]_P%!//\!03S_ 4$\_P"^0@  KTD  *-.  "94   CU$  (50  ![3
M;T8  &5"  !:/0( 5#L. %$[%0!/.Q\ 33LG $L[+P!)/#8 1SP] $<\1 !&
M/4L 13U4 $0^7 !#/F< 0C]S $ _@0 _/Y$ /D"B #U M0$\0<X!/$'N 3Q!
M_P$\0/\!/$#_ 3T__P&Z10  K$P  *%1  "75   C54  (-4  !X40  ;$L
M &%'  !60@  3T , $P_$P!)0!P 1T D $9 + !$0#, 0T Z $)!0@!!04D
M0$)1 #]"6@ ^0V4 /4-Q #M#?P Z1(\ .42@ #A%LP$W1<L!-T7L 3=%_P$W
M1/\!.$3_ 3A#_P"W20  J5   )Y5  "46   BUD  (!8  !V5@  :%   %U,
M  !32   2D4) $9$$0!$1!D 0D0B $%%*0 _13$ /D4X #U%/P \1D< .T9/
M #I'6  Y1V( .$AN #9(?  U2(T -$F> #-)L0 R2<D ,4GK #))_@ R2/\
M,DC_ #-(_P"T3   IU0  )Q9  "27   B%T  'Y=  !S6@  954  %M2  !0
M3@  1DH% $!)#@ ^218 /4D> #M*)@ Z2BX .4HU #A+/0 W2T0 -DM- #1,
M5@ S3&  ,DQL #%->@ P38L +DV< "U.KP L3L< +$[I "Q-_0 M3?\ +4S_
M "U,_P"P4   I%@  )E=  "/80  AF(  'MA  !P7P  8EL  %A8  !.50
M0U$! #M/#  X3Q, -D\; #5/(P T4"L ,U R #)0.@ Q4$( ,%%* "Y14P M
M4ET +%)I "M2>  I4H@ *%.: "=3K0 F4\4 )E/G "93_  G4O\ )U'_ "=1
M_P"L50  H%P  )9B  "-9@  @V<  'AF  !M90  8&$  %5>  !*6P  /U@
M #56"  Q51  ,%87 "Y6'P M5B< +%8O "M7-@ J5SX *5=' "A74  F6%H
M)5AG "18=0 C688 (5F8 "!9JP ?6<( 'UGE !]8^@ @6/\ (%?_ "%7_P"H
M6@  G6(  )-G  "*:P  ?VP  '5L  !J:P  76@  %%E  !&8P  .V   #%>
M P J70T *%T3 "9=&P E7B, )%XJ "->,@ B7CH (5Y# "!?3  ?7U< 'E]C
M !Q@<0 ;8(( &6"5 !A@J0 78,  %F#B !=?^0 87O\ &5[_ !E=_P"D8
MF6@  )!N  "&<   ?'(  ')R  !F<0  6&X  $QL  !!:P  -FD  "UG   C
M9@@ 'V8/ !UF%0 <9AT &V8E !IF+0 99S4 &&<^ !=G2  69U, %6A? !-H
M;@ 2:'\ $6B2 !!HI@ /:+T #FC@ !!G]P 09O\ $67_ !%E_P"?9P  EF\
M (QS  ""=@  >'@  &UX  !@=P  4W8  $9T   [<P  ,7(  "=Q   ><0
M%G * !-P$  3<!< $G ? !%Q)P 0<2\ $'$X  YQ0@ .<4X #7%;  QQ:0 +
M<7H "G&-  AQH0 &<;8 !G#2  =P[P (;_\ "6[_  EN_P";;P  D74  (=Y
M  !^?   ='X  &9^  !9?@  37X  $!]   U?0  *GP  "%\   8?   $7P$
M  Q\#  *?!$ "7P9  A\(0 '?"D !GPR  1\/0 #?$@  7Q5  !\8P  ?'0
M 'R'  ![G   >[$  'K+  !YZP  >?H  'G_  !X_P"6=P  C'P  (.   !Y
M@P  ;(0  %Z%  !1A@  18<  #F'   MAP  (X<  !J'   2AP  #8@!  :)
M"@ !B0\  (D4  "(&P  B",  (DL  ")-@  B4(  (A.  "(70  B&T  (B!
M  "'E0  AZL  (;$  "%Y@  A/@  (3_  "$_P"0?@  AX,  'Z'  !QB0
M8XL  %:-  !)CP  /)$  #"1   DD0  &I(  !*3   -E   !I4   "6!@
ME@P  )40  "6%0  EAT  )8D  "6+@  ECD  )9&  "650  EF4  )9X  "5
MC@  E:0  )2\  "3WP  D_4  )+_  "2_P"+A@  @XH  '6-  !GD   690
M $R7   _F0  ,IH  ":;   ;G   $IT   R?   $H    *(   "C 0  HP<
M *,,  "C$   I!4  *0<  "E)0  IB\  *8\  "F2P  IEL  *9N  "EA
MI9L  *2S  "CT   H^\  *+\  "B_P"&C0  >)$  &J5  !<F0  3IT  $&@
M   SH@  )J,  !NE   1IP  "JD   &K    K0   *\   "P    L    + %
M  "Q"P  L@\  +,4  "T&P  M20  +<P  "W/P  MU   +=B  "W>   MY
M +:I  "VP@  MN0  +;U  "U_@![DP  ;9@  %^=  !0H@  0J8  #2I   F
MJP  &JT  !"O   )L@   +0   "W    N@   +P   "]    O@   +X   #
M @  P0@  ,(-  #$$@  QAD  ,DD  #*,@  RT,  ,M5  #,:@  S(,  ,R<
M  #+M0  S,X  ,SI  #,]@!PFP  8:$  %*F  !$JP  -K   ">R   :M0
M$+@   >[    O@   ,$   #$    R    ,L   #+    S0   ,X   #0
MT@   -4#  #8"@  VQ   -X8  #B)   XS4  .1(  #E7   YG,  .:-  #F
MI0  YKP  .;3  #GYP!CI   5:H  $:P   XM0  *+D  !J\   /P   !<0
M  #'    RP   ,\   #4    V    -P   #=    WP   .$   #C    Y0
M .@   #J    [08  /$.  #U%@  ^"4  /DX  #Y30  ^F,  /M\  #\E0
M_*H  /R[  #]RP#_  \ _P . /\ #@#_ !  _P 6 /\ (P#_ #  _P ] /\
M20#_ %0 _P!> /\ 9@#_ &X _P!V /\ ? #_ (( _P") /\ CP#_ )4 _@";
M /T HP#[ *L ^@"U /D PP#W -L ]@#P /0 _P#S /\ \@#_ .P _P#B /\
MW #_ -8 _P#_  P _P ) /\ " #_  H _P 2 /\ '@#_ "L _P X /\ 1 #_
M $\ _P!9 /X 80#\ &D ^@!P /@ =P#W 'T ]@"# /0 B0#R (\ \0"6 .\
MG0#M *4 [ "O .H O #H ,T Y@#H .0 ^@#C /\ X@#_ .  _P#5 /\ S@#_
M ,L _P#_  8 _P ! /\   #_  0 _P . /\ &0#_ "4 _0 R /L /@#W $D
M\P!3 /  7 #N &, [ !J .H <0#H '< Y@!] .0 @P#B (D X "0 -X EP#<
M )\ V0"I -8 M #3 ,0 T #> ,X \P#, /\ RP#_ ,H _P#( /\ P@#_ +X
M_P#_    _P   /\   #_    ^P + /8 $P#Q "  [0 L .H . #G $, XP!-
M .  5@#< %T V0!D -4 :P#2 '$ T !V ,X ? #, (, R@") ,@ D0#& )D
MQ "C ,$ K0"_ +L O0#/ +L ZP"Y /P MP#_ +< _P"V /\ M #_ +$ _P#_
M    _P   /\   #V    [@ % .< #P#A !D VP E -4 ,0#2 #P S@!& ,H
M3P#' %< Q !> ,$ 9 "_ &H O0!P +L =@"Y 'P N "# +8 B@"S ), L0"<
M *\ IP"M +, JP#% *D X0"G /4 I@#_ *4 _P"D /\ I #_ *0 _P#_
M_    /$   #H    X    -0 "P#, !, QP ? ,( *@"_ #4 O  _ +@ 2 "U
M %  LP!7 +  7@"N &0 K !I *L ;P"I '4 IP!\ *4 A "C (P H0"6 )\
MH0"= *T F@"\ )@ T@"7 .X E0#^ )0 _P"5 /\ E0#_ )4 _P#\ 0  \ 4
M .,'  #5!0  S    ,4 ! "^  X N  7 +, (P"O "X JP X *D 00"F $H
MHP!1 *$ 5P"? %T G0!C )L :0": &\ F !V )8 ?0"4 (8 D@"0 )  FP".
M *< C "V (H R0"( .< AP#Y (< _P"& /\ A@#_ (8 _P#T#   Y!   -$2
M  #%$0  O0X  +8(  "Q  @ JP 1 *8 &P"A "8 G@ Q )H .@"8 $, E0!*
M ), 40"1 %< CP!= (X 8P", &D B@!P (@ =P"& (  A "+ (( E@"  *,
M?@"Q 'T Q ![ N$ >@/U 'H%_P!Y!?\ > ;_ '@&_P#J$P  UAH  ,8=  "Z
M'   L1D  *H3  "D#0  GP4, )D % "5 !\ D0(I (T#,P"+!#P B 5$ (8&
M2P"$!E$ @@=7 ($'70!_!V, ?0AJ 'L(<@!Z"'P > F& '8)D@!T"J  <PJO
M '$+P0!P#-\ ;PWV &X._P!M#O\ ;0[_ &T._P#A'   RR,  +PF  "Q)@
MJ"0  * >  "9&   DQ " (X+#@"("Q< A PB ($-+ !^#34 ? X] 'H.10!X
M#DL =PY1 '4/6 !S#UX <1!E ' 0;@!N$'< ;!"" &L0CP!I$9T :!&M &82
MP !E$M\ 9!/V &,4_P!C%/\ 8A3_ &(4_P#6)   PRH  +4N  "J+P  H"T
M )@H  "0(@  B1L  ((3" !]$1( >1(< '83)P!S%#  <10X &\5/P!M%48
M;!5, &H64P!H%ED 9Q9A &46:0!D%W( 8A=^ &$8BP!?&)D 7AFI %P9O !<
M&M@ 6AOS %H<_P!9'/\ 61S_ %D<_P#-*@  O3$  *\U  "D-@  FS0  )(Q
M  ")*P  @24  'D= P!S& X ;QD8 &P:(@!I&RL 9QLS &4<.P!D'$$ 8AU(
M & =3@!?'54 71U< %P>9 !;'FX 61]Y %@?AP!6()8 52"F %0AN !3(=(
M4B+Q %(C_P!2(_\ 4B+_ %(B_P#(+P  N#8  *LZ  "@/   ECL  (TX  "#
M,@  >BT  '(F  !J( P 9B 3 &,A'0!A(28 7R(O %TB-@!;(CT 6B-$ %@C
M2@!7(U$ 52-8 %0D80!3)&H 425V % E@P!/)I, 3B>C $PGM0!,*,X 2RCN
M $LI_P!+*/\ 2RC_ $LH_P##-   LSL  *<_  "<00  DD   (D^  !_.0
M=3,  &PM  !C)P@ 7B81 %PF&0!9)R( 5R<K %4H,@!4*#D 4BA  %$H1@!0
M*4T 3BE5 $TI70!,*F< 2RIS $DK@ !(*Y  1RRA $8MLP!%+<L 12[L $0N
M_P!$+O\ 12W_ $4M_P"^.   L#\  *1#  "910  CT4  (5#  ![/@  <3D
M &<T  !>+@0 6"L. %4K%@!2+!\ 4"PG $\L+P!-+38 3"T\ $HM0P!)+4H
M2"Y2 $<N6@!&+V0 12]P $,P?@!",(T 03&> $ RL0 _,L@ /S/J #\S_@ _
M,O\ /S+_ #\R_P"[/   K4,  *%'  "620  C$D  (-(  !X1   ;3X  &,Y
M  !:-   4C , $\P$P!,,!P 2C D $DQ*P!',3( 1C$Y $0Q0 !#,D< 0C)/
M $$S6 ! ,V( /S1M #XT>P ]-8L /#:< #LVKP Z-\8 .3?H #DW_  Z-_\
M.C;_ #HV_P"W0   JD8  )Y+  "430  BDX  (!,  !U2   :D,  & ^  !6
M.0  334) $DT$0!'-1D 134A $,U* !!-2\ 0#4V #\V/0 ^-D4 /3=- #PW
M50 [.&  .CAK #DY>0 X.8D -SJ; #4ZK0 U.\0 -#OF #0[^P U._\ -3K_
M #4Z_P"T0P  ITH  )Q.  "240  B%(  'Y0  !S30  9T@  %Q$  !2/P
M2#H& $0Y#P!!.18 /SD> #XY)@ \.2T .SHT #HZ.P Y.T( .#M* #<\4P V
M/%T -3UI #0]=P S/H< ,3Z9 # _JP O/\( +S_D "\_^@ P/_\ ,#[_ # ^
M_P"Q1P  I$T  )E2  "/50  AE8  'Q5  !Q4@  9$P  %E)  !/10  14 #
M #\^#0 \/A, .CX; #D^(P W/BH -C\Q #4_.  T/T  ,T!( #) 40 Q05L
M,$%G "Y"=0 M0H4 +$.7 "M#J@ J0\  *43B "I#^0 J0_\ *T+_ "M"_P"N
M2@  H5$  )=6  "-60  @UH  'E:  !N5P  85(  %=.  !-2P  0T<  #I#
M"@ V0Q$ -$,8 #-#(  R1"< ,40O #!$-@ O13T +45& "Q%3P K1ED *D9D
M "E'<@ H1X, )D>5 "5(J  D2+X (TC@ "1(]P E1_\ )4?_ "9'_P"J3P
MGU4  )1:  "+7@  @5\  '=>  !K7   7U@  %55  !+40  0$T  #5*!P P
M20X +DD5 "U)'0 L220 *THK "I*,P H2CL )TM# "9+3  E2U8 )$QB "-,
M<  A3(  ($V3 !]-I@ >3;L '4[= !Y-]@ >3/\ 'TS_ "!+_P"G4P  G%H
M ))?  "(8P  ?F0  '1C  !I80  7%X  %);  !'6   /%4  #)2 @ J4 P
M)T\2 "90&0 E4"  )% H "-0+P B43< (5%  "!120 >4E, '5)? !Q2;0 :
M4WT &5.0 !A3I  64[D %5/9 !93]  74O\ &%'_ !E1_P"C60  F&   (]E
M  "%:   >VD  '%I  !F9P  660  $UA  !"7P  .%P  "Y:   E6 @ (%<.
M !Y7%  =5QP '%@C !M8*P :6#, &5@\ !A810 665  %5E; !19:0 36GH
M$EJ- !%:H0 06K< #EK5 !!9\P 06?\ $5C_ !%8_P"?7P  E68  (QK  ""
M;0  >&X  &YO  !B;0  56H  $AH   ^9@  ,V4  "EC   @80$ && + !5@
M$  48!< $V > !)@)@ 28"X $6$W !!A0  /84L #F%8  UA9@ ,8G8 "V*)
M  IAG0 )8;( "&'+  AAZP )8/T "E__  M?_P";9@  DFT  (AQ  !^<P
M=74  &IT  !<<P  3W(  $-P   X;P  +6X  "1L   ;:P  $VL$  YJ#  -
M:A( #&H9  MJ(0 *:BD "6HR  AJ/  ':T< !6M3  1K80 ":W$  &J$  !J
MF   :JT  &G&  !IYP  :?@  &C_  !H_P"7;0  C7,  (1W  ![>@  <'L
M &-[  !6>@  27H  #UY   Q>   )W<  !UV   5=@  #W8"  EV"@ $=@\
M '85  !V'   =B0  '4L  !U-@  =4$  '5.  !U7   =6P  '5^  !TDP
M=*@  '/   !SXP  <O<  '+_  !Q_P"2=0  B7H  (!^  !V@   :8$  %N"
M  !.@@  08(  #6#   I@@  'X$  !:!   0@@  "H(   *#!P  @@T  ((1
M  ""%P  @AX  ((F  ""+P  @CL  ()'  ""50  @64  (%X  "!C0  @*(
M '^Z  !_W0  ?O0  'W_  !]_P"-?   A($  'N$  !NA@  8(@  %**  !%
MBP  .8P  "R,   AC   %XP  !"-   )C@   H\   "0 P  CPD  (\.  "/
M$@  D!@  ) ?  "0*   D#(  ) _  "030  D%T  (]P  "/A0  CIP  (ZS
M  "-T   C/   (O^  "+_P"(A   @(@  '*+  !DC0  5I   $B3   [E0
M+I8  "*6   7EP  #Y@   B9    FP   )T   "=    G0,  )T)  "=#0
MGA$  )X7  "?'P  GRD  * U  "@0P  H%0  *!F  "?>P  GI,  )ZK  "=
MQ@  G>D  )SY  "<_P"#BP  =8X  &>2  !9E@  2YD  #V<   PG@  (Y\
M !>@   .H@  !Z0   "F    J    *H   "J    J@   *L!  "K!P  K P
M *T0  "N%@  KQX  +$I  "Q.   L4@  +%:  "Q;P  L8@  +&@  "PN@
MK]T  *_R  "O_0!XD0  :I8  %R:  !-GP  /Z,  #&F   CIP  %ZD   ZK
M   %K@   +    "R    M0   +<   "W    N    +D   "Z    O ,  +T)
M  "^#@  P!0  ,,>  #%*P  Q3P  ,9.  #&8@  QGH  ,:4  #&K0  QL@
M ,7E  #%\P!LF0  7IX  $^D  !!J   ,JP  "2O   6L0  #;0   .W
MN@   +T   #     Q    ,8   #&    R    ,D   #+    S    ,X   #0
M!@  TPT  -@3  #<'@  WBT  -]   #@5   X6L  .&%  #AGP  X;<  .'/
M  #AY@!@H0  4J<  $.M   TL@  );4  !>Y   -O    ;\   ##    QP
M ,H   #/    TP   -8   #7    V@   -P   #?    X0   .,   #F
MZ0$  .P+  #P$@  \Q\  /0Q  #V1@  ]UP  /AT  #XCP  ^:8  /FX  #X
MR0#_  T _P + /\ "P#_  X _P 3 /\ 'P#_ "P _P Y /\ 10#_ %  _P!9
M /\ 8@#_ &H _P!Q /\ =P#_ 'X _P"$ /X B@#] )  _ "7 /H G@#Y *<
M]P"Q /8 O@#U -( \P#L /$ _@#P /\ \ #_ .8 _P#< /\ T@#_ ,T _P#_
M  < _P $ /\  @#_  8 _P 0 /\ &P#_ "< _P S /\ /P#_ $H _@!4 /L
M70#Y &0 ]P!K /4 <@#S '@ \@!^ /  A #O (H [0"1 .P F0#J *$ Z "K
M .8 M@#D ,< X@#C .  ]P#> /\ W0#_ -D _P#, /\ Q0#_ ,$ _P#_
M_P   /\   #_  $ _P - /\ %@#\ "( ^0 N /8 .0#S $4 [P!. .P 5P#I
M %X Y@!E .0 ; #B '( X !W -\ ?@#= (0 VP"+ -@ D@#5 )L T@"D ,\
MKP#- +X RP#5 ,D [P#' /\ Q0#_ ,0 _P"^ /\ N #_ +4 _P#_    _P
M /\   #^    ]P ) /$ $0#K !P YP H .0 ,P#A #X W0!( -@ 40#3 %@
MT !? ,X 90#, &L R@!Q ,@ =P#& 'T Q "$ ,( C #  )0 O@"> +L J "Y
M +8 MP#( +4 Y@"S /H L0#_ +  _P"P /\ K #_ *D _P#_    _P   /H
M  #Q    Z  # .  #0#8 !8 T0 B ,T +0#* #< Q@!! ,( 2@"_ %( O0!9
M +H 7P"X &4 MP!J +4 < "S '8 L0!] *\ A0"M (T JP"7 *D H0"G *X
MI0"^ *( V "@ /( GP#_ )X _P"> /\ G@#_ )P _P#_    ]P   .L   #A
M    U@   ,L "0#% !$ OP ; +L )@"W #$ M  Z +$ 0P"N $L JP!2 *D
M6 "G %X I@!D *0 :0"B '  H !V )X ?@"< (8 F@"0 )@ FP"6 *< E "V
M )( R@"0 .D CP#\ (X _P"- /\ C #_ (T _P#X    Z0(  -L#  #, 0
MQ    +T  @"V  T L  5 *L ( "G "H I  T *$ / "> $0 G !+ )H 4@"8
M %@ E@!= )4 8P"3 &D D0!P (\ =P"- (  BP"* (D E0"' *$ A0"O (,
MP0"! .  @ #U '\ _P!_ /\ ?P#_ '\ _P#N"@  W X  ,H0  "^#@  M0L
M *\#  "I  < HP 0 )X & "9 ", E@ L ), -0"0 #X C@!% (P 2P"* %$
MB !7 (8 70"% &, @P!J ($ <0!_ 'H ?0"$ 'L CP!Y )P =P"J '4 NP!T
M -0 <@#P '( _P!R /\ <0#_ '$ _P#C$0  S1<  +\9  "S&0  JA4  *,0
M  "="@  EP$* )$ $@"- !L B0 E (4 +P"# #< @  ^ 'X 10!] $L >P!1
M 'D 5P!X %T =@!D '0!:P!R 70 < )_ &X"BP!L Y@ :P.F &D$MP!H!<X
M9P?L &8(_0!F"?\ 90G_ &4)_P#6&@  Q"   +8C  "K(P  H2   )D;  "2
M%   C X! (8'#0" !!0 ? 8> 'D'* !V"#  = @X '()/P!P"44 ;PI, &T*
M4@!L"E@ :@M? &@+9P!G"W  90QZ &,,AP!B#)4 8 VD %\-M@!>#<X 7 [M
M %P/_P!;$/\ 6Q#_ %L0_P#-(0  O"@  *\K  "D*P  FBD  )(D  ")'P
M@A@  'L1!0!U#0\ <0T7 &X.(0!K#BH :0\R &<0.0!E$$  9!!& &,030!A
M$%, 7Q%: %X18@!<$6L 6Q%V %D2@P!8$I( 5A.B %43M !4$\L 4Q3L %(5
M_P!2%O\ 4A7_ %(5_P#&*   MBX  *DR  "?,@  E3$  (PM  "#)P  >B$
M '(:  !K$PL 9Q,3 &04' !A%"4 7Q4M %T5- !<%3L 6Q9" %D62 !8%D\
M5A=6 %477@!3%V< 4AAR % 8?P!/&8X 3AJ? $P:L !+&\< 2QOI $H<_0!*
M'/\ 2AS_ $H<_P#!+0  L30  *4W  ":.   D#<  (<T  !]+P  ="D  &PC
M  !D' < 7AD0 %L:& !9&R$ 5QLI %4;, !4'#< 4AP] %$<1 !/'4L 3AU2
M $T=6@!+'F, 2AYN $D?? !''XL 1B"< $4AK@!$(<0 0R+F $,B_ !#(O\
M0R+_ $,B_P"\,@  K3@  *$\  "7/@  C3T  (,Z  !Y-0  ;S   &8J  !>
M) ( 5R - %0@% !1(!T 3R$E $XA+ !,(3, 2R(Z $DB0 !((D< 1R). $8C
M5P!$(V  0R1K $(D>0!!)8@ /R:9 #XFJP ])\$ /2?C #TH^@ ]*/\ /2?_
M #TG_P"X-@  JCT  )Y   "40@  BD(  ( _  !V.P  ;#8  &(P  !9*@
M424+ $TE$0!+)1D 224A $<F* !%)B\ 1"8V $,F/0!")T0 02=+ #\H5  ^
M*%T /2EI #PI=@ [*H8 .2N7 #@KJ0 W++\ -RS@ #<L^  W+/\ -RS_ #@L
M_P"U.@  IT   )Q$  "11@  AT8  'U$  !S0   :#L  %\V  !5,0  3"L'
M $<I#P!%*A8 0RH> $$J)0 _*BP /BLS #TK.0 \*T$ .RQ( #HL40 Y+5L
M."YF #8N<P U+X, -"^5 #,PIP R,+T ,3'> #$Q]P R,?\ ,C#_ #,P_P"Q
M/@  I$0  )E(  "/2@  A4H  'M)  !P10  94   %L[  !2-@  2#$$ $(N
M#0 _+A, /2X; #LN(@ Y+RD ."\O #<O-@ V,#X -3!& #0Q3P S,5D ,C)D
M #$R<0 P,X$ +S23 "XTI@ L-;L +#7; "PU]0 M-?\ +33_ "XT_P"N00
MHD@  )=,  "-3@  @TX  'E-  !N2@  8D4  %A   !./   13<  #TS"P Y
M,Q$ -S,8 #8S'P T,R8 ,S,M #(T-  Q-#P ,#5$ "\U3  N-E8 +39B "PW
M;P K-W\ *CB1 "@XI  G.;D )CG8 "<Y]  H.?\ *#C_ "DX_P"K10  GTL
M )1/  "+4@  @5,  '=2  !L3P  7TD  %9&  !,0@  0CT  #@X"  T. \
M,C@5 #$X'0 O."0 +C@K "TY,@ L.3D *SI! "HZ2@ I.U0 *#M? "<\;0 E
M/'T )#V/ ",]H@ B/;< (3[4 "$^\P B/?\ (SW_ ",\_P"H20  G4\  ))3
M  ")5@  ?U<  '56  !J4P  74\  %-,  !*2   0$0  #9 !0 O/0T +3T3
M "L]&@ J/B$ *3XH "@^+P G/C< )C\_ "0_2  C0%( (D!= "%!:@ @07H
M'D&- !U"H  <0K4 &T+1 !M"\0 <0O\ '4'_ !Y!_P"E30  FE,  )!8  "&
M6P  ?5P  ');  !G6   6U0  %%2  !(3@  /4H  #-'   J0PL )D,0 "5#
M%@ D0QX (T0E ")$+  A1#0 ($4\ !Y%10 =14\ '$9: !M&:  91G@ &$>*
M !='G@ 61[, %$C. !5'[P 61_\ %T;_ !=&_P"B4@  EU@  (U=  "$8
M>F$  '!@  !E7@  65H  $]8  !$5   .5$  "].   F2P8 ($H. !Y*$P =
M2AH '$HA !M+*  :2S  &4LX !=+0@ 63$P %4Q7 !1,90 3374 $DV( !%-
MG  03;$ #D[,  ]-[@ 03?\ $4S_ !%,_P">5P  E%T  (MB  "!90  =V8
M &UF  !C9   5F$  $I>   _6P  -5@  "M6   B5 $ &E(* !92$  54A8
M%%(= !-2)  24BP $5(T !%2/@ 04T@ #U-4  Y38@ -5'( #%2$  M4F  )
M5*T "%3%  E4YP *4_L "U+_  M2_P";70  D60  (AH  !^:P  =&P  &ML
M  !?:@  4F<  $5D   Z8@  ,&   "9>   =70  %5L% !!:#  .6A$ #EH8
M  U;(  ,6R< "ULP  I;.@ )6T4 !UM1  9;7@ $6VT  UN   %;E   6Z@
M %O   !:X@  6O8  5K_  )9_P"79   CFL  (1N  ![<   <G(  &=Q  !9
M<   3&X  $!L   U:P  *FD  "%G   89@  $68!  QE"@ '90\ !&44  -D
M&P "9",  &0L  !D-0  9$   &1,  !D6@  9&D  &1[  !DCP  8Z0  &.[
M  !BW0  8O0  &+_  !A_P"3;   B7$  (!U  !X=P  ;7@  &!W  !2=@
M1G4  #ET   N=   (W(  !IQ   2<0  #7$   9Q"   < T  ' 2  !P%P
M;Q\  &\F  !O,   ;SL  &]'  !O5   ;V0  &]U  !NB@  ;:   &VV  !L
MU@  :_(  &O_  !K_P".<P  A7@  'U[  !S?0  97X  %A^  !+?@  /GX
M #)^   F?0  ''P  !-\   -?   !GT   !]!0  ? L  'P/  !\$P  ?!D
M 'PA  !\*0  ?#0  'M   ![3@  >UX  'MO  !ZA   >IH  'FQ  !XS@
M=^\  ';^  !V_P")>@  @7\  'B"  !K@P  784  $^&  !"AP  -8@  "F'
M   =AP  %(<   V(   &B0   (H   "*    B08  (D,  ")#P  B1,  (D:
M  "*(@  BBP  (HX  "*1@  B58  (EH  ")?   B)0  (>K  "&Q@  A>H
M (7[  "$_P"%@@  ?88  &^(  !ABP  4XT  $6/   XD0  *Y$  !^2   4
MD@  #9,   24    E@   )<   "8    EP   )<%  "7"P  F X  )@3  "9
M&@  F2(  )HN  ":/0  F4T  )E>  "9<P  F(L  )BC  "7O   EN(  );W
M  "5_P" B0  <HP  &2/  !6DP  2)8  #J9   LF@  'YL  !2<   ,G@
M Y\   "A    HP   *4   "E    I0   *4   "F @  IP@  *<-  "H$0
MJ1D  *LC  "K,0  JT$  *Q3  "L9P  JX   *J:  "JLP  JM   *GO  "I
M^P!UCP  9Y0  %F8  !*G   /)\  "VB   @HP  $Z4   NG   !J0   *L
M  "N    L0   +(   "R    LP   +0   "U    M@   +@$  "Y"P  NQ
M +T8  "_)   OS4  ,!'  # 6P  P'(  ,"-  #!I@  P,$  +_C  "^\P!J
MEP  6YP  $VA   ^I0  +ZD  "&K   3K0  "[    "S    M0   +@   "\
M    OP   ,$   #!    PP   ,0   #&    QP   ,D   #+    S@@  -$/
M  #5&   V"<  -DY  #:30  VV0  -M^  #<F0  W+   -S)  #<XP!=GP
M3Z4  $"J   RKP  (K(  !2U   *N    +L   "_    PP   ,8   #+
MS@   -$   #1    U    -8   #9    VP   -X   #@    Y    .<&  #K
M#@  [QD  / J  #R/P  \U4  /1M  #TB   ]*$  /2V  #TQP#_  D _P &
M /\ !P#_  P _P 1 /\ ' #_ "@ _P T /\ 00#_ $P _P!5 /\ 70#_ &4
M_P!L /\ <@#^ '@ _ !^ /L A #Z (L ^0"2 /< F0#V *( ] "L /, N0#Q
M ,L \ #H .X ^P#M /\ [ #_ .$ _P#2 /\ R0#_ ,0 _P#_  $ _P   /\
M  #_  0 _P . /\ %P#_ ", _P O /\ .P#] $8 ^@!0 /< 6 #T %\ \@!F
M /  ; #O '( [0!X .P ?@#J (4 Z0", .< DP#E )P XP"F .$ L0#? ,$
MW0#= -L ] #9 /\ U@#_ ,\ _P#$ /\ O0#_ +D _P#_    _P   /\   #_
M    _P + /P $P#W !X ]  J /( -0#N $  Z0!* .8 4@#C %D X !@ -X
M9@#< &P V@!R -< > #4 'X T@"% -  C0#. )4 S "? ,D J@#' +@ Q0#-
M ,, ZP#  /X OP#_ +X _P"V /\ L #_ *T _P#_    _P   /\   #Y
M\@ & .L #P#F !D X0 D -X +P#: #D TP!# ,\ 3 #, %, R0!: ,< 8 #%
M &8 PP!K ,$ <0"_ '< O0!^ +L A@"Y (X MP"8 +4 HP"S +  L0#" *X
MX "L /< JP#_ *H _P"H /\ HP#_ *  _P#_    _P   /4   #K    X0
M -8 # #/ !, R@ > ,8 *0#" #, OP ] +L 10"X $T M@!4 +, 6@"Q %\
ML !E *X :@"L '  JP!W *D ?P"G (< I0"1 *, G "@ *D G@"X )P S@":
M .X F0#_ )< _P"6 /\ E@#_ ), _P#]    \0   .4   #9    S0   ,0
M!@"]  \ MP 8 +, (@"P "P K0 V *D /@"G $8 I !- *( 4P"@ %D GP!>
M )T 9 "; &H F@!P )@ =P"6 (  E "* )$ E0"/ *( C0"P (L PP") .,
MB #Y (8 _P"& /\ A@#_ (8 _P#S    XP   -$   #%    O0   +8   "N
M  L J  2 *0 ' "@ "8 G  O )H -P"7 #\ E0!& )( 3 "1 %( CP!8 (T
M70"+ &, B@!J (@ <0"& 'D A "# (( CP!_ )L ?@"I 'P NP!Z -4 > #R
M '@ _P!W /\ =P#_ '< _P#G!P  T0P  ,,-  "X#   K@@  *@   "B  4
MFP . )8 %0"2 !\ C@ H (L ,0"( #D A@!  (0 1@"" $P @ !2 '\ 5P!]
M %T >P!C 'H :P!X ', =@!] '0 B !Q )4 < "D &X M !L ,H :P#J &H
M_ !J /\ :@#_ &H _P#:$   QA0  +@6  "M%0  I!(  )P.  "6!P  D  )
M (H $ "% !@ @0 A 'X *@![ #( >0 Y '< 0 !U $8 <P!, '( 40!P %<
M;@!> &T 90!K &X :0!W &< @P!E )$ 8P"? &( KP!@ ,0 7P#D %\!^ !>
M O\ 7@+_ %X"_P#.&   O1T  + @  "E'P  FQP  ),7  "+$0  A P  'X$
M"P!Y !( =0 ; '( (P!O "L ;0$S &L!.@!I D  9P-& &8#3 !D!%( 8P19
M &$$8 !?!6D 7@5S %P&?P!:!HT 60>< %<(K0!6",$ 50GA %0+]@!4"_\
M5 O_ %0+_P#&'P  MB4  *DH  ">*   E"4  (LA  "#&P  >Q0  '0. P!N
M"0T :0@4 &8)'0!D"B4 8@HM & +- !>"SH 70M  %L,1P!:#$T 6 Q4 %<-
M7 !5#60 5 UO %(->P!0#HH 3PZ: $X.K !,#\( 3!#C $L0^0!+$/\ 2Q'_
M $L0_P"_)@  L"L  *0O  "9+P  CRT  (8I  !])   =!X  &P7  !E$0<
M7PX0 %P/%P!:$!\ 6! G %80+@!4$#4 4Q [ %(10@!0$4@ 3Q%0 $X15P!,
M$F  2Q)K $D2> !($X< 1A.7 $44J0!$%+X 0Q7? $,6^ !#%O\ 0Q;_ $,6
M_P"Z*P  JS$  * T  "5-0  BS0  ($Q  !X*P  ;R8  &8@  !>&0$ 5Q0-
M %04$P!1%!L 3Q4C $X5*@!,%3$ 2Q8W $D6/@!(%D0 1Q=, $475 !$%UT
M0QAG $$8= ! &8, /QJ4 #T:I@ \&[L .QO; #L<]@ \'/\ /!S_ #P<_P"U
M,   J#8  )PY  "1.P  ASH  'XW  !S,@  :BT  &$G  !9(0  41L) $P9
M$ !*&A< 2!H? $8:)@!%&RT 0QLS $(;.@!!'$$ 0!Q( #X<4  ]'5D /!YD
M #L><0 Y'X  .!^2 #<@I  V(+@ -2'6 #4A]  U(O\ -2'_ #8A_P"R-
MI#H  )D^  "//P  A3\  'L\  !P.   9S(  %TM  !4*   3"(% $8?#@!#
M'Q0 01\; #\?(@ ^("D /2 P #L@-@ Z(3T .2%% #@B30 W(E< -B-B #0C
M;@ S)'X ,B2/ #$EH@ O);8 +R;2 "\F\@ O)O\ ,";_ # F_P"O.   HCX
M )9"  ",0P  @D,  'A!  !N/0  8S@  %HS  !1+@  2"@! $ D#  ](Q$
M.R08 #DD'P X)"8 -B0L #4E,P T)3H ,R9" #(F2@ Q)U0 ,"=? "\H;  N
M*'L +"F- "LJH  J*K0 *2K/ "DK\  J*_\ *BK_ "LJ_P"L/   GT(  )1&
M  "*1P  @$<  '9%  !L0@  83T  %<X  !.,P  1"X  #PI"0 W*!  -2@5
M #,H'  R*", ,"@I "\I,  O*C< +BH_ "TK2  L*U( *RQ= "HL:@ H+7D
M)RV+ "8NG@ E+K, )"_- "0O[@ E+_\ )2__ "8N_P"I/P  G44  )))  "(
M2P  ?DP  '1*  !J1P  7D(  %0]  !+.0  030  #@O!@ R+0T ,"T3 "XM
M&0 M+2  *RTG "HN+@ I+C4 *2\] "@O1@ G,$\ )3!; "0Q:  C,7< (C*)
M "$RG0 ?,[$ 'C/+ !XS[0 ?,_\ (#/_ "$R_P"F0P  FDD  )!-  "&3P
M?%   '-/  !H3   7$8  %)#  !)/P  /SL  #8V @ N,@P *S(1 "DR%P H
M,AX )C(D "4S*P D,S( (S0Z "(T0P A-4T (#58 !\V90 >-G4 '#>' !LW
MFP :-Z\ &3C( !DXZP :./\ &S?_ !LW_P"C1P  F$T  (Y1  "$4P  >U0
M '%3  !F4   6DP  %!)  !'10  /4$  #,]   J.0D )3<. ",W%  B.!L
M(3@B " X*  ?.#  'CDX !TY00 <.DL &CI6 !D[8P 8.W( %CN% !4\F0 4
M/*T $SW& !,]Z0 4//T %3S_ !8[_P"@2P  E5$  (M5  ""6   >5D  &Y8
M  !D5@  6%$  $Y/  !%2P  .D<  #!#   G0 4 (#X- !T^$0 </A< &SX>
M !H^)0 9/BT &#\U !8_/@ 5/T@ %$!3 !- 8  207  $4&" !!!EP /0:P
M#D+$  Y"YP /0?P $$'_ !! _P"=4   DU8  (E:  " 70  =EX  &Q=  !B
M6P  5E<  $Q5  !!40  -DX  "Q+   C2   &T4) !=$#P 51!0 %$4; !-%
M(@ 212D $44Q !%%.P 01D4 #T90  Y'7@ -1VT #$=_  M'DP )1Z< "$>^
M  A'X  )1_8 "D;_  M&_P":50  D%L  (=@  !]8@  <V,  &IB  !@80
M4UX  $=:   \5P  ,E4  "A2   ?4   %TX$ !%,#  /3!$ #DP7  Y,'@ -
M324 #$TN  M--P *34( "4U-  =.6@ &3FD !$Y[  ).CP !3J0  $VZ  !-
MVP !3?(  4W_  ),_P"66P  C6(  (1F  !Z:   <6D  &AI  !<9P  3V0
M $)A   W7P  +5P  "-:   :6   $E<!  U6"0 )50X !U43  95&@ $52(
M U4J  )5-   53X  %5*  !65P  5F4  %5W  !5BP  5:   %6V  !4U
M5/$  %/]  !3_P"38@  BF@  (!L  !W;@  ;V\  &-N  !6;   26H  #UH
M   R9@  )V4  !UC   58@  #F$   E@"  #8 T  %\1  !?%P  7QX  %\F
M  !?+P  7SH  %]%  !?4P  7V$  %YR  !>AP  79P  %VR  !<SP  7.\
M %O]  !;_P"0:@  AF\  'UR  !U=   :G4  %UT  !/<P  0G(  #9P   K
M;P  (&X  !=M   0;   "FP   )K!@  :PL  &H/  !J%   :AH  &HA  !I
M*@  :30  &E   !I3@  :5P  &EM  !H@@  :)@  &>N  !FR@  9>T  &7\
M  !D_P"+<0  @G8  'IY  !P>P  8GL  %5[  !(>@  .WH  "]Z   C>0
M&7@  !%W   *=P   W<   !W @  =P@  '8-  !V$   =A4  '8;  !V(P
M=BX  '4Z  !U1P  =58  '5H  !T?   =)(  '.J  !RQ   <>D  '#[  !P
M_P"&>0  ?WT  '9_  !H@0  6H(  $R"   _@P  ,H0  "6#   :@P  $8,
M  J#   "@P   (0   "%    A ,  (,(  "##0  @Q   (,5  "$'   A"8
M (0R  "$/P  @T\  (-@  ""=0  @HP  (&D  " O0  ?^,  '[Y  !^_P""
M@   >H0  &R&  !>B   4(H  $*+   UC0  )XT  !N-   1C@  "HX   "/
M    D0   )(   "2    D@   )(!  "2!P  D@P  )(0  "3%0  DQT  )0H
M  "4-@  E$4  )-7  "3:P  DX(  )*<  "1M@  D-@  (_S  "/_P!^AP
M<(H  &&-  !3D   19,  #>5   IE@  ')<  !&8   )F0   )L   "<
MG@   *    "@    H    *    "A    H00  *()  "C#@  I!0  *4=  "F
M*@  ICH  *9,  "E8   I7@  *62  "DK   I,D  */K  "B^@!SC@  9)$
M %:5  !'F0  .9P  "J>   =H   $:$   BC    I0   *<   "I    K
M *X   "N    K@   *\   "P    L0   +(   "S!@  M0T  +<3  "Y'@
MN2X  +I   "Z5   NVH  +J%  "YH0  N;L  +K>  "Y\@!GE0  6)D  $J>
M   [H@  +*8  !VH   1J@  !ZP   "O    L0   +0   "X    NP   +P
M  "\    O@   +\   #     P@   ,0   #&    R ,  ,L+  #/$@  T2
M -$R  #21@  TUT  -1V  #4D@  U:L  -7$  #4X@!;G0  3*(  #VG   O
MK   'Z\  !&Q   'M0   +@   "[    O@   ,(   #'    R@   ,P   #,
M    S@   -    #2    U0   -@   #;    WP   .(   #F"P  ZQ,  .PD
M  #M.   [DX  .]G  #P@@  \)P  /"R  #QQ0#_  , _P ! /\ ! #_  D
M_P / /\ & #_ "0 _P P /\ / #_ $< _P!1 /\ 60#_ &  _0!G /P ;0#Z
M ', ^0!Y /@ ?P#V (4 ]0", /, E #R )T \ "G .X LP#L ,0 ZP#A .H
M^ #I /\ YP#_ -D _P#+ /\ P@#_ +T _P#_    _P   /\   #_    _P ,
M /\ % #_ "  _P K /X -P#Z $( ]@!+ /( 4P#P %L [@!A .P 9P#J &T
MZ !S .< >0#E '\ XP"& .$ C@#? )8 W0"@ -L K #8 +L U #1 -, \ #0
M /\ S@#_ ,@ _P"] /\ M@#_ +( _P#_    _P   /\   #_    _0 ( /<
M$ #S !H [P F .T ,0#H #L XP!% .  30#< %4 V0!; -8 80#3 &< T0!L
M ,\ <@#- '@ RP!_ ,D AP#' )  Q0": ,, I0#  +( O@#% +P Y0"Z /L
MN #_ +< _P"P /\ J0#_ *4 _P#_    _P   /X   #U    [  # .4 #0#?
M !4 V@ @ -0 *@#0 #4 RP ^ ,@ 1P#% $X P@!5 ,  6P"^ &$ O !F +H
M; "X '( M@!X +4 @ "S (@ L0"2 *X G@"L *H J0"[ *@ U0"F /, I #_
M *, _P"A /\ FP#_ )@ _P#_    ^P   /    #E    V    ,X "0#' !$
MP@ : +X ) "[ "X MP X +0 0 "Q $@ K@!. *P 5 "J %H J0!? *< 90"E
M &L I !Q *( > "@ ($ G@"+ )P E@"9 *, EP"R )8 QP"3 .@ D@#^ )$
M_P"0 /\ C0#_ (L _P#Y    ZP   -T   #/    Q@   +P ! "U  T L  5
M *P '@"H "@ I0 Q *( .0"? $$ G0!( )L 3@"9 %, EP!9 )8 7@"4 &0
MD@!J )  <0". 'H C "# (H CP"( )P A@"J (0 O "" -P @0#V (  _P!_
M /\ ?P#_ 'X _P#L    V@   ,D   "^    M@   *X   "G  D H0 0 )P
M& "8 "( E0 J )( ,@"0 #H C0!! (L 1P") $T AP!2 (8 6 "$ %T @@!D
M ($ :P!_ ', ?0!] 'L B !X )4 =@"C '4 M !S ,P <0#M '  _P!P /\
M< #_ '  _P#?!0  R@H  +P+  "Q"0  J 0  *$   ";  , E  , (\ $P"*
M !L AP D (0 + "! #, ?P Z 'T 00![ $< >0!, '< 4@!V %< = != '(
M9 !P &T ;P!V &P @@!J (\ :0"= &< K@!E ,, 9 #D &, ^@!C /\ 8@#_
M &, _P#0#@  OQ(  +(3  "G$@  G1   )4+  "/ P  B0 ' (( #@!^ !4
M>@ > '8 )0!T "T <0 T &\ .@!N $  ; !& &H 3 !I %( 9P!8 &8 7P!D
M &< 8@!Q &  ? !> (D 7 "8 %L J0!9 +P 6 #< %@ ] !8 /\ 5P#_ %<
M_P#&%@  MAH  *H=  "?'   E1D  (T4  "%#P  ?@D  '<!"@!R !  ;@ 7
M &H 'P!H "< 90 N &0 - !B #L 8 !  %\ 1@!= $P 7 !3 %H 6@!8 &(
M5P!L %4 =P!3 (4 4@"4 % !I0!/ ;@ 3@+2 $T$\ !-!?\ 307_ $T%_P"_
M'0  L"(  *,E  "9)0  CR(  (4=  !]&   =1(  &X- @!G!@P 8P,1 %\"
M&0!= R$ 6P0H %D$+P!7!34 5@4[ %0&00!3!D< 409. % '50!.!UX 30AG
M $L(<P!)"8$ 2 F2 $<*HP!%"K8 1 O0 $0,[P!##?\ 0PW_ $0-_P"Y)
MJBD  )XL  "4+   BBH  ( F  !W(0  ;AL  &84  !?#P4 60L- %4*$P!3
M"QL 40LB $\,*0!-#"\ 3 PV $L-/ !)#4( 2 U) $8-40!%#EH 1 YD $(.
M< ! #G\ /P^0 #X0H@ \$+8 .Q#1 #L1\0 [$?\ .Q'_ #P1_P"T*0  IB\
M )HR  "0,@  AC$  'PM  !R*   :2,  &$=  !9%@  41$( $P/$ !*$!8
M2! = $80) !%$"L 0Q$Q $(1-P!!$3X 0!%% #X230 ]$E8 /!)A #H3;0 Y
M$WP -Q2- #84GP U%;, -!7- #,6[@ T%O\ -!;_ #06_P"O+@  HC0  )<W
M  ",.   @C8  '@T  !N+@  92H  %PD  !4'@  3!@$ $84#0!"%!( 0!09
M #\4(  ]%2< /!4M #L5-  Y%CH .!9" #<62@ V%U, -1=> #,8:@ R&7D
M,!F* "\:G0 N&K$ +1O* "T;[  M'/\ +AO_ "X;_P"L,@  GS@  )0[  "*
M/   @#P  '8Y  !K-   8B\  %DJ  !0)0  1Q\  $ :"@ \&1  .AD6 #@9
M'0 V&B, -1HI #0:,  S&C< ,AL^ #$;1P O'%  +AU; "T=9P L'G8 *AZ(
M "D?FP H'ZX )R#' "8@Z@ G(/X *"#_ "@@_P"I-@  G3P  )(_  "'00
M?4   '0^  !I.@  7S4  %8P  !-*P  1"4  #L@!P V'@X ,QX3 #(>&0 P
M'B  +QXF "X?+0 M'S0 +" [ "L@1  J(4X *2%8 "<B90 F(G0 )2.% ",C
MF0 B)*T (23% "$EZ  B)?T (B3_ ",D_P"F.@  FC\  (]#  "%10  >T0
M ')#  !G/P  73H  %,V  !*,0  02P  #@F P Q(PP +B(1 "PB%@ J(AT
M*2(C "@C*@ G(S$ )B0Y "4E00 D)4L (R96 "(F8P A)W( 'R># !XHEP =
M**L &RG# !LIY@ <*?L '2G_ !XH_P"C/@  F$,  (U'  "#20  >DD  '!'
M  !F1   6C\  %$[  !'-P  /C(  #4M   L* D *"</ "<G%  E)QH )"<A
M ",H)P B*"X (2DV " I/P ?*DD 'BI4 !TK8  ;*V\ &BR! !DLE0 7+:D
M%BW! !8MY  7+?H &"W_ !DM_P"A00  E4<  (M+  ""30  >$T  &Y,  !D
M20  6$0  $]   !&/0  /3@  #,T   J+P8 )"P- "$L$@ @+!@ 'RT> !XM
M)0 =+2P '"XT !LN/  :+T8 &"]1 !<P7@ 6,&T %3%_ !,QDP 2,:@ $3*_
M !$RX@ 2,OD $S'_ !,Q_P">10  DTL  (E/  " 40  =E(  &U0  !B3@
M5DD  $U&  !$0P  .S\  #$Z   G-@, 'S(+ !PR$  ;,A4 &3(; !@R(@ 7
M,RD %C,Q !4T.@ 4-$0 $S1/ !(U7  1-6L $#9]  \VD0 .-J8 #3>\  TW
MW0 --O8 #C;_  \V_P";20  D4\  (=3  !^5@  =58  &I5  !@4P  54\
M $Q,  !"20  .$4  "Y!   D/0  '#H( !8X#@ 5.!( %#@8 !,Y'P 2.28
M$3DN ! Y-P /.D$ #CI,  T[60 -.V@ "SMZ  H[C0 )/*( !SRX  <\U0 (
M//  "3O_  H[_P"83@  CE0  (58  !\6P  <EL  &A:  !>6   4U4  $E2
M   ^3@  -$L  "I'   A1   &$(# !) "P 0/Q  #C\5  X_'  -0", #$ K
M  M -  *0#X "4%*  =!5@ &064 !$%V  -!B@ !09\  $&T  !!T  !0>X
M 4'\  ) _P"55   C%D  (->  !Y8   <&   &9@  !=7@  45L  $57   Z
M5   +U$  "5/   <3   %$H   Y("  +1PX "$<2  ='&0 &1R  !4@H  -(
M,0 "2#L  $A'  !(4P  2&(  $AS  !(A@  2)L  $BQ  !'S   1^T  $?[
M  !'_P"26@  B6   (!C  !W90  ;F8  &5F  !99   3&   $!=   U6P
M*ED  "!7   750  $%,   M2!P %40T  5 1  !0%@  4!T  % E  !0+@
M4#@  %!#  !04   4%X  %!O  !0@P  3Y@  $^N  !.R0  3NL  $W[  !-
M_P"/80  AF8  'UI  !T;   ;&T  &%K  !3:0  1F<  #ID   O8P  )&$
M !I?   27@  #%P   9<!@  6PL  %H/  !:$P  6AD  %DA  !9*0  63,
M %D_  !93   65H  %EK  !8?@  6)0  %>K  !7Q0  5ND  %7[  !5_P",
M:   @FT  'IP  !R<@  9W(  %IQ  !,<   /VX  #-M   H:P  '6H  !1H
M   -9P  !V<   !F P  9@D  &4-  !E$0  9!4  &0<  !D)   9"X  &0Z
M  !C1P  8U4  &-F  !C>@  8I   &&G  !@P0  7^8  %_Z  !>_P"';P
M?W0  'AW  !N>   8'@  %)W  !%=P  .'8  "MV   @=   %G,   YS   '
M<@   '(   !R    <04  '$*  !Q#@  <!$  ' 7  !P'@  <"<  ' S  !O
M0   ;U   &]@  !N=   ;HL  &VB  !LO   :^(  &KX  !I_P"#=P  ?'L
M '-]  !E?@  5W\  $E_   \?P  +X   ")_   7?@  #WX   =^    ?P
M '\   !_    ?@   'X%  !^"@  ?@T  'X1  !^%P  ?B   'XK  !].0
M?4@  'U9  !\;0  ?(0  'N<  !ZM@  >=H  'CU  !W_P" ?P  =X(  &F#
M  !;A0  388  #^(   RB0  )(D  !B)   /B0  !XH   "+    C    (T
M  "-    C    (P   ", P  C @  (T-  "-$0  C1<  (XB  ".+P  CC\
M (U0  "-9   C'L  (R5  "+K@  BLT  (GO  ")_P![A0  ;8@  %Z*  !0
MC0  0H\  #21   FD@  &9,   Z4   &E0   )8   "8    F@   )L   ";
M    FP   )L   ";    G    )T%  "="P  GA   )\7  "@)   H#0  *!&
M  "@60  GW   )^*  ">I0  GL(  )WH  "<^0!PC   88\  %.2  !$E@
M-ID  ">;   9G   #YT   6?    H0   *,   "E    J    *D   "I
MJ0   *H   "K    K    *T   "N 0  L D  +(/  "S&   M"<  +0Y  "U
M30  M&0  +1^  "SF@  L[0  +/5  "S\ !DDP  59<  $>;   XGP  *:(
M !JD   .I@  !*@   "K    K0   +    "T    M@   +@   "X    N0
M +H   "\    O0   +\   #     PP   ,4'  #)#P  RAH  ,LL  #,0
MS58  ,YO  #-BP  S*@  ,S"  #,X@!8FP  2:   #JE   LJ0  '*L   ^N
M   $L0   +0   "W    N@   +X   ##    Q@   ,@   #(    R@   ,L
M  #-    SP   -(   #5    V0   -T   #A!0  Y@\  .<>  #H,@  Z4@
M .I@  #K>P  ZY<  .RN  #LP@#_    _P   /\   #_  8 _P - /\ %0#_
M "$ _P L /\ . #_ $, _P!, /X 5 #[ %L ^@!B /@ : #V &X ]0!T /0
M>@#R (  \0"' .\ CP#M )< ZP"A .D K0#G +T Y0#8 .0 \P#B /\ X #_
M -  _P#$ /\ O #_ +8 _P#_    _P   /\   #_    _P ) /\ $0#_ !P
M_0 G /D ,@#U #T \0!& .T 3P#K %8 Z !< .8 8@#D &@ XP!N .$ <P#?
M 'D W0"  -H B #8 )$ U "; -( I@#/ +0 S #) ,D Z0#( /\ QP#_ ,$
M_P"W /\ KP#_ *L _P#_    _P   /\   #_    ^  % /( #@#N !< Z@ B
M .8 + #A #< W0!  -@ 20#3 %  T !6 ,X 7 #, &( R@!G ,@ ;0#& ',
MQ !Y ,( @0#  (H O@"4 +P GP"Y *P M@"^ +0 W0"S /< L0#_ +  _P"H
M /\ H@#_ )X _P#_    _P   /D   #O    Y@   -\ "P#6 !( T  < ,P
M)@#( #  Q  Z ,  0@"] $H NP!0 +@ 5@"V %L M0!A +, 9@"Q &P L !R
M *X >@"L (( J0", *< F "E *4 HP"T *  RP"? .X G0#_ )P _P"9 /\
ME #_ )$ _P#_    ]@   .H   #=    SP   ,< !@#   \ NP 7 +< ( "S
M "H L  S *T .P"J $, IP!) *4 3P"C %4 H@!: *  7P"> &4 G0!K )L
M<@"9 'L EP"% )0 D "2 )T D "L (X OP", .( BP#Z (D _P") /\ A@#_
M (, _P#T    Y    -0   #(    OP   +4  0"N  L J0 2 *4 &P"A ",
MG@ L )L - "8 #P E@!# )0 20"2 $X D !3 (X 60"- %X BP!D (D :P"'
M ', A0!] (, B "! )4 ?P"D 'T M0![ ,\ >0#Q '@ _P!W /\ =P#_ '4
M_P#E    T0   ,,   "X    KP   *@   "@  8 F@ . )4 %0"1 !X C@ F
M (L +0"( #4 A@ \ (0 0@"" $< @ !- '\ 4@!] %@ >P!> 'D 90!X &T
M=@!V ', @0!Q (X ;P"= &T K@!L ,0 :@#G &D _0!H /\ : #_ &D _P#5
M P  PP<  +8(  "K!@  H@   )L   "4    C0 * (@ $ "# !@ ?P @ 'P
M)P!Z "X =P U '4 .P!T $$ <@!' '  3 !O %( ;0!8 &L 7P!I &8 9P!P
M &4 >P!C (@ 8@"7 &  IP!> +L 70#< %P ]@!< /\ 6P#_ %L _P#)#0
MN1   *P1  "A$   EPT  (\(  "(    @@ % 'L #0!W !( <P : &\ (0!L
M "@ :@ O &@ -0!G #L 90!! &, 1@!B $P 8 !2 %\ 60!= &$ 6P!J %D
M=0!7 (( 50"1 %0 H@!3 +4 40#/ %  [P!0 /\ 4 #_ %  _P"_%   L!@
M *0:  "9&0  CQ8  (<1  !_#0  =P8  '$ " !K  X 9P 4 &0 &P!A "(
M7@ I %T +P!; #4 60 [ %@ 00!6 $8 50!- %, 5 !2 %P 4 !E $X < !,
M 'T 2P"- $D G@!( +  1P#' $8 Z0!& /L 1@#_ $4 _P"X&P  JB   )XB
M  "3(@  B1\  ( :  !W%0  ;Q   &@+  !A! H 70 0 %D %@!6 !T 5  C
M %( *@!0 #  3P U $X .P!, $$ 2P!( $D 3P!' 5< 1@%A $0"; !# GD
M00.) $ #F@ ^!*T /03$ #P%Y0 \!_@ / ?_ #P'_P"R(@  I2<  )DI  ".
M*0  A"<  'LC  !Q'@  :1@  &$2  !:#0, 4P@, $\%$0!,!1< 2@8> $@&
M) !'!BH 10<P $0'-@!#"#T 00A# $ (2P ^"5, /0E= #L*:  Z"G8 . N'
M #<+F0 U"ZP - S" #,,Y  S#?D ,PW_ #0-_P"M)P  H"P  )4O  "++P
M@"X  '<J  !M)0  9"   %P:  !4%   3 \& $8,#0!##!( 00P8 #\,'P ^
M#"4 / TK #L-,@ Z#3@ . T_ #<.1P V#E  - Y: #,.9@ Q#W0 , ^% "X0
MF  M$*L +!## "L1Y0 L$?H +!'_ "T1_P"J+   G3$  )(T  "'-0  ?30
M '0Q  !J*P  8"<  %@A  !/&P  1Q8  $ 1"0 [$ \ .1 4 #<0&P V$"$
M-! G #,1+0 R$30 ,1$[ # 10P N$DT +1)7 "P28P J$W$ *1." "<4E0 F
M%*D )17  "05XP E%OH )A;_ "85_P"F,0  FC8  (\Y  "%.@  >SD  '$V
M  !G,0  72T  %0H  !,(@  0QT  #L7!0 U% T ,A,1 #$4%P O%!T +A0D
M "P4*@ K%3$ *A4X "D60  H%DH )Q=4 "878  D&&\ (QB  "$9DP @&:<
M'QF^ !X:X  ?&O@ (!K_ " :_P"C-   F#H  (T]  "#/@  >3T  &\[  !E
M-P  6S(  %(M  !)*   0",  #@> 0 P&0H +!@/ "H8%  I&!H )Q@@ "89
M)P E&2T )!HU ",:/@ B&T< (1M2 " <7@ ?'6P '1U^ !P=D0 :'J4 &1Z\
M !@?W0 9'_8 &A__ !L>_P"A.   E3T  (M!  "!0@  =T(  &U   !C/
M63<  $\S  !&+@  /2D  #4D   M( < )QT- "4=$@ C'1< (1T= "$=)  @
M'BL 'QXR !X?.P ='T4 '"!/ !HA7  9(6H &")[ !8BCP 5(J, %".Z !,C
MV@ 4(_4 %2/_ !8C_P">/   DT$  (E$  !_1@  =48  &Q$  !B00  5SP
M $TX  !$-   /#   #,K   J)@, (R(+ " A$  >(14 '"(; !LB(0 :(B@
M&B,P !DC.  8)$( %B5- !4E60 4)F@ $R9Y !(FC0 1)Z( $">X  XGU@ 0
M*/0 $2?_ !$G_P"<0   D44  (=(  !]2@  =$H  &I)  !@1@  54$  $P^
M  !#.@  .C8  #$R   H+0  ("D) !LG#@ 9)Q( &"<8 !8G'P 5*"4 %"@M
M !,H-@ 2*4  $BE+ !$J5P 0*F8 #BMW  XKBP -+)\ #"RU  LLSP ,+.\
M#2S_  TK_P"91   CTD  (5,  !\3@  <T\  &E.  !>2P  4T<  $I$  !"
M0   .3T  "\X   E-   '3 % !8M#  4+!  $RT5 !(M'  1+2, $"TJ  \N
M,P .+CT #2](  TO50 ,,&, "C!T  DPB  (,9P !C&Q  8QRP &,>L !S#\
M  @P_P"72   C4T  (-1  !Z4P  <50  &=2  !=4   4DP  $E*  ! 1@
M-4(  "L^   B.@  &C<! !(T"0 /,PX #C,3  TS&0 -,R  ##0H  LT,0 *
M-3L "#5&  <U4@ %-F  !#9Q  (VA   -ID  #:O   VR   -N@  #;Y  $U
M_P"430  BE(  (%6  !X6   ;UD  &58  !;50  45(  $=/   \3   ,4@
M "=$   >00  %C\  ! \!P +.@T "3H1  @[%P &.QX !3LF  0[+@ ".S@
M 3Q#   \3P  /%X  #QN   \@0  /)<  #RL   [Q0  .^<  #OX   [_P"1
M4@  B%@  ']<  !V70  ;5X  &-=  !:7   3E@  $)4   W40  +4X  "-+
M   :20  $D8   U$!@ '0PP  T,0  !#%0  0QL  $,C  !#*P  0S4  $-
M  !#30  0UL  $-K  !#?@  0Y0  $*J  !"PP  0>8  $'Y  !!_P".6
MAEX  'UA  !S8P  :V0  &)C  !780  25T  #U:   R6   )U4  !Y3   5
M40  #D\   E-!0 "30L  $P.  !,$P  2Q@  $L?  !+*   2S(  $L]  !+
M20  2U<  $MG  !*>P  2I   $FG  !)P   2.0  $CX  !'_P"+7P  @V0
M 'IG  !Q:0  :6H  %YI  !09@  0V0  #=A   L7P  (5T  !A;   060
M"E@   -7 P  5PD  %8-  !5$   514  %0;  !4(P  5"T  %0Y  !410
M5%,  %1D  !3=P  4XT  %*D  !1O0  4.(  %#X  !/_P"(9P  ?VL  '=N
M  !O<   97   %=N  !*;   /6L  #!I   E:   &F8  !%D   +8P  !&(
M  !B 0  808  & +  !@#@  7Q(  %\7  !?'@  7B@  %XS  !>0   7D\
M %Y?  !=<@  78@  %R@  !;N0  6M\  %GW  !8_P"$;@  ?'(  '5U  !K
M=@  774  $]T  !"<P  -7,  "AR   =<   $V\   QN   $;@   &X   !N
M    ; (  &P'  !K"P  :PX  &L2  !J&0  :B(  &HM  !J.@  :4D  &E:
M  !I;   :(,  &>;  !FM0  9=@  &3U  !D_P" =0  >GD  '![  !B>P
M5'P  $9\   Y?   +'P  !][   4>@  #7H   1Z    >@   'H   !Z
M>0   'D!  !X!@  > L  '@.  !X$P  >!H  '@E  !X,@  =T$  '=2  !W
M90  =GP  '65  !TKP  <\X  '+Q  !Q_P!^?0  =8   &>!  !8@@  2H,
M #R$   NA0  (84  !6%   -A0   X4   "&    AP   (@   "(    AP
M (<   "'    AP0  (<)  "'#@  B!,  (@<  "(*0  B#@  (=*  "'70
MAG,  (:-  "%IP  A,4  (/L  ""_@!XA   :H8  %R(  !-B@  /XP  #&.
M   CCP  %H\   V0   "D0   )(   "3    E0   )8   "6    E@   )8
M  "6    EP   )<   "7!P  F T  )D3  ":'P  FBT  )H_  ":4@  FF@
M )F#  "9GP  F+H  )?B  "6^ !MB@  7XT  %"0  !!DP  ,Y8  "27   6
MF   #9D   &;    G0   )\   "A    I    *4   "D    I0   *4   "F
M    IP   *@   "I    J@0  *P,  "N$P  KB$  *XS  "N1P  KET  *YV
M  "NDP  KJX  *W-  "L[P!AD0  4Y4  $28   UG   )I\  !>A   -HP
M *4   "G    J@   *P   "P    L@   +0   "S    M    +4   "W
MN    +D   "[    O0   +\!  ##"P  Q14  ,4E  #&.0  QT\  ,=H  #&
MA0  QJ(  ,:\  #&W@!5F0  1YT  #BB   II@  &:@   VK    K0   +$
M  "T    MP   +H   "_    P0   ,0   ##    Q0   ,8   #(    R@
M ,T   #/    T@   -8   #;    X P  .$8  #C*P  Y$$  .5:  #F=
MYI$  .6L  #EQ #_    _P   /\   #_  $ _P * /\ $@#_ !T _P H /\
M- #_ #X _0!( /H 4 #W %< ]0!= /0 8P#R &D \ !O .\ = #M 'L ZP"!
M .D B0#H )( Y@"< .0 J #B +< WP#- -P [@#9 /\ V0#_ ,H _P"^ /\
MM0#_ +  _P#_    _P   /\   #_    _P & /\ #P#\ !@ ^  C /0 +@#P
M #@ ZP!" .@ 2@#E %$ X@!8 .  70#> &, W !H -D ;@#6 '0 U ![ -$
M@@#/ (L S0"5 ,H H0#( *\ Q0#! ,( XP#  /L P #_ +L _P"P /\ J #_
M *0 _P#_    _P   /\   #[    \P ! .T # #H !, XP > .  * #: #(
MTP \ ,\ 1 #, $L R0!1 ,8 5P#$ %T P@!B ,$ 9P"_ &T O0!T +L >P"Y
M (0 MP". +0 F0"R *< KP"W *T T "K /( J@#_ *D _P"A /\ FP#_ )<
M_P#_    _P   /0   #I    X    -4 " #. !  R0 8 ,4 (@#! "L O  U
M +D /0"V $4 LP!+ +$ 40"O %8 K@!; *P 80"J &8 J0!M *8 = "D 'P
MH@"& *  D@"> )\ G "N )D PP"7 .< E@#_ )4 _P"2 /\ C0#_ (H _P#\
M    \    .,   #4    R    +\  P"Y  T LP 3 *\ ' "L "4 J0 N *4
M-@"C #X H !$ )X 2@"= %  FP!5 )D 6@"7 %\ E@!F )0 ; "2 '4 D !^
M (X B@"+ )< B0"F (< N "% -8 A #V (( _P"! /\ ?@#_ 'P _P#M
MW0   ,P   #!    N    *X   "G  D H@ 0 )X %P": !\ EP G )0 +P"1
M #< CP ] (T 0P"+ $D B0!. (@ 4P"& %D A !? (( 90"  &T ?@!W 'P
M@@!Z (\ > "> '4 KP!S ,< <@#L '$ _P!P /\ < #_ &X _P#=    R0
M +P   "Q    J0   *$   "9  , DP , (X $@"* !D AP A (0 *0"! #
M?P W 'T /0![ $( >0!( '@ 30!V %( = !8 '( 7P!Q &< ;P!P &P >P!J
M (@ : "7 &8 J !E +P 8P#A &( ^@!A /\ 80#_ &$ _P#- 0  O 4  *\%
M  "E @  G    )0   "-    A@ ( ($ #@!\ !0 >  ; '4 (P!R "D <  P
M &X -@!M #P :P!! &D 1P!H $P 9@!2 &0 60!C &  80!I %\ = != ($
M6P"0 %D H0!7 +0 5@#0 %4 \@!5 /\ 5 #_ %4 _P#!#   L@X  *8/  ";
M#@  D@L  (D%  ""    >P " '4 "P!P !  ;  6 &@ '0!F ", 8P J &$
M, !@ #8 7@ [ %T 00!; $8 6@!, %@ 4P!6 %L 5 !D %( ;@!1 'L 3P"*
M $T FP!, *X 2P#& $H Z@!) /X 20#_ $D _P"Y$@  JA8  )X7  "4%@
MBA,  ($0  !Y"P  <0,  &L !@!E  T 80 1 %T & !: !X 6  D %8 *@!4
M #  4P V %$ .P!0 $$ 3@!' $T 3@!+ %8 20!? $< :0!& '8 1 "% $,
MEP!! *D 0 "_ #\ X@ _ /@ /@#_ #\ _P"R&0  I!X  )@?  ".'P  A!P
M 'H8  !R$@  :@X  &((  !< 0@ 5P . %, $P!0 !D 3@ ? $P )0!* "L
M2  P $< -@!& #P 1 !" $, 20!! %$ /P!: #X 90 \ '( .@"! #D DP X
M *4 -@"Z #8 VP U /0 -0#_ #4 _P"L(   GR0  )0F  "))@  ?R0  '4@
M  !L&P  9!4  %P0  !4# $ 3@8* $H"#P!' !0 1  : $( ( !  "4 /P K
M #X!,0 \ 3< .P(^ #D"10 X TT -@-6 #4$80 S!&X ,05^ # %D  O!:,
M+0:X "P&U  L!_  + C_ "P(_P"H)0  FRH  ) L  "&+0  >RL  '(G  !H
M(@  7QT  %<7  !/$@  2 X$ $$*"P ^!Q  .P85 #D'&P X!R$ -@@F #4(
M+  S"#( ,@DY #$)00 O"4D +@I3 "P*7@ K"VP *0M\ "@,CP F#*( )0RW
M "0,TP C#?  ) W_ "4-_P"D*@  F"\  (TR  "#,@  >3$  &\N  !E*0
M7"0  %,?  !+&0  0Q,  #P0!@ U#0P ,PP1 #$,%@ O#!P +@TB "T-*  K
M#2X *@TU "D-/0 G#D8 )@Y0 "0.7  C#VH (@][ " 0C@ ?$*( '1"W !P0
MU  =$?( '1'_ !X1_P"A+P  E3,  (HV  " -P  =C8  &TS  !C+P  62H
M % E  !((   /QH  #@5   P$0@ +! . "H0$@ H$!@ )Q > "40)  D$"H
M(Q$R "(1.@ A$4, (!). !X26@ =$V@ &Q-X !H3BP 8%*  %Q2U !84T0 6
M%?$ %Q7_ !@4_P">,P  DS<  (@Z  !^.P  =#L  &LX  !A-   5R\  $XK
M  !%)@  /2$  #0<   M%P4 )A,, ",3$  B$Q4 (!,: !\3(0 >%"< '10O
M !P5-P ;%4$ &A9+ !D65P 7%V4 %A=V !08B0 3&)X $ABS !$9S@ 1&>\
M$AG_ !,9_P"<-@  D3L  (8^  !\/P  <S\  &D]  !?.0  534  $PP  !#
M+   .B<  #(B   J'@$ (AD) !X7#@ <%Q( &A<7 !D8'@ 9&"0 &!DL !<9
M-  6&CX %1I) !,;50 2&V, $1QT ! <AP /'9P #AVQ  T=RP -'>P #AW_
M  \=_P"9.@  CS\  (1"  ![1   <4,  &A"  !>/@  4SH  $HV  !!,@
M.2T  #$I   H)0  (" & !H=#  7'!  %1P5 !0=&P 4'2( $QTI !(>,@ 1
M'SP $!]& ! @4P .(&$ #2%Q  PAA0 +(ID "B*N  DBQP )(N< "B+[  LA
M_P"7/@  C$,  (-&  !Y2   <$@  &=&  !<1   4C\  $D[  ! .   .#0
M "\P   G+   'B<# !8C"@ 2(0X $2$3 ! B&0 0(B  #R(G  XC+P -)#D
M#"1$  LE4  *)5X "29O  <F@@ &)I8 !":L  ,FQ  $)N4 !";W  8F_P"5
M0@  BD<  (%*  !X3   ;TP  &5+  !;2   4$0  $=!   _/@  -SL  "TV
M   D,0  &RT  !,J!P /* T #2<1  TH%@ ,*!T "R@E  HI+0 )*3< !RI"
M  8J3@ $*UP  RML  $K?P  *Y0  "NI   KP0  *^,  "OV   J_P"21@
MB$L  ']/  !V40  ;5$  &-0  !:30  3TH  $='   ^1   ,T   "D\   @
M.   %S0  !$Q!0 ,+PP "2X0  <N%0 &+QL !2\C  ,O*P ",#4  # _   P
M3   ,5D  #%I   Q?   ,9$  #&G   POP  ,.$  ##U   O_P"02P  AE
M 'U4  !U5@  :U8  &)5  !84P  3E   $5-   Z20  +T4  "5"   </@
M%#L   XY!0 )-PL !#8/  $V$P  -AD  #8@   V*0  -C(  #<]   W20
M-U<  #=G   W>0  -X\  #:E   VO0  -N   #7U   U_P"-4   A%8  'Q:
M  !R6P  :5L  &!;  !760  3%8  $!2   U3@  *DL  "!(   71@  $$,
M  M!!  $0 H  #\.   ^$0  /A8  #X=   ^)@  /B\  #XZ   ^1@  /E0
M #YD   ^=@  /8P  #VC   \NP  /-X  #OU   [_P"*5P  @EP  'E?  !P
M80  :&$  %]A  !47@  1UL  #I7   O50  )5(  !M0   230  #$L   9*
M P  20D  $@-  !'$   1Q0  $8:  !&(@  1BP  $8W  !&0P  1E$  $9@
M  !%<P  18D  $2@  !$N   0]P  $+U  !"_P"(70  ?V(  '=E  !N9P
M9V@  %MF  !.8P  06$  #1>   I7   'UH  !57   .5@  !U0   !3 0
M4@8  %$+  !1#@  4!$  $\6  !/'@  3R<  $\R  !//P  3TT  $Y=  !.
M;P  3H4  $V=  !,M0  2]@  $KU  !*_P"%90  ?&D  '1L  !M;@  8FT
M %1K  !':0  .F<  "UE   B9   &&(  !!@   )7P   %X   !>    70,
M %P(  !;#   6@\  %H3  !9&0  62(  %DM  !9.@  64@  %A8  !8:P
M5X$  %>9  !6L@  5=(  %3T  !3_P"!;   >7   '-S  !H<P  6G(  $QQ
M   _<   ,F\  "5N   :;   $6L   EJ    :@   &D   !I    :    &<#
M  !F"   9@P  &8/  !E%   91P  &4G  !D-   9$,  &13  !D90  8WL
M &*4  !AK0  8,T  %_Q  !>_P!]=   =W<  &YY  !?>0  47D  $-Y   V
M>   *7@  !QW   1=@  "G4   !U    =0   '8   !U    =    '0   !S
M @  <P<  ',,  !R$   <A4  '(@  !R+   <CL  '%,  !Q7P  <70  '".
M  !OJ   ;L8  &SM  !K_P![>P  <GX  &1^  !5?P  1X   #F!   K@@
M'H$  !*!   *@0   ($   ""    @P   (,   "#    @@   ((   ""
M@@   ((%  """@  @@\  ((7  ""(P  @C(  ()#  "!5@  @6P  ("&  !_
MH0  ?KT  'WF  !\_ !V@@  :(,  %F%  !+AP  /(D  "Z*   @BP  $XL
M  J+    C    (T   "/    D0   )(   "1    D0   )$   "1    D0
M )(   "2 @  DPD  )0/  "4&0  E"<  )0X  "43   DV(  )-\  "3F
MDK,  )'8  "0]@!JB   7(H  $V-   _D   ,)(  "&4   4E0  "I8   "7
M    F0   )L   "=    GP   *    "@    H    *    "A    H@   *,
M  "D    I0   *8'  "H$   J!P  *@M  "I0   J58  *EO  "IBP  J*@
M *?'  "F[ !?CP  4)(  $&6   SF0  (YP  !2=   *GP   *$   "C
MI@   *@   "L    K@   *\   "O    L    +    "R    LP   +0   "V
M    MP   +H   "]!P  OQ   +\?  # ,P  P$D  ,!B  # ?@  P)L  ,"W
M  "_V !3EP  1)L  #6?   FHP  %J4   NG    J@   *T   "P    LP
M +8   "[    O0   ,    "_    P0   ,(   #$    Q@   ,@   #*
MS    ,\   #3    V@<  -L3  #=)0  WCL  -]3  #@;@  WXP  -VI  #=
MP@#_    _P   /\   #_    _P ' /\ $ #_ !D _P D /\ +P#\ #H ^0!#
M /4 2P#S %( \0!9 .\ 7@#M &0 ZP!I .D ;P#G '4 Y@!\ .0 A #B (T
MX "7 -T H@#: +$ U0#% -( Z #0 /\ SP#_ ,0 _P"X /\ KP#_ *D _P#_
M    _P   /\   #_    _P " /L #0#W !4 \P ? .\ *0#J #0 Y@ ] .(
M10#> $P VP!3 -@ 6 #4 %X T@!C -  :0#. &X S !U ,H ?0#( (4 Q@"0
M ,( FP#  *D O@"Z +L V0"Y /< N #_ +0 _P"I /\ H@#_ )T _P#_
M_P   /\   #V    [@   .< "@#A !$ W  : -< (P#0 "X RP W ,< /P#$
M $8 P0!- +\ 4@"] %@ NP!= +D 8@"X &@ M@!N +0 =0"Q 'X KP"( *T
MDP"J *$ J "Q *8 R "D .T H@#_ *( _P"; /\ E0#_ )$ _P#_    _
M .X   #C    V    ,T !0#&  X P0 5 +T '@"Y "< M0 P +( . "O $
MK !& *H 3 "H %$ IP!6 *4 6P"C &$ H0!G )\ ;@"> '8 FP"  )D C "7
M )D E "H )( O "0 -\ C@#[ (X _P"+ /\ A@#_ (, _P#X    Z0   -P
M  #,    P0   +@   "R  H K  1 *@ & "E "$ H@ I )X ,@"< #D F0 _
M )< 10"5 $H E !0 )( 50"0 %H CP!@ (T 9P"+ &\ B0!X (8 A "$ )$
M@@"@ (  L@!] ,P ? #Q 'L _P!Z /\ =P#_ '4 _P#F    TP   ,8   "[
M    L0   *<   "A  4 FP - )< $P"3 !L D  C (P *P"* #( B  X (8
M/@"$ $0 @@!) ($ 3@!_ %, ?0!9 'L 8 !Y &@ =P!Q '4 ? !S (D < "8
M &\ J0!M +\ :P#F &H _P!I /\ :0#_ &< _P#3    PP   +4   "K
MHP   )L   "2    C  * (< $ "# !8 ?P = 'T ) !Z "L >  R '8 . !T
M #T <@!" '$ 2 !O $T ;0!3 &P 60!J &$ : !J &8 = !D ($ 80"1 %\
MH@!> +8 7 #5 %L ]P!; /\ 6@#_ %H _P#%    M@(  *D"  "?    E@
M (X   "'    @  % 'H # !U !$ <0 8 &X '@!K "4 :0 K &< ,0!F #<
M9  \ &, 00!A $< 7P!- %X 4P!< %L 6@!D %@ ;@!6 'L 5 "* %( FP!1
M *X 4 #( $\ [@!. /\ 3@#_ $T _P"["@  K T  * -  "5#   C @  (,"
M  !\    =0   &X " !I  X 90 3 &( &0!? !\ 70 E %L *P!9 #$ 6  V
M %8 .P!5 $$ 4P!' %$ 3@!0 %4 3@!> $P : !* '4 2 "$ $< E0!% *@
M1 "_ $, Y !" /P 0@#_ $( _P"R$0  I10  )D5  ".$P  A!$  'L-  !S
M"   ;    &4  P!?  L 6P / %< % !4 !H 40 ? $\ )0!. "L 3  P $L
M-@!) #P 2 !" $8 2 !% %  0P!9 $$ 8P _ &\ /@!^ #P D  [ *, .@"X
M #D V0 X /4 . #_ #@ _P"L%P  GQL  ),=  ")'   ?QD  '45  !L$
M9 P  %T&  !6  8 40 , $T $ !* !4 1P : $4 ( !$ "8 0@ K $$ ,0 _
M #8 /@ ] #P 1  [ $L .0!4 #< 7P V &L - !Z #( C  Q )X , "S "\
MS@ O .\ +@#_ "X _P"G'@  FB(  (\D  "$)   >B$  '$=  !G&   7Q,
M %<.  !0"@  20,( $4 #0!! !$ /@ 6 #P &P Z "$ .0 F #< +  V #(
M-  X #, /P Q $< , !0 "X 6P M &< *P!V "H B  H )P )P"P "8 R0 E
M .H )0'[ "4!_P"B(P  EB@  (LJ  "!*@  =R@  &TE  !D(   6QL  %(5
M  !+$   0PP" #T'"0 Y PX -@$2 #,!%P Q 1P , $B "\")P M BT + ,T
M "H#.P I!$, * 1- "8%6  E!64 (P9T "(&A@ @!IH 'P>N !X'Q@ =!^<
M'0CX !T)_P"?*   DRT  (@O  !^+P  ="X  &HK  !A)@  6"$  $\<  !'
M%P  /Q(  #@.!  Q"PH +@@. "L'$@ I!Q< * @= "<((P E""D ) DP ",)
M-P A"D  ( I* !\+50 ="V( &PQR !H,A0 8#)D %PRM !8,Q@ 5#>8 %0WY
M !8-_P"<+0  D#$  (8T  !\-   <C,  &@Q  !?+   52<  $PC  !$'0
M/!@  #03   M$ 8 )@T+ "0,#P B#!, (0P9 !\,'P >#24 '0TL !L--  :
M#CT &0Y' !<.4P 6#F$ % ]Q !,0A  2$)@ $1"N ! 0Q@ 0$.@ $!#[ !$0
M_P"9,0  CC4  (0X  !Z.0  <#@  &<V  !=,@  4RT  $HH  !")   .1\
M #$:   J%0$ (Q$' !T0#0 ;#Q  &0\5 !@0&P 7$"$ %A I !40,0 4$3H
M$Q%% !(240 1$E\ $!)O  X3@@ .$Y8 #1.K  L3P@ +%., #!3Z  T3_P"7
M-0  C#D  ((\  !X/0  ;ST  &4Z  !;-P  4C(  $DN  ! *@  -R4  "\A
M   H'   (!@# !D4"@ 5$@X %!(2 !,3&  2$Q\ $10F !$4+@ 0%#@ #Q5"
M  X63P -%EP #!=L  L7?P )&), "!BH  88OP '&.  !QCU  D8_P"5.
MBCT  (!   !W00  ;4$  &0_  !:/   4#@  $<S   ^,   -BL  "XG   G
M(P  'Q\  !<:"  2%PT $!<1  \7%@ .&!P #A@C  T9+  ,&C4 "QI   H;
M3  )&UH !QQI  4<?  $'9$  AVF  $=O  "'-T  ASR  ,<_P"3/   B$$
M ']$  !U10  ;$4  &-$  !900  3ST  $8Y   ^-@  -3(  "XN   E*@
M'24  !0A!  /'0L #1T0  P=%  +'1H "AXB  @>*@ ''S, !B ^  0@2@ #
M(5<  2%G   A>0  (8X  "&D   AN@  (=L  "'R   @_@"00   AD4  'U(
M  !T2@  :TH  &))  !81@  3D(  $4_   ]/   -3D  "LT   B+P  &2L
M !(H!  -) H "2,.  8C$@ %(QD !"0@  (D*  !)3$  "4\   E2   )E4
M "9E   F=P  )HP  ":B   FN0  )MD  "7R   E_@".10  A$D  'M-  !S
M3P  :D\  &!.  !72P  34@  $1%   \0@  ,3T  "<Y   >-0  %3(   \N
M P *+ H !2L.  $J$0  *A8  "H>   J)@  *R\  "LY   K10  +%,  "QB
M   L=0  +(H  "N@   KMP  *]8  "KR   J_P",20  @DX  'I2  !Q5
M:%0  %]3  !640  3$X  $-+   W1P  +4,  ",_   :/   $C@   PV P &
M,PD  #(-   R$   ,10  #$;   Q(P  ,2P  #(W   R0P  ,E   #)@   R
M<@  ,H<  #&>   QM0  ,-0  ##R   O_P")3P  @%0  'A7  !O60  9ED
M %Y9  !55P  25,  #Y/   R3   *$@  !Y%   50@  #D    @] @ !/ @
M #L,   Z#P  .1(  #D8   Y(   .2D  #DT   Y0   .4X  #E=   Y;P
M.(4  #B<   WLP  -](  #;R   U_P"'50  ?UH  '9=  !M7P  95\  %U?
M  !27   1%@  #A5   M4@  (D\  !A,   02@  "D@   -& 0  108  $0*
M  !##0  0A   $$5  !!'0  028  $$Q  !!/0  04H  $%:  !!;   0($
M #^9   _L0  /M   #WR   \_P"$7   ?&   '-C  !L90  9&8  %ED  !+
M80  /EX  #);   F60  '%8  !)4   ,4@  !%$   !/    3@,  $T(  !,
M#   2PX  $L2  !*&0  2B(  $HL  !*.0  2D<  $I6  !):   27X  $B6
M  !'KP  1LT  $7Q  !$_P"!8P  >6<  ')J  !K;   8&L  %)I  !$9@
M-V0  "IB   ?8   %5X   U=   &6P   %H   !9    6    %<$  !6"
M5@P  %40  !4%   5!T  %0G  !4-   5$(  %-2  !39   4GD  %*2  !1
MJP  4,H  $_O  !._P!^:@  =VX  '!Q  !F<0  6'   $IO   \;0  +VP
M ")J   7:0  #F<   9F    90   &4   !E    8P   &(   !B!   80@
M &$-  !@$   8!<  & A  !?+@  7SP  %]-  !>7@  7G0  %V-  !<IP
M6\4  %KM  !9_P![<@  =78  &MW  !==@  3W8  $%U   S=0  )G0  !ES
M   0<@  !W$   !Q    <0   '$   !Q    ;P   &\   !N    ;@(  &X(
M  !M#   ;1$  &T:  !M)@  ;#4  &Q&  !K6   :VT  &J&  !IH0  :+X
M &?H  !F_@!Y>@  <'P  &%\  !3?0  1'T  #9^   H?@  &WT  !!]   '
M?0   'T   !]    ?@   '\   !^    ?0   'T   !\    ?    'P   !\
M!@  ? P  'P2  !\'0  ?"P  'P\  !\3P  >V4  'M^  !ZF@  >;8  'C?
M  !W^@!S@   98$  %:#  !(A   .88  "N'   =AP  $8<   >(    B
M (D   "*    C    (T   "-    C    (P   ",    C    (P   "-
MC00  (X,  ".$P  CR$  (XR  ".1@  CEL  (UT  "-D   C*T  (O.  "*
M\P!HA@  6H@  $N+   \C0  +8\  !Z0   1D0  !Y(   "3    E0   )<
M  "9    FP   )P   ";    FP   )P   "<    G0   )X   ">    GP
M *$#  "B#   HA8  *,F  "C.@  HT\  *-H  "BA@  HJ(  *+   "AZ !<
MC0  39   #^3   PE@  (9D  !*:   'FP   )T   "@    H@   *0   "H
M    J@   *L   "J    JP   *P   "M    K@   *\   "Q    L@   +0
M  "W 0  N0T  +D:  "Z+0  ND,  +I;  "Z=P  NY0  +NQ  "YT@!0E0
M09@  #*<   CH   $Z(   BD    IP   *H   "L    KP   +(   "W
MN0   +L   "Z    O    +T   "_    P    ,(   #$    Q@   ,D   #-
M    T@$  -0/  #5'P  US4  -A-  #8:0  UX8  ->C  #6O0#_    _P
M /\   #_    _P # /\ #0#_ !4 _P @ /P *P#X #4 ]  _ /  1P#N $X
MZP!4 .D 6@#G %\ Y0!D ., :@#A '  WP!V -T ?@#; (< V "1 -, G0#/
M *L S0"] ,L X #) /L QP#_ +T _P"Q /\ J0#_ *, _P#_    _P   /\
M  #_    _    /8 "P#Q !$ [0 ; .D )0#D #  WP Y -H 00#5 $@ T0!.
M ,\ 5 #- %D RP!> ,D 8P#' &D Q0!O ,, =P#  '\ O@"* +L E0"X *,
MM@"T +0 S0"R /( L #_ *P _P"C /\ G #_ )< _P#_    _P   /H   #Q
M    Z    .  !@#9  X T@ 6 ,X 'P#( "D Q  R ,  .@"] $$ N@!( +@
M30"V %, M !8 +( 70"P &( K@!I *P ;P"J '@ J "" *8 C@"D )L H0"K
M )\ P "= .8 FP#_ )H _P"4 /\ C@#_ (H _P#_    ]@   .@   #<
MS@   ,8  0"_  L N@ 1 +8 &@"R "( K@ K *H - "H #L I0!! *, 1P"A
M $P GP!1 )X 5@"< %P F@!B )D : "7 '  E0!Z )( A@"0 ), C0"B (L
MM0") -, AP#W (8 _P"$ /\ ?P#_ 'P _P#R    XP   -(   #%    N@
M +$   "K  < I0 . *$ % "> !P F@ E )< +0"4 #0 D@ Z )  0 ". $4
MC0!* (L 4 ") %4 B !; (8 80"$ &D @@!R '\ ?0!] (L >P": '@ JP!V
M ,0 = #K ', _P!S /\ < #_ &X _P#?    S    +\   "T    JP   *$
M  ":  ( E  + )  $ ", !< B  > (4 )@"# "T @0 S '\ .0!] #\ >P!$
M 'D 20!X $X =@!4 '0 6@!S &( < !K &X =0!L (, :@"2 &@ HP!F +@
M9 #> &, ^P!B /\ 8@#_ &  _P#,    O    *\   "E    G0   )0   ",
M    A@ ' ($ #0!\ !( >  9 '4 'P!S "8 <0 M &\ ,@!M #@ :P ] &H
M0@!H $@ 9P!. &4 5 !C %L 80!D %\ ;@!= 'L 6P"* %D FP!7 *\ 5@#+
M %4 \@!4 /\ 5 #_ %0 _P"^    L    *0   "9    D    (@   "!
M>0 " ', "@!O  \ :P 4 &< &@!E "  8P F &$ + !? #( 7@ W %P / !;
M $( 60!' %< 3@!6 %4 5 !> %( : !0 '0 3@"# $P E0!* *@ 20#  $@
MZ !' /\ 1P#_ $< _P"T"0  I@L  )L,  "0"@  A@4  'X   !V    ;P
M &@ !0!C  P 7P 0 %L %0!8 !H 5@ A %0 )@!3 "P 40 Q %  -@!. #P
M30!" $L 2 !) %  2 !8 $8 8@!$ &X 0@!] $  C@ _ *( /0"X #T W0 \
M /@ / #_ #P _P"L$   GQ(  )02  ")$0  ?P\  '8,  !N!0  9@   &
M 0!9  @ 50 - %$ $0!. !8 2P ; $D (0!( "8 1@ K $4 ,0!# #8 0@ \
M $  0P ^ $L /0!3 #L 70 Y &D -P!X #8 B0 T )P ,P"Q #( S@ R /$
M,0#_ #$ _P"F%@  FAD  (X:  "$&@  >A8  ' 2  !H#@  7PH  %@#  !1
M  0 3  * $@ #@!$ !( 00 6 #\ &P ] "$ /  F #H +  Y #$ -P W #8
M/@ T $8 ,P!/ #$ 60 O &4 +@!S "P A0 K )@ *@"M "D Q@ H .H * #^
M "@ _P"A'   E2   (HA  !_(0  =1\  &P:  !C%@  6A$  %(-  !+!P
M1  & $  "P \  \ .  2 #8 %P T !P ,P A #$ )P P "P +@ S "T .@ K
M $( *@!+ "@ 50 F &$ )0!P "0 @0 B )4 (0"I "  P0 @ .0 'P#Y !\
M_P"=(@  D28  (8H  !\)P  <B4  &DB  !?'0  5Q@  $X3  !&#@  /PL
M #@%!P T  P ,0 0 "X $P L !@ *@ = "D (@ G "@ )@ N "0 -@ C #X
M(@!' "  4@ ? %X '0!M !P ?@ : )( &0"G !@ O0 7 -\ %P'U !<"_P":
M)P  CBL  (0M  !Y+0  <"L  &8H  !=)   5!\  $L:  !#%   .Q   #0-
M @ M"0D *04- "8#$  D 1, (@(9 "$"'@ @ B0 '@,J !T#,@ ;!#H &@5$
M !D%3P 7!EP %@9J !0'?  3!Y  $@>E !$'NP 0!]L $ CR ! )_P"7*P
MC"\  ($Q  !W,@  ;C$  &0N  !;*@  424  $D@  ! &P  .!8  #$2   I
M#@0 (PP) !\)#0 =!Q  &P<5 !D(&@ 8""  %PDG !8)+@ 5"C< $PI! !(+
M30 1"UH $ MI  X,>P .#)  #0RE  P-NP +#=D "PWQ  P-_P"5+P  BC,
M '\V  !V-@  ;#4  &,S  !9+P  4"L  $<F   ^(0  -AT  "X8   G$P
M(! % !D."@ 5# X % P1 !,,%@ 2#!P $0TC ! -*P /#30 #@X_  T.2@ ,
M#U@ "P]G  H0>0 ($(T !Q"B  80N  %$-0 !1#O  80_P"2,P  B#<  'XZ
M  !T.P  :SH  &$X  !8-0  3C   $4L   ])P  -2,  "T?   F&@  'A8!
M !<3!@ 1$ L #@X.  X/$P -$!D #1 @  P0*  +$3( "A$\  @22  '$E4
M!A-E  03=@ #$XL  12@   3M@  $]$  !/N   3^P"0-@  ACL  'P^  !S
M/P  :C\  & ]  !7.0  338  $0Q   \+@  -"H  "PF   E(@  'AX  !8:
M @ 0%0D #!,.  H3$@ )%!< "!0?  <5)@ &%2\ !!8Z  ,61@ !%U,  !=B
M   8=   &(D  !B?   8M0  %]   !?M   7^P"..@  A#\  'M"  !R0P
M:$,  %]"  !6/P  3#L  $,W   [-   ,S   "PL   D*0  &R0  !,? @ -
M&PD "1D-  89$0 $&18  AD=  $:)   &BT  !LX   ;1   '%$  !Q@   =
M<@  '8<  !R=   <LP  ',X  !OM   ;_ ",/@  @D,  'E&  !P2   :$@
M %Y&  !51   2T   $,]   [.@  ,S<  "HR   @+0  %RD  ! E @ +(@D
M!2 -  $?$   'Q0  !\;   @(@  ("L  "$V   A00  (4\  "%>   B<
M(H4  "&;   AL@  (<T  "#M   ?_ "*0P  @$@  'A+  !O3   9DT  %U+
M  !420  2D8  $)#   Z0   +SL  "4W   <,P  $R\   TL @ '*0@  2<,
M   F#@  )1(  "89   F(0  )BD  "8S   G/P  )TT  "=<   G;0  )X(
M ">9   FL   )<P  "7N   D_0"(2   ?TP  '90  !N40  95(  %Q1  !3
M3P  2DP  $%)   U1   *T   "$\   7.0  $#8   HR 0 #, <  "\+   N
M#@  +1$  "T6   M'@  +2<  "TQ   M/0  +4H  "U9   M:P  +8   "R7
M   LKP  *\L  "KN   J_@"%30  ?5(  '55  !L5P  8U<  %M6  !350
M1U$  #M-   P20  )48  !Q#   3/P  #3T   8Z    . 4  #<)   V#0
M-0\  #04   T&P  -"0  #0N   T.@  -$<  #17   T:   -'T  #.5   R
MK0  ,<H  #'N   P_P"#4P  >U@  '-;  !J70  8ET  %M=  !/6@  0E8
M #92   J3P  ($P  !9)   .1P  "$0   !"    00,  #\'   ^"P  /0X
M #T1   \&   /"$  #PK   \-P  /$0  #Q3   \90  .WH  #J2   ZJP
M.<@  #CM   W_P"!6@  >5X  '%A  !I8P  8F0  %=B  !)7@  /%L  "]8
M   D50  &5,  !!1   *3P   4T   !,    2@   $D$  !("   1PP  $8/
M  !&%   11P  $4G  !%,P  14   $50  !$80  1'8  $./  !"J   0<8
M $#L   __P!^80  =F4  &]H  !H:@  76D  $]F  !"9   -&$  "A?   =
M70  $EL   M9   "6    %8   !6    5    %,   !2!   40D  % -  !0
M$   3Q@  $\B  !/+@  3SP  $]+  !.70  3G(  $V+  !,I0  2\(  $GJ
M  !(_P![:0  =&P  &YO  !D;P  56T  $=L   Y:@  +&D  "!G   490
M#60   -B    8@   &$   !@    7P   %X   !=    7 0  %P)  !;#0
M6Q(  %L<  !:*   6C8  %I&  !96   66T  %B%  !7H   5KT  %7H  !3
M_@!Y<   <W0  &EU  !;=   3',  #YS   P<@  (W$  !9O   -;@  !&T
M  !M    ;0   &T   !L    :P   &H   !I    :0   &D#  !H"0  : X
M &@5  !G(0  9R\  &<_  !F4@  9F8  &5_  !DF@  8[<  &+A  !A_ !W
M>   ;7H  %]Z  !0>@  0GH  #-[   E>P  &'H   YY   $>0   'D   !Y
M    >@   'H   !Z    >    '@   !W    =P   '<   !W 0  =P@  '<.
M  !W&   =R8  '8V  !V20  =5\  '5W  !TDP  <Z\  '+3  !Q]P!Q?@
M8W\  %2   !%@@  -H,  "B$   :A   #H,   2$    A    (4   "&
MB    (D   "(    AP   (<   "'    AP   (<   "(    B    (@'  ")
M$   B1P  (DL  "(/P  B%4  (AM  "'B0  AJ<  (7'  "$[P!FA   5X8
M $B(   YB@  *HP  !N-   /C0  !(X   "0    D0   ),   "5    EP
M )@   "6    EP   )<   "7    F    )@   "9    F@   )L   "=!P
MG1$  )TA  "=,P  G4D  )QB  "<?P  G)P  )RY  ";X@!:BP  2XX  #R1
M   MDP  'I4  !"6   $F    )H   "<    G@   *$   "D    I@   *<
M  "F    IP   *<   "H    J0   *H   "L    K0   *\   "Q    LPD
M +,5  "T)P  M#T  +55  "U<   M(X  +2L  "TS !-D@  /Y8  "^:   @
MG0  $9\   6A    HP   *8   "I    K    *\   "S    M0   +<   "V
M    MP   +@   "Z    NP   +T   "_    P0   ,0   #'    RP   ,T,
M  #.&@  SR\  ,](  #08@  T(   -"=  #0N
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ME)66EYB9FIN<G9Z?H*&BHZ2EIJ>HJ:JKK*VNK["QLK.TM;:WN+FZN[R]OK_
MP<+#Q,7&Q\C)RLO,S<[/T-'2T]35UM?8V=K;W-W>W^#AXN/DY>;GZ.GJZ^SM
M[N_P\?+S]/7V]_CY^OO\_?[_;69T,0     # 2$   $
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M_____\]T-0L    *4J?______________________________Y8T
M3Z?_____________________________]FD=   )# 8)4K'_____________
M________________RSL.$S5,6TU,7L/_____________________________
MJ6 V8(:?MJRIN-G_____________________________X)>-ON7_________
M_____________________________^WY____________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________KV<J\Q___________
M________________________SYJ!;5I&B.K_________________________
M_______$?#XF$   5+#______________________________^"#/
M+H?M_____________________________ZQ3$       %VW6____________
M________________^X Q        "6',____________________________
MTEH"         %W,____________________________J#4          %S3
M____________________________?0T          %36________________
M___________N?44          $34___________________________\JF0O
M @  !"(W25C.____________________________Z:1K02@_8W^5I[K:____
M___________________________5LJRRS.3Z________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________ENY=W8LC_________________________________VYYG-@H
M HS________________________________(?S\%     %[/____________
M_________________]F!.0       #RJ____________________________
M_YY,         ".0____________________________W&\:         !!]
M^?__________________________KT@           !O[O______________
M____________A!,           !DYO_________________________L40
M          !7WO________________________^X%0            !(UO__
M______________________]T%              XS___________________
M______FB6A,            CQ?_________________________?FUPL
M       -NO__________________________[[%]53DB$0<! A$BLO______
M________________________W[^EF9B:H*R]VO______________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________X[Z=@'S[____________
M____________________\K>$5S . !VL____________________________
M___2BDP5      !R\____________________________]9_-@        !+
MR?__________________________^I$^           OJ_______________
M____________P%H            :E?__________________________C20
M           (A/_________________________G7@              =___
M______________________^T)0              :O__________________
M______]]                6_3_______________________TK
M        3.O______________________Z4                 /.'_____
M_________________S ,                +=G_____________________
MF8IA)P              )]?______________________^V^B54G
M    )=S__________________________LJ==EU*/#(M+# Y1][_________
M______________________WFW=;2T-/9Y/__________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________OU+O6_________________________________^>XCVI++Q5O
M_______________________________DH6<T!P     \R?______________
M_____________]:".P         2E___________________________[84Q
M            ;___________________________ID(             4.'_
M_______________________L:0              -\G_________________
M______^S+P              (K;_______________________]Y
M        $*?_______________________(T                 )G_____
M_________________ZD                  (S_____________________
M_T8                  '______________________WP
M     '3_____________________EP                   &K_________
M____________S@                   &/______________________RDB
M 0               &'______________________[FC@%<W%P
M &C___________________________K3KI2&?'5Q<')W@93_____________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________V[J=@FEIT_______________________________
MR)-E/1D    =GO___________________________]N.3!,         ;O__
M________________________VWPL            1=?_________________
M________BRH             (K3________________________"1
M         Y?_______________________]] 0               '______
M_________________^<V                 &K_____________________
M_YT                  %C______________________T8
M     $?X____________________Z0                   #7I________
M____________E@                   "7;____________________O
M                 !C.____________________ZP
M  _"_____________________P                    JY____________
M_________R<                   JU_____________________W
M              VY_____________________^"<C'!50C,F&Q0/#0X2&B:_
M____________________________^>38TL[,R\S/UN#\________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________Z].\X___
M_____________________________]*IA65(+!(!A?__________________
M__________&K<3P/        3^#_________________________U7\U
M        '[+________________________C=1T              (G_____
M__________________^0(P               &?_____________________
M_]5#                 $CV_____________________XH
M     "[=_____________________S@                  !?(________
M____________O@                    2V____________________G
M                  "E____________________N@
M  "3____________________W                     ""____________
M_________P                    !T_____________________Q,
M              !H_____________________T(                   !@
M_____________________WH                   !=________________
M_____]$                   !A______________________\D
M          !F_______________________)K)F)?79Q;&EG9F=K<'J,____
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
MXL6JD7EA=______________________________=IG=0+ P     ,<3_____
M____________________X)).$P           (______________________
M___2<!T              &#______________________^YO#P
M     #?B_____________________Y8<                 !3 ________
M_____________T                    "C____________________K@
M                  ")____________________G@
M  !R____________________O                     !?____________
M________V@                    !-____________________^@
M               [_____________________PX                    J
M^?___________________S,                    ;Z?______________
M_____UX                    /V____________________X\
M           &T/___________________]                      RO__
M__________________\K                    R/__________________
M__^                     R______________________W%@$%!0,!
M   !!@T8R________________________.OAV,_,S<_0TM37W.+J________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________':QO______________________
M________\<:CA&A-,A@ %:O__________________________[E\1A@
M     ''________________________7?"\              #OC________
M_____________]]D"0                RU_____________________W0#
M                  "-____________________Q14
M  !J____________________F0                    !+____________
M________M@                     P_?__________________UP
M               9Y___________________]@                     %
MT____________________PX                     P?______________
M_____R\                     K____________________U(
M            GO___________________WD                     CO__
M_________________Z4                     @/__________________
M_]@                     =/____________________\V
M        ;?____________________]\                    :?______
M_______________7#0                  :/______________________
M<                   8?_______________________U \1DY465UA9&AL
M<'9^B?______________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________[]6[HXMS6I7_________
M__________________B_CF1!(04      %+\_______________________W
MG588             !?!_____________________^5L%@
M  "-_____________________V,                   !>____________
M________G0                     U_/__________________H0
M               1V?__________________R@
MN___________________[@                      H?______________
M_____PP                     BO___________________RT
M            =O___________________TT                     9/__
M_________________V\                     4O__________________
M_Y0                     0/___________________[P
M        ,/___________________^H.                    (O______
M______________]$                    %?____________________^!
M                    "_7____________________("P
M     NS_____________________7@                   .7_________
M____________R1P                  -K______________________YT!
M              <.%\7________________________5N;S!Q\[5V^'F[?3[
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________XW\______________________________[,:EB&U4.R$'
M #+>________________________UY)9*0            "@____________
M__________^)-@                !G_____________________V8
M               R]O__________________E0                     #
MR/__________________IP                      H/______________
M____UP                      ?/___________________P
M            7O___________________R4                     0___
M_________________T@                     +/__________________
M_VH                     &/___________________XL
M        !?/__________________Z\                      .'_____
M_____________]4                      ,____________________\D
M                     +[___________________]4
M     *[___________________^+                     )__________
M___________+#@                   )+_____________________5P
M                 (;_____________________J@H
M 'G______________________VT                  &;_____________
M__________=5                 $7_________________________:B,K
M-3]*56!J=7Z'D9S_____________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________^C/MIV#:4ZY_________________________^RR
M@UPZ'0(       ![_______________________%;2D               !
M_____________________X,;                   'R_______________
M____D@                      F/__________________I
M            :O__________________W0                      0?__
M_________________PX                     '?__________________
M_SD                      .C__________________V
M         ,[__________________X4                      +?_____
M_____________Z@                      */__________________\L
M                     )#__________________^\6
M     'W___________________\^                     &S_________
M__________]I                     %K___________________^9
M                 $G____________________2%@
M #G_____________________6                    "G_____________
M________H@                   !G_____________________]58
M              3______________________[LO                  #X
M______________________^K*0                #/________________
M________R4<     !Q,@+CY2:(3M________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________________________]-7)
M____________________________^M*PDG==0B@,  !*________________
M________Q7U%%P             1V/___________________\10
M            G___________________H@P                     :/__
M________________E                       -O__________________
MV@                      !^S__________________Q4
M         ,3__________________T@                      *+_____
M_____________W4                      (/__________________YT
M                     &G__________________\,
M     %+__________________^</                     #[_________
M__________\S                     "O___________________]8
M                 !C___________________^!
M  7___________________^L                      #_____________
M_______>(@                    #R____________________7
M              #?____________________GP                    #,
M____________________Z$H                   "W________________
M_____Z 6                  "<______________________]Z @
M          !W________________________>@L               5,____
M_____________________Z)7:'2 C9RKO-#G________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________^WC___________________________2HWI8.BDC'!8.!@  G___
M__________________^L4@X                 :?__________________
MY$,                     -/__________________>0
M         ./_________________S0                       ++_____
M_____________Q,                      (7__________________T\
M                     %W__________________X,
M     #K__________________[(                      !S_________
M_________]L#                      +___________________\J
M                  #[__________________]/
M  #G__________________]T                      #4____________
M______^;                      # ___________________$!P
M              "M___________________P,P                    ":
M____________________9P                    "&________________
M____HP                    !R____________________XT0
M          !<_____________________Y$&                  !!____
M_________________^M?                   =____________________
M___*2P                  ________________________RU<   P8)#$_
M3F!TBZ?'___________________________7Y_+_____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________________KU,W'PKZZ
MM[.PK:FHI?___________________]U^4S\P(QD1"0(          -O_____
M____________=@                       *?_________________N@
M                     '7__________________P<
M     $;__________________TX                      !K_________
M_________XP                       #]_________________\$
M                  #;__________________$9
M  "^__________________]$                      "D____________
M______]K                      "-__________________^1
M              !Y__________________^W                      !F
M___________________>(0                    !3________________
M____2@                     _____________________=P
M           K____________________K H                    6____
M________________YT4                     ____________________
M_XH                     _____________________]9-
M        _?____________________^G+@                  U?______
M________________F"H           88+45@X/______________________
M_ZAC=(&/G*N[S>+Z____________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________GR[>IG96.B82 ?'AT
M<&QH99#_________________O&I(+1D*                 #'_________
M_________P                        /__________________T(
M                  #<_________________XX
M  "R_________________\X                       "-____________
M______\I                      !K__________________]:
M              !.__________________^&                       T
M__________________^N                       >________________
M___4%P                     *___________________Z/0
M            ____________________90                      ____
M________________C@                      ____________________
MO!D                     [___________________\4X
M        V/___________________XL                     O_______
M_____________\Q#                    H?____________________^1
M&0                  >O_____________________R= H
M   17_______________________Z'03'RPX15-B<H6;M-+U____________
M_______________7Z/3_________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M______OW\_'N[.OK[/'__________________]FRF8=Y;61=5E%+1D$\.#(M
M*"/$_________________TLE"P                    "2____________
M_____X@                       !F_________________]<
M               ]__________________\S                       8
M__________________]L                        ________________
M__^=                        ___________________)#
M            ]O_________________Q-0                      W___
M________________6P                      R___________________
M@@                      M___________________J08
M        H___________________TR\                     C?______
M_____________UX                     =____________________Y,'
M                    7O___________________\U#
M    0/____________________^'$                   '/__________
M___________87@                   /______________________OTX
M      X<+#Y2:H:ER/_______________________\)\C)JGML76Z/W_____
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________________________^[AU\_)
MP[ZZMK&MJ:>FIJ>N_________________[Z&;5M,0#<O*"(<%A +!      4
M_________________]<%                        ________________
M__\T                        ]O________________]V
M            TO________________^P                        LO__
M_______________A)                       EO__________________
M40                      ?/__________________>0
M        9O__________________H                       4?______
M____________QR,                     //__________________[DL
M                    )____________________W0
M    $/___________________Z,6                     /__________
M_________]A,                     /____________________^(#P
M                 /_____________________+4P
M /______________________I3@           D=-$YKC/______________
M_________YDY0U%?;GV.H+7+Y?_____________________________K^?__
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________________KS+FLH9F1BX:!
M?'AT<&MH9F9H\?________________]A13(C& X&                GO__
M______________]^                        =?_________________#
M                        4O_________________[-P
M        ,O__________________:@                      %O______
M____________E@                       /__________________OQL
M                     /__________________YD(
M     /___________________VD                      /__________
M_________Y "                     /___________________[DL
M                 /3__________________^A<
M -G___________________^1&                    +S_____________
M_______*4P                   )W_____________________F"X
M        $"E&9L3_____________________[G\=#!HH-T97:7Z5K\SN____
M_____________________^>@JKG(V.G\____________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____?7PZ^;BW]O8U-+1T-+7X/_________________.GHI\<6EA6U913$A#
M/CHV,B\N,?_________________2)1$#                     /______
M____________0@                       /__________________?0
M                     /__________________L L
M     /;_________________W3D                      -S_________
M_________V(                      ,7__________________XD
M                 *___________________Z\B
M )G__________________]9(                     (+_____________
M______]R                     &G___________________^A*
M             $[____________________37                    #/_
M____________________EBX              !4R4G?_________________
M____X'(3   !#Q\O0EAPBZC([/_______________________\IO;GZ.GK##
MV.__________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________________________^>#2
MR,"ZM;"LJ*6BGYV;FYR@I___________________@F162T,\-C K)R(=&!,.
M"00  -3_________________D@                       *W_________
M________S!X                      (O_________________^U(
M                 &W__________________X
M %'__________________ZD;                     #K_____________
M_____]!"                     "/___________________5H
M              S___________________^/%                     #_
M__________________^X/@                    #_________________
M___E;0,                   #_____________________GS<
M     ! O4'3_____________________W7(4      87*D%:=92VVO______
M_________________[Q81%1D=8::K\CC____________________________
M___2S>'Q____________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________\^_K[_?______________________[KFHG9:/
MBH:"?WMX=G1R<W5X?Y#_________________ZT\Z,"@A&Q40"P<"
M "/__________________VD                       #_____________
M_____YL*                      #__________________\@Y
M              #___________________!C                      #_
M__________________^*#@                    #_________________
M__^P-                     #____________________56P
M          #_____________________A1H                   /L____
M________________L4D              !@Y78'_____________________
MY7L>       ,(3A2;X^SV?_______________________[M8*3E)6FR E[#-
M[?____________________________^SGK3%U^O_____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______Z[^?AW-G6U-+0T-#1T]G@Z_?__________________[B*?G=Q;&AD
M85Y;65A75UE>97'__________________[\Q'Q80"@4               #_
M_________________^U6                      #H________________
M__^"!                     #,__________________^K+P
M          "S___________________25P                    ";____
M_______________W?!                    "%____________________
MHC<                 !2N4____________________RV$"
M#"Q0=I[1____________________]8TP       -(SM7=IF^Y?__________
M_____________\-C&"H[3%]TC:?&Y_____________________________^H
M?Y:HN]#G_____________________________________?______________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___=SL6_O+FVM+.QLK*UN<#)U>/___________________^7;&1>65513TQ*
M2$=&2$M066:A__________________^G)@X' @                !6____
M_______________.4                      Z___________________T
M>0L                    A____________________GS(
M       .____________________Q%@                (,5J$________
M____________Z7\?           &)TMQFL+I_____________________Z=)
M      (7+TIHBJ[5_/_______________________]-U'B8X2EYUCZO+[___
M__________________________^N<H68K,+;]O______________________
M____________W^______________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
MO[*JIJ.AH)^?H:.FK+3 S=WL____________________BEI33TM(1D1#0D%"
M0T=.66E]____________________GBX&                    ________
M____________PU8                  !5!____________________YWL:
M              DT8(NT_____________________Y\_          0E2G&9
MPNO______________________\9F#P   !,J1&*#I\WU________________
M_________^N.-2L^46B!G;S>______________________________^^=G^4
MJ<'<^?__________________________________TMCS________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________V\O#O[^_Q\_C]____________________________^+"?
MFI>6EI:8FY^DK+;"T>'N_____________________HY02D=%1$1$149'2U%:
M:(.I_____________________Z9! 0          !S9CC[KA____________
M_________\9E"@      !"=,<YS$[/_______________________^6(+P
M$RI$8H*FS/3___________________________^K4#9*87N6M-;Z________
M_______________________2AWR8L<OI____________________________
M________U,[M________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________MY>/CY.;H[?'Y______________________________VQE)*2
ME9F=HZFRO-#M__________________________^=4T=)35%68'.*K];\____
M______________________^R5@ :-5!MBZ[2]_______________________
M_______-;SY?>YFWU_G________________________________NGX.FPN'_
M____________________________________X\[K____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________
M
M
M                      #_____________________________________
M____________________________________________________________
M____________________________________________________________
M_____________P    #_X4#&:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP
M+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.
M5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O
M(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 Y+C M8S P," W.2XQ-S%C,C=F
M+" R,#(R+S X+S$V+3$X.C R.C0S(" @(" @(" B/@H@(" \<F1F.E)$1B!X
M;6QN<SIR9&8](FAT=' Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y
M;G1A>"UN<R,B/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB
M(@H@(" @(" @(" @("!X;6QN<SIP9&8](FAT=' Z+R]N<RYA9&]B92YC;VTO
M<&1F+S$N,R\B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87 O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z>&UP34T](FAT
M=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\B"B @(" @(" @(" @('AM
M;&YS.G-T179T/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O
M4F5S;W5R8V5%=F5N=",B"B @(" @(" @(" @('AM;&YS.G-T4F5F/2)H='1P
M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C(@H@
M(" @(" @(" @("!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE
M;G1S+S$N,2\B"B @(" @(" @(" @('AM;&YS.G!H;W1O<VAO<#TB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]P:&]T;W-H;W O,2XP+R(*(" @(" @(" @(" @>&UL
M;G,Z=&EF9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]T:69F+S$N,"\B"B @(" @
M(" @(" @('AM;&YS.F5X:68](FAT=' Z+R]N<RYA9&]B92YC;VTO97AI9B\Q
M+C O(CX*(" @(" @(" @/'!D9CI0<F]D=6-E<CY-:6-R;W-O9G3"KB!7;W)D
M(#(P,3D\+W!D9CI0<F]D=6-E<CX*(" @(" @(" @/'AM<#I#<F5A=&]R5&]O
M;#Y-:6-R;W-O9G3"KB!7;W)D(#(P,3D\+WAM<#I#<F5A=&]R5&]O;#X*(" @
M(" @(" @/'AM<#I#<F5A=&5$871E/C(P,C(M,3$M,C94,#(Z,#(Z,C0K,#4Z
M,S \+WAM<#I#<F5A=&5$871E/@H@(" @(" @(" \>&UP.DUO9&EF>41A=&4^
M,C R,RTP,2TP.%0Q,SHT,SHS,BLP-3HS,#PO>&UP.DUO9&EF>41A=&4^"B @
M(" @(" @(#QX;7 Z365T861A=&%$871E/C(P,C,M,#$M,#A4,3,Z-#,Z,S(K
M,#4Z,S \+WAM<#I-971A9&%T841A=&4^"B @(" @(" @(#QX;7!-33I$;V-U
M;65N=$E$/F%D;V)E.F1O8VED.G!H;W1O<VAO<#IC9#0X864Y8BTT8SAC+65D
M-#8M830R8RUC9C<R,6%B.#=C,C4\+WAM<$U-.D1O8W5M96YT240^"B @(" @
M(" @(#QX;7!-33I);G-T86YC94E$/GAM<"YI:60Z.3<T96(R.&(M968P."TT
M.#0S+3EF9# M-S5A-CEE93<X-S4T/"]X;7!-33I);G-T86YC94E$/@H@(" @
M(" @(" \>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/G5U:60Z03E!-C R140M
M.$4S.2TT,49&+4$P03 M-D0T,$8V-31&034V/"]X;7!-33I/<FEG:6YA;$1O
M8W5M96YT240^"B @(" @(" @(#QX;7!-33I(:7-T;W)Y/@H@(" @(" @(" @
M(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I
M;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T
M179T.FEN<W1A;F-E240^>&UP+FEI9#HU-F$U9F$X."UB9#8Y+3%E-#@M86)C
M-2TS,6(T-S(S-# Q-C,\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IW:&5N/C(P,C(M,3$M,C94,#0Z,3(Z,3DK,#4Z,S \
M+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R
M94%G96YT/D%D;V)E(%!H;W1O<VAO<" R,RXU("A7:6YD;W=S*3PO<W1%=G0Z
M<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG
M960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^
M"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S
M=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC
M94E$/GAM<"YI:60Z-#<W.3EF.&8M8F4P8BTV930U+6)A,S,M-31D.&,T-V0W
M96(V/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z=VAE;CXR,#(S+3 Q+3 X5#$S.C0S.C,R*S U.C,P/"]S=$5V=#IW:&5N
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B
M92!0:&]T;W-H;W @,C0N,2 H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E
M;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T
M.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @
M(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @(" @(" @/'-T179T.F%C=&EO;CYC;VYV97)T960\+W-T179T.F%C
M=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G!A<F%M971E<G,^9G)O
M;2!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P('1O(&EM86=E+V5P
M<V8\+W-T179T.G!A<F%M971E<G,^"B @(" @(" @(" @(" @(#PO<F1F.FQI
M/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U
M<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYD97)I=F5D
M/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A
M;65T97)S/F-O;G9E<G1E9"!F<F]M(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP
M:&]T;W-H;W @=&\@:6UA9V4O97!S9CPO<W1%=G0Z<&%R86UE=&5R<SX*(" @
M(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z.3<T96(R.&(M968P
M."TT.#0S+3EF9# M-S5A-CEE93<X-S4T/"]S=$5V=#II;G-T86YC94E$/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(S+3 Q+3 X5#$S.C0S
M.C,R*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @,C0N,2 H5VEN9&]W
M<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @
M(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO
M>&UP34TZ2&ES=&]R>3X*(" @(" @(" @/'AM<$U-.D1E<FEV961&<F]M(')D
M9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @/'-T4F5F.FEN
M<W1A;F-E240^>&UP+FEI9#HT-S<Y.68X9BUB93!B+39E-#4M8F$S,RTU-&0X
M8S0W9#=E8C8\+W-T4F5F.FEN<W1A;F-E240^"B @(" @(" @(" @(#QS=%)E
M9CID;V-U;65N=$E$/F%D;V)E.F1O8VED.G!H;W1O<VAO<#HV,F8Q-3 W92TY
M93DP+6,Q-#8M.3@X-2TU,35D93 W9#$W-SD\+W-T4F5F.F1O8W5M96YT240^
M"B @(" @(" @(" @(#QS=%)E9CIO<FEG:6YA;$1O8W5M96YT240^=75I9#I!
M.4$V,#)%1"TX13,Y+30Q1D8M03!!,"TV1#0P1C8U-$9!-38\+W-T4F5F.F]R
M:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/"]X;7!-33I$97)I=F5D1G)O
M;3X*(" @(" @(" @/&1C.F-R96%T;W(^"B @(" @(" @(" @(#QR9&8Z4V5Q
M/@H@(" @(" @(" @(" @(" \<F1F.FQI/E-T97!H96X@36$\+W)D9CIL:3X*
M(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+V1C.F-R96%T;W(^
M"B @(" @(" @(#QD8SIF;W)M870^:6UA9V4O97!S9CPO9&,Z9F]R;6%T/@H@
M(" @(" @(" \<&AO=&]S:&]P.D-O;&]R36]D93XT/"]P:&]T;W-H;W Z0V]L
M;W)-;V1E/@H@(" @(" @(" \<&AO=&]S:&]P.DE#0U!R;V9I;&4^52Y3+B!7
M96(@0V]A=&5D("A35T]0*2!V,CPO<&AO=&]S:&]P.DE#0U!R;V9I;&4^"B @
M(" @(" @(#QT:69F.D]R:65N=&%T:6]N/C$\+W1I9F8Z3W)I96YT871I;VX^
M"B @(" @(" @(#QT:69F.EA297-O;'5T:6]N/CDY.30W,"\Q,# P,#PO=&EF
M9CI84F5S;VQU=&EO;CX*(" @(" @(" @/'1I9F8Z65)E<V]L=71I;VX^.3DY
M-#<P+S$P,# P/"]T:69F.EE297-O;'5T:6]N/@H@(" @(" @(" \=&EF9CI2
M97-O;'5T:6]N56YI=#XR/"]T:69F.E)E<V]L=71I;VY5;FET/@H@(" @(" @
M(" \97AI9CI#;VQO<E-P86-E/C8U-3,U/"]E>&EF.D-O;&]R4W!A8V4^"B @
M(" @(" @(#QE>&EF.E!I>&5L6$1I;65N<VEO;CXV,S,\+V5X:68Z4&EX96Q8
M1&EM96YS:6]N/@H@(" @(" @(" \97AI9CI0:7AE;%E$:6UE;G-I;VX^,S,X
M/"]E>&EF.E!I>&5L641I;65N<VEO;CX*(" @(" @/"]R9&8Z1&5S8W)I<'1I
M;VX^"B @(#PO<F1F.E)$1CX*/"]X.GAM<&UE=&$^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"CP_>'!A8VME="!E;F0](G<B/S[_VP!#  $!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0'_VP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1
M" %% F # 1$  A$! Q$!_\0 'P !  $% 0$! 0$           @!!08'"00#
M @H+_\0 =Q    8" 0$$! 8'#P@2#@D% 0(#! 4&  <($0D2$R$4%3%!%A<9
M46&7&")6<974UR,W.%=867=X@9&6H;&VMR0G,C:4P=7P)28H*3,U.4)&1TEG
M@Y.GT];A-$-25&1E=':'IL?1X_%$14A356-UA;1FA+7#Q?_$ !T! 0 " P$!
M 0$            !! (#!08'" G_Q !T$0 " @$"! ($!@D,"0X* Q$" P$$
M!0 1!A(3(10Q!Q5!40@6%R)A<2,R55:!D932\!@D)517DY6AL='3U3,T-39"
M4Y+!X28G-T1%1E)B9826U-;Q0T=R<X*%IK*TM61V=Z2V8V9T=8.BI;/$Q<;C
MAJ/D_]H # ,!  (1 Q$ /P#^_C&FF--00VSS'F]177>M3G=<P3Y'75<T=)ZX
M?,+V^*YOLYO>\K:QK$#:63NDH-Z,1K=R((NY*-D;JGZB<!*>CD=IGBPFJJQ>
MJ+FJ"RR3^+V\+)JM9*ZLBO#8S/ED3MB!N@$8N\Y]FL%-C!.F:JQ6B:O?="H\
M:22D_")X3R/%3W@(38%6*];^+IJKL8M)M9.)D*;&6T@YME0NBO$$6M/5[M()
M67MYZ<\U#!M'VM+1#TKDLJSV:J])KNPV;;=HTY6E==E6H['XR860G:C*V!PZ
MFS:ZDV-348N#0ZLZX/ ([:(HR$TK*&,'%99M;&XNVU4#8;Q U%LK6*M55M8*
M%T;E4<>Z\NQ84U]JNVN#:D6+"<\A4;C:]@WDB;%5&3R+069RCU3C,3P[G3L"
MTE@[Q=C%\34F(K%5%/B:UZNRV'22Q^^^97./5_#2M1<A;4'%HMT^<AX*A0SY
MDUG'T:#CT9W-J"\.!&\2S6_,%'0D/WW!BHID,?KT['#V L\172IUVJ1TU2UC
M6P4B(Q,1$0(Q)213VCV1MWG7S/TD^D;%^C3!JS>3J6KT6+:Z=>I3Z4.8PXDB
M*3<8+$%C',4R7-/:!&9GMZ](\[N.FZ:'6;BC?Z[2Y*P,S+KTVVSD;'6*)<(B
M8KIJY;G7 BQ$C$,*;MN)VSA( 51.8@YED^&<OC++Z[*K7@DX&+*%F2&1.W*0
MEMO&^_D404>4Q$ZPX4]*?!W%>*H9&OE:E%]Y'6+%WK*%7ZQ1]NMJX.8F0F/M
MPD@*.XE,3J0;+<.J)'PO0MD4ASXQ4SH^'9HCJJ54 %,Q %V'> X&*("'7VA\
MX9R9HW8WWJ6/F^?V%D[=]O8.O8QG<*7+MEL=\^((-[B(YHGO$QNR-_./QQ[]
M9:VLM<> !FD_".BF 1 S:58K@(![1 4ES (![^GL]^:24T>Q*8,^X@*/Y8C5
MU=RHV(E5JNR)[Q*WJ.)CWQ(E,3^#5W3525+WDE$U2_\ =)G*<OS^THB'L\\U
M[3'G&VM\3$^4Q/U3$_R:_>-3IC33&FF--,::8TTQIIC33&FF--,::8TTQIIC
M33&FF--,::8TTQIIC33&FF--,::8TTQIIC33&FF--,::8TTQIIC33&FF--,:
M:8TTQIIC33&FF--,::8TTQIIC33&FF--,::8TTQIIC33&FF--,::8TTQIIC3
M3&FF--,::8TTQIIC33&FF--,::8TTQIK"[]>HK7=:>V259S,J5L )LX2N1B\
MS89M\IU!O&0T6WZ*O7SDP=U-,#$(4 ,HJHFF4QPTM;*X&!4QS#G8%*'F,IB)
M(I[S$0(C!$1%,1$1.V\[1.U*NK,[FM0!',QK2Y5K'>!B2F(F>Y$(C$1,R4Q$
M1WU&[6W+9]<;,A7KOQVWQIII(B4L39M@59LE75UE3%*V9R;V,>O#0;YUWOS!
MN_3 IC )!6*;H VTJZL$/44#QC?HD7]DF(F2!#=N1K!&)(@B1GE[QOY:K-.5
M[$*V,3);2P!WE8^4,8K?G!<EL,%$%WGO$1WU>;MP_P!:;#O&U+W:[!L&2=;:
MIE-IDM!^OHQ&NUQ#7TW\)J7/TUJE %D(BSUZRF4GX^4=2DDD235,H=HHB1%!
M*NH315;62UJB/.U^(E6@*(MU,I7KUZ8MK,Y>05-IU*M6PAJVJ?70*F"0-L0Z
MR3>:S7LR ?8<+D>'W(CG%%[%Y0K,VT7($X81$-VXL&):@P"RS:><5&O%(?@1
MHV%FJC84'=_<RU?D"3-I=/;0BH?;\\A=)38S"<VSX42A\(9"*ODW,6B,)%#7
MV#1[).F1&0PQB1A+*'>&L"ZLI25*K5:]6D E-*DRG5L4DWJR#(Y'(^'M6(=<
M8;&6&LBR_J65(<J+#GVD,18<;9:5N&/+DAQUKZ<;5MT)D0A7@W4\/BZ4A"H:
M%:BI:W#).)N2<YZ#3;[Q-Y (W&O1\^G6=/[,N,!Z<F<5(FS5JD3LM!S#)5(Z
M2J+IA(-&[A/H?PE13\)PFLB8Z9M]#(W<98BU0L,K/&)&&+Y=^4O.)@H(2B?=
M(S[XUP<_PY@^*<<S$\0XVOE,<T@,ZUB#B.<)YA,#6:VK,9\B68S[)G:9C6Q-
M(T*DQ&D]5P<=5*^WB&^OZ@HC'A%,E&Q5%X%BX64\-5%0#**KJJ*G4-WC&.<Q
MA'J.:W7+5A[++K#6/:4FQLF7.13.\S,Q,><^R-H]T:LTL/BL92KXRA0JUJ%1
M8IK55I#I*6OL C!04SM[YF9F>\S,ZODSHS2EB 0GM0ZQF!$%NAY&B5=VJ07
ME,N9-9:+.JD=8Q"&4.F<ISF*4QC")0$-BLED4?V&_<5Y;PNTX(G;RW@3B)V]
MF_E[-5+?#'#=_;QW#^$MR//RS9Q=%Q#U)B3Y28@B&3D1DY&8DMHWWVC6)GXL
M<>^[W&VJJQ%$\^A(!-[72$ P=TQ4R03R.*F4P?V1" 4IA^V$!-YYM]<9.9W*
MZYD^<RV8=,SY[S+8.9_#Y^W58>#^& "%IPM*JN-^4*8%2$=_.!BH28&)W[P.
MT3/>8WU8?L0=*H+E<1+;8,"L0P'(,1N#:R2)50,(^+Z(ZN+MF<W='P^XHW.D
M"8%*5,.Z40WSG\B0\C"J,&8VF"Q]")V]W.%83COWW@HGZ=<Y?H^X90V'UU9:
MNP2DHE?$?$,A!3OO/1;DV)F-IVY27(Q&W+$;1KTJ<:8Y$A2PNWMZUX"&4,0&
M%];OB@4YQ4!(WP@@IHYTDSCU(!E/$Z?:&5,3[7, RQ1,RRAC7[Q$3U*YCWB-
MMXZ+E;3M[NWMVWU8?PB#!$:_$'$U"!*9CPN246\3O, 7BZEJ2")G>.\%[)+;
MMK]I:3V4P*(1O)79JP]_OE-88BES0AU#H8AO1H2' R8^0D*'=$@]1$QNOD+(
M5&3N>)IAVVV0=A41M[8YFMG?W[S,3[HUFKA[*5PY5<69IQ1.\,O*Q]DN_G$P
MJK5&1_X,;;C._>?9;S:TY-,5!/&<DX*01[Y1!K/Z:B3F\-,W4J0O(^T(G RI
M1$BRX-NOD4Y$@$! =D7,*0['AFB?+MSKR3-N:?\ "Z95_*/.!D]O9,[:ISA>
M-0=SJXTJ&GGB818X:1)<D%$].7AD(G>1W&6=/>/. ]FKBI$<K&1.C.WZ:G#E
M.'G+0%FAP43,7J83!&*ONXH0_4I *)B')T,<2FZAFH3PQ3\]-]8__@F)9,?5
MU.2)B?;OY>S5MR>-5A^MKG#]ED3VFW7NU@D9\YF*\NF"&>PQ&\3'>>_:/RE.
M\K&93^GT'4$R).[W/4EQL#$RQ2_:G 0EXHA4U#CT.3S,F4.I3#U !&37A2VZ
M5F^&_GU4*G:?9MTV3O$>4^4ZQ18XW6)>+QW#SRB8Y(I7KH<T1'SN:;-<8$IG
MN.VXQ':9WU;E=J<D(U0Y9#C(231*H<A'%?VS5514(0>OCBU>LT%DBG)YD2,(
MJ"?[7K[\V11Q!CN.:D"Y8F090?&T[?:\PE,3,3VWB-O;MJL>=XR4X@+@B'*@
MY$7HXAQ_S@B8B&=)BH,8D=YY)^=OVUZ5M^7>.3,I+<<-NAW#D R<"VB;$J*:
M@E*4Z9&KM %!*83>*0! R1"B<1$! ,P#&UV3RAE:,=O-Q&D=XC?:9D2[>Z=I
MWGMM&K+^)K]59,?PKGCY9'['14FZR8*8&)$08$3RS,R<;[B,27?RU1MRCKX]
MXLOJW>M=.GT!7UQK"5(D4W>[IP(LU7=%5!+^R.8@"'=^V+W@R3PS1VY+N,?O
MOMT;@%/EOWW@=M_9O.M=;C.N^"ZV!XHH\FW--W#-6,[S,3R$#&<\#_A3$=O9
MOKU?98Z204%&5G9Z"4+U[Q9FD7)H4H^TA15)!KHB90O4Z92J&$Q ,/0! 0R(
MP>2.():EL&?*0LUIW]D]I;!=I]\1$^S?4MX\X9KL)5FY9K,&(DA=C,G&V\;Q
MN05##O$[QL4]O/:=9"CR5T.L0%#;2J;1,2IG\23?'B"%(H'4ASGE$692$Z?V
M1SB4J8^2@E'RS1ZJR.^T4WG.\QLL.I.\>R("2F9^B.^NC'%?#G)U"S%%2X&"
MDWM\.(C,;\Q2^%P(Q'G);0/^%MK)8O<^GYSIZGVIKJ3,(=[N,KK7'"H%[W<Z
MF22DC*E 3?:@)B!U'H >T,ULQ]]/]EHVUQ[V5G!$_5)!$3K=6XDX>NS,5,[A
M[)1&\BC)4VE$;[;R(.DHC?MO,;;]M9PSFH:1Z>KY:,?]X>Z7T-^U==XW=[_0
M/ 5/U'N_;= \^[]M[//*I 8_; 0_^4,Q]'MB/;VUU@<EG]C:MF_ER,$_+O/V
MLSY1WU<\QULUCC6X5)]/.ZLRM%>=V9@B#A]76TS'+SC- ?8LZBDG)GR"7F'Y
MHJ@4OF'GYAFXJ[Q4+R2T4G,B#B6<*(HVF8%DQRS,;QVB9G5,,A09;907=J,O
M*"&-IA925I:Y[0;*XG+0&?81!$3[]9'FG5S3&FF--,::8TTQIIC33&FF--,:
M:8TTQIIC33&FF--,::QJV7*IT.&5L-TL<+58-!5%!66GI%K%L"KN!$J"'I+M
M1),RZPE-X2)3"H?NF$I1 IA#<BN^RR%5TM>V8F86H"8<Q'G/*,3.T>V?*-4[
M^0H8NL5S)7*M"J!")6+;UUTB1SR@,L:0CS%/81WW*?*)U=XR4C9N/9RT/(,I
M6+D$".F,C'.D7K%XV4#JFNU=-SJ(+I'#^Q43.8H^?0?(<UF!K,EL @,)D2 Q
MD2$H\X(9B)B8]L3&^MZ'ILI78KM6]#@%BG),6*:LHW$UL"2 Q*.\$,S$QY3K
MW9CK;IC33&FF--,::8TTQIIC33&FF--,::8TTQIIC33&FF--,::8TTQIIC33
M&FF--,::8TTQIIC33&FF--,::8TTQIIC33&FF--,::CGR?VC&:=UL:]OK-+5
MUW$R[#U.A!ZXM6V92Q2"QC)A7T*-186>N,JB_0,MZ:O7F(/8QF1>2,X;MVJR
MQ*SGPE]2(CG-S6*&ORLY71*&R<L>L"FHNN,39FP<BD)4,.@UE*SM5Z\O5:F=
M@4I(&VQ+%+FO]F6*I"'$*W,<Z0KK1L3'&V 5$-(9B#W"*BI2FZ[SNR6O2AG^
MS(9U,Q](DJQ8(N3L$2]>)*A+OK!/2(-[2SKSA,8]C&EJ]6L=45(>/LL.W=$3
M46Z=2MZKQUK&\W6:+D-> FK]:RPS<JR8*)P.;9!D)')5K!T[20"!%+X-(T+K
MYOY&G?(2KCT7I2)+8,-A:UH-"NH*F5EKE4V2HV5S8%C3<#7UB!I=;<JZVZ8T
MU'KEQ^A1Y.?M>MT?T;V7&FMA:B_.HUC^QY2OYMQN--;#QIIC33&FF--,::8T
MTQIIC33&FF--,::^:B22Q>XJFFJ3KU[JA"G+U#J #W3 (=0 1#KTZ^8_/C>8
M\IVU$Q$]IB)CSVF(GO[^^K"\I]2D"B20J]=?$,4Q#%>0D8Y*8AO,Q1*LU. E
M,/F8HAT'W@.;1>\)W!S0GSW%AC._OWB8U6;1I/&1=3JN$HF"%M=+!F)\XF#"
M8F)]L3&TZQ!WI'3SXYU'.L**=13KWSDK$0@<_>+W1[QT&J1A 2^701Z>_P!O
MGF^,A?C:/&69B.\1+V%$3[]I*=4/B[@-Y*,-C DO.5TJZYG?WRM8S,?1Y:PZ
M2XJ\>I4XJN=4U<C@2@4'+1NNR<$ H^0)JM7"1B=0^U$2]!$H]WKT\LLKS>55
M'*%Y\#OO(S,%$_7$Q.N;:X&X2NE!V,%2-D1 P< 8&(Q,SM$@8S'>9WV[SJW'
MXHZE(@+>++=:ZEX9T2!6[];(8R*1NG<31,TDR&3(WZ!Z,!1#P.@=P0QZYNR7
M.<H:4ES3+JR&;S[9F"#:=^_-V[[SOI\3,("H36B_26*^D$4LE=K2 1&PB!+=
M$CTXB.GM/S-NVN<VM.RAM=)Y0V3=#SD1=3520<S;N.&"EY^(V2L264!1O&2U
MQ3E3N'+9@ BFHY$IEGQ$D3*D(KXBA_97>/$V<(C&#AJD.7"X*6K2VG$AVDU5
M97RB1>[?YLS.V\3$1\/P?P?KV*X]R'%3N-LPRC9FU*@K6KE7-2-C;D3:RH69
M-RT^6_)!,@0YOG1)3T&^Q;;_ *>_);ZZ[E^/?X^SV>6>4]>']S,+_!=7\S^3
M7U_XAIVV^-/''_2O*[_CZ^^@<5HE40+(;IY(R+;S$S9;=]X2(8P /=,)V\DF
MH D,(&#H;H/0 $!#RQZ]9'<<=AAGWQBZO^=?MU/Q"K3V9Q+QLP?:)<5Y>(GM
MM$[C8B>WGY]_;OO.OW]B;2_TR.0OU\['_P -9'KVQ^T<1_!53_,OS]\ZGX@8
M_P"[W&?M_P!]N:]O_.?T]N^GV)M+_3(Y"_7SL?\ PUCU[8_:6(\MO[E4_P"C
M\_I\]/B!CMMO7O&?_2W-?A_VU[?*=O9I]B;2_P!,CD+]?.Q_\-8]>V/VEB(^
MK%4X]FW^+TC@#'QY9WC/_I;FO\UG\'^GOI]B;2_TR.0WU\['_P -9/KZQ^TL
M/_!5/^C_ $]OLT^(&/[_ +.\9SO[^+<UO[OVSI]B;2_TR.0OU\['_P -9'KZ
MQ^T</^#%4X\_;V7^GXM/B!C_ +N\9[>[XVYK;_XGW=OJT^Q-I?Z9'(7Z^=C_
M .&L>O;&VW@</_!5/?\ 'T]_H^K3X@X_[N\9_P#2W-?1M._B=^VW;ZYU3[$R
ME?ID<AOKYV/_ (:Q&>L1_M+$?AQ5.?Y5_I^/4_$''_=SC*?KXMS4_P MG5?L
M3:7^F1R%^OG8_P#AK'KU_?\ 66(C?W8JG'\B_I]N_P"+4?$''?=SC+_I;FO^
MM?7^/3[$VE_ID<A?KYV/_AK'KU_[1P_;;OZJI[]O_P!'^#ZM/B!C]]_7O&?U
M?&W-;>[]L^[MI]B;2P_VR.0OU\[''^6:QZ]L?M'$?P74_H](X QT?[N\9^W_
M 'VYKV_59C3[$VE_ID<A?KXV-_AK'KVQMMX+$?7ZJI[_ /[O3X@8[[N\9_\
M2W-?@_VS[/9I]B;2_P!,CD+]?.Q_\-8]>V-]_!8C^"J?OW]J_;Y3]&GQ!Q_W
M>XS_ .EV:]W_ .5?A^OZ.VGV)M+_ $R.0OU\['_O36/7UC]I8CW?W*I_T?\
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MRI*H.0=BBO >EE\4\<I*&*5P9,K98&KM=% _>N<!9RICD9 0"T3N3>I5YW6
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ME,00\<$_5?BCYI][_7=&FOTBCNCU@P%=WKH8L*RN23*D2P>G&N H'!LHR$R
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MLY)Q)#&\1.V\1Y3K6J/%V<"$BC!HKB/$616Z %C"LJ;!K\037Y5BF([A74-
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MT8JDPK&UV-=L$MG*14655>1RN R8 P_$^&CAWARAPM2K07*CJB[&XVNVVV8
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MX9_A2O\ G:?*$<)_U2NK?PZ/XOCXJ<2?<3(?DY_S:3Z7?1A'GQWPS'UY2O\
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MM_#H_B^/BGQ+]Q,C^3G_ #:CY7?1A]_?#/\ "E?\[5?E!^%'ZI75OX='[_\
M]QD?%3B3[BY#\G/3Y7?1A]_?#/\ "E?\[Z)U3Y0GA/\ JE=6_AT?Q?'Q4XD^
MXN0_)ST^5WT8;[?'OAG?W>M*^_\ [VGRA/"?]4KJW\.C^+Y/Q4XDGRPF1G_F
MY_S:?*[Z,)WVX[X9G;S_ &4K]OK^=JORA'"?]4KJW\.C^+X^*G$D^6$R,_\
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MRD3((Y]OMOLG%OP><,NIFJ7!7K6SQ!2XDX>P^/3E\SC!J6J^4P+\O:DY.A0
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MFE4XAX@H8QC.%\3>R(ILOMUINLQM+)LQH7IK#*W.0+A%;'K0*^IWV$=M18Z
M'7J'G[ ]Q0^CR]X!U'Z?=UZ@(^F\NVWMF8[[1'MCO_ICS]^OED3(]MO+>=HG
MZBGW[_QS.\Z>X?8']E[!]OL]GS!Y=1Z^[W]!R(GS\YG??Z/I[>_Z8VGZMIWQ
M[]]H[=IGMY;]Y^J)_CC;3K[!Z]>@^WS\P#]X/?[_ #Z^\>O3)GO,[^[MMM._
M?;MY>W\.T?AT]OGO]/>?H]L=Y]O?\>J]>GET]P>?LZ] #V]0]GS^SH'7Y^F3
MMOY>43[9\^\Q&WT=H\MO=WG;66T3&\S.^_GO/?W3[)VWCR\]O/MWB@^?O\A]
M_P#+]'7KYB #T'H'3W=8^OS\]O='NCSC;?:([S&T[[=M1,_AF.T[;=MI[;=H
MV_![/Q:>8>7M\^G3V>7E^]UZAU\O;[_GF?;'T>6\]HCVS,;QWCSB//M[=)WC
MVS'T;=MO?MOMWW[Q[_.??4!#KYA[_9_W/EU$?F]OM]@AY]?FR(G>=YVVGZ.T
M=HWV\^\;1MV[_1J>T;1$Q,><]HB(]GEM/T=IB8G??MMOJGS^?3KUZ!TZ>_V#
M[A /W?(1#RQ'GM'?O,3WVB8[^S?Z9V]GX9UCO._:=M_=VC^;M[-_Y]//W=.@
M=?GZ>?D'4>OM'K\_EY=>F)WC?:(VCM,^_P"B=MM_=,?C]^IVF-_;&_GOYQ[N
MTS,;[_R>S3W]!Z%]_E]/D/N$!Z_2/D'T=0Q]MVWCO[HG??OY_CGOO/E^&4?@
M\]XG:>TQMVW\X\^\^R)CVS.@B _]UU^GY_>'N]OOZ>SW=/9D>^>T^6_U]_*8
MV]V\^_RWGSU'G._M[S[O;Y1[>_;R]OU:!T#V]>@] ']X!Z>7S^0^P!Z /F(^
MV8B)CM,]HGW1V[[S]/N\_KG;:-.WOG???]._G[=]5Z '3YNGF'3S]OM_='IT
MZ@'[@@&.T3'M]O;Z)\]OP?1$1O$;^>I]L3/MB8W[^43],^<_5^"=]M4 0]_L
M#YNG7KY>?7R$/<'3]_S <=MI[1Y>[;R^KOOWC?ZI[S$:B>\1.T=NV\[;^SM'
MMCZ=O/?OJ@>P?/SZ?O>\.H_3]_RZ=1]GD^K:=^\1M'MB?/?SV^G?V;3WU,]]
MMO/OO$^_VSW\OI\MMOHU7W= Z#Y>?0H^77W_ #^8?,'N#R\\;;=MXC;S[1MY
M>\IVB2^CV><>R,IF//>8[;;]^^WEYQO&^^_GY>?>=! !$.GGY"(]/;[^G7W=
M0\OI^CV!CRF([1^/?O[=]H[Q[.W:?JG6,3$;^4S[>\^4QY=O;]<=MO;VVSO5
M@?USM<!Y_P!O51Z^0#T_RPQ_F'M]_P X>0?Q4LCO&/O3[/!6H[Q[T'M&WLGM
MOY_3YSW[?#$_ZI>'MMO[N8G;VQVR"/?WCOY]XF//7^@U$?Z4QG_Z>R__ (R6
M?DL_MR_\HOY9U_8]/]B5_P";#_W8U<,QULTQIIC33&FF--,::8TTQIIC33&F
MF--,::8TTQIIC35CLZ"[JN3S5LR;R3AS#R2",>\("C5\JLS63(T<IB( =!P8
MP)*D$0 Y#&*(@ ]<J7P)E.RL%@XC48PLQ@@.)C:8D2^:7;>8&>Q3$1[=;ZQ]
M.PD^>5\C0*#$I"1D2B8F"B)D=IC[;:=O/7*'@EI.CZPVY+K4S6B\3-?!F02V
M)87.AZUJ.,K$TZ7;*HU*ISD.@U=VF/!4%4S$.>4:>CMDI$S_ -*6.3.M5)8X
M^V%<S\#^M%57..56[I),N>'TXV$ 4'*V#Y1Z;2E($P!YM4[L$S(J>^(*X3;S
M6B.S@0#YYNK%DI*2*P?S9D3DF1L1K"-HCKUE36W3&FH]<N//BER<_:];H_HW
MLN-//6P]1_G4:Q_8]I?L]G]K<;[,:F?.?KGR\OP:_A+Y-V:#NG)'D)<JM)HS
M%9MF\-L6:N2S8JQ6TK!3M]GI6(DD"KII+$1?1[MNZ2*NDDJ4BA043(?O%+^L
M,(AM?#8FJ\"4^MC*"7+*8F5M554#0+:9&9 Q(>Q;><QOWF?X]\=WJN5XXXSR
M6/<%JAD.*^(;U*ROF@+%2YE[MBL\(,1* :E@F,$(E$%$3$3VC1_F'M]GL]GE
MY>SR^?[_ $]O4?(1Z]*-X]GOCO$[;S.W;:/JW]_>/=KR?>-YV]\>4;;^Z/9O
M^GEIYATZB'D'S^8=!#IU]_M]WGT#KT .GE/:8C[7MM$]]ICWS/;V]HW[Q'XY
MU,[;1[NWLVF.\;S/?>?HCZ9]VGL$/:/7V?O!TZ?>'W>SR ,G>!GO&^T1MV]^
M\[QWV\_J\^WEI$3O'?>(WF/+:.^V_P""8WVWVU7S'RZCT#H'7IU]_E]X?;U\
M_H]W3(\Y*?=$]XCM^/?\?GVWV]FD[3,^R(B(WVGO[(WV]_O_ (M  WS=/=[_
M "\A#K]/3K[NH^X.GEU;3M]/:8VCM^./;_-,^W?2=XCW;_ACV3O&WX/?[>\:
MH #T$?I#V??]OET 0Z^X!_>Z8[Q,^_OM/GOM/^CO/T3YSJ/+V^???_-V^F/;
M[8W[1H( (^P ^GK_ "AY]/O>7S>?3([QOVG:9C[;M]/>=]OTGRT\IGZ-_?'T
M?@_3?01'W>0!](?-[O(.GWOG$>@>WI,S,[^[MOWCV?3WGSCMY^?MW[SWF-O*
M(C>/IV\^_P".?QZ>8=1Z?.'O'Y^H?,(=>H_/](XWG;V;>S??V;;1O[^V_;MY
M[_1$[S'GV[Q$_5Y1.V\;Q/EO[=5_?Z /M .@^X1 ?W1\O=U]GE[)VYHF>\>6
M_P!.WN]OGVVWB/+SF-3$3,>Z)GOY[1MMO,Q]/;_N\@#U$/;[>H]>O7H'G[O;
M]'EU]WLZ9CM[-O.>WOW\MN_>/.(F)F?+>-]1[_;W]D^V?=]>WN]D>6J=?8'0
M0\AZA\_F/L\A'R#KYC]/T]<MYF/;._>/HG?O'T_1[OHVWB9WWVB)VVYHC?V;
M;;S[=Y]GX8]NOT(??  Z^P?9T]OE[PZB/S= 'S\A\DQY1,^>_?>(CM[_ 'S[
M^_G].IVVVYM]N\1M]'M^GO/;?;\6J>S^00]@#Y>\.G\O3J(CTZ=!',?*=]HV
MV[^6V\1]'LWVG:)[_7VB-Y[3,;]N_?SV[=_/V[?7JG7Z.O\ )Y?1T'KY=?,?
M/][SG>(G?;:?/_1MOWC;RF.WE$^W3>.W;VS/NCS\O=/;V>^=X]V@!Y=0\_I\
MP$!_<]OM\NGT]0'IY1]41W]^WG$1[XB(\_IWGWQI,;1[/.?K_#MY;>[?S]^G
MG](^?T]>H>8]/W>OM#RZ@/O')B>W>?/>-_9[9^N9B=O/WSM'MT\_;]&\R7?_
M +HG;O[_ *>TA]?;^>:SHK>L5&#DJ_8SW2/M,W?:W>K/6INP1D<4Z3:I2"$0
ML@V"%(DLX.4G?.(.W!WAB'5*F4G,LXWQ>1IW7.%E6I7LJC&V*R7U6,L$!S;F
M&B>SU])(KF(GE4#%C,0]DS[?"<9S@>'[F(H4#KY"WDZ609Q!3RM_'Y&4TN<1
MQLQ5, *BT'V9<J9V-Y(>6YUDQ$J[)VD<M9;1<; [TA1V[:_%J#RU13:?L*?K
M2S45VBX@+.>0#NNB2!4DBMGZ0 +=\F(** 10@"/FZ/!*J*:BU9.SO0R%J_CY
MZ*9&K-Y+$W*X*C<2KM@^<0+NID3(S\Z8GZ?D?A!9')VLC9L<+8D5YC$4L3EE
MA<NPR_.-LKLT+K+,1#1MIZ?18<1RN46Q1$@,ZS0G:MVHEA1L@:0I8OD=H.=L
M@3X46?P!L3JJ2%160$GD/J\8Y^HJ5(![Q5RE-WA#J TP]'M4*A48REJ4EA\C
MA8^PU^;PF2R-;)/G?RZ@NK"('/: DHVF=M=%WPE<J^]&0+A+$"^,YC.(.U_(
M2$W\3AK6$KSR]IA,U+;"-<>;.4M^VTZ1G.?%XG:/0:*ZJJ;9AK:7L#BNGCKO
M<XMLZK<]8#V *Q8XN+D&+&>+#JB#:&F'1"OV290.'>4,8<Z2^#JJKC+\6S)]
MC%XVA:(ZM4^9^,IS5JY"K+ /P5HOFML=&)%LA$3$#R\OF[_ITS&0Q]?'6,0D
M4T<[G<Q0Z&6RE: J\19";][#W@JM0&3I!!L33*U$LK1(&/,0E!YQ"=I9<ZV2
M[+PNK:DTFKG#5&(=6#UQ,*RZ:E/>&?-)>3<=P@3TP]<& KY_) *ZS=--$QS]
MP#YK+@JN<50F^^%5<JW*@B$I%'.ZN-:4*3O (3"X81"G:"<TF;#/;5Y'P@,I
M7+)&'#>,E^2PU;#.MS<M^-)=:V5T+%BUMU+EB&0A0'8YS"L@$<Y1,EKWQ/:=
MW6'G"R+35-2+$JH[%<R%>&>G_ ?679R;5"RV SP1%R@;T=N9*/C4P]%:^*<P
M&4,!0"D[T>T'T;-([]J(/'T<579"T\]7'T6M:"1B8B&FQI@37,^=,*$8B-YF
M>I4^$MGZ643D5<.XKEC*Y+.WZLVKG3R.8R*U)*T9_;H6A0O%-97S.:P9$12(
M1&I+OS.1O^S:%LZ?T[ C*:[U.PU;7V;.VV1HFW&%;/6U=MJ+Q,/2V]@@BR#I
MRR.B8$@D"M7@@"K4A3==/#3*R>)5(RCU%Q-E"RMIHH3)):Y2D7$*[[2BVFO7
M2P#WD5PT1G[/,CXR]Z65Y+*\$96YPGCW,X%X>3P]C$SD;T*=7I,=8QEE\Q'-
MXO'OMVW@83 L<Q,LB8K#!>Q/G38GNJJ5K>X4<E[DZ%;W=RK>Q+/?;D]N3!^[
M_,U6K>1%UZ2@Q]&*FD1$CH2IJ%](*'>$28=PJD\IZTJVIQQ'C?5;D4Z=5==Z
M)GG,G! P),)FYP1#/+$0/SACMNJ>F.X'#2.',EA%YM=7.%GZ.2RN;RUG(T[<
M?,4%>R3):"5H@4$ F/4CF.=B(M?9YSOL#IY>'Y-8U%)2ZUXL&\04D)1RR5<$
MB$XE"PSL<KTC[+86IR>M6DP]:(R"4L8'7I)Q*!!TKX14H*XJR%@)JWPR""!2
MA\.:[P7NG2B/G4P* BL8I.%E7DP)<P>VK3?3A=;8O.9PQB71?Q98NVM]BTX+
MX%CVTH?EP/9>58+&>+ [*^L+UIF'?8XF?7>>T#O^P+W6-ASM9%.<@X^*;/T(
MZ]W5G#OY&(BAADYV(AR2(QM7DW<>HZ2DC1S99!^*P>D(G2!1-;*EP=1H!?37
M?,UKC++04ZM5<Q06K*;3JQO8HFV*DMK+@:S9@!"6<NQ$)+QRWIRS6;OX7*7L
M6KQV)JHK-.KE\M4KW#JT+U*O>"DFP->E?6-]C?%) B,T5@." &"[Q)<ZI--2
MV";4=*%I:K:PMIXE"0EF\)%2$?),Y,KF(BP[S2/EECL44%IF/39NE4U' JD4
M,L'<R1PH->,5(Y*T9XD' II"N6FMD6>9/4WZ@58\44>&DS7(+2,"/)O.#/33
M9;\8(+A;#PO/W%W')!]H*J7*C'\KPK?V";T%CX8-\ 39ZMFRPI*61$2%3[6N
MU)S3:>^(FDF=M-C.MGMP&V6H$D[(\@75=6 Q0Z]]B+!XJ)&YNG182J ;RSC!
MZ.ZH(Z$9:U*_5=W$]T(YO"7[B;KX\O[+U:ZX$]_FCO'?>)CV+_A-Y:P\;#.$
M</SAEL?FQB,AD(CQN-QMG%HGM.\KFM9;SKGS9(E$Q$;:TS8.T4O=E^+$92FM
MOZU=B3D8AHQNMOCX28KS6V(VR+K=A@&KM.)E%8M9N@Q93[AL>2*S!7O%,=0#
M)=*GP;4IV'V5VC8=G'5ZMCK5J["FW7HMI#D$&8D=9K2=+WJ5(K:8 'S1&=_/
M9CT_Y_-Q0\3B*ZSQN<R>5J^&R>3KJ.CE<FB_8Q%VNEJTWTH4B*=*Q8$FUEFY
MO(9L*-9Q*=J);W\U7IUOJ"FLG4!>[K>2D"P6)=-VYOT6$188Y4%3!X391L F
M:+$'QFJ@@8H' .F4$^CVHJN=2<C;-3,(S!S$J2)^&.^[(K;!#']D59=/LF#
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M?KC6?:I(HOM/6J*":BJRM_IR:*213'4544L4:1-)),H=XYU#&*4I2E,8PB
M ^0#1R4Q&.O;S$1X*U)%,S_B#F9GR[1Y^[V[^>N[PM$EQ-PZ(Q,D6=P\1M$R
M4S.0K[0,;1WGV1YSY1OVU_H,113%BXTIRF*<L>S*8I@$#%,#=,#%, ]! P"
M@("'4!\A\\_)9_;%_P"5/\LZ_L:KLI<3Y],/_=C7OS'6S3&FF--,::8TTQII
MC33&FF--,::8TTQIIC33&FF--:VVC5&-EKP/':MI\>JJKV6-9U6R3%;=24@Q
M8.R(,':L0<%'S1?QC +)RW>-S+ DL+191),@T[L])3+(@UIIK7%BI;""#&Y5
M;4;,P(G\\%/,TMY".NT0>K9BQ*-Z/GE""D16Y]0S*0@BCPMM%M<#,R,\IL0
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M=!V96NM66,5I X-=V\"5,R$^EN8_!U FN5C7"L'8[3C(B8JDNVU;='<"TC;
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MQXH3P=6S!N(%*N\0QRXE;7,D$THR3.4*RK3H(#8A360QZ89KMXO'57/$\;6
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M8N<Y9  0A/4Y"*&$(R0 4QK.?@M>BP5\YJSBPY8F#/,3$G$'"]P&*TFS[),
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M,7HIL*6Y09XU. &+,<Q/*2S&" AWK;[2)1,>7GWC7J^17X3?_A^T/O?#\_\
M@GZ _>S#Y2N)MMN>C[/]J1[/+_PGZ=_?.L_U+OHLWF>EG^__ "Q__P W:=/D
M5^$W_P"'[0_A^I_@G$^DKB:?,Z/Y)_\ W._X??/OU/ZEWT6?XG/^>\_LQ/>>
M_OK?3/;RU7Y%CA-Y?Y'[0\OFOQP_DB,CY2>)?^%1_)/_ .YJ/U+GHL_Q.?\
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MQ+R3#:_QGW;5\[J=R\C!8O['5&%+C'LO<R/BG.V>4U_;JO&OFA4TI&4>I =
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M3TN66T@0CS=0;52:_.<6$L=)+(40!3RB_P#P"<L.5KE=I@UJ<EFT\PG,CR%
M#@U5'1-MV2X;EVCOS;N_%D+!$1]KN-PC9W4(TD"QB[AO28+5A&^B*\IZS!P=
MNC$1[6] R\)*R+KCT*'4K^&"K;B@@E0]-8KQW>JV^U:[3?"3XBSN);&1=8,5
M(8V)D9A<,B2U1NP96Z$66BR4I/H!3$$TE6S5M>B5*$7[=.$B@LM)VYB#E9<D
MS,]-=F/++':]N<C3Y-&'L\=7)60A9)>B3>SR-'S)HJZ34+KNM3]6L%T7,"0D
M;5N%L$5)RK@Z31FZ*NH0IN7>8U-8VIF>=9+.1&LRV;%PP>JI:5,6<L8OF &0
M1"DBAQK8 $LKU)2W6DI9 \KBZ(R=I5)8,;$@ICK3P8E*5-(&.)D",J$QEBM^
MJ'):@]H5N6X(ZNDDT=?.&%?JNH9'>L>MKJ^UFP6^=VWN2[:7/#4:'FK4>1U5
M/Z]EJ'*25PJEF9;&<I2[@E-++MP:C:''917!MZH1B,8[*3PYCZ*ZUM=QJ<AG
M>%JO$190KPI2B[@5G=KHJ-"K4;:J1<N,*LVG-)VFRAE7&6WF<S;JV>/['SJS
M5<V+X+R%%=6NRDR8:F_E\?D%--LV6#1>"XBK;5: URR[0'>M=U?QZWA4Y>D[
MKLKVX<?=Q$8RNMM'[2V96(@5Z1/QI36RTT>KS<#4B$56*Y6/87\>5&/(K(J"
M5FBHL6CK"(WGW?R_@CSG\&I6ZC_.HUC^QY2_;[?[6XWVXU$^<_Y_/\.OY_\
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M\,4_ZJU,^@?CV8_V?N.X^H\S_GXMGZ//?V^_M'?D/PLW;HAOI&^7WF_NC?L
M7DSHJ'-0+TK;3P1WDC=&PMI@2S.T+:R]+C0;J WZQ J_U0?PW* =[O\ 7Q'$
MF,RDY2K4X8QF);.$RC/%U8K]6 "M,$O[%1KERGO$E\__  >\%VV\7QGZ+N*>
M$0X4R^8]*O%'&%...N$ZLX?+%D9IRU^4#IVIBUGLBKJ(Y)Z?ZVDOGSRL#V_T
M09\AU^T-,::8TTQIIC33&FF--,::8TTQIIC33&FF--,::8TTQIJ&?.%NXD]5
M04 KKFW[:KL_?:VPN&NJ5)H0\M:ZZFNH]<Q*\@YD(M$D0X7:MRR[8SY'T^/]
M(8AWQ< 0U1@P>2Q MJ^+K]:^;5'$&B&KQ%\Z37JDHAPJNC78M<P8RX5\X$N#
M&;2Y,,?E&I?X:RM5"%.&>5L*=EJ%>Z"2B)E9LHML!U1Y34)$8&!#!1H'B148
M:C[H,UUKPRN_$BDS5/EOA*P<_!]G1;',LG+12+<MX*N2CY@RL229EB+20MFR
MKUF (JJ+&3+W>G78TE9)3K/-7!--U2LS<I7:.RQ;SKE,3TUS7@88D)%>_*SD
M@MYGG6(B7X\P1,NY[:[5H=HDJT(62%6)YHENSY(E&4&P9DAYH&9B>CMZH];V
M15I6F6YJ^>UZ:302D6T;.S]:>JD;N47:0(S58DX><9""Z"1C&8R+8RI ,BJ)
MT5%$STV)6WDZD3/38+0V,PV,8F(F>0AYHV*=P+F"?:,[1M<2YB"(U2,$2V*F
M2!;(Y&@2V1$,$XB9 IB#B(,)GF A*(F-8AQ>T$64UW-!K.#]9ZJ1\"CNO'E1
M-&%!X,F11^F,B*-E<HRYU)M!Y:$YEVWG5G$X@NG+.%WBED',7;=>7(JM6*J:
M+&* %C%2LAM6LA2@$4H"M5>ZI7Z"URBJUM94@@R7.B!@:@48DYK YSX C,CE
MMEBVVB-Q%+V1;:E++@,806S4H[(M)82/EY<_H4>3O[7K=/\ 1O9<U:RUL/4?
MYU&L?V/*7[NG^QN-]WN^][L:F?.?K]VW\7L^K4->RF_0!<?/_(=@_P!+5]SU
M_'O]]F7_ /*IS^/'U)]NOB_P>_\ 8>X-^A69CV>SB++Q[-HU[*;+:Z1YP6V/
MK_(2P6"W/*<Z3M>FGD^_F(>/>HJ)+-'45%@@6'@$HEF"AG)45CO7"[@@+]2]
M #167=+@^V98=1X\,B@J^9Z(B];))@V!98F>JT'G((2$#T1%92/SH*9ZC+6
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M3/9=_$M6,,\ !CK<XZ,#/G2$/)A(-&CAN)H]105")[4U^O;NU1/;PM:E861
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M28@.=66);#99!+-52@FH*P"%,8J(5:8THGGZC!'K3,CL1L+YTSVU1.&BX)7
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MBUBHM)!!Q&2OJI1TFJ9)L]!LL3T&5PN9;PKPPA-#)KLU<AEGN6K'M8\ )R9
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MDK]0G+(2FM;>B)A9R.MC[5MO K<PZ^^'6^]&.QUA8VUII_JS?-+AA8OV[0S
M6SCU;:D/3XAVR,+1]$NO$8O6_1)=$Y Z9A/#N:.W-UF#RCGG3R-!O5QEMBW5
M<JJ$WE.629!HN"(GY\3RE',.Q=]8CZ0N 5TYH!QQP>JOU:-A<+XEPH&EV-9+
M*34,&[!I-)3,"2Y&>69&?FS,:P[3C/L\]%V-Q9Z)R%U29Z5K*QM<96;DM7;7
M"Z_A)QZC(S%=UQ#SMQ>,:/7I)XV:+O(>OI,V2QF;0#)"5LB4EA>(XC7696]4
MYED/BHM[VXZXVU95CP:%%+[)IEK54X>[PZR*17+F2/<YU@[C_P!'KK V)XVX
M,7TR>P$(XDPB:H.M<OB;(UEW13%FQTPAKX#J' [26V^\@9WD7PZL[3T&Q;\X
MWS+0!,)49';.M7)4C'*)#'1,I81.@H)1$OB(F(?H(AWNF:)X>S<E$S@\MS#,
M<L^K;D%'>"C:83O&\B,S$3M.T;[QK:/I%X"&"@>.N$($H^='QFPO*4=X^='C
M=IB-YVWB=I\MIU:[=O7AO=ZLXID_R*T.K7701Q%V+3=U#8^(C%NVSQJV,LVL
MZ:HM@5:(%60$XIKHE,BJ!DSF*.4X+/$]-D\+EC:FR-H9+&VR$G#)2),"4<IQ
M!%)P)1(\\"41N,3&*O2'P"A9*3QSP@H2KG6CDXGPPD"3#I& %%[F'F5,KF8G
M>0(AF=BG6O[M<.$>P[; 6FT\I]=OV->;,&[?7Z?)ZOM=52*L4_1E(N0GM<-[
MB2K3DG'/F[9=F^D8]==$S=$"F[J92A-?!Y^O:9<##9=E@SABS?C;C_"N$.2+
M%,6)**MB(DIAR8$X,R.)@YWU#/2%Z/V50I_'?@U2 !JC%/$N%5-BNT)4VK:,
M+L%8JFN962&R2Y">61F.VLPGMP<);/-.YZP[[X^3#YW3W]%$C_<^OW#-K6I=
M4ZTRS8,E+*+9DI,]6Z4LZ;ID</V["/;KJ&19HD+H=PUF'U[U5N#RQ*R(+5<B
M<=<YFJ5#.FF3Z/,*@)K&0L9@>J4MF).!F-Z_25P*DZ;%\=\'K.B\[58AXEP@
M\CV"L.MVN_.(%KY%%._3!KQ#87,@M4Z9+V?.@=<6K6&KN16J:_ 7$[H\S*'Y
M+5Q];@\>*2@F18^VO+BK.1J<##MVL96R-':18)FT;(1P($1( ;[V$XAR%,:-
MK$YHE##Y,QHWEV'MM-AMNS8>"H:ZU;.(FS884M=$;,*8B(UH3Z0O1\BZR^OC
M;@SK,E<0)<1X,T*4F6DFNA$W96FLDWM-*%B*UFPR$8DIG6O;'K7LY[3JO4NH
M93E5"%K>D;DA?]?3##F2G'WB-M34[XS64>W=I?$[%*G;!)/DT$WSY9)-)RJD
M!>X80S9ZGX@];8S,QA<H-W%564JT#B[0USK.2FNY5JK"(3:AZ$BEW6 ^HLF"
M6_4+>0](7 (4\E1+CKA%E?*V1M7.OQ/AFL)J[,W%PMK+LFH%6>1RP"8@"4J1
MVA8ZQNY<?^RKO=X<W^P[OUH>7<7Y3:R4<PY61\768_:3JNNJO(['BJTPO2$/
M&W:8C'9S3-A:M4Y"4D$F\B\55=HE5RDKA?,)2:$X7,K'H9BK6,:-Z&X^IG;#
M+>5J8UG2YJ-6W::VTQ%>07#VL9 P1EOO9Z2^!6DPG<<\'-Z]?$U[0LXDPA#>
M'">##%-NC-W:U8IUZ-:DE[>9@T0FK!=(I'6(07$_LHX1LS8FY'0D]'1M!5UK
M$QMIYJK6..B*N>=&SHIQ324V"NDPDV%B[LS&R[8"2#"032<METU$RB%V<1Q'
MRF(XG,+,CQ35N7CKB[%9N$K33Q;:KA3#*YU*9%462Y&?#&2IW IC6H?2)P ,
M<OQVX,)1,R36I/B/!FBP68<5C)Q83-V0<-RR16'BR)@G3+)CFUNY*K]G]\)-
M+V^1Y;0]ALFAY"9DZ/+V7F4G.NW3J?8!$RGPP/(WQ?X8I.(HI(SP)\'B2;%-
M-L0H)D N8#@LX%NQ<C Y+JVL18P=A98FT5=N/MN&S: ZY(E1-L6038:\AEAN
M0@Y+=0;:#X]]'K*@4BXZX1E*\K6S*ICBG#PU5ZFIE>L2G1>Z@*17?9KK2)0L
M4VK2^79[-[0TUCV:#.GW_7(<@M<N=;[ !R*FNGO*J+=4:D*.I@+"HXU=65;N
M,9KAP2=(G+MUZJA'*-GZ*+A 4SI)B71\7,[%.C3]4YS?&-ILQ]V:5^<G2C'&
MHJ*J^0E7BEII^'2*%0SE6"0"/FCMJV7I+X#.Y:N%QQP7)7YOG?1\8L%-.^S*
M)<C(.N5?&=&PVXNS:\0Q@S+"MV2+<G%,YUH=MV=W'/XQ%M<;[TZ:6VS)-YC8
MUBMW(ZM72R6^1;1+>#2=S,U8[B_>NE?5S9)$YC*?FAN^<W4QS".UV!S;L=.)
MG Y%6/D[C)JIQ-E2Y;>DIMM* KQ),<1D1E,S,D4SYSK2/I#X"BTB[\>^$CM5
MZU>HEY\4X<V#7JM-M=?--Z9F%2<"$SWA8+")Y0C6AZ9KGAF5MK:M;'Y4:>EZ
MOQNV/.W/CJO5.3D/556<98FKQJK#W^"B[>WB;.:,8RLM7R'>BY9R$,^<(J,F
M_I*Y#[0P_$+#"[<PN3LY(\'9X9R$NQ=MU+(XIX+6PW5&HE0/L@FM-D8$XAU.
MLU9CTEB&=KTB>C]A6T5>.>$*V/N9&KG86CB7!UG4\HALMZ59J+@%X)+>=M:)
M*#$;+E,YYDF'LNI4CL[:-3[#K^K\HZQ%4F9.B$/5T>8#<87735"5+,I1NJV)
MKV*&O(HL@F@KZMK1633PVK5#PO ;IIETMP'$#JU>N_%9QQ5Y/EMNI7F7F 6/
M;C(2^X:9<]"Z;V I32(5D?5'9D06LX])/ 47W9 >-N"A;8*&.0'$."&F;_$#
M999FH-R$19<\9-[H"#;)L@IF#*-?6&I'9NP1M9%C^0VM2LM3O&<G6HA?E)"N
M89[,,'<G(MYJT1:UT,TLLP$G+R$HI(2J:[E20<&='.*A2B6Q&)XB&\&0C"9,
M7JJ!2KC&*M0BK774514-5'0Z:"542M"R6,2*]QCL4[UV^D'@!]5M1O'?")K=
M8;9L'/%&%Z[S<Z'M![O&]1BC:(D2RF1W =MMM7CD#"]G9R7?.)+9G(?5Q9%W
MKRQZK?/J?R<@:4Z?T6V.4'4W!/EJY<V)W2#HR)TR'6$RB#=X_12,5-XN!N=/
M"N7D[9^I,S$WO5<V8BA>@6%A;;[N./:$[0=>Q8<4''<A.0F9&(B+J/2AP/7.
MBQ7'7!G4QK[UBF1<18(R2S(U45;>TE<F9%@5JC8&>PV*M9XQ#% 4:30XU]E\
MF6R^F<I6DTO:EM1.Y![/<WG4P^:OM&*H'UG(Q+I]L)56*D*^F@9H5VT%-5VS
M<O6KDRB3I8IK\X?B"7%8]2Y2'%G<EQ&1QC+>Y97,8AN RK2^P]U9'#&K'7*\
M_8G5J=!9#M31R<X>//1X'8.-^#P#U&GAV%#Q/AA6.)JY2<S1KB$7HB)Q^4*Q
M<H-^WJON7240^*=S6N1XI]E?(-D62?*!O$L&]4MM(1CX+G&^AF2=8O-G6N%H
MBBMF.Q$DO E+"N+];J43 9)N0! B"8%K_%[.2HTSALN2SK8&H0EC[A1T.&1
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M$8//565&(P>35-*KPI4JP&+M0"U<#W[60X6*!Z'++<.=M]:JV8DQH2-*9FN
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MH=3\H? 'W\\'_P#2;"_]=T^ROXM?JE- _7'KO_I'CU!G?N+EOX.N?T.GRA<
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M&I+.%#*N%4V,<@V:D475,958Y4@,JH8QSB8PB.;)(B@((B* & ")F9@ C>8
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M.<,B ")F!B3+U;RC$E,#$E,1,S$1WG5S^Q3[5+]<!K/U?1G[_P#:E^[D^O\
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M]R?&CM/X1BM)S7:*4F(CFP%,YD).E0C!BW Q@(45G;NK(H) 8Y@*45%"@)A
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MVSK*?1[\((1ZA>F*A 00!)3AD0/.<\H!)3C=H(R[".^Y3V&-]7'[%/M4NO\
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M;-K+,E63E:*F&)TWD;(HI+G,T?M#D7:KE(LB8IR%$.1=IHOU7TK$$5>R$J<
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MW(_A*GDO$JW>C,W0R\C853YHY#]7!479@J4S*HM"32<IB)+^@N\[3EJ=8Z3
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MO9C66L'Y%.:?"7;6M^:0^L)8(5"D=IMR(YYK4-NTDF352,6J.T*;7ZAK$'*
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MD0-384U3 *88HHVUM7\*W@58M4?"W'+J]A,HLUF8K%0EZ#V*5,Z7$2V#W$2
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MJ'=?Y;\:CM[/Y=_\T:IZI[03],#AQ]4&[/RX8TU7U3V@?OO_  Y^J#=8?^W
M<:GM[8G\>W^:=/5/:!_=_P .?JAW7^6_&H[>S^7?_-&GJGM _N_X<]?V(-U_
MR?'A_?QIIZI[0/I_;_PXZ_L0;KZ?O?'A_?QIJGJGM!/TP.''U0;L_+AC33U3
MV@GZ8'#CZH-V?EPQIJOJGM _N_X<_3_6@W7^7#R_CQIIZI[0/[O^'/U0;K_+
MAC33U3V@?W?\.?JAW7^6_&FGJGM _N_X<_5#NO\ +?C3M^D_C]G_ '?3IZI[
M0/[O^'/U0;K_ '?]O#_'Z<:=OTG_ $:IZI[03[O^''U0;L_+A]__ !]K35?5
M/:!_=_PY^J'=?Y;\::>J>T#^[_AS]4.Z_P M^-3V]D3^/?\ S1K46_MA<^]#
MZ.V]NMY9>']D:ZFUO<MB.:^VU=NB,<3:%/@'\\K%H2"NYWB;)5\1B+9-THU<
MD0.H"AD50*)!:1&\Q'OG;6W?5/:!_=_PY^J'=?Y;\:CM^D_Z/K_3S>J>T#^[
M_AS]4.Z_RWXT[?I/^C5/5/:"?I@<./J@W9^7#&FJ^J>T#^[_ (<_5#NO\M^-
M.WZ3_HT]4]H']W_#GZH=U_EOQIV_2?;^+^+^/5/5/:"?I@<./J@W9^7#&FGJ
MGM!/TP.''U0;L_+AC35?5/:!_=_PY^J#=?L^O#^/^+&G;])]GXOX_P"+5/5/
M:"?I@<./J@W9^7#&FJ^J>T#^[_AS]4.Z_P M^-.WM_E_T3IZI[0/[O\ AS]4
M.Z_RWXU/;W3^/_1JGJGM!/N_X<?5!NS\N&-1IZI[03],#AQ]4&[/RX8TU7U3
MV@?W?\.?JAW7^6_&G;])_P!&GJGM _N_X<_5!NO\N&--4]4]H)[[_P ./J@W
M9^7 <::>J>T$_3 X<?5!NS\N&--:CUYL+GWL"];ZI"-EX?QBNB]D5S7;N05U
M=NATG8U[#IG5NX22K=N3<Z!HY%JUV<W@CM%579U5XA9\"Z:;PC9!J9CR^F-_
MXYC_ #:V[ZI[0/WW_AS]4&Z_RX#C4:>J>T#^[_AS]4.Z_P M^-.WZ3_HU3U3
MV@GW?\./J@W9^7#[W^/L::KZI[0/[O\ AQ]4&Z_RX8TU3U3V@GZ8'#CZH-V?
MEPQIJOJGM _N_P"''U0;K_+A][_$?)IJGJGM!/N_X<?5!NSV?7A_'_%C35?5
M/:!_=_PY^J'=?Y;\:GM[I_'_ */K_2.]/5/:"?I@<./J@W9^7#&HT]4]H)^F
M!PX^J#=GY<,::KZI[0/[O^'/U0[K_+?C4]O=/X_]&GJGM _N_P"'/U0;K_+A
MC4:>J>T#^[_AQ]4&Z_RX8TT]4]H']W_#CZH-U_EPQJ>WT_C_ -&J>J>T$^[_
M (<?5!NS\N'WO\1\FHT]4]H)]W_#CZH-V?EPQIK5&[=G<Y= Z[?;5L\[Q/M=
M=K]DU]&S4! ZWV_!S3^.N6PZM2'0Q<M(;=F&+)\T2L9GS=1W&/4#*-BI*(F*
M<1!J>WTQY^W?ZNVWX//Z=='L:C3&FF--,::8TU$[F'?+C2-;UUG2[(XHKZ_[
M&J>O9+8K:)K$VM0(2QJNBR%D2C;K%S=1773*V(P0"QPLK%%4? 9PQ7$"%&N6
M[+E.MXJ*:V#>L&TA64/*A3;;70B6[P,W#7RE(1UNBMT))3)%R[B!6-/*W#6#
MSHT1<BNR60+6MN5:L<W1:ADPL;!&/*SLV%R0-7!J*_<1=D6G;/'O75XNBS9[
M8I2+60?3#-BRC6=@]7/%V"%A:Q\<HI'LT)I%N1^1NR[C1+QA*W112 B1.I<$
M8*LV*9XXK=&G<;C6FQC,<ZU7!S:1FV(:15S*0W9N>VW-,SWFF:IK7,G1AS+*
M\=E<ACT6VPF&W$4[)I3:.*X*1S. 8.>DM:^^X@,=HDGE/33&FF--,::8TTQI
MIC33&FF--,::8TTQIIC33&FF--,::@W1+WL%CS:V1K*<M>QINAS.L&EUJD=9
MJQH]2H1[^.FFD3(-:;;-:H1NR&K./(Z$CN(W(UE)%X]?'<5^5(Q;G;CEC-G8
MW,0\2*U1RE2*]A\\CF4;*;$G >%CU<U$/@%I NGDUPEAV )1"P]N1"5LQ+TJ
MD*]FO8KV)0?-6B\G9RQ>JT)7PMLKP;3>EWJJ0Z:5*FP1D$Y,QUJTQIIC33&F
MF--,::8TTQIIC33&FF--,::8TTQIIC33&FH;\ZMM[3U%HH[O2D;1'NS[[=J?
MJRI/]H2ZL%KNN2-XD#QPV"V2B,#:#(M&2!%D8Q%2NS+9]8'40P=Q[EJY62-3
ML%8.UC::)((N/OLM."5PY=##X++<17PIRY-A$9"W4P[J6/FPAM8+EA3+ $D#
M$K*9K*KWKEF",:B:L)2(2P6W,EEL=A*,V1%]5GJ^O<RB+F3E%A5B,=7M>'8#
M^F49YQ(OTYL_CEJJ\6=]99.RS4 N2Q2%N&H*3CN>BI>2AIA99S0JI1J>_8FD
M8]SZFDX&H5UG)PP,) 8IHX<K)AV\B%<7H93&1J6\9ALC5$@-;O#9/$4L@B;:
MCL6NC?)5D2R"5V&5TW9>NK,5A4(\?',>Q5D;1<UBKE<W0?(R))ZN-S%Z@<5#
M%%<F41*M(T6.5%HZ<(*X3+4N84C,H:OZ8TTQIIC33&FF--,::8TTQIIC33&F
MF--,::8TTQIIC37-72G,FX; YC7[0,O'Z[91;%YN!F6FQ4188_<-"^*.6HT3
M!7C8LF\L,A!V.G[E@[6C+TIRPJE/4A$&+&.2D+H1TY>0^6)B,AB;-TN8FI0B
MX3T1(TZ;6Y6[BV\.7A9!-'.HBNN^!@T56:JLB44T*K5;-ZWFJZL:^DI3N?KL
MQ=>5G$$RZ&4X<=GRR](QE<+QV,LU78"ZDE6BG(OK'-U#>MCPZ59CJIIC33&F
MF--,::8TTQIIC33&FF--,::8TTQIIC33&FF--1;V5L?9,%O_ %EK*#3U[*4W
M8E#V'(C%V* GTYYO<:<E'/H5V:W,[,YBDJVX,[*C(18Z]>RJ2B97S2; 2@S&
M:@'9G/*W 64,;C+U)FT\@3:R#*-H;2MY*U  ,/0*G4OG#*&,V9#U38($#B&?
M.Y+>1MU+8]B,EIJ!9658OFPD]YE;):-@9B8(1&1D3]_'"\[GM[?949N9'7<B
M_I5_>5FMWG5T18:W4;Q"I1D8^6=M:W:+1=96,>UZ7>2-3E5OA/(LY.1@W,DT
M2C4G01C3?(USQV+MKEHV+2[DV4LVD?UMD;=2K;1L(D%?)TT(R*%'+I4JR(A:
MMK@+#,7;AD+M<=IKJBH:MX/JI*Q42]U1[) $V6UFL-96*XK"=NFU%>PMRADK
ME?4Z8TTQIIC35@M%4J]W@9*JW2MP%OK$R@+67KEHAXZ?@95J)BF%M)0\LV=Q
M[Y 3%*8473=5,3%*(EZ@ Y@:ULY>H 'R,!H<XB7(U902V#S1/*Q91! <;$)1
M$C,3&^MBVM27.IC%'(D,DLR I$XD3'F&8GE(9D2C?8HF8F)B=7&-C(V%CV43
M#Q[&)BHULBRCHR-:(,(]@S;D!)NT9,FJ:39JV03*5-%!!)-)(A0(0A2@ 9N8
MQCC-K6&UAE)&QA$9F4^9&93)$4^V9F9G6A:UI 5*6"EA$""UB(  QY"(#$",
M1[(B(C7NS#6>F--,::8TTQIIC33&FF--,::8TTQIIC33&FF--,::8TU@U5UA
MK2BRUEGZ3KRC4Z=N;X).X355J4!7I:UR0!T"0LLC$1[-Y.O@ 1 '<HLZ7 !Z
M IA?V&N%1/V*HMC&KJK^QUUM;,DU@('90L84R3#$8(YF9*9F=2R9<[Q+9EMB
M5BF7L^>[I! P"NJ6Y],8 8$.;E&!&(B(&-LYQJ-,::8TTQIIC33&FF--,::8
MTTQIIC33&FF--:]=[;U2PFSUE]L[7K.QD>$CCU]W=*VWFR2"IRIIL#Q2TD1^
M5XHH8J9&HMP7.<Q2E()A !A4P^8A$PZ9(@B%?9)DQ*1((@-]R$HD2&.\%$Q,
M1,3&I9$IB2=$J& ADRR.2(60P8G,EM$ 03!P4_-D9@HG;OK.6KQH^3,LR=-G
MB)%EFYU6JZ3A,J[94R+A QTC'*59!8ATEDQ$#I*D,F<I3E$ GV1/L*-QGV%'
M>-XGRF-XF-X[=ITF)$I$HD2'EYAF-BCF$3'>)[QS 0F._F)"4=IB9].-1K ]
MF-=82%-EXO<;:A/M>RA$F,]';,1KSFFR*:RI!09R[2TE/".R*KD(*3=XFH4Z
MI2"0@G*'34T4%*H<*BF'+8B&P$S%A,]53%0>\PY4AU%D'SPD><9B1WC:J7#+
M)1+8GHM%LJDXGH,"5.%DA_X%BSE;8+YA <@<2)3$_"MW;4Z2-;JU0MVNTV[F
M,22J%=K<_6B(N(:/*+-%.MQ$8[ BL8Q*W%JD2+;F:MBH"@0" D)2VVD][WDX
MG.M;18LRV38_9T=2'ODY)FS1GGAK.QQ/-!3$[ZK M5=*A %HK\W01 "*D\P;
M1*51$"',,D,=,.X[Q&T;QK8>:=;-4$0 !$1   !$1$>@  >8B(CY  ![1QY>
M>FO.T>-)!NF[8.FSUHL BBZ:+I.6ZH%,)#"FLB8Z:@ 8IBB)3" & 0'S 0QM
M.T3MV(1,9]A 8P0%'O$AF"$H[$,Q,3,3&GM*/:)$!1[1,"D3 H\X("B1(9VD
M2B8F(F)C7IQIIC33&FF--,::8TTQIIC33&FF--,::8TTQIK7-3U-0J39K;<J
M_#.B6F[O57MAG9>P62S2*H++^DFC(M>S2\N-<KI'0F=-ZM6PB:TU='.Y;122
MZAU#%?8*PU%?-0)RR8^V8T^=IB5AY<S[,JE[A1-AK?#K::D=-12&I<4V'C9;
M/,T$!77.T"M2@6A4PE(<J4DX*U>;;5+!MUB%.MFYJQ.-C8U&F--,::8TTQII
MC33&FF--,::8TTQIIC33&FF--,::8TUIF[<?]5[#OU7V?:X2;>7>F0D[7:U+
MQU\V!74(V)LJ7@3: 0M;M$1 NUWJ0%(,@_C'4BW[B8M':!DDQ+K%0#&0@8F(
MRE,<?>^>?V:H#.J*HW+[#(L^>+$=)HE)3#(YBWS-A,"FL^61Q]Z,E4CD")7<
MA4IZA% P3@E92)5W2RN?:25)",Q72^@-7<?8)_6]61-AB(>2?>L7+>Q;"V+L
M1<B_A$1*DQD-CVNV2,8P3(0/"BHUVTC$3F4529D555.>T;VL2E!E$K1!0OYB
MX9/-/>6N@8<\MH@1-YL,5B"Q*%@(QJ(8)QO+>6L&!(I(N7E@S9L*]^F&YL8<
M\@C)$4R6^MRYIUEIC33&FF--,::8TTQIIC33&FF--,::8TTQIIC33&FF--,:
M:8TTQIIC33&FF--,::8TTQIIC33&FF--,::8TTQIIC33&FF--,::8TUQ[VMI
M32)^THU)'N-*F=,Y_C'R;E;7=6VE;-.U\FSKOM'2UKJS^8V6UJ#ZM-+@LQI]
M_>P8/K(A)Q:#,[) &8S,6WD<\08UZ?&TUI&K8HCZ/+>(F%PHHL81W'M[*,IP
M<!%E@-S'#[;@JZI73<"R%Y5; (MY4_%4L -J8L^(R.6KW@(X:18ZQBL/AZ2K
M C)$NOM4=67SP$) "?/3 H:4/YOFWS+KM?ASP;W:44]0;[Y4D8YKP4V6\3LE
MDJ>[U(W78+)Q&ISHQ07K7#HDN^?$!%!YT4DFSHD@9;IKJR+)QW,<D#\'P58-
M4@285<R$,5Q&,R8C"9K'#+,U3Y"K&L!@(2W8[^0K41O7E+?  &:R=;KPR;,Q
MCPP"[%%H'$LBS%7+JC%*:,G%A!P920K!D7EQS>[0YY-TV J-8L<I M-NSL)-
M;(N/'?9=(:6BO(V.!/"0LE (Z5L<I%QK^K/I0&MGBHF#;$?MD!D[$V.DZ1-=
MQZUORF*78$%TVI%+@)T05TEY.[2NVY+F :EE-1=6[60ZS3K.8S81>@IZ?"R4
MQ7QMMU4C=:FDNY$ &_@+3<*BXN@,R)S9K!EY?0M,"M;M0A<DN09*S9.SEJXB
MI/>=2A]Q1))S5(<3-\V>G556LRES86+=T;)4@CM!M4&,1+/+5;H2A.I-[3H)
MM$2,VHS6MDC%QAU(UVNUXEA?/5X\@0ZEY.+X41P_(+EUM5+(V^,*W$MFNH(9
M(J7D4\!IO7HB%T?%4P:]*;ARSH5F6 ;PD6Z5XQV7RQY]IM6GER-6EA7<,4^H
MQBFFBWCV<>/.J($NTW'U^J$V$4P/EGIJO;8TM]BI>:['; VK?JYPEMS&BU68
MX=OJ"EJ>W%;5Q$U9=S\7K"$56G&SAG/G:,;G*MY&:<,S.2&6&7*X=]O,/,.*
M.,22WJ^)QV+6S/*B)ZF/;F:33.K37,5;+48L6/BD@3=76LJ<I$OUN6=@*ML<
M63"$*/QTSEE..B.89DL;F8IN-A?KBI7?>=CT==DJ1N\'<\>'ZBMZV_EGV@M<
MJ$I9X1ULZTU0M=W!&TJWEXFRC>V6VZQ%$AK51#3FM4J66?K2*5J]?TE)PYAF
M$%.HM4G?CG=*M5U]7*A9U1<<Q+QYQ@()@'4H\3TZIW6&L2\.[)\/N=<*HWIM
M3*R*L@&A*]:L6NO9(YMF2A5EL$FR)<JNBC+8C)SDZR"(IBTK"Y5%(5W5\X,E
M\+L.:B9;K.*'RAYA6G55ZVA+7_9+)I6-WNJW$U%;AS<H>ZVVBFK#6?BV,%"2
MNK3/5#OK!)EJZMD?QK2'1BXMRHZFH^74.]+DD$@6$FRN;<9 ^(*]BLIJUG/J
M_BV]B<79<QC%(K+R'#EG'Y=@/?5Y[(5(205XRZXYJ)>VSDU%(5U51PK4V'P<
MJY+W#&-R&4$)1#'-/&Y^EF,>N5)LG*G618ES2PA'T'XC+*DM/).*KZ)D-61>
MTXTU)0 YS-HZ?E*E%2>R(:/*4RK)!K'69R47;.-<+,F,ZZF61/!5;JH)ZJP\
MN%I"9+.$Y/.5,:Q4P:W\/UK%<,>X&3,L:J,A.9K5V-B"\-60 QT@7K)['LRI
MF:A5#\'@K=R)@!L1F;,Y(KT7E!,BF[-$,0UR_FE(M6XHGK=0YKYKUMTQIIC3
M3&FF--,::8TTQIIC33&FF--,::8TTQIIC33&FF--,::8TTQIIC33&FF--,::
M8TTQIIC33&FF--,::8TTQIIC33&FF--,::8TTQIIC33&FF--,::8TTQIIC33
M&FF--,::8TTQIIC33&FF--,::8TTQIIC33&FF--,::8TTQIIC33&FF--,::8
MTTQIIC33&FF--6*;J]<LIH<]@@XN:/7YEE88,\DR0>'B)V-,8["7CC+$.9I(
M-#&,*#I$2*I]XP%, "(#(3*W!87\QZUV$@T>S!5;0=:TL3CO 6*[6):._*:S
MD2B8G4&(L62F1!J,TL)91N!'7<%A!R,]I)+U+:LMMP8 D,Q,:ON1J=,::H8I
M3E,0P 8IBB4Q1#J!BF#H(" ^0@("("'O#(F(*)B8B8F-IB>\3$^<3&D3,3O$
M[3'>)CSB??JS5ZMP%2B6T%6(:-@(9F*QFL7$LT&+% SA8[A<R39N0B13++J*
M*JF O>.H<QS"(B(YEO/*L-_F)4I"A_P5I2 J4H(\A!:Q$ &-H$8B(C4;1SM/
M_#<YMAQ_X37O,F.:PO,F,81&93,R13,S.KUD:G3&FF--,::8TTQIIC33&FF-
M-,::8TTQIIC33&FF--,::8TTQIIC33&FF--,::8TTQIIC33&FF--,::8TTQI
'IC33&FO_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>g428534g56j49.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g428534g56j49.jpg
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MU2,W.4%9=7:1D[?8)"4U-E&T)C(S56%Q<_"AL;/_Q  > 0$   <! 0$
M         0(#! 4&!P@)"O_$ &,1  $# @,# @X)#0P) P4!  (! P0 !081
M$@<3(10Q%187&")!4556E)66U=8(&5-45V&1T]0C,C9Q=8&2EZ&TM=+P-#4W
M<W1V=[&RL\'1"20S.$)2D]?A);;Q0T1B<GC"_]H # ,!  (1 Q$ /P" _/']
M?K(IQ2G%*<4IQ2G%*<4IQ2G%*<4J[U__ ,>"?ZW&_P#O6>5&?]JU_&!_:2K*
MY?O=/_D4K^X<KM7X?[^.Y4_YO-%_KMLWG0-IOV1,_<N-^<2Z\'?Z-_\ @$O/
M])F(?T!A.N'O.=U[^IQ2G%*<4IQ2G%*<4IQ2G%*F3X/'^/-U1_ESU]_3L7F?
MPK]D=E^Z,;^\2N'>R8_W?ML7]'V)?T<]7H\(-_'B[8?R];*_K//Y+B?[(KW]
MTYG]^=5/8V?P ;'/Z.L*_HF-4/>8*NVTXI3BE.*5T1\$Y_E#>LO^U=C_ .7U
MOYM6"/LIM'\<]^:2*\R^S(_W9]J_W'M?_N6R5ICO3_'5[;_SDMV?\QK%S'XD
M^R&^?=:X?G3M;W['S^ ?8Q_19@'_ -KVNHJ\PM=?IQ2G%*<4KM7X!/\ CT3/
MY$-@?TQ3>=!V:?9&7W.E?WD>O!W^D6_W?6/Y_P"&_P QOM<:[!_X\;_UN2_]
MZ]S0GO\ :N_QA_VEKW);?WN@?R*+_<-U:.4ZO:<4IQ2G%*[#^!5_C#[[_F;;
MK_IG7_-\V>_OK<ON#</[R+7B+V>'\&FS?^G/ ?Z/Q-7'CFAU[=J6%8Z8;LN0
MX$2K4.N%6CU-K]^;CL',)G0*M:LVR/72,Z&]$;>6HH6I1X$W%&I(2HI5N W/
M9B1"HV7*S;.'[C(%LV19<1V.U*1$=1"%E_?HR1"2(JJ9QW6T0-2B:"AZ4,"+
MCMVVZ8"L<FX1;J_<X9VZ^7/#ANN6]5CR+O9TLSMSC1WP>(!2)#OUNN!/2EC-
M/0RD%&-YZ'*89T'(UML2(N8W+H-TC.#BT< 0;D58XRN =E+@-Q0LQ+D%*HI:
M2LJ+1''/X1,>62@);95F9'PYC%B2QU9Q9":#1HLV7$TN%HTMEF/ UW@9 N1+
MK#).R3/HK6*,,O"P3.(K$\,J&Y<8Q-7>WN#(M[*22=G,*$A4>AM##F*Y*;4F
M 2+)4C1&'=%O*4ZW@X;I$U5;(''LDDAGIQ0&3'PVBZXJIJ!3LJ7%98;)*A)5
M+3!4O$I45*I&&LM8RO$IQWVQ4W&'FP0]VI&V8BAY:M"D0HB'IXZ57/+CEE5S
M$O=EN#XQ8%WM<V2<59P1XEPB27SA"\D<I@M,O&X447U1A9""K2/*C:GK5!J\
MWK7)W7[5,DF)8&?$OM/9NU>E@#,4PPZ(6?L%6D-3,Q\X<@D(-AJQT=(C2&TI
M?Q#;)#GIP><.(RYY,1V*D=7%;(9+"26B;<$T5M77650LN(D+K+@*BIDNE#!2
M;(#*PP]B>WXD.^M0F;C'>P[>W+!<V;E!>@N!-&VVV[M&QO44)$:1;+O;Y3;S
M1DK:OE%E!'G1I45CJ7X+#_%-X3O^8?MC^K5EYN>"_P!Q8O\ YMS?[EZO(WLO
M?LR]B=__ $1@W]*VNN._-#KVY3BE.*4XI3BE=B/!_?Q!/"V?R9Z#_I;;O-\P
MO]C../Y';?[<^O$7LD?]XWV&7\Z]HWYG@JN._-#KV[3BE.*4XI3BE=H^KG^1
MR\(O_*/I;^NNM.="LOV!8J_E4+^^B5X4VM_[\'L8OYK8]_0&*ZXN<Y[7NNG%
M*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4J5'6/6VOM
M@0=_%=A^BL#]7:>$;"&$",ZSPA,.>_O/3.N9_KG%0'&#TD>JM[#//,M#14R6
MT9BAY?D.P8\^%-S=FB190W,Y>2!#@!* B)X0$EN,"*:N;@3<(=S*<5$ ")'$
M;+)10A+D.U?%.),-R-G$/#.^<DXNQM-PU+C1H]I?F/QV]GV.L41^0K>I4&W-
M24NN&;<VX<J8PR<!V<RA!(=C2(\C[GTJI%VAP;CH O9XFME:AV!L86:N0W$V
M?:8]6M7;XN!]9^;G#<!3AG6/78+&DC1 P@VBS&53ECA0CTQR'E9&'H\D0?MC
MCPQ%@R93;D@-1/(R]?3:4UU!NW'(EJ;0@; T1UQ2T VA*/+[%MWO]A?D6/:/
M"M+V*DQKAK#$R!8Y2L1K0[>+/L4A7'DFJ/*6?;X.+-ILYUJ5-EQB*U04CC*E
MS=P+_FY=+]?U"J;(@1+#925DJ5RV",?LM@KR1:V:QJ74E*V>=(T^NP+;Z.?)
MV5ZP3X$* 5>5&9 ^08R5&?@_/D&DC#\5AB6".O$ZQ(E"KSK6A49@P8\QPF&1
M?073>)TA$3541OL]8[HE<6+;KB2]WC"\AZV6N+:[S8\-2V[5;;D4M#NV,L:7
M["5OC7NYR+-O+=$M3=LC2)$B&VCIW'.%R25T1CMP<9+]"XM9./UJR[B;;-P:
MWL"W$&J]0W#D! +7^^S'7^>J'.EV\'F22F6,0LLV-E1AZX@Y[$::\T09>CIH
MN89%EQ679Z;P6I3YHU%5P4;BW([8>DE?;S-7@UH!"&0KD2H:*E96%[(EV[6]
MN[6K!)%;Y%TPW98QW/$(V^05PQ)LY@[2(Z2([-DN",Q6+7."&<IIV2+\D%=8
M XQMNE&_L/H61H,]5@SMG9M+=F"VTBB8V)<#*B3:/N+:&E+!"S&60)X?BKLV
MJS)(//Q(9=F@B(M^:.%$%2QL7$W6V+;'66U>1]'FWSU(VK>DHT^9;W1TJ1YC
MOH3A@6:*39@I !:A3J&S/:*UM&MUWG!:3M!6F?9HJL'-&<C\?$&!\)8]MLA'
M1C15;>&U8P@Q)T96C"/<8LQN/)F148E/1]YBZZ33BE7>O_\ CP3_ %N-_P#>
ML\J,_P"U:_C _M)5E<OWNG_R*5_<.5VK\/\ ?QW*G_-YHO\ 7;9O.@;3?LB9
M^Y<;\XEUX._T;_\  )>?Z3,0_H#"=</><[KW]3BE29ZBUJFVW=<4-?QX\E5L
MZWWB3DL$VDO16S@'2>P#M(?0VJ6/P_/;O@ZL8%#LSHZ#954("]Z2P4<AR<O8
MV6'[@C<D!-GDEQ,D)-2(XU;Y+L=434.9))!G0&I$<-1:7-#45Y3MINM\LV W
MI^'),F+=TQ1L_BMN1#4'2M]QQ[ANWW]LC1F2K<8\.RKMRR4D=TH$1'[B&Z<B
M ^UO4MJ7K)LH& O]%EW.EJM#.TQ<*F/2  ])FQ:'T#K6USECA$J?;Y];G=@M
MI';4,H8/!^QPPF1\P0";L<^+'KD?)G M$QIF5&61'WXS0&.I-CO'K9;(CY:&
MR.0;172:X\$9I'7D;T$VTCI"C0\^AXSVKX6N-RPWB!BQWY+2YA"6_?&VKC(6
M#:]HFTC%5FCA)FLQK+&NL?9KA"W6>7B*X+;K6_<.4LS;B5KCO.71W9$3H?J+
M"1LE>SKA8 1:TE Z;;6H IROB80NV;*K\U98CB 2 ,(@M4ZM0VS+]FA-G+1:
M7Q(H+ZK&PCIN['#4%4 N6/NM&^;:/M"&Z 0?EM%O"03;1!1AE$<5X4<>>5MM
MM0 77-7>]D-C3.6TF$[);;C"M$2:5ENLF6-SF2)=GPK<F!A15D1;B9/E?+J^
M4%NU2"@6BT-S)D])<J1;H&!5OJ+J@Y1!NPY=X."QY,/>[-$K6;'49E@=#CM2
M[_V;2($F5'$Y&P#),KJ&L:[)(8P6>>L][3'R+!&8$:LDK9JQ07(P2BD.@)MR
M'D9WK!.[H8-SF1Q54;T"X9068IHFM5>DY:&S!&CV&Z;:<8V_$4K##.'[?+E1
M)N';2]=4MEY8MH3I6,]F^$\026F'9B2Y$&)#QM=L3Q2<6$ 6G#Q.\KN$&2[=
MHFF>SVBJ#IQ-=D4.UE;&P4MNQ*Q-9+3 LZ0U'J3%*)!C;+@:/$0U$-1+D\+2
MV\R\V_/JY(A$F>:F+%",?>;;%@;I8KYO(;\MDD<)LE1&$C&VXBMH*(+@R%#)
M47,F3-%1"T-[SLFVA8DQNMS:Q%9H=L<B67#-V8<A,3X[1NWIR_19UO,9[KQ&
M_ >L82R(# FX]WBQGF-;"2YL3.8.NRTXI4R?!X_QYNJ/\N>OOZ=B\S^%?LCL
MOW1C?WB5P[V3'^[]MB_H^Q+^CGJ]'A!OX\7;#^7K97]9Y_)<3_9%>_NG,_OS
MJI[&S^ #8Y_1UA7]$QJA]CYLXSXL*\6<?O<^/Q9^?^#/DYQGQ9_@SXLXS_Z9
MQGY^8*NVKS+QR^-,LT^/BBI\J*GQ5U#L_6+2+]LN^L!S$JBWV2[HG.E2]A.D
M$T2R7"YZ.K>Q[!JN^D"DU&02+T7,2A](M<>>-:KYE(L38G_4Q6180.YOV:W*
M_)A BQI2K;>A[CKI\G=?D6UF8["E$9INTDN.$$9Y"#=.(#;J[LR=;\DVG:QC
MYNS6#%LHV<08<:':&F/(5MMT9<16NQV+:!=<+VW&&'(T1@DN!8>A06I.(+.Y
M%E'<H)3)EL;6?":MEQ_<WJ[J>:0UR%Q5RU< W41VM)VG9$<R==BZ[8TQ>MA@
MZ>?(K*R)P#-9C1JP$@VF'/8:(G%3G& ID28FP,9B=F@D<-O<FRU("]F_+1QW
M**EODRFH[IJX1M;E!9;%X21"<4E1MP#(*A'VN8Q8C8HG+=85TN-AF['8EHPN
MY!@"]B9S'6'L,W"]VV*,-N/<>BSKMVGR+0_'<.+;TCBY/@S(+$G+EQS2Z];U
MT1\$Y_E#>LO^U=C_ .7UOYM6"/LIM'\<]^:2*\R^S(_W9]J_W'M?_N6R5ICO
M3_'5[;_SDMV?\QK%S'XD^R&^?=:X?G3M;W['S^ ?8Q_19@'_ -KVNMS:KTIU
MV(ZCT9:-G2BPVQ[8L&R*R-9$3+(X5L-HJU_U>&K V''8%3:R/ 20]ML+-PED
MB@4BVRP.G5V2LE%=&ELA"MUI.!;7IA&#LUV6R*-D]K=>9E0VV1%$ F1:5MYU
M)!&;9HB 32ZTT'HN+\>[38N--H-HPFS#E6S!MMPM=I3DUBUC$MEHN^&\6SKM
M*?<<F1[K)N+4ZS6P[(S%B3XIN.2H]S:&*\$J%<+3T#(R2MR+46TRUTN+5=E7
MFL.%:TIIU$>@3NS[4RGE9"+%+7DHK/6*Q11,\:@S(),6$ 5)B@C6"[0Z9[#!
M*Y(.,^2QT9ER65-G+(8Q7E"8,M\2Z_\ T=T0,$<(T=;,VVT1Q!M[1[(Z*U#L
M<+$%H9&_.WC"N'KL,.ZH8$[B2/LE-B]PVUMC(I$%-K-K>FQI106XKELN4.),
MGFL(Y6";.Z2E=8T&P["G[#'%0L"01A5I\35RQ>%:)H9]K)!,HA7)5@:ID:5"
M7-]49N+0DD@_7[94;>*IEAK!6$S;S<.G"BNRBEB;8J0LJ##AH\0*FK431.I'
M%1U:-_H-'&WF7PCN,FB;#A/;U#Q9B.V8:CX9E0Y\EJ-(NK<V[0H4BT,3FSY*
MK4:Z-6T[ZZT^+'+>@9S8I6ZYV6]629?;9=X;YZ2V#KVLUW2>@+^(9,MG=D9V
MFFT+(D&)8]UZFV<8&&*"1F1L!0^+Z')5F2Q)D%)"YBGG<SL,*8B1L=*B,M6Z
MURFT<1R7RU'M9H0*L=X&P5M$ -(Y$NI%4UU9KJRR%-]PWB6[7/'NTC#DTX)V
M["Z80*T)%C.,R0"^6F7.EC<'7)4@9+V_:'=.--1&QC[L.3JXCCSO3/P"?\>B
M9_(AL#^F*;S;MFGV1E]SI7]Y'KRC_I%O]WUC^?\ AO\ ,;[7&NP?^/&_];DO
M_>O<T)[_ &KO\8?]I:]R6W][H'\BB_W#==,]5==>LAZ'U8%7V2;AW'?6O:C9
M( <+/LRYYJQ2>R>U-6VM<Y:QCE;$4Z-K&@X,PLQ3T6SXV"VPVW"FU<J]'$;?
M"M-G<&RMR2<&1<XL=X6VR>4W'2NTR&_J505EMA(<93#)T7DE(G8FR:H'E/&&
MT[:O;G]KTS#C,!^R;.L2WJUR9L^/:ACP+8SLKPAB^SI'$98W2;?'<68CY#(1
MZW.VA<-$Z1/Q[O#;<FZW']!K(9'3SHJ[*S6_P4H=S!G"%,GMM$15RI6D;[.@
MS!P8R?+-GZN!W@!43&UN#;H^9,)##A"(HZ"]-M PPZX!.A)^I;B-(:,XY(A@
M_'M\DQ(6W'31UENXM:P:%]%4<E(=XWJVB3[(RU094>W3+"*77HQB*QW"WQK[
M&(XLRQW['^'(\AB3.@VZ$=NNUQV?W)(DJZ2+*ZC3Y.#%>2W7'D^";BZ@E=.T
M"3?"UW@$X[\N%BMQ1@.0:&V,7(&4$DZ0;N=-)6^D#7G8VP@Y<)&FV#$0Y5E1
MB[!..2+B:_+MI]A.!%*4<D312'="#2N"Z"A%/5RB.<B,"J,IMQL3=07&5$T-
M#<!HMAP1MKAXWQ&UAZ'8),1QME_HJ[+GMP)5KF-R\1Q0C'8KY%LE_E #F&IL
M*>ZQ;5>M]W1V"Y$<BPIMR8PK>>M@]$INDBD?7.P=>6&X54N3L#-NR2DAC\9J
M;">K!T'.(A R,%BH A%+V 0+7/%#!Y2K2&'8TDI,A1[>Y1&XT>W.)$E1'7V7
M#=1_6K;J(0JRZT1MM]F;1H;H-ZFP$V511(R%,]L_Q3-Q#?,>PW,3X;Q-;+)>
M(<2VG94BM3[<Z;#X7:WW"-&N$XEAP[C&=A6V;+&-,ER8=W;<!UJ(Q(=GKX%7
M^,/OO^9MNO\ IG7_ #9=GO[ZW+[@W#^\BUYT]GA_!ILW_ISP'^C\35QXYH=>
MW:F<,[1;8'N:7*PJ[8?P-U9KYG6XZMM%[.FEVV4B'?0\&RSX;2,"UVEAW8!Q
MB(_&:=6WAF/"8PC.9BI.P!>9P+;S%IW<0HJ1 91Q[D[ZZ9+8/$*)HWR+*<05
M1%YD%$3,M7#)6R3!TD<=PW[G;5OF+\2.8IE70X5I6^V9DGL.37[5'?(N6):'
M1PW;W'FW3!#4W'S541A&LSC]]+(*'D1D;5E8&%I@;7U<F6&(7/P;.PUJ^?UP
MGUR6S/PYYV"7C3NL]2<D99;:'J=*EUK%^>1%6W<)B9T!,$A,@X3<5HG1<<%Y
M.1G:C9+5SB8E:&,\D05UN9AF@Z<&Y['>US),64[B^[2X3$_$MT8MC\.W2+2X
M>+HVU&-=&7(RCHD0G8^U:]"VCA')08<)!F:">$]5;F[6V/<M+$TJ;4:_41X9
M]3,=%.EEZ\%FAFSAVSP(Q:D!Y0VA/E8%@M%DF0R@^LBX8R$76#KX0('A#8<.
MRN%[>N$<(Y,-, "Y)N"<: FT<<> 7([9!%4P=>>(7!9 0%S=M-MMB(IM^!MC
MUKP/?IM^8O5RO,F>VCCI7QF%<Y[$XK?;[3(>A8@G,RL1MPY-LM%J8?B2;M,?
MER((W"Y3Y\Z1*?>UUN7:%CV/)I4 T'F@1-!I[57I8@J1,G"8VI3C1BVC1V3U
MB4X;( QZ[&_#J<>2\ZP+K+(N#'<E+1)(SK2X3'I91Q=;)H(T=&6 <-QPQ8)Q
MQ\1WKRJX38J\2,(JJ@,H HI*A&6SX'PE;,+M7Z1!FL7&9B.]G=[[-B1H-OB2
MKTQ @V:7*Z'6P0@1KA)&UMOWEUH!=EW8Y<AT6A)J+'Z0^"P_Q3>$[_F'[8_J
MU9>;9@O]Q8O_ )MS?[EZO+GLO?LR]B=__1&#?TK:ZX[\T.O;E23Z[T34E_QL
M(1MD\0I#+@$-#IFQV5N. *-=2]AA#0Q&^CT,ON3* 0<?4+L\J"C!BOQ9*+*-
M20]420A?+VJ+!E<J"<Z49-TV,>4G%J/(<=$&SE#DJK%)5T/$*:VD)'AU(V3;
MG+=IF(<9X<Z6IN#;=&OYA<9S]]PN8B-RQ!885M?E3HN')).-BQB2,+:2[2S(
M)8-R>:*U2EC<M:N$*53W56E"&ZQ7S^NC<^XDNRM"T/;AM-MLN=)#QS6G:3:[
M=+JI-#MA 22(FU&#<L>7(,':ZL)&0AUEZ*G!1&:6RQV]PT[$<)\[O%MKXL/D
M2@CD".^^3!HKC1&#[CA"9(XTK0HBHJ?5*X^WM@OLXKM<K;B>!&L<799B/:)9
M95\LS+#4UR#CB_6>RLWB(06VY-19EG@P&9,*,Y;KF-P=(@-MU>2%IJR=7J\-
MTKMRY5VVQ[9<-8WI)J*D84"N0;)UVS=3FIOQCQ@#$V18X:_QAL521B4_$6#>
MK%Q%3HI-U2'T\L'K,T%OG/M/B^_#D[P=!MJCUIY0Y!Y6C2&KH_ZWN%S4=VK,
M@#%Q>*5O-KVMW*7CO!=CN=E=LUDQ9A\H#Q2XD\9%JVF] ;?C-,+/7)QANUOC
MTL.7EO=-O#< NUCF1GH@"395"?FNUWFNQ'@_OX@GA;/Y,]!_TMMWF^87^QG'
M'\CMO]N?7B+V2/\ O&^PR_G7M&_,\%5"OJ3JS7&QKG*8V\5C :<;\G5M>+S'
M#C4<?M/9XPR&HAV1D(+(K=&4N5'E6\KB<N"(PX+%PB\QJ(4PA[7['"B2Y!)/
M-&F',H31DKB(,V8#C<9Q=V!]C'5"?/7I;10!#)$/)>\;9L78HPQ8FG,%0W;C
M>X&>+KG"8&WF[)PAA.7!G8BMS71"7&$)=^9<:LD-8XR)NF9+D0F#>B9AOC7'
M1RG6<;I^'<;E;JA;]ER(<)R$F !G"'CC>_=C:1.U"MR52&7"-C&P:8SL)O.5
MNP7 D4W"<6CRAY/F2B8<CO! %^0_'?F$(*.EHVU=2Y2[>\PT6I-;H#'24/%1
M5L715?K'*YYBC;_?+3*QL_8[%9KW9,*-/OB^LBXQYH0"V<88Q];[W=&D:,(M
MKE2+Z>&232$@9[UO?%%RDQ*L2^J.E/5E9FYVE:(4VWEX(N*'(1:VU(K1A.DJ
MKMR?2+)(S)1X[:1,E"NLZ_F-%8;S9EB%%1L2:P8 QZ?02WZ&2Y8\)2' ;%LA
M916G.A[,XHSRYI_K!N&<-K(43?*WK!"1QM,BFV''G*[K'Z4;2]'LL&1,>G1W
MKH;=UA+CZ\8+CX@M;2-%E98L&'#Q9<D=></H2,T8<IYAR#<7:6+U1TQ/+U,"
MQNV+#+G+O5*0>@%"0"))JI>]4'7FQP4&6A:$HD*$9*;0U/:R+SH^()VA11:)
M;,&#8TP84!LEO)QEI+B(N.2&(S@&;0DRY)C1);8$B\%W>N;!>-5 0FQ@0D 7
M= U7ML6.HT*\W%S +[\*WV"\W^W2(<6XO-7B%A[$>)L+W"0R0J1-I-2)A+&5
MGB@$EZ;A+$,Q6')$BUK(D5Y#K?K:F:5[ VSSI"UF(VLO3:B^:]#&D-9W<!V&
MZX5PQ3BXV!*<??OCM%M^PICC!%H=A^DLOG?P7'$8I1BM1.TQ(]ONC_9O.)$U
M,*[I X<AJZ6EHV# "52DE&?E&J&@_P"KHKNY D-&K>/M0Q3?,=[-K-HC6>"[
MBO<7IN C\J-BNP7'9GM1ND*]PI4ED6V\.AB&RX:8%R*4I6[^XW;NBTJ,[$<N
MLC^KG^1R\(O_ "CZ6_KKK3F8LOV!8J_E4+^^B5R[:W_OP>QB_FMCW] 8KKBY
MSGM>ZZ<4IQ2G%*G?:M9T1VOZPL "JB6:Q<>N^L(9.U#W9<J%C<Q7;HNKW=N/
M,D$'X+&P8E<;+NO592<>A"VW#[0!N&ELCC9GH<96H;K3#:,R+3"$GQS(.B!S
MP8D9$I**2A:1Q2:YQ%-XC:#D5>>[1BO$(W+%EMN5VF'=;)M,Q8_$M$D&67UP
M-$P7+N]@)QAJ,W(<PT]<SA W>$7*1,(;:=R-]3BUF&QNF&N*8]=,0-BV*8]2
M2YJL66MSV:M#ME05#N6[J8+VA81SQ.-B1J^1,UC3)II,%+)H(+V9!(-NDT1Z
MRU>*TO#\..LC3+=)8[CC+K1(R+[&E^XQPFNMJ2*L)2AQR<0<G&VY@FBN:6DD
M8+"^W3%%];L2R<+VU@+_  H%VM-UCN7=ZS7M'['@&^S,)6V2$1U6\6M,8LOL
M> LA3@W"9A21&((BNW4\/Y",Z/Z@E$)\.7MTRG.+4Q4X3$/%8?G169-NWO5H
M%W(M^DYC/UPR-U16+L+A1I,=;H:\QHJ#3\#U):CU8,.0",@*<XB[\6!0494A
M0G[DR$DTU*BM.!!9D-@BHJMR4'>*&Z?=QLO;[C5J-&?9P7!7.SN7E]Q];LVP
M\XS9=GEXDV"*6Y1UNZ09.,KM89<AUIP0G8?=>* W(Z(6BVTTCJ9J2/3),]VQ
M%WX@X1+V&TY!]6)NLR*4Z]]?]L1*#-)N2GP2\A[!L6TTA4R/4X\]-AK9>6XR
MZO+U:$RK8X21U-77%$6REHHH"2"$[7:YJ1B-55M=V[+>CZD9$MZTX2HJYM-U
MFMLF-';XU&&UPFWI4YG#)C(26MA8>B;2]I.#7L1L1!:;N(I-MN&+1?T8=O+D
M<K;=(3 N *-W69@6^^H-7TWKBVW,1:KA=5!=C6.EB#4"L._@?-AUS<NWM9R"
M1,M BDA V/("Z_IEC%3'K*AP[/V,@0-$*AUU1HS:W*Q,P(CT@'GY"MRW8[;@
MLKN#%J?/B*9F(FV"*W%CO 2O?52E;L&U%K>.;#LYVUW;'&*+-8IMGLEA2=AB
MUWV; DW8.C;#]SP-@G%;<6)"D.Q9LMQJ?B6^VN8P%J(+?&PN4Z5-1^Z# @[X
M-Z2ZVOUC9%N$5<2U:%=:R26=<,&+"N;0-P:\N]) 6>T,#Y!3,A<G8=(M%7N%
M2@S'28E,LKL1J&#BQ:V(D-95RW6A69<@&6T?6TFB0Q-S5%G19$=IUY (E75+
MCO,/L"6L$(Y>EM!:;5.>P,>[4F[OA>RSKO-*T)M3BD>*#@VQ(^),$8FP_?[C
M:+0Y):A[L6L,X@M%WLEZD,!$FJS"PR;UQ>=NLULO3NWJ7IQ+5MF5XT( ?B\F
M[NC285%1B3+M0\9V)WE5*K>HXH_9B^4TFK5>K:]AE&D'D^C5>V@;#(L;Z&G9
MIF2XV.WY/$TX#2Q2N2$,?)2>$+K<F&)* Z\XO)F66(HFB.)DR^V\KJY*KLV
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MFB-DIM4W_9 XUC"_*79\LIEB-+$+5%&Z+>)\AK9_C;&,.=$1&'4Z&W.7A"'
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M% B72$=LM68)DNK)./!:Y/ME]F#M0VY80#!6+[5@F%:0N\*](]A^U7F'/Y7
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MMDFWGP?V7>0,3>N5/D_72CZ<=C_MQKWX3\=3+#ONUT\9C_1*>V2;>?!_9=Y
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M.GT7<UPJ.R-]T[L)U@WC-G&[8X2HUC=T)M/2M^O(VM%8^IJX7HPW9[FO;Z8
MUPH"NS=,*7[-;;LB:/'' JPIFF?<3)4^/CGEV^XJ=S_%;CO/K!M?9^I(-" 5
M77]7/C-IWG>P"V"]@,X77]DW>?OF6VP;HEDT?;=?;1 1H-[J=:N0R\PI ZRA
MK/=R8>,%M=#HILXJ"*B?X_DSX\/C_JXHJU=NP>E.U^QM(ZA!:NFZ?UKN;5T[
M:ZHAN"?,.587)G]2NQFC]5V^D3">M3AJJ%(.TMB:SNL\6Q">G5JEC;;56[==
MHK\L9;E11415[:+E\7;15YE^)4Y__'F9UTW_ & #IA.Q+-7ME(T_VLVSM4G0
MK/92!@/LO2UFK6Z:OJRHV(V2JB$D+3JUS8U,N B%9!!@&H_K^ W@TV1C +6&
M5#-./QHB?:7A_EE]I<^>M'T'J/W:IM(':_G[4KI(+5]LZQO%'9K>Y=@4H)7]
M4-[]U?L^\]?)049J]9 F-UW4J[L.CZOV(Q8!#UDI5K&T:ST<2,$AI=;5%5%>
MUVLEX)SY*F?/PSX+EVESRK#"_37PCQJY:PV4CLO1 ^TJ%K E0T7Y$LB41D_:
M#G1^Q;5+D*O+H"!Q_76T2NA=_2A^LWWH<?7DC8=*=KD^&S'7$HRB*.7%%Y\\
ML^'_ !9?'PS3[?'[\O.N>GNUE3M)ZP;VV1*N )>CZ57JY1$[9F6H8SMQ5TW2
M:VB2*%T:<UW,D5\C6[!IZNT8Y(BD[ '@U4VP1A/2DMDSBH*J+S)EQ7Y.&7;7
MMY]S_!(F:P\'YN\%LZB;#G!M+ZF$#+V,NI?6^KK_ &6SU"E9BW?;-XO@W5T.
M9J#6PP.(W= V.%UI<@,0&"BL5RF-V8V0N)XS,B\5'/M<_#N(GQ)W>;N\_'G2
MLQZZ=&-]:QV=TYO-OM-(0-T!U[UOIZ^5X%93YT6>*4N@=CZQ.L /).H@R7KA
MD[M:I.UN;B<%KI:ID=C-7^FFKA6]/6*M**J+G\:JO'M9Y?Y9?U99KGUZXJ6G
M%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*@;V8_Q@PO]EQW](%^8"Y_ND?XH
M?[1UWO9C]CTC[JR?S:%4>>8ZNBTXI3BE9O6#PT(*,9E1F)\]9$)(@P9+:EQY
M3$9HNW/9E*]'>0J&ZJ5"S)B9<CJEH:QA+R%LH5BNT8 !ZD0BU-J(JG!4%#U(
MJY*FE=29IFBKVE141:P=T@2ITN'NG7([ QI[;[[1Z76G'3A%'<:1' )'A1I]
M&GM+J,J2Z@435%RQ=IK+7IST+,7$SSU0?C*F07I,.3D54"X\LTN(H=XFV)!N
M1!5+8=RX@GE/I3O_ -+&<UE=9[)4R0LV23,55%T,F)HJ:<N)J.:+FAY9KS5B
MAM=S/< _O=PK=Z;=%E\6GVTF7F'(ADCR2>+C4%I]&7&])14+= N9JE8V4GUJ
M;!G+@,KB,Y!0\0AK^<..CK$[9,R9<>&_E2GY(UH,X12S)>SX\,.#XTU3DQAE
MS-(R:(5THJ)NTTBO.+BNJ1(B]L$!2R5>UI0LR3.LE%CW-E]A)!B\?+WM_);1
M1&3;@MB-,N/-Y(VU)*8,97&@R17!D.L(+!F"8!RWK/TXI3BE:4VE5+U8K=J.
M71:26ODP38S[4L,$+4\00PD[6IH>"\V]=;-51*V_39#2'L>L\.MH5ESS:DIS
MG& O42;)>MAPHCDPF7W];33L5HT1Z.30*BRY$=M4UJB+DYFB<<LJWC"EVL-M
MM&+V;]?(E@9EVVWFS-FP[Q,CJL"YLS'P(+);+K+$MPV9 O)M!$FG4BJE93^*
M3L]]5K97V^ZV_'7EMT,Q!X/SO';'Z6K%].&RWX5,-^;VTGU%I^*3L]]5K97V
M^ZV_'7CH9B#P?G>.V/TM3IPV6_"IAOS>VD^HM/Q2=GOJM;*^WW6WXZ\=#,0>
M#\[QVQ^EJ=.&RWX5,-^;VTGU%I^*3L]]5K97V^ZV_'7CH9B#P?G>.V/TM3IP
MV6_"IAOS>VD^HM/Q2=GOJM;*^WW6WXZ\=#,0>#\[QVQ^EJ=.&RWX5,-^;VTG
MU%I^*3L]]5K97V^ZV_'7CH9B#P?G>.V/TM3IPV6_"IAOS>VD^HM/Q2=GOJM;
M*^WW6WXZ\=#,0>#\[QVQ^EJ=.&RWX5,-^;VTGU%I^*3L]]5K97V^ZV_'7CH9
MB#P?G>.V/TM3IPV6_"IAOS>VD^HM/Q2=GOJM;*^WW6WXZ\=#,0>#\[QVQ^EJ
M=.&RWX5,-^;VTGU%I^*3L]]5K97V^ZV_'7CH9B#P?G>.V/TM3IPV6_"IAOS>
MVD^HM/Q2=GOJM;*^WW6WXZ\=#,0>#\[QVQ^EJ=.&RWX5,-^;VTGU%I^*3L]]
M5K97V^ZV_'7CH9B#P?G>.V/TM3IPV6_"IAOS>VD^HM/Q2=GOJM;*^WW6WXZ\
M=#,0>#\[QVQ^EJ=.&RWX5,-^;VTGU%I^*3L]]5K97V^ZV_'7CH9B#P?G>.V/
MTM3IPV6_"IAOS>VD^HM/Q2=GOJM;*^WW6WXZ\=#,0>#\[QVQ^EJ=.&RWX5,-
M^;VTGU%I^*3L]]5K97V^ZV_'7CH9B#P?G>.V/TM3IPV6_"IAOS>VD^HM/Q2=
MGOJM;*^WW6WXZ\=#,0>#\[QVQ^EJ=.&RWX5,-^;VTGU%I^*3L]]5K97V^ZV_
M'7CH9B#P?G>.V/TM3IPV6_"IAOS>VD^HM/Q2=GOJM;*^WW6WXZ\=#,0>#\[Q
MVQ^EJ=.&RWX5,-^;VTGU%I^*3L]]5K97V^ZV_'7CH9B#P?G>.V/TM3IPV6_"
MIAOS>VD^HM/Q2=GOJM;*^WW6WXZ\=#,0>#\[QVQ^EJ=.&RWX5,-^;VTGU%I^
M*3L]]5K97V^ZV_'7CH9B#P?G>.V/TM3IPV6_"IAOS>VD^HM/Q2=GOJM;*^WW
M6WXZ\=#,0>#\[QVQ^EJ=.&RWX5,-^;VTGU%I^*3L]]5K97V^ZV_'7CH9B#P?
MG>.V/TM3IPV6_"IAOS>VD^HM/Q2=GOJM;*^WW6WXZ\=#,0>#\[QVQ^EJ=.&R
MWX5,-^;VTGU%I^*3L]]5K97V^ZV_'7CH9B#P?G>.V/TM3IPV6_"IAOS>VD^H
MM/Q2=GOJM;*^WW6WXZ\=#,0>#\[QVQ^EJ=.&RWX5,-^;VTGU%I^*3L]]5K97
MV^ZV_'7CH9B#P?G>.V/TM3IPV6_"IAOS>VD^HM/Q2=GOJM;*^WW6WXZ\=#,0
M>#\[QVQ^EJ=.&RWX5,-^;VTGU%I^*3L]]5K97V^ZV_'7CH9B#P?G>.V/TM3I
MPV6_"IAOS>VD^HM/Q2=GOJM;*^WW6WXZ\=#,0>#\[QVQ^EJ=.&RWX5,-^;VT
MGU%I^*3L]]5K97V^ZV_'7CH9B#P?G>.V/TM3IPV6_"IAOS>VD^HM/Q2=GOJM
M;*^WW6WXZ\=#,0>#\[QVQ^EJ=.&RWX5,-^;VTGU%K](TKVL)NLCAW7"Q )LY
MYF(P=NNPM)MU,-E]U#:RI_\  W:-OM3HV VI<J1& 5LJ3EI:]&C,(6]A]J*6
MG$3BHV%C>8(U04>E3;5R=K-<MX]R6X29"@"=DHLL..%EI%$SS2!8WV310.3(
MVDV^X,L ;QP++AW&RW::C8J21+?T9PO:+4$F02(TV[<+E$BLJ>]=<40T'TGZ
M\=:JIH47-G>F.7+9UGCQDWK9A2&U&*&O1U*=C@P<%#DAJJT<2\XYZBJ8^0ZR
MQE3A,Q--V.84.S]ZLEBC6=LBU+*GOH/*Y[@H+CN7%&FA3-(\1M57<Q@54'-3
M<)UXG'3\S;1=IEVQ_+885D;+A>UN.K8<,1'C=BP4<1 <G3GU%L[M?)8"/+[O
M);!QQ$&-#9@VUF+ CR1YG:YK3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.
M*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*5"KL-5[,9O4.6'KITM%
M37(#"I(T00G1TO(G%%K94]%CNMX=2AQM2F\JPM*5H5G&,*3G.$N+3IR$(&G#
M3=BF8@1)GJ+AFB*F?%.%=LV=76V0K$^S,N,"(ZMSD.(U)F1V'% H\04- =<
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M!55,^5RQ5%3G14(T5%XHO-Q145."U1?E";/_ /N\'\SC?U?D.B,K_G'\ ?\
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M"F/O$!<:4-GQQRG/,QDH\Q$=C6B3V$G/S$A-B#P/(D='.Q9<?;42=8(FR$2
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M7BY7T>F0?>;&$"EPE!)4B :@QQC,R2(B9KX]"6()89+D85,\Y-0E]M$>JMU
MFHK;D1'.22Y4QO-Y4;-R4;)$#P"VA$T.X!,@=;(NRS-,T1+(<%269MWEQ;X4
M7HU8K-A^23=O I4>+9F9K+<B"^Y+-EJ8\EPD$KC\.4RVJ,Z6%4")RZ >Q9T5
M9&[*0"0#TDJ6OIF]QI^!F6[C*V'%6..Q\2E WB-?%O"_,CW1PJ9YEQAG&6U1
MUN.9549OCS;Z/FT#Q.NS'9HFC>4HIPJ#PZMRIL-DWDVK;1:51.&G-:M;ALV@
M3+85LCSGX#42)8(5@<C<J0K*UAUY),!U6DGA&N,L)>N2,F6QK%QQ=2.((HD>
M'LM*==4PVMIA3B\LM.NI><;:RK.6VW'DM,)=6A'B2MU++*7%8RO#3>,^1C"+
MEFN2*B9KDBKFJ)VD541$543G5$3/GR3FKHX(: ".$)N((H9 *@!&B)J(04W%
M 5+-1%7#445$4R5-2^OD*FIQ2G%*<4IQ2O&<X3C*E9QA.,9SG.<XQC&,8\><
MYSGYL8QCY\YS\V,<41%5<D3-5X(B<ZKW*ESU.Z<V;L_*AW*T+*U#KY'D>4LS
M%6^-LNW5,.>2Z)H\E/FY0BE*6E3!C8#&42B:/.CJ,YYY;UH#;1AK"S]_(94K
M>1K,)?[05)N1<LEXMQ23(FHBY*+LQ.R<3,(BH2E(:X_M<VS6O9<T]9;4D2\;
M0W&\DA.BW*MF#T,<PEWUI=34R^(BHY#P\XA-12TR;\.A M4WZ$*K5*U1JX%J
M%.!"ZS5ZZ/CB@8$+#9'BQ8^*CR&(L.)'0AIIM./&I7B3Y3CBENN*6ZM:U=JC
MQV(C#4:*RVQ'8 6V66A0&VP%,D$1%$1$3\JYJN:JJU\[[M=KG?;E-O%YGRKI
M=;E(<ES[A->.1*ER75U..O/.*1F2KP3-<A%$$4011$R#E:L?3BE.*4XI3BE.
M*4XI3BE.*4XI3BE<_)OA%])%Z[L]_6P^R[#N&M:Q<[/-J4.&PS'4,JE$U]>H
MUA)'1[QUB#2R3.UM>#Y9X;"/$Z[)-$'#5<C8K-@0/5'++BO,O;_;M_)_56'@
M/";ZBGD*\+)TV[1#IBNNY52 -=,6_9$S9$5A@R0I%6J]:%$1UG;13DS+A#(P
M;*@N1@1V!<:MKL+K@J.IDJY]Q.VO#]EK:'M -!9,X"*@;*68C6J[U4O!B:\*
M%R58DZRN6:3L8Q9A@59(L#!4?)"IVZP$)D)MR/K785)V%&CRJB8D%(*FE?ZO
MBSSYLL_VX+5#0N]U1MM*W#L<I1;2+J% [":&T/2VARQY>T7]SLIK?JK;M2'I
M 65($0JPY8[+VJJ=8?$S#,O 2%%2</3QOG"@X*IES?&BK\F?^58$0\*+HENO
MP+L$ 7R3KZ 9+C;M9B]<F!,@T ^F5\[L$A  2AHC-.W09J^H1%D0!/%8#L*F
M%(\>T2[ .&5RP*CI7/+A\7%/^;3][CW:HY'?CJ!KX]N;:QL!>J;;1H&9$V42
M+!X2R9L'HLGO(47A#(T6WDA9)VA2=8[4=2-#X;*GD/1UUN+99)-EI"H9+P3N
MKP^^B?\ C]N?>M:[M:DMETK=(@5_8L<C<[[N;7-))$ZV-A!;?;>OFUA^G=N0
MJ]-6?6],<J5CDF"ZVEQ6)Q6DTN]V\'$)!:F5D,J*BI^3/+M9IFG_ )[G,O&L
M2V/X1'KMK"W6ZD%D7,Q:*7.>@$A]7!B"F7UP:YN.T%E193E@AQ8Z@PW1FQ?6
M$$N^**^>B#%0Q\N*=&RI"F2_M][N?;2JJC]ZZ#L.\[0A56OFS&J]9Z4L>V5[
M%&QYQ O:Y]"VEM+5&QJI6M>Q1R[%)DU2SZHL >.X]YDG9#C3\,,$=')&&#*B
MHJ<.W_GDJ+GS9+GW:IJUX0_KQ>Y>(-(B[ O4J:5G5>OOT^F_A2 N%V$ZOB;J
M*:_J=Y#$9U!-W.-J<DU>1P1BTX7:Q.",6DNV4P),"X*F2_M_7]I5[OW\LTJR
MV;PF76"L39H^2]>2*X@4S;)2Q52;>8SKP"2W &G["QF44AJ>K'I6@MP(B14M
MJM,YFDOKAUIY)VJ8/*9+_A]_N?U?%QYZLJO"9:7'6/8KMD&%!6L*D+U>5IU^
MC/0R$Z]#KXO>F#-BAU)2X9*%7*[#T@8(1?1'BUG-#)R9B*S$2A#+JHZ>;NYJ
MF7QIEPSYNW6XZ!W5U/LF[4NB!Z]L4>;V-G8KFO9%BK8P6.N4#4=I&5/9A0!*
M6?><D0:8;(P\%\.L1YBHV$3H$2:P[#7(5!47+/[6?Q9\4SK#3_A&.O\ 7IJF
M)(S:TD9BQ7T U:8^NR+%2(,:ON2Z#?K"$L)62-@V(+6+1%)CR;5>64L#:!N9
M: 2XIBL/'5,E^+FS_J_S3XOCX+6N5>%'T\/(7HJ:J-TSK$,)KEFH-WK<./8I
MU\I<[2NRM^V.\.5C#P^<! "-:ZJMMC%0E/DK,?@P&HK(&+928NM2E,ESR_;G
MR^_QX?;^+C5\LGA.^O@4H,;'J.F KE>-W4G,;%$6"TFB1WKT*J]OJ K$%^&<
M&6VQ:SO@V'%.F:D8BQ*S,(O#5IG XY532O<_;A_FG#GK(!/A&]'$C,X;)"7X
M&.@6&BTB18#D&L0!,2_W>X[MH2*>3E*M:XPR8+MNA[=6DE)$G(2S66;6JY2R
M%C,VBLPS2HZ5^WS\V?:3/N=Q<_Z\LEJ?W%2TXI5+.@PBD*8,)PXI$:1BR()
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M!*6RP:8@"YDK B&03DE>A$XTZN>I#!74S?)!'6)+R<T(#['(T5'T)40T$")
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M<XS))J9_M^W<JRR^LO6^?*+SI_7[24Z;8"MA.'9<W55%ER3)JW26)EK+%'Y
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M...#2"!D4G1;3 >(2HT>&B6-0QE[SA$6F;D&L68U?2.K;\=>5"1QT)JVMDZ
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M:<=<2UDNMT'6P64V@1Q%\9(,M(,)/J;1B0,$YK<;95&Q+2.2WEPV+XFN$&!
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M.47$[#G);/%N8/@J;RX,2WM\CT-R1&F+&C-6]YA@A=.2 .O AN$)M-./(8-
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M9G(Y>TN27X\RH;5UQK:="$21*U@-/B,>==A21XH(IFG#AS+G]O@GQ?$J_?\
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M'AR/B>%;+C;8,2=87;?AQ6&F4E0IX,R MTRXNM6J,9G$<?-XTCO+#)Y^0ZS
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MU:_D;+%6H*NB:["1]0 F(^LWXMU,$K)20[E7A6^U5^CV>PS77VS,!"H*O/\
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M98Q4*<WK,W>GWV7&7+>[$NB@A1GD49+\.:$8-TZPZ#9C,-@H[C32M,M(RX:
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MO?)_^G?O-[+_ &QUC\'^=3ZCN%_?E[\9@>C:^8/M@&VCO!LW\C8E];Z?)_\
MIW[S>R_VQUC\'^.H[A?WY>_&8'HVGM@&VCO!LW\C8E];Z?)_^G?O-[+_ &QU
MC\'^.H[A?WY>_&8'HVGM@&VCO!LW\C8E];Z?)_\ IW[S>R_VQUC\'^.H[A?W
MY>_&8'HVGM@&VCO!LW\C8E];Z?)_^G?O-[+_ &QUC\'^.H[A?WY>_&8'HVGM
M@&VCO!LW\C8E];Z?)_\ IW[S>R_VQUC\'^.H[A?WY>_&8'HVGM@&VCO!LW\C
M8E];Z?)_^G?O-[+_ &QUC\'^.H[A?WY>_&8'HVGM@&VCO!LW\C8E];Z?)_\
MIW[S>R_VQUC\'^.H[A?WY>_&8'HVGM@&VCO!LW\C8E];Z?)_^G?O-[+_ &QU
MC\'^.H[A?WY>_&8'HVGM@&VCO!LW\C8E];Z?)_\ IW[S>R_VQUC\'^.H[A?W
MY>_&8'HVGM@&VCO!LW\C8E];Z?)_^G?O-[+_ &QUC\'^.H[A?WY>_&8'HVGM
M@&VCO!LW\C8E];Z?)_\ IW[S>R_VQUC\'^.H[A?WY>_&8'HVGM@&VCO!LW\C
M8E];Z?)_^G?O-[+_ &QUC\'^.H[A?WY>_&8'HVGM@&VCO!LW\C8E];Z?)_\
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MV(V<824>32C;+LI QNN/3;!:MW!O9]*(QB]5+1;;K&-LZI*IU"VB/ZW!;.8
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ME21"DN7&UQRM)V:7!L_+R)=3SL^,K4AJ.3C;W,7FOUV"IB^#XNU6UMW?ZL[
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&%*<4K__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>g428534g64p61.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g428534g64p61.jpg
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M 0$! 0$! 0$! 0'_P  1" $+ F8# 1$  A$! Q$!_\0 'P !  (" P$! 0$
M          <(!@D$!0H# @$+_\0 7A    8" 0 $"08(" @+!P4  @,$!08'
M  $("1,85Q$2%!<9E9;5UA4A4U:8U!8T-5ATD[/7(B,Q=7B4M+<V-SA4=Y>V
MTPHD)3(S.4%1<G.R)F%C<7:UN"="0T1B_\0 '0$!   ' 0$
M  $"! 4&!P@#"?_$ &@1   % @$%!@X)#PH$! 4%   ! @,$!081!Q(3(3$7
M05%6E=,4%1884E5789&6H='4U0@B-51Q@9*4UB,R,S13='63E[&SM+72\"0V
M-T)S=G>RML$F1'+A)2=B\3A&1Z*W0V>#A*;_V@ , P$  A$#$0 _ /?Q@ P
M8 , & # #19PPZ4!.KO*Q>+_ ",?"4RQ+:\[CM168YG )(6IR9>[(VF!3!69
ML)92XHL)*&+R \00.  D,SH9IQTB5N6T;DL<TTN'7*.T:DJ@17JA"01FI)G'
M;4Y+CI+$S29XK?9+$T'BZV69G)1R/DNR_H=NVMV!>\M+;K=QU>#;5>?42$/(
M14Y+4:CU-Q6"4O)226J?,69$^1(BR#)\FG']Z>:N'7 8 , & # !@ P \WW
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M9E:6W7T16E.*:;6LC0E2R+ E*(R(]9C2MZ?>I?S?K%]J8U]WS96Y14.VT/\
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M91K]*WXTHTQOC<;;S#2MKW9?LH>]:V,I(A2%*7-S4HVQ&K5DW2CT>=7)S4"
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M5<R;V]S=1RIF)=G&OHRW3"8-C5IUM5()>Y,T=>&E?MO(T)6XF.:)N:"7!S/
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M<VD,1'6(\TGCBNJ?J,.&HG28=9=,B;D+4G,=0>>E.)FG$C\]/IZ^2O=#1O\
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M?R?R9<!C(VUM/23OL_X+7+Q1O)6XODL'%XRDJ>PCM'+ESTB9)M%7,Z(S$_\
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M'BJA&J-';Z+>(JSRN\7)YX^-=:.\K'.WQWG2^9;<'P4C<)=7S4-*A8'J$+)
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M+E5E;3[W0ZT1WY$"'(=AMOZ(I)I)+:L5)QAO+B,6# !@ P 8 , & # !@ P
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M !@ P 8 , & # !@ P 8 6.IOD4]TO75SPJ-H'$EYMLB DDR]MD6VA5%_P
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MH[A)=9IK+U1DNQJK-3[9#E0<;4AV&P><F E27G,9QH3"W59K4=3A@ P 8 ,
M& # #1_P0Z+M%!['D7)7D0T)7&;+)M(Y#5U=+0%*T$-3*7U:L:YA)RM]80KE
MQQ0RE;&TCZQ/%0"*<%FC)-L@F-;/NJ^52H;5%H[BD1DQF6ITU)FE<A1-)2N.
MP>HTQR/%+KFHWS(T(P8Q-_D_)!D :I%<G7W>L9M^K/56=-M^B.DEUJEMN3'7
M8]3GI/.0Y4UI-+D2.>*:<1I==QGFE$'>!FL!U@& # #S8+?QQ7^DG_M1Y7IV
M%\!?F'@K:?PG^<<;(B VA]'K^0;-_G>-?V)VRF?VI^ _SCU1L/X?]B&Q7/ 3
MA@!JOZ1WHXHUR[C1\^@)#;&^0L;;=@:78>BT;;83:C+WLB)RP_6M  K #74Q
MR1G>$QL,V!O<!C9Q@&VYW9MY/6^\426:WJ0\O%:"Q4N&M1ZY$<MIH,];S)?7
MZW$$3N).<]9<<AT#*5!76:,AB#>D%C"-)/-:8K3#23-%.J*R(B)PB+-A358J
M849,O&<8R-FO/0:122P6!\F8=,61RC<IC=N,K0_,+NE,1N36Y(XV,I2D5IC=
M:& P ]>'6]>$LTO8#2AC*& 8KOE0?9E2Z+(CNH>8>I[CC3K:B4AQ"GL4J2HM
M1D9>#8>LAA?L2J=/I%&ORF5.(_!J$&Y8L:9#DMJ:?COM0,U;;B%$1D9&6H]:
M5),E),TF1GO6S5HZY# !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@
M P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 <%T
M_)KC^@J_[.9DR/KT_P#4G\Y#R?\ L#W]DY_D4/(7T:71I/'*-X0VY;B%P8^/
MC&X;VF3;V>@<[8<T!^PG,S,<'9:A)$TB@L2>1R-.(!IYH#F%A.TY:<G*/]"7
MI>C=";73Z>I#M7=1K/4M$!"RU.NEK)4A1'G,LJQ(B,G72S,Q#WS4R#Y").4"
M4U<MRLO1+,B/8MMGGLOW%(97@N+%46:MNG-K2:)LU!D:U$J)$5IB?>B>NYD9
M&>-,[7'H\UM[&PL;>D:F9F:DA"!L:VQ 0!,B0($28!:=(D2)RRR4Z<DL!110
M @ '0=:UG/KKKC[CCSSBW775J<<<<4:UN+69J4M:E&9J4HS,S,S,S,\3'THB
M1(L&+'A0H[,2'$9;CQ8L=M#+$=AE!-M,LM-DE#;;:$DE"$D24I(B(L!VF>8J
M P 8 , & # !@ P 8 , & # !@ P 8 , & # #&FB915^?I9%V9^;'&1P5:U
M-\P9$RD W./*GQE12)F YH][T<04Z,KBE7(%/B;3*@;/*).&>C6%$>[D9]EJ
M.^XTM#,M+BXSJDF3;R6G5,NYBMAFVZA2%IQSDGFF9$2DF=#&J=/F2ZC BS&'
MYM(=CLU*(APCD0G)<5J;%)]K4M"9$5]MUES VW"STH4:VG4HR7/ 5P\V"W\<
M5_I)_P"U'E>G87P%^8>"MI_"?YQQLB(#:'T>OY!LW^=XU_8G;*9_:GX#_./5
M&P_A_P!B&Q7/ 3A@ P ZA&P,;<ZO+Z@:6Y$\R+3=\O.:5(00M>=M"<Q(V&.:
M@H 3%QJ%(8)(F.4B,-*2!*2A'H@DDLOT4\ZMMMI;BU-LY^B0I1FEK2*SEDVD
MS,D$M7ME$G C49J,L3,SIFH<1B1*ELQF&I4W0]&/MMH0[*.,@VV%2%I(E.J9
M;,VVU+-2DMDE!'F)21=OGF*D, & # !@ P 8 , & # !@ P 8 , & # !@ P
M 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & #
M !@!^#"P&@&48'0RS "+&'?\@@#UL(@[_P#=L.]ZW_[MX(\#Q+:6LA R)1&D
MRQ)1&1EPD98&7QD.N9&1GC3.UQZ/-;>QL+&WI&IF9FI(0@;&ML0$ 3(D"!$F
M 6G2)$B<LLE.G)+ 444 ( !T'6M9Z.NN/N.//.+===6IQQQQ1K6XM9FI2UJ4
M9FI2C,S,S,S,SQ,>$2)%@18\*%'9B0XC+<>+%CMH98CL,H)MIEEILDH;;;0E
M*4(21)2DB(B(B':9YBH# !@ P 8 , & # !@ P \[O.OI8N2/&;E/9])P"+4
MXY1.&!A6VI;*XU,'!^.W(Z]BDK7>7*VJ?,B WJW)\6%)>H;$W5HP)RC>N. 8
M>;M^UK"HU;H4*IRWZBB1).3I$L/QT-%H9;[",U+D1U98H:2:L5JQ49F6!&1%
MQ/E>]D9?-A90J_:E&IUKOTVEE2CCNU&!4WIBNCJ+3JB]IG8]9B,JS7Y;J6\R
M.WFM$A*L]1*6JHWIVN87U(X]>QM@?O3S(-RVW??-7^<Q/01K;KO,IO:FRN2Z
MU](0].US"^I''KV-L#]Z>-RVW??-7^<Q/00Z[S*;VILKDNM?2$/3M<POJ1QZ
M]C; _>GC<MMWWS5_G,3T$.N\RF]J;*Y+K7TA#T[7,+ZD<>O8VP/WIXW+;=]\
MU?YS$]!#KO,IO:FRN2ZU](0].US"^I''KV-L#]Z>-RVW??-7^<Q/00Z[S*;V
MILKDNM?2$/3M<POJ1QZ]C; _>GC<MMWWS5_G,3T$.N\RF]J;*Y+K7TA#T[7,
M+ZD<>O8VP/WIXW+;=]\U?YS$]!#KO,IO:FRN2ZU](0].US"^I''KV-L#]Z>-
MRVW??-7^<Q/00Z[S*;VILKDNM?2$5)3=(GR%1<K'/ERV*8ZP3N2%1YNF$5CZ
M1V1P"61Z/LC1'@Q]W97%Z=UQR)8WLJ0\9XG4:U [>%U:%#>I*3]3D"K/I"J"
MW;[B7GHK!O+C/O*;5+CO/.N/&\VZAIM)*2MU1$6CS5M_4W"6DSQUNWENO5K*
M(_E)87!AU><B$Q4Z=";DM4:HPH<2-"*')BORY+RFW&8S:S6<A3K,G^41E,K2
M@D^N7B+R]JWF)6:>=P!7I ]MX4J.=P->I*,D$)?#BA"\D6A $KRYI6[*/-87
M].26C=TI1FNK1N21S;$'/UPV].MV:<66G/:7G*BRT),F9+1']<G'',<3B1.L
MJ,U-J,CQ4A2%K^DV3;*7;V4V@HJ]%=T,IDFVJO1WEI5-I,M23/1/$6;I8[II
M6J',0DFI+:5:FWVWV&?,3S&NR55P8T1:&JMM+G(/E-Q<'L!19BI*WIE6DQ*5
MOV< PHDY4=L\2A3H'7IRR"M)Q &>(P&;6!;<&L*E3:BC3L1#:::C&I24./+2
M:U+>S32I26TDDDHQS%J6K/(R3FGI/V2^5BX;$8HMOVM(Z75"MM2YDRK);;<D
M1H4=Q##<>%IDN-MO275NF[(S#=8;903"D+=TC<!\:N1-A*+$98;+GU=*624*
M#&\ W4>E;@UN B#34BI*M$'RD9!AQ8$RE,>:80 DW9Y(2S"MZ,R>\K1I**1(
MJ-/C-P9,)*75$SBAE]G/2EQ"V\302TI4:T+0E*C4DD+,TJ(TZ@R#9<+VD7O2
MK6N:KRKAI-P.NPVUU TOS:?--EUV-(8EFDGULN.-)COQWG'&D-N:9DFUMF3O
MJ)Z/7\@V;_.\:_L3MFBW]J?@/\X^A:-A_#_L0V*YX"<, & # !@ P 8 , &
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M1LMFI28D1"C9BM*-*36ZMYY[SN7_ $2R76E))4N!K&_LBM>)G>BDP5@ %*S
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MZ!.CU_(-F_SO&O[$[9K=_:GX#_..GT;#^'_8AL5SP$X8 , & # !@ P 8 ,
M& # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P
M 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , /%%
MTN?_ %@]^?\ @JO^Y>N\Z5R??S1I7PS_ -I3!\J_9*?TT7C_ --N_P"EJ(-B
M_P#P??\ &.6/_DT=_P"NW<P_*ULH'PU3\U.&[_88[<HWP6E^>Y1Z1LTT.Y0P
M 8 , & # !@!C[5%(TQO,GD+0QMK>^S5<W.4L=TJ4HMQD"UG9D,>:CG17H/7
M*ODUE;43>B+&/928@H74E@&>>,WV<D/NML,N.K6U&0M$=M2C-#*7'5O.$VG8
MG/=6I:C(L5&>LS(B(J*/3H$25/FQHC#,RJ.L/U&2VVE+\QV-%9A1U2',,]S0
M16&F6DF>:VA)YJ2-:S5D&>(K1YL%OXXK_23_ -J/*].PO@+\P\%;3^$_SCC9
M$0&T/H]?R#9O\[QK^Q.V4S^U/P'^<>J-A_#_ +$-BN> G# !@ P 8 , & #
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M .#[_C'+'_R:._\ 7;N8?E:V4#X:I^:G#=_L,=N4;X+2_/<H](V::'<H8 ,
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MWHF-IYN1M*>22<0TOZQI;UR97L(-E/ %A9WC(1(ULBU&G-/5@9D1ZC,]>S#
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M_P 'W_&.6/\ Y-'?^NW<P_*ULH'PU3\U.&[_ &&.W*-\%I?GN4>D;--#N4,
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M">I3Q1_.BRAT,<S>I+$X/!ZB*DG:<1=5LLQZD@@DZV\'>)*2$EF_^DL"^/\
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M? \8H8FELZB#7/>449BLH65Y-I-7[^Y1XVJ;B>#F@4AB3FTNY:$YR9VM8<F
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M@]<2;WWC2+[(PS$\'E/SAV4./G=N@]<2;WWC2+[(PS$\'E/SB@_,ZK8%6+I
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M\K<1OZ8=:_[$V=F16_\ 8[A_N[,_6X UGE(^V<F_^)E"_95?%P\QT;,# !@
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MD18$1XF=O\Z:&D@P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 ,
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M<1OZ8=:_[$V=F16_]CN'^[LS];@#6>4C[9R;_P")E"_95?%P\QT;,# !@ P
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MFV0]5RT@'$5Y)$[-:5W9&AV;IA9,=D0F$#J[.[6VD/L;G26#3EE51K8"29^
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MB\980;6$Q=HIJ.&M9[IU\D&O'*3GE>J)/;$S<!22+8>/ME)^3AK\HW!8$H8
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MW #\A65_.T;_ +&[9WS[#'W)OW\(T+]6J0Y.]DC[HVK]Y53]/#&PK.UQS0&
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M!W*,H'XVR?IB/D?RELI*2:I4\)^3J=.06,X\\]?QU*))*+#L9AIIIE]! 66
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M)H$ZA5UBOP*A%B0IRT2F*?4J<3:XT]MV*MM353>4>D;7@I","VF(Y\Q7)_\
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M[9WS[#'W)OW\(T+]6J0Y.]DC[HVK]Y53]/#&PK.UQS0& # !@ P 8 , & #
M!@ P 8 , & $<7'_ (HK4_T<3C_9ATRLIWNA!^_(OZ= L=S_ ,VKA_ =6_4)
M POBI_DO<;O] E/?W>1W*JO^[M:_"U1_7'A:\GG\P+&_N?;/[%A">\M(S ,
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MGH6KXL!TD=IWA%#U38MB/%;GI%E;)()A)&=4P5?RJ:UC8OG=.02A)&2D7)E
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M & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@
MP 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 ><=7
M^-JOT@[]H+/AO+^VY7WP]^D4/J&Q]@9_LF_\B1Q\IQZC9MP _(5E?SM&_P"Q
MNV=\^PQ]R;]_"-"_5JD.3O9(^Z-J_>54_3PQL*SM<<T!@ P 8 , & # !@ P
M 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & #
M !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8
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M B>CO$1FA9$1D9*;<2AU#C:<RS*!8PP 8 , & # !@ P 8 , & # !@ P 8
M, & # !@ P \XZO\;5?I!W[06?#>7]MROOA[](H?4-C[ S_9-_Y$CCY3CU%[
M.'MOUS6+3.4TYDA;">[N+(>W &VO*_RDI(F<"U ]":VY<$OJQGE:WHX18A>/
MX0:%K0MZZ^]C%E+L>P:==S%W5UNCNU*;278*%P:G+T[<9B<A]1'3X4M*,Q3S
M9&3IH-6=BDE$1F7/&6^R;GNR;;[MOTI=1;A19[<E294*/HEO.QE-I,I<F.:L
MY+:SQ02B+#VQD9EC<OM8<?N\,CV=EWN#.I>N,R,<=F.1KC]3C1>XYE)XLN\I
M4;UB':PX_=X9'L[+O<&.N,R,<=F.1KC]3AN.92>++O*5&]8AVL./W>&1[.R[
MW!CKC,C''9CD:X_4X;CF4GBR[RE1O6(=K#C]WAD>SLN]P8ZXS(QQV8Y&N/U.
M&XYE)XLN\I4;UB':PX_=X9'L[+O<&.N,R,<=F.1KC]3AN.92>++O*5&]8AVL
M./W>&1[.R[W!CKC,C''9CD:X_4X;CF4GBR[RE1O6(=K#C]WAD>SLN]P8ZXS(
MQQV8Y&N/U.&XYE)XLN\I4;UB':PX_=X9'L[+O<&.N,R,<=F.1KC]3AN.92>+
M+O*5&]8AVL./W>&1[.R[W!CKC,C''9CD:X_4X;CF4GBR[RE1O6(=K#C]WAD>
MSLN]P8ZXS(QQV8Y&N/U.&XYE)XLN\I4;UB':PX_=X9'L[+O<&.N,R,<=F.1K
MC]3AN.92>++O*5&]8AVL./W>&1[.R[W!CKC,C''9CD:X_4X;CF4GBR[RE1O6
M(=K#C]WAD>SLN]P8ZXS(QQV8Y&N/U.&XYE)XLN\I4;UB':PX_=X9'L[+O<&.
MN,R,<=F.1KC]3AN.92>++O*5&]8AVL./W>&1[.R[W!CKC,C''9CD:X_4X;CF
M4GBR[RE1O6(=K#C]WAD>SLN]P8ZXS(QQV8Y&N/U.&XYE)XLN\I4;UB':PX_=
MX9'L[+O<&.N,R,<=F.1KC]3AN.92>++O*5&]8AVL./W>&1[.R[W!CKC,C''9
MCD:X_4X;CF4GBR[RE1O6(=K#C]WAD>SLN]P8ZXS(QQV8Y&N/U.&XYE)XLN\I
M4;UB':PX_=X9'L[+O<&.N,R,<=F.1KC]3AN.92>++O*5&]8AVL./W>&1[.R[
MW!CKC,C''9CD:X_4X;CF4GBR[RE1O6(=K#C]WAD>SLN]P8ZXS(QQV8Y&N/U.
M&XYE)XLN\I4;UB':PX_=X9'L[+O<&.N,R,<=F.1KC]3AN.92>++O*5&]8AVL
M./W>&1[.R[W!CKC,C''9CD:X_4X;CF4GBR[RE1O6(=K#C]WAD>SLN]P8ZXS(
MQQV8Y&N/U.&XYE)XLN\I4;UB':PX_=X9'L[+O<&.N,R,<=F.1KC]3AN.92>+
M+O*5&]8AVL./W>&1[.R[W!CKC,C''9CD:X_4X;CF4GBR[RE1O6(=K#C]WAD>
MSLN]P8ZXS(QQV8Y&N/U.&XYE)XLN\I4;UB':PX_=X9'L[+O<&.N,R,<=F.1K
MC]3AN.92>++O*5&]8AVL./W>&1[.R[W!CKC,C''9CD:X_4X;CF4GBR[RE1O6
M(=K#C]WAD>SLN]P8ZXS(QQV8Y&N/U.&XYE)XLN\I4;UB':PX_=X9'L[+O<&.
MN,R,<=F.1KC]3AN.92>++O*5&]8AVL./W>&1[.R[W!CKC,C''9CD:X_4X;CF
M4GBR[RE1O6(=K#C]WAD>SLN]P8ZXS(QQV8Y&N/U.&XYE)XLN\I4;UB':PX_=
MX9'L[+O<&.N,R,<=F.1KC]3AN.92>++O*5&]8AVL./W>&1[.R[W!CKC,C''9
MCD:X_4X;CF4GBR[RE1O6(=K#C]WAD>SLN]P8ZXS(QQV8Y&N/U.&XYE)XLN\I
M4;UB':PX_=X9'L[+O<&.N,R,<=F.1KC]3AN.92>++O*5&]8AVL./W>&1[.R[
MW!CKC,C''9CD:X_4X;CF4GBR[RE1O6(=K#C]WAD>SLN]P8ZXS(QQV8Y&N/U.
M&XYE)XLN\I4;UB':PX_=X9'L[+O<&.N,R,<=F.1KC]3AN.92>++O*5&]8AVL
M./W>&1[.R[W!CKC,C''9CD:X_4X;CF4GBR[RE1O6(=K#C]WAD>SLN]P8ZXS(
MQQV8Y&N/U.&XYE)XLN\I4;UB':PX_=X9'L[+O<&.N,R,<=F.1KC]3AN.92>+
M+O*5&]8AVL./W>&1[.R[W!CKC,C''9CD:X_4X;CF4GBR[RE1O6(=K#C]WAD>
MSLN]P8ZXS(QQV8Y&N/U.&XYE)XLN\I4;UB':PX_=X9'L[+O<&.N,R,<=F.1K
MC]3AN.92>++O*5&]8AVL./W>&1[.R[W!CKC,C''9CD:X_4X;CF4GBR[RE1O6
M(=K#C]WAD>SLN]P8ZXS(QQV8Y&N/U.&XYE)XLN\I4;UB':PX_=X9'L[+O<&.
MN,R,<=F.1KC]3AN.92>++O*5&]8AVL./W>&1[.R[W!CKC,C''9CD:X_4X;CF
M4GBR[RE1O6(=K#C]WAD>SLN]P8ZXS(QQV8Y&N/U.&XYE)XLN\I4;UB*_\F[]
MJ.?5&\1J(R\IX>U3DQGD(0L\A1B,*2.1!Z@?7N#2D2AZLH A[",\(A>#P T(
M7@UFE\OV6/)M>636IT*VKF:J=6D3Z2\S$13:S&-;<:<T\^K2S*=&83F-I-1D
MITC5A@DE*,B&RLDV3F]+<O2%5:U1'(,!J)4&W)"IM->)*WHJVVDZ.-,>=/.6
M9)Q)LR+'%1D6L4KI>Z)+3,E [M Q+65:(HJ11TTT0$;LC +?@&#?@$%*Y)0B
M&) O" 0R1B$4:$Y(<H3F\J9*\JE>R6UY-2IJE2Z5+4VW6Z(XX:8U2C),\%)/
M!11Y\<E+5#F)0:FU&IMQ+L9UYES?%^6'2KZI1PYA%'J$<EKIE30@E/0WE%]:
MHM1O1'C))2(YJ(E$1+0:'D-N)W60.>1JR(T@E457A7-BX/BC +Q0*V]6 (=J
M&YQ3Z$(25<E$+032A;$$01%GD&')CB3C/JQ9]X4&^J##N*W9B9<"6G!23P3)
MA24DDWX,Y@E*./+CFHB<;,S2I)H>96['=:=7P9<5NU6UJK)H]8C''EQSQ(RQ
M4S)949Z*5%=P(GH[Q$9H61$9&2FW$H=0XVG,<R@6,, & # !@ P 8 , & #
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M5>>1(K+<",FI/-YAI7+)M.E/.;2EM2B5J6MM)(6LE+01)40Q/,<%Y# !@ P
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M49XF9F>LS,]9F>LSUF/UDP@& # !@ P 8 , & # !@ P 8 , & # !@ P 8
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MC,U*49XF9F>LS,]9F>LSUF/UDP@& # !@ P 8 , & # !@ P 8 , & # !@
MP 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , &
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F+ 8ZI2E*-2C-2E&:E*49FI2C/$S,SUF9GK,SUF>LQ^LF$ P _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>g428534g73e11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g428534g73e11.jpg
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M 0$! 0$! 0$! ?_  !$(  T D0,!$0 "$0$#$0'_Q  :   " P$!
M       '" 4&"@0)_\0 )Q   @,! 0$   4% 0$     !08#! <" 0@3%!46
M%P 1$E>7UAG_Q  6 0$! 0                   0+_Q  J$0 ! P($!@("
M P         ! !$A,4%187&1@:&QP>'P M$2\2*RTO_:  P# 0 "$0,1 #\
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MADX(#*;&(#GZD-0X(%$J)'8#7Y#D%TH&>O(?CY[W@@Y)!-\.*J)G+YS7RO\
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DH:A/9%7Y:E3JN03&)'O5>,O_ ,R^/]U]?\Y\_P#=_P!%%__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>g428534g89q11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g428534g89q11.jpg
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M 0$! 0$! 0$! 0'_P  1" &H AX# 1$  A$! Q$!_\0 '@ !  (" P$! 0
M          8'!0@#! D" 0K_Q !2$  !! ("  $)! 8'!04&! <% @,$!@$'
M  @1"1(3%!475973%B%6E"(Q4U32U",V06&6M-4R4723M20U<7-U&#-"=H&S
M)31B@B9C<H6AP='_Q  = 0$  04! 0$             ! $" P4&!P@)_\0
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M^M>ZFP;3W6[-:3DE$)U'JWKXWMFK2;'J:Y!-@!#DMJB27HMHJGL\3<2$ /\
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MW&C/SZ^BL35-E:DDAB- K&8C-!RT[2(I#R&011QA"Q#L_P!\;M6/N!)&@O\
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M"7D42<'W05)5F]U26\LR6^J-)1>Y'8MN)-=6@M[%(JER=Z%:RI>&6XD%>1X
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MIQ'5^KO)P4S,P<=/U;M1JV-+F.NO!0Y>Q-,N2B4E+F6"<H0&F&GI"VE9C$I
MT>ZWA;4UUG*7=CT],MFSU!-PR)+K;)  #NL9/"CCE0[A..?-0S?C'/.<]Z0*
MDFMUO0-3OCFGK=2:U6<EH89; !:1N>)6BA>8L0>V1HXR.0Y'!G.P?)^[E[%;
MC[I[FN<D'IY>\-!P=$:MK#%BQ9YV71JZ,5<M-\( HB8,401+T.&/;&CG"Q#
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MO;*UP/@7GAM:Z#S'F5%7R^ <\<GK8>DZ:J/'L6)'_&8_#B3_ %*R2M_K[_\
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MG^NQ[R+K\<<_)#?Y/C^WIZ5OUMF^JM%_"\>S^G^9CZ:S_78]Y%U^..?DAO\
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MY;C'&,D%3_K17/\ UP5_GF.=EZ.O\8'0_P#[W=.?_-Z>0=G_ (-O_P#<[/\
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M,M>&S<J5D<A9)5-UY8V=(%2=XT-&:NVK50)%J>M&9E*J UE6\HU8@E4=B/,
M]@! +>[EA67K5MRD]L>RMZ>ZJ:3[?Z9[0SZ%;1Q&\GJ$#N>H;16M95O5=CJ5
MGC[!JE@^T>M; .J@@R-<JJIT\'EPK"=JQ5R5Z9S75>I-3<Z3Z;HKU5N^D-ST
MO'L*DD=&"_-3W%6UM+6VK6ZK:^W7]6V=>2Y-#(+02.QQ"XMPA.T9&K3);L/Z
MK!;AM%'!=D5X76)(F5_$1NZ)@@8=G)7S'8>>3Z74JL$*7JL)5!H*EU8C7ZDD
M6)J^M0T8)0ZR]%@N-BJ[3Q,EN!$9 @L8C"ABGX8>-,CQ$2W!05J1D;#\TNV4
MN;.Q:DGNVDL6VEEM;*5IK]D/)W2V;DJF1FGG):64!YF1G*>-.R^*^Q12D2H%
M1"J<!8E"QKP/)44\#M7R \E!XYX4'@>;PO3VS2A&%9-Y]3MK]H;=!DLSXA#>
MW8311^F!R+"\/1YM5TJ!?KND:O-@/82H<<&:\Q;FD-1LS;,0DQTRL^D2[;61
M1O7T?5FIZ8J.IC>/1=/[ZO<FC8<,EK=3I9WEJ.0<^+7EV)IDEO#JQ(Q3->(9
M"0T]66TX/(,\\#(#^(K"O; A'XF$?>/QL3YYN9$VION-9A0.9U*.MTPA2H)!
MNS5[;NI)[M;MRG93$JE6>KEC-8<C"X,9B(]'L]/(71F2W+2S@+&7'=3SC'U>
MB:K-,G5=<W([LD1JV-3MHUM4PJLEVK:B@M!I)&9E:K<BI,A0MXS!AS+\6<.%
M-5NPH"'66(]K\GE'5F0@ <$,AD!YXX'&?'3[KXKK-I*%K1]X-F?-O>U]DEAM
M70^U3ZR3VWLRU[*E4VF-28L!_%3IJK0FL Y+XX8^3ABD%WQ0I\@X-BUZNZ@]
MI=T^R F[$H:G6Q26BIN68M1JZFL2Y=96D4V[HJ>M6%$DJQ22F%9I5C61E2OZ
MM"(^1R7ED(7GL0RR-(40'CW$[NU?(<@=Q4$D#:#G,Y)QQC-O]?\ ]30/_"+_
M ,R_S],O0S_BPZ/_ /#9/^-M9Y9O/\*W?^U'_EIDQYZ=FJQQC'&,<8QQC'&,
M<8QQC'&,<8QQC'&,<8QQC'&,<8RD]U?]W@O^,E__ &&N?*/]E3_@?I _B^Z6
MT_X6M_0?]F=?TC_?[G_91?\ [VS7OGQ;G<XXQFO]YT5+LVUPNY:MMG8FM;8)
MHLR@3A=93425+N05TXBP"_MO6K76#WM.37"#A-5>(!2%=,#&CIV/'*IBEIT>
M1OJ6\6MJIM/:U6NV566\E^.6UZY'=I3B$UY?4K-2U7\-+,8B%B.:.Q#*U>N[
M1%X8V7 \'=*LRRR1N$,9"=A1U[NX=ZNC<E3SVE2I'<PYX)YIN-T-UUD?V7(%
MKUL@GMCMA*H\[:6[(L^OUZ]CI&K84*!JE&O6:]7AM<IK&LT06)52=:"D"_M3
M&2M@+'R&$2$;E^NMEW]-114=;'JNE$O1ZO2-%8L:^1=I(\FV.P-BS)9N-M/$
M9+BM8CA\+B&O#7BY0X11C_NEB\AEM&,RS JL@\( 1>'VJ%3PP!VGM+$^;,Q\
M\SMRZ>C=L6'3)+=^VMA;<KV@]DU_<6OZD=%ZYK\&?M*H0R$2GW:]3Z52:Y.L
M1"JJ*SYP@8)75ZT\0?Q(.@S>&(S;$>EU?+J:^ZBTFJU^IGW^ML::_;@DV-B1
M-5<>-[E&DEZ]9CKQVQ%''-+,+-H1J5@G@[G+7/4$K0F:6258)%F1&$2@RH"$
M=RD:EBO<2%!5>?,J>!QLEL.FN7ZI$*LQ;+51I,R6$GP[92I F-9@LT >&6&%
M)&+/A[ #=])+%,QIL0N#*C9X]^7!FP9$>0XC/.4+@HVH[+5*MY42:-ZEU9FK
M3)/!+7=9!7FKS@A92T;PSQ2QR*DB.K*#DB1.]2O<R$E2&0@,"K!@1W*R_$<$
M%2".01P<U#V!Y._0FVF^P$K939PO9.QX+6 .\6NM+$T$T+?TR9+V36MMJSU5
M%PDP]@5ZQF'C:KF8P=*3GH@X._G%3@1:VWUNO](.^U!Z?77-!%7Z;L;2>C5L
MB6]#*NZAAK;.G:6U+)WZ^S6@6#U*'P(D5Y)E_NR1[31)*$$WK'B=Q:RL2R.G
M$;#P6+QLG:!PZL>>]NXG@*?< 7)M6>HP]_7MSUMOO<VWNU=?N]',ZT)L;HD4
M* Q&HI^*B$7%L0=3T36L(@:(L,Q52;S8F3MY8DQ_2B+$);DS&)$*SU9(-C2V
M>ATVHZ5LT;T.SB;2KL)&-Z!_$AE,FWO[22.&)BW91K-!096[9JTQ5&6]:@,;
MQSS2VE=#&?&,8'81P0!"D0)(X^^-W2<_!QR<ZM?Z:5.(!T93KOL38NUZ1UML
M5;MFHZW>W:BYF#8Z,*EAM=&[@9K]5!%[P3US"F+S4WRLIII9)B!8K5'M%J&#
MCT6^QUC<>QO;E+7Z[57>I*UJIMK%!;8[ZU^99MC!3AL6[$-*+8N@%M8D)$1D
MK5&JU)9:[EJ(%@1Y))4KLKQ+)V>31@B-G*HK.T8/NECYL [=S@-GWJWI;KK7
M%;[/4LK9[KL^F=N-@[*V1MRL7_['X'/F=MUH54+P,".TVI5&?!KY*N!H(UJ!
M,F$I$1*79#,[$EYQY5-IUGLME9Z8NQUZ.LN=(Z[6ZW46M>+@E6+4VI;E&:<7
M;EV-[,5F:24R)'$C$A6C[5"A%3BC6RA:25+<DDDRR%."TJA' [$0A2J@<<GC
M\O/GF/T!TW?T/ J=4=[*]B=L:PUNW#C:QUALTMK9\%480AK#%=B$+'4-:U+8
M5\BU2.EIBKCK]<;$$%8ABYF!+Y8($)#LF_ZP7?26[8Z;Z>U6TV3.^SVFLBV:
MSVWF/=9>.M<V=O74&MMRUJ37TJTTO?,AE$-BQ%+2"GX 1/6;$L48 BBE,7:@
M7\'EDB21PHX"B1V4< \%@I%R;KTJSN6)3TM7<WKPW1K/BUUZU5NE:5N)T<3P
M,G"O/&>^S5>UA0&1F//=S[7K@L/8<)PJ(DQ@=)G0Y6GTNY;3O<)HU]C!>JFI
M8J6KF[J5Y8C+'+Q+]Q-MJ)IU[HU^\V99J_\ EF$R+&Z9IH1,$]]HV1^]71(7
M8$ CR\>*8*?/\)0K?B[N"08U5-(;6K]C#FC/<;L#>A8V:W*G5"RT[JA! V!A
M&%84.*S*9UIJEICQ'<YQEQP'8P\_&4X]%-;QE6%2;>[U=BO-!#T?T[1ED0JE
MRK:ZL>Q78D??(DN]3W*C./@!/6FC\SRA/'%JP2JP8W+#@'DHRU K?S$I51^/
M^JRG^?.:3UOKULV74ML[<L9S:EDUT0D&M8UPNT/$ZQUI8Y,9^ Y;:I1AD?&)
M]Q0/D/PAMMOIF\6&M,R9Z*@1KK9,BW*HG4=BIK;>JU->#5UMC&(-G9A,DNSV
M=97605+=Z1O<IF1%>6IKX:-:T4C-R*P8HRHUU>1)96:5HSW1J>!%&Y!!=$ \
MWX/ :1I&3D]A7D\[&\YW)&.,9(*G_6BN?^N"O\\QSLO1U_C Z'_][NG/_P!-
MO3YR#L_\&W_^YV?_ "7S=#GZG9Y+CC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQ
MCC&.,9U)\5,Z#-@JSYJ9D23%4K]?FID,K9SGP_M\,+SGFNW&N3;ZG::F5NV/
M9ZZ]KI&XY[4NUI:SMQ^/A92>/QYEAD,,T4P')BECD ^')1PP'/\ .1FD4N*_
M!E2(<E&6I$5YV.^WG]:'65Y0M/\ ?X*3GPS^K./#./NSS\G-CK[>JOW=9>B:
M"[K[4].U"WQCL5I6AE3\7(#H>"/)AP1Y$9[!%(DT<<L9[HY461&'XU<!E/\
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M1C"$N*QEMQ.$(<RWYOI,?.WIA]"*=;3/U'TW)7I]2")$N5ISX53<I"H2)GF
M/JVPCB584F=3#.B113M"$$XZ72[XT%%:T&DJ\DHR^;P%CRW"D^]&22Q4>\I)
M*AN>TT#-K-A'.J:F!232DY\/.Q$==:5G_P#EOLI<8=Q_>VXK']_/C;:] ]:Z
M2=Z^SZ6WE9T)7O&NL6*SD'@F&Y62:I.O/EW0SR+_ #YV\.QHV%#0VX'!'/'B
M*KC_ *R.5=?]#*#G1]E%/AL_\G(^GS4^SV__ $'N/JR[_49F]8K_ )^'Z5/M
M8]E%/AL_\G(^GQ[/;_\ 0>X^K+O]1CUBO^?A^E3[6/913X;/_)R/I\>SV_\
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M9QC.,XSCPSC.,_=G&<?=G&?NSCE&565E90RL"K*P!5E(X*L#R"""001P1Y'
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M2^DK]3-Y^R__ %X^[.K^?0?_ !'^C'V&MWX?(_\ )Q_%Q_:E])7ZF;S]E_\
MKQ]V=7\^@_\ B/\ 1C[#6[\/D?\ DX_BX_M2^DK]3-Y^R_\ UX^[.K^?0?\
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M'J+!0?7L8$IUE7J6VVF3I1AKJFDFW\.^D=X;;O7V"0O32R9XWLVS%!2EDK+
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MGE?2'95O6)=6)Y1/+#"ZO%ZS2:<";[G[(7=>LA?LJJLTRR6FG%XDLJ-)"U@
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M2&(/-- D:F261(HPS O(Z(O+, ;DM5I&"1V('<\\*DL;,> 2>%5B3P 2>!Y
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M!JZP1U+'C=E:1+,CR213*T2!.3B$I,SQ>%* B*_BE0(G[B1V(W<6+KQRP*@
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M:$I0A.$XQC&%V9V9W9G=V+.[DLS,Q)9F8DEF8DDDDDDDD\Y<      !P /(
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M.41X*ID1[,1A&4(REJ/EMM.4ISA.,IQX5AOWZPD%>[;@$K%I1#9FB$K'D%I
MCJ'8@GDMR?,^?GAHXVX[HT;M' [D4\#\@Y'D/YADHQC&,8QC&,8QC&,8QCPQ
MC&/NQC&,?=C&,?=C&/U<B9?D(=UCK9]F7'?U[1WH\\O*/SF':F!<9FGIJ<(F
MFY;2X&422\M&,(E$GDKF2$XPEUY>,8QR>-KM%9'797U>.%*T;"Y8#1UXR3'
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M-=WU%UJ=SI^F]32J['5)H=$FAL$;GUFOM:ZW+EWQ+%6'740C>+=D54>6RBQ
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M^2[Z3/SO37UK9_AV/:_4_P FW]"G];CW,7#]H'_.O?RG'R7?29^=Z:^M;/\
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MY;+?0!49MA-&W-362<+KXV\:XAOLD.OY?JF]I#*U#24*D:1-Q/>CC!:5U/\
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M\RJ?LT/V,?: ]\;+_,IOUN/;+J_]:NI/KS:?O6/4*/S*I^S0_8Q]H#WQLO\
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M924=DT4<<:D78F/$H5O$  C9BH3AA\,L]K26YX7=/M9O2)0@!*E[1ZN4/45
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MF&M&EAC7>$RI+,]N-)I/>4>LN/&=7K6EV$5IX0B&BU:3NL>+(LGC))W,2OO
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M%CE;;5<3JRQ)LC(R5.@Q9(T1'E&')$R.W"'R_/\ '%LNHO1 %XX^?6Q191/
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M?##*2Z]L<<P2P. 29H82>8U>.35BQ]":L1<[1#ZO=I-$I?:NGAZI=:. JP_
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M26X;TFNJO90HT[,TICL-''X8<PEC'&[<*[,JD>(H957W@UD?2,L&IN:.OO\
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M+95]S#(D\MEHDL/9BDCB[[L'@Q5JRP5VK2UXK $JKW(6=8Y!P&\5N_A.<O\
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MQ"U-QH[DF&M_$EV7)??2%K$D=6**>S;J7Y) \C*+51VD5TC;R".[%F1F?S)
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MX)2G&"SSHH5)I44<\*LCJHY/)X ('F22?+S.4DI4Y7,DM2K+(>.9)*\3N>
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ME.^E]+)+9AQF?:,AST[_ *1Z9Z9Q?IG?.5GTB_&K2ROV=\DC]@X3N=F[ ..
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M0YYY8'\C<C!J566)&K5V2!@\"F&,K"X\PT2E>(V!\PR!2/RYB<:YJ:+>=NS
MU$8U; <*NW)#7F*&7$8*1+:#)L@M]MZ'/F"(Y"?"A$DM,D%C92A,V3+%QX<.
M-=ZQ+X20EN4B=I(N?PHF;M+F-APRABJDKR5[AW@!B2<?J%46IKBQ]LUJ%*]L
M#@QVXX@XA%B)@4=HEDD1) !(8V\)V>-41<6>T[KBQ ':E,JHB+4IY$>2/U@.
M/@A@MJ4+D-S(,"S11L6,LL(1-8C2)8EYU, NTQ[,,L$0LF<-EWI;L1OXHE<R
MA65)79G>+N'#-&6)['[>0' [DY[D*N%88I]50L0&J]:):KR1R3UXD2**SX3!
MD2PL:J98@X5GB)"2A?#F$D+/&\T=KE>?08;? AGF["XTZ?;=%P7$''6([$1A
MPPE;&4DW&8D6-%:7-P^IN/'891G#;3:4X1)(.PB1P8P1&0S#L!))">?N@DDG
MMXY))^).2S7@(E!@A(G(,P,:$3%5"J905^^$*JJ"_/"J /( 9WI8^!/5$5.A
M1)BA\MLA 5+C,R%0I[3;K+4V)EY"\QI;;3[[3<EG*'D-O.H2O"7%X5:&9>>U
MBO<"K<$CN4D$J>/B"0"0?+D#\F9&1'[2Z*Y1@Z=RANQP" Z\@]K ,0&'! )
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MTZK",KSG.,YA,C(S*1^ Q0D<\=P)''/\_!X_'QFXCE25(W4\>+&LJ*W ?L8
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M$=F:IOF[!K6S ]L%%9NA::8?I3M=K( * KPF*0V0/UA+:GPHKILP%IRL6V'
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MZ]N^ 6$[X8)1+/'9@8&!RG,BP30=LLH<"=0&<Y(V73&VM3[UJ]5&AVE/J!/
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I;#84PLT,H]4N>%(H[8(H(HF$HE:2..&*/Q'9D0!N3N;S49UF.,9__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139838689878528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">S-1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Scilex Holding Company/DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001820190<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139838691948496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2021</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 2,483,000<span></span>
</td>
<td class="nump">$ 4,338,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 4,839,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">17,474,000<span></span>
</td>
<td class="nump">14,268,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">13,126,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">933,000<span></span>
</td>
<td class="nump">2,562,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,145,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses and other</a></td>
<td class="nump">10,583,000<span></span>
</td>
<td class="nump">1,835,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,314,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets:</a></td>
<td class="nump">31,473,000<span></span>
</td>
<td class="nump">23,003,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">22,424,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">782,000<span></span>
</td>
<td class="nump">805,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">846,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">1,271,000<span></span>
</td>
<td class="nump">1,303,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,675,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangibles, net</a></td>
<td class="nump">41,617,000<span></span>
</td>
<td class="nump">38,802,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">42,540,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">13,481,000<span></span>
</td>
<td class="nump">13,481,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">13,481,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term deposit</a></td>
<td class="nump">153,000<span></span>
</td>
<td class="nump">538,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">538,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">88,777,000<span></span>
</td>
<td class="nump">77,932,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">81,504,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">11,684,000<span></span>
</td>
<td class="nump">4,284,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">8,120,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AccruedPayroll', window );">Accrued payroll</a></td>
<td class="nump">1,426,000<span></span>
</td>
<td class="nump">3,733,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,754,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">23,862,000<span></span>
</td>
<td class="nump">10,621,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">10,622,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Current portion of deferred consideration</a></td>
<td class="nump">133,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">37,950,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">15,888,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Related party payable</a></td>
<td class="nump">166,145,000<span></span>
</td>
<td class="nump">92,724,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">26,664,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RelatedPartyNotePayableCurrent', window );">Related party note payable</a></td>
<td class="nump">47,108,000<span></span>
</td>
<td class="nump">19,608,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">13,008,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">717,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">424,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities:</a></td>
<td class="nump">251,075,000<span></span>
</td>
<td class="nump">169,420,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">78,480,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Long-term deferred consideration</a></td>
<td class="nump">3,517,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">72,037,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">92,255,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RelatedPartyNotePayableNoncurrent', window );">Related party note payable, net</a></td>
<td class="nump">62,717,000<span></span>
</td>
<td class="nump">23,503,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">15,403,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DerivativeLiabilityNoncurrent', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">35,700,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">35,400,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">863,000<span></span>
</td>
<td class="nump">1,148,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,649,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Warrant liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">35,700,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">35,400,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">318,172,000<span></span>
</td>
<td class="nump">301,808,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">223,187,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (See Note 8)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Deficit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value, 20,000,000 shares authorized; none issued or outstanding at September 30, 2022 and December 31, 2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value, 350,000,000 shares authorized; 197,566,338 and 197,266,338 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">20,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">128,615,000<span></span>
</td>
<td class="nump">128,654,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">122,423,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(358,030,000)<span></span>
</td>
<td class="num">(352,550,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(264,126,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' deficit</a></td>
<td class="num">(229,395,000)<span></span>
</td>
<td class="num">(223,876,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(141,683,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' deficit</a></td>
<td class="nump">88,777,000<span></span>
</td>
<td class="nump">77,932,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">81,504,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vickers Vantage [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">34,961<span></span>
</td>
<td class="nump">507,921<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">30,511<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses and other</a></td>
<td class="nump">130,788<span></span>
</td>
<td class="nump">4,536<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets:</a></td>
<td class="nump">165,749<span></span>
</td>
<td class="nump">512,457<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">30,511<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCosts', window );">Deferred offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">168,973<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsHeldInTrustNoncurrent', window );">Investments held in Trust Account &#8211; U.S. Treasury Securities Money Market Fund</a></td>
<td class="nump">101,293,086<span></span>
</td>
<td class="nump">139,410,739<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">101,458,835<span></span>
</td>
<td class="nump">139,923,196<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">199,484<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities:</a></td>
<td class="nump">809,292<span></span>
</td>
<td class="nump">208,704<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">180,760<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">809,292<span></span>
</td>
<td class="nump">208,704<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">25,760<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AdvancesFromRelatedParty', window );">Advances from related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">30,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent', window );">Promissory note &#8212; related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">125,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Convertible promissory notes &#8212; related party, net of discount</a></td>
<td class="nump">2,035,000<span></span>
</td>
<td class="nump">483,099<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Conversion option liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,892<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLongTermNotesPayable', window );">Simple promissory notes</a></td>
<td class="nump">2,971,667<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent', window );">Mandatorily redeemable ordinary shares liability</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Warrant liability</a></td>
<td class="nump">1,162,800<span></span>
</td>
<td class="nump">3,351,600<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent', window );">Deferred underwriting fee payable</a></td>
<td class="nump">5,190,000<span></span>
</td>
<td class="nump">5,190,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">12,168,759<span></span>
</td>
<td class="nump">9,240,295<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">180,760<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (See Note 8)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Deficit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value, 20,000,000 shares authorized; none issued or outstanding at September 30, 2022 and December 31, 2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value, 350,000,000 shares authorized; 197,566,338 and 197,266,338 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively</a></td>
<td class="nump">345<span></span>
</td>
<td class="nump">345<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">345<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">24,655<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(12,003,355)<span></span>
</td>
<td class="num">(8,697,444)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(6,276)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ordinary shares subject to possible redemption 9,726,395 and 13,800,000 as of September 30, 2022 and December 31, 2021, respectively, at redemption value of $10.41 and $10.00, respectively, per share</a></td>
<td class="nump">101,293,086<span></span>
</td>
<td class="nump">139,380,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' deficit</a></td>
<td class="num">(12,003,010)<span></span>
</td>
<td class="num">(8,697,099)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">18,724<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' deficit</a></td>
<td class="nump">$ 101,458,835<span></span>
</td>
<td class="nump">$ 139,923,196<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 199,484<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">At December 31, 2020, includes an aggregate of up to 450,000 ordinary shares that are subject to forfeiture depending on the extent to which the underwriters&#8217; over-allotment option is exercised (see Note 6). On January 6, 2021, the Company effected a share capitalization of 0.2 shares for each share outstanding, resulting in 3,450,000 ordinary shares issued and outstanding (see Note 6). All share and per share amounts have been retroactively restated to reflect the share capitalization. As a result of the underwriters&#8217; full exercise of their overallotment option on January 11, 2021, no shares were forfeited.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AccruedPayroll">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued payroll</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AccruedPayroll</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AdvancesFromRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Advances from related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AdvancesFromRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_DerivativeLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative liability, noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_DerivativeLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_RelatedPartyNotePayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related party note payable, current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_RelatedPartyNotePayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_RelatedPartyNotePayableNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related party note payable, non current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_RelatedPartyNotePayableNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldInTrustNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash, securities, or other assets held by a third-party trustee pursuant to the terms of an agreement which assets are available to be used by beneficiaries to that agreement only within the specific terms thereof and which agreement is expected to terminate more than one year from the balance sheet date (or operating cycle, if longer) at which time the assets held-in-trust will be released or forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsHeldInTrustNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleLongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable beyond one year (or the operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount for notes payable (written promise to pay), due to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableRelatedPartiesClassifiedCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term notes classified as other, payable after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount that is required to be paid, determined under the conditions specified in the contract, if as of the reporting date, the holder of the share has exercised the right to or the shares are mandatorily redeemable after one year from the reporting date or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=109262807&amp;loc=d3e22047-110879<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_VickersVantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_VickersVantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139838691727136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 11, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 06, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preference shares, par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preference shares, authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preference shares, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preference shares, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,266,338<span></span>
</td>
<td class="nump">197,566,338<span></span>
</td>
<td class="nump">197,266,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,266,338<span></span>
</td>
<td class="nump">197,566,338<span></span>
</td>
<td class="nump">197,266,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_OrdinarySharesRedemptionSubjectedToForfeiture', window );">Ordinary shares redemption subjected to forfeiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,266,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,266,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,266,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vickers Vantage [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_OrdinarySharesSubjectToPossibleRedemption', window );">Subject to possible redemption shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,726,395<span></span>
</td>
<td class="nump">13,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityRedemptionPricePerShare', window );">Ordinary shares subject to possible redemption per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.41<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preference shares, par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preference shares, authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preference shares, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preference shares, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,450,000<span></span>
</td>
<td class="nump">3,450,000<span></span>
</td>
<td class="nump">3,450,000<span></span>
</td>
<td class="nump">3,450,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,450,000<span></span>
</td>
<td class="nump">3,450,000<span></span>
</td>
<td class="nump">3,450,000<span></span>
</td>
<td class="nump">3,450,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SubjectToPossibleRedemptionPerShares', window );">Subject to possible redemption per shares (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SharesCapitalization', window );">Shares capitalization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vickers Vantage [Member] | Over-Allotment Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_OrdinarySharesRedemptionSubjectedToForfeiture', window );">Ordinary shares redemption subjected to forfeiture</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_OrdinarySharesRedemptionSubjectedToForfeiture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Redemption subjected to forfeiture.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_OrdinarySharesRedemptionSubjectedToForfeiture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_OrdinarySharesSubjectToPossibleRedemption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_OrdinarySharesSubjectToPossibleRedemption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_SharesCapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares capitalization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_SharesCapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_SubjectToPossibleRedemptionPerShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Subject To possible redemption per shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_SubjectToPossibleRedemptionPerShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityRedemptionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount to be paid per share that is classified as temporary equity by entity upon redemption. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityRedemptionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_VickersVantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_VickersVantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139838692515936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Unaudited Condensed Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">10 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2020</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,115,000<span></span>
</td>
<td class="nump">$ 23,054,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 31,317,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 23,560,000<span></span>
</td>
<td class="nump">$ 21,033,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpensesAbstract', window );"><strong>Operating costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,284,000<span></span>
</td>
<td class="nump">2,549,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,634,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,149,000<span></span>
</td>
<td class="nump">5,802,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,457,000<span></span>
</td>
<td class="nump">7,031,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">9,201,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">9,961,000<span></span>
</td>
<td class="nump">10,216,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AcquiredinprocessresearchAndDevelopment', window );">Acquired&#160;in-process&#160;research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="nump">75,301,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,371,000<span></span>
</td>
<td class="nump">36,092,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">50,582,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">42,970,000<span></span>
</td>
<td class="nump">64,696,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Intangible amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,896,000<span></span>
</td>
<td class="nump">2,803,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,738,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,738,000<span></span>
</td>
<td class="nump">3,713,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpenses', window );">Total operating costs and expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,008,000<span></span>
</td>
<td class="nump">48,475,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">67,155,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">58,818,000<span></span>
</td>
<td class="nump">159,728,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30,893,000)<span></span>
</td>
<td class="num">(25,421,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(35,838,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(35,258,000)<span></span>
</td>
<td class="num">(138,695,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_GainLossOnDerivative', window );">Gain on derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,300,000)<span></span>
</td>
<td class="num">(100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">300,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(800,000)<span></span>
</td>
<td class="nump">23,300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_GainLossOnExtinguishmentOfDebtt', window );">(Gain) loss on debt extinguishment, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28,634,000)<span></span>
</td>
<td class="nump">12,463,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">12,463,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ScilexPharmaNotesPrincipalIncrease', window );">Scilex Pharma Notes principal increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">28,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,596,000)<span></span>
</td>
<td class="num">(8,617,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(11,764,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(13,116,000)<span></span>
</td>
<td class="num">(16,889,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="num">(460,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">(Gain) loss on foreign currency exchange</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39,000)<span></span>
</td>
<td class="nump">48,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">54,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(2,000)<span></span>
</td>
<td class="nump">168,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Total other (income) expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,377,000)<span></span>
</td>
<td class="nump">21,028,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">52,581,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">12,314,000<span></span>
</td>
<td class="nump">39,897,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,516,000)<span></span>
</td>
<td class="num">(46,449,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(88,419,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(47,572,000)<span></span>
</td>
<td class="num">(178,592,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (benefit) expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(36,400)<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(53,000)<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,480,000)<span></span>
</td>
<td class="num">$ (46,459,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (88,424,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (47,519,000)<span></span>
</td>
<td class="num">$ (178,594,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net (loss) income per share, ordinary shares (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (0.45)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="num">$ (0.95)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net (loss) income per share, ordinary shares (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (0.45)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="num">$ (0.95)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding, ordinary shares (in Shares) , Basic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,550<span></span>
</td>
<td class="nump">197,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">197,266<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">197,315<span></span>
</td>
<td class="nump">187,524<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding, ordinary shares (in Shares) , diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,550<span></span>
</td>
<td class="nump">197,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">197,266<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">197,315<span></span>
</td>
<td class="nump">187,524<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vickers Vantage [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpensesAbstract', window );"><strong>Operating costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpenses', window );">Total operating costs and expenses</a></td>
<td class="nump">$ 657,746<span></span>
</td>
<td class="nump">$ 283,346<span></span>
</td>
<td class="nump">$ 2,412,297<span></span>
</td>
<td class="nump">$ 620,642<span></span>
</td>
<td class="nump">$ 6,276<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 1,005,498<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(657,746)<span></span>
</td>
<td class="num">(283,346)<span></span>
</td>
<td class="num">(2,412,297)<span></span>
</td>
<td class="num">(620,642)<span></span>
</td>
<td class="num">(6,276)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,005,498)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ChangeInFairValueOfWarrantLiability', window );">Change in fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4,377,600<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="nump">68,400<span></span>
</td>
<td class="num">(1,162,800)<span></span>
</td>
<td class="nump">2,188,800<span></span>
</td>
<td class="nump">2,872,800<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4,377,600<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfDerivatives', window );">Loss on initial issuance of private warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,599,200)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(2,599,200)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_TransactionCostsAllocatedToWarrantLiabilities', window );">Transaction costs allocated to warrant liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(30,212)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(30,212)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOptionChangesInFairValueGainLoss1', window );">Change in fair value of conversion option liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,892<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">11,835<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DistributionsOnMandatorilyRedeemableSecurities', window );">Interest on mandatorily redeemable ordinary shares liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">192,049<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Income earned on investments held in Trust Account</a></td>
<td class="nump">459,114<span></span>
</td>
<td class="nump">1,794<span></span>
</td>
<td class="nump">664,973<span></span>
</td>
<td class="nump">28,006<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">30,739<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(1,155)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(16,901)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,826)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Total other (income) expense</a></td>
<td class="nump">526,359<span></span>
</td>
<td class="num">(1,161,006)<span></span>
</td>
<td class="nump">3,035,813<span></span>
</td>
<td class="nump">271,394<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,788,935<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (131,387)<span></span>
</td>
<td class="num">$ (1,444,352)<span></span>
</td>
<td class="nump">$ 623,516<span></span>
</td>
<td class="num">$ (349,248)<span></span>
</td>
<td class="num">$ (6,276)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 783,438<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net (loss) income per share, ordinary shares (in Dollars per share)</a></td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="num">$ (0.08)<span></span>
</td>
<td class="nump">$ 0.04<span></span>
</td>
<td class="num">$ (0.02)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net (loss) income per share, ordinary shares (in Dollars per share)</a></td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="num">$ (0.08)<span></span>
</td>
<td class="nump">$ 0.04<span></span>
</td>
<td class="num">$ (0.02)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding, ordinary shares (in Shares) , Basic</a></td>
<td class="nump">13,176,395<span></span>
</td>
<td class="nump">17,250,000<span></span>
</td>
<td class="nump">15,862,288<span></span>
</td>
<td class="nump">16,675,824<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">16,820,548<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding, ordinary shares (in Shares) , diluted</a></td>
<td class="nump">13,176,395<span></span>
</td>
<td class="nump">17,250,000<span></span>
</td>
<td class="nump">15,862,288<span></span>
</td>
<td class="nump">16,675,824<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">16,834,110<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="11"></td></tr>
<tr><td colspan="11"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">At December 31, 2020, excludes an aggregate of up to 450,000 ordinary shares that were subject to forfeiture.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AcquiredinprocessresearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Acquired&#160;in-process&#160;research and development</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AcquiredinprocessresearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ChangeInFairValueOfWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ChangeInFairValueOfWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_GainLossOnDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) on derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_GainLossOnDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_GainLossOnExtinguishmentOfDebtt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) on extinguishment of debtt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_GainLossOnExtinguishmentOfDebtt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ScilexPharmaNotesPrincipalIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Scilex Pharma Notes principal increase</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ScilexPharmaNotesPrincipalIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_TransactionCostsAllocatedToWarrantLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transaction costs allocated to warrant liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_TransactionCostsAllocatedToWarrantLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DistributionsOnMandatorilyRedeemableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of distributions during the period on mandatorily redeemable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=118255708&amp;loc=d3e21951-110878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DistributionsOnMandatorilyRedeemableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOptionChangesInFairValueGainLoss1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For each line item in the statement of financial position, the amounts of gains and losses from fair value changes included in earnings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14172-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOptionChangesInFairValueGainLoss1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126980362&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the book value and the sale price of options, swaps, futures, forward contracts, and other derivative instruments. This element refers to the gain (loss) included in earnings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.13(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest bearing assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_VickersVantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_VickersVantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139838689843072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Unaudited Condensed Consolidated Statements of Operations (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">10 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding, ordinary shares (in Shares) , diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,550<span></span>
</td>
<td class="nump">197,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,266<span></span>
</td>
<td class="nump">197,315<span></span>
</td>
<td class="nump">187,524<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net (loss) income per share, ordinary shares (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.45)<span></span>
</td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="num">$ (0.95)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_OrdinarySharesRedemptionSubjectedToForfeiture', window );">Ordinary shares redemption subjected to forfeiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vickers Vantage [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding, ordinary shares (in Shares) , diluted</a></td>
<td class="nump">13,176,395<span></span>
</td>
<td class="nump">17,250,000<span></span>
</td>
<td class="nump">15,862,288<span></span>
</td>
<td class="nump">16,675,824<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="nump">16,834,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net (loss) income per share, ordinary shares (in Dollars per share)</a></td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="num">$ (0.08)<span></span>
</td>
<td class="nump">$ 0.04<span></span>
</td>
<td class="num">$ (0.02)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_OrdinarySharesRedemptionSubjectedToForfeiture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Redemption subjected to forfeiture.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_OrdinarySharesRedemptionSubjectedToForfeiture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_VickersVantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_VickersVantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139838685899360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Unaudited Condensed Consolidated Statements of Changes in Shareholders' Equity (Deficit) - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Vickers Vantage [Member]</div></th>
<th class="th"><div>Ordinary Shares</div></th>
<th class="th">
<div>Ordinary Shares </div>
<div>Vickers Vantage [Member]</div>
</th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>Vickers Vantage [Member]</div>
</th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th">
<div>Accumulated Deficit </div>
<div>Vickers Vantage [Member]</div>
</th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2018</a></td>
<td class="nump">$ 35,464,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73,462,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (38,013,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,270,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(178,594,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(178,594,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Shares issued related to Semnur Acquisition , shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,040,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Shares issued related to Semnur Acquisition</a></td>
<td class="nump">54,591,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,586,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Distribution to Sorrento</a></td>
<td class="num">(5,800,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,800,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="nump">$ 4,330,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,330,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock options excercised , shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="num">$ (90,009,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126,578,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(216,607,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,310,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(47,519,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(47,519,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Distribution to Sorrento</a></td>
<td class="num">(9,600,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,600,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="nump">$ 5,395,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,395,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock options excercised , shares</a></td>
<td class="nump">56,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock options excercised</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited', window );">Cancellation of shares held in escrow related to Semnur Acquisition , shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="num">(141,683,000)<span></span>
</td>
<td class="nump">$ 18,724<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="nump">$ 345<span></span>
</td>
<td class="nump">122,423,000<span></span>
</td>
<td class="nump">$ 24,655<span></span>
</td>
<td class="num">(264,126,000)<span></span>
</td>
<td class="num">$ (6,276)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,266,000<span></span>
</td>
<td class="nump">3,450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Feb. 20, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Feb. 20, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,276)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,276)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Distribution to Sorrento</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Distribution to Sorrento , shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Cancellation of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Cancellation of ordinary shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of ordinary shares to Sponsor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,655<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of ordinary shares to Sponsor (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="num">(141,683,000)<span></span>
</td>
<td class="nump">$ 18,724<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="nump">$ 345<span></span>
</td>
<td class="nump">122,423,000<span></span>
</td>
<td class="nump">$ 24,655<span></span>
</td>
<td class="num">(264,126,000)<span></span>
</td>
<td class="num">$ (6,276)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,266,000<span></span>
</td>
<td class="nump">3,450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRedeemedOrCalledDuringPeriodValue', window );">Accretion of Ordinary shares subject to possible redemption amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,499,261)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24,665)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,474,606)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,328,853<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,328,853<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,151,684)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,152,029)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="num">(141,683,000)<span></span>
</td>
<td class="nump">18,724<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="nump">$ 345<span></span>
</td>
<td class="nump">122,423,000<span></span>
</td>
<td class="nump">24,655<span></span>
</td>
<td class="num">(264,126,000)<span></span>
</td>
<td class="num">(6,276)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,266,000<span></span>
</td>
<td class="nump">3,450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(46,459,000)<span></span>
</td>
<td class="num">(349,248)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(46,459,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="nump">4,368,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,368,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AdjustmentsToAdditionalPaidInCapitalSharesIssuedInSemnurAcquisition', window );">Adjustment to shares issued in Semnur Acquisition</a></td>
<td class="nump">409,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">409,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2021</a></td>
<td class="num">(183,365,000)<span></span>
</td>
<td class="num">(9,829,785)<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="nump">$ 345<span></span>
</td>
<td class="nump">127,200,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(310,585,000)<span></span>
</td>
<td class="num">(9,830,130)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,266,000<span></span>
</td>
<td class="nump">3,450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="num">(141,683,000)<span></span>
</td>
<td class="nump">18,724<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="nump">$ 345<span></span>
</td>
<td class="nump">122,423,000<span></span>
</td>
<td class="nump">24,655<span></span>
</td>
<td class="num">(264,126,000)<span></span>
</td>
<td class="num">(6,276)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,266,000<span></span>
</td>
<td class="nump">3,450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRedeemedOrCalledDuringPeriodValue', window );">Accretion of Ordinary shares subject to possible redemption amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,499,261)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24,655)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,474,606)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(88,424,000)<span></span>
</td>
<td class="nump">783,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(88,424,000)<span></span>
</td>
<td class="nump">783,438<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="nump">$ 5,822,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,822,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock options excercised , shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AdjustmentsToAdditionalPaidInCapitalSharesIssuedInSemnurAcquisition', window );">Adjustment to shares issued in Semnur Acquisition</a></td>
<td class="nump">$ 409,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">409,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="num">(223,876,000)<span></span>
</td>
<td class="num">(8,697,099)<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="nump">$ 345<span></span>
</td>
<td class="nump">128,654,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(352,550,000)<span></span>
</td>
<td class="num">(8,697,444)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,266,000<span></span>
</td>
<td class="nump">3,450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,151,684)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,152,029)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(233,749)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(233,749)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,385,433)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,385,778)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,444,352)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,444,352)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2021</a></td>
<td class="num">(183,365,000)<span></span>
</td>
<td class="num">(9,829,785)<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="nump">$ 345<span></span>
</td>
<td class="nump">127,200,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(310,585,000)<span></span>
</td>
<td class="num">(9,830,130)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,266,000<span></span>
</td>
<td class="nump">3,450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="num">(223,876,000)<span></span>
</td>
<td class="num">(8,697,099)<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="nump">$ 345<span></span>
</td>
<td class="nump">128,654,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(352,550,000)<span></span>
</td>
<td class="num">(8,697,444)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,266,000<span></span>
</td>
<td class="nump">3,450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRedeemedOrCalledDuringPeriodValue', window );">Accretion of Ordinary shares subject to possible redemption amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,035,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,035,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(806,222)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(806,222)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,538,321)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,538,666)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="num">(223,876,000)<span></span>
</td>
<td class="num">(8,697,099)<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="nump">$ 345<span></span>
</td>
<td class="nump">128,654,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(352,550,000)<span></span>
</td>
<td class="num">(8,697,444)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,266,000<span></span>
</td>
<td class="nump">3,450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(5,480,000)<span></span>
</td>
<td class="nump">623,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,480,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="nump">4,027,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,027,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock options excercised , shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock options excercised</a></td>
<td class="nump">96,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AdjustmentsToAdditionalPaidInCapitalNetOfDiscount', window );">Aardvark SP-104 license transfer from Sorrento, net of discount</a></td>
<td class="num">(4,127,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,127,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AdjustmentsToAdditionalPaidInCapitalDiscountAmortization', window );">Aardvark SP-104 discount amortization</a></td>
<td class="num">(35,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(35,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2022</a></td>
<td class="num">(229,395,000)<span></span>
</td>
<td class="num">(12,003,010)<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="nump">$ 345<span></span>
</td>
<td class="nump">128,615,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(358,030,000)<span></span>
</td>
<td class="num">(12,003,355)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,566,000<span></span>
</td>
<td class="nump">3,450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,538,321)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,538,666)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetSharesReclassifiedToMandatorilyRedeemableCapitalStockValue', window );">Mandatorily redeemable ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(192,049)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(192,049)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRedeemedOrCalledDuringPeriodValue', window );">Accretion of Ordinary shares subject to possible redemption amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,595,486)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,595,486)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,561,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,561,125<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,764,731)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,765,076)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRedeemedOrCalledDuringPeriodValue', window );">Accretion of Ordinary shares subject to possible redemption amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,106,892)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,106,892)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(131,387)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(131,387)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2022</a></td>
<td class="num">$ (229,395,000)<span></span>
</td>
<td class="num">$ (12,003,010)<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="nump">$ 345<span></span>
</td>
<td class="nump">$ 128,615,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (358,030,000)<span></span>
</td>
<td class="num">$ (12,003,355)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,566,000<span></span>
</td>
<td class="nump">3,450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AdjustmentsToAdditionalPaidInCapitalDiscountAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to additional paid in capital discount amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AdjustmentsToAdditionalPaidInCapitalDiscountAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AdjustmentsToAdditionalPaidInCapitalNetOfDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to additional paid in capital net of discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AdjustmentsToAdditionalPaidInCapitalNetOfDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AdjustmentsToAdditionalPaidInCapitalSharesIssuedInSemnurAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments To Additional Paid In Capital shares issued in Semnur Acquisition</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AdjustmentsToAdditionalPaidInCapitalSharesIssuedInSemnurAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetSharesReclassifiedToMandatorilyRedeemableCapitalStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of net shares reclassified to mandatorily redeemable capital stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetSharesReclassifiedToMandatorilyRedeemableCapitalStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares (or other type of equity) forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRedeemedOrCalledDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock bought back by the entity at the exercise price or redemption price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRedeemedOrCalledDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139838686533888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Unaudited Condensed Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">10 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (5,480,000)<span></span>
</td>
<td class="num">$ (46,459,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (88,424,000)<span></span>
</td>
<td class="num">$ (47,519,000)<span></span>
</td>
<td class="num">$ (178,594,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used for operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">2,926,000<span></span>
</td>
<td class="nump">2,832,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,779,000<span></span>
</td>
<td class="nump">3,777,000<span></span>
</td>
<td class="nump">3,750,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt issuance costs and debt discount</a></td>
<td class="nump">3,108,000<span></span>
</td>
<td class="nump">5,904,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,909,000<span></span>
</td>
<td class="nump">10,664,000<span></span>
</td>
<td class="nump">15,033,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Payment on the Scilex Pharma Notes attributed to accreted interest related to the debt discount</a></td>
<td class="num">(21,190,000)<span></span>
</td>
<td class="num">(11,813,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,487,000)<span></span>
</td>
<td class="num">(10,866,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">(Gain) loss on debt extinguishment, net</a></td>
<td class="num">(28,634,000)<span></span>
</td>
<td class="nump">12,463,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,463,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_NonCashOperatingLeaseCosts', window );">Non-cash operating lease cost</a></td>
<td class="nump">351,000<span></span>
</td>
<td class="nump">276,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">372,000<span></span>
</td>
<td class="nump">825,000<span></span>
</td>
<td class="nump">528,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">4,027,000<span></span>
</td>
<td class="nump">4,368,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,822,000<span></span>
</td>
<td class="nump">5,395,000<span></span>
</td>
<td class="nump">4,330,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Gain on derivative liability</a></td>
<td class="num">(5,300,000)<span></span>
</td>
<td class="num">(100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="num">(800,000)<span></span>
</td>
<td class="nump">23,300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_IncreaseInNotesPayableOne', window );">Scilex Pharma Notes principal increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Semnur-related IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">75,301,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="nump">1,629,000<span></span>
</td>
<td class="nump">186,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,417,000)<span></span>
</td>
<td class="nump">2,379,000<span></span>
</td>
<td class="num">(1,116,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivables, net</a></td>
<td class="num">(3,206,000)<span></span>
</td>
<td class="nump">517,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,142,000)<span></span>
</td>
<td class="num">(598,000)<span></span>
</td>
<td class="num">(12,356,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other</a></td>
<td class="num">(3,478,000)<span></span>
</td>
<td class="num">(1,647,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,479,000<span></span>
</td>
<td class="num">(1,035,000)<span></span>
</td>
<td class="num">(1,307,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInSecurityDeposits', window );">Long-term deposits</a></td>
<td class="nump">385,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,580,000<span></span>
</td>
<td class="num">(88,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Accounts payable</a></td>
<td class="nump">2,967,000<span></span>
</td>
<td class="num">(2,784,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,836,000)<span></span>
</td>
<td class="num">(4,062,000)<span></span>
</td>
<td class="nump">4,271,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Increase (Decrease) in Employee Related Liabilities</a></td>
<td class="num">(2,307,000)<span></span>
</td>
<td class="nump">360,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,000)<span></span>
</td>
<td class="nump">1,247,000<span></span>
</td>
<td class="nump">1,131,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">12,403,000<span></span>
</td>
<td class="num">(522,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">409,000<span></span>
</td>
<td class="nump">2,051,000<span></span>
</td>
<td class="nump">3,689,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities', window );">Increase (Decrease) in Other Current Liabilities</a></td>
<td class="num">(255,000)<span></span>
</td>
<td class="num">(53,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(80,000)<span></span>
</td>
<td class="num">(604,000)<span></span>
</td>
<td class="num">(147,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent', window );">Related party payable</a></td>
<td class="nump">21,521,000<span></span>
</td>
<td class="nump">13,765,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,210,000<span></span>
</td>
<td class="nump">5,105,000<span></span>
</td>
<td class="nump">1,854,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used for operating activities</a></td>
<td class="num">(20,533,000)<span></span>
</td>
<td class="num">(22,707,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28,664,000)<span></span>
</td>
<td class="num">(31,461,000)<span></span>
</td>
<td class="num">(60,421,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property, plant, and equipment</a></td>
<td class="num">(7,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(25,000)<span></span>
</td>
<td class="num">(584,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Acquisition consideration paid in cash for Romeg intangible asset acquisition</a></td>
<td class="num">(2,060,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisition of Semnur, net of cash acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(17,040,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used for investing activities</a></td>
<td class="num">(2,067,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,000)<span></span>
</td>
<td class="num">(17,624,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfSeniorDebt', window );">Repayment of principal on the Scilex Pharma Notes</a></td>
<td class="num">(84,808,000)<span></span>
</td>
<td class="num">(32,376,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33,387,000)<span></span>
</td>
<td class="num">(58,927,000)<span></span>
</td>
<td class="num">(2,334,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfOtherLongTermDebt', window );">Repayment on other loans</a></td>
<td class="num">(18,800,000)<span></span>
</td>
<td class="num">(36,900,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(48,832,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt', window );">Proceeds from other loans</a></td>
<td class="nump">9,857,000<span></span>
</td>
<td class="nump">34,799,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,832,000<span></span>
</td>
<td class="nump">11,007,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from stock options exercised</a></td>
<td class="nump">96,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from related party payable</a></td>
<td class="nump">51,900,000<span></span>
</td>
<td class="nump">45,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,850,000<span></span>
</td>
<td class="nump">18,400,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfMediumTermNotes', window );">Proceeds from related party note payable</a></td>
<td class="nump">62,500,000<span></span>
</td>
<td class="nump">11,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,700,000<span></span>
</td>
<td class="nump">10,300,000<span></span>
</td>
<td class="nump">21,628,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfMediumTermNotes', window );">Repayment of related party note payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,518,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">20,745,000<span></span>
</td>
<td class="nump">22,073,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,163,000<span></span>
</td>
<td class="num">(19,170,000)<span></span>
</td>
<td class="nump">15,776,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="num">(1,855,000)<span></span>
</td>
<td class="num">(634,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(501,000)<span></span>
</td>
<td class="num">(50,656,000)<span></span>
</td>
<td class="num">(62,269,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">4,338,000<span></span>
</td>
<td class="nump">4,839,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,839,000<span></span>
</td>
<td class="nump">55,495,000<span></span>
</td>
<td class="nump">117,764,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">2,483,000<span></span>
</td>
<td class="nump">4,205,000<span></span>
</td>
<td class="nump">$ 4,839,000<span></span>
</td>
<td class="nump">4,338,000<span></span>
</td>
<td class="nump">4,839,000<span></span>
</td>
<td class="nump">55,495,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosures of non-cash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1', window );">Deferred consideration for Romeg intangible asset acquisition</a></td>
<td class="nump">3,650,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1', window );">Non-cash&#160;consideration in Semnur acquisition</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">409,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">409,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">54,591,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_OtherLoanForgiveness', window );">Other loan forgiveness</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,536,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,536,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PromissoryNoteIssuedNetOfDiscount', window );">Promissory Note issued to Sorrento in exchange for the&#160;SP-104&#160;license, net of discount</a></td>
<td class="nump">4,162,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_NonCashFairValueAdjustmentToDerivativeLiability', window );">Fair value adjustment to derivative liability in troubled debt restructuring</a></td>
<td class="nump">30,400,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_NonCashRightOfUseAsset', window );">Live Action&#160;right-of-use&#160;asset in Palo Alto</a></td>
<td class="nump">320,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AcquistionCostsIncurredButNotPaidIncludedInAccountsPayable', window );">Semnur acquisition costs incurred but not paid in accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">601,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_NonCashDistributionToAcquiree', window );">Non-cash distribution to Sorrento</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,600,000<span></span>
</td>
<td class="nump">5,800,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_NonCashIncreaseInPrincipal', window );">Scilex Pharma Notes principal increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Reconciliation of cash, cash equivalents and restricted cash within the Company's balance sheet</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">2,483,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,839,000<span></span>
</td>
<td class="nump">4,338,000<span></span>
</td>
<td class="nump">4,839,000<span></span>
</td>
<td class="nump">10,295,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 45,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vickers Vantage [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">623,516<span></span>
</td>
<td class="num">(349,248)<span></span>
</td>
<td class="num">(6,276)<span></span>
</td>
<td class="nump">783,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used for operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_FormationCostPaidThroughAdvancesFromAffiliateOfSponsor', window );">Formation cost paid through advances from affiliate of Sponsor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt issuance costs and debt discount</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestAndDividendIncomeSecuritiesHeldToMaturity', window );">Income earned on investments held in Trust Account</a></td>
<td class="num">(664,973)<span></span>
</td>
<td class="num">(28,006)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(30,739)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DistributionsOnMandatorilyRedeemableSecurities', window );">Interest on mandatorily redeemable ordinary shares liability</a></td>
<td class="num">(192,049)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="num">(2,188,800)<span></span>
</td>
<td class="num">(2,872,800)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(4,377,600)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_LossOnInitialIssuanceOfWarrantLiability', window );">Loss on initial issuance of private warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,599,200<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,599,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ChangeInFairValueOfConversionOptionLiability', window );">Change in fair value of conversion option liability</a></td>
<td class="num">(6,892)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(11,835)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="nump">16,901<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_TransactionsCostsAllocatedToPrivateWarrants', window );">Transaction costs allocated to warrant liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">30,212<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">30,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="num">(126,252)<span></span>
</td>
<td class="num">(116,536)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(4,536)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">600,588<span></span>
</td>
<td class="nump">43,569<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">208,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used for operating activities</a></td>
<td class="num">(1,937,961)<span></span>
</td>
<td class="num">(693,609)<span></span>
</td>
<td class="num">(1,276)<span></span>
</td>
<td class="num">(801,330)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_InvestmentOfCashInTrustAccounts', window );">Investment of cash in Trust Account</a></td>
<td class="num">(3,041,666)<span></span>
</td>
<td class="num">(139,380,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(139,380,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDecommissioningFund', window );">Cash withdrawn from Trust Account in connection with redemption</a></td>
<td class="nump">41,824,292<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used for investing activities</a></td>
<td class="nump">38,782,626<span></span>
</td>
<td class="num">(139,380,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(139,380,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt', window );">Proceeds from other loans</a></td>
<td class="nump">1,535,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from related party payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of Units, net of underwriting discounts paid</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">135,600,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">135,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from sale of Private Placement Warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,130,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Repayment of advances from related party</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(55,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(55,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ProceedsFromSimplePromissoryNoteRelatedParty', window );">Proceeds from simple promissory note &#8211; related party</a></td>
<td class="nump">2,971,667<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RepaymentOfPromissoryNoteRelatedParty', window );">Repayment of promissory note &#8211; related party</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(125,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ProceedsFromPromissoryNoteRelatedParty', window );">Proceeds from promissory note &#8211; related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt', window );">Repayment of promissory note &#8211; related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(125,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of offering costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(416,260)<span></span>
</td>
<td class="num">(118,213)<span></span>
</td>
<td class="num">(416,260)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfOtherEquity', window );">Redemption of ordinary shares</a></td>
<td class="num">(41,824,292)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="num">(37,317,625)<span></span>
</td>
<td class="nump">140,158,740<span></span>
</td>
<td class="nump">31,787<span></span>
</td>
<td class="nump">140,658,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="num">(472,960)<span></span>
</td>
<td class="nump">85,131<span></span>
</td>
<td class="nump">30,511<span></span>
</td>
<td class="nump">477,410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">507,921<span></span>
</td>
<td class="nump">30,511<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">30,511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">34,961<span></span>
</td>
<td class="nump">115,642<span></span>
</td>
<td class="nump">30,511<span></span>
</td>
<td class="nump">507,921<span></span>
</td>
<td class="nump">$ 30,511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosures of non-cash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DeferredUnderwritingFeePayable', window );">Deferred underwriting fee payable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5,190,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,190,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_OfferingCostIncludedInAccruedOfferingCost', window );">Offering costs included in accrued offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,760<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesIssued1', window );">Offering costs paid through promissory note &#8211; related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AcquistionCostsIncurredButNotPaidIncludedInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Acquistion costs incurred but not paid included in accounts payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AcquistionCostsIncurredButNotPaidIncludedInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ChangeInFairValueOfConversionOptionLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in fair value of conversion option liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ChangeInFairValueOfConversionOptionLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_DeferredUnderwritingFeePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Underwriting Fees means the amount of deferred underwriting fees held in the Trust Account in connection with SPAC's initial public offering payable to the underwriters upon consummation of a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_DeferredUnderwritingFeePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_FormationCostPaidThroughAdvancesFromAffiliateOfSponsor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Formation cost paid through advances from affiliate of Sponsor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_FormationCostPaidThroughAdvancesFromAffiliateOfSponsor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_IncreaseInNotesPayableOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase in notes payable one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_IncreaseInNotesPayableOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_InvestmentOfCashInTrustAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment of cash in Trust Account.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_InvestmentOfCashInTrustAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_LossOnInitialIssuanceOfWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_LossOnInitialIssuanceOfWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_NonCashDistributionToAcquiree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non cash distribution to acquiree.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_NonCashDistributionToAcquiree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_NonCashFairValueAdjustmentToDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non cash fair value adjustment to derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_NonCashFairValueAdjustmentToDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_NonCashIncreaseInPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non cash increase in principal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_NonCashIncreaseInPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_NonCashOperatingLeaseCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non cash operating lease costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_NonCashOperatingLeaseCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_NonCashRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non cash right of use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_NonCashRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_OfferingCostIncludedInAccruedOfferingCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Offering cost included in accrued offering cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_OfferingCostIncludedInAccruedOfferingCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_OtherLoanForgiveness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other loan forgiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_OtherLoanForgiveness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ProceedsFromPromissoryNoteRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from promissory note related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ProceedsFromPromissoryNoteRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ProceedsFromSimplePromissoryNoteRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from simple promissory note &#8211; related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ProceedsFromSimplePromissoryNoteRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PromissoryNoteIssuedNetOfDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Promissory note issued net of discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PromissoryNoteIssuedNetOfDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_RepaymentOfPromissoryNoteRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repayment of promissory note &#8211; related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_RepaymentOfPromissoryNoteRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_TransactionsCostsAllocatedToPrivateWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transaction costs allocated to warrant liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_TransactionsCostsAllocatedToPrivateWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for allocation of cost of tangible and intangible assets over their useful lives directly used in production of good and rendering of service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DistributionsOnMandatorilyRedeemableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of distributions during the period on mandatorily redeemable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=118255708&amp;loc=d3e21951-110878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DistributionsOnMandatorilyRedeemableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInSecurityDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in security deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInSecurityDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndDividendIncomeSecuritiesHeldToMaturity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating interest income, including amortization and accretion of premiums and discounts, on held-to-maturity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndDividendIncomeSecuritiesHeldToMaturity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of intangibles that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of notes issued in noncash investing and financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the noncash (or part noncash) consideration given (for example, liability, equity) in a transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of a transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfOtherEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to reacquire equity classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfOtherEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDecommissioningFund">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of assets held in a decommissioning trust fund.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDecommissioningFund</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfMediumTermNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt funding received on a regular basis with maturities ranging from 5-10 years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfMediumTermNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of long-term debt classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from long-term debt by a related party. Related parties, include, but are not limited to, affiliates, owners or officers and their immediate families, and pension trusts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfMediumTermNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to pay off borrowing used to receive debt funding on a regular basis with maturities ranging from 5-10 years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfMediumTermNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfOtherLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the payment of debt classified as other, maturing after one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfOtherLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfSeniorDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfSeniorDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_VickersVantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_VickersVantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139838694461488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Organization and Business Operations<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DescriptionOfOrganizationAndBusinessOperationsLineItems', window );"><strong>Description of Organization and Business Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Nature of Operations and Basis of Presentation </div></div></div></div></td></tr></table><div style="clear: both; max-height: 0px; text-indent: 0px;"/><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-indent: 0px; text-align: left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Organization and Principal Activities </div></div></div></div><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-align: left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Scilex Holding Company (&#8220;Scilex Holding&#8221; (now known as Scilex, Inc.) and together with its wholly owned subsidiaries, the &#8220;Company&#8221;) was incorporated in Delaware in February 2019 and is a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, &#8220;Sorrento&#8221;). The Company is a commercial biopharmaceutical company focused on acquiring, developing and commercializing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-opioid</div> management products for the treatment of acute and chronic pain. The Company launched its first commercial product in October 2018, ZTlido (lidocaine topical system) 1.8% (&#8220;ZTlido&#8221;), a prescription lidocaine topical system that is designed with novel technology to address the limitations of current prescription lidocaine therapies by providing significantly improved adhesion and continuous pain relief throughout the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12-hour</div> administration period. The Company <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> the exclusive right to commercialize GLOPERBA (colchicine USP) oral solution, an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FDA-approved</div> prophylactic treatment for painful gout flares in adults, in the U.S. (see Note 2). The Company is planning to commercialize GLOPERBA in 2023. The Company is currently developing three product candidates, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-102</div> (10&#160;mg, dexamethasone sodium phosphate viscous gel), a Phase 3, novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;SP-102&#8221;</div> or &#8220;SEMDEXA&#8221;) and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-103</div> (lidocaine topical system) 5.4% <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;SP-103&#8221;),</div> for the treatment of acute low back pain, and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-104</div> (4.5 mg, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-dose</div> naltrexone hydrochloride delayed-release capsules) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;SP-104&#8221;),</div> a novel formulation for the treatment of </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">fibromyalgia. </div></div></div><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-align: left;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;18, 2019, the Company entered into a Contribution and Loan Agreement with Sorrento and the holders of the outstanding shares of capital stock of Scilex Pharmaceuticals Inc. (&#8220;Scilex Pharma&#8221;) pursuant to which the Company acquired </div>100<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the outstanding shares of capital stock of Scilex Pharma in exchange for shares of the Company&#8217;s common stock (the &#8220;Contribution&#8221;), which was accounted for as a reorganization of entities under common control. Pursuant to the Contribution and Loan Agreement, Sorrento provided the Company with a loan with an initial principal amount of $</div>16.5<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in the form of a note payable, which was used by the Company to fund the acquisition of Semnur Pharmaceuticals, Inc. (&#8220;Semnur&#8221;). Concurrently therewith, the Company entered into an Agreement and Plan of Merger with Semnur, Sigma Merger Sub, Inc., the Company&#8217;s prior wholly-owned subsidiary (&#8220;Merger Sub&#8221;), Fortis Advisors LLC, solely as representative of the holders of Semnur equity (the &#8220;Semnur Equityholders&#8217; Representative&#8221;), and Sorrento, for limited purposes (the &#8220;Merger Agreement&#8221;), which was accounted for as an asset acquisition. Pursuant to the Merger Agreement, Merger Sub merged with and into Semnur (the &#8220;Merger of Semnur&#8221;), with Semnur surviving as the Company&#8217;s wholly-owned subsidiary. As a result of the Contribution and the Merger of Semnur, Scilex Pharma and Semnur became wholly-owned subsidiaries of the Company. Upon completion of the Contribution and the Merger of Semnur, the historical consolidated financial statements of Scilex Pharma became the historical consolidated financial statements of </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Scilex Holding. </div></div></div><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-align: left;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Since inception, the Company had devoted substantially all of its efforts to the product development of </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-102</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-103</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and the commercialization of ZTlido.</div></div><div style="text-align: left; margin-bottom: 1em; margin-top: 1em"/><div style="text-align: left; margin-bottom: 1em; margin-top: 1em"/><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px; text-align: left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Business Combination </div></div></div></div><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-align: left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;17, 2022, the Company entered into an Agreement and Plan of Merger (as amended on September&#160;12, 2022, the &#8220;BCA&#8221;) with Vickers Vantage Corp. I (&#8220;Vickers&#8221;), a special purpose acquisition</div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">company, and<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vantage Merger Sub, Inc., a wholly-owned subsidiary of Vickers (&#8220;Vickers Merger Sub&#8221;). Pursuant to the terms of the BCA, Vickers Merger Sub merged with and into the Company, with the Company surviving the merger (&#8220;Legacy Scilex&#8221;) and becoming a wholly-owned subsidiary of Vickers (collectively, the &#8220;Business Combination&#8221;).</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On November&#160;</div>10<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Vickers consummated the Business Combination pursuant to the terms of the BCA. Vickers acquired all of the outstanding equity interests of Legacy Scilex. As a result of the Business Combination, New Scilex (as defined below) received gross proceeds of approximately $</div>12.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, prior to the settlement of transaction-related costs and expenses. Additionally, all existing related party indebtedness between the Company, Scilex Pharma, and Sorrento totaling $</div>290.6<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million was converted into equity interests in Vickers in connection with the consummation of the Business Combination and pursuant to the terms of the Debt Exchange Agreement (see Note </div>10)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. In connection with the Business Combination (as more fully described in the notes to these financial statements), Scilex Holding Company was renamed to Scilex, Inc. These financial statements are those of Scilex Holding Company (now known as Scilex, Inc.) prior to the completion of such Business Combination. Additionally, in connection with the completion of the Business Combination, Vickers was renamed to, and will operate as, &#8220;Scilex Holding Company&#8221; and the Company began trading on the Nasdaq Capital Market under the new ticker symbol &#8220;SCLX&#8221; on November&#160;</div>11<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. Scilex Holding Company following the completion of the Business Combination is sometimes referred to herein as &#8220;New Scilex.&#8221;</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Business Combination will be accounted for as a reverse recapitalization in accordance with U.S. GAAP. Under this method of accounting, Vickers is treated as the &#8220;acquired&#8221; company for accounting purposes and the Business Combination is treated as the equivalent of the Company issuing stock for the net assets of Vickers, accompanied by a recapitalization. The net assets of Vickers are stated at historical cost, with </div>no<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> goodwill or other intangible assets recorded.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s legal, accounting and other fees directly attributable to the Business Combination were capitalized within prepaid expenses and other current assets on the consolidated balance sheets. As of September&#160;</div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company had capitalized $</div>7.3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million of costs incurred in relation to the Business Combination. There were </div>no<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> capitalized costs in relation to the Business Combination as of December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">.</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and include all adjustments necessary for the fair presentation of the Company&#8217;s financial position for the periods presented.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying consolidated financial statements include the accounts of the Company&#8217;s subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These consolidated financial statements should be read in conjunction with the consolidated financial statements for the fiscal year ended December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. Operating results for quarter periods are not expected to be indicative of operating results for the Company&#8217;s </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> fiscal year, or any subsequent period.</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of these consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of these consolidated financial statements and the reported amounts of expenses during the reporting period. Management believes that these estimates are reasonable; however, actual results may differ from these estimates.</div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Significant Accounting Policies </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the </div>nine<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> months ended September&#160;</div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, there have been </div>no<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> changes to the Company`s significant accounting policies as described in the notes to the audited financial statements for the years ended December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> included in the proxy statement/prospectus filed by Vickers with the SEC on October&#160;</div>28<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> beginning on page </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-48</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> thereof.</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Segments </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating segments </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">are identified as components of an entity where separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions on how to allocate resources and assesses performance. The Company has determined that its chief operating decision maker is its Chief Executive Officer, as he is responsible for making decisions regarding the allocation of resources and assessing performance as well as for strategic operational decisions. The Company is engaged primarily in the development of </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-opioid</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> products focused on pain management based on its platform technologies and all sales are based in the United States. Accordingly, the Company has determined that it operates its business as a single reportable segment.</div></div><span></span>
</td>
<td class="text"> <div style="clear: both; max-height: 0px; text-indent: 0px;"/>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Nature of Operations and Basis of Presentation </div></div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Organization and Principal Activities </div></div></div></div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Scilex Holding Company (&#8220;Scilex Holding&#8221; and together with its wholly owned subsidiaries, <div style="letter-spacing: 0px; top: 0px;;display:inline;">the</div> &#8220;Company&#8221;) was incorporated in </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"/> Delaware in February&#160;2019 and is a majority-owned subsidiary of Sorrento Therapeutics, Inc. (&#8220;Sorrento&#8221;). The Company is a commercial-stage, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-opioid</div> pain management company focused on the development and commercialization of topical and injectable therapies. The Company launched its first commercial product in October&#160;2018, ZTlido (lidocaine topical system) 1.8% (&#8220;ZTlido&#8221;), a prescription lidocaine topical system that is designed with novel technology to address the limitations of current prescription lidocaine therapies by providing significantly improved adhesion and continuous pain relief throughout the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12-hour</div> administration period. The Company is currently developing two product candidates, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-102</div> (10 mg, dexamethasone sodium phosphate viscous gel), a Phase&#160;3, novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;SP-102&#8221;),</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-103</div> (lidocaine topical system) 5.4% <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;SP-103&#8221;),</div> for the treatment of acute low back pain. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">&#160;18, 2019, the Company entered into a Contribution and Loan Agreement with Sorrento and the holders of the outstanding shares of capital stock of Scilex Pharmaceuticals Inc. (&#8220;Scilex Pharma&#8221;) pursuant to which the Company acquired 100% of the outstanding shares of capital stock of Scilex Pharma in exchange for shares of the Company&#8217;s common stock (the &#8220;Contribution&#8221;), which was accounted for as a reorganization of entities under common control. Pursuant to the Contribution and Loan Agreement, Sorrento provided the Company with a loan with an initial principal amount of $16.5&#160;million <div style="letter-spacing: 0px; top: 0px;;display:inline;">in the form of a note payable, which was used by the Company to fund the acquisition of Semnur Pharmaceuticals, Inc. (&#8220;Semnur&#8221;). Concurrently therewith, the Company entered into an Agreement and Plan of Merger with Semnur, Sigma Merger Sub, Inc., the Company&#8217;s prior wholly owned subsidiary (&#8220;Merger Sub&#8221;), Fortis Advisors LLC, solely as representative of the holders of Semnur equity (the &#8220;Semnur Equityholders&#8217; Representative&#8221;), and Sorrento, for limited purposes (the &#8220;Merger Agreement&#8221;), which was accounted for as an asset acquisition. Pursuant to the Merger Agreement, Merger Sub merged with and into Semnur (the &#8220;Merger&#8221;), with Semnur surviving as the Company&#8217;s wholly owned subsidiary. As a result of the Contribution and the Merger, Scilex Pharma and Semnur became wholly owned subsidiaries of the Company. Upon completion of the Contribution and the Merger, the historical consolidated financial statements of Scilex Pharma became the historical consolidated financial statements of Scilex Holding.</div> </div></div> <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Since inception, the Company had devoted substantially all of its efforts to the product development of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">SP</div></div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">-102</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">SP-103</div> and the commercialization of ZTlido. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and include all adjustments necessary for the fair presentation of the Company&#8217;s financial position for the periods presented. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying consolidated financial statements include the accounts of the Company&#8217;s subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vickers Vantage [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DescriptionOfOrganizationAndBusinessOperationsLineItems', window );"><strong>Description of Organization and Business Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 1. DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vickers Vantage Corp. I (the &#8220;Company&#8221;) is a blank check company incorporated as a Cayman Islands exempted company on February&#160;21, 2020. The Company was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities (a &#8220;Business Combination&#8221;). </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has one wholly owned subsidiary which was formed on February&#160;2, 2022, Vantage Merger Sub Inc., a Delaware corporation. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is not limited to a particular industry or sector for purposes of consummating a Business Combination. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As of September&#160;30, 2022, the Company had not commenced any operations. All activity for the period from February&#160;21, 2020 (inception) through September&#160;30, 2022 relates to the Company&#8217;s formation and the initial public offering (&#8220;Initial Public Offering&#8221;), which is described below, and, subsequent to the Initial Public Offering, identifying a target company for a Business Combination and in connection therewith entering into the Merger Agreement, which is described below in Note 6. The Company will not generate any operating revenues until after the completion of a Business Combination, at the earliest. The Company will generate <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-operating</div> income in the form of interest income from the proceeds derived from the Initial Public Offering. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The registration statement for the Company&#8217;s Initial Public Offering was declared effective on January&#160;6, 2021. On January&#160;11, 2021 the Company consummated the Initial Public Offering of&#160;13,800,000&#160;Units (the &#8220;Units&#8221; and, with respect to the ordinary shares included in the Units sold, the &#8220;Public Shares&#8221;), which includes the full exercise by the underwriter of its over-allotment option in the amount of&#160;1,800,000&#160;Units, at $10.00&#160;per Unit, generating gross proceeds of $138,000,000&#160;which is described in Note 3. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of&#160;6,840,000 warrants (the &#8220;Private Placement Warrants&#8221;) at a price of $0.75&#160;per Private Placement Warrant in a private placement to Vickers Venture Fund VI Pte Ltd and Vickers Venture Fund VI (Plan) Pte Ltd, (the &#8220;Sponsor&#8221;), generating gross proceeds of $5,130,000, which is described in Note 4. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transaction costs amounted to $8,149,473, consisting of $2,400,000&#160;in cash underwriting fees, $5,190,000&#160;in deferred underwriting fees, and $559,473&#160;of other offering costs </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Following the closing of the Initial Public Offering on January&#160;11, 2021, an amount of $139,380,000&#160;($10.10&#160;per Unit) from the net proceeds of the sale of the Units in the Initial Public Offering and the sale of the Private Placement Warrants was placed in a trust account (the &#8220;Trust Account&#8221;), and invested in U.S. government securities, within the meaning set forth in Section&#160;2(a)(16) of the Investment Company Act, with a maturity of 185 days or less, or in any open-ended investment company that holds itself out as a money market fund investing solely in U.S.&#160;Treasuries and meeting certain conditions under Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2a-7</div> of the Investment Company Act, as determined by the Company, until the earliest of: (i)&#160;the completion of a Business Combination and (ii)&#160;the distribution of the funds in the Trust Account to the Company&#8217;s shareholders, as described below. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On January&#160;10, 2022, the Company extended the period of time to consummate a Business Combination from January&#160;11, 2022 to April&#160;11, 2022. On April&#160;11, 2022, the Company extended the period of time to consummate a Business Combination to July&#160;11, 2022. On July&#160;11, 2022, the Company extended the period of time to </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">consummate a Business Combination to August&#160;11, 2022 and without another shareholder vote, to elect to extend the date to consummate a business combination on a monthly basis for up to five times by an additional one month each time after, upon five days&#8217; advance notice prior to the applicable deadlines, until January&#160;11, 2023. As of the date of this filing, the Company has extended the period of time to consummate a Business Combination to November&#160;11, 2022. In connection with the extensions, the Sponsors deposited an aggregate of $3,365,554 into the trust account in the form of a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest-bearing</div> loans as of the date of this filing. The Company will have until November&#160;11, 2022 to consummate a Business Combination. As a result, an aggregate of $101,293,086&#160;as of September&#160;30, 2022 is held in the Trust Account. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and the sale of the Private Placement Warrants, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination.&#160;The stock exchange listing rules require that the Business Combination must be with one or more operating businesses or assets with a fair market value equal to at least 80% of the assets held in the Trust Account (as defined below) (less any deferred underwriting commissions and taxes payable on the interest earned on the Trust Account). The Company will only complete a Business Combination if the post-Business Combination company owns or acquires 50% or more of the issued and outstanding voting securities of the target or otherwise acquires a controlling interest in the target business sufficient for it not to be required to register as an investment company under the Investment Company Act of 1940, as amended (the &#8220;Investment Company Act&#8221;). There is no assurance that the Company will be able to successfully effect a Business Combination. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company will provide the holders of the public shares (the &#8220;Public Shareholders&#8221;) with the opportunity to redeem all or a portion of their public shares upon the completion of the Business Combination, either (i)&#160;in connection with a general meeting called to approve the Business Combination or (ii)&#160;by means of a tender offer. The decision as to whether the Company will seek shareholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The Public Shareholders will be entitled to redeem their Public Shares, equal to the aggregate amount then on deposit in the Trust Account, calculated as of two business days prior to the consummation of the Business Combination (anticipated to be $10.38&#160;per Public Share as of the date of this filing), including interest (which interest shall be net of taxes payable), divided by the number of then issued and outstanding public shares, subject to certain limitations as described in the prospectus. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">per-share</div> amount to be distributed to the Public Shareholders who properly redeem their shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriters (as discussed in Note 6). </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company will proceed with a Business Combination only if the Company has net tangible assets of at least $5,000,001&#160;and, if the Company seeks shareholder approval, it receives an ordinary resolution under Cayman Islands law approving a Business Combination, which requires the affirmative vote of a majority of the shareholders who attend and vote at a general meeting of the Company. If a shareholder vote is not required and the Company does not decide to hold a shareholder vote for business or other legal reasons, the Company will, pursuant to its Amended and Restated Memorandum and Articles of Association, conduct the redemptions pursuant to the tender offer rules of the Securities and Exchange Commission (&#8220;SEC&#8221;), and file tender offer documents containing substantially the same information as would be included in a proxy statement with the SEC prior to completing a Business Combination. If the Company seeks shareholder approval in connection with a Business Combination, the Company&#8217;s Sponsors have agreed to vote its Founder Shares (as defined in Note 5) and any Public Shares purchased during or after the Initial Public Offering in favor of approving a Business Combination. Additionally, each Public Shareholder may elect to redeem their Public Shares, without voting, and if they do vote, irrespective of whether they vote for or against a proposed Business Combination. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notwithstanding the foregoing, if the Company seeks shareholder approval of the Business Combination and the Company does not conduct redemptions pursuant to the tender offer rules, a Public Shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a &#8220;group&#8221; (as defined under Section&#160;13 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;)), will be restricted from redeeming its shares with respect to more than an aggregate of&#160;20% of the Public Shares without the Company&#8217;s prior written consent. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Sponsors have agreed (a)&#160;to waive their redemption rights with respect to any Founder Shares and Public Shares held by them in connection with the completion of a Business Combination and (b)&#160;not to propose an amendment to the Amended and Restated Memorandum and Articles of Association (i)&#160;to modify the substance or timing of the Company&#8217;s obligation to allow redemption in connection with the Company&#8217;s initial Business Combination or to redeem&#160;100% of the Public Shares if the Company does not complete a Business Combination within the Combination Period (as defined below) or (ii)&#160;with respect to any other provision relating to shareholders&#8217; rights or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-initial</div> business combination activity, unless the Company provides the Public Shareholders with the opportunity to redeem their Public Shares upon approval of any such amendment at a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">per-share</div> price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest (which interest shall be net of taxes payable), divided by the number of then issued and outstanding Public Shares. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">If the Company has not completed a Business Combination within the Combination Period and shareholders do not further extend such period, the Company will (i)&#160;cease all operations except for the purpose of winding up, (ii)&#160;as promptly as reasonably possible but not more than ten business days thereafter, redeem&#160;100% of the Public Shares, at a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">per-share</div> price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest (less up to $50,000&#160;of interest to pay dissolution expenses and which interest shall be net of taxes payable), divided by the number of then issued and outstanding Public Shares, which redemption will completely extinguish the rights of the Public Shareholders as shareholders (including the right to receive further liquidating distributions, if any), and (iii)&#160;as promptly as reasonably possible following such redemption, subject to the approval of the Company&#8217;s remaining Public Shareholders and its Board of Directors, liquidate and dissolve, subject in each case to the Company&#8217;s obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law. There will be no redemption rights or liquidating distributions with respect to the Company&#8217;s warrants, which will expire worthless if the Company fails to complete a Business Combination within the Combination Period. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Sponsors have agreed to waive their rights to liquidating distributions from the Trust Account with respect to the Founder Shares if the Company fails to complete a Business Combination within the Combination Period. However, if the Sponsors or any of their respective affiliates acquire Public Shares, such Public Shares will be entitled to liquidating distributions from the Trust Account if the Company fails to complete a Business Combination within the Combination Period. The underwriters have agreed to waive their rights to their deferred underwriting commission (see Note 6) held in the Trust Account in the event the Company does not complete a Business Combination within the Combination Period, and in such event, such amounts will be included with the other funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the assets remaining available for distribution will be less than the amount of funds deposited into the Trust Account ($10.38&#160;per share). </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In order to protect the amounts held in the Trust Account, the Sponsors have agreed that it will be liable to the Company if and to the extent any claims by a third party (other than the Company&#8217;s independent registered public accounting firm) for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Trust Account to below (1) $10.10&#160;per Public Share or (2)&#160;such lesser amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account due to reductions in the value of trust assets, in each case net of the interest which may be withdrawn to pay taxes, except as to any claims by a third party who executed a waiver of any and all rights to seek access to the Trust Account and except as to any claims under the Company&#8217;s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). In the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsors will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsors will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (other than the Company&#8217;s independent registered public accounting firm), prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On June&#160;30, 2022, the Company held an extraordinary general meeting of its shareholders (the &#8220;Meeting&#8221;), to amend the Company&#8217;s Amended and Restated Memorandum and Articles of Association (the &#8220;Extension Amendment&#8221;) to (i)&#160;extend the date by which the Company has to consummate an initial business combination from July&#160;11, 2022 (the &#8220;Original Termination Date&#8221;) to August&#160;11, 2022 (the &#8220;Extended Date&#8221;) and (ii)&#160;allow the Company without another shareholder vote, to elect to extend the date to consummate a business combination on a monthly basis for up to five times by an additional one month each time after the Extended Date, upon five days&#8217; advance notice prior to the applicable deadlines, until January&#160;11, 2023 or a total of up to nine months after the Original Termination Date (the &#8220;Extension Proposal&#8221;). The Company&#8217;s shareholders approved the Extension Amendment at the Meeting. On July&#160;5, 2022, the Company filed the Extension Amendment with the Cayman Islands Registrar of Companies. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In connection with its solicitation of proxies in connection with the Extension Proposal, the Company was required to permit its public shareholders to redeem their ordinary shares. Of the 13,800,000 ordinary shares outstanding with redemption rights, the holders of 4,073,605 ordinary shares elected to redeem their shares at a per share redemption price of $10.25. As a result, approximately $41.8 million was removed from the Trust Account to pay such holders and approximately $99.8 million remained in the Trust Account. Following the redemptions, the Company has 9,726,395 ordinary shares with redemption rights outstanding and the Company will deposit $323,888 (or approximately $0.0333 per ordinary share that remains outstanding) for each calendar month, or portion thereof, that is needed by the Company to complete an initial business combination from July 11, 2022.</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has deposited an aggregate of $1,295,556&#160;into the Trust Account to extend the date to consummate a business combination to November&#160;11, 2022 (the &#8220;Combination Period&#8221;). </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Going Concern and Liquidity </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of September&#160;30, 2022, the Company had $34,961&#160;in its operating bank accounts, and working capital deficit of $643,543. As of September&#160;30, 2022, approximately $696,000&#160;of the amount on deposit in the Trust Account represented interest income, which is available to pay the Company&#8217;s tax obligations. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If the Company is unable to raise additional capital, it may be required to take additional measures to conserve liquidity, which could include, but not necessarily be limited to, suspending the pursuit of a Business Combination. The Company cannot provide any assurance that new financing will be available to it on commercially acceptable terms, if at all. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;">As a result of the above, in connection with the Company&#8217;s assessment of going concern considerations in accordance with Financial Accounting Standard Board&#8217;s Accounting Standards Codification Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">205-40,</div> &#8220;Presentation of Financial Statements &#8212; Going Concern,&#8221; management has determined that the liquidity condition and date for mandatory liquidation and dissolution raise substantial doubt about the Company&#8217;s ability to continue as a going concern through November&#160;11, 2022 (extension date), the scheduled liquidation date of the Company if it does not complete a Business Combination prior to such date. These condensed consolidated financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If the Company is unable to raise additional capital, it may be required to take additional measures to conserve liquidity, which could include, but not necessarily be limited to, suspending the pursuit of a Business Combination. The Company cannot provide any assurance that new financing will be available to it on commercially acceptable terms, if at all. </div></div> <span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 1&#160;&#8212;&#160;DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vickers Vantage Corp. I (the &#8220;Company&#8221;) is a blank check company incorporated as a Cayman Islands exempted company on February&#160;21, 2020. The Company was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities (a &#8220;Business Combination&#8221;). </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is not limited to a particular industry or sector for purposes of consummating a Business Combination. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As of December&#160;31, 2021, the Company had not commenced any operations. All activity for the period from February&#160;21, 2020 (inception) through December&#160;31, 2021 relates to the Company&#8217;s formation and the initial public offering (&#8220;Initial Public Offering&#8221;), which is described below, and, subsequent to the Initial Public Offering, identifying a target company for a Business Combination. The Company will not generate any operating revenues until after the completion of a Business Combination, at the earliest. The Company will generate <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-operating</div> income in the form of interest income from the proceeds derived from the Initial Public Offering. The Company has selected December&#160;31 as its fiscal year end. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The registration statement for the Company&#8217;s Initial Public Offering was declared effective on January&#160;6, 2021. On January&#160;11, 2021 the Company consummated the Initial Public Offering of 13,800,000&#160;Units (the &#8220;Units&#8221; and, with respect to the ordinary shares included in the Units sold, the &#8220;Public Shares&#8221;), which includes the full exercise by the underwriter of its over-allotment option in the amount of 1,800,000&#160;Units, at $10.00 per Unit, generating gross proceeds of $138,000,000 which is described in Note 3. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of 6,840,000 warrants (the &#8220;Private Placement Warrants&#8221;) at a price of $0.75 per Private Placement Warrant in a private placement to Vickers Venture Fund&#160;VI Pte Ltd and Vickers Venture Fund&#160;VI (Plan) Pte Ltd, (the &#8220;Sponsor&#8221;), generating gross proceeds of $5,130,000, which is described in Note 4. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transaction costs amounted to $8,149,473, consisting of $2,400,000 in cash underwriting fees, $5,190,000 in deferred underwriting fees, and $559,473 of other offering costs. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Following the closing of the Initial Public Offering on January&#160;11, 2021, an amount of $139,380,000 ($10.10 per Unit) from the net proceeds of the sale of the Units in the Initial Public Offering and the sale of the Private Placement Warrants was placed in a trust account (the &#8220;Trust Account&#8221;), and invested in U.S. government securities, within the meaning set forth in Section&#160;2(a)(16) of the Investment Company Act, with a maturity of 185&#160;days or less, or in any open-ended investment company that holds itself out as a money market fund investing solely in U.S. Treasuries and meeting certain conditions under <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Rule&#160;2a-7</div> of the Investment Company Act, as determined by the Company, until the earliest of: (i)&#160;the completion of a Business Combination and (ii)&#160;the distribution of the funds in the Trust Account to the Company&#8217;s shareholders, as described below. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">The Company&#8217;s management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and the sale of the Private Placement Warrants, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. <div style="letter-spacing: 0px; top: 0px;;display:inline;">The stock exchange listing rules require that the Business Combination must be with one or more operating businesses or assets with a fair market value equal to at least 80% of the assets held in the Trust Account (as defined below) (less any deferred underwriting commissions and taxes payable on the interest earned on the Trust Account). The</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"/> </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Company will only complete a Business Combination if the post-Business Combination company owns or acquires 50% or more of the issued and outstanding voting securities of the target or otherwise acquires a controlling interest in the target business sufficient for it not to be required to register as an investment company under the Investment Company Act of 1940, as amended (the &#8220;Investment Company Act&#8221;). There is no assurance that the Company will be able to successfully effect a Business Combination. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;">The Company will provide the holders of the public shares (the &#8220;Public Shareholders&#8221;) with the opportunity to redeem all or a portion of their public shares upon the completion of the Business Combination, either (i)&#160;in connection with a general meeting called to approve the Business Combination or (ii)&#160;by means of a tender offer. The decision as to whether the Company will seek shareholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The Public Shareholders will be entitled to redeem their Public Shares, equal to the aggregate amount then on deposit in the Trust Account, calculated as of two business days prior to the consummation of the Business Combination (initially anticipated to be $10.10 per Public Share), including interest (which interest shall be net of taxes payable), divided by the number of then issued and outstanding public shares, subject to certain limitations as described in the prospectus. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">per-share</div> amount to be distributed to the Public Shareholders who properly redeem their shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriters (as discussed in Note 6). </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company will proceed with a Business Combination only if the Company has net tangible assets of at least $5,000,001 and, if the Company seeks shareholder approval, it receives an ordinary resolution under Cayman Islands law approving a Business Combination, which requires the affirmative vote of a majority of the shareholders who attend and vote at a general meeting of the Company. If a shareholder vote is not required and the Company does not decide to hold a shareholder vote for business or other legal reasons, the Company will, pursuant to its Amended and Restated Memorandum and Articles of Association, conduct the redemptions pursuant to the tender offer rules of the Securities and Exchange Commission (&#8220;SEC&#8221;), and file tender offer documents containing substantially the same information as would be included in a proxy statement with the SEC prior to completing a Business Combination. If the Company seeks shareholder approval in connection with a Business Combination, the Company&#8217;s Sponsors have agreed to vote its Founder Shares (as defined in Note 5) and any Public Shares purchased during or after the Initial Public Offering in favor of approving a Business Combination. Additionally, each Public Shareholder may elect to redeem their Public Shares, without voting, and if they do vote, irrespective of whether they vote for or against a proposed Business Combination. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notwithstanding the foregoing, if the Company seeks shareholder approval of the Business Combination and the Company does not conduct redemptions pursuant to the tender offer rules, a Public Shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a &#8220;group&#8221; (as defined under Section&#160;13 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;)), will be restricted from redeeming its shares with respect to more than an aggregate of 20% of the Public Shares without the Company&#8217;s prior written consent. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;">The Sponsors have agreed (a)&#160;to waive their redemption rights with respect to any Founder Shares and Public Shares held by them in connection with the completion of a Business Combination and (b)&#160;not to propose an amendment to the Amended and Restated Memorandum and Articles of Association (i)&#160;to modify the substance or timing of the Company&#8217;s obligation to allow redemption in connection with the Company&#8217;s initial Business Combination or to redeem 100% of the Public Shares if the Company does not complete a Business Combination within the Combination Period (as defined below) or (ii)&#160;with respect to any other provision relating to shareholders&#8217; rights or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-initial</div> business combination activity, unless the Company provides the Public<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">Shareholders with the opportunity to redeem their Public Shares upon approval of any such amendment at a&#160;</div> </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">per-share</div> price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest (which interest shall be net of taxes payable), divided by the number of then issued and outstanding Public Shares. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On January&#160;10, 2022, the Company extended the period of time to consummate a Business Combination from January&#160;11, 2022 to April&#160;11, 2022. In connection with the extension, the Sponsors deposited $1,035,000 into the trust account in the form of a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest</div> bearing loan. The Company will have until April&#160;11, 2022 to consummate a Business Combination. However, if the Company anticipates that it may not be able to consummate a Business Combination by April&#160;11, 2022, the Company may extend the period of time to consummate a Business Combination by an additional three&#160;months (until July&#160;11, 2022 to complete a Business Combination (the &#8220;Combination Period&#8221;). In order to extend the time available for the Company to consummate a Business Combination, the Sponsor or its affiliate or designees must deposit into the Trust Account $1,035,000 ($0.075 per Public Share), on or prior to the date of the applicable deadline, for the three-month extension. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">If the Company has not completed a Business Combination within the Combination Period, the Company will (i)&#160;cease all operations except for the purpose of winding up, (ii)&#160;as promptly as reasonably possible but not more than ten business days thereafter, redeem 100% of the Public Shares, at a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">per-share</div> price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest (less up to $50,000 of interest to pay dissolution expenses and which interest shall be net of taxes payable), divided by the number of then issued and outstanding Public Shares, which redemption will completely extinguish the rights of the Public Shareholders as shareholders (including the right to receive further liquidating distributions, if any), and (iii)&#160;as promptly as reasonably possible following such redemption, subject to the approval of the Company&#8217;s remaining Public Shareholders and its Board of Directors, liquidate and dissolve, subject in each case to the Company&#8217;s obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law. There will be no redemption rights or liquidating distributions with respect to the Company&#8217;s warrants, which will expire worthless if the Company fails to complete a Business Combination within the Combination Period. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Sponsors have agreed to waive their rights to liquidating distributions from the Trust Account with respect to the Founder Shares if the Company fails to complete a Business Combination within the Combination Period. However, if the Sponsors or any of their respective affiliates acquire Public Shares, such Public Shares will be entitled to liquidating distributions from the Trust Account if the Company fails to complete a Business Combination within the Combination Period. The underwriters have agreed to waive their rights to their deferred underwriting commission (see Note 6) held in the Trust Account in the event the Company does not complete a Business Combination within the Combination Period, and in such event, such amounts will be included with the other funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the assets remaining available for distribution will be less than the amount of funds deposited into the Trust Account ($10.10 per share). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">In order to protect the amounts held in the Trust Account, the Sponsors have agreed that it will be liable to the Company if and to the extent any claims by a third party (other than the Company&#8217;s independent registered public accounting firm) for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account to below (1)&#160;$10.10 per Public Share or (2)&#160;such lesser amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account due to reductions in the value of trust assets, in each case net of the interest which may be withdrawn to pay taxes, except as to any claims by a third party who<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">executed a waiver of any and all rights to seek access to the Trust Account and except as to any claims under the&#160;</div> </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Company&#8217;s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). In the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsors will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsors will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (other than the Company&#8217;s independent registered public accounting firm), prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Going Concern and Liquidity </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2021, the Company had $507,921 in its operating bank accounts, and working capital of $303,753. As of December&#160;31, 2021, approximately $31,000 of the amount on deposit in the Trust Account represented interest income, which is available to pay the Company&#8217;s tax obligations. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If the Company is unable to raise additional capital, it may be required to take additional measures to conserve liquidity, which could include, but not necessarily be limited to, suspending the pursuit of a Business Combination. The Company cannot provide any assurance that new financing will be available to it on commercially acceptable terms, if at all. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As a result of the above, in connection with the Company&#8217;s assessment of going concern considerations in accordance with Financial Accounting Standard Board&#8217;s Accounting Standards Update (&#8220;ASU&#8221;) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2014-15,</div> &#8220;Disclosures of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern,&#8221; management has determined that the liquidity condition and date for mandatory liquidation and dissolution raise substantial doubt about the Company&#8217;s ability to continue as a going concern through July&#160;11, 2022 (extension date), the scheduled liquidation date of the Company if it does not complete a Business Combination prior to such date. These financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If the Company is unable to raise additional capital, it may be required to take additional measures to conserve liquidity, which could include, but not necessarily be limited to, suspending the pursuit of a Business Combination. The Company cannot provide any assurance that new financing will be available to it on commercially acceptable terms, if at all. </div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_DescriptionOfOrganizationAndBusinessOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_DescriptionOfOrganizationAndBusinessOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_VickersVantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_VickersVantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139838692441232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Significant Accounting Policies </div></div></div> </td> </tr> </table> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of these consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of these consolidated financial statements and the reported amounts of expenses during the reporting period. Management believes that these estimates are reasonable; however, actual results may differ from these estimates. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cash and Cash Equivalents </div></div></div></div></div> <div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company considers all highly liquid investments purchased with original maturities of three months or less to be cash equivalents. The Company minimizes its credit risk associated with cash and cash equivalents by periodically evaluating the credit quality of its primary financial institution. Although the balance at times may exceed federally-insured limits, the Company has not experienced any losses on such accounts. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value of Financial Instruments </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company follows accounting guidance on fair value measurements for financial instruments measured on a recurring basis, as well as for certain assets and liabilities that are initially recorded at their estimated fair values. Fair value is defined as the exit price, or the amount that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company uses the following three-level hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs to value its financial instruments: </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 5%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">a.</div></td>
<td style="vertical-align: top; font-size: 10pt;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;1: Observable inputs such as unadjusted quoted prices in active markets for identical instruments. </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 5%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">b.</div></td>
<td style="vertical-align: top; font-size: 10pt;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;2: Quoted prices for similar instruments that are directly or indirectly observable in the marketplace. </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 5%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">c.</div></td>
<td style="vertical-align: top; font-size: 10pt;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;3: Significant unobservable inputs which are supported by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation. </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety requires it to make judgments and consider factors specific to the asset or liability. The use of different assumptions and/or estimation methodologies may have a material effect on estimated fair values. Accordingly, the fair value estimates disclosed or initial amounts recorded may not be indicative of the amount that the Company or holders of the instruments could realize in a current market exchange. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2021 and 2020, the carrying amount of cash equivalents approximates their fair value based upon quoted market prices. Certain of the Company&#8217;s financial instruments are not measured at fair value on a recurring basis, but are recorded at amounts that approximate their fair value due to their liquid or short-term nature, such as cash, prepaid expenses, accounts receivable, and accounts payable. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accounts Receivable, Net </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable are presented net of allowances for expected credit losses and consist of trade receivables from product sales to one customer, which are generally unsecured. Estimated credit losses related to trade accounts receivable are recorded as general and administrative expenses and as an allowance for expected credit losses within accounts receivable, net. The Company reviews reserves and makes adjustments based on historical experience and known collectability issues and disputes. When internal collection efforts on accounts have been exhausted, the accounts are written off by reducing the allowance for expected credit losses. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Inventory </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company determines inventory cost on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-in,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-out</div> basis. The Company reduces the carrying value of inventories to a lower of cost or net realizable value for those items that are potentially excess, obsolete or slow-moving. The Company reserves for excess and obsolete inventory based upon historical experience, sales trends, and specific categories of inventory and expiration dates for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">on-hand</div> inventory. As of December&#160;31, 2021 and 2020, the Company&#8217;s inventory was primarily comprised of finished goods. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px;"/> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Property and Equipment </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment are carried at cost less accumulated depreciation. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the assets, which are generally five to seven years. Leasehold improvements are amortized over the lesser of their estimated useful lives or the term of the respective lease on a straight-line basis. The cost of repairs and maintenance is expensed as incurred. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Goodwill and Other Long-Lived Assets </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill, which has an indefinite life, represents the excess cost over fair value of net assets acquired. Goodwill is reviewed for impairment at least annually during the fourth quarter, or more frequently if events occur indicating the potential for impairment. The Company has determined that only one reporting unit exists for examination under impairment review. During its goodwill impairment review, the Company may assess qualitative factors to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company. If, after assessing the totality of these qualitative factors, the Company determines that it is not more likely than not that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company performs a quantitative goodwill impairment test. The Company may also elect to bypass the qualitative assessment in a period and elect to proceed to perform the quantitative goodwill impairment test. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company evaluates its long-lived and intangible assets with definite lives, such as property and equipment, patent rights, and acquired technology, for impairment by considering competition by products prescribed for the same indication, the likelihood and estimated future entry of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-generic</div> and generic competition with the same or similar indication and other related factors. The factors that drive the estimate of useful life are often uncertain and are reviewed on a periodic basis or when events occur that warrant review. Recoverability is measured by comparison of the assets&#8217; book value to future net undiscounted cash flows that the assets are expected to generate to determine if a write-down to the recoverable amount is appropriate. If such assets are written down, an impairment will be recognized as the amount by which the book value of the asset group exceeds the recoverable amount. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Debt </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company may enter financing arrangements, the terms of which involve significant assumptions and estimates. This involves estimating future net product sales, determining interest expense, determining the amortization period of the debt discount, as well as determining the classification between current and long-term portions. In estimating future net product sales, the Company assesses prevailing market conditions using various external market data against the Company&#8217;s anticipated sales and planned commercial activities as well as actual ZTlido sales up to the date the financial statements were issued. See Note 8 for discussion of the Scilex Pharma Notes, which include repayments based on a percentage of net sales of ZTlido. Consequently, the Company imputes interest on the carrying value of the debt and records interest expense using an imputed effective interest rate. The Company reassesses the expected payments each reporting period and accounts for any changes through an adjustment to the effective interest rate on a prospective basis, with a corresponding impact to the classification of the Company&#8217;s current and long-term portions. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research and Development Costs </div></div></div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company expenses the cost of research and development as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including clinical trial costs, manufacturing costs for both clinical and preclinical materials as well as other contracted services, </div></div></div> <div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="background: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>   <div style="letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">license fees and other external costs. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity is performed or when the goods have been received, rather than when payment is made, in accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic 730, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research and Development</div></div>. </div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">In-Process</div> Research and Development Expense </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company has acquired and may continue to acquire the rights to develop and commercialize new product candidates. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">up-front</div> payments to acquire a new drug compound or drug delivery device, as well as future milestone payments associated with asset acquisitions that do not meet the definition of a derivative and are deemed probable to achieve the milestones, are immediately expensed as acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development provided that the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, have no alternative future use. Intangible assets acquired in a business combination that are used for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development (&#8220;IPR&amp;D&#8221;) activities are considered indefinite-lived until the completion or abandonment of the associated research and development efforts. Upon commercialization of the relevant research and development project, the Company amortizes the acquired IPR&amp;D over its estimated useful life. Capitalized IPR&amp;D is reviewed annually for impairment or more frequently as changes in circumstance or the occurrence of events suggest that the remaining value may not be recoverable. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The provisions of the FASB ASC Topic 740, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes</div></div>, addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC Topic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">740-10,</div> the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based on the technical merits of the position. The Company has determined that it has uncertain tax positions. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for income taxes using the asset and liability method to compute the differences between the tax basis of assets and liabilities and the related financial amounts, using currently enacted tax rates. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has deferred tax assets, which are subject to periodic recoverability assessments. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount that more likely than not will be realized. As of December&#160;31, 2021 and 2020, the Company maintained a full valuation allowance against its deferred tax assets, with the exception of an amount equal to its deferred tax liabilities that are scheduled to reverse against the Company&#8217;s deferred tax assets. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Leases </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company determines if an arrangement is a lease at inception. Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> (&#8220;ROU&#8221;) assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As the Company&#8217;s leases do not provide an implicit rate, it uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any lease payments made and is reduced by lease incentives. The Company&#8217;s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term in selling, general and administrative expenses. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Derivative Liabilities </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivative liabilities are recorded on the Company&#8217;s consolidated balance sheets at their fair value on the date of issuance and are revalued on each balance sheet date until such instruments are exercised or expire, with changes in the fair value between reporting periods recorded as other income or expense. </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="null;text-indent: 0px;;font-style:italic;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Revenue Recognition&#160;</div> </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s revenue is generated from product sales within the United States. The Company does not have significant costs associated with costs to obtain a contract with its customer. All of the Company&#8217;s revenue and accounts receivable result from a sole customer. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue from product sales is fully comprised of sales of ZTlido. The Company&#8217;s performance obligation with respect to sales of ZTlido is satisfied at a point in time, which transfers control upon delivery of product to the customer. The Company considers control to have transferred upon delivery because the customer has legal title to the product, physical possession of the product has been transferred to the customer, the customer has significant risks and rewards of ownership of the product, and the Company has a present right to payment at that time. Invoicing typically occurs upon shipment and the length of time between invoicing and when payment is due is not significant. The aggregate dollar value of unfulfilled orders as of December&#160;31, 2021 and 2020 were not material. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">For product sales, the Company records <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">gross-to-net</div></div> sales adjustments for commercial and government rebates, fees and chargebacks, wholesaler and distributor fees, sales returns and prompt payment discounts. Such variable consideration is estimated in the period of the sale and is estimated using a most likely amount approach based primarily upon provisions included in the Company&#8217;s customer contract, customary industry practices and current government regulations. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Gross-to-net</div></div> adjustments are generally recorded as contract liabilities under accrued expenses within the Company&#8217;s consolidated balance sheet. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Rebates </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">Rebates are discounts which the Company pays under either government or private health care programs. Government rebate programs include state Medicaid drug rebate programs, the Medicare coverage gap discount programs and the Tricare programs. Commercial rebate and fee programs relate to contractual agreements with commercial healthcare providers, under which the Company pays rebates and fees for access to and position on that provider&#8217;s patient drug formulary. Rebates and chargebacks paid under government programs are generally mandated under law, whereas private rebates and fees are generally contractually negotiated by the Company with commercial healthcare providers. Both types of rebates vary over time. The Company records a reduction to gross product sales at the time the customer takes title to the product based on estimates of expected rebate claims. The Company monitors the sales trends and adjust for these rebates on a regular basis to reflect the most recent rebate experience and contractual obligations.</div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Service Fees </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company compensates its customer and others in the distribution chain for wholesaler and distribution services. The Company has determined such services received up to the date the financial statements were issued are not distinct from the Company&#8217;s sale of products to the customer and, therefore, these payments have been recorded as a reduction of revenue. </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Product Returns </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is obligated to accept the return of products sold that are expiring within six months, damaged or do not meet certain specifications. The Company may authorize the return of products sold in accordance with the term of its sales contracts, and estimates allowances for such amounts at the time of sale. The Company estimates the amount of its product sales that may be returned by its customer and record this estimate as a reduction of revenue in the period the related product revenue is recognized.</div></div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"/></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Co-Payment</div> Assistance </div></div></div></div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Patients who have commercial insurance or pay cash and meet certain eligibility requirements may receive <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-payment</div> assistance. The Company accrues for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-payment</div> assistance based on actual program participation and estimates of program redemption using data provided by third-party </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">administrators. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Customer Concentration Risk </div></div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">During the fiscal years ended December<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">31, 2021, 2020 and 2019, sales to the Company&#8217;s sole distributor represented 100% of net revenue. This exposes the Company to concentration of customer risk. The Company monitors the financial condition of its sole customer, limits its credit exposure by setting credit limits, and has not experienced any credit losses for the&#160;years ended December&#160;31, 2021, 2020 and 2019. As the Company continues to expand the commercialization of its product, the Company is not limited to the current customer and has the option of expanding its distribution network with additional distributors through establishing its own affiliates, by acquiring existing third-party business or product rights or by partnering with additional third parties. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock-Based Compensation </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts </div></div> for stock-based compensation in accordance with FASB ASC Topic 718,<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> Compensation</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#8212;</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock Compensation </div></div>which establishes accounting for equity instruments exchanged for employee and consulting services. Under such provisions, stock-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense, under the straight-line method, over the employee&#8217;s requisite service period (generally the vesting period of the equity grant) or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee&#8217;s</div> vesting period. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For purposes of determining </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> the inputs used in the calculation of stock-based compensation, the Company uses historical data in estimating the expected term of options and determines an estimate of option volatility based on an assessment of historical volatilities of comparable companies whose share prices are publicly available. The Company uses these estimates as inputs in the Black-Scholes option pricing model. Depending upon the number of stock options granted, any fluctuations in these calculations could have a material effect on the results presented in the Company&#8217;s consolidated statement of operations. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Net Loss per Share </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic net loss </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">per share is computed by dividing net loss for the period by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share reflects the additional dilution from potential issuances of common stock, such as stock issuable pursuant to the exercise of stock options. The treasury stock method is used to calculate the potential dilutive effect of these common stock equivalents. Potentially dilutive shares are excluded from the computation of diluted net loss per share when their effect is anti-dilutive. In periods where a net loss is presented, all potentially dilutive securities are anti-dilutive and are excluded from the computation of diluted net loss per share. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Segments </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating segments </div></div> are identified as components of an entity where separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions on how to allocate resources and assesses performance. The Company has determined that its chief operating decision maker is its Chief Executive Officer, as he is responsible for making decisions regarding the allocation of resources and assessing performance as well as for strategic operational decisions. The Company is engaged primarily in the development of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">non-opioid<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">products focused on pain management based on its platform technologies and all sales are based in the United States. Accordingly, the Company has determined that it operates its business as a single reportable segment.</div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"/> <br/></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recent Accounting Pronouncements </div></div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In October 2021, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2021-08,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers</div></div>, which requires an acquirer in a </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">business </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">combination to recognize and measure contract assets and contract liabilities in accordance with ASC Topic 606. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2021-08</div> is effective for fiscal years beginning after December&#160;15, 2022 and early adoption is permitted. The Company is evaluating the impact the standard will have on its consolidated financial statements. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In December 2019, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2019-12,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</div></div>. The amendments in this update simplify the accounting for income taxes by removing certain exceptions to the general principles in ASC Topic 740. The amendments also improve consistent application of and simplify U.S. GAAP for other areas of ASC Topic 740 by clarifying and amending existing guidance. The amendments in this update were effective for interim and annual periods for the Company beginning after December&#160;15, 2020. The Company adopted the standard on January&#160;1, 2021. The adoption of the standard had no impact on its consolidated financial statements. </div></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vickers Vantage [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) for interim financial information and in accordance with the instructions to Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</div> and Article 8 of Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-X</div> of the SEC. Certain information or footnote disclosures normally included in condensed financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the Company&#8217;s Annual Report on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Form&#160;10-K</div> as filed with the SEC on February&#160;24, 2022. The interim results for the three and nine months ended September&#160;30, 2022 are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2022 or for any future periods. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Principles of Consolidation </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All significant intercompany balances and transactions have been eliminated in consolidation. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Emerging Growth Company </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is an &#8220;emerging growth company,&#8221; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced </div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Further, Section&#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-emerging</div> growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&#8217;s financial statement with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. </div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of the condensed consolidated financial statements in conformity with GAAP requires the Company&#8217;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the condensed consolidated financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. One of the more significant accounting estimates included in these condensed consolidated financial statements is the determination of the fair value of the warrant liabilities. Such estimates may be subject to change as more current information because available and accordingly, the actual results could differ significantly from those estimates. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cash and Cash Equivalents </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of September&#160;30, 2022 and December&#160;31, 2021. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Investments Held in Trust Account </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At September&#160;30, 2022 and December&#160;31, 2021, the majority of the assets held in the Trust Account were held in money market funds, which are invested primarily in U.S. Treasury securities. The Company presents its investments in money market funds on the condensed consolidated balance sheets at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of these securities is included in interest income in the accompanying unaudited condensed consolidated statements of operations. The estimated fair value of investments held in the Trust Account are determined using available market information. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Offering Costs </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Offering costs consist of legal, accounting, underwriting fees and other costs incurred through the balance sheet date that are directly related to the Initial Public Offering. Offering costs were allocated to the separable financial instruments issued in the Initial Public Offering based on a relative fair value basis, compared to total proceeds received. Offering costs allocated to warrant liabilities were expensed as incurred in the statements of operations. Offering costs associated with the ordinary shares issued were initially charged to temporary equity and then accreted to ordinary shares subject to redemption upon the completion of the Initial Public Offering. Offering costs amounting to $8,119,261&#160;were charged to temporary equity upon the completion of the Initial Public Offering, and $30,212&#160;of the offering costs were related to the warrant liabilities and charged to the condensed consolidated statement of operations for the period ended September&#160;30, 2021. The Company classifies deferred underwriting commissions as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> liabilities as their liquidation is not reasonably expected to require the use of current assets or require the creation of current liabilities. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Ordinary Shares Subject to Possible Redemption </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for its ordinary shares subject to possible redemption in accordance with the guidance in Accounting Standards Codification (&#8220;ASC&#8221;) Topic 480 &#8220;Distinguishing Liabilities from Equity.&#8221; Ordinary shares subject to mandatory redemption is classified as a liability instrument and is measured at fair value. Conditionally redeemable ordinary shares (including ordinary shares that features redemption rights that is either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#8217;s control) is classified as temporary equity. At all other times, ordinary shares are classified as shareholders&#8217; equity. The Company&#8217;s ordinary shares features certain redemption rights that are considered to be outside of the Company&#8217;s control and subject to occurrence of uncertain future events. Accordingly, at September&#160;30, 2022 and December&#160;31, 2021, ordinary shares subject to possible redemption is presented as temporary equity, outside of the shareholders&#8217; deficit section of the Company&#8217;s condensed consolidated balance sheets. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Under ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">480-10-S99,</div></div> the Company has elected to recognize changes in the redemption value immediately as they occur and adjust the carrying value of redeemable ordinary shares to equal the redemption value at the end of each reporting period. This method would view the end of the reporting period as if it were also the redemption date for the security. Immediately upon the closing of the Initial Public Offering, the Company recognized the accretion from initial book value to redemption amount value. The change in the carrying value of redeemable ordinary shares resulted in charges against additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital and accumulated deficit. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At September&#160;30, 2022 and December&#160;31, 2021, the ordinary shares reflected in the condensed consolidated balance sheets are reconciled in the following table: </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 77%; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross proceeds</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">138,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ordinary shares issuance costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8,119,261</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Plus:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accretion of carrying value to redemption value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,499,261</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ordinary shares subject to possible redemption as of December&#160;31, 2021</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">139,380,000</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Mandatorily redeemable ordinary shares</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(41,824,292</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Plus:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accretion of carrying value to redemption value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,737,378</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ordinary shares subject to possible redemption as of September&#160;30, 2022</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">101,293,086</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Warrant Liability </div></div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 480, Distinguishing Liabilities from Equity (&#8220;ASC 480&#8221;) and ASC 815,&#160;Derivatives and Hedging&#160;(&#8220;ASC 815&#8221;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company&#8217;s own ordinary shares, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. We account for the warrants issued in connection with our Initial Public Offering in accordance with the guidance contained in ASC 815 under which the public warrants meet the criteria for equity treatment and the private warrants do not meet the criteria for equity treatment and must be recorded as liabilities. Accordingly, we classify the private warrants as liabilities at their fair value and adjust the private warrants to fair value at each reporting period. This liability is subject to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-measurement</div> at each balance sheet date until exercised, and any change in fair value is recognized in our statement of operations. The fair value of the warrants was estimated using a Black-Scholes option pricing formula. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes </div></div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for income taxes under ASC Topic 740, &#8220;Income Taxes,&#8221; which prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company&#8217;s management determined that the Cayman Islands is the Company&#8217;s major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. As of September&#160;30, 2022 and December&#160;31, 2021, there were no unrecognized tax benefits and no amounts accrued for interest and penalties. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is considered to be an exempted Cayman Islands company with no connection to any other taxable jurisdiction and is presently not subject to income taxes or income tax filing requirements in the Cayman Islands or the United States. As such, the Company&#8217;s tax provision was zero for the periods presented. </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Net Income (Loss) per Ordinary Share </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, &#8220;Earnings Per Share&#8221;. Net income (loss) per ordinary share is computed by dividing net income (loss) by the weighted average number of ordinary shares outstanding for the period. Accretion associated with the redeemable shares of ordinary shares is excluded from earnings per share as the redemption value approximates fair value. Mandatorily redeemable ordinary shares are excluded from the weighted average number of ordinary shares outstanding. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The calculation of diluted income (loss) per share does not consider the effect of the warrants issued in connection with the (i)&#160;Initial Public Offering, and (ii)&#160;the private placement since the exercise of the warrants is contingent upon the occurrence of future events. The warrants are exercisable to purchase&#160;13,740,000&#160;ordinary shares in the aggregate. As of September&#160;30, 2022 and 2021, the Company did not have any dilutive securities or </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">other contracts that could, potentially, be exercised or converted into ordinary shares and then share in the earnings of the Company. As a result, diluted net income (loss) per ordinary share is the same as basic net income (loss) per ordinary share for the periods presented. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table reflects the calculation of basic and diluted net income (loss) per ordinary share (in dollars, except per share amounts): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 48%;">&#160;</td>
<td style="width: 4%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="width: 4%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="width: 4%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="width: 4%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For&#160;the&#160;Three&#160;Months&#160;Ended</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the Nine Months Ended</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Ordinary Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basic and diluted net income (loss) per ordinary share</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allocation of net income (loss)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(131,387</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,444,352</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">623,516</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(349,248</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted weighted average ordinary shares outstanding</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,176,395</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,250,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,862,288</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,675,824</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net income (loss) per ordinary share</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.01</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.08</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.04</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.02</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Concentration of Credit Risk </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times may exceed the Federal Deposit Insurance Corporation coverage limit of $250,000. As of September&#160;30, 2022 and December&#160;31, 2021, the Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such account.</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value of Financial Instruments </div></div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the Company&#8217;s assets and liabilities, which qualify as financial instruments under ASC Topic 820, &#8220;Fair Value Measurement,&#8221; approximates the carrying amounts represented in the accompanying condensed consolidated balance sheets, primarily due to their short-term nature, other than the derivative warrant liability and conversion option liability (Note 9). </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recent Accounting Standards </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In August 2020, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06,</div> Debt &#8212; Debt with Conversion and Other Options (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">470-20)</div> and Derivatives and Hedging &#8212; Contracts in Entity&#8217; Own Equity (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">815-40):</div> Accounting for Convertible Instruments and Contracts in an Entity&#8217; Own Equity (&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06&#8221;),</div> which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU also removes certain settlement conditions that are required for equity-linked contracts to qualify for the derivative scope exception, and it simplifies the diluted earnings per share calculation in certain areas. Management is currently evaluating the new guidance but does not expect the adoption of this guidance to have a material impact on the Company&#8217;s condensed consolidated financial statements. <br/></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 10pt; letter-spacing: 0px;;display:inline;">Management does not believe that any other recently issued, but not yet effective, accounting standard if currently adopted would have a material effect on the accompanying condensed consolidated financial statements.</div></div><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 2&#160;&#8212;&#160;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and pursuant to the rules and regulations of the SEC. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Emerging Growth Company </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is an &#8220;emerging growth company,&#8221; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">registered public accounting firm attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.</div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Further, Section&#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-emerging</div> growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&#8217;s financial statement with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of the financial statements in conformity with GAAP requires the Company&#8217;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. One of the more significant accounting estimates included in these financial statements is the determination of the fair value of the warrant liabilities. Such estimates may be subject to change as more current information because available and accordingly, the actual results could differ significantly from those estimates. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Offering Costs </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Offering costs consist of legal, accounting, underwriting fees and other costs incurred through the balance sheet date that are directly related to the Initial Public Offering. Offering costs were allocated to the separable financial instruments issued in the Initial Public Offering based on a relative fair value basis, compared to total proceeds received. Offering costs allocated to warrant liabilities were expensed as incurred in the statements of operations. Offering costs associated with the ordinary shares issued were initially charged to temporary equity and then accreted to ordinary shares subject to redemption upon the completion of the Initial Public Offering. Offering costs amounting to $8,119,261 were charged to temporary equity upon the completion of the Initial Public Offering, and $30,212 of the offering costs were related to the warrant liabilities and charged to the statements of operations. </div><br/></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Ordinary Shares Subject to Possible Redemption </div></div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for its ordinary shares subject to possible redemption in accordance with the guidance in Accounting Standards Codification (&#8220;ASC&#8221;) Topic 480 &#8220;Distinguishing Liabilities from Equity.&#8221; Ordinary shares subject to mandatory redemption is classified as a liability instrument and is measured at fair value. Conditionally redeemable ordinary shares (including ordinary shares that features redemption rights that is either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#8217;s control) is classified as temporary equity. At all other times, ordinary shares are classified as shareholders&#8217; equity. The Company&#8217;s ordinary shares, sold in the IPO, features certain redemption rights that are considered to be outside of the Company&#8217;s control and subject to occurrence of uncertain future events. Accordingly, at December&#160;31, 2021 and 2020, ordinary shares subject to possible redemption is presented as temporary equity, outside of the shareholders&#8217; (deficit) equity section of the Company&#8217;s balance sheets. </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Under ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">480-10-S99,</div></div> the Company has elected to recognize changes in the redemption value immediately as they occur and adjust the carrying value of redeemable ordinary shares subject to possible redemption to equal the redemption value at the end of each reporting period. This method would view the end of the reporting period as if it were also the redemption date for the security. Immediately upon the closing of the Initial Public Offering, the Company recognized the accretion from initial book value to redemption amount value. The change in the carrying value of redeemable ordinary shares resulted in charges against additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital and accumulated deficit. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At December&#160;31, 2021, the ordinary shares reflected in the balance sheets are reconciled in the following table: </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 77%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 77%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross proceeds</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">138,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 77%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less:</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 77%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ordinary shares issuance costs</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8,119,261</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 77%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Plus:</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 77%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accretion of carrying value to redemption value</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,499,261</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 77%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 77%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ordinary shares subject to possible redemption</div></div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">139,380,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 77%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 77%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><br/></td>
<td style="vertical-align: bottom;"><br/></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"/><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Warrant Liability </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 480, Distinguishing Liabilities from Equity (&#8220;ASC 480&#8221;) and ASC 815, Derivatives and Hedging (&#8220;ASC 815&#8221;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company&#8217;s own ordinary shares, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. We account for the warrants issued in connection with our Initial Public Offering in accordance with the guidance contained in ASC 815 under which the public warrants meet the criteria for equity treatment and the private warrants do not meet the criteria for equity treatment and must be recorded as liabilities. Accordingly, we classify the private warrants as liabilities at their fair value and adjust the private warrants to fair value at each reporting period. This liability is subject to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-measurement</div> at each balance sheet date until exercised, and any </div><br/></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">change in fair value is recognized in our statements of operations. The fair value of the warrants was estimated using a Black-Scholes option pricing formula. </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes </div></div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for income taxes under ASC Topic 740, &#8220;Income Taxes,&#8221; which prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company&#8217;s management determined that the Cayman Islands is the Company&#8217;s major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. As of December&#160;31, 2021 and 2020, there were no unrecognized tax benefits and no amounts accrued for interest and penalties. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is considered to be an exempted Cayman Islands company with no connection to any other taxable jurisdiction and is presently not subject to income taxes or income tax filing requirements in the Cayman Islands or the United States. As such, the Company&#8217;s tax provision was zero for the periods presented. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Net income (Loss) per Ordinary Share </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, &#8220;Earnings Per Share&#8221;. Net income (loss) per ordinary share is computed by dividing net income (loss) by the weighted average number of ordinary shares outstanding for the period. Accretion associated with the redeemable shares of ordinary shares is excluded from earnings per share as the redemption value approximates fair value. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The calculation of diluted income (loss) per share does not consider the effect of the warrants issued in connection with the (i)&#160;Initial Public Offering, and (ii)&#160;the private placement since the exercise of the warrants is contingent upon the occurrence of future events. The warrants are exercisable to purchase 13,740,000 ordinary shares in the aggregate. As of December&#160;31, 2021 and 2020, the Company did not have any dilutive securities or other contracts that could, potentially, be exercised or converted into ordinary shares and then share in the earnings of the Company, except for the 450,000 founder shares in December&#160;31, 2021 which are no longer forfeitable and thus included for dilutive purposes. As a result, diluted net loss per ordinary share is the same as basic net loss per ordinary share for the periods presented. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table reflects the calculation of basic and diluted net income per ordinary share (in dollars, except per share amounts): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/>December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the Period<br/>from&#160;February&#160;21,<br/>2020 (Inception)<br/>Through<br/>December&#160;31,<br/>2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Ordinary&#160;Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Ordinary&#160;Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basic net income (loss) per ordinary share</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allocation of net income (loss), as adjusted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">783,438</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6,276</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic weighted average ordinary shares outstanding</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,820,548</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic net income (loss) per ordinary share</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.05</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Diluted net income (loss) per ordinary share</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allocation of net income (loss), as adjusted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">783,438</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6,276</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diluted weighted average ordinary shares outstanding</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,834,110</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diluted net income (loss) per ordinary share</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.05</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr></table><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Concentration of Credit Risk </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times may exceed the Federal Depository Insurance Corporation coverage limit of $250,000. The Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such account. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value of Financial Instruments </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the Company&#8217;s assets and liabilities, which qualify as financial instruments under ASC Topic 820, &#8220;Fair Value Measurement,&#8221; approximates the carrying amounts represented in the accompanying balance sheets, primarily due to their short-term nature, other than the derivative warrant liability. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recent Accounting Standards </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;">Management does not believe that any other recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company&#8217;s condensed financial statements. In August&#160;2020, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2020-06,</div> Debt&#160;&#8212;&#160;Debt with Conversion and Other Options (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">470-20)</div> and Derivatives and Hedging&#160;&#8212;&#160;Contracts in Entity&#8217; Own Equity (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">815-40):</div> Accounting for Convertible Instruments and Contracts in an Entity&#8217; Own Equity (&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06&#8221;),</div> which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU also removes certain settlement conditions that are required for equity-linked contracts to qualify for the derivative scope exception, and it simplifies the diluted earnings per share calculation in certain areas. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06</div> is effective for fiscal&#160;years beginning after December&#160;15, 2023, including interim periods within those fiscal&#160;years, with early adoption permitted. Management is currently evaluating the new guidance but does not expect the adoption of this guidance to have a material impact on the Company&#8217;s condensed financial statements. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Management does not believe that any other recently issued, but not yet effective, accounting standard if currently adopted would have a material effect on the accompanying condensed financial statements. </div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_VickersVantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_VickersVantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139838694731776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity and Going Concern<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_LiquidityAndGoingConcernAbstract', window );"><strong>Liquidity And Going Concern [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_LiquidityAndGoingConcernTextBlock', window );">Liquidity and Going Concern</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liquidity and Going Concern </div></div></div></div></td></tr></table><div style="clear: both; max-height: 0px; text-indent: 0px;"/><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Management has assessed the Company&#8217;s ability to continue as a going concern for at least </div>one<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> year after the date the financial statements are issued.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of September&#160;</div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company&#8217;s negative working capital was $</div>219.6<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, including cash and cash equivalents of approximately $</div>2.5<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million. During the </div>nine<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> months ended September&#160;</div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company had operating losses of $</div>30.9<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and cash flows used for operations of $</div>20.5<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million. The Company had an accumulated deficit of approximately $</div>358.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million as of September&#160;</div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In </div>September 2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company exercised the Early Paydown Provision to fully extinguish the Scilex Pharma Notes (see Note </div>6)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. In </div>August 2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div>September 2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company made principal payments towards the outstanding Scilex Pharma Notes totaling $</div>41.4<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million. Pursuant to Amendment </div>No<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">.&#160;</div>4<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, a principal balance of $</div>28.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million was forgiven by the Scilex Pharma Note Purchasers (see Note </div>6)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> upon the Company&#8217;s exercise of the Early Paydown Provision. The Company funded the principal payments with </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">cash-on</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> hand and $</div>34.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million received from Sorrento on September&#160;</div>28<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> (see Note </div>10)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On September&#160;</div>12<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company and Scilex Pharma entered into a Debt Exchange Agreement with Sorrento, pursuant to which all related party payables and related party note payables that remain outstanding as of immediately prior to, and contingent upon, the closing of the Business Combination were contributed by Sorrento to the Company in exchange for the issuance by the Company to Sorrento of preferred stock of the Company and such shares were subsequently converted into shares of New Scliex common stock and preferred stock (see Note </div>10)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On October&#160;</div>17<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Sorrento and Scilex entered into a Funding Commitment Letter (see Note </div>10)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. Pursuant to the terms of the Funding Commitment Letter, upon the written request of the Company, Sorrento shall fund </div>one<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> or more loans to the Company in the amount to achieve $</div>5,000,001<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> in net tangible assets immediately following the effective time of the Business Combination. Such related party payables or related party note payables will be converted into shares of preferred stock pursuant to the Debt Exchange Agreement. Any loans made under the Funding Commitment Letter will not exceed the lesser of (a) $</div>10,000,000<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and (b)&#160;an amount that, when taken together with all other Outstanding Indebtedness, will result in the Aggregate Outstanding Amount equaling $</div>310,000,000<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> (see Note </div>10)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. The Company did not draw funds from the Funding Commitment Letter at the effective time of the Business Combination.</div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;18, 2019, the Company acquired Semnur and the acquisition was accounted for as an asset acquisition (see Note 3). The Company anticipates the cash needed for the development of Semnur&#8217;s primary product candidate in development, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-102,</div> as well in the development of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-103,</div> will be in excess of the Company&#8217;s cash available within one year after the date these consolidated financial statements are issued. Semnur has no historical revenue and the Company will be responsible for funding all development and commercialization efforts and capital funding needs possibly through private or public equity or debt financings, strategic collaborations or other arrangements. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">On May&#160;12, 2022, the Company entered into a Bill of Sale (see Note 3), with Sorrento to acquire rights, title and interest in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-104</div> Assets (see Note 3). <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-104</div> has not been approved for commercialization and, as such, no revenues have been generated to date by the asset. The Company will be responsible for funding all development and commercialization efforts. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On June&#160;14, 2022, the Company entered into a license and commercialization agreement with Romeg (see Note 3). The transaction was accounted for as an asset acquisition since substantially all the value of the gross assets was concentrated in the single asset, acquired licenses. The Company anticipates incurring costs related to the commercial launch and marketing of the acquired licenses. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company has plans to obtain additional resources to fund its currently planned operations and expenditures for at least twelve months from the issuance of these consolidated financial statements through a combination of equity offerings, debt financings, collaborations, government contracts or other strategic transactions. The Company&#8217;s plans are also dependent upon the success of future sales of ZTlido, which is still in the early stages of commercialization, and are dependent upon, among other things, the success of the Company&#8217;s marketing of ZTlido. Should the Company&#8217;s sales of ZTlido not materialize at the expected rate contemplated in the Company&#8217;s business plan, due to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic or other factors, the Company believes that there are a number of ongoing and potential actions that would maintain its projected cash and projected financial position including but not limited to, additional reductions in general and administrative costs, sales and marketing costs, suspension or winding down of clinical development programs for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-102,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-103,</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-104,</div> and other discretionary costs. Although the Company believes such plans, if executed, should provide the Company with financing to meet its needs, successful completion of such plans is dependent on factors outside the Company&#8217;s control. As such, management cannot conclude that such plans will be effectively implemented within one year after the date that these consolidated financial statements are issued. As a result, management has concluded that the aforementioned conditions, among other things, raise substantial doubt about the Company&#8217;s ability to continue as a going concern for one year after the date the financial statements </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">are issued. </div></div></div><span></span>
</td>
<td class="text"><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liquidity and Going Concern </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Management has assessed the Company&#8217;s ability to continue as a going concern at least one year after the date the financial statements are issued. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">31, 2021, the Company&#8217;s negative working capital was $146.4&#160;million, including cash and cash equivalents of approximately $4.3&#160;million. During the year ended December&#160;31, 2021, the Company<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>had operating losses of $35.8&#160;million and negative cash flows from operations of $28.7&#160;million. The Company had an accumulated deficit of approximately $352.6&#160;million as of December&#160;31, 2021. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In September </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2018, Scilex Pharma issued $224.0&#160;million of the Scilex Pharma Notes (see Note 8) for a purchase price of $140.0&#160;million. Pursuant to the Indenture, as amended (see Note 8), Scilex Pharma is required to maintain a minimum unrestricted cash balance of $4.0&#160;million at the end of each month. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In December </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">2020, Scilex Pharma repurchased an aggregate of $65.0&#160;million of the Scilex Pharma Notes (see Note 8) and amended the terms of the Scilex Pharma Notes to release $45.0&#160;million in restricted funds held in the Reserve Account (see Note 8) and Collateral Account (see Note 8) for the purpose of consummating the repurchase of an aggregate of $45.0&#160;million of principal amount. <div style="letter-spacing: 0px; top: 0px;;display:inline;">In February&#160;</div>2021 and <div style="letter-spacing: 0px; top: 0px;;display:inline;">April&#160;</div>2021, Scilex Pharma effected specified principal repurchases totaling $40.0&#160;million of the principal amount of the Scilex Pharma Notes. On December&#160;31, 2021, Scilex Pharma triggered a cumulative sales-related contingency that triggered an increase in the principal amount of the Scilex Pharma Notes by $28.0&#160;million. <div style="letter-spacing: 0px; top: 0px;;display:inline;">In February&#160;</div>2022, Scilex Pharma drew down on the Letter of Credit (see Note 8) with Sorrento, which also triggered Scilex Pharma&#8217;s obligation to repurchase $20.0&#160;million of the outstanding principal amount of the Scilex Pharma Notes and to maintain a minimum unrestricted cash balance of $10.0&#160;million. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;</div></div>18, 2019, the Company acquired Semnur and the acquisition was accounted for as an asset acquisition (See Note 4). The Company anticipates the cash needed for the development of Semnur&#8217;s primary product candidate in development, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-102,</div> as well in the development of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-103,</div> will be in excess of the Company&#8217;s cash available within one year after the date these consolidated financial statements are issued. Semnur has no historical revenue and the Company will be responsible for funding all development and commercialization efforts and capital funding needs possibly through private or public equity or debt financings, strategic collaborations or other arrangements. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has plans to obtain additional resources to fund its currently planned operations and expenditures for at least </div></div>twelve&#160;months from the issuance of these consolidated financial statements through debt and equity financing. The Company&#8217;s plans are also dependent upon the success of future sales of ZTlido, which is still in the early stages of commercialization, and are dependent upon, among other things, the success of the Company&#8217;s marketing of ZTlido. Should the Company&#8217;s sales of ZTlido not materialize at the expected rate contemplated in the Company&#8217;s business plan, due to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic or other factors, the Company believes that there are a number of ongoing and potential actions that would maintain its projected cash and projected financial position including but not limited to, additional reductions in general and administrative costs, sales and marketing costs, suspension or winding down of clinical development programs for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-102</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-103,</div> and other discretionary costs. Although the Company believes such plans, if executed, should provide the Company with financing to meet its needs, successful completion of such plans is dependent on factors outside the Company&#8217;s control. As such, management cannot conclude that such plans will be effectively implemented within one year after the date that these consolidated financial statements are issued. As a result, management has concluded that the aforementioned conditions, among other things, raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date the financial statements are issued. </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_LiquidityAndGoingConcernAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liquidity and going Concern.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_LiquidityAndGoingConcernAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_LiquidityAndGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liquidity and going concern.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_LiquidityAndGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139838694837664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Public Offering<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vickers Vantage [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PublicOfferingDetailsLineItems', window );"><strong>Public Offering (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ProposedPublicOfferingTextBlock', window );">PUBLIC OFFERING</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 3. PUBLIC OFFERING </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Pursuant to the Initial Public Offering, the Company sold to&#160;13,800,000&#160;Units which includes a full exercise by the underwriters of their over-allotment option in the amount of&#160;1,800,000&#160;Units, at a purchase price of $10.00 per Unit. Each Unit consists of one ordinary share and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-half</div> of one redeemable warrant (&#8220;Public Warrant&#8221;). Each whole Public Warrant entitles the holder to purchase one ordinary share at an exercise price of $11.50 per whole share (see Note 7). </div><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 3&#160;&#8212;&#160;PUBLIC OFFERING </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Pursuant to the Initial Public Offering, the Company sold to 13,800,000&#160;Units which includes a full exercise by the underwriters of their over-allotment option in the amount of 1,800,000&#160;Units, at a purchase price of $10.00 per Unit. Each Unit consists of one ordinary share and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-half</div> of one redeemable warrant (&#8220;Public Warrant&#8221;). Each whole Public Warrant entitles the holder to purchase one ordinary share at an exercise price of $11.50 per whole share (see Note 7). </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ProposedPublicOfferingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ProposedPublicOfferingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PublicOfferingDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PublicOfferingDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_VickersVantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_VickersVantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139838694553344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Private Placement<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vickers Vantage [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PrivatePlacementDetailsLineItems', window );"><strong>Private Placement (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PrivatePlacementTextBlock', window );">PRIVATE PLACEMENT</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 4. PRIVATE PLACEMENT </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Simultaneously with the closing of the Initial Public Offering, the Sponsors purchased an aggregate of&#160;6,840,000 Private Placement Warrants at a price of $0.75&#160;per Private Placement Warrant, for an aggregate purchase price of $5,130,000, in a private placement. Each Private Placement Warrant is exercisable to purchase one ordinary share at a price of $11.50&#160;per share, subject to adjustment (see Note 7). A portion of the proceeds from the Private Placement Warrants were added to the proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the proceeds from the sale of the Private Placement Warrants will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law) and the Private Placement Warrants will expire worthless. </div></div><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 4&#160;&#8212;&#160;PRIVATE PLACEMENT </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Simultaneously with the closing of the Initial Public Offering, the Sponsors purchased an aggregate of 6,840,000 Private Placement Warrants at a price of $0.75 per Private Placement Warrant, for an aggregate purchase price of $5,130,000, in a private placement. Each Private Placement Warrant is exercisable to purchase one ordinary share at a price of $11.50 per share, subject to adjustment (see Note 9). A portion of the proceeds from the Private Placement Warrants were added to the proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the proceeds from the sale of the Private Placement Warrants will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law) and the Private Placement Warrants will expire worthless. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PrivatePlacementDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PrivatePlacementDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PrivatePlacementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for private placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PrivatePlacementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_VickersVantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_VickersVantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139838694538704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAbstract', window );"><strong>Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionTextBlock', window );">Acquisitions</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquisitions </div></div></div></div></td></tr></table><div style="clear: both; max-height: 0px; text-indent: 0px;"/><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Semnur Acquisition</div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;</div>18<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company completed the Merger of Semnur. At the closing of the Merger of Semnur, the Company issued to the holders of Semnur&#8217;s capital stock and options to purchase Semnur&#8217;s common stock, upfront consideration with a value of $</div>70.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million. The upfront consideration was comprised of the following: (a)&#160;a cash payment of approximately $</div>15.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, and (b) $</div>55.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million of shares of the Company&#8217;s common stock </div>(47,039,315<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares issued and </div>352,972<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares issuable, valued at $</div>1.16<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> per share) (the &#8220;Stock Consideration&#8221;). Following the issuance of the Stock Consideration, Sorrento ownership in the Company diluted to approximately </div>58<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the Company&#8217;s issued and outstanding capital </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">stock. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">Pursuant to the Merger Agreement, and upon the terms and subject to the conditions contained therein, the Company also agreed to pay the holders of Semnur equity (the &#8220;Semnur Equityholders&#8221;) up to $</div>280.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">&#160;million in aggregate contingent cash consideration based on the achievement of certain milestones, comprised of a $</div>40.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">&#160;<div style="display:inline;">million payment that will be due upon obtaining the first approval of a New Drug Application (&#8220;NDA&#8221;) of a Semnur product by the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) and additional payments that will be</div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="null;text-indent: 0px;;display:inline;">due upon the achievement of certain amounts of net sales of Semnur products, as follows: (1) a<div style="display:inline;">&#160;</div></div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div>20.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>payment upon the achievement of $</div>100.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in cumulative net sales of a Semnur product, </div>(2)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;a $</div>20.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million payment upon the achievement of $</div>250.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in cumulative net sales of a Semnur product, </div>(3)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;a $</div>50.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million payment upon the achievement of $</div>500.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in cumulative net sales of a Semnur product, and </div>(4)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;a $</div>150.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million payment upon the achievement of $</div>750.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in cumulative net sales of a Semnur </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">product. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On August&#160;</div>7<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company entered into an amendment to the Merger Agreement to provide that, following the consummation of the Company&#8217;s first bona fide equity financing with </div>one<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> or more third-party financing sources on an arms&#8217; length basis with gross proceeds to the Company of at least $</div>40.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, certain of the former Semnur optionholders will be paid cash in lieu of: </div>(1)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;the </div>352,972<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares of the Company&#8217;s common stock otherwise issuable to such former Semnur optionholders pursuant to the Merger Agreement, and </div>(2)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;any shares that would otherwise be issued to such former Semnur optionholders upon release of shares held in escrow pursuant to the Merger Agreement, with such shares in each case valued at $</div>1.16<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> per share. The amendment resulted in a reclassification of $</div>0.4<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million from additional </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> capital to accrued </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">liabilities. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In </div>March 2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Semnur Equityholders that received the Stock Consideration were required to sign an Exchange and Registration Rights Agreement with the Company (the &#8220;Exchange Agreement&#8221;). Pursuant to the Exchange Agreement, and upon the terms and subject to the conditions contained therein, if within </div>18<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> months following the closing of the Merger, </div>100<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the outstanding equity of the Company has not been acquired by a third party or the Company has not entered into a definitive agreement with respect to, or otherwise consummated, a firmly underwritten offering of the Company capital stock on a major stock exchange that meets certain requirements, then holders of the Stock Consideration may collectively elect to exchange, during the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">60-day</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> period commencing the date that is the </div>18<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> month anniversary of the Closing (the &#8220;Share Exchange&#8221;), the Stock Consideration for shares of Sorrento&#8217;s common stock with a value of $</div>55.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million based on a price per share of Sorrento&#8217;s common stock equal to the greater of (a)&#160;the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-day</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> trailing volume weighted average price of </div>one<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> share of Sorrento&#8217;s common stock as reported on The Nasdaq Stock Market LLC as of the consummation of the Share Exchange and (b) $</div>5.55<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> (subject to adjustment for any stock dividend, stock split, stock combination, reclassification or similar transaction) (the &#8220;Exchange Price&#8221;). Pursuant to an amendment to the Exchange Agreement entered into by Sorrento on September&#160;</div>28<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, on October&#160;</div>9<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Sorrento paid $</div>55.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in cash to the Semnur Equityholders in lieu of issuing $</div>55.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million of shares of Sorrento&#8217;s common stock at the Exchange Price. Following the completion of the Share Exchange and as of December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Sorrento held approximately </div>82.3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the outstanding common stock of the Company. On January&#160;</div>29<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Sorrento acquired additional shares of the Company, resulting in Sorrento holding approximately </div>99.97<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the outstanding common stock of the </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Company. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The </div>March 2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> transaction was accounted for as an asset acquisition since substantially all the value of the gross assets was concentrated in the single asset, </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-102.</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> As a result, approximately $</div>75.3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million was expensed as a component of acquired </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> research and development during the year ended </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">December&#160;31, 2019. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">No<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> contingent consideration was recorded as of September&#160;</div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> since the related regulatory approval milestones are not deemed probable until they actually occur.</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"/></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; font-size: 10pt;;font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-104</div> Acquisition</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;">On May&#160;12, 2022, the Company entered into a bill of sale and assignment and assumption agreement (the &#8220;Bill of Sale&#8221;), with Sorrento. Pursuant to the Bill of Sale, Sorrento sold, conveyed, assigned and transferred to the Company all of its rights, title and interest in and to Sorrento&#8217;s Delayed Burst Release Low Dose Naltrexone <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;DBR-LDN&#8221;)</div> asset and intellectual property rights, for the treatment of chronic pain, fibromyalgia and chronic post- COVID syndrome (collectively, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;SP-104</div> Assets&#8221;). These assets had previously been acquired by Sorrento from Aardvark Therapeutics, Inc. (&#8220;Aardvark&#8221;) in April 2021 pursuant to an asset purchase agreement (the &#8220;Aardvark Asset Purchase Agreement&#8221;). Pursuant to the Bill of Sale, the Company assumed all of Sorrento&#8217;s rights, liabilities and obligations under the Aardvark Asset Purchase Agreement (the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;SP-104</div> Acquisition&#8221;). </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">consideration for the </div><div style="font-size: 10pt; text-indent: 0px; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-104</div><div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"> Acquisition, the Company issued a promissory note in the aggregate principal amount of $</div>5.0<div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million to Sorrento (the &#8220;</div>2022<div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"> Promissory Note&#8221;). Upon issuance of the note, the Company recorded a related party note payable liability of $</div>4.1<div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, net of discount, with an offset to additional paid in capital, given the common control relationship between Sorrento and the Company. The </div>2022<div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"> Promissory Note matures </div>seven years<div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"> from the date of issuance and bears interest at the rate equal to the lesser of (a) </div>2.66<div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">% simple interest per annum and (b)&#160;the maximum interest rate permitted under law. The </div>2022<div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"> Promissory Note is payable in cash, shares of the Company&#8217;s common stock or any combination thereof, at the Company&#8217;s sole discretion, and may be prepaid in whole or in part at any time without </div><div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">penalty.</div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As the successor to the Aardvark Asset Purchase Agreement, the Company is obligated to pay Aardvark (i) $</div>3,000,000<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, upon initial approval by the FDA of a new drug application for the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-104</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Assets (which amount may be paid in shares of the Company&#8217;s common stock or cash, in the Company&#8217;s sole discretion) (the &#8220;Development Milestone Payment&#8221;) and (ii) $</div>20,000,000<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, in cash, upon achievement of certain net sales by the Company of a commercial product that uses the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-104</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company will also pay Aardvark certain royalties in the single digits based on percentages of annual net sales by the Company of a commercial product that uses the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-104</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Assets. The transaction was accounted for as an asset acquisition as substantially all the value of the gross assets was concentrated in a single asset, </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-104</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Assets. The contingent milestones and sale volume-based future royalties were determined to meet a scope exception for derivative under ASC Topic </div>815<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Derivatives and Hedging, and will not be recognized until the contingencies are realized in accordance with the Company&#8217;s accounting policy for contingent consideration in an asset acquisition. </div>No<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> contingent consideration was recognized at September&#160;</div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">,&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Tien-Li</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Lee, MD, a member of the board of directors of the Company, is the founder and chief executive officer of Aardvark. Kim D. Janda, Ph.D., a member of the Board of Directors of Sorrento, is a member of the advisory board of </div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">Aardvark.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">GLOPERBA License Agreement </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On June&#160;</div>14<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company entered into a license agreement (the &#8220;Romeg License Agreement&#8221;) with RxOmeg Therapeutics, LLC (a/k/a Romeg Therapeutics, Inc.) (&#8220;Romeg&#8221;). Pursuant to the Romeg License Agreement, among other things, Romeg granted the Company (a)&#160;a transferable license, with the right to sublicense, under the patents and </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> specified therein (with such license to </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> being exclusive for the limited purposes specified therein) to (i)&#160;commercialize the pharmaceutical product comprising liquid formulations of colchicine for the prophylactic treatment of gout in adult humans (the &#8220;Initial Licensed Product&#8221; or &#8220;GLOPERBA&#8221;) in the United States of America (including its territories) (the &#8220;Territory&#8221;), (ii) develop other products comprising the Initial Licensed Product as an active pharmaceutical ingredient (the &#8220;Licensed Products&#8221;) and commercialize any such products and (iii)&#160;manufacture Licensed Products anywhere in the world, solely for commercialization in the Territory and (b)&#160;an exclusive, transferable license, with right to sublicense, to use the trademark GLOPERBA and logos, designs, translations, and modifications thereof in connection with the commercialization of the Initial Licensed Product solely in the Territory. The Initial Licensed Product, GLOPERBA, was approved and made available in the </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">United States in 2020. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As consideration </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">for the license under the Romeg License Agreement, the Company paid Romeg an </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">up-front</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"> license fee of $</div>2.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">&#160;million, and has agreed to pay Romeg (a)&#160;upon the Company&#8217;s achievement of certain net sales milestones, certain milestone payments in the aggregate amount of up to $</div>13.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">&#160;million, (b)&#160;certain royalties in the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">mid-single</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"> digit to </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">low-double</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"> digit percentages based on annual net sales of the Licensed Product by the Company during the applicable royalty term under the Romeg License Agreement, and (c)&#160;minimum quarterly royalty payments totaling $</div>7.1<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">million commencing on the first year anniversary of the effective date of the Romeg License Agreement and ending on the later of (i) expiration of the last to expire of the licensed patents covering the Licensed Products in the Territory or (ii) the tenth anniversary of the effective date of the Romeg License Agreement.&#160;</div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The transaction was accounted for as an asset acquisition since substantially all the value of the gross assets was concentrated in a single asset, which is the Initial Licensed Product. In connection with the Romeg License Agreement, the Company recorded an intangible asset for acquired licenses of $</div>5.7<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, which is comprised of the upfront license fee of $</div>2.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and a deferred consideration of $</div>3.7<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million that is the present value of the future minimum royalty payments and immaterial transaction costs. The contingent s</div>ale<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">s milestones and sales volume-based future royalties were determined to meet a scope exception for derivative under ASC Topic </div>815<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, and will not be recognized until the contingencies are realized. </div>No<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> contingent consideration was recognized as a liability or included in the fair value of the asset as of September&#160;</div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. The Company determined the useful life of the intangible asset to be approximately </div>15 years<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, which approximates the life of the licensed patents covering the Initial Licensed Product.</div></div><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><span></span>
</td>
<td class="text"><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4.</div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Semnur Acquisition </div></div></div></td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">On March</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;18, 2019, the Company completed the Merger. At the closing of the Merger, the Company issued to the holders of Semnur&#8217;s capital stock and options to purchase Semnur&#8217;s common stock, upfront consideration with a value of $70.0&#160;million. The upfront consideration was comprised of the following: (a)&#160;a cash payment of approximately $15.0&#160;million, and (b)&#160;$55.0&#160;million of shares of the Company&#8217;s common stock (47,039,315 shares issued and 352,972 shares issuable, valued at $1.16 per share) (the &#8220;Stock Consideration&#8221;). Following the issuance of the Stock Consideration, Sorrento ownership in the Company diluted to approximately 58% of the Company&#8217;s issued and outstanding capital stock. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Merger Agreement, and upon the terms and subject to the conditions contained therein, the Company also agreed to pay the Semnur Equityholders up to $280.0&#160;million in aggregate contingent cash consideration based on the achievement of certain milestones, comprised of a $40.0&#160;million payment that will be due upon obtaining the first approval of a New Drug Application (&#8220;NDA&#8221;) of a Semnur product by the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) and additional payments that will be due upon the achievement of certain amounts of net sales of Semnur products, as follows: (1)&#160;a $20.0&#160;million payment upon the achievement of $100.0&#160;million in cumulative net sales of a Semnur product, (2)&#160;a $20.0&#160;million payment upon the achievement of $250.0&#160;million in cumulative net sales of a Semnur product, (3)&#160;a $50.0&#160;million payment upon the achievement of $500.0&#160;million in cumulative net sales of a Semnur product, and (4)&#160;a $150.0&#160;million payment upon the achievement of $750.0&#160;million in cumulative net sales of a Semnur product. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On August&#160;7, 2019, the Company </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">entered into an amendment to the Merger Agreement to provide that, following the consummation of the Company&#8217;s first bona fide equity financing with one or more third-party financing sources on an arms&#8217; length basis with gross proceeds to the Company of at least $</div>40.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, certain of the former Semnur optionholders will be paid cash in lieu of: (1)&#160;the </div>352,972<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares of the Company&#8217;s common stock otherwise issuable to such former Semnur optionholders pursuant to the Merger Agreement, and (2)&#160;any shares that would otherwise be issued to such former Semnur optionholders upon release of shares held in escrow pursuant to the Merger Agreement, with such shares in each case valued at $</div>1.16<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> per share. The amendment resulted in a reclassification of $</div>0.4<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million from additional </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> capital to accrued liabilities.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In March 2019, the </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Semnur Equityholders that received the Stock Consideration were required to sign an Exchange and Registration Rights Agreement with the Company (the &#8220;Exchange Agreement&#8221;).Pursuant to the Exchange Agreement, and upon the terms and subject to the conditions contained therein, if within </div>18<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;months</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>following the closing of the Merger, </div>100<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the outstanding equity of the Company has not been acquired by a third party or the Company has not entered into a definitive agreement with respect to, or otherwise consummated, a firmly underwritten offering of the Company capital stock on a major stock exchange that meets certain requirements, then holders of the Stock Consideration may collectively elect to exchange, during the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">60-day</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> period commencing the date that is the </div>18<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> month anniversary of the Closing (the &#8220;Share Exchange&#8221;), the Stock Consideration for shares of Sorrento&#8217;s common stock with a value of $</div>55.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million based on a price per share of Sorrento&#8217;s common stock equal to the greater of (a)&#160;the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-day</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> trailing volume weighted average price</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">of<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">one share of Sorrento&#8217;s common stock as reported on The Nasdaq Stock Market LLC as of the consummation of the Share Exchange and (b)&#160;$</div>5.55<div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"> (subject to adjustment for any stock dividend, stock split, stock combination, reclassification or similar transaction) (the &#8220;Exchange Price&#8221;). Pursuant to an amendment to the Exchange Agreement entered into by Sorrento on September&#160;</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">28</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">, </div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">2020</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">, on October&#160;</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">9</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">, </div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">2020</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">, Sorrento paid $</div>55.0<div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in cash to the Semnur Equityholders in lieu of issuing $</div>55.0<div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million of shares of Sorrento&#8217;s<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">common stock at the Exchange Price. Following the completion of the Share Exchange and as of December&#160;31, 2020, Sorrento held approximately </div>82.3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the outstanding common stock of the Company. On January&#160;29, 2021, Sorrento acquired additional shares of the Company, resulting in Sorrento holding approximately </div>99.97<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the outstanding common stock of the </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Company.</div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The transaction was accounted for as an asset acquisition since substantially all the value of the gross assets was concentrated in the single asset, </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-102.</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> As a result, approximately $</div>75.3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">million was expensed as a component of acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development during the year ended December&#160;31, 2019. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">No<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> contingent consideration was recorded as of December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> since the related regulatory approval milestones are not deemed probable until they actually occur.</div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 15<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6911878&amp;loc=d3e8732-128492<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139838694451872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Related Party Transactions </div></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div></div><div style="clear:both;max-height:0pt;;text-indent: 0px;"/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;18, 2019, the Company </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">entered into a merger agreement with Sorrento, Semnur, Merger Sub, and Fortis Advisors LLC. Jaisim Shah, a member of Sorrento&#8217;s board of directors, was Semnur&#8217;s Chief Executive<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Officer, a member of its board of directors and a stockholder of Semnur prior to the acquisition transaction. The upfront consideration was comprised of the following: (a)&#160;a cash payment of approximately $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">15.0</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, and (b) $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">55.0</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million of shares of the Company&#8217;s common stock (</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">47,039,315</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares issued and </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">352,972</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares issuable, valued at $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1.16</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> per share) (i.e., the Stock Consideration). Following the issuance of the Stock Consideration, Sorrento was the owner of approximately </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">58</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the Company&#8217;s issued and outstanding capital stock as of December&#160;</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">31</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2019</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. Following the completion of the Share Exchange and as of December&#160;</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">31</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2020</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Sorrento held approximately </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">82.3</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the outstanding common stock of the Company.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;of December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, approximately </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">14.7</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the outstanding capital stock of the Company was held by Itochu. On January&#160;</div>13<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">34,889,868</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares of the Company representing all outstanding capital stock of the Company held by Itochu were acquired by </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-related</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> minority shareholders. Thus, Itochu is not a shareholder subsequent to January&#160;</div>13<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. On January&#160;</div>29<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Sorrento acquired </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">34,889,868</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares of the Company, resulting in Sorrento holding approximately </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">99.97</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the Company. During the </div>nine<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> months ended September&#160;</div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company purchased approximately $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4.0</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4.8&#160;million,</div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">respectively, of inventory from Itochu, a previous minority shareholder of the Company and a Developer in the aforementioned Product Development Agreement. These costs are recorded within cost of revenues and selling, general and administrative expenses in the Company&#8217;s statement of operations. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; font-size: 10pt; top: 0px;;display:inline;">Semnur is party to an Assignment Agreement, dated August&#160;6, 2013 (the &#8220;Assignment Agreement&#8221;), with Shah Investor LP (&#8220;Shah Investor&#8221;). Mahendra Shah, Ph.D., who served on the Company&#8217;s board of directors from March 2019 through September 2020, is the managing partner of Shah Investor. Pursuant to the Assignment Agreement, Shah Investor assigned certain intellectual property to Semnur and Semnur agreed to pay Shah Investor a contingent quarterly royalty in the </div><div style="letter-spacing: 0px; font-size: 10pt; white-space: nowrap; top: 0px;;display:inline;">low-single</div><div style="letter-spacing: 0px; font-size: 10pt; top: 0px;;display:inline;"> digits based on quarterly net sales of any pharmaceutical formulations for local delivery of steroids by injection developed using such intellectual property, which would include </div><div style="letter-spacing: 0px; font-size: 10pt; white-space: nowrap; top: 0px;;display:inline;">SP-102.</div><div style="letter-spacing: 0px; font-size: 10pt; top: 0px;;display:inline;"> Through September&#160;30, 2022, the Company has made no royalty payments pursuant to the Assignment Agreement.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On January&#160;1, 2017, a Transition Services Agreement (&#8220;TSA&#8221;) was executed between Scilex Pharma and Sorrento. Pursuant to the TSA, Sorrento agreed, at the Company&#8217;s request, to provide directly or indirectly certain administrative, financial, legal, tax, insurance, facility, information technology and other services. In addition to the services provided under the TSA, Sorrento retains insurance coverage on behalf of the Company. During the nine months ended September&#160;30, 2022 and 2021, the total cost of services and insurance, including an agreed-upon markup, provided to the Company and recognized in general and administrative expenses was $<div style="letter-spacing: 0px; top: 0px;;display:inline;">3.2</div>&#160;million and $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">3.0</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, respectively.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;18, 2019, the Company entered into a note payable with Sorrento with an initial principal amount of $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">16.5</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million for the acquisition of Semnur. The note is interest bearing at the lesser of (a) </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">10</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% simple interest per annum, and (b)&#160;the maximum interest rate permitted under law. Interest is due and payable annually. The note payable is payable upon demand and may be prepaid in whole or in part at any time without penalty or premium. During the nine months ended September&#160;30, 2022 and 2021, Sorrento made advances to the Company in the amount of $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">27.5</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">3.4</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, respectively, under the note payable. The outstanding principal balance of the note on September&#160;30, 2022 and December&#160;31, 2021 was $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">47.1</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">19.6</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, respectively, which was recorded under the current related party note payable in the Company&#8217;s consolidated balance sheets. As of September&#160;30, 2022 and December&#160;31, 2021, the Company had ending balances resulting from the accrued interest on the note payable of $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">6.8</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">3.9</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, respectively, which was recorded under related party payable in the Company&#8217;s consolidated balance sheets. During the nine months ended September&#160;30, 2022, the proceeds from the note payable were used to finance the operations of the Company.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On October&#160;5, 2018, Scilex Pharma issued to Sorrento a promissory note i</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">n the amount of approximately $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">21.7</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million for certain amounts previously advanced to Scilex Pharma by Sorrento. Scilex Pharma may borrow up to an aggregate of $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">25.0</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million of principal amount under the note payable. The promissory note is interest bearing at the lesser of (a) </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">10</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% simple interest per annum, and (b)&#160;the maximum interest rate permitted under<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">law. All outstanding principal amounts and accrued interest are due upon maturity on August&#160;31, 2026. On October&#160;22, 2018, Sorrento purchased from the Company </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">24,117,608</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares of the Company&#8217;s common stock in exchange for the repayment of $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">21.7</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million of indebtedness under this promissory note. During the nine months ended September&#160;30, 2022 and 2021, Sorrento made advances to Scilex Pharma in the amount of $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">0</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">8.1</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, respectively, under the promissory note. As of September&#160;30, 2022 and December&#160;31, 2021, the Company had ending balances resulting from the accrued interest on the note payable of $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">4.9</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">3.1</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, respectively, which was recorded under related party payable in the Company&#8217;s consolidated balance sheets. As of September&#160;30, 2022 and December&#160;31, 2021, Scilex Pharma&#8217;s outstanding principal balance under the promissory note was $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">23.5</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, which was recorded under the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> related party note payable in the Company&#8217;s consolidated balance sheets.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company received $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">35.0</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in February 2022 to fund the payment of Scilex Pharma Notes in February 2022 totaling $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">20.0</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, as described in Note 6. The $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">35.0</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million received in February 2022 is due no earlier than February 2030 and was recorded under the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> related party note payable in the Company&#8217;s consolidated balance sheets.</div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additional funding received from Sorrento is due on demand and recorded under the related party payable in the Company&#8217;s consolidated balance sheets. As of September&#160;30, 2022, related party payables due to Sorrento included $<div style="letter-spacing: 0px; top: 0px;;display:inline;">48.7</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million to cover working capital requirements, $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">100.0</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million for repurchases of Scilex Pharma Notes, and $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">17.5</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million for litigation fees (see Note 8). As of December&#160;31, 2021, related party payables due to Sorrento consisted of $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">35.7</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million to cover working capital requirements, $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">51.0</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million for repurchases of Scilex Pharma Notes, and $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">6.0</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million to pay litigation fees (see Note 8).</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">On</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;May&#160;12, 2022, the Company entered into the Bill of Sale, with Sorrento (see Note 3). Pursuant to the Bill of Sale, the Company assumed all of Sorrento&#8217;s rights, liabilities and obligations under Aardvark Asset Purchase Agreement. The Company issued the 2022 Promissory Note to Sorrento as consideration transferred. The 2022 Promissory Note matures </div>seven years<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> from the date of issuance and bears interest at the rate equal to the lesser of (a) </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2.66</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% simple interest per annum and (b)&#160;the maximum interest rate permitted under law. As of September&#160;30, 2022, the outstanding balance, net of discount, under the 2022 Promissory Note was $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">4.2</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, which was recorded under the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> related party note payable in the Company&#8217;s consolidated balance sheets.</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Debt Exchange Agreement </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On September</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;12, 2022, the Company and Scilex Pharma entered into a Contribution and Satisfaction of Indebtedness Agreement (the &#8220;Debt Exchange Agreement&#8221;) with Sorrento, pursuant to which (i)&#160;Sorrento shall contribute to the Company all amounts (including accrued interest thereon, if any) for certain loans and other amounts provided by Sorrento to the Company and Scilex Pharma that remain outstanding as of immediately prior to the closing of the Business Combination (the &#8220;Aggregate Outstanding Amount&#8221; or &#8220;Outstanding Indebtedness), including with respect to the Scilex Pharma Notes, an intercompany promissory note issued by Scilex Pharma to Sorrento in the amount of approximately $<div style="letter-spacing: 0px; top: 0px;;display:inline;">27.5</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million for certain amounts previously advanced to Scilex Pharma by Sorrento, and the other notes payable to Sorrento described above (see Note 6), in exchange for the issuance by the Company to Sorrento of preferred stock of the Company, </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(ii)&#160;the Company shall contribute to Scilex Pharma the portion of such Outstanding Indebtedness that is owed by Scilex Pharma to Sorrento as a</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">contribution of capital for no consideration, and (iii)&#160;upon the occurrence of the events described in clauses (i)&#160;and (ii), the Aggregate Outstanding Amount and the Outstanding Indebtedness shall be satisfied in full.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the terms of the Debt Exchange Agreement effective</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">as of immediately prior to, and contingent upon, the closing of the</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Business Combination, </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sorrento has elected to contribute the Outstanding Indebtedness</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">to the Company in exchange for the issuance by the Company to</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Sorrento of that number of shares of preferred stock, par value $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">0.0001</div> per share, of the Company (subject to adjustment for recapitalizations, stock splits, stock dividends and similar transactions) (the &#8220;Exchange Shares&#8221; and such transaction, the &#8220;Debt Contribution&#8221;) </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">tha</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">t is equal to (i)&#160;the Aggregate Outstanding Amount plus the amount equal to </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">10</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the Aggregate Outstanding Amount divided by (ii) $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">11.00</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> (rounded up to the nearest whole share); provided, that in no event shall the Aggregate Outstanding Amount exceed $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">310,000,000</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. As of September&#160;30, 2022, the Aggregate Outstanding Amount was $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">276.8</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million.</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"/><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">On</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;November&#160;10, 2022, pursuant to the terms of the Debt Exchange Agreement, all existing related party indebtedness between the Company, Scilex Pharma, and Sorrento, totaling $</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">290.6</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, was contributed by Sorrento to the Company in exchange for </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">29,057,097</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares of the Company&#8217;s preferred stock. At the Effective Time, such shares were then exchanged for </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">29,057,097</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares of New Scilex preferred stock and </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,905,710</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares of New Scilex common stock.</div></div><span></span>
</td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">13.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Related Party Transactions&#160;</div></div></div></div></td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;18, 2019, the Company entered into a merger agreement with Sorrento, Semnur, Merger Sub, and Fortis Advisors LLC. Jaisim Shah, a member of Sorrento&#8217;s board of directors, was Semnur&#8217;s Chief Executive Officer, a member of its board of directors and a stockholder of Semnur prior to the acquisition transaction. The upfront consideration was comprised of the following: (a)&#160;a cash payment of approximately $</div>15.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, and (b)&#160;$</div>55.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million of shares of the Company&#8217;s common stock (</div>47,039,315<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares issued and </div>352,972<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares issuable, valued at $</div>1.16<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> per share) (i.e., the Stock Consideration). Following the issuance of the Stock Consideration, Sorrento was the owner of approximately </div>58<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the Company&#8217;s issued and outstanding capital stock as of December&#160;31, 2019. Following the completion of the Semnur Share Exchange and as of December&#160;31, 2020, Sorrento held approximately </div>82.3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the outstanding common stock of the Company.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the year ended December&#160;31, 2021, 2020 and 2019, the Company purchased approximately $</div>5.7<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, $</div>1.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, and $</div>8.4<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, respectively, of inventory from Itochu, a previous minority shareholder of the Company and a Developer in the aforementioned Product Development Agreement. These costs are recorded within cost of revenues and selling, general and administrative expenses in the Company&#8217;s statement of operations. As of December&#160;31, 2020, approximately </div>14.7<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the outstanding capital stock of the Company was held by Itochu. On January&#160;13, 2021, </div>34,889,868<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares of the Company representing all outstanding capital stock of the Company held by Itochu were acquired by </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-related</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> minority shareholders. Thus, Itochu is not a shareholder subsequent to January&#160;13, 2021. On January&#160;29, 2021, Sorrento acquired </div>34,889,868<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares of the Company, resulting in Sorrento holding approximately </div>99.97<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the Company.</div><br/></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Semnur is party to an Assignment Agreement, dated August&#160;6, 2013 (the &#8220;Assignment Agreement&#8221;), with Shah Investor LP (&#8220;Shah Investor&#8221;). Mahendra Shah, Ph.D., who has served on the Company&#8217;s board of directors since March&#160;2019, is the managing partner of Shah Investor. Pursuant to the Assignment Agreement, Shah Investor assigned certain intellectual property to Semnur and Semnur agreed to pay Shah Investor a contingent quarterly royalty in the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-single</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> digits based on quarterly net sales of any pharmaceutical formulations for local delivery of steroids by injection developed using such intellectual property, which would include </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-102.</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> To date, the Company has made no royalty payments pursuant to the Assignment Agreement.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On January&#160;1, 2017, a Transition Services Agreement (&#8220;TSA&#8221;) was executed between Scilex Pharma and Sorrento. Pursuant to the TSA, Sorrento agreed, at the Company&#8217;s request, to provide directly or indirectly certain administrative, financial, legal, tax, insurance, facility, information technology and other services. In addition to the services provided under the TSA, Sorrento retains insurance coverage on behalf of the Company. During the&#160;years ended December&#160;31, 2021, 2020, and 2019, the total cost of services and insurance, including an agreed-upon markup, provided to the Company and recognized in general and administrative expenses was $</div>4.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, $</div>2.3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, and $</div>0.9<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, respectively.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;18, 2019, the Company entered into a note payable with Sorrento with an initial principal amount of $</div>16.5<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million. The note is interest bearing at the lesser of (a)&#160;</div>10<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% simple interest per annum, and (b)&#160;the maximum interest rate permitted under law. Interest is due and payable annually. The note payable is payable upon demand and may be prepaid in whole or in part at any time without penalty or premium. The outstanding principal balance of the note on December&#160;31, 2021 and 2020 was $</div>19.6<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div>13.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, respectively, which was recorded under the current related party note<div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div> payable in the Company&#8217;s consolidated balance sheets. As of December&#160;31, 2021 and 2020, the Company had ending balances resulting from the accrued interest on the note payable of $</div>3.9<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div>2.6<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, respectively, which was recorded under related party payable in the Company&#8217;s consolidated balance sheets. The proceeds from the note payable were used to finance the acquisition of Semnur.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On October&#160;5, 2018, Scilex Pharma issued to Sorrento a promissory note in the amount of approximately $</div>21.7<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million for certain amounts previously advanced to Scilex Pharma by Sorrento (the &#8220;Intercompany Note&#8221;). Scilex Pharma may borrow up to an aggregate of $</div>25.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million of principal amount under the note payable. The promissory note is interest bearing at the lesser of (a)&#160;</div>10<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% simple interest per annum, and (b)&#160;the </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">maximum<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">interest rate permitted under law. All outstanding principal amounts and accrued interest are due upon maturity on August&#160;31, 2026. On October&#160;22, 2018, Sorrento purchased from the Company </div>24,117,608<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares of the Company&#8217;s common stock in exchange for the repayment of $</div>21.7<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million of indebtedness under this promissory note. During 2021 and 2020, Sorrento made advances to Scilex Pharma in the amount of $</div>8.1<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div>10.3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, respectively, under the promissory note. As of December&#160;31, 2021 and 2020, the Company had ending balances resulting from the accrued interest on the promissory note of $</div>3.1<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div>1.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, respectively, which was recorded under related party payable in the Company&#8217;s consolidated balance sheets. As of December&#160;31, 2021 and 2020, Scilex Pharma&#8217;s outstanding principal balance under the promissory note was $</div>23.5<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div>15.4<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, respectively, which was recorded under the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> related party note payable in the Company&#8217;s consolidated balance sheets.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company received $</div>17.3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div>20.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, in February&#160;2021 and April&#160;2021, respectively, from Sorrento to fund the payment of Scilex Pharma Notes in February&#160;2021 and April&#160;2021, totaling $</div>40.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, as described in Note 8. The $</div>37.3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million received in February&#160;2021 and April 2021 is due on demand to Sorrento and was recorded under the related party payables in the Company&#8217;s consolidated balance sheets. As of December&#160;31, 2021, related party payables due to Sorrento included $</div>35.7<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million to cover working capital requirements, $</div>51.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million for repurchases of Scilex Pharma Notes, and $</div>6.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million to pay litigation fees (see Note 11). As of December&#160;31, 2020, related party payables due to Sorrento consisted of $</div>13.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million to cover working capital requirements and $</div>13.7<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million for repurchases of Scilex Pharma Notes.</div><br/></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vickers Vantage [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 5. RELATED PARTY TRANSACTIONS </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Founder Shares </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On July&#160;16, 2020, the Company issued an aggregate of&#160;3,593,750&#160;ordinary shares to an affiliate of the Sponsors for an aggregate purchase price of $25,000. In August 2020, the affiliate transferred his Founder Shares to the Sponsors for the same price paid for such shares. On October 8. 2020, the Company effected a share<br/></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">capitalization<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">of </div>0.2&#160;<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">shares for each share outstanding, on December&#160;7, 2020, the Sponsors forfeited </div>1,437,500 <div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ordinary shares, which were cancelled by the Company, and on January&#160;6, 2021, the Company effected a share capitalization of&#160;</div>0.2<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;shares for each share outstanding, resulting in&#160;</div>3,450,000&#160;<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ordinary shares issued and outstanding (the &#8220;Founder Shares&#8221;). All share and </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">per-share</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> amounts have been retroactively restated to reflect the share transactions. The Founder Shares included an aggregate of up to&#160;</div>450,000&#160;<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">shares that were subject to forfeiture depending on the extent to which the underwriters&#8217; over-allotment option is exercised, so that the number of Founder Shares will equal, on an </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">as-converted</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> basis, approximately&#160;</div>20<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the Company&#8217;s issued and outstanding ordinary shares after the Initial Public Offering. As a result of the underwriters&#8217; election to partially exercise their over-allotment option, no Founder Shares are currently subject to forfeiture.</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Sponsors have agreed, subject to limited exceptions, not to transfer, assign or sell any of its Founder Shares until six months after the consummation of a Business Combination or earlier if, subsequent to a Business Combination, the Company consummates a liquidation, merger, share exchange or other similar transaction that results in all of the Public Shareholders having the right to exchange their ordinary shares for cash, securities or other property. </div><br/></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Advances from Related Party </div></div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">During 2020, an affiliate of the Sponsors advanced the Company an aggregate of $30,000&#160;to fund expenses in connection with the Initial Public Offering. The advances were <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest</div> bearing and payable upon demand. Such advances were repaid in connection with the closing of the Initial Public Offering. Accordingly, as of September&#160;30, 2022 and December&#160;31, 2021, there were no advances outstanding. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Promissory Note &#8212; Related Party </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On July&#160;16, 2020, the Company issued an unsecured promissory note (the &#8220;Promissory Note&#8221;) to an affiliate of the Sponsors, pursuant to which the Company may borrow up to an aggregate principal amount of $125,000. The Promissory Note is <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest</div> bearing and payable on the earlier of (i)&#160;December&#160;31, 2020 or (ii)&#160;the completion of the Initial Public Offering. The outstanding balance under the Promissory Note of $125,000&#160;was repaid subsequent to the closing of the Initial Public Offering on January&#160;14, 2021. Borrowings under the Promissory Note are no longer available to the Company. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Related Party Loans </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In order to finance transaction costs in connection with a Business Combination, the Sponsors or an affiliate of the Sponsors, or certain of the Company&#8217;s officers and directors may, but are not obligated to, loan the Company funds as may be required (&#8220;Working Capital Loans&#8221;). Such Working Capital Loans would be evidenced by promissory notes.&#160;The notes may be repaid upon completion of a Business Combination, without interest, or, at the lender&#8217;s discretion, up to $1,500,000 of notes may be converted upon completion of a Business Combination into warrants at a price of $0.75 per warrant.&#160;Such warrants would be identical to the Private Placement Warrants. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On December&#160;20, 2021, the Company entered issued two convertible promissory notes to the Sponsors to evidence Working Capital Loans pursuant to which the Sponsors agreed to loan the Company up to an aggregate principal amount of $500,000&#160;(the &#8220;Convertible Promissory Notes&#8221;). The Convertible Promissory Notes are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest</div> bearing and payable upon Business Combination. If a Business Combination is not consummated,<br/></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">the<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Convertible Promissory Notes will not be repaid by the Company and all amounts owed thereunder by the Company will be forgiven except to the extent that the Company has funds available to it outside of its Trust Account. Up to $</div>500,000&#160;<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">of the Convertible Promissory Notes may be converted into warrants at a price of $</div>0.75&#160;<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">per warrant at the option of the Sponsors. The warrants would be identical to the Private Placement Warrants.</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On January&#160;10, 2022, the Company borrowed an additional $1,035,000, as discussed below. On January&#160;27, 2022, Company entered into two additional Convertible Promissory Notes with the Sponsors pursuant to which the Sponsors agreed to loan the Company up to an aggregate principal amount of $500,000. As of September&#160;30, 2022 and December&#160;31, 2021, the principal balance of the Convertible Promissory Notes amounted to an aggregate of $2,035,000&#160;and $500,000, respectively. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company assessed the provisions of the Convertible Promissory Notes under ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">470-20.</div> The derivative component of the obligation is initially valued and classified as a derivative liability (see Note 9). </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The debt discount is being amortized to interest expense as a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> charge over the term of the Convertible Promissory Notes, which is assumed to mature in at Business Combination. During the three and nine months<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ended September&#160;30, 2022, the Company recorded $</div>1,155&#160;<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">and $</div>16,901&#160;<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">of interest expense related to the amortization of the debt discount. The remaining balance of the debt discount at September&#160;30, 2022 and December&#160;31, 2021 amounted to $</div>0 <div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">and $</div>16,901<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, respectively.</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On April&#160;11, 2022, the Company entered into two simple promissory notes with the Sponsors pursuant to which the Sponsors agreed to loan the Company up to an aggregate principal amount of $1,500,000&#160;(the &#8220;Simple Promissory Notes&#8221;). The Simple Promissory Notes are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest</div> bearing and payable upon Business Combination. If a Business Combination is not consummated, the Simple Promissory Notes will not be repaid by the Company and all amounts owed thereunder by the Company will be forgiven except to the extent that the Company has funds available to it outside of its Trust Account. On April&#160;18, 2022, the Company entered into two additional Simple Promissory Notes with the Sponsor pursuant to which the Sponsor agreed to loan the Company up to an aggregate principal amount of $500,000. As of September&#160;30, 2022 and December&#160;31, 2021, the principal balance of the Simple Promissory Notes amounted to an aggregate of $2,971,667&#160;and $0, respectively. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Related Party Extension Loans </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As discussed in Note 1, the Company may extend the period of time to consummate a Business Combination by an additional three months.&#160;In order to extend the time available for the Company to consummate a Business Combination, the Sponsor or its affiliates or designees must deposit into the Trust Account $1,035,000 ($0.075 per Public Share in either case), on or prior to the date of the applicable deadline, for each three-month extension., </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On January&#160;10, 2022, the Company extended the period of time to consummate a Business Combination to April&#160;11, 2022. The Sponsors deposited $1,035,000&#160;into the Trust Account made in the form of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest-bearing</div> loans. If the Company completes an initial business combination, the Company will, at the option of the Sponsors, repay the amounts evidenced by the Convertible Promissory Notes or convert a portion or all of the total amount into warrants at a price of $0.75&#160;per warrant, which warrants are identical to the Private Placement Warrants issued. If a Business Combination is not consummated, the Convertible Promissory Notes will not be repaid by the Company and all amounts owed thereunder by the Company will be forgiven except to the extent that the Company has funds available to it outside of its Trust Account. <br/></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">April&#160;11, 2022, the Company extended the period of time to consummate a Business Combination to July&#160;11, 2022. The Sponsors deposited $</div>1,035,000&#160;<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">into the Trust Account made in the form of </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest-bearing</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> loans. If the Company completes an initial business combination, the Company will, at the option of the Sponsors, repay the amounts evidenced by simple promissory notes. If a Business Combination is not consummated, the simple promissory notes will not be repaid by the Company and all amounts owed thereunder by the Company will be forgiven except to the extent that the Company has funds available to it outside of its Trust Account.</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On July&#160;11, 2022, the Company extended the period of time to consummate a Business Combination to August&#160;11, 2022. The Sponsors deposited $323,889&#160;into the Trust Account made in the form of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest-bearing</div> loans. If the Company completes an initial business combination, the Company will, at the option of the Sponsors, repay the amounts evidenced by simple promissory notes. If a Business Combination is not consummated, the simple promissory notes will not be repaid by the Company and all amounts owed thereunder by the Company will be forgiven except to the extent that the Company has funds available to it outside of its Trust Account. </div> <div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&#160;10, 2022, the Company extended the period of time to consummate a Business Combination to&#160;September&#160;11, 2022. The Sponsors deposited $323,889&#160;into the Trust Account made in the form of non-interest-bearing loans. If the Company completes an initial business combination, the Company will, at the option of the Sponsors, repay the amounts evidenced by simple promissory notes. If a Business Combination is not consummated, the simple promissory notes will not be repaid by the Company and all amounts owed thereunder by the Company will be forgiven except to the extent that the Company has funds available to it outside of its Trust Account. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On</div></div><div style="font-size: 10pt; text-align: center; letter-spacing: 0px; top: 0px;;display:inline;">&#160;September&#160;9, 2022, the Company extended the period of time to consummate a Business Combination to October&#160;11, 2022. The Sponsors deposited $</div>323,889<div style="font-size: 10pt; text-align: center; letter-spacing: 0px; top: 0px;;display:inline;">&#160;into the Trust Account made in the form of </div><div style="font-size: 10pt; text-align: center; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest-bearing</div><div style="font-size: 10pt; text-align: center; letter-spacing: 0px; top: 0px;;display:inline;"> loans. If the Company completes an initial business combination, the Company will, at the option of the Sponsors, repay the amounts evidenced by simple promissory notes. If a Business Combination is not consummated, the simple promissory notes will not be repaid by the Company and all amounts owed thereunder by the Company will be forgiven except to the extent that the Company has funds available to it outside of its Trust Account.</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On October&#160;10, 2022, the Company extended the period of time to consummate a Business Combination to November&#160;11, 2022. The Sponsors deposited $323,889&#160;into the Trust Account made in the form of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest-bearing</div> loans. If the Company completes an initial business combination, the Company will, at the option of the Sponsors, repay the amounts evidenced by simple promissory notes. If a Business Combination is not consummated, the simple promissory notes will not be repaid by the Company and all amounts owed thereunder by the Company will be forgiven except to the extent that the Company has funds available to it outside of its Trust Account. </div><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 5&#160;&#8212;&#160;RELATED PARTY TRANSACTIONS </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Founder Shares </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On July&#160;16, 2020, the Company issued an aggregate of 3,593,750 ordinary shares to an affiliate of the Sponsors for an aggregate purchase price of $25,000. In August&#160;2020, the affiliate transferred his Founder Shares to the Sponsors for the same price paid for such shares. On October&#160;8, 2020, the Company effected a share capitalization of 0.2 shares for each share outstanding, on December&#160;7, 2020, the Sponsors forfeited 1,437,500 ordinary shares, which were cancelled by the Company, and on January&#160;6, 2021, the Company effected a share capitalization of 0.2 shares for each share outstanding, resulting in 3,450,000 ordinary shares issued and outstanding (the &#8220;Founder Shares&#8221;). All share and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">per-share</div> amounts have been retroactively restated to reflect the share transactions. The Founder Shares included an aggregate of up to 450,000 shares that were subject to forfeiture depending on the extent to which the underwriters&#8217; over-allotment option is exercised, so that the number of Founder Shares will equal, on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">as-converted</div> basis, approximately 20% of the Company&#8217;s issued and outstanding ordinary shares after the Initial Public Offering. As a result of the underwriters&#8217; election to partially exercise their over-allotment option, no Founder Shares are currently subject to forfeiture. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Sponsors have agreed, subject to limited exceptions, not to transfer, assign or sell any of its Founder Shares until six&#160;months after the consummation of a Business Combination or earlier if, subsequent to a Business Combination, the Company consummates a liquidation, merger, share exchange or other similar transaction that results in all of the Public Shareholders having the right to exchange their ordinary shares for cash, securities or other property. </div><br/></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Advances from Related Party </div></div></div></div></div> <div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">During 2020, an affiliate of the Sponsors advanced the Company an aggregate of $30,000 to fund expenses in connection with the Initial Public Offering. The advances are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest</div> bearing and payable upon demand. As<br/></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">of<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, there was $</div>0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and $</div>30,000<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> advances outstanding, respectively. The outstanding amount of $</div>30,000<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> was repaid on February&#160;</div>26<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">.</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Promissory Note&#160;&#8212;&#160;Related Party </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On July&#160;16, 2020, the Company issued an unsecured promissory note (the &#8220;Promissory Note&#8221;) to an affiliate of the Sponsors, pursuant to which the Company may borrow up to an aggregate principal amount of $125,000. The Promissory Note is <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest</div> bearing and payable on the earlier of (i)&#160;December&#160;31, 2020 or (ii)&#160;the completion of the Initial Public Offering. The outstanding balance under the Promissory Note of $125,000 was repaid subsequent to the closing of the Initial Public Offering on January&#160;14, 2021. Borrowings under the Promissory Note are no longer available to the Company. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Related Party Loans </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In order to finance transaction costs in connection with a Business Combination, the Sponsors or an affiliate of the Sponsors, or certain of the Company&#8217;s officers and directors may, but are not obligated to, loan the Company funds as may be required (&#8220;Working Capital Loans&#8221;). Such Working Capital Loans would be evidenced by promissory notes. The notes may be repaid upon completion of a Business Combination, without interest, or, at the lender&#8217;s discretion, up to $1,500,000 of notes may be converted upon completion of a Business Combination into warrants at a price of $0.75 per warrant. Such warrants would be identical to the Private Placement Warrants. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. As of December&#160;31, 2021 and 2020, there were no amounts outstanding under the Working Capital Loans. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On December&#160;20, 2021, the Company entered into two convertible promissory notes with the Sponsors pursuant to which the Sponsors agreed to loan the Company up to an aggregate principal amount of $500,000 (the &#8220;Convertible Promissory Notes&#8221;). The Convertible Promissory Notes are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest</div> bearing and payable upon Business Combination. If a Business Combination is not consummated, the Convertible Promissory Notes will not be repaid by the Company and all amounts owed thereunder by the Company will&#160;be forgiven except to the extent that the Company has funds available to it outside of its Trust Account. Up to $500,000 of the Convertible Promissory Notes may be converted into warrants at a price of $0.75 per warrant at the option of the Sponsors. The warrants would be identical to the Private Placement Warrants. As of December&#160;31, 2021, the outstanding principal balance under the Convertible Promissory Notes amounted to an aggregate of $500,000. Subsequent to December&#160;31, 2021, on January&#160;10, 2022, the Company borrowed an additional $1,035,000, as discussed below. On January&#160;27, 2022, Company entered into two additional Convertible Promissory Notes with the Sponsors pursuant to which the Sponsors agreed to&#160;loan&#160;the Company up to an aggregate principal amount of $500,000. Subsequent to December&#160;31, 2021, the&#160;principal balance of the Convertible Promissory Notes amounted to an aggregate of $2,035,000 (see Note 11). </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company assessed the provisions of the Convertible Promissory Notes under ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">470-20.</div> The derivative component of the obligation is initially valued and classified as a derivative liability (see Note 9). <br/></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">The debt discount is being amortized to interest expense as a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash </div> charge over the term of the Convertible Promissory Notes, which is assumed to mature in April&#160;2022, the Company&#8217;s expected Business Combination date. During<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the year ended December&#160;31, 2021, the Company recorded $</div>1,826<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> of interest expense related to the amortization of the debt discount. The remaining balance of the debt discount at December&#160;31, 2021&#160;amounted to $</div>16,901<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">.</div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>  <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Related Party Extension Loans </div></div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">As discussed in Note 1, the Company may extend the period of time to consummate a Business Combination up to two times, each by an additional three&#160;months (until July&#160;11, 2022 to complete a Business Combination). In order to extend the time available for the Company to consummate a Business Combination, the Sponsor or its affiliates or designees must deposit into the Trust Account $1,035,000 ($0.075 per Public Share in either case), on or prior to the date of the applicable deadline, for each three-month extension, providing a total possible Business Combination period up until July 11, 2022 for a total payment value of $2,070,000 ($0.15 per unit in either case). Any such deposits would be made in the form of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest</div> bearing loans. Such notes would either be paid upon consummation of a Business Combination, or, at the relevant insider&#8217;s discretion, converted upon consummation of a Business Combination into additional Private Placement Warrants at a price of $0.75 per Private Placement Warrant. The Sponsor and its affiliates or designees intend, but are not obligated, to fund the Trust Account to extend the time for the Company to complete a Business Combination. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On January&#160;10, 2022, the Company extended the period of time to consummate a Business Combination to April&#160;11, 2022. The Sponsors deposited $1,035,000 into the Trust Account made in the form of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest-bearing</div> loans. If the Company completes an initial business combination, the Company will, at the option of the Sponsors, repay the amounts evidenced by the Convertible Promissory Notes or convert a portion or all of the total amount into warrants at a price of $0.75 per warrant, which warrants are identical to the Private Placement Warrants issued. If a Business Combination is not consummated, the Convertible Promissory Notes will not be repaid by the Company and all amounts owed thereunder by the Company will be forgiven except to the extent that the Company has funds available to it outside of its Trust Account. </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_RelatedPartyTransactionsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_RelatedPartyTransactionsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_VickersVantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_VickersVantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139838693465136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair Value Measurements </div></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div></div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The follo<div style="display:inline;">w</div>ing t<div style="letter-spacing: 0px; top: 0px;;display:inline;">a</div>ble presents the Company&#8217;s financial assets and liabilities that are measured at fair value (in thousands):</div><br/></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><br/></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 40%;"/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Fair value measurements at September&#160;30, 2022</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Balance</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Quoted&#160;Prices&#160;in<br/>Active Markets<br/>(Level&#160;1)</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level&#160;2)</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Significant<br/>Unobservable&#160;Inputs<br/>(Level&#160;3)</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr>
<td style="vertical-align: top; font-size: 10pt; background-color: rgba(255, 255, 255, 0);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,483</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,483<div style="letter-spacing: 0px; top: 0px;;display:inline;"/></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr>
<td style="vertical-align: top; font-size: 0pt; line-height: 0pt; background-color: rgba(255, 255, 255, 0);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 0pt;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; padding-bottom: 0.375pt; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets measured at fair value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">2,483</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt; background-color: rgb(204, 238, 255);;text-align:right;">2,483</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"> <div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"> <div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"> <div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"> <div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td></tr></table><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><br/></div><div style="clear:both;max-height:0pt;;text-indent: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 40%;"/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;">Fair&#160;value&#160;measurements&#160;at&#160;December&#160;31.&#160;2021</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt; border-bottom: 0.75pt solid black;;text-align:center;">Balance</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;">Quoted&#160;Prices&#160;in<br/>Active&#160;Markets<br/>(Level&#160;1)</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level&#160;2)</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;">Significant<br/>Unobservable&#160;Inputs<br/>(Level&#160;3)</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,338</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,338</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets measured at fair value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,338</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,338</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivative liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,700</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,700</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Total liabilities measured at fair <br/>value</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,700</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,700</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <div style="clear: both; max-height: 0px; text-indent: 0px;"/><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Company&#8217;s financial assets carried at fair value are comprised of cash and cash equivalents. Cash and cash equivalents consist of money market accounts and bank deposits which are highly liquid and readily tradable. These assets are valued using inputs observable in active markets for identical securities.</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Derivative liabilities </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">The Company recorded a gain of $</div>5.3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">&#160;million and $</div>0.1<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">&#160;million on derivative liabilities for the </div>nine<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"> months ended September&#160;</div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"> and </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">, respectively, which was attributed to compound derivative liabilities associated with the Scilex Pharma Notes (see Note </div>6)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">. The fair value of the derivative liability associated with the Scilex Pharma Notes decreased by $</div>30.4<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">million immediately after the entry into Amendment No. 4 (see Note 6) associated with the Scilex Pharma Notes on June 2, 2022 (see Note 6). Amendment No. 4 was accounted for as troubled debt restructuring; therefore, the carrying amount of the Scilex Pharma Notes, net, was adjusted to reflect the aforementioned change in fair value of the derivative liability. The fair value of the derivative liability associated with the Scilex Pharma Notes was estimated using the discounted cash flow method combined with a&#160;</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"/></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">Monte Carlo simulation model including consideration of the terms of Amendment No. 4. Significant Level 3 assumptions used in the measurement included a</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div>6.1<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% risk adjusted net sales forecast and an effective debt yield of </div>21.5<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% as of June&#160;30, 2022. The Scilex Pharma Notes were fully extinguished in September 2022 (see Note 6) and, as such, there were </div>no<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> remaining derivative liabilities as of September&#160;30, 2022.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table includes a summary of the derivative liabilities measured at fair value using significant unobservable inputs (Level 3) during the nine months ended September&#160;30, 2022:</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 84%;"/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;">Fair<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>value</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,700</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value measurement</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(35,700</td>
<td style="vertical-align: bottom; white-space: nowrap;">)</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at September&#160;30, 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">5</div>.</div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair Value Measurements </div></div></div></td></tr></table> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents the Company&#8217;s financial assets and liabilities that are measured at fair value (in </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">thousands): </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 52%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair value measurements at December&#160;31, 2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Balance</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Quoted&#160;Prices<br/>in&#160;Active<br/>Markets<br/>(Level 1)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level&#160;2)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 0px;">
<td style="width: 52%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-size: 0px;">
<td style="width: 52%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 52%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 52%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,338</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,338</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 52%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 52%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets measured at fair value</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,338</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,338</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 52%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 52%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivative liabilities</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,700</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,700</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 52%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 52%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities measured at fair value</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,700</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,700</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap;"/></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 52%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair value measurements at December&#160;31, 2020</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Balance</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Quoted&#160;Prices<br/>in&#160;Active<br/>Markets<br/>(Level&#160;1)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level&#160;2)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 52%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 52%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,839</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,839</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 52%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 52%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets measured at fair value</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,839</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,839</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 52%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 52%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivative liabilities</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,400</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,400</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 52%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Total liabilities measured at fair value</div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,400</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,400</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s financial assets carried at fair value are comprised of cash and cash equivalents. Cash and cash equivalents consist of money market accounts and bank deposits which are highly liquid and readily tradable. These assets are valued using inputs observable in active markets for identical securities. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="null;text-indent: 0px;;font-style:italic;display:inline;">Derivative liabilities</div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company recorded a loss of $</div>0.3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, a gain of $</div>0.8<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and a loss of $</div>23.3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million on derivative liabilities for the&#160;years ended December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, respectively, which was attributed to compound derivative liabilities associated with the Scilex Pharma Notes. The compound derivative liabilities consist of the fair value of various embedded features as further described in Note </div>8<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. The fair value of the derivative liabilities associated with the Scilex Pharma Notes was estimated using the discounted cash flow method under the income approach combined with a Monte Carlo simulation model. This involves significant Level&#160;</div>3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> inputs and assumptions.</div><br/></div> <div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">The<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">key assumptions for the compound derivative liabilities associated with the Scilex Pharma Notes for the year ended December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> included a </div>6.2<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% risk-adjusted net sales forecast and an effective debt yield of </div>15.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">%. The key assumptions for the compound derivative liabilities associated with the Scilex Pharma Notes for the year ended December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> included a </div>7<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% risk-adjusted net sales forecast, an effective debt yield of </div>15<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% and an estimated probability of </div>100<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of not obtaining marketing approval before March&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. The key assumptions for the compound derivative liabilities associated with the Scilex Pharma Notes for the year ended December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> included an </div>8<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% risk adjusted net sales forecast, an effective debt yield of </div>19.7<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% and estimated probabilities of </div>100<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% and </div>55<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of not obtaining marketing approval before March&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and July&#160;</div>1<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2023<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, respectively, and an estimated high probability of an initial public offering of the Company that satisfies certain valuation thresholds occurring prior to October&#160;</div>1<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table includes a summary of the derivative liabilities measured at fair value using significant unobservable inputs (Level 3) during the years ended December&#160;31, 2021, 2020 and 2019: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 84%;"/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 84%; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Beginning Balance at December&#160;31, 2018</div></div></div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 84%; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additions</div></div></div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,100</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 84%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-measurement</div> of fair value</div></div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">23,300</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 84%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 84%; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ending Balance at December&#160;31, 2019</div></div></div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">33,400</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 84%; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additions</div></div></div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,800</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 84%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-measurement</div> of fair value</div></div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(800</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 84%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 84%; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ending Balance at December&#160;31, 2020</div></div></div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,400</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 84%; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additions</div></div></div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 84%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-measurement</div> of fair value</div></div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">300</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 84%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em;">Ending Balance at December&#160;31, 2021</div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,700</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vicker's Vantage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 9. FAIR VALUE MEASUREMENTS </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the Company&#8217;s financial assets and liabilities reflects management&#8217;s estimate of amounts that the Company would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 10%; vertical-align: top;;text-align:left;">Level&#160;1:</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis. </div></div> </td> </tr> </table>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 10%; vertical-align: top;;text-align:left;">Level&#160;2:</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Observable inputs other than Level&#160;1 inputs. Examples of Level&#160;2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active. </div></div></td></tr></table><div style="clear: both; max-height: 0px;"/><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 10%; vertical-align: top;;text-align:left;">Level&#160;3:</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability. </div></div></td></tr></table><div style="clear: both; max-height: 0px;"/><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At September&#160;30, 2022 and December&#160;31, 2021, assets held in the Trust Account were comprised of $101,293,086&#160;and $139,410,739, respectively, in money market funds which are invested primarily in U.S. Treasury Securities.&#160;Through September&#160;30, 2022, the Company did not withdraw any interest earned on the Trust Account. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents information about the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis at September&#160;30, 2022 and December&#160;31, 2021 and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 58%; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Description</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investments held in Trust Account <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div> U.S. Treasury Securities Money Market Fund</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">101,293,086</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">139,410,739</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Warrant Liability <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div>&#160;Private Placement Warrants</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,162,800</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,351,600</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Conversion Option Liability (see Note 5)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,892</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Private Placement Warrants were accounted for as liabilities in accordance with ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">815-40</div> and are presented within warrant liabilities on our accompanying September&#160;30, 2022 unaudited condensed consolidated balance sheets. The warrant liabilities are measured at fair value at inception and on a recurring basis, with changes in fair value presented within change in fair value of warrant liabilities in the unaudited condensed consolidated statements of operations. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Warrant Liability Measurement </div></div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company established the initial fair value for the private warrants on January&#160;11, 2021, the date of the Company&#8217;s Initial Public Offering, using a Monte Carlo simulation and subsequently implemented the Black-Scholes Option Pricing Model that was modified to capture the redemption features of the public warrants. The underlying assumptions in the Black-Scholes option pricing model include the underlying share price, risk-free interest rate, estimated volatility and the expected term. The primary unobservable inputs utilized in determining the fair value of the private warrants are the expected volatility of the Company&#8217;s ordinary shares and the Company&#8217;s ordinary share price. The expected volatility of the ordinary shares was determined based on implied volatilities of public warrants issued by selected guideline companies and was estimated to be 10% before the expected business combination and 20% after the expected business combination. The ordinary share price was determined based on an iterative procedure that matched the estimated value of the ordinary shares and fractional warrant price to equate to the observed price of the outstanding units. The risk-free interest rate is based on the U.S. Treasury yield curve in effect on the date of valuation equal to the remaining expected life of the private warrants. The dividend yield percentage is zero because the Company does not currently pay dividends, nor does it intend to do so during the expected term of the warrants. The expected life of the warrants is assumed to be </div>equivalent to their remaining contractual term. Inputs are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-evaluated</div> each quarterly reporting period to estimate the fair market value of the private placement warrants as of the reporting <div style="letter-spacing: 0px; top: 0px;;display:inline;">period</div>. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There were no transfers between Levels 1, 2 or 3 during the three and nine months ended September&#160;30, 2022 and 2021. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table provides quantitative information regarding Level&#160;3 fair value measurements: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 65%;">&#160;</td>
<td style="width: 13%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="width: 12%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock price</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.33</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.04</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Strike price</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11.50</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11.50</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Term (in years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.28</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Volatility</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.03</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.28</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dividend yield</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of warrants</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.17</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.49</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents the changes in the fair value of warrant liabilities: </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 80%;">&#160;</td>
<td style="width: 7%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Private</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Placement</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value as of January&#160;1, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Initial measurement on January&#160;11, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,729,200</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation inputs or other assumptions</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,104,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of as of March&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,625,200</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation inputs or other assumptions</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">68,400</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of as of June&#160;30, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,693,600</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation inputs or other assumptions</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,162,800</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of as of September&#160;30, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,856,400</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation inputs or other assumptions</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,504,800</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of as of December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,351,600</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation inputs or other assumptions</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">410,400</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value as of March&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,762,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation inputs or other assumptions</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,530,800</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value as of June&#160;30, 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,231,200</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation inputs or other assumptions</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(68,400</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value as of September&#160;30, 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,162,800</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"/><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Conversion Option Liability Measurement </div></div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company assessed the provisions of the Convertible Promissory Notes under ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">470-20.</div> The derivative component of the obligation is initially valued and classified as a derivative liability. The conversion option was valued using the compound option pricing model, which is considered to be a Level&#160;3 fair value measurement (See Note 6). </div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 65%;">&#160;</td>
<td style="width: 12%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="width: 11%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,<br/>2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Underlying warrant value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0103</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercise price</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.75</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.75</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Holding period</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.50</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.28</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.03</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.28</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Volatility</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dividend yield</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents the change in the fair value of conversion option liability: </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 83%;">&#160;</td>
<td style="width: 13%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Conversion</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Option</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Liability</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value as of January&#160;1, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Initial measurement on December&#160;20, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18,727</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation inputs or other assumptions</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(11,835</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of as of December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,892</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Initial measurement on January&#160;10, 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Initial measurement on January&#160;27, 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation inputs or other assumptions</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">69,896</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value as of March&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">76,788</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation inputs or other assumptions</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(76,788</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value as of June&#160;30, 2022 and September&#160;30, 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 9&#160;&#8212;&#160;FAIR VALUE MEASUREMENTS </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the Company&#8217;s financial assets and liabilities reflects management&#8217;s estimate of amounts that the Company would have received in connection with the sale of the assets or paid in connection with the transfer </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 9%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td style="width: 89%;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="display:inline;">Level&#160;1:</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"><div style="display:inline;"/></td>
<td colspan="2" style="height: 6pt;"><div style="display:inline;"/></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="display:inline;">Level&#160;2:</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">Observable inputs other than Level&#160;1 inputs. Examples of Level&#160;2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"><div style="display:inline;"/></td>
<td colspan="2" style="height: 6pt;"><div style="display:inline;"/></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="display:inline;">Level&#160;3:</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability.</div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div><div style="clear: both; max-height: 0px;"/></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At December&#160;31, 2021, assets held in the Trust Account were comprised of $139,410,739 in money market funds which are invested primarily in U.S. Treasury Securities. Through December&#160;31, 2021, the Company did not withdraw any of interest earned on the Trust Account. At December&#160;31, 2020, there were no assets in the Trust Account. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents information about the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis at December&#160;31, 2021 and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 71%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Description</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investments held in Trust Account&#160;&#8212;&#160;U.S. Treasury Securities Money Market Fund</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">139,410,739</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Warrant Liability&#160;&#8212;&#160;Private Placement Warrants</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,351,600</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Conversion Option Liability (see Note 5)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,892</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Warrant Liability Measurement </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">The Company established the initial fair value for the private warrants on January&#160;11, 2021, the date of the Company&#8217;s Initial Public Offering, using a Monte Carlo simulation and subsequently implemented the Black-Scholes Option Pricing Model that was modified to capture the redemption features of the public warrants. The underlying assumptions in the Black-Scholes option pricing model include the underlying share price, risk-free interest rate, estimated volatility and the expected term. The primary unobservable inputs utilized in determining the fair value of the private warrants are the expected volatility of the Company&#8217;s ordinary shares and the Company&#8217;s ordinary share price. The expected volatility of the ordinary shares was determined based on implied volatilities of public warrants issued by selected guideline companies and was estimated to be 10% before the expected business combination and 20% after the expected business combination. The ordinary share price was<div style="display:inline;">&#160;</div><div style="display:inline;">determined based on an iterative procedure that matched the estimated value of the ordinary shares and fractional&#160;</div> </div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">warrant price to equate to the observed price of the outstanding&#160;units. The risk-free interest rate is based on the U.S. Treasury yield curve in effect on the date of valuation equal to the remaining expected life of the private warrants. The dividend yield&#160;percentage is zero because the Company does not currently pay dividends, nor does it intend to do so during the expected term of the warrants. The expected life of the warrants is assumed to be equivalent to their remaining contractual term. Inputs are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-evaluated</div> each quarterly reporting period to estimate the fair market value of the private placement warrants as of the reporting period. </div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There were no transfers between Levels 1, 2 or 3 during the year ended December&#160;31, 2021. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table provides quantitative information regarding Level&#160;3 fair value measurements: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 80%;"/>
<td style="width: 15%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of<br/>December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock price</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.04</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Strike price</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11.50</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Term (in&#160;years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.28</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Volatility</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.28</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dividend yield</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of warrants</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.49</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents the changes in the fair value of warrant liabilities: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 80%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Private<br/>Placement</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value as of January&#160;1, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Initial measurement on January&#160;11, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,729,200</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation inputs or other assumptions</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,377,600</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value as of December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,351,600</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Conversion Option Liability Measurement </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company assessed the provisions of the Convertible Promissory Notes under ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">470-20.</div> The derivative component of the obligation is initially valued and classified as a derivative liability. The conversion option was valued using the compound option pricing model, which is considered to be a Level&#160;3 fair value measurement (See Note 6). </div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 65%;"/>
<td style="width: 12%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;20,<br/>2021<br/>(Initial<br/>Measurement)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Underlying warrant value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0103</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0281</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercise price</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.75</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.75</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Holding period</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.28</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.31</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free rate %</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.28</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.19</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Volatility%</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dividend yield %</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents the change in the fair value of conversion option liability: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 84%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 9%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value as of January&#160;1, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Initial measurement on December&#160;20, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18,727</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(11,835</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value as of December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,892</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table>  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_VickersVantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_VickersVantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139838697405504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and Equipment </div></div></div></div></td></tr></table> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment consisted of the following as of December&#160;31, 2021 and 2020 (in thousands): </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 80%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Computers&#160;&amp; equipment</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">77</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">77</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Furniture</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">118</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">118</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leasehold improvements</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">48</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">48</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Construction in progress</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">689</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">691</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment, gross</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">932</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">934</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: Accumulated depreciation</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(127</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(88</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment, <div style="letter-spacing: 0px; top: 0px;;display:inline;">net</div></div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">805</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">846</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation expense<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">for each of the&#160;years ended December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> was $</div>39<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;thousand, $</div>40<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;thousand and $</div>40<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;thousand, respectively.</div><br/></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139838697480256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill and Intangible Assets </div></div></div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of September&#160;30, 2022 and December&#160;31, 2021, the Company had recorded goodwill of $</div>13.5<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million. The Company performed a qualitative test for goodwill impairment during the fourth quarter of 2021. Based upon the results of the qualitative testing, the Company concluded that it is </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">more-likely-than-not</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> that the fair value of the Company&#8217;s goodwill was in excess of the carrying value and therefore performing the first step of the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-step</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> impairment test was unnecessary. The conclusion has not changed as of September&#160;30, 2022 and </div>no<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> goodwill impairment was recognized for the nine months ended September&#160;30, 2022 and 2021.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s intangible assets, excluding goodwill, are composed of patent rights, acquired technology, acquired licenses, and assembled workforce. Amortization of the intangible assets that have finite useful lives is generally recorded on a straight-line basis over their useful lives. </div>A summary of the Company&#8217;s identifiable intangible assets as of September&#160;30, 2022 and December&#160;31, 2021 is as follows (in thousands):</div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 55%;"/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Nine<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>months<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>ended<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>September<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>30,<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Gross&#160;carrying<br/> amount</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Accumulated<br/> amortization</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Intangibles,&#160;net</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Patent rights</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32,630</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,871</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19,759</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquired technology</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,940</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,851</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,089</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquired licenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,711</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">92</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,619</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assembled workforce</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">350</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">150</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total intangible assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">60,781</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19,164</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">41,617</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 55%;"/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">December<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>31.<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>2021</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Gross&#160;carrying<br/> amount</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Accumulated<br/> amortization</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Intangibles,&#160;net</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Patent rights</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32,630</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,239</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,391</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquired technology</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,940</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,754</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,186</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assembled workforce</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">275</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">225</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total intangible assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">55,070</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,268</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">38,802</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On June&#160;14, 2022, the Company entered into Romeg License Agreement to acquire an exclusive license to use GLOPERBA from Romeg (see Note 3). The Company determined the acquisition of licenses to be an asset acquisition. The fair value of consideration transferred of $</div>5.7<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million was assigned to acquired licenses with an amortization period of approximately </div>15<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">years. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">As of September&#160;30, 2022, the weighted average remaining life for identifiable intangible assets was </div></div>10.6<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">years. Aggregate amortization expense was $</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2.9</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">million and $</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2.8</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;million for the nine months ended September&#160;30,</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022 and 2021, respectively. Patent rights and acquired technology are amortized over a </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">15-year</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> period. Assembled workforce is amortized over a </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">5-year</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> period.</div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; font-size: 10pt; top: 0px;;display:inline;">Estimated future amortization expense related to intangible assets at September&#160;30, 2022 is as follows (in tho</div>us<div style="letter-spacing: 0px; font-size: 10pt; top: 0px;;display:inline;">ands):</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 85%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap;">Year ended December&#160;31,</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Amount</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022 (remaining three months)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,027</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,106</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,031</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,006</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2026</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,006</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Thereafter</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">24,441</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">41,617</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table> <span></span>
</td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill and Intangible Assets </div></div></div></div></td></tr></table><div style="clear: both; max-height: 0px; text-indent: 0px;"/><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company had recorded goodwill of $</div>13.5<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million. The Company performed a qualitative test for goodwill impairment during the fourth quarter of </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. Based upon the results of the qualitative testing, the Company concluded that it is </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">more-likely-than-not</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> that the fair value of the Company&#8217;s goodwill was in excess of the carrying value and therefore performing the first step of the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-step</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> impairment test was unnecessary. </div>No<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> goodwill impairment was recognized for the&#160;years ended December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, and </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">.</div><br/></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">The</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;Company&#8217;s intangible assets, excluding goodwill, are composed of patent rights, acquired technology and assembled workforce. Amortization of the intangible assets that have finite useful lives is generally recorded on a straight-line basis over their useful lives. </div>A summary of the Company&#8217;s identifiable intangible assets as of December&#160;31, 2021 and 2020 is as follows (in thousands):</div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 61%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross&#160;<br/>carrying</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">amortization</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Intangibles,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">net</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 61%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Patent rights</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32,630</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,239</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,391</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 61%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquired technology</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,940</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,754</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,186</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em;">Assembled workforce</div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">275</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">225</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 61%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em;">Total intangible assets</div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">55,070</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,268</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">38,802</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 61%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross&#160;<br/>carrying</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">amortization</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Intangibles,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">net</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 61%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Patent rights</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32,630</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,064</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">23,566</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 61%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquired technology</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,940</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,291</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18,649</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em;">Assembled workforce</div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">175</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">325</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 61%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em;">Total intangible assets</div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">55,070</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,530</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">42,540</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the weighted average remaining life for identifiable intangible assets is </div>10.6<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;years. Aggregate amortization expense was $</div>3.7<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million for each of the&#160;years ended December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, and </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. Patent rights and acquired technology are amortized over a </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">15-year</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> period. Assembled workforce is amortized over a </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">5-year</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> period.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Estimated future amortization expense related to intangible assets at December&#160;31, 2021 is as follows (in thousands): </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 85%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ending December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,738</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,738</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,663</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,638</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2026</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,638</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Thereafter</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20,387</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">38,802</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">No<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> impairment charges related to intangible assets were recorded during the&#160;years ended </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">December&#160;31, 2021 and 2020. </div></div><br/></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI https://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139838697766176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Debt </div></div></div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2018 Purchase Agreements and Indenture </div></div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On September&#160;7, 2018, Scilex Pharma and Sorrento entered into Purchase Agreements (the &#8220;2018 Purchase Agreements&#8221;) with certain investors (collectively, the &#8220;Scilex Pharma Note Purchasers&#8221;). Pursuant to the 2018 Purchase Agreements, on September&#160;7, 2018, Scilex Pharma, among other things, issued and sold to the Scilex Pharma Note Purchasers senior secured notes due </div>2026<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> in an aggregate principal amount of $</div>224.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million (the &#8220;Scilex Pharma Notes&#8221;) for an aggregate purchase price of $</div>140.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million (the &#8220;Offering&#8221;). The Scilex Pharma Notes are governed by an indenture (as amended, the &#8220;Indenture&#8221;) with Scilex Pharma, as issuer, U.S. Bank National Association, a national banking association, as trustee (the &#8220;Trustee&#8221;) and collateral agent (the &#8220;Collateral Agent&#8221;), and Sorrento, as guarantor. Pursuant to the Indenture, Sorrento agreed to irrevocably and unconditionally guarantee, on a senior unsecured basis, the punctual performance and payment when due of all obligations of Scilex Pharma under the Indenture (the &#8220;Guarantee&#8221;).</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Actual cumulative net sales of ZTlido from the issue date of the Scilex Pharma Notes through December&#160;31, 2021 did not equal or exceed $</div>481.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, which resulted in a $</div>28.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million increase in the principal amount of the Scilex Pharma Notes, effective <div style="letter-spacing: 0px; top: 0px;;display:inline;">February&#160;15, 2022</div>. As a result, the Company recorded the increase of $</div>28.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in principal and </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-operating</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> expense at December&#160;31, 2021.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Effective February&#160;14, 2022, Scilex Pharma issued to Sorrento a draw notice under the Letter of Credit as required under the terms of the Indenture because actual cumulative net sales of ZTlido from the issue date of the Scilex Pharma Notes through December&#160;31, 2021 were less than a specified sales threshold for such period. As a result of the draw notice being issued, Sorrento paid to Scilex Pharma $</div>35.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in a single </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lump-sum</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> amount as a subordinated loan and Scilex Pharma became subject to a minimum cash requirement of $</div>10.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million. In February 2022, Scilex Pharma repurchased Scilex Pharma Notes from the holders thereof on a pro rata basis in an aggregate amount equal to $</div>20.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">On June&#160;2, 2022, Sorrento and Scilex Pharma entered into a Consent Under and Amendment No.&#160;4 to Indenture (the &#8220;Amendment No.&#160;4&#8221;) with U.S. Bank Trust Company, National Association (as successor in interest to U.S. Bank National Association) and the Scilex Note Purchasers. Pursuant to Amendment </div><div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;4, (1)&#160;on </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"> June&#160;3, 2022, Scilex Pharma repurchased approximately $41.4&#160;million of the aggregate principal amount of the outstanding Scilex Pharma Notes at 100% of the principal amount thereof, (2)&#160;the Scilex Note Purchasers agreed that Scilex Pharma can repurchase the remaining principal amount of the Scilex Pharma Notes at any time on or before September 30, 2022 for $41.4&#160;million (subject to reduction for any quarterly royalty payments) and upon such repurchase the Scilex Note Purchasers will forgive and discharge $28.0&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">million of the aggregate principal amount of the Scilex Pharma Notes (the &#8220;Early Paydown Provision&#8221;), (3) the minimum cash requirement under the Indenture was reduced to $5.0 million in aggregate unrestricted cash equivalents at the end of each calendar month, and (4) the maximum aggregate principal amount on the promissory note issued by Scilex Pharma to Sorrento on October 5, 2018 was increased from up to $25.0 million to up to $50.0 million. The Company funded the repurchase with cash-on-hand and $15.0 million received from Sorrento on June 2, 2022,</div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">which was recorded under the current related party notes payable in the Company&#8217;s consolidated balance sheets (see Note 10). The Company concluded that the Amendment No.&#160;4 was a troubled debt restructuring for accounting purposes. The future undiscounted cash flows of the Scilex Pharma Notes were higher than the carrying value of the Scilex Pharma Notes at the time of the entry into the Amendment No.&#160;4, and accordingly, </div>no<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> gain was recognized in the quarter ended June&#160;30, 2022. Due to a decrease of $</div>30.4<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in the fair value of the Scilex Notes Derivative caused by the Amendment No.&#160;4, the carrying value of the Scilex Notes was increased by $</div>30.4<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In September 2022, the Company exercised the Early Paydown Provision to fully extinguish the Scilex Pharma Notes. In August and September 2022, the Company made principal payments towards the outstanding Scilex Pharma Notes totaling $</div>1.7<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div>39.7<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, respectively. Pursuant to Amendment No.&#160;4, $</div>28.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million of principal amount on the Scilex Pharma Notes was forgiven by the Scilex Pharma Note Purchasers and the Scilex Pharma Notes were fully extinguished in September 2022. The C<div style="letter-spacing: 0px; top: 0px;;display:inline;">o</div>mpany recorded a gain on debt extinguishment of $</div>33.4<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million as a result of the extinguishment. There are </div>no<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> derivative liabilities as of September&#160;30, 2022.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Borrowings of the Scilex Notes consisted of the following (in thousands):</div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><br/></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 67%;"/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">September&#160;30,<br/>2022</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">December&#160;31,<br/>2021</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Principal</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">133,997</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unamortized debt discount</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(30,597</td>
<td style="vertical-align: bottom; white-space: nowrap;">)</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unamortized debt issuance costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,228</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Carrying value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">101,172</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current portion</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(29,135</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long term portion</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">72,037</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Estimated fair value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">115,400</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company made principal payments of $</div>106.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div>44.2<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million during the nine months ended September&#160;30, 2022 and 2021, respectively. The imputed effective interest rate at December&#160;31, 2021 was </div>7.7<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">%. The amount of debt discount and debt issuance costs included in interest expense for the nine months ended September&#160;30, 2022 and 2021 was approximately $</div>3.1<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div>5.9<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, respectively. The Company recorded a gain on debt extinguishment of $</div>28.6<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and a loss on debt extinguishment of $</div>14.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in connection with its repayments of principal made during the nine months ended September&#160;30, 2022 and 2021, respectively.</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Related Party Notes Payable </div></div></div><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On October&#160;5, 2018, Scilex Pharma issued to Sorrento a promissory note (see Note 10). On March&#160;18, 2019, the Company entered into a note payable with Sorrento (see Note 10). On February&#160;14, 2022, Sorrento paid to Scilex Pharma $</div>35.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in a single </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lump-sum</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> amount as a subordinated loan (see Note 10). On May&#160;12, 2022, the Company issued Sorrento a promissory note of $</div>5.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in exchange for the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-104</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Assets (see Note 3).</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2020 Revolving Credit Facility </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On December&#160;</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">14, 2020, Scilex Pharma entered into the Credit and Security Agreement (the &#8220;Credit Agreement&#8221;) with CNH Finance Fund I, L.P. (&#8220;CNH&#8221;) which provides Scilex Pharma with the ability to incur<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>indebtedness under an accounts receivable revolving loan facility in an aggregate amount of $10.0&#160;million and the incurrence of liens and the pledge of collateral to CNH in connection with the revolving loan facility. Under the terms of the Credit Agreement, interest will accrue daily on the principal amount outstanding at a rate per annum equal to the Wall Street Journal Prime Rate plus 1.75%. All indebtedness incurred and outstanding will be</div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;">due and payable in full on January&#160;1, 2024; unless the Credit Agreement is earlier terminated. As of December&#160;31, 2021, the outstanding balance was $</div>8.8<div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;">&#160;million. On February&#160;16, 2022, the Company notified CNH that it was terminating the Credit Agreement, effective</div> March 18, 2022<div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;">. Upon termination, all principal balances and interest accrued were settled.</div></div><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><span></span>
</td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">8.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Debt </div></div></div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2018 Purchase Agreements and Indenture </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On September&#160;</div>7<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2018<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Scilex Pharma and Sorrento entered into Purchase Agreements (the &#8220;</div>2018<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Purchase Agreements&#8221;) with certain investors (collectively, the &#8220;Scilex Pharma Note Purchasers&#8221;). Pursuant to the </div>2018<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Purchase Agreements, on September&#160;</div>7<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2018<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Scilex Pharma, among other things, issued and sold to the Scilex Pharma Note Purchasers senior secured notes due </div>2026<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> in an aggregate principal amount of $</div>224.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million (the &#8220;Scilex Pharma Notes&#8221;) for an aggregate purchase price of $</div>140.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million (the &#8220;Offering&#8221;). The Scilex Pharma Notes are governed by an indenture (as amended, the &#8220;Indenture&#8221;) with Scilex Pharma, as issuer, U.S. </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bank </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">National</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;Association, a national banking association, as trustee (the &#8220;Trustee&#8221;) and collateral agent (the &#8220;Collateral Agent&#8221;), and Sorrento, as guarantor. Pursuant to the Indenture, Sorrento agreed to irrevocably and unconditionally guarantee, on a senior unsecured basis, the punctual performance and payment when due of all obligations of Scilex Pharma under the Indenture (the &#8220;Guarantee&#8221;).</div></div> <div style="clear: both; max-height: 0px;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The net proceeds of the Offering were approximately $</div>89.3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, after deducting the Offering expenses payable by Scilex Pharma and funding a segregated reserve account with $</div>20.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million (the &#8220;Reserve Account&#8221;) and a segregated collateral account with $</div>25.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million (the &#8220;Collateral Account&#8221;) pursuant to the terms of the Indenture. Funds in the Reserve Account were to be released to Scilex Pharma upon receipt by the Trustee of an officer&#8217;s certificate under the Indenture from Scilex Pharma confirming receipt of a marketing approval letter from the FDA with respect to </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-103</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> or a similar product with a concentration of not less than </div>5<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% (the &#8220;Marketing Approval Letter&#8221;) on or prior to July&#160;</div>1<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2023<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. Funds in the Collateral Account were to be released to Scilex Pharma only upon receipt of a written consent authorizing such release from the holders of a majority in principal amount of the Scilex Pharma Notes issued, upon the occurrence and during the continuance of an event of default at the direction of the holders of a majority in principal amount of the Scilex Pharma Notes issued or upon the repayment in full of all amounts owed under the Scilex Pharma Notes.</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On each February&#160;</div>15<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, May&#160;</div>15<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, August&#160;</div>15<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and November&#160;</div>15<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, beginning with February&#160;</div>15<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the holders of the Scilex Pharma Notes were initially entitled to receive quarterly payments of the principal of the Scilex Pharma Notes equal to a fixed&#160;percentage, ranging from </div>10<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% to </div>20<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">%, of the net sales of ZTlido for the prior fiscal quarter. However, because Scilex Pharma did not receive the Marketing Approval Letter by March&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the&#160;percentage of net sales payable was increased to be in the range of </div>15<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% to </div>25<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">%. If actual cumulative net sales of ZTlido from October&#160;</div>1<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> through September&#160;</div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2023<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> are less than approximately $</div>218.1<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, then Scilex Pharma will be obligated to pay an additional installment of the principal of the Scilex Pharma Notes each quarter in an amount between approximately $</div>10.1<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and approximately $</div>30.6<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, with the amount of the additional installment of principal to be determined by reference to the amount by which cumulative net sales of ZTlido from October&#160;</div>1<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> through September&#160;</div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2023<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> are less than approximately $</div>218.1<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million.</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the terms of the Indenture, the aggregate principal amount due under the Scilex Pharma Notes was to be increased by $</div>28.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million on February&#160;</div>15<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> if actual cumulative net sales of ZTlido from September&#160;</div>7<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2018<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> through December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> were less than approximately $</div>481.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million. As actual cumulative net sales of ZTlido from the issue date of the Scilex Pharma Notes through December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> did not equal or exceed the $</div>481.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million threshold for such period, the Company recorded the increase of $</div>28.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in the debt principal balance with an offset to Scilex Pharma Notes principal increase at December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">.</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If actual cumulative net sales of ZTlido for the period from October&#160;</div>1<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> through September&#160;</div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2023<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> are less than approximately $</div>290.7<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, then the aggregate principal amount due under the Scilex Pharma Notes will be increased on </div>November 15, 2023<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> by between approximately $</div>2.6<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and approximately $</div>84.8<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, with the amount of the principal increase to be determined by reference to the amount by which the cumulative net sales of ZTlido from October&#160;</div>1<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> through September&#160;</div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2023<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> is less than approximately $</div>290.7<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million.</div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">final maturity date of the Scilex Pharma Notes is </div>August 15, 2026<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. The Scilex Pharma Notes may be redeemed in whole at any time upon </div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;days&#8217; written notice at Scilex Pharma&#8217;s option prior to August&#160;</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">15</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2026</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">at a redemption price equal to 100% of the then-outstanding principal amount of the Scilex Pharma Notes. In addition, upon a change of control of Scilex Pharma (as defined in the Indenture), each holder of a Scilex Pharma Note shall have the right to require Scilex Pharma to repurchase all or any part of such holder&#8217;s Scilex Pharma Note at a repurchase price in cash equal to 101% of the then-outstanding principal amount </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">thereof.</div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">The 2018 Purchase&#160;</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Agreements include the terms and conditions of the offer and sale of the Scilex Pharma Notes, representations and warranties of the parties, indemnification and contribution obligations and other terms and conditions customary in agreements of this </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">type. </div></div><br/></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">The<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Indenture governing the Scilex Pharma Notes contains customary events of default with respect to the Scilex Pharma Notes (including a failure to make any payment of principal on the Scilex Pharma Notes when due and payable), and, upon certain events of default occurring and continuing, the Trustee by notice to Scilex Pharma, or the holders of at least </div>25<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% in principal amount of the outstanding Scilex Pharma Notes by notice to Scilex Pharma and the Trustee, may (subject to the provisions of the Indenture) declare </div>100<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the then-outstanding principal amount of the Scilex Pharma Notes to be due and payable. Upon such a declaration of acceleration, such principal will be due and payable immediately. In the case of certain events, including bankruptcy, insolvency or reorganization involving Sorrento or Scilex Pharma, the Scilex Pharma Notes will automatically become due and payable.</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the Indenture, the Company and Scilex Pharma must also comply with certain covenants with respect to the commercialization of ZTlido, as well as customary additional affirmative covenants, such as furnishing financial statements to the holders of the Scilex Pharma Notes, minimum cash requirements and net sales reports; and negative covenants, including limitations on the following: the incurrence of debt; the payment of dividends, the repurchase of shares and under certain conditions making certain other restricted payments; the prepayment, redemption or repurchase of subordinated debt; a merger, amalgamation or consolidation involving Scilex Pharma; engaging in certain transactions with affiliates; and the making of investments other than those permitted by the Indenture.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Scilex Pharma Notes and related Guarantee have not been, and will not be, registered under the Securities Act or the securities laws of any other jurisdiction and may not be offered or sold in the United States without registration or an applicable exemption from registration requirements. The holders of the Scilex Pharma Notes do not have any registration rights. Pursuant to a Collateral Agreement by and among Scilex Pharma, the Trustee and the Collateral Agent (the &#8220;Collateral Agreement&#8221;), the Scilex Pharma Notes will be secured by ZTlido and all of the existing and future property and assets of Scilex Pharma necessary for, or otherwise relevant to, now or in the future, the manufacture and sale of ZTlido, on a worldwide basis (exclusive of Japan), including, but not limited to, the intellectual property related to ZTlido, the marketing or similar regulatory approvals related to ZTlido, any licenses, agreements and other contracts related to ZTlido, and the current assets related to ZTlido such as inventory, accounts receivable and cash and any and all future iterations, improvements or modifications of such product made, developed or licensed (or </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-licensed)</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> by Scilex Pharma or any of its affiliates or licensees (or </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-licensees)</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> (including </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-103).</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the terms of the Indenture, Sorrento issued an irrevocable standby letter of credit to Scilex Pharma (the &#8220;Letter of Credit&#8221;), which provides that, in the event that </div>(1)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;Scilex Pharma did not hold at least $</div>4.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in unrestricted cash as of the end of any calendar month during the term of the Scilex Pharma Notes, </div>(2)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;actual cumulative net sales of ZTlido from September&#160;</div>7<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2018<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> through December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> were less than a specified sales threshold for such period, or </div>(3)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;actual cumulative net sales of ZTlido for any calendar year during the term of the Scilex Pharma Notes, beginning with the </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> calendar year, were less than a specified sales threshold for such calendar year, Scilex Pharma as beneficiary of the Letter of Credit, would be required to draw, and Sorrento would be required to pay to Scilex Pharma, $</div>35.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in a single </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lump-su</div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">m</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> amo</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">unt as a subordinated loan. The Letter of Credit was to terminate upon the earliest to occur of: (a)&#160;the repayment of the</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">Scilex<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">Pharma Notes in full, (b)&#160;the actual net sales of ZTlido for any calendar year during the term of the Scilex Pharma Notes exceeding a certain threshold, (c)&#160;the consummation of an initial public offering on a major international stock&#160;</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">exchange by the Company that satisfies certain valuation thresholds, and (d)&#160;the replacement of the Letter of Credit with another letter of credit in form and substance, including as to the identity and creditworthiness of issuer, reasonably acceptable to the holders of at least 80% in principal amount of outstanding Scilex Pharma Notes.</div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">On<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">December&#160;14, 2020, Scilex,</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Sorrento, the Trustee and the Agent, and the beneficial owners of the Scilex Pharma Notes and the Scilex Note Purchasers entered into a Consent Under and Amendment No.&#160;</div>3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> to Indenture and Letter of Credit (&#8220;Amendment No.&#160;</div>3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8221;), which amended: (i)&#160;the Indenture, and (ii)&#160;the Letter of </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Credit.</div></div><br/></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> to Amendment No.&#160;</div>3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Holders agreed to release all of the aggregate $</div>45.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in restricted funds held in the Reserve Account and the Collateral Account for the purpose of consummating the repurchase of an aggregate of $</div>45.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million of principal amount of the Scilex Pharma Notes from the Holders on a pro&#160;rata basis at a purchase price equal to </div>100<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the principal amount thereof (such repurchase, the &#8220;Scilex Repurchase&#8221;). In connection with the Scilex Repurchase, the parties also agreed to remove (i)&#160;Sorrento&#8217;s obligations under the Indenture to repurchase $</div>25.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million of Scilex Pharma Notes from the Holders if the Letter of Credit is drawn on and (ii)&#160;Scilex Pharma&#8217;s obligation to repurchase $</div>20.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million of Scilex Pharma Notes from the Holders if Scilex Pharma did not receive the Marketing Approval Letter on or prior to</div> July 1, 2023<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. On December&#160;</div>14<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the restricted funds in the Reserve Account and the Collateral Account were released and the Scilex Repurchase was effected.</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">Amendment</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;No.&#160;</div>3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> also revised the minimum cash covenant in the Indenture to provide that the amount of cash equivalents in bank accounts that Scilex Pharma is required to have as of the end of any calendar month shall, commencing with the month ending December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, be equal to at least $</div>4.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in the aggregate, provided that if Scilex Pharma did not effectuate (i)&#160;the December Optional Repurchase (as defined below) and (ii)&#160;at least one of either (x)&#160;the February Optional Repurchase (as defined below) or (y)&#160;the April Optional Repurchase (as defined below), then, commencing with the month ending April&#160;</div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, and for each month thereafter, such amount would have been required to be at least $</div>10.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in the aggregate. If Scilex Pharma fails to meet the foregoing minimum cash requirements, then Scilex Pharma will be required to draw on the Letter of Credit.</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">Amendment</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> No.&#160;</div>3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> also provided Scilex Pharma with the option, in its sole and absolute discretion, to repurchase Scilex Pharma Notes from the holders thereof on a pro&#160;rata basis on each of December&#160;</div>16<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> (the &#8220;December Optional Repurchase&#8221;), February&#160;</div>12<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> (the &#8220;February Optional Repurchase&#8221;) and April&#160;</div>13<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> (the &#8220;April Optional Repurchase&#8221;), in each case in an aggregate amount equal to the lesser of $</div>20.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million or the then-outstanding principal amount of the Scilex Pharma Notes, at a purchase price in cash equal to </div>100<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the principal amount thereof. Scilex Pharma effectuated the December Optional Repurchase, the February Optional Repurchase, and the April Optional Repurchase, which reduced the aggregate principal amount of the Scilex Pharma Notes by $</div>60.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and resulted in the minimum unrestricted requirement remaining at $</div>4.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million.</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">Amendment</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> No.&#160;</div>3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> further provided that in the event that the Letter of Credit is drawn upon by Scilex Pharma, then Scilex Pharma had to, within five business days of such draw, repurchase the Scilex Pharma Notes from the holders thereof on a pro&#160;rata basis in an aggregate amount equal to the lesser of $</div>20.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million or the then-outstanding principal amount of Scilex Pharma Notes, at a purchase price in cash equal to </div>100<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the principal amount thereof. In addition, upon the Letter of Credit being drawn on, Scilex Pharma is required to have minimum cash of $</div>10.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million at all times thereafter. In February&#160;</div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Scilex Pharma drew upon the Letter of Credit with Sorrento and, as such, repaid $</div>20.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million of the principal amount of the Scilex Pharma Notes and became subject to a minimum cash requirement of $</div>10.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million.</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">Pursuant</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;to Amendment No.&#160;</div>3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Holders also consented to Scilex Pharma incurring up to $</div>10.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million of indebtedness in connection with an accounts receivable revolving loan facility (discussed below).</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">The</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Company accounted for Amendment No.&#160;</div>3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> as a debt modification under ASC Topic </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">470-50</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> as modified terms were not substantially different than the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-modified</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> terms. The execution of Amendment No.&#160;</div>3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> resulted</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>in an additional derivative liability of $</div>2.8<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, which pertains to a $</div>9.6<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million distribution to Sorrento with respect to a contingent accelerated repayment on the Scilex Pharma Notes in connection with the Letter of Credit and $</div>6.8<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million reduction to the debt discount on the Scilex Pharma Notes.</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">To</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;estimate the fair value of the Scilex Pharma Notes, the Company uses the discounted cash flow method under the income approach, which involves significant Level&#160;</div>3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> inputs and assumptions, combined with a Monte Carlo simulation, as appropriate. The value of the debt instrument is based on the present value of future principal payments and the discounted rate of return reflective of the Company&#8217;s credit </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">risk. </div></div><br/></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Borrowings of the Scilex Pharma Notes are as follows (in thousands): </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 72%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Principal</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">133,997</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">151,872</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unamortized debt discount</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(30,597</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(51,022</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unamortized debt issuance costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,228</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,711</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Carrying value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">101,172</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">97,139</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current portion</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(29,135</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,881</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long term portion</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">72,037</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">92,258</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Estimated fair value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">115,400</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">122,300</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"/><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Future minimum payments under the Scilex Pharma Notes, based on a percentage of projected net sales of ZTlido are estimated as follows (in thousands): </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 83%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ending December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 83%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">29,135</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 83%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,005</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 83%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,637</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 83%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,746</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 83%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2026</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">64,474</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 83%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 83%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total minimum future payments</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">133,997</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">The</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Company made principal payments of $</div>45.9<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, $</div>69.8<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, and $</div>2.3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million during the fiscal&#160;years ended December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, and </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, respectively.</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Debt </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> discount and debt issuance costs, which are presented as a direct reduction of the Scilex Pharma Notes in the consolidated balance sheets, are amortized as interest expense using the effective interest method. As principal repayments on the Scilex Pharma Notes are based on a&#160;percentage of net sales of ZTlido and </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-103,</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> if the Marketing Approval Letter is received, the Company has elected to account for changes in estimated cash flows from future net sales prospectively. Specifically, a new effective interest rate will be determined based on revised estimates of remaining cash flows and changes in expected cash flows will be recognized prospectively. The imputed effective interest rate at December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> was </div>7.7<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% and </div>9.15<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">%, respectively. The amount of debt discount and debt issuance costs included in interest expense for the&#160;years ended December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> was approximately $</div>7.9<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, $</div>10.7<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div>15.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, respectively.</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">The</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Company identified a number of embedded derivatives that require bifurcation from the Scilex Pharma Notes and separate accounting in the consolidated financial statements as derivative liabilities. Certain of these embedded features included default interest provisions, contingent rate increases, contingent put options, optional and automatic acceleration provisions and indemnified taxes. The Company recorded this derivative within its consolidated financial statements (See Note </div>5)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. The Company </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-evaluates</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> this assessment each reporting period.</div><br/></div><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Scilex Pharma Notes also provide that, upon the occurrence of an event of default, the holders of at least </div>25<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% in principal amount of the outstanding Scilex Pharma Notes may, by written notice to Scilex Pharma, declare all of the outstanding principal and premium under such Scilex Pharma Notes immediately due and payable. For purposes of the Scilex Pharma Notes, an event of default includes, among other things, (i)&#160;Scilex Pharma&#8217;s failure to pay outstanding material indebtedness, including the Scilex Pharma Notes, when due (ii)&#160;Scilex Pharma&#8217;s breach of its representations and warranties or failure to comply with its covenants and obligations under the Scilex Pharma Notes or (iii)&#160;the occurrence of certain insolvency or bankruptcy events (both voluntary and involuntary) involving Scilex Pharma. The Company is in compliance with event of default clauses.</div><br/></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"/><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Related Party Notes Payable </div></div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On October&#160;</div>5<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2018<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Scilex Pharma issued to Sorrento a promissory note (see Note </div>13)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. On March&#160;</div>18<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company entered into a note payable with Sorrento (see Note </div>13)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">.</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2020 Revolving Credit Facility </div></div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On December&#160;</div>14<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Scilex Pharma entered into the Credit and Security Agreement (the &#8220;Credit Agreement&#8221;) with CNH Finance Fund&#160;I, L.P. (&#8220;CNH&#8221;) which provides Scilex Pharma with the ability to incur indebtedness under an accounts receivable revolving loan facility in an aggregate amount of $</div>10.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and the incurrence of liens and the pledge of collateral to CNH in connection with the revolving loan facility. Under the terms of the Credit Agreement, interest will accrue daily on the principal amount outstanding at a rate per annum equal to the Wall Street Journal Prime Rate plus </div>1.75<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">%. All indebtedness incurred and outstanding will be due and payable in full on January&#160;</div>1<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2024<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">; unless the Credit Agreement is earlier terminated. As of December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the outstanding balance was $</div>8.8<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div>9.5<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, respectively. On February&#160;</div>16<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company notified CNH that it was terminating the Credit Agreement, effective </div>March 18, 2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. Upon termination, all principal balances and interest accrued were </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">settled.</div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Paycheck Protection Program </div></div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In May&#160;</div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company received the proceeds from a loan in the amount of $</div>1.6<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million (the &#8220;PPP Loan&#8221;) from Bank of America, as the lender, pursuant to the Paycheck Protection Program (&#8220;PPP&#8221;) of the Coronavirus Aid, Relief, and Economic Security Act (the &#8220;CARES Act&#8221;). The PPP Loan matures on </div>May 05, 2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and bears interest at a rate of </div>1.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% per annum. The PPP Loan is evidenced by a promissory note dated May </div>03<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> (the &#8220;Note&#8221;), which contains customary events of default relating to, among other things, payment defaults and breaches of representations and </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">warranties.</div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the CARES Act, loan forgiveness is available for the sum of documented payroll costs, covered rent payments, covered mortgage interest and covered utilities during the twenty-four-week period, beginning on the date of loan approval. For purposes of the CARES Act, payroll costs exclude compensation of an individual employee in excess of $</div>100,000<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, prorated annually. Not more than </div>25<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the forgiven amount may be for </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-payroll</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> costs. Forgiveness is reduced if full-time headcount declines, or if salaries and wages for employees with salaries of $</div>100,000<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> or less annually are reduced by more than </div>25<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">%. In the event the PPP Loan, or any portion thereof, is forgiven pursuant to the PPP, the amount forgiven is applied to outstanding principal. The Company used all of the proceeds from the PPP Loan to retain employees and maintain payroll. In May&#160;</div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company received confirmation from the SBA that the entire PPP Loan was forgiven and recorded a gain on debt extinguishment of $</div>1.6<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, which is included in loss on debt extinguishment, net, on the consolidated statements of operations for the year ended </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">December&#160;31, 2021. </div></div></div><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139838694476800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vicker's Vantage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_WarrantsLineItems', window );"><strong>Warrants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_WarrantsTextBlock', window );">WARRANTS</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 8. WARRANTS </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of September&#160;30, 2022 and December&#160;31, 2021, there were&#160;6,900,000&#160;Public Warrants outstanding. Public Warrants may only be exercised for a whole number of shares. No fractional shares will be issued upon exercise of the Public Warrants. The Public Warrants will become exercisable on the later of (a)&#160;the completion of a Business Combination and (b) 12 months from the closing of the Initial Public Offering. The Public Warrants will expire five years from the completion of a Business Combination or earlier upon redemption or liquidation. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">No Public Warrants will be exercisable for cash unless the Company has an effective and current registration statement covering the issuance of the ordinary shares issuable upon exercise of the warrants and a current prospectus relating to such ordinary shares. Notwithstanding the foregoing, if a registration statement covering the issuance of the ordinary shares issuable upon exercise of the Public Warrants is not effective within 90 days from the closing of a Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company shall have failed to maintain an effective registration statement, exercise warrants on a cashless basis pursuant to an available exemption from registration under the Securities Act. If an exemption from registration is not available, holders will not be able to exercise their warrants on a cashless basis. The Public Warrants will expire five years after the completion of a Business Combination or earlier upon redemption or liquidation. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company may redeem the Public Warrants: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">in whole and not in part; </div></div> </td> </tr> </table>  <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8226;</div></td>
<td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">at a price of $0.01 per warrant; </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8226;</div></td>
<td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">at any time while the warrants become exercisable; </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8226;</div></td>
<td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">upon not less than 30 days&#8217; prior written notice of redemption to each warrant holder; </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8226;</div></td>
<td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">if, and only if, the reported last sale price of the Company&#8217;s ordinary shares equals or exceeds $18.00&#160;per share (subject to adjustment) for any 20 trading days within a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-trading</div> day period commencing after the warrants become exercisable and ending on the third trading business day prior to the notice of redemption to the warrant holders; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8226;</div></td>
<td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">if, and only if, there is a current registration statement in effect with respect to the issuance of the ordinary shares underlying such warrants at the time of redemption and for the entire <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-day</div> trading period referred to above and continuing each day thereafter until the date of redemption. </div></div> </td> </tr> </table>  <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If the Company calls the Public Warrants for redemption, management will have the option to require all holders that wish to exercise the Public Warrants to do so on a &#8220;cashless basis,&#8221; as described in the warrant agreement. </div></div></div> <div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The exercise price and number of ordinary shares issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a share dividend, extraordinary dividend or recapitalization, reorganization, merger or consolidation. However, the warrants will not be adjusted for issuance of ordinary shares at a price below its exercise price. The Company has agreed to use its best efforts to have declared effective a prospectus relating to the ordinary shares issuable upon exercise of the warrants and keep such prospectus current until the expiration of the warrants. However, if the Company does not maintain a current prospectus relating to the ordinary shares issuable upon exercise of the warrants, holders will be unable to exercise their warrants for cash and the Company will not be required to net cash settle or cash settle the warrant exercise. There will be no redemption rights upon the completion of a Business Combination with respect to the Company&#8217;s warrants. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company&#8217;s assets held outside of the Trust Account with the respect to such warrants. Accordingly, the warrants may expire worthless. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, if (x)&#160;the Company issues additional ordinary shares or equity-linked securities for capital raising purposes in connection with the closing of a Business Combination at an issue price or effective issue price of less than $<div style="letter-spacing: 0px; top: 0px;;display:inline;">9.20 </div>per ordinary share (with such issue price or effective issue price to be determined in good faith by the Company&#8217;s board of directors and, in the case of any such issuance to the Sponsors or its affiliates, without taking into account any Founder Shares held by the Sponsors or such affiliates, as applicable, prior to such issuance) (the &#8220;Newly Issued Price&#8221;), (y) the aggregate gross proceeds from such issuances represent more than <div style="letter-spacing: 0px; top: 0px;;display:inline;">60</div>% of the total equity proceeds, and interest thereon, available for the funding of a Business Combination on the date of the consummation of a Business Combination (net of redemptions), and (z)&#160;the volume weighted average trading price of its ordinary shares during the <div style="letter-spacing: 0px; top: 0px;;display:inline;">20 </div>trading day period starting on the trading day prior to the day on which the Company consummates its Business Combination (such price, the &#8220;Market Value&#8221;) is below $<div style="letter-spacing: 0px; top: 0px;;display:inline;">9.20 </div>per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to <div style="letter-spacing: 0px; top: 0px;;display:inline;">115</div>% of the higher of the Market Value and the Newly Issued Price, the $<div style="letter-spacing: 0px; top: 0px;;display:inline;">18.00 </div>per share redemption trigger price will be adjusted (to the nearest cent) to be equal to <div style="letter-spacing: 0px; top: 0px;;display:inline;">180</div>% of the higher of the Market Value and the Newly Issued Price. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At September&#160;30, 2022 and December&#160;31, 2021, there were&#160;6,840,000&#160;Private Placement Warrants outstanding. The Private Placement Warrants are identical to the Public Warrants underlying the Units sold in the Initial Public Offering, except that the Private Placement Warrants will be exercisable for cash (even if a registration</div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> statement covering the issuance of the ordinary shares issuable upon exercise of such warrants is not effective) or on a cashless basis, at the holder&#8217;s option and will not be redeemable by the Company, in each case so long as they are held by the initial purchasers or their affiliates.<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 8&#160;&#8212;&#160;WARRANTS </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2021 and 2020, there were 6,900,000 and 0 Public Warrants outstanding, respectively. Public Warrants may only be exercised for a whole number of shares. No fractional shares will be issued upon exercise of the Public Warrants. The Public Warrants will become exercisable on the later of (a)&#160;the completion of a Business Combination and (b)&#160;12&#160;months from the closing of the Initial Public Offering. The Public Warrants will expire five&#160;years from the completion of a Business Combination or earlier upon redemption or liquidation. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">No Public Warrants will be exercisable for cash unless the Company has an effective and current registration statement covering the issuance of the ordinary shares issuable upon exercise of the warrants and a current prospectus relating to such ordinary shares. Notwithstanding the foregoing, if a registration statement covering the issuance of the ordinary shares issuable upon exercise of the Public Warrants is not effective within 90&#160;days from the closing of a Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company shall have failed to maintain an effective registration statement, exercise warrants on a cashless basis pursuant to an available exemption from registration under the Securities Act. If an exemption from registration is not available, holders will not be able to exercise their warrants on a cashless basis. The Public Warrants will expire five&#160;years after the completion of a Business Combination or earlier upon redemption or liquidation. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company may redeem the Public Warrants: </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8226;</div></td>
<td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">in whole and not in part; </div></div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8226;</div></td>
<td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">at a price of $0.01 per warrant; </div></div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8226;</div></td>
<td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">at any time while the warrants become exercisable; </div></div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8226;</div></td>
<td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">upon not less than 30&#160;days&#8217; prior written notice of redemption to each warrant holder; </div></div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8226;</div></td>
<td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">if, and only if, the reported last sale price of the Company&#8217;s ordinary shares equals or exceeds $18.00 per share (subject to adjustment) <div style="display:inline;">fo</div>r any 20 trading days within a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-trading</div> day period commencing after the warrants become exercisable and ending on the third trading business day prior to the notice of redemption to the warrant holders; and </div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div>  <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><br/></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">if, and only if, there is a current registration statement in effect with respect to the issuance of the ordinary shares underlying such warrants at the time of redemption and for the entire <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-day</div> trading period referred to above and continuing each day thereafter until the date of redemption. </div></td></tr></table><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If the Company calls the Public Warrants for redemption, management will have the <div style="display:inline;">option </div>to <div style="display:inline;">require </div>all holders that wish to exercise the Public Warrants to do so on a &#8220;cashless basis,&#8221; as described in the warrant agreement. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The exercise price and number of ordinary shares issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a share dividend, extraordinary dividend or recapitalization, reorganization, merger or consolidation. However, the warrants will not be adjusted for issuance of ordinary shares at a price below its exercise price. The Company has agreed to use its best efforts to have declared effective a prospectus relating to the ordinary shares issuable upon exercise of the warrants and keep such prospectus current until the expiration of the warrants. However, if the Company does not maintain a current prospectus relating to the ordinary shares issuable upon exercise of the warrants, holders will be unable to exercise their warrants for cash and the Company will not be required to net cash settle or cash settle the warrant exercise. There will be no redemption rights upon the completion of a Business Combination with respect to the Company&#8217;s warrants. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company&#8217;s assets held outside of the Trust Account with the respect to such warrants. Accordingly, the warrants may expire worthless. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, if (x)&#160;the Company issues additional ordinary shares or equity-linked securities for capital raising purposes in connection with the closing of a Business Combination at an issue price or effective issue price of less than $9.20 per ordinary share (with such issue price or effective issue price to be determined in good faith by the Company&#8217;s board of directors and, in the case of any such issuance to the Sponsors or its affiliates, without taking into account any Founder Shares held by the Sponsors or such affiliates, as applicable, prior to such issuance) (the &#8220;Newly Issued Price&#8221;), (y)&#160;the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of a Business Combination on the date of the consummation of a Business Combination (net of redemptions), and (z)&#160;the volume weighted average trading price of its ordinary shares during the 20 trading day period starting on the trading day prior to the day on which the Company consummates its Business Combination (such price, the &#8220;Market Value&#8221;) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, the $18.00 per share redemption trigger price will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At December&#160;31, 2021 and 2020, there were 6,840,000 and 0 Private Placement Warrants outstanding, respectively. The Private Placement Warrants are identical to the Public Warrants underlying the Units sold in the Initial Public Offering, except that the Private Placement Warrants will be exercisable for cash (even if a registration statement covering the issuance of the ordinary shares issuable upon exercise of such warrants is not effective) or on a cashless basis, at the holder&#8217;s option and will not be redeemable by the Company, in each case so long as they are held by the initial purchasers or their affiliates. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_WarrantsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants [Line item]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_WarrantsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_WarrantsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_WarrantsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_VickersVantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_VickersVantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139838696877840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Deficit<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">SHAREHOLDERS' DEFICIT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">9.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stockholders&#8217; Equity </div></div></div></div></td></tr></table><div style="clear: both; max-height: 0px; text-indent: 0px;"/><div style="clear: both; max-height: 0px; text-indent: 0px;"/><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The total number of authorized shares of preferred stock of Scilex Holding is </div>20,000,000<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, of which </div>no<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;shares were issued and outstanding at December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. The total number of authorized shares of</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">common<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">stock of Scilex Holding is </div>350,000,000<div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">, of which </div>197,266,338<div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"> shares were issued and outstanding at&#160;</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">December&#160;31, 2021 and 2020.</div></div></div><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vickers Vantage [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">SHAREHOLDERS' DEFICIT</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 7. SHAREHOLDERS&#8217; DEFICIT </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Preference Shares</div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#8212;</div></div>&#160;The Company is authorized to issue&#160;1,000,000&#160;preference shares with a par value of $0.0001&#160;per share, with such designations, voting and other rights and preferences as may be determined from time to time by the Company&#8217;s board of directors. At September&#160;30, 2022 and December&#160;31, 2021, there were&#160;no&#160;preference shares issued or outstanding. <br/></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Ordinary Shares</div></div></div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#8212; The Company is authorized to issue&#160;</div>200,000,000<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;ordinary shares with a par value of $</div>0.0001<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;per share. Holders of ordinary shares are entitled to one vote for each share. At September&#160;30, 2022, there were&#160;</div>3,450,000<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;shares of ordinary shares issued and outstanding, excluding&#160;</div>9,726,395<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;ordinary shares subject to possible redemption which are presented as temporary equity. At December&#160;31, 2021, there were&#160;</div>3,450,000<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;shares of ordinary shares issued and outstanding, excluding&#160;</div>13,800,000&#160;<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ordinary shares subject to possible redemption which are presented as temporary equity.</div></div><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 7&#160;&#8212;&#160;SHAREHOLDERS&#8217; EQUITY </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Preference Shares</div></div></div></div>&#160;&#8212;&#160;The Company is authorized to issue 1,000,000 preference shares with a par value of $0.0001 per share, with such designations, voting and other rights and preferences as may be determined from time to time by the Company&#8217;s board of directors. At December&#160;31, 2021 and 2020, there were no preference shares issued or outstanding. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Ordinary Shares</div></div></div></div>&#160;&#8212;&#160;The Company is authorized to issue 200,000,000 ordinary shares with a par value of $0.0001 per share. Holders of ordinary shares are entitled to one vote for each share. At December&#160;31, 2021, there were 3,450,000 shares of ordinary shares issued and outstanding, excluding 13,800,000 ordinary shares subject to possible redemption which are presented as temporary equity. At December&#160;31, 2020, there were 3,450,000 ordinary shares issued or outstanding. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_VickersVantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_VickersVantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139838697532384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive and Employee Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CompensationAndEmployeeBenefitPlansAbstract', window );"><strong>Compensation And Employee Benefit Plans [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Stock Incentive and Employee Benefit Plans</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock Incentive and Employee Benefit Plans </div></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"/><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2017 Equity Incentive Plan </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">In June </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2017, Scilex Pharma adopted the Scilex Pharmaceuticals Inc. 2017 Equity Incentive Plan (the &#8220;Scilex Pharma 2017 Plan&#8221;). The Scilex Pharma 2017 Plan reserved </div><div style="letter-spacing: 0px; top: 0px;;display:inline;">24.0</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million shares of Scilex Pharma common stock. </div>Stock options granted under the Scilex Pharma 2017 Plan typically vest 1/4th of the shares on the first anniversary of the vesting commencement date and 1/48th of the remaining options vest each month thereafter. <div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Scilex Pharma 2017 Plan was amended and restated on July&#160;5, 2018.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Upon the closing of the Merger of Semnur, the Scilex Pharma 2017 Plan was terminated, and each option to purchase Scilex Pharma&#8217;s common stock outstanding and unexercised immediately prior to the closing of the Merger of Semnur was cancelled and substituted for that number of options <div style="letter-spacing: 0px; top: 0px;;display:inline;">to</div> acquire common stock of Scilex </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Holding. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Scilex Holding Company 2019 Stock Option Plan </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The board of </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">directors of the Company adopted the Scilex Holding Company 2019 Stock Option Plan (the &#8220;2019 Stock Option Plan&#8221;) on May&#160;28, 2019. The 2019 Stock Option Plan was approved by the Company&#8217;s stockholders on June&#160;7, 2019. As of December&#160;31, 2019, 30.0&#160;million shares of common stock of the Company were reserved for issuance pursuant to the 2019 Stock Option Plan. On December&#160;21, 2020, the board of directors approved an amendment to the 2019 Stock Option Plan to reserve an additional </div>15.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million shares of common stock for issuance under the 2019 Stock Option Plan. As of December&#160;31, 2020, </div>45.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million shares of common stock of the Company were reserved for issuance pursuant to the 2019 Stock Option Plan. </div>Stock options granted under the 2019 Stock Option Plan typically vest with respect to 1/4th of the shares on the first anniversary of the vesting commencement date and 1/48th of the remaining shares on each monthly anniversary thereafter.</div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of September&#160;30, 2022, options to purchase </div>25,159,760<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares of the common stock of Scilex Holding were outstanding, which is comprised of options to purchase </div>24,054,760<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares of common stock that were outstanding under the 2019 Stock Option Plan and options to purchase </div>1,105,000<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares of common stock that were outstanding pursuant to options previously granted under the Scilex Pharma 2017 Plan. As of September&#160;30, 2022, </div>20,945,240<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares of the Company&#8217;s common stock were reserved for awards available for future issuance under the 2019 Stock Option Plan.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total stock-based compensation recorded within operating expenses was $</div>4.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div>4.4<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million for the nine months ended September&#160;30, 2022 and 2021, respectively.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">T</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">he total unrecognized compensation costs related to unvested employee and </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> stock option grants as of September&#160;30, 2022 was $</div>3.9<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and the weighted average period over which these grants are expected to vest is </div>1.4<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> years.</div><br/></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Employee Benefit Plan </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company maintains a defined contribution 401(k) plan available to eligible employees, which is administered by Sorrento. Employee contributions are voluntary and are determined on an individual basis, limited to the maximum amount allowable under federal tax regulations. The Company made matching contributions to the 401(k) plan totaling $</div>0.3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div>0.2<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million for each of the nine months ended September&#160;30, 2022 and 2021, respectively.</div><br/></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><span></span>
</td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock Incentive and Employee Benefit Plans </div></div></div></div></td></tr></table><div style="clear: both; max-height: 0px; text-indent: 0px;"/><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2017 Equity Incentive Plan </div></div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In June&#160;</div>2017<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Scilex Pharma adopted the Scilex Pharmaceuticals Inc. </div>2017<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Equity Incentive Plan (the &#8220;Scilex Pharma </div>2017<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Plan&#8221;). The Scilex Pharma </div>2017<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Plan reserved </div>24.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million shares of Scilex Pharma common stock. </div>Stock options granted under the Scilex Pharma 2017 Plan typically vest 1/4th of the shares on the first anniversary of the vesting commencement date and 1/48th of the remaining options vest each month thereafter.<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> The Scilex Pharma </div>2017<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Plan was amended and restated on July&#160;</div>5<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2018<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">.</div><br/></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"/><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">Upon<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the Merger Closing, the Scilex Pharma </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2017</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Equity Incentive Plan was terminated, and each option to purchase Scilex Pharma&#8217;s common stock outstanding and unexercised immediately prior to the Merger Closing was cancelled and substituted for that number of options to acquire common stock of Scilex Holding.</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Scilex Holding Company 2019 Stock Option Plan </div></div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The board of directors of the Company adopted the Scilex Holding Company </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Stock Option Plan (the &#8220;</div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Stock Option Plan&#8221;) on May&#160;</div>28<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. The </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Stock Option Plan was approved by the Company&#8217;s stockholders on June&#160;</div>7<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. As of December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>30.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million shares of common stock of the Company were reserved for issuance pursuant to the </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Stock Option Plan. On December&#160;</div>21<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the board of directors approved an amendment to the </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Stock Option Plan to reserve an additional </div>15.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million shares of common stock for issuance under the </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Stock Option Plan. As of December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>45.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million shares of common stock of the Company were reserved for issuance pursuant to the </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Stock Option Plan. </div>Stock options granted under the 2019 Stock Option Plan typically vest with respect to 1/4th of the shares on the first anniversary of the vesting commencement date and 1/48th of the remaining shares on each monthly anniversary thereafter.</div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, options to purchase </div>28,163,510<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares of the common stock of Scilex Holding were outstanding, which is comprised of options to purchase </div>26,743,510<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares of common stock that were outstanding under the </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Stock Option Plan and options to purchase </div>1,420,000<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares of common stock that were outstanding pursuant to options previously granted under the Scilex Pharma </div>2017<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Plan. As of December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>18,256,490<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares of the Company&#8217;s common stock were reserved for awards available for future issuance under the </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Stock Option Plan.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total stock-based compensation recorded within operating expenses was $</div>5.8<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, $</div>5.4<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div>4.3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million for the&#160;years ended December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, respectively.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The total unrecognized compensation costs related to unvested employee and nonemployee stock option grants as of December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> was $</div>8.8<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and the weighted average period over which these grants are expected to vest is </div>1.8<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;years.</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Option Valuation </div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company calculates the fair value of stock-based compensation awards granted to employees and nonemployees using the Black-Scholes option-pricing method. The Black-Scholes option-pricing method requires the use of subjective assumptions, including stock price volatility, the expected life of stock options, risk free interest rate and the fair value per share of the underlying common stock on the date of grant. The </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">assumptions used in the Black-Scholes option-pricing method related to options issued to employees and nonemployees for the years ended 2020 and 2019 is set forth below: </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 67%;"/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average grant date fair value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">$0.83</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;&#160;$0.87</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected dividend yield</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.00%</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.00%</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;;text-indent: 0px;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected stock-price volatility</div></div></td>
<td style="vertical-align: bottom;;text-indent: 0px;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-indent: 0px;;text-align:right;">90.00%</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-indent: 0px;;text-align:right;">89.00%<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;-&#160;</div>104.00%</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-indent: 0px;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free interest rate</div></div></td>
<td style="vertical-align: bottom;;text-indent: 0px;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-indent: 0px;;text-align:right;">0.53%</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-indent: 0px;;text-align:right;">1.63%<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;-&#160;</div>2.50%</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;;text-indent: 0px;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Term of options</div></div></td>
<td style="vertical-align: bottom;;text-indent: 0px;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-indent: 0px;;text-align:right;">5.60</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-indent: 0px;;text-align:right;">5.76<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;-&#160;</div>6.08</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value per share of common stock on date of grant</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">$1.16</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">$1.16</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercise price</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">$1.16</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">$1.16</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expected<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div><div style="font-size: 10pt; letter-spacing: 0px;;font-style:italic;display:inline;">dividend yield</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. The Company bases the expected dividend yield assumption on the fact that the Company has never paid cash dividends and has no present intention to pay cash dividends on the Company&#8217;s common stock.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expected stock-price volatility</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. The expected stock-price volatility assumption is based on volatilities of a peer group of similar companies whose share prices are publicly available. The peer group was developed based on companies in the transdermal patch industry. In selecting the peer group, management considered publicly-traded transdermal patch companies with existing clinical stage branded and generic transdermal patches. Management further considered the development stage of the peer group companies.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Risk-free interest rate</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. The Company bases the risk-free interest rate assumption on the U.S. Treasury&#8217;s rates for U.S. Treasury </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">zero-coupon</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> bonds with maturities similar to those of the expected term of the award being valued.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expected term of options</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. The expected term of options represents the period of time when options are expected to be outstanding. Because the Company does not have historic exercise behavior, the Company determines the expected life assumption for options issued to directors and employees using the simplified method, which is an average of the contractual term of the option and its ordinary vesting period.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the&#160;years ended December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Scilex Holding issued stock options to certain employees and nonemployees. Significant inputs utilized in determining the fair value of the common shares are as </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">follows: </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">March&#160;17 and March&#160;31, 2019 Valuations </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the valuation </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">performed on March&#160;</div>17<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and March&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the fair value of the Company&#8217;s common stock was estimated using the market and income approaches. The Company weighted a guideline public company method, a market approach that uses comparable company data and applies to the subject company, equally with a discounted cash flow method, an income approach that derives value by estimating reasonable future cash flows to the equityholders and discounting them to present value using a risk-adjusted discount rate. The Company then used the Option Pricing Method (&#8220;OPM&#8221;) to allocate the concluded equity value amongst the different equity classes and determine the common stock value. These valuations resulted in a valuation of the Company&#8217;s common stock of $</div>1.16<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> per share as of March&#160;</div>17<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and March&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">.</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">May&#160;31, 2019 Valuation </div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the valuation performed on May&#160;31, 2019, the fair value of the Company&#8217;s common stock was estimated using a hybrid Probability Weighted Expected Return Method (&#8220;PWERM&#8221;), which estimates the value by </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">probability</div></div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">-weighting different scenarios. The Company used three going public scenarios and one stay-private scenario. For the three public scenarios, the Company utilized recent comparable initial public offerings to estimate value, which was allocated on a fully diluted basis to derive a common stock value for each scenario. For the stay-private scenario, the Company utilized the income and market approaches in line with the March&#160;</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">31</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">, </div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">2019</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"> valuation then allocated the concluded equity value using an OPM to derive a common stock value for the stay-private scenario. The Company then probability weighted (based on the Company&#8217;s best estimates at the time) each scenario&#8217;s common stock value to arrive at the Company&#8217;s concluded common stock value. This valuation resulted in a valuation of the Company&#8217;s common stock of $</div>1.16<div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"> per share as of May&#160;</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">31</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">, </div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">2019</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">.</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">December&#160;31, 2019 Valuation </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the valuation performed on December&#160;31, 2019, the fair value of the Company&#8217;s common stock was estimated using PWERM, which estimates the value by probability-weighting different scenarios. The Company used three going public scenarios and one stay-private scenario. For the three public scenarios, the </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Company<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 0px; top: 0px;;display:inline;">utilized recent comparable initial public offerings to estimate value, which was allocated on a fully diluted basis to derive a common stock value for each scenario. For the stay-private scenario, the Company utilized the income approach in line with the March&#160;31, 2019 valuation then allocated the concluded equity value using an OPM to derive a common stock value for the stay-private scenario. The Company then probability weighted (based on the Company&#8217;s best estimates at the time) each scenario&#8217;s common stock value to arrive at the Company&#8217;s concluded common stock value. This valuation resulted in a valuation of the Company&#8217;s common stock of $</div>1.16<div style="font-size: 10pt; letter-spacing: 0px; text-indent: 0px; top: 0px;;display:inline;"> per share as of December&#160;31, 2019.</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">July&#160;31, 2020 Valuation </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the valuation performed on July&#160;31, 2020, the fair value of the Company&#8217;s common stock was estimated using PWERM, which estimates the value by probability-weighting different scenarios. The Company used three going public scenarios and one stay-private scenario. For the three public scenarios, the Company utilized recent comparable initial public offerings to estimate value, which was allocated on a fully diluted basis to derive a common stock value for each scenario. For the stay-private scenario, the Company utilized the income approach in line with the March&#160;31, 2019, May&#160;31, 2019 and December&#160;31, 2019 valuations then allocated the concluded equity value using an OPM to derive a common stock value for the stay-private scenario. The Company then probability weighted (based on the Company&#8217;s best estimates at the time) each scenario&#8217;s common stock value to arrive at the Company&#8217;s concluded common stock value. This valuation resulted in a valuation of the Company&#8217;s common stock of $1.16 per share as of July&#160;31, 2020.</div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following represents a summary of the options outstanding at December&#160;31, 2021, 2020, and 2019 changes during the years then ended (in thousands, other than weighted-average exercise price): </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 62%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Options</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/>average<br/>exercise&#160;price</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate<br/>Intrinsic<br/>Value</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 0px;">
<td style="width: 62%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 62%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at December&#160;31, 2018</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,781</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.63</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,291</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 62%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,468</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.16</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 62%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercised</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 62%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited/Cancelled</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(838</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.94</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 62%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 62%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at December&#160;31, 2019</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,411</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.07</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,183</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 62%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,194</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.16</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 62%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercised</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(56</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.90</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 62%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited/Cancelled</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(745</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.94</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 62%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 62%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30,804</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.10</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,172</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt; width: 62%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt; width: 62%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercised</div></div></div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt; width: 62%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited/Cancelled</div></div></div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(2,641</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">0.68</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; width: 62%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt; width: 62%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at December&#160;31, 2021</div></div></div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">28,163</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1.13</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">915</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt; width: 62%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercisable at December&#160;31, 2021</div></div></div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">17,177</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1.11</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr></table><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Employee Benefit Plan </div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/><br/></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color:#ffffff;;display:inline;">The </div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Company maintains a defined contribution </div>401<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(k) plan available to eligible employees, which is administered by Sorrento. Employee contributions are voluntary and are determined on an individual basis, limited to the maximum amount allowable under federal tax regulations. The Company made matching contributions to the </div>401<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(k) plan totaling $</div>0.3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million for each of the&#160;years ended December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_CompensationAndEmployeeBenefitPlansAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Compensation and employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_CompensationAndEmployeeBenefitPlansAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI https://asc.fasb.org/topic&amp;trid=2197446<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI https://asc.fasb.org/topic&amp;trid=2127225<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139838691716080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">8.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commitments and Contingencies </div></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"/><div style="clear:both;max-height:0pt;;text-indent: 0px;"/><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; font-size: 10pt;;font-style:italic;display:inline;">Product Development Agreement</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In February 2013, Scilex Pharma became a party to a product development agreement (as amended, the &#8220;Product Development Agreement&#8221;) with two parties (the &#8220;Developers&#8221;), one of which is ITOCHU CHEMICAL FRONTIER Corporation (&#8220;Itochu&#8221;), pursuant to which the Developers will manufacture and supply lidocaine tape products, including ZTlido and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-103</div> (the &#8220;Products&#8221;), for Scilex Pharma. The Developers initially developed, and have intellectual property rights relating to, the Products. Pursuant to the Product Development Agreement, Scilex Pharma acquired an exclusive right to develop and commercialize the Products worldwide except for Japan. The Developers are responsible for sourcing and supplying lidocaine for development and commercialization purposes. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the Product Development Agreement, Scilex Pharma is required to make aggregate royalty payments </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">between </div>25<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% and </div>35<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% to the Developers based on net profits. During the nine months ended September&#160;30, 2022, Scilex Pharma made the first royalty payments in the amount of $0.2&#160;million. Net profits are defined as net sales, less cost of goods and marketing expenses. Net sales are defined as total gross sales of any Product, less all applicable deductions, to the extent accrued, paid or allowed in the ordinary course of business with respect to the sale of such Product, and to the extent that they are in accordance with U.S. GAAP. If Scilex Pharma were to sublicense the licensed technologies, the Developers will receive the same proportion of any sublicensing fees received therefrom. The Product Development Agreement will continue in full force and effect until </div>October 2, 2028<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the date that is </div>ten years<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> from the date of the first commercial sale of ZTlido. The Product Development Agreement will renew automatically for subsequent successive </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">one-year</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> renewal periods unless Scilex Pharma or the Developers terminate it upon </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">6-month</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> written notice. In addition, Scilex Pharma or the Developers may terminate the Product Development Agreement if (1)&#160;the other party is in material breach of the agreement and the breach is not curable, or if the breach is curable and the breaching party has not cured such material breach within </div>180<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> days after notice requesting to cure; (2)&#160;the FDA determines that the formulation of the Products would not be eligible for FDA approval in the absence of efficacy studies, and the Developers are unable to address the efficacy study requirements despite good faith efforts; (3)&#160;the market conditions are such that (a)&#160;commencing with the quarter ending March&#160;31, 2023, Scilex Pharma&#8217;s total net profits of the Products are equal to or less than </div>5<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/><div style="letter-spacing: 0px; top: 0px;;display:inline;">% of Scilex Pharma&#8217;s net sales of the Products for a period of four or more consecutive quarters, or (b)&#160;the Products&#8217; economic viability is affected by documented external circumstances deemed detrimental to all parties as agreed to by Scilex Pharma and the Developers, and the parties are unable to resolve the economic viability concerns under the foregoing clauses (a)&#160;and (b) after 30 days of good-faith discussion; (4)&#160;the parties fail to reach mutual agreement as to who will conduct the clinical studies and how the costs will be allocated; or (5)&#160;Scilex Pharma or either one of the Developers are bankrupt or make assignment for the benefit of creditors. Up to the date the financial statements were issued, the Company&#8217;s net profits for ZTlido and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-103</div> have not exceeded five percent of net sales. Accordingly, Oishi and Itochu have the right to terminate the Product Development Agreement and Commercial Supply Agreement. As of the date of this prospectus, neither Oishi nor Itochu has exercised its right of termination. Additionally, Scilex Pharma may terminate the Product Development Agreement if (i)&#160;any of the pivotal human clinical trials for any of the Products fail, or (ii)&#160;the FDA issues a &#8220;Refusal to File&#8221; for any of the Products&#8217; regulatory approval application and, after reasonable consultation with the Developers, Scilex Pharma believes that it is commercially unreasonable to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-file.</div> The Developers may terminate the Product Development Agreement if Scilex Pharma fails to file for regulatory approval for any of the Products within three months of the date on which all required components of the regulatory approval application are received by Scilex Pharma.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">On February&#160;16, 2017, Scilex Pharma entered into a Commercial Supply Agreement (as amended, the &#8220;Supply Agreement&#8221;) with the two Developers to provide commercial supply of ZTlido and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-103</div> to Scilex Pharma. The Supply Agreement contains standard terms regarding term, termination, payment, product quality and supply. In addition, the agreement provides additional terms regarding the calculation and amount of marketing expenses that may be deducted from net sales for purposes of determining the amount of net profit under the Product Development Agreement. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; font-size: 10pt;;font-style:italic;display:inline;">Exclusive Distribution Agreement</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In August 2015, Scilex Pharma entered into an Exclusive Distribution Agreement (the &#8220;Distribution Agreement&#8221;) to appoint an exclusive third-party logistics distribution provider (the &#8220;Distributor&#8221;) and as an authorized distributor of record of ZTlido (&#8220;Product&#8221;) in the United States, its territories, possessions and commonwealths for an agreed schedule of fees, subject to a </div>3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% annual adjustment. The Distribution Agreement has an initial term of </div>three years<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> following the first shipment of </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FDA-approved</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Product to a commercial customer and shall automatically renew for additional terms of one year each, unless written notice of termination is given by either party at least 30 days prior to the end of the initial term or any renewal term. In the event of Product recalls, Scilex Pharma is solely responsible for all Product recalls, except in the event where the recalls arise from the Distributor&#8217;s negligence or willful misconduct. Pursuant to the Distribution Agreement, Scilex Pharma will be responsible for delivery of Product to and from the Distributor&#8217;s facility, including all costs, expenses and risk of loss associated with such delivery. From late 2018 to early 2022, ZTlido was sold, and title was transferred, to the Distributor for distribution and sale to wholesalers for a fee of between </div>1<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% to </div>2<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% which was recorded as a </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">gross-to-net</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> sales adjustment. Beginning in April 2022, Scilex Pharma began directly selling and transferring title to distributors.</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Sales Operations Services </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In January 2016, Scilex Pharma entered into a project agreement with a vendor to provide sales operations services and detailing services, which was subsequently superseded by a new project agreement entered into in September 2018 (the &#8220;Project Agreement&#8221;). In connection with the detailing services, the Project Agreement provides that the vendor will provide Scilex Pharma with full-time sales representatives who shall detail the Product by making calls pursuant to a call plan on targets. These sales representatives are to be managed by field talent managers and a national project director, each of whom will also be provided by the vendor. In connection with the sales operation services, the vendor will provide certain services required for the initial implementation and ongoing operation of the sales force.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color:#ffffff;;display:inline;">On </div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">July&#160;1, 2020, Scilex Pharma and the vendor entered into a work order in which the parties agreed to convert substantially all of the sales representatives allocated under the Project Agreement to become employees of Scilex Pharma. The vendor will continue to provide sales operations services, fleet management services and sample accountability services. The work order was in effect until June&#160;30, 2022 and was extended for one year upon the mutual agreement of both parties. Either party may terminate the work order with </div>90<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> days&#8217; notice. Scilex Pharma paid an implementation fee of $</div>59.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;thousand and will pay fixed monthly fees of $</div>63.7<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;thousand to $</div>65.8<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;thousand for ongoing </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">services.</div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company recognized an expense of $</div>0.5<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div>1.6<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million within selling, general and administrative expenses for services performed for the nine months ended September&#160;30, 2022 and 2021, respectively, including implementation fees, fixed monthly fees and pass-through costs.</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Litigation </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the normal course of business, the Company may be named as a defendant in one or more lawsuits. Other than the following three lawsuits, the Company is not a party to any outstanding material litigation and management is not aware of any legal proceedings that, individually or in the aggregate, are deemed to be material to the Company&#8217;s financial condition or results of operations. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Sanofi-Aventis U.S. LLC and Hisamitsu America, Inc. Litigation </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On February&#160;23, 2021, the Company filed an action in the U.S. District Court for the Northern District of California against Sanofi-Aventis U.S. LLC and Hisamitsu America, Inc., two manufacturers of OTC lidocaine patch products, alleging, among other things, false and deceptive advertising and unfair competition under the Lanham Act and California state laws by those companies regarding their respective OTC patch products (the </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Sanofi- Aventis&#160;&amp; Hisamitsu Litigation&#8221;). This lawsuit seeks, among other relief, damages and an injunction enjoining the defendants from continuing to make false or misleading statements of fact about their respective OTC lidocaine patch products. The defendants have filed motions to dismiss, which have narrowed slightly our claims, but which motions the court has largely rejected. Discovery is proceeding. The case is currently scheduled for trial to begin on July&#160;24, 2023. The Company cannot make any predictions about the outcome in this matter or the timing thereof. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Former Employee Litigation </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;12, 2021, the Company filed an action in the Delaware Court of Chancery against Anthony Mack, former President of Scilex Pharma, and Virpax Pharmaceuticals, Inc. (&#8220;Virpax&#8221;), a company now headed by Mr.&#160;Mack, alleging, among other things, breach by Mr.&#160;Mack of his <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compete</div> agreement with us, breach of fiduciary duty, and tortious interference by Virpax with that <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compete</div> agreement (the &#8220;Former Employee Litigation&#8221;). This lawsuit seeks, among other relief, damages and an injunction enjoining Mr.&#160;Mack from further violating his <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compete</div> agreement and enjoining Virpax from tortiously interfering with Mr.&#160;Mack&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compete</div> agreement. The case was tried from September <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12-14,</div> 2022. Post-trial briefing is completed and closing arguments remain. The Company cannot make any predictions about the outcome in this matter or the timing thereof. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">ZTlido Patent Litigation </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">On June&#160;22, 2022, the Company filed a complaint against Aveva Drug Delivery Systems, Inc., Apotex Corp., and Apotex, Inc. (together, &#8220;Aveva&#8221;) in the U.S. District Court for the Southern District of Florida (the &#8220;Aveva Patent Litigation&#8221;) alleging infringement of certain Orange Book listed patents covering ZTlido (the &#8220;ZTlido Patents&#8221;). The Aveva Patent Litigation was initiated following the submission by Aveva, in accordance with the procedures set out in the Hatch-Waxman Act, of an ANDA. Aveva&#8217;s ANDA seeks approval to market a generic version of ZTlido prior to the expiration of the ZTlido Patents and alleges that the ZTlido Patents are invalid, unenforceable, and/or not infringed. The Company is seeking, among other relief, an order that the effective date of any FDA approval of Aveva&#8217;s ANDA be no earlier than the expiration of the asserted patents listed in the Orange Book, the latest of which expires on May&#160;10, 2031, and such further and other relief as the court may deem appropriate. Aveva is subject to a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-month</div> stay preventing it from selling a generic version of ZTlido during that time. The stay should expire no earlier than November&#160;11, 2024. Trial in the Aveva Patent Litigation has not yet been scheduled. The Company cannot make any predictions about the final outcome of this matter or the timing thereof.</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; font-size: 10pt;;font-style:italic;display:inline;">Operating Leases</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplemental quantitative information related to leases includes the following: </div></div><br/></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><br/></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 81%;"/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Nine&#160;Months&#160;Ended<br/>September&#160;30,</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2022</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2021</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 0px;">
<td style="width: 69%;"/>
<td style="width: 14%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 13%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt; width: 69%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash paid for amounts included in the measurement of lease liabilities:</div></div></div></td>
<td style="vertical-align: bottom; width: 14%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-size: 0px;">
<td style="width: 69%;"/>
<td style="width: 14%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 13%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 69%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Operating cash flows from operating leases</div></td>
<td style="vertical-align: bottom; width: 14%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">531</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">489</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 69%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">ROU assets obtained in exchange for new operating lease<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>liabilities</div></td>
<td style="vertical-align: bottom; width: 14%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">320</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 69%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Weighted average remaining lease term in years &#8212; operating leases</div></td>
<td style="vertical-align: bottom; width: 14%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 69%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Weighted average discount rate &#8212; operating leases</div></td>
<td style="vertical-align: bottom; width: 14%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">June 2022</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company entered into a new </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cancelable</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> lease agreement for an administrative facility in Palo Alto. The lease includes annual rent increases and the option to extend. The term of the new lease is </div>26<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> months and the Company expects to exercise the extension option at the end of the lease.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Maturities of lease liabilities were as follows (in thousands):</div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 87%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Year Ending December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); text-align: center;">Amount</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022 (Remaining three months)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">215</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">872</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">703</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2026</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total lease payments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,790</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less imputed interest</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(210</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total lease liabilities as of September&#160;30, 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,580</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">11.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commitments and Contingencies </div></div></div></div></td></tr></table> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Product Development Agreement </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In February&#160;</div>2013<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Scilex Pharma became a party to a product development agreement (as amended, the &#8220;Product Development Agreement&#8221;) with </div>two<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> parties (the &#8220;Developers&#8221;), </div>one<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> of which is ITOCHU CHEMICAL FRONTIER Corporation (&#8220;Itochu&#8221;), pursuant to which the Developers will manufacture and supply lidocaine tape products, including ZTlido and </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-103</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> (the &#8220;Products&#8221;), for Scilex Pharma. The Developers initially developed, and have intellectual property rights relating to, the Products. Pursuant to the Product Development Agreement, Scilex Pharma acquired an exclusive right to develop and commercialize the Products worldwide except for Japan. The Developers are responsible for sourcing and supplying lidocaine for development and commercialization purposes.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the Product Development Agreement, Scilex Pharma is required to make aggregate royalty payments between </div>25<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% and </div>35<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% to the Developers based on net profits. Up to the date the financial statements were issued, the Company made </div>no<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> aggregate royalty payments. Net profits are defined as net sales, less cost of goods and marketing expenses. Net sales are defined as total gross sales of any Product, less all applicable deductions, to the extent accrued, paid or allowed in the ordinary course of business with respect to the sale of such Product, and to the extent that they are in accordance with U.S. GAAP. If Scilex Pharma were to sublicense the licensed technologies, the Developers will receive the same proportion of any sublicensing fees received therefrom. The Product Development Agreement will continue in full force and effect until </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">October 2, 2028</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the date that is </div><div style="letter-spacing: 0px; top: 0px;;display:inline;">ten</div> years<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> from the date of the first commercial sale of ZTlido. The Product Development Agreement will renew automatically for subsequent successive </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-year</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> renewal periods unless Scilex Pharma or the </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">Developers terminate it upon </div><div style="font-size: 10pt; text-indent: 4%; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">6-month</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"> written notice. In addition, Scilex Pharma or the Developers may terminate the Product Development Agreement if </div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">(1)</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">&#160;the other party is in material breach of the agreement and the breach is not curable, or if the breach is curable and the breaching party has not cured such material breach within </div>180<div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">&#160;days after notice requesting to cure; </div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">(2)</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">&#160;the FDA determines that the formulation of the Products would not be eligible for FDA approval in the absence of efficacy studies, and the Developers are unable to address the efficacy study requirements despite good faith efforts; </div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">(3)</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">&#160;the market conditions are such that (a)&#160;commencing with the quarter ending March&#160;</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">31</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">, </div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">2023</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">, Scilex Pharma&#8217;s total net profits of the Products are equal to or less than </div>5<div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">% of Scilex Pharma&#8217;s net sales of the Products for a period of </div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">four</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"> or more consecutive quarters, or (b)&#160;the Products&#8217; economic viability is affected by documented external circumstances deemed detrimental to all parties as agreed to by Scilex Pharma and the Developers, and the parties are unable to resolve the economic viability concerns under the foregoing clauses (a)&#160;and (b)&#160;after </div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">30</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">&#160;days of good-faith discussion; </div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">(4)</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">&#160;the parties fail to reach mutual agreement as to who will conduct the clinical studies and how the costs will be allocated; or </div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">(5)</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">&#160;Scilex Pharma or either </div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">one</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"> of the Developers are bankrupt or make assignment for the benefit of creditors.<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>Up to the date the financial statements were issued, Scilex&#8217;s net profits for ZTlido and </div><div style="font-size: 10pt; text-indent: 4%; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-103</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"> have not exceeded </div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">five</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"> percent of net sales. Accordingly, Oishi and Itochu have the right to terminate the Product Development Agreement and Commercial Supply Agreement. As of the date of this prospectus, neither Oishi nor Itochu has exercised its right of termination. Additionally, Scilex Pharma may terminate the Product Development Agreement if (i)&#160;any of the pivotal human clinical trials for any of the Products fail, or (ii)&#160;the FDA issues a &#8220;Refusal to File&#8221; for any of the Products&#8217; regulatory approval application and, after reasonable consultation with the Developers, Scilex Pharma believes that it is commercially unreasonable to </div><div style="font-size: 10pt; text-indent: 4%; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-file.</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"> The Developers may terminate the Product Development Agreement if Scilex Pharma fails to file for regulatory approval for any of the Products within </div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">three</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">&#160;months of the date on which all required components of the regulatory approval application are received by Scilex Pharma.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On February&#160;</div>16<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2017<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Scilex Pharma entered into a Commercial Supply Agreement (as amended, the &#8220;Supply Agreement&#8221;) with the </div>two<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Developers to provide commercial supply of ZTlido and </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-103</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> to Scilex Pharma. The Supply Agreement contains standard terms regarding term, termination, payment, product quality and supply. In addition, the agreement provides additional terms regarding the calculation and amount of marketing expenses that may be deducted from net sales for purposes of determining the amount of net profit under the Product Development Agreement.</div><br/></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-size: 10pt;;font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Exclusive Distribution Agreement</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color:#ffffff;;display:inline;">In </div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> August&#160;</div>2015<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Scilex Pharma entered into an Exclusive Distribution Agreement (the &#8220;Distribution Agreement&#8221;) to appoint an exclusive third-party logistics distribution provider (the &#8220;Distributor&#8221;) and as an authorized distributor of record of ZTlido (&#8220;Product&#8221;) in the United States, its territories, possessions and commonwealths for an agreed schedule of fees, subject to a </div>3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% annual adjustment. The Distribution Agreement has an initial term of </div><div style="letter-spacing: 0px; top: 0px;;display:inline;">three</div> years<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> following the first shipment of </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FDA-approved</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Product to a commercial customer and shall automatically renew for additional terms of </div>one<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> year each, unless written notice of termination is given by either party at least </div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;days prior to the end of the initial term or any renewal term. In the event of Product recalls, Scilex Pharma is solely responsible for all product recalls, except in the event where the recalls arise from the Distributor&#8217;s negligence or willful misconduct. Pursuant to the Distribution Agreement, Scilex Pharma will be responsible for delivery of Product to and from the Distributor&#8217;s facility, including all costs, expenses and risk of loss associated with such delivery. From late </div>2018<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> to early </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, ZTlido was sold, and title was transferred, to the Distributor for distribution and sale to wholesalers for a fee of between </div>1<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% to </div>2<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% which was recorded as a </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">gross-to-net</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> sales adjustment. Beginning in </div>April 2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Scilex Pharma began directly selling and transferring title to distributors.</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Sales Operations Services </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In January&#160;</div>2016<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Scilex Pharma entered into a project agreement with a vendor to provide sales operations services and detailing services, which was subsequently superseded by a new project agreement entered into in</div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">September&#160;</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">2018</div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"> (the &#8220;Project Agreement&#8221;). In connection with the detailing services, the Project Agreement provides that the vendor will provide Scilex Pharma with full-time sales representatives who shall detail the Product by making calls pursuant to a call plan on targets. These sales representatives are to be managed by field talent managers and a national project director, each of whom will also be provided by the vendor. In connection with the sales operation services, the vendor will provide certain services required for the initial implementation and ongoing operation of the sales force.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On July&#160;</div>1<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Scilex Pharma and the vendor entered into a work order in which the parties agreed to convert substantially all of the sales representatives allocated under the Project Agreement to become employees of Scilex Pharma. The vendor will continue to provide sales operations services and fleet management services and sample accountability services. The work order will remain in effect until June&#160;</div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, and may be extended for additional periods of </div>one<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> year upon the mutual agreement of both parties. Either party may terminate the work order with </div>90<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;days&#8217; notice. Scilex Pharma paid an implementation fee of $</div>59.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;thousand and will pay fixed monthly fees of $</div>63.7<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;thousand to $</div>65.8<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;thousand for ongoing services.</div><br/></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company recognized an expense of $</div>1.9<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, $</div>10.5<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, and $</div>25.3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million within selling, general and administrative expenses for services performed for the&#160;years ended December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, and </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, respectively, including implementation fees, fixed monthly fees and pass-through costs.</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Litigation </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the normal course of business, the Company may be named as a defendant in </div>one<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> or more lawsuits. Other than the following </div>two<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> lawsuits, the Company is not a party to any outstanding material litigation and management is currently not aware of any legal proceedings that, individually or in the aggregate, are deemed to be material to the Company&#8217;s financial condition or results of operations.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In February&#160;</div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company filed a lawsuit in the U.S. District Court for the Northern District of California against Sanofi-Aventis U.S. LLC and Hisamitsu America, Inc., </div>two<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> manufacturers of </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">over-the-counter</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> (OTC) lidocaine patch products, alleging, among other things, false and deceptive advertising and unfair competition under the Lanham Act and California state laws by those companies regarding those patch products.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In March&#160;</div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company filed a lawsuit in the Delaware Court of Chancery against Anthony Mack, former President of the Company, and Virpax Pharmaceuticals, Inc., a company now headed by Mr.&#160;Mack,<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">alleging</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, among other things, breach by Mr.&#160;Mack of his </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compete</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> agreement with the Company and his fiduciary duties to the Company, and tortious interference by Virpax with that </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compete</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> agreement. Both lawsuits are ongoing.</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Operating Leases </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company leases administrative and research and development facilities under various </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cancelable</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> lease agreements. Facility leases generally provide for periodic rent increases and may include options to extend. As of December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company&#8217;s leases have remaining lease terms of approximately </div>2.7<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> to </div>2.9<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;years. The term of the Company&#8217;s leases does not include extension options that were not reasonably certain to be exercised from its lease terms, ranging from </div>3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> to </div>5<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;years. Many of the Company&#8217;s leases are subject to variable lease payments. Variable lease payments are recognized in the period in which the obligation for those payments are incurred, are not included in the measurement of the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> assets or lease liabilities and are immaterial. Additionally, the Company subleases certain properties to third parties. Sublease income is recognized on a straight-line basis and is immaterial.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As the Company&#8217;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The Company calculates the associated lease liability and corresponding </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> asset upon lease commencement using a discount rate based on a credit-adjusted secured borrowing rate commensurate with the term of the lease. As of December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company has </div>no<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> finance leases.</div></div>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The components of lease expense were as follows (in thousands):</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 76%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease cost*</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">623</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">904</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">776</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">*</div></td>
<td style="vertical-align: top; font-size: 10pt;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inclusive of variable lease costs, sublease income, and impairment, which were immaterial for the periods presented. </div></div></div></td></tr></table> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplemental quantitative information related to leases includes the following: </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 74%;"/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;Ended&#160;December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;2021&#160;&#160;&#160;&#160;&#160;&#160;</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;2020&#160;&#160;&#160;&#160;&#160;&#160;</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 0px;">
<td style="width: 74%;"/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 74%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash paid for amounts included in the measurement of lease <br/>liabilities:</div></div></td>
<td style="vertical-align: bottom; width: 10%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 74%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating cash flows from operating leases</div></div></td>
<td style="vertical-align: bottom; width: 10%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(654</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(833</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 74%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average remaining lease term in&#160;years&#160;&#8212;&#160;operating <br/>leases</div></div></td>
<td style="vertical-align: bottom; width: 10%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 74%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average discount rate&#160;&#8212;&#160;operating leases</div></div></td>
<td style="vertical-align: bottom; width: 10%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Maturities of lease liabilities were as follows (in thousands): </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 86%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Year Ending December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">674</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">694</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">596</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2026</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total lease payments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,964</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less imputed interest</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(316</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total lease liabilities as of December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,648</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Operating</div> lease expense totaled approximately $</div>0.7<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, $</div>1.1<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div>0.8<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million for the&#160;years ended December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, respectively.</div></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vickers Vantage [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 6. COMMITMENTS AND CONTINGENCIES </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Risks and Uncertainties </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Management continues to evaluate the impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company&#8217;s financial position, results of its operations and/or search for a target company, the specific impact is not readily determinable as of the date of these condensed consolidated financial statements. The condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Registration and Shareholder Rights </div></div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to a registration rights agreement entered into on January&#160;6, 2021, the holders of the Founder Shares, Private Placement Warrants and underlying ordinary shares and any securities issued upon conversion of Working Capital Loans will be entitled to registration rights pursuant to a registration rights agreement requiring the Company to register such securities for resale. The holders of these securities will be entitled to demand that the Company register such securities at any time after the Company consummates a Business Combination. In addition, the holders have certain &#8220;piggy-back&#8221; registration rights with respect to registration statements filed subsequent to the consummation of a Business Combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Underwriting Agreement </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The underwriters are entitled to a deferred fee of (i) 3.5% of the gross proceeds of the initial 12,000,000 Units sold in the Initial Public Offering, or $4,200,000, and (ii) 5.5% of the gross proceeds from the Units sold pursuant to the over-allotment option, or $990,000.&#160;The deferred fee will be paid in cash upon the closing of a Business Combination from the amounts held in the Trust Account, subject to the terms of the underwriting agreement. </div><br/></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Business Combination Merger Agreement </div></div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;17, 2022, the Company entered into an agreement and plan of merger (the &#8220;Merger Agreement&#8221;) by and among Scilex Holding Company (&#8220;Scilex&#8221;), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE) (&#8220;Sorrento&#8221;), VCKA, and Vantage Merger Sub Inc., a Delaware corporation and a wholly owned subsidiary of VCKA (&#8220;Merger Sub&#8221;). Parent and Merger Sub are sometimes referred to collectively as the &#8220;Parent Parties.&#8221; Pursuant to the Merger Agreement, VCKA will, prior to the closing of the Merger, migrate to and domesticate as a Delaware corporation in accordance with Section&#160;388 of the Delaware General Corporation Law, as amended and the Cayman Islands Companies Law (the &#8220;Domestication&#8221;). Thereafter, a business combination between VCKA and Scilex will be effected through the merger of Merger Sub with and into Scilex with Scilex surviving the merger as a wholly owned subsidiary of VCKA (the &#8220;Merger&#8221;). Upon the closing of the Merger (the &#8220;Closing&#8221;), it is anticipated that VCKA will change its name to &#8220;Scilex Holding Company&#8221;. The board of directors of VCKA has (i)&#160;approved and declared advisable the Merger Agreement, the Additional Agreements (as defined in the Merger Agreement) and the transactions contemplated thereby and (ii)&#160;resolved to recommend approval of the Merger Agreement and related transactions by the shareholders of VCKA. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">On September&#160;12, 2022, Vickers, Merger Sub and Scilex entered into Amendment No.&#160;1 to the Merger Agreement (the &#8220;Amendment&#8221;). The Amendment amends the Merger Agreement to, among other things, provide that: (i)&#160;the Plan of Domestication attached to the Merger Agreement shall constitute a plan of domestication for purposes of Section&#160;388 of the DGCL and shall include the corporate acts identified therein and any act or transaction contemplated by the Merger Agreement; (ii)&#160;at the Effective Time, each Domesticated Parent Unit shall separate automatically into its component parts, comprised of one share of Domesticated Parent Common Share and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-half</div> of one Domesticated Parent Warrant (provided that no fractional Domesticated Parent Warrants shall be issued and any holder who would be entitled to receive a fractional Domesticated Parent Warrant will have such fraction rounded down to the nearest whole number of Domesticated Parent Warrants); (iii) immediately after Closing, New Scilex&#8217;s board of directors shall consist of seven directors, five of whom will be designated by Scilex (including one director who shall satisfy the independence requirements of the applicable Stock Exchange (which shall be Nasdaq, unless the parties otherwise agree to list on another national securities exchange, which may include the New York Stock Exchange, prior to the Closing)) and two of whom </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">will be independent directors to be designated by Scilex and agreed to by Vickers prior to the Closing; (iv)&#160;at the Effective Time, by virtue of the Merger, each share of Series A Preferred Stock of Scilex issued and outstanding immediately prior to the Effective Time shall be canceled and automatically converted into the right to receive, without interest, one Domesticated Parent Preferred Share and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">one-tenth</div> of one Domesticated Parent Common Share; (v)&#160;Vickers shall use its reasonable best efforts to ensure that Vickers remains listed as a public company, and that the Parent Ordinary Shares and public Parent Warrants remain listed on Nasdaq through the Closing and Scilex shall use its reasonable best efforts to prepare and file an initial listing application with the Stock Exchange in connection with the transactions contemplated by the Merger Agreement; (vi)&#160;each party shall use its reasonable best efforts to, among other things, obtain approval for the listing of the Domesticated Parent Common Shares and Domesticated Parent Warrants issued pursuant to the Merger Agreement on the Stock Exchange; (vii)&#160;following the consummation of the Domestication, and the filing of the Parent Certificate of Incorporation, but prior to the Effective Time, Vickers shall file with the Secretary of State of Delaware a certificate of designations, in the form attached to the Merger Agreement as a new Exhibit F, which provides for, among other things, the designations, powers, rights and preferences and qualifications, limitations and restrictions of certain preferred stock of Vickers; (viii)&#160;as a condition of Scilex to the Closing, that the shares of Domesticated Parent Common Shares and Domesticated Parent Warrants shall remain listed on Nasdaq through the Effective Time, the listing application for the listing of the Domesticated Parent Common Shares and Domesticated Parent Warrants following the Effective Time shall have been approved by the applicable Stock Exchange, and, as of the Closing Date, Vickers shall not have received any written notice from Nasdaq of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">non</div></div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">-compliance</div> with Nasdaq&#8217;s applicable continued listing requirements for any reason, where such notice has not been subsequently withdrawn by Nasdaq or the underlying failure appropriately remedied or satisfied; and (ix)&#160;extend the Outside Date to November&#160;11, 2022. The Amendment also sets forth the agreement of Vickers and Scilex to amend the Parent Certificate of Incorporation to increase the number of authorized shares of preferred stock set forth therein from&#160;20,000,000&#160;to&#160;45,000,000&#160;and, as a result, increase the total number of shares of all classes of stock that Vickers shall have authority to issue from&#160;750,000,000&#160;to&#160;785,000,000&#160;and, in connection with the Domestication, to name the initial incorporator and initial board of directors of Vickers for the period between the Domestication and the Effective Time. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Merger is expected to be consummated by the fourth quarter of 2022, following the receipt of the required approval by the shareholders of VCKA and Scilex and the satisfaction of certain other customary closing conditions. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Merger Consideration </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The total consideration to be paid to the holders of Scilex common stock at Closing (the &#8220;Merger Consideration&#8221;) by VCKA twill be an amount equal to the quotient of (a) the sum of (i) $1,500,000,000 minus (ii) the aggregate amount of Scilex long term debt excluding intercompany debt owed to Sorrento existing as of immediately prior to the date of the closing of the transaction (the &#8220;Closing Date&#8221;); divided by (b) $10.00, and will be payable in shares of common stock, par value $0.0001 per shares, of VCKA upon its domestication in Delaware (&#8220;VCKA Common Stock&#8221;).&#160;The number of shares of VCKA Common Stock to be paid as Merger Consideration will be determined in accordance with the terms of the Business Combination Agreement. In addition, each outstanding share of Scilex Preferred Stock as of immediately prior to the Effective Time of the Business Combination will be cancelled in exchange for the right to receive (a)&#160;one&#160;share of Series A Preferred Stock of Vickers (following the Domestication), par value $0.0001&#160;per share (the &#8220;New Scilex Series A Preferred Stock&#8221;), and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(b)&#160;one-tenth</div> of one share of New Scilex Common Stock, and (iii)&#160;each option to purchase Scilex Common Stock that is outstanding as of immediately prior to the Effective Time will be exchanged for a number of options exercisable for newly issued shares of New Scilex Common Stock based upon the Exchange Ratio. The total consideration to be received by holders of Scilex Common Stock and Scilex options at the Closing will be newly issued shares of <br/></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">New</div></div> Scilex Common Stock with an aggregate value equal to $1.5&#160;billion, subject to adjustments for certain debt obligations of Scilex (the &#8220;Merger Consideration&#8221;).&#160;The maximum number of shares of New Scilex Series A Preferred Stock and New Scilex Common Stock to be issued to the holders of Scilex Preferred Stock at the Closing shall not exceed 31,000,000 and 3,100,000, respectively, such newly issued shares being collectively referred to herein as the &#8220;Preferred Consideration&#8221;. It is anticipated that upon completion of the Business Combination, if none of the 9,726,395 VCKA Ordinary Shares are redeemed, VCKA&#8217;s public shareholders would retain an ownership interest of approximately 5.6% in New Scilex, the Sponsors, officers, directors and other holders of founder shares will retain an ownership interest of approximately 2.2% of New Scilex, and the Scilex stockholders will own approximately (i) 77.2% of New Scilex in the form of New Scilex Common Stock and (ii) 15.0% of New Scilex in the form of New Scilex Series A Preferred Stock. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of the Effective Time, each Scilex stock option that is then outstanding shall be converted into the right to receive an option relating to VCKA Common Stock upon substantially the same terms and conditions as are in effect with respect to such option immediately prior to the Effective Time; provided that the exercise price per share for each such Scilex stock option shall be equal to the exercise price per share of such Scilex stock option in effect immediately prior to the Effective Time, divided by the Exchange Ratio.</div><br/></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Representations and Warranties </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Merger Agreement contains customary representations and warranties of Scilex with respect to, among other things: (i)&#160;corporate existence and power; (ii)&#160;authorization to enter into the Merger Agreement and related transactions; (iii)&#160;governmental authorization; <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(iv)&#160;non-contravention;</div> (v)&#160;capital structure; (vi)&#160;organizational documents; (vii)&#160;assumed names; (viii)&#160;subsidiaries; (ix) financial statements; (x)&#160;absence of certain changes; (xi)&#160;properties and title to assets; (xii)&#160;litigation; (xiii) contracts; (xiv)&#160;licenses and permits; (xv)&#160;compliance with laws; (xvi)&#160;intellectual property; (xvii)&#160;customers and suppliers; (xviii)&#160;employees and employee benefits; (xix)&#160;employment matters; (xx)&#160;withholding; (xxi) real property; (xxii)&#160;tax matters; (xxiii)&#160;environmental laws; (xiv)&#160;finders&#8217; fees; (xv)&#160;directors and officers; (xvi)&#160;certain business practices; (xvii)&#160;international trade matters and anti-bribery compliance; (xviii)&#160;that Scilex is not an investment company; (xvix) compliance with health care laws and certain contracts; (xxx)&#160;insurance; (xxxi)&#160;related party transactions; (xxxii)&#160;privacy and data security and (xxxiii)&#160;exclusivity of representations and warranties. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Merger Agreement contains customary representations and warranties of the Parent Parties with respect to, among other things: (i)&#160;corporate existence and power; (ii)&#160;authorization to enter into the Merger Agreement and related transactions; (iii)&#160;governmental authorization; <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(iv)&#160;non-contravention;</div> (v)&#160;finders&#8217; fees; (vi)&#160;issuance of shares; (vii)&#160;capitalization; (viii) information supplied; (ix)&#160;amount in the trust account; (x)&#160;listing of VCKA securities; (xi)&#160;that VCKA is a reporting company; (xii)&#160;no market manipulation; (xiii)&#160;board approval; (xiv)&#160;SEC documents and financial statements; (xv)&#160;absence of changes; (xvi)&#160;litigation; (xvii) compliance with laws; (xviii)&#160;money laundering laws; (xix)&#160;OFAC; (xx) that VCKA is not an investment company; (xxi)&#160;tax matters; (xxii)&#160;contracts; (xxiii) investigation; and (xiv)&#160;exclusivity of representations and warranties. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">All representations and warranties by all parties shall terminate upon the Effective Time, and no representations, warranties, covenants, obligations or other agreements contained in the Merger Agreement shall survive the Effective Time. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Covenants </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Merger Agreement includes customary covenants of the parties with respect to operation of their respective businesses prior to consummation of the Merger and efforts to satisfy conditions to consummation of the Merger. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Merger Agreement also contains additional covenants of the parties, including, among others, access to information, cooperation in the preparation of the Registration Statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</div> (the &#8220;Registration Statement&#8221;) and Proxy Statement (as each such term is defined in the Merger Agreement) required to be filed in connection with the Merger and to obtain all requisite approvals of each party&#8217;s respective stockholders. VCKA has also agreed to include in the Proxy Statement the recommendation of its board that its stockholders approve all of the proposals to be presented at the special meeting. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Conduct between Signing and Closing </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Each of VCKA, Merger Sub and Scilex has agreed that from the date of the Merger Agreement until the Closing Date or, if earlier, the valid termination of the Merger Agreement in accordance with its terms, it will not initiate, encourage or engage in any negotiations with any party relating to an Alternative Transaction (as defined in the Merger Agreement), take any action intended to facilitate an Alternative Transaction or approve, recommend or enter into any agreement relating to an Alternative Transaction. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Conditions to Closing </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consummation of the Merger is conditioned upon, among other things, (i)&#160;the absence of any applicable law or order that makes the transactions contemplated by the Merger Agreement illegal or otherwise prohibits consummation of such transactions; (ii)&#160;the Registration Statement shall have become effective under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;); (iii) approval by VCKA&#8217;s shareholders of the Merger and related transactions; (iv)&#160;approval by Scilex&#8217;s stockholders of the Merger and related transactions; and (v)&#160;all required filings under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and with any other governmental authority shall have been completed and cleared. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Solely with respect to the Parent Parties, the consummation of the Merger is conditioned upon, among other things: (i)&#160;Scilex having duly performed or complied with all of its obligations under the Merger Agreement in all material respects; (ii)&#160;the representations and warranties of Scilex being true and correct in all respects unless failure to be true and correct would not have or reasonably be expected to have a Company Material Adverse Effect (as defined in the Merger Agreement) on Scilex&#8217;s ability to consummate the Merger and related transactions; (iii)&#160;no event having occurred that would result in a Company Material Adverse Effect; (iv)&#160;Scilex providing VCKA a certificate from the chief executive officer and chief financial officer of Scilex as to the accuracy of the foregoing conditions; (v)&#160;Scilex providing VCKA a certificate from the secretary which has attached true and complete copies of (a)&#160;Scilex&#8217;s organizational documents, (b)&#160;Scilex&#8217;s board resolutions approving the Merger Agreement and the transactions contemplated thereby, (c)&#160;Scilex&#8217;s stockholder written consent approving the Merger Agreement and the transactions contemplated thereby and (d)&#160;certified certificate of good standing; (vi)&#160;Scilex shall have executed and delivered to VCKA each Additional Agreement to which it is a party; (vi)&#160;Sorrento shall have executed the Registration Rights Agreement (as defined below). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Solely with respect to Scilex, the consummation of the Merger is conditioned upon, among other things: (i)&#160;the Parent Parties having duly performed or complied with all of their obligations under the Merger Agreement in all material respects; (ii)&#160;the representations and warranties of the Parent Parties being true and correct in all respects unless failure to be true and correct would not have or reasonably be expected to have a Parent Material Adverse Effect (as defined in the Merger Agreement) on the ability of VCKA or Merger Sub to consummate the Merger and related transactions; (iii)&#160;no event having occurred that would result in a Parent Material Adverse Effect; (iv)&#160;each of the Parent Parties providing Scilex a certificate from an authorized officer as to the accuracy of the foregoing conditions; (v)&#160;VCKA having been in material compliance with reporting requirements under the Securities Act and the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;); (vi)&#160;each of VCKA </div></div></div>  <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">the Parent Parties shall have executed and delivered to Scilex each Additional Agreement to which it is a party; (vii)&#160;the directors designated by Scilex shall have been appointed to the board of directors of VCKA in accordance with the terms of the Merger Agreement, effective as of the Closing Date; (viii)&#160;VCKA shall remain listed on Nasdaq and the additional listing application for the VCKA Common Stock issued in connection with the Merger shall have been approved by Nasdaq, and VCKA not having received any written notice from Nasdaq that it has failed, or would reasonably be expected to fail to meet the Nasdaq listing requirements as of the Closing Date for any reason, where such notice has not been subsequently withdrawn by Nasdaq or the underlying failure appropriately remedied or satisfied; (ix)&#160;after giving effect to the Merger, VCKA shall have at least $5,000,001 in net tangible assets (as determined in accordance with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Rule&#160;3a51-1(g)(1)&#160;of</div> the Exchange Act); (x) the Domestication shall have been completed as provided in the Merger Agreement and a time-stamped copy of the certificate issued by the Secretary of State of the State of Delaware in relation thereto shall have been delivered to the Company; and (xi)&#160;the Investment Management Trust Agreement (as defined in the Merger Agreement) shall have been amended solely to the extent necessary to enable the intended effects of the Amended Underwriting Agreement (as defined in the Merger Agreement) without breach of, or other conflict with, the Investment Management Trust Agreement as so amended. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">Scilex</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Scilex Pharmaceuticals, Inc. and Sorrento entered into a Contribution and Satisfaction of Indebtedness Agreement dated September&#160;</div>12<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> (the &#8220;Debt Exchange Agreement&#8221;), in order to facilitate the satisfaction of the closing condition under the Merger Agreement that requires Vickers to have at least $</div>5,000,001<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;in net tangible assets (as determined in accordance with Rule </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3a51-1(g)(1)</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> of the United States Securities and Exchange Act of </div>1934)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> (the &#8220;Net Tangible Assets Condition&#8221;).</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Termination </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Merger Agreement may be terminated as follows: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">i.</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">By the mutual consent of VCKA and Scilex; </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">ii.</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">by VCKA, if any of the representations or warranties of Scilex set forth in the Merger Agreement shall not be true and correct, or if Scilex has failed to perform any covenant or agreement set forth in the Merger Agreement (including an obligation to consummate the Merger), in each case such that the conditions to closing would not be satisfied and the breach or breaches causing such representations or warranties not to be true and correct, or the failure to perform any covenant or agreement, as applicable, are not cured (or waived by VCKA) by the earlier of (i)&#160;the Outside Date (as defined below) or (ii) 30 days after written notice thereof is delivered to Scilex; provided, however that VCKA is not then in material breach of any representation, warranty, covenant, or obligation in the Merger Agreement, which breach has not been cured; </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">iii.</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">by Scilex, if any of the representations or warranties of VCKA or Merger Sub set forth in the Merger Agreement shall not be true and correct, or if VCKA or Merger Sub has failed to perform any covenant or agreement set forth in the Merger Agreement (including an obligation to consummate the Merger), in each case such that the conditions to closing would not be satisfied and the breach or breaches causing such representations or warranties not to be true and correct, or the failure to perform any covenant or agreement, as applicable, are not cured (or waived by Scilex) by the earlier of (i)&#160;the Outside Date or (ii) 30 days after written notice thereof is delivered to VCKA; provided, however that Scilex is not then in material breach of any representation, warranty, covenant, or obligation in the Merger Agreement, which breach has not been cured; </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>  <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 5%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">iv.</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">by either VCKA or Scilex </div></div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">a.</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">on or after November&#160;11, 2022 (the &#8220;Outside Date&#8221;), if the Merger shall not have been consummated prior to the Outside Date; provided that if an Extension Amendment (as defined in the Merger Agreement) shall be in effect, the Outside Date shall be the Extension Date (as defined in the Merger Agreement); provided, however, that the right to terminate this Agreement under Section&#160;9.1(d)(i) of the Merger Agreement shall not be available to a party if the failure of the Merger to have been consummated before the Outside Date (or the Extension Date if applicable) was due to such party&#8217;s breach of or failure to perform any of its covenants or agreements set forth in the Merger Agreement; or </div></div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">b.</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">if any applicable law or order that makes the transactions contemplated by the Merger Agreement illegal or otherwise prohibits consummation of such transactions shall have become final and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-appealable;</div> </div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 5%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">v.</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">by Scilex if VCKA has not received approval from its stockholders of the Merger and related transactions at the Parent Special Meeting (as defined in the Merger Agreement), unless such meeting has been adjourned or postponed, in which case at the final adjournment or postponement thereof; </div></div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 5%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">vi.</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">by VCKA if the Scilex stockholder written consent approving the Merger and related transactions shall not have been obtained within five business days following the Registration Statement being declared effective by the Securities and Exchange Commission (the &#8220;SEC&#8221;), provided that upon Scilex receiving such stockholder approval, prior to the termination by VCKA of the Merger Agreement, VCKA will no longer have this right to so terminate; or </div></div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 5%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">vii.</div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">by VCKA, in the event that Scilex&#8217;s audited financial statements for 2020 and 2021 have not been delivered to the Parent Parties on or before March&#160;31, 2022 and remain undelivered prior to the termination of the Merger Agreement </div></div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="clear: both; max-height: 0px;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Sponsor Support Agreement </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Concurrently with the execution of the Merger Agreement, VCKA, Scilex and certain stockholders of VCKA entered into a certain Sponsor Support Agreement dated March&#160;17, 2022 (the &#8220;Sponsor Support Agreement&#8221;) pursuant to which those certain VCKA shareholders who are parties thereto agreed to vote all shares of VCKA Ordinary Shares beneficially owned by them, including any additional shares of VCKA they acquire ownership of or the power to vote, in favor of the Merger and related transactions. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On September&#160;12, 2022, Vickers and Scilex entered into Amendment No.&#160;1 to the Original Support Agreement with the Vickers Shareholders (the &#8220;Support Agreement Amendment&#8221;). The Support Agreement Amendment amends the Original Support Agreement to, among other things, provide that if, as of immediately prior to the Closing, the holders of more than seventy-five percent (75%) of the aggregate amount of Parent Ordinary Shares issued and outstanding as of March&#160;17, 2022 shall have exercised redemption rights in conjunction with the shareholder vote on the Extension Amendment or the Parent Shareholder Approval Matters, then automatically and without any further action by any other Person, such Vickers Shareholder shall forfeit a number of Parent Warrants equal to forty percent (40%) of all Parent Warrants held by such Vickers Shareholder immediately prior to Closing, and all such Parent Warrants shall be cancelled and forfeited for no consideration, and shall cease to exist.</div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Company Stockholder Support Agreement </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Concurrently with the execution of the Merger Agreement, VCKA, Scilex and Sorrento entered into a certain Company Stockholder Support Agreement dated March&#160;17, 2022 (the &#8220;Company Stockholder Support Agreements&#8221;), pursuant to which Sorrento agreed to vote all Scilex Common Stock beneficially owned by it, including any additional shares of Scilex it acquires ownership of or the power to vote, in favor of the Merger and related transactions. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">On September&#160;12, 2022, Vickers entered into a Stockholder Agreement with Sorrento (the &#8220;Stockholder Agreement&#8221;). Pursuant to the Stockholder Agreement, from and after the Effective Time, and for so long as Sorrento beneficially owns any shares of Vickers Series A Preferred Stock, par value $0.0001&#160;per share (&#8220;New Scilex Series A Preferred Stock&#8221;), among other things, (i)&#160;Sorrento shall have the right, but not the obligation, to designate each director to be nominated, elected or appointed to the Board of Directors of New Scilex (each, a &#8220;Stockholder Designee&#8221; and collectively, the &#8220;Stockholder Designees&#8221;), regardless of (i)&#160;whether such Stockholder Designee is to be elected to the Board of Directors of New Scilex (&#8220;New Scilex Board&#8221;) at a meeting of stockholders called for the purpose of electing directors (or by consent in lieu of meeting) or appointed by the New Scilex Board in order to fill any vacancy created by the departure of any director or increase in the authorized number of members of the New Scilex Board, or (ii)&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">the size of the New Scilex Board and New Scilex will be required to take all actions reasonably necessary, and not otherwise prohibited by applicable law, to cause each Stockholder Designee to be so nominated, elected or appointed to the New Scilex Board as more fully described in the Stockholder Agreement. Sorrento shall also have the right to designate a replacement director for any Stockholder Designee that has been removed from the New Scilex Board and the right to appoint a representative of Sorrento to attend all meetings of the committees of the New Scilex Board. The Stockholder Agreement also provides that New Scilex will be prohibited from taking certain actions without the consent of Sorrento. Such actions include, among other things, amendments to the certificate of designations designating the New Scilex Series A Preferred Stock, increases or decreases in the size of the New Scilex Board, the incurrence of certain amounts of indebtedness and the payment of dividends on New Scilex Common Stock.&#160;</div> </div><br/></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Underwriting Agreement Amendment </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;17, 2022, VCKA and Maxim Group, LLC, the representative of the underwriters for the VCKA initial public offering (&#8220;Maxim&#8221;) entered into an amendment (the &#8220;UWA Amendment&#8221;) of the underwriting agreement between VCKA and Maxim dated January&#160;6, 2021. The UWA Amendment provides for a potential deferral of the Deferred Underwriting Commission&#160;(as defined in the UWA Amendment) as follows: </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If in connection with the consummation of a business combination, after redemptions of Ordinary Shares by VCKA&#8217;s shareholders, the balance in the trust account is $25,000,000&#160;or less, then the Deferred Underwriting Commission will be payable as follows: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(A)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">50% of the Deferred Underwriting Commission will be payable to Maxim directly from the trust account; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(B)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the remaining&#160;50% of the Deferred Underwriting Commission will be payable to Maxim in the form of a Promissory Note on or before the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-year</div> anniversary of the effective date of a Business Combination. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="clear:both;max-height:0pt;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Maxim has also agreed to enter into any such amendment to the Investment Management Trust Agreement (as defined in the Merger Agreement) as may be required to effectuate the intent of the UWA Amendment. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>  <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Agreements to be Executed at Closing </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Merger Agreement contemplates that, at or prior to the Closing, VCKA and Sorrento will enter into an Amended and Restated Registration Rights Agreement (the &#8220;Registration Rights Agreement&#8221;), whereby, subject to certain customary exceptions, the parties will agree, among other things, not to transfer any shares of VCKA Common Stock or any security convertible into or exercisable or exchanged for VCKA Common Stock beneficially owned or owned of record by such holder until the date that is the earlier of (i)&#160;one hundred eighty (180)&#160;days from the date of the Registration Rights Agreement or (ii)&#160;the date on which the Company completes a liquidation, merger, stock exchange, reorganization or other similar transaction that results in all of the Company&#8217;s stockholders having the right to exchange their shares of VCKA Common Stock for cash, securities or other property. The Registration Rights Agreement will govern the registration of certain shares of VCKA Common Stock for resale and be effective as of the Closing. </div></div> <span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 6&#160;&#8212;&#160;COMMITMENTS AND CONTINGENCIES </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Risks and Uncertainties </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Management continues to evaluate the impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company&#8217;s financial position, results of its operations and/or search for a target company, the specific impact is not readily determinable as of the date of these financial statements. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Registration and Shareholder Rights </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to a registration rights agreement entered into on January&#160;6, 2021, the holders of the Founder Shares, Private Placement Warrants and underlying ordinary shares and any securities issued upon conversion of Working Capital Loans will be entitled to registration rights pursuant to a registration rights agreement requiring the Company to register such securities for resale. The holders of these securities will be entitled to demand that the Company register such securities at any time after the Company consummates a Business Combination. In addition, the holders have certain &#8220;piggy-back&#8221; registration rights with respect to registration statements filed subsequent to the consummation of a Business Combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements. </div><br/></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Underwriting Agreement </div></div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The underwriters are entitled to a deferred fee of (i)&#160;3.5% of the gross proceeds of the initial 12,000,000&#160;Units sold in the Initial Public Offering, or $4,200,000, and (ii)&#160;5.5% of the gross proceeds from the Units sold </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">pursuant to the over-allotment option, or $990,000. The deferred fee will be paid in cash upon the closing of a Business Combination from the amounts held in the Trust Account, subject to the terms of the underwriting agreement. </div></div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_CommitmentsandContingenciesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_CommitmentsandContingenciesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_VickersVantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_VickersVantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139838697659872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restatement of Previously Issued Financial Statements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vicker's Vantage</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Condensed Financial Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock', window );">RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 10&#160;&#8212;&#160;RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restatement 1 </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company previously accounted for its outstanding Private Placement Warrants (the &#8220;Warrants&#8221;) issued in connection with its Initial Public Offering as components of equity instead of as derivative liabilities. The warrant agreement governing the Warrants includes a provision that provides for potential changes to the settlement amounts dependent upon the characteristics of the holder of the warrant. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On April&#160;12, 2021, the Acting Director of the Division of Corporation Finance and Acting Chief Accountant of the Securities and Exchange Commission together issued a statement regarding the accounting and reporting considerations for warrants issued by special purpose acquisition companies titled &#8220;Staff Statement on Accounting and Reporting Considerations for Warrants Issued by Special Purpose Acquisition Companies (&#8220;SPACs&#8221;)&#8221; (the &#8220;SEC Statement&#8221;). Specifically, the SEC Statement focused on certain settlement terms and provisions related to certain tender offers following a business combination, which terms are similar to those contained in the warrant agreement.</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In further consideration of the SEC Statement, the Company&#8217;s management further evaluated the Warrants under Accounting Standards Codification (&#8220;ASC&#8221;) Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">815-40,</div> Contracts in Entity&#8217;s Own Equity. ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;815-40-15</div></div> addresses equity versus liability treatment and classification of equity-linked financial instruments, including warrants, and states that a warrant may be classified as a component of equity only if, among other things, the warrant is indexed to the issuer&#8217;s ordinary shares. Under ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;815-40-15,</div></div> a warrant is not indexed to the issuer&#8217;s ordinary shares if the terms of the warrant require an adjustment to the exercise price upon a specified event and that event is not an input to the fair value of the warrant. Based on management&#8217;s evaluation, the Company&#8217;s audit committee, in consultation with management, concluded that the Company&#8217;s Private Placement Warrants are not indexed to the Company&#8217;s ordinary shares in the manner contemplated by ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;815-40-15</div></div> because the holder of the instrument is not an input into the pricing of a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">fixed-for-fixed</div></div> option on equity shares. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In accordance with ASC Topic 340, Other Assets and Deferred Costs, as a result of the classification of the private warrants as derivative liabilities, the Company expensed a portion of the offering costs originally recorded as a reduction in equity. The portion of offering costs that was expensed was determined based on the relative fair value of the Private Warrants. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restatement 2 </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In addition, in connection with the preparation of the Company&#8217;s financial statements as of September&#160;30, 2021, the Company concluded it should restate its financial statements to classify all Public Shares in temporary equity. The September&#160;30, 2021 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q/A,</div> filed with the SEC on December&#160;8, 2021, includes the restatement of the unaudited March&#160;31, 2021 and June&#160;30, 2021 financial information. Included in the table below is the restatement </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">of the audited IPO Balance Sheet as of January&#160;11, 2021 originally filed on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</div> filed with the SEC on January&#160;15, 2021. In accordance with ASC 480, paragraph <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-S99,</div> redemption provisions not solely within the control of the Company require ordinary shares subject to redemption to be classified outside of permanent equity. The Company previously determined the ordinary shares subject to possible redemption to be equal to the redemption value of $10.10 per ordinary share while also taking into consideration a redemption cannot result in net tangible assets being less than $5,000,001. Previously, the Company did not consider redeemable shares classified as temporary equity as part of net tangible assets. Effective with these financial statements, the Company revised this interpretation to include temporary equity in net tangible assets. Accordingly, effective with this filing, the Company presents all redeemable ordinary shares as temporary equity and recognizes accretion from the initial book value to redemption value at the time of its Initial Public Offering and in accordance with ASC 480. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As a result, management has noted a reclassification adjustment related to temporary equity and permanent equity. This resulted in an adjustment to the initial carrying value of the ordinary shares subject </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">to possible redemption with the offset recorded to additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital (to the extent available), accumulated deficit and ordinary shares. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In connection with the change in presentation for the ordinary shares subject to redemption, the Company also revised its income (loss) per ordinary share calculation to allocate net income (loss) to ordinary shares. This presentation contemplates a Business Combination as the most likely outcome, in which case, ordinary shares share pro&#160;rata in the income (loss) of the Company. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The impact of these adjustments to the financial statement, as previously reported, is presented below. </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 48%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As Previously<br/>Reported</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Adjustments<br/>Restatement&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Adjustments<br/>Restatement 2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As<br/>Restated</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance sheet as of January&#160;11, 2021</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Warrant Liability</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,729,200</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,729,200</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,345,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,729,200</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,074,200</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ordinary Shares Subject to Possible Redemption</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">129,999,029</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7,729,200</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,110,171</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">139,380,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ordinary Shares</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">438</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">76</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(169</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">345</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Paid-in</div> Capital</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,006,060</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,629,336</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7,635,396</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated Deficit</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6,490</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,629,412</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(9,474,606</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(12,110,508</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Shareholders&#8217; Equity (Deficit)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,000,008</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(17,110,171</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(12,110,163</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedFinancialStatementsCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedFinancialStatementsCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for condensed financial information, including the financial position, cash flows, and the results of operations of the registrant (parent company) as of the same dates or for the same periods for which audited consolidated financial statements are being presented. Alternatively, the details of this disclosure can be reported by the specific parent company taxonomy elements, indicating the appropriate date and period contexts in an instance document.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.5-04(Schedule I))<br> -URI https://asc.fasb.org/extlink&amp;oid=126898705&amp;loc=d3e5864-122674<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=d3e5283-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_VickersVantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_VickersVantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139838697480384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">9.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income Taxes </div></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">maintains deferred tax assets that reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. These deferred tax assets include net operating loss carryforwards, research credits and temporary differences. In assessing the Company&#8217;s ability to realize deferred tax assets, management considers, on a periodic basis, whether it is more likely than not that some portion or all the deferred tax assets will not be realized. As such, management has determined that it is appropriate to maintain a valuation allowance against the Company&#8217;s deferred tax assets.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s income tax (benefit) expense of $</div>(36.4<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">) thousand and $</div>10.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;thousand reflect effective tax rates of </div>0.7<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% and </div>0.02<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% for the </div>nine<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> months ended September&#160;</div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, respectively.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The difference between the expected statutory federal tax rate of </div>21.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% and the </div>0.7<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% effective tax rate for the </div>nine<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> months ended September&#160;</div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> was primarily attributable to income tax expense associated with changes in a valuation </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">allowance. </div></div></div><span></span>
</td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">12.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income Taxes </div></div></div></div></td></tr></table><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total loss before income taxes for the&#160;years ended December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> did not include a foreign component. The components of benefits for income taxes were as follows for the period ended December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> (in thousands):</div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 76%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current expense:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Federal</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">State</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(53</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(53</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Federal</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">State</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(53</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The components of the Company&#8217;s net deferred tax liabilities and related valuation allowance are as follows at December&#160;31 (in thousands): </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 73%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 73%; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax assets</div></div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 73%; background-color: rgb(255, 255, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest expense limitations</div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">12,205</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">8,225</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 73%; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tax credit carryforwards</div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">1,630</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">1,623</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 73%; background-color: rgb(255, 255, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net operating loss carryforwards</div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">39,714</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">31,732</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 73%; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock based compensation</div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">3,233</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">2,037</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 73%; background-color: rgb(255, 255, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease liabilities</div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">404</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">510</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em;">Others</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">1,753</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">2,285</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(255, 255, 255); width: 73%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 73%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Deferred Tax Assets</div></div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">58,939</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">46,412</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr>
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 73%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Valuation allowance</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="line-height: normal;"><div style="null;text-indent: 0px;;font-weight:bold;display:inline;width:100%;">&#160;</div><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">(56,643</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">(43,514</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="line-height: normal;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td>
<td style="background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td>
<td style="background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255);"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Deferred Tax Assets</div></div></div></div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,296</div></div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,898</div></div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td>
<td style="background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td>
<td style="background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred Tax Liabilities:</div></div></div></div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr>
<td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 73%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amortization of intangibles</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; text-align: right; background-color: rgb(255, 255, 255);">(1,975</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">(2,486</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">)&#160;</td></tr>
<tr>
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em;">Other</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; text-align: right; background-color: rgb(204, 238, 255);">(2</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr>
<td style="vertical-align: top; background-color: rgb(255, 255, 255); padding-bottom: 0.375pt; width: 73%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); padding-bottom: 0.375pt; width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; text-align: right; background-color: rgb(255, 255, 255); border-bottom: 0.75pt solid black;">(319</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); padding-bottom: 0.375pt;">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); padding-bottom: 0.375pt; width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); border-bottom: 0.75pt solid black;;text-align:right;">(412</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); padding-bottom: 0.375pt;">)&#160;</td></tr>
<tr>
<td style="vertical-align: top; background-color: rgb(204, 238, 255); padding-bottom: 0.75pt; width: 73%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Deferred Tax Liabilities</div></div></div></td>
<td style="vertical-align: bottom; padding: 0px 0px 0.75pt; background-color: rgb(204, 238, 255); width: 6%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px; text-align: right; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2,296</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.75pt; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; padding: 0px 0px 0.75pt; background-color: rgb(204, 238, 255); width: 6%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2,898</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); padding-bottom: 0.75pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td>
<td style="background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td></tr></table><div style="clear: both; max-height: 0px; text-indent: 0px;"/><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color:#ffffff;;display:inline;">The</div><div style="display:inline;"><div style="background-color:#ffffff;;display:inline;">&#160;</div></div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Company </div>has evaluated the available evidence supporting the realization of its gross deferred tax assets, including the amount and timing of future taxable income, and has determined that it is more likely than not that the deferred tax assets will not be realized. Due to such uncertainties surrounding the realization of the domestic deferred tax assets, the Company maintains a valuation allowance of $</div>56.6<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and $</div>43.5<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million against its deferred tax assets as of December&#160;</div><div style="font-size: 10pt;;display:inline;">31</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div><div style="font-size: 10pt;;display:inline;">2021</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div><div style="font-size: 10pt;;display:inline;">2020</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, respectively. Realization of the deferred tax assets will <div style="letter-spacing: 0px; top: 0px;;display:inline;">b</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">e<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">primarily<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">dependent upon the Company&#8217;s ability to generate sufficient taxable income prior to the expiration of its net operating losses.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The reconciliation between U.S. federal income taxes at the statutory rate and the Company&#8217;s benefit from income taxes are as follows for the year ended December 31: </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 75%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Statutory Federal Income Tax Rate</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">State taxes, net of federal tax benefit</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Debt discount and interest limitation</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(10.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">In-process</div> research and development</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(11.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Return to provision adjustments and carryback</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(11.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Others</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1.6</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation allowance</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(14.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(13.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(14.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4.8em;">Income Tax Benefit</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company had net operating loss carryforwards of approximately $</div>167.5<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million for federal and $</div>81.7<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million for state income tax purposes, respectively. These may be used to offset future taxable income and will begin to expire in </div>2034<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> for state and </div>2035<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> for federal, except for $</div>154.8<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million of the federal net operating losses that have an indefinite carryforward period.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Internal Revenue Code Section&#160;382 rules apply to limit a corporation&#8217;s ability to utilize existing net operating loss and tax credit carryforwards once the corporation experiences an ownership change as defined in Section&#160;382. For the&#160;years ended December&#160;31, 2021, 2020, and 2019, there was no impact of such limitations on the Company&#8217;s income tax provision.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company also has research and development and orphan drug credits of approximately $</div>2.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million for federal income taxes purposes. The federal credits may be used to offset future income tax and will begin to expire in </div>2035<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is subject to taxation in the U.S., various state tax jurisdictions and various foreign tax jurisdictions. All of the Company&#8217;s tax&#160;years will remain open for three year for examination by the Federal and state tax authorities from the date of utilization of the net operating loss. The Company does not have any tax audits pending.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company applies the accounting guidance for uncertainty in income taxes pursuant to </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">ASC-740-10.</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Under ASC 740, the impact of an uncertain income tax position taken on a tax return must be recognized at the largest amount that is cumulatively &#8220;more likely than not&#8221; to be sustained upon audit by relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a </div>50<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% likelihood of being sustained.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The unrecognized tax benefits balances as of December&#160;31, 2021, 2020 and 2019 and the related increases and decreases to the balances were immaterial.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s policy is to recognize interest and penalties related to income tax matters in income tax expense. </div>No<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> interest and penalties have been recognized as of and for the periods ended December&#160;31, 2021, 2020 and 2019.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company believes that no material amount of liabilities for uncertain tax positions will expire within 12&#160;months of December&#160;31, 2021.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139838697467344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Loss Per Share</a></td>
<td class="text"><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">11.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss Per Share </div></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div></div><div style="clear:both;max-height:0pt;;text-indent: 0px;"/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the nine months ended September&#160;30, 2022 and 2021, basic loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. Diluted loss per common share is calculated to give effect to all dilutive securities, using the treasury stock method.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> table sets forth the reconciliation of basic and diluted loss per share for the nine months ended September&#160;30, 2022 and 2021 (in thousands except per share data):</div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 72%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Nine&#160;Months&#160;Ended<br/>September&#160;30,</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">2021</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5,480</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(46,459</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator for Basic Loss Per Share</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">197,550</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">197,266</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Effect of Dilutive Securities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator for Diluted Loss per Share &#8212; Adjusted for Dilutive Securities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">197,550</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">197,266</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic Loss Per Share</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.03</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.24</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dilutive Loss Per Share</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.03</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.24</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr></table> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The stock </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">options that could potentially dilute basic earnings per share in the future were excluded from the computation of diluted net loss per share because the effect would have been anti-dilutive due to the net loss for the nine months ended September&#160;30, 2022 and 2021 were </div>25.2<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and </div>30.3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, respectively.</div></div><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><span></span>
</td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">14.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss Per Share </div></div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div></div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the&#160;years ended December&#160;31, 2021, 2020 and 2019, basic loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. Diluted loss per common share is calculated to give effect to all dilutive securities, using the treasury stock method.</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth the reconciliation of basic and diluted loss per share for the&#160;years ended December&#160;31, 2021, 2020, and 2019 (in thousands except per share data):</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 60%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt; border-bottom: 0.75pt solid black;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt; border-bottom: 0.75pt solid black;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(88,424</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(47,519</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(178,594</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator for Basic Loss Per Share</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">197,266</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">197,315</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">187,524</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Effect of Dilutive Securities</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Denominator for Diluted Loss per Share &#8212; Adjusted for Dilutive Securities</div><br/></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">197,266</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">197,315</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">187,524</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic Loss Per Share</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(0.45</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(0.24</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(0.95</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dilutive Loss Per Share</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">(0.45</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">(0.24</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">(0.95</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">)&#160;</td> </tr> </table>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The stock options that could potentially dilute basic earnings per share in the future were excluded from the computation of diluted net loss per share because the effect would have been anti-dilutive due to the net loss for the&#160;years ended December&#160;31, 2021, 2020, and 2019 of </div>28.2<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, </div>30.8<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, and </div>25.4<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">respectively. </div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139838689812848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">12.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Subsequent Events </div></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"/><div style="background: none;;text-indent: 0px;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"/></div><div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has evaluated subsequent events for recognition and disclosure purposes in the unaudited consolidated financial statements as of September&#160;30, 2022, and the nine months then ended, through November&#160;17, 2022, the date the financial statements were available to be issued and, for disclosure purpose, through January&#160;12, 2023. Except as described below, or as otherwise indicated in the footnotes, the Company has concluded that no events or transactions have occurred that require disclosure. </div><div style="letter-spacing: 0px; top: 0px; background: none;;text-indent: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="letter-spacing: 0px; top: 0px; background: none;;text-indent: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Funding Commitment Letter </div></div></div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">On</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;October&#160;17, 2022, Sorrento and the Company entered into a letter agreement (the &#8220;Funding Commitment Letter&#8221;). Pursuant to the terms of the Funding Commitment Letter, upon the written request of the Company (which request the Company shall make to the extent necessary to satisfy the closing condition in the BCA that requires the combined company to have $</div>5,000,001<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> in net tangible assets as of immediately following the effective time of the Business Combination (the &#8220;Effective Time&#8221;) under the BCA (the &#8220;Net Tangible Assets Condition&#8221;)), Sorrento agreed to fund one or more loans to the Company in the amount set forth in such written request (a &#8220;Loan Request&#8221;); provided, that any amounts funded by Sorrento in respect of any Loan Request were to be treated as Outstanding Indebtedness for all purposes under the Debt Exchange Agreement and </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">included in </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the calculation of the Aggregate Outstanding Amount thereunder with such amount to be contributed to the Company in exchange for shares of Legacy Scilex preferred stock. The Funding Commitment Letter also provides that, in no event shall the aggregate amount of loans made and funded by Sorrento pursuant to Loan Requests exceed the lesser of (a) $10,000,000 and (b)&#160;an amount that, when taken together with all other Outstanding Indebtedness, will result in the Aggregate Outstanding Amount equaling $310,000,000. The Company did not draw funds from the Funding Commitment Letter at the Effective Time. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Amendment to Amended and Restated Certificate of Incorporation</div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;November&#160;10, 2022, the Company filed with the Secretary of State of the State of Delaware (i)&#160;a Certificate of Amendment to its Amended and Restated Certificate of Incorporation to increase the authorized number of shares of preferred stock of the Company from </div>20,000,000<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> to </div>45,000,000<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and (ii)&#160;a certificate of designation setting forth the designations, powers, rights and preferences and qualifications, limitations and restrictions of the Series A Preferred Stock, par value $</div>0.0001<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> per share, of Legacy </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Scilex.</div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; font-size: 10pt;;font-style:italic;display:inline;">Sorrento Absorbed Liabilities</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In October </div></div><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 0px; top: 0px;;display:inline;">and November 2022, Sorrento entered into agreements with certain of the Company&#8217;s third party professional service providers to assume $</div>11.9<div style="font-size: 10pt; letter-spacing: 0px; text-indent: 0px; top: 0px;;display:inline;">&#160;million of liabilities accrued by the Company, of which $</div>10.0<div style="font-size: 10pt; letter-spacing: 0px; text-indent: 0px; top: 0px;;display:inline;">&#160;million and $</div>1.9<div style="font-size: 10pt; letter-spacing: 0px; text-indent: 0px; top: 0px;;display:inline;">&#160;million were recorded under accounts payable and accrued expenses, respectively, within the consolidated balance sheet. The liabilities assumed by Sorrento were reclassified under related party payable within the consolidated balance sheet and subsequently exchanged on November&#160;10, 2022 under the terms of the Debt Exchange<div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">Agreement (see Note 10).</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Committed Equity Financings </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&#160;17, 2022, the Company entered into a standby equity purchase agreement (the &#8220;Yorkville Purchase Agreement&#8221;) with YA II PN, Ltd., a Cayman Islands exempt limited partnership (&#8220;YA II&#8221;). Pursuant to the Yorkville Purchase Agreement, the Company has the right to sell to YA II, from time to time during the term of the Yorkville Purchase Agreement, up to $500,000,000 of shares of New Scilex common stock, subject to certain limitations and conditions set forth therein. Upon the satisfaction of the conditions to YA II&#8217;s purchase obligation set forth in the Yorkville Purchase Agreement, including that a registration statement with respect to the shares to be issued to YA II thereunder be declared effective by the SEC, the Company will have the right, but not the obligation, from time to time at its discretion until the first day of the month next following the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">36-month</div> anniversary of the date on which such registration statement has been declared effective by the SEC, to direct the YA II to purchase a specified amount of shares of Common Stock (each such sale, a &#8220;Yorkville Advance&#8221;) by delivering written notice to YA II (each, a &#8220;Yorkville Advance Notice&#8221;). </div><div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"/><div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"/></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">While there is no mandatory minimum amount for any Yorkville Advance, Yorkville Advance may be for a number of shares of New Scilex common stock not to exceed<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>200<div style="font-size: 10pt; letter-spacing: 0px; text-indent: 0px; top: 0px;;display:inline;">% of the average of the daily trading volume of the New Scilex common stock on the Nasdaq Capital Market during regular trading hours as reported by Bloomberg L.P. during the </div><span style="-sec-ix-hidden:hidden63196045">five</span><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 0px; top: 0px;;display:inline;"> trading <div style="letter-spacing: 0px; top: 0px;;display:inline;">days immediately preceding the date of the Yorkville Advance Notice. The shares of New Scilex common stock, if any, that the Company elects to sell to YA II pursuant to a Yorkville Advance will be purchased at a price equal</div>&#160;to </div>98<div style="font-size: 10pt; letter-spacing: 0px; text-indent: 0px; top: 0px;;display:inline;">% <div style="letter-spacing: 0px; top: 0px;;display:inline;">of the lowest daily VWAP (as defined below) during the</div>&#160;</div><span style="-sec-ix-hidden:hidden63196046">two</span><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 0px; top: 0px;;display:inline;"> <div style="letter-spacing: 0px; top: 0px;;display:inline;">consecutive trading days commencing on the date of delivery of a Yorkville Advance Notice. &#8220;VWAP&#8221; means, for any trading day, the daily volume weighted average price of the New Scilex common stock for such trading day on the Nasdaq Capital Market as reported by Bloomberg L.P. during regular trading hours. The Company may also specify a certain minimum acceptable price per share in each Yorkville Advance.&#160;</div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">As consideration for YA II&#8217;s commitment to purchase shares of New Scilex common stock at the Company&#8217;s direction upon the terms and subject to the conditions set forth in the Yorkville Purchase Agreement, the Company issued</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 0px; top: 0px;;display:inline;"> </div>250,000<div style="font-size: 10pt; letter-spacing: 0px; text-indent: 0px; top: 0px;;display:inline;"> <div style="letter-spacing: 0px; top: 0px;;display:inline;">shares of New Scilex common stock to YA II in connection with the execution of the Yorkville Purchase Agreement<div style="letter-spacing: 0px; top: 0px;;display:inline;">. </div></div></div></div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January 8, 2023, the Company entered into a standby equity purchase agreement (the &#8220;B. Riley Purchase Agreement&#8221;) with B. Riley Principal Capital II, LLC, a Delaware limited liability company (&#8220;B.&#160;Riley&#8221;). Pursuant to the B. Riley Purchase Agreement, the Company has the right to sell to B. Riley, from time to time during the term of the B. Riley Purchase Agreement, up to $500,000,000 of shares of New Scilex common stock, subject to certain limitations and conditions set forth therein. Upon the satisfaction of the conditions to B. Riley&#8217;s purchase obligation set forth in the B. Riley Purchase Agreement, including that a registration statement with respect to the shares to be issued to B. Riley thereunder be declared effective by the SEC, the Company will have the right, but not the obligation, from time to time at its discretion until the first day of the month next following the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">36-month</div> anniversary of the date on which such registration statement has been declared effective by the SEC, to direct the B. Riley to purchase a specified amount of shares of New Scilex common stock (each such sale, an &#8220;Advance&#8221;) by delivering an irrevocable written notice to B. Riley (each, an &#8220;Advance Notice&#8221;). </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The shares of New Scilex common stock, if any, that the Company elects to sell to B. Riley pursuant to an Advance will be purchased at a price equal to 98% of the VWAP (as defined below) during the period (such </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">period, the &#8220;Pricing Period&#8221;) beginning at 9:30:01 a.m., New York City time, on the date of purchase of Advance Shares or such later time publicly announced as the official open of the primary (or &#8220;regular&#8221;) trading session on the Nasdaq Capital Market on such purchase date (the &#8220;Purchase Commencement Time&#8221;) and ending at the earliest of (i) 3:59 p.m., New York City Time, on the purchase date or such earlier time publicly announced as the official close of the primary (or &#8220;regular&#8221;) trading session on the Nasdaq Capital Market on such purchase date, (ii)&#160;immediately at such time following the Purchase Commencement Time for such purchase that the total number (or volume) of shares of New Scilex common stock traded on the Nasdaq Capital Market during such period has exceeded the Advance Share Volume Maximum (as defined below) for such purchase and (iii)&#160;if the Company so elects in the applicable Advance Notice for such Advance (such election, a &#8220;Limit Order Discontinue Election&#8221;), such time the sale price of the shares of New Scilex common stock traded on the Nasdaq Capital Market during such Pricing Period is less than the applicable minimum price threshold determined in accordance with the B. Riley Purchase Agreement. &#8220;VWAP&#8221; means, for the New Scilex common stock for a specified period, the dollar volume-weighted average price of the New Scilex common stock on the Nasdaq Capital Market for such period as reported by Bloomberg through its &#8220;AOR&#8221; function, subject to certain exceptions, qualifications and limitations. &#8220;Advance Share Volume Maximum&#8221; means, with respect to an Advance, if such Advance is a (i)&#160;purchase-Type A, a number of shares of New Scilex common stock that is equal to the quotient obtained by dividing (a)&#160;the Advance Share amount to be purchased by B. Riley, by (b) 0.10, and (ii)&#160;purchase-Type B, a number of shares of New Scilex common stock that is equal to the quotient obtained by dividing (a)&#160;the Advance Share amount to be purchased by B. Riley, by (b) 0.25 (in each case, subject to certain adjustments). The Company may also specify a certain minimum acceptable price per share in each Advance. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">While there is no mandatory minimum amount for any Advance, subject to the terms and conditions of the B. Riley Purchase Agreement, an Advance may be for a number of shares of New Scilex common stock not to exceed (i)&#160;with respect to an Advance, purchase-Type A, such number of shares of New Scilex common stock that is equal to the lesser of: (a) 1,000,000, and (b)&#160;the product of (1) 0.10, multiplied by (2)&#160;the total number (or volume) of shares of New Scilex common stock traded on the Nasdaq Capital Market during the Pricing Period for such purchase-Type A, and (ii)&#160;with respect to an Advance, purchase-Type B, such number of shares of New Scilex common stock equal to the lesser of: (a) 1,000,000 and (b)&#160;the product of (1) 0.25, multiplied by (2)&#160;the total number (or volume) of shares of New Scilex common stock traded on the Nasdaq Capital Market during the Pricing Period for such purchase-Type B. The Company may also specify a certain minimum acceptable price per share in each Advance. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The B. Riley Purchase Agreement also provides that the Company has the right, but not the obligation, to sell to B. Riley, from time to time subject to certain limitations, at the Company&#8217;s sole and absolute discretion an additional number of shares of New Scilex common stock (each such additional sale, an &#8220;Additional Advance&#8221;) by delivering an irrevocable written notice to B. Riley. The purpose of the Additional Advance is to allow the Company to execute more than one advance request on a purchase date with B. Riley as each prior advance has been completed under the terms of the B. Riley Purchase Agreement. Each Additional Advance is generally subject to terms and conditions consistent with those of an Advance, except for, among other things, the time period of the pricing period for such Additional Advance. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As consideration for B. Riley&#8217;s commitment to purchase shares of New Scilex common stock at the Company&#8217;s direction upon the terms and subject to the conditions set forth in the B. Riley Purchase Agreement, the Company issued 250,000 shares of New Scilex common stock to B. Riley in connection with the execution of the B. Riley Purchase Agreement. </div></div></div><span></span>
</td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">15.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Subsequent Events </div></div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following events were identified subsequent to the balance sheet date. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">SPAC Transaction </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;17, 2022, the Company entered into an Agreement and Plan of Merger (as amended, the &#8220;Merger Agreement&#8221;) with Vickers Vantage Corp. I (&#8220;Vickers&#8221;), a SPAC, and Vantage Merger Sub, Inc., a wholly owned subsidiary of Vickers (&#8220;Merger Sub&#8221;). Pursuant to the terms of the Merger Agreement, (i)&#160;Merger </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sub will </div></div><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;">merge with and into the Company</div><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;">, with the Company surviving the merger (&#8220;combined company&#8221;) and (ii)&#160;become a wholly<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>owned subsidiary of Vickers (collectively, the &#8220;SPAC Transaction&#8221;). The Merger is expected to close during the fourth quarter of 2022, and the Combined Company is expected to be listed on the Nasdaq Capital Market under the new ticker symbol &#8220;SCLX&#8221;. Completion of the SPAC Transaction is subject to the approval of Vickers and Company shareholders and the satisfaction or waiver of certain other closing conditions.</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Scilex Pharma Note </div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color:rgba(255, 255, 255, .0);;display:inline;">Effective </div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> February&#160;14, 2022, Scilex Pharma issued to Sorrento a draw notice under the Letter of Credit as required under the terms of the Indenture because actual cumulative net sales of ZTlido from the issue date of the Scilex Pharma Notes through December&#160;31, 2021 were less than a specified sales threshold for such period. As a result of the draw notice being issued, the Company paid to Scilex Pharma $</div>35.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in a single </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lump-sum</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> amount as a subordinated loan. Per the terms of the Amendment No.&#160;3, in February&#160;2022, Scilex Pharma repurchased Scilex Pharma Notes in an aggregate amount equal to $</div>20.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million at a purchase price in cash equal</div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>to 100% of the principal amount. In addition, the draw down of the Letter of Credit triggered a requirement for Scilex Pharma to maintain a minimum cash balance of $10.0&#160;million at all times going </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">forward. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Effective</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;February&#160;15, 2022, in accordance with the Indenture, the principal amount of the Scilex Pharma Notes was increased by $</div>28.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million as actual cumulative net sales of ZTlido from the issue date of the Scilex Pharma Notes through December&#160;31, 2021 did not equal or exceed a $</div>481.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million sales threshold for such period<div style="display:inline;">.</div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; font-size: 10pt;;font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Advances on Related Party Note Payable</div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;30, 2022, Sorrento made advances to the Company in the amount of $</div>23.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million under the related party note payable entered into on March&#160;18, 2019 with Sorrento. See Note 13 for further discussion of the related party note </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">payable. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-104</div> Acquisition from Sorrento </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">On May&#160;12, 2022</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company and Sorrento entered into a bill of sale and assignment and assumption agreement (the &#8220;Bill of Sale&#8221;), pursuant to which Sorrento sold, conveyed, assigned and transferred to Scilex all of its rights, title and interest in and to Sorrento&#8217;s Delayed Burst Release Low Dose Naltrexone </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(DBR-LDN)</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> asset and intellectual property rights, for the treatment of chronic pain, fibromyalgia and chronic post-COVID syndrome (collectively, the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;SP-104</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Assets&#8221;) and the Company is currently analyzing the accounting treatment for the transaction. These assets had previously been acquired by Sorrento from Aardvark Therapeutics, Inc. (&#8220;Aardvark&#8221;) in April 2021 pursuant to an asset purchase agreement (the &#8220;Aardvark Asset Purchase Agreement&#8221;). Pursuant to the Bill of Sale, the Company assumed all of Sorrento&#8217;s rights, liabilities and obligations under the Aardvark Asset Purchase Agreement (the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;SP-104</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Acquisition&#8221;).</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As consideration for the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-104</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Acquisition, the Company issued a promissory note in the aggregate principal amount of $</div>5.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million to Sorrento (the &#8220;2022 Promissory Note&#8221;). The 2022 Promissory Note matures </div>seven years<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> from the date of issuance and bears interest at the rate equal to the lesser of (a) </div>2.66<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% simple interest per annum and (b)&#160;the maximum interest rate permitted under law. The 2022 Promissory Note is payable in cash, shares of the Company common stock (any shares so issued, the </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">&#8220;</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consideration Shares&#8221;) or any combination thereof, at the Company&#8217;s sole discretion, and may be prepaid in whole or in part at any time without penalty. The Company also agreed to file with the SEC, a resale registration statement, relating to the resale by Sorrento of any Consideration Shares that may be issued to Sorrento, within </div>60<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> days of the issuance of such Consideration Shares.</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As the successor to the Aardvark Asset Purchase Agreement, the Company is obligated to pay Aardvark (i)&#160;$</div>3,000,000<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, upon initial approval by the FDA of a new drug application for the LDN Formulation (as defined in<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;Aardvark Asset Purchase Agreement) (which amount may be paid in shares of the Company&#8217;s common stock or cash, in the Company&#8217;s sole discretion) (the &#8220;Development Milestone Payment&#8221;) and (ii)&#160;$</div>20,000,000<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, in cash, upon achievement of certain net sales by the Company of a commercial product that uses the LDN Formulation (the &#8220;Commercial Product&#8221;). The Company will also pay Aardvark certain royalties in the single digits based on percentages of annual net sales by the Company of a commercial product that uses the LDN Formulation. The royalty percentage is subject to reduction in certain circumstances. Royalties are due for so long as Commercial Product is covered by a valid patent in the country of sale or for ten years following the first commercial sale of the Commercial Product, whichever is longer.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In connection with its acquisition of the </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SP-104</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Assets, the Company has agreed that if it issues any shares of the Company&#8217;s common stock in respect of the Development Milestone Payment, the Company will prepare and file one or more registration statements with the SEC for the purpose of registering for resale such shares and is required to file such registration statement with the SEC within </div>60<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>days following the date on which any such shares are issued.</div></div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Tien-Li</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Lee, MD, a member of the board of directors of the Company, is the founder, chief executive officer and a member of the board of directors of Aardvark.</div></div> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vicker's Vantage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 10. SUBSEQUENT EVENTS </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the unaudited condensed consolidated financial statements were issued. Based upon this review, other than as described below and elsewhere in these unaudited condensed consolidated financial statements, the Company did not identify any subsequent events that would have required adjustment or disclosure in the unaudited condensed consolidated financial statements. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On October&#160;10, 2022, the Company extended the period of time to consummate a Business Combination to November&#160;11, 2022. The Sponsors deposited $323,889&#160;into the Trust Account made in the form of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest-bearing</div> loans. If the Company completes an initial business combination, the Company will, at the option of the Sponsors, repay the amounts evidenced by simple promissory notes. If a Business Combination is not consummated, the simple promissory notes will not be repaid by the Company and all amounts owed thereunder by the Company will be forgiven except to the extent that the Company has funds available to it outside of its Trust Account. <br/></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">On<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">October&#160;17, 2022, the Company and its Sponsors entered into a Debt Contribution Agreement (the &#8220;Debt Contribution Agreement&#8221;). The Debt Contribution Agreement relates to certain amounts owed by the Company to the Sponsors for payment of certain outstanding loans (the &#8220;Company Obligations&#8221;) as set forth in the Debt Contribution Agreement. Pursuant to the Debt </div>Contribu<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">tion Agreement, the Sponsors have agreed to contribute the Company Obligations to the Company in</div> exc<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">hange for the issuance of that number of shares of shares of common stock, par value $</div>0.0001<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;per share, of the Company, determined by dividing the Company Obligations by $</div>10.00<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;(the &#8220;Contribution Shares&#8221;) to the Sponsors immediately prior to the consummation of the Business Combination but after the Domestication (as defined in the Merger Agreement). Upon the occurrence of the debt contribution and issuance of the Contribution Shares to the Sponsors pursuant to the Debt Contribution Agreement, the Company Obligation owed to the Sponsors shall be extinguished in its entirety and shall be of no further force or effect and shall be deemed satisfied in full.</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In connection with the Debt Exchange Agreement, on October&#160;17, 2022, Sorrento and Scilex entered into a letter agreement (the &#8220;Funding Commitment Letter&#8221;) pursuant to which, upon the written request of the Company (which request the Company shall make to the extent necessary to satisfy Net Tangible Asset Condition), Sorrento shall fund one or more loans to the Company in the amount set forth in such written request. </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On October&#160;17, 2022, as consideration for Sorrento agreeing to provide for funding under the Funding Commitment Letter, Vickers, the Sponsors, Sorrento and Maxim Group LLC, entered into the Warrant Transfer Agreement (the &#8220;Warrant Transfer Agreement&#8221;) for the transfer of certain private placement warrants held by the Sponsors to Sorrento in the event redemptions exceed certain thresholds specified in the Warrant Transfer Agreement. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;">On October&#160;17, 2022, the Company entered into a Letter Agreement with Sorrento and the Sponsors (the &#8220;Letter Agreement&#8221;) to provide that certain shares held by the Sponsors will be released from the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up</div> restrictions only in an amount necessary to help satisfy the minimum public float requirement under the Listing Standards of the Nasdaq Stock Market LLC, which amount shall not exceed&#160;1,500,000&#160;shares. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On October&#160;28, 2022, the proxy statement/prospectus was declared effective and the Company commenced with mailing the proxy materials to the Company&#8217;s shareholders ahead of the extraordinary general meeting of the Company&#8217;s shareholders on November&#160;9, 2022. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To the Board of Directors and Stockholders of Scilex Holding Company </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Opinion on the Financial Statements </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have audited the accompanying consolidated balance sheets of Scilex Holding Company (the Company) as of December&#160;31, 2021 and 2020, the related consolidated statements of operations, stockholders&#8217; deficit and cash flows for each of the two years in the period ended December&#160;31, 2021, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December&#160;31, 2021 and 2020, and the results of its operations and its cash flows for the years then ended in conformity with U.S. generally accepted accounting principles. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s Ability to Continue as a Going Concern </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company has suffered recurring losses from operations, has a working capital deficiency, and has stated that substantial doubt exists about the Company&#8217;s ability to continue as a going concern. Management&#8217;s evaluation of the events and conditions and management&#8217;s plans regarding these matters are also described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basis for Opinion </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We conducted our audits in accordance with the standards of the PCAOB and in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Ernst&#160;&amp; Young LLP </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have served as the Company&#8217;s auditor since 2020. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">San Diego, California </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">May&#160;13, 2022 </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To the stockholders and the Board of Directors of </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Scilex Holding Company </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Opinion on the Financial Statements </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have audited the accompanying consolidated statements of operations, stockholders&#8217; equity, and cash flows of Scilex Holding Company and subsidiaries (the &#8220;Company&#8221;) for the year ended December&#160;31, 2019, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the results of the Company&#8217;s operations and cash flows for the year ended December&#160;31, 2019, in conformity with accounting principles generally accepted in the United States of America. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Going Concern </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company has suffered negative working capital, recurring losses from operations, recurring negative cash flows from operations and cumulative net losses that raise substantial doubt about its ability to continue as a going concern. Management&#8217;s plans in regard to these matters are also described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basis for Opinion </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We conducted our audit in accordance with the standards of the PCAOB and in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provide a reasonable basis for our opinion. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other Matter </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As discussed in Note 1 to the financial statements, the accompanying financial statements have been prepared from the separate records maintained by the Company and may not necessarily be indicative of the conditions that would have existed or the results of operations if the Company had been operated as an unaffiliated company of Sorrento Therapeutics, Inc. Portions of certain income and expenses represent allocations made from home-office items applicable to the Company as a whole. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Deloitte&#160;&amp; Touche LLP </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">San Diego, California </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">April&#160;23, 2020 </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We began serving as the Company&#8217;s auditor in 2018. In 2020 we became the predecessor auditor. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 11&#160;&#8212;&#160;SUBSEQUENT EVENTS </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the financial statements were issued. The Company did not identify any subsequent events, other than noted below, that would have required adjustment or disclosure in the financial statements. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;">On January&#160;10, 2022, the Company extended the period of time to consummate a Business Combination to April&#160;11, 2022. The Sponsors deposited $1,035,000 into the Trust Account made in the form of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest-bearing</div> loans. If the Company completes an initial business combination, the Company will, at the option of the Sponsors, repay the amounts evidenced by the Convertible Promissory Notes or convert a portion or all of the<div style="display:inline;">&#160;</div><div style="display:inline;">total amount into warrants at a price of $0.75 per warrant, which warrants are identical to the Private Placement&#160;</div> </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="null;text-indent: 0px;;display:inline;">Warrants issued.</div> If a Business Combination is not consummated, the Convertible Promissory Notes will not be repaid by the Company and all amounts owed thereunder by the Company will be forgiven except to the extent that the Company has funds available to it outside of its Trust Account. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On January&#160;27, 2022, the Company entered into two additional Convertible Promissory Notes with the Sponsors pursuant to which the Sponsors agreed to loan the Company up to an additional aggregate principal amount of $500,000. The aggregate principal balance of the Convertible Promissory Notes amounted to $2,035,000. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_VickersVantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_VickersVantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139838696566736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and include all adjustments necessary for the fair presentation of the Company&#8217;s financial position for the periods presented.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying consolidated financial statements include the accounts of the Company&#8217;s subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These consolidated financial statements should be read in conjunction with the consolidated financial statements for the fiscal year ended December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. Operating results for quarter periods are not expected to be indicative of operating results for the Company&#8217;s </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> fiscal year, or any subsequent period.</div></div><span></span>
</td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and include all adjustments necessary for the fair presentation of the Company&#8217;s financial position for the periods presented. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying consolidated financial statements include the accounts of the Company&#8217;s subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Significant Accounting Policies</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Significant Accounting Policies </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the </div>nine<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> months ended September&#160;</div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, there have been </div>no<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> changes to the Company`s significant accounting policies as described in the notes to the audited financial statements for the years ended December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> included in the proxy statement/prospectus filed by Vickers with the SEC on October&#160;</div>28<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> beginning on page </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-48</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> thereof.</div></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combination</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px; text-align: left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Business Combination </div></div></div></div><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-align: left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;17, 2022, the Company entered into an Agreement and Plan of Merger (as amended on September&#160;12, 2022, the &#8220;BCA&#8221;) with Vickers Vantage Corp. I (&#8220;Vickers&#8221;), a special purpose acquisition</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">company, and<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vantage Merger Sub, Inc., a wholly-owned subsidiary of Vickers (&#8220;Vickers Merger Sub&#8221;). Pursuant to the terms of the BCA, Vickers Merger Sub merged with and into the Company, with the Company surviving the merger (&#8220;Legacy Scilex&#8221;) and becoming a wholly-owned subsidiary of Vickers (collectively, the &#8220;Business Combination&#8221;).</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On November&#160;</div>10<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, Vickers consummated the Business Combination pursuant to the terms of the BCA. Vickers acquired all of the outstanding equity interests of Legacy Scilex. As a result of the Business Combination, New Scilex (as defined below) received gross proceeds of approximately $</div>12.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, prior to the settlement of transaction-related costs and expenses. Additionally, all existing related party indebtedness between the Company, Scilex Pharma, and Sorrento totaling $</div>290.6<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million was converted into equity interests in Vickers in connection with the consummation of the Business Combination and pursuant to the terms of the Debt Exchange Agreement (see Note </div>10)<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. In connection with the Business Combination (as more fully described in the notes to these financial statements), Scilex Holding Company was renamed to Scilex, Inc. These financial statements are those of Scilex Holding Company (now known as Scilex, Inc.) prior to the completion of such Business Combination. Additionally, in connection with the completion of the Business Combination, Vickers was renamed to, and will operate as, &#8220;Scilex Holding Company&#8221; and the Company began trading on the Nasdaq Capital Market under the new ticker symbol &#8220;SCLX&#8221; on November&#160;</div>11<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">. Scilex Holding Company following the completion of the Business Combination is sometimes referred to herein as &#8220;New Scilex.&#8221;</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Business Combination will be accounted for as a reverse recapitalization in accordance with U.S. GAAP. Under this method of accounting, Vickers is treated as the &#8220;acquired&#8221; company for accounting purposes and the Business Combination is treated as the equivalent of the Company issuing stock for the net assets of Vickers, accompanied by a recapitalization. The net assets of Vickers are stated at historical cost, with </div>no<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> goodwill or other intangible assets recorded.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s legal, accounting and other fees directly attributable to the Business Combination were capitalized within prepaid expenses and other current assets on the consolidated balance sheets. As of September&#160;</div>30<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2022<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company had capitalized $</div>7.3<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million of costs incurred in relation to the Business Combination. There were </div>no<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> capitalized costs in relation to the Business Combination as of December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">.</div></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of these consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of these consolidated financial statements and the reported amounts of expenses during the reporting period. Management believes that these estimates are reasonable; however, actual results may differ from these estimates.</div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of these consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of these consolidated financial statements and the reported amounts of expenses during the reporting period. Management believes that these estimates are reasonable; however, actual results may differ from these estimates. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cash and Cash Equivalents </div></div></div></div></div> <div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company considers all highly liquid investments purchased with original maturities of three months or less to be cash equivalents. The Company minimizes its credit risk associated with cash and cash equivalents by periodically evaluating the credit quality of its primary financial institution. Although the balance at times may exceed federally-insured limits, the Company has not experienced any losses on such accounts. </div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Warrant Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Derivative Liabilities </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivative liabilities are recorded on the Company&#8217;s consolidated balance sheets at their fair value on the date of issuance and are revalued on each balance sheet date until such instruments are exercised or expire, with changes in the fair value between reporting periods recorded as other income or expense. </div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accounts Receivable, Net </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable are presented net of allowances for expected credit losses and consist of trade receivables from product sales to one customer, which are generally unsecured. Estimated credit losses related to trade accounts receivable are recorded as general and administrative expenses and as an allowance for expected credit losses within accounts receivable, net. The Company reviews reserves and makes adjustments based on historical experience and known collectability issues and disputes. When internal collection efforts on accounts have been exhausted, the accounts are written off by reducing the allowance for expected credit losses. </div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Inventory </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company determines inventory cost on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-in,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-out</div> basis. The Company reduces the carrying value of inventories to a lower of cost or net realizable value for those items that are potentially excess, obsolete or slow-moving. The Company reserves for excess and obsolete inventory based upon historical experience, sales trends, and specific categories of inventory and expiration dates for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">on-hand</div> inventory. As of December&#160;31, 2021 and 2020, the Company&#8217;s inventory was primarily comprised of finished goods. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Property and Equipment </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment are carried at cost less accumulated depreciation. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the assets, which are generally five to seven years. Leasehold improvements are amortized over the lesser of their estimated useful lives or the term of the respective lease on a straight-line basis. The cost of repairs and maintenance is expensed as incurred. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill and Other Long-Lived Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Goodwill and Other Long-Lived Assets </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill, which has an indefinite life, represents the excess cost over fair value of net assets acquired. Goodwill is reviewed for impairment at least annually during the fourth quarter, or more frequently if events occur indicating the potential for impairment. The Company has determined that only one reporting unit exists for examination under impairment review. During its goodwill impairment review, the Company may assess qualitative factors to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company. If, after assessing the totality of these qualitative factors, the Company determines that it is not more likely than not that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company performs a quantitative goodwill impairment test. The Company may also elect to bypass the qualitative assessment in a period and elect to proceed to perform the quantitative goodwill impairment test. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company evaluates its long-lived and intangible assets with definite lives, such as property and equipment, patent rights, and acquired technology, for impairment by considering competition by products prescribed for the same indication, the likelihood and estimated future entry of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-generic</div> and generic competition with the same or similar indication and other related factors. The factors that drive the estimate of useful life are often uncertain and are reviewed on a periodic basis or when events occur that warrant review. Recoverability is measured by comparison of the assets&#8217; book value to future net undiscounted cash flows that the assets are expected to generate to determine if a write-down to the recoverable amount is appropriate. If such assets are written down, an impairment will be recognized as the amount by which the book value of the asset group exceeds the recoverable amount. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InProcessResearchAndDevelopmentPolicy', window );">Acquired In-Process Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">In-Process</div> Research and Development Expense </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company has acquired and may continue to acquire the rights to develop and commercialize new product candidates. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">up-front</div> payments to acquire a new drug compound or drug delivery device, as well as future milestone payments associated with asset acquisitions that do not meet the definition of a derivative and are deemed probable to achieve the milestones, are immediately expensed as acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development provided that the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, have no alternative future use. Intangible assets acquired in a business combination that are used for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development (&#8220;IPR&amp;D&#8221;) activities are considered indefinite-lived until the completion or abandonment of the associated research and development efforts. Upon commercialization of the relevant research and development project, the Company amortizes the acquired IPR&amp;D over its estimated useful life. Capitalized IPR&amp;D is reviewed annually for impairment or more frequently as changes in circumstance or the occurrence of events suggest that the remaining value may not be recoverable. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The provisions of the FASB ASC Topic 740, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes</div></div>, addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC Topic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">740-10,</div> the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based on the technical merits of the position. The Company has determined that it has uncertain tax positions. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for income taxes using the asset and liability method to compute the differences between the tax basis of assets and liabilities and the related financial amounts, using currently enacted tax rates. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has deferred tax assets, which are subject to periodic recoverability assessments. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount that more likely than not will be realized. As of December&#160;31, 2021 and 2020, the Company maintained a full valuation allowance against its deferred tax assets, with the exception of an amount equal to its deferred tax liabilities that are scheduled to reverse against the Company&#8217;s deferred tax assets. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Debt </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company may enter financing arrangements, the terms of which involve significant assumptions and estimates. This involves estimating future net product sales, determining interest expense, determining the amortization period of the debt discount, as well as determining the classification between current and long-term portions. In estimating future net product sales, the Company assesses prevailing market conditions using various external market data against the Company&#8217;s anticipated sales and planned commercial activities as well as actual ZTlido sales up to the date the financial statements were issued. See Note 8 for discussion of the Scilex Pharma Notes, which include repayments based on a percentage of net sales of ZTlido. Consequently, the Company imputes interest on the carrying value of the debt and records interest expense using an imputed effective interest rate. The Company reassesses the expected payments each reporting period and accounts for any changes through an adjustment to the effective interest rate on a prospective basis, with a corresponding impact to the classification of the Company&#8217;s current and long-term portions. </div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research and Development Costs </div></div></div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company expenses the cost of research and development as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including clinical trial costs, manufacturing costs for both clinical and preclinical materials as well as other contracted services, </div></div></div> <div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">license fees and other external costs. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity is performed or when the goods have been received, rather than when payment is made, in accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic 730, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research and Development</div></div>. </div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Income (Loss) per Ordinary Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Net Loss per Share </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic net loss </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">per share is computed by dividing net loss for the period by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share reflects the additional dilution from potential issuances of common stock, such as stock issuable pursuant to the exercise of stock options. The treasury stock method is used to calculate the potential dilutive effect of these common stock equivalents. Potentially dilutive shares are excluded from the computation of diluted net loss per share when their effect is anti-dilutive. In periods where a net loss is presented, all potentially dilutive securities are anti-dilutive and are excluded from the computation of diluted net loss per share. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RebatesPolicyTextBlock', window );">Rebates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Rebates </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">Rebates are discounts which the Company pays under either government or private health care programs. Government rebate programs include state Medicaid drug rebate programs, the Medicare coverage gap discount programs and the Tricare programs. Commercial rebate and fee programs relate to contractual agreements with commercial healthcare providers, under which the Company pays rebates and fees for access to and position on that provider&#8217;s patient drug formulary. Rebates and chargebacks paid under government programs are generally mandated under law, whereas private rebates and fees are generally contractually negotiated by the Company with commercial healthcare providers. Both types of rebates vary over time. The Company records a reduction to gross product sales at the time the customer takes title to the product based on estimates of expected rebate claims. The Company monitors the sales trends and adjust for these rebates on a regular basis to reflect the most recent rebate experience and contractual obligations.</div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ServiceFeesPolicyTextBlock', window );">Service Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Service Fees </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company compensates its customer and others in the distribution chain for wholesaler and distribution services. The Company has determined such services received up to the date the financial statements were issued are not distinct from the Company&#8217;s sale of products to the customer and, therefore, these payments have been recorded as a reduction of revenue. </div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SalesReturnsPolicyTextBlock', window );">Product Returns</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Product Returns </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is obligated to accept the return of products sold that are expiring within six months, damaged or do not meet certain specifications. The Company may authorize the return of products sold in accordance with the term of its sales contracts, and estimates allowances for such amounts at the time of sale. The Company estimates the amount of its product sales that may be returned by its customer and record this estimate as a reduction of revenue in the period the related product revenue is recognized.</div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CoPaymentAssistancePolicyTextBlock', window );">Co-Payment Assistance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Co-Payment</div> Assistance </div></div></div></div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Patients who have commercial insurance or pay cash and meet certain eligibility requirements may receive <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-payment</div> assistance. The Company accrues for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-payment</div> assistance based on actual program participation and estimates of program redemption using data provided by third-party </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">administrators. </div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Customer Concentration Risk </div></div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">During the fiscal years ended December<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">31, 2021, 2020 and 2019, sales to the Company&#8217;s sole distributor represented 100% of net revenue. This exposes the Company to concentration of customer risk. The Company monitors the financial condition of its sole customer, limits its credit exposure by setting credit limits, and has not experienced any credit losses for the&#160;years ended December&#160;31, 2021, 2020 and 2019. As the Company continues to expand the commercialization of its product, the Company is not limited to the current customer and has the option of expanding its distribution network with additional distributors through establishing its own affiliates, by acquiring existing third-party business or product rights or by partnering with additional third parties. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value of Financial Instruments </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company follows accounting guidance on fair value measurements for financial instruments measured on a recurring basis, as well as for certain assets and liabilities that are initially recorded at their estimated fair values. Fair value is defined as the exit price, or the amount that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company uses the following three-level hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs to value its financial instruments: </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 5%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">a.</div></td>
<td style="vertical-align: top; font-size: 10pt;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;1: Observable inputs such as unadjusted quoted prices in active markets for identical instruments. </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 5%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">b.</div></td>
<td style="vertical-align: top; font-size: 10pt;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;2: Quoted prices for similar instruments that are directly or indirectly observable in the marketplace. </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 5%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">c.</div></td>
<td style="vertical-align: top; font-size: 10pt;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;3: Significant unobservable inputs which are supported by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation. </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety requires it to make judgments and consider factors specific to the asset or liability. The use of different assumptions and/or estimation methodologies may have a material effect on estimated fair values. Accordingly, the fair value estimates disclosed or initial amounts recorded may not be indicative of the amount that the Company or holders of the instruments could realize in a current market exchange. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2021 and 2020, the carrying amount of cash equivalents approximates their fair value based upon quoted market prices. Certain of the Company&#8217;s financial instruments are not measured at fair value on a recurring basis, but are recorded at amounts that approximate their fair value due to their liquid or short-term nature, such as cash, prepaid expenses, accounts receivable, and accounts payable. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Segments </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating segments </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">are identified as components of an entity where separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions on how to allocate resources and assesses performance. The Company has determined that its chief operating decision maker is its Chief Executive Officer, as he is responsible for making decisions regarding the allocation of resources and assessing performance as well as for strategic operational decisions. The Company is engaged primarily in the development of </div><div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-opioid</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> products focused on pain management based on its platform technologies and all sales are based in the United States. Accordingly, the Company has determined that it operates its business as a single reportable segment.</div></div><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Segments </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating segments </div></div> are identified as components of an entity where separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions on how to allocate resources and assesses performance. The Company has determined that its chief operating decision maker is its Chief Executive Officer, as he is responsible for making decisions regarding the allocation of resources and assessing performance as well as for strategic operational decisions. The Company is engaged primarily in the development of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">non-opioid<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">products focused on pain management based on its platform technologies and all sales are based in the United States. Accordingly, the Company has determined that it operates its business as a single reportable segment.</div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"/> <br/></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Standards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recent Accounting Pronouncements </div></div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In October 2021, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2021-08,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers</div></div>, which requires an acquirer in a </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">business </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">combination to recognize and measure contract assets and contract liabilities in accordance with ASC Topic 606. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2021-08</div> is effective for fiscal years beginning after December&#160;15, 2022 and early adoption is permitted. The Company is evaluating the impact the standard will have on its consolidated financial statements. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In December 2019, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2019-12,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</div></div>. The amendments in this update simplify the accounting for income taxes by removing certain exceptions to the general principles in ASC Topic 740. The amendments also improve consistent application of and simplify U.S. GAAP for other areas of ASC Topic 740 by clarifying and amending existing guidance. The amendments in this update were effective for interim and annual periods for the Company beginning after December&#160;15, 2020. The Company adopted the standard on January&#160;1, 2021. The adoption of the standard had no impact on its consolidated financial statements. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Leases </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company determines if an arrangement is a lease at inception. Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> (&#8220;ROU&#8221;) assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As the Company&#8217;s leases do not provide an implicit rate, it uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any lease payments made and is reduced by lease incentives. The Company&#8217;s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term in selling, general and administrative expenses. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="null;text-indent: 0px;;font-style:italic;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Revenue Recognition&#160;</div> </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s revenue is generated from product sales within the United States. The Company does not have significant costs associated with costs to obtain a contract with its customer. All of the Company&#8217;s revenue and accounts receivable result from a sole customer. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue from product sales is fully comprised of sales of ZTlido. The Company&#8217;s performance obligation with respect to sales of ZTlido is satisfied at a point in time, which transfers control upon delivery of product to the customer. The Company considers control to have transferred upon delivery because the customer has legal title to the product, physical possession of the product has been transferred to the customer, the customer has significant risks and rewards of ownership of the product, and the Company has a present right to payment at that time. Invoicing typically occurs upon shipment and the length of time between invoicing and when payment is due is not significant. The aggregate dollar value of unfulfilled orders as of December&#160;31, 2021 and 2020 were not material. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">For product sales, the Company records <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">gross-to-net</div></div> sales adjustments for commercial and government rebates, fees and chargebacks, wholesaler and distributor fees, sales returns and prompt payment discounts. Such variable consideration is estimated in the period of the sale and is estimated using a most likely amount approach based primarily upon provisions included in the Company&#8217;s customer contract, customary industry practices and current government regulations. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Gross-to-net</div></div> adjustments are generally recorded as contract liabilities under accrued expenses within the Company&#8217;s consolidated balance sheet. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock-Based Compensation </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts </div></div> for stock-based compensation in accordance with FASB ASC Topic 718,<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> Compensation</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#8212;</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock Compensation </div></div>which establishes accounting for equity instruments exchanged for employee and consulting services. Under such provisions, stock-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense, under the straight-line method, over the employee&#8217;s requisite service period (generally the vesting period of the equity grant) or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee&#8217;s</div> vesting period. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For purposes of determining </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> the inputs used in the calculation of stock-based compensation, the Company uses historical data in estimating the expected term of options and determines an estimate of option volatility based on an assessment of historical volatilities of comparable companies whose share prices are publicly available. The Company uses these estimates as inputs in the Black-Scholes option pricing model. Depending upon the number of stock options granted, any fluctuations in these calculations could have a material effect on the results presented in the Company&#8217;s consolidated statement of operations. </div></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vickers Vantage [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) for interim financial information and in accordance with the instructions to Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</div> and Article 8 of Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-X</div> of the SEC. Certain information or footnote disclosures normally included in condensed financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the Company&#8217;s Annual Report on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Form&#160;10-K</div> as filed with the SEC on February&#160;24, 2022. The interim results for the three and nine months ended September&#160;30, 2022 are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2022 or for any future periods. </div><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and pursuant to the rules and regulations of the SEC. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Principles of Consolidation </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All significant intercompany balances and transactions have been eliminated in consolidation. </div></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock', window );">Emerging Growth Company</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Emerging Growth Company </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is an &#8220;emerging growth company,&#8221; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Further, Section&#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-emerging</div> growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&#8217;s financial statement with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. </div> <span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Emerging Growth Company </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is an &#8220;emerging growth company,&#8221; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">registered public accounting firm attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.</div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Further, Section&#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-emerging</div> growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&#8217;s financial statement with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of the condensed consolidated financial statements in conformity with GAAP requires the Company&#8217;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the condensed consolidated financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. One of the more significant accounting estimates included in these condensed consolidated financial statements is the determination of the fair value of the warrant liabilities. Such estimates may be subject to change as more current information because available and accordingly, the actual results could differ significantly from those estimates. </div></div><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of the financial statements in conformity with GAAP requires the Company&#8217;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. One of the more significant accounting estimates included in these financial statements is the determination of the fair value of the warrant liabilities. Such estimates may be subject to change as more current information because available and accordingly, the actual results could differ significantly from those estimates. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cash and Cash Equivalents </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of September&#160;30, 2022 and December&#160;31, 2021. </div></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsPolicy', window );">Investments Held in Trust Account</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Investments Held in Trust Account </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At September&#160;30, 2022 and December&#160;31, 2021, the majority of the assets held in the Trust Account were held in money market funds, which are invested primarily in U.S. Treasury securities. The Company presents its investments in money market funds on the condensed consolidated balance sheets at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of these securities is included in interest income in the accompanying unaudited condensed consolidated statements of operations. The estimated fair value of investments held in the Trust Account are determined using available market information. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Offering Costs</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Offering Costs </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Offering costs consist of legal, accounting, underwriting fees and other costs incurred through the balance sheet date that are directly related to the Initial Public Offering. Offering costs were allocated to the separable financial instruments issued in the Initial Public Offering based on a relative fair value basis, compared to total proceeds received. Offering costs allocated to warrant liabilities were expensed as incurred in the statements of operations. Offering costs associated with the ordinary shares issued were initially charged to temporary equity and then accreted to ordinary shares subject to redemption upon the completion of the Initial Public Offering. Offering costs amounting to $8,119,261&#160;were charged to temporary equity upon the completion of the Initial Public Offering, and $30,212&#160;of the offering costs were related to the warrant liabilities and charged to the condensed consolidated statement of operations for the period ended September&#160;30, 2021. The Company classifies deferred underwriting commissions as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> liabilities as their liquidation is not reasonably expected to require the use of current assets or require the creation of current liabilities. </div><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Offering Costs </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Offering costs consist of legal, accounting, underwriting fees and other costs incurred through the balance sheet date that are directly related to the Initial Public Offering. Offering costs were allocated to the separable financial instruments issued in the Initial Public Offering based on a relative fair value basis, compared to total proceeds received. Offering costs allocated to warrant liabilities were expensed as incurred in the statements of operations. Offering costs associated with the ordinary shares issued were initially charged to temporary equity and then accreted to ordinary shares subject to redemption upon the completion of the Initial Public Offering. Offering costs amounting to $8,119,261 were charged to temporary equity upon the completion of the Initial Public Offering, and $30,212 of the offering costs were related to the warrant liabilities and charged to the statements of operations. </div><br/></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock', window );">Ordinary Shares Subject to Possible Redemption</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Ordinary Shares Subject to Possible Redemption </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for its ordinary shares subject to possible redemption in accordance with the guidance in Accounting Standards Codification (&#8220;ASC&#8221;) Topic 480 &#8220;Distinguishing Liabilities from Equity.&#8221; Ordinary shares subject to mandatory redemption is classified as a liability instrument and is measured at fair value. Conditionally redeemable ordinary shares (including ordinary shares that features redemption rights that is either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#8217;s control) is classified as temporary equity. At all other times, ordinary shares are classified as shareholders&#8217; equity. The Company&#8217;s ordinary shares features certain redemption rights that are considered to be outside of the Company&#8217;s control and subject to occurrence of uncertain future events. Accordingly, at September&#160;30, 2022 and December&#160;31, 2021, ordinary shares subject to possible redemption is presented as temporary equity, outside of the shareholders&#8217; deficit section of the Company&#8217;s condensed consolidated balance sheets. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Under ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">480-10-S99,</div></div> the Company has elected to recognize changes in the redemption value immediately as they occur and adjust the carrying value of redeemable ordinary shares to equal the redemption value at the end of each reporting period. This method would view the end of the reporting period as if it were also the redemption date for the security. Immediately upon the closing of the Initial Public Offering, the Company recognized the accretion from initial book value to redemption amount value. The change in the carrying value of redeemable ordinary shares resulted in charges against additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital and accumulated deficit. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At September&#160;30, 2022 and December&#160;31, 2021, the ordinary shares reflected in the condensed consolidated balance sheets are reconciled in the following table: </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 77%; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross proceeds</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">138,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ordinary shares issuance costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8,119,261</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Plus:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accretion of carrying value to redemption value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,499,261</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ordinary shares subject to possible redemption as of December&#160;31, 2021</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">139,380,000</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Mandatorily redeemable ordinary shares</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(41,824,292</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Plus:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accretion of carrying value to redemption value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,737,378</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ordinary shares subject to possible redemption as of September&#160;30, 2022</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">101,293,086</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Ordinary Shares Subject to Possible Redemption </div></div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for its ordinary shares subject to possible redemption in accordance with the guidance in Accounting Standards Codification (&#8220;ASC&#8221;) Topic 480 &#8220;Distinguishing Liabilities from Equity.&#8221; Ordinary shares subject to mandatory redemption is classified as a liability instrument and is measured at fair value. Conditionally redeemable ordinary shares (including ordinary shares that features redemption rights that is either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#8217;s control) is classified as temporary equity. At all other times, ordinary shares are classified as shareholders&#8217; equity. The Company&#8217;s ordinary shares, sold in the IPO, features certain redemption rights that are considered to be outside of the Company&#8217;s control and subject to occurrence of uncertain future events. Accordingly, at December&#160;31, 2021 and 2020, ordinary shares subject to possible redemption is presented as temporary equity, outside of the shareholders&#8217; (deficit) equity section of the Company&#8217;s balance sheets. </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Under ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">480-10-S99,</div></div> the Company has elected to recognize changes in the redemption value immediately as they occur and adjust the carrying value of redeemable ordinary shares subject to possible redemption to equal the redemption value at the end of each reporting period. This method would view the end of the reporting period as if it were also the redemption date for the security. Immediately upon the closing of the Initial Public Offering, the Company recognized the accretion from initial book value to redemption amount value. The change in the carrying value of redeemable ordinary shares resulted in charges against additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital and accumulated deficit. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At December&#160;31, 2021, the ordinary shares reflected in the balance sheets are reconciled in the following table: </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 77%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 77%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross proceeds</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">138,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 77%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less:</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 77%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ordinary shares issuance costs</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8,119,261</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 77%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Plus:</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 77%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accretion of carrying value to redemption value</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,499,261</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 77%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 77%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ordinary shares subject to possible redemption</div></div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">139,380,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 77%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap;"/></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 77%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><br/></td>
<td style="vertical-align: bottom;"><br/></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"/><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Warrant Liability</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Warrant Liability </div></div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 480, Distinguishing Liabilities from Equity (&#8220;ASC 480&#8221;) and ASC 815,&#160;Derivatives and Hedging&#160;(&#8220;ASC 815&#8221;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company&#8217;s own ordinary shares, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. We account for the warrants issued in connection with our Initial Public Offering in accordance with the guidance contained in ASC 815 under which the public warrants meet the criteria for equity treatment and the private warrants do not meet the criteria for equity treatment and must be recorded as liabilities. Accordingly, we classify the private warrants as liabilities at their fair value and adjust the private warrants to fair value at each reporting period. This liability is subject to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-measurement</div> at each balance sheet date until exercised, and any change in fair value is recognized in our statement of operations. The fair value of the warrants was estimated using a Black-Scholes option pricing formula. </div><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Warrant Liability </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 480, Distinguishing Liabilities from Equity (&#8220;ASC 480&#8221;) and ASC 815, Derivatives and Hedging (&#8220;ASC 815&#8221;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company&#8217;s own ordinary shares, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. We account for the warrants issued in connection with our Initial Public Offering in accordance with the guidance contained in ASC 815 under which the public warrants meet the criteria for equity treatment and the private warrants do not meet the criteria for equity treatment and must be recorded as liabilities. Accordingly, we classify the private warrants as liabilities at their fair value and adjust the private warrants to fair value at each reporting period. This liability is subject to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-measurement</div> at each balance sheet date until exercised, and any </div><br/></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">change in fair value is recognized in our statements of operations. The fair value of the warrants was estimated using a Black-Scholes option pricing formula. </div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes </div></div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for income taxes under ASC Topic 740, &#8220;Income Taxes,&#8221; which prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company&#8217;s management determined that the Cayman Islands is the Company&#8217;s major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. As of September&#160;30, 2022 and December&#160;31, 2021, there were no unrecognized tax benefits and no amounts accrued for interest and penalties. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is considered to be an exempted Cayman Islands company with no connection to any other taxable jurisdiction and is presently not subject to income taxes or income tax filing requirements in the Cayman Islands or the United States. As such, the Company&#8217;s tax provision was zero for the periods presented. </div></div></div><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes </div></div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for income taxes under ASC Topic 740, &#8220;Income Taxes,&#8221; which prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company&#8217;s management determined that the Cayman Islands is the Company&#8217;s major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. As of December&#160;31, 2021 and 2020, there were no unrecognized tax benefits and no amounts accrued for interest and penalties. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is considered to be an exempted Cayman Islands company with no connection to any other taxable jurisdiction and is presently not subject to income taxes or income tax filing requirements in the Cayman Islands or the United States. As such, the Company&#8217;s tax provision was zero for the periods presented. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Income (Loss) per Ordinary Share</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Net Income (Loss) per Ordinary Share </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, &#8220;Earnings Per Share&#8221;. Net income (loss) per ordinary share is computed by dividing net income (loss) by the weighted average number of ordinary shares outstanding for the period. Accretion associated with the redeemable shares of ordinary shares is excluded from earnings per share as the redemption value approximates fair value. Mandatorily redeemable ordinary shares are excluded from the weighted average number of ordinary shares outstanding. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The calculation of diluted income (loss) per share does not consider the effect of the warrants issued in connection with the (i)&#160;Initial Public Offering, and (ii)&#160;the private placement since the exercise of the warrants is contingent upon the occurrence of future events. The warrants are exercisable to purchase&#160;13,740,000&#160;ordinary shares in the aggregate. As of September&#160;30, 2022 and 2021, the Company did not have any dilutive securities or </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">other contracts that could, potentially, be exercised or converted into ordinary shares and then share in the earnings of the Company. As a result, diluted net income (loss) per ordinary share is the same as basic net income (loss) per ordinary share for the periods presented. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table reflects the calculation of basic and diluted net income (loss) per ordinary share (in dollars, except per share amounts): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 48%;">&#160;</td>
<td style="width: 4%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="width: 4%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="width: 4%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="width: 4%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For&#160;the&#160;Three&#160;Months&#160;Ended</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the Nine Months Ended</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Ordinary Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basic and diluted net income (loss) per ordinary share</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allocation of net income (loss)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(131,387</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,444,352</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">623,516</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(349,248</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted weighted average ordinary shares outstanding</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,176,395</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,250,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,862,288</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,675,824</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net income (loss) per ordinary share</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.01</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.08</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.04</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.02</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Net income (Loss) per Ordinary Share </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, &#8220;Earnings Per Share&#8221;. Net income (loss) per ordinary share is computed by dividing net income (loss) by the weighted average number of ordinary shares outstanding for the period. Accretion associated with the redeemable shares of ordinary shares is excluded from earnings per share as the redemption value approximates fair value. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The calculation of diluted income (loss) per share does not consider the effect of the warrants issued in connection with the (i)&#160;Initial Public Offering, and (ii)&#160;the private placement since the exercise of the warrants is contingent upon the occurrence of future events. The warrants are exercisable to purchase 13,740,000 ordinary shares in the aggregate. As of December&#160;31, 2021 and 2020, the Company did not have any dilutive securities or other contracts that could, potentially, be exercised or converted into ordinary shares and then share in the earnings of the Company, except for the 450,000 founder shares in December&#160;31, 2021 which are no longer forfeitable and thus included for dilutive purposes. As a result, diluted net loss per ordinary share is the same as basic net loss per ordinary share for the periods presented. </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table reflects the calculation of basic and diluted net income per ordinary share (in dollars, except per share amounts): </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/>December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the Period<br/>from&#160;February&#160;21,<br/>2020 (Inception)<br/>Through<br/>December&#160;31,<br/>2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Ordinary&#160;Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Ordinary&#160;Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basic net income (loss) per ordinary share</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allocation of net income (loss), as adjusted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">783,438</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6,276</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic weighted average ordinary shares outstanding</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,820,548</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic net income (loss) per ordinary share</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.05</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Diluted net income (loss) per ordinary share</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allocation of net income (loss), as adjusted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">783,438</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6,276</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diluted weighted average ordinary shares outstanding</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,834,110</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diluted net income (loss) per ordinary share</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.05</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Concentration of Credit Risk </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times may exceed the Federal Deposit Insurance Corporation coverage limit of $250,000. As of September&#160;30, 2022 and December&#160;31, 2021, the Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such account.</div></div><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Concentration of Credit Risk </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times may exceed the Federal Depository Insurance Corporation coverage limit of $250,000. The Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such account. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value of Financial Instruments </div></div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the Company&#8217;s assets and liabilities, which qualify as financial instruments under ASC Topic 820, &#8220;Fair Value Measurement,&#8221; approximates the carrying amounts represented in the accompanying condensed consolidated balance sheets, primarily due to their short-term nature, other than the derivative warrant liability and conversion option liability (Note 9). </div></div><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value of Financial Instruments </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the Company&#8217;s assets and liabilities, which qualify as financial instruments under ASC Topic 820, &#8220;Fair Value Measurement,&#8221; approximates the carrying amounts represented in the accompanying balance sheets, primarily due to their short-term nature, other than the derivative warrant liability. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Standards</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recent Accounting Standards </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In August 2020, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06,</div> Debt &#8212; Debt with Conversion and Other Options (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">470-20)</div> and Derivatives and Hedging &#8212; Contracts in Entity&#8217; Own Equity (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">815-40):</div> Accounting for Convertible Instruments and Contracts in an Entity&#8217; Own Equity (&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06&#8221;),</div> which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU also removes certain settlement conditions that are required for equity-linked contracts to qualify for the derivative scope exception, and it simplifies the diluted earnings per share calculation in certain areas. Management is currently evaluating the new guidance but does not expect the adoption of this guidance to have a material impact on the Company&#8217;s condensed consolidated financial statements. <br/></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 10pt; letter-spacing: 0px;;display:inline;">Management does not believe that any other recently issued, but not yet effective, accounting standard if currently adopted would have a material effect on the accompanying condensed consolidated financial statements.</div></div><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recent Accounting Standards </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;">Management does not believe that any other recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company&#8217;s condensed financial statements. In August&#160;2020, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2020-06,</div> Debt&#160;&#8212;&#160;Debt with Conversion and Other Options (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">470-20)</div> and Derivatives and Hedging&#160;&#8212;&#160;Contracts in Entity&#8217; Own Equity (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">815-40):</div> Accounting for Convertible Instruments and Contracts in an Entity&#8217; Own Equity (&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06&#8221;),</div> which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU also removes certain settlement conditions that are required for equity-linked contracts to qualify for the derivative scope exception, and it simplifies the diluted earnings per share calculation in certain areas. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06</div> is effective for fiscal&#160;years beginning after December&#160;15, 2023, including interim periods within those fiscal&#160;years, with early adoption permitted. Management is currently evaluating the new guidance but does not expect the adoption of this guidance to have a material impact on the Company&#8217;s condensed financial statements. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Management does not believe that any other recently issued, but not yet effective, accounting standard if currently adopted would have a material effect on the accompanying condensed financial statements. </div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_CoPaymentAssistancePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Co payment assistance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_CoPaymentAssistancePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_RebatesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rebates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_RebatesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_SalesReturnsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_SalesReturnsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ServiceFeesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Service fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ServiceFeesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41675-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=SL94080555-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InProcessResearchAndDevelopmentPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InProcessResearchAndDevelopmentPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126900757&amp;loc=d3e543-108305<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI https://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognition of changes in redemption value of mandatorily redeemable shares. Provides the period over which changes in redemption value are accreted, usually from the issuance date (or from the date that it becomes probable that the security will become redeemable, if later) to the earliest redemption date of the security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5212-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_VickersVantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_VickersVantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139838696472896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of reflects the calculation of basic and diluted net income (loss) per ordinary share</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> table sets forth the reconciliation of basic and diluted loss per share for the nine months ended September&#160;30, 2022 and 2021 (in thousands except per share data):</div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 72%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Nine&#160;Months&#160;Ended<br/>September&#160;30,</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">2021</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5,480</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(46,459</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator for Basic Loss Per Share</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">197,550</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">197,266</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Effect of Dilutive Securities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator for Diluted Loss per Share &#8212; Adjusted for Dilutive Securities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">197,550</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">197,266</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic Loss Per Share</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.03</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.24</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dilutive Loss Per Share</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.03</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.24</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr></table><span></span>
</td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth the reconciliation of basic and diluted loss per share for the&#160;years ended December&#160;31, 2021, 2020, and 2019 (in thousands except per share data):</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 60%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt; border-bottom: 0.75pt solid black;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt; border-bottom: 0.75pt solid black;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(88,424</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(47,519</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(178,594</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator for Basic Loss Per Share</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">197,266</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">197,315</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">187,524</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Effect of Dilutive Securities</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Denominator for Diluted Loss per Share &#8212; Adjusted for Dilutive Securities</div><br/></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">197,266</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">197,315</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">187,524</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic Loss Per Share</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(0.45</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(0.24</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(0.95</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dilutive Loss Per Share</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">(0.45</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">(0.24</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">(0.95</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">)&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vickers Vantage [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfCondensedBalanceSheetTableTextBlock', window );">Schedule of ordinary shares reflected in condensed consolidated balance sheets are reconciled</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 77%; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross proceeds</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">138,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ordinary shares issuance costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8,119,261</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Plus:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accretion of carrying value to redemption value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,499,261</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ordinary shares subject to possible redemption as of December&#160;31, 2021</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">139,380,000</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Mandatorily redeemable ordinary shares</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(41,824,292</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Plus:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accretion of carrying value to redemption value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,737,378</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ordinary shares subject to possible redemption as of September&#160;30, 2022</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">101,293,086</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 77%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 77%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross proceeds</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">138,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 77%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less:</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 77%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ordinary shares issuance costs</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8,119,261</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 77%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Plus:</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 77%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accretion of carrying value to redemption value</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,499,261</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 77%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 77%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ordinary shares subject to possible redemption</div></div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">139,380,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 77%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of reflects the calculation of basic and diluted net income (loss) per ordinary share</a></td>
<td class="text"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 48%;">&#160;</td>
<td style="width: 4%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="width: 4%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="width: 4%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="width: 4%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For&#160;the&#160;Three&#160;Months&#160;Ended</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the Nine Months Ended</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Ordinary Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basic and diluted net income (loss) per ordinary share</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allocation of net income (loss)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(131,387</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,444,352</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">623,516</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(349,248</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted weighted average ordinary shares outstanding</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,176,395</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,250,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,862,288</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,675,824</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net income (loss) per ordinary share</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.01</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.08</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.04</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.02</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/>December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the Period<br/>from&#160;February&#160;21,<br/>2020 (Inception)<br/>Through<br/>December&#160;31,<br/>2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Ordinary&#160;Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Ordinary&#160;Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basic net income (loss) per ordinary share</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allocation of net income (loss), as adjusted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">783,438</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6,276</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic weighted average ordinary shares outstanding</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,820,548</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic net income (loss) per ordinary share</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.05</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Diluted net income (loss) per ordinary share</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allocation of net income (loss), as adjusted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">783,438</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6,276</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diluted weighted average ordinary shares outstanding</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,834,110</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diluted net income (loss) per ordinary share</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.05</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfCondensedBalanceSheetTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Paragraph (a)<br> -Subsection 04<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfCondensedBalanceSheetTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_VickersVantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_VickersVantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139838689904560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of valued using the compound option pricing model</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">assumptions used in the Black-Scholes option-pricing method related to options issued to employees and nonemployees for the years ended 2020 and 2019 is set forth below: </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 67%;"/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average grant date fair value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">$0.83</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;&#160;$0.87</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected dividend yield</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.00%</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.00%</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;;text-indent: 0px;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected stock-price volatility</div></div></td>
<td style="vertical-align: bottom;;text-indent: 0px;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-indent: 0px;;text-align:right;">90.00%</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-indent: 0px;;text-align:right;">89.00%<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;-&#160;</div>104.00%</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-indent: 0px;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free interest rate</div></div></td>
<td style="vertical-align: bottom;;text-indent: 0px;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-indent: 0px;;text-align:right;">0.53%</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-indent: 0px;;text-align:right;">1.63%<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;-&#160;</div>2.50%</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;;text-indent: 0px;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Term of options</div></div></td>
<td style="vertical-align: bottom;;text-indent: 0px;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-indent: 0px;;text-align:right;">5.60</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-indent: 0px;;text-align:right;">5.76<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;-&#160;</div>6.08</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value per share of common stock on date of grant</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">$1.16</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">$1.16</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercise price</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">$1.16</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">$1.16</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The follo<div style="display:inline;">w</div>ing t<div style="letter-spacing: 0px; top: 0px;;display:inline;">a</div>ble presents the Company&#8217;s financial assets and liabilities that are measured at fair value (in thousands):</div><br/></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><br/></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 40%;"/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Fair value measurements at September&#160;30, 2022</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Balance</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Quoted&#160;Prices&#160;in<br/>Active Markets<br/>(Level&#160;1)</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level&#160;2)</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Significant<br/>Unobservable&#160;Inputs<br/>(Level&#160;3)</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr>
<td style="vertical-align: top; font-size: 10pt; background-color: rgba(255, 255, 255, 0);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,483</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2,483<div style="letter-spacing: 0px; top: 0px;;display:inline;"/></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr>
<td style="vertical-align: top; font-size: 0pt; line-height: 0pt; background-color: rgba(255, 255, 255, 0);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 0pt;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);"><div style="font-size: 0pt; line-height: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; padding-bottom: 0.375pt; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets measured at fair value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">2,483</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt; background-color: rgb(204, 238, 255);;text-align:right;">2,483</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"> <div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"> <div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"> <div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td style="vertical-align:bottom"> <div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</div></td>
<td>&#160;</td></tr></table><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><br/></div><div style="clear:both;max-height:0pt;;text-indent: 0px;"/><div style="clear: both; max-height: 0px;"/><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 40%;"/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;">Fair&#160;value&#160;measurements&#160;at&#160;December&#160;31.&#160;2021</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt; border-bottom: 0.75pt solid black;;text-align:center;">Balance</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;">Quoted&#160;Prices&#160;in<br/>Active&#160;Markets<br/>(Level&#160;1)</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level&#160;2)</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;">Significant<br/>Unobservable&#160;Inputs<br/>(Level&#160;3)</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,338</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,338</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets measured at fair value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,338</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,338</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivative liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,700</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,700</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Total liabilities measured at fair <br/>value</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,700</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,700</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents the Company&#8217;s financial assets and liabilities that are measured at fair value (in </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">thousands): </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 52%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair value measurements at December&#160;31, 2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Balance</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Quoted&#160;Prices<br/>in&#160;Active<br/>Markets<br/>(Level 1)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level&#160;2)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 0px;">
<td style="width: 52%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-size: 0px;">
<td style="width: 52%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 52%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 52%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,338</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,338</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 52%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 52%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets measured at fair value</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,338</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,338</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 52%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 52%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivative liabilities</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,700</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,700</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 52%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 52%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities measured at fair value</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,700</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,700</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap;"/></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 52%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair value measurements at December&#160;31, 2020</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Balance</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Quoted&#160;Prices<br/>in&#160;Active<br/>Markets<br/>(Level&#160;1)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level&#160;2)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 52%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 52%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,839</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,839</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 52%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 52%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets measured at fair value</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,839</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,839</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 52%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 52%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivative liabilities</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,400</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,400</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 52%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Total liabilities measured at fair value</div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,400</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,400</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table includes a summary of the derivative liabilities measured at fair value using significant unobservable inputs (Level 3) during the nine months ended September&#160;30, 2022:</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 84%;"/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight:bold;display:inline;width:100%;">Fair<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>value</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,700</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value measurement</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(35,700</td>
<td style="vertical-align: bottom; white-space: nowrap;">)</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at September&#160;30, 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table includes a summary of the derivative liabilities measured at fair value using significant unobservable inputs (Level 3) during the years ended December&#160;31, 2021, 2020 and 2019: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 84%;"/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 84%; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Beginning Balance at December&#160;31, 2018</div></div></div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 84%; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additions</div></div></div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,100</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 84%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-measurement</div> of fair value</div></div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">23,300</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 84%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 84%; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ending Balance at December&#160;31, 2019</div></div></div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">33,400</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 84%; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additions</div></div></div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,800</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 84%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-measurement</div> of fair value</div></div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(800</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 84%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 84%; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ending Balance at December&#160;31, 2020</div></div></div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,400</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 84%; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additions</div></div></div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 84%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Re-measurement</div> of fair value</div></div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">300</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 84%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em;">Ending Balance at December&#160;31, 2021</div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,700</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vicker's Vantage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of fair value hierarchy of the valuation inputs</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 58%; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Description</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investments held in Trust Account <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div> U.S. Treasury Securities Money Market Fund</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">101,293,086</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">139,410,739</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Warrant Liability <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div>&#160;Private Placement Warrants</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,162,800</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,351,600</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Conversion Option Liability (see Note 5)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,892</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><span></span>
</td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 71%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Description</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investments held in Trust Account&#160;&#8212;&#160;U.S. Treasury Securities Money Market Fund</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">139,410,739</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Warrant Liability&#160;&#8212;&#160;Private Placement Warrants</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,351,600</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Conversion Option Liability (see Note 5)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,892</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueConcentrationOfRiskTextBlock', window );">Schedule of quantitative information regarding Level 3 fair value measurements</a></td>
<td class="text"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 65%;">&#160;</td>
<td style="width: 13%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="width: 12%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock price</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.33</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.04</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Strike price</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11.50</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11.50</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Term (in years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.28</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Volatility</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.03</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.28</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dividend yield</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of warrants</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.17</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.49</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><span></span>
</td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 80%;"/>
<td style="width: 15%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of<br/>December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock price</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.04</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Strike price</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11.50</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Term (in&#160;years)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.28</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Volatility</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.28</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dividend yield</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of warrants</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.49</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock', window );">Schedule of changes in the fair value of warrant liabilities</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 80%;">&#160;</td>
<td style="width: 7%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Private</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Placement</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value as of January&#160;1, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Initial measurement on January&#160;11, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,729,200</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation inputs or other assumptions</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,104,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of as of March&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,625,200</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation inputs or other assumptions</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">68,400</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of as of June&#160;30, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,693,600</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation inputs or other assumptions</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,162,800</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of as of September&#160;30, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,856,400</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation inputs or other assumptions</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,504,800</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of as of December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,351,600</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation inputs or other assumptions</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">410,400</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value as of March&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,762,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation inputs or other assumptions</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,530,800</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value as of June&#160;30, 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,231,200</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation inputs or other assumptions</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(68,400</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value as of September&#160;30, 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,162,800</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 83%;">&#160;</td>
<td style="width: 13%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Conversion</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Option</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Liability</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value as of January&#160;1, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Initial measurement on December&#160;20, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18,727</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation inputs or other assumptions</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(11,835</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of as of December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,892</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Initial measurement on January&#160;10, 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Initial measurement on January&#160;27, 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation inputs or other assumptions</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">69,896</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value as of March&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">76,788</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation inputs or other assumptions</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(76,788</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value as of June&#160;30, 2022 and September&#160;30, 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 80%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Private<br/>Placement</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value as of January&#160;1, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Initial measurement on January&#160;11, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,729,200</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation inputs or other assumptions</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,377,600</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value as of December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,351,600</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of valued using the compound option pricing model</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 65%;">&#160;</td>
<td style="width: 12%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="width: 11%; vertical-align: bottom;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September&#160;30,<br/>2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Underlying warrant value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0103</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercise price</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.75</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.75</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Holding period</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.50</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.28</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.03</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.28</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Volatility</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dividend yield</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table><span></span>
</td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 65%;"/>
<td style="width: 12%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;20,<br/>2021<br/>(Initial<br/>Measurement)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Underlying warrant value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0103</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0281</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercise price</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.75</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.75</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Holding period</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.28</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.31</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free rate %</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.28</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.19</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Volatility%</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dividend yield %</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock', window );">Schedule of change in the fair value of conversion option liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 84%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 9%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value as of January&#160;1, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Initial measurement on December&#160;20, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18,727</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(11,835</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value as of December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,892</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"/>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=SL7498348-110258<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueConcentrationOfRiskTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of all significant concentrations of risk, including credit risk and market risk, arising from all financial instruments (as defined), whether from an individual counterparty or groups of counterparties. The disclosure concerning concentrations of risk may consist of the following information: (1) for concentrations of credit risk disclosure may include: (a) information about the (shared) activity, region, or economic characteristic that identifies the concentration, (b) the maximum amount of loss due to credit risk that, based on the gross fair value of the financial instrument, the entity would incur if parties to the financial instruments that make up the concentration failed completely to perform according to the terms of the contracts and the collateral or other security, if any, for the amount due proved to be of no value to the entity, (c) the policy of requiring collateral or other security to support financial instruments subject to credit risk, information about the entity's access to that collateral or other security, and the nature and a brief description of the collateral or other security supporting those financial instruments, and (d) the policy of entering into master netting arrangements to mitigate the credit risk of financial instruments, information about the arrangements for which the entity is a party, and a brief description of the terms of those arrangements, including the extent to which they would reduce the entity's maximum amount of loss due to credit risk and (2) for disclosure of quantitative information about the market risks of financial instruments that is consistent with the way the company manages or adjusts those risks, disclosure may include: (a) more details about current positions and perhaps activity during the period, (b) the hypothetical effects on comprehensive income (or net assets), or annual income, of several possible changes in market prices, (c) a gap analysis of interest rate re-pricing or maturity dates, (d) the duration of the financial instruments, (e) the entity's value at risk from derivatives and from other positions at the end of the reporting period and the average value at risk during the year, or (f) other ways of reporting quantitative information as internally developed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13572-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 23<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13587-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueConcentrationOfRiskTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of beginning and ending balances of the fair value of plan assets of pension plans and/or other employee benefit plans showing separately, if applicable, the effects during the period attributable to each of the following: actual return on plan assets, foreign currency exchange rate changes, contributions by the employer, contributions by plan participants, benefits paid, business combinations, divestitures, and settlements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative liabilities at fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_VickersVantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_VickersVantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139838697777184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment  (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment consisted of the following as of December&#160;31, 2021 and 2020 (in thousands): </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 80%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Computers&#160;&amp; equipment</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">77</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">77</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Furniture</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">118</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">118</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leasehold improvements</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">48</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">48</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Construction in progress</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">689</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">691</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment, gross</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">932</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">934</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: Accumulated depreciation</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(127</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(88</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment, <div style="letter-spacing: 0px; top: 0px;;display:inline;">net</div></div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">805</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">846</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139838694696352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Summary of the Company's Identifiable Intangible Assets</a></td>
<td class="text">A summary of the Company&#8217;s identifiable intangible assets as of September&#160;30, 2022 and December&#160;31, 2021 is as follows (in thousands):
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 55%;"/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Nine<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>months<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>ended<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>September<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>30,<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Gross&#160;carrying<br/> amount</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Accumulated<br/> amortization</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Intangibles,&#160;net</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Patent rights</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32,630</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,871</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19,759</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquired technology</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,940</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,851</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,089</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquired licenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,711</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">92</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,619</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assembled workforce</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">350</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">150</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total intangible assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">60,781</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19,164</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">41,617</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 55%;"/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">December<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>31.<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>2021</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Gross&#160;carrying<br/> amount</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Accumulated<br/> amortization</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Intangibles,&#160;net</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Patent rights</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32,630</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,239</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,391</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquired technology</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,940</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,754</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,186</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assembled workforce</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">275</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">225</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total intangible assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">55,070</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,268</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">38,802</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
<td class="text">A summary of the Company&#8217;s identifiable intangible assets as of December&#160;31, 2021 and 2020 is as follows (in thousands):
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 61%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross&#160;<br/>carrying</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">amortization</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Intangibles,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">net</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 61%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Patent rights</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32,630</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,239</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,391</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 61%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquired technology</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,940</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,754</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,186</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em;">Assembled workforce</div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">275</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">225</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 61%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em;">Total intangible assets</div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">55,070</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,268</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">38,802</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 61%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross&#160;<br/>carrying</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">amortization</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Intangibles,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">net</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 61%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Patent rights</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32,630</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,064</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">23,566</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 61%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquired technology</div></div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,940</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,291</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18,649</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em;">Assembled workforce</div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">175</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">325</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 61%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em;">Total intangible assets</div></td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">55,070</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,530</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">42,540</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Summary of Estimated Future Amortization Expense</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; font-size: 10pt; top: 0px;;display:inline;">Estimated future amortization expense related to intangible assets at September&#160;30, 2022 is as follows (in tho</div>us<div style="letter-spacing: 0px; font-size: 10pt; top: 0px;;display:inline;">ands):</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 85%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap;">Year ended December&#160;31,</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;">Amount</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022 (remaining three months)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,027</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,106</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,031</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,006</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2026</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,006</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Thereafter</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">24,441</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">41,617</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><span></span>
</td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Estimated future amortization expense related to intangible assets at December&#160;31, 2021 is as follows (in thousands): </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 85%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ending December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,738</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,738</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,663</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,638</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2026</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,638</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Thereafter</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20,387</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">38,802</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139838694631584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Summary of Borrowings of the Scilex Pharma Notes</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Borrowings of the Scilex Notes consisted of the following (in thousands):</div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><br/></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 67%;"/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">September&#160;30,<br/>2022</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">December&#160;31,<br/>2021</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Principal</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">133,997</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unamortized debt discount</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(30,597</td>
<td style="vertical-align: bottom; white-space: nowrap;">)</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unamortized debt issuance costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,228</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Carrying value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">101,172</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current portion</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(29,135</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long term portion</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">72,037</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Estimated fair value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">115,400</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><span></span>
</td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Borrowings of the Scilex Pharma Notes are as follows (in thousands): </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 72%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Principal</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">133,997</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">151,872</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unamortized debt discount</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(30,597</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(51,022</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unamortized debt issuance costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,228</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,711</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Carrying value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">101,172</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">97,139</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current portion</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(29,135</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,881</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long term portion</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">72,037</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">92,258</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Estimated fair value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">115,400</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">122,300</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtTableTextBlock', window );">Summary of Future Minimum Payments Under the Scilex Pharma Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Future minimum payments under the Scilex Pharma Notes, based on a percentage of projected net sales of ZTlido are estimated as follows (in thousands): </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 83%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ending December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 83%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">29,135</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 83%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,005</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 83%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,637</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 83%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,746</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 83%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2026</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">64,474</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 83%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 83%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total minimum future payments</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">133,997</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of future minimum payments of long term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21538-112644<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139838696428272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive and Employee Benefit Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CompensationAndEmployeeBenefitPlansAbstract', window );"><strong>Compensation And Employee Benefit Plans [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary Of Share Based Payment Award Options Issued To Employees And Nonemployees Valuation Assumptions</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">assumptions used in the Black-Scholes option-pricing method related to options issued to employees and nonemployees for the years ended 2020 and 2019 is set forth below: </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 67%;"/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average grant date fair value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">$0.83</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;&#160;$0.87</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected dividend yield</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.00%</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.00%</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;;text-indent: 0px;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected stock-price volatility</div></div></td>
<td style="vertical-align: bottom;;text-indent: 0px;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-indent: 0px;;text-align:right;">90.00%</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-indent: 0px;;text-align:right;">89.00%<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;-&#160;</div>104.00%</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-indent: 0px;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free interest rate</div></div></td>
<td style="vertical-align: bottom;;text-indent: 0px;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-indent: 0px;;text-align:right;">0.53%</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-indent: 0px;;text-align:right;">1.63%<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;-&#160;</div>2.50%</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;;text-indent: 0px;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Term of options</div></div></td>
<td style="vertical-align: bottom;;text-indent: 0px;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-indent: 0px;;text-align:right;">5.60</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-indent: 0px;;text-align:right;">5.76<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;-&#160;</div>6.08</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value per share of common stock on date of grant</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">$1.16</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">$1.16</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercise price</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">$1.16</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">$1.16</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary Of The Options Outstanding</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following represents a summary of the options outstanding at December&#160;31, 2021, 2020, and 2019 changes during the years then ended (in thousands, other than weighted-average exercise price): </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 62%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Options</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/>average<br/>exercise&#160;price</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate<br/>Intrinsic<br/>Value</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 0px;">
<td style="width: 62%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 62%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at December&#160;31, 2018</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,781</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.63</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,291</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 62%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,468</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.16</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 62%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercised</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 62%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited/Cancelled</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(838</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.94</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 62%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 62%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at December&#160;31, 2019</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,411</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.07</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,183</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 62%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,194</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.16</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 62%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercised</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(56</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.90</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 62%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited/Cancelled</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(745</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.94</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 62%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 62%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30,804</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.10</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,172</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt; width: 62%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt; width: 62%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercised</div></div></div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt; width: 62%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited/Cancelled</div></div></div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(2,641</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">0.68</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; width: 62%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt; width: 62%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at December&#160;31, 2021</div></div></div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">28,163</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1.13</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">915</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt; width: 62%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercisable at December&#160;31, 2021</div></div></div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">17,177</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1.11</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 7%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_CompensationAndEmployeeBenefitPlansAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Compensation and employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_CompensationAndEmployeeBenefitPlansAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139838694731904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Summary of Components of Lease Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The components of lease expense were as follows (in thousands):</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 76%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease cost*</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">623</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">904</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">776</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">*</div></td>
<td style="vertical-align: top; font-size: 10pt;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inclusive of variable lease costs, sublease income, and impairment, which were immaterial for the periods presented. </div></div></div></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ScheduleOfSupplementalQuantitativeInformationRelatedToLeasesTableTextBlock', window );">Summary of Supplemental Quantitative Information Related To Leases</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplemental quantitative information related to leases includes the following: </div></div><br/></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><br/></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 81%;"/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Nine&#160;Months&#160;Ended<br/>September&#160;30,</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2022</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2021</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 0px;">
<td style="width: 69%;"/>
<td style="width: 14%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 13%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt; width: 69%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash paid for amounts included in the measurement of lease liabilities:</div></div></div></td>
<td style="vertical-align: bottom; width: 14%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-size: 0px;">
<td style="width: 69%;"/>
<td style="width: 14%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 13%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 69%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Operating cash flows from operating leases</div></td>
<td style="vertical-align: bottom; width: 14%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">531</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">489</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 69%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">ROU assets obtained in exchange for new operating lease<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>liabilities</div></td>
<td style="vertical-align: bottom; width: 14%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">320</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 69%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Weighted average remaining lease term in years &#8212; operating leases</div></td>
<td style="vertical-align: bottom; width: 14%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 69%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Weighted average discount rate &#8212; operating leases</div></td>
<td style="vertical-align: bottom; width: 14%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 13%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table><span></span>
</td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplemental quantitative information related to leases includes the following: </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 74%;"/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;Ended&#160;December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;2021&#160;&#160;&#160;&#160;&#160;&#160;</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;2020&#160;&#160;&#160;&#160;&#160;&#160;</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 0px;">
<td style="width: 74%;"/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 74%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash paid for amounts included in the measurement of lease <br/>liabilities:</div></div></td>
<td style="vertical-align: bottom; width: 10%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 74%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating cash flows from operating leases</div></div></td>
<td style="vertical-align: bottom; width: 10%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(654</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(833</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 74%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average remaining lease term in&#160;years&#160;&#8212;&#160;operating <br/>leases</div></div></td>
<td style="vertical-align: bottom; width: 10%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 74%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average discount rate&#160;&#8212;&#160;operating leases</div></div></td>
<td style="vertical-align: bottom; width: 10%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Maturities of Lease Liabilities</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Maturities of lease liabilities were as follows (in thousands):</div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 87%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Year Ending December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); text-align: center;">Amount</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022 (Remaining three months)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">215</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">872</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">703</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2026</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total lease payments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,790</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less imputed interest</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(210</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total lease liabilities as of September&#160;30, 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,580</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Maturities of lease liabilities were as follows (in thousands): </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 86%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Year Ending December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">674</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">694</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">596</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2026</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total lease payments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,964</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less imputed interest</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(316</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total lease liabilities as of December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,648</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ScheduleOfSupplementalQuantitativeInformationRelatedToLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of supplemental quantitative information related to leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ScheduleOfSupplementalQuantitativeInformationRelatedToLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139838696428272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restatement of Previously Issued Financial Statements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vicker's Vantage</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Condensed Financial Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfCondensedFinancialStatementsTableTextBlock', window );">Schedule of impact of these adjustments to the financial statement, as previously reported</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The impact of these adjustments to the financial statement, as previously reported, is presented below. </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 48%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As Previously<br/>Reported</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Adjustments<br/>Restatement&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Adjustments<br/>Restatement 2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As<br/>Restated</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance sheet as of January&#160;11, 2021</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Warrant Liability</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,729,200</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,729,200</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,345,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,729,200</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,074,200</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ordinary Shares Subject to Possible Redemption</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">129,999,029</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7,729,200</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,110,171</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">139,380,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ordinary Shares</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">438</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">76</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(169</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">345</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Paid-in</div> Capital</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,006,060</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,629,336</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7,635,396</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated Deficit</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6,490</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,629,412</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(9,474,606</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(12,110,508</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Shareholders&#8217; Equity (Deficit)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,000,008</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(17,110,171</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(12,110,163</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedFinancialStatementsCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedFinancialStatementsCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfCondensedFinancialStatementsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of condensed financial statements, including, but not limited to, the balance sheet, income statement, and statement of cash flows.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Paragraph (a)<br> -Subsection 04<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfCondensedFinancialStatementsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_VickersVantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_VickersVantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139838694492976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of components of income tax expense (benefit)</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total loss before income taxes for the&#160;years ended December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2021<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2020<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> and </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> did not include a foreign component. The components of benefits for income taxes were as follows for the period ended December&#160;</div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> (in thousands):</div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 76%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current expense:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Federal</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">State</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(53</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(53</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Federal</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">State</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(53</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of deferred tax assets and liabilities</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The components of the Company&#8217;s net deferred tax liabilities and related valuation allowance are as follows at December&#160;31 (in thousands): </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 73%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 73%; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax assets</div></div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 73%; background-color: rgb(255, 255, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest expense limitations</div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">12,205</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">8,225</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 73%; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tax credit carryforwards</div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">1,630</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">1,623</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 73%; background-color: rgb(255, 255, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net operating loss carryforwards</div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">39,714</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">31,732</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 73%; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock based compensation</div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">3,233</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">2,037</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 73%; background-color: rgb(255, 255, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease liabilities</div></div></td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">404</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">510</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em;">Others</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">1,753</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">2,285</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(255, 255, 255); width: 73%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 73%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Deferred Tax Assets</div></div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">58,939</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">46,412</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr>
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 73%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Valuation allowance</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="line-height: normal;"><div style="null;text-indent: 0px;;font-weight:bold;display:inline;width:100%;">&#160;</div><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">(56,643</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">(43,514</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="line-height: normal;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td>
<td style="background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td>
<td style="background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255);"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Deferred Tax Assets</div></div></div></div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,296</div></div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,898</div></div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td>
<td style="background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td>
<td style="background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred Tax Liabilities:</div></div></div></div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr>
<td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 73%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amortization of intangibles</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; text-align: right; background-color: rgb(255, 255, 255);">(1,975</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">(2,486</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">)&#160;</td></tr>
<tr>
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em;">Other</div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; text-align: right; background-color: rgb(204, 238, 255);">(2</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr>
<td style="vertical-align: top; background-color: rgb(255, 255, 255); padding-bottom: 0.375pt; width: 73%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets</div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); padding-bottom: 0.375pt; width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; text-align: right; background-color: rgb(255, 255, 255); border-bottom: 0.75pt solid black;">(319</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); padding-bottom: 0.375pt;">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); padding-bottom: 0.375pt; width: 6%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); border-bottom: 0.75pt solid black;;text-align:right;">(412</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); padding-bottom: 0.375pt;">)&#160;</td></tr>
<tr>
<td style="vertical-align: top; background-color: rgb(204, 238, 255); padding-bottom: 0.75pt; width: 73%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Deferred Tax Liabilities</div></div></div></td>
<td style="vertical-align: bottom; padding: 0px 0px 0.75pt; background-color: rgb(204, 238, 255); width: 6%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px; text-align: right; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2,296</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.75pt; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; padding: 0px 0px 0.75pt; background-color: rgb(204, 238, 255); width: 6%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2,898</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); padding-bottom: 0.75pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td>
<td style="background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of effective income tax rate reconciliation</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The reconciliation between U.S. federal income taxes at the statutory rate and the Company&#8217;s benefit from income taxes are as follows for the year ended December 31: </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 75%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Statutory Federal Income Tax Rate</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">State taxes, net of federal tax benefit</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Debt discount and interest limitation</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(10.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">In-process</div> research and development</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(11.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Return to provision adjustments and carryback</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(11.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Others</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1.6</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation allowance</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(14.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(13.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(14.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4.8em;">Income Tax Benefit</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139838694588304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Summary of reconciliation of basic and diluted loss per share</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> table sets forth the reconciliation of basic and diluted loss per share for the nine months ended September&#160;30, 2022 and 2021 (in thousands except per share data):</div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 72%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Nine&#160;Months&#160;Ended<br/>September&#160;30,</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">2022</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">2021</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5,480</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(46,459</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator for Basic Loss Per Share</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">197,550</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">197,266</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Effect of Dilutive Securities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator for Diluted Loss per Share &#8212; Adjusted for Dilutive Securities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">197,550</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">197,266</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic Loss Per Share</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.03</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.24</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dilutive Loss Per Share</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.03</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.24</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr></table><span></span>
</td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth the reconciliation of basic and diluted loss per share for the&#160;years ended December&#160;31, 2021, 2020, and 2019 (in thousands except per share data):</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 60%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt; border-bottom: 0.75pt solid black;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt; border-bottom: 0.75pt solid black;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(88,424</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(47,519</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(178,594</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator for Basic Loss Per Share</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">197,266</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">197,315</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">187,524</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Effect of Dilutive Securities</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Denominator for Diluted Loss per Share &#8212; Adjusted for Dilutive Securities</div><br/></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">197,266</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">197,315</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">187,524</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic Loss Per Share</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(0.45</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(0.24</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(0.95</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dilutive Loss Per Share</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">(0.45</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">(0.24</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">(0.95</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">)&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139838684077024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Organization and Business Operations (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 11, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 10, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Feb. 28, 2019</div></th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>Day </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 11, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 18, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 11, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 20, 2021 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 18, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems', window );"><strong>Description of Organization and Business Operations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Company place of incorporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sclx_SorrentoMember', window );">Sorrento [Member] | Reorganization [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems', window );"><strong>Description of Organization and Business Operations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vickers Vantage [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems', window );"><strong>Description of Organization and Business Operations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Warrant price per share (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DemutualizationByInsuranceEntitySecuritiesIssuedGrossCashProceeds', window );">Gross proceeds</a></td>
<td class="nump">$ 138,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Sale of warrants (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,840,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts', window );">Transaction costs amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,149,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherUnderwritingExpense', window );">Cash underwriting fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DeferredUnderwritingFees', window );">Deferred underwriting fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,190,000<span></span>
</td>
<td class="nump">5,190,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOwnershipInterestsOfferingCosts', window );">Other offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">559,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoninterestBearingDepositLiabilities', window );">Non-interest-bearing loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,365,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsHeldInTrust', window );">Deposited trust account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 101,293,086<span></span>
</td>
<td class="nump">$ 139,410,739<span></span>
</td>
<td class="nump">$ 1,295,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SaleOfStockDescriptionOfTransactions', window );">Sale of stock, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The stock exchange listing rules require that the Business Combination must be with one or more operating businesses or assets with a fair market value equal to at least 80% of the assets held in the Trust Account (as defined below) (less any deferred underwriting commissions and taxes payable on the interest earned on the Trust Account). The Company will only complete a Business Combination if the post-Business Combination company owns or acquires 50% or more of the issued and outstanding voting securities of the target or otherwise acquires a controlling interest in the target business sufficient for it not to be required to register as an investment company under the Investment Company Act of 1940, as amended (the &#8220;Investment Company Act&#8221;). There is no assurance that the Company will be able to successfully effect a Business Combination.<span></span>
</td>
<td class="text">The stock exchange listing rules require that the Business Combination must be with one or more operating businesses or assets with a fair market value equal to at least 80% of the assets held in the Trust Account (as defined below) (less any deferred underwriting commissions and taxes payable on the interest earned on the Trust Account). TheCompany will only complete a Business Combination if the post-Business Combination company owns or acquires 50% or more of the issued and outstanding voting securities of the target or otherwise acquires a controlling interest in the target business sufficient for it not to be required to register as an investment company under the Investment Company Act of 1940, as amended (the &#8220;Investment Company Act&#8221;). There is no assurance that the Company will be able to successfully effect a Business Combination.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PricePerPublicShare', window );">Anticipated public share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.38<span></span>
</td>
<td class="nump">$ 10.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIntangibleAssetsNet', window );">Net tangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PercentageOfPublicShares', window );">Percentage of public shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_BusinessCombinationRedeemPercentage', window );">Business combination redeem percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherExpenses', window );">Dissolution expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DepositIntoTheTrustAccountPerShare', window );">Deposit into the trust account per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_LesserPublicPerShare', window );">Lesser public per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquiredReceivablesDescription', window );">Business combination description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In connection with its solicitation of proxies in connection with the Extension Proposal, the Company was required to permit its public shareholders to redeem their ordinary shares. Of the 13,800,000 ordinary shares outstanding with redemption rights, the holders of 4,073,605 ordinary shares elected to redeem their shares at a per share redemption price of $10.25. As a result, approximately $41.8 million was removed from the Trust Account to pay such holders and approximately $99.8 million remained in the Trust Account. Following the redemptions, the Company has 9,726,395 ordinary shares with redemption rights outstanding and the Company will deposit $323,888 (or approximately $0.0333 per ordinary share that remains outstanding) for each calendar month, or portion thereof, that is needed by the Company to complete an initial business combination from July 11, 2022.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Opening bank account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_WorkingCapital', window );">Working capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">643,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeDepositWithFinancialInstitutionIncreaseDecrease', window );">Deposit interest income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">696,000<span></span>
</td>
<td class="nump">$ 31,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ProceedsOfInitialPublicOffering', window );">Proceeds of initial public offering</a></td>
<td class="nump">$ 138,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_Transactioncostsamount', window );">Transaction costs amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,149,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_Otherofferingcosts', window );">OtherOfferingCosts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 559,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_Numberofbusinessdays', window );">Number of business days | Day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_NetTangibleAssets', window );">Net tangible assets (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,001<span></span>
</td>
<td class="nump">$ 5,000,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_Depositintotrustaccount', window );">Deposit into trust account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,035,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_Interestexpenses', window );">Interest Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,961<span></span>
</td>
<td class="nump">507,921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Working capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 303,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member] | Vickers Vantage [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems', window );"><strong>Description of Organization and Business Operations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Number of shares (in Shares) | shares</a></td>
<td class="nump">13,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Warrant price per share (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 10.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of units amount</a></td>
<td class="nump">$ 139,380,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_Numberofshares', window );">Number of shares (in Shares) | shares</a></td>
<td class="nump">13,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_Saleofwarrants', window );">Sale of warrants (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,840,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option [Member] | Vickers Vantage [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems', window );"><strong>Description of Organization and Business Operations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Number of shares (in Shares) | shares</a></td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PricePerPublicShare', window );">Anticipated public share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_Numberofshares', window );">Number of shares (in Shares) | shares</a></td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_Depositintotrustaccount', window );">Deposit into trust account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,035,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sclx_PrivatePlacementWarrantMember', window );">Private Placement Warrant [Member] | Vickers Vantage [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems', window );"><strong>Description of Organization and Business Operations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Warrant price per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_Grossproceedsofwarrants', window );">Gross proceeds of amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember', window );">Business Combination [Member] | Vickers Vantage [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems', window );"><strong>Description of Organization and Business Operations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage', window );">Redeem percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sclx_ScilexPharmaMember', window );">Scilex Pharma [Member] | Contribution And Loan Agreement [Member] | Reorganization [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems', window );"><strong>Description of Organization and Business Operations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Business combination equity interest acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sclx_VantageMergerSubIncMember', window );">Vantage Merger Sub Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems', window );"><strong>Description of Organization and Business Operations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts', window );">Transaction costs amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,300,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Gross proceeds from business combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sclx_VantageMergerSubIncMember', window );">Vantage Merger Sub Inc [Member] | Debt Exchange Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems', window );"><strong>Description of Organization and Business Operations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Equity interest from business combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 290,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=sclx_SponsorMember', window );">Sponsor [Member] | Vickers Vantage [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems', window );"><strong>Description of Organization and Business Operations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_BusinessCombinationRedeemPercentage', window );">Business combination redeem percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_BusinessCombinationRedeemPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business combination redeem percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_BusinessCombinationRedeemPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_DeferredUnderwritingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred underwriting fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_DeferredUnderwritingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_DepositIntoTheTrustAccountPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deposit into the trust account per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_DepositIntoTheTrustAccountPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_Depositintotrustaccount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deposit Into Trust Account.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_Depositintotrustaccount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_Grossproceedsofwarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross Proceeds Of Warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_Grossproceedsofwarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_Interestexpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_Interestexpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_LesserPublicPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lesser public per share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_LesserPublicPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_NetTangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net tangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_NetTangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_Numberofbusinessdays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Business Days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_Numberofbusinessdays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_Numberofshares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_Numberofshares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_Otherofferingcosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>OtherOfferingCosts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_Otherofferingcosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PercentageOfPublicShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of public shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PercentageOfPublicShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PricePerPublicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PricePerPublicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ProceedsOfInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds Of Initial Public Offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ProceedsOfInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_SaleOfStockDescriptionOfTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of stock description of transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_SaleOfStockDescriptionOfTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_Saleofwarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_Saleofwarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_Transactioncostsamount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transaction Costs Amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_Transactioncostsamount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_WorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Working capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_WorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldInTrust">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of cash and securities held by third party trustees pursuant to terms of debt instruments or other agreements as of the date of each statement of financial position presented, which can be used by the trustee only to pay the noncurrent portion of specified obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsHeldInTrust</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquiredReceivablesDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of receivable acquired in business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquiredReceivablesDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of equity in the acquiree held by the acquirer immediately before the acquisition date in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DemutualizationByInsuranceEntitySecuritiesIssuedGrossCashProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share or unit times the number of shares or units issued in an insurance entity stock offering in connection with its conversion from a mutual form of ownership to a stock entity. Amount is gross, before offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 805<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124505872&amp;loc=d3e30785-158569<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DemutualizationByInsuranceEntitySecuritiesIssuedGrossCashProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeDepositWithFinancialInstitutionIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in interest income on deposit with financial institution.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph (c)<br> -Subparagraph (2)(iii)<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph (a)<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph (c)<br> -Subparagraph (2)(i)<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph (c)<br> -Subparagraph (2)(ii)<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeDepositWithFinancialInstitutionIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoninterestBearingDepositLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of all domestic and foreign noninterest-bearing deposits liabilities held by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.12)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoninterestBearingDepositLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4,6)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated amortization of finite-lived and indefinite-lived intangible assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOwnershipInterestsOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of offering costs allocated to the other unit holders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB TOPIC 4.F)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187171-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOwnershipInterestsOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherUnderwritingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Costs incurred during the period, such as those relating to general administration and policy maintenance that do not vary with and are not primarily related to the acquisition or renewal of insurance contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 720<br> -Section 25<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=35755714&amp;loc=d3e28434-158551<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherUnderwritingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sclx_SorrentoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sclx_SorrentoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_EventAxis=sclx_ReorganizationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_EventAxis=sclx_ReorganizationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_VickersVantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_VickersVantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sclx_PrivatePlacementWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sclx_PrivatePlacementWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=sclx_ScilexPharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=sclx_ScilexPharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AgreementAxis=sclx_ContributionAndLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AgreementAxis=sclx_ContributionAndLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=sclx_VantageMergerSubIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=sclx_VantageMergerSubIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AgreementAxis=sclx_DebtExchangeAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AgreementAxis=sclx_DebtExchangeAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=sclx_SponsorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=sclx_SponsorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139838692012560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Credit losses on accounts receivable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Sole Distributor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vicker's Vantage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherDeferredCostsNet', window );">Offering costs amount</a></td>
<td class="nump">$ 8,119,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,119,261<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExcessStockSharesIssued', window );">Purchase of ordinary shares (in Shares)</a></td>
<td class="nump">13,740,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,740,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Federal depository insurance coverage</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_Foundershares', window );">Founder shares (in Shares)</a></td>
<td class="nump">450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vicker's Vantage | Initial Public Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherDeferredCostsNet', window );">Offering costs amount</a></td>
<td class="nump">$ 30,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,212<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_Foundershares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Founder Shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_Foundershares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExcessStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of excess stock shares of an entity that have been sold or granted to shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExcessStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherDeferredCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net amount of other deferred costs capitalized at the end of the reporting period. Does not include deferred finance costs or deferred acquisition costs of insurance companies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherDeferredCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=sclx_SoleDistributorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=sclx_SoleDistributorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_VickersVantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_VickersVantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139838683946112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - Schedule of ordinary shares reflected in condensed consolidated balance sheets are reconciled - Vickers Vantage [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_GrossProceeds', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 138,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_LessAbstract', window );"><strong>Less:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_OrdinarySharesIssuanceCost', window );">Ordinary shares issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,119,261)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PlusAbstract', window );"><strong>Plus:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AccretionOfCarryingValueToRedemptionValue', window );">Accretion of carrying value to redemption value</a></td>
<td class="nump">$ 3,737,378<span></span>
</td>
<td class="nump">9,499,261<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment', window );">Accretion of carrying value to redemption value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,499,261<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SharesSubjectToPossibleRedemption', window );">Ordinary shares subject to possible redemption</a></td>
<td class="nump">101,293,086<span></span>
</td>
<td class="nump">$ 139,380,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_LessAbstract0', window );"><strong>Less:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityOtherChanges', window );">Mandatorily redeemable ordinary shares</a></td>
<td class="num">$ (41,824,292)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AccretionOfCarryingValueToRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AccretionOfCarryingValueToRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_GrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_GrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_LessAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_LessAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_LessAbstract0">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_LessAbstract0</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_OrdinarySharesIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_OrdinarySharesIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PlusAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PlusAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_SharesSubjectToPossibleRedemption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ordinary shares subject to possible redemption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_SharesSubjectToPossibleRedemption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityOtherChanges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in temporary equity from changes classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityOtherChanges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_VickersVantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_VickersVantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139838691499232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - Schedule of reflects the calculation of basic and diluted net income (loss) per ordinary share - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">10 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2020</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DenominatorAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic and diluted net income (loss) per ordinary share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (0.45)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="num">$ (0.95)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding, ordinary shares (in Shares) , Basic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,550<span></span>
</td>
<td class="nump">197,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">197,266<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">197,315<span></span>
</td>
<td class="nump">187,524<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding, ordinary shares (in Shares) , diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,550<span></span>
</td>
<td class="nump">197,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">197,266<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">197,315<span></span>
</td>
<td class="nump">187,524<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net income (loss) per ordinary share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (0.45)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="num">$ (0.95)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vickers Vantage [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_NumeratorAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityNetIncome', window );">Allocation of net income (loss)</a></td>
<td class="num">$ (131,387)<span></span>
</td>
<td class="num">$ (1,444,352)<span></span>
</td>
<td class="nump">$ 623,516<span></span>
</td>
<td class="num">$ (349,248)<span></span>
</td>
<td class="num">$ (6,276)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 783,438<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DenominatorAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic', window );">Basic and diluted weighted average ordinary shares outstanding</a></td>
<td class="nump">13,176,395<span></span>
</td>
<td class="nump">17,250,000<span></span>
</td>
<td class="nump">15,862,288<span></span>
</td>
<td class="nump">16,675,824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic and diluted net income (loss) per ordinary share</a></td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="num">$ (0.08)<span></span>
</td>
<td class="nump">$ 0.04<span></span>
</td>
<td class="num">$ (0.02)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding, ordinary shares (in Shares) , Basic</a></td>
<td class="nump">13,176,395<span></span>
</td>
<td class="nump">17,250,000<span></span>
</td>
<td class="nump">15,862,288<span></span>
</td>
<td class="nump">16,675,824<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">16,820,548<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding, ordinary shares (in Shares) , diluted</a></td>
<td class="nump">13,176,395<span></span>
</td>
<td class="nump">17,250,000<span></span>
</td>
<td class="nump">15,862,288<span></span>
</td>
<td class="nump">16,675,824<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">16,834,110<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net income (loss) per ordinary share</a></td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="num">$ (0.08)<span></span>
</td>
<td class="nump">$ 0.04<span></span>
</td>
<td class="num">$ (0.02)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="11"></td></tr>
<tr><td colspan="11"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">At December 31, 2020, excludes an aggregate of up to 450,000 ordinary shares that were subject to forfeiture.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_DenominatorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_DenominatorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_NumeratorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_NumeratorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityNetIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of net income or loss attributable to temporary equity interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityNetIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesIssuedBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e2646-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesIssuedBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_VickersVantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_VickersVantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139838691623792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - Schedule of reflects the calculation of basic and diluted net income (loss) per ordinary share (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">10 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Basic and diluted weighted average ordinary shares outstanding (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,550<span></span>
</td>
<td class="nump">197,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,266<span></span>
</td>
<td class="nump">197,315<span></span>
</td>
<td class="nump">187,524<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Basic and diluted net income (loss) per ordinary share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.45)<span></span>
</td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="num">$ (0.95)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vickers Vantage [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Basic and diluted weighted average ordinary shares outstanding (in Shares)</a></td>
<td class="nump">13,176,395<span></span>
</td>
<td class="nump">17,250,000<span></span>
</td>
<td class="nump">15,862,288<span></span>
</td>
<td class="nump">16,675,824<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="nump">16,834,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Basic and diluted net income (loss) per ordinary share (in Dollars per share)</a></td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="num">$ (0.08)<span></span>
</td>
<td class="nump">$ 0.04<span></span>
</td>
<td class="num">$ (0.02)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_VickersVantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_VickersVantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139838691426672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity and Going Concern (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Oct. 17, 2022</div></th>
<th class="th"><div>Sep. 28, 2022</div></th>
<th class="th"><div>Feb. 28, 2022</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_LiquidityAndGoingConcernLineItems', window );"><strong>Liquidity And Going Concern [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_NetWorkingCapital', window );">Net working capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 219,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 146,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,483,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,338,000<span></span>
</td>
<td class="nump">$ 4,839,000<span></span>
</td>
<td class="nump">$ 10,295,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,893,000<span></span>
</td>
<td class="nump">$ 25,421,000<span></span>
</td>
<td class="nump">35,838,000<span></span>
</td>
<td class="nump">35,258,000<span></span>
</td>
<td class="nump">138,695,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash flow from operation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,533,000<span></span>
</td>
<td class="nump">$ 22,707,000<span></span>
</td>
<td class="nump">28,664,000<span></span>
</td>
<td class="nump">31,461,000<span></span>
</td>
<td class="nump">60,421,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">358,030,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">352,550,000<span></span>
</td>
<td class="nump">264,126,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAnnualPrincipalPayment', window );">Debt Instrument, Annual Principal Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,900,000<span></span>
</td>
<td class="nump">$ 69,800,000<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinimumNetWorthRequiredForCompliance', window );">Minimum net worth to consummate business combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=sclx_FundingCommitmentLetterMember', window );">Funding Commitment Letter [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_LiquidityAndGoingConcernLineItems', window );"><strong>Liquidity And Going Concern [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of Credit Facility, Maximum Borrowing Capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AggregateOutstandingAmount', window );">Aggregate Outstanding Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">310,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sclx_ScilexPharmaNotesMember', window );">Scilex Pharma Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_LiquidityAndGoingConcernLineItems', window );"><strong>Liquidity And Going Concern [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAnnualPrincipalPayment', window );">Debt Instrument, Annual Principal Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentDecreaseForgiveness', window );">Debt instrument, decrease, forgiveness</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent', window );">Notes Payable, Related Parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_LiquidityAndGoingConcernLineItems', window );"><strong>Liquidity And Going Concern [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinimumNetWorthRequiredForCompliance', window );">Minimum net worth to consummate business combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Funding Commitment Letter [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_LiquidityAndGoingConcernLineItems', window );"><strong>Liquidity And Going Concern [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of Credit Facility, Maximum Borrowing Capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AggregateOutstandingAmount', window );">Aggregate Outstanding Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 310,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_ScilexPharmaMember', window );">Scilex Pharma [Member] | Senior Secured Notes Due Two Thousand And Twenty Six [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_LiquidityAndGoingConcernLineItems', window );"><strong>Liquidity And Going Concern [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="nump">$ 224,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt', window );">Proceeds from senior secured notes</a></td>
<td class="nump">140,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_MinimumUnrestrictedCashBalance', window );">Minimum unrestricted cash balance</a></td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Debt instrument face amount of debt repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000<span></span>
</td>
<td class="nump">$ 65,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RestrictedFundsRelesableForFutureRepurchaseOfDebt', window );">Restricted funds releasable for future repurchase of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_ScilexPharmaMember', window );">Scilex Pharma [Member] | Senior Secured Notes Due Two Thousand And Twenty Six [Member] | Cumulative Sales Related Contingency [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_LiquidityAndGoingConcernLineItems', window );"><strong>Liquidity And Going Concern [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_ScilexPharmaMember', window );">Scilex Pharma [Member] | Senior Secured Notes Due Two Thousand And Twenty Six [Member] | Letter Of Credit Drawn Down [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_LiquidityAndGoingConcernLineItems', window );"><strong>Liquidity And Going Concern [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_MinimumUnrestrictedCashBalance', window );">Minimum unrestricted cash balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DebtInstrumentRepurchaseObligation', window );">Debt instrument repurchase obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AggregateOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate outstanding amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AggregateOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_DebtInstrumentRepurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Repurchase Obligation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_DebtInstrumentRepurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_LiquidityAndGoingConcernLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liquidity and going concern.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_LiquidityAndGoingConcernLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_MinimumUnrestrictedCashBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum unrestricted cash balance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_MinimumUnrestrictedCashBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_NetWorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net working capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_NetWorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_RestrictedFundsRelesableForFutureRepurchaseOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restricted funds relesable for future repurchase of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_RestrictedFundsRelesableForFutureRepurchaseOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAnnualPrincipalPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the total principal payments made during the annual reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAnnualPrincipalPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDecreaseForgiveness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease for amounts of indebtedness forgiven by the holder of the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDecreaseForgiveness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchasedFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of the original debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchasedFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinimumNetWorthRequiredForCompliance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum net worth required for mortgage banking as defined by regulatory framework.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 948<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6490092&amp;loc=d3e47304-110998<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 948<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6490092&amp;loc=d3e47304-110998<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 948<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=6490092&amp;loc=d3e47080-110998<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 948<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6490092&amp;loc=d3e47304-110998<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinimumNetWorthRequiredForCompliance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount for notes payable (written promise to pay), due to related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=sclx_FundingCommitmentLetterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=sclx_FundingCommitmentLetterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=sclx_ScilexPharmaNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=sclx_ScilexPharmaNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_ScilexPharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_ScilexPharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=sclx_SeniorSecuredNotesDueTwoThousandAndTwentySixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=sclx_SeniorSecuredNotesDueTwoThousandAndTwentySixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_EventAxis=sclx_CumulativeSalesRelatedContingencyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_EventAxis=sclx_CumulativeSalesRelatedContingencyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_EventAxis=sclx_LetterOfCreditDrawnDownMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_EventAxis=sclx_LetterOfCreditDrawnDownMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139838683947584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Public Offering (Details) - Vickers Vantage [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PublicOfferingDetailsLineItems', window );"><strong>Public Offering (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PurchasePricePerShare', window );">Purchase price per unit (in Dollars per share)</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PublicOfferingDetailsLineItems', window );"><strong>Public Offering (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Shares issued related to Semnur Acquisition , shares</a></td>
<td class="nump">13,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockDescriptionOfTransaction', window );">Sale of stock, description</a></td>
<td class="text">Each Unit consists of one ordinary share and one-half of one redeemable warrant (&#8220;Public Warrant&#8221;). Each whole Public Warrant entitles the holder to purchase one ordinary share at an exercise price of $11.50 per whole share (see Note 7).<span></span>
</td>
<td class="text">Each Unit consists of one ordinary share and one-half of one redeemable warrant (&#8220;Public Warrant&#8221;). Each whole Public Warrant entitles the holder to purchase one ordinary share at an exercise price of $11.50 per whole share (see Note 7).<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_NumberOfSaleUnits', window );">Number of sale units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Over-Allotment Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PublicOfferingDetailsLineItems', window );"><strong>Public Offering (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Shares issued related to Semnur Acquisition , shares</a></td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_NumberOfSaleUnits', window );">Number of sale units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_NumberOfSaleUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of sale units</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_NumberOfSaleUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PublicOfferingDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PublicOfferingDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PurchasePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PurchasePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockDescriptionOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of stock transaction which may include details of the offering (IPO, private placement), a description of the stock sold, percentage of subsidiary's or equity investee's stock sold, a description of the investors and whether the stock was issued in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569655-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockDescriptionOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_VickersVantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_VickersVantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139838685928096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Private Placement (Details) - Vickers Vantage [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">10 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PrivatePlacementDetailsLineItems', window );"><strong>Private Placement (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Aggregate purchase of private placement warrants (in Shares)</a></td>
<td class="nump">6,840,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Aggregate purchase price (in Dollars)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5,130,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 5,130,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PrivatePlacementDetailsLineItems', window );"><strong>Private Placement (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Aggregate purchase of private placement warrants (in Shares)</a></td>
<td class="nump">6,840,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,840,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Price per warrant</a></td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Aggregate purchase price (in Dollars)</a></td>
<td class="nump">$ 5,130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,130,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Ordinary share, per share</a></td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PrivatePlacementDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PrivatePlacementDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_VickersVantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_VickersVantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139838657131184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="6">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">10 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 10, 2022</div></th>
<th class="th"><div>Oct. 10, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 12, 2022</div></th>
<th class="th"><div>Sep. 09, 2022</div></th>
<th class="th"><div>Aug. 11, 2022</div></th>
<th class="th"><div>Jul. 11, 2022</div></th>
<th class="th"><div>May 12, 2022</div></th>
<th class="th"><div>Apr. 01, 2022</div></th>
<th class="th"><div>Jan. 10, 2022</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Jan. 14, 2021</div></th>
<th class="th"><div>Jan. 11, 2021</div></th>
<th class="th"><div>Jan. 06, 2021</div></th>
<th class="th"><div>Jan. 06, 2021</div></th>
<th class="th"><div>Dec. 07, 2020</div></th>
<th class="th"><div>Oct. 08, 2020</div></th>
<th class="th"><div>Jul. 16, 2020</div></th>
<th class="th"><div>Mar. 18, 2019</div></th>
<th class="th"><div>Oct. 22, 2018</div></th>
<th class="th"><div>Oct. 02, 2018</div></th>
<th class="th"><div>Sep. 11, 2022</div></th>
<th class="th"><div>Feb. 28, 2022</div></th>
<th class="th"><div>Jan. 27, 2022</div></th>
<th class="th"><div>Dec. 20, 2021</div></th>
<th class="th"><div>Feb. 26, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jul. 11, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Nov. 11, 2022</div></th>
<th class="th"><div>Oct. 17, 2022</div></th>
<th class="th"><div>Apr. 18, 2022</div></th>
<th class="th"><div>Apr. 11, 2022</div></th>
<th class="th"><div>Jan. 29, 2021</div></th>
<th class="th"><div>Jan. 13, 2021</div></th>
<th class="th"><div>Aug. 07, 2019</div></th>
<th class="th"><div>Oct. 05, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Aggregate purchase price value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54,591,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 128,615,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 122,423,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 128,615,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 122,423,000<span></span>
</td>
<td class="nump">$ 128,654,000<span></span>
</td>
<td class="nump">$ 122,423,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt issuance costs and debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,108,000<span></span>
</td>
<td class="nump">$ 5,904,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,909,000<span></span>
</td>
<td class="nump">10,664,000<span></span>
</td>
<td class="nump">15,033,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PaymentToAcquireInventory', window );">Payment to acquire inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="nump">4,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,700,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">8,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_NumberOfSharesAcquired', window );">Number of shares acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,117,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Related party payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 166,145,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,664,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 166,145,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,664,000<span></span>
</td>
<td class="nump">92,724,000<span></span>
</td>
<td class="nump">26,664,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToAffiliateCurrent', window );">Advances outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchaseAmount', window );">Debt instrument, repurchase amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preference shares, par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfMediumTermNotes', window );">Proceeds from Issuance of Medium-term Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62,500,000<span></span>
</td>
<td class="nump">11,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,700,000<span></span>
</td>
<td class="nump">$ 10,300,000<span></span>
</td>
<td class="nump">21,628,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PeriodAxis=sclx_DueOnOrAfterFebruaryTwoThousandAndThirtyMember', window );">Due On Or After February Two Thousand And Thirty [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfMediumTermNotes', window );">Proceeds from Issuance of Medium-term Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Aggregate purchase price value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited', window );">Ordinary shares, subject to forfeiture (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sclx_SorrentoMember', window );">Sorrento [Member] | Debt Exchange Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PerShareCalculationOfOutstandingAmountInExchangeOfShares', window );">Per share calculation of Outstanding Amount In Exchange of Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_LimitationOfOutstandingAmountInExchangeOfShares', window );">Limitation of Outstanding Amount In Exchange of Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 310,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 290.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 276.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">276.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sclx_SorrentoMember', window );">Sorrento [Member] | Debt Exchange Agreement [Member] | Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt Conversion, Converted Instrument, Shares Issued</a></td>
<td class="nump">29,057,097<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sclx_SorrentoMember', window );">Sorrento [Member] | Debt Exchange Agreement [Member] | Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt Conversion, Converted Instrument, Shares Issued</a></td>
<td class="nump">2,905,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=sclx_TwoThousandAndTwentyTwoPromissoryNoteMember', window );">Two Thousand And Twenty Two Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Notes payable, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=sclx_TwoThousandAndTwentyTwoPromissoryNoteMember', window );">Two Thousand And Twenty Two Promissory Note [Member] | Sorrento [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.66%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_InvesteeAxis=sclx_SorrentoMember', window );">Sorrento [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Debt discount amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="nump">$ 17,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sclx_ItochuMember', window );">Itochu [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PercentageOfSharesOutstanding', window );">Percentage of shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PercentageOfCapitalSharesOutstanding', window );">Percentage of capital shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_NumberOfSharesOutstanding', window );">Capital stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,889,868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sclx_SorrentoMember', window );">Sorrento [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PercentageOfSharesOutstanding', window );">Percentage of shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.97%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_NumberOfSharesAcquired', window );">Number of shares acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,889,868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty', window );">Related Party transaction, selling, general and administrative expenses from transactions with related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PercentageOfSimpleInterest', window );">Percentage of simple interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Related party note payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,000,000<span></span>
</td>
<td class="nump">19,600,000<span></span>
</td>
<td class="nump">13,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Related party payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600,000<span></span>
</td>
<td class="nump">3,900,000<span></span>
</td>
<td class="nump">2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Debt discount amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,500,000<span></span>
</td>
<td class="nump">3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_WorkingCapitalRequirements', window );">Working capital requirements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,000,000<span></span>
</td>
<td class="nump">35,700,000<span></span>
</td>
<td class="nump">13,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchaseAmount', window );">Debt instrument, repurchase amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sclx_SorrentoMember', window );">Sorrento [Member] | Debt Exchange Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preference shares, par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PercentageOfOutstandingAmountIndebtedness', window );">Percentage of Outstanding Amount Indebtedness</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sclx_SorrentoMember', window );">Sorrento [Member] | Reorganization [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=sclx_SenmurMember', window );">Senmur [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Payments to acquire productive assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable', window );">Asset acquistion consideration transferred equity interest issued and issuable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Stock issued during period shares purchase of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,039,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesSubscribedButUnissued', window );">Common stock shares subscribed but not issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">352,972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">352,972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AssetAcquisitionPricePerShare', window );">Asset acquisition price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PercentageOfOwnershipInterest', window );">Percentage of ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=sclx_SenmurMember', window );">Senmur [Member] | Sorrento [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PercentageOfSharesOutstanding', window );">Percentage of shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.97%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=sclx_SenmurMember', window );">Senmur [Member] | Sorrento [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PercentageOfSharesOutstanding', window );">Percentage of shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_aggregatePurchasePrice', window );">Aggregate purchase price value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,035,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Two Thousand And Twenty Two Promissory Note [Member] | Sorrento [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.66%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=sclx_PromissoryNoteRelatedPartyMember', window );">Promissory Note - Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Related party payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vickers Vantage [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationControlObtainedDescription', window );">Business combination, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The notes may be repaid upon completion of a Business Combination, without interest, or, at the lender&#8217;s discretion, up to $1,500,000 of notes may be converted upon completion of a Business Combination into warrants at a price of $0.75 per warrant.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The notes may be repaid upon completion of a Business Combination, without interest, or, at the lender&#8217;s discretion, up to $1,500,000 of notes may be converted upon completion of a Business Combination into warrants at a price of $0.75 per warrant.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_WarrantsExercisePrice', window );">Warrant price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,035,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,655<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,655<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 24,655<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,971,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseRelatedParty', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt issuance costs and debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">Description of related party extension loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In order to extend the time available for the Company to consummate a Business Combination, the Sponsor or its affiliates or designees must deposit into the Trust Account $1,035,000 ($0.075 per Public Share in either case), on or prior to the date of the applicable deadline, for each three-month extension.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In order to extend the time available for the Company to consummate a Business Combination, the Sponsor or its affiliates or designees must deposit into the Trust Account $1,035,000 ($0.075 per Public Share in either case), on or prior to the date of the applicable deadline, for each three-month extension, providing a total possible Business Combination period up until July 11, 2022 for a total payment value of $2,070,000 ($0.15 per unit in either case).<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DepositedInTrustAccount', window );">Trust account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 323,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 323,889<span></span>
</td>
<td class="nump">$ 323,889<span></span>
</td>
<td class="nump">$ 1,035,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,035,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 323,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,035,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PricePerWarrants', window );">Price per warrant (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsHeldInTrust', window );">Trust account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 101,293,086<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 101,293,086<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 139,410,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,295,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Warrant price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTaxExpenseDueToAffiliatesDeferred', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Debt discount amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AggregatePrincipalAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RepaidAmount', window );">Repaid amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preference shares, par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vickers Vantage [Member] | Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of aggregate ordinary shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vickers Vantage [Member] | Founder Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Shareholder issued and outstanding shares percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vickers Vantage [Member] | IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesRelatedParty', window );">Fund expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Outstanding balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Warrant price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vickers Vantage [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,035,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_aggregatePurchasePrice', window );">Aggregate purchase price value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsHeldInTrust', window );">Trust account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,035,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Warrant price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vickers Vantage [Member] | Founder Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of aggregate ordinary shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,593,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Aggregate purchase price value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CapitalizationOfShareOutstanding', window );">Capitalization of share outstanding (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited', window );">Ordinary shares, subject to forfeiture (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,437,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_OrdinarySharesIssuedAndOutstanding', window );">Ordinary shares issued and outstanding (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,450,000<span></span>
</td>
<td class="nump">3,450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_aggregatePurchasePrice', window );">Aggregate purchase price value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vickers Vantage [Member] | Promissory Note - Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vickers Vantage [Member] | Convertible Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_aggregatePurchasePrice', window );">Aggregate purchase price value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,035,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vickers Vantage [Member] | Convertible Notes Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_aggregatePurchasePrice', window );">Aggregate purchase price value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_ScilexPharmaMember', window );">Scilex Pharma [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Debt discount amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Notes payable, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,400,000<span></span>
</td>
<td class="nump">23,500,000<span></span>
</td>
<td class="nump">$ 15,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_ScilexPharmaMember', window );">Scilex Pharma [Member] | Promissory Note - Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,700,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Outstanding balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,700,000<span></span>
</td>
<td class="nump">$ 21,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_NumberOfSharesAcquired', window );">Number of shares acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,117,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PercentageOfSimpleInterest', window );">Percentage of simple interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Related party payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">3,100,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AccruedInterest', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 8,100,000<span></span>
</td>
<td class="nump">$ 10,300,000<span></span>
</td>
<td class="nump">$ 8,100,000<span></span>
</td>
<td class="nump">$ 10,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_ScilexPharmaMember', window );">Scilex Pharma [Member] | Promissory Note - Related Party [Member] | Debt Exchange Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Outstanding balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AggregatePrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate Principal Amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AggregatePrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AssetAcquisitionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset acquisition price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AssetAcquisitionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_CapitalizationOfShareOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capitalization of share outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_CapitalizationOfShareOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_DepositedInTrustAccount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deposited in trust account</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_DepositedInTrustAccount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_LimitationOfOutstandingAmountInExchangeOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Limitation of Outstanding Amount In Exchange of Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_LimitationOfOutstandingAmountInExchangeOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_NumberOfSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares acquired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_NumberOfSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_NumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_NumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_OrdinarySharesIssuedAndOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ordinary shares issued and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_OrdinarySharesIssuedAndOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PaymentToAcquireInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment to acquire inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PaymentToAcquireInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PerShareCalculationOfOutstandingAmountInExchangeOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share calculation of Outstanding Amount In Exchange of Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PerShareCalculationOfOutstandingAmountInExchangeOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PercentageOfCapitalSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of capital shares outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PercentageOfCapitalSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PercentageOfOutstandingAmountIndebtedness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of outstanding amount indebtedness</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PercentageOfOutstandingAmountIndebtedness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PercentageOfOwnershipInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of ownership interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PercentageOfOwnershipInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PercentageOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of shares outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PercentageOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PercentageOfSimpleInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of simple interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PercentageOfSimpleInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PricePerWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price per warrant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PricePerWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_RelatedPartyTransactionsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_RelatedPartyTransactionsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_RepaidAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repaid Amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_RepaidAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_WarrantsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants Exercise Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_WarrantsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_WorkingCapitalRequirements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Working capital requirements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_WorkingCapitalRequirements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_aggregatePurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>aggregate purchase price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_aggregatePurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of acquirer's equity interest issued and issuable as part of consideration transferred in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9215-128498<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9212-128498<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=127000608&amp;loc=d3e9135-128495<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldInTrust">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of cash and securities held by third party trustees pursuant to terms of debt instruments or other agreements as of the date of each statement of financial position presented, which can be used by the trustee only to pay the noncurrent portion of specified obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsHeldInTrust</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationControlObtainedDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents a description of how the entity obtained control of the acquired entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationControlObtainedDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesSubscribedButUnissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesSubscribedButUnissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Costs of sales and operating expenses for the period incurred from transactions with related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchaseAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value amount of debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchaseAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToAffiliateCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of payable due to an entity that is affiliated with the reporting entity by means of direct or indirect ownership. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e603758-122996<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToAffiliateCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense incurred on a debt or other obligation to related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9212-128498<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9215-128498<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=127000608&amp;loc=d3e9135-128495<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfMediumTermNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt funding received on a regular basis with maturities ranging from 5-10 years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfMediumTermNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTaxExpenseDueToAffiliatesDeferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of any deferred tax-related balances due to affiliates as of the date of each statement of financial position presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTaxExpenseDueToAffiliatesDeferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A description of the related party transaction, including transactions to which no amounts or nominal amounts were ascribed and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements. Examples of common related party transactions are, sales, purchases and transfers of realty and personal property, services received or furnished, loans and leases to and from top management and affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123395306&amp;loc=d3e36975-112693<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919370-209981<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918703-209980<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=128295416&amp;loc=SL77919784-209982<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionDescriptionOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of selling, general and administrative expenses resulting from transactions, excluding transactions that are eliminated in consolidated or combined financial statements, with related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares (or other type of equity) forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PeriodAxis=sclx_DueOnOrAfterFebruaryTwoThousandAndThirtyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PeriodAxis=sclx_DueOnOrAfterFebruaryTwoThousandAndThirtyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=sclx_SorrentoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=sclx_SorrentoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AgreementAxis=sclx_DebtExchangeAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AgreementAxis=sclx_DebtExchangeAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=sclx_TwoThousandAndTwentyTwoPromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=sclx_TwoThousandAndTwentyTwoPromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_InvesteeAxis=sclx_SorrentoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_InvesteeAxis=sclx_SorrentoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sclx_ItochuMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sclx_ItochuMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sclx_SorrentoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sclx_SorrentoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_EventAxis=sclx_ReorganizationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_EventAxis=sclx_ReorganizationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=sclx_SenmurMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=sclx_SenmurMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=sclx_PromissoryNoteRelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=sclx_PromissoryNoteRelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_VickersVantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_VickersVantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=sclx_FounderSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=sclx_FounderSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=sclx_FounderSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=sclx_FounderSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=sclx_ConvertiblePromisoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=sclx_ConvertiblePromisoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_ScilexPharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_ScilexPharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139838682111840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 17, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 12, 2022</div></th>
<th class="th"><div>Jun. 01, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SellingGeneralAndAdministrativeExpenses', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="nump">$ 10,500,000<span></span>
</td>
<td class="nump">$ 25,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease, expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sclx_PaloAltoAadministrativeFacilityMember', window );">Palo Alto Aadministrative Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">26 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_ProductDevelopmentAgreementMember', window );">Product Development Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AgreementExpirationDate', window );">Agreement expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Oct.  02,  2028<span></span>
</td>
<td class="text">Oct.  02,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AgreementExpirationTerm', window );">Agreement expiration term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AgreementAutomaticRenewalPeriodOnExpirationOfInitialTerm', window );">Agreement automatic renewal period on expiration of initial term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_NoticeOfTerminationPeriodForCancellationOfAutomaticRenewal', window );">Notice of termination period for cancellation of automatic renewal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_TerminationOfAgreementNoticePeriodForARequestToCureMaterialBreachOfTheAgreement', window );">Termination of aggrement notice period for a request to cure material breach of the agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">180 days<span></span>
</td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ThresholdMinimumPercentageOfSales', window );">Threshold minimum percentage of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_ExclusiveDistributionAgreementMember', window );">Exclusive Distribution Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AgreementExpirationTerm', window );">Agreement expiration term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PercentageOfAnnualAdjustmentToFees', window );">Percentage of annual adjustment to fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sclx_ProjectAgreementMember', window );">Project Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_NoticePeriodForTerminationOfWorkOrder', window );">Notice period for termination of work order</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_WorkOrderImplementationFee', window );">Work order implementation fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59,000<span></span>
</td>
<td class="nump">$ 59,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Leases remaining lease terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lessee, Operating Lease, renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Product Development Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PercentageOfAggregateRoyalityPayments', window );">Percentage of aggregate royality payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Exclusive Distribution Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PercentageOfDistributionFeeReceivedOverThePeriod', window );">Percentage of distribution fee received over the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Project Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SalesOperationsServicesMonthlyFee', window );">Sales operations services monthly fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63,700<span></span>
</td>
<td class="nump">$ 63,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Leases remaining lease terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lessee, Operating Lease, renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Product Development Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PercentageOfAggregateRoyalityPayments', window );">Percentage of aggregate royality payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Exclusive Distribution Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PercentageOfDistributionFeeReceivedOverThePeriod', window );">Percentage of distribution fee received over the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Project Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SalesOperationsServicesMonthlyFee', window );">Sales operations services monthly fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,800<span></span>
</td>
<td class="nump">$ 65,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vickers Vantage [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsDescription', window );">Underwriting agreement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The underwriters are entitled to a deferred fee of (i) 3.5% of the gross proceeds of the initial 12,000,000 Units sold in the Initial Public Offering, or $4,200,000, and (ii) 5.5% of the gross proceeds from the Units sold pursuant to the over-allotment option, or $990,000.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The underwriters are entitled to a deferred fee of (i)&#160;3.5% of the gross proceeds of the initial 12,000,000&#160;Units sold in the Initial Public Offering, or $4,200,000, and (ii)&#160;5.5% of the gross proceeds from the Units soldpursuant to the over-allotment option, or $990,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_MergerConsiderationDescription', window );">Merger consideration description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The total consideration to be paid to the holders of Scilex common stock at Closing (the &#8220;Merger Consideration&#8221;) by VCKA twill be an amount equal to the quotient of (a) the sum of (i) $1,500,000,000 minus (ii) the aggregate amount of Scilex long term debt excluding intercompany debt owed to Sorrento existing as of immediately prior to the date of the closing of the transaction (the &#8220;Closing Date&#8221;); divided by (b) $10.00, and will be payable in shares of common stock, par value $0.0001 per shares, of VCKA upon its domestication in Delaware (&#8220;VCKA Common Stock&#8221;).<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommonStockAggregateValue', window );">Common stock aggregate value (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_NetTangibleAssets', window );">Net tangible assets (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,001<span></span>
</td>
<td class="nump">$ 5,000,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AggregatePercentage', window );">Aggregate percentage</a></td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_WarrantsPercentage', window );">Warrants percentage</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_BalanceInTheTrustAccount', window );">Balance in the trust account (in Dollars)</a></td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DeferredUnderwritingCommission', window );">Deferred underwriting commission percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DeferredUnderwritingCommissionPayable', window );">Underwriting commission payable percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vickers Vantage [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredUnitsAuthorized', window );">Stock authority to issue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vickers Vantage [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredUnitsAuthorized', window );">Stock authority to issue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">785,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vickers Vantage [Member] | Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Preferred Stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockNoParValue', window );">Series A preferred stock, par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vickers Vantage [Member] | Series of Individually Immaterial Business Acquisitions [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationReasonForBusinessCombination', window );">Business combination, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The maximum number of shares of New Scilex Series A Preferred Stock and New Scilex Common Stock to be issued to the holders of Scilex Preferred Stock at the Closing shall not exceed 31,000,000 and 3,100,000, respectively, such newly issued shares being collectively referred to herein as the &#8220;Preferred Consideration&#8221;. It is anticipated that upon completion of the Business Combination, if none of the 9,726,395 VCKA Ordinary Shares are redeemed, VCKA&#8217;s public shareholders would retain an ownership interest of approximately 5.6% in New Scilex, the Sponsors, officers, directors and other holders of founder shares will retain an ownership interest of approximately 2.2% of New Scilex, and the Scilex stockholders will own approximately (i) 77.2% of New Scilex in the form of New Scilex Common Stock and (ii) 15.0% of New Scilex in the form of New Scilex Series A Preferred Stock.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vickers Vantage [Member] | Scilex Common Stock [Member] | Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Preferred Stock, par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AggregatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate Percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AggregatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AgreementAutomaticRenewalPeriodOnExpirationOfInitialTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreement automatic renewal period on expiration of initial term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AgreementAutomaticRenewalPeriodOnExpirationOfInitialTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AgreementExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreement expiration date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AgreementExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AgreementExpirationTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreement expiration term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AgreementExpirationTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_BalanceInTheTrustAccount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Balance in the trust account.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_BalanceInTheTrustAccount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_CommitmentsandContingenciesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_CommitmentsandContingenciesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_CommonStockAggregateValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock with an aggregate value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_CommonStockAggregateValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_DeferredUnderwritingCommission">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Underwriting Commission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_DeferredUnderwritingCommission</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_DeferredUnderwritingCommissionPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Underwriting Commission Payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_DeferredUnderwritingCommissionPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_MergerConsiderationDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Merger consideration description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_MergerConsiderationDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_NetTangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net tangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_NetTangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_NoticeOfTerminationPeriodForCancellationOfAutomaticRenewal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notice of termination period for cancellation of automatic renewal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_NoticeOfTerminationPeriodForCancellationOfAutomaticRenewal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_NoticePeriodForTerminationOfWorkOrder">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notice period for termination of work order.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_NoticePeriodForTerminationOfWorkOrder</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PercentageOfAggregateRoyalityPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of aggregate royality payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PercentageOfAggregateRoyalityPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PercentageOfAnnualAdjustmentToFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of annual adjustment to fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PercentageOfAnnualAdjustmentToFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PercentageOfDistributionFeeReceivedOverThePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of distribution fee received over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PercentageOfDistributionFeeReceivedOverThePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_SalesOperationsServicesMonthlyFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales operations services monthly fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_SalesOperationsServicesMonthlyFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_SellingGeneralAndAdministrativeExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_SellingGeneralAndAdministrativeExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_TerminationOfAgreementNoticePeriodForARequestToCureMaterialBreachOfTheAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Termination of agreement notice period for a request to cure material breach of the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_TerminationOfAgreementNoticePeriodForARequestToCureMaterialBreachOfTheAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ThresholdMinimumPercentageOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold minimum percentage of sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ThresholdMinimumPercentageOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_WarrantsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants Percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_WarrantsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_WorkOrderImplementationFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Work order implementation fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_WorkOrderImplementationFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationReasonForBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents a description of the primary reason for the business combination which may consist of general categories such as top-line growth, synergistic benefits, market share, and diversification and the more detailed factors that might apply.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationReasonForBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessor's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919359-209981<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the nature and terms of commitment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockNoParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount per share of no-par value preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockNoParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredUnitsAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of preferred units authorized to be issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 4.F)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187171-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredUnitsAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sclx_PaloAltoAadministrativeFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=sclx_PaloAltoAadministrativeFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sclx_ProductDevelopmentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sclx_ProductDevelopmentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sclx_ExclusiveDistributionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sclx_ExclusiveDistributionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sclx_ProjectAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sclx_ProjectAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_VickersVantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_VickersVantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=sclx_ScilexCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=sclx_ScilexCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139838697502672">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Summary of Components of Lease Expense (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease, Cost [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 623<span></span>
</td>
<td class="nump">$ 904<span></span>
</td>
<td class="nump">$ 776<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Inclusive of variable lease costs, sublease income, and impairment, which were immaterial for the periods presented.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139838691239856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Summary of Maturities of Lease Liabilities (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Lessee, Operating Lease, Liability, to be Paid [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2022 (Remaining three months)</a></td>
<td class="nump">$ 215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">872<span></span>
</td>
<td class="nump">$ 674,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">703<span></span>
</td>
<td class="nump">694,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">596,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">1,790<span></span>
</td>
<td class="nump">1,964,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(210)<span></span>
</td>
<td class="num">(316,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities as of December&#160;31, 2021</a></td>
<td class="nump">$ 1,580<span></span>
</td>
<td class="nump">$ 1,648,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139838694715312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Summary of Supplemental Quantitative Information Related To Leases (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowOperatingActivitiesLesseeAbstract', window );"><strong>Cash Flow, Operating Activities, Lessee [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_OperatingCashFlowsFromOperatingLeases', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 531<span></span>
</td>
<td class="nump">$ 489<span></span>
</td>
<td class="num">$ (654)<span></span>
</td>
<td class="num">$ (833)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">ROU assets obtained in exchange for new operating lease liabilities</a></td>
<td class="nump">$ 320<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term in&#160;years&#160;&#8212;&#160;operating leases</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">3 years 1 month 6 days<span></span>
</td>
<td class="text">2 years 9 months 18 days<span></span>
</td>
<td class="text">3 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate&#160;&#8212;&#160;operating leases</a></td>
<td class="nump">11.80%<span></span>
</td>
<td class="nump">12.20%<span></span>
</td>
<td class="nump">12.20%<span></span>
</td>
<td class="nump">12.20%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_OperatingCashFlowsFromOperatingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating cash flows from operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_OperatingCashFlowsFromOperatingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowOperatingActivitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowOperatingActivitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139838692400640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Shareholders' Deficit (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 06, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preference shares, authorized</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preference shares, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">350,000,000<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, issued</a></td>
<td class="nump">197,566,338<span></span>
</td>
<td class="nump">197,266,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,266,338<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ordinary shares, outstanding</a></td>
<td class="nump">197,566,338<span></span>
</td>
<td class="nump">197,266,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,266,338<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vickers Vantage [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preference shares, authorized</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preference shares, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, issued</a></td>
<td class="nump">3,450,000<span></span>
</td>
<td class="nump">3,450,000<span></span>
</td>
<td class="nump">3,450,000<span></span>
</td>
<td class="nump">3,450,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ordinary shares, outstanding</a></td>
<td class="nump">3,450,000<span></span>
</td>
<td class="nump">3,450,000<span></span>
</td>
<td class="nump">3,450,000<span></span>
</td>
<td class="nump">3,450,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_OrdinarySharesSubjectToPossibleRedemption', window );">Ordinary shares subject to possible redemption</a></td>
<td class="nump">9,726,395<span></span>
</td>
<td class="nump">13,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_OrdinarySharesSubjectToPossibleRedemption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_OrdinarySharesSubjectToPossibleRedemption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_VickersVantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_VickersVantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139838692009728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants (Details) - Vicker's Vantage - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_WarrantsDetailsLineItems', window );"><strong>Warrants (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PublicWarrantsRedemptionDescription', window );">Public warrants redemption, description</a></td>
<td class="text">The Company may redeem the Public Warrants:  &#160;


&#160;
&#8226;
&#160;
 in whole and not in part;      &#160;


&#160;
&#8226;
&#160;
 at a price of $0.01 per warrant;      &#160;


&#160;
&#8226;
&#160;
 at any time while the warrants become exercisable;      &#160;


&#160;
&#8226;
&#160;
 upon not less than 30 days&#8217; prior written notice of redemption to each warrant holder;      &#160;


&#160;
&#8226;
&#160;
 if, and only if, the reported last sale price of the Company&#8217;s ordinary shares equals or exceeds $18.00&#160;per share (subject to adjustment) for any 20 trading days within a 30-trading day period commencing after the warrants become exercisable and ending on the third trading business day prior to the notice of redemption to the warrant holders; and      &#160;


&#160;
&#8226;
&#160;
 if, and only if, there is a current registration statement in effect with respect to the issuance of the ordinary shares underlying such warrants at the time of redemption and for the entire 30-day trading period referred to above and continuing each day thereafter until the date of redemption.     <span></span>
</td>
<td class="text"> The Company may redeem the Public Warrants:  &#160;


&#160;
&#8226;
&#160;
in whole and not in part;   &#160;


&#160;
&#8226;
&#160;
at a price of $0.01 per warrant;   &#160;


&#160;
&#8226;
&#160;
at any time while the warrants become exercisable;   &#160;


&#160;
&#8226;
&#160;
upon not less than 30&#160;days&#8217; prior written notice of redemption to each warrant holder;   &#160;


&#160;
&#8226;
&#160;
if, and only if, the reported last sale price of the Company&#8217;s ordinary shares equals or exceeds $18.00 per share (subject to adjustment) for any 20 trading days within a 30-trading day period commencing after the warrants become exercisable and ending on the third trading business day prior to the notice of redemption to the warrant holders; and     &#160;


&#160;
&#8226;
&#160;
if, and only if, there is a current registration statement in effect with respect to the issuance of the ordinary shares underlying such warrants at the time of redemption and for the entire 30-day trading period referred to above and continuing each day thereafter until the date of redemption. <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CapitalRaisingDescription', window );">Capital raising, description</a></td>
<td class="text">In addition, if (x)&#160;the Company issues additional ordinary shares or equity-linked securities for capital raising purposes in connection with the closing of a Business Combination at an issue price or effective issue price of less than $9.20 per ordinary share (with such issue price or effective issue price to be determined in good faith by the Company&#8217;s board of directors and, in the case of any such issuance to the Sponsors or its affiliates, without taking into account any Founder Shares held by the Sponsors or such affiliates, as applicable, prior to such issuance) (the &#8220;Newly Issued Price&#8221;), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of a Business Combination on the date of the consummation of a Business Combination (net of redemptions), and (z)&#160;the volume weighted average trading price of its ordinary shares during the 20 trading day period starting on the trading day prior to the day on which the Company consummates its Business Combination (such price, the &#8220;Market Value&#8221;) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, the $18.00 per share redemption trigger price will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price. <span></span>
</td>
<td class="text">In addition, if (x)&#160;the Company issues additional ordinary shares or equity-linked securities for capital raising purposes in connection with the closing of a Business Combination at an issue price or effective issue price of less than $9.20 per ordinary share (with such issue price or effective issue price to be determined in good faith by the Company&#8217;s board of directors and, in the case of any such issuance to the Sponsors or its affiliates, without taking into account any Founder Shares held by the Sponsors or such affiliates, as applicable, prior to such issuance) (the &#8220;Newly Issued Price&#8221;), (y)&#160;the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of a Business Combination on the date of the consummation of a Business Combination (net of redemptions), and (z)&#160;the volume weighted average trading price of its ordinary shares during the 20 trading day period starting on the trading day prior to the day on which the Company consummates its Business Combination (such price, the &#8220;Market Value&#8221;) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, the $18.00 per share redemption trigger price will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price. <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Public Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_WarrantsDetailsLineItems', window );"><strong>Warrants (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_WarrantsOutstandingShares', window );">Warrants outstanding shares</a></td>
<td class="nump">6,900,000<span></span>
</td>
<td class="nump">6,900,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_WarrantsDetailsLineItems', window );"><strong>Warrants (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_WarrantsOutstandingShares', window );">Warrants outstanding shares</a></td>
<td class="nump">6,840,000<span></span>
</td>
<td class="nump">6,840,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_CapitalRaisingDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_CapitalRaisingDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PublicWarrantsRedemptionDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PublicWarrantsRedemptionDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_WarrantsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_WarrantsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_WarrantsOutstandingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants outstanding shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_WarrantsOutstandingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_VickersVantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_VickersVantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139838657050576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 11, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 20, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLossOnDerivative', window );">Derivative, Loss on derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainOnDerivative', window );">Derivative, Gain on Derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,700,000<span></span>
</td>
<td class="nump">$ 35,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember', window );">Derivative Financial Instruments, Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease', window );">Fair value, Measurement with unobservable inputs reconciliation, Recurring basis, Liability, Period increase decrease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(35,700,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember', window );">Derivative Financial Instruments, Liabilities [Member] | Scilex Pharma Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease', window );">Fair value, Measurement with unobservable inputs reconciliation, Recurring basis, Liability, Period increase decrease</a></td>
<td class="nump">$ 30,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=sclx_MeasurementInputRiskadjustedNetSalesForecastMember', window );">Measurement Input, RiskAdjusted Net Sales Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, Measurement input</a></td>
<td class="nump">6.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=sclx_MeasurementInputEffectiveDebtYieldMember', window );">Measurement Input, Effective Debt Yield [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, Measurement input</a></td>
<td class="nump">21.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">19.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=sclx_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeMarch312021Member', window );">Measurement Input, Estimated Probability Of Not Obtaining Marketing Approval Before March 31, 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, Measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=sclx_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeJuly12023Member', window );">Measurement Input, Estimated Probability Of Not Obtaining Marketing Approval Before July 1, 2023 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, Measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vicker's Vantage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsHeldInTrust', window );">Assets Held-in-trust</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,293,086<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">139,410,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,295,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsHeldInTrustCurrent', window );">Assets held in the trust account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 101,293,086<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 139,410,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementsHighestAndBestUseDescription', window );">Initial measurement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company established the initial fair value for the private warrants on January&#160;11, 2021, the date of the Company&#8217;s Initial Public Offering, using a Monte Carlo simulation and subsequently implemented the Black-Scholes Option Pricing Model that was modified to capture the redemption features of the public warrants. The underlying assumptions in the Black-Scholes option pricing model include the underlying share price, risk-free interest rate, estimated volatility and the expected term. The primary unobservable inputs utilized in determining the fair value of the private warrants are the expected volatility of the Company&#8217;s ordinary shares and the Company&#8217;s ordinary share price. The expected volatility of the ordinary shares was determined based on implied volatilities of public warrants issued by selected guideline companies and was estimated to be 10% before the expected business combination and 20% after the expected business combination. The ordinary share price was determined based on an iterative procedure that matched the estimated value of the ordinary shares and fractional warrant price to equate to the observed price of the outstanding units. The risk-free interest rate is based on the U.S. Treasury yield curve in effect on the date of valuation equal to the remaining expected life of the private warrants. The dividend yield percentage is zero because the Company does not currently pay dividends, nor does it intend to do so during the expected term of the warrants. The expected life of the warrants is assumed to be equivalent to their remaining contractual term. Inputs are re-evaluated each quarterly reporting period to estimate the fair market value of the private placement warrants as of the reporting period. <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company established the initial fair value for the private warrants on January&#160;11, 2021, the date of the Company&#8217;s Initial Public Offering, using a Monte Carlo simulation and subsequently implemented the Black-Scholes Option Pricing Model that was modified to capture the redemption features of the public warrants. The underlying assumptions in the Black-Scholes option pricing model include the underlying share price, risk-free interest rate, estimated volatility and the expected term. The primary unobservable inputs utilized in determining the fair value of the private warrants are the expected volatility of the Company&#8217;s ordinary shares and the Company&#8217;s ordinary share price. The expected volatility of the ordinary shares was determined based on implied volatilities of public warrants issued by selected guideline companies and was estimated to be 10% before the expected business combination and 20% after the expected business combination. The ordinary share price was&#160;determined based on an iterative procedure that matched the estimated value of the ordinary shares and fractional&#160;  warrant price to equate to the observed price of the outstanding&#160;units. The risk-free interest rate is based on the U.S. Treasury yield curve in effect on the date of valuation equal to the remaining expected life of the private warrants. The dividend yield&#160;percentage is zero because the Company does not currently pay dividends, nor does it intend to do so during the expected term of the warrants. The expected life of the warrants is assumed to be equivalent to their remaining contractual term. Inputs are re-evaluated each quarterly reporting period to estimate the fair market value of the private placement warrants as of the reporting period.  <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,162,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,351,600<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldInTrust">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of cash and securities held by third party trustees pursuant to terms of debt instruments or other agreements as of the date of each statement of financial position presented, which can be used by the trustee only to pay the noncurrent portion of specified obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsHeldInTrust</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldInTrustCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash, securities, or other assets held by a third-party trustee pursuant to the terms of an agreement which assets are available to be used by beneficiaries to that agreement only within the specific terms thereof and which agreement is expected to terminate within one year of the balance sheet date (or operating cycle, if longer) at which time the assets held-in-trust will be released or forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsHeldInTrustCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainOnDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainOnDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLossOnDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLossOnDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementsHighestAndBestUseDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of reasons that a nonfinancial asset is being used in a manner that differs from its highest and best use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementsHighestAndBestUseDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=sclx_ScilexPharmaNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=sclx_ScilexPharmaNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=sclx_MeasurementInputRiskadjustedNetSalesForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=sclx_MeasurementInputRiskadjustedNetSalesForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=sclx_MeasurementInputEffectiveDebtYieldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=sclx_MeasurementInputEffectiveDebtYieldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=sclx_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeMarch312021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=sclx_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeMarch312021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=sclx_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeJuly12023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=sclx_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeJuly12023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_VickersVantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_VickersVantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139838683925248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements  (Details) - Schedule of fair value hierarchy of the valuation inputs - Vicker's Vantage - USD ($)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Conversion Option Liability</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 6,892<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeSecuritiesUSTreasury', window );">Investments held in Trust Account &#8211; U.S. Treasury Securities Money Market Fund</a></td>
<td class="nump">101,293,086<span></span>
</td>
<td class="nump">139,410,739<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueAdjustment', window );">Warrant Liability &#8211; Private Placement Warrants</a></td>
<td class="nump">1,162,800<span></span>
</td>
<td class="nump">3,351,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Conversion Option Liability</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 6,892<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeSecuritiesUSTreasury">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest income on US treasury securities. US treasury securities are negotiable debt obligations of the US government, secured by its full faith and credit and issued at various schedules and maturities. The income from treasury securities is exempt from state and local, but not federal, taxes. There are three types of securities issued by the US treasury (bonds, bills, and notes), which are distinguished by the amount of time from the initial sale of the bond to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeSecuritiesUSTreasury</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_VickersVantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_VickersVantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139838656994784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements  (Details) - Schedule of changes in the fair value of warrant liabilities and conversion option liability: - USD ($)<br></strong></div></th>
<th class="th" colspan="7">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityLineItems', window );"><strong>Fair Value Measurements (Details) - Schedule of changes in the fair value of warrant liabilities and conversion option liability: [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair value beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair value ending</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">35,700,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vicker's Vantage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityLineItems', window );"><strong>Fair Value Measurements (Details) - Schedule of changes in the fair value of warrant liabilities and conversion option liability: [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair value beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,351,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair value ending</a></td>
<td class="nump">1,162,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,351,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,162,800<span></span>
</td>
<td class="nump">3,351,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member] | Vicker's Vantage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityLineItems', window );"><strong>Fair Value Measurements (Details) - Schedule of changes in the fair value of warrant liabilities and conversion option liability: [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair value beginning</a></td>
<td class="nump">1,231,200<span></span>
</td>
<td class="nump">$ 3,762,000<span></span>
</td>
<td class="nump">3,351,600<span></span>
</td>
<td class="nump">4,856,400<span></span>
</td>
<td class="nump">$ 3,693,600<span></span>
</td>
<td class="nump">$ 3,625,200<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,762,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_InitialMeasurementOne', window );">Initial measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,729,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,729,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ChangeInValuationInputsOrOtherAssumptions', window );">Change in valuation inputs or other assumptions</a></td>
<td class="num">(68,400)<span></span>
</td>
<td class="num">(2,530,800)<span></span>
</td>
<td class="nump">410,400<span></span>
</td>
<td class="num">(1,504,800)<span></span>
</td>
<td class="nump">1,162,800<span></span>
</td>
<td class="nump">68,400<span></span>
</td>
<td class="num">(4,104,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,377,600)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair value ending</a></td>
<td class="nump">1,162,800<span></span>
</td>
<td class="nump">1,231,200<span></span>
</td>
<td class="nump">3,762,000<span></span>
</td>
<td class="nump">3,351,600<span></span>
</td>
<td class="nump">$ 4,856,400<span></span>
</td>
<td class="nump">$ 3,693,600<span></span>
</td>
<td class="nump">3,625,200<span></span>
</td>
<td class="nump">1,162,800<span></span>
</td>
<td class="nump">3,351,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sclx_ConversionOptionLiabilityMember', window );">Conversion Option Liability [Member] | Vicker's Vantage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityLineItems', window );"><strong>Fair Value Measurements (Details) - Schedule of changes in the fair value of warrant liabilities and conversion option liability: [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair value beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76,788<span></span>
</td>
<td class="nump">6,892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">76,788<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_InitialMeasurementOne', window );">Initial measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,727<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ChangeInValuationInputsOrOtherAssumptions', window );">Change in valuation inputs or other assumptions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,896<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(76,788)<span></span>
</td>
<td class="num">(11,835)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair value ending</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76,788<span></span>
</td>
<td class="nump">$ 6,892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 6,892<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ChangeInValuationInputsOrOtherAssumptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in valuation inputs or other assumptions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ChangeInValuationInputsOrOtherAssumptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_InitialMeasurementOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_InitialMeasurementOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_VickersVantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_VickersVantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sclx_ConversionOptionLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sclx_ConversionOptionLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139838691603936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements  (Details) - Schedule of valued using the compound option pricing model - $ / shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 20, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.16<span></span>
</td>
<td class="nump">$ 1.16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.53%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vicker's Vantage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_UnderlyingWarrantValue', window );">Underlying warrant value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0.0103<span></span>
</td>
<td class="nump">$ 0.0281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="nump">0.75<span></span>
</td>
<td class="nump">0.75<span></span>
</td>
<td class="nump">0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_HoldingPeriod', window );">Holding period</a></td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 0.28<span></span>
</td>
<td class="nump">$ 0.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate</a></td>
<td class="nump">4.03%<span></span>
</td>
<td class="nump">1.28%<span></span>
</td>
<td class="nump">1.19%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">5.30%<span></span>
</td>
<td class="nump">8.30%<span></span>
</td>
<td class="nump">9.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_HoldingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Holding period return is the total return received from holding an asset or portfolio of assets over a period of time, generally expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_HoldingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_UnderlyingWarrantValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Underlying warrant value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_UnderlyingWarrantValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_VickersVantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_VickersVantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139838692857136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements  (Details) - Financial assets and liabilities that are measured at fair value - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 2,483,000<span></span>
</td>
<td class="nump">$ 4,338,000<span></span>
</td>
<td class="nump">$ 4,839,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">2,483,000<span></span>
</td>
<td class="nump">4,338,000<span></span>
</td>
<td class="nump">4,839,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">35,700,000<span></span>
</td>
<td class="nump">35,400,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,700,000<span></span>
</td>
<td class="nump">35,400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">2,483,000<span></span>
</td>
<td class="nump">4,338,000<span></span>
</td>
<td class="nump">4,839,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">$ 2,483,000<span></span>
</td>
<td class="nump">4,338,000<span></span>
</td>
<td class="nump">4,839,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,700,000<span></span>
</td>
<td class="nump">35,400,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,700,000<span></span>
</td>
<td class="nump">$ 35,400,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139838681972944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - Derivative liabilities measured at fair value using significant unobservable inputs - Derivative Financial Instruments, Liabilities [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning Balance</a></td>
<td class="nump">$ 35,700<span></span>
</td>
<td class="nump">$ 35,400<span></span>
</td>
<td class="nump">$ 33,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800<span></span>
</td>
<td class="nump">$ 10,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Re-measurement&#160;of fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="num">(800)<span></span>
</td>
<td class="nump">23,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease', window );">Change in fair value measurement</a></td>
<td class="num">$ (35,700)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,700<span></span>
</td>
<td class="nump">$ 35,400<span></span>
</td>
<td class="nump">$ 33,400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139838693930128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements  (Details) - Schedule of quantitative information regarding Level 3 fair value measurements - $ / shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vicker's Vantage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price</a></td>
<td class="nump">$ 10.33<span></span>
</td>
<td class="nump">$ 10.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_FairValueMeasurementStrikePrice', window );">Strike price</a></td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term (in years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years 3 months 10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Volatility</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">8.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1', window );">Risk-free rate</a></td>
<td class="nump">4.03%<span></span>
</td>
<td class="nump">1.28%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_FairValueOfWarrantsinDollars', window );">Fair value of warrants</a></td>
<td class="nump">$ 0.17<span></span>
</td>
<td class="nump">$ 0.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_FairValueMeasurementStrikePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Strike price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_FairValueMeasurementStrikePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_FairValueOfWarrantsinDollars">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_FairValueOfWarrantsinDollars</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_VickersVantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_VickersVantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139838694614160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - Schedule of change in the fair value of conversion option liability - Vicker's Vantage<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityLineItems', window );"><strong>Schedule Of Change In The Fair Value Of Conversion Option Liability [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Fair value, beginning balance</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1', window );">Initial measurement</a></td>
<td class="nump">18,727<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue', window );">Change in fair value</a></td>
<td class="num">(11,835)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Fair value, ending balance</a></td>
<td class="nump">$ 6,892<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of change in the fair value of conversion option liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetAssetLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of asset after deduction of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetAssetLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from changes in fair value classified as other for a contract to service financial assets under which the estimated future revenues from contractually specified servicing fees, late charges, and other ancillary revenues are not expected to adequately compensate the servicer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 50<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(4)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128311188&amp;loc=d3e122625-111746<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_VickersVantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_VickersVantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139838657092432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment (Details) - Property and equipment consisted - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 932<span></span>
</td>
<td class="nump">$ 934<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(127)<span></span>
</td>
<td class="num">(88)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, Plant and Equipment, Net</a></td>
<td class="nump">$ 782<span></span>
</td>
<td class="nump">805<span></span>
</td>
<td class="nump">846<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">118<span></span>
</td>
<td class="nump">118<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Progress [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 689<span></span>
</td>
<td class="nump">$ 691<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139838694761264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseGross', window );">Depreciation</a></td>
<td class="nump">$ 39<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated depreciation, of lessor's underlying asset for which right to use has been conveyed to lessee under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919398-209981<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123405975&amp;loc=d3e41551-112718<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123422147&amp;loc=d3e41457-112716<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertySubjectToOrAvailableForOperatingLeaseGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139838692392048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets (Details) - Summary of the company's identifiable intangible assets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amount</a></td>
<td class="nump">$ 60,781<span></span>
</td>
<td class="nump">$ 55,070<span></span>
</td>
<td class="nump">$ 55,070<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="nump">19,164<span></span>
</td>
<td class="nump">16,268<span></span>
</td>
<td class="nump">12,530<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangibles, net</a></td>
<td class="nump">41,617<span></span>
</td>
<td class="nump">38,802<span></span>
</td>
<td class="nump">42,540<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patent rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amount</a></td>
<td class="nump">32,630<span></span>
</td>
<td class="nump">32,630<span></span>
</td>
<td class="nump">32,630<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="nump">12,871<span></span>
</td>
<td class="nump">11,239<span></span>
</td>
<td class="nump">9,064<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangibles, net</a></td>
<td class="nump">19,759<span></span>
</td>
<td class="nump">21,391<span></span>
</td>
<td class="nump">23,566<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember', window );">Acquired technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amount</a></td>
<td class="nump">21,940<span></span>
</td>
<td class="nump">21,940<span></span>
</td>
<td class="nump">21,940<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="nump">5,851<span></span>
</td>
<td class="nump">4,754<span></span>
</td>
<td class="nump">3,291<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangibles, net</a></td>
<td class="nump">16,089<span></span>
</td>
<td class="nump">17,186<span></span>
</td>
<td class="nump">18,649<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">Acquired licenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amount</a></td>
<td class="nump">5,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="nump">92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangibles, net</a></td>
<td class="nump">5,619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=sclx_AssembledWorkforceMember', window );">Assembled workforce</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amount</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="nump">350<span></span>
</td>
<td class="nump">275<span></span>
</td>
<td class="nump">175<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangibles, net</a></td>
<td class="nump">$ 150<span></span>
</td>
<td class="nump">$ 225<span></span>
</td>
<td class="nump">$ 325<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=sclx_AssembledWorkforceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=sclx_AssembledWorkforceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139838657093040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets (Details) - Summary of estimated future amortization expense - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">2022 (Remaining three months)</a></td>
<td class="nump">$ 1,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2023</a></td>
<td class="nump">4,106<span></span>
</td>
<td class="nump">$ 3,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2024</a></td>
<td class="nump">4,031<span></span>
</td>
<td class="nump">3,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2025</a></td>
<td class="nump">4,006<span></span>
</td>
<td class="nump">3,663<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2026</a></td>
<td class="nump">4,006<span></span>
</td>
<td class="nump">3,638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour', window );">Thereafter</a></td>
<td class="nump">24,441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 41,617<span></span>
</td>
<td class="nump">$ 38,802<span></span>
</td>
<td class="nump">$ 42,540<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finite lived intangible assets amortization expense after year four.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139838651306704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 14, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,481,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,481,000<span></span>
</td>
<td class="nump">$ 13,481,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill, Impairment loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,896,000<span></span>
</td>
<td class="nump">$ 2,803,000<span></span>
</td>
<td class="nump">3,738,000<span></span>
</td>
<td class="nump">3,738,000<span></span>
</td>
<td class="nump">$ 3,713,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of Intangible assets excluding goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted Average [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite lived intangible asset, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Finite lived intangible assets, remaining amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite lived intangible asset, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember', window );">Technology-Based Intangible Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite lived intangible asset, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Finite lived intangible assets, remaining amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=sclx_AssembledWorkforceMember', window );">Assembled Workforce [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite lived intangible asset, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">Licensing Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Finite lived intangible assets acquired</a></td>
<td class="nump">$ 5,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Acquired finite lived intangible assets, weighted average useful life</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinitelivedIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinitelivedIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=sclx_AssembledWorkforceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=sclx_AssembledWorkforceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139838673385760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1">40 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 02, 2022</div></th>
<th class="th"><div>Feb. 16, 2022</div></th>
<th class="th"><div>Feb. 15, 2022</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th"><div>Dec. 14, 2020</div></th>
<th class="th"><div>Feb. 15, 2019</div></th>
<th class="th"><div>Sep. 07, 2018</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 03, 2022</div></th>
<th class="th"><div>May 12, 2022</div></th>
<th class="th"><div>Feb. 28, 2022</div></th>
<th class="th"><div>Feb. 14, 2022</div></th>
<th class="th"><div>Dec. 20, 2021</div></th>
<th class="th"><div>Oct. 05, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchaseAmount', window );">Debt instrument, repurchase amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,700,000<span></span>
</td>
<td class="nump">$ 35,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAnnualPrincipalPayment', window );">Debt instrument, annual principal payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,900,000<span></span>
</td>
<td class="nump">69,800,000<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="nump">45,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on debt extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,634,000<span></span>
</td>
<td class="num">$ (12,463,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,463,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from Related Party Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,900,000<span></span>
</td>
<td class="nump">45,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,850,000<span></span>
</td>
<td class="nump">18,400,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sclx_SorrentoMember', window );">Sorrento [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchaseAmount', window );">Debt instrument, repurchase amount</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from Related Party Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sclx_SorrentoMember', window );">Sorrento [Member] | Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AmendmentAxis=sclx_AmendmentNoFourMember', window );">Amendment No Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCollateralAmount', window );">Debt instrument, collateral amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnRestructuringOfDebt', window );">Gains (Losses) on Restructuring of Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AmendmentAxis=sclx_AmendmentNoFourMember', window );">Amendment No Four [Member] | Sorrento [Member] | Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=sclx_PaycheckProtectionProgramMember', window );">Paycheck Protection Program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt instrument, maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May  05,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on debt extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=sclx_PaycheckProtectionProgramMember', window );">Paycheck Protection Program [Member] | Coronavirus Aid, Relief, and Economic Security Act [Member] | Non Payroll Costs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_MaximumCompensationCostToBeAvailableProratedBasis', window );">Maximum compensation cost to be available, prorated basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PercentageOfLoanForgivenessUnderTheAct', window );">Percentage of loan forgiveness under the act</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=sclx_PaycheckProtectionProgramMember', window );">Paycheck Protection Program [Member] | Coronavirus Aid, Relief, and Economic Security Act [Member] | Payroll Costs Basis [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PercentageOfLoanForgivenessUnderTheAct', window );">Percentage of loan forgiveness under the act</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_MinimumPayrollCostToBeAvailable', window );">Minimum payroll cost to be available</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of debt</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from lines of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Repayments of lines of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Debt instrument face amount of debt repurchased</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_MinimumCashRequirementsToRepurchaseOfNotes', window );">Minimum cash requirements to repurchase of Notes</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PercentageOfThePrincipalAmountOfTheNotes', window );">Percentage of the principal amount of the Notes</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=sclx_AccountsReceivableRevolvingLoanFacilityMember', window );">Accounts receivable revolving loan facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_LineOfCreditFacilityindebtednessAmount', window );">Line of credit facility, indebtedness amount</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AgreementAxis=sclx_IndebentureMember', window );">Indebenture [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt instrument, maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul.  01,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed', window );">Debt instrument, redemption price, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Debt instrument face amount of debt repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PercentageOfThePrincipalAmountFromHoldersOnProRataBasis', window );">Percentage of the principal amount from Holders on pro rata basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=sclx_IfLetterOfCreditIsDrawnMember', window );">If Letter Of Credit Is Drawn [Member] | Indebenture [Member] | Letter of Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Debt instrument face amount of debt repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=sclx_MarketingApprovalLetterMember', window );">Marketing Approval Letter [Member] | Indebenture [Member] | Letter of Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Debt instrument face amount of debt repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Letter of Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_MinimumCashRequirementsToRepurchaseOfNotes', window );">Minimum cash requirements to repurchase of Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Indebenture [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed', window );">Debt instrument, redemption price, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Letter of Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_MinimumCashRequirementsToRepurchaseOfNotes', window );">Minimum cash requirements to repurchase of Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Indebenture [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed', window );">Debt instrument, redemption price, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sclx_TwoThousandAndEighteenPurchaseAgreementsMember', window );">2018 Purchase Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 224,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchaseAmount', window );">Debt instrument, repurchase amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2026 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 89,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PaymentToDepositIntoASeggregateReserveFund', window );">Payment to deposit into a seggregate reserve fund</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PaymentToDepositIntoASegregatedCollateralAccount', window );">Payment to deposit into a segregated collateral account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PercentageOfConcentrationOnASimilarProduct', window );">Percentage of concentration on a similar product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Debt instrument, periodic payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sclx_TwoThousandAndEighteenPurchaseAgreementsMember', window );">2018 Purchase Agreements [Member] | Scenario, Adjustment [Member] | Debt Instrument, Redemption, Period One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Revenue not from contract with customer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 218,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sclx_TwoThousandAndEighteenPurchaseAgreementsMember', window );">2018 Purchase Agreements [Member] | Scenario, Adjustment [Member] | Debt Instrument, Redemption, Period Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Revenue not from contract with customer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">481,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sclx_TwoThousandAndEighteenPurchaseAgreementsMember', window );">2018 Purchase Agreements [Member] | Scenario, Adjustment [Member] | Debt Instrument, Redemption, Period Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Revenue not from contract with customer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 290,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt instrument, maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nov. 15,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sclx_TwoThousandAndEighteenPurchaseAgreementsMember', window );">2018 Purchase Agreements [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PercentageOfQuarterlyPaymentsOfThePrincipalNotesEqualToAFixedPercentage', window );">Percentage of quarterly payments of the principal Notes equal to a fixed percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PercentageOfNetSalesPayable', window );">Percentage of net sales payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sclx_TwoThousandAndEighteenPurchaseAgreementsMember', window );">2018 Purchase Agreements [Member] | Maximum [Member] | Debt Instrument, Redemption, Period One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sclx_TwoThousandAndEighteenPurchaseAgreementsMember', window );">2018 Purchase Agreements [Member] | Maximum [Member] | Scenario, Adjustment [Member] | Debt Instrument, Redemption, Period Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sclx_TwoThousandAndEighteenPurchaseAgreementsMember', window );">2018 Purchase Agreements [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PercentageOfQuarterlyPaymentsOfThePrincipalNotesEqualToAFixedPercentage', window );">Percentage of quarterly payments of the principal Notes equal to a fixed percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PercentageOfNetSalesPayable', window );">Percentage of net sales payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sclx_TwoThousandAndEighteenPurchaseAgreementsMember', window );">2018 Purchase Agreements [Member] | Minimum [Member] | Debt Instrument, Redemption, Period One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sclx_TwoThousandAndEighteenPurchaseAgreementsMember', window );">2018 Purchase Agreements [Member] | Minimum [Member] | Scenario, Adjustment [Member] | Debt Instrument, Redemption, Period Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sclx_ScilexPharmaNoteMember', window );">Scilex Pharma Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt instrument, maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug. 15,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DebtInstrumentredemptionPeriod', window );">Debt instrument,redemption period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Debt instrument face amount of debt repurchased</a></td>
<td class="nump">$ 60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PercentageOfThePrincipalAmountOfTheNotes', window );">Percentage of the principal amount of the Notes</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_MinimumUnrestrictedCashRequirementsToRepurchaseOfNotes', window );">Minimum unrestricted cash requirements to repurchase of Notes</a></td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AmountDistributionToAcquireRelatedContingentAcceleratedRepaymentNotes', window );">Amount distribution to acquire related contingent accelerated repayment notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountCurrent', window );">Debt instrument, unamortized discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.70%<span></span>
</td>
<td class="nump">9.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts', window );">Debt related commitment Fees and debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,100,000<span></span>
</td>
<td class="nump">5,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,900,000<span></span>
</td>
<td class="nump">$ 10,700,000<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on debt extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease', window );">Change in fair value measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet', window );">Debt instrument, increase (decrease), net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt instrument interest rate effective percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sclx_ScilexPharmaNoteMember', window );">Scilex Pharma Note [Member] | 2018 Purchase Agreements and Indenture [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,000,000<span></span>
</td>
<td class="nump">44,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on debt extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,600,000<span></span>
</td>
<td class="nump">$ 14,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sclx_ScilexPharmaNoteMember', window );">Scilex Pharma Note [Member] | Amendment No Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchaseAmount', window );">Debt instrument, repurchase amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Debt instrument face amount of debt repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DebtInstrumentPercentageOfPrincipalAmountRepurchased', window );">Debt instrument, percentage of principal amount repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentDecreaseForgiveness', window );">Debt instrument, decrease, forgiveness</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sclx_ScilexPharmaNoteMember', window );">Scilex Pharma Note [Member] | Subordinated Debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchaseAmount', window );">Debt instrument, repurchase amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sclx_ScilexPharmaNoteMember', window );">Scilex Pharma Note [Member] | December Optional Repurchase [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Debt instrument face amount of debt repurchased</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sclx_ScilexPharmaNoteMember', window );">Scilex Pharma Note [Member] | February Optional Repurchase [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Debt instrument face amount of debt repurchased</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sclx_ScilexPharmaNoteMember', window );">Scilex Pharma Note [Member] | April Optional Repurchase [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Debt instrument face amount of debt repurchased</a></td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sclx_ScilexPharmaNoteMember', window );">Scilex Pharma Note [Member] | Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_LineOfCreditFacilityindebtednessAmount', window );">Line of credit facility, indebtedness amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,800,000<span></span>
</td>
<td class="nump">$ 9,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DebtInstrumentTerminationDate', window );">Debt instrument, termination date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 18,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sclx_ScilexPharmaNoteMember', window );">Scilex Pharma Note [Member] | Revolving Credit Facility [Member] | Prime Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sclx_ScilexPharmaNoteMember', window );">Scilex Pharma Note [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed', window );">Debt instrument, redemption price, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sclx_ScilexPharmaNoteMember', window );">Scilex Pharma Note [Member] | Maximum [Member] | Amendment No Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchaseDate', window );">Debt instrument, repurchase date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Sep. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sclx_ScilexPharmaNoteMember', window );">Scilex Pharma Note [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed', window );">Debt instrument, redemption price, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AmountDistributionToAcquireRelatedContingentAcceleratedRepaymentNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount distribution to acquire related contingent accelerated repayment notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AmountDistributionToAcquireRelatedContingentAcceleratedRepaymentNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_DebtInstrumentPercentageOfPrincipalAmountRepurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument, percentage of principal amount repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_DebtInstrumentPercentageOfPrincipalAmountRepurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_DebtInstrumentTerminationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument, termination date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_DebtInstrumentTerminationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_DebtInstrumentredemptionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument,redemption period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_DebtInstrumentredemptionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_LineOfCreditFacilityindebtednessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line of credit facility ,indebtedness amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_LineOfCreditFacilityindebtednessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_MaximumCompensationCostToBeAvailableProratedBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum compensation cost to be available, prorated basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_MaximumCompensationCostToBeAvailableProratedBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_MinimumCashRequirementsToRepurchaseOfNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum cash requirements to repurchase of notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_MinimumCashRequirementsToRepurchaseOfNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_MinimumPayrollCostToBeAvailable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum payroll cost to be available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_MinimumPayrollCostToBeAvailable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_MinimumUnrestrictedCashRequirementsToRepurchaseOfNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum unrestricted cash requirements to repurchase of notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_MinimumUnrestrictedCashRequirementsToRepurchaseOfNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PaymentToDepositIntoASeggregateReserveFund">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment to deposit into a seggregate reserve fund.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PaymentToDepositIntoASeggregateReserveFund</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PaymentToDepositIntoASegregatedCollateralAccount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment to deposit into a segregated collateral account.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PaymentToDepositIntoASegregatedCollateralAccount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PercentageOfConcentrationOnASimilarProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of concentration on a similar product.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PercentageOfConcentrationOnASimilarProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PercentageOfLoanForgivenessUnderTheAct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of loan forgiveness under the act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PercentageOfLoanForgivenessUnderTheAct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PercentageOfNetSalesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of net sales payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PercentageOfNetSalesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PercentageOfQuarterlyPaymentsOfThePrincipalNotesEqualToAFixedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of quarterly payments of the principal notes equal to a fixed percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PercentageOfQuarterlyPaymentsOfThePrincipalNotesEqualToAFixedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PercentageOfThePrincipalAmountFromHoldersOnProRataBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the principal amount from Holders on pro rata basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PercentageOfThePrincipalAmountFromHoldersOnProRataBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PercentageOfThePrincipalAmountOfTheNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the principal amount of the notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PercentageOfThePrincipalAmountOfTheNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAnnualPrincipalPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the total principal payments made during the annual reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAnnualPrincipalPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCollateralAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets pledged to secure a debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCollateralAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDecreaseForgiveness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease for amounts of indebtedness forgiven by the holder of the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDecreaseForgiveness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net increase or decrease in the carrying amount of the debt instrument for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments including both interest and principal payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of principal amount of debt redeemed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchaseAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value amount of debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchaseAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchaseDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the debt instrument was repurchased, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchaseDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchasedFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of the original debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchasedFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of debt discount to be amortized within one year or within the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the charge against earnings during the period for commitment fees and debt issuance expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnRestructuringOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For a debtor, the aggregate gain (loss) recognized on the restructuring of payables arises from the difference between the book value of the debt before the restructuring and the fair value of the payments on the debt after restructuring is complete.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 60<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6402221&amp;loc=d3e15743-112638<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnRestructuringOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueNotFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue that is not accounted for under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueNotFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sclx_SorrentoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sclx_SorrentoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=sclx_PromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=sclx_PromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AmendmentAxis=sclx_AmendmentNoFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AmendmentAxis=sclx_AmendmentNoFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=sclx_PaycheckProtectionProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=sclx_PaycheckProtectionProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_EventTypeAxis=sclx_CoronavirusAidReliefAndEconomicSecurityActMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_EventTypeAxis=sclx_CoronavirusAidReliefAndEconomicSecurityActMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ClassificationOfCostAxis=sclx_NonPayrollCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ClassificationOfCostAxis=sclx_NonPayrollCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ClassificationOfCostAxis=sclx_PayrollCostsBasisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ClassificationOfCostAxis=sclx_PayrollCostsBasisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=sclx_AccountsReceivableRevolvingLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=sclx_AccountsReceivableRevolvingLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AgreementAxis=sclx_IndebentureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AgreementAxis=sclx_IndebentureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=sclx_IfLetterOfCreditIsDrawnMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=sclx_IfLetterOfCreditIsDrawnMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=sclx_MarketingApprovalLetterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=sclx_MarketingApprovalLetterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=sclx_TwoThousandAndEighteenPurchaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=sclx_TwoThousandAndEighteenPurchaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=us-gaap_ScenarioAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=us-gaap_ScenarioAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=sclx_ScilexPharmaNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=sclx_ScilexPharmaNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sclx_TwoThousandAndEighteenPurchaseAgreementsAndIndentureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sclx_TwoThousandAndEighteenPurchaseAgreementsAndIndentureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SubordinatedDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SubordinatedDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_StatementAxis=sclx_DecemberOptionalRepurchaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_StatementAxis=sclx_DecemberOptionalRepurchaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_StatementAxis=sclx_FebruaryOptionalRepurchaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_StatementAxis=sclx_FebruaryOptionalRepurchaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_StatementAxis=sclx_AprilOptionalRepurchaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_StatementAxis=sclx_AprilOptionalRepurchaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_PrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139838681986432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt (Details) - Summary of borrowings of the scilex pharma notes - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (37,950,000)<span></span>
</td>
<td class="num">$ (15,888,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long term portion</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">72,037,000<span></span>
</td>
<td class="nump">92,255,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sclx_ScilexPharmaNotesMember', window );">Scilex Pharma Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">133,997,000<span></span>
</td>
<td class="nump">151,872,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized debt discount</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(30,597,000)<span></span>
</td>
<td class="num">(51,022,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnamortizedDebtIssuanceExpense', window );">Unamortized debt issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,228,000)<span></span>
</td>
<td class="num">(3,711,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Carrying value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">101,172,000<span></span>
</td>
<td class="nump">97,139,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(29,135,000)<span></span>
</td>
<td class="num">(4,881,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long term portion</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">72,037,000<span></span>
</td>
<td class="nump">92,258<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Estimated fair value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 115,400,000<span></span>
</td>
<td class="nump">$ 122,300,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnamortizedDebtIssuanceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnamortizedDebtIssuanceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=sclx_ScilexPharmaNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=sclx_ScilexPharmaNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139838694682704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt (Details)  - Summary of future minimum payments under the scilex pharma notes<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtLineItems', window );"><strong>Schedule Of Future minimum payments Of Long Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_LongtermDebtfutureMinimumPaymentYearOne', window );">2022</a></td>
<td class="nump">$ 29,135<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_LongtermDebtFutureMinimumPaymentYearTwo', window );">2023</a></td>
<td class="nump">12,005<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_LongtermDebtFutureMinimumPaymentYearThree', window );">2024</a></td>
<td class="nump">13,637<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_LongtermDebtFutureMinimumPaymentYearFour', window );">2025</a></td>
<td class="nump">14,746<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_LongtermDebtFutureMinimumPaymentYearFive', window );">2026</a></td>
<td class="nump">64,474<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_LongtermDebtFutureMinimumPayment', window );">Total minimum future payments</a></td>
<td class="nump">$ 133,997<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_LongtermDebtFutureMinimumPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-term debt, future minimum payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_LongtermDebtFutureMinimumPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_LongtermDebtFutureMinimumPaymentYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-term debt, future minimum payment , year five.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_LongtermDebtFutureMinimumPaymentYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_LongtermDebtFutureMinimumPaymentYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-term debt, future minimum payment , year four.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_LongtermDebtFutureMinimumPaymentYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_LongtermDebtFutureMinimumPaymentYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-term debt, future minimum payment , year three.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_LongtermDebtFutureMinimumPaymentYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_LongtermDebtFutureMinimumPaymentYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-term debt, future minimum payment , year two.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_LongtermDebtFutureMinimumPaymentYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_LongtermDebtfutureMinimumPaymentYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-Term Debt,&#160;Future minimum payment , year one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_LongtermDebtfutureMinimumPaymentYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of future minimum payments of long term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139838673222256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive and Employee Benefit Plans (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>May 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 17, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CompensationAndEmployeeBenefitPlansLineItems', window );"><strong>Compensation And Employee Benefit Plans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingNumber', window );">Share based compensation arrangement,Options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,163,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share based compensation arrangement,Options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,804,000<span></span>
</td>
<td class="nump">25,159,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,163,000<span></span>
</td>
<td class="nump">30,804,000<span></span>
</td>
<td class="nump">25,411,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,781,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant', window );">Fair value per share of common stock on date of grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.16<span></span>
</td>
<td class="nump">$ 1.16<span></span>
</td>
<td class="nump">$ 1.16<span></span>
</td>
<td class="nump">$ 1.16<span></span>
</td>
<td class="nump">$ 1.16<span></span>
</td>
<td class="nump">$ 1.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CompensationAndEmployeeBenefitPlansLineItems', window );"><strong>Compensation And Employee Benefit Plans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToEmployees', window );">Payment to employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanNameAxis=sclx_FourHundredAndOneKPlanMember', window );">401(k) Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CompensationAndEmployeeBenefitPlansLineItems', window );"><strong>Compensation And Employee Benefit Plans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Defined contribution plan matching contribution amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=sclx_OperatingExpensesMember', window );">Operating Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CompensationAndEmployeeBenefitPlansLineItems', window );"><strong>Compensation And Employee Benefit Plans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.0<span></span>
</td>
<td class="nump">$ 4.4<span></span>
</td>
<td class="nump">$ 5.8<span></span>
</td>
<td class="nump">$ 5.4<span></span>
</td>
<td class="nump">$ 4.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sclx_ScilexPharmaTwoThousandSeventeenPlanMember', window );">Scilex Pharma 2017 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CompensationAndEmployeeBenefitPlansLineItems', window );"><strong>Compensation And Employee Benefit Plans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for issuance under plan</a></td>
<td class="nump">24,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Share based compensation arrangement,vesting rights</a></td>
<td class="text">Stock options granted under the Scilex Pharma 2017 Plan typically vest 1/4th of the shares on the first anniversary of the vesting commencement date and 1/48th of the remaining options vest each month thereafter.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share based compensation arrangement,Options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,105,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,420,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sclx_TwoThousandNineteenStockOptionPlanMember', window );">2019 Stock Option Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CompensationAndEmployeeBenefitPlansLineItems', window );"><strong>Compensation And Employee Benefit Plans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for issuance under plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,000,000<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Share based compensation arrangement,vesting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Stock options granted under the 2019 Stock Option Plan typically vest with respect to 1/4th of the shares on the first anniversary of the vesting commencement date and 1/48th of the remaining shares on each monthly anniversary thereafter.<span></span>
</td>
<td class="text">20,945,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18,256,490<span></span>
</td>
<td class="text">Stock options granted under the 2019 Stock Option Plan typically vest with respect to 1/4th of the shares on the first anniversary of the vesting commencement date and 1/48th of the remaining shares on each monthly anniversary thereafter.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share based compensation arrangement,Options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,054,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,743,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sclx_AmendmentToTwoThousandNineteenStockOptionPlanMember', window );">Amendment to 2019 Stock Option Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CompensationAndEmployeeBenefitPlansLineItems', window );"><strong>Compensation And Employee Benefit Plans [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for issuance under plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_CompensationAndEmployeeBenefitPlansLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Compensation and employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_CompensationAndEmployeeBenefitPlansLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sharebased compensation arrangement by sharebased payment award fair value assumptions per share of common stock on date of grant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments of cash to employees, including wages and salaries, during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanNameAxis=sclx_FourHundredAndOneKPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanNameAxis=sclx_FourHundredAndOneKPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=sclx_OperatingExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=sclx_OperatingExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sclx_ScilexPharmaTwoThousandSeventeenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sclx_ScilexPharmaTwoThousandSeventeenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sclx_TwoThousandNineteenStockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sclx_TwoThousandNineteenStockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sclx_AmendmentToTwoThousandNineteenStockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sclx_AmendmentToTwoThousandNineteenStockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139838686252320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive and Employee Benefit Plans (Details) - Summary of share based payment award options issued to employees and nonemployees valuation assumptions - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>May 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 17, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value</a></td>
<td class="nump">$ 0.83<span></span>
</td>
<td class="nump">$ 0.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock-price volatility</a></td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected stock-price volatility, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected stock-price volatility, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.53%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.63%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term of options</a></td>
<td class="text">5 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant', window );">Fair value per share of common stock on date of grant</a></td>
<td class="nump">$ 1.16<span></span>
</td>
<td class="nump">$ 1.16<span></span>
</td>
<td class="nump">$ 1.16<span></span>
</td>
<td class="nump">$ 1.16<span></span>
</td>
<td class="nump">$ 1.16<span></span>
</td>
<td class="nump">$ 1.16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 1.16<span></span>
</td>
<td class="nump">$ 1.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 9 months 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sharebased compensation arrangement by sharebased payment award fair value assumptions per share of common stock on date of grant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139838686244240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive and Employee Benefit Plans (Details) - Summary of the options outstanding - USD ($)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract', window );"><strong>Share-Based Payment Arrangement, Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Beginning, Options</a></td>
<td class="nump">28,163,000<span></span>
</td>
<td class="nump">30,804,000<span></span>
</td>
<td class="nump">25,411,000<span></span>
</td>
<td class="nump">4,781,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted, Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,194,000<span></span>
</td>
<td class="nump">21,468,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised, Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(56,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Forfeited/Cancelled, Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,641,000)<span></span>
</td>
<td class="num">(745,000)<span></span>
</td>
<td class="num">(838,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Ending, Options</a></td>
<td class="nump">25,159,760<span></span>
</td>
<td class="nump">28,163,000<span></span>
</td>
<td class="nump">30,804,000<span></span>
</td>
<td class="nump">25,411,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable, Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,177,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, Beginning, Weighted average exercise price</a></td>
<td class="nump">$ 1.13<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="nump">$ 1.07<span></span>
</td>
<td class="nump">$ 0.63<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted, Weighted average exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1.16<span></span>
</td>
<td class="nump">1.16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised, Weighted average exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Forfeited/Cancelled, Weighted average exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.68<span></span>
</td>
<td class="nump">0.94<span></span>
</td>
<td class="nump">0.94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, Ending, Weighted average exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.13<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="nump">$ 1.07<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable, Weighted average exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding, Beginning, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 915<span></span>
</td>
<td class="nump">$ 2,172<span></span>
</td>
<td class="nump">$ 2,183<span></span>
</td>
<td class="nump">$ 1,291<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding, Ending, Aggregate Intrinsic Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 915<span></span>
</td>
<td class="nump">$ 2,172<span></span>
</td>
<td class="nump">$ 2,183<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139838686611344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 07, 2019</div></th>
<th class="th"><div>Mar. 18, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jan. 29, 2021</div></th>
<th class="th"><div>Mar. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PeriodDuringWhichShareTransferIsRestricted', window );">Period during which share transfer is restricted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PeriodDuringWhichTheSharesMayBeExchanged', window );">Period during which the shares may be exchanged</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">In process research and development costs expensed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 75,301,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=sclx_AsRestatedMember', window );">As Restated [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Accrued Liabilities</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_InvesteeAxis=sclx_SorrentoMember', window );">Sorrento [Member] | 2022 Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent', window );">Notes Payable, Related Parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.66%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=sclx_SenmurMember', window );">Senmur [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Asset acquisition total consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Payments to acquire productive assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable', window );">Asset acquistion consideration transferred equity interest issued and issuable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Stock issued during period shares purchase of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,039,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesSubscribedButUnissued', window );">Common stock shares subscribed but not issued</a></td>
<td class="nump">352,972<span></span>
</td>
<td class="nump">352,972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AssetAcquisitionPricePerShare', window );">Asset acquisition price per share</a></td>
<td class="nump">$ 1.16<span></span>
</td>
<td class="nump">$ 1.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PercentageOfOwnershipInterest', window );">Percentage of ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationLiability', window );">Asset acquistion contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 280,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PercentageOfSharesIssuedSubjectToRestrictionOfTransfer', window );">Percentage of shares issued subject to restriction of transfer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PeriodDuringWhichShareTransferIsRestricted', window );">Period during which share transfer is restricted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PeriodDuringWhichTheSharesMayBeExchanged', window );">Period during which the shares may be exchanged</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_CommonStockValueToBeExchanged', window );">Common stock value to be exchanged</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_NumberOfDaysForDeterminingTheWeightedVolumeAveragePriceForShares', window );">Number of days for determining the weighted volume averge price of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PricePerShareForDeterminingTheExchangeOfShares', window );">Price per share for determining the exchange of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PaymentMadeInSurrenderingTheShares', window );">Payment made in surrendering the shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">In process research and development costs expensed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Proceeds from Divestiture of Businesses</a></td>
<td class="nump">$ 40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=sclx_SenmurMember', window );">Senmur [Member] | As Restated [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Accrued Liabilities</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=sclx_SenmurMember', window );">Senmur [Member] | Sorrento [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PaymentMadeInSurrenderingTheShares', window );">Payment made in surrendering the shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PercentageOfSharesOutstanding', window );">Percentage of shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.97%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=sclx_SenmurMember', window );">Senmur [Member] | Regulatory Based Milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationLiability', window );">Asset acquistion contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=sclx_SenmurMember', window );">Senmur [Member] | Reveue Based Milestone [Member] | Tranche 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationLiability', window );">Asset acquistion contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RevenueToBeEarnedByTheAcquireeValue', window );">Revenue to be earned by the acquiree value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=sclx_SenmurMember', window );">Senmur [Member] | Reveue Based Milestone [Member] | Tranche 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationLiability', window );">Asset acquistion contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RevenueToBeEarnedByTheAcquireeValue', window );">Revenue to be earned by the acquiree value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=sclx_SenmurMember', window );">Senmur [Member] | Reveue Based Milestone [Member] | Tranche 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationLiability', window );">Asset acquistion contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RevenueToBeEarnedByTheAcquireeValue', window );">Revenue to be earned by the acquiree value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=sclx_SenmurMember', window );">Senmur [Member] | Reveue Based Milestone [Member] | Tranche 4 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationLiability', window );">Asset acquistion contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_RevenueToBeEarnedByTheAcquireeValue', window );">Revenue to be earned by the acquiree value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=sclx_AardvarkMember', window );">Aardvark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationLiability', window );">Asset acquistion contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=sclx_AardvarkMember', window );">Aardvark [Member] | Reveue Based Milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationLiability', window );">Asset acquistion contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=sclx_AardvarkMember', window );">Aardvark [Member] | Approval Based Milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationLiability', window );">Asset acquistion contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=sclx_RomegLicenseAgreementMember', window );">Romeg License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationLiability', window );">Asset acquistion contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_UpfrontlicenseFee', window );">Upfront License Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_MilestonePayment', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue', window );">Acquired Finite-Lived Intangible Asset, Residual Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DeferredConsideration', window );">Deferred consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite lived intangible asset, Useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AssetAcquisitionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset acquisition price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AssetAcquisitionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_CommonStockValueToBeExchanged">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock value to be exchanged.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_CommonStockValueToBeExchanged</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_DeferredConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>deferred consideration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_DeferredConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_MilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>milestone payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_MilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_NumberOfDaysForDeterminingTheWeightedVolumeAveragePriceForShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of days for determining the weighted volume average price for shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_NumberOfDaysForDeterminingTheWeightedVolumeAveragePriceForShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PaymentMadeInSurrenderingTheShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment made in surrendering the shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PaymentMadeInSurrenderingTheShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PercentageOfOwnershipInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of ownership interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PercentageOfOwnershipInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PercentageOfSharesIssuedSubjectToRestrictionOfTransfer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of shares issued subject to restriction of transfer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PercentageOfSharesIssuedSubjectToRestrictionOfTransfer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PercentageOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of shares outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PercentageOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PeriodDuringWhichShareTransferIsRestricted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period during which share transfer is restricted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PeriodDuringWhichShareTransferIsRestricted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PeriodDuringWhichTheSharesMayBeExchanged">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period during which the shares may be exchanged.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PeriodDuringWhichTheSharesMayBeExchanged</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PricePerShareForDeterminingTheExchangeOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price per share for determining the exchange of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PricePerShareForDeterminingTheExchangeOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_RevenueToBeEarnedByTheAcquireeValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue to be earned by the acquiree value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_RevenueToBeEarnedByTheAcquireeValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_UpfrontlicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>up-front&#160;license fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_UpfrontlicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expected value at the end of their useful life of a major finite-lived intangible asset class acquired during the period either individually or as part of a group of assets (in either an asset acquisition or business combination). A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9215-128498<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 55<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6829253&amp;loc=SL6831962-166255<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=127000608&amp;loc=d3e9135-128495<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9212-128498<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of acquirer's equity interest issued and issuable as part of consideration transferred in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9215-128498<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9212-128498<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=127000608&amp;loc=d3e9135-128495<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized from contingent consideration in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 15<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6911878&amp;loc=d3e8732-128492<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesSubscribedButUnissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesSubscribedButUnissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount for notes payable (written promise to pay), due to related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9212-128498<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9215-128498<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=127000608&amp;loc=d3e9135-128495<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=sclx_AsRestatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=sclx_AsRestatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_InvesteeAxis=sclx_SorrentoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_InvesteeAxis=sclx_SorrentoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=sclx_TwoThousandTwentyTwoPromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=sclx_TwoThousandTwentyTwoPromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=sclx_SenmurMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=sclx_SenmurMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_MilestoneAxis=sclx_RegulatoryBasedMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_MilestoneAxis=sclx_RegulatoryBasedMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_MilestoneAxis=sclx_ReveueBasedMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_MilestoneAxis=sclx_ReveueBasedMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_TrancheAxis=sclx_TrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_TrancheAxis=sclx_TrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_TrancheAxis=sclx_TrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_TrancheAxis=sclx_TrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_TrancheAxis=sclx_TrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_TrancheAxis=sclx_TrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_TrancheAxis=sclx_TrancheFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_TrancheAxis=sclx_TrancheFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=sclx_AardvarkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=sclx_AardvarkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_MilestoneAxis=sclx_ApprovalBasedMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_MilestoneAxis=sclx_ApprovalBasedMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=sclx_RomegLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=sclx_RomegLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139838694676400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Restatement of Previously Issued Financial Statements (Details) - Vicker's Vantage<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Condensed Financial Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockRedemptionPricePerShare', window );">Ordinary per share | $ / shares</a></td>
<td class="nump">$ 10.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsCurrent', window );">Net tangible assets | $</a></td>
<td class="nump">$ 5,000,001<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedFinancialStatementsCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedFinancialStatementsCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current portion of nonphysical assets, excluding financial assets, if these assets are classified into the current and noncurrent portions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockRedemptionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity is redeemed or may be called at. The redemption features of this preferred stock are solely within the control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21488-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21564-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockRedemptionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_VickersVantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_VickersVantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139838651118400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Restatement of Previously Issued Financial Statements (Details) - Schedule of impact of these adjustments to the financial statement, as previously reported - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jan. 10, 2022</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jan. 11, 2021</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Feb. 20, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Condensed Financial Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Warrant liability</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,700,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,400,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">318,172,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">301,808,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">223,187,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary Shares</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional Paid-in Capital</a></td>
<td class="nump">128,615,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128,654,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122,423,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated Deficit</a></td>
<td class="num">(358,030,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(352,550,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(264,126,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Shareholders' Equity (Deficit)</a></td>
<td class="num">(229,395,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(223,876,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (183,365,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(141,683,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (90,009,000)<span></span>
</td>
<td class="nump">$ 35,464,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vicker's Vantage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Condensed Financial Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Warrant liability</a></td>
<td class="nump">1,162,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,351,600<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">12,168,759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,240,295<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,760<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ordinary Shares Subject to Possible Redemption</a></td>
<td class="nump">101,293,086<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">139,380,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary Shares</a></td>
<td class="nump">345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">345<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">345<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional Paid-in Capital</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,035,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,655<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated Deficit</a></td>
<td class="num">(12,003,355)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,697,444)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,276)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Shareholders' Equity (Deficit)</a></td>
<td class="num">$ (12,003,010)<span></span>
</td>
<td class="num">$ (10,764,731)<span></span>
</td>
<td class="num">$ (10,538,321)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (8,697,099)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (9,829,785)<span></span>
</td>
<td class="num">$ (8,385,433)<span></span>
</td>
<td class="num">$ (8,151,684)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,724<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vicker's Vantage | Previously Reported [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Condensed Financial Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,345,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ordinary Shares Subject to Possible Redemption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129,999,029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional Paid-in Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,006,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated Deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,490)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Shareholders' Equity (Deficit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vicker's Vantage | Adjustments Restatement 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Condensed Financial Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,729,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,729,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ordinary Shares Subject to Possible Redemption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,729,200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional Paid-in Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,629,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated Deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,629,412)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Shareholders' Equity (Deficit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vicker's Vantage | Adjustments Restatement 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Condensed Financial Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ordinary Shares Subject to Possible Redemption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,110,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(169)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional Paid-in Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,635,396)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated Deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,474,606)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Shareholders' Equity (Deficit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,110,171)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vicker's Vantage | As Restated [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Condensed Financial Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,729,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,074,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ordinary Shares Subject to Possible Redemption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">139,380,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional Paid-in Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated Deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,110,508)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Shareholders' Equity (Deficit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (12,110,163)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="16"></td></tr>
<tr><td colspan="16"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">At December 31, 2020, includes an aggregate of up to 450,000 ordinary shares that are subject to forfeiture depending on the extent to which the underwriters&#8217; over-allotment option is exercised (see Note 6). On January 6, 2021, the Company effected a share capitalization of 0.2 shares for each share outstanding, resulting in 3,450,000 ordinary shares issued and outstanding (see Note 6). All share and per share amounts have been retroactively restated to reflect the share capitalization. As a result of the underwriters&#8217; full exercise of their overallotment option on January 11, 2021, no shares were forfeited.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedFinancialStatementsCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedFinancialStatementsCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_VickersVantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_VickersVantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RestatementAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RestatementAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=sclx_AdjustmentsRestatement2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=sclx_AdjustmentsRestatement2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=sclx_AsRestatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=sclx_AsRestatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139838685944528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (benefit) expense</a></td>
<td class="num">$ (36,400)<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="num">$ (53,000)<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rates</a></td>
<td class="nump">0.70%<span></span>
</td>
<td class="nump">0.02%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory federal tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,643,000<span></span>
</td>
<td class="nump">$ 43,514,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_TaxCreditCarryforwardExpirationYear', window );">Tax credit carryforward expiration year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_MinimumThresholdPercentageForRecognitionOfUncertainIncomeTaxPosition', window );">Minimum threshold percentage for recognition of uncertain income tax position</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense', window );">Income tax examination, penalties and interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 167,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_OperatingLossCarryforwardsExpirationYear', window );">Operating loss carryforward expiration year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal [Member] | Research Tax Credit Carryforward [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal [Member] | Indefinite Carryforward Period [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_OperatingLossCarryforwardsExpirationYear', window );">Operating loss carryforward expiration year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_IncomeTaxDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_IncomeTaxDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_MinimumThresholdPercentageForRecognitionOfUncertainIncomeTaxPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum threshold percentage for recognition of uncertain income tax position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_MinimumThresholdPercentageForRecognitionOfUncertainIncomeTaxPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_OperatingLossCarryforwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards expiration year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_OperatingLossCarryforwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_TaxCreditCarryforwardExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax credit carryforward, expiration year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_TaxCreditCarryforwardExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=sclx_IndefiniteCarryforwardPeriodMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=sclx_IndefiniteCarryforwardPeriodMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139838689907088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - Schedule of components of income tax expense (benefit) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="num">(53,000)<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current income tax expense (benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="num">(53,000)<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income tax expense (benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total</a></td>
<td class="num">$ (36,400)<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="num">$ (53,000)<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139838694822016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details) - Schedule of deferred tax assets and liabilities - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DeferredTaxAssetsInterestExpenseLimitations', window );">Interest expense limitations</a></td>
<td class="nump">$ 12,205<span></span>
</td>
<td class="nump">$ 8,225<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credit carryforwards</a></td>
<td class="nump">1,630<span></span>
</td>
<td class="nump">1,623<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">39,714<span></span>
</td>
<td class="nump">31,732<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock based compensation</a></td>
<td class="nump">3,233<span></span>
</td>
<td class="nump">2,037<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_DeferredTaxAssetsOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="nump">404<span></span>
</td>
<td class="nump">510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Others</a></td>
<td class="nump">1,753<span></span>
</td>
<td class="nump">2,285<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total Deferred Tax Assets</a></td>
<td class="nump">58,939<span></span>
</td>
<td class="nump">46,412<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(56,643)<span></span>
</td>
<td class="num">(43,514)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total Deferred Tax Assets</a></td>
<td class="nump">2,296<span></span>
</td>
<td class="nump">2,898<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred Tax Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Amortization of intangibles</a></td>
<td class="num">(1,975)<span></span>
</td>
<td class="num">(2,486)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Operating lease&#160;right-of-use&#160;assets</a></td>
<td class="num">(319)<span></span>
</td>
<td class="num">(412)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Total Deferred Tax Liabilities</a></td>
<td class="num">$ (2,296)<span></span>
</td>
<td class="num">$ (2,898)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_DeferredTaxAssetsInterestExpenseLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets interest expense limitations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_DeferredTaxAssetsInterestExpenseLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_DeferredTaxAssetsOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_DeferredTaxAssetsOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139838691633888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - Schedule of effective income tax rate reconciliation<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Effective Income Tax Rate Reconciliation, Percent [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory Federal Income Tax Rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal tax benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_EffectiveIncomeTaxRateReconciliationDebtDiscountAndInterestLimitation', window );">Debt discount and interest limitation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10.10%)<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment', window );">In-process&#160;research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(11.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustmentsAndCarryback', window );">Return to provision adjustments and carryback</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
<td class="num">(11.20%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Others</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.60%)<span></span>
</td>
<td class="num">(0.80%)<span></span>
</td>
<td class="num">(0.80%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14.80%)<span></span>
</td>
<td class="num">(13.20%)<span></span>
</td>
<td class="num">(14.20%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Income Tax Benefit</a></td>
<td class="nump">0.70%<span></span>
</td>
<td class="nump">0.02%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_EffectiveIncomeTaxRateReconciliationDebtDiscountAndInterestLimitation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation debt discount and interest limitation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_EffectiveIncomeTaxRateReconciliationDebtDiscountAndInterestLimitation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustmentsAndCarryback">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation return to provision adjustments and carryback.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustmentsAndCarryback</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139838691713376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="nump">25.2<span></span>
</td>
<td class="nump">30.3<span></span>
</td>
<td class="nump">28.2<span></span>
</td>
<td class="nump">30.8<span></span>
</td>
<td class="nump">25.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139838694350944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share (Details) - Summary of reconciliation of basic and diluted loss per share - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (5,480,000)<span></span>
</td>
<td class="num">$ (46,459,000)<span></span>
</td>
<td class="num">$ (88,424,000)<span></span>
</td>
<td class="num">$ (47,519,000)<span></span>
</td>
<td class="num">$ (178,594,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Denominator for Basic Loss Per Share</a></td>
<td class="nump">197,550,000<span></span>
</td>
<td class="nump">197,266,000<span></span>
</td>
<td class="nump">197,266,000<span></span>
</td>
<td class="nump">197,315,000<span></span>
</td>
<td class="nump">187,524,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DilutiveSecurities', window );">Effect of Dilutive Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Denominator for Diluted Loss per Share &#8212; Adjusted for Dilutive Securities</a></td>
<td class="nump">$ 197,550,000<span></span>
</td>
<td class="nump">$ 197,266,000<span></span>
</td>
<td class="nump">$ 197,266,000<span></span>
</td>
<td class="nump">$ 197,315,000<span></span>
</td>
<td class="nump">$ 187,524,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic Loss Per Share</a></td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="num">$ (0.45)<span></span>
</td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="num">$ (0.95)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Dilutive Loss Per Share</a></td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="num">$ (0.45)<span></span>
</td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="num">$ (0.95)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise stock options, restrictive stock units (RSUs), convertible preferred stock of an employee stock ownership plan (ESOP), and other dilutive convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139838654976496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">10 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Jan. 08, 2023</div></th>
<th class="th"><div>Nov. 17, 2022</div></th>
<th class="th"><div>Oct. 17, 2022</div></th>
<th class="th"><div>May 12, 2022</div></th>
<th class="th"><div>Feb. 15, 2022</div></th>
<th class="th"><div>Jan. 10, 2022</div></th>
<th class="th"><div>Jan. 27, 2022</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Nov. 10, 2022</div></th>
<th class="th"><div>Oct. 10, 2022</div></th>
<th class="th"><div>Apr. 18, 2022</div></th>
<th class="th"><div>Apr. 11, 2022</div></th>
<th class="th"><div>Mar. 30, 2022</div></th>
<th class="th"><div>Feb. 28, 2022</div></th>
<th class="th"><div>Feb. 14, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 20, 2021</div></th>
<th class="th"><div>Jan. 11, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchaseAmount', window );">Debt instrument, repurchase amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preference shares, authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinimumNetWorthRequiredForCompliance', window );">Minimum net worth to consummate business combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=sclx_FundingCommitmentLetterMember', window );">Funding Commitment Letter [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of Credit Facility, Maximum Borrowing Capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AggregateOutstandingAmount', window );">Aggregate Outstanding Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">310,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sclx_SorrentoMember', window );">Sorrento [Member] | Two Thousand And Twenty Two Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.66%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sclx_SorrentoMember', window );">Sorrento [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchaseAmount', window );">Debt instrument, repurchase amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="nump">$ 13,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sclx_ScilexPharmaNoteMember', window );">Scilex Pharma Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sclx_ScilexPharmaNoteMember', window );">Scilex Pharma Note [Member] | Subordinated Debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchaseAmount', window );">Debt instrument, repurchase amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vicker's Vantage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Contribution per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SponsorLoan', window );">Sponsor loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,035,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preference shares, authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock Issued During Period, Shares, Issued for Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vicker's Vantage | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preference shares, authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=sclx_VickersVantageMember', window );">Vicker's Vantage | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preference shares, authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_MinimumTimeDeclaredToFileWithSecRegardingResaleRegistrationStatement', window );">Minimum time declared to file with sec regarding resale registration statement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinimumNetWorthRequiredForCompliance', window );">Minimum net worth to consummate business combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Yorkville [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of aggregate ordinary shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | B. Riley [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of aggregate ordinary shares (in Shares)</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | B. Riley [Member] | PurchaseType A [Member] | Scilex Common Stock Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock Issued During Period, Shares, Issued for Services</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | B. Riley [Member] | PurchaseType B [Member] | Scilex Common Stock Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock Issued During Period, Shares, Issued for Services</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Standby Equity Purchase Agreement [Member] | Yorkville [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PeriodAfterRegistrationWhenTheRequestCouldBeMadeToTheInvesteeToPurchaseTheShares', window );">Period After Registration When The Request Could Be Made To The Investee To Purchase The Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_MaximumPercentageOfVolumeWeightedAveragePriceOfSharesMeasuredOnADailyBasisThatIsEligibleToBeReceivedAsAdvance', window );">Maximum Percentage Of Volume Weighted Average Price Of Shares Measured On A Daily Basis That Is Eligible To Be Received As Advance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_NumberOfThresholdTradingDaysPriorToDateOfNoticeToTheShareholdersForDeterminingTheVolumeWeightedAveragePriceOfShares', window );">Number Of Threshold Trading Days Prior To Date Of Notice To The Shareholders For Determining The Volume Weighted Average Price Of Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PercentageOfDailyVolumeWeightedAveragePriceOfSharesAtWhichTheSharesAreEligibleToBePurchased', window );">Percentage Of Daily Volume Weighted Average Price Of Shares At Which The Shares Are Eligible To Be Purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_NumberOfConsecutiveTradingDaysForDeterminingTheVolumeWeightedAveragePriceOfShares', window );">Number Of Consecutive Trading Days For Determining The Volume Weighted Average Price Of Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesSubscriptions', window );">Common stock shares subscribed but not issued value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Standby Equity Purchase Agreement [Member] | B. Riley [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PeriodAfterRegistrationWhenTheRequestCouldBeMadeToTheInvesteeToPurchaseTheShares', window );">Period After Registration When The Request Could Be Made To The Investee To Purchase The Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PercentageOfDailyVolumeWeightedAveragePriceOfSharesAtWhichTheSharesAreEligibleToBePurchased', window );">Percentage Of Daily Volume Weighted Average Price Of Shares At Which The Shares Are Eligible To Be Purchased</a></td>
<td class="nump">98.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesSubscriptions', window );">Common stock shares subscribed but not issued value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Funding Commitment Letter [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of Credit Facility, Maximum Borrowing Capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AggregateOutstandingAmount', window );">Aggregate Outstanding Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 310,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preference shares, authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preference shares, authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Aardvark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Asset acquisition, consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Payments to acquire productive assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Sorrento [Member] | Two Thousand And Twenty Two Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.66%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_MinimumTimeDeclaredToFileWithSecRegardingResaleRegistrationStatement', window );">Minimum time declared to file with sec regarding resale registration statement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Sorrento [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent', window );">Notes payable, related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Scilex Pharma Note [Member] | Subordinated Debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchaseAmount', window );">Debt instrument, repurchase amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_PercentageOfPurchasePriceInCashEqualIsToPrincipalAmountOfTheLoan', window );">Percentage of purchase price in cash equal is to principal amount of the loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SalesThresholdLimit', window );">Sales threshold limit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 481,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Scilex Pharma Note [Member] | Subordinated Debt [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Vicker's Vantage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseDepositLiability', window );">Sponsors deposited (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 323,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNoParValue', window );">Common stock par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Contribution per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_NumberOfSharesLimits', window );">Number of shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_WarrantExercisePrice', window );">Warrant Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_AdditionalPrincipalAmount', window );">Additional principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_ConvertiblePromissoryNote', window );">Convertible Promissory Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,035,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Sorrento [Member] | Agreement With Certain Of The Third Party Professional Service Providers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAssumed1', window );">Liabilities assumed in a non cash transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Sorrento [Member] | Agreement With Certain Of The Third Party Professional Service Providers [Member] | Accounts Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAssumed1', window );">Liabilities assumed in a non cash transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Sorrento [Member] | Agreement With Certain Of The Third Party Professional Service Providers [Member] | Accrued Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sclx_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAssumed1', window );">Liabilities assumed in a non cash transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AdditionalPrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional principal amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AdditionalPrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AggregateOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate outstanding amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AggregateOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_ConvertiblePromissoryNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible promissory note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_ConvertiblePromissoryNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_MaximumPercentageOfVolumeWeightedAveragePriceOfSharesMeasuredOnADailyBasisThatIsEligibleToBeReceivedAsAdvance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of volume weighted average price of shares measured on a daily basis that is eligible to be received as advance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_MaximumPercentageOfVolumeWeightedAveragePriceOfSharesMeasuredOnADailyBasisThatIsEligibleToBeReceivedAsAdvance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_MinimumTimeDeclaredToFileWithSecRegardingResaleRegistrationStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum time declared to file with sec regarding resale registration statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_MinimumTimeDeclaredToFileWithSecRegardingResaleRegistrationStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_NumberOfConsecutiveTradingDaysForDeterminingTheVolumeWeightedAveragePriceOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of consecutive trading days for determining the volume weighted average price of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_NumberOfConsecutiveTradingDaysForDeterminingTheVolumeWeightedAveragePriceOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_NumberOfSharesLimits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares limits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_NumberOfSharesLimits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_NumberOfThresholdTradingDaysPriorToDateOfNoticeToTheShareholdersForDeterminingTheVolumeWeightedAveragePriceOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of threshold trading days prior to date of notice to the shareholders for determining the volume weighted average price of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_NumberOfThresholdTradingDaysPriorToDateOfNoticeToTheShareholdersForDeterminingTheVolumeWeightedAveragePriceOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PercentageOfDailyVolumeWeightedAveragePriceOfSharesAtWhichTheSharesAreEligibleToBePurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of daily volume weighted average price of shares at which the shares are eligible to be purchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PercentageOfDailyVolumeWeightedAveragePriceOfSharesAtWhichTheSharesAreEligibleToBePurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PercentageOfPurchasePriceInCashEqualIsToPrincipalAmountOfTheLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of purchase price in cash equal is to principal amount of the loan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PercentageOfPurchasePriceInCashEqualIsToPrincipalAmountOfTheLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_PeriodAfterRegistrationWhenTheRequestCouldBeMadeToTheInvesteeToPurchaseTheShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period after registration when the request could be made to the investee to purchase the shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_PeriodAfterRegistrationWhenTheRequestCouldBeMadeToTheInvesteeToPurchaseTheShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_SalesThresholdLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales threshold limit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_SalesThresholdLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_SponsorLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sponsor loan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_SponsorLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_SubsequentEventsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_SubsequentEventsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_WarrantExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_WarrantExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sclx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9215-128498<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 55<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6829253&amp;loc=SL6831962-166255<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=127000608&amp;loc=d3e9135-128495<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9212-128498<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNoParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount per share of no-par value common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNoParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesSubscriptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Monetary value of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=65888546&amp;loc=d3e21300-112643<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesSubscriptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchaseAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value amount of debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchaseAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseDepositLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability for lease payments received, including variable lease payments, when collectability is not probable at commencement date for sales-type lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 25<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123408481&amp;loc=SL77919106-209958<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseDepositLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of liabilities assumed in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinimumNetWorthRequiredForCompliance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum net worth required for mortgage banking as defined by regulatory framework.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 948<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6490092&amp;loc=d3e47304-110998<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 948<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6490092&amp;loc=d3e47304-110998<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 948<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=6490092&amp;loc=d3e47080-110998<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 948<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6490092&amp;loc=d3e47304-110998<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinimumNetWorthRequiredForCompliance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount for notes payable (written promise to pay), due to related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9212-128498<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9215-128498<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=127000608&amp;loc=d3e9135-128495<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=sclx_FundingCommitmentLetterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=sclx_FundingCommitmentLetterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=sclx_SorrentoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=sclx_SorrentoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=sclx_TwoThousandAndTwentyTwoPromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=sclx_TwoThousandAndTwentyTwoPromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sclx_SorrentoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sclx_SorrentoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=sclx_ScilexPharmaNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=sclx_ScilexPharmaNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SubordinatedDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SubordinatedDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_VickersVantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_VickersVantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_InvesteeAxis=sclx_YorkvilleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_InvesteeAxis=sclx_YorkvilleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_InvesteeAxis=sclx_B.RileyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_InvesteeAxis=sclx_B.RileyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sclx_PurchasetypeAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sclx_PurchasetypeAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=sclx_ScilexCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=sclx_ScilexCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sclx_PurchasetypeBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sclx_PurchasetypeBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AgreementAxis=sclx_StandbyEquityPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AgreementAxis=sclx_StandbyEquityPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=sclx_AardvarkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=sclx_AardvarkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=sclx_SorrentoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=sclx_SorrentoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sclx_AgreementAxis=sclx_AgreementWithCertainOfTheThirdPartyProfessionalServiceProvidersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sclx_AgreementAxis=sclx_AgreementWithCertainOfTheThirdPartyProfessionalServiceProvidersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>d428534ds1_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:sclx="http://www.vickersvantagecorp.com/20220930"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="sclx-20220930.xsd" xlink:type="simple"/>
    <context id="PAsOn12_31_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="P01_01_2021To09_30_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P02_01_2019To02_28_2019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="PAsOn07_31_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn05_31_2019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <instant>2019-05-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_17_2019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <instant>2019-03-17</instant>
        </period>
    </context>
    <context id="P03_01_2019To03_31_2019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="PAsOn10_02_2018">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <instant>2018-10-02</instant>
        </period>
    </context>
    <context id="PAsOn10_17_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <instant>2022-10-17</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis_WarrantMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_MinimumMembersrtRangeAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_MaximumMembersrtRangeAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_PrivatePlacementWarrantMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:PrivatePlacementWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_VantageMergerSubIncMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sclx:VantageMergerSubIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_ScilexCommonStockMemberusgaapRelatedPartyTransactionAxis_SeriesAPreferredStockMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:ScilexCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_FounderSharesMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">sclx:FounderSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMemberusgaapBusinessAcquisitionAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_LicensingAgreementsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_AssembledWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sclx:AssembledWorkforceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_TwoThousandNineteenStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_ScilexPharmaTwoThousandSeventeenPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:ScilexPharmaTwoThousandSeventeenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_SenmurMemberusgaapAssetAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">sclx:SenmurMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_RomegLicenseAgreementMemberusgaapAssetAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">sclx:RomegLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_AardvarkMemberusgaapAssetAcquisitionAxis_ApprovalBasedMilestoneMemberSCLXMilestoneAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">sclx:AardvarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:MilestoneAxis">sclx:ApprovalBasedMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_AardvarkMemberusgaapAssetAcquisitionAxis_ReveueBasedMilestoneMemberSCLXMilestoneAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">sclx:AardvarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:MilestoneAxis">sclx:ReveueBasedMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_AardvarkMemberusgaapAssetAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">sclx:AardvarkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:SorrentoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:PromissoryNoteRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_MinimumMembersrtRangeAxis_ProjectAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProjectAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_MaximumMembersrtRangeAxis_ProjectAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProjectAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:PromissoryNoteRelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:ScilexPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ScilexPharmaNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_ScilexPharmaMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:ScilexPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_TwoThousandAndTwentyTwoPromissoryNoteMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:TwoThousandAndTwentyTwoPromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_SorrentoMemberSCLXInvesteeAxis_TwoThousandTwentyTwoPromissoryNoteMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:TwoThousandTwentyTwoPromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:InvesteeAxis">sclx:SorrentoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_DecemberOptionalRepurchaseMemberSCLXStatementAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ScilexPharmaNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:StatementAxis">sclx:DecemberOptionalRepurchaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_FebruaryOptionalRepurchaseMemberSCLXStatementAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ScilexPharmaNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:StatementAxis">sclx:FebruaryOptionalRepurchaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_AprilOptionalRepurchaseMemberSCLXStatementAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ScilexPharmaNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:StatementAxis">sclx:AprilOptionalRepurchaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ScilexPharmaNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_LetterOfCreditMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_AccountsReceivableRevolvingLoanFacilityMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sclx:AccountsReceivableRevolvingLoanFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_DebtExchangeAgreementMemberSCLXAgreementAxis_SorrentoMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sclx:SorrentoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:AgreementAxis">sclx:DebtExchangeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis_WarrantMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_PrivatePlacementWarrantMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:PrivatePlacementWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_VantageMergerSubIncMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sclx:VantageMergerSubIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FounderSharesMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">sclx:FounderSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_SponsorMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CumulativeSalesRelatedContingencyMemberSCLXEventAxis_ScilexPharmaMemberdeiLegalEntityAxis_SeniorSecuredNotesDueTwoThousandAndTwentySixMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:SeniorSecuredNotesDueTwoThousandAndTwentySixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:EventAxis">sclx:CumulativeSalesRelatedContingencyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:ScilexPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AssembledWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sclx:AssembledWorkforceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ScilexPharmaTwoThousandSeventeenPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:ScilexPharmaTwoThousandSeventeenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_TwoThousandNineteenStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_SenmurMemberusgaapAssetAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">sclx:SenmurMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ConstructionInProgressMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:SorrentoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:PromissoryNoteRelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:ScilexPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:PromissoryNoteRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_MinimumMembersrtRangeAxis_ProjectAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProjectAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_MaximumMembersrtRangeAxis_ProjectAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProjectAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_IndefiniteCarryforwardPeriodMemberusgaapTaxPeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">sclx:IndefiniteCarryforwardPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_ResearchMemberusgaapTaxCreditCarryforwardAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ScilexPharmaMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:ScilexPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ScilexPharmaNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ScilexPharmaNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ScilexPharmaNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_FounderSharesMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:FounderSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMemberusgaapBusinessAcquisitionAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_ConvertiblePromisoryNoteMemberusgaapShortTermDebtTypeAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">sclx:ConvertiblePromisoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_WeightedAverageMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_TwoThousandNineteenStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_DerivativeFinancialInstrumentsLiabilitiesMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_OperatingExpensesMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">sclx:OperatingExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:SorrentoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_MaximumMembersrtRangeAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProductDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_MinimumMembersrtRangeAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProductDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProductDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_ExclusiveDistributionAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ExclusiveDistributionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_ExclusiveDistributionAgreementMemberusgaapTypeOfArrangementAxis_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ExclusiveDistributionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_ExclusiveDistributionAgreementMemberusgaapTypeOfArrangementAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ExclusiveDistributionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_ProjectAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProjectAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ScilexPharmaNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_SorrentoMemberSCLXInvesteeAxis_TwoThousandTwentyTwoPromissoryNoteMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:TwoThousandTwentyTwoPromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:InvesteeAxis">sclx:SorrentoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_TwoThousandAndEighteenPurchaseAgreementsAndIndentureMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ScilexPharmaNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:TwoThousandAndEighteenPurchaseAgreementsAndIndentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_RomegLicenseAgreementMemberusgaapAssetAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">sclx:RomegLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ScilexPharmaNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis_YorkvilleMemberSCLXInvesteeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:InvesteeAxis">sclx:YorkvilleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2022To09_30_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="PAsOn10_10_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-10</instant>
        </period>
    </context>
    <context id="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To09_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To09_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To09_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To09_30_2021_OperatingExpensesMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">sclx:OperatingExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To09_30_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:SorrentoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To09_30_2021_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_TwoThousandAndEighteenPurchaseAgreementsAndIndentureMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ScilexPharmaNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:TwoThousandAndEighteenPurchaseAgreementsAndIndentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To09_30_2021_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ScilexPharmaNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To09_30_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="PAsOn10_17_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-17</instant>
        </period>
    </context>
    <context id="PAsOn10_17_2022_FundingCommitmentLetterMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sclx:FundingCommitmentLetterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-17</instant>
        </period>
    </context>
    <context id="PAsOn10_17_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-17</instant>
        </period>
    </context>
    <context id="PAsOn10_17_2022_FundingCommitmentLetterMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sclx:FundingCommitmentLetterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-17</instant>
        </period>
    </context>
    <context id="P10_17_2022To10_17_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-17</startDate>
            <endDate>2022-10-17</endDate>
        </period>
    </context>
    <context id="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2022To09_30_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2022To09_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2022To09_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2022To09_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2021To09_30_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2021To09_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2021To09_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P07_01_2021To09_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ConversionOptionLiabilityMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:ConversionOptionLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_FounderSharesMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:FounderSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ConvertiblePromisoryNoteMemberusgaapShortTermDebtTypeAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">sclx:ConvertiblePromisoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ConvertibleNotesPayableMemberusgaapShortTermDebtTypeAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_PrivatePlacementWarrantMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:PrivatePlacementWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_AssembledWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sclx:AssembledWorkforceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_WeightedAverageMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_TwoThousandNineteenStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_DerivativeFinancialInstrumentsLiabilitiesMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_OperatingExpensesMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">sclx:OperatingExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_SoleDistributorMembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:SoleDistributorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:SorrentoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_FourHundredAndOneKPlanMemberusgaapRetirementPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">sclx:FourHundredAndOneKPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_IndebentureMemberSCLXAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sclx:AgreementAxis">sclx:IndebentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ScilexPharmaNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CoronavirusAidReliefAndEconomicSecurityActMemberSCLXEventTypeAxis_NonPayrollCostsMemberSCLXClassificationOfCostAxis_PaycheckProtectionProgramMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:PaycheckProtectionProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:ClassificationOfCostAxis">sclx:NonPayrollCostsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:EventTypeAxis">sclx:CoronavirusAidReliefAndEconomicSecurityActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CoronavirusAidReliefAndEconomicSecurityActMemberSCLXEventTypeAxis_PaycheckProtectionProgramMemberusgaapLongtermDebtTypeAxis_PayrollCostsBasisMemberSCLXClassificationOfCostAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:PaycheckProtectionProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:ClassificationOfCostAxis">sclx:PayrollCostsBasisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:EventTypeAxis">sclx:CoronavirusAidReliefAndEconomicSecurityActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_ConversionOptionLiabilityMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:ConversionOptionLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2022To06_30_2022_AmendmentNoFourMemberSCLXAmendmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sclx:AmendmentAxis">sclx:AmendmentNoFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="P01_01_2021To03_31_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To03_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To03_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To03_31_2021_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P10_01_2021To12_31_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P04_01_2022To09_30_2022_ConversionOptionLiabilityMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:ConversionOptionLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="PAsOn11_11_2022_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-11</instant>
        </period>
    </context>
    <context id="PAsOn03_17_2022_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-17</instant>
        </period>
    </context>
    <context id="PAsOn09_12_2022_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-12</instant>
        </period>
    </context>
    <context id="PAsOn09_12_2022_DebtExchangeAgreementMemberSCLXAgreementAxis_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:SorrentoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:AgreementAxis">sclx:DebtExchangeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-12</instant>
        </period>
    </context>
    <context id="PAsOn09_12_2022_DebtExchangeAgreementMemberSCLXAgreementAxis_SorrentoMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sclx:SorrentoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:AgreementAxis">sclx:DebtExchangeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-12</instant>
        </period>
    </context>
    <context id="P03_17_2022To03_17_2022_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-17</startDate>
            <endDate>2022-03-17</endDate>
        </period>
    </context>
    <context id="P08_10_2022To09_11_2022_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-10</startDate>
            <endDate>2022-09-11</endDate>
        </period>
    </context>
    <context id="P04_11_2022To07_11_2022_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-11</startDate>
            <endDate>2022-07-11</endDate>
        </period>
    </context>
    <context id="P01_04_2021To01_11_2021_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-01-11</endDate>
        </period>
    </context>
    <context id="P01_04_2021To01_11_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-01-11</endDate>
        </period>
    </context>
    <context id="P01_04_2021To01_11_2021_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-01-11</endDate>
        </period>
    </context>
    <context id="PAsOn01_11_2021_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-11</instant>
        </period>
    </context>
    <context id="PAsOn01_11_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-11</instant>
        </period>
    </context>
    <context id="PAsOn01_11_2021_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-11</instant>
        </period>
    </context>
    <context id="PAsOn01_11_2021_AsRestatedMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">sclx:AsRestatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-11</instant>
        </period>
    </context>
    <context id="PAsOn01_11_2021_AdjustmentsRestatement2MembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">sclx:AdjustmentsRestatement2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-11</instant>
        </period>
    </context>
    <context id="PAsOn01_11_2021_RestatementAdjustmentMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-11</instant>
        </period>
    </context>
    <context id="PAsOn01_11_2021_ScenarioPreviouslyReportedMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-11</instant>
        </period>
    </context>
    <context id="P04_01_2022To04_01_2022_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="PAsOn04_18_2022_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-18</instant>
        </period>
    </context>
    <context id="PAsOn04_11_2022_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-11</instant>
        </period>
    </context>
    <context id="P01_01_2022To01_27_2022_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-27</endDate>
        </period>
    </context>
    <context id="P01_01_2022To01_27_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-27</endDate>
        </period>
    </context>
    <context id="PAsOn01_10_2022_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-10</instant>
        </period>
    </context>
    <context id="PAsOn01_10_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-10</instant>
        </period>
    </context>
    <context id="PAsOn12_20_2021_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-20</instant>
        </period>
    </context>
    <context id="PAsOn12_20_2021_ScilexPharmaMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:ScilexPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-20</instant>
        </period>
    </context>
    <context id="PAsOn12_20_2021_MeasurementInputEffectiveDebtYieldMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sclx:MeasurementInputEffectiveDebtYieldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-20</instant>
        </period>
    </context>
    <context id="PAsOn12_20_2021_MeasurementInputRiskadjustedNetSalesForecastMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sclx:MeasurementInputRiskadjustedNetSalesForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-20</instant>
        </period>
    </context>
    <context id="PAsOn12_20_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:SorrentoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-20</instant>
        </period>
    </context>
    <context id="P01_05_2021To01_14_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-05</startDate>
            <endDate>2021-01-14</endDate>
        </period>
    </context>
    <context id="PAsOn07_16_2020_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:PromissoryNoteRelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-16</instant>
        </period>
    </context>
    <context id="P12_01_2020To12_31_2020_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P12_01_2020To12_31_2020_TwoThousandNineteenStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P07_02_2020To07_16_2020_FounderSharesMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:FounderSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-02</startDate>
            <endDate>2020-07-16</endDate>
        </period>
    </context>
    <context id="P10_01_2020To10_08_2020_FounderSharesMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:FounderSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-08</endDate>
        </period>
    </context>
    <context id="P12_01_2020To12_07_2020_FounderSharesMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:FounderSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-07</endDate>
        </period>
    </context>
    <context id="P01_03_2021To01_06_2021_FounderSharesMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:FounderSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-03</startDate>
            <endDate>2021-01-06</endDate>
        </period>
    </context>
    <context id="P12_01_2021To12_20_2021_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-20</endDate>
        </period>
    </context>
    <context id="P08_01_2022To08_11_2022_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-11</endDate>
        </period>
    </context>
    <context id="P10_10_2022To10_10_2022_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-10</startDate>
            <endDate>2022-10-10</endDate>
        </period>
    </context>
    <context id="P09_09_2022To09_09_2022_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-09</startDate>
            <endDate>2022-09-09</endDate>
        </period>
    </context>
    <context id="P01_01_2022To01_10_2022_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-10</endDate>
        </period>
    </context>
    <context id="P01_01_2022To01_10_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-10</endDate>
        </period>
    </context>
    <context id="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-21</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P02_21_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-21</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P02_21_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-21</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P02_21_2020To12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-21</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis_WarrantMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_CommonClassAMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_AssembledWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">sclx:AssembledWorkforceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_TwoThousandNineteenStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_AmendmentToTwoThousandNineteenStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:AmendmentToTwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_SenmurMemberusgaapAssetAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">sclx:SenmurMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_SenmurMemberusgaapAssetAcquisitionAxis_SorrentoMemberSCLXInvesteeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">sclx:SenmurMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:InvesteeAxis">sclx:SorrentoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_ConstructionInProgressMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_SenmurMemberusgaapAssetAcquisitionAxis_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">sclx:SenmurMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:SorrentoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_ItochuMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:ItochuMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:SorrentoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:PromissoryNoteRelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:ScilexPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_ScilexPharmaMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:ScilexPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeMarch312021MemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sclx:MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeMarch312021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_MeasurementInputEffectiveDebtYieldMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sclx:MeasurementInputEffectiveDebtYieldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_MeasurementInputRiskadjustedNetSalesForecastMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sclx:MeasurementInputRiskadjustedNetSalesForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ScilexPharmaNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ScilexPharmaNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ScilexPharmaNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_TwoThousandNineteenStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_DerivativeFinancialInstrumentsLiabilitiesMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_OperatingExpensesMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">sclx:OperatingExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_SoleDistributorMembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:SoleDistributorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:SorrentoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_FourHundredAndOneKPlanMemberusgaapRetirementPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">sclx:FourHundredAndOneKPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ScilexPharmaNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_DerivativeFinancialInstrumentsLiabilitiesMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_OperatingExpensesMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">sclx:OperatingExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_SoleDistributorMembersrtMajorCustomersAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sclx:SoleDistributorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_SenmurMemberusgaapAssetAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">sclx:SenmurMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:SorrentoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_FourHundredAndOneKPlanMemberusgaapRetirementPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">sclx:FourHundredAndOneKPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2019To12_31_2019_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ScilexPharmaNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="PAsOn03_18_2019_ReorganizationMemberSCLXEventAxis_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:SorrentoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:EventAxis">sclx:ReorganizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-18</instant>
        </period>
    </context>
    <context id="PAsOn03_18_2019_ContributionAndLoanAgreementMemberSCLXAgreementAxis_ReorganizationMemberSCLXEventAxis_ScilexPharmaMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sclx:ScilexPharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:AgreementAxis">sclx:ContributionAndLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:EventAxis">sclx:ReorganizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-18</instant>
        </period>
    </context>
    <context id="PAsOn03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">sclx:SenmurMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-18</instant>
        </period>
    </context>
    <context id="PAsOn03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheTwoMemberSCLXTrancheAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">sclx:SenmurMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:MilestoneAxis">sclx:ReveueBasedMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:TrancheAxis">sclx:TrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-18</instant>
        </period>
    </context>
    <context id="PAsOn03_18_2019_RegulatoryBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">sclx:SenmurMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:MilestoneAxis">sclx:RegulatoryBasedMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-18</instant>
        </period>
    </context>
    <context id="PAsOn03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheOneMemberSCLXTrancheAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">sclx:SenmurMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:MilestoneAxis">sclx:ReveueBasedMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:TrancheAxis">sclx:TrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-18</instant>
        </period>
    </context>
    <context id="PAsOn03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheThreeMemberSCLXTrancheAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">sclx:SenmurMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:MilestoneAxis">sclx:ReveueBasedMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:TrancheAxis">sclx:TrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-18</instant>
        </period>
    </context>
    <context id="PAsOn03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheFourMemberSCLXTrancheAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">sclx:SenmurMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:MilestoneAxis">sclx:ReveueBasedMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:TrancheAxis">sclx:TrancheFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-18</instant>
        </period>
    </context>
    <context id="PAsOn03_18_2019_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:SorrentoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-18</instant>
        </period>
    </context>
    <context id="PAsOn02_14_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_SubordinatedDebtMemberusgaapLongtermDebtTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ScilexPharmaNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SubordinatedDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-14</instant>
        </period>
    </context>
    <context id="PAsOn02_14_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_SubordinatedDebtMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ScilexPharmaNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SubordinatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-14</instant>
        </period>
    </context>
    <context id="PAsOn02_28_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_SubordinatedDebtMemberusgaapLongtermDebtTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ScilexPharmaNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SubordinatedDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-28</instant>
        </period>
    </context>
    <context id="PAsOn02_28_2022_LetterOfCreditDrawnDownMemberSCLXEventAxis_ScilexPharmaMemberdeiLegalEntityAxis_SeniorSecuredNotesDueTwoThousandAndTwentySixMemberusgaapLongtermDebtTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:SeniorSecuredNotesDueTwoThousandAndTwentySixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:EventAxis">sclx:LetterOfCreditDrawnDownMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:ScilexPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-28</instant>
        </period>
    </context>
    <context id="PAsOn02_28_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_SubordinatedDebtMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ScilexPharmaNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SubordinatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-28</instant>
        </period>
    </context>
    <context id="PAsOn02_15_2022_MaximumMembersrtRangeAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_SubordinatedDebtMemberusgaapLongtermDebtTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ScilexPharmaNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SubordinatedDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-15</instant>
        </period>
    </context>
    <context id="PAsOn02_15_2022_MaximumMembersrtRangeAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:TwoThousandAndEighteenPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-15</instant>
        </period>
    </context>
    <context id="P02_15_2022To02_15_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_SubordinatedDebtMemberusgaapLongtermDebtTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ScilexPharmaNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SubordinatedDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-15</startDate>
            <endDate>2022-02-15</endDate>
        </period>
    </context>
    <context id="P02_15_2022To02_15_2022_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:TwoThousandAndEighteenPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-15</startDate>
            <endDate>2022-02-15</endDate>
        </period>
    </context>
    <context id="PAsOn03_30_2022_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:SorrentoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2018_ScilexPharmaMemberdeiLegalEntityAxis_SeniorSecuredNotesDueTwoThousandAndTwentySixMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:SeniorSecuredNotesDueTwoThousandAndTwentySixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:ScilexPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="P09_01_2018To09_30_2018_ScilexPharmaMemberdeiLegalEntityAxis_SeniorSecuredNotesDueTwoThousandAndTwentySixMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:SeniorSecuredNotesDueTwoThousandAndTwentySixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:ScilexPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="PAsOn04_30_2021_ScilexPharmaMemberdeiLegalEntityAxis_SeniorSecuredNotesDueTwoThousandAndTwentySixMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:SeniorSecuredNotesDueTwoThousandAndTwentySixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:ScilexPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2020_ScilexPharmaMemberdeiLegalEntityAxis_SeniorSecuredNotesDueTwoThousandAndTwentySixMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:SeniorSecuredNotesDueTwoThousandAndTwentySixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:ScilexPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2017_ScilexPharmaTwoThousandSeventeenPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:ScilexPharmaTwoThousandSeventeenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-06-30</instant>
        </period>
    </context>
    <context id="P06_30_2017To06_30_2017_ScilexPharmaTwoThousandSeventeenPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:ScilexPharmaTwoThousandSeventeenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-06-30</startDate>
            <endDate>2017-06-30</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2019_TwoThousandNineteenStockOptionPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sclx:TwoThousandNineteenStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeJuly12023MemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sclx:MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeJuly12023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeMarch312021MemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sclx:MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeMarch312021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_MeasurementInputEffectiveDebtYieldMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sclx:MeasurementInputEffectiveDebtYieldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_MeasurementInputRiskadjustedNetSalesForecastMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sclx:MeasurementInputRiskadjustedNetSalesForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="P03_18_2019To03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">sclx:SenmurMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-18</startDate>
            <endDate>2019-03-18</endDate>
        </period>
    </context>
    <context id="P03_18_2019To03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheFourMemberSCLXTrancheAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">sclx:SenmurMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:MilestoneAxis">sclx:ReveueBasedMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:TrancheAxis">sclx:TrancheFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-18</startDate>
            <endDate>2019-03-18</endDate>
        </period>
    </context>
    <context id="P03_18_2019To03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheThreeMemberSCLXTrancheAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">sclx:SenmurMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:MilestoneAxis">sclx:ReveueBasedMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:TrancheAxis">sclx:TrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-18</startDate>
            <endDate>2019-03-18</endDate>
        </period>
    </context>
    <context id="P03_18_2019To03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheTwoMemberSCLXTrancheAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">sclx:SenmurMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:MilestoneAxis">sclx:ReveueBasedMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:TrancheAxis">sclx:TrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-18</startDate>
            <endDate>2019-03-18</endDate>
        </period>
    </context>
    <context id="P03_18_2019To03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheOneMemberSCLXTrancheAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">sclx:SenmurMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:MilestoneAxis">sclx:ReveueBasedMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:TrancheAxis">sclx:TrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-18</startDate>
            <endDate>2019-03-18</endDate>
        </period>
    </context>
    <context id="P01_01_2022To06_30_2022_DerivativeFinancialInstrumentsLiabilitiesMemberusgaapFairValueByLiabilityClassAxis_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ScilexPharmaNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="PAsOn03_01_2019_SenmurMemberusgaapAssetAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">sclx:SenmurMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-01</instant>
        </period>
    </context>
    <context id="P03_01_2019To03_31_2019_SenmurMemberusgaapAssetAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">sclx:SenmurMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="P03_01_2019To03_31_2019_SenmurMemberusgaapAssetAcquisitionAxis_SorrentoMemberSCLXInvesteeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">sclx:SenmurMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:InvesteeAxis">sclx:SorrentoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="PAsOn01_29_2021_SenmurMemberusgaapAssetAcquisitionAxis_SorrentoMemberSCLXInvesteeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">sclx:SenmurMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:InvesteeAxis">sclx:SorrentoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-29</instant>
        </period>
    </context>
    <context id="PAsOn01_29_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:SorrentoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-29</instant>
        </period>
    </context>
    <context id="PAsOn01_13_2021_ItochuMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:ItochuMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-13</instant>
        </period>
    </context>
    <context id="PAsOn08_07_2019_SenmurMemberusgaapAssetAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">sclx:SenmurMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-07</instant>
        </period>
    </context>
    <context id="PAsOn08_07_2019_AsRestatedMembersrtRestatementAxis_SenmurMemberusgaapAssetAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">sclx:AsRestatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">sclx:SenmurMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-07</instant>
        </period>
    </context>
    <context id="PAsOn08_07_2019_AsRestatedMembersrtRestatementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">sclx:AsRestatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-07</instant>
        </period>
    </context>
    <context id="P08_07_2019To08_07_2019_SenmurMemberusgaapAssetAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">sclx:SenmurMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-07</startDate>
            <endDate>2019-08-07</endDate>
        </period>
    </context>
    <context id="P11_10_2020To11_10_2020_VantageMergerSubIncMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sclx:VantageMergerSubIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-10</startDate>
            <endDate>2020-11-10</endDate>
        </period>
    </context>
    <context id="P11_10_2020To11_10_2020_DebtExchangeAgreementMemberSCLXAgreementAxis_VantageMergerSubIncMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sclx:VantageMergerSubIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:AgreementAxis">sclx:DebtExchangeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-10</startDate>
            <endDate>2020-11-10</endDate>
        </period>
    </context>
    <context id="P01_01_2021To01_06_2021_FounderSharesMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:FounderSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-06</endDate>
        </period>
    </context>
    <context id="PAsOn09_30_2021_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:PromissoryNoteRelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:ScilexPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="P12_31_2021To12_31_2021_MaximumMembersrtRangeAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProductDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-31</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P12_31_2021To12_31_2021_MinimumMembersrtRangeAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProductDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-31</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P12_31_2021To12_31_2021_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProductDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-31</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P12_31_2021To12_31_2021_ExclusiveDistributionAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ExclusiveDistributionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-31</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P12_31_2021To12_31_2021_ExclusiveDistributionAgreementMemberusgaapTypeOfArrangementAxis_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ExclusiveDistributionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-31</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P12_31_2021To12_31_2021_ExclusiveDistributionAgreementMemberusgaapTypeOfArrangementAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ExclusiveDistributionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-31</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P12_31_2021To12_31_2021_ProjectAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sclx:ProjectAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-31</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P02_01_2021To02_26_2021_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-26</endDate>
        </period>
    </context>
    <context id="PAsOn10_05_2018_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:PromissoryNoteRelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:ScilexPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-05</instant>
        </period>
    </context>
    <context id="PAsOn10_05_2018_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:PromissoryNoteRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-05</instant>
        </period>
    </context>
    <context id="PAsOn10_05_2018_AmendmentNoFourMemberSCLXAmendmentAxis_PromissoryNoteMemberusgaapRelatedPartyTransactionAxis_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:SorrentoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:AmendmentAxis">sclx:AmendmentNoFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-05</instant>
        </period>
    </context>
    <context id="PAsOn10_22_2018_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:PromissoryNoteRelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:ScilexPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-22</instant>
        </period>
    </context>
    <context id="P10_22_2018To10_22_2018_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:PromissoryNoteRelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:ScilexPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-22</startDate>
            <endDate>2018-10-22</endDate>
        </period>
    </context>
    <context id="P08_01_2022To09_30_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ScilexPharmaNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="PAsOn09_28_2022_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ScilexPharmaNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-28</instant>
        </period>
    </context>
    <context id="P06_14_2022To06_14_2022_LicensingAgreementsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-14</startDate>
            <endDate>2022-06-14</endDate>
        </period>
    </context>
    <context id="P05_12_2022To05_12_2022_SorrentoMemberusgaapBusinessAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_TwoThousandAndTwentyTwoPromissoryNoteMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sclx:SorrentoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:TwoThousandAndTwentyTwoPromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-12</startDate>
            <endDate>2022-05-12</endDate>
        </period>
    </context>
    <context id="P05_12_2022To05_12_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-12</startDate>
            <endDate>2022-05-12</endDate>
        </period>
    </context>
    <context id="P05_12_2022To05_12_2022_AardvarkMemberusgaapAssetAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">sclx:AardvarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-12</startDate>
            <endDate>2022-05-12</endDate>
        </period>
    </context>
    <context id="P05_12_2022To05_12_2022_SorrentoMemberusgaapBusinessAcquisitionAxis_TwoThousandAndTwentyTwoPromissoryNoteMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sclx:SorrentoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:TwoThousandAndTwentyTwoPromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-12</startDate>
            <endDate>2022-05-12</endDate>
        </period>
    </context>
    <context id="PAsOn05_12_2022_SorrentoMemberusgaapBusinessAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_TwoThousandAndTwentyTwoPromissoryNoteMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sclx:SorrentoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:TwoThousandAndTwentyTwoPromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-12</instant>
        </period>
    </context>
    <context id="PAsOn05_12_2022_SorrentoMemberusgaapBusinessAcquisitionAxis_TwoThousandAndTwentyTwoPromissoryNoteMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sclx:SorrentoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:TwoThousandAndTwentyTwoPromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-12</instant>
        </period>
    </context>
    <context id="PAsOn05_12_2022_PromissoryNoteMemberusgaapRelatedPartyTransactionAxis_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:SorrentoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-12</instant>
        </period>
    </context>
    <context id="PAsOn09_07_2018_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:TwoThousandAndEighteenPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-07</instant>
        </period>
    </context>
    <context id="P10_02_2018To10_02_2018_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:PromissoryNoteRelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:ScilexPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-02</startDate>
            <endDate>2018-10-02</endDate>
        </period>
    </context>
    <context id="P09_07_2018To09_07_2018_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:TwoThousandAndEighteenPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-07</startDate>
            <endDate>2018-09-07</endDate>
        </period>
    </context>
    <context id="P02_28_2021To02_28_2021_SorrentoMemberSCLXInvesteeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sclx:InvesteeAxis">sclx:SorrentoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-28</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="P02_28_2021To02_28_2021_ScilexPharmaMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:ScilexPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-28</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="PAsOn06_30_2022_MeasurementInputRiskadjustedNetSalesForecastMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sclx:MeasurementInputRiskadjustedNetSalesForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_MeasurementInputEffectiveDebtYieldMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sclx:MeasurementInputEffectiveDebtYieldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_01_2022_PaloAltoAadministrativeFacilityMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sclx:PaloAltoAadministrativeFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-01</instant>
        </period>
    </context>
    <context id="P09_30_2022To09_30_2022_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:SorrentoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-30</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P09_30_2022To09_30_2022_LetterOfCreditMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-30</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P09_30_2022To09_30_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ScilexPharmaNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-30</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P02_15_2019To02_15_2019_MinimumMembersrtRangeAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:TwoThousandAndEighteenPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-15</startDate>
            <endDate>2019-02-15</endDate>
        </period>
    </context>
    <context id="P02_15_2019To02_15_2019_MaximumMembersrtRangeAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:TwoThousandAndEighteenPurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-15</startDate>
            <endDate>2019-02-15</endDate>
        </period>
    </context>
    <context id="P02_15_2019To02_15_2019_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ScilexPharmaNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-15</startDate>
            <endDate>2019-02-15</endDate>
        </period>
    </context>
    <context id="P02_15_2019To02_15_2019_MinimumMembersrtRangeAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ScilexPharmaNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-15</startDate>
            <endDate>2019-02-15</endDate>
        </period>
    </context>
    <context id="P02_15_2019To02_15_2019_MaximumMembersrtRangeAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ScilexPharmaNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-15</startDate>
            <endDate>2019-02-15</endDate>
        </period>
    </context>
    <context id="P02_15_2019To02_15_2019_IndebentureMemberSCLXAgreementAxis_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:AgreementAxis">sclx:IndebentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-15</startDate>
            <endDate>2019-02-15</endDate>
        </period>
    </context>
    <context id="P02_15_2019To02_15_2019_IndebentureMemberSCLXAgreementAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:AgreementAxis">sclx:IndebentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-15</startDate>
            <endDate>2019-02-15</endDate>
        </period>
    </context>
    <context id="P10_01_2022To09_30_2023_DebtInstrumentRedemptionPeriodOneMemberusgaapDebtInstrumentRedemptionPeriodAxis_ScenarioAdjustmentMembersrtStatementScenarioAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">us-gaap:ScenarioAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:TwoThousandAndEighteenPurchaseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P10_01_2022To09_30_2023_DebtInstrumentRedemptionPeriodThreeMemberusgaapDebtInstrumentRedemptionPeriodAxis_ScenarioAdjustmentMembersrtStatementScenarioAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">us-gaap:ScenarioAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:TwoThousandAndEighteenPurchaseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P10_01_2022To09_30_2023_DebtInstrumentRedemptionPeriodOneMemberusgaapDebtInstrumentRedemptionPeriodAxis_MinimumMembersrtRangeAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:TwoThousandAndEighteenPurchaseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P10_01_2022To09_30_2023_DebtInstrumentRedemptionPeriodOneMemberusgaapDebtInstrumentRedemptionPeriodAxis_MaximumMembersrtRangeAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:TwoThousandAndEighteenPurchaseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P10_01_2022To09_30_2023_DebtInstrumentRedemptionPeriodThreeMemberusgaapDebtInstrumentRedemptionPeriodAxis_MinimumMembersrtRangeAxis_ScenarioAdjustmentMembersrtStatementScenarioAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">us-gaap:ScenarioAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:TwoThousandAndEighteenPurchaseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P10_01_2022To09_30_2023_DebtInstrumentRedemptionPeriodThreeMemberusgaapDebtInstrumentRedemptionPeriodAxis_MaximumMembersrtRangeAxis_ScenarioAdjustmentMembersrtStatementScenarioAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">us-gaap:ScenarioAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:TwoThousandAndEighteenPurchaseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="P09_07_2018To12_31_2021_DebtInstrumentRedemptionPeriodTwoMemberusgaapDebtInstrumentRedemptionPeriodAxis_ScenarioAdjustmentMembersrtStatementScenarioAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">us-gaap:ScenarioAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:TwoThousandAndEighteenPurchaseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-07</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P09_07_2018To12_31_2021_LetterOfCreditMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-07</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="PAsOn12_14_2020_IndebentureMemberSCLXAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sclx:AgreementAxis">sclx:IndebentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-14</instant>
        </period>
    </context>
    <context id="PAsOn12_14_2020_IfLetterOfCreditIsDrawnMembersrtStatementScenarioAxis_IndebentureMemberSCLXAgreementAxis_LetterOfCreditMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">sclx:IfLetterOfCreditIsDrawnMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:AgreementAxis">sclx:IndebentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-14</instant>
        </period>
    </context>
    <context id="PAsOn12_14_2020_IndebentureMemberSCLXAgreementAxis_LetterOfCreditMemberusgaapCreditFacilityAxis_MarketingApprovalLetterMembersrtStatementScenarioAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">sclx:MarketingApprovalLetterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:AgreementAxis">sclx:IndebentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-14</instant>
        </period>
    </context>
    <context id="PAsOn12_14_2020_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ScilexPharmaNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-14</instant>
        </period>
    </context>
    <context id="PAsOn12_14_2020_PrimeRateMemberusgaapVariableRateAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ScilexPharmaNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-14</instant>
        </period>
    </context>
    <context id="P12_14_2020To12_14_2020_IndebentureMemberSCLXAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sclx:AgreementAxis">sclx:IndebentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-14</startDate>
            <endDate>2020-12-14</endDate>
        </period>
    </context>
    <context id="P04_30_2021To04_30_2021_SorrentoMemberSCLXInvesteeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sclx:InvesteeAxis">sclx:SorrentoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-30</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="P04_30_2021To04_30_2021_LetterOfCreditMemberusgaapCreditFacilityAxis_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-30</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="P04_30_2021To04_30_2021_LetterOfCreditMemberusgaapCreditFacilityAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-30</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="P09_12_2022To09_12_2022_DebtExchangeAgreementMemberSCLXAgreementAxis_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:PromissoryNoteRelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:AgreementAxis">sclx:DebtExchangeAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:ScilexPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-12</startDate>
            <endDate>2022-09-12</endDate>
        </period>
    </context>
    <context id="PAsOn11_10_2022_MinimumMembersrtRangeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-10</instant>
        </period>
    </context>
    <context id="PAsOn11_10_2022_MaximumMembersrtRangeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-10</instant>
        </period>
    </context>
    <context id="PAsOn11_10_2022_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-10</instant>
        </period>
    </context>
    <context id="PAsOn11_10_2022_DebtExchangeAgreementMemberSCLXAgreementAxis_SorrentoMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sclx:SorrentoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:AgreementAxis">sclx:DebtExchangeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-10</instant>
        </period>
    </context>
    <context id="P11_10_2022To11_10_2022_DebtExchangeAgreementMemberSCLXAgreementAxis_PreferredStockMemberusgaapStatementEquityComponentsAxis_SorrentoMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sclx:SorrentoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:AgreementAxis">sclx:DebtExchangeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-10</startDate>
            <endDate>2022-11-10</endDate>
        </period>
    </context>
    <context id="P11_10_2022To11_10_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_DebtExchangeAgreementMemberSCLXAgreementAxis_SorrentoMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sclx:SorrentoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:AgreementAxis">sclx:DebtExchangeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-10</startDate>
            <endDate>2022-11-10</endDate>
        </period>
    </context>
    <context id="P02_16_2022To02_16_2022_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ScilexPharmaNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-16</startDate>
            <endDate>2022-02-16</endDate>
        </period>
    </context>
    <context id="P05_01_2020To05_31_2020_PaycheckProtectionProgramMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:PaycheckProtectionProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="PAsOn05_31_2020_PaycheckProtectionProgramMemberusgaapLongtermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sclx:PaycheckProtectionProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="PAsOn06_02_2022_AmendmentNoFourMemberSCLXAmendmentAxis_PromissoryNoteMemberusgaapRelatedPartyTransactionAxis_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:SorrentoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:AmendmentAxis">sclx:AmendmentNoFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-02</instant>
        </period>
    </context>
    <context id="PAsOn06_02_2022_AmendmentNoFourMemberSCLXAmendmentAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ScilexPharmaNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:AmendmentAxis">sclx:AmendmentNoFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-02</instant>
        </period>
    </context>
    <context id="PAsOn06_02_2022_AmendmentNoFourMemberSCLXAmendmentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sclx:AmendmentAxis">sclx:AmendmentNoFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-02</instant>
        </period>
    </context>
    <context id="PAsOn06_03_2022_AmendmentNoFourMemberSCLXAmendmentAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ScilexPharmaNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:AmendmentAxis">sclx:AmendmentNoFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-03</instant>
        </period>
    </context>
    <context id="P06_02_2022To06_02_2022_AmendmentNoFourMemberSCLXAmendmentAxis_MaximumMembersrtRangeAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ScilexPharmaNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:AmendmentAxis">sclx:AmendmentNoFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-02</startDate>
            <endDate>2022-06-02</endDate>
        </period>
    </context>
    <context id="P06_02_2022To06_02_2022_AmendmentNoFourMemberSCLXAmendmentAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ScilexPharmaNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:AmendmentAxis">sclx:AmendmentNoFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-02</startDate>
            <endDate>2022-06-02</endDate>
        </period>
    </context>
    <context id="P06_02_2022To06_02_2022_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:SorrentoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-02</startDate>
            <endDate>2022-06-02</endDate>
        </period>
    </context>
    <context id="P06_02_2022To06_02_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ScilexPharmaNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-02</startDate>
            <endDate>2022-06-02</endDate>
        </period>
    </context>
    <context id="P09_01_2022To09_30_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sclx:ScilexPharmaNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="P10_01_2022To11_30_2022_AgreementWithCertainOfTheThirdPartyProfessionalServiceProvidersMemberSCLXAgreementAxis_SorrentoMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:AgreementAxis">sclx:AgreementWithCertainOfTheThirdPartyProfessionalServiceProvidersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:SorrentoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="P10_01_2022To11_30_2022_AccountsPayableMemberusgaapBalanceSheetLocationAxis_AgreementWithCertainOfTheThirdPartyProfessionalServiceProvidersMemberSCLXAgreementAxis_SorrentoMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:AgreementAxis">sclx:AgreementWithCertainOfTheThirdPartyProfessionalServiceProvidersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:SorrentoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="P10_01_2022To11_30_2022_AccruedLiabilitiesMemberusgaapBalanceSheetLocationAxis_AgreementWithCertainOfTheThirdPartyProfessionalServiceProvidersMemberSCLXAgreementAxis_SorrentoMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:AgreementAxis">sclx:AgreementWithCertainOfTheThirdPartyProfessionalServiceProvidersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:SorrentoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="P11_17_2022To11_17_2022_StandbyEquityPurchaseAgreementMemberSCLXAgreementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_YorkvilleMemberSCLXInvesteeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:AgreementAxis">sclx:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:InvesteeAxis">sclx:YorkvilleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-17</startDate>
            <endDate>2022-11-17</endDate>
        </period>
    </context>
    <context id="P02_01_2022To02_28_2022_ScilexPharmaMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:ScilexPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="P02_01_2022To02_28_2022_DueOnOrAfterFebruaryTwoThousandAndThirtyMemberSCLXPeriodAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="sclx:PeriodAxis">sclx:DueOnOrAfterFebruaryTwoThousandAndThirtyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="PAsOn01_06_2021_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-06</instant>
        </period>
    </context>
    <context id="P01_11_2021To01_11_2021_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-11</startDate>
            <endDate>2021-01-11</endDate>
        </period>
    </context>
    <context id="PAsOn02_28_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sclx:SorrentoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="P12_21_2020To12_20_2021_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-21</startDate>
            <endDate>2021-12-20</endDate>
        </period>
    </context>
    <context id="P07_11_2022To07_11_2022_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-11</startDate>
            <endDate>2022-07-11</endDate>
        </period>
    </context>
    <context id="P01_10_2022To01_10_2022_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-10</startDate>
            <endDate>2022-01-10</endDate>
        </period>
    </context>
    <context id="PAsOn01_31_2023_B.RileyMemberSCLXInvesteeAxis_PurchasetypeAMembersrtProductOrServiceAxis_ScilexCommonStockMemberusgaapRelatedPartyTransactionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sclx:PurchasetypeAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:ScilexCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:InvesteeAxis">sclx:B.RileyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="PAsOn01_31_2023_B.RileyMemberSCLXInvesteeAxis_PurchasetypeBMembersrtProductOrServiceAxis_ScilexCommonStockMemberusgaapRelatedPartyTransactionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sclx:PurchasetypeBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:ScilexCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:InvesteeAxis">sclx:B.RileyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="P01_31_2023To01_31_2023_B.RileyMemberSCLXInvesteeAxis_StandbyEquityPurchaseAgreementMemberSCLXAgreementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:AgreementAxis">sclx:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:InvesteeAxis">sclx:B.RileyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-31</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="P01_31_2023To01_31_2023_B.RileyMemberSCLXInvesteeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:InvesteeAxis">sclx:B.RileyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-31</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="P01_31_2023To01_31_2023_B.RileyMemberSCLXInvesteeAxis_PurchasetypeAMembersrtProductOrServiceAxis_ScilexCommonStockMemberusgaapRelatedPartyTransactionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sclx:PurchasetypeAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:ScilexCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:InvesteeAxis">sclx:B.RileyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-31</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="P01_31_2023To01_31_2023_B.RileyMemberSCLXInvesteeAxis_PurchasetypeBMembersrtProductOrServiceAxis_ScilexCommonStockMemberusgaapRelatedPartyTransactionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sclx:PurchasetypeBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sclx:ScilexCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:InvesteeAxis">sclx:B.RileyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-31</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="PAsOn11_17_2022_StandbyEquityPurchaseAgreementMemberSCLXAgreementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_YorkvilleMemberSCLXInvesteeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:AgreementAxis">sclx:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:InvesteeAxis">sclx:YorkvilleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-17</instant>
        </period>
    </context>
    <context id="P01_08_2023To01_08_2023_B.RileyMemberSCLXInvesteeAxis_StandbyEquityPurchaseAgreementMemberSCLXAgreementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:AgreementAxis">sclx:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:InvesteeAxis">sclx:B.RileyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-08</startDate>
            <endDate>2023-01-08</endDate>
        </period>
    </context>
    <context id="PAsOn01_08_2023_B.RileyMemberSCLXInvesteeAxis_StandbyEquityPurchaseAgreementMemberSCLXAgreementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:AgreementAxis">sclx:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sclx:InvesteeAxis">sclx:B.RileyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-08</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_DerivativeFinancialInstrumentsLiabilitiesMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2021_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_ConversionOptionLiabilityMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:ConversionOptionLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ConversionOptionLiabilityMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:ConversionOptionLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_ConversionOptionLiabilityMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:ConversionOptionLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2022_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2022_ConversionOptionLiabilityMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sclx:ConversionOptionLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="PAsOn02_20_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-20</instant>
        </period>
    </context>
    <context id="PAsOn02_20_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-20</instant>
        </period>
    </context>
    <context id="PAsOn02_20_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-20</instant>
        </period>
    </context>
    <context id="PAsOn02_20_2020_VickersVantageMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">sclx:VickersVantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-20</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_DerivativeFinancialInstrumentsLiabilitiesMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_DerivativeFinancialInstrumentsLiabilitiesMemberusgaapFairValueByLiabilityClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001820190</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <unit id="Unit_shares">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Year">
        <measure>utr:Year</measure>
    </unit>
    <unit id="Unit_pure">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Day">
        <measure>utr:Day</measure>
    </unit>
    <unit id="Unit_Month">
        <measure>utr:Month</measure>
    </unit>
    <unit id="Unit_USD_per_Share">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="P01_01_2022To09_30_2022">false</dei:AmendmentFlag>
    <dei:EntityRegistrantName contextRef="P01_01_2022To09_30_2022" id="hidden63195201">Scilex Holding Company/DE</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey contextRef="P01_01_2022To09_30_2022">0001820190</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="P01_01_2022To09_30_2022">S-1</dei:DocumentType>
    <dei:EntityFilerCategory contextRef="P01_01_2022To09_30_2022">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="P01_01_2022To09_30_2022">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="P01_01_2022To09_30_2022">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="P01_01_2022To09_30_2022">false</dei:EntityExTransitionPeriod>
    <sclx:NumberOfThresholdTradingDaysPriorToDateOfNoticeToTheShareholdersForDeterminingTheVolumeWeightedAveragePriceOfShares
      contextRef="P11_17_2022To11_17_2022_StandbyEquityPurchaseAgreementMemberSCLXAgreementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_YorkvilleMemberSCLXInvesteeAxis"
      id="hidden63196045">P5D</sclx:NumberOfThresholdTradingDaysPriorToDateOfNoticeToTheShareholdersForDeterminingTheVolumeWeightedAveragePriceOfShares>
    <sclx:NumberOfConsecutiveTradingDaysForDeterminingTheVolumeWeightedAveragePriceOfShares
      contextRef="P11_17_2022To11_17_2022_StandbyEquityPurchaseAgreementMemberSCLXAgreementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_YorkvilleMemberSCLXInvesteeAxis"
      id="hidden63196046">P2D</sclx:NumberOfConsecutiveTradingDaysForDeterminingTheVolumeWeightedAveragePriceOfShares>
    <us-gaap:Cash
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">507921</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">30511</us-gaap:Cash>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">4536</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">512457</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">30511</us-gaap:AssetsCurrent>
    <us-gaap:DeferredCosts
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:DeferredCosts>
    <us-gaap:DeferredCosts
      contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">168973</us-gaap:DeferredCosts>
    <us-gaap:AssetsHeldInTrustNoncurrent
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">139410739</us-gaap:AssetsHeldInTrustNoncurrent>
    <us-gaap:AssetsHeldInTrustNoncurrent
      contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:AssetsHeldInTrustNoncurrent>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">139923196</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">199484</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">208704</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">25760</us-gaap:OtherAccruedLiabilitiesCurrent>
    <sclx:AdvancesFromRelatedParty
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</sclx:AdvancesFromRelatedParty>
    <sclx:AdvancesFromRelatedParty
      contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">30000</sclx:AdvancesFromRelatedParty>
    <us-gaap:NotesPayableRelatedPartiesClassifiedCurrent
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:NotesPayableRelatedPartiesClassifiedCurrent>
    <us-gaap:NotesPayableRelatedPartiesClassifiedCurrent
      contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">125000</us-gaap:NotesPayableRelatedPartiesClassifiedCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">208704</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">180760</us-gaap:LiabilitiesCurrent>
    <us-gaap:ConvertibleLongTermNotesPayable
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">483099</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:ConvertibleLongTermNotesPayable
      contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">6892</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">3351600</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">5190000</us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent>
    <us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent
      contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">9240295</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">180760</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <sclx:OrdinarySharesSubjectToPossibleRedemption
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">13800000</sclx:OrdinarySharesSubjectToPossibleRedemption>
    <sclx:OrdinarySharesSubjectToPossibleRedemption
      contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">0</sclx:OrdinarySharesSubjectToPossibleRedemption>
    <sclx:SubjectToPossibleRedemptionPerShares
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">10.1</sclx:SubjectToPossibleRedemptionPerShares>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">139380000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">3450000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">3450000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">3450000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">3450000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      id="Fact_63193285"
      unitRef="Unit_USD">345</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      id="Fact_63193284"
      unitRef="Unit_USD">345</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">24655</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-8697444</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-6276</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-8697099</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">18724</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">139923196</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">199484</us-gaap:LiabilitiesAndStockholdersEquity>
    <sclx:OrdinarySharesRedemptionSubjectedToForfeiture
      contextRef="P01_01_2020To12_31_2020_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">450000</sclx:OrdinarySharesRedemptionSubjectedToForfeiture>
    <sclx:SharesCapitalization
      contextRef="PAsOn01_06_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.2</sclx:SharesCapitalization>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn01_06_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">3450000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn01_06_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">3450000</us-gaap:CommonStockSharesIssued>
    <sclx:OrdinarySharesRedemptionSubjectedToForfeiture
      contextRef="P01_11_2021To01_11_2021_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">0</sclx:OrdinarySharesRedemptionSubjectedToForfeiture>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1005498</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">6276</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-1005498</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-6276</us-gaap:OperatingIncomeLoss>
    <sclx:ChangeInFairValueOfWarrantLiability
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-4377600</sclx:ChangeInFairValueOfWarrantLiability>
    <sclx:ChangeInFairValueOfWarrantLiability
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:GainLossOnSaleOfDerivatives
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-2599200</us-gaap:GainLossOnSaleOfDerivatives>
    <us-gaap:GainLossOnSaleOfDerivatives
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">11835</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
    <us-gaap:InterestExpense
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1826</us-gaap:InterestExpense>
    <sclx:TransactionCostsAllocatedToWarrantLiabilities
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">30212</sclx:TransactionCostsAllocatedToWarrantLiabilities>
    <sclx:TransactionCostsAllocatedToWarrantLiabilities
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:InterestIncomeOther
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">30739</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1788935</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">783438</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-6276</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      id="Fact_63193636"
      unitRef="Unit_shares">16820548</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      id="Fact_63193637"
      unitRef="Unit_shares">3000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.05</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">16834110</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">3000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.05</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0</us-gaap:EarningsPerShareDiluted>
    <sclx:OrdinarySharesRedemptionSubjectedToForfeiture
      contextRef="P01_01_2020To12_31_2020"
      decimals="INF"
      unitRef="Unit_shares">450000</sclx:OrdinarySharesRedemptionSubjectedToForfeiture>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn02_20_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn02_20_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn02_20_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn02_20_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn02_20_2020_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P02_21_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">1</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P02_21_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P02_21_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P02_21_2020To12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="P02_21_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">-1</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="P02_21_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="P02_21_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="P02_21_2020To12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="P02_21_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">3450000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="P02_21_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">345</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="P02_21_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">24655</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="P02_21_2020To12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">25000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:NetIncomeLoss
      contextRef="P02_21_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="P02_21_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="P02_21_2020To12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-6276</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-6276</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">3450000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">345</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">24655</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-6276</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">18724</us-gaap:StockholdersEquity>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="P01_01_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">24655</us-gaap:StockRedeemedOrCalledDuringPeriodValue>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="P01_01_2021To12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">9474606</us-gaap:StockRedeemedOrCalledDuringPeriodValue>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">9499261</us-gaap:StockRedeemedOrCalledDuringPeriodValue>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">783438</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">783438</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">3450000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">345</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-8697444</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-8697099</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">783438</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-6276</us-gaap:NetIncomeLoss>
    <sclx:FormationCostPaidThroughAdvancesFromAffiliateOfSponsor
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <sclx:FormationCostPaidThroughAdvancesFromAffiliateOfSponsor
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">5000</sclx:FormationCostPaidThroughAdvancesFromAffiliateOfSponsor>
    <us-gaap:InterestAndDividendIncomeSecuritiesHeldToMaturity
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">30739</us-gaap:InterestAndDividendIncomeSecuritiesHeldToMaturity>
    <us-gaap:InterestAndDividendIncomeSecuritiesHeldToMaturity
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-4377600</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <sclx:LossOnInitialIssuanceOfWarrantLiability
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">2599200</sclx:LossOnInitialIssuanceOfWarrantLiability>
    <sclx:LossOnInitialIssuanceOfWarrantLiability
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <sclx:ChangeInFairValueOfConversionOptionLiability
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-11835</sclx:ChangeInFairValueOfConversionOptionLiability>
    <sclx:ChangeInFairValueOfConversionOptionLiability
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1826</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <sclx:TransactionsCostsAllocatedToPrivateWarrants
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">30212</sclx:TransactionsCostsAllocatedToPrivateWarrants>
    <sclx:TransactionsCostsAllocatedToPrivateWarrants
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">4536</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">208704</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-801330</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-1276</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <sclx:InvestmentOfCashInTrustAccounts
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">139380000</sclx:InvestmentOfCashInTrustAccounts>
    <sclx:InvestmentOfCashInTrustAccounts
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-139380000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">135600000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">5130000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">25000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">25000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">55000</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <sclx:ProceedsFromPromissoryNoteRelatedParty
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <sclx:ProceedsFromPromissoryNoteRelatedParty
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">125000</sclx:ProceedsFromPromissoryNoteRelatedParty>
    <us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-125000</us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt>
    <us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">500000</us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">416260</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">118213</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">140658740</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">31787</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">477410</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">30511</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">30511</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn02_20_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">507921</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">30511</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <sclx:DeferredUnderwritingFeePayable
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">5190000</sclx:DeferredUnderwritingFeePayable>
    <sclx:DeferredUnderwritingFeePayable
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <sclx:OfferingCostIncludedInAccruedOfferingCost
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <sclx:OfferingCostIncludedInAccruedOfferingCost
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">25760</sclx:OfferingCostIncludedInAccruedOfferingCost>
    <us-gaap:NotesIssued1
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:NotesIssued1
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">25000</us-gaap:NotesIssued1>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 1&#160;&#x2014;&#160;DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Vickers Vantage Corp. I (the &#x201c;Company&#x201d;) is a blank check company incorporated as a Cayman Islands exempted company on February&#160;21, 2020. The Company was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities (a &#x201c;Business Combination&#x201d;). &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is not limited to a particular industry or sector for purposes of consummating a Business Combination. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;As of December&#160;31, 2021, the Company had not commenced any operations. All activity for the period from February&#160;21, 2020 (inception) through December&#160;31, 2021 relates to the Company&#x2019;s formation and the initial public offering (&#x201c;Initial Public Offering&#x201d;), which is described below, and, subsequent to the Initial Public Offering, identifying a target company for a Business Combination. The Company will not generate any operating revenues until after the completion of a Business Combination, at the earliest. The Company will generate &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-operating&lt;/div&gt; income in the form of interest income from the proceeds derived from the Initial Public Offering. The Company has selected December&#160;31 as its fiscal year end. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The registration statement for the Company&#x2019;s Initial Public Offering was declared effective on January&#160;6, 2021. On January&#160;11, 2021 the Company consummated the Initial Public Offering of 13,800,000&#160;Units (the &#x201c;Units&#x201d; and, with respect to the ordinary shares included in the Units sold, the &#x201c;Public Shares&#x201d;), which includes the full exercise by the underwriter of its over-allotment option in the amount of 1,800,000&#160;Units, at $10.00 per Unit, generating gross proceeds of $138,000,000 which is described in Note 3. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of 6,840,000 warrants (the &#x201c;Private Placement Warrants&#x201d;) at a price of $0.75 per Private Placement Warrant in a private placement to Vickers Venture Fund&#160;VI Pte Ltd and Vickers Venture Fund&#160;VI (Plan) Pte Ltd, (the &#x201c;Sponsor&#x201d;), generating gross proceeds of $5,130,000, which is described in Note 4. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Transaction costs amounted to $8,149,473, consisting of $2,400,000 in cash underwriting fees, $5,190,000 in deferred underwriting fees, and $559,473 of other offering costs. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Following the closing of the Initial Public Offering on January&#160;11, 2021, an amount of $139,380,000 ($10.10 per Unit) from the net proceeds of the sale of the Units in the Initial Public Offering and the sale of the Private Placement Warrants was placed in a trust account (the &#x201c;Trust Account&#x201d;), and invested in U.S. government securities, within the meaning set forth in Section&#160;2(a)(16) of the Investment Company Act, with a maturity of 185&#160;days or less, or in any open-ended investment company that holds itself out as a money market fund investing solely in U.S. Treasuries and meeting certain conditions under &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rule&#160;2a-7&lt;/div&gt; of the Investment Company Act, as determined by the Company, until the earliest of: (i)&#160;the completion of a Business Combination and (ii)&#160;the distribution of the funds in the Trust Account to the Company&#x2019;s shareholders, as described below. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;The Company&#x2019;s management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and the sale of the Private Placement Warrants, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The stock exchange listing rules require that the Business Combination must be with one or more operating businesses or assets with a fair market value equal to at least 80% of the assets held in the Trust Account (as defined below) (less any deferred underwriting commissions and taxes payable on the interest earned on the Trust Account). The&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;Company will only complete a Business Combination if the post-Business Combination company owns or acquires 50% or more of the issued and outstanding voting securities of the target or otherwise acquires a controlling interest in the target business sufficient for it not to be required to register as an investment company under the Investment Company Act of 1940, as amended (the &#x201c;Investment Company Act&#x201d;). There is no assurance that the Company will be able to successfully effect a Business Combination. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;The Company will provide the holders of the public shares (the &#x201c;Public Shareholders&#x201d;) with the opportunity to redeem all or a portion of their public shares upon the completion of the Business Combination, either (i)&#160;in connection with a general meeting called to approve the Business Combination or (ii)&#160;by means of a tender offer. The decision as to whether the Company will seek shareholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The Public Shareholders will be entitled to redeem their Public Shares, equal to the aggregate amount then on deposit in the Trust Account, calculated as of two business days prior to the consummation of the Business Combination (initially anticipated to be $10.10 per Public Share), including interest (which interest shall be net of taxes payable), divided by the number of then issued and outstanding public shares, subject to certain limitations as described in the prospectus. The &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;per-share&lt;/div&gt; amount to be distributed to the Public Shareholders who properly redeem their shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriters (as discussed in Note 6). &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company will proceed with a Business Combination only if the Company has net tangible assets of at least $5,000,001 and, if the Company seeks shareholder approval, it receives an ordinary resolution under Cayman Islands law approving a Business Combination, which requires the affirmative vote of a majority of the shareholders who attend and vote at a general meeting of the Company. If a shareholder vote is not required and the Company does not decide to hold a shareholder vote for business or other legal reasons, the Company will, pursuant to its Amended and Restated Memorandum and Articles of Association, conduct the redemptions pursuant to the tender offer rules of the Securities and Exchange Commission (&#x201c;SEC&#x201d;), and file tender offer documents containing substantially the same information as would be included in a proxy statement with the SEC prior to completing a Business Combination. If the Company seeks shareholder approval in connection with a Business Combination, the Company&#x2019;s Sponsors have agreed to vote its Founder Shares (as defined in Note 5) and any Public Shares purchased during or after the Initial Public Offering in favor of approving a Business Combination. Additionally, each Public Shareholder may elect to redeem their Public Shares, without voting, and if they do vote, irrespective of whether they vote for or against a proposed Business Combination. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Notwithstanding the foregoing, if the Company seeks shareholder approval of the Business Combination and the Company does not conduct redemptions pursuant to the tender offer rules, a Public Shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a &#x201c;group&#x201d; (as defined under Section&#160;13 of the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;)), will be restricted from redeeming its shares with respect to more than an aggregate of 20% of the Public Shares without the Company&#x2019;s prior written consent. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;The Sponsors have agreed (a)&#160;to waive their redemption rights with respect to any Founder Shares and Public Shares held by them in connection with the completion of a Business Combination and (b)&#160;not to propose an amendment to the Amended and Restated Memorandum and Articles of Association (i)&#160;to modify the substance or timing of the Company&#x2019;s obligation to allow redemption in connection with the Company&#x2019;s initial Business Combination or to redeem 100% of the Public Shares if the Company does not complete a Business Combination within the Combination Period (as defined below) or (ii)&#160;with respect to any other provision relating to shareholders&#x2019; rights or &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-initial&lt;/div&gt; business combination activity, unless the Company provides the Public&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Shareholders with the opportunity to redeem their Public Shares upon approval of any such amendment at a&#160;&lt;/div&gt; &lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;per-share&lt;/div&gt; price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest (which interest shall be net of taxes payable), divided by the number of then issued and outstanding Public Shares. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;On January&#160;10, 2022, the Company extended the period of time to consummate a Business Combination from January&#160;11, 2022 to April&#160;11, 2022. In connection with the extension, the Sponsors deposited $1,035,000 into the trust account in the form of a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-interest&lt;/div&gt; bearing loan. The Company will have until April&#160;11, 2022 to consummate a Business Combination. However, if the Company anticipates that it may not be able to consummate a Business Combination by April&#160;11, 2022, the Company may extend the period of time to consummate a Business Combination by an additional three&#160;months (until July&#160;11, 2022 to complete a Business Combination (the &#x201c;Combination Period&#x201d;). In order to extend the time available for the Company to consummate a Business Combination, the Sponsor or its affiliate or designees must deposit into the Trust Account $1,035,000 ($0.075 per Public Share), on or prior to the date of the applicable deadline, for the three-month extension. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;If the Company has not completed a Business Combination within the Combination Period, the Company will (i)&#160;cease all operations except for the purpose of winding up, (ii)&#160;as promptly as reasonably possible but not more than ten business days thereafter, redeem 100% of the Public Shares, at a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;per-share&lt;/div&gt; price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest (less up to $50,000 of interest to pay dissolution expenses and which interest shall be net of taxes payable), divided by the number of then issued and outstanding Public Shares, which redemption will completely extinguish the rights of the Public Shareholders as shareholders (including the right to receive further liquidating distributions, if any), and (iii)&#160;as promptly as reasonably possible following such redemption, subject to the approval of the Company&#x2019;s remaining Public Shareholders and its Board of Directors, liquidate and dissolve, subject in each case to the Company&#x2019;s obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law. There will be no redemption rights or liquidating distributions with respect to the Company&#x2019;s warrants, which will expire worthless if the Company fails to complete a Business Combination within the Combination Period. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Sponsors have agreed to waive their rights to liquidating distributions from the Trust Account with respect to the Founder Shares if the Company fails to complete a Business Combination within the Combination Period. However, if the Sponsors or any of their respective affiliates acquire Public Shares, such Public Shares will be entitled to liquidating distributions from the Trust Account if the Company fails to complete a Business Combination within the Combination Period. The underwriters have agreed to waive their rights to their deferred underwriting commission (see Note 6) held in the Trust Account in the event the Company does not complete a Business Combination within the Combination Period, and in such event, such amounts will be included with the other funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the assets remaining available for distribution will be less than the amount of funds deposited into the Trust Account ($10.10 per share). &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;In order to protect the amounts held in the Trust Account, the Sponsors have agreed that it will be liable to the Company if and to the extent any claims by a third party (other than the Company&#x2019;s independent registered public accounting firm) for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account to below (1)&#160;$10.10 per Public Share or (2)&#160;such lesser amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account due to reductions in the value of trust assets, in each case net of the interest which may be withdrawn to pay taxes, except as to any claims by a third party who&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;executed a waiver of any and all rights to seek access to the Trust Account and except as to any claims under the&#160;&lt;/div&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Company&#x2019;s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;). In the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsors will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsors will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (other than the Company&#x2019;s independent registered public accounting firm), prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Going Concern and Liquidity &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December&#160;31, 2021, the Company had $507,921 in its operating bank accounts, and working capital of $303,753. As of December&#160;31, 2021, approximately $31,000 of the amount on deposit in the Trust Account represented interest income, which is available to pay the Company&#x2019;s tax obligations. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;If the Company is unable to raise additional capital, it may be required to take additional measures to conserve liquidity, which could include, but not necessarily be limited to, suspending the pursuit of a Business Combination. The Company cannot provide any assurance that new financing will be available to it on commercially acceptable terms, if at all. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;As a result of the above, in connection with the Company&#x2019;s assessment of going concern considerations in accordance with Financial Accounting Standard Board&#x2019;s Accounting Standards Update (&#x201c;ASU&#x201d;) &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2014-15,&lt;/div&gt; &#x201c;Disclosures of Uncertainties about an Entity&#x2019;s Ability to Continue as a Going Concern,&#x201d; management has determined that the liquidity condition and date for mandatory liquidation and dissolution raise substantial doubt about the Company&#x2019;s ability to continue as a going concern through July&#160;11, 2022 (extension date), the scheduled liquidation date of the Company if it does not complete a Business Combination prior to such date. These financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;If the Company is unable to raise additional capital, it may be required to take additional measures to conserve liquidity, which could include, but not necessarily be limited to, suspending the pursuit of a Business Combination. The Company cannot provide any assurance that new financing will be available to it on commercially acceptable terms, if at all. &lt;/div&gt;&lt;/div&gt; </us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <sclx:Numberofshares
      contextRef="P01_04_2021To01_11_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">13800000</sclx:Numberofshares>
    <sclx:Numberofshares
      contextRef="P01_04_2021To01_11_2021_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">1800000</sclx:Numberofshares>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn01_11_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10</us-gaap:SaleOfStockPricePerShare>
    <sclx:ProceedsOfInitialPublicOffering
      contextRef="P01_04_2021To01_11_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">138000000</sclx:ProceedsOfInitialPublicOffering>
    <sclx:Saleofwarrants
      contextRef="P01_01_2021To12_31_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">6840000</sclx:Saleofwarrants>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn12_31_2021_PrivatePlacementWarrantMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.75</us-gaap:SaleOfStockPricePerShare>
    <sclx:Grossproceedsofwarrants
      contextRef="P01_01_2021To12_31_2021_PrivatePlacementWarrantMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">5130000</sclx:Grossproceedsofwarrants>
    <sclx:Transactioncostsamount
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">8149473</sclx:Transactioncostsamount>
    <us-gaap:OtherUnderwritingExpense
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">2400000</us-gaap:OtherUnderwritingExpense>
    <sclx:DeferredUnderwritingFees
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">5190000</sclx:DeferredUnderwritingFees>
    <sclx:Otherofferingcosts
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">559473</sclx:Otherofferingcosts>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="P01_04_2021To01_11_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">139380000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn01_11_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10.1</us-gaap:SaleOfStockPricePerShare>
    <sclx:SaleOfStockDescriptionOfTransactions contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis">The stock exchange listing rules require that the Business Combination must be with one or more operating businesses or assets with a fair market value equal to at least 80% of the assets held in the Trust Account (as defined below) (less any deferred underwriting commissions and taxes payable on the interest earned on the Trust Account). TheCompany will only complete a Business Combination if the post-Business Combination company owns or acquires 50% or more of the issued and outstanding voting securities of the target or otherwise acquires a controlling interest in the target business sufficient for it not to be required to register as an investment company under the Investment Company Act of 1940, as amended (the &#x201c;Investment Company Act&#x201d;). There is no assurance that the Company will be able to successfully effect a Business Combination.</sclx:SaleOfStockDescriptionOfTransactions>
    <sclx:Numberofbusinessdays
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_Day">2</sclx:Numberofbusinessdays>
    <sclx:PricePerPublicShare
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10.1</sclx:PricePerPublicShare>
    <sclx:NetTangibleAssets
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">5000001</sclx:NetTangibleAssets>
    <sclx:PercentageOfPublicShares
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_pure">0.20</sclx:PercentageOfPublicShares>
    <sclx:BusinessCombinationRedeemPercentage
      contextRef="PAsOn12_31_2021_SponsorMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_pure">1</sclx:BusinessCombinationRedeemPercentage>
    <sclx:Depositintotrustaccount
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1035000</sclx:Depositintotrustaccount>
    <sclx:Depositintotrustaccount
      contextRef="PAsOn12_31_2021_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1035000</sclx:Depositintotrustaccount>
    <sclx:PricePerPublicShare
      contextRef="P01_01_2021To12_31_2021_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="3"
      unitRef="Unit_USD_per_Share">0.075</sclx:PricePerPublicShare>
    <sclx:BusinessCombinationRedeemPercentage
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_pure">1</sclx:BusinessCombinationRedeemPercentage>
    <sclx:Interestexpenses
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">50000</sclx:Interestexpenses>
    <us-gaap:Cash
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">507921</us-gaap:Cash>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">303753</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:InterestIncomeDepositWithFinancialInstitutionIncreaseDecrease
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">31000</us-gaap:InterestIncomeDepositWithFinancialInstitutionIncreaseDecrease>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 2&#160;&#x2014;&#160;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Basis of Presentation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and pursuant to the rules and regulations of the SEC. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Emerging Growth Company &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is an &#x201c;emerging growth company,&#x201d; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;registered public accounting firm attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Further, Section&#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-emerging&lt;/div&gt; growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&#x2019;s financial statement with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The preparation of the financial statements in conformity with GAAP requires the Company&#x2019;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. One of the more significant accounting estimates included in these financial statements is the determination of the fair value of the warrant liabilities. Such estimates may be subject to change as more current information because available and accordingly, the actual results could differ significantly from those estimates. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Offering Costs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Offering costs consist of legal, accounting, underwriting fees and other costs incurred through the balance sheet date that are directly related to the Initial Public Offering. Offering costs were allocated to the separable financial instruments issued in the Initial Public Offering based on a relative fair value basis, compared to total proceeds received. Offering costs allocated to warrant liabilities were expensed as incurred in the statements of operations. Offering costs associated with the ordinary shares issued were initially charged to temporary equity and then accreted to ordinary shares subject to redemption upon the completion of the Initial Public Offering. Offering costs amounting to $8,119,261 were charged to temporary equity upon the completion of the Initial Public Offering, and $30,212 of the offering costs were related to the warrant liabilities and charged to the statements of operations. &lt;/div&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Ordinary Shares Subject to Possible Redemption &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company accounts for its ordinary shares subject to possible redemption in accordance with the guidance in Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 480 &#x201c;Distinguishing Liabilities from Equity.&#x201d; Ordinary shares subject to mandatory redemption is classified as a liability instrument and is measured at fair value. Conditionally redeemable ordinary shares (including ordinary shares that features redemption rights that is either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#x2019;s control) is classified as temporary equity. At all other times, ordinary shares are classified as shareholders&#x2019; equity. The Company&#x2019;s ordinary shares, sold in the IPO, features certain redemption rights that are considered to be outside of the Company&#x2019;s control and subject to occurrence of uncertain future events. Accordingly, at December&#160;31, 2021 and 2020, ordinary shares subject to possible redemption is presented as temporary equity, outside of the shareholders&#x2019; (deficit) equity section of the Company&#x2019;s balance sheets. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Under ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;480-10-S99,&lt;/div&gt;&lt;/div&gt; the Company has elected to recognize changes in the redemption value immediately as they occur and adjust the carrying value of redeemable ordinary shares subject to possible redemption to equal the redemption value at the end of each reporting period. This method would view the end of the reporting period as if it were also the redemption date for the security. Immediately upon the closing of the Initial Public Offering, the Company recognized the accretion from initial book value to redemption amount value. The change in the carrying value of redeemable ordinary shares resulted in charges against additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;paid-in&lt;/div&gt; capital and accumulated deficit. &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;At December&#160;31, 2021, the ordinary shares reflected in the balance sheets are reconciled in the following table: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 77%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 77%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross proceeds&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;138,000,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 77%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 77%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Ordinary shares issuance costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(8,119,261&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 77%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Plus:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 77%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accretion of carrying value to redemption value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9,499,261&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; width: 77%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 77%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Ordinary shares subject to possible redemption&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;139,380,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; width: 77%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; width: 77%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Warrant Liability &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#x2019;s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) 480, Distinguishing Liabilities from Equity (&#x201c;ASC 480&#x201d;) and ASC 815, Derivatives and Hedging (&#x201c;ASC 815&#x201d;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company&#x2019;s own ordinary shares, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. We account for the warrants issued in connection with our Initial Public Offering in accordance with the guidance contained in ASC 815 under which the public warrants meet the criteria for equity treatment and the private warrants do not meet the criteria for equity treatment and must be recorded as liabilities. Accordingly, we classify the private warrants as liabilities at their fair value and adjust the private warrants to fair value at each reporting period. This liability is subject to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-measurement&lt;/div&gt; at each balance sheet date until exercised, and any &lt;/div&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;change in fair value is recognized in our statements of operations. The fair value of the warrants was estimated using a Black-Scholes option pricing formula. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company accounts for income taxes under ASC Topic 740, &#x201c;Income Taxes,&#x201d; which prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company&#x2019;s management determined that the Cayman Islands is the Company&#x2019;s major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. As of December&#160;31, 2021 and 2020, there were no unrecognized tax benefits and no amounts accrued for interest and penalties. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is considered to be an exempted Cayman Islands company with no connection to any other taxable jurisdiction and is presently not subject to income taxes or income tax filing requirements in the Cayman Islands or the United States. As such, the Company&#x2019;s tax provision was zero for the periods presented. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Net income (Loss) per Ordinary Share &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, &#x201c;Earnings Per Share&#x201d;. Net income (loss) per ordinary share is computed by dividing net income (loss) by the weighted average number of ordinary shares outstanding for the period. Accretion associated with the redeemable shares of ordinary shares is excluded from earnings per share as the redemption value approximates fair value. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The calculation of diluted income (loss) per share does not consider the effect of the warrants issued in connection with the (i)&#160;Initial Public Offering, and (ii)&#160;the private placement since the exercise of the warrants is contingent upon the occurrence of future events. The warrants are exercisable to purchase 13,740,000 ordinary shares in the aggregate. As of December&#160;31, 2021 and 2020, the Company did not have any dilutive securities or other contracts that could, potentially, be exercised or converted into ordinary shares and then share in the earnings of the Company, except for the 450,000 founder shares in December&#160;31, 2021 which are no longer forfeitable and thus included for dilutive purposes. As a result, diluted net loss per ordinary share is the same as basic net loss per ordinary share for the periods presented. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table reflects the calculation of basic and diluted net income per ordinary share (in dollars, except per share amounts): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 66%;"/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended&lt;br/&gt;December&#160;31,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Period&lt;br/&gt;from&#160;February&#160;21,&lt;br/&gt;2020 (Inception)&lt;br/&gt;Through&lt;br/&gt;December&#160;31,&lt;br/&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Ordinary&#160;Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Ordinary&#160;Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Basic net income (loss) per ordinary share&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Numerator:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Allocation of net income (loss), as adjusted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;783,438&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(6,276&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Denominator:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic weighted average ordinary shares outstanding&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,820,548&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,000,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic net income (loss) per ordinary share&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.05&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Diluted net income (loss) per ordinary share&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Numerator:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Allocation of net income (loss), as adjusted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;783,438&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(6,276&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Denominator:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Diluted weighted average ordinary shares outstanding&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,834,110&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,000,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Diluted net income (loss) per ordinary share&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.05&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Concentration of Credit Risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times may exceed the Federal Depository Insurance Corporation coverage limit of $250,000. The Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such account. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Fair Value of Financial Instruments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value of the Company&#x2019;s assets and liabilities, which qualify as financial instruments under ASC Topic 820, &#x201c;Fair Value Measurement,&#x201d; approximates the carrying amounts represented in the accompanying balance sheets, primarily due to their short-term nature, other than the derivative warrant liability. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Recent Accounting Standards &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;Management does not believe that any other recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company&#x2019;s condensed financial statements. In August&#160;2020, the FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;) &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2020-06,&lt;/div&gt; Debt&#160;&#x2014;&#160;Debt with Conversion and Other Options (Subtopic &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;470-20)&lt;/div&gt; and Derivatives and Hedging&#160;&#x2014;&#160;Contracts in Entity&#x2019; Own Equity (Subtopic &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;815-40):&lt;/div&gt; Accounting for Convertible Instruments and Contracts in an Entity&#x2019; Own Equity (&#x201c;ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-06&#x201d;),&lt;/div&gt; which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU also removes certain settlement conditions that are required for equity-linked contracts to qualify for the derivative scope exception, and it simplifies the diluted earnings per share calculation in certain areas. ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-06&lt;/div&gt; is effective for fiscal&#160;years beginning after December&#160;15, 2023, including interim periods within those fiscal&#160;years, with early adoption permitted. Management is currently evaluating the new guidance but does not expect the adoption of this guidance to have a material impact on the Company&#x2019;s condensed financial statements. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Management does not believe that any other recently issued, but not yet effective, accounting standard if currently adopted would have a material effect on the accompanying condensed financial statements. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Basis of Presentation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and pursuant to the rules and regulations of the SEC. &lt;/div&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Emerging Growth Company &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is an &#x201c;emerging growth company,&#x201d; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;registered public accounting firm attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Further, Section&#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-emerging&lt;/div&gt; growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&#x2019;s financial statement with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. &lt;/div&gt;</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The preparation of the financial statements in conformity with GAAP requires the Company&#x2019;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. One of the more significant accounting estimates included in these financial statements is the determination of the fair value of the warrant liabilities. Such estimates may be subject to change as more current information because available and accordingly, the actual results could differ significantly from those estimates. &lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:DeferredChargesPolicyTextBlock contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Offering Costs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Offering costs consist of legal, accounting, underwriting fees and other costs incurred through the balance sheet date that are directly related to the Initial Public Offering. Offering costs were allocated to the separable financial instruments issued in the Initial Public Offering based on a relative fair value basis, compared to total proceeds received. Offering costs allocated to warrant liabilities were expensed as incurred in the statements of operations. Offering costs associated with the ordinary shares issued were initially charged to temporary equity and then accreted to ordinary shares subject to redemption upon the completion of the Initial Public Offering. Offering costs amounting to $8,119,261 were charged to temporary equity upon the completion of the Initial Public Offering, and $30,212 of the offering costs were related to the warrant liabilities and charged to the statements of operations. &lt;/div&gt;&lt;br/&gt;&lt;/div&gt;</us-gaap:DeferredChargesPolicyTextBlock>
    <us-gaap:OtherDeferredCostsNet
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">8119261</us-gaap:OtherDeferredCostsNet>
    <us-gaap:OtherDeferredCostsNet
      contextRef="PAsOn12_31_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">30212</us-gaap:OtherDeferredCostsNet>
    <us-gaap:SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Ordinary Shares Subject to Possible Redemption &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company accounts for its ordinary shares subject to possible redemption in accordance with the guidance in Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 480 &#x201c;Distinguishing Liabilities from Equity.&#x201d; Ordinary shares subject to mandatory redemption is classified as a liability instrument and is measured at fair value. Conditionally redeemable ordinary shares (including ordinary shares that features redemption rights that is either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#x2019;s control) is classified as temporary equity. At all other times, ordinary shares are classified as shareholders&#x2019; equity. The Company&#x2019;s ordinary shares, sold in the IPO, features certain redemption rights that are considered to be outside of the Company&#x2019;s control and subject to occurrence of uncertain future events. Accordingly, at December&#160;31, 2021 and 2020, ordinary shares subject to possible redemption is presented as temporary equity, outside of the shareholders&#x2019; (deficit) equity section of the Company&#x2019;s balance sheets. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Under ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;480-10-S99,&lt;/div&gt;&lt;/div&gt; the Company has elected to recognize changes in the redemption value immediately as they occur and adjust the carrying value of redeemable ordinary shares subject to possible redemption to equal the redemption value at the end of each reporting period. This method would view the end of the reporting period as if it were also the redemption date for the security. Immediately upon the closing of the Initial Public Offering, the Company recognized the accretion from initial book value to redemption amount value. The change in the carrying value of redeemable ordinary shares resulted in charges against additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;paid-in&lt;/div&gt; capital and accumulated deficit. &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;At December&#160;31, 2021, the ordinary shares reflected in the balance sheets are reconciled in the following table: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 77%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 77%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross proceeds&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;138,000,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 77%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 77%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Ordinary shares issuance costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(8,119,261&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 77%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Plus:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 77%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accretion of carrying value to redemption value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9,499,261&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; width: 77%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 77%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Ordinary shares subject to possible redemption&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;139,380,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; width: 77%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; width: 77%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; </us-gaap:SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock>
    <srt:ScheduleOfCondensedBalanceSheetTableTextBlock contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis">
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 77%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 77%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross proceeds&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;138,000,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 77%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 77%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Ordinary shares issuance costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(8,119,261&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 77%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Plus:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 77%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accretion of carrying value to redemption value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9,499,261&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; width: 77%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 77%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Ordinary shares subject to possible redemption&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;139,380,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; width: 77%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</srt:ScheduleOfCondensedBalanceSheetTableTextBlock>
    <sclx:GrossProceeds
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">138000000</sclx:GrossProceeds>
    <sclx:OrdinarySharesIssuanceCost
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">8119261</sclx:OrdinarySharesIssuanceCost>
    <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">9499261</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
    <sclx:SharesSubjectToPossibleRedemption
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">139380000</sclx:SharesSubjectToPossibleRedemption>
    <us-gaap:DerivativesPolicyTextBlock contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Warrant Liability &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#x2019;s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) 480, Distinguishing Liabilities from Equity (&#x201c;ASC 480&#x201d;) and ASC 815, Derivatives and Hedging (&#x201c;ASC 815&#x201d;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company&#x2019;s own ordinary shares, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. We account for the warrants issued in connection with our Initial Public Offering in accordance with the guidance contained in ASC 815 under which the public warrants meet the criteria for equity treatment and the private warrants do not meet the criteria for equity treatment and must be recorded as liabilities. Accordingly, we classify the private warrants as liabilities at their fair value and adjust the private warrants to fair value at each reporting period. This liability is subject to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-measurement&lt;/div&gt; at each balance sheet date until exercised, and any &lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;change in fair value is recognized in our statements of operations. The fair value of the warrants was estimated using a Black-Scholes option pricing formula. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company accounts for income taxes under ASC Topic 740, &#x201c;Income Taxes,&#x201d; which prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company&#x2019;s management determined that the Cayman Islands is the Company&#x2019;s major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. As of December&#160;31, 2021 and 2020, there were no unrecognized tax benefits and no amounts accrued for interest and penalties. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is considered to be an exempted Cayman Islands company with no connection to any other taxable jurisdiction and is presently not subject to income taxes or income tax filing requirements in the Cayman Islands or the United States. As such, the Company&#x2019;s tax provision was zero for the periods presented. &lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Net income (Loss) per Ordinary Share &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, &#x201c;Earnings Per Share&#x201d;. Net income (loss) per ordinary share is computed by dividing net income (loss) by the weighted average number of ordinary shares outstanding for the period. Accretion associated with the redeemable shares of ordinary shares is excluded from earnings per share as the redemption value approximates fair value. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The calculation of diluted income (loss) per share does not consider the effect of the warrants issued in connection with the (i)&#160;Initial Public Offering, and (ii)&#160;the private placement since the exercise of the warrants is contingent upon the occurrence of future events. The warrants are exercisable to purchase 13,740,000 ordinary shares in the aggregate. As of December&#160;31, 2021 and 2020, the Company did not have any dilutive securities or other contracts that could, potentially, be exercised or converted into ordinary shares and then share in the earnings of the Company, except for the 450,000 founder shares in December&#160;31, 2021 which are no longer forfeitable and thus included for dilutive purposes. As a result, diluted net loss per ordinary share is the same as basic net loss per ordinary share for the periods presented. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table reflects the calculation of basic and diluted net income per ordinary share (in dollars, except per share amounts): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 66%;"/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended&lt;br/&gt;December&#160;31,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Period&lt;br/&gt;from&#160;February&#160;21,&lt;br/&gt;2020 (Inception)&lt;br/&gt;Through&lt;br/&gt;December&#160;31,&lt;br/&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Ordinary&#160;Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Ordinary&#160;Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Basic net income (loss) per ordinary share&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Numerator:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Allocation of net income (loss), as adjusted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;783,438&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(6,276&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Denominator:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic weighted average ordinary shares outstanding&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,820,548&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,000,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic net income (loss) per ordinary share&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.05&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Diluted net income (loss) per ordinary share&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Numerator:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Allocation of net income (loss), as adjusted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;783,438&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(6,276&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Denominator:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Diluted weighted average ordinary shares outstanding&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,834,110&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,000,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Diluted net income (loss) per ordinary share&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.05&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ExcessStockSharesIssued
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">13740000</us-gaap:ExcessStockSharesIssued>
    <sclx:Foundershares
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">450000</sclx:Foundershares>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 66%;"/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended&lt;br/&gt;December&#160;31,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Period&lt;br/&gt;from&#160;February&#160;21,&lt;br/&gt;2020 (Inception)&lt;br/&gt;Through&lt;br/&gt;December&#160;31,&lt;br/&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Ordinary&#160;Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Ordinary&#160;Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Basic net income (loss) per ordinary share&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Numerator:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Allocation of net income (loss), as adjusted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;783,438&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(6,276&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Denominator:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic weighted average ordinary shares outstanding&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,820,548&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,000,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic net income (loss) per ordinary share&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.05&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Diluted net income (loss) per ordinary share&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Numerator:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Allocation of net income (loss), as adjusted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;783,438&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(6,276&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Denominator:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Diluted weighted average ordinary shares outstanding&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,834,110&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,000,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Diluted net income (loss) per ordinary share&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.05&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:TemporaryEquityNetIncome
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">783438</us-gaap:TemporaryEquityNetIncome>
    <us-gaap:TemporaryEquityNetIncome
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-6276</us-gaap:TemporaryEquityNetIncome>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">16820548</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">3000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.05</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0</us-gaap:EarningsPerShareBasic>
    <us-gaap:TemporaryEquityNetIncome
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">783438</us-gaap:TemporaryEquityNetIncome>
    <us-gaap:TemporaryEquityNetIncome
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-6276</us-gaap:TemporaryEquityNetIncome>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">16834110</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">3000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.05</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P02_21_2020To12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Concentration of Credit Risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times may exceed the Federal Depository Insurance Corporation coverage limit of $250,000. The Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such account. &lt;/div&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashFDICInsuredAmount
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Fair Value of Financial Instruments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value of the Company&#x2019;s assets and liabilities, which qualify as financial instruments under ASC Topic 820, &#x201c;Fair Value Measurement,&#x201d; approximates the carrying amounts represented in the accompanying balance sheets, primarily due to their short-term nature, other than the derivative warrant liability. &lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Recent Accounting Standards &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;Management does not believe that any other recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company&#x2019;s condensed financial statements. In August&#160;2020, the FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;) &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2020-06,&lt;/div&gt; Debt&#160;&#x2014;&#160;Debt with Conversion and Other Options (Subtopic &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;470-20)&lt;/div&gt; and Derivatives and Hedging&#160;&#x2014;&#160;Contracts in Entity&#x2019; Own Equity (Subtopic &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;815-40):&lt;/div&gt; Accounting for Convertible Instruments and Contracts in an Entity&#x2019; Own Equity (&#x201c;ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-06&#x201d;),&lt;/div&gt; which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU also removes certain settlement conditions that are required for equity-linked contracts to qualify for the derivative scope exception, and it simplifies the diluted earnings per share calculation in certain areas. ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-06&lt;/div&gt; is effective for fiscal&#160;years beginning after December&#160;15, 2023, including interim periods within those fiscal&#160;years, with early adoption permitted. Management is currently evaluating the new guidance but does not expect the adoption of this guidance to have a material impact on the Company&#x2019;s condensed financial statements. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Management does not believe that any other recently issued, but not yet effective, accounting standard if currently adopted would have a material effect on the accompanying condensed financial statements. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <sclx:ProposedPublicOfferingTextBlock contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 3&#160;&#x2014;&#160;PUBLIC OFFERING &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Pursuant to the Initial Public Offering, the Company sold to 13,800,000&#160;Units which includes a full exercise by the underwriters of their over-allotment option in the amount of 1,800,000&#160;Units, at a purchase price of $10.00 per Unit. Each Unit consists of one ordinary share and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-half&lt;/div&gt; of one redeemable warrant (&#x201c;Public Warrant&#x201d;). Each whole Public Warrant entitles the holder to purchase one ordinary share at an exercise price of $11.50 per whole share (see Note 7). &lt;/div&gt;</sclx:ProposedPublicOfferingTextBlock>
    <sclx:NumberOfSaleUnits
      contextRef="PAsOn12_31_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">13800000</sclx:NumberOfSaleUnits>
    <sclx:NumberOfSaleUnits
      contextRef="PAsOn12_31_2021_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">1800000</sclx:NumberOfSaleUnits>
    <sclx:PurchasePricePerShare
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">10</sclx:PurchasePricePerShare>
    <us-gaap:SaleOfStockDescriptionOfTransaction contextRef="P01_01_2021To12_31_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">Each Unit consists of one ordinary share and one-half of one redeemable warrant (&#x201c;Public Warrant&#x201d;). Each whole Public Warrant entitles the holder to purchase one ordinary share at an exercise price of $11.50 per whole share (see Note 7).</us-gaap:SaleOfStockDescriptionOfTransaction>
    <sclx:PrivatePlacementTextBlock contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 4&#160;&#x2014;&#160;PRIVATE PLACEMENT &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Simultaneously with the closing of the Initial Public Offering, the Sponsors purchased an aggregate of 6,840,000 Private Placement Warrants at a price of $0.75 per Private Placement Warrant, for an aggregate purchase price of $5,130,000, in a private placement. Each Private Placement Warrant is exercisable to purchase one ordinary share at a price of $11.50 per share, subject to adjustment (see Note 9). A portion of the proceeds from the Private Placement Warrants were added to the proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the proceeds from the sale of the Private Placement Warrants will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law) and the Private Placement Warrants will expire worthless. &lt;/div&gt;&lt;/div&gt;</sclx:PrivatePlacementTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn12_31_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">6840000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn12_31_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="P01_01_2021To12_31_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">5130000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="PAsOn12_31_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">11.5</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 5&#160;&#x2014;&#160;RELATED PARTY TRANSACTIONS &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Founder Shares &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;On July&#160;16, 2020, the Company issued an aggregate of 3,593,750 ordinary shares to an affiliate of the Sponsors for an aggregate purchase price of $25,000. In August&#160;2020, the affiliate transferred his Founder Shares to the Sponsors for the same price paid for such shares. On October&#160;8, 2020, the Company effected a share capitalization of 0.2 shares for each share outstanding, on December&#160;7, 2020, the Sponsors forfeited 1,437,500 ordinary shares, which were cancelled by the Company, and on January&#160;6, 2021, the Company effected a share capitalization of 0.2 shares for each share outstanding, resulting in 3,450,000 ordinary shares issued and outstanding (the &#x201c;Founder Shares&#x201d;). All share and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;per-share&lt;/div&gt; amounts have been retroactively restated to reflect the share transactions. The Founder Shares included an aggregate of up to 450,000 shares that were subject to forfeiture depending on the extent to which the underwriters&#x2019; over-allotment option is exercised, so that the number of Founder Shares will equal, on an &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;as-converted&lt;/div&gt; basis, approximately 20% of the Company&#x2019;s issued and outstanding ordinary shares after the Initial Public Offering. As a result of the underwriters&#x2019; election to partially exercise their over-allotment option, no Founder Shares are currently subject to forfeiture. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Sponsors have agreed, subject to limited exceptions, not to transfer, assign or sell any of its Founder Shares until six&#160;months after the consummation of a Business Combination or earlier if, subsequent to a Business Combination, the Company consummates a liquidation, merger, share exchange or other similar transaction that results in all of the Public Shareholders having the right to exchange their ordinary shares for cash, securities or other property. &lt;/div&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Advances from Related Party &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;During 2020, an affiliate of the Sponsors advanced the Company an aggregate of $30,000 to fund expenses in connection with the Initial Public Offering. The advances are &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-interest&lt;/div&gt; bearing and payable upon demand. As&lt;br/&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;of&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; and &lt;/div&gt;2020&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, there was $&lt;/div&gt;0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; and $&lt;/div&gt;30,000&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; advances outstanding, respectively. The outstanding amount of $&lt;/div&gt;30,000&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; was repaid on February&#160;&lt;/div&gt;26&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;.&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Promissory Note&#160;&#x2014;&#160;Related Party &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;On July&#160;16, 2020, the Company issued an unsecured promissory note (the &#x201c;Promissory Note&#x201d;) to an affiliate of the Sponsors, pursuant to which the Company may borrow up to an aggregate principal amount of $125,000. The Promissory Note is &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-interest&lt;/div&gt; bearing and payable on the earlier of (i)&#160;December&#160;31, 2020 or (ii)&#160;the completion of the Initial Public Offering. The outstanding balance under the Promissory Note of $125,000 was repaid subsequent to the closing of the Initial Public Offering on January&#160;14, 2021. Borrowings under the Promissory Note are no longer available to the Company. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Related Party Loans &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In order to finance transaction costs in connection with a Business Combination, the Sponsors or an affiliate of the Sponsors, or certain of the Company&#x2019;s officers and directors may, but are not obligated to, loan the Company funds as may be required (&#x201c;Working Capital Loans&#x201d;). Such Working Capital Loans would be evidenced by promissory notes. The notes may be repaid upon completion of a Business Combination, without interest, or, at the lender&#x2019;s discretion, up to $1,500,000 of notes may be converted upon completion of a Business Combination into warrants at a price of $0.75 per warrant. Such warrants would be identical to the Private Placement Warrants. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. As of December&#160;31, 2021 and 2020, there were no amounts outstanding under the Working Capital Loans. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;On December&#160;20, 2021, the Company entered into two convertible promissory notes with the Sponsors pursuant to which the Sponsors agreed to loan the Company up to an aggregate principal amount of $500,000 (the &#x201c;Convertible Promissory Notes&#x201d;). The Convertible Promissory Notes are &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-interest&lt;/div&gt; bearing and payable upon Business Combination. If a Business Combination is not consummated, the Convertible Promissory Notes will not be repaid by the Company and all amounts owed thereunder by the Company will&#160;be forgiven except to the extent that the Company has funds available to it outside of its Trust Account. Up to $500,000 of the Convertible Promissory Notes may be converted into warrants at a price of $0.75 per warrant at the option of the Sponsors. The warrants would be identical to the Private Placement Warrants. As of December&#160;31, 2021, the outstanding principal balance under the Convertible Promissory Notes amounted to an aggregate of $500,000. Subsequent to December&#160;31, 2021, on January&#160;10, 2022, the Company borrowed an additional $1,035,000, as discussed below. On January&#160;27, 2022, Company entered into two additional Convertible Promissory Notes with the Sponsors pursuant to which the Sponsors agreed to&#160;loan&#160;the Company up to an aggregate principal amount of $500,000. Subsequent to December&#160;31, 2021, the&#160;principal balance of the Convertible Promissory Notes amounted to an aggregate of $2,035,000 (see Note 11). &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company assessed the provisions of the Convertible Promissory Notes under ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;470-20.&lt;/div&gt; The derivative component of the obligation is initially valued and classified as a derivative liability (see Note 9). &lt;br/&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The debt discount is being amortized to interest expense as a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-cash &lt;/div&gt; charge over the term of the Convertible Promissory Notes, which is assumed to mature in April&#160;2022, the Company&#x2019;s expected Business Combination date. During&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;the year ended December&#160;31, 2021, the Company recorded $&lt;/div&gt;1,826&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; of interest expense related to the amortization of the debt discount. The remaining balance of the debt discount at December&#160;31, 2021&#160;amounted to $&lt;/div&gt;16,901&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;.&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Related Party Extension Loans &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;As discussed in Note 1, the Company may extend the period of time to consummate a Business Combination up to two times, each by an additional three&#160;months (until July&#160;11, 2022 to complete a Business Combination). In order to extend the time available for the Company to consummate a Business Combination, the Sponsor or its affiliates or designees must deposit into the Trust Account $1,035,000 ($0.075 per Public Share in either case), on or prior to the date of the applicable deadline, for each three-month extension, providing a total possible Business Combination period up until July 11, 2022 for a total payment value of $2,070,000 ($0.15 per unit in either case). Any such deposits would be made in the form of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-interest&lt;/div&gt; bearing loans. Such notes would either be paid upon consummation of a Business Combination, or, at the relevant insider&#x2019;s discretion, converted upon consummation of a Business Combination into additional Private Placement Warrants at a price of $0.75 per Private Placement Warrant. The Sponsor and its affiliates or designees intend, but are not obligated, to fund the Trust Account to extend the time for the Company to complete a Business Combination. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;On January&#160;10, 2022, the Company extended the period of time to consummate a Business Combination to April&#160;11, 2022. The Sponsors deposited $1,035,000 into the Trust Account made in the form of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-interest-bearing&lt;/div&gt; loans. If the Company completes an initial business combination, the Company will, at the option of the Sponsors, repay the amounts evidenced by the Convertible Promissory Notes or convert a portion or all of the total amount into warrants at a price of $0.75 per warrant, which warrants are identical to the Private Placement Warrants issued. If a Business Combination is not consummated, the Convertible Promissory Notes will not be repaid by the Company and all amounts owed thereunder by the Company will be forgiven except to the extent that the Company has funds available to it outside of its Trust Account. &lt;/div&gt; </us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P07_02_2020To07_16_2020_FounderSharesMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">3593750</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <sclx:aggregatePurchasePrice
      contextRef="P07_02_2020To07_16_2020_FounderSharesMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">25000</sclx:aggregatePurchasePrice>
    <sclx:CapitalizationOfShareOutstanding
      contextRef="P10_01_2020To10_08_2020_FounderSharesMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">0.2</sclx:CapitalizationOfShareOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited
      contextRef="P12_01_2020To12_07_2020_FounderSharesMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">1437500</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited>
    <sclx:CapitalizationOfShareOutstanding
      contextRef="P01_01_2021To01_06_2021_FounderSharesMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="1"
      unitRef="Unit_shares">0.2</sclx:CapitalizationOfShareOutstanding>
    <sclx:OrdinarySharesIssuedAndOutstanding
      contextRef="P01_01_2021To01_06_2021_FounderSharesMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">3450000</sclx:OrdinarySharesIssuedAndOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited
      contextRef="P01_01_2021To12_31_2021_FounderSharesMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">450000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="PAsOn12_31_2021_FounderSharesMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_pure">0.20</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:CostsAndExpensesRelatedParty
      contextRef="P12_01_2020To12_31_2020_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">30000</us-gaap:CostsAndExpensesRelatedParty>
    <us-gaap:DueToAffiliateCurrent
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:DueToAffiliateCurrent>
    <us-gaap:DueToAffiliateCurrent
      contextRef="PAsOn12_31_2020"
      decimals="0"
      unitRef="Unit_USD">30000</us-gaap:DueToAffiliateCurrent>
    <sclx:RepaidAmount
      contextRef="P02_01_2021To02_26_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">30000</sclx:RepaidAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn07_16_2020_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">125000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:RepaymentsOfDebt
      contextRef="P01_05_2021To01_14_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">125000</us-gaap:RepaymentsOfDebt>
    <us-gaap:BusinessCombinationControlObtainedDescription contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis">The notes may be repaid upon completion of a Business Combination, without interest, or, at the lender&#x2019;s discretion, up to $1,500,000 of notes may be converted upon completion of a Business Combination into warrants at a price of $0.75 per warrant.</us-gaap:BusinessCombinationControlObtainedDescription>
    <sclx:AggregatePrincipalAmount
      contextRef="P12_01_2021To12_20_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">500000</sclx:AggregatePrincipalAmount>
    <us-gaap:ConvertibleDebt
      contextRef="PAsOn12_20_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">500000</us-gaap:ConvertibleDebt>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn12_20_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.75</us-gaap:SaleOfStockPricePerShare>
    <sclx:aggregatePurchasePrice
      contextRef="P01_01_2021To12_31_2021_ConvertibleNotesPayableMemberusgaapShortTermDebtTypeAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">500000</sclx:aggregatePurchasePrice>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn01_10_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1035000</us-gaap:AdditionalPaidInCapital>
    <sclx:aggregatePurchasePrice
      contextRef="P01_01_2022To01_27_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">500000</sclx:aggregatePurchasePrice>
    <sclx:aggregatePurchasePrice
      contextRef="P01_01_2021To12_31_2021_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      unitRef="Unit_USD">2035000</sclx:aggregatePurchasePrice>
    <us-gaap:RelatedPartyTaxExpenseDueToAffiliatesDeferred
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1826</us-gaap:RelatedPartyTaxExpenseDueToAffiliatesDeferred>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">16901</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionDescriptionOfTransaction contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis">In order to extend the time available for the Company to consummate a Business Combination, the Sponsor or its affiliates or designees must deposit into the Trust Account $1,035,000 ($0.075 per Public Share in either case), on or prior to the date of the applicable deadline, for each three-month extension, providing a total possible Business Combination period up until July 11, 2022 for a total payment value of $2,070,000 ($0.15 per unit in either case).</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
    <sclx:PricePerWarrants
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.75</sclx:PricePerWarrants>
    <us-gaap:AssetsHeldInTrust
      contextRef="PAsOn01_10_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1035000</us-gaap:AssetsHeldInTrust>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn01_10_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.75</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 6&#160;&#x2014;&#160;COMMITMENTS AND CONTINGENCIES &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Risks and Uncertainties &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Management continues to evaluate the impact of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; pandemic and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company&#x2019;s financial position, results of its operations and/or search for a target company, the specific impact is not readily determinable as of the date of these financial statements. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Registration and Shareholder Rights &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pursuant to a registration rights agreement entered into on January&#160;6, 2021, the holders of the Founder Shares, Private Placement Warrants and underlying ordinary shares and any securities issued upon conversion of Working Capital Loans will be entitled to registration rights pursuant to a registration rights agreement requiring the Company to register such securities for resale. The holders of these securities will be entitled to demand that the Company register such securities at any time after the Company consummates a Business Combination. In addition, the holders have certain &#x201c;piggy-back&#x201d; registration rights with respect to registration statements filed subsequent to the consummation of a Business Combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements. &lt;/div&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Underwriting Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The underwriters are entitled to a deferred fee of (i)&#160;3.5% of the gross proceeds of the initial 12,000,000&#160;Units sold in the Initial Public Offering, or $4,200,000, and (ii)&#160;5.5% of the gross proceeds from the Units sold &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pursuant to the over-allotment option, or $990,000. The deferred fee will be paid in cash upon the closing of a Business Combination from the amounts held in the Trust Account, subject to the terms of the underwriting agreement. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; </us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:OtherCommitmentsDescription contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis">The underwriters are entitled to a deferred fee of (i)&#160;3.5% of the gross proceeds of the initial 12,000,000&#160;Units sold in the Initial Public Offering, or $4,200,000, and (ii)&#160;5.5% of the gross proceeds from the Units soldpursuant to the over-allotment option, or $990,000</us-gaap:OtherCommitmentsDescription>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 7&#160;&#x2014;&#160;SHAREHOLDERS&#x2019; EQUITY &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Preference Shares&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&#160;&#x2014;&#160;The Company is authorized to issue 1,000,000 preference shares with a par value of $0.0001 per share, with such designations, voting and other rights and preferences as may be determined from time to time by the Company&#x2019;s board of directors. At December&#160;31, 2021 and 2020, there were no preference shares issued or outstanding. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Ordinary Shares&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&#160;&#x2014;&#160;The Company is authorized to issue 200,000,000 ordinary shares with a par value of $0.0001 per share. Holders of ordinary shares are entitled to one vote for each share. At December&#160;31, 2021, there were 3,450,000 shares of ordinary shares issued and outstanding, excluding 13,800,000 ordinary shares subject to possible redemption which are presented as temporary equity. At December&#160;31, 2020, there were 3,450,000 ordinary shares issued or outstanding. &lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="4"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="4"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">3450000</us-gaap:CommonStockSharesIssued>
    <sclx:OrdinarySharesSubjectToPossibleRedemption
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">13800000</sclx:OrdinarySharesSubjectToPossibleRedemption>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">3450000</us-gaap:CommonStockSharesIssued>
    <sclx:WarrantsTextBlock contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 8&#160;&#x2014;&#160;WARRANTS &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December&#160;31, 2021 and 2020, there were 6,900,000 and 0 Public Warrants outstanding, respectively. Public Warrants may only be exercised for a whole number of shares. No fractional shares will be issued upon exercise of the Public Warrants. The Public Warrants will become exercisable on the later of (a)&#160;the completion of a Business Combination and (b)&#160;12&#160;months from the closing of the Initial Public Offering. The Public Warrants will expire five&#160;years from the completion of a Business Combination or earlier upon redemption or liquidation. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No Public Warrants will be exercisable for cash unless the Company has an effective and current registration statement covering the issuance of the ordinary shares issuable upon exercise of the warrants and a current prospectus relating to such ordinary shares. Notwithstanding the foregoing, if a registration statement covering the issuance of the ordinary shares issuable upon exercise of the Public Warrants is not effective within 90&#160;days from the closing of a Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company shall have failed to maintain an effective registration statement, exercise warrants on a cashless basis pursuant to an available exemption from registration under the Securities Act. If an exemption from registration is not available, holders will not be able to exercise their warrants on a cashless basis. The Public Warrants will expire five&#160;years after the completion of a Business Combination or earlier upon redemption or liquidation. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company may redeem the Public Warrants: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2022;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in whole and not in part; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2022;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;at a price of $0.01 per warrant; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2022;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;at any time while the warrants become exercisable; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2022;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;upon not less than 30&#160;days&#x2019; prior written notice of redemption to each warrant holder; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2022;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;if, and only if, the reported last sale price of the Company&#x2019;s ordinary shares equals or exceeds $18.00 per share (subject to adjustment) &lt;div style="display:inline;"&gt;fo&lt;/div&gt;r any 20 trading days within a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;30-trading&lt;/div&gt; day period commencing after the warrants become exercisable and ending on the third trading business day prior to the notice of redemption to the warrant holders; and &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;  &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;if, and only if, there is a current registration statement in effect with respect to the issuance of the ordinary shares underlying such warrants at the time of redemption and for the entire &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;30-day&lt;/div&gt; trading period referred to above and continuing each day thereafter until the date of redemption. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;If the Company calls the Public Warrants for redemption, management will have the &lt;div style="display:inline;"&gt;option &lt;/div&gt;to &lt;div style="display:inline;"&gt;require &lt;/div&gt;all holders that wish to exercise the Public Warrants to do so on a &#x201c;cashless basis,&#x201d; as described in the warrant agreement. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The exercise price and number of ordinary shares issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a share dividend, extraordinary dividend or recapitalization, reorganization, merger or consolidation. However, the warrants will not be adjusted for issuance of ordinary shares at a price below its exercise price. The Company has agreed to use its best efforts to have declared effective a prospectus relating to the ordinary shares issuable upon exercise of the warrants and keep such prospectus current until the expiration of the warrants. However, if the Company does not maintain a current prospectus relating to the ordinary shares issuable upon exercise of the warrants, holders will be unable to exercise their warrants for cash and the Company will not be required to net cash settle or cash settle the warrant exercise. There will be no redemption rights upon the completion of a Business Combination with respect to the Company&#x2019;s warrants. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company&#x2019;s assets held outside of the Trust Account with the respect to such warrants. Accordingly, the warrants may expire worthless. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In addition, if (x)&#160;the Company issues additional ordinary shares or equity-linked securities for capital raising purposes in connection with the closing of a Business Combination at an issue price or effective issue price of less than $9.20 per ordinary share (with such issue price or effective issue price to be determined in good faith by the Company&#x2019;s board of directors and, in the case of any such issuance to the Sponsors or its affiliates, without taking into account any Founder Shares held by the Sponsors or such affiliates, as applicable, prior to such issuance) (the &#x201c;Newly Issued Price&#x201d;), (y)&#160;the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of a Business Combination on the date of the consummation of a Business Combination (net of redemptions), and (z)&#160;the volume weighted average trading price of its ordinary shares during the 20 trading day period starting on the trading day prior to the day on which the Company consummates its Business Combination (such price, the &#x201c;Market Value&#x201d;) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, the $18.00 per share redemption trigger price will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;At December&#160;31, 2021 and 2020, there were 6,840,000 and 0 Private Placement Warrants outstanding, respectively. The Private Placement Warrants are identical to the Public Warrants underlying the Units sold in the Initial Public Offering, except that the Private Placement Warrants will be exercisable for cash (even if a registration statement covering the issuance of the ordinary shares issuable upon exercise of such warrants is not effective) or on a cashless basis, at the holder&#x2019;s option and will not be redeemable by the Company, in each case so long as they are held by the initial purchasers or their affiliates. &lt;/div&gt;&lt;/div&gt;</sclx:WarrantsTextBlock>
    <sclx:WarrantsOutstandingShares
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis_WarrantMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">6900000</sclx:WarrantsOutstandingShares>
    <sclx:WarrantsOutstandingShares
      contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis_WarrantMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">0</sclx:WarrantsOutstandingShares>
    <sclx:PublicWarrantsRedemptionDescription contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"> The Company may redeem the Public Warrants:  &#160;


&#160;
&#x2022;
&#160;
in whole and not in part;   &#160;


&#160;
&#x2022;
&#160;
at a price of $0.01 per warrant;   &#160;


&#160;
&#x2022;
&#160;
at any time while the warrants become exercisable;   &#160;


&#160;
&#x2022;
&#160;
upon not less than 30&#160;days&#x2019; prior written notice of redemption to each warrant holder;   &#160;


&#160;
&#x2022;
&#160;
if, and only if, the reported last sale price of the Company&#x2019;s ordinary shares equals or exceeds $18.00 per share (subject to adjustment) for any 20 trading days within a 30-trading day period commencing after the warrants become exercisable and ending on the third trading business day prior to the notice of redemption to the warrant holders; and     &#160;


&#160;
&#x2022;
&#160;
if, and only if, there is a current registration statement in effect with respect to the issuance of the ordinary shares underlying such warrants at the time of redemption and for the entire 30-day trading period referred to above and continuing each day thereafter until the date of redemption. </sclx:PublicWarrantsRedemptionDescription>
    <sclx:CapitalRaisingDescription contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis">In addition, if (x)&#160;the Company issues additional ordinary shares or equity-linked securities for capital raising purposes in connection with the closing of a Business Combination at an issue price or effective issue price of less than $9.20 per ordinary share (with such issue price or effective issue price to be determined in good faith by the Company&#x2019;s board of directors and, in the case of any such issuance to the Sponsors or its affiliates, without taking into account any Founder Shares held by the Sponsors or such affiliates, as applicable, prior to such issuance) (the &#x201c;Newly Issued Price&#x201d;), (y)&#160;the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of a Business Combination on the date of the consummation of a Business Combination (net of redemptions), and (z)&#160;the volume weighted average trading price of its ordinary shares during the 20 trading day period starting on the trading day prior to the day on which the Company consummates its Business Combination (such price, the &#x201c;Market Value&#x201d;) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, the $18.00 per share redemption trigger price will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price. </sclx:CapitalRaisingDescription>
    <sclx:WarrantsOutstandingShares
      contextRef="PAsOn12_31_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">6840000</sclx:WarrantsOutstandingShares>
    <sclx:WarrantsOutstandingShares
      contextRef="PAsOn12_31_2020_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">0</sclx:WarrantsOutstandingShares>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 9&#160;&#x2014;&#160;FAIR VALUE MEASUREMENTS &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value of the Company&#x2019;s financial assets and liabilities reflects management&#x2019;s estimate of amounts that the Company would have received in connection with the sale of the assets or paid in connection with the transfer &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 9%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td style="width: 89%;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="display:inline;"&gt;Level&#160;1:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td colspan="2" style="height: 6pt;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="display:inline;"&gt;Level&#160;2:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;Observable inputs other than Level&#160;1 inputs. Examples of Level&#160;2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td colspan="2" style="height: 6pt;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="display:inline;"&gt;Level&#160;3:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;At December&#160;31, 2021, assets held in the Trust Account were comprised of $139,410,739 in money market funds which are invested primarily in U.S. Treasury Securities. Through December&#160;31, 2021, the Company did not withdraw any of interest earned on the Trust Account. At December&#160;31, 2020, there were no assets in the Trust Account. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents information about the Company&#x2019;s assets and liabilities that are measured at fair value on a recurring basis at December&#160;31, 2021 and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 71%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Description&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investments held in Trust Account&#160;&#x2014;&#160;U.S. Treasury Securities Money Market Fund&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;139,410,739&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liabilities:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Warrant Liability&#160;&#x2014;&#160;Private Placement Warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,351,600&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Conversion Option Liability (see Note 5)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,892&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Warrant Liability Measurement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;The Company established the initial fair value for the private warrants on January&#160;11, 2021, the date of the Company&#x2019;s Initial Public Offering, using a Monte Carlo simulation and subsequently implemented the Black-Scholes Option Pricing Model that was modified to capture the redemption features of the public warrants. The underlying assumptions in the Black-Scholes option pricing model include the underlying share price, risk-free interest rate, estimated volatility and the expected term. The primary unobservable inputs utilized in determining the fair value of the private warrants are the expected volatility of the Company&#x2019;s ordinary shares and the Company&#x2019;s ordinary share price. The expected volatility of the ordinary shares was determined based on implied volatilities of public warrants issued by selected guideline companies and was estimated to be 10% before the expected business combination and 20% after the expected business combination. The ordinary share price was&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;determined based on an iterative procedure that matched the estimated value of the ordinary shares and fractional&#160;&lt;/div&gt; &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;warrant price to equate to the observed price of the outstanding&#160;units. The risk-free interest rate is based on the U.S. Treasury yield curve in effect on the date of valuation equal to the remaining expected life of the private warrants. The dividend yield&#160;percentage is zero because the Company does not currently pay dividends, nor does it intend to do so during the expected term of the warrants. The expected life of the warrants is assumed to be equivalent to their remaining contractual term. Inputs are &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-evaluated&lt;/div&gt; each quarterly reporting period to estimate the fair market value of the private placement warrants as of the reporting period. &lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;There were no transfers between Levels 1, 2 or 3 during the year ended December&#160;31, 2021. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table provides quantitative information regarding Level&#160;3 fair value measurements: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 80%;"/&gt;
&lt;td style="width: 15%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of&lt;br/&gt;December&#160;31,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.04&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Strike price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11.50&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Term (in&#160;years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5.28&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Volatility&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8.3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk-free rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.28&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dividend yield&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value of warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.49&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents the changes in the fair value of warrant liabilities: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 80%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Private&lt;br/&gt;Placement&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value as of January&#160;1, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Initial measurement on January&#160;11, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,729,200&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in valuation inputs or other assumptions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4,377,600&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value as of December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,351,600&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Conversion Option Liability Measurement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company assessed the provisions of the Convertible Promissory Notes under ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;470-20.&lt;/div&gt; The derivative component of the obligation is initially valued and classified as a derivative liability. The conversion option was valued using the compound option pricing model, which is considered to be a Level&#160;3 fair value measurement (See Note 6). &lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 65%;"/&gt;
&lt;td style="width: 12%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;20,&lt;br/&gt;2021&lt;br/&gt;(Initial&lt;br/&gt;Measurement)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Underlying warrant value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.0103&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.0281&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercise price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.75&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.75&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Holding period&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.28&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.31&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk-free rate %&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.28&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.19&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Volatility%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8.3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9.3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dividend yield %&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents the change in the fair value of conversion option liability: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 9%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value as of January&#160;1, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Initial measurement on December&#160;20, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;18,727&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(11,835&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value as of December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,892&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  </us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:AssetsHeldInTrust
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">139410739</us-gaap:AssetsHeldInTrust>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis">
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 71%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Description&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investments held in Trust Account&#160;&#x2014;&#160;U.S. Treasury Securities Money Market Fund&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;139,410,739&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liabilities:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Warrant Liability&#160;&#x2014;&#160;Private Placement Warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,351,600&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Conversion Option Liability (see Note 5)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,892&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:InterestIncomeSecuritiesUSTreasury
      contextRef="P01_01_2021To12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">139410739</us-gaap:InterestIncomeSecuritiesUSTreasury>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="P01_01_2021To12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">3351600</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">6892</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:FairValueMeasurementsHighestAndBestUseDescription contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis">The Company established the initial fair value for the private warrants on January&#160;11, 2021, the date of the Company&#x2019;s Initial Public Offering, using a Monte Carlo simulation and subsequently implemented the Black-Scholes Option Pricing Model that was modified to capture the redemption features of the public warrants. The underlying assumptions in the Black-Scholes option pricing model include the underlying share price, risk-free interest rate, estimated volatility and the expected term. The primary unobservable inputs utilized in determining the fair value of the private warrants are the expected volatility of the Company&#x2019;s ordinary shares and the Company&#x2019;s ordinary share price. The expected volatility of the ordinary shares was determined based on implied volatilities of public warrants issued by selected guideline companies and was estimated to be 10% before the expected business combination and 20% after the expected business combination. The ordinary share price was&#160;determined based on an iterative procedure that matched the estimated value of the ordinary shares and fractional&#160;  warrant price to equate to the observed price of the outstanding&#160;units. The risk-free interest rate is based on the U.S. Treasury yield curve in effect on the date of valuation equal to the remaining expected life of the private warrants. The dividend yield&#160;percentage is zero because the Company does not currently pay dividends, nor does it intend to do so during the expected term of the warrants. The expected life of the warrants is assumed to be equivalent to their remaining contractual term. Inputs are re-evaluated each quarterly reporting period to estimate the fair market value of the private placement warrants as of the reporting period.  </us-gaap:FairValueMeasurementsHighestAndBestUseDescription>
    <us-gaap:FairValueConcentrationOfRiskTextBlock contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis">
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 80%;"/&gt;
&lt;td style="width: 15%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of&lt;br/&gt;December&#160;31,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.04&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Strike price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11.50&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Term (in&#160;years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5.28&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Volatility&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8.3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk-free rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.28&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dividend yield&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value of warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.49&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:FairValueConcentrationOfRiskTextBlock>
    <us-gaap:SharePrice
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10.04</us-gaap:SharePrice>
    <sclx:FairValueMeasurementStrikePrice
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">11.5</sclx:FairValueMeasurementStrikePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis">P5Y3M10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="3"
      unitRef="Unit_pure">0.083</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <sclx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="4"
      unitRef="Unit_pure">0.0128</sclx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1>
    <sclx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="3"
      unitRef="Unit_pure">0</sclx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1>
    <sclx:FairValueOfWarrantsinDollars
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.49</sclx:FairValueOfWarrantsinDollars>
    <us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis">
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 80%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Private&lt;br/&gt;Placement&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value as of January&#160;1, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Initial measurement on January&#160;11, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,729,200&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in valuation inputs or other assumptions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4,377,600&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value as of December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,351,600&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn12_31_2020_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <sclx:InitialMeasurementOne
      contextRef="P01_01_2021To12_31_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">7729200</sclx:InitialMeasurementOne>
    <sclx:ChangeInValuationInputsOrOtherAssumptions
      contextRef="P01_01_2021To12_31_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-4377600</sclx:ChangeInValuationInputsOrOtherAssumptions>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn12_31_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">3351600</us-gaap:DerivativeLiabilities>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis">
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 65%;"/&gt;
&lt;td style="width: 12%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;20,&lt;br/&gt;2021&lt;br/&gt;(Initial&lt;br/&gt;Measurement)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Underlying warrant value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.0103&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.0281&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercise price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.75&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.75&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Holding period&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.28&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.31&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk-free rate %&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.28&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.19&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Volatility%&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8.3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9.3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dividend yield %&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <sclx:UnderlyingWarrantValue
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="4"
      unitRef="Unit_USD_per_Share">0.0103</sclx:UnderlyingWarrantValue>
    <sclx:UnderlyingWarrantValue
      contextRef="P12_21_2020To12_20_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="4"
      unitRef="Unit_USD_per_Share">0.0281</sclx:UnderlyingWarrantValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="PAsOn12_20_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <sclx:HoldingPeriod
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.28</sclx:HoldingPeriod>
    <sclx:HoldingPeriod
      contextRef="P12_21_2020To12_20_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.31</sclx:HoldingPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="4"
      unitRef="Unit_pure">0.0128</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P12_21_2020To12_20_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="4"
      unitRef="Unit_pure">0.0119</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="3"
      unitRef="Unit_pure">0.083</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P12_21_2020To12_20_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="3"
      unitRef="Unit_pure">0.093</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="3"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P12_21_2020To12_20_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="3"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis">
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 9%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value as of January&#160;1, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Initial measurement on December&#160;20, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;18,727&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(11,835&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value as of December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,892&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"/&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock>
    <us-gaap:FairValueNetAssetLiability
      contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">18727</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1>
    <us-gaap:ServicingLiabilityAtFairValueOtherChangesInFairValue
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-11835</us-gaap:ServicingLiabilityAtFairValueOtherChangesInFairValue>
    <us-gaap:FairValueNetAssetLiability
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">6892</us-gaap:FairValueNetAssetLiability>
    <us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 10&#160;&#x2014;&#160;RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Restatement 1 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company previously accounted for its outstanding Private Placement Warrants (the &#x201c;Warrants&#x201d;) issued in connection with its Initial Public Offering as components of equity instead of as derivative liabilities. The warrant agreement governing the Warrants includes a provision that provides for potential changes to the settlement amounts dependent upon the characteristics of the holder of the warrant. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On April&#160;12, 2021, the Acting Director of the Division of Corporation Finance and Acting Chief Accountant of the Securities and Exchange Commission together issued a statement regarding the accounting and reporting considerations for warrants issued by special purpose acquisition companies titled &#x201c;Staff Statement on Accounting and Reporting Considerations for Warrants Issued by Special Purpose Acquisition Companies (&#x201c;SPACs&#x201d;)&#x201d; (the &#x201c;SEC Statement&#x201d;). Specifically, the SEC Statement focused on certain settlement terms and provisions related to certain tender offers following a business combination, which terms are similar to those contained in the warrant agreement.&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In further consideration of the SEC Statement, the Company&#x2019;s management further evaluated the Warrants under Accounting Standards Codification (&#x201c;ASC&#x201d;) Subtopic &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;815-40,&lt;/div&gt; Contracts in Entity&#x2019;s Own Equity. ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Section&#160;815-40-15&lt;/div&gt;&lt;/div&gt; addresses equity versus liability treatment and classification of equity-linked financial instruments, including warrants, and states that a warrant may be classified as a component of equity only if, among other things, the warrant is indexed to the issuer&#x2019;s ordinary shares. Under ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Section&#160;815-40-15,&lt;/div&gt;&lt;/div&gt; a warrant is not indexed to the issuer&#x2019;s ordinary shares if the terms of the warrant require an adjustment to the exercise price upon a specified event and that event is not an input to the fair value of the warrant. Based on management&#x2019;s evaluation, the Company&#x2019;s audit committee, in consultation with management, concluded that the Company&#x2019;s Private Placement Warrants are not indexed to the Company&#x2019;s ordinary shares in the manner contemplated by ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Section&#160;815-40-15&lt;/div&gt;&lt;/div&gt; because the holder of the instrument is not an input into the pricing of a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;fixed-for-fixed&lt;/div&gt;&lt;/div&gt; option on equity shares. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In accordance with ASC Topic 340, Other Assets and Deferred Costs, as a result of the classification of the private warrants as derivative liabilities, the Company expensed a portion of the offering costs originally recorded as a reduction in equity. The portion of offering costs that was expensed was determined based on the relative fair value of the Private Warrants. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Restatement 2 &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In addition, in connection with the preparation of the Company&#x2019;s financial statements as of September&#160;30, 2021, the Company concluded it should restate its financial statements to classify all Public Shares in temporary equity. The September&#160;30, 2021 &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10-Q/A,&lt;/div&gt; filed with the SEC on December&#160;8, 2021, includes the restatement of the unaudited March&#160;31, 2021 and June&#160;30, 2021 financial information. Included in the table below is the restatement &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;of the audited IPO Balance Sheet as of January&#160;11, 2021 originally filed on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;8-K&lt;/div&gt; filed with the SEC on January&#160;15, 2021. In accordance with ASC 480, paragraph &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10-S99,&lt;/div&gt; redemption provisions not solely within the control of the Company require ordinary shares subject to redemption to be classified outside of permanent equity. The Company previously determined the ordinary shares subject to possible redemption to be equal to the redemption value of $10.10 per ordinary share while also taking into consideration a redemption cannot result in net tangible assets being less than $5,000,001. Previously, the Company did not consider redeemable shares classified as temporary equity as part of net tangible assets. Effective with these financial statements, the Company revised this interpretation to include temporary equity in net tangible assets. Accordingly, effective with this filing, the Company presents all redeemable ordinary shares as temporary equity and recognizes accretion from the initial book value to redemption value at the time of its Initial Public Offering and in accordance with ASC 480. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As a result, management has noted a reclassification adjustment related to temporary equity and permanent equity. This resulted in an adjustment to the initial carrying value of the ordinary shares subject &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;to possible redemption with the offset recorded to additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;paid-in&lt;/div&gt; capital (to the extent available), accumulated deficit and ordinary shares. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In connection with the change in presentation for the ordinary shares subject to redemption, the Company also revised its income (loss) per ordinary share calculation to allocate net income (loss) to ordinary shares. This presentation contemplates a Business Combination as the most likely outcome, in which case, ordinary shares share pro&#160;rata in the income (loss) of the Company. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The impact of these adjustments to the financial statement, as previously reported, is presented below. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 48%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As Previously&lt;br/&gt;Reported&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Adjustments&lt;br/&gt;Restatement&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Adjustments&lt;br/&gt;Restatement 2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&lt;br/&gt;Restated&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance sheet as of January&#160;11, 2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Warrant Liability&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,729,200&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,729,200&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total Liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,345,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,729,200&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13,074,200&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Ordinary Shares Subject to Possible Redemption&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;129,999,029&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(7,729,200&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17,110,171&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;139,380,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Ordinary Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;438&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;76&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(169&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;345&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Paid-in&lt;/div&gt; Capital&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,006,060&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,629,336&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(7,635,396&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accumulated Deficit&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(6,490&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,629,412&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(9,474,606&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(12,110,508&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total Shareholders&#x2019; Equity (Deficit)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,000,008&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(17,110,171&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(12,110,163&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock>
    <us-gaap:PreferredStockRedemptionPricePerShare
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10.1</us-gaap:PreferredStockRedemptionPricePerShare>
    <us-gaap:IntangibleAssetsCurrent
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">5000001</us-gaap:IntangibleAssetsCurrent>
    <srt:ScheduleOfCondensedFinancialStatementsTableTextBlock contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The impact of these adjustments to the financial statement, as previously reported, is presented below. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 48%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As Previously&lt;br/&gt;Reported&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Adjustments&lt;br/&gt;Restatement&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Adjustments&lt;br/&gt;Restatement 2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&lt;br/&gt;Restated&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance sheet as of January&#160;11, 2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Warrant Liability&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,729,200&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,729,200&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total Liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,345,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,729,200&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13,074,200&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Ordinary Shares Subject to Possible Redemption&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;129,999,029&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(7,729,200&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17,110,171&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;139,380,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Ordinary Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;438&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;76&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(169&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;345&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Paid-in&lt;/div&gt; Capital&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,006,060&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,629,336&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(7,635,396&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accumulated Deficit&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(6,490&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,629,412&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(9,474,606&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(12,110,508&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total Shareholders&#x2019; Equity (Deficit)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,000,008&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(17,110,171&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(12,110,163&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</srt:ScheduleOfCondensedFinancialStatementsTableTextBlock>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn01_11_2021_ScenarioPreviouslyReportedMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn01_11_2021_RestatementAdjustmentMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">7729200</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn01_11_2021_AdjustmentsRestatement2MembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn01_11_2021_AsRestatedMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">7729200</us-gaap:DerivativeLiabilities>
    <us-gaap:Liabilities
      contextRef="PAsOn01_11_2021_ScenarioPreviouslyReportedMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">5345000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="PAsOn01_11_2021_RestatementAdjustmentMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">7729200</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="PAsOn01_11_2021_AdjustmentsRestatement2MembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:Liabilities
      contextRef="PAsOn01_11_2021_AsRestatedMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">13074200</us-gaap:Liabilities>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn01_11_2021_ScenarioPreviouslyReportedMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">129999029</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn01_11_2021_RestatementAdjustmentMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-7729200</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn01_11_2021_AdjustmentsRestatement2MembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">17110171</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn01_11_2021_AsRestatedMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">139380000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockValue
      contextRef="PAsOn01_11_2021_ScenarioPreviouslyReportedMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">438</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="PAsOn01_11_2021_RestatementAdjustmentMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">76</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="PAsOn01_11_2021_AdjustmentsRestatement2MembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-169</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="PAsOn01_11_2021_AsRestatedMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">345</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn01_11_2021_ScenarioPreviouslyReportedMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">5006060</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn01_11_2021_RestatementAdjustmentMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">2629336</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn01_11_2021_AdjustmentsRestatement2MembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-7635396</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn01_11_2021_AsRestatedMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn01_11_2021_ScenarioPreviouslyReportedMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-6490</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn01_11_2021_RestatementAdjustmentMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-2629412</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn01_11_2021_AdjustmentsRestatement2MembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-9474606</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn01_11_2021_AsRestatedMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-12110508</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn01_11_2021_ScenarioPreviouslyReportedMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">5000008</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn01_11_2021_RestatementAdjustmentMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn01_11_2021_AdjustmentsRestatement2MembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-17110171</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn01_11_2021_AsRestatedMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-12110163</us-gaap:StockholdersEquity>
    <us-gaap:SubsequentEventsTextBlock contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 11&#160;&#x2014;&#160;SUBSEQUENT EVENTS &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the financial statements were issued. The Company did not identify any subsequent events, other than noted below, that would have required adjustment or disclosure in the financial statements. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;On January&#160;10, 2022, the Company extended the period of time to consummate a Business Combination to April&#160;11, 2022. The Sponsors deposited $1,035,000 into the Trust Account made in the form of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-interest-bearing&lt;/div&gt; loans. If the Company completes an initial business combination, the Company will, at the option of the Sponsors, repay the amounts evidenced by the Convertible Promissory Notes or convert a portion or all of the&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="display:inline;"&gt;total amount into warrants at a price of $0.75 per warrant, which warrants are identical to the Private Placement&#160;&lt;/div&gt; &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="null;text-indent: 0px;;display:inline;"&gt;Warrants issued.&lt;/div&gt; If a Business Combination is not consummated, the Convertible Promissory Notes will not be repaid by the Company and all amounts owed thereunder by the Company will be forgiven except to the extent that the Company has funds available to it outside of its Trust Account. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On January&#160;27, 2022, the Company entered into two additional Convertible Promissory Notes with the Sponsors pursuant to which the Sponsors agreed to loan the Company up to an additional aggregate principal amount of $500,000. The aggregate principal balance of the Convertible Promissory Notes amounted to $2,035,000. &lt;/div&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <sclx:SponsorLoan
      contextRef="P01_01_2022To01_10_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1035000</sclx:SponsorLoan>
    <sclx:WarrantExercisePrice
      contextRef="P01_01_2022To01_10_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.75</sclx:WarrantExercisePrice>
    <sclx:AdditionalPrincipalAmount
      contextRef="P01_01_2022To01_27_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">500000</sclx:AdditionalPrincipalAmount>
    <sclx:ConvertiblePromissoryNote
      contextRef="P01_01_2022To01_27_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">2035000</sclx:ConvertiblePromissoryNote>
    <us-gaap:Cash
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">34961</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">507921</us-gaap:Cash>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">130788</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">4536</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">165749</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">512457</us-gaap:AssetsCurrent>
    <us-gaap:AssetsHeldInTrustNoncurrent
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">101293086</us-gaap:AssetsHeldInTrustNoncurrent>
    <us-gaap:AssetsHeldInTrustNoncurrent
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">139410739</us-gaap:AssetsHeldInTrustNoncurrent>
    <us-gaap:Assets
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">101458835</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">139923196</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">809292</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">208704</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">809292</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">208704</us-gaap:LiabilitiesCurrent>
    <us-gaap:ConvertibleLongTermNotesPayable
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">2035000</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:ConvertibleLongTermNotesPayable
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">483099</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">6892</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLongTermNotesPayable
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">2971667</us-gaap:OtherLongTermNotesPayable>
    <us-gaap:OtherLongTermNotesPayable
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:OtherLongTermNotesPayable>
    <us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1162800</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">3351600</us-gaap:DerivativeLiabilities>
    <us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">5190000</us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent>
    <us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">5190000</us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent>
    <us-gaap:Liabilities
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">12168759</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">9240295</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <sclx:OrdinarySharesSubjectToPossibleRedemption
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">9726395</sclx:OrdinarySharesSubjectToPossibleRedemption>
    <sclx:OrdinarySharesSubjectToPossibleRedemption
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">13800000</sclx:OrdinarySharesSubjectToPossibleRedemption>
    <us-gaap:TemporaryEquityRedemptionPricePerShare
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">10.41</us-gaap:TemporaryEquityRedemptionPricePerShare>
    <us-gaap:TemporaryEquityRedemptionPricePerShare
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">10</us-gaap:TemporaryEquityRedemptionPricePerShare>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">101293086</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">139380000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">3450000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">3450000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">3450000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">3450000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">345</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">345</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-12003355</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-8697444</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-12003010</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-8697099</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">101458835</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">139923196</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">657746</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">283346</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">2412297</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">620642</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-657746</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-283346</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-2412297</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-620642</us-gaap:OperatingIncomeLoss>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-68400</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1162800</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-2188800</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-2872800</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:GainLossOnSaleOfDerivatives
      contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:GainLossOnSaleOfDerivatives>
    <us-gaap:GainLossOnSaleOfDerivatives
      contextRef="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:GainLossOnSaleOfDerivatives>
    <us-gaap:GainLossOnSaleOfDerivatives
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:GainLossOnSaleOfDerivatives>
    <us-gaap:GainLossOnSaleOfDerivatives
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-2599200</us-gaap:GainLossOnSaleOfDerivatives>
    <sclx:TransactionCostsAllocatedToWarrantLiabilities
      contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</sclx:TransactionCostsAllocatedToWarrantLiabilities>
    <sclx:TransactionCostsAllocatedToWarrantLiabilities
      contextRef="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</sclx:TransactionCostsAllocatedToWarrantLiabilities>
    <sclx:TransactionCostsAllocatedToWarrantLiabilities
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</sclx:TransactionCostsAllocatedToWarrantLiabilities>
    <sclx:TransactionCostsAllocatedToWarrantLiabilities
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">30212</sclx:TransactionCostsAllocatedToWarrantLiabilities>
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1
      contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1
      contextRef="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">6892</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
    <us-gaap:DistributionsOnMandatorilyRedeemableSecurities
      contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:DistributionsOnMandatorilyRedeemableSecurities>
    <us-gaap:DistributionsOnMandatorilyRedeemableSecurities
      contextRef="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:DistributionsOnMandatorilyRedeemableSecurities>
    <us-gaap:DistributionsOnMandatorilyRedeemableSecurities
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">192049</us-gaap:DistributionsOnMandatorilyRedeemableSecurities>
    <us-gaap:DistributionsOnMandatorilyRedeemableSecurities
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:DistributionsOnMandatorilyRedeemableSecurities>
    <us-gaap:InterestExpense
      contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1155</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">16901</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:InterestExpense>
    <us-gaap:InterestIncomeOther
      contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">459114</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1794</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">664973</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">28006</us-gaap:InterestIncomeOther>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">526359</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-1161006</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">3035813</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">271394</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-131387</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-1444352</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">623516</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-349248</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">13176395</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">13176395</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">17250000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">17250000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">15862288</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">15862288</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">16675824</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">16675824</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.01</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.01</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.08</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.08</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.04</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.04</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.02</us-gaap:EarningsPerShareDiluted>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">3450000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">345</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-8697444</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-8697099</us-gaap:StockholdersEquity>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="P01_01_2022To03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:StockRedeemedOrCalledDuringPeriodValue>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="P01_01_2022To03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:StockRedeemedOrCalledDuringPeriodValue>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="P01_01_2022To03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1035000</us-gaap:StockRedeemedOrCalledDuringPeriodValue>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="P01_01_2022To03_31_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1035000</us-gaap:StockRedeemedOrCalledDuringPeriodValue>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-806222</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To03_31_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-806222</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">3450000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">345</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-10538666</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-10538321</us-gaap:StockholdersEquity>
    <us-gaap:NetSharesReclassifiedToMandatorilyRedeemableCapitalStockValue
      contextRef="P04_01_2022To06_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:NetSharesReclassifiedToMandatorilyRedeemableCapitalStockValue>
    <us-gaap:NetSharesReclassifiedToMandatorilyRedeemableCapitalStockValue
      contextRef="P04_01_2022To06_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:NetSharesReclassifiedToMandatorilyRedeemableCapitalStockValue>
    <us-gaap:NetSharesReclassifiedToMandatorilyRedeemableCapitalStockValue
      contextRef="P04_01_2022To06_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-192049</us-gaap:NetSharesReclassifiedToMandatorilyRedeemableCapitalStockValue>
    <us-gaap:NetSharesReclassifiedToMandatorilyRedeemableCapitalStockValue
      contextRef="P04_01_2022To06_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-192049</us-gaap:NetSharesReclassifiedToMandatorilyRedeemableCapitalStockValue>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="P04_01_2022To06_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:StockRedeemedOrCalledDuringPeriodValue>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="P04_01_2022To06_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:StockRedeemedOrCalledDuringPeriodValue>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="P04_01_2022To06_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1595486</us-gaap:StockRedeemedOrCalledDuringPeriodValue>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="P04_01_2022To06_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1595486</us-gaap:StockRedeemedOrCalledDuringPeriodValue>
    <us-gaap:NetIncomeLoss
      contextRef="P04_01_2022To06_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P04_01_2022To06_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P04_01_2022To06_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1561125</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P04_01_2022To06_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1561125</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn06_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">3450000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">345</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-10765076</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-10764731</us-gaap:StockholdersEquity>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="P07_01_2022To09_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:StockRedeemedOrCalledDuringPeriodValue>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="P07_01_2022To09_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:StockRedeemedOrCalledDuringPeriodValue>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="P07_01_2022To09_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1106892</us-gaap:StockRedeemedOrCalledDuringPeriodValue>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1106892</us-gaap:StockRedeemedOrCalledDuringPeriodValue>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2022To09_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2022To09_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2022To09_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-131387</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-131387</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn09_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">3450000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">345</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-12003355</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-12003010</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">3450000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">345</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">24655</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-6276</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">18724</us-gaap:StockholdersEquity>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="P01_01_2021To03_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:StockRedeemedOrCalledDuringPeriodValue>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="P01_01_2021To03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">24665</us-gaap:StockRedeemedOrCalledDuringPeriodValue>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="P01_01_2021To03_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">9474606</us-gaap:StockRedeemedOrCalledDuringPeriodValue>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="P01_01_2021To03_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">9499261</us-gaap:StockRedeemedOrCalledDuringPeriodValue>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To03_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To03_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1328853</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To03_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1328853</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn03_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">3450000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">345</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-8152029</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-8151684</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="P04_01_2021To06_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P04_01_2021To06_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P04_01_2021To06_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-233749</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P04_01_2021To06_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-233749</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn06_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">3450000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">345</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-8385778</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-8385433</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2021To09_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2021To09_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2021To09_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-1444352</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-1444352</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn09_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">3450000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">345</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-9830130</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-9829785</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">623516</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-349248</us-gaap:NetIncomeLoss>
    <us-gaap:InterestAndDividendIncomeSecuritiesHeldToMaturity
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">664973</us-gaap:InterestAndDividendIncomeSecuritiesHeldToMaturity>
    <us-gaap:InterestAndDividendIncomeSecuritiesHeldToMaturity
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">28006</us-gaap:InterestAndDividendIncomeSecuritiesHeldToMaturity>
    <us-gaap:DistributionsOnMandatorilyRedeemableSecurities
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">192049</us-gaap:DistributionsOnMandatorilyRedeemableSecurities>
    <us-gaap:DistributionsOnMandatorilyRedeemableSecurities
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:DistributionsOnMandatorilyRedeemableSecurities>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-2188800</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-2872800</us-gaap:FairValueAdjustmentOfWarrants>
    <sclx:LossOnInitialIssuanceOfWarrantLiability
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</sclx:LossOnInitialIssuanceOfWarrantLiability>
    <sclx:LossOnInitialIssuanceOfWarrantLiability
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">2599200</sclx:LossOnInitialIssuanceOfWarrantLiability>
    <sclx:ChangeInFairValueOfConversionOptionLiability
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-6892</sclx:ChangeInFairValueOfConversionOptionLiability>
    <sclx:ChangeInFairValueOfConversionOptionLiability
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</sclx:ChangeInFairValueOfConversionOptionLiability>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">16901</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:AmortizationOfDebtDiscountPremium>
    <sclx:TransactionsCostsAllocatedToPrivateWarrants
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</sclx:TransactionsCostsAllocatedToPrivateWarrants>
    <sclx:TransactionsCostsAllocatedToPrivateWarrants
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">30212</sclx:TransactionsCostsAllocatedToPrivateWarrants>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">126252</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">116536</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">600588</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">43569</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-1937961</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-693609</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <sclx:InvestmentOfCashInTrustAccounts
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">3041666</sclx:InvestmentOfCashInTrustAccounts>
    <sclx:InvestmentOfCashInTrustAccounts
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">139380000</sclx:InvestmentOfCashInTrustAccounts>
    <us-gaap:ProceedsFromDecommissioningFund
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">41824292</us-gaap:ProceedsFromDecommissioningFund>
    <us-gaap:ProceedsFromDecommissioningFund
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromDecommissioningFund>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">38782626</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-139380000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">135600000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">5130000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">25000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">55000</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1535000</us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt>
    <sclx:ProceedsFromSimplePromissoryNoteRelatedParty
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">2971667</sclx:ProceedsFromSimplePromissoryNoteRelatedParty>
    <sclx:ProceedsFromSimplePromissoryNoteRelatedParty
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</sclx:ProceedsFromSimplePromissoryNoteRelatedParty>
    <sclx:RepaymentOfPromissoryNoteRelatedParty
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</sclx:RepaymentOfPromissoryNoteRelatedParty>
    <sclx:RepaymentOfPromissoryNoteRelatedParty
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">125000</sclx:RepaymentOfPromissoryNoteRelatedParty>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">416260</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsForRepurchaseOfOtherEquity
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">41824292</us-gaap:PaymentsForRepurchaseOfOtherEquity>
    <us-gaap:PaymentsForRepurchaseOfOtherEquity
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:PaymentsForRepurchaseOfOtherEquity>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-37317625</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">140158740</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-472960</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">85131</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">507921</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">30511</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">34961</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">115642</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <sclx:DeferredUnderwritingFeePayable
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</sclx:DeferredUnderwritingFeePayable>
    <sclx:DeferredUnderwritingFeePayable
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">5190000</sclx:DeferredUnderwritingFeePayable>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 1. DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Vickers Vantage Corp. I (the &#x201c;Company&#x201d;) is a blank check company incorporated as a Cayman Islands exempted company on February&#160;21, 2020. The Company was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities (a &#x201c;Business Combination&#x201d;). &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has one wholly owned subsidiary which was formed on February&#160;2, 2022, Vantage Merger Sub Inc., a Delaware corporation. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is not limited to a particular industry or sector for purposes of consummating a Business Combination. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;As of September&#160;30, 2022, the Company had not commenced any operations. All activity for the period from February&#160;21, 2020 (inception) through September&#160;30, 2022 relates to the Company&#x2019;s formation and the initial public offering (&#x201c;Initial Public Offering&#x201d;), which is described below, and, subsequent to the Initial Public Offering, identifying a target company for a Business Combination and in connection therewith entering into the Merger Agreement, which is described below in Note 6. The Company will not generate any operating revenues until after the completion of a Business Combination, at the earliest. The Company will generate &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-operating&lt;/div&gt; income in the form of interest income from the proceeds derived from the Initial Public Offering. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The registration statement for the Company&#x2019;s Initial Public Offering was declared effective on January&#160;6, 2021. On January&#160;11, 2021 the Company consummated the Initial Public Offering of&#160;13,800,000&#160;Units (the &#x201c;Units&#x201d; and, with respect to the ordinary shares included in the Units sold, the &#x201c;Public Shares&#x201d;), which includes the full exercise by the underwriter of its over-allotment option in the amount of&#160;1,800,000&#160;Units, at $10.00&#160;per Unit, generating gross proceeds of $138,000,000&#160;which is described in Note 3. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of&#160;6,840,000 warrants (the &#x201c;Private Placement Warrants&#x201d;) at a price of $0.75&#160;per Private Placement Warrant in a private placement to Vickers Venture Fund VI Pte Ltd and Vickers Venture Fund VI (Plan) Pte Ltd, (the &#x201c;Sponsor&#x201d;), generating gross proceeds of $5,130,000, which is described in Note 4. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Transaction costs amounted to $8,149,473, consisting of $2,400,000&#160;in cash underwriting fees, $5,190,000&#160;in deferred underwriting fees, and $559,473&#160;of other offering costs &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Following the closing of the Initial Public Offering on January&#160;11, 2021, an amount of $139,380,000&#160;($10.10&#160;per Unit) from the net proceeds of the sale of the Units in the Initial Public Offering and the sale of the Private Placement Warrants was placed in a trust account (the &#x201c;Trust Account&#x201d;), and invested in U.S. government securities, within the meaning set forth in Section&#160;2(a)(16) of the Investment Company Act, with a maturity of 185 days or less, or in any open-ended investment company that holds itself out as a money market fund investing solely in U.S.&#160;Treasuries and meeting certain conditions under Rule &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2a-7&lt;/div&gt; of the Investment Company Act, as determined by the Company, until the earliest of: (i)&#160;the completion of a Business Combination and (ii)&#160;the distribution of the funds in the Trust Account to the Company&#x2019;s shareholders, as described below. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On January&#160;10, 2022, the Company extended the period of time to consummate a Business Combination from January&#160;11, 2022 to April&#160;11, 2022. On April&#160;11, 2022, the Company extended the period of time to consummate a Business Combination to July&#160;11, 2022. On July&#160;11, 2022, the Company extended the period of time to &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;consummate a Business Combination to August&#160;11, 2022 and without another shareholder vote, to elect to extend the date to consummate a business combination on a monthly basis for up to five times by an additional one month each time after, upon five days&#x2019; advance notice prior to the applicable deadlines, until January&#160;11, 2023. As of the date of this filing, the Company has extended the period of time to consummate a Business Combination to November&#160;11, 2022. In connection with the extensions, the Sponsors deposited an aggregate of $3,365,554 into the trust account in the form of a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-interest-bearing&lt;/div&gt; loans as of the date of this filing. The Company will have until November&#160;11, 2022 to consummate a Business Combination. As a result, an aggregate of $101,293,086&#160;as of September&#160;30, 2022 is held in the Trust Account. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and the sale of the Private Placement Warrants, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination.&#160;The stock exchange listing rules require that the Business Combination must be with one or more operating businesses or assets with a fair market value equal to at least 80% of the assets held in the Trust Account (as defined below) (less any deferred underwriting commissions and taxes payable on the interest earned on the Trust Account). The Company will only complete a Business Combination if the post-Business Combination company owns or acquires 50% or more of the issued and outstanding voting securities of the target or otherwise acquires a controlling interest in the target business sufficient for it not to be required to register as an investment company under the Investment Company Act of 1940, as amended (the &#x201c;Investment Company Act&#x201d;). There is no assurance that the Company will be able to successfully effect a Business Combination. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company will provide the holders of the public shares (the &#x201c;Public Shareholders&#x201d;) with the opportunity to redeem all or a portion of their public shares upon the completion of the Business Combination, either (i)&#160;in connection with a general meeting called to approve the Business Combination or (ii)&#160;by means of a tender offer. The decision as to whether the Company will seek shareholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The Public Shareholders will be entitled to redeem their Public Shares, equal to the aggregate amount then on deposit in the Trust Account, calculated as of two business days prior to the consummation of the Business Combination (anticipated to be $10.38&#160;per Public Share as of the date of this filing), including interest (which interest shall be net of taxes payable), divided by the number of then issued and outstanding public shares, subject to certain limitations as described in the prospectus. The &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;per-share&lt;/div&gt; amount to be distributed to the Public Shareholders who properly redeem their shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriters (as discussed in Note 6). &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company will proceed with a Business Combination only if the Company has net tangible assets of at least $5,000,001&#160;and, if the Company seeks shareholder approval, it receives an ordinary resolution under Cayman Islands law approving a Business Combination, which requires the affirmative vote of a majority of the shareholders who attend and vote at a general meeting of the Company. If a shareholder vote is not required and the Company does not decide to hold a shareholder vote for business or other legal reasons, the Company will, pursuant to its Amended and Restated Memorandum and Articles of Association, conduct the redemptions pursuant to the tender offer rules of the Securities and Exchange Commission (&#x201c;SEC&#x201d;), and file tender offer documents containing substantially the same information as would be included in a proxy statement with the SEC prior to completing a Business Combination. If the Company seeks shareholder approval in connection with a Business Combination, the Company&#x2019;s Sponsors have agreed to vote its Founder Shares (as defined in Note 5) and any Public Shares purchased during or after the Initial Public Offering in favor of approving a Business Combination. Additionally, each Public Shareholder may elect to redeem their Public Shares, without voting, and if they do vote, irrespective of whether they vote for or against a proposed Business Combination. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Notwithstanding the foregoing, if the Company seeks shareholder approval of the Business Combination and the Company does not conduct redemptions pursuant to the tender offer rules, a Public Shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a &#x201c;group&#x201d; (as defined under Section&#160;13 of the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;)), will be restricted from redeeming its shares with respect to more than an aggregate of&#160;20% of the Public Shares without the Company&#x2019;s prior written consent. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Sponsors have agreed (a)&#160;to waive their redemption rights with respect to any Founder Shares and Public Shares held by them in connection with the completion of a Business Combination and (b)&#160;not to propose an amendment to the Amended and Restated Memorandum and Articles of Association (i)&#160;to modify the substance or timing of the Company&#x2019;s obligation to allow redemption in connection with the Company&#x2019;s initial Business Combination or to redeem&#160;100% of the Public Shares if the Company does not complete a Business Combination within the Combination Period (as defined below) or (ii)&#160;with respect to any other provision relating to shareholders&#x2019; rights or &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-initial&lt;/div&gt; business combination activity, unless the Company provides the Public Shareholders with the opportunity to redeem their Public Shares upon approval of any such amendment at a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;per-share&lt;/div&gt; price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest (which interest shall be net of taxes payable), divided by the number of then issued and outstanding Public Shares. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;If the Company has not completed a Business Combination within the Combination Period and shareholders do not further extend such period, the Company will (i)&#160;cease all operations except for the purpose of winding up, (ii)&#160;as promptly as reasonably possible but not more than ten business days thereafter, redeem&#160;100% of the Public Shares, at a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;per-share&lt;/div&gt; price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest (less up to $50,000&#160;of interest to pay dissolution expenses and which interest shall be net of taxes payable), divided by the number of then issued and outstanding Public Shares, which redemption will completely extinguish the rights of the Public Shareholders as shareholders (including the right to receive further liquidating distributions, if any), and (iii)&#160;as promptly as reasonably possible following such redemption, subject to the approval of the Company&#x2019;s remaining Public Shareholders and its Board of Directors, liquidate and dissolve, subject in each case to the Company&#x2019;s obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law. There will be no redemption rights or liquidating distributions with respect to the Company&#x2019;s warrants, which will expire worthless if the Company fails to complete a Business Combination within the Combination Period. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Sponsors have agreed to waive their rights to liquidating distributions from the Trust Account with respect to the Founder Shares if the Company fails to complete a Business Combination within the Combination Period. However, if the Sponsors or any of their respective affiliates acquire Public Shares, such Public Shares will be entitled to liquidating distributions from the Trust Account if the Company fails to complete a Business Combination within the Combination Period. The underwriters have agreed to waive their rights to their deferred underwriting commission (see Note 6) held in the Trust Account in the event the Company does not complete a Business Combination within the Combination Period, and in such event, such amounts will be included with the other funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the assets remaining available for distribution will be less than the amount of funds deposited into the Trust Account ($10.38&#160;per share). &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In order to protect the amounts held in the Trust Account, the Sponsors have agreed that it will be liable to the Company if and to the extent any claims by a third party (other than the Company&#x2019;s independent registered public accounting firm) for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Trust Account to below (1) $10.10&#160;per Public Share or (2)&#160;such lesser amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account due to reductions in the value of trust assets, in each case net of the interest which may be withdrawn to pay taxes, except as to any claims by a third party who executed a waiver of any and all rights to seek access to the Trust Account and except as to any claims under the Company&#x2019;s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;). In the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsors will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsors will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (other than the Company&#x2019;s independent registered public accounting firm), prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On June&#160;30, 2022, the Company held an extraordinary general meeting of its shareholders (the &#x201c;Meeting&#x201d;), to amend the Company&#x2019;s Amended and Restated Memorandum and Articles of Association (the &#x201c;Extension Amendment&#x201d;) to (i)&#160;extend the date by which the Company has to consummate an initial business combination from July&#160;11, 2022 (the &#x201c;Original Termination Date&#x201d;) to August&#160;11, 2022 (the &#x201c;Extended Date&#x201d;) and (ii)&#160;allow the Company without another shareholder vote, to elect to extend the date to consummate a business combination on a monthly basis for up to five times by an additional one month each time after the Extended Date, upon five days&#x2019; advance notice prior to the applicable deadlines, until January&#160;11, 2023 or a total of up to nine months after the Original Termination Date (the &#x201c;Extension Proposal&#x201d;). The Company&#x2019;s shareholders approved the Extension Amendment at the Meeting. On July&#160;5, 2022, the Company filed the Extension Amendment with the Cayman Islands Registrar of Companies. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In connection with its solicitation of proxies in connection with the Extension Proposal, the Company was required to permit its public shareholders to redeem their ordinary shares. Of the 13,800,000 ordinary shares outstanding with redemption rights, the holders of 4,073,605 ordinary shares elected to redeem their shares at a per share redemption price of $10.25. As a result, approximately $41.8 million was removed from the Trust Account to pay such holders and approximately $99.8 million remained in the Trust Account. Following the redemptions, the Company has 9,726,395 ordinary shares with redemption rights outstanding and the Company will deposit $323,888 (or approximately $0.0333 per ordinary share that remains outstanding) for each calendar month, or portion thereof, that is needed by the Company to complete an initial business combination from July 11, 2022.&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has deposited an aggregate of $1,295,556&#160;into the Trust Account to extend the date to consummate a business combination to November&#160;11, 2022 (the &#x201c;Combination Period&#x201d;). &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Going Concern and Liquidity &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of September&#160;30, 2022, the Company had $34,961&#160;in its operating bank accounts, and working capital deficit of $643,543. As of September&#160;30, 2022, approximately $696,000&#160;of the amount on deposit in the Trust Account represented interest income, which is available to pay the Company&#x2019;s tax obligations. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;If the Company is unable to raise additional capital, it may be required to take additional measures to conserve liquidity, which could include, but not necessarily be limited to, suspending the pursuit of a Business Combination. The Company cannot provide any assurance that new financing will be available to it on commercially acceptable terms, if at all. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;As a result of the above, in connection with the Company&#x2019;s assessment of going concern considerations in accordance with Financial Accounting Standard Board&#x2019;s Accounting Standards Codification Subtopic &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;205-40,&lt;/div&gt; &#x201c;Presentation of Financial Statements &#x2014; Going Concern,&#x201d; management has determined that the liquidity condition and date for mandatory liquidation and dissolution raise substantial doubt about the Company&#x2019;s ability to continue as a going concern through November&#160;11, 2022 (extension date), the scheduled liquidation date of the Company if it does not complete a Business Combination prior to such date. These condensed consolidated financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;If the Company is unable to raise additional capital, it may be required to take additional measures to conserve liquidity, which could include, but not necessarily be limited to, suspending the pursuit of a Business Combination. The Company cannot provide any assurance that new financing will be available to it on commercially acceptable terms, if at all. &lt;/div&gt;&lt;/div&gt; </us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:SharesIssued
      contextRef="PAsOn01_11_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">13800000</us-gaap:SharesIssued>
    <us-gaap:SharesIssued
      contextRef="PAsOn01_11_2021_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">1800000</us-gaap:SharesIssued>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn01_11_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:DemutualizationByInsuranceEntitySecuritiesIssuedGrossCashProceeds
      contextRef="P01_04_2021To01_11_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">138000000</us-gaap:DemutualizationByInsuranceEntitySecuritiesIssuedGrossCashProceeds>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">6840000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn09_30_2022_PrivatePlacementWarrantMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.75</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:DemutualizationByInsuranceEntitySecuritiesIssuedGrossCashProceeds
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">5130000</us-gaap:DemutualizationByInsuranceEntitySecuritiesIssuedGrossCashProceeds>
    <us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">8149473</us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts>
    <us-gaap:OtherUnderwritingExpense
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">2400000</us-gaap:OtherUnderwritingExpense>
    <sclx:DeferredUnderwritingFees
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">5190000</sclx:DeferredUnderwritingFees>
    <us-gaap:OtherOwnershipInterestsOfferingCosts
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">559473</us-gaap:OtherOwnershipInterestsOfferingCosts>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="P01_04_2021To01_11_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">139380000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn01_11_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10.1</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:NoninterestBearingDepositLiabilities
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">3365554</us-gaap:NoninterestBearingDepositLiabilities>
    <us-gaap:AssetsHeldInTrust
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">101293086</us-gaap:AssetsHeldInTrust>
    <sclx:SaleOfStockDescriptionOfTransactions contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">The stock exchange listing rules require that the Business Combination must be with one or more operating businesses or assets with a fair market value equal to at least 80% of the assets held in the Trust Account (as defined below) (less any deferred underwriting commissions and taxes payable on the interest earned on the Trust Account). The Company will only complete a Business Combination if the post-Business Combination company owns or acquires 50% or more of the issued and outstanding voting securities of the target or otherwise acquires a controlling interest in the target business sufficient for it not to be required to register as an investment company under the Investment Company Act of 1940, as amended (the &#x201c;Investment Company Act&#x201d;). There is no assurance that the Company will be able to successfully effect a Business Combination.</sclx:SaleOfStockDescriptionOfTransactions>
    <sclx:PricePerPublicShare
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10.38</sclx:PricePerPublicShare>
    <us-gaap:OtherIntangibleAssetsNet
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">5000001</us-gaap:OtherIntangibleAssetsNet>
    <sclx:PercentageOfPublicShares
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_pure">0.20</sclx:PercentageOfPublicShares>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage
      contextRef="PAsOn09_30_2022_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMemberusgaapBusinessAcquisitionAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_pure">1</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage>
    <sclx:BusinessCombinationRedeemPercentage
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_pure">1</sclx:BusinessCombinationRedeemPercentage>
    <us-gaap:OtherExpenses
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">50000</us-gaap:OtherExpenses>
    <sclx:DepositIntoTheTrustAccountPerShare
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10.38</sclx:DepositIntoTheTrustAccountPerShare>
    <sclx:LesserPublicPerShare
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10.1</sclx:LesserPublicPerShare>
    <us-gaap:BusinessCombinationAcquiredReceivablesDescription contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">In connection with its solicitation of proxies in connection with the Extension Proposal, the Company was required to permit its public shareholders to redeem their ordinary shares. Of the 13,800,000 ordinary shares outstanding with redemption rights, the holders of 4,073,605 ordinary shares elected to redeem their shares at a per share redemption price of $10.25. As a result, approximately $41.8 million was removed from the Trust Account to pay such holders and approximately $99.8 million remained in the Trust Account. Following the redemptions, the Company has 9,726,395 ordinary shares with redemption rights outstanding and the Company will deposit $323,888 (or approximately $0.0333 per ordinary share that remains outstanding) for each calendar month, or portion thereof, that is needed by the Company to complete an initial business combination from July 11, 2022.</us-gaap:BusinessCombinationAcquiredReceivablesDescription>
    <us-gaap:AssetsHeldInTrust
      contextRef="PAsOn11_11_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1295556</us-gaap:AssetsHeldInTrust>
    <us-gaap:RestrictedCashCurrent
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">34961</us-gaap:RestrictedCashCurrent>
    <sclx:WorkingCapital
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">643543</sclx:WorkingCapital>
    <us-gaap:InterestIncomeDepositWithFinancialInstitutionIncreaseDecrease
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">696000</us-gaap:InterestIncomeDepositWithFinancialInstitutionIncreaseDecrease>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Basis of Presentation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) for interim financial information and in accordance with the instructions to Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10-Q&lt;/div&gt; and Article 8 of Regulation &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;S-X&lt;/div&gt; of the SEC. Certain information or footnote disclosures normally included in condensed financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the Company&#x2019;s Annual Report on &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Form&#160;10-K&lt;/div&gt; as filed with the SEC on February&#160;24, 2022. The interim results for the three and nine months ended September&#160;30, 2022 are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2022 or for any future periods. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Principles of Consolidation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All significant intercompany balances and transactions have been eliminated in consolidation. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Emerging Growth Company &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is an &#x201c;emerging growth company,&#x201d; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Further, Section&#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-emerging&lt;/div&gt; growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&#x2019;s financial statement with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. &lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The preparation of the condensed consolidated financial statements in conformity with GAAP requires the Company&#x2019;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the condensed consolidated financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. One of the more significant accounting estimates included in these condensed consolidated financial statements is the determination of the fair value of the warrant liabilities. Such estimates may be subject to change as more current information because available and accordingly, the actual results could differ significantly from those estimates. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Cash and Cash Equivalents &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of September&#160;30, 2022 and December&#160;31, 2021. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Investments Held in Trust Account &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;At September&#160;30, 2022 and December&#160;31, 2021, the majority of the assets held in the Trust Account were held in money market funds, which are invested primarily in U.S. Treasury securities. The Company presents its investments in money market funds on the condensed consolidated balance sheets at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of these securities is included in interest income in the accompanying unaudited condensed consolidated statements of operations. The estimated fair value of investments held in the Trust Account are determined using available market information. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Offering Costs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Offering costs consist of legal, accounting, underwriting fees and other costs incurred through the balance sheet date that are directly related to the Initial Public Offering. Offering costs were allocated to the separable financial instruments issued in the Initial Public Offering based on a relative fair value basis, compared to total proceeds received. Offering costs allocated to warrant liabilities were expensed as incurred in the statements of operations. Offering costs associated with the ordinary shares issued were initially charged to temporary equity and then accreted to ordinary shares subject to redemption upon the completion of the Initial Public Offering. Offering costs amounting to $8,119,261&#160;were charged to temporary equity upon the completion of the Initial Public Offering, and $30,212&#160;of the offering costs were related to the warrant liabilities and charged to the condensed consolidated statement of operations for the period ended September&#160;30, 2021. The Company classifies deferred underwriting commissions as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; liabilities as their liquidation is not reasonably expected to require the use of current assets or require the creation of current liabilities. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Ordinary Shares Subject to Possible Redemption &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company accounts for its ordinary shares subject to possible redemption in accordance with the guidance in Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 480 &#x201c;Distinguishing Liabilities from Equity.&#x201d; Ordinary shares subject to mandatory redemption is classified as a liability instrument and is measured at fair value. Conditionally redeemable ordinary shares (including ordinary shares that features redemption rights that is either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#x2019;s control) is classified as temporary equity. At all other times, ordinary shares are classified as shareholders&#x2019; equity. The Company&#x2019;s ordinary shares features certain redemption rights that are considered to be outside of the Company&#x2019;s control and subject to occurrence of uncertain future events. Accordingly, at September&#160;30, 2022 and December&#160;31, 2021, ordinary shares subject to possible redemption is presented as temporary equity, outside of the shareholders&#x2019; deficit section of the Company&#x2019;s condensed consolidated balance sheets. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Under ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;480-10-S99,&lt;/div&gt;&lt;/div&gt; the Company has elected to recognize changes in the redemption value immediately as they occur and adjust the carrying value of redeemable ordinary shares to equal the redemption value at the end of each reporting period. This method would view the end of the reporting period as if it were also the redemption date for the security. Immediately upon the closing of the Initial Public Offering, the Company recognized the accretion from initial book value to redemption amount value. The change in the carrying value of redeemable ordinary shares resulted in charges against additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;paid-in&lt;/div&gt; capital and accumulated deficit. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;At September&#160;30, 2022 and December&#160;31, 2021, the ordinary shares reflected in the condensed consolidated balance sheets are reconciled in the following table: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 77%; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 7%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross proceeds&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;138,000,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Ordinary shares issuance costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(8,119,261&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Plus:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accretion of carrying value to redemption value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9,499,261&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Ordinary shares subject to possible redemption as of December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;139,380,000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Mandatorily redeemable ordinary shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(41,824,292&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Plus:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accretion of carrying value to redemption value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,737,378&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Ordinary shares subject to possible redemption as of September&#160;30, 2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;101,293,086&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Warrant Liability &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#x2019;s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) 480, Distinguishing Liabilities from Equity (&#x201c;ASC 480&#x201d;) and ASC 815,&#160;Derivatives and Hedging&#160;(&#x201c;ASC 815&#x201d;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company&#x2019;s own ordinary shares, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. We account for the warrants issued in connection with our Initial Public Offering in accordance with the guidance contained in ASC 815 under which the public warrants meet the criteria for equity treatment and the private warrants do not meet the criteria for equity treatment and must be recorded as liabilities. Accordingly, we classify the private warrants as liabilities at their fair value and adjust the private warrants to fair value at each reporting period. This liability is subject to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-measurement&lt;/div&gt; at each balance sheet date until exercised, and any change in fair value is recognized in our statement of operations. The fair value of the warrants was estimated using a Black-Scholes option pricing formula. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company accounts for income taxes under ASC Topic 740, &#x201c;Income Taxes,&#x201d; which prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company&#x2019;s management determined that the Cayman Islands is the Company&#x2019;s major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. As of September&#160;30, 2022 and December&#160;31, 2021, there were no unrecognized tax benefits and no amounts accrued for interest and penalties. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is considered to be an exempted Cayman Islands company with no connection to any other taxable jurisdiction and is presently not subject to income taxes or income tax filing requirements in the Cayman Islands or the United States. As such, the Company&#x2019;s tax provision was zero for the periods presented. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Net Income (Loss) per Ordinary Share &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, &#x201c;Earnings Per Share&#x201d;. Net income (loss) per ordinary share is computed by dividing net income (loss) by the weighted average number of ordinary shares outstanding for the period. Accretion associated with the redeemable shares of ordinary shares is excluded from earnings per share as the redemption value approximates fair value. Mandatorily redeemable ordinary shares are excluded from the weighted average number of ordinary shares outstanding. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The calculation of diluted income (loss) per share does not consider the effect of the warrants issued in connection with the (i)&#160;Initial Public Offering, and (ii)&#160;the private placement since the exercise of the warrants is contingent upon the occurrence of future events. The warrants are exercisable to purchase&#160;13,740,000&#160;ordinary shares in the aggregate. As of September&#160;30, 2022 and 2021, the Company did not have any dilutive securities or &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;other contracts that could, potentially, be exercised or converted into ordinary shares and then share in the earnings of the Company. As a result, diluted net income (loss) per ordinary share is the same as basic net income (loss) per ordinary share for the periods presented. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table reflects the calculation of basic and diluted net income (loss) per ordinary share (in dollars, except per share amounts): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 48%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For&#160;the&#160;Three&#160;Months&#160;Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Nine Months Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Ordinary Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Basic and diluted net income (loss) per ordinary share&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Numerator:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Allocation of net income (loss)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(131,387&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,444,352&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;623,516&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(349,248&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Denominator:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic and diluted weighted average ordinary shares outstanding&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13,176,395&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17,250,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15,862,288&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,675,824&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic and diluted net income (loss) per ordinary share&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.01&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.08&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.04&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.02&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Concentration of Credit Risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times may exceed the Federal Deposit Insurance Corporation coverage limit of $250,000. As of September&#160;30, 2022 and December&#160;31, 2021, the Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such account.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Fair Value of Financial Instruments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value of the Company&#x2019;s assets and liabilities, which qualify as financial instruments under ASC Topic 820, &#x201c;Fair Value Measurement,&#x201d; approximates the carrying amounts represented in the accompanying condensed consolidated balance sheets, primarily due to their short-term nature, other than the derivative warrant liability and conversion option liability (Note 9). &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Recent Accounting Standards &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In August 2020, the FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;) &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-06,&lt;/div&gt; Debt &#x2014; Debt with Conversion and Other Options (Subtopic &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;470-20)&lt;/div&gt; and Derivatives and Hedging &#x2014; Contracts in Entity&#x2019; Own Equity (Subtopic &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;815-40):&lt;/div&gt; Accounting for Convertible Instruments and Contracts in an Entity&#x2019; Own Equity (&#x201c;ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-06&#x201d;),&lt;/div&gt; which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU also removes certain settlement conditions that are required for equity-linked contracts to qualify for the derivative scope exception, and it simplifies the diluted earnings per share calculation in certain areas. Management is currently evaluating the new guidance but does not expect the adoption of this guidance to have a material impact on the Company&#x2019;s condensed consolidated financial statements. &lt;br/&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px;;display:inline;"&gt;Management does not believe that any other recently issued, but not yet effective, accounting standard if currently adopted would have a material effect on the accompanying condensed consolidated financial statements.&lt;/div&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Basis of Presentation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) for interim financial information and in accordance with the instructions to Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10-Q&lt;/div&gt; and Article 8 of Regulation &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;S-X&lt;/div&gt; of the SEC. Certain information or footnote disclosures normally included in condensed financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the Company&#x2019;s Annual Report on &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Form&#160;10-K&lt;/div&gt; as filed with the SEC on February&#160;24, 2022. The interim results for the three and nine months ended September&#160;30, 2022 are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2022 or for any future periods. &lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Principles of Consolidation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All significant intercompany balances and transactions have been eliminated in consolidation. &lt;/div&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Emerging Growth Company &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is an &#x201c;emerging growth company,&#x201d; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Further, Section&#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-emerging&lt;/div&gt; growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&#x2019;s financial statement with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. &lt;/div&gt; </us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The preparation of the condensed consolidated financial statements in conformity with GAAP requires the Company&#x2019;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the condensed consolidated financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. One of the more significant accounting estimates included in these condensed consolidated financial statements is the determination of the fair value of the warrant liabilities. Such estimates may be subject to change as more current information because available and accordingly, the actual results could differ significantly from those estimates. &lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Cash and Cash Equivalents &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of September&#160;30, 2022 and December&#160;31, 2021. &lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:EquityMethodInvestmentsPolicy contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Investments Held in Trust Account &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;At September&#160;30, 2022 and December&#160;31, 2021, the majority of the assets held in the Trust Account were held in money market funds, which are invested primarily in U.S. Treasury securities. The Company presents its investments in money market funds on the condensed consolidated balance sheets at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of these securities is included in interest income in the accompanying unaudited condensed consolidated statements of operations. The estimated fair value of investments held in the Trust Account are determined using available market information. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsPolicy>
    <us-gaap:DeferredChargesPolicyTextBlock contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Offering Costs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Offering costs consist of legal, accounting, underwriting fees and other costs incurred through the balance sheet date that are directly related to the Initial Public Offering. Offering costs were allocated to the separable financial instruments issued in the Initial Public Offering based on a relative fair value basis, compared to total proceeds received. Offering costs allocated to warrant liabilities were expensed as incurred in the statements of operations. Offering costs associated with the ordinary shares issued were initially charged to temporary equity and then accreted to ordinary shares subject to redemption upon the completion of the Initial Public Offering. Offering costs amounting to $8,119,261&#160;were charged to temporary equity upon the completion of the Initial Public Offering, and $30,212&#160;of the offering costs were related to the warrant liabilities and charged to the condensed consolidated statement of operations for the period ended September&#160;30, 2021. The Company classifies deferred underwriting commissions as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt; liabilities as their liquidation is not reasonably expected to require the use of current assets or require the creation of current liabilities. &lt;/div&gt;</us-gaap:DeferredChargesPolicyTextBlock>
    <us-gaap:OtherDeferredCostsNet
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">8119261</us-gaap:OtherDeferredCostsNet>
    <us-gaap:OtherDeferredCostsNet
      contextRef="PAsOn09_30_2022_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">30212</us-gaap:OtherDeferredCostsNet>
    <us-gaap:SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Ordinary Shares Subject to Possible Redemption &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company accounts for its ordinary shares subject to possible redemption in accordance with the guidance in Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 480 &#x201c;Distinguishing Liabilities from Equity.&#x201d; Ordinary shares subject to mandatory redemption is classified as a liability instrument and is measured at fair value. Conditionally redeemable ordinary shares (including ordinary shares that features redemption rights that is either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#x2019;s control) is classified as temporary equity. At all other times, ordinary shares are classified as shareholders&#x2019; equity. The Company&#x2019;s ordinary shares features certain redemption rights that are considered to be outside of the Company&#x2019;s control and subject to occurrence of uncertain future events. Accordingly, at September&#160;30, 2022 and December&#160;31, 2021, ordinary shares subject to possible redemption is presented as temporary equity, outside of the shareholders&#x2019; deficit section of the Company&#x2019;s condensed consolidated balance sheets. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Under ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;480-10-S99,&lt;/div&gt;&lt;/div&gt; the Company has elected to recognize changes in the redemption value immediately as they occur and adjust the carrying value of redeemable ordinary shares to equal the redemption value at the end of each reporting period. This method would view the end of the reporting period as if it were also the redemption date for the security. Immediately upon the closing of the Initial Public Offering, the Company recognized the accretion from initial book value to redemption amount value. The change in the carrying value of redeemable ordinary shares resulted in charges against additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;paid-in&lt;/div&gt; capital and accumulated deficit. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;At September&#160;30, 2022 and December&#160;31, 2021, the ordinary shares reflected in the condensed consolidated balance sheets are reconciled in the following table: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 77%; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 7%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross proceeds&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;138,000,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Ordinary shares issuance costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(8,119,261&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Plus:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accretion of carrying value to redemption value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9,499,261&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Ordinary shares subject to possible redemption as of December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;139,380,000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Mandatorily redeemable ordinary shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(41,824,292&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Plus:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accretion of carrying value to redemption value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,737,378&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Ordinary shares subject to possible redemption as of September&#160;30, 2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;101,293,086&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock>
    <srt:ScheduleOfCondensedBalanceSheetTableTextBlock contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 77%; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 7%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross proceeds&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;138,000,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Ordinary shares issuance costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(8,119,261&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Plus:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accretion of carrying value to redemption value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9,499,261&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Ordinary shares subject to possible redemption as of December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;139,380,000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Mandatorily redeemable ordinary shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(41,824,292&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Plus:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accretion of carrying value to redemption value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,737,378&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Ordinary shares subject to possible redemption as of September&#160;30, 2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;101,293,086&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</srt:ScheduleOfCondensedBalanceSheetTableTextBlock>
    <sclx:GrossProceeds
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">138000000</sclx:GrossProceeds>
    <sclx:OrdinarySharesIssuanceCost
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">8119261</sclx:OrdinarySharesIssuanceCost>
    <sclx:AccretionOfCarryingValueToRedemptionValue
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">9499261</sclx:AccretionOfCarryingValueToRedemptionValue>
    <sclx:SharesSubjectToPossibleRedemption
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">139380000</sclx:SharesSubjectToPossibleRedemption>
    <us-gaap:TemporaryEquityOtherChanges
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-41824292</us-gaap:TemporaryEquityOtherChanges>
    <sclx:AccretionOfCarryingValueToRedemptionValue
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">3737378</sclx:AccretionOfCarryingValueToRedemptionValue>
    <sclx:SharesSubjectToPossibleRedemption
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">101293086</sclx:SharesSubjectToPossibleRedemption>
    <us-gaap:DerivativesPolicyTextBlock contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Warrant Liability &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#x2019;s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) 480, Distinguishing Liabilities from Equity (&#x201c;ASC 480&#x201d;) and ASC 815,&#160;Derivatives and Hedging&#160;(&#x201c;ASC 815&#x201d;). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company&#x2019;s own ordinary shares, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. We account for the warrants issued in connection with our Initial Public Offering in accordance with the guidance contained in ASC 815 under which the public warrants meet the criteria for equity treatment and the private warrants do not meet the criteria for equity treatment and must be recorded as liabilities. Accordingly, we classify the private warrants as liabilities at their fair value and adjust the private warrants to fair value at each reporting period. This liability is subject to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-measurement&lt;/div&gt; at each balance sheet date until exercised, and any change in fair value is recognized in our statement of operations. The fair value of the warrants was estimated using a Black-Scholes option pricing formula. &lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company accounts for income taxes under ASC Topic 740, &#x201c;Income Taxes,&#x201d; which prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company&#x2019;s management determined that the Cayman Islands is the Company&#x2019;s major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. As of September&#160;30, 2022 and December&#160;31, 2021, there were no unrecognized tax benefits and no amounts accrued for interest and penalties. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is considered to be an exempted Cayman Islands company with no connection to any other taxable jurisdiction and is presently not subject to income taxes or income tax filing requirements in the Cayman Islands or the United States. As such, the Company&#x2019;s tax provision was zero for the periods presented. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Net Income (Loss) per Ordinary Share &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, &#x201c;Earnings Per Share&#x201d;. Net income (loss) per ordinary share is computed by dividing net income (loss) by the weighted average number of ordinary shares outstanding for the period. Accretion associated with the redeemable shares of ordinary shares is excluded from earnings per share as the redemption value approximates fair value. Mandatorily redeemable ordinary shares are excluded from the weighted average number of ordinary shares outstanding. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The calculation of diluted income (loss) per share does not consider the effect of the warrants issued in connection with the (i)&#160;Initial Public Offering, and (ii)&#160;the private placement since the exercise of the warrants is contingent upon the occurrence of future events. The warrants are exercisable to purchase&#160;13,740,000&#160;ordinary shares in the aggregate. As of September&#160;30, 2022 and 2021, the Company did not have any dilutive securities or &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;other contracts that could, potentially, be exercised or converted into ordinary shares and then share in the earnings of the Company. As a result, diluted net income (loss) per ordinary share is the same as basic net income (loss) per ordinary share for the periods presented. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table reflects the calculation of basic and diluted net income (loss) per ordinary share (in dollars, except per share amounts): &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 48%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For&#160;the&#160;Three&#160;Months&#160;Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Nine Months Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Ordinary Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Basic and diluted net income (loss) per ordinary share&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Numerator:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Allocation of net income (loss)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(131,387&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,444,352&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;623,516&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(349,248&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Denominator:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic and diluted weighted average ordinary shares outstanding&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13,176,395&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17,250,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15,862,288&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,675,824&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic and diluted net income (loss) per ordinary share&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.01&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.08&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.04&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.02&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ExcessStockSharesIssued
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">13740000</us-gaap:ExcessStockSharesIssued>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 48%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For&#160;the&#160;Three&#160;Months&#160;Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Nine Months Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Ordinary Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Basic and diluted net income (loss) per ordinary share&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Numerator:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Allocation of net income (loss)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(131,387&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,444,352&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;623,516&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(349,248&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Denominator:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic and diluted weighted average ordinary shares outstanding&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13,176,395&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17,250,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15,862,288&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,675,824&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic and diluted net income (loss) per ordinary share&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.01&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.08&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.04&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.02&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:TemporaryEquityNetIncome
      contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-131387</us-gaap:TemporaryEquityNetIncome>
    <us-gaap:TemporaryEquityNetIncome
      contextRef="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-1444352</us-gaap:TemporaryEquityNetIncome>
    <us-gaap:TemporaryEquityNetIncome
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">623516</us-gaap:TemporaryEquityNetIncome>
    <us-gaap:TemporaryEquityNetIncome
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-349248</us-gaap:TemporaryEquityNetIncome>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">13176395</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic
      contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">13176395</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">17250000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic
      contextRef="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">17250000</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">15862288</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">15862288</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">16675824</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesIssuedBasic
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">16675824</us-gaap:WeightedAverageNumberOfSharesIssuedBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.01</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.01</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.08</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P07_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.08</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.04</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.04</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.02</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2021To09_30_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Concentration of Credit Risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times may exceed the Federal Deposit Insurance Corporation coverage limit of $250,000. As of September&#160;30, 2022 and December&#160;31, 2021, the Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such account.&lt;/div&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashFDICInsuredAmount
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Fair Value of Financial Instruments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value of the Company&#x2019;s assets and liabilities, which qualify as financial instruments under ASC Topic 820, &#x201c;Fair Value Measurement,&#x201d; approximates the carrying amounts represented in the accompanying condensed consolidated balance sheets, primarily due to their short-term nature, other than the derivative warrant liability and conversion option liability (Note 9). &lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Recent Accounting Standards &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In August 2020, the FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;) &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-06,&lt;/div&gt; Debt &#x2014; Debt with Conversion and Other Options (Subtopic &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;470-20)&lt;/div&gt; and Derivatives and Hedging &#x2014; Contracts in Entity&#x2019; Own Equity (Subtopic &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;815-40):&lt;/div&gt; Accounting for Convertible Instruments and Contracts in an Entity&#x2019; Own Equity (&#x201c;ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020-06&#x201d;),&lt;/div&gt; which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU also removes certain settlement conditions that are required for equity-linked contracts to qualify for the derivative scope exception, and it simplifies the diluted earnings per share calculation in certain areas. Management is currently evaluating the new guidance but does not expect the adoption of this guidance to have a material impact on the Company&#x2019;s condensed consolidated financial statements. &lt;br/&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px;;display:inline;"&gt;Management does not believe that any other recently issued, but not yet effective, accounting standard if currently adopted would have a material effect on the accompanying condensed consolidated financial statements.&lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <sclx:ProposedPublicOfferingTextBlock contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 3. PUBLIC OFFERING &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Pursuant to the Initial Public Offering, the Company sold to&#160;13,800,000&#160;Units which includes a full exercise by the underwriters of their over-allotment option in the amount of&#160;1,800,000&#160;Units, at a purchase price of $10.00 per Unit. Each Unit consists of one ordinary share and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-half&lt;/div&gt; of one redeemable warrant (&#x201c;Public Warrant&#x201d;). Each whole Public Warrant entitles the holder to purchase one ordinary share at an exercise price of $11.50 per whole share (see Note 7). &lt;/div&gt;</sclx:ProposedPublicOfferingTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="P01_01_2022To09_30_2022_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">13800000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="P01_01_2022To09_30_2022_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">1800000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <sclx:PurchasePricePerShare
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">10</sclx:PurchasePricePerShare>
    <us-gaap:SaleOfStockDescriptionOfTransaction contextRef="P01_01_2022To09_30_2022_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis">Each Unit consists of one ordinary share and one-half of one redeemable warrant (&#x201c;Public Warrant&#x201d;). Each whole Public Warrant entitles the holder to purchase one ordinary share at an exercise price of $11.50 per whole share (see Note 7).</us-gaap:SaleOfStockDescriptionOfTransaction>
    <sclx:PrivatePlacementTextBlock contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 4. PRIVATE PLACEMENT &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Simultaneously with the closing of the Initial Public Offering, the Sponsors purchased an aggregate of&#160;6,840,000 Private Placement Warrants at a price of $0.75&#160;per Private Placement Warrant, for an aggregate purchase price of $5,130,000, in a private placement. Each Private Placement Warrant is exercisable to purchase one ordinary share at a price of $11.50&#160;per share, subject to adjustment (see Note 7). A portion of the proceeds from the Private Placement Warrants were added to the proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the proceeds from the sale of the Private Placement Warrants will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law) and the Private Placement Warrants will expire worthless. &lt;/div&gt;&lt;/div&gt;</sclx:PrivatePlacementTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn09_30_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">6840000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn09_30_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="P01_01_2022To09_30_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">5130000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="PAsOn09_30_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">11.5</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 5. RELATED PARTY TRANSACTIONS &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Founder Shares &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;On July&#160;16, 2020, the Company issued an aggregate of&#160;3,593,750&#160;ordinary shares to an affiliate of the Sponsors for an aggregate purchase price of $25,000. In August 2020, the affiliate transferred his Founder Shares to the Sponsors for the same price paid for such shares. On October 8. 2020, the Company effected a share&lt;br/&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;capitalization&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;of &lt;/div&gt;0.2&#160;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;shares for each share outstanding, on December&#160;7, 2020, the Sponsors forfeited &lt;/div&gt;1,437,500 &lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ordinary shares, which were cancelled by the Company, and on January&#160;6, 2021, the Company effected a share capitalization of&#160;&lt;/div&gt;0.2&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;shares for each share outstanding, resulting in&#160;&lt;/div&gt;3,450,000&#160;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ordinary shares issued and outstanding (the &#x201c;Founder Shares&#x201d;). All share and &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;per-share&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; amounts have been retroactively restated to reflect the share transactions. The Founder Shares included an aggregate of up to&#160;&lt;/div&gt;450,000&#160;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;shares that were subject to forfeiture depending on the extent to which the underwriters&#x2019; over-allotment option is exercised, so that the number of Founder Shares will equal, on an &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;as-converted&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; basis, approximately&#160;&lt;/div&gt;20&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% of the Company&#x2019;s issued and outstanding ordinary shares after the Initial Public Offering. As a result of the underwriters&#x2019; election to partially exercise their over-allotment option, no Founder Shares are currently subject to forfeiture.&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Sponsors have agreed, subject to limited exceptions, not to transfer, assign or sell any of its Founder Shares until six months after the consummation of a Business Combination or earlier if, subsequent to a Business Combination, the Company consummates a liquidation, merger, share exchange or other similar transaction that results in all of the Public Shareholders having the right to exchange their ordinary shares for cash, securities or other property. &lt;/div&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Advances from Related Party &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;During 2020, an affiliate of the Sponsors advanced the Company an aggregate of $30,000&#160;to fund expenses in connection with the Initial Public Offering. The advances were &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-interest&lt;/div&gt; bearing and payable upon demand. Such advances were repaid in connection with the closing of the Initial Public Offering. Accordingly, as of September&#160;30, 2022 and December&#160;31, 2021, there were no advances outstanding. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Promissory Note &#x2014; Related Party &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;On July&#160;16, 2020, the Company issued an unsecured promissory note (the &#x201c;Promissory Note&#x201d;) to an affiliate of the Sponsors, pursuant to which the Company may borrow up to an aggregate principal amount of $125,000. The Promissory Note is &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-interest&lt;/div&gt; bearing and payable on the earlier of (i)&#160;December&#160;31, 2020 or (ii)&#160;the completion of the Initial Public Offering. The outstanding balance under the Promissory Note of $125,000&#160;was repaid subsequent to the closing of the Initial Public Offering on January&#160;14, 2021. Borrowings under the Promissory Note are no longer available to the Company. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Related Party Loans &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In order to finance transaction costs in connection with a Business Combination, the Sponsors or an affiliate of the Sponsors, or certain of the Company&#x2019;s officers and directors may, but are not obligated to, loan the Company funds as may be required (&#x201c;Working Capital Loans&#x201d;). Such Working Capital Loans would be evidenced by promissory notes.&#160;The notes may be repaid upon completion of a Business Combination, without interest, or, at the lender&#x2019;s discretion, up to $1,500,000 of notes may be converted upon completion of a Business Combination into warrants at a price of $0.75 per warrant.&#160;Such warrants would be identical to the Private Placement Warrants. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;On December&#160;20, 2021, the Company entered issued two convertible promissory notes to the Sponsors to evidence Working Capital Loans pursuant to which the Sponsors agreed to loan the Company up to an aggregate principal amount of $500,000&#160;(the &#x201c;Convertible Promissory Notes&#x201d;). The Convertible Promissory Notes are &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-interest&lt;/div&gt; bearing and payable upon Business Combination. If a Business Combination is not consummated,&lt;br/&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;the&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Convertible Promissory Notes will not be repaid by the Company and all amounts owed thereunder by the Company will be forgiven except to the extent that the Company has funds available to it outside of its Trust Account. Up to $&lt;/div&gt;500,000&#160;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;of the Convertible Promissory Notes may be converted into warrants at a price of $&lt;/div&gt;0.75&#160;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;per warrant at the option of the Sponsors. The warrants would be identical to the Private Placement Warrants.&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On January&#160;10, 2022, the Company borrowed an additional $1,035,000, as discussed below. On January&#160;27, 2022, Company entered into two additional Convertible Promissory Notes with the Sponsors pursuant to which the Sponsors agreed to loan the Company up to an aggregate principal amount of $500,000. As of September&#160;30, 2022 and December&#160;31, 2021, the principal balance of the Convertible Promissory Notes amounted to an aggregate of $2,035,000&#160;and $500,000, respectively. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company assessed the provisions of the Convertible Promissory Notes under ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;470-20.&lt;/div&gt; The derivative component of the obligation is initially valued and classified as a derivative liability (see Note 9). &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The debt discount is being amortized to interest expense as a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-cash&lt;/div&gt; charge over the term of the Convertible Promissory Notes, which is assumed to mature in at Business Combination. During the three and nine months&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ended September&#160;30, 2022, the Company recorded $&lt;/div&gt;1,155&#160;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;and $&lt;/div&gt;16,901&#160;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;of interest expense related to the amortization of the debt discount. The remaining balance of the debt discount at September&#160;30, 2022 and December&#160;31, 2021 amounted to $&lt;/div&gt;0 &lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;and $&lt;/div&gt;16,901&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, respectively.&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;On April&#160;11, 2022, the Company entered into two simple promissory notes with the Sponsors pursuant to which the Sponsors agreed to loan the Company up to an aggregate principal amount of $1,500,000&#160;(the &#x201c;Simple Promissory Notes&#x201d;). The Simple Promissory Notes are &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-interest&lt;/div&gt; bearing and payable upon Business Combination. If a Business Combination is not consummated, the Simple Promissory Notes will not be repaid by the Company and all amounts owed thereunder by the Company will be forgiven except to the extent that the Company has funds available to it outside of its Trust Account. On April&#160;18, 2022, the Company entered into two additional Simple Promissory Notes with the Sponsor pursuant to which the Sponsor agreed to loan the Company up to an aggregate principal amount of $500,000. As of September&#160;30, 2022 and December&#160;31, 2021, the principal balance of the Simple Promissory Notes amounted to an aggregate of $2,971,667&#160;and $0, respectively. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Related Party Extension Loans &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As discussed in Note 1, the Company may extend the period of time to consummate a Business Combination by an additional three months.&#160;In order to extend the time available for the Company to consummate a Business Combination, the Sponsor or its affiliates or designees must deposit into the Trust Account $1,035,000 ($0.075 per Public Share in either case), on or prior to the date of the applicable deadline, for each three-month extension., &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;On January&#160;10, 2022, the Company extended the period of time to consummate a Business Combination to April&#160;11, 2022. The Sponsors deposited $1,035,000&#160;into the Trust Account made in the form of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-interest-bearing&lt;/div&gt; loans. If the Company completes an initial business combination, the Company will, at the option of the Sponsors, repay the amounts evidenced by the Convertible Promissory Notes or convert a portion or all of the total amount into warrants at a price of $0.75&#160;per warrant, which warrants are identical to the Private Placement Warrants issued. If a Business Combination is not consummated, the Convertible Promissory Notes will not be repaid by the Company and all amounts owed thereunder by the Company will be forgiven except to the extent that the Company has funds available to it outside of its Trust Account. &lt;br/&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;April&#160;11, 2022, the Company extended the period of time to consummate a Business Combination to July&#160;11, 2022. The Sponsors deposited $&lt;/div&gt;1,035,000&#160;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;into the Trust Account made in the form of &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-interest-bearing&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; loans. If the Company completes an initial business combination, the Company will, at the option of the Sponsors, repay the amounts evidenced by simple promissory notes. If a Business Combination is not consummated, the simple promissory notes will not be repaid by the Company and all amounts owed thereunder by the Company will be forgiven except to the extent that the Company has funds available to it outside of its Trust Account.&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;On July&#160;11, 2022, the Company extended the period of time to consummate a Business Combination to August&#160;11, 2022. The Sponsors deposited $323,889&#160;into the Trust Account made in the form of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-interest-bearing&lt;/div&gt; loans. If the Company completes an initial business combination, the Company will, at the option of the Sponsors, repay the amounts evidenced by simple promissory notes. If a Business Combination is not consummated, the simple promissory notes will not be repaid by the Company and all amounts owed thereunder by the Company will be forgiven except to the extent that the Company has funds available to it outside of its Trust Account. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;On August&#160;10, 2022, the Company extended the period of time to consummate a Business Combination to&#160;September&#160;11, 2022. The Sponsors deposited $323,889&#160;into the Trust Account made in the form of non-interest-bearing loans. If the Company completes an initial business combination, the Company will, at the option of the Sponsors, repay the amounts evidenced by simple promissory notes. If a Business Combination is not consummated, the simple promissory notes will not be repaid by the Company and all amounts owed thereunder by the Company will be forgiven except to the extent that the Company has funds available to it outside of its Trust Account. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; text-align: center; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;September&#160;9, 2022, the Company extended the period of time to consummate a Business Combination to October&#160;11, 2022. The Sponsors deposited $&lt;/div&gt;323,889&lt;div style="font-size: 10pt; text-align: center; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;into the Trust Account made in the form of &lt;/div&gt;&lt;div style="font-size: 10pt; text-align: center; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-interest-bearing&lt;/div&gt;&lt;div style="font-size: 10pt; text-align: center; letter-spacing: 0px; top: 0px;;display:inline;"&gt; loans. If the Company completes an initial business combination, the Company will, at the option of the Sponsors, repay the amounts evidenced by simple promissory notes. If a Business Combination is not consummated, the simple promissory notes will not be repaid by the Company and all amounts owed thereunder by the Company will be forgiven except to the extent that the Company has funds available to it outside of its Trust Account.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;On October&#160;10, 2022, the Company extended the period of time to consummate a Business Combination to November&#160;11, 2022. The Sponsors deposited $323,889&#160;into the Trust Account made in the form of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-interest-bearing&lt;/div&gt; loans. If the Company completes an initial business combination, the Company will, at the option of the Sponsors, repay the amounts evidenced by simple promissory notes. If a Business Combination is not consummated, the simple promissory notes will not be repaid by the Company and all amounts owed thereunder by the Company will be forgiven except to the extent that the Company has funds available to it outside of its Trust Account. &lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P07_02_2020To07_16_2020_FounderSharesMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">3593750</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="P07_02_2020To07_16_2020_FounderSharesMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">25000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <sclx:CapitalizationOfShareOutstanding
      contextRef="P10_01_2020To10_08_2020_FounderSharesMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="1"
      unitRef="Unit_shares">0.2</sclx:CapitalizationOfShareOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited
      contextRef="P12_01_2020To12_07_2020_FounderSharesMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">1437500</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited>
    <sclx:CapitalizationOfShareOutstanding
      contextRef="P01_03_2021To01_06_2021_FounderSharesMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="1"
      unitRef="Unit_shares">0.2</sclx:CapitalizationOfShareOutstanding>
    <sclx:OrdinarySharesIssuedAndOutstanding
      contextRef="P01_03_2021To01_06_2021_FounderSharesMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">3450000</sclx:OrdinarySharesIssuedAndOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited
      contextRef="P01_01_2022To09_30_2022_FounderSharesMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">450000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="PAsOn09_30_2022_FounderSharesMembersrtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_pure">0.20</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:CostsAndExpensesRelatedParty
      contextRef="P12_01_2020To12_31_2020_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">30000</us-gaap:CostsAndExpensesRelatedParty>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn07_16_2020_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">125000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:RepaymentsOfDebt
      contextRef="P01_04_2021To01_11_2021_IPOMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">125000</us-gaap:RepaymentsOfDebt>
    <us-gaap:BusinessCombinationControlObtainedDescription contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">The notes may be repaid upon completion of a Business Combination, without interest, or, at the lender&#x2019;s discretion, up to $1,500,000 of notes may be converted upon completion of a Business Combination into warrants at a price of $0.75 per warrant.</us-gaap:BusinessCombinationControlObtainedDescription>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn12_20_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ConvertibleDebt
      contextRef="PAsOn12_20_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">500000</us-gaap:ConvertibleDebt>
    <sclx:WarrantsExercisePrice
      contextRef="P12_01_2021To12_20_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.75</sclx:WarrantsExercisePrice>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn01_10_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1035000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="P01_01_2022To01_27_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">500000</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
    <sclx:aggregatePurchasePrice
      contextRef="P01_01_2022To09_30_2022_ConvertiblePromisoryNoteMemberusgaapShortTermDebtTypeAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">2035000</sclx:aggregatePurchasePrice>
    <sclx:aggregatePurchasePrice
      contextRef="P01_01_2021To12_31_2021_ConvertiblePromisoryNoteMemberusgaapShortTermDebtTypeAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">500000</sclx:aggregatePurchasePrice>
    <us-gaap:InterestExpenseRelatedParty
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1155</us-gaap:InterestExpenseRelatedParty>
    <us-gaap:InterestExpenseRelatedParty
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">16901</us-gaap:InterestExpenseRelatedParty>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">16901</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn04_11_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn04_18_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">2971667</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
    <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
    <us-gaap:RelatedPartyTransactionDescriptionOfTransaction contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">In order to extend the time available for the Company to consummate a Business Combination, the Sponsor or its affiliates or designees must deposit into the Trust Account $1,035,000 ($0.075 per Public Share in either case), on or prior to the date of the applicable deadline, for each three-month extension.</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
    <sclx:DepositedInTrustAccount
      contextRef="P01_10_2022To01_10_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1035000</sclx:DepositedInTrustAccount>
    <sclx:DepositedInTrustAccount
      contextRef="P04_11_2022To07_11_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1035000</sclx:DepositedInTrustAccount>
    <sclx:WarrantsExercisePrice
      contextRef="P04_01_2022To04_01_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.75</sclx:WarrantsExercisePrice>
    <sclx:DepositedInTrustAccount
      contextRef="P07_11_2022To07_11_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1035000</sclx:DepositedInTrustAccount>
    <sclx:DepositedInTrustAccount
      contextRef="P08_01_2022To08_11_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">323889</sclx:DepositedInTrustAccount>
    <sclx:DepositedInTrustAccount
      contextRef="P08_10_2022To09_11_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">323889</sclx:DepositedInTrustAccount>
    <sclx:DepositedInTrustAccount
      contextRef="P09_09_2022To09_09_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">323889</sclx:DepositedInTrustAccount>
    <sclx:DepositedInTrustAccount
      contextRef="P10_10_2022To10_10_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">323889</sclx:DepositedInTrustAccount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 6. COMMITMENTS AND CONTINGENCIES &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Risks and Uncertainties &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Management continues to evaluate the impact of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; pandemic and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company&#x2019;s financial position, results of its operations and/or search for a target company, the specific impact is not readily determinable as of the date of these condensed consolidated financial statements. The condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Registration and Shareholder Rights &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pursuant to a registration rights agreement entered into on January&#160;6, 2021, the holders of the Founder Shares, Private Placement Warrants and underlying ordinary shares and any securities issued upon conversion of Working Capital Loans will be entitled to registration rights pursuant to a registration rights agreement requiring the Company to register such securities for resale. The holders of these securities will be entitled to demand that the Company register such securities at any time after the Company consummates a Business Combination. In addition, the holders have certain &#x201c;piggy-back&#x201d; registration rights with respect to registration statements filed subsequent to the consummation of a Business Combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Underwriting Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The underwriters are entitled to a deferred fee of (i) 3.5% of the gross proceeds of the initial 12,000,000 Units sold in the Initial Public Offering, or $4,200,000, and (ii) 5.5% of the gross proceeds from the Units sold pursuant to the over-allotment option, or $990,000.&#160;The deferred fee will be paid in cash upon the closing of a Business Combination from the amounts held in the Trust Account, subject to the terms of the underwriting agreement. &lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Business Combination Merger Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On March&#160;17, 2022, the Company entered into an agreement and plan of merger (the &#x201c;Merger Agreement&#x201d;) by and among Scilex Holding Company (&#x201c;Scilex&#x201d;), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE) (&#x201c;Sorrento&#x201d;), VCKA, and Vantage Merger Sub Inc., a Delaware corporation and a wholly owned subsidiary of VCKA (&#x201c;Merger Sub&#x201d;). Parent and Merger Sub are sometimes referred to collectively as the &#x201c;Parent Parties.&#x201d; Pursuant to the Merger Agreement, VCKA will, prior to the closing of the Merger, migrate to and domesticate as a Delaware corporation in accordance with Section&#160;388 of the Delaware General Corporation Law, as amended and the Cayman Islands Companies Law (the &#x201c;Domestication&#x201d;). Thereafter, a business combination between VCKA and Scilex will be effected through the merger of Merger Sub with and into Scilex with Scilex surviving the merger as a wholly owned subsidiary of VCKA (the &#x201c;Merger&#x201d;). Upon the closing of the Merger (the &#x201c;Closing&#x201d;), it is anticipated that VCKA will change its name to &#x201c;Scilex Holding Company&#x201d;. The board of directors of VCKA has (i)&#160;approved and declared advisable the Merger Agreement, the Additional Agreements (as defined in the Merger Agreement) and the transactions contemplated thereby and (ii)&#160;resolved to recommend approval of the Merger Agreement and related transactions by the shareholders of VCKA. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;On September&#160;12, 2022, Vickers, Merger Sub and Scilex entered into Amendment No.&#160;1 to the Merger Agreement (the &#x201c;Amendment&#x201d;). The Amendment amends the Merger Agreement to, among other things, provide that: (i)&#160;the Plan of Domestication attached to the Merger Agreement shall constitute a plan of domestication for purposes of Section&#160;388 of the DGCL and shall include the corporate acts identified therein and any act or transaction contemplated by the Merger Agreement; (ii)&#160;at the Effective Time, each Domesticated Parent Unit shall separate automatically into its component parts, comprised of one share of Domesticated Parent Common Share and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-half&lt;/div&gt; of one Domesticated Parent Warrant (provided that no fractional Domesticated Parent Warrants shall be issued and any holder who would be entitled to receive a fractional Domesticated Parent Warrant will have such fraction rounded down to the nearest whole number of Domesticated Parent Warrants); (iii) immediately after Closing, New Scilex&#x2019;s board of directors shall consist of seven directors, five of whom will be designated by Scilex (including one director who shall satisfy the independence requirements of the applicable Stock Exchange (which shall be Nasdaq, unless the parties otherwise agree to list on another national securities exchange, which may include the New York Stock Exchange, prior to the Closing)) and two of whom &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;will be independent directors to be designated by Scilex and agreed to by Vickers prior to the Closing; (iv)&#160;at the Effective Time, by virtue of the Merger, each share of Series A Preferred Stock of Scilex issued and outstanding immediately prior to the Effective Time shall be canceled and automatically converted into the right to receive, without interest, one Domesticated Parent Preferred Share and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;one-tenth&lt;/div&gt; of one Domesticated Parent Common Share; (v)&#160;Vickers shall use its reasonable best efforts to ensure that Vickers remains listed as a public company, and that the Parent Ordinary Shares and public Parent Warrants remain listed on Nasdaq through the Closing and Scilex shall use its reasonable best efforts to prepare and file an initial listing application with the Stock Exchange in connection with the transactions contemplated by the Merger Agreement; (vi)&#160;each party shall use its reasonable best efforts to, among other things, obtain approval for the listing of the Domesticated Parent Common Shares and Domesticated Parent Warrants issued pursuant to the Merger Agreement on the Stock Exchange; (vii)&#160;following the consummation of the Domestication, and the filing of the Parent Certificate of Incorporation, but prior to the Effective Time, Vickers shall file with the Secretary of State of Delaware a certificate of designations, in the form attached to the Merger Agreement as a new Exhibit F, which provides for, among other things, the designations, powers, rights and preferences and qualifications, limitations and restrictions of certain preferred stock of Vickers; (viii)&#160;as a condition of Scilex to the Closing, that the shares of Domesticated Parent Common Shares and Domesticated Parent Warrants shall remain listed on Nasdaq through the Effective Time, the listing application for the listing of the Domesticated Parent Common Shares and Domesticated Parent Warrants following the Effective Time shall have been approved by the applicable Stock Exchange, and, as of the Closing Date, Vickers shall not have received any written notice from Nasdaq of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;non&lt;/div&gt;&lt;/div&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;-compliance&lt;/div&gt; with Nasdaq&#x2019;s applicable continued listing requirements for any reason, where such notice has not been subsequently withdrawn by Nasdaq or the underlying failure appropriately remedied or satisfied; and (ix)&#160;extend the Outside Date to November&#160;11, 2022. The Amendment also sets forth the agreement of Vickers and Scilex to amend the Parent Certificate of Incorporation to increase the number of authorized shares of preferred stock set forth therein from&#160;20,000,000&#160;to&#160;45,000,000&#160;and, as a result, increase the total number of shares of all classes of stock that Vickers shall have authority to issue from&#160;750,000,000&#160;to&#160;785,000,000&#160;and, in connection with the Domestication, to name the initial incorporator and initial board of directors of Vickers for the period between the Domestication and the Effective Time. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Merger is expected to be consummated by the fourth quarter of 2022, following the receipt of the required approval by the shareholders of VCKA and Scilex and the satisfaction of certain other customary closing conditions. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Merger Consideration &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The total consideration to be paid to the holders of Scilex common stock at Closing (the &#x201c;Merger Consideration&#x201d;) by VCKA twill be an amount equal to the quotient of (a) the sum of (i) $1,500,000,000 minus (ii) the aggregate amount of Scilex long term debt excluding intercompany debt owed to Sorrento existing as of immediately prior to the date of the closing of the transaction (the &#x201c;Closing Date&#x201d;); divided by (b) $10.00, and will be payable in shares of common stock, par value $0.0001 per shares, of VCKA upon its domestication in Delaware (&#x201c;VCKA Common Stock&#x201d;).&#160;The number of shares of VCKA Common Stock to be paid as Merger Consideration will be determined in accordance with the terms of the Business Combination Agreement. In addition, each outstanding share of Scilex Preferred Stock as of immediately prior to the Effective Time of the Business Combination will be cancelled in exchange for the right to receive (a)&#160;one&#160;share of Series A Preferred Stock of Vickers (following the Domestication), par value $0.0001&#160;per share (the &#x201c;New Scilex Series A Preferred Stock&#x201d;), and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(b)&#160;one-tenth&lt;/div&gt; of one share of New Scilex Common Stock, and (iii)&#160;each option to purchase Scilex Common Stock that is outstanding as of immediately prior to the Effective Time will be exchanged for a number of options exercisable for newly issued shares of New Scilex Common Stock based upon the Exchange Ratio. The total consideration to be received by holders of Scilex Common Stock and Scilex options at the Closing will be newly issued shares of &lt;br/&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;New&lt;/div&gt;&lt;/div&gt; Scilex Common Stock with an aggregate value equal to $1.5&#160;billion, subject to adjustments for certain debt obligations of Scilex (the &#x201c;Merger Consideration&#x201d;).&#160;The maximum number of shares of New Scilex Series A Preferred Stock and New Scilex Common Stock to be issued to the holders of Scilex Preferred Stock at the Closing shall not exceed 31,000,000 and 3,100,000, respectively, such newly issued shares being collectively referred to herein as the &#x201c;Preferred Consideration&#x201d;. It is anticipated that upon completion of the Business Combination, if none of the 9,726,395 VCKA Ordinary Shares are redeemed, VCKA&#x2019;s public shareholders would retain an ownership interest of approximately 5.6% in New Scilex, the Sponsors, officers, directors and other holders of founder shares will retain an ownership interest of approximately 2.2% of New Scilex, and the Scilex stockholders will own approximately (i) 77.2% of New Scilex in the form of New Scilex Common Stock and (ii) 15.0% of New Scilex in the form of New Scilex Series A Preferred Stock. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of the Effective Time, each Scilex stock option that is then outstanding shall be converted into the right to receive an option relating to VCKA Common Stock upon substantially the same terms and conditions as are in effect with respect to such option immediately prior to the Effective Time; provided that the exercise price per share for each such Scilex stock option shall be equal to the exercise price per share of such Scilex stock option in effect immediately prior to the Effective Time, divided by the Exchange Ratio.&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Representations and Warranties &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Merger Agreement contains customary representations and warranties of Scilex with respect to, among other things: (i)&#160;corporate existence and power; (ii)&#160;authorization to enter into the Merger Agreement and related transactions; (iii)&#160;governmental authorization; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(iv)&#160;non-contravention;&lt;/div&gt; (v)&#160;capital structure; (vi)&#160;organizational documents; (vii)&#160;assumed names; (viii)&#160;subsidiaries; (ix) financial statements; (x)&#160;absence of certain changes; (xi)&#160;properties and title to assets; (xii)&#160;litigation; (xiii) contracts; (xiv)&#160;licenses and permits; (xv)&#160;compliance with laws; (xvi)&#160;intellectual property; (xvii)&#160;customers and suppliers; (xviii)&#160;employees and employee benefits; (xix)&#160;employment matters; (xx)&#160;withholding; (xxi) real property; (xxii)&#160;tax matters; (xxiii)&#160;environmental laws; (xiv)&#160;finders&#x2019; fees; (xv)&#160;directors and officers; (xvi)&#160;certain business practices; (xvii)&#160;international trade matters and anti-bribery compliance; (xviii)&#160;that Scilex is not an investment company; (xvix) compliance with health care laws and certain contracts; (xxx)&#160;insurance; (xxxi)&#160;related party transactions; (xxxii)&#160;privacy and data security and (xxxiii)&#160;exclusivity of representations and warranties. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Merger Agreement contains customary representations and warranties of the Parent Parties with respect to, among other things: (i)&#160;corporate existence and power; (ii)&#160;authorization to enter into the Merger Agreement and related transactions; (iii)&#160;governmental authorization; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(iv)&#160;non-contravention;&lt;/div&gt; (v)&#160;finders&#x2019; fees; (vi)&#160;issuance of shares; (vii)&#160;capitalization; (viii) information supplied; (ix)&#160;amount in the trust account; (x)&#160;listing of VCKA securities; (xi)&#160;that VCKA is a reporting company; (xii)&#160;no market manipulation; (xiii)&#160;board approval; (xiv)&#160;SEC documents and financial statements; (xv)&#160;absence of changes; (xvi)&#160;litigation; (xvii) compliance with laws; (xviii)&#160;money laundering laws; (xix)&#160;OFAC; (xx) that VCKA is not an investment company; (xxi)&#160;tax matters; (xxii)&#160;contracts; (xxiii) investigation; and (xiv)&#160;exclusivity of representations and warranties. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;All representations and warranties by all parties shall terminate upon the Effective Time, and no representations, warranties, covenants, obligations or other agreements contained in the Merger Agreement shall survive the Effective Time. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Covenants &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Merger Agreement includes customary covenants of the parties with respect to operation of their respective businesses prior to consummation of the Merger and efforts to satisfy conditions to consummation of the Merger. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Merger Agreement also contains additional covenants of the parties, including, among others, access to information, cooperation in the preparation of the Registration Statement on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;S-4&lt;/div&gt; (the &#x201c;Registration Statement&#x201d;) and Proxy Statement (as each such term is defined in the Merger Agreement) required to be filed in connection with the Merger and to obtain all requisite approvals of each party&#x2019;s respective stockholders. VCKA has also agreed to include in the Proxy Statement the recommendation of its board that its stockholders approve all of the proposals to be presented at the special meeting. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Conduct between Signing and Closing &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Each of VCKA, Merger Sub and Scilex has agreed that from the date of the Merger Agreement until the Closing Date or, if earlier, the valid termination of the Merger Agreement in accordance with its terms, it will not initiate, encourage or engage in any negotiations with any party relating to an Alternative Transaction (as defined in the Merger Agreement), take any action intended to facilitate an Alternative Transaction or approve, recommend or enter into any agreement relating to an Alternative Transaction. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Conditions to Closing &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The consummation of the Merger is conditioned upon, among other things, (i)&#160;the absence of any applicable law or order that makes the transactions contemplated by the Merger Agreement illegal or otherwise prohibits consummation of such transactions; (ii)&#160;the Registration Statement shall have become effective under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;); (iii) approval by VCKA&#x2019;s shareholders of the Merger and related transactions; (iv)&#160;approval by Scilex&#x2019;s stockholders of the Merger and related transactions; and (v)&#160;all required filings under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and with any other governmental authority shall have been completed and cleared. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Solely with respect to the Parent Parties, the consummation of the Merger is conditioned upon, among other things: (i)&#160;Scilex having duly performed or complied with all of its obligations under the Merger Agreement in all material respects; (ii)&#160;the representations and warranties of Scilex being true and correct in all respects unless failure to be true and correct would not have or reasonably be expected to have a Company Material Adverse Effect (as defined in the Merger Agreement) on Scilex&#x2019;s ability to consummate the Merger and related transactions; (iii)&#160;no event having occurred that would result in a Company Material Adverse Effect; (iv)&#160;Scilex providing VCKA a certificate from the chief executive officer and chief financial officer of Scilex as to the accuracy of the foregoing conditions; (v)&#160;Scilex providing VCKA a certificate from the secretary which has attached true and complete copies of (a)&#160;Scilex&#x2019;s organizational documents, (b)&#160;Scilex&#x2019;s board resolutions approving the Merger Agreement and the transactions contemplated thereby, (c)&#160;Scilex&#x2019;s stockholder written consent approving the Merger Agreement and the transactions contemplated thereby and (d)&#160;certified certificate of good standing; (vi)&#160;Scilex shall have executed and delivered to VCKA each Additional Agreement to which it is a party; (vi)&#160;Sorrento shall have executed the Registration Rights Agreement (as defined below). &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Solely with respect to Scilex, the consummation of the Merger is conditioned upon, among other things: (i)&#160;the Parent Parties having duly performed or complied with all of their obligations under the Merger Agreement in all material respects; (ii)&#160;the representations and warranties of the Parent Parties being true and correct in all respects unless failure to be true and correct would not have or reasonably be expected to have a Parent Material Adverse Effect (as defined in the Merger Agreement) on the ability of VCKA or Merger Sub to consummate the Merger and related transactions; (iii)&#160;no event having occurred that would result in a Parent Material Adverse Effect; (iv)&#160;each of the Parent Parties providing Scilex a certificate from an authorized officer as to the accuracy of the foregoing conditions; (v)&#160;VCKA having been in material compliance with reporting requirements under the Securities Act and the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;); (vi)&#160;each of VCKA &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;the Parent Parties shall have executed and delivered to Scilex each Additional Agreement to which it is a party; (vii)&#160;the directors designated by Scilex shall have been appointed to the board of directors of VCKA in accordance with the terms of the Merger Agreement, effective as of the Closing Date; (viii)&#160;VCKA shall remain listed on Nasdaq and the additional listing application for the VCKA Common Stock issued in connection with the Merger shall have been approved by Nasdaq, and VCKA not having received any written notice from Nasdaq that it has failed, or would reasonably be expected to fail to meet the Nasdaq listing requirements as of the Closing Date for any reason, where such notice has not been subsequently withdrawn by Nasdaq or the underlying failure appropriately remedied or satisfied; (ix)&#160;after giving effect to the Merger, VCKA shall have at least $5,000,001 in net tangible assets (as determined in accordance with &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rule&#160;3a51-1(g)(1)&#160;of&lt;/div&gt; the Exchange Act); (x) the Domestication shall have been completed as provided in the Merger Agreement and a time-stamped copy of the certificate issued by the Secretary of State of the State of Delaware in relation thereto shall have been delivered to the Company; and (xi)&#160;the Investment Management Trust Agreement (as defined in the Merger Agreement) shall have been amended solely to the extent necessary to enable the intended effects of the Amended Underwriting Agreement (as defined in the Merger Agreement) without breach of, or other conflict with, the Investment Management Trust Agreement as so amended. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;Scilex&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, Scilex Pharmaceuticals, Inc. and Sorrento entered into a Contribution and Satisfaction of Indebtedness Agreement dated September&#160;&lt;/div&gt;12&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; (the &#x201c;Debt Exchange Agreement&#x201d;), in order to facilitate the satisfaction of the closing condition under the Merger Agreement that requires Vickers to have at least $&lt;/div&gt;5,000,001&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;in net tangible assets (as determined in accordance with Rule &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3a51-1(g)(1)&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; of the United States Securities and Exchange Act of &lt;/div&gt;1934)&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; (the &#x201c;Net Tangible Assets Condition&#x201d;).&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Termination &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Merger Agreement may be terminated as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;i.&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;By the mutual consent of VCKA and Scilex; &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;ii.&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;by VCKA, if any of the representations or warranties of Scilex set forth in the Merger Agreement shall not be true and correct, or if Scilex has failed to perform any covenant or agreement set forth in the Merger Agreement (including an obligation to consummate the Merger), in each case such that the conditions to closing would not be satisfied and the breach or breaches causing such representations or warranties not to be true and correct, or the failure to perform any covenant or agreement, as applicable, are not cured (or waived by VCKA) by the earlier of (i)&#160;the Outside Date (as defined below) or (ii) 30 days after written notice thereof is delivered to Scilex; provided, however that VCKA is not then in material breach of any representation, warranty, covenant, or obligation in the Merger Agreement, which breach has not been cured; &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;iii.&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;by Scilex, if any of the representations or warranties of VCKA or Merger Sub set forth in the Merger Agreement shall not be true and correct, or if VCKA or Merger Sub has failed to perform any covenant or agreement set forth in the Merger Agreement (including an obligation to consummate the Merger), in each case such that the conditions to closing would not be satisfied and the breach or breaches causing such representations or warranties not to be true and correct, or the failure to perform any covenant or agreement, as applicable, are not cured (or waived by Scilex) by the earlier of (i)&#160;the Outside Date or (ii) 30 days after written notice thereof is delivered to VCKA; provided, however that Scilex is not then in material breach of any representation, warranty, covenant, or obligation in the Merger Agreement, which breach has not been cured; &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;iv.&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;by either VCKA or Scilex &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 9%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;a.&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;on or after November&#160;11, 2022 (the &#x201c;Outside Date&#x201d;), if the Merger shall not have been consummated prior to the Outside Date; provided that if an Extension Amendment (as defined in the Merger Agreement) shall be in effect, the Outside Date shall be the Extension Date (as defined in the Merger Agreement); provided, however, that the right to terminate this Agreement under Section&#160;9.1(d)(i) of the Merger Agreement shall not be available to a party if the failure of the Merger to have been consummated before the Outside Date (or the Extension Date if applicable) was due to such party&#x2019;s breach of or failure to perform any of its covenants or agreements set forth in the Merger Agreement; or &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 9%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;b.&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;if any applicable law or order that makes the transactions contemplated by the Merger Agreement illegal or otherwise prohibits consummation of such transactions shall have become final and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-appealable;&lt;/div&gt; &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;v.&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;by Scilex if VCKA has not received approval from its stockholders of the Merger and related transactions at the Parent Special Meeting (as defined in the Merger Agreement), unless such meeting has been adjourned or postponed, in which case at the final adjournment or postponement thereof; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;vi.&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;by VCKA if the Scilex stockholder written consent approving the Merger and related transactions shall not have been obtained within five business days following the Registration Statement being declared effective by the Securities and Exchange Commission (the &#x201c;SEC&#x201d;), provided that upon Scilex receiving such stockholder approval, prior to the termination by VCKA of the Merger Agreement, VCKA will no longer have this right to so terminate; or &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;vii.&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;by VCKA, in the event that Scilex&#x2019;s audited financial statements for 2020 and 2021 have not been delivered to the Parent Parties on or before March&#160;31, 2022 and remain undelivered prior to the termination of the Merger Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Sponsor Support Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Concurrently with the execution of the Merger Agreement, VCKA, Scilex and certain stockholders of VCKA entered into a certain Sponsor Support Agreement dated March&#160;17, 2022 (the &#x201c;Sponsor Support Agreement&#x201d;) pursuant to which those certain VCKA shareholders who are parties thereto agreed to vote all shares of VCKA Ordinary Shares beneficially owned by them, including any additional shares of VCKA they acquire ownership of or the power to vote, in favor of the Merger and related transactions. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On September&#160;12, 2022, Vickers and Scilex entered into Amendment No.&#160;1 to the Original Support Agreement with the Vickers Shareholders (the &#x201c;Support Agreement Amendment&#x201d;). The Support Agreement Amendment amends the Original Support Agreement to, among other things, provide that if, as of immediately prior to the Closing, the holders of more than seventy-five percent (75%) of the aggregate amount of Parent Ordinary Shares issued and outstanding as of March&#160;17, 2022 shall have exercised redemption rights in conjunction with the shareholder vote on the Extension Amendment or the Parent Shareholder Approval Matters, then automatically and without any further action by any other Person, such Vickers Shareholder shall forfeit a number of Parent Warrants equal to forty percent (40%) of all Parent Warrants held by such Vickers Shareholder immediately prior to Closing, and all such Parent Warrants shall be cancelled and forfeited for no consideration, and shall cease to exist.&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Company Stockholder Support Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Concurrently with the execution of the Merger Agreement, VCKA, Scilex and Sorrento entered into a certain Company Stockholder Support Agreement dated March&#160;17, 2022 (the &#x201c;Company Stockholder Support Agreements&#x201d;), pursuant to which Sorrento agreed to vote all Scilex Common Stock beneficially owned by it, including any additional shares of Scilex it acquires ownership of or the power to vote, in favor of the Merger and related transactions. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;On September&#160;12, 2022, Vickers entered into a Stockholder Agreement with Sorrento (the &#x201c;Stockholder Agreement&#x201d;). Pursuant to the Stockholder Agreement, from and after the Effective Time, and for so long as Sorrento beneficially owns any shares of Vickers Series A Preferred Stock, par value $0.0001&#160;per share (&#x201c;New Scilex Series A Preferred Stock&#x201d;), among other things, (i)&#160;Sorrento shall have the right, but not the obligation, to designate each director to be nominated, elected or appointed to the Board of Directors of New Scilex (each, a &#x201c;Stockholder Designee&#x201d; and collectively, the &#x201c;Stockholder Designees&#x201d;), regardless of (i)&#160;whether such Stockholder Designee is to be elected to the Board of Directors of New Scilex (&#x201c;New Scilex Board&#x201d;) at a meeting of stockholders called for the purpose of electing directors (or by consent in lieu of meeting) or appointed by the New Scilex Board in order to fill any vacancy created by the departure of any director or increase in the authorized number of members of the New Scilex Board, or (ii)&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;the size of the New Scilex Board and New Scilex will be required to take all actions reasonably necessary, and not otherwise prohibited by applicable law, to cause each Stockholder Designee to be so nominated, elected or appointed to the New Scilex Board as more fully described in the Stockholder Agreement. Sorrento shall also have the right to designate a replacement director for any Stockholder Designee that has been removed from the New Scilex Board and the right to appoint a representative of Sorrento to attend all meetings of the committees of the New Scilex Board. The Stockholder Agreement also provides that New Scilex will be prohibited from taking certain actions without the consent of Sorrento. Such actions include, among other things, amendments to the certificate of designations designating the New Scilex Series A Preferred Stock, increases or decreases in the size of the New Scilex Board, the incurrence of certain amounts of indebtedness and the payment of dividends on New Scilex Common Stock.&#160;&lt;/div&gt; &lt;/div&gt;&lt;br/&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Underwriting Agreement Amendment &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On March&#160;17, 2022, VCKA and Maxim Group, LLC, the representative of the underwriters for the VCKA initial public offering (&#x201c;Maxim&#x201d;) entered into an amendment (the &#x201c;UWA Amendment&#x201d;) of the underwriting agreement between VCKA and Maxim dated January&#160;6, 2021. The UWA Amendment provides for a potential deferral of the Deferred Underwriting Commission&#160;(as defined in the UWA Amendment) as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;If in connection with the consummation of a business combination, after redemptions of Ordinary Shares by VCKA&#x2019;s shareholders, the balance in the trust account is $25,000,000&#160;or less, then the Deferred Underwriting Commission will be payable as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;(A)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;50% of the Deferred Underwriting Commission will be payable to Maxim directly from the trust account; and &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;(B)&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;the remaining&#160;50% of the Deferred Underwriting Commission will be payable to Maxim in the form of a Promissory Note on or before the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-year&lt;/div&gt; anniversary of the effective date of a Business Combination. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="clear:both;max-height:0pt;"/&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Maxim has also agreed to enter into any such amendment to the Investment Management Trust Agreement (as defined in the Merger Agreement) as may be required to effectuate the intent of the UWA Amendment. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Agreements to be Executed at Closing &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Merger Agreement contemplates that, at or prior to the Closing, VCKA and Sorrento will enter into an Amended and Restated Registration Rights Agreement (the &#x201c;Registration Rights Agreement&#x201d;), whereby, subject to certain customary exceptions, the parties will agree, among other things, not to transfer any shares of VCKA Common Stock or any security convertible into or exercisable or exchanged for VCKA Common Stock beneficially owned or owned of record by such holder until the date that is the earlier of (i)&#160;one hundred eighty (180)&#160;days from the date of the Registration Rights Agreement or (ii)&#160;the date on which the Company completes a liquidation, merger, stock exchange, reorganization or other similar transaction that results in all of the Company&#x2019;s stockholders having the right to exchange their shares of VCKA Common Stock for cash, securities or other property. The Registration Rights Agreement will govern the registration of certain shares of VCKA Common Stock for resale and be effective as of the Closing. &lt;/div&gt;&lt;/div&gt; </us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:OtherCommitmentsDescription contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">The underwriters are entitled to a deferred fee of (i) 3.5% of the gross proceeds of the initial 12,000,000 Units sold in the Initial Public Offering, or $4,200,000, and (ii) 5.5% of the gross proceeds from the Units sold pursuant to the over-allotment option, or $990,000.</us-gaap:OtherCommitmentsDescription>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn09_30_2022_MinimumMembersrtRangeAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn09_30_2022_MaximumMembersrtRangeAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">45000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredUnitsAuthorized
      contextRef="PAsOn09_30_2022_MinimumMembersrtRangeAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">750000000</us-gaap:PreferredUnitsAuthorized>
    <us-gaap:PreferredUnitsAuthorized
      contextRef="PAsOn09_30_2022_MaximumMembersrtRangeAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">785000000</us-gaap:PreferredUnitsAuthorized>
    <sclx:MergerConsiderationDescription contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">The total consideration to be paid to the holders of Scilex common stock at Closing (the &#x201c;Merger Consideration&#x201d;) by VCKA twill be an amount equal to the quotient of (a) the sum of (i) $1,500,000,000 minus (ii) the aggregate amount of Scilex long term debt excluding intercompany debt owed to Sorrento existing as of immediately prior to the date of the closing of the transaction (the &#x201c;Closing Date&#x201d;); divided by (b) $10.00, and will be payable in shares of common stock, par value $0.0001 per shares, of VCKA upon its domestication in Delaware (&#x201c;VCKA Common Stock&#x201d;).</sclx:MergerConsiderationDescription>
    <us-gaap:SharesIssued
      contextRef="PAsOn09_30_2022_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">1</us-gaap:SharesIssued>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="PAsOn09_30_2022_ScilexCommonStockMemberusgaapRelatedPartyTransactionAxis_SeriesAPreferredStockMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="4"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:SharesIssuedPricePerShare>
    <sclx:CommonStockAggregateValue
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="-8"
      unitRef="Unit_USD">1500000000</sclx:CommonStockAggregateValue>
    <us-gaap:BusinessCombinationReasonForBusinessCombination contextRef="P01_01_2022To09_30_2022_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMemberusgaapBusinessAcquisitionAxis_VickersVantageMemberdeiLegalEntityAxis">The maximum number of shares of New Scilex Series A Preferred Stock and New Scilex Common Stock to be issued to the holders of Scilex Preferred Stock at the Closing shall not exceed 31,000,000 and 3,100,000, respectively, such newly issued shares being collectively referred to herein as the &#x201c;Preferred Consideration&#x201d;. It is anticipated that upon completion of the Business Combination, if none of the 9,726,395 VCKA Ordinary Shares are redeemed, VCKA&#x2019;s public shareholders would retain an ownership interest of approximately 5.6% in New Scilex, the Sponsors, officers, directors and other holders of founder shares will retain an ownership interest of approximately 2.2% of New Scilex, and the Scilex stockholders will own approximately (i) 77.2% of New Scilex in the form of New Scilex Common Stock and (ii) 15.0% of New Scilex in the form of New Scilex Series A Preferred Stock.</us-gaap:BusinessCombinationReasonForBusinessCombination>
    <sclx:NetTangibleAssets
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">5000001</sclx:NetTangibleAssets>
    <sclx:AggregatePercentage
      contextRef="PAsOn03_17_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_pure">0.75</sclx:AggregatePercentage>
    <sclx:WarrantsPercentage
      contextRef="PAsOn03_17_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_pure">0.40</sclx:WarrantsPercentage>
    <us-gaap:PreferredStockNoParValue
      contextRef="PAsOn09_12_2022_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="4"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockNoParValue>
    <sclx:BalanceInTheTrustAccount
      contextRef="PAsOn03_17_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">25000000</sclx:BalanceInTheTrustAccount>
    <sclx:DeferredUnderwritingCommission
      contextRef="P03_17_2022To03_17_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_pure">0.50</sclx:DeferredUnderwritingCommission>
    <sclx:DeferredUnderwritingCommissionPayable
      contextRef="P03_17_2022To03_17_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_pure">0.50</sclx:DeferredUnderwritingCommissionPayable>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 7. SHAREHOLDERS&#x2019; DEFICIT &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Preference Shares&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#x2014;&lt;/div&gt;&lt;/div&gt;&#160;The Company is authorized to issue&#160;1,000,000&#160;preference shares with a par value of $0.0001&#160;per share, with such designations, voting and other rights and preferences as may be determined from time to time by the Company&#x2019;s board of directors. At September&#160;30, 2022 and December&#160;31, 2021, there were&#160;no&#160;preference shares issued or outstanding. &lt;br/&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Ordinary Shares&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#x2014; The Company is authorized to issue&#160;&lt;/div&gt;200,000,000&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;ordinary shares with a par value of $&lt;/div&gt;0.0001&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;per share. Holders of ordinary shares are entitled to one vote for each share. At September&#160;30, 2022, there were&#160;&lt;/div&gt;3,450,000&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;shares of ordinary shares issued and outstanding, excluding&#160;&lt;/div&gt;9,726,395&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;ordinary shares subject to possible redemption which are presented as temporary equity. At December&#160;31, 2021, there were&#160;&lt;/div&gt;3,450,000&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;shares of ordinary shares issued and outstanding, excluding&#160;&lt;/div&gt;13,800,000&#160;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ordinary shares subject to possible redemption which are presented as temporary equity.&lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="4"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="4"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="4"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="4"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">3450000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">3450000</us-gaap:CommonStockSharesIssued>
    <sclx:OrdinarySharesSubjectToPossibleRedemption
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">9726395</sclx:OrdinarySharesSubjectToPossibleRedemption>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">3450000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">3450000</us-gaap:CommonStockSharesIssued>
    <sclx:OrdinarySharesSubjectToPossibleRedemption
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">13800000</sclx:OrdinarySharesSubjectToPossibleRedemption>
    <sclx:WarrantsTextBlock contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 8. WARRANTS &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of September&#160;30, 2022 and December&#160;31, 2021, there were&#160;6,900,000&#160;Public Warrants outstanding. Public Warrants may only be exercised for a whole number of shares. No fractional shares will be issued upon exercise of the Public Warrants. The Public Warrants will become exercisable on the later of (a)&#160;the completion of a Business Combination and (b) 12 months from the closing of the Initial Public Offering. The Public Warrants will expire five years from the completion of a Business Combination or earlier upon redemption or liquidation. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No Public Warrants will be exercisable for cash unless the Company has an effective and current registration statement covering the issuance of the ordinary shares issuable upon exercise of the warrants and a current prospectus relating to such ordinary shares. Notwithstanding the foregoing, if a registration statement covering the issuance of the ordinary shares issuable upon exercise of the Public Warrants is not effective within 90 days from the closing of a Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company shall have failed to maintain an effective registration statement, exercise warrants on a cashless basis pursuant to an available exemption from registration under the Securities Act. If an exemption from registration is not available, holders will not be able to exercise their warrants on a cashless basis. The Public Warrants will expire five years after the completion of a Business Combination or earlier upon redemption or liquidation. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company may redeem the Public Warrants: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in whole and not in part; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2022;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;at a price of $0.01 per warrant; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2022;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;at any time while the warrants become exercisable; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2022;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;upon not less than 30 days&#x2019; prior written notice of redemption to each warrant holder; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2022;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;if, and only if, the reported last sale price of the Company&#x2019;s ordinary shares equals or exceeds $18.00&#160;per share (subject to adjustment) for any 20 trading days within a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;30-trading&lt;/div&gt; day period commencing after the warrants become exercisable and ending on the third trading business day prior to the notice of redemption to the warrant holders; and &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2022;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;if, and only if, there is a current registration statement in effect with respect to the issuance of the ordinary shares underlying such warrants at the time of redemption and for the entire &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;30-day&lt;/div&gt; trading period referred to above and continuing each day thereafter until the date of redemption. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;If the Company calls the Public Warrants for redemption, management will have the option to require all holders that wish to exercise the Public Warrants to do so on a &#x201c;cashless basis,&#x201d; as described in the warrant agreement. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The exercise price and number of ordinary shares issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a share dividend, extraordinary dividend or recapitalization, reorganization, merger or consolidation. However, the warrants will not be adjusted for issuance of ordinary shares at a price below its exercise price. The Company has agreed to use its best efforts to have declared effective a prospectus relating to the ordinary shares issuable upon exercise of the warrants and keep such prospectus current until the expiration of the warrants. However, if the Company does not maintain a current prospectus relating to the ordinary shares issuable upon exercise of the warrants, holders will be unable to exercise their warrants for cash and the Company will not be required to net cash settle or cash settle the warrant exercise. There will be no redemption rights upon the completion of a Business Combination with respect to the Company&#x2019;s warrants. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company&#x2019;s assets held outside of the Trust Account with the respect to such warrants. Accordingly, the warrants may expire worthless. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In addition, if (x)&#160;the Company issues additional ordinary shares or equity-linked securities for capital raising purposes in connection with the closing of a Business Combination at an issue price or effective issue price of less than $&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;9.20 &lt;/div&gt;per ordinary share (with such issue price or effective issue price to be determined in good faith by the Company&#x2019;s board of directors and, in the case of any such issuance to the Sponsors or its affiliates, without taking into account any Founder Shares held by the Sponsors or such affiliates, as applicable, prior to such issuance) (the &#x201c;Newly Issued Price&#x201d;), (y) the aggregate gross proceeds from such issuances represent more than &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;60&lt;/div&gt;% of the total equity proceeds, and interest thereon, available for the funding of a Business Combination on the date of the consummation of a Business Combination (net of redemptions), and (z)&#160;the volume weighted average trading price of its ordinary shares during the &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;20 &lt;/div&gt;trading day period starting on the trading day prior to the day on which the Company consummates its Business Combination (such price, the &#x201c;Market Value&#x201d;) is below $&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;9.20 &lt;/div&gt;per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;115&lt;/div&gt;% of the higher of the Market Value and the Newly Issued Price, the $&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;18.00 &lt;/div&gt;per share redemption trigger price will be adjusted (to the nearest cent) to be equal to &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;180&lt;/div&gt;% of the higher of the Market Value and the Newly Issued Price. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;At September&#160;30, 2022 and December&#160;31, 2021, there were&#160;6,840,000&#160;Private Placement Warrants outstanding. The Private Placement Warrants are identical to the Public Warrants underlying the Units sold in the Initial Public Offering, except that the Private Placement Warrants will be exercisable for cash (even if a registration&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; statement covering the issuance of the ordinary shares issuable upon exercise of such warrants is not effective) or on a cashless basis, at the holder&#x2019;s option and will not be redeemable by the Company, in each case so long as they are held by the initial purchasers or their affiliates.</sclx:WarrantsTextBlock>
    <sclx:WarrantsOutstandingShares
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis_WarrantMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">6900000</sclx:WarrantsOutstandingShares>
    <sclx:WarrantsOutstandingShares
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis_WarrantMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">6900000</sclx:WarrantsOutstandingShares>
    <sclx:PublicWarrantsRedemptionDescription contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">The Company may redeem the Public Warrants:  &#160;


&#160;
&#x2022;
&#160;
 in whole and not in part;      &#160;


&#160;
&#x2022;
&#160;
 at a price of $0.01 per warrant;      &#160;


&#160;
&#x2022;
&#160;
 at any time while the warrants become exercisable;      &#160;


&#160;
&#x2022;
&#160;
 upon not less than 30 days&#x2019; prior written notice of redemption to each warrant holder;      &#160;


&#160;
&#x2022;
&#160;
 if, and only if, the reported last sale price of the Company&#x2019;s ordinary shares equals or exceeds $18.00&#160;per share (subject to adjustment) for any 20 trading days within a 30-trading day period commencing after the warrants become exercisable and ending on the third trading business day prior to the notice of redemption to the warrant holders; and      &#160;


&#160;
&#x2022;
&#160;
 if, and only if, there is a current registration statement in effect with respect to the issuance of the ordinary shares underlying such warrants at the time of redemption and for the entire 30-day trading period referred to above and continuing each day thereafter until the date of redemption.     </sclx:PublicWarrantsRedemptionDescription>
    <sclx:CapitalRaisingDescription contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">In addition, if (x)&#160;the Company issues additional ordinary shares or equity-linked securities for capital raising purposes in connection with the closing of a Business Combination at an issue price or effective issue price of less than $9.20 per ordinary share (with such issue price or effective issue price to be determined in good faith by the Company&#x2019;s board of directors and, in the case of any such issuance to the Sponsors or its affiliates, without taking into account any Founder Shares held by the Sponsors or such affiliates, as applicable, prior to such issuance) (the &#x201c;Newly Issued Price&#x201d;), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of a Business Combination on the date of the consummation of a Business Combination (net of redemptions), and (z)&#160;the volume weighted average trading price of its ordinary shares during the 20 trading day period starting on the trading day prior to the day on which the Company consummates its Business Combination (such price, the &#x201c;Market Value&#x201d;) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, the $18.00 per share redemption trigger price will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price. </sclx:CapitalRaisingDescription>
    <sclx:WarrantsOutstandingShares
      contextRef="PAsOn12_31_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">6840000</sclx:WarrantsOutstandingShares>
    <sclx:WarrantsOutstandingShares
      contextRef="PAsOn09_30_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">6840000</sclx:WarrantsOutstandingShares>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 9. FAIR VALUE MEASUREMENTS &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value of the Company&#x2019;s financial assets and liabilities reflects management&#x2019;s estimate of amounts that the Company would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 10%; vertical-align: top;;text-align:left;"&gt;Level&#160;1:&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 10%; vertical-align: top;;text-align:left;"&gt;Level&#160;2:&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Observable inputs other than Level&#160;1 inputs. Examples of Level&#160;2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 10%; vertical-align: top;;text-align:left;"&gt;Level&#160;3:&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability. &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;At September&#160;30, 2022 and December&#160;31, 2021, assets held in the Trust Account were comprised of $101,293,086&#160;and $139,410,739, respectively, in money market funds which are invested primarily in U.S. Treasury Securities.&#160;Through September&#160;30, 2022, the Company did not withdraw any interest earned on the Trust Account. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents information about the Company&#x2019;s assets and liabilities that are measured at fair value on a recurring basis at September&#160;30, 2022 and December&#160;31, 2021 and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 58%; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Description&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investments held in Trust Account &lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&lt;/div&gt; U.S. Treasury Securities Money Market Fund&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;101,293,086&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;139,410,739&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liabilities:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Warrant Liability &lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&lt;/div&gt;&#160;Private Placement Warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,162,800&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,351,600&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Conversion Option Liability (see Note 5)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,892&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Private Placement Warrants were accounted for as liabilities in accordance with ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;815-40&lt;/div&gt; and are presented within warrant liabilities on our accompanying September&#160;30, 2022 unaudited condensed consolidated balance sheets. The warrant liabilities are measured at fair value at inception and on a recurring basis, with changes in fair value presented within change in fair value of warrant liabilities in the unaudited condensed consolidated statements of operations. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Warrant Liability Measurement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company established the initial fair value for the private warrants on January&#160;11, 2021, the date of the Company&#x2019;s Initial Public Offering, using a Monte Carlo simulation and subsequently implemented the Black-Scholes Option Pricing Model that was modified to capture the redemption features of the public warrants. The underlying assumptions in the Black-Scholes option pricing model include the underlying share price, risk-free interest rate, estimated volatility and the expected term. The primary unobservable inputs utilized in determining the fair value of the private warrants are the expected volatility of the Company&#x2019;s ordinary shares and the Company&#x2019;s ordinary share price. The expected volatility of the ordinary shares was determined based on implied volatilities of public warrants issued by selected guideline companies and was estimated to be 10% before the expected business combination and 20% after the expected business combination. The ordinary share price was determined based on an iterative procedure that matched the estimated value of the ordinary shares and fractional warrant price to equate to the observed price of the outstanding units. The risk-free interest rate is based on the U.S. Treasury yield curve in effect on the date of valuation equal to the remaining expected life of the private warrants. The dividend yield percentage is zero because the Company does not currently pay dividends, nor does it intend to do so during the expected term of the warrants. The expected life of the warrants is assumed to be &lt;/div&gt;equivalent to their remaining contractual term. Inputs are &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-evaluated&lt;/div&gt; each quarterly reporting period to estimate the fair market value of the private placement warrants as of the reporting &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;period&lt;/div&gt;. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;There were no transfers between Levels 1, 2 or 3 during the three and nine months ended September&#160;30, 2022 and 2021. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table provides quantitative information regarding Level&#160;3 fair value measurements: &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 65%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 13%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="width: 12%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.33&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.04&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Strike price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11.50&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11.50&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Term (in years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5.28&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Volatility&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8.3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk-free rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4.03&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.28&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dividend yield&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value of warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.17&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.49&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents the changes in the fair value of warrant liabilities: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 80%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 7%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Private&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Placement&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value as of January&#160;1, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Initial measurement on January&#160;11, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,729,200&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in valuation inputs or other assumptions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4,104,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value of as of March&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,625,200&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in valuation inputs or other assumptions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;68,400&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value of as of June&#160;30, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,693,600&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in valuation inputs or other assumptions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,162,800&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value of as of September&#160;30, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,856,400&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in valuation inputs or other assumptions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,504,800&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value of as of December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,351,600&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in valuation inputs or other assumptions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;410,400&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value as of March&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,762,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in valuation inputs or other assumptions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,530,800&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value as of June&#160;30, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,231,200&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in valuation inputs or other assumptions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(68,400&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value as of September&#160;30, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,162,800&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Conversion Option Liability Measurement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company assessed the provisions of the Convertible Promissory Notes under ASC &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;470-20.&lt;/div&gt; The derivative component of the obligation is initially valued and classified as a derivative liability. The conversion option was valued using the compound option pricing model, which is considered to be a Level&#160;3 fair value measurement (See Note 6). &lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 65%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 12%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="width: 11%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;br/&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Underlying warrant value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.0000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.0103&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercise price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.75&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.75&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Holding period&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.50&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.28&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk-free rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4.03&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.28&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Volatility&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5.3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8.3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dividend yield&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents the change in the fair value of conversion option liability: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 83%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 13%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Conversion&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Option&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Liability&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value as of January&#160;1, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Initial measurement on December&#160;20, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;18,727&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in valuation inputs or other assumptions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(11,835&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value of as of December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,892&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Initial measurement on January&#160;10, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Initial measurement on January&#160;27, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in valuation inputs or other assumptions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;69,896&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value as of March&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;76,788&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in valuation inputs or other assumptions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(76,788&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value as of June&#160;30, 2022 and September&#160;30, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:AssetsHeldInTrustCurrent
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">101293086</us-gaap:AssetsHeldInTrustCurrent>
    <us-gaap:AssetsHeldInTrustCurrent
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">139410739</us-gaap:AssetsHeldInTrustCurrent>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 58%; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Description&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investments held in Trust Account &lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&lt;/div&gt; U.S. Treasury Securities Money Market Fund&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;101,293,086&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;139,410,739&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liabilities:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Warrant Liability &lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&lt;/div&gt;&#160;Private Placement Warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,162,800&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,351,600&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Conversion Option Liability (see Note 5)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,892&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:InterestIncomeSecuritiesUSTreasury
      contextRef="P01_01_2022To09_30_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">101293086</us-gaap:InterestIncomeSecuritiesUSTreasury>
    <us-gaap:InterestIncomeSecuritiesUSTreasury
      contextRef="P01_01_2021To12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">139410739</us-gaap:InterestIncomeSecuritiesUSTreasury>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="P01_01_2022To09_30_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1162800</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="P01_01_2021To12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">3351600</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn09_30_2022_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">6892</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:FairValueMeasurementsHighestAndBestUseDescription contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">The Company established the initial fair value for the private warrants on January&#160;11, 2021, the date of the Company&#x2019;s Initial Public Offering, using a Monte Carlo simulation and subsequently implemented the Black-Scholes Option Pricing Model that was modified to capture the redemption features of the public warrants. The underlying assumptions in the Black-Scholes option pricing model include the underlying share price, risk-free interest rate, estimated volatility and the expected term. The primary unobservable inputs utilized in determining the fair value of the private warrants are the expected volatility of the Company&#x2019;s ordinary shares and the Company&#x2019;s ordinary share price. The expected volatility of the ordinary shares was determined based on implied volatilities of public warrants issued by selected guideline companies and was estimated to be 10% before the expected business combination and 20% after the expected business combination. The ordinary share price was determined based on an iterative procedure that matched the estimated value of the ordinary shares and fractional warrant price to equate to the observed price of the outstanding units. The risk-free interest rate is based on the U.S. Treasury yield curve in effect on the date of valuation equal to the remaining expected life of the private warrants. The dividend yield percentage is zero because the Company does not currently pay dividends, nor does it intend to do so during the expected term of the warrants. The expected life of the warrants is assumed to be equivalent to their remaining contractual term. Inputs are re-evaluated each quarterly reporting period to estimate the fair market value of the private placement warrants as of the reporting period. </us-gaap:FairValueMeasurementsHighestAndBestUseDescription>
    <us-gaap:FairValueConcentrationOfRiskTextBlock contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 65%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 13%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="width: 12%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.33&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.04&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Strike price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11.50&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11.50&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Term (in years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5.28&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Volatility&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8.3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk-free rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4.03&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.28&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dividend yield&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value of warrants&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.17&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.49&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueConcentrationOfRiskTextBlock>
    <us-gaap:SharePrice
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10.33</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10.04</us-gaap:SharePrice>
    <sclx:FairValueMeasurementStrikePrice
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">11.5</sclx:FairValueMeasurementStrikePrice>
    <sclx:FairValueMeasurementStrikePrice
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">11.5</sclx:FairValueMeasurementStrikePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis">P5Y3M10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="3"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="3"
      unitRef="Unit_pure">0.083</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <sclx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="4"
      unitRef="Unit_pure">0.0403</sclx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1>
    <sclx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="4"
      unitRef="Unit_pure">0.0128</sclx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1>
    <sclx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="3"
      unitRef="Unit_pure">0</sclx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1>
    <sclx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="3"
      unitRef="Unit_pure">0</sclx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1>
    <sclx:FairValueOfWarrantsinDollars
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.17</sclx:FairValueOfWarrantsinDollars>
    <sclx:FairValueOfWarrantsinDollars
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.49</sclx:FairValueOfWarrantsinDollars>
    <us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 80%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 7%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Private&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Placement&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value as of January&#160;1, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Initial measurement on January&#160;11, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,729,200&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in valuation inputs or other assumptions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4,104,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value of as of March&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,625,200&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in valuation inputs or other assumptions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;68,400&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value of as of June&#160;30, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,693,600&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in valuation inputs or other assumptions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,162,800&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value of as of September&#160;30, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,856,400&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in valuation inputs or other assumptions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,504,800&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value of as of December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,351,600&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in valuation inputs or other assumptions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;410,400&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value as of March&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,762,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in valuation inputs or other assumptions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,530,800&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value as of June&#160;30, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,231,200&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in valuation inputs or other assumptions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(68,400&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value as of September&#160;30, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,162,800&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 83%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 13%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Conversion&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Option&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Liability&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value as of January&#160;1, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Initial measurement on December&#160;20, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;18,727&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in valuation inputs or other assumptions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(11,835&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value of as of December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,892&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Initial measurement on January&#160;10, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Initial measurement on January&#160;27, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in valuation inputs or other assumptions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;69,896&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value as of March&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;76,788&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in valuation inputs or other assumptions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(76,788&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value as of June&#160;30, 2022 and September&#160;30, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn12_31_2020_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <sclx:InitialMeasurementOne
      contextRef="P01_01_2021To03_31_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">7729200</sclx:InitialMeasurementOne>
    <sclx:ChangeInValuationInputsOrOtherAssumptions
      contextRef="P01_01_2021To03_31_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-4104000</sclx:ChangeInValuationInputsOrOtherAssumptions>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn03_31_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">3625200</us-gaap:DerivativeLiabilities>
    <sclx:ChangeInValuationInputsOrOtherAssumptions
      contextRef="P04_01_2021To06_30_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">68400</sclx:ChangeInValuationInputsOrOtherAssumptions>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn06_30_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">3693600</us-gaap:DerivativeLiabilities>
    <sclx:ChangeInValuationInputsOrOtherAssumptions
      contextRef="P07_01_2021To09_30_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1162800</sclx:ChangeInValuationInputsOrOtherAssumptions>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn09_30_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">4856400</us-gaap:DerivativeLiabilities>
    <sclx:ChangeInValuationInputsOrOtherAssumptions
      contextRef="P10_01_2021To12_31_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-1504800</sclx:ChangeInValuationInputsOrOtherAssumptions>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn12_31_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">3351600</us-gaap:DerivativeLiabilities>
    <sclx:ChangeInValuationInputsOrOtherAssumptions
      contextRef="P01_01_2022To03_31_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">410400</sclx:ChangeInValuationInputsOrOtherAssumptions>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn03_31_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">3762000</us-gaap:DerivativeLiabilities>
    <sclx:ChangeInValuationInputsOrOtherAssumptions
      contextRef="P04_01_2022To06_30_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-2530800</sclx:ChangeInValuationInputsOrOtherAssumptions>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn06_30_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1231200</us-gaap:DerivativeLiabilities>
    <sclx:ChangeInValuationInputsOrOtherAssumptions
      contextRef="P07_01_2022To09_30_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-68400</sclx:ChangeInValuationInputsOrOtherAssumptions>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn09_30_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1162800</us-gaap:DerivativeLiabilities>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 65%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 12%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="width: 11%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;September&#160;30,&lt;br/&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Underlying warrant value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.0000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.0103&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercise price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.75&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.75&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Holding period&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.50&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.28&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk-free rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4.03&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.28&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Volatility&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5.3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8.3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dividend yield&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <sclx:UnderlyingWarrantValue
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="4"
      unitRef="Unit_USD_per_Share">0</sclx:UnderlyingWarrantValue>
    <sclx:UnderlyingWarrantValue
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="4"
      unitRef="Unit_USD_per_Share">0.0103</sclx:UnderlyingWarrantValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <sclx:HoldingPeriod
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.5</sclx:HoldingPeriod>
    <sclx:HoldingPeriod
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.28</sclx:HoldingPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="4"
      unitRef="Unit_pure">0.0403</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="4"
      unitRef="Unit_pure">0.0128</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="3"
      unitRef="Unit_pure">0.053</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="3"
      unitRef="Unit_pure">0.083</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis"
      decimals="3"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis"
      decimals="3"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn12_31_2020_ConversionOptionLiabilityMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <sclx:InitialMeasurementOne
      contextRef="P01_01_2021To12_31_2021_ConversionOptionLiabilityMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">18727</sclx:InitialMeasurementOne>
    <sclx:ChangeInValuationInputsOrOtherAssumptions
      contextRef="P01_01_2021To12_31_2021_ConversionOptionLiabilityMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-11835</sclx:ChangeInValuationInputsOrOtherAssumptions>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn12_31_2021_ConversionOptionLiabilityMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">6892</us-gaap:DerivativeLiabilities>
    <sclx:InitialMeasurementOne
      contextRef="P01_01_2022To03_31_2022_ConversionOptionLiabilityMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <sclx:InitialMeasurementOne
      contextRef="P01_01_2022To03_31_2022_ConversionOptionLiabilityMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <sclx:ChangeInValuationInputsOrOtherAssumptions
      contextRef="P01_01_2022To03_31_2022_ConversionOptionLiabilityMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">69896</sclx:ChangeInValuationInputsOrOtherAssumptions>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn03_31_2022_ConversionOptionLiabilityMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">76788</us-gaap:DerivativeLiabilities>
    <sclx:ChangeInValuationInputsOrOtherAssumptions
      contextRef="P04_01_2022To09_30_2022_ConversionOptionLiabilityMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-76788</sclx:ChangeInValuationInputsOrOtherAssumptions>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn09_30_2022_ConversionOptionLiabilityMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:SubsequentEventsTextBlock contextRef="P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 10. SUBSEQUENT EVENTS &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the unaudited condensed consolidated financial statements were issued. Based upon this review, other than as described below and elsewhere in these unaudited condensed consolidated financial statements, the Company did not identify any subsequent events that would have required adjustment or disclosure in the unaudited condensed consolidated financial statements. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;On October&#160;10, 2022, the Company extended the period of time to consummate a Business Combination to November&#160;11, 2022. The Sponsors deposited $323,889&#160;into the Trust Account made in the form of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-interest-bearing&lt;/div&gt; loans. If the Company completes an initial business combination, the Company will, at the option of the Sponsors, repay the amounts evidenced by simple promissory notes. If a Business Combination is not consummated, the simple promissory notes will not be repaid by the Company and all amounts owed thereunder by the Company will be forgiven except to the extent that the Company has funds available to it outside of its Trust Account. &lt;br/&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;On&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;October&#160;17, 2022, the Company and its Sponsors entered into a Debt Contribution Agreement (the &#x201c;Debt Contribution Agreement&#x201d;). The Debt Contribution Agreement relates to certain amounts owed by the Company to the Sponsors for payment of certain outstanding loans (the &#x201c;Company Obligations&#x201d;) as set forth in the Debt Contribution Agreement. Pursuant to the Debt &lt;/div&gt;Contribu&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;tion Agreement, the Sponsors have agreed to contribute the Company Obligations to the Company in&lt;/div&gt; exc&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;hange for the issuance of that number of shares of shares of common stock, par value $&lt;/div&gt;0.0001&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;per share, of the Company, determined by dividing the Company Obligations by $&lt;/div&gt;10.00&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;(the &#x201c;Contribution Shares&#x201d;) to the Sponsors immediately prior to the consummation of the Business Combination but after the Domestication (as defined in the Merger Agreement). Upon the occurrence of the debt contribution and issuance of the Contribution Shares to the Sponsors pursuant to the Debt Contribution Agreement, the Company Obligation owed to the Sponsors shall be extinguished in its entirety and shall be of no further force or effect and shall be deemed satisfied in full.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In connection with the Debt Exchange Agreement, on October&#160;17, 2022, Sorrento and Scilex entered into a letter agreement (the &#x201c;Funding Commitment Letter&#x201d;) pursuant to which, upon the written request of the Company (which request the Company shall make to the extent necessary to satisfy Net Tangible Asset Condition), Sorrento shall fund one or more loans to the Company in the amount set forth in such written request. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On October&#160;17, 2022, as consideration for Sorrento agreeing to provide for funding under the Funding Commitment Letter, Vickers, the Sponsors, Sorrento and Maxim Group LLC, entered into the Warrant Transfer Agreement (the &#x201c;Warrant Transfer Agreement&#x201d;) for the transfer of certain private placement warrants held by the Sponsors to Sorrento in the event redemptions exceed certain thresholds specified in the Warrant Transfer Agreement. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;On October&#160;17, 2022, the Company entered into a Letter Agreement with Sorrento and the Sponsors (the &#x201c;Letter Agreement&#x201d;) to provide that certain shares held by the Sponsors will be released from the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;lock-up&lt;/div&gt; restrictions only in an amount necessary to help satisfy the minimum public float requirement under the Listing Standards of the Nasdaq Stock Market LLC, which amount shall not exceed&#160;1,500,000&#160;shares. &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On October&#160;28, 2022, the proxy statement/prospectus was declared effective and the Company commenced with mailing the proxy materials to the Company&#x2019;s shareholders ahead of the extraordinary general meeting of the Company&#x2019;s shareholders on November&#160;9, 2022. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;To the Board of Directors and Stockholders of Scilex Holding Company &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Opinion on the Financial Statements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;We have audited the accompanying consolidated balance sheets of Scilex Holding Company (the Company) as of December&#160;31, 2021 and 2020, the related consolidated statements of operations, stockholders&#x2019; deficit and cash flows for each of the two years in the period ended December&#160;31, 2021, and the related notes (collectively referred to as the &#x201c;consolidated financial statements&#x201d;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December&#160;31, 2021 and 2020, and the results of its operations and its cash flows for the years then ended in conformity with U.S. generally accepted accounting principles. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s Ability to Continue as a Going Concern &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company has suffered recurring losses from operations, has a working capital deficiency, and has stated that substantial doubt exists about the Company&#x2019;s ability to continue as a going concern. Management&#x2019;s evaluation of the events and conditions and management&#x2019;s plans regarding these matters are also described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basis for Opinion &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;These financial statements are the responsibility of the Company&#x2019;s management. Our responsibility is to express an opinion on the Company&#x2019;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;We conducted our audits in accordance with the standards of the PCAOB and in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;/s/ Ernst&#160;&amp;amp; Young LLP &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;We have served as the Company&#x2019;s auditor since 2020. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;San Diego, California &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;May&#160;13, 2022 &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;To the stockholders and the Board of Directors of &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Scilex Holding Company &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Opinion on the Financial Statements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;We have audited the accompanying consolidated statements of operations, stockholders&#x2019; equity, and cash flows of Scilex Holding Company and subsidiaries (the &#x201c;Company&#x201d;) for the year ended December&#160;31, 2019, and the related notes (collectively referred to as the &#x201c;financial statements&#x201d;). In our opinion, the financial statements present fairly, in all material respects, the results of the Company&#x2019;s operations and cash flows for the year ended December&#160;31, 2019, in conformity with accounting principles generally accepted in the United States of America. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Going Concern &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company has suffered negative working capital, recurring losses from operations, recurring negative cash flows from operations and cumulative net losses that raise substantial doubt about its ability to continue as a going concern. Management&#x2019;s plans in regard to these matters are also described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basis for Opinion &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;These financial statements are the responsibility of the Company&#x2019;s management. Our responsibility is to express an opinion on the Company&#x2019;s financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;We conducted our audit in accordance with the standards of the PCAOB and in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#x2019;s internal control over financial reporting. Accordingly, we express no such opinion. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provide a reasonable basis for our opinion. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other Matter &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As discussed in Note 1 to the financial statements, the accompanying financial statements have been prepared from the separate records maintained by the Company and may not necessarily be indicative of the conditions that would have existed or the results of operations if the Company had been operated as an unaffiliated company of Sorrento Therapeutics, Inc. Portions of certain income and expenses represent allocations made from home-office items applicable to the Company as a whole. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;/s/ Deloitte&#160;&amp;amp; Touche LLP &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;San Diego, California &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;April&#160;23, 2020 &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;We began serving as the Company&#x2019;s auditor in 2018. In 2020 we became the predecessor auditor. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:LeaseDepositLiability
      contextRef="PAsOn10_10_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">323889</us-gaap:LeaseDepositLiability>
    <us-gaap:CommonStockNoParValue
      contextRef="PAsOn10_17_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="4"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockNoParValue>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn10_17_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">10</us-gaap:SaleOfStockPricePerShare>
    <sclx:NumberOfSharesLimits
      contextRef="P10_17_2022To10_17_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis_VickersVantageMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">1500000</sclx:NumberOfSharesLimits>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">4338000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">4839000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">14268000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">13126000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2562000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1145000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1835000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">3314000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">23003000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">22424000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">805000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">846000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1303000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1675000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">38802000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">42540000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">13481000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">13481000</us-gaap:Goodwill>
    <us-gaap:LongTermInvestments
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">538000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">538000</us-gaap:LongTermInvestments>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">77932000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">81504000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">4284000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">8120000</us-gaap:AccountsPayableCurrent>
    <sclx:AccruedPayroll
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">3733000</sclx:AccruedPayroll>
    <sclx:AccruedPayroll
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">3754000</sclx:AccruedPayroll>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">10621000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">10622000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">37950000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">15888000</us-gaap:LongTermDebtCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">92724000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">26664000</us-gaap:DueToRelatedPartiesCurrent>
    <sclx:RelatedPartyNotePayableCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">19608000</sclx:RelatedPartyNotePayableCurrent>
    <sclx:RelatedPartyNotePayableCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">13008000</sclx:RelatedPartyNotePayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">500000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">424000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">169420000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">78480000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">72037000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">92255000</us-gaap:LongTermDebtNoncurrent>
    <sclx:RelatedPartyNotePayableNoncurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">23503000</sclx:RelatedPartyNotePayableNoncurrent>
    <sclx:RelatedPartyNotePayableNoncurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">15403000</sclx:RelatedPartyNotePayableNoncurrent>
    <sclx:DerivativeLiabilityNoncurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">35700000</sclx:DerivativeLiabilityNoncurrent>
    <sclx:DerivativeLiabilityNoncurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">35400000</sclx:DerivativeLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1148000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1649000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">301808000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">223187000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2020"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2020"
      decimals="INF"
      unitRef="Unit_shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2020"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2020"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2020_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2020_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2020_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">197266338</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">197266338</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2020_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">197266338</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">197266338</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">20000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">20000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">128654000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">122423000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-352550000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-264126000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-223876000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-141683000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">77932000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">81504000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">31317000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">23560000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">21033000</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">3634000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">2149000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">5802000</us-gaap:CostOfRevenue>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">9201000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">9961000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">10216000</us-gaap:ResearchAndDevelopmentExpense>
    <sclx:AcquiredinprocessresearchAndDevelopment
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</sclx:AcquiredinprocessresearchAndDevelopment>
    <sclx:AcquiredinprocessresearchAndDevelopment
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</sclx:AcquiredinprocessresearchAndDevelopment>
    <sclx:AcquiredinprocessresearchAndDevelopment
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">75301000</sclx:AcquiredinprocessresearchAndDevelopment>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">50582000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">42970000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">64696000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">3738000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">3738000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">3713000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">67155000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">58818000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">159728000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-35838000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-35258000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-138695000</us-gaap:OperatingIncomeLoss>
    <sclx:GainLossOnDerivative
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">300000</sclx:GainLossOnDerivative>
    <sclx:GainLossOnDerivative
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-800000</sclx:GainLossOnDerivative>
    <sclx:GainLossOnDerivative
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">23300000</sclx:GainLossOnDerivative>
    <sclx:GainLossOnExtinguishmentOfDebtt
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">12463000</sclx:GainLossOnExtinguishmentOfDebtt>
    <sclx:GainLossOnExtinguishmentOfDebtt
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</sclx:GainLossOnExtinguishmentOfDebtt>
    <sclx:GainLossOnExtinguishmentOfDebtt
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">0</sclx:GainLossOnExtinguishmentOfDebtt>
    <sclx:ScilexPharmaNotesPrincipalIncrease
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">28000000</sclx:ScilexPharmaNotesPrincipalIncrease>
    <sclx:ScilexPharmaNotesPrincipalIncrease
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</sclx:ScilexPharmaNotesPrincipalIncrease>
    <sclx:ScilexPharmaNotesPrincipalIncrease
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">0</sclx:ScilexPharmaNotesPrincipalIncrease>
    <us-gaap:InterestExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">11764000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">13116000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">16889000</us-gaap:InterestExpense>
    <us-gaap:InvestmentIncomeInterest
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">460000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">54000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-2000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">168000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">52581000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">12314000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">39897000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-88419000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-47572000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-178592000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">5000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-53000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">2000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-88424000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-47519000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-178594000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2021To12_31_2021"
      decimals="INF"
      unitRef="Unit_USD_per_Share">-0.45</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2021To12_31_2021"
      decimals="INF"
      unitRef="Unit_USD_per_Share">-0.45</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2020To12_31_2020"
      decimals="INF"
      unitRef="Unit_USD_per_Share">-0.24</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2020To12_31_2020"
      decimals="INF"
      unitRef="Unit_USD_per_Share">-0.24</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2019To12_31_2019"
      decimals="INF"
      unitRef="Unit_USD_per_Share">-0.95</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2019To12_31_2019"
      decimals="INF"
      unitRef="Unit_USD_per_Share">-0.95</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_shares">197266</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_shares">197266</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_shares">197315</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_shares">197315</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2019To12_31_2019"
      decimals="0"
      unitRef="Unit_shares">187524</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2019To12_31_2019"
      decimals="0"
      unitRef="Unit_shares">187524</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">150270000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">15000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2018_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">73462000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2018_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-38013000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">35464000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="P01_01_2019To12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">47040000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="P01_01_2019To12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">5000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="P01_01_2019To12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">54586000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">54591000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2019To12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-5800000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-5800000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="P01_01_2019To12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">4330000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">4330000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2019To12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-178594000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-178594000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">197310000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">20000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">126578000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-216607000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-90009000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">56000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">50000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">50000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">5395000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">5395000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2020To12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-9600000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-9600000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited
      contextRef="P01_01_2020To12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">-100000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2020To12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-47519000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-47519000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">197266000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">20000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">122423000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-264126000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-141683000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">5822000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">5822000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <sclx:AdjustmentsToAdditionalPaidInCapitalSharesIssuedInSemnurAcquisition
      contextRef="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">409000</sclx:AdjustmentsToAdditionalPaidInCapitalSharesIssuedInSemnurAcquisition>
    <sclx:AdjustmentsToAdditionalPaidInCapitalSharesIssuedInSemnurAcquisition
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">409000</sclx:AdjustmentsToAdditionalPaidInCapitalSharesIssuedInSemnurAcquisition>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-88424000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-88424000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">197266000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">20000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">128654000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-352550000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-223876000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-88424000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-47519000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-178594000</us-gaap:NetIncomeLoss>
    <us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">3779000</us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">3777000</us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">3750000</us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">7909000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">10664000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">15033000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <sclx:IncreaseInNotesPayableOne
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">28000000</sclx:IncreaseInNotesPayableOne>
    <sclx:IncreaseInNotesPayableOne
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</sclx:IncreaseInNotesPayableOne>
    <sclx:IncreaseInNotesPayableOne
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">0</sclx:IncreaseInNotesPayableOne>
    <us-gaap:InterestPaidNet
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">12487000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">10866000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:InterestPaidNet>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-12463000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <sclx:NonCashOperatingLeaseCosts
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">372000</sclx:NonCashOperatingLeaseCosts>
    <sclx:NonCashOperatingLeaseCosts
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">825000</sclx:NonCashOperatingLeaseCosts>
    <sclx:NonCashOperatingLeaseCosts
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">528000</sclx:NonCashOperatingLeaseCosts>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">5822000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">5395000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">4330000</us-gaap:ShareBasedCompensation>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-300000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">800000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-23300000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">75301000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1142000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">598000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">12356000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1417000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-2379000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">1116000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-1479000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1035000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">1307000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInSecurityDeposits
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:IncreaseDecreaseInSecurityDeposits>
    <us-gaap:IncreaseDecreaseInSecurityDeposits
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">2580000</us-gaap:IncreaseDecreaseInSecurityDeposits>
    <us-gaap:IncreaseDecreaseInSecurityDeposits
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-88000</us-gaap:IncreaseDecreaseInSecurityDeposits>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-3836000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-4062000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">4271000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-21000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1247000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">1131000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">409000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">2051000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">3689000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-80000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-604000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-147000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">18210000</us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent>
    <us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">5105000</us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent>
    <us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">1854000</us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-28664000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-31461000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-60421000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">25000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">584000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">17040000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-25000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-17624000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:RepaymentsOfSeniorDebt
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">33387000</us-gaap:RepaymentsOfSeniorDebt>
    <us-gaap:RepaymentsOfSeniorDebt
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">58927000</us-gaap:RepaymentsOfSeniorDebt>
    <us-gaap:RepaymentsOfSeniorDebt
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">2334000</us-gaap:RepaymentsOfSeniorDebt>
    <us-gaap:RepaymentsOfOtherLongTermDebt
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">48832000</us-gaap:RepaymentsOfOtherLongTermDebt>
    <us-gaap:RepaymentsOfOtherLongTermDebt
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:RepaymentsOfOtherLongTermDebt>
    <us-gaap:RepaymentsOfOtherLongTermDebt
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:RepaymentsOfOtherLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">47832000</us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">11007000</us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">50000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">47850000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">18400000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromIssuanceOfMediumTermNotes
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">14700000</us-gaap:ProceedsFromIssuanceOfMediumTermNotes>
    <us-gaap:ProceedsFromIssuanceOfMediumTermNotes
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">10300000</us-gaap:ProceedsFromIssuanceOfMediumTermNotes>
    <us-gaap:ProceedsFromIssuanceOfMediumTermNotes
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">21628000</us-gaap:ProceedsFromIssuanceOfMediumTermNotes>
    <us-gaap:RepaymentsOfMediumTermNotes
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:RepaymentsOfMediumTermNotes>
    <us-gaap:RepaymentsOfMediumTermNotes
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:RepaymentsOfMediumTermNotes>
    <us-gaap:RepaymentsOfMediumTermNotes
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">3518000</us-gaap:RepaymentsOfMediumTermNotes>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">28163000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-19170000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">15776000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-501000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-50656000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-62269000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">4839000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">55495000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">117764000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">4338000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">4839000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">55495000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationGiven1
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">409000</us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationGiven1>
    <us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationGiven1
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationGiven1>
    <us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationGiven1
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">54591000</us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationGiven1>
    <sclx:AcquistionCostsIncurredButNotPaidIncludedInAccountsPayable
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</sclx:AcquistionCostsIncurredButNotPaidIncludedInAccountsPayable>
    <sclx:AcquistionCostsIncurredButNotPaidIncludedInAccountsPayable
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</sclx:AcquistionCostsIncurredButNotPaidIncludedInAccountsPayable>
    <sclx:AcquistionCostsIncurredButNotPaidIncludedInAccountsPayable
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">601000</sclx:AcquistionCostsIncurredButNotPaidIncludedInAccountsPayable>
    <sclx:OtherLoanForgiveness
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1536000</sclx:OtherLoanForgiveness>
    <sclx:OtherLoanForgiveness
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</sclx:OtherLoanForgiveness>
    <sclx:OtherLoanForgiveness
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">0</sclx:OtherLoanForgiveness>
    <sclx:NonCashDistributionToAcquiree
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</sclx:NonCashDistributionToAcquiree>
    <sclx:NonCashDistributionToAcquiree
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">9600000</sclx:NonCashDistributionToAcquiree>
    <sclx:NonCashDistributionToAcquiree
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">5800000</sclx:NonCashDistributionToAcquiree>
    <sclx:NonCashIncreaseInPrincipal
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">28000000</sclx:NonCashIncreaseInPrincipal>
    <sclx:NonCashIncreaseInPrincipal
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</sclx:NonCashIncreaseInPrincipal>
    <sclx:NonCashIncreaseInPrincipal
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">0</sclx:NonCashIncreaseInPrincipal>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">4338000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">4839000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">10295000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">45200000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">4338000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">4839000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">55495000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="P01_01_2021To12_31_2021"> &lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Nature of Operations and Basis of Presentation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Organization and Principal Activities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Scilex Holding Company (&#x201c;Scilex Holding&#x201d; and together with its wholly owned subsidiaries, &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;the&lt;/div&gt; &#x201c;Company&#x201d;) was incorporated in &lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt; Delaware in February&#160;2019 and is a majority-owned subsidiary of Sorrento Therapeutics, Inc. (&#x201c;Sorrento&#x201d;). The Company is a commercial-stage, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-opioid&lt;/div&gt; pain management company focused on the development and commercialization of topical and injectable therapies. The Company launched its first commercial product in October&#160;2018, ZTlido (lidocaine topical system) 1.8% (&#x201c;ZTlido&#x201d;), a prescription lidocaine topical system that is designed with novel technology to address the limitations of current prescription lidocaine therapies by providing significantly improved adhesion and continuous pain relief throughout the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;12-hour&lt;/div&gt; administration period. The Company is currently developing two product candidates, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-102&lt;/div&gt; (10 mg, dexamethasone sodium phosphate viscous gel), a Phase&#160;3, novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(&#x201c;SP-102&#x201d;),&lt;/div&gt; and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-103&lt;/div&gt; (lidocaine topical system) 5.4% &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(&#x201c;SP-103&#x201d;),&lt;/div&gt; for the treatment of acute low back pain. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On March&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&#160;18, 2019, the Company entered into a Contribution and Loan Agreement with Sorrento and the holders of the outstanding shares of capital stock of Scilex Pharmaceuticals Inc. (&#x201c;Scilex Pharma&#x201d;) pursuant to which the Company acquired 100% of the outstanding shares of capital stock of Scilex Pharma in exchange for shares of the Company&#x2019;s common stock (the &#x201c;Contribution&#x201d;), which was accounted for as a reorganization of entities under common control. Pursuant to the Contribution and Loan Agreement, Sorrento provided the Company with a loan with an initial principal amount of $16.5&#160;million &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;in the form of a note payable, which was used by the Company to fund the acquisition of Semnur Pharmaceuticals, Inc. (&#x201c;Semnur&#x201d;). Concurrently therewith, the Company entered into an Agreement and Plan of Merger with Semnur, Sigma Merger Sub, Inc., the Company&#x2019;s prior wholly owned subsidiary (&#x201c;Merger Sub&#x201d;), Fortis Advisors LLC, solely as representative of the holders of Semnur equity (the &#x201c;Semnur Equityholders&#x2019; Representative&#x201d;), and Sorrento, for limited purposes (the &#x201c;Merger Agreement&#x201d;), which was accounted for as an asset acquisition. Pursuant to the Merger Agreement, Merger Sub merged with and into Semnur (the &#x201c;Merger&#x201d;), with Semnur surviving as the Company&#x2019;s wholly owned subsidiary. As a result of the Contribution and the Merger, Scilex Pharma and Semnur became wholly owned subsidiaries of the Company. Upon completion of the Contribution and the Merger, the historical consolidated financial statements of Scilex Pharma became the historical consolidated financial statements of Scilex Holding.&lt;/div&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Since inception, the Company had devoted substantially all of its efforts to the product development of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;SP&lt;/div&gt;&lt;/div&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;-102&lt;/div&gt; and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;SP-103&lt;/div&gt; and the commercialization of ZTlido. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Basis of Presentation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and include all adjustments necessary for the fair presentation of the Company&#x2019;s financial position for the periods presented. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying consolidated financial statements include the accounts of the Company&#x2019;s subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; </us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <dei:EntityIncorporationStateCountryCode contextRef="P02_01_2019To02_28_2019">DE</dei:EntityIncorporationStateCountryCode>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="PAsOn03_18_2019_ContributionAndLoanAgreementMemberSCLXAgreementAxis_ReorganizationMemberSCLXEventAxis_ScilexPharmaMemberusgaapBusinessAcquisitionAxis"
      decimals="2"
      unitRef="Unit_pure">1</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn03_18_2019_ReorganizationMemberSCLXEventAxis_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">16500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Basis of Presentation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and include all adjustments necessary for the fair presentation of the Company&#x2019;s financial position for the periods presented. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying consolidated financial statements include the accounts of the Company&#x2019;s subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <sclx:LiquidityAndGoingConcernTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liquidity and Going Concern &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Management has assessed the Company&#x2019;s ability to continue as a going concern at least one year after the date the financial statements are issued. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;31, 2021, the Company&#x2019;s negative working capital was $146.4&#160;million, including cash and cash equivalents of approximately $4.3&#160;million. During the year ended December&#160;31, 2021, the Company&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;had operating losses of $35.8&#160;million and negative cash flows from operations of $28.7&#160;million. The Company had an accumulated deficit of approximately $352.6&#160;million as of December&#160;31, 2021. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In September &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018, Scilex Pharma issued $224.0&#160;million of the Scilex Pharma Notes (see Note 8) for a purchase price of $140.0&#160;million. Pursuant to the Indenture, as amended (see Note 8), Scilex Pharma is required to maintain a minimum unrestricted cash balance of $4.0&#160;million at the end of each month. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In December &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;2020, Scilex Pharma repurchased an aggregate of $65.0&#160;million of the Scilex Pharma Notes (see Note 8) and amended the terms of the Scilex Pharma Notes to release $45.0&#160;million in restricted funds held in the Reserve Account (see Note 8) and Collateral Account (see Note 8) for the purpose of consummating the repurchase of an aggregate of $45.0&#160;million of principal amount. &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;In February&#160;&lt;/div&gt;2021 and &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;April&#160;&lt;/div&gt;2021, Scilex Pharma effected specified principal repurchases totaling $40.0&#160;million of the principal amount of the Scilex Pharma Notes. On December&#160;31, 2021, Scilex Pharma triggered a cumulative sales-related contingency that triggered an increase in the principal amount of the Scilex Pharma Notes by $28.0&#160;million. &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;In February&#160;&lt;/div&gt;2022, Scilex Pharma drew down on the Letter of Credit (see Note 8) with Sorrento, which also triggered Scilex Pharma&#x2019;s obligation to repurchase $20.0&#160;million of the outstanding principal amount of the Scilex Pharma Notes and to maintain a minimum unrestricted cash balance of $10.0&#160;million. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On March&#160;&lt;/div&gt;&lt;/div&gt;18, 2019, the Company acquired Semnur and the acquisition was accounted for as an asset acquisition (See Note 4). The Company anticipates the cash needed for the development of Semnur&#x2019;s primary product candidate in development, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-102,&lt;/div&gt; as well in the development of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-103,&lt;/div&gt; will be in excess of the Company&#x2019;s cash available within one year after the date these consolidated financial statements are issued. Semnur has no historical revenue and the Company will be responsible for funding all development and commercialization efforts and capital funding needs possibly through private or public equity or debt financings, strategic collaborations or other arrangements. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has plans to obtain additional resources to fund its currently planned operations and expenditures for at least &lt;/div&gt;&lt;/div&gt;twelve&#160;months from the issuance of these consolidated financial statements through debt and equity financing. The Company&#x2019;s plans are also dependent upon the success of future sales of ZTlido, which is still in the early stages of commercialization, and are dependent upon, among other things, the success of the Company&#x2019;s marketing of ZTlido. Should the Company&#x2019;s sales of ZTlido not materialize at the expected rate contemplated in the Company&#x2019;s business plan, due to the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; pandemic or other factors, the Company believes that there are a number of ongoing and potential actions that would maintain its projected cash and projected financial position including but not limited to, additional reductions in general and administrative costs, sales and marketing costs, suspension or winding down of clinical development programs for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-102&lt;/div&gt; and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-103,&lt;/div&gt; and other discretionary costs. Although the Company believes such plans, if executed, should provide the Company with financing to meet its needs, successful completion of such plans is dependent on factors outside the Company&#x2019;s control. As such, management cannot conclude that such plans will be effectively implemented within one year after the date that these consolidated financial statements are issued. As a result, management has concluded that the aforementioned conditions, among other things, raise substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year after the date the financial statements are issued. &lt;/div&gt; </sclx:LiquidityAndGoingConcernTextBlock>
    <sclx:NetWorkingCapital
      contextRef="PAsOn12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">146400000</sclx:NetWorkingCapital>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">4300000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">-35800000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">-28700000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">-352600000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn09_30_2018_ScilexPharmaMemberdeiLegalEntityAxis_SeniorSecuredNotesDueTwoThousandAndTwentySixMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">224000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromIssuanceOfSecuredDebt
      contextRef="P09_01_2018To09_30_2018_ScilexPharmaMemberdeiLegalEntityAxis_SeniorSecuredNotesDueTwoThousandAndTwentySixMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">140000000</us-gaap:ProceedsFromIssuanceOfSecuredDebt>
    <sclx:MinimumUnrestrictedCashBalance
      contextRef="PAsOn09_30_2018_ScilexPharmaMemberdeiLegalEntityAxis_SeniorSecuredNotesDueTwoThousandAndTwentySixMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">4000000</sclx:MinimumUnrestrictedCashBalance>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="PAsOn09_30_2020_ScilexPharmaMemberdeiLegalEntityAxis_SeniorSecuredNotesDueTwoThousandAndTwentySixMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">65000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <sclx:RestrictedFundsRelesableForFutureRepurchaseOfDebt
      contextRef="PAsOn09_30_2020_ScilexPharmaMemberdeiLegalEntityAxis_SeniorSecuredNotesDueTwoThousandAndTwentySixMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">45000000</sclx:RestrictedFundsRelesableForFutureRepurchaseOfDebt>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="PAsOn04_30_2021_ScilexPharmaMemberdeiLegalEntityAxis_SeniorSecuredNotesDueTwoThousandAndTwentySixMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">40000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn12_31_2021_CumulativeSalesRelatedContingencyMemberSCLXEventAxis_ScilexPharmaMemberdeiLegalEntityAxis_SeniorSecuredNotesDueTwoThousandAndTwentySixMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">28000000</us-gaap:DebtInstrumentFaceAmount>
    <sclx:DebtInstrumentRepurchaseObligation
      contextRef="PAsOn02_28_2022_LetterOfCreditDrawnDownMemberSCLXEventAxis_ScilexPharmaMemberdeiLegalEntityAxis_SeniorSecuredNotesDueTwoThousandAndTwentySixMemberusgaapLongtermDebtTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">20000000</sclx:DebtInstrumentRepurchaseObligation>
    <sclx:MinimumUnrestrictedCashBalance
      contextRef="PAsOn02_28_2022_LetterOfCreditDrawnDownMemberSCLXEventAxis_ScilexPharmaMemberdeiLegalEntityAxis_SeniorSecuredNotesDueTwoThousandAndTwentySixMemberusgaapLongtermDebtTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">10000000</sclx:MinimumUnrestrictedCashBalance>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Significant Accounting Policies &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The preparation of these consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of these consolidated financial statements and the reported amounts of expenses during the reporting period. Management believes that these estimates are reasonable; however, actual results may differ from these estimates. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Cash and Cash Equivalents &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company considers all highly liquid investments purchased with original maturities of three months or less to be cash equivalents. The Company minimizes its credit risk associated with cash and cash equivalents by periodically evaluating the credit quality of its primary financial institution. Although the balance at times may exceed federally-insured limits, the Company has not experienced any losses on such accounts. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Fair Value of Financial Instruments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company follows accounting guidance on fair value measurements for financial instruments measured on a recurring basis, as well as for certain assets and liabilities that are initially recorded at their estimated fair values. Fair value is defined as the exit price, or the amount that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company uses the following three-level hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs to value its financial instruments: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;a.&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-size: 10pt;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;1: Observable inputs such as unadjusted quoted prices in active markets for identical instruments. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;b.&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-size: 10pt;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;2: Quoted prices for similar instruments that are directly or indirectly observable in the marketplace. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;c.&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-size: 10pt;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;3: Significant unobservable inputs which are supported by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial instruments measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#x2019;s assessment of the significance of a particular input to the fair value measurement in its entirety requires it to make judgments and consider factors specific to the asset or liability. The use of different assumptions and/or estimation methodologies may have a material effect on estimated fair values. Accordingly, the fair value estimates disclosed or initial amounts recorded may not be indicative of the amount that the Company or holders of the instruments could realize in a current market exchange. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December&#160;31, 2021 and 2020, the carrying amount of cash equivalents approximates their fair value based upon quoted market prices. Certain of the Company&#x2019;s financial instruments are not measured at fair value on a recurring basis, but are recorded at amounts that approximate their fair value due to their liquid or short-term nature, such as cash, prepaid expenses, accounts receivable, and accounts payable. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Accounts Receivable, Net &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts receivable are presented net of allowances for expected credit losses and consist of trade receivables from product sales to one customer, which are generally unsecured. Estimated credit losses related to trade accounts receivable are recorded as general and administrative expenses and as an allowance for expected credit losses within accounts receivable, net. The Company reviews reserves and makes adjustments based on historical experience and known collectability issues and disputes. When internal collection efforts on accounts have been exhausted, the accounts are written off by reducing the allowance for expected credit losses. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Inventory &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company determines inventory cost on a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;first-in,&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;first-out&lt;/div&gt; basis. The Company reduces the carrying value of inventories to a lower of cost or net realizable value for those items that are potentially excess, obsolete or slow-moving. The Company reserves for excess and obsolete inventory based upon historical experience, sales trends, and specific categories of inventory and expiration dates for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;on-hand&lt;/div&gt; inventory. As of December&#160;31, 2021 and 2020, the Company&#x2019;s inventory was primarily comprised of finished goods. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px;"/&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Property and Equipment &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment are carried at cost less accumulated depreciation. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the assets, which are generally five to seven years. Leasehold improvements are amortized over the lesser of their estimated useful lives or the term of the respective lease on a straight-line basis. The cost of repairs and maintenance is expensed as incurred. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Goodwill and Other Long-Lived Assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Goodwill, which has an indefinite life, represents the excess cost over fair value of net assets acquired. Goodwill is reviewed for impairment at least annually during the fourth quarter, or more frequently if events occur indicating the potential for impairment. The Company has determined that only one reporting unit exists for examination under impairment review. During its goodwill impairment review, the Company may assess qualitative factors to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company. If, after assessing the totality of these qualitative factors, the Company determines that it is not more likely than not that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company performs a quantitative goodwill impairment test. The Company may also elect to bypass the qualitative assessment in a period and elect to proceed to perform the quantitative goodwill impairment test. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company evaluates its long-lived and intangible assets with definite lives, such as property and equipment, patent rights, and acquired technology, for impairment by considering competition by products prescribed for the same indication, the likelihood and estimated future entry of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-generic&lt;/div&gt; and generic competition with the same or similar indication and other related factors. The factors that drive the estimate of useful life are often uncertain and are reviewed on a periodic basis or when events occur that warrant review. Recoverability is measured by comparison of the assets&#x2019; book value to future net undiscounted cash flows that the assets are expected to generate to determine if a write-down to the recoverable amount is appropriate. If such assets are written down, an impairment will be recognized as the amount by which the book value of the asset group exceeds the recoverable amount. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Debt &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company may enter financing arrangements, the terms of which involve significant assumptions and estimates. This involves estimating future net product sales, determining interest expense, determining the amortization period of the debt discount, as well as determining the classification between current and long-term portions. In estimating future net product sales, the Company assesses prevailing market conditions using various external market data against the Company&#x2019;s anticipated sales and planned commercial activities as well as actual ZTlido sales up to the date the financial statements were issued. See Note 8 for discussion of the Scilex Pharma Notes, which include repayments based on a percentage of net sales of ZTlido. Consequently, the Company imputes interest on the carrying value of the debt and records interest expense using an imputed effective interest rate. The Company reassesses the expected payments each reporting period and accounts for any changes through an adjustment to the effective interest rate on a prospective basis, with a corresponding impact to the classification of the Company&#x2019;s current and long-term portions. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Research and Development Costs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company expenses the cost of research and development as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including clinical trial costs, manufacturing costs for both clinical and preclinical materials as well as other contracted services, &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="background: none; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;   &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;license fees and other external costs. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity is performed or when the goods have been received, rather than when payment is made, in accordance with Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 730, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Research and Development&lt;/div&gt;&lt;/div&gt;. &lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Acquired &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In-Process&lt;/div&gt; Research and Development Expense &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has acquired and may continue to acquire the rights to develop and commercialize new product candidates. The &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;up-front&lt;/div&gt; payments to acquire a new drug compound or drug delivery device, as well as future milestone payments associated with asset acquisitions that do not meet the definition of a derivative and are deemed probable to achieve the milestones, are immediately expensed as acquired &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-process&lt;/div&gt; research and development provided that the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, have no alternative future use. Intangible assets acquired in a business combination that are used for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-process&lt;/div&gt; research and development (&#x201c;IPR&amp;amp;D&#x201d;) activities are considered indefinite-lived until the completion or abandonment of the associated research and development efforts. Upon commercialization of the relevant research and development project, the Company amortizes the acquired IPR&amp;amp;D over its estimated useful life. Capitalized IPR&amp;amp;D is reviewed annually for impairment or more frequently as changes in circumstance or the occurrence of events suggest that the remaining value may not be recoverable. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The provisions of the FASB ASC Topic 740, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income Taxes&lt;/div&gt;&lt;/div&gt;, addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC Topic &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;740-10,&lt;/div&gt; the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based on the technical merits of the position. The Company has determined that it has uncertain tax positions. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company accounts for income taxes using the asset and liability method to compute the differences between the tax basis of assets and liabilities and the related financial amounts, using currently enacted tax rates. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has deferred tax assets, which are subject to periodic recoverability assessments. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount that more likely than not will be realized. As of December&#160;31, 2021 and 2020, the Company maintained a full valuation allowance against its deferred tax assets, with the exception of an amount equal to its deferred tax liabilities that are scheduled to reverse against the Company&#x2019;s deferred tax assets. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Leases &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company determines if an arrangement is a lease at inception. Operating lease &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; (&#x201c;ROU&#x201d;) assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As the Company&#x2019;s leases do not provide an implicit rate, it uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any lease payments made and is reduced by lease incentives. The Company&#x2019;s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term in selling, general and administrative expenses. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Derivative Liabilities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Derivative liabilities are recorded on the Company&#x2019;s consolidated balance sheets at their fair value on the date of issuance and are revalued on each balance sheet date until such instruments are exercised or expire, with changes in the fair value between reporting periods recorded as other income or expense. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="null;text-indent: 0px;;font-style:italic;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenue Recognition&#160;&lt;/div&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s revenue is generated from product sales within the United States. The Company does not have significant costs associated with costs to obtain a contract with its customer. All of the Company&#x2019;s revenue and accounts receivable result from a sole customer. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenue from product sales is fully comprised of sales of ZTlido. The Company&#x2019;s performance obligation with respect to sales of ZTlido is satisfied at a point in time, which transfers control upon delivery of product to the customer. The Company considers control to have transferred upon delivery because the customer has legal title to the product, physical possession of the product has been transferred to the customer, the customer has significant risks and rewards of ownership of the product, and the Company has a present right to payment at that time. Invoicing typically occurs upon shipment and the length of time between invoicing and when payment is due is not significant. The aggregate dollar value of unfulfilled orders as of December&#160;31, 2021 and 2020 were not material. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;For product sales, the Company records &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;gross-to-net&lt;/div&gt;&lt;/div&gt; sales adjustments for commercial and government rebates, fees and chargebacks, wholesaler and distributor fees, sales returns and prompt payment discounts. Such variable consideration is estimated in the period of the sale and is estimated using a most likely amount approach based primarily upon provisions included in the Company&#x2019;s customer contract, customary industry practices and current government regulations. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross-to-net&lt;/div&gt;&lt;/div&gt; adjustments are generally recorded as contract liabilities under accrued expenses within the Company&#x2019;s consolidated balance sheet. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Rebates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;Rebates are discounts which the Company pays under either government or private health care programs. Government rebate programs include state Medicaid drug rebate programs, the Medicare coverage gap discount programs and the Tricare programs. Commercial rebate and fee programs relate to contractual agreements with commercial healthcare providers, under which the Company pays rebates and fees for access to and position on that provider&#x2019;s patient drug formulary. Rebates and chargebacks paid under government programs are generally mandated under law, whereas private rebates and fees are generally contractually negotiated by the Company with commercial healthcare providers. Both types of rebates vary over time. The Company records a reduction to gross product sales at the time the customer takes title to the product based on estimates of expected rebate claims. The Company monitors the sales trends and adjust for these rebates on a regular basis to reflect the most recent rebate experience and contractual obligations.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Service Fees &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company compensates its customer and others in the distribution chain for wholesaler and distribution services. The Company has determined such services received up to the date the financial statements were issued are not distinct from the Company&#x2019;s sale of products to the customer and, therefore, these payments have been recorded as a reduction of revenue. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Product Returns &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is obligated to accept the return of products sold that are expiring within six months, damaged or do not meet certain specifications. The Company may authorize the return of products sold in accordance with the term of its sales contracts, and estimates allowances for such amounts at the time of sale. The Company estimates the amount of its product sales that may be returned by its customer and record this estimate as a reduction of revenue in the period the related product revenue is recognized.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Co-Payment&lt;/div&gt; Assistance &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Patients who have commercial insurance or pay cash and meet certain eligibility requirements may receive &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;co-payment&lt;/div&gt; assistance. The Company accrues for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;co-payment&lt;/div&gt; assistance based on actual program participation and estimates of program redemption using data provided by third-party &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;administrators. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Customer Concentration Risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;During the fiscal years ended December&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;31, 2021, 2020 and 2019, sales to the Company&#x2019;s sole distributor represented 100% of net revenue. This exposes the Company to concentration of customer risk. The Company monitors the financial condition of its sole customer, limits its credit exposure by setting credit limits, and has not experienced any credit losses for the&#160;years ended December&#160;31, 2021, 2020 and 2019. As the Company continues to expand the commercialization of its product, the Company is not limited to the current customer and has the option of expanding its distribution network with additional distributors through establishing its own affiliates, by acquiring existing third-party business or product rights or by partnering with additional third parties. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Stock-Based Compensation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company accounts &lt;/div&gt;&lt;/div&gt; for stock-based compensation in accordance with FASB ASC Topic 718,&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt; Compensation&lt;/div&gt;&lt;/div&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Stock Compensation &lt;/div&gt;&lt;/div&gt;which establishes accounting for equity instruments exchanged for employee and consulting services. Under such provisions, stock-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense, under the straight-line method, over the employee&#x2019;s requisite service period (generally the vesting period of the equity grant) or &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employee&#x2019;s&lt;/div&gt; vesting period. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For purposes of determining &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; the inputs used in the calculation of stock-based compensation, the Company uses historical data in estimating the expected term of options and determines an estimate of option volatility based on an assessment of historical volatilities of comparable companies whose share prices are publicly available. The Company uses these estimates as inputs in the Black-Scholes option pricing model. Depending upon the number of stock options granted, any fluctuations in these calculations could have a material effect on the results presented in the Company&#x2019;s consolidated statement of operations. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Net Loss per Share &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic net loss &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;per share is computed by dividing net loss for the period by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share reflects the additional dilution from potential issuances of common stock, such as stock issuable pursuant to the exercise of stock options. The treasury stock method is used to calculate the potential dilutive effect of these common stock equivalents. Potentially dilutive shares are excluded from the computation of diluted net loss per share when their effect is anti-dilutive. In periods where a net loss is presented, all potentially dilutive securities are anti-dilutive and are excluded from the computation of diluted net loss per share. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Segments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating segments &lt;/div&gt;&lt;/div&gt; are identified as components of an entity where separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions on how to allocate resources and assesses performance. The Company has determined that its chief operating decision maker is its Chief Executive Officer, as he is responsible for making decisions regarding the allocation of resources and assessing performance as well as for strategic operational decisions. The Company is engaged primarily in the development of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;non-opioid&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;products focused on pain management based on its platform technologies and all sales are based in the United States. Accordingly, the Company has determined that it operates its business as a single reportable segment.&lt;/div&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"/&gt; &lt;br/&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Recent Accounting Pronouncements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;In October 2021, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021-08,&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers&lt;/div&gt;&lt;/div&gt;, which requires an acquirer in a &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;business &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;combination to recognize and measure contract assets and contract liabilities in accordance with ASC Topic 606. ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021-08&lt;/div&gt; is effective for fiscal years beginning after December&#160;15, 2022 and early adoption is permitted. The Company is evaluating the impact the standard will have on its consolidated financial statements. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;In December 2019, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2019-12,&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/div&gt;&lt;/div&gt;. The amendments in this update simplify the accounting for income taxes by removing certain exceptions to the general principles in ASC Topic 740. The amendments also improve consistent application of and simplify U.S. GAAP for other areas of ASC Topic 740 by clarifying and amending existing guidance. The amendments in this update were effective for interim and annual periods for the Company beginning after December&#160;15, 2020. The Company adopted the standard on January&#160;1, 2021. The adoption of the standard had no impact on its consolidated financial statements. &lt;/div&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The preparation of these consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of these consolidated financial statements and the reported amounts of expenses during the reporting period. Management believes that these estimates are reasonable; however, actual results may differ from these estimates. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Cash and Cash Equivalents &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company considers all highly liquid investments purchased with original maturities of three months or less to be cash equivalents. The Company minimizes its credit risk associated with cash and cash equivalents by periodically evaluating the credit quality of its primary financial institution. Although the balance at times may exceed federally-insured limits, the Company has not experienced any losses on such accounts. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Fair Value of Financial Instruments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company follows accounting guidance on fair value measurements for financial instruments measured on a recurring basis, as well as for certain assets and liabilities that are initially recorded at their estimated fair values. Fair value is defined as the exit price, or the amount that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company uses the following three-level hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs to value its financial instruments: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;a.&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-size: 10pt;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;1: Observable inputs such as unadjusted quoted prices in active markets for identical instruments. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;b.&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-size: 10pt;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;2: Quoted prices for similar instruments that are directly or indirectly observable in the marketplace. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;c.&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-size: 10pt;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;3: Significant unobservable inputs which are supported by little or no market activity and that are financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial instruments measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#x2019;s assessment of the significance of a particular input to the fair value measurement in its entirety requires it to make judgments and consider factors specific to the asset or liability. The use of different assumptions and/or estimation methodologies may have a material effect on estimated fair values. Accordingly, the fair value estimates disclosed or initial amounts recorded may not be indicative of the amount that the Company or holders of the instruments could realize in a current market exchange. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December&#160;31, 2021 and 2020, the carrying amount of cash equivalents approximates their fair value based upon quoted market prices. Certain of the Company&#x2019;s financial instruments are not measured at fair value on a recurring basis, but are recorded at amounts that approximate their fair value due to their liquid or short-term nature, such as cash, prepaid expenses, accounts receivable, and accounts payable. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Accounts Receivable, Net &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounts receivable are presented net of allowances for expected credit losses and consist of trade receivables from product sales to one customer, which are generally unsecured. Estimated credit losses related to trade accounts receivable are recorded as general and administrative expenses and as an allowance for expected credit losses within accounts receivable, net. The Company reviews reserves and makes adjustments based on historical experience and known collectability issues and disputes. When internal collection efforts on accounts have been exhausted, the accounts are written off by reducing the allowance for expected credit losses. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:InventoryPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Inventory &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company determines inventory cost on a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;first-in,&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;first-out&lt;/div&gt; basis. The Company reduces the carrying value of inventories to a lower of cost or net realizable value for those items that are potentially excess, obsolete or slow-moving. The Company reserves for excess and obsolete inventory based upon historical experience, sales trends, and specific categories of inventory and expiration dates for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;on-hand&lt;/div&gt; inventory. As of December&#160;31, 2021 and 2020, the Company&#x2019;s inventory was primarily comprised of finished goods. &lt;/div&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Property and Equipment &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment are carried at cost less accumulated depreciation. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the assets, which are generally five to seven years. Leasehold improvements are amortized over the lesser of their estimated useful lives or the term of the respective lease on a straight-line basis. The cost of repairs and maintenance is expensed as incurred. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Goodwill and Other Long-Lived Assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Goodwill, which has an indefinite life, represents the excess cost over fair value of net assets acquired. Goodwill is reviewed for impairment at least annually during the fourth quarter, or more frequently if events occur indicating the potential for impairment. The Company has determined that only one reporting unit exists for examination under impairment review. During its goodwill impairment review, the Company may assess qualitative factors to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company. If, after assessing the totality of these qualitative factors, the Company determines that it is not more likely than not that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company performs a quantitative goodwill impairment test. The Company may also elect to bypass the qualitative assessment in a period and elect to proceed to perform the quantitative goodwill impairment test. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company evaluates its long-lived and intangible assets with definite lives, such as property and equipment, patent rights, and acquired technology, for impairment by considering competition by products prescribed for the same indication, the likelihood and estimated future entry of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-generic&lt;/div&gt; and generic competition with the same or similar indication and other related factors. The factors that drive the estimate of useful life are often uncertain and are reviewed on a periodic basis or when events occur that warrant review. Recoverability is measured by comparison of the assets&#x2019; book value to future net undiscounted cash flows that the assets are expected to generate to determine if a write-down to the recoverable amount is appropriate. If such assets are written down, an impairment will be recognized as the amount by which the book value of the asset group exceeds the recoverable amount. &lt;/div&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:DebtPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Debt &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company may enter financing arrangements, the terms of which involve significant assumptions and estimates. This involves estimating future net product sales, determining interest expense, determining the amortization period of the debt discount, as well as determining the classification between current and long-term portions. In estimating future net product sales, the Company assesses prevailing market conditions using various external market data against the Company&#x2019;s anticipated sales and planned commercial activities as well as actual ZTlido sales up to the date the financial statements were issued. See Note 8 for discussion of the Scilex Pharma Notes, which include repayments based on a percentage of net sales of ZTlido. Consequently, the Company imputes interest on the carrying value of the debt and records interest expense using an imputed effective interest rate. The Company reassesses the expected payments each reporting period and accounts for any changes through an adjustment to the effective interest rate on a prospective basis, with a corresponding impact to the classification of the Company&#x2019;s current and long-term portions. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DebtPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Research and Development Costs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company expenses the cost of research and development as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including clinical trial costs, manufacturing costs for both clinical and preclinical materials as well as other contracted services, &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;license fees and other external costs. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity is performed or when the goods have been received, rather than when payment is made, in accordance with Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 730, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Research and Development&lt;/div&gt;&lt;/div&gt;. &lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; </us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:InProcessResearchAndDevelopmentPolicy contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Acquired &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In-Process&lt;/div&gt; Research and Development Expense &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has acquired and may continue to acquire the rights to develop and commercialize new product candidates. The &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;up-front&lt;/div&gt; payments to acquire a new drug compound or drug delivery device, as well as future milestone payments associated with asset acquisitions that do not meet the definition of a derivative and are deemed probable to achieve the milestones, are immediately expensed as acquired &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-process&lt;/div&gt; research and development provided that the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, have no alternative future use. Intangible assets acquired in a business combination that are used for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-process&lt;/div&gt; research and development (&#x201c;IPR&amp;amp;D&#x201d;) activities are considered indefinite-lived until the completion or abandonment of the associated research and development efforts. Upon commercialization of the relevant research and development project, the Company amortizes the acquired IPR&amp;amp;D over its estimated useful life. Capitalized IPR&amp;amp;D is reviewed annually for impairment or more frequently as changes in circumstance or the occurrence of events suggest that the remaining value may not be recoverable. &lt;/div&gt;&lt;/div&gt;</us-gaap:InProcessResearchAndDevelopmentPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The provisions of the FASB ASC Topic 740, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income Taxes&lt;/div&gt;&lt;/div&gt;, addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC Topic &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;740-10,&lt;/div&gt; the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based on the technical merits of the position. The Company has determined that it has uncertain tax positions. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company accounts for income taxes using the asset and liability method to compute the differences between the tax basis of assets and liabilities and the related financial amounts, using currently enacted tax rates. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has deferred tax assets, which are subject to periodic recoverability assessments. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount that more likely than not will be realized. As of December&#160;31, 2021 and 2020, the Company maintained a full valuation allowance against its deferred tax assets, with the exception of an amount equal to its deferred tax liabilities that are scheduled to reverse against the Company&#x2019;s deferred tax assets. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Leases &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company determines if an arrangement is a lease at inception. Operating lease &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; (&#x201c;ROU&#x201d;) assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As the Company&#x2019;s leases do not provide an implicit rate, it uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any lease payments made and is reduced by lease incentives. The Company&#x2019;s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term in selling, general and administrative expenses. &lt;/div&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:DerivativesPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Derivative Liabilities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Derivative liabilities are recorded on the Company&#x2019;s consolidated balance sheets at their fair value on the date of issuance and are revalued on each balance sheet date until such instruments are exercised or expire, with changes in the fair value between reporting periods recorded as other income or expense. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="null;text-indent: 0px;;font-style:italic;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenue Recognition&#160;&lt;/div&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s revenue is generated from product sales within the United States. The Company does not have significant costs associated with costs to obtain a contract with its customer. All of the Company&#x2019;s revenue and accounts receivable result from a sole customer. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenue from product sales is fully comprised of sales of ZTlido. The Company&#x2019;s performance obligation with respect to sales of ZTlido is satisfied at a point in time, which transfers control upon delivery of product to the customer. The Company considers control to have transferred upon delivery because the customer has legal title to the product, physical possession of the product has been transferred to the customer, the customer has significant risks and rewards of ownership of the product, and the Company has a present right to payment at that time. Invoicing typically occurs upon shipment and the length of time between invoicing and when payment is due is not significant. The aggregate dollar value of unfulfilled orders as of December&#160;31, 2021 and 2020 were not material. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;For product sales, the Company records &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;gross-to-net&lt;/div&gt;&lt;/div&gt; sales adjustments for commercial and government rebates, fees and chargebacks, wholesaler and distributor fees, sales returns and prompt payment discounts. Such variable consideration is estimated in the period of the sale and is estimated using a most likely amount approach based primarily upon provisions included in the Company&#x2019;s customer contract, customary industry practices and current government regulations. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross-to-net&lt;/div&gt;&lt;/div&gt; adjustments are generally recorded as contract liabilities under accrued expenses within the Company&#x2019;s consolidated balance sheet. &lt;/div&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <sclx:RebatesPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Rebates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;Rebates are discounts which the Company pays under either government or private health care programs. Government rebate programs include state Medicaid drug rebate programs, the Medicare coverage gap discount programs and the Tricare programs. Commercial rebate and fee programs relate to contractual agreements with commercial healthcare providers, under which the Company pays rebates and fees for access to and position on that provider&#x2019;s patient drug formulary. Rebates and chargebacks paid under government programs are generally mandated under law, whereas private rebates and fees are generally contractually negotiated by the Company with commercial healthcare providers. Both types of rebates vary over time. The Company records a reduction to gross product sales at the time the customer takes title to the product based on estimates of expected rebate claims. The Company monitors the sales trends and adjust for these rebates on a regular basis to reflect the most recent rebate experience and contractual obligations.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</sclx:RebatesPolicyTextBlock>
    <sclx:ServiceFeesPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Service Fees &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company compensates its customer and others in the distribution chain for wholesaler and distribution services. The Company has determined such services received up to the date the financial statements were issued are not distinct from the Company&#x2019;s sale of products to the customer and, therefore, these payments have been recorded as a reduction of revenue. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</sclx:ServiceFeesPolicyTextBlock>
    <sclx:SalesReturnsPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Product Returns &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is obligated to accept the return of products sold that are expiring within six months, damaged or do not meet certain specifications. The Company may authorize the return of products sold in accordance with the term of its sales contracts, and estimates allowances for such amounts at the time of sale. The Company estimates the amount of its product sales that may be returned by its customer and record this estimate as a reduction of revenue in the period the related product revenue is recognized.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</sclx:SalesReturnsPolicyTextBlock>
    <sclx:CoPaymentAssistancePolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Co-Payment&lt;/div&gt; Assistance &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Patients who have commercial insurance or pay cash and meet certain eligibility requirements may receive &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;co-payment&lt;/div&gt; assistance. The Company accrues for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;co-payment&lt;/div&gt; assistance based on actual program participation and estimates of program redemption using data provided by third-party &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;administrators. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</sclx:CoPaymentAssistancePolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Customer Concentration Risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;During the fiscal years ended December&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;31, 2021, 2020 and 2019, sales to the Company&#x2019;s sole distributor represented 100% of net revenue. This exposes the Company to concentration of customer risk. The Company monitors the financial condition of its sole customer, limits its credit exposure by setting credit limits, and has not experienced any credit losses for the&#160;years ended December&#160;31, 2021, 2020 and 2019. As the Company continues to expand the commercialization of its product, the Company is not limited to the current customer and has the option of expanding its distribution network with additional distributors through establishing its own affiliates, by acquiring existing third-party business or product rights or by partnering with additional third parties. &lt;/div&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2020To12_31_2020_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_SoleDistributorMembersrtMajorCustomersAxis"
      decimals="2"
      unitRef="Unit_pure">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2019To12_31_2019_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_SoleDistributorMembersrtMajorCustomersAxis"
      decimals="2"
      unitRef="Unit_pure">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="P01_01_2021To12_31_2021_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis_SoleDistributorMembersrtMajorCustomersAxis"
      decimals="2"
      unitRef="Unit_pure">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="P01_01_2019To12_31_2019"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Stock-Based Compensation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company accounts &lt;/div&gt;&lt;/div&gt; for stock-based compensation in accordance with FASB ASC Topic 718,&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt; Compensation&lt;/div&gt;&lt;/div&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#x2014;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Stock Compensation &lt;/div&gt;&lt;/div&gt;which establishes accounting for equity instruments exchanged for employee and consulting services. Under such provisions, stock-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense, under the straight-line method, over the employee&#x2019;s requisite service period (generally the vesting period of the equity grant) or &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employee&#x2019;s&lt;/div&gt; vesting period. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For purposes of determining &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; the inputs used in the calculation of stock-based compensation, the Company uses historical data in estimating the expected term of options and determines an estimate of option volatility based on an assessment of historical volatilities of comparable companies whose share prices are publicly available. The Company uses these estimates as inputs in the Black-Scholes option pricing model. Depending upon the number of stock options granted, any fluctuations in these calculations could have a material effect on the results presented in the Company&#x2019;s consolidated statement of operations. &lt;/div&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Net Loss per Share &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic net loss &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;per share is computed by dividing net loss for the period by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share reflects the additional dilution from potential issuances of common stock, such as stock issuable pursuant to the exercise of stock options. The treasury stock method is used to calculate the potential dilutive effect of these common stock equivalents. Potentially dilutive shares are excluded from the computation of diluted net loss per share when their effect is anti-dilutive. In periods where a net loss is presented, all potentially dilutive securities are anti-dilutive and are excluded from the computation of diluted net loss per share. &lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Segments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating segments &lt;/div&gt;&lt;/div&gt; are identified as components of an entity where separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions on how to allocate resources and assesses performance. The Company has determined that its chief operating decision maker is its Chief Executive Officer, as he is responsible for making decisions regarding the allocation of resources and assessing performance as well as for strategic operational decisions. The Company is engaged primarily in the development of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;non-opioid&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;products focused on pain management based on its platform technologies and all sales are based in the United States. Accordingly, the Company has determined that it operates its business as a single reportable segment.&lt;/div&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"/&gt; &lt;br/&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Recent Accounting Pronouncements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;In October 2021, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021-08,&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers&lt;/div&gt;&lt;/div&gt;, which requires an acquirer in a &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;business &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;combination to recognize and measure contract assets and contract liabilities in accordance with ASC Topic 606. ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021-08&lt;/div&gt; is effective for fiscal years beginning after December&#160;15, 2022 and early adoption is permitted. The Company is evaluating the impact the standard will have on its consolidated financial statements. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;In December 2019, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2019-12,&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/div&gt;&lt;/div&gt;. The amendments in this update simplify the accounting for income taxes by removing certain exceptions to the general principles in ASC Topic 740. The amendments also improve consistent application of and simplify U.S. GAAP for other areas of ASC Topic 740 by clarifying and amending existing guidance. The amendments in this update were effective for interim and annual periods for the Company beginning after December&#160;15, 2020. The Company adopted the standard on January&#160;1, 2021. The adoption of the standard had no impact on its consolidated financial statements. &lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:AssetAcquisitionTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Semnur Acquisition &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;On March&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;18, 2019, the Company completed the Merger. At the closing of the Merger, the Company issued to the holders of Semnur&#x2019;s capital stock and options to purchase Semnur&#x2019;s common stock, upfront consideration with a value of $70.0&#160;million. The upfront consideration was comprised of the following: (a)&#160;a cash payment of approximately $15.0&#160;million, and (b)&#160;$55.0&#160;million of shares of the Company&#x2019;s common stock (47,039,315 shares issued and 352,972 shares issuable, valued at $1.16 per share) (the &#x201c;Stock Consideration&#x201d;). Following the issuance of the Stock Consideration, Sorrento ownership in the Company diluted to approximately 58% of the Company&#x2019;s issued and outstanding capital stock. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pursuant to the &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Merger Agreement, and upon the terms and subject to the conditions contained therein, the Company also agreed to pay the Semnur Equityholders up to $280.0&#160;million in aggregate contingent cash consideration based on the achievement of certain milestones, comprised of a $40.0&#160;million payment that will be due upon obtaining the first approval of a New Drug Application (&#x201c;NDA&#x201d;) of a Semnur product by the U.S. Food and Drug Administration (the &#x201c;FDA&#x201d;) and additional payments that will be due upon the achievement of certain amounts of net sales of Semnur products, as follows: (1)&#160;a $20.0&#160;million payment upon the achievement of $100.0&#160;million in cumulative net sales of a Semnur product, (2)&#160;a $20.0&#160;million payment upon the achievement of $250.0&#160;million in cumulative net sales of a Semnur product, (3)&#160;a $50.0&#160;million payment upon the achievement of $500.0&#160;million in cumulative net sales of a Semnur product, and (4)&#160;a $150.0&#160;million payment upon the achievement of $750.0&#160;million in cumulative net sales of a Semnur product. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On August&#160;7, 2019, the Company &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;entered into an amendment to the Merger Agreement to provide that, following the consummation of the Company&#x2019;s first bona fide equity financing with one or more third-party financing sources on an arms&#x2019; length basis with gross proceeds to the Company of at least $&lt;/div&gt;40.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, certain of the former Semnur optionholders will be paid cash in lieu of: (1)&#160;the &lt;/div&gt;352,972&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; shares of the Company&#x2019;s common stock otherwise issuable to such former Semnur optionholders pursuant to the Merger Agreement, and (2)&#160;any shares that would otherwise be issued to such former Semnur optionholders upon release of shares held in escrow pursuant to the Merger Agreement, with such shares in each case valued at $&lt;/div&gt;1.16&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; per share. The amendment resulted in a reclassification of $&lt;/div&gt;0.4&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million from additional &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;paid-in&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; capital to accrued liabilities.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In March 2019, the &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Semnur Equityholders that received the Stock Consideration were required to sign an Exchange and Registration Rights Agreement with the Company (the &#x201c;Exchange Agreement&#x201d;).Pursuant to the Exchange Agreement, and upon the terms and subject to the conditions contained therein, if within &lt;/div&gt;18&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;months&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;following the closing of the Merger, &lt;/div&gt;100&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% of the outstanding equity of the Company has not been acquired by a third party or the Company has not entered into a definitive agreement with respect to, or otherwise consummated, a firmly underwritten offering of the Company capital stock on a major stock exchange that meets certain requirements, then holders of the Stock Consideration may collectively elect to exchange, during the &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;60-day&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; period commencing the date that is the &lt;/div&gt;18&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; month anniversary of the Closing (the &#x201c;Share Exchange&#x201d;), the Stock Consideration for shares of Sorrento&#x2019;s common stock with a value of $&lt;/div&gt;55.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million based on a price per share of Sorrento&#x2019;s common stock equal to the greater of (a)&#160;the &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;30-day&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; trailing volume weighted average price&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;of&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one share of Sorrento&#x2019;s common stock as reported on The Nasdaq Stock Market LLC as of the consummation of the Share Exchange and (b)&#160;$&lt;/div&gt;5.55&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt; (subject to adjustment for any stock dividend, stock split, stock combination, reclassification or similar transaction) (the &#x201c;Exchange Price&#x201d;). Pursuant to an amendment to the Exchange Agreement entered into by Sorrento on September&#160;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;28&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, on October&#160;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;9&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, Sorrento paid $&lt;/div&gt;55.0&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million in cash to the Semnur Equityholders in lieu of issuing $&lt;/div&gt;55.0&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million of shares of Sorrento&#x2019;s&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;common stock at the Exchange Price. Following the completion of the Share Exchange and as of December&#160;31, 2020, Sorrento held approximately &lt;/div&gt;82.3&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% of the outstanding common stock of the Company. On January&#160;29, 2021, Sorrento acquired additional shares of the Company, resulting in Sorrento holding approximately &lt;/div&gt;99.97&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% of the outstanding common stock of the &lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Company.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The transaction was accounted for as an asset acquisition since substantially all the value of the gross assets was concentrated in the single asset, &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-102.&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; As a result, approximately $&lt;/div&gt;75.3&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;million was expensed as a component of acquired &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-process&lt;/div&gt; research and development during the year ended December&#160;31, 2019. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;No&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; contingent consideration was recorded as of December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; and &lt;/div&gt;2020&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; since the related regulatory approval milestones are not deemed probable until they actually occur.&lt;/div&gt;&lt;/div&gt; </us-gaap:AssetAcquisitionTextBlock>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="P03_18_2019To03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">70000000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="P03_18_2019To03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">15000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable
      contextRef="P03_18_2019To03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">55000000</us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable>
    <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets
      contextRef="P03_18_2019To03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="0"
      unitRef="Unit_shares">47039315</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
    <us-gaap:CommonStockSharesSubscribedButUnissued
      contextRef="PAsOn03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="0"
      unitRef="Unit_shares">352972</us-gaap:CommonStockSharesSubscribedButUnissued>
    <sclx:AssetAcquisitionPricePerShare
      contextRef="PAsOn03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.16</sclx:AssetAcquisitionPricePerShare>
    <sclx:PercentageOfOwnershipInterest
      contextRef="PAsOn03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="2"
      unitRef="Unit_pure">0.58</sclx:PercentageOfOwnershipInterest>
    <us-gaap:AssetAcquisitionContingentConsiderationLiability
      contextRef="PAsOn03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">280000000</us-gaap:AssetAcquisitionContingentConsiderationLiability>
    <us-gaap:AssetAcquisitionContingentConsiderationLiability
      contextRef="PAsOn03_18_2019_RegulatoryBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">40000000</us-gaap:AssetAcquisitionContingentConsiderationLiability>
    <us-gaap:AssetAcquisitionContingentConsiderationLiability
      contextRef="PAsOn03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheOneMemberSCLXTrancheAxis"
      decimals="-5"
      unitRef="Unit_USD">20000000</us-gaap:AssetAcquisitionContingentConsiderationLiability>
    <sclx:RevenueToBeEarnedByTheAcquireeValue
      contextRef="P03_18_2019To03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheOneMemberSCLXTrancheAxis"
      decimals="-5"
      unitRef="Unit_USD">100000000</sclx:RevenueToBeEarnedByTheAcquireeValue>
    <us-gaap:AssetAcquisitionContingentConsiderationLiability
      contextRef="PAsOn03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheTwoMemberSCLXTrancheAxis"
      decimals="-5"
      unitRef="Unit_USD">20000000</us-gaap:AssetAcquisitionContingentConsiderationLiability>
    <sclx:RevenueToBeEarnedByTheAcquireeValue
      contextRef="P03_18_2019To03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheTwoMemberSCLXTrancheAxis"
      decimals="-5"
      unitRef="Unit_USD">250000000</sclx:RevenueToBeEarnedByTheAcquireeValue>
    <us-gaap:AssetAcquisitionContingentConsiderationLiability
      contextRef="PAsOn03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheThreeMemberSCLXTrancheAxis"
      decimals="-5"
      unitRef="Unit_USD">50000000</us-gaap:AssetAcquisitionContingentConsiderationLiability>
    <sclx:RevenueToBeEarnedByTheAcquireeValue
      contextRef="P03_18_2019To03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheThreeMemberSCLXTrancheAxis"
      decimals="-5"
      unitRef="Unit_USD">500000000</sclx:RevenueToBeEarnedByTheAcquireeValue>
    <us-gaap:AssetAcquisitionContingentConsiderationLiability
      contextRef="PAsOn03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheFourMemberSCLXTrancheAxis"
      decimals="-5"
      unitRef="Unit_USD">150000000</us-gaap:AssetAcquisitionContingentConsiderationLiability>
    <sclx:RevenueToBeEarnedByTheAcquireeValue
      contextRef="P03_18_2019To03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheFourMemberSCLXTrancheAxis"
      decimals="-5"
      unitRef="Unit_USD">750000000</sclx:RevenueToBeEarnedByTheAcquireeValue>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="P08_07_2019To08_07_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">40000000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:CommonStockSharesSubscribedButUnissued
      contextRef="PAsOn08_07_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="0"
      unitRef="Unit_shares">352972</us-gaap:CommonStockSharesSubscribedButUnissued>
    <sclx:AssetAcquisitionPricePerShare
      contextRef="PAsOn08_07_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.16</sclx:AssetAcquisitionPricePerShare>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="PAsOn08_07_2019_AsRestatedMembersrtRestatementAxis"
      decimals="-5"
      unitRef="Unit_USD">400000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <sclx:PercentageOfSharesIssuedSubjectToRestrictionOfTransfer
      contextRef="PAsOn03_01_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="2"
      unitRef="Unit_pure">1</sclx:PercentageOfSharesIssuedSubjectToRestrictionOfTransfer>
    <sclx:PeriodDuringWhichTheSharesMayBeExchanged contextRef="P03_01_2019To03_31_2019_SenmurMemberusgaapAssetAcquisitionAxis">P60D</sclx:PeriodDuringWhichTheSharesMayBeExchanged>
    <sclx:PeriodDuringWhichShareTransferIsRestricted contextRef="P03_01_2019To03_31_2019_SenmurMemberusgaapAssetAcquisitionAxis">P18M</sclx:PeriodDuringWhichShareTransferIsRestricted>
    <sclx:CommonStockValueToBeExchanged
      contextRef="P03_01_2019To03_31_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">55000000</sclx:CommonStockValueToBeExchanged>
    <sclx:NumberOfDaysForDeterminingTheWeightedVolumeAveragePriceForShares contextRef="P03_01_2019To03_31_2019_SenmurMemberusgaapAssetAcquisitionAxis">P30D</sclx:NumberOfDaysForDeterminingTheWeightedVolumeAveragePriceForShares>
    <sclx:PricePerShareForDeterminingTheExchangeOfShares
      contextRef="PAsOn03_01_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">5.55</sclx:PricePerShareForDeterminingTheExchangeOfShares>
    <sclx:PaymentMadeInSurrenderingTheShares
      contextRef="P03_01_2019To03_31_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">55000000</sclx:PaymentMadeInSurrenderingTheShares>
    <sclx:PaymentMadeInSurrenderingTheShares
      contextRef="P03_01_2019To03_31_2019_SenmurMemberusgaapAssetAcquisitionAxis_SorrentoMemberSCLXInvesteeAxis"
      decimals="-5"
      unitRef="Unit_USD">55000000</sclx:PaymentMadeInSurrenderingTheShares>
    <sclx:PercentageOfSharesOutstanding
      contextRef="PAsOn12_31_2020_SenmurMemberusgaapAssetAcquisitionAxis_SorrentoMemberSCLXInvesteeAxis"
      decimals="3"
      unitRef="Unit_pure">0.823</sclx:PercentageOfSharesOutstanding>
    <sclx:PercentageOfSharesOutstanding
      contextRef="PAsOn01_29_2021_SenmurMemberusgaapAssetAcquisitionAxis_SorrentoMemberSCLXInvesteeAxis"
      decimals="4"
      unitRef="Unit_pure">0.9997</sclx:PercentageOfSharesOutstanding>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="P01_01_2019To12_31_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">75300000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:AssetAcquisitionContingentConsiderationLiability
      contextRef="PAsOn12_31_2021_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:AssetAcquisitionContingentConsiderationLiability>
    <us-gaap:AssetAcquisitionContingentConsiderationLiability
      contextRef="PAsOn12_31_2020_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:AssetAcquisitionContingentConsiderationLiability>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="P01_01_2021To12_31_2021">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;5&lt;/div&gt;.&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair Value Measurements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents the Company&#x2019;s financial assets and liabilities that are measured at fair value (in &lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 52%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair value measurements at December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Quoted&#160;Prices&lt;br/&gt;in&#160;Active&lt;br/&gt;Markets&lt;br/&gt;(Level 1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 52%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 52%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 52%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 52%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,338&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,338&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; width: 52%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 52%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total assets measured at fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,338&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,338&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 52%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 52%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Derivative liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35,700&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35,700&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; width: 52%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 52%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total liabilities measured at fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35,700&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35,700&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"/&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 52%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair value measurements at December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Quoted&#160;Prices&lt;br/&gt;in&#160;Active&lt;br/&gt;Markets&lt;br/&gt;(Level&#160;1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 52%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 52%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,839&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,839&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; width: 52%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 52%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total assets measured at fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,839&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,839&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 52%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 52%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Derivative liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35,400&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35,400&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; width: 52%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Total liabilities measured at fair value&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35,400&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35,400&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s financial assets carried at fair value are comprised of cash and cash equivalents. Cash and cash equivalents consist of money market accounts and bank deposits which are highly liquid and readily tradable. These assets are valued using inputs observable in active markets for identical securities. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="null;text-indent: 0px;;font-style:italic;display:inline;"&gt;Derivative liabilities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company recorded a loss of $&lt;/div&gt;0.3&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, a gain of $&lt;/div&gt;0.8&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million and a loss of $&lt;/div&gt;23.3&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million on derivative liabilities for the&#160;years ended December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2020&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; and &lt;/div&gt;2019&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, respectively, which was attributed to compound derivative liabilities associated with the Scilex Pharma Notes. The compound derivative liabilities consist of the fair value of various embedded features as further described in Note &lt;/div&gt;8&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;. The fair value of the derivative liabilities associated with the Scilex Pharma Notes was estimated using the discounted cash flow method under the income approach combined with a Monte Carlo simulation model. This involves significant Level&#160;&lt;/div&gt;3&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; inputs and assumptions.&lt;/div&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;The&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;key assumptions for the compound derivative liabilities associated with the Scilex Pharma Notes for the year ended December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; included a &lt;/div&gt;6.2&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% risk-adjusted net sales forecast and an effective debt yield of &lt;/div&gt;15.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;%. The key assumptions for the compound derivative liabilities associated with the Scilex Pharma Notes for the year ended December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2020&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; included a &lt;/div&gt;7&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% risk-adjusted net sales forecast, an effective debt yield of &lt;/div&gt;15&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% and an estimated probability of &lt;/div&gt;100&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% of not obtaining marketing approval before March&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;. The key assumptions for the compound derivative liabilities associated with the Scilex Pharma Notes for the year ended December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2019&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; included an &lt;/div&gt;8&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% risk adjusted net sales forecast, an effective debt yield of &lt;/div&gt;19.7&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% and estimated probabilities of &lt;/div&gt;100&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% and &lt;/div&gt;55&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% of not obtaining marketing approval before March&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; and July&#160;&lt;/div&gt;1&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2023&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, respectively, and an estimated high probability of an initial public offering of the Company that satisfies certain valuation thresholds occurring prior to October&#160;&lt;/div&gt;1&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2020&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table includes a summary of the derivative liabilities measured at fair value using significant unobservable inputs (Level 3) during the years ended December&#160;31, 2021, 2020 and 2019: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 84%;"/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 84%; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Beginning Balance at December&#160;31, 2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 84%; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Additions&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10,100&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 84%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Re-measurement&lt;/div&gt; of fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;23,300&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; width: 84%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 84%; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Ending Balance at December&#160;31, 2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;33,400&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 84%; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Additions&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,800&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 84%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Re-measurement&lt;/div&gt; of fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(800&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; width: 84%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 84%; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Ending Balance at December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35,400&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 84%; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Additions&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 84%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Re-measurement&lt;/div&gt; of fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;300&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; width: 84%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em;"&gt;Ending Balance at December&#160;31, 2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35,700&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; </us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents the Company&#x2019;s financial assets and liabilities that are measured at fair value (in &lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 52%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair value measurements at December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Quoted&#160;Prices&lt;br/&gt;in&#160;Active&lt;br/&gt;Markets&lt;br/&gt;(Level 1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 52%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 52%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 52%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 52%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,338&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,338&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; width: 52%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 52%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total assets measured at fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,338&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,338&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 52%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 52%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Derivative liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35,700&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35,700&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; width: 52%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 52%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total liabilities measured at fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35,700&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35,700&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"/&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 52%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair value measurements at December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Quoted&#160;Prices&lt;br/&gt;in&#160;Active&lt;br/&gt;Markets&lt;br/&gt;(Level&#160;1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 52%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 52%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,839&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,839&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; width: 52%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 52%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total assets measured at fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,839&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,839&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 52%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 52%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Derivative liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35,400&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35,400&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; width: 52%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Total liabilities measured at fair value&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35,400&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35,400&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">4338000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      unitRef="Unit_USD">4338000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">4338000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      unitRef="Unit_USD">4338000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">35700000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      unitRef="Unit_USD">35700000</us-gaap:DerivativeLiabilities>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">35700000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      unitRef="Unit_USD">35700000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">4839000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn12_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      unitRef="Unit_USD">4839000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">4839000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      unitRef="Unit_USD">4839000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">35400000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn12_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      unitRef="Unit_USD">35400000</us-gaap:DerivativeLiabilities>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">35400000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      unitRef="Unit_USD">35400000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:DerivativeLossOnDerivative
      contextRef="P01_01_2021To12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">300000</us-gaap:DerivativeLossOnDerivative>
    <us-gaap:DerivativeGainOnDerivative
      contextRef="P01_01_2020To12_31_2020"
      decimals="1"
      unitRef="Unit_USD">0.8</us-gaap:DerivativeGainOnDerivative>
    <us-gaap:DerivativeLossOnDerivative
      contextRef="P01_01_2019To12_31_2019"
      decimals="-5"
      unitRef="Unit_USD">23300000</us-gaap:DerivativeLossOnDerivative>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="PAsOn12_20_2021_MeasurementInputRiskadjustedNetSalesForecastMemberusgaapMeasurementInputTypeAxis"
      decimals="1"
      unitRef="Unit_pure">6.2</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="PAsOn12_20_2021_MeasurementInputEffectiveDebtYieldMemberusgaapMeasurementInputTypeAxis"
      decimals="1"
      unitRef="Unit_pure">15</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="PAsOn12_31_2020_MeasurementInputRiskadjustedNetSalesForecastMemberusgaapMeasurementInputTypeAxis"
      decimals="0"
      unitRef="Unit_pure">7</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="PAsOn12_31_2020_MeasurementInputEffectiveDebtYieldMemberusgaapMeasurementInputTypeAxis"
      decimals="0"
      unitRef="Unit_pure">15</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="PAsOn12_31_2020_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeMarch312021MemberusgaapMeasurementInputTypeAxis"
      decimals="0"
      unitRef="Unit_pure">100</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="PAsOn12_31_2019_MeasurementInputRiskadjustedNetSalesForecastMemberusgaapMeasurementInputTypeAxis"
      decimals="0"
      unitRef="Unit_pure">8</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="PAsOn12_31_2019_MeasurementInputEffectiveDebtYieldMemberusgaapMeasurementInputTypeAxis"
      decimals="1"
      unitRef="Unit_pure">19.7</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="PAsOn12_31_2019_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeMarch312021MemberusgaapMeasurementInputTypeAxis"
      decimals="0"
      unitRef="Unit_pure">100</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="PAsOn12_31_2019_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeJuly12023MemberusgaapMeasurementInputTypeAxis"
      decimals="0"
      unitRef="Unit_pure">55</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table includes a summary of the derivative liabilities measured at fair value using significant unobservable inputs (Level 3) during the years ended December&#160;31, 2021, 2020 and 2019: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 84%;"/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Fair&#160;value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 84%; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Beginning Balance at December&#160;31, 2018&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 84%; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Additions&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10,100&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 84%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Re-measurement&lt;/div&gt; of fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;23,300&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; width: 84%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 84%; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Ending Balance at December&#160;31, 2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;33,400&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 84%; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Additions&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,800&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 84%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Re-measurement&lt;/div&gt; of fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(800&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; width: 84%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 84%; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Ending Balance at December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35,400&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 84%; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Additions&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 84%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Re-measurement&lt;/div&gt; of fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;300&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; width: 84%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em;"&gt;Ending Balance at December&#160;31, 2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35,700&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
      contextRef="P01_01_2019To12_31_2019_DerivativeFinancialInstrumentsLiabilitiesMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      unitRef="Unit_USD">10100000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P01_01_2019To12_31_2019_DerivativeFinancialInstrumentsLiabilitiesMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      unitRef="Unit_USD">23300000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn12_31_2019_DerivativeFinancialInstrumentsLiabilitiesMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      unitRef="Unit_USD">33400000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
      contextRef="P01_01_2020To12_31_2020_DerivativeFinancialInstrumentsLiabilitiesMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      unitRef="Unit_USD">2800000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P01_01_2020To12_31_2020_DerivativeFinancialInstrumentsLiabilitiesMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      unitRef="Unit_USD">-800000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn12_31_2020_DerivativeFinancialInstrumentsLiabilitiesMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      unitRef="Unit_USD">35400000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P01_01_2021To12_31_2021_DerivativeFinancialInstrumentsLiabilitiesMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      unitRef="Unit_USD">300000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn12_31_2021_DerivativeFinancialInstrumentsLiabilitiesMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      unitRef="Unit_USD">35700000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="P01_01_2021To12_31_2021">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and Equipment &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment consisted of the following as of December&#160;31, 2021 and 2020 (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 80%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Computers&#160;&amp;amp; equipment&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;77&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;77&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Furniture&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;118&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;118&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leasehold improvements&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;48&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;48&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Construction in progress&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;689&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;691&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment, gross&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;932&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;934&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: Accumulated depreciation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(127&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(88&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment, &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;net&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;805&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;846&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Depreciation expense&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;for each of the&#160;years ended December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2020&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; and &lt;/div&gt;2019&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; was $&lt;/div&gt;39&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;thousand, $&lt;/div&gt;40&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;thousand and $&lt;/div&gt;40&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;thousand, respectively.&lt;/div&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment consisted of the following as of December&#160;31, 2021 and 2020 (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 80%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Computers&#160;&amp;amp; equipment&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;77&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;77&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Furniture&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;118&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;118&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leasehold improvements&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;48&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;48&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Construction in progress&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;689&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;691&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment, gross&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;932&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;934&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: Accumulated depreciation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(127&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(88&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment, &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;net&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;805&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;846&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">77000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2020_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">77000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2021_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">118000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2020_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">118000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2021_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">48000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2020_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">48000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2021_ConstructionInProgressMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">689000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2020_ConstructionInProgressMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">691000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">932000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">934000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">127000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">88000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">805000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">846000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertySubjectToOrAvailableForOperatingLeaseGross
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_USD">39</us-gaap:PropertySubjectToOrAvailableForOperatingLeaseGross>
    <us-gaap:PropertySubjectToOrAvailableForOperatingLeaseGross
      contextRef="PAsOn12_31_2020"
      decimals="0"
      unitRef="Unit_USD">40</us-gaap:PropertySubjectToOrAvailableForOperatingLeaseGross>
    <us-gaap:PropertySubjectToOrAvailableForOperatingLeaseGross
      contextRef="PAsOn12_31_2019"
      decimals="0"
      unitRef="Unit_USD">40</us-gaap:PropertySubjectToOrAvailableForOperatingLeaseGross>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="P01_01_2021To12_31_2021">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Goodwill and Intangible Assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; and &lt;/div&gt;2020&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, the Company had recorded goodwill of $&lt;/div&gt;13.5&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million. The Company performed a qualitative test for goodwill impairment during the fourth quarter of &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;. Based upon the results of the qualitative testing, the Company concluded that it is &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;more-likely-than-not&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; that the fair value of the Company&#x2019;s goodwill was in excess of the carrying value and therefore performing the first step of the &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;two-step&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; impairment test was unnecessary. &lt;/div&gt;No&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; goodwill impairment was recognized for the&#160;years ended December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2020&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, and &lt;/div&gt;2019&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;.&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;The&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;Company&#x2019;s intangible assets, excluding goodwill, are composed of patent rights, acquired technology and assembled workforce. Amortization of the intangible assets that have finite useful lives is generally recorded on a straight-line basis over their useful lives. &lt;/div&gt;A summary of the Company&#x2019;s identifiable intangible assets as of December&#160;31, 2021 and 2020 is as follows (in thousands):&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 61%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gross&#160;&lt;br/&gt;carrying&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Accumulated&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;amortization&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Intangibles,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;net&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Patent rights&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;32,630&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,239&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21,391&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Acquired technology&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21,940&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,754&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17,186&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em;"&gt;Assembled workforce&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;275&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;225&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; width: 61%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em;"&gt;Total intangible assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;55,070&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,268&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;38,802&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 61%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gross&#160;&lt;br/&gt;carrying&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Accumulated&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;amortization&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Intangibles,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;net&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Patent rights&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;32,630&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9,064&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;23,566&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Acquired technology&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21,940&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,291&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;18,649&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em;"&gt;Assembled workforce&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;175&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;325&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; width: 61%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em;"&gt;Total intangible assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;55,070&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,530&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;42,540&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, the weighted average remaining life for identifiable intangible assets is &lt;/div&gt;10.6&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;years. Aggregate amortization expense was $&lt;/div&gt;3.7&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million for each of the&#160;years ended December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2020&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, and &lt;/div&gt;2019&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;. Patent rights and acquired technology are amortized over a &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;15-year&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; period. Assembled workforce is amortized over a &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5-year&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; period.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Estimated future amortization expense related to intangible assets at December&#160;31, 2021 is as follows (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 85%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ending December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amount&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,738&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,738&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,663&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,638&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2026&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,638&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Thereafter&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;20,387&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;38,802&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;No&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; impairment charges related to intangible assets were recorded during the&#160;years ended &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;December&#160;31, 2021 and 2020. &lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">13500000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2020"
      decimals="-5"
      unitRef="Unit_USD">13500000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="P01_01_2019To12_31_2019"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="P01_01_2021To12_31_2021">A summary of the Company&#x2019;s identifiable intangible assets as of December&#160;31, 2021 and 2020 is as follows (in thousands):
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 61%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gross&#160;&lt;br/&gt;carrying&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Accumulated&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;amortization&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Intangibles,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;net&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Patent rights&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;32,630&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,239&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21,391&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Acquired technology&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21,940&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,754&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17,186&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em;"&gt;Assembled workforce&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;275&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;225&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; width: 61%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em;"&gt;Total intangible assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;55,070&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,268&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;38,802&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 61%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gross&#160;&lt;br/&gt;carrying&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Accumulated&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;amortization&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Intangibles,&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;net&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Patent rights&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;32,630&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9,064&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;23,566&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 61%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Acquired technology&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21,940&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,291&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;18,649&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em;"&gt;Assembled workforce&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;175&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;325&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; width: 61%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em;"&gt;Total intangible assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;55,070&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,530&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;42,540&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2021_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">32630000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn12_31_2021_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">11239000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2021_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">21391000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2021_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">21940000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn12_31_2021_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">4754000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2021_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">17186000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2021_AssembledWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">500000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn12_31_2021_AssembledWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">275000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2021_AssembledWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">225000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">55070000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">16268000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">38802000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2020_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">32630000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn12_31_2020_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">9064000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2020_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">23566000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2020_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">21940000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn12_31_2020_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">3291000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2020_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">18649000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2020_AssembledWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">500000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn12_31_2020_AssembledWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">175000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2020_AssembledWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">325000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">55070000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">12530000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">42540000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 contextRef="P01_01_2021To12_31_2021_WeightedAverageMembersrtRangeAxis">P10Y7M6D</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="P01_01_2021To12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">3700000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="P01_01_2020To12_31_2020"
      decimals="-5"
      unitRef="Unit_USD">3700000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="P01_01_2019To12_31_2019"
      decimals="-5"
      unitRef="Unit_USD">3700000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="P01_01_2021To12_31_2021_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="P01_01_2021To12_31_2021_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="P01_01_2021To12_31_2021_AssembledWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Estimated future amortization expense related to intangible assets at December&#160;31, 2021 is as follows (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 85%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ending December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amount&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,738&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,738&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,663&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,638&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2026&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,638&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Thereafter&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;20,387&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;38,802&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">3738000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">3738000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">3663000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">3638000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">3638000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">20387000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">38802000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:DebtDisclosureTextBlock contextRef="P01_01_2021To12_31_2021">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;8.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Debt &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;2018 Purchase Agreements and Indenture &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On September&#160;&lt;/div&gt;7&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2018&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, Scilex Pharma and Sorrento entered into Purchase Agreements (the &#x201c;&lt;/div&gt;2018&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Purchase Agreements&#x201d;) with certain investors (collectively, the &#x201c;Scilex Pharma Note Purchasers&#x201d;). Pursuant to the &lt;/div&gt;2018&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Purchase Agreements, on September&#160;&lt;/div&gt;7&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2018&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, Scilex Pharma, among other things, issued and sold to the Scilex Pharma Note Purchasers senior secured notes due &lt;/div&gt;2026&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; in an aggregate principal amount of $&lt;/div&gt;224.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million (the &#x201c;Scilex Pharma Notes&#x201d;) for an aggregate purchase price of $&lt;/div&gt;140.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million (the &#x201c;Offering&#x201d;). The Scilex Pharma Notes are governed by an indenture (as amended, the &#x201c;Indenture&#x201d;) with Scilex Pharma, as issuer, U.S. &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Bank &lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;National&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;Association, a national banking association, as trustee (the &#x201c;Trustee&#x201d;) and collateral agent (the &#x201c;Collateral Agent&#x201d;), and Sorrento, as guarantor. Pursuant to the Indenture, Sorrento agreed to irrevocably and unconditionally guarantee, on a senior unsecured basis, the punctual performance and payment when due of all obligations of Scilex Pharma under the Indenture (the &#x201c;Guarantee&#x201d;).&lt;/div&gt;&lt;/div&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The net proceeds of the Offering were approximately $&lt;/div&gt;89.3&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, after deducting the Offering expenses payable by Scilex Pharma and funding a segregated reserve account with $&lt;/div&gt;20.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million (the &#x201c;Reserve Account&#x201d;) and a segregated collateral account with $&lt;/div&gt;25.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million (the &#x201c;Collateral Account&#x201d;) pursuant to the terms of the Indenture. Funds in the Reserve Account were to be released to Scilex Pharma upon receipt by the Trustee of an officer&#x2019;s certificate under the Indenture from Scilex Pharma confirming receipt of a marketing approval letter from the FDA with respect to &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-103&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; or a similar product with a concentration of not less than &lt;/div&gt;5&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% (the &#x201c;Marketing Approval Letter&#x201d;) on or prior to July&#160;&lt;/div&gt;1&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2023&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;. Funds in the Collateral Account were to be released to Scilex Pharma only upon receipt of a written consent authorizing such release from the holders of a majority in principal amount of the Scilex Pharma Notes issued, upon the occurrence and during the continuance of an event of default at the direction of the holders of a majority in principal amount of the Scilex Pharma Notes issued or upon the repayment in full of all amounts owed under the Scilex Pharma Notes.&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On each February&#160;&lt;/div&gt;15&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, May&#160;&lt;/div&gt;15&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, August&#160;&lt;/div&gt;15&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; and November&#160;&lt;/div&gt;15&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, beginning with February&#160;&lt;/div&gt;15&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2019&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, the holders of the Scilex Pharma Notes were initially entitled to receive quarterly payments of the principal of the Scilex Pharma Notes equal to a fixed&#160;percentage, ranging from &lt;/div&gt;10&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% to &lt;/div&gt;20&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;%, of the net sales of ZTlido for the prior fiscal quarter. However, because Scilex Pharma did not receive the Marketing Approval Letter by March&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, the&#160;percentage of net sales payable was increased to be in the range of &lt;/div&gt;15&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% to &lt;/div&gt;25&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;%. If actual cumulative net sales of ZTlido from October&#160;&lt;/div&gt;1&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; through September&#160;&lt;/div&gt;30&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2023&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; are less than approximately $&lt;/div&gt;218.1&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, then Scilex Pharma will be obligated to pay an additional installment of the principal of the Scilex Pharma Notes each quarter in an amount between approximately $&lt;/div&gt;10.1&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million and approximately $&lt;/div&gt;30.6&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, with the amount of the additional installment of principal to be determined by reference to the amount by which cumulative net sales of ZTlido from October&#160;&lt;/div&gt;1&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; through September&#160;&lt;/div&gt;30&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2023&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; are less than approximately $&lt;/div&gt;218.1&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million.&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Under the terms of the Indenture, the aggregate principal amount due under the Scilex Pharma Notes was to be increased by $&lt;/div&gt;28.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million on February&#160;&lt;/div&gt;15&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; if actual cumulative net sales of ZTlido from September&#160;&lt;/div&gt;7&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2018&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; through December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; were less than approximately $&lt;/div&gt;481.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million. As actual cumulative net sales of ZTlido from the issue date of the Scilex Pharma Notes through December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; did not equal or exceed the $&lt;/div&gt;481.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million threshold for such period, the Company recorded the increase of $&lt;/div&gt;28.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million in the debt principal balance with an offset to Scilex Pharma Notes principal increase at December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;.&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;If actual cumulative net sales of ZTlido for the period from October&#160;&lt;/div&gt;1&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; through September&#160;&lt;/div&gt;30&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2023&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; are less than approximately $&lt;/div&gt;290.7&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, then the aggregate principal amount due under the Scilex Pharma Notes will be increased on &lt;/div&gt;November 15, 2023&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; by between approximately $&lt;/div&gt;2.6&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million and approximately $&lt;/div&gt;84.8&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, with the amount of the principal increase to be determined by reference to the amount by which the cumulative net sales of ZTlido from October&#160;&lt;/div&gt;1&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; through September&#160;&lt;/div&gt;30&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2023&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; is less than approximately $&lt;/div&gt;290.7&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million.&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;final maturity date of the Scilex Pharma Notes is &lt;/div&gt;August 15, 2026&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;. The Scilex Pharma Notes may be redeemed in whole at any time upon &lt;/div&gt;30&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;days&#x2019; written notice at Scilex Pharma&#x2019;s option prior to August&#160;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;15&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2026&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;at a redemption price equal to 100% of the then-outstanding principal amount of the Scilex Pharma Notes. In addition, upon a change of control of Scilex Pharma (as defined in the Indenture), each holder of a Scilex Pharma Note shall have the right to require Scilex Pharma to repurchase all or any part of such holder&#x2019;s Scilex Pharma Note at a repurchase price in cash equal to 101% of the then-outstanding principal amount &lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;thereof.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;The 2018 Purchase&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Agreements include the terms and conditions of the offer and sale of the Scilex Pharma Notes, representations and warranties of the parties, indemnification and contribution obligations and other terms and conditions customary in agreements of this &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;type. &lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;The&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Indenture governing the Scilex Pharma Notes contains customary events of default with respect to the Scilex Pharma Notes (including a failure to make any payment of principal on the Scilex Pharma Notes when due and payable), and, upon certain events of default occurring and continuing, the Trustee by notice to Scilex Pharma, or the holders of at least &lt;/div&gt;25&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% in principal amount of the outstanding Scilex Pharma Notes by notice to Scilex Pharma and the Trustee, may (subject to the provisions of the Indenture) declare &lt;/div&gt;100&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% of the then-outstanding principal amount of the Scilex Pharma Notes to be due and payable. Upon such a declaration of acceleration, such principal will be due and payable immediately. In the case of certain events, including bankruptcy, insolvency or reorganization involving Sorrento or Scilex Pharma, the Scilex Pharma Notes will automatically become due and payable.&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pursuant to the Indenture, the Company and Scilex Pharma must also comply with certain covenants with respect to the commercialization of ZTlido, as well as customary additional affirmative covenants, such as furnishing financial statements to the holders of the Scilex Pharma Notes, minimum cash requirements and net sales reports; and negative covenants, including limitations on the following: the incurrence of debt; the payment of dividends, the repurchase of shares and under certain conditions making certain other restricted payments; the prepayment, redemption or repurchase of subordinated debt; a merger, amalgamation or consolidation involving Scilex Pharma; engaging in certain transactions with affiliates; and the making of investments other than those permitted by the Indenture.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Scilex Pharma Notes and related Guarantee have not been, and will not be, registered under the Securities Act or the securities laws of any other jurisdiction and may not be offered or sold in the United States without registration or an applicable exemption from registration requirements. The holders of the Scilex Pharma Notes do not have any registration rights. Pursuant to a Collateral Agreement by and among Scilex Pharma, the Trustee and the Collateral Agent (the &#x201c;Collateral Agreement&#x201d;), the Scilex Pharma Notes will be secured by ZTlido and all of the existing and future property and assets of Scilex Pharma necessary for, or otherwise relevant to, now or in the future, the manufacture and sale of ZTlido, on a worldwide basis (exclusive of Japan), including, but not limited to, the intellectual property related to ZTlido, the marketing or similar regulatory approvals related to ZTlido, any licenses, agreements and other contracts related to ZTlido, and the current assets related to ZTlido such as inventory, accounts receivable and cash and any and all future iterations, improvements or modifications of such product made, developed or licensed (or &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;sub-licensed)&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; by Scilex Pharma or any of its affiliates or licensees (or &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;sub-licensees)&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; (including &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-103).&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pursuant to the terms of the Indenture, Sorrento issued an irrevocable standby letter of credit to Scilex Pharma (the &#x201c;Letter of Credit&#x201d;), which provides that, in the event that &lt;/div&gt;(1)&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;Scilex Pharma did not hold at least $&lt;/div&gt;4.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million in unrestricted cash as of the end of any calendar month during the term of the Scilex Pharma Notes, &lt;/div&gt;(2)&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;actual cumulative net sales of ZTlido from September&#160;&lt;/div&gt;7&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2018&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; through December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; were less than a specified sales threshold for such period, or &lt;/div&gt;(3)&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;actual cumulative net sales of ZTlido for any calendar year during the term of the Scilex Pharma Notes, beginning with the &lt;/div&gt;2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; calendar year, were less than a specified sales threshold for such calendar year, Scilex Pharma as beneficiary of the Letter of Credit, would be required to draw, and Sorrento would be required to pay to Scilex Pharma, $&lt;/div&gt;35.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million in a single &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;lump-su&lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;m&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; amo&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;unt as a subordinated loan. The Letter of Credit was to terminate upon the earliest to occur of: (a)&#160;the repayment of the&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;Scilex&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pharma Notes in full, (b)&#160;the actual net sales of ZTlido for any calendar year during the term of the Scilex Pharma Notes exceeding a certain threshold, (c)&#160;the consummation of an initial public offering on a major international stock&#160;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;exchange by the Company that satisfies certain valuation thresholds, and (d)&#160;the replacement of the Letter of Credit with another letter of credit in form and substance, including as to the identity and creditworthiness of issuer, reasonably acceptable to the holders of at least 80% in principal amount of outstanding Scilex Pharma Notes.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;On&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt;December&#160;14, 2020, Scilex,&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Sorrento, the Trustee and the Agent, and the beneficial owners of the Scilex Pharma Notes and the Scilex Note Purchasers entered into a Consent Under and Amendment No.&#160;&lt;/div&gt;3&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; to Indenture and Letter of Credit (&#x201c;Amendment No.&#160;&lt;/div&gt;3&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x201d;), which amended: (i)&#160;the Indenture, and (ii)&#160;the Letter of &lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Credit.&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pursuant &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; to Amendment No.&#160;&lt;/div&gt;3&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, the Holders agreed to release all of the aggregate $&lt;/div&gt;45.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million in restricted funds held in the Reserve Account and the Collateral Account for the purpose of consummating the repurchase of an aggregate of $&lt;/div&gt;45.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million of principal amount of the Scilex Pharma Notes from the Holders on a pro&#160;rata basis at a purchase price equal to &lt;/div&gt;100&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% of the principal amount thereof (such repurchase, the &#x201c;Scilex Repurchase&#x201d;). In connection with the Scilex Repurchase, the parties also agreed to remove (i)&#160;Sorrento&#x2019;s obligations under the Indenture to repurchase $&lt;/div&gt;25.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million of Scilex Pharma Notes from the Holders if the Letter of Credit is drawn on and (ii)&#160;Scilex Pharma&#x2019;s obligation to repurchase $&lt;/div&gt;20.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million of Scilex Pharma Notes from the Holders if Scilex Pharma did not receive the Marketing Approval Letter on or prior to&lt;/div&gt; July 1, 2023&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;. On December&#160;&lt;/div&gt;14&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2020&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, the restricted funds in the Reserve Account and the Collateral Account were released and the Scilex Repurchase was effected.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;Amendment&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;No.&#160;&lt;/div&gt;3&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; also revised the minimum cash covenant in the Indenture to provide that the amount of cash equivalents in bank accounts that Scilex Pharma is required to have as of the end of any calendar month shall, commencing with the month ending December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2020&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, be equal to at least $&lt;/div&gt;4.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million in the aggregate, provided that if Scilex Pharma did not effectuate (i)&#160;the December Optional Repurchase (as defined below) and (ii)&#160;at least one of either (x)&#160;the February Optional Repurchase (as defined below) or (y)&#160;the April Optional Repurchase (as defined below), then, commencing with the month ending April&#160;&lt;/div&gt;30&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, and for each month thereafter, such amount would have been required to be at least $&lt;/div&gt;10.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million in the aggregate. If Scilex Pharma fails to meet the foregoing minimum cash requirements, then Scilex Pharma will be required to draw on the Letter of Credit.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;Amendment&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; No.&#160;&lt;/div&gt;3&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; also provided Scilex Pharma with the option, in its sole and absolute discretion, to repurchase Scilex Pharma Notes from the holders thereof on a pro&#160;rata basis on each of December&#160;&lt;/div&gt;16&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2020&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; (the &#x201c;December Optional Repurchase&#x201d;), February&#160;&lt;/div&gt;12&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; (the &#x201c;February Optional Repurchase&#x201d;) and April&#160;&lt;/div&gt;13&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; (the &#x201c;April Optional Repurchase&#x201d;), in each case in an aggregate amount equal to the lesser of $&lt;/div&gt;20.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million or the then-outstanding principal amount of the Scilex Pharma Notes, at a purchase price in cash equal to &lt;/div&gt;100&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% of the principal amount thereof. Scilex Pharma effectuated the December Optional Repurchase, the February Optional Repurchase, and the April Optional Repurchase, which reduced the aggregate principal amount of the Scilex Pharma Notes by $&lt;/div&gt;60.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million and resulted in the minimum unrestricted requirement remaining at $&lt;/div&gt;4.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;Amendment&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; No.&#160;&lt;/div&gt;3&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; further provided that in the event that the Letter of Credit is drawn upon by Scilex Pharma, then Scilex Pharma had to, within five business days of such draw, repurchase the Scilex Pharma Notes from the holders thereof on a pro&#160;rata basis in an aggregate amount equal to the lesser of $&lt;/div&gt;20.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million or the then-outstanding principal amount of Scilex Pharma Notes, at a purchase price in cash equal to &lt;/div&gt;100&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% of the principal amount thereof. In addition, upon the Letter of Credit being drawn on, Scilex Pharma is required to have minimum cash of $&lt;/div&gt;10.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million at all times thereafter. In February&#160;&lt;/div&gt;2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, Scilex Pharma drew upon the Letter of Credit with Sorrento and, as such, repaid $&lt;/div&gt;20.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million of the principal amount of the Scilex Pharma Notes and became subject to a minimum cash requirement of $&lt;/div&gt;10.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;Pursuant&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;to Amendment No.&#160;&lt;/div&gt;3&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, the Holders also consented to Scilex Pharma incurring up to $&lt;/div&gt;10.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million of indebtedness in connection with an accounts receivable revolving loan facility (discussed below).&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;The&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Company accounted for Amendment No.&#160;&lt;/div&gt;3&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; as a debt modification under ASC Topic &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;470-50&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; as modified terms were not substantially different than the &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-modified&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; terms. The execution of Amendment No.&#160;&lt;/div&gt;3&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; resulted&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;in an additional derivative liability of $&lt;/div&gt;2.8&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, which pertains to a $&lt;/div&gt;9.6&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million distribution to Sorrento with respect to a contingent accelerated repayment on the Scilex Pharma Notes in connection with the Letter of Credit and $&lt;/div&gt;6.8&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million reduction to the debt discount on the Scilex Pharma Notes.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;To&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;estimate the fair value of the Scilex Pharma Notes, the Company uses the discounted cash flow method under the income approach, which involves significant Level&#160;&lt;/div&gt;3&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; inputs and assumptions, combined with a Monte Carlo simulation, as appropriate. The value of the debt instrument is based on the present value of future principal payments and the discounted rate of return reflective of the Company&#x2019;s credit &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;risk. &lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Borrowings of the Scilex Pharma Notes are as follows (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 72%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Principal&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;133,997&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;151,872&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Unamortized debt discount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(30,597&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(51,022&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Unamortized debt issuance costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,228&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3,711&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Carrying value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;101,172&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;97,139&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current portion&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(29,135&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4,881&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Long term portion&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;72,037&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;92,258&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Estimated fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;115,400&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;122,300&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Future minimum payments under the Scilex Pharma Notes, based on a percentage of projected net sales of ZTlido are estimated as follows (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 83%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ending December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 83%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;29,135&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 83%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,005&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 83%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13,637&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 83%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14,746&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 83%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2026&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;64,474&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; width: 83%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 83%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total minimum future payments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;133,997&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;The&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Company made principal payments of $&lt;/div&gt;45.9&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, $&lt;/div&gt;69.8&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, and $&lt;/div&gt;2.3&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million during the fiscal&#160;years ended December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2020&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, and &lt;/div&gt;2019&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, respectively.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Debt &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; discount and debt issuance costs, which are presented as a direct reduction of the Scilex Pharma Notes in the consolidated balance sheets, are amortized as interest expense using the effective interest method. As principal repayments on the Scilex Pharma Notes are based on a&#160;percentage of net sales of ZTlido and &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-103,&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; if the Marketing Approval Letter is received, the Company has elected to account for changes in estimated cash flows from future net sales prospectively. Specifically, a new effective interest rate will be determined based on revised estimates of remaining cash flows and changes in expected cash flows will be recognized prospectively. The imputed effective interest rate at December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; and &lt;/div&gt;2020&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; was &lt;/div&gt;7.7&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% and &lt;/div&gt;9.15&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;%, respectively. The amount of debt discount and debt issuance costs included in interest expense for the&#160;years ended December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2020&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; and &lt;/div&gt;2019&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; was approximately $&lt;/div&gt;7.9&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, $&lt;/div&gt;10.7&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million and $&lt;/div&gt;15.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, respectively.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;The&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Company identified a number of embedded derivatives that require bifurcation from the Scilex Pharma Notes and separate accounting in the consolidated financial statements as derivative liabilities. Certain of these embedded features included default interest provisions, contingent rate increases, contingent put options, optional and automatic acceleration provisions and indemnified taxes. The Company recorded this derivative within its consolidated financial statements (See Note &lt;/div&gt;5)&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;. The Company &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-evaluates&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; this assessment each reporting period.&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Scilex Pharma Notes also provide that, upon the occurrence of an event of default, the holders of at least &lt;/div&gt;25&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% in principal amount of the outstanding Scilex Pharma Notes may, by written notice to Scilex Pharma, declare all of the outstanding principal and premium under such Scilex Pharma Notes immediately due and payable. For purposes of the Scilex Pharma Notes, an event of default includes, among other things, (i)&#160;Scilex Pharma&#x2019;s failure to pay outstanding material indebtedness, including the Scilex Pharma Notes, when due (ii)&#160;Scilex Pharma&#x2019;s breach of its representations and warranties or failure to comply with its covenants and obligations under the Scilex Pharma Notes or (iii)&#160;the occurrence of certain insolvency or bankruptcy events (both voluntary and involuntary) involving Scilex Pharma. The Company is in compliance with event of default clauses.&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"/&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Related Party Notes Payable &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On October&#160;&lt;/div&gt;5&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2018&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, Scilex Pharma issued to Sorrento a promissory note (see Note &lt;/div&gt;13)&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;. On March&#160;&lt;/div&gt;18&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2019&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, the Company entered into a note payable with Sorrento (see Note &lt;/div&gt;13)&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;2020 Revolving Credit Facility &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On December&#160;&lt;/div&gt;14&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2020&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, Scilex Pharma entered into the Credit and Security Agreement (the &#x201c;Credit Agreement&#x201d;) with CNH Finance Fund&#160;I, L.P. (&#x201c;CNH&#x201d;) which provides Scilex Pharma with the ability to incur indebtedness under an accounts receivable revolving loan facility in an aggregate amount of $&lt;/div&gt;10.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million and the incurrence of liens and the pledge of collateral to CNH in connection with the revolving loan facility. Under the terms of the Credit Agreement, interest will accrue daily on the principal amount outstanding at a rate per annum equal to the Wall Street Journal Prime Rate plus &lt;/div&gt;1.75&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;%. All indebtedness incurred and outstanding will be due and payable in full on January&#160;&lt;/div&gt;1&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2024&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;; unless the Credit Agreement is earlier terminated. As of December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; and &lt;/div&gt;2020&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, the outstanding balance was $&lt;/div&gt;8.8&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million and $&lt;/div&gt;9.5&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, respectively. On February&#160;&lt;/div&gt;16&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, the Company notified CNH that it was terminating the Credit Agreement, effective &lt;/div&gt;March 18, 2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;. Upon termination, all principal balances and interest accrued were &lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;settled.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Paycheck Protection Program &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In May&#160;&lt;/div&gt;2020&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, the Company received the proceeds from a loan in the amount of $&lt;/div&gt;1.6&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million (the &#x201c;PPP Loan&#x201d;) from Bank of America, as the lender, pursuant to the Paycheck Protection Program (&#x201c;PPP&#x201d;) of the Coronavirus Aid, Relief, and Economic Security Act (the &#x201c;CARES Act&#x201d;). The PPP Loan matures on &lt;/div&gt;May 05, 2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; and bears interest at a rate of &lt;/div&gt;1.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% per annum. The PPP Loan is evidenced by a promissory note dated May &lt;/div&gt;03&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2020&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; (the &#x201c;Note&#x201d;), which contains customary events of default relating to, among other things, payment defaults and breaches of representations and &lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;warranties.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Under the CARES Act, loan forgiveness is available for the sum of documented payroll costs, covered rent payments, covered mortgage interest and covered utilities during the twenty-four-week period, beginning on the date of loan approval. For purposes of the CARES Act, payroll costs exclude compensation of an individual employee in excess of $&lt;/div&gt;100,000&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, prorated annually. Not more than &lt;/div&gt;25&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% of the forgiven amount may be for &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-payroll&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; costs. Forgiveness is reduced if full-time headcount declines, or if salaries and wages for employees with salaries of $&lt;/div&gt;100,000&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; or less annually are reduced by more than &lt;/div&gt;25&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;%. In the event the PPP Loan, or any portion thereof, is forgiven pursuant to the PPP, the amount forgiven is applied to outstanding principal. The Company used all of the proceeds from the PPP Loan to retain employees and maintain payroll. In May&#160;&lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, the Company received confirmation from the SBA that the entire PPP Loan was forgiven and recorded a gain on debt extinguishment of $&lt;/div&gt;1.6&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, which is included in loss on debt extinguishment, net, on the consolidated statements of operations for the year ended &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;December&#160;31, 2021. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentTerm contextRef="P09_07_2018To09_07_2018_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis">P2026Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn09_07_2018_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">224000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentRepurchaseAmount
      contextRef="PAsOn09_07_2018_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">140000000</us-gaap:DebtInstrumentRepurchaseAmount>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="P09_07_2018To09_07_2018_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">89300000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <sclx:PaymentToDepositIntoASeggregateReserveFund
      contextRef="P09_07_2018To09_07_2018_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">20000000</sclx:PaymentToDepositIntoASeggregateReserveFund>
    <sclx:PaymentToDepositIntoASegregatedCollateralAccount
      contextRef="P09_07_2018To09_07_2018_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">25000000</sclx:PaymentToDepositIntoASegregatedCollateralAccount>
    <sclx:PercentageOfConcentrationOnASimilarProduct
      contextRef="P09_07_2018To09_07_2018_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis"
      decimals="2"
      unitRef="Unit_pure">0.05</sclx:PercentageOfConcentrationOnASimilarProduct>
    <sclx:PercentageOfQuarterlyPaymentsOfThePrincipalNotesEqualToAFixedPercentage
      contextRef="P02_15_2019To02_15_2019_MinimumMembersrtRangeAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis"
      decimals="2"
      unitRef="Unit_pure">0.10</sclx:PercentageOfQuarterlyPaymentsOfThePrincipalNotesEqualToAFixedPercentage>
    <sclx:PercentageOfQuarterlyPaymentsOfThePrincipalNotesEqualToAFixedPercentage
      contextRef="P02_15_2019To02_15_2019_MaximumMembersrtRangeAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis"
      decimals="2"
      unitRef="Unit_pure">0.20</sclx:PercentageOfQuarterlyPaymentsOfThePrincipalNotesEqualToAFixedPercentage>
    <sclx:PercentageOfNetSalesPayable
      contextRef="P02_15_2019To02_15_2019_MinimumMembersrtRangeAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis"
      decimals="2"
      unitRef="Unit_pure">0.15</sclx:PercentageOfNetSalesPayable>
    <sclx:PercentageOfNetSalesPayable
      contextRef="P02_15_2019To02_15_2019_MaximumMembersrtRangeAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis"
      decimals="2"
      unitRef="Unit_pure">0.25</sclx:PercentageOfNetSalesPayable>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="P10_01_2022To09_30_2023_DebtInstrumentRedemptionPeriodOneMemberusgaapDebtInstrumentRedemptionPeriodAxis_ScenarioAdjustmentMembersrtStatementScenarioAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">218100000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RepaymentsOfDebt
      contextRef="P10_01_2022To09_30_2023_DebtInstrumentRedemptionPeriodOneMemberusgaapDebtInstrumentRedemptionPeriodAxis_MinimumMembersrtRangeAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">10100000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="P10_01_2022To09_30_2023_DebtInstrumentRedemptionPeriodOneMemberusgaapDebtInstrumentRedemptionPeriodAxis_MaximumMembersrtRangeAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">30600000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="P10_01_2022To09_30_2023_DebtInstrumentRedemptionPeriodOneMemberusgaapDebtInstrumentRedemptionPeriodAxis_ScenarioAdjustmentMembersrtStatementScenarioAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">218100000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="P02_15_2022To02_15_2022_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">28000000</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="P09_07_2018To12_31_2021_DebtInstrumentRedemptionPeriodTwoMemberusgaapDebtInstrumentRedemptionPeriodAxis_ScenarioAdjustmentMembersrtStatementScenarioAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">481000000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn02_15_2022_MaximumMembersrtRangeAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">28000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="P10_01_2022To09_30_2023_DebtInstrumentRedemptionPeriodThreeMemberusgaapDebtInstrumentRedemptionPeriodAxis_ScenarioAdjustmentMembersrtStatementScenarioAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">290700000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:DebtInstrumentMaturityDate contextRef="P10_01_2022To09_30_2023_DebtInstrumentRedemptionPeriodThreeMemberusgaapDebtInstrumentRedemptionPeriodAxis_ScenarioAdjustmentMembersrtStatementScenarioAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis">2023-11-15</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:RepaymentsOfDebt
      contextRef="P10_01_2022To09_30_2023_DebtInstrumentRedemptionPeriodThreeMemberusgaapDebtInstrumentRedemptionPeriodAxis_MinimumMembersrtRangeAxis_ScenarioAdjustmentMembersrtStatementScenarioAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">2600000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="P10_01_2022To09_30_2023_DebtInstrumentRedemptionPeriodThreeMemberusgaapDebtInstrumentRedemptionPeriodAxis_MaximumMembersrtRangeAxis_ScenarioAdjustmentMembersrtStatementScenarioAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">84800000</us-gaap:RepaymentsOfDebt>
    <us-gaap:DebtInstrumentMaturityDate contextRef="P02_15_2019To02_15_2019_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis">2026-08-15</us-gaap:DebtInstrumentMaturityDate>
    <sclx:DebtInstrumentredemptionPeriod contextRef="P02_15_2019To02_15_2019_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis">P30D</sclx:DebtInstrumentredemptionPeriod>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
      contextRef="P02_15_2019To02_15_2019_MinimumMembersrtRangeAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis"
      decimals="2"
      unitRef="Unit_pure">1</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
      contextRef="P02_15_2019To02_15_2019_MaximumMembersrtRangeAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis"
      decimals="2"
      unitRef="Unit_pure">1.01</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
      contextRef="P02_15_2019To02_15_2019_IndebentureMemberSCLXAgreementAxis_MinimumMembersrtRangeAxis"
      decimals="2"
      unitRef="Unit_pure">0.25</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
      contextRef="P02_15_2019To02_15_2019_IndebentureMemberSCLXAgreementAxis_MaximumMembersrtRangeAxis"
      decimals="2"
      unitRef="Unit_pure">1</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="P09_07_2018To12_31_2021_LetterOfCreditMemberusgaapCreditFacilityAxis"
      decimals="-5"
      unitRef="Unit_USD">4000000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="P09_07_2018To12_31_2021_LetterOfCreditMemberusgaapCreditFacilityAxis"
      decimals="-5"
      unitRef="Unit_USD">35000000</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn12_14_2020_IndebentureMemberSCLXAgreementAxis"
      decimals="-5"
      unitRef="Unit_USD">45000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="PAsOn12_14_2020_IndebentureMemberSCLXAgreementAxis"
      decimals="-5"
      unitRef="Unit_USD">45000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <sclx:PercentageOfThePrincipalAmountFromHoldersOnProRataBasis
      contextRef="P12_14_2020To12_14_2020_IndebentureMemberSCLXAgreementAxis"
      decimals="2"
      unitRef="Unit_pure">1</sclx:PercentageOfThePrincipalAmountFromHoldersOnProRataBasis>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="PAsOn12_14_2020_IfLetterOfCreditIsDrawnMembersrtStatementScenarioAxis_IndebentureMemberSCLXAgreementAxis_LetterOfCreditMemberusgaapCreditFacilityAxis"
      decimals="-5"
      unitRef="Unit_USD">25000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="PAsOn12_14_2020_IndebentureMemberSCLXAgreementAxis_LetterOfCreditMemberusgaapCreditFacilityAxis_MarketingApprovalLetterMembersrtStatementScenarioAxis"
      decimals="-5"
      unitRef="Unit_USD">20000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentMaturityDate contextRef="P12_14_2020To12_14_2020_IndebentureMemberSCLXAgreementAxis">2023-07-01</us-gaap:DebtInstrumentMaturityDate>
    <sclx:MinimumCashRequirementsToRepurchaseOfNotes
      contextRef="P04_30_2021To04_30_2021_LetterOfCreditMemberusgaapCreditFacilityAxis_MinimumMembersrtRangeAxis"
      decimals="-5"
      unitRef="Unit_USD">4000000</sclx:MinimumCashRequirementsToRepurchaseOfNotes>
    <sclx:MinimumCashRequirementsToRepurchaseOfNotes
      contextRef="P04_30_2021To04_30_2021_LetterOfCreditMemberusgaapCreditFacilityAxis_MaximumMembersrtRangeAxis"
      decimals="-5"
      unitRef="Unit_USD">10000000</sclx:MinimumCashRequirementsToRepurchaseOfNotes>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="PAsOn09_30_2022_DecemberOptionalRepurchaseMemberSCLXStatementAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">20000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="PAsOn09_30_2022_FebruaryOptionalRepurchaseMemberSCLXStatementAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">20000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="PAsOn09_30_2022_AprilOptionalRepurchaseMemberSCLXStatementAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">20000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <sclx:PercentageOfThePrincipalAmountOfTheNotes
      contextRef="P09_30_2022To09_30_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis"
      decimals="2"
      unitRef="Unit_pure">1</sclx:PercentageOfThePrincipalAmountOfTheNotes>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="PAsOn09_30_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">60000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <sclx:MinimumUnrestrictedCashRequirementsToRepurchaseOfNotes
      contextRef="P09_30_2022To09_30_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">4000000</sclx:MinimumUnrestrictedCashRequirementsToRepurchaseOfNotes>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="PAsOn09_30_2022_LetterOfCreditMemberusgaapCreditFacilityAxis"
      decimals="-5"
      unitRef="Unit_USD">20000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <sclx:PercentageOfThePrincipalAmountOfTheNotes
      contextRef="P09_30_2022To09_30_2022_LetterOfCreditMemberusgaapCreditFacilityAxis"
      decimals="2"
      unitRef="Unit_pure">1</sclx:PercentageOfThePrincipalAmountOfTheNotes>
    <sclx:MinimumCashRequirementsToRepurchaseOfNotes
      contextRef="P09_30_2022To09_30_2022_LetterOfCreditMemberusgaapCreditFacilityAxis"
      decimals="-5"
      unitRef="Unit_USD">10000000</sclx:MinimumCashRequirementsToRepurchaseOfNotes>
    <us-gaap:RepaymentsOfDebt
      contextRef="P09_30_2022To09_30_2022_LetterOfCreditMemberusgaapCreditFacilityAxis"
      decimals="-5"
      unitRef="Unit_USD">20000000</us-gaap:RepaymentsOfDebt>
    <sclx:MinimumCashRequirementsToRepurchaseOfNotes
      contextRef="P09_30_2022To09_30_2022_LetterOfCreditMemberusgaapCreditFacilityAxis"
      decimals="-5"
      unitRef="Unit_USD">10000000</sclx:MinimumCashRequirementsToRepurchaseOfNotes>
    <sclx:LineOfCreditFacilityindebtednessAmount
      contextRef="PAsOn09_30_2022_AccountsReceivableRevolvingLoanFacilityMemberusgaapCreditFacilityAxis"
      decimals="-5"
      unitRef="Unit_USD">10000000</sclx:LineOfCreditFacilityindebtednessAmount>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn12_31_2021_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">2800000</us-gaap:DerivativeLiabilities>
    <sclx:AmountDistributionToAcquireRelatedContingentAcceleratedRepaymentNotes
      contextRef="P01_01_2021To12_31_2021_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">9600000</sclx:AmountDistributionToAcquireRelatedContingentAcceleratedRepaymentNotes>
    <us-gaap:DebtInstrumentUnamortizedDiscountCurrent
      contextRef="PAsOn12_31_2021_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">6800000</us-gaap:DebtInstrumentUnamortizedDiscountCurrent>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Borrowings of the Scilex Pharma Notes are as follows (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 72%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Principal&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;133,997&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;151,872&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Unamortized debt discount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(30,597&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(51,022&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Unamortized debt issuance costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,228&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3,711&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Carrying value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;101,172&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;97,139&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current portion&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(29,135&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4,881&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Long term portion&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;72,037&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;92,258&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Estimated fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;115,400&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;122,300&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="PAsOn12_31_2021_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">133997000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="PAsOn12_31_2020_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">151872000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="PAsOn12_31_2021_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">30597000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="PAsOn12_31_2020_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">51022000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:UnamortizedDebtIssuanceExpense
      contextRef="PAsOn12_31_2021_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">2228000</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:UnamortizedDebtIssuanceExpense
      contextRef="PAsOn12_31_2020_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">3711000</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:LongTermDebt
      contextRef="PAsOn12_31_2021_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">101172000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="PAsOn12_31_2020_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">97139000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent
      contextRef="PAsOn12_31_2021_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">29135000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="PAsOn12_31_2020_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">4881000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="PAsOn12_31_2021_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">72037000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="PAsOn12_31_2020_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis"
      decimals="0"
      unitRef="Unit_USD">92258</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtFairValue
      contextRef="PAsOn12_31_2021_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">115400000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="PAsOn12_31_2020_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">122300000</us-gaap:LongTermDebtFairValue>
    <sclx:ScheduleOfFutureMinimumPaymentsOfLongTermDebtTableTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Future minimum payments under the Scilex Pharma Notes, based on a percentage of projected net sales of ZTlido are estimated as follows (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 83%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ending December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 83%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;29,135&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 83%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,005&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 83%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13,637&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 83%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14,746&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 83%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2026&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;64,474&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; width: 83%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 83%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; padding-top: 0pt; padding-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total minimum future payments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;133,997&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</sclx:ScheduleOfFutureMinimumPaymentsOfLongTermDebtTableTextBlock>
    <sclx:LongtermDebtfutureMinimumPaymentYearOne
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">29135000</sclx:LongtermDebtfutureMinimumPaymentYearOne>
    <sclx:LongtermDebtFutureMinimumPaymentYearTwo
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">12005000</sclx:LongtermDebtFutureMinimumPaymentYearTwo>
    <sclx:LongtermDebtFutureMinimumPaymentYearThree
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">13637000</sclx:LongtermDebtFutureMinimumPaymentYearThree>
    <sclx:LongtermDebtFutureMinimumPaymentYearFour
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">14746000</sclx:LongtermDebtFutureMinimumPaymentYearFour>
    <sclx:LongtermDebtFutureMinimumPaymentYearFive
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">64474000</sclx:LongtermDebtFutureMinimumPaymentYearFive>
    <sclx:LongtermDebtFutureMinimumPayment
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">133997000</sclx:LongtermDebtFutureMinimumPayment>
    <us-gaap:DebtInstrumentAnnualPrincipalPayment
      contextRef="PAsOn12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">45900000</us-gaap:DebtInstrumentAnnualPrincipalPayment>
    <us-gaap:DebtInstrumentAnnualPrincipalPayment
      contextRef="PAsOn12_31_2020"
      decimals="-5"
      unitRef="Unit_USD">69800000</us-gaap:DebtInstrumentAnnualPrincipalPayment>
    <us-gaap:DebtInstrumentAnnualPrincipalPayment
      contextRef="PAsOn12_31_2019"
      decimals="-5"
      unitRef="Unit_USD">2300000</us-gaap:DebtInstrumentAnnualPrincipalPayment>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="PAsOn12_31_2021_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis"
      decimals="3"
      unitRef="Unit_pure">0.077</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="PAsOn12_31_2020_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis"
      decimals="4"
      unitRef="Unit_pure">0.0915</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts
      contextRef="P01_01_2021To12_31_2021_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">7900000</us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts>
    <us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts
      contextRef="P01_01_2020To12_31_2020_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">10700000</us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts>
    <us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts
      contextRef="P01_01_2019To12_31_2019_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">15000000</us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
      contextRef="P01_01_2021To12_31_2021_IndebentureMemberSCLXAgreementAxis"
      decimals="2"
      unitRef="Unit_pure">0.25</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <sclx:LineOfCreditFacilityindebtednessAmount
      contextRef="PAsOn12_14_2020_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">10000000</sclx:LineOfCreditFacilityindebtednessAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="PAsOn12_14_2020_PrimeRateMemberusgaapVariableRateAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis"
      decimals="4"
      unitRef="Unit_pure">0.0175</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="PAsOn12_31_2021_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">8800000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="PAsOn12_31_2020_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">9500000</us-gaap:LongTermDebt>
    <sclx:DebtInstrumentTerminationDate contextRef="P02_16_2022To02_16_2022_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis">2022-03-18</sclx:DebtInstrumentTerminationDate>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="P05_01_2020To05_31_2020_PaycheckProtectionProgramMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">1600000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentMaturityDate contextRef="P05_01_2020To05_31_2020_PaycheckProtectionProgramMemberusgaapLongtermDebtTypeAxis">2022-05-05</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="PAsOn05_31_2020_PaycheckProtectionProgramMemberusgaapLongtermDebtTypeAxis"
      decimals="3"
      unitRef="Unit_pure">0.01</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <sclx:MaximumCompensationCostToBeAvailableProratedBasis
      contextRef="P01_01_2021To12_31_2021_CoronavirusAidReliefAndEconomicSecurityActMemberSCLXEventTypeAxis_NonPayrollCostsMemberSCLXClassificationOfCostAxis_PaycheckProtectionProgramMemberusgaapLongtermDebtTypeAxis"
      decimals="0"
      unitRef="Unit_USD">100000</sclx:MaximumCompensationCostToBeAvailableProratedBasis>
    <sclx:PercentageOfLoanForgivenessUnderTheAct
      contextRef="P01_01_2021To12_31_2021_CoronavirusAidReliefAndEconomicSecurityActMemberSCLXEventTypeAxis_NonPayrollCostsMemberSCLXClassificationOfCostAxis_PaycheckProtectionProgramMemberusgaapLongtermDebtTypeAxis"
      decimals="2"
      unitRef="Unit_pure">0.25</sclx:PercentageOfLoanForgivenessUnderTheAct>
    <sclx:MinimumPayrollCostToBeAvailable
      contextRef="P01_01_2021To12_31_2021_CoronavirusAidReliefAndEconomicSecurityActMemberSCLXEventTypeAxis_PaycheckProtectionProgramMemberusgaapLongtermDebtTypeAxis_PayrollCostsBasisMemberSCLXClassificationOfCostAxis"
      decimals="0"
      unitRef="Unit_USD">100000</sclx:MinimumPayrollCostToBeAvailable>
    <sclx:PercentageOfLoanForgivenessUnderTheAct
      contextRef="P01_01_2021To12_31_2021_CoronavirusAidReliefAndEconomicSecurityActMemberSCLXEventTypeAxis_PaycheckProtectionProgramMemberusgaapLongtermDebtTypeAxis_PayrollCostsBasisMemberSCLXClassificationOfCostAxis"
      decimals="2"
      unitRef="Unit_pure">0.25</sclx:PercentageOfLoanForgivenessUnderTheAct>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="P05_01_2020To05_31_2020_PaycheckProtectionProgramMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">1600000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="P01_01_2021To12_31_2021">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;9.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stockholders&#x2019; Equity &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The total number of authorized shares of preferred stock of Scilex Holding is &lt;/div&gt;20,000,000&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, of which &lt;/div&gt;no&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;shares were issued and outstanding at December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; and &lt;/div&gt;2020&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;. The total number of authorized shares of&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;common&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;stock of Scilex Holding is &lt;/div&gt;350,000,000&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, of which &lt;/div&gt;197,266,338&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt; shares were issued and outstanding at&#160;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;December&#160;31, 2021 and 2020.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2020"
      decimals="0"
      unitRef="Unit_shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2020"
      decimals="0"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2020"
      decimals="0"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_shares">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2020"
      decimals="0"
      unitRef="Unit_shares">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_shares">197266338</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2020"
      decimals="0"
      unitRef="Unit_shares">197266338</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_shares">197266338</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2020"
      decimals="0"
      unitRef="Unit_shares">197266338</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock contextRef="P01_01_2021To12_31_2021">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;10.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock Incentive and Employee Benefit Plans &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;2017 Equity Incentive Plan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In June&#160;&lt;/div&gt;2017&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, Scilex Pharma adopted the Scilex Pharmaceuticals Inc. &lt;/div&gt;2017&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Equity Incentive Plan (the &#x201c;Scilex Pharma &lt;/div&gt;2017&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Plan&#x201d;). The Scilex Pharma &lt;/div&gt;2017&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Plan reserved &lt;/div&gt;24.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million shares of Scilex Pharma common stock. &lt;/div&gt;Stock options granted under the Scilex Pharma 2017 Plan typically vest 1/4th of the shares on the first anniversary of the vesting commencement date and 1/48th of the remaining options vest each month thereafter.&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; The Scilex Pharma &lt;/div&gt;2017&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Plan was amended and restated on July&#160;&lt;/div&gt;5&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2018&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;.&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"/&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;Upon&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;the Merger Closing, the Scilex Pharma &lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2017&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Equity Incentive Plan was terminated, and each option to purchase Scilex Pharma&#x2019;s common stock outstanding and unexercised immediately prior to the Merger Closing was cancelled and substituted for that number of options to acquire common stock of Scilex Holding.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Scilex Holding Company 2019 Stock Option Plan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The board of directors of the Company adopted the Scilex Holding Company &lt;/div&gt;2019&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Stock Option Plan (the &#x201c;&lt;/div&gt;2019&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Stock Option Plan&#x201d;) on May&#160;&lt;/div&gt;28&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2019&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;. The &lt;/div&gt;2019&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Stock Option Plan was approved by the Company&#x2019;s stockholders on June&#160;&lt;/div&gt;7&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2019&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;. As of December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2019&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;30.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million shares of common stock of the Company were reserved for issuance pursuant to the &lt;/div&gt;2019&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Stock Option Plan. On December&#160;&lt;/div&gt;21&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2020&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, the board of directors approved an amendment to the &lt;/div&gt;2019&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Stock Option Plan to reserve an additional &lt;/div&gt;15.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million shares of common stock for issuance under the &lt;/div&gt;2019&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Stock Option Plan. As of December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2020&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;45.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million shares of common stock of the Company were reserved for issuance pursuant to the &lt;/div&gt;2019&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Stock Option Plan. &lt;/div&gt;Stock options granted under the 2019 Stock Option Plan typically vest with respect to 1/4th of the shares on the first anniversary of the vesting commencement date and 1/48th of the remaining shares on each monthly anniversary thereafter.&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, options to purchase &lt;/div&gt;28,163,510&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; shares of the common stock of Scilex Holding were outstanding, which is comprised of options to purchase &lt;/div&gt;26,743,510&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; shares of common stock that were outstanding under the &lt;/div&gt;2019&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Stock Option Plan and options to purchase &lt;/div&gt;1,420,000&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; shares of common stock that were outstanding pursuant to options previously granted under the Scilex Pharma &lt;/div&gt;2017&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Plan. As of December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;18,256,490&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; shares of the Company&#x2019;s common stock were reserved for awards available for future issuance under the &lt;/div&gt;2019&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Stock Option Plan.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total stock-based compensation recorded within operating expenses was $&lt;/div&gt;5.8&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, $&lt;/div&gt;5.4&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million and $&lt;/div&gt;4.3&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million for the&#160;years ended December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2020&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; and &lt;/div&gt;2019&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, respectively.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The total unrecognized compensation costs related to unvested employee and nonemployee stock option grants as of December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; was $&lt;/div&gt;8.8&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million and the weighted average period over which these grants are expected to vest is &lt;/div&gt;1.8&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;years.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Option Valuation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company calculates the fair value of stock-based compensation awards granted to employees and nonemployees using the Black-Scholes option-pricing method. The Black-Scholes option-pricing method requires the use of subjective assumptions, including stock price volatility, the expected life of stock options, risk free interest rate and the fair value per share of the underlying common stock on the date of grant. The &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;assumptions used in the Black-Scholes option-pricing method related to options issued to employees and nonemployees for the years ended 2020 and 2019 is set forth below: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 67%;"/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted-average grant date fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;$0.83&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#160;&#160;$0.87&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected dividend yield&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.00%&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.00%&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;;text-indent: 0px;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected stock-price volatility&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-indent: 0px;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-indent: 0px;;text-align:right;"&gt;90.00%&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-indent: 0px;;text-align:right;"&gt;89.00%&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;-&#160;&lt;/div&gt;104.00%&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;;text-indent: 0px;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk-free interest rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-indent: 0px;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-indent: 0px;;text-align:right;"&gt;0.53%&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-indent: 0px;;text-align:right;"&gt;1.63%&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;-&#160;&lt;/div&gt;2.50%&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;;text-indent: 0px;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Term of options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-indent: 0px;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-indent: 0px;;text-align:right;"&gt;5.60&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-indent: 0px;;text-align:right;"&gt;5.76&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;-&#160;&lt;/div&gt;6.08&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value per share of common stock on date of grant&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;$1.16&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;$1.16&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercise price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;$1.16&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;$1.16&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Expected&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px;;font-style:italic;display:inline;"&gt;dividend yield&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;. The Company bases the expected dividend yield assumption on the fact that the Company has never paid cash dividends and has no present intention to pay cash dividends on the Company&#x2019;s common stock.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Expected stock-price volatility&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;. The expected stock-price volatility assumption is based on volatilities of a peer group of similar companies whose share prices are publicly available. The peer group was developed based on companies in the transdermal patch industry. In selecting the peer group, management considered publicly-traded transdermal patch companies with existing clinical stage branded and generic transdermal patches. Management further considered the development stage of the peer group companies.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Risk-free interest rate&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;. The Company bases the risk-free interest rate assumption on the U.S. Treasury&#x2019;s rates for U.S. Treasury &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;zero-coupon&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; bonds with maturities similar to those of the expected term of the award being valued.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Expected term of options&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;. The expected term of options represents the period of time when options are expected to be outstanding. Because the Company does not have historic exercise behavior, the Company determines the expected life assumption for options issued to directors and employees using the simplified method, which is an average of the contractual term of the option and its ordinary vesting period.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the&#160;years ended December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2020&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; and December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2019&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, Scilex Holding issued stock options to certain employees and nonemployees. Significant inputs utilized in determining the fair value of the common shares are as &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;follows: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;March&#160;17 and March&#160;31, 2019 Valuations &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For the valuation &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;performed on March&#160;&lt;/div&gt;17&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2019&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; and March&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2019&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, the fair value of the Company&#x2019;s common stock was estimated using the market and income approaches. The Company weighted a guideline public company method, a market approach that uses comparable company data and applies to the subject company, equally with a discounted cash flow method, an income approach that derives value by estimating reasonable future cash flows to the equityholders and discounting them to present value using a risk-adjusted discount rate. The Company then used the Option Pricing Method (&#x201c;OPM&#x201d;) to allocate the concluded equity value amongst the different equity classes and determine the common stock value. These valuations resulted in a valuation of the Company&#x2019;s common stock of $&lt;/div&gt;1.16&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; per share as of March&#160;&lt;/div&gt;17&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2019&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; and March&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2019&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;May&#160;31, 2019 Valuation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For the valuation performed on May&#160;31, 2019, the fair value of the Company&#x2019;s common stock was estimated using a hybrid Probability Weighted Expected Return Method (&#x201c;PWERM&#x201d;), which estimates the value by &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;probability&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;-weighting different scenarios. The Company used three going public scenarios and one stay-private scenario. For the three public scenarios, the Company utilized recent comparable initial public offerings to estimate value, which was allocated on a fully diluted basis to derive a common stock value for each scenario. For the stay-private scenario, the Company utilized the income and market approaches in line with the March&#160;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;31&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt; valuation then allocated the concluded equity value using an OPM to derive a common stock value for the stay-private scenario. The Company then probability weighted (based on the Company&#x2019;s best estimates at the time) each scenario&#x2019;s common stock value to arrive at the Company&#x2019;s concluded common stock value. This valuation resulted in a valuation of the Company&#x2019;s common stock of $&lt;/div&gt;1.16&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt; per share as of May&#160;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;31&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;December&#160;31, 2019 Valuation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For the valuation performed on December&#160;31, 2019, the fair value of the Company&#x2019;s common stock was estimated using PWERM, which estimates the value by probability-weighting different scenarios. The Company used three going public scenarios and one stay-private scenario. For the three public scenarios, the &lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Company&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 0px; top: 0px;;display:inline;"&gt;utilized recent comparable initial public offerings to estimate value, which was allocated on a fully diluted basis to derive a common stock value for each scenario. For the stay-private scenario, the Company utilized the income approach in line with the March&#160;31, 2019 valuation then allocated the concluded equity value using an OPM to derive a common stock value for the stay-private scenario. The Company then probability weighted (based on the Company&#x2019;s best estimates at the time) each scenario&#x2019;s common stock value to arrive at the Company&#x2019;s concluded common stock value. This valuation resulted in a valuation of the Company&#x2019;s common stock of $&lt;/div&gt;1.16&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 0px; top: 0px;;display:inline;"&gt; per share as of December&#160;31, 2019.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;July&#160;31, 2020 Valuation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For the valuation performed on July&#160;31, 2020, the fair value of the Company&#x2019;s common stock was estimated using PWERM, which estimates the value by probability-weighting different scenarios. The Company used three going public scenarios and one stay-private scenario. For the three public scenarios, the Company utilized recent comparable initial public offerings to estimate value, which was allocated on a fully diluted basis to derive a common stock value for each scenario. For the stay-private scenario, the Company utilized the income approach in line with the March&#160;31, 2019, May&#160;31, 2019 and December&#160;31, 2019 valuations then allocated the concluded equity value using an OPM to derive a common stock value for the stay-private scenario. The Company then probability weighted (based on the Company&#x2019;s best estimates at the time) each scenario&#x2019;s common stock value to arrive at the Company&#x2019;s concluded common stock value. This valuation resulted in a valuation of the Company&#x2019;s common stock of $1.16 per share as of July&#160;31, 2020.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following represents a summary of the options outstanding at December&#160;31, 2021, 2020, and 2019 changes during the years then ended (in thousands, other than weighted-average exercise price): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 62%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Options&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;exercise&#160;price&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 62%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 62%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding at December&#160;31, 2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,781&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.63&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,291&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 62%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21,468&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.16&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 62%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercised&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 62%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited/Cancelled&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(838&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.94&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; width: 62%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 62%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding at December&#160;31, 2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;25,411&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.07&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,183&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 62%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,194&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.16&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 62%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercised&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(56&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.90&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 62%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited/Cancelled&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(745&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.94&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; width: 62%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 62%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding at December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;30,804&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,172&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 62%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 62%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercised&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 62%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited/Cancelled&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(2,641&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;0.68&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; width: 62%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 62%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding at December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;28,163&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1.13&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;915&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 62%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercisable at December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;17,177&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1.11&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Employee Benefit Plan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;br/&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color:#ffffff;;display:inline;"&gt;The &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Company maintains a defined contribution &lt;/div&gt;401&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(k) plan available to eligible employees, which is administered by Sorrento. Employee contributions are voluntary and are determined on an individual basis, limited to the maximum amount allowable under federal tax regulations. The Company made matching contributions to the &lt;/div&gt;401&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(k) plan totaling $&lt;/div&gt;0.3&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million for each of the&#160;years ended December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2020&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; and &lt;/div&gt;2019&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;.&lt;/div&gt;&lt;/div&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn06_30_2017_ScilexPharmaTwoThousandSeventeenPlanMemberusgaapPlanNameAxis"
      decimals="-5"
      unitRef="Unit_shares">24000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights contextRef="P06_30_2017To06_30_2017_ScilexPharmaTwoThousandSeventeenPlanMemberusgaapPlanNameAxis">Stock options granted under the Scilex Pharma 2017 Plan typically vest 1/4th of the shares on the first anniversary of the vesting commencement date and 1/48th of the remaining options vest each month thereafter.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2019_TwoThousandNineteenStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="-5"
      unitRef="Unit_shares">30000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2020_AmendmentToTwoThousandNineteenStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="-5"
      unitRef="Unit_shares">15000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2020_TwoThousandNineteenStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="-5"
      unitRef="Unit_shares">45000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights contextRef="P01_01_2020To12_31_2020_TwoThousandNineteenStockOptionPlanMemberusgaapPlanNameAxis">Stock options granted under the 2019 Stock Option Plan typically vest with respect to 1/4th of the shares on the first anniversary of the vesting commencement date and 1/48th of the remaining shares on each monthly anniversary thereafter.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <sclx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingNumber
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_shares">28163510</sclx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2021_TwoThousandNineteenStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">26743510</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2021_ScilexPharmaTwoThousandSeventeenPlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">1420000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights contextRef="P01_01_2021To12_31_2021_TwoThousandNineteenStockOptionPlanMemberusgaapPlanNameAxis">18,256,490</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2021To12_31_2021_OperatingExpensesMemberusgaapIncomeStatementLocationAxis"
      decimals="-5"
      unitRef="Unit_USD">5800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2020To12_31_2020_OperatingExpensesMemberusgaapIncomeStatementLocationAxis"
      decimals="-5"
      unitRef="Unit_USD">5400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2019To12_31_2019_OperatingExpensesMemberusgaapIncomeStatementLocationAxis"
      decimals="-5"
      unitRef="Unit_USD">4300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="PAsOn12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">8800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="P01_01_2021To12_31_2021">P1Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;assumptions used in the Black-Scholes option-pricing method related to options issued to employees and nonemployees for the years ended 2020 and 2019 is set forth below: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 67%;"/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted-average grant date fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;$0.83&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#160;&#160;$0.87&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected dividend yield&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.00%&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.00%&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;;text-indent: 0px;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected stock-price volatility&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-indent: 0px;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-indent: 0px;;text-align:right;"&gt;90.00%&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-indent: 0px;;text-align:right;"&gt;89.00%&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;-&#160;&lt;/div&gt;104.00%&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;;text-indent: 0px;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk-free interest rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-indent: 0px;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-indent: 0px;;text-align:right;"&gt;0.53%&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-indent: 0px;;text-align:right;"&gt;1.63%&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;-&#160;&lt;/div&gt;2.50%&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;;text-indent: 0px;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Term of options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-indent: 0px;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-indent: 0px;;text-align:right;"&gt;5.60&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-indent: 0px;;text-align:right;"&gt;5.76&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;-&#160;&lt;/div&gt;6.08&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;;text-indent: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value per share of common stock on date of grant&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;$1.16&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;$1.16&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercise price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;$1.16&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;$1.16&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="PAsOn12_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.83</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="PAsOn12_31_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.87</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2020To12_31_2020"
      decimals="4"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2019To12_31_2019"
      decimals="4"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2020To12_31_2020"
      decimals="4"
      unitRef="Unit_pure">0.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="P01_01_2019To12_31_2019"
      decimals="4"
      unitRef="Unit_pure">0.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="P01_01_2019To12_31_2019"
      decimals="4"
      unitRef="Unit_pure">1.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2020To12_31_2020"
      decimals="4"
      unitRef="Unit_pure">0.0053</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="P01_01_2019To12_31_2019"
      decimals="4"
      unitRef="Unit_pure">0.0163</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="P01_01_2019To12_31_2019"
      decimals="4"
      unitRef="Unit_pure">0.025</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2020To12_31_2020">P5Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2019To12_31_2019_MinimumMembersrtRangeAxis">P5Y9M3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2019To12_31_2019_MaximumMembersrtRangeAxis">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <sclx:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant
      contextRef="PAsOn12_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.16</sclx:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant>
    <sclx:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant
      contextRef="PAsOn12_31_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.16</sclx:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="PAsOn12_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="PAsOn12_31_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <sclx:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant
      contextRef="PAsOn03_17_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.16</sclx:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant>
    <sclx:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant
      contextRef="PAsOn03_31_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.16</sclx:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant>
    <sclx:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant
      contextRef="PAsOn05_31_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.16</sclx:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant>
    <sclx:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant
      contextRef="PAsOn12_31_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.16</sclx:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant>
    <sclx:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant
      contextRef="PAsOn07_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.16</sclx:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following represents a summary of the options outstanding at December&#160;31, 2021, 2020, and 2019 changes during the years then ended (in thousands, other than weighted-average exercise price): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 62%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Options&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;exercise&#160;price&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 62%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 62%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding at December&#160;31, 2018&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,781&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.63&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,291&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 62%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21,468&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.16&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 62%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercised&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 62%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited/Cancelled&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(838&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.94&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; width: 62%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 62%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding at December&#160;31, 2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;25,411&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.07&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,183&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 62%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,194&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.16&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 62%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercised&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(56&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.90&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 62%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited/Cancelled&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(745&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.94&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; width: 62%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 62%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding at December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;30,804&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,172&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 62%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 62%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercised&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 62%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited/Cancelled&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(2,641&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;0.68&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; width: 62%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 62%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Outstanding at December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;28,163&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1.13&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;915&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 62%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exercisable at December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;17,177&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1.11&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_shares">4781000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2018"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="PAsOn12_31_2018"
      decimals="0"
      unitRef="Unit_USD">1291</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_shares">21468000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2019To12_31_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.16</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2019To12_31_2019"
      decimals="0"
      unitRef="Unit_USD_per_Share">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_shares">838000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2019To12_31_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_shares">25411000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="PAsOn12_31_2019"
      decimals="0"
      unitRef="Unit_USD">2183</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_shares">6194000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2020To12_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.16</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_shares">56000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2020To12_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.9</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_shares">745000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2020To12_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_shares">30804000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="PAsOn12_31_2020"
      decimals="0"
      unitRef="Unit_USD">2172</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_USD_per_Share">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_USD_per_Share">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_shares">2641000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2021To12_31_2021"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_shares">28163000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2021"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_USD">915</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_shares">17177000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2021"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="P01_01_2021To12_31_2021_FourHundredAndOneKPlanMemberusgaapRetirementPlanNameAxis"
      decimals="-5"
      unitRef="Unit_USD">300000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="P01_01_2020To12_31_2020_FourHundredAndOneKPlanMemberusgaapRetirementPlanNameAxis"
      decimals="-5"
      unitRef="Unit_USD">300000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="P01_01_2019To12_31_2019_FourHundredAndOneKPlanMemberusgaapRetirementPlanNameAxis"
      decimals="-5"
      unitRef="Unit_USD">300000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="P01_01_2021To12_31_2021">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;11.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Commitments and Contingencies &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Product Development Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In February&#160;&lt;/div&gt;2013&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, Scilex Pharma became a party to a product development agreement (as amended, the &#x201c;Product Development Agreement&#x201d;) with &lt;/div&gt;two&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; parties (the &#x201c;Developers&#x201d;), &lt;/div&gt;one&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; of which is ITOCHU CHEMICAL FRONTIER Corporation (&#x201c;Itochu&#x201d;), pursuant to which the Developers will manufacture and supply lidocaine tape products, including ZTlido and &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-103&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; (the &#x201c;Products&#x201d;), for Scilex Pharma. The Developers initially developed, and have intellectual property rights relating to, the Products. Pursuant to the Product Development Agreement, Scilex Pharma acquired an exclusive right to develop and commercialize the Products worldwide except for Japan. The Developers are responsible for sourcing and supplying lidocaine for development and commercialization purposes.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pursuant to the Product Development Agreement, Scilex Pharma is required to make aggregate royalty payments between &lt;/div&gt;25&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% and &lt;/div&gt;35&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% to the Developers based on net profits. Up to the date the financial statements were issued, the Company made &lt;/div&gt;no&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; aggregate royalty payments. Net profits are defined as net sales, less cost of goods and marketing expenses. Net sales are defined as total gross sales of any Product, less all applicable deductions, to the extent accrued, paid or allowed in the ordinary course of business with respect to the sale of such Product, and to the extent that they are in accordance with U.S. GAAP. If Scilex Pharma were to sublicense the licensed technologies, the Developers will receive the same proportion of any sublicensing fees received therefrom. The Product Development Agreement will continue in full force and effect until &lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;October 2, 2028&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, the date that is &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;ten&lt;/div&gt; years&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; from the date of the first commercial sale of ZTlido. The Product Development Agreement will renew automatically for subsequent successive &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-year&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; renewal periods unless Scilex Pharma or the &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Developers terminate it upon &lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;6-month&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt; written notice. In addition, Scilex Pharma or the Developers may terminate the Product Development Agreement if &lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(1)&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;the other party is in material breach of the agreement and the breach is not curable, or if the breach is curable and the breaching party has not cured such material breach within &lt;/div&gt;180&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;days after notice requesting to cure; &lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(2)&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;the FDA determines that the formulation of the Products would not be eligible for FDA approval in the absence of efficacy studies, and the Developers are unable to address the efficacy study requirements despite good faith efforts; &lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(3)&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;the market conditions are such that (a)&#160;commencing with the quarter ending March&#160;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;31&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2023&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, Scilex Pharma&#x2019;s total net profits of the Products are equal to or less than &lt;/div&gt;5&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% of Scilex Pharma&#x2019;s net sales of the Products for a period of &lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;four&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt; or more consecutive quarters, or (b)&#160;the Products&#x2019; economic viability is affected by documented external circumstances deemed detrimental to all parties as agreed to by Scilex Pharma and the Developers, and the parties are unable to resolve the economic viability concerns under the foregoing clauses (a)&#160;and (b)&#160;after &lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;30&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;days of good-faith discussion; &lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(4)&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;the parties fail to reach mutual agreement as to who will conduct the clinical studies and how the costs will be allocated; or &lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(5)&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;Scilex Pharma or either &lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt; of the Developers are bankrupt or make assignment for the benefit of creditors.&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;Up to the date the financial statements were issued, Scilex&#x2019;s net profits for ZTlido and &lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-103&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt; have not exceeded &lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;five&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt; percent of net sales. Accordingly, Oishi and Itochu have the right to terminate the Product Development Agreement and Commercial Supply Agreement. As of the date of this prospectus, neither Oishi nor Itochu has exercised its right of termination. Additionally, Scilex Pharma may terminate the Product Development Agreement if (i)&#160;any of the pivotal human clinical trials for any of the Products fail, or (ii)&#160;the FDA issues a &#x201c;Refusal to File&#x201d; for any of the Products&#x2019; regulatory approval application and, after reasonable consultation with the Developers, Scilex Pharma believes that it is commercially unreasonable to &lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-file.&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt; The Developers may terminate the Product Development Agreement if Scilex Pharma fails to file for regulatory approval for any of the Products within &lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;three&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;months of the date on which all required components of the regulatory approval application are received by Scilex Pharma.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On February&#160;&lt;/div&gt;16&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2017&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, Scilex Pharma entered into a Commercial Supply Agreement (as amended, the &#x201c;Supply Agreement&#x201d;) with the &lt;/div&gt;two&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Developers to provide commercial supply of ZTlido and &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-103&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; to Scilex Pharma. The Supply Agreement contains standard terms regarding term, termination, payment, product quality and supply. In addition, the agreement provides additional terms regarding the calculation and amount of marketing expenses that may be deducted from net sales for purposes of determining the amount of net profit under the Product Development Agreement.&lt;/div&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt;;font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Exclusive Distribution Agreement&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color:#ffffff;;display:inline;"&gt;In &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; August&#160;&lt;/div&gt;2015&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, Scilex Pharma entered into an Exclusive Distribution Agreement (the &#x201c;Distribution Agreement&#x201d;) to appoint an exclusive third-party logistics distribution provider (the &#x201c;Distributor&#x201d;) and as an authorized distributor of record of ZTlido (&#x201c;Product&#x201d;) in the United States, its territories, possessions and commonwealths for an agreed schedule of fees, subject to a &lt;/div&gt;3&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% annual adjustment. The Distribution Agreement has an initial term of &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;three&lt;/div&gt; years&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; following the first shipment of &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;FDA-approved&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Product to a commercial customer and shall automatically renew for additional terms of &lt;/div&gt;one&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; year each, unless written notice of termination is given by either party at least &lt;/div&gt;30&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;days prior to the end of the initial term or any renewal term. In the event of Product recalls, Scilex Pharma is solely responsible for all product recalls, except in the event where the recalls arise from the Distributor&#x2019;s negligence or willful misconduct. Pursuant to the Distribution Agreement, Scilex Pharma will be responsible for delivery of Product to and from the Distributor&#x2019;s facility, including all costs, expenses and risk of loss associated with such delivery. From late &lt;/div&gt;2018&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; to early &lt;/div&gt;2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, ZTlido was sold, and title was transferred, to the Distributor for distribution and sale to wholesalers for a fee of between &lt;/div&gt;1&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% to &lt;/div&gt;2&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% which was recorded as a &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;gross-to-net&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; sales adjustment. Beginning in &lt;/div&gt;April 2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, Scilex Pharma began directly selling and transferring title to distributors.&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Sales Operations Services &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In January&#160;&lt;/div&gt;2016&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, Scilex Pharma entered into a project agreement with a vendor to provide sales operations services and detailing services, which was subsequently superseded by a new project agreement entered into in&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;September&#160;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt; (the &#x201c;Project Agreement&#x201d;). In connection with the detailing services, the Project Agreement provides that the vendor will provide Scilex Pharma with full-time sales representatives who shall detail the Product by making calls pursuant to a call plan on targets. These sales representatives are to be managed by field talent managers and a national project director, each of whom will also be provided by the vendor. In connection with the sales operation services, the vendor will provide certain services required for the initial implementation and ongoing operation of the sales force.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On July&#160;&lt;/div&gt;1&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2020&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, Scilex Pharma and the vendor entered into a work order in which the parties agreed to convert substantially all of the sales representatives allocated under the Project Agreement to become employees of Scilex Pharma. The vendor will continue to provide sales operations services and fleet management services and sample accountability services. The work order will remain in effect until June&#160;&lt;/div&gt;30&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, and may be extended for additional periods of &lt;/div&gt;one&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; year upon the mutual agreement of both parties. Either party may terminate the work order with &lt;/div&gt;90&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;days&#x2019; notice. Scilex Pharma paid an implementation fee of $&lt;/div&gt;59.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;thousand and will pay fixed monthly fees of $&lt;/div&gt;63.7&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;thousand to $&lt;/div&gt;65.8&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;thousand for ongoing services.&lt;/div&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company recognized an expense of $&lt;/div&gt;1.9&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, $&lt;/div&gt;10.5&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, and $&lt;/div&gt;25.3&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million within selling, general and administrative expenses for services performed for the&#160;years ended December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2020&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, and &lt;/div&gt;2019&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, respectively, including implementation fees, fixed monthly fees and pass-through costs.&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Litigation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In the normal course of business, the Company may be named as a defendant in &lt;/div&gt;one&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; or more lawsuits. Other than the following &lt;/div&gt;two&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; lawsuits, the Company is not a party to any outstanding material litigation and management is currently not aware of any legal proceedings that, individually or in the aggregate, are deemed to be material to the Company&#x2019;s financial condition or results of operations.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In February&#160;&lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, the Company filed a lawsuit in the U.S. District Court for the Northern District of California against Sanofi-Aventis U.S. LLC and Hisamitsu America, Inc., &lt;/div&gt;two&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; manufacturers of &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;over-the-counter&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; (OTC) lidocaine patch products, alleging, among other things, false and deceptive advertising and unfair competition under the Lanham Act and California state laws by those companies regarding those patch products.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In March&#160;&lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, the Company filed a lawsuit in the Delaware Court of Chancery against Anthony Mack, former President of the Company, and Virpax Pharmaceuticals, Inc., a company now headed by Mr.&#160;Mack,&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt;alleging&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, among other things, breach by Mr.&#160;Mack of his &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-compete&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; agreement with the Company and his fiduciary duties to the Company, and tortious interference by Virpax with that &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-compete&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; agreement. Both lawsuits are ongoing.&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Operating Leases &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company leases administrative and research and development facilities under various &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-cancelable&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; lease agreements. Facility leases generally provide for periodic rent increases and may include options to extend. As of December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, the Company&#x2019;s leases have remaining lease terms of approximately &lt;/div&gt;2.7&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; to &lt;/div&gt;2.9&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;years. The term of the Company&#x2019;s leases does not include extension options that were not reasonably certain to be exercised from its lease terms, ranging from &lt;/div&gt;3&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; to &lt;/div&gt;5&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;years. Many of the Company&#x2019;s leases are subject to variable lease payments. Variable lease payments are recognized in the period in which the obligation for those payments are incurred, are not included in the measurement of the &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; assets or lease liabilities and are immaterial. Additionally, the Company subleases certain properties to third parties. Sublease income is recognized on a straight-line basis and is immaterial.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As the Company&#x2019;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The Company calculates the associated lease liability and corresponding &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; asset upon lease commencement using a discount rate based on a credit-adjusted secured borrowing rate commensurate with the term of the lease. As of December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, the Company has &lt;/div&gt;no&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; finance leases.&lt;/div&gt;&lt;/div&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The components of lease expense were as follows (in thousands):&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 76%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating lease cost*&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;623&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;904&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;776&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;*&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-size: 10pt;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Inclusive of variable lease costs, sublease income, and impairment, which were immaterial for the periods presented. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Supplemental quantitative information related to leases includes the following: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 74%;"/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year&#160;Ended&#160;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;2021&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;2020&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 74%;"/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 74%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash paid for amounts included in the measurement of lease &lt;br/&gt;liabilities:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 74%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating cash flows from operating leases&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(654&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(833&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 74%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average remaining lease term in&#160;years&#160;&#x2014;&#160;operating &lt;br/&gt;leases&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2.8&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3.8&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 74%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average discount rate&#160;&#x2014;&#160;operating leases&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12.2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12.2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Maturities of lease liabilities were as follows (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 86%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Year Ending December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;674&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;694&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;596&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2026&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total lease payments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,964&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less imputed interest&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(316&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total lease liabilities as of December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,648&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating&lt;/div&gt; lease expense totaled approximately $&lt;/div&gt;0.7&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, $&lt;/div&gt;1.1&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million and $&lt;/div&gt;0.8&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million for the&#160;years ended December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2020&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; and &lt;/div&gt;2019&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, respectively.&lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <sclx:PercentageOfAggregateRoyalityPayments
      contextRef="P12_31_2021To12_31_2021_MinimumMembersrtRangeAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="2"
      unitRef="Unit_pure">0.25</sclx:PercentageOfAggregateRoyalityPayments>
    <sclx:PercentageOfAggregateRoyalityPayments
      contextRef="P12_31_2021To12_31_2021_MaximumMembersrtRangeAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="2"
      unitRef="Unit_pure">0.35</sclx:PercentageOfAggregateRoyalityPayments>
    <sclx:AgreementExpirationDate contextRef="P12_31_2021To12_31_2021_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis">2028-10-02</sclx:AgreementExpirationDate>
    <sclx:AgreementExpirationTerm contextRef="P12_31_2021To12_31_2021_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis">P10Y</sclx:AgreementExpirationTerm>
    <sclx:AgreementAutomaticRenewalPeriodOnExpirationOfInitialTerm contextRef="P12_31_2021To12_31_2021_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis">P1Y</sclx:AgreementAutomaticRenewalPeriodOnExpirationOfInitialTerm>
    <sclx:NoticeOfTerminationPeriodForCancellationOfAutomaticRenewal contextRef="P12_31_2021To12_31_2021_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis">P6M</sclx:NoticeOfTerminationPeriodForCancellationOfAutomaticRenewal>
    <sclx:TerminationOfAgreementNoticePeriodForARequestToCureMaterialBreachOfTheAgreement contextRef="P12_31_2021To12_31_2021_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis">P180D</sclx:TerminationOfAgreementNoticePeriodForARequestToCureMaterialBreachOfTheAgreement>
    <sclx:ThresholdMinimumPercentageOfSales
      contextRef="P12_31_2021To12_31_2021_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="2"
      unitRef="Unit_pure">0.05</sclx:ThresholdMinimumPercentageOfSales>
    <sclx:PercentageOfAnnualAdjustmentToFees
      contextRef="P12_31_2021To12_31_2021_ExclusiveDistributionAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="2"
      unitRef="Unit_pure">0.03</sclx:PercentageOfAnnualAdjustmentToFees>
    <sclx:AgreementExpirationTerm contextRef="P12_31_2021To12_31_2021_ExclusiveDistributionAgreementMemberusgaapTypeOfArrangementAxis">P3Y</sclx:AgreementExpirationTerm>
    <sclx:PercentageOfDistributionFeeReceivedOverThePeriod
      contextRef="P12_31_2021To12_31_2021_ExclusiveDistributionAgreementMemberusgaapTypeOfArrangementAxis_MinimumMembersrtRangeAxis"
      decimals="2"
      unitRef="Unit_pure">0.01</sclx:PercentageOfDistributionFeeReceivedOverThePeriod>
    <sclx:PercentageOfDistributionFeeReceivedOverThePeriod
      contextRef="P12_31_2021To12_31_2021_ExclusiveDistributionAgreementMemberusgaapTypeOfArrangementAxis_MaximumMembersrtRangeAxis"
      decimals="2"
      unitRef="Unit_pure">0.02</sclx:PercentageOfDistributionFeeReceivedOverThePeriod>
    <sclx:NoticePeriodForTerminationOfWorkOrder contextRef="P12_31_2021To12_31_2021_ProjectAgreementMemberusgaapTypeOfArrangementAxis">P90D</sclx:NoticePeriodForTerminationOfWorkOrder>
    <sclx:WorkOrderImplementationFee
      contextRef="P12_31_2021To12_31_2021_ProjectAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-2"
      unitRef="Unit_USD">59000</sclx:WorkOrderImplementationFee>
    <sclx:SalesOperationsServicesMonthlyFee
      contextRef="PAsOn12_31_2021_MinimumMembersrtRangeAxis_ProjectAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-2"
      unitRef="Unit_USD">63700</sclx:SalesOperationsServicesMonthlyFee>
    <sclx:SalesOperationsServicesMonthlyFee
      contextRef="PAsOn12_31_2021_MaximumMembersrtRangeAxis_ProjectAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-2"
      unitRef="Unit_USD">65800</sclx:SalesOperationsServicesMonthlyFee>
    <sclx:SellingGeneralAndAdministrativeExpenses
      contextRef="P01_01_2021To12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">1900000</sclx:SellingGeneralAndAdministrativeExpenses>
    <sclx:SellingGeneralAndAdministrativeExpenses
      contextRef="P01_01_2020To12_31_2020"
      decimals="-5"
      unitRef="Unit_USD">10500000</sclx:SellingGeneralAndAdministrativeExpenses>
    <sclx:SellingGeneralAndAdministrativeExpenses
      contextRef="P01_01_2019To12_31_2019"
      decimals="-5"
      unitRef="Unit_USD">25300000</sclx:SellingGeneralAndAdministrativeExpenses>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm contextRef="PAsOn12_31_2021_MinimumMembersrtRangeAxis">P2Y8M12D</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm contextRef="PAsOn12_31_2021_MaximumMembersrtRangeAxis">P2Y10M24D</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="PAsOn12_31_2021_MinimumMembersrtRangeAxis">P3Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="PAsOn12_31_2021_MaximumMembersrtRangeAxis">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LeaseCostTableTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The components of lease expense were as follows (in thousands):&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 76%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating lease cost*&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;623&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;904&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;776&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;*&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-size: 10pt;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Inclusive of variable lease costs, sublease income, and impairment, which were immaterial for the periods presented. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      id="Fact_63195336"
      unitRef="Unit_USD">623000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      id="Fact_63195335"
      unitRef="Unit_USD">904000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      id="Fact_63195334"
      unitRef="Unit_USD">776000</us-gaap:OperatingLeaseCost>
    <sclx:ScheduleOfSupplementalQuantitativeInformationRelatedToLeasesTableTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Supplemental quantitative information related to leases includes the following: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 74%;"/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year&#160;Ended&#160;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;2021&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;2020&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 74%;"/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 74%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash paid for amounts included in the measurement of lease &lt;br/&gt;liabilities:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 74%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating cash flows from operating leases&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(654&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(833&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 74%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average remaining lease term in&#160;years&#160;&#x2014;&#160;operating &lt;br/&gt;leases&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2.8&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3.8&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 74%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average discount rate&#160;&#x2014;&#160;operating leases&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12.2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12.2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</sclx:ScheduleOfSupplementalQuantitativeInformationRelatedToLeasesTableTextBlock>
    <sclx:OperatingCashFlowsFromOperatingLeases
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_USD">-654</sclx:OperatingCashFlowsFromOperatingLeases>
    <sclx:OperatingCashFlowsFromOperatingLeases
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_USD">-833</sclx:OperatingCashFlowsFromOperatingLeases>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="PAsOn12_31_2021">P2Y9M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="PAsOn12_31_2020">P3Y9M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="PAsOn12_31_2021"
      decimals="3"
      unitRef="Unit_pure">0.122</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="PAsOn12_31_2020"
      decimals="3"
      unitRef="Unit_pure">0.122</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Maturities of lease liabilities were as follows (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 86%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Year Ending December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;674&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;694&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;596&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2026&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total lease payments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,964&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less imputed interest&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(316&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total lease liabilities as of December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,648&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">674000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">694000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">596000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1964000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">316000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1648000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">700000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-5"
      unitRef="Unit_USD">1100000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="P01_01_2019To12_31_2019"
      decimals="-5"
      unitRef="Unit_USD">800000</us-gaap:OperatingLeaseExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="P01_01_2021To12_31_2021">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;12.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total loss before income taxes for the&#160;years ended December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2020&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; and &lt;/div&gt;2019&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; did not include a foreign component. The components of benefits for income taxes were as follows for the period ended December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; (in thousands):&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 76%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current expense:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Federal&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;State&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(53&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(53&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Federal&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;State&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(53&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The components of the Company&#x2019;s net deferred tax liabilities and related valuation allowance are as follows at December&#160;31 (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 73%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 73%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred tax assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 73%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Interest expense limitations&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"&gt;12,205&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"&gt;8,225&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 73%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Tax credit carryforwards&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;1,630&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;1,623&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 73%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net operating loss carryforwards&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"&gt;39,714&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"&gt;31,732&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 73%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock based compensation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;3,233&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;2,037&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 73%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating lease liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"&gt;404&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"&gt;510&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em;"&gt;Others&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;1,753&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;2,285&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgb(255, 255, 255); width: 73%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 73%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total Deferred Tax Assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;58,939&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;46,412&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 73%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Valuation allowance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="null;text-indent: 0px;;font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(56,643&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(43,514&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(255, 255, 255);"&gt;&lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total Deferred Tax Assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,296&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,898&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred Tax Liabilities:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 73%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Amortization of intangibles&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; text-align: right; background-color: rgb(255, 255, 255);"&gt;(1,975&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"&gt;(2,486&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em;"&gt;Other&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; text-align: right; background-color: rgb(204, 238, 255);"&gt;(2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&#x2014;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; background-color: rgb(255, 255, 255); padding-bottom: 0.375pt; width: 73%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Operating lease &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); padding-bottom: 0.375pt; width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; text-align: right; background-color: rgb(255, 255, 255); border-bottom: 0.75pt solid black;"&gt;(319&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); padding-bottom: 0.375pt;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); padding-bottom: 0.375pt; width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); border-bottom: 0.75pt solid black;;text-align:right;"&gt;(412&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); padding-bottom: 0.375pt;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); padding-bottom: 0.75pt; width: 73%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total Deferred Tax Liabilities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0px 0px 0.75pt; background-color: rgb(204, 238, 255); width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px; text-align: right; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(2,296&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.75pt; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0px 0px 0.75pt; background-color: rgb(204, 238, 255); width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(2,898&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); padding-bottom: 0.75pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color:#ffffff;;display:inline;"&gt;The&lt;/div&gt;&lt;div style="display:inline;"&gt;&lt;div style="background-color:#ffffff;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Company &lt;/div&gt;has evaluated the available evidence supporting the realization of its gross deferred tax assets, including the amount and timing of future taxable income, and has determined that it is more likely than not that the deferred tax assets will not be realized. Due to such uncertainties surrounding the realization of the domestic deferred tax assets, the Company maintains a valuation allowance of $&lt;/div&gt;56.6&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million and $&lt;/div&gt;43.5&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million against its deferred tax assets as of December&#160;&lt;/div&gt;&lt;div style="font-size: 10pt;;display:inline;"&gt;31&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;&lt;div style="font-size: 10pt;;display:inline;"&gt;2021&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; and &lt;/div&gt;&lt;div style="font-size: 10pt;;display:inline;"&gt;2020&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, respectively. Realization of the deferred tax assets will &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;b&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;e&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;primarily&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;dependent upon the Company&#x2019;s ability to generate sufficient taxable income prior to the expiration of its net operating losses.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The reconciliation between U.S. federal income taxes at the statutory rate and the Company&#x2019;s benefit from income taxes are as follows for the year ended December 31: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 75%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Statutory Federal Income Tax Rate&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;State taxes, net of federal tax benefit&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2.8&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2.7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Debt discount and interest limitation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(10.1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In-process&lt;/div&gt; research and development&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(11.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Return to provision adjustments and carryback&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2.7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(11.2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Others&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1.6&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.8&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.8&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in valuation allowance&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(14.8&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(13.2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(14.2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4.8em;"&gt;Income Tax Benefit&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, the Company had net operating loss carryforwards of approximately $&lt;/div&gt;167.5&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million for federal and $&lt;/div&gt;81.7&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million for state income tax purposes, respectively. These may be used to offset future taxable income and will begin to expire in &lt;/div&gt;2034&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; for state and &lt;/div&gt;2035&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; for federal, except for $&lt;/div&gt;154.8&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million of the federal net operating losses that have an indefinite carryforward period.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Internal Revenue Code Section&#160;382 rules apply to limit a corporation&#x2019;s ability to utilize existing net operating loss and tax credit carryforwards once the corporation experiences an ownership change as defined in Section&#160;382. For the&#160;years ended December&#160;31, 2021, 2020, and 2019, there was no impact of such limitations on the Company&#x2019;s income tax provision.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company also has research and development and orphan drug credits of approximately $&lt;/div&gt;2.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million for federal income taxes purposes. The federal credits may be used to offset future income tax and will begin to expire in &lt;/div&gt;2035&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is subject to taxation in the U.S., various state tax jurisdictions and various foreign tax jurisdictions. All of the Company&#x2019;s tax&#160;years will remain open for three year for examination by the Federal and state tax authorities from the date of utilization of the net operating loss. The Company does not have any tax audits pending.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company applies the accounting guidance for uncertainty in income taxes pursuant to &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;ASC-740-10.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Under ASC 740, the impact of an uncertain income tax position taken on a tax return must be recognized at the largest amount that is cumulatively &#x201c;more likely than not&#x201d; to be sustained upon audit by relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a &lt;/div&gt;50&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% likelihood of being sustained.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The unrecognized tax benefits balances as of December&#160;31, 2021, 2020 and 2019 and the related increases and decreases to the balances were immaterial.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s policy is to recognize interest and penalties related to income tax matters in income tax expense. &lt;/div&gt;No&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; interest and penalties have been recognized as of and for the periods ended December&#160;31, 2021, 2020 and 2019.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company believes that no material amount of liabilities for uncertain tax positions will expire within 12&#160;months of December&#160;31, 2021.&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total loss before income taxes for the&#160;years ended December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2020&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; and &lt;/div&gt;2019&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; did not include a foreign component. The components of benefits for income taxes were as follows for the period ended December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; (in thousands):&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 76%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current expense:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Federal&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;State&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(53&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(53&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Federal&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;State&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(53&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">5000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-53000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">2000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">5000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-53000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">2000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">5000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-53000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">2000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The components of the Company&#x2019;s net deferred tax liabilities and related valuation allowance are as follows at December&#160;31 (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 73%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 73%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred tax assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 73%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Interest expense limitations&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"&gt;12,205&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"&gt;8,225&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 73%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Tax credit carryforwards&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;1,630&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;1,623&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 73%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net operating loss carryforwards&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"&gt;39,714&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"&gt;31,732&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 73%; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock based compensation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;3,233&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;2,037&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 73%; background-color: rgb(255, 255, 255);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating lease liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"&gt;404&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"&gt;510&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em;"&gt;Others&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;1,753&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;2,285&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgb(255, 255, 255); width: 73%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 73%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total Deferred Tax Assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;58,939&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;46,412&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 73%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Valuation allowance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="null;text-indent: 0px;;font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(56,643&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;(43,514&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(255, 255, 255);"&gt;&lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total Deferred Tax Assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,296&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2,898&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred Tax Liabilities:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 73%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Amortization of intangibles&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; text-align: right; background-color: rgb(255, 255, 255);"&gt;(1,975&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"&gt;(2,486&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em;"&gt;Other&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; text-align: right; background-color: rgb(204, 238, 255);"&gt;(2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&#x2014;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; background-color: rgb(255, 255, 255); padding-bottom: 0.375pt; width: 73%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Operating lease &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); padding-bottom: 0.375pt; width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; text-align: right; background-color: rgb(255, 255, 255); border-bottom: 0.75pt solid black;"&gt;(319&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); padding-bottom: 0.375pt;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); padding-bottom: 0.375pt; width: 6%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); border-bottom: 0.75pt solid black;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); border-bottom: 0.75pt solid black;;text-align:right;"&gt;(412&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); padding-bottom: 0.375pt;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); padding-bottom: 0.75pt; width: 73%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total Deferred Tax Liabilities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0px 0px 0.75pt; background-color: rgb(204, 238, 255); width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px; text-align: right; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(2,296&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0.75pt; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0px 0px 0.75pt; background-color: rgb(204, 238, 255); width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(2,898&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); padding-bottom: 0.75pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <sclx:DeferredTaxAssetsInterestExpenseLimitations
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">12205000</sclx:DeferredTaxAssetsInterestExpenseLimitations>
    <sclx:DeferredTaxAssetsInterestExpenseLimitations
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">8225000</sclx:DeferredTaxAssetsInterestExpenseLimitations>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1630000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1623000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">39714000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">31732000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">3233000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">2037000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <sclx:DeferredTaxAssetsOperatingLeaseLiabilities
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">404000</sclx:DeferredTaxAssetsOperatingLeaseLiabilities>
    <sclx:DeferredTaxAssetsOperatingLeaseLiabilities
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">510000</sclx:DeferredTaxAssetsOperatingLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1753000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">2285000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">58939000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">46412000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">56643000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">43514000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2296000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">2898000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1975000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">2486000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">319000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">412000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilities
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2296000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">2898000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">56600000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn12_31_2020"
      decimals="-5"
      unitRef="Unit_USD">43500000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The reconciliation between U.S. federal income taxes at the statutory rate and the Company&#x2019;s benefit from income taxes are as follows for the year ended December 31: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 75%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Statutory Federal Income Tax Rate&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;State taxes, net of federal tax benefit&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2.8&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2.7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Debt discount and interest limitation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(10.1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In-process&lt;/div&gt; research and development&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(11.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Return to provision adjustments and carryback&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2.7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(11.2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Others&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1.6&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.8&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.8&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in valuation allowance&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(14.8&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(13.2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(14.2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: Times New Roman; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4.8em;"&gt;Income Tax Benefit&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2021To12_31_2021"
      decimals="3"
      unitRef="Unit_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2020To12_31_2020"
      decimals="3"
      unitRef="Unit_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2019To12_31_2019"
      decimals="3"
      unitRef="Unit_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="P01_01_2021To12_31_2021"
      decimals="3"
      unitRef="Unit_pure">0.028</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="P01_01_2020To12_31_2020"
      decimals="3"
      unitRef="Unit_pure">0.027</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="P01_01_2019To12_31_2019"
      decimals="3"
      unitRef="Unit_pure">0.05</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <sclx:EffectiveIncomeTaxRateReconciliationDebtDiscountAndInterestLimitation
      contextRef="P01_01_2021To12_31_2021"
      decimals="3"
      unitRef="Unit_pure">-0.101</sclx:EffectiveIncomeTaxRateReconciliationDebtDiscountAndInterestLimitation>
    <sclx:EffectiveIncomeTaxRateReconciliationDebtDiscountAndInterestLimitation
      contextRef="P01_01_2020To12_31_2020"
      decimals="3"
      unitRef="Unit_pure">0.017</sclx:EffectiveIncomeTaxRateReconciliationDebtDiscountAndInterestLimitation>
    <sclx:EffectiveIncomeTaxRateReconciliationDebtDiscountAndInterestLimitation
      contextRef="P01_01_2019To12_31_2019"
      decimals="3"
      unitRef="Unit_pure">0</sclx:EffectiveIncomeTaxRateReconciliationDebtDiscountAndInterestLimitation>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="P01_01_2021To12_31_2021"
      decimals="3"
      unitRef="Unit_pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="P01_01_2020To12_31_2020"
      decimals="3"
      unitRef="Unit_pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="P01_01_2019To12_31_2019"
      decimals="3"
      unitRef="Unit_pure">-0.11</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
    <sclx:EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustmentsAndCarryback
      contextRef="P01_01_2021To12_31_2021"
      decimals="3"
      unitRef="Unit_pure">0.027</sclx:EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustmentsAndCarryback>
    <sclx:EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustmentsAndCarryback
      contextRef="P01_01_2020To12_31_2020"
      decimals="3"
      unitRef="Unit_pure">-0.112</sclx:EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustmentsAndCarryback>
    <sclx:EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustmentsAndCarryback
      contextRef="P01_01_2019To12_31_2019"
      decimals="3"
      unitRef="Unit_pure">0</sclx:EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustmentsAndCarryback>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="P01_01_2021To12_31_2021"
      decimals="3"
      unitRef="Unit_pure">-0.016</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="P01_01_2020To12_31_2020"
      decimals="3"
      unitRef="Unit_pure">-0.008</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="P01_01_2019To12_31_2019"
      decimals="3"
      unitRef="Unit_pure">-0.008</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="P01_01_2021To12_31_2021"
      decimals="3"
      unitRef="Unit_pure">-0.148</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="P01_01_2020To12_31_2020"
      decimals="3"
      unitRef="Unit_pure">-0.132</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="P01_01_2019To12_31_2019"
      decimals="3"
      unitRef="Unit_pure">-0.142</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="P01_01_2021To12_31_2021"
      decimals="3"
      unitRef="Unit_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="P01_01_2020To12_31_2020"
      decimals="3"
      unitRef="Unit_pure">0.002</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="P01_01_2019To12_31_2019"
      decimals="3"
      unitRef="Unit_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:OperatingLossCarryforwards
      contextRef="PAsOn12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-5"
      unitRef="Unit_USD">167500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="PAsOn12_31_2021_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-5"
      unitRef="Unit_USD">81700000</us-gaap:OperatingLossCarryforwards>
    <sclx:OperatingLossCarryforwardsExpirationYear contextRef="P01_01_2021To12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis">2034</sclx:OperatingLossCarryforwardsExpirationYear>
    <sclx:OperatingLossCarryforwardsExpirationYear contextRef="P01_01_2021To12_31_2021_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">2035</sclx:OperatingLossCarryforwardsExpirationYear>
    <us-gaap:OperatingLossCarryforwards
      contextRef="PAsOn12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_IndefiniteCarryforwardPeriodMemberusgaapTaxPeriodAxis"
      decimals="-5"
      unitRef="Unit_USD">154800000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="PAsOn12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_ResearchMemberusgaapTaxCreditCarryforwardAxis"
      decimals="-5"
      unitRef="Unit_USD">2000000</us-gaap:TaxCreditCarryforwardAmount>
    <sclx:TaxCreditCarryforwardExpirationYear contextRef="P01_01_2021To12_31_2021">2035</sclx:TaxCreditCarryforwardExpirationYear>
    <sclx:MinimumThresholdPercentageForRecognitionOfUncertainIncomeTaxPosition
      contextRef="PAsOn12_31_2021"
      decimals="2"
      unitRef="Unit_pure">0.50</sclx:MinimumThresholdPercentageForRecognitionOfUncertainIncomeTaxPosition>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="P01_01_2021To12_31_2021">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;13.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Related Party Transactions&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On March&#160;18, 2019, the Company entered into a merger agreement with Sorrento, Semnur, Merger Sub, and Fortis Advisors LLC. Jaisim Shah, a member of Sorrento&#x2019;s board of directors, was Semnur&#x2019;s Chief Executive Officer, a member of its board of directors and a stockholder of Semnur prior to the acquisition transaction. The upfront consideration was comprised of the following: (a)&#160;a cash payment of approximately $&lt;/div&gt;15.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, and (b)&#160;$&lt;/div&gt;55.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million of shares of the Company&#x2019;s common stock (&lt;/div&gt;47,039,315&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; shares issued and &lt;/div&gt;352,972&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; shares issuable, valued at $&lt;/div&gt;1.16&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; per share) (i.e., the Stock Consideration). Following the issuance of the Stock Consideration, Sorrento was the owner of approximately &lt;/div&gt;58&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% of the Company&#x2019;s issued and outstanding capital stock as of December&#160;31, 2019. Following the completion of the Semnur Share Exchange and as of December&#160;31, 2020, Sorrento held approximately &lt;/div&gt;82.3&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% of the outstanding common stock of the Company.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the year ended December&#160;31, 2021, 2020 and 2019, the Company purchased approximately $&lt;/div&gt;5.7&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, $&lt;/div&gt;1.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, and $&lt;/div&gt;8.4&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, respectively, of inventory from Itochu, a previous minority shareholder of the Company and a Developer in the aforementioned Product Development Agreement. These costs are recorded within cost of revenues and selling, general and administrative expenses in the Company&#x2019;s statement of operations. As of December&#160;31, 2020, approximately &lt;/div&gt;14.7&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% of the outstanding capital stock of the Company was held by Itochu. On January&#160;13, 2021, &lt;/div&gt;34,889,868&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; shares of the Company representing all outstanding capital stock of the Company held by Itochu were acquired by &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-related&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; minority shareholders. Thus, Itochu is not a shareholder subsequent to January&#160;13, 2021. On January&#160;29, 2021, Sorrento acquired &lt;/div&gt;34,889,868&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; shares of the Company, resulting in Sorrento holding approximately &lt;/div&gt;99.97&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% of the Company.&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Semnur is party to an Assignment Agreement, dated August&#160;6, 2013 (the &#x201c;Assignment Agreement&#x201d;), with Shah Investor LP (&#x201c;Shah Investor&#x201d;). Mahendra Shah, Ph.D., who has served on the Company&#x2019;s board of directors since March&#160;2019, is the managing partner of Shah Investor. Pursuant to the Assignment Agreement, Shah Investor assigned certain intellectual property to Semnur and Semnur agreed to pay Shah Investor a contingent quarterly royalty in the &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;low-single&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; digits based on quarterly net sales of any pharmaceutical formulations for local delivery of steroids by injection developed using such intellectual property, which would include &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-102.&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; To date, the Company has made no royalty payments pursuant to the Assignment Agreement.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On January&#160;1, 2017, a Transition Services Agreement (&#x201c;TSA&#x201d;) was executed between Scilex Pharma and Sorrento. Pursuant to the TSA, Sorrento agreed, at the Company&#x2019;s request, to provide directly or indirectly certain administrative, financial, legal, tax, insurance, facility, information technology and other services. In addition to the services provided under the TSA, Sorrento retains insurance coverage on behalf of the Company. During the&#160;years ended December&#160;31, 2021, 2020, and 2019, the total cost of services and insurance, including an agreed-upon markup, provided to the Company and recognized in general and administrative expenses was $&lt;/div&gt;4.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, $&lt;/div&gt;2.3&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, and $&lt;/div&gt;0.9&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, respectively.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On March&#160;18, 2019, the Company entered into a note payable with Sorrento with an initial principal amount of $&lt;/div&gt;16.5&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million. The note is interest bearing at the lesser of (a)&#160;&lt;/div&gt;10&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% simple interest per annum, and (b)&#160;the maximum interest rate permitted under law. Interest is due and payable annually. The note payable is payable upon demand and may be prepaid in whole or in part at any time without penalty or premium. The outstanding principal balance of the note on December&#160;31, 2021 and 2020 was $&lt;/div&gt;19.6&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million and $&lt;/div&gt;13.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, respectively, which was recorded under the current related party note&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;s&lt;/div&gt; payable in the Company&#x2019;s consolidated balance sheets. As of December&#160;31, 2021 and 2020, the Company had ending balances resulting from the accrued interest on the note payable of $&lt;/div&gt;3.9&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million and $&lt;/div&gt;2.6&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, respectively, which was recorded under related party payable in the Company&#x2019;s consolidated balance sheets. The proceeds from the note payable were used to finance the acquisition of Semnur.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On October&#160;5, 2018, Scilex Pharma issued to Sorrento a promissory note in the amount of approximately $&lt;/div&gt;21.7&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million for certain amounts previously advanced to Scilex Pharma by Sorrento (the &#x201c;Intercompany Note&#x201d;). Scilex Pharma may borrow up to an aggregate of $&lt;/div&gt;25.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million of principal amount under the note payable. The promissory note is interest bearing at the lesser of (a)&#160;&lt;/div&gt;10&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% simple interest per annum, and (b)&#160;the &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;maximum&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;interest rate permitted under law. All outstanding principal amounts and accrued interest are due upon maturity on August&#160;31, 2026. On October&#160;22, 2018, Sorrento purchased from the Company &lt;/div&gt;24,117,608&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; shares of the Company&#x2019;s common stock in exchange for the repayment of $&lt;/div&gt;21.7&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million of indebtedness under this promissory note. During 2021 and 2020, Sorrento made advances to Scilex Pharma in the amount of $&lt;/div&gt;8.1&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million and $&lt;/div&gt;10.3&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, respectively, under the promissory note. As of December&#160;31, 2021 and 2020, the Company had ending balances resulting from the accrued interest on the promissory note of $&lt;/div&gt;3.1&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million and $&lt;/div&gt;1.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, respectively, which was recorded under related party payable in the Company&#x2019;s consolidated balance sheets. As of December&#160;31, 2021 and 2020, Scilex Pharma&#x2019;s outstanding principal balance under the promissory note was $&lt;/div&gt;23.5&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million and $&lt;/div&gt;15.4&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, respectively, which was recorded under the &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; related party note payable in the Company&#x2019;s consolidated balance sheets.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company received $&lt;/div&gt;17.3&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million and $&lt;/div&gt;20.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, in February&#160;2021 and April&#160;2021, respectively, from Sorrento to fund the payment of Scilex Pharma Notes in February&#160;2021 and April&#160;2021, totaling $&lt;/div&gt;40.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, as described in Note 8. The $&lt;/div&gt;37.3&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million received in February&#160;2021 and April 2021 is due on demand to Sorrento and was recorded under the related party payables in the Company&#x2019;s consolidated balance sheets. As of December&#160;31, 2021, related party payables due to Sorrento included $&lt;/div&gt;35.7&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million to cover working capital requirements, $&lt;/div&gt;51.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million for repurchases of Scilex Pharma Notes, and $&lt;/div&gt;6.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million to pay litigation fees (see Note 11). As of December&#160;31, 2020, related party payables due to Sorrento consisted of $&lt;/div&gt;13.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million to cover working capital requirements and $&lt;/div&gt;13.7&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million for repurchases of Scilex Pharma Notes.&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; </us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="P03_18_2019To03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">15000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable
      contextRef="P03_18_2019To03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">55000000</us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable>
    <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets
      contextRef="P03_18_2019To03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="0"
      unitRef="Unit_shares">47039315</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
    <us-gaap:CommonStockSharesSubscribedButUnissued
      contextRef="PAsOn03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="0"
      unitRef="Unit_shares">352972</us-gaap:CommonStockSharesSubscribedButUnissued>
    <sclx:AssetAcquisitionPricePerShare
      contextRef="PAsOn03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.16</sclx:AssetAcquisitionPricePerShare>
    <sclx:PercentageOfOwnershipInterest
      contextRef="PAsOn03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="2"
      unitRef="Unit_pure">0.58</sclx:PercentageOfOwnershipInterest>
    <sclx:PercentageOfSharesOutstanding
      contextRef="PAsOn12_31_2020_SenmurMemberusgaapAssetAcquisitionAxis_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="3"
      unitRef="Unit_pure">0.823</sclx:PercentageOfSharesOutstanding>
    <sclx:PaymentToAcquireInventory
      contextRef="P01_01_2021To12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">5700000</sclx:PaymentToAcquireInventory>
    <sclx:PaymentToAcquireInventory
      contextRef="P01_01_2020To12_31_2020"
      decimals="-5"
      unitRef="Unit_USD">1000000</sclx:PaymentToAcquireInventory>
    <sclx:PaymentToAcquireInventory
      contextRef="P01_01_2019To12_31_2019"
      decimals="-5"
      unitRef="Unit_USD">8400000</sclx:PaymentToAcquireInventory>
    <sclx:PercentageOfSharesOutstanding
      contextRef="PAsOn12_31_2020_ItochuMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="3"
      unitRef="Unit_pure">0.147</sclx:PercentageOfSharesOutstanding>
    <sclx:NumberOfSharesOutstanding
      contextRef="PAsOn01_13_2021_ItochuMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      unitRef="Unit_shares">34889868</sclx:NumberOfSharesOutstanding>
    <sclx:NumberOfSharesAcquired
      contextRef="PAsOn01_29_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      unitRef="Unit_shares">34889868</sclx:NumberOfSharesAcquired>
    <sclx:PercentageOfSharesOutstanding
      contextRef="PAsOn01_29_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="4"
      unitRef="Unit_pure">0.9997</sclx:PercentageOfSharesOutstanding>
    <us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
      contextRef="P01_01_2021To12_31_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">4000000</us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
      contextRef="P01_01_2020To12_31_2020_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">2300000</us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
      contextRef="P01_01_2019To12_31_2019_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">900000</us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn03_18_2019_ReorganizationMemberSCLXEventAxis_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">16500000</us-gaap:DebtInstrumentFaceAmount>
    <sclx:PercentageOfSimpleInterest
      contextRef="PAsOn03_18_2019_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="2"
      unitRef="Unit_pure">0.10</sclx:PercentageOfSimpleInterest>
    <us-gaap:NotesPayableCurrent
      contextRef="PAsOn12_31_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">19600000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="PAsOn12_31_2020_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">13000000</us-gaap:NotesPayableCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="PAsOn12_31_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">3900000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="PAsOn12_31_2020_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">2600000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn10_05_2018_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis"
      decimals="-5"
      unitRef="Unit_USD">21700000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn10_05_2018_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis"
      decimals="-5"
      unitRef="Unit_USD">25000000</us-gaap:DebtInstrumentFaceAmount>
    <sclx:PercentageOfSimpleInterest
      contextRef="PAsOn10_05_2018_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_pure">0.10</sclx:PercentageOfSimpleInterest>
    <sclx:NumberOfSharesAcquired
      contextRef="PAsOn10_02_2018"
      decimals="0"
      unitRef="Unit_shares">24117608</sclx:NumberOfSharesAcquired>
    <us-gaap:RepaymentsOfDebt
      contextRef="P10_02_2018To10_02_2018_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis"
      decimals="-5"
      unitRef="Unit_USD">21700000</us-gaap:RepaymentsOfDebt>
    <sclx:AccruedInterest
      contextRef="PAsOn12_31_2021_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis"
      decimals="-5"
      unitRef="Unit_USD">8100000</sclx:AccruedInterest>
    <sclx:AccruedInterest
      contextRef="PAsOn12_31_2020_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis"
      decimals="-5"
      unitRef="Unit_USD">10300000</sclx:AccruedInterest>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="PAsOn12_31_2021_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis"
      decimals="-5"
      unitRef="Unit_USD">3100000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="PAsOn12_31_2020_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis"
      decimals="-5"
      unitRef="Unit_USD">1000000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:LongTermNotesPayable
      contextRef="PAsOn12_20_2021_ScilexPharmaMemberdeiLegalEntityAxis"
      decimals="-5"
      unitRef="Unit_USD">23500000</us-gaap:LongTermNotesPayable>
    <us-gaap:LongTermNotesPayable
      contextRef="PAsOn12_31_2020_ScilexPharmaMemberdeiLegalEntityAxis"
      decimals="-5"
      unitRef="Unit_USD">15400000</us-gaap:LongTermNotesPayable>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="P02_28_2021To02_28_2021_SorrentoMemberSCLXInvesteeAxis"
      decimals="-5"
      unitRef="Unit_USD">17300000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="P04_30_2021To04_30_2021_SorrentoMemberSCLXInvesteeAxis"
      decimals="-5"
      unitRef="Unit_USD">20000000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="P02_28_2021To02_28_2021_ScilexPharmaMemberdeiLegalEntityAxis"
      decimals="-5"
      unitRef="Unit_USD">40000000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="PAsOn02_28_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">37300000</us-gaap:DueToRelatedPartiesCurrent>
    <sclx:WorkingCapitalRequirements
      contextRef="PAsOn12_31_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">35700000</sclx:WorkingCapitalRequirements>
    <us-gaap:DebtInstrumentRepurchaseAmount
      contextRef="PAsOn12_20_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">51000000</us-gaap:DebtInstrumentRepurchaseAmount>
    <us-gaap:LegalFees
      contextRef="P01_01_2021To12_31_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">6000000</us-gaap:LegalFees>
    <sclx:WorkingCapitalRequirements
      contextRef="PAsOn12_31_2020_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">13000000</sclx:WorkingCapitalRequirements>
    <us-gaap:DebtInstrumentRepurchaseAmount
      contextRef="PAsOn12_31_2020_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">13700000</us-gaap:DebtInstrumentRepurchaseAmount>
    <us-gaap:EarningsPerShareTextBlock contextRef="P01_01_2021To12_31_2021">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;14.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss Per Share &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For the&#160;years ended December&#160;31, 2021, 2020 and 2019, basic loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. Diluted loss per common share is calculated to give effect to all dilutive securities, using the treasury stock method.&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table sets forth the reconciliation of basic and diluted loss per share for the&#160;years ended December&#160;31, 2021, 2020, and 2019 (in thousands except per share data):&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 60%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt; border-bottom: 0.75pt solid black;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt; border-bottom: 0.75pt solid black;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net loss&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(88,424&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(47,519&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(178,594&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(255, 255, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Denominator for Basic Loss Per Share&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"&gt;197,266&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"&gt;197,315&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"&gt;187,524&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Effect of Dilutive Securities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(255, 255, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Denominator for Diluted Loss per Share &#x2014; Adjusted for Dilutive Securities&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"&gt;197,266&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"&gt;197,315&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"&gt;187,524&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic Loss Per Share&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(0.45&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(0.24&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(0.95&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(255, 255, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dilutive Loss Per Share&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"&gt;(0.45&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"&gt;(0.24&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"&gt;(0.95&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The stock options that could potentially dilute basic earnings per share in the future were excluded from the computation of diluted net loss per share because the effect would have been anti-dilutive due to the net loss for the&#160;years ended December&#160;31, 2021, 2020, and 2019 of &lt;/div&gt;28.2&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, &lt;/div&gt;30.8&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, and &lt;/div&gt;25.4&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;respectively. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table sets forth the reconciliation of basic and diluted loss per share for the&#160;years ended December&#160;31, 2021, 2020, and 2019 (in thousands except per share data):&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 60%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt; border-bottom: 0.75pt solid black;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt; border-bottom: 0.75pt solid black;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2019&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net loss&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(88,424&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(47,519&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(178,594&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(255, 255, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Denominator for Basic Loss Per Share&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"&gt;197,266&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"&gt;197,315&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"&gt;187,524&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Effect of Dilutive Securities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;0.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(255, 255, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Denominator for Diluted Loss per Share &#x2014; Adjusted for Dilutive Securities&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"&gt;197,266&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"&gt;197,315&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"&gt;187,524&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic Loss Per Share&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(0.45&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(0.24&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(0.95&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(255, 255, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dilutive Loss Per Share&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"&gt;(0.45&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"&gt;(0.24&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"&gt;(0.95&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-88424000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-47519000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">-178594000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">197266000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">197315000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">187524000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:DilutiveSecurities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-2"
      unitRef="Unit_USD">0</us-gaap:DilutiveSecurities>
    <us-gaap:DilutiveSecurities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-2"
      unitRef="Unit_USD">0</us-gaap:DilutiveSecurities>
    <us-gaap:DilutiveSecurities
      contextRef="P01_01_2019To12_31_2019"
      decimals="-2"
      unitRef="Unit_USD">0</us-gaap:DilutiveSecurities>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">197266000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">197315000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="P01_01_2019To12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">187524000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2021To12_31_2021"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.45</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2020To12_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.24</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2019To12_31_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.95</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2021To12_31_2021"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.45</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2020To12_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.24</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2019To12_31_2019"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.95</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2021To12_31_2021"
      decimals="-5"
      unitRef="Unit_shares">28200000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2020To12_31_2020"
      decimals="-5"
      unitRef="Unit_shares">30800000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2019To12_31_2019"
      decimals="-5"
      unitRef="Unit_shares">25400000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SubsequentEventsTextBlock contextRef="P01_01_2021To12_31_2021">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;15.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Subsequent Events &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following events were identified subsequent to the balance sheet date. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;SPAC Transaction &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On March&#160;17, 2022, the Company entered into an Agreement and Plan of Merger (as amended, the &#x201c;Merger Agreement&#x201d;) with Vickers Vantage Corp. I (&#x201c;Vickers&#x201d;), a SPAC, and Vantage Merger Sub, Inc., a wholly owned subsidiary of Vickers (&#x201c;Merger Sub&#x201d;). Pursuant to the terms of the Merger Agreement, (i)&#160;Merger &lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sub will &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;"&gt;merge with and into the Company&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;"&gt;, with the Company surviving the merger (&#x201c;combined company&#x201d;) and (ii)&#160;become a wholly&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;owned subsidiary of Vickers (collectively, the &#x201c;SPAC Transaction&#x201d;). The Merger is expected to close during the fourth quarter of 2022, and the Combined Company is expected to be listed on the Nasdaq Capital Market under the new ticker symbol &#x201c;SCLX&#x201d;. Completion of the SPAC Transaction is subject to the approval of Vickers and Company shareholders and the satisfaction or waiver of certain other closing conditions.&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Scilex Pharma Note &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color:rgba(255, 255, 255, .0);;display:inline;"&gt;Effective &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; February&#160;14, 2022, Scilex Pharma issued to Sorrento a draw notice under the Letter of Credit as required under the terms of the Indenture because actual cumulative net sales of ZTlido from the issue date of the Scilex Pharma Notes through December&#160;31, 2021 were less than a specified sales threshold for such period. As a result of the draw notice being issued, the Company paid to Scilex Pharma $&lt;/div&gt;35.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million in a single &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;lump-sum&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; amount as a subordinated loan. Per the terms of the Amendment No.&#160;3, in February&#160;2022, Scilex Pharma repurchased Scilex Pharma Notes in an aggregate amount equal to $&lt;/div&gt;20.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million at a purchase price in cash equal&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;to 100% of the principal amount. In addition, the draw down of the Letter of Credit triggered a requirement for Scilex Pharma to maintain a minimum cash balance of $10.0&#160;million at all times going &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;forward. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Effective&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;February&#160;15, 2022, in accordance with the Indenture, the principal amount of the Scilex Pharma Notes was increased by $&lt;/div&gt;28.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million as actual cumulative net sales of ZTlido from the issue date of the Scilex Pharma Notes through December&#160;31, 2021 did not equal or exceed a $&lt;/div&gt;481.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million sales threshold for such period&lt;div style="display:inline;"&gt;.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; font-size: 10pt;;font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Advances on Related Party Note Payable&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On March&#160;30, 2022, Sorrento made advances to the Company in the amount of $&lt;/div&gt;23.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million under the related party note payable entered into on March&#160;18, 2019 with Sorrento. See Note 13 for further discussion of the related party note &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;payable. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-104&lt;/div&gt; Acquisition from Sorrento &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;On May&#160;12, 2022&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, the Company and Sorrento entered into a bill of sale and assignment and assumption agreement (the &#x201c;Bill of Sale&#x201d;), pursuant to which Sorrento sold, conveyed, assigned and transferred to Scilex all of its rights, title and interest in and to Sorrento&#x2019;s Delayed Burst Release Low Dose Naltrexone &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(DBR-LDN)&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; asset and intellectual property rights, for the treatment of chronic pain, fibromyalgia and chronic post-COVID syndrome (collectively, the &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x201c;SP-104&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Assets&#x201d;) and the Company is currently analyzing the accounting treatment for the transaction. These assets had previously been acquired by Sorrento from Aardvark Therapeutics, Inc. (&#x201c;Aardvark&#x201d;) in April 2021 pursuant to an asset purchase agreement (the &#x201c;Aardvark Asset Purchase Agreement&#x201d;). Pursuant to the Bill of Sale, the Company assumed all of Sorrento&#x2019;s rights, liabilities and obligations under the Aardvark Asset Purchase Agreement (the &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x201c;SP-104&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Acquisition&#x201d;).&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As consideration for the &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-104&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Acquisition, the Company issued a promissory note in the aggregate principal amount of $&lt;/div&gt;5.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million to Sorrento (the &#x201c;2022 Promissory Note&#x201d;). The 2022 Promissory Note matures &lt;/div&gt;seven years&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; from the date of issuance and bears interest at the rate equal to the lesser of (a) &lt;/div&gt;2.66&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% simple interest per annum and (b)&#160;the maximum interest rate permitted under law. The 2022 Promissory Note is payable in cash, shares of the Company common stock (any shares so issued, the &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&#x201c;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Consideration Shares&#x201d;) or any combination thereof, at the Company&#x2019;s sole discretion, and may be prepaid in whole or in part at any time without penalty. The Company also agreed to file with the SEC, a resale registration statement, relating to the resale by Sorrento of any Consideration Shares that may be issued to Sorrento, within &lt;/div&gt;60&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; days of the issuance of such Consideration Shares.&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As the successor to the Aardvark Asset Purchase Agreement, the Company is obligated to pay Aardvark (i)&#160;$&lt;/div&gt;3,000,000&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, upon initial approval by the FDA of a new drug application for the LDN Formulation (as defined in&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;the&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;Aardvark Asset Purchase Agreement) (which amount may be paid in shares of the Company&#x2019;s common stock or cash, in the Company&#x2019;s sole discretion) (the &#x201c;Development Milestone Payment&#x201d;) and (ii)&#160;$&lt;/div&gt;20,000,000&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, in cash, upon achievement of certain net sales by the Company of a commercial product that uses the LDN Formulation (the &#x201c;Commercial Product&#x201d;). The Company will also pay Aardvark certain royalties in the single digits based on percentages of annual net sales by the Company of a commercial product that uses the LDN Formulation. The royalty percentage is subject to reduction in certain circumstances. Royalties are due for so long as Commercial Product is covered by a valid patent in the country of sale or for ten years following the first commercial sale of the Commercial Product, whichever is longer.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In connection with its acquisition of the &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-104&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Assets, the Company has agreed that if it issues any shares of the Company&#x2019;s common stock in respect of the Development Milestone Payment, the Company will prepare and file one or more registration statements with the SEC for the purpose of registering for resale such shares and is required to file such registration statement with the SEC within &lt;/div&gt;60&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;days following the date on which any such shares are issued.&lt;/div&gt;&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Tien-Li&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Lee, MD, a member of the board of directors of the Company, is the founder, chief executive officer and a member of the board of directors of Aardvark.&lt;/div&gt;&lt;/div&gt; </us-gaap:SubsequentEventsTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn02_14_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_SubordinatedDebtMemberusgaapLongtermDebtTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">35000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentRepurchaseAmount
      contextRef="PAsOn02_28_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_SubordinatedDebtMemberusgaapLongtermDebtTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">20000000</us-gaap:DebtInstrumentRepurchaseAmount>
    <sclx:PercentageOfPurchasePriceInCashEqualIsToPrincipalAmountOfTheLoan
      contextRef="PAsOn02_28_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_SubordinatedDebtMemberusgaapLongtermDebtTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="2"
      unitRef="Unit_pure">1</sclx:PercentageOfPurchasePriceInCashEqualIsToPrincipalAmountOfTheLoan>
    <us-gaap:RestrictedCash
      contextRef="PAsOn02_28_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_SubordinatedDebtMemberusgaapLongtermDebtTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">10000000</us-gaap:RestrictedCash>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn02_15_2022_MaximumMembersrtRangeAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_SubordinatedDebtMemberusgaapLongtermDebtTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">28000000</us-gaap:DebtInstrumentFaceAmount>
    <sclx:SalesThresholdLimit
      contextRef="P02_15_2022To02_15_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_SubordinatedDebtMemberusgaapLongtermDebtTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">481000000</sclx:SalesThresholdLimit>
    <us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent
      contextRef="PAsOn03_30_2022_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">23000000</us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn05_12_2022_SorrentoMemberusgaapBusinessAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_TwoThousandAndTwentyTwoPromissoryNoteMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">5000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentTerm contextRef="P05_12_2022To05_12_2022_SorrentoMemberusgaapBusinessAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_TwoThousandAndTwentyTwoPromissoryNoteMemberusgaapLongtermDebtTypeAxis">P7Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="PAsOn05_12_2022_SorrentoMemberusgaapBusinessAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_TwoThousandAndTwentyTwoPromissoryNoteMemberusgaapLongtermDebtTypeAxis"
      decimals="4"
      unitRef="Unit_pure">0.0266</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <sclx:MinimumTimeDeclaredToFileWithSecRegardingResaleRegistrationStatement contextRef="P05_12_2022To05_12_2022_SorrentoMemberusgaapBusinessAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_TwoThousandAndTwentyTwoPromissoryNoteMemberusgaapLongtermDebtTypeAxis">P60D</sclx:MinimumTimeDeclaredToFileWithSecRegardingResaleRegistrationStatement>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="P05_12_2022To05_12_2022_AardvarkMemberusgaapAssetAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      unitRef="Unit_USD">3000000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="P05_12_2022To05_12_2022_AardvarkMemberusgaapAssetAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      unitRef="Unit_USD">20000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <sclx:MinimumTimeDeclaredToFileWithSecRegardingResaleRegistrationStatement contextRef="P05_12_2022To05_12_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis">P60D</sclx:MinimumTimeDeclaredToFileWithSecRegardingResaleRegistrationStatement>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">2483000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">4338000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">17474000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">14268000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">933000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2562000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">10583000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1835000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">31473000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">23003000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">782000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">805000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">1271000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1303000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">41617000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">38802000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">13481000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">13481000</us-gaap:Goodwill>
    <us-gaap:LongTermInvestments
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">153000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">538000</us-gaap:LongTermInvestments>
    <us-gaap:Assets
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">88777000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">77932000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">11684000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">4284000</us-gaap:AccountsPayableCurrent>
    <sclx:AccruedPayroll
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">1426000</sclx:AccruedPayroll>
    <sclx:AccruedPayroll
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">3733000</sclx:AccruedPayroll>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">23862000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">10621000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">133000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredRevenueCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">37950000</us-gaap:LongTermDebtCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">166145000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">92724000</us-gaap:DueToRelatedPartiesCurrent>
    <sclx:RelatedPartyNotePayableCurrent
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">47108000</sclx:RelatedPartyNotePayableCurrent>
    <sclx:RelatedPartyNotePayableCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">19608000</sclx:RelatedPartyNotePayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">717000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">500000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">251075000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">169420000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">3517000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">72037000</us-gaap:LongTermDebtNoncurrent>
    <sclx:RelatedPartyNotePayableNoncurrent
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">62717000</sclx:RelatedPartyNotePayableNoncurrent>
    <sclx:RelatedPartyNotePayableNoncurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">23503000</sclx:RelatedPartyNotePayableNoncurrent>
    <sclx:DerivativeLiabilityNoncurrent
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">0</sclx:DerivativeLiabilityNoncurrent>
    <sclx:DerivativeLiabilityNoncurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">35700000</sclx:DerivativeLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">863000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1148000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">318172000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">301808000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn09_30_2022"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn12_31_2021"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn09_30_2022"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn09_30_2022"
      decimals="INF"
      unitRef="Unit_shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn09_30_2022"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn09_30_2022"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn09_30_2022"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn09_30_2022"
      decimals="INF"
      unitRef="Unit_shares">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_shares">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn09_30_2022"
      decimals="INF"
      unitRef="Unit_shares">197566338</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn09_30_2022"
      decimals="INF"
      unitRef="Unit_shares">197566338</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_shares">197266338</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_shares">197266338</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">20000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">20000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">128615000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">128654000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-358030000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-352550000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-229395000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-223876000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">88777000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">77932000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">26115000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">23054000</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">6284000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">2549000</us-gaap:CostOfRevenue>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">6457000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">7031000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">41371000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">36092000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">2896000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">2803000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">57008000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">48475000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-30893000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-25421000</us-gaap:OperatingIncomeLoss>
    <sclx:GainLossOnDerivative
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-5300000</sclx:GainLossOnDerivative>
    <sclx:GainLossOnDerivative
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-100000</sclx:GainLossOnDerivative>
    <sclx:GainLossOnExtinguishmentOfDebtt
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-28634000</sclx:GainLossOnExtinguishmentOfDebtt>
    <sclx:GainLossOnExtinguishmentOfDebtt
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">12463000</sclx:GainLossOnExtinguishmentOfDebtt>
    <us-gaap:InterestExpense
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">8596000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">8617000</us-gaap:InterestExpense>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-39000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">48000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-25377000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">21028000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-5516000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-46449000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-36000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">10000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-5480000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-46459000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2022To09_30_2022"
      decimals="INF"
      unitRef="Unit_USD_per_Share">-0.03</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2022To09_30_2022"
      decimals="INF"
      unitRef="Unit_USD_per_Share">-0.03</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2021To09_30_2021"
      decimals="INF"
      unitRef="Unit_USD_per_Share">-0.24</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2021To09_30_2021"
      decimals="INF"
      unitRef="Unit_USD_per_Share">-0.24</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2022To09_30_2022"
      decimals="0"
      unitRef="Unit_shares">197550</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2022To09_30_2022"
      decimals="0"
      unitRef="Unit_shares">197550</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2021To09_30_2021"
      decimals="0"
      unitRef="Unit_shares">197266</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2021To09_30_2021"
      decimals="0"
      unitRef="Unit_shares">197266</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">197266000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">20000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">128654000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-352550000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-223876000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="P01_01_2022To09_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">300000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2022To09_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2022To09_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">96000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2022To09_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">96000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <sclx:AdjustmentsToAdditionalPaidInCapitalNetOfDiscount
      contextRef="P01_01_2022To09_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-4127000</sclx:AdjustmentsToAdditionalPaidInCapitalNetOfDiscount>
    <sclx:AdjustmentsToAdditionalPaidInCapitalNetOfDiscount
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-4127000</sclx:AdjustmentsToAdditionalPaidInCapitalNetOfDiscount>
    <sclx:AdjustmentsToAdditionalPaidInCapitalDiscountAmortization
      contextRef="P01_01_2022To09_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-35000</sclx:AdjustmentsToAdditionalPaidInCapitalDiscountAmortization>
    <sclx:AdjustmentsToAdditionalPaidInCapitalDiscountAmortization
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-35000</sclx:AdjustmentsToAdditionalPaidInCapitalDiscountAmortization>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="P01_01_2022To09_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">4027000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">4027000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To09_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-5480000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-5480000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn09_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">197566000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">20000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">128615000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-358030000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-229395000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">197266000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">20000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">122423000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-264126000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-141683000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="P01_01_2021To09_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="P01_01_2021To09_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">4368000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="P01_01_2021To09_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">4368000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <sclx:AdjustmentsToAdditionalPaidInCapitalSharesIssuedInSemnurAcquisition
      contextRef="P01_01_2021To09_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">409000</sclx:AdjustmentsToAdditionalPaidInCapitalSharesIssuedInSemnurAcquisition>
    <sclx:AdjustmentsToAdditionalPaidInCapitalSharesIssuedInSemnurAcquisition
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">409000</sclx:AdjustmentsToAdditionalPaidInCapitalSharesIssuedInSemnurAcquisition>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To09_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-46459000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-46459000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn09_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">197266000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">20000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">127200000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-310585000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-183365000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-5480000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-46459000</us-gaap:NetIncomeLoss>
    <us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">2926000</us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">2832000</us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">3108000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">5904000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:InterestPaidNet
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">21190000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">11813000</us-gaap:InterestPaidNet>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">28634000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-12463000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <sclx:NonCashOperatingLeaseCosts
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">351000</sclx:NonCashOperatingLeaseCosts>
    <sclx:NonCashOperatingLeaseCosts
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">276000</sclx:NonCashOperatingLeaseCosts>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">4027000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">4368000</us-gaap:ShareBasedCompensation>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">5300000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">100000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">3206000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-517000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-1629000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-186000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">3478000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">1647000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInSecurityDeposits
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">385000</us-gaap:IncreaseDecreaseInSecurityDeposits>
    <us-gaap:IncreaseDecreaseInSecurityDeposits
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:IncreaseDecreaseInSecurityDeposits>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">2967000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-2784000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-2307000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">360000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">12403000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-522000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-255000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-53000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">21521000</us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent>
    <us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">13765000</us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-20533000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-22707000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">2060000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">7000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-2067000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:RepaymentsOfSeniorDebt
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">84808000</us-gaap:RepaymentsOfSeniorDebt>
    <us-gaap:RepaymentsOfSeniorDebt
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">32376000</us-gaap:RepaymentsOfSeniorDebt>
    <us-gaap:RepaymentsOfOtherLongTermDebt
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">18800000</us-gaap:RepaymentsOfOtherLongTermDebt>
    <us-gaap:RepaymentsOfOtherLongTermDebt
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">36900000</us-gaap:RepaymentsOfOtherLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">9857000</us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">34799000</us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">96000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">51900000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">45050000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromIssuanceOfMediumTermNotes
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">62500000</us-gaap:ProceedsFromIssuanceOfMediumTermNotes>
    <us-gaap:ProceedsFromIssuanceOfMediumTermNotes
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">11500000</us-gaap:ProceedsFromIssuanceOfMediumTermNotes>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">20745000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">22073000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-1855000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-634000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">4338000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">4839000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">2483000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">4205000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">3650000</us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1>
    <us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1>
    <us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationGiven1
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationGiven1>
    <us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationGiven1
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">409000</us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationGiven1>
    <sclx:OtherLoanForgiveness
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">0</sclx:OtherLoanForgiveness>
    <sclx:OtherLoanForgiveness
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">1536000</sclx:OtherLoanForgiveness>
    <sclx:PromissoryNoteIssuedNetOfDiscount
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">4162000</sclx:PromissoryNoteIssuedNetOfDiscount>
    <sclx:PromissoryNoteIssuedNetOfDiscount
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">0</sclx:PromissoryNoteIssuedNetOfDiscount>
    <sclx:NonCashFairValueAdjustmentToDerivativeLiability
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">30400000</sclx:NonCashFairValueAdjustmentToDerivativeLiability>
    <sclx:NonCashFairValueAdjustmentToDerivativeLiability
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">0</sclx:NonCashFairValueAdjustmentToDerivativeLiability>
    <sclx:NonCashRightOfUseAsset
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">320000</sclx:NonCashRightOfUseAsset>
    <sclx:NonCashRightOfUseAsset
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">0</sclx:NonCashRightOfUseAsset>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="P01_01_2022To09_30_2022">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Nature of Operations and Basis of Presentation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-indent: 0px; text-align: left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Organization and Principal Activities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-align: left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Scilex Holding Company (&#x201c;Scilex Holding&#x201d; (now known as Scilex, Inc.) and together with its wholly owned subsidiaries, the &#x201c;Company&#x201d;) was incorporated in Delaware in February 2019 and is a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, &#x201c;Sorrento&#x201d;). The Company is a commercial biopharmaceutical company focused on acquiring, developing and commercializing &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-opioid&lt;/div&gt; management products for the treatment of acute and chronic pain. The Company launched its first commercial product in October 2018, ZTlido (lidocaine topical system) 1.8% (&#x201c;ZTlido&#x201d;), a prescription lidocaine topical system that is designed with novel technology to address the limitations of current prescription lidocaine therapies by providing significantly improved adhesion and continuous pain relief throughout the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;12-hour&lt;/div&gt; administration period. The Company &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-licensed&lt;/div&gt; the exclusive right to commercialize GLOPERBA (colchicine USP) oral solution, an &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;FDA-approved&lt;/div&gt; prophylactic treatment for painful gout flares in adults, in the U.S. (see Note 2). The Company is planning to commercialize GLOPERBA in 2023. The Company is currently developing three product candidates, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-102&lt;/div&gt; (10&#160;mg, dexamethasone sodium phosphate viscous gel), a Phase 3, novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(&#x201c;SP-102&#x201d;&lt;/div&gt; or &#x201c;SEMDEXA&#x201d;) and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-103&lt;/div&gt; (lidocaine topical system) 5.4% &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(&#x201c;SP-103&#x201d;),&lt;/div&gt; for the treatment of acute low back pain, and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-104&lt;/div&gt; (4.5 mg, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;low-dose&lt;/div&gt; naltrexone hydrochloride delayed-release capsules) &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(&#x201c;SP-104&#x201d;),&lt;/div&gt; a novel formulation for the treatment of &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;fibromyalgia. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-align: left;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On March&#160;18, 2019, the Company entered into a Contribution and Loan Agreement with Sorrento and the holders of the outstanding shares of capital stock of Scilex Pharmaceuticals Inc. (&#x201c;Scilex Pharma&#x201d;) pursuant to which the Company acquired &lt;/div&gt;100&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% of the outstanding shares of capital stock of Scilex Pharma in exchange for shares of the Company&#x2019;s common stock (the &#x201c;Contribution&#x201d;), which was accounted for as a reorganization of entities under common control. Pursuant to the Contribution and Loan Agreement, Sorrento provided the Company with a loan with an initial principal amount of $&lt;/div&gt;16.5&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million in the form of a note payable, which was used by the Company to fund the acquisition of Semnur Pharmaceuticals, Inc. (&#x201c;Semnur&#x201d;). Concurrently therewith, the Company entered into an Agreement and Plan of Merger with Semnur, Sigma Merger Sub, Inc., the Company&#x2019;s prior wholly-owned subsidiary (&#x201c;Merger Sub&#x201d;), Fortis Advisors LLC, solely as representative of the holders of Semnur equity (the &#x201c;Semnur Equityholders&#x2019; Representative&#x201d;), and Sorrento, for limited purposes (the &#x201c;Merger Agreement&#x201d;), which was accounted for as an asset acquisition. Pursuant to the Merger Agreement, Merger Sub merged with and into Semnur (the &#x201c;Merger of Semnur&#x201d;), with Semnur surviving as the Company&#x2019;s wholly-owned subsidiary. As a result of the Contribution and the Merger of Semnur, Scilex Pharma and Semnur became wholly-owned subsidiaries of the Company. Upon completion of the Contribution and the Merger of Semnur, the historical consolidated financial statements of Scilex Pharma became the historical consolidated financial statements of &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Scilex Holding. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-align: left;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Since inception, the Company had devoted substantially all of its efforts to the product development of &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-102&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; and &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-103&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; and the commercialization of ZTlido.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: left; margin-bottom: 1em; margin-top: 1em"/&gt;&lt;div style="text-align: left; margin-bottom: 1em; margin-top: 1em"/&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px; text-align: left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Business Combination &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-align: left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On March&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;17, 2022, the Company entered into an Agreement and Plan of Merger (as amended on September&#160;12, 2022, the &#x201c;BCA&#x201d;) with Vickers Vantage Corp. I (&#x201c;Vickers&#x201d;), a special purpose acquisition&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;company, and&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Vantage Merger Sub, Inc., a wholly-owned subsidiary of Vickers (&#x201c;Vickers Merger Sub&#x201d;). Pursuant to the terms of the BCA, Vickers Merger Sub merged with and into the Company, with the Company surviving the merger (&#x201c;Legacy Scilex&#x201d;) and becoming a wholly-owned subsidiary of Vickers (collectively, the &#x201c;Business Combination&#x201d;).&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On November&#160;&lt;/div&gt;10&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, Vickers consummated the Business Combination pursuant to the terms of the BCA. Vickers acquired all of the outstanding equity interests of Legacy Scilex. As a result of the Business Combination, New Scilex (as defined below) received gross proceeds of approximately $&lt;/div&gt;12.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, prior to the settlement of transaction-related costs and expenses. Additionally, all existing related party indebtedness between the Company, Scilex Pharma, and Sorrento totaling $&lt;/div&gt;290.6&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million was converted into equity interests in Vickers in connection with the consummation of the Business Combination and pursuant to the terms of the Debt Exchange Agreement (see Note &lt;/div&gt;10)&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;. In connection with the Business Combination (as more fully described in the notes to these financial statements), Scilex Holding Company was renamed to Scilex, Inc. These financial statements are those of Scilex Holding Company (now known as Scilex, Inc.) prior to the completion of such Business Combination. Additionally, in connection with the completion of the Business Combination, Vickers was renamed to, and will operate as, &#x201c;Scilex Holding Company&#x201d; and the Company began trading on the Nasdaq Capital Market under the new ticker symbol &#x201c;SCLX&#x201d; on November&#160;&lt;/div&gt;11&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;. Scilex Holding Company following the completion of the Business Combination is sometimes referred to herein as &#x201c;New Scilex.&#x201d;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Business Combination will be accounted for as a reverse recapitalization in accordance with U.S. GAAP. Under this method of accounting, Vickers is treated as the &#x201c;acquired&#x201d; company for accounting purposes and the Business Combination is treated as the equivalent of the Company issuing stock for the net assets of Vickers, accompanied by a recapitalization. The net assets of Vickers are stated at historical cost, with &lt;/div&gt;no&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; goodwill or other intangible assets recorded.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s legal, accounting and other fees directly attributable to the Business Combination were capitalized within prepaid expenses and other current assets on the consolidated balance sheets. As of September&#160;&lt;/div&gt;30&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, the Company had capitalized $&lt;/div&gt;7.3&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million of costs incurred in relation to the Business Combination. There were &lt;/div&gt;no&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; capitalized costs in relation to the Business Combination as of December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Basis of Presentation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and include all adjustments necessary for the fair presentation of the Company&#x2019;s financial position for the periods presented.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying consolidated financial statements include the accounts of the Company&#x2019;s subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;These consolidated financial statements should be read in conjunction with the consolidated financial statements for the fiscal year ended December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;. Operating results for quarter periods are not expected to be indicative of operating results for the Company&#x2019;s &lt;/div&gt;2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; fiscal year, or any subsequent period.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The preparation of these consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of these consolidated financial statements and the reported amounts of expenses during the reporting period. Management believes that these estimates are reasonable; however, actual results may differ from these estimates.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Significant Accounting Policies &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the &lt;/div&gt;nine&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; months ended September&#160;&lt;/div&gt;30&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, there have been &lt;/div&gt;no&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; changes to the Company`s significant accounting policies as described in the notes to the audited financial statements for the years ended December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; and &lt;/div&gt;2020&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; included in the proxy statement/prospectus filed by Vickers with the SEC on October&#160;&lt;/div&gt;28&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; beginning on page &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;F-48&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; thereof.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Segments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating segments &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;are identified as components of an entity where separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions on how to allocate resources and assesses performance. The Company has determined that its chief operating decision maker is its Chief Executive Officer, as he is responsible for making decisions regarding the allocation of resources and assessing performance as well as for strategic operational decisions. The Company is engaged primarily in the development of &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-opioid&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; products focused on pain management based on its platform technologies and all sales are based in the United States. Accordingly, the Company has determined that it operates its business as a single reportable segment.&lt;/div&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="PAsOn03_18_2019_ContributionAndLoanAgreementMemberSCLXAgreementAxis_ReorganizationMemberSCLXEventAxis_ScilexPharmaMemberusgaapBusinessAcquisitionAxis"
      decimals="2"
      unitRef="Unit_pure">1</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn03_18_2019_ReorganizationMemberSCLXEventAxis_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">16500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:BusinessCombinationsPolicy contextRef="P01_01_2022To09_30_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px; text-align: left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Business Combination &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-align: left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On March&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;17, 2022, the Company entered into an Agreement and Plan of Merger (as amended on September&#160;12, 2022, the &#x201c;BCA&#x201d;) with Vickers Vantage Corp. I (&#x201c;Vickers&#x201d;), a special purpose acquisition&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;company, and&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Vantage Merger Sub, Inc., a wholly-owned subsidiary of Vickers (&#x201c;Vickers Merger Sub&#x201d;). Pursuant to the terms of the BCA, Vickers Merger Sub merged with and into the Company, with the Company surviving the merger (&#x201c;Legacy Scilex&#x201d;) and becoming a wholly-owned subsidiary of Vickers (collectively, the &#x201c;Business Combination&#x201d;).&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On November&#160;&lt;/div&gt;10&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, Vickers consummated the Business Combination pursuant to the terms of the BCA. Vickers acquired all of the outstanding equity interests of Legacy Scilex. As a result of the Business Combination, New Scilex (as defined below) received gross proceeds of approximately $&lt;/div&gt;12.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, prior to the settlement of transaction-related costs and expenses. Additionally, all existing related party indebtedness between the Company, Scilex Pharma, and Sorrento totaling $&lt;/div&gt;290.6&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million was converted into equity interests in Vickers in connection with the consummation of the Business Combination and pursuant to the terms of the Debt Exchange Agreement (see Note &lt;/div&gt;10)&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;. In connection with the Business Combination (as more fully described in the notes to these financial statements), Scilex Holding Company was renamed to Scilex, Inc. These financial statements are those of Scilex Holding Company (now known as Scilex, Inc.) prior to the completion of such Business Combination. Additionally, in connection with the completion of the Business Combination, Vickers was renamed to, and will operate as, &#x201c;Scilex Holding Company&#x201d; and the Company began trading on the Nasdaq Capital Market under the new ticker symbol &#x201c;SCLX&#x201d; on November&#160;&lt;/div&gt;11&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;. Scilex Holding Company following the completion of the Business Combination is sometimes referred to herein as &#x201c;New Scilex.&#x201d;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Business Combination will be accounted for as a reverse recapitalization in accordance with U.S. GAAP. Under this method of accounting, Vickers is treated as the &#x201c;acquired&#x201d; company for accounting purposes and the Business Combination is treated as the equivalent of the Company issuing stock for the net assets of Vickers, accompanied by a recapitalization. The net assets of Vickers are stated at historical cost, with &lt;/div&gt;no&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; goodwill or other intangible assets recorded.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s legal, accounting and other fees directly attributable to the Business Combination were capitalized within prepaid expenses and other current assets on the consolidated balance sheets. As of September&#160;&lt;/div&gt;30&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, the Company had capitalized $&lt;/div&gt;7.3&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million of costs incurred in relation to the Business Combination. There were &lt;/div&gt;no&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; capitalized costs in relation to the Business Combination as of December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;.&lt;/div&gt;&lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="P11_10_2020To11_10_2020_VantageMergerSubIncMemberusgaapBusinessAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">12000000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="P11_10_2020To11_10_2020_DebtExchangeAgreementMemberSCLXAgreementAxis_VantageMergerSubIncMemberusgaapBusinessAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">290600000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts
      contextRef="PAsOn09_30_2022_VantageMergerSubIncMemberusgaapBusinessAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">7300000</us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts>
    <us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts
      contextRef="PAsOn12_31_2021_VantageMergerSubIncMemberusgaapBusinessAcquisitionAxis"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="P01_01_2022To09_30_2022">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Basis of Presentation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and include all adjustments necessary for the fair presentation of the Company&#x2019;s financial position for the periods presented.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying consolidated financial statements include the accounts of the Company&#x2019;s subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;These consolidated financial statements should be read in conjunction with the consolidated financial statements for the fiscal year ended December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;. Operating results for quarter periods are not expected to be indicative of operating results for the Company&#x2019;s &lt;/div&gt;2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; fiscal year, or any subsequent period.&lt;/div&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates contextRef="P01_01_2022To09_30_2022">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The preparation of these consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of these consolidated financial statements and the reported amounts of expenses during the reporting period. Management believes that these estimates are reasonable; however, actual results may differ from these estimates.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="P01_01_2022To09_30_2022">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Significant Accounting Policies &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the &lt;/div&gt;nine&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; months ended September&#160;&lt;/div&gt;30&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, there have been &lt;/div&gt;no&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; changes to the Company`s significant accounting policies as described in the notes to the audited financial statements for the years ended December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; and &lt;/div&gt;2020&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; included in the proxy statement/prospectus filed by Vickers with the SEC on October&#160;&lt;/div&gt;28&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; beginning on page &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;F-48&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; thereof.&lt;/div&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="P01_01_2022To09_30_2022">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Segments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating segments &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;are identified as components of an entity where separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions on how to allocate resources and assesses performance. The Company has determined that its chief operating decision maker is its Chief Executive Officer, as he is responsible for making decisions regarding the allocation of resources and assessing performance as well as for strategic operational decisions. The Company is engaged primarily in the development of &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-opioid&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; products focused on pain management based on its platform technologies and all sales are based in the United States. Accordingly, the Company has determined that it operates its business as a single reportable segment.&lt;/div&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <sclx:LiquidityAndGoingConcernTextBlock contextRef="P01_01_2022To09_30_2022">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liquidity and Going Concern &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Management has assessed the Company&#x2019;s ability to continue as a going concern for at least &lt;/div&gt;one&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; year after the date the financial statements are issued.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of September&#160;&lt;/div&gt;30&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, the Company&#x2019;s negative working capital was $&lt;/div&gt;219.6&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, including cash and cash equivalents of approximately $&lt;/div&gt;2.5&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million. During the &lt;/div&gt;nine&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; months ended September&#160;&lt;/div&gt;30&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, the Company had operating losses of $&lt;/div&gt;30.9&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million and cash flows used for operations of $&lt;/div&gt;20.5&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million. The Company had an accumulated deficit of approximately $&lt;/div&gt;358.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million as of September&#160;&lt;/div&gt;30&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In &lt;/div&gt;September 2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, the Company exercised the Early Paydown Provision to fully extinguish the Scilex Pharma Notes (see Note &lt;/div&gt;6)&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;. In &lt;/div&gt;August 2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; and &lt;/div&gt;September 2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, the Company made principal payments towards the outstanding Scilex Pharma Notes totaling $&lt;/div&gt;41.4&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million. Pursuant to Amendment &lt;/div&gt;No&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;.&#160;&lt;/div&gt;4&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, a principal balance of $&lt;/div&gt;28.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million was forgiven by the Scilex Pharma Note Purchasers (see Note &lt;/div&gt;6)&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; upon the Company&#x2019;s exercise of the Early Paydown Provision. The Company funded the principal payments with &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;cash-on&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; hand and $&lt;/div&gt;34.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million received from Sorrento on September&#160;&lt;/div&gt;28&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; (see Note &lt;/div&gt;10)&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On September&#160;&lt;/div&gt;12&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, the Company and Scilex Pharma entered into a Debt Exchange Agreement with Sorrento, pursuant to which all related party payables and related party note payables that remain outstanding as of immediately prior to, and contingent upon, the closing of the Business Combination were contributed by Sorrento to the Company in exchange for the issuance by the Company to Sorrento of preferred stock of the Company and such shares were subsequently converted into shares of New Scliex common stock and preferred stock (see Note &lt;/div&gt;10)&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On October&#160;&lt;/div&gt;17&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, Sorrento and Scilex entered into a Funding Commitment Letter (see Note &lt;/div&gt;10)&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;. Pursuant to the terms of the Funding Commitment Letter, upon the written request of the Company, Sorrento shall fund &lt;/div&gt;one&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; or more loans to the Company in the amount to achieve $&lt;/div&gt;5,000,001&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; in net tangible assets immediately following the effective time of the Business Combination. Such related party payables or related party note payables will be converted into shares of preferred stock pursuant to the Debt Exchange Agreement. Any loans made under the Funding Commitment Letter will not exceed the lesser of (a) $&lt;/div&gt;10,000,000&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; and (b)&#160;an amount that, when taken together with all other Outstanding Indebtedness, will result in the Aggregate Outstanding Amount equaling $&lt;/div&gt;310,000,000&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; (see Note &lt;/div&gt;10)&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;. The Company did not draw funds from the Funding Commitment Letter at the effective time of the Business Combination.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;On March&#160;18, 2019, the Company acquired Semnur and the acquisition was accounted for as an asset acquisition (see Note 3). The Company anticipates the cash needed for the development of Semnur&#x2019;s primary product candidate in development, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-102,&lt;/div&gt; as well in the development of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-103,&lt;/div&gt; will be in excess of the Company&#x2019;s cash available within one year after the date these consolidated financial statements are issued. Semnur has no historical revenue and the Company will be responsible for funding all development and commercialization efforts and capital funding needs possibly through private or public equity or debt financings, strategic collaborations or other arrangements. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;On May&#160;12, 2022, the Company entered into a Bill of Sale (see Note 3), with Sorrento to acquire rights, title and interest in the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-104&lt;/div&gt; Assets (see Note 3). &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-104&lt;/div&gt; has not been approved for commercialization and, as such, no revenues have been generated to date by the asset. The Company will be responsible for funding all development and commercialization efforts. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On June&#160;14, 2022, the Company entered into a license and commercialization agreement with Romeg (see Note 3). The transaction was accounted for as an asset acquisition since substantially all the value of the gross assets was concentrated in the single asset, acquired licenses. The Company anticipates incurring costs related to the commercial launch and marketing of the acquired licenses. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has plans to obtain additional resources to fund its currently planned operations and expenditures for at least twelve months from the issuance of these consolidated financial statements through a combination of equity offerings, debt financings, collaborations, government contracts or other strategic transactions. The Company&#x2019;s plans are also dependent upon the success of future sales of ZTlido, which is still in the early stages of commercialization, and are dependent upon, among other things, the success of the Company&#x2019;s marketing of ZTlido. Should the Company&#x2019;s sales of ZTlido not materialize at the expected rate contemplated in the Company&#x2019;s business plan, due to the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; pandemic or other factors, the Company believes that there are a number of ongoing and potential actions that would maintain its projected cash and projected financial position including but not limited to, additional reductions in general and administrative costs, sales and marketing costs, suspension or winding down of clinical development programs for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-102,&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-103,&lt;/div&gt; and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-104,&lt;/div&gt; and other discretionary costs. Although the Company believes such plans, if executed, should provide the Company with financing to meet its needs, successful completion of such plans is dependent on factors outside the Company&#x2019;s control. As such, management cannot conclude that such plans will be effectively implemented within one year after the date that these consolidated financial statements are issued. As a result, management has concluded that the aforementioned conditions, among other things, raise substantial doubt about the Company&#x2019;s ability to continue as a going concern for one year after the date the financial statements &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;are issued. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</sclx:LiquidityAndGoingConcernTextBlock>
    <sclx:NetWorkingCapital
      contextRef="PAsOn09_30_2022"
      decimals="-5"
      unitRef="Unit_USD">219600000</sclx:NetWorkingCapital>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn09_30_2022"
      decimals="-5"
      unitRef="Unit_USD">2500000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2022To09_30_2022"
      decimals="-5"
      unitRef="Unit_USD">-30900000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2022To09_30_2022"
      decimals="-5"
      unitRef="Unit_USD">-20500000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn09_30_2022"
      decimals="-5"
      unitRef="Unit_USD">-358000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:DebtInstrumentAnnualPrincipalPayment
      contextRef="PAsOn09_30_2022_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">41400000</us-gaap:DebtInstrumentAnnualPrincipalPayment>
    <us-gaap:DebtInstrumentDecreaseForgiveness
      contextRef="P01_01_2022To09_30_2022_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">28000000</us-gaap:DebtInstrumentDecreaseForgiveness>
    <us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent
      contextRef="PAsOn09_28_2022_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">34000000</us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:MinimumNetWorthRequiredForCompliance
      contextRef="PAsOn10_17_2022"
      decimals="0"
      unitRef="Unit_USD">5000001</us-gaap:MinimumNetWorthRequiredForCompliance>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="PAsOn10_17_2022_FundingCommitmentLetterMemberusgaapCreditFacilityAxis"
      decimals="0"
      unitRef="Unit_USD">10000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <sclx:AggregateOutstandingAmount
      contextRef="PAsOn10_17_2022_FundingCommitmentLetterMemberusgaapCreditFacilityAxis"
      decimals="0"
      unitRef="Unit_USD">310000000</sclx:AggregateOutstandingAmount>
    <us-gaap:AssetAcquisitionTextBlock contextRef="P01_01_2022To09_30_2022">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Acquisitions &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Semnur Acquisition&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On March&#160;&lt;/div&gt;18&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2019&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, the Company completed the Merger of Semnur. At the closing of the Merger of Semnur, the Company issued to the holders of Semnur&#x2019;s capital stock and options to purchase Semnur&#x2019;s common stock, upfront consideration with a value of $&lt;/div&gt;70.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million. The upfront consideration was comprised of the following: (a)&#160;a cash payment of approximately $&lt;/div&gt;15.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, and (b) $&lt;/div&gt;55.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million of shares of the Company&#x2019;s common stock &lt;/div&gt;(47,039,315&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; shares issued and &lt;/div&gt;352,972&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; shares issuable, valued at $&lt;/div&gt;1.16&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; per share) (the &#x201c;Stock Consideration&#x201d;). Following the issuance of the Stock Consideration, Sorrento ownership in the Company diluted to approximately &lt;/div&gt;58&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% of the Company&#x2019;s issued and outstanding capital &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;stock. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;Pursuant to the Merger Agreement, and upon the terms and subject to the conditions contained therein, the Company also agreed to pay the holders of Semnur equity (the &#x201c;Semnur Equityholders&#x201d;) up to $&lt;/div&gt;280.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&#160;million in aggregate contingent cash consideration based on the achievement of certain milestones, comprised of a $&lt;/div&gt;40.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&#160;&lt;div style="display:inline;"&gt;million payment that will be due upon obtaining the first approval of a New Drug Application (&#x201c;NDA&#x201d;) of a Semnur product by the U.S. Food and Drug Administration (the &#x201c;FDA&#x201d;) and additional payments that will be&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="null;text-indent: 0px;;display:inline;"&gt;due upon the achievement of certain amounts of net sales of Semnur products, as follows: (1) a&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;20.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;payment upon the achievement of $&lt;/div&gt;100.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million in cumulative net sales of a Semnur product, &lt;/div&gt;(2)&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;a $&lt;/div&gt;20.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million payment upon the achievement of $&lt;/div&gt;250.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million in cumulative net sales of a Semnur product, &lt;/div&gt;(3)&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;a $&lt;/div&gt;50.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million payment upon the achievement of $&lt;/div&gt;500.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million in cumulative net sales of a Semnur product, and &lt;/div&gt;(4)&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;a $&lt;/div&gt;150.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million payment upon the achievement of $&lt;/div&gt;750.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million in cumulative net sales of a Semnur &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;product. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On August&#160;&lt;/div&gt;7&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2019&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, the Company entered into an amendment to the Merger Agreement to provide that, following the consummation of the Company&#x2019;s first bona fide equity financing with &lt;/div&gt;one&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; or more third-party financing sources on an arms&#x2019; length basis with gross proceeds to the Company of at least $&lt;/div&gt;40.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, certain of the former Semnur optionholders will be paid cash in lieu of: &lt;/div&gt;(1)&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;the &lt;/div&gt;352,972&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; shares of the Company&#x2019;s common stock otherwise issuable to such former Semnur optionholders pursuant to the Merger Agreement, and &lt;/div&gt;(2)&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;any shares that would otherwise be issued to such former Semnur optionholders upon release of shares held in escrow pursuant to the Merger Agreement, with such shares in each case valued at $&lt;/div&gt;1.16&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; per share. The amendment resulted in a reclassification of $&lt;/div&gt;0.4&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million from additional &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;paid-in&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; capital to accrued &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;liabilities. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In &lt;/div&gt;March 2019&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, the Semnur Equityholders that received the Stock Consideration were required to sign an Exchange and Registration Rights Agreement with the Company (the &#x201c;Exchange Agreement&#x201d;). Pursuant to the Exchange Agreement, and upon the terms and subject to the conditions contained therein, if within &lt;/div&gt;18&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; months following the closing of the Merger, &lt;/div&gt;100&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% of the outstanding equity of the Company has not been acquired by a third party or the Company has not entered into a definitive agreement with respect to, or otherwise consummated, a firmly underwritten offering of the Company capital stock on a major stock exchange that meets certain requirements, then holders of the Stock Consideration may collectively elect to exchange, during the &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;60-day&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; period commencing the date that is the &lt;/div&gt;18&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; month anniversary of the Closing (the &#x201c;Share Exchange&#x201d;), the Stock Consideration for shares of Sorrento&#x2019;s common stock with a value of $&lt;/div&gt;55.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million based on a price per share of Sorrento&#x2019;s common stock equal to the greater of (a)&#160;the &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;30-day&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; trailing volume weighted average price of &lt;/div&gt;one&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; share of Sorrento&#x2019;s common stock as reported on The Nasdaq Stock Market LLC as of the consummation of the Share Exchange and (b) $&lt;/div&gt;5.55&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; (subject to adjustment for any stock dividend, stock split, stock combination, reclassification or similar transaction) (the &#x201c;Exchange Price&#x201d;). Pursuant to an amendment to the Exchange Agreement entered into by Sorrento on September&#160;&lt;/div&gt;28&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2020&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, on October&#160;&lt;/div&gt;9&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2020&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, Sorrento paid $&lt;/div&gt;55.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million in cash to the Semnur Equityholders in lieu of issuing $&lt;/div&gt;55.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million of shares of Sorrento&#x2019;s common stock at the Exchange Price. Following the completion of the Share Exchange and as of December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2020&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, Sorrento held approximately &lt;/div&gt;82.3&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% of the outstanding common stock of the Company. On January&#160;&lt;/div&gt;29&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, Sorrento acquired additional shares of the Company, resulting in Sorrento holding approximately &lt;/div&gt;99.97&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% of the outstanding common stock of the &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Company. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The &lt;/div&gt;March 2019&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; transaction was accounted for as an asset acquisition since substantially all the value of the gross assets was concentrated in the single asset, &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-102.&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; As a result, approximately $&lt;/div&gt;75.3&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million was expensed as a component of acquired &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-process&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; research and development during the year ended &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;December&#160;31, 2019. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;No&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; contingent consideration was recorded as of September&#160;&lt;/div&gt;30&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; and December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; since the related regulatory approval milestones are not deemed probable until they actually occur.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; font-size: 10pt;;font-style:italic;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-104&lt;/div&gt; Acquisition&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;On May&#160;12, 2022, the Company entered into a bill of sale and assignment and assumption agreement (the &#x201c;Bill of Sale&#x201d;), with Sorrento. Pursuant to the Bill of Sale, Sorrento sold, conveyed, assigned and transferred to the Company all of its rights, title and interest in and to Sorrento&#x2019;s Delayed Burst Release Low Dose Naltrexone &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(&#x201c;DBR-LDN&#x201d;)&lt;/div&gt; asset and intellectual property rights, for the treatment of chronic pain, fibromyalgia and chronic post- COVID syndrome (collectively, the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x201c;SP-104&lt;/div&gt; Assets&#x201d;). These assets had previously been acquired by Sorrento from Aardvark Therapeutics, Inc. (&#x201c;Aardvark&#x201d;) in April 2021 pursuant to an asset purchase agreement (the &#x201c;Aardvark Asset Purchase Agreement&#x201d;). Pursuant to the Bill of Sale, the Company assumed all of Sorrento&#x2019;s rights, liabilities and obligations under the Aardvark Asset Purchase Agreement (the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x201c;SP-104&lt;/div&gt; Acquisition&#x201d;). &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;consideration for the &lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 0px; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-104&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Acquisition, the Company issued a promissory note in the aggregate principal amount of $&lt;/div&gt;5.0&lt;div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million to Sorrento (the &#x201c;&lt;/div&gt;2022&lt;div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Promissory Note&#x201d;). Upon issuance of the note, the Company recorded a related party note payable liability of $&lt;/div&gt;4.1&lt;div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, net of discount, with an offset to additional paid in capital, given the common control relationship between Sorrento and the Company. The &lt;/div&gt;2022&lt;div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Promissory Note matures &lt;/div&gt;seven years&lt;div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt; from the date of issuance and bears interest at the rate equal to the lesser of (a) &lt;/div&gt;2.66&lt;div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% simple interest per annum and (b)&#160;the maximum interest rate permitted under law. The &lt;/div&gt;2022&lt;div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Promissory Note is payable in cash, shares of the Company&#x2019;s common stock or any combination thereof, at the Company&#x2019;s sole discretion, and may be prepaid in whole or in part at any time without &lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;penalty.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As the successor to the Aardvark Asset Purchase Agreement, the Company is obligated to pay Aardvark (i) $&lt;/div&gt;3,000,000&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, upon initial approval by the FDA of a new drug application for the &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-104&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Assets (which amount may be paid in shares of the Company&#x2019;s common stock or cash, in the Company&#x2019;s sole discretion) (the &#x201c;Development Milestone Payment&#x201d;) and (ii) $&lt;/div&gt;20,000,000&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, in cash, upon achievement of certain net sales by the Company of a commercial product that uses the &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-104&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company will also pay Aardvark certain royalties in the single digits based on percentages of annual net sales by the Company of a commercial product that uses the &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-104&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Assets. The transaction was accounted for as an asset acquisition as substantially all the value of the gross assets was concentrated in a single asset, &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-104&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Assets. The contingent milestones and sale volume-based future royalties were determined to meet a scope exception for derivative under ASC Topic &lt;/div&gt;815&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, Derivatives and Hedging, and will not be recognized until the contingencies are realized in accordance with the Company&#x2019;s accounting policy for contingent consideration in an asset acquisition. &lt;/div&gt;No&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; contingent consideration was recognized at September&#160;&lt;/div&gt;30&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;,&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Tien-Li&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Lee, MD, a member of the board of directors of the Company, is the founder and chief executive officer of Aardvark. Kim D. Janda, Ph.D., a member of the Board of Directors of Sorrento, is a member of the advisory board of &lt;/div&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Aardvark.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;GLOPERBA License Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On June&#160;&lt;/div&gt;14&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, the Company entered into a license agreement (the &#x201c;Romeg License Agreement&#x201d;) with RxOmeg Therapeutics, LLC (a/k/a Romeg Therapeutics, Inc.) (&#x201c;Romeg&#x201d;). Pursuant to the Romeg License Agreement, among other things, Romeg granted the Company (a)&#160;a transferable license, with the right to sublicense, under the patents and &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;know-how&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; specified therein (with such license to &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;know-how&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; being exclusive for the limited purposes specified therein) to (i)&#160;commercialize the pharmaceutical product comprising liquid formulations of colchicine for the prophylactic treatment of gout in adult humans (the &#x201c;Initial Licensed Product&#x201d; or &#x201c;GLOPERBA&#x201d;) in the United States of America (including its territories) (the &#x201c;Territory&#x201d;), (ii) develop other products comprising the Initial Licensed Product as an active pharmaceutical ingredient (the &#x201c;Licensed Products&#x201d;) and commercialize any such products and (iii)&#160;manufacture Licensed Products anywhere in the world, solely for commercialization in the Territory and (b)&#160;an exclusive, transferable license, with right to sublicense, to use the trademark GLOPERBA and logos, designs, translations, and modifications thereof in connection with the commercialization of the Initial Licensed Product solely in the Territory. The Initial Licensed Product, GLOPERBA, was approved and made available in the &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;United States in 2020. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As consideration &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;for the license under the Romeg License Agreement, the Company paid Romeg an &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;up-front&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt; license fee of $&lt;/div&gt;2.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&#160;million, and has agreed to pay Romeg (a)&#160;upon the Company&#x2019;s achievement of certain net sales milestones, certain milestone payments in the aggregate amount of up to $&lt;/div&gt;13.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&#160;million, (b)&#160;certain royalties in the &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;mid-single&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt; digit to &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;low-double&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt; digit percentages based on annual net sales of the Licensed Product by the Company during the applicable royalty term under the Romeg License Agreement, and (c)&#160;minimum quarterly royalty payments totaling $&lt;/div&gt;7.1&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;million commencing on the first year anniversary of the effective date of the Romeg License Agreement and ending on the later of (i) expiration of the last to expire of the licensed patents covering the Licensed Products in the Territory or (ii) the tenth anniversary of the effective date of the Romeg License Agreement.&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The transaction was accounted for as an asset acquisition since substantially all the value of the gross assets was concentrated in a single asset, which is the Initial Licensed Product. In connection with the Romeg License Agreement, the Company recorded an intangible asset for acquired licenses of $&lt;/div&gt;5.7&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, which is comprised of the upfront license fee of $&lt;/div&gt;2.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million and a deferred consideration of $&lt;/div&gt;3.7&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million that is the present value of the future minimum royalty payments and immaterial transaction costs. The contingent s&lt;/div&gt;ale&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;s milestones and sales volume-based future royalties were determined to meet a scope exception for derivative under ASC Topic &lt;/div&gt;815&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, and will not be recognized until the contingencies are realized. &lt;/div&gt;No&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; contingent consideration was recognized as a liability or included in the fair value of the asset as of September&#160;&lt;/div&gt;30&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;. The Company determined the useful life of the intangible asset to be approximately &lt;/div&gt;15 years&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, which approximates the life of the licensed patents covering the Initial Licensed Product.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:AssetAcquisitionTextBlock>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="P03_18_2019To03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">70000000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="P03_18_2019To03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">15000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable
      contextRef="P03_18_2019To03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">55000000</us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable>
    <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets
      contextRef="P03_18_2019To03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="0"
      unitRef="Unit_shares">47039315</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
    <us-gaap:CommonStockSharesSubscribedButUnissued
      contextRef="PAsOn03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="0"
      unitRef="Unit_shares">352972</us-gaap:CommonStockSharesSubscribedButUnissued>
    <sclx:AssetAcquisitionPricePerShare
      contextRef="PAsOn03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.16</sclx:AssetAcquisitionPricePerShare>
    <sclx:PercentageOfOwnershipInterest
      contextRef="PAsOn03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="2"
      unitRef="Unit_pure">0.58</sclx:PercentageOfOwnershipInterest>
    <us-gaap:AssetAcquisitionContingentConsiderationLiability
      contextRef="PAsOn03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">280000000</us-gaap:AssetAcquisitionContingentConsiderationLiability>
    <us-gaap:AssetAcquisitionContingentConsiderationLiability
      contextRef="PAsOn03_18_2019_RegulatoryBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">40000000</us-gaap:AssetAcquisitionContingentConsiderationLiability>
    <us-gaap:AssetAcquisitionContingentConsiderationLiability
      contextRef="PAsOn03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheOneMemberSCLXTrancheAxis"
      decimals="-5"
      unitRef="Unit_USD">20000000</us-gaap:AssetAcquisitionContingentConsiderationLiability>
    <sclx:RevenueToBeEarnedByTheAcquireeValue
      contextRef="P03_18_2019To03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheOneMemberSCLXTrancheAxis"
      decimals="-5"
      unitRef="Unit_USD">100000000</sclx:RevenueToBeEarnedByTheAcquireeValue>
    <us-gaap:AssetAcquisitionContingentConsiderationLiability
      contextRef="PAsOn03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheTwoMemberSCLXTrancheAxis"
      decimals="-5"
      unitRef="Unit_USD">20000000</us-gaap:AssetAcquisitionContingentConsiderationLiability>
    <sclx:RevenueToBeEarnedByTheAcquireeValue
      contextRef="P03_18_2019To03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheTwoMemberSCLXTrancheAxis"
      decimals="-5"
      unitRef="Unit_USD">250000000</sclx:RevenueToBeEarnedByTheAcquireeValue>
    <us-gaap:AssetAcquisitionContingentConsiderationLiability
      contextRef="PAsOn03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheThreeMemberSCLXTrancheAxis"
      decimals="-5"
      unitRef="Unit_USD">50000000</us-gaap:AssetAcquisitionContingentConsiderationLiability>
    <sclx:RevenueToBeEarnedByTheAcquireeValue
      contextRef="P03_18_2019To03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheThreeMemberSCLXTrancheAxis"
      decimals="-5"
      unitRef="Unit_USD">500000000</sclx:RevenueToBeEarnedByTheAcquireeValue>
    <us-gaap:AssetAcquisitionContingentConsiderationLiability
      contextRef="PAsOn03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheFourMemberSCLXTrancheAxis"
      decimals="-5"
      unitRef="Unit_USD">150000000</us-gaap:AssetAcquisitionContingentConsiderationLiability>
    <sclx:RevenueToBeEarnedByTheAcquireeValue
      contextRef="P03_18_2019To03_18_2019_ReveueBasedMilestoneMemberSCLXMilestoneAxis_SenmurMemberusgaapAssetAcquisitionAxis_TrancheFourMemberSCLXTrancheAxis"
      decimals="-5"
      unitRef="Unit_USD">750000000</sclx:RevenueToBeEarnedByTheAcquireeValue>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="P08_07_2019To08_07_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">40000000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:CommonStockSharesSubscribedButUnissued
      contextRef="PAsOn08_07_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="0"
      unitRef="Unit_shares">352972</us-gaap:CommonStockSharesSubscribedButUnissued>
    <sclx:AssetAcquisitionPricePerShare
      contextRef="PAsOn08_07_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.16</sclx:AssetAcquisitionPricePerShare>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="PAsOn08_07_2019_AsRestatedMembersrtRestatementAxis_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">400000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <sclx:PercentageOfSharesIssuedSubjectToRestrictionOfTransfer
      contextRef="PAsOn03_01_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="2"
      unitRef="Unit_pure">1</sclx:PercentageOfSharesIssuedSubjectToRestrictionOfTransfer>
    <sclx:PeriodDuringWhichTheSharesMayBeExchanged contextRef="P03_01_2019To03_31_2019">P60D</sclx:PeriodDuringWhichTheSharesMayBeExchanged>
    <sclx:PeriodDuringWhichShareTransferIsRestricted contextRef="P03_01_2019To03_31_2019">P18M</sclx:PeriodDuringWhichShareTransferIsRestricted>
    <sclx:CommonStockValueToBeExchanged
      contextRef="P03_01_2019To03_31_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">55000000</sclx:CommonStockValueToBeExchanged>
    <sclx:NumberOfDaysForDeterminingTheWeightedVolumeAveragePriceForShares contextRef="P03_01_2019To03_31_2019_SenmurMemberusgaapAssetAcquisitionAxis">P30D</sclx:NumberOfDaysForDeterminingTheWeightedVolumeAveragePriceForShares>
    <sclx:PricePerShareForDeterminingTheExchangeOfShares
      contextRef="PAsOn03_01_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">5.55</sclx:PricePerShareForDeterminingTheExchangeOfShares>
    <sclx:PaymentMadeInSurrenderingTheShares
      contextRef="P03_01_2019To03_31_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">55000000</sclx:PaymentMadeInSurrenderingTheShares>
    <sclx:PaymentMadeInSurrenderingTheShares
      contextRef="P03_01_2019To03_31_2019_SenmurMemberusgaapAssetAcquisitionAxis_SorrentoMemberSCLXInvesteeAxis"
      decimals="-5"
      unitRef="Unit_USD">55000000</sclx:PaymentMadeInSurrenderingTheShares>
    <sclx:PercentageOfSharesOutstanding
      contextRef="PAsOn12_31_2020_SenmurMemberusgaapAssetAcquisitionAxis_SorrentoMemberSCLXInvesteeAxis"
      decimals="3"
      unitRef="Unit_pure">0.823</sclx:PercentageOfSharesOutstanding>
    <sclx:PercentageOfSharesOutstanding
      contextRef="PAsOn01_29_2021_SenmurMemberusgaapAssetAcquisitionAxis_SorrentoMemberSCLXInvesteeAxis"
      decimals="4"
      unitRef="Unit_pure">0.9997</sclx:PercentageOfSharesOutstanding>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="P01_01_2019To12_31_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">75300000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:AssetAcquisitionContingentConsiderationLiability
      contextRef="PAsOn09_30_2022_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:AssetAcquisitionContingentConsiderationLiability>
    <us-gaap:AssetAcquisitionContingentConsiderationLiability
      contextRef="PAsOn12_31_2021_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:AssetAcquisitionContingentConsiderationLiability>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn09_30_2022_SorrentoMemberSCLXInvesteeAxis_TwoThousandTwentyTwoPromissoryNoteMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">5000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent
      contextRef="PAsOn09_30_2022_SorrentoMemberSCLXInvesteeAxis_TwoThousandTwentyTwoPromissoryNoteMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">4100000</us-gaap:NotesPayableRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:DebtInstrumentTerm contextRef="P01_01_2022To09_30_2022_SorrentoMemberSCLXInvesteeAxis_TwoThousandTwentyTwoPromissoryNoteMemberusgaapLongtermDebtTypeAxis">P7Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="PAsOn09_30_2022_SorrentoMemberSCLXInvesteeAxis_TwoThousandTwentyTwoPromissoryNoteMemberusgaapLongtermDebtTypeAxis"
      decimals="4"
      unitRef="Unit_pure">0.0266</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:AssetAcquisitionContingentConsiderationLiability
      contextRef="PAsOn09_30_2022_AardvarkMemberusgaapAssetAcquisitionAxis_ApprovalBasedMilestoneMemberSCLXMilestoneAxis"
      decimals="0"
      unitRef="Unit_USD">3000000</us-gaap:AssetAcquisitionContingentConsiderationLiability>
    <us-gaap:AssetAcquisitionContingentConsiderationLiability
      contextRef="PAsOn09_30_2022_AardvarkMemberusgaapAssetAcquisitionAxis_ReveueBasedMilestoneMemberSCLXMilestoneAxis"
      decimals="0"
      unitRef="Unit_USD">20000000</us-gaap:AssetAcquisitionContingentConsiderationLiability>
    <us-gaap:AssetAcquisitionContingentConsiderationLiability
      contextRef="PAsOn09_30_2022_AardvarkMemberusgaapAssetAcquisitionAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:AssetAcquisitionContingentConsiderationLiability>
    <sclx:UpfrontlicenseFee
      contextRef="P01_01_2022To09_30_2022_RomegLicenseAgreementMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">2000000</sclx:UpfrontlicenseFee>
    <sclx:MilestonePayment
      contextRef="P01_01_2022To09_30_2022_RomegLicenseAgreementMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">13000000</sclx:MilestonePayment>
    <us-gaap:RoyaltyExpense
      contextRef="P01_01_2022To09_30_2022_RomegLicenseAgreementMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">7100000</us-gaap:RoyaltyExpense>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetResidualValue
      contextRef="PAsOn09_30_2022_RomegLicenseAgreementMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">5700000</us-gaap:AcquiredFiniteLivedIntangibleAssetResidualValue>
    <sclx:UpfrontlicenseFee
      contextRef="P01_01_2022To09_30_2022_RomegLicenseAgreementMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">2000000</sclx:UpfrontlicenseFee>
    <sclx:DeferredConsideration
      contextRef="PAsOn09_30_2022_RomegLicenseAgreementMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">3700000</sclx:DeferredConsideration>
    <us-gaap:AssetAcquisitionContingentConsiderationLiability
      contextRef="PAsOn09_30_2022_RomegLicenseAgreementMemberusgaapAssetAcquisitionAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:AssetAcquisitionContingentConsiderationLiability>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="P01_01_2022To09_30_2022_RomegLicenseAgreementMemberusgaapAssetAcquisitionAxis">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="P01_01_2022To09_30_2022">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair Value Measurements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The follo&lt;div style="display:inline;"&gt;w&lt;/div&gt;ing t&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;a&lt;/div&gt;ble presents the Company&#x2019;s financial assets and liabilities that are measured at fair value (in thousands):&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 40%;"/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value measurements at September&#160;30, 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Quoted&#160;Prices&#160;in&lt;br/&gt;Active Markets&lt;br/&gt;(Level&#160;1)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;Inputs&lt;br/&gt;(Level&#160;2)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Significant&lt;br/&gt;Unobservable&#160;Inputs&lt;br/&gt;(Level&#160;3)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; font-size: 10pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,483&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,483&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; font-size: 0pt; line-height: 0pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 0pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; padding-bottom: 0.375pt; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total assets measured at fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;2,483&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt; background-color: rgb(204, 238, 255);;text-align:right;"&gt;2,483&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"/&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;br/&gt;&lt;/div&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 40%;"/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"&gt;Fair&#160;value&#160;measurements&#160;at&#160;December&#160;31.&#160;2021&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt; border-bottom: 0.75pt solid black;;text-align:center;"&gt;Balance&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"&gt;Quoted&#160;Prices&#160;in&lt;br/&gt;Active&#160;Markets&lt;br/&gt;(Level&#160;1)&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;Inputs&lt;br/&gt;(Level&#160;2)&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"&gt;Significant&lt;br/&gt;Unobservable&#160;Inputs&lt;br/&gt;(Level&#160;3)&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,338&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,338&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total assets measured at fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,338&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,338&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Derivative liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35,700&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35,700&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Total liabilities measured at fair &lt;br/&gt;value&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35,700&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35,700&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Company&#x2019;s financial assets carried at fair value are comprised of cash and cash equivalents. Cash and cash equivalents consist of money market accounts and bank deposits which are highly liquid and readily tradable. These assets are valued using inputs observable in active markets for identical securities.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Derivative liabilities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;The Company recorded a gain of $&lt;/div&gt;5.3&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&#160;million and $&lt;/div&gt;0.1&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&#160;million on derivative liabilities for the &lt;/div&gt;nine&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt; months ended September&#160;&lt;/div&gt;30&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;, &lt;/div&gt;2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt; and &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;, respectively, which was attributed to compound derivative liabilities associated with the Scilex Pharma Notes (see Note &lt;/div&gt;6)&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;. The fair value of the derivative liability associated with the Scilex Pharma Notes decreased by $&lt;/div&gt;30.4&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;million immediately after the entry into Amendment No. 4 (see Note 6) associated with the Scilex Pharma Notes on June 2, 2022 (see Note 6). Amendment No. 4 was accounted for as troubled debt restructuring; therefore, the carrying amount of the Scilex Pharma Notes, net, was adjusted to reflect the aforementioned change in fair value of the derivative liability. The fair value of the derivative liability associated with the Scilex Pharma Notes was estimated using the discounted cash flow method combined with a&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Monte Carlo simulation model including consideration of the terms of Amendment No. 4. Significant Level 3 assumptions used in the measurement included a&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;6.1&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% risk adjusted net sales forecast and an effective debt yield of &lt;/div&gt;21.5&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% as of June&#160;30, 2022. The Scilex Pharma Notes were fully extinguished in September 2022 (see Note 6) and, as such, there were &lt;/div&gt;no&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; remaining derivative liabilities as of September&#160;30, 2022.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table includes a summary of the derivative liabilities measured at fair value using significant unobservable inputs (Level 3) during the nine months ended September&#160;30, 2022:&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 84%;"/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;Fair&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;value&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35,700&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in fair value measurement&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(35,700&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at September&#160;30, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="P01_01_2022To09_30_2022">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The follo&lt;div style="display:inline;"&gt;w&lt;/div&gt;ing t&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;a&lt;/div&gt;ble presents the Company&#x2019;s financial assets and liabilities that are measured at fair value (in thousands):&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 40%;"/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value measurements at September&#160;30, 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Quoted&#160;Prices&#160;in&lt;br/&gt;Active Markets&lt;br/&gt;(Level&#160;1)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;Inputs&lt;br/&gt;(Level&#160;2)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Significant&lt;br/&gt;Unobservable&#160;Inputs&lt;br/&gt;(Level&#160;3)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; font-size: 10pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,483&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,483&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; font-size: 0pt; line-height: 0pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px; line-height: 0pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 0pt; font-size: 0pt; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="font-size: 0pt; line-height: 0pt;"&gt;&lt;div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; padding-bottom: 0.375pt; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total assets measured at fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;2,483&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt; background-color: rgb(204, 238, 255);;text-align:right;"&gt;2,483&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"/&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;br/&gt;&lt;/div&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt;&lt;div style="clear: both; max-height: 0px;"/&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 40%;"/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"&gt;Fair&#160;value&#160;measurements&#160;at&#160;December&#160;31.&#160;2021&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt; border-bottom: 0.75pt solid black;;text-align:center;"&gt;Balance&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"&gt;Quoted&#160;Prices&#160;in&lt;br/&gt;Active&#160;Markets&lt;br/&gt;(Level&#160;1)&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;Inputs&lt;br/&gt;(Level&#160;2)&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:center;"&gt;Significant&lt;br/&gt;Unobservable&#160;Inputs&lt;br/&gt;(Level&#160;3)&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,338&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,338&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total assets measured at fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,338&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,338&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Derivative liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35,700&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35,700&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Total liabilities measured at fair &lt;br/&gt;value&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35,700&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35,700&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">2483000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn09_30_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      unitRef="Unit_USD">2483000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">2483000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn09_30_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      unitRef="Unit_USD">2483000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">4338000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      unitRef="Unit_USD">4338000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">4338000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      unitRef="Unit_USD">4338000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">35700000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      unitRef="Unit_USD">35700000</us-gaap:DerivativeLiabilities>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">35700000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      unitRef="Unit_USD">35700000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:DerivativeGainOnDerivative
      contextRef="P01_01_2022To09_30_2022"
      decimals="1"
      unitRef="Unit_USD">5.3</us-gaap:DerivativeGainOnDerivative>
    <us-gaap:DerivativeLossOnDerivative
      contextRef="P01_01_2021To09_30_2021"
      decimals="1"
      unitRef="Unit_USD">0.1</us-gaap:DerivativeLossOnDerivative>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="P01_01_2022To06_30_2022_DerivativeFinancialInstrumentsLiabilitiesMemberusgaapFairValueByLiabilityClassAxis_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">30400000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="PAsOn06_30_2022_MeasurementInputRiskadjustedNetSalesForecastMemberusgaapMeasurementInputTypeAxis"
      decimals="1"
      unitRef="Unit_pure">6.1</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="PAsOn06_30_2022_MeasurementInputEffectiveDebtYieldMemberusgaapMeasurementInputTypeAxis"
      decimals="1"
      unitRef="Unit_pure">21.5</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn09_30_2022"
      decimals="INF"
      unitRef="Unit_USD">0</us-gaap:DerivativeLiabilities>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="P01_01_2022To09_30_2022">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table includes a summary of the derivative liabilities measured at fair value using significant unobservable inputs (Level 3) during the nine months ended September&#160;30, 2022:&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 84%;"/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="font-weight:bold;display:inline;width:100%;"&gt;Fair&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;value&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35,700&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in fair value measurement&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(35,700&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at September&#160;30, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn12_31_2021_DerivativeFinancialInstrumentsLiabilitiesMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      unitRef="Unit_USD">35700000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="P01_01_2022To09_30_2022_DerivativeFinancialInstrumentsLiabilitiesMemberusgaapFairValueByLiabilityClassAxis"
      decimals="-3"
      unitRef="Unit_USD">-35700000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="P01_01_2022To09_30_2022">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Goodwill and Intangible Assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of September&#160;30, 2022 and December&#160;31, 2021, the Company had recorded goodwill of $&lt;/div&gt;13.5&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million. The Company performed a qualitative test for goodwill impairment during the fourth quarter of 2021. Based upon the results of the qualitative testing, the Company concluded that it is &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;more-likely-than-not&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; that the fair value of the Company&#x2019;s goodwill was in excess of the carrying value and therefore performing the first step of the &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;two-step&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; impairment test was unnecessary. The conclusion has not changed as of September&#160;30, 2022 and &lt;/div&gt;no&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; goodwill impairment was recognized for the nine months ended September&#160;30, 2022 and 2021.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s intangible assets, excluding goodwill, are composed of patent rights, acquired technology, acquired licenses, and assembled workforce. Amortization of the intangible assets that have finite useful lives is generally recorded on a straight-line basis over their useful lives. &lt;/div&gt;A summary of the Company&#x2019;s identifiable intangible assets as of September&#160;30, 2022 and December&#160;31, 2021 is as follows (in thousands):&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 55%;"/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;Nine&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;months&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;ended&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;September&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;30,&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;2022&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;Gross&#160;carrying&lt;br/&gt; amount&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;Accumulated&lt;br/&gt; amortization&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;Intangibles,&#160;net&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Patent rights&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;32,630&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,871&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;19,759&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Acquired technology&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21,940&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,851&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,089&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Acquired licenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,711&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;92&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,619&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assembled workforce&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;350&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;150&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total intangible assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;60,781&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;19,164&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;41,617&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 55%;"/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;December&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;31.&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;2021&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;Gross&#160;carrying&lt;br/&gt; amount&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;Accumulated&lt;br/&gt; amortization&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;Intangibles,&#160;net&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Patent rights&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;32,630&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,239&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21,391&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Acquired technology&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21,940&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,754&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17,186&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assembled workforce&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;275&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;225&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total intangible assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;55,070&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,268&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;38,802&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On June&#160;14, 2022, the Company entered into Romeg License Agreement to acquire an exclusive license to use GLOPERBA from Romeg (see Note 3). The Company determined the acquisition of licenses to be an asset acquisition. The fair value of consideration transferred of $&lt;/div&gt;5.7&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million was assigned to acquired licenses with an amortization period of approximately &lt;/div&gt;15&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;years. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of September&#160;30, 2022, the weighted average remaining life for identifiable intangible assets was &lt;/div&gt;&lt;/div&gt;10.6&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;years. Aggregate amortization expense was $&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.9&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;million and $&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.8&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million for the nine months ended September&#160;30,&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022 and 2021, respectively. Patent rights and acquired technology are amortized over a &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;15-year&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; period. Assembled workforce is amortized over a &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;5-year&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; period.&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; font-size: 10pt; top: 0px;;display:inline;"&gt;Estimated future amortization expense related to intangible assets at September&#160;30, 2022 is as follows (in tho&lt;/div&gt;us&lt;div style="letter-spacing: 0px; font-size: 10pt; top: 0px;;display:inline;"&gt;ands):&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 85%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;Year ended December&#160;31,&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;Amount&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022 (remaining three months)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,027&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,106&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,031&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,006&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2026&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,006&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Thereafter&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;24,441&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;41,617&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:Goodwill
      contextRef="PAsOn09_30_2022"
      decimals="-5"
      unitRef="Unit_USD">13500000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="PAsOn12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">13500000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="P01_01_2022To09_30_2022"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="P01_01_2021To09_30_2021"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="P01_01_2022To09_30_2022">A summary of the Company&#x2019;s identifiable intangible assets as of September&#160;30, 2022 and December&#160;31, 2021 is as follows (in thousands):
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 55%;"/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;Nine&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;months&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;ended&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;September&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;30,&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;2022&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;Gross&#160;carrying&lt;br/&gt; amount&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;Accumulated&lt;br/&gt; amortization&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;Intangibles,&#160;net&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Patent rights&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;32,630&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,871&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;19,759&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Acquired technology&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21,940&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,851&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,089&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Acquired licenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,711&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;92&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,619&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assembled workforce&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;350&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;150&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total intangible assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;60,781&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;19,164&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;41,617&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 55%;"/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;December&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;31.&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;2021&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;Gross&#160;carrying&lt;br/&gt; amount&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;Accumulated&lt;br/&gt; amortization&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;Intangibles,&#160;net&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Patent rights&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;32,630&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,239&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21,391&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Acquired technology&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21,940&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,754&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17,186&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assembled workforce&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;275&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;225&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total intangible assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;55,070&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,268&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;38,802&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn09_30_2022_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">32630000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn09_30_2022_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">12871000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn09_30_2022_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">19759000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn09_30_2022_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">21940000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn09_30_2022_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">5851000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn09_30_2022_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">16089000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn09_30_2022_LicensingAgreementsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">5711000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn09_30_2022_LicensingAgreementsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">92000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn09_30_2022_LicensingAgreementsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">5619000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn09_30_2022_AssembledWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">500000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn09_30_2022_AssembledWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">350000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn09_30_2022_AssembledWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">150000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">60781000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">19164000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">41617000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2021_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">32630000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn12_31_2021_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">11239000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2021_PatentsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">21391000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2021_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">21940000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn12_31_2021_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">4754000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2021_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">17186000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2021_AssembledWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">500000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn12_31_2021_AssembledWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">275000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2021_AssembledWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-3"
      unitRef="Unit_USD">225000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">55070000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">16268000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">38802000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="P06_14_2022To06_14_2022_LicensingAgreementsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="-5"
      unitRef="Unit_USD">5700000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife contextRef="P06_14_2022To06_14_2022_LicensingAgreementsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">P15Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="P01_01_2022To09_30_2022_WeightedAverageMembersrtRangeAxis">P10Y7M6D</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="P01_01_2022To09_30_2022"
      decimals="-5"
      unitRef="Unit_USD">2900000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="P01_01_2021To09_30_2021"
      decimals="-5"
      unitRef="Unit_USD">2800000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 contextRef="P01_01_2022To09_30_2022_TechnologyBasedIntangibleAssetsMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">P15Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="P01_01_2022To09_30_2022">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; font-size: 10pt; top: 0px;;display:inline;"&gt;Estimated future amortization expense related to intangible assets at September&#160;30, 2022 is as follows (in tho&lt;/div&gt;us&lt;div style="letter-spacing: 0px; font-size: 10pt; top: 0px;;display:inline;"&gt;ands):&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 85%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;Year ended December&#160;31,&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;;text-align:center;"&gt;Amount&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022 (remaining three months)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,027&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,106&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,031&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,006&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2026&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,006&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Thereafter&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;24,441&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;41,617&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">1027000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">4106000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">4031000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">4006000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">4006000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <sclx:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">24441000</sclx:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">41617000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:DebtDisclosureTextBlock contextRef="P01_01_2022To09_30_2022">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Debt &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;2018 Purchase Agreements and Indenture &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On September&#160;7, 2018, Scilex Pharma and Sorrento entered into Purchase Agreements (the &#x201c;2018 Purchase Agreements&#x201d;) with certain investors (collectively, the &#x201c;Scilex Pharma Note Purchasers&#x201d;). Pursuant to the 2018 Purchase Agreements, on September&#160;7, 2018, Scilex Pharma, among other things, issued and sold to the Scilex Pharma Note Purchasers senior secured notes due &lt;/div&gt;2026&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; in an aggregate principal amount of $&lt;/div&gt;224.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million (the &#x201c;Scilex Pharma Notes&#x201d;) for an aggregate purchase price of $&lt;/div&gt;140.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million (the &#x201c;Offering&#x201d;). The Scilex Pharma Notes are governed by an indenture (as amended, the &#x201c;Indenture&#x201d;) with Scilex Pharma, as issuer, U.S. Bank National Association, a national banking association, as trustee (the &#x201c;Trustee&#x201d;) and collateral agent (the &#x201c;Collateral Agent&#x201d;), and Sorrento, as guarantor. Pursuant to the Indenture, Sorrento agreed to irrevocably and unconditionally guarantee, on a senior unsecured basis, the punctual performance and payment when due of all obligations of Scilex Pharma under the Indenture (the &#x201c;Guarantee&#x201d;).&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Actual cumulative net sales of ZTlido from the issue date of the Scilex Pharma Notes through December&#160;31, 2021 did not equal or exceed $&lt;/div&gt;481.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, which resulted in a $&lt;/div&gt;28.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million increase in the principal amount of the Scilex Pharma Notes, effective &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;February&#160;15, 2022&lt;/div&gt;. As a result, the Company recorded the increase of $&lt;/div&gt;28.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million in principal and &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-operating&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; expense at December&#160;31, 2021.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Effective February&#160;14, 2022, Scilex Pharma issued to Sorrento a draw notice under the Letter of Credit as required under the terms of the Indenture because actual cumulative net sales of ZTlido from the issue date of the Scilex Pharma Notes through December&#160;31, 2021 were less than a specified sales threshold for such period. As a result of the draw notice being issued, Sorrento paid to Scilex Pharma $&lt;/div&gt;35.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million in a single &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;lump-sum&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; amount as a subordinated loan and Scilex Pharma became subject to a minimum cash requirement of $&lt;/div&gt;10.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million. In February 2022, Scilex Pharma repurchased Scilex Pharma Notes from the holders thereof on a pro rata basis in an aggregate amount equal to $&lt;/div&gt;20.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;On June&#160;2, 2022, Sorrento and Scilex Pharma entered into a Consent Under and Amendment No.&#160;4 to Indenture (the &#x201c;Amendment No.&#160;4&#x201d;) with U.S. Bank Trust Company, National Association (as successor in interest to U.S. Bank National Association) and the Scilex Note Purchasers. Pursuant to Amendment &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;4, (1)&#160;on &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt; June&#160;3, 2022, Scilex Pharma repurchased approximately $41.4&#160;million of the aggregate principal amount of the outstanding Scilex Pharma Notes at 100% of the principal amount thereof, (2)&#160;the Scilex Note Purchasers agreed that Scilex Pharma can repurchase the remaining principal amount of the Scilex Pharma Notes at any time on or before September 30, 2022 for $41.4&#160;million (subject to reduction for any quarterly royalty payments) and upon such repurchase the Scilex Note Purchasers will forgive and discharge $28.0&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;million of the aggregate principal amount of the Scilex Pharma Notes (the &#x201c;Early Paydown Provision&#x201d;), (3) the minimum cash requirement under the Indenture was reduced to $5.0 million in aggregate unrestricted cash equivalents at the end of each calendar month, and (4) the maximum aggregate principal amount on the promissory note issued by Scilex Pharma to Sorrento on October 5, 2018 was increased from up to $25.0 million to up to $50.0 million. The Company funded the repurchase with cash-on-hand and $15.0 million received from Sorrento on June 2, 2022,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;which was recorded under the current related party notes payable in the Company&#x2019;s consolidated balance sheets (see Note 10). The Company concluded that the Amendment No.&#160;4 was a troubled debt restructuring for accounting purposes. The future undiscounted cash flows of the Scilex Pharma Notes were higher than the carrying value of the Scilex Pharma Notes at the time of the entry into the Amendment No.&#160;4, and accordingly, &lt;/div&gt;no&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; gain was recognized in the quarter ended June&#160;30, 2022. Due to a decrease of $&lt;/div&gt;30.4&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million in the fair value of the Scilex Notes Derivative caused by the Amendment No.&#160;4, the carrying value of the Scilex Notes was increased by $&lt;/div&gt;30.4&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In September 2022, the Company exercised the Early Paydown Provision to fully extinguish the Scilex Pharma Notes. In August and September 2022, the Company made principal payments towards the outstanding Scilex Pharma Notes totaling $&lt;/div&gt;1.7&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million and $&lt;/div&gt;39.7&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, respectively. Pursuant to Amendment No.&#160;4, $&lt;/div&gt;28.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million of principal amount on the Scilex Pharma Notes was forgiven by the Scilex Pharma Note Purchasers and the Scilex Pharma Notes were fully extinguished in September 2022. The C&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;o&lt;/div&gt;mpany recorded a gain on debt extinguishment of $&lt;/div&gt;33.4&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million as a result of the extinguishment. There are &lt;/div&gt;no&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; derivative liabilities as of September&#160;30, 2022.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Borrowings of the Scilex Notes consisted of the following (in thousands):&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;br/&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 67%;"/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;September&#160;30,&lt;br/&gt;2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;December&#160;31,&lt;br/&gt;2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Principal&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;133,997&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Unamortized debt discount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(30,597&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Unamortized debt issuance costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,228&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Carrying value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;101,172&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current portion&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(29,135&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Long term portion&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;72,037&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Estimated fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;115,400&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company made principal payments of $&lt;/div&gt;106.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million and $&lt;/div&gt;44.2&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million during the nine months ended September&#160;30, 2022 and 2021, respectively. The imputed effective interest rate at December&#160;31, 2021 was &lt;/div&gt;7.7&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;%. The amount of debt discount and debt issuance costs included in interest expense for the nine months ended September&#160;30, 2022 and 2021 was approximately $&lt;/div&gt;3.1&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million and $&lt;/div&gt;5.9&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, respectively. The Company recorded a gain on debt extinguishment of $&lt;/div&gt;28.6&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million and a loss on debt extinguishment of $&lt;/div&gt;14.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million in connection with its repayments of principal made during the nine months ended September&#160;30, 2022 and 2021, respectively.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Related Party Notes Payable &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On October&#160;5, 2018, Scilex Pharma issued to Sorrento a promissory note (see Note 10). On March&#160;18, 2019, the Company entered into a note payable with Sorrento (see Note 10). On February&#160;14, 2022, Sorrento paid to Scilex Pharma $&lt;/div&gt;35.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million in a single &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;lump-sum&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; amount as a subordinated loan (see Note 10). On May&#160;12, 2022, the Company issued Sorrento a promissory note of $&lt;/div&gt;5.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million in exchange for the &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-104&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Assets (see Note 3).&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;2020 Revolving Credit Facility &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On December&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;14, 2020, Scilex Pharma entered into the Credit and Security Agreement (the &#x201c;Credit Agreement&#x201d;) with CNH Finance Fund I, L.P. (&#x201c;CNH&#x201d;) which provides Scilex Pharma with the ability to incur&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;indebtedness under an accounts receivable revolving loan facility in an aggregate amount of $10.0&#160;million and the incurrence of liens and the pledge of collateral to CNH in connection with the revolving loan facility. Under the terms of the Credit Agreement, interest will accrue daily on the principal amount outstanding at a rate per annum equal to the Wall Street Journal Prime Rate plus 1.75%. All indebtedness incurred and outstanding will be&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;"&gt;due and payable in full on January&#160;1, 2024; unless the Credit Agreement is earlier terminated. As of December&#160;31, 2021, the outstanding balance was $&lt;/div&gt;8.8&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;"&gt;&#160;million. On February&#160;16, 2022, the Company notified CNH that it was terminating the Credit Agreement, effective&lt;/div&gt; March 18, 2022&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 4%; top: 0px;;display:inline;"&gt;. Upon termination, all principal balances and interest accrued were settled.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentTerm contextRef="P09_07_2018To09_07_2018_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis">P2026Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn09_07_2018_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">224000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentRepurchaseAmount
      contextRef="PAsOn09_07_2018_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">140000000</us-gaap:DebtInstrumentRepurchaseAmount>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="P09_07_2018To12_31_2021_DebtInstrumentRedemptionPeriodTwoMemberusgaapDebtInstrumentRedemptionPeriodAxis_ScenarioAdjustmentMembersrtStatementScenarioAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">481000000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="P02_15_2022To02_15_2022_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">28000000</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn02_15_2022_MaximumMembersrtRangeAxis_TwoThousandAndEighteenPurchaseAgreementsMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">28000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn02_14_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_SubordinatedDebtMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">35000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:RestrictedCash
      contextRef="PAsOn02_28_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_SubordinatedDebtMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">10000000</us-gaap:RestrictedCash>
    <us-gaap:DebtInstrumentRepurchaseAmount
      contextRef="PAsOn02_28_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_SubordinatedDebtMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">20000000</us-gaap:DebtInstrumentRepurchaseAmount>
    <us-gaap:DebtInstrumentRepurchaseAmount
      contextRef="PAsOn06_03_2022_AmendmentNoFourMemberSCLXAmendmentAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">41400000</us-gaap:DebtInstrumentRepurchaseAmount>
    <sclx:DebtInstrumentPercentageOfPrincipalAmountRepurchased
      contextRef="PAsOn06_03_2022_AmendmentNoFourMemberSCLXAmendmentAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis"
      decimals="2"
      unitRef="Unit_pure">1</sclx:DebtInstrumentPercentageOfPrincipalAmountRepurchased>
    <us-gaap:DebtInstrumentRepurchaseDate contextRef="P06_02_2022To06_02_2022_AmendmentNoFourMemberSCLXAmendmentAxis_MaximumMembersrtRangeAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis">2022-09-30</us-gaap:DebtInstrumentRepurchaseDate>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="PAsOn06_02_2022_AmendmentNoFourMemberSCLXAmendmentAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">41400000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentDecreaseForgiveness
      contextRef="P06_02_2022To06_02_2022_AmendmentNoFourMemberSCLXAmendmentAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">28000000</us-gaap:DebtInstrumentDecreaseForgiveness>
    <us-gaap:DebtInstrumentCollateralAmount
      contextRef="PAsOn06_02_2022_AmendmentNoFourMemberSCLXAmendmentAxis"
      decimals="-5"
      unitRef="Unit_USD">5000000</us-gaap:DebtInstrumentCollateralAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn10_05_2018_AmendmentNoFourMemberSCLXAmendmentAxis_PromissoryNoteMemberusgaapRelatedPartyTransactionAxis_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">25000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn06_02_2022_AmendmentNoFourMemberSCLXAmendmentAxis_PromissoryNoteMemberusgaapRelatedPartyTransactionAxis_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">50000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="P06_02_2022To06_02_2022_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">15000000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:GainsLossesOnRestructuringOfDebt
      contextRef="P04_01_2022To06_30_2022_AmendmentNoFourMemberSCLXAmendmentAxis"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:GainsLossesOnRestructuringOfDebt>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="P06_02_2022To06_02_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">30400000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:DebtInstrumentIncreaseDecreaseForPeriodNet
      contextRef="P06_02_2022To06_02_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">30400000</us-gaap:DebtInstrumentIncreaseDecreaseForPeriodNet>
    <us-gaap:RepaymentsOfDebt
      contextRef="P08_01_2022To09_30_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">1700000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="P09_01_2022To09_30_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">39700000</us-gaap:RepaymentsOfDebt>
    <us-gaap:DebtInstrumentDecreaseForgiveness
      contextRef="P06_02_2022To06_02_2022_AmendmentNoFourMemberSCLXAmendmentAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">28000000</us-gaap:DebtInstrumentDecreaseForgiveness>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="P09_01_2022To09_30_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">33400000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DerivativeLiabilities
      contextRef="PAsOn09_30_2022"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:DerivativeLiabilities>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock contextRef="P01_01_2022To09_30_2022">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Borrowings of the Scilex Notes consisted of the following (in thousands):&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;br/&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 67%;"/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;September&#160;30,&lt;br/&gt;2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;December&#160;31,&lt;br/&gt;2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Principal&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;133,997&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Unamortized debt discount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(30,597&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Unamortized debt issuance costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,228&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Carrying value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;101,172&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current portion&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(29,135&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Long term portion&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;72,037&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Estimated fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;115,400&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="PAsOn09_30_2022_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="PAsOn12_31_2021_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">133997000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="PAsOn09_30_2022_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="PAsOn12_31_2021_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">30597000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:UnamortizedDebtIssuanceExpense
      contextRef="PAsOn09_30_2022_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:UnamortizedDebtIssuanceExpense
      contextRef="PAsOn12_31_2021_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">2228000</us-gaap:UnamortizedDebtIssuanceExpense>
    <us-gaap:LongTermDebt
      contextRef="PAsOn09_30_2022_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="PAsOn12_31_2021_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">101172000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent
      contextRef="PAsOn09_30_2022_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="PAsOn12_31_2021_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">29135000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="PAsOn09_30_2022_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="PAsOn12_31_2021_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">72037000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtFairValue
      contextRef="PAsOn09_30_2022_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="PAsOn12_31_2021_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">115400000</us-gaap:LongTermDebtFairValue>
    <us-gaap:RepaymentsOfDebt
      contextRef="P01_01_2022To09_30_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_TwoThousandAndEighteenPurchaseAgreementsAndIndentureMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_USD">106000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="P01_01_2021To09_30_2021_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_TwoThousandAndEighteenPurchaseAgreementsAndIndentureMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_USD">44200000</us-gaap:RepaymentsOfDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="PAsOn12_31_2021_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis"
      decimals="3"
      unitRef="Unit_pure">0.077</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts
      contextRef="P01_01_2022To09_30_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">3100000</us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts>
    <us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts
      contextRef="P01_01_2021To09_30_2021_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">5900000</us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="P01_01_2022To09_30_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_TwoThousandAndEighteenPurchaseAgreementsAndIndentureMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_USD">28600000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="P01_01_2021To09_30_2021_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_TwoThousandAndEighteenPurchaseAgreementsAndIndentureMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_USD">14000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn02_14_2022_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis_SubordinatedDebtMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">35000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn05_12_2022_PromissoryNoteMemberusgaapRelatedPartyTransactionAxis_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">5000000</us-gaap:DebtInstrumentFaceAmount>
    <sclx:LineOfCreditFacilityindebtednessAmount
      contextRef="PAsOn12_14_2020_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">10000000</sclx:LineOfCreditFacilityindebtednessAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="PAsOn12_14_2020_PrimeRateMemberusgaapVariableRateAxis_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis"
      decimals="4"
      unitRef="Unit_pure">0.0175</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="PAsOn12_14_2020_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">8800000</us-gaap:LongTermDebt>
    <sclx:DebtInstrumentTerminationDate contextRef="P02_16_2022To02_16_2022_RevolvingCreditFacilityMemberusgaapCreditFacilityAxis_ScilexPharmaNoteMemberusgaapDebtInstrumentAxis">2022-03-18</sclx:DebtInstrumentTerminationDate>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock contextRef="P01_01_2022To09_30_2022">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock Incentive and Employee Benefit Plans &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;2017 Equity Incentive Plan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt;In June &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2017, Scilex Pharma adopted the Scilex Pharmaceuticals Inc. 2017 Equity Incentive Plan (the &#x201c;Scilex Pharma 2017 Plan&#x201d;). The Scilex Pharma 2017 Plan reserved &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;24.0&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million shares of Scilex Pharma common stock. &lt;/div&gt;Stock options granted under the Scilex Pharma 2017 Plan typically vest 1/4th of the shares on the first anniversary of the vesting commencement date and 1/48th of the remaining options vest each month thereafter. &lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Scilex Pharma 2017 Plan was amended and restated on July&#160;5, 2018.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Upon the closing of the Merger of Semnur, the Scilex Pharma 2017 Plan was terminated, and each option to purchase Scilex Pharma&#x2019;s common stock outstanding and unexercised immediately prior to the closing of the Merger of Semnur was cancelled and substituted for that number of options &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;to&lt;/div&gt; acquire common stock of Scilex &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Holding. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Scilex Holding Company 2019 Stock Option Plan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The board of &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;directors of the Company adopted the Scilex Holding Company 2019 Stock Option Plan (the &#x201c;2019 Stock Option Plan&#x201d;) on May&#160;28, 2019. The 2019 Stock Option Plan was approved by the Company&#x2019;s stockholders on June&#160;7, 2019. As of December&#160;31, 2019, 30.0&#160;million shares of common stock of the Company were reserved for issuance pursuant to the 2019 Stock Option Plan. On December&#160;21, 2020, the board of directors approved an amendment to the 2019 Stock Option Plan to reserve an additional &lt;/div&gt;15.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million shares of common stock for issuance under the 2019 Stock Option Plan. As of December&#160;31, 2020, &lt;/div&gt;45.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million shares of common stock of the Company were reserved for issuance pursuant to the 2019 Stock Option Plan. &lt;/div&gt;Stock options granted under the 2019 Stock Option Plan typically vest with respect to 1/4th of the shares on the first anniversary of the vesting commencement date and 1/48th of the remaining shares on each monthly anniversary thereafter.&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of September&#160;30, 2022, options to purchase &lt;/div&gt;25,159,760&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; shares of the common stock of Scilex Holding were outstanding, which is comprised of options to purchase &lt;/div&gt;24,054,760&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; shares of common stock that were outstanding under the 2019 Stock Option Plan and options to purchase &lt;/div&gt;1,105,000&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; shares of common stock that were outstanding pursuant to options previously granted under the Scilex Pharma 2017 Plan. As of September&#160;30, 2022, &lt;/div&gt;20,945,240&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; shares of the Company&#x2019;s common stock were reserved for awards available for future issuance under the 2019 Stock Option Plan.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total stock-based compensation recorded within operating expenses was $&lt;/div&gt;4.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million and $&lt;/div&gt;4.4&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million for the nine months ended September&#160;30, 2022 and 2021, respectively.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;T&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;he total unrecognized compensation costs related to unvested employee and &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-employee&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; stock option grants as of September&#160;30, 2022 was $&lt;/div&gt;3.9&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million and the weighted average period over which these grants are expected to vest is &lt;/div&gt;1.4&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; years.&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Employee Benefit Plan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company maintains a defined contribution 401(k) plan available to eligible employees, which is administered by Sorrento. Employee contributions are voluntary and are determined on an individual basis, limited to the maximum amount allowable under federal tax regulations. The Company made matching contributions to the 401(k) plan totaling $&lt;/div&gt;0.3&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million and $&lt;/div&gt;0.2&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million for each of the nine months ended September&#160;30, 2022 and 2021, respectively.&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn06_30_2017_ScilexPharmaTwoThousandSeventeenPlanMemberusgaapPlanNameAxis"
      decimals="-5"
      unitRef="Unit_shares">24000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights contextRef="P06_30_2017To06_30_2017_ScilexPharmaTwoThousandSeventeenPlanMemberusgaapPlanNameAxis">Stock options granted under the Scilex Pharma 2017 Plan typically vest 1/4th of the shares on the first anniversary of the vesting commencement date and 1/48th of the remaining options vest each month thereafter.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2019_TwoThousandNineteenStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="-5"
      unitRef="Unit_shares">30000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2020_AmendmentToTwoThousandNineteenStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="-5"
      unitRef="Unit_shares">15000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2020_TwoThousandNineteenStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="-5"
      unitRef="Unit_shares">45000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights contextRef="P12_01_2020To12_31_2020_TwoThousandNineteenStockOptionPlanMemberusgaapPlanNameAxis">Stock options granted under the 2019 Stock Option Plan typically vest with respect to 1/4th of the shares on the first anniversary of the vesting commencement date and 1/48th of the remaining shares on each monthly anniversary thereafter.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn09_30_2022"
      decimals="0"
      unitRef="Unit_shares">25159760</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn09_30_2022_TwoThousandNineteenStockOptionPlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">24054760</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn09_30_2022_ScilexPharmaTwoThousandSeventeenPlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_shares">1105000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights contextRef="P01_01_2022To09_30_2022_TwoThousandNineteenStockOptionPlanMemberusgaapPlanNameAxis">20,945,240</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2022To09_30_2022_OperatingExpensesMemberusgaapIncomeStatementLocationAxis"
      decimals="-5"
      unitRef="Unit_USD">4000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2021To09_30_2021_OperatingExpensesMemberusgaapIncomeStatementLocationAxis"
      decimals="-5"
      unitRef="Unit_USD">4400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="PAsOn09_30_2022"
      decimals="-5"
      unitRef="Unit_USD">3900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="P01_01_2022To09_30_2022">P1Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:PaymentsToEmployees
      contextRef="P01_01_2022To09_30_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">300000</us-gaap:PaymentsToEmployees>
    <us-gaap:PaymentsToEmployees
      contextRef="P01_01_2021To09_30_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">200000</us-gaap:PaymentsToEmployees>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="P01_01_2022To09_30_2022">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;8.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Commitments and Contingencies &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; font-size: 10pt;;font-style:italic;display:inline;"&gt;Product Development Agreement&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;In February 2013, Scilex Pharma became a party to a product development agreement (as amended, the &#x201c;Product Development Agreement&#x201d;) with two parties (the &#x201c;Developers&#x201d;), one of which is ITOCHU CHEMICAL FRONTIER Corporation (&#x201c;Itochu&#x201d;), pursuant to which the Developers will manufacture and supply lidocaine tape products, including ZTlido and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-103&lt;/div&gt; (the &#x201c;Products&#x201d;), for Scilex Pharma. The Developers initially developed, and have intellectual property rights relating to, the Products. Pursuant to the Product Development Agreement, Scilex Pharma acquired an exclusive right to develop and commercialize the Products worldwide except for Japan. The Developers are responsible for sourcing and supplying lidocaine for development and commercialization purposes. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pursuant to the Product Development Agreement, Scilex Pharma is required to make aggregate royalty payments &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;between &lt;/div&gt;25&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% and &lt;/div&gt;35&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% to the Developers based on net profits. During the nine months ended September&#160;30, 2022, Scilex Pharma made the first royalty payments in the amount of $0.2&#160;million. Net profits are defined as net sales, less cost of goods and marketing expenses. Net sales are defined as total gross sales of any Product, less all applicable deductions, to the extent accrued, paid or allowed in the ordinary course of business with respect to the sale of such Product, and to the extent that they are in accordance with U.S. GAAP. If Scilex Pharma were to sublicense the licensed technologies, the Developers will receive the same proportion of any sublicensing fees received therefrom. The Product Development Agreement will continue in full force and effect until &lt;/div&gt;October 2, 2028&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, the date that is &lt;/div&gt;ten years&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; from the date of the first commercial sale of ZTlido. The Product Development Agreement will renew automatically for subsequent successive &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-year&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; renewal periods unless Scilex Pharma or the Developers terminate it upon &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;6-month&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; written notice. In addition, Scilex Pharma or the Developers may terminate the Product Development Agreement if (1)&#160;the other party is in material breach of the agreement and the breach is not curable, or if the breach is curable and the breaching party has not cured such material breach within &lt;/div&gt;180&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; days after notice requesting to cure; (2)&#160;the FDA determines that the formulation of the Products would not be eligible for FDA approval in the absence of efficacy studies, and the Developers are unable to address the efficacy study requirements despite good faith efforts; (3)&#160;the market conditions are such that (a)&#160;commencing with the quarter ending March&#160;31, 2023, Scilex Pharma&#x2019;s total net profits of the Products are equal to or less than &lt;/div&gt;5&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;% of Scilex Pharma&#x2019;s net sales of the Products for a period of four or more consecutive quarters, or (b)&#160;the Products&#x2019; economic viability is affected by documented external circumstances deemed detrimental to all parties as agreed to by Scilex Pharma and the Developers, and the parties are unable to resolve the economic viability concerns under the foregoing clauses (a)&#160;and (b) after 30 days of good-faith discussion; (4)&#160;the parties fail to reach mutual agreement as to who will conduct the clinical studies and how the costs will be allocated; or (5)&#160;Scilex Pharma or either one of the Developers are bankrupt or make assignment for the benefit of creditors. Up to the date the financial statements were issued, the Company&#x2019;s net profits for ZTlido and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-103&lt;/div&gt; have not exceeded five percent of net sales. Accordingly, Oishi and Itochu have the right to terminate the Product Development Agreement and Commercial Supply Agreement. As of the date of this prospectus, neither Oishi nor Itochu has exercised its right of termination. Additionally, Scilex Pharma may terminate the Product Development Agreement if (i)&#160;any of the pivotal human clinical trials for any of the Products fail, or (ii)&#160;the FDA issues a &#x201c;Refusal to File&#x201d; for any of the Products&#x2019; regulatory approval application and, after reasonable consultation with the Developers, Scilex Pharma believes that it is commercially unreasonable to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-file.&lt;/div&gt; The Developers may terminate the Product Development Agreement if Scilex Pharma fails to file for regulatory approval for any of the Products within three months of the date on which all required components of the regulatory approval application are received by Scilex Pharma.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;On February&#160;16, 2017, Scilex Pharma entered into a Commercial Supply Agreement (as amended, the &#x201c;Supply Agreement&#x201d;) with the two Developers to provide commercial supply of ZTlido and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;SP-103&lt;/div&gt; to Scilex Pharma. The Supply Agreement contains standard terms regarding term, termination, payment, product quality and supply. In addition, the agreement provides additional terms regarding the calculation and amount of marketing expenses that may be deducted from net sales for purposes of determining the amount of net profit under the Product Development Agreement. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; font-size: 10pt;;font-style:italic;display:inline;"&gt;Exclusive Distribution Agreement&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In August 2015, Scilex Pharma entered into an Exclusive Distribution Agreement (the &#x201c;Distribution Agreement&#x201d;) to appoint an exclusive third-party logistics distribution provider (the &#x201c;Distributor&#x201d;) and as an authorized distributor of record of ZTlido (&#x201c;Product&#x201d;) in the United States, its territories, possessions and commonwealths for an agreed schedule of fees, subject to a &lt;/div&gt;3&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% annual adjustment. The Distribution Agreement has an initial term of &lt;/div&gt;three years&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; following the first shipment of &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;FDA-approved&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Product to a commercial customer and shall automatically renew for additional terms of one year each, unless written notice of termination is given by either party at least 30 days prior to the end of the initial term or any renewal term. In the event of Product recalls, Scilex Pharma is solely responsible for all Product recalls, except in the event where the recalls arise from the Distributor&#x2019;s negligence or willful misconduct. Pursuant to the Distribution Agreement, Scilex Pharma will be responsible for delivery of Product to and from the Distributor&#x2019;s facility, including all costs, expenses and risk of loss associated with such delivery. From late 2018 to early 2022, ZTlido was sold, and title was transferred, to the Distributor for distribution and sale to wholesalers for a fee of between &lt;/div&gt;1&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% to &lt;/div&gt;2&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% which was recorded as a &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;gross-to-net&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; sales adjustment. Beginning in April 2022, Scilex Pharma began directly selling and transferring title to distributors.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Sales Operations Services &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In January 2016, Scilex Pharma entered into a project agreement with a vendor to provide sales operations services and detailing services, which was subsequently superseded by a new project agreement entered into in September 2018 (the &#x201c;Project Agreement&#x201d;). In connection with the detailing services, the Project Agreement provides that the vendor will provide Scilex Pharma with full-time sales representatives who shall detail the Product by making calls pursuant to a call plan on targets. These sales representatives are to be managed by field talent managers and a national project director, each of whom will also be provided by the vendor. In connection with the sales operation services, the vendor will provide certain services required for the initial implementation and ongoing operation of the sales force.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color:#ffffff;;display:inline;"&gt;On &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;July&#160;1, 2020, Scilex Pharma and the vendor entered into a work order in which the parties agreed to convert substantially all of the sales representatives allocated under the Project Agreement to become employees of Scilex Pharma. The vendor will continue to provide sales operations services, fleet management services and sample accountability services. The work order was in effect until June&#160;30, 2022 and was extended for one year upon the mutual agreement of both parties. Either party may terminate the work order with &lt;/div&gt;90&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; days&#x2019; notice. Scilex Pharma paid an implementation fee of $&lt;/div&gt;59.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;thousand and will pay fixed monthly fees of $&lt;/div&gt;63.7&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;thousand to $&lt;/div&gt;65.8&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;thousand for ongoing &lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;services.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company recognized an expense of $&lt;/div&gt;0.5&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million and $&lt;/div&gt;1.6&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million within selling, general and administrative expenses for services performed for the nine months ended September&#160;30, 2022 and 2021, respectively, including implementation fees, fixed monthly fees and pass-through costs.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Litigation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In the normal course of business, the Company may be named as a defendant in one or more lawsuits. Other than the following three lawsuits, the Company is not a party to any outstanding material litigation and management is not aware of any legal proceedings that, individually or in the aggregate, are deemed to be material to the Company&#x2019;s financial condition or results of operations. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Sanofi-Aventis U.S. LLC and Hisamitsu America, Inc. Litigation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On February&#160;23, 2021, the Company filed an action in the U.S. District Court for the Northern District of California against Sanofi-Aventis U.S. LLC and Hisamitsu America, Inc., two manufacturers of OTC lidocaine patch products, alleging, among other things, false and deceptive advertising and unfair competition under the Lanham Act and California state laws by those companies regarding their respective OTC patch products (the &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x201c;Sanofi- Aventis&#160;&amp;amp; Hisamitsu Litigation&#x201d;). This lawsuit seeks, among other relief, damages and an injunction enjoining the defendants from continuing to make false or misleading statements of fact about their respective OTC lidocaine patch products. The defendants have filed motions to dismiss, which have narrowed slightly our claims, but which motions the court has largely rejected. Discovery is proceeding. The case is currently scheduled for trial to begin on July&#160;24, 2023. The Company cannot make any predictions about the outcome in this matter or the timing thereof. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Former Employee Litigation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;On March&#160;12, 2021, the Company filed an action in the Delaware Court of Chancery against Anthony Mack, former President of Scilex Pharma, and Virpax Pharmaceuticals, Inc. (&#x201c;Virpax&#x201d;), a company now headed by Mr.&#160;Mack, alleging, among other things, breach by Mr.&#160;Mack of his &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-compete&lt;/div&gt; agreement with us, breach of fiduciary duty, and tortious interference by Virpax with that &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-compete&lt;/div&gt; agreement (the &#x201c;Former Employee Litigation&#x201d;). This lawsuit seeks, among other relief, damages and an injunction enjoining Mr.&#160;Mack from further violating his &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-compete&lt;/div&gt; agreement and enjoining Virpax from tortiously interfering with Mr.&#160;Mack&#x2019;s &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-compete&lt;/div&gt; agreement. The case was tried from September &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;12-14,&lt;/div&gt; 2022. Post-trial briefing is completed and closing arguments remain. The Company cannot make any predictions about the outcome in this matter or the timing thereof. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;ZTlido Patent Litigation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;On June&#160;22, 2022, the Company filed a complaint against Aveva Drug Delivery Systems, Inc., Apotex Corp., and Apotex, Inc. (together, &#x201c;Aveva&#x201d;) in the U.S. District Court for the Southern District of Florida (the &#x201c;Aveva Patent Litigation&#x201d;) alleging infringement of certain Orange Book listed patents covering ZTlido (the &#x201c;ZTlido Patents&#x201d;). The Aveva Patent Litigation was initiated following the submission by Aveva, in accordance with the procedures set out in the Hatch-Waxman Act, of an ANDA. Aveva&#x2019;s ANDA seeks approval to market a generic version of ZTlido prior to the expiration of the ZTlido Patents and alleges that the ZTlido Patents are invalid, unenforceable, and/or not infringed. The Company is seeking, among other relief, an order that the effective date of any FDA approval of Aveva&#x2019;s ANDA be no earlier than the expiration of the asserted patents listed in the Orange Book, the latest of which expires on May&#160;10, 2031, and such further and other relief as the court may deem appropriate. Aveva is subject to a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;30-month&lt;/div&gt; stay preventing it from selling a generic version of ZTlido during that time. The stay should expire no earlier than November&#160;11, 2024. Trial in the Aveva Patent Litigation has not yet been scheduled. The Company cannot make any predictions about the final outcome of this matter or the timing thereof.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; font-size: 10pt;;font-style:italic;display:inline;"&gt;Operating Leases&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Supplemental quantitative information related to leases includes the following: &lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 81%;"/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Nine&#160;Months&#160;Ended&lt;br/&gt;September&#160;30,&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 69%;"/&gt;
&lt;td style="width: 14%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 13%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 69%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 14%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 69%;"/&gt;
&lt;td style="width: 14%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 13%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 69%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Operating cash flows from operating leases&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 14%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;531&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;489&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 69%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;ROU assets obtained in exchange for new operating lease&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 14%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;320&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 69%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Weighted average remaining lease term in years &#x2014; operating leases&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 14%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3.1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 69%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Weighted average discount rate &#x2014; operating leases&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 14%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11.8&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12.2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In &lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;June 2022&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, the Company entered into a new &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-cancelable&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; lease agreement for an administrative facility in Palo Alto. The lease includes annual rent increases and the option to extend. The term of the new lease is &lt;/div&gt;26&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; months and the Company expects to exercise the extension option at the end of the lease.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Maturities of lease liabilities were as follows (in thousands):&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 87%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Year Ending December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); text-align: center;"&gt;Amount&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022 (Remaining three months)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;215&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;872&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;703&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2026&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total lease payments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,790&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less imputed interest&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(210&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total lease liabilities as of September&#160;30, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,580&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <sclx:PercentageOfAggregateRoyalityPayments
      contextRef="P01_01_2022To09_30_2022_MinimumMembersrtRangeAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="2"
      unitRef="Unit_pure">0.25</sclx:PercentageOfAggregateRoyalityPayments>
    <sclx:PercentageOfAggregateRoyalityPayments
      contextRef="P01_01_2022To09_30_2022_MaximumMembersrtRangeAxis_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="2"
      unitRef="Unit_pure">0.35</sclx:PercentageOfAggregateRoyalityPayments>
    <sclx:AgreementExpirationDate contextRef="P01_01_2022To09_30_2022_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis">2028-10-02</sclx:AgreementExpirationDate>
    <sclx:AgreementExpirationTerm contextRef="P01_01_2022To09_30_2022_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis">P10Y</sclx:AgreementExpirationTerm>
    <sclx:AgreementAutomaticRenewalPeriodOnExpirationOfInitialTerm contextRef="P01_01_2022To09_30_2022_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis">P1Y</sclx:AgreementAutomaticRenewalPeriodOnExpirationOfInitialTerm>
    <sclx:NoticeOfTerminationPeriodForCancellationOfAutomaticRenewal contextRef="P01_01_2022To09_30_2022_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis">P6M</sclx:NoticeOfTerminationPeriodForCancellationOfAutomaticRenewal>
    <sclx:TerminationOfAgreementNoticePeriodForARequestToCureMaterialBreachOfTheAgreement contextRef="P01_01_2022To09_30_2022_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis">P180D</sclx:TerminationOfAgreementNoticePeriodForARequestToCureMaterialBreachOfTheAgreement>
    <sclx:ThresholdMinimumPercentageOfSales
      contextRef="P01_01_2022To09_30_2022_ProductDevelopmentAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="2"
      unitRef="Unit_pure">0.05</sclx:ThresholdMinimumPercentageOfSales>
    <sclx:PercentageOfAnnualAdjustmentToFees
      contextRef="P01_01_2022To09_30_2022_ExclusiveDistributionAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="2"
      unitRef="Unit_pure">0.03</sclx:PercentageOfAnnualAdjustmentToFees>
    <sclx:AgreementExpirationTerm contextRef="P01_01_2022To09_30_2022_ExclusiveDistributionAgreementMemberusgaapTypeOfArrangementAxis">P3Y</sclx:AgreementExpirationTerm>
    <sclx:PercentageOfDistributionFeeReceivedOverThePeriod
      contextRef="P01_01_2022To09_30_2022_ExclusiveDistributionAgreementMemberusgaapTypeOfArrangementAxis_MinimumMembersrtRangeAxis"
      decimals="2"
      unitRef="Unit_pure">0.01</sclx:PercentageOfDistributionFeeReceivedOverThePeriod>
    <sclx:PercentageOfDistributionFeeReceivedOverThePeriod
      contextRef="P01_01_2022To09_30_2022_ExclusiveDistributionAgreementMemberusgaapTypeOfArrangementAxis_MaximumMembersrtRangeAxis"
      decimals="2"
      unitRef="Unit_pure">0.02</sclx:PercentageOfDistributionFeeReceivedOverThePeriod>
    <sclx:NoticePeriodForTerminationOfWorkOrder contextRef="P01_01_2022To09_30_2022_ProjectAgreementMemberusgaapTypeOfArrangementAxis">P90D</sclx:NoticePeriodForTerminationOfWorkOrder>
    <sclx:WorkOrderImplementationFee
      contextRef="P01_01_2022To09_30_2022_ProjectAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-2"
      unitRef="Unit_USD">59000</sclx:WorkOrderImplementationFee>
    <sclx:SalesOperationsServicesMonthlyFee
      contextRef="PAsOn09_30_2022_MinimumMembersrtRangeAxis_ProjectAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-2"
      unitRef="Unit_USD">63700</sclx:SalesOperationsServicesMonthlyFee>
    <sclx:SalesOperationsServicesMonthlyFee
      contextRef="PAsOn09_30_2022_MaximumMembersrtRangeAxis_ProjectAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-2"
      unitRef="Unit_USD">65800</sclx:SalesOperationsServicesMonthlyFee>
    <sclx:SellingGeneralAndAdministrativeExpenses
      contextRef="P01_01_2022To09_30_2022"
      decimals="-5"
      unitRef="Unit_USD">500000</sclx:SellingGeneralAndAdministrativeExpenses>
    <sclx:SellingGeneralAndAdministrativeExpenses
      contextRef="P01_01_2021To09_30_2021"
      decimals="-5"
      unitRef="Unit_USD">1600000</sclx:SellingGeneralAndAdministrativeExpenses>
    <sclx:ScheduleOfSupplementalQuantitativeInformationRelatedToLeasesTableTextBlock contextRef="P01_01_2022To09_30_2022">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Supplemental quantitative information related to leases includes the following: &lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 81%;"/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Nine&#160;Months&#160;Ended&lt;br/&gt;September&#160;30,&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 69%;"/&gt;
&lt;td style="width: 14%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 13%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt; width: 69%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 14%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 69%;"/&gt;
&lt;td style="width: 14%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 13%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 69%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Operating cash flows from operating leases&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 14%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;531&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;489&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 69%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;ROU assets obtained in exchange for new operating lease&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 14%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;320&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 69%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Weighted average remaining lease term in years &#x2014; operating leases&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 14%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3.1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 69%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Weighted average discount rate &#x2014; operating leases&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 14%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11.8&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 13%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12.2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</sclx:ScheduleOfSupplementalQuantitativeInformationRelatedToLeasesTableTextBlock>
    <sclx:OperatingCashFlowsFromOperatingLeases
      contextRef="P01_01_2022To09_30_2022"
      decimals="0"
      unitRef="Unit_USD">531</sclx:OperatingCashFlowsFromOperatingLeases>
    <sclx:OperatingCashFlowsFromOperatingLeases
      contextRef="P01_01_2021To09_30_2021"
      decimals="0"
      unitRef="Unit_USD">489</sclx:OperatingCashFlowsFromOperatingLeases>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="P01_01_2022To09_30_2022"
      decimals="0"
      unitRef="Unit_USD">320</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="P01_01_2021To09_30_2021"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="PAsOn09_30_2022">P2Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="PAsOn09_30_2021">P3Y1M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="PAsOn09_30_2022"
      decimals="3"
      unitRef="Unit_pure">0.118</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="PAsOn09_30_2021"
      decimals="3"
      unitRef="Unit_pure">0.122</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LessorOperatingLeaseTermOfContract contextRef="PAsOn06_01_2022_PaloAltoAadministrativeFacilityMemberusgaapPropertyPlantAndEquipmentByTypeAxis">P26M</us-gaap:LessorOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="P01_01_2022To09_30_2022">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Maturities of lease liabilities were as follows (in thousands):&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 87%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Year Ending December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); text-align: center;"&gt;Amount&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022 (Remaining three months)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;215&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;872&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;703&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2026&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total lease payments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,790&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less imputed interest&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(210&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total lease liabilities as of September&#160;30, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,580&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="PAsOn09_30_2022"
      decimals="0"
      unitRef="Unit_USD">215</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="PAsOn09_30_2022"
      decimals="0"
      unitRef="Unit_USD">872</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="PAsOn09_30_2022"
      decimals="0"
      unitRef="Unit_USD">703</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="PAsOn09_30_2022"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="PAsOn09_30_2022"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="PAsOn09_30_2022"
      decimals="0"
      unitRef="Unit_USD">1790</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="PAsOn09_30_2022"
      decimals="0"
      unitRef="Unit_USD">210</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="PAsOn09_30_2022"
      decimals="0"
      unitRef="Unit_USD">1580</us-gaap:OperatingLeaseLiability>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="P01_01_2022To09_30_2022">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;9.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;maintains deferred tax assets that reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. These deferred tax assets include net operating loss carryforwards, research credits and temporary differences. In assessing the Company&#x2019;s ability to realize deferred tax assets, management considers, on a periodic basis, whether it is more likely than not that some portion or all the deferred tax assets will not be realized. As such, management has determined that it is appropriate to maintain a valuation allowance against the Company&#x2019;s deferred tax assets.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s income tax (benefit) expense of $&lt;/div&gt;(36.4&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;) thousand and $&lt;/div&gt;10.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;thousand reflect effective tax rates of &lt;/div&gt;0.7&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% and &lt;/div&gt;0.02&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% for the &lt;/div&gt;nine&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; months ended September&#160;&lt;/div&gt;30&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; and &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, respectively.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The difference between the expected statutory federal tax rate of &lt;/div&gt;21.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% and the &lt;/div&gt;0.7&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% effective tax rate for the &lt;/div&gt;nine&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; months ended September&#160;&lt;/div&gt;30&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; was primarily attributable to income tax expense associated with changes in a valuation &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;allowance. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2022To09_30_2022"
      decimals="-2"
      unitRef="Unit_USD">-36400</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2021To09_30_2021"
      decimals="-2"
      unitRef="Unit_USD">10000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="P01_01_2022To09_30_2022"
      decimals="3"
      unitRef="Unit_pure">0.007</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="P01_01_2021To09_30_2021"
      decimals="4"
      unitRef="Unit_pure">0.0002</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2022To09_30_2022"
      decimals="3"
      unitRef="Unit_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2021To09_30_2021"
      decimals="3"
      unitRef="Unit_pure">0.007</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="P01_01_2022To09_30_2022">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;10.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Related Party Transactions &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On March&#160;18, 2019, the Company &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;entered into a merger agreement with Sorrento, Semnur, Merger Sub, and Fortis Advisors LLC. Jaisim Shah, a member of Sorrento&#x2019;s board of directors, was Semnur&#x2019;s Chief Executive&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Officer, a member of its board of directors and a stockholder of Semnur prior to the acquisition transaction. The upfront consideration was comprised of the following: (a)&#160;a cash payment of approximately $&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;15.0&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, and (b) $&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;55.0&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million of shares of the Company&#x2019;s common stock (&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;47,039,315&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; shares issued and &lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;352,972&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; shares issuable, valued at $&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1.16&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; per share) (i.e., the Stock Consideration). Following the issuance of the Stock Consideration, Sorrento was the owner of approximately &lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;58&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% of the Company&#x2019;s issued and outstanding capital stock as of December&#160;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;31&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2019&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;. Following the completion of the Share Exchange and as of December&#160;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;31&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2020&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, Sorrento held approximately &lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;82.3&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% of the outstanding common stock of the Company.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;of December&#160;&lt;/div&gt;31&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2020&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, approximately &lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;14.7&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% of the outstanding capital stock of the Company was held by Itochu. On January&#160;&lt;/div&gt;13&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;34,889,868&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; shares of the Company representing all outstanding capital stock of the Company held by Itochu were acquired by &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-related&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; minority shareholders. Thus, Itochu is not a shareholder subsequent to January&#160;&lt;/div&gt;13&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;. On January&#160;&lt;/div&gt;29&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, Sorrento acquired &lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;34,889,868&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; shares of the Company, resulting in Sorrento holding approximately &lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;99.97&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% of the Company. During the &lt;/div&gt;nine&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; months ended September&#160;&lt;/div&gt;30&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;2022&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; and &lt;/div&gt;2021&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, the Company purchased approximately $&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;4.0&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million and $&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;4.8&#160;million,&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;respectively, of inventory from Itochu, a previous minority shareholder of the Company and a Developer in the aforementioned Product Development Agreement. These costs are recorded within cost of revenues and selling, general and administrative expenses in the Company&#x2019;s statement of operations. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; font-size: 10pt; top: 0px;;display:inline;"&gt;Semnur is party to an Assignment Agreement, dated August&#160;6, 2013 (the &#x201c;Assignment Agreement&#x201d;), with Shah Investor LP (&#x201c;Shah Investor&#x201d;). Mahendra Shah, Ph.D., who served on the Company&#x2019;s board of directors from March 2019 through September 2020, is the managing partner of Shah Investor. Pursuant to the Assignment Agreement, Shah Investor assigned certain intellectual property to Semnur and Semnur agreed to pay Shah Investor a contingent quarterly royalty in the &lt;/div&gt;&lt;div style="letter-spacing: 0px; font-size: 10pt; white-space: nowrap; top: 0px;;display:inline;"&gt;low-single&lt;/div&gt;&lt;div style="letter-spacing: 0px; font-size: 10pt; top: 0px;;display:inline;"&gt; digits based on quarterly net sales of any pharmaceutical formulations for local delivery of steroids by injection developed using such intellectual property, which would include &lt;/div&gt;&lt;div style="letter-spacing: 0px; font-size: 10pt; white-space: nowrap; top: 0px;;display:inline;"&gt;SP-102.&lt;/div&gt;&lt;div style="letter-spacing: 0px; font-size: 10pt; top: 0px;;display:inline;"&gt; Through September&#160;30, 2022, the Company has made no royalty payments pursuant to the Assignment Agreement.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On January&#160;1, 2017, a Transition Services Agreement (&#x201c;TSA&#x201d;) was executed between Scilex Pharma and Sorrento. Pursuant to the TSA, Sorrento agreed, at the Company&#x2019;s request, to provide directly or indirectly certain administrative, financial, legal, tax, insurance, facility, information technology and other services. In addition to the services provided under the TSA, Sorrento retains insurance coverage on behalf of the Company. During the nine months ended September&#160;30, 2022 and 2021, the total cost of services and insurance, including an agreed-upon markup, provided to the Company and recognized in general and administrative expenses was $&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3.2&lt;/div&gt;&#160;million and $&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3.0&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, respectively.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On March&#160;18, 2019, the Company entered into a note payable with Sorrento with an initial principal amount of $&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;16.5&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million for the acquisition of Semnur. The note is interest bearing at the lesser of (a) &lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;10&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% simple interest per annum, and (b)&#160;the maximum interest rate permitted under law. Interest is due and payable annually. The note payable is payable upon demand and may be prepaid in whole or in part at any time without penalty or premium. During the nine months ended September&#160;30, 2022 and 2021, Sorrento made advances to the Company in the amount of $&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;27.5&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million and $&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3.4&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, respectively, under the note payable. The outstanding principal balance of the note on September&#160;30, 2022 and December&#160;31, 2021 was $&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;47.1&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million and $&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;19.6&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, respectively, which was recorded under the current related party note payable in the Company&#x2019;s consolidated balance sheets. As of September&#160;30, 2022 and December&#160;31, 2021, the Company had ending balances resulting from the accrued interest on the note payable of $&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;6.8&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million and $&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3.9&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, respectively, which was recorded under related party payable in the Company&#x2019;s consolidated balance sheets. During the nine months ended September&#160;30, 2022, the proceeds from the note payable were used to finance the operations of the Company.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On October&#160;5, 2018, Scilex Pharma issued to Sorrento a promissory note i&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;n the amount of approximately $&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;21.7&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million for certain amounts previously advanced to Scilex Pharma by Sorrento. Scilex Pharma may borrow up to an aggregate of $&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;25.0&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million of principal amount under the note payable. The promissory note is interest bearing at the lesser of (a) &lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;10&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% simple interest per annum, and (b)&#160;the maximum interest rate permitted under&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;law. All outstanding principal amounts and accrued interest are due upon maturity on August&#160;31, 2026. On October&#160;22, 2018, Sorrento purchased from the Company &lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;24,117,608&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; shares of the Company&#x2019;s common stock in exchange for the repayment of $&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;21.7&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million of indebtedness under this promissory note. During the nine months ended September&#160;30, 2022 and 2021, Sorrento made advances to Scilex Pharma in the amount of $&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;0&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; and $&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;8.1&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, respectively, under the promissory note. As of September&#160;30, 2022 and December&#160;31, 2021, the Company had ending balances resulting from the accrued interest on the note payable of $&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;4.9&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million and $&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3.1&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, respectively, which was recorded under related party payable in the Company&#x2019;s consolidated balance sheets. As of September&#160;30, 2022 and December&#160;31, 2021, Scilex Pharma&#x2019;s outstanding principal balance under the promissory note was $&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;23.5&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, which was recorded under the &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; related party note payable in the Company&#x2019;s consolidated balance sheets.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company received $&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;35.0&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million in February 2022 to fund the payment of Scilex Pharma Notes in February 2022 totaling $&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;20.0&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, as described in Note 6. The $&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;35.0&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million received in February 2022 is due no earlier than February 2030 and was recorded under the &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; related party note payable in the Company&#x2019;s consolidated balance sheets.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Additional funding received from Sorrento is due on demand and recorded under the related party payable in the Company&#x2019;s consolidated balance sheets. As of September&#160;30, 2022, related party payables due to Sorrento included $&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;48.7&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million to cover working capital requirements, $&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;100.0&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million for repurchases of Scilex Pharma Notes, and $&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;17.5&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million for litigation fees (see Note 8). As of December&#160;31, 2021, related party payables due to Sorrento consisted of $&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;35.7&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million to cover working capital requirements, $&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;51.0&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million for repurchases of Scilex Pharma Notes, and $&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;6.0&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million to pay litigation fees (see Note 8).&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;On&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;May&#160;12, 2022, the Company entered into the Bill of Sale, with Sorrento (see Note 3). Pursuant to the Bill of Sale, the Company assumed all of Sorrento&#x2019;s rights, liabilities and obligations under Aardvark Asset Purchase Agreement. The Company issued the 2022 Promissory Note to Sorrento as consideration transferred. The 2022 Promissory Note matures &lt;/div&gt;seven years&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; from the date of issuance and bears interest at the rate equal to the lesser of (a) &lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2.66&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% simple interest per annum and (b)&#160;the maximum interest rate permitted under law. As of September&#160;30, 2022, the outstanding balance, net of discount, under the 2022 Promissory Note was $&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;4.2&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, which was recorded under the &lt;/div&gt;&lt;div style="font-size: 10pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-current&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; related party note payable in the Company&#x2019;s consolidated balance sheets.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Debt Exchange Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On September&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;12, 2022, the Company and Scilex Pharma entered into a Contribution and Satisfaction of Indebtedness Agreement (the &#x201c;Debt Exchange Agreement&#x201d;) with Sorrento, pursuant to which (i)&#160;Sorrento shall contribute to the Company all amounts (including accrued interest thereon, if any) for certain loans and other amounts provided by Sorrento to the Company and Scilex Pharma that remain outstanding as of immediately prior to the closing of the Business Combination (the &#x201c;Aggregate Outstanding Amount&#x201d; or &#x201c;Outstanding Indebtedness), including with respect to the Scilex Pharma Notes, an intercompany promissory note issued by Scilex Pharma to Sorrento in the amount of approximately $&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;27.5&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million for certain amounts previously advanced to Scilex Pharma by Sorrento, and the other notes payable to Sorrento described above (see Note 6), in exchange for the issuance by the Company to Sorrento of preferred stock of the Company, &lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(ii)&#160;the Company shall contribute to Scilex Pharma the portion of such Outstanding Indebtedness that is owed by Scilex Pharma to Sorrento as a&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;contribution of capital for no consideration, and (iii)&#160;upon the occurrence of the events described in clauses (i)&#160;and (ii), the Aggregate Outstanding Amount and the Outstanding Indebtedness shall be satisfied in full.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pursuant to the terms of the Debt Exchange Agreement effective&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;as of immediately prior to, and contingent upon, the closing of the&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Business Combination, &lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sorrento has elected to contribute the Outstanding Indebtedness&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;to the Company in exchange for the issuance by the Company to&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; Sorrento of that number of shares of preferred stock, par value $&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;0.0001&lt;/div&gt; per share, of the Company (subject to adjustment for recapitalizations, stock splits, stock dividends and similar transactions) (the &#x201c;Exchange Shares&#x201d; and such transaction, the &#x201c;Debt Contribution&#x201d;) &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;tha&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;t is equal to (i)&#160;the Aggregate Outstanding Amount plus the amount equal to &lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;10&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% of the Aggregate Outstanding Amount divided by (ii) $&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;11.00&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; (rounded up to the nearest whole share); provided, that in no event shall the Aggregate Outstanding Amount exceed $&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;310,000,000&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;. As of September&#160;30, 2022, the Aggregate Outstanding Amount was $&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;276.8&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"/&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;On&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;November&#160;10, 2022, pursuant to the terms of the Debt Exchange Agreement, all existing related party indebtedness between the Company, Scilex Pharma, and Sorrento, totaling $&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;290.6&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, was contributed by Sorrento to the Company in exchange for &lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;29,057,097&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; shares of the Company&#x2019;s preferred stock. At the Effective Time, such shares were then exchanged for &lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;29,057,097&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; shares of New Scilex preferred stock and &lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;2,905,710&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; shares of New Scilex common stock.&lt;/div&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="P03_18_2019To03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">15000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable
      contextRef="P03_18_2019To03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">55000000</us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable>
    <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets
      contextRef="P03_18_2019To03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="0"
      unitRef="Unit_shares">47039315</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
    <us-gaap:CommonStockSharesSubscribedButUnissued
      contextRef="PAsOn03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="0"
      unitRef="Unit_shares">352972</us-gaap:CommonStockSharesSubscribedButUnissued>
    <sclx:AssetAcquisitionPricePerShare
      contextRef="PAsOn03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.16</sclx:AssetAcquisitionPricePerShare>
    <sclx:PercentageOfOwnershipInterest
      contextRef="PAsOn03_18_2019_SenmurMemberusgaapAssetAcquisitionAxis"
      decimals="2"
      unitRef="Unit_pure">0.58</sclx:PercentageOfOwnershipInterest>
    <sclx:PercentageOfSharesOutstanding
      contextRef="PAsOn12_31_2020_SenmurMemberusgaapAssetAcquisitionAxis_SorrentoMemberSCLXInvesteeAxis"
      decimals="3"
      unitRef="Unit_pure">0.823</sclx:PercentageOfSharesOutstanding>
    <sclx:PercentageOfCapitalSharesOutstanding
      contextRef="PAsOn12_31_2020_ItochuMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="3"
      unitRef="Unit_pure">0.147</sclx:PercentageOfCapitalSharesOutstanding>
    <sclx:NumberOfSharesOutstanding
      contextRef="PAsOn01_13_2021_ItochuMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="INF"
      unitRef="Unit_shares">34889868</sclx:NumberOfSharesOutstanding>
    <sclx:NumberOfSharesAcquired
      contextRef="PAsOn01_29_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="INF"
      unitRef="Unit_shares">34889868</sclx:NumberOfSharesAcquired>
    <sclx:PercentageOfSharesOutstanding
      contextRef="PAsOn01_29_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="4"
      unitRef="Unit_pure">0.9997</sclx:PercentageOfSharesOutstanding>
    <sclx:PaymentToAcquireInventory
      contextRef="P01_01_2022To09_30_2022"
      decimals="-5"
      unitRef="Unit_USD">4000000</sclx:PaymentToAcquireInventory>
    <sclx:PaymentToAcquireInventory
      contextRef="P01_01_2021To09_30_2021"
      decimals="-5"
      unitRef="Unit_USD">4800000</sclx:PaymentToAcquireInventory>
    <us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
      contextRef="P01_01_2022To09_30_2022_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">3200000</us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
      contextRef="P01_01_2021To09_30_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">3000000</us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn03_18_2019_ReorganizationMemberSCLXEventAxis_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">16500000</us-gaap:DebtInstrumentFaceAmount>
    <sclx:PercentageOfSimpleInterest
      contextRef="PAsOn03_18_2019_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="2"
      unitRef="Unit_pure">0.10</sclx:PercentageOfSimpleInterest>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="P01_01_2022To09_30_2022_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">27500000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="P01_01_2021To09_30_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">3400000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:NotesPayableCurrent
      contextRef="PAsOn09_30_2022_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">47100000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="PAsOn12_31_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">19600000</us-gaap:NotesPayableCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="PAsOn09_30_2022_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">6800000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="PAsOn12_31_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">3900000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn10_05_2018_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis"
      decimals="-5"
      unitRef="Unit_USD">21700000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn10_05_2018_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis"
      decimals="-5"
      unitRef="Unit_USD">25000000</us-gaap:DebtInstrumentFaceAmount>
    <sclx:PercentageOfSimpleInterest
      contextRef="PAsOn10_05_2018_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_pure">0.10</sclx:PercentageOfSimpleInterest>
    <sclx:NumberOfSharesAcquired
      contextRef="PAsOn10_22_2018_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">24117608</sclx:NumberOfSharesAcquired>
    <us-gaap:RepaymentsOfDebt
      contextRef="P10_22_2018To10_22_2018_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis"
      decimals="-5"
      unitRef="Unit_USD">21700000</us-gaap:RepaymentsOfDebt>
    <sclx:AccruedInterest
      contextRef="PAsOn09_30_2022_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis"
      decimals="-6"
      unitRef="Unit_USD">0</sclx:AccruedInterest>
    <sclx:AccruedInterest
      contextRef="PAsOn09_30_2021_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis"
      decimals="-5"
      unitRef="Unit_USD">8100000</sclx:AccruedInterest>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="PAsOn09_30_2022_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis"
      decimals="-5"
      unitRef="Unit_USD">4900000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="PAsOn12_31_2021_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis"
      decimals="-5"
      unitRef="Unit_USD">3100000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:LongTermNotesPayable
      contextRef="PAsOn12_31_2021_ScilexPharmaMemberdeiLegalEntityAxis"
      decimals="-5"
      unitRef="Unit_USD">23500000</us-gaap:LongTermNotesPayable>
    <us-gaap:LongTermNotesPayable
      contextRef="PAsOn09_30_2022_ScilexPharmaMemberdeiLegalEntityAxis"
      decimals="-5"
      unitRef="Unit_USD">23500000</us-gaap:LongTermNotesPayable>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="P02_01_2022To02_28_2022_ScilexPharmaMemberdeiLegalEntityAxis"
      decimals="-5"
      unitRef="Unit_USD">35000000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="P01_01_2022To09_30_2022_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">20000000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:ProceedsFromIssuanceOfMediumTermNotes
      contextRef="P02_01_2022To02_28_2022_DueOnOrAfterFebruaryTwoThousandAndThirtyMemberSCLXPeriodAxis"
      decimals="-5"
      unitRef="Unit_USD">35000000</us-gaap:ProceedsFromIssuanceOfMediumTermNotes>
    <sclx:WorkingCapitalRequirements
      contextRef="PAsOn09_30_2022_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">48700000</sclx:WorkingCapitalRequirements>
    <us-gaap:DebtInstrumentRepurchaseAmount
      contextRef="PAsOn09_30_2022_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">100000000</us-gaap:DebtInstrumentRepurchaseAmount>
    <us-gaap:LegalFees
      contextRef="P09_30_2022To09_30_2022_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">17500000</us-gaap:LegalFees>
    <sclx:WorkingCapitalRequirements
      contextRef="PAsOn12_31_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">35700000</sclx:WorkingCapitalRequirements>
    <us-gaap:DebtInstrumentRepurchaseAmount
      contextRef="PAsOn12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">51000000</us-gaap:DebtInstrumentRepurchaseAmount>
    <us-gaap:LegalFees
      contextRef="P01_01_2021To12_31_2021_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">6000000</us-gaap:LegalFees>
    <us-gaap:DebtInstrumentTerm contextRef="P05_12_2022To05_12_2022_SorrentoMemberusgaapBusinessAcquisitionAxis_TwoThousandAndTwentyTwoPromissoryNoteMemberusgaapLongtermDebtTypeAxis">P7Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="PAsOn05_12_2022_SorrentoMemberusgaapBusinessAcquisitionAxis_TwoThousandAndTwentyTwoPromissoryNoteMemberusgaapLongtermDebtTypeAxis"
      decimals="4"
      unitRef="Unit_pure">0.0266</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermNotesPayable
      contextRef="PAsOn09_30_2022_TwoThousandAndTwentyTwoPromissoryNoteMemberusgaapLongtermDebtTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">4200000</us-gaap:LongTermNotesPayable>
    <us-gaap:RepaymentsOfDebt
      contextRef="P09_12_2022To09_12_2022_DebtExchangeAgreementMemberSCLXAgreementAxis_PromissoryNoteRelatedPartyMemberusgaapRelatedPartyTransactionAxis_ScilexPharmaMemberdeiLegalEntityAxis"
      decimals="1"
      unitRef="Unit_USD">27.5</us-gaap:RepaymentsOfDebt>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn09_12_2022_DebtExchangeAgreementMemberSCLXAgreementAxis_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="4"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <sclx:PercentageOfOutstandingAmountIndebtedness
      contextRef="PAsOn09_12_2022_DebtExchangeAgreementMemberSCLXAgreementAxis_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="2"
      unitRef="Unit_pure">0.10</sclx:PercentageOfOutstandingAmountIndebtedness>
    <sclx:PerShareCalculationOfOutstandingAmountInExchangeOfShares
      contextRef="PAsOn09_12_2022_DebtExchangeAgreementMemberSCLXAgreementAxis_SorrentoMemberusgaapBusinessAcquisitionAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">11</sclx:PerShareCalculationOfOutstandingAmountInExchangeOfShares>
    <sclx:LimitationOfOutstandingAmountInExchangeOfShares
      contextRef="PAsOn09_12_2022_DebtExchangeAgreementMemberSCLXAgreementAxis_SorrentoMemberusgaapBusinessAcquisitionAxis"
      decimals="0"
      unitRef="Unit_USD">310000000</sclx:LimitationOfOutstandingAmountInExchangeOfShares>
    <us-gaap:LongTermDebt
      contextRef="PAsOn09_30_2022_DebtExchangeAgreementMemberSCLXAgreementAxis_SorrentoMemberusgaapBusinessAcquisitionAxis"
      decimals="1"
      unitRef="Unit_USD">276.8</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="PAsOn11_10_2022_DebtExchangeAgreementMemberSCLXAgreementAxis_SorrentoMemberusgaapBusinessAcquisitionAxis"
      decimals="1"
      unitRef="Unit_USD">290.6</us-gaap:LongTermDebt>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="P11_10_2022To11_10_2022_DebtExchangeAgreementMemberSCLXAgreementAxis_PreferredStockMemberusgaapStatementEquityComponentsAxis_SorrentoMemberusgaapBusinessAcquisitionAxis"
      decimals="0"
      unitRef="Unit_shares">29057097</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="P11_10_2022To11_10_2022_DebtExchangeAgreementMemberSCLXAgreementAxis_PreferredStockMemberusgaapStatementEquityComponentsAxis_SorrentoMemberusgaapBusinessAcquisitionAxis"
      decimals="0"
      unitRef="Unit_shares">29057097</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="P11_10_2022To11_10_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_DebtExchangeAgreementMemberSCLXAgreementAxis_SorrentoMemberusgaapBusinessAcquisitionAxis"
      decimals="0"
      unitRef="Unit_shares">2905710</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:EarningsPerShareTextBlock contextRef="P01_01_2022To09_30_2022">&lt;div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;11.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss Per Share &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;the nine months ended September&#160;30, 2022 and 2021, basic loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. Diluted loss per common share is calculated to give effect to all dilutive securities, using the treasury stock method.&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; table sets forth the reconciliation of basic and diluted loss per share for the nine months ended September&#160;30, 2022 and 2021 (in thousands except per share data):&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 72%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;Nine&#160;Months&#160;Ended&lt;br/&gt;September&#160;30,&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;2022&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;2021&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(5,480&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(46,459&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Denominator for Basic Loss Per Share&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;197,550&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;197,266&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Effect of Dilutive Securities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Denominator for Diluted Loss per Share &#x2014; Adjusted for Dilutive Securities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;197,550&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;197,266&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic Loss Per Share&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.03&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.24&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dilutive Loss Per Share&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.03&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.24&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The stock &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;options that could potentially dilute basic earnings per share in the future were excluded from the computation of diluted net loss per share because the effect would have been anti-dilutive due to the net loss for the nine months ended September&#160;30, 2022 and 2021 were &lt;/div&gt;25.2&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million and &lt;/div&gt;30.3&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, respectively.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="P01_01_2022To09_30_2022">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; table sets forth the reconciliation of basic and diluted loss per share for the nine months ended September&#160;30, 2022 and 2021 (in thousands except per share data):&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 72%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;Nine&#160;Months&#160;Ended&lt;br/&gt;September&#160;30,&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;2022&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;2021&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(5,480&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(46,459&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Denominator for Basic Loss Per Share&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;197,550&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;197,266&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Effect of Dilutive Securities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Denominator for Diluted Loss per Share &#x2014; Adjusted for Dilutive Securities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;197,550&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;197,266&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic Loss Per Share&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.03&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.24&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dilutive Loss Per Share&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.03&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.24&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">-5480000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-46459000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">197550000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">197266000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:DilutiveSecurities
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DilutiveSecurities>
    <us-gaap:DilutiveSecurities
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DilutiveSecurities>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="P01_01_2022To09_30_2022"
      decimals="-3"
      unitRef="Unit_USD">197550000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="P01_01_2021To09_30_2021"
      decimals="-3"
      unitRef="Unit_USD">197266000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2022To09_30_2022"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.03</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2021To09_30_2021"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.24</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2022To09_30_2022"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.03</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2021To09_30_2021"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.24</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2022To09_30_2022"
      decimals="-5"
      unitRef="Unit_shares">25200000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2021To09_30_2021"
      decimals="-5"
      unitRef="Unit_shares">30300000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SubsequentEventsTextBlock contextRef="P01_01_2022To09_30_2022">
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;12.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Subsequent Events &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt;&lt;div style="background: none;;text-indent: 0px;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company has evaluated subsequent events for recognition and disclosure purposes in the unaudited consolidated financial statements as of September&#160;30, 2022, and the nine months then ended, through November&#160;17, 2022, the date the financial statements were available to be issued and, for disclosure purpose, through January&#160;12, 2023. Except as described below, or as otherwise indicated in the footnotes, the Company has concluded that no events or transactions have occurred that require disclosure. &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px; background: none;;text-indent: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px; background: none;;text-indent: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"/&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Funding Commitment Letter &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;On&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;October&#160;17, 2022, Sorrento and the Company entered into a letter agreement (the &#x201c;Funding Commitment Letter&#x201d;). Pursuant to the terms of the Funding Commitment Letter, upon the written request of the Company (which request the Company shall make to the extent necessary to satisfy the closing condition in the BCA that requires the combined company to have $&lt;/div&gt;5,000,001&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; in net tangible assets as of immediately following the effective time of the Business Combination (the &#x201c;Effective Time&#x201d;) under the BCA (the &#x201c;Net Tangible Assets Condition&#x201d;)), Sorrento agreed to fund one or more loans to the Company in the amount set forth in such written request (a &#x201c;Loan Request&#x201d;); provided, that any amounts funded by Sorrento in respect of any Loan Request were to be treated as Outstanding Indebtedness for all purposes under the Debt Exchange Agreement and &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;included in &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;the calculation of the Aggregate Outstanding Amount thereunder with such amount to be contributed to the Company in exchange for shares of Legacy Scilex preferred stock. The Funding Commitment Letter also provides that, in no event shall the aggregate amount of loans made and funded by Sorrento pursuant to Loan Requests exceed the lesser of (a) $10,000,000 and (b)&#160;an amount that, when taken together with all other Outstanding Indebtedness, will result in the Aggregate Outstanding Amount equaling $310,000,000. The Company did not draw funds from the Funding Commitment Letter at the Effective Time. &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Amendment to Amended and Restated Certificate of Incorporation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;November&#160;10, 2022, the Company filed with the Secretary of State of the State of Delaware (i)&#160;a Certificate of Amendment to its Amended and Restated Certificate of Incorporation to increase the authorized number of shares of preferred stock of the Company from &lt;/div&gt;20,000,000&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; to &lt;/div&gt;45,000,000&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; and (ii)&#160;a certificate of designation setting forth the designations, powers, rights and preferences and qualifications, limitations and restrictions of the Series A Preferred Stock, par value $&lt;/div&gt;0.0001&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; per share, of Legacy &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Scilex.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; font-size: 10pt;;font-style:italic;display:inline;"&gt;Sorrento Absorbed Liabilities&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In October &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 0px; top: 0px;;display:inline;"&gt;and November 2022, Sorrento entered into agreements with certain of the Company&#x2019;s third party professional service providers to assume $&lt;/div&gt;11.9&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 0px; top: 0px;;display:inline;"&gt;&#160;million of liabilities accrued by the Company, of which $&lt;/div&gt;10.0&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 0px; top: 0px;;display:inline;"&gt;&#160;million and $&lt;/div&gt;1.9&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 0px; top: 0px;;display:inline;"&gt;&#160;million were recorded under accounts payable and accrued expenses, respectively, within the consolidated balance sheet. The liabilities assumed by Sorrento were reclassified under related party payable within the consolidated balance sheet and subsequently exchanged on November&#160;10, 2022 under the terms of the Debt Exchange&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;Agreement (see Note 10).&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Committed Equity Financings &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On November&#160;17, 2022, the Company entered into a standby equity purchase agreement (the &#x201c;Yorkville Purchase Agreement&#x201d;) with YA II PN, Ltd., a Cayman Islands exempt limited partnership (&#x201c;YA II&#x201d;). Pursuant to the Yorkville Purchase Agreement, the Company has the right to sell to YA II, from time to time during the term of the Yorkville Purchase Agreement, up to $500,000,000 of shares of New Scilex common stock, subject to certain limitations and conditions set forth therein. Upon the satisfaction of the conditions to YA II&#x2019;s purchase obligation set forth in the Yorkville Purchase Agreement, including that a registration statement with respect to the shares to be issued to YA II thereunder be declared effective by the SEC, the Company will have the right, but not the obligation, from time to time at its discretion until the first day of the month next following the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;36-month&lt;/div&gt; anniversary of the date on which such registration statement has been declared effective by the SEC, to direct the YA II to purchase a specified amount of shares of Common Stock (each such sale, a &#x201c;Yorkville Advance&#x201d;) by delivering written notice to YA II (each, a &#x201c;Yorkville Advance Notice&#x201d;). &lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;While there is no mandatory minimum amount for any Yorkville Advance, Yorkville Advance may be for a number of shares of New Scilex common stock not to exceed&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;200&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 0px; top: 0px;;display:inline;"&gt;% of the average of the daily trading volume of the New Scilex common stock on the Nasdaq Capital Market during regular trading hours as reported by Bloomberg L.P. during the &lt;/div&gt;&lt;span style="-sec-ix-hidden:hidden63196045"&gt;five&lt;/span&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 0px; top: 0px;;display:inline;"&gt; trading &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;days immediately preceding the date of the Yorkville Advance Notice. The shares of New Scilex common stock, if any, that the Company elects to sell to YA II pursuant to a Yorkville Advance will be purchased at a price equal&lt;/div&gt;&#160;to &lt;/div&gt;98&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 0px; top: 0px;;display:inline;"&gt;% &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;of the lowest daily VWAP (as defined below) during the&lt;/div&gt;&#160;&lt;/div&gt;&lt;span style="-sec-ix-hidden:hidden63196046"&gt;two&lt;/span&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 0px; top: 0px;;display:inline;"&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;consecutive trading days commencing on the date of delivery of a Yorkville Advance Notice. &#x201c;VWAP&#x201d; means, for any trading day, the daily volume weighted average price of the New Scilex common stock for such trading day on the Nasdaq Capital Market as reported by Bloomberg L.P. during regular trading hours. The Company may also specify a certain minimum acceptable price per share in each Yorkville Advance.&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As consideration for YA II&#x2019;s commitment to purchase shares of New Scilex common stock at the Company&#x2019;s direction upon the terms and subject to the conditions set forth in the Yorkville Purchase Agreement, the Company issued&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;250,000&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 0px; top: 0px;;display:inline;"&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;shares of New Scilex common stock to YA II in connection with the execution of the Yorkville Purchase Agreement&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On January 8, 2023, the Company entered into a standby equity purchase agreement (the &#x201c;B. Riley Purchase Agreement&#x201d;) with B. Riley Principal Capital II, LLC, a Delaware limited liability company (&#x201c;B.&#160;Riley&#x201d;). Pursuant to the B. Riley Purchase Agreement, the Company has the right to sell to B. Riley, from time to time during the term of the B. Riley Purchase Agreement, up to $500,000,000 of shares of New Scilex common stock, subject to certain limitations and conditions set forth therein. Upon the satisfaction of the conditions to B. Riley&#x2019;s purchase obligation set forth in the B. Riley Purchase Agreement, including that a registration statement with respect to the shares to be issued to B. Riley thereunder be declared effective by the SEC, the Company will have the right, but not the obligation, from time to time at its discretion until the first day of the month next following the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;36-month&lt;/div&gt; anniversary of the date on which such registration statement has been declared effective by the SEC, to direct the B. Riley to purchase a specified amount of shares of New Scilex common stock (each such sale, an &#x201c;Advance&#x201d;) by delivering an irrevocable written notice to B. Riley (each, an &#x201c;Advance Notice&#x201d;). &lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The shares of New Scilex common stock, if any, that the Company elects to sell to B. Riley pursuant to an Advance will be purchased at a price equal to 98% of the VWAP (as defined below) during the period (such &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;period, the &#x201c;Pricing Period&#x201d;) beginning at 9:30:01 a.m., New York City time, on the date of purchase of Advance Shares or such later time publicly announced as the official open of the primary (or &#x201c;regular&#x201d;) trading session on the Nasdaq Capital Market on such purchase date (the &#x201c;Purchase Commencement Time&#x201d;) and ending at the earliest of (i) 3:59 p.m., New York City Time, on the purchase date or such earlier time publicly announced as the official close of the primary (or &#x201c;regular&#x201d;) trading session on the Nasdaq Capital Market on such purchase date, (ii)&#160;immediately at such time following the Purchase Commencement Time for such purchase that the total number (or volume) of shares of New Scilex common stock traded on the Nasdaq Capital Market during such period has exceeded the Advance Share Volume Maximum (as defined below) for such purchase and (iii)&#160;if the Company so elects in the applicable Advance Notice for such Advance (such election, a &#x201c;Limit Order Discontinue Election&#x201d;), such time the sale price of the shares of New Scilex common stock traded on the Nasdaq Capital Market during such Pricing Period is less than the applicable minimum price threshold determined in accordance with the B. Riley Purchase Agreement. &#x201c;VWAP&#x201d; means, for the New Scilex common stock for a specified period, the dollar volume-weighted average price of the New Scilex common stock on the Nasdaq Capital Market for such period as reported by Bloomberg through its &#x201c;AOR&#x201d; function, subject to certain exceptions, qualifications and limitations. &#x201c;Advance Share Volume Maximum&#x201d; means, with respect to an Advance, if such Advance is a (i)&#160;purchase-Type A, a number of shares of New Scilex common stock that is equal to the quotient obtained by dividing (a)&#160;the Advance Share amount to be purchased by B. Riley, by (b) 0.10, and (ii)&#160;purchase-Type B, a number of shares of New Scilex common stock that is equal to the quotient obtained by dividing (a)&#160;the Advance Share amount to be purchased by B. Riley, by (b) 0.25 (in each case, subject to certain adjustments). The Company may also specify a certain minimum acceptable price per share in each Advance. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;While there is no mandatory minimum amount for any Advance, subject to the terms and conditions of the B. Riley Purchase Agreement, an Advance may be for a number of shares of New Scilex common stock not to exceed (i)&#160;with respect to an Advance, purchase-Type A, such number of shares of New Scilex common stock that is equal to the lesser of: (a) 1,000,000, and (b)&#160;the product of (1) 0.10, multiplied by (2)&#160;the total number (or volume) of shares of New Scilex common stock traded on the Nasdaq Capital Market during the Pricing Period for such purchase-Type A, and (ii)&#160;with respect to an Advance, purchase-Type B, such number of shares of New Scilex common stock equal to the lesser of: (a) 1,000,000 and (b)&#160;the product of (1) 0.25, multiplied by (2)&#160;the total number (or volume) of shares of New Scilex common stock traded on the Nasdaq Capital Market during the Pricing Period for such purchase-Type B. The Company may also specify a certain minimum acceptable price per share in each Advance. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The B. Riley Purchase Agreement also provides that the Company has the right, but not the obligation, to sell to B. Riley, from time to time subject to certain limitations, at the Company&#x2019;s sole and absolute discretion an additional number of shares of New Scilex common stock (each such additional sale, an &#x201c;Additional Advance&#x201d;) by delivering an irrevocable written notice to B. Riley. The purpose of the Additional Advance is to allow the Company to execute more than one advance request on a purchase date with B. Riley as each prior advance has been completed under the terms of the B. Riley Purchase Agreement. Each Additional Advance is generally subject to terms and conditions consistent with those of an Advance, except for, among other things, the time period of the pricing period for such Additional Advance. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As consideration for B. Riley&#x2019;s commitment to purchase shares of New Scilex common stock at the Company&#x2019;s direction upon the terms and subject to the conditions set forth in the B. Riley Purchase Agreement, the Company issued 250,000 shares of New Scilex common stock to B. Riley in connection with the execution of the B. Riley Purchase Agreement. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:MinimumNetWorthRequiredForCompliance
      contextRef="PAsOn10_17_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      unitRef="Unit_USD">5000001</us-gaap:MinimumNetWorthRequiredForCompliance>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="PAsOn10_17_2022_FundingCommitmentLetterMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      unitRef="Unit_USD">10000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <sclx:AggregateOutstandingAmount
      contextRef="PAsOn10_17_2022_FundingCommitmentLetterMemberusgaapCreditFacilityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      unitRef="Unit_USD">310000000</sclx:AggregateOutstandingAmount>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn11_10_2022_MinimumMembersrtRangeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn11_10_2022_MaximumMembersrtRangeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">45000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn11_10_2022_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:LiabilitiesAssumed1
      contextRef="P10_01_2022To11_30_2022_AgreementWithCertainOfTheThirdPartyProfessionalServiceProvidersMemberSCLXAgreementAxis_SorrentoMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">11900000</us-gaap:LiabilitiesAssumed1>
    <us-gaap:LiabilitiesAssumed1
      contextRef="P10_01_2022To11_30_2022_AccountsPayableMemberusgaapBalanceSheetLocationAxis_AgreementWithCertainOfTheThirdPartyProfessionalServiceProvidersMemberSCLXAgreementAxis_SorrentoMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">10000000</us-gaap:LiabilitiesAssumed1>
    <us-gaap:LiabilitiesAssumed1
      contextRef="P10_01_2022To11_30_2022_AccruedLiabilitiesMemberusgaapBalanceSheetLocationAxis_AgreementWithCertainOfTheThirdPartyProfessionalServiceProvidersMemberSCLXAgreementAxis_SorrentoMemberdeiLegalEntityAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">1900000</us-gaap:LiabilitiesAssumed1>
    <us-gaap:CommonStockSharesSubscriptions
      contextRef="PAsOn11_17_2022_StandbyEquityPurchaseAgreementMemberSCLXAgreementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_YorkvilleMemberSCLXInvesteeAxis"
      decimals="0"
      unitRef="Unit_USD">500000000</us-gaap:CommonStockSharesSubscriptions>
    <sclx:PeriodAfterRegistrationWhenTheRequestCouldBeMadeToTheInvesteeToPurchaseTheShares contextRef="P11_17_2022To11_17_2022_StandbyEquityPurchaseAgreementMemberSCLXAgreementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_YorkvilleMemberSCLXInvesteeAxis">P36M</sclx:PeriodAfterRegistrationWhenTheRequestCouldBeMadeToTheInvesteeToPurchaseTheShares>
    <sclx:MaximumPercentageOfVolumeWeightedAveragePriceOfSharesMeasuredOnADailyBasisThatIsEligibleToBeReceivedAsAdvance
      contextRef="P11_17_2022To11_17_2022_StandbyEquityPurchaseAgreementMemberSCLXAgreementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_YorkvilleMemberSCLXInvesteeAxis"
      decimals="2"
      unitRef="Unit_pure">2</sclx:MaximumPercentageOfVolumeWeightedAveragePriceOfSharesMeasuredOnADailyBasisThatIsEligibleToBeReceivedAsAdvance>
    <sclx:PercentageOfDailyVolumeWeightedAveragePriceOfSharesAtWhichTheSharesAreEligibleToBePurchased
      contextRef="P11_17_2022To11_17_2022_StandbyEquityPurchaseAgreementMemberSCLXAgreementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_YorkvilleMemberSCLXInvesteeAxis"
      decimals="2"
      unitRef="Unit_pure">0.98</sclx:PercentageOfDailyVolumeWeightedAveragePriceOfSharesAtWhichTheSharesAreEligibleToBePurchased>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2022To09_30_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis_YorkvilleMemberSCLXInvesteeAxis"
      decimals="0"
      unitRef="Unit_shares">250000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CommonStockSharesSubscriptions
      contextRef="PAsOn01_08_2023_B.RileyMemberSCLXInvesteeAxis_StandbyEquityPurchaseAgreementMemberSCLXAgreementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      unitRef="Unit_USD">500000000</us-gaap:CommonStockSharesSubscriptions>
    <sclx:PeriodAfterRegistrationWhenTheRequestCouldBeMadeToTheInvesteeToPurchaseTheShares contextRef="P01_08_2023To01_08_2023_B.RileyMemberSCLXInvesteeAxis_StandbyEquityPurchaseAgreementMemberSCLXAgreementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">P36M</sclx:PeriodAfterRegistrationWhenTheRequestCouldBeMadeToTheInvesteeToPurchaseTheShares>
    <sclx:PercentageOfDailyVolumeWeightedAveragePriceOfSharesAtWhichTheSharesAreEligibleToBePurchased
      contextRef="P01_31_2023To01_31_2023_B.RileyMemberSCLXInvesteeAxis_StandbyEquityPurchaseAgreementMemberSCLXAgreementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="2"
      unitRef="Unit_pure">0.98</sclx:PercentageOfDailyVolumeWeightedAveragePriceOfSharesAtWhichTheSharesAreEligibleToBePurchased>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="PAsOn01_31_2023_B.RileyMemberSCLXInvesteeAxis_PurchasetypeAMembersrtProductOrServiceAxis_ScilexCommonStockMemberusgaapRelatedPartyTransactionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.1</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="PAsOn01_31_2023_B.RileyMemberSCLXInvesteeAxis_PurchasetypeBMembersrtProductOrServiceAxis_ScilexCommonStockMemberusgaapRelatedPartyTransactionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.25</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="P01_31_2023To01_31_2023_B.RileyMemberSCLXInvesteeAxis_PurchasetypeAMembersrtProductOrServiceAxis_ScilexCommonStockMemberusgaapRelatedPartyTransactionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      unitRef="Unit_shares">1000000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="PAsOn01_31_2023_B.RileyMemberSCLXInvesteeAxis_PurchasetypeAMembersrtProductOrServiceAxis_ScilexCommonStockMemberusgaapRelatedPartyTransactionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.1</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="P01_31_2023To01_31_2023_B.RileyMemberSCLXInvesteeAxis_PurchasetypeBMembersrtProductOrServiceAxis_ScilexCommonStockMemberusgaapRelatedPartyTransactionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      unitRef="Unit_shares">1000000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="PAsOn01_31_2023_B.RileyMemberSCLXInvesteeAxis_PurchasetypeBMembersrtProductOrServiceAxis_ScilexCommonStockMemberusgaapRelatedPartyTransactionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.25</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_31_2023To01_31_2023_B.RileyMemberSCLXInvesteeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      unitRef="Unit_shares">250000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fact_63193284"
          xlink:label="Fact_63193284"
          xlink:type="locator"/>
        <link:footnote id="FN_220028" xlink:label="FN_220028" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">At December 31, 2020, includes an aggregate of up to 450,000 ordinary shares that are subject to forfeiture depending on the extent to which the underwriters&#x2019; over-allotment option is exercised (see Note 6). On January 6, 2021, the Company effected a share capitalization of 0.2 shares for each share outstanding, resulting in 3,450,000 ordinary shares issued and outstanding (see Note 6). All share and per share amounts have been retroactively restated to reflect the share capitalization. As a result of the underwriters&#x2019; full exercise of their overallotment option on January 11, 2021, no shares were forfeited.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_63193284"
          xlink:to="FN_220028"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_63193285"
          xlink:label="Fact_63193285"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_63193285"
          xlink:to="FN_220028"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_63193636"
          xlink:label="Fact_63193636"
          xlink:type="locator"/>
        <link:footnote id="FN_220029" xlink:label="FN_220029" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">At December 31, 2020, excludes an aggregate of up to 450,000 ordinary shares that were subject to forfeiture.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_63193636"
          xlink:to="FN_220029"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_63193637"
          xlink:label="Fact_63193637"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_63193637"
          xlink:to="FN_220029"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_63195334"
          xlink:label="Fact_63195334"
          xlink:type="locator"/>
        <link:footnote id="FN_220030" xlink:label="FN_220030" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Inclusive of variable lease costs, sublease income, and impairment, which were immaterial for the periods presented.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_63195334"
          xlink:to="FN_220030"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_63195335"
          xlink:label="Fact_63195335"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_63195335"
          xlink:to="FN_220030"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_63195336"
          xlink:label="Fact_63195336"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_63195336"
          xlink:to="FN_220030"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>113
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MPG/;_.^@A<'[G1>< C0O0&;FC'Q#!YT?CDKG1>@VU+)VDAW=QN%)9%OR@I^
M8C9S+4 RD79BN=T^7#'_*&&81;!I49%$U*5N<D?;VJ;>29-PWH<W>?N1FC54
MA,,:I<'Y%=X6LDF%346+RJ:?E="8S&PQQ]\'D&8 ]J^%T(>*F:#](8G_ E!+
M P04    " "BA2Q6I!]6'S\-  "Z2   &    'AL+W=O<FMS:&5E=',O<VAE
M970R+GAM;-U<;7/;-A+^*QBWTVMG_$*\DG02SR2R<M>;RS53]^5#YS[0$F3Q
M0A$J2=EQ?_TM*$J0A"4HY]29F_O01J(?+/DL@,6#78BOGTSUJ9YKW9#/BZ*L
MWYS-FV9Y?7553^9ZD=679JE+^,O,5(NL@:_5PU6]K'0V;1LMBBL61>IJD>7E
MV<WK]MK'ZN:U635%7NJ/%:E7BT56/;_3A7EZ<T;/-A=^S!_FC;UP=?-ZF3WH
M.]W\O/Q8P;>KK95IOM!EG9N25'KVYNPMO7X?1[9!B_@EUT_USF=BJ=P;\\E^
M^7[ZYBRR3Z0+/6FLB0S^>=0C7136$CS'[YW1L^T];</=SQOK[UOR0.8^J_7(
M%+_FTV;^YBPY(U,]RU9%\Z-Y^ION"$EK;V**NOT_>>JPT1F9K.K&++K&\ 2+
MO%S_FWWN'+'3@(J>!JQKP(YMP+L&_+ ![VD@N@;BV#O(KH$\]@ZJ:Z!:WZ^=
MU7KZ-FNRF]>5>2*518,U^Z'MKK8U.#@O[<BZ:RKX:P[MFIN1*:<P3O24P*?:
M%/DT:^#+NZS(RHDF=]9P32[(SW>WY-NOOWM]U<!-;=.K27>#=^L;L)X;W.GE
M)>'1.6$18TCS4;CYK9Y <]HVITCS\?'-H_WF5^"IK;O8UEVLM<?[W+6J*ETV
M)*MK\,LUYHZU 8$;L('BNEYF$_WF#")!K:M'?7;SS5=41:\PYYS2V/A$QO8<
MQ[>.XR'K-Z.LGI.LG)*)_:!_7^6/60&>K#$7KDW)UI0-C8\W3"0\BJ ''W>]
MX^,$YXF'&R.XA*>[N#U.8LM)!#F]G4S,"BA A)UHX'-?Z'-2Z@:CM+:D=AZ!
MQB(6/B<$*)A"2"% 3IGJ926WK&20U??E(_2+J9XQ&M*[:<J1CO%A3"KF<_!Q
ME K92T%M*:@@A8^57F;YE.C/2QO;ZG;@F6:N*XR3\A\BDMAP0X )ESXK'\<Y
M%;VLXBVK.,CJ)]-D!:P)@Q$H]N]/18P0\H$,4#YPC "98/V4DBVE9*"C0")5
MS7/;038H+$&T-+V3*/$>(T[\437R84F$=!,"$_W3)]U22H.4?@!"69.7#Z30
MH'A(9:7-A9E=K.!+VVD8L]0?6BRF/C4$Q[$.0W J[I]8-')R(1J(#DU6/N00
MZNK>;NI,[-Y=4$5CGPZ"Y$D2(9$"L\FD'8%]E'84$ U2^JLQTZ>\*% J%'&X
M2)">.1HY/@:Y3\6I$QI<PV_^8<J'BT97"Q#72U/G>/<P__X2B0X(3F*KZS!N
MGXV3##2L&=8!;QWH4"+<G\%)'&/CS$?&<<JQ<8;8I#+J#W74J04JCM*.19[=
MYT7>Y!H/WS2H.EZJ($]J;7PJ:_LN=-*$AK7)5G$MLV<KMU#W8:)")8C40I""
M(< Q DPH"\0>)U1H6*D H6H%^RW@4YF>$(3(#K&O\SHZB.Z($74V1H$R,,2=
M0J%AB;*ALQ%>*!],=22(.APA2!HIAH54',GZ*3F%0L,293-KEZ9J4R%F9A,7
M&B["7@:VS/FT7>]-B7+U-0;%]#*"\R@&'_-+9YY3-30L:U WW./KBR\^/+X^
MA,>IC)">192,3)+^Y84Y*</"4N9'7;2YCF5F%6@@HC!?>U"E#C8JW7[=AZ8L
M9DA,09!,*=4_"YD3-"PL:/:)E:;107:^'!$@/?V%?H0@::H0Y!A#PK /]-I.
M B8L<9"!: XD]\X"BQ+V]4J,B5,$UXY0CZR/"^V-F-,_[!C],SE2-C!?N3!)
MHQ@;I3Z4JE0PC!RBG!*1]*]]S.DA%DZ?[(K58P,J\[,>7**=YP,]:G^&EF%.
MR["PEMFE?]^_YV6^]O"X^I"81=SWRAA!IHS)_HTA<TJ&A95,?]#II^;K$,7P
MJ>@C&9?8QA=!4I VO)^A$S<L+&YN=94_9K80,AAA?#GB,4*2-#)&PPN&%%%@
M!CIMP\+:YC!7,40+R9@H1,T@.$H%MDP@0"7Z$[/,R146EBN_9E65[01--)G)
MAH4* NGK)@P9ZB;NA H/"Y7U.C#0.1Q)I="$QHBNQJ 13;"%'($R!G;C?EI.
MIO"P3!F9Q2)O;,)OG:"%X&_'HBXG0)%\>Z<U^:<-(PE:=0H;QZ,WP3;(IS(T
M_A)#P_45)XQXN#1UUYC)I[DI8/FL_T)N]2R?Y VJ%/A)2U0GM38^E;5])^Y4
MJ<*2ZV.UD2*U=><Y^3JZA*%.[;)&'K-BI6TI\1PNV?](/<\J6UY8-7-3Y7_H
MZ2M8^4I-\KJVVV!3$;-JZ@9&MPVR64/N]++1BWM=;4NB[="_U9/N:G^E\QWW
MI9@WLP<AXR!DWVM.R?&PDK,S&:1XO\M@K0[YC*;QN53JG/.D=8?]SKKO';SS
M:%O(^3*7GA.PL]3M288"70^XKQD123PZ#C8>A.T[V^E&/I #FTYS*X]A2;!%
MKHN\))-LF<,2@7)"LF$L4139%?1 );)Y1:%,L'Z9Q9V0Y(,IL=5BM1:3TW44
M0XGY0N^"RZ15>AXS%+O6O1XU!,N4"%56N9.0_)@27KT7J4,<?>EWP5C*4ZSW
M4"Q/8C]3.,:P5%"5!/K/B4H>%I6>6FFGX_&<$9&))_419$]2'[,93.IS)S1Y
M6&C^DD\^ 27R"ZC-[$&3WSZT4>=?*+6@J1>ONZ>T-CZ5M?V#%$[BBNBHVDB@
MJBV"(OFEWCNIM?&IK.U[SREI,:"DLWJ.NLQ/PW&1*GIXY,2'R2A.V0%NC)F+
M)*7X'!).N8IP2N]EQS4$4K[D49PDAZR0M)SDZI"3C^H[%>1$I'A)WBXTI+$\
MG(Q%>DC%QTG*A(P/R?BX4 ?MG',*Z[O;C2@V,_A@==?$U'A--FSIQ;-T.(N'
M0& A2V/>0]KI+#%\#JKNMJ=S74P)"*V?JE7=D*X*2;[Y*F&4OB(_7]Y=PI]T
M5J^J9]"CT//KA>\#[ 6>R8>L^J0;\GY53E&/(5HJHK#*1XDZ' <(E*>"1C%/
M#]T22AON>\0I,Q%69D/U>(&=I*)")@F7ATP0*$]3QFGJS5 $FJ8B$3UTG!@3
M\5%KSE!B700UW8N']"FMC4]E;=^%3NN)8[3>L14*@1W,2EG*#@>'CV-1$D?B
M<&0@Z<,D L';,S*<J!-A47=XS*!=D+(C:MO"3P+B#'T<SC"4H=P_W>FDE@QG
M$S<U^N%8'C;TTH$O_52B=QP4R3;*WOZ43A_)L#YZ.WVTI]EK,JO,@E2[E0J4
M]XD2>1UO7S5YO#%AU7^0UPDK.22LS"*O:U-U!9EVP6*OCO# 23.$,J2Q.@\@
MHH[UEZ6DTV)RX-RY@66\:NR!1;+<=T>-^Z,M5[7G&_*Z#0.H@Y!B:X2<!1XA
M0'N4/3U<KQ%<'W<GV^106LYR;W\#9)9ML3Q8#I&#8FN$0$!KL4,N?T9A5>Z<
M7P\+M[M\L41Z&Z6,'%1/8ZI4?$A\L H[#C_5E[)VXDR&Q=D'6*.RQE1Y\0SC
M>:KUHEVY3#7-RPQ\T.51PR,@>(L7U%1.96C\)8:&G>HDH@SGZXXJ(TKD\!E5
M+/%C 5+)Y1(>UAM*H?KQ/A4GU618JFWW<+ -T=63W:' VC_3P;-!TE=8DJ9(
MAO58X!@!]E%S<DV&Y=I1]5&)';&'G6(L#W?;"#)E(F*I/.2"F SH3^4DF@I+
MM/^N,AHV_H)9?"I#XQ,8VO>D4WZ*GJ@HJDXJ^DYJ;7PJ:_M.=#)2#>;G_F>+
MHFI06XZ&(>,@9-]K3GFJ(>7Y?U$454A.41RF<XX!W0[XZS>*%4W&QYA^_U+3
M^UWJ!+4:^,'GBTJO86,OB<,G,C162$E:*"E[AKI3W&KP9QG'E&R5+Z(O[,\H
M0 1Y PJ!)BJ-A3A,D6!(Q6+5PVGG)Z1A/?W#@7"N5_?_AGE"&D.6IJ[;#:75
MV8OUSBH]CQG,S52NYRH_3[J9G=5V+_EE\_'<3N6=F[2!PYK[FD:7@K8F[$>X
MU4&[)=AL'QSM!S1/BV:<,2A/>8(H.P3:%T.=_E8GK9<KK*YM!UA$O44!@=H!
MYN_,$21-8M:3?E9.D*L_M4[>69?[G8@FVS%H3[(=@P:2[<IJ]/T?,SN1&X=%
M+@3EMXTW V DY^6D6$U;?Y#LX:'2#Q!8[*A?+>WL$^MET]O9-G.8+/!I=Z;.
M3#73>;."JU.]U.OE$292,]=$?VYLTAI03_-\,F^O;?=&X/TV.12_(N915Q=9
M49A6D&\R*7D-!G0UR>VK,[ZM-XI<?7=)?BC)W[-R91]-;6:U-0Z"8)F5ST3/
M9O!X=MU>/_IF#<G_R#:_:(@NV8864" Z@^=;8W?6^7;.KXIV'P<K$3_O\TR/
M3-A_ZK=%T=W"XK;Q@V2+=2I\GCUJ<J^U?9],4YFL"S7V&9HV\(,C02<6K>>!
M+48-[@*]VCVVY=GG\]D*GF;CWPZ85VU7>#UAG+OI-HJ69D/^2<-C=.- 3R\Q
M'7"U\_J4A:X>VA?=U*1-_JW?!K&]NGZ9SHA>W[;OG#FX/J;7[['K;U5Z_1[F
M"O*7.-J\E^?*W7K]5I\/6?60ES4I] P>([J,8596ZQ?EK+\T9MF^V.7>-(U9
MM!_G.@-O6@#\?6:@<[LO]@;;UQ7=_ =02P,$%     @ HH4L5CQ)5"Z%!@
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M-,9BZ^NBL]39B7G0LN=723Y+ZJ),L^]6*69"K!+U>/OPCHQ9($=S<>^.0T(
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MJ^;C4B0S42J _/]Y4=3/7U2 W>\0W?X?4$L#!!0    ( **%+%:X65H11 0
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M,*FO3XH6DZ(E5&C];B&%!4LO+!QW"SY^NW.,5E,3O[9=HN6]@F'4/^O1)R\
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MJ=$7.CE#%R5:1(JV<$>C9^)QDP28>)K;T*Y4F%R]PG1(>\+7\BX?D&#X:&<
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M@/_[0\F[Y/X74<!+6?W9OL[-_P%02P,$%     @ HH4L5FUGINZ+'P  QZ(
M !@   !X;"]W;W)K<VAE971S+W-H965T."YX;6SM/8ENW,B5OT(HWD "*+D/
M299F; .R;$\4^! L>[)(L,!6D]7=->;1PT-RY^OW'76RR;;L\3C)3@/!6,VC
MZM6[3^;Q75E]K)=2-M&G/"OJ)WO+IEG]\/!AG2QE+NJC<B4+N#,OJUPT\+-:
M/*Q7E10IO91G#R>CT>G#7*AB[^ECNG9=/7U<MDVF"GE=176;YZ):/Y-9>?=D
M;[QG+KQ3BV6#%QX^?;P2"WDCFP^KZPI^/;2KI"J71:W*(JKD_,G>Q?B'RT?X
M/#WPLY)WM?=WA">9E>5'_'&5/MD;(4 RDTF#*PCXYU9>RBS#A0",7_6:>W9+
M?-'_VZS^DLX.9YF)6EZ6V=]4VBR?[)WM1:F<BS9KWI5W?Y'Z/">X7E)F-?TW
MNN-G3T_VHJ2MFS+7+P,$N2KX7_%)X\%[X6PT\,)$OS"Y[PM3_<*4#LJ0T;&>
MBT8\?5R5=U&%3\-J^ ?AAMZ&TZ@"J7C35'!7P7O-T^>R3BJU(I26\^AMM1"%
M^J=@%!=I]*RMX8VZCMZN9$67Z\</&]@87W^8Z$V>\2:3@4W.H]=ET2SKZ$61
MRK3G_<OM[X\G6Q9X"">VQYZ88S^;;%WQ1JZ.HNDHCB:CR:0/H.VO/Y<)O#ZF
MU\=;P)E:*DQIO>FWHT+TCU=P*;IJ9%[_3Q])>,?C_AU1.?Q0KT0BG^R!]->R
MNI5[3__\I_'IZ,<^='RCQ0+D'%OD'&];_>GS%S>7[ZZNWU^]?1.]?1F]???3
MQ9NKOU_0[XLWSZ-G'VZNWKRXN8G>7K]X1Y=O^O"Q?9/Q4?1&-&TE"?\.RX1]
M4:L:KU_CX8J&Z;)!I.M*%8E:B2RZ0-VD&B7KZ"91F?P4_:7,4E4LHLLR7XEB
M'>W_^4]GD\GHQ_ V71S_&.T7@*&/\!]8V"P11U=%<G1 .S7E0C9+68&N:):1
M:NKH;EEFV3J"-V0*&GE6JU2)"@"((W@PTKOIW?4V!]$=K XPE]6JA//"FZJ(
MGLM,W G  _S]4LZJ%G0[L/GXG'8&/ A0/[^4E6K6AYWMUHBCF[*J $=E]!X
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M[L4$";ZF./P3&WCBS$WOVR2G)+8 51.ZDW6C3?FB+%-F>'!D*<$%>A-TEX(
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M:&:^8]-Y0=Q1/QC8J)02\39?I*V9X,3#NF-B.76[(0_1OO64#N#IJFP7RQY
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M!'WR<RA,<W;%NND)?8W"2K) H#4R3 TPRD-,(,G3^LD2.>==4ZH.8M^L$D7
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MO #/EPYV;2Z80?<Z\OS?4$L#!!0    ( **%+%:N]^?<$0,  "P)   9
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M^+67&5/ZNJB7 'U;^0MTX;HIR%' H0U51>HM>SA.L"O#D.%3;"ZC-L;'^,#
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M?0_F:O"V[8^X:(S?@:NMKXM^&S45=_\-E!ZP#ZA+GMWR!-8S<@%>X+F"08D
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M/ER1"SU/B].S071LNB%ACX"4R@?N3(TNVZQY#M*"X6)!*6D+6/N]\3$E4LT
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M;DJ!P]ND*PJ,9!.XCF.A9FYK"QWW7$0)CXO<?5GVPK8F8Y7UUJCUV<G:-%?
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ME(QO'^>4XN39LM@Z<=STTB<E581%(Y)U"K[4LK;; )Y,[MYF<*]%PN?+'$
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MKV=^EDQO5%'ILA!&+;\YN)Q_]>8,WZ<7_E.K715\%KB315E^Q#^^S[XYF"%
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M1)HD*M+PS4V9RD6^IUF;(BV+3//VX#L[L5)$O-+15%,XJ@+UK"O&]Q8&UPU
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MF"2]TI(Q-& 9R5]2])*,UC7A%"U.1DM>8B?>QPH)I&(B640QP9Y;;BT(LGO
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MCDY-5U=7XD=XOVW/A'-05R,.,AKP7[A7$47]D=J37C>8*?@/VY7:[B4N4F3
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MSUIRNZ,;$L^JTEB/(,^E\\))2-WHVLJ**(:[5R/4ITKFCKUTERJ5.?%L=#I
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M$O)N(N YI2/K=8P"C6A JHI%'KMXW&,@HL%MT^E=6J=P.?W511:^MF7J:F@
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M/Q3&_?C-?2CR)?]^;)H719[RVX6" PP-P/59GA?5!UJ@_@7BU?\!4$L#!!0
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MTM3)"U%H>JR!/>N3H\_@"\]MP8R360(2_@*]SP ?)?LSD#45S/#:I!]'%-B
M';R#FP?5B%6+2!-@*_6GO%X9_2JU'7E3&F%HZHGBAWS<W0BUK8&A7R4+0$'6
MHE^#]LRK[V8-$L@)1N#N%B0@R@/F!O9&GR='!Y,'S@!_9RB@&@.;%+.C(PUV
M#\":3@.(2GD1 LM+>VF2YW4W1\BS*^)BW6"ZBS+,LU75 C Q3V',L.1O%'9M
M!88.G'JDW(7FW/#F[>#W%X!S&_S^NZ*J\\Q$?(MWNW%Z[X:4VX!%9VBF.UU3
M+92W8,//;?)M57T$WM"@QKZBV3!(#X</DB'"=2.P-R%/M,F6/8GNC&9/2\0:
MN@;!O$"^@H\!;M ,HZ& .!DIR!(RD%2HY;=(G@K2'Y"E'?QL/H$X0^DQ8F4#
MLW?.QHF[!5(*\#OFVCZ>1VR6(FB&M4R,K8! %!M,#AV[_#ZM\MA*BT'#7!]O
M(33-^\]0]!]VD&?HH+0EV7@<2H7Q]RL*=+H[S&(NAIY!.,<&S:G\0?.[9M$J
MR[/Y@B)!P^DX3Q3:A.\&X(4Z)SO \E"5W 0"*+N 8 $R"6[)1058QW2)#C9.
M"6%903.BJ8$L$XQ<TLDQ(,EI/"FZ+4@E8HLY."^%GIR$0449=44^&-P<K".8
M0' +?=['AQ*'%V\5 /*5-6A-4+C$2H#O5_1OY&SHXI50RB9GCA:$V3!9P>/8
M4K!-K&\_N?,&Y6^837B'# X4"7?.3;-@4XU\?I1KXV9R %S" EWMJ)G6 QBS
M_0JJT),[_A ISCB#M46OJ-POLLU[R<GQ!/Y]\.CQG?=O?Z3+0VUBBAR"U[2?
MT@5=&6X*_6"]26#T\=$A_$OX<O3TSL^4I8H\%@@(U!^ #F;N^@'D&(>9T2QN
M=-CFWH[&A\GQ>+(Y'P8G*0^I1A3>.GXR&3]*O@)I,3Z"_[U4H8#@CB5"ST."
M9R1Q@[RGH.@K[]M;[!I0B4U0]4/CV=Z9HDK.BE9247@"AQ028:G)0BK3FC>L
MCIMJ14B%_F;R)/ 4&E@A6Q&V*%,V:LSJ:'>J3ZC\-3P-QE,D2XCF9+[&ZRAG
M\!$,FAIE-!@%A%.#B,;13],(>H-631C*WH!F_\F=_T2WQPLV%9^#.< V-E#R
M&:$V8_[>>X<=;(SR<?8!H8XF)_C,<?+HX1%^>) \/#S&#R<.U^"/4_?'!\I*
MX'VZS+7)Z.'CPSNO,/ #-GO'G CO&WC.WM'D,-F/QH7G,^R2VG0/W(-93QX=
M#F6M[DX$!93\8IF@?XHLT!MG@/YULS_W-B$3' PYP8#3,MB0N'N+M=Z"E5@1
M65"(BP66#W3L$H$A<'DU<KR&Q0H;@<[W+R;;[\I)-:FXI*,8."U*EA[/X0+)
M'(S-_S?*+<-,J;K(KM %*Q%'A,7?#3"?#1B@EM./]C4@I5/U"? %$?-V=\0A
MP0!Q>]MA1 &$6%64,_I72-/]O8DEG*B[?6.WJ;BWJ;A?*!7W;=I6%,HDH?=H
M*#47LRANTW-OTW-OTW/_Z/3<A'V:?27P-D'W-D'W_T6"KNCF'(0 9H :*&7K
MS!#'8(%4W",.8\?)&8EU #9&<M_FS2*GX[&%P5/A@DX-_AR>S8;<UFQ<6-R1
MC)>3'.,@G:4#Y"H%7KRU$L[OMM8X$SZCW$_>8YRY"&NX%$@\8;_ Z_.%4+[/
M$5_>]RJ_)*:RZ-#%ZC"%HBZ:8KK>Y N BTSJ>>ZY/FFV&+L6N^J]G74-$^AW
ML&LQK[9-JEP": ?%1(7A$&7\HFEJ*'HD1(0>EHH)%9E15TC<WO'9D,K[=G61
MVTN53SDI/EZS@5ONRF!V(CO)Z.X90;_A"N*=("R)=G%Z LX0!+;=A(CHT,D2
MHZ1F QE2O,06PB@)$'#I)<BU4"=;3]33/E>-T]Q'&TZ,/R3!_7<EM\.( 7M_
M8W>H96-4*:%D"5-GDI4<Q*GA[U%(P".UXD;.;X/R&46'-Y%[NF>L^[E$P(UD
MZ"@\CLEYJ2I8%*1P99V;!B"CO62=L/%F)1_7:P.(<VJ(XS2JU>F"?@&ODL3I
M8=OI8/PY]02WM03_BK4$S+/^#!4%7[Z:X,]42K#J#[XM)?CBI02NBN!?IX+@
MGU$W<%LS<%LS<%LS\/DU YLJ]VVY0$#N7[9B@%W8&-X>KAS R^"P"VG74=U
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MJVPCR<>\W7[FH!@/E *!SSDW^-IIM,Q=??""C&^\WV"K(!Q-27C,IKG;Y^O
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M">(:L4@L.Q+-6%/O=K0Q),0V .<@HNH97?5OMJWC5V0D#AJ#0:%(Y##A?,Z
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M_U7'+W"X<5]2%LI:E;G+-=ZAA*8->+Y4:-+5@@PTG]:N_@-02P,$%     @
MHH4L5M!%_?$+"@  (1P  !D   !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL
MU5E9;]M($G[7KVAHDH$-*+)(23YR&'"<#3; SDX03V:Q6.Q#BVQ)/2'96G;3
MLN?7[U?5S4NAY3SLRSY8YM%57>=75<VW>U-^LUNEG'C(L\*^&V^=V[T^.[/)
M5N723LU.%7BS-F4N'6[+S9G=E4JF3)1G9_%L=GZ62UV,K]_RL\_E]5M3N4P7
MZG,I;)7GLGQ\KS*S?S>.QO6#+WJS=?3@[/KM3F[4G7)?=Y]+W)TU7%*=J\)J
M4XA2K=^-;Z+7MPM:SPM^UVIO.]>"-%D9\XUN/J7OQC,22&4J<<1!XM^]NE59
M1HP@QG\"SW&S)1%VKVON'UEWZ+*25MV:[!\Z==MWX\NQ2-5:5IG[8O9_54&?
M)?%+3&;Y5^S]VOE\+)+*.I,'8DB0Z\+_EP_!#AV"R]D3!'$@B'^48!X(YJRH
MEXS5^B"=O'Y;FKTH:36XT07;AJFAC2[(BW>NQ%L-.G?]J4A,KL1O\D'9MV<.
M'.GY61*HWWOJ^ GJ*_&+*=S6BK\4J4H'Z&^/TT?Q$09G4*71)Z[U>1\?Y7BG
M=E,QGTU$/(OC(8&.DW]0"<@C)H^.B#-OS#MG?O-GS2L^:)MDQE:E$O^Z65E7
M(H+_/61RSW$QS)&R^K7=R42]&R-MK2KOU?CZYY^B\]F;(77_1\QZRB\:Y1?'
MN#\;6T>IAV6[FHHN5_';5HE;D^]D\2@(LQS^+*6Q*DN5"@>[2VN5L\)MI2/8
M(?S C1(%()+>J_4:CZPP:^%4OC,EP$RD&D]+52388Z7<7JF"B1)9EH^ZV B9
MFZKP5&$#6:0BTW*E,^TTR("P8JT+621:9M@9G!U1[JIR9ZSR!,2S9E592$Q4
MVFM(PM6+IZ2I58.:87E6I5XAH'LI>1N$FO7B@N5>EJF="#*C+).M2,!"!YD'
ME28S,W]KB9EKS?SS3Y=Q=/$&M*SIHW &?&6F_QR4;@*W%"@' 'XG$@/T3U6)
MIX3@ L)JD^J$@%CCX7ZKL!,,X(2V(C=(E4Q_4]DC>:\0A7'>C9;,P_8$&QA,
M9AF+.&2=O<9+HERI6LYT*FXLZE:R[4FWE10Y3I6 6>)!.WE)Y&Y7FEVII5.D
M;AUHT.!>9I7T]2A#082SX<\-!:$;--J A--N$#<+.S%PLE*%6FMW*M0#BC>B
M $'W0IQB U-9<B']O6AOZRCWD8TJR6P0%XKC]26O?\FA1C+F'H$5(;  ?B(@
M5G#"A)=QT.P\F^S1R]K&22\W2+K$@8=UTE7.(*+6"MY&]-?[M]L3P<L!"9^7
M:@\WP1?H.30"0SI7ZE7EY"ICWW3L5EL+9C8)^2Y%,#@$/V)IH\C$PPZ<BB$@
M/0YU47P(3,9!;T["E5I3)+>2!7 @+1^1C[62J#VUCM[VJ4XY<NL$ET2&OJ1
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M>/Y:\_ %XW:TF(J/Q_KE^KR&?V>3 .'1%4<@/$430X'1 )&8<++3Z-?K()Y
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M6)B*_U6?A _1"T^.M[QP*B^<[OO"F;QP1@MERFA95ZI5/WQ7VU56X],P&OY
MO*&W836FPEV\:6OXUL![[0\WW:31/W>Z:K,7=_#_YKNC%H;%+X]R&>*"ASC=
M,L33[+6MVGF3O:@*70R\?[G[_9/3'0,<P7K\HD[=HBY.=XYXHY?C[.QXE)T>
MGYX.$;3[]2N=P^LG]/K)#G+./(_/:+QOMI'ST\7-B__YZ<6;V^S%>_C_S1"/
M=PZ!NORL6:I<?_\ E+71]9U^ (P;9QO[E]W.=79I%TM5K;.Y:C)]I\I.M;H
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MS,3P@C%K<8/8H!$D"=^"O"PMV!?XM\8(HJ%!>7Y=@=NASR0A-#J_4AK8:OY
MWP/9H-CB_QUS=6W@]?/LVB_F!A<#$ZHZ0Y"'?F>I1=='&[H^#FIV/FELC3CF
ME5$34X+5AY%?!IB -'BAZ.&%%!\XB]>P?"#;('3L,1C-^,FWS]%@F+I >MLU
M6I$IZ!<L$1$<(%J3:V=::O(GX#.[!2YJ 1HH5K.,"%9Y7G=L0*+):.$,"L*;
MN*#PB>P_XMX:I8Y-+ S&[F2IU@0=\14W@_X$47.#*$[<"FA?N1[1FIUUCQ'Q
M1)4 375&<1FK?D(X+2RU?(ZF$KX$T?!TU:!*.*0P38C;:V):0@#] #:<2T '
MOJGUD5]+4-HV)W?0: VC@(:<' /28X.%5+P C 3$_L@ O9HUJ9'Y=LC(]& G
M&57@C^:AP"_ ](W>@D/_8>N/=["Y&N$F/^C)]&B(!/0?Y]G+E]GUFU'VJBW&
M(S1.:KT ?_&R <X5Z&?T M ^::2PO0)YG)ME=N!FPS&V(]Q=Q&R& ?B9+ 5A
M48W>TS*5([%+" 1Q:/RWZ&H'%7&+W [MGK);XOL/'Q\'1YE8QS=ZY>   -D%
MFC@V+" [_T0,!6\[Q>Y;*H^4FPCD$7(QU3C[R8%X!MD<T3BBHU?=DKVA\/MM
M)Z69>;L;0.3]JV;XQ=Q"Q B:-#-@5F4P%S*R6#BT*%LHO$FB1T=CC,LF:/M!
M95%P W07>W3SXC+=;@(2%!_X31]E@-X("N"OPF*']AX6@<X28S[PO[@(L%>F
ME%BX!EQ;J+5C+L75$()\:GL1QME?'_%W'^:FU+P86")".% #L"(6'/O"5&;1
M+1R((@ ,"P@,/R_NT,Z,-G\%HZR1+_3.H#/>(F[,!>N WI_=2H!?M9IYC%%
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M*P'>F*V+;6L!TJZ<?#[ZLJAB)Q.#4#'GM@84KJJ-CE'6>O[VG5OJ%,P'B\L
MG-%4]N;\=)JO)@F.T(YGXR[=Z+&W#RR"&R27FL@VR(4B&^I4Z-'M>@G;./K,
M! -9$AC,NU)D\,\=:!2:'SO!93,#"W-GR")B@6E3ZY,B7/#6R'F/3^$#5J*.
MQYA=]86%= 47OX\5G#X&XB58S!4V2PR(BRK^V344#S:'OT:4ZF/3+\A;><GJ
MQ9$AP(P ]SYA0P3:OE*Z"\5[ETYLB#YIR"^6'5]*?4:"<N*BH)$OI3*$L$7'
MM?2#$R?3BZYL#=AG%IN#T\/?UDD3CDC]QX:K#7;"Z=_^++[X A;OQ=K=G#U]
M_#OB[,6OJNBWN[5PH!=A>PYA>QRY9W)A=[P_VI;5:JRK)$[@QZ[5<7B*70H%
MFYVPLWOMY@%QBAM"P@@(V<@V>7?LOQ*FAOAN[9*J%+)4F:EK?6<9:[G>G(JQ
M9L09WA3I@_%-+!O3H)E!Y4+,G^P)V3M,EFEN'2*DA[U$2E[T35X5!KY),)0F
MK1"6(P] BM#RRNNXYQ.M*\I-E;KU5=2-FN9.5/B"Y7!H63-= 8@K(;Z)?<F0
M'Z$$:M/Z+$H[%Y[%-H=!%NK7")T6IK[1LV58W9U)TR!'?:R((:8C]5SVU'.3
MYBVYW(V4TK]K.G?OE*$DHDX?LY'=*ZOK!]\WL;M3:H8:C7<W!I\\WM; &^)E
M:0JE]@#8PZKE<"/JY14NIJ5_5!D8_/K\,KL-S:28>@9C#Y*R3Q&^ZC6T79>*
M./$:(@OT0:!L:N&;=GVZ1+[>DG9^;_*/V-_Q7E4M!D.7MEZ.LY<^BRS?A[!4
MT2K8A[N79 K@W0@;@ZB.OX)X$-32KBIA#^!?:5)R<QZD%,+K>_:I]I<T(KP6
MAN'4W0(_2U]9)4R,N3L*DN5#_JZ^ Z0N7G<AC!4R^^VE2;:)X,Q$PU<Z+%[D
M_!J$?Z&X-2-TB_VH)S6W-G_CFX"3YT,N-[1]<HN:>()@2Z4C#=AS"?)BI*1%
MK;%;32YVU54M-ET#V:K#3$C>(F#*NP7U10*-V#.+;HQ>^M_;TA0V=,81?4GU
M='.]C0]YKW0NG>?2R<\Z%#(,<?3.<X:T0B_ )BNJ7!.@JT1'G)EHW$-F8*I2
M2V68I0FIH1?)$"'P-CA>P'/+1TV(7U#!4)1M76#7+U9?K*K&B,HVV1NZZM[8
M<79&?9E^RX>VN]8A\!MBI&&$TN_C]" WZJYJ8V_-P Y-JFKF\CCP<Z5JX..0
M.#YVXK@E@^,%9^2<G]2K0F?I-F%8J<8W"A*:CHAN?FOY<UV?S!*0,(G]8G&X
M1Q"SL7/L#6*D=](<=DW-8:3OU](AYBU].'CAM9H[<-TX.SNW8:&!N*#8:5<:
MGG#PK6F)#['>WU"E\^0I[ZJC!#R4;R$[H[5.NYH $,+D3K+1TWNF1#_WZ.3X
M&UZS/[IQFJ6:B%9S2Q=C-D'[C=!;.;S>8$NG=WW4L;=DU#Y<=I4!;F" X+OB
M0@^W)'H"(!P 2P&HXTZOT6;PA-($2^<_I,DSV [%4V NCWM+87VF%8(-+:AI
M66T3*^Y!&19S8;+LHL-J& @/]<^^ I!^A=CTC2K;6G]"/'YP=?'NT:NK-X=\
M<,'/4&+6&*47XBZ02-@(1XG+EU)#/;$'2,U!%RJ3HQ'$DIV9@"JM53DSBM&R
M^]HV[:/+M^]?7F7-NBIJ]&D'N:7)I-,R8K5L-I]:2'QBB@<S.C%#?8\*$/'Z
M7\[-2JLG??34!OH]6J)HI_%G-^:*&GGOC.V:<LUQALK%Y\6MG&0PSL'<W4%<
MC6/4:JD!1^8-HQ7OX-TS?A&P=^=@WDJV%[TR(>_$/>5_/RVQ9T<3P$!U/A+A
MGN9(OZH(X(9<.1E(>ESQE(B/L^,S$_>2F"S([38RNDF.IVP);<@N;[PT&"Q@
M;=4NX /F#LFB../GG=Z0LPD&,89*,=%D?:[#V&CA MD(\(>> +N,7BXZ"^!\
M#=)+/A&Y.M&J;H*^2P!6XZ/#"2C*/_T90 ;&Q.'%)35Z5P@WHHS40DI9_C$:
M>(E%EC;$TZ5:[5B'"5W4 @-&44 6;T2:U9!#6_A<8Q,T)7S%,TK1=G--V6N/
M9'OSZ) 4I8GM='=^)J1D.,J0E"[H.H$W6 +":RK'PL_H?S(Y@D2A.7HTVR$_
MP<JTZS0G1DFJZ/"4*2-@0QT0!"O1[0RW8(S8\9&QLN((Z?'8XL@AIR'N<&),
MEK2)\'T/.[7@R>YX<;-2B1D:F-2/ZH)=CL?I4/7L?@K>5T9G*)@T$)TP!,99
M#S,Y#FCPF"JJXA+3?O"#=)+\>'7.K8$5Q/I%W<U<Y3 Q"N#.,CSZ[<Y@Q<5:
M=Z[G/LH/W7E#L09.5$1.!H4\R;&$^EXMBB%3WR.9AXE]N=+@%>V2C.5K$"D8
MLB+HE\3;/DQ$!GI%)$ZJ?&Y@#.^G):49X&]ZIH*Y2PV:-748N+PU"5?7R'G(
M#0Y')%^&EZ_YY=0@)DU G-J-Y<!16%O #^1@A&\2.A5FAKAH0C@?I@:#E6M*
M%C2L'15:QJ^[/B:<*5I',Z)$1RDN@ ==[@Z3NG7DIH:P UO[<E2E=WY9F HO
M.JGP6PCX,#_;9)OL(X1C[[2@#X5'@ S"8THY^L,A(*6<!"&C@0@;U0&@RYK<
M2-J8P6U2$1_X)2_./1)&#&I!D&HJW@.MNA[C0:)^-@WW1@5O[..G&,IMM@ Z
MNTF5*P2^;,":+'(4^^A:>AP4']^I0 -=:>0+:CFVB#8\/@ [;+B;Q,Y[*Q0E
MS_D]3L'S27QB-UE<61WA[BBUXEP(/;.K9\]-*];]UNCJT2N3O=( [5Y?H==9
M:%=OH.RA!4VC7FM*W-JZS]D1)?4I-4D0 &(7,"%3ER.]D_8C.3RVW_!.N\<[
M+EGXQE^R\,W.7"KG^/[+)Q:'[EC8.<+P'0M_^=/)7X^?#Z5VO])@R6(?^\4^
M_N4W2NP<8IC -V]O7V0GQQ!0]R=(;/2N*R5\^.JN+R#M]=<7J&DK8<!FOEJZ
M<3WP]26]Y-Z) D_B[7,#!:?,"?&,LPMR#%*+((VZ,QIO<)!R"\57_0L>N*VO
M;/2*NPW(IC9?2$]J55PN2%+Z:S9I&]PD%JQL5Q;<&.L-06BWR-(++8:NZMB7
MQ'%R5<3@66"Z0<'UPD5%*:F5XA1X'Q"F"X>O+8"'PDE SHR=LB.]62)]->X"
M6$BB_>'9Z=GHR9.G(9=^6\.R(;#+!7X5?L5XHQ&24MGJD0M>'F&LA.9U\ J,
M?G((G90GHI<@HC.0E^Z\/2YD.%S=\5R*=W8-R*FN)FFOD<L.[&KCP*O3&4\Z
M^I(EN[(8W-GHJ#J?Q._A,QKL;8C9 Y <*,SMH'\SM4 /IP^-4II)ND.<%&XV
M2%8:$3>0M@RW'?2#&+YA9:# 'GY*N[JW'ZE.7&+4?1CW7&TCF?+/*=,C_O6B
MV?ZNIN?)3 BWO,[%A<HAU<,6B&!_K^P"-,0%20/!4+_H=1@=6A![7H4^1KPQ
M(6R;.W.=;H+.!A:\L=#ED/ ,2]IH"ZM93?H#\^44$[H&!K8)P.B<5XN*CV88
M0BVV!/Y)LB<^*0VBE1/LX[,,Z:,%DE3(<0[# T^[LAS$PWY=F\>JJ1?\GOMZ
M)"'\5:_JV4Q6_S]<PK-Y+TVXEB:^CH9'_56NHAD/.PLUE&M,K\>1'(VT)$DY
M@[D>LI\[KCR2,G5J&7L[3]VTV=]J"UB)CF@E,H O?E!UC;MX*S6$+8YJ^V->
M()*4^)1-IW,F8('N*#%8*FG?7_& 8,IUZ5V4U[TX4RH;PC?& .V:*RO^CA<W
MAZ^"-5&E5E[>3OZ6_4M 3*HW4LP.?$IJ5+ZRX-<2L['_;FR^G2"0]W&+$H\S
MR"1W *CFRDP1$L$E>*5'L.71TDZ?Q$N#N3ZM Y0[@L\4\'9< QTXA=4OF,CQ
M6W?3RT*9TA\BHL$1U=4 &/L*%E)6N#3<+^RU4'.M?+\2J'RMN(H-^BX]5! B
M:LIK;@GAD^'B^RJ>>M0HA0L77%[YX)*,)+IR__[4&<V_PV]$ =EK+$T5'7KY
MT>/BFQ!*?- "4 13MU)%HA'DPK MEW#LFOH@6O:AW VV63;&M< /QZ.D#)K,
M&$4], 16YEQ?8A,Q03A+?CXW[+ZH1C^%6(=A(_74R7[@8>VUU!IBN,_X?X/.
M<+&?(Y$NODL+>9F_NX;N=XES^_=&)P$_OT0P"^:(=V[D4=#N>)#"7*ST*5-C
M21%1-;DF%FN7(A+[&X:@8"3"5CYD:'=N5N &-HTTKG(;-L?''+T]P)>8[ZV_
M%5$ZU##&P3-CI*$_C6_&43\BM];J(BYO2O6JU.G!<:]BYW*4%S;CTAT,HJ:3
MOUF64Q#CNJ)7MXO[(+-)7:A$*JDSJ:'[(Z<;*;8\(6!F91XD@$H-TA' O* R
MTZDS1/>'VYA-;+KIE,P^& D KQP&-8VKM\5:0\E'NH"6J) V:=8;L)%KWET:
ME"^KHB5A^ X!%I4H"ML!NM.?#-Y=IB98'QJR<2ILP,[UOU:5FGD'0Z]*$B82
MS"@#$[54<D5KXW5PW!6F06:J=C%+0Q7(EJPWYCHQ"1\R(I[K+$KWBT!A.</!
MU^#QE7WAD(C4I>B M_15>6\'W**^-EJ7P=JQ>$^LKEVHQK"B.,M]2Z0/WT):
M:Z>$Z&2-L'N+QPEL A#1U?VWN*M9?T)#@GQU!LBYCOYP@Q3Y"@5:,/(GH)O@
M7XCC<K@S5N&IJ1<^4ZRC:]BN^5$GX>?AE;=WL(7$6/:,!S]5Y+7(H36'V<'U
MY?G;"ZX/J5HGV>4)76*JEYIZK@;/?T>X>JA;B\S25!?DXO&FCYH; DJU:KQ1
MC$[VU5VIW:UG,ZFL1)>>^??Q"1\M$7KF]B W)"V*6(G"W^6XXL#C;=121@28
MY&>D8:3?9>,-&HN.+_K7!@RPN,N$ZY3N7H"CR17J#U8 PACN.E?.]A&HYG6!
M2:*T%K$,Y\8]X&->&?:TV4K)Y:)=S?T!9&E6<RUIS1UJ,07$BE1Y_X<,#55G
M-P;6HE#JZQHT#B.:&@AA]?"<E7LNA5IV/!:09"?A/7:N-.XT1O.QV3JMVX1A
M@[Z3I%',L#X)?',K*K-D!9#_1 HV8-,Q O^P7X[^I/#82C4;\7&$%D/;"5H?
MB+H0V/.!A<B ^BQ=>H^R!U!;<JZ!E61R P%BX3?;EH)?Q^(D]XQA^QB=T<3L
M<=.:!8D=94@GZ\BT42B[PB,OX7)H-P66$Q67NQ J)=YEF/@/Z.5+K"5+HC\L
MQH4_*A;5B;?>$8(;9T?-4?:BKH#!?U&+Y?/L'[#2&02XUQYZ4X7"'W7?\*,X
M)59,#6X* C#86%"B*Z-G=I1=XO%56U=&<8/@F30(2@ 1@V1O3P:BBM\RB/@\
M2,]WPXSZD'X[P>YJ0&J21_,ZD O>2 0@*AV&_R=/?RG\_WS$_Q5 ?H3-AZ2J
MA]6WX/3M'!D [<-*_"5.Y!Z(_KM#Y14VW&%BH@>[1WO@]?"$'R7>K/1QWLNT
MYUL&9D>A\"KW33#/OI7,])>C=H;=Y+[1<0BO/@MY_P&V?P'8_@-K_^I8^P^H
M_76A]FTL!PVI>2Q%:--'\-N:&QY6> )CIF;22\FKHE/!O"I)0U&%',^)4LG.
ME@3]HA7P=2+ ?[+RU/.*,,3M\0CGZ<NS<$O)01%?;,8I]YW.G],>Z)<28R G
MEGOVP">VJ>RYQ>9\SJI)'K&Y<$V+=9:HLEPU\M#U;23W?P1"7R40^D^*@SXK
M#'I+V_I:<4UI"%V=W(^NO@@&>CC0X"^PLL?WHR/G0&O\O3)) EQZY5%=7377
ME&OQ:]19<.<K__&5AKVF)LJ2H@=Q9\L\*(] 6^^N+#R,0RO@1S@R),NCIE-
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MJ@U?V%AMX-5FIUBJ%BJ@CA(]>+I&D"9P.+UT\0:F%[V]9@GF\:<]K1308JU
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M#Y7]@;;%AH;(?D+9BA8S!VEFLI@4+13N(0>5^ ]R3FU\9%/E-:U9!*VJ<MJ
M'-=)S@Z:LE "24$!=K7(\*S#*%R<K8&=2Y%]#*R&TNW;>-/0.J!^DRUS\XE$
M>F!JGB*W!?+D@]6RI- @+]PB]*V!&&2!WF-<S#9_A].#^*%(=HH[0U5(M^*
M$Y(P<,(\2]7Q2GJ)'4KB#!:.1J?5:4"KA@3^KPM5L NP((,W-\@G-8-IL85H
M1^\%X*X7"0Q(3>-VR ^7] I$7:U01YRAN('U:%(C7VZS:/V'TH,<C7H/Y7L0
MS 6L3Y"5][][YU-XRY&T=GNJT"&*1BOI$/P VK>TY"!K*UV#G(SEK[+!'PZ
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M7 #?YT+H>H(;-)>RX_\ 4$L#!!0    ( **%+%8$0RAQY0@  '<D   9
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M!1>X4*#KLF3J?8Z%W$R\T-MM//)U;NR&/QU7;(U/:'Y4"T4KOT7)>(E"<RE
MX6KBS<+1/+;VSN GQXW>FX-5LI3RV2Z^9A,OL(2PP-18!$:O5[S!HK! 1.-E
MB^FU(:WC_GR'?N^TDY8ETW@CBU\\,_G$2SS(<,7JPCS*S1?<ZKFT>*DLM!MA
MT]C&%#&MM9'EUIG6)1?-F[UM[V'/(0F..$1;A\CQ;@(YEK?,L.E8R0TH:TUH
M=N*D.F\BQX5-RI-1=,K)STP7BO*KS#LPD<'=2\TKNG$#T/W.E@7JWM@W%,7:
M^ND6<=X@1D<0PP@>I#"YACN18?81P"=Z+<=HQW$>G42\Q?0"^N$Y1$$4GL#K
MMYK[#J__'\WGL"@8B?TH_?=LJ8VBK^7/(>T-<GP8V5;02%<LQ8E'):)1O:(W
M/?L4#H+K$[SCEG=\"OU(K@ZQ/(ESF.4'<&QO(Y54?]I@!G(%)D=8R8(*F8LU
M,&WW*#E8+E&U"7( - F@RP6YR%K3CNZ-.GNF'6=IK3HWLJQJ@TK#&2NKZ[W8
MGV$X=$/GOE:"FUHAA&%BG\XWI%+,99$!+RLE7]%Z:(@3^A&DH!363=T3"3)8
MDU -@^0*!E=AY[#8<U@K2597_8B>F&)H/8)9FM9E73![!QG2A:6<.>!N& VA
M!]TD@=Y11(%61Q)<VC$>P*'/P-\KWQ+5VC4I35=?"]-4<KO;]L%94_[_S)LF
M^L#4F@L-!:[(-;@87GJ@FL;4+(RL7#-82D.MQ4USZN6HK &=KZ0TNX4-T/X[
M3/\"4$L#!!0    ( **%+%8&_M4A9@0  -L-   9    >&PO=V]R:W-H965T
M<R]S:&5E=#,Q+GAM;-576V_;-A1^]Z\@U*)K "(BJ:M3QX"3IFT>.@1-MF$8
M]D#+M$U4$EV2KI/]^AU2LN(LBI8- 8:]V(<4S^T[%QY.=DI_-6LA++JMRMJ<
M!FMK-R=A:(JUJ+@Y5AM1PY>ETA6WL-2KT&RTX O/5)4A(R0-*R[K8#KQ>U=Z
M.E%;6\I:7&EDME7%]=V9*-7N-*#!?N.+7*VMVPBGDPU?B6MA?]I<:5B%G92%
MK$1MI*J1%LO38$9/SA-WWA_X68J=.:"1\V2NU%>WN%R<!L09)$I16">!P]]W
M<2[*T@D",[ZU,H-.I6,\I/?2/WC?P9<Y-^)<E;_(A5V?!GF %F+)MZ7]HG:?
M1.N/-[!0I?&_:-><3=( %5MC5=4R@P65K)M_?MOB<,"0DR<86,O GLL0M0R1
M=[2QS+OUGEL^G6BU0]J=!FF.\-AX;O!&UBZ*UU;#5PE\=OI1J<5.EB7B]0)=
MUI;7*SDO!9H9(ZQ!;V\XK,S1)+2@S+&$12OXK!',GA \1I]5;=<&7=0+L>CA
M/Q_FIVQ 0 A>=JZRO:MG;%#BM=@<HXA@Q AC?08-L[\7!;!3STX'S(DZY",O
M+_IWR+^7IBB5V6J!?IO-C=60\+_WA:'1$O=K<4W@Q&QX(4X#J'(C]'<13-^\
MHBEYUP?!"PE[ $C< 1(/29]>-XT$J26R:X'.5;7A]=T/!ETN1&WE4KI4?(Q4
M'R;#BF;[GO4756]>Y8QF[PR2APKEO4+>A(8;QPCI9$4U%[K+*1])2)-VMTT5
M)#W'4I70,:&B9 TZU=; 87-T,OH1C!M]U,H85'"M[V2]0K.BV%;;DEMQF!D&
MHUK8T15LUQ9IUY\,>HTBAM.( $$9SC/JB#'.DO%H5GS;2@TBK"C6M2K5Z@XQ
MBL<Q00G.$XIHBDE^<*Z4!;1G8>!S1BD:,R!2"@? [0H,6/B6##='(5!""(H2
M@FA"1C?*\K('I]<H)3C+6Y-H&@,14Q"9C?8HO9#G%+-H# 2X%XWID.<Q0!,C
MFF&:IT\ZQK($,98,.)8DF&1>=8I9FCMC<IR3WK8RF(S]-?4R&?HX%5V" D'^
M)B<?,;9AXI7:0@ .@P1;VLH_N+^3_X\1>^0L>7%GQYCXW&<13M)TR-<(LS'4
M98[3^.FRH^!K]$Q?&4Z\"3$0('^@2R==ETZ>VZ4OC)65!^;#UKJ+:G:(S\7M
MQG63OO8\J*&_(NYU+1M=#V(A&ETP5C:!LJJO*&Q?S^ZM!-06PJ^":R3<_/&P
MF&8^-T9>P%LMW+3LNI==:R%0Y<>6(P<_)BQSIR(7 DQ)ZA:^#6(24;=(FD7S
M)>T6-VL!,_G2@C[(FQC',6WCO6^AJ*_5_&? _M-;SP,+@YU#[4EDH81P%N4-
M@!T9 YFF40,>D,UNVI('P#&"HSSK8&O*O;<$PH/YN1)ZY9\5<"LY4YI1NMOM
M7BXS/["']\>;9\]GKE>R-J@42V EQQF$1#=/B69AU<9/XW-E8;;WY!I>7T*[
M _!]J93=+YR"[CTW_1-02P,$%     @ HH4L5BS9$OKX P    L  !D   !X
M;"]W;W)K<VAE971S+W-H965T,S(N>&ULK59M;]LV$/[N7T&H0Y$ 0O1NV:EM
M('%:;, R&'6R81OV@9;.-E=)U$@J3OKK>Z1DQ89E(1WZQ3Z2]QSO[KFC;K+C
MXHO< BCRG&>%G%I;I<IKQY')%G(JKW@)!9ZLN<BIPJ78.+(40%,#RC/'=]VA
MDU-66+.)V5N(V817*F,%+ 2159Y3\7(+&=]-+<_:;WQFFZW2&\YL4M(-+$$]
ME@N!*Z>UDK(<"LEX002LI]:-=SV/M+Y1^)W!3A[(1$>RXOR+7OR23BU7.P09
M)$I;H/CW!'/(,FT(W?BOL6FU5VK@H;RW_LG$CK&LJ(0YS_Y@J=I.K9%%4EC3
M*E.?^>YG:.(Q#B8\D^:7[&K=8621I)**YPT8/<A94?_3YR8/!X"1>P;@-P#_
MK8"@ 00FT-HS$]8=570V$7Q'A-9&:UHPN3%HC(85FL6E$GC*$*=F=[!2Y.*!
MKC*0EQ-'H4E]X"0-_+:&^V?@8W+/"[65Y&.10MJ!G_?C/;_'@(.QM 'Y^X!N
M_5Z+2RBO2.#:Q'=]O\NA?O@=) CW#-SK<2=H\QL8>T%??N^83#(N*P'D[YN5
M5 *+]Y^N9->VPFY;NJ&O94D3F%K8L1+$$UBS]^^\H?NA*] ?9.PH[+ -.^RS
M/EO6CP+A:W++!8)9L9%ZI;9 E@G+X)DLMA3[D/S&%<BN9/3>T.W_V;O,)23A
M^/I(!>G^=,VSS.B3"U;@#J\D+5)Y>3W ,E*0KT"86L*J:!:>/5@(5B2LI!GY
MB;Q_-_(]_P-*7A#8XW$\>"QHSH5B7_&65).?(OF\*E2K>X$6HW%,+D]UF905
M+1) 3Z62KPC?]OT1 N94B!?M[A/-*FC//=>SO=@?S"LA &\JM5%\(U_Q8]L+
M(C3P*T>P I&?Z,2^[0;QX*-4#!]'=&A-F6CN.8K3B^S0=4E7Q?U(Q@ZK@U#L
M'"H;NN0)64?TZ,;5W>L>$=70HZ7(LT>8K/-$M021"]3%9^0-5.TI0K =>]XI
M5PU'9!PC%>,3JEJ*R$5HCT9>)U<U1V2,=T6C<U3M"4+)]^W@A*JC?H[:?H[>
MVL^?*J4?LGM6L+S*R8*^X$<=,_"(#[CXGO[NO?%['[O_8:P))&\"*?>!5'V!
MV&9HP <$)Q!2@D@0@M..3DPI^+\XG.!A@=.7I/A%U=M_/60LY::$H66LIYC_
M!"KTUU"7SF%AFR^2KFX?J:VK1:\"I-EV72.'6.;V$+L8Y8AXH1V'0RT/R3"T
MPS@</'"%W;"/>%TGH W\M4NZ*L8Y&#)R$!LS>^DW%5NFGC?:W7:\NS%3C?.J
M7L^&]U1L6"%)!FN$NE<QLB?J>:M>*%Z:D67%%0Y 1MSBB I"*^#YFB,7S4)?
MT Z]LV]02P,$%     @ HH4L5B>F #=U!   E@H  !D   !X;"]W;W)K<VAE
M971S+W-H965T,S,N>&ULE5;;;MLX$'WW5PS4M$@ Q1;EFYS:!I(TW<U#-T&<
M;;%8[ ,MC2TB$NDE:3O^^QU2MIP$CMM]H7B9RYGA&6J&:Z6?3(YHX;DLI!D%
MN;6+BU;+I#F6W#35 B6=S)0NN:6EGK?,0B//O%)9M.(HZK5*+F0P'OJ]>ST>
MJJ4MA,1[#699EEQOKK!0ZU' @MW&@YCGUFVTQL,%G^,$[9^+>TVK5FTE$R5*
M(Y0$C;-1<,DNKKI.W@M\%[@V+^;@(IDJ]>06M]DHB!P@+#"US@*GSPJOL2B<
M(8+Q[]9F4+MTBB_G.^M??>P4RY0;O%;%#Y'9?!0D 60XX\O"/JCU[[B-QP-,
M56'\".NM;!1 NC16E5ME0E *67WY\S8/OZ(0;Q5BC[MRY%%^X9:/AUJM03MI
MLN8F/E2O3>"$=)<RL9I.!>G9\<2J] EN98K2I0>XS."F7!1J@PA7*'$F+-P7
M7!HX?>33 LW9L&7)L5-OI5LG5Y63^!TG+(9O2MK<P(W,,'MMH$6(:]CQ#O95
M?-3B%TR;T&8AQ%',CMAKUVEH>WOM=^Q=JY)H;KAGRN7[.?C[<FJL)BK]<R@+
ME8_.81^NO"[,@J<X"JA^#.H5!N-/'U@O^GPD@DX=0>>8]?&DJBJXF\$DYYJ
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MH>E"LL.,_@&@-!OH^48(?9B8 .U_BMG?4$L#!!0    ( **%+%;!2BF_/04
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MT57B@:IO,W7'R)V[$&RDH>N%:Q9T 41E ^A]+J5I.W:"[DJY_ M02P,$%
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M>5&(994;__Y9+*Y%\1_C+^-7D>_N>;>O]-6H%C^V1DG,)C&'Q%P2\TC,)[&
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MOC0V$G.0F(O$/!#6F=FOCC/[U8\7 IN(%6VR-";I8=Y/$]YL+Y2&SO97_66
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MAH #H+*#>#XCA*\OY #E,9'S%U!+ P04    " "CA2Q6'\@Y<>!@  "J=0@
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MR^R>!5&Z+IQ?%JXO#]^"2)YC;:*:A6I55+-1S4$U%]5JJ%9'M0:J>:CFHUJ
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MC6H.JKFH5D.U.JHU4,U#-1_5 E0+4:V):BU4BU M1K4VJG50K8MJ/53KH]H
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M+-=BN8CE8I9KLUR'Y;HLUV.Y/LL-6$Z"/7@.$#P(")X$!(\"@F<!P<. X&E
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MP540G 5Q7?!HB=M=6>(VGNC\[,?";V9>OK!)KFBYTAWWR\J- #^_^W'OX4T
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M16O)V;4KJQ];N<RZ0X"JQ%":!Z7Y4%H I850&H72&)3&4333);26[$Y?9H<
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MTPMTR,?$GMK@]WW&WUYH/. $PZ.< !K  :7Y4%H I850&H72&)3&4333"70
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M(KG/407D]W=Y7JW?J 8>\N)S/9RK_P%02P,$%     @ HX4L5LP[K6#\ @
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M+.DZTW>B_ )U/@/#%XM,V5]2UKZ>0^*UTB*OP1A!SGCUI$^U#CL OW< $-2
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MV:^([*]#'UWFDUCZ;%[RJ44@D@QKTR[4$>-K21=-A*X%;E;[STBP<Y5D/%U
M-B]H-Y$P"\.%(J5CCQES-K)7^%M^_OGUL-<;G"P'F$S9/%*Q8#P-6*HL#F1<
MVQ-&/YN!<,LXR[3T!5,A>^/M>5V6"5W2\F0L,,]"FP#-)&B&YE4$3X2O8$;<
M"NU+PR>Q>!)ZGD'70#-C80P@\Q22F@5\87!M]_ $S5"@N9;6"EI:6+7T++.*
M">Y'I5(,^ N$?I(>,MPEQE4:+^@"C=0B4]J*@,7<6&8XV%Z1:I>N+S0U3.E
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MX*-*X*-6@=L=UJ/989UL;[%@GZ=7I,C$PCBDBX01GN4%;+TDBP0L \BMYG+
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MV::*BUV+[Q>"__'.)J]^?7TYY&)$9;^&\Z;WUW7OM2=ZKY.;+.7K@CCI@BT
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MHPN6EPW$[\LLX[N+TL#^0/3T/U!+ P04    " "CA2Q6Q)!!NB4$  ! %@
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MPPI@0W?+V*UP,58XF@I^0,)8:S;S8-6W:*T78:9.'I30;XG&J>@&$X&^8EH
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M=SG6/HGRI%\.%-_9H^R:*WTPMH^9OAR!, ;Z_89S=1R8!>KK5O0?4$L#!!0
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M;"A,@'Z_X5R]-,P'FEO@ZA]02P,$%     @ HX4L5E1H=0#  @  T 8  !D
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M!4!=7S$FGTZ*S:9Z-W+^/U!+ P04    " "CA2Q6,56#1U$#  #K#0  &0
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MF>C3& @3H)_/.%?/';-]K\YWX5]02P,$%     @ HX4L5F%:%WL2!@  \#8
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M)*:1F/[FE\<@AS/?',XBA[/?',XAAW-)S'O"+FO[?C&Z:JMT+S_DQ6C8\L:
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MHQZ:88=J(JI)J":CFH)J*JIIJ*:CFH%J)JI9.ZWCF5LV.J"#:BZJ>:CFHUJ
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M R^NV3E\-$ 0U414DU!-1C4%U514TU!-1S4#U4Q4LU#-1C4'U5Q4\U#-1[4
MU4)4BU M1K4$U5)4RU MI[1F^3^D#%YTIPSZY4/Q8Q,6O.QZ', .N:Q=-QOT
M>BU7SKYT#W=V04=#_5!-1C4%U514TU!-1S4#U4Q4LU#-1C4'U5Q4\U#-1[4
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M=JE'P_-034(U&=64T<MXPM>NY:/!>*BFHYJ!:B:J6:AFHYJ#:BZJ>:CFHUJ
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M@W]AJ[L3/2>V3*:\*I3-473541\Q\;W YLB"#+!>=0<=Q9VC^/L<,2DK6J2
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MOQ"4=H&9+X0I'7W'EK7AIY3^!5!+ P04    " "CA2Q6$RR)\T(*  !]>
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MX:JDV_&P5U9P=V^R>%,\//1;G&7QNGBY8I1'BWP __PECK/=FUS!_HG#L_\
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MW<^+39W%B63K?$_A,Y.2)?GA"F@(/&N@[B\8DV\G60?5UMK9_U!+ P04
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M:%-K+0/%:RYH5@?+&F1)7OV2MQK$3H#T40?8=8#=#?#V!#AU@-,-</<$N'6
M>VS H XHFVY6;2_!38@@XR&C&\0*M70K+DKZ9;3DE>1%HDP%DV\3&2?&4T'C
M%_28QY 7/89(/D-1MDKI.P"ZAQSFB4!/*<DY^C0!09*4?T;7:%KE%:)S)):
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M%9C0>G0BM.YZ#WF^J<HJ7<WK2N@<_F@\C6HAJD6H%J-:TFHO;M!W$0Q?;*!
M>Y7=O5Y>7D[M;A75K3VN3?8\<F?/AXN$'_IVLTBKYE,3OJ1EO5[^EBUT6>4K
M]P<HN/OI/=C1)!K5(E2+42U!-8%J$M44I=EU8]+J$?UARR,TF4:U$-4B5(M1
M+4$U@6H2U12EV06R]['+[O3Z39L_W7;O6MEIUHU;NO=^HOU&J!:C6H)J M4D
MJBE*L^O Y->COOGU#WVO-_KHY*I^Q/\4Z6I6KZQ]]XP+S;=1+42U"-5B5$M0
M3:":1#5%:78AF7Q[1.?;(S3?1K40U2)4BU$M036!:A+5%*79!6+R[=&I#X1^
MRXP+W<C=:OLSKN#(C O-O5$M1K4$U02J2513E&;7@<F]1^[<NYE?K<QNU+18
M-3?(>]QF%>WMA_5NPVIG(:#Q=ZM9]QP>'*D$--M&M1C5$E03J"9135&:70DF
MVQZYMVB_9>T1N-<>: :.:B&J1:@6HUJ":@+5)*HI2K,*:6PR\/$ 7GN,T>@;
MU4)4BU M1K4$U02J2513E&87B(G'Q^YX_$UK#[?=NU8.;]-]9.V!]ANA6HQJ
M":H)5).HIBC-K@,3IX_=<?K;UAYNO'<A'-[).Q@?J00T($>U&-425!.H)E%-
M49I="28@'[NW<[]E[3%TKCW<'?>N$C1(1[4(U6)42U!-H)I$-45I=B&9('T\
MHM<>:'J.:B&J1:@6HUJ":@+5)*HI2K,+Q"3LXW_C;<;==N]:&1],N8[-N-"
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M+4*U&-425!.H)E%-49I=(B87G_KP5&J*AN2H%J):A&HQJB6H)E!-HIJB-+M
M3$@^=>\=?]-4RFWWKA4T+T>U:'JXK?WE) KM,$$U@6H2U12EV05@0O"I.P3_
M?7U3U$/^>1H5Z\XW"[J5WD,=C;M1+9H>QMU!YZH![39!-8%J$M44I=D#WH3>
M4W?H;2ZYKG<?LM0YW-%(&]5"5(M:S7H'>_<J&>TW036!:A+5%*79X]W$U5/W
M3NT?^6.ZJ!Z?1GOG9X:YB=[#'0VH42V:'FX6G_J=HQW-GE%-H)I$-45I]F@W
MV?/T1/:\V_8P]^)LE57Z+[]E]_4W<E6EJ]OL>J&][83_7?-A]ME\DRZ\OQW;
M'N'NJ'=-H$$TJD73CGWCT\Z:0'-H5!.H)E%-49I=$R:'GKISZ%#?Z**IB=,+
M6C1H1K40U:+IX0>.#[O'/)HAHYI -8EJBM+L,6\RY*G[?N2[EW]OL7WYS\S+
M?[I[^?^]U#>;1?WKF^[7?C1/1K40U:(3?T9_[#WJM.B:-,;H@22H)E!-HIJB
MM%UEG)=W6E=A6J57'Y>ZN-5?]6)1UB_UFU7--]=!GW_J%?JFKAS_P^?@[/S@
MY['_0?C-S\\-<_5QG=[J;VEQFZU*;Z%O:G+POIGB%=GMW?,W5;[^=.:?>==Y
M5>7+[9=W.JU/-,T#ZM_?Y'GU]$W3P4->_-H>]M6_ %!+ P04    " "CA2Q6
MIL6F$5("  #P!   &0   'AL+W=O<FMS:&5E=',O<VAE970W,RYX;6Q]5%UO
MVC 4_2M76;6U4H>30+NM"Y%64+5*^T!%[1ZF/9CD0JPZ=F8;:*7]^%T[(6(3
ME ?BCWO./<>^U]E6FT=;(3IXJJ6RXZARKKEBS!85UMP.=(.*=I;:U-S1U*R8
M;0SR,H!JR=(XOF0U%RK*L[ V,WFFUTX*A3,#=EW7W#Q?H]3;<91$NX4[L:J<
M7V!YUO 5SM'=-S-#,]:SE*)&98568' YCCXE5]<C'Q\"'@1N[=X8O).%UH]^
M<EN.H]@+0HF%\PR</AN<H)2>B&3\[CBC/J4'[H]W[#?!.WE9<(L3+7^(TE7C
MZ'T$)2[Y6KH[O?V,G9\+SU=H:<,_;+O8.()B;9VN.S IJ(5JO_RI.X<]P'!X
M!)!V@#3H;A,%E5/N>)X9O07CHXG-#X+5@"9Q0OE+F3M#NX)P+K]#Z[A#.F8'
M>@DS@QNAUU8^PZVU:RSA1BBN"L$ES'>!%DZGZ+B0]@S>PH,H'M&\L?# E:-[
MS)@C79Z=%9V&ZU9#>D3#%(L!#)-S2.,T@?OY%$Y/SN $&-B*&[3_,C)RV-M,
M>YMI2#$\DF*B54F5=,3/.4QXXXO$PL\OA(1;VK"_#CEITXP.I_$==&4;7N X
MHA:Q:#88Y:]?)9?QQQ=,#'L3PY?8\^^F)/'F&1HT[=' GZ/'U,IM"3\$0M^?
MFSR)!TG&-@=DC'H9HQ=E?*.GPG&U$@N)P*U%*@C2<2A]2W2QE_XB]K__%;"]
M O9OP5=N5H)N0^*2D/'@'5&8MK_:B=--J.F%=M0A85C1DX3&!]#^4FNWF_@V
MZ1^Y_"]02P,$%     @ HX4L5A]W9%)\$   0N0  !D   !X;"]W;W)K<VAE
M971S+W-H965T-S0N>&ULO=U;<YM8NL;QKT)Y=LUT5\4Q1QTRB:LR%@P'15#)
MGIZ+KKG $K:9EH0'4-S9M3_\!ED61BRO@/N_TQ?=MLSZO;#P>BVDI]'[ARS_
MK;A+DE+Y?;/>%A_.[LKR_MW%1;&\2S9Q\3:[3[;53VZR?!.7U;?Y[45QGR?Q
M:C]HL[[0575TL8G3[=GE^_UC47[Y/MN5ZW2;1+E2[#:;./_VMV2=/7PXT\Z>
M'OB<WMZ5]0,7E^_OX]OD2U+^XS[*J^\NCLHJW23;(LVV2I[<?#C[J+V++*L>
ML-_BES1Y*)Y]K=2'<IUEO]7?>*L/9VJ]1\DZ698U$5?_^9I<)>MU+57[\9\#
M>G:L60]\_O63[NP/OCJ8Z[A(KK+U/]-5>??A;'*FK)*;>+<N/V</;G(XH/T.
M+K-UL?^W\G#85CU3EKNBS#:'P=4>;-+MXW_CWP\3\6R 9KXP0#\,T/L., X#
MC+X#S,, L^\ ZS# ZCM@=!@P.AU@O#!@?!@P[EMA<A@PZ3M@>A@P[3M 4Y_.
MG-I[R/%D]S[;VM/IUCKG^Z6YTIY.N-;[C&M/IUSK?<ZUIY.N]3[KVM-IU_;G
M_>)QD>Q7V"PNX\OW>?:@Y/7VE5=_L5^F^_'5PDJW=4?Y4N;53]-J7'GY.2G*
MN$RJ'E$JV8T2Y<G7--L5ZV^*5Q2[9*4XZ3;>+M-XK7QYVK!0?IHE99RNBY^5
M<^5+U>16NW52#T\W]U6+J+\J[Y(B4>+5OZN#>!Q39O6#RLW1.Q9^H\2%<M]4
MSI/[+"^KVN?*/[[,E)_^Z^?W%V5UK/4>7RP/Q_6WQ^/27SBN+\G]6\50WRBZ
MJNN"X5?RX?YN*QT^DP__%.?5<.W%X?9WJL=5=>WEZHY\^"Q9'JMK@N%N_ZD3
M#??Z3YUHN-]_ZD3#@SY3]_+P>?^I4P7#%_+A3G+]MAKZXO"P=W5M*A@>]1\^
M:0^_J-K"L3?HQ]Z@[SWC!>\JVZZJYPXO-($WRE5\7S\K*)1?Y]5(Q:M^4/Q+
MM%0?RYCB,O5SIG=%U3>2#V=5$RB2_&MR=OGG/VDC]:^BA4MB,Q*S2<PA,9?$
M/!+S22P@L3F)+4@L)+$(PEH-QC@V&$.F7_XSSO.X>N*Q3N/K=)V6WT3-XY&P
M]D1]??3ULNJL7Y]W!&F1H1V!Q&P2<[H385ACM?ZG/1\N6=4C,9_$ A*;BR;7
M%$SN@JP:DE@$8:V5;!Y7LBE=R?^=E=63@_EA':=)(5K)C\3H^1QK$VVL=R;Y
M2EILZ(HF,9O$',&$5,_<U$EW29-E/1+S22P@L7EW=G6]^H4;=]<T638DL0C"
M6FO:.JYI2[JFPWQ5/>W/ORE?[N)<O**M[A1W6^:5M,S0U4QB-HDYO2;#)4MZ
M).:36$!B\UXSNR!+AB0605AK%8^.JW@D7<4?5ZNTODJO_CQ'<;HZ3[?U=7M:
M_;D6+>A19Z8U?3+2K.ZBEE8=NJA)S"8Q1SPA^Z>&)PN;+.N1F$]B 8G-1;.K
MF[K17=QDV9#$(@AK+>[Q<7&/Y8M[N=QM=NNX?K%\EMRDR[04K>IQ9YK/#6NB
M&H*_U=)Z0Y<UB=DDY@AG1+<LP1]LLJY'8CZ)!20V%TRO/C(U?=1=V&3=D,0B
M"&LM[,EQ84]Z7$_OGWC?9>M5DA=_4>S_[-+R6_W>VWZA"]\4FP@F7I\:4\$?
M<.D.#%WI)&:3F".<$6,R[OXJNI/.:T#GVL0P1MW)\\A=]$DL(+&Y8/(T4QM-
M!'^@R;JAX$Q,JY+33MFHNZ5AF:/6T[/6 IP>%^!4N@!_29>_)?E?"N67>%O&
MMXEHL4F%H6]KD=B,Q&P2<TC,)3&/Q'P2"TAL3F(+$@M)+(*P5N_0U&/SJ(-+
M/^*=\T,=J,>@V@S5;%1S4,U%-0_5?%0+4&V.:@M4"U$MHK1VOWD6XM/^^!OI
M!Z/U:HLVTB>=*P-YL<%M@M1L5',$4V(85K7UZ:4!6M9#-1_5 E2;"R;X],(!
M+1BB6D1I[67=Y.\T:?JFW[OJ!Z/](FIUC3:VIJ?K&HW.H9J-:HY@3J:ZJ>I3
MZW1=H\DX5/-1+4"UN>B7;J*.1YW%C0;?4"VBM/;B;K)OFCS\=O+VNO)E=_WO
M9%G6.?DH*XKT>ITHGY-5LME?*@A7OM$]":JF3PUU,CI=^FA&#M5L5'-$DV),
MC8G@E7VTL(=J/JH%J#873'%GW:,Q.52+**V][INDG":/RO6(U6B"8)AIG2YI
M-"2':C:J.7VFX^_?F?5?-='K*RZZHQZJ^:@6H-J\SRGY]*I3LD!W-$2UB-+:
MK:,)Y&GR1-ZP+(\<$^^L(GS9$ WPH9I]T)Z_ :2I1O<=.X>:#1?=?P_5?%0+
M4&VN"5)\YLBR3I\YH#$^5(LHK;W\FR2?]ITH7[^TC]9-59UKNJH:QNED7\D+
M#E[9:(P/U1S1I$Q&T[%IFJ=7!6B0#]5\5 M0;2Z:X9$^'IVN;S3)AVH1I;77
M=Q/FT^1IOM>&?@ZLU5GPJM9Y:5^TJ3H>F6-#:V\Z$V]J&1-#/]G4EA_7X*4J
M*%PO574Z/5VJ@BVG$WTZGIPT.D]H&A/+-(SVEKYP2\W21I.31A&@1ST7U-4F
M8]T\73ZO*"IZ&A.B>Q]16GOE-&DY31Z7.TWK*/_[_$X6GY_N)_'KIV1SG>3B
M=]K) -,5JLU0S48U!]5<5/-0S4>U -7FJ+9 M1#5(DIK=YHF%JA-?U"R!TT/
MHMH,U6Q4<U#-134/U7Q4"U!MCFH+5 M1+:*T]AUXFB2A+DT.]4OVR(VAO035
M9JAFHYJ#:BZJ>:CFHUKP&DUT$3)'=VN!:B&J1936;B--0%"7!P1[)8GDQN V
M@J8(4<U&-0?57%3S4,U'M4#OA@,MP^R^=S-'RRY0+42UB-+:;:()'.KRP.$?
MSR3)"PSN(>S-_MB[_;&W^V/O]\?>\(^]XQ][RS]1^G5:_:/JT],NPM[1C[VE
M'WM/O_^/9*/>)!OU0<E&89L@$UU7J#9#-1O5'%1S4<U#-1_5 KT;632-R6F#
M($LN4"U$M8C2V@VBB4#J\N37L!R3'!O<*TAMAFHVJCFHYJ*:AVH^J@4'K759
MHJHC]?1_;IBC91>H%J):1&GM?M'D'O7OY![[!9_DRN!&@:8>4<U&-0?57%3S
M4,U'M4#O)AK/1^:TTR;(H@M4"U$MHK1VFVCRD;H\'_G:_)2<'=PWT$PEJMFH
MYJ":BVH>JOFH%NC=I.3^QG-JYX*$++M M1#5(DIK=XXF>:G+DY>"_-C'9Q]=
M]/G9AR1ITA29O,[@5H+>C1'5;%1S4,U%-0_5?%0+4&V.:@M4"U$MHK1VOVGR
MJOKDQZ3(=#2UBFHS5+-1S4$U%]4\5/-1+4"U.:HM4"U$M8C2VOVF2:WJ\KM9
M]DN1H8E45)NAFHUJ#JJYJ.:AFH]JP4%[?ADT'NM3O1O_0,.FJ!:B6D1I[4]C
M:\*FACQLVBLE)C>&M@E4FZ&:C6H.JKFHYJ&:CVK!0?M^FT#++E M1+6(TMIM
MH@F3&O(PZ1]/B<D+#.XA:-(4U6Q4<U#-134/U7Q4"XQNTO3\A2:"1DU1+42U
MB-+:341OFLB@J*FP2Z!94E2;H9J-:@ZJN:CFH9J/:H'1S9*>WKYBCE9<H%J(
M:A&EM?O#LX^&EH=(AV7$Y-C@5L%^HC3[D=+L9TJC>5)4\U#-1[7 Z.9)]9$^
M-8Q.OT SI:@6HEI$:>U^T61*#6D&K6]&3*X,;A2D-D,U&]4<5'-1S4,U']6"
M@W;R47CZU-3TTTY!UEV@6HAJ$:6U.T63)C7D:=+7QL3D[.#6@<9+4<U&-0?5
M7%3S4,U'M> UFO#_LD=W:X%J(:I%E-;N+$T U9 '4 ?$R'1IC$Q>9W"K01.I
MJ&:CFH-J+JIYJ.:C6H!J<U1;H%J(:A&EM?M-$ULUQC\F1F:@L554FZ&:C6H.
MJKFHYJ&:CVH!JLU1;8%J(:I%E-;N-TULU9#?9K57C$QN#.XE:"05U6Q4<U#-
M134/U7Q4"UZCB2^3T#0JJH6H%E%:NXTT:51#GD;M%S-#TZBH-D,U&]4<5'-1
MS4,U']6"UVCB-H*F55$M1+6(TEIMQ&S2JJ8\K?K'8VCR D-[#*K-4,U&-0?5
M7%3S4,U'M<#L1EFUL::IU;].W@Q"ZRY0+42UB-+:3:3)LIJ#LJS"+H&&55%M
MAFHVJCFHYJ*:AVH^J@6F(*RJC4[O9HC67*!:B&H1I;4[A-YT"'E0=5@038X-
M;A9H9A75;%1S4,U%-0_5?%0+S&YF]7P\,BQC>II$0^LN4"U$M8C2V@VC2:Z:
MWTFN]DNBR97!G0*-K**:C6H.JKFHYJ&:CVJ!V8VLGD_-L3E2.YT"S:RB6HAJ
M$:6U.T63636E2;=7)]'D[.#606HS5+-1S4$U%]4\5/-1+3AH[2N2%UZX( LO
M4"U$M8C2VKVC2;&:\A2K*&MVC)C)/^I2+@]N'VB0%=5L5'-0S44U#]5\5 M0
M;8YJ"U0+42VBM':':=*LYNC'I,M,-,V*:C-4LU'-0347U3Q4\U$M0+4YJBU0
M+42UB-+:_:9)LYKRF[#V2I?)C<&]!$VJHIJ-:@ZJN:CFH9J/:L%!^_[=A]"R
M"U0+42VBM':;:$*HICR$VBL])C<&MPDTA(IJ-JHYJ.:BFH=J/JH%!ZV5[##4
ML2GH$VC*%-5"5(LHK=TGFI2I*4^9 O$P-(**:C-4LU'-0347U3Q4\U$M,+LW
M1-6,J3%1NY^(BQ9>H%J(:A&EM;J(U81,K4$A4U&;D M#VP2JS5#-1C4'U5Q4
M\U#-1[7 ZJ9(#=,Z:1!HR06JA:@645J[030!4DL>(!T6#Y-C@WL%FB5%-1O5
M'%1S4<U#-1_5@M=HPO^K!=VM!:J%J!916KN?Z$T_^4[<M%]Z3*X,;B1HSA35
M;%1S4,U%-0_5?%0++$'.5-,U3;4ZGUJ'%EZ@6HAJ$:6U6T43-+7D0=/7QL?D
M[.#>@29/4<U&-0?57%3S4,U'M>"@69W>H8V,T]Z!1D]1+42UB-+:O:..GK8?
M:0)EECQ0]JOVKX]E]91CN0^.*8;V1M%577VCI-OE>K=*"B7>*O'M;9[<5D].
ME.Q&V=W7+Z::EOI&554E>WJEI'A\O;6\BTNE^DHIFA=>;[+\)DG+7?7H*KE/
MMM6(6R7;5MLF2O)[6=\8K=KJX2Y=WNT?VVVKKO:0IV75V_[\IXFNC?^J9%^3
M_#Q>K[/]7=64;/_RK9(6%9#DR[3.J_Q4)(FRR*J]'/W\5@FWBA]O=_6NC?;'
M5!U9C5]EF_MX^TU);FZJW:N&Q8^[KBP?K]_2_XGW='6DZEO]Z;"J0U"2N-J_
MQVVS75F4\?Y WBC5SW?KLCZFZBK0>//2S*1%L:O+;5?/AY_L]<?U^E"BWNZ^
M.B.'[S;9KKZ9W%W\-5&NDV1;52WS+%Z6Z==D_:W>A\<$8#61>7*SWL]\=;2B
M0WM;1P;CPV[7Q_G2G-_LJKUYFM_#AFF^/Q6=,Y$UTZUI3_.]S9X._B&I=N/P
M>Y"LWHI^F2^*NR0I9W$97[[?)/EM<I6LUX6RK ^\_OU]]FA]B%5GUM[]73N[
MZ#P^U]Y]$CW^T3+?1=5:$?W$JGYBU3^Y:$I?OK^/;Y-/<7Z;;@MEG=Q4NZ&^
M'5?K*4]O[X[?E-G]A[/JZN$Z*\MLL__R+HFKV:PWJ'Y^DU4G]_!-7> ARW_;
M'^KE_P%02P,$%     @ HX4L5DFTZ^[0!0  SRL  !D   !X;"]W;W)K<VAE
M971S+W-H965T-S4N>&ULM9IM;Z,X$,>_BI4[G7:EW08(D+;71MK6H*UTU57M
M[=Z+U;UP89*@!9PS3M-*]^'//!1"XKA!FKYI YGY&<\?/\S$%QLN?A9+ $F>
MLS0O+D=+*5?GXW$1+2%CQ0E?0:Z^F7.1,:DNQ6)<K 2PN'+*TK%C6?XX8TD^
MFEU4]^[$[(*O99KD<"=(L<XR)EZN(.6;RY$]>KUQGRR6LKPQGEVLV (>0'Y;
MW0EU-6XI<9)!7B0\)P+FEZ,O]GGHN*5#9?$]@4VQ]9F477GD_&=Y<1-?CJSR
MB2"%2)8(IOX]P36D:4E2S_%O QVU;9:.VY]?Z6'5>=691U; -4__3F*YO!R=
MCD@,<[9.Y3W??(6F0U[)BWA:5'_)IK:=*N-H74B>-<[J";(DK_^SYR806PZ*
MHW=P&@=GU\$]X#!I'":[#OX!![=Q<(]MP6L<O&,=_,;!KV)?!ZN*-&62S2X$
MWQ!16BM:^:&2J_)6 4[R\LUZD$)]FR@_.;O)(YX!^8L]0T$^4) L28N/Y#/Y
M]D#)AU\_7HRE:J6T'4<-\:HF.@>(9^26YW)9D""/(=;X4[._[1@ 8]6]MH_.
M:Q^O'"/Q 58G9&)](H[E.)H'NC[>W=;UQ^Q.(5+N]D'WX'AW2^,>'NUNGQEB
M.6G?ETG%F[SYOA":%%'*B[4 \N,/949N)&3%/[HWIF:Z>F8Y>9X7*Q;!Y4C-
MC@6()QC-?OO%]JW?=6IAPB@F+,"$A4BPGLINJ[)KHK^J+)7*'QXAAWDB/Q)X
M5LM9 3I]:YI7T<JU[&GV>>*[EGI?G[:5VS>S+6O7BNY;>7M&@:9%;[)G%NZ;
M.=M&O>!X;7 \8W""^1RJ];"*CV 2"EU,:H@]V6K;.K&LZ4Y,#IA9SDY4&CMK
MVVXG)@=0.Z302.I%Q&\CXALC\B"97$LN7L@<8A L;2.C"XRO:?^DG!I[<?&/
M"A\]"A8<916^9=6+S;2-S=08F^\L7;-Z$Y6J;1S+(VU0C)"A,R0FC$[WAZ/O
MN_MC+=@W=">>[>X/2J3'Z\EQVLIQ:I2C7+@B 7$B2<2$>%%[\PT3<3FY):+6
MZ068T$ED! ^5"!-&S5UVK(FG6ZTP'R%$@O4T/6LU/3-V\#;)DVR=$;E4["5/
M8[("$4$N56I$E, J XKX(D\J=?F<K-48%&JCFY.D6^=6O*@,=,H;FQ^J/":,
MGNFF+&]G8&*V&"+!>D+;5I>M6,=N3."9J7RH&K*?E. Y2V6B<AB6QTI6":IU
M:=JRF!L:*BHJC38TS[#6OVT2&DWZ\=_*%FUC_,-F??]Q"]DC".UFWXP8'%E,
M&D6E!:BT$(O6E];II'7>(;-KH%AB8](H*BU I858M+[8719O&]/'V9]JA513
M9[X@2N>BMQ72JHR:P*/2:$/K997^M$P9]W:HJ V'6+2^A%V*;IMS=(.$Q^QF
MS?3!DF+2Z!L]5QM:5SM",1\BQ*+UY>V*#+:YRK"[TI+_R+UJAHEH6<W1UW42
M<[TMNW%5-C8W6&],&D6E!:BT$(O6?PVZRHKMO\>J;*S7#!8;DT91:0$J+<2B
M]<7N2D6VN59TH#BA51BU8(1*H_9^)<BQM.LQ9K,A%JTO7E=8LLUE%LV$?9/'
M,$_R1$)_GKX#D? WIFO4:A,JC:+2 E1:B$7KOP1=)<H^>X_I&K7 A$JCJ+0
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M    >&PO=V]R:W-H965T<R]S:&5E=#<V+GAM;*U876_:,!3]*U8V39VT-A]
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M)I?O=[H%VG&!:B*J2:@FHYJ":BJJ::BFHYJ!:B:J6:AFHYJ#:BZJ>:CFHUJ
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M-::T;LRT)0SUS<'#-$VX"%I9KIIRO%61+>^:5,GRV<>G9*EW:#:/WC;I4V]
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MTNX-7N?+,IVNJNQ[VMT?I/?QT&X45!/?^&%-7M_'0VM04$U!-175-%334<U
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MH9J/:@&JA:@6H5I,:=U<:QL^+L_?;SD1+?- -1'5)%2344U!-175-%334<U
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MMU"(>M5Z_ W2"^/FV*]C,9'2!4U']51.QV;HZ8&.6E_@L(O<F,N-8#X6<R.
M87$P!9B/]<+B_$_Y]-!\+(9IZSF1'NK30WVLEPL9F0\6Q^V3Z,N=:9)$41QC
M%1V-G I&6-WB&'[<;)@V\,#B0*27U1K?;;Q#]O<!MJ?[.@3+%.]$+%.\UH"X
MZP8>2>+>;2P.>&"[@/4.Q'?'@9YR^T01["JF#7N"<21), 1ZT=VC<8Q4)X:/
M>W^PIR2*DL2- .96$$48 D\CCF *0 .&1)%Y#^Z\CX+5>RI8_P=W^ =02P,$
M%     @ HX4L5I>*NQS     $P(   L   !?<F5L<R\N<F5L<YV2N6[#, Q
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M2P$"% ,4    " "BA2Q6##BQ3^X    K @  $0              @ &O
M9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " "BA2Q6F5R<(Q &  "<)P
M$P              @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0
M   ( **%+%9M.%+.S@(  )P(   8              " @0T(  !X;"]W;W)K
M<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " "BA2Q6I!]6'S\-  "Z2
M&               @($1"P  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L!
M A0#%     @ HH4L5CQ)5"Z%!@  7S,  !@              ("!AA@  'AL
M+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( **%+%8R(?#(H0T
M )-H   8              " @4$?  !X;"]W;W)K<VAE971S+W-H965T-"YX
M;6Q02P$"% ,4    " "BA2Q6N%E:$40$  # %0  &               @($8
M+0  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ HH4L5O6G
M S9$$@  2,T  !@              ("!DC$  'AL+W=O<FMS:&5E=',O<VAE
M970V+GAM;%!+ 0(4 Q0    ( **%+%8@0?#.TA4  *:N   8
M  " @0Q$  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " "B
MA2Q6;6>F[HL?  #'H@  &               @($46@  >&PO=V]R:W-H965T
M<R]S:&5E=#@N>&UL4$L! A0#%     @ HH4L5O'3-HZI)P  A:@  !@
M         ("!U7D  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0
M   ( **%+%:SAQEWAPD  )H<   9              " @;2A  !X;"]W;W)K
M<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ HH4L5J[WY]P1 P  + D
M !D              ("!<JL  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q0
M2P$"% ,4    " "BA2Q6#U@V7>(#  #H#0  &0              @(&ZK@
M>&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( **%+%:E(,=P
MFQ   .1$   9              " @=.R  !X;"]W;W)K<VAE971S+W-H965T
M,3,N>&UL4$L! A0#%     @ HH4L5CZ+&6&W%P  U'P  !D
M ("!I<,  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " "B
MA2Q6?'!]R.$/  #12P  &0              @(&3VP  >&PO=V]R:W-H965T
M<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( **%+%:V;,@-[P(  +0&   9
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M970R,"YX;6Q02P$"% ,4    " "BA2Q6.CX->5$-  "-.   &0
M    @($3(P$ >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    (
M **%+%:>@CEHDRX  .._   9              " @9LP 0!X;"]W;W)K<VAE
M971S+W-H965T,C(N>&UL4$L! A0#%     @ HH4L5J6T0?L "   9A,  !D
M             ("!95\! 'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"
M% ,4    " "BA2Q6T$7]\0L*   A'   &0              @(&<9P$ >&PO
M=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( **%+%88E4+(A 0
M #\/   9              " @=YQ 0!X;"]W;W)K<VAE971S+W-H965T,C4N
M>&UL4$L! A0#%     @ HH4L5AAG\NA/'@  3W,  !D              ("!
MF78! 'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " "BA2Q6
M1;:GZE(P  "XX   &0              @($?E0$ >&PO=V]R:W-H965T<R]S
M:&5E=#(W+GAM;%!+ 0(4 Q0    ( **%+%99,R>UVP4  * 5   9
M      " @:C% 0!X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%
M  @ HH4L5@1#*''E"   =R0  !D              ("!NLL! 'AL+W=O<FMS
M:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " "BA2Q6^@Q[N,("   I!@
M&0              @('6U $ >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+
M 0(4 Q0    ( **%+%8&_M4A9@0  -L-   9              " @<_7 0!X
M;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ HH4L5BS9$OKX
M P    L  !D              ("!;-P! 'AL+W=O<FMS:&5E=',O<VAE970S
M,BYX;6Q02P$"% ,4    " "BA2Q6)Z8 -W4$  "6"@  &0
M@(&;X $ >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( **%
M+%;&*ZT4N 0  (H.   9              " @4?E 0!X;"]W;W)K<VAE971S
M+W-H965T,S0N>&UL4$L! A0#%     @ HH4L5F?B '"= P  7P@  !D
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M=#,Y+GAM;%!+ 0(4 Q0    ( **%+%;[WHN<J0,  '$-   9
M  " @3H1 @!X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @
MHH4L5N=+4%E;!@  ,BH  !D              ("!&A4" 'AL+W=O<FMS:&5E
M=',O<VAE970T,2YX;6Q02P$"% ,4    " "BA2Q6_^S_G7 $  !!&0  &0
M            @(&L&P( >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4
M Q0    ( **%+%:GTG*\I@L  +:2   9              " @5,@ @!X;"]W
M;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ HH4L5M:5GT#P P
M%1   !D              ("!,"P" 'AL+W=O<FMS:&5E=',O<VAE970T-"YX
M;6Q02P$"% ,4    " "BA2Q6)6 '09H#   R$@  &0              @(%7
M, ( >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( *.%+%8?
MR#EQX&   *IU"  9              " @2@T @!X;"]W;W)K<VAE971S+W-H
M965T-#8N>&UL4$L! A0#%     @ HX4L5H[(\=76%   UP ! !D
M     ("!/Y4" 'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( *.%+%;3N>KN: <  +TC   9              "
M@8ZY @!X;"]W;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @ HX4L
M5@)HWL\."@  X$H  !D              ("!+<$" 'AL+W=O<FMS:&5E=',O
M<VAE970U,RYX;6Q02P$"% ,4    " "CA2Q6ID)?%WX#   O#   &0
M        @(%RRP( >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0
M   ( *.%+%;"0#]0KP8  !P]   9              " @2?/ @!X;"]W;W)K
M<VAE971S+W-H965T-34N>&UL4$L! A0#%     @ HX4L5L200;HE!   0!8
M !D              ("!#=8" 'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q0
M2P$"% ,4    " "CA2Q6'E[/FIT#  #.$@  &0              @(%IV@(
M>&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    ( *.%+%9Q*6WX
MH0,  'H-   9              " @3W> @!X;"]W;W)K<VAE971S+W-H965T
M-3@N>&UL4$L! A0#%     @ HX4L5I^+DFN1 P  $0X  !D
M ("!%>(" 'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6Q02P$"% ,4    " "C
MA2Q65&AU , "  #0!@  &0              @('=Y0( >&PO=V]R:W-H965T
M<R]S:&5E=#8P+GAM;%!+ 0(4 Q0    ( *.%+%9B\MQQZ@,  ,X6   9
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M970V-2YX;6Q02P$"% ,4    " "CA2Q6B6J57S,]  ",4@4 &0
M    @($7_@( >&PO=V]R:W-H965T<R]S:&5E=#8V+GAM;%!+ 0(4 Q0    (
M *.%+%9'[9"@IP,  .@.   9              " @8$[ P!X;"]W;W)K<VAE
M971S+W-H965T-C<N>&UL4$L! A0#%     @ HX4L5K9RO.*2 @  H 8  !D
M             ("!7S\# 'AL+W=O<FMS:&5E=',O<VAE970V."YX;6Q02P$"
M% ,4    " "CA2Q6$RR)\T(*  !]>   &0              @($H0@, >&PO
M=V]R:W-H965T<R]S:&5E=#8Y+GAM;%!+ 0(4 Q0    ( *.%+%;YA.&]NP4
M &8K   9              " @:%, P!X;"]W;W)K<VAE971S+W-H965T-S N
M>&UL4$L! A0#%     @ HX4L5DNO,[/2!   <!<  !D              ("!
MDU(# 'AL+W=O<FMS:&5E=',O<VAE970W,2YX;6Q02P$"% ,4    " "CA2Q6
M$C>8X> 0   U\   &0              @(&<5P, >&PO=V]R:W-H965T<R]S
M:&5E=#<R+GAM;%!+ 0(4 Q0    ( *.%+%:FQ:814@(  / $   9
M      " @;-H P!X;"]W;W)K<VAE971S+W-H965T-S,N>&UL4$L! A0#%
M  @ HX4L5A]W9%)\$   0N0  !D              ("!/&L# 'AL+W=O<FMS
M:&5E=',O<VAE970W-"YX;6Q02P$"% ,4    " "CA2Q62;3K[M %  #/*P
M&0              @('O>P, >&PO=V]R:W-H965T<R]S:&5E=#<U+GAM;%!+
M 0(4 Q0    ( *.%+%;R[0[&DP,  )$2   9              " @?:! P!X
M;"]W;W)K<VAE971S+W-H965T-S8N>&UL4$L! A0#%     @ HX4L5L8/!3#9
M P  _0T  !D              ("!P(4# 'AL+W=O<FMS:&5E=',O<VAE970W
M-RYX;6Q02P$"% ,4    " "CA2Q6&<U-H$ $  !1$P  &0
M@('0B0, >&PO=V]R:W-H965T<R]S:&5E=#<X+GAM;%!+ 0(4 Q0    ( *.%
M+%:2,1?&RP(  -\(   9              " @4>. P!X;"]W;W)K<VAE971S
M+W-H965T-SDN>&UL4$L! A0#%     @ HX4L5KQ[@$BZ P  K@X  !D
M         ("!29$# 'AL+W=O<FMS:&5E=',O<VAE970X,"YX;6Q02P$"% ,4
M    " "CA2Q68M-G_B4J   23P, &0              @($ZE0, >&PO=V]R
M:W-H965T<R]S:&5E=#@Q+GAM;%!+ 0(4 Q0    ( *.%+%95T!$35@,  ,X5
M   -              "  9:_ P!X;"]S='EL97,N>&UL4$L! A0#%     @
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H0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !9 %D 9A@  -#. P    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>523</ContextCount>
  <ElementCount>605</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>123</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="d428534ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>1001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="d428534ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="d428534ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1003 - Statement - Condensed Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheetsParentheticals</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="d428534ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1004 - Statement - Unaudited Condensed Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations</Role>
      <ShortName>Unaudited Condensed Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="d428534ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1005 - Statement - Unaudited Condensed Consolidated Statements of Operations (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsParentheticals</Role>
      <ShortName>Unaudited Condensed Consolidated Statements of Operations (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="d428534ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1006 - Statement - Unaudited Condensed Consolidated Statements of Changes in Shareholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit</Role>
      <ShortName>Unaudited Condensed Consolidated Statements of Changes in Shareholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="d428534ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1007 - Statement - Unaudited Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Unaudited Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="d428534ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1008 - Disclosure - Description of Organization and Business Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperations</Role>
      <ShortName>Description of Organization and Business Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="d428534ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>1009 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="d428534ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>1010 - Disclosure - Liquidity and Going Concern</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcern</Role>
      <ShortName>Liquidity and Going Concern</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="d428534ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>1011 - Disclosure - Public Offering</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/PublicOffering</Role>
      <ShortName>Public Offering</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="d428534ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>1012 - Disclosure - Private Placement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/PrivatePlacement</Role>
      <ShortName>Private Placement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="d428534ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>1013 - Disclosure - Acquisitions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/Acquisitions</Role>
      <ShortName>Acquisitions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="d428534ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>1014 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="d428534ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>1015 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="d428534ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>1016 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/PropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="d428534ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>1017 - Disclosure - Goodwill and Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssets</Role>
      <ShortName>Goodwill and Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="d428534ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>1018 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="d428534ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>1019 - Disclosure - Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/Warrants</Role>
      <ShortName>Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="d428534ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>1020 - Disclosure - Shareholders' Deficit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/ShareholdersDeficit</Role>
      <ShortName>Shareholders' Deficit</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="d428534ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>1021 - Disclosure - Stock Incentive and Employee Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlans</Role>
      <ShortName>Stock Incentive and Employee Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="d428534ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>1022 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="d428534ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>1023 - Disclosure - Restatement of Previously Issued Financial Statements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatements</Role>
      <ShortName>Restatement of Previously Issued Financial Statements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="d428534ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>1024 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="d428534ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>1025 - Disclosure - Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/LossPerShare</Role>
      <ShortName>Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="d428534ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>1026 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="d428534ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>1027 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/AccountingPoliciesByPolicyPolicies</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="d428534ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>1028 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="d428534ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>1029 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/FairValueMeasurements</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="d428534ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>1030 - Disclosure - Property and Equipment  (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/PropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment  (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/PropertyAndEquipment</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="d428534ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>1031 - Disclosure - Goodwill and Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsTables</Role>
      <ShortName>Goodwill and Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssets</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="d428534ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>1032 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/DebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/Debt</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="d428534ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>1033 - Disclosure - Stock Incentive and Employee Benefit Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansTables</Role>
      <ShortName>Stock Incentive and Employee Benefit Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlans</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="d428534ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>1034 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="d428534ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>1035 - Disclosure - Restatement of Previously Issued Financial Statements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsTables</Role>
      <ShortName>Restatement of Previously Issued Financial Statements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatements</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="d428534ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>1036 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/IncomeTaxes</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="d428534ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>1037 - Disclosure - Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/LossPerShareTables</Role>
      <ShortName>Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/LossPerShare</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="d428534ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>1038 - Disclosure - Description of Organization and Business Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails</Role>
      <ShortName>Description of Organization and Business Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperations</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="d428534ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>1039 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="d428534ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>1040 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of ordinary shares reflected in condensed consolidated balance sheets are reconciled</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfOrdinarySharesReflectedInCondensedConsolidatedBalanceSheetsAreReconciled</Role>
      <ShortName>Summary of Significant Accounting Policies (Details) - Schedule of ordinary shares reflected in condensed consolidated balance sheets are reconciled</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="d428534ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>1041 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of reflects the calculation of basic and diluted net income (loss) per ordinary share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShare</Role>
      <ShortName>Summary of Significant Accounting Policies (Details) - Schedule of reflects the calculation of basic and diluted net income (loss) per ordinary share</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="d428534ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>1042 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of reflects the calculation of basic and diluted net income (loss) per ordinary share (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareParentheticals</Role>
      <ShortName>Summary of Significant Accounting Policies (Details) - Schedule of reflects the calculation of basic and diluted net income (loss) per ordinary share (Parentheticals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="d428534ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>1043 - Disclosure - Liquidity and Going Concern (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails</Role>
      <ShortName>Liquidity and Going Concern (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcern</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="d428534ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>1044 - Disclosure - Public Offering (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/PublicOfferingDetails</Role>
      <ShortName>Public Offering (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/PublicOffering</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="d428534ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>1045 - Disclosure - Private Placement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/PrivatePlacementDetails</Role>
      <ShortName>Private Placement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/PrivatePlacement</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="d428534ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>1046 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/RelatedPartyTransactions</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="d428534ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>1047 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="d428534ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>1048 - Disclosure - Commitments and Contingencies - Summary of Components of Lease Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesSummaryOfComponentsOfLeaseExpenseDetail</Role>
      <ShortName>Commitments and Contingencies - Summary of Components of Lease Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="d428534ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>1049 - Disclosure - Commitments and Contingencies - Summary of Maturities of Lease Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetail</Role>
      <ShortName>Commitments and Contingencies - Summary of Maturities of Lease Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="d428534ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>1050 - Disclosure - Commitments and Contingencies - Summary of Supplemental Quantitative Information Related To Leases (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesSummaryOfSupplementalQuantitativeInformationRelatedToLeasesDetail</Role>
      <ShortName>Commitments and Contingencies - Summary of Supplemental Quantitative Information Related To Leases (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="d428534ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>1051 - Disclosure - Shareholders' Deficit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/ShareholdersDeficitDetails</Role>
      <ShortName>Shareholders' Deficit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/ShareholdersDeficit</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="d428534ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>1052 - Disclosure - Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/WarrantsDetails</Role>
      <ShortName>Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/Warrants</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="d428534ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>1053 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="d428534ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>1054 - Disclosure - Fair Value Measurements  (Details) - Schedule of fair value hierarchy of the valuation inputs</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfFairValueHierarchyOfTheValuationInputs</Role>
      <ShortName>Fair Value Measurements  (Details) - Schedule of fair value hierarchy of the valuation inputs</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="d428534ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>1055 - Disclosure - Fair Value Measurements  (Details) - Schedule of changes in the fair value of warrant liabilities and conversion option liability:</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfChangesInTheFairValueOfWarrantLiabilitiesAndConversionOptionLiability</Role>
      <ShortName>Fair Value Measurements  (Details) - Schedule of changes in the fair value of warrant liabilities and conversion option liability:</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="d428534ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>1056 - Disclosure - Fair Value Measurements  (Details) - Schedule of valued using the compound option pricing model</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfValuedUsingTheCompoundOptionPricingModel</Role>
      <ShortName>Fair Value Measurements  (Details) - Schedule of valued using the compound option pricing model</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="d428534ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>1057 - Disclosure - Fair Value Measurements  (Details) - Financial assets and liabilities that are measured at fair value</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsFinancialAssetsAndLiabilitiesThatAreMeasuredAtFairValue</Role>
      <ShortName>Fair Value Measurements  (Details) - Financial assets and liabilities that are measured at fair value</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="d428534ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>1058 - Disclosure - Fair Value Measurements (Details) - Derivative liabilities measured at fair value using significant unobservable inputs</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsDerivativeLiabilitiesMeasuredAtFairValueUsingSignificantUnobservableInputs</Role>
      <ShortName>Fair Value Measurements (Details) - Derivative liabilities measured at fair value using significant unobservable inputs</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="d428534ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>1059 - Disclosure - Fair Value Measurements  (Details) - Schedule of quantitative information regarding Level 3 fair value measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements  (Details) - Schedule of quantitative information regarding Level 3 fair value measurements</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="d428534ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>1060 - Disclosure - Fair Value Measurements (Details) - Schedule of change in the fair value of conversion option liability</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfChangeInTheFairValueOfConversionOptionLiability</Role>
      <ShortName>Fair Value Measurements (Details) - Schedule of change in the fair value of conversion option liability</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="d428534ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>1061 - Disclosure - Property and Equipment (Details) - Property and equipment consisted</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/PropertyAndEquipmentDetailsPropertyAndEquipmentConsisted</Role>
      <ShortName>Property and Equipment (Details) - Property and equipment consisted</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/PropertyAndEquipmentTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="d428534ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>1062 - Disclosure - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/PropertyAndEquipmentDetails</Role>
      <ShortName>Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/PropertyAndEquipmentTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="d428534ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>1063 - Disclosure - Goodwill and Intangible Assets (Details) - Summary of the company's identifiable intangible assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfTheCompanysIdentifiableIntangibleAssets</Role>
      <ShortName>Goodwill and Intangible Assets (Details) - Summary of the company's identifiable intangible assets</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="d428534ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>1064 - Disclosure - Goodwill and Intangible Assets (Details) - Summary of estimated future amortization expense</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfEstimatedFutureAmortizationExpense</Role>
      <ShortName>Goodwill and Intangible Assets (Details) - Summary of estimated future amortization expense</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="d428534ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>1065 - Disclosure - Goodwill and Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="d428534ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>1066 - Disclosure - Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/DebtDetails</Role>
      <ShortName>Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/DebtTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="d428534ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>1067 - Disclosure - Debt (Details) - Summary of borrowings of the scilex pharma notes</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/DebtDetailsSummaryOfBorrowingsOfTheScilexPharmaNotes</Role>
      <ShortName>Debt (Details) - Summary of borrowings of the scilex pharma notes</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/DebtTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="d428534ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>1068 - Disclosure - Debt (Details)  - Summary of future minimum payments under the scilex pharma notes</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/DebtDetailsSummaryOfFutureMinimumPaymentsUnderTheScilexPharmaNotes</Role>
      <ShortName>Debt (Details)  - Summary of future minimum payments under the scilex pharma notes</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/DebtTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="d428534ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>1069 - Disclosure - Stock Incentive and Employee Benefit Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetails</Role>
      <ShortName>Stock Incentive and Employee Benefit Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="d428534ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>1070 - Disclosure - Stock Incentive and Employee Benefit Plans (Details) - Summary of share based payment award options issued to employees and nonemployees valuation assumptions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfShareBasedPaymentAwardOptionsIssuedToEmployeesAndNonemployeesValuationAssumptions</Role>
      <ShortName>Stock Incentive and Employee Benefit Plans (Details) - Summary of share based payment award options issued to employees and nonemployees valuation assumptions</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="d428534ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>1071 - Disclosure - Stock Incentive and Employee Benefit Plans (Details) - Summary of the options outstanding</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfTheOptionsOutstanding</Role>
      <ShortName>Stock Incentive and Employee Benefit Plans (Details) - Summary of the options outstanding</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="d428534ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>1072 - Disclosure - Acquisitions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/AcquisitionsDetails</Role>
      <ShortName>Acquisitions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/Acquisitions</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="d428534ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>1073 - Disclosure - Restatement of Previously Issued Financial Statements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsDetails</Role>
      <ShortName>Restatement of Previously Issued Financial Statements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="d428534ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>1074 - Disclosure - Restatement of Previously Issued Financial Statements (Details) - Schedule of impact of these adjustments to the financial statement, as previously reported</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsDetailsScheduleOfImpactOfTheseAdjustmentsToTheFinancialStatementAsPreviouslyReported</Role>
      <ShortName>Restatement of Previously Issued Financial Statements (Details) - Schedule of impact of these adjustments to the financial statement, as previously reported</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsTables</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="d428534ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>1075 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/IncomeTaxesTables</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="d428534ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>1076 - Disclosure - Income Taxes (Details) - Schedule of components of income tax expense (benefit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfComponentsOfIncomeTaxExpenseBenefit</Role>
      <ShortName>Income Taxes (Details) - Schedule of components of income tax expense (benefit)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/IncomeTaxesTables</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="d428534ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>1077 - Disclosure - Income Taxes (Details) - Schedule of deferred tax assets and liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfDeferredTaxAssetsAndLiabilities</Role>
      <ShortName>Income Taxes (Details) - Schedule of deferred tax assets and liabilities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/IncomeTaxesTables</ParentRole>
      <Position>77</Position>
    </Report>
    <Report instance="d428534ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>1078 - Disclosure - Income Taxes (Details) - Schedule of effective income tax rate reconciliation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfEffectiveIncomeTaxRateReconciliation</Role>
      <ShortName>Income Taxes (Details) - Schedule of effective income tax rate reconciliation</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/IncomeTaxesTables</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="d428534ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>1079 - Disclosure - Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/LossPerShareDetails</Role>
      <ShortName>Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/LossPerShareTables</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="d428534ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>1080 - Disclosure - Loss Per Share (Details) - Summary of reconciliation of basic and diluted loss per share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/LossPerShareDetailsSummaryOfReconciliationOfBasicAndDilutedLossPerShare</Role>
      <ShortName>Loss Per Share (Details) - Summary of reconciliation of basic and diluted loss per share</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/LossPerShareTables</ParentRole>
      <Position>80</Position>
    </Report>
    <Report instance="d428534ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>1081 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vickersvantagecorp.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vickersvantagecorp.com/role/SubsequentEvents</ParentRole>
      <Position>81</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 2 fact(s) appearing in ix:hidden were eligible for transformation: sclx:NumberOfConsecutiveTradingDaysForDeterminingTheVolumeWeightedAveragePriceOfShares, sclx:NumberOfThresholdTradingDaysPriorToDateOfNoticeToTheShareholdersForDeterminingTheVolumeWeightedAveragePriceOfShares -  d428534ds1.htm 17482</Log>
  </Logs>
  <InputFiles>
    <File doctype="S-1" original="d428534ds1.htm">d428534ds1.htm</File>
    <File>d428534dex231.htm</File>
    <File>d428534dex232.htm</File>
    <File>d428534dex233.htm</File>
    <File>d428534dex51.htm</File>
    <File>d428534dexfilingfees.htm</File>
    <File>sclx-20220930.xsd</File>
    <File>sclx-20220930_cal.xml</File>
    <File>sclx-20220930_def.xml</File>
    <File>sclx-20220930_lab.xml</File>
    <File>sclx-20220930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>g428534g00a01.jpg</File>
    <File>g428534g00a02.jpg</File>
    <File>g428534g00a03.jpg</File>
    <File>g428534g03v30.jpg</File>
    <File>g428534g04a04.jpg</File>
    <File>g428534g05a05.jpg</File>
    <File>g428534g07q47.jpg</File>
    <File>g428534g30m75.jpg</File>
    <File>g428534g42x62.jpg</File>
    <File>g428534g43v59.jpg</File>
    <File>g428534g47j55.jpg</File>
    <File>g428534g47l56.jpg</File>
    <File>g428534g56j49.jpg</File>
    <File>g428534g64p61.jpg</File>
    <File>g428534g73e11.jpg</File>
    <File>g428534g89q11.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="3">http://fasb.org/srt/2022</BaseTaxonomy>
    <BaseTaxonomy items="1944">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="9">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>119
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d428534ds1.htm": {
   "axisCustom": 10,
   "axisStandard": 37,
   "baseTaxonomies": {
    "http://fasb.org/srt/2022": 3,
    "http://fasb.org/us-gaap/2022": 1944,
    "http://xbrl.sec.gov/dei/2022": 9
   },
   "contextCount": 523,
   "dts": {
    "calculationLink": {
     "local": [
      "sclx-20220930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "sclx-20220930_def.xml"
     ]
    },
    "inline": {
     "local": [
      "d428534ds1.htm"
     ]
    },
    "labelLink": {
     "local": [
      "sclx-20220930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "sclx-20220930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "sclx-20220930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/currency/2022/currency-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/exch/2022/exch-2022.xsd",
      "https://xbrl.sec.gov/naics/2022/naics-2022.xsd",
      "https://xbrl.sec.gov/sic/2022/sic-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 938,
   "entityCount": 1,
   "hidden": {
    "http://www.vickersvantagecorp.com/20220930": 2,
    "http://xbrl.sec.gov/dei/2022": 3,
    "total": 5
   },
   "keyCustom": 187,
   "keyStandard": 418,
   "memberCustom": 73,
   "memberStandard": 44,
   "nsprefix": "sclx",
   "nsuri": "http://www.vickersvantagecorp.com/20220930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "1001 - Document - Cover Page",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.vickersvantagecorp.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sclx:LiquidityAndGoingConcernTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1010 - Disclosure - Liquidity and Going Concern",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcern",
     "shortName": "Liquidity and Going Concern",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sclx:LiquidityAndGoingConcernTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sclx:ProposedPublicOfferingTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1011 - Disclosure - Public Offering",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.vickersvantagecorp.com/role/PublicOffering",
     "shortName": "Public Offering",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sclx:ProposedPublicOfferingTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sclx:PrivatePlacementTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1012 - Disclosure - Private Placement",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.vickersvantagecorp.com/role/PrivatePlacement",
     "shortName": "Private Placement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sclx:PrivatePlacementTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1013 - Disclosure - Acquisitions",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.vickersvantagecorp.com/role/Acquisitions",
     "shortName": "Acquisitions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1014 - Disclosure - Related Party Transactions",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.vickersvantagecorp.com/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1015 - Disclosure - Fair Value Measurements",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.vickersvantagecorp.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1016 - Disclosure - Property and Equipment",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.vickersvantagecorp.com/role/PropertyAndEquipment",
     "shortName": "Property and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1017 - Disclosure - Goodwill and Intangible Assets",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssets",
     "shortName": "Goodwill and Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1018 - Disclosure - Debt",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.vickersvantagecorp.com/role/Debt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sclx:WarrantsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1019 - Disclosure - Warrants",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.vickersvantagecorp.com/role/Warrants",
     "shortName": "Warrants",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sclx:WarrantsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "PAsOn09_30_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002 - Statement - Condensed Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "PAsOn09_30_2022",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1020 - Disclosure - Shareholders' Deficit",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.vickersvantagecorp.com/role/ShareholdersDeficit",
     "shortName": "Shareholders' Deficit",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1021 - Disclosure - Stock Incentive and Employee Benefit Plans",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlans",
     "shortName": "Stock Incentive and Employee Benefit Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1022 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://www.vickersvantagecorp.com/role/CommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1023 - Disclosure - Restatement of Previously Issued Financial Statements",
     "menuCat": "Notes",
     "order": "23",
     "role": "http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatements",
     "shortName": "Restatement of Previously Issued Financial Statements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1024 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "24",
     "role": "http://www.vickersvantagecorp.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1025 - Disclosure - Loss Per Share",
     "menuCat": "Notes",
     "order": "25",
     "role": "http://www.vickersvantagecorp.com/role/LossPerShare",
     "shortName": "Loss Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1026 - Disclosure - Subsequent Events",
     "menuCat": "Notes",
     "order": "26",
     "role": "http://www.vickersvantagecorp.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1027 - Disclosure - Accounting Policies, by Policy (Policies)",
     "menuCat": "Policies",
     "order": "27",
     "role": "http://www.vickersvantagecorp.com/role/AccountingPoliciesByPolicyPolicies",
     "shortName": "Accounting Policies, by Policy (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1028 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis",
      "decimals": null,
      "lang": "en-US",
      "name": "srt:ScheduleOfCondensedBalanceSheetTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1029 - Disclosure - Fair Value Measurements (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://www.vickersvantagecorp.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003 - Statement - Condensed Consolidated Balance Sheets (Parentheticals)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheetsParentheticals",
     "shortName": "Condensed Consolidated Balance Sheets (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "PAsOn12_31_2020_CommonClassAMemberusgaapStatementClassOfStockAxis",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1030 - Disclosure - Property and Equipment  (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://www.vickersvantagecorp.com/role/PropertyAndEquipmentTables",
     "shortName": "Property and Equipment  (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1031 - Disclosure - Goodwill and Intangible Assets (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsTables",
     "shortName": "Goodwill and Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1032 - Disclosure - Debt (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://www.vickersvantagecorp.com/role/DebtTables",
     "shortName": "Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1033 - Disclosure - Stock Incentive and Employee Benefit Plans (Tables)",
     "menuCat": "Tables",
     "order": "33",
     "role": "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansTables",
     "shortName": "Stock Incentive and Employee Benefit Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1034 - Disclosure - Commitments and Contingencies (Tables)",
     "menuCat": "Tables",
     "order": "34",
     "role": "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ScheduleOfCondensedFinancialStatementsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1035 - Disclosure - Restatement of Previously Issued Financial Statements (Tables)",
     "menuCat": "Tables",
     "order": "35",
     "role": "http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsTables",
     "shortName": "Restatement of Previously Issued Financial Statements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ScheduleOfCondensedFinancialStatementsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1036 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "36",
     "role": "http://www.vickersvantagecorp.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1037 - Disclosure - Loss Per Share (Tables)",
     "menuCat": "Tables",
     "order": "37",
     "role": "http://www.vickersvantagecorp.com/role/LossPerShareTables",
     "shortName": "Loss Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": null
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P02_01_2019To02_28_2019",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityIncorporationStateCountryCode",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1038 - Disclosure - Description of Organization and Business Operations (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails",
     "shortName": "Description of Organization and Business Operations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P02_01_2019To02_28_2019",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityIncorporationStateCountryCode",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ProvisionForDoubtfulAccounts",
       "us-gaap:ProvisionForDoubtfulAccounts",
       "div",
       "div",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProvisionForDoubtfulAccounts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1039 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetails",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ProvisionForDoubtfulAccounts",
       "us-gaap:ProvisionForDoubtfulAccounts",
       "div",
       "div",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProvisionForDoubtfulAccounts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004 - Statement - Unaudited Condensed Consolidated Statements of Operations",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations",
     "shortName": "Unaudited Condensed Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "srt:ScheduleOfCondensedBalanceSheetTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "sclx:GrossProceeds",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1040 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of ordinary shares reflected in condensed consolidated balance sheets are reconciled",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfOrdinarySharesReflectedInCondensedConsolidatedBalanceSheetsAreReconciled",
     "shortName": "Summary of Significant Accounting Policies (Details) - Schedule of ordinary shares reflected in condensed consolidated balance sheets are reconciled",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "srt:ScheduleOfCondensedBalanceSheetTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021_VickersVantageMemberdeiLegalEntityAxis",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "sclx:GrossProceeds",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EarningsPerShareBasic",
      "reportCount": 1,
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1041 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of reflects the calculation of basic and diluted net income (loss) per ordinary share",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShare",
     "shortName": "Summary of Significant Accounting Policies (Details) - Schedule of reflects the calculation of basic and diluted net income (loss) per ordinary share",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P07_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:TemporaryEquityNetIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding",
      "reportCount": 1,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1042 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of reflects the calculation of basic and diluted net income (loss) per ordinary share (Parentheticals)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareParentheticals",
     "shortName": "Summary of Significant Accounting Policies (Details) - Schedule of reflects the calculation of basic and diluted net income (loss) per ordinary share (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "sclx:LiquidityAndGoingConcernTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "PAsOn09_30_2022",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "sclx:NetWorkingCapital",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1043 - Disclosure - Liquidity and Going Concern (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails",
     "shortName": "Liquidity and Going Concern (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "sclx:LiquidityAndGoingConcernTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "PAsOn09_30_2022",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "sclx:NetWorkingCapital",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "sclx:ProposedPublicOfferingTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "sclx:PurchasePricePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1044 - Disclosure - Public Offering (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.vickersvantagecorp.com/role/PublicOfferingDetails",
     "shortName": "Public Offering (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "sclx:ProposedPublicOfferingTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "sclx:PurchasePricePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "reportCount": 1,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1045 - Disclosure - Private Placement (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.vickersvantagecorp.com/role/PrivatePlacementDetails",
     "shortName": "Private Placement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "sclx:PrivatePlacementTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "PAsOn09_30_2022_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2019To12_31_2019",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodValueAcquisitions",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1046 - Disclosure - Related Party Transactions (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails",
     "shortName": "Related Party Transactions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": "-5",
      "lang": null,
      "name": "sclx:PaymentToAcquireInventory",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockSharesAuthorized",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1047 - Disclosure - Commitments and Contingencies (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": "-5",
      "lang": null,
      "name": "sclx:SellingGeneralAndAdministrativeExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1048 - Disclosure - Commitments and Contingencies - Summary of Components of Lease Expense (Detail)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesSummaryOfComponentsOfLeaseExpenseDetail",
     "shortName": "Commitments and Contingencies - Summary of Components of Lease Expense (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "PAsOn09_30_2022",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1049 - Disclosure - Commitments and Contingencies - Summary of Maturities of Lease Liabilities (Detail)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetail",
     "shortName": "Commitments and Contingencies - Summary of Maturities of Lease Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "PAsOn09_30_2022",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding",
      "reportCount": 1,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005 - Statement - Unaudited Condensed Consolidated Statements of Operations (Parentheticals)",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsParentheticals",
     "shortName": "Unaudited Condensed Consolidated Statements of Operations (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "sclx:ScheduleOfSupplementalQuantitativeInformationRelatedToLeasesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "sclx:OperatingCashFlowsFromOperatingLeases",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1050 - Disclosure - Commitments and Contingencies - Summary of Supplemental Quantitative Information Related To Leases (Detail)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesSummaryOfSupplementalQuantitativeInformationRelatedToLeasesDetail",
     "shortName": "Commitments and Contingencies - Summary of Supplemental Quantitative Information Related To Leases (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "sclx:ScheduleOfSupplementalQuantitativeInformationRelatedToLeasesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "sclx:OperatingCashFlowsFromOperatingLeases",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "PAsOn09_30_2022",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1051 - Disclosure - Shareholders' Deficit (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.vickersvantagecorp.com/role/ShareholdersDeficitDetails",
     "shortName": "Shareholders' Deficit (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "sclx:WarrantsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sclx:PublicWarrantsRedemptionDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1052 - Disclosure - Warrants (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.vickersvantagecorp.com/role/WarrantsDetails",
     "shortName": "Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "sclx:WarrantsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sclx:PublicWarrantsRedemptionDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2021To09_30_2021",
      "decimals": "1",
      "first": true,
      "lang": null,
      "name": "us-gaap:DerivativeLossOnDerivative",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1053 - Disclosure - Fair Value Measurements (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetails",
     "shortName": "Fair Value Measurements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2021To09_30_2021",
      "decimals": "1",
      "first": true,
      "lang": null,
      "name": "us-gaap:DerivativeLossOnDerivative",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherLiabilitiesNoncurrent",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1054 - Disclosure - Fair Value Measurements  (Details) - Schedule of fair value hierarchy of the valuation inputs",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfFairValueHierarchyOfTheValuationInputs",
     "shortName": "Fair Value Measurements  (Details) - Schedule of fair value hierarchy of the valuation inputs",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_VickersVantageMemberdeiLegalEntityAxis",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:InterestIncomeSecuritiesUSTreasury",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DerivativeLiabilities",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1055 - Disclosure - Fair Value Measurements  (Details) - Schedule of changes in the fair value of warrant liabilities and conversion option liability:",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfChangesInTheFairValueOfWarrantLiabilitiesAndConversionOptionLiability",
     "shortName": "Fair Value Measurements  (Details) - Schedule of changes in the fair value of warrant liabilities and conversion option liability:",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2021To03_31_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_VickersVantageMemberdeiLegalEntityAxis",
      "decimals": "0",
      "lang": null,
      "name": "sclx:InitialMeasurementOne",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
      "reportCount": 1,
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1056 - Disclosure - Fair Value Measurements  (Details) - Schedule of valued using the compound option pricing model",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfValuedUsingTheCompoundOptionPricingModel",
     "shortName": "Fair Value Measurements  (Details) - Schedule of valued using the compound option pricing model",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022_VickersVantageMemberdeiLegalEntityAxis",
      "decimals": "4",
      "lang": null,
      "name": "sclx:UnderlyingWarrantValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "PAsOn09_30_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1057 - Disclosure - Fair Value Measurements  (Details) - Financial assets and liabilities that are measured at fair value",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsFinancialAssetsAndLiabilitiesThatAreMeasuredAtFairValue",
     "shortName": "Fair Value Measurements  (Details) - Financial assets and liabilities that are measured at fair value",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "PAsOn09_30_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "PAsOn12_31_2021_DerivativeFinancialInstrumentsLiabilitiesMemberusgaapFairValueByLiabilityClassAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1058 - Disclosure - Fair Value Measurements (Details) - Derivative liabilities measured at fair value using significant unobservable inputs",
     "menuCat": "Details",
     "order": "58",
     "role": "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsDerivativeLiabilitiesMeasuredAtFairValueUsingSignificantUnobservableInputs",
     "shortName": "Fair Value Measurements (Details) - Derivative liabilities measured at fair value using significant unobservable inputs",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2020To12_31_2020_DerivativeFinancialInstrumentsLiabilitiesMemberusgaapFairValueByLiabilityClassAxis",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2020To12_31_2020",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1059 - Disclosure - Fair Value Measurements  (Details) - Schedule of quantitative information regarding Level 3 fair value measurements",
     "menuCat": "Details",
     "order": "59",
     "role": "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurements",
     "shortName": "Fair Value Measurements  (Details) - Schedule of quantitative information regarding Level 3 fair value measurements",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueConcentrationOfRiskTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "PAsOn09_30_2022_VickersVantageMemberdeiLegalEntityAxis",
      "decimals": "2",
      "lang": null,
      "name": "us-gaap:SharePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "PAsOn12_31_2018",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006 - Statement - Unaudited Condensed Consolidated Statements of Changes in Shareholders' Equity (Deficit)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit",
     "shortName": "Unaudited Condensed Consolidated Statements of Changes in Shareholders' Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "PAsOn12_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis",
      "decimals": null,
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueNetAssetLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "true"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1060 - Disclosure - Fair Value Measurements (Details) - Schedule of change in the fair value of conversion option liability",
     "menuCat": "Details",
     "order": "60",
     "role": "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfChangeInTheFairValueOfConversionOptionLiability",
     "shortName": "Fair Value Measurements (Details) - Schedule of change in the fair value of conversion option liability",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "PAsOn12_31_2020_VickersVantageMemberdeiLegalEntityAxis",
      "decimals": null,
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueNetAssetLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "true"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1061 - Disclosure - Property and Equipment (Details) - Property and equipment consisted",
     "menuCat": "Details",
     "order": "61",
     "role": "http://www.vickersvantagecorp.com/role/PropertyAndEquipmentDetailsPropertyAndEquipmentConsisted",
     "shortName": "Property and Equipment (Details) - Property and equipment consisted",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertySubjectToOrAvailableForOperatingLeaseGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1062 - Disclosure - Property and Equipment (Details)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://www.vickersvantagecorp.com/role/PropertyAndEquipmentDetails",
     "shortName": "Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertySubjectToOrAvailableForOperatingLeaseGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "PAsOn09_30_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1063 - Disclosure - Goodwill and Intangible Assets (Details) - Summary of the company's identifiable intangible assets",
     "menuCat": "Details",
     "order": "63",
     "role": "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfTheCompanysIdentifiableIntangibleAssets",
     "shortName": "Goodwill and Intangible Assets (Details) - Summary of the company's identifiable intangible assets",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "PAsOn09_30_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "PAsOn09_30_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1064 - Disclosure - Goodwill and Intangible Assets (Details) - Summary of estimated future amortization expense",
     "menuCat": "Details",
     "order": "64",
     "role": "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfEstimatedFutureAmortizationExpense",
     "shortName": "Goodwill and Intangible Assets (Details) - Summary of estimated future amortization expense",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "PAsOn09_30_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "PAsOn09_30_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1065 - Disclosure - Goodwill and Intangible Assets (Details)",
     "menuCat": "Details",
     "order": "65",
     "role": "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetails",
     "shortName": "Goodwill and Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:GoodwillImpairmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentRepurchaseAmount",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1066 - Disclosure - Debt (Details)",
     "menuCat": "Details",
     "order": "66",
     "role": "http://www.vickersvantagecorp.com/role/DebtDetails",
     "shortName": "Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P06_02_2022To06_02_2022_SorrentoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:ProceedsFromRelatedPartyDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "PAsOn09_30_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtCurrent",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1067 - Disclosure - Debt (Details) - Summary of borrowings of the scilex pharma notes",
     "menuCat": "Details",
     "order": "67",
     "role": "http://www.vickersvantagecorp.com/role/DebtDetailsSummaryOfBorrowingsOfTheScilexPharmaNotes",
     "shortName": "Debt (Details) - Summary of borrowings of the scilex pharma notes",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "PAsOn09_30_2022_ScilexPharmaNotesMemberusgaapDebtInstrumentAxis",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "sclx:ScheduleOfFutureMinimumPaymentsOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "sclx:LongtermDebtfutureMinimumPaymentYearOne",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1068 - Disclosure - Debt (Details)  - Summary of future minimum payments under the scilex pharma notes",
     "menuCat": "Details",
     "order": "68",
     "role": "http://www.vickersvantagecorp.com/role/DebtDetailsSummaryOfFutureMinimumPaymentsUnderTheScilexPharmaNotes",
     "shortName": "Debt (Details)  - Summary of future minimum payments under the scilex pharma notes",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "sclx:ScheduleOfFutureMinimumPaymentsOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "sclx:LongtermDebtfutureMinimumPaymentYearOne",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "sclx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1069 - Disclosure - Stock Incentive and Employee Benefit Plans (Details)",
     "menuCat": "Details",
     "order": "69",
     "role": "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetails",
     "shortName": "Stock Incentive and Employee Benefit Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "sclx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1007 - Statement - Unaudited Condensed Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows",
     "shortName": "Unaudited Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1070 - Disclosure - Stock Incentive and Employee Benefit Plans (Details) - Summary of share based payment award options issued to employees and nonemployees valuation assumptions",
     "menuCat": "Details",
     "order": "70",
     "role": "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfShareBasedPaymentAwardOptionsIssuedToEmployeesAndNonemployeesValuationAssumptions",
     "shortName": "Stock Incentive and Employee Benefit Plans (Details) - Summary of share based payment award options issued to employees and nonemployees valuation assumptions",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1071 - Disclosure - Stock Incentive and Employee Benefit Plans (Details) - Summary of the options outstanding",
     "menuCat": "Details",
     "order": "71",
     "role": "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfTheOptionsOutstanding",
     "shortName": "Stock Incentive and Employee Benefit Plans (Details) - Summary of the options outstanding",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P03_01_2019To03_31_2019",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sclx:PeriodDuringWhichShareTransferIsRestricted",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1072 - Disclosure - Acquisitions (Details)",
     "menuCat": "Details",
     "order": "72",
     "role": "http://www.vickersvantagecorp.com/role/AcquisitionsDetails",
     "shortName": "Acquisitions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P03_01_2019To03_31_2019",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sclx:PeriodDuringWhichShareTransferIsRestricted",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockRedemptionPricePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1073 - Disclosure - Restatement of Previously Issued Financial Statements (Details)",
     "menuCat": "Details",
     "order": "73",
     "role": "http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsDetails",
     "shortName": "Restatement of Previously Issued Financial Statements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "PAsOn12_31_2021_VickersVantageMemberdeiLegalEntityAxis",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockRedemptionPricePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "PAsOn09_30_2022",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DerivativeLiabilities",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1074 - Disclosure - Restatement of Previously Issued Financial Statements (Details) - Schedule of impact of these adjustments to the financial statement, as previously reported",
     "menuCat": "Details",
     "order": "74",
     "role": "http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsDetailsScheduleOfImpactOfTheseAdjustmentsToTheFinancialStatementAsPreviouslyReported",
     "shortName": "Restatement of Previously Issued Financial Statements (Details) - Schedule of impact of these adjustments to the financial statement, as previously reported",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "srt:ScheduleOfCondensedFinancialStatementsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "PAsOn01_11_2021_ScenarioPreviouslyReportedMembersrtRestatementAxis_VickersVantageMemberdeiLegalEntityAxis",
      "decimals": null,
      "lang": null,
      "name": "us-gaap:DerivativeLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "true"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": "-2",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1075 - Disclosure - Income Taxes (Details)",
     "menuCat": "Details",
     "order": "75",
     "role": "http://www.vickersvantagecorp.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "lang": "en-US",
      "name": "sclx:TaxCreditCarryforwardExpirationYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1076 - Disclosure - Income Taxes (Details) - Schedule of components of income tax expense (benefit)",
     "menuCat": "Details",
     "order": "76",
     "role": "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfComponentsOfIncomeTaxExpenseBenefit",
     "shortName": "Income Taxes (Details) - Schedule of components of income tax expense (benefit)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "sclx:DeferredTaxAssetsInterestExpenseLimitations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1077 - Disclosure - Income Taxes (Details) - Schedule of deferred tax assets and liabilities",
     "menuCat": "Details",
     "order": "77",
     "role": "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfDeferredTaxAssetsAndLiabilities",
     "shortName": "Income Taxes (Details) - Schedule of deferred tax assets and liabilities",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "sclx:DeferredTaxAssetsInterestExpenseLimitations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1078 - Disclosure - Income Taxes (Details) - Schedule of effective income tax rate reconciliation",
     "menuCat": "Details",
     "order": "78",
     "role": "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfEffectiveIncomeTaxRateReconciliation",
     "shortName": "Income Taxes (Details) - Schedule of effective income tax rate reconciliation",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": "3",
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1079 - Disclosure - Loss Per Share (Details)",
     "menuCat": "Details",
     "order": "79",
     "role": "http://www.vickersvantagecorp.com/role/LossPerShareDetails",
     "shortName": "Loss Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1008 - Disclosure - Description of Organization and Business Operations",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperations",
     "shortName": "Description of Organization and Business Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1080 - Disclosure - Loss Per Share (Details) - Summary of reconciliation of basic and diluted loss per share",
     "menuCat": "Details",
     "order": "80",
     "role": "http://www.vickersvantagecorp.com/role/LossPerShareDetailsSummaryOfReconciliationOfBasicAndDilutedLossPerShare",
     "shortName": "Loss Per Share (Details) - Summary of reconciliation of basic and diluted loss per share",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2022To09_30_2022",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentRepurchaseAmount",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1081 - Disclosure - Subsequent Events (Details)",
     "menuCat": "Details",
     "order": "81",
     "role": "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2022To01_10_2022_VickersVantageMemberdeiLegalEntityAxis",
      "decimals": "0",
      "lang": null,
      "name": "sclx:SponsorLoan",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1009 - Disclosure - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d428534ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 123,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r689"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AccountingPoliciesByPolicyPolicies",
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingencies",
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails",
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheetsParentheticals",
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperations",
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurements",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetails",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfChangeInTheFairValueOfConversionOptionLiability",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfChangesInTheFairValueOfWarrantLiabilitiesAndConversionOptionLiability",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfFairValueHierarchyOfTheValuationInputs",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurements",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfValuedUsingTheCompoundOptionPricingModel",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsTables",
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails",
      "http://www.vickersvantagecorp.com/role/PrivatePlacement",
      "http://www.vickersvantagecorp.com/role/PrivatePlacementDetails",
      "http://www.vickersvantagecorp.com/role/PublicOffering",
      "http://www.vickersvantagecorp.com/role/PublicOfferingDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactions",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails",
      "http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatements",
      "http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsDetails",
      "http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsDetailsScheduleOfImpactOfTheseAdjustmentsToTheFinancialStatementAsPreviouslyReported",
      "http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsTables",
      "http://www.vickersvantagecorp.com/role/ShareholdersDeficit",
      "http://www.vickersvantagecorp.com/role/ShareholdersDeficitDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEvents",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails",
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPolicies",
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetails",
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfOrdinarySharesReflectedInCondensedConsolidatedBalanceSheetsAreReconciled",
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShare",
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareParentheticals",
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesTables",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsParentheticals",
      "http://www.vickersvantagecorp.com/role/Warrants",
      "http://www.vickersvantagecorp.com/role/WarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r689"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r690"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r689"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Company place of incorporation"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r689"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r689"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AccountingPoliciesByPolicyPolicies",
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingencies",
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails",
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheetsParentheticals",
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperations",
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurements",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetails",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfChangeInTheFairValueOfConversionOptionLiability",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfChangesInTheFairValueOfWarrantLiabilitiesAndConversionOptionLiability",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfFairValueHierarchyOfTheValuationInputs",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurements",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfValuedUsingTheCompoundOptionPricingModel",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsTables",
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails",
      "http://www.vickersvantagecorp.com/role/PrivatePlacement",
      "http://www.vickersvantagecorp.com/role/PrivatePlacementDetails",
      "http://www.vickersvantagecorp.com/role/PublicOffering",
      "http://www.vickersvantagecorp.com/role/PublicOfferingDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactions",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails",
      "http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatements",
      "http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsDetails",
      "http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsDetailsScheduleOfImpactOfTheseAdjustmentsToTheFinancialStatementAsPreviouslyReported",
      "http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsTables",
      "http://www.vickersvantagecorp.com/role/ShareholdersDeficit",
      "http://www.vickersvantagecorp.com/role/ShareholdersDeficitDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEvents",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails",
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPolicies",
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetails",
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfOrdinarySharesReflectedInCondensedConsolidatedBalanceSheetsAreReconciled",
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShare",
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareParentheticals",
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesTables",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsParentheticals",
      "http://www.vickersvantagecorp.com/role/Warrants",
      "http://www.vickersvantagecorp.com/role/WarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_AardvarkMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aardvark.",
        "label": "Aardvark [Member]"
       }
      }
     },
     "localname": "AardvarkMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_AccountsReceivableRevolvingLoanFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts receivable revolving loan facility.",
        "label": "Accounts receivable revolving loan facility [Member]"
       }
      }
     },
     "localname": "AccountsReceivableRevolvingLoanFacilityMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_AccretionOfCarryingValueToRedemptionValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accretion Of Carrying Value To Redemption Value",
        "terseLabel": "Accretion of carrying value to redemption value"
       }
      }
     },
     "localname": "AccretionOfCarryingValueToRedemptionValue",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfOrdinarySharesReflectedInCondensedConsolidatedBalanceSheetsAreReconciled"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_AccruedInterest": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued interest.",
        "label": "Accrued Interest",
        "terseLabel": "Accrued interest"
       }
      }
     },
     "localname": "AccruedInterest",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_AccruedPayroll": {
     "auth_ref": [],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 24.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued payroll",
        "label": "Accrued payroll",
        "terseLabel": "Accrued payroll"
       }
      }
     },
     "localname": "AccruedPayroll",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_AcquiredinprocessresearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquired\u00a0in-process\u00a0research and development",
        "label": "Acquiredinprocessresearch and development",
        "terseLabel": "Acquired\u00a0in-process\u00a0research and development"
       }
      }
     },
     "localname": "AcquiredinprocessresearchAndDevelopment",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_AcquistionCostsIncurredButNotPaidIncludedInAccountsPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquistion costs incurred but not paid included in accounts payable.",
        "label": "Acquistion Costs Incurred But Not Paid Included In Accounts Payable",
        "terseLabel": "Semnur acquisition costs incurred but not paid in accounts payable"
       }
      }
     },
     "localname": "AcquistionCostsIncurredButNotPaidIncludedInAccountsPayable",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_AdditionalPrincipalAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional principal amount.",
        "label": "Additional Principal Amount",
        "terseLabel": "Additional principal amount"
       }
      }
     },
     "localname": "AdditionalPrincipalAmount",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_AdjustmentsRestatement2Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments restatement 2.",
        "label": "Adjustments Restatement 2 [Member]",
        "terseLabel": "Adjustments Restatement 2 [Member]"
       }
      }
     },
     "localname": "AdjustmentsRestatement2Member",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsDetailsScheduleOfImpactOfTheseAdjustmentsToTheFinancialStatementAsPreviouslyReported"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_AdjustmentsToAdditionalPaidInCapitalDiscountAmortization": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to additional paid in capital discount amortization.",
        "label": "Adjustments To Additional Paid In Capital Discount Amortization",
        "terseLabel": "Aardvark SP-104 discount amortization"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalDiscountAmortization",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_AdjustmentsToAdditionalPaidInCapitalNetOfDiscount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to additional paid in capital net of discount.",
        "label": "Adjustments To Additional Paid In Capital Net Of Discount",
        "terseLabel": "Aardvark SP-104 license transfer from Sorrento, net of discount"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalNetOfDiscount",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_AdjustmentsToAdditionalPaidInCapitalSharesIssuedInSemnurAcquisition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments To Additional Paid In Capital shares issued in Semnur Acquisition",
        "label": "Adjustments To Additional Paid In Capital shares issued in Semnur Acquisition",
        "terseLabel": "Adjustment to shares issued in Semnur Acquisition"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharesIssuedInSemnurAcquisition",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_AdvancesFromRelatedParty": {
     "auth_ref": [],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 42.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Advances from related party.",
        "label": "Advances From Related Party",
        "terseLabel": "Advances from related party"
       }
      }
     },
     "localname": "AdvancesFromRelatedParty",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_AggregateOutstandingAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate outstanding amount.",
        "label": "Aggregate Outstanding Amount",
        "terseLabel": "Aggregate Outstanding Amount"
       }
      }
     },
     "localname": "AggregateOutstandingAmount",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_AggregatePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate Percentage.",
        "label": "Aggregate Percentage",
        "terseLabel": "Aggregate percentage"
       }
      }
     },
     "localname": "AggregatePercentage",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sclx_AggregatePrincipalAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate Principal Amount.",
        "label": "Aggregate Principal Amount",
        "terseLabel": "Aggregate principal amount"
       }
      }
     },
     "localname": "AggregatePrincipalAmount",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_AgreementAutomaticRenewalPeriodOnExpirationOfInitialTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement automatic renewal period on expiration of initial term.",
        "label": "Agreement Automatic Renewal Period On Expiration Of Initial Term",
        "terseLabel": "Agreement automatic renewal period on expiration of initial term"
       }
      }
     },
     "localname": "AgreementAutomaticRenewalPeriodOnExpirationOfInitialTerm",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sclx_AgreementAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement.",
        "label": "Agreement [Axis]"
       }
      }
     },
     "localname": "AgreementAxis",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails",
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_AgreementDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement.",
        "label": "Agreement [Domain]"
       }
      }
     },
     "localname": "AgreementDomain",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails",
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_AgreementExpirationDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement expiration date.",
        "label": "Agreement Expiration Date",
        "terseLabel": "Agreement expiration date"
       }
      }
     },
     "localname": "AgreementExpirationDate",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "sclx_AgreementExpirationTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement expiration term.",
        "label": "Agreement Expiration Term",
        "terseLabel": "Agreement expiration term"
       }
      }
     },
     "localname": "AgreementExpirationTerm",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sclx_AgreementWithCertainOfTheThirdPartyProfessionalServiceProvidersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement with certain of the third party professional service providers.",
        "label": "Agreement With Certain Of The Third Party Professional Service Providers [Member]"
       }
      }
     },
     "localname": "AgreementWithCertainOfTheThirdPartyProfessionalServiceProvidersMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_AmendmentAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment.",
        "label": "Amendment [Axis]"
       }
      }
     },
     "localname": "AmendmentAxis",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_AmendmentDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment.",
        "label": "Amendment [Domain]"
       }
      }
     },
     "localname": "AmendmentDomain",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_AmendmentNoFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment no four.",
        "label": "Amendment No Four [Member]"
       }
      }
     },
     "localname": "AmendmentNoFourMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_AmendmentToTwoThousandNineteenStockOptionPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to two thousand nineteen stock option plan.",
        "label": "Amendment to two thousand nineteen Stock Option Plan [Member]",
        "terseLabel": "Amendment to 2019 Stock Option Plan [Member]"
       }
      }
     },
     "localname": "AmendmentToTwoThousandNineteenStockOptionPlanMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_AmountDistributionToAcquireRelatedContingentAcceleratedRepaymentNotes": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount distribution to acquire related contingent accelerated repayment notes.",
        "label": "Amount Distribution To Acquire Related Contingent Accelerated Repayment Notes",
        "terseLabel": "Amount distribution to acquire related contingent accelerated repayment notes"
       }
      }
     },
     "localname": "AmountDistributionToAcquireRelatedContingentAcceleratedRepaymentNotes",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_ApprovalBasedMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Approval Based Milestone [Member]"
       }
      }
     },
     "localname": "ApprovalBasedMilestoneMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_AprilOptionalRepurchaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "April optional repurchase.",
        "label": "April Optional Repurchase [Member]"
       }
      }
     },
     "localname": "AprilOptionalRepurchaseMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_AsRestatedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "As restated.",
        "label": "As Restated [Member]",
        "terseLabel": "As Restated [Member]"
       }
      }
     },
     "localname": "AsRestatedMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails",
      "http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsDetailsScheduleOfImpactOfTheseAdjustmentsToTheFinancialStatementAsPreviouslyReported"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_AssembledWorkforceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assembled Workforce [Member]",
        "terseLabel": "Assembled workforce"
       }
      }
     },
     "localname": "AssembledWorkforceMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetails",
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfTheCompanysIdentifiableIntangibleAssets"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_AssetAcquisitionPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition price per share.",
        "label": "Asset Acquisition Price Per Share",
        "terseLabel": "Asset acquisition price per share"
       }
      }
     },
     "localname": "AssetAcquisitionPricePerShare",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "sclx_B.RileyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "B. Riley.",
        "label": "B. Riley [Member]"
       }
      }
     },
     "localname": "B.RileyMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_BalanceInTheTrustAccount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Balance in the trust account.",
        "label": "Balance In The Trust Account",
        "terseLabel": "Balance in the trust account (in Dollars)"
       }
      }
     },
     "localname": "BalanceInTheTrustAccount",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_BusinessCombinationRedeemPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business combination redeem percentage.",
        "label": "Business Combination Redeem Percentage",
        "terseLabel": "Business combination redeem percentage"
       }
      }
     },
     "localname": "BusinessCombinationRedeemPercentage",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sclx_CapitalRaisingDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Raising Description",
        "terseLabel": "Capital raising, description"
       }
      }
     },
     "localname": "CapitalRaisingDescription",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/WarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_CapitalizationOfShareOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capitalization of share outstanding.",
        "label": "Capitalization Of Share Outstanding",
        "terseLabel": "Capitalization of share outstanding (in Shares)"
       }
      }
     },
     "localname": "CapitalizationOfShareOutstanding",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sclx_ChangeInFairValueOfConversionOptionLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 40.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of change in fair value of conversion option liability.",
        "label": "Change In Fair Value Of Conversion Option Liability",
        "terseLabel": "Change in fair value of conversion option liability"
       }
      }
     },
     "localname": "ChangeInFairValueOfConversionOptionLiability",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_ChangeInFairValueOfWarrantLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": {
       "order": 14.0,
       "parentTag": "us-gaap_OtherOperatingIncomeExpenseNet",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in fair value of warrant liability.",
        "label": "Change In Fair Value Of Warrant Liability",
        "negatedLabel": "Change in fair value of warrants"
       }
      }
     },
     "localname": "ChangeInFairValueOfWarrantLiability",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_ChangeInValuationInputsOrOtherAssumptions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in valuation inputs or other assumptions.",
        "label": "Change In Valuation Inputs Or Other Assumptions",
        "terseLabel": "Change in valuation inputs or other assumptions"
       }
      }
     },
     "localname": "ChangeInValuationInputsOrOtherAssumptions",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfChangesInTheFairValueOfWarrantLiabilitiesAndConversionOptionLiability"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_ClassificationOfCostAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of cost.",
        "label": "Classification of cost [Axis]"
       }
      }
     },
     "localname": "ClassificationOfCostAxis",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_ClassificationOfCostDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of cost.",
        "label": "Classification of cost [Domain]"
       }
      }
     },
     "localname": "ClassificationOfCostDomain",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_CoPaymentAssistancePolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Co payment assistance.",
        "label": "Co Payment Assistance [Policy Text Block]",
        "terseLabel": "Co-Payment Assistance"
       }
      }
     },
     "localname": "CoPaymentAssistancePolicyTextBlock",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AccountingPoliciesByPolicyPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sclx_CommitmentsandContingenciesDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies (Details) [Line Items]"
       }
      }
     },
     "localname": "CommitmentsandContingenciesDetailsLineItems",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingencies",
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_CommitmentsandContingenciesDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies (Details) [Table]"
       }
      }
     },
     "localname": "CommitmentsandContingenciesDetailsTable",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingencies",
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_CommonStockAggregateValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock with an aggregate value.",
        "label": "Common Stock Aggregate Value",
        "terseLabel": "Common stock aggregate value (in Dollars)"
       }
      }
     },
     "localname": "CommonStockAggregateValue",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_CommonStockValueToBeExchanged": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock value to be exchanged.",
        "label": "Common Stock Value To Be Exchanged",
        "terseLabel": "Common stock value to be exchanged"
       }
      }
     },
     "localname": "CommonStockValueToBeExchanged",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_CompensationAndEmployeeBenefitPlansAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Compensation and employee benefit plans.",
        "label": "Compensation And Employee Benefit Plans [Abstract]"
       }
      }
     },
     "localname": "CompensationAndEmployeeBenefitPlansAbstract",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "xbrltype": "stringItemType"
    },
    "sclx_CompensationAndEmployeeBenefitPlansLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Compensation and employee benefit plans.",
        "label": "Compensation And Employee Benefit Plans [Line Items]"
       }
      }
     },
     "localname": "CompensationAndEmployeeBenefitPlansLineItems",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_CompensationAndEmployeeBenefitPlansTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Compensation and employee benefit plans.",
        "label": "Compensation And Employee Benefit Plans [Table]"
       }
      }
     },
     "localname": "CompensationAndEmployeeBenefitPlansTable",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_ContributionAndLoanAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contribution and loan agreement.",
        "label": "Contribution And Loan Agreement [Member]"
       }
      }
     },
     "localname": "ContributionAndLoanAgreementMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_ConversionOptionLiabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion Option Liability Member",
        "terseLabel": "Conversion Option Liability [Member]"
       }
      }
     },
     "localname": "ConversionOptionLiabilityMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfChangesInTheFairValueOfWarrantLiabilitiesAndConversionOptionLiability"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_ConvertiblePromisoryNoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Promisory Note Member",
        "terseLabel": "Convertible Promissory Note [Member]"
       }
      }
     },
     "localname": "ConvertiblePromisoryNoteMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_ConvertiblePromissoryNote": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible promissory note.",
        "label": "Convertible Promissory Note"
       }
      }
     },
     "localname": "ConvertiblePromissoryNote",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_CoronavirusAidReliefAndEconomicSecurityActMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Coronavirus aid, relief, and economic security act.",
        "label": "Coronavirus Aid, Relief, and Economic Security Act [Member]"
       }
      }
     },
     "localname": "CoronavirusAidReliefAndEconomicSecurityActMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_CumulativeSalesRelatedContingencyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cumulative sales related contingency.",
        "label": "Cumulative Sales Related Contingency [Member]"
       }
      }
     },
     "localname": "CumulativeSalesRelatedContingencyMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_DebtExchangeAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt exchange agreement.",
        "label": "Debt Exchange Agreement [Member]"
       }
      }
     },
     "localname": "DebtExchangeAgreementMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_DebtInstrumentPercentageOfPrincipalAmountRepurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument, percentage of principal amount repurchased.",
        "label": "Debt Instrument, Percentage of Principal Amount Repurchased",
        "terseLabel": "Debt instrument, percentage of principal amount repurchased"
       }
      }
     },
     "localname": "DebtInstrumentPercentageOfPrincipalAmountRepurchased",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sclx_DebtInstrumentRepurchaseObligation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument Repurchase Obligation",
        "label": "Debt Instrument Repurchase Obligation",
        "terseLabel": "Debt instrument repurchase obligation"
       }
      }
     },
     "localname": "DebtInstrumentRepurchaseObligation",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_DebtInstrumentTerminationDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument, termination date.",
        "label": "Debt Instrument, termination Date",
        "terseLabel": "Debt instrument, termination date"
       }
      }
     },
     "localname": "DebtInstrumentTerminationDate",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "sclx_DebtInstrumentredemptionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument,redemption period.",
        "label": "Debt Instrument,Redemption period",
        "terseLabel": "Debt instrument,redemption period"
       }
      }
     },
     "localname": "DebtInstrumentredemptionPeriod",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sclx_DecemberOptionalRepurchaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "December optional repurchase.",
        "label": "December Optional Repurchase [Member]"
       }
      }
     },
     "localname": "DecemberOptionalRepurchaseMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_DeferredConsideration": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "deferred consideration",
        "label": "Deferred Consideration",
        "terseLabel": "Deferred consideration"
       }
      }
     },
     "localname": "DeferredConsideration",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_DeferredTaxAssetsInterestExpenseLimitations": {
     "auth_ref": [],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfDeferredTaxAssetsAndLiabilities": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets interest expense limitations.",
        "label": "Deferred Tax Assets Interest expense limitations",
        "terseLabel": "Interest expense limitations"
       }
      }
     },
     "localname": "DeferredTaxAssetsInterestExpenseLimitations",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfDeferredTaxAssetsAndLiabilities"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_DeferredTaxAssetsOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfDeferredTaxAssetsAndLiabilities": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets operating lease liabilities.",
        "label": "Deferred Tax Assets Operating Lease Liabilities",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLeaseLiabilities",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfDeferredTaxAssetsAndLiabilities"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_DeferredUnderwritingCommission": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Underwriting Commission.",
        "label": "Deferred Underwriting Commission",
        "terseLabel": "Deferred underwriting commission percentage"
       }
      }
     },
     "localname": "DeferredUnderwritingCommission",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sclx_DeferredUnderwritingCommissionPayable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Underwriting Commission Payable.",
        "label": "Deferred Underwriting Commission Payable",
        "terseLabel": "Underwriting commission payable percentage"
       }
      }
     },
     "localname": "DeferredUnderwritingCommissionPayable",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sclx_DeferredUnderwritingFeePayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Underwriting Fees means the amount of deferred underwriting fees held in the Trust Account in connection with SPAC's initial public offering payable to the underwriters upon consummation of a business combination.",
        "label": "Deferred Underwriting Fee Payable",
        "terseLabel": "Deferred underwriting fee payable"
       }
      }
     },
     "localname": "DeferredUnderwritingFeePayable",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_DeferredUnderwritingFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred underwriting fees.",
        "label": "Deferred Underwriting Fees",
        "terseLabel": "Deferred underwriting fees"
       }
      }
     },
     "localname": "DeferredUnderwritingFees",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_DenominatorAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Denominator Abstract",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "DenominatorAbstract",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShare"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_DepositIntoTheTrustAccountPerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deposit into the trust account per share.",
        "label": "Deposit Into The Trust Account Per Share",
        "terseLabel": "Deposit into the trust account per share (in Dollars per share)"
       }
      }
     },
     "localname": "DepositIntoTheTrustAccountPerShare",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "sclx_DepositedInTrustAccount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deposited in trust account",
        "label": "Deposited In Trust Account",
        "terseLabel": "Trust account"
       }
      }
     },
     "localname": "DepositedInTrustAccount",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_Depositintotrustaccount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deposit Into Trust Account.",
        "label": "DepositIntoTrustAccount",
        "terseLabel": "Deposit into trust account"
       }
      }
     },
     "localname": "Depositintotrustaccount",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_DerivativeLiabilityNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 39.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative liability, noncurrent.",
        "label": "Derivative Liability Noncurrent",
        "terseLabel": "Derivative liabilities"
       }
      }
     },
     "localname": "DerivativeLiabilityNoncurrent",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_DescriptionOfOrganizationAndBusinessOperationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of Organization and Business Operations [Line Items]"
       }
      }
     },
     "localname": "DescriptionOfOrganizationAndBusinessOperationsLineItems",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_DescriptionofOrganizationandBusinessOperationsDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of Organization and Business Operations (Details) [Line Items]"
       }
      }
     },
     "localname": "DescriptionofOrganizationandBusinessOperationsDetailsLineItems",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_DescriptionofOrganizationandBusinessOperationsDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of Organization and Business Operations (Details) [Table]"
       }
      }
     },
     "localname": "DescriptionofOrganizationandBusinessOperationsDetailsTable",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_DescriptionofOrganizationandBusinessOperationsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of Organization and Business Operations [Table]"
       }
      }
     },
     "localname": "DescriptionofOrganizationandBusinessOperationsTable",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_DueOnOrAfterFebruaryTwoThousandAndThirtyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due on or after february two thousand and thirty.",
        "label": "Due On Or After February Two Thousand And Thirty [Member]"
       }
      }
     },
     "localname": "DueOnOrAfterFebruaryTwoThousandAndThirtyMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_EffectiveIncomeTaxRateReconciliationDebtDiscountAndInterestLimitation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation debt discount and interest limitation.",
        "label": "Effective Income Tax Rate Reconciliation Debt Discount and Interest Limitation",
        "terseLabel": "Debt discount and interest limitation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationDebtDiscountAndInterestLimitation",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfEffectiveIncomeTaxRateReconciliation"
     ],
     "xbrltype": "percentItemType"
    },
    "sclx_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustmentsAndCarryback": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation return to provision adjustments and carryback.",
        "label": "Effective Income Tax Rate Reconciliation Return to Provision Adjustments and Carryback",
        "terseLabel": "Return to provision adjustments and carryback"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustmentsAndCarryback",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfEffectiveIncomeTaxRateReconciliation"
     ],
     "xbrltype": "percentItemType"
    },
    "sclx_EventAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event.",
        "label": "Event [Axis]"
       }
      }
     },
     "localname": "EventAxis",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails",
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_EventDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event.",
        "label": "Event [Domain]"
       }
      }
     },
     "localname": "EventDomain",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails",
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_EventTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event type.",
        "label": "Event Type [Axis]"
       }
      }
     },
     "localname": "EventTypeAxis",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_EventTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event type.",
        "label": "Event Type [Domain]"
       }
      }
     },
     "localname": "EventTypeDomain",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_ExclusiveDistributionAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exclusive distribution agreement.",
        "label": "Exclusive Distribution Agreement [Member]"
       }
      }
     },
     "localname": "ExclusiveDistributionAgreementMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_FairValueMeasurementStrikePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Strike price.",
        "label": "Fair Value Measurement Strike Price",
        "terseLabel": "Strike price"
       }
      }
     },
     "localname": "FairValueMeasurementStrikePrice",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurements"
     ],
     "xbrltype": "perShareItemType"
    },
    "sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements (Details) - Schedule of changes in the fair value of warrant liabilities and conversion option liability: [Line Items]"
       }
      }
     },
     "localname": "FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityLineItems",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfChangesInTheFairValueOfWarrantLiabilitiesAndConversionOptionLiability"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements (Details) - Schedule of changes in the fair value of warrant liabilities and conversion option liability: [Table]"
       }
      }
     },
     "localname": "FairValueMeasurementsDetailsScheduleofchangesinthefairvalueofwarrantliabilitiesandconversionoptionliabilityTable",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfChangesInTheFairValueOfWarrantLiabilitiesAndConversionOptionLiability"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_FairValueMeasurementsDetailsScheduleoffairvaluehierarchyofthevaluationinputsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements (Details) - Schedule of fair value hierarchy of the valuation inputs [Line Items]"
       }
      }
     },
     "localname": "FairValueMeasurementsDetailsScheduleoffairvaluehierarchyofthevaluationinputsLineItems",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfFairValueHierarchyOfTheValuationInputs"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_FairValueMeasurementsDetailsScheduleoffairvaluehierarchyofthevaluationinputsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements (Details) - Schedule of fair value hierarchy of the valuation inputs [Table]"
       }
      }
     },
     "localname": "FairValueMeasurementsDetailsScheduleoffairvaluehierarchyofthevaluationinputsTable",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfFairValueHierarchyOfTheValuationInputs"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_FairValueOfWarrantsinDollars": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Of Warrantsin Dollars",
        "terseLabel": "Fair value of warrants"
       }
      }
     },
     "localname": "FairValueOfWarrantsinDollars",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurements"
     ],
     "xbrltype": "perShareItemType"
    },
    "sclx_FebruaryOptionalRepurchaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "February optional repurchase.",
        "label": "February Optional Repurchase [Member]"
       }
      }
     },
     "localname": "FebruaryOptionalRepurchaseMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfEstimatedFutureAmortizationExpense": {
       "order": 8.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite lived intangible assets amortization expense after year four.",
        "label": "Finite Lived Intangible Assets Amortization Expense After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfEstimatedFutureAmortizationExpense"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_FormationCostPaidThroughAdvancesFromAffiliateOfSponsor": {
     "auth_ref": [],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 52.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Formation cost paid through advances from affiliate of Sponsor.",
        "label": "Formation Cost Paid Through Advances From Affiliate Of Sponsor",
        "terseLabel": "Formation cost paid through advances from affiliate of Sponsor"
       }
      }
     },
     "localname": "FormationCostPaidThroughAdvancesFromAffiliateOfSponsor",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_FounderSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Founder Shares Member",
        "terseLabel": "Founder Shares [Member]"
       }
      }
     },
     "localname": "FounderSharesMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_Foundershares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Founder Shares.",
        "label": "FounderShares",
        "terseLabel": "Founder shares (in Shares)"
       }
      }
     },
     "localname": "Foundershares",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sclx_FourHundredAndOneKPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Four hundred and one (k) Plan .",
        "label": "Four hundred and one (k) Plan [Member]",
        "terseLabel": "401(k) Plan [Member]"
       }
      }
     },
     "localname": "FourHundredAndOneKPlanMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_FundingCommitmentLetterMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funding commitment letter.",
        "label": "Funding Commitment Letter [Member]"
       }
      }
     },
     "localname": "FundingCommitmentLetterMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_GainLossOnDerivative": {
     "auth_ref": [],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": {
       "order": 10.0,
       "parentTag": "us-gaap_OtherOperatingIncomeExpenseNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (Loss) on derivative.",
        "label": "Gain (Loss) on Derivative",
        "verboseLabel": "Gain on derivative liability"
       }
      }
     },
     "localname": "GainLossOnDerivative",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_GainLossOnExtinguishmentOfDebtt": {
     "auth_ref": [],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": {
       "order": 11.0,
       "parentTag": "us-gaap_OtherOperatingIncomeExpenseNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (Loss) on extinguishment of debtt.",
        "label": "Gain (Loss) on Extinguishment of Debtt",
        "terseLabel": "(Gain) loss on debt extinguishment, net"
       }
      }
     },
     "localname": "GainLossOnExtinguishmentOfDebtt",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_GrossProceeds": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross Proceeds",
        "terseLabel": "Gross proceeds"
       }
      }
     },
     "localname": "GrossProceeds",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfOrdinarySharesReflectedInCondensedConsolidatedBalanceSheetsAreReconciled"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_Grossproceedsofwarrants": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross Proceeds Of Warrants.",
        "label": "GrossProceedsOfWarrants",
        "terseLabel": "Gross proceeds of amount"
       }
      }
     },
     "localname": "Grossproceedsofwarrants",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_HoldingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Holding period return is the total return received from holding an asset or portfolio of assets over a period of time, generally expressed as a percentage.",
        "label": "Holding Period",
        "terseLabel": "Holding period"
       }
      }
     },
     "localname": "HoldingPeriod",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfValuedUsingTheCompoundOptionPricingModel"
     ],
     "xbrltype": "perShareItemType"
    },
    "sclx_IfLetterOfCreditIsDrawnMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "If Letter Of Credit Is Drawn [Member]"
       }
      }
     },
     "localname": "IfLetterOfCreditIsDrawnMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_IncomeTaxDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax disclosure.",
        "label": "Income Tax Disclosure [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureLineItems",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_IncomeTaxDisclosureTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax disclosure.",
        "label": "Income Tax Disclosure [Table]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTable",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_IncreaseInNotesPayableOne": {
     "auth_ref": [],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 43.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase in notes payable one.",
        "label": "Increase In Notes Payable One",
        "terseLabel": "Scilex Pharma Notes principal increase"
       }
      }
     },
     "localname": "IncreaseInNotesPayableOne",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_IndebentureMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indebenture.",
        "label": "Indebenture [Member]"
       }
      }
     },
     "localname": "IndebentureMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_IndefiniteCarryforwardPeriodMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "indefinite carryforward period.",
        "label": "Indefinite Carryforward Period [Member]"
       }
      }
     },
     "localname": "IndefiniteCarryforwardPeriodMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_InitialMeasurementOne": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Initial Measurement One",
        "terseLabel": "Initial measurement"
       }
      }
     },
     "localname": "InitialMeasurementOne",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfChangesInTheFairValueOfWarrantLiabilitiesAndConversionOptionLiability"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_Interestexpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest expenses.",
        "label": "InterestExpenses",
        "terseLabel": "Interest Expense"
       }
      }
     },
     "localname": "Interestexpenses",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_InvesteeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investee [Axis]"
       }
      }
     },
     "localname": "InvesteeAxis",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_InvesteeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investee [Domain]"
       }
      }
     },
     "localname": "InvesteeDomain",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_InvestmentOfCashInTrustAccounts": {
     "auth_ref": [],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment of cash in Trust Account.",
        "label": "Investment Of Cash In Trust Accounts",
        "negatedLabel": "Investment of cash in Trust Account"
       }
      }
     },
     "localname": "InvestmentOfCashInTrustAccounts",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_ItochuMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Itochu.",
        "label": "Itochu [Member]"
       }
      }
     },
     "localname": "ItochuMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_LessAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Less Abstract",
        "terseLabel": "Less:"
       }
      }
     },
     "localname": "LessAbstract",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfOrdinarySharesReflectedInCondensedConsolidatedBalanceSheetsAreReconciled"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_LessAbstract0": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Less Abstract0",
        "terseLabel": "Less:"
       }
      }
     },
     "localname": "LessAbstract0",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfOrdinarySharesReflectedInCondensedConsolidatedBalanceSheetsAreReconciled"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_LesserPublicPerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lesser public per share",
        "label": "Lesser Public Per Share",
        "terseLabel": "Lesser public per share (in Dollars per share)"
       }
      }
     },
     "localname": "LesserPublicPerShare",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "sclx_LetterOfCreditDrawnDownMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Letter of credit drawn down.",
        "label": "Letter Of Credit Drawn Down [Member]"
       }
      }
     },
     "localname": "LetterOfCreditDrawnDownMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_LimitationOfOutstandingAmountInExchangeOfShares": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Limitation of Outstanding Amount In Exchange of Shares",
        "label": "Limitation of Outstanding Amount In Exchange of Shares",
        "terseLabel": "Limitation of Outstanding Amount In Exchange of Shares"
       }
      }
     },
     "localname": "LimitationOfOutstandingAmountInExchangeOfShares",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_LineOfCreditFacilityindebtednessAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line of credit facility ,indebtedness amount.",
        "label": "Line of Credit Facility ,indebtedness Amount",
        "terseLabel": "Line of credit facility, indebtedness amount"
       }
      }
     },
     "localname": "LineOfCreditFacilityindebtednessAmount",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_LiquidityAndGoingConcernAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liquidity and going Concern.",
        "label": "Liquidity And Going Concern [Abstract]"
       }
      }
     },
     "localname": "LiquidityAndGoingConcernAbstract",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "xbrltype": "stringItemType"
    },
    "sclx_LiquidityAndGoingConcernLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liquidity and going concern.",
        "label": "Liquidity And Going Concern [Line Items]"
       }
      }
     },
     "localname": "LiquidityAndGoingConcernLineItems",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_LiquidityAndGoingConcernTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liquidity and going concern.",
        "label": "Liquidity And Going Concern [Table]"
       }
      }
     },
     "localname": "LiquidityAndGoingConcernTable",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_LiquidityAndGoingConcernTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liquidity and going concern.",
        "label": "Liquidity And Going Concern [Text Block]",
        "terseLabel": "Liquidity and Going Concern"
       }
      }
     },
     "localname": "LiquidityAndGoingConcernTextBlock",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcern"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sclx_LongtermDebtFutureMinimumPayment": {
     "auth_ref": [],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/DebtDetailsSummaryOfFutureMinimumPaymentsUnderTheScilexPharmaNotes": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term debt, future minimum payment.",
        "label": "LongTerm Debt, Future Minimum Payment",
        "totalLabel": "Total minimum future payments"
       }
      }
     },
     "localname": "LongtermDebtFutureMinimumPayment",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetailsSummaryOfFutureMinimumPaymentsUnderTheScilexPharmaNotes"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_LongtermDebtFutureMinimumPaymentYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/DebtDetailsSummaryOfFutureMinimumPaymentsUnderTheScilexPharmaNotes": {
       "order": 5.0,
       "parentTag": "sclx_LongtermDebtFutureMinimumPayment",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term debt, future minimum payment , year five.",
        "label": "LongTerm Debt, Future Minimum Payment , Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LongtermDebtFutureMinimumPaymentYearFive",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetailsSummaryOfFutureMinimumPaymentsUnderTheScilexPharmaNotes"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_LongtermDebtFutureMinimumPaymentYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/DebtDetailsSummaryOfFutureMinimumPaymentsUnderTheScilexPharmaNotes": {
       "order": 4.0,
       "parentTag": "sclx_LongtermDebtFutureMinimumPayment",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term debt, future minimum payment , year four.",
        "label": "LongTerm Debt, Future Minimum Payment , Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongtermDebtFutureMinimumPaymentYearFour",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetailsSummaryOfFutureMinimumPaymentsUnderTheScilexPharmaNotes"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_LongtermDebtFutureMinimumPaymentYearThree": {
     "auth_ref": [],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/DebtDetailsSummaryOfFutureMinimumPaymentsUnderTheScilexPharmaNotes": {
       "order": 3.0,
       "parentTag": "sclx_LongtermDebtFutureMinimumPayment",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term debt, future minimum payment , year three.",
        "label": "LongTerm Debt, Future Minimum Payment , Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongtermDebtFutureMinimumPaymentYearThree",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetailsSummaryOfFutureMinimumPaymentsUnderTheScilexPharmaNotes"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_LongtermDebtFutureMinimumPaymentYearTwo": {
     "auth_ref": [],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/DebtDetailsSummaryOfFutureMinimumPaymentsUnderTheScilexPharmaNotes": {
       "order": 2.0,
       "parentTag": "sclx_LongtermDebtFutureMinimumPayment",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term debt, future minimum payment , year two.",
        "label": "LongTerm Debt, Future Minimum Payment , Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongtermDebtFutureMinimumPaymentYearTwo",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetailsSummaryOfFutureMinimumPaymentsUnderTheScilexPharmaNotes"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_LongtermDebtfutureMinimumPaymentYearOne": {
     "auth_ref": [],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/DebtDetailsSummaryOfFutureMinimumPaymentsUnderTheScilexPharmaNotes": {
       "order": 1.0,
       "parentTag": "sclx_LongtermDebtFutureMinimumPayment",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-Term Debt,\u00a0Future minimum payment , year one.",
        "label": "LongTerm Debt,Future minimum payment , year one",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LongtermDebtfutureMinimumPaymentYearOne",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetailsSummaryOfFutureMinimumPaymentsUnderTheScilexPharmaNotes"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_LossOnInitialIssuanceOfWarrantLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 39.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss On Initial Issuance Of Warrant Liability",
        "terseLabel": "Loss on initial issuance of private warrants"
       }
      }
     },
     "localname": "LossOnInitialIssuanceOfWarrantLiability",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_MarketingApprovalLetterMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketing approval letter.",
        "label": "Marketing Approval Letter [Member]"
       }
      }
     },
     "localname": "MarketingApprovalLetterMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_MaximumCompensationCostToBeAvailableProratedBasis": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum compensation cost to be available, prorated basis.",
        "label": "Maximum Compensation Cost To Be Available, Prorated Basis",
        "terseLabel": "Maximum compensation cost to be available, prorated basis"
       }
      }
     },
     "localname": "MaximumCompensationCostToBeAvailableProratedBasis",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_MaximumPercentageOfVolumeWeightedAveragePriceOfSharesMeasuredOnADailyBasisThatIsEligibleToBeReceivedAsAdvance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum percentage of volume weighted average price of shares measured on a daily basis that is eligible to be received as advance.",
        "label": "Maximum Percentage Of Volume Weighted Average Price Of Shares Measured On A Daily Basis That Is Eligible To Be Received As Advance"
       }
      }
     },
     "localname": "MaximumPercentageOfVolumeWeightedAveragePriceOfSharesMeasuredOnADailyBasisThatIsEligibleToBeReceivedAsAdvance",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sclx_MeasurementInputEffectiveDebtYieldMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input, effective debt yield .",
        "label": "Measurement Input, Effective Debt Yield [Member]"
       }
      }
     },
     "localname": "MeasurementInputEffectiveDebtYieldMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeJuly12023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input, estimated probability of not obtaining marketing approval before july 1, 2023 .",
        "label": "Measurement Input, Estimated Probability Of Not Obtaining Marketing Approval Before July 1, 2023 [Member]"
       }
      }
     },
     "localname": "MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeJuly12023Member",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeMarch312021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input, estimated probability of not obtaining marketing approval before march 31, 2021 .",
        "label": "Measurement Input, Estimated Probability Of Not Obtaining Marketing Approval Before March 31, 2021 [Member]"
       }
      }
     },
     "localname": "MeasurementInputEstimatedProbabilityOfNotObtainingMarketingApprovalBeforeMarch312021Member",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_MeasurementInputRiskadjustedNetSalesForecastMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input, risk-adjusted net sales forecast .",
        "label": "Measurement Input, RiskAdjusted Net Sales Forecast [Member]"
       }
      }
     },
     "localname": "MeasurementInputRiskadjustedNetSalesForecastMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_MergerConsiderationDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Merger consideration description.",
        "label": "Merger Consideration Description",
        "terseLabel": "Merger consideration description"
       }
      }
     },
     "localname": "MergerConsiderationDescription",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_MilestoneAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Milestone [Axis]"
       }
      }
     },
     "localname": "MilestoneAxis",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_MilestoneDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Milestone [Domain]"
       }
      }
     },
     "localname": "MilestoneDomain",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_MilestonePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "milestone payment",
        "label": "Milestone Payment",
        "terseLabel": "Milestone payment"
       }
      }
     },
     "localname": "MilestonePayment",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_MinimumCashRequirementsToRepurchaseOfNotes": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum cash requirements to repurchase of notes.",
        "label": "Minimum Cash Requirements To Repurchase Of Notes",
        "terseLabel": "Minimum cash requirements to repurchase of Notes"
       }
      }
     },
     "localname": "MinimumCashRequirementsToRepurchaseOfNotes",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_MinimumPayrollCostToBeAvailable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum payroll cost to be available.",
        "label": "Minimum payroll cost to be available",
        "terseLabel": "Minimum payroll cost to be available"
       }
      }
     },
     "localname": "MinimumPayrollCostToBeAvailable",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_MinimumThresholdPercentageForRecognitionOfUncertainIncomeTaxPosition": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum threshold percentage for recognition of uncertain income tax position.",
        "label": "Minimum Threshold Percentage for Recognition of Uncertain Income Tax Position",
        "terseLabel": "Minimum threshold percentage for recognition of uncertain income tax position"
       }
      }
     },
     "localname": "MinimumThresholdPercentageForRecognitionOfUncertainIncomeTaxPosition",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sclx_MinimumTimeDeclaredToFileWithSecRegardingResaleRegistrationStatement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum time declared to file with sec regarding resale registration statement.",
        "label": "Minimum Time Declared To File With SEC Regarding Resale Registration Statement",
        "terseLabel": "Minimum time declared to file with sec regarding resale registration statement"
       }
      }
     },
     "localname": "MinimumTimeDeclaredToFileWithSecRegardingResaleRegistrationStatement",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sclx_MinimumUnrestrictedCashBalance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum unrestricted cash balance.",
        "label": "Minimum Unrestricted Cash Balance",
        "terseLabel": "Minimum unrestricted cash balance"
       }
      }
     },
     "localname": "MinimumUnrestrictedCashBalance",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_MinimumUnrestrictedCashRequirementsToRepurchaseOfNotes": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum unrestricted cash requirements to repurchase of notes.",
        "label": "Minimum Unrestricted Cash Requirements To Repurchase Of Notes",
        "terseLabel": "Minimum unrestricted cash requirements to repurchase of Notes"
       }
      }
     },
     "localname": "MinimumUnrestrictedCashRequirementsToRepurchaseOfNotes",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_NetTangibleAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net tangible assets.",
        "label": "Net Tangible Assets",
        "terseLabel": "Net tangible assets (in Dollars)"
       }
      }
     },
     "localname": "NetTangibleAssets",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails",
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_NetWorkingCapital": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net working capital.",
        "label": "Net Working Capital",
        "terseLabel": "Net working capital"
       }
      }
     },
     "localname": "NetWorkingCapital",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_NonCashDistributionToAcquiree": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non cash distribution to acquiree.",
        "label": "Non Cash Distribution To Acquiree",
        "terseLabel": "Non-cash distribution to Sorrento"
       }
      }
     },
     "localname": "NonCashDistributionToAcquiree",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_NonCashFairValueAdjustmentToDerivativeLiability": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non cash fair value adjustment to derivative liability.",
        "label": "Non Cash Fair Value Adjustment To Derivative Liability",
        "terseLabel": "Fair value adjustment to derivative liability in troubled debt restructuring"
       }
      }
     },
     "localname": "NonCashFairValueAdjustmentToDerivativeLiability",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_NonCashIncreaseInPrincipal": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non cash increase in principal.",
        "label": "Non Cash Increase In Principal",
        "terseLabel": "Scilex Pharma Notes principal increase"
       }
      }
     },
     "localname": "NonCashIncreaseInPrincipal",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_NonCashOperatingLeaseCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 46.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non cash operating lease costs.",
        "label": "Non Cash Operating Lease Costs",
        "terseLabel": "Non-cash operating lease cost"
       }
      }
     },
     "localname": "NonCashOperatingLeaseCosts",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_NonCashRightOfUseAsset": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non cash right of use asset.",
        "label": "Non Cash Right Of Use Asset",
        "terseLabel": "Live Action\u00a0right-of-use\u00a0asset in Palo Alto"
       }
      }
     },
     "localname": "NonCashRightOfUseAsset",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_NonPayrollCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-payroll costs.",
        "label": "Non Payroll Costs [Member]"
       }
      }
     },
     "localname": "NonPayrollCostsMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_NoticeOfTerminationPeriodForCancellationOfAutomaticRenewal": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Notice of termination period for cancellation of automatic renewal.",
        "label": "Notice of Termination Period for Cancellation of Automatic Renewal",
        "terseLabel": "Notice of termination period for cancellation of automatic renewal"
       }
      }
     },
     "localname": "NoticeOfTerminationPeriodForCancellationOfAutomaticRenewal",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sclx_NoticePeriodForTerminationOfWorkOrder": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Notice period for termination of work order.",
        "label": "Notice Period for Termination of Work Order",
        "terseLabel": "Notice period for termination of work order"
       }
      }
     },
     "localname": "NoticePeriodForTerminationOfWorkOrder",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sclx_NumberOfConsecutiveTradingDaysForDeterminingTheVolumeWeightedAveragePriceOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of consecutive trading days for determining the volume weighted average price of shares.",
        "label": "Number Of Consecutive Trading Days For Determining The Volume Weighted Average Price Of Shares"
       }
      }
     },
     "localname": "NumberOfConsecutiveTradingDaysForDeterminingTheVolumeWeightedAveragePriceOfShares",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sclx_NumberOfDaysForDeterminingTheWeightedVolumeAveragePriceForShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of days for determining the weighted volume average price for shares.",
        "label": "Number Of Days For Determining The Weighted Volume Average Price For Shares",
        "terseLabel": "Number of days for determining the weighted volume averge price of shares"
       }
      }
     },
     "localname": "NumberOfDaysForDeterminingTheWeightedVolumeAveragePriceForShares",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sclx_NumberOfSaleUnits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of sale units",
        "label": "Number Of Sale Units",
        "terseLabel": "Number of sale units"
       }
      }
     },
     "localname": "NumberOfSaleUnits",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/PublicOfferingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sclx_NumberOfSharesAcquired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares acquired.",
        "label": "Number Of Shares Acquired",
        "terseLabel": "Number of shares acquired"
       }
      }
     },
     "localname": "NumberOfSharesAcquired",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sclx_NumberOfSharesLimits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares limits.",
        "label": "Number Of Shares Limits",
        "terseLabel": "Number of shares (in Shares)"
       }
      }
     },
     "localname": "NumberOfSharesLimits",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sclx_NumberOfSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares outstanding.",
        "label": "Number Of Shares Outstanding",
        "terseLabel": "Capital stock, shares outstanding"
       }
      }
     },
     "localname": "NumberOfSharesOutstanding",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sclx_NumberOfThresholdTradingDaysPriorToDateOfNoticeToTheShareholdersForDeterminingTheVolumeWeightedAveragePriceOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of threshold trading days prior to date of notice to the shareholders for determining the volume weighted average price of shares.",
        "label": "Number Of Threshold Trading Days Prior To Date Of Notice To The Shareholders For Determining The Volume Weighted Average Price Of Shares"
       }
      }
     },
     "localname": "NumberOfThresholdTradingDaysPriorToDateOfNoticeToTheShareholdersForDeterminingTheVolumeWeightedAveragePriceOfShares",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sclx_Numberofbusinessdays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Business Days.",
        "label": "NumberOfBusinessDays",
        "terseLabel": "Number of business days"
       }
      }
     },
     "localname": "Numberofbusinessdays",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "sclx_Numberofshares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares.",
        "label": "NumberOfShares",
        "terseLabel": "Number of shares (in Shares)"
       }
      }
     },
     "localname": "Numberofshares",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sclx_NumeratorAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Numerator Abstract",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NumeratorAbstract",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShare"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_OfferingCostIncludedInAccruedOfferingCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Offering cost included in accrued offering cost.",
        "label": "Offering Cost Included In Accrued Offering Cost",
        "terseLabel": "Offering costs included in accrued offering costs"
       }
      }
     },
     "localname": "OfferingCostIncludedInAccruedOfferingCost",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_OperatingCashFlowsFromOperatingLeases": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating cash flows from operating leases.",
        "label": "Operating Cash Flows From Operating Leases",
        "terseLabel": "Operating cash flows from operating leases"
       }
      }
     },
     "localname": "OperatingCashFlowsFromOperatingLeases",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesSummaryOfSupplementalQuantitativeInformationRelatedToLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_OperatingExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating expenses.",
        "label": "Operating Expenses [Member]"
       }
      }
     },
     "localname": "OperatingExpensesMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_OperatingLossCarryforwardsExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards expiration year.",
        "label": "Operating Loss Carryforwards Expiration Year",
        "terseLabel": "Operating loss carryforward expiration year"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsExpirationYear",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_OrdinarySharesIssuanceCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Ordinary Shares Issuance Cost",
        "negatedLabel": "Ordinary shares issuance costs"
       }
      }
     },
     "localname": "OrdinarySharesIssuanceCost",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfOrdinarySharesReflectedInCondensedConsolidatedBalanceSheetsAreReconciled"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_OrdinarySharesIssuedAndOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ordinary shares issued and outstanding.",
        "label": "Ordinary Shares Issued And Outstanding",
        "terseLabel": "Ordinary shares issued and outstanding (in Shares)"
       }
      }
     },
     "localname": "OrdinarySharesIssuedAndOutstanding",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sclx_OrdinarySharesRedemptionSubjectedToForfeiture": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redemption subjected to forfeiture.",
        "label": "Ordinary Shares Redemption Subjected To Forfeiture",
        "terseLabel": "Ordinary shares redemption subjected to forfeiture"
       }
      }
     },
     "localname": "OrdinarySharesRedemptionSubjectedToForfeiture",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheetsParentheticals",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "sclx_OrdinarySharesSubjectToPossibleRedemption": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ordinary Shares Subject To Possible Redemption",
        "terseLabel": "Subject to possible redemption shares",
        "verboseLabel": "Ordinary shares subject to possible redemption"
       }
      }
     },
     "localname": "OrdinarySharesSubjectToPossibleRedemption",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheetsParentheticals",
      "http://www.vickersvantagecorp.com/role/ShareholdersDeficitDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sclx_OtherLoanForgiveness": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other loan forgiveness.",
        "label": "Other Loan Forgiveness",
        "terseLabel": "Other loan forgiveness"
       }
      }
     },
     "localname": "OtherLoanForgiveness",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_Otherofferingcosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "OtherOfferingCosts.",
        "label": "OtherOfferingCosts"
       }
      }
     },
     "localname": "Otherofferingcosts",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_PaloAltoAadministrativeFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Palo Alto Aadministrative Facility",
        "label": "Palo Alto Aadministrative Facility [Member]"
       }
      }
     },
     "localname": "PaloAltoAadministrativeFacilityMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_PaycheckProtectionProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Paycheck protection program.",
        "label": "Paycheck Protection Program [Member]"
       }
      }
     },
     "localname": "PaycheckProtectionProgramMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_PaymentMadeInSurrenderingTheShares": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment made in surrendering the shares.",
        "label": "Payment Made In Surrendering The Shares",
        "terseLabel": "Payment made in surrendering the shares"
       }
      }
     },
     "localname": "PaymentMadeInSurrenderingTheShares",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_PaymentToAcquireInventory": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment to acquire inventory.",
        "label": "Payment To Acquire Inventory",
        "terseLabel": "Payment to acquire inventory"
       }
      }
     },
     "localname": "PaymentToAcquireInventory",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_PaymentToDepositIntoASeggregateReserveFund": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment to deposit into a seggregate reserve fund.",
        "label": "Payment To Deposit Into A Seggregate Reserve Fund",
        "terseLabel": "Payment to deposit into a seggregate reserve fund"
       }
      }
     },
     "localname": "PaymentToDepositIntoASeggregateReserveFund",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_PaymentToDepositIntoASegregatedCollateralAccount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment to deposit into a segregated collateral account.",
        "label": "Payment To Deposit Into A Segregated Collateral Account",
        "terseLabel": "Payment to deposit into a segregated collateral account"
       }
      }
     },
     "localname": "PaymentToDepositIntoASegregatedCollateralAccount",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_PayrollCostsBasisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payroll costs basis.",
        "label": "Payroll Costs Basis [Member]"
       }
      }
     },
     "localname": "PayrollCostsBasisMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_PerShareCalculationOfOutstandingAmountInExchangeOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share calculation of Outstanding Amount In Exchange of Shares",
        "label": "Per share calculation of Outstanding Amount In Exchange of Shares",
        "terseLabel": "Per share calculation of Outstanding Amount In Exchange of Shares"
       }
      }
     },
     "localname": "PerShareCalculationOfOutstandingAmountInExchangeOfShares",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "sclx_PercentageOfAggregateRoyalityPayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of aggregate royality payments.",
        "label": "Percentage of Aggregate Royality Payments",
        "terseLabel": "Percentage of aggregate royality payments"
       }
      }
     },
     "localname": "PercentageOfAggregateRoyalityPayments",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sclx_PercentageOfAnnualAdjustmentToFees": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of annual adjustment to fees.",
        "label": "Percentage Of Annual Adjustment To Fees",
        "terseLabel": "Percentage of annual adjustment to fees"
       }
      }
     },
     "localname": "PercentageOfAnnualAdjustmentToFees",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sclx_PercentageOfCapitalSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of capital shares outstanding.",
        "label": "Percentage Of Capital Shares Outstanding",
        "terseLabel": "Percentage of capital shares outstanding"
       }
      }
     },
     "localname": "PercentageOfCapitalSharesOutstanding",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sclx_PercentageOfConcentrationOnASimilarProduct": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of concentration on a similar product.",
        "label": "Percentage of concentration on a similar product",
        "terseLabel": "Percentage of concentration on a similar product"
       }
      }
     },
     "localname": "PercentageOfConcentrationOnASimilarProduct",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sclx_PercentageOfDailyVolumeWeightedAveragePriceOfSharesAtWhichTheSharesAreEligibleToBePurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of daily volume weighted average price of shares at which the shares are eligible to be purchased.",
        "label": "Percentage Of Daily Volume Weighted Average Price Of Shares At Which The Shares Are Eligible To Be Purchased"
       }
      }
     },
     "localname": "PercentageOfDailyVolumeWeightedAveragePriceOfSharesAtWhichTheSharesAreEligibleToBePurchased",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sclx_PercentageOfDistributionFeeReceivedOverThePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of distribution fee received over the period.",
        "label": "Percentage Of Distribution Fee Received Over The Period",
        "terseLabel": "Percentage of distribution fee received over the period"
       }
      }
     },
     "localname": "PercentageOfDistributionFeeReceivedOverThePeriod",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sclx_PercentageOfLoanForgivenessUnderTheAct": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of loan forgiveness under the act.",
        "label": "Percentage Of Loan Forgiveness Under The Act",
        "terseLabel": "Percentage of loan forgiveness under the act"
       }
      }
     },
     "localname": "PercentageOfLoanForgivenessUnderTheAct",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sclx_PercentageOfNetSalesPayable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of net sales payable.",
        "label": "Percentage Of Net Sales Payable",
        "terseLabel": "Percentage of net sales payable"
       }
      }
     },
     "localname": "PercentageOfNetSalesPayable",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sclx_PercentageOfOutstandingAmountIndebtedness": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of outstanding amount indebtedness",
        "label": "Percentage of Outstanding Amount Indebtedness",
        "terseLabel": "Percentage of Outstanding Amount Indebtedness"
       }
      }
     },
     "localname": "PercentageOfOutstandingAmountIndebtedness",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sclx_PercentageOfOwnershipInterest": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of ownership interest.",
        "label": "Percentage Of Ownership Interest",
        "terseLabel": "Percentage of ownership interest"
       }
      }
     },
     "localname": "PercentageOfOwnershipInterest",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sclx_PercentageOfPublicShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of public shares.",
        "label": "Percentage Of Public Shares",
        "terseLabel": "Percentage of public shares"
       }
      }
     },
     "localname": "PercentageOfPublicShares",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sclx_PercentageOfPurchasePriceInCashEqualIsToPrincipalAmountOfTheLoan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of purchase price in cash equal is to principal amount of the loan.",
        "label": "Percentage Of Purchase Price In Cash Equal Is To Principal Amount Of The Loan",
        "terseLabel": "Percentage of purchase price in cash equal is to principal amount of the loan"
       }
      }
     },
     "localname": "PercentageOfPurchasePriceInCashEqualIsToPrincipalAmountOfTheLoan",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sclx_PercentageOfQuarterlyPaymentsOfThePrincipalNotesEqualToAFixedPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of quarterly payments of the principal notes equal to a fixed percentage.",
        "label": "Percentage Of Quarterly Payments Of The Principal Notes Equal To A Fixed Percentage",
        "terseLabel": "Percentage of quarterly payments of the principal Notes equal to a fixed percentage"
       }
      }
     },
     "localname": "PercentageOfQuarterlyPaymentsOfThePrincipalNotesEqualToAFixedPercentage",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sclx_PercentageOfSharesIssuedSubjectToRestrictionOfTransfer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of shares issued subject to restriction of transfer.",
        "label": "Percentage Of Shares Issued Subject To Restriction Of Transfer",
        "terseLabel": "Percentage of shares issued subject to restriction of transfer"
       }
      }
     },
     "localname": "PercentageOfSharesIssuedSubjectToRestrictionOfTransfer",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sclx_PercentageOfSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of shares outstanding.",
        "label": "Percentage Of Shares Outstanding",
        "terseLabel": "Percentage of shares outstanding"
       }
      }
     },
     "localname": "PercentageOfSharesOutstanding",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sclx_PercentageOfSimpleInterest": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of simple interest.",
        "label": "Percentage Of Simple Interest",
        "terseLabel": "Percentage of simple interest"
       }
      }
     },
     "localname": "PercentageOfSimpleInterest",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sclx_PercentageOfThePrincipalAmountFromHoldersOnProRataBasis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the principal amount from Holders on pro rata basis.",
        "label": "Percentage Of The Principal Amount From Holders On Pro Rata Basis",
        "terseLabel": "Percentage of the principal amount from Holders on pro rata basis"
       }
      }
     },
     "localname": "PercentageOfThePrincipalAmountFromHoldersOnProRataBasis",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sclx_PercentageOfThePrincipalAmountOfTheNotes": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the principal amount of the notes.",
        "label": "Percentage Of The Principal Amount Of The Notes",
        "terseLabel": "Percentage of the principal amount of the Notes"
       }
      }
     },
     "localname": "PercentageOfThePrincipalAmountOfTheNotes",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sclx_PeriodAfterRegistrationWhenTheRequestCouldBeMadeToTheInvesteeToPurchaseTheShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period after registration when the request could be made to the investee to purchase the shares.",
        "label": "Period After Registration When The Request Could Be Made To The Investee To Purchase The Shares"
       }
      }
     },
     "localname": "PeriodAfterRegistrationWhenTheRequestCouldBeMadeToTheInvesteeToPurchaseTheShares",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sclx_PeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period.",
        "label": "Period [Axis]"
       }
      }
     },
     "localname": "PeriodAxis",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_PeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period.",
        "label": "Period [Domain]"
       }
      }
     },
     "localname": "PeriodDomain",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_PeriodDuringWhichShareTransferIsRestricted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period during which share transfer is restricted.",
        "label": "Period During Which Share Transfer Is Restricted",
        "terseLabel": "Period during which share transfer is restricted"
       }
      }
     },
     "localname": "PeriodDuringWhichShareTransferIsRestricted",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sclx_PeriodDuringWhichTheSharesMayBeExchanged": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period during which the shares may be exchanged.",
        "label": "Period During Which The Shares May Be Exchanged",
        "terseLabel": "Period during which the shares may be exchanged"
       }
      }
     },
     "localname": "PeriodDuringWhichTheSharesMayBeExchanged",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sclx_PlusAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plus Abstract",
        "terseLabel": "Plus:"
       }
      }
     },
     "localname": "PlusAbstract",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfOrdinarySharesReflectedInCondensedConsolidatedBalanceSheetsAreReconciled"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_PricePerPublicShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Price Per Public Share",
        "terseLabel": "Anticipated public share (in Dollars per share)"
       }
      }
     },
     "localname": "PricePerPublicShare",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "sclx_PricePerShareForDeterminingTheExchangeOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price per share for determining the exchange of shares.",
        "label": "Price Per Share For Determining The Exchange Of Shares",
        "terseLabel": "Price per share for determining the exchange of shares"
       }
      }
     },
     "localname": "PricePerShareForDeterminingTheExchangeOfShares",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "sclx_PricePerWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price per warrant.",
        "label": "Price Per Warrants",
        "terseLabel": "Price per warrant (in Dollars per share)"
       }
      }
     },
     "localname": "PricePerWarrants",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "sclx_PrivatePlacementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Abstract]"
       }
      }
     },
     "localname": "PrivatePlacementAbstract",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "xbrltype": "stringItemType"
    },
    "sclx_PrivatePlacementDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement (Details) [Line Items]"
       }
      }
     },
     "localname": "PrivatePlacementDetailsLineItems",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/PrivatePlacement",
      "http://www.vickersvantagecorp.com/role/PrivatePlacementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_PrivatePlacementDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement (Details) [Table]"
       }
      }
     },
     "localname": "PrivatePlacementDetailsTable",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/PrivatePlacement",
      "http://www.vickersvantagecorp.com/role/PrivatePlacementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_PrivatePlacementTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for private placement.",
        "label": "Private Placement Text Block",
        "terseLabel": "PRIVATE PLACEMENT"
       }
      }
     },
     "localname": "PrivatePlacementTextBlock",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/PrivatePlacement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sclx_PrivatePlacementWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Private Placement Warrant [Member].",
        "label": "Private Placement Warrant Member",
        "terseLabel": "Private Placement Warrant [Member]"
       }
      }
     },
     "localname": "PrivatePlacementWarrantMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_ProceedsFromPromissoryNoteRelatedParty": {
     "auth_ref": [],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from promissory note related party.",
        "label": "Proceeds From Promissory Note Related Party",
        "terseLabel": "Proceeds from promissory note \u2013 related party"
       }
      }
     },
     "localname": "ProceedsFromPromissoryNoteRelatedParty",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_ProceedsFromSimplePromissoryNoteRelatedParty": {
     "auth_ref": [],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from simple promissory note \u2013 related party.",
        "label": "Proceeds From Simple Promissory Note Related Party",
        "terseLabel": "Proceeds from simple promissory note \u2013 related party"
       }
      }
     },
     "localname": "ProceedsFromSimplePromissoryNoteRelatedParty",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_ProceedsOfInitialPublicOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds Of Initial Public Offering.",
        "label": "Proceeds Of Initial Public Offering",
        "terseLabel": "Proceeds of initial public offering"
       }
      }
     },
     "localname": "ProceedsOfInitialPublicOffering",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_ProductDevelopmentAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product development agreement.",
        "label": "Product Development Agreement [Member]"
       }
      }
     },
     "localname": "ProductDevelopmentAgreementMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_ProjectAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Project agreement.",
        "label": "Project Agreement [Member]",
        "terseLabel": "Project Agreement [Member]"
       }
      }
     },
     "localname": "ProjectAgreementMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_PromissoryNoteIssuedNetOfDiscount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Promissory note issued net of discount.",
        "label": "Promissory Note Issued Net Of Discount",
        "terseLabel": "Promissory Note issued to Sorrento in exchange for the\u00a0SP-104\u00a0license, net of discount"
       }
      }
     },
     "localname": "PromissoryNoteIssuedNetOfDiscount",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_PromissoryNoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Promissory note.",
        "label": "Promissory Note [Member]"
       }
      }
     },
     "localname": "PromissoryNoteMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_PromissoryNoteRelatedPartyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Promissory Note Related Party Member",
        "terseLabel": "Promissory Note - Related Party [Member]"
       }
      }
     },
     "localname": "PromissoryNoteRelatedPartyMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_ProposedPublicOfferingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public Offering [Abstract]"
       }
      }
     },
     "localname": "ProposedPublicOfferingAbstract",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "xbrltype": "stringItemType"
    },
    "sclx_ProposedPublicOfferingTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proposed Public Offering Text Block",
        "terseLabel": "PUBLIC OFFERING"
       }
      }
     },
     "localname": "ProposedPublicOfferingTextBlock",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/PublicOffering"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sclx_PublicOfferingDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public Offering (Details) [Line Items]"
       }
      }
     },
     "localname": "PublicOfferingDetailsLineItems",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/PublicOffering",
      "http://www.vickersvantagecorp.com/role/PublicOfferingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_PublicOfferingDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public Offering (Details) [Table]"
       }
      }
     },
     "localname": "PublicOfferingDetailsTable",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/PublicOffering",
      "http://www.vickersvantagecorp.com/role/PublicOfferingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_PublicWarrantsRedemptionDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public Warrants Redemption Description",
        "terseLabel": "Public warrants redemption, description"
       }
      }
     },
     "localname": "PublicWarrantsRedemptionDescription",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/WarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_PurchasePricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Price Per Share",
        "terseLabel": "Purchase price per unit (in Dollars per share)"
       }
      }
     },
     "localname": "PurchasePricePerShare",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/PublicOfferingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "sclx_PurchasetypeAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase-type A.",
        "label": "PurchaseType A [Member]"
       }
      }
     },
     "localname": "PurchasetypeAMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_PurchasetypeBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase-Type B",
        "label": "PurchaseType B [Member]"
       }
      }
     },
     "localname": "PurchasetypeBMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_RebatesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rebates.",
        "label": "Rebates [Policy Text Block]",
        "terseLabel": "Rebates"
       }
      }
     },
     "localname": "RebatesPolicyTextBlock",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AccountingPoliciesByPolicyPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sclx_RegulatoryBasedMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Regulatory Based Milestone [Member]"
       }
      }
     },
     "localname": "RegulatoryBasedMilestoneMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_RelatedPartyNotePayableCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 28.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related party note payable, current.",
        "label": "Related Party Note Payable Current",
        "terseLabel": "Related party note payable"
       }
      }
     },
     "localname": "RelatedPartyNotePayableCurrent",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_RelatedPartyNotePayableNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 38.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related party note payable, non current.",
        "label": "Related Party Note Payable Noncurrent",
        "terseLabel": "Related party note payable, net"
       }
      }
     },
     "localname": "RelatedPartyNotePayableNoncurrent",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_RelatedPartyTransactionsDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions (Details) [Line Items]",
        "verboseLabel": "Related Party Transactions [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDetailsLineItems",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactions",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_RelatedPartyTransactionsDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions (Details) [Table]",
        "verboseLabel": "Related Party Transactions [Table]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDetailsTable",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactions",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_ReorganizationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reorganization.",
        "label": "Reorganization [Member]"
       }
      }
     },
     "localname": "ReorganizationMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_RepaidAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repaid Amount.",
        "label": "Repaid Amount",
        "terseLabel": "Repaid amount"
       }
      }
     },
     "localname": "RepaidAmount",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_RepaymentOfPromissoryNoteRelatedParty": {
     "auth_ref": [],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repayment of promissory note \u2013 related party.",
        "label": "Repayment Of Promissory Note Related Party",
        "negatedLabel": "Repayment of promissory note \u2013 related party"
       }
      }
     },
     "localname": "RepaymentOfPromissoryNoteRelatedParty",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_RestrictedFundsRelesableForFutureRepurchaseOfDebt": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted funds relesable for future repurchase of debt.",
        "label": "Restricted Funds Relesable For Future Repurchase Of Debt",
        "terseLabel": "Restricted funds releasable for future repurchase of debt"
       }
      }
     },
     "localname": "RestrictedFundsRelesableForFutureRepurchaseOfDebt",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_RevenueToBeEarnedByTheAcquireeValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue to be earned by the acquiree value.",
        "label": "Revenue To Be Earned By The Acquiree Value",
        "terseLabel": "Revenue to be earned by the acquiree value"
       }
      }
     },
     "localname": "RevenueToBeEarnedByTheAcquireeValue",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_ReveueBasedMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reveue Based Milestone [Member]"
       }
      }
     },
     "localname": "ReveueBasedMilestoneMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_RomegLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Romeg License Agreement",
        "label": "Romeg License Agreement [Member]"
       }
      }
     },
     "localname": "RomegLicenseAgreementMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_SaleOfStockDescriptionOfTransactions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of stock description of transaction.",
        "label": "Sale Of Stock Description Of Transactions",
        "terseLabel": "Sale of stock, description"
       }
      }
     },
     "localname": "SaleOfStockDescriptionOfTransactions",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_Saleofwarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Warrants.",
        "label": "SaleOfWarrants",
        "terseLabel": "Sale of warrants (in Shares)"
       }
      }
     },
     "localname": "Saleofwarrants",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sclx_SalesOperationsServicesMonthlyFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales operations services monthly fee.",
        "label": "Sales Operations Services Monthly Fee",
        "terseLabel": "Sales operations services monthly fee"
       }
      }
     },
     "localname": "SalesOperationsServicesMonthlyFee",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_SalesReturnsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales returns.",
        "label": "Sales Returns [Policy Text Block]",
        "terseLabel": "Product Returns"
       }
      }
     },
     "localname": "SalesReturnsPolicyTextBlock",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AccountingPoliciesByPolicyPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sclx_SalesThresholdLimit": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales threshold limit.",
        "label": "Sales Threshold Limit",
        "terseLabel": "Sales threshold limit"
       }
      }
     },
     "localname": "SalesThresholdLimit",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of change in the fair value of conversion option liability.",
        "label": "Schedule Of Change In The Fair Value Of Conversion Option Liability [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityAbstract",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "xbrltype": "stringItemType"
    },
    "sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of change in the fair value of conversion option liability.",
        "label": "Schedule Of Change In The Fair Value Of Conversion Option Liability [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityLineItems",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfChangeInTheFairValueOfConversionOptionLiability"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of change in the fair value of conversion option liability.",
        "label": "Schedule Of Change In The Fair Value Of Conversion Option Liability [Table]"
       }
      }
     },
     "localname": "ScheduleOfChangeInTheFairValueOfConversionOptionLiabilityTable",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfChangeInTheFairValueOfConversionOptionLiability"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_ScheduleOfChangesInTheFairValueOfWarrantLiabilitiesAndConversionOptionLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Changes In The Fair Value Of Warrant Liabilities And Conversion Option Liability Abstract"
       }
      }
     },
     "localname": "ScheduleOfChangesInTheFairValueOfWarrantLiabilitiesAndConversionOptionLiabilityAbstract",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "xbrltype": "stringItemType"
    },
    "sclx_ScheduleOfFairValueHierarchyOfTheValuationInputsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Fair Value Hierarchy Of The Valuation Inputs Abstract"
       }
      }
     },
     "localname": "ScheduleOfFairValueHierarchyOfTheValuationInputsAbstract",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "xbrltype": "stringItemType"
    },
    "sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of future minimum payments of long term debt.",
        "label": "Schedule Of Future minimum payments Of Long Term Debt [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfFutureMinimumPaymentsOfLongTermDebtLineItems",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetailsSummaryOfFutureMinimumPaymentsUnderTheScilexPharmaNotes"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of future minimum payments of long term debt.",
        "label": "Schedule Of Future minimum payments Of Long Term Debt [Table]"
       }
      }
     },
     "localname": "ScheduleOfFutureMinimumPaymentsOfLongTermDebtTable",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetailsSummaryOfFutureMinimumPaymentsUnderTheScilexPharmaNotes"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_ScheduleOfFutureMinimumPaymentsOfLongTermDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of future minimum payments of long term debt.",
        "label": "Schedule Of Future minimum payments Of Long Term Debt [Table Text Block]",
        "terseLabel": "Summary of Future Minimum Payments Under the Scilex Pharma Notes"
       }
      }
     },
     "localname": "ScheduleOfFutureMinimumPaymentsOfLongTermDebtTableTextBlock",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sclx_ScheduleOfOrdinarySharesReflectedInCondensedConsolidatedBalanceSheetsAreReconciledAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Ordinary Shares Reflected In Condensed Consolidated Balance Sheets Are Reconciled Abstract"
       }
      }
     },
     "localname": "ScheduleOfOrdinarySharesReflectedInCondensedConsolidatedBalanceSheetsAreReconciledAbstract",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "xbrltype": "stringItemType"
    },
    "sclx_ScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Quantitative Information Regarding Level3 Fair Value Measurements Abstract"
       }
      }
     },
     "localname": "ScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurementsAbstract",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "xbrltype": "stringItemType"
    },
    "sclx_ScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Reflects The Calculation Of Basic And Diluted Net Income Loss Per Ordinary Share Abstract"
       }
      }
     },
     "localname": "ScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareAbstract",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "xbrltype": "stringItemType"
    },
    "sclx_ScheduleOfSupplementalQuantitativeInformationRelatedToLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of supplemental quantitative information related to leases.",
        "label": "Schedule Of Supplemental Quantitative Information Related To Leases [Table Text Block]",
        "terseLabel": "Summary of Supplemental Quantitative Information Related To Leases"
       }
      }
     },
     "localname": "ScheduleOfSupplementalQuantitativeInformationRelatedToLeasesTableTextBlock",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sclx_ScheduleOfValuedUsingTheCompoundOptionPricingModelAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Valued Using The Compound Option Pricing Model Abstract"
       }
      }
     },
     "localname": "ScheduleOfValuedUsingTheCompoundOptionPricingModelAbstract",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "xbrltype": "stringItemType"
    },
    "sclx_ScilexCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scilex Common Stock Member",
        "terseLabel": "Scilex Common Stock [Member]"
       }
      }
     },
     "localname": "ScilexCommonStockMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_ScilexPharmaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scilex pharma.",
        "label": "Scilex Pharma [Member]"
       }
      }
     },
     "localname": "ScilexPharmaMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails",
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_ScilexPharmaNoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scilex pharma note.",
        "label": "Scilex Pharma Note [Member]"
       }
      }
     },
     "localname": "ScilexPharmaNoteMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_ScilexPharmaNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scilex pharma notes.",
        "label": "Scilex Pharma Notes [Member]"
       }
      }
     },
     "localname": "ScilexPharmaNotesMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetailsSummaryOfBorrowingsOfTheScilexPharmaNotes",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetails",
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_ScilexPharmaNotesPrincipalIncrease": {
     "auth_ref": [],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": {
       "order": 21.0,
       "parentTag": "us-gaap_OtherOperatingIncomeExpenseNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scilex Pharma Notes principal increase",
        "label": "Scilex Pharma Notes principal increase",
        "terseLabel": "Scilex Pharma Notes principal increase"
       }
      }
     },
     "localname": "ScilexPharmaNotesPrincipalIncrease",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_ScilexPharmaTwoThousandSeventeenPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scilex pharma two thousand seventeen plan.",
        "label": "Scilex Pharma two thousand seventeen Plan [Member]",
        "terseLabel": "Scilex Pharma 2017 Plan [Member]"
       }
      }
     },
     "localname": "ScilexPharmaTwoThousandSeventeenPlanMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_SellingGeneralAndAdministrativeExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Selling, general and administrative expense.",
        "label": "Selling, General And Administrative Expenses",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpenses",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_SeniorSecuredNotesDueTwoThousandAndTwentySixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior secured notes due two thousand and twenty six.",
        "label": "Senior Secured Notes Due Two Thousand And Twenty Six [Member]"
       }
      }
     },
     "localname": "SeniorSecuredNotesDueTwoThousandAndTwentySixMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_SenmurMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senmur [Member]"
       }
      }
     },
     "localname": "SenmurMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_ServiceFeesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Service fees.",
        "label": "Service Fees [Policy Text Block]",
        "terseLabel": "Service Fees"
       }
      }
     },
     "localname": "ServiceFeesPolicyTextBlock",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AccountingPoliciesByPolicyPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate1",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurements"
     ],
     "xbrltype": "percentItemType"
    },
    "sclx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate1",
        "terseLabel": "Risk-free rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurements"
     ],
     "xbrltype": "percentItemType"
    },
    "sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sharebased compensation arrangement by sharebased payment award fair value assumptions per share of common stock on date of grant.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Per Share Of Common Stock On Date Of Grant",
        "terseLabel": "Fair value per share of common stock on date of grant",
        "verboseLabel": "Fair value per share of common stock on date of grant"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsPerShareOfCommonStockOnDateOfGrant",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetails",
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfShareBasedPaymentAwardOptionsIssuedToEmployeesAndNonemployeesValuationAssumptions"
     ],
     "xbrltype": "perShareItemType"
    },
    "sclx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "ShareBased Compensation Arrangement by ShareBased Payment Award, Option, Outstanding, Number",
        "terseLabel": "Share based compensation arrangement,Options outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingNumber",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sclx_SharesCapitalization": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares capitalization.",
        "label": "Shares Capitalization",
        "terseLabel": "Shares capitalization"
       }
      }
     },
     "localname": "SharesCapitalization",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "sclx_SharesSubjectToPossibleRedemption": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ordinary shares subject to possible redemption.",
        "label": "Shares Subject To Possible Redemption",
        "terseLabel": "Ordinary shares subject to possible redemption"
       }
      }
     },
     "localname": "SharesSubjectToPossibleRedemption",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfOrdinarySharesReflectedInCondensedConsolidatedBalanceSheetsAreReconciled"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_SoleDistributorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sole distributor.",
        "label": "Sole Distributor [Member]"
       }
      }
     },
     "localname": "SoleDistributorMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_SorrentoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sorrento.",
        "label": "Sorrento [Member]"
       }
      }
     },
     "localname": "SorrentoMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails",
      "http://www.vickersvantagecorp.com/role/DebtDetails",
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_SponsorLoan": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sponsor loan.",
        "label": "Sponsor Loan",
        "terseLabel": "Sponsor loan"
       }
      }
     },
     "localname": "SponsorLoan",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_SponsorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sponsor Member.",
        "label": "Sponsor [Member]"
       }
      }
     },
     "localname": "SponsorMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_StandbyEquityPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Standby equity purchase agreement.",
        "label": "Standby Equity Purchase Agreement [Member]"
       }
      }
     },
     "localname": "StandbyEquityPurchaseAgreementMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_StatementAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statement .",
        "label": "Statement [Axis]"
       }
      }
     },
     "localname": "StatementAxis",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_StatementDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statement.",
        "label": "Statement [Domain]"
       }
      }
     },
     "localname": "StatementDomain",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_SubjectToPossibleRedemptionPerShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subject To possible redemption per shares.",
        "label": "Subject To Possible Redemption Per Shares",
        "terseLabel": "Subject to possible redemption per shares (in Dollars per share)"
       }
      }
     },
     "localname": "SubjectToPossibleRedemptionPerShares",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "sclx_SubsequentEventsDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events (Details) [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventsDetailsLineItems",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_SubsequentEventsDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events (Details) [Table]"
       }
      }
     },
     "localname": "SubsequentEventsDetailsTable",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_SummaryofSignificantAccountingPoliciesDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies (Details) [Line Items]"
       }
      }
     },
     "localname": "SummaryofSignificantAccountingPoliciesDetailsLineItems",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AccountingPoliciesByPolicyPolicies",
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPolicies",
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetails",
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfOrdinarySharesReflectedInCondensedConsolidatedBalanceSheetsAreReconciled",
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShare",
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareParentheticals",
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_SummaryofSignificantAccountingPoliciesDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies (Details) [Table]"
       }
      }
     },
     "localname": "SummaryofSignificantAccountingPoliciesDetailsTable",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AccountingPoliciesByPolicyPolicies",
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPolicies",
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetails",
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfOrdinarySharesReflectedInCondensedConsolidatedBalanceSheetsAreReconciled",
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShare",
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareParentheticals",
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_TaxCreditCarryforwardExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax credit carryforward, expiration year.",
        "label": "Tax Credit Carryforward, Expiration Year",
        "terseLabel": "Tax credit carryforward expiration year"
       }
      }
     },
     "localname": "TaxCreditCarryforwardExpirationYear",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_TerminationOfAgreementNoticePeriodForARequestToCureMaterialBreachOfTheAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Termination of agreement notice period for a request to cure material breach of the agreement.",
        "label": "Termination Of Agreement Notice Period For a Request To Cure Material Breach Of The Agreement",
        "terseLabel": "Termination of aggrement notice period for a request to cure material breach of the agreement"
       }
      }
     },
     "localname": "TerminationOfAgreementNoticePeriodForARequestToCureMaterialBreachOfTheAgreement",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sclx_ThresholdMinimumPercentageOfSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold minimum percentage of sales.",
        "label": "Threshold Minimum Percentage Of Sales",
        "terseLabel": "Threshold minimum percentage of sales"
       }
      }
     },
     "localname": "ThresholdMinimumPercentageOfSales",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sclx_TrancheAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tranche [Axis]"
       }
      }
     },
     "localname": "TrancheAxis",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_TrancheDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tranche [Domain]"
       }
      }
     },
     "localname": "TrancheDomain",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_TrancheFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tranche Four [Member]",
        "terseLabel": "Tranche 4 [Member]"
       }
      }
     },
     "localname": "TrancheFourMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_TrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tranche One [Member]",
        "terseLabel": "Tranche 1 [Member]"
       }
      }
     },
     "localname": "TrancheOneMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_TrancheThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tranche Three [Member]",
        "terseLabel": "Tranche 3 [Member]"
       }
      }
     },
     "localname": "TrancheThreeMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_TrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tranche Two [Member]",
        "terseLabel": "Tranche 2 [Member]"
       }
      }
     },
     "localname": "TrancheTwoMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_TransactionCostsAllocatedToWarrantLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": {
       "order": 17.0,
       "parentTag": "us-gaap_OtherOperatingIncomeExpenseNet",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction costs allocated to warrant liabilities.",
        "label": "Transaction Costs Allocated To Warrant Liabilities",
        "negatedLabel": "Transaction costs allocated to warrant liabilities"
       }
      }
     },
     "localname": "TransactionCostsAllocatedToWarrantLiabilities",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_Transactioncostsamount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction Costs Amount.",
        "label": "TransactionCostsAmount",
        "terseLabel": "Transaction costs amount"
       }
      }
     },
     "localname": "Transactioncostsamount",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_TransactionsCostsAllocatedToPrivateWarrants": {
     "auth_ref": [],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 42.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction costs allocated to warrant liabilities.",
        "label": "Transactions Costs Allocated To Private Warrants",
        "terseLabel": "Transaction costs allocated to warrant liabilities"
       }
      }
     },
     "localname": "TransactionsCostsAllocatedToPrivateWarrants",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_TwoThousandAndEighteenPurchaseAgreementsAndIndentureMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and eighteen purchase agreements and indenture.",
        "label": "Two Thousand and Eighteen Purchase Agreements and Indenture [Member]",
        "terseLabel": "2018 Purchase Agreements and Indenture [Member]"
       }
      }
     },
     "localname": "TwoThousandAndEighteenPurchaseAgreementsAndIndentureMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_TwoThousandAndEighteenPurchaseAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand and Eighteen Purchase Agreements [Member]",
        "terseLabel": "2018 Purchase Agreements [Member]"
       }
      }
     },
     "localname": "TwoThousandAndEighteenPurchaseAgreementsMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_TwoThousandAndTwentyTwoPromissoryNoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and twenty two promissory note.",
        "label": "Two Thousand And Twenty Two Promissory Note [Member]"
       }
      }
     },
     "localname": "TwoThousandAndTwentyTwoPromissoryNoteMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_TwoThousandNineteenStockOptionPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand nineteen stock option Plan .",
        "label": "Two thousand nineteen Stock Option Plan [Member]",
        "terseLabel": "2019 Stock Option Plan [Member]"
       }
      }
     },
     "localname": "TwoThousandNineteenStockOptionPlanMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_TwoThousandTwentyTwoPromissoryNoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand Twenty Two Promissory Note [Member]",
        "terseLabel": "2022 Promissory Note [Member]"
       }
      }
     },
     "localname": "TwoThousandTwentyTwoPromissoryNoteMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_UnderlyingWarrantValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underlying warrant value",
        "label": "Underlying Warrant Value",
        "terseLabel": "Underlying warrant value"
       }
      }
     },
     "localname": "UnderlyingWarrantValue",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfValuedUsingTheCompoundOptionPricingModel"
     ],
     "xbrltype": "perShareItemType"
    },
    "sclx_UpfrontlicenseFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "up-front\u00a0license fee",
        "label": "Upfront License Fee"
       }
      }
     },
     "localname": "UpfrontlicenseFee",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_VantageMergerSubIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vantage merger sub inc.",
        "label": "Vantage Merger Sub Inc [Member]"
       }
      }
     },
     "localname": "VantageMergerSubIncMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_VickersVantageMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vickers vantage .",
        "label": "Vickers Vantage [Member]",
        "terseLabel": "Vicker's Vantage"
       }
      }
     },
     "localname": "VickersVantageMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AccountingPoliciesByPolicyPolicies",
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingencies",
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails",
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheetsParentheticals",
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperations",
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurements",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetails",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfChangeInTheFairValueOfConversionOptionLiability",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfChangesInTheFairValueOfWarrantLiabilitiesAndConversionOptionLiability",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfFairValueHierarchyOfTheValuationInputs",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurements",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfValuedUsingTheCompoundOptionPricingModel",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsTables",
      "http://www.vickersvantagecorp.com/role/PrivatePlacement",
      "http://www.vickersvantagecorp.com/role/PrivatePlacementDetails",
      "http://www.vickersvantagecorp.com/role/PublicOffering",
      "http://www.vickersvantagecorp.com/role/PublicOfferingDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactions",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails",
      "http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatements",
      "http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsDetails",
      "http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsDetailsScheduleOfImpactOfTheseAdjustmentsToTheFinancialStatementAsPreviouslyReported",
      "http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsTables",
      "http://www.vickersvantagecorp.com/role/ShareholdersDeficit",
      "http://www.vickersvantagecorp.com/role/ShareholdersDeficitDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEvents",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails",
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPolicies",
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetails",
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfOrdinarySharesReflectedInCondensedConsolidatedBalanceSheetsAreReconciled",
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShare",
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareParentheticals",
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesTables",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsParentheticals",
      "http://www.vickersvantagecorp.com/role/Warrants",
      "http://www.vickersvantagecorp.com/role/WarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_WarrantExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant exercise price.",
        "label": "Warrant Exercise Price"
       }
      }
     },
     "localname": "WarrantExercisePrice",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "sclx_WarrantsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants Abstract"
       }
      }
     },
     "localname": "WarrantsAbstract",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "xbrltype": "stringItemType"
    },
    "sclx_WarrantsDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants (Details) [Line Items]"
       }
      }
     },
     "localname": "WarrantsDetailsLineItems",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/WarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_WarrantsDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants (Details) [Table]"
       }
      }
     },
     "localname": "WarrantsDetailsTable",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/WarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_WarrantsExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Exercise Price",
        "label": "Warrants Exercise Price",
        "terseLabel": "Warrant price per share (in Dollars per share)"
       }
      }
     },
     "localname": "WarrantsExercisePrice",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "sclx_WarrantsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants [Line item]",
        "label": "Warrants [Line Items]"
       }
      }
     },
     "localname": "WarrantsLineItems",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/Warrants"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_WarrantsOutstandingShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants outstanding shares.",
        "label": "Warrants Outstanding Shares",
        "terseLabel": "Warrants outstanding shares"
       }
      }
     },
     "localname": "WarrantsOutstandingShares",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/WarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sclx_WarrantsPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Percentage.",
        "label": "Warrants Percentage",
        "terseLabel": "Warrants percentage"
       }
      }
     },
     "localname": "WarrantsPercentage",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sclx_WarrantsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants [Table]"
       }
      }
     },
     "localname": "WarrantsTable",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/Warrants"
     ],
     "xbrltype": "stringItemType"
    },
    "sclx_WarrantsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants Text Block",
        "terseLabel": "WARRANTS"
       }
      }
     },
     "localname": "WarrantsTextBlock",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/Warrants"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sclx_WorkOrderImplementationFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Work order implementation fee.",
        "label": "Work Order Implementation Fee",
        "terseLabel": "Work order implementation fee"
       }
      }
     },
     "localname": "WorkOrderImplementationFee",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_WorkingCapital": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Working capital.",
        "label": "Working Capital",
        "terseLabel": "Working capital"
       }
      }
     },
     "localname": "WorkingCapital",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_WorkingCapitalRequirements": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Working capital requirements.",
        "label": "Working Capital Requirements",
        "terseLabel": "Working capital requirements"
       }
      }
     },
     "localname": "WorkingCapitalRequirements",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sclx_YorkvilleMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Yorkville.",
        "label": "Yorkville [Member]"
       }
      }
     },
     "localname": "YorkvilleMember",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sclx_aggregatePurchasePrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "aggregate purchase price.",
        "label": "aggregate Purchase Price",
        "terseLabel": "Aggregate purchase price value"
       }
      }
     },
     "localname": "aggregatePurchasePrice",
     "nsuri": "http://www.vickersvantagecorp.com/20220930",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Financial Information Disclosure [Abstract]"
       }
      }
     },
     "localname": "CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract",
     "nsuri": "http://fasb.org/srt/2022",
     "xbrltype": "stringItemType"
    },
    "srt_CondensedFinancialStatementsCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Condensed Financial Statements, Captions [Line Items]"
       }
      }
     },
     "localname": "CondensedFinancialStatementsCaptionsLineItems",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatements",
      "http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsDetails",
      "http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsDetailsScheduleOfImpactOfTheseAdjustmentsToTheFinancialStatementAsPreviouslyReported",
      "http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of investment including named security. Excludes entity that is consolidated.",
        "label": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r354",
      "r677",
      "r748",
      "r876"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name or description of a single external customer or a group of external customers.",
        "label": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r385",
      "r386",
      "r387",
      "r388",
      "r468",
      "r603",
      "r626",
      "r649",
      "r650",
      "r675",
      "r683",
      "r688",
      "r744",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upper limit of the provided range.",
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails",
      "http://www.vickersvantagecorp.com/role/DebtDetails",
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfShareBasedPaymentAwardOptionsIssuedToEmployeesAndNonemployeesValuationAssumptions",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r385",
      "r386",
      "r387",
      "r388",
      "r468",
      "r603",
      "r626",
      "r649",
      "r650",
      "r675",
      "r683",
      "r688",
      "r744",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lower limit of the provided range.",
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails",
      "http://www.vickersvantagecorp.com/role/DebtDetails",
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfShareBasedPaymentAwardOptionsIssuedToEmployeesAndNonemployeesValuationAssumptions",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r354",
      "r677",
      "r748",
      "r876"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Single external customer or group of external customers.",
        "label": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r352",
      "r605",
      "r676",
      "r687",
      "r739",
      "r740",
      "r748",
      "r875"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by product and service, or group of similar products and similar services.",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r352",
      "r605",
      "r676",
      "r687",
      "r739",
      "r740",
      "r748",
      "r875"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product or service, or a group of similar products or similar services.",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r385",
      "r386",
      "r387",
      "r388",
      "r457",
      "r468",
      "r501",
      "r502",
      "r503",
      "r601",
      "r603",
      "r626",
      "r649",
      "r650",
      "r675",
      "r683",
      "r688",
      "r738",
      "r744",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails",
      "http://www.vickersvantagecorp.com/role/DebtDetails",
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetails",
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfShareBasedPaymentAwardOptionsIssuedToEmployeesAndNonemployeesValuationAssumptions",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r385",
      "r386",
      "r387",
      "r388",
      "r457",
      "r468",
      "r501",
      "r502",
      "r503",
      "r601",
      "r603",
      "r626",
      "r649",
      "r650",
      "r675",
      "r683",
      "r688",
      "r738",
      "r744",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails",
      "http://www.vickersvantagecorp.com/role/DebtDetails",
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetails",
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfShareBasedPaymentAwardOptionsIssuedToEmployeesAndNonemployeesValuationAssumptions",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAdjustmentMember": {
     "auth_ref": [
      "r288",
      "r289",
      "r290",
      "r298",
      "r299",
      "r321",
      "r547",
      "r548",
      "r719",
      "r720",
      "r721",
      "r722",
      "r724",
      "r728",
      "r729"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cumulative increase (decrease) for adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision.",
        "label": "Revision of Prior Period, Adjustment [Member]",
        "terseLabel": "Adjustments Restatement 1 [Member]"
       }
      }
     },
     "localname": "RestatementAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsDetailsScheduleOfImpactOfTheseAdjustmentsToTheFinancialStatementAsPreviouslyReported"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAxis": {
     "auth_ref": [
      "r239",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r321",
      "r363",
      "r364",
      "r527",
      "r546",
      "r547",
      "r548",
      "r549",
      "r573",
      "r587",
      "r588",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision.",
        "label": "Revision of Prior Period [Axis]"
       }
      }
     },
     "localname": "RestatementAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails",
      "http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsDetailsScheduleOfImpactOfTheseAdjustmentsToTheFinancialStatementAsPreviouslyReported"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RestatementDomain": {
     "auth_ref": [
      "r239",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r321",
      "r363",
      "r364",
      "r527",
      "r546",
      "r547",
      "r548",
      "r549",
      "r573",
      "r587",
      "r588",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision.",
        "label": "Revision of Prior Period [Domain]"
       }
      }
     },
     "localname": "RestatementDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails",
      "http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsDetailsScheduleOfImpactOfTheseAdjustmentsToTheFinancialStatementAsPreviouslyReported"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioPreviouslyReportedMember": {
     "auth_ref": [
      "r239",
      "r288",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r302",
      "r321",
      "r527",
      "r546",
      "r547",
      "r548",
      "r573",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r723",
      "r724",
      "r726",
      "r727",
      "r728",
      "r734",
      "r735",
      "r852",
      "r861",
      "r862"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents amount as previously reported before adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision.",
        "label": "Previously Reported [Member]",
        "terseLabel": "Previously Reported [Member]"
       }
      }
     },
     "localname": "ScenarioPreviouslyReportedMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsDetailsScheduleOfImpactOfTheseAdjustmentsToTheFinancialStatementAsPreviouslyReported"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r303",
      "r473",
      "r692",
      "r725"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.",
        "label": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfCondensedBalanceSheetTableTextBlock": {
     "auth_ref": [
      "r715",
      "r878"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations.",
        "label": "Condensed Balance Sheet [Table Text Block]",
        "terseLabel": "Schedule of ordinary shares reflected in condensed consolidated balance sheets are reconciled"
       }
      }
     },
     "localname": "ScheduleOfCondensedBalanceSheetTableTextBlock",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srt_ScheduleOfCondensedFinancialStatementsTable": {
     "auth_ref": [
      "r287",
      "r655",
      "r656",
      "r657",
      "r658",
      "r693"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about condensed financial statements, including, but not limited to, the balance sheet, income statement, and statement of cash flows.",
        "label": "Condensed Financial Statements [Table]"
       }
      }
     },
     "localname": "ScheduleOfCondensedFinancialStatementsTable",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatements",
      "http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsDetails",
      "http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsDetailsScheduleOfImpactOfTheseAdjustmentsToTheFinancialStatementAsPreviouslyReported",
      "http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ScheduleOfCondensedFinancialStatementsTableTextBlock": {
     "auth_ref": [
      "r715",
      "r878"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of condensed financial statements, including, but not limited to, the balance sheet, income statement, and statement of cash flows.",
        "label": "Condensed Financial Statements [Table Text Block]",
        "terseLabel": "Schedule of impact of these adjustments to the financial statement, as previously reported"
       }
      }
     },
     "localname": "ScheduleOfCondensedFinancialStatementsTableTextBlock",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of investment including named security. Excludes entity that is consolidated.",
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r303",
      "r473",
      "r692",
      "r694",
      "r725"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.",
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_WeightedAverageMember": {
     "auth_ref": [
      "r649",
      "r650",
      "r866",
      "r868",
      "r871"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average of a range of values, calculated with consideration of proportional relevance.",
        "label": "Weighted Average [Member]"
       }
      }
     },
     "localname": "WeightedAverageMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 44.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "terseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r16",
      "r686"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 23.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableMember": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Obligations incurred and payable to vendors for goods and services received.",
        "label": "Accounts Payable [Member]"
       }
      }
     },
     "localname": "AccountsPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r355",
      "r356"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 25.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r201",
      "r221"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.",
        "label": "Accrued Liabilities",
        "terseLabel": "Accrued Liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesMember": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered.",
        "label": "Accrued Liabilities [Member]"
       }
      }
     },
     "localname": "AccruedLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r92",
      "r248"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/PropertyAndEquipmentDetailsPropertyAndEquipmentConsisted"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue": {
     "auth_ref": [
      "r79"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expected value at the end of their useful life of a major finite-lived intangible asset class acquired during the period either individually or as part of a group of assets (in either an asset acquisition or business combination). A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Acquired Finite-Lived Intangible Asset, Residual Value",
        "terseLabel": "Acquired Finite-Lived Intangible Asset, Residual Value"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetResidualValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Acquired finite lived intangible assets, weighted average useful life"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r10",
      "r686"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 18.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "definitionGuidance": "Additional Paid-in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital",
        "verboseLabel": "Additional amount borrowed"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails",
      "http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsDetailsScheduleOfImpactOfTheseAdjustmentsToTheFinancialStatementAsPreviouslyReported"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r507",
      "r508",
      "r509",
      "r716",
      "r717",
      "r718",
      "r851"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used for operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r505"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Stock based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r36",
      "r50",
      "r187",
      "r422"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 41.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of Debt Discount (Premium)",
        "terseLabel": "Amortization of debt discount"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r422",
      "r571",
      "r673",
      "r674",
      "r707"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 51.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of debt issuance costs and debt discount"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r50",
      "r77",
      "r85"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": {
       "order": 6.0,
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Intangible amortization",
        "verboseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetails",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share, amount"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/LossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails",
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "AssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionAxis": {
     "auth_ref": [
      "r845"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by asset acquisition.",
        "label": "Asset Acquisition [Axis]"
       }
      }
     },
     "localname": "AssetAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionConsiderationTransferred": {
     "auth_ref": [
      "r684",
      "r846",
      "r847",
      "r848"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.",
        "label": "Asset Acquisition, Consideration Transferred",
        "terseLabel": "Asset acquisition, consideration transferred",
        "verboseLabel": "Asset acquisition total consideration transferred"
       }
      }
     },
     "localname": "AssetAcquisitionConsiderationTransferred",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable": {
     "auth_ref": [
      "r846",
      "r847",
      "r848"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of acquirer's equity interest issued and issuable as part of consideration transferred in asset acquisition.",
        "label": "Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable",
        "terseLabel": "Asset acquistion consideration transferred equity interest issued and issuable"
       }
      }
     },
     "localname": "AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetAcquisitionContingentConsiderationLiability": {
     "auth_ref": [
      "r845"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized from contingent consideration in asset acquisition.",
        "label": "Asset Acquisition, Contingent Consideration, Liability",
        "terseLabel": "Asset acquistion contingent consideration"
       }
      }
     },
     "localname": "AssetAcquisitionContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetAcquisitionDomain": {
     "auth_ref": [
      "r845"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition.",
        "label": "Asset Acquisition [Domain]"
       }
      }
     },
     "localname": "AssetAcquisitionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Asset Acquisition [Line Items]"
       }
      }
     },
     "localname": "AssetAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionTable": {
     "auth_ref": [
      "r845"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset acquisition.",
        "label": "Asset Acquisition [Table]"
       }
      }
     },
     "localname": "AssetAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionTextBlock": {
     "auth_ref": [
      "r845"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for asset acquisition.",
        "label": "Asset Acquisition [Text Block]",
        "verboseLabel": "Acquisitions"
       }
      }
     },
     "localname": "AssetAcquisitionTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/Acquisitions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r196",
      "r215",
      "r252",
      "r283",
      "r337",
      "r346",
      "r350",
      "r361",
      "r389",
      "r390",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r398",
      "r399",
      "r540",
      "r542",
      "r558",
      "r686",
      "r742",
      "r743",
      "r864"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS",
        "verboseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfFairValueHierarchyOfTheValuationInputs"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r242",
      "r261",
      "r283",
      "r361",
      "r389",
      "r390",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r398",
      "r399",
      "r540",
      "r542",
      "r558",
      "r686",
      "r742",
      "r743",
      "r864"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets:"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r168"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Total assets measured at fair value"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsFinancialAssetsAndLiabilitiesThatAreMeasuredAtFairValue"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsHeldInTrust": {
     "auth_ref": [
      "r709"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "definitionGuidance": "Assets Held-in-trust",
        "documentation": "The total amount of cash and securities held by third party trustees pursuant to terms of debt instruments or other agreements as of the date of each statement of financial position presented, which can be used by the trustee only to pay the noncurrent portion of specified obligations.",
        "label": "Assets Held-in-trust",
        "terseLabel": "Deposited trust account",
        "verboseLabel": "Trust account"
       }
      }
     },
     "localname": "AssetsHeldInTrust",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsHeldInTrustCurrent": {
     "auth_ref": [
      "r709"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash, securities, or other assets held by a third-party trustee pursuant to the terms of an agreement which assets are available to be used by beneficiaries to that agreement only within the specific terms thereof and which agreement is expected to terminate within one year of the balance sheet date (or operating cycle, if longer) at which time the assets held-in-trust will be released or forfeited.",
        "label": "Assets Held-in-trust, Current",
        "terseLabel": "Assets held in the trust account"
       }
      }
     },
     "localname": "AssetsHeldInTrustCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsHeldInTrustNoncurrent": {
     "auth_ref": [
      "r709"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash, securities, or other assets held by a third-party trustee pursuant to the terms of an agreement which assets are available to be used by beneficiaries to that agreement only within the specific terms thereof and which agreement is expected to terminate more than one year from the balance sheet date (or operating cycle, if longer) at which time the assets held-in-trust will be released or forfeited.",
        "label": "Assets Held-in-trust, Noncurrent",
        "terseLabel": "Investments held in Trust Account \u2013 U.S. Treasury Securities Money Market Fund"
       }
      }
     },
     "localname": "AssetsHeldInTrustNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r476",
      "r477",
      "r478",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r165",
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Significant Accounting Policies"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AccountingPoliciesByPolicyPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AccountingPoliciesByPolicyPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r538",
      "r681",
      "r682"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails",
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r148",
      "r149",
      "r538",
      "r681",
      "r682"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails",
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.",
        "label": "Business Acquisition, Transaction Costs",
        "terseLabel": "Transaction costs amount"
       }
      }
     },
     "localname": "BusinessAcquisitionCostOfAcquiredEntityTransactionCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.",
        "label": "Business Acquisition, Percentage of Voting Interests Acquired",
        "terseLabel": "Business combination equity interest acquired"
       }
      }
     },
     "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_BusinessCombinationAcquiredReceivablesDescription": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of receivable acquired in business combination.",
        "label": "Business Combination, Acquired Receivables, Description",
        "terseLabel": "Business combination description"
       }
      }
     },
     "localname": "BusinessCombinationAcquiredReceivablesDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": {
     "auth_ref": [
      "r154",
      "r155"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.",
        "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable",
        "terseLabel": "Equity interest from business combination"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationControlObtainedDescription": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents a description of how the entity obtained control of the acquired entity.",
        "label": "Business Combination, Control Obtained Description",
        "terseLabel": "Business combination, description"
       }
      }
     },
     "localname": "BusinessCombinationControlObtainedDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationReasonForBusinessCombination": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents a description of the primary reason for the business combination which may consist of general categories such as top-line growth, synergistic benefits, market share, and diversification and the more detailed factors that might apply.",
        "label": "Business Combination, Reason for Business Combination",
        "terseLabel": "Business combination, description"
       }
      }
     },
     "localname": "BusinessCombinationReasonForBusinessCombination",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of equity in the acquiree held by the acquirer immediately before the acquisition date in a business combination.",
        "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage",
        "terseLabel": "Redeem percentage"
       }
      }
     },
     "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Business Combination"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AccountingPoliciesByPolicyPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Cash": {
     "auth_ref": [
      "r638",
      "r639",
      "r686",
      "r695"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r52",
      "r245",
      "r659"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsFinancialAssetsAndLiabilitiesThatAreMeasuredAtFairValue"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r53"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AccountingPoliciesByPolicyPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r47",
      "r52",
      "r57"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]",
        "terseLabel": "Reconciliation of cash, cash equivalents and restricted cash within the Company's balance sheet"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r47",
      "r186"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Net change in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFDICInsuredAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.",
        "label": "Cash, FDIC Insured Amount",
        "terseLabel": "Federal depository insurance coverage"
       }
      }
     },
     "localname": "CashFDICInsuredAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosures of non-cash investing and financing activities"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashFlowOperatingActivitiesLesseeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Operating Activities, Lessee [Abstract]"
       }
      }
     },
     "localname": "CashFlowOperatingActivitiesLesseeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r255",
      "r256",
      "r257",
      "r283",
      "r307",
      "r308",
      "r315",
      "r317",
      "r325",
      "r326",
      "r361",
      "r389",
      "r392",
      "r393",
      "r394",
      "r398",
      "r399",
      "r430",
      "r431",
      "r434",
      "r438",
      "r445",
      "r558",
      "r651",
      "r691",
      "r710",
      "r730"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails",
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheetsParentheticals",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurements",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetails",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurements",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfValuedUsingTheCompoundOptionPricingModel",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsTables",
      "http://www.vickersvantagecorp.com/role/SubsequentEvents",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/ShareholdersDeficit",
      "http://www.vickersvantagecorp.com/role/ShareholdersDeficitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Price per warrant"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/PrivatePlacementDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Sale of warrants (in Shares)",
        "verboseLabel": "Aggregate purchase of private placement warrants (in Shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails",
      "http://www.vickersvantagecorp.com/role/PrivatePlacementDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r26",
      "r202",
      "r220"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 20.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (See Note 8)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r95",
      "r383",
      "r384",
      "r645",
      "r741"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonClassAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock representing ownership interest in a corporation.",
        "label": "Common Class A [Member]"
       }
      }
     },
     "localname": "CommonClassAMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Number of shares reserved for issuance under plan"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r716",
      "r717",
      "r851"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Ordinary Shares"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockNoParValue": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount per share of no-par value common stock.",
        "label": "Common Stock, No Par Value",
        "terseLabel": "Common stock par value"
       }
      }
     },
     "localname": "CommonStockNoParValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Ordinary shares, par value (in Dollars per share)",
        "verboseLabel": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheetsParentheticals",
      "http://www.vickersvantagecorp.com/role/ShareholdersDeficitDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "verboseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheetsParentheticals",
      "http://www.vickersvantagecorp.com/role/ShareholdersDeficitDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common Stock, Shares, Issued",
        "verboseLabel": "Ordinary shares, issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheetsParentheticals",
      "http://www.vickersvantagecorp.com/role/ShareholdersDeficitDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r9",
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common Stock, Shares, Outstanding",
        "verboseLabel": "Ordinary shares, outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheetsParentheticals",
      "http://www.vickersvantagecorp.com/role/ShareholdersDeficitDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesSubscribedButUnissued": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.",
        "label": "Common Stock, Shares Subscribed but Unissued",
        "terseLabel": "Common stock shares subscribed but not issued"
       }
      }
     },
     "localname": "CommonStockSharesSubscribedButUnissued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesSubscriptions": {
     "auth_ref": [
      "r9",
      "r107"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Monetary value of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.",
        "label": "Common Stock, Value, Subscriptions",
        "terseLabel": "Common stock shares subscribed but not issued value"
       }
      }
     },
     "localname": "CommonStockSharesSubscriptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r9",
      "r686"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 17.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.0001 par value, 350,000,000 shares authorized; 197,566,338 and 197,266,338 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively",
        "verboseLabel": "Ordinary Shares"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsDetailsScheduleOfImpactOfTheseAdjustmentsToTheFinancialStatementAsPreviouslyReported"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "auth_ref": [
      "r122",
      "r123",
      "r125",
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.",
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "terseLabel": "Stock Incentive and Employee Benefit Plans"
       }
      }
     },
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets [Abstract]",
        "terseLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfDeferredTaxAssetsAndLiabilities"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets and Liabilities [Abstract]"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/PropertyAndEquipmentDetailsPropertyAndEquipmentConsisted"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r66",
      "r67",
      "r179",
      "r180",
      "r354",
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r66",
      "r67",
      "r179",
      "r180",
      "r354",
      "r637",
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r66",
      "r67",
      "r179",
      "r180",
      "r354",
      "r644",
      "r877"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r212",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AccountingPoliciesByPolicyPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r66",
      "r67",
      "r179",
      "r180",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r66",
      "r67",
      "r179",
      "r180",
      "r354",
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock": {
     "auth_ref": [
      "r240",
      "r287",
      "r693"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for condensed financial information, including the financial position, cash flows, and the results of operations of the registrant (parent company) as of the same dates or for the same periods for which audited consolidated financial statements are being presented. Alternatively, the details of this disclosure can be reported by the specific parent company taxonomy elements, indicating the appropriate date and period contexts in an instance document.",
        "label": "Condensed Financial Information of Parent Company Only Disclosure [Text Block]",
        "terseLabel": "RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS"
       }
      }
     },
     "localname": "CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r157",
      "r663"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AccountingPoliciesByPolicyPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/PropertyAndEquipmentDetailsPropertyAndEquipmentConsisted"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleDebt": {
     "auth_ref": [
      "r7",
      "r198",
      "r216"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.",
        "label": "Convertible Debt",
        "terseLabel": "Convertible promissory notes"
       }
      }
     },
     "localname": "ConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleLongTermNotesPayable": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 31.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.",
        "label": "Convertible Notes Payable, Noncurrent",
        "terseLabel": "Convertible promissory notes \u2014 related party, net of discount"
       }
      }
     },
     "localname": "ConvertibleLongTermNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleNotesPayableMember": {
     "auth_ref": [
      "r5",
      "r197",
      "r213",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder.",
        "label": "Convertible Notes Payable [Member]"
       }
      }
     },
     "localname": "ConvertibleNotesPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization": {
     "auth_ref": [
      "r702"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 50.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for allocation of cost of tangible and intangible assets over their useful lives directly used in production of good and rendering of service.",
        "label": "Cost, Depreciation and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSoldDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r31",
      "r283",
      "r361",
      "r389",
      "r390",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r398",
      "r399",
      "r558",
      "r742"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of Revenue",
        "terseLabel": "Cost of revenue"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesRelatedParty": {
     "auth_ref": [
      "r31"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Costs of sales and operating expenses for the period incurred from transactions with related parties.",
        "label": "Costs and Expenses, Related Party",
        "terseLabel": "Fund expenses"
       }
      }
     },
     "localname": "CostsAndExpensesRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails",
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails",
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r713",
      "r841",
      "r843"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfComponentsOfIncomeTaxExpenseBenefit": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfComponentsOfIncomeTaxExpenseBenefit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r144",
      "r523",
      "r531",
      "r713"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfComponentsOfIncomeTaxExpenseBenefit": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Current income tax expense (benefit)"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfComponentsOfIncomeTaxExpenseBenefit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Current expense:"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfComponentsOfIncomeTaxExpenseBenefit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r713",
      "r841",
      "r843"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfComponentsOfIncomeTaxExpenseBenefit": {
       "order": 3.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfComponentsOfIncomeTaxExpenseBenefit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r65",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "auth_ref": [
      "r54",
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Shares Issued",
        "terseLabel": "Debt Conversion, Converted Instrument, Shares Issued"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r101",
      "r281",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r416",
      "r423",
      "r424",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/Debt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAnnualPrincipalPayment": {
     "auth_ref": [
      "r7"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the total principal payments made during the annual reporting period.",
        "label": "Debt Instrument, Annual Principal Payment",
        "terseLabel": "Debt Instrument, Annual Principal Payment",
        "verboseLabel": "Debt instrument, annual principal payment"
       }
      }
     },
     "localname": "DebtInstrumentAnnualPrincipalPayment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails",
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r5",
      "r6",
      "r7",
      "r197",
      "r198",
      "r213",
      "r287",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r406",
      "r412",
      "r413",
      "r414",
      "r415",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r572",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r711"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails",
      "http://www.vickersvantagecorp.com/role/DebtDetailsSummaryOfBorrowingsOfTheScilexPharmaNotes",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetails",
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r7",
      "r198",
      "r213",
      "r427"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-Term Debt, Gross",
        "terseLabel": "Principal"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetailsSummaryOfBorrowingsOfTheScilexPharmaNotes"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentCollateralAmount": {
     "auth_ref": [
      "r209"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets pledged to secure a debt instrument.",
        "label": "Debt Instrument, Collateral Amount",
        "terseLabel": "Debt instrument, collateral amount"
       }
      }
     },
     "localname": "DebtInstrumentCollateralAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentDecreaseForgiveness": {
     "auth_ref": [
      "r711"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease for amounts of indebtedness forgiven by the holder of the debt instrument.",
        "label": "Debt Instrument, Decrease, Forgiveness",
        "terseLabel": "Debt instrument, decrease, forgiveness"
       }
      }
     },
     "localname": "DebtInstrumentDecreaseForgiveness",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails",
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r188",
      "r190",
      "r400",
      "r572",
      "r671",
      "r672"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "disclosureGuidance": "Debt Instrument, Face Amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Aggregate principal amount",
        "verboseLabel": "Debt instrument face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails",
      "http://www.vickersvantagecorp.com/role/DebtDetails",
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails",
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet": {
     "auth_ref": [
      "r711"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net increase or decrease in the carrying amount of the debt instrument for the period.",
        "label": "Debt Instrument, Increase (Decrease), Net",
        "terseLabel": "Debt instrument, increase (decrease), net"
       }
      }
     },
     "localname": "DebtInstrumentIncreaseDecreaseForPeriodNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r23",
      "r188",
      "r429",
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Debt instrument interest rate effective percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r23",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Debt instrument, interest rate, stated percentage",
        "verboseLabel": "Debt Instrument, Interest Rate, Stated Percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails",
      "http://www.vickersvantagecorp.com/role/DebtDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetailsSummaryOfBorrowingsOfTheScilexPharmaNotes"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "auth_ref": [
      "r262",
      "r670",
      "r853"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.",
        "label": "Debt Instrument, Maturity Date",
        "terseLabel": "Debt instrument, maturity date"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r24",
      "r287",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r406",
      "r412",
      "r413",
      "r414",
      "r415",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r572",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r711"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails",
      "http://www.vickersvantagecorp.com/role/DebtDetailsSummaryOfBorrowingsOfTheScilexPharmaNotes",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetails",
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentPeriodicPayment": {
     "auth_ref": [
      "r24",
      "r208"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the required periodic payments including both interest and principal payments.",
        "label": "Debt Instrument, Periodic Payment",
        "terseLabel": "Debt instrument, periodic payment"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPayment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about timing of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features.",
        "label": "Debt Instrument, Redemption, Period [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodOneMember": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period One [Member]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodOneMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodThreeMember": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period three representing third most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period Three [Member]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodThreeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period Two [Member]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of principal amount of debt redeemed.",
        "label": "Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed",
        "terseLabel": "Debt instrument, redemption price, percentage"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentRepurchaseAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value amount of debt instrument that was repurchased.",
        "label": "Debt Instrument, Repurchase Amount",
        "terseLabel": "Debt instrument, repurchase amount"
       }
      }
     },
     "localname": "DebtInstrumentRepurchaseAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentRepurchaseDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date the debt instrument was repurchased, in YYYY-MM-DD format.",
        "label": "Debt Instrument, Repurchase Date",
        "terseLabel": "Debt instrument, repurchase date"
       }
      }
     },
     "localname": "DebtInstrumentRepurchaseDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DebtInstrumentRepurchasedFaceAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of the original debt instrument that was repurchased.",
        "label": "Debt Instrument, Repurchased Face Amount",
        "terseLabel": "Debt instrument face amount of debt repurchased"
       }
      }
     },
     "localname": "DebtInstrumentRepurchasedFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails",
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r24",
      "r111",
      "r115",
      "r116",
      "r117",
      "r187",
      "r188",
      "r190",
      "r211",
      "r287",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r406",
      "r412",
      "r413",
      "r414",
      "r415",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r425",
      "r572",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r711"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetailsSummaryOfBorrowingsOfTheScilexPharmaNotes"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Debt instrument, term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails",
      "http://www.vickersvantagecorp.com/role/DebtDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r187",
      "r190",
      "r745"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument, Unamortized Discount",
        "negatedLabel": "Unamortized debt discount"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetailsSummaryOfBorrowingsOfTheScilexPharmaNotes"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountCurrent": {
     "auth_ref": [
      "r187",
      "r190"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of debt discount to be amortized within one year or within the normal operating cycle, if longer.",
        "label": "Debt Instrument, Unamortized Discount, Current",
        "terseLabel": "Debt instrument, unamortized discount"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtPolicyTextBlock": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.",
        "label": "Debt, Policy [Policy Text Block]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "DebtPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AccountingPoliciesByPolicyPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts": {
     "auth_ref": [
      "r36"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the charge against earnings during the period for commitment fees and debt issuance expenses.",
        "label": "Debt Related Commitment Fees and Debt Issuance Costs",
        "terseLabel": "Debt related commitment Fees and debt issuance costs"
       }
      }
     },
     "localname": "DebtRelatedCommitmentFeesAndDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredChargesPolicyTextBlock": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges.",
        "label": "Deferred Charges, Policy [Policy Text Block]",
        "terseLabel": "Offering Costs"
       }
      }
     },
     "localname": "DeferredChargesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AccountingPoliciesByPolicyPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 36.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable beyond one year (or the operating cycle, if longer).",
        "label": "Deferred Compensation Liability, Classified, Noncurrent",
        "terseLabel": "Deferred underwriting fee payable"
       }
      }
     },
     "localname": "DeferredCompensationLiabilityClassifiedNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCosts": {
     "auth_ref": [
      "r195",
      "r214",
      "r696"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 13.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent.",
        "label": "Deferred Costs, Noncurrent",
        "terseLabel": "Deferred offering costs"
       }
      }
     },
     "localname": "DeferredCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r713",
      "r842",
      "r843"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfComponentsOfIncomeTaxExpenseBenefit": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfComponentsOfIncomeTaxExpenseBenefit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r50",
      "r144",
      "r524",
      "r530",
      "r531",
      "r713"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfComponentsOfIncomeTaxExpenseBenefit": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Deferred income tax expense (benefit)"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfComponentsOfIncomeTaxExpenseBenefit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Deferred"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfComponentsOfIncomeTaxExpenseBenefit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredRevenueCurrent": {
     "auth_ref": [
      "r697"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 30.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Deferred Revenue, Current",
        "terseLabel": "Current portion of deferred consideration"
       }
      }
     },
     "localname": "DeferredRevenueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueNoncurrent": {
     "auth_ref": [
      "r698"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 45.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Deferred Revenue, Noncurrent",
        "terseLabel": "Long-term deferred consideration"
       }
      }
     },
     "localname": "DeferredRevenueNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r713",
      "r842",
      "r843"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfComponentsOfIncomeTaxExpenseBenefit": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfComponentsOfIncomeTaxExpenseBenefit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r519"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfDeferredTaxAssetsAndLiabilities": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total Deferred Tax Assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfDeferredTaxAssetsAndLiabilities"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r839"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfDeferredTaxAssetsAndLiabilities": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total Deferred Tax Assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfDeferredTaxAssetsAndLiabilities"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r142",
      "r840"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfDeferredTaxAssetsAndLiabilities": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfDeferredTaxAssetsAndLiabilities"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r142",
      "r840"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfDeferredTaxAssetsAndLiabilities": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Others"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfDeferredTaxAssetsAndLiabilities"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "auth_ref": [
      "r140",
      "r142",
      "r840"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfDeferredTaxAssetsAndLiabilities": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "terseLabel": "Tax credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfDeferredTaxAssetsAndLiabilities"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r142",
      "r840"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfDeferredTaxAssetsAndLiabilities": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Stock based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfDeferredTaxAssetsAndLiabilities"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r520"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfDeferredTaxAssetsAndLiabilities": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance",
        "terseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetails",
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfDeferredTaxAssetsAndLiabilities"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r136",
      "r839"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfDeferredTaxAssetsAndLiabilities": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Total Deferred Tax Liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfDeferredTaxAssetsAndLiabilities"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "auth_ref": [
      "r142",
      "r840"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfDeferredTaxAssetsAndLiabilities": {
       "order": 9.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "negatedLabel": "Amortization of intangibles"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfDeferredTaxAssetsAndLiabilities"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "auth_ref": [
      "r142",
      "r840"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfDeferredTaxAssetsAndLiabilities": {
       "order": 11.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.",
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "negatedLabel": "Operating lease\u00a0right-of-use\u00a0assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfDeferredTaxAssetsAndLiabilities"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Net [Abstract]",
        "terseLabel": "Deferred Tax Liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfDeferredTaxAssetsAndLiabilities"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r142",
      "r840"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfDeferredTaxAssetsAndLiabilities": {
       "order": 10.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities, Other",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfDeferredTaxAssetsAndLiabilities"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "Defined contribution plan matching contribution amount"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DemutualizationByInsuranceEntitySecuritiesIssuedGrossCashProceeds": {
     "auth_ref": [
      "r227"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share or unit times the number of shares or units issued in an insurance entity stock offering in connection with its conversion from a mutual form of ownership to a stock entity. Amount is gross, before offering costs.",
        "label": "Demutualization by Insurance Entity, Securities Issued, Gross Cash Proceeds",
        "terseLabel": "Gross proceeds"
       }
      }
     },
     "localname": "DemutualizationByInsuranceEntitySecuritiesIssuedGrossCashProceeds",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents derivative instrument obligations meeting the definition of a liability which are reported as of the balance sheet date. Derivative instrument obligations are generally measured at fair value, and adjustments to the carrying amount of hedged items reflect changes in their fair value (that is, losses) that are attributable to the risk being hedged and that arise while the hedge is in effect.",
        "label": "Derivative Financial Instruments, Liabilities [Member]"
       }
      }
     },
     "localname": "DerivativeFinancialInstrumentsLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetails",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsDerivativeLiabilitiesMeasuredAtFairValueUsingSignificantUnobservableInputs"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "auth_ref": [
      "r850"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 48.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.",
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "negatedLabel": "Gain on derivative liability"
       }
      }
     },
     "localname": "DerivativeGainLossOnDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeGainOnDerivative": {
     "auth_ref": [
      "r544"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in the fair value of derivatives recognized in the income statement.",
        "label": "Derivative, Gain on Derivative",
        "terseLabel": "Derivative, Gain on Derivative"
       }
      }
     },
     "localname": "DerivativeGainOnDerivative",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r263",
      "r264",
      "r557",
      "r662"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 35.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "periodEndLabel": "Fair value ending",
        "periodStartLabel": "Fair value beginning",
        "terseLabel": "Warrant liability",
        "verboseLabel": "Derivative liabilities"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.vickersvantagecorp.com/role/DebtDetails",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetails",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsFinancialAssetsAndLiabilitiesThatAreMeasuredAtFairValue",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfChangesInTheFairValueOfWarrantLiabilitiesAndConversionOptionLiability",
      "http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsDetailsScheduleOfImpactOfTheseAdjustmentsToTheFinancialStatementAsPreviouslyReported"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityMeasurementInput": {
     "auth_ref": [
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure derivative liability.",
        "label": "Derivative Liability, Measurement Input",
        "terseLabel": "Derivative liability, Measurement input"
       }
      }
     },
     "localname": "DerivativeLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_DerivativeLossOnDerivative": {
     "auth_ref": [
      "r544"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in the fair value of derivatives recognized in the income statement.",
        "label": "Derivative, Loss on Derivative",
        "terseLabel": "Derivative, Loss on derivative"
       }
      }
     },
     "localname": "DerivativeLossOnDerivative",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r161",
      "r162",
      "r163",
      "r164",
      "r167",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Warrant Liability"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AccountingPoliciesByPolicyPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DilutiveSecurities": {
     "auth_ref": [
      "r63"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise stock options, restrictive stock units (RSUs), convertible preferred stock of an employee stock ownership plan (ESOP), and other dilutive convertible securities.",
        "label": "Dilutive Securities, Effect on Basic Earnings Per Share",
        "terseLabel": "Effect of Dilutive Securities"
       }
      }
     },
     "localname": "DilutiveSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/LossPerShareDetailsSummaryOfReconciliationOfBasicAndDilutedLossPerShare"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DistributionsOnMandatorilyRedeemableSecurities": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 37.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": {
       "order": 19.0,
       "parentTag": "us-gaap_OtherOperatingIncomeExpenseNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of distributions during the period on mandatorily redeemable securities.",
        "label": "Distributions on Mandatorily Redeemable Securities",
        "negatedLabel": "Interest on mandatorily redeemable ordinary shares liability",
        "terseLabel": "Interest on mandatorily redeemable ordinary shares liability"
       }
      }
     },
     "localname": "DistributionsOnMandatorilyRedeemableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal [Member]"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DueToAffiliateCurrent": {
     "auth_ref": [
      "r4",
      "r191",
      "r228",
      "r714"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payable due to an entity that is affiliated with the reporting entity by means of direct or indirect ownership. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Due to Affiliate, Current",
        "terseLabel": "Advances outstanding"
       }
      }
     },
     "localname": "DueToAffiliateCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrent": {
     "auth_ref": [
      "r16",
      "r391",
      "r392",
      "r393",
      "r397",
      "r398",
      "r399",
      "r592",
      "r714"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 27.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Due to Related Parties, Current",
        "terseLabel": "Related party payable"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r273",
      "r293",
      "r294",
      "r296",
      "r297",
      "r298",
      "r304",
      "r307",
      "r315",
      "r316",
      "r317",
      "r321",
      "r548",
      "r549",
      "r621",
      "r624",
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "definitionGuidance": "Basic Loss Per Share",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic net (loss) income per share, ordinary shares (in Dollars per share)",
        "verboseLabel": "Basic and diluted net income (loss) per ordinary share"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/LossPerShareDetailsSummaryOfReconciliationOfBasicAndDilutedLossPerShare",
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShare",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r273",
      "r293",
      "r294",
      "r296",
      "r297",
      "r298",
      "r307",
      "r315",
      "r316",
      "r317",
      "r321",
      "r548",
      "r549",
      "r621",
      "r624",
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "definitionGuidance": "Dilutive Loss Per Share",
        "disclosureGuidance": "Diluted net income (loss) per ordinary share",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted net (loss) income per share, ordinary shares (in Dollars per share)",
        "verboseLabel": "Basic and diluted net income (loss) per ordinary share (in Dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/LossPerShareDetailsSummaryOfReconciliationOfBasicAndDilutedLossPerShare",
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShare",
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareParentheticals",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsParentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r62",
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Income (Loss) per Ordinary Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AccountingPoliciesByPolicyPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r318",
      "r319",
      "r320",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/LossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective tax rates",
        "verboseLabel": "Income Tax Benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetails",
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfEffectiveIncomeTaxRateReconciliation"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r284",
      "r515",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Statutory federal tax rate",
        "verboseLabel": "Statutory Federal Income Tax Rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetails",
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfEffectiveIncomeTaxRateReconciliation"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r836",
      "r844"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfEffectiveIncomeTaxRateReconciliation"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment": {
     "auth_ref": [
      "r836",
      "r844"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent",
        "terseLabel": "In-process\u00a0research and development"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfEffectiveIncomeTaxRateReconciliation"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r836",
      "r844"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "Others"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfEffectiveIncomeTaxRateReconciliation"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r836",
      "r844"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State taxes, net of federal tax benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfEffectiveIncomeTaxRateReconciliation"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r506"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Total unrecognized compensation costs"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted average period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r110",
      "r238",
      "r268",
      "r269",
      "r270",
      "r288",
      "r289",
      "r290",
      "r292",
      "r299",
      "r302",
      "r324",
      "r362",
      "r447",
      "r507",
      "r508",
      "r509",
      "r526",
      "r527",
      "r547",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r588",
      "r627",
      "r628",
      "r629"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit",
      "http://www.vickersvantagecorp.com/role/WarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Shareholder issued and outstanding shares percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestmentsPolicy": {
     "auth_ref": [
      "r46",
      "r74",
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.",
        "label": "Equity Method Investments [Policy Text Block]",
        "terseLabel": "Investments Held in Trust Account"
       }
      }
     },
     "localname": "EquityMethodInvestmentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AccountingPoliciesByPolicyPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ExcessStockSharesIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of excess stock shares of an entity that have been sold or granted to shareholders.",
        "label": "Excess Stock, Shares Issued",
        "terseLabel": "Purchase of ordinary shares (in Shares)"
       }
      }
     },
     "localname": "ExcessStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r50",
      "r102"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 38.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": {
       "order": 15.0,
       "parentTag": "us-gaap_OtherOperatingIncomeExpenseNet",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Fair Value Adjustment of Warrants",
        "negatedLabel": "Change in fair value of warrant liability",
        "terseLabel": "Change in fair value of warrant liability"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsFinancialAssetsAndLiabilitiesThatAreMeasuredAtFairValue"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r550",
      "r551",
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsFinancialAssetsAndLiabilitiesThatAreMeasuredAtFairValue"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r168",
      "r169",
      "r170",
      "r175",
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r168",
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of fair value hierarchy of the valuation inputs"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r414",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r551",
      "r598",
      "r599",
      "r600",
      "r671",
      "r672",
      "r678",
      "r679",
      "r680"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsFinancialAssetsAndLiabilitiesThatAreMeasuredAtFairValue",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfFairValueHierarchyOfTheValuationInputs"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r174",
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Liability Class [Axis]"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetails",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsDerivativeLiabilitiesMeasuredAtFairValueUsingSignificantUnobservableInputs"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueConcentrationOfRiskTextBlock": {
     "auth_ref": [
      "r179",
      "r181",
      "r182",
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of all significant concentrations of risk, including credit risk and market risk, arising from all financial instruments (as defined), whether from an individual counterparty or groups of counterparties. The disclosure concerning concentrations of risk may consist of the following information: (1) for concentrations of credit risk disclosure may include: (a) information about the (shared) activity, region, or economic characteristic that identifies the concentration, (b) the maximum amount of loss due to credit risk that, based on the gross fair value of the financial instrument, the entity would incur if parties to the financial instruments that make up the concentration failed completely to perform according to the terms of the contracts and the collateral or other security, if any, for the amount due proved to be of no value to the entity, (c) the policy of requiring collateral or other security to support financial instruments subject to credit risk, information about the entity's access to that collateral or other security, and the nature and a brief description of the collateral or other security supporting those financial instruments, and (d) the policy of entering into master netting arrangements to mitigate the credit risk of financial instruments, information about the arrangements for which the entity is a party, and a brief description of the terms of those arrangements, including the extent to which they would reduce the entity's maximum amount of loss due to credit risk and (2) for disclosure of quantitative information about the market risks of financial instruments that is consistent with the way the company manages or adjusts those risks, disclosure may include: (a) more details about current positions and perhaps activity during the period, (b) the hypothetical effects on comprehensive income (or net assets), or annual income, of several possible changes in market prices, (c) a gap analysis of interest rate re-pricing or maturity dates, (d) the duration of the financial instruments, (e) the entity's value at risk from derivatives and from other positions at the end of the reporting period and the average value at risk during the year, or (f) other ways of reporting quantitative information as internally developed.",
        "label": "Fair Value, Concentration of Risk [Table Text Block]",
        "terseLabel": "Schedule of quantitative information regarding Level 3 fair value measurements"
       }
      }
     },
     "localname": "FairValueConcentrationOfRiskTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "FAIR VALUE MEASUREMENTS"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r414",
      "r458",
      "r463",
      "r551",
      "r598",
      "r678",
      "r679",
      "r680"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsFinancialAssetsAndLiabilitiesThatAreMeasuredAtFairValue",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfFairValueHierarchyOfTheValuationInputs"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r414",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r551",
      "r600",
      "r671",
      "r672",
      "r678",
      "r679",
      "r680"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsFinancialAssetsAndLiabilitiesThatAreMeasuredAtFairValue",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfFairValueHierarchyOfTheValuationInputs"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value by Liability Class [Domain]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetails",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsDerivativeLiabilitiesMeasuredAtFairValueUsingSignificantUnobservableInputs"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsDerivativeLiabilitiesMeasuredAtFairValueUsingSignificantUnobservableInputs"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r171",
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsDerivativeLiabilitiesMeasuredAtFairValueUsingSignificantUnobservableInputs"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r171",
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1": {
     "auth_ref": [
      "r554"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings",
        "terseLabel": "Initial measurement"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfChangeInTheFairValueOfConversionOptionLiability"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r554"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "terseLabel": "Re-measurement\u00a0of fair value"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsDerivativeLiabilitiesMeasuredAtFairValueUsingSignificantUnobservableInputs"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease": {
     "auth_ref": [
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)",
        "terseLabel": "Change in fair value measurement",
        "verboseLabel": "Fair value, Measurement with unobservable inputs reconciliation, Recurring basis, Liability, Period increase decrease"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetails",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsDerivativeLiabilitiesMeasuredAtFairValueUsingSignificantUnobservableInputs"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases": {
     "auth_ref": [
      "r172"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsDerivativeLiabilitiesMeasuredAtFairValueUsingSignificantUnobservableInputs"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r171"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsDerivativeLiabilitiesMeasuredAtFairValueUsingSignificantUnobservableInputs"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r414",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r598",
      "r599",
      "r600",
      "r671",
      "r672",
      "r678",
      "r679",
      "r680"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsFinancialAssetsAndLiabilitiesThatAreMeasuredAtFairValue",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfFairValueHierarchyOfTheValuationInputs"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsHighestAndBestUseDescription": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of reasons that a nonfinancial asset is being used in a manner that differs from its highest and best use.",
        "label": "Fair Value Measurements, Highest and Best Use, Description",
        "terseLabel": "Initial measurement, description"
       }
      }
     },
     "localname": "FairValueMeasurementsHighestAndBestUseDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueNetAssetLiability": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of asset after deduction of liability.",
        "label": "Fair Value, Net Asset (Liability)",
        "periodEndLabel": "Fair value, ending balance",
        "periodStartLabel": "Fair value, beginning balance"
       }
      }
     },
     "localname": "FairValueNetAssetLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfChangeInTheFairValueOfConversionOptionLiability"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r177",
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AccountingPoliciesByPolicyPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueOptionChangesInFairValueGainLoss1": {
     "auth_ref": [
      "r185"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": {
       "order": 18.0,
       "parentTag": "us-gaap_OtherOperatingIncomeExpenseNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For each line item in the statement of financial position, the amounts of gains and losses from fair value changes included in earnings.",
        "label": "Fair Value, Option, Changes in Fair Value, Gain (Loss)",
        "terseLabel": "Change in fair value of conversion option liability"
       }
      }
     },
     "localname": "FairValueOptionChangesInFairValueGainLoss1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Finite lived intangible asset, Useful life",
        "verboseLabel": "Finite lived intangible asset, useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails",
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r250",
      "r378"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "terseLabel": "Accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfTheCompanysIdentifiableIntangibleAssets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfEstimatedFutureAmortizationExpense": {
       "order": 7.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfEstimatedFutureAmortizationExpense"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfEstimatedFutureAmortizationExpense": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfEstimatedFutureAmortizationExpense"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfEstimatedFutureAmortizationExpense": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "terseLabel": "2022 (Remaining three months)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfEstimatedFutureAmortizationExpense"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfEstimatedFutureAmortizationExpense": {
       "order": 6.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfEstimatedFutureAmortizationExpense"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfEstimatedFutureAmortizationExpense": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfEstimatedFutureAmortizationExpense"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfEstimatedFutureAmortizationExpense": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfEstimatedFutureAmortizationExpense"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfEstimatedFutureAmortizationExpense": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfEstimatedFutureAmortizationExpense"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r375",
      "r377",
      "r378",
      "r379",
      "r606",
      "r607"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetails",
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfTheCompanysIdentifiableIntangibleAssets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r84",
      "r607"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross carrying amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfTheCompanysIdentifiableIntangibleAssets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfTheCompanysIdentifiableIntangibleAssets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r78",
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetails",
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfTheCompanysIdentifiableIntangibleAssets"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r84",
      "r606"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfEstimatedFutureAmortizationExpense": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Intangibles, net",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfEstimatedFutureAmortizationExpense",
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfTheCompanysIdentifiableIntangibleAssets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": {
     "auth_ref": [
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Assets, Remaining Amortization Period",
        "terseLabel": "Finite lived intangible assets, remaining amortization period"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FinitelivedIntangibleAssetsAcquired1": {
     "auth_ref": [
      "r376"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.",
        "label": "Finite-Lived Intangible Assets Acquired",
        "terseLabel": "Finite lived intangible assets acquired"
       }
      }
     },
     "localname": "FinitelivedIntangibleAssetsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r559",
      "r560",
      "r561",
      "r562"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": {
       "order": 13.0,
       "parentTag": "us-gaap_OtherOperatingIncomeExpenseNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "verboseLabel": "(Gain) loss on foreign currency exchange"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/PropertyAndEquipmentDetailsPropertyAndEquipmentConsisted"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnSaleOfDerivatives": {
     "auth_ref": [
      "r50",
      "r205"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": {
       "order": 16.0,
       "parentTag": "us-gaap_OtherOperatingIncomeExpenseNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the book value and the sale price of options, swaps, futures, forward contracts, and other derivative instruments. This element refers to the gain (loss) included in earnings.",
        "label": "Gain (Loss) on Sale of Derivatives",
        "terseLabel": "Loss on initial issuance of private warrants"
       }
      }
     },
     "localname": "GainLossOnSaleOfDerivatives",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r50",
      "r98",
      "r99"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 45.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedLabel": "(Gain) loss on debt extinguishment, net",
        "verboseLabel": "Gain on debt extinguishment"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnRestructuringOfDebt": {
     "auth_ref": [
      "r100"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For a debtor, the aggregate gain (loss) recognized on the restructuring of payables arises from the difference between the book value of the debt before the restructuring and the fair value of the payments on the debt after restructuring is complete.",
        "label": "Gains (Losses) on Restructuring of Debt"
       }
      }
     },
     "localname": "GainsLossesOnRestructuringOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r249",
      "r371",
      "r620",
      "r669",
      "r686",
      "r736",
      "r737"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 11.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Goodwill and Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [
      "r75",
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Goodwill and Other Long-Lived Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AccountingPoliciesByPolicyPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r50",
      "r372",
      "r373",
      "r374",
      "r669"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "terseLabel": "Goodwill, Impairment loss"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "terseLabel": "IPO [Member]",
        "verboseLabel": "Initial Public Offering [Member]"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails",
      "http://www.vickersvantagecorp.com/role/PublicOfferingDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails",
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r50",
      "r88"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.",
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Impairment of Intangible assets excluding goodwill"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentPolicy": {
     "auth_ref": [
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.",
        "label": "In Process Research and Development, Policy [Policy Text Block]",
        "terseLabel": "Acquired In-Process Research and Development Expense"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AccountingPoliciesByPolicyPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r29",
      "r194",
      "r203",
      "r224",
      "r337",
      "r345",
      "r349",
      "r351",
      "r622",
      "r668"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": {
       "order": 8.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "terseLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement Abstract"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r381",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r284",
      "r516",
      "r517",
      "r522",
      "r528",
      "r533",
      "r535",
      "r536",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r837"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.",
        "label": "Income Tax Examination, Penalties and Interest Expense",
        "terseLabel": "Income tax examination, penalties and interest expense"
       }
      }
     },
     "localname": "IncomeTaxExaminationPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r285",
      "r301",
      "r302",
      "r336",
      "r514",
      "r529",
      "r534",
      "r625"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfComponentsOfIncomeTaxExpenseBenefit": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": {
       "order": 9.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "totalLabel": "Total",
        "verboseLabel": "Income tax (benefit) expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetails",
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetailsScheduleOfComponentsOfIncomeTaxExpenseBenefit",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r267",
      "r512",
      "r513",
      "r517",
      "r518",
      "r521",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AccountingPoliciesByPolicyPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 25.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 30.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Payable, Trade",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableTrade",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 35.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivables, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 32.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 34.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.",
        "label": "Increase (Decrease) in Due to Related Parties, Current",
        "terseLabel": "Related party payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInDueToRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 31.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Increase (Decrease) in Employee Related Liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 27.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": {
     "auth_ref": [
      "r706"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 33.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in current liabilities classified as other.",
        "label": "Increase (Decrease) in Other Current Liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherCurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 28.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 26.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.",
        "label": "Increase (Decrease) in Prepaid Expense",
        "negatedLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInSecurityDeposits": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 29.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in security deposits.",
        "label": "Increase (Decrease) in Security Deposits",
        "terseLabel": "Long-term deposits"
       }
      }
     },
     "localname": "IncreaseDecreaseInSecurityDeposits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Indefinite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsCurrent": {
     "auth_ref": [
      "r0"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current portion of nonphysical assets, excluding financial assets, if these assets are classified into the current and noncurrent portions.",
        "label": "Intangible Assets, Current",
        "terseLabel": "Net tangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r76",
      "r82"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 10.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangibles, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestAndDividendIncomeSecuritiesHeldToMaturity": {
     "auth_ref": [],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 36.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating interest income, including amortization and accretion of premiums and discounts, on held-to-maturity securities.",
        "label": "Interest Income, Debt Securities, Held-to-Maturity",
        "negatedLabel": "Income earned on investments held in Trust Account"
       }
      }
     },
     "localname": "InterestAndDividendIncomeSecuritiesHeldToMaturity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r189",
      "r207",
      "r271",
      "r335",
      "r570"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": {
       "order": 12.0,
       "parentTag": "us-gaap_OtherOperatingIncomeExpenseNet",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseRelatedParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense incurred on a debt or other obligation to related party.",
        "label": "Interest Expense, Related Party",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeDepositWithFinancialInstitutionIncreaseDecrease": {
     "auth_ref": [
      "r651",
      "r652",
      "r653",
      "r654"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in interest income on deposit with financial institution.",
        "label": "Interest Income, Deposit with Financial Institution, Increase (Decrease)",
        "terseLabel": "Deposit interest income"
       }
      }
     },
     "localname": "InterestIncomeDepositWithFinancialInstitutionIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeOther": {
     "auth_ref": [],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": {
       "order": 20.0,
       "parentTag": "us-gaap_OtherOperatingIncomeExpenseNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest income earned from interest bearing assets classified as other.",
        "label": "Interest Income, Other",
        "terseLabel": "Income earned on investments held in Trust Account"
       }
      }
     },
     "localname": "InterestIncomeOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeSecuritiesUSTreasury": {
     "auth_ref": [
      "r206"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest income on US treasury securities. US treasury securities are negotiable debt obligations of the US government, secured by its full faith and credit and issued at various schedules and maturities. The income from treasury securities is exempt from state and local, but not federal, taxes. There are three types of securities issued by the US treasury (bonds, bills, and notes), which are distinguished by the amount of time from the initial sale of the bond to maturity.",
        "label": "Interest Income, Securities, US Treasury",
        "terseLabel": "Investments held in Trust Account \u2013 U.S. Treasury Securities Money Market Fund"
       }
      }
     },
     "localname": "InterestIncomeSecuritiesUSTreasury",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfFairValueHierarchyOfTheValuationInputs"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r276",
      "r278",
      "r279"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 44.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "negatedLabel": "Payment on the Scilex Pharma Notes attributed to accreted interest related to the debt discount"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r259",
      "r660",
      "r686"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r244",
      "r258",
      "r323",
      "r366",
      "r367",
      "r368",
      "r604",
      "r664"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AccountingPoliciesByPolicyPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r35",
      "r334"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": {
       "order": 22.0,
       "parentTag": "us-gaap_OtherOperatingIncomeExpenseNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "negatedLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Abstract]"
       }
      }
     },
     "localname": "LeaseCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r858"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Summary of Components of Lease Expense"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseDepositLiability": {
     "auth_ref": [
      "r583"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability for lease payments received, including variable lease payments, when collectability is not probable at commencement date for sales-type lease.",
        "label": "Lease Deposit Liability",
        "terseLabel": "Sponsors deposited (in Dollars)"
       }
      }
     },
     "localname": "LeaseDepositLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/PropertyAndEquipmentDetailsPropertyAndEquipmentConsisted"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LegalFees": {
     "auth_ref": [
      "r32"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.",
        "label": "Legal Fees",
        "terseLabel": "Legal fees"
       }
      }
     },
     "localname": "LegalFees",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AccountingPoliciesByPolicyPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r859"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Maturities of Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r581"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r581"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r581"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r581"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r581"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r581"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r859"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2022 (Remaining three months)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r581"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "auth_ref": [
      "r856"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "terseLabel": "Leases remaining lease terms"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r857"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Lessee, Operating Lease, renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LessorOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r860"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessor's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessor, Operating Lease, Term of Contract",
        "terseLabel": "Lease term"
       }
      }
     },
     "localname": "LessorOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
        "label": "Letter of Credit [Member]"
       }
      }
     },
     "localname": "LetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r20",
      "r283",
      "r361",
      "r389",
      "r390",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r398",
      "r399",
      "r541",
      "r542",
      "r543",
      "r558",
      "r667",
      "r742",
      "r864",
      "r865"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 21.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "terseLabel": "Total Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsDetailsScheduleOfImpactOfTheseAdjustmentsToTheFinancialStatementAsPreviouslyReported"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfFairValueHierarchyOfTheValuationInputs"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r14",
      "r199",
      "r218",
      "r686",
      "r712",
      "r733",
      "r854"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' deficit"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS' DEFICIT"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAssumed1": {
     "auth_ref": [
      "r54",
      "r55",
      "r56"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of liabilities assumed in noncash investing or financing activities.",
        "label": "Liabilities Assumed",
        "terseLabel": "Liabilities assumed in a non cash transaction"
       }
      }
     },
     "localname": "LiabilitiesAssumed1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r22",
      "r243",
      "r283",
      "r361",
      "r389",
      "r390",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r398",
      "r399",
      "r541",
      "r542",
      "r543",
      "r558",
      "r686",
      "r742",
      "r864",
      "r865"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 22.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueAdjustment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties.",
        "label": "Liabilities, Fair Value Adjustment",
        "terseLabel": "Warrant Liability \u2013 Private Placement Warrants"
       }
      }
     },
     "localname": "LiabilitiesFairValueAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfFairValueHierarchyOfTheValuationInputs"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r168"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Liabilities, Fair Value Disclosure",
        "terseLabel": "Total liabilities measured at fair value"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsFinancialAssetsAndLiabilitiesThatAreMeasuredAtFairValue"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsFinancialAssetsAndLiabilitiesThatAreMeasuredAtFairValue"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicensingAgreementsMember": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
        "label": "Licensing Agreements [Member]",
        "terseLabel": "Acquired licenses"
       }
      }
     },
     "localname": "LicensingAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetails",
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfTheCompanysIdentifiableIntangibleAssets"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r17"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Line of Credit Facility, Maximum Borrowing Capacity",
        "verboseLabel": "Line of Credit Facility, Maximum Borrowing Capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r7",
      "r198",
      "r216",
      "r413",
      "r428",
      "r671",
      "r672"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-Term Debt",
        "terseLabel": "Long-term debt",
        "verboseLabel": "Carrying value"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails",
      "http://www.vickersvantagecorp.com/role/DebtDetailsSummaryOfBorrowingsOfTheScilexPharmaNotes",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 26.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-Term Debt, Current Maturities",
        "negatedLabel": "Current portion",
        "terseLabel": "Current portion of debt"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.vickersvantagecorp.com/role/DebtDetailsSummaryOfBorrowingsOfTheScilexPharmaNotes"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.",
        "label": "Long-Term Debt, Fair Value",
        "terseLabel": "Estimated fair value"
       }
      }
     },
     "localname": "LongTermDebtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetailsSummaryOfBorrowingsOfTheScilexPharmaNotes"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r253"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 37.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt, net",
        "verboseLabel": "Long term portion"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.vickersvantagecorp.com/role/DebtDetailsSummaryOfBorrowingsOfTheScilexPharmaNotes"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermInvestments": {
     "auth_ref": [
      "r246"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 12.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).",
        "label": "Long-Term Investments",
        "terseLabel": "Long-term deposit"
       }
      }
     },
     "localname": "LongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermNotesPayable": {
     "auth_ref": [
      "r24"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.",
        "label": "Notes Payable, Noncurrent",
        "verboseLabel": "Notes payable, noncurrent"
       }
      }
     },
     "localname": "LongTermNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails",
      "http://www.vickersvantagecorp.com/role/DebtDetails",
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r24",
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails",
      "http://www.vickersvantagecorp.com/role/DebtDetails",
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Working capital"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinimumNetWorthRequiredForCompliance": {
     "auth_ref": [
      "r640",
      "r641",
      "r642",
      "r643"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of minimum net worth required for mortgage banking as defined by regulatory framework.",
        "label": "Banking Regulation, Mortgage Banking, Net Worth, Minimum",
        "terseLabel": "Minimum net worth to consummate business combination",
        "verboseLabel": "Minimum net worth to consummate business combination"
       }
      }
     },
     "localname": "MinimumNetWorthRequiredForCompliance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r277"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r277"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used for investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r47",
      "r48",
      "r51"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 24.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "negatedLabel": "Cash flow from operation",
        "totalLabel": "Net cash used for operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r30",
      "r51",
      "r204",
      "r223",
      "r241",
      "r265",
      "r266",
      "r270",
      "r283",
      "r291",
      "r293",
      "r294",
      "r296",
      "r297",
      "r301",
      "r302",
      "r313",
      "r337",
      "r345",
      "r349",
      "r351",
      "r361",
      "r389",
      "r390",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r398",
      "r399",
      "r549",
      "r558",
      "r668",
      "r742"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 53.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "presentationGuidance": "Net loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/LossPerShareDetailsSummaryOfReconciliationOfBasicAndDilutedLossPerShare",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r293",
      "r294",
      "r296",
      "r297",
      "r304",
      "r305",
      "r314",
      "r317",
      "r337",
      "r345",
      "r349",
      "r351",
      "r668"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "Denominator for Basic Loss Per Share"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/LossPerShareDetailsSummaryOfReconciliationOfBasicAndDilutedLossPerShare"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r306",
      "r309",
      "r310",
      "r311",
      "r312",
      "r314",
      "r317"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "terseLabel": "Denominator for Diluted Loss per Share \u2014 Adjusted for Dilutive Securities"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/LossPerShareDetailsSummaryOfReconciliationOfBasicAndDilutedLossPerShare"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetSharesReclassifiedToMandatorilyRedeemableCapitalStockValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of net shares reclassified to mandatorily redeemable capital stock.",
        "label": "Net Shares Reclassified to Mandatorily Redeemable Capital Stock, Value",
        "terseLabel": "Mandatorily redeemable ordinary shares"
       }
      }
     },
     "localname": "NetSharesReclassifiedToMandatorilyRedeemableCapitalStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AccountingPoliciesByPolicyPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1": {
     "auth_ref": [
      "r54",
      "r55",
      "r56"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of intangibles that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Noncash or Part Noncash Acquisition, Intangible Assets Acquired",
        "terseLabel": "Deferred consideration for Romeg intangible asset acquisition"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoninterestBearingDepositLiabilities": {
     "auth_ref": [
      "r200"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of all domestic and foreign noninterest-bearing deposits liabilities held by the entity.",
        "label": "Noninterest-Bearing Deposit Liabilities",
        "terseLabel": "Non-interest-bearing loans"
       }
      }
     },
     "localname": "NoninterestBearingDepositLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesIssued1": {
     "auth_ref": [
      "r54",
      "r55",
      "r56"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of notes issued in noncash investing and financing activities.",
        "label": "Notes Issued",
        "terseLabel": "Offering costs paid through promissory note \u2013 related party"
       }
      }
     },
     "localname": "NotesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableCurrent": {
     "auth_ref": [
      "r19"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.",
        "label": "Notes Payable, Current",
        "terseLabel": "Related party note payable"
       }
      }
     },
     "localname": "NotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableRelatedPartiesClassifiedCurrent": {
     "auth_ref": [
      "r15",
      "r192",
      "r714"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 43.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount for notes payable (written promise to pay), due to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Notes Payable, Related Parties, Current",
        "terseLabel": "Promissory note \u2014 related party"
       }
      }
     },
     "localname": "NotesPayableRelatedPartiesClassifiedCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r191",
      "r222",
      "r714"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "definitionGuidance": "Notes Payable, Related Parties",
        "documentation": "The amount for notes payable (written promise to pay), due to related parties.",
        "label": "Notes Payable, Related Parties",
        "terseLabel": "Notes payable, related parties",
        "verboseLabel": "Notes Payable, Related Parties"
       }
      }
     },
     "localname": "NotesPayableRelatedPartiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails",
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingCostsAndExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.",
        "label": "Operating Costs and Expenses",
        "totalLabel": "Total operating costs and expenses"
       }
      }
     },
     "localname": "OperatingCostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingCostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Costs and Expenses [Abstract]",
        "terseLabel": "Operating costs and expenses:"
       }
      }
     },
     "localname": "OperatingCostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r337",
      "r345",
      "r349",
      "r351",
      "r668"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "negatedLabel": "Operating loss",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r577",
      "r685"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesSummaryOfComponentsOfLeaseExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r855"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Operating lease, expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid [Abstract]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r575"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Total lease liabilities as of December\u00a031, 2021"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesSummaryOfMaturitiesOfLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r575"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 29.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r575"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 40.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r574"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 9.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r580",
      "r685"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate\u00a0\u2014\u00a0operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesSummaryOfSupplementalQuantitativeInformationRelatedToLeasesDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r579",
      "r685"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term in\u00a0years\u00a0\u2014\u00a0operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesSummaryOfSupplementalQuantitativeInformationRelatedToLeasesDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r140"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Operating loss carryforward"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r1",
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r58",
      "r59",
      "r71",
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.",
        "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]",
        "terseLabel": "Emerging Growth Company"
       }
      }
     },
     "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AccountingPoliciesByPolicyPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 41.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Accrued offering costs"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentsDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the nature and terms of commitment.",
        "label": "Other Commitments, Description",
        "terseLabel": "Underwriting agreement, description"
       }
      }
     },
     "localname": "OtherCommitmentsDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherDeferredCostsNet": {
     "auth_ref": [
      "r696"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net amount of other deferred costs capitalized at the end of the reporting period. Does not include deferred finance costs or deferred acquisition costs of insurance companies.",
        "label": "Other Deferred Costs, Net",
        "terseLabel": "Offering costs amount"
       }
      }
     },
     "localname": "OtherDeferredCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherExpenses": {
     "auth_ref": [
      "r34",
      "r225"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense classified as other.",
        "label": "Other Expenses",
        "terseLabel": "Dissolution expenses"
       }
      }
     },
     "localname": "OtherExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Component of Operating Income [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "OtherIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherIntangibleAssetsNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated amortization of finite-lived and indefinite-lived intangible assets classified as other.",
        "label": "Other Intangible Assets, Net",
        "terseLabel": "Net tangible assets"
       }
      }
     },
     "localname": "OtherIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 32.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Conversion option liability",
        "verboseLabel": "Conversion Option Liability"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfFairValueHierarchyOfTheValuationInputs"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLongTermNotesPayable": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 33.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term notes classified as other, payable after one year or the normal operating cycle, if longer.",
        "label": "Other Notes Payable, Noncurrent",
        "terseLabel": "Simple promissory notes"
       }
      }
     },
     "localname": "OtherLongTermNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.",
        "label": "Other Operating Income (Expense), Net",
        "totalLabel": "Total other (income) expense"
       }
      }
     },
     "localname": "OtherOperatingIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOwnershipInterestsOfferingCosts": {
     "auth_ref": [
      "r119"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of offering costs allocated to the other unit holders.",
        "label": "Other Ownership Interests, Offering Costs",
        "terseLabel": "Other offering costs"
       }
      }
     },
     "localname": "OtherOwnershipInterestsOfferingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1": {
     "auth_ref": [
      "r54",
      "r55",
      "r56"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the noncash (or part noncash) consideration given (for example, liability, equity) in a transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of a transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Other Significant Noncash Transaction, Value of Consideration Given",
        "terseLabel": "Non-cash\u00a0consideration in Semnur acquisition"
       }
      }
     },
     "localname": "OtherSignificantNoncashTransactionValueOfConsiderationGiven1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherUnderwritingExpense": {
     "auth_ref": [
      "r225",
      "r226"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Costs incurred during the period, such as those relating to general administration and policy maintenance that do not vary with and are not primarily related to the acquisition or renewal of insurance contracts.",
        "label": "Other Underwriting Expense",
        "terseLabel": "Cash underwriting fees"
       }
      }
     },
     "localname": "OtherUnderwritingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Over-Allotment Option [Member]"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheetsParentheticals",
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails",
      "http://www.vickersvantagecorp.com/role/PublicOfferingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PatentsMember": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.",
        "label": "Patents [Member]",
        "terseLabel": "Patent rights"
       }
      }
     },
     "localname": "PatentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetails",
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfTheCompanysIdentifiableIntangibleAssets"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfOtherEquity": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 22.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to reacquire equity classified as other.",
        "label": "Payments for Repurchase of Other Equity",
        "negatedLabel": "Redemption of ordinary shares"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfOtherEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 21.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedLabel": "Payment of offering costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r39",
      "r539"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "negatedLabel": "Acquisition consideration paid in cash for Romeg intangible asset acquisition"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedLabel": "Acquisition of Semnur, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "auth_ref": [
      "r275",
      "r846",
      "r847",
      "r848"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Payments to Acquire Productive Assets",
        "terseLabel": "Payments to acquire productive assets"
       }
      }
     },
     "localname": "PaymentsToAcquireProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property, plant, and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToEmployees": {
     "auth_ref": [
      "r705"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments of cash to employees, including wages and salaries, during the current period.",
        "label": "Payments to Employees",
        "terseLabel": "Payment to employees"
       }
      }
     },
     "localname": "PaymentsToEmployees",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockNoParValue": {
     "auth_ref": [
      "r8",
      "r746"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount per share of no-par value preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, No Par Value",
        "terseLabel": "Series A preferred stock, par value (in Dollars per share)"
       }
      }
     },
     "localname": "PreferredStockNoParValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r8",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preference shares, par value (in Dollars per share)",
        "verboseLabel": "Preferred Stock, Par or Stated Value Per Share"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheetsParentheticals",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails",
      "http://www.vickersvantagecorp.com/role/ShareholdersDeficitDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockRedemptionPricePerShare": {
     "auth_ref": [
      "r109",
      "r111",
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity is redeemed or may be called at. The redemption features of this preferred stock are solely within the control of the issuer.",
        "label": "Preferred Stock, Redemption Price Per Share",
        "terseLabel": "Ordinary per share"
       }
      }
     },
     "localname": "PreferredStockRedemptionPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preference shares, authorized",
        "verboseLabel": "Preferred stock shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails",
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheetsParentheticals",
      "http://www.vickersvantagecorp.com/role/ShareholdersDeficitDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r8",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preference shares, shares issued",
        "verboseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheetsParentheticals",
      "http://www.vickersvantagecorp.com/role/ShareholdersDeficitDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preference shares, shares outstanding",
        "verboseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheetsParentheticals",
      "http://www.vickersvantagecorp.com/role/ShareholdersDeficitDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r8",
      "r686"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 16.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.0001 par value, 20,000,000 shares authorized; none issued or outstanding at September 30, 2022 and December 31, 2021"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredUnitsAuthorized": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of preferred units authorized to be issued.",
        "label": "Preferred Units, Authorized",
        "terseLabel": "Stock authority to issue"
       }
      }
     },
     "localname": "PreferredUnitsAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r260",
      "r369",
      "r370",
      "r661"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses and other"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrimeRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers.",
        "label": "Prime Rate [Member]"
       }
      }
     },
     "localname": "PrimeRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.",
        "label": "Private Placement [Member]",
        "terseLabel": "Private Placement [Member]",
        "verboseLabel": "Private Placement Warrants [Member]"
       }
      }
     },
     "localname": "PrivatePlacementMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfChangesInTheFairValueOfWarrantLiabilitiesAndConversionOptionLiability",
      "http://www.vickersvantagecorp.com/role/PrivatePlacementDetails",
      "http://www.vickersvantagecorp.com/role/WarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromDecommissioningFund": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of assets held in a decommissioning trust fund.",
        "label": "Proceeds from Decommissioning Trust Fund Assets",
        "terseLabel": "Cash withdrawn from Trust Account in connection with redemption"
       }
      }
     },
     "localname": "ProceedsFromDecommissioningFund",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDivestitureOfBusinesses": {
     "auth_ref": [
      "r37"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.",
        "label": "Proceeds from Divestiture of Businesses",
        "terseLabel": "Proceeds from Divestiture of Businesses",
        "verboseLabel": "Gross proceeds from business combination"
       }
      }
     },
     "localname": "ProceedsFromDivestitureOfBusinesses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails",
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from sale of Units, net of underwriting discounts paid"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "auth_ref": [
      "r703"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.",
        "label": "Proceeds from Issuance of Debt",
        "terseLabel": "Proceeds from issuance of debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r42"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-Term Debt",
        "terseLabel": "Proceeds from issuance of long-term debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfMediumTermNotes": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt funding received on a regular basis with maturities ranging from 5-10 years.",
        "label": "Proceeds from Issuance of Medium-term Notes",
        "terseLabel": "Proceeds from related party note payable"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfMediumTermNotes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of long-term debt classified as other.",
        "label": "Proceeds from Issuance of Other Long-Term Debt",
        "terseLabel": "Proceeds from other loans"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfOtherLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSecuredDebt": {
     "auth_ref": [
      "r42"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.",
        "label": "Proceeds from Issuance of Secured Debt",
        "terseLabel": "Proceeds from senior secured notes"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSecuredDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).",
        "label": "Proceeds from Issuance of Warrants",
        "terseLabel": "Proceeds from sale of Private Placement Warrants",
        "verboseLabel": "Aggregate purchase price (in Dollars)"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/PrivatePlacementDetails",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "auth_ref": [
      "r42",
      "r711"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Proceeds from Lines of Credit",
        "terseLabel": "Proceeds from lines of credit"
       }
      }
     },
     "localname": "ProceedsFromLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromNotesPayable": {
     "auth_ref": [
      "r42"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.",
        "label": "Proceeds from Notes Payable",
        "terseLabel": "Proceeds from notes payable"
       }
      }
     },
     "localname": "ProceedsFromNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRelatedPartyDebt": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.",
        "label": "Proceeds from Related Party Debt",
        "terseLabel": "Proceeds from related party payable"
       }
      }
     },
     "localname": "ProceedsFromRelatedPartyDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt": {
     "auth_ref": [],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from long-term debt by a related party. Related parties, include, but are not limited to, affiliates, owners or officers and their immediate families, and pension trusts.",
        "label": "Proceeds from (Repayments of) Related Party Debt",
        "terseLabel": "Repayment of promissory note \u2013 related party"
       }
      }
     },
     "localname": "ProceedsFromRepaymentsOfRelatedPartyDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r41",
      "r132"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from stock options exercised"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails",
      "http://www.vickersvantagecorp.com/role/PropertyAndEquipmentDetailsPropertyAndEquipmentConsisted"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r94",
      "r646",
      "r647",
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/PropertyAndEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r91",
      "r247"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property, Plant and Equipment, Gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/PropertyAndEquipmentDetailsPropertyAndEquipmentConsisted"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/PropertyAndEquipmentDetailsPropertyAndEquipmentConsisted"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r93",
      "r219",
      "r623",
      "r686"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "verboseLabel": "Property, Plant and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.vickersvantagecorp.com/role/PropertyAndEquipmentDetailsPropertyAndEquipmentConsisted"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r93",
      "r646",
      "r647"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AccountingPoliciesByPolicyPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/PropertyAndEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails",
      "http://www.vickersvantagecorp.com/role/PropertyAndEquipmentDetailsPropertyAndEquipmentConsisted"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertySubjectToOrAvailableForOperatingLeaseGross": {
     "auth_ref": [
      "r236",
      "r237",
      "r380",
      "r584"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated depreciation, of lessor's underlying asset for which right to use has been conveyed to lessee under operating lease.",
        "label": "Property, Plant, and Equipment, Lessor Asset under Operating Lease, before Accumulated Depreciation",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "PropertySubjectToOrAvailableForOperatingLeaseGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r274",
      "r365"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "terseLabel": "Credit losses on accounts receivable"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r464",
      "r591",
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails",
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTaxExpenseDueToAffiliatesDeferred": {
     "auth_ref": [
      "r838"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of any deferred tax-related balances due to affiliates as of the date of each statement of financial position presented.",
        "label": "Related Party Tax Expense, Due to Affiliates, Deferred",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "RelatedPartyTaxExpenseDueToAffiliatesDeferred",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "auth_ref": [
      "r193",
      "r591"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transactions with related party during the financial reporting period.",
        "label": "Related Party Transaction, Amounts of Transaction",
        "terseLabel": "Debt discount amount"
       }
      }
     },
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r234",
      "r591",
      "r592",
      "r863"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails",
      "http://www.vickersvantagecorp.com/role/DebtDetails",
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDescriptionOfTransaction": {
     "auth_ref": [
      "r235",
      "r254",
      "r582",
      "r585",
      "r586",
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A description of the related party transaction, including transactions to which no amounts or nominal amounts were ascribed and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements. Examples of common related party transactions are, sales, purchases and transfers of realty and personal property, services received or furnished, loans and leases to and from top management and affiliates.",
        "label": "Related Party Transaction, Description of Transaction",
        "terseLabel": "Description of related party extension loans"
       }
      }
     },
     "localname": "RelatedPartyTransactionDescriptionOfTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails",
      "http://www.vickersvantagecorp.com/role/DebtDetails",
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of selling, general and administrative expenses resulting from transactions, excluding transactions that are eliminated in consolidated or combined financial statements, with related party.",
        "label": "Related Party Transaction, Selling, General and Administrative Expenses from Transactions with Related Party",
        "terseLabel": "Related Party transaction, selling, general and administrative expenses from transactions with related party"
       }
      }
     },
     "localname": "RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r464",
      "r591",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r863"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails",
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r589",
      "r590",
      "r592",
      "r593",
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfDebt": {
     "auth_ref": [
      "r704"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.",
        "label": "Repayments of Debt",
        "terseLabel": "Outstanding balance",
        "verboseLabel": "Repayments of debt"
       }
      }
     },
     "localname": "RepaymentsOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLinesOfCredit": {
     "auth_ref": [
      "r44",
      "r711"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Repayments of Lines of Credit",
        "terseLabel": "Repayments of lines of credit"
       }
      }
     },
     "localname": "RepaymentsOfLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfMediumTermNotes": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 23.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to pay off borrowing used to receive debt funding on a regular basis with maturities ranging from 5-10 years.",
        "label": "Repayments of Medium-term Notes",
        "negatedLabel": "Repayment of related party note payable"
       }
      }
     },
     "localname": "RepaymentsOfMediumTermNotes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfOtherLongTermDebt": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for the payment of debt classified as other, maturing after one year or the operating cycle, if longer.",
        "label": "Repayments of Other Long-Term Debt",
        "negatedLabel": "Repayment on other loans"
       }
      }
     },
     "localname": "RepaymentsOfOtherLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfRelatedPartyDebt": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.",
        "label": "Repayments of Related Party Debt",
        "negatedLabel": "Repayment of advances from related party"
       }
      }
     },
     "localname": "RepaymentsOfRelatedPartyDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfSeniorDebt": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period.",
        "label": "Repayments of Senior Debt",
        "negatedLabel": "Repayment of principal on the Scilex Pharma Notes"
       }
      }
     },
     "localname": "RepaymentsOfSeniorDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r134",
      "r230",
      "r872"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AccountingPoliciesByPolicyPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentInProcess": {
     "auth_ref": [],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 49.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.",
        "label": "Research and Development in Process",
        "terseLabel": "Semnur-related IPR&amp;D",
        "verboseLabel": "In process research and development costs expensed"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcess",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research Tax Credit Carryforward [Member]"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r695",
      "r708",
      "r873",
      "r874"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r52",
      "r57",
      "r245"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Current",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r695",
      "r708"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "terseLabel": "Opening bank account"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r11",
      "r118",
      "r217",
      "r631",
      "r636",
      "r686"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 19.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "definitionGuidance": "Accumulated Deficit",
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Retained earnings accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails",
      "http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsDetailsScheduleOfImpactOfTheseAdjustmentsToTheFinancialStatementAsPreviouslyReported"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r238",
      "r288",
      "r289",
      "r290",
      "r292",
      "r299",
      "r302",
      "r362",
      "r507",
      "r508",
      "r509",
      "r526",
      "r527",
      "r547",
      "r627",
      "r629"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanNameAxis": {
     "auth_ref": [
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r683",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans.",
        "label": "Retirement Plan Name [Axis]"
       }
      }
     },
     "localname": "RetirementPlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanNameDomain": {
     "auth_ref": [
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r683",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans.",
        "label": "Retirement Plan Name [Domain]"
       }
      }
     },
     "localname": "RetirementPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r665"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AccountingPoliciesByPolicyPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueNotFromContractWithCustomer": {
     "auth_ref": [
      "r701"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue that is not accounted for under Topic 606.",
        "label": "Revenue Not from Contract with Customer",
        "terseLabel": "Revenue not from contract with customer"
       }
      }
     },
     "localname": "RevenueNotFromContractWithCustomer",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r272",
      "r283",
      "r332",
      "r333",
      "r344",
      "r347",
      "r348",
      "r352",
      "r353",
      "r354",
      "r361",
      "r389",
      "r390",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r398",
      "r399",
      "r558",
      "r622",
      "r742"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": {
       "order": 7.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Net revenue"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r578",
      "r685"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "ROU assets obtained in exchange for new operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesSummaryOfSupplementalQuantitativeInformationRelatedToLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyExpense": {
     "auth_ref": [
      "r32"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.",
        "label": "Royalty Expense",
        "terseLabel": "Royalty payments"
       }
      }
     },
     "localname": "RoyaltyExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Sale of units amount"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockDescriptionOfTransaction": {
     "auth_ref": [
      "r156",
      "r158",
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of stock transaction which may include details of the offering (IPO, private placement), a description of the stock sold, percentage of subsidiary's or equity investee's stock sold, a description of the investors and whether the stock was issued in a business combination.",
        "label": "Sale of Stock, Description of Transaction",
        "terseLabel": "Sale of stock, description"
       }
      }
     },
     "localname": "SaleOfStockDescriptionOfTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/PublicOfferingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails",
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheetsParentheticals",
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfChangesInTheFairValueOfWarrantLiabilitiesAndConversionOptionLiability",
      "http://www.vickersvantagecorp.com/role/PrivatePlacementDetails",
      "http://www.vickersvantagecorp.com/role/PublicOfferingDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails",
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetails",
      "http://www.vickersvantagecorp.com/role/WarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Warrant price per share (in Dollars per share)",
        "verboseLabel": "Contribution per share"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r354",
      "r732"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScenarioAdjustmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Domain member used to indicate figures that are adjustments during a period or as of a point in time. This domain member would never be expected to appear in a relationship group without the \"Scenario, Previously Reported\" Member with the same parent.",
        "label": "Scenario, Adjustment [Member]"
       }
      }
     },
     "localname": "ScenarioAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock": {
     "auth_ref": [
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of beginning and ending balances of the fair value of plan assets of pension plans and/or other employee benefit plans showing separately, if applicable, the effects during the period attributable to each of the following: actual return on plan assets, foreign currency exchange rate changes, contributions by the employer, contributions by plan participants, benefits paid, business combinations, divestitures, and settlements.",
        "label": "Schedule of Changes in Fair Value of Plan Assets [Table Text Block]",
        "terseLabel": "Schedule of change in the fair value of conversion option liability"
       }
      }
     },
     "localname": "ScheduleOfChangesInFairValueOfPlanAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of components of income tax expense (benefit)"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r24",
      "r111",
      "r115",
      "r116",
      "r117",
      "r187",
      "r188",
      "r190",
      "r211",
      "r671",
      "r673",
      "r715"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
        "terseLabel": "Summary of Borrowings of the Scilex Pharma Notes"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of deferred tax assets and liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of derivative liabilities at fair value.",
        "label": "Schedule of Derivative Liabilities at Fair Value [Table Text Block]",
        "terseLabel": "Schedule of changes in the fair value of warrant liabilities"
       }
      }
     },
     "localname": "ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r731"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of reflects the calculation of basic and diluted net income (loss) per ordinary share",
        "verboseLabel": "Summary of reconciliation of basic and diluted loss per share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/LossPerShareTables",
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of effective income tax rate reconciliation"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r78",
      "r83",
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfTheCompanysIdentifiableIntangibleAssets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r78",
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Summary of the Company's Identifiable Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r87",
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/PropertyAndEquipmentDetailsPropertyAndEquipmentConsisted"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfShareBasedPaymentAwardOptionsIssuedToEmployeesAndNonemployeesValuationAssumptions"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r127",
      "r128",
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary Of The Options Outstanding"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of valued using the compound option pricing model",
        "verboseLabel": "Summary Of Share Based Payment Award Options Issued To Employees And Nonemployees Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsTables",
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShortTermDebtTable": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.",
        "label": "Schedule of Short-Term Debt [Table]"
       }
      }
     },
     "localname": "ScheduleOfShortTermDebtTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r105",
      "r107",
      "r108",
      "r111",
      "r112",
      "r114",
      "r115",
      "r116",
      "r117",
      "r118",
      "r255",
      "r256",
      "r257",
      "r325",
      "r430",
      "r431",
      "r432",
      "r434",
      "r438",
      "r443",
      "r445",
      "r675",
      "r691",
      "r710"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/ShareholdersDeficit",
      "http://www.vickersvantagecorp.com/role/ShareholdersDeficitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Summary of Estimated Future Amortization Expense"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segments"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AccountingPoliciesByPolicyPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "auth_ref": [
      "r699",
      "r700",
      "r747"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A preferred stock.",
        "label": "Series A Preferred Stock [Member]",
        "terseLabel": "Series A Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesAPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the aggregation and reporting of combined amounts of individually immaterial business combinations that were completed during the period.",
        "label": "Series of Individually Immaterial Business Acquisitions [Member]",
        "terseLabel": "Business Combination [Member]",
        "verboseLabel": "Series of Individually Immaterial Business Acquisitions [Member]"
       }
      }
     },
     "localname": "SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails",
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue": {
     "auth_ref": [
      "r602"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from changes in fair value classified as other for a contract to service financial assets under which the estimated future revenues from contractually specified servicing fees, late charges, and other ancillary revenues are not expected to adequately compensate the servicer.",
        "label": "Servicing Liability at Fair Value, Other Changes in Fair Value",
        "terseLabel": "Change in fair value"
       }
      }
     },
     "localname": "ServicingLiabilityAtFairValueOtherChangesInFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfChangeInTheFairValueOfConversionOptionLiability"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Disclosure [Abstract]"
       }
      }
     },
     "localname": "ShareBasedArrangementsToObtainGoodsAndServicesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": {
       "order": 47.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights",
        "terseLabel": "Share based compensation arrangement,vesting rights"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price",
        "terseLabel": "Exercise price",
        "verboseLabel": "Exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfValuedUsingTheCompoundOptionPricingModel",
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfShareBasedPaymentAwardOptionsIssuedToEmployeesAndNonemployeesValuationAssumptions"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield",
        "verboseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfValuedUsingTheCompoundOptionPricingModel",
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfShareBasedPaymentAwardOptionsIssuedToEmployeesAndNonemployeesValuationAssumptions"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Volatility",
        "verboseLabel": "Expected stock-price volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfValuedUsingTheCompoundOptionPricingModel",
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfShareBasedPaymentAwardOptionsIssuedToEmployeesAndNonemployeesValuationAssumptions"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected stock-price volatility, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfShareBasedPaymentAwardOptionsIssuedToEmployeesAndNonemployeesValuationAssumptions"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected stock-price volatility, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfShareBasedPaymentAwardOptionsIssuedToEmployeesAndNonemployeesValuationAssumptions"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free rate",
        "verboseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfValuedUsingTheCompoundOptionPricingModel",
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfShareBasedPaymentAwardOptionsIssuedToEmployeesAndNonemployeesValuationAssumptions"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfShareBasedPaymentAwardOptionsIssuedToEmployeesAndNonemployeesValuationAssumptions"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfShareBasedPaymentAwardOptionsIssuedToEmployeesAndNonemployeesValuationAssumptions"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "auth_ref": [
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate",
        "terseLabel": "Volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurements"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfShareBasedPaymentAwardOptionsIssuedToEmployeesAndNonemployeesValuationAssumptions"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable, Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfTheOptionsOutstanding"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable, Weighted average exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfTheOptionsOutstanding"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r816"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedLabel": "Forfeited/Cancelled, Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfTheOptionsOutstanding"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r816"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited/Cancelled, Weighted average exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfTheOptionsOutstanding"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted, Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfTheOptionsOutstanding"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r131"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Outstanding, Ending, Aggregate Intrinsic Value",
        "periodStartLabel": "Outstanding, Beginning, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfTheOptionsOutstanding"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r480",
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding, Ending, Options",
        "periodStartLabel": "Outstanding, Beginning, Options",
        "terseLabel": "Share based compensation arrangement,Options outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetails",
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfTheOptionsOutstanding"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r480",
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding, Ending, Weighted average exercise price",
        "periodStartLabel": "Outstanding, Beginning, Weighted average exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfTheOptionsOutstanding"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r476",
      "r477",
      "r478",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised, Weighted average exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfTheOptionsOutstanding"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted, Weighted average exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfTheOptionsOutstanding"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r479",
      "r498",
      "r499",
      "r500",
      "r501",
      "r504",
      "r510",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AccountingPoliciesByPolicyPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Stock price"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurements"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Term (in years)",
        "verboseLabel": "Term of options"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurements",
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfShareBasedPaymentAwardOptionsIssuedToEmployeesAndNonemployeesValuationAssumptions"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of non-vested options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price",
        "terseLabel": "Weighted-average grant date fair value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfShareBasedPaymentAwardOptionsIssuedToEmployeesAndNonemployeesValuationAssumptions"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "terseLabel": "Number of shares (in Shares)",
        "verboseLabel": "Preferred Stock shares"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails",
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Ordinary share, per share",
        "verboseLabel": "Preferred Stock, par value (in Dollars per share)"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails",
      "http://www.vickersvantagecorp.com/role/PrivatePlacementDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance (in Shares)",
        "periodStartLabel": "Balance (in Shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognition of changes in redemption value of mandatorily redeemable shares. Provides the period over which changes in redemption value are accreted, usually from the issuance date (or from the date that it becomes probable that the security will become redeemable, if later) to the earliest redemption date of the security.",
        "label": "Shares Subject to Mandatory Redemption, Changes in Redemption Value, Policy [Policy Text Block]",
        "terseLabel": "Ordinary Shares Subject to Possible Redemption"
       }
      }
     },
     "localname": "SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AccountingPoliciesByPolicyPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 34.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount that is required to be paid, determined under the conditions specified in the contract, if as of the reporting date, the holder of the share has exercised the right to or the shares are mandatorily redeemable after one year from the reporting date or operating cycle, if longer.",
        "label": "Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount, Noncurrent",
        "terseLabel": "Mandatorily redeemable ordinary shares liability"
       }
      }
     },
     "localname": "SharesSubjectToMandatoryRedemptionSettlementTermsAmountNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermDebtLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Short-Term Debt [Line Items]"
       }
      }
     },
     "localname": "ShortTermDebtLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of short-term debt arrangement.",
        "label": "Short-Term Debt, Type [Axis]"
       }
      }
     },
     "localname": "ShortTermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.",
        "label": "Short-Term Debt, Type [Domain]"
       }
      }
     },
     "localname": "ShortTermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r58",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State [Member]"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r255",
      "r256",
      "r257",
      "r283",
      "r307",
      "r308",
      "r315",
      "r317",
      "r325",
      "r326",
      "r361",
      "r389",
      "r392",
      "r393",
      "r394",
      "r398",
      "r399",
      "r430",
      "r431",
      "r434",
      "r438",
      "r445",
      "r558",
      "r651",
      "r691",
      "r710",
      "r730"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails",
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheetsParentheticals",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurements",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetails",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurements",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfValuedUsingTheCompoundOptionPricingModel",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsTables",
      "http://www.vickersvantagecorp.com/role/SubsequentEvents",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r28",
      "r110",
      "r238",
      "r268",
      "r269",
      "r270",
      "r288",
      "r289",
      "r290",
      "r292",
      "r299",
      "r302",
      "r324",
      "r362",
      "r447",
      "r507",
      "r508",
      "r509",
      "r526",
      "r527",
      "r547",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r588",
      "r627",
      "r628",
      "r629"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit",
      "http://www.vickersvantagecorp.com/role/WarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheetsParentheticals",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurements",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetails",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurements",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfValuedUsingTheCompoundOptionPricingModel",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsTables",
      "http://www.vickersvantagecorp.com/role/SubsequentEvents",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsParentheticals"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r288",
      "r289",
      "r290",
      "r324",
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheetsParentheticals",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurements",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetails",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfQuantitativeInformationRegardingLevel3FairValueMeasurements",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfValuedUsingTheCompoundOptionPricingModel",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsTables",
      "http://www.vickersvantagecorp.com/role/SubsequentEvents",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsParentheticals"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "auth_ref": [
      "r8",
      "r9",
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.",
        "label": "Stock Issued During Period, Shares, Acquisitions",
        "terseLabel": "Shares issued related to Semnur Acquisition , shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/PublicOfferingDetails",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "terseLabel": "Issuance of ordinary shares to Sponsor"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r8",
      "r9",
      "r110",
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of aggregate ordinary shares (in Shares)",
        "verboseLabel": "Distribution to Sorrento , shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued attributable to transactions classified as other.",
        "label": "Stock Issued During Period, Shares, Other",
        "terseLabel": "Cancellation of ordinary shares (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.",
        "label": "Stock Issued During Period, Shares, Purchase of Assets",
        "terseLabel": "Stock issued during period shares purchase of assets"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesPurchaseOfAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AcquisitionsDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares (or other type of equity) forfeited during the period.",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, Forfeited",
        "terseLabel": "Ordinary shares, subject to forfeiture (in Shares)",
        "verboseLabel": "Cancellation of shares held in escrow related to Semnur Acquisition , shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationForfeited",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r8",
      "r9",
      "r110",
      "r118",
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised, Options",
        "terseLabel": "Stock options excercised , shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/StockIncentiveAndEmployeeBenefitPlansDetailsSummaryOfTheOptionsOutstanding",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "auth_ref": [
      "r28",
      "r110",
      "r118"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued pursuant to acquisitions during the period.",
        "label": "Stock Issued During Period, Value, Acquisitions",
        "terseLabel": "Aggregate purchase price value",
        "verboseLabel": "Shares issued related to Semnur Acquisition"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Value, Issued for Services",
        "terseLabel": "Issuance of ordinary shares to Sponsor (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r8",
      "r9",
      "r110",
      "r118"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Distribution to Sorrento"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares of stock issued attributable to transactions classified as other.",
        "label": "Stock Issued During Period, Value, Other",
        "terseLabel": "Cancellation of ordinary shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.",
        "label": "Stock Issued During Period, Value, Purchase of Assets",
        "terseLabel": "Aggregate principal amount"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValuePurchaseOfAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r28",
      "r110",
      "r118"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Stock options excercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRedeemedOrCalledDuringPeriodValue": {
     "auth_ref": [
      "r110"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock bought back by the entity at the exercise price or redemption price.",
        "label": "Stock Redeemed or Called During Period, Value",
        "negatedLabel": "Accretion of Ordinary shares subject to possible redemption amount"
       }
      }
     },
     "localname": "StockRedeemedOrCalledDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r9",
      "r12",
      "r13",
      "r72",
      "r686",
      "r712",
      "r733",
      "r854"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 14.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "terseLabel": "Total Shareholders' Equity (Deficit)",
        "totalLabel": "Total stockholders' deficit"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsDetailsScheduleOfImpactOfTheseAdjustmentsToTheFinancialStatementAsPreviouslyReported",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' Deficit:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r121",
      "r282",
      "r431",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r444",
      "r447",
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "SHAREHOLDERS' DEFICIT"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/ShareholdersDeficit"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubordinatedDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents domestic or foreign subordinated debt. Subordinated debt has a lower priority of repayment in liquidation of the entity's assets.",
        "label": "Subordinated Debt [Member]"
       }
      }
     },
     "localname": "SubordinatedDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r569",
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r569",
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r569",
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/LiquidityAndGoingConcernDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails",
      "http://www.vickersvantagecorp.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r595",
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails",
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheetsParentheticals",
      "http://www.vickersvantagecorp.com/role/DescriptionOfOrganizationAndBusinessOperationsDetails",
      "http://www.vickersvantagecorp.com/role/FairValueMeasurementsDetailsScheduleOfChangesInTheFairValueOfWarrantLiabilitiesAndConversionOptionLiability",
      "http://www.vickersvantagecorp.com/role/PrivatePlacementDetails",
      "http://www.vickersvantagecorp.com/role/PublicOfferingDetails",
      "http://www.vickersvantagecorp.com/role/RelatedPartyTransactionsDetails",
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetails",
      "http://www.vickersvantagecorp.com/role/WarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r140"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforward"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about the period subject to enacted tax laws.",
        "label": "Tax Period [Axis]"
       }
      }
     },
     "localname": "TaxPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified tax period.",
        "label": "Tax Period [Domain]"
       }
      }
     },
     "localname": "TaxPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TechnologyBasedIntangibleAssetsMember": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights.",
        "label": "Technology-Based Intangible Assets [Member]",
        "terseLabel": "Acquired technology"
       }
      }
     },
     "localname": "TechnologyBasedIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetails",
      "http://www.vickersvantagecorp.com/role/GoodwillAndIntangibleAssetsDetailsSummaryOfTheCompanysIdentifiableIntangibleAssets"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders.",
        "label": "Temporary Equity, Accretion to Redemption Value, Adjustment",
        "terseLabel": "Accretion of carrying value to redemption value"
       }
      }
     },
     "localname": "TemporaryEquityAccretionToRedemptionValueAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfOrdinarySharesReflectedInCondensedConsolidatedBalanceSheetsAreReconciled"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "auth_ref": [
      "r389",
      "r392",
      "r393",
      "r394",
      "r398",
      "r399"
     ],
     "calculation": {
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 15.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "terseLabel": "Ordinary shares subject to possible redemption 9,726,395 and 13,800,000 as of September 30, 2022 and December 31, 2021, respectively, at redemption value of $10.41 and $10.00, respectively, per share",
        "verboseLabel": "Ordinary Shares Subject to Possible Redemption"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.vickersvantagecorp.com/role/RestatementOfPreviouslyIssuedFinancialStatementsDetailsScheduleOfImpactOfTheseAdjustmentsToTheFinancialStatementAsPreviouslyReported"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityNetIncome": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of net income or loss attributable to temporary equity interest.",
        "label": "Temporary Equity, Net Income",
        "terseLabel": "Allocation of net income (loss)"
       }
      }
     },
     "localname": "TemporaryEquityNetIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShare"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityOtherChanges": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in temporary equity from changes classified as other.",
        "label": "Temporary Equity, Other Changes",
        "terseLabel": "Mandatorily redeemable ordinary shares"
       }
      }
     },
     "localname": "TemporaryEquityOtherChanges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfOrdinarySharesReflectedInCondensedConsolidatedBalanceSheetsAreReconciled"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityRedemptionPricePerShare": {
     "auth_ref": [
      "r3",
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount to be paid per share that is classified as temporary equity by entity upon redemption. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Redemption Price Per Share",
        "terseLabel": "Ordinary shares subject to possible redemption per share (in Dollars per share)"
       }
      }
     },
     "localname": "TemporaryEquityRedemptionPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CondensedConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r231",
      "r232",
      "r233",
      "r357",
      "r358",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Accounts Receivable, Net"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AccountingPoliciesByPolicyPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r849"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/CommitmentsAndContingenciesDetails",
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnamortizedDebtIssuanceExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.",
        "label": "Unamortized Debt Issuance Expense",
        "negatedLabel": "Unamortized debt issuance costs"
       }
      }
     },
     "localname": "UnamortizedDebtIssuanceExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetailsSummaryOfBorrowingsOfTheScilexPharmaNotes"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r68",
      "r69",
      "r70",
      "r327",
      "r328",
      "r330",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/AccountingPoliciesByPolicyPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Public Warrant [Member]"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/WarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r306",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average shares outstanding, ordinary shares (in Shares) , diluted",
        "verboseLabel": "Basic and diluted weighted average ordinary shares outstanding (in Shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShare",
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareParentheticals",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperationsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesIssuedBasic": {
     "auth_ref": [
      "r60",
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).",
        "label": "Weighted Average Number of Shares Issued, Basic",
        "terseLabel": "Basic and diluted weighted average ordinary shares outstanding"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesIssuedBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShare"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r304",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average shares outstanding, ordinary shares (in Shares) , Basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vickersvantagecorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsScheduleOfReflectsTheCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShare",
      "http://www.vickersvantagecorp.com/role/UnauditedCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=6402221&loc=d3e15743-112638",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=118255708&loc=d3e21951-110878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=109262807&loc=d3e22047-110879",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21564-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.F)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187171-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.F)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187171-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "710",
   "URI": "https://asc.fasb.org/topic&trid=2127225",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "712",
   "URI": "https://asc.fasb.org/topic&trid=2197446",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a)(5))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5227-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6578-128477",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6613-128477",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569655-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL7498348-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13572-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13587-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14172-108612",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(19)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.12)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.13(h))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.2)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "(c)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "(d)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.17)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.7)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "720",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=35755714&loc=d3e28434-158551",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "805",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124505872&loc=d3e30785-158569",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123395306&loc=d3e36975-112693",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123422147&loc=d3e41457-112716",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123405975&loc=d3e41551-112718",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-04(Schedule I))",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=126898705&loc=d3e5864-122674",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(n))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(27)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4,6)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19)(a)(5))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=SL94080555-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28228-110885",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918703-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123408481&loc=SL77919106-209958",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919398-209981",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919370-209981",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128295416&loc=SL77919784-209982",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "https://asc.fasb.org/topic&trid=2122394",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2646-109256",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=6490092&loc=d3e47080-110998",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=6490092&loc=d3e47304-110998",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=6490092&loc=d3e47304-110998",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=6490092&loc=d3e47304-110998",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r651": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r652": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r653": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r654": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r655": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "04",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r656": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "c",
   "Publisher": "SEC",
   "Section": "5",
   "Subparagraph": "Schedule I",
   "Subsection": "04",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r657": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "c",
   "Publisher": "SEC",
   "Section": "7",
   "Subparagraph": "Schedule II",
   "Subsection": "05",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r658": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "9",
   "Subsection": "06",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6829253&loc=SL6831962-166255",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r689": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=d3e5283-111683",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(2))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(b))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r755": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r756": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r757": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r758": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r759": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(9)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r760": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r761": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r762": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r763": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r764": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r765": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r766": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r767": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r768": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r769": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r770": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r771": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r772": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r773": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r774": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r775": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r776": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r777": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r778": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r779": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r780": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r781": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r782": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r783": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r784": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r785": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r786": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r787": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r788": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r789": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r790": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r791": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r792": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r793": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r794": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r795": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r796": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r797": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r798": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r799": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r800": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r801": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r802": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r803": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r804": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r805": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r806": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r807": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r808": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r809": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r810": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r811": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r812": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r813": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r814": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r815": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r816": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r817": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r818": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r819": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r820": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r821": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r822": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r823": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r824": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r825": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r826": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r827": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r828": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r829": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r830": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r831": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r832": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r833": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r834": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r835": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r836": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r837": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r838": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r839": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r840": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r841": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r842": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r843": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r844": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r845": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r846": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=127000608&loc=d3e9135-128495",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r847": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9212-128498",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r848": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9215-128498",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r849": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r850": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r851": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r852": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r853": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r854": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r855": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r856": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r857": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r858": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r859": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r860": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919359-209981",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r861": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r862": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r863": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r864": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r865": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r866": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r867": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r868": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r869": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r870": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r871": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r872": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r873": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r874": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r875": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r876": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r877": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r878": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "04",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b),(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "https://asc.fasb.org/topic&trid=2144416",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>120
<FILENAME>0001193125-23-007234-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-23-007234-xbrl.zip
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MY#]5K_&P_6^$5T3B!KCU!O0O"V[CS<$WW5P@O"W&9ZX5.NLC]QM02P,$%
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MTLM(L!/62OE$;(\RP7\'C5,R%$=\GLC0OGCA#K]\UF+OK8T"M86]&G]P*X[
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MM&JMOS-7[4[[YCU<M5J#:D[=Q<>YL!U4+[O-?^#R?:/;Z?8O4I^OVWHK)1[
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M7 H+OZJJX.6HT%6@*EI%9K;,:JX*HV.^+&R)&'0WYGM&Y.!$]-J#+^)U+*/
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M:QN<<=8RLJ=#L<//.*4(>G<1E-"Q?+VZ,PO7;AL;+<Y#_=CHRZ2ZBGM14K,
M=5/]^.:UJKLO7IL+%_=UTRB,N'XWCD:[:H.I(KOJ12!0I*YZB^7L,VNEGL!T
MV2OS'7IEYL%@/]CLZ9&8=L-T[0;1QX:%*7BBGP/1>->'*'=!-X87N3/L0NVB
MLO*W9_"D]<^SO6#T>N,79L Z5,F;X5GU/PBC">.1A=*']%YG0]%HPIU%'J;
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M@R7=R8%HZ5-J@66OF03!//<I]&=KNQ&\B2WX/4=%%"H\/-PUG $)F@3P[Z+
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M/#ZH81%SYO##3A2Y_G'W36 =^&DQX8EW.SSQ7A3%H%$'[AKA0HQ0E7,L5(N
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MDYB4F-P-)H?,?O8E)D:P\+_=$0)P8" DY&8M@;>SS1IC TV3BJ 4@"!:UK/
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MM!E&'> ;4I<H[W")P=-^LZ9D'SO&^V)?NC"40:)9HGFG:/[;PRQ.4-DQ*A]
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M+V?&I#779<IW\&FG#W^J"76CW,M]0*JXAYN1K^-5/IZ,+WDR"&JR\42T'5)
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MH.>P8*#,)&%37'W,%?U)@]N9ZO]Y$KV%JWJ-^#3V0!Q8[F[2],ZJB!YY!D4
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M70 \X)$+U/NE;_?HH&\[H+=:"K;E[%Z$8*S$EF'/4!&J(5>N,&QE,V!4)$P
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MU7 PPJ;!6FZI*M4\,R6 F1<R:[#R4!+?3Q,BK 25&/U6-@8[S"05/>A%6=W
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MY-BW<;2@NN.%9P/"SF8@J"(#DF(MBPQN<1IZQZQOP4)ESBW,=E6=]>8!41B
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M3VYJ_T9BA:5A:FPX3B\0]@+4**ZH #]%0[7UVLEXIH+,4] B',; BU'J0RC
M,1\<P("P\V8:EU+WQ'YHM6<:5_?PDS<):YG<-(U@$PSJ_YGXG2+#MK.YMA+M
MX(VB=D57*9EU%LDT  KZ\I'L7\4J;_;48SA+2C32$?03([6/%_)0#G@[-ED
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M_A][;]KDQI5D"WX?L_D/L+)I,\DLF*.UJKKUNLTH2JIFF=3DB*K6?'L6  )
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M:/,.KVP90O58;_ D@D*!\XR[@N.BK*\63^LA!8Q\/MQC,0TJS8KLJU:6O!R
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M*WEO#MSQ=.!S<J$"*FT!E2MGZUV)%Z7"$)!4)^_2!4N>'!1P^62]2;&.,GY
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MZY3/I@8&""N>PJ!T7K\4*&7XXYK;+I$V"W;F-X$4AJ.@:>DL<84B7^-DN(C
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M;0>,*5DK'USQ8 ^BZN" 50+Z(K:V8+2T62>9AL<(HYY3!\2Z:)G^EQFC(YE
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M3JV"(9@A8?+((Y%DP43?UL[H@3W)\]]%;S[UUI>%<GBB*IFPEE\M?IXQOS2
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MD?"7SK%$L7F@0@M6O_HNE>0L5F5(&:::+%TSPP<!+I\H,#=9+,*OS?7D>.Y
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M29$L3^SIR&M9P6?TJ2,<6XRX#_^VX^K(:1TI&]LK9(-FXR2Z&#*':?5[JFY
M+QO+;]%$!J\[V(/P3C^>_T)R$/*6X9T]L4C,V69YM=F"-8![,2*>]J_>K'OH
M(TV@?WE)H']<30&)>*)P 3NW&UF]6@JNT?+M(E$NLUIK]C?&2^M$,G[DU=J?
MGJA+FXMLBS,_5K,EMT5IZ0IN6I=V78KE)HW6<-=.Q5S.'X9[Z; O(/9PA_7
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M8G6"G4=#2AQ"=XK/%<L8 CB)N_BP2)%^&LLN3[ GY D3?6'B*F<H:-@7THC
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MIR:"#UP-JAVCIC@W&BA2[KH(QPZ95#;8,IS.X9(T0*03G+FWL[T2N7H>MT3
MQ/$FRM4Y*''66X@+^:D;P5"%51$>^5"N.H.V>$>)YSJ'V(=8KK;0D$JP*?]@
M7EW;+3$;BI@G[)%C+\;#[:FXDG2$(<51KW9T!GO&4N.]83 .=@3GQ7]#A7+R
M!CPM_(3$ +D/SFR'/*DV=(9=+J-"8Z"9&;&_9>O7<W"<V;.G6BR-%<B&R42
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M:$H!#-@'+9=)*3<AW^"F+$VR684I.)6K'2@0;91I8':G"G IYC]4$.F6VJC
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M^50:[-8JS&BQ]#5* QH)K,"Q9PY!6D[Y8U)-0:<N5U3T2+S).^TN6W\3TWO
MA.A7&R0D.1350H[T]1YR3GV&>2;H:%WHL&>:#B,X+YL[*003O\.^WVM%@6#B
M_N/!#=9%52HV#ID;XE'VOT6?FX+N7&+*\CVVYRU;R8/A[0]#W?&ZH_'= Z\
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M2CR=V2[SJN7$I*M'2WM-3PQT1]MKP7_O2NP6<0G&^PI5#\7'LNNQ47> A=Z
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M)+,]Z\!'N$Z5=^RG)LAUI&"1-VJ80V&==#\Z>R 90TM;ZWU@8'0+4&+03,2
M9I)Q;HXK]2ZI00?GB!E"7DKA_$2$"G]K6=3%IL2XAM,**F.##(TP[$<7]7VO
MC6_3/2[4LA*J:C+[E';Z6]RFT\.K1YVJE'<=3N'&=]@EI;(L$=+VR$CYVF#
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M$T(L&"#D5/NND*@!>R.3N1.0H6XM*:+SD5K<?#;:Z+4%;XKR4-;WO6G7#9+
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MJKQXE+1ROT,- 4H(EJ8FJADJIFOQ#[R3J=36<Y&?9H2+7EM*WW$QSS6;N>%
M4 D]&@9DKW0W(^_,:$IK6(1 P*^[U8E<TU$="UL\Y2]P=)WAPN\H66W1IK;X
M.(92S0U<DN"M6S;4>RISN781N3HO!. 1(1).^Z/^OQW1\\:=)S%!\X;87S4^
M,="KJBS-#1BS8]4QIS$7\JX[Q):KWDQ9V,9O>9.[4IB9E87VVOC;,RMY<PDP
M]A[#JA3D[]ZB*M@!\M%J:PSU/:51CP6CH>-F7;/:9G+1>Q!\%.^J!U@6_[BV
M,T1YIB_^\RY$J'2I6$>1_F**JN?9DQNSR#["QQ@-?S&QF+C3<$BMRZ5M-BN'
MQ);8-JHB%_G%CL;;+BQY+DBH4BHML@J)U .^,6J1)#B(&3=@YOZGTWA"6V6
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M5TH9V1;QK?@X#L0YQDKL1I%%OW&BP"6(<2F+Y;]? G76K>J78>^/,6,;H1O
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MH)R.VNMG/SU]]M]'GC9=MIJT_G/I33\D9;91!)7#@]@TC-L=!!GD%A)KH 8
MH^ /_)E8H)N4$R_.@I\ ^B__X7B@-*UR!EDN?=&^M+T\3;_((H%6NB'??L84
M*07[%NO>^+MYE+HJ9J#I3FLY6 JWE%4Q1C_QD!B>A1@:9Y\$2.HN>!MW$_J
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MS2?19Y8^@!%/>6!,(SJ2O[B>?G:89KXK7",:3%C?-JH:2+HX_Y/1D[R#E+/
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MTA5"!U4&K&G2*:6<)35<"3R#/*QZ<5$/;2,B4GQ4/73&H<".=ZN31ECZ98=
MQYKJT/LW@ZV[Y0K/E07Y2G/SN[#6BW5C2J@*/O;"3^J2A@VK_5!48B,8UDFC
M7[_%?$F4%OZ=O%>8_?5F1U!R%GQ26\\A4AW=RRQ0<]^O'TV; -O9_0SOL;0T
M_28]KB$XMR# 8Y;.@W%&;W"X5DRWS](7^06634>3T(T@V W?TK+'[,3 -G=0
MRWG:CL/N7(@FMS$,NZ;#+6:7T35F6;:H-D7&AS:O$%PC#<TKS*'"GRWUQALY
M_F5A66[0N/7.1B !)QIN=@,!#4$(8I/Y4T4?]_BK$+I=A>"I"0O2"?6UMG9P
M1/'H424]-X!'$A[1?1SA <;3'<$_+B,:4;8_73@&=X\K8//A4>YAP<0S.A5,
MRF[8(&]'>7,N+X7/ZZ\:>?(8]E/\6=S/N,F1B4?.=>5'2R/%0-&.3;.A2,>4
M.MJY<F4C)^;=V3J%)'.;IWVL8[9,;P%V @TU&7D>93=TO_=6^+!'\'5S7@_H
MW*KR;B&:MFM]P2<O_O7\Z<'#;\T+#-_6G+7+O"/EX0/?DL*GO.MW3#:_E>*H
MXJ&(F/.<O%R4P]H.CKQ6X"FX#(N>$65%<56V\]G;O\G?OFV(!2/<7J*/1Z];
M&:C54P_G[U^15 U)Z,P-X'#Q.KC4#&6@:0U#^<_=YNH=YH'VR%GL*[P>6-X=
MD+B!KL5M!^ZODQI*4 ?']0@B7Q3M5)EOO!K#]-%=QX"Q%?2@Z"(<^R4GH:6A
MXM;;A_P)<H0U=Z[D/6CN/D>#F/LJJJ0+WJ<PFVFGUR.)A[9BQV5N=<5M<F:7
MG@NZ_A$P'?JQNDBZ/6>?PSI)@/ZCN]C*2=Q9<;AX5;[TPD#'5G064[ [KD-J
M?K90+V69&XR-%[[/65@S5.'>YWF_E?7F_NN337\<S.(IUQY(_*BA7(32_ I4
M&[Z]KJY]RHQC $]?Z'TE?=KJ+P_ISN$K8*S*S[1;Z1VOFNL&^HE?17<397Y?
M)C26#63I;%%*H:\#OX%+*> \\.0IA-;MTVFKKOA"\S0UQ&W>7H :O$TI;GDI
MC.3"46%,L.Y8)IEY8-!X.>@O=/'N*ES\A<,Q ,GZ8,R.PYUI:19W70A5>B4\
MZ2+&!D-XHS61C)C 6S&GRZNXI*,TIR*^FAA <4CQ8";?03VV"K.WM;YJE>O=
M]A6EGIJ!("]EAO=\='DW"'QI_5,IG3[O%"OYLA],6YD>1. 38N&4?Y(2[\-O
MO_W:*D@_/']Y=)0TXL,5\-TRR7!XJ)@92KF';Z<N2D,AT#?H+\GA\*2V.KOV
MJ=-9H'03S5&^;GXF4M42,W[RK$^Y,O+HOC+R,?=NT,/?#%3 ?M*?R<W(_>!L
M1=BB2^D4% !(QG"S=3LN-[VE5=WV#A/'9^5 ^Z?SU"-$OYP^R(<.U8[4UW7$
M-<X$PXA4JD5'/Y<&R3K,TP7*+,^(CI4P ,/B.^UB/%*G??%Y'0&LP37$\[ZH
M$BZ;&O1E]#:4>4;JMD:R&K8H:E8:]/#RM(?VE,@>,(,3U&ZWW(8\(O?AG%1*
MD1,5-R$0\1D[U$.$U2$K1'.E&*P]3:=(=>Y>@/RFR&3M@H\+S;&TJQ2VSWPB
M:9"4?OMXFT,1-TOL*0D5UQ<*-E9@$^VPXL]O$M-IV3U" TKI19Q78ZV19Z<?
M[)00LPO87YEZ6Z98?X8=8%7]UIZ[:JWL4+H'")V9::Y10*GNTK#<G1%F=XGD
M62-^3ZK.-/6E!)1)"AN :EI?483BD]_-<-D6UJXP\TKAI!EJ?/!!=@*0ZN<<
MOY7) $5D%_W?7!^05G=^DAXOFE\GE<20!CB(DE><_3!>43%$_:"V*)7']2-#
MT[4?P^];LA<IP]2.\>'%44A7IOI, J88E\%)55DAF2G)"# ;R'&NN:)391Q=
M!'J-3=<$,.$@BCFS<!,QIP@\>\'$#LX\\ <SU=R'-\$)2<[(T7<]2+\MQX7,
M0A;.!>6?E5\-!!KTCP:,QT]PTXAJH&"LZO))GEE9Y69";7/K,D?:2K.14H=S
M(?,FH"P)_82P _W0M;7C?6O\/S_1<;R4D4X88YZ\G $KCI@5UUJC'RN:E93:
M=F_2+V:[(A0>K66=BC/EM$3(--&4X R&65BAQ<<N<\PV5 SU+6 G#^<"%.7"
M(1*^1:>+0D<V(U$]T2&W47"(_@4W=^GX66-BA]A=_E:)^C".S%/A;SJM1=:'
MHM%EXS1BY4GZ>'HU^93TTNNSA.?;@S :S> X%J>QEJLX',MN7 NQ1LG[T682
M'DT<B.DA<5!L*MO2-H%^EV#;EK'=1=]->D@C-UXM8>/] J![D3 7.$A$+^0+
M%@Y@<-QD:9K=^0K.G.$8W?;2_?N*-]]D&[]\Y;9Q"+6(FFNK'"\L*5M3C\8X
MLL?T,_7 ,+76HP<\)K[-:60G/1NVF)SYS[JCY*3DA9$6?BS?'-Y,OXW2:Y,2
MNF(&C*9\JS.$VBC(.A05C$TAX3@7,DF&QW*S2B< +(U&FMPHQ6F0]-E;&58U
M-XDOXW5SQ*]+Y_*EDY<GBSH7W<*><J\6 VQ!JV-3(5<1/>]P\:^6S#OU\M&7
M<U$VK+G:K1K#_S,-^X#ZF9FHBO[<_M!LV5,ZA',&[5]/$XOFSCR3-(R\87EF
M+0>+7<5[\PG%=>%FJ.B%V/[+'4_V/[?U*?O6LH_TS_G.IIGRU"CZ:6&W4:H<
M_5^X%^4RPE;S&=1@0\Z;Z>72=!?MT'/:B]M$R+DZ7"BWHDN&J/Z<4/7$-E&T
M$S,!"SP#3J6&[3TL3K )!V_I=3I$@VS49KPPV#7[=$@?640!^U*P/ MP$EF^
M"1A0_8+H)L3QJ\OF$T1$!T*  ;()2)_@CSSE'I-^+CD78I2RX>R27AT?4NM
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MI';.SN^\<:OL*LP5IL2IBN5&0P+0X"NAIT.[-.#]E>]Z=,]AX"I"=#VNR=X
M>:B$.)1A">YET]@564O24*IWU2(5<>-:%3FO3+Q!D6,ZTTE*60@844)BD[(*
M>YV9EN1GR#,'1_3)IF[/8@R&$@R;F=2WLGQ+4JFND&51"L^(12ZNNS 4!G]L
ME:P=7;)N:1-J,@5XK?N=^!V@KU<@#:?>]>:C*N@!9XC$?5V%&[7S-Z<C_YI
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MA?+FJI>,'>++*NXS=F:"6W)E!\!/&69%2@_+$-)=Z?PM/75-[\T*3VMK71]
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MC\6VL=OR+>!@?ZTO^G8EO[9*=]E7?XH?M5T5?^7QG_YV03YCL*.R$\,$?;;
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M@J>"Y$9YVZ59(XZZPB N:VU4:L$;J@<(4"T!X6J^GLH[!$ ;!O1&0CAM-%@
MI9TT2$!]/".8\:5Y'I8D$>.HB!6=#RM[AO2T8PU]Y+T4=Y"&*H"IYUS*H$PQ
M,L0++A"PB"!^+;@()RW7\"_)\UCM&IEJ<C:$XUAQY<EN4==$1,_7_2#VACY@
MO])OVN.ZU])PF);&5S570>G6PF6UXO^-NP%_G!!64\BQU34BLAUA,DH^1IH+
M# 2%"6W:30P;")D&DU%/UD0,SRK2T[1;=X*B37W\Y8/O]#!]>&?ER M>^JOA
M=U\+YVZQBO>"W >\D!WZABX<Y"S:4RLY@]HS.'LLA-!V25>7L0"&1?2Y$;+4
MJ$5ZP,/7+*RC 28O;5*6UO*LE/WV[4>N.^7CP3F/KGHM%.A)BB4[+M&ZP9A*
M6[=W:"P&*#XNW(EDX0Z8+T&HC.TC*W=NKK_<.*E>3*Q&(#QAB-98%FMP'2.X
MMIX>#!H_R<C&!@$=7:ILD\WEX>*%1XW:):K($LHNU5RX#/>*"B*6 44YS?->
M2V,^86VM=(S-N(.R6E(IPJ F77B@4</\R[QPMSD;*QAC99(5\L!T$@9W:NEB
MHH4V'@]%TC*1KO9L*3IZKPW@&MV2NLY7M5V-HZ.ZG6*2J.R>%L<X+1BMZBT^
MU]>4/N64_K?W*?V//:5?/$U,4+(1)H++TT9*I\W5[8_2:^,P2'UDO;["OY)!
M-NH7@=1'%Z9T6!*_9]T/J:L?[P(ZJSE68D&8>W^Y3._RF>Q>^!1V,9CI^G%^
MXL\("'4.WD(H)]&IM[>OT=[<G1#5%/ADY)13D58)42OY+[7=TY0P4KE&!)2R
MEH."<?&=.$#+M]JDQV\]6/4C)TPI3\"9T.N!C?RGN[&)8!D\F )(^*TM3Q-E
MV\*6(<>=-D%*5I0/4'C1>7<]?/ GV.P>MQXAA!HB'P\;VWR;_.\9:Q"<67K7
MX2*]:;AJ(LD#OQA%G@MT ENK>R0FHX$]^HKM9M@!2\EZ\<ZBYTF:.0(7K K/
M[P%,(=Q)TV]?;Y3H_1@;T;=OI/N)^QQZZKWQ^8)C+EBL9T\'H&18!X1#WG%;
MASB"6XVD-:_FW[=A?7A'09CT7S5"LX3]^UK!VT=I15 I47]X]=I(4>=];,>T
MM)VRH5HTDP5)8D%2I?CYG9)K$V #9A)EG;!:($8E-X\W.#N$C6=2F@\*2CCH
MP\7S@D.*<"[QZ]FN-1FLQ/MC,!I&?16#S[G [Z>)KV-=4 6'9SK-&FSS]_>[
MK=:SS,^C)=;Y",_H.,$/ L$M\<*$7^''9G/(O"<RP<'ZT'.DCCMU[D4)2.\,
MG^?5;(9E"[>1909YFYL'@A%B9L*C^4Z=P[L_AG,9EAN?T367U(!M7(H4I^6I
M]&"*SW> T8[]9I><FJ.GK^S0H(HTRC)PD_+QU60R9R?.-8';?A9FO-4D6:9/
M29Y^E4Z^=?EC-TIW&\AB1BD9K';,T.58<B7-(^.O!PTKA>!C%;$)(:A^^HJ@
MGLTF*U_TZ 2@NMO0T.H@AT"=>NA'D Z@\/?'"!.#L1*\\B+2_P?+3[N.7T'S
MV@@''^T0O6ZR2:0\2[B'*?#3@AYVA-N"Q;R1 UG$-O<(;B?*G_@KDK5UV'::
M:LB#F&73&R1%G"6FT#P\R4U)ATR:>=!\.KCX$B^.$L\%0YLFK[I;.&(?^HIZ
M,F?\X[[84,_E- ?[>?L%'V3C,M'FV7A#</X3'3*="K7%,K]4&#Q+GBQCW,-5
M>,_LBYAN@+CX@T%F1= $L)U0!X*%9NI2X 7Z!G*N1L'&:^+6[#X/G-.RI/A(
M"9[PC9##A'O[>7MQ_91,+TVVYZNRR1<<ISHU2IO6<M,J P:2O<>Y.=>]2\>=
MZ2&YFJY4#L78YBCITN5[2G@LDC_V-V;&&^,:?0U;BP2_&A5#33O"AK)<$3,G
ME7WD]%0; </<M7O';2O[\R>"'5?-I'KQEQ YZ$U FPU2$XN.'*<20G?;,B7A
M)"!Y*@*&X1(  .62G TN+Z0_8%R&I#SED)S4YX2YB!Q_R2.W H)Q88(/#Q*8
M'+CZ=MW8 /H5#H=]FT]-A]-*1/$C0^"(_@@EZL3HY']XN/@G]HO(KYO^Y*Q/
M:Z'2O&$S(V#+ E!%1%W(1,5FRKEXRD;+G?/!MT#])D&4%&<O#ZZ>_F'!5>%J
M_+1BK&S^8/)D$N/'FY< 9RU>W=CJ&YT<%QM8I.3NILO&_/[\EJ(DK:9H<RD.
M[PMD,*J9M3>4?D-^0X_^"B;1P5GQ"Z]520TZ),MZVE+WE#4S$<]N,4-SJ:=A
M2?X?#$A$(MVTS8JHX\2V:RIE?G=1A:8=4W+ :3=?VI?.QIZ@>[&@GW#C('WD
ML:U:BEFYOH]NGUZ*-'@OK7/BI.FP-:X8Z:,K53G1DUA..^Y7IF:%YK%&M+GM
MX%"N:JN$&-;LG@ZB2A&(\?$*RA%X!7:,[^1@#?'!W,=/,Z7^EP?W*?4/GE+_
M?8 5(FNHN0Z54A6:XG3L?J<IX@ @9\7.U)GSHXE<"O-.'ARC@)M$DC%2^]?1
MXGMQ,5_OP"CZ>GG:D""T8N7?#&V*,J<@9SZ(G7,B%&:9@=63,28)*+J3)#W-
M.,-1LAD>?DRV&Y08<LO';V12RBS!99FV,;^+"G.*V&="USLW6W&F"B 7Z1E,
MLV%(&[/'L\ZNCSBPX/A$@,-9_99N-\K30)S#YF*4>$,$?*]L8I-/IH5SF0-'
M=CIA#Z)!?(^-]X1S*=1]&HUK"0%#7B7?)-AM5O'(0U/95F$@Y\2"Q+F39"5(
M[%.I D 1&NGZ&!=:Q3N8N825Z"6%#]P.,?#>X7 ?&8SR%R'.4;UT1H@*W O4
MADD7C_)V66.99AYB6.79X6634EJNV1#F:!S[98M(FZ4.T*>J@-4BC\OO)&FZ
M"_0A99;=?)"WBS3%BGF9FWTTA<(+4.J@,JYK6I9R\?52*%L@H,#%#KH?-N0.
M$3Q]>(M^ RN4V"-?OGD1V2RW5^=43=Q<*248X_G0E@JO?-_:QR:4L.\:THJP
MFD.L''!6OULS.32C=C7JQ"/QL#@B[ PR_7T$QQ9>3Q%9NU6*.[;F_.\=-EG8
MU6&2>6]![UGI[C@UC,M!)YC?)$P?5T[;8,^W1[YM;],!%$<*?B-40@3'CH.>
MWPT*:K_F"7@QVSX PND3-+,@XS8D>]P(XF;$"*!,IRK=/I.O8LF1A'TJ"9&U
M3L<H1F:622ZC.KRP93*6PDIRF(]O^I]=,%5K+3)YI+5]"U,Z4P*,M/C:3@CH
M(GZ?+*)4:Q+H?<<)C"7Q:RAZ6W8 @B!52[0V@>-=2Z&QX[R34?-W"1"3TRUQ
M?*U+<G*S/+>[;>F^30GKN,,OYP_S#'N)>,;LSOD8;QI$=+&NCB8.:I7\7N0W
MGO3#L L[_:6)(Z0.!O24EOQ+K>DD.X'PL"E9<Y/[Y_CGR]T8/G%4F2:#R)N[
MXKR7B-=-V=+U));Z#;9.&6$&R6]<XD9'Z4#[IK=#.N2;M%TNTT:H_D"V]KNY
M*U],E1+\O$D2IKSP\:K!D7WR\JBZ9K,LG$8"?'MM)V3!5*P>DV#&:71=E<U
MURG2!)NVP\VQ);]1;ZHP@NL&$),A6LHD]UK;PYJPJ_JKQMK^J%) NP)CQ&5]
M/(2_(2>6)52.62:"5%=JR#S9-8IG1^J/7' VUC.MPR5\WBB@2_$"X9#C?QG;
M?OBGDUI;."5E8W(Q*Y+JJD\:,IT5/BCI.QZVG:EHD7T+0]BTS+.''="PG8R,
MC8F"PT(DS:GCR<1DHDN!R3=5C5$[G#(DVK+?;.KCWCOIGF2C++Z")'^=-($F
M2K.))%$)%(&QA9G;]-S&.]T763;SLMAMQQUVP80MPWP)7UO#_#\F\F3(N22R
M#^-BPT'SGC :^L-W!DT,9[GZ,KV+7:LLK*1_I0@#+AH-7G[GP^>RW^! 2^6U
MZRGR$.(^I=[5OE;&I<,MC/ *RBX0U9_>!!,Y";IOHB=R4_L4#QO;];21RW3;
MR&](+C%&JV0QL-_];N-+P83-X1Y+1(L[>1&EK>E*KA;/=L3D'^;OGYU$W/*L
M";$Q!]&=!<\:N'7:B;=3E9G?=3\EI9[Q%*^^)$?W)O(?[SXC916=A%=:KG>O
MC^-D<-R-D+;GE6[\Z,J@LK1DD44T&N6>0($=XF;IC+@BTO0<]N *Q,GN]3=)
M?>SW)C[=[/G#^^SYQPQ(G\8>(?CZ^V?!._KRT3=?/?[R_SS\RV?_\2HX"".1
MY&D'(>WF5YY/"W;A-;42$L7C[=W>/S9:>A)[6FCDJY8Z'I7^ ,Z;RC3SH6<E
MJ=XKDU*"90.E4Q6I ZE"(C9(+ Z"7QW3&;FK@."GX9#/_7_6[=B>+5Z?UJ?5
MXJG^ZP]-%YR;_VRKA?WB4TIQ=2&()%@XW>KA9Z/\[,<ZW/KRO,/%#_3.\.-K
MZ[#VNC=MTQW\V&HQ]L>F\2^N+]I5^+<S\>#M!V^"UWL50H)@O(-'#18=8W+X
MKJ^'X ^5/A,/*7PI41.C^QB)G&:Y8["O;((JXFK/&O*<S04XIE<Q[EYW3_@/
MV_*?<XR1M T7WHZZN.V1\#LD-XYL1[5X<DH<E,]L3"]X3/B0)Z=UBX6YT6B^
MN -*"]"DV9H L&H\*4(A]>EL,MH$D5"ZH>0<$%LZV4H.1X=<%CWX'9T@^IPO
MZSO4P9K8+]]2)P:C"9*PHD3$43'G^_7CG\RHIJX'<")H(3 2=PU0;1UOL9OW
MK1[]WH]-O0J!5YRMI_+H9&=B*-ELTUXIC71,APJA#3;%Y"5)@9=>/7=RW(L+
M5L]A>'_/]J)6;G2D]HA1J[TC0C'')IT&>!1.RT4]O/64G<+A<\& :D[Z$@'6
M5@F:A$&S=J546[M"F55_%N6@EF'CQ4X+'8/]' 4FPMWLB&R7=,/IG43S@I8F
M<LV'YC>2J*4<C@+J>8B:;-F0(M6.^ZB"+QMB>$X<A_ K@I(F(^.P3.O%.K"D
M)5<BN[GIJ.)4G!-2,^S?4T[)G]8#]QE-OO=U@Z30=V2.28$<![ GF?G8U!:&
M8P\^#6Z':67]!L:B$/%^\Z?BPTE@>("79'Y#C6$\;9:X8Q(NZ8=A?NCZ<<BM
MD2DL=&(*6WGQ:R]F=NYJL)D,G_%3<'3X3?9!M&CV*TSO8UHZ)MHFN:>D8)^P
M[-TQF!7SM,>Y@\"';0+[=M&C&WG!^W/KEK;==<T?Q7C>?DR&G>!ZEV%.#9?A
M%!)4%D8VTA\VH&0<R>]K%.Y*3C@D(EW->7C-8B)R'HQ_/_Y$OT-Z">E0\N<Z
M7Y@J,\E&HPT3#X5(]N93U^>#)\3:5AB@:/#\W\HET-2<D")R^K*O+AACALP6
M]PAZ1NNEUM.U'T62I2XKH&B2+=<^?=W//L.PJ/$Q^%M6_LLXJ:^+,Z1$ 8:O
M@GV7[EOM/9(9U:ZDC"%,J8^3)=F-6>,>>6[F^QIT/N=@@=GE13;ME]@.[.+#
M;:29U_=OA<8BN$U48GMYS118U5IF89TI?LT9J,GEZ,W544JNP[LCAG]A7]6#
M<#SRD'P"ZSQL(B;Q8Y5:E0C2.LO)T%]"Y<0QD7]TA<1H/W;X'U1+X<K,R 1F
MY^>0J#ES=7OAD\2\J*#:6E32PC=2%2HFN!P;D/95*+R*FD6.&R6:Y3!,MH6A
M:5WIFJEI*5W.*7%.OY7@0KPY3NN5$+5Q082YE#JJ/VNQ9"4[\"IU%:7<(6+O
M2Z3YE^RGJ]0[TU^0C-/_S][;-L=M)-G"?P7AQQ,A14!<DI(H:;SK"(J2/9IK
MB[JB/+Y[OSP!=J-)6-U &VB0XO[Z6WDRLRH+0+]0HD32TQOA'8KL!NHE*RM?
M3IX</\JF9 DQ&:(^\+8\?DD,AS:@6O1-50Q89L_D154-5E[]%J81R2.! #+M
M?IV'[,<E4@%NZF>H3[Q@5=P0WD"I384UBAJ42%;KJ)J=%J5 \F6L0J+TD8TL
MM7+XY><%%P<&,$3(ZE$<2E)=VH6].P+WD9Z%Z1,N7F D\-PIZHSG'>YP?YJ%
MU:Q9<(<<SU.SD[P*S4 XO<1>C:7LH;_!7V#B*[=1C)!AK7F1AYO6]Q&*:SOX
MQF59]%ERTZ"/H/9:$H%81\/,FJE7T(MB)@XK5Q2P!AB9ZY^?[OR;7B>&6VBL
M=1U%M5)#>8R0/ZI+-9;TU?7D"%+BU>3ANJO8.YM2.I)IZZCN+KI:.%=S[D2K
MJI'G7JD= 0W":T4C;J8-046[7"6:+W$_BDP2/L04M4*/<96H/^>4#_F#,E97
MC\B"0ZEM4U!2/5*A[CJW&.Q@/D2-Y\WM'=W2:=2.T%J//3XK+85JY:*'^7J?
MTR7[VW3)74Z7T,-%87H-$/<F:ZRFX7I<;R2[ P_M('0L' 0$Q(U.R/A1.R<8
M::YPI>BPL!VBS-W-0OF\J#0Q'H\D$@4RR"H#J&3?@YR.#(JJPGFU=S%?!9U[
M=T.KYW#U!U@5VKO+K)X:(J++S3JB7P^<KH"RE45@  *17WO]2A@NUL>YH(3Y
M6V&V4=B@TRA@8-4%Y#$-"Q]X 770A%$4L\F"%3K6$X.Y6?/-X<CH3B5N)YGI
MC)^">*"$U"E;/;H*5AG9'?X69.P2HQEEY;J;>PO\UK:&6M">1EBC"[2.&C<'
M:'%B^<K-'4*5N_!.)58LEZ-==>Q3*F&+ $5E/*]!K%"W)KIE(_'0KH-M'=U<
M<3[OT)^,*>7ZO:5KON$KTZW3&,"OR@T=GUUCPTZI015#RD[#)^DO@D?&<418
M@^:3 [)$\X$042PL4@G^2YVS\+L\ %1[UJCN*K.&^G4CTJG]R:7%)S,-DG:Z
MI'.5_]G2UZT/X5%MX6E4%T'BP-C=VJY,F.[,]BLP3=8N!P5,!VZQ%@&&-+T2
ME+"1"I$30R@?:+JE21B!$_,^H@QSCE2.R-)8Z\BF08_9!4]]:708OV\K591K
MQ(Z0D9 +3SO4>QL$>US ESD'3)9+I)&NT<#-L$-VYZ(3<BL)A&@:Z[54P(0:
M(AJZ)BK.76%S^2)"Z)3"KGE]>S4M/K*&H@#=2BUM:IO4QG6EWT:<:WAQL'/P
M-YW:106'=EY=4OY)Y"O/?&=?*?TKF6"8N0"H##K^7O^5-$+W&2Z]GU)-T0*L
MG($^!;4C^A$:"N+/?GE14ZT , AFSJ<\A$E#@Q84&4PEKBGK8Y+P(;>,2Y1Z
M@(LQI!Z>C[3BN 8.VE0BVW!B2&=&,_691F@O[]_H*X\XKB[IH-@3,;I'<""A
M'7RF)>/LP6&&,JDCC3G5X5-%"(@:"K1XSH*6E; C8KQMV: (&]&M.*EGWO3M
M+0#K_M% WMM"J?=<0.(Y77Q$XLB7FF+9WI2ZMW%:#_3HVFP8SPI!#5/G02S"
M ?2NH2T&K4N7B,">%(A>2*2GTV%YCIMNKYV7;^-JL@(Y#SD=0N9;8V91:0\4
MM5@F:$07UYSY^ '#R]$^E;_ >*20*.K*,J-UF93F]&KY<_7MP,SXY9J V6<G
M.<G5^>!C>[VVAZ\,98P;(H5A3JC8C@&QB-CM_S"TQJ*V%88QB;M=V4+N**O1
MY#X'_;M<X;2HFJ\87M>)I[2(5'3"H2>A0 :^?\SEV8U[1,-=OIN(@;EC17"_
M7>YA4E#,TL@)=[G%S>UUTQD27A+2>RH<GI1*:Q=PN&B25J,/:[!UYRPRF/H"
M[/--YJ!-2!=>9-3A5N@9O=ZB!/JLNK IMP=<H5C[H"U4Y\.4"$FFY#P*S&.6
MYTJ1U3V(*3>#7C^7![8!B%;&6KW*>)3PM)=7C!#_<&Z'3-0M4ZZZ#M@:+(+@
MMZ_2;BF6SY]QD< X/W7?+K7AET4(M5/OLYO.[^1C$L>FE6M)" ??DY.]!$&6
MO'#HN$&&*QU99)QSJA/GTL./6FAB+LMO<8@/"2/^P;T>739^%4-"[-V??5+Q
M535J0_2?.91>Y5/NI_%+=ODY![^/?NG<$0PHT?35M[XJ7U^0_W5N,[+AW*OE
M$-LE$##$4+KG_614H,?*-0P>BP PMN'0E8$R_/C)-!3_])_KJIW38QL8)P:E
MP/B:PSZ^)C:HFD7'K#*#0Y799-HRB<,Z6TE@ ?[$:\410^[@(0>%XC_I_/J1
MTQ]C4.*EII"7.V_3TA=4(AR/FJ%V9AG#.*511J/Q)!JDV_7L3)CHO)M*T1^E
MA&56G9WD980NCMX0X!-^"<[S:<<]0HYCFC6-^Q;=\EB<.!;E[9'&72]9*29]
M)Q*"/3:K9<CX*.K%.;NJ;H9\<JF6L'9NY)Y7=CU8[X(UJ-2;F';63Q:ZDRTU
M/L*R-!3:/JM,<3*;RN-\7A<2F[#W!R,DD@H.,Q%J7W%\BH-!5 R?SXIV9CIL
M!U&.<#8&I)6!O%$'=)]3$(^W*8B[GH(X,LDY;9E(U?"H'C1$_L).YOGSNAH]
MW/U?VL'<@"?X4A!=L5+Y!^VI;MS<T[QI"S&J!LL#1YXX;J+L0C,Q_2(01#0,
MH]G<&,S![ZU!QZ;XUO=_MX^GB6=U\7JJ6Z?<Y%5L<1/CDLHXJ^I8RQ>J$J>$
MTB9KV-8!FV=+'.*4J>#,0(8?WW&)H]%VH'*+[),M?:#G4-3FK!C)Y:?\J4>:
M*K+5>.%*I1A6P-0%,T]I6Y YDYBV5#82$DY6B2&*7%%+J1VZP. Z<T[>T%Q8
MH[T;[^^9E,-WLRRFGE8.3S;:EI=RU8!04ZA2\"^Q.28 R!@3'2U1I<T/S',-
M%KH1%#D_.ES!8E;>,EXW0B BG1&*V*6]*&K83^O*"2ULJ-K=RF+-70A]O\VU
M!?"0V!ENG*V3LZM %>";^\',R] .E-IFA!JN4()OWK)JK*8=JD2:^%M"A,!/
M#8=)P82AP:8Y:/6Z QTJFZ6"F:'I<(2(T8YX#&0"JC39D>7\!X'MY%]D/^<"
MG@K=J8G=3FJ3NH::$/1VGLXL$]K@F 02%"%!VXH[O=)1]X$&#EB+$TU)35)$
MT@-W3@FUA60WP>97TOFQ6G)@=Y0_BQ'+DFZD8W5Y7FF2-;-+G'K//U5L,);W
M3,)!;: )G72X%U("2V7][]/%YN2TF&?35+D;4@ENIV( NQ\4VY;*RX3'33E-
M I7XQ=I9/\C16ZW4^_L-,P61'_ ."^&[$H1+&*#A5HWA20U0("DG3ZD.*1>)
MRTSDW5K2-E&)!CS26*=_JL#B0+^DR?B_>V8$[O';(;<@:=-&"-J3!G$.\DC&
M4K/.DNT;2J[8,*9'U^F%^&;W;+%\PFW4G*IP68E8"40<)ZJQK^V\3U<P77(J
MTYM=/\Z(=@*/FY^NI"<V'7$)T4UXMTB]A7E[<)@,UJR#-\\&FL71@_\"LB7I
MKY"(B\TCX,7S.&OCI^K[@ AL@,&C "#75QI("-,NQZEM%)N*JE[^[$&*>T!E
M.K+2M^A 'VS(@A7V;EX&T@8<H 68,P-I0V2;L*XO."WY1SL^XYB"DDZ?9VKN
MV=HGRJ[1]*C%",?.[2/9 Y+2.3@UC:Y6' "H_1*@;W2@G;]MH\AM5:<N;%>;
M'1I]7U9M.=*Z6EJB@:HO="$2TD/RN4S*5:/"4;"'K4WC*;D'5?58BM6B'CDO
M,*3'0+Z>G9$-SI?ZLX-T=W>7_EN5>?('*X"8NL$KZK<K,#7-9JVKP!Y7[G6T
MH75^47UDK];/DRDXW:?B5C\RCU2@VLPS&WK9C@4&4U/@(C40"JDTDX</Q3 M
M2)66M).^?_IXY_&2]'VP9^,E7.9&<V$Q?Y12!MRM@I"$^2<JB&%C\A)%,8ME
M963]/!'K2?F$3WALX*>/D0\@(BW$$=A%#TO$#7H6@W%3\=<W2=&N<NAY<_O_
M_^[A6SXK:D+G^C;C);<$FB$?8ND9*!IM25>57(X1&\>L&=RAO" OA&0(:,/E
M!X!]%K,,2U]][?B5L^&+BCDKBP&S;(-'29!YQ29U^;*\J25!;F]F,E@%\>L>
M7B45.B.V[\9N@7V%(65O.>/<SCM@DY0#Z$JWK14K;>@3S"&8<)PI\#.FW'MQ
MVJHI&=W6'#C6HL;P.6$D0[NE-3H!V]D?EA.,[_=V=]Q]-<\ERA\GC<=_M!)Z
M 4D!BF11U#>4?'Z%SC.<PGT(ELN0E)*$+$P/=[^PFR@7B&3,^XGZ3>0/EXZQ
MH%-&G8O1NI;9X,L_D#6/Y&#E8W?\'W&&Q"L)^S^2-I'65(!ZVXO4@PO6J)_[
MFUMYLLVMW*]>$IO> L$MUDB:6'5ZIU[D6G2FCJWZ+ ^\JB9<2Z6\H\)*)UI9
MRPG7IM2E&CIC[*]'3H.!0_(+9"1*G9]$F)L V, UY4S%CZQ&G&)!K$PP.WQW
MX7Y=OA)QRMN?;EV)6G^"D6JNF+1[QZQ5/7()/6KGJF Z$$L/!2"$C^*YUL*&
M"@:"@JB3K^T..7#3U5+K]^7V,9A12?^2?#["?; 1?47#:\_C^0'8A\U (,&?
MGEY=#Q%BC@ EKLJS)@T!2/\6]R0+Q!),I;,+F+KRW +O!$S)=[,S>3)#$R)1
MG;+B4HUQZI%>7/]?%:7AO..K'+%5,G,DMFK7DDV /-=L(N-VIU.%U/$17/%%
MY99ZF"YI2X K<^B;("+";'0*T:BYJ6P U446%F'O\K%/P3D/41-FC,AV7S$(
M/LH1HY]!(SFI:9&W]&%Y_,-X\=QGPS L4A+ 09(+!@\JIP>^ ?>=*DZ 5?&4
M%DJ<)"7YTL/*8/$HU!%(CX?PXZE2\3:@?.\BAT(X6%"OEJ@?>#'@%#V>*&LJ
MPK1?A:XQJ13-6N?5D$@3VK;3E<@#R"&;@YO+.]M4UQ/53!IU<GE8<,UES0:U
M@*$%XE.&HL#XJ,4G*M/:+HZ:Z"9I?Y/A^9!>]617C!(5)HT^DLN_4Z;);UR6
M#J'/+= B!$4++)->\Y%Y2G'N/):*G>1MM:"[RV-I(V"14/<)BS4'0E&TR87,
MZ):TT!)L'CS3YFHVH$-R/-3X.F:'BS.;2JLVBK]Z*US0PV+#8A(E\A0W;H2?
MZW(XV=W!YD<L#JI<HJ+R$P/4E-7)AR\,?]_[_D@K7+74ZY*&N^OH/S3=T-43
MBM.PC E^,C-NQEE-^K!?%J$KM4,"-G?  ?SV.TM(#B@+"Z.MRMAV6'YO-]\
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MVSL:@N(''E"!)0@=G%]/[L^8.+D8KD6S2)X>/'ZJRS8TRX=IX/= T^K>^H9
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MB @P:%+=.31<^!T"9LNB/21L_T%P"7H*P6Z<X85V9:'=B*DK%[R/=-/U[WS
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M0S/5PQT?(5=*RS7;JGD2!!#HD?Z^">L0,E@":1\ZZS[)@K_%WEFL*3R8Q]=
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MN2_MPB_9'=]T=>7JIS%N8] 1B@Z#L/L+Z(J>\JM N0[)$7>'Z9#5&'C,E=U
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M-B=3_WZQ)D+P2H(_J_0-A6'Z54=S,@'!G0Q@"JZ/Z\ #I)9)"IMJ5*<6-6V
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M+I]7^-$IP^B5:=QH80@+V8O]OX42$1[FWW>]$$%T_W-1_R@_=(HPGKCSP+4
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MN3DZ-47<Q[>:TBY FJ;3UM=#@U\+70 6*+\LQYYT.6]X\Z3.,Y?F>(UEJ82
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M8E+[Q*O8@KTU#TT./<=DZ1MF"UMWCZM6VR[L)/^H+MU]4J=*-Z@/Z=-BKV'
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MK^IF>-4C,'DB#_"-5?V,/*T]$$E3XI*4S=TYWCR!.\<9Z\CL'?68&342DQI
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M!.&HSP/:H'?(?;- %_Q/K73!-GW+C1X@N7U3N1ZJYX)+=5[N$ANP7JZ5C-3
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M[*YO->TL(VHK'+OH-31(H-DA6=R70K99OQS;T<0VL/5\;$PC+W"\J>T;\/_
MHIA;4S18>S!/=H@GK$CJ,H_L<ISC@0LB3G3LO2E*PN+N;@.SS\TI6 LT1 N
M,V&MEFC&OL2CTS;# -M2""#-<-(H$H%SCZ<-CNW@IC$:HK; L-5TN"$'H&HK
M&*PQMB;,["ADCH+,S4$5 =^[-I[>Y]\;D7"%F,@CDB/7"^SH7AY%&V=[X_=-
MT1PM:UB7W/\:0T*]YFS5*6N"8NNU/GZLU=XUYS35#]Z%'07"17CW@ENA#BXU
MQL)WX0OC6Y3"-2>.@\>+-P;/#P_75P&RL^A06[-WFV5=*PI&$WC0:YV<U$IK
M-'.-5.@FKAS;*A%<[<2\?)&\K(/WR///E6-/:5M7K!]KC%_2-=M=KL!XU^KT
MS>[1:AOZ#6'$:L>UO(BX8STG;F#V-IL+R\Y";90R&[C,R[H0P<X"SS]G/3TN
MZVDD,.E);W G]H_F%',?=M9V8/CN6L]]LV^Q._7NR*K)&::[J%&V*;\]TQJL
MSP%D'Z)N1+#=R[Q\D;RL->+S_/.&0SE32KL'3=MOX R@JCT8]ACJ*QB[J$\:
M(LSL/M2-"#9YF9<ODI>UAGN>?]Z">)1?\44DAA_&O.70).^A;_8&W#N6MQQV
M= WCED./3\=Y&;J9[5SF95V(>-F(S_//6PY%U^#? M6Q</=MH!&&KCMKI+%P
MC20TG' R31.!+<+)A3"F(I+7&':21-XH3:@S!USZE^=\%U$\VZ3#-$9V[#E-
M\3VLOCDX[)B=04W.MZ\Q"#&U]0'XC5W)89>%V/H><:\*.</K16#9%)1L'[1K
M$J*I\1IF:AD?V<1<BXGI>CX\PFT*?+*1R=36@-K:T,Q&YD)T_2"1C\U,1DBF
MEA&2S<PUF)GJT"NX8Q(&,+30^:ZBF(8=N!LQ-FLLX_6"?&MX9/9[0_-HR,C?
M+&IK0S-;FP^$- L@N,#NK$!0ALNMI-F B;S:V38OHK/3;E%;&YK9ZERCU8E/
MK<#-<>B[X,*S <K4OGAJZZAAK9YEMH<#<]!?VXF(;("N;( N %.&3*;V95%;
M1\A<KU-": G/^94L*7QD :K*2'4\AU-&$7\&TZ28-+KX,55X]P08.R8<E"-R
M!!Z/ VJDW37HI?_\!X[%]6[?R?_"<.A?^+:*' LA=(8<_*J@,&3SN3>V?V??
MQPCD\!IXVCA3+DH7#.F?XS&9M&^ZTQ_'=YZ;C&$\[5=[QJ]T3__=6]L81^+Z
MM[U_ :#NO?LF#V:[-DYAO'B@S]M?;: <+M14PR#TBRK&7?Q9OFYPT/=*+$(5
M<EQ4)X:=)J'^AF1*?K7W;MG<KSII]-N=9,X(C/*J6?SSR\F?'\Z_G7TP+K]>
M&!\OOGX^,4XOOGPX^W(%WYU>?'Y__@7^N/IV\NWL\]F7;\;%1^/B\NSKR;?S
MBR]7QF:E[C$#^!A&1C(6QO\*.S+.0%.[Q@?AB,E(1')A="W3Z+0[5@UH;7D!
MT!JF,9@#X!^)'XZ !:V<*[ 0"J[6! ^5BE_/$EV@J).CPT*P*($#(A?)OB-\
M'S'+"VY^VVOOT>>I[;KZLWK7^XNO'\Z^[I]>?/IT<GEU]D;_\30++E^1QS+]
M_4U;T?FFG:T!6GEO"15G );N[ENOE!Z9_;T2;?4[7Y64S_*_^<&;?_ FO(3!
M@[&7U?9/YN\"W0.+!VP#:Y"9"6J!ZR>J.@^U#JG4(RF7>BPR$QZ-9C]E S9L
M CKKYW_K2Y@(H_/Z[2@"^T$EHZ@/=I  L^2'TS":'ACG\D/KQ/T[C<&UJSH:
M;&.[>9MD@W)$_P ]!DI!#WD"K[M70_[#B_&T6[BU,8.^C$(#UM_$ED.4DSJ1
M%N)V1KCI=]5O_<W, <C<R LP</RS:)?;%AR8FN^Q$8E;$:3<M&_3*VR+/ &#
MH6NM=EY0$]A06]'@2-P6Q9FW@R^F(K(3,/) K<=)3&$(U<HU?L.;#TSMRZ*V
M-C3SCNI"R#H%H,+X/1NOC;?:NN;ABB<%-H$+M96,703RID@SFZY?12SLR!G+
MY!I0!GXXQ7 =*X3F0N'0[+1KTCZ3)8,50IVDF3V&A9KB2OB^%]R8QHT(1&3[
MI#%L=^(%7IQ@^..6O8@&PV6_;?8'G1?/AE:GN[[VQ3O+A5[K_?NJ+>M-RT(=
M>=&WS,-A(X+I.QOG:ZR]52])M_KL-?1:'S[4"ODXIL[(M1O4;A.Y3&LX9.QJ
MG9TQ=KWH<.]YD-C!C8<%#/8D!"K_"XY[&+#CWMQ5WS6/NC5I*,J2L7T,W/$5
MOE9IKJ4M6P]%D:>T89CW&K/)45'(!+>FJ O+;+=7B^8Q-#:3)RVKS:<L<IBW
MN,VX/J2H4#M\:N%6B=BX.<>\9%[6D9>U=C-X_NNR,U@/G^1;F-B^$2XIMF''
MI$E&^.&1:?69#2 ,5DVXL(M:9)L"/#2M(W8;7H1Z9E.7>5D7(EXVX//\\Q['
MH_R)3]@_^#H*)]JG"(/&>!"MU5V(1H2P6]V^.5AQQ[ 9C%C=C7@19X+4<NZZ
M1^:@OSXA9D^B;D2P]<N\?)&\K#7D\_SS!D0I*2H9B\AH>8$33L1KO>O ';Z8
MVA=&;6UHYNC&0K!J_6Y[P6MY2%(8& #^WBU5Z1N^9X\\WTN\YFR8@G=[-%RM
M.K$17GYWQ;3%)O#@R%K;D6P[RX->Z_24,S<5-ARMN ?[0.CDA1G!GS*%,DK
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M[3UT5BM<XKT'WGO8^MY#K[V^HBGV%.I&!%NWS,L7R<M:0S[//^\]/,J%^+=
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MLJBM(S*"4[+B:<]SY0#PG%_)8,)'%J"JC%3'<SAE%/%G,$V*B:2+'U.%=T^
ML6/"03DB1^!1.J MVCV#7OK/?^!87._VG?PO#(?^A6^KR+$00F?(P:\*>D'V
MIWMC^W?V?8Q #J^!IXTS':),["']<SPFR_5-=_KC^,YSDS&,I_UJ#]QXO*?_
M[JUMC"-Q_=O>OP!0]]Y](RL5$/<4QHN'_[S]U0;*X4)--0Q"OZABW,6?Y>L&
M!WVOQ")4(<=%=6+8:1+J;TBFY%=[[Y;-_:J31K_=2>:,P/:NFL4O%]_.KHQO
M%\:W/\Z,/[^<_/GA_-O9!^/RZX7Q\>+KYQ/C].++A[,O5_#=Q_,O)U].ST\^
M&>=?Z+=OYQ=?C,5R9W4V, :@. 0GQ#)4.P;C@XB=R)LF'FA,F-1D+(SW:>P%
M A3L:3@9>8%-ORVF\W !F47=WWOU1+5_$1B?[<@9R\5I'9E&I]WIF-E>)[%?
MX)E3X"\AT9]%= /VP,E-) 2>267<><E8?WN5CLB$^"1N;.=>V0D'QF4:Q:D-
MURYXAFG$Z>AOX607P#LG,3W)"0/70\;$1@SV"*PW>!MVDQ=>8!9?.\$_74D-
MWD@$E^B@K^GW\M<C 8:,%]P8MG$'KI]_;X1W>/06T 1FGX<;O?GF[X%Q<@W4
M&3?>+=X"GG.![*H)S5DIGVK[OIY_+XY3_ ;("M,D3N />N9_4B^YQP'026 Q
M7CX_$ ]^R"CT!!!V'B"W J 'Y8@&BF^![^)T,K$?DKR<T#L[-B(1V!,D+B8)
M[K2/U;O_ .%&*N'.J1W<TX_6L=%25^7FH?KE]<'/++V59/HDH4&>@O$*E)J&
ML)UQB<.9,5MFZZFT9Z_0GL6!PP7>!)C@V8D J9A&7AAE$NIA3Z%%BQA$"KBG
MI,.[%?@T>'M""VG!,H)+]+F?+LJYCFN0!B@2!I/_V!%=@CX1$:[?1PWJ+*,7
M>5I!$EY$:@'OB(0C\-J6K8R&,!"%<+5 J31.YFD ^M^"*1(L-D[ D!GES]Q'
M[3=^^RO>\PX?77I/D3<'QADRILP#<D^,4"%O@6=/80,L(C28-!#:1I!.1C!_
M2,U4PI/X(2+'BTEK(Z\"<0</5FM\P5R.; Q:I=-0"L698K;Q%<5( D- JQQH
M3CP;L0FOBU&X*C&25CV\::I02?SPX@0'BT<($L;!]7BGDM3]2/@DEM,HO/5B
M?,:!\0U>H48CD#-.,0\&AR;%3W(4/Y?&Y,6(8+:/KV]Y:AH3>J2BI>+9BZ<,
M\PYOP?MVC=$]/*_XP!EVM5QQ[2'$CH0?WKTV6A3F)/[JF0V$38<K(LX#,H)<
M;0&>D+VY^"R0#)0;'::L8(X*44H1(3[I;V;8;_QBF?UVVVRK_QDP\VD\P\@K
M$!?OV@-6G<.81B /A&@G$SQ=<I:OI0GYQ6IGT*\@#<Q5C)9$)%^Y$L!1:TVR
M['5:H8QM%R4CL>G5:O[L&\#+&Q!8PY:TA7>2CC*+ &/U&D .BP 7=RR<%%$H
M +LL-MQ4H*5SJ!<H2DJ4P2;,R03@*"4/*08RG8-LF*5K]/ARV^(JQ$.<$2-B
M(GEJXT?C)K4C6,-A=&" R74EIHE "9!ST!EHLZOT<!C$- 7;C$"B8#<402SG
M""RFP/&F,/.:-_+J\B/1*D4C9KDBR%]LSO#]"6\AX+2G@"P_O(E\R2^'1P='
M<LRP-GQ:WLBYQ<->]&R$'5 A.6&.'8^!V?>D3(&H7[K#F5?I&=$K90GE\/0;
M&]4VA<-BH(6,R](+\1V=P4&[_ [X]BDL\JIMMIP#N'"\N/ %_.FFCN;,TH4+
MD_D+K'A8"JE/P MOJUJD1@*B&2LE/8<W%3LC%;!C)]K>PN%:_0QQ%@#<\\/N
M54;',JMOUGDIZ2(0:3#)9XV!)7::O@WAP &S/A(+KC8U8('5X=^;.%.D9!V<
M<6DE*!M!H5!9]YD:-<&6@KM*.L N /V<VD'G(/&2E,2C8)>6Y*.L@D>%YX%C
M@0_+U/P"C^8!AN?*Z%'WEV?D228M 1]YCW(F,<&I+Q.<Z*6=OFGU+;/7&13F
MZ>?%9796*XP6,BYMWTFE&094CX31/C@\ZO:&@P/CS\PT+(W#-*QNUVP?MLU^
MM[-( &F$2Y=V>4W'J*LRM*H2!*G%(S$!I8SS,@5OO.!55LM.)HG6H3GL#LWN
MT7#A(B"DBT5T6_ WRB274.?Y061>=UL=K;OG??0RXI="*3:%]6@WFE037@T,
MBZ]M1[.T#.F9H]@JH, 'N""7J.R:S"HI622F,2W$82129"LW,UL<35:5P* 1
M(I5:3*?Y^:DT0APG2N7(Y.'EM,1P\KUK&-K]:YI,1UISAA_:@5(A="R@?B"Y
M( IE,G(J@SAEOB9C4#Y2*$49-Q[ AH+"6NC)%[E]DNG^B\)+RF8K/%U=7;RF
M.)5F-CL(\GKNM+23W1^ 5S1GU&*NK.8*61G:K5:0,P-49@%69Q5Z:89GF2F*
MRSI.04@6C41RWHLS*UR%V7=SEZ#/NP1UWB7 A\^(:EARMNQ<L)7P.O;4P]-'
M*1I#R%;42\KRT&LD"\*$#OB)\%1':& 0M\A8PZ4(_DC&\!S?3F,1YP"J#1FI
MY9=!A8S!C,7B=85&@8M0#HN;E((G7WJ=^O[SZ[S9Z+T,/"G>+-! Y=#G A V
M=?0*K4^\">? ?"PTF_GL"Q_>I;._-+@M9_&<7ED)C D(JV(Z,RAMHHEEW-I^
M*L U.P#WR,I#:^:\L=DJ[(O8[M]IG!!SD;Y(*/'V_FLK8U,J@GCJ>TGV25KN
M@2L5;NS!% ,%9!5*2R-^7=)QV51*=TFK-;H9=4'A3M.8M42*)DVFY8@W%$JN
MC HN72E3/Y4^N_*D<UNR_4K+QM('S,0.C5\L3(YY.#1($_*:]E1L5P97S4KC
M8=;L*QMY>CFHP*RV@!RXPDM"Y4AG@@2_2*NL_$CDG0_?8/0W E$G;_ Z"B?@
M*FBW#4B;T$;5"" ;B)3AK,SB\NR1!U*! 7FZD?:%-!'2JJ<[[<Q=A2OBPC65
MSH0F'-CT@(DE126ALZ#SH$B1K.*CB<3%ZPWY ?-H#@9M<]CKFXII1*'MQ^'L
M9N("B)+#7BH]I0=Y>A<@)H,]CW<0/9TA^&)'0-!A3]-3VC8@:="OJD**Y1LW
MRC$NLF'9EL5T!K(7H32\MS,TV_TCLST\TL0H]41CK'@VP8"ZE'A>WB*:?]Y#
MFT$=<]CNFT=6?4)%X.5=.$F8^WC9MGAN<,QY_C/NG2\2W">V*_VVCVF@-U$G
MGL3T3W1]'B]?JG47WF_JRV'X^&T@'-!VB P8J");0FXA.4IXL[VCA1N3RKVB
MZ%6L=I11"0N74JW!O<-GCS%<^DM?1?TL?!KF#\*"NO'00K7C6"15T9KKT/?#
M.XUCM*V:X>"R_=40YRRW,HK<Q<;-W_2+3^2+3_4X-8<+<WD7ICX(;TK;;0)=
MN D>.RG]U#E#0:J,+*SVBY6'.LD&'&4&H88ZY""B%"RIQ/Z._PUO!+F^,EL!
M(_OT<:'+"!?"13*0JR=J*7*1HL3/OW1S^@Z,DR1'Y$(B)P7JU6:3[8P],'CI
M%4L92<2#MZUD0R90(,\D?F?<E:IHJ=126 YQQ40[77%-9B'\)P6E7+7'\ZC'
M;F-K3U87T%Z9 ;,&-AMX'&KE5 '_4FPL!?3&PJ]@1#F(5TI]F&- 83"=W!U?
MZ)V7O'%,**2A.<+W<;<>7O#;7GN//D_12E*?U;O>7WS]</9U__3BTZ>3RZNS
M-_J/I]6K2)_TZ/#5L6Q4^::MR'S3SGQ.\G3?4J[B3-HCW7S8>Z6R.V=_K\R!
M5*_,;I*W+/][8P_>1%[ZX,&T]-7J=I]X%V@1%*?@M[U.ELZJHQ-R;<@'GLB2
MQVR5J+BE3#[?5*+QVD<D%[0<RL_3KC)SM>!SB5@9AD$Y5VY&-*532SV.^*HC
M9PK;8EP:M+;E-'J]W-K,W=S<*EO@<C9E">9N+J\\R1#MQ6]PW?%A%%LEXGFL
MIY?*42[Y7^Q68^"8-4=#-8?5[9O#PT.STUNOS5:H7'S&$!!5(*@P+4;1]XL)
M*9?IR/<<X]]VA,G ,M1^&7FW:%==^C!$BEYE/X\Q+A?,YLMCXJEE'?3;A:S\
M\A:>NOP2+\_WX?(<Q%(!A:[ZN=!=+>7.7V49@!K7G2;0BXM[)+;AAG?!/D%-
M7E"09XD$_GTA8OOD5!RJ>E+I>YA1@9G<)J9%8BD4O-C,=OCE3LE89O :W@2$
M)XNC.[X=Q]XUR(].$U"CP2>5(FOD91T=Q\:?@9VZ'IJWEU%H? PQ^0##H'B6
MN*M(A#_>VSYM%E^-A4@.\ J92)# L+/,7F"HDU8DS15JX?2$T%[67/W=U10&
M&6+-VQ3S=(K[6>=!GJX@N:X>E8UD*N6/YEZ'#+,IAM>(B2SJH)49Z] _1IUC
M'78N7 4C..J_RN+ERZO:%H@9[@C0+M)\WE9E76*!!;'<7-%)DR5![+5?X6[4
MM?"25)*V;)FIN"IEW&K^5F:-97'58B =A MWI0N,P=#UT#HX>J7WTI3 ]O)=
MZR7D$#L4\5B9,[,1M$0 =CK_ZI#SKYX]_VI#NZ1RY[M08( ;P_G6*0HL;?B%
M.N>3-M_D8HKS/4OS,9L\&5Z6L6%FJ_:S_<.;S(.I6G/&-Y5]4-CVG,N5Q636
MF1R0QY?64HY&!?B2CD+DH&2O?GL.3=5-ZT-/VNC5.2UZ(&6HS)!H=%_&6TRN
M HR3J>KE'^?A: :K:0=39WD4$QG,<A(,7:<-%=P:E;H(GN8EOM"EW3+-V)-&
M <XQ[J%& /PS*>E+8+8E4Y(\-!'O57:53CZ1U;UAMAU=J";#_6X5U%(:\3%:
M3B4%N!Z8/U0/)G<"36F.&%2>AEL=6/FALZI'F.YCQW(P^-I(E(T7<RX)S%1F
M'>6 E3*TX5),71'%"UZ;^&*G**<ZEP,?74@XRS8LZ8Z*+#+Z'FF4C]=99_BM
MZ\5Y5N;4]BB343[M]9QR6[P@0>?.ZEDE^TK3%C2RS!Z0AHO,G.R:5KM'>_1+
M)$*E4U4G.9&D6=E6_X./B80J7<1L=KT(GC+<Y]Z[+J6ZA0NQ/;-. [>\P.?
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M-(ST(;"N&#4F4Y#-BGISYL7PA,V.K\*WZ3QA&UMI<-B4<89Q9G=PI@&F3AF
M@C 1C$*,0HQ".X1"NP,V%7Y5.-._9U-Y&,T4*>8, Q#G9#>C\(8YRF5A]2*"
M7:B?. "A@08,;Q>QP;*M;6@V4&JC IBC;*#4BPB.KJQZV &7O>P$S36@EAV
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M'//DQ4L+&P&/=9?,*ACK2!!;!&1=L]>7/S[8^1 P;S_OS*:;'ZIG*BQ$;Z@
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M-J8/3SWB#<R3%\P3COKF1UT[8:R:_8D?4Q'$(G[#+7B8VLHK.<%C20U13.=
ML[)FQ<0\866]3FSY*F)A1\Z8M+0+ ..'4W0U&61X03%/:@TR#;!LKH3O@Z-@
M&C<B *?!)Q2RW8D7>'&"3L0M6SN\Z)@G]0:BW<&;\R"Q@QMJEFY/0J#ROS+.
MSAC#ZXEY4F>,:8"QD\=%T<JY#J,)@8^,DC8%@CIFSZK:&><%]M)YLE;)J("9
MAN6[[G+EPT9V'IB7S$NNR%E+14ZX9(>6#9$F*5TV1-@0><& S\J3>5D7(CA*
M\B@+Y5,8Q\9U%$ZTE1(&C;%)6JNK'NY?TE"K9,VRP79)W8A@7<J\K#LO.4!R
MD8Q%I(,A1LL+G' B7G/:.E-;?25;\LLM^3 P ).\6\KE*K8":HI-S[9LI2UK
M#0_9SUDS'U@[_VY[@82440)*&K<P4B\>8\*Z:02"L]8;#"K,$T[DJ@<*Z>-2
MQW8TL8TO80(_3R-P%;RI[1OP_\"BF!/7>=TQ3^J-1;L#.>?8>$7$B8Y,,+@T
M=R%91\R"M;& S9@'XS/8UA!(,YPTBD3@W /&.&,[N&&0:? *8YZP!?.\34P(
M4L [,JYM3YU^C$U-[NPHLH,D"PTWYM!A#/X-5FOPW8@@Z.IL: (7=A!;&F3B
M>(&7>!B;B>/4#AP"GBGM2@D-0+PAQ:N/>5)O1-H=X%ED[3AA $3'6/8;3JGZ
MMWEVSVJ^>R-L'H[@[""Z-,#>F0T3&VH:Y(:YZ\4.C*XQN^0<*'W76I$'C4#;
M'<2:W8&4;^ <Q;:3=RH!YONA YZ3:R3A7/B&,_L:C3?,DT; 3Y-,'9FBCU$>
M^-ZU\4P8_]Z(A"O$1)ZJ%;E>8$?W1CRVX8X&>ES6D(L*&9HV+1EL"^7NE1T%
M8/]09/E6J,.9C+'P70SY?(M2N.;$:92SU3H\[#/(,,AL6#(J0(;KEK=*Q/ID
ME'G)O-RMNN4&^$FJXUNQK+DQ)DG7;'>YS)"-DLW+!ILE=2."52GSLNZ\Y(@)
M)>"-!)88Z$!M8O]HSA[18:?WXE4MFQ\;E0LV/>I&!*M+YF7=><D1D26[.-H.
M:5I A#4Q\Z1^&2MLK=1&*["&95[6A0@.E!2-DB\B,?PPYL (J]E&\X0#(T]
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M@T(U[$_P%S'5GN(3*KDZ!9H(8F2U[0(>PSA\&R!OC )!6BJ*D\+LZZG#D5_
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MI<,6"5SCTH9 'G#%7;\\G$EKD,J_0&Y&J>>[.O*+M=H^6M>I-+] 4H!C: 2
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MFZCS=P)Q#7Y&=W,=)?M+AT[7[_7W-,BW43JT_59WY[OU]D=:-(C>S9H;5=S
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M[(U/O/=@Q&+5)QD;TAE0NYJ*K4001JF[M6@NPMXJ!A1C!J\(ZT(S0>CC">!
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M%B(",)V"$?!TIF2+P[HS1'%$-PQZXD0T$,W8Z:(I]_28P!N'W<2.#-,1C:-
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M4FD"QV>@E)Y32$1%\U-/7N/AA&:V)(F'44+C#VF>FLO!DE %-QQK"O00OV2
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M&D8<!!')^VRBU.J3]4U*.CXS_V[):])/)U]<\[D):\ )$.J*4>>P!@D(#-.
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M3$KPL.X.D]1M.*GOLKA' I:^-DM<6O H-8AN/165[^B2*G>IV^]3_0UCC"Q
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M)WU<I4F<% );G:U =G@F8#X'6 Q1-?#-X# 1+\PRQ$J[O/[[_< $>.EQZ]S
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M&A"X+C\(@BDNL#3 !^P#FF> H#^,Y>09O'T6%!J^EO"X9"<E6"X$DAO#&4Q
MA1M<.!R3A,!XE8=5D9(8BF[1S8-30.=>!KVM0M,FE.39#*&]"24-(6UH2IB
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MB'*C)7](/664-_,"X#2 >XS$7CKR:=1"K"IE(G<N#Y4Y:KC2X^S(SR4$2G'
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MY3WN5UX VLP'LM04<1>5&%?/;UA[7LL'P>G(U%G1S\%FF()J&Y:]0H3<1,9
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M\K8^4'I*&K6YA;KW-SVVYS;@ARE8I@VV5Y5UCOJ'QZK=M)D6(6+*.*#'EF@
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M)36N7*.;5@'HM68PC@].UU*QDV/G6,HQYP$&[S:FT8-@L=M*4H?2./OXJ5=
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M;N'NMLHP$:8$(I<B)-3QYPZ'?95%!)9K#6OM9VZ=R1*Q4R)=LQ%]<*<2.B6
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M;DW3"2\]FT..1WT=L&A#V+Q0^TQGJS.HD_7!,!56<BO=I/-XX\=*/6A'FZ"
M:&0:<H"-FB1 VS_.QET))<,-.S5L=N!=F^@K](E XC-B&BLR?8!"L("2X]39
M:P6^3@]Y(NY+(SV]S58ZA\?]'EEKP)T"&:M&XE3X"0.TM]E]D=$3R\@AN)YA
M^UV@#1[&#D;!U/QJI!ZNG,C9FVH\#IM\@9_91@]DN_,F,F.,PO>9W"LK^S!4
M /9=)I_)?Y?)?#%  S!#I14DM&@,/5($7";P8 (V===V).^->Z[#SB>/5.?-
M8ND8)ZKNOM]JHDHJRP.T&:EG<Y-GOH5-VN;6$\YD<8M)1W1*O2W<Q,%#Y 8-
M"+!&^56=JV<UYET%2-= .:9=!)>7UV"EU5WHAF0Q><#$PK$N!L:"M2#$"H)>
MOVJ&+%4FT7>X)4QDB]/X\I74U<?-@T0R/L\014(T8#C)%++7U=M2-XE,1M:T
MZ7;K!.DC>UW.=%O/'DV3H F=:R)]=HN2N;\>@2+"G!MCTMGZ&9E>UB]+37F(
M +7F5=J[$Q_YP95/?$PT6S;/&%8UH./D0][NI]OYENNTAT/;PK;*- MHG'7#
MO69PJ)<!R"$+^MFXG57\;F=9^;GL]7FV!/G4X6FB-E(XWOSSL%4H.<$Y*A:S
MI,FYX*'1#@6DDTHX'-1\> / M9;I@LEH^.9!<R(%P4X@%1NC=G<LRH<N7KQ)
M>[%P4!QG"V[^G:=-#G=ID^^K_3X@9@MJME)9'6?7E?!VCW-NLM^0>>;$YLIB
M7T=FIWN9.]S0LMPX5U[<?_Z^"4Z"N*+VNXF./,V$#\&)-^;L,^=2-G[5!P'T
MVP+=T_D,N4GSZ.5CLK36E3D"<*^#E-&&IQ#(*1]UB))8$P0X4H;C&UK]UG-N
M\W0%?CJ2Y4Q9V6LF>=[&#QIV_X1^R[R@$UZ3"'2E,E>^N7QT)9!Z;"TG3@HG
M?LU<H$="I]M:F0(6+)U(W[50D7UF#EN?@9+;=3H^Q2W3V,@[9FF2%[SVBA@0
M3NX--RDFW$3.?GO9S6BA^P&@ 8;P%0C) <056DM^/.>LZ47]".WJ-!-_9*K.
MZ]RDQ:,NJY5;IQUV!U&1X[@V\H1QT#U"Q_F6W,/JK2K#PU9$Q);6&TEGON/U
ME9Y2Z5J>"E91J>-7=$'X+\RD$_/3<PY#B2'-;=#6D_!^=_HK3TY[(@?C2K=^
MA*F6%KGFPU62?MKO]T&%/,N8O!6%+%/OX\YQ4 ,)]Q14,U+A%@+OA&EHS&FW
M%Y*ZZ7R=C4/8*5"KFW$+-96*7(:)&6&\@S==YC&>6GF;/7$FK<HZ=T)$<A&7
M.)%)#;4^1EJEXW$K$RA"39&L,?972_VJQ)?)%=$(O'?''>V2M*L[.A_G= YF
MR@IZCAOM!8N+42+\;C%SY)BB_/CJ(P<KR24W*#1W?T$94CWS*'1#]!MI<E;2
ME,^2%^<O+E/^?TS&6SJYZ,D6\!=IN&\JJ.S0I/ -?H'R$GY;C'/4M?_XZB/$
M"A>-7H0&\)JI%-($3_03&I[3Y)*KV3J*8* %^Y#GM(!HADI(.?S$FM3T SD>
M)0#\-.%I\GJ4391S\U?:EI/D9?:A:K,.BVINBID!P/*?D.G[2QE&+!D.[M7V
M.>$A%C2"M'95T_4+I55W"CL!U0'MM6FEX;&KG80O18RDM[PQ"1BMSSD2;0O>
MSL9X#<-"Q[9P)S,OP+!JD&R'O<FF5T7FD^?(S3><BPLD9;^^Z-N=>.#MM+R/
MS$[O7;YZ^_+5_YSM/U)3QH.'RY!_40,_3J6O ^\0: IVHZ^+9@A('SHBP\H&
M>\!AJ#D$)<J0.<G!-LP>[+R BLY4KR=\+I4>)0U<;UH G-Y[=?E: DV/C%S;
M0/78[3>7.NAOA$K_C/8<9GW![(/D:+ _DID"L4=-0*0IXRW:3@09B82?/DR0
M \R\7QOPQ,]R'.!.#4M9'\W3% ;YNJKH&$"&9MG-;B'_GLUF0BLBN).J[E0<
MX"5)QY@:]6:81#SZ7.;0Z[B6HVR&;C0M%/MQ& V*_TTT;A-C6\P&&0@OKT*_
MN9DCG.%G!^=^-?S08XXV/-E"&C_?O+CHG%DBR9'AR1C9Q93]S+S"EY1YUN&$
MG&R#!2V$X0<MK7!>L^3>LY03J2V_;PYX+ X8T\/HTPF!/)\!)M@4O'ZZB%+D
M KNTX/SF"D.]20>$],I+>=Z29L<Y8[CB5#-3.3B"N)P\8CT[#!*G) JL$NO:
MNA*Y-158.^S_@!=UTG>]P'\]N#P(",<5;#0 1NYNSM8R[[63HAX%90=)*FL.
M&$>]"5BYQT1?H_.>,V8S[Q"29LJ@AE7\DAQG7B^_Y0T#]9OD+_3JYE*/:H)I
M$"U6UF4\>-:ARO?')XU(2-%E0MPLW2)K</3X%N^[I1@_:]:M,M ::;%A_9JU
MW$V9:ZJ3_1EEH)4S"LUXAOP,W4ES%3L-\DIDW#<BXV>I''?0P;1@0#PP&D,M
MP;_YG#"^7H?AZ/2'1ZP&^*YJ1WM.FY_#2<F5^/-$)U$IR9%1%\4?.H0:86?F
M(T*^O4Q7%-OB.6=:8O=^F$!:[%E IT[[>%:YPM8M5^/)Q_:UAF'7L*S,<MS
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MNY&*]+%V8?#6&>DA4AYQ$I"<YZ7"C6_W"238M:06WNYMMBP28;SGY.(1FL4
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MOV1>39*0)J-;0-IXF!N%FZM?(!'+M*Q*,U(,U4\UXV#679U4&R]](@R/V>"
M!EH3)('MTS8M,J8Y!8+LI:Y05\6&UDUY0"K";'-:\13F>5=[='5,&CUB6:$$
M04[%=JC%SSR=KFW,^<X\HU$4<_3T-.Y0U!B&?>#C?J=]D=GN \X>3V1TU+F,
M=,!Q1_V(F68L#;N Y0E*PR[08B-^G5N+GSKAZP:PN7V2+Y!=>6^E"< )?.#0
MX_UW5BZ07)"0Q5(X#:CL\^ 208*(;GP.&BZ-9,[QLO<"L\H93C[!:]8-+$''
M^NHC0XPI/D9XT]S]!7T<'RTE/I>:)F<4?^6SY,7YB\N4_Q^/\I;6>S:<+)J\
M1?;D3;4H&C+/XE/\0I?-\-MBG(,$ZH^O/@*72=Z67(0&\)J\'.3G\$0_(4&>
M4FS'*TC)ZOU "WZ%YV2V:&)*9*U_XE9V^H%<]!+4J[3HT^3U*)MHIN]7VE63
MY&7VH4)8][M_*W@I97Y52<+>S7CH!F,!QT5;ES]Q45_!C#O)H*I$'FN M"=-
M^2/8>5TH/^FV7=*<Z$.Q-3GZD5N5D^="(?^&5_&YKG9:9Z]+NKK,AX!3OE/9
MJ_M "8_[LZ>G]Q48^E('()EK]CM0P5ZT7)Z\YH*A<,Q)1,$,3IM/FF14U,)(
MG 4T[T;:Z%TPPUEPIH;IL++E5J7=NXD@%FVO&O?FU9#.RP/G38AG]+LG6INC
M6KHR_E0 '&,CBI?QTZH&!D72W( )+-E#Y8N$F=#"6<LPI</;/IA<>DTY8AJ;
M73Z\0"JF3*D^Q4WWNJGJ#QB<2ZK+7#(8"DYHA1)O'MD#%1B1V$SXF?DL530.
MCDV$]$!*:'7*F_GOF^#B27^7Y_F6\SQW%T]/__!?YP;T>QD@\0*2BV^K;*K[
M_<%1RV=%=[JI$TG)GRTA]>A1E6.Y\-5&]FV?]/N>0 NFRQ[ $)H^,@D2'YP!
M4 ]2TUB<1[>$5>,J )J;HJVU56IJ?<&!JTN*\FB0NFHEKV.84LD-#HH*QI:9
M1X9A9E (-@5]8D2ZZ6;>14']U!! <0*J^"Z*NT+'&%Q;6! SD(<)-6=(Q2JD
MIYPN)=<8E-T'R0NEC;0BGSQ6*C47 =6-))LB=]A1-.QZL1[0BQ6%^YV=$6P#
M9OIC@-*G^WUW9QG/7_?>O'[YKG?Q2Z_?/SK[,?8-/7';KAMQMP,^O<=ZPD+=
M5RS(J#S^="CE""^P!1 %NS/ CD,-C3D,L%-1D1O@&]4_?99BT.-LO;.7/]/>
M.]QMO=W6^^);CQS'7&)=VV;AR<-)O>4T*QT<0\4,5I KNE'@_7W5K?+S2QQ3
MZW?*5F6US[YOCW?[=K=OO]R^O<FDU6N69RBG"""IX.R\5/0G@#'B$/V(/***
MY7[U,^SG5_^S.\-V>^'+[P73Y!CDPH$LP3Z?;K65A0?(:#"^P1$8/Z)C=[)A
M4^Q87G8;XW-E%HH1'Q+8!BY=2.>$/S0L>U8 4:QBP9]O2[@53POL+<Z!;HGI
M7I0S7Z7G7W.%ESP#+YF_Y1,2PI]U:!?:)O8B3A'Q4&U"K7C\""FBS4?\UTVB
M*["/,4FJUR0B**P.)=WZW3[#/;8#_1\O?N$?#G_<USU@C,RZ+$2V7J,BT1-1
M&9'M9$%NO*J&UP3!CCL]45S0TB4SF'*#>Y]% T)NEPKOLW[(=#1&7OW*A,=$
M;,KP*"8^Y09O*DG"8*P@T(1.4H;1:MK#4NR=I(@A?AARY]J56(5^4<_=_8$Q
MY4F\$8( AUWJ)CEMDH..64=K<L-XJ):&S!T5*C_%\KY-@&(.T_WGL^PC#_WL
MK^=X-[!^3II]7%PMN*UY'0?3%^\@8;*"&Q9,<#@G?FK=VG%))R@UIWB0HC7@
MY"CLEC4X]Z N1E?Q;-*:BPD---P/BA;<KQ+HF@5U%-<1'>0"&!.567M_U='@
MB^!I&X>8@CX"4()1#SJ5N7]L=T=+(MR@?\X5Y@-!0^Y.UF6A3^*2$P#[HH%\
M&#$B=#^DA;'OO(A_N"OB?U]%_/]Z2\X7;R?)FUU,LV:682(8."L6%E>!$ $Z
MWAMWJ%_F=(OJ*KFDK9+_:V"^3I[^[?3>F*^OI$Z@-OO,,J:/[HAIP> ;=,3*
M0$0L-4_,]<:ZWXC;X?X9UN?70@ <7X-WG])DLIAE@29:RTQ%IOBZ]C(>(N!:
M&#]/V<@T^T(72<;,744!*H)%TMB?TI& I8%&@*,N@MFO&_^ O*@)(!^XX=9%
MM%L_R >[AYJT?N K%;8-[5-G7Z84EVXN_NV=/!=[! ]6_T@+P_Z^GP!ZWDIG
M[E:SE#JUMFP$N5OE,6)XO'1.*0.,FY[OW)DXVCD3WYDSH=;BK5_9?]&5_1XK
M&ZO9G4_O[F/<?@XVHG@C8M+^1;R.Z>F3>WL=7RYB]&'TAKC1V77YI- 'K84
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M19%S6C1N+Q)B*.8CYM\C4IXN3<>GF3.DD0ZG44!_2D%8]C=6?5C(>7Y+1U+
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MK<:5/+( 07WOP]'8@:>L \I,,GP_ATNTVA$]<AJVYK&V=I,L&HE]Z:TNYNK
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MZ!K'GW(-TV-^>J38;^& &A=ULZY#8,L9<BVQTG M[PL^'V ; DBD26M:78/
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MVFAMMU@NO?<'!S7LQW:QU0$K--V !+2LO4[K^B=KN<[IN#1F($&B29D&T]A
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M"+9SA=WY<UZI[=(6\0_LUW)HH5P7!!MHR>+(YR7YMA=YN>1F*V%V-_3VA&V
M"\,*^$H.VLG@9H\C.OR^,SD/[C(YWU>AAZ F=@*%K\VI/^9N!3\X%R0?8K++
M\@-5\..7,R<R$<6A!,*L*==<38ST<CGC8_3K^^<CI/_"G^[C'*_#'X/>8>BM
M/&)XQT#UO"\N\FSR\Y;,/UB*>:-Q+1,FKZH9<:NK0T30RL^:&3\A NOCR*""
M9L+WUN5<Y"K@OE(T_<N[TU<OJ)%EUQ*ZETIX/^8HB@[_#>H;O;5S!=O0[X)B
MO>B6+5]DK;L:DEM(B;1%\2'6/.QK"O"-QM/&I_E<VG-&S8$R&ZH5<:FQO:_X
MZ<7I@3Y4W]-O[6:'9W0"M>GQX>3W<PIM<\$XF:W1:*JNT2!R;"0OW[U"9K9D
M"^G*]W.4CEY]F7,?\5G1;/+KME^2;^VYWJZP@.PSI]VN'<Z^XI3\AXY'UC\;
M8B@U9]J!0T# AQX03-4[:G!45.I+K?IF'Z28)!BF;3@I>54 ]T9@W@9/XTO;
M3:D^  <9Z6D(X$,FTA(BL3@0CM=R1>O%@LG3/(555^EL:AINVG BT\M(ETG1
M=G]?_Z!?>3"<^Y1T(G1.S ZW9/P\>*_K,\\$;T7/!*$%*^X3F X@IP=L*!"Z
M5OY;,2;]-U&%="3]&F&?4G/X4[5U='P'>OF*'0A/,!80??7M42297XX]PLD0
MKC((=>G*1OF3U M2+$3','(U\P%KC\Y$ICPB7"Y(.Z<^*_ ;+0PJ&U2T,E4)
MBB""1JT C^-: W&9FMTFORXC%^3GR)%- 3AEV/$9[52&TE$ZCO,HR 6U3,5&
M6?8ZZ4'M?#GW %=/459_]1&2$<D-">8PQ!E[\9O\@Z""1^G[!I5M]=3VL90:
MP+K$'+JB [4W6HG!]T:3Q1,O8>5!;&UL_,N\JV;G0._PYK"@=&&(X4$IW%<'
MHL2X^HK A(('R6?_ZLJ6B21UNPY]V)[G*KY_*:HI=OH&;\B*Z1YU[TP+R5Z1
MY])H.*5W!*3K%C\I&_C!]!9>XK'5E#=2B %\CKQ7(5L%)LI+B1)87,L<0W)"
M=97X(ET_/G36>$MV_>'D'7$V$18E;'0R9T6TQK&&/ZB&X_B"-F3O3:(/.+51
M*4-O2EVVCY4D\B*QIP5PVA,0>=-0.(4S,A C$!!9$A]P(8CW-N4:XI DO[.#
M.FR1<":;KK1-#APICEXLF_+U@WR*-$031$-;5U6Q3&,526LV3@US':LO[DR*
M T<+7)UL0D\W(-WZ50J<E$9(O"&$$F# 54%!>:EWR-0O%;WG0VUBBW%S<:WU
MS^/FA>,RO\B5A:J7D57:%2.#388&\TC$J(1W[$()\N##N;!1>]?Q:8F'DA6U
M>VF-M'U7T9.8R0RUX&%G%VAX&XP!$&31T1QH)TY8\*F-LCQSLULK'DQJXQ,@
MQC3HQ3:+!PEZE,YF[R#20RBQ.*O;C9YB4I<#V<E/N.R;:T[-P/3B:VBUY"_(
MST0K?[Q$F=7Z>+ @*=*)P3<*SR4P-OZ%?:?L@405:S!OQ!@0C0)%6BF%$HNE
MKZ\T7CI9L2MZ*2>"-B15NU^4#/LCN/F2+1-@\U"M-0A#+B0'0D^C[G M6S_7
M*KT7#*)E%GH/P@+P;J> \*X%ETUG-EO01#-J! UC+ANL#GVL.Q#1[@A"2JRL
M#:?Y,T?\!H/$^!T:FQ$<)+=ST\K&\M]<:SDG:#$T*1B_8(=]_;U 87E"PGC[
MEO07]BP?8TV<<H;3@UEOZI!_0MN+FY*J-87Z(*QL6>$KNB<L2Z><W9E0*I$4
M*R6V"/J GH1NBG(U[9I6 &<D,QS&.QJD _J'[ST"__ N O\MUU+L3R?^2$P$
M0R#/S=.*_UE@P,WJ$6\7&,#'6V!J5X\3MO7-RGMI"F0VGI\7*VCDGQJ"GP?Y
M\KQNUK68R7H[7YQYR%<:9!#XBV-OE<$&@UU?>SAYT\/?7?EA_+3X&$;CSKEN
M#[_,HJ&XW H*/O-]G/.U(0"2I(M+(=VT):[[0AG]IW]?4,5L 12L$6(]-5ML
M&9S+E'*B\ ^&BW"VK*=P".D6*H79$-TX22:IG/[:JOY5117,#5"Q6L?HS;8&
M#>G:$JJO9 *L\87.I*&Q*;[J+%Q][_@^ZRK!&@O'#<H5H5C9)1A$'<ZHZLI'
M5VT6Z1<]_HE[)_(2I33*)RU'FQDE/*];<MRY2&.1/JX-_BU?6H_'C\+C'\CC
MA3;<;,N$[HT^!%/D',Q>_X5%N10(8M+L>=>;A]].LW?O86\T:>!J[QEIPP07
M!]W:K*,X<%Z<81RN/P[D%G(._?#NX/G;L07R=,"P?HF32%JU,<UZS\$?O#,\
M9VK/ =1<G^.FCB>XI?+HII%6BDKV0M1TZ CA^?W(0N?1.I+4:,F1%]]MSNN&
MYZ?/=C!<FUD<8G0@+6@XG$1E$L=?M%-)>NC4E9J51(=UL.)PJ90"ZI (,:LC
M2@.39,?*IDO??AM.A9(*1>TPJS6H3=*1V@XM<JR/IXJZ/&?M1<>)<LEU$R=N
MX(Q=N4K9M81.AG!$WA+Q&$(E!!GG)C@=,;W%'WN"B$#-%/?':+EN$Q6KT3^E
M8%)-[)',$^@X)85Q?D>Q8#,A'O]BN(SO4W&,:'_,/$-+H4:-M%TQ,EL+&7,<
M[12-<E;<H$=7#,&2/Z@&0DMMM,0^'!SZM3KY#-;:2*DK5VTB3 G]5^0SBEYV
M%<');E_[_1:^>,ETDA_79>0BXXV7D"C?S/PY:W(4JW9M$B++)DV])8#8P2+<
M22Q]4PYM<*5O9&N1@,?DWE4\*_>E7U2YL4P@LY<@!S7.,JQV"YC9A6M_(,;H
M%]$R X5E6+:XYTY;[J@[+UR$-IT!X9=)0T#A8\]$Y_'(KV=W16FQSA7(2:5N
ME14=ASTI$VML_B>/?L"W/ C_+]_HUH>:[\QU!U,9<7P040^6KJ3(OEJ*I<'5
M'7.$=+.[):+[Y 0N$%:BNK]YWNAK/&=ZTI"*% 55"@)!'IXMG0.#6@U')FA2
M-6=_"6]]7;=FSL84LQ#>D&@ENV["W4!H_?0>"!LIF9/&&!0(Y4TS'&F',Y(^
M 50DX$/*<'.XBU(4RDN/J!J:96#?_OWT],WAY+?KKKC$I3<UX]CC]$8 _J=X
M S0[F%E4*DL(&K'G!91!6 ,185I:+NR-B\]X:;^'&G8#J2^*[M$9*F8=5EBG
M>R!)3*";*%?A5.R?3#O-5Q#GX#C+ED70?4@\E-F4?)FE$,*V#5BDBCFJ^=(E
ML.GOQ6C9=78N\>=/S^=.3249?1Y:%2;&AM9:C]TYA#2/$9D@TR]]U%_8_9?:
M0J^ .(D)ET5!QC@%&^GW/K9HBJ0 P0_+ I&W471:J0MI V*A($F,?@GA<">O
M&8K,VS$85:W1A%U+$_>J\UEX_3K;U$9I<0(NBZ>N;ID>>GQ$5=-51>72<-T2
M(>YK"7..)&HET"D)\LM@?JMMF8XDC)XH6+LP)<#'+27X08",((VX;A(Q=%KN
M_1BLJC@@M@X]27@\J7<FO0C?"[%VR="25)+$@U%NN&G>?E^Q_'@0/+K-N>%Y
M&J*6K>CPED(@HE5\V?A;*8MRDR,9]K_%##;6BH%W>=ER]R4)7U+@.*R@=KD8
M"#WY>[B+9 UQV\+*HJ3JHG>!_+%W*R=[Z,UTEN4AZ#H1[NH/0]BECI\>$>&4
M:GB>*%!@,E,J-'-XRM]BU$)]47-XVFA>^+*>?NCB$AX%#8M<B7#6U0]/DU#B
M7>9APY%*#D^QNF8CVM7O]H&=AHZ/P2KF\X859I'>WJ-WGP<;E4BDG"L7+J=*
M\K_%.(K#5L7>IEHQ=\X?;U&#<5N@/Q>?H=T'T:4;*NSP5PM-^&>I"?Q=YWL>
MW>5[ON5\#SU<"><G%Z5F*$O-TQ;S'G*/;!(*OH)#(7CZP<GK5NRB&VNZ0063
MLFRJH:NV(&=N**@Z*YMP*S-)T;D/ H#"5)NFE,B9\'19S,>'?<+#NG9$ZD1)
M9+<E8HBP9DNQ^( S:Q)?DK845P7.EM3@J(UB!.$Y/:8LFQ^(I [[A,35 8LK
M2MAWH)[_6XRU^A$MB$L/8R&QO^K@7SOM P?K\KPV4X19"CV/A@<XGM>7\CGM
MIK6^N.3' 6[_-\B71S(.5K%B<;KNRCVY/<VK#TU'_8P:1D00Z==9E<"5I\%T
M"*(4>"-0G#$V+S%&!59S4_U=VIS',OV]P5YW<93&8:I9P)9E3UF6;=L5KD?S
MVV+1M;SK?BJ71<(S,'RRRN8QB*'O!9-3/Q3>+1:Y8SW0+3>]=C%^%U_2_"[+
MXD(P3.5FP/W;5>Z)U\'!,.]/8>PH[S_;T+HL;#/3DW<E(G8NCY@\W*\;=F+/
M7:IBXRQK2,*XG:JHHA;?NPK65)R%UA[^K/]0J/ & :NA-14)/.>9KY;52@".
M\W&)"5,&%ZN*>GRPB<LI"@W7])R_I<A]%I=EJ[F\VIG2=$^TE\FHB6P62: 6
M([@$I'0C&-=/BMN9=4MOIEU&T:6P=BJ[%M+"VW/8@YXPYF&6^:685P^<+>C&
M715G861LU380G=0;= 5^..XP<!L^:U1"3)O>K5;.H32W@<YJW_Z\(DQ!1F]P
MW:NY$<"J>]#B\(*.NOAX7DY+3DO+P8HPVI9X:35,S^>R3S#-C\NAZ@XG_[?N
M)M0NC],6<WOAN,?5&R ;TLH*Q?N&C(6Y9D"9QI&A6&Y-,2W?(%/%3;BH;PF.
M\M(0MC\5TR;X)UL^-<>/0>+Y))N\FX6=\E&*3QETBI"M;)>K/@D'M#\)0Q3%
M3:;)PGEF%B9-1JB-"+55"L\2SUR)%K7?A"9!I0G)0#_=(XAN,'*J2"QWY4&[
M/X&J)KMC)H:T<>OKA\5<1-?,4&05K16*S,4(I0P<0;?S<KT>S<(^JPT0Y**:
M[BT]:F?5%[%MB@(,4MJDZ!BW/N<H<0A5HQYG0]27%$L@@+BF)*VG"G?IYKQG
M:PG0A)S#>C #V:I()<D[69"A:T=RF+>GRV^V78G#)UA9:^3<B.><ZC$7%)YJ
MC-M38; 2'5\GC:QRDH9L]NO?N=>>_BF+25+:6B.& C5X774KH3_^%YT]:'Z'
MR1 [R^V>:]!*'I^DD3XB;$?\2[<YJ;49N@#S\M&96R&Z' <Q.(%AP!0RU&H!
M-A(I]TVE H<RYVBHEPQZM>:R3'0Y$T=1EBJ8K<&87A+I,KM-X7C.2L;?$<3#
M_$ :*^>P;328,]W[YFHY5<I=&A=E^)=&.NW[<?/AY(4TPSAGVN0K6).)+[G[
MC)TF+YX[ F@-Y7$Z, SVST>'3_F=*VI90>F$&PSP^/HO@EW^$0L>1OKG1X=/
M>J\ER\<7,5GA3%FYY\9W$1,TRI2HH*.3TBV8P0PGIZQSF+(/Z: 6)<&7^,-H
MAMF[HF>U1%OL"/D'5ZI1CE(N6#A<IYM<=GP[)N.-C O)*X!HF:0%XT8Z@S+<
M%+S0=_K%0K]F-/]&0S=WI/1]EK] <#^M;^4HO7BGCY-X?"S42%,9T@3+V$&K
MG+M2^40!^R+JUY0>#I!F_B52I$&&X+11T*JB4@.-S%#CTN8&89F>RS=;YN6J
M[^SE.BF@N^(+96"IAV<.WC9U[SY97,'6=TY>'C'1B7\WXMLQAN)J/TZ:Y^;H
MDJUBV^E&U-(!M,?"_1I;_KL.RC^^"\I_7S1(GQH6N)%PO8L2W'Z48!<-[RU%
M!'ZM>H8?!0%.CHX?96HJ(11(W1Z(4?>R*CC_4\[+G/@/WQ6KJFNX044_6+#S
M4QGSQ7_-0,RW(%RVX&=V,$,/(PF[^9[U+XF73!7.277!&*>TRYBXIG&T":6;
M 3NI*>90'0 2;E;%Z[LC.W1(D@O?P4-/EBUWW*07%$U#.KY,F<9HA$D[*69P
M0#Z)P+/.US*J_-\J7P7T\K?[O9(;BD[(U'U]*_?ZJSL"^"2'F^KSI2ASC-67
M4$R#J3Z<_#1&!,Y '7X6K GN.:1P4'%GF;Z%G;[W<CW0443U4$O.IS\,M4Y'
MR<?']D*;4&<&^?E'Q]7^+8<!X)C4%(6J7$ OBYU,.+U$9BR'#/!!\?NF1EG#
MIA%P#,!%//HAON%VO)Z=$F2M/;19/0#!P;ZL[&=:'<%HD%.87]2:43 RP!T.
MTO&1=#N* -Q(3("DE4"HR$VD"COS=D:AK>IO(1;1%/4B$TM7 5^&T.H1GL=O
M4NC6O5$ZA?N9@I62?$U/ROAY >%"L=$4.[6>@7<A;<>+LF(AUQO0W@#1YK).
MH&<Z;CR49U.GKG1NW1F@_^)DP8[W_BD"C@;5.7ZJ6<2P>9D=@$5UQ.;S7(3_
M50<>&W@X>>E?.G13=^ZU+X0W(^>G56R7NIX",.CYC9(@3;D11/\@2\R'M6ZX
M_!]SM#<]J_>'5>^+"HI^]'U\G8Z;352Y01W2G!MUN3Y,_4ZQYY',N1]1QW95
MQ HI2! %G>&D4)BZ]4J\M;CWR4/9&NI4*P+Q=R*=F'^123+=3XX_-2@SOK;<
MHN)51\84@V:Y TP[L"@8%MD'P?.\6M]=P2M_6W,?-X8 'ME(Z3@B!X=BHS5-
M?:3U;HT>!6R.!_V<;Y,PY$,*TV[.88X.R%[$A1$Z?HR#-(Z$:F!^47Z!?R2L
M;5P7@C5P>\ K;391T-<QW00/(Y!+16XL2A"A!O,,T*B--24J9:<,'T1-3ST8
MQ$-!]KHV_^&<R-6F6?C4N$=N'],P(IQO &X 48=#-T"7P0E-97;OD6<-%<'L
M1Q_TT=%NPM()B1[-C6>CITNR80XU/],L*FH4N8)1:T2SI,M@^.H%Y;.P_7,"
M2_-_*253:W$<+]QH0\.1G7Y+<)U/C;CL%L$N2V21%-AK"*9\[5C*-0,GB/)\
MH[&2_3V#;B]JDI@')T\4/_'909/]WSP,A.R_)[8&XUQJ4I3?)]NS?3_LK.1M
MTJ1AI1I.B3>AF>JV")N7CGJZW:E9Z3U<8!A-&^4[?^7OX<I(R_%=!^:?W 7F
MO[_ O.*ZD\.:3W9OUD$\)@H(W[2.!;X]9H#IV4.8$JZ"0>48-07J,R0\24ZL
M)RP9/_J"Q3%T.Y&EL(=@371^1\N5>1R^YB<3SI,!/^\NZ1+'QK-R"=I.ZJ1-
MBM18#T#KP::$B!;<]O7-AY_D:\-ZKNN6@ZTZ%>;"?=I4.'L3.D*I N)&"?Y%
MY2@#(BL .%@=@8#1!'#>%J5*4$>(>@(;M^0-O9L(("&K<;9CC(B3^TK&I@L6
MX=Z,^QFBG@Y'I]THW>_H&V_'"+R&E8'X$K>"'X7)G&0:V7+)?3+_@TE,>@_T
MMA\+M+#(+>#7-]GVAJBN,=(OA)](@U6HN4N+&%UE3 J3V./G_2V-=*V(T)(1
M0Z@W[4$NQ+Y)/F+X75;!PPSLK<$I-IX2B&)FXO%73&P"HEXI!N)*H2SR\Z 8
MHPK32R</<?Y)D#WYO)V<=>62D0LYM:FBWE3A[Q=E;53A1.ASF1!H^("G20=M
M+L6>Y%Q>S'U*F;.8.&;"3+)$U(6CD,<JB%XB$:GK.6+9CHD&L20UQU#=,[@M
MP0!I!:L-"YUHR?T#^ )M::M\U2_EM;TXW*9Y$CHM8V&2EI( (DE 08)UB9!O
M>0/(OM(87G]O)84^J(+'5@N_CC57('7BY5GE?Y"@0R\Q+FF7)(>-'LF1>5U(
M\2Y?R?:Y38@. @DV[65!E+9KE+9-9N'O-,4 LFU:"ZY)#F^6--;Z]H2;=="<
M=2WE)!H*-LU*BJ<QO3M"$%IIXX,AI/&C4@JSPQ/W_?CRUY@=XW=52 *'@!"<
M^::A$__CD!.\N28_HV'!MQ "^)E::TA^X"GL^Q^#7"S.J/!=ZBB8%[W0DY%8
M_^%CTVWVAMI_4?2;OY %.=]'=0I860JDTL)KE^SQ.8FD/^_*LU6N?W_73;F/
M6+#N=T4G8,<FWV =N7N/BB_YB9A"PJ&97Y0M,4"_?OT\([AMP>7$*<N7;MWP
M^KGD1N0K*+Q.ZGSX?2_Q%[E#=</;Y+%Q-)JZU(2,6NAA,FKD#.IA!&7'/ [G
MC_MEB);%F2-?4%=IU\HX$B:WJ&T7I V0IF&2DCF/JF=\D6Z'!91:-3@"/=0V
MY+/8$*D(DB;?1(#E[DF5=6"[V!FA;-6YG4$$<"JRVF!KL9^EW0\8_DT;R%<M
M9>S9@%Y5'H];!Q?VGD.06LQS&%AZ MB"9=N =A8ZP^LCTTL)?A<FZ!V>Z/?#
M<QU3F*X8RW*-3G0._(69$C3&5#<JBU>K)-F=3'2_ABL8Q43H<X,##TVN2R2W
M8W7"G<T0ZO_DR0^#9]@&1A$VM_KR:YG,_.@T7/E-T=;0\8U_G("@DJ'=0K<=
MK>VO6U?AU?O WH[C:9,U'XA*F]YT!U]'<AIC=+V6C)8#L/6?SIL9#P\>[GI!
MI-(]8C\6A)%[\L]/C@Z/1BH_=MR=<[^%!@Q8RJA4$T5=F*J_.J( PBZ=D^>@
MYE.OWN3X4>^U$L$*WL+DSX_Z?T0JRN3)54?XX9/LZ,&/V8/C1WJ#V](/'IUD
M/SXY\7]A!B%,!^)6?SX^/'X,?!HNNI\N$M[QW$^)DPT38>#2><$,I/,'@7D9
M)H]F1K/-;G<ER\]5, 414%"LB&%!:PH/H84Q)=3[LOL:BI?G^6'VY.&/V=&/
MCZXWK7'<.F<@./B>(_M/[R+[WSH/SOBAH&Z/*+($?H]Z ->7*M:08I<P$PY/
M."6*DZ%C<I5WG,KY]*6QC&:'D<1"4XXGA:SFTB,+H^..?64%^&9!7;B6# E;
MRU,3+U=NRM-GCXX+X1 CTL#XAB**I\P79%*-DD 3V4KB7F#.\Y58LN>^"Q.<
M2 C'MZ>MM.;HR#PEL50$E4!H75$-//LD.X2Q;,=8G;$)\X7JK&F94]E$@G%>
M+CNM:DY4RZ.GGVW?W#:6>J<ECH+KM<":>=,(PY.&<,7F5 HV"1;QYF"H:,]X
MI$9Q*3Q[]RE8TR5_/GG:-QD0_#P[HX+U3>'9?$=48$+42Y1\Q86%6&))]+((
M2U$5('YWYD8^^?/#P<O5R.#*42DFHU E9BKM+LGLC[&=$SWR%V*-IW^HTR_Q
M0%&MVI#294ODC>V.5U[Q95Q_BZ.>4-:EK^9N>&Q7M8E5]>>3G9^_Z]5_#@IE
M9+UF'=,07A3I2/K3D+D([J>]_^319[_?#6#XL+T#>/29$\"&Z44<P_$G#.+)
M9\W"]8AK735,#*_:9H46@OX)#NO9&:7&;R?TNRLR:#TT8QW$(E$@?6=Z7,;S
M&9^&DQK^.2\T3B6]<:E0F'29=.N5\HF(S(N7:1-4AO$'1]8LZF51G85' ,_/
M3V, (3"MQ;P=AB1H20D83UF4H0C+3#[$U5LAOHV)8M?/#" 1-\CF0\"&^Y9E
MT86;G:R@Q_3\G4^Q\9%+O&HXZYOH+B=*JJT.BX4H@N9Q#-/".=5[!X%3)U:5
M\Q7/BZ4W$J\]5"PI7JJ>HN?PV.DL)H9:.L#(#JS=%N:>2R*Q_UZJ5>;2Q([W
MAG%=B:%U'WE2G/C>X3<2;<PW?9$*JGZ0#,D/:RZ!'K7E6JK;,%D(H-G8_(AX
M#+<2Y$1,7T+Y.^V6S[227WHK^:VWDM^RE7QZA96\,Q4P7.7=G:R&UWX94Y 8
M Y7D6 MU>A+WRB"8%E BVNC,:9&X WESGBN[<5'%7 OH!;SG1FG*T?MZ@"[L
M/VYFV7-48F.-S #.$"NF0=#H ,0P8&X,NT#3Q@!,RS>GP^C%L2O+6/,O[#AA
MOU'%EDIU7XF 35#Y&.&N#<G]9:@S-&?ZPD"+I:RMO@NM+G6Q]E9\/3XZF.?;
MM-Z+<=^L\<RZ,!(6^HWNC3$V]:OV1QHZ2\1'3+#L^G@ UDUMJ5,X&NH<QC2'
M\4/S.G(IHS2AO?_QQD)-8]4.SU2VD#M5NW?N'R1S'R0(MPZ[J)<=Q<,1!2+I
M'B8X/]-B3TJI^.3%U0/EW%W=;/A3?\G;>?XO*='9F8M(Q;J0ZA(?T*-'DWN>
MDL,*62?*'LIOG9>@'YYG\G.[7I8;_2&,;RJE@>BINR2"E!A^"6L@#=9==BJ-
MN=K0WM",C,M(,L]BOG^7S$S%1Y Z25[K9E%4FM]WQ7KCL&4G3Y4C*OPM:5#P
MH_[!7@C;;62;DD= %MU54>%H[<%"HDVT+V"^9]MLT@G#1'\_H)!=WL2]M/A^
M  BY?VN(D$\?\9? B'RO ?L?[P+VWW+ _A,00J=Y,[\@X.)I2VFN-YK6O&VL
M4/ K3H/^70JCGDGMU/PD0"H-V[*QT0;U^FOO1UJ6%V:,71[$8; ;T,JP9120
M(7OTFFA%#:H4QDL1HL)3V]L_"IKA1;',M^$/SSH*HKP5E_IU\)Y?U.$?O^3+
M35-\)*-DK\5S[\6SMP>O7_QRWQIV808$A;,3P)Z9.[HA6\LBJ.=-794S4IW!
ME%B4TZ9>;?/E69D+/ZG\N6XW!\]__>]7+R;MMIJ'BX*OZFWH['JFLIJM2=]Y
M+*%OT<8)$$AM4-</*TOF0-C\4E]XSAZQ%))]\KXC%V-G'=58)0K?LJ=?KW5K
M!N$K^J:ZFH"4[D3P%]=K_O70MT2+4*VO;3:\BWV71&%C<[=E+YT4%B@(2ZQ&
MZM6%OQ%0'+K3%X!(EQO&A7-$X(83DS,%C57''Y]H]<$5 )Z>CSLM6:6C2Q72
M$)%A4'[L5FO&QX_*GV?R@'?YLKAJ,]D B'<3F*R+8@LO&2^4P),2Y#9CN"M7
MHJI'F0M*],AK10EW,+_>01P[@=Y2>O/\_5]^>T>2^B]'CQX\?OC(B)6X::G0
M3W #TZ1+,S=Q!>\B(%MEK*$Q@XON[7TD37@QUX\=F-;ZY4F%=Z\J/0;^]JO
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M.V 9N]K:K*3M\Q>DQJZX-Z0"U8?))L214&\++D0**YBS;P,7Z(RS2Y_!=RR
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M"PQE-(AYDU]>K14-3<(.",?<(]E\2\&FL%+YG*0 O4%[&N#&KHU(GW527Y"
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M0;OEK $TR1<ZY+H:$3>K3%HN\@#J1R1QXK*&.>^J?$:DAI#_[&5C60XG[SC
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M#D9>MAO-IU)LKXD&&++A)&QU4SD>A+UJ,^C! WV):LZD@",)3T8MJLVUE*-
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M@*24.1<^\4KZ/#(5R;E4ULJU,3&9:NQA*,QW.4V">^(4TH928&[?=Q7&2SY
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MT(C$BTV]B4$M ;?DG5?B0N1C712Z*1"C(8X=::\I@&$&ZZ X UZSPL!'HQ"
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MT;_L45IH+1":!:B#,2R]5R/("'$Y'Y^&0]A@84)7[5J?.,SJ5R(='_L-9(K
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MO*N/I1<_B+5U+SU7Q@,N;LUJ6"HV,1*#F2_EW*Y3TAN#!1'WL"]I,B)<?N^
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M <^=Q[OF@E.$#X&!3DJ\31^XFR&K3/N2B1HKTREV1_1 FZF'W\+7T7Q1&GO
M,]2WTE:B@=-TU#?SGJ-BXNL:I4P]DB >',_\FO@V9#Q&^/]9=S6)@M648.RK
MCT=<^5XSHP$NA#*"$QN)K_HG^!'+>57/TQD9$I_2=.:K@[50GF,AU#;HYTA"
ME(KJ<8_V9>B.',Q)&T?%$8]G+A=D.<TH6HVA"G+^K.?.W3=LM\@3V*O,JOX1
MW5=3D,PG/9E@;<$*/Z 3[".KB+J"V0R.42#L X;PAFP?^. Z/"D(WI[QEK)C
M\_A^\L"%)&#U#X=SOQ6\ 0SR2U0=GBT0]8:;DFT;I IAQT5-II[9I'8NND:X
MA3DSI.-W+\J\X1BB;F HDP1(-))H0LW,9R,A3/DLJTN!!3DYWN12V\'RK97<
M5D6V]$4:JA1!-;EH<LR@T)TJ)$)7T!Z$$>@8)G6R*2\?UTS"O87EU]C6=B[<
M[^=-4HW0&FLI+J?[YAL<%9^?GY1%J>2*+$X=H0V C4ED$=F(EXTY6C"]B0T#
M&YVK%W0IF^IP'H*^-@[RM^YREN$$@N_A>- *ARME "N8QAYEX*M/0R#X?TPR
MV,C+5(._G#/CDN-SP=W:Z#5^CR8RS1EUW-&3J+[";P(>]KG/Q=+7IRRX5)_I
MV;L$ (G--:D0]XM)0L4WH3'\?4D+G6A?W+$;G9A*#W7<X#O&B.=UH<28?PX'
M(7V.A2X?_R1GNCOPO[[HG+OH4U_5HYN>:SF>+8[GQ"8; 99Q+:CHT1](?1I6
M)U$HWY>F.[J+)5Z?BG/[<)MO[T9'F.0LJR)+:'M)$"OMH-<<"A7('9T>LCK%
M?T5=O'F=<LBLX/I_1(NE+4H&3*P*CC(5 60JS'V',?:O5:3RP.JC@(ET/.KA
MUIH"*N:A:(Z;L5ABY'P)KB*C#TIL;HA$ T-?G"Q:G%Y)J42P#DHMAS L$X4@
M?P2UC.CZI28!/TJF"6)8A<OESK,+KM-J2[V%745G1(C:SX4:S5]8[@Y0%$X'
M+^ R[*4KG Y.G.V$[]N'W>C4'9D5H]8BC-8I:P6\>;V,')JS$T='IQ\0-PIY
MFI):LF7FNQ?EG/?K'<@9!N0%[DF!H#)4+(SV8@O#NJA5;IE#EH@1)7I(QD>4
M<L/CT#-65S_!VO+H5 ^+>9,9BZ@HG!S3OL&JHX,W<N:@Q^7J MT>/(SNDQ%K
M.EK4J0:-Q/X&O"MAM:(H6V7?HPX>&.W&6_%[AMY=>R-PO+\?'9_*;K3[I$OA
M_3$030?[[ N)5KGJ'+V]<X1!7-!%&#"D 5$"73P9V#?'<4CM_.U'-WGX7-X7
MF@H72I\>.AA!U,B<218];ITOV..D<@7#=*BX*XI+7\M*8E^]QK!<G4[,=/N5
MILY[G-T"7F[K8]N+WC$M,M $?G\L;)S4]3*14$C'RD):J6(7K+P+ D^B<XR[
MCZ6B(S3:9"PUQ=$2Z=EH"E?0B1&907;>4.?$G4Y//-FF)VY[>L*X1<'-BG<,
MG@SPF+$Y#^PB@IE> AW/9T.,4V<VNS,IR*62;"6\48>4B7:<(V*5PTHE850C
MAN^R[I4C]G-A#[EF4JQF,P$A*L4K+C)PF>3ZSA7)S'@YK1 1S'C,%EVB[^K7
M.5Q'N#0N0D'R;E"=*HIB?U_'0@-*T4X-CXNB8N-ADW1-418[OFY<<S9A^?@-
MP(V&^19P%U'+NHX.;*Y!&:*+7WM+,/FMK09B?KJB/:<]793/<B3XLOG U*?.
M2VU1,]^OLOH36536)]F(KBQ<;,UWD09WE,%PQW =+D5!?CX^_=!;68:=YC,4
MBY/?/L#]R4H:%C.74LA'K@-:.+7.\W) ;=!,MDP!,AB/#D?=^844LJ%=C#;"
M.87Y!!]2.FS"Q8W#Z*[<T+H5DL;Z06H7AXHGQ)M&Y]=YVNIT\;"I#3A>XF%I
MRW&?IT6UQ_8062 ;!HX-K,YA0E"09H8P$ (88.ZJ0GI!STON1 Z;+$S7@5V'
M,'PE31BE+ILK#'3?<#8^EU$//Z62L," '_@[%X(= Y8/Y@6D/!"QK_&4ZJ]W
M;7^9YAXD]T95AQDV#A$9+84U&#!;M5_,8,OL43E,.ED]*K)$76]GZKTDVGO3
MT>*6,!B2,EQ:E.<!@SA[ZI_VHRBNUN(HN8FD&:D=S4Z<3A8U(J44T:E6E)\U
MB,=6,&&06S5U!CJ<=8)E-DJE?<V#_5#:EMR:W->V=SL:T()OH49Y*),V4OW1
M),M'5>HUB[2^O7;([Z>:2V/EKR7"#NZ7!9BUB2LZP#\API$]@.:R]-7VVBA,
MF8&Q+ %5Q[L0X4R75-C^4*1;6*TF_^HK]-E\N$@5V<(5[$_27%@^P@=3;#R;
MXA*3B4U[KM!7@1O,%W[F6AKM!1$')?PF(J^( QP< .,1*8#@TA@IZ($BFXW
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M@_- .1*II6XKF,-<6-41/&>(YW,H]0(+G0-=L0<O/.0CMG][N[=E4?#>U1H
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MV[7\000]1(]R*)VNWYB2U)XD.L*[NY0X/2SS#7!XM4_&HWL_O:&,^RD#[&(
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MY5(*0K4JI4F-GCYA=(!UNXS;N;L>-^*7<CP&S;[S)M&0Z8=RB"@-/T=4O"]
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MP^Q>:)4N\Z;(V:!-VH>K6#9I?]DF'1O5X1RLX[9L4. !=KQW5\]PL DN6."
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MSO,,5Q,'*5]?:,X4<PYH7I]@Y2-,MOD<';[L[*MKXL>*J+-=;YV^!<,]&4[
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MW36##C0Y;,0E)^(2)1<:^HF;1FCD%4*)EWMNFB:%P17A7''TAFMGH@]-GMZ
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MRN$OXB](K2-&%Z;^9\T\&E?EM LB$+?&R-EW&@Y/3+N!Z"M?,@8)T,H"64Q
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MJ0859WZ &#.6L&H@) B,OU>N0H04$K@EN)>3A 9!Y*X">3H2K@Q&ZLL=A'-
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M4C , &W"!,S!GN3F<WA5UEH-!'*ZB=HIADO;3:GX46 F",;("G;CTY&Y4CW
M->;C'"Z8>495NI^]C110UG@^ X:J'.24@X PN^X(P7!-!6 W/A8# L-!E4\S
M6XX[?9";>@0WM<35MK<0EOV#GOG;;)S5 #\."J4>]+(&G!7NQMFU71E7FJ7?
M7MI9283IC&);]&Q%O4B0]\Q>DK1W\&.<X=$H$083,LS:TSEX(7I;+_9W#[&\
MAMB&@!,([X1W$5'EX<V=\J;@2(0E5)UU&%P)I2T6MVNC;]W*TJW9B*#IWOD>
MR2[[F#$8P.@:&G[S9_H8)/L,1 \* XX4GA+UJKF6O^:-D3*KC\O_-5-]^:ZT
M)P7CC@]\ZK]X04F*^%FN0;.KLS0O/<2A.9CFUR5)0;<(7.C#_+,768& .Z%X
M6_<$$3"N:]_]4KH87CCA-W8,K!7MA4.OX>@"77:@6%H1Y)'#>C]\G/F=>>+H
MW_-&3GK 5.P*93A*^T=6GYM;=VH9+L1&BX./6V?\J49R(>UQ\U#N_JN;A'+W
M[@N.]_S@1_;@[RT.__"!>)8Y)+:OVTZROXW\V:JCY,W#]QO;Q14+],&HJAM.
M[E%E7&BC*>7R=ZS@?FO,M#\CV/6_*!)"2_%&56C3;QYP61[)@GR0NB]:@,9V
M6:"?,1]=+.R2S4NI"1O1+R10M/6_MND7_'>P.?Z,!^S.U]-^XL^ZHEIXR6+1
M3UB5R/_,:EYPJ%[<>K']O%+3G# R]//HEI+M.<W^9\NA'OUT]!,633])O.5Z
M_=GO/F7X4__DIS5*S1]A?_C][Z\__'%RU#])7NV>/,TS? ^882"M?Z*K<9=0
M<J"5>)JK<$]B?N_.Q/PF\53?PW[T]W[:Z\../-%"APTI7K5LSYIW\Z?XI+^?
M[!T\44US3ZOQ1"WI9[U[KW)^_QFC^G H^*3WZ6+G[<[WXJ*_,N?GV4=_]M&?
MLJ70-_[Y07*\=_0TS_ ]Z(6CY-7)WM-<C6=;X3[E_/?AI#\.B^#[K5KI[_[4
M/WBV"FYPQ_:?J%5P\/U9!?M[)\G^W;E&3_Q*'Q\FQT=/-)CR;!+<JY2_8YO@
MK['RQ"(OLY=,:G*RL[L*@@P8Y0#C,/T6 !P8(-S_,0Y6YA??#1C9(I U&4L(
M?P[@T>L91Z&Y(VP2X6J#F);] SL&X9-ZW_3?[M)VNB&E#HWQDRH17(EI;S/G
MKMOQIDT6O.O(@KMJ#*Z Y=N"\-.&RQB:GWM;^38]AHH!VM3TOV?GZ7 1XZ.G
MNJHK;$;D7KRBK\ [.VU84/SVL"IA\\S K$V)E^L_GCC!TM[N,\'271 L?2]B
M+J;6UI5D?_T+=B&#&X3+0SSCV/%#M92@1C)0\Q,IU\'JZF8^@)L*==G%PE6M
M1OG 4Y8;4.N*M[95$H3<]?SN=6^\;I-&"#S;%XT+5U&L;'UCN83O^*CFES7T
M9) ]%Y4Y%JU>#'AVU<RW,!@/577552G#*C/XK#P#O[GM.FG@)R+/72(-%0F5
M&G/2FP")_+3(B58]TM/!/'9WY^AX_^#5R<_<='QKP;/'G@%^6PG;W@-+$5WG
M"OI=.'><$767Z'R.="'@57;[O>:>)CVDU>J<H%U_JLULKSZ(CFUJL4&+WO@E
M9;JC. U9/N9IGDBW\F5%<D$5-S5I.#<S ?5)"R#3]>8#!6<1'?5]"*DU;+&]
MQV^+O5/&#)@8PM,PMRT.E]42_KFW=_]I;:_T$T*MT/_IH-7F*-[-3CK8V8:$
M90G=PQIN3[ZZ,V&TI5+\7?&61])V"'O$0(VL&D%'#R3LVF.92EA6HVB_S*C1
MTG?<1,=57M^N5]'S':<0Z"._XU^@K\O2"V2O_+KW<-F-XTN.WG=G0[3GR_A@
MEW&#E!4G1L%@].0E-9/R:6UO0HQTJ^&M;,QEEO98/))/YOQ/TF$VQ\O;P-AW
MXO2\&^K/!3;^ /E^S+&5MHBZXR'-P!S[W+P7O53D N+K#Y0XR 9L_(81LF#H
M+E@W7 GMDOJCP ?"9ZR/:@[N;_,R8[EPA'+AF%R7CJ]2Z^L)T;3 ',#Q2;GS
MXF_S8D'/.L1'G3Q\]\LE0T<Y$1MZXIJIH2/N?W]8S8L1][Z.][INDM6,+V55
MOH2WS<T!D4Y#X4/H1PIRRD_S,I\%OX)#D@US$I<8/Z%@!]'[Z(?03E9EL:!6
ML2!;-2E*VY%8MNM2G:KCJ2Z6,"0_'5__\-M^NCQ..ZSJ:05T>&;/J_H\+?/_
MH>6S05]RD4G"8]LW5I'P[4GZ+9_,)]$0BIYV^][CX^D #3)IO+K>:N\="-EM
M L^E9MG]DV3W%;+@FHE,4E1)Z66:%ZCI((+"K&%$*_[P^]!!ZMZY_I'57K8H
MML_F:*=WBLP[1FD7T/\7PQT8]Z%>TV6E6ZWKQ,':AUY:D+:S".MN?QC/407?
MW6?UC>;_PHP"L L5A9B,$//,C1R!YLA 6!=MP2L=V"_3 LRHZP7_>.*EV585
M=0BLT.M$6M>:ZT[O0^5+Q/:"XG/UJHX]8BC_<&U*"G7%YV+R\_C@(#$'3FU+
M*]+=FK-F[Y1G1E@\USC?CZXK*X_T'^;#,%/N_M!A;F_0YO/O#C$^BF&G5GS-
M>6B++?X1;;#]D;*-M7="?AQI^8YGH[DF5N5@X8_<TK)Y1J@0,#[51&7_.5'Y
MX)U@KG6#_OH7Y70<R"'^)V3T\!)AHFE_5^R?]1)6! J8SRZ,K_4_K!O!X$)J
MOM61\LY;;73;&G?&7C&@Z@07 Z,7MJM,]&J:__JJ8H]4Q2Y\SW@:$.K(XKD[
M-4_7.0:N=_\P6#7L5WQ-I=0_2OJO#I/^\<FU]-)ZZ8B'=@8[%O_"LR:!NQ/M
M$8*L" FJL:9K=*J$W-)\:9!EY=H9&!7ZWC':@!F*EWP>VP9)QQ_8E'-SJNK2
MMR1I,#(&=P VL\#.! .J:&,F3B8J[3 QRUL#;[H'('HL!V1EEWAWS\[P)K#)
M8:35BIU/4!*<G]=&=E"C[QL)M-RX_X1N &;6^I(%FW!#LWQ+V#UD.0$Z7^0'
M]@$_<%(A=T('90U)/B5/1,*8QRN+G]!6*-1:<6%AL*>66,!NWT2;:WF^D@2)
MR6P?9OETQA3XD!+@$/1 5D8S<*>]"<+/$OPP  N9 -:W_N'G83K%G72_,8]A
M5Q1_06.A?'\Y2NR_8))&H$^S>K;0;/S#M+E(>@4T30:&XQH(OI"_&/Z@GD//
M;:9%/H.W0E@^\W]9Y,8[&Q&^Q7UOJ*%Q(NV1 ]TV"9#?K3&[<$&&-K3M_/%F
M5L^'<)@2B,TWN;DGP,),42((D-&?T<,R J=)A^1:G5KG&MQO/C0<X- ."@NK
M-02E.3QPZ.I,]-"(.B;P[\VQ'V<Y1NO0P81T12,O-D=]:(9<4^K4/T1C[KM@
MP13 0R^JCL CE-V@F!@YIT!1W8P7O5GZ#8_J!5ORU<!84BFI3,+OC(2@&[Z=
MD  ?9&8CLR61F4>H*U>)PB^+*8DL8KNV@G")CK515=D"G#M#0K?Z# KJB*DB
ME3V&:LWZ$I7XHD>"+?IQMZ)OJI$YS5M[_'QS3VW@-?@.4^DC4;IZ!6:Z8F\Q
M3]T7(%=7*-9\YH _@]<GQZBB']K=.NSZA KW$G3JB#\9"^X^MB/RKH"^%;F1
M;XL=<<[?=VP7!44Q-#UP,3FSU7%CV_+3P_U4/U 3EW0,72/3F=#7ZV72XKOK
M[$"S!G\4B@_?I74XSM7,B]EFHJLKPR?J"M)PZ3>G^IA^QF/JW=^8XV,[3HQB
M<#NXT?X:JG6/70H_PQ)YHFLA0D<#[J39DP(0X[AYX#V+_3A.\QI6]VLVZUVF
MQ3Q;84LQ/F;$IAANM)?^%KY[ FTZ\<[P4TPI&^4VF4HG'QN&955M0Y9U]RJ0
MYO6CXZG2Q4K!4A,%L^EF44B?-3.;#P_Z2KPZ-6]-H%&(RWHGP8?V#K;2;==4
M=92!!8MK:Q6?39#+7O'5N3)[E-@: +%.<"D)OC#(?G;2''<VK8N<_-7^B>38
MS<)01R3<>N&GE"%5;F$[5@\GJ$=@O V&$HRR=';QVDG\< Q[#S$&X&A%T8<@
M!ZLG9A=F5?G]2[Y.L 9/6,$5PYDEZN'P; 14[/3>CUN; N8A]XAUC\:/TP9Z
MG6>7S).L&.L>>_%[!EY#HB7ZYL0V.+!-0<J9F$5PM"Z,BL#D15U-1 A( '_U
MT!Z?T/WL=#@)&VI!%?SRGZ#8 ],)LRQM(X$STQUV@;JGN>L5!-E=5D\@QQJW
M0['TS*Q3YF?0G@.#648JFPVW8L** B?)!6KCCRKI?#JV!@%!FX^-D**.4'@E
M0-2KWX^D 1HT.#:;#RX!]25Q>1ZW/!SE>@^.*)R5:6X^Z()T?!WL63:7T!\;
M:1NI/C#7M9J?@UAF?P-,=KMX<#!3Y:&(5,#F.K9WE$)NA1E"Z8["7B\-5I5,
MB8)25VM'GR5W&!I<M07H/X*3B2QVCE*D ]W8?W-@7N&AFH?[W9AWF&<:O:,W
M?.=IYPCVGG,$3ZM;_$KW%&RGL;$@24]:&7OF)Y2766<097!6*%ROF7UHD4D]
MC[F]J,RJ6BYRD5[A!89>B=+@9P1=ZB6)#Z(A*D%71P%:=Y^=&HLI\8;( ]**
M%STL7V?'- *&^\*+'O=?M:A?JDMLQSKH(P5(-RB.,0LSK+/-I.=71GM'9KRP
M<42=OD:$ R+>_*6LI@1K)2T S>H4$.,\OW"_0T]SE!44%$9AZKUS>7R<8+.@
M4/+9+,LX=.L>8,X99"@0RCNMKK*:C&/>!S,>HXC.K8EIE&FC#/>KB\I::>((
MTV%3EO7514;=ZRZJ*T(?2W<M[XNOG?U[A>[>8DI!MHX/'RC#7;4I!;B:>\<6
MQ[BSS#J'$#5%0.2V#A#3(+G7I+,\815FXMZK6*"[EV($8#"WJKN4N+NU.+#7
M+IS356?G?5U'U4MYA!?KB7NX"M*LOOKX;E$+0/W3&^OA?G$>[G4BB!RIZ\P\
MD%^-8&WM0Z\/W$X@<:5$' >$O 2( Y-IE+P9AE36J(H]\=92&UL*K>:H0*6P
M"I8_JC^3^H@\Q_5TO*KA:"N0N_GH[ HRE7-4>B" ;) LYJ E/:.KK($W:*0]
M,0[&7DF$U>&OO#4@?0B)'V.'EW:IEB8Z5^YL-"IRG1UU0O>"U933/1C32;]"
MZTUW7_E<MG)75N6B X(VL@01 HH#-50O8X7]IZ65].I8DH2)H]\S1MJ$5RET
M1%#3RL#U<^QFL?\D)U9]AD"&*KT,37/3KX@WDQ;AL:<_/OES*O +*V!<5UYG
MWLF9X,RGN:NPT_!5A[;V 8]T&=N^$T3GT!NG,^#0'SGY:./TLJI%;+>NG6MO
M'(D,>@D^E8/=0'??FT/WC*_UF$HV/I:]C\-9Y0A'CAWA2.U#^=I' %$^T+Z:
M[#P- 2)I%YVI.8$AS<DK_=+N$I".QWWI^A-D'@&7Z^A8JLXW4[QA$8!SC0DT
M$C%!T8B2P04*'R,][#=@?=P4<=*QDO=[C5;?FD]SH^::;.DH-XASG:XSO!S1
M8]CL+./H)>92T,RA^%OCROJ6Y]02!*)QSVJ;KFN<8416?2-&_,P69Y@C;WQ7
M^B1>JKG1>@V]0#T3T"-0]@9N/!YK[ZF2"#3O+ E9;XR0&<3;4#](GW8,70O"
M!O6B34*U8'(240SSWRU@Q",]H=S<>G-G,'[HK/WH80LP(=R1Y-UBA/7[LX^-
MQ5-S*2C*#7,N>&^"W-F>3IPE0D?CLM!8?&5^8Q2[Q'_ I,N-5,5:7 O):=AH
M"-NMM^:P!+,@T_B@IK&D,BSIB.+$_N#5FIDK@:V_P1%0@ 3R-^ OC3K%X9(L
MN>'X,WHN8]\M:2].1\+]J<:<]Y]CSH\;EWYM-.B&I.)[ 86N+D^,J*-T)FJN
M58\8%[546Y?/&-;6*.L2/7]P<L"-,8_:RK=[_8/DR-B7Q_V])>,P\J68&V&6
M"V%?6NH0RTH2K.745LIL7P*<7A5]3W"QDJ#&S$W>)NNZ5B[I;:4R/6!YJF:R
MY&"FSQG<[X(\1BB"N:'BP/0WA"H0],D%*UU&TV)IV_G'(:#''9,5/>XB15(H
M!++3>,Q !S<<**+/0>M"KG4V*R@P0SC9K:%ZJ$M+0D<1W)K: WN:,<X;^T('
M]"G K#0?GV39# -#'(89$AC"YF;KC!&@HDU5E,-1B@'Z;J2&A>!.R,KB:"R*
M5$- %58)%&V=?XUB2.O>5G:M!Z=+T*610-KZUUM"WAYD/%(+$[_N^&V0ML:1
M@MBZ<0MM,0K4^*?EW)@U[#S;&#W2#F$]*E@.>36B-':)?S"+/LB,""R9D,1_
M!CJD^Q0^I8N*D3Y$87,(;3ORE7VB/,."FVIN["9/)D 2FU9KJ[_=.[#(L5DU
MZY OK;74HJ-5J[/?ER?&_6>8-H)0>\?)?K^?[!\>=<@RYLC;UPR!:XU/(?1T
MWJG'Q]_(ZFE6-F0,VJ21/(D^:HMQV[N:LA<$$\$ 1FS3$AU# [VXUL"-=6&$
MACEU-HCKUFU8X/6W1*ZM6H:]W63O^"@Y.CHR@J0AW@F&P&3G%<8K;08)2HIG
M<,%4%?8",U^N)J&<U6"EY^%3(*:786T%3M%6<MQ6VUKXF62@QCWP2%9>2R-@
M6YI5ZC[X LB]=^OE\P ][+7+U[MV-[ERK6MFS(AU[UEN38[GF^;=-#C?R*=
MY_&6%^_4V2+J3GELE]TE1N;590;1&R2'JHR(G1:4U@+3@Y)^&':!"7.4W%6R
M<):H&=;Y $T88[UM/WRD\JQEBXJSK'5TVQB-7W_\$AF">.PL-E.,OT&&3)^.
M7Z(D(( UT8WU,1]VU9-ZE2KKF@H4B":S3W)2@1%KT<5L%-[O<,[B4L6:8O0
M.Z8;&'F=A4++C+GU)NT=BYNNP+_"W.42+#-"@SI "K;L2GQ$1!!Y.ZVRV!T
MXB'JAUE%QQ[G+E[4G6WY>SIR2V1@K"C-8M[7<4Q\ Y[<%"LUE;^2WH.W\EJY
MR+<ZKH1*SV,/6WIT8XE)6^RF/,UVG=[R9<0#@I61O", @X"L0;1V;OWSL.EP
M.0IK'TBVJ42G Z*A6S:: _N<,R#BA@I7,#I4V]*TY@U?82QB,B*1P@DWUE)%
MK<[:)0I!5R'G+6 5JMJ^I1J/S>FO(PE^>VV->9"?H_YTT>8M57PAC]BFM(]+
M^^/00+SFXSQS6 '.,M&]Q$H=AS<S$D-AMXKT*O$G2H :AMJQC6J'R89G9P3
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M^!!ISX@/,2^-I570*"Y7/ACM&TO[KY<;0+2N(5;Z#8<-3UW]4".^)DJ<</>
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M*='$OA;L=DH!-=JND%SF2FM.7S'Q,<-$7*C%;Y@A""!!Y,_;U9UKM3KQ$JC
MW7%>.O0"-\FNZJZA(FZ+/GG3V;JR;%ITM^;^DO=LCV_QHA"HX3K!1<PTW=_
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MG'] (4:006P?1^F0XEY;HUN&:)-J.WK ]:TVM_E)1_;[SY']QXY2IY9/$AT
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M)U,HJ9@1(?DOAS0.@Y*#".>=XI]PY+E\^!AG%NKM]LLQ9_'?<RHBX;=OHBE
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M(7]:(B7J2>(@SR@URPL 'YE0',)%^/J[.WO'5%L^@-C+:#X4O\NF)R)KC^W
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M3K$HSH%7&4-[F9LK@)Z]0VBS;U]8CT&GVM&8[#R-B8(U,YK<8L#<2:2X 0S
MFGUL4=EU9=(TI6+LGV@LK9U']51C0@B$2#J%-P\S\THG)[U;"@]]Z%,RX"[<
MQ%$7M1:Z3LTCU(QGJL^TM41I%F<5YO:KS>5@ B>ZOQ<$F-M>VQK3>7B]]$GY
MR"@NS7VQLC,ZXH0,;HQBVV!&RW<L&;-%>3Z01OA V;:_&\-@JL"A4)1P53:D
M(AQ?4U;#.3T%XD3&D)T1\M/<6[AVC,^$A&/BDJGV+>1<HBEA0VN)D6(S0E2
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MY! 5MY>U^[GA2-O/]3^19PHPA*5RYM,0 L K*?=,E668.P<!%+!"S8#>7'M
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M:AVDU0HF0EI#8,_('*?Z_['W[EUMH]GZX%?1RG3-#V84&LB]JCMK.4 J]"'
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MH!;IT,X/F=G:Z23#KH3DCS*?VM^VMJ5JU3EHI7R/B] =]XQ2B'%Q1;%BMQ]
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M_=1&4#&%R\*PKY8KA]':K;<O@E%T4YKB3_FFJB5.0XX;.6^U*5F)H<P09)6
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M38MO_''; (.D-!A8)QR.$]-4NB:UR+>>Q-PBO>UMP76$870*^3/F+W+)6*4
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M0#0667QC(O#C.":(+$'+A!+4:7$N[6B9]\X>UEI0FF+8N&Q=?0\YJ%J/K7=
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MMP;U@V\@B+H:('C$SKXQG2<Z?ML*!.96%1:T26QBXT)@ZYYC %-&:XGX^[0
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M2L=,BYS.I 86A8KU9TR)(D6QN !&;;5V6Y+PA)90Q^EO$@8R*EN[PY8C4B>
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MCY\R0)T#QM?HIS.IVY0$Y>5 \'SK(-B8A.!/68Q-6%#PRS\<V_W^<V .V<B
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M;^N(SS?1<3#(. [>0!74V)046;HQOAK>;WOPI^^-M#O6]R/#?^.7)[FTAS;
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M0X&&[[\!$VJ-L#:@%8:^W8]"C*##61N5BQ#C"*GFI8H15P\5]CI&K-P=E55
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M.%\Q J@.5%O5B&=/MJDP0F&$ZD"U)\GXO -5%5/RJ]H!94N[ZLQ0T\C=*3"
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MKPX*C?++DS,;L&K2@!+[\?G*C2CT<H%)^FA+@I#OI[_EFXY%9RPOZ:-!@LU
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M,4.9/.KXMW@\][#+4HQ>(W@GMP7X)V;D^[ _DC[)=&8NGCYPN,+:@*<ZQCB
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MC)/D*C@G^(@AA=OP^Z$1P_%S_)CK]#$Q4',V[G*P;1&:7@^ZR8<*:.1ZH>8
MD!$E0@^.#UT!MADAT$&X1T'HO]%!P/G"/WCVXMP#/'C@E4$T&AGB[(O@F\4C
MQ%Q78X;OO*%_X8E1@15#I,%'@!QZ@4.-D1.^0\31@L@<ZH1TTG."J/\7K(J6
M[3BQ^\*W@^\!(IL'0@1W15@RWPL!6=:-!2T"XPTS23AE]8KLCH>&1:<%2P6I
M:")](_F.&1?2L/(60$$4J+VE5$J=1OBLW6)"UPZ!:[ Q/N0HB686KTA,X@T0
MYM+:B-M?? I$S 5I$X&,5]@NT"!ZF**^ UI!DL-W*"BR+;Y_X-_' =:8*'6,
MLYA#/&X+I+1O]W&F#G.\%YTC!R!!P/Z.<)JD6%/)$W6P<Y C#-XXJH9P&BQ,
M, W!-0_^OM@ 9#R&)^8BY)E\"O!@GSTST!T"+8)WP7$,@#AI6?@BH%7B:X.2
M5\&>0KH8T160,2QX=_+>I9= @O)VG&PDJ8.$=5.3;'(-PO'BZM%O"$I;&']-
MR$7(%H]VM@#FS\Q*ORDYE>P&ATCJI&S!K7D,1#Y@AX!C-L;XM#> $;!X*R'8
M76;8/GNR@1-STDK<L@F-Y\FP!-@DQ$&M!]X.\!4R^YFA"O OPTT9PSDG]A.M
MD_NB'K,!F2\E(H!9TTX:\69*:B.8#7#6WH!4@J*)2*="O8??ZT*];S]TN$X?
M!6AD=($5V)8-J^T:#A.#-%'!?V=P.5[*NZ8G-?7+DG'7')3XAB"CX]$G@N]Q
MWD:2"Y8P%E(.+_9\"Y@%R&2^NDRB-'[/GPOVE<6EAWBX.(PNW33!7/DS D[C
M$3 9T!)]TP;=KO]&'R;5@\#,D/[A%=XS(#'(72_DHWQ)?L2K,$9@3H8K./(.
MO+45O[1#[ZPL"LR# <3Q?YB>3"%MY0$L:_; ?#K'HKZ>*:3>G5#Q#43 -_&"
M=-^-^?==.RG8,^HAA)QZ+,&$]@42,)$:@"\EL""$B4>:=P:"QW"LCCG,?!BT
M[C%JS4O$@4(\*-)M@( P>49K[HDYTK5'D1,:+O.BP'GC+(_4)<<+A-28JM1-
MDT2!P2,Y4U *:<L;O!B^;TPV@2KQ*E58[)SKEZ=EN";VF)$YP$^>49=\<$!S
M)#[^I[@L<34 ?P*C$/G.%/)\!ZN2 "I6D2Q"K&&50%X"GZN=7)P5L[E2J%(U
M$P*3OAXG7X-L3[Q \'?D,^T.1"Z7$W^TM0>X^DMHD5$U]<)#>"48<>)Z/7/6
MW3'Z7?U4^+^;#_^*5\<7+TH]FSGL=Q?=-XO)J= NC7GWZ9[P[AX<7"#0@R=$
M<[V/NY*F89!T)]W([ZMDXX5+O7YZI9]>3$ZZUTG@V+Q-T&S>V %:].6V K>O
M8^8&U6PWT=!/RY06P'(:<9SO* *Z[+0C+VFL4,WAM^7=-G#[5EE3E8"<4E/!
M0%@0>\$(]ZO5Z?6L&-<1OSU<>JX*=]V<[LX#X^\%7S^_DCCAWZ@G_E7#E4S5
M^74;C&#:EG"\/C*3H:^KXTI<K1(.C \8+5=Z\[*$  Y78JZN'A1+L&L+)J<E
M=NU1ZNMT69C1I61;)/71"%=)&=+&#G3YQG)UG5Q[I%#RDGDM!$"&E/J)V"WK
M@3WZIL6_2;5!?!_O>L<?\?6D>Z(]H9?'I3<%S(Q\BJ=QQY18_H@9--X'8WL
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M911PFERZ9WV,%^/ZA!<FIDS"E\23S3$H+&,*0P\7"H\"K,MP \&XDXH!DO7
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MZ%(T?( !=^;'L](Q/!6@HA)G/5!_ CLL+V#.ZFVFX>+SXV ^>36S_19=@/*
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M>4C6>:.3,UX,/I^"?QM$"3'@;!YJLV"$HF<][R& Z"0W\H\'H.E\,883T&0
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M[EC?3Y,9!+6?;P>#.EEU_N:N=+E\\+V1'038OAI3WXM29>?R^U8LPS-R*:H
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M]."^+P%-EBU.*%)#4G8\O_Z=4U4DBQ(I498H+BJ@V[&UL*I.G7UE?8EB66Q
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MX,/K2OC(!WV*Q#H O6>-@82,=<8$6FS=C>W:S[;DGJ48BOM-9LJ:?28F( K
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M7H.8'ZAN3LI2A93C(.LPEFZ_-:",E0;L?3&AVA4[$3(1R-,XCI,Q5Q":YL>
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MGZQ7=9UG\LJO%Z!]*KI6FW:N*2Q;#;$$ZVU#A1>?HW.GF5AMF%==5WWE:6R
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M'4,_9?H4"JP)#QLV)HP(B!E:ZP.18H:*>"*Q/3,U'D-K 0<O )30YQ*.M(G
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M$*SRA4YVOM 4](**,09)\ONG8\1"VY+D]R;Y0+4/ 'LTDM]!%6A<'-[REZI
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M"!F^&C &P5%W-PICR<KDLW)[-_IS//D^_?I_RG@Z_3ZZSAITSJ/9:'ISS$H
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M:+KNS!>:C8W\ (=\K-MRX65;,>'$3ZYF@?'M^M@GU9\1CX JH"T-$_/+0+&
M>_38;]3I0-/.'DU;LW43ONAAZ2+M]GVAQ'$J^:[[66WC!(@)3S@$TN>'!MG.
MM+?2<AP,^GS>ZBI)EG<*OZ-NC-7#XVN"@^>!@ Z)#A[K17OU!-*,_S,+]2HN
M@YJ-QN\?E8"JV[ASP2/4[+95)?AQ]O'='^D<IWW1ZN.W8QN_Z%TF[)V__%'4
M$Q6J*,*V-67FHL[\/Z"4APT1[:5E)7'!>V2C2&78%1])YB]_:!FQ<46^<'#T
M+[HFX*+X>70EA4=PV6:UI>^L^)KH2TG^KTU$<'@'V"99$?]GAWM,72SQ!AE*
M;X-^'L!/(:"$[3?"SIKTV,WH;WXUJ^QIS:81=LG.].YO?XZO_CFZFRI_#F_N
MAW\?*5>3N]L+9:RL0^3XFU-, ^[9M#NM?K?=^=%_][?O-\/OU^/[T37L\^9Z
M=#-EOTTG7\?70WQY>@__?!O=W$^5R6=E<CNZ&Z)/<9IP'F&S**]7CK=VNKCT
M0"V)TK%.+&NA&5C]2*UB_)LS568OB\"CR,UQ@>E][!4^3Y@RL5#39EQN#]+C
MFB4\U=(6'KP<_!:^%>/^25289M5&[QHK]-!M_T[I"13'I+?A727=/11^:^NO
MI_Y8JI._+<[2WY+1ELD:Y"@?<=:+[MZ:35P[6X7=\7>2LI^P]W'OW;:]<3)C
M?XI1J\BRBW\D('V!?/D[=*4/+.+W<9U7'E"IS->+]MGAU=]@8[!?[D%WXK]^
M@Z_///;["!B1\9<']X^_K5>4K^NA9<"7$N]$XNR>.(LFL7(#?RJUP5$I0HH7
M(2U)CKN3(\:!2T]=9=N)1+D]4:XI44ZBG.1R$N5JC7+EYW)[J*T'RC#=VL<B
M?N(J)90>:13H@KB:3_O%V0;/(\)\)]WQ?.]-J)>0M[)'3M%O^SU@]VXT(4"N
M$ )#VQC]6F"\=756<N/R1X/F<[7NG>)R(GO=2_6RDS)P[S#-(7:Y\_K?=E.X
M[:-G\K7Z;;4M;SO_VVZ6@;9;:J?94EN#2WG?Q[KO0JF[UVJHO4XKS]M.4=C$
M]-A\LV/?C'L[?ZVR!5VG=<;<>5$MH'0*9Y28(#%!8H+$A#1,R,_9E$WIJ:XG
MJ8RER9;C><JCZ\P5ARGICNWMX>\\B)I82,U:^4LAM[2U"8VLL:T[<_(5+K8H
M5UFV_C;I/K.W.-J++H5,:VYS!,$IZ25G>LG;'9&-7M*]CI)>)+V4@5Z.Y:[-
M2"\;_+:28B3%E(EBRB%ATCW?=:*7+<YW?]4.#0R[WFKYUKX>]S SI_-.KE7J
MM62"3?43;/P9<163<F+E/6$!R+,/1TVM.5ZXKIY+E7EO]5RJS'NKYU)EWEOU
MEBHL6%$^D=PNG4B^FFGV$P&9K#QJIJL\X^17; +RHKDNF#ZP6=;=[[4$^:^'
M>,KNB5.? 2YT(.[0^/?2\[&;T.3Q7PP\9??N]]5.XA3O2J;,Y77]6SP(;[K_
M0I/GFFJSUU+[.=S\6<VN_H W7S:_:[/?SP4%) 9LPX!R^!&! 5SFPP2D3Z9.
M"B!ZQ!4'FRV:/K9,-#UOJ=DZ50(7KOFL^210!LM0 U4,'_B[9MH(J(D]!2J<
M/%X3"AGSN1RE4(_F+V*<_Y>XSKM@8G?")._"+J':,N -=W],[4_>?3GNOH@R
M*7GW>1I^;[C\LJA^W<% ;>5L_TFW7HFUNGO0USR.U;1\7=$LR]%I>VS?6?/N
MF>3T=#M/MWY]$.#$ZB(#*-T[W,P3QIM(5:_R+#]O5)":W\FC@E0$*X<**8K@
MX7"AT'! NZ$"0E14%Y1^P((#P8#0 $X/J<)94.*0(>$P+#"A$&&@\\9V^'I@
M.C:EREAYX9 W*DB5\>11H10MEGIJ?Y!KPQV) =LQX$28@?0=EE@3'&-S6.+Y
M&!6&YQJ:[[BPK.(2@Y YFQ+F&J:MN:^*-]/@HU(E_'!M>KYK/BQI\X:)_2V"
MVUT(MBG1EZ[T))Z")#@,.IR(-)#HL!D=2J$>-@<MM=$92 6Q>#PX$;8@G8KU
M425YK:?"40@P[\%7X.,ZW(%?8Z5Q2XI) !_>B[<,:F%2-4&W*RL)]N+[&>_Y
M1!A['>Y[/\(NAT;74P>-IJ3L/"E;JFS2KU<>98SVW2"::Q.#E7P\$U;4Y"DS
M8AD8_+UWEZ"N#?6Z*V;9J)J!C+8M*:5NUND.U&:S(XWR(UUVP66]EP-YU7E?
M=2E4LUZOHPXNV_*RCW39!4^R4AN-7 =9I:AE<M1-*1O]G\(9<^=$M8#2*9Q1
M8H+$!(D)$A../^JFIE' \K5]O7=\S5*<Q.:OJF*3T_4S4:-DI44Y]R3?$+^4
M+J=NJZ>VNS(/9+_XT-LNOASM!;"]7#,7D_6T0D>[X4 I_%)MM='NJOVF]$P5
M<//%.JDNFVH[7_>S]%)524<_A3-*BU1B@L0$B0D2$R0FR(',IS.0&91PY3U.
M93[C_JIZ3V/^K7YC_^ &JS*"N=D&RZHO!V26?$#FJ1))67R.G4Y';7?K/A=3
MDDD!9+('E93"*]MKM=5NLRY#R25EE(<R]A$@Y>J)W>X,U%:G7Q,:>>-89>E"
MYPZ$]N*78CA+;&537R])20Y9=H=92<!T$H>4N"!Q0>*"Q 69\%GKA,]_T7T0
M ^!.7+B-H$V@L_0]7[,->(BZVD/P9'-  V -&:QNEF@231ZG%"J3"&*?-,_4
M\W1ELWMXFPOB34>\-JTEO+IVTK(>LME6FY<]M3U(:H<C\^$*)H%#^!E*3P)%
M'[)YJ;:Z#;61.%M,DD!!)'!(+W1I2: LAVQVU7ZOI;;Z2<Y$20(%DT#1#/(H
M)%#T(9L]M7<)9-!*R@>7">+2NWTZAY1>+(D+$A<D+DA<D+@@$\5/+5&<FB(*
M*.N*P51X[&803QU7%L1E+NXM+F^955[Z?*>1YMJPJG=+7&JKY>Z2_SZ]_@'X
M\X.N)MIJK=TSH'8[&C=)JW*XQD5B)^M:)WO)C,B*<X@#94:6DT.4[7# (3(Y
M;"6'D!PBQVJ"3 SBP%4%&6@H?[Y0LC,!.\CDO*XB.Y#<H#S<X!#ZPH$K*<JE
M+Y3U<, @DHH-:\$@9/E(+?R*)W%(Z4B7N"!Q0>*"Q 6)"YD#;/ #1RG'%M0M
MHKF@$/FSCW/M5[ Y/-+'6!B,Z2%\B56UBJM"K;<$B]@CE?4]*713BK"KV"9B
MWQ",&44G..%F1=W:'D$4;YF=).&:"PNIW<^(HNFZ,U]H]BM\ [#'AX5 H5<T
M'%GGDR=7LY2%YOJ*\QB#S=JS_!GQ>.\FL!2TI6%BB [L#P-;K=+?:!LQ#5]^
M-&W-UDUXMN?#"W0LWH4B(IR2@@[]K,'/!* *3]B?(O+$E&QGVMMN.0Z2?3YO
M]90X+UF#7XQ,,$Z]>GA\38C&/Q"P)S$:;[UHKYY O>(RL]"R>C$-?X;[;_S^
M40G(OHW[%DK3FMVVJ@0_SCZ^^R.5([4O6GW\<FS7%[W+A(WSES^*=J)"#478
MLZ;,7+2G_\=W]'?!0O;2LI*8Y#TR6:3"*S3I@5[^\H>6P#D3,#%^\QP6_8NN
M"6@H?AS3!,(#N&RKVM)W5O((Z$L)J0V;T/_PN0T;Y,@.1/HN_HD\8%/:?(I4
M..7LLB_^M.M4<R)'EM=\$D?>334Y$F^N^S7\.;[ZY^ANJOPYO+D?_GVD7$WN
M;B^4<8+F(UZ2:< F3;O3ZG?;G1^#=_+6CGMKWV^&WZ_']Z-KN*^;Z]'-E/TV
MG7P=7P_QY>D]_/-M=',_52:?E:LOPYN_CZ;*^$:9?AG>C;Y,OE[#I=/)[Y<?
ME='_?A_?_Y_R_GKT>7PUOC_;<OGYWW6JR7F2E_UY<J?<?QG!_W>CD3*\N59N
MQC<CY=ODYO[+5!G!_<-]CV[AOC^-[IC%UVZH"@;/L]WD/E"+^F6@$P?>_E@2
M."IK.V.:L4%T!X>J.':PX;7];3/[)+RVPDN"Z^WHM>9%+(48W,>MF>28I<=&
MURQU$.C$LA::@16M- "/?_/'LX"\Z'"ARW [EKF:V2OZTG7A^-0Y\E&)>4_V
MP /NS(:G6MK"@Y>#W\*W8G!(N@@E+6 NO!VZX?F^._W?J9;L&\GOM^%4Z1[[
MZ&M9?I>//LJC:=PA 1>R>%O[6PI[E"RA'(636,0Y+KI[^V?CQ+T&PN-O)6U#
M0+?P)/NO[WKOMFV.$S;[4VP$%H6OXA\)F(W ,/@[=*4/;!9)+-$LT<VY#YL^
M1L;@^L^_/+A__&T25"U--U4M%8T8ZUMQG1>&$JVM*%$@OL+F=MBHQ-VU3P_A
MZE ETRR*K3'?>4*>W<[ZS:UF&L"1^17B$E?:PO1AN8V$4 KL*^FV)%'D3A2Z
MOIPO+0QL4Y2])H^F;OH290^W+8FLAT)6.A^>HBG5,&;P(>)ZW(%98?25)D%I
MI(DDREV)LF+*OL2^6F'?<.XL[2W\OA38MP^//U"[\DS@>)<0WY.-7_9H_&)I
MMDX4JJ2T/BK_T.REYKXR_&BR^%Q2)" S^B84-F7\7N%UIIGV6>8:[6U].(?>
MQ&ZV?K19W>*/*V<^=^RI[^@_6:'BTL/'3(,LXM%_EJ;_"I]:.#8F26+E8@%-
M.]MJ)[5S\YL8;-%5C/N@7Q7(:[W<N?J4A43"[3M&%J4AK3=/7VQWDL8!2(JJ
MRJ'?2&;9FUY7E/8BOSIZP,<V]WJ7A0X?S5_$./\O<1W$/*J%K9%ADH4F25(*
MN9R;>NQ*:7?$U^#!1M QHT@2R]8<HZ_V!I<XDKLNDB^M(\9.="8IK*P45BR=
M- :#VM-)FA\LZ!WCKSFJ L=/#_TOA^D8L^IZ[;R3B\G%Q,5R=-=N<\3Z='!D
M9;VPQ_&K#G7=)93A.X_*)-XN6_&6#_\FN@_?5Q:.YYFT[00QR'Q!OZ&MQ0R.
MX&_=/K7FL-8D-W4*W6Q58)5!A[@#] 'UVIBX5YIE$>-ZZ0*>WA+7=(P_-6M)
M-K6Q;'/]HE5&/]7N]K'$HH*QJ'8>%XE1B1B5Q;@Y$$J5R;6P>:2<VFAW4Z)3
M>][CV5OQ2&+0/AV:RXT'TEZ5BU5@L=*G%TFK-H-5>T-\!6="2=M4ZH"9K I
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M/8"6Y^&V'X AT/=?3'\&^R?XP3F8T>&GX)[@)8($;<+O[[4 CI^"QUQ%CPF
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M1>)5/Q$;;Y>(-PU+N>29@/+G*4LX#ESY(VR!+HUG 8; 1X DGP; YM,/(TT
MQOL):X?K'CRC$;3O\_ @85HC[)OVW<)M(0;A[C'^ 5JW'[Q-$9@B=#!4UP#
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M,&PJB2@M9T@IA@AA8*150GG4_Y4))28OP)*]F;D8<Y^*%Z@[Y2.&;C>9%!A
M<+ MGFAEI/F1&>5G!RS,%UP]NV*YYD()/"5XC9$UO(,6A#%JT^#>WSNB$W2&
M36R!U64S8G+VDNQA[0S4=G\3>;S/Q2S.'QX'L)^;V^SGL\@M:A,_IH0)EHS@
M$.)^F33T#=SYXA?357SJ1Z3ZI\%T4A^@Z=-L=\1S48&\I^\,V3N1&LE\[ECO
MSA[Q_6)ZH3RA2\FF*WFA*LB\8'S[<Z+1SL$8V 48^NBZ4J;,:\^C'N^UL_?-
MWEE$K[@(?69@]@UUG[O6-&  /J[SBA]O]KN*H;W24*X%2H>*O^#QF'?>/B<V
M\[.%3PR""_X,;)V98\$% *R)!6QLZ;-H^-RQR2ORF9^XY65X;'H*QR+6:W!\
MMO][;'8.6\)* ?CPG!#Z49VXOL:"% 95@SPF,92[I96#'[^EG5]R]_T6.%*'
M,CQ[;MILIJ)@8*L\@B&&(^!Y'Y3W)F_OGS6J06'QWA2_9J _W'Q8!E]DKDO,
M.."X$L.\M( 6-9KQYH#2^6%B,9S:!Q?6//R)P4E@I@SYA9 CPAPVA9"-'"EI
M]T>Y59* ;.'WAV#36O&7:>PAX?4#[PL^](^E]9JP]OK+.RT=3R>*)::5OT*G
MT.1S61Z4O3QHL"5M[4#50;&?>Y<&E:8RJ/"BEQ(F@]<R-?I-Y1;RCF3MA;S*
MHY1F@'K$4]Z95H:53BEI[QMRXX<+,-*,\*,_FN^VU+WOI6J]K71^!UWK4)I-
M)B5XN'P":VE%,T>C"^UD:LS:S#,G&$S*L^,3%;]-;X#^0I5BJA)CN?J:#IZ8
M58WF'=K)_@R,X0?-,VF>H;)<X-<?,3_)IZ!X>*6^-(,9P)I%,XGI]\"ZU&=,
M]:;9<F!X+M#HP.^B1<_-/?CN,T:;,/D.HY)@76#^%+,,M<7",G6J+!A$,_"^
MO," 33)<VA?*,/2WT,/2WW'SIK46:L;$YT,8*S?.LY"V&1DLXUC^8A@5ITMZ
MZ"Y@V^'A/#1S%XY'TX(1I$]/+GGB1]CB=+MQ["!U[Q/8]'#0:_:HKZ;V  =/
MF--=<%MQM=WKJMUN9SVP'>9TQMU7*YF*6CYID@$40>>F8.3&C^5H-B8X;\"L
MA(S.F?9,.*XF8T@F!*,8K6'"V=+RU5TQ8XCE%MX78AECF_I>2H4&S493;0W:
M:J/?2W&M:IMRM3&&.X.C)3J7:N\DND_PG,'SX=ZH0Q"9VX/K: 8ZY7271#QH
M)7<1_S ?33U@MJ+O+LF-?1AO-6"RA4+L:4:SR7UX#1X*LD:H*XBMCJ4C2)Z,
M63O* Y<.\!=+?\ O^\Z+YAJ92B1B"47QZD0:U!0B#]?4_;A@A8A"K.>P 4YZ
MH1ZN%Y9+*1:/0[M+"W#()32^SCS;"*!$@31'(@#HK-5%1<GL\0HI6I+E!<[W
M1\UT ]?XLV8M05[]9PG7C24?/B"I!D_O-WX/[HA_.94,E??4?_O(/-'HO3U3
MWJ,CGWKPDR.M6&UA>E1",JS2?L%.>1=*A94"1+GJP*EM5I2TMOA9 E=V;.LU
M<&^G"G63'0YDJ'^>^(&P;N[%9C!DJ0^>TD70! !G3S%IW@P]"2AMB.HX,145
M-18U"8(JP>=YD00\A6IW+YCQ&SY?HRCG.I;%"R""A'WQJZ%&YRT?@;+-("O=
M]&F) Z,>CDV4F%@F.W%I>,1.BJ:PP$9ZT('&:D#%I_YZH")*IF+,*?EK4=G=
M/99WL/(H1"J6@A2A>NP.D?81%6#GWE+7X:28'_W*D^?3*'[=XWO4"/8:)@)K
M>S8-0H_'HQT!"O#"'9Y-'DOQ$U+&^9?"W+Y0PW06"\?U44B_LMLU")DSSHH%
M-_AFQ.1-=V4YJJ:O!X'2&(ZJ$)-:(6$ R5S7>[6 24?!,YJ%2=G* B%!TCF:
MXPIA)C X,.#H,2V0R@.>FL"('94+CT:G:,'4RXS0S:WAD$?(SYCAQ+:A61L"
M7K 1C/4M*8Z)2X=H.=<,LA9PBT**&/2-Q#';<,*-AH^CQ:M60*/T%MF-Q2H'
MU(A%4Y8<ZH<\Q0%>I 8=MR\2^;2*%X(UB+QD&"_\Q8DX"8W!QFRS2,ANQ@^0
M ' *W5QH?BBY-V43!6D#[(A)R0.'3B0Z0&Y N[\I=U2XK,U6Q)G*RSYBS/U]
M4!#"_P:L9>B!"A(^0)2/\ A@9:81!7YMF@'-5[73Q%&,!ZABI6<0YJ8UJZSN
M,1Z4Y?@$Y$,5RZ7'$/O@%MH"/XS[XV99@-X4I<+0,T,R/XVR9@YN%!X%%!DC
M*<[]PD) *B*!UB- ;M=6UK@,7$JP&Z%:QV-:$3""I><)Z:>]LU.R6D(IB I^
M(":2^2[J;%PG$YTWB/^ OT\F*@-<$T7N'>BI61+UQG;P!&8KWY!RV<A=7GZR
M/H2-6\A8D[8"&Y1M7J)P4U$'=%GB&E7UPLHUP'W'8HD;3-=;:1EA:2_\*>E&
M59!;S55+1@\:J*"T0!E$/#HGF7R=:_]V@AP?:C6N$JGF4Z\ELBGZ+5JXL*I$
M.+%S7RAC?/2J-S2HN0\5WL!2#<!E.(1] H%N4+42OY[T*-2B0YD8:.B ;7#W
M"B8)A4X]$<=5K-_WEAKC5:@##+F"C#O!P654- (J.:#U&LLY?7V(30$L9A8,
M>6T]A7&@@OBT!-7 3AZ4^8B+4&- 5%"8!<GA%>7TTY5&@;EY%;*RL%1\.KJ*
M)XB!H%IYM.'H2]J0AY(-2 IJUL2,>N87H 7'0K4Z7+2SM- LC!5,8C6%\^M5
MJ*@-%5O83:2$!.KIAC8(XZQTH23JK,DXGI2R%/IPJ=-/PSIT*H88_@%H/CN,
MJJ9<I1>LXH#[=\\H@'&C,?4N;(UB*,:2Y;6Z0@%ZFC\&'ONH/3M4\&\CW ME
M&'KP+=!8J>M^77P"U;Y&<85-"FD0H6!&+D\MI)>!Y,:#%*;+75&TW/E1U-5?
M(W+#PSX!5GFL<LG!1AA&RBDV6G1ER^?Y8R7")C-\*I+ATV[(#!^9X2-3#F2&
M3_7O2&;XU.8J#Y_ALYZ\LT.F3TMF^A3H9P&+ G7PT+W'DR?(D_/_L_>F39$C
M6;KP]VMV_X.LWFHS,!,,P4[5S)B19&85/94)-\GL?N^G,A'A :J,D**E$"3]
MZ^_9?-,2"T0$ <ALIIH$+2[WX\?/\ISG,"W7S([1I,ANHR.M7=3YW%.D":PZ
M'0AFNF''@-TR)*GK8[Q4XJ?(5.>-'3T&S,W1/2.5Y=JCN[]-A]7+D1^/:2O9
M"<1X)^=% T,9B4RX(TT#Y#IOXM6YU4Z=O1H_V_C8)E>VM]^8*W,OUMXW\@))
M5B SK<ZYA(,=,?J <6[CF'ZJGS*2XUO$C_@0DDG,&AR05QFJ;3!7+_I.4'ZI
MY;T@+ W!^*W=:47.U3(]DZWV_6KMI-8Y]!QEP' MR"GE.I2#*5EARK VLK 1
MZ:*K-+B/8DZ>@1=N]UM %G%5#'!CE&(1N(O]B:%L/@>]AW61D?DJQ*YEK))Z
M%A>>2W!!]C5;!C[T"7$QIWX-A;T7]R7LQ(&H+N$@QO&P&C8T:Y["'-P85!^R
M:-V[,]HP$>6G:/+%I@RBB9S,0FFC'^(\XVJL1@[UP@?X:?R@J\S/$R%A4';7
M3@YG7RFL:[SHGR>4-BHP '1.@+0,OJ*&ZR%W*W5K_OZ$.MTG[/I.3<5RP[8O
MG7W.H349%.*4O+J_OF30: W.Q<M;UVU$.:$P-$=!5R+ZI-,Z]0+B&BHK>QJ>
MN_C<6J:V1'(E'E0+"]94IPC")12/.Y,":,B;DV^3 0HUD40&(WBI>317\ BW
MRH-2 TO/-A)I4FA@2,*5L9C<^W,E?;VY7EWN\;PFE>=LP-[C=B!^G)=&ZJ7T
MV'Z1T3X3'#P)#R.]JZD:>XIT582'%&)F#-TO O/4R#)\.MSG]S'/:#$*G4T?
M$143G!\(;,PE0P0+]H#0LIS2EM<%@[*L?88&AX^[P.$K =%//SO(:*LY.+[0
MG;.>"VNLP<-7NN-)H7*%Q2R9:V$:6E.:G4DD(B[5,%J$T0."(4S^6<F'<:W+
MJM6@36(;RX\T@]9. RHSA]O X.'33!_+55'5FBCR20V(_5N6WSR #T+*S!N5
M-8C!K.JQ3>!R*^3DP8/2DJ0L:)PY5$[?<.F0+K0?ZL%^QEQ_XT4!RK9NIH:2
M[ZW]:DSZP<2\2Q&4#8]X#X8I<MK#\/67,3<\K_Z=L@.($TY"=E$+-_!$6'L]
M;\8LL,=!0$M4V]U!% ^91Q^^.\;!F#"&  0XEVUHCYP:)'B>!JIJ7SQ):YRN
M=,+*U6+PRU]V;U#RTGPA)OK?$:*_[Y%BA51%R9#M1_$@=Q+CCS-DWP0"J2E=
M[_G2O);PV^:U-'P_/N:];HE+3O>2UN[W]%[=H9D@SS<?JF-B&O+K9-Y-,"W7
M,/.R0B0U48Z=5!&J<\_3DB;A:QEM-],J\[^G8?R"C5PIC=:;4/8@O\2N 3Z
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M%,4$75=E7,GU!P6FT&&?DI9ZPOX]7+?M>SJ)@;I\+DSM#?K%E&YB"^6S(LO
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M:AH;TH@W.3B6=V]5K\"LJ3MF%^_FU$"!LS5S?:3)5'-5(3R0O+^<.I/TD$"
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M5?('D!ZR&^E.1^PZ\INX< <Y[YC16U[\H"*L"B&7X3T\R'F/=KA)ZS&O4[]
MX=:R9HWW<L?;26;9F9$#6%4RO!Y>JMFU/"-\M7;7I;4W.(=E%^@9K:]G!%(N
M\ 31!U*16.Y&[7!KYL+[VQ2MA_0>XW0848M[,2@0.)&QJ,TZ+*P^=*_LZVB
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M%P0V8T@/3SN;"^Y$@<B)NXINC1G:4Q+^2"-SFA";#'8"OT..KW'>HG?6P9+
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M"^!2U[BU$*0CNNE- E,JF>)<^Z:._+"G' ^'JA=SJRHV"A]8YAGR1EQKK)K
MP*;\L,GH3E".",_\%V+C:M\Y4QJ<RQ$(#A/<$[+N+E;W[HUU(%GRQXE16J(/
M>5H>@^'5YF@$I<I!_YP[$V&]MD&:"[?<1)?-70HS]SV=6\^4[8UINF>FZ7>9
M#E^G2V<L.8Z^>LG^N=>!H0/"-L0AQB"Z08#!V.4_7KC(CJ*XMQ4G(JBZ)YR
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MHGL;UOJGY%IGZ5V<4^ <?,=_JRP-_&Z 3ON=1K_(=X,FA1P_1%D"'Y1?JHP
M.*\TL?S"@HJ?U3B0 -/&'VF>;^+:!WY[NC?=?H[:FE)77-S_MB$Q;6VX$QOH
M%%DI9P@^#69WG8#>[J$-Z.F=$,!6X!F6J-YV@,LA.F!C8);#SPFR AN."F*%
M?H!!W,64=DPJ-U]SRH<%$!-%=RJ#?1,D!6X<RE&4X)).!JZD#2BM))4"=7U]
MG4H[_:SJX[$GW ],DV* "(,O2L\%?B=_'C=IJFFJ- *-]8-2)+G7T6ZV>C]*
M,/HO?_S</&<GL!5OA&XTZ&([(\FR]^)!P63E92GEU>NEBMOQZ3.6&UKU^WCB
ME=->S6E<O&PCEJJ\B8V$-V)]F9N:A._H<A WCS'-1X.0S%[-,,0LO<$;&GH.
MEOKA?2WGKN7I)'H(-BZR[FV4*S'R)A9D?OC157E.#8HM)Z#J+:.6A$7YL70)
M(>8EZM@2I)EQ>;?S/$8W-QF,:CQ3--H2Y6L-W(M[)%"WL$,#_@6(($)OI+=9
MS+;3LR; ##YCC%.2.S'J,!BE&-VBON8A&ILFPXRCAEL0.<G!_VH;<]/K7%0_
MSZC1FGXW0YK?2(+BH=FJU7.A_E"A=G$@F*B!L;]\=[8[9S4:7[.2+/5=T$T=
M<FEHYVE0GEHV'^98H U8^QYR^&=YB.<8["'WT.3LRV:IX\/$1M.FFT+9-'^'
M(SQ->N]Y?*OKJ[#^O2E6T/GA9'?M.S_L'_]M DI>7]3<SZ%Z[R-^T;YN,:][
M0HG<\5.*LW6=ANPBNX^W#V@GSULZ-?DYE:?!KH!]D/S73X<_37NR;!O^IUOL
M9\L1_$MT^LW9CO(7\>ZI2-*KD*K-;"TW!OTQS8SAS#]\O<V4_/@);K_-^></
M";A,WKERG?W'"@=:M1<?5_"T&DEK9<R7,;*!/L,_ Y:IX V)TUO7K;MO5>ZK
MY</KKZ3>\F)UVL5Z.8NUUCNK7;+5[J^W?L1V]M^J6/E9RL<1.BY9PEH.F6D<
M,JM-=[][5.SU&7A@7AS'WYJ]:IW']CI?M<YC>YVO:G5+2U6Z)J?XBH#HF,=$
MI$]+[?N27K7.8WN=KUKGL;W.5[6ZY26=Q:W?O2IR\<$@[1KD4\777@-JU9^?
MN_W&9S5F 'X96'6T5KTW.GN=<._X:*F--Y9SM+W4=>\XZ[Z,UF@SKGNXO[\?
M[ATLM^7*"U_YQ2S\6M ,'^[NA0>=.HKAE39M>"M*OK-6FWUO_R3<W5]\NXC5
M=%=J[;4GVVOO59(2:5(;8WE9KUKGL;W.5ZWSV%[GJUK=TL98GOW,7K\&;E5,
M0Z6F>4(E\QJ$8!;QE/F]LG_*))WR''VFLN^+OM2\,:3HPL[3,J,S3RG*?=1'
MNE7&)#ZK_;KSSQ_G*3KN'!V&>R<'-5[)>OBH;UK^%^&XKJ_\+^?KYI+_HW#W
MH+[HOI7_9Y3_10;KUD_^E_MU<\G_07A\N!ON'M=%I=9#_MM=\$I/@>5^W5R[
MX# \/(*=L+N_TEW0X!VVK?C6LN_M6_C&I=LHKV*6WL(WMI+02L+3)*&5A]?Y
MC2V>_X5DFQ=1C?=&\"1EBC9QT):,&?P39O]/>I_KN.S.#RR9[^.6'I)>Y*?M
M;.]TEN^4O2*PW&(E?4' J764]'7[-)#T%03A7I&D+T30%XP*G4$:EBW?:_9%
M(-:KC:JU]LJRX*_KI,77]=- W.NP_*M'_+91Y)+WO ?><R\MB#_ZU88(UN0C
MUSUZN";3]"8^LI6%5A9>5BQY32;K37QD)9H,_\$. )6^T)5_3VJ^<)8FR)B7
M46WTESC_?I:I'IA\\%/;">U9J.&\%:&NQ+0B 2[)F^N ]C%.HJ2+/9?B) ?1
MX;9FU-3&Z69C.QDZ[7K&U"+13B4UJ>GR7&8XE]08*J=F4-TH-SW5J%U0%/2]
M-\?C I\1HI>!O0SA_6/ZY&'T0$U0%+7'"3XJ4!MPSWM%G=R#\R0OL@@[-YVE
M&19BTJ)V4\'##^)A3 /X>;*C=P;C^_C^_(P>IWJGU&1E&6V9'EVNVX0-G:75
MTGO5=?_4H3^5FB_=1MS-2_W ]C[8"ZL78&(&BPBH%U&N[ +B0T$*X;NI\]:U
M&L3J3N7> V/SO#3G]IOHML9].#\2%A!Z,K:NU _>KG2=+&M=OPME_<YT*%^?
MH>^\\_:%M8DMYQ;E]*WMG[R8;K OLO?KQZV]HSH%WF";=&J:VN^HH9<)OE:P
M*3$3/+B/'G+\M.KC;TVT0[/I[NS\[== VRU[.&JG+JISL!<&^C^;O_[T'TTR
MU-G;WCW&F[U!;Q\>U8Q;?OVK>_@&=/K"D*/@-D,%]/^-T^Y/__V5>R;"L8?*
M#7;S?_Y'-)N@^0LK'WN\?1"#E+F78Q;:C##CL7!+)"]-3;^JR9Q/DNZV._A"
M=LH_SL_^Y\.7J^ ?IY^_GO[V(3B[^'*Y'9RW'=S7:(T^7WS]<!5\O0B^?3[]
M]O[\ZX?WL$R?WW_X?,4_75W\<?[^%'_]\?SSZ>>S\],_@JNO\(M/'SY_O6J7
M<HV6\NK#)2S+NP]?2K;9S,[&O-WQEC[+B^VU5_WJZ@A*QE\0]_[K)VQ5>*4&
MW$[V=#122>_/P[W.R?[.R?&?!S])K]<"[/GQE(L/?YKLQ7^,XNP?V(3XHF\\
MIG/K,'&+\Q?FS[^0+;K:X  N=$ K3;V]C8_J+';SMGW5D0+J?FJ:<9<:TF)?
M\\[1KSDV#%?B( [BZ#H>4-=><>N#?Q4PZ_T'[#O;KPT\% DVDK;=U(]W;3=U
M9VD^J0C]=+PGE);J?M=P[L::90_4P)U;I@:9,AUK3<?B;I<_ *^#W0LRC\XJ
M1BX0W4J-SZ^C 048\EL%GQ9BYVE8%^Q!WBNH S0\*,;VK&DVWH(I'8+NP [2
M8<"]@L>W$;\,/@U[5F-#8VDH;>;H@6:,6P3G%);BANCV[QN?T[$*3C9+O79+
M3G(P48N!4)R:OO:769K C]P\6S08_W<5'6 GZ&;2R@>=H[TVBCE!47U1:+$%
M=CV#*RS=B[+>! 6U;-5TG@2GQ4V1C]&^V>$ T\?3JW>Z_WOM:+^-<)\%&[+-
M3Z^^R9;>##Q_LP9^,/<DX["V=@ZE#V#P7EV/2;UT=G_E?U!/^C.[#W%;7M V
MOAAQD'/CJK@>DW):^.CVCW:V=G>$+%4B=UIEL$[]7?5N</;TF-&'YS[DH-!X
MLXDJ#B[NX3?$2;?,(1]W#K;V=S:%0\Q=8.P6SA,YCC'BX)Z@^"G>T*-)H[>"
ML32!T!*G!8./JSP>CN"\PK;SD?]A7>?#W//K^@%.F6%ZA]<-H[_@RER-(HE*
M#].>&N Q!-^5P6[@PTY:0P>_G9Z"#XZG+'YH-,A3?A2\O NOBF"6X&@=#SCD
MBF=5S ))P7IL#6X>C"-4-'E;\)G?^4#3_>I3<PKK?N[.N91WTY&2IN,4CL>5
MBL?N3- =@N(W[>EM?_*NTP,=AJR'#G^*\NW@DPT:Q[G^=#A)%1H5$4TO/C\!
M3713P/F+Y^YU,0YZJ;+A:<E#1#TY),D4@<>9.^ ;;R/XFBA :R C(P-.>;B/
M0]D5JZ7AY+<V2CZ&7] 2P_E+34P;CM\9@M3KXG57CH=@RBB7'_];H3E;\\DS
M/;/Y27-[J(>SN+6S6$/S'=]>&&$>Q^^1\^/L>;.-)6,DNBMY$%,Y(Z-F\"#V
M0DA['Z]_4+#U^WV<DCLPK!UMG(L=$<1]1Y^0;D""K+08]"K*@)^DE<$L/D"M
M)J@8XJ6-7_Y-5=A6(^J!(Z$5WR#O#G[\ KX 9>DNBVLP-B]@>C)X\BK\@)=E
MXJ\N\AOL;0>7W][]<7X67'S\^.'+^>??:LSZ9HE:E$5_661Y@9XJ^[E@Q<4(
M"0A84@(M*GXN&?8-)GPET#<Q\7XU!OEB9H[W!3[I$IZ7"A_):1>,F)S-G-ED
M\/SR@@6OR/'Q8/?F<2^.LH>K:* N^O0VE,+G8C@[WJG/XO-4X3MRL3WCI#LH
M>FAY!OUB #KKA\JZ<:[0Q,2Y)N/Q/@,3.,LE&!-G >(>X!@>I&/2MV(@Z6 '
MQ4'@XF=8F L8V*D>%[M2:[Q0LZP3852B8%1DW=L(UF4$.E5-@)JPHI6K+_%B
M757P+&4S<\W'SG;-7)#1CR_9GAQU<E;T/>C^+*;5O^A_S:(DYV<]S^;^[P\1
M;#3\ @U5HIV4)F4>3?*"%NYZI@ANC 9]4>7R9O#?E!I2CEX'";4#+#KWG_QK
M[;)N!_09][<IW.)?$B!^"SQ&=MK@ O0W09$;F:W[5+3'K+:Q4MWI;!_LT)KS
MJ_CRC5RI@$*31YO;->[0[$%*,430$U67@XCCDJT)\HPFR#Z8(%_._W$*/U[^
M<7I&B>5G,4*>*VT;#XL!N!<J+7+P*2@T2(F%09JCKR ID(DFT=4(W0@XHO6>
MZ^'VBFYN,I#)L9KQ,#X;1'E^T9=M?9%]08DQ[&8*_!Y*LYS!R:]Z[Q[DNEPN
M+!_1)2!C><^M]ER>HV%)>+Q??RH'\@F!^0:M 7,YI*><S1/G^8/H0CJSS1_-
MY';69W874B-[5.7?91%%U=\XT2%%$SW1GMDRTK,/7BCB?/./63I$RQ-C>7:^
M9SL!5CS=CY/D@["S5R_)(6.C1S+-(_T9<L@W3C]&4^7,)M-AAD-^YF5QV1,G
MV:TO6_#)O)D@^31QH07"IT'4^ZO(V<_RK*#@-!BEF8U,XP9@P0[Z(-GTFPD*
MZU[A O5ZC)FNO[WAR ENU<"DMK]FF(>3A,QV<.[EZVTD#F-?<#!B?.Q= <>:
MRG.\Z!I[P^ GX*D7FZBY^35[@V'#^/)H8! "DSXU!L?V&GQ9 8CWP:FE>] (
M'H[<*90O95F$^;;+P-=3YH-S,'!'-!K!U;03!M'])MGOLXQ%_1C!8X)[6+Y;
M,)OSIR3;OZ@!A@XOHVS\X+@Z^?LX1P.BR-2:Y-E/6@NXR0(^V Z^?/B#0):7
MIU^^_M_@ZY?3SU>G9U_/+S[702P7%>%]I%F\SGB%CRFG.V4'-T$4EN],7"3!
MWXO! VOVSF'H0!5LZ0JA%1YAJ$^,FL'8Z4\54^;HSYU=W.,[L-^/_NP<TL]_
MRHSQO>[IV:!9GLDLWPL/3O;"H\;#L]R2!$].F-A^/Q[$/+&^H_1T.[)A$0@Z
M-BER^>S+\(3BL(;:L#I CIWZ,8X:3 ?$#& "O;1'Y7#U5H9/]Z%>C%$4,]R
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MIW*.@HZUKHJ)\^_<V.-;(FU J!GES'B!99;#S/OMGZ($-B&!7?4.DSX!T:#
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M G#:-6H!.*]L*5<.P%D^9&;1?LFC2/H(7C,'%F=W827MR[&;M+EO;?6QXSN
ME=OD"I!G9?HWP>\ECE%K'Z,S<S?9%88GW,79N%#E8"SYR,:%O5(96N^GP:6)
M&;.!CG_CD3FN'Y9WC>$'=%A<1\H;HS\2ZW-T,9 [T$ZDYWP+M[SIC@5/(:/#
M<25#"G?" $S3RK#1[W6^96%N>$7IU3OF:([=3O?,W2@!+*9>2[WF/&=%SM%1
M4V&B8!JQ66<?+-HQU\@D6/TFD56YF;MQYN2UZ8;'(T[7FEH0#Y(B8[K0$)XK
M"^&1^\IA 7Z%?@-\"/N37AQ;1-6-O<W\62.L;I2%0TB)6\V)+Z7GLK/K@S]*
M;F\#1*0Y+ML<>KK3H2?:/R-J1S3K]]2'^])KPN&8\*YN2*,_4(?<IH@/+]3$
M*([LX')NO1(NE&"_/XGT[?KC^^E@D-[K-$,9U>,/EQ+U.A1N43F.Q)UA5X(^
M)X+@+^>)D_\!#09[?8)B,9%>60:2$RL(JINIL<[YC>4-)E$4$0S*>;?6R2@2
MH5?7/#7(2ALL@5/GPX_;^#H>!Q]U#$3";@0BJY<!JJ[R7CU*[REZK:%KN E)
MG6'4A__]KP(,OKY,,5PZB(?QV!:"(4YKG,4BWO!M&O$U,FHQURI>II#7V 17
M\8.P:"O6"RO[US^$0JM!!/0W0TAT!FGEY9Q%Q90%PMT]KGI8WL[R]T/MR4=!
MS6M, YI<E&B9QG =;9O0*<#3NO0]#*(L]U@N1^^0@Y(#M @P@;,(_XIM5PB\
M(C.X@$+]&0[#)&VDU%F(M;E%I?XQVA1RW-+>YV\T\5MGBHV-:<3 "Z%2S23A
M,E&+XPY6F02C90XQK\C%]S"O%N(X>* W][+HGAJGZ5G.+-J'(;+]*![@84UB
M (J-32=\?P^S)%B^2<%>^,>ODAC\H<\<V\7L0BKLWTM"?1)GA9..&N1I@(T2
M\3M%15J8AE4$[FF-V?JA?NT,&ILH )(N3B"'?&UD'JR]VS0#0[SGJ(JR.H+A
MV=%1P@BEUFLVU] ITMA[M(UX[YZ:5]8U)[6PNT]@5PR+(>/M\FS\!3<@(NT>
MR<+!W_?(IID[&GG7P,6AZ167.!W1C[69COV#*=.AM60DQ<"A+W_<D<I*H14]
MRN ,HERRG2Q_GA'MZ&X1WC'AQ,F4FE\P">'X$D7RZ&#!,CG?3*R1-!X=SR2.
M#2Y'R2P&26+,BX.[C8TRI:.H9_EKZK$N(JG:N!'.(XTYJKS4F.*^E;+=1#RV
M<!ZG9XK<?;4V>YQ3&4%7>C)?.QZ,M<KZ:8%G$!C9V9CU!N-*?%./C*V1(:00
M4\(!ZTS WKB'K%X4/OIEZS@V.[L+W2+'< EX,QJ(9<SS6:L8YES&.2H75@O6
ME:4\P_Q[3_@OYN&.61@>MZX8@*B_>(3> )=:#,#'7->;$)9N@KJ+T^;(H(A>
MEUT=/OS@Z--.1@U"U_L8%Z5+XCS604_$_G+_1X4^JGXU[N18[,R-:)/EO1CJ
MRH2?.Z&T;*>:@R$8Z3G7#K"5JKNFVR[U\@$#]*<16P_Z_'J," 3!4E"$4&)=
M_#?FP4HM^E?]T'XBTZDT!3/=!K0E$*2+7ZI!0I*%KN?J5]#=C,"!2=NXQH_>
MV=9U$K8RX8$\%=CVUE1Q5RG$N%. M#@JP*ZZ.SL=:JN;2[F>UB]4U1 3FXI[
M ,!S30!$(XSI>NWTXCL,H*VYK*+.HJH\QQ5!F./:;6NQ,4P[PYC*,NJW4D%1
MB]<_M9447OT;A>O<N+4-?;,4E0/?4P2BY.-/&I+^/ Y\#_CK-$[&G-OE0#=N
MD5DL*K;KSRFT-]F*XAC_J>\6L$XI<GS6E2Z).T.;^*)/%ZS$S-K*51=-K7M8
M\5PE%$-OL*YF2EEHHVC#/ZT]0VC3VT:S3S+UHKU4F;2*G3CC)%J\'2JSW= ;
MG>9[^E(9 /<53.?3EZJQ_^W^'/UO41%-Z(#+*^>J2(NT:UQ-IZ!C&2!*T,$\
MP(:DC9$V9ZBN>C,5;EY:0*@C,8-19+#/P1&MN9<]33!&7;4TG]HQ%02B37K"
M^655,P\%#5[JI&Q:WB?J'M&NG!&P^KOA,X/K*-<UVS0,K;V^X%;B*%.S_6$B
MDM</-?:']Q[')-8CUP73<ISJ3V[X +=P;LGPP);AZT4##/=:@&$+,'Q.25]'
M?-,+@Q.^@15YG>#!-[!PSPP5?*',7%6@WQRHP,4UNGG)QLX,67EXA[LLM::X
MU!H[D3=VE4U,;U+? \?G/=7W_P-O7RPQ^\3.!UO'QG<]F=;(=ON@P7&]!G>#
M D@.EX?+1(R^E [2<XCQ&A1I9$ WNL)KQF#JMA?RJ:>8T4$F)\;TA= *'].L
MYF^SS3C[WQ?]\X0BE 7B,<\I(Y+%T4 _]K3[KR)F&NK<#4?4_'V>8 3%KX><
MY*L-*\X0*"#7L<E]93]4G,7&2'CEB;[G:7$VV!X!KMKKF&@UOGPO[&C:&Z'(
M(K*%4- C-?[JM>(<CL/,X%(VZ'I9GZS!7%$G0&"KU=?;"]T:M<5P8'IU <LP
MB*GQH(EJGH1'NX?AWLD!AW<K -$,7?P>AEU[S EA<#>"&_6R7UPHBJ@\J@4F
M1H(LOXU'!M%+J7E,H(% < SD8/OP;Q@UM>O+*"_;E2/M]^,N(>9L=I2@RI0X
M<]:Z+]QVL@043IAO,+O;NW_SA=+B&S7"%>7'?#"^ NM6_<=@SN/HJ/*L<C.5
M)I$VS$J=@^V=V9_1M'TJ<?[7G@\^-7F$VNIQ=R%-/$_B=7!34LXE2(A_.H"=
MI(R?1V0-%)M.:Q(GM&,17S;&S4SX>,X0#W4>!$7 )H ) 9-1VDA:"I39^D@/
MR;MGC##^&O@UXWB%A!*Q,0WBX6QH%\]"+BLH&F;03)27&&Q\()X!38^RGSGC
MIX1N[JTFB#D[\=:"<NC+Y]9=,6?K"&0-OL6!( M ]EE[DCC #PO61I.(JB,L
MI"*K&?^]';\U$TK;J@[1[=!V6#X,RC53T3ZAN1'@[7%9"!C*1,[)$[>*9&:^
MEU_=?,0-,N<E>#WL-^\5ORXAFV*JD;!C%\YQ%MTA'P2\33P-4^/2%9+7?)P5
MW7'!]2]ZU&EV$R4R3KBFEW8+,K>](H0(;"G8^60=EZ#KAM\HIK_$/S9KVXS
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MPNA-KM'B03/M4JX_$.>18)?]>< N!W5@E[5#_"P;C_,TN:MQ%68*=X@7\:B
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ML;+"S>QAO%=B?Z2TBVR$>36XC(TUQ&29%V-EW/6# 8]1]R]54,* '[_I+XY
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ML.**QEG: ":\RP5T0 Y,X8/W+6*= X\+F2LY L!GQ7MR?7;"!,J8+(81DW
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M%,R&F3CPA!([_PV^%A+6]&LYJJHT,3*TALOW>5:E@?>)%Z0?+<E.UCWSX*W
M)ES1O+Z4$PH^&RG/>^110I\9@>=RPD%-P^>[%#?ORXC) N\EPF#H,W[C).8"
MDE'\$3U9PXIXSB[8.-C;S8>OP4:$4$@@RR^\9+="1?=,9D4R]]Y K4/81KX=
M_!DL?&R,A'P%9^F6]#3 9K<PXN%&%&$R91_AS[=RJMUC^F_JP\EQV*N!<4OW
MB6=D&UJ(6<V/>-WH2?5K5J%(ZMEP*]/J],3HS*\^3X&2JR#3#4B-)UX\SP+2
M(A2BO$K ?G)M4-@P^HY5%V-.=KQ4^?$M)=!YRL0+PT+98/81WC.GY=BRS&A;
M^9O_%VJ]C@VJF(!RBN/BV+:1)M7'Y+I.&;R[KL#?DVCZ.?A9N_3=()1-=HSQ
MY(OV!^#T2;N^OCT.&,0NJ(#YS]Q&RC<3D(* 1@(;>0P]#T="(O<@^"]L]N3I
MVKGAV, GKFT<Q]&_&_&8G&9N?N)<*'K+(/3!AYQW&S;NK)5.6E3LMUKQ7N4"
MNGO.PJZ(:^'N\G9P]Z -OFE7-Q>7MY>8_?Z@W5W^<G7_<'EW>:'=_O;U^NI<
MZY^?#WZ[>;BZ^47[=G7WO9"PZ1%$0M/AG,1VS0F/8G.=W25,[^_JIX@O17SW
M&_'=+/2*3HM0A@92P;[%<6)NI<9M7M&1E=.I92[)'6.&2\*T];-MP[2;1V8+
M",:FPJ=Y]L],.'5!*'4%6'*"J_DNA/>XL$@L+>4["J4N"J56+GKJLB?>[GHV
M/*JO$5>=?B)9)<W+V8\+5H_&W/,/GW19&"\L')B&C5[CN:"K\/ER]^'[HZLB
M/,K=RNC0E+#:*$)*05%EQ \%10\G*$HQ48J)EA(3I9!HL2'1AS3UB^ZV:=Y!
M'4?'!O^B13><B;E/($_XF_)4.J^HY*>2B96\ [!K"(7']QP>HDN=P.>I_0!_
MKO6 ZL2_F>!8Q^?,<K&$%CR*EUTF[3/QD>L^CG=ZPR/&!LDD\B>(0EA$BD#\
MU+P43"KF>.^X!9)VDU-S>H1?T>A"H$KYZWJBL=/*$.-AL_X@Q>T4IB\D3'](
M4?KB@_3'JW3SN7Y@6_%J_R/6MW.M[_IJZ_M=;H+$7 SP!>Q\ 3:WAQK$&$U%
M(VY4FZESX!G"O+%\TK< X"*U6]ZN]#EI)YK*+)X=2\&SG5&C\F=]>BFCWL[6
M6(P,2YQ ?$2D0/";V!@.P8Z0]3#BP^A*C5M,@';A&Q,6A;8)\+IRS5/M%N]
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MV\\\8SP9Q?YV%(;CD@JY7P X"*:!>Y% 9]>ILC4JD7B_3;$Q%LLV$WMEH/,
M;<1BT%E:!^&F7CI?4HWJ/MI*[/,NYI?P8PBF(WH_(CL88?FUCJ/RZ"*.>?XR
M YS!\ (@5G*CB7FW4$-O=4K.BS\B,;X12JFQQ*&BMJ#+>J^H)3.;S.S9]A.F
M[;!7[79DP!FT&R^$ITQ\VS7MB>%H\"_@.CCF#A1<9 @H"2!Q&-W&(+J2$-KQ
M'=_HZ34RO?>&5;KF#QB[=-,?O'E^6'?X%0Z+9$&8%]4]LMLZSM*(0;*?QE#U
MNM[MT$"$76&QI!J?>E.OE]VRE[!8>F5/1^_U2IYL078UW<F+[F2;IPG2E0QB
MX!G@@8XVD3D90XC:,!\56LET5@2M*_*<-\1K6==WJXPAQBKE-].UO,>L,B ]
M.)2KF9'O,]=\ PO:'!GN$]W7D\_?!&S.)6@>?,,-Q ?C -I7AO![,%YWW7>9
M3.OMY7L!Z"T[&ZV$UMI'DXM6')K+,\RIW49Q=\>AU)@?R3&IN0)1!%$$402U
MV]A_K:ZR+3-DA\=%!;M':I?R N:9*GP96KIAN\ZU;C?T=H]&M>X)J64%?AMZ
MLTX^AOT@M;1A 6=Z[ZQ+%B=9G*1-DGU!%$$4012Q+XN3;,G]!#X?N:M?IB1I
MH?%Z)#,"5J8ZQ)W<OOG>^!Q ;;L10'60-*H4,1+QN0<$V^5KZ!O P;9K^&]7
M(1L'-YZ+^JSO\7&7Y24WK=G(H:>WZB5D/1Y@_$P]XB@[KMKJZNTN!5<K21SE
M-Y7L]O3V6=G40>[L<E60724YQXI$[)_6/CXREPWM\-.!JQ3KR 7@=^GN^BJ
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M<"B@CX^;>"9SG(EAH7.2.Q+Q;[FP<#&F[63^ &FCB9Q%\8H8\Q-R^_:+EC&
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M4I2RU]-;#1KFO!="J"HZJ<2F@MFB1W),2I,FBJ 2&Z(+DA1$$4011!%48J.
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MFS3(WE99D''X51+KE =/VY/P/2'XY0O-+P?4!_3F_N-#?<H6B]:6]"G^3)>
M3YV!V8_$/).B>_D.?])GD1";"? GUNWNQ#;>-8NNFJR0*0@+1'0QT36.E>;F
M\W$+I:V"%R)\S8\H('RIC2^<RJ>D[-Y9EY5L9*['CY&Y1,0K&06QE'H,^:#2
M"C(4M^KD\3?=I;2*W2<-4P>?[=!F.6&SC>/ FU%%XZ<E<;7WG2NK%&S(G%LA
M8/[@Y9R-3G7 IU*#?0@9=*J*G8H81R%DT*F4.-6>ZZ_)0B@KQ>Z=%)+7]_'(
M-/R\JJ?U3E3T,?Z^P[U3<[;]X_O3<2DVZ@#^$!BMEF*T,D:VM;IZNUYX[VAB
M-&*T:C%:_6S*:/6S,F8C=GMZ^^QPKS0*7>S$,&D>EF&2FK2 ]3T^ ^8T;8=I
MKK18\%7\W32"D1;AL$A,Y?-R8AB?C]BXJ9R#@DYU8*=2@WT(&72JBIV*&$<A
M9-"IE#@5A2^VM!*ZAV4E7+ )6 8VK^7AE3G&V .T_7=N8/R1J?WJ. 1V?H#-
MFW>>>T$X&/[B>5;0=RTY1#FX]QPK35[P5C]%7#L>X]?4N]T#<<8>ESI4>;A7
MEA/?'R!9R8E=XD3BQ H=8+^<N$4$914G%M^W6!6*H*C)3NRA]F'90VENQ$8'
M%GL,-3L((AS3 =P9A $WD_CK\&T3B" D.TE)":#<G9 FKL'PFVBRYS[A58&7
MQ(4DIQ)2PY9> UW]K/@9YY4B C58D)A/9>8KR1JJU_1.YT!R5XC[*@7W"G%?
M6190O:W7FLU#Y3X*]E!*6*9%*.9_O6JW(P,.H=WPUL\3WP9.G!B.!O\"H@-&
MUHR2S*R,2 ],Y_7SE226*Y>3T:WQAEW<!B[;L>W2Z.FUVL'ZL"K$<<1KZO!:
M,:;*T'YEULE_F>\AB'J->N/+/)^1["8^KCC<E>7C@HP>XN,J&%044SK8F!(P
M.I;A:)[+&V7G66%&&/KV8X2-MD,/)_3X#'^WL0L?"T+-9XXAW\0E*/JDOJQ0
MKUCS2E(33LR^8>&.+;5Z0V_U#B3OA\JAB<VV9;/RXDF]3N%#K(G-E*;2RA]@
M\X#2>EQ&)I1JA$0Q*3*.TL_%QB%H&7&3!F +7XKL8(0&DX[M"<BZ49*-E;L/
M?C% &" QL6#@7F;H:#"\ .+:5[\UM'LZ!YMB4"$N)/Y3DO\H6%5%TB*6KMH!
M=L?29'2I1EH4MSJ4WA#Y5+9ISVK//<&N;]*>FK9\<S \S:N<R.!2C(65N1UX
M*@-0T#D04#+PZ!H)AR=S[[JM0[=!IM7>^8TX32%.*RFPU&NTB=.(TRIT@+(Y
MK:RBI':C=ZB<1M$?]4V,G58DA9[YY\FC@=VG36\\86Y G>?495]E!';LHKH?
M&3[[BN1SGJ*>'=L@;;W7("MD_PQ'K*8.JY5DA+3UYAF9(<1J53I R:Q6EA72
MTIO-@RVLI8#(3JR5L\.R5GBNVL<GPW8_B90UWWX&UGQF<$;CT7;L\(T,%R7Y
M73D1?Y'0#D;9D; &[O2U4JISUDM7:U(W!058D)BOU!*==W-?6;&50V$ZJM@Y
M9JXKA^E*GQ_::.H'?.M1R(5"+IF0"QN[D7\2=Q2XNKW[/\9X\N6"+!<EV5<Y
M,7[' F;XY@B[=K)GYG@33 B^<F]]SV2+IZT7$WNAG&"RAHX![A5@:*K;J2)A
M$4-7[0"[8NBRXDC=-EA7=;*N*)"TA0UV8(VXST>&^P1+VVZJ^,8( B:G"\7A
M))L%GX_8+ML*)?,'5^0JH%-5YU1JL \A@TY5L5,1XRB$##J5$J>B2 REDZ6?
M^^ ;%M-\9C+[&3O!!]3P3%U#7[TDEGB<P 6+QPKT33%$[2XAJ5WW>-;KK0.I
MA*%,%F*]4EBOK,J8LP,I&B;&(\8K@_%*&R':T)OMPVVX3@$.,FTV)Z0K]QE
MZ?E4#Z,"6U=3LL<T9+-=-Q6KZZTZ3:I1@/.(Y\H=H?$.EGN_^;)F,K[>[)X=
M!N\1ZU4*[LI?=Z59,'J]3@8,15V.H_[EUF<3P[8T]HJ=-9A(N/+"$?/)5E&
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MS?7<DVF//\UVGUD08CDTYBZLUS6=S%<22@0!@@#IJD0.! &" (D$(@>" $&
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M[7-?E.0$W$C%.T?.UD*A+;XI^O*@1PH.,4Z%#Y)^!,Z;[$*C8^S @X-QYU<
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M@2<@'!.*&#@BBH%%6Y:<(V71E'(IBB06#D >C2X;#2'&#EPOW8LSE0##R^E
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MR>P6^4'+" W->#(P@S._J74R$,9*-8N/ASI,IQ7$]1.\/>04/++=HAP=(!8
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M^_BI'%)V$+X$N7(-[NP:; ;5X-_\8/F#!X<'2'7DB$0AOT)[T(:M8/A21WQ
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M8_@S[OZP%"[O(@1Q.\:63(57F POA#(\X0N]FLY7!)6T?&^;0+R[,=5&J]?
MIR!!YNY$V%WPZ#"5A!]0=R?^#-Q+</$BZD=4(A$D2%8NC:D=8NU#(!M!Y6*T
MW<.R/\1XI](3,^J&EL.TE6AF/ ;?B..W1?H9H\)KWA[9"[N+0_31]/!D^+?"
M(]^HH7@U+\7Y^2H"XS/U)0&C$<%;0)D#UC7@Q>*)$AQ :H)Z0;YBJ6KY"B2?
M*JM@.1:)NVBU,MBES"[9K<>G!\U V7JI246\KQ+I<VPP83$)DC>00:9)G,A3
MIM,'RZ8U1,^-ERA[VF0ALQZ!LCE$Q;@J+M8R4/6>A$3,K*$C2ZA]N22Z$!4.
M& +XDPC*)()O30MY5C.!1Z;U4GXGQPU84E-C*%Q9U'*>A%H9KQAA6*64GRK%
MH%,*35JPP1DZ]U;]V%[&/Y<DYC)W"3(0=='P=D8FPF0U8=503+#YY8(0]QF>
M=J2>A" D$9@C-7S2'#5Y)TM33!VL5H]?-;%:,0Z]&! S\8 (MG*']]@ET"<>
M4$]^4\"5K-=:[59QE^ #>\*'&<HK4*BP)ZD>@[/[>23F48&X;HO!GUCTNP[#
MD1,(/'X)%CP?=5^@11XP'H '#H"6JM-1PU%J1,#A%-2(QT](?8%3_J8:!CBF
M<@BB:6[^(%18_$/_@AJ<9^X3M?W8< RYQ=QW0T]AH;!K(1)(6$5F]O@;5\,I
MQBNZZN-/$%\DJFZF4_! /)H..9--*_X"X6;4>V?> =&3O$DTJX;?(VJ3R;Z,
M#"9$N%[Z'$J*R^)V/( 8BZQZU"KJ<<F7QTRM\T!]3C%&C6H3U4;NP5)VC9D4
M.!(817$7EFM-2J[/624JZ%9;VT6J@VOJCD/IQ"Y,XD['E+,1(N^64G&@Y7&W
M>)B4:[L/:EP0JD,))^"IDOA\9,!+BJC#^NQETF]?,7**]U[V D?I,NK#0@8B
M&#_49W0<I23H9JE5T48K$1XCOF8T<K:@.UEONZD&M:H2U)5F HCJ>%SWK><Z
M;BAG(OBE60QKZEEY#/U@V'M.I>S)-I6RIRT<?XU 1H3,H<V!3W+6AA+6 _2#
M#\?&RRP=W*";<>"BB\LE'2BG*?4I40TN[WXK/_6 CSKJG7=6A7KJ9=CW2M5<
MQ:.1?>,-YWW/>R=O?]69&>T5!76-S8QJKD[TF3Z#@IP^]8W$5(IJX72V4?"D
MLMV.@M%R(+#' YP/]G1$FGQ%(UA*8[:M87MIOMI$IZ9PT_71Z7DNLNH*%5)2
MZ]3NO5('T"JEF;9[,54/3[8E67"C#;N3P;O.AJU'!FS?2QWI4\9P4^.4N>.<
MRCABX%-M1ETN&&I.C59<GG7:.^U6:JO(/<;@ X64,7""ID"B86<D@*24:C>G
M\)!4W6S_A"IF!]PA;GJ8YYW(]*Q%T9ZY!6N;9,,=,NPDPRT6?"&A\"CS8'H3
MGLY&.5?IP"<2I_G3M6LQ6RNJK@"[51%7M@[58KA^=;N\E_C,H_Z@(1:L/M==
M&:YGQSTP7.]HD.)TJ7@G9<BN&@@O8=*!429R@I_#\#CA@@#1?'E;#O\E[YD8
M:#U"P(BY^TC]"PI>0DWAC3J]U&"_A0<_MA8VGW:M^/*XEUD13U><8^F8!,?V
M \$PUK851R/QK$6K_:U[US7^=GEY2POEP5TF@7W"E8G'X<+'MNE)TE'@:RXK
M)J+R[H?0FL3!V=74(I2XI-BP4(]:<[ZQXQ":A$Q'J<2D$@"%A$HO!9&!<D5,
MDC(""/(/$Q[E+>5/N8Q?KGX25\TG?C4S)\#&2N@\3[JLL/-3,\'61:K(T;H<
M<T4=7%YI2 J4R<E*2[^_^V"U?EF3U?[O__D+1T/'PK87F$)V'JAU!/\M;\Q-
M);R&$8TTH >H#@JR6=\9":-V!P.*GW TQK$*"Q\^5G]%7R7>]Y>_XBM$IK5F
MAUN$=@^VX:-K3>1UDY3%B:KI42#VBFDKDQ,(*.T8_H!,T#JC;\<IG*]@DES[
M,Q:<-:DK[KXW\%V.E&\CE=C.8<AZ3/([,7="S]!D16[@ ;8%_N/A?_ $)57X
MV ;S#%VK8(;T^1F10MK$AQCI:TRW^XUC?#&]\:P!Y4)2#YYW-!M2!Z>%^TDE
M^D5X#S2#2HZ/MEW*:4IER=^F^];(#)46S@R.",+9P@^80>,*1W.!9IVLD2'D
MV]@X6H1 *)R%G/Y1HOHG7$P]EX9LZ2-"N(DLKGK_X_K6QK2&O=)O=A\/%DHK
MW.'W_KGLQHS__GXGG'GHZ0W$Z?OG=0*GNB&/3J)VR-,-C<!GO6ZV$YBW%QC)
MIC'5:.:L()4L&8@&55'[KHLPE<1';\RW?"^3$=/4L!:T+W%JRD\JQ05_;@.-
M)1*>?^]><FQ70JR"5<B1Y&82MW^RB;C<2/%F),E4$JM]I!Z(3V@J"S_X1 <*
MVQ1E>5LSB76RD5C)8L+\JF>M;.[->F)2)P_3AG%$;LF/H.I:_U;*CYMI]?S%
MKU2DFSE+M..S3F]XT1GV3S*D4Z12*-O.9JP/)!Z1A8EP%X[\L6>-Q.1]&,!2
MZ48I2ESZ-\Y>*3 \&70NS@9K7Q^9OF/(,=AFL$K:$)QJ>KVWV&6@RMRK>'DX
M,=_!A?TN'Y 'Y[")!OUN_S1+@*@>\JWQ!@\+GI)![YWJ8--$!WW3?_>V:UPK
MV<T!,S5+7!ZWG)]VC#N7_"%7FWJ7[$F(*C6Q<BLA]==L0XSA<3.]43=6$JV*
M;=@!3./D/!\I(T]"::=1+X!.&#.''6'<DTEZFRK9;H"5S-:M<:EF [&RC_J&
ML(Z+P_9^./I=:(,S%>H)0X&;LM@+6-]*-7)1+(]F#TWDV$@^I^S*L1F@+&@>
MS;"]A8$1.UA\XM2K5'T:Y: L@?A,$V)POM&:I6Q(-,5R'+T>VZ=)ZS;1%&MB
MC>ACU$6E8K)P6Q!(KH-8%@E+V*R7U-]XZ)_K+0DBX8M:%A/_[NKS?T<?,>I0
MS5MSO'EGE'- 98V4EQD)FD9*)X8G'<=P;YXO)R\^FC;3&P_P!QQV=:E%LM](
MK??UPZ72<GRU/"/1N"8^.13HOG9=EM!\MQB6EVZHJ=)K[:8\FRGJ18EFCN2_
MS1J.4H#^$FHI&M>;7+#?X1I@5-<^.%K]R-&JF>T>12C*9+GOZ,>,9^)&OY'\
MK&1I49PE5^W9.D-2PH'=N^\%=DN"$;T$1UKZK^*?:(P6\RH.F<;]7B&)/ [G
MU ;[*)(\GSZF'>/-X*4Q^OV3VS+ZX=/XI&Q&'[XX1I\!.U2\#05VX:6S>BU4
M+IG9*0AZ_-(8_MI5UU:G7UN&KX'*9^4*]S:^\YQ>5L>X#!]"/V"RG^6E'M?C
MA.WP<*K>I7X]&K\<ERRID$TZU$/1&!Y00QY@)\Z*J1"/'\[G4;557JB0?=P1
MN)/PYR1"MI)50PKM$@X-HES-74\D8#/CRU17J<3?\>:^? 20P7F 6_"P8+I;
M-/UX+,0D#2A.O!S KTP?8^A,YDVPKW2C:\^=?[ ('2L(/7$S5:TC(I-9.?_>
M.U/B(_J[&>&*4EDJE094WG^40_40G%7*#4YLJT">"B;0P&X*6\'O;$N$\&,M
M$J %02M*^^RZ/56D?4K=HVVRC504^808(1&*")P>PA=9MYEII)'\F''L]<(I
ME(OBP!)A1L7/'@FM?F+CP\DB\ 0>:*$E5V>"IU4*8 /WJ< 2273P1&"9=(,?
M@Y6!W"D2>;<U_/B\[%L)(J*2[%NY?*A!FR0J9B4>&'>2X]3-L8UCUZ9:'6\A
M.7U)D^$F6@?>%5<Y7CJ3KZXC2Q[7T__2_R:HCG420=C+#V@X9:GBN=<]KE$Z
M<S>B%MPM8&&44C6/$AZLP0H,FBCAR$-T<?/UGI%N:Z!N3=)/LCQ/LTLKLT?S
M,WRD$:)1["L2]EQ4+]ME64U8#V09?I0XM*1QOHF'..?QC>'68^LV&EZL+$,]
M*Q+=)[H^JB]()VFSEY:3([6F:LHS$[]_7H5T<'%X= 6[6Q8@2LKER"^]W*B2
M]4H,-A"Y:.J.-^3>12D/:AI_=S-556CY,1<Y?Z+^$HW<>2=E[EE4\*%7=4B/
M+6D^$HH+3F88"1'UJA..GJG-*U@:J6X6]:ND*PK4 $?/8N2TY/%$+"(^,!U#
M->V0C1CYG@32AF[FW%XR7O.3AXUT:#=,>:!":NG)FEMT*$%\_ZX XB,D:SE!
M7&!;HG)L]'FX)!T=O;9WE;#"P;G8"<$=0+!,ZC?AN1C\K(X.'EB78EX]C9N+
M"+F@\%^(3 #V&I^:+^;RO5 "+Z<:.)K- G\/MSPGZ8DG0)*)N?SEKZ>]-"[
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MIM^VN#1(HS>0089MBTN5K/LB"KE?PSNVK-&R1LL:+6NT+2YMBTM3O-"VQ>4
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M HQ9[(<&PJ^$"%H$IEYX^36#90Y1:Z>M\U7@!Y&W%4T&U(8%"8,\4F!,.0X
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MUKG=(0 9.:*5[0\?E6HC661:>>+1\N4LDD0GF6H,RV#U4"43%]5RYBB)::M
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M<FIJ9#V>4O*.&M 1+O#;S:<?4:+4654G$TD\@ONCNU H#"Q+MKY%V*O?A(3
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M+QQ(EV1F["=&X?K=+>;]%FZMK6O>;[G=MMD.XW71UKO '?^0/68?_QV"[L,
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MM:P#M,VPV^-Z,:OB?'-RISF(Q:GG;I&V3R+_>QQLF+!QL;OJ@8K:WB_C2^0
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M?L(PL\,TGNT/@P(&KC[$9#R_@(W'AN.0_QWH,:[" NV&.C3P>DDUJ^"]8YA
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M(,]0'E3E->4@IE%PY._X!*K)1YG<6Q&1W4]NN8M3!VH#IYO8M@(6Y3A%MXU
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MX=F.VRZJ67NK$@*.KX1F#"P9//1F977E1+%RU]GMCEFJCT//"LO+&+;_5&(
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M#G"$S]M;54'[@D?"Z\[@YKX3UEK%=I'5.AA$=>^G]N34=UEY@2 5"!G#K([
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M'!EQ1<5MZVMSU2]3^8_%R4^%2ML54< ,UR6"W%L:O&_+ )<DJRKB5@F6V=F
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MGN%5X3]74967Q44 >,$@5++7D>J#,)QPOG:D>CLC@E@DJ7(6 P%C$JR '*H
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MMGAP?!*&2S%/).*>TAY8*R,(DB-+O[/A&.'G%HKWRS<$VEDU_%(C[!?;I1D
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M57S %HW/P>W2OO,N*EUGS)O:^O*<;>56R6I[Y%&;,MTWV?TD;9E\1B2.+%T
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M(B PV>*J)J,O_;\GT]#M*-]#YR._))1S"\R"&2? QO-T25:&NT%P TI-6?"
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MQ2(@6%/=*<=HE>W.A0:[XRX(4&4V.;J:^?8K,!"NRP,'_7[R($#Q@)"XM:X
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M9!H;RX!"[":+))4QELV! $;?ECZHNM@:'%9-PI_^C)I"%34LI_P8J]#Z+"Z
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M=EK#R^(#7R?--2B+P^WVMF3.S2J#UEFO^"SBB8P%-%5BWWM3YB@?#2+=DR
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M>=BB@%-? Q70@BU(._U!SEC&=GHF/P1M-1=*]5-52XE"NGF;I6X%>I2BSFP
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M\^SL/-(_L9$2<%)+T:[&B[^P*QD#U7AL,E>FDS:?+=>8CJ\Y&"2^8/S?:RM
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MT!( ]<Q!!1B!8!HSPQ.R , @=+'<1Q):(?L8+_# +P81EANUC $Z,&;X#FQ
MU<%.")B04"-MWR7(@F%A&FP"*SJV_SRU?8^V4SI&] <'L+@CT$'59X9EN)YH
MP\;G?B8ON?0=H*.15VWJ,<.$O6DF&"(OC">OX+7$J8,IO]S<W5\^?!LIGT%Q
MU::&AO#_]?'^BP+LPL0)NSZ> ?##*G_/5Q>C W7.KU%L&OZ83Q<FQANU&.D@
M,>%]@OVI/.,M3DP5F]C##:NZ;WK ?;@IJOS:?00FY#+&ZUX'RZP&]F!9B$_Y
MP("UP$89+GU5X"V9P"'+ =R"IP5T"=BID[,'ME0ZP*@\=R! ];G?XZ&:&;'
M-[#I@#A=&R[0M77#GRESL)"!D0(87JB.RE6>F4FT?@\?9,JPPPFW$W^?@L*^
MJ0;6K(JV$H,C$^,%00(W8P,K<(#]T;VPN:'[B"R&]1NWV+@C "]/,?W9V'95
M#=]W5-W08&5^E1W ,,4%T".'+Q]4H?0ED D^)R '#P[>O?Q^<?GO42@MD854
M<VO#X-;R^?-1]_ O%0-B&#)\L9T54LH$!05KK,1M50>:PP TA]TC!9&Y],?
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M6'--0'*COM)94WN'/_JG/Q# /^) '%DZ@C"$X'<V VWZ\?SFW^%+HS?#_?'
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MQ\Q\^J3-\.I^; Q-GS8QMDX#XSZK7XIAUPV Z&YR#GLV<-XF!>"_JV^(<=^
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M3+"8&]$C,JMD9(=:W^"T; NI *(D%4',?0B+.F(UJV0%)6VHL(LX3Q*ADK'
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M+VSW!:H8IYKOZN(;"SA*1C6KH WR?0[Y[PFD/G"9]C.<55<7G_Y^W$NG.![
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MW[S"K&-V@R/-KL,GD(;RP%Q#!\TN:])Y*L5CQRK/4;?B1K,I6RB\>>&J9GJ
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MD9J\M#7.4J?J"_(YP%+,NF(3'YLCO@"X088\,XLY*N8XAMH+UN\"!!T5MWJ
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MN\G#?N>X?R*-0ZG\?9PS2GR0^"#Q0>+#QET=,QJ%X<&G>+"P55A^9["&MB[
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MR!VG*Q,"4K9MZ3!*8D"?W[(?0?7R7!4D!UW8CVG:KZ[RV;! ,;4YXOENJ><
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M1[@7N0AP]RY-3T\!'_= \V6S$E &(A?M6>QFIQ+&\.BW58X.]'^H'KR)HO1
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M8#'^,[>7@T\LP<DFG*!C8D,4V C;BJBZ);#AD8X]M27#(VA,S6_V-)K&77-
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M[%WBB'OV3V&5#]R'770MK4D])J'[<8FI:EC4DNUFJ*9-.<7D"F38,5O+E%1
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MVU3-.,,1D_#+6>3//+VB4=TJ"N3<8ILY'Q>G+J8JQT 4OIDLG*07TKI^>$'
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M@C4+'RP@WWLV';B?)/>*50S5W)]S:,OQG@ZQ[8\C5GWB/+O2LN\IE9HL/B"
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M]0R9N2VC96DUJS@(A:U8</PD_4Q!4? @L&4_S@\HGRHX!XFR?G8+]2Q$/?F
M0,L^I9 7VRUC/])&XZJP6>HM]DZG^A").T\C4%L$>P5TQP5Y8PW.U7'8.PAW
M_?;9KJ-=&N'6 ;=5+$(&MIG4F1/L2COQL':'QMR ><B!)<'E;'&NQ@Z7O-;A
M [T:AUZ\=P-R@IZV,O$_V?\ DPCB,!_N[!2^P/P>]E5M@.ZR-OH6TK%WP9_:
M[7SI#-#M=?KE.MYE5,QT.*D 0.QOI:/DD^3?6,*^Q,#I1S>T:[?HN^5UI]OP
MJL9!8SG"2N6:80=S]@0Q':?H>_2LA;?37Y%;"[[SGHQH)G.:S/M['_8OW$<5
MYV6(L$;ZFM- ;0MMU')AG7D^A!Q"?N?>_!>'M>_7Z[_#K4TI'C',U%]G^4QV
M-<V:G9C+B^$+F<P21I1-#'_74TNEI7M,U;PI=0>51*GO*+TF*?V*%<9,S]P]
MX,K*5;? D6"_OB!'KM/(KW?4ZG9/6L>=+5J]R_31!"U$J!Y4*N"+T;&X(^Y^
MJ0XW:NG!U035B PY):1TY[TX6>VG_DHU$Q9LK;!<T =BW<(.LJK$!F.D&<MO
M/Z.DW/*2I<6\](+$A[<;='I<F4ZWJ([LD7-OV7/O[LBY5\>GTQ>+995'3W/@
MU,0B7BP6L4.F^M&+>:CW"+'6#4?LT'GW=P::MA"16!WB4@I6_+#Y^2:E6+NY
M/)*YU'KIN?=WPI^7A90-FVU52M:R>CW"NUT;I%^8%;?U&2!STQBVV>1.IDQL
M0K>M-POC-<4&[U*]$L?"QO+H_1*J96*/78I7$^VS; YE3\N;[7WIG;X$#O1?
M,-8!Q/])C'RL,661AO'Q2$ZDUGQ8:7<!(6K1;T,3J[:^'_+9\;3KS@L6E($X
ML80<$X.D@C1C''/$;+_H0\_'OI"#0*XFOPK+CJ:Q?E$-6$#]OW*O_.$$EJ=X
MY^[)NWOPH@"TPJ%KW3W8L5*/!54\(NGU $XL8G+H(4M47,\0IN_8I'^8J8OZ
M'=*X&TUE?4WE%7>0TUM!56O@U722TSK)G36=Y)I.<HLZR6WXEBNT>%O0O:U.
MRZP:RZ\_041V*<'^0Q%[C&+A25[Q.+@G)6>Z4+- 0F[)+=8J?A O4D\NE5V.
MK$UT$:$0T1^>_Q7N(2=\W A*D*#8]GYD^A^=OER4&LZ'>ML83[R)\:P$7]O&
MUIZI\NF\R!NATH#*6Q[L'E& ;'PY]1T37/QXVX(2UT!K#R,SY-[Y)/*67$P!
M.VGC=U^PM)HZX8&,NF>9/('-,PX"(=C6/WVCY$19B*2BF*#1Y$'(@\CW@ZB6
MESZ[6'HT:*3/RTJ?A"AJ'$W>;:3'%J6'UJ1A!UG\^.5H0;:CG2L_=BC.MIL>
MG)SWH:CV;\,'^JNIVI/VBEJZIGJKX1?O;2P" ,XW<5)ZNKU:<OK]-_D.I.E?
MIAI8!@%@JL7SW2;Q_9)VI.@C 6!Q;'.$+4-MV3S3&SF2^E0:[M#TK4?3_VK0
M)%A< F%5ILMXTEY(EDS"1^3$3O)T^#52M91L5,<3PXT0N7PBX&N+[UIX"ZIW
M@/7* TS-R)@K8# VD86CP9=N3RFS\=\+X>@]=BP609 =AIL)5SS![S"$D4Y0
MTF^$:1A  E-<W-WS3,[,U6#I,!#CGZS(!U%O!<+]X>< V[,;S\+T@WDS0=;W
MM<?)A9:L\HOGO"-Q8.V65LHE2[BH[ :4$-!%)%ENOJAK":U"I</>P#)O0Q(;
M<>U6D7W[HD10VVRO7ONXM"E(G2<QIV1KK3YM"_QIV<&KTAW7HL;EU*T^&*,*
MJ6?K%F+)_K4C6CZ):R.TN4YZ;%GKWB:S:\_BI2LJF*<E"F91[*C>""O^'0\.
MR--9CZFU^Z$9;H_SER/[&!]5)5S2C+XH3+M)A?YXC_7YHLX=L538,&H4J^\T
M$R!EHV>:)6.0T[='4:@2\F]!N0TF$LQ!.%WHM6[:C )M DP)Z22S"W0CH94:
M!,$0=V!+N1LKV\$#V@)CM3B1[0N*WZJ:XP.M<7ZVR@2G!PC$4ILF@[Q)=9]P
M/%#@M2D#23<*V6=?ZSB16T!N8\,'$]N%3?'.NK0W23FPIV#@V-P19>;;6&C*
M-QP['LT6D;6J2F7#!XULERV-U+B=N*V%-L/58!^4W'%LTRJOUJ_13_*-/FZ
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M76HFL>#.DD3XGX>:P@#<C?_W)GN)TC8TTI/?R/8 U LAY<F*)>1G8#/9Y(F
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M'-6D]Z_V+2@K,P_L*/@OI:X&=&=F)>&.!?^;U!.Z.__$B4=U\_<XP=RW9=A
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M(; ])1IELN7!/$53Q20S/MR4@L*#.J1FU])T0Z6DR!/C [@G+X<\N:GL2KI
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M$9V=G9P.WH;37J\W..UWK.X78OX7<EG=BEE(.8SUV%T-?&P,/M8\J:,&0BI
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M/)#YSNRNE+/'*!2YH4EH1R4EX0MG+G[^Q?ADNR8R^Z<(N_BUC,OV]3*@T.0
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MY4^_]P*GW\N=_D??7;$,\;_,Z>R=\2\@@WLP'*]7H)AB0Q5)I=W02HI6^B]
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MI!^><('*14N!RK^>W>E@@X4?RRA\_7]02P,$%     @ HX4L5MHL5S4U\P
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M,V_:)APX;1N&"4T#0#S6E7B[.1_!\/%^;=;T<4Q-81"V\V&?[R.NB;:/8YL
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M5-M@7[3!JL??1>ND*Q=+)24::E*LY(C^+(T%>=RK.78+J <<?QP<EE&FAU9
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M<IL,80O59%2!!3<&)Q-1(IRM*#DK05%9G4K;V8J7PULV[8J>+7';"\U(H>#
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MP'>5V<R691?(B235R[JXB]689$DLUZLPF0",;>VI#=<I,(E$"-.A^%XT61>
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MVUZ!*Y;#KI3I45+!['I3%^'S:(QK]W*^85T.QG0XF^OVM!S62$= K.S'E $
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M[6YV\1/2SK\7VFR5.^.#TW'_E8P*__\WHX;G02-I[UWUWM0\^,-)_D]0[4C
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M8S:WJ"=#&]8M?,E0NT<>LO?DJX]<QJRFGC[K9QO[^TV_/G76VELV9'[Q)^;
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MDNKXJU0[W,9$OFM?6XLNXKEX$77_<9W&E/-RG?<VQRYY%';29@%T^1U$[.(
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M<9B\N^.9;S3;,C-2[DIK8"6,Z->CB3+\:+!*U1S9JI:KJGON:M(]?&ERE6J
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MPN^J_7J)/Q2-GIT8)V^E-?.V"5!O%2WP8]08CTSYDGYT9HWOOS^-?E\.EQ+
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M3<L'BC'O4<J:Q"!,CO#^,'\8\DVVH&*5&6VT*.VE,@D:)DZ&6@&L% Z'='!
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MN.@>O3+W08/>BARP.3> ?WST.;V-W3YL^G%B^D\X0_@<551OITW+G@ 9X4^
M^[09K!Z=K)FV.]C,VQ1G]$V"LW!_ 4_A)T"6\(Z+R3L8:7;X-.PA&,S.-\.@
M YDXFP;=5/U1MN\\;--V"M#Z64;:J(.Z>&&6@F45DLXDQY._[*U@>-&79N)E
MQ_7E\X0M2UR/0B"I]K*#$>?2%#.XRF8TQNI>,H4G3[F/,#/H$UCY5VL.$4GG
M1#,'I^!WVV3<L$B]3A)'J^K9T]+Q.9PJV^>>*7557^K,X;E5K7[--/0C_0AN
MI='KLBJNJJDEKS+%MGQ0"I>"<L2(P)O1M,XH,L5QSF6U>Q,Y&<:((C+"\@T#
MCN2WPH+NOH+.KN2ME ;>/%-.J8_67M[4D@1S283=?M#&78(.[)9@J$_4?%P3
MEW+!MJ^[^1E(*\\P33>,3Z/M8]+W4#P8$<J(A=\$?2Q->,?PA>\^I=6S"LP3
M^@ZEY.\]VOR?V7>?O9&L/NQ<1FQ1A9D6M(V6I..@U@"?T6*RL^OV,#\!,&BN
MUCI>J=OG.8W7Q!Q%>/#OW4%O6MIO[,.-VB0,HO4T9NTH5'\?%HGJV0AP.\]9
M 7M'A"&]W[B?YG*P)W%E'F43X19VH<4+LDL/&18-I-34491T=E(Z:2R-B'WW
M.CL%C]7+\/RDZ582>PF]0:<S(T*B,..K9ZJGH3NEU<$K34\0J&8%!<I5>5G/
M[E)X*'V=0_[$GK^QPIN4]T]C@-=)PAVE9V\C*^%/</*O&PA :FW(^#*MS'RH
M[)>^):WT>9[21&NJ;I]ZYR!=PR<]M2)+BW6"$<A7L/!#<#P$IU<P%%O)$8^+
MFCO ^W[-8KO\].(S*@Q=@;$V89&B<"V?+6Q""WY'(;1,XD2 0;)7A+$NW%_7
M(YX5L/R=K:Y[\BC8GY?ZB+'^CO (J3$R-/IB*O2$!%-GXWQ]%44I(V[J8(%=
M*TEPA\ILN5FSD828N8.?"'X-6J$!;"(:7&GA9-_3]\6HM"D>V3JE</67N2B?
MY[KQ&8-T3?\5L);/373LJ=5)](\O==5P5B=./.MZ"#!-0_3\?3Q=UMGK&UY.
M^O<2;NS7?>=R"_-O:J\;TT\8 S^!MC (#/'^O7@38QWMW^P>\N12[*YQ<.[H
M@//4BDT%7LQ?6?-:*&OS:O=QQ!<VSD@V4E,91DF*QAUZ^$^,\H##ETX8/SX!
M2G[3R$5>]F'Q+X"P<+UEEIE.>W$KIN#*(E1J5=K"X*RL-;47:]O(-J=;&JQ\
M3A[._ZIY[C86P"1CPC:FV OKNRY='?AH+DE:7E$N04OBW7VWN]W74?\1A(?I
MVL1.A/J!4Q/0BA8:='?WYEX?\<P$Z?#4VE:)E@QSQI/6\G7\H F\G.AM//0H
M=K,=Q"W]R<?)$V#M3[*P!/[K5P71OX!U TS/C#0M%$>K6#KM)1.F<3-(^O1M
M]Q/^"^)Z/62(J%KS@?)V#T/2'W5:>Y;QXC@-C5A4)E"E,7\Q4,1-V[>_B#M\
M%N=)</^,Z+_-RF-B>/84IW"^R+RBA0TUVPIC;;:;JS(ZPT L9[VHS?V6317K
MKS/V$%DNDFP.ZOB7M1;D&6^_Q)3^#M<3W S\*:W5@.*_R?HQ:(L=#0T0$85Q
M*%K(O5^6M<,.SW,_X^'L\["^<[$H\B\BC=Y*76BJF1GFH?+9IUC:?DAYUI;[
MSG0_5N?Z=:^?P#UY^S*%$QYH1#QE]PF IU9O_P08JDW^[[*8WMX_+Z97YJ'C
M*2U-QB/0G^!C$M+WNINRF%%@!8.%Z]\IE;K.C2E(+X"T*BHIU35+UT12<[/J
M?PKCU;D6>F;G5XT('@V=:0+P(3AS9GB> $HCY-AK]?E=QAI]7[(XAW5M3HV[
M46>Z18O[+),7MC%Z;L#65D5&\6T,AQV7-4=6D<C@,!:[\B7* GKZA-S<^!-A
M[+$9\=P+E4+RM+@A R>&MVF3-R,&#8_@A2]J%;FX34NTTKEU"X?R2LHCB9J\
M@Z@R%F-:T4(ZI*/]R@+LG(N;Z\(_S!LA+OM^;:O_'Y9.,D9\1.8K();] VVR
M;9D("FP'^NFXPI]-)QGGMI3UQH$)_&O=&D6=Z 74T**!I7R%GT<R_T;/"D+@
M0V2A[ U3OF+"S],:;)-X^("+@#M!E<*]4P[]E_$_89"7ZW!S"*B_:QDU#RDJ
M:%Z.)[9P$?@"H_SNMY,YY'[N^LD79L5-BK6%)Q3<^V:<,\GL]5\G*7]5X*45
MU0ZDRNU-H@F#.D6WR]B\?AM6FY2>9+'T;Z]-0P&5;/5%5%9OM_3)*,UL.'<3
M[Y[6F:/^KB&P[O_LV,ENYJ9.K"2Q>Z<R6J@$O%CP=8?G0H?\Z6BGP)&3 6EI
M(=XU5Z<)[D!=Y]O\1*Y%$T^[5K65ACH*$VN0I)2J4WUE:4I&07A==LI D$%R
MB8MA1XJ,9;@]2:6R]!B2O;+TJ>+($R#.:'S;HM,9VBH1>\^Q4GL%-T9.>5*^
MG]3+5^X LC5#8O'2C)A'=*!D7$2K2H0/\_ITR3N)/;$:VF3W8NGA:Y4K^=P6
M:FO^*8+3=55/F.B,"X,9/F^=3B[<UX.7ZK<M/%+&QS)50U1><H=MZ*YC08V'
MFP<DO0E[Y^W5+9^E!%3SS"R7H6O=/C$4XLVLCV(S88 66W)<_Y!Q?D"7VLX^
MROCU0KCQ7ATL1KS7E%@=B:]9-O%F_-*7]D$[_7<(+CJAO*9=(!?[RVCPH-.M
M[KSV=[+,HHGJ6AN(!=Z.Q"GXO1.3<,S0TD/M<5O.)9S@>=><(TO+.DG=)E4U
M\G47*G5>K4K[V&D@4_N[!H.0 WP.H05E*PO*I0$J^@0UZ@RL];\&)>WQWUY9
M7C?K-FD<J7F(J@MWYX3AU523)(7;+TO>M"?92$Y+@_- #)X\NV;KM=3AJBH\
M5L>0DG0V!YZXTJ5!I^-^LH5Z(86&G$H:L@3)PIBDC90DHP0LL*>-!VA>D^.C
M58:>U&[@'X;G*FEV 97T6[57EUAX[VDLO%3OM_ BN&KAD30^%OV/XT4\DFYF
MQ\_,0S#!NPPX/M>,8GD&HZ/$4]:=P:I/W]3@(?EMQ?&0W71U*7=NSDHS;PG$
MBC.R24GRZ6R4C*45FE05E^EP<I3W]-"NSBE#W<A;J[+E\*_ID:G?H67P@0F(
MQQ#!7M\^1]WTR2J\+*5DK,XQJ]#(6FM2D48SD;;!891&\VK39V7#+1K93!X)
M"5D="8D3"0F_@9@"F>C6YWUA=?5 86$1!'5A44IAL96RLO+:+[\@8\V$Q=HZ
MN@8;B^7IS8>KF@8ZC_F5%0^-JYHRG^/-.H:K^5;QQ7N' H?F7LY,/L/]DK'#
MDVW+^--6=,74S<.;IFT+L.4-3^JF!7APT/K]JPO/BEHU\/-%W04TPM%2D@ :
MI7!:7$A,>!BE:RH%:@,UG[.XUXO;SZ@0TV^WQ;;W*%4;#N25G3A2QW-DK+?/
MB=[_3 T0WVVD%?E+V!+-G:>T2;=!X1389^0SJ(V_YX*O?(2[*SK,^YM[I->E
MMSS2JF".'4LJMN"HWT*Q14WS'-*T2MI5 W1ARGW$; Y(6^7@7;Q<UF__6CF]
M^B/1],*)?7^,N^27T_T1D\V#Y1=EZ*%VT9@64#30-M4!,69<BP:76:GH2L7'
M0D&HX%!;"XL9)D[_!$,3UHUR+ZCK^R"] -K7S"A8IFF,(29P^O2<V%BEZHZ>
MBUHT12J>FISW)?%=!!@:'8>?!N604"P5K _18)(EA$2U2TB;4!:U*;\?!TU:
M]A.+IW(%BEPK\!N^E2L&(ELQI$1&Z%/V"IA^3J;@;SY=!\(34"#@MZ6"4NUK
MUN6,;Y(DV*B1[\$!-4#_,'@OBRQC>M8JD&\+Z."=WKHXM-8K+ ?7?I!N47;H
M2T5FF3%$ =HP8J3C::'V1&#7X,&5C/&')6UF9V]&"RLDA6O 8NTKS9%U6XES
M+0MRI.GY44=.;"6EI>)+3<)H&!82C]P96K0N):XDK7N/^^>"EJZ6!@X>'K?>
ME1,C.SMR12>P<.6D!#*H!]Q-'.N2U='KE)],+@7Q8<"$07M #_MX:,+0+U&"
MO>I-SU= ;;O5YS=FK]@0!9W KS0EB/U1AB38[R0X^0W!X,%D+RR?3DO\)T!X
M (,JB2X#J7@'YH)L6BU_F 1F/ZXH/H40%4R0> *BWNR+P82UAAV*Z.VN?>DS
M:#GT[(T8SW+0)4*GW[:,)J=J7F!JU+ TTGJK<C;G0'A<CT@<F$ZQ9JV1B?*S
M;E1,%SGEV]F.BXUII J2)KJYMU%IT';%H_G!C%'Q;,WKO=$2MV$> ?+EJ\-<
MG"QW+#):][G(EHG8V+.\2[F9J,S&)ZZ<9IY8]G"P]=@:AJ=LE6^&]'O51VN5
M*H6PO3!N6K[VBZ0P<K(+T,0.D!6T&7R$!T:'!$(20#9Z+M[W)S17:MSOXX\1
M5+.*#-*,;AV/I52Y"U^^A:H:]%/SG[<M+20I"4T+8&:&4G'!'6'BC6"*IHYP
M$R;H1[%=^R[_52K1&!>+@=YL9_2[T[PD)?A(IT( V_\=@>P8 C(+;@"?? [H
MX$0 ]:,90G( 0=\FL]ZG"(X4(/!07N%=]SCE@5 %YEEQBIB=O8*Q""=&-+<[
M)Y(\W\6N#-DHLI92"AF^&E(N"?BLY:3UW,_2UD]T&?\UP\S;$_DT=#8TZ^/A
M%%SU,SH=B.J#C7 M;&;7##4HZH_& X:PVA#KHPHG)S^> .YN;O(LC:*&GLY-
MQY CY8+)2#1,E)--=D+M\YQ0C(_$K\0RLDUL=/(UF2+JS1P=##H03%+C5X8_
MD=.++&%XK;V,"V[?N'-RH,!OJV+!%P/U'J\.VW=@4MT76]=$Q7W3S3\GG#2V
MJ2+^\%5>O&)F:\7R6K&>4K(YC)?#T@+CTE*')B09\^-P%>PJ.CTV)&3;/:?]
MVL:HWX<-,XP5M]T66;_JVLT-R_KI60>#D*BHO+ \.GP=.VLN6$EU;D*@X7"7
M.J90_3M,(=ROSF#U.FP4SEA2$7*N*(;AOE0DU+1JOMZ<9EY.B$<T2N1LMRM8
MA9D84]$LNRMZ9#WR-16;%K!]#LZ 9OT[ JP&:T*PGEJP1,B9Z3T'(;E6NOWG
M/$TH;80*9WHMK<'NSN[^.(-RUS.D[(GN@'3>C-G7I?KO>L6*!P :]+? W/"(
M%$MQ+,GAC.*$.=9%&<-CKB+D?7C:0NJWH&CY%TPG&8:_O&;%I&QK-%7C2\TK
MCAX:LZ*P$+&<N9Y^*7:)LQBC7A&\?A*-*[[^5BWS7KEOTL%?4;DWX\BLD!>S
M]3M48CQGR1CL'\[Z ;4_F%\/[@,S8,]N:F[>1\(S6]-)2Q%\Z>+5$B0:T7_?
M "I_\ZH\\F52A#<T;4\O++'DCN*[ 5T584<06O_PF1X^8B$7BWT%[,#'S>ZC
M;QF9UV48RH^JCT%.JNKP38P*39KV-GNAF8>3C]0HPP1Q*S]Z\![NGP";%Q2C
M2RYCZV/_N^8UY+0)<@54:<_WMWMNG-.CJK.$JL&B0:ACS"-$X(H")E/UZE1)
M0T:H)@HH]:CV6BIC,L/1=O$)SOHOR:A]%4+"T*[C/J=G/C6Q3P#-R&EL@1LZ
MCH<,?-ZVX>J@/5T'79Z%3^I:8 W\<(P(S_2S'UOC(QP$R=+9%6Z[,1F8;_-*
M%=-6)T\K%6$GPV0KPL)=';L^+^C9+&?[7<F>@E;Z)NVH3=I3C"Z/]]G2/R%,
M+N0%<T[TA0F[[.*UG"$[+"\*!JTENHD90H"L6@C%6$FI0"NDTT.Z[_0;U_G5
MH6.38%N-><@U,RC*?!%@I@VPB)%F"U(HD'.;XQ7C.:M&^>DTJM8YSR/:9C5&
M@W#5>IQ$/'')XG@M)6CKNK7"4/0%>X?\.[<LOQG[3D5]:'!GT 1SDI[IOC>V
M9@<$W,95R^<%;* 8(J.D*ZNN)*[H$)L<(/O_FR;8K)];I?_%^GS:GOGSES95
M;,N%$8+$/4:]K=[17JM1TO'>=\T+8A)SG1EZ-#KT1CCYZ7&C=Q6MKO-/@!7S
M_?!A:^<[T,@:6T\E#&?.9XG9FPV)^1L>8@I3-E7-:HVB&#OB@N\Z<?#XK?JT
M? :Y%1I[UC6(VCJ\W\?>[62B\OG)XU]?UGTJGG#0S&G&!HI,YWU=F3T*T1%<
M8#B=6#F=L;_2">#ELCX+R) [TFDD")XY8DP\)*A806WUK=79S&O;S'.Z-NA,
M..(T_??XFI?CGNR$G@D6-VH<!RW521L>-Z6H5ULOP"8TRIS40,N^E3=1_82B
M!(N]\V[2=HWTX.ZTAJ>T$Q^WSJW3-=#]X?L]L,W-O]E;>.@AXOKK.5SE$X".
M[_F/I^S7,>(_A[39_B<,L%M'7*,)]I4F0"7+8:<AZE1O\'X !X&[%JH-AW$7
MN>T;$WMC(>2$V-!4>1[W;3MIR^Y*@'OE'4^ ,KIEV['E-D?6)\#BWE62U!6^
M<CWO>BR-)HVI5Z*']G1+F>G$LM3\Y6;-P4/F2<U/R9!_2'[X-U#_GT#@6N0:
M0[!]";(WAX2E:G%B8ZWHH"NX&UGA1W$6S +L023934V,/&]KV/' RMHS=;V!
MS\0M,STS)X!2MJS'L.AE$R I(@(CJL4LHQ10(:ET5G.0 4,^1^O02:-SM4!K
M7W,R,/-PV5)F?EH]$)&@2KP52C*%QD9-$R_OF>\=,\$VE)MG$:VQU8ZB%5J"
M&UV#AK$M*AW7KSIT%_)K'^?CS5C#[0#:H8>2,DAFZ[P 1;/A >J/AA KS@3J
M:)&,T7QZC6HPUXR!9$]S?TTW_<]V"HJ9K 1WW<Q0$Y=[/S]-:\0$VO7PK2:,
MC+[A;[$IY<"&7<0I/H_O\)UY;AM)+16&:GR3W%>EG^V>OW\PX7]^G4MQ7@Z=
MYEZN5WI15_-.11<8:#0__D? +)TYTU)5US!8@44OM#CET8]V<M.L^:/W1*'I
MEP7*GII<J!+9K=-PR!WG43BC[_@0>(QT(?D$(&>#L?_^LXO5Z)?]#;]\Q11F
M"N0MMB^H4/@;CO^XG*#OF;= [U*HBUTJ7[JQD67_=J0?OD'>C<RO]-0)B\@%
MKD%%TI*KQCK&9? .MVVVCNS@;J^BCJ-ZH?2*QY^#6J)P/>0367C,CFDML"\X
MQ2QKJ]2=WMZ!.AVNZ9"\32],P+"P7&O7R@D-(W!BE(ZY@H"42I0W=:%Z]GQL
MP@#T+:@ARS8CY0E@=4C+QS7L XY\ GPN73^D@;E&CLR257-3;5W>P>< >5?C
M?_9>6%1S=W@>VTOP!! "KI>7^5+>DE[X_?N-.)8X2>Y&,MZI(6DTIE_(N59G
M'5<VYNB%7).L9J2;:DK@7$DSE/'CR%])C!GDZ+C1I'6S:ZIOIEM]SQ_,^02X
M\VN=_G4F7)V'V)&'NOKR\VVV)T"$P./']&X]G9?RYY)[D%XMX[S6C0^F?$+G
M7SJ:T^XG D%"-'%Q]M8B[JB,OO:C-@' S!;-]&TM!L=CV;<%F60--A&8"U<^
M3FXSJ(I"XD'TD]45[-BN-*01F,D989;2E18.REJQV\I\*PU+';4'OL?= V!Y
M,I"342%T8:'1H&>*JID9WRWEY+A6+&_TVP=+"M:_W7L6%+Z&NLUY L1B?^(R
M_7GX&R0TMHJ@9E/]VKRTC<29D$H9\-.?7Y]E.US$T2Q>YA<VI@[O*)#7.=PB
M_A$ 3#ERJ3)54@9K>,S+D!U*>V+#W6(M0D"_MXO',Z*<;,J2G>TO8CQ5O?!R
M:4Y2SVM14[KZ?C:BYY<M@_9H@!Z+_E,RWN*6"O1E-,Y?_EB/_] I]E>3<S+9
MW9YLQ1GJ$.%6-UTQ7 VNO=JR95N-XZY;Q [ONUX=<MS"N6I^RC;H%XA"R0@>
M/X'RD+$WNVO0(C>@CD)]0?)-V S54>GFT;)1<2P3&R=L-!1(LCH=Y^N53Z\A
M@G0V^TW8\@)]P_BE'JGT^2"2;-9'>;6EG([^=QV^R0GH,+HW0RK<S9^K8D6U
MQ9DCN#!(ASD5Z6%G6#?6SA^24R^7YU*;X9<F#"_R@W$[&"@F_:)C*+'A^.+,
MIT^AZY"TF#H6AD ;KUG=\BKX0"R+BKG$:7UJ#0I,^.1*F\6,;/V,2,S]#E>K
M.D"1FN<DU:T]%1B*6UH28\X,D7'<.J 8ZJ7<@IQ4+J6?N?;P..V*M'NR=K(E
M_TTW]\X0:4;B_0'3]-S>-E FQZ\./JC'5YYE!RRCI7WO*0[6.H'NVE"@P+X!
M%VTC4^R)7%AFZ[8QY%\U]?,S.",E]5&EQ=#@(V"1HI%SE_#F;&QBR[ (FQR>
MP%?TU4=_@Q?O:8"-38W]Q(61JK$9L\N>>@2DQAHD>U\_#6%8L@[(@TSZ3*!L
M5?^#BU%B4=P_./N#_!VFF[,QA2(KV=TD?;5(XX$$2V+W64BTB9]OS#0FY!N=
MY4R!*X]"O,!)30';P4OI>0K^#]5!$$%AZ!'PIY&6Z#1QW/NHG".R[0-0;W0T
MWF=;QT<1H#AFL[R$--A8'ZAF'!-G(""$XA)H6LD;ZQS7B7\"9.$I3PN7#J&6
M3B^FWJYOW_WE%*[X)L<M4Z"/C\"-E^39%>C<M?J/W=<8;% %H0[I-%D''ALN
M>Z=8B!:5Z\YXQ03=@%JJEGIN5Y1),92+=?S L))QRI5$" UE]P \#J?R:]Z"
M,)_W#)F7-SZ/LN/A VU;>Y"/F[G/P8)R@5KJ*T./=783W5&:IEG'<ES<*+&Z
M%=7+(*F:N0<>A@B_*1DG P>LWHP M7[$IA\%0]DC*J$%+P47$@^08@E/\K!Y
M((-=.=E,$DI103XF"%0S-ZR93J/LQ9%\ZGS$!/I#KBWH' H2BC)C^0OX2!N+
MKQB9J6W"K(RB#!WD*N<AX*29G<]@7R*MD"R(VQ,9''2'BVC5([FA!&Z#R%:W
M^]U1Y,7'%:"'>(+>,*;UO"?]*-8YUZN&'G.0'DP&+].!?-W3/ >I'_P^F;:U
M(ZZ.!RZJS]C>_@OQ2+9K3P1.91?$T9AA '1[^V!G ?ON'<OJQF#@O#+47W^
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MN 07W$;B\ \Q&K07H>65<%B+S/*]@?ZIL>GI6'4C7WCJ3ODIQFQU=>S)Y%W
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ML[.6BI&/ZU8$522"E-QFGDJ)8K3=<M_?WJK\^(,'_KG"_:\KW+('A7TTMF<
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M\9?V]_*U7_7#BV.6^ Z/J?BIJ_M$[Q9S-_0;O+_QQ-CG_;KS)UPI_KSY4/>
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M\5?K/STU?A'IU6=KBM-D4=>G^'./[OA\?HBBNK^S[<*E.:*11^M-.]3D4'I
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MYS:G5YV!$V>[3FC?;TT/3\,Z+8=/"S1K/Z_'HN%30E>ZZ_=HHL^^L:UC4SB
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M.>(@=;HBT$IN;Z[JYM%NNOIIG3KS6[][]=ZNKUKM_4/ZOK 0^8M;][7J4R5
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MI%^WWL1RHY+96#I62A/(ACB_B+X0LT]V95>WU_L49-GQ'H98=$&>>+EH=AQ
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MW3D,9]0W+.EX78%,76!6E, ^227WM](QKJ@Q#7_-D8VC>D@9E;UB3%04K3:
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MVLZA;+A:Y)R65UY,<8HJ27QCQJ:2)RY00$H/:#+44$)@38]R>KRCV1^\("/
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M(#8AHHU]10>,Y9!Z9L@0<$^K7L'OR/6MF_L4G84HOOB/5U"J@H=5IDVON,/
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MEW$35R";1N<@<D_DWG*E10\JS-SRNHT/3=VEG[_GJ#6(<56V+EC$2%R\;5*
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M<- QPQOP1-XL0O2ZF+WJ^0Z<0.OL:*8'NCN,P/U"6-\HU]QOK#S11U/ZPRE
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M2#Q?;B9R+RKV4VJMH\G;B#YJ>F&/;=3M'*V0-[H.VW5\<PL@SAU9=X>=7"A
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M1Y"-BS!]&;T21J8O>6I#ZQCCU?52%NQ:S[!HL\>?6BAECEAVNG/C5 ^1@"V
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MOF^WF_36]8\A4>;[R'\ 4$L#!!0    ( *.%+%:]1+G/-FP* *MI#0 1
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MG7APW#I<TKL/7;.<98WKD\CN_;].91B?'>^W_!%Y[DE3;M,\\$J^^_[[%_/
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M%?)Q'!V:'?L!=Q)VQ.<TS@V^9(\!+AU^2V."D(U@/=+%Y>(ZKW[!;<5^:7R
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M#214E(02GGM)$T&E6CY3M2-?-FP@WSYN6(TEW7%*+;<E[;"X7IQ-'-GXJ3"
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MGV-]Z\QHK\N7BJ>H"<5IS/.4906JL'.DN^+L<%GB2!;<\RSA5_KM_6""L^C
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MXR&&998)A#%59/$%@D9K(#81?=3MY?7$@\JKF[6D<L6*J%FDN[)OWOM))MD
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MZCXX,#@S^/9<B>FMOEZP#?C._*4X-C?:5%+:OS'%\+/\Q\J)^K\KQR^^KV>
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M!NU3D29;'^D#'<D5Y.3#Q_,?12:6](!-/(:0^I"7IE<1+-BTWXMX4S>6NPB
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MID!_$HMBSG1S8_P3@D7>D*W);<+=V9YIC8(OL4.9=@*;S;.SE_%Y3K>R*?S
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M/DH1>^T0F:0GV(^+Z)G[S6K$U=DE\[RE2[.O_(DKXX#3HX&6_:6BN-QO&9#
M5;SHK*>>HSPUP,_N*N]]GN^J&_Q+0([A T$C\(\%9Z> IY_$@1/\I2*EK)2\
M\  3UK'\^ U][+6%]G;:;";HP"H+CBNXSU# &0$?_B/9"Y^N^B#-?+N(.MK;
M(K_--G0YY(S'8?HOF)?M:D8\/-U4PS@$_V+HRP3"I_?E2J<M%VVF"RE\#_D>
M(F93+&406>K^B^J)@JY'4ZFEEBN_4SM+2PP7TWBE_.G/EOKO,0S[0G3% OPU
M),=R,_<<TLGR+IM'Y%DXW95EI,>XQ0:7*)ZXZ0XX\G\J@L+B<>?()7[/";KD
M<V[["*/D+S8 PDN*UHIO! [YNP&"A*),CS:=\&\J]"+V.FO4CX\+8=UQ0^$M
M6$TV/GAO5O1**UP9*]O@S)_YU?^W_-^_ 34UH1%]7MNK^Z,?.K95J^,NK>FM
M24ST-2;6NR4EZR;5[$\!_A/1YTW'-:7S_U*;O32C\7J>*1I9XC4'!TU-2H%%
M=&5 6I$1LKHEW5EWKF9IYF8M+>8 :-J3+]?^2VT*5"U+)6SP4:U(OVN_6K4I
M2\?<1W4UNWE1L_I(CKG.!<79W.E:%-AT;0\1^Y?R1\FHV3\]$F1-@$]VRV67
M\WI60^0@X).%OQ57\^UT>J7ZA=,>,G): U!GHAN_6O&2@EIWK!@&6F<;(NX'
M8\UJ))9%T0N[I(N*(#HUPG'H]'QA]?X]&KXG^>]@ +=. 1_.7*\0/"PN-M,7
M!A6_7;A9V%Y\1:>3KXN</M.&Z/L?:BG7MM36]0/W5^EKFR\\/)JX2LH[@!Y>
M\)@W@.;I5'+&L=/]T?\\4_Y_*1\*:R_>P!7 /HNGV. X8/S *B=.%;Y[01LG
M$J_20;)U2/;_=[Y\YC-Z:38NCYF?:/$VAJPM-%?3^ZQ3-.T%2E8.S4E'R!30
M?O]?2DOK]^___4448=W^O*6EI_LG2-#6^N_/_^?_/R^=/R\K/;-94[-A<ZX9
M>!IRYQV=_WNAZZ)<(['QR.)[2PV7N9FD+R>NJ%ZYP_3"JM>KK<TS+?AKMEM.
MK?UMO79=B$W1>IYME]U1^R>.<YS6.T>XP%R%;IWNASUN;?CNM7SC!N]$'X2O
MT*_#__"F6YN_!!H%V08'A>2$EH?)PWLBCD3>C/H<8QSK$!<<GYF 2N0EU2=O
M3SF>>COM4\;\S+59/MF).44 0JXHKP[8G[^_X&SA'=#;(AV(,70MS!T>5)Q4
MDHN (-$H4BD;+2E38^JQ;>6]N&WX$<(^XA'2,?)IRAGJ:=HI^DG&<>91UCC[
M,.< =R]OA#\D&!#VB-K%C9)JJ5+&DY,5I4J0*J,B1AV@<:]<5[6B>E[U[YIW
MM0_JKM0?:]C;V-_4U"QKH;3"V]+;0SO<.RVZ%G3]Z'[6<[5WO&]H2TN_?("Z
MM7@P<UOX=L\AJV'C'5H[7NZ<&CFV:\?NMCV*O;31XGV9^\,/;#AH>6C1H5^'
M7QR9&CLZOF.B[:CR&.UXR8G,DR&GG$XO/Z-]YOG9R^?VG^^ZH+A(O)1_.?**
MZ]7EDUJ3CZZ=GMI^O?H&]6;!K?#;#G<6W?EP=_+>WON-#\@/TQ^Y/U[P^,F3
M0T]KGZ&?1[PP>_'FY9%7E:]Q;U+?NK];^.[9^R,?ZC]B/D5^7OWY_9>)KYIO
M^=]MOS__T?4SYY?AK^'?6?^L&NTGNEVS'/0YLP_,>6R@9[ALWJKYJQ>L6KAB
MD8G1$N-%BPV7Z"WYL?3]LD<FD\M/K;BR\I;IW55WS6ZOOFY^Q>+\FI.68VOW
M6^VR'EHW8-.[OM.VU:[9OM&AP;'62>.L=)'^60T\=[8'<P/=D^Y%W\CP9OG0
M?6E^%'_*)LIF:@ ]D!7$#1:&2$-58=7AM1%UD0U13=%M,9VQO7%;XX<3]B0>
M3#J:?";E<NK5M&OIUS-N9=[)NI_]..<9X&7NV[R/P"_Y/PJU0+I@;?#OHA^0
M;] OL(_P]\5O2EXAGB.?H!Z6WD7?*IO"7,&>+C^"VXW?2N@@UI$49"Z%1$71
M0/0,1BPSD+6!;<M9Q5W$_<5[R;\N."'<)>H4:R1L*5H&E,<I_)4.*M,*@XIO
MZJ>::Y7'J_94=]54U#+J$/59#1&-GDW6S4M:]%H^MCYJFVP_T;&O<UM79W==
MC[*7WT??@N]'#4"V @>SMJ5LCQ^*&8[<$;8S="1D5^CNL#T1>Z-&X_8E[4\_
M #A8> A^N.P(>8PS+II0'*T\UG"\XT3_R9VG#IP^=N;"V1OG'IU_>^'[)?W+
MQE=67[6;]+H6,I5X/?=&\4WB+=YM]9WZNZWWNN_W/]C^<.>C/8_W/3GX],BS
M2\\?OOCX2N^U\1N+MP[O-KX/_A#W,?-3X6?X%^17U+>2[Z ?:3]#?CG_-OEG
M_G5FZ4[.@NI/S-&?ZV:09 B>5S:?L("TD+2(9$0T+E]<N@2Z-'=9DDGH<J\5
MMBL]3/U7!9AM7NUC[F'AL&:MY8JU"ZWTK+Y:OUIWWV9R_2G;0W8[[?L<FAPK
MG/C.%)=25Y!;IGNL1^ &3T][KS4;EWD;^FCY?/)]Z7??__JFBYM/!HP%[@L:
M"=X>LB6T,ZPEO#ZB*E(=I8B6Q8AC17'">$&"(%&8)$@6I A2!6G"=%&&.%.:
M)<]6YE0 *G.K_^B%AORF@N;"%E ;N+VH$](%[8;UP'N+>TOZ$'W(/E1?:0^Z
MNZP#TX9M+F_ U> U!"510N*3610*%4=#T6&,?&86*Y$=P=G$W<"SYZ\1F CG
MB71$G\4O)?>DD[+3\B.*W<JMJHZ*>K5*(ZQD5!&J2VO@M85UN?69#:F-24T)
MS?$M\:T);4GMJ1V9G7E=1=W('D(OJT^VI;Z_;V#OUE.#M[>]'YH[;+%CX\[$
MD9)=_-WM>P[OO;M/>_^: \$'P8?XAWN/G!E[.['TJ/>QW..L$YTG3YQZ>6;1
M6;=S*>>Q%]07MU\Z>_GY5?W)U=<\IV*NY]_ WN3?JK[==6?H[OY[1^^??G#^
MX85'YQZ?>C+V=,^S+<_K7O!?HEYEO,YYD_TV[5W,>_\/=A^-/W[Z=.7ST!?I
MUX)OSM\^?-_VH^BGT<^A7[&_[OY&3]__UW2EL^;JI\RFSZF<VV+0;M@TKV(^
M:T'IPKQ%,49>QFL6SUW\9LF5I7N7-9FPES-74%=B38M6I9H%KG8P-['0LGBV
MYJ+EOK6=5@IKTCJ03=QZ;UMKNT5V/^V?.5QU''/:YMSH(G$END'<4SU"-KAY
M6GH9;=3>^-;[GL]%WS&_'?Z=FZHWBP*H@:B@@N#4D,A0OS"7\+41)I&&D;^C
MWD<_B;D1>RYN/'YW0G]B2Y+FSSH@I2+2\M(3,X(S-V2MRUZ>,S?G&^!Y[HV\
M4\!]^5L*Z@J%( *XJ"@%$@1U@:V&&\*_%#\LN8#8C^Q%59:RT"5E:9@ K&VY
M<?EWW /\:<).8B.)1T92TJB;:-;T^?0/C.O,PZQNMI13QDWG^?(M!+,$SX1G
M14/B:@E56B +ESLJC!5?E+=48Q6]:J6&4 FL"J]VKEE>JUW[K.Y2_8&&WL;*
M)G8SNB6O-;YM<[M+AV7GTJXY73^[W_<\Z[W7=WW+Y?YS R>W'AT<VW9X^Z&A
M0\.'=XSO/#9R>M?%W=?WW-_[<O3+?KT#1@<M#KD<#CB2-%8T3IJ0'^T\MO_X
ME1-O3\T[;7<F_&SA.<;YI@L'+MZYK'O%YFK,).9:W=38]=<W5]X*NXVYTW+W
M['V=![$/:QX]?N+YE/=L\H7]2\:KJV]<WRK>O?X0^['WL]Z7K*]]WS[]\/E)
M_K7W]Y\%\(\?\2B>?H:><;J&WDT[/3Q%KZ$1ZY?0VVA@=@Q]@L:%<^F_: <3
M#S *Z?[>6DQCQL(?XS2*V./!#EJAL.14  W /S542T/RBFHG:=7<8-9RVC5.
M/"R+[LR&) S0M[):-BYAX)B/OHU2/2O1][Y372I4)TY2-RG.;O>APF2Y-174
M+1('QFO:;)$E-(Y6+E@<?X@^CZ?E%4A_PM[RY3[%J67D;B#%O>' <7=*;,V;
MP<,4;F5Z=2CE=L5*^DEJO/P])(UZ7K(C[C6-(HSUY-,AW)S/7N3"?MW;'>2B
MKN='>\G\-H.M0/+Q1ECE%XI]S1?:=LI6S4@1DAJL#(QSHOZ4D#<\I'W@O?XX
M2CJQ*_66,^GH]B43P:0'6Y8,K" [=.9K;I!KFJ>H[12KNDRPAG),TQW+HBKE
MS W9-*4@[P.>E'2D]\8+4MBHV_A<$F"'P9:OI*X!7_53LGE7'>4:>6?S$] D
M!5AS,^8E=8,JP>,)S5_8];Z0^/FL]O5)XOV)@"/?B._V/>C[3/+9\4*M0]HU
M8$6Q(&=W!H B*(L:'L:@*,_4]SV$U,^B\7?EQ.&IK*GGQ*IS;D<6$ILFU'W+
MB??WP2M\2:!A.!E/GM\74'B8?*JE,F8N96N5NX<_=;]XYZMDP76:YU4>?XQZ
M^& 3[PBUM$?"?41-525Q[:CEY-D<'G6B<(S]EK8A1LXFT)YN4/WSA-X7_GRJ
MX.25)7]"H( #Q5PV]WYW(6<OYY!R-<>4?9MXB:UF.Q;4L\U8TF@5ZPAKF<<D
M2\$\](S$"Z\ 7\)R8Q53^WYP4#),ER%[3)(A?\GV%N$))U@G!/OR=[)@?-VH
MTZQUW!@/=]9L-NK)=6Y\PZ\+=SAYM=A1$EM6M:2CC_6XXHELF%6F-,3O92V5
M!0*O,(^*05'+F54"J'LK4\S5>YS#$7<WGR]A-[0OW;N(=:EI3WLVRZM.+64P
M#U=I<'N8A(J]P#E,;_GVR'+F2C'8W8IISB,_TF*_'8H^9\K6Z]^S^S3+ISNC
MS8W9UN8H(3,]&RW*CS%>U2S)BV+LK[@>\8"Q5>;CMIMQB'_VP64V9M^7,]]8
M_)&T73N8HX/W6IV9ZWJ[Q4V,L791N1&#W9B:V\5(J3H? 6,D*ZZY 1EE@N_W
MK[ 7'.LX,XME=?#>R 0S?7=R2Q3CP+9OHG.,_-Z]V&*&4UM.KBUC=ITF0H<Q
MN\+7S83A(OQU7XNU[V+*:2_FE1.9.[\Q9Q^J;18PD+L7B]8RC 9;,5/T>]WZ
M@!'Z1.//\#[Z.4V:ZPWZ=]'56\;*>Y3!8Z_D;RF%0]MDRRD^C;X2*"5<(!7=
MHLC+QH4PJ@' B/^#VAU.YM70*MP2N=[TMS?L%,.\JJ-JV2%NTG:5Y /'K\%3
MG,[.YLN$#U@[T1<$ I9_CCW?G3D9MIO[E-GJ>I+3RFR8:I/+%)H);VFW+'U;
MF?BF9%/]4E&ZJ)1'$'P17"L]Q]_!AV9'\/#<'V&SN&&<)M<4S@JVQ[4@65UM
MU=BDY$!5R>!L\6QU<>TQ(4O9SDT2>,O-4-?XLR3=66SNI&A=*(JSAR]W><%N
MYFR]^DIZMUU]A"^9V\P<V"/*KJ^KD0MN53_@^/"EFGCD&UZQ\G+F&6Z4S"/D
M"<=?E.VB9&_@&5[9(8T>J#^<(\;W-/37"$^TCU6S!$G-)NP8_IPZ&G(E]V[E
MO4Q[SAF560B&?4[RVR64-<4/N=PE.;>K[5".Z/?VP2TMPL0M4U5U_)M==BP>
MKZY%A,!S277G,EHX!9IS(<9LC+S$919+*DB[=%@"/]QYD"=JV+N][ZS@[?"E
MRO-\\H Q\PS/ORN[Y#[7MIF5X<E95A,7?(AMHZQW/L^*$P9>TI,L/M5SX+(H
M=JRYSUS0-MI1:<-W'-[/].*^W7*K!,*YTWXY_1+[6CTBF,#Z4,%U[F*9BF:=
MB:\S)3/VM%9GDA,[7VNVD,/^^*<V9 SMB6*"/ 7OEI53\&D"B275.ZA2>)B6
MX!S$#Z+?.]50NY!S83>SRH^]OU-?7<6ZK/)06;"L:(OE%YG]L"EI-;,P=4*<
MR70-_"$T8GHYO>9U,DDG@VJ,9&MVA52&2IS:OU8TB+*43DHOP66JA>P;GPK3
MD9SG1:4N$'5PS0.Q@E*.@5,'SY3U[<2:ZM55LI'EFD+U[K:3JN,J;86I(ETN
MH9C)'*6)4 O)$K%M2H;PJ^!KP#O^==XA)S"WB9-[['=54?.GG;/5_0TAK5M5
MIC4'9-_D^RIA9 NIL,(=DBBF*XR2]PL1DM,!(CY F._DQ/7@MAQ]43G9"QS^
MI;;LN-HRH%2UE,H,Y=X-KJ08Z=P:G:(JT1?UF61/P1L%-L"%]UI\T?$W9Y)W
M:.)[)6CHP+!%Q<! 6O-5I7G/+&F@[%C;>6*CI*6QJ\A 5%%3F#0A8%7<V_R8
M)Y?-=YSD2/A[)YPJ=?>M& )7Q.T<:UZC.#A(D:ADL-X0PB])6+L16"@*:=B3
M5"SPK%JVN9<7J#!TW,6)$2C&N9JM$^CMIU4_#JQJ$BK*1B;$OV1F@W@"6?R]
M9SW80OBK97O22O[/FA>;2WE&RL..39R5PH #%NU\4O^6X\W?2-):>@.%5"E8
M4FM.FBPOJ[Q%3BL8KNB@S$NP4V13GOK?E;RB63C A;[TB_M:V^K9I7WWFMZQ
M*#5GZC','7QDC3G3&CNN><VX4&"@.LH8B!?*Y8Q.?Z1D ^.&0Z2@BIDYRF[M
MD7CVWFC2%R&K7]1Q!6=YDNI ?CGFO685+R$_2:7+38A[+[O&R?8W$"O87 <'
MP2S6V%Y6RTWUBYYSC2&J[*IKM:?D7[F:*IKT,&:Q&B0^#:Q6I@@?Q17)//C?
M_+:+OO,6.2SF<SA&>SI:5C8<Z7[:(*L%5SZN75/EP6FIG%*O*_.KZ%%NSGND
MZ)$5Q]Z5JL54OWP12H"S_\E?RO7?/=HL[ZSM7EW_LQ56:54C:02R;U=&UM+1
M@@K[RJUYL0I+U50L3KI4=M_/4OA+-&+_C#?""]WULMEB:U87L%[4FZ%!UJSL
M0+,W:*XW]Y9^5HW5/<^]*C]0M31VM:1+9>C[1E@G.6A_G0?EV^WR:CJZ:V[G
MH7K'[3;J*]6C6S)8'1I:9WTI1E7<_" 7(2^MFQ=S59*I?N][5!@MD]B?Y:WG
M/Q]I;B(>'.[<5'=M]RUU6C5\: '+5N.R):ITCLJB0YB[4F[7V!Y3([&H8OHV
M"5<IEMB/<S\(A(,- ^M)ZYI$/:=)<V6R#AK)E,IHB2#!2Z(:UI"^9,^J?D,^
M&#57W4S9Y@U7&%%_VYX3KZ*/;<WI3V(5-5[JOL9DR?3;.8QSE%_-"8RLX@/U
M;@S++&KU0H99I+3B!,/3>XT\FE%A>T=4S/0>P&\I%C4UZG1]%GR6)K4U\,F4
M\"8,+[QX<1V &Y'YM"J4@XE<66'('MCX0%;'7F3[2GB6I>P?[JM3G6UPZO)0
MP"68UOLR-S*Y<9MD SRGMDU4FIE2J1(<BAA4 ?G&&[=*?W&1MM^$X>SC6U[V
M_JS]6 _OK*RZ).YMC50_)@TWKE YP 9KOLK9&:<U[R1?(E*4XZ*TC2PIFM]A
MIR<XS[FS):2WH,VK[GC'SZ8DL6'+8%T-:64#IWH.;&U-D9J;D:9)5,Z*T%&Z
M2(LW9DG>"+?:S1<@N9?Z&GM>]^76A70P.KM%LA;'UN7$A@:MAJW0H>K7-2GI
M/]6/U _#QQ5[%;$;-TD$8K[=$L$J7D>??D_5$+3V2(=Y_Y1H1?.)[A*B:WUC
MFSDTI;JBX7KZH%I330FO4,!5+S;:239(K>U6\"?Y*;WLGIB]H-KT]N/#3X3#
MS>4#7,+E^MCN0.CLZK#6N>D$=73=CG"DPEGCOM%$HBMCV:WFM_'OM]X=^4$\
M6J&]_12QC>W7WTO<A2GOKB09%=:T44E;D@\T1I#9(6'5MRF\#5$5JZB/;>B2
M:_2=+0]&')E2%7[;$\8@Z\J64<8\C%%7&[V[T+Y50N<G9S0 Z(W!;ZN^T:]L
M<%"%,%)M1B4KF*M:-N\,$P8IKV^;RQ]DQ?=-\F++.)V'N=X%W2T#G)RDY_4\
M]D!P1Y4=>\F&94HVJ]OFG;B45= \LJ-,\4@9,KA)UL'LZ3.6:- O.MZ)Q@HL
MFA\+'9.8=1/\;<' 2C3/9\,LQ37.U/HUHEML0;/#\-%JOF)DJTJC9J[HA:FN
MH;,[8A3Q^9W-[M*G26OK5HGK@FTT9X0!'E\4P;P'ZR-$^1QI4]UP4+.UPFNK
M7CV1T=9SI4:G]%7['LUH?DA3NTJ8>+F6)D\-^JK9*%GB\5)^0'!H/4SXF8ML
M<AK:TS4HOS) :@M@1/;$-.F6UK=OJ'T'_-ED7?DJL:561W4]Z(JZ3];K\5 >
M)BI:SQ4V\YP;1X9RMJZ02P?F]9QF+.B^T#Y<FMNVK>DT\'!C1^VW1'1-;:51
MT*@Z13G+XZ'LE7AJ?9TPDW>V,7;(8"=$[M<_,.A!/]F-Z74I7=^6W@X"UC<F
M- XG9M=$5+\.&E8OJICO\4RV4VJ\OE]HP4_4O#CTDTCGN^U]1TP@*'=\(1;
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MF:MS!'P.)^V9+[^[_W,G67ILI\#@*CXP.(+IA(^[YU%&$Z$MJ3EJP;%::H(
M2]2G!=Q'_I7?=?:$M83=MAEU@33/YCRS/>V<.M?H2V=#[W0%C B2L[J)Z9<5
MJ;C/RHJSR/YDM_O[B)V!<,<>8@EOW=#$6@?NCZ8FTVSN=E6OP8XK@\*UF5Q1
M%4_5S!W<W"1_SQL=-T7JR2OUNR+*X4]UM. %_-=;%UOF"?8T]M1,Q^J5%_7+
MT'HP7Y.+7*P<5.Y$'#;]*Y\/U\7R)"7P4C^NL /:[2@7'(3*!AW,#O+<ADZC
MC92O.*0+%>_A<]0\T>R*VXI'A'E3A"P9=XGY*1[ ]OAY",>A,8Z(P ,^,1!G
MBC4LK3]J2-92Y=>T=-4#GERU6Y%;,4\Q6_H]LUZJ$;?$8.*QPE6K7Q'E@D%'
M%C:$CNVGUG35WZR?H.^W%,@7:RX9OW'/J>;K&LISY: Z)7.*Y(?\=\Q"$4.B
M7-V/OR'>.Y*P&.SOOMTUKAVLNF2]=XN?K$235O\OUT9I,0^6G9-/-M VJB5"
MC6WT4>%/>?=J&$=%7QU+T/>"27W+C><&?M7NU5WI?BF]HG[?M@]0*WT:B;*U
MLF;+NHU6$E?#Q&BVL$6%K\[$G21''//03L&EWDXCM(M>&ZDCAB#I.G53;P8P
M2_&P?5'I-5E2P_V,T^+;)EFTCW"+=LIJ=\%[6;1C%DK"F6VCVW=1#^IYS;=H
MF?B.AB7T:0R3A49_4+3:>([Q9/T1W7S6HL@&502;Z7-/%@XXVKL)?_'6MGJV
M'>%.T?W;= \XC_O4+P:V,Q:8*<#)PFV&B]RIZZ.U=EQFI*\RBS?:IUU:P3MA
M'RM<Q;_8PF_=CP7J5C8^0OT$TKHER 9ZJ0F NPMGZQ_"CFD'-5'0J8B+"@G$
M]F%*NJ X^WQ"!/DW'VLY+\W4%C;\$-=B [5!HE&TSAHC(2LHTL_ (]-\U5S!
MS(AJ^05TQ"=._!OILV?C[V&L>5S+G]I236M#L.H+^MJ"*5JH3XT/9=7Y)W0Q
MDIAU.U4G1/X1B^4VQ-\^]N)\[(6]%"<A74UYS7D6N69BO:$F!TTTW]&OH288
M S2K\P.TK4K?=3&J^;)5X5=DB-C.9Y+H!O[1WHR/1KL;SS<];M&I1?7S&IJ1
M*^;UEB'*>4.?\5S>,>T*[?O4?Y1UJLGA>MD8V2CO-Z(BX7G[#D$K)FQ,:")Z
MV.H_Z[:W'T VF]XW?:1L-D36.>5E:W;5%*4:E*%:17B.M$VA\QX13157V@\)
M,@5A#<^:@K>M5?76E?;M@#^9&CI^D[_HWS<'Y4W6%-3BJ>F*UX;]X2NEV:IK
MWD>$YR6G[/<(E@IN&+L'RZDEXH">X]1O@*7#C]93L:]Y*UV2U5^_@&%);#3E
M,!^$_-+1V8F>MY3AP&R;3^+MO #C@@$Q$"!ZW'T+& W$M(=Q/E24- T ?V>M
MKYL'D!.3:_* [R'[M2"WR?.B(I,GL0T0/>0/&QKZA<@+T>:N!_ GSJ6V,-BQ
M_%GC$&39?+]V&124\*^1 4T(@35UX //XW(1^-26+7* 9AI6].G$'.')S@_"
M$8YKZT8BMSRCX3B^<'.N)5@P-D%E:,!&AT2IKZ 3//?++B%+;?N$!!RE-_2>
M4X\5!G2Z*7:QS2UZF;[L>,,$B6[3/V:::"#!3_^(N!_REWHY/M%SA\P5<[.]
M1?Q",O4S>[UK!,2^#K5>P;9J_JP9*DNK+U!^V(2;KLC#XM_JO27*X!<JKO"Z
MYU9I+3[3;@PA0F-U73TM#6^)C1T3:B-8AYI+:]I+O]9=UR_>M,H4HS;&[]#U
M*J8&GU4^D91Z]DL7$;OLEA..V#Q=5$]DAR^QH+V^^0Q+T/2Q/J-T6UVRZ5WF
MQYI#>F,\3^>G7A7<I41D!SW[)+M%GG;^^"WLD/9#]X_^+?B%]O@N!U9@D[GE
M2FEU[<=Z0>;^F@)3<OQ&[1W=[&"#TDMQ_#^*)2ZW2\0M@CCIGWM2J(OXC<,/
MJ?7DN0,H+3D_OWL>W7>]N97/6+?V97TOL\M_3XV![>CFKK$"QEB/ED;SW"7[
M=S,Y,)\[/)H35OVV7\KQSU_=-9U3M;ZBI9QS=^VQ.@N ^7<9Q=PXMQ2U%2_=
MNE*2SZ^5H+LJX4&^Z]!OZ'AU1Q\*3<M[WCD&K%EOVYP';EZKJ36#\?X&@Q9<
MYT92!8,2Z[-B"_A<$KJS7+B/=W5H-.%='=PK$MS,DW6,P7:E76NJ1"^LS;8,
MHJ/],?UV)-A-I*3!9INEHG?PG^(W.[2*?3QXJZ/,0'K:,RBIS_-L=Q)=2M,T
M*H3V:SW,#W&#/UWW03#!K5%Q#$5L\D79R!RQ?OL[_0Z>UR!?\Y;4T#-:%9O[
M;QM3?C(ML^&.-&OM#+.#Z+=_J2Z*,+L-*UP$ 39UPD?()W'$=E*MA/OOP&?3
M0E))=Y5^7^[^UGL:?II[0YQR?=0'DUGFY%^@[1-]=CLA;\</VYP3\M$A\<SA
M3RV>W*,#0,,?I."N=^9/N:;6;,._:3/KSVK'1MTT.2BG^V_2!DAGNMV0>PO_
MLODH=,%21%>&6[OV<@<&EK1>)GET00TW<[&6$?.WM#'UP88U43=J&M0*_U+-
M9=D=M[>RER(WV]G$2^PB-/U8/N43573 BYI?]&O7>-K4S)*MW;1_$V[U3&0L
M"(-;IS+Y/H=KA]@SG$[I'G,^KHB0#?-LH(E'^>RO5./^1'9;\;B=$]BUF46#
M2O9(PO6N6YRL,''S+6"QST,+SAWEO$![DN>XXIKT !^'9A[)@?JI^#Y_\&#1
MV^VOP.F9,0,5_(&$PYW#?$68L&D?O\7GEYG*_Y]SCN8LZ&^5)GD!'H7^.!Q.
M^%))>Y<)=A4=&[Z$43,=^I-0:D)W1R,R%(8U;D?F^,XU<6&1<ZWZ+6QC=4"R
M$KH+?C^4*NNC9NYQE#05]6^[)CJ?.:UOO= EH;Z]%=\9)FPX*RCP=:MIQOYV
M_I_:'7EBO4AL@/\'WCJHT2ZEQN[.4?&*.K>-4TS.G-X+20\EU+?]3VP(T]3_
M$"*^,<8G.,UEHDJ"<:R+Q7.13G#O@:^F7&K(KET&JZ+.H53M^,R_>LZI9B9T
MM#G)O<.:ZS=*\GT+C&N$>I>5JM&"V]9MHFYT$UAW@-= IJ[>M=(B*>K;>LBX
M.W-1C[=N1L+65KT*"ANLNR;[Y@L83HE9+AN4"F*&]4U1&OH&Q _,;TNBKMIY
MH'%KT:ZMX;5+,EVZ!XU#"2=;YVC)8>?K-BL#?6L,>=*_7)C*0.$DFS&B/[&"
M)]OI Y3BBVD,]7^_"9@DFE>+'VLMW5'6P+9FK&:\X?S!+-B2"/S!ZHPYSPWD
MV'OU\78#OQ]MHU[C4<YOI=WG.>WZ@WZ/^ZWI'\8(]ZF4Q!SA?J#?9+W@+<A)
MY<S@Q41_!K)Y.J\)W.^\'P\>4^*%HK/OJ"7$@AT8C2\XTLBE:[%VB1-C*]I'
MV\]\@)S.SF?;P@^BO3A:Z.-*$C<.?'3?OOJ'1GIF)<5*-6GX"C52WE+_DU8M
M+1-=IW>+2ZGUC,]"2A:7E8Z7K 79][$ SU= 'SQX5T-Z5L<^U4K^R_3OMEA*
MJ(&HDU"9VC"AG'9$-8\B9CC*IVQN9#:*KT:-L-<0V9YLP!K-NA-*^JLS[61&
M=7#+M:$QY,J&+;4)E&[+!()$&V<X0,;I# VPZ1IS@N+OJ$C6'O%ZS_F<'NSA
M;:>JBFWS3\20#'TM@V^J#W4NLX12QC1WX'QJ05U4]6[:$^/5378,2&,3>8(5
M(YOC<9(3A?O?2JG\=_^NXW32PIWQ@W]6!PT.FS>16=WS!<V4^RVRZK$T4NW[
MS!K&WX91D9N8+Q4:#P'[7Z)P9&MERRFK8S>KCAT:'-A"NKU[C,E,GK'5'WM!
MH77Q2#FT*4UMF7_1]YH8$9^99M4QCV1VGW#+M67\.>0%AVOX\RFK^T"^/36A
MYB0_A%:,=?+SZ7I2+E_'>)RYDG^=E1"Y! QB?_3@@7> GU>;N(6 \1"9*P9J
M>HNY6X$FXP[N ^ @6LM; GRO*N%5<!,W)O,N<@<C"OF;>;X>H\#EO$=7K#C_
MXK,/7 /L!>.Z_P%RL#&&%* #M4<*N*.1LLI-7!)\**.:^P[^.WP'SP"1W)5\
M&CATJ98]J*3N#V>_D9=TY7"\I96ZCQR)6 *[ J.%5RK2 "%ALZ&.:R,H#%_,
M?8J*W=UXM^"BBZZL=M.QO;=9+PQG.WZQ5VMO:QO9%M4/:#QGL<*E/)-S0$I-
MOPU01/HU"FX<#KG=Y*4AG\]_9=YHG;6GF[6XT;W]$JNB-DR#L*[7; 3'L/-U
MW#(&9Z;*G.["N2&K7?,7<$(4[:;B/L"VG/O)].Z/V[V5R>[BMEUC'F^5J&4L
MKP8-WXYUVMQ:>I"-ZEO6&SCK515A74"ZY(9;.A<2U)U;S=BSJWC7&^:HH<ZV
M2<RHWE[5'F9?NXFWA17;*"N=S_[+7+'^;_8[W;BP%,XWN8.;+=<='SC;QR@]
MDK5K$Z-[;VMK-N/9L$8UB1G1MY&[DWFOW;I$R.JK_U]:,[O&&!#ZF].O='7]
M#;PAM"<FXY>JQP_["9Z1(YNV"Y92Z HZ5D5M^R^Q<[2WQ7=1?\:F-!MD@/DB
M%$?6L/>X<N"OP-=CMP11[,?;O# >9VEC&WJ2LU%.11TX+9RSB F84CP:60Z(
MUV7#0]QE(:_A0NXM5SO8CW?ZZ%;T/GIJ:!3J@HYI:$0@)$RV$?X(U[*/PBQX
M0=%">![4G5H'G8+"0[9 %O")RQU(!B)'-B(M,MF@$?X@>52_ LX0!TBG0;>$
M;:PZB$_X%-I!JP3G4AY 8[&LX#O@:^2ZBP7\!"\Y/ -N-H0,)$"?M/MJ[T$%
M:A_Q"/A>T<_4@K4RGX)8L%I\.<4?3!:F!%> J8)ZET*P&M$>_ B--'SL]X<\
M:TV62V"CR5HT GKIFQG]_.<:AWR"?T#1F]S!WRY=&#R9?T[HY^++_XT^.C@+
M"NPR]66 AK9<\S_@N,9/PJ]\?6TU_2D_W?@^[S'?3UN0[,I?J>@)VL[/$EM<
M9O+K!9,/Y(/'MCGVMH(V_=/-+GQQ9X/0AS^W93+=DW>CCID7Q3MCO):T@W=)
M,RJ(Q!\C/>3\EI^,C]O_#TC=U]"[A']UA\$DXGL,+B"$O+ZN;)J.5]7<EWN*
M5V)YGY3)X^I^!'GR=LLMSM?XL_"K.QF*7E)DQRS9DVJ5_HLTCGQ!L$1\A?HG
MY:*HA%:Y9:-P(OU]XGR\A6D*'"M(8LN=6K&)P+\[>/)PEK;=66IFO="/E\QF
MK\%\16WL7O)G80S')T>+_^#<3B@7] ,U 4*,QB6<>.@:WN!VMO0K?+IMG"0/
M#M9^%]V'AE%G(0;%DJ<2_N#7[+/X.'!?_!GL B@)6(SV@J5.&Q$UN&ZX6')4
M,JIE1+Q:9-$<%IX0^B"V! E_7KT #Q0,9T\0+,#D\5[H;S37?S?R%7%V\H._
M0M>V)8C/:&V;KXG6J#ZI=Q,W% ?A6;A<)B<Y"_(EQ5E!6*8H,:X>32$6^V]!
MLK 33LM@"N(SM%$\O3:ZZ9Y0:(I7G2"6&59#+H(1[:*J'&Q8-7JS!NV1W8^S
M1K:+._SGP#<(+Z?)\"BT8JM*1&]+:_J;^-R$*W_CDCH)6"J(- &5@YB#OG3S
M9-1!'1F['_&4??.[#A>*BAT_00T8,/A)-*9_;2.#(+J:E>OP^:T[^0>P,PVM
ME;/1 ;-R$X@<T!?%;H8OJ:;Z-<*3)%F.3Z$40>X@(>S=N;SA&[%J:YWBD.!0
MSU:^ U;>)J^0H0D-I9OF(EM,[K&384ASQ*\,.B*;ZG@3^@M?VK71>*!JM]E*
M[U0]19*@.4Y.YEQ2093&TI>*-;0_,^[*QM [HA>(AYF%JVJ$^6R*PP1\+/"J
M4VW@,R%3M6XT\ZE8KFYC;> L4!:P[I3ZR=W8:$:HY!<G=JU&= AP7K660+EA
M#A,%WCQCQV']&LBYAJ^Y#NX3#:I@,(OMIT@$%Y2090[\?S<8)5/YC]?.$C[D
M/_#]A>_B?W68A/%!N_:K.B?AD!%4'R5P88N2C1>P,N5K!8G%;5(?+"/]L]@1
M+8NJ%<Y%N+[[\;&PS&$R>A=2MWW2.JEB#2;5!<5F8J]"+JMF4F6%$K3HC211
MU)J>(\H@KD9Y$QL$[WT)P6;TJ\,4- V^U>:H(=?<U3]6+3!X$%/EU[0DQG9I
MOZJC*$#<)'^T_H*P1[HX\CR^1Q3JFXQ=P5<Y3$'N(;]:^>K[3:EZ'Z6\[B&^
M41YMCF;,D"XS6 K;Q/,UK]=O$#HH/2)YN+<TQ=<>RQ(&.4Q%^.CGEL]J:E>+
MKE-ITU8N."X;:7Q/YTJZ:M<5+A.U&@?3'A,'-3\BW027%,M\QZ,_Q9/^H]RP
M4RU:M=76.[H Q;7>_PFB97A'*>V')*'I5$&?*+S6+DU*Y!HH$2\%D,KH,X+N
ME(@=IL)O! S+V::I59GREKIMI";PJUE<_;KZD)%"B<GUTJ52CZ<HU59TTIH8
M^75FD%>QI)J=;=M(W <>67P:/C":Y':UG<P9(,G$94JK PPY++LM6[5AK"<I
M2U6+V*?#WLAN<\YXA8H%W FVIXE)/-!LK#_)/R(KM<CX)?SC-3G\%229/HX_
M:LM\C1_O=W*CTIJ_($PK_<2/]%HL&N2K;-_B:_G?30_J!O%C4HN9)]C.>V',
MQ'947=5%HU=R*.JUZ(SD98HUR(:P(*DMW+SRN_ C]-WN#T$#M,ZTHO:\?$AR
MWU0K_<IS-H"2M56SM1114_9=59EP7%*7G(DS0S](2K [*^\)X]#5=HZ"/V%A
M#58[23\@":MYH WG2O7'5.<J>9KMBG79Z<I!Z>VDM;(=XN+0;>)=Q-.5)XEM
M@K5V(9@!T1M_6%AU<O&9FO7F2NY<O:?1H>*W9I'V2M9MY1(5DOA<YBIW" 7$
MSN(=*X>(U82572JV$N49)98_V\+%&XUOFDJ .MW1NJ0*L;K5-#^+HFC7/4J4
M20^I&D-#14=E42L;\2O"(W:YZ'TLQ+C*?*3WINBWL:XS %BMJVP)J;!6KZV?
MG[5 $5GS,3%&ND5[+'2FJ%H!KQ3C,O%RNTJT'KNK>-TMJQJ/;&_GD<+H2YJE
MU;+BA?4UY \9-\TB*C_68$BGKPX\I?[*7.".R O8"=:0R B,*+ N$_TF4MXF
M9*RAG6K"&:>+3M9A3&:&R%3-2HI-UX>S4P(MJC<<LCLA*P4N6%\0#O"*%0L[
M63P6_*25S'.@I366<3\5Q=>6<__-6%J3PYL3.UX7RML86*'\QAMT%TL)_DJ;
M.<03_F5Y34<.]A9.:LE"OU/[&K+1Q85'+%N0_ VMQ@+X?$RW=AT<'^BO7 Q=
M=1=)]D/5-LF$#[10_D<[7;H!.M3,$A^F+JSGBX(+/<P(<7:#KP'!JV,R-(C
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M X*:^J$#C AM,41B3A;P(2OF;OH!\#FKJK .W,]V6[\1[.&,C2P&.SE/?$;
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M5?G=,AO&EO3QDA!F6?1&T1:6(L"!X++/NDD%38"G]5KT,G>W:(DJ'=C,?:X
M@-IJ.UD;<#7OD^0*=];Z$O%4;M;:%\)([A[_ISB/9^L&8H=X+=8L= ;?0YBF
MG(N.X3K(HY 64IF4@WCD^8JWP0-I3X7OX95K,2(:.N[?(S!!&]P8Z#?PE74S
M4@#RB![%'^). )8EB#JJ3DB$0FYNL^@PX9E6*)PL>+36_[_\Z_PA[-Q_ME:!
MQB-CK4_ _X,:"1MYE-H%F"95*255Z\3'Y;6Y=L+O4FC=2R)&G!MU4S DC/!/
MPZQP*[=\9!?ZR/HQG -;\)VRK34\3JUTM&%5Y7VQAQ;;LDN8I5*NP_ ^>4T4
M(+"3-/C/1QN%+6Z;D3"!T/HG/ JIPHMED0VUG$B)MG:PDB_:8_+<DD'<U6]>
MYX4[J_&H,*Q#/N#W#ETIONX6#S_%7]C,A+:B"\&P^FGYF=1/EE6%^TNL:^"2
MY9M.ZP^529-<-+<KYZS1*$=(IWU!V7Y*E_-8L99^9_EUHI*=S]]5NZOL)U5A
M^E!A+-YK]*P*W437Y9-^)[Y4\\FWUI0J1-0'OA0IR)CB;"VJ8%%6K,*S@5E\
M'XLG)8_RK@:AIA;[Z8_3$C*_:,?0MR0*5<X,Y1HG>3SSH6^F)).=X!PDS.,\
M7B$1D+EF7JUI&]M$B3;^Q?ZW"-<5<^(R2>I^SK;$>8KW@%?8/9D3<-+77YS*
MK7).))@\]Q57L6;>;]ZX&CITD#R@OP<1A6^T@5#8QELJ*?@I8:O\!K@[3"=U
M!!6^"T0E8*GS)KP#3+*:A7X$_;E<(X^X3?;2O2-F%3(UB?B*C<7*>L'2A'C9
M6VQ)6($D!+7WG2C4(ZN<2P0?X5"K2'0+E,"=9>B5GZL^KG.4E1=.50LE9S>.
M4HR(I\5_E'D*UX:YB"6XP'<,<1<[[LP29" _K4C(4W@UL->P6*>MUFMK->T%
M(ZHWJH2,8PI'^;;X75*N=$7H:]$_(H//=2*-F.,,8B,89*5"4/@G .B'+/;5
MZ5KGFM8"K8JBEV3PY:V:Y?&0Y)-B7^AQ4:FTP.<P_D TSQG"N(+#5KV(-V*A
MONQ(RGM6FMCRL# P.Z>17-RP;FGMA;(E:W?6O*[8%UBENT%2>.Y3U5$D]@=D
M:^DWEJT0?F'G4FGMWF56I3.;=Y3ORG9IL*ZL3/UM*26%K^TP(N2P0*J61:WT
MO*U,I.]UF"B=P8I;5DN, &.I<UKWD&>7U#5%4Z9GW:C;1EV4.F#Z24M=2S58
MT7L"LS6N3'?/EXH%K',.8>)/'-/R*?@#+H_2W1+ O%ABUW"%%9R57AO'VIFZ
MOJ:1G;C617>+,S[03_6+\S_/U_)QP!X'DN@G]^#R(GPJ[S(EI.D3'R@^4*_G
M%VU^:YG+3TSYQTCF^T6]U@[S0P-G*]_PLSQ?R6;P,0>=R)J_;_DV01K_-_E^
MXW?!DN+*NGH,V]QD7HR>3VDR_+<-47V:0\C&@"^*W_ .SU?2E? RAR%A,21;
M_AG; XTCJQI])?)BM]H1,6USJ2E%M"BE6-])M$;1U=]POX ;BE#LAN<'"1U%
M'"X1QQ#'%2Y8('2?G-%@5!TM^EX;H%RQV;.F3VZ=XJ$?(_D4%:Y>)SH?T"'O
M(OH\'XL?"1H<WA+!J&)%!GH--I*=&MP-5XM^6D[H]FYVJ['5C$M9I,M1_(CR
M5[7*I@4,R<>*O3P_B;,(FN,X_":V<P6 8HA;Z>3!:WFEV3]ZGQ5TI-WOW%D\
M/;:_U;K4% HV.%5L\!6:GI'B70-U5$J9S5[%#?KE)?7B3>R<$L/ ^]*0[&L]
ME\I.I_VOHZ1"&+NK>:"*&6JNZZTV^>ZLH5+^=<6T?]!)MO9R*<M^J8_(G?.Q
M)+,?)1W*5G?G_'[P^W?TFC7922F)D=%Q$:/&3*[>G=;=]IX\$FML\J;ZAJIJ
M V@'?4\;YS#8KCO4QUG)MK LC[-^Z7:A$S>_Q+KW*V-2=F+G" -)RVZE,Q?$
MEC6<8-X-I9OOLR[XGM5?8C]TO:VJ V;8GI%NXF8NLR-B>9W%+WH:N:NS%W6(
MN:%I+BT.W'6Q7O40EQ&:;VKG'O$]I^OGN;K^4.IY;793)72^SS(,E_)/%6_O
M-B)YV:/:V?#7M'G-<V!.[)*Z*NA7:&)-':3WO:+MA^+<YBOZH;_L0L7]X)-E
MEP6OP4/%LJY3PLRL=VVU!"]M1I/[_RDZQ_:X%H8+5Z?MJ>TVMANK<1K;'-N>
M/=M[/)F)C2I)[?:4J6V[J>V>6N=]WM]P7VNMZ_ZT#)ST*3T6?5)<0OL174#H
M]::'V@"_T-H71**;Q/(W3G&8IN=BC2S!6K_:N57O^M];3Q9.7"ZOF9L^OON4
M.2DNK'VT$0L]VQ2NO^ 75YNM"W5K,R/$6H<4_5 \CE6V9E_3LJHO_92&FX4S
ME]VH,Z9/[':S_HZ+:F-:B-#;C2M,SGX9MK/Z>VYKS-.T_SA(=.OQLX?.LR:0
M[F].XV11]R_)Y:D9-36'!.WL3/5AT6'>5$:+=+3@??X2N43\,?:YREX>Y3=:
MXZT>=N M/8F+;+S,/,%/ZAG)\12.LBSAH:(SJKV"1Y(.^@8Q38;DW9"-48"Q
MA8K/JLV^!X%H3?A^#\H-Q8@-CG2]8D=7,VN6DF=.XG2J0I2U?'_U)-IFX5/U
MK[S)DB/ UY@S\F?@9%],38?R!]BD36CI.@Z50"=TO&2$(&>,=UF/D!9%'G<U
MHJ9N$-0AS-PL\3*D-"9=]@W)]TU3]2$9>\Y7W337K'E*/FDJ;1?3.HTN!@63
MH?\D]^-DZ\Y1]O(9VCTYG:(^HGO139D[+O2=H_R#S=N-558UK5V]FD1M:&U+
MH*;4\?1%#"];I,R#[5\SD?R<1S,]R_XC/&/8OD@F5>K*?3XJ!?C^7<H*GY[^
M51NJXSHWM&92_-M,.B[=J3E?FL^*:W @AW+K;<^R0>$T2\,B)\D#XUB?"XHO
M6O^=F\L35PE6OJ\B]]:T6,CY2UG:-;2,+A=))U/3^HS4QGG2N"1[E "O]8F^
M(V&8%3[;%0TZ_L[ LM[-+U>**@^M']O\D[1AY1WM%&KO<JMD/.-&=P+)GI/7
M^BIKB6!8 R6Z7ORGQN:S1!&O5VZ'A1M(57TKQ*Y4:O,,23<CGC@NF\4>*_XL
M7\&]5?U)F2HXFA6@GBR^$;53,T,>YNT#B=0SM\WB3^6H>YL$YWBBIMDBF2 /
M'Y3,$OF)[:3G)=.K(^6K9-,R>Y0K%0NC"M0O5";O$2"L"=G2SMDO$RS_Q>N7
M,QK6"V2* LPD2E(F"W])O%3)56FR,'59QD,%%T B;ZON:XYZW=?T0R&;Q[$V
MPD'+>)Q_X.1Z=UX_G($F"]KA7,$]T2:87DF7O(3U&1'R3'A]I%3Y";[G=0!X
MBDS;V,EX:7BP=#Q[G&%.[27N;'T4_!_?4Y?''Q16:P45M>+C1%OZ4EDAOCMR
MIM(5.^_5!\2B)S<(Z7 ]TO.2N:7VOFTO^Z)M%O2-^[TF@O=>D&(N+[\J.F6$
MTV=+47U[Q#&%4EOK95-OP7/78[22CN\]0QD=;8CU.NM0\W'(CO.]X3W/FT^N
MFU$>*OQC#4I;)SEECHC0RQ\9IGIIU)'$JG47J*K>V.YL^H&ESZSSF:^[PT$6
MQ[V=Q$5Y2YMU9<N$)?5+TN(ET=:VB"PYVU3@Q57=U)Y;5TT97!_3=8'NNNI/
MC969UINGN<0FED@XWWC#.AK+@@3'FU>F/A(?JFN*&",?98GSJE:9=8=7&91&
MTLB._VTD=:[YF^H=8SCP4'V(=9$3 _1S5Y;R-2L$/2E/P 'Q@;!-\'AYL >$
M]*H]5G+DD]G:=COY'VZ/Z8[B.;]'_4!Y3]C$KE*]%C>7; 5F2+>D%&E(\C=A
M9>!C%=U# J_7!/2'22Y+WK3>EGZ0S3->D0^31ZIN*^8K\EF(,DNI+AFJZE-M
M7WP#L /^"INBN:Y1>;"@2]#LWENBRZ!G"R29#!H-#&D">$ZY7@9#8Y@R^3TH
MM]A+285Z%T>KQ\!#0_< ;V&.!PF:!-]=T2!TTF4U1XM4VH?Z /%1;;["))U+
M;& TR5J(L44211(N2=ZCFH9="Y4!#IB_1RG(1E7+=?SC-F93J-#'ZJ<+$9DL
MA^7=XL_F$/H!J='85WA)GFF8FIRNC-6!H:%J"7'4(U]S"WNZ;"-O?6MY(UE@
MWURHI0MUC7_)KHO^U-70)TA6V<86)LET%BSIO:+&^#ATM&I0O\ C2T,E7)9-
MY%Y9.K]A#S^[.Y'8*=C1,5;F+PIJZ:*)Q6\:70KV2A_7KDAJ4 RK&1ER5T4S
M!GND:89J0Y;V<:-6=37$\W;UOB%\!'.7'I:N$#9W%5,_B_-;GQ:42XL;64F+
MY&;;Z9 5JA&F7QZ+@:VZF9W/D>[JB[;#"$!YA.Y#"/H9\2UD-6L)A8\,<N&\
M:ZBS $MH11'QYJ!=V$AYJ.LW[(@ZM.,'M)BUWWH9XG)>(/NA);P?HG^AA\*_
MR/UPF'A!7BC<)RU(<$(\Y6N#4&10%><V#CVF\6Q_KW$5&VIZ-1K)?7BOYIS,
M5?@#7"AGDFZ":Q7;<MN@.-6,^)W0!W5M4!9\2>/K-A]Y OYL.Z\. 6(L2O5Z
MX#)4 SAH,H2S@"6:@Z1IFA@P//<OS2_P0'P9>!7*"W*!'D&?W;P1.[B_=:.R
M#;]K!E4N^&ZP0;49%P@FJ5/POZO3@"%8?TXE\!3+B'NJ>8)^"'P+S40;W,)A
M.>K1LE^191&:+(J79JMFC9(PB?GA*B_CPBJSZIO^=?8E]0?=RCBC9K*V*O @
MR,!_N25 CS&T^3]Y7.,-XQGYRX9@X(/"7)?$,RL7V5PKWZ@66'YGEZB]36?B
MXH$*@S5PA>:"SLLM ^+AJYMY,G'71&.PW*E]-5 H/]HRR/VBT#1>KZ0J675'
MLP95M=;^V/?J2V9%H$Y3:)CKE@_]3?0UCY3>ZAUI."AK6#JHOB+W[P[@*N0/
MVR,JOB@N-8=E650CZCUC5ZLKK",#BX&OQ@&W4G"W5E[;:GA7O9I0&B93-BJ,
M>C:]A756=YLE+&O3Y7%+,I*TYP7L1>7:8G&__Q/BMSS*N8\XK8ZWG=:=9$W"
MM^A\.;'RG=I^7A5KAM9;H"G]C]@M6I-^D2B1_%@TD1@NY_E?P"^J[)VOX8<U
M#M87Q %1+K:.*!(?D%W%7TD=F%&X58:59N*1\@_IZ=AOI3IZ-W9>/<?_'^P(
M\,1E*'8+O%/S!GNG$J'+L1ZUK_0@EJ.^P>!@HP%U21MZ2^.2=@P]J!F,9J,[
MP7[_+O0*1+BX81-@B>4'FH-BR!YT-MHD>8(\1'7T9F0K6E4R#VE"(]/XR%+4
M(3H<V8N.\6]$_D,^NR2CU<@]BSLRVUB+C(0_&CY+(N##!B?:"[A3[U7,@^MU
MOJGOX0W:L*BG\',BUE^*9. A+F3D-&9O1N Y=0*X#/JOUD7<!%VQ6FA9T';+
MP:*[T![3VU0">F&<&;4)#M"'^U/A+=H8%R62@P>;?D %;3.@JU!\RSSQ!&A6
MXT[J!?!;_90B%C3:1DF=#658UD3QH5[C2_]".$C_MXL)?DTL,+6!AY=H(1[X
M3]<=41=H;.^CDD!JR[RB<:"TP9AR#3QH>QL5"OE84OQ#H2L&LTLKW$4,$GUU
M7=5255GM& J5Q[2NI2=7GZXI8WGD73#_YCHDG3!U"!+#(XVAXB:?*/T3^2)'
MDVZC.AU_8UO/+%'NM6:SM=SC-4.YZZN3S#OY]_+H)J[(+0DQ.DN:PF?J[\E=
M?=)TFY2_':]I.S4S\8":?<+IBB<6BZB..]5<(/F[JM/D(#7EWC>\DR](<M2?
M4)P/>Z[K5W7[Y&@[@0ZG.<0J<#]&,G]1;%",-MU6&CE^QGVJHLI/AJ5JM]P"
M?2TP+/&(S@Q\"-NEK=%\],DG^J%)3H7X53@.;32)87]YKI$%2]B$H0)NKXS7
MY\$;<M[H,N'CB8"6"W\,:R5LB*-/&7X&J7 RX/9(.S)H#->ME_4;$G09K ?Z
M&.U Q6Y=F'9\CEH;3Y0DIA,L?'L8@J_#9_E4XA,QB=,FS(@>1S(,R=:_9,'Z
MJIHQ+*6NS+R_(D:;;8K-_DTP#0<37N#+]%EA9=@[[3V?,DQ,%#M=QL9@I^ ;
M^IHF-^E!W=J&.M8P;5^=KOP*T6H+RN["MUJ>)ECPH::>,'NLRE#E4XJ^U0UU
M>H>NP%? B'YHYS0I7>?8]IBY1#NS94JYG!C>\#0[&Y]7>S"A&!/7](4-1^^;
M:GWR4:.>X?P7FDL4J@+;&=4>_/VM"RFC*0>;'6@OBB,:_V)>2Q?6'>$,QFRT
M\00S@Z":T6+(XX5IC3S:?HV!I<Y1VEIW,I;PDYO[6$<I68UUG*]%#^OY_*CT
MA;6!PB4Q=34?)-Y!L'FE[)[G3"-;><MABCY9,U[QM?D!_P&OO?&=D$X^5/]*
M]+Z(5'M-4I]VV;I5EA938K$IW(,D)KK*R3/*D ;D._!U*6"O(JO)7O:=^[ A
M3OZ"/*RN0'&C\)*M2'DYC5R3J[H?,\6<#HP**C4F:A(\"_49X J'/5H^/%7>
MW[ 2',*-K;L)DDETVW=P:V&D=13X._4_RS2H>-%9DQ]T)"C*D Q'>S)T OB$
MPQ]B,U(FGUH/X[\XNVKWX>>K7U@?X9J"HY8O^*34=O,$;,VBY48_K##(2T_#
MQGK*M1O0 X[!Q#14*>NLTYM.<1)L5TQCJY4UOXWC"DHMT_3/4J--(;K#BY@&
MIG9-D)=N"='I:=3^C6..5+P!X\BB:B_6\3BC;1ZU[M4Q-6E66<$"<[8%2OW;
M*#0U+/+1[S#\$S1<-U+WPK.)P+1C'8VX.QXL_5B;VG*-?=#:TSRZZK-E5T-'
M_DW3KMKK*9<--ZR.B\;J7<Q(X!>MWO#:LY.8K<MS[,<NX[?Y\<N%59NHJB6]
M9+2TK.L:C9KUM/T6DY*8T;*<8PB_V!C'?^CWN?:DF.UZOB9='F\WROA17<!;
MO?07?8 ZKR>(^;!T8F<.QRGKG[9$'I$8TCQ..";\1OU>\4'_>;9R68^;G?FG
M<I^=T7!(,XP7L"2"9Z6T=^D$\TO6M:\3'LJJ:EDM-B7\:=1)1>%'Z[+EF'^
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MMS6&ZI'OVSR'_B&UK^$,ZU;,Y[H2[HL0CO6FT,M':RF6M+J4&]\JTA;4Z/<
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MKOXB>6))@.Y.'E'5K'V9**/'$5]#_N4EX+\\7TO3L#\M]Q;9-6PUAR<"=<?
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M%\6]%9<H7*DY:SLS76Z)F\;C*]<&31(_!4:[:Y00V%^GR)3+0[7S\OP5,<K
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MK:S.I]T00Y35S*6T>L9D#JLXF[V*'Y/Z@Z\5A40[B[NEQ?ZO%&,5IUSG 5U
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MV3]YO9(9"1]%7C)2F%3Z6''&IU-Y3ZUP#M#<!8O B(I?XLWBU22F=#:CF7I
M!I2/8[K*KV6G<@XH8Q)H@F[5@3 [22]0XF-4/ 9G.U=J9D"?-6YE^>H]HO65
MOP$1?3NY33.A+)F>J%F:U<MV *,2_L<0?!/Z4FR"-OH@BM&PSAD'A @52"F9
M@-F$3\K?8W7TX=6',%;I:NHJS"=K'O, ^C-^.6\&>B/TN*@9/>*#RC/0;<[+
MU(_1I>K.(E_3;&%J6:Q10!-7Q1C@4@]*KEZ4N9K1J1/$+^*Z:=6AM<(K1)T/
M)-N"+W7>K99BZ]4+"K;5I0FNE;RQ_:;^J9Q@32K91XZUD#(+Z6M-IOA1G$K#
MP5"2,%0_S(<JB]4N<CZGGH6;E3SIR-R_>!]DQ85>E'GR,Z6THJO*PLK-Z?&J
M]Y3Y,5N S8R!H(U@&[?-LQ@^(KKO0,.F*MKE-X2S2@:XYT57*S+(OI*>ZH=%
M<V52JB[M'P6%F1!3I(*Y_D%ZX* PVY,')4I/.PP@MU3=,@-73,(Y3?P&*H<4
M)%S/*"J,$U]DIZ=-D$WEE2QZI- +:X*RU0Z2UYYRS4=%B^,8^ 2@D6:P%K#"
MV4Q. T=>/9/WG;>] !32!#]3>>)?XOQ%&MDAZ>D@!^4&!=T3 4ZJPQPSH9N@
MG\2.[B%\Q,IC/A%+J^PY==(A^<OY\3)+RA?1 H7'(D_I0N6#H!$*AGJ39YWZ
MB&:UHPX:!^T0.U"ZE HF3F]5D2M%+$0=FO>#*P)&I%0)3,!@]$7Q#<VEP*OR
M=/"&9YWJ*?31<3M(0B:*\DE<^!+C*+4+F5UQG+$+"<ZCL^\CL8OO\0.0XFBU
M:#N"!^Z6%2,#GNTJ=^2WXQW-131,N*FJ7?>$$43^JK-6Q-'CM.]RW[,:M8&+
M5;S)A#;:07@2?Q9HE3;CI9Y+E6;LN.,O326V4!A>Z5RSAGZ<M,:RO_P:;8:9
MGFMC&HVW%_MR70RDJ'^%0W3? YF2;]HEGC;E3"+9:;IF"/8?[Q)P-G<Z-4UC
M*/0MY8.44E*V!Y14N3&Q%_:AN$3X(SZ,J_Z%:!IWGUL8UB&>8(<2(Q1;N"RE
M74DA)5$55?ZDI%E=54UD:0&<&ISHI]G*_#O\+32".]$_#98(%[NQT"G2:W:O
ML?VJY9Q8Z<KJI60?N1VEM7B/PD)ORSRF_,1:E="G%G&OA7=HI@C]_/W!"Y(M
M;F9XET)CGXHN [AL=Q' N$>:+XEFAQ7MD;[AMF:.E_<(1B1,5K)$IO!H=;$T
MP'^\ABS_X;8,LJJ^V;<C:\ Q+&=^KV!L=:!PM?!8X6-QNQC/2);62!/B>^7-
M\EEA_RK/*2?X?0'FJF>[[0;UFA3[0?@Z!#(CN9YRUZIJ/E^16.@C;%<6I.\0
M'U&1XX-EH]10V%F%!-CE]U'U QSI=D6S%&(XS(1=X(,,D#T*G%QYF&L VPK6
M\I^!W]*317%0>MPYR79H4YA67@#[^CU6_07O<WL&#"+9#LE0 W*=_I@9C>^J
M#&>_Q=<5^/% O")M4/ '^QBG$'=A76$1,@Y6X7= &8_YNGT&8M"?#CQH#GJ0
M+OE?)\^KN,#J-1+YI[DE!C3-P/^ISX\+$^W018;-E/9I(_U6*_J(#+</ZA-X
MM8,%W(VA%"U^)^=!Z2?\0\'7W&F$?:GGXLM$>B6QJ)P04,8'#R<Z&=>\,XG;
MW!O.%&V".'C^5>T1Q7%R L(IWE$Z'+E;GIVS&$VK^KDX!%U#.1+]"1O-^"?H
M*J;AW/,NQX<)PYS7X)NE@POR"+&JCY0 SJ^J*QD'/B#W9&NA.MJNY%K8E_DZ
M&H4O<!."VI :P4GO,K1"HG!^B&4KR OVX:E >76!>@*]JM@1F,F\F=6G&<ZI
M3GJO><S[$3T*/"?<$E0 79+4>V?!+^2U+N/1>:H]=O.P5,VS*M'_L6]746VG
M:\/_N_?L9V2/RY[9NV/M=-KI3-U=H+B[N[M+W(TD! @$0H2X)Q 20G!W+RVT
MI;2E[NYZOVEGGGG6^_[_:Q4Z)\]!6>M[P-GGOLA!KM_O)L\]Y4<_MWQVVKNN
M9R&=Z7=M[:"SF5=VR^#OYBS:_ W"+6_K:FND!()=OA[].>S*C\F8-*1]J"S[
M7-:P;T5N2LY25_N\L=PTFR[(TKS.W590%&3EIB>P>]#JU;8(+-QNN3=J)>+R
MCSJT&04+N9<Y"+7QN9-=!'O?Q9R[$F:P<<O3P -W78%L07RU:0)Z%'%A=2B<
MB!Q:#D6&HVI^/(O^$8T)B<OX.YKN0\EZ#]WO$I]]$-UG\Y_<;+1A5W_^=^CF
M37+(-?2)U=:P3LQ7RXL0+9C]2SY%23$AP<_2BHD<GY\SVHDN+A]FU1&J#HSG
M0/ '=U7D[<8OVU0"^157M'H/["?<I\NY"&LL?<E&E#7VTP J;:='I,<C:ID/
MUG$Q=5% V_X3!6&AJ[9G4A21A]9O)-^(ZUS))ULGGUMZE%2?Z?M=!,DS[YA_
M)OFYWQ&/?Y$;@K .+N2@,-O]>TEGHM9N_XP4$.>P_@OBD:2JE>W$N/0E/VTA
M?IM]YKOKA-L0A1^;,!7JZ+Z+<#0BUYY':(@V[E,2\N*_W%9#6)G$6W<%?RDM
M8.44OC%KZT]8?$V>W??Q^#:8B^\D]D1TC5L>[OLX;[M9W+;$]_8MPVU./KK-
M [<R;7Q=.VYUYK65<[A]N<M_:L-E0;#?3^#JX?V^GZ-_3?K8M1.M25EAMP/]
M(LUE;P5F0P9NVS\QD5FGUW$QTMSPE9<P]_)O_'0;&P$K^>%7[&'D-S[AB)Z,
M8-?OD=3,*[:UJ&^R87O7H!"Y_]K:AIK-&UU'0;M"%"OOHB=AM&7?87(0.3]D
M8[]![?+NA1GSH"YE\(9\C*TU @[)V7,,^1$T;2L<60'#KTM&;80;?GT?-8VX
ML<P&K48M_4&/@:,W>5M!+B("7;Z&K4-,VTS!5R#7["'!YY"XK?L1=.2==3N1
M7BC(K^^@/D5_LBP=!=#E/YQ&/\>\XS67GXG[P7D$\@#WC8T0]B.V?4\F[#HV
M8*LO7()=O"X!@< \^O479#3FTC(J"H49^_%]-!NC=3M:^MQ=XN#$)'A/6F66
M?![P_<X]1<00Z<;3A<<B\U8UTY?%E2ZWHL*2S_U81GF0F?[M?\AU>1==1XJ?
M^#;:>Q5=#T3NQS!J0L-W( OW169N3*'I8CM7E5._3W)?GD(1I+^S9!'9*_O\
MMR:2/43A^E7AH^!A.WKAZO#O]DW1?XTB;+]"O13WW<;/"PH2SZZ"4C:DSBTO
M)EW/?+@DF'@B;]UWNX@?P/:Z0&B?1T[87J$B8J3[-A34Q!=MAU.T28(-@^2"
MU+E5L:3T3+OE-<2DG(XE2D(%Q/6[&OPCN-IYAA(6/V;K3?DL:>G>:C(\A6+Y
M!"K3W]\@)K9G-JX*(9S)H2X?)WR3'[7D&AX)L_K^,_QGB&O.5L2;J?TV?<3;
MZ:R]^XF5F6G;>@@/LL,V9!-VY&:LBL87Y$N7W\+=ALXL78&C(S[X/A+GAGK'
MJ04_D5UJXT)8DC.[YQSA[WD_;2/A:?GP#2ZX^Y [JX)PJ3#<BB^P#Q'?+ W&
M=B!YWTNQU:B;3BZX1=!U!R[B*J!W]K!P-3#!-C]<&#Q@PQKL%<3&5;98&G+)
MBL78C:BOEQ*P_T$]_GX&NQI=Y_@4@T#)#E1@O5#']_AB^:@+VS9@4U"/-_R,
M_12]?I4/9@B-6+$24XX^N)2#J<)\^\-_87HP/HL6 ? _I<;E;%AD^7GG'TL7
M+?K;HO_[Y__O][_]_9U__->[[[W_P3\__.CC3S[][/,OOOSJ7U]_\^__+/[V
MN^]_^'')TI^6_;Q\Q2\K?_UMU>HU:]>MW[!QT^8M6[=MW[%SU^X]>_?MM[(^
M8&-K9^_@Z.3LXNKF[N'IY>WCZ^<?$!@4'!(:%AX1&14=$QL7GY"8E)R2FI:>
MD9F5G9.;EP^!PN () J-P>+P!"*)3"F@TNB%C*+B$F9I&:N\@EW)X?+X50*A
M2"R1RN0*I4JMT>JJ:_2U!F.=J=[<T-C4W-+:UM[1V=7=T]O7/S X-#PR.C8^
M<7#RT.&IZ2-'C\T<GSUQ\M3<Z3-GSYV_</'2Y2M7KUV_<?/6[3MW[]U_\/#1
MXR=/GSU_ 1;][6]___L[[_S#,H-WWWOO_?<_L,SAPX\^^M@RBD\_^^QSRS2^
M_,HRCZ^_L4SD/XLM,[$,Q3(5RU@L<[$,YN5D7HWF]]G\/\-Y-1O+:%Q<W3V\
MO'W] X)"PB*B8N(2DE+3,W/RH @4%D\JH#&*F:R*2BY?()+(%$JU5E>C-Q@M
MAWQUQO_GB+^?\=4A7Y[2<DS+.2T'M9S4<E3+6<]?L)SVTF7+>:]>LYSXQLV;
MMRR'OG/W[CW+N1\\?/CHT6/+V9\^>_;\^8NWYP?R'1N!V,[IN= UXK;4)>N"
MPH4PH_0H'Y<'ROME,;4]BO3Z3@6DN56![6B2D?OJ)>1AHY \4<.G3&LXM!.R
M"M:%O]I;PUO#6\-;PUO#6\-;PUO#FQELG9Z+7"+NR)PS+ZB<\#-J5]:XRD\V
MH(S4]ZJ335W:W*8V#;*]28WOK5>2APQR\H1&3)Z65A7,<CA%I_]J0+Y](Y!8
M#&+GB#MRQ\P+:@?<<9U3Z8362S*H#:WIJXDW=M=F-K0;H:T--=@>@YH\K)63
M)F02TA1?0)HIY=-._M6 XK\-3N%W% X9%[5VV-D:>^:DWDTT5.NO&ZB/TO<V
MI9B:C) V0S6V5V<Q*!3$<:&4<(@M(AXI$E!F_FJ_&VR<7T@<P^^J[-(O5=M@
M3A@/%!^J=Q",F#W50QTAVM:&%+/1 .G056/[5&K2D%A)&./*" ?+)(3#=!'Y
MR%\-*+;];I#9A]U5VZ1=KK5"GVK8RYANM>:.=SM)N]I":NK-*8W5M9!.E<4@
MTQ 'JU2$$;8"/UXB(TQ2):3#?S6@M!BD%H/<+NR>SCKU2MU>Y.G67;29OMWE
M0WT.TL:6$$--?6JSJA;:*:O&]8JTA &N&C_,4N%'BQ2$\0(YZ>!?[7?# 6>@
M/!!ZOV9?RK6&G;!SW=O()PYM*>[L<534-H695*:T%FDMK$-<@^OAZPC];"UA
MD*DF#!>JB*,4)6GLKP946S<"F;4S4%N%/##L2KK1NC7_TO FS,3DIM*&;F>E
MNC&B7FK*:!$9X!U5>GPWIYK0R[(XBBT.FH8X1%:31OYJ0+7E=X-V3] C\[;X
MVST;,D\=60WOG=C"TG>YJ:0-T6:!*:N%;T2T<VOQG14UA&ZFQ<'0$?NH6M(
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MUP+UCFV@;LN^!QU;;"Z.[[ ]<FJWQ^!%JYCF\W9YVEDWHN!0$),U$L]C6.9
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M(OLRB;D]^;2T;E1Q8B>I+*:CJ"*B@\,)[9!Q@SMJN4&=G=S@EB%>J'F(_[I
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M6])ATC]A3RB/P^[2GH;=ID\/_- ,_F@&L=Y:B#!5@E@;%8C''8$XH@E$T>U
MZDGX)190O_F'N$T(HKD?O9,%[SRS_-^X%P:^8I4'CS%K):/T)NE+:FO8"\JY
M\!?DKH@7Y'L13ZF/(N[1GT3<8#R.O/Y_ /__R1"LNP:B3;9#@O4!2'+0AD1G
M8XBCVD*D&_ZWA$?]%ACH-B&,\/[@D^C[EI,1\-HC/VC,K4PRRJR1OF TA8_0
M3D6,4,]'#5-ZH@:H?5%]]/ZHFXQ'T5=9CV(NLQY."P*VS(  U84@T5D#L<;;
M(=E*^;_G8E((1I!$MH%8%OYW.(?R+=C?;3Q ZOU!$"=\XYT6^,HK+V34O53Z
M@E43/L)HBARFGXY^3KT4\YS:&_N0_C#V%O-A;!?KG[CS[ ?QY]RF]U\&$9HA
M[.@:2##:!FF6^_][)B7=T1!2B=:0R'#Z'>U!^285N(V+0[S?^T4+W_!3Q&/<
M',E+CY+P$79-U'-F<\P0_6S<(*TK_@GM?OQMYH/X+G9?PGFW^XEGW.\GMGE,
M#T1HAD T0\21U9!DN!4RS?=!EK4Z9-GK0P;!$E(IN-^);J2O4=[L\5"1][O
M"+_7PD3Q2UY6Z+!74>2@>W7,4U93?#_S;,(#1E?B'>;]I"[VO:1.]WO)ISWN
MIK1XWDTY[C4]"$0SB%470;3V:D@UV K9IGLAU_(PY&+T(,?)_'<6R?YK&I/X
M,8'#?!/EQWTI"14.!<8%/?%-"_N'EQ]UEU,>=]NC/O&&V\F4Z^SSJ5WLVVF=
M'G?2VCQ[TXY[]:8W<'O3ZKAWI@5B-$,0FB%6:Q6DZVV!7.,]D&]Q" IL=:
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M21><=QP%TDYMH.W2!-9N#?#8<QBX>]1 L/<0^.]3A:!]*B#=?P"BE0] [+3
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M"2AH!A<T T-]'G!TEH' 9 /XVNX @=,!\*9H@H>['K"$ID +M0)R' :(Z0Y
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MWAO?%N5'.2X-83<$1W)J1(G\<K],_V+?PL "?G5PKD^+)(MW/C33YUYH&G]
MDB(8#$D6# 8G"8:"I@+N: ;A1GF(4E*$=/3\+-!8]*?TR++Q"KW5KZI--@S6
M6FV[7VZOVEU U+^0Q; ^D^+E=#S.EU(?*6972<,XI2%Q@@)QFG].0)XXPZ\B
M)%78&)HL[) F"F])$_R>A<;Y#4AB_0=#4,%30=_RY< ?[3@QVQ4A4WD.%!U>
M\+-<<\F'&IT5+QN,5C\Y9K[U=C7VX-42%[V./+K5B0P/IX8D'W)57 "[)"J4
MDQ<6+<B2)/NG!N>($\5H(E&#-%IT)BQ*U!,6&?A,&A'X+#0B<$ 2$3@8,A7P
M0#.(ULM#W/89D+U_-I0<FO>M2GWAVP;M)</']9?_TVRRI:<.HW*A@J#;5D2U
M;,IQ<ZQ.]R:7)/FQ\N*".9G1D?R4B$3_>&FF.%I2) D/J96&AIP*DX1<"P^1
M/ T+"7D6&A(R()$$#X9,!3S1#.*U<I"P;0;D[IL%90?G?*Y5G?>J66/!P"F=
MQ7=/&&_N.F9[H*,:K]-22K:H*V#ARK(YI/QT7U9FLM@K.2&,'Q<;YQ\9G2X.
MC2R0!(=72P/#3X8%A%\)]X]XBGY]%BH*&Y"(I(,A4P&O#7(0O ;MO>CY6;!'
M\6^E\JR/QP[,>=%Z:,[C=HU%MTX9;;QTW$:YK=[Q:&,5R;RRA.%06.#IFI7#
M9R9GB#QC4T-](I)C_"0)*>+ N+P0O]@*J2#F>)A/S,4PG]C^,'[,LU!!U(#$
M-W(P9"K 1;N_!,V0BEZSBW?/^%FS1_'=\3V*S]L/*/:=5UMX_:S!AG.M5OM.
M-.&T:^N(9B65=/N<4G=B2B&/$9OG[Q&>'<(+R8P4!J0EB7Q3LH-YR66AG.1&
MJ6=R9YA'2I_4*^E9*#=A0.(=-Q@R%>"A^R%LE2QDH.='V4Z%KPU*"F.GMLL_
MN[1+KO?2H?F7._76G3YCN??827NMBB9GD[QZ*B:MVLTYKH)+BR@5N@<7B;G^
M^>$"?FY\ #<G4^R151+"SFJ0,+/:0QG9=R3,S($0=MI@L'O*T)3 =[4L1*V4
MA6STN*C<)C=^?*/<R+GULO]<WRS;W75PWKE+NFM;.LUWUYS!:A2U$HPRCU-L
M$QI9^(AZ+W)PC8#E7RGR\BF7^GB5Q@K9)>D!].(B,:6H+IA4? 9U*YA4-!1$
MS1L*HF4_%T\%_-'Y<2MDH&"=[)^Z];)OVU;(/+NV"+E]<X/LY1O*<]JN'5W5
M<,5T1]D%.[7L#B?]I-,DJ\A6!BZDQ8/HW^Q#]VD,</-LD'!8]3$^U-I47U)-
M@;]+3:V(4'-:A*^](7*J&1$YEX^(B"4C 5.!H&6RD(SV_Y*5,E^;ER*/+LQ!
M[MZ>@UR[NU:F_<Z^6<VWM%94]AAOR[]F<S#E,DXG^@+13-))P_BWN^-Y9[Q)
M'J?]Z,Q3(6Z4UB@OXLD4;_S)?!_<B1J!_8DV ?9D#VI$8-\TZHNKGQJ$+9:!
MS$4(5"]"'K7-1FY=GH5TW9V-=#Y:)7/BX6[%F@<:2XON&6Y.[[7:'WO37BNT
MV]G0_QK5BM?EAO6XPL4S+@M=R9>"J2X7HYA.%U+8#A?R/3 7JCUM+YSRLKG8
MC1KQM.EXR[$]_98[%8A9B.Z'^4A_XTSDYMF9R.4N1:3]P1RD96"U3.W ;L7B
M9QJ+,Y\:K(_OM]@E?8@]%-!'T.'=HQB[WV5;,NYP,>1>(<ZY-YC@>#N*B+V=
M0K*]G4^QOEU#L[S=1K/H[:%9]KZ@FM\:9UA<&V=.!5+G(<\JY9%;)V8@%SMG
M(*=OS$2:GLY%JEZLDRM\L7=.^@N-Y;$C^AM#A\UW^3VW/<@=<M)R&R3IT0:9
MQJX#''/"@*\U;B#(#C,0B;492,99#>0Y6@Q6.9D-GL2;#EU%#>!-!C[BC9]\
M<9[*NWQYY$Z#/'*Q30$Y=4D!:;@S$RE_MU F[]U&A=1W^^;'O-5<*7EKL$GX
MUGP7YZWM >8;W&'R&Q=MYS=T7<<W'@;8-S[&MF]$9E9OPRS,W\9;F;[-M#9Z
M5V)K\.Z8G?[[=CN]#S<P>A]>8'3??;*;ROT*!+E\7 YI;9=#ZJXK(,4/9R)9
MGY?()'W9JACUY<""X*]:*P5?]3=Z?C558GRUV>OZS>$ _IOS(8=O5'6[;VPM
MJ^_<(^;?A3HFWX/U#']$&>C_2#'2_9EG?/1GI8GVKV93K5_GS#1_WS;3^#T\
MI:X&!#EU2A:IO22+%/;*(VG#LY#X/RMEP_\J*0:BG=L'U)>[@>Y:*AAO=@&K
M[3C [L( ?J\UD)3-@:%B AZJAL [I <!AW4@5%T;8C4U(4U+'0JTU:#JR"%H
M/JH*YXX>A&Z=J;0=1Y#:#@0IZ$:0E(>R2/2O>3(AL$I6"%MG<&#O7"8<6DP"
M[15.8+ &"V;KK<%FDSDX;#4&Y^T&0%;2!>;.H^"Q2PM\=FM P%XU"-VG"K'[
M#Z W(\J0?V ?5*CLA<:#>^#4E.K:$*3P"H(DWT60L$$$"8(%,CZP7)8-Z^4I
MH#23 /OGVL/AA=9P=(D9&"XW O.5>F"SZB@XK-$"_%H-(*U3 _IZ57#;H +>
M&_>#WZ:]$+)Y-T1MV?'?^D+.MNU0LGT;5$VIZ#SZ^F^B\Q\CB/]7680+\V3H
ML%C6!5;)V<-&>6M0FF$*^V<:@-IL'=">JPWZ\]7!9,$AL%QX$.P6*0-N\3X@
M+-D#I*6[@+%T!W@LVPZ\Y5L@8,5F"%VY$6)6KH>45>L@:TJ 4Y('.Q4%P!U2
M!-*1^4 W6@Y,ZPU =U(""G4_N'(. 2% "QS#=< ^R0#LLHW!IM@4K*O,P>J8
M!5B>M 2+=BLPOVP-9K=LP.R9#9B^L@73<=O?9E]MOUG\L/UD^=/FC?4OV]<V
MD_O?#$ZJBD#5F@\LP^7@9K4!6#@EH)'W ]GC$+CX:8&35!<<$@P!FVD"MD5F
M8%-I =8-5F!UPAHLVVW XHHMF-^V [-!U!N[OV;CF!\6WS 35C_LWMG\M'MI
M^Q/S8@K@J"0'F ,*0%!1!+KF?'#77PZ>%AO W5X)6*[[@<I6 U>!-A D>N 8
M9P3V&:: *3 'VPI+L&FP!NL3-F#5;@>65^S X@X&S)^CA^X[["^+">P7RV_8
M]S;?L6.V/[!#F)_V@YB?#I,!I^UR8*^L ,0#BL!2GP]>NLN!:[8>.!@E<'?9
M#PRF&E!XVD ,T@-\M#'@4LW /M\2,.768%MG"S8M=F!]%@-6E[%@==O^K^6@
MPR_+-P[?+3\[?+3YYO#*[KO#<\QWW&/['XZ/I@!X-(/C/@4@[U<$]_]9B^&;
MK@<?N^W )>P#=YH:,#C:0!'I S'"! A)YN"8;04.Q;9@7XWYBVG$_K$[Y?#;
M]CSNITT/[KO-$\<O-J\<QVTF'%]COCH.8;\Y]3M\Q]_!?2?<GL)_&0A[%("^
M5Q$X!^>![Y%EX&^\#OQLMH' :2]XDP^!N[LV,(7Z0 TU^>L:9_'+.=WF![X
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M[*%-<DF#RK,B![46!PT8KO%]9K65\]1A-^N)BPKU,?TP\;&'%K[?1\>A7V2
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M.OOQHF.4$#+3Q-&N6 IMZF31JDT>Z;V*:+E2"2W6J*#%>A4TGU5%\YUJ:'Z
M+.N4.IK]1=PC7A ?U=$<U;\17_ZE\=D<->?[WQKL#$@^X?+]?8PE![HY<J&;
M#Q^Z1@BC4XHX.A1((Z-&#FU;%-"F6PFM!\D(5JLB?9T:TC>IH^4V8I\&6AXG
M_M!$RSO$,\UOEA\TYRR_:7RBH\9'2]0BM-__ EJ1-3!U23[A8<"&7A;LZ,WD
M0B\O/O0,%4:W1 ETR95!QTIY9"XBH^]40;M^5;1=I8:VX^IH,ZV!-ELTT7JW
M%EH?(<YI?;.^J3UG_43[H_4[K?<VW[3>VJ#V&VO4>6V-NB^L46\^M-&CHI,6
M%3VT:,C294,_4W;TM^-"?P\^] T21N\X"?3(DD&W4@5T7JB,CNVJZ+!,'9E#
M&F@_JHGVDUK?&#/:7QD[=+XP#NI\9IS6^<"XJON.\4CW%>.MS@O&5]UG#-1[
M:H<&3^S0\ 'C9VBO344W=2JR2.?V)^L(-F;'$!M.#''EQ2 _8?2/DD#?-%GT
M+E1$CQJ5KVZ+U>=<EVI^=AG0^NB\2ON#TX3..Z=IW;>.6_7>..[5>^UX0O^E
MXU_Z3QT?Z#]R>J-WW_&+X5T'-+KC@,:W'-#DJB.:SH>.&E3T)-W;G_3=4 T:
M1I+SB*)S8K0C+T:PA# T5.);4*+L9_\<Q0^^Y:IOO1LT7GNU:[WT6*;SPGV%
MWC/W4?VG;I,&CUUG#!ZY[C)\X'K4\+[K[X:WW>X9WG!];?R/ZYSI91<TN^2"
MYK^[H,5O;C]#%U4J^I"N&ZQ _=^_SH@CYY%@QH&)]@LPWD/P<W2@^+N(&-E7
MH1F*SX.*U)X$U&@^]&O6N>^S5.\NJ]_@MO<JPUM>$T8WO#887_/<;O*/YR'3
M*Q[GS"YYWC4[[_G2_#>/.<M3'FAU@CCFB=8'O7Z&'DI4#)"C8@3IOO%D%BGD
M/-+(>:3;<']*=1%XG>0K]BPN0OIA=++BW8@\M5NA%5K7@QMT_PEL,[CLWV-\
MT6_0]'??4;/S/I,69UFSEF=8>^BG6">M3K"N61WQ>69]D/7)=A\+;?>PT&Z7
M#]IM\_T9>I/N'RQ-P1@BA<PCD]R-''VV3[F6G*]S''B?9'H*WTL+D;J1%*_P
M=URFVL6H8NWS$=4&OX4M,CX5LL3L1'"OQ;' (?J1@#76!P.F;?;[;[?;ZW^8
ML<?_#\9._X>,K?[OF9O]D3D3@,R-Q%3@S]!7EH+AI',FDNZ;2;I_G@KU:Y$V
M[4VQ"?N38EN>.P6N E=S B0N9D0KG$U.43^5D*=S++;,\%!TG>G^R,46>\.7
M6NT*Z[?9$;K*;EO(6OLMP;,.L\%['3<%G7&<#K[CM#[XC=/:D&].$R'HM"84
MG5;_ @9(43"*]+U4TKMSR2R*%2D?RM6ISRKU:7<K+3FOECOQ_5[D(WXZ-US^
M6&:"^L'43-V]R45&.Q.JS+;%-= WQ[39;(KJ86R('&2NCQAS7!<^[3P1OL-E
M3=AQU]'PZZXCX2]<AR.^N Y%H.M@)+HL_P4,(C.()7WO^]_W%DH ELM27M<H
M4Q[4:5&OUYNP_5%CSWNZW$OL2'&P_+Z\6+6=V:FZ6S+RC&=2R\RGDVNM)A.;
M;2?BE]BOB>US7!VSRGDX>IWK4/06]\&H0QX#47]Z]$4_]>B-^>R^+ ;=NV/1
MK2L67>?#4-*[$TC?RQ8&+!&#N6I)>+90#FXO4J'\N4B?=F:A[8*C->ZB>RL"
MY+871ZG-%B3I3N=D&:_+*K(83Z^T7IW:8#><W,9<D=3C-)"PPK4O?MR])WZ3
M9U?</J_.N/->2^(?>G4D?/1L3T"/MD1T;_T%#!>A8#+INWFD=Y<+PX=Z47BX
M2 *NM<K"^59=VO%F:Y[]#:XB.VK\9&<JPE6G2N)U)@K3C4;S\LV'<\JL![-J
M&?T9S0[+TCJ=NU('W)8DK_9H2Y[V:DG:Y=V<=(:U*/D^JRGEO5=3"GHVIJ)G
M0RIZS(>1Y!Q22><M).NH$H0WC8)PMU4(_EPB :<[M*F'VBRY=S4["6]N\)&9
MJ@E5F:B,U1DI334:*LHQ'R@HMEZ65\7HRFETZ,AJ=V[-['5KSECEV9@^Z;TP
M;3NK+NV$3VWZ'9_:C+>LF@ST(CQ_!:-)Y\T@G;.8'^9J^>!Q,^G>2WCA?)<8
M'._2H.Y;8LZUK<U!:$.SM_3:AF#EU;71VBNJD@S[RC/-NDL*K)845=BU%=0[
M-.>WNC3F=KO7YPQYU62O955E;_6IR#KF6YY]T[<LYS6K+.>;=UD.>A&>\V$L
MF4$6'V 9+SQ?N #^:>6&BTMYX,PR$3BT3(VZL]N4<V8)4W"RS5-JM#E0::@A
M4JNO+L&@JSK=K*,RC]Y27FK;5%KKL+"XV;FF:*E[9<&@5UG^.*LX?[-O4?YA
MWX+\:[Z%!2]]"@N^>A<6H->O8#R9 >F]7RIXX'H3!USJX()S/:3[]PO!OGX5
MRM9>8X[I;H; >*>[Y'";OV+_XG#-[J8X_8Z%J::+ZW+HC37%MG55U<RJBB;G
M\K(E[L6E UX%)6.LO)(9WYSB@[[9)5>(%S[9)5]8V27HG5."7O-A(IE!/@^\
MK.: OYO9X7PG)YSJXX)#@X*P<U"),K/<D&-=GRW_2(^KQ/*EO@H][:$:':TQ
M>HN;DTT:FK(L:QL*;2OJ*YBEM0W.A37M;GE5?9Y9E:M9&94;?=(J]OFF5EXB
MGOFD5<ZQTBK1.[T"O>;#9![ (BZX54>%BZWL<+J; XXLYX"]*_EAZ[ "96JE
M/OO8H#7O4+^S6.\REOR2[F"UQ9U1N@T=B<8UK1D6Y2WY-L7-9?;Y375..8TM
MKAD+EWFDUJ_R3JJ;8B74[?&)K[M /"'?/WDGU*%78BUZSH=I7#!7R@97&RAP
M;@D;'.MCA_U#[+!]A!<VCLK"Q&I=MN%5] 7]*QU%EPYZR;;T!ZHT]$9JU_3$
M&Y9WI9D5=>9:Y764V&6UUSBDM3:[)+5TN<<O7ND9TSSI'=V\BQ79?)85U?S(
M.VK11Z^H1>@9W?0SS&*'QY4 EYH!3G71X.!R&NQ<18.9<6Y8-R$%JR>T:,O7
MF'-WC3*%6T<\I!N&_96JA\(URP9C]0L'4DQR^K(M,WJ+;%)ZJNP3NIL<8Y=V
MND0N7>$>WKG.,[1SAU=(YQGB@6?(D@\>(1WH$=J![O-A'@5NU@*<:P,XTDN%
MW2NI,#L&L&Z2'59/B<'@E#JU9[TI9]LD0Z!QK9M$];BO?.E8J%K!ZFB=[)$D
MP_3A3-.DE07TN*$*F^C!!OOPY1V.(0/+G0,')ES]![:Y^0V<<O/KO^_FU_>.
M0%>_WI^]+P&XW AP<BG _D$*;"']=_U:TO])_UP^*P0]FY4I[;.&[(TS-KS5
M&UU$2S>P9/*G@I6RUD=JI*Y+T$U<FVX8.Y%G&CE>9AFZIMXZ:*S-SF^TW]YG
M=(V#]^@61Z_1$\1=1\^1MXZ>J]#I5^Y4D1FT APB_7L[Z;_3XZ1_?^^?6P$Z
M=_)#ZRYY2L,N/5K53CIWR0Y'P;QM7A(96P/DDK>$*\=OCE./GDW5"9_)T0_>
M5&(<L*G.S&=CJZ77QCXKCPUC-FX;-MNZ;CA.W+%QF7YCZ[+^FYWS>F3,]_="
M@.-D!KM7D/Y/SF#-^N_[)_F[*-!TD!OJ#DE"Q2%-:M$A,XZ<@_:\:0?<A1/W
M^TG$[ N5C=@7HQBR-UDU<$^VAM^>8FWOW35Z'KM;#-UV]QH[[QXU==P]:^JP
M^ZB9X^[;I@X[WY@Q=WRUL-^./SE+9K"_'V!V!&!B'< *<@9+=P T':!"Q0E.
M*#PM#+EGE"D9IPUIR:=M..-.._-&GF()A9X*%@L\%27E=S)1EG4R4\'S9*&R
MVXEJ5><3S1J.)Y9I,D^LUF:<F-&Q.WF$N*5M=_RUCNVQ+WHV1U%_OB/= -O(
M&:PC9S"T :!K.\DG';SB. URSW%"RI]\D/B7-,1>UJ9$7C:GA5YF<@1>]N#Q
MO>S/YWTY7-#CKW@1U[_2Q)W_RI=T^*M2VO[R(EG;R]WR-I='%*RN;%*D7SE,
MW%"D__5"T?+2)V6+BZ@RWTYR!NO)&0Q/ 723.[!H'\D_!I![E@9)?W)"U!U^
M"+\C \%W-"C^=XVIK+LV;!YWG3A<[WES.=\+XG&X%\EK?R^1W^Y^IJ#U_6)A
M^OU:48L';6)F#P;$31^LE3!^N$/2^.$92:.']R2-[K^5-+KWY2<;R',P,@GD
M_@,T[_TW/^<L0,*?% B]S@Z!SP7![X4,>+]0I[B_-* ZO[2D,5\QV.Q>N;+;
MO&9Q6+T.XK1X'<EE]B:1V^1-%H_1VQ)>@[?U?'IOE_#KO!L2T'Z_7E#K_1Y!
MS?=GA30^W!?2>/?J)Z/D.>PE=[!Y-\D_^F]^_%\ P=<!6"\YP>.S(+C,28'#
MG#*%\46;8OW5F&KYE4XU^\:@&7]SH1FB%YL^!K#K8#B[%L9S:& &ARH6<ZI@
M/9<2=G(IXA"W J[GEL==W')XDEL6K_VDG]S!EET E4=(_F\D_S) $,EWOPO@
M-,<.#.0':Q0#2Y0%4U2E&*$.10^-*-IH3B5EEZJ&#E05=*,J(HLFCT$T68RB
M26$*FP3FLXEA#9LHMK&+X')V81QG%\)98L]/VL@S4'6(Y)_Y-S_P!H#K/0"[
M5P!TI)#<!6"(@J"+XJ!%UJ&.RJ",&A0%U*7(DK5(HSE%$FTH8LBDB)"U"*$/
M51!#J'P81^7%3"H/EE&YL8G&A5TT3ARB<>":GZ"1$17-]:G_>P=@;4Q#:SH;
M6CNR(]V'$RTC>= \E0]-"P71N%88C5I%T;!'' T')=!@-;%6$O4W2J'^5F(/
M<50:]<\1-XDGQ%OBB_07 Y2:,T#IS_HH0\C.AR8DFZY+15L]*MH9TI!ASH8,
M)CO:>G.B31@/6B7QHV6^$)I7B:!9LQB:+I5 DP%)-%DEA<;CQ)0T&FTF=LF@
MT2'B#'&->"3SU>B-S&?C.9F/QBCSP1AEWQNAW#LCE)\/S4B^#>G_W]\!?/_=
M&,?O[X,8[.C@P8G,8!YDQ/.C;;806I>+(KU!'"T[)-&B5PK-A\@QC,F@V:0L
MFFTBMLNAV7[BI-P7L\MRG\T>R'TP>R7WUNRSW&LSE']EA@HOS5#QA2DJS8>6
M))M!^K\CZ9DN6E1T)^?A;L..;JZ<Z!*P )UB!- A71CMB\70KI8<?8L4VG3)
MH/5RV:]6J^2^6$W(S=&GY3_3MRA\HN]1^$@_IO">_H?":_I=A1?TEPI/K3XK
M/*:CTB,ZJCRDH^J#?ZG]"&V^YZM0T8UT;B^R#A\#&OK2V9'ER(E>/@O0(T(
MW9)%T#E/_(MCI=1GAR:9C\P.V??VO?+O&$,*;QBCBJ_M)A5?V<THO;3;J?3<
M[K#2,[MS2H_M;BO=9[Q0NF/W2>66+:K=L$6-Z[:H>?47D*%"05=%"GK)4]!/
ME8I!NC0,-F/#( 8'!GCP?/,-%OC,BA=Y[YDE\<:]1/JE:YWL<Y<6^:?.78I/
MG :4'CFN4G[H.*%RWW&#RCV';:IW'0ZHWG8\HWK#\:;J/X[/U/YT^*CYAP-J
M7W! G7-,U#G+1-WYT)'D>Y#N[2M#P1 E"D9H4C&2G$>$-<>7,!?N]\%^_*\"
MHT2>^:5*//+)E[[O72EWU[-1\;9'A])-]V4JU]U6J%YU'57_VW6]QF67S9J7
M7/9H_N%R0NN"RU7MWUR?:I]T^:![W(7\7')!@\/$(>+@/.A"^CZ+]/Y@(I+,
M(E:-BO%ZM"_Q%NQO8YE<SZ.\^!Z&APK?"4V0N!&4+?./?XG"9=]:Y8L^BU4O
M>'=JG//JT_S-:Z7V:<]QG9,>T[K'/;;K'?,XI'_$XX+!0<\'!GL]WAKM]D#C
M'<1V3S39]@OH0?J^/^F]X:3[QY%9)"M1OJ5J4=^F&M.>IMAPW$MT6W C+E#P
M2G2TQ.\1:;)G0_,53P=7J)X(7*AQU+]5^[!?E^Y!WP']_3XC!GM]UAKM9LT8
M[V3M,=G..F6ZE77+=);URFRCSU?S:1\TGR+6_P)ZD^X?1#IGC"A@LB1@AASE
M8Y8JY5FV+O5>ECG;M0Q'KHLI/H*_)89+G(A-E#L2E:5\,*)8?6]8M=;ND$;=
M'<'M!MN">HRV!*XPF0T8,]WD/VT^[;_=8LK_J.6D_]^6$_[/Z&L"/M-' Y"^
MFA@)1,OYT$>4@F&D[R:0[I].UI$C!:_S%>!^H3KE6J$1]8\\!M?I+$^!HVG!
M$@>28^5V)Z0I;X_-T]@27:8S$UFKOR&BV6@J;(G)9&B?V43(L,6:D+7TT>#-
M5B/!!ZR'@W^W&0I^9#,8\M%F>0C:#(2B=?^_K'Z$_F0&D:3O?>__64+PN4 4
MGI1(PLTR!;A8ID<]76S#>23?C7]?3H#XCHQ(N<VI2<H;D[(TIA**=-;%51J,
MQS08CT:WFHU$=5NLC!RDKX@8LQX(WVC;%[[;KC?\#*,G_!ZC*^*=W=((M.N,
M1%O"9LD\&"0$&$/Z7AI91QX_O"L1A/L50G"E2A+.5FE3CU;0.?:5./-O+_05
MF\D-DYW.BE=>FYZFL28U3W<DN=1@96*MR6#\(O/^N"66O;']UMTQ([9+H]<S
MED3OL&^//L%LC;[%;(EY8[\X!AF+8]&N^5^V/\(0TKOC>0$S>>%C(2\\*N>%
MZ]6\\'N=&)RHTZ <J#'GV%'IP#=;ZBTV510L,Y$?H[PZ)UEC96:V[F!ZD6%?
M:J5)3TJ#^=*D-GI'XC*;MH25=HOCU]HOBM_JT!A_U*$A_KKCPH17#O4)7YGU
MB6A/,.;#,++_Q 6 V3SPN(0+_JGB@HOUI/LW",/A1E7*[H6F[)MK[7FG*SU%
MQ\L"94:*(Y56%"2J]^=EZ/3DY!LLS2HSZ<BH,V]-7TQO3NVR:4P99-0GCS-K
MDV<=JY,/.E4E7W&J3'GA6)GRA5F9BO;_C_$CC" S2.&&#WF<<+V<'2[6<L+9
M1M+]%Y'NWZQ,V;;(B&UC@]V"M77N(JNK_*57E(<K]I7$J7<7I>HL*<@Q:,TK
M,6G.J39OS&ZRJL]:8EN3,<"HS!AU*$O?Y%B:OM^I./VB<W'&,\?BC#F'X@QD
M%F>2GSSS8!3IW6F<\+20!G]7LL'YA1QPLID3#K<(P*Y61<ILBP';^F8;GK%&
M5^&A.E^I_NI0A>[*&+6.LF3MEI(L_::B0N/ZPDKSFOP&>F5>NVU9;J]]<<Z(
M0V'V!J?\[+W.N=D7G'-SGCCEYGQVS,M!)F&?E_M?&,-%_DQ@@UO% !=K:'"Z
MB1V.MG+ OG8^V+I$'C9TZ-'&VZRXAQ<["PTTL22[%P;+=]1&J2ZN3M1JK,S0
MJRO/-ZXJ+3,K+ZFGEQ2WVA04+6/D%0X[9!=,.646[';.*#A+/'+**/CHF%&
M#ID%R"3L?X1Q[/ YFP+7R@#.UU/A^&(V.-#!!CN7\L),EPRLZ]*AK>ZTY!IL
M=Q3H:?&2Z&@.E%O<&*'2L#!>L[8N3:^R)M>HM+K$K*BRQC*OHMDFN[R+D5$V
MQ$PMG71,+MWAE%1ZQCFI] 'Y_$#^&QT()F'_(TRDP?,\TGM)_S_=2(7#;338
MO90&FWNX8:I7$M;T:E*'>LPY>[N8_)U+/,1:VOUE&UK#E6L6QVI4+$K1+6G,
M-BQ86&2:4U]ED5G79)U6TVF77#W(3*A>ZQA7M<TIMNJD4TS5/<?8JO<.L57(
MC*M"^_DP!>!.(<#O-:1W-E-@WQ(J;%M&@0W]'#"^7 R&EZM3^P=,.);V,7A;
ME[F)-G;[2M<L#54L7Q*C5MR>I)W?FJF?W5)@G-Y<89Z\J(&>T-1A$]LXP(AJ
M&&=&-&QQ"&\X[AC><,<A?.%;9L1"M/]_C!]A.L#U4H#?2/<]U :PDW2_3:1_
M3@Q18=6P, P,JU"Z5QJQMPW9+&@<=!&N&6!)EO<%RQ?U1JGD]B1H9G:EZZ8N
MS3-,ZBPSC>NHMXAN;[,*;^NS#6T;8P2WSMH'MAXE;MD'MKQA!+5\8P0M1KOY
M7N0 _$G.X<0B@+VD?V\A^9.D_ZTB_6M@3!"ZURA2VL;T:8VC=.Z:U8X"9:N\
MQ N' V1RAL(5TU?$J24O3]5*&,C1B^DO,8SHJS4-[6VQ"%JVC.Z_;+6U;\\F
M6Y^>P\0-&Y_NUS8^75\)M/%9^E]WR3F<J_MW!CMZ :9)_BCIX/VD?W5.\D'K
M>AEH7*]-K9XTYRA=Q^3-7^LNG#7A)YDV'BJ;.!:C%#N:K!:U.DLK;*1(-WBD
MVB!@5;.QSW"WF??P*@O/E1LM/58>M'1?><W2?>BEI?N*+Y;N@TB?[Y_R?V>P
MIPM@9CG ^"K2_TD'7THZ\*(9+JB;%8?*S>J4XED3MKQ96^Z,&5?^Y$T^(O$;
M@R6C-T3)AD\G*H9,9:@$3A6H^ZZOU/*>;-+UF.PR<%LW;.BR;MK8>=U^8Z?)
MOXV=UKXP=IR8,W$<1Q/'-6CZH_-D!@<[ +:2,U@W#+!R#>G?)+^9=-#*G50H
MWB4$^;N5('NW/C5UMQ5'XBY'GIA=7OP1.P.$0W:$BP?NB)/RVYXFR]J>I^"Y
MK5S9;5N#FO.V3@W'K4-:S*U3VO;;]FDSMEW69FQYKFVW^;.N[2SJV<[\U_'%
MY!XN Y@:(OU[C/3?]:1_DOP:T@$+]M,@_0@OI!R5AH2CFI28HV:TB*,,]I"C
M;MR!1WQY?8^$"G@?B1'V.)PLYG8X6\+Y<*FTP^%Z6?O#'?)VAU<HV!Q>KVA]
M>(^2U>%+2M:'GBO1#WQ2MMR/JO-]OX>;!@'&R!WLGP1HFP&HW0E0M!\@_1@;
M1)_A@K!SPA!R7@F"SNM3_,[3J:SSCFR>Y[TXW,\'<+F<CUC@>#Z!CWD^0\#N
M?)&0S85:$:L+;:*6%Y:+FU]8)V%V8;>$Z>^_2YB=?RIN>NZ#I,E9E)YO\P"Y
M ^0.+E\'T$'RZ[[G'R#YQP&B?Z-!X$4N\+K&!Q[7),'MNCJX7#>F.-VPH3K<
M<*8Q;GBSV=X,8K>^&<5!OYG,97$SA]OL5CF/R:TF7J-;/7R&MT?Y]6]OYM>_
M<YQ?[\X=?KV;K_EU;\P)Z-[X*OBCM=_OX 3 DDT "\G\BP^2_),D_QQ P"4*
MN%_E .=' N#P2 KL'ZN"[6-]L'IB3K%\:D<Q?^I"-7GF33-Z%D0S>![%IO<\
MB5WG>2Z[UHL*#LT7BSG57_9QJKV<X%)]M8-+Y=49+N77][B47[[A4G[Q[C]6
M?G\&-@(TD/R2_\^/.@_@]Q> RS4 QF-VL'G/#_3W$F#^01%,/FB"T4=#T/]D
M3M'Y9$O1^NQ$T?CL056;\Z>JS(53%;\DT.2_9--DOU;09+XM9I/ZUL\FB6O9
M)' [FSB>(&X2=_^C>P- XW: T@/_G_\[@.\5 *<; %9W <P^T, 8>4$?A4$'
MI4$3E4 =-4 %]4 134 >Z1199%"DT)DB@=X4,0RBB& ,10C3J8)82N7'140O
ME0_'J+RXB=A''/J/1=L RLC]R_@^_S](_C\ CC<!+.\!&+P$D@N@@5R@BOR@
MA"(D4PID4!XD407$4!-$R%J$T!@$T1+XD0&\Z$+A01\*)X91V#")0L%\"F =
ML808)":(=?^!N@84--2EH+$N%4T,J6AD3D-#)@T-O-E0+YP#=9(Y4:N "S6K
M>5"C>0%J+.5%C0$^5!\FUO"C^GIB1@#5=Q 'B)/$7\1]XJ7 -_5/ G,:*/#I
M.W44^O@OX1^A/LDWT:*@F385S?4(4RJ:,6AHXLF&QB$<:)C(B?JYW*A;P8.Z
MC;RHT\&'.KW\J#TD@-JCQ#I!U-XHB%K;B+U"J'6<^$/HF]8=H3GM%T(?M3\*
MOM=!P;?:*$R(O-%&T3=:_X5&)-]<G8)TPDKK^_L@PI:&=#=VM CD0+-83C3)
MY$;C$EXTK.=#PU9^-.@60(/E@JB_2@CUQXDILI?-PM_T=PE_U3\B/*=_3N2C
M_BWA=_K/A%\9?!!^88 BS_51[)D^BC_51XGYT/1[/NG_MH2=.A69WW\WA4Y#
MAC,;VOIRH'4D%])3>="B@ _-J_G1;)'@5],E0E],>X4_FPR)?#(9%?EHLD[T
M@\DFT?<FVT7?FAP0?6-R1O2ER7719R9/1!^9OA=[8((2]TU0\JXQ2MTU0>D[
MQO^%EM_S2?]G*E#0^?N["'(O7,F=<+%G0R<O#F2&<B$C<<&<70[_)YLRP??6
M"X7>6K6*O*%WB[ZB#XB^M%PE]MQR7/R9Y;3X4\LMXH\M]XH_LCPI_L#R'_$[
M],?B-RW?25ZS1.E_+%#VB@7*_47\:8'R/T+K[_FR))_T;T_RW5N3@BQR'MXV
M;.CARO'9+8#KO4O,@M=.Z?PO' J%GC*K11[;+Q)]R.@0NV_7*W[/;H7$'=M1
MR=NVDY(W;6<E;]CNEKIF>TSJ']O+TG_:/I+^W?:=W%G;;PIG;%#QM TJG?P%
M9'S/)]W;D_"5HV" *@4#R=T,L*!]\'-@?\7RYGKJ%;[@H4>2P#VW'*';KF6B
M-YSKQ:\YM4C\[;A4ZK+#@/0EAV&9/YCCLA>8&^3.,;?+GV4>E#_#/*]PTN&>
MPE&'-TJ'F-]4#C!1=1^QEXEJ\Z&#) 7=10!]2><.E@(,([,(UZ1\"#>FO@BU
M97L8Y,YY)R"(Y[I?+/\55KKP1:]"\?.>E9)GW1MDSKBUR9YR[98_X;I<X9C+
MB-(1EW7*AYQG5 XZ[U'9[WQ2=:_+#;6=+B_4M[G,:6QQ0<W-Q"PQ,P^ZB %Z
MD]X;1+I_A#A@M Q\BE6AO(C5I=R/-J?=B'1BOQSFRW,A)$+@3&"2Z G_;,FC
MOB4RAWUJY ZPFA3V>7<H[?%:IK++<X7J#H\Q]6T>4QI;/+9I;G8_K#7C_J?6
M!H_'VNL]/NJL\T"=M9ZH,_$+Z$ZR?4GG_/X.(H9\3Q"'UTER\"!)#:XG&E$N
MQC/8?XOUY#D>%2QP*#Q6;%]HFM3NX#S9'8%E"ML"ZI0W^S>KSOAVJF_T[=.<
M]AG66L]:J[..-:L[P=JG-\XZJS_*NJ\_XO-.?]@']5<20]_Y_A=ZD>Q TOVC
MR#H2!.!3BA \21.#&^FR\$>Z+N5TJC7;T217[OWQ_@*[8B/%MD4E2<U&9,EM
M#"M2F@JM5)D,7J@^$=2JN2:P6WLT8%!W)&!4?]A_VF#(?Z?AH/])HP'_VT9]
M :^->@/0:%D@&O4$HN%\Z$.R0TGOCET <\F\\#*##^YF\<.?V>)P)D>3<B3+
M@FUOAA/W]E0?@=FD4+$-\7'2D[%I\A/1N4IC4:5J(Q$U&L/AB[17A'7H+@_M
MT^\/666X+'C2N#MXJ\G2X*.FG<'73#M"7IJVAWPU:0O%[XP)HQ^A'^G=$=QD
M!ESP))T3KF5SP>4\'CB7+P+'"M0H^_)-:=MSF5PS65[\4^E!HA,IT5*C24GR
MJQ*RE%?$%:HMCZW0[(M>J-,3U:K7%=EMN"1BA7%[^+AI:_BLV>+P@^:+PO\T
M;XIX9MX8,6?6&(FF#9%H,A\&D-X=Q0'ODMG@1A8-+N5SP/DB;CA9+ 0'2I1A
M1[$1;:;0CG-]GCO_>+:_Z$AFA-106KS<0$JZ<F]RGEIW8JEF9T*-3GO<(OV6
MV$[#YI@!D\:84;.%T1O-ZZ+W6=9&7["LB7EL41WSV;PZ%LT(T_DPB/3N6#9X
MF ;P=RZ-Y+/#J5+2_<L%8'>% FPN-Z!.E=IPCA>Y\(T4^(JLR V5[,N.E>O.
M2%'J3,]6:T\MTFQ)J=19E-R@WY#8;E27T&M:DS!B7AD_;5$>OYM>%G^67IKP
MT+(TX:-%:2*:$V;S80@[8#P%;F62[E] A=.E;'"T@AWV5?'!MFHYV%BM2UU;
M2><8*7/B75'"$NXK#);LRH^2[<A-5&S)SE!=E)FOV9!1KE.77J]?G=9B5)':
M8UJ:,FQ>G#QI69B\DUZ0?-HJ/_D^/3_E@V5^"EKDIZ(Y8?8C#*/"^R0@]X#T
MK6(*'*^@P8$:TOUK2?>OEX;)>FWJ:*T%^U"5PX*^"D^AKM) B?;B")G%A?&*
MC?EIJG5YN1K5.24Z%=DU^J59S4;%F5VF!1DKS'/3UUIFIV^WRDH_:969?M<J
M*^.=958&6A#F\V$$P!/2O:^0_G^F#.!P-15VU]-@2P,W3#=*PGBC)F6XP8Q]
MH-Z>I[O&7;"]RE]\<4683$-9K$)M28I*95&V1EEAD79Q095^07Z346Y>IVE6
M[J!Y1LZ$95K.5JO4G.-6*3FWB;>6J3EH09C/A]$ =TGW_H/TSA.D^^XG_]NU
MO9$"&Q=QPMK%8C"R6(TRV&S"UM-DQ]W1X"JPN,Y7K*$F1+JF.EJ^HC))N;0\
M4[VPK$ [K[1"+[NDP3"CN,,DM6C /+EPC65BP69Z?,$1J_B"F\0;RX0"M"#,
MY\,X@)M9Y!Q* ([4 .QN!-A,NM=D*PU&VT1@1;L*I;?-D-;9:L/5LMB9OV$1
M2Z2F,4BR8F&D7$E]@E)!;;I:3DV>5F95F6Y:9;U!<D6K<4)YGUELV:A%=-F,
M9539(7IDV35Z5-DKRZC2;Q;1I6A.F/WH72+ U5R 4Z3['E@(L(WD;V@GO6L)
MP-!20>CK4H2E2_5I+9UTSH8.1]Z:=B_A\M8 B:+%X3)YS7&*V4VI*NF-.1HI
M#24Z"0MK]&/K%QM%U?681-2.F(?5;+0(J3E@&5+S-_E\:1%:_=4\M!K-YGN4
M2IX'<@['JLD,2/^>)?EK2?];V4.Z9R\_+.V3A=8^'6ICKP5[30^3IZS;7;"P
MRT\LMS-4*G-)C%QJ1[)24EN66EQKH69T2Y5NQ.)%!J'-749!BX9- A9-F_DO
MVF?FM^A/,[^FYV;^C7.F_HWXG<F/[I!G\BRYBP>_SZ"5=%^2OYITX#[2 9<,
M+H"6(4EH&-*@5*\P92L;M.,J6.[*ES/@(YS>'RR1W!<ED[ L03ZF)UTYLCM?
M+:RK0C-H::.._]).?=_.(4-6YWHCK\X]QEZ=?QA[+7EF[-7QV=BK'8V\VO[K
M*GD>3GR?03/ #,D?[R7=;SE YS# HM4<4#<J"I5C*I22,4-:_J@U1]9JIP6I
M(UX"B:L"16*'PR6B5L;)A VER@</Y2H%K"A3]1U<J.&]O$/+8_F@KMOR=7JN
M [OT7):?UW/I?Z+GTO=)WZ47?W*!W,6##60&'>0>DOVO(AU\&<EO&0.H(CVX
M9+T@%*R7AYPI74KZ>@NVI/5,SKA)]P51Z_P$PM>%BH2LC1$/F$B6\IW(EO4>
M+U;P6%.GY+:F3=5YS8"ZX]A:#8>Q'9K,L;,:S-''&O:K/VK:CZ"6_:K_.DEF
ML(N<P49R_J-D__VD [>O :B?)/V;].#,S;R0MD42DK9H4.*VF%"CM]BRA6]Q
MX0S>S.()V!S$Y[LY4M![-D'$8S9#W'6F4-)YIEK:85.+G/VF/GF[3>.*-INV
M$V<4;38^5+3>\$'):AJ5K:90Y4<'FLBSV 4P0<Y_!=E_)^G #5.D_\T 9)$>
M&K>'':+V"D/X/D4(W:='"=QG2?7;Y\#&VN?!X;7/G\M]7QB/R[Y87J=]J?S,
MO7E"C+V5(C9[F\6L]BX3M]P[)F&Q=ZND^=Y3DA9['DB8[7XO9;8+I4UWHLR/
M=I!G<+(?8)CD=Y/\122_8C- SDZ A'T H4?8P/<$+WB?D "ODVK@<<H(7$]9
M4YQ/.5$=3WG1F*<"V>Q.17+8G$KDM#J=S6UYNI3'_'0CK^GI+C[CTZOYC4[/
M"AB>.2Y@>/H>O\')=P+Z)[X*Z1]'X1]MZ ,864GN )G_XFF RBT N;L!$@\"
MA!T#8)VF@?-Y+K"[Q ^VEZ3!YD]UL/[+".B7K<'RBC/%_(HWQ>Q*,-7D[VBJ
MT=^I-,-_"MCT_ZEAU_VGG5W[ZA"'UM5I#LUK!XGK'!K_O.!4O_*)2_WR-^X?
MC0V1.T#R6TE^-<G/VP.0=)CDDQ[N_1OIX']0P.H*!YC=Y0.3N^)@=%<1#.]I
M@_Y]$]"[;P,Z#YQ ^X$71?-A($7C811%[5$*5>51 57Y<1U5\?%2FL*3$9K<
MDUF:[-/CQ"V:S.-7-)E'G_YC.;G_[63^-5L!\O>2_*,D_S2 UWD YB4 RZL
M!K>HH/>*#W1>B8#F:UE0?ZT*JF]T0/FM,2B]I8/".R;(O7,'F?=^(/4AG"+Q
M(8DB]C&?(OJICB+RJ8LB_'DU5>CS9JK@W#'B&O'H/Y:L!Z@C^R\@^<ED]F%D
M[YY_ -A? 3"[#J![!T#]%8#J-QY00D%00'&015F00F600$T00WT003,01AL0
M1$?@1R_@PV!8@/' C3G A3443NRDL.,J"AMN(/90:'C\/Q:2_"*2GT+RP\^1
M?+)W!MF[R2T K7L 2D\!Y+\"2",[R>0EF8(D3Y3D29$\>9*G0O(T298^D)(.
M-+0%0!?"CX@B,H@*@OP!@.3A0W+P./4?J*%+06UM"NH0VOH45#>EHAJ#BBJ>
M-%0*I:%B(AO*Y[*A7 71R(YR'40OL8(#Y59SH.Q:8@,GRFXA=A.'B;.<*'>#
M>,+Y1>X=YR>Y;QP?Y)'S@QQRO9=#[OE0BV3K:E!0G]#[_MV8K,>6BEKN--0(
MHJ%:'!NJ9+&A<BD[*M>SHU(K!RIU$\LY46D5L898SX5*,\0.XB!QFNN+TE6N
M3TJ/N-XKO>5ZH_R5\[4R<K]21IY72KC@Y3RHJTY!0])SC4CO-R+?C0W(IQ45
M#5QHJ.=/0YUH-M1*8T?-(G;4J.% C69.5.\D>KE0?8CKF_HH]U?U==Q?U#=R
MSZEOX_ZLOH_[H_H)[O?J5[A?JS_D?J'QAON9QE>>)^JXX+$Z\CTB'JHC_X_0
M@&2;D)YKID!!"_+=DIR-I045S1VH:,JBH7$X&QHFL:-^+L<WO0K.+WH-7)]U
MV[@_ZG9S?] =X'FOLXKGK<XXSQN=J06O=38O>*6S>\$+G6,+GNM>7/!8]_Z"
M^[JO%]S5_<)W6Q<%;NFBX$WBABX*_0A-OF?+4-!*^M]W(0Q-@IR'K1T5K<EY
MT(/8YBSB.#Z897*^,RWF>FU2P_W2>!'/"^,E"YX9]RYX:K2"]['1:MY'1NMX
M'QIMXKMOM)/OGM%AOCO&%_AN&-_CO6K\2N"RT1>A2T8H_+L1BEPP0M'S\_PO
MWUH"D$$ZMZ,LN=+D7%S(W72B4[\X.-'>,WS97ME&<CRS2>%\;)W'_="JG.<>
M?>&".Y:MO+<MN_AN6@SPW; 8YK]F,<[_C\6TP!7S;8)_F1\4O&1^5O""Q1VA
MWRQ>B9RRF!,[88'BQRQ0XJ@%2AZ9YW_Y]B* SH2[)*"7(J%%^>QI0GGM9D=]
MZN+!]L IF...8SS7#68FSU7[(MXKC&J^2W9- G_8M@M>L.T1.F<S*/R;S6J1
M,S;K1$]9SXB>L-XM=MSZA/A1FZOB!VV>2>RS^22UVP:E=]F@S$YBQSQH)PKH
M1+JWAQ"@#_GN)P-S_BKPRD^/\LC'DG+;VYEVU=./_4_W2*X+KLD+SKKD\I]V
M+A4\X50K?,QQD>@1APZQPP[+Q \R5TCL9XY)[K6?DMICOTUZE_TAZ1WVO\ML
M93Z4F66^E]O$1/D-Q#0Q-0\ZD&Q7TOV_]^\ \CU8#-Z$R,+#8#6X&61$^2N
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M.^GAFQX)AVU\*S-L RLR7_]?UM/X+Z'\K@7DW]3WJN7DGZN!E/5 )+FX[S;
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M0?;F98A^?0S9&V\@>_W]/W10_O150-D&((OZ'DO]#J!LU^/ N-/ R// D$N
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M15"S:GE0IWII4)]&<=" 9F'0'JV"H//:^4'WM?*#WVKF![.#:!#J7WGJ2>-
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M@HL:5 ,+9ZO[%_9J^!:LU_0I.*CE7?"3ED_!GYH^^1\T??-9#=^\_W(A 3A
M-=A22.NQG+RS<O ,"&@@*NBZ>*HL\JK5,+G:&)DU%DQ:S7A.4HTS-[[:DQ];
M%2 5514N#)\:)PJ=FBH.JLR5"Z@H4_2KJ%/VGM*FZCFE1\VC?$#=O7R_AGOY
M50WWLJ?JDTK_)ECU226LVE=.T_S?0^._@?J_HHJ\KP:825031:0%D^N%R&A0
M0NIT?20U#D=\HS43TSB1$SG=G1L^W8\?,CU4*J@A1NA?GRSRK<\6>]<5RWG4
MU2BX3YNEY#JM6\6Y=HVJ4^T>5<?:RZI.-8]5G:K?JSI5L?_#$:K!=JK[VL%S
M*'+PCGKRK@;RGNGD7<WDOBU<),R21VRK%J+;3!#1-AJA;79,<)L+)Z#-B^O7
M&L3W:8T4>,Y*D)XT*T/&;6:AK//,*HEC2[/<A)8%"O8MJQ3M6G8IVK9<5+2;
M\5#1KNF=DETC^S_L*Z"Y2#7OI^R%3;069@ UE%TT"TB=3>XY%PCODD7(/%4$
MS3-$P/P1\)UO#>_Y$QG/^9,XD^;[<=WFA?)<YL7RG>:E"B9TY4G;=U4(;;N:
M1..ZNF2M._O%5IT[)&,[SXG'SOU#/+;C+\G8V:S<MVPO_WP.U4O9<UN!QC:J
M 67G4';B?"!T$?E_KP">??*8U*<%]R5#X;K$$BY+;>&TU)F9N-23<5@:R+%;
M&LD9OS21:[,DFV>UI)0_9DF]8-22#BG+)<ND1R[92IR6'MEW3WK$XC?"$3VL
MS(A%_V4C*=ARZO=\RFZEW!K2PL(%0%H/^?\2\O\5@!MIXH0ULK!?JPS;M7H8
MO]8,XP9&PV; #E8#+AB[SANCUP4SH];%,!;KTC@CUA5PAJVKX9JO:^.:KNOE
MF:S;Q!NZ[CAOZ,#OW"%K7O&&K&;Y0U;]EU64OZ@=F$-JW+ 0*.\E_UT&Q*\$
M@M<"'J2&#IN L5NYL-@NP8CMJAB^71_#=IC!?,=HF.VTA>E.%YCL],'07:$P
MWA4/HUW9,-Q5SNCOFL'H[5K(Z.P>8+1W'V*T=_W*:.]XSFAM_YNCM8W]AS[*
M[Z2^SZ":5Y*.YE)VT@ 01KE>I*03=P!6NX'AI.W&!P70.R*&SA%E:!_1A=;1
MH= \:@&-8^.@?LP):L>\H'H\%"K'$Z%\(@]*)VJ@>&(.%$ZN@/S)W9 [>07R
M)YY _M@[R!]E_V'^/%J+5/=JZGO!&EH'Y.$1VP!O<G''O91_@!S\,&!T'- Z
MS4#YG #RWXD@N:0 \24-P@"RE\R)L1!=G@"9RYX0?A]*)$'Z^T((KC2 ?V4!
M>%<&P+UZ",S5:\1CXO4_M"T&:E=\/@-*VPQ$4K;/?NK_(:K_4<#\)&!P!M"X
M "A>!L0_,!#^PH?@FAB\:PK@7E<'"19PPQ3X=11PDS:HMR;1QB@$N)W\^1]E
M^ITF_.]4Z#L;".K0G:NT>;OW#_647[+N\QE0%/7;E[[%\1@PYM/Y#Z#W':!V
M!9#_"1!=!_BW0/<C[DC1SXN!>PK ?57@#QW@P1#@X4C@\?C/&_4_:7/TC%[(
MS^CA_[P%>$$%?T$3["4%O3SU#V7K/Y\!Q5#?_2G;\33EGP=,+@$Z/P#*UP#)
M34#Z-L#<I>P'Q),O/.51C@QE2.C>BG0_=> UU>0O<^"=%?"!-JL?@[[\+DCI
ME]])Z29HTK&;_H%5-0*K0IZK0(B-P0K)=P4V8+FN8!%(Q!(91"%12=03+<0<
M8A[10RS%!ZS$>ZS#6VS%&^S%*QS'"US"<RK:,_K?4[RC9K.?>/PO6 U]L.HZ
MU Y"7@^LQ RL[%BP,DY@I7S!\B/!\E*(7&I7&5%+-!&M^,"9B_><A7C+Z<4;
MS@J\XJS%"V83GC&[\)0Y@L?,13QD;N,!\Q3W.>]QC\?B+I\0_"^L-GFVE@98
M-?7/[5 :0C6QI/8X4'L\J3VA8$4)1!8^B(KP7C05;V7J\4:F!:]D9N.ES#R\
MD%F$9S)+\52X"H^%&_!0N /WA8=P5W@>OPM_PV\R?^)7T7O<D&5Q3?R97\0L
M\Q563PVLKA*U0Y':0VW1,J2Z#)X'C?MT'O11,0!O%:+Q2CX-+^3S\*=\&9[(
MU^"1?",>R,_"'_(=N"^_ '?E>G%'KA^WY=;AEMPVW)0[@!MRY_"S_"U<5?@3
MEQ7?XZ(BRUQ08IGS7SCW!=:0L@W)_PT(0^7/YT+Z)F!U1N,OK0EXKN&-)^IA
M>*"6@'NJ6?A=M1"_J5;@IFH=;JC.P#75=ORBVH6?5!?A!]5EN**Z!I=5-^,[
MM;VXH'8:Y]1OX)3&$^:XYGOFJ";+.:S%<@[]"W:H!.P0$5A36;!F\O2IBH]#
M]?'2>!@>&8S#77U7W-(+P'6]:/RDFXJKNCFXK%>"[_2J<$&O'N?T6IBS>K.9
MTWKSF5-ZO<P)O7[FN/YZYJC^3N:P_C'FD,$/S#[#!YS=AG]Q=QBRW.U&+'>;
M$<O;^@VL&>6;\\&.E 9K0>T8(8\7P]1PW]00-X=:X*>A#KALXH7S)J$X8QJ/
MDZ89S''3/.:H21ESV*2:.6C2P!PPF<G99]+!V6NRD+/;9 EGI\D:[@[3K=QM
MI@>Y6TTO<C>9W>6M-WO-&S!G^6O,6<'J?\&.H'S+P6--#EZ/%>#I:!G<'RF/
M:\/5<6FD*<Y:V."$I2L.6_KC@&4DL]<RB=EEF<7985' V6Y1SMEJ4</=;-'(
MW631RMTPLI.W?F0/;V#D"OX:BPW\U19[^"LMS@A66/XF6&KY0JK/DI7N'<5*
M+R9ZON%3/CU.GHZCQZLM\,MX'GZP$N+"6"6<L#;$P7&CL&?<1.P8Y\5L'1?"
M;+*)Y:RW2>$,6$_FKK$NXJVVGL);:57+7V'5Q%]NU2Y8:C5?JL]JB52OU5KI
M'JL=THNLC@L76ET7SK-^*M-I_4%FK@TKT_$O!H]U7U/V[Q/)^9R!"\X,3D\0
MX)B='/9.T,'VB<.Q>:(MUD]T8]9,]&=63HC@+'>(YRYU2.?UV>?P%]L7"WKL
M*@7==G52"^Q:I.?9S15VV?;(S+5=*9ICNT4TV^Z0;)O=5=E9]H_$+?;OQ<WV
M[""R,[Z!M:''+^5?H\?[!?+?X\1!=P[VN,ABJZL&UKN98+6[%5:X.3%+W+PY
MBUV#.=TNT=P%+DG\><Z9@DZG?*D.IU+IV8[5PC;'1IE6QS;13,<%LLV.R\1-
MCALDTQWWR34X7I2K<_I#;IK36[E:)U:NUIF5?,L[.WK]N))S>I/K^-$^G_QS
M%WGP%D\A!CQ5T.]MA"7>H]#C[< L\)K$Z?+TYW9XAO-F>\3QVR:E"F9.RI9J
M=B\4SG"?(M/H5B=J<&L1U[EU2FI=^^2J70?DI[KM5JAT.ZM0X79788K[&X5R
M=U;^"W)?^9-J\"OU_3QE'Z;7W"YZY6ZFU\R 'Q\K_!30ZZ^/A0$CT!4PGNGP
M=V':_'RX,WV#><V^4?Q&GT1!@W>&=)UWKK#6JU14[54M.]6S25+A.4>NW+-'
MOM1SM6*QYP[%(L]32H5>MY4*O%XI%GBQ"@7>GY#_RB-ZM?U$_3Y%^?O#@6T1
MY%OTV1_$H#=8#@M"M#$WQ SM(5:8&>S(S CVX$P/"N#5!8;S:P+B!%4!*=*5
M_MG"*?Z%HC*_2G&)7X.DR+=-OL!WH4*>;[]2CN]6Y<F^QY6S_6X1+Y6R_5C%
M+RA\Y;X[C4, N7\8N7\4N3^YWTKZ[*.O%X2)T1&N@;:(H6B.&(W&" >F+MR-
M4Q/FRYT:&L*?$A(M* M)E"X)SA 6!>>+"H+*Q7E!T^1R@F;*9P?.5\P,7*Z4
M'KA9.2WPJ$IJT WBN7)J$*M$*'[+X'G<X%G8(<K='D<U(/=;1I_=Y,(=42*T
M1JMB1HP1&F(L4!MMRU1%NW"F1'ES2R.#>,41$8*"B'BIO/ T84YXCB@[K$2<
M&58MEQ[6K) :VJ68'+I4.2ETHTIBZ&'5A-!?5!/"GJDDA'U43@ACE1+#6,6O
MW/0E]Z<^[X^E>3AX!D3;C<7TV45?M\8)T12GA/IX?=3$#T=EO U3%N?(*8[S
MX!;$^O/R8L+XDV-BI+*BDX49T=FBM*@B<4K45+FDJ":%A,BYBG&12Y1C(S>H
M1$<>5(V._)%X2M<?E&,B625"\2O7:!Q.#I[%4?\WTK9K!?GG0OJ<35_/2!2@
M+DD!U<DZJ$@V1VGR6*8HR8')2W+G3$[TY64EAO#3$Z*D4A,2I9/C,V42XPMD
MX^,J)+%QT^6CX^8H1L;V*D?$KE,)C]VO&A9[E7A"UW\KA\>R2H3B5P;/! ?/
MXW92_]=E $N(KG2@A;ZN3^6@*DT.Y6F:*$XW04'Z:.2FVS'9:2Z<C#1O;FIJ
M$#\Y-5*0F!(O'9>2+A.3G"<;E5PNB4BNEP]+:E<,2>I1"DY:JQ*4M%<E,.FR
M2F#B8Y6@Q/?*08FL4G BJ_B52V&?S^.VI@%KLH$>8C9Y\'1J1U4F4)8E1E&V
M&O*RC3%YL@4R)X]CTK*=.,G9GMS$[ !>7%:X("8K5BHJ,U48D9DC"LTH%0=G
M3),+3&]5\$_O5O1+7Z/LF[Y;V2?]HK)/VD-EW[3W2KYIK*)?ZG\Y1W-Q'_5Y
M$^7VY]%:R!T\ Z+]_F3*I\^"7!%R\I21F6^ M(+A2"FP9A(+)C!Q!>Z<F'Q?
M;F1^"#\\/UH0FI<D'9R7)1.06R3KEULM\<EID??*6:#@.7F5HL?D74J3)I\G
M'BAY9+]3],AF%3VR6(6OG*0UL(OZO(ZREQ:2]Q8.G@$!%40!76<72R&M1 ')
MI3I(*#-%7-D81)?;,Y%E+IRP,F]N2%D0+Z@TDA]0FB#E5Y(A[5U2(.-9/%5V
M4O$,B5O1/#F7HGYYYZ(="DY%9Q6<"^\3?RDX%[#R+OG_Y7#RY]_)6EU$WDG;
M[[9/9T#D'$0F.7ER!0=Q4R6(J=) 9+4QPFLL$%HSC@FN<60":CPX?M7^7)_J
M,)Y7=2S?HRI5X%Z5*^TR=8J,T]1&T<3*3O&$RN42^\JMQ"F)?<5=B?V4-Q+[
M<O83#F6?V4=S<"/U=\448%X%K05B*I$_E?)KR#OJ@/ &$8*G*R.P41_^C>;P
M:QH+GR9[QJO)E?%H\N:X-P5S7!NCN,Z-23S'QLF""=-+I>RFUTN/GSY'9ES#
M$I%UPV;BA,BZ_G>1==UKD?4T5M:Z]K_LH#FPMOSS[P+-KJ:U0)]EM30&E!W7
M!(22'OG-$L"K31X>[9J8U#X$;K,MX#I[')QG.\)Q]B1FXFQ_QF%V&,=N=CQG
M_.P,KDU[$<^JO98_IKU-,*J]5\JR;:.41=M1XI:4Q:R7TA8S66F+ED\(!]E$
M->^GW 4-M!Z)JNE4 \I.I>RH-G*O#L"=O-QI@2PF+%"&PT(]V"TTA6WW*(SO
MMH5-MS.LN[U@U1W$C.F.8D9UIS 6W7F<$=V5G.'=+5SS[FZN6?<ZGFGW(9[)
MPAM<D_G/>2;S/O!-NMA_6$-][Z7<#M*PAD^_!T3NUTXUF N$S <\254=^P";
M93R,7B[!J.5JL%QA@)$KS#%BQ6@,[[?%L'X7F/=[PZP_!*;]<1C:GXDA_:6,
M4?]TQK!_'J._<C6CU[^7T>W_#Z.[XBFCN^P]1W<I^P_+&H'YE#N3<JOF 'F=
M- \6T!P@'_=="KCT ^-6 Y;DY:8;I&"\41Y&&]5@L-$ ^IO,H+=I%'0WV4)G
MLS.T-_M :W,8-#<G0F-+'M2W5$-URVRH;%D&Y2T[H+3E I0V/X32QK=0VL R
M7^ENI7E ]6Z@/I>0CF90GZ.7 P&4ZT8^;D=:.FH+.3!YL?XN0'V/%)3W2:"T
M3P6*^W2AL'\H,1+R^VT@?\ )D@,^1#C$!U(A>[ 8HH.-D#FP$-('UD'JP!'B
M5[K^$]+[WQ%_?V(N];MI(3T/*'LR]3EA+1"\$9BT%;#?0?F4:T*JKG< 4#L,
M*!QC('M*&M*G)9 ZK0S!:6WP3QN#=V8XN&>LP3GC2"]!VI"<I9?065IT9VG!
MG:-"GZ6 LW33L^3[YWXCGA+//M%"?9]*-<];!22MIW5 W^8Q^#LXE&M)N4,I
M5^<8H$(_*G<6D+D \"YS:--!SO^]''!%&;BJ"?Q@"/R'G/^GL<#/@QM4VAQ>
MHX?P=7H 7Z\B:*"OKP!N4,=NT,UNW"!^^T3-US,@JGG83IJ#^ZC_AP +RC4^
M"6A1KM)%0'P9D/H!M/DGZ,?Q*Q>X*01N24@*%(';:K0QU07NF@#W1]%&V0%X
M1.UX1.UX3 _!)[3@GU#1GU"QGVPCCA G/E%,M4^C\8[8#7A3ML-QRC]-^><!
MC4M4>\H542YW,'?P#.8.<9_XX\MYR$,!98A(4*@F?RH!SZDF+XV -R.!M[1A
M?D^;I+^C@0_T\OE [?A("^XC=?PC%?WCQD]\/G,@YY<A&'VP,"6L""?"CX@B
M4HE<HHRHP4<TXF_,PGMTX"WFXR_TX V6X356X176XP6VXSGVXQE.XRFNX0D>
MXC%]QR/ZZ8?$@W_!*I%G*Y#SBPD!77.'T)^.(B807D08D4ADXP.*\ Z5=+=Z
MRFK&2[135B=E+<2?Z*.L%90U0%E;Z-Y[J%PG< \_4.GNXW?ZB=O4^M_H3K?^
M!:NB3NT@YY=3_MP.D2%8Z1%@>>.I+NZ?SH,^(H:RTZB?>9191GVKIJSIU*>9
ME#6'$N915@_N8BEEK::LC73O7?@51W$=EV@*W<5/5)W_4"^N<EA<&83[7UAU
M)6H'.;^B'*%"-:$QD9C^<Q[T5MH'KP3A>"9(Q&-!%O[@%^(NOP*_\Z?A-WX3
M;@I:\:N@ ]<%"_"+H!<_"?KQ'\%Z7!%LQV7!(7PG=1$7I._@G/ ESHA8G))E
M<?(+)[[ :DG :I#SJXL)A<]G0LJ&>*\P$B_D;?%8XH[[XB#<$<?@EC@5-\0Y
M^$5<@A_%4W%57(?OQ<VX)&['=^(N7!#WX+QD.<Y*!G!:L@VG)(=P0G(11^7O
MXI#"*^Q79+&/V$OL4629K[!Z,F"U>6#UI EJAXXB_M+4PA/5H;BK/ 8WE2;B
M9R5O7%$*PW=*\;B@G(&SRGDXK5R&DRI5.*'2@&,J+3BJ,@>'51?@D&H?#JBN
MPCZU3=BKM@^[U<YBI_IOV*KQG-FLR3(;M5AFPQ?6?X$UI'QZO+!#./C;6 IO
M#&3QB-IQ2U,;/VJ:XSNM<3BKXX:3.@$XJAN%0[I).*";A7UZ!=BC5X[=>M78
MJ3<=._1F89O>7&S5ZV8VZR]G-NFO8S;H[V36&9Q@!@RN,ZL,GW+Z#3]PEAO1
M.^H+2[_ #J%\4UK6](B[,XP>/:9\7#,0X;*!,DX;&^/HD-$X,'0B]IAX8:=)
M"+:9Q&*+20HVF4S&!I-"9KW)%&; I(99:]+(K#9I8U:9S./TF_1REINNYBPS
MW<I98GJ8TV=ZE=-C]HC;;?Z.N\"<Y<W_PKPO#.8/_IK;G3'TB+4"OAO#X-P(
M 4Z8R^/ "%WL&CD<6RULL='"#>LL_;'&(@*K+.*9?HLT9KE%#K/4HHBS9&0%
MIW?D-,[BD<V<12/G<!>.[.8N&+F"-\]B(Z_+8C]OKL5%WAS+^_QVR[_XK:/8
M3\SZ!G8$/>XH^YHM<($>KR?L::]OP\'>,6)L':N!#=8F6&,S%OTVCEAFXX4^
MFV!FL744L\@ZD5EHG<&9;Y7'Z;(JX79:3>5V6#7P9ENU\MJMYO%;K9;P9UH-
M"%JL=@MF6)V1:K*^(S7=^K54@PTK5?^%NB^\'$V/>GJD7G:B?%=R/O+PG?3*
MV6PGQ%H[9?3;&V*)@R46.]AAH8,;YCGX,9WV84R'?2QGMGTRI\TNBSO+KH#7
M8E?.FV%;RV^RG2&8;MLAJ+?MD9IFNUJZUG:[L-KNA+#*[I:PTOX%P0HK[%GI
M;WEB0Z\SRC]+_GW0$]A!;*#K-4X\+'=2P&)G72QP&88N%QO,<7%"F[,7,\LY
MB&EVBN0T.<5SISNE<>L=<WC3'(OYM8Z5@NJ)#5)3)[9)5TQ<*"R?V"]3YKA%
MIL3QJ*C8\;JHR.F9J-")E?F"\"M_4.VON@''Z16WQX]<AUA%U\NH'8O<)9@W
M21-S/$S0YC$&+1X.:)KDSC1,\F/JW$,YM>XQW&JW)-Y4MTQ>A5L^O]RU7%#J
M.DVZV'6FL-!UGDR^ZS)1GNM&V5S70[(Y;C^))[L]E<UV^R#*=F<'D?G*'=IR
M7*2^'_8G]Q\\?R&6TO4B>MUU>LFBW5L-,WV,T>1C@08?6TSS<6&JO;V92N\@
MSA2O"&Z95SROQ#.-7^29(RCP+)'*\ZR6SO&8(<SVF"O*\NB3S?!8+T[WW"].
M\[PB2?5\+$[U^ELVU8L5?<M-F@-GR?_W4_86<L^5H>2<=-U%]6CS$Z+97QG3
M _0Q+6 XJ@-L4!G@R)0'># E_OZ<(K]0;H%?#"_/+YF?XYLER/8ME,KTK91.
M]YTND^H[1Y3BLU@VR7= G.B[5Y+@>XEX1+P7)_BRLH3H*]<FD?N3_^^F_ VT
M_5H6,7C^0GO,0* Y2(#Z8 74!.N@,L0,Y2%C41+BP!0&NS'YP3Z<G*!@3G90
M)#<S*(&7'I@N2 W,DTH.+)=."JR720AL%\4%+!+'!JR11 ?N)B[(104^H,]W
MXNA 5O8+HD%^H)H?)?_?0?D#,;3/IVW/7+J>&4+[W# NJL/D41&NB=+PH2B*
M&(7\<%ODA#LS6>&>G(RP $Y:6#@W)2R.EQ2:RD\(S9&*"RV5C@V=)A,=VBJ*
M#.D61X2LDH2%[I(+"SU'_$'7;\5AH:PX/(25_<HE&H=#U.^ME+]J\ PH%FBG
MZT:J1PVU94J4&,71:BB(-D)N]$AD1]L@(]J128V>Q"1'^7$2HT*Y\5$QO-BH
M9'Y,5+8@*K)8.B*R1B8L<J8H)'*!.#ABI20H<H<D,/*,7&#D/4E@Q%_BH AV
M$-FOG*>:[Z.L3?' \D1RS@2J 5U/H^W7%&I/49PL\N)4D!VOCXSX84A+L$)R
M@@.3&._&Q,?[<&+C@[G1\5&\R+A$?GA<IB TKE Z.*Y*&!C;+ J(G2?K%[M"
M[!N[3>(3>XJX*_&-?2/VC6%E!_'[PFFJ^6[J]WKR[SZB@VA*HKTVM:68VI2;
M)$1FLB+2DG60G&**Q)31B$NQ0TR*"Q.5XL6)2 GDA*5$<$-2XGE!R>G\@.1\
M*;_D"FF?I$89[Z1.D6?2,EF/I"WB24DGB=_%'HFO93T265F/!%;D^85C5//M
ME+<VC=8CT4K4I9+SI5 ^?6:D\9&<+H^$#$W$9@Y!=)8%(K/&(3S+D0G-FL0$
M9_EQ K-"N?Z9L3S?S!2^=V:.P#.C7&I21H/0/:-#QC5]J<@E?;.L<_IQXC=9
MY[17LBYIK,@E];\<I!ILIKR5I 'S,FDM9'X^ RH@TNG/DB8SB,T1(S)7%>%Y
M!@C-'X;@?"L$YCL@(-^-\<OW87SR@SE>^5%<C_PDGGM>-M\UKT3@G%<GY9C;
M+IR8VROCD+N1.")CGWM3QB'GI8S#9%;&(9N5F?"%P?.X]92W)!>80]OO!J*<
MF$Q?)^:3]Q62=Q3+(*A$$0&E.O K,X%/V2AXEX^'9[D3/,H]&??R ,:U+)SC
M7!;/=2S+X$XH*^+9E]8(;$M;I<:7]DC;E*PG#DE;E]R0MBE^+FU3]%':II#]
MA^V#9V%YM!X*:"X2U401Y684 3&EY-ZD:GZ5?'A5R<&C6AWN-49PJQD.EUHK
M.-<ZP*G6#1-K?1B'VA#&OC:&8UN3RAE7D\>UKIG*&UO3PAM=T\T?5;U68%F]
MG_A98%GUI\"R\@/!"BPK/K.)%&A%"3V7B49B"N7FEI%[4W8X*9K_-'+/!L"Y
M4183FY3@,$,']C-,8-=L"=OF<1C7[ B;9@]8-_MC;',$,Z8YD1G5/)FQ:"[G
MC&ANX@QOGL\UG[&*:S9C#W&%:];XA&LV_6^>60/[#VN+Z;E42<_E"J"6**;K
MC&H@EK*#II/[-0-.I*SC9_-A-4<.8SK4,+K# *,ZS& Y=S1&SK7%B+E.&#[7
M"\,Z@V#>&0/3SG28=!8Q0SKK&./.N8SAW!6,P=R=C/[<BXQ!QR-&?_8[CGX[
M^P\KI@+S2<&::H!*^LRMHWE(V>&4[=M&_>\ ;.<!H\G-S7N$,%VL@*&+-3!D
ML2&,>\UAU#L:AKVV,.AUAGZO-_3Z0J';EP#MOAQH]4V%9E\KU/OZH-:W!:I]
MIZ':>Q^J/6^@NHAEU+ZPN)Z>BXVT'HGB)EH+,VD>M@,!I(7N"\A_>X Q2X!A
MRP&CE8#V:A$TURA ?8TZU-880'6M&536CH+RVO%06NL"I0%?* Y$0&$@%?(#
MQ9 ,-!(+(1Y8!]F!PY!=^RMDUSR'>/7?!/N)>2VT'JG6%:VT%DC/$[IH'G;3
M&/0!$RG7:A7EDQ<;;2 ')S=7WLI ;KL,Q#OD(;M#%:(=>I#980+A#@M([Q@/
MJ9TN$.ST!V]G-+@[L\ 9_(>8=E)!=RZEEQ+Y]@X2^1TDSMN?$6\^,?AO\DPC
M)2^<#Z12GR/H6WVHOTX#@ UI\7!R<J/M@.8N0&DO(-D/" _QP3TLIDV' D'.
M?X2<_\A0PH)>@..!8[0A.#;X'T7H!72<%MUQFES'J7/'5Q/[Z,])Z(_=)9Y\
MHI'J/67P]W"HS[%K: RHOZY;*7\'Y>\&#.E'- X""D< V>. X!3Y/G4%YZ0(
M:L=Y:L=Y5=H0Z]!FR)@VYK1)OCP.N$+MN$(;D:OTP+]*"_T'&N@?%A'D_/^A
M&_YX@;C^B<HEGW\/)X'^*IBRW:B_XRAW&'V; >6JG0#D3P,RYP#.=Y1]A?@/
M\2/Q,Q_X142;<@EP0XGD1 .X94";Y$%9L0;NT0;YWN _6$8/XC]HP?]!@_Z
M!OD!=?3!'N+H)_*I/$E4\U#J]R3*'G^(^G\,T*?^JE*NA'*E!G-_(JY_.0>Y
M_>7W409_+^0>0_>FFCR4!1[) T]4@#^I)B],@-<D+6^H'7_1B_$M/0S?TN)_
M1W/C'17^/17]_:9/L"(ML%+D_!A$FQ@\?QA-3"2\B7 BZ=/Y XLBLO=*O$<=
MWF$&_D(KWJ #K[$ K[ 8+[&,#'\-GF$3GI+[/R'W?T3N_Y :^P?]S7U\)-C_
M!U9"GBU#SL\HTU=T#4-B)&%'3"*"*3>.,M,I+X^RRNANU7B.!OR)9LIJIZQ.
MRNJFK#[*ZJ?[KJ/4;52J@U2R<U2ZW_ K??<-:OT-NN/U+US[ BNO!%9,SB^0
M!\NAMD"7,".L"6?*]J/^15+?DB@KF[(*\0!3**<&]S ==S"3LF93RCS*ZJ&L
M973_-?@9FVG*[,55G,+E3R<AC_$=WN(BW?4"<?X;6 4YJ@4YORPA4OP\+AQC
M^AM+JK$]]=.3,H,I+Y:RTB@GAW**Z:Z5^ 73:)HTX@?,HJG:05D+**>7,E92
M[S?@#(W'*1S#"9K$Q^DN1ZF21^C.AQD6ASC_A54642T$A)"04'MH3&1T\4I@
MAH<\:]SF.N-7KA]^X87C!UX"ON=EX#M>'B[P2W&./Q5G^'4XS9^!D_PVG.!W
MXAA_$8[PE^.08  '!-NQ7W $>Z6O8(_P#^P4_87MLBRV_0M6C4?M(/]7Y=(G
MM4-!@N<2%=R7-< -F9'X062'[V0GX9QL($[+1N&$. G'Q%DX(B[ (7$9#HJK
ML%]2CWV2%NR1S,%NR0+LE"S!#LD:;)/;ABURA[%9_@HV*#S$@.([K%%DL5J)
MQ:IO^/1_+].B94,\I.5]1UF .U2/GR1JN*@P%*<4Q^*8DB,.*GMCGW((=JO$
M8J=*"K:K9&.;2@&VJ)1CLVHU-JI.QP;565BGVHD!M1ZL45N)5>J;L%)]/U:H
M7\0RS7OHTWR#Q5HLT_.%15]@:2F_H<?*?7K$71]"CR #!A>UI'%&30%'-/6Q
M3WL$=NK88JNN&S;I^F.];C@&=..Q1B\-J_4F8Z5>$?KUIF"Y7BV6Z35AB7X[
M^O078+'^,BS27\=T&^QF%AB<8>89_LYT&KUB.HQ89@XQ^QL&SX$>FE'^2'K4
MTN/^)#UJ#YMPL=]0C!U&FM@TQ!3KAH[%ZJ&.Z#?QQ++_8^LLX*.ZTK#_W)F)
M"W$C[IFXZ\0]$W=W]Q /24B 0(! <*>X%Z?0%FA+A5+9RFZ[N^U6EKH;=9GO
MF23P\>WO^_'[,Y+)>=[SGG//?9_#O8-+#O:[E&"?2S7VN#1BMTL[=KKT8H?+
MB+#-95+8ZK)6V.RR1=CHND^8=3TAK'>]+)IQ>TZTUNT]T;3T>]$JJ4(T]3_<
M=>6RYPN\QJ7U62[SU_CXB ^]I[L&3GD8X:BG/0YZ>6.?5QAV>\5CAW<ZMGGG
M8XM7&39YU6#6JUG8X-4IS'CU"^N\QH0U7E.BU5X;1*N\=HE6>A\1+_>^()[T
MOBF>\'E+/.[SC7C4]R^B$"]]@*_8][>#@=LRX$8D_58$<)JQ'/.7X*"?/O8&
M6&%GH!1; P.Q*3 :&P)3,!.8A;6!A9@.K!!6!=8)*P-:A14!/:+)@"'1LH!)
MT5C 6O%HP#;Q2. !R5#@&<E@X V5@:!_J/0'?:72&_P'44@>Y)- GN:H_W0L
M<)6GNM-\/,Q8'N(I>%>(+K:$F6,VS!DSX;Y8$QZ.5>'Q6!$NQV1XKK LK$08
M"ZL21L,:12-A':*AL#[10-B8N#]LM:0W;+.D)VR?2G?8*97.\,=5.\)?46T/
M_URU/>(WU;8(A<J#W*'62]2]0?]]/ADXD@CLY6EF>Q0]5Z069J*,,1UEAY71
MGIB,#L9X=#1&HY,Q$ITI#$47" -1Y4)?5*UH252+J#NJ1]P5-2SNB%HA:8N:
M56F-VJ/:''5"M2GJJEIC]$MJ#=&?DE]5ZZ,5]U!1\A_V^19U'TUC#N3T&?3A
MVQG/1L:Q-DX=4W$&F(RWQEB\&T82 C"4($-_0@)ZX^5"3WRNT!5?+'3$5XG:
MXAI%K7&=XN:X 4ECW(1*0]R,:EW<3M6:N&-JU?&/J%?%OT ^5J],^$6M,D&A
M5I6@4*V*G^?-&(Z#<A]*N0>DW'^A#]_$>-8QCI5)$BQ+TL/29 L,)CNC+\4'
M2U+"T)42BXZ4%*$M.4MH22X0FI++10W)=:+ZY#9Q;7*?I#II7*4J:8UJ1?)V
MM?+D(^JER9?(+8V2Y _52U)^(@JUDF2%ZCU>2P">4%X'Q)+G$#WX=I9@,XQG
MBOE8EBI@.$T7_7)3],@=T"GW1'MZ$%KD46B2)Z)!GB[4R7.%&GF)J%I>+:J4
M-XLKY#V2,OE2E1+Y:M5B^5:U0ODA]0+Y!?5\^7,:^?([Y$<^5Z@I*9 K5)6\
MQ#EPC;IG\SD.+#4VL^R99BP3S,<P8^G+U$97IC':LVS1DB5%8Y8_ZK,B4)L5
MA^JL5*$R*ULHSRH2E655BDJR&L7%65V2PJQAE?RL*=6\K,UJ.5D'U+.SSFMD
M93U#_DON\K5"+3MS#E4EMYGW1ZE[JA#84\ ZG[&L9"Q+&5<?8^G*T4!KK@&:
M\JQ0G^>"FCQ?5.6%HB(O!F5YR4))7J90G%<@%.:5BPKRZL5Y>1V2G+Q!E>R\
M%:J9>1O5,O+VJ\OSSI*;&FEY[VG(\WY0E^<JU)2DYRI4E3S+OCY"[6,EP [E
M'E 1<\!X!AA'%^-I*5!%0Z$>:@HM4%7DB/(B+Y06!Z.X. J%Q8DH*$X7\HKS
MA-SB4E%V<:THLZA-G%'4+Y$73:JD%FU032G:IY9<=$8]J>A)\@[Y7CVI4*&6
M/(^JDJ?8UPO4/E1&SUE*OT5&&4\/8VGE^_4E8E25ZJ*\S!0E978H*G='07D
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MRUI[.*^5PFF=+QS7A<)A72SL9U)A-Y,'VYD*V,RTPFIF")8S:[!X9@_,9\[
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M[?$UT!K;"\VQ<] 8?0Z:HQ]"<^E=:(W\":UA!:;J.1=)"ZEFO@MHU>6M\WM
MH4L WP'Z;UIWAS'JTY\;TY_KK5*'SK0NM*>-R&)H33M <]H=&M/^4)^6074Z
M&2K3>9!,5T,TW0UA>CD'G(9Z-<W[*GK,56]Q0?R2_$A^PQCSW$T:J5O:QGG0
M1>_;RS%@G_U'J4]=AY74IS\W7D?]#8#V)E6H;M:&:#.+T2WTN%NLB",/,!9C
M6WGBWQH]O_F]K7C^QK.M[,36]?S, 4(SO9EF>1-]_Z;O"9TC-=M)50^/!>8[
M98C' ?L<R- ]J.LP RRF53:B35VTG1Y\%R#92R.P3P-XB 7Y0P8\Z;(HWL\X
M#K H/<CBYR!/_(>XT!_*(LJ;$3F8AYC @SL)S?6!F^0_Y O^WO=8TL\UB?DN
M'@'2:8ECV>>0M8#7+/WW5NI3TV@?H,LN:-"RBX[1A)PDIVB.3M$8G*;G?YCY
M>)CY.$.O?9;Y.,<XSH<2GG@N\("_P$&^P,XI_T/B\_3;%Z[PD6;^_/OD,[0I
MK\.9!')6<0S8Y_#-G(,,UYFZEORX(35U3@%J9Q;V7YA*&BK04M,$B(@Z\)@V
MBW(:@FM&P'6:A"=8%#_%.&ZR"+G)D\_3/-B?5OZ'\11ZALE\A@T^H[POYT7R
M%NJGN28RO#3V.6HWY\!!'H/' 2NFS.@\]1\!5._MOSQ!GKYW+0IYCBCW)VXS
M)R]P;%Y<N#_G%3/@=1J&-QC'FRQ"_L63TK\Y)F]QDK^U!GB;'7R;G7K[,1J+
MIU'!Z9J]A^LQ^QS"''M0UY;]-'Z<^IS"DIL+>K<7]D&4UZ&\OH!R/^3-!_9#
MWJ5I?)_C<X>&[2..S:>VP)>,XRL6BE_QQ/,U#[YO.#^_X<3^]B'"?'Q[\8']
M!]V%_0>KA7M [GTG2#K=>@%^I\?\9>Z[,-IQ%[UT\4/TY^/X%BOP-3WF5]A
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M3=:_$P4:%WC-F3F0,O=DKW+OPY5>@_&LMF=Y8:6*Y8OU,&YI@:56CABV\L*
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M^I@&U<6TJS:V5]6QPZJ*FZ'*^,6JB&<D)9RCTH0K5)*X5\6)]X.7P*>\_@>
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MDSOG&KER;@./RIGS&[FR_RQW]C^UVNR'RK+N@>H#';G$'X\UH!Q[BD$^[^>
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M7-REO\/OOH7/? W'_%QU^A@>\R%\^W>PB-\R0-_QWH\R6Z\S0%Z%=;U$H+X
MEW@67O4T'?>D]Y30JS'I1CT,ISC"U0?T)QU&P_W@;M_]'_N.J3_\0]8^B,_@
M5G]4)+IBT)6F=^&8;ZG2^TNMS\&WG\:.)[#C<5C.HS"?A^$R1V"2#S!H#F/'
M(8+H/ACJ/03I703,';#HV]&V'R?M0]K-M&ZO;_^%J4%LEW4RI]']B:P?('X9
M7SP#YWY";MJ1B)XL]!0AOQJW-^D@S.@N[+@#.VZ':=W&A+4?9KF/2</<67 3
M=ECG89Q.V&S!@BN]O]5J_4+)\[SZ,Z$%MP*7@(O U[+J+^9DT,=]76M.YCR
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M.T\QL:OEB6/&C;M<47$WRQWW@-RQKX!/%17[G7<_TBQ3AR(=[P&M*?2!J;V
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MS\$2GH1!/(X=CV#'$7C, S"M^V%@/V/0W <+/$CPWHT==\)6;R=X;B5@;B%
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MS9_F2,.Z0 NHYW4-Z7(E[Y7;_506$:2RT'"5!MM5$N1246"T"@/B51"0HOR
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M1FT-H[R&$5FC'\!1[S)CEH39YL\A++_C0 _H]+/2E%9\T8(OFG^L/[A #$A
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M15*AN_'0]PD6^GY%*_%WW&#SE =&VJ>]=J']O@T76Z=7M0>>T\0"'UFMSK2
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M+@VNU:K$=NMEV!-*,>[DZ!N,T1L,.I\Q0A<(3E$;Q"<H+%DOF:'HNIW^8W!
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MY W98!&;#MNJE&'ZF0+B&2I/.$QFR7I)=%4'L5[;0J3H&XED8X)$,D?'$]!
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M"-:\MQ=L^G 'V+%H"]BW=",XM'P].+IR'<A9M0;DKUX-BM>L F5K5X*J=2M
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M4@,/PXU50;2UU$]T%'GIS@(OSY7OE3MSO7I7ML?A.69S>?(,MP[((8/ZN2E
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MGX%R>>@HCXN&\CKJ45Y[/<IGNU6 >M]$0(<,#,C 6_0<D"YZ Z@7+P"&I2N
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M&_B;E4&X10F"Y10A8JL"Q&_;"6G;=T+.OP)!2\3!?[TD")7G@)_Q"O!SD(-
M5Q4(9.B#OY<E^ ;@P2?2[2<OR?T'-\MCS*.0]Y5=YC/*K/;[S&CP'W%O#ARF
MMP8-4]N"/U([0CY0.D4?R#="A]P>A?93GH>^H/:)'M%?BQ[\"___<5@G"0'*
M<T%HM ("[+=""%$%1'1]".9:@;^?$_B%DR=]$IG?>9G<K]Q\[U&/4K]/[*J
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MA^GP@(?9T+MI&:Y!J/N8.#I]5A(=ZI9$=<]GB.V%)3.S8?.2)-BU/A*T=P2
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M58"[21E\-RM!\!8%B)23AZ2M.R!KVW8HVKX-JG9L@]IIJ;Z(U;^+4&P?0B&
M$!]DQ.@P5]P%\["'Y5(6L%[:&+;+Z(/R+&W0G*,)>O/4P&3^;K"4W05V"Q0!
MOU >B(MV &7Q=F NV0K<I5M L&PS!"_;")'+-V OHW60M7(=Y$P+>*X0!]8F
M2: I20/50!:8UBO!PVD+>%*4@..Q!UA"0V!$6  ]R0XHV3AP*W8&4H4K$.O<
MP*6)\MNYE?:+T$;_Z73:_:?3)<8DOIOY _>,.8;K9W[&#S(_.'UD]CN/,%ZZ
M?&).!W"7BP,;<Z K2@,-<^!8K@0O_!;@D7<!EZT%'KY&P JS!$:"/= RG8!2
M2 2W<C<@U5)^$??3?KH<<I]T;F-,$$ZS)@B7V#^<;K&_XWLY7_#]G&'"(&?
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M1CK&_^IZQOLK\:K/J,M]P;#+*T&_:[^@E_S>IX<R*.BF#OE>I4T/\#$'+N;
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M['2 <+$8"+!SG&#[#(C:-0]2-9=!CN$&R+>2AP)'=<@C&D(VW7HRS8/P+5Y
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M:;TNH_1[Q"_N-UR_,2Z[?6-T3@.XKQ 'RB8)("E( 5M)YN\<),!P!019;X)
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MX![-_3%E/P>:+U N@#I11CY00&&007&01!D0H[&(H"H(HA;PHP'PH!FP:%V
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MOM:^(7V70UWZ!<?:].?VM1EH1VQJ,M"*6-2DH_E$&$*].XZZ?R9U_P+J_N4
M1ZM9<*"&NG\M=?]Z-5A?;\Y>6>O,OV2*O]A@981L7WFB<F]IID97<8'NK,(*
MP]:">M-I>:T639-G6]?G+K2KR1EQJ,K>[EB1?=:I/.>I8WD.VI7GH@VQIO>6
MY=EH,1&&<?[^JG&7.M_E$NK^U/L.U@+L;F#!UB8AV-"L#"/-)JRE34Y\@PT^
MHGVU83(]4^*5.JK2U6=43-:97E9JV%1::UI?/-UB2E&7=67A@%U9P4K'DORM
M3D7YIYP*\Q\[%A9\LR\L0-NB K0NRD>KHCRTF @C -ZF /R>1]V?UN (Y>^A
M_KNMF;KW='Y8W:H RUH-60M;''C[IGF)]#2%2+<WQ"JVU:6H-=?D:#=4%QO4
M5E6;5%5,M2@O[[ N+NNW*RA=[C"Y9(M3;LEQIYR21XXYI5_L<TO1-K<$K2<7
MH]7D(K2<:/PL/*7KX5H1]5Y:@P,-U#OIJ]<FZCZK9_# LEFRL*A=G^F?9<O3
M,\-#J*,U2+)U6I3\U*E)JO5-65I3&@KU*^HJC4MJ&\T+:V9:3:Z>9YM=->R0
M4;7),:WJJ%-:U0-Z_6R?7H6V&95HG5&.5IEE:#D1QM)9R*9]H/Y_;'P-:/Y;
M9@"LH_ZWK),%B[JE8/YL'::WVXK;T>DJV-KN+SYU9H1<75N"<E5KAD;9]#S=
MHFEEAGE3ZTQSFMHL,QI[;5(;%MLGU8\Z)-0?<DRHOT>OG^P2Z] VJ0ZMDVO0
M*J4:+2?Z1F?ASO@^5-(YH#W8WD9[T$&]IYMZ1R] WUQQZ)FGP73,-6>WSIG$
MW]3K*UH[.TRFLBM.L;0S5:V@/5<[=U:)?N:,&N.TMNGF2:VSK>);%MG$3%]O
M%S7]@'W4]#MV4=,^VD9/0^OH9K2*;4++N :TF.A%*L!OM \GQM> ^O<6RE_=
M ["$.N@\^BK<M4 $9@VJ0,N@":MQ@0-OS7POX8K^8,GBOFBYO+G)RMESLM33
M>PMUDF=7&21T-QO'='69178.6H9UKK4.Z=Q'?K<.Z?A@%=*.EJ&ST"*L#<W#
M6[[WA#Z7+M-9/-Q$:S"3NB_E+YL',$ =L)-Z<,L2 9BZ5![JA_69ZJ4VW+(E
M;@*%BP-$<X<BI#(7)<BG+LQ03AS,5X]=4*$=-="H'S:_W2BX?\ DH'^UF7__
M7G.__AMF?O/>F_G-13._.6CFWX.F 5W?NYM/GTDU 'OI#&ZF_KN*\A<N .@=
M FBC'EZ[B@U5(Y)0OEH+BE9;L/-63^+)&O$13%L5*IJT,E8J;D6J7-3R7*7P
MY:6JP<OJ-0.&9^KX#O?K>2U=9> YO-O08_BZ@<>2=X;N0VCHO@B-W!>BD>=\
M-)SHES*Z'J?2&G0"K*7\)90_;S' K.74?ZF2E% /S-LD KF;E2%KLQ&3MMF.
MG;3)@R=N4Z! U,9(D?"-2>+!HUG2 :/%<KX;:A2]-K2IN*_O4W-9OU+#><,N
MS4D;KFE,6O=.TVD-:CN.H([C*K+B>V?'SP'MP>@<V@/*GT_YG2NH?ZX%J*0>
M/'DK0/(N'DC8+05Q>[0@>H\Y$[%G$CMTCP\W:$\HK__N. &?W>G"GKL+Q-QV
M5TLZ[VJ1=MHU5]9^UW(YNUT[Y&UW_RQON_.M@O5V5++:BBJ68ZAJN075)CI$
MYW KG?]5M/\+*7\V=>!IZP"J-@/D;P=(V0L0>8@-@<>$(>"8//@=UP/?X];@
M=<*5\3CASW8]$<%Q/I'$XW@BA\_^1+F [8FI0E8G>H0M3@R+F)_<)FIV\B=1
ML^-OQ4R.HJ3Q890V.H0RA@=1=J*=7;0'\P$64WXOY;>L!YBRA?)W :0>H'RJ
MA/XG6>!ZCA<<+HN _65%L/M)#VQ_L@:;*ZY@=36 L;P:Q9C_G,HR_;F ;?Q+
M+<?P6@?7X-H05^_7S3RZU\_QZ/[R@D?G"O)K7T9!K4LHI'D1A2<:I>MO*9V_
M>;3^;91?0VM?L(?RJ8=''J<.?@; ^2* ]54.&-\4 *,[DF!X5Q7T[QF WGUK
MT+WO CH/_$'K811H/DQCU!\5,6J/&EDJ?_2PE!^O8"D^WLM2>'*7I?#P"TO^
M ;+E[R-'[AYR)UI.^?V4/Y/R:[=1_CY:_Z, $:>I@Y\'</H)P.(Z@ 'U<>WG
M_*#Y4AS47\F#ZBL-4'YM"(IOK$#^K3/(OO4%Z7?A(/D^!23>%S'B'Z8R8G_-
M8T0_KF5$/AXGSQCA]\@(OR5OOK> SG\'Y==3?N%^RJ>YAY\#\+H,8'\-P/1W
M )V[ *I/ )0^\X \]7Y9E 0IZOP2J YBJ <B: ;": ^"Z '\& P\="/F8 &P
M<"HP?W?^#80FA2\)_D<7G;\&RB^BO4\]2?FT[AZ_ -C>!%IS (V' /*4+_T1
M*!,HDX\R14 (Q2E/AO*4@(HQ_2X#8DDF$3\20^A+$=(- /L(311/D#_(I^],
MI?P2RD\[1?FT[AZ_T=[? ="G;)7Q[.>4^Q=0+M \ ?@(!WGH_RM 1(@XD2:*
M1),8$AOB0>B+P?@_3"!] "!=?+B*["07OH-*I@RJ&3&H3E1,&%2P9%#*B4%1
M;P:%(UDHF,9"_F)21]I(#UE EI(1LH%L)7L9Y#]&+M'[>^0%^<B@ /Z+]7\(
M(OL[JL8,:NHSJ$4TJ.NJF#$H9T?C\&!0/)2%8LDL%,DGU60ZZ2)]9(BL(&O)
M9K*+'"+GR"WR)_F+X#]$*>L?'!3[@:8!@SK4__6H\^M2U]4<'P>MA:(K@_)!
M+)2)9Z%4#@LERTDCF<5&R5ZR@-!:2([0ZRC91O:34^0Z&Z4>L[])O6=_ED+V
M1^F_<?Z21B[A^='?^0;4<8W4:"OI58]^UJ6UT*+]T/!CH6H4"Y736:A8Q$;%
M6C8JM) NTD<6<5!A.0<5UY(M9#<YQOFB^!/GH^(CSCNEMYS72LA]I80\+Y60
M]X4R\A'^%TK(_WR"O_--E '-%(D2T2!T-DQL&;JKL5 OC(4Z26S4FLQ&S4I:
MMR;.-\V9G*^:O=S/F@/<3YI+N7]ICO!\T!SE>:>Y@^>MYB&>UUH7>)YKW>=Y
MHOV:YP_M;WP/M5#@OC8*WM-&H7M:*'27W-%"X7^AB0I=4G* UC*$.K<=C<>.
M]L26]L/*A4&+ !::QK(_FV1R_C(NYKPSJN6^,9K.\\JHD^>%T3S>9T:+^/XT
M6L[WQ&@=WV.C,;Y'1OOY'QJ=Y;]K?)?O=^-7 K\9?1/ZV1A%KABAZ&4C%+M$
M+I#SQO\76L@#VE+W=J#NZR0!Z$(_N]):.--9=;)G/CEXL=[:A;-?VB9S_K3)
MXSZVKN!Y:-W(=]]J!M]=JQ[^VU8# K];+1&X83DB>-URD] URSU"5RU/"5^V
MNB5\WNJEZ&FKKQ(GK%#RF!5*';%"Z2.6*'V07@_0S_]"&YJ[(_5>9V&ZI$4!
MO6D\WK0GWCKPWM.">>'NPCQV#63?=XGCW'+.Y/EM4C'?-:<:@2M.TX0N.78(
M7W"<*WK.85#LC,,R\5,.ZR1..FR3/.YP6/*HPU6I@XY/I?<Z?);=Y8!R.QQ0
M?CO91N^W.*+<Y@G0?GSNX_G4^7RI>P;0> *EX5V@*CSU-X#[?K;,33]OUE6?
M",Y%[Q2^LUZ3!4]YE@L?]Z@7.^+>(G'(O5/R@%N?]#ZW(9D]KJMD=[MNDMOI
MNE=^N^M9A3&WAPH;W3XH;7!#Y75DC1LJC5OEAHHK)\!)E.D^GD_=.X@/,%00
M/H:)PM-0:;@3H@;70LWA0J@;ZU1(,/=H<#S_P<!,X7T!A6*[_:LD=_@U2F_S
MG2$[YC-;?K//?,6-WDN5-GBO55GGM5UUC==QU1'OVVHKO-^J#7NC^A(?5%O\
M#]6%/J@R. &ZTAIX4]\+!/@KG 5_1''@3A0?W(T2AJM1\G VQ@B.Q3BQ#D3[
M\^R.BA+8'I$BLB4\5V)C:*GT^I :N;7!S0JK@]J55P;.45T>N$AM.&"5QI*
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M;N%\I,D!'0)R6.<XZ@92=PYUG:D[CKHVMP"3.X#^/?IP>G/A)1TN-&IN/,R
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M^9$5.JV1#:KFB Z]QHA>=7W$&H/:\.U&U>%'C2O#KQI7A+]I7![QHU%9A&1
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MW#HHSQV"XMR3O'X.K;,2M,^0TQ)T3@TS1#N\BK'NIFX#=0NIFTS=\ . SQ'
M]03U3U.?OMSR F!TB3[X<1'*:RJ(UXP@7+<"KML#-^BU;W S\@0W/T]P ;K)
MB?<F!]M-=JB;#.1-WN F#?Q-&N4GI']C[3J.A:'A<SAEM,09U(UF77WY5USI
MQR?1(H^Y IC3EQL^ >C>H@^_0Y]]EY[_+CW_/2/@64MB!SP_F9LA;DQ?Y*;L
M)6Y"7N+$\S('W,OL5"\SF*_<(#3PK_Q)I+]9MIEC<1=0<9#C0/,<UCG C[JS
MJ#OQ.C#J)F!Z&]!_!E ^2^T7R/^0U\CK+,>;*FZ&#;DA-P/>&P5\0(/P$3>(
MGS >GW(2_I03\&?L])^Q4W]^G/ F7WQ#_B+2 SHT.2"V=?8I();:?JSO+-9W
M G5MJ&O\'*!Z$1!?I>9;Y#WR(=&<1_ED)"_QA1;PE3[P#6/R'=OFO@/P\W3@
M5VY.?N/&Z+<RFA<.N-_9)G^PDG^P(G]^1>X_H%:3 V+<XUCO -9YUM/ ^'N
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MG@$D&:\P&VF3J2/YH&!JQE,OBUK%[ 8U[ XMU.BD1@\^QW)JK.7]!WF_'?@
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MZ,^GKJ8'6ZL'AW4F&+?.%O;KQ\-NO0O&KG?'F U^&+TA J,VI,!V0P&L-S;
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M-WFSZ)Y\5)R=?)-\(LY.^E.<G2B)LQ-(O"2ZD\=8_X-)[ N)'"'<F+>02E)
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M[*$TKR(\O)KP[&K"L6L(CZXA)+FVVIX.OY;.=2V5O'8?GU\%4.%7(Y^O^A+
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MJ64:2*U5?UJK>M.ZU9,VK.ZT^>I*7Z'.]"UJ3S]?K1G'U))QLYHR'E9CQI_
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M=)TF7LOP=?8X?7"!%+X4?G@]^-.9FR6+R;_LD@DR"?ADWX]RT.1$"(0/FW^
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MS UJ<:'7N%RB1I<;U>#RD.I=7E&=ZV>J<[/^@#M9[H_[H_<("3<1CBWG=3*
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MW!REQ"U5<MP6)<8=4GS<-8J-NULQ<<^#CWEO55RL'9? LQ/.E68/3C(R"'2
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MQQ(6W*5,_DN3[ F_I12VM(_/EP TWF*$\Z*'I87OV/:A:))X"J[&1G,?$#[
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M[PSY"*$% Q$##D8,CC!6Q@V3[0C$,",QH8S"@#Y:2S2X>4 7'E"<1W]^N"_
M'_*# -(C#)\CMG%'8#;Z.+[S(_!9F(>9S=<"X?81P$# T5F4 [+$7U.\-W"%
M?%1) +DJ;D0*(XFD$<[3&,1S8S'AC\<$.P&Z\,2DXX7!?9*1*-$Z"968- 1
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MLTE?X$NZ@DC2%J20EB"7- 2'2%UP"?@)KS\#&#=1_C+(F@67? +<X9'Z\.T
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MAN'334 >V+8 SX0KX&S$HQ_7 <\!+8 +,D52Y!+QW,=@O.:N$W?=,..A=!E
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M*EIRI*0M3PHZ"B2KITQ2!JHD88 &,] 1)2SX@@E#!(^&"$H-$3 8(<XS7 [
M636$DVH !U@?WI+>>W##W(FOC8)<%[[_R@#M )CJ_Y7_T=:!#K1E2%U;FM0
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ML?8)#A\ZIXY^?77NW&??+ Z]_]6RE,X+*W-:V@,/'&P.;BRN#VW-.1A^,OU
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M6^[,BR'Z1WX?;5/%Q@XN9!/'9;%9T[>^]UZP_K>5RV)?!:^,?!FY*N3YFI#
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M3"4[8CYF.EE^R,//%"A;C-SNFHWTW9B+-']<(54!>Q;DP(G5B7!FBP!4]G%
M^R@3C$]3P>X<!0@J1'#7< :ZEB/XZ>" HXN%$'U;"#>P@2A##,0:64&2L06D
MFYA#CNE,N7M>!NGIG84TW9V-E,(JF6S8NR >Y%:&P:D- :"XG0Z:>\E@>,@%
M,$<= 7_"'LBG[( J;P.,,QCP/VL)W',6P%,T!X&B&40IF4*<L@DDJQA!QHRY
MV"J#- S*(,7/9DMDP!K9.-@UGP\'EOG!L36><&8#$=2V.H#>#FLPWVT)V'WF
M0-AO"I2#)D ]9 R,PT; .FP(@4<,(%A.'T+E]"#BJ"Z(CNI PK&9TM MA13=
ME$12O\Z3C(5_9$)@ZUQ?V+V( H>7X^'4:EM0^L<"M#>8@/$F0[#:H@?V6W7
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M.MP.O(L=YES#/@X8L!_Q^QO 0AT8Z/J%B:[C?N\%B91?#B+5=9"@OQ/B,4=
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M"4LKC.07E(3SJTOY_+92'J\[C\^[G,KG74G\&_\Z!&Z5@1CTGDC?-P<*CRZ
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M>1L[?0LPPWWC66"_"S$VWQ*L,5_3;"V^Y-F9?2ZU-_E<AS/^U($S_'39X6]
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M,80:+B-4? ^A+.!&"2!," ,)8@#(D'Q B9L*FKRN8,CO"!8"MF O: FN0F9
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MIY;@\\[JN_><]9S7=^L/7F#]UALL7WF#V<O_ 1AX#=Z:7,#6Y(9P'5Z(-A*
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M'T:V^MX+[67=YFQDWPR:Y%QG[PB]$G@H[%+@A?#S 8_"S[#?AYSB? LX&K+
M.!@*7K-A0-T7!AY+^7L-8;CQDM;^^OT#+BC&9Z+"4 "JK407:IQ7?JFAR;^K
M"-1\411E\C@GQ?Y^6I['K<1R[^NQ#<S+49WL"Q'K.6?#-H6="IF*.,[9&W4T
M^$3TX>#?8PYP7D;-AG_A[([XSMH1N<#8%@GTZ4CP7 H$R!$A$K=_*N[N GP]
M*G!WU^KS0X.%\'R3XXKW312Y%W5,S3\KPDSO%"4X7L_)HEQ,+_8YDUS-.A'?
M$GPDMB?L8-10Y&SD>,R>\)FX76&'XG>$74K8%O8D?CKJ4\26Z*]!$S$_F&.Q
MX#,:"]Y+@4"\AE_-F?'K_5Y\/6KP^6S2Y?W99BKTJ<-.XE6GVYK'+0R-.W4<
MTZL5L8[G"M,H)W+R?0]GE ?,IM9S=B>U1^R([XN>CAV)VQJ]-6$R:F_2>-3I
MY$U1]Y,WQ;V/V1@_%SJ4,!\XD/#3;R!A@;$48./.C</SLW'SEN/]:%#F@C9M
MGOEN8\&WO3;+G_:YR-[K\E:_UL(V/5<;Y7"\/)ERH"C;=T]N<>!,9G7(5%IS
MY&1*=\QHXF#"<,)$TE#\SI2!N&.I_7'_2>U/>A._+OEC1&_RU^#NE!_,[I2?
M_DN!X#5$2,#S\W!O5>'F;<;?L[HTN3_W&?*_'+04?33D+/V?/KK:A8X DQ.-
MX0X':A(HN\HR?+<5%01NSJL(&<VNC]R8T1X[D-:?V)>R*:4G>5M:9]+!]/;D
M*^D=:2^3VM,_1+6ESX6TI'\+:$G_SEH*</#<)-R[A5@MWI,V!>+/=>I<[X?T
M>)^.F"^[M\EQY=5!FNKI'J;QH;90^]T-L1[3U:F^$V6Y@2/%)2&#!361?;DM
M<=U9O8GMF1M36]*WI#>FSV;4IY_/;,AZFM*0_2ZF/OMS6%WV/+LN^UO 4B 4
M=_>OWBO&S5N/F[=3CC@_H$)Z/:+#_>>$B<#O$W8K+@Q35([U^QGMZ^+8;6^)
M=I^L3_89J<X*&"@O"NDMJ8SL*&R,:\GO2FK('4RMS9G,J,K>G5F1?3JK,N]Q
M6E7^V[C*_$\1E?E?@RKSY]E+@7!\%M(E"%"*F[=)F@"]:PAS&Q2)+R8TN!Y,
M&_!>VV(C>7K40^G@$,-PY[I@VRV=D>Z;6A*]!QHR6#TU^2'ME>61367U<74E
M[4E51>M3RPK',HH+=F85%IS,*BQZD%Y<_":^N/AC9''1E^#BHJ]!2X%(? XR
M<7-6X'6TKB1 OPSAPR8YPE]3*L0[.W5X+DU;2QR?=%/<-^*C/SW MAGKC7 ;
MZHCWZFU)8[4WYG*:ZDHB:JMK8BLJ6Y-*RM>E%I1MRL@MG<G*+CV6E55V-R.W
MXG5";OF'J+RR+YR\LJ_!2X%H? ZR<7/^^MQ]AR1:&)1";R9E"8]VR!-^VZ/!
M?7:'I?BA*;+"SG%OO<W# =8;!\)<^WICZ1V=*<RFMNS@FN:BB/+&JMBB^N;$
MW-J>U*SJX?2TJNG,E*K#6<G5_\E,KWV=F%[S(2JC>BXDH_H+9RD0B_<@#W=W
MG1B"[N5H?E@"O9B21'?WK4279]6X3NPQ%]LWXR(WO86N.SK&M%P_'.+2.1CM
MV=27Y%?3DQE4UED07MA>$9/3VI"0WMR5DMPTE);0N#4CKO%@9FSCM<R$EM>)
MB4WOHY,:YD*2&KYPE@()^/D7BA"@411!GRCZ-"Z"GNQ:AGX[+(K.'5(A'=YO
M*KISM].:R>TT[0U;_<U[)H*=6C9%4FLW)C#*!M,#"_KS0K/7E4:E]=3%)79U
M),5V#J1&=6Q.#^^830_KO)P>U?TJ(;KS?51,^UQ(3-L7SE(@&>]#*6[_5F'T
M84@(W=[*CZ[O%4"7C@NC$\<42?L.&PM/[W>0'=E#T>C;P3!MFV;;UVT)=R^?
MB/,N&$UE98WD!*=L+ Z/'ZJ)CAYHC0]?OSZ)LWXB)6C]OA3V^HLIG,&7\:'K
M/T2&K9L+">O]$KP42,?[4"F$OG4)H#N;>-#5[7SH_'X^=.JT(#IX6HXX<])
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M?A[48?]70+_S8^:(VR._+90'OCMI=WT/T^_X7J3_Q^>1US7?=[0K_M_=+P6
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M<NYSMH2]9VV)7/"9C ;:>#2XCT:#RU+ '\^-P/-3</?FX^XN5\#]K<$UWV#
M^[;)<MG3)J<5]^J\Y&]4L+4O%$69G<Q)MC^2D4W>GU)"W9-8X[TCKL5O6TP/
M:TO4$'LR<H(S%K$S9%/XL=#A\-_"-D:^#MH8^]U_0QQX#<8#92 >W)8"+#PW
M&C=W.NZM(MS=U7)$:%0E?6K3Y7G182;XL,-!_&8S3>Y"+4O[9'FXZ:'">+N]
MN1GD'9D%M*FT"I_)Y ;_L<2.P.'X_N"AV$TA S';PONB#T;T1E^*Z(E]%KHN
M<3Z@-PE\NY/ LRL)/)8"@7@?8G'O9OUJ;RG<?*L)/UJ5B.^ZM;B>K#/B^V.=
MK=CE#LK:4TW^6H=J0DSWE,7:;2]*)6_)RZ6-99?X#&?4, =36]A]R3V<GL0-
M89T)6R+:$_9%M<:?C6I)?!S1FHI?R6D+?BUIX(51EP)!>&X\[KW<7^V-KT>3
M#.%KISSA99\:Z>&0'L]O ]:BYWK<UQQM\]7<UQ!LLKTZRG9S69+K:%$6;4-^
MH4]_3B6S)ZN1W9'1R6E-&PAO2IV(K$_9%5V;<C*Z)N5!5%W&I^#ZK!_,NBSP
MKLT"VE* @WL_"?=>_G*\#Q*X^:0(GWI7$YX.*1+O;M+DNKS!4N1D/WGU@2X?
MC9TM;.,M]1&VH]4)KD/EZ=2^DCR?KL(R_[:\.G933EM(759_>'7F:%1%QDQ,
M6<:QF)*,.S'E.1]"*O*^LRIRP1?S7 J$XG.0@GNO"'=WW7+TJ__?K9=&?VY:
M0_C/N!KI_"9SX:.#+C)[UGFI3W<&&(VUA-ELJ(]SZ:M.I716Y'BWE!;[-Q17
MLVL*6T(J\GO#2_*&HPISM\7DYQZ.S<N]&5M0\"ZTJ.A;0%'A J.H$+R6 N'X
M'*3A[B[%W=THAG[T+$>O-HBC^Y,KT-4M*J33XZ;+#@P[K=HQX*DZV<LT'.X(
ML>YOB7'N:DBFM-1F>==7%?I7550&EI4U<8I*NL/SBC=$91=MC<DL.AB;7G0M
M-JOT35A.V;? G+(%O]Q2\%H*1.)SD(F[NQQK$4:?^X31LU%A=&M:!%V85B(>
MVVPLM'?,47IJ(TUE=+V?_D!OL&5W9Y132VNB1WU3AE=50[Y?:6UY8$%U/2>G
MJC,LHV(P,K5\<TQ2^6QL8OFEV.2JE^%IU?/L]*J??NF5X+T4B,%GX5?W5BU#
M<^U"Z-X0/[HY(8"NS2Q#IV<4B >G#05V;+9?.3E&4=JPD:'7.Q!DT;8NPJ&^
M.]ZMLB.-7M*6R\AO+@W(:JP-3FMH"TNJ6Q\97SL1'5.[-R:Z]GQ,;/WS\(3&
M>79BPT__Q#KP7@K$X[.0+XC/@@!ZU,.#;@[SH2M;^-'Y78+HZ.ZUA+T[]?FG
MMMFN&-GBKM _[J/3,1)HUC 49E<U$$LNZ4NAY?5F^V1V%3%3.JK9">TM(3%M
M?>$1K6.182V[HT):ST:%M3T-B^SXRHYN^^D?W0K>2X$DO ?%_.A]$S>ZU<>-
M+H_RHK/3O.C$/CZT?U:6,+-7EW=\E[7XX':R7->4EV;3),NX:BS$IF13M'/>
MQB2/C*%,K^2! D9<?R4KJJ\I*&Q=;TAP[V@8NW=G>$#OZ?# =4]".'U? D/6
M+?B%]H#W4B -7X-R;G2_G8#;EPN=G>1!1V>XT?Z#7&CG82FT^9 6]\;]%F*]
M>YU7M^SR5*N>\3<HF0ZVR-T:Z9"^.8&<-)%.C1W+\XH8+??CC#2RV,,];.;P
M2+#?\ X.8_@4AS'R.(@Y,L<,& ;?P U 7PID\Z)WM0C=Q/U_?H2$CF[E0OMV
MD]#,$2ZT^:0$&CZIQM5WS%2X]8BC=.U!BE+)+$,G=R_;)&UWN'7BSCC'Z!VI
MY+#MN93@;:7T@.EZ7[_I;C^?J6$F?6J&Y3EU"GO,])J:\_69 KKO%J N!0H1
MNH_[_])ZW/_C1+1O&Q%MFR6B\1/<:,,%$=1W09'8=LY0H/:,K63I*;>UN2>\
MU=*.!>C%'PTUC3H<8Q5Z*,6>?3#'F7F@U,WW0#W%:W^7)VW_L!=E_PYO]_VG
ML,?XZSD:=18\:/O ;2EO*Q&ZT8G[?QCW]Q8"VK;SUV< 2&C@+ _JO"&(6GY;
M3:B]H<-3<LU*-.>*BW3J94_YN$M,]8B+'%W.A6BC@/-)YG[GLJV]SY78>9ZM
M=Z2<[79V.SOBZGIV!]GEW!GL+_SU%V?7,^!(/@T.2[G7B/>@'Z&#8PAMQ_T]
M.HM0_PD2:K_,B^KN"J'*^ZL)1?>UN+/NF0HFWW,4C[E+717V!T,NZ$Z0"O-.
MI(;O[40=^NTL ^KM$F/WV_6FKK>[S9UOCU@ZWMEIY?#'&2N'.T\L'6Y_LG"X
MM6#A^#N8+^5*%T)'\368V8*?_RX\'_=OZSD2JK[)BTJ>BZ'<YW+$M.=:W/'/
M300BGMN*!#\G2[">>TDSG@7(>CT/DZ,]CU?T>)ZA3'Y>J.KRO$;#\7F[IOV+
M(6V[%],Z-B^/Z%B_NJ-C_>*MCO6S'SK63T%[*2<'$=HU@=#X=CP?]V_+:80J
MKA%0WGT>E/%)'"5^DB-&?=+@XGPRX@OX;"WH^]E9Q/,S93GE,T/";2YHI<M<
MI)337-(J^[EL6=LOI:NMOS2NM?S2*V?^=53>[.LN!=/Y,PHF\W\JF'S]J&#R
MY<>2]HPB-#&%Y^_#\T\@5'X9H>P[""7/":!H$">$X.8. %62+^AQ>X(9GSO8
M";@ 6<@1/(7MP$_$&H)%+2%RN1DDB9M MH01E$D:0/,*/>A;J0L3*W5@CY0V
MG)'2@H?8VR5MWHS0 -Z#EJ,(E5U */,60K&/$0H%?A0(8L@7I DT4""Z@2:7
M$QAPVX$%CQ78\YJ#*Y\)T/@-P5= 'P(%=2!,2 OBA=0A<YDJE @K0Z.P$JP3
M48114078(2H/1[$K2QJ<P?M_"#__<WC^382B'R$4^![AV3R(!L*(#!($!Y E
M6H,2T1PT2<9@P*4/9EPZ8,.M"8[<:N#&HPR>/(K@QRL/0;QK())/%I+YI"&/
M?R54\Z^ #GY)&!20@$ELQY+:]^/]QV<@\SJ>_Q AYC.$:-\1GHV0/0@@2Q E
MF( D01]D"=KX>JB#&E$9M(D*8$!:"V8D6; FK0('TDH@<TD"C4L<&%QB$,2-
M0Y%[&:1Q"T$AMP#4\@A .P\_]"\);#6(8*M' B>,;,@%;N8\0';@ Q>J(#@'
M"H-CK!C89XN#7:4DV+:N )L^*; 9D0+KS=)@O6,56,]BQU>!U049L+J#/<7>
M85]EP!K^&_[O0'I)=G@-]CHD<,7<];F 8LH#'G9\X.XA"&26"+A$BX%3I@0X
MEJT AV8IL.^5!ON-J\!N0@;LMLN [5Y9L#V"G5T-MC>Q)]A;[,L:L%W C_ /
M.Y!=L .9I?R]!D<M$KAI_7,OQM.8!^@V?$!S$P**GPBX1RP'<IHDN!9+@4N]
M-#AWR8#3H"PXC:T&QZDUX+AK+3@<Q$[)@<-5[)$\.+S&/F,_Y7\Z@/QW1Y#[
MY@AKYQUAS5+ 7IT(+AHDH*B3P$N+"WP,>,#7B@]\787 RUL$/$/$@9J\$B@%
MTN!>(PMN;6N W+<67(?EP76S KC,*(+++'9<"=>M,CC?PUZH_'#^I#+O_$-E
MSAE4/KN TB<74/SH"O)+ 0<UXM_WI.@J)&"H<0%3EQL"S/D@P$D(_#U%@<&6
M )\X*?#*E@'/\K5 :Y(':K<B4 :5P6-,!=RG5,%]M_J"VR&-GVYG-;Z1;VE^
M(3_5^D3^H/6>_%WKK1MHO'8'M5?NH/K2 Y1?4OX-'/$:_KX'H4B" &42!&MQ
M0X@)+X38"T(P110"_26!%24-_FEK@%&DL.!3J_S#JUWM&[U/8]YS6.L+;5)G
MCCJC^XDRJ_>1<L+@@\=5PS<>CXU>N+\S>NKQS? )%?0>TT#[D2=H/J2#^E+
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M?IR]VN%QV5J[QTWR-D_Z%*V>3"I9_G5 R>*OZTKF3]XHF?_Y3='\$2@MY?
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M,COM/69QTFN;Y7'Z?JNC]+/6A^GWK0]XO;.<]?EANH\!AGO]07</$[0QS<6
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M^:X/(O/85WT0_O)_S2T"QFH$L%(F@)T2$1Q5__E<BI,I%S@X\H"=)Q]8LP7
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ME_<+ZE^^(:!W\;6@[@_?A'3.$V&=<T1DNDU] *MP__7@_%LQOPIGGSN)^4<
MPDYB!S\',/L2':RO"H#%#0Z8WY #TYM:8'++%(QOV8'A;3<PN.U/Z=V.I'3O
M)-.T[^33-._6T#7N+J2KW1MBJ-[;SE"Y=XZA?/<I0_GV9X;2+<)4NOE/PWC]
M]>'^:]LT]0P.(&\_YA\'"#V#'?P"@.,5 ,M? 8SN\8'!,P[H/>>"SG-5T'JA
M!QHOS$'M]YF@\KL+*+WT!857X93<JR1*]G4^Q7U=1\F\Z:))O5E#DWR[AR;Q
M]B>:Q)L7-/%77VCBOY-_6(K77SNN?PWFYQ_ _!.8?Q[ XS* W34 LQL NG<
M--\P0?VS"*A\D0#%KW(@_U459+_I@,PW$Y BUB!!9H$8\00."0$VB0=ADDL)
MDUI*D'13 F2$XB=[*#[R(WI"L<B[?UB(^[\6\PNF\D]A_D4 ]Y\!;'\#,+Z-
MV?<!E'X'D"< LD0 I D;)(D$YLF"*%$$$:(.0D0/!(@IL(@MT(DSX(TZPC=#
M@B^ 4_\S((*;CJQ&N-$(#IG\] _S=DP] P1(FLK'<W?[!<#F)H#A/0"U1P"\
M9P!27P'$\1@XA(;G*("9(L!/.,# 8Z$(%W^.(E)'>LCLK^<@'B@4_O@-&H(O
MQ 3?" E>_&0=&O\'HJ%'$6T=BN@@;7V*J)E21-&61GAN-"(30B=2"70BD4<G
MXE6H&2U"_6@0K44;Z41L.]J+CJ+SZ 9Z0B/B[] W1/[?IO+UL&OK([VIXS"B
MB*H5C2@[TXA"()W(Q=()-XM.9,H91*8!=: >!I$>0,-H QI'N]!!.I$^C7Y!
M#_&_>8.^TK_($-IG&4*?\NE_070QVQ"[MI$JTJ#^>"ZC:T$C6K-H1-V73E2C
MZ$0YC4$4BQA$H1;-1UU,HK 4#:&U:"/:CO]\$IU /S*^*=QG?%9XQ7BO^)G^
M5I$PWJ#7?WGU+\00LTVQ:YLK4L1,&;_'8S+%]3"RIQ%]3SS&,#K12F(0S3PF
MT:AD$O5&U,$BZCUH *U&&UA?U<=97]1WLSZK'V%]5/^!]4[]#NN5^N_,YQJ?
MF,\T".L)>HP>_2^(*69;8M>VDD5R%+'!F5@;4,3*AD8L7.G$-)!!C&/Q6#.9
MQ*"$]56_EN^3?BO?1[U%?._U^OG?ZJWD?Z,WPO]:;R/_2[T=_+_K'>!_KG>&
M_XG>#?X'^L_Y[^I_XK^M3P1NHNOZA'_*;_]"+'A ;+!KVV'_=I !,DL)X;YP
M-*>(':Z'C0_]BU4D\X-E,NN-13[?2_-*_A=F#0+/S-H%GI@N%GQDNDSPH>DJ
MH?NF&X3NFFX5OF.Z5_B6Z4GA&Z:_"E\S?2IRQ>R#R"4S(G+!C B?1^?,B=#9
M?R'6F&\OCKG8_UTD@+CC3-S5@;@94=^<;6GO9[O17SH$,Y_:Q[$>SLSDOV=;
M(G#;MD;HIDV+\&_6G2*_6/>RKUJM$/W):H3SH]4FL4M6.\4N6!T1/V]U6?RT
MU4/Q$];OQ8]:$['#-H1SR(:('K0A[ /_0NPP=S9V;U>1/Y]#^.(Q^2G!5U\=
MZHVW.?74?1;MOILOXZ9+%.L7YQ2!GV;G"5^:5<[^P7$>YYSC?+'3#HLD3CGT
M2YZP'Y0Z9K].^HC]N,PA^WTR!^W/<"?M;W/WV+^2V>E I'<X$LGMCD1BVRPB
MACC3$4?,=17&?.S_ 7@<4Y_'".;"ZV!5>!1H0-WRMZ6N^7G0+_F$\)WUBA,Z
MZ9'!/N9>*';8K5+B@&N]U*1+F\Q>EV[N;N>ELCN=5O%V.(W*;7>:D-_J=%1A
MB]-5Q8U.SQ1&7;[PUKL0[CI7(HVDUKH1B>F(,QN()S\0?^R=(7@<X2+P/D(,
M'H=SX4:8.OP89D&=#7%F' _VYS\4&"4\Z9_,V>V;+3'A4R*]W7LN=]RKD;?9
MLUUNH\<2A5&/ <7U[B/*:]VWJ*QQGU0==O]!=<C]H>J@QP?%E5Y$;H47D1WP
M)C)(>CKBAMW?![M_, W>1S+@R1P^>#!'"&Y%<^#R'$4X/<>8.A+MP)B,].;?
M&1XFO"TT3FQS<+KD6%"^S/J ,MY:_UKY8;]FQ55^"Y4'??M45O@,J2WW&55?
MZK-+H]_[I&:/]VW-);YO51?[$:7%_D1^<0#A(>YTQ&-J!@"?PP'NQ0#\ED"'
MGQ+YX,=X03B=( N'$_6IO0FV].UQ[OR;YP0);XB*%AN)3)):'9[%'0PKDAL(
MJ518%EROW!_<IMH3U*V^.'! HRM@K59GP#;MCH C.NT!O^DN"'REV19,5-M"
MB&);*)%'O.F(-P/W ,!3?)N[@7WGQQ0*SJ<QX4PJ/QQ.E88]:=K4ME0K^L9D
M%[YUB?["J^,CQ%;&QDLMFY/&[8O.DUL26:K8'5&CTAG>K-81ME!C05B_5FOH
M:IWFT,VZC2$']!I"K^C7A[W0J0__IEX?090;(HDBDI^.^%(PU;WO8>?[&=_B
MSF=@W\FBPY%,)NS+$H?MV1JP,<N"OC9C-M]0JH_P\N10L;[$&*G%"<G<17%9
M<AVQ18H+8BI56N?4JS=%+]!LB%JB71<YJ%L3.:8_-W*O057D#X:544_UJJ*_
M:%;-(:IS8X@24IAN:AW>8O>^A?W_$N:?RL%[_3P*)O/H,)''@4WYJK NSY0V
ME./ 6I[E*=2;$<3I2HN2[$A)X+8EI\NU).8I-B:4J<R+KU6OC6O5G!O;I5,9
M,Z!7%K/>H"1FEV%QS%FCHIA'!L5QG[1*XHE::0)11HK33?U6Q]0Z_#HU@VSL
M_@4 DT78N8HHV%+$AO7%2K"JR(BVO,".V9OG)K@H)T"T/2M"LC4C3J8Q/55N
M7EJ.8DU*L<K<Y+GJ%4E-6J6)G3K%B<OT"Q+6&N8E3!CE)IPRRDFX;YB;]%$[
M+YFHYZ<0%:0T'0D&>(CK\)]T@-/8N0X6 ^S&6XZM:+1,!(;+%6!%F0'56VK#
M["IV$5Q0X,MNR0N5:,B-D:G-3N+-S<I4J,@L5"[-J%0K2J_7+$AKU\E-[=?/
M2EECF)&RS2@]Y;AQ6LI=HXRT]SJ9Z40C*YVH9F40Y>FF]L)=W(N7L/\?Q^X[
MB=D[*K%W5@&LJ1*$E7-YT%^E2W576C':RYT$6DJ]V?7%P>(UA5'2E04)LF5Y
MZ0K%N7G*!3EE:KG9=9I966TZ&5F]^JF9JPV3,[<:)64>-4[(O&64E/5.-R6;
M:"*UU!RB/-T[W LWDW$=L/\?+L$98/9X#7;O6NS>M7S07R<#B^NTJ8Y:"WI+
M]2S^^BI/D>J*0+&*L@BIDM(XV<*25/F\HARE[,(2M8R"&LW4_%:=I/PE>@EY
M0P9Q>5N,8O(.&\W)NV$4F_]6-RZ?:,87$+6$ J(\W8NIO3"U#K@/]E?@##![
M(_;/X4;LWHUT6-PH"1U-&E1K@QF]OMZ>K[K.7:B\QI]37!TFF3\WAIM3F2R7
M69&EF%9>I)I<-E<CH;19.[:D6S>Z9*5^9/$FPXCB@X;AQ;\91I2\UHTJ(9K1
MI40-*4_W. [@"J[#,9S!'NR>XYB_K@5[%_;PQ7@;VCY?#%K:5*!^OC&MNM66
M6=[L(EC4Y,O.:P@1SZJ/EDZ?E\A+J<M02*@M4(ZMJ52+KF[4C)B[2">L:H5>
M2-68?E#5?H/ JFL&056O=$*JB$9H%5$-JR+*T]U+ O@!]^(AG,%$/<X LU<O
MP.[;@?G8Q9LZV5"W2 'F=NI390NM&(4=L_ESVKV$,Q8$<5+G1THFML;+Q+6D
MR<UISE.,;"I7"6VL5P]N7*@9T+!<VZ]A@ZY/PS[T'UV?^I=:?O5$W;^>J"*E
MZ:[C.IS":V$?KL%6//]U[0 #B[![8@]N[ &H[A6"\EY9*.[5IO)[+>A9/0ZL
MM"7N@DF+_47BN\/$YG3%2$4N2N&&=>;(!2\L50SHJ%/V[6A7\VI?JN'1OE[3
MO7VOEEO[CUIN"WY7=U] 5#W:B+)G&U&<[@J^)AW!ZV GKO\8YJ_J NC%[ 78
M@VN6 Q2O8$+>2@G(7JD&Z2N-J>05MHSX%2Y\<P9\!".7!XN$+8L6"UZ:*!FP
M-%/&M[](UJNO1MZ]KTW1I;=?V:EWG<KLWCVJLWHOJ\[J>:$\>\DWQ=E+B(+3
M8B(_W=FI&=3A/L#YCV#^LE[L_UA%&K$'EV,URL NGKR6#8GKY"%NG1XU9YTE
M+6*M(R-TK0<K:"1 P'\D0MAG31S;<TVZF-MP@:3S\%SIV:M;N0ZK>WEVJ]?*
MS5R]6]YV]24YVU4OY&P'O_%L5Q+9F2L)=[JC>"U.X![8@/DK,7\)GGOK$/9?
M[.'Y&[!_81>.'.>'L'%)"-FJ!D%;C2G_K;8TGZW.=*]Q'Z;[> B?R_@< :?Q
M9"''+;DB]ELJ1&VW-(M9;^Z1F+%Y1-)R\RY)BRT7)2TVO9 TW_A-TGR,2)J/
M_M->7(/-6 =78W[? *X!GGLMUK$B[,%I6P&BL8OZ[Z' 8Y\(N.^3!==)+7"9
M- .G23MJUJ0;Y3#I3[.;#*?;3,8SK28S69:3I?SFDPT"II/=@L:3PT)&DSN%
M#?=?$#+<]US88,\W$?W=1$1_%V%/MPWW_@CF+\/\A9A?C^=>L@77 'MHS!Z
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M./QBHP07;$W@]$Q'.#K3ASHX,YRVSS:>OMLV@SEA4\#:;E/!M]6ZCG^+=8O
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M\,)_O@ - ;S P;[ DWCQ!.#W=__5@&M?C+-/Q5^.. #@A><\$\_9" ]9_1(
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MA[_/:E"@QVI4<+'5+L%NZ]-"BZSO"2VT>2_8;D,$%M@2?L0WW53^2\R_@V^
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M10<-O!<]H?1>_*:!=]>/!MZ=HC[1\U[X#T\R!V?F P>I/T+=]<OIAGN!SI5
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M(5T14"=;%M J7QJP2-'MOU)KD?^0=J?_#IV%_H=UVOTOZ+8%O*C;&O"U[OS
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MUHLL.: ?47+!(+SD%7)7/[Q8U(TH%G4T:*MXCN? $^R#$VS[7I:=VYK8#\W
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M)7/LOB]W7"S*'1?]PUF.@4-LZT@W<[",<T*OZNXD]D,?QP$]>=HJ((8$K9+
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MQA'5JVH]QI+,@?HN'=5Z4!JU"JE319TF:G10HYM'[J7&:FJLI\86'G,GCWF
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MCC*.8RR*CO%"=(P3[3'5H\HYD(XR@4=Y@*,TUD=HG@__0OXFHGH-9H-Z#::
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M!L4VK2BR68J"F6N1/W,$>;;'D6/W%/D(V;-^1]8L\1_L.%^Q_+KJI5Z#.1#
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M2DHN2*<<"8(>Q,^>)OHV>P<&,?LC,[/T6W^87\6/(2'OQY"7"K+8!C:2@O
M#6&H<1G4+P=3!09Z71T)A_AR/<2YH1#Y!H..K ,^", '#N01 -36 A?$6TJ]
MH=<]01/<9T_Q=,V>P7#Y<0:#F(FOP)W^,001A\'L'T,S<8D\"601@[ "O25
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M!7)Q@BG'F@G\"ABW5H&=&(!NZ (?VF KFF"S&L '%ED.(ZDRT-( ;=4'6B9
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M+PA\<,G2(FQ2+ B#! ="LPR,9AD8SS)07@D0E 0HDB0(4=(8,OC2DA!C24$
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M:$ T"H">_9&U*, P&F"+ GQ% U:@6\&) BBBUW(U4 !1M!/CAP(L03LQ^U
MQCLHP!TTE[?07"JA &3KXEM1@"XTX#<!&@8&NCF7D(:10X@,,//]U=C]V\07
M[?ON#3T<7W3CC9K^I6EZN&.QDH[RG<&VZD((/\7UQY84<Z%Y;=A 7CR4LG#Y
M8 69%_,(S[)0G]C)O.)8.E*-RT25M_.3EI,%&(5HK;=& <ZB 6J_H]J !@BC
M3I-^0@,8T-$<VOR1JRB *AIP"@5P0@/0\6 2&I"% E2@ 5M1@/MH )D3HXT"
MA*,!*2A "!HPQ$$*(%\F085!Y$[,C(.!N9V+IV\ /C@L*GXS!9^4FOZUZ>W
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M*!G &,4#670@C@+HD57QG!3@3P9 [6#L(@.<(P4<)P.@%EJZR "H VMO!="
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MJJRL(MWYNY0:[FVS2D=57DI,@(N-GJ@6?"2 (08RNT$IE"8Y@-1X*012?22
MT^0 4B=FC&R#$SE RH0C&0"U%TR^VH.*0(Z0 1Q) 3>DT0 #E*2MT8#EI #R
M=10N%*"<;"L'!;AO\S> F33T<C :T.7\-X"9BC]/_K.(:]JMIW 8O5!OM>/:
MB$U91YJZ%KG?Z!7U8J/_'>E5=TOMT<*</:G;B$'0^N"@H&!2+R; 3%U:B)-D
M<B4]0KF9S/)0ZRCD6R"H/9!O.F0 =5(NR8YIH(-_]*MJ9'9Q6?1O )/DP1I*
M5&2[K&A -NW? %J4T0"4&_^<;!<%_<Y^CA *T(H"W$*/#Z4HP$S!@B4,+@7S
M(++W%]YL$6<7D=<Q=P_9G'^JF]+E*,^.G&CIO/^"^J(<-1'3[Q_?O9H<?S1R
M_U[?W3M]0Z1+7KV',E(VA 1XNSG:6*PVTM=65U4A74?ID^4FVP0AK9_".@HI
M8-/? 4Z3!5HH+V>4_*P(ZK*+0#( Z@!D.AD =1C]%-DF*NJE_D&R#6GT"W/1
M: #ZI/A1>10 M=@STX\>8C10@)D#"Y<X^=6=R#91'T?S(@C-DF6J)AY1>XYW
M4KA&\E9DQ.:L0Z>OWW]+7D9-U/2/I2^/^SJOG&\Z77N\HNQP:7%QR1'4;1G;
M\6[6JPVTU9262XD+\7*RT*-W.,E/HZ$V,+N7D@'VD "^D;U(@GZ+8RL9 !6!
M5).Y(*C-XCMDXYPT*>!C,!K CA+5/CXT @5H)CM,A@),A*,'8Q1@YO!"=XU+
MU8'L=9?1Z%DN& 45C;WB\LY2N%6LU</4!1^76G2J<['WL_MZQJ87*:(F:OJG
MT_=O7[^1KXJ]:3E>>F!?1NKV+1L3XV.C8^(2MY!N!KVRUU>3EQ3EYV)CFG?R
M4;9)'AV@#*<8O7^)!G22NR"D@'?HEW;(;#.#[$@L"G":;+D'!1@@6XE%RVJ7
M"&DY'7K^K[=<4"JDY[L-7</$QKG1EEU2URER7R.%VY<O>"CH67J%;3UXNF>1
M$YR-A\ZT#RU^^3PU4=._-GU]^VSLX8/!>WUW[MRYV__@\2O4W>G-&9L3-H0%
MXP/\O#T]W-T]_0BHUWXO8Y<)<+&2K->2 EZCSD\C9,?9M].C :@SEC5D>R"-
MI( ^]&L@2#$IX+<4U 8&^LS<3!GI:@Z#$OK&KJZ G^LD[,H.\8?0'[+ZF*DV
M6\@AO<(]OI#2%>S7<4***VS6QF96=2QR1O/XE@/'+_SE 4[JW@@U_4>ET=[V
MRZTM9\\TUC<T-+5<N3F ]IT/AN']/%T=[6VL+-:86U@[> :ACB=4R7$RD:Y1
MNI$">M&G]M$ARJ])Z(442103A]51 $X4H(WDN#HSU@M]N^J++<OF2QF76V\H
MNH:^TF.F:M;#H!54M0K.J!N@L K9'[=43M?*+VY?3=<B*Q!UT;L*:J^-+/Y]
MFYE'U+4+:OI?EBXWG*@L/WKD\.&CY96U9Z[TC*)]^PPO9WMK"W/3U2;&)JO7
MV'F&H-]5.Z2"/H>! EQ'>3'\Z$/:SS8N"#!8-/WWD-VN>'CECU)Z6:L-A=?(
MHX".(.(N*J^B:>".JAY*!ZA>96DI&3D&;RMM7>S"XDOQ6_*JKS[\BVW0OON4
MKZ:F)FKZ7YP^O7_W]NW;Z0^?*?O7GT\?+CIXX,"!@N+#QVK/7KL[AMY>_"/+
MP6J-F:FIJ9GY&FM'K^ =U>@J*HW_O(>"21NW[SS9[<P=A+FE%OKE-C$E;12V
M)R;25.>&A^V5W90/4M8X:%L%;#QP9G"Q$]I]NU,*ZKO(/),%Z5XO]>53:J*F
M__'T>N+)DZ>3SU]/+S(Y_UZ?EYN;7UA:7MW0>H>B#98ZK[&T=73SC\DX-4CQ
M#$.#&R*BY1"^IZYOD2_@]40:K=U8>&YH4?_@S>$=E=<HW!O_,SWII2Y?_@<G
M=*#\KT[_+[1_9FS5N>#8V"A]5=6(&)4 ?&0@0047&:Z:&!"EBE514T4,5B9&
M!>#6$V(E @GK0B(,I=Y>N"PE$8(WE'+7LE6SC5I-" ZQ2(XF."?;N>"2U^/T
M\%(KC5@-$O43PZ/"";$!$HGA81$Q^HF&4K.5Z\/?Q)]5I21F(;'K#:6,B042
M'K8.$JLCHPD2.BKJ&)R:FIJ$CIX*-E!;*T!'3UE"74U=755-6Q6K@<'JZ&MJ
MZV,U)7XD*2-6^'^#:'R0OI.I^0]Z\%^&4C\:EI"0H)*@H1(9O4X5JZ>GIZJF
MKJJNC@$$)B8I(C8@$1,1(SU7R7P]IH087'1(5&Q(9(0$\;\# B/C8@VEI%@E
M%J0Y0E$+")%($ I @AJJE!Z"AE-^:%[LBSQD:_O7CX6'4WPR)M8L/O:OGXQQ
M28HBJ#H18B+CHG$$LWA"1*PTY:J<"(LTF')5 *=8$1[W9RU1<=%AL[V#QZD2
MP@CA0#L&:L)2;$M4<&1L9$QPY"("_+-X43'&A@0MT@!BR:*/$1)#%GF,6#+W
MF-'/YPR@^_4=HB/Q<3A"M)%M""XZ,B8R*/9:G81[9#0>U!FK9Z!*@EGP+/2T
M_NIH0D!L9+1+9&388H^C891J()A"-B):#P:+Q:AKNZBIZ\/_U#65U+3T-=06
M5#*'1-5A&XD/"4J:KT,#HX;%J.FZ8+'Z6EKZZMB%=2Q HNL <\<'Q ;\EVI9
MB"6MQ]96WS02%T?4#DM3H[G!!!^)"\'_5 E]32V\=F 05@^CHZ:MA2%H:09A
M @B:&IA +34-'"Z H$70P\X2(JV,C)!E1$QL0 2. &7P@TH($-'14]<+T@D,
MP&CC\)H8#3U-;8Q>H%80!D<(P.H&877Q01J!\U4O>)RL:OOH$!A& \(6D(^+
M@_J-]8RUU=3-3#&Z9AIZ&$VLN3G&6,U8#:-MJJEFKJVE:6ZLI3U?/X4ZR.A8
MA,2 7B09D:CR[.#F3-A ^NM\05C([& 7%1 =0R#:L*'4O!%+D3U ?&9V6-$/
MP!&'2:.8@'@"WD"5Y+?%'PHA%W  CJ"KIZ6N!V._A@Y&6T]3$Z-'P(.\ S4T
M<.HX CY0CS!??P@E :-I) 03(D@T7T-?0T\?JS6O;PM0BU="M+J$@&B"\3J0
ML]'<3.4PKV\2ZAHJ6A+R[B$1^,B$&(7Y*DF?6;QN7'! Q#H"WDAU_L'Y'\AZ
M1W6N>_Y?[#8\(4A+2QNZC: 1I('1T-+4Q03B W&8('4"'A>@A=/0T-;YI[IM
ML6&"VFW01;C(B'A"=.P_T'5 )P <+T)TC%%0=&2X1$!45%@(+H#XE&I\!/['
M?/;G4"H1&RD1$AZPCJ!*B(H)FJ>RH))_86/QA.B0?T1+%W#YIYPD_M,:_=\V
MS/_:A$4U3-2OI+/C_(Q+/IO.NR1SNFE.U*[_6F<;S+K0_YVA%/4XI=KQ_Y1W
M0?8LI:HC_UL.S*)UD,M\@6@7EN)Q^K@YI_<?\VV,G&,)4:"<$K8!_TC_4R1'
M9"(H,CH\(-9HX7CQ\]>%@<"?WNGJR+#(:/"3"4::!JJ4?J;XE.7JU1 C!(6$
M$8Q<59Q5)-P)@1 G!Q#'-'EG=WL'!8EX]875+< OJ(\8VQ#]1A#V[/!G!'XP
MV6]HO =1A</BYO!8-77(JEB(S-5^/+NP'/VLY]\\Z_D7S_XL<HT(B352__$(
MZN<%3Q%#L#DY.D>!'VFDK:6EH66@BOX9_81#2"(AS,,T!%0PALB'MI[NCX?0
M)12?]/Q9KJFMMO!)3[(GYY1KP;K"W**%ZH]5"R-6T/KY)1-*0]S_?*(2H1*A
M$J$2H1*A$J$2H1*A$J$2H1*A$J$2H1*A$J$2H1*A$J$2H1*A$J$2H1*A$J$2
MH1*A$J$2H1*A$J$2H1*A$J$2H1*A$J$2H1*A$J$2H1*A$J$2H1*A$J$2^1\F
MPOKS$@)"!-Y0*D%JI=',"+(:H?EO)F(E_]TZ:&:N(-S,-#FT_G0TW @M-PT=
M-\U,&[(406CHZ:#XYWT/#(Q,S#3T++1TK%#NS84@C#1TM RT]'3T](P<S&PT
MM'3T $&8N7DD67CYL,;\C@)2 1L$M^5(RZ@?%:J_^DY64]OD[IB<AI:NF;F3
MJWL@(6]:6-[4)3HV_\S \C5N<0G;CS6=:X#*Q8$L+9'X3^HT]+1T1 98H-@=
M^*2E <(,#(Q G9&6%\#T# @W(P^O)!!FDG(,>,>_85O.469I]?JK=P5DQJ9E
M-4PTM5<["6KI!$:?D5MNBHN+;S)W=G6+=<$3@F*VI^96S@PC['1 EYN.&UF)
M_/X]I#)3\VYED6:_>5%POZU(2+FMYG_UIVJ[UPDN(Y$\?(I/1.WT Q(Z7S\K
M=GCAGFB3^N6/58U8/_&]ALF,04?:$T6^YJI_P$XK7CYGF+7/.$0[*VM,V_:P
M\L']XW[28M(*1Y3OLB7LNFY7<>87C0O^LJN.R3:MRDW'>;'M;_"G4^;)W<I;
M\&VH?A^NYU.Q=]K[ U@Q>QS-M:D;.FF-]]F^:_B=XQBO57F]YX%!IMAH/C[:
MV"U?5,?DK,#%&F5?=QD7^_ H_;LL+2OY$V*PF*"4E2^X<SCQ]W7R<^PU^A[*
M7]-:9RGWY067W9NC@RO,.URCCQ7RZ:?:,#L)F;(:\#V[6,[K@GE\?H^C&D.5
ML%>C1(O\#MVT<QKJTJUMIC:](^'Z7\^N?K!V*KE(QW?UIYS;(ZTG#G@ZU4>I
MQ 4$]?41?'D(6YD]6DZS[9<2$E(HS$E[9"TXVIYX9+6?R@;-\+1^3.SQ&M\,
M_</K8@H4IGO#\H,TEH@,/2M9TW)>.^IJ2%I>D<6)GOB>P= $1F,7'D<-.=]S
M&H?NN$8/5[_;9,TO2'A5X]\0M^JPCTC@;B[^>HD#)^B?XLW-K4/2"D9<$F,>
M[)[*W[C[G7OBCD]IO0&-0VKWNSQ;K9JE=4(\:B]F6,1;BUU0O*H53YMY/<XA
M>?A*U DA=JR\PJ:)UHEQ7J^L#K;QDZ6NT?2[MN_L6R>KL6G_RW?'COFY;IX6
M=#4/O=A4KWPAJ-LI>$JF2/P)@?WQS?R;>XTE(_#OOZ_WP7[('$L>LKVW[5S;
M>_X!?A7+/'[__0U<=[FWJ1RQW/LAO.?4BJM^MR\'E9P\A%DK]"VJ.VH@)9+[
MTC[6%C'9@Q<-C*]?]67<VW55:".OY<G3]C8#44?+V7CS5^59:G$_7):>7K]W
M[]<1L:KEN0Z73*[?Z%NMXF+3,R$^L#EIJOWX^ZL;!-+U,@^M8^(JV7"(^]H+
MJ^,3VK?D1LV<3PK7&95L7&8@[:::.2"ON*G*._M%KEAXX[UIG]/64;(./"GM
M'+G;"H0+IC0>5$U5B'F[BUP>9M+V4>P5NYS<NSE156O)&J[ER[-.K>'4_./Z
M;I&33PYGGW<+X*D0EW34M3Q"_^::\/4VD1&=D) B[237#K6[][R5+P99K5CN
MILS:.UJ@R:"43\C>U]196AQ2Y7.D-N-%V6CU%OTZ1YJ7;!Y[+XL\",_IBFH/
M2SYH^[JN_:G2>=\PIEAW23;E'(&#(7K;N#_*#PD.,S7.( ].L:WF?$/_Z5'!
M>-=@\VY^:XS3;9:)^NM95SQBLYQ5.!IWUZJ&,X1=J:7O.+\N/Q3?,9PAF: P
M7O<F2+;V]N[?I;0ENXL9WS<H3"9[O53+]!RV-$HNHF^5C\L:J,Z/<DDK[#V2
MS>PDUD&[3TOO;7#; %NB2MD]&YJ0#K?:3A4KB5XI3'=WVELL-Z_&V1&[B_DS
M"&%+_7CP:-RR86O#T)<G/,/U*ZZT#&3NL;8L37YZ[0KSUI8[K/MSN9>&*$B"
MZB?\WO;Y\&J_-W=^M4UWQN0E%H?G:A>'Q('JUX4-F/.J>@V%<4J7C(HT^[=V
MF]@\=<6/-<8-'W_:J;A=40[?=?9-Y#!KG;>KT9+JH*+:BW%A!^Q.W&KW#\E8
M:JT4:(QQ89-A!MT_$"BG/;0R]?>"/VXF?$Z@V9AV.3AE4C1-96R#VX?FN"B[
MB+YZO3V:#E.'M.)=MX=.U>WJWP3*/]#LRLXHE,=W*?IL]#1+G?%X5>*%=:[6
M3P<RLDK..NS9F*?$=?/.F]24\XINPBKO[]W42VW#FXK3[]#R.\>KJ+!C&];T
M:(SLP2<NR\4\W@B>W'"JFJ-3&72?[[5EMVV4-.C^UC25#?N7?HN)'SK\^-&Z
M&:31SFD&$5J^YV)SD&Y\EFH:YT'FD34LA+J#W/Z!S4(3M0JZ":4"^=NU$M=M
M%ST=$UO&RF8;_VW[M*J1RL'3NO<_ZHD5#/_NFYI>GNI]O+!D%__'Y#N?KJYW
M\E&1NLND]F'Z8\'.\JQW6;ZRNHUYQ8K[M?+-FR>;/VWH28K*]^CDN*<0^T??
M28G8'@&.0<(EI0,L]O2*@LOI'5[("V\MS+JPJ>B/6SO:[]7O^?V(QKIKF6/=
M%=]*C T$BW8/CHM\,3!+B1 *L>,1:_?K>-#EN\(DU\E^*:OVMHO^MV,-KWP^
M8".98/@$S_?UQ+1F4G6REVU#CY7IV8WE:Z6?#^QF"M\0S?WZZ?F#'V3$V.*?
M)QE/ZMH?UW/NV?#*_.'#,<6F=%>1X6P]Q1OCF'VJ5BW1PRK&01,M!^6S1F_I
M#!J838U\<BWK7;9TV:<9I+A;Y2V70T6I]KN@T-KQ*)74Q*GS8\UFB:FN.6LQ
MA(]>OR1-.(:/.(M&"+8-QW]SWMU9+%S9+]_G'%;D%6ZK_MK$L9M>_41LZWX3
MO9,W1PYF:-M_R#^/.>AH/.724QL<]/GWH?6*,PCS0+5M%DTC/CJNP-+E=FNG
MQ["ZPK*=[&_?#;Y1_+3NFSRN.49C8^K*8(/)A#3%.QM/?UX7Y19:UN"^-<',
MW"N>@W75F8L/0IH"C:(=*WLC1W>G?5+*[^K/\9:NL!E[N$%ZRX',SB7J%T/.
MOV_N.S+I^63%GN.:X5O<C=<-!#^='$JWTGBI(%_](&=?M;SDB2\1,D]J8]0C
MUK+<BU!)'PU\<\BJ>;^\JURVETS[H5K+(>80%<%[Z85"G)$)OA'()ZUO*M.[
MC%AO//STK;2\X[NC=^J+X;%C4?&.>ZK:DYJ<5K\+Z5RZ[*J:TB2&GV%TQ6:^
M-LD)7(5Z3RR.\6EGZXT,A4(5@:MKS[2/".DG]UUURZQO6V7)?:;\^9,:4='P
ML-Z. ;X!?"R?3#G^@/H+Q3*"P#/3CM]T][RZA0M]Y+P_('[57E_?2"=/VNLL
M^76=.SJD3 (#=O"VVMRX@-7_?O4UT\XW43K"ZQ*=_M"133N7VI"W0O1@TYX+
MN2=LJ_WN[*KQ<%\I\$0B\710N0U#$.+,P9MV0*MO*/.?]$[^[_U4I_:Y\/4S
MS4G;CC"_T;T;?AV]UI*I6B>KZC0=Y,]18[,DN2.:$/M=O#7L>*6R9(78[BK;
MF*2P <Y#1R5MWU\RNCK1T-++U;COV(C%T:C"#379VU;9WF*?-(H1'LFQ48U?
M?OIVU]KS,+8N"6EENO)+-ZB8JL &#/M2YXS/<7&ZR?GUC9A;][.6CI_/+7J_
M4U.BK.=EQN\OZO0.B7_Z!=<X_+7R,NMB?!]WCLY_<"%U5..C5:-8:WM6_R[U
MBOC+//><F=3WQ\1Z/N\\/CE>W6<AF/Q[?WQGQ@FYPP75R;TF[_V?/LM^Y6'0
M$SJ&V51B9\;L\;K[AG[Q@=/BD](QZMR9D]));[$BOUVZU5#P?5G3DJ OM4T5
M?>WCNK_M>%^H='(RW^7&D\^[Q2,F*M^S'+:[&%M?U2GC<]2@7..,S<JQM_LB
M$JN"[JLNP^M_&S[9V^AS,&3%VAP^ABG<08%7;+\Z^GC5CG%6"%\(:TEIRA)G
M/9A#%TW3_?B$6_U#U=T52<O]!F+5?/9/[/?D/UAB''V3\[V,QO"Z,Z]&-O<]
MM-W^9%F$WYWF@ZG1%MW^#0_T56[@:U9+"MRK55%OY(B:J"YFZQNXK<O^@?XU
MKZC-PXO)I2D:_PZ%"E$)C.8YW_D^GB6M6?Y>;U&HA8V%YEZ\&;\:MY3XR$#V
MJBJ'<0:;2@?V&&:^(](CGHBHC=MI.;5)?P$ZN75JZLZT=#QF:M*R*TRGL!J&
M97&5[1D?>>+##;5J:@X>_\9!7Y$R@1B\#F!FPF9O_< 7848GVMVVGJO_3KRV
ML:Q?849IEOINTV77+1KS\$JR-PJR]0,;GK.F?Q2LW5KEJ,=YA'.U9Y.*\2I#
M6\O.JZN:\ TYI9_D>=,*A8?C2\^65H6\KE5\6)T4_=*MQL=&#.;FEZ>;L6FY
M+(%I'9P2J?B$7R3*@K0+^NJ:0GMS\%/Y]UU'SA8>VI4>/95Q8J"UI%R K<5V
MJ<&$Z+$7L7D>Z=%+0_H5,@Y+#DKVGL5@8KME;<+V[K119IZ4K6+SL6&W:3L]
MB4AM+.QF?JO!?6)0Q;F*3ONU6PT3AT3Q$B>)CO/I;R5?%GPP<:*?[(YD<]B_
M)(\Q2*#IE%OLQHTO*HLS'H;*KS$H\.KW,9?2>_#DJ2Q_R5X[O3V_=IN([[]Q
M(Y:C>(7D/4G.!W$6]3;1?!:T_C0CS+&YVWD>K*!CW+:K9/_VI+-:G".GUV6?
ME=B^+_;"I](3=B9;Z[HR7AO;:O-$:(=5"CI>IY&I6;[\5BH[-GK5 ]HTM<*T
M2?&^@9O-HXSA>+=.S9VX1_)C<O8#35<J>\9/TN^*+79?LYE9U[$^ST:,6[JD
M,[V3E<:T_=FZ[2VW%=\=2#Y->W.M<>L[)EDD6JSD#H.4@RRVWB+/M+OMM5=,
M@>.J!\J75)1$.8P#H_DE&>]P2SN<]>V70PIR=O)EI[-WF_+9O*V_T/>T72WS
MW,!3!O\PO/'>[];U+J?<5[@%'LY^;:\F?M[6O&=GZ_97E;%.KQPJY8WOG>%5
MBZNE;^OL%O'0H%?80Z_!@SW3GK2[.^E:D*C1TP_K QON5[59J2?^9LS,9U7G
MAK=HZ.[W--W!*N,9+7?<)GX%5E[XP+?S[G9^LIZR8[EY66Z^-;&C+1FVKW W
M=4+K=QYO\4UW%;0XY]*.=?8TS2CL=J0M,*77JJF,OE1+\VO+Q"8[SQ<?I20J
M4KY%?[C2;9/U_2XO+_;,RT>^XDDG!]W3=UVOO.R@_RZWD#NL9O,QY0P9_R])
M08&!RQ-+Y5]QA(,=C0GNX?_EA=NHX.YCA,#1=74W[)\F8)[A'E=-E GUZ+#O
M3A_9SM.#&Y78F2$QVG^,9GEZK;WLK1<;[C3LTKEQ\9C/.>^T1-FXUQXFHXF[
MKAQL6G5WNOGN@S)ZJ<X)J<PL.6VI?0JE6TQ7XB*679DTS/FC[]/[^S;F3H,Z
MJ7P/XTJRM/-?\0D;:'0HOW2*RZO/M_.H4+>E9^BM.#R-=,>WMW_*Z/.T$'2W
M*@YILY'Q$F[/$A?&9[$D;Y/*N66@=$V(B\O#"K_*6/6U[O/OP]]T!T^'%-/X
M=FS;GAM5O;-@JP)=(9Y]YRHQ"[Z;8;(\&F<ZAO^(.N0L=&&#<:&(9#*>44'\
M_),(RVWL'NV!>'W"'DFU-(YN5N8$X?3![<+60N<_7%0Q+]/[]07;KN][-FV*
ME$3T>/D/O'_*,2'#*E\4>/2K!9/#+MXXL2,K@G:-34Q61.AUNXD.QL:H_?:4
MYJ'A$TQ5'BX:4Q5<VN2;-"5Z;$ROUIJP7D==,*<RNDE%!V>?WW_K=-8DX?3>
M!(5,W8/U[L,-23*3\<*ML=$[S8V_OM^;@[_J:G *LSPKS^>XEJ.](>=VE:/L
MD7HJV<O42H9VJ5L&L.G)=6>D(L<*')S4E80R>_UWIOH'!C$'&8S'I9QT8VBJ
M"D".+5E19.MQ4E*2?4?(S56U27)+"B:E<_W/#0?&UA:EUQ;R6SQUE;5PY774
MX'MQO/ 6HV1G=%K>4SU3=F<^TTKYK5O3..L+<@IYTGF$"R0+()56RBUOM;$/
M27_+>[+,)%".7HY1;15.S<3$L3D[S^8JBVE;6UNWC=WTBO6_E'NB!NMM.BY?
MIOR&?I->+C1]+S8OGKY;M?RI4+-G^:"J%VZ$-W6?\(6(V*'0%R=>5%Y(8)8W
MR_'8Z:B1-Z&P([,M:/W8U"L!_%E5CCPU-05>.A%[237) DE)^72>]/3T-&!L
MZ.[%K*%3D<//&FZ=O5.L%?;-_''&I_4>#OH7,]Z,AP4^W%VQW3K4JT&VR8:'
MD89+J+.[;6@M9^W6>Q=X1S+W2/G>42X9B _76A=QUN7J]\9K/E,OY,QDGOE]
MW?W&:KMEI5-AG*NB9?96Q(2/KGCJMW:_,1N9&:2@!?^RN7=+4L S[O GO<YO
M3Y<9WITL_?1:],OZD<V#KZZ]>WMN!@F)<Q)J%< (UT8K#CG<Z\#UV5P)++Y;
ME[W3S>?TQ-X7QW$%QVZ'%"H,?!$6>A?](/M2T)*E.JXCVMM?(-&O3]!FJTPT
MB&\.?7V7_RZ#F\5N6ZRG2B-3@1VHXA3AEL^)G%1[Y:D6/5UFO1'__?DE[ (/
M^YC.?F\\]^Q+Z)$\GH&KK39WU''=CUU4O*S$?_.O$ZE69RY@#GQ:J7=C2UYL
MJ\U503<I)WU'[3I7_ N+9R</<S>VT=/$[REM.)$O*)^V57'[=E=G;D0/B9,Y
M2T\C),1&*]0B*9E*W]TF9--FO+/;QIAS6H/WD4,-<\H9IPG=[)O68S:,5CY8
M'JLP&IN3.^@UE PSI )A ANTQ_!9:AZU7[[4<M=PZ7OL\N3[#>O5;<8+?Y&Y
MXLIDI26U5:'T*@]?1A1/^I4KDD=J.SFV,UK[I)UN"S+&;[DBYRA6+CN#V/"U
M':S\RMO'X<1QBZG9(\12C>$D0_1'2^O"'?ZG"I)W2JN)7>_!MD8<K=4Z1^8G
M,!UBVO8X<<KH^Y)'F:9OL5C>,]UV_6>_V8U61?I67?KE_/I#4Y%)V]EBDDSV
MK^^U]\&5>*:_%$XU.UK_FEMB<U]T\N!P*,T:]J-W"TT,C[FPTHA,L*R^F7/_
M>..Y)1:!YY;883.RA")LZ@/==FL_Y!+<>ZY'XY.9DE53%P=?3WI+1(+/":7<
M(^Z=LA?BWE^K;WOU*371?(,WCB>+MZ;]S2FA%%-5W#A[G5'ORFJMK,=.K$+O
M),.\5VQ_K]VU5\*Y8OCL[\=U@IJ8FE((!V0>^#ZK5.*RYU]ODAXT'J^N=ZQ+
M3C9.:U-6Q.5Q^=WIACMC>]8H#^B)W3",ZG L/V 9] OO!;^K@XT1F0DJ6_$V
MS"?5.EI]"6PE7;;F#<+[HK],[4R=JEW?9-_N+A_46/':F7O_2:])#>[BBTZ_
MN'6("[CIYKD3.F\L7Y[U=%/KR3B1&*W1OK([ZOQ^SO5?5&GB\)FZ? _##GD<
MZKR_8\F-^R\\ _,L'LCUG1,2J3VYV5R6+>2(G,^1NVQ;FVV/*"V3NKNVNDI4
MQ:W*RDE*VZ(JU/7$8%M&Z/B'@QS:4:_/Y_G5I1JZ;8N7%Q^@;UC/M4,DUUM0
M89KK C=_G5G2JUNGO,>?/3VU@8GE\:N1CFE;@YB3.,Q3Q;M-^]8K/@V]<^;^
M*OR]#JF+NWE*QZT*]<\9/@S[91FK]CI%;>_,B]YO\R:;NL0T3HB^Q_J9KW\N
M@S-P%GM>^%V*NS]7O=W?M<^5!Z,AS)7 :/,LK.@F4X'!H)/6DY=X_1,29\.9
M+:XG=^;GO?]X+$]AM&9;%&O1M5T%UA(R95HO7@8-1&KD76NWMHS'QA5K>[D:
M: W<]UCF=.1$?_BO]ZXI3JW0JME[T9;?VE2F2?GE@0O)FOT>:N]H#9@A,S6_
M$WNWK.Y(59[%V<*)]-+RWOC,3_M*OJRY;1MS63S")/Y.G[W<+XW\UH*FNCW:
M#[WITJ<<-D@\W%O]B3!FJ-1R53*<=6T8NV>U\@.UZ!)]A8L1H\R$3N/-6YR^
M!RH.=%3$>N^/N[1T#==P:^I9EH"@HYY:_1:;'Y_ I1WTNW?&VW^XJJ1%-&/U
M1+YNY4!72^NN-Q+5UW^M?TA(V!$<H#QTPOIT=]S /4$(7_.G;P;EJ5PT=AW.
MR#@55'944,]J)$6TK9']%+VUC-8R9?LVF+,ZU!*6<3N'Y>U/'@T-&CQSG3](
MQ3$=L_23"J.%Z#%% =OR,_WAJLN$RFY^D+WFR=?)<<ZYTME8<)@3E_9JQ\DG
M+V-+F%=G>##L/]&GM9IK_<MK8D/R PP;O<>^95]OO]--R!>N&N-Z&7J$^5R
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MSM79^IIP_4-X<1&B?+M.)#J[OL8)?^NV4LXBW?\EP[,YWH&\[*8]\M8C9.9
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MFH:*N!L3/SEXAL]]U'"W>/Q?:Y.(I?JOM/2^PZY[<KR!X>%"5W*K0M<Q_A(
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M&&GL]\:,9*I'@I>^7$8]:NO9 L*Y;.:M"-!#!66(00:G*+G8YVHA&8I[@^7
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MJR1T_C@_! X[::_<+5!]]Y52Q&V?F+[N*+(F0HI_%^"X)?@H;)O^CC":*JX
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MAO/)Y7K?6CWAR+(/_&^3X,=6#O2NU?G&=OHOXQR3FS\9KDEDEN7PL[J_->9
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M;'_?4UA8#A:UGU^@Q9T HW6>M3$L!/;PYEC/&**9\LS_>N<BNQX[ODC^_.!
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M)XRO(Y'(BY[ [N&Q(Y3QZ<+JY &% G'4</_[B/@XB49-;JL$BA1!).*A&#Y
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ME">M^#.Y4K?2Q26P^6O+.7Z/A_,YV;9!,O#U#4U01QBM_9)Y::RLIVC!BW$
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M9[+RS7*[$I]@'"<Z;S\EZ_WM=CMJ6+6XUVI (:@/-\@%H[9/2IHBA/!C&*4
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M36O_-6Y L\8KA,6;W_C^)7\4#<XD@MKRL#YG86#J0.#[FNH#*_&TN'4(_WL
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M\35.+3$N89Y M9FFNRXD2IP21>'8F>68TJZ2PZ)I!M?PI4Q04S"P3&/MXVO
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M&W;7,;;D-NUS3,V'2:HGM/Q7+?Q4'(<:CDA7+BD UL:\W'1T0X0KM,<.EZ+
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M9!I(^6D+E&9+(E.9!N8.#-T1)9%S0L6+(%R.MX^IBK!"(B#<?1& IUI5$0J
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M5',(YPNI'T3+;T];G[;C?(MNKM"L;<UY:2)K+7[72FM&GE@CXHL_(/%3QT;
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MOYP-EN9E MFBM%+K=4,KA6LE+5***:<O2;D.?K$*VIFB%F'5RY_$*DTBMA'
M3V,0=%>02>3&#H0%B+2^0C-BBK.&5(Y(DEV63,!5?S+BO8)3R:D5RT.+B.(_
M%A>J3*,<QW*0#=U$9-+&JV[<UAV0.V<-9+&5HQ2W\RNY5F%DY)P_A,D0$R[
MAV:L79HR'E''X>(H$=VD376V'/$G+4_$W)KA,P=B$<6L5<I!)2"X@^"+KP:+
M6+0_)U*MJ6'D$(?KEK&>A67+(&WM2KV+)Q)5H!W!>7IYJQ*X$F21<:_X>RF-
M-:I?5QM?)K6*ILE5L.>\;==]V5Z=#0UNQKEAO:8['V[*LIW!SGO& V1DVR5E
M'%MNQE74;5$9--.F U3HK^!4<%Z64:NK'M7KE)B*SI"H"ED"A?S;QC?9L-\D
M$2BR-WAG.Y1N<[A(\S'UK",@+'2M=B#Y).+8FD;%-Y#3R56S EXGB7)VZD-
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MAGY U+@,T=1'A]MBK?4IN>%9LCY',V9E)M5_:^>=6!_G_K&]KM_/'5D?L1>
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M@OF<,)NM-%81N/O?,/>YP$.^:UC'+$]!(CE"TCV%RUXGRFM>YT^?IVN1Q\#
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M_07!?'-QR65\5JL(^KV&F32W^SB9>5J"4S8Z7=SRN>L@836%4V__E[SF;:J
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MNG7,?4K!>'G4ZVM[]/4G4'A82OA+R-/+6((KUN.?3.C!\<L; /41IBJRA'.
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M2J?.#D#$RBK7]5.IN<@6:9Y4,^.E&U. @BZ,XSTC53%4 @,HFJ;;4K5M4A:
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M_%V>?^NY0MAW_<J=QC#_HJ60?%"<"N(4JDN+7*$WA:_T29Y9,%P.4"N_60M
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M=$@IFFY]Y*YDZ9-?QFXOK^KL;PR1J'V7PT_W6AW7H1O.7Q)$?0R_JYKFQ&L
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M;4)W#*@6"!3R[=TX49:Y=#YIMARZ+WQMUV4\_?7M7IQ//^8M+^[&Q-O.6<1
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M^U><_I8+!@//'3B= <$VZG=8P5NG[<F.Y-?I_5:ZE8)??1&N6^KDK07MS,P
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M&T8EY]-_&&B97PC/U>/[+.M''2KF'MY0VHCO70N0.-1B #:1+:D.MT2!VTP
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M^ON6=..'/SGR9E@';8KX<ZO37YFQ9TUI"Z:/N_'(I1-ZE"(*_QDW;*9'Y&#
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MS&6LC(U]@:] $UD<P)FG@3>N$SALRXE.N4GHHSZ&&?#P]XQ-6P-CAX_DZ%N
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M](7\%.K,# N\@[5#%OI]8!+1J*]A[V\/0UZ&!0[!Y[-'HX4F)@9V>%S48F\
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M2]"9=+)DOK:PL%^,9UV@;S"&2:W05%V"DU:YP(&,85+9,/GN:NNC<:2@ K,
ML41Z]9H!"S_21)Y9U>D]#9=U!K[*OW''^PW5'HQ;=C7R#KO O U/9W'7<O/\
MS.M3S)WC"X2/)<,(W+QU5O<VF!M:XLBI]J!PGZ*(FJ#/Z@=S)0FUZWU5\=+
M-())X:.Q6X%V\E#H7M%55K\7X<.4W#OM0=\J5_L)M=,F3?7+Q#.Y;69]+N9+
MW(D5](--.# G*.?%[$IP$H->1RK%<&ED309YO[).;UBA='1+N+:5]0@SJNEY
M68PK<V9Q@??'188,M7[5,_-B5XE65Z9QO&=<;"<XAN&PHM]L)/>>8T+)-+=.
M<,1?=KNG-R]!L,9;J":1M#C%'8^17_TG2+*J;(](-:MM:FU',I/OQ;;<9HK2
M6EELX\_%.W8(-:B9=<_@"XONQ*GKC065DC9[AULLY._B=(R!;.,DH8<ST>K>
MKVT]JMN:KV'<G.?ZG]GI\#XJN^,3-;%Q@E<P,JI<B3F*[CJV=1K:&P4J/4=6
MO,2I](396"!#RL4LN@UGKD%^O7:&]-$5CLMH\A<K%R+RD7S9:)04.2=&M6%U
M-UB3YQ4UM1D&-;&[.)6/)$7,U36!JH*JX'B7VL^8?3G:'">*U4BOR:MAJ?<Q
MUM,F#3YKJOAU(T^:%+25F"F_DP?,HU1X$76X\Y&_IK(;IHG2MT>>6* IZ0%3
MLO&F&"CW;";\G>NT"5Q&=B*J3.6/-)!+!X8;Y.1TN:Q1X >RWK\OF!._P;&+
M63FLQEV[LXCC)R'P+:QR$IJV2]>;$9W02!$6'K^<LCG&\99*,6J+EGY"2AJD
MU)6OQ3<66C)IYL[TQ9]GN,3[+4HOSV"?R08 Q2YI3ART[KL8S]JP8B:77<Y:
MB!98IV;TG1/;ZIJ49[/S(0^!9)&!$E0'S46'U9B#M8PC3]5H[JZ=V (4BBS%
M'D3AG1!2!=*)UA^4VJM:,Y3**FQ&&'^X<]N+6I$R.+N9'HE-8'P:L[K0"T/&
M8$A'&(;+OFI4%O1Y6&0X'UD_T]G^J[34=8OL;VU7O QMV]&.W!A/<9.$S_*L
M((>:S,HDO_1XPH^S1#9TXQS!.!?R-=^BP88U/D[X8V9&IOFH0FO$"%?R#$V]
ME/6[L-C/[Y@P.YVCA6*:DZ7%LXYU9K:E^-@@Q@',ACOL04KI- REWA1'\41?
MP9-4A)R!WVW9E!0<RI>F(7I-GL)HEN1\E/4=+9:Z/A[Y$E^XXS_MI0P_QM$?
M4 [K3'@D6.3$A8NDY?%Z5)79'4F#:.5=>!J61,(-OY6S,7&P3YI5[SDN5WG7
MS _K36A*Z]_X*2!3EFM N*=#5#D@3YT?ZRT'V=HN90HXW&(-3+G6I']*127H
M+U]60O2=&--S@?9DK75[8;4&Q'+5A QE\^:_+"'IG29N3P?5'9!IUQ)&]S&U
M&9;E=AT'__PLF,,X<_>Z-3#YNZST'&&1[!J9@46=:MH]N2-[2SR&.0/?VB)(
MZ=DC+D96) \:<C+@ 7A/FI: KZ84T2_ $]W!H).<Y&@TY0UE]EAK>"+BEB=S
M)$NT(FUM)B<LZ!J]X\]K8G-D^",4L#HTM31B4.Y91C#NEU*K+-U-F./I9+$X
M.=EMRK)>,YG:$  I:)IFO57ZL>+L<ELU'=F2II@.0S%L\#TH*J_P[,S6+*:M
M555-.%"MVR1JU5%\I:>(,8!P:5T,&_.Z'/>[?AIL]5JTI)C>.)5V_R0W)24R
MW3@,_>1?EM4;;LT]G*FHJ8T^(9-^<\H@0L;1HUU;]6N6?GEXH^YSF'[XR!QJ
MIS:YR""H-KG>B;18L"F]$?$G85]E4X=S:=D1U]9N];M"NZPM^27P_M]/,^)Q
MR!U3&57I\V.SM$N'%G9Z\B<A+:\4VN, /A;F8\7%&@.^F>AN4HB]>  [Y4/5
M:;_:LVI.-#&VA(_.>U2OW[6FKH3WRVW:Z[5.Z.RM:F.F.OKQV?H3F*5L"M6:
MKDMGG1Y; L0;_O-5,@55SC4$]M/:5ACPZW"$-+)KR@NNRV'[/TB510-FW#5'
M&<EJP]V-S^J$:38C#CV)4&,+9*HLIKZ]=@(>0P/"E<!TC3Q'_'^OU#J9\'>9
MA;\:>E:B,<:7V$]SI@OZO'=:,@#%_VH)GZ20XSUVR8>FZ_-1DFY<22888G95
ML:5R37=+3[%.<#2@CNZP[S;^$<NZ_H-\!G<C-E;%PW$:OG9+38M3JWQ.[H+$
MIJ8^Y-#YH7^XHCJ%PDD^I@%.046B4K<RO=>M.WI#>Y2QY>BJQ6AQT;Y;?.WD
M0$=9+SU.6%[HF^:Z18"D4^Y7;S=/JS;*-'MPUF I!Y:2K4]%5 K;F"(3!F:N
M[8,<"?98KDUL^< O<J5)T[]V>ZC=#I1>U[')O'8)?EYZQ.\X0HU8_WZGH<,W
M5;QREYCE>WR4.14?NO$Q@(JW"K5@7UU0"*>,?"$/>JGITRCW)X]29TAH@;Y3
M#.UZ&5Y0 XH\+K-JQAS: \Z1>::NX]M:CWH%VL[Y*0SVF)=3UBY.SY+V5G?F
MI;P3BK#<ZP8RQL:B.R2!96S%++A[<8P<,%:4#V(E-@7I#A=(VZ>UM4#<Y-5D
MN9392M4B#OK.@:]PXPB6\6-H,H$!G(/DZE.+/I?=W_6G9)-SE/B&*B(YQ^1T
M+'&'KR0^E;KCLX<P9R75,4ZE86["?;"$N*F[<27S37)0F3(Z\-FGQ0<6%3.V
MB#Q;9/E;*K(W65N^(.'3@:V.*,M_;N><D5?DE$U)*]=B?*?5:O( )Y?,O2^H
M5<#C+@;''*K-LDB6%F'I <,!\HQT!I%J]IN,(&(6(3Q+6M.OY&P&14CA7:O<
M;:&2%5-,N;8<.^8,E!8U'O\[LU8;26)7M\]&H=Y%6VE*X%B39*--:R&HU:/Z
M(E>ID41?L\"O':FFS*9ZR0PA/=>7GIK\&,BXV=UJ0=[-QD\+ICXP<6KJ[LL0
MXIZ%?X$]X% :D#G+\:0YRCL9EE6C QM;=Y:\!."<]-*$S-"D(J?0:[8PW<H8
M46.AK&L=&#14%G"LUR=9'<,:])TF&I6T/'1'E?\^2BZUX&N$,65+3TN 11SB
M]_<T/P-.D2<FIRB+Q^&E91@;QVR2XD=%KYI:); ;VFSWG9(X"+*^Q]#ND1Z(
MY9*/4TZ6U!D7\R4^QQUBN[WB'5(>"!8';%LK. #1M4/U!,$$--\=EO2 @Y>D
M5E&E<#Q<4\LATGMJ9)J"(1%<PY@TG[,&$5D27>%#HD-E)0@HAB#[+!**9K\
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M[1H$>. Y[A\@'<!YY]Q'VX[>_P"^H^'Z_+2(WWG;M/I,^<;3'E$>>_?^6LB
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MA92+L%ZF^FZ:LB1B_,:2,]02CW&:"Y\I-&SM5J@/#X,O=WDNQQ7(_P"'R\,
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MRN&<SDE#%47-K6J5*EQ'524 [_$3[]8VIJ&JY'46=16=J71!A8JOF\C<.C(
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MEU;B_;XZ@<*72D2CA_7Y3Z9&I/K0@G)G1 LF>.3$JA>4FA<WSR_M)F-#,-N
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M*@SK5TDJSFV0"UHR/$W$^<JK!ALE-;B+/9#/A5;SK#9E$LD='G$F#8"L%O\
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M"W"5B_AL45DV/(010!=:*W7NE9EL!9K+IL2!B%I]H3$G0TVV,3DL'(% MZ9
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M5B;4ZR8:%GK&X<989UB<I=EKZD=5U8QW*1Q//;Q!']I@I^+D3D6=)NVIVNM
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M?7640ILUD+-[1:^N I V2WW=I[5"E%UA@3>@(]$>L0<R0-]A594.*"@P VN
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M/I5552/_ #TDFKCB6[LU7U5D R%E>3V,F2)18I8J[D:U<0Y"@RNMJ14&8.#
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MH+J V 4*'X_'4^B<6 6<GS4S(MHD) QC>9WB+P*4FF+)II+5&L*I(D%)))2
MBCII)F5.N*:9#-!*0@KJ*+"0H 453G4$.LPF'RLQ$SS3&\[#&\]YV 9$(W\]
M@&9$8_Z1F8C:)VU]AWG;;>=MY+;>=N8N6)+;RWF!'>?.>4=_*-"E)IBWE^;4
M:PKY**+='S("*/Y2#81%N@GU-!Z$4!$113+P1(1$2%+R.D]Y(I[R<[E,]Y*>
M2%[E/F4],17O.\\D0/\ #$1J([1$1VB.;:([1',1&6T1Y<QD1E\2(BGO,SJ
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MI$TD<!MV)13,<_),=PDI&.;EVWD8WWVC6$2# F8V,'+")[;BQ<#,+$HG^((
MI@1G>(&9B(B)F-;K2OP+!ZO),82(92+KK]2_:1K-L]<>88#*>>Z11(NKYA@
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M%#LJ\R?/\+%;)S62%I&';U*2FZ?0J3D1%R5[C7#]1LK5ZTK-?3= T?G>L7L
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M6&,&O64!R,4:],T7;E@GF^'HI(%K)+KOFIXF)M7",FML7GBX!?<LVKENP*E
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M*KP#Q&%CU(/'3US;:X1X05YU]%N(%J@Y?NF:1^34M2S+MHVX!51-KAPWVQ,
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MW"#IJW<H/6CY!ZBY1372<%5*!]:7H59E!.'F*M=I9&N0D2B3>QUM-^E942I
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M_9N9J-.9!E1CN_YS=!#F HG$I3& I>.HW2 CTEY$ Y'C@.1 .1[CJNPI!9G
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M >_?X$ '[<?O[]]3O\/3O\?KTTCN,_+RF?A$?&8^._W;[=M'WX'V[<B''Z<
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M,R_I0J'&J (_=2UHUVBSIN!W:5<AK8>'-$R,#[XDE+I8,C(#%@V"@"WF#DG
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M)]W*Y(<2FUV*JFXQ;36%DPDF")M *W[E3R4YZC>"JT.L)K6FC4IY"XS>8QM
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MFW5IFD"@B.+'/;6P88M:)6)_O^K *.QX=LTVW0'JK3;HU&J7O+AF^PDH= %
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MW5E!5>+D)BQ2TGB^^1L?"1[&+ITJ@O)NWD&D@R^MI7^ILZV5PHF:?E)9.,C
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MUB[K=ER<Q7?7MT+#NHF80XLI?D*M<FF1Q;8/"6H,[N9E<]DR"QCJK,Y)6O\
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MD>,Y;2$196I&F]EKM,P=6OUK-#PRCKK-+3L\U]*&8K*8E)])&1J8NN)L@[#
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MKR[N <N-RVY9\[@G\_95+?-2<,Z?9;<.(N5D[$LM)/)-BH@^6.NN@9QZ591
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M8\J_;67B]3-P,,:/AEM]]C=H[I'+M FP;W6Z_VQ7Y6A^%PN?:NVM,O6-N$W
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MZ,@LF3# 375*6DJQ4IGA+ )+9/AN:F:;DEA4*/+BFB9D^IOP-4VV>C">GMO
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M4=NR-*]X;7MS<^'4DDFUB35-MN8E@JMY= Q\HE^C_%@+WM O%@818(!2>CP
MOM?TU)2+,7M<=QANN%[OK;<$Z</-2E-R4</C&/YL)[HMM$[/?02+LZX1$I<&
M>*@Q#MF--#)4F?W$*2D-T>FPVV7Y&1&6N4X]S\HYM^$\!4.[]M&C[9/^I-[.
MH$Z44#KESNHQ2S,IJ,M&K[FZ*(6G:"=_&PQ#A4$\)%N23K8TT'*I'#BM\941
M7P9#$V<9]_Q*T.;R2\-/2.HBJ9&4=@DB^K0N(UM]$@\YA1WX-S]33*>]:)ZE
MWYSMHV:?\?3R8"<&GA-T<,K]$VKPG(JP@/#/W@]4<N:G[Q,_6-$[&<XC8!/4
M\5_'3"#:G/.F/%@7HW+2$0.?9KWD(KF9NS9S:]^/JF_O7?2F2VYNUPK5EER.
M3(L,WD#FF[RL/[1_^\*GI91)W90)XL&X03_+86AX5J8L819D,9+%9->@BON0
M/Q8IBNQMXYYW4H0F]^+[]/3#[S#N[]\Y6O:6WS>8)!)VXX9DW$[?FN#G_J"I
MZW<4ZU,+P7<1?<]'H=&X!>Q -$K?@UMS>C V<SI]1/QX:HMRUQV3FZ+NY:/W
MHO\HGI0CR:GJ.V%-4PAJC/_^ ".#+ 74BE" ZU,2HX:6/#C=;GEN'8M3GIUT
MIU0)<G_[PL9%_TDQNXX+N5_^'N<C[5Q?1R5;!CY.LBQ0>%E=^?NY&48\=(XD
M(R-O^O-%GI@0J#7/_JS+SSB/8VT.O7LGJ(^B#9W^ ^?EF I1'M!DFG"T43\"
M_<#EVM,XQQ6@N1,H@'@0CRZ77;^U[-]Y%;OI>_W#J*^)I'Y/#6=)D4=Y4"S8
M]V",K8TX.DA.MD\+#D^T698'&5O]:8@"7NR;5O>F"?,3:.+^:(Q2PF39]UG<
M/V^G ]>H^?>-79:H5/8HVVP_A\9QNN$@@KIZ10D#4](5@.P[#:Q$UHHKB=/(
MP\/S%A.D%=SI:7M"WTIFR4Y/S7*1W9ZK^,.=ZO!HHB8#86!QP:$M/L 864I#
MVB59Z(@I '"#SL=#^KR% 5&K'?!?_DA 1BK56(@<7&G-D]B#D\QFG\300"/'
M5%80S%*@&9=9JEFZ)XU$ S=BQSO_Y?Y9]14P<W6]94 '^2.HBF"S;:#TS.7I
M-F^#9:F+'_*H8Y=>8/JIM P7\8P C@&F+YJ>\_:]6X$<XXQ_]2N@ZQ70TI[T
MXU.),(3";.U%X+-<7EUQ#EBI5] G9W5=PRP\IR %[H"\C-,)!T#?F&//!I0.
ML&.^]K==,'DWE*T]B:@55A;BY&)Y.JXP]+/-4#8R8CU4QU=A]1':=A,1\WCS
MK'6*NF)D8M.%#O6.V$JNE<J&"44+2CRUCQ$)UO-YD4^PB^)[8G8V#Q:Z)Q7)
MIIB=3^=(XH.H<GS9ZRS25X:M3E/L-]+"0%,'XJ/DH]'CW *XI./O,;:$;[V>
MJB=ZJLXNH+BM TV>MN:Z=A[35II*1B="SF(I?I>*JTFI1MRHI=-X3K_&XE'[
MD%DJ')D!,BAP\^MO\\KER(,;Y!)B/S+3Y#Y7]8+V75\C^ .P*C-B^7=2:.RE
MQ9*,PA ?4*]86\D$JGVB_51F]YL,:3@33.F^T;IU@GMR_I)0C0,](TW%_H^H
M-I?5)=IJQY7WW<V5\LH)7,"C8Q;3;T,!8V$@,B6S/^KS&A/8)Q+^X&<_$S%[
M'4Y+Q(*]JS:K.>MJ6H(;ZM&V1'VGC*2_3Z4(U,KJL$STKP#8P/7"=3Z12;^D
M>T]_,>5!M9%QT-75P^4<*;C9?#]6W2V*.4"_X4A0087SUQ "MI V581,%[(K
MW@^I4RHRC$*-"8I/D[X0OQ^=T*/SI<&6#:ZBA:KDB7VG85^VY]VD 4:V#NN,
M^0,480?F$@0LY:"&4ARLPGNX )A?O/.IXCP'/:79+^0OY+?0VJ::S8NNL=6R
M^Z+RZ'Z^(BU'5:#+G=5H"0V" ,+3"(#SFLP[W3LVUTMA\ FT1PJ^!]_YKHT\
MB('\\U-_'.[Y9>IK3<*(5_3DG"1;R3$(Y,PO[D6YC%.8W$FN9ZV[+$S:GXAU
M];3.C(O>YN7^D(->D<GRI5M-%95K9,<]@,Y%*PZX,A]*SH0U.=.2XPZ:%;P&
M$H[@"%<&2K+D'N_O?<0D,&O[^<K)6]% !,_)23I.OX[%=CY/11=U'./5D+#)
MSN+&*_:-HS!HX,2984BON"PX#5]P=8&/*(R]CX5G[AK)YB]R;2<YS/;I]FP6
M#.,2TRRBKT(1_%XP>GB^:%2PXM-+)1@)VE@DJ9>7H?=)"F(] S3R4UIYN3Q9
M?W([JX9,.' :-F@9=)+#_;LT4 &,T 05N\EC]YJ&[47"NYA!=.AK4^^F_3U-
MWD<:HWY=Y$P<Z7%I79@NW-]6SZ!TC*0N)YWMV1H^8X//!FY[;C?_.OK2*8#X
M8[S[?E269')?YE1A>$B 2#OV;BHK*HE('V73]'MZ -.[BSXA$D.>%+9I3/)D
M*GK\(>+QT8=$T5KSFZ0]"OM[1XD!\E*PES_8!SG/:G.A;2!PWM(=.'!;L4C*
M4KU-<.C&G3)M5KWH_M&ZF99K46S4XG;3VR#EW!)FRE@\MU*?*R0ZT95ED3-1
MCPRNU?)0;\00=<%EL&=;63KHI/W9]7(UYN:,JW7@H)IIHQL47L1 RF/-HEU*
M*T=_1Z'OG#XYM"/P6SN:?H_V(91]I.K'@^30C8"P_?7]*\!7GLX7_-SY(O+R
MZ63#'P"JF%SX^J2EJ*DP)(BD@M%4,$$'5-+"@S\B^JZ5]@US#WM'A<I<M/5A
M:Z_Z'7HKB)AQ>I><-YWPO6'-D2-=QRY5U9YT15ER@!1LLJJS@_HI3"]22]8K
M0&U^0H$H'#+C']MJQ?\8RZAKL_VHJ,4TS<U/3<D"=(E$^YU)-Y2AK,X4F,R"
M'(\GT3X):X8AK]7]?'!RN> D/^QG]-0-M7__K8S#YI0%I3F12&^5D7M*ZQU]
M8)^Q"%5)?>POU"67P<)[+:Q?;^RD7-::()5Q7Y-8?CP2YK'7VZ1FMM!O2F5Q
MUE"2%D>@3U-7'M.MRDLO#T\6;?:51OR-@N1 19;MX#A_<C4GQWBU]1=RN=Q&
MWKV3N;[@\O3I#0I9894=:7:6CC%\E_9#KCDN20SU74^F.+B25P#DZ@U"*G/^
M*ZC(@T_I]F5<WHQB%#2/0$@?N&C)S<)6$47VP;(7R: 4'X.*7!3@2N2!:8JQ
M!5-2"O[QN7L+4TV-_150.S/S$;<-DT(OAL":H2&,R$.PX^0]@X9%0$+=892;
MC#J*QA4!"Z@_BO2*26PDAO?-T]WY44X\-PGV>EPL^O$W5>I+14;&QR=^R; D
M8.D]5N$_ZL G@+UFDF+5[D 6"Z>B@=M2.RJ9;?+I*EV>/_^[//S>/OTWN5!P
M!F\*,Z,Y,,0/1:FF5 L_E]LG7W,W?Z^"@Q:"F4Z6CH+TOGY$1?[-6N2QMUY?
M;<V K9#LV_9;^<@E".:T$[E4DSPF3Y1J&F2-),XCWD I?;]>>%:Z?/!F86:[
M;AY_,/J'/BPD06*Y4^.]&2Z*VG,D7#I'&%2-7$8MLYDLM7'BW_5]7#+#218A
MS(73ZOG[+&)C:B[:W?74_<:3KQ_!)Z133&/RDWO*;M@:=5,A0L"D(Q#>0O1J
M\CJ>5S(+<S+&]UNA=LY;<KG"M.['F8-;GQ]N9_G@'R#7WT3]3'-Z>O(B7M?U
M'_0=U G]9)!_:6N5ENWAM'PL*EPI@!OISGKP]7I+G!#H9+[[N9O2N%&D;,#T
M& ]-)9% J"F!:"V3SY(#2)<*E/X^)0N4Q%(?VH.#69+0B(1EP(#;45&=;=ET
MO'J\??%2#H5T\P4F@=Y3S.G5@M:QYT&L;!WE0>6W3#E<3##CE/>T*RYS<@SF
MWC=/S=]K5NO-QYG*5Y7?I0@E2^!B (1CS;B"X4I;:<Q>#*W+]B[/Q+K]2]/2
M[-D%P8+\WQR3V;H@UGP4*5G\5%:7M@)J\_4R6'8:RB%8N+"FY%:W;['S)D1D
MY$6#7WK\FG0A?X0<T881Y!IZU&(]+J[,4X%.%1B4V'CK[Q9AK\D*=([^XDD'
MA2.'=6<ZC2QO/[<\-G>B?V/"XG(3]+AIL+"TMM@(K@<FZ0/Q[%9!-?$T^5$+
M$7VRZ M.EPP8 -^F!>CMS-'Y'?A\[JOJ1GT16]8[*[:]R$N^.8ZU#$7+!6H=
MR5\%YDY$763?S</H*?K)P]X*Q_<V[VT0$O?+G-/]>M=LF6)X6N*UI'Y</C@1
M ",<BILN*>P-B BK<P/\XOU'/'OQ36-C$\SW*H+5>N(A3DFJQN"FQ#A-\SG!
M4'NZ1I>^1AJ4+WA:U#(%#DPOH,<W<<M4&#S;](:>_X6>SSEU>@^?]#<$:A25
MC7"^>8QV6*"#-KF$; 4&FJOD#WGJ)*MPO" R/,E^\DEA>PER(=#]DYBO:+=&
M:Q5XS847LBD (F;'V2@JUY^"H_+14JJQ1,,^R1FP9Y=ZSWR>/\FXDUOW"ZG.
MQCWG=JO+W^C-FQV-470^^(B)B<C86M4'UD/E''-"\:L*-)45SL.)/?G29%#N
MH]+W'F:Y)$NPOT)-J>+(&7&R19+Y2-)CNOW1;Z ]>:4U"6D0.7:GCAJ\SUS[
M51513/3IAM]96!R%!@'O5N#[Q;ZMB+P51>S%5H_=\\T=^-9:SOF-?@-T755)
M^B!1!VWD_(04?9QWG[YGN?0B:X8CW5CCEDFW1Y-+;ZD\=1L;.(ULW=X^^77*
M%]FZ22.JTYW4\;FK6 PSM+@?1%'3+='L\B8-;0E?Z<)&+,)Q;$M1D<8&(>.)
MX/$N0)_]*+J]AR%^F?.6K>L._?S&S)U"DI_YY:Q[F/<(A"9U4,D''!3?@''(
MGV0X>@5@^6E _W7"OY![&R%0C^?9ULSRSLO#6L6O;'^5/#/+8%N&["+[BK\C
MC@R-P=)+W(X4=3FX>"A^GX3UB@]BDY")1))Y%P;!UY1IJ:\ *,E'UU8VBTO9
MP8+)O2%(VO@HB_E$C29J2C;Q>"BSL R*AO8P%I4;;)R"VYS(V^=\'^_!K240
M<$ORZ1TC)61O*3O#EJ'P^J?5JG1KDC[\4PLZML56,7>R))HVEC*:O3-I$J8C
M.>\_JA6"?_#?WUQ?+\\.HW_OJ)2?3P$S<"8DQC*0E.!\A OPVN,I*D]VG'_3
ME4@B&"X ;!PLQ9J-6TR)N-C+6>>?^=2H6%M!:-,W@SF.63D5%T-A)+L%-Q#3
M!D])>OPXX!T Q=D)YH\HYG">B4EJ 2*2;^O9Q:+BQC(,J PY_!6P+K^Y96^L
MCGU#(?8B2.EP/_]ATRT\_,E?K.OQWE-9V=.'3_W^#VVOOQ2%A$FLR-/C2Z;;
MRTO>UM4S'ZGJ+/G+\TZ7C[AS:\FCSW7N.B;<:'B8^"^8F9-S\I&MO#<WY;XI
M$%- XW:9D=-MW+@FVG)]1G(I84K1MR)_MI774^?;*[%<#H7XYVU?/3[[<[P"
MWH7G7K7,'U &>WIZW;OGY6YT/F#?[,13;'Q;\6T[:/,.LW\A\=UXZ<G;Z-DJ
M"X>*0+DN\@3OH&L^I?YA?B\=5S-B][O2/9>8K79PU[L2]O$+<J7CC"VS]_?W
M9TUG$LAK?J\ IB49E:L1TX.GNV?IK4#H*T#!QELM^6T\\K>/?@6T^O>T>L04
MCEN9?[8/\^V4/VEY[CYC_O9+.M83&PMP]Y)]+C$I'7?E\W)X-W/S6.@K!K*&
M?#GC@?CW>$:D9USE=#T^#*_BA+\4SO2(GE/^%.N!0&]BJ K$-5I3(;XO6A(:
M+0]PL=YAH@ DBH%USQM*OR?G=;A;=#7/)[_#:\C)WN6<3Z?JQK[[U=^S3?%/
M#\HSV5"1DY_(2+U(9,Z7XENT-\_>+UW6)Y">@8.JSYXQ^Y^[KT@G9=QR'_WM
MMF*[KD;H89Z%3LF\ <\_ L2>7R2,Q%\!>6E'EQ!?U7D1@BVQSND7?Y^SR\OK
M/+U%Q2W!N <N"PX9_QW>+0>L5\!(Y!G<*.!V!Q+XTG'C-_,*.#,6Z7DF['X%
M/"+D#=BK20R88#X7FDO\E1@2D?&?ZE5VWWH%#).I[9"J58WLG=AVO8-'LM67
ME!0\D)A^!9AL+_$=&-G;2#S<I+T"G+1> =-&RS'/B1(W_GG0UE> LIV?Q+DR
MH:_;O G?\K'O_^^QJ4(5OJ'WN _3--GKL0.;NX;5$I)Y$3UM!FD(V-$I7<UM
M8D^>T00\S,1%?_@:%G%9%V@S'AI'5 )*J2I[J&#"OQ_L4?RTW2'/^77U(]&5
ML>)(1;N60A=Q]F[2YY+4?)RFR;D7B?>;-UGJYO[0X_R-TH1CC<BJ/10CENC7
MNCO.CIW#[P&QA,ZAP('IOL(GD:%\S&K)\PS%2;)ER]*_<E/O@JK>'2NOA++<
MZ@O41ARV9*_"))C7Z#V0(FCC=NG7NNDLNK+,G:.(B9JR(D[WV&9W\KHU)4@5
M?20-$2_;_PG$\==0]6/_($Y9K/)73GSC,E0*.*XY$$-$47SB[J0Y.\+RG4'?
M*+I-*2'RM*$RQ2Q"-,3&Y@O9"WYF3%0*<W39_@8J\7ML=)A:XV8^]EN,P1:=
M0R/MQIP;S31-_>K%DH7UC[;1]3&-*;I4.R3#P&2+6\*^3RE<U'H6&1VXS+(*
ME:7(<N3 XU96L*< +A/U2?H0_,4^I. [?UIT5++LNK==3E,*C4%5IL[O"O[,
M]"]DR\\CX5XQ??3Z\T -AD>\/)LXJ@DM\%AL2?LBA4#@=$TK#MZ\7ENR;6B5
M,AX_-5M@H]%7QWY9]P3-!6XA8GTGJ6DH6>';</AW=-> 27H8/Z.H.'3#!'GE
M<O3OL^A,GJ_T7!/K2\$#ET.%Z4E9MV1>_('4) >BJBE5#M^PVD:01S!O/(^(
MW;;A +UC>Z\R61S;6?7V8W^"R1D*/D<"ID<^IPS.:N"FF;JI&5OZ7A L^2UQ
M^.>N=0Y:D%UDN6"G3A*QC<UR,%N%?@7T.#B"6#(R6OKX3\E/PKB#%+#@,3U3
MRPPD(\7<TWTZ/<HMV.M=$KAI-'-5DVER %'N*_YLBQ-^H74J/OURS<0L)SE@
MW'R</I=#B.Y[,$MCJJ(;Q!6%,]:!4/U<S+6I<.,3BA,R'EL)^BZ!UP<-X&5S
ME)_]P%^FB+$)NX]%_2/+K&&MDU%19!H;C57)N:8JT4X8*7Y53D,XWSXSM6@(
M,'(A!R8+C6OTU1@(=93"C-DT$]CW_*F&."48H8='I'#%>(4B9'=*]1$,G-D@
M.6-SW@[^/&&ENLTOJVEIAVH//ZL;S,TS8X#S/Q_SD,0UZ)QP,?#7+IZ.3^!L
MXUHT[1Q#0JP;DTL_+F9:M,;HZU0OI3:FCB*AL5CQ[$=U>DT)$>,TZ9$U17ID
MX.%\%@E5JN&JGQ7AOQ2\;.BG?*=YPT/N3G><NH)CU<JG]XBB$)2!]2+E22W+
M'H->5S?22D/ZPS23@"!XA"\*>$G,XM'<74;(Q*7DNYM5HL>#$JH44DVDH>=Q
M3W3OQDY/D\>3%!UOE]2"P_4GWFOH!#B*0K-7V#("[$P]P>IU2965+LF'1Y-&
M1L9HY.1+#HR B3[] **1EGA'')Z>U\W7IJ D@!,4,RY '!$S;*$D$*?!E,!T
M%1$1<89;/04JG]>YLD81XY]UY"6;2D[Q8!;:,[4=":';;>!2P?=J9"K4V[?]
M*7EOD2#TZ5G'CCV]O)?M B=.7?N' Y.V[W!U%=#AF%,+-=7E-RA[F&@(K7_8
M8ESHODC.%'Y:!F5*>,AMT2M@J.RT#0OQ3Q&;2@B [+*XZ3==":VC/KC["IMT
M4FH9?5&#V=LA:GTRQ^WX=S$?@GYF3"4O6%=UMZ)E<;4I/,S)D]70EX;]L-/G
MV^<&[F4KOO +!+*N.IK14-?J>YU8EBF#8ES'-#NM0AT;IW"AUF"];]\ZM+=M
M4]*$7#N^0N<1LL()M"]&B$EFFK& A/J$>19?WW%%DGF35,*-*7'@ZB,68.%)
MFW82\L)CH[U3NQ#H=>N$>I.W5>YE1D^%X1.RXD_5=.I)1=O2DZFTV.LX);-/
M.YFKCIY?WV-*7M;BFA;U".UD\;1QW!AP57;UAFQ9WWEFX<:@>0*028SBK>1*
M$'^S:M=^M=6K-24<; MI]K0$\3N#JRW&ABWV<\OJN/ Z!OB>+">+^7%5<#)Y
M(IH32\VG*JV=K1OR.W$]$A\(.$:DK!L.5;Q=UAX9\[*'5F\JL\A7U7CD@NO
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M4$04<R3QM%,F\<21<'D%/*72;IE,J4)1+7J+]U*:87>=L<BVK-Y)A:2G?G=
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M-JY>JH$6E5[JK*\?=JONU[52NRD3PKV17:W3%%=D63(P#(,,AG,<T)Z<RIN
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MEL,[%$C/*0P0EM,1.Q#,$,^1#,%&\3$ZQ P8/,!"8\Q#,C,%$$!2!C,Q,Q!
M8D!CYB8D,[3$QI0UCK+1IIJ@N4/$/Q1BN2SNTDZ'D^>C=O;:&"YS]>7Q$5I(
M3<XJP195V"@[%EFO74BP'?E!6T6:JUO'8&:O$D[HJLAY9N;.5K!CXR31<NLS
M-C@T>Y#6N?#[5=UJ%5R:2*R3IO(5V_#W[RH!N*I7P:N2M>%GQJZ'57XDL=]I
ML&1L#"*Q+!BIYB1'BY;#JXR6-\:FJUXIO-JN3:"O93$><ZAFMDE*4EE8%8DU
M9JUC<RLBQ9M&+%Q;8Q*:8U=RHG(N5#VAC$N6<A,,FB3IE'(/F(*R)E7:*9^T
M^LRNVVL^21JW&41<);KMNKR8VRJC,"Z4U&B-=S7J0,VB961UGT\@NIR:MU=Q
M%!ZEM@+]$<@(L$1.LAIP%8;,09##K40YB023]DUR<\DKL42MS-JOJYJAV[OC
M\24__P#@CX?GV!\'/M\_/\O?3Z^O]-8E_IZ><[1'GVV\XGS\_+X5$[!VY]N>
M1Y'WX]P[ASQ[<>_]1'36/>>^V^^VT=OX=^V_:=M_OV^?:(T<>_?M^4?8 ZOT
M#@.?M[>W(\@.FG?X?&/XMY'[_3X^<]_C':- #V'G@>.?<>>_ ?// ^_L'M\^
M_=I,=^V\=XB=NVT=_.-MX].\^?IVC6.X<&$ '_:(\C_D/Z:F-O[SO]?EWF?3
M;4SZC$SY=HV\MMH\_G^6TS,ZSP;GV[CV$>?O]P]N ]A#CCW_ '!VF?\ :)G^
MWR[3\(U&\;>?KVC:>WGY>N_SWC\/+6.![\]P#MR/?@/GMSS[=^WM_F#X_#S_
M !B)VU,SY;=IG:=H[;[[>OEZ>O\ I)W 1XX[B/3^_L/'^K]1X[#[Z1MZ_#\_
MEZ_GV\MOGJ/.(^Z-_+R[3$SY?"?*=^\SO'EH$?UY_J!N>.!^/V_3MQWXT_KW
M_G\?K\=(C^WI([><?#S^[UW[;ZP/8P"/ >P_?@?U]A_E\?&G;O\ 7K\-OZ_C
MJ8WF/CYQ\-X\NT^7X[=_6(VUG@!_YW'_ #0]Q^?]7'';D>.>X_=Y?I/Y]]1O
M.W\._G,SVB8^?WQ._?;OMY>>V0$ $>0X-^W(=^.W'/S_ -6HTVF8B=]X^_:8
M_';RC:-_CMOMICY#P@EN/K1L+K652HIWF:K,>>QIQ!9P\:#:QQ<F"Q8H\E$@
M\,?T0(] R+8"@?S.LW0!#=GA_+S@\K7R<5XM37%\=&6]&#ZU=J?^9TV\O+#.
M;^"=]MNV^\>)]HO!@\?\(Y3A0\A.)')G0/QP58NDCP.1J7HCP\V*D,ALUNE/
M[\)#J2>Q<LC,N,L-W_PL-E647F*,DUS(4\CD^(O;F2N.$;1:&_TFPDI=(DH6
M-H-(S!69V7EVZ$:$I'.&MJ SA=08_P"CJF,1QK#C/BL\WEL%=.N&/JLN4,-=
M&!;D&Q7M6+$>*02_"],Z[+ .8)I>)H2Q>ZB9#D\KV4>S1?LKX4XAQ*\M.?:R
MQ=X@KV')3A$@\:>.K>$?!OR(DLUTB@6PY,BUX3(D*I!K_P =>)10*EBS"E@W
M86>H4ZY9[MMLBL7*4N!G(V)N-.B;6SKE?O$C5)2QW*7QR,G]8A"3M9G+5.OJ
MQ*O@C7SXZR:I4:7(IM_&8A'NY:UA,=D[]2+*KE:F[(^(\*M.24FNBTB^%>74
M6@J(.>LB#;->7M^C"PQIYG*,GFQ&.R;:*+95VT[#8KTP??78H.8UR+&+M*R=
M2US$,-3CXOBM 61KKV \22DH[BEZ2<DM*85DX"-C*I;8C$=^/(R^2'60#T7J
MB+666>5^W4&0D"J1C:<B:S'-8V;9*-EYJ0(\1(ARZ%Q5BG?LNAD$18NUA0!9
M VSC+O#G$/$1S8K'U&]>S0X?9?P[1) Y&K8%2JI-7#G;<@Y=)U1<$,K#QZ,J
MZ2ABZUQ&:PF#6H#" %<T\AEO!Y=9]8J;PW8:A!@:DMOXD^U=>M-[J:P75M2_
MX=OLG3-O=XWN*%9J%?8Q$O.&9W:9-%BQJEC=1L')+,("95:R#PR*:2*9E7"!
M%-CK*$):^6@Q(CB/#M44&O(.S@X,\;5QS(F N6WCQ+A)\.LNH'V@KGB-F<FU
M42U@I@2%_P!H97'6$'$BZBW"V<O3R+[ZNYU*5>Q@LHN;C8A!35/E*=QWB&[>
M*#BJS4?&UDVTS:%YE;9E;$56GV4QCVW3,;7*G>,T5;$T^6U24+-P3;'=B.>P
M/'%0?6%Q)LI.2B3LBPDBFN*J%^I5:_.X7''RQ2O'8&T\?=WWP.:R=6O4M',I
M\<#L6+;-0D/85&'2/1(U/&%-K-I9MLFP+-#$YZY4" DR\1A,7.5AMFI$0]F+
MM"*J'C%MKK38N*=U6Q6=59+6Z?>I'X-N^/:%4TS3]B6R+CN/RFS_ (>V^WQU
M?H-X6EFJ:);+79F'BZE>Y K!26JK.:2L'UQG&/V2, =1XVD&G-KW$%>+K2?V
M747Q G(N4LH:-_%\'Y/BQ*J;)Z@6V5D4*Y9*@M!O&GDDVAL5NA(/6Q)%.97R
M3?L%B"I(-D0/ALAQ)1P)V;*HB#76<QURO3M2U:IOU#5,-@&!'U@O$?VWS[^%
M8(IY8COQ)%TF<KSV<Q#>8>-FH*_V1&H5Z;CGKV+21<10V1=**D'A1!.-<FX=
M=!0ZM6NWBF4I*!LIM4ZC5%.Q >2H9S)8UA?_ &C(U>',M-)W\#V5Q4,]1JQ*
MB61JC55<YC.NZC?R"S!9%NC%W<-0R0;1&_7HV,]C(LH_C6MQLF)!+9%XX3WK
MX=W-3F6Z7A-]:'-HQ,T62L$I:,>6:.JL?*KN9B-C4A>.SPZ,P<7\*]6<0K65
MCI0[!#S3G8IN6[D:-MUB>%[G$='I0D*S2J': B!E@<6K*K$JXM0UR@K6:A6>
MBX>D5@$FQ;MQ'J,$*>7#%71,G QOB55S&"A56Y-*Q$/Z;EJ(W+<NLTU,6[IF
MU0N4.\Q%@CQ%<;7.CX";9/<.&.7,JT#'<[8T*/1[:XQW!7'(<([EZ]5E)Q=>
M>;UZ2M01L@-3@9NP/).0*D1 CIRLHF97LY)=:O?R=:IUV+QZ6F MB"=<?3P=
M;/Y&C0D5J&_>I8ZP-QU:N'5&M(LD>Q3J+Z"Q=O)U;3TF-#B7-82'C'2VJT.+
M[O"6/R5Q,M<5.M=O(KUI>QDI\8XE@4#&PM'+OB?8N;X6N%PP6YE9K)E?>S;)
M.H6W%5WEPA5Z=)025I-?8:&EJU(U.#,WF6T6VMK^81BXR7D&:Z[:5*V7C%ZM
M.(NY/A:NEBVT<WF.&*]JPLX@%XSB#B=?"\RNW,DBKD9M3:904Y-F+AT&UP3,
M-AZM%\OLZMG"M :K>-Q6;M5:Y^Z=BUC<(_+K8"=NI;H*$:Y7B22B77L 4.7)
M!,]1VBIEVK9<X% RS=%4P%Y H&43*<0* B80* B/'(B/'N(^^I,>4S'_ ,I$
M/?S[3,=]8J.6*6<Q$2:P.8CRB2&)F(WWG;>>VMC6.MFN(7BEXBR3D7<ML&L%
M)J,G8H:E9!</K2_8F: C#-!O^+7H+NO4.43B06L<^7_L2*FZ&RGY>KI WR7V
MAXR_?SW!KJE5CU5+I'9,.7E2,W<>?,>Y1VY5G/;?L,Z_?O[(?&W"O"_LI_:,
MQN?S53%WL]PVNOB*UB'2R^Z.&^+D2M/24P8GK6JZ]S((YFCWVWF+89MV'_Z0
M,_E&P7^^T]DZM\+"P503IN(CPZ3%K6+G WFLN,O$FLC6=+-#N,E*XQCE 22Q
MY'+0#J6CFL='K/B/6OU"M7*KTK*I0627EZ.6(G(EN'8=%=ZL(SB.L+(?9I9!
MZ+5W[2EY$NJVOX>$=,_P6UX.(4L _ CC<CCX@'2&4",M1BK<)61Y"0%=3][U
M&F>-:I%C;Q17@ED,;]S\/AW8]K$#MVB,D4&(E8O/->S\ZLDI@Y29Q^E/0>4T
M<KGJU2Q+&Y4K"U1IKF5;(0"4>7(,N^;5A>59K2+Z1DU)5';T058X797DV)X7
MJWZJ0R93D;%X,AA,WAG1;LQX4)6F,]9L5*X5XKUQJ8RF"YK4^1NE11TN*0LC
M[W%*(18\ 1445H&<0$&M+)N&PW(PZSMS+@E^1LVKX2@3"J% \C>$OFNAXTE8
M:D6W'F<BVES0H.QT6LX5/B@OT>L7^^9 -9E'$MNWK*DNX8N+@G6VL7#Y%Q]+
MLZ]&Q0-K%(M8Y_6[%HLK)T8&B:"?4HY%5UMEK>:%S3X M\%A+U"U#FEDMZ5R
MZ])-$K W!LT;=:X(5-@<D3EK8,"K:?4M"A-=$#UW7N,,#GB2MQPY55-*G3R@
M(!J&D;GH*M8QMD(N1/N3=BN4'N']NU2J6-L5.KC&Y$Q82V)A1ZU,8WPUC6D4
MB?K"S-I2+CE]C-6MD*L[)/G,5%Y'GI-26FI)09"::I@N\W9.H.0X@I%%J4T#
M'B]N7R@C/4/[:X49PS4K44 M9UVJ5]E#3L^"FM7C")O6*96015;01SU\18D$
M=2\EG#AXVM)37L,/%<6*XG?9R=B;5Y-ITM+(K?RVTNMINKHC;4KJ64J]K\)(
MUG=0K9SGQD\K-9PXOA^OQ5BPZ2;EF\9(54\+*+2TNTR9!QECCU)Y-E98F/FJ
MTZEH!--Y7XZREBG38(]95XJSE[;)@GY1]1@DP>H"E8[*<+Y3&B]<R(/M)/AY
M]>U=KQ1=D:^4.+4$VG7;.0)Y:F+J0<K"BBV#IKB".K8OKXCK7+%+E&2QX,I<
M0PE-.3MU:SL93LI7!.O!:6#^%O*M*]*5R'R=@P47N1:[D%K.V7:O)3MM3;1M
MLC;S+XZE9J/W"UQ">QFK8&*C:H5U[&D>TNKG95SZQ/IQB#Q38<2SP/-R3%&W
MDW2,A'+DE6Z_$%6B68")$+N3HHX@<-C*+&L>297![JZK#GM.6)%U=B6&T#?0
MP-4SKD"1JNP=3AZGU<4'3,Z%7(!PY6=:I,=<Y;%NZ:;  :%(Z";9,.S. ,'T
M3#\W:H*YN*,Q>Q;2>KE,>4"(5C%91Z_CF32JO;E?%8Q&+;.R1J"9+(Z1%NU1
M\E%L0 1+NDA\-BZ\%9:6.PN%Q#+5RQ%FS>/#8NIBHOV&PE.]FZNFNS;F8.3M
ML>R"@3$ Q6HPL91Y$O;)9S.9H5*5*@JSG<K;S#ZBXEC()%:U>>JI,0N0IC72
M8FQ1O=/.M>M^FG?:\_MM)MM5BY-I"R%DKDS!-)=_%K3;.,7E6"[$CYS$-Y:"
M7DDFWG^:9FE,QAU^GRP>(<]84,G3/(8^W1!PH*T@T=8U2\5PR.4BZ4-1)SRS
M.T=48B=IG>(VFW0LC3NU+9+ET5;"K'2%D*DY4<,$>I*VP,20QO/3*=MXC:9B
M8J-.;3;_ &3:_7=M<OF"G'9P=,K=<?3[?#3\T3:9"M3#5V1.R4Z5RW+)OJ'.
MP[0L+9:4E/MY5_YSAXRN\60Z;%+?F*\99ZF3R FN[#M55>!6%,\!7L(O!<E;
M*IO&U,T7T)KE3+&/JN)Y90;*PJ4\9SXU;5BUG,^,W!6*YS6MHG)6%V*3:3IZ
MX(=1Y[J[)M59"^#Z_37C_#-BXAPNPR(9X;IF)I?(KB0=4^F7*MM;[&5!E$VU
MK(6)206K)Z[)O)J=DX&G8W5E%U*;27$I- V480*KJ?<*Q1CO-F2 KO.:WV L
M3BL9C?%6V1:?==CT5J[<EFS2%&<I<R"*[$VR&:4=.]D)1TG/4ZNQ KQG0@TI
M<I.<LY>*2%^&QR:MFVZX6'HU3*T=.BIA5EKCKNB4TTJ>MP>Z/U:[<;-A#8#F
M? Y;S,YBLY\/[@48V;>L%X=1](7:"N,A%5F"B9&PV9S%0D2K+-X* 8/[-+K-
MF3= J\BIW$NGBUQ9+ 7T(K0+5<+MQ@")03+3D8QM>&F4 N.9I[ H)B24@4I8
MYYK*PSW/L<=5POM8]GF5R%L$4*WM(X)R=MQ"8IITZ&9P@6;+(@FF3G+I-RF4
M<$"-K*6LA;16JJ>NHEL;0<'V6;\.3$F#;F=W1I.2JKJ"NC-PR2D7H5QUD66?
MV:NF2;R39)$]IJIWL%Z]-VM],3F/7^F>';>C6\SP10;6X:X65>4Q1XN[0R;J
MDR$2YN)S'VK5JODA:$U'VJU4;Z9 XM4)LT]U38ZZOI/[3N?Q>>]O'M2S.!OQ
M=Q^6:ROB\M1:Q)H=:X3IXU.4IL-8L"UB[A^,K3(!,6JJYW&/>TH9=\/J$S%<
M;2O/9'<L,46:2E+F.-8VI))2D?DR1Q7-8?3L:%W+8B%4K+&JSKMVA3AJB:XS
MQ4WIK-Z I8HOHJ]1E4+QHM,7?9&8G%W1&)G'NSN5PN8OVK"F$<9"P%O!H72(
M64@34MWU/7;<Q%BM\(1:.G9JOI"%9<1A5Y-,#!Q>K\/$3<36KS,0&/2JP-.S
M9@562>W&TX659,VU6OK/;%YNT;;L\X9L.6J_,W_<#*,9:VY+D<3*K5=HYB6E
M=B(A./Q>GDA!SZ=A!UE@S*53(?GJ/3KR(N"@8C0EFVN')Q240"XQN</B _$A
MXH7WK6?;Q%?%8@56:]=MU[%5%R3V5*T+!C;;!)K*F*$<9:N6)YK(V,6K#J41
M0'2I5<$. J=8I%D6'Q7"+-M@KKJLVB82D5%2"ET0O_A3YGJE#NKVF7_$V2YZ
M;8Y08+4"E[>E<4#/,<K7*E6IW'%F[#NH69HQ5*<U18]7B33T Y(28E :6>'D
MG/U4-%H3A=1*JY/5,X&M:F6P) O$Y_.YO[1,8;48^Q"LR.+4*K5=R:51(BYR
MHFK.Q(1N918BNT&(M(:0P1<]7A"EP@503*M=6I>313^ULB3*=A=G,,FS((V
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MA2C 'UH4AHFM"!7?2/8H1C!E&M1<"UCVC9DV%V\>2+L4&B)$$1<R$@NZ?OG
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MVC= V'TAO=5[N;;+3#3P.S7^ZYPME%:4TL%2\YS #Y1?H6Q$/Z\I#*VHV<V
M[]2X+<[>4^=FP*=Q63FQGAQ]HG+O,1:?:'U70B9NVU?SM?W;81DH^6"(F?)S
MMB+5*P 2Q:WE( (ILA7+60;7="6D%B@8,0]+=*=6#K77#V A-S&[6UGOH+@9
MGTQJ6J_%W%;+_[UC:[)NC-;" @H"G8&P"]+R3SJZG].7^M2QVK[4T' P#BY_
MWFVTSPT#_VP-M\E64;.&H!9HU\73^G&A>O5X*-ON-A!ZN,EOXBU H$/"L(&O
MB+\BZA6'8Y>LY@V+:F,G,I=N<KK42.R.!@/TJ =FR23R7::=4J7J%UB^*X]@
M-EAT=I?]5!6DYFX4E^<T9,75E1631_W$(<L-##ZNJ',A'%?]*!_C,*G6;!Y&
MB5(?NAU01^H62A5FCB;&3@F/B1^-9A/G1:.3)NKQS,2AH$=7TV?:J,&@1627
M3#)_::;.ZM(77+T)CJ4-K'NDC6FJ(M&BMT&6NMK^FN-48LOZ!J#3^]P @N ;
M3"V6UB,(;]$?W_!%DXLXQ&9$\===<GGN<RR:S:9F)?^4D=.*?1UO2JP7W%77
M_@FR=(2%Z@KZZM++7=GVF=@+_7RW:A#3O=BXBL6'J$$_^F?<CK=D=4:R.= )
M5^HEA9F5#FU#P%2:<4L5S(-_N\O0*]6?B'EK8!0SFK.J&M<"O*WR#/IEAK\&
M<PF<WZU1$IE)-4OABUQZ\#Q@$$Q(-9F1C&FI+-IK+'%05AC[_G&5T@W3,7BX
M0A);!P\]N3RS5'Z?*E!J-G6 K\P2>R6=^$<C-OQ[EB(TM ^4H:'AH- "9 MZ
M>FH34Q6#XX;095F4BK[T/4+,3.(5S&_BIASTM'0X")S4*@(#XXK@YEJ]IO^S
M.97ZVKB]L 3<5Y/TLD%5<DDC6%PE1P/^6-MQ,M9!DOLH!TMS^S&RU4BE64@;
MX_M#IN444*+9$J[SX:@98+_AQ\$^5I3J@CPX=F2Y4DC1HN&&RRU)OS)R)$P<
MSH;5(&NO!C42TS@5O:&!(]:T 8BM8K@GR8\NQOAADB;[8PP:U;L&2A+-<I*&
ML0_O::5HF\=T/\60V\7]W"OWZ1;XO8S].^K(/3:(BRB>$RTFVY1PD-,<3#S8
MJ\-8 F'1J/HH4W]"JBCLNK<2.9=%[BUK3J>ATYY:_\#8%M&W%C:.5Q70&*;3
M/8*W$_T&('+<;K!KN8M-+H]FH>_=98Y-/MP ZX8Y6[=\VQW$OO)P2J&CK,S[
MDYF6*7?6D(&X"Z-SJYB_*]FK2I.IYBTD0NGNMK%H/S=I==[I(1P18+TBUCC-
MO'NOLG-:^Q>H6I[OK*QZ.U13>TMB9\((<\<6[FS2O]:MM9F>L<R\.C$*_3(M
MI(8_4QW.IYC$:]RBRNQ#C'>"Y\;J/"0YYT@VR<F?OLGWRPD=LM1W<S119]Z1
MF0SB&4IDSK5>G?]*:HQ=E"MNGI7UH5@50FAR;[Z /XN5^2.-HSZC#AW/525N
MU$T&1Y^%@R;I0FZ5S32XH#.JQNX-@+UC$V[8;,I,ELSI9%\,ZW^7]VZ,9R&:
MZ8@X9W"!.TNPV9#W#YL2*PG?IV\)=FA_3G1$W"CC2+ION2#. W,7I'B#7KT_
MV#.M3[^M]57JJ[>BR2PY+V:#K=)2_V1"-.TE:_!H^I>N8W!G1W8/W^$YW3\?
MH)L"JFW?U0]?X$7;UCUF<]-WA9EV3W +V<EEIW(5$;FA?%M_ Z#FK@_;ZV&S
MJC9/J)WP=,JJ#_R57SK6$>70CVL.FZ*06";283G-X3#_1&8J4(IA^AW*1T0K
MRS&X+?NU2X4K-*^2.LA$FA85X8:#X&*!^9<QGHH-Q9_@\Q-]0**0HD;D.[F/
MSF9"?,@X;&BUOZ'\W]:[+&KVCM!,XUH*BKYSW$]+EADW/4;&>A)G+088ID5K
M(@\9C)&!%BGTKO]GM[8*LHZ>!TGE3:37[6XLBF_H%$@O@@E34#4*E8O'ZX='
MQ7I6\!EP;X5[8VKJ?(7[^BKOL<SPOR@"C%8,N WHS1VYR*K>(XP"0_M5C<3A
MYKC3#EQUMF&_WM7YI'BQU_2JM@?^"=CTN3@5_KV$E "VWX)!* 3==U1N;AZM
MZ;][PGHR[ XZA]X Y$^@A[.>DI=M5]>K2\&('JJ-H!. T!O Z<7KQ4W@%NH@
M<G/V.)7W&)5;VB0%?927=UCY/GMZ;W=8V../@"#@<DD!V^0E1[IF[\XO77OM
M60\H*057*;[<7C^W0'OLMKGCK_8V_,RD@^!VI3=6?7R?,!P/3BB.9B<#E(S:
MA?VZN+#V@$"L%<'"GM(<Q;5N3J'N^\M+:N%GI+-A9XI2JCL ^?K+&\"..^_I
MF>?IZ3' \WI##8NL@-[/Q-0*>I:9^PQ.2'\#8/#>0)2NT+=IW@"\PEX4K0G@
M%V]OI8R]EM?<+I':_"GMLYXADT]-[OGN?L(B"7[=!LU!\$C^&V6!2 ZM"?;2
M=_=G=S,\ER_"+GL/;P"VQS&GAU>!!R\83D]I_X+['_A3:BK8QHD('#3>$R-_
M,?%^ML<R?_'X/+_#00$$29\6]NL&DOO[P'IR(&,].6>%27!GP[?HO:2.-"<4
MK;Z.E$(]A8L!$+4F>?<5@2FOO"MR-8&SO8L'!_#XKO0I',1^-1")U#_D"=G'
M?_5(Q$CG#6# '0E;^>[7>9MU<S]N=P@4#O"'SL5=N4/)010!9U].!9[]>6N0
MIHQA2_Y^'9?\MWG_N_O@XFK7U1O@!%5@ZF;#"/VEL.=69)"LY\(12V# ^P*?
M.4!A9ZK)2ZEDW;OY%2$GH&!2:><-H'350QKPQ#_4^>]-+0CQ\9/J!FQ%X WP
M\$O ;YWCMM/A) G\FG %#7@T=9E] VRVLHOD;VP8-"U.<#WF_[\DV/ZO(2?I
M@3< W]ZX1AM9Q/S%_*UW(5RBPRE-C9,3,W7*5QSJ#6"HEYY,&@@/./M>M8&U
M57XD>]2]S&4X]>ME@B5?;!Z/P.^;OZMN9@;M8G8V27N>DN.>SGD[G& :-!]Y
M=\;%,Z5EYN4S1*>$AHT5"O:!9[[X";-6FPB"[XC.?S]GQWHYGN$OIR\D?D,C
MB"S5Z3[/$2OZ9->A9#DD%!2ZSXEO@:?XH8)Z&0L/%PX+$9U:4=$1AU!T?[>7
MFAI^U>W&KM"N):YC".J^8IINZI!YFQ_KGK?R3-3Y_'V4YCQJG>8T*C(S0?:L
MED(^;HORT84<$QX/<!UW#RHY*"M'RNC[9B]=AC(#/WPU15.>]S1^ETRNFG5#
MUK*7'PF#6L' =BUSOC0S]!^$)7%P$"E0_LV5SYL9=14G\6!JWYK-Q5T-[I)8
MFB5.;6],Q"CSHJ#;Y@M76DQPP?U;,6EBXT=O(2YT8@.1IY"0%?%"?Z@,4_;\
M[3I)M_!++ORHME=,6\,&MX"(8P56;G5]LE1MG4)[J"]A:_JW-<V^(Z1<@PX>
M&ZLZ5_QOLM"DN/4Z';-^%X;<"9T[D\[>Q9=UQF9S(>NXK^9*SI&[A!(<9@92
MM:A$%!A$<+@SW(PIGK<?Y4;P/JQEJT<'(Z<>8TDJ(LB$,>1JH!<$OS-'=XG,
M]$B23<WI'9A<"X3[]AF(20UX1UF''(D)P (0!L%A14;6%+_#_Z"/"P -N!#5
M[5M8R,3%4IL2]F5Q<X7*6R61(,=&%O>*8W&DAC+*B -PBZC^RV'D?9?Z$X (
M0.\%  !D(=KCXW=9Z_Z<U4G_3C]W0JC-PO^!O3FJMO+#Z!8H&/%[K0QO5'Z-
M,5JM$!+#GT'FLN7(:-+G4+,04\(21GU.[S4DALQ!H!AHE%H%L.G%=\?=@LIE
M_%[.&\CWB2[D^:MU>>N":??%^/O/*IU*GHL]MRKQA9FWQ2>+."E5'9FKI13G
M]@)4"M,<V:X.3OC\S>T304E9>G\6&+;IZ4$'5E%G97K],UOFHWILO1F^$6S;
M:[:Y-6-=&3F93&SDW>XK6R86(6&Q*)AYU@H_P* (:C-,)MH'=.F,W_@GZUN^
M7%#[3U!G8GDOV!QU##MR5F;DRC<II"9IR\76EU+> -2^]36_@O,[#-/*;<?,
MU6+<Z:'YX.B;U'%ZX"Z 7DH/1W]('DNIT_P0JO69IG"T?!4OAJ.F7%X#__WP
MNPK<9[?4(SC^2;5S,E%39)+ @USOW$(KLL)TWQW[V0W_BSVAI[N;L]I0!X&!
MLW6!@<<!6,N%L!,4O ;5K13M8TOZHTG/.\*0- T4RW9&IO?WCI9(XL@5WL>!
M2P'*JR7H@#[V'K\OMU?#_KVO%YC^.RII'Q[E7;QQ$L,=O12M!;*)WW+4@C@(
M@9ZS'D4L=APT@"LO+S\P,' 7F145%743-<<3>3L6[NBTEPIQ.]PO_&P.)P[E
MX/XZ8@7ZHC-M6(FA*DVO!_L[PQSA#5HG;E2@_>AI0)N27^(U0N]\"D]9@V?B
M%6C\6<%6HJ;3!CY#W6Z7#,G_KSHJOM1/O8:+RNWJ42H7ZX%&/9"!XQF'R#@A
MT']W-/'= JH!8UG;ATB>>FMF-#E\R#5S3.10N[&+SS^THYDVF4V7CQNFD'68
MJ0!CAK.+AN3#L-B5HUJQ=I*P=G)-+Z]AT-.XPLO(R(10]\L%H^/'AU?_=NC_
MS88V,J:FH6@JWX;ES!'5<'5_4IJ#"E24>QG/F5! <I\HQNFPT#VQ/DI-0YO<
MHR(?Q )PI?M0+3=VCHONLK+..%NNA%W&!.*OCION$D(?;-['QHE(Z_O@/,AZ
M,=Y\L7=@)4<03';.O*;KC?0RW\Q!OCTKSXQ*SHK;;0G.NF)(8&"/7\\^/'^0
M'_<M\=T7QA%N) YKR%NI>S7ST4WJ%-?Q,U?X;@UB_CJ2)4'PKJR'6G982JDX
MEDW]VBY1%84ZF0/O6-5%62F)/?F(SRS6!/VGN/BR01IK#7]5P?PR'%AQ4*J!
M>$ 7LARAW(3P&^<- -1I1,0" EL:TSE4_H30#7"3EM)[$]CP S+02Q.5%&_P
M>W$'.')#2>51Q%R0Q^61>\5X[$/4J0J2;><1LKE%DV!RR1__R$<61(,0VF62
M96E_F%&)?E#%# , &  .QMG:0TU1<5;9A/U9-*:$SOV<C.LRL?ORT19FT68E
M%M_]+.4T#)AJPH*5PZH9Y4(UBQF_AC%^A8O$U)W'K(.+Q$(.C R"%9ND%C/*
MJ0;)*;]++0;\XQ=2.#FX__@% $#ZWQPS/CYY);3_??+[#O\R%A8)R YKA5JP
M0)AX\G]6NON*Y?9]^3'*Z"&9-2LB]<A?*2*OJB;.D8EK(5>XHCX^A\<]5: !
MI2K0P]"KCU(M1/8,!V?]D]VV;ZD#Z\ZH^_5B;WW] $<)S7M)CCT@ 5#WIQJ+
M1&3FGKK89[P/+LB9@[R9:-34E-0T92M\7N[QANNGTV.G#^Z7L,/SZ]D%U->R
M=1,_D^^3)KY/C\=B-Q8]U"-S/L.6-\2=UHV?$&C,_O!ELR5-*T?5K&([KJ[K
M1KQC6E-/!PT=2XJ3 GZ73)BMUII4!Z9(%G%W]'V,H?FZ(&<I@2LZ/\)2Y+7P
MS;1[6P*(0U0=6L+Z"_B^$!]A."H6$Y=P/.@WG/07!VIQ<8/- A,++ESC-? V
MVD?L(P)2446PV4G5-'^&8%A20U6V.U:1#F^K]G)GN5V[ FC11&9KQ(39R1EM
MDSIZKU=:JN5J_KC=P0:7B2,$B].*"/GK^CZ ,9U-)^F"Q_;'7'-NC)W/B T@
M72869)G&9MN^P3;E&9D3.UPE2@CY,*MOP;R@SU7EH-B>BMU/DY1\5E[<B"\_
ML#V=K5G@R$"JQR,)QXN32$DQ2N4=^)/F7R$F2-J)=ROU@MH].7""2ZX.1'QA
M)%/Y=K9O (?^K>KJ_]$_^=_NEKF?0F+(I&]"_""OSW"W%-VE#K6C(K5^)H9.
MSX5V!XL+I@Y;5_,@. " 7#K_  (W9?_2<2[H>U4*V1)Q?8&^.) [$0^96%AP
MQW5V=GVW.UCP,PU0Z/#ZBX4%.YNCIEKU"_2+2/RGM2BN6QX?GTHO9[BCSE9,
M!(:F[QQPR+K\_$72$7AWD9(>3D2NGR*?7UI?KO,5U_,"R#K? .PWN?**+SN6
MURL^MQM[ZS1;&W8']FM-@)<0L+WGP4N.;^1KR D<5*$'ZE"K^!B5$/OL<WMO
M=]S3)PC.O,HZ:VGL=<?<]&M#]^OPWR1U@@;!+AZMA7NZ<Y\&SG VK*!3/0ZR
MN7>Y3QYG/?E^I)'N@*>+WB>?J^&[VX,>Q[/G9@&E@(S\@Y9L$(Q3Z,#N+D$D
M?+K)/;=#<6WGX"?(ZP[N*<B_5ZA7V.?V =VO>R6 \?'9_?%J3IH]'2KOG>H]
M[IYU_<R=GP Q!"$=W  >L%[:[C!N_-IF[:>O[L\..E\I,*IO4N4]5C[9ST*;
M0.Y7T 7N_&X!#UBMJ.#UI:#/'28<W&O KLA!T8MT_^+ES6MC&=3>KN/!2WX
M<KT1H#0J /L) HB*>FUZ @X>D %.3QX/!ZO2,F<O![/'8Q>SW6L[=J]8Y/XI
MG#V3%J8M4&^IQ][(NS-HTNW9"=75.=FK@'_N=?SLG<>SZ>P5K AD1]8Q+AW
M-MOCUV7!O=$3D ,K\3O^P@%=17%!_;MGGC6S?\R>'@_*E:N1YF88/DW.F'28
MHQ-H**,ZP/1DB$1^PC"%CQ9<4"#\8\90A;J/5MKDJKPPE4J0@S"@.+MNVFDS
M^"2Z?>/XZ8-9:\&@2U.5#4-4$8TS7T=B)<@]_ALTW39*J5,HW/<6J@5O2Q(-
M/DM.X$FYF$@:^AQ1M9*KG"?.%V9_?F:V-""AK9[&%"WH_HVIVM:.*/C;+P!B
M5BS"[II4X\ 2_!:TO&0H)JI9:IQP?!Q$HE]CN/U/C^:S&PDY^Z7[2$DWK>*=
MK.E&R+HV3 QB9Y,V2%6X5H] SHA6I#:'GAX2,O)N<QB\ OY*&3_KPV40F0BP
M]/PAOHUCYL(2]"C]M^>3L=+"'O<AA85+TH8>1@IG&]<)^0$&W6>+<EP_+%1B
MB9SR1G[S8U#E-<8!0NT7#QMBBFAMZ*G%* 1F&"A+DP7Q%'EY[+ZL>%S=OP%*
MBSP2\A[%S1-<Q#%TV<XX0DHBV^TKTWLB=%/FP JJ9&;\O5Z?<C*)A.M.#6M\
MG$IR;^.>7[X_N4./%XUT! .RR&1EVHPSN^ ),-9J1A*V]J,?Z6W8"N)^>(63
MJU^/$$8^A*R^D$FLNLYX@6$M&RA/S\_=Q%KU,Y>I252HB"FOX18JR(WI(M-Z
M[42R'"SU\\F;VX"('UDS\BKL>^QI<V00!>[\^#= JL.CTIP-B"'+E1(W@;1Y
M?*1XQC,'\D?W5::/0P>1QH\70_0A?C*[5N!9;,_5A]!USF>M U+RY"_PZ,N]
M<&.=D5KXD8ES6>3XYRG9%>_F(XU[CV** 0U6408M!:R+.EA#,,5?@]^3PD_)
M(?QEY_(F :(0XW76Y"T%??%U#9TBMT@U:-&9M+AA37:,C@$_\__)\Z95#E?!
MXL6@NY)Y3YDITC\_[&/])9,]UO<-4'N; %FT6EQ1HMB75E5ER[1@%_W=?V#3
M8'KO5= =53")J]*A]*5_KK04-" ]3H[POU9G;HJG9+V[\=X[P(]%^]!+2I:0
M6FSWK("ICXH^^<@/JS&_4A9/(DN6+242/N!S.*-@LK_RWUVAZSF?Z6.<N]O[
MY]*]!]^;G[KT!LB(A1/I@;.?,FTO&!-^MF P >D5_QARSE[]<1!:F<CUVGD8
M.7R$KX<H* 74'NP=B&"P;0@Y8PR0C2L0")ULHWX!L696W8[%I+=.+BSH6 >W
MKKB"Y=W'DZ/K+=9F?5!5$A.CDS6%_M L> 93:PQ+SAWL/7OY$.AQ]<GV1,6<
M^1V>M_C*_BQ/U2O@_ R/S8K-J4?[U?XH,FKE>\"J44/IQXLAT^4>\',$ZL7J
M>0LG43_-[2VY8S-']#8".5+4!AR[5W63;OL-3 .)7H[//BMY-YW$K;Y&8$*6
MS[8R=N((4\$UOITB@AAG2B8:=Y1N#G[$=Z!W  <)+!C1TOVKMC\%4> N\NQ!
MNO;1RY]X*>VG!8]S@^).(])L8<ZPD&.?R/F31A<J74Y9I::_4RA:6;/H@,0X
M^<'E(Z0U_D>^S]YS2WZ'U>.&W *QH4J2%')BF\C?BKIHA:+V?)#]P=$,G89:
MGG1( K)75-:7Y^17U0??P$M^:V[6#GDOKRD(.,!(*3^_I E58NPW0@>\>;?Y
M%,OR"L>&J#6YNK/\6L$VK_*NG+!/L1[?5<^ D=(?N-__D,T>ZW!\#NW)R!@2
M81=BT#C,DF(=N[$E$CC^RQOM/5T84 "V^KNKI51<%$@:3%U:+')P&7%9?L*?
MM_'Q";)W3!&?3>#_!O" G.5-[YT_'))S4NQ+-0 GC?8I# <[]F.Z_@&NPK"Y
M@ U'94SI<^&H_R_L7$QE@93:RE4N8EN]AZ$-Y'^U>*IGK=;E"VG?K:[*KJ'A
MHYE-.<&DZ4X/1K/1X8F6<T4UX<,0>;$?$Y("QI??<P'L93[Q/Z2YKSH'()<O
M7%NG(N,Q:9%<X\*IRB;)Z)#S*[5'L)F**<-9$,7)<Q\9M9?YB1%SWHNNU9FW
MO+](P-KYU:M*=4*OE\]?<^-GO6U]NO@3\^[ Q4[+)@5L:2_2ZXBOR;E3N:]4
MQW]O&:R*KMQ73,=Z)MVO+N^/@:GR[?-5HTJ7?T0<;WE)!FNO\4<03,_4EXWT
M9MZ_0M,/V3;&>!Q@CR^CQ-8^=V?GT)V#C5D'5BN(Z<GXBEA(Q'+"0J/]3<,4
MT2NY=4:59?*NBGOW-PS&F-!HU_:QU5P_L>'P'QX;LW:%X#X_=]C>W>,S%\ZI
M<W42C>/")@P[8W>_[.)^C$5I1#D]2J%=#4^S6>>!P W/' MH0)E]'SH7KO(H
MCEJB$=9G\@$72;\3BIO#;;" A:]<97#+7X\;N*1Z]"4S&'@73HSY-9E\!['3
M(\XGP$*]@8_"2GCJXKXS:ZO!XWXG]'#'Y8/J"0^.]X)W,)-9FD$_HP_#D@GL
MG1YV"_9/=%HY4Q7N$<HJ#X-R8P$VBH;:**?5- OYFR/XY$_6AG"TU>ZXI$5>
M=S+-AJ+Z70K]O2H@9,8T1Q! [//GRWO6^2K'(:JYHWNFH7"YBAO9-:P8]BCR
M<I#LJ;)DYX#=!#C59LU_QO/YE!T:T41,*IE-3C.Q,*I"\E!?U.EJ1JBM;XJ8
MAP(:+$RB+[H,&E=2RO=,SIP?<_HZ*J=A6I TLAD7UIE=JE1% ;)WT/VM>KZ6
M4'3P2T3186(_\#+ &%:K4ALA+_^@N%9Z</-@(\X6D?$#G*4HP?IXDS>$JMW\
M&CB/%9-(4+6 ]$*'A7AO'9/>K=+#?I?/N?9Y=O;@8G;]07IL:D'PP"'\HF4C
MH7_-.2:#YCN-D:)Y8':D[6Y%=_0CJD7? X Q4/EJ6$C6V9CA!LE_H^:'QU76
MLX#= ZQG2I>#\(FSU??"72=A^HO.;)C>EV?^:2/Y-4EY,[V'<$R<!\8HM2-R
MA#4AB0T%D)C4R[8_>7Z^U6O[:E:!^6(-,2-!NC@K0L$.<9OT7]8, NR/644Q
M#^B%&+LWDY&%B2 1)L/OHNX,UM\=9* OKX4*,3N=9SV>+\(]59/@536.Z#0I
M+ :S,_J!=879TG2* AZ>JF_E"-5+WF+DH<\AR*0:&./^O.0K<=QY:T^0_#[3
MQ=G+&5<##'8N.?UD/H>C#X)1&D4F^:+6";-FL3?1(\/7J9YZORK05Q[HGPN/
M!IXOLUSG)E^S'6XNG]X #+!UM],>T%C2K%-"2</4@HD>OX+6A<2[^=9N>T-O
MZ,,N>5'[PQN 2")QDW?V_/'Q5=?C!GK^='?O3^[?6#1XL6"CXA8?;WFIRE^1
M^Z7G8Q-/>E:\*7V^<D( 2P'BP4'\?X7UN=O@ 'RXX<>BI'+9?S40*ZR!'-P4
M%&U,K1)LNW/$^1$36V;LTO@5<L3L6%O*O@N"+VJW]KE]ZGAY V24;G4^VOV:
MH&!A-HR)EV *QK$S&N8-X+RF'[HY6<6JU^&\[A-BA*<IV5PWEBY7$@EZ P"L
M;I[? +.7<[9&%$9&$6.S ?UV;P"C6 4<MB8YLV0^FR,FH4B-'-V>_Q:(-OXB
M>F3$-15$<+GR$P9.=A@5KAW'V@TJ29D0088]GMV!8&"K5R/2Q;]MSOSVP),%
M'93,DII9C6>C/WH\-["8^86-*8:HY&,X]@,&YW?P0S]L#1MOH&-C!V1WL&K9
M?VK'0*;;N1_H_9ZYW4 SM@>#2VN&6T6"B/[5*A3AGPE5?X0D\9 F_%,1$?V+
M5\_7=]U 87^_[K.$Z^N'8Q/#B(P\AH'I-H?#(G%ZKL(&/[B*]1K91M!, ,U(
M1.J+2W(N))DB3;@[\(0XCIOUP"JNU$%$*6&C9X-X]%JPLTC0A]9Y(XUA#3J?
M-_("5]]E:CX<R&6WZ^9:>BC_8^@8;O?5 _X5<_8?^B@\+L_ UZ]^J<:,69*Q
MDEDY+8J/53G94F6](PC,KL*A>W0: A'"LB"YXSEZU]F_(B8/?H;[9%Q"M]<;
M.Q?/PCV*AXE-++VC*B'E^ATW,K>G,H7#;X!^F/)-)*X7/[F5=+EPW29_2*O'
MTY%'0JC7/\4C(B0UV/UT"X,^0#(V'JWXY%VRY0M*Z*TNA\UQ.<R>N?]X(YLB
M)W9&WOU%7WU^BB\\/CYRS7.0C>OP>NW.ZR'?<,_1'#5434]G;M]7_'#B"+0(
MA,0R>_AV2&+29!@Z#7Q\V5/&$^PQ<:8DMK;X-.-/GO1/MQK-7DSK1F4H(0]&
MZ]B,IHL=SZ^-OB#6!T$U9NTUJWV#R%-?&&>U7[\Y,WFM(B/)_#N<X1L)BV/'
MH]QL:SO_#!?OXX/TAK#W>ECQ'KV*IE1RFR =K=D26/R#*!7)3TS[6>T#G8UD
ME:W%G*3(C'1_0!=I1'>AVC\WTO$X</OB[_TUXN<^O7/2:='E&V!N!]HN^;U*
M!*-9>H&':M1<[Z&87.U*YIUAW2GI);&U$.R%&P;=.SX\.%](7CKFSC573+="
MF.$OY;#R)[%T8.4D!84>'>UZ(U,:2F_\T[I^7^Y:KL[ ^5,.'3MW[L]-.RVS
M'*&=%?;'7@+GNT[:G/9% =-ZG<>>T29:[()[2&5"L@,8>T\X\? *\E<>4(?4
M5T._[I=/U1)CI:%F@RS@/;E?U#=C;48_N7@JS-I9D><SDH;Q1.0J%'&OX-M>
MI&7> (%?'A__B[7L I>F0FK'K"YS#Z:TOTN,#0]];79+?U$/Z:M'7GP#B%HK
ME42CYIQ"1N$.]>:+3(I_]_R>'O8Y+!GLR?%Z\/<#0X^G9O4TK*4TH_,L7OM3
M^WZC1Y'#9^;_ ENRR3<BL:YD3U%&11T:,H5TP[\N'S[7;Z+S6YOZ0Z<VKEZ$
MSVYF:&(]?LP9F/[Z(9@:7Q$AR]X?]W&/WC1SI'2.9J3] Z6B]"I ^C]Z]AY7
M6ER[$?"]+A8"C=7N+KAAI'<G_A:G1/G\"*\%2(J,-M->MX*4K5L7\W=BW'L_
M2M2YE)1V7^T!#P^%C3P@Q[-Z,[B=!=M@HSCSE!?2$Z_=CUQ\UU*C?F;QY+PZ
M27Z?$R0"I)9!>LY*3]]3%H3&^:T$U_\Y;Y%\AXQ^/\OZ O,Y&GK=CC%1V--,
M S+X#2!FFSE$A#?I(749Z*UU(TM8[FC\G"LDMNKSY>SB#+S%^>#]FOW<#%8M
M-I>)@4=!I5=!)64.T#BF>@U?R^R\TN$3Z[D+A92+*,) 9.YPQY?\2/41"@+_
M(-:2<'AGQ;@@,EXQPN>\\?G1_8.PABOA/_D20/5KE0BTXE5 :>IE&:5\A=0:
MY!W1>ECVCVWN7O/T? 5>7CJ;*JV+]F1UTO(6G3.V[AM_CGPI% Y?VTAM^(@E
MN;+N-8#FH+X;W7;X!LC:=P6<PY5D$PQQ0Y]\N]\ .E>7L*87TIG+Z&:9^U2.
M@"13!Z8]*)1@FB1_09HA:S34HQ#K<O82W83Q '!#4AITPF_M!^NB#V!7@BPJ
M6N/Y[P%6))GC(!?!IUJB)QF/WBJO4;2S?)I??U%AJDWPIKY(K'8)(AG_JSWW
M_L12KXUW?G848[,:/![&$_&_8%/3%#YO@+O--X"_L-]+H(3:AL/4HU)&:4;^
M[1S^M,!4_^SQP<%ASY"):6X#7RT92"=OGJZXJ-#<U&"HP;_R:"*MB(8'YYUC
MI,)$G&6PUC3+CU .>77!1-I#U6B&G*-S!;?C36?WHXH]L_)1WTY5./NJ92O-
M(&9 >ZYE@T42%3=RA8SXMWT^^D^&W&\ \O,A=M;OJ/YK[>Y'GM0M!]O.._$5
M?)QTRC:75U]/FIEV1&<-2AW%:N,C,[0<YVK@AQWA5T$((!^?9Z0 _U5W=-Z/
MSH(=2I"QJZBS>W^1\*X NVWW=6X8U@9XR%\-IP?2'03  AS<PB[.IFB>$C9V
MZB[*Y@8F9SFQ]C8"$M)G*4)]A7R&'J-MERO)9ZO8;+CY=!B6Z6U)Y+JT;V(X
M_HP7DC-I_I45K...T$6I9%=U!FO,1B%,BT%N4<M^!-*A#[+@2U-IVZGKZA;4
M<XE:K&ETI5.:;:'60%"79I%3M-^-:@,Y,%5JJ7[LU!!O/4>9-"S8SS6T Y-M
M_(?'NJ.!Y\,JT/H427K3XT4U9,U;_C\?9(9(1L8%.JOQ[S_8.>W5>!W%?=.F
M7O-PR&[PH]NC/E1/D@R@YNH ?Y(994O,4J4UFY$?TE'#HX[JRY73M%^3$F[?
MMEMRU5+-[%7B[()ET&\C!BFQQ+HD#J3WDU^ E$Q9?PP9?[[C?"!(OOC"-'',
MG1A#P,>8P)(6),G%!U.&D]"64W%F0BD>K3../U'?=5TV>\]ECH<\\@G(+C@T
MN?+@\./!W]O\1J: N414.9<-$Y&DC*;/.KNHEWA-IWD+81HKHH2\1@U^7S\I
M5E8TR9G@,ZXS*0K(CD- WL$Z3[SXLH5+?DG=-DU \-"ZC1Q5STR+15M".NG7
MY[F1&K^_X2XHSA47D"FGVYT\I/@7"/CJR6FCN\G/][6[F[^K<\HJ@9T/!O7;
M:?)X[CCKZ9^BN:2F?^FO<Q8A?>EJ?34AWRI9-]CI60RH><T^XKF.3&CWF1IU
M7Z<)$'HE;R2Q$?1WR!,5%85OO;L[@_5B7-[-^7[96(,UW6;FR\#VH),6IELB
M8]J 4YIA]]=@>.BJ )+@&X#M#6"GE.&0$6#T[V2,W\;/7B3$RON6=L+6_7A@
M/Y'R^FBFG- ! NXPB+\GYBU@)U>PM 7J>YO/GK 8H "".#!<KWMD/CWOV&W[
M??=*,'PL%]A_ W3%4-T!7B\4X#:1\A:C-YVF8(^!& $;AE/+;X"7(TC N2'L
M[D_C?Y]#RQ;[>RS/7A(NE/*?5Q'N,L\HMEGT;R.A4U[_V.,"JMG3FY*T,JET
M\%^.<:?3[2N9J='=/]EIT;X^%W #HWC=+7T#Y'3=W-D,O8Z(/(E,!=SMN+P!
M>EM9_S]"]H8=L&(EHYW9-KEUO@V3A%4;CZQHK'G,/:;NZ2IZG<IYVM3P>5NV
MEHZ;+15BEAM*088^3$Z[BFF:(P;F?IRC>OT.X>VT>U[\T'[JW,TZSSHR7W5T
MXK3!" 8]VGS^)K[_\5O7*$:'E/L*_:=;\,GOH57SOM>)KHX=3YOE=*UXI^63
M=]/9$Z97>,#A+74II*CCP8ZT$_6ZL5\,S1:K[[23=XL&KUP^RWB?NB1Q$$FB
MJ6*& 2==D/^[4Y4W)>SOQ2T&8&%A 0!P6+#:8J+H@=AA48#,^.@W$,C$+#+:
M/1(K,BLK*S(R*FMQNRR*,8@PBS'SOZ>LK!5J:H'Q\=O(^"O^$L5.L9;T%>YJ
MCCQE73GRG>^-&E1[FX<$#W\'C-39RG<JT8J._WKW[\]'QY 43!QO>=0S$BB[
MWD!%I+G;%:%E)7B&E;6#BV)*:IS2)(F0F]!*UN'QMK3S3;OZ#[JLYE4,TW%%
MEP9C-9$&KI^'31S;)1(451:B$3Z/-W7&,C_W8WT!1H[ORFL8E4$*B6(:*ML$
MD/%IR.-_Z9MXL^[ZF=JMP^[8DA[J;_Y>C4KOFIH4$_L3M4C+"+0E\;"A+S )
MJWY,68YTYC![E;F-;");D,4CHV/P<H;4N6^1I94.+D)T0;(TS(83[6;B7[-J
M53MU7:I"*!43774,U7@0R:DRG ZE5=H^?'NP$C?R;WL#3 SA*;>-8/>^:SVO
M"-+30NC V5;ZN51C]Q>HB?C"5_6:FS9WY/H?A&:9GI(8[T>16P2*VDQ,-9/C
MP\U0FGSHJ!@YV79CM[>VMJFA@FF9:?Z;FRDR?Q?L<VLHC:FI54DE"'FSOQQA
M +5[S)CFE5&P@,4(9I)C.*CBN&CU]F-FS',5)<L-\U3RW_KI\0SG6WR:#[68
MN76:QEG%Q;%6>&A,]0>U:A*#[6+8%%SA2>>#>*GV212:!!;B]O1HI1,RHUTP
M&_ZP#6K?V7#HJ )_F/W>CEW0@"\;?,#D9*0/E[Q"7&TTP)M*]< 4D0+4F?C@
MBCDT??YDJC.T?KE$;0IUBMO1R1Q=LLDBHMR-2J0R.<C]:NO\A39](BSX$Z4D
MJBWPT^A\'6(>D68RG]$]/?NN;-+[T!IY.5;=FR &R)?]JPEFQ2)=7=Q85@-H
M20K[,I<'VKJQ3OJ Z]K,"?*T*AOO(E7C;8:45RGFJJ[#;U!5JD[J;FX<);YS
M6I@VFA3(^V:K7,^:B_6SJZABZ6?FEF!B_:J1TD\FB0.R_5H1]D ^<A-D2ME%
MP4F>.T6ZYE]FVHDF@Z$<; T+WE]FE6__+;BM-CS?XL&)0OFY6J8/??^$GF&S
MQA5_IWPNDUUJ7!04%T_,(^X744W3#YB* 9X^[=S?DHKOO*1\7LV,][;MI!<5
M&29GY2WR9GWM62J]D$10;&*1A;8$(K8R)Q:P^_'V=;S68/!)YM8O>6A[+6=X
MIW4CC%VY;]%1JSZC0TU(?%!?E^4S89, Y4U-08[-9Y56^<!0"_I/2WY2E1(K
M4GAE,QQH]AH5?8M[>OV[A)[@S],MZGC-2OP:4&U(O"&?)8BTU2 H16>TA",.
M_2<R[J;J5:MPL[<O5W2UZM$EUTSZAYIRL^(EHKKM%+PD(C0QW-"!U#NBW*?C
M9?]IHDX(EH_ESO@BIN-$#?JXT8B:^2EQAQT/S"23T-=9C*TEC(J-OMBF$>$#
M<J!C^"P-)_>!8881_O]U3_8_6?'_UY#RRUK J%Q$[PO678 CQMGO)T>A'@/A
M .B#GU0=^Z3@[1G)7>35BL<_.N??#3OX8'2ZX!N=E%XZI,Z!.:/;GH)2GK$@
M<[\2TBBD/+$Y5#,)E&ZH0-$K<6K XIT);-N[N!<5"F?FBX.H#5P-[J\.&@QO
M(,1Y;VE,MB?*+6B6+'_!SU/\E:I.;7]9A@<YX[J89-B,IYO:;ZTLTF;*5&0<
MV*R+;_<XZV"4JZ$?S.8V[)0WP=-H81U,J4G,&0TNBH2F- *W7 5^XQ]\9)M4
M3HX7=Q8_7;&OHF_111MH#LT=X'/"8AZ0%<Z!.93R4A*E,*JG,#>G,'6A5A /
M<-Z\ ]JDU:5&*RA*6[MYQ4^S4S:U=XZ5Z#+%]*E]I,5*)L!YAJ-I7H5/-[O@
M#!YT6V[+*G>(*(7E-)4!1]Q1;JUW05:1LVZ-_?B#&CH Y55?%$Q@P1#F#O.U
M9#XN1]V@DLYLM52C[-%-I5LD9;H[?E:IN88'>CD;EBNKJ4:\KEA3TZ!H16)Y
MD^QNGQ4NUC$-:YRE1:[.WW+N8O$>$KE:?1 PZBLM/D]_JL+YDOJBP4[(6HH.
MMB]DC^T\ UNC_C<>1U.M^0&N!Y%EW?)XE0J' V;#GF%A5G\<-I<:[41BEPM"
M.H-)Q>D:HC-:6BH07:Q]M;J6&K<$6*/GM*)]XT7$E]7\B4;%\0VPV),F!=?\
M;?I,0QZMT,(VSMQ2 ^G72LTT)G[[C@G'THIZ8J4A[X81=^P 6P/6M*V&_H=I
M;AU;[9JJ 1P2/#UFPK1>3G_C6U+C/D&EW$G#QMA8;*<V-O3A\T)6PV&CF.9"
MIN$+'@GB6 GFY?.Q>'7*AGGO$UY.:RI'-*L5;EB24=Q6JOD("J%.12JK2=V0
M1=^I4*B/Y9PQ- LE<VAN.6TU%S-.9T>6NS%4^;A#!['06Y'MZY_"0<)Y3@J3
M0114F<D\PV,5?6+[]?X3-$WC5=$2"V*N.% XAH))K^.XZUA0UJW10(M*_J_X
M*;<+,"\#K])'Q5>Q9F:--T#XPF!= UY:R##_4H)L%IVNH9A"#!I3;/6L""YZ
MF3Z9-<L1#DZ"<63BNAVV0^'*DFWRQ&*1MC:3B63Q$8W)A]A&HE"=JHTGSB^2
ME1%]R2_^NDRJ@C=4U<@RVHRQ&NH2Z,UFF6:'4"3J 9FV2[?]'A7[#0L.214J
M8%N"=2G<_A2M#LD9)%8)9Y=UPG7WLF5NG7AL:T/J5I@JC>&#P\<=A='.GZ.'
M+\\Q)G((V6=U]/*.^W\*P+@E:C^ZM+[K%ETNL^(/-_]MDV8GXWR/-;>7]\^T
M<CF%,Y0*, R)U8^Z1?9.8%.GVSBA4UD/!JG0*<AE:)@MJB@Z+=<KVH0@5K47
M-W\R$5\.6E3#'AA@@<XQQOM++)\1"$]AM^GT-A')UQ O"&DV<O^=DQ(.UR'(
MU3Y6_[U4KSMZ&'(Q:GVI.>V$L3Q<.4N4)1X6_T-B'98\03S9$&Q=Y:T"O(H6
MUBOQ>A^?.?95HL-0;%@@/"E.T#*Q O,GMG"S&!4^0VI.99N$/5N%MMNR>:F%
M0F18U$>:+X2:#?7JSH(LY45(B)Q;P^]Y4*+8=<*V?ERW9C [M]=^(OTU='V\
MSDS?.%Z,O[":QS_&TE@I>\WZ"Q^'"8MD/BY[C';S>R#ZVDN//W_$#MAX%\"[
M<TK6[775X[&X>'BU^.?[E%UA0(>_=N[=NL_0VO.K2_=:H3;L[@!,*?B/ZPSY
M7GV?G: ;:@<"#T.OC5C_G&_&#MCRJ>GR.O/Z:EW@$=9S*.QSNS&F@W50&@\2
MY=L4>A6"!+WF($W]???@  WX9^TW5%I69X%8G>,>]UXPK)Z]=1\8UC$0X\!6
M@B</V-3RJ7I\X?@J T6W$I\3_ZZ6QB8VU<XJ/)$CV8%0>E1 C*;DSV&)F38O
M,)W?'"BGAC+VUU.+/D?8N43LJ&Z/TDZ,K0Z5U$"W1N82I=Y4 (?ZJPM9.+VI
MU\JG _*%>]4[$L?W-N'U=\ Y5C.B&-J54;ZR@K+R]&+7K0DYEB:S#/WT;O4\
M&%WL96P26F5PA9=1WY19EB*$,AQCPKG,0DJSM*QN+(-8@5^XV3SVU\R\X^7*
M%(H92O*X9)<)!RKHEXQC2.1\"K]SD5._Z7=(CES.I =@M%E/MQFB\KLM"_L'
MK ::7BUI@ZK@MAKS(9M=/(=C#GM.T=--03S"L2O,1WC8AW>SFQ:RUT!XTOQK
MQ' ;(2 BTT-YKI8BNF:TVN[/T"C+AR-MQQ,PG)*8"\U';OIIV,$ 6TS63ST9
M*$8,L#-%ST*K5I$R7C>KH7<$M*V=62[[%/\E.W/PBZR *[S*#[/0WVQX.<:,
MF.KY;;*A%0S<!-VNT74S"@\VFNG&J!PW?,PD7/#/DM\C,!5U;;555#LLL@WD
M5@P7ZUAV5(_P-IQB*F\I>28Z7%?28K!22^-K!IOB".A/W]=BHL'5(YO M"K-
MTNS;F)3!LQU,[;M%Q,NG(EX"AFD)%7(0BPJ]UN/F)&LWXVW%W&ALS51<,3I*
M-"<+0)_Z*+^UNLZ(-Y<^:DG?:D7P(<HY0Z+)G,IGB$ICLHQ=9TL:L$XSIPL<
M[NE9;DWZ,\MYM",T Z$Q<CSGET9$"H*&ZJ!UB^)WRZ^GXO0_2;UZEV(T]N2A
M18Z;F<*/2O1W+075C@N[+FZ2WBMV1D*:.JU?>6U#M-OV*BZ_MB+0X&JTT9Q\
MS %U7:7(ZW;:M]O P=$AM&8%_[8SCF2L*+MI&D4$Q8S4FQ2V-WYN59O6[ ]*
M5B;C&AD1'1X_3>1M.')&W$X\6'3SUTD/J924=2XRX3E [E$TH?'B]91[*/0*
M_Q)^6R&16K\G5\)[="/:MKI_V BNV)=+=Q*1="().R$JX9<R3'KF_N*RX(+9
M#(G\B58KZLSA0<(244V "ODRXD3]'.V HD;J3Q#%,?"JZKS7R3[0R=6?Q>)2
M8,PBF280N;!P&=+.4C;Z'(L?%OG'05;KYU$$?E;2\*;5+QIJTOG&^\YUQ>)S
M8=-]G7A*.#AJS/,&!?H"F[[UZ(,!"43N,5?=)-@<W, R>IA+?N"X2!SM-+]'
MN]!^UM<T2,/<@7K)7\GH48,= ZY\)T=$N;W*X;LZM&%6BK8?XIJY255.'^HB
MM]RWTQ$_D@[:TY$S8G(UNO51J$(^K&A%$#9P2XTB&Y9&+2QH$>*)%PI=85LX
MZ3!2)L9:&<^'>KJ W#[NV.G$>[&I][UORG%;6.:R&7?8_H7EZ_#>U,2#%_:B
M]5F!9_3OWLAF:&2=B< :4^QML6,<J>3BNXOCC@&'&L\^J5[,!KO5P1!9$"**
MAILF=5U)@_?7X.J^%J<]%D9-&<]LYHRAP$7;*@L4E5B=V7W]P2=NQ4I!Y)^V
M2VW^/:%EQ]] OTL3+00H2Q&HFC(%F;]'I5^%Y6;RKS:QL9Y$A6@0%2>KGC2,
MU5^O?IG"ZLI;W5C9FAYO;HVJ,(-MOS,1UF^0#^N[WQKF  ^+5W1Z&VE$QGEK
M)-$DT\<T#T>V7J,4-;Q7XY\E8%SH,21B ),>X4<H]I:W038MZT>"A?-7N#,,
MTDS0[C2.@I?U1J(,)([H)Z(3D/4J/64X<4*J1IH#BP?4&'Q[76JZ2)+9N-^Y
MVWU5I98%6*VUQ&=W6R\?2\HU:L5-NRZ;! 56@!VS-"55@P)+WI5EC3K"XZ(!
MA'J1$A<L$!JY<IQ_# <.N:_*6( *W-<%Y.7=L^+$,]%U5PM"]$0)&^-N*8'!
M[^)N<R,MZ'DB\QZ7%OBG_O>O\!B#S!B[)PEM=B%+EDTC,5]8/U&V^MDDQDG2
MD8@U<;T!\+L0-X@D4X X^$FU&>C!.=[$92( ^$LC2\_.L.>[]]VY4DO_I0UH
MMT;A)L1!\H'CXW:DE1PW)YRU&ST-%"3G&:@^3"^%3CD2N;^B>O*VBK7Z-5HL
M/@X+\SK$'%\?]P:)$1C.N]FJ A&F[\\(;@^;&8^=M>AE3C.<\>Y]( L)[,@S
M[B$\A/,Z:9.F=.]SP13:_\!O-BA)#=5<8DGSDHK (Y?B]T1T-BIC K.JS[DH
M+E%:.W/\H:HV9>;C)AZCFPD"\Q#G;U3T E'5B PK*@N,G>XI#4;L[0&B/!ZB
MT9E[C#9?="2=5!?^B<9\ WN%GRM06XV:8X<Z/QT'7H6MB#;>LAP; I*TB^)?
M+Q1?]GPC,.SJRZIU+8)7KK*FAYVXD8>CV6A-]49*A-S:"FU;O<?[\A6(ENG6
MQ=:(@+%QHAWUCJ/+B@1MUOC, ]N?EY[+2RNM,E*DJ;S7]?#^M Z3((]IM&V5
M6:R9$[&1M\&G*PBFA0;+U3@Y^2=@S9=(OP'PHJ?%N*DTTG3F/:51@GZY&ZE(
MC;X!S,V X;<[ZMEXO F8*(-F.G(L>JY++(-UST61X\O<<180/>_V8;/;QA=E
M>Q9,E4LN'<*[@)CBW6)3&Q<E/7V+D]%^;7.J%1 SJFEP!1=D\KMQ(0M'2AQA
M'8O?.&'J;Q,FH=_NB=+MT>\&&N)TRQGV1K24:_YH_W(>Q.U>E^03[L2')Y,;
MK,31.![A.LS6JE(OT; E8)6:E&'5B W1L_*G2I,;8G5WFF?_Q6:'6?]M42;;
M>T>I@@7;-03?LLM1RT'%<NV3?70FM19;"BC4<;,<$$FKD09?AA(8B8F&N.MY
MH$GZE;MI#KL8!RV]C<U+=[A$E+:$6D[4 NF'"5_+AOUCJ3YQ^U^D%M)SN:#)
MP,-^7<K/0[T.@HG]P;P?#](_V1W8W317>Z\5*G"I@B5E6[Z.;<HG:-?*&)"8
MH)79D*5GX;N^%M+ ?:N84LN9E&Q2YDM*KF#E#FT%VG_S;S*F>P_\E RR_KVF
M42/Q.1MQ@K$C9.)\-WWO0^5WCE6UP[46L??S*N';^W&5C&KQ/PU)Y-75%4J9
M29SF!CL1X][/#IMRBJ?6?,S"VQ'4/3$US1I!IM8X'*%4U,$ QU2KX[%[:W=K
M@L\O-KZ2"(F/#]XB2[YP6(7\Y1E<,]R4J7*1(LGA_K99/PHK'_>-/G72*T>3
M9Y!]5PT%NYJ#3@L'B$M= $;?!?"A];2RO_JUGV.P:"QC@:LTZ5OC8ZJ5HL6"
MIRMM2I1E'E*&&I15Q/J4Y@&?'Y??[WISW4F&.]E8QP2,I0KP2.-7T87W(>_1
MA8Z93@F@J!'2/B&JR.MN5G'TV4N;9]?V[!/;2Q6N,Q*A3"C&RO#ZM*B/82_%
MPS3RW#(./0Y,\>!";R=?*TV"XJHTS6R<]O)=0PXUZ.4Y 2A%'JC*Y0;#;6Y_
M_E9IVCDZ3HI]UF33+NP?WD'<HU^CQ_-6^<XBJ($7Q#7A5LF6LX)]U*1:8R^I
MYMP>2D)I'+^],BV3#M3MRJ,F)SB7UCT?7_^[8]2O8E;\4[%N3(QTC+@>/6S5
MT^84-JIV]6&WRMI'P(:,7E>HOA'?CE"_F@K/KET&RNZQ*%60I>]DFEX()9Y6
MJU0W/OV3_/&7S,LU5$R3KXB^H6RK<.NX3HNUW(6<BS:>V>3=%(K1;YWA/^#/
M8UJV>XVV TYT%=QX*MK'A!I,Q5#69HOEZ_ YO#/L=4ORKVPV@;B*K?T3FPU+
MG6K3[U*92C$6ALR=W)QM.-S%!$5O._#DK1#UOK9@8,#VE78(Y7(L)""N7QNT
M^=OB8. 2(@B]_EQ=3SDC*=H6\\55*S'SN2UK6CL'J%Z?HK6CD[U6'4,T2T-)
M-6TU%6\\3W,;8JUUV6K;MD-7T$/X>'TQ7[OHUO/AO%"Q:99;5?SO>LP48U.
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MV; -,]MW%&S*WA*4D9V876G$ QN6(<PY=C+_M.+=K?QL+2RT].Y>?^!T9<@
M)GSQ7.1K<?,4NLOU7+M<]O@Y*4.$F#<6.KM73L*DW\HBD&U ,: GQ,R*^-BR
M]8)A>K>4F2,[&X>55B6CHAH9-L7#8G'C*OH#=[8_M1VYG&.CWOQ\O]F";==.
M+.F,=/7<Y-,WYC;;S&)W-42QE0K=SEN!*X,A_*? $ K<Y12N#B)<N- D,5:C
M@"DW9\=%;&X/+L$S\L[4AKDRXQSG>VN@;SHX<[T,7YLRK-S[SRFG_SKB[%\
M>;OIUQSR2AM86ZOX5#VG!?/Q]IH:&!QNBZ4.GA>/-D4,154';M=\G0Y>.8O/
MFJGR5&G3,BI:T1F*&#WY[&!#>NV!D<^O[=@:VM@=A@HMGU3\[MVV[D._99IH
M_W4II;Q>$O#O=N$*.,=6TU/M,LB78,%_*8I44-OH>CERW9SA:Q8WM-#4(8BQ
M0PP[W0?"C1N/8ZX6@&9-Z61F6T=;:0F0+2,_81FD>$]2TS2@8:?35V6G='JC
M93;[UOX#Y)C)W%!KMM6E\3BM=J&9J/.;NLJ&I1_E':49Q(3OI;,D,D+_ 8:S
M@GO=QKE]^[X8)TAQ55F.Z=->*D\U3Z^"646WAT;36(M6*0T@9*-<B>EXUE*>
M7U;;[<I&"RM+].UV[?9[_"A \?76Y%O?3, +\,SC2XUZ6S9['\>Z*O4.Y#^-
M8C2JHT9,:D[E.E$1-E04XT\/(2P-?[90/;_EMH>[<BPW>[9.K,6=6'+8=ACN
M5;!X([8>>.P"B7YS[J^3]^MNP<E=XF45]!8V_HYD:6GF)LRBIA]C^C2-=$BM
M&5$6BTB@!:9LB\SJ\;;)&6]FT5>EQ\V,KX2&$L]E;DKKZY)RF>C@9TY.V?$5
MX[KOHML)+@W+*[9)Q];N*D@3ZO71G;H2 XV(WX%,5-_QD-C;_6)U1["C^#20
M>OTBNXICKA.SP\Z]2C>NEAG;]JP042;[RCI0G*A_:[IJY&+GZO5#\#3]2;QQ
M;:/H9--QL^^T$K%]OQ$HR,@R(.&9,WF/RL\81#/03 B=&*A O'#H4;\6^X!S
M,]MM,94]CZSH]593FKTX<2BEN;%$VR/]T"+"Y6@#NK^'*2#K_: VUI%IX4UE
M"G.F-LR;EK-!C;*H@-0+_6]'*MWI2_.4]!WF%O%)_.-- &/Y^/UYV6!6WK%8
M[6,PX>%-[+(XJUO-L2#J3& =S'JQ)G?W1ZY]*E(DR_\/U4$\Y9KJTG6:7(@!
M;RY4D8YFR6913VNN@$MS.JZ>VN,S-C]8RB-\)*YKDY<H(,MU%<GR]\N:D)<6
M 5.$"3'8,VJ94&LTA; :'E-[A36X<GN>WJ]-V2#NN6\LF"S8C(5Q44G ^(?U
M],)FTYC)=9?OX?E*VVP@-I;1:5%ZD,I?(!TE1UV#W5S#&G-=^4JTK47W;\0.
M&V<8U72S?KPD&EOR+M7L%=H48+5*F +9+R5&>=4%PM\T19AIB+39EH0FV#^[
M_4<VC-&D:4\8MG6,7?56A7YT2&69(M8 ;:K3WT*9R"S$T4_L8P?'@X//.JSR
ME2F,_@&(C@0"OT>2DG58U5ZM<;.F>FGSL7TV!79!)/I]CY#;-/MY3<+Z59QG
M7&^?:M3RM.C%IA^D>E5CL_+;.^,;8:QI;:U(9OG@2DRGJ=?/&N;<1+E*O<:)
MW#7S7!-JJ36.)M!1;3!9;76HYTTSP*OT&VQ=U$MG?;+[-18QN3<J&=+/_ X1
M"7(?#2%EJ>[OX[K@K%[?:.0J[I2IV@;>4!@(9_*@FJDBY%-S<XTDAZS=--<?
MXLHGRUFI^/?Y-9H"@UPZD_:91",I<K+;A]E\RJ&5C/3J2I;OZ=DHY8MTN=U9
MKK98FE;5+;8&%\@UV*=D2'O.[,B)UWB8_$=35'+#6<CI^+^):+#H)28KUV.Q
MV!133CUOY=9 KWJCBR(]#&39??ZX!U;WY;I&/WW=T!GRNMK6$1'*/>]5LH&$
M-F@Q,JT5',HIN1_,L_[TJSV9249RI@5@B.:?(B8X*R0<Y@<D"7]P]@F_0=P,
M-[>Y8%H2C@28>L\+B\;'6?K)9U5N!FC<T 9!CD([])!^L]7H:8:)G$*2]4H[
MM$'@3*BCC>_H\0XI69GJI="+8J"SNX#8_GQI\A[*>1JUQ<!P;.1N0O%\<T?T
MTN.[H2TY_Z;>CS$;$(H:25@^C(FM 5K6N$A09,"J;2B(M\UVHR)M 9H*<K&5
M022TW)&]4U0\X^P$O,9(B_@XRV'X=.V,J%?3O@W!1U439D<TP2.YA&W2/)7*
ME%H$W^_L#="P44N;$\[X_VIPJ;OJ.G6Q:M1O.H4P<3B++J'5.L=2[U9:C*7-
M[ML[(B(D"3Q=3KAYD L\D^\MN+D?'.^:=-_?WR6KL_:+72;?)@::=M[>WS_)
M+8LSGIL^)BT/EJMM+I!U_1(\7I=/>@OZ^G9[?06[ $V4AT @]\NAKY?<%(2)
M#\D1;WSW]SG0&<GH@Z[;B:[K']%4US\0%L1)'Q_0Q-7K[P@O!H?MA.5>1R^$
M_2[%%^9%WIHTR*6;/L+?0_\!8'?O7QV?WN4;RCMRBED?+@]OGOQV^)*S[^XH
M23U%_'Z)2Z!O]R(BN H>'S^?U%G9AY2%0A?<!(M97T<70AZ@RU>K:CNW5:Q\
MRRFDK>Z]^DP]5<C._(8R>@J[B6??J?-BD7 I8Q"CZ3A\L1@?L-""V& (V9@G
MD!(P)TVWE*BM?,OL@BOI15[?W]\.S+'?2Q-C'Z3'X"N)<UA_W+3+2'@,8N[O
M^U(RYEP(J[CA<'+C;-H'( SO8O1M-8RU-(CFS!#QDV&%3&<9*IL"5I!0%$))
MJ_>?QSE'Q72__]Z\IEF@W>CYJZ3T),R?P51ZC;MJ4GLG6J-_N!\,5]YUEL6*
MQZ5D)#6HN.:\.<A;<37*\1M[ ^43,\]4LS*",A906L3OO'R!Y!P2SVP6V]/[
MIA@:KC12-Z,79240G(_$X:Z0&I-7E8<J0SQL$-Y-3."Q$&E&G15 PV0W9QS9
M-FL$%!3:2#VLL.6X93!D'LMPS)Q&+2AXX=WB1J P%0UMUXT&&3HG$FFL\[M_
MVYEIS_4LR8#,PU!&4+<KY,74)/D02]1DS0GS^=<'.]IS5!KGH[G*ODG%9<WY
MYEKCH]3VU(S7MH*8)TX1/F\$ :%,+0^;E6OY,):H$TO#.WOWEJH.GZN;)Q*G
M=K0+65Y-YD=;N,*4&A=?^ZXZQK&5AR>5[ LGI]2X)A<%C::X_CIC(NXV\JXR
MU:PQL&(B64;4G.] J!F;,O] ,J:W56]23I4BTKN1B.0]D8WJ=I%2QFUPV]WB
M@.G@-2JF!M];/<^L5C]##DT'LDP[LU^;NLZ\)V$]*#5Z36N-*!!++*?(\R#"
M293V/TO1T90;]<ECD$QK!\9G6[=&I=%Y2=D0?2#7^91!$%AE;27?<QV?KP-R
M,V<[H#*GRQ@\EAJ?4N?"HD<<<'"PZ)U6'.N V;2F1!>'RKF])KE2<%\);\=E
M"YUZUD^KJ[#>2DW-O2&*;SC7%>%6K2M3XI8 F#+R57$2H:>96)7D)F#]-IDG
M=^K1\XBH_<'NI,4,D0"UL4.G&N#\0) Q9A<$$6*R&%>!=!\<!I$.8!6>7.9]
M"Y'2-EY++[/G1BM;#)@<GV<Z8=73BL"[M];5J&=QWLHZS:]3SJ%TGP5=\=<X
M.@H32:<<G]Y?DL5*BF=7PODVDW0E!D99Q%+$2K7Z#JX#;G1G5/-\>;Q*:"9'
MF<EUDC1.UG3'(-"EHY$I;'2G:@'5:+Y WVE7::RV\9BMWB82KX*RXF!WI*&A
M*]WBQGW%)EVIE>IHQUN<(JL[H7/P,JD&-N7T&2[QPD767]O2?](_1]?S;VB&
MZ_;<H3!W]-)3!4( ?&<:'5,62J'09KD<=;PBHV,O'7*_V+Y6=:+5D?Q4OVMD
M#6,-@N:T3=8P$.*9]E75=C^"$5%AB<&"JSMA F,C\QN*Q%7'[;,!V)1-%X6Q
MA7EJ>8#W;+JCA7S>-W-&3$@IT%!TF=^Y?CW/W_CL$T\>V4,B:0ACVVM,JPN9
MB:G:F+9U1<W-!^Z*HA]^>M*QG\108?E&L$Z\E6E;(*/W+:@4[-%-@UDVU]&7
M>K-<4#G4B,K5>(AK%<?2H2NOT*41KHGT9P6LLCD#H]6)K@LO7(7&L1>\NO67
M9X/Q<T33A7D@2*$.KKW[,XP:4?!V2*O_I@FKHFSG_88I1P@5XUZ5>PKR5"4D
MAAW!\GZ<;HQK336<QATX=)0<?>')- ??M!;JM"W=:-_+=G!8Y<:'Z.W:#"%!
MV9]5U6%)Y4EPU(O.+-LZ1^DO:*&Q+S0T..RA*2/LB<$'EM2O>3 ?\0U]^L%A
MT#<@3L2<E4]*5!!Y]D'\AP0.RQC=C_(ZZ62C8T35J\G#<W 3X_OA5.F5EW)N
M)CHQ..7L;Q>>^P+Z_I-=@U3-6B;A[X;]IC;&7;V9<4$$]]+JL2S:%X'_*3Z1
M_N\( B!88!S6&T$/#^M._J^OR;_DX^L*TLE6GSQ+IR5O>4QMJFB]X_6=.Q6G
MQ&.>8@K1<12E\*SNJCWOJN'1TW,&QCDPQD,J.;^-FJ!2CL"P',)]LN'0/&A.
M;991D7G(37I]R(7<?7E@!NM--%]NAB37FQX5X>M4;V4VK8KOA?*PKLEQ4PG'
MS!]P[E '[].S=KA>(_580^_HA<HO.G;MF_OG9CEC<Q8V_K3[=2A!H_#;QW>U
M[7F=XW3IL=F9YY>BOHC8N>@[:?B6?&XDS#2O7^M"QW(&1"J/'7MF9\"W=DH:
M1,!%RF;>>M;54_9<U1]NE3H"&)BNBH]M(^A+_RH7T%L;8WL;E,5*G]N82Q"W
M)$DYPC%VZ)I)47+Z649- DM2\_\!\ (;E,?2RL=S'EG6/'D7R&06#O9+J&+@
MG02R9HTM)\=;J4\A+,+2BMN?V.!>:PCSN05Q*XI:5>N"93;1X_+R_/- UM=$
M8)VZ.K+8\4//8R<IPHCED?TKP63L.^*I#D=H$>689HB3]4,&\UP6)9@X;*FU
MO+V*4RY)K2]56-PZ.JY89'9]>GG?9!=M?2(>W&9).^[^H;0:%/6CA@47ALMH
M/J%*\JE:TKH6371-I?(H(3;U D4#7-&@9\&X\-%*/T!4;P.6+2JFT'(8.[$F
ML&<&WU,>9?CPE7^OF\:+-[CI=%$[4CA-QH2.+C<<,G*+&)4=A0=Q>G.0RB;_
M6#"24A_]3I%9\I-VQ.7)E[?32*8FYY<UX:.ETV[387MKXMYRVOOFI^WS(VZ&
M#*5])0#V5&-,_YI@Y&I4O;+"W_6=D'8WYO$WN3G]^G7&>LX.Q?&K3B6T#[$!
M[&<&,ML@0NV#"\SK.3)VC^K>V$!8;G//YU[?M"J7#VPU7J]J])+G$Z9X?VT/
M&<C4,>M59(\TIMO$81$O!D'*-0M;PO#6] =]-\E0#C@+BFS:ONSO"HK)$V2(
MJR]EW-,?O6<M##CYS;RB&CYI58&6PIE&]F.'*WNIA_!5>+W<UV'G!+WC=.W_
M)4?[VBNK(^_4FVN(ARMKT_&:FZFHDV2SJBAS/9?R6Y,7D=*341I &,WX+<X"
M%E=" L'$C"XWB6QA5F5TG("%DU-8144S>'1TPC^GZ)KSL+$BB!!@WT%ABV(1
M^^U5Z9<&!V<8[*?]!(.4E P5S R5(=31T=%9%9!013[C.+;@PHB?ZRK!ACK5
MHE6ETX-<)\TRUD3R[@X+>[T?XH93\.U6LL0D"D=4IDWW3R\:;>+5]FH8#!S;
M)(VO(0%_X6OSW\C"2*[T'5L2VXTGNF:=3?&A;L!U3SI! .V-NO+P3CW.O,:>
MBX1$",U#"V/9JVR0%C)EK8N9/:&N"Y5R>*7UR'KID12J6NPMT5".88VEC206
MU:0JO@%HS*6TN"NN0[BB>XI@UM9H/+(Q@C:$O*0S7BII$%D\,K4![_;M..P6
M-]Z&QD2BF3GAN^DP9X[;<7LQ"+BM#ARXG@U)&$N %LE[3G$F$*D:Z)N.>9I]
MK.Z-J\;/D:>;3$^G&K.4L(4[?H FI*X-1O<=&3_5,O$3#W@Z&^(6RGC\+M[A
MR*#EC;( AH6M-W7OO8;UN,[F=MAWDY!;S_I"Q>Q0 ^<C#L,[M7&5/G:T@@*U
M.+MHQX0CX!H_&_U!;'/Z_4FUEQC$]7VN+0^TS2=)H? SAHSVO):K8!S+C(A*
M@G"C6I43<)9OX#+ED]5LM629@IYLF&B"$M:KB<=?E1P"<V@I!D ^J5=N0\;'
M465!_A$GU0M'B2_GI-+-\H=TFL+1%ZLU:[9Y9\_QMAV8Z#J%@<%M5+^Z:;"I
MI*?,:^)HYLO%TA=F]U%!I?L2620_$^2L9=7)MF8R9YT7*'=]K9FPJ=F=7._3
MLH8$K&*LR_X;GQ6H4(^7'G=*2C(PIZYUF!EZ>P%G,FG4UKN_6*WKI^\!P6O<
M=F=+=T+E^41O\BA=F$)/J[71897GLQ=\G6P::%6A:6(Z/2]94<A799U=:EWI
MSZS5MWD<YS%6C V!VIPP>5N<>QM'<C!IN1R?-W&DMVHNU6G*1MPRR?F<\&PK
M-'$SN"!N_^EVK(IU7-]'VC>D;DC;WR)7A\T0P"&JS;\DJ>Y6L%)#R_A;AUC;
M%>$"H6=CU;.; [I3Z<,/D!NM3<BCVC3G BW;)C?H)$2X?V[ *CWV*R3"V63L
MHDX1L+4*1X%9*!"!VKX3 O<#WOV[+L]Q \-MRG1[[+^VYP67-+S',\*UB"!L
M0:'2I+,:/R.=_UA#\L>03,9P JO6\ [5>N][UXB_S1;I1>O0=:-L*'-;8*M-
M[DQ"QW=\\FW)U%%L\3EUK'K=;6, <5>K5/#+A,?[JW:5M)P=J,@XRD3)U;SK
M5W)" W@!Q"OT$8JP,48%A>,;C5FN9D)9@<"0)K#AHONIL%##,H><Z8_4 &L6
M)JP<6_:EEFQ]-/<7?J/A7,Q3U!&C4H^N++$$.1=-G0O+*>OR#3RG+8D&/7]/
M+*F;&[QPNIBJJ"90A*X)4R-L;GN(?8:=WOH6W[T^7,AE"QA8G5>/NVX?:>L7
M1@X6.&0A"%S=!"->TY8AMXBT.Q%S3HWKYY4VY,MHY-VO5_#.R_#2?"Y5Y 6&
MF_J;6SL*J_3/>XFYR@U9I4V4)1%.SJI80E#T]A8SOQM0%TH0 8%;D^RPEA,>
M..Z+['-46DXW2@%P+,[CDWCA(>=A]#9FK;2&4_;N?7)G+(<,[$Q?IPX]<XX1
M3$PZAA=X4ZH]/'PK,@PRIB17:U=.B6.NNC99T?M%[.B/T'P28O#?[*3Q"W0W
M__Y14J%?<K(V@^@PK]&O";+A)\=.)=[QAV*3!&N=$*3FF-VT@4[Z0^6HAQR-
MN&&-*D"W7%IK4X=N["L#O\ZL>(WCN/F#:.[,K'$=-.F%E_B]4/?2Y4 IC3QG
M8RKUGQ$BRS*_]WGH2>*JTD;!-Z(VU4!M6JGF[%&4ZH51VCU7K2-GY+I$UXBA
M+#0(>ATN#-OU =EOQM_MS$:F0YK:>[Y+6/?X-$[Q-=?FU54K5^#327PWC1TB
M,0J(;=1\R(>;F]M##8BQN!*C3\EU1B4 E+;Y3ON."0>GU*^=M&?SQ:-"&<=M
M; UK9:3EI/5SZN"#:)C?C+VMAG+M0&T2;,<7!^BGX*$QYKNG@ "E=9NU,\XU
M8[M9VQM#8'T4\?*^*PV%4BEX_\U.*8PQT7;_A"ZQ(!1/$*L<S8;$Z'R$L6>J
M3U)9@X6TAVE\?YQN3:W-H#-P^=PD8KFK9Q'\PK,L\8H1*JYQD/(>]#7Z'@9C
M69.S3T7F/SX950'UN9V1C(Y?'Y.,3HS3"SO6WBI#1T/TKM-:3,;E)XF0W].<
M4U?:73KI_<?PG+QC#%%PV\B46C&4Q^]>H#&3-<(RK:,[T+UZ7R0<LMZ [AHY
M4*J+J54.JFV"NSK3MKOAI(T@KI_;NJICC>X:_EB1D B9E]-9#2Z.^>,\/]VL
M(^F%M6*G(U2 2$^(34[HZRV:$4V:B#-72C:2G,+'HH@<1YUJ_%\Z?UY_0?#L
M3KEMYW:6U,7166CO\)%)JD=(*IE(6DYRJ_5%#82(,\>/  G54,!O/1ZT/CP)
M79K0/]"2(UNYW=QL0-R7/&?I9D@J8FW74AC#IZ.5P,2'X_M5-:8OK/_W]\Y/
MLC><A(;=II\DWN>5/8>Z8"9>K?)(NSJR4/99%VTK("_%>+;"BBZE(4Y/1]JG
M"&;:VHV&HYS4_GJ^#M4QN<V6>P&1>/,F5QPAFS5#+H6%H[7NJHA]&^+24XD%
MN@/#R0-2SF2R?F>>264S_YO)\CNHT+ZC[-",3"KM"ANREKY<XB<%09UBT]^N
M]*D[>?NR4_ZR85&)^=H$GK1M%1O*-!VR'6 2YU8^+]57P<^<&866;@:)VILL
MR@FVJK7'TO4U;7@XYH1FM-&DI>G5S$TL_@%C)#RCZUZL=BJ#6@$@D7%GE[F,
M>T\E*<I5XE?\1$TG.UT[K)^:+0[M)M6T='*^5L'-L=F+DB'T K(Y^^V(>ZZ_
M<NGLBJ0^E*ELL^QK;*,S0L[XM%3()7E];O35",<*1_##BAVGZG4=UAQ-?H-M
M?EBB@^7:X>C$+OR1P0V9?/@FOULC=.H:T@AK/989$C7;K6:VE8G]77: @NC8
M-:ENJ8X7=IF)5)SE=.;D:A5HKH-K3!O #?)XW:F?:Z3:8D JYWF8< 3L'"C3
MRI&=%!:L.*R\LH)T52+/"#/W13<+1.<O&<@A"FNYV2^J&32FL;#)&)>-EX7X
M9_>JT#FG=7#5-D*4QI2Y,Z#\B@="#=,9E,BZW;).U([W=%[#+QROD2%4QB)R
MMMG -]WC5IGY@SBIQK7&N)-N?P&Y@"SJF/$65R0ZDQKSNQU];AXY':'J +^<
MG)E8NWW-A-X%3H*[L'!F93L%FEN!9'PN5/@L7ILM-;4CI7Z1"G20-^MM;8'2
M^.#*SAF'WA0W/'W+TVQP;-24YZ&+%=@O(JI3<J]O1(+M%>*GH,D$!EF[M-*)
M]R1L6"G-LN]FC-.(6L>FU/YMA30CNCH>@%:WCLN%.&I+#/78X6I0W$,I5M['
MS=D[@_B\%E;YGBDHM#D3LS)EO\2L+Q?JG&!G(_D?.?$W[:/PW%X'/SS::6D*
MYG\NXT6];JG+X_ @(FQ5PM((=-$FA@!O/8HP[953_6"Q!3*^ A@!RR:Z1C=T
M^V<HDWK:<J/TQJ;] E.&B&/#@0Y 21.A.H/97&XJ+SS7YZX\E:-KR\@)3<\P
M I,:6@A2U$;+,:=M'_/#NXW<,IES]Q&+J.>R*6&%TY)76];/9GQ]PK6:.#HN
MH.(>YYU*%]3VE*?VE)U0:7I: RKFT-J5I^/6$)P?SQ;FY%*+KN<R&/C.$,,(
MC2W(QNM,O-0M93<&]]07,80DI([K$K%\0A=":2)<-Y4XIJ3NJ\K.R<0]U9ZD
M5I(T])C8-PXK/5LJ2M<X[8H:HU-CZEK-8/(UZM@*:U&E"V8KJ?5!\#ZWS'6-
MD=V\WEY&-EW?9%ZGQH89YY_V^F(XQ8?O+A -9^U3;(N$&^/PQS%\3EJFM'5D
M?IUHW8Q'6)&UF7*<B2\+=5RU#JZ7YY>RG3S:[^+L1KFF>QA=9SNV=:=;;LJK
M.%"3P$L[2(R5?EO8UV,(4F+9?N/#9CACY?I#WQ(RVTDDC2%WT1)(=H 7"9;%
M/X&X$VV&Z&AUVO_(D VMD9/GB4Y,CDU6P+3$'ROWH@7(2.(G&%=NM$C0;$GR
M:%$!Y+NN)\\8^CO,SMB8^ V<R9>+N9W5#(:+<XE4%G8;?)2JR_3:F8>0Z[5Z
MG" F :QX:\P:<A]?F["2>XTW5\'$/,L:'?[#<[=C3(5,VR^W2:GVH!KHC'!R
M>BF3 'C:^T#XLW=@24H-P1_Q2J'0L2X%/ &9W>IO*OGV%Y^/!'[!3*6,V5C$
MJ>/XNM;VW3P% ?,6P,SM36.QZDHS07K-AGW+.*N/5KRU2_IN%"D3'7QF4FWZ
M#!$98O\-%+:NC=Q<1;5;D:2R$>N*GI-Y*@JE/I0<UOZH%UX+<).=SX(L[<1@
MF912A8KDL%CRZ>]'JK^]^PPF-,H:/^=ZGEK)Z@]_7%!A5U7_ 6&O\FA0:VI*
M:G%C<JX"QUXZ<T"Y1U4\IW,R>E4HF='1D?DJE>O&+2J.ZC%?\3X];!RU"L32
MT(V3U[^ \7Z 7+G4ZE[1.X$X;(VB0DU8>D[5LIQD3.DN+;AC0>2-^W6W=@NS
MMVR*K:I0M7/;4^V<6\>?]QZR5I-8\;Z>7?\ ()V$M-EFFU0=Q!/4KX9$):HT
MFSOKN+=J#;-?GE']-OKK&IPB YPCL#>HKE+T:#D/E!J%X;\GK,4M)IEK1L0I
M<DHRV,G63?;DJY1V+;7:#6NEP&.P-O0UPT/#G38 ^=U#M_83\BKZ?%.H356-
MRWR\G>?.N6[/$**UY*3+  (* O)9%@T0#!'Q6/?Q,3 -WR%KY'-O!L@+.QW,
MPOQ^-G%.&LYXF\5*MV3J)U"G2!B_KL,94Q$XYPRWG!JE3YR!D]2HU\B1EJWK
MJ)-3MS)"P%L._)IJ8'.,EY_1:/ MZ 0MALB-$V5^1K82*IS-32C2SY%*29XQ
M25CLF%PH;F,0E=A%&#(&^=WP!UI2#2LA!S<ZJIT';LMPT$-W20.4(VZ:KIOS
M,'T[E6O+:MN[ :L6==_?HS$R6_0@Y#/_HB::(K2R8RB3Y21T8%[!YQ*I8?QA
M]4O$! J24%Z5;=<-?#*J<.HR>:6L4\1I1F6 '<FT]Q@5G(R"&HTZ#PUYD)M&
M_DI5,5-OX"LY'=^'*-7NB(BVZ(Y00YQD)C53C"WB\^:\U >157DB9Y(M;DOG
M:$$"M5+D4S$M<$IR!1&]?E5RBR@.%289,=E*O#W-C;_F^,6EB1*ES)-<I:BF
MAJXVN^PB98;F@C--?+U@\H?6IV:YVFL;2@28[T%P)':]?Q7,F&2#T$?1SWZ/
MP^5,#)]V4A4FW.?C *]Y_IH,'S43=6I:*ZWZ\=-NC=R@Q.N\\-(M5$8FTQG7
MF-;YRX-NXKVU]F0&;(T"Q..N SS*44WD=G>^3UN)S;_L[_?Q;;SA<*<?.MZD
MWWABF(P:L+>B--U+%8:\<9)PL;@6,26,1M'B>EZ-T+6#XW_IL54;@+N<,B_&
M!&KPQ>;* N(K'#H&:3_YL4*S#,[.VB(-4;]ZWEG3IYCF&N(@H[,>-+;_R9>U
M<L;+S^EI;(KP/L&2##NMUV(A(2CL\, I_.O6D-R:Y3/A2G%PU'6H$.Q(%;]?
M&H\>V</V:^]GO?585NZQJZW)6!:UG9 <Z,)*#>;L":)[+RH!+!2H[LX/.\GG
MO32>V&Q6^U%]VL1YWZ@;YZ(##%P%1DG6^0\8W:^K.N,6:U;CY-]Z#!"WNW_3
M62F(K1RN"+<Q36W(.[0P7GE?/D/&]XGKHZ?\%;E_3U3W/>8? )ELD#<QIE[!
MK%7D'ENH;PE>FF)*Q7K-)Y_ZJJDC[E MU-+H+T]X<V=FE2349EV2MU%]2!\?
MUWIW06).L95FT:BZMYU$;9%DW",RL?H!-S/!>WUO^HTE95 WO8_O0QW#3!.4
M"]-O@CZ6I5FO9LJ)M^094\OT#0:<F=#(F" CDCVV>U![ET\2E%%[+5%%70W>
MNR LT:DS"B&OL'/6$^&V:#IT*EB MV/94ED3_Z".@!6FLP?(K!SK3OM4OZ@<
MO+X0'@!TZOCX,T^A7& S'S)>&'X:VC"Z5H/R5(W3BI:;^6L^8Y;<WF_MPQ";
MKV/6L3/'UP62A9UZ%79K4C>=H'W.<_2"TK#YVE_,=62^K/JJWI",9JG@.R__
M#]KOV![BUT V')JP,>U6VYEFVZZADLS)E2]&(%/<;<?2'P/]L#4_^\PE$\9R
M3M.3J""&*[;TK5C&#A=3V*HCP[*MBC5%;'EPU$RU%S+S>S)+C/2Y&=B80DK$
MO;;#C_GX W']/Y4"#@MQ&>$4]#7ZCY32 -BVEZ3)/(^Y:[R:>RG(C[2E!BZ9
ML9\.&RR[EYKX!(8\UTB_DAA)<']2$8QE"CF3J_N?GL3V]C_ M%*TVQO\/\!!
M*L;EV%^*II/[M\&.9L9=UX_F-G6'XNP#DM.(OK'UU;?I+/X,I?R:PRWJPX!L
M3,[IJ;J]P4]QTWW"7@*:.C*P,X(9.)@20C*\2VKFC'G7FH(H\74<&KP0R["2
M\ ]&O"'/";Z/A\7=@7\ LH!\$XIAB"?JC.G>%F]=R?3L#?N$#FB$YP*)IL4Y
M:[:!YC%XXN^+WX68SEC.HLX2=09S6(3KD>;F9]%0X)CJUAZ,8#93AC$BEJ-.
MG):X1A_9AO)25S6 .&;&EB8@(;)K6U'FPK)PV:3\#/PT>%A^I"CYQL*T947O
MT]0E'X4:G1_==#OC='B=.[%:I-RYBMSO8J>[.=<^RC8S>"08A)0Q 0K4)K#V
M(2'+_>-#PZM%AXA'7#1(:*../+M?9I">8@P@%NR>99#\_O5[2DPLXB>:JLUG
MM="J30*A(GI791'I@*.M4=2-HZ/=QAE,4?.#36K!CIB8Y*MD%"6KMJL'?.=Q
M 0_,XM;3NX&9*!($"I03!7].Q]PQPZ0$(I4?,K.7V3F#)).9>^:+S.J?%(CP
MGDTEY!HP%$F1LD3(8*"$!/@2<93K.K#(E&FAYF1T:!*V+<XIF;_9/E=OKDZN
M.TRO?S@&1 S),_&I'*:3*'KAOUX*%P^+L#L!(XLH1M9-RW7K'8R3JZTM<2U#
MT=###:7Q]'"K)2@XP)6D*2+A3<O$&M9:3@6R4H.?RQT40IBV>&2"@[IL;6,H
MWU>4_O SY?2Z6\*IM0#@A<J9YA$X@_(SIP;KT09!S9;.RMT[(V=,W*)X+8A5
M!01S(F'&/T9GY8M:P,-]O,K#F4!\^A*M$+!W7#OR%'-6_<T8&&_*B4BY>(;,
M[W,LEX7"M!VUY9!IF+-QK"/FJGW2] ;G;?%D(6\YK4E.8'9*JGL<Z^3>;86@
MX=*AI#BO-N$VW'&B0[O-1=>61+NDVW1&0A@VR>QPVF=9RJ:T',!1#@558<?J
MFYV@08]B995!Z_*W4^.N'Z ST"&F,#\IBD;/S'<YHQT)>EROHD,ZKLX?R184
MKKNP-Y]$@A\N+K<$#@9%P4X?UV1'(H]/$^6C;N3&"U\8[W<[&P3(AR;.?MR0
MO3X<GY--=$6+#U0%7-SLWE_<BP46;1]?Y>Z&+K9==B[\SYSDM3WEEY)H%^
M.K@0*DB^>X=!,U]V=@9B\&>\W/%+NNZL KWZ/0>J;;<7_0-\@ET8I-G]>OQP
M\/61(C1@6;,M0$4%=-CFNV,E]GYD/S.8M0F[+ETD^/9#[!?,0N<SAAM(/>-Q
MT_>_J^B[YF@R+RKR,X,%LQ/%C>,,NB3!(_\ <_%4R3 ;<_P'33%F+$4'MPN#
M7;<+(F_.&T'B_P#]_G]W[\Q>_P'.\8."Q56#Y1^2+LZ_Q 7] ^S_$O[R(1MW
M0R&>737B9FJ,\4E-?-&>T>,?H.IY)^3]'R#: %(<^@]0V?/Q/U$P]H_?X'^
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M_ OP*PLJ88IXK(4K,#V*"VJ#Z7.6T<E:@"(V^,<;@A_]K"R?$,?]DQ,4GF7
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M<^0WO0&0D0T@"2L^-8?W?I;Y"JD8M/2>[9.U9H2YV@_R"_AZ=FQ@'3EA@M-
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M)0ZZA"(HR4E;7<P7[#OEIE,N[U.4Y>P+&U&;CZ5>5!]_O98U;16"K3?@\!J
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M,*J3=+$E)\]2KQ8PV)8:)5QFR)*KR-<JR>"3"O)('/':F%C(=*]_5BQ>VMN
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M\7=_/$KD/A<N^H38ZOFW.N9[7U1;WD5 RT.?$#;'GQ GP;&\EZ]G,,-OE=%
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M6,\@30EU0^MH3/7Y1O6]BUQJFXA'?#1GB%'"E*DOPAR^/5<HQA),-#*^7C3
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M$V0?P1,UVPK3_<KQICZ9<E*G=Y=IW)%Y1+]+2^2)H9\G\S&8$PRM@Q ?F0M
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M16S$+=OIJ>L?D]6-IL8EIQ(, Z5?7[X@IQQ@_ , ]_[AJ&_\+Z#:\<43_VG
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MFZ.I'B6T,2TT>4TD'T7ZE@8+;AU<KD\57\-B[K 1M8@3\,-_VATE%TS/94[
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M>-^]JCO\\NP"OG.^K  7>#XU>BWX[N5<[3<0Z2\@A7!64BSBR^/3R7J@Q%]
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MBX\D0Z2!9K6$_U6NF'#'6R8!)2B*OY=ESDEA8$=7'=%+C<I3LE0A?(Q&^(#
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M\I\:\9K ZTK0-D^""?^.;T*?S;3/WXV ;JGQ-#'!VW'3#P=\O_SA@[:W'C]
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MEC(>N[:X_.51PX]_I\!&P"*)CR/XA9PFT!YEN .I#0X(0W=<OPLYUZJ19IP
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M*E;@%.G/'C3*O@;E8A7+?"T3<=R6P [A"44UT/7\G][\OFOH2?CV\^ITK^0
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MF6_G661G]E=!NM8,M&X0KG;Y2C"D;30KWUD_S#_\QSN>HE#'KZDQL;K;!%]
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MEE8(9M3R\B9$A-&K-L?,X;HN+W@%>-5"?O8;]$8PYLK.3PJ(.\)+89E;&,B
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MG)6W:F2R\=YE?H#4)?7LN!L 9T['Z8C1A(Y.Y^8R[@5<S @U6?QZ8X*0XR:
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M>?6&]FS%RI;BWECF2/TO]4T1R<0!J# !KQNG%SM3]"UY8-1A Q ?(-(8#S
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M!82A87-5G89E,FY:4"MB*\XF'@::J:%L@"P(*'164E65,N =BY'$=@K*C7)
M:.P,D)9AGVJ4TWQ>:@R*.C_N8GC6:9%#P@%YM:H(P:!I+#8[@1BI#S7&7'CS
M./;B4B5%?;HU$6.ZJK7\+MH.N"[52@@5&9G,2&Y/6TD'H(F\;)!P.9("8@J-
M5QTSU75T$P\59S&0%(FO F=.\&$[:4?]H%EV1#XV"'?:L+HH2!+%L$#:17]0
M4+8-()BR*D%HNP2RZE#NR+V56E5)F-^P@+Y4<@LYK3$$$\0K>U$$N3 6!^M=
MFO&T')9*%=NM-JI$;"MX&BDIPAH!W#<'J4NXEC5,Y!;FH&5IQGGLAIKQO*<H
M35=1Y XU!\"N-U7*OJ1%FLT#'X<C70KG$XHJ.(,,9!PJ?$LHS,I*'L@I(#%B
M7F<RT51:$XEV-]2L1K=:^1Q;>HR?.4G?XHN\.BNZWHRV&W9*9&(AKC -$WUZ
MI0E&42(ZZ*@T[V.=U3@>@L 30+X5%<J,4X-XXX=COSZ;X,ZB:(<5)$+F<9.)
M,;YBDI -*"6;57@"7ZHM=6ZE=6]LY"&68,TR,:'<%M-"6M2 ZBA1B;;9Z2;:
MZ'R'$!B].W0UT")80^ &A)?H0JI4G84@:VODM>S-TISQTF6\:H]F/LC(OL)7
M!MT2*8[+_9DKD:TF+N[E*134-!>V:%MP967%5D]L*VBL5.R27Z4C B5;JSXT
M(6)TJH/UV!\K?9_TTD)?5$I4U>F.*8K1Y/%L"HA];P,XES,)-U%%$ZL#+>+\
M_LH<Z:M:/"9AVFQ[0V?1A)5%CU<H+Z17[7A2BWI+CM-G:"NH":UZ*PH<9%Y>
M,6X+VBR]( .+O2550=I4BP0U1W!E9-@$A<L< $AQ8]#5J_M*X:AIP_'423(%
M#6#?3\'27!=1K7 8 ZDM@P\UT(H5U,)30T70)1E1@ZD4->H8C89AK"M3#ECC
M9F(@XHD!UKH=9Z%J1PRLX J4K+8,6A&9E1=<;+FKA%  X&LE:2_+.FP:J;ZC
MDG*1!9G*(J-RN:+J".,2UG#:=.,FQ E3LKSB5CC&3I)<+*?3#0'/L/8T:I<,
MJ-KDZ(4!53QYA<_CJ5NCQSF2X%X[ E[FQ-V,@[UHUJ.9ZB25RM,5G2%Q;%<1
M-5U1UI)L%ILQ=&OXDD,">IGD9%DLDT7$QJ69/%?<15DU>W(Q1BL4G2@ZRHHV
M-VU)71X'B'VLDBO*([/F'&$F%:D(>\6<WC*(U1KYDAG,VA-I6&G-:L)<,9WD
MP(^8!D%7M)(^&.M9$T3PUK0R5^1@X"9+;^&&2[IO:S(_V1B,"*LVKRV%,=Z8
MS$C0,;L>3RLV%W@8$J(#0NCE&#6U>FJ5X5 &2MB\WNOS>87 [1HYFY'C00M,
M>-81](UC&P66H@:&%I;=G1L];])=LB-6 (27H&R0RH9>M3YS68YOB''3LT%Z
M]V896H+=TFP.W+%B89[KJ0&T:O?WYA1.\'3.*A$2/DW(CCX&*=.6.P9%TN.0
MJ*,@;3EQ!$W*!*_E-;0$,(;2Z601'U:[( )P:<$&*H_:$Y55]J*O(&[W&7<V
M'WLCE3(BT+Y9E=6 IQ[X,2$!9JQW.V <X;8H@(70Z[86B :[KLJ!$A;>@'9J
M&$^S=LUG%&^H*!7)S,>LZ3A>%:D-:TZ-K.5*?R2V>[S56,W+6A<8ZF MA0>_
M(S%&Q05&$G&7&9>#J;AEL&0+!("%-0_GQMUN; V;G23K-P$^#05O$60%0-3-
M".#6I<4O826MD&+)7@,]$(<*'$Y-L\"4BI'2%M[<3$J,^C5:2H0:/VB+=2E$
M84XH%_@D;9<I)ZK52K-@O7>7E]"HHB^&S>$T[TF9'J,M.&T+@9>3A5YI5GBF
M)&^V^Y;+WJ3EM.I9[H$Q2I0X@"EF!KI4\V>T,R(H IZI,;;$G+FI.-6)E>GR
M *XT5L60D EN-J"'.9X;FD]V-N114Y.B7AEW6".CC>Z\64?"^L3KH7#1LB"R
M[T7]&E4"*()N,E[!9YC1+.N9'5I"V@W&5A2A>:M/MFG6SC8YI;LR!@NXRMD1
M3O3@D65G?9(#; ]1ROUA5< SOK:"]-36 +SM"K)3"MKNK#)K*V2AY/U)#0Y#
M,%%T'%3<; /GZITQ60J+@AA25-E:K)-X@UOUVZEES3 ^RI2F,$_Z,-50%E.8
M;B)=,BU'YBHC1FJS0:9=N9LQDF?W9'QSQ$:T+6ZEN>+8GL/JU!S ;:XO"/U*
M FA4X#NL9-3U$C/MZ(,6P.ZU*ESO5T>M-M574DMK#W.>D76R&/;P=+3A*;-.
M:R&H"L?/$H%QHR9B=/0B70+/IX:VV&0&I;PS81LE#B+5"#AUNP<"!4LORPVY
MG8.0-.GID,E/VDI5W^R*< K>0I-F'JV,A3"UT:'2IY;6$$+)$0JZ/^QJ\#Q:
MMC <!&K8WX)Q$>/#U=98D5%1\ JM3:)D#TF3V88%#,5QOP$0ZI)MS;*6;P<>
MU$:5M+?LU?A05?HDJQ6&$/D3L2XWRGX:PU6VJ892F9ASC*I- 2R X\8:6#J#
MO1M!]5)B = XMGB;Y@*BF @82*9S$AYIX_9*+4I&&POYN)V$,*_;#&\H.$+B
ME>:H56-K<3!9])I^4ZF$Y>4F!1@>UVR[2$2(J-.)88GL.PF\[!4==V%8# D<
M',,#6Q6[O1*;4E))H!BX+RL2U.@6J)!Q!:Q/4PD55\AF#%N2V45\+:M3S6#6
M;H^!^RMJQ>.C$E8,K 99C9("$I;!)'$(U!+4K!-$P#O]/%/"KMVHII H9'*$
MCQKA!A]6VPW3F-@BZ80S0(KD)0UIHUXV=O#4L1<5NC'%HH5FDEF5'>#5>&"1
M>6B60Q A9+T^1,GE?%;JT)GFB.--"DAL#4!:48#"CH4K8UUK-P67Q-H@/P^8
MEJ66*I#:&/=H (J'8R_*%P,P#@6']E6QW9CI7#A%C#Z<5%=2ONER-ZA+4(M@
MJF&/P6'=,)IID4)>1UTDHCPR"H3L8!G4=@EU$L['2=+ PD+Q-)2A]&FWU)H'
MRQ9H.V_VLMHFZ_&=46RK%*^R^E@SEJW L!=2K^*.A@VF+S1$!3-I0ERJ,->4
MFPRDV5C+"C0U*E2G8Y:R^M"FFR$(Q1*$;,Y3=$"X\)*"&YV93S7&NH]B,$6)
MZ6@TM]IRW$ZS'.K*/)12MN%X/3*;"B"E,EUKQ+EFN0FQL&DH97LL0>+F"*FO
M8V:<UQVE*\$CGC*J;N:T$1JMTZ[7=4A^&)B(,EGE7EWJF2C/2AK>GO$3;\*-
MQTB#IVJB8GHSP55GV&8/EM5\V;+%E>JO5P]&9'FAV6%=:7*I,65Y-N<:NLQW
M6NX4'2TSQD,H'^L1XU98U;)5@RB7!@-:MRN#+ DWV\ZZ.H=C45_!M;B]:@W+
M?#.T55.1FUW";U6)0:7F3A1Z"<_\2KD1:8V@L*0J/FKR@>NBW6ZWXDQ\#5_.
M!X; ;2:%6M$DDGM&N1"G)<,>QK/ =XFEW9[%@$>@K@4-JJ5E6BUUS2B5/-GJ
M=MF053Q5[:J-=CBRI+"K8G+"^9LT6I]G@.O1:^ "#:<9%%H&J[!BPG9&4 *P
M%13:$FX;4)R/[=0P;8X=>$0F0U8SK%0ZMCGT9"SF1S4*KV]V17B.T!HU;PBS
M>-9F$&B5BQK(8;G+% "&3YFB0\\&)2*6G7XOT9.8<*93(2^%6#NH=M0FI(QC
MI!1-9Q,^WS"I=JFA=C4:<(%,#QX&%[8^/#LP%-- @B*W]&GHAP(\*-M]*"E-
MM0 /6HHRK'7'&K\ACT)C4JD#!#9KS:74[L(5#RX'B(,N8&'E]JJ%+C>(16AT
MQX64*I.LF;5#1^XL0(!J%075+I XY)6@E-K$6-\;#VEH:&DPU9R,ZP="%8!2
M0AR#\[)-Y(![ THA[-=T=::H@WA)MZRP6UXR%(B[6P8[8R]+.[6YH>JRWBQJ
M%<!^&KUN:I>L[E#EYC#G>B-IL:K \3C@$WY%U1*CD$"N<*L,XM#+N &SRWS%
M$ZU-EP>.F$)0*<B[!$U8%:Q.<++2H.!9;Q+@/51<YN7Q!'?7]?329=4EX%*S
M445U,DU*V$1?Z7*K#Q&^4VG7-BME9!9Q@N+5RK22CKR\TLS;]9XU8@.2HKTA
M*=;'M."$;B85VIAN,\*8ZRZEY8"'>KIOARN0]9V^UH2LE1ML'+MID*PAJ&FI
MM84 2#SMP!6G >-K&&T.;= 8'T"WO Y(SD"DG5CP7-?K1<W0I%%E.N!P&@P)
M,Y78Z68,O9Y1[^,U/0^DJB6+)-HA[&K>:P7E4FEHIW2E,C!%QN[C?<#$S7E#
MEZ $I5?]5K?<'$O]"=\R_294P%!L;UI8ZC:ZFCWUY_9<7, #9]!)W(6X4(B%
MCCW$(X-LYA852#=A2Z]"#JFEB=TG)7?J(%!M5*E:F^!08KA!TO;:&8.!!5.T
M8\*OQ_$LJL2QCTXK.BS&0C\2+)S(=7O<I1OIHJ[2D.>QRP;C+],X\8.91?F3
M=&.P%5BII2=-L07Y\,PV=(SK5*:HCF9F$XH[G&#D8PI&DUF=K^7IL"[EK)A.
MJ$; >&,G7HGL@$LTF&MD8(PWV(;SX?)DK S-(60919G( $O3TJZ718*)I$)>
MIV#6G[HC2PSG!6*CE-5O4V$M(;1E6>D;)*\'IJIZF57:K.6HP]N(U>/Q5FU8
MT=3.S/%M5"$EJA'URG%A4\E!J!7XT$W&E!- ?TFE&=.3=D^2-I"X+A4#.P9@
M8;P@1$B.8L!3EH)"0<Y,L>HUDF_;"TB">RM"AH9I'8 (S I*QJK3F%?MD5NN
M3>0<5[1RFG&;/=AY3BHQ7QXVE+IF*@1L H,6-@08PHL768[!<]U;L(M^U,8G
M,<\7&%-EE#2*)[#03FB/*==[^#0L>N518T,KQGD7)E9XKL.SIEF?"Y9NX$BR
M\N;HW _K:92N*LI"-5"V9]>D'JW9EI_4VG"K"L"SLN@G8WT>*G",%QUJ\U6^
M^;)L!1G%-S0?(H0)$=NTO(!:4589"D$O&2RHQ.L42K^@Q$X\8:8Z;$Z4-@"F
M6ZME1*.#JMLL'+[N%ILDU9!J\Q8[2NRDF$T(:^[ XJ(,<Y6*@H<V$L*ZB,)V
MM;32-0^ YA&)+92AX=0-'Q\XQ5BO+?A:-%"X?JFK;E) (?DDGTY;3$CD<N25
M#LZ7T03$20VL]15=P 0@>?,VS ?X;#;1IWK)G #R9.P]7$!&HYF4*98S)R9E
M:3E1>+P1P84[;<U3%$Q0&<S]L."@;FU0Y$JIM7B4C\W>%P8#.#Z#B9RVR1X!
MX$^=6.KY6,4J":29';6\: Z-4GE1LEI=S:7;PVJ+0JPV5X98O>I&",[5$R2@
M8A7:Q$,1ZG8,N"K"7KG4BOQU'V6\A*@M=,$G#A;XJCHF(DM2_"&:+-):F70!
M8T.:>=$."W^\L ==Q4.E '"5S7=%>I*6%+G1SZMVE71K(SO2JCV8L: 1Y\@N
MV8.:,.M6;0L=4R(25.*BZ\8-:5($83$+85H8%C5VFC2;)<%B-^=Z!QE_JED&
ME((FE@3@)#6J'!,6W,)6H=DBYGAFIY$@YRN](-JRVC;:(<>RPP4.A9NST1Y4
M(!"6]H$YRP6$3QQ4!7FT8A!CA<$UNT^O)'O!:ZY0'S9C0BVC@YDO.0E/U!]A
M4O8O TD ICH')($A"$X>K%8Q A&X5<>@T51$_$I-,*QY)J)]7<C)%H\J;(58
M;"!QB@.^6*7=@3\@B;DUS#HFV3%=A6Q8""/&5E"/656D0H;R/1N)NC:?S3UJ
MK).-QM9R&J:A$N>#4&[PFQ/P6*D)Z5QG7*,$7 UYH+6Q4)H;;:TW:_5(K3\,
M8)63LJBAR,O)+)_; F' [+S1(]P%4P,!VBR9E4T\+%67#:O;@S,^](VRTNFU
MW+&2@*PZ2C61]5PF+T^L$266(;1HJX';K7FTQ/6BB8\:"XP2)4#NX\0FZBB]
M.?0WN0XS2S!(@OHNQZV3JB8TZ-\QZQ%.UVI<U D!H F).2/(\Y 2-EL$N.XD
MC-GO#6.PTF!WN6:@ZY76BKQ5*_9GS3I8C=TE!49,&5LZ+)B9V5/GBTC%5QC?
MG&HHV[&:L>XI=6BS]R4D7NYZDMEIIY);H]K3D;[(.NI47<U=K#=,:OS8]Y29
M2W:%ZJB]Y*)63ZY),VY@-0N^9DA-SHMTJ9(CPL9M^&8YY)?>/&[ADNPS8Z+D
M]9ILA?$SK-^85(=,A!TDHQQ\QVX38!_ &RM&@%% U6.WK<A848'S/+%AJ@%^
MZF.#54EMAN)=!&0#,ZUUNG.C42+5D<=;,Y#4VFX";W:)8;D-%G9FQL5L6"OW
MZ@.*Q"J(5D"\-%0C-$ \,1):FH;*O7K=M9Q4Y,AJ6JJ8]8(Q2AHSFC7+$P&/
MM$Z\R2D5+QG[(=EBYGQ0ZLDEI,>T! 8S*[0Z<"1=$9E9UG1FDJ%JI;E'^ G-
MBRP.J&$B+\<3N%90:M_KS,J!'FX(>"LN ]RB)'E>"+DWZ$9XO*QQY4IC(#4'
MDBXUW7%+0R4%7H#P Q<]';!S83P1PR);Z@"0V  )X0W;T5;4YNN"7%8M5>>&
M+)N(:COBM#[VAW-STA5S$EI  ]T519HJFDQFKEE&":,=U_.H3I83+!G$NL:F
M7'<8,;23=C?Q4)_BC$T7.,>7S0&_9.)F5L"#O"C3#8EU*S&&EE"N%"D]B :D
MDJO.PG%*6-P K9)9-K188:$HIL;Q,L 0&^1 #T;#.ET,&6:,< E?0W0XU&%<
M;(N+7KDW8'ECM6HMIC@?KAJM[AAC6JVFVVY6U')O&DM-18RY4BQ&/,5O_!"#
MFLV./"?Y8"2Q@F@3C"NY+=>:MHC1B.^VIK[A#AJ34JYX4$VI6_E\5)UA"SX<
M5H09*G0,L.J$4.58)]KLVSAA%V+D9FDXH_A:L]+L#T);")*L$[>5F"SF=*TT
MDS@?P-96N[/46G96ITN0@"W;?GTUSUH#*HV2;I$VK?%FZ[Y72J02WK15I^WW
M4K8V2.0^L69TE8.GRH=ER7@P</- J3!0:8.Q,]Z>ZOVQ.I>X)4_T;=Y<@?[Q
ML&#/Z)5@%2MWT.F.AF&Y("09\]/9:#(?4=%XSE:ZVGBLP_020GJ]<2O:'+8>
M&',/#+>*K2EHK2;PM#$;^5PU53IROU1JP%K;&(Q&2Z??$%G \9;E<M&L=39^
MV%F9^+PTRSJCT@1*?0H9#R)NX"FU6LN8*"6!MA?=13\?\3+%NWV.IZ0.5?+(
M*,F">5X:+C*A+@A-K$&8PF92.+<1UN&,2AM)P>O.U)4#S19FJ:WK20715THU
MD$0Y()6&U>XOY13OK[RN@UB\-1AW6FT5([H+5JFO4&VU^6H'9V+-18=NDRDQ
M3&>=E2%Y1-=H8:R<<[&BZ$QUD&"Y8O.)'43"8I!#*@QHDD8BM%4B;-;W1^9*
M<JRQS6X"[ PKV3:K#LKL@]%NP"<MS%-@;#STAHS0'"@.W1]6*WVQ!GCE,LNB
MN>M[W2C!(A6:91'F8X-A(VAO4L"L,4*%^I3CZW(WJ@*M,&V-&8LIRFG5Z/2#
MAJJQ2A.60"!]@/DNJ5YCY+IQ-X7!,H0INM$#99LS>J7/^G1+Z>C :6H0,:P+
M,BW7?<3GA:)1(:V1+=4HEY[W+$V-^(3,5TP0YJUAD,ND*!<5P 4D)@\-2 XV
M&T$ LK6R4D63Y84M>Y..X)BM7$8JL44G:L:8XZ*<AP..X].6"ZFV-UDZ%#ZD
MZPTIZ[>1"CM$6PGJ56ON-*UOM@@0N.A7A@BLB$BBJR,GPPL.S929 4&\@"I!
M:Q8-R;G27SUD(V(>!/W";?0R?#BO\ U?I3;(0>KS0G.DS1A*FS94/?1%IFJ8
M^*#;"F$Y59&JDM0%L%8"=C5:C3-YIH;TN-'JR"%7E0-630 EPV($ R1B@QS@
MF)OE"CJ%,R76X/6F\A8K;N>* (($('$I3 9P ;+4&A)3>C5*\UCU5ZJ26;+*
MS"/9QRB5<6JCO>?+"U[QFD(KTA*L2H)TUZ@2$:17)R#]$$B'U,8QFC;0@,E!
M8NZCS3@MN';24W@(Q8AV*]7]BDJ4M$ZE8ZF;IXUG#1DURGW::-)XO]-01UVM
MN9@/(<'I,7I*J15[E"M+(K&,T&BIC1*1UU1/EQ4?BL.@)4N19I/EA/4KG>9F
M$P-W#7?>P8=Q45;"5C7(USN6#SL[*@-P0U!;X :DC]@=8N-.4#'2ZF+L]4KD
MS)M'5+R7+TNU62AZZ]P^6.^J]DN-0)O/PWFYE.6-P4*5.Q,0Q?."@AFE Q)'
M'02J '8T@ 10TQ#AJ.D /*3/ZXO-J5DN5,;K@YED!),\HP&O5YP$\!,F\U>
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M!?FD'^##L@IO(#&(\^L9K]9( 84XR(.'< #14=^NQT%LHP;,\F2?[-H1A@Q
M!"_'MBKV(YV ;)JL%-"J &&QB("[,>5-UFMI9-M6DU4 !9E*=G2[G*PW@RR6
MB?*R072#>E;58A(O1Y8/TF4%\.P2^"W/:EO=@30#]B(G#N!%?P.)UY&8B\AA
MV:[8XE2KXDJN#&"L8Q/[C<)>M76^WCL*%+@U$$%W(QHG(PP0=8O;\)2TCT"*
M#BL5>WTZ48,\.RF%L )+I(@OUSO& "U!2;Y...XCC.D"#,76S.P]0J+VNT]0
M6PUY8.8 I<JZW'H"EIAMEUW F<,^ J^_4T3BXESA(,C& @W2ZLE*E/>=2?ER
M@(H#&-%P+K2\#!^4X4B#*B%(0#&Y .0B(I2NVDK('EP9H$LCP#DTF(B@#R0/
M97 V@A>)CT'IYCN<H*M &FT/1"VQR98UY7 1U1"K!?E]M#76;;J/M^M*_W=U
M=]W3S;G>HW2WAN?03$0D>YS%, =6BAITTVYM&</PZ,''*S?/3C[LD=''\.SQ
MP9])_8]\]KC=?O2'B&>S@SZ /$\ERWYTS?GZ45AXWY.P0/R9!S?$9.EC,<1D
M5I ^\Z%/-;?;NYO!/-6#L=6D]X""78YC[F:I&EXJD6B)(5B&1E&R@A(,4D=(
MI@;^J-6W!OA U8>9I?<^QK[7K/D8S.ZG^C"SW<29.('N[R>S6 #;%;J$$&2I
M3&(UEJX!VVB9(BJ 3&-H!2'JQ#[;!]%_6!V2%9C.V@_JOCZ?[]G[GJI]%AYR
M]^$=MQ(GLTPV"6>_Y^/-9V]YQ6[G(!-!_JX1>YCJP2R;!YF+W].R>;!Q>M!R
M^+\\'8^H?[!JDD>8D8/>?4@@.'!*'CY?G#-/PZ0XR(/KLA7_QSRXOK58=^OC
MK9@SUT%3UDW?K^R1E0[B% A-TA6J6D?I1YZZAZ@^LOWEU H.>(< MGZQ49G<
M]PZ!_:0>V<@\M-.EGEC4!$SA[WZ9P,&4'MGXWA?([('W*>XK^/T2Q/\=<_:[
M0]^_9\X>\MZ'_\_/V:;TP.6W;RT_9+G^A^5TY\&^'SRM[B>P>;_(_HW;[^9N
M.=63=!&)26@[OK5'7+_QZ&SX423^-\"3OO@[7G*2PM'D$1 *[<Q^'V !Q*Q@
M_3J?^2, %#;XO0 *&ZYQR2.\K.5WO:GEH7@&]'LWI\\59^X8OM7=]\*I/?UD
M86UYT",)/)J9?J('<Q XK&!<[&%U?WXP4P<(/=Q:1P28=KX'?4!S;\'#)=MZ
MOKXE.ROK]\</8#)V+_=@U5TX2F"EZGK9;8H.)CC=@U9WE4H(@J+[!*<'%5P$
M3KI'=,;Z?)_<5LE#%N5#&GV0+JVG^&!OAJGID_^H8 V<;??Z/4WK5V;MV>_]
M2^N&'W#OT=59?>;XQ<; _JI[RW^7\MC:\[!:MTH?77'=Q3WKCQWH_II;Q8^L
MF6W>IB6GP($G>\!L[D(09)_^@3<?V<CZ95CAW$FM?8[]T.+?T640OS9#WI1>
M#"YDE\C6GKMCOW^U#QB+?>*/)0\<Z"4/N-Q#G6J?LXF^GFY5<C"/>Q1(MZ=>
MK"?NT3'$GK:^3GWZ[Y0;6NLW??U.L:V7>CW&)/B(G=PW O)R_3!B(PD7T6,<
M@\?^/J;=DW4U6W-*;U#YCDWU.[;JWY#Z_80>W<Z6QR/[*QUT#?PO#-C!QN0_
M+.%&YB-P>G #)"KLP#0%"G>#U&\NQE:R%WB)-+O#=XQ$3XH=*+(+ 6'@ *E'
M;?"F5*+9/8\'W=WWGNN#C?1__/6'2OY0R1\J^4,E?ZCD#Y7\H9+_JRIY_(/_
MIPPK,,_9N=SYO#V__=:V^K9#_IW7VLB_U\8AO_W,MNU''?+D0Y7##MF^[=#M
MAQRV_9#?WKSM&=L.V7;H85L"V_9>1Q[UN"../ORP0PY]/+C_IT_>=LCAAQYR
MZ*&''W7$DPX_\HC#CG[<H8<=?L0A1VX[:OO1QSSEV.-.>>J)*$%IRTN//V%G
M+[_[F:7J0+_D/UUVW0TWWG3['7>6R=I'GW4J)L7)>:=5\+H\-U[QQN><3C?Z
M]OFON@N8?_HA^ZK?5_NV0X#]QQUQY%%'@]O#[:!V4/D1AS_QL,<][O CCCKR
M,' ?W-Y^S"E'/N58E.KI\1NO.VYG23*2\]YTY6>_\;.G/O.VXY^%U>X_JER_
M_N>GRN>_LT+/T[^\$^\/%/65;[Z+&9O6)9?>_-M[MSWQ,%#S]L.V;WO>MM]N
MFWRJ\>WPI.\\\8*/O/4KYUO_;)QP'/7UU44?Q5_[ZNY]WW^=_+7.A]YTW>UG
M7G72X4^?77+#GUZ(X:==\\MG[;S/N?R2XH8O_X)P[PR:[UQ=>2$_/O63-S[_
M]H]\U&-?6CYLVS>/NN_=DW//N.#^G2=]8WC%;VY\^9^\U7O]52\^XIBGOOI%
M]\]/?'_E9[]Y;ONV(W8B'WOSJ<LW7YC^RW7+:]GW3"Y\_:N5._C==UQ7>4;O
M-=._1,M7?!C[<_>:__GVB[NK-YWI_N#CO]CUGK-_]MH]-YU\UC=N.GWG9[_3
MH5_-7OZB%]:Q"T^[^;O$+_^%N>"I5R+?N^B99YS]S3E^W<]O_CN<N?*UYW[^
M!2=><NO1KW-_?.OMUQ[SU/>^YY1O'FN>=L%KCODW]I2C[^*Q5[X(?<-SI..'
MSKTC>W+GWU[GG7[-#=GE'SOCGLM/@&X]L7;7U9?>>,K;CS=?<<,+NM,;?KOM
MBC-^>>XO;W[^R1>?_H0WWN3_T1O^>M=3K_G4^\U[WG#(D;<?\8-[DXO^XGT_
M^O&]C2]]X,5_C[[P^B>=^[.7?/>H>[S^^3]IO'F7>^)?/^-,N'3I<2?\I\N^
M^)[5FS^H'O*CVXYZ[0O_L?3*6NNIO[G@YCN?]8,G_N/G3WG'4^Y]VB>;1\[_
MPKS?>-F?WG5+"[W\,^;UY=*)W[K[C/[7=[]+/.;;?G;\_=LNO?0ET7OR4ZX8
MW?"U[-5G?%G?_?WIUS]F?'IXQK5W+<*?W/=MNGWB!Y[]I;O@>[YWCY<]XVU7
M#O_Z/W_IZD^>_<R7*C^H6]^]]#3FU._S"/N7[DLNO_%'U-4[V"<][K([;OW*
M^W+[LOO.GF3HIY[\(>'DF\__X^MO-M4K1]^ZKGY:X]^(T6&?VV5\_@MW7 J?
MN.=;W[OSI#O>\;EC+SOZ15?<6[U!"__NQ__ZA5>_RSWSJF=@[TN5Q__T5V]X
M[:V?^=Z%)UWE?OOZ]QD<\W>O?N'XO:LSS__(/5]XC=%>??/#9]Z[^M1+OTQY
M[]M^ST>:V2D,](47//OI'_K\Y[[6GU5N?=P/U'>>_[;HF1>_ZR_5&S[S\1>\
M[5]?*F#/O?6<Q>KYM[[E@]N?2Y]^SU]PV/QI1[SX"Q\Z3(C+KSODN/><<M,A
MVLO?=-+=VY][+/NY3]YQ_?!'O[$O_=.;C[SEK=6+3KWW5Z>'3RM]_)R?CDO'
MULT[7B/>?0:'//=7KTT^_*Z_N[;Z@X^_YZZW7';J+^Z4WN7?]@+C%[V+/_M?
M,/OO/]NXR?VZ_NTWX%_I[_E1[QFOR<]XY_8_AY[TJ1-6__"Q[6<UA4]]_)(?
MXD?\ZOD?.=+X_,O>MN>]][WRPR?\$G__=TX_J7?(S5][]B6]G[4N_?(_.^6;
MWO"D9V)O_'+KW6<><?G[+OO(1;>8-USU[B_=\ZK1/>_\JP_\?6F4O6?X_)M^
M?K>U71B^=%?\S_]PV6=^=O&]SS+<-__/:_[3B\D;?OGR;W&WO?0YJJ^>_JZW
M7T,\_L/'ZW=?[5WSTV\<9AB5>^_:<<)3SE3]KQ_VS5=_:O+E/WEEKG_C#/>4
MR_[F-3_X\'GCQ[_JQR_]ZK$?E#S,>Z+\Q;]Z5W0'?_SJ([=*KV4/_^+1'R(^
M?L4];[TUN?S7__K5B[]SQ5?J5__RF=M^_>WGO?5EVG,NNF3W85^Y#3_FTBNO
MS@[[XO>\_M7VL?#Y-S[_*9^^,_OIT6I^T=<_\_2+;])^\S/QURS6OA<[_(EW
MK;X67OZVKZ1G'K]-S,Y[_Q^];"A=^=7AS=H++M]VA?8M?/7CE_RWOW[C4[:W
MCGW65[%OG7#DU;N.B?_$>=<QG9_\.'K'/YYYSXW_]!?/ONP6:MMY^0G9X=\M
M7_#D+[W.>/*+GGO7JO.YNX\^\]^.?^\3M!-._N.K;IQ^XYK3Y;]QGZ"^[^[K
M[&L_\<L/W'S'C\?7?NY_;+_KU)\O7GKWM=8G;CKMG,8=WW_KV\4WCC[VVD_7
MOSG[X8VGR?>^[P.?D3[WJQLG895(OW'C;<<)Y_W;TW<Q%WP.\R^^_ V7E>I?
M>.T7?OFYX^"1YFT_]DSZS@ND_MO^^[=><<]+/G/6XN=?._&6Q7=??M.-Y=K7
M_\+Z],G-X^/R!<]XQT=N*5]ZX857G/R>E]WZX>MN__K?O(7XP2>,'W^H=\=U
MISW^B6^\[FO=[S:N^"\GW_3*G_WPZOXK7G7W<89+[_[T.QEW]Y'2C7]Z[N<^
M]]/DW9YQI'QO^0BU^X/GJ[^Z\&5_>^-//_NJZZ?/^L1I'T..>_*[/W/7*?]U
MYY_FGRTWS_VKMS[Y]AO?_5__UKVX<=<_- Y[4_9"YJ(7LI6G/.F::VK$ZYZ\
M_>J;B3=CDPM>\\<G_NR?V[?9.[>_XK#CWO8)YX<_?.N1[]).N.?>J]I/2RXY
MB^K<[7WQS@\^8=!\^<<._8</C6XZ#S\+PD\XS_CI8;]YP[O>_A9Q)AWRK;-_
M7K[_^+^*WV%_^O'U'6>F%ZC7W/<OKSEQ3_GV\1_7](NO>])+3U_<]9.G/.VP
M9WWX*:=<POV/XOYK'X]<<<%?;#_U38/77WTWO^LE]UXH4U<A7^ZBS?NN/UZ[
M)6*^M/V3YIX]ERUN>?;]_F$G0\5AZN?O^M+%^H^-RYWOW/R7,'W;'WWBDI_0
M3_W\47<>]]6O_F)\,22?>MFQR@F[+SGLFNE-W.A\?&'?_*_=&WYY*AQ]DCCC
MC,<Q=[G*7[WC\U^&RZ^[ZY^.N>KY1R._:+[AYI-QZVWB"Z]YX>X?_?.[OO*T
MX\_YY+'O;SUSU[>[[[WRX@]?Y/SE#1=-/G34I?').^[\P0E?ON[8=][VK.\>
M]<:/FO;K;DE^H/^&>H8X<O_D;W[]G__NO>EW8)D[[@4GON18]&.'WO&!%SS[
M[.NI4^K]FXX8OG[;6?]ML-SQ/N'KI\;_>N;37Z1^]Z(OGB]^X/8SKYM]JGK>
M62+^[9=_,GW^5]\-"[=#YE&WO/G/[GO"KCVM(]ZY_9JW:N_?]C<7:Z_,CCKO
MMA?"S_C[VV]Y\V^WO36XX9 S?OVFBSYS^57;CW[U-;]J'\7O#-"OEHZ]\B4^
M)<AO?M7.8\X\_26?N&VPXQ6KC[[L?>&33KWR?=^\Y5MN_]J[/OB!Y.N?_P9Y
M2^M-/_X518Q._/E=W_G4UU_PQ,?YE7,;'_FCM_RY<M*;>V\:?^&+T+'/9_&7
MOF;7'[T#/>.?3MR=H<WG'GKTO][_E3?><&[ZO,_^]V?E_WRA\H['H<CA]USY
MQ:]F+^E?\C=//.+YYY]\__9;7[4Z\XRO?N^\UYW\^M><]*8G7"P><MD5D?FS
M[?_8N_FZ-QYYQ 6K_WS>QYG;+[E6^Z/SM:>/+O[:%[_3?LO[_NGVM_W5J\ZW
MZ\EQL[>?TAE\XNG_]/P;W_OJ:]]T^VD_O*=\P>"O7_;+7WWMHZ/=K_MF^9VO
M^-K=/]R9OOQ-GS[TVN&5@Y.><_B=]W[[X[7++[O@DH]]_MV[3OYH^=PSS2*Y
MZ OG2B>^\",GG>T\\==W_=/=1YQTR7L%]D/"59TKA:.??O\IR@<O/.T=/R\W
MGG':5[_QXM='TZ\>\XS_MGS=3UZXZ\^?<_%=O[YO<.Y][[GPVG?_XBKCBJ?]
M_=_>\IF9=?WHFFNO1Z=O^?)]]%.???GJK<]YXV$OR0C]J,YS/__K^_XE_S/J
MLCN7WSIOIKSDJEN?<$5YQT_Z3WC+VQ/WLI]M^^*>T@=?=BO)S&^\[O7#?NUC
M^!=WF^J'3C_4NXW=_5^RY;>>IFCG_=W[M>7-NQG_C?2\\F^S7PO7/?''@Q\9
MSWO%;[=]=GK2MLO-;T^TZ5<N"S_S9_(E3[WAPU=_^,3GGK2Z\_7??_']J[M^
M?N>I5U?VO.U<]YCOO^SEX^N/^=N?/_LK?_8U^J;/];ZXP[UC\B+I(R>.CN^G
MSH^W_=E;?O)M\KI_^+-W/F$7]0']KJO2'TQ.ES]]T27?N^&L=_,7"_35T$77
M_^AG1]W\I<Z7WE*Y\_NOG'___(_\/PR7A4(3"J.  >EN&-TYD-'IH3M';30;
M#!@AG>JA<W2GTK4!HT.4'(W$@)'22JFH(-:Y]W^)+P" JHU_"[\XLO2BKF\7
MXR.E+/^9W3_A9 8B(OUTG7OARMOO5](:>'1J+8,;2WQ&_L FDI/,<D17?KS+
M68RO=(_&BL.P?*AZR?23Z-D4TNI# K&KE[\)A#MIX_<2VX*,6'Y72_8>H9G!
MX#_,<UD)RO*^B_I/*89C>9I#8[= O0X%Y/JXHJFDVNJ*H)D :FJ]%#ZSP85I
MHJNTN]'R@U;BM73RIA+JU2>K=N!,(H#-C$/'I GY*^6D2\<+#5++V@[;!9AH
M'%OF$DRX*%5.IGSF['JK&=*;2=L83^[9$]32D23F$M.F?]+EB6L?VA5E:1O&
M.EX^2O!?:@B_6W.83@42'?7B%_UN( &J<6&=3(+122XE:OWT.>J<*WHI$X0)
MS;3X?$$MPDE-0Y=X$J0\R(:RW; JW6_Y'4W?$6/Q=BUUCR;BDV1ZHD2J=7$_
M4) \IM_S>T8N5M-7\BB";*%<UX?,K8PX"X:+C=U ;HOGORNA8TZI#>"0VFD-
M6C+;$%MK"N.R)GV+^1?_OYV9I.,[&"-$"7O]V&N)YV/1I0L(>%*QJ]]WT[RY
MFQ-.!LJ/V.7I"I\_+2JU\1<Q,F0ORP!CX2^I98Z-Y=G#8HNNJ#E;9A?-O#M.
M9T^.@GEDCV5*RY.8MQ4B7"%>ZSQNH$M/M4E_J7[D!A&\8LGKAK IPJNV.;DQ
MB^LOQ?M,G$+0&N&W-IV&MU*PCTOHT<J)/&!^NN%KS[@++2OPO47-J'.MP].2
M5#1KK.S,4@[G&*-V<M,U550(C+K&I%VB9^5]8IP[0?I\HHL>>CMM/?/7X0^M
M>35]27"D'Q&N/S8^>+O/JK5H2:ADR7BCG)ROA91U!];/0MD!285'_0>W2F5>
MRM@BH&]^A0=_E_])N3=UK) ;K=TD%0&*J?-NW\2&8-P[@VWI%I5V'"YU:V43
MI^!_#W1@94X#=JXZK&N2[6S4A^+)#E24(Y^B3U_ZB\ NFI<-6KCRZ,6K&4Y/
M#<I?/HOO_; ZSX"6T0M+^4<FN1U.D9YJVPG@1.N-%8=TDK^@\BH#=TN4.&M$
M@"]KP2] HH=6A0;[8;^T-R,5Z^'7]L5J]C,U_<YV8]]RW;0>2\-Q3M4ZMXJ_
MK6M6>T@*GX'MQ[QTEKV2GKBWTAW><#A_4H[X-9]'Z+VA"MK]TDR<"Q&D;GLB
MT<[<ILQBW&/I\>RHR=QA\5B1Z99V29#\31AP2B][RO;A"Z&_+XKG!V=P,US&
MG5>UQ"@Y5XU1QD,HV. #53J">SXL[X2JS'EN^W2IIT/)"\NI9<&CL*W\%%#_
MU:G(H$F=@EU3N#/B=B!0Z9NV&%F[7:#<!/&.9(KE>\KC6^YEK;8(L0#RJ3<D
M!"89!ZZVI[R:-F,0_?061;XR__!U24Q6KH<#9>(_3P"__Q:7 6>9A5:^N%BB
MZLJXI*F*EQ8X;=BKP?CBX)?=YS*L(J)IHOEPX':H:F5\77**-8,XC)'6C4KN
M8>ZU(S=_1^#:TKGDN5'>2$Y ?^;4^HA3O[P2-K+/4@% _67X[W.-5+;%I0=J
M!8RSH#K:5RNGK@?$FB3<OF_&?43:Z/7M4-NV(RK"Z5">LC$R.!8 2;3J;]4#
M,I]MGL>:H*W8*_%<5;I'S@)>SV9F*!0$7E3Z72?=@0CFMA ,-$%%8HG9F2==
MW'<1E''2ZT9ZW8T5S#]4FV[2P3W/^%[<=+1K_#DT_.)$?LAG-E7QVD;&12O!
M87C9](>IJ>A>EU+D0A:/AA(L3@<X[H"?+%(8E0X&QJ[%P$HJ&H/F7'9+>&H_
MVH5&R(]]%!;@*$4HP+CL+BA/8*2!1I=K;;9>.LJ:.#MX#W8WBSEIFL]SA!A%
M(4>72W\CK=<EOUN5QDBIP/GJ6[Y[JV: 08-D[L]GU6<R64[]Z4\]+& X/5[#
MOS(F8:FZ4X09:&M:A[3(6^1'H+,BD7I^7-E7N!G(F:[ZYIFO/GR:,-SWR@YG
M+.J%#F"26AX"]$UF/[-_?AR)5+PBHL:OU7*F^1:\PSAF[%Q>/&'M33 \ZO'@
M.@U99SV911RMWU\SO6+!B_^8L!8YUE-\A"26K)/7C'\WX4OTU\2(F=I2LK>9
MM_R]VV<3SH# &,*HGI+K>PIWFPW2J[7\S\=TD<4DA%:F4W'Z[OROJO<C#G/2
MSJRR)-94;F#?>3NZ+KX_FQ.FQ%#D=,3S87O94Y+%60-6/OL*#/(SVSDONKH[
M[251H\.^.XCXH[=;'-V[.[756N9L618NY=NSEN_[\RPY=]';:&NU:#$5M7:3
MZAP!9@7>S'/6'3W$ 8]UT:O;PE^TRO7MY3E^%8W7SZO_*1"3EK3\@]2*A^:H
MIT)"DUN<WT+&L3ESX&X ]50C=KANS A 1OVCZ;JRN46+D2,Z91M9S[<-%W7V
M#2_;&$Y0-P@=$7K6F3@.#,UPG'/.JBBC:YGOX4F!)=!+S@6]EGJ=</*W3*^S
M@%R%J5@6V#MBW6JI=+.=C]9=S>8TZF5E M2ZP#/<7+4;).=ULT"TWU[R:+J5
MOFV+:,IK;4?ZO&1YJDGBU?708HWC9S%%+5HEM;D+7D#FH+U.6.Y3F<R/1C1>
M1>W@=+WM)9D>O#V?#O45,*='E?I]U\UP#2;,7/O_B,B6KM7][R%DTN9JA65*
M5*$H6YGX9 X@8T1TN4=6+L\;9RGBKW]^3.[X @X\8%O-[@*Q>_I7TY8+)'"-
M ?L-DSH-I7D=VAXYG)LDS4^$YR_(58#Y.U-&LI^V<XANIS#^8L^-AR>;_AP:
M1UA#YIOG+99FD-?9ZIL!>#+A[9:3E&JT;7'9LHI347G?I@QC7]-!@7QDM<SH
MM*=PQ&^PF7_L^I=ZYTQ]I"7.$VC9KFENZI,F=DIB +:4[H/<L^>#0J*\FS#Z
MRU2N,[C@.09FBP^!A"CSM>*0N1.+'QD$KVAF.E6&]D+>B<_LI:3/)8^S33FF
M$_$]Q+W3V>[./SE]EY>I45.:Q0E3Y8.*-+G5F8O(YN":20@/]LL(NW2N)S;"
MWP!3V(45JL>*;UY\BVA7X3X<[_-!%N=7NI8]M@,F<Q<_34.64+U8R4YB($6S
MUY"][O"S637L;QV<X/W']PL-;EJU9E%VOL]D>1*B>?M9N8LR>#-/Z&F&+"8S
M9*RSUTC-XL'A["#_EC7 -?FVO'L5QT'&4^-!-+/ J_NF+MX[^S5"S#R&!/_B
M=2#27@*JI1PE$T_+%-H94=B6R69U-&^Y]71%Q+IO&;^S?FA**<L$[LU6\<QV
M'2IC%4CXF+P=:&G%!1NX>8C/#^PH3$0,'DET^DBT!"M?1SHRM5E@]FIU63)\
M5.DWC>65///R6%]][A53N).7WE(4$>X565#ZE-?U\#EEYPPXYI,V?LFK[U&
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MU8WA-Q'.MN_C+:E77\\LHJM:0_G"%._HMK'[.[)P9:4*_*G)=C(6?-QF)+P
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M'>/I)V+'T2 7^PD2+I"?N1XBTF^VL,IAY6&GD-8 L;O2VA+*U<R/$K>1PO=
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M4S-0T9,R77HX9]^D><71MQ:FK-19\XKG%&DC^N;U(T]J(R#%;?]^>0-+CT>
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M3%6(#N7V!=8*VK2[K<3IH>JYEX$*EOK1[]V_SU0NZ7YV/J@+H-UJ^DS?\DG
MMT<,WZVUJM'TKB^% >M5[0#5I1\2=@FHNTA4S#?T(I,/3V[-VR]1)-?]M+NL
MY,R6G2G@LCI]V,Z%]X3GHG$DR>=\'5-&Y(@AXV>V\?N9@KJ@0OU4V)<O.U1?
M'Q8QO*Y.UY(<#N%)A<WIDB$= (<-*)V!BTKLGQ @%[B&0<,[^1$!=;DS&,H*
M%I"\AWHN5YTSM]M=.6!6>S[EVLH.7Y[SG*4,2QFW+KD%J?TZ'+I^U$P.4!M:
MKS.T+YM*E^H&F"%-:76>R@A6DR].10)Y.'>4*I:<BS,%M9I3MU($>?)"MP4%
M;I,;QGD0XWR_!\__O%]=T&=]N ZDS6E]=R::-7\D7]SA&J#'>]9\,W'&R,4&
M*O8O$97#_;A>?!R[1=/C1!N)>C'SRP<-P43^;AA1JM%*G/EW\[>BYN"+Z:>L
M"R\Z*"L(DMJ[P6:#I42OR,P9$'Q1HLXBFJV&,%50*"#T_]EUJZ X "5:D.#N
M,FAPAP"##!I<!G<GZ&"#NP9W9W!WE\$)$G1P=TWPH D: B%W[];^O*W:K7IO
MO[:VMG_.9Y^?[G-.5PMB"+MOM)C0H\0)\2XQVZU_=6SQ'PBP-K06P448Q+_C
M]W'#2G)C+9Y?[IS#2.U+G[)3^<R D],.DGBSQFE3^MY?7%*[ZD1< >[X,K19
ML[XVB!-2SH:62$0=H9M4=D&[D@5U>>ENL]DD^,M*X-7_;4XT.]*:97 FM"ZV
M/-U_%$1Y;CU*H-,2@6:>Q"I/P3A&@&9GFY=SZ5FU'I Y7W8.DELE[S2)=)D:
M-R/C)EX%N$UT5)JB<:@S"N;K,.=ZD/K;T(0MD7*=LI]9>9ZY-<%F3GFFCDP;
MIBQFC^H/"<3Y+#UP?3PZ'%?+Q59PDO3EG]@<BJRP&+,VY/#W)\S59[S[D)U.
MN)@X*Y5B<I&IDDE)U<H0K<\G&=KQ>>BLY&:^0>F :)*EL7C:+5V+S&KQ3#+C
M=5(C5[FA>PE6Y7QS/:QW\4\%<@VI)BK014>)JO[*:T!'D"]?6'<.NL$6"X0,
M_L1N.$$CI**FZ33N3,XSD<3KUZ$Q96:F TQX]QYS'(NPG9F0NA)\;;=)PKF#
M_VC!8+[S>^ZK2B@*Z<EPU=0V-ZF-I79D=)9A&L<%6O@H,U:E#*!M,D'XTG8<
MD%!-92<IZT125$.R6N] 3:M+ZUCY1&5@(X-XY"&$BQ,UQ4=C^J3!+&7:AR*S
M;RXGUWYL)V-A]OQ=MTBO<S)#5(TK\R- </E50CC-/&N3CLV4A9%S6YLSGMX1
M0\,.3--B<I\H,ECAP<^ D&OS]HGLGU[P1?),[>HMJBY-5EK!] '5M1MGUD@=
M@16K%2"6ENSQ5."[7'0L90EJ1>+H9-X%4UJ1S4H=Q?7S;LSB-0]=-X6%OC/>
M\Y6&N5DLFU<PI+"J?<0&LJ7S5='H9>U5$&B<(??LI7M>DUY P>BK;IQ)9\AB
M56CT?;@)?;*,2N.7>QSW+SZHRO..1\7#Y7N+K9.")NAU/"9EHVZ-*?L/<Q6A
M'<GR++T6G5+C8_"XZ0%[@,+EH]AN$&CZX."=1@^5E*VTO".$$;;1F1L4%I<*
M+DS@7:%Z^MKO,X36@-[)IRCY64<Y:1WW.T.4;'S<J_H)T32MA&)<# 6]J3?P
M#URO:[/MV(/[^;0B]!\;K2HI]3W;\-M@'??RA':,[ !U5OU.EI'$*(!\\<IY
MP3M3TT>^FG7.*L[]Y*OB/G<LQE C0:9SVP]J"U<?4[)L7"V7N!+'MKPQR!-:
M-NA9OK$\!A,P'=W&2Y4_O1TQZJY4BQO%^0=<2GH:T.ENU_!D$P5,-TM#PAA[
M&+E/&Y(E=AWS5 WA>'!+RBQL"OW1M#MUSMWY:HDO 9S\MM3+-GWTTP+S0LC&
M]L.VU810Z#NBG^LM1D2!M\UL*=,BU=-Q53+1A%-7ZTA7?3'?ZO2^379'Z__<
M@)I\XA$FV:++NXN4$_)N-XYX5\(I;Q6K"CJE#?9&BI0_+'8:!ITQ)+8(<3Y?
MDE,GQP5FF>&"IGJ>&8VQ6Y%T$#P<<= =P6/CS& J"FKC$0:3WDV.L[;  NJ4
M$ONBX%![KE_AW*0Z%T9C]5P!IK\O5OA9Q7YS]^?K(#DAM^L\'%FL,K.W1YI
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MF8$FN:: 01Y\VJ#5.:-+;2(+F]_1)*9$+LJ=1XLZA.!."K2KUC.#U6.QW,$
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M(:TIV\:=BIN2S#[=5CBV_<X[?RV_O?.>/+U$^.Q$$J&EH])?^\:?8MU&%F%
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M*S[1U)T[R,*G_P/*8V'US <RKA0@XO/EJQ;=5DJI=2O;]5@::^2R5J13RV!
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M-FZ:-91\4>NKYD=B37T+?P*Z1\*- CY_F7M49IDC1O[N;F$,G%.X/Z(XZ\W
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M&8],Z,JT^57WS#_@@"'<)GVDS6T ZL-KI1KKPG0-$ @6'O+%+P25:UP#H-<
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MLI<>=+OR!B!\E5VK^MI?%9HI=(LSP.YI9CWZ/*]/9A9O\O16@O:7:X ^29G
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M/#W#!;0;VV6OI'?,;SRTWC)(,<I/)6;+Z6.#&1B5G?**&?O=?G]\+?A_VUP
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MB^\O; TS_%W&R[8LY%U1M5 LW/M)QUS*&*7XH%*VC([MKMN2'ZH,U5W!-)L
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MX_;[Z;OQ6M9T)@*K-HLSU6_??TC&E;LHR[SY*L'0/[B@F4)R8$[2'K'1R$=
M_.HUVSAQ.Q9&0CAX;($8"!@Y!,, 6F^T8+8ZPOZ_5(9-V<<F^S=KL4W&(8*
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MI%SK)I>Z!"+7D*2TY8]^+%]=MPMKRU3>_W''5N+Y)''-=C3*0[(H[>$'<T:
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M:WQFD5AI#*++L4Q^RN?;L5GT5[@;9UO\ZW4WFGUD4".F'21H,%X03"=%>B:
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MV0:F*N&5Q-PL?Y3$\I*D-8!>'JJ*DQ):D25$5H8=9+T^[E5)I$&G6*)%8Z@
MP9Y(1I&G'89+T6B=4HI>+^)H<;<C5<YQE=)8W.[1,45P G:;)3$!2ZN6HY$
M:+.!3CY9%1(;=7Y%Q&P+B6T(5QYF^?Q6LE'@X/ ,(E,$(4*>1$Q$/RND %*
M4EAITOFK<Q[UQ3>;R6JT<F&.UL$3H0*]Q1R!J2;<D;0([7H>PV.*)^4>S&+W
MQ%.&S8\[ W2V(RFU.*(:CDEM\E*\C+C08$[(21B1$+D2!PL6!#&RTQ5"U2Z
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MH &5@TI6Z&0JN=>>5,7<)BK?1PL:XL94]86"@J!2RA=(!0&*T<XRX7(R.XX
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MHG2-'HE8\(19H*:8'4*!0^!)& 4NEU)@9BH90;;4:V61;(">8?93I/%$V(,
MD@@8Y0@]T1I C&OVXDF5F":7)35BBID12RCD(7X",6GPH)IJ4VLD,=CN#= "
M'+M.[>3(^7I:@.$ 31 -L^ TE\5+B;'\.JHU9@^G3HEU C)'#$N$+ILX#H \
M$<]'"8O$!C8**-B^N$1)23KAN$B/HF2YAZX-AG!1@@Y$XCJ0;0)LW#ANQEQL
MS*7@>!2IDMAI9I.9>JI'(75S<7="SE>P=&:ABFT)"GQ:.."EL:DJ-,E_G&)C
M<L*D]%$%*D[B,E;$P;8J(%7(9A9S4CK4Z9,2EAM!)>2 *>C4PUZO7J[GT6T"
MD8JG% F"1,+D:GB/DV7T%?7/WZE@']_"3C8-=#'($89*H_%%C4%<XX']9H-1
ME#I9X@N3<;Y9X>/SV:)X#!,PHW&N2>" XC(^:I Q0$ 9<9E4J@CFL="M"G/"
MS'2RG'$.Z&0A9A[=[J1!?(6>SI!ZE5%E:H2X4"YRX1(O'T$ADA&743"]2QX6
M^3 G6Z6CV%P67U2!0RY>2,8(^.4AIML6D4.AF(4JT0JL\A!- #CB #-()):4
M+P-$EF<+E6RE5YC@Z\4FO==KYZ-AC._F26 =@O+,<;)=[U1$(+U"8I5B29I=
M[PN!;A.:3*BD%ALJAYD<-[$7E^A3OU8HV'@2=/'M>K+;!WMX;D%"2V3,H-Y*
M%;A])CAFXXM1=40>C'+X3!60B)D!-C<A-Y"(Q EH(QX7.RR*$CD(\0*AU*-/
M6)2L"-( !<\.L&M:'S9P^01O3/ <+U=90X7R*?(8&Z?&\*2#&C9JO0&/_J$.
M8SS8XH01%. 1=9+9RL>,$B*TJ1Y#/(7)K9;,U4A#&B*.LIX9=0W@BX;^ET9-
M) 2#1H$QW0Y=G!I6)..RU*E(F&P)HE8RB9Q@L2&I$^;HY920060TD=Q.,<"P
M*HA1,40RP""RN((6791DYM.(/8I.[R+'332FB&P'?# .D*H;'AIVJI4K(W@!
MKS' (3;QSX&9Y$PR*P& 9C).<9B=N(3']>CU$:M1:A**S.H$A2D@UCGU-!BN
M9D<L(K>0@X&QI([(PA29E,CR/KY!3'>HT;!$(-=2=$2.$@'_X A?,%V%G>1*
MX"$'RY (^C!%*(&D#M-\2E$D3E3/"JG/P 25>ESD\ <,'B/+B@8<5#91Y_!?
M4(T07JVE\.-PE,6GA^U("(X$ V[?PY_AW/1(R$C66%D$1IA,,]!Q#>Y"V?:H
MS*S7VQ@RN8/J]7M!$U4CE$=8ZIKR5/YDP. R\9!0C.I2._JX1>C!!"*Y-^[1
MRG14CU6)FVUF&RAT&N4!(EQ)_BC)B3S 9 6A@!X3H>(@E1*0)]@43\#O0:Q8
M1 ZKM:E38KM$9'02*I?I0B0W:,%\292,D\,B!FKAJ[P^KT=G5@D]1CE?9$,@
M/FR2T9A&U&$RF"D1S,R"]73<YHTH(*W)XT^YGE7M$81,9J-7(C*Q$KJ@21 1
M*0((+..B%#E9!(6(2N11F>2!J&$3S9:DAH,"G45(Y!B,2VQD8!2$61+L8;3Q
MA-0^*LE'Y9N=D60$$=% LRGB\$2E#"?-&6$IDT1]]]3YDMYCTBB,ZJ#!H@Q%
M%0A-1>.)[ :%@"DS/JP/U2S8Z/5XL01'!\?4<3%%:3*H*'1J4FY6B(Q2AHJB
MXE%42I/]J=/(%Y4CJ6CS9)O>GI0P7#Z*4ZH3.#!0(Y3!-I=!$38H[$14TVK9
M3K4$$T6)N.#UT1AB=B*I3R2T)-".T)2AAS\N2,,,+L])XZ.A""1'/&@T!HL1
M%J%W><@-D4P*E"F74UA&L3JFAYPP@(:=&C]H#MHD.I\RY&)9Y"B)XX11,\;@
M4E(_J:NI, P3LF(*>UPA$DM]?IU<P0]+483&M=@1BX1D! ,^<HR**@P)%XK2
MP$0"C"L<L3!30PS<;PT*)!#",I$%J8=/$K 2E8:E$G>4V/+Y(-Y+=X8OVP^Z
M_JR<^]O;[L>;A=3!^+,^^M_<5KWH$..)K1;JCP;)$@E%K5*A4$COE^- )$JJ
M_MG-6QV_:1: R[,!"2,1JU@8L=\+ PSYPQ&R.!0@_K@/20*/6$0!0%8=N&J0
M2/KJ7.%TL<U$2'O<_+2 U*(\(^4_$9#*RW\RC;\C(%4Y_,DT_HZ %""!9/9S
MQ&X&%(J'HA:*G" % -OC!P533P$^]_#CWW@H]:5/5V;7O).3)0V$<3#@@*2"
M'*(A$T&<61P.B\)D0.P,D,VD9I#)=%8&ATYE9S@X+!K-2:6!3C98 _PT^W/0
M@H?/]3Z$=OY-Z"?8GX-68PB,!$#?$S21"('/$%#); Z5SB&BIH!'H7 H="Z;
MP2$+:!0&F<UG/\)^ ?]S,G10P(E4/\G+]X'A<,[#%T$>(3S3^_SD(0R)0DX1
M%O3_Q8=4LVM>=<I"'FNT9DH<!@/BV,G4#!?; 6;0&51F!IM*)F>PV50ZD\$F
MVSEV>S;P'.^+H)W/+PA$9K*8=@HG@T)E4S-H=F)!0!J3DT$HD5@/E\M!@1B/
MT)TO4M9C].!_>TU>RO\B,=A+EN6%O<]XPM/K\ORB29 P'L02+W@&60^A_\PS
MR#6OH66!CII'Q,,@,93JH3_1]G(FY'E7I8.$YS@I]@PGFTG)H++H]@P['6)E
M,.@4NH,#DB$7W?X(_V7&\92,F!L*//5,.#6+P<XB4QX]$_X$U<M!PD$7'@,Q
MB L3R_@7'@Y_$=?+T1UN, !#SAS@$>.CAK\6)O]G+-Q?"X3_R<(]\S#___L+
MEVI]VA$?>?7SCIO]Q#N867H<Q/!(2(,%78@/RM%@2("(&*^@> G.PS<8]!'[
MBU][>!KS&>JGHXU! V=)P+ )"2-V'Z2.0EBH>E0Y!BP"U<SJ902O@C%@8"!,
M6#04<"1R1* O_"*HIXB>1U-IB)(CG$/Y@_-AP_.42C!>W:5'DM!?3W$"Q)\5
MRZ&Q,HD$0Z;7&&:JZ46$U2]I9%(8; Z+_8C0_4+"2 #!<S2( PP_HJMI><90
MGAGT"Z94_9KKBUY!X8'P/Q5%1 $\J_K5J^I7X'*>>*6J>N!/];V:703Z$5\B
M!? DZ\/V/V-V0#G/2:UI?35C]11SJF_IE"<Y:YI?SAE-O1VGQPD#AG/(9$HF
MF4Q^Q/]TY\M!JM]O"X81''IDV,\V_\F4";=.J5RJZTM<F1H1KUOZXR_*IS3Q
MB/C_=$IY@3&DWJ+[OVX-SXO]_\4<I$^:@_0?,(=4Z],AXX_X\VR$>11Y-#X0
MKQ'RHO#SBNHSAY^H]N)7FV6.$JS.S>"?TEFAZM<U_Y2LYLW,OYFE7SK)1QK0
MQT#<X19CP4CH;^K@[[\%F 57BZE94T%J Y&>$I]>(S^U 7^"Z-4X-?9.?I+I
MI1Y00\*O?A46?"[3_/E\_Z.)/S.(<,U\:V9G=A,.\W#X3S3_.88_Z(1RJE_)
M?<A<\_W/V:I?A\[1Z-1\H5[_D!-_B<*>X700QIY#KHX7-2'C<=M?&&O*!9[E
M?M3\YP")&M]XEO]AZY^SVZM]YEGN5./+E_EECOB8XA\UA(=^_:\AO!+@'S$$
M"OD?-847A=TG.O\D[/RS9<TSL5.,@8GP?R>B4O[?C:C\[N1T)?&Q$A]Y=\H?
MB_RO4[T,X/\7IWIE??22$B@[1+!HL* SXH"PAZ<.&H$HW8?8,1!+I%.8F616
M-O 45=TGQ0F>^;,4J5:=0)13EY#]Z ^FO5+-_]CUKY!_A?PKY%\A_PKY5\B_
M0OY'":G[^$^N0@%G]W:Q=CUR'AQ*XZ>]]A]>U2#_*<9K#WY,:U#[M;&O]WWC
MM09IKS=X[8T&KSU8G]8F[;6TUU]_@^A/>W2]7>NMVJ^]7N?--^H2_;W?)QI>
M3WO]S;??K?U6K;IOUDI+>_V--]]Z^[5:M1M\T.1#8\-&C2GC=C=MQF!RT4C>
M-XM+=NVKTX[*TIKBI33PT_$+VW>@\_A#ONXHTNG-=@?VV?I.8N>ZC\:,G;9H
MYW$"OG7UR-*JY?\A_K77WWK[C3=KU:Y#=/<D1OK:ZZ^_7>O-6F^^5:OVV^]4
M=Q/B&[S]P8<4[=>UN"#ZZ;2=#:D+US1JW*0=]L-O36D\7>WV]N-7.]+UX<\&
MC^GP$8/OP(<L8AJ<8Q>O$QHC@S[_(F_<](*U#PZFU7N#D-S@C09I/=+NGYO-
M:'%C<I)S_>S%S'/]LGZ;?7O7[JH![U[(&_K[4(Z2>D.O&'RWPC$U,W':=X9S
M3:9DCKW6JWXK^T3E?-;ZKV^^-_,(^_>+H^?5N[!E])@;C%EMV@1W1QXUOKVB
M]'> ^V_;OVW_MOW;]F_;_^"VP7WF:+[:J>Q5OG =M/MKY1M3RUL7;VO/B$\;
MNK-W1#H*EGQ[[I-29E;VPBG6[;3O-RTMN1F--L_7]6S:-X@PIMW9-?3VE'O3
M?W,-N/[;[?::6^;1&\9<'?M?1$IK)#3CLSA+;\U8^.U\YKR-YX8=_6%19++T
M<$[77Z-K_;G115^@MT>Z\YM_^'71-P> O([44ZQOC7PZE2/8,W=,O_"UCW+O
M=*?]/@YOVV3NZ+X5N6U.]4$,>WIQ)P:_']\1ZL4>^YFTR\A!8,7XT@79]G=_
MSK@VR#1Q8F?'Y"[)W<O:7QAFSZV_>R+4"_/#2[KM&Z7.Y+ F!*[!RV[VR!AY
M^LZ^C#+%RDY#8?WFT)W.T*P/>\Z^VJ-MA^O6;AU^F-]Q>N^;VNWK9O%[V3JW
M.3#Q@Z;O#FQ+8N5O[*9EU]G[]NR6#:V]ZZS;NK0R>&;L]2TKEET^L'I+,7Q\
MTR3[A^K3P9$/TK:TS!U^^*KA?I,C2T;/\)19M_D6*#> :YAYZW5S%HR=UWK0
M^HKHVB]'8>>F[?VOK1^=ZG-LS(@CY86;NQOO[REHW=JVX]U9Z*AR_;+5WXU;
MV<+(Z#V84\0V[1N.CMMUYX=-LRIFUCNWG1:>./K8T?$]"BL!?Q'S-BS>TWGG
MVANY#8(?K"Q;NL_&#0<[[RQ=B'N^WUWPN;AJ<R"$!RYW*4)E1;4K"CKG1M9<
M:8)G4B(-6T^2<W<+!K$LGY7MGGHC+Z$O^6YGV4STF]QC6IZ-XVPUO;)=[X6U
MQ7-;=3RIW"_M4,68NO7&\+2RG8=Y)G,FX\./[_3L^:5OY(:RO(+FYT\?X<QL
MVB+OU*01N_;D'3O.&3#_[(Y"7]O"2RT*1A_7S/+;)JNGG=CO]YTRO[<>5#7N
M<NA.;\O:$Y]/TS7VST,*9^_,[U_X\;Z1MD9+O@]U^OG'M'_T(HV<?+DE,&YG
MU=BKI<'^O]#MN1,&;OIV6-N5[*E#KQP$WIRZXFY.[05/&&X+N-=WVY5HXPW7
M=H5,M8>Y=N]MT6=L[\49K6;[.A[>.ZUR1>]UF\Z?Z4[?UF!2/ZG&>K5YP<>1
M486\^9.6]G;>G/+3J97PU6T-1WM_[[CTZ_]:>7S[G1)ZWSK9=!O884[SG4CZ
M+G?/>D/0.L<81R>L.'=^8DFGWSGO_^"Z]:%[6 FM@WW8E ]6;%86S_Q)?Y]4
M[_R%#J<Z[ILB'^+OOG(+/.!BY=BN%6K&^)ZY2WP#BR==2S0\.&3V?J9[^UON
M2MF*P9$!34=MSD5D'/6T>BN'#/Z^4TD&QBSX*#",:8K5\;88OW?4B06G5O1V
M=39%^6OW]UXTU.1:=:MR_([;8P\=&=^'<[EYC[(#J^<$>E*WS'J0%MWV_0VZ
M<^>Q":<RC\6XOHP]<^=GG.[E[=:]PM]XJ6[/_L5]VU.4TK7*?4N+&O49JBF;
M;9^WC54DC5ZOPPQ5"@N^;?+6^IE]*OJ>TWYZHU/X,_?1,;:C]JOEG4WS_=VL
MY1'Z@(K&YWKN6K%J^H.T^:7K/(9Q6V?]7+)O^?;R$Y-7="QNMO%T%O=>G0=I
M0?.M+$>!N7(Y)0;%>.._*L?;_E#A/&<H-EH8XU8NZ5Z;=S3O\CQL<7'+Y8S+
MORPNZFPZM(VT]M+KHVV0\'C!B.(SO,%#K147S_ZTK&(LLK$TN>QH=^LITZ49
MIH7@EG%[LN:9OM*_TR40YRSZN?R='6!_VMG Y".JZ,T;^I;K"Z?/.2A;U>D+
M1][N=F-&]LM<\B'RY<'O-S@+3.431ZE=R)1+/<Y>+>S=ZOAB\MVFTN7\G;YV
M@V9U<^MG3B]=]?8I6\$L75&WV56T7'^XR[@.ISCE]PMG'-RN!N.Y[U[UK5O2
M?D1E1>^V.S=<^.+=7-JN4Z=_*R_<X0TD=L#RC\>U2ES_[.2B9A=76]UW'Z0E
M"K A ZOFT1+JS"N%.U=NV6BYF;,5'RV^>ZBHF7D+MN%&V[>6[QBR:.U\<O:=
M2(1VD;T5:+/3<I:Y/[O3D8:=SL[*F!/=UOC$[0=I&VR I[>U(/_D_=GLVYGA
M_&M,SB=J9/HXYN9=;9<$9T^^WS;2^/!,T-OI)-WHK;BWZJ>3O5N?^+IWY,9
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MO1J4ZI/@;:V*<5;4(PAQ? J;EOAIQ35\K"9E2-O) Q<=/NZ0SS&?>?NB+):
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M\DGV&K9$_,:STUR;@Q =F!%RQQK#''.E!LM\!/OP:_<G,LY0T;$O5,^8]OW
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MK+!!E.S#_D=E0+HIDJ:OS\<"Q+IR.5'C3$,W>XW\:-7OVZ9TAS\!4FU6D0D
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MK9E#/P".XQP5:E8MV/6[E3?<= >&TSQV@4%R5*8VH_D!'$"+'LW'=HKSIG#
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MZ?C X!VNVWPQ(>?YSVBQ[&J50.=PA]B!QX\:?-(WW^.:/=/+%U!!8VV\TJE
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MV]EQI=SQ#2)S824_B0T4^G+ZQ6,QPS8:0E([[%_5 2(7E%.@&DHQ!C/*@ U
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M#N5+FX3X#/+K SP\=0RSP]88);7_91K_Z&++6@[5ZRB3"7@W4#^GJ#3C&<!
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M\ZNQ_K!0=^WD;"%C8%PA1&3Z7GVCWLBO+LA MKYE$T%H*Y5_ -;XS9QRH;E
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M0S9'W]O.:N:4)(U I6?LR^[46G;>RTV7HXFI4/<VV,>+'WO:6STP/F$WJ :
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M5X %,Z*D!U N7G.3)]40&#31Z+I>S1WGC,+@ZH2/W9S3PM&B+*F-YY,0[%P
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M=,48%/:^FO4%,)I,3HCBF[=2$OC0\_LRV4F$"VC08W_ )U3&;70<U.V]KWX
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M!,%.I88IQ]06)T-*\\7Y0L+)96%V%<:F<V%54"E#^ Q1 M,F6:RD15MK=JU
M@FI&DX94-!&$+%R:4"AS29P^CM0EE)NM9H=$FHAX<)639PJ'Q<PPCZK7ZI^C
MWY(,9:)?H/%R@5":72O0H$+35&1Y,:K6RC%-PA6'P[\G5!X-D$RFU$8))F;
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M4B-BNS%MY,OB*HG)$@\H'3:^7A 1Q.4 C%M""IPG<?A@D\&48'%Y!"OSW :
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M&KV%6_*71&@&0-_;7"2558:96QF@!2A[!S4^7-KUYQE?:=G<4U1O:;[/,S*
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M#O/S/>1TC>-L7DV<<5TM&ORF0--L]&T9&:+D+A>M6,(A>S!S8YT]3;]VN$K
MU+X36FA*ZF,O9M0^GRCCD%'R4?,H+NPS=A4WBX7TO$Z -TQ3 U;2(C6J<CI?
M@,?ND8DD;]:-)UH?%XPPX'?#7MH>K@0 ]@EZ1$,\JC3A:S#::J;_3^@O$3I
M.> /N)RM90Q3?@W)&I\DTB*52;:\]"XC4)[LSSVN;LF9YCW!&U4X#G$8GV'S
M.-F]FE34@BRC*%89@\GTUWO0'?UCJ(,T;,Z_@%_# M@.^@K\?.![2=E0S4'<
MT\2D[!=J23PO[#0UP[N(.>)<EV/Q7[C/P_2TYY^X;RN-&]:63/.!Q/SZ_RL2
M_1/Q9V)I]^1P5;]!Q%CS\RO;#[M@(OD]9F8Q%1CAM\(Q!/;@P9P/#6;T&[4,
M=^,KJ!&K4A_=F-G+?"1&6"76AC#I1?;[]<O49ID6+F\JS?VD0_/&BXV^D+BE
MPYJA.5,JA5^HE'__/(OFK!Z$W?[Q!;HR[F_]1@*)-D.4Y.+QO>W;"76RY>"M
MD!*H)!ZT%],3T92\K #U6&PX;E:\Y>^U8W85A4+IGN:7+[53M5=8^7(R]*V3
M?8)^H#(O[.^QE]A_)U_F,JM@!9P1"'=WU%O'Y\$ZC#)BLBC11J[PA^/5'M^+
MX54V)X9SS'VD9 7N2.7MH(<\>P:R?%S65IH41=<) PO'-'U56&^Z@XV9/M0'
MHC:O9JKR=SMY9X<,WI\UL25%1M;VZ@*FI@M&QC?U/V$Z'_1,=XCVA45I!,94
MX+EKO9_H47V/X6;+MQN\+>2I0MMS9Z9F/E6]Z7LU6[I^YK*!QKT3I;<>FSQ)
M"8<CXP?8NX]K/H_5J,P$8$0>RL<+:8>$0"_HODVBR&!US&7>"NZ_AN7)R"35
M3"?6-! (.0,I0;$K7XKW_:=H'-5.CZE(>_:6,%TGQZ"_#0'2O[6<7.6(][%K
M3<*O/5OS?MO;OE=CS!<;TM^QR;L8T(YV4EBP9R9>!\MPDU,WO=X;AIB@DYKO
M"'A*4]LN?0+9T?B_H6S;_UW0^V8LB4%PE?A()ZJMRVW"3;XP/M7I!51T]CE^
M_<Y'LM%P;UT(WVW)><.0O#Y^C;C4.QWSL[-;(7!(W3TGA!-4)Z2]L?VI4;9%
MM$F-(1J<]+(G$PSZ<=I>QS71EGF!>]CA_.DHQMDHTY<)IE>FYEJD6<7Z^PQ2
M-C#SI70_XYOX1'MF-'."M@3P1J<;]F75JT]<.H0JLJ%3_QA_4*7%@C9K6E9"
MF1W!I=Z)_EK?B!5>)/X:T2$[G57GR=^H:> G0WY2B:5XQ9!1HB,PH<BGG &[
M?<GFLLR*Q\;K,1&1FY+O8NPH%I3B7UU=A[8*-5TK4P+!67%X#;U)-ORI,+%J
MKGH2J3NS=EJR&PZ<!-_[^;S/1^)#%0'LI-N&+APLR=FRALU/V"FE&8I[18]7
M67_37O-?9 Z^8?5/,L?S_)]DCH=[8)#BYW!@7C0,)=<Q'<JMR_1[P+P-U\S
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M.)VI6#?D1NTTS$_<(G<Z2:ZFHQ2;QZ>QPB)QJ/F#UK89,*(G=1["_D,?Z#&
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M6N'+=E-%W#63C0EPS?"HFAF(&A&YSC9I5YT_3IX,0)X+964CU+9F$4]R1;S
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MK33-KV:2O'WO=H*[D\L*R&L2]WBE%HAL?A^.'Q)/&8!4="K:"5ID.6J!AX;
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M>F+:PLJ46%])@/EI%HU6E@)-\,;>L2YW%?2%-:L 4I80&M^1]!]JE"4>RXB
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MB%"*$W5S7AR(%TL.N!^EN!;.H[PAS^ *==-OAER$6BF^G@</3#"AP(;)H-L
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M \XD9VXWB;YD:Y+3]92AU99L'[Q?@WF%VUEP0(.(Q4@RDKP"FF>:?S8 @^N
M=:R&\HP8$];9(?R5+_! /U6\VPBVJ8 ?%#.AG_ :_WNG(L4G HFY#!)N[6(
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MR)G']Q>_!GCVGG+9=O_R[K!]G?C*#839FKYVT"M:K3K'".LNZX:PO#NMJBW
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MOQ:7\"@7MZR[46,M1M+3=(&47Y\QY?%\=\O&[5/14%* 7W+<33-WL\=D:-+
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M "R5;Y_O?2P_\_2-9C@Z TG^]/Y;" H8G=:?J?MK^X5W)'<D_P\%?K8_E@N
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M-DFQ?S8G_AM#]G-AA,A)R,I!I/Z-0Z9N)O6_>\2@GAY'C\[_"Z.&P7'$W/K
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M0>3OV/^AT]^XIAI:2H28LOCQ[//OIO^_OYV G("<@)R G("<@)R G("<@)R
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M.VK-8'INGV 1+^5AO!0=QN3%A,T"K:\ $(,OZ+SUY:'4,LFFU%*9<\XT5XM
MJ6USM_TVG[1<KIOG]4M_BO@\=B_;W08&W?7<[T42*<5'Z(WSN$ZUYM/%"D(G
MK[%H'L:&)U\ \^;SAE2V\[$E[/2I;3?6[]UQ^Q@R((WN.F=>=U!3I5%$S=&C
MRO5)83&N)A;MU&5UJ+F7PV!+%MGZ!,@Q(-=-!QR-TDI2:ZJQY'AQ3;_QTIJ
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MDS"S.EX=^/!?7V"LF+\"C"K;$AG&I3I(4]Z\C[C,\D5HT%JW!FT:<^$6"Z$
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MO.H<V>S3*4X!!@$WG*NB?'V61CE,JSGK2G;09P(R3E8AI4;I#JNU4WF0915
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M7:)T(BR&N6^Z%?-P;&Q%R^#@69V"MHN^"L-%QQ)#1TD<Y'_1_Z)<1ZGK44_
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M\"C"0P32);?Y;/\4ZXN4^FS"UB,>[1P'?+:T315OWGRM?P(Z7$M5ZMT.)PA
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MI$7U"\Q<-Z -=3_]Q+5!&,E"S-((/D9]YW=2G<QY_ !8/MTW3WJ)L5RHPWX
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MEW0FR;D^D]$@!^'#STN"%L_$9XV+66C+-P9_4UOU-V=*5(\<?H;;VP@W0$V
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M4Q$!@@P18G+4A\C?=>9'KO"P3$1#B69G"IU8"YR7NK5RI2I:\3Q%/OLSX,0
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M2]7;Z&')NNX>D41,693A%WDRCA5 >!R"TJNRHYW!YY]&;8,">2DWY^4ZMIX
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MK2]?@&!/]9MHAD$9<5Q4]W-%*MX@>8Y8!/;J<'I,JW@H5=TQMB1/'',AJ>R
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MQ- QINSOAE9,R.V6@ V3O<L-I[_DCA,P7I_ N2'F=X]P<@KNSFCJ\O5&?'A
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MRC$%_FS19NI(2X3XHCX/U_Y!$;F,6Q_>! UEI*P2; S&GL)NAH<'C/XAD%6
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MJHI4<1'5;^O\&692_-;W.+P\41A*NA1)PFOO*$U<>8-VJ[O#<]79W'R_^XB
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M(E=]+^L\?X8N:O='O?K&!K[H2,N>2U9Z=-55CKZ;UT_.^*=FGX4FVL>2\HQ
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MO;=4MC@R28QL,:R(/&Y7C#46D9\;-&GIH(W&B0MNTT>1 33X^7876.<&?LO
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M[$JX%@/VI\07;&7 S-S$>#87Z7RCM;=2[DY_IC'5J/TJ"$D0RDF#Z;H'D.5
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M(P8@ G2_,%;^;VL"_-\4IA0+:U5Z)1543=1%RTXFZH]"D<4%>&+UT1*%,.4
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M^8"IP4;C_HSKZPG";.X4'U  QR^CJAYQ#YJN8(A?'VKSYKP2(4TF4@E0E .
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M9X&##HT;!/IJXFA._:Y?P>CZ:V&8\00X;M_/K>Y OO:6+&2I\292&0*[X/\
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M+%\X5G[^HQZ,STFYA'3DGN&>'[U*BF<5!V@JYHFO<7$L\CAR:=+/LY;748+
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MG]?@OY(QT*9BP+@SR1',T8AW6M@YBE>!*'[ZS\7$5GRW2E^4:YQUD=P3N)6
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MJB@IQ\T_J)+5JKJ88)74P$ +JN/O7L0=ZYN1PY%Q+&@/N2/?N&I^\>M7Z<!
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M!]E<,%UEX020BO+79:ZOGJ%W!6GN(;P8E@N.Q>8HQX [@<[&0(;J%VQ 9.!
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M?9]&6JQ<0;3&P+)B2 V/^L:N3B?>H-*N46K;:*[WV4:"?V(9)#XG91H\TO=
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M=LH>XHATK%PEB"C<'RB+%D=)";37&L9J=.H=G7MDF?K:'5>(.;O[: Y<JU-
M /%O9?2L3GFV*V*G^2IS9W71[PJ'3KQ=1GA:F$I3"'=I5G1&42S6M65CZVLG
M,P8!9;H\[/6>17"#[V$U5?CH6I2H* F' D<?!7:YJTBP&+GMHDOF,CJL?/S0
M0MBK;RG\&N+A80^L>WJLHK32SKPLM: ";?9?JT%%2VY/K'X_]R0@3[<?+G%
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MM1KF\"P&&KL;5W* A29,U4B8M (:74<)5#%EK=YL$K Y2:"%L1D?82HV#?/
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M[FJHR$EYN=*Z;F-.QX2J@>T"L(9$RZZ&5 0B8;\;IZ425*X;U;/#HJ(N(.C
M2=Q)2!$.M9J#F2H#^S4JP2 ,YW&2":AL8=-X*S@D/!R0<SOKF8Q Y^+.K*BB
M!";Q28[)01$+5H-AQ6(-N[22GM$S27<EE>%A2:^6;5(")A4?9/#39,V6S17Y
MUOWE2B2@J5B%3Q ^BN>SH%4Q5;/)<#I<YMP91\2BIXLF%>',4--7*Y!$' ]G
M2G&AC.D"'V9BMGB:0!M=]P*C4+.5]6S!- X!C70F&"*@ I*OZZVDO;=\;131
M$*')J(RG-U\SI:SQ+77*EFQH4B+F>KQ%3?$<Y\DDLH&*RK YE&I&126N)K1B
MVE5,F43(D[1D_+6TW2AT:V:E2(@RZT6:I5;XHH@2T0B7+18<36I<%&75IL=G
M+?.J"\S6JDFTR%:++)J-IZK.ABMBK34-NU-Q*;+S]?ZNR_>M>!B*:%$FK(AH
MJ8A'W&57,T^;0(1T S#M"HI2T)-NN$@HU11K.1%3Z6:CV6S0#;TABFFYF,*I
MID<E$!1*N1VMI[3((IS)4DDTR81@D:=THL#Q(:BA5M1HUI,QB\:"N\R%2 :"
MZ4)#;L!<536S(5NC&B*K.UR0R$1;Z*LKIV:9=)H0O8A1=!121+F1A:HXZDZC
M"J98DJB8R^MZS$ S5!"B("U/QHNA(DW:I50I&5=,R;"C$(C6[-9TZQ(!&K3A
M'."3:D50Y2)@ @VQK Y"=;:1M.EU/VG.2*&"I)=0,2EF*2TFECB+#TNI0HD!
MC H(*Y.6?(8QZL)LMB70ZDX5=1BM%1T!V+#:BB-0(+WF%!I,V;S6=$SSI*RQ
M>%2OFJ)),>&!!)TN2:5&K5YOU!H.*@$'J7(H:&1TK[O2*AY+!"@2T9)1:O*Z
MG8Q'##@00**X!X.S9D6W-C 1,G(G#XF)M$*[S)6R:FVDX;BOZ.-4-)$Q4[9(
MSFU$6ME HRW N162HB%=E+R6NK5FAC6@D@:@=)95+.%22%<5O, TF2PG)! C
M!:LV7ZE0%.QT%,+(HM=/RA;#\!TM.W1@@.'[L-G-F23#&\1:E3"11KC*&-X0
MSL  DJM&5 ")6XTJ)KX+3;D*(D##G)0!F\/?&J%>CSL;2$RWECR2/1@Q"PF'
MF4\DJ 0A*$F+'I(35:Q9<,<LFZT70P!)1I.9:#4<LI)J7<M@$JI3=I)LM&X4
MI@WH6*I;>+N'\RLL(*3J2![RJ'4L5/4I7?<\@TU-RC,56$Z"LI<.DRFG5%>T
M&$ FP[R@$?F,Q0DWJKJ3YOVMZX>"%[++*HLX&,)75;R1+*?L=(_5^,H#*,AS
MQ:I5-XJ)O+^A9\*FN-6GPCP;M]&H/YD% J:6V62:!MYB?>9FD_!#E7(SP;M"
M42QGBJ-$*&O$/(U2PZHGFZ@FO(S;$8F:,AZA@*(24R;,K(.ODDHM98K$.2^(
MM<J*4BD?MSD**5O&EFY8*PFL*QYY?4%3UBBKH"+%9'G:SR49NM:HD2R8)DI<
MU<59"@J6<0:IH VQ&/XE1/WY")?;?'.A"M@\(=*4=V<-S[7&$PJ ^PSTZN2*
MO+/IS)@1,8A&@'H0@$LZ"5A(P)31C!Z'*8Q2)@H"0KJ!L)5RC,]O\64B"TA6
M;PZK50M\K%JL[(F9KF(4@)?*L:RIN".+"$C!A-^Z6:"M:I%3L*EHR:6M)5#.
M"<YHS!NAPF)"17E_@X^$*;O&PG*L&<)810B50Q2AI6DQ*$5VNKW9NNF_8Y L
M('*Y4<B8F+"CJ"5\A8H90$0Q0N)"S%E%S#J8L9K@M$>$['6ZJD*,!OOH HW*
MD*-6;=DA44V7 YC >"PZ'*#J8<CN-?$P%W:DBD&O'P25HD? :2!(8W#*R@2\
M)!%RB;Z8C0(A>P$O.M,I-)OB)),Q4[95WO(ZZ#:5O W62EO*)@\-Q[T4Z3;2
MK5*SQ\5P-,K5HJ0D^K@<LA7(&# ^(*M"N2%CC6R3R>F*RGFQS4^S.!*6E#LH
M 06B5G<JI*MFJ0(B5Y5!&"Z =J(D-ZRR _*4R@P1-C<SM:0;8NNUJ,^(F:$:
M%0ES<%H*V^S6(MJZ TY%[6F.M5%),&]*>HM&QJHJ"I4H,#(7*U;3]HJ-Q*4P
M;?8G+732R 22BB62N(N5,^808?<VTVG)AVS>@1;ZZMZ+C!_@=*Q@*N]R)YJ1
M81IKFC3SSC>OC:^\C.:S8CUE8C)92]W6VF5=3^43Q7B-Q$(Y+^EG,B#FA#SI
M2A'*USV%JKN.F6RT5S)E]128C.'>JMQ57\*Z52)*9<X1:09J<)HVTEBNWJKU
M?$UW/9R'8F:/7U$1- Z$,LT@FC'7$QH "74[HJD6W4-X<UG=#V@T#3<*A&).
M1[)$-<,F%-&)$#'. Q!$H\YM1K 6V1E6P0KB+_&Z&ZA13MDP ;]4;G 2[06M
ME8PS01)$6G2732FB**% !6?TN!U K#Y?U43+SE B46P43*[6$^&U9HV(A1%"
M!AKQC+7!0$PH$ >X1CD(-#+!5!VLQ(":2$MY)%_@M:R<12D-2F?LZ:XJ#^8=
M4B D(WS4GL<=WM;]9=D+IXO&"$IRV><4*U@=@P"I@$I8K817P)S&$9D4K%>H
M2!0P:UDKG0VF>#A#V!4EA9O2;#!82E-8KEZ@]9:G5'&JZK,&:CD>K:@T%?';
M8S*"YR)H)!WK>GI RH%U(>W)X1@0E#&MG&D@GJ ),",>G0K2Q3"8LUO*7D,5
M++7JE%R&X^SE,,-*-9-L19A4..++R%*S&;(W=HK;<4W&8:1!6+2='YV)E[)I
MHMDJP"U-8>?':KJ_Q$J53^!NR *:2A:5*;.D4+47-(L+!]FL2S4E$F8-U-(5
M?XJN=STCX,^&6G? 4:.8MC6;C)TS2KF,F$F8?071AMD,A)\W<!&J:P13I/50
MS!RA2:_)527T&&;LMQY(%6+A2"7(D4"EKC123:R%OMPQ O2&\T["D?7E*L&@
M.T"$_$FQG+"Z8S6PV<#+E5+$#5IJ<D7(PHH93I,8K-:]H!Q T11I4G(ALQFE
M4+L,M*I1!"N$F8J<2"904/-%RE'2135=O)M,A+-RO"I*=LE*"]T/Y!2,C )E
MB(2Q.P9ZR09UW>(1X4;=G3?A4L:LMI"#"D10A&A8>)@IA&6Y&&X$Y13&IISI
M,*9FO'MYY&G7IYU:26J/CSQM^\J5"V384Z$2E: #D5+68H/TH4065[S^0M#'
M"@F_X 29?.MVL#=J=B:<=)GQX8SJ]*A8I.9QH6E9HA0A@GK3B<9NJL0]/#[1
MJI>W=,< A,<CR1BD-BR0 8R06A8U2H6:*5 Q.8&@D1V]FQL!FZW5:', IJV-
M3G,KT5O-!%8%\D9^Q[RF)+"5WQ;Q_FZAK31J2/YW"6U%F\W#W:O0.AZ1@(#,
M5X/N.+UYKP @O>UI[=:CV+L\@?X[CC+L_A'W?^=1AE!H[V<2)&FWYQDTG>2S
M>^?4NIZL![8\6&^0#]^](%=5_SV"7%5>UH?O?$@B%.KPR9K.R"SO<W8:#6,$
M@>L ';@3M5D=D!-SNYP0A*,0Y@(=(.ZR&S_8'=T+O"/K+F*=FT_B;!;+_0ZQ
MV['N(C92%G*"S(C;T50JAFS4"8,8#IMQQ.YVV@W9D-F&H3CH1" 4Q!S8%MF[
MX=]%!\G+G-!E!PZ1T;3.S>>+MTC8J7?7B?-EH<IS[K(B_8.G)<9U6T6'L)N-
ML/_6BNW"NCO)W&[VXA^4S.UNG;9)5O[I[=@C_^[4E/>P([OMW2D0[+@EN^Z7
M5]!TI=S8S3D8BB_]>\[!=#MK!\-VQQR-,8;2-?3MVO;,M!NCX!@VPV+6S&@K
M@F9'6U S/SICAM'1&9PU\Q#&H+ 9W2)_3X:Q@XY:GI>[CB7!HR%H-&RA0;C#
M;.X D2W'DK:CVK,03<GJ-:;,VW+&-N[F?%+7P=OM#RCMCFO/TMD\(^=XKA/8
MPKBEX1_+$O\=&_?;\>^?V+0]G27[MVS:3H?*_J-[UFK=T0>W./1./OMO2^S"
MMKGO/K=N1] ZL[C]X+;K[*!TIJQ75**L9 61[R3*@FS$J[U0[$'.YC-\5"6S
M^W-_.\K<B?I_ ??0Q&\<QM0!-;<'Z.,4I'\$L1ADO-QU!EK; _)QR_\0\G$K
M78!G#X=*?^M$Z<Y R9AWAY?1XH(F9$0^4N7+:M>6=M+E"M]ME7LBV)L8H]B0
M-2,8\3+;Z'0SHK8[43L0[2HM3!A@6>N$MG)N;MB5,L34N[HHH<G_X\#$V(R.
M6B=B&0-;K"AB[7+E5M/N"/.=D'4,"J&8!=]"F-\M8446]$Y"8!EM"UUWRTZ.
MOM.@=S.EKBW>W0E6.Y/[=R4 P]@ZN@ZW=[UHH'/;H?6N<>_0M7=N-R,)8J/%
MOSWKYO;?8F;YSIV5=C?NG:]K@IU=7^W0]IS=S7OFK+9>0$#IAOGF.D'0\ <0
MW,*_8^>>A72]/T#1!)W?8M8[-__&C(V(V%IPG_U4XP..(=SVL>W;_1;:82VV
MD/]OHX'=&$/WBPK^X]:PB];_7\R!W,$<R'^'.;1:=PP96^//SA%F2^0A1$;O
M5K*[\+.7PJ'3T>C:N+V;96>(Z<)6S&_2I?BN5V+\)EGWRRU^)\K:XR2WK !5
M8W0V[RDK%?5WKL'O?XE 1ZY+3?>>.ENU7WM+?7NW_M:EH^V(]BZGV^+![9GV
MZ /=)(ZNUXTPNV2:WY[OOS3QG0:A=<^W>W:[OLQD\URVH_EM@5UODNDDR(C#
M15&;^?4]+,/.G%VX!@+!KDC0'0RVM?XVLZ1PQ@Q"J<!FMN[??YN--=RF$X/'
M("B,X=AFWN[&?T!ERYLZ870,B&-&"-NB>G/[;TMH=/M9)V(> T%6"XAL%K"Y
M^;?Y,UT.V F-,9C1K0O6:MRSS>S)J[=1_%NMRC"CK4/[78;4O8,>TI;Z?3OZ
MS]M?KLPTC,U$MWHPL]N<N9GE/[Z,Z#^UBO\'W7$GC;_3&W?B_MW.N!/_[_1%
M="?V_SIGA/^PHKUJ_*^P(@@?@W=]L/].*]KEU63_GYC43HGV]\,$,P["_[Q-
MX=@8,P*90?,_9U3_[9'I_Q!( /\K(<(N;P3\_\0MK98QH!4S_[-^B2)CK#!J
MWAIL_\.Q_M_JEKLKN[?K_(VR\Y\HY7=7K?_;[@NHW!Z>:3 Z &@,LN/5=*.Q
M@R@K7(7ERYMO:!!.=[LH9,I,N=']TE/K.& 'JKT.N-5*.MV=_8WI;GD_^U[W
M]=_V^4/)'TK^4/*'DC^4_*'D#R7_54KZ;_L?7GB9&S^L-NRDSDUKVQQM/?[%
M3Y>0?U5&CTU+VP;LT^.0GB?UZC&@K>> 'KT&]-CT5-N?VGJT]>C33="V^;-/
MG[[]]NW?JW?/'OL9!!,.;FOKV[-'CUY]>Q]T0)^^??JT]>C9JW>?OFW]]AFP
M[R&''3KPF/@5KP["HI4CCAS6]7_,V+3:95?=>]_]_0\?CB=3>O7*>Q8]\/JQ
ML)U9/0(AJ=*9Q]/9LVZT9LHS+C>$#S6T]NC=:YON-D-ZWW[[& KV[6_T<P/:
M>O3JU:-WGSZ]]Q_2LT_O7L9HN[0/.*;O(5"TWZ&VTF4#8>;,N_<95KYQT.'#
M$0NIZ5?>]_A7AQTQPHQ:[10=BR<SE>J,F5?,O>?>1?>O6+GJU=?>W_>L8QWL
MY5\?YYPZ[03^KYO>;-N_ER%U0*\!;2>U;?APGZN=3QPW #Q_VI\/?/29TM_[
M/.86A]UWPZT;KSCFF)GDP[VUZT:-6X=_,/PE;?:R =!%[)&+S[^(&7#H$<ZN
M3_-]LFWI*^J0,V.GCXQO+/1:\_4[7YZ-#3YW2J1_[)'TE._'U1YF0/R@MNL&
MWM9<U..+^H;J$Z>5A_88MY5XVM*/QO6LDW=\]FJ_NS]\9.V^9SY7[_W5O FO
M+3B(?7;2_8?VNO2K?=_W/W ;,?39Z3^(Q_4[YKU#G[A"B=\P_I(AZ]<$#W0L
M/?[L4>_<<?*DH6/?ONOJ/]3^H?;_KMI1HZ<O.D7J<\+[2WJ/VF_NLMB U!'S
M1YXX8UH;-#!D;Z<N_1ALF_DQ>,3<MO9VC#CY\5?4\6>>BL6Z'3<XC#ETJQ<'
MAWU5^1ZY9.GHGQ!F4.=CWY]SZ-_.>_?5RYXXYZLA3ZZY]>_D-KH=F/[U7P;U
M7/4#COS:XR_KWW<L'OKA%[%?1NZ&WO7>YU_D_C1EPG?9)T9-_LN7^Q^_;,!C
MMPP_^X#WQIY[=^RK>?^01M-Q7]ZS\9E%F4,F';:IS7^CYXC],R<]^.9IGQ]P
M8)]-;9.>7SSK].>/[=UOQ2OG@N?]U-9Q27 #\>;Z!+Y_?.WDRA/19SI&^3Z[
M;NS:WN4![YP\L3#KA0[+AM=>H\A[IV]T?FU_]\C!*[Y>,*'R)?'>G"&N:SO>
MN;MZ_(*-GZR\XI0')E#)P.L+A@,']/[@47GND+8(:+]VP3Y'.!:<O<&QPOUN
MXIP'K]Q7^&OUX8VOF77^L?Y'WGHT,7;:B&^_B'\97BLN@T97ELU8?$9VUE'G
M/[Y^!G;1\9O:2NY;_N>M=X:YC_CTR5=K%\_\>$#/$Y??0D[GU!Z?OC.(WR"^
M<VF_SV?V'>>Y^>>ET>_XER.O=*YY<2K*GW/UT&,V5F:,:][XP"/G&E+JWWQW
M%<,,ZY@T^ZT+3[N9C1SXQJA9Z_]R]1<;;Z^O>^!.]R!;WUDGB6.N>F?L-:.F
MQD[Z(332>O9!F]I>U58H#_[/+Y[''GWSJ(9EU+,''7KH04\])']J?_.@1^Y/
M#%BV\N15[PW>4/CIB.^_RP_:O\>Q\Q[H9=_XW86'#WRPE_[YQJ6WO?Q,VR61
M1]YI^_R3SW_XYIJ.MC<'?'O;V]>LV]067;3B\W?>;)Q>^BR&W/1SZMLO7_OR
M[P?>_)?[XR?>/>'+A]Z?]L;*$;=-?#+<Z[R>%R9/6'')P5[/YU<_22]*)?!>
M'P_7!CM6?;1T\I$?T=\=>?\K/3.560\,/CIRJFGP7\Y>2=XW](</5S[\RG>7
MW;N2O5UZXOIKKKQF>J]-;9G&]/&I[T8&G%\.?;_O4QW>I=_ 9P]]Z)&55^QW
MZST/?;+TQH?TP NGLD5I^1E?_>!X_L0;PXH]>Q(Q8)'I)W3M;?DQ"]YX>-K%
M1_[PZK"CKYSZP&$_%D[I)]_1^\!V0+ZJ>+]\^YF#WKEBVJ<77'[L,2^?^!I\
M<"0[;>H:_]5J?-2O\]%]9SWUQ?CIQSQ7D4Q]CGOAS^A2O<=G4S_9^!9*=^QS
M$/V:]8:3S_@[?TTT%/69;KCUK()P[3I']-#WKWBL/W[4Z]/[G3=XT.,#[PX_
M/@)^UIR;^L$DCEFO[2ML')1</NBY_QY_&W2;OF05NJRQ\?Y-;<4[R<\'3-OP
MV'7WOGCWM ND5WM[74.?&_/V02<NF.F=6I[]XF)JKO>XN>>,]#S@LDTHWS)]
M^KL^:D)LY%/Z=W<]/V[Y,["SM&CYVW)YW8"'5MQVWE$+^\^:U<3FC*>_IIYX
MN2-UDUB:?O*#'^T_.X_,T-NNF+_05GWODX=&OO-$_H*9[_QMMO.%81,&7S:;
M7.!=T'-$GVM'_3AK]?EW^>Q7!\]L?W\6'EE<O?SX8WY^?];]M1MNVUCG?OCI
MN1,O'8RM<CT\454_2+]_]%I?7T^_RK>/W'S,5V>!=W_Y^DW72I;OJHM'+'X.
M[EBW@2*G+INW#'EQZANO/;42%2\,_GSMH@FS)EWLN7A3V^D;T;,GOW[ZO#L+
M\:GA8?M>OV!?^PNQ=R>^>NAQ[:[^\VX@K(XC+EZUX>I^:*KCN#47GL ^ZMKO
M#D=IUK5/_G+?XHNUC^;=_<K%E=[DN=7#!Y\XJ;1V\MS%AQ\TVAP=.XUN6S6E
M\_;];@W/&OSRU.=&G_Y2Z*4UW.# RR\^O]R_!%NP/LS\? O>SW_0ZV//O3,V
M\85U?WJ4CT&/K;OFD"/:YU]\UZHG!QY\%W.9X^AA%T^]/+ET]7W-MA[I>WPC
M[M1G//<C5WKQ^N&S?UC\K38[</Z&4=?,OG7:EOU<,O+: W]=>.Q^UCL7?O^F
M^?']'8>1-[)7W?%<)=B\_+;%M8M>!P<VOQLY_=A/AO4<TOOD9NS^M9.7#^_S
MS%G3'SUD'RA..:BA2R9_]-*D,XY=<_-MM_ZU?N6,^4VA;Z<0,5_Z6'CH3U;S
M+T5^UH3[QU[=?-!]T9??7O'K:Q-/ID+NP_\^<\++ ^[^R[NFL17U;OC<^E^6
M?+-TSJ7]AXV?,'OL#:?PDSXYE1USXX:_GC7W>?*+RXY]-/-9^=NECTZ_>>%Y
MX.1C\?DOKSIPU%</Z&?>-W#"'=<E%X(7]7QS\=*9U@>J<X<NM*\/7[OPF?J
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M$B\N/<)Z\*2:)TV:(/AI((R:_JS >TF+-#]I>65""B'Q!Z$L*EL,_4);X\"
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M ]#915F'KA_RN27TUBH"N9WJYXFIR2[:/5#[NA6P\9HJI@IHER3(\I3^G6%
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MT^($L$:**KM^F^)&>,X[G*(N?Z3)3+7P,B+7UHD_0\3K42071 MXNGLX5@A
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MZ)EK3X55;CV8=T @'",2J[C<L(IJ=N:+^E61=/)6@G8AV[(L3@5D314R(YH
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MH:Q@<6.UU4)NO!7!S<[9N>32(OM""5&#;<_\J5/($8WO*^O^X^#LH*:O&%K
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M_;!6\IEWVH_G6/.5<T_:A@;+@@V%L7*KKGA15]#UNR/&Y</!FH>F3(NCJRM
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MWA)$Z-D?G^D@@=/%BVP7(CXD5YTZ^11]<^^ <&D8YK&3.R\O\XN9/L2',PO
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M6)]T/<_@B#U^]?/J-MS^8-KN9Z$0#Y< 1/:>U+EV-MFC79G8X$LB5 1(?O;
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MW2KECI\NKQ5"[8&*5TG.P$AY[',N8X3S A!4ANNI<IJG5 3:!9*5+XQ*9A7
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MF;J_=$5(@\L67.I4->;5-+B=O$!F(9HWW^P8>00K>,;T.9QER,7*?U]6MK:
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M)OP@?OQ#]UO)J=25<< U2\OKU!R8XQNFXJ>W -#Y6$#_D,CS6\"3R==8Q;>
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M,N[Y8RPK61[W8Z13^9DGF(WWLYN3?3WB ]2=WQ,DNE.M=NOSS4P3?O'1(:J
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MS9;%#"0G<D<BF 2QTA^SNDY@M;="+UHY8,4<<Q0YS_5<_'/5SVU=W?!)./J
M>:6G0:J8'U4Z(LDFM]4Y:645Q#YPWK!A:)RDGYP*\7-<#O1 -ZELM<U](ZFX
MH+=.)Q/4BA\,7I+R:=*EZ0?U1#38SF#S'LM?%Y+9,'3A/<JN>JN$X=-(ZMN
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MM;!GP1150HL:D!&%_8X'ZNKAA?I6<D1*9,KX I?S<9'E7"*L+<GQ&2D>>@/
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MAD3G']R+O>QAGN\!N"C 0]>E@'V%+X:]M&I'4>P"R569NL9&5/=$6KXLY<D
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M.+M>?UJ=;:.IF<'/!!&KNM9:ZQRD))8B^;5B)M)?)?BAQLO&W_VRP;F1Y9J
MU\;MS$_4^0:>D/BJL[7.,[=Q\*OISUI+#FJA>G\^;]]-DA\1(4NG!YEEWK>
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M= "A]@.,O9SQ)2@I YR1G921:;-VC0/@ZN47H*\/:&7&C>X@XC]4P'J>SCY
MSVKIMGFZ *#]-T\W")@<"H[/3(I/MPF(GNBY=*+GM$7+%C="'^C81X0%Z._,
M<]\\X7.;\#T<]VLWG0G-)!.4G [>!0%G0L!:U6#<%I0-#HW)R$B=Z.&7#HZ/
M3X>D_=4>WWNG@L;UJ1-L:#)TO(=7,GB<^<>8\:# Z+3XW5OW[O[[8+^!(%!&
M1D)H/!B2N2OF<*S6; H$ 2 @0_M) &R 4" >  ,0(',"F9SY=^^_AO%*!:?_
MB<@T!I*<"DY.GQA2JQM/]/8.B-CQ.XT;Q_OKKOZ7&9O_TXQW98*3,]*SM5;+
MB7EE@M/_FH1VDC&@OY60Q.R ?WA Z=[_4-+!_U!VQJ1F_ZT$)H)S_E:VIJ7Z
M_*UH\_B/H;UB4Q+_).)W@$#(-B]O[4YOHAUG8Q.7 8GQR+@#_"7;0.G_8?-*
M_<]^7J"XW7O2P;Z+0U+!P#^)5VJ<S7^SAV2G@B?L0=!4C_UW/_\Q3\Z)CP5G
M@'RBP=%_KXJ@Q*#LOU;%>/O/WGLB"?$)X/\V_&[M O]O]M#8U-_V(%"L1\3?
MYFFQH(S,<.W2#AH_7\GIB7]E;,JX(T0;DU<&&)R1EIJ1GO@',?W+,Q["/]G-
M_K*')"<F_;/#Y"^'-K:_S>,K1^_E[Q@ X?"P]K3H_K6?6%6V$[XI_YB!._8W
MI6\VH8Y?K?LF]#E_Z]83H[Z?T(W_XG0FJ&73?J?YK]/_^RAZ'R?:VP'[A 2M
M)U7[/>D/]-M2E)?_M\5IXGN?]OLOB\O$]^I_6";&_#+1UEY)8_]5])Z,N__?
M]TWDPNA/1B>6N:['[^V/S^=OG^Y_^*S_SN%O?>YX2\_S[YG]GIZOENF<L"4"
MSMI\0(%U?[+RG_)/MG%FG/T_[?"W_.,& J1#4E-_API,BLF I,=E_]OU&PMV
M_"OD\47_3PL.^+>5"7C]O8)_AQ'R]P+]/9WLU.38^.RPU)WCEYC.OQS'8,*G
M;9AK-\,)Q<_GG\8V3 1E0#+_Q30I Y2<F/SWW7-KZ#BT:\*FU<VB(>",;?'I
M\:!H<'S<1/2PS+]N_I-_=QZWC'O\TA)M_C^8OQX$E/HOCY")Y/^K)2 [\5\?
M,Y.B4\&[HQ/_Q38E-E[+Q4/!?MG;=P?L_.M&9O27^5\Z&R=E@.">J<F)?V5J
MZN_);__+/)[=N/B$:,C$G<PX)QX$_B_=P_XR_VMWDYA$[XS4#- _)7?Z;\!K
MV]^.\3 ",]+']\;@C$SMXRH[_I\3-SE5F\C_L)K&3-P2_\-N AJ_\?V;>>)J
M6OZ;&U_.[F^ ?]AG3C3'3Z'>A&XZD1?BGQ05:K<=VN8= & 6CN<+F WHC%T=
M>PF8>L9EQ,1'>0< NF.O@"D3&A"''>?&K@-$P-3(R,C8R-38V'2ZR623Z193
M34VG6LR>,<-BQHS9TTTGY,_NOXN.F8F)V12S:5.F3)LY9<J4F>-?4V;^1J;_
MWQE@K!>8;J0-OE!/9Q&@.UU';[K.V$WM1">/#>BX:Z,TT)F0/XG3 W1T]0TF
M&1H93S;1^7>G]GF@]Y=S&J"CKZ.GJZ]K8#C)R$#/=*W6.5U/?Z&YHX%G</2,
M15DXITDS>47U7HN76(0<C5GK#,*?]S9<R@]]<_=M;+;+K.(&@BWP/_F?_$_^
M)_^3_\G_Y'_R/_G_L8S=&QOS\_:."@K9Y>NW<RN@8]P]_.N7-6"$S?3T\=JJ
MJRTX,T%@T/B/63NC8VP,SP&&P%S  %@!N$3'9F=Z!@7M'!]FO.^_C:Q]/_UT
M^7<I<W'U?_'_7\GDN/CL\7+NAW8#QVJ#T XY_NO;JEQPYGA;KFW/]'3R<M"V
MZP"@>)*V[?1/;6WQIVH;;WLY>3H .EM[ 5W7)FW;$=!#@_^TG0"#UN7C[<3H
M-#!@^/H& '!Y?XX[+G/WK E=8Q,>'V/CG3%>C=HL#PW?%;3")L?I_T'*_YN
MM<7?^-X[(Q,V4279.#DX.-A,%"XVH;!L<'Q:MIV-7WKL&@#8&['/YC?5O \
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M-$[E/$;.K0EA?3^LJ3C#C-V+*JUDK-X:4?2)'NX@4LZ@VUD>4,ZCUVFI+5A
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MT 670C7?.H+SI\Q898>#DM&&,W%?B,N/[L9WY4777,6;B7_*(#BXL("R F?
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M^39U:M<C0G5)_> U CO]XI8SA,'EOAM?$-W#,WK51+J/9KV8N,%Y9L\QHB\
M8)709]M4UTXL'592L:V&[IDNVEQ">Y+PMH]$NQ4>U#.%]MI'U_V6]MD9M.XN
M[0H 4 =F-=L4=<="'JMDT8 /]UIZ[J:IW-4)6S8$<"Z'3UFWC6/QJ>T2<!J<
MN[M#.!L   N<#;"IM.UQTITEGEMG2HZG)_8#Q#<2&GHGB%W"OG=K1%J?^LX8
MT3[GAYWKA;_7>&;U?VK^($OSLV3*EA3UL?3XC6XJ;D)MSPPE/.Q-5YWBCD]G
M1Z@RR65V1X'T"0!@NOV?FK#MG;F@Q'5S@_%A>F)?@2$G0;L^5>\8=K_S:.V
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M)$Q+$%+Z.[4%X2 VY;J.@]Y<$=VIP^"R36U;L)')MUKL<",B7S1NQ^WPF]&
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M[X3'8\'XSX2:LN>$OXE9:Y*)1TD1D1-) M(+CWJ2EOQG!YSFUGP(]8'V2:O
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MQ]/=JK"^^#]G;JEWC?;@402S>#_D))%)X<% I&1(#/PYZ4O>'B2<W)HT#76
MLBSD*%I"V>9Z O6<(O]3%<'HFX!'6$XB$*B#%4<.@Y2RDD&?H5]8T;E'X&)6
M8&(TX@5K7LAT9 /+TS43Z<!\/3RRU=*JGHJUPC7 V^*Q)%]0ARBWYA,D2RC/
MN01](1A:SH*G"0(6B.&/^'NG/8%C^?MLV5Q56:F=) !6UZBO$)-K(E0U-;-
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M<M9J]?:XHL00W3;\S,@C6CI^F_](S7I"D'NM=B9AUNB%:G_"K3_CC.U?MRC
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M/)#;6NIMFE+P=_E/D:CX9=41XH2R*S7D*G9E(\1E[27@;)@BYGS-(\1?LX'
M*RBXW3&*%0-JOY$Y!%884G)SH#C!MX).^!J\OO@(<F9E:-E.U.VT@<I2C#KZ
M0;4;;NJL_LI^O+M=+^4$L;+UR]HL[,U::I8W[AH_+K<9?P'G5?"&<*S\3LD4
MXLY4<]E?I*[H$15T,GG6V')[\A<[/>4M]4-+Z)JE# _MW^DK&(G</5G?&6!,
M7QZ"(2P[5+B9L6Y-0XF8<24JIFP6<X0WM>0XT\..0YW"O-VT<66;J$ C2[TI
MW,C19&P7_$+7YZ0)TDH/YG?SNU=?*9+P/2--)1-XF[U'%+WG-=FAJ2'<@$9B
M"D8C59-7GU=/8#>L/:,4H0YEL11C2S[EOI&M6^U7<$5*C)Q>M%2B\FHK)$@,
M=I74%=R5#?RDGKHV5>NJ8/,:UM]I\8;7J.D9OVK7E^3EL+2-JY3Y</7MB+J"
M[:J-7CD%2Y47[7*IQ=R$^KN)9>U"E?.*URTK63FI8QJG(NO23UNG%3_+SC)C
M5RW*BS>NB%B:#S%X>_[,3]3^LDNEPKAQ]:)*WRRVLJT:F)?/_%BC+W) QH"W
ME8J+*Z"'*QZNS(!W UW#-R,=0"]F7$9P(7_6O8C7=8=*74KPBM+R_O)JQK4J
MOZI%B 0@$_BPB _:!B:MT$(&H/?#76%VB!$S0-!4Y)_O8;'G+>,*"T$%LH:2
MY9 :^MJR#[!BV% E$Q%7&%=]%S4FA53S#;TK+  <A V>O@.DP9[Y1Y%XILS<
M'QA?R<O"V=@RZH82.YP(2BX;P-<7.%8F$3J3"=488EMH!5! (DX/ ,:2_NR,
MT R&P>Q1U.=B0EX)K8RRLA!*VPWQ+%E"'YL_LNPI/3=)63F/WK:PMVH&_?_8
M>@NH)K@_X%\44<$"451L0:0;!.GN[APP&!LP&!OK[N[!Z.X.14(QP!9;$.NQ
MN["P_S[(>][G=]X_9W#.=N[GL-U[]XW[C?MX4T^&%WY>>I"T%,!P*OT RRE:
MA0Y$&\=9TKYEKT_4IU%C5R8_I&EY70?H48<L-P,^4BF;_-(:J0N5=_+PT&PA
MG.D:J29(17G&A/*-0:[Q"=S9&(\D8\XU+^,4*/N)16NJ-CMBXP] ,'M!Z\DH
MP8>4FQFX\+QB+R0[:D+NGR6)O26-B*Y,&!3+//E)WT2F%B;):"%^XU"JP[_=
M^/^EI!^#4+4E]-=A]M6J15\B915>6<MBVDM+H_7CV27^GB:))Q4"\S-)Z^3?
M-\:G9(F1?RE)'+@C,IU6E1,4:X[XD/LNX7RF+E2<8A^UMF!W&MJ] Z8$DDV+
M"AM!*]9=AI\$S7OTL$>BLYDGDHY0(T%'4P?A!\&UZ1S@DIS\3/O(37D&H*-N
MT] NR&:34_G2W,7KT@J>YD;\2R$5PL!THZP=Y#O PFS_0E$6'Q*;_BR;DNL9
M80B)@>JX;<AYF3]AXI#;"%N_3@N:#)OOSH3MYP^F/,N'DB+3L@NF"GYEM!?J
MI]5FGH3'A?T"G4"@777!&45D8QCX)=);2YKKBYS/QR;Z\KR35J(/$693#F#
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MR<SKN))=JDP9KDFSA?D8QUM<0*<28O^' C S*./>;&8$Y9WC-.,S9<I\):.
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M)T"TE,Y:SN#'T^(6+:+"_I>J^AYY/?BZZ'3L\HBM9-6$73%A^4G))@D9R8V
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M:_$X".JK%-G&# 6."&YXW0ZYQC]H>2)T(U]7US*JFW=.Y33^)\5&:FVWIG*
M?F3_;/DR),S=0\D$J?JL* Z,R0UPE6=X-0;'2Q]:<H)3I&&;OT1>%+U3N8#_
M1-DGHR4<"7[#\$Q.B]B!3$S]&>.014CG)IA'4X!?D[][.H-TTD3FH=ENP-X-
M;>"BK/F3O;PK$DQT:6PI[7K<2,*O(M/$@RD!F:0401HRJC[-$HCV(&= 0 %F
M0\!D\."&D"P 9.9?JK!'5!;V*,V?NC@J+V,*7AH[E!4&7)QP,;L[,B:Y$3+K
MGI'Z/F^MZ65 )71F?6_&/W\]*52ZX&R0#/*2[!L&SVV&?8I2@<:D#\1&Y,]&
M&";$P]!ND*3NPJ>FZY+5$1O7[TL[A(#/RVTD?XM?%X))G BZ580KD(9U(C/2
M %$F**=PF]@D]"I7>?P(^IH)+'X8@].^GOH4,Z^7B1^XO=Y^1%T"W?\0,3@?
M&SQ.+ 1DA2.)_+"0J#%BJ\O'V*W$:\:?8HZ25FBS4H"DA2H)#MLCD56%)_JJ
ML59!2P*]F'FI5:';&!="Y1%$AJ=+7-0U^CWC\J@@^KAV='(=?2$JS:YU?2?^
MC>OS.BOJS'O@;R$,2%4)WL/_$+HD3,&[Y'PNXC;WJ[%IA"_WI+91\DO.0AR6
M]=M%LVP;;HOG2N6&O!A?KN)3"C-0*IL-J0E5EWH[4\.])5N-[H=U2M:MNY<"
M%K@M_*^M::]"5F)/ )=%;,WMS=H3HY-<GNT0_RHX!F*6+-G?D#,#>&LPFZO,
M:%TM*W@)S)[7LP-,@Z2OL;H8OU1> BHG(^U7\L$D'# <<#4H/JLPXX3C^6S#
MK"(#CVQ6MGRU)U0S>_YL&9E-A\:E WQ0 XF)Z?<@IBE;,C,2DP#UH(E </HS
MR!)'#6!M[JH]0T!I7NGJ=3FLO/G>Z5@>=23* @Q&ZL1B<CRR%0F(/(T$[60+
MZ'" :VI-08"#=EHT;$#_*^!TX>%5A\#HOR=FQ-T4J["<0C:B+?(CO WD'FN(
M&(J[EK"FJ,\_*:D:6;DO*"40!=,')=/0*U81P9;HA:X"I)?!.W'-<'+8?;Q.
MEEV4+SX_]EYL#/Z 'R[^,_ZK?5^BF."I]SGA/(&S*@*,_S\V-O%^0#!]H% 8
MXD1'9R:&GZ5OBMT8-4?K\3T:VTB+M]\4OX=FJ-<4)Z%YK7("U]+6+5#K?#\)
M&F%7@M3Y)X!MH0=Y?3&HB#ENA:]!=!OGD!T]5IUCK&<?<YR3ODH??)JU$(<E
M4'UV%(-@?@&1\EG@]A!-F5WTA_!$"=9G.$I#K&-G&1TJ"M]]+SI,!%QY'^+$
M/O"7PBO \)!U!6HYJ\)_I _G#D9?B4J#QL73O$[FWTGZ;BV"&0/6;;\&ZTAW
M6&:-.IBQ=E[/,K']P+X8";0B:S#^=AHMNS59(S(.0@"L]WR0NS/]A=65O,S,
M[.U>>:$@]67;$2] \UG<F$[,5H!WJG&>3GI3VAF /W &&!)AGS63U>WQ/KLT
M^Y'56O!9R.2V87!PSI=EJQ#K<QOG]6P$2IID!KJ:4Y8R SZ2\BC-*Z<D?']&
M85Z<ATYF(/2E95Y69H'WMKC,NS"59:L1ZV +$0'D[CA6 1J2DI@/.YQ\(&5%
MX>NPQ8 HA(J[:;I[T2*+LHS]13>V'DK_CG16>XJ(1M'_4H@/T9&8G6"/.##F
M5%)/HC$V)%0SN1@[ZA:5RL'MLE@&B,/1MH8".+@1M1N(0OR+OQ3\9X2$,I0-
MB+Y(.9EX/ZZ7TA02EFA%@;O6).^AA)H7)8]3 K>N3"%2V&K3B'S*0C4WW#G,
MD^L ZHZLYPPEVL54L>>"^^.-V :NRQ(WL)AF=Q/Q+/<ME4F/6!-J5Q%H^D(=
M?6%_2(&T#&0:_EI2E] 3]4D<&&P>2Q4^<%'&IPFNF''CY0+,%K?$*L$FM4K$
M53KF+U5P&08/?I"I5B@+;XA#PR]$1P=<+E*+N[O_ M(T:8?14Y1GRLT-E6@+
MP(9%S<0GZ?,6*7HF?TWNR^C;&2-02/RZV-3\VTEF_L]A=JD[]Z\JA*1=,HJ
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M8)/#@M]17MNB1:DQL2O)DCLQG_]XH]RD^9K6W,Z_5*",<RY<[K&/\R2*9W^
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M?FWEXZ!\_ OY0QL.X0MW8K8(,S"3,/,24W+)ZL0:3/5)>?M&S,/#$-E^+'
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M0O;&L:$\4&1O7BMC<8OW)/!DS+39B[@,3,^M.[A1S)7Q%OP6[+).?3P-FZ*
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MN0VL\GA4RV>/<UBN/<VQ6W]=>@CDPW./Y<#]9/X!'^AP\;M=KZ'9&=$#E>!
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MR%OKA_'-T+<:,>$-X8B11(K.<].ED$\F*]465'Q(M/P&W=^M1$)@9ELW"1X
MCVL]&C_2FN4V=9WT.1#>Q*9+";Z&'(9-[DYM,.-I\AK52N;9X+>R.ZQS;D%B
M'GN*]5G!- Y48VPX#1Z3E=7*P%+P9'4.N!XOT\>"XW*7:;PY?Y*:E);@\F"M
M]#,8[K9*- BJK-_Q(\$?IH?U@_P3TMH:#F\7YZ4Q ]N-NZ:+0J_FD-21Z)RD
MM8H09%NPO]2:V[+IA_ 3_,/F+UXCO,6TONZB?$CRP%0G_<9Q,$"22-Q"+4G4
MG'U/52Z<E-@EI_/I01\EI=C=3?>%L>AF&SO>/*ZP&JN;IA^0!%<_U(:RI?H3
MJ@M5',TNQ9;L-.6@]$YBI&RWN"1H6#PJ>+;IM&"8%VD3B!D0O?%G+:->+CY7
MO;6FBKU8[VJTK?RC6:F]FG5'N5J%)+R0;93;!@%B!_'N34."S0(+FQ1L$\HQ
M2FKGM86*MQO?-I<"];KC]8F58K79M"R+I&C7/4Z028^HFH*"1,=E$9N:^%>%
MQVSRT =8H-&KYECO+=$?8WVG+[!95]4:6&FICFQ8EK5<$5[]*2%:FJL]$317
M1%!P-XGY,O$ZFRJT ;NG>-,MPTU&=K5S\,'4U2U2@JQD14,U\6/ZK1H1&8PQ
M&-*HF_W.J+_1ESLC\D)FO"4L,@)C"JS+1+V%5+0):2&4,\U\VMGBT_48G9XN
M,A$8B3%I^E!FLE^MZBV+Z"R0E0&7+"\)!S@EBA6=# Z#^]1,Y-A24IO*V9^+
MX^HJV/^FKZG.X2R*F:P+XFSWJU1^YPPZBZ4"<)/5(L%3\(J\NB,'>\=-;,U"
M?Y#[&K/1547':G.1@FUF8R'W8G2W=@LWSL]'N0J^YBR2'(0)5DD"#WB%_*]V
MJG0;?*2%(3Y*7M$ B@**7&H0P?EMG@:$3XA.UR \*[\YBG3TZG_4G/\&E%_/
M]9/)VHYJ]L 1S:=5"*FE_JPBIG"_Z;QL1=HE_7GQA^C%ZB/"<[ZOY69^L[-$
M3,0JK'KYZQ!OF6.;I>D']+#9V;B:Y%_OHK,OS#"YJEW3 +V[PCOJCMI1ZNM[
M73Y)M,E9+GK&7VEUF;<;G2>];M[?O SJ:3I9KR1-J=MMNERXI+I)_R/-4]>@
MV1A5J^I69/OVR;02GK-"! @,5F]X^>AQJ=I,[)P/E3416Z\1#]2E-P847*CV
MJ^%O_:[SU-^+(JA"U9Z^.IFW3.0L$;D(KUI/YJW!TM"](^%5G?3< 01WJ_Q$
M]RF"==:+MK=$7=*KIGMDE[!)M6K*'Z\VPRS:)X>/*B^FW_HFB0UP&86'JZB+
MZ=']1BJ]O*OK &U:UGGS>=K)I$N-.^F[0S_5E#-N>G7K7K%6.%HI;8!:BT5B
M9TX*&CL4Q_:A?>]C ^_+2SJK@0M96&LK\#Q)TZ!@.X5>,J6RZ[S,VH<<:\=X
MQ2;.F 5=M WL0R?NW(!NI)EZ,Y&XLF\='*XTR[%%#/],BJY'8$-H4_56.,[+
MI/D(SW/$R3.@#Q;GA770,Z3GOU.91POI*1'6E=6T2P7A.\XU5_.G)$VK4V#/
M0JE&,GK72Z%9^Y^M261UW/N6BP5_X!](^@!%^9KZI;M+_K0LI>V,],D.7M-5
M\;^)9VO/BA:$IA@Z!(%> G4!#^?8(OV*-EHF"YC<Y\A?_4\,==31[L6Z<67+
MV^S5B3OBFYP438GZ6CO9Q% /PVQQB1=?=5!PSG%46LISLD0%LY%![MW^TOK5
M5$F7P?2@])6YS0#L6-MHULY.K*II4':&SM,K9.%>3%6PZ*GC1<E;/M^RAS^$
MIG-[^U>V<JE8ET]C0^E]LWMMZ8Z)C2N,RQ*WU4S7O J=I?NE...%*"]*AAT?
M2DP"L^5Y?B7Z@+'\D'-5825[]"P.RKTP'(T_N75&'T3TBX[HR"0]]=_=](!R
M>M.9FB6TJ[;MFG^8+FN_2Y7 :<:<@Z447*5^SV/*X=QG0YNH25O7]T;05D=G
MMR^DV_B/-9H8Q6[CJV\PS]I-41\!".ND$@''GS'W@#^PNA+>O8=U,??OP3^L
MX:VS>J:S7D2GFF\ R?Y/&\J UVX;C,/L9KM4U1Z.>/TL<3,H8TS</Y&KJ,S<
M!<-[<AL'3L-_I3[KN@XU1?NV#D"5_D_JDZ%M;F&&?BC=SJ"\"''6,T3WH#WT
M9WL_"?ZI#!@A\;6Y4/\H+S?U8.=I+"G:L:45+?=_6I>.F-UR]*>Y+^TN*R=P
M(]?_+?*"#])/[+66AU8Z#ANEQ;GDOAMB8^I0QQ/AH^CUS<<%$?ZO:QF\HVY,
MW2\LQGZR(AEY8F$A[.8VT-M',6U%I>70"_647'S?2H4NM;_#2N8:O;9YMOB)
M_\>:,T*SFUH7SR?8N\KW8TD6>4)O9 ==-CK;E%NY?FB'H2R7U MK$U,'VA&5
M1_3*IBJYF_^G&A])@%N+]K0PW7ZK/)@GM- *[B#?Z:P]0XW6E38[7]8J<X&>
MW\9#J2-M7[7/HRT;'ZF< B:;=LN$;D/:=-$7^TK9<[[0XH! C3)NM1+>5=J=
M,).2JHX-VI-;\&FU:RDO"2_X0S1GDI!H3<<HP9G#C']IBR(J61J&A6L/6\12
MWQC!C=&7'5]"**<+^T\0'S$FFQZ3$Q@JGH9R@.E&6$_S8[[*.$>_RNH+[V'6
M 1I7*V /N^7OMU5+D<E',W 'N4E]H80M<&\UBW@7=L?2R#CH.GX^=2$DVOZ2
M]C_(+^P7XR#XT:6']0.LO>96(9=>/%Q;%2:9W:/"O1;E&\<1E(*_T>FD$#ZE
MZ@=E!F_E]K^H+]"1L.WTKXB72R@K"69>:2J/,+ /S:^<ICW>/:-JOWJ%7H(G
M*C#N*:*/;'+E/^1UXIKT .IJX<+0X_1HWC;G%\Q]B.OE;651S4L/7*SXJY[:
M>:KRM.F4;@M.8+" NPC9&DG%1])6Q>=M$ 4GC0@-H T+HYUKF#[HX?\EEL(]
M^OUGRZ,Z9G<<K)S0LDT;5W6\OA8Z@.^L?E/A2!S4N:;=(=]2AH1<I'E()CEG
M,"[RUE\2E+S=]7K_E+*105K[JXJ2[CT:0I6-^2[X K^P<78YG6AO<DQ+)1=H
MIX7@J!=D+&<;!H6?<O%WB>+(Q'U 6<I>37MD^9>A8^J]E3T])T$OG,%\ONPN
M87?]P:V72;\,Q2%_4:F*)J=?# =!RMECS&45EGOTS+K*#^;]K VX=K4#:X2P
M!5P/Q))FE;T$WI/O;?V;W46]%/R"(V>,<ZH&=[$,9W+H3E3Q;C;]/LVWM8<A
MH+U0V3"=Z;6<#<R'C(*R*:P.9O#6.8"0Y1H<S]8#44Z;.<_8ZE//J5SHSL@3
M6A0$MVRF3X7L%"?IY\"7P&=&/7BP=")3#)I3O5E24!$T".P#D8V/./8@Z60!
M9;9XYG *Y8%P7U,7M5^ E^-I0KXSZSB=S9M;,HG!1S]O(3,[D"M!UJQOW-J-
M!C8*NQ__1KJBM=GYCMRO^M 80Y$I1F2KJ309FVFFL20)Q0OI+2*7E/V,!_PO
M@1VL.$RQ<1OP@7OYV 7B[?K-@R=)!VLL&ZS)C8;WTDD4C7:$T49M4W&*O&EW
MY"$I2QGNXG>!WLQ10>K&=0 %#3]ZA[B\PW7@.FE<JW?])M*#QIF2Q>0;-2?I
M_Z-\-:"%0IJ_QCE91F^2]P;<9?J+[CM^!&9BTJ,V!.'.R0.KB+C>#77EI)CV
MK^)8<D!S/7TNI:@NO. )=;_A5O)"NHO:)4#.N"&U<[S &N*9C_02[/:U]NN(
MLT9NUIXGWNZO$3623G3:T'#D?YI["W908VO7)371+NA2 OP8F-S2<8!5Q5?L
MS^&RRI.[[W!75P:8A/!MW$QA%MR+/T7M@25$3?XIF$X&D^;!1*K8GP]+Z7<<
M=L(W6*9]4= (9477:8A/'5>=#V53;PEBH'#:"&40\J$WY;V!0AEMB1G0#N9A
M_TE0-3#)@0%/84-[K<$EG)N=$G *YX1Q&^<]IY_OP7G+:2;OX?S@=.6M!-=R
MCB<,@=LY3_T4X#YPH4,X% 5&[;G"[A&0.SS8K7Q,_Y3=PA-A7]A#F))4RWZ
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MG_%5.X&:FR!4.="4(?;R./HCSPQ)!C/>P5^8SWJR7L(CLFLX=:9AIHD495S
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MO)O]GB%WB^=<9FVT604^ 7X8+C(\F %B&J.'>84M8:YCQ>*6,NM9AW,6L@*
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M5$,=)YNGJQ];V^BG@X=(]CV-<@4A9%FLPC;;==$RQ86DJ9W;E<V1CJT]*BB
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MO)KIS XX#9K#7@87\XW<S7 .<0W_$YR9NT0DA GQ$Z6S8&;@4,5(&'4)4WO
M"]LSJL\8AIDG,(;K:: 3RTG7Q>OEE&HW53W@[=(<SYTL+,$?QZV5>.(C L[)
M4[#I+C&J%G1Z&Y_*J1\TA=(VU14"I8P7EG[N<W:0^4Y5.'>;:4).K4!J"(\C
MBZMUI( !V0H-UR51-0LK:SU&*>R(,#95][>-4F^DOVX&N)FLI(9]E2LY=^K^
MR9G 'ZQ)B!LO.FZ4!M3)''2H2ZIR/2YL+2&;EO*,LZG/%K'57G2/SB^<8TQC
M6T9E*,>S:4GV#KY5W=O8 Z*D&H^ "NF@(=$E4UFE(32N59)*#;I,Y<W*24H[
M%4R2L]W4X=23Y1N L0SOK#G )_:.Z*?@+[[,SP..$3<ZKD+V*[P;VF3-E 1M
MIIQ4_4%AKPAEF%FI2ENV5=D7E35W3Z91'25 HW4 +&;[C01_RA8[GH$WJGSJ
M%9*1[ >:Z=))W"-R*]DT?A>S2.XB9)3Y*XK$\1E?E*NEP=&N:GMYJN\CX)JR
MSO$M= "86)<HW"018;=%KZ0MTC>2N;*E#+6T4+ZR5"G;K-B8(5)$*,]%W50^
M4P_W/:&^#!0ZC0/?@8=KY_ '@2?H#>$L,%_R5L0 %](EXH/@V9*-TA1H=/II
M^7 H,XJON MU^BY6?8,^.#F"D7"!Q8YGJTU!GO&;--\EXP4_-4I:MTB*7R7\
MD<S$ ]+SI:^Q]B@;^2?TCR^L"D,KG4*!Y<C&FE+.:0N N/(*:D3B(OXILVWU
M#V&I<06!*9YM<$F[)YV@6Q'Y2.ZI=?!E*]MPBU,:X( ^-.]C[V^1P?7<XJ8!
MT2#O>H.IFBL0U7D7/_K[C,ZD\20E)DYDEZS1,,RW6#E9JW8BJ'=AC\T%K.\+
MG>#YG([.7E$LS[IM)?4C?V<S_>\1JJW!+LU!O,MR/;),-LFD\_56].OG.E'4
M3'RG[BW*+=6H,32DXB>_'/4CE9,A-(&ZN= ;K638))]&#>PM8??0(WS("\'\
MQ+WV'.R,(E;[#3I+WJ9:!3VM9O+T\ 3&6-(Q.):UMF QC'$IR33XNB RK!=)
M$\=X <AS6:U]/[I9Y:7Y#1!9YY5MP$;.4>X2<!AO$_$#6"Y8F/\!/"KJ2'H&
MY4K6AU5"'V5/O03P(66A_0-D4/T9_Z#R$IU0&%4K)=,X=6HK:2;12]TN@_+3
M@0#YCB0)\%(Y)LP:W*/B>=&A?>I/#E/AAV ;]EZ1H!J4URONJDO8O4JI^FI5
MH6HBD)AW5'4$V)$T5;T6# ]]!:P!CWI1P%L0S2$"=H,G8--EN[!%LJMR(=;
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MZO>R5KLQT%&56IS!L&*$,NFL1I:T:B;G&V=S <"G\GZD<H0_A?E1:LE^\8D
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M3+]A#"X];PXCG##%<F8-R?+)JES#L+JLIE^)<7;+*2T=E?2N%D[%0".#-]I
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M6AQ&5(-9@V_5R*G=4C%[0" 2#7,$JE$FSS1&9UN&Z2S;P&+\W*#RV@;TGG[
MZAGQQ.Z5=+_1-^=F6U#)A9X(Q/Q0$G9_;W9%7PM$T>0H-5=;$?55>FRK3$/N
M%B@J^EDRP1!=HA@A2TRC9(%EF,RS#BP&4*W] "AV+0=JSZW Z.$+JG>'/ZOW
M2'C0XIUYHSL0<FXXLO381"I\;""KHJ,C7^YH+#$9[3"'THIN$1J(7:PJ1A]5
MPQLDJJ3#6)5Q!">U#.'%UH'% .J?&C0>6X%IEP^HW1D&&G?%/>CP2KLZ&)AS
M9CHZ;VXF"3XXDL%L[LF3V=J*C)I&:)VX#M7,KL9W4"VT7KR),X R2H;@1OTP
M0FL=0BEM XOQ<X-VUQ9@V>$-'-M"GK;LB+G3ZY%X<3(H9?Y83,;DH418UV0Z
MW3&4(S7T0 RRMK):;A/"17/BVO .2A?*SNHMKQ'UEU5K!DIMM@&HH;I_,8!Z
MS0= N7,YT.W8#&Q;/8%S<]"#SFT15T<]8DX="8X],!^2.W D%M4TD\RP3F2)
M50.%.F$7M)K5BFZ@N C-N 9*.]+![(35\;O+[+*>$KNAI\A>O2A L_IYPP_
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M-E6FI;/5<DJEOI*H-@GP9@L7[[2R\9U6%J'+4D'H-KN97@;0W0T,=X-DVZ=
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M/L^(D=[/J%%>3RNB/)[RHSV>B&)>IKWS]Z_9)W[_FO;DZ[^M!.^^P02?OTL
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M[/D<#?%LIIER.KV.=BJUE7$R99!Y+.4 <S)]CCF8.5O1E76 U9)]@-64\\L
MW-V <#>0MGX V!Y? I'?<E 9M %4AN\"PM@ P$N*?,+*2KA/@63>QL$AUQ D
MZ.4R%O)\827N3)Z*?#+;1#N>86<>26^MF$L;9.U//\ >S)QA=V;/<)ISIKGU
MN=-<1]XO PAW W+-7P%URP> M_M+(/99!J0!ZX$T=">01/L]J4P(O\]/C[M9
MD9]^A0(M.(_%E9U",%#'2OF$@X5RRG2^CC&98V.-93FYPYE=O,',27YGSGY^
M4^X4WY$W):@NF.);"_;_(H!T-Z#<#?3-_P*"G5\ J==2(/=?"Q1[M@-%I,]#
M65S(+7'*WBO\G-2S%:5Y)\CHTD-8"G(_G$T8*ZND#1:I*OH*C-RN/#N_([=5
MV)HS)&K,FQ39"R9$5LBDR% X*=07_;*?&YB;_@4J=WP.Y,_/(/BN >J@+8\U
MX9YWU;%!5Q5)T><D64DG^,79LTQ$R02)@!K",(@]<#Z]HTS&;BFNXC<66D7U
M!8WBNH(><35D7&PJ&A?KBL?%ZI*)2M5+ )2[ ;/ZKX"U\9] \GS_[_X6:+Q7
M@:J 30_UH;MOZJ+]+U8EA)]29<8=%$,R)[CE)0-T+*J+2"6U8-@,)Z*24P=5
M":I+C966XCJ)L;A=IB\>E:E+1Z6*LC&I%#HND4#'Q;\$H#]_'6!7O0,X&_X)
M9.[]K][U#=!YK7AF\-]PU[1GQU5SE/=9<]R>8_KTV"E%?N:@L+2XDX5"-=.(
MI'H"DUF-X7/-2)E0!]-)--!JF1+:+)=#A^22\A%Y)6Q4)H2/207P,<DO>=&
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M4YVA:V=:HKT'ZQ.BVFSI:0Y]7J%958S02.%$J0C'$/"H7!:;(Z(Q)5(B7:O
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M)NBL2P33K1%H]P\ 9R,!8"V80+2A LV!"&QG' A<L2!RPT 0U@7"/9P@%N<
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MNK_!3N__9B#K*0''9"X(;)>"#V8="$AJX,W2!):?/M##3("<: G$;%O ESB
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M7] YZ'S#=S9@],;V?P.[;7+@A.9PWRX/1$T%H.Q4!KKU7*!AE@#9<Q60O%4
M%[ 9L)'JX+IK!SCG:H%CJ0XX5.N!?:,^V+4;@-TA]%IZ#7_;7C#\97O+Z+O-
M<Z,OMN^-)FV_&GU$9XS;@O%;.S 9L0?3X6F /9KAW_,@PE9YH&Q7 "]])6!;
MS@&V\V+P(JP$*A.]U?Q4@1"J#AX)&N"6J?W;M4COETNE_D_GNIT_G%H,OSD>
M,/KJ>-3XB\,9D\\.UTPF' 9-WCN\,WGK^,7DM0.8O7( \V>.8/'0&2SO3P,<
MU-$U^/<, NW?7NKRX*VK!'RS.<!W6 1<CY7 HJD 7: Z10G:]H,4H_D-GZK[
MQ2-/_Y-[Z<X)MVJCCYA&DW'7=M/WKH?-WKF<-'OKTF_^VN6Q^0O7-V;/73Y;
M#+K\MGKL#-9W7,'F&@9LKKC];^"\!5T#M.O2T:[IO44>A%J*(#*9!2+;A>#K
MMN(WG[SN.YNS^;.7_[8)6KC6.#E1[QTI<^<;0I'1*+["Y*5'G=D+CQ;S8?>#
M%L^PQRV'L!<MGV+O6SW CEK=P7ZR&7#[;7?=#>PON8/]&0]P.#4-P&R6!4^T
M9[+0[B]$UT*LH0!!AC,AR&K^5*#+LJ_^A#430J]-8UP?]==LJ=8+KUB]Y[14
MPR%*KLD3S]WFCXC5EO<)C=9W\1TVMW#=M@.X,W;7<0/V5W O["_A)AS/XZ:<
MSN# N9< SMU$<#XR#7#?* NTM;+ 1?FCZQ&\31["])5_AYO/_1+FL/B#U'W5
MFP#JAA$_WM8A08#F(^\(_7NL1.-;C SS&[0"JZN4<IM^<JW=)<]FAPND@T[G
M2+W.9XB77?J(@RZ]I/>N1TD_,-TDP!PD Z:# IBV:0 >[?Y>J_^G_TLVR$(X
MNC?1VDK?8HUG?8BQ6? ZTG7Y\U#/=8^#V%ON^/MIWO"1&ESAQ9A<Y.RR/,?*
MMCGM56S?QZAT[*75NQRCMKOV4+K=CE#.8@]1[F(/4-^X=U"_NK=1P7T?#=SK
MZ2@&8/]?0$*OGXWV/1':.T/0/-&;Y:82-!0FDW?.>)-L,?=Y@N.21S'X-3?#
M&&I7@@1:%\2!.\_XAIN>%,1;'>.EV75[YSD>8I>Z'&168_9[[<.V,PYZM#).
MXIH9U_&-C!?X>J]/^+U>@*]F JZ2!;B*:0 9O7XNVC4#5\A Q!H9B-\H^RU%
M76XL74=Q),-DYN,TNX4W$]U7]\=05<^%>VN>#!;M/!H@-3LLBK8^Z)MLWR'(
M<F[E%6+V<2NP#9QZ7!V[@U#+/DJL9E\B5;&?D2HX'XEEG"GB;F\@%'.!4,0%
M_/\+J.CU"]#>'8SFB%F%]DX5F<D,5=G1' WYP3P#I3M95@NNI&)6G4OT5#T1
MP]+L#O<Q."B5F'5(PJU;Q/$.C:(TYSK?7+<:8:E'E: &7\YO(9;R#GL6\\Z1
MBWB/R 7\<<]\_B_/7,%O4H[@-S%;^+\!'>W\/FC?#$5[9_P*F:FT-3+C.1MD
M1@JWRCXLTE:\GF<Q[T*FR\J3*<3-W0E>&@=B^ 9M$6+3IM 0Z[K@&(?JP&27
M2G&66ZFH"%?L5T4H\&WRS/,Y2,GV.47-\KE+S?!]1\GP_4%.]YOR3/6;(J7Z
M_?Y?P N]?A':]\+1WIFT#/F>N1)Y6[!&9JATH\SM4DV%_B*SN:=SG58<S<!O
M.IA"V]&6P-5OC/4SK8T,LJX*BW0H"TEP*0Y.Q^9+\G$Y >7$3'$].<U_/S7%
M_P0MV7^ EB1^34T2?Z,D!OPB)P9,>4X'6.@^B!>@O7<1VK<6(U]RER*O2I8C
MCRI7(S<J=LB?WVTRI[?08?FA'(^-[1F4[4TI;+W:1)__P[9=AD=U?FW#7S,3
M=W=W=W=W=W=W=Q?B'A)BA @)(0D6)+@[Q6FA18N[:X#U7OQ[/^]!0S_\CAF^
M]-Q[K6MG<@[4=+@RR[J_K-"AI[C"M:-PA6=+?KM/8VZ_?UW.6%!-]EQ(9?:N
ML(KL,V'E.0]#RW,^A)3E? TF LMROOT"8\C]9Y-K*.<&;.2!-]T\<'>0!ZZ,
M"L.IU:IT!X>,V1;[[04W=7O*S+0'J8XW1^H.KT@TZ:_-L.JNRK=OJRAS:2JK
M\Z@O:?6I*5H94%$X&E1:L#ZT.'\QK##_5%AAP?VPPL+W(84%2\&%!5^#B,#E
M,([L(9?T[BJBA0M>KN2 6ZO9X?RX(!P;4Z;M76W(NG705F"NSUUJLCM 9:0]
M0J>_)=ZXNS'-JJT^U[ZQML2EKJK:HZJRV:>LO,>_J&PD*+]T76ANR?:P[)+C
MQ-]AV:5O0[)+EX)S2KX&_1=,)#/()[V[E@/>M;/#7P,L<'F,%<Y,\L.A247:
MXK@!RZ;5-OS3@VZ2:_K]E =ZPK1[.F.-VMI2+!N;L^UJ&XN<*U94NI?4-7H7
MU'3YYU8/!656386D5VX-2ZT\&I9:=8MX$Y):M12<5O$U*/T_8#+I_D6D>]>S
MP=_=I'L/,</9"68XOHX']JZ3IVZ=TF.>';?BG1AUD1@:\E'L716BU;XRVK"Q
M.\F\IC/3MJ*]P*FXM=PMO[G>*[NQW2^]82 P9<5D<&+]YM#X^D/$=>)52$+]
M4G!B[=<@(G Y3"/YI6SPIHD9KJUD@'.KF>#D%!,<G.6"Q5D9ZL;U.DQ3TQ8\
MJR>=Q/K&O.4[5@=I- Y%ZM<,))B5]Z5;%_7F.>1VE[IF=M9ZIG:T^B2V]_G'
MM8T'1;=N#(YL/1 2V7J-O+X@EH*BF[\%1C?]"C/9 "N9X58;#2ZN8H!3XPQP
M:(8!=FWD@"V;I"@S&S09QN;,N%;-.(AT37O*-DT&J-6.A^N6C\89%XZD6N8,
M9=ME#!8[):^J=HOO;_:*7MGK&[%RC7]H[WQ@2._>H.#>RX'!O<\"@WL^!X1V
M??</[?P5YC+#^SHZN-I%@S/#]*1[TL/N>=+_%]A@=IL896*K&OW0%F..[DUV
M@LWS[E*ULW[*Y3-A6H73,0;9:Y/-TB8SK9/&"^WCQBJ=(T<;W<)6=WL&K5[M
M$S RZ^LWLL?/=^0"\=37=_B3K]\@^OH-_ J+&.!.$\#Y/BIY#FBP9X;T_TT4
MF%UD@LE=0C"\2YG6N]. M76'-5_=-A?QL@4?^8+-(6I9&Z-T4C<D&B7,9YC%
MS.9;1:POMPN96>$4L*[+Q7?=B+OW]'H/SW6[/#W6G?/TF'[LZ3[UT=-]+7IZ
M3/[J2R7 U7: DT,4V+>6"EOG2?XV@+']=#!TD ]Z#\I36P_H,M7MM^ NV^LD
MG+_'2SIS5Y!BRLY(]?C%>)VH'6D&8=OS3(*VE5GX;ZVW]M[::>>Q,.S@MC#C
MY+*PT\EYZUDGYX7'3DZ;/S@[;4*7__+W"H"SO0"'2/_>/D/Z[V:2OXL"JP[3
M0^=)+F@^*46I/:E)7WK"E#WON#U?QC$/T:2C =*Q1\(5(P['J88<2M4,.)BC
MZWNPU,#S0)VQVX$.,Y<#0Q:.!]99.AQ8M+(_\!OQR-)NWP=KV[UH8[L';9?[
MO0W@V!# XEJ ^0T XS_^#GX_%=I.,$#M!5:HO"@"Q1=5:#D7#9G2+MAP)EQP
MY8\^[RL2=BY4,NA<C*S?V61%[[/9*NYG2]1=SM9J.9UMU[$_.ZAG>W:=OLW9
M10/K<[_I6Y]]I&_UVWM#R]/?C2U.XR].]0'L&0?8N!Y@8H'DD_[9=HP&-><8
MH>@:*^3>%(*,FPK4I)NZ]#$W+5C";SIQ!M_TXO._&23H?3-*U.-FHH3KC4PI
MIYM%L@XWJ^5M;[8J6M]<I6QY<TK%XM8V%?/;)U3,;]U5,;OQ6M7T^I*ZR?5O
M&LL=& 78/ TPN8GD[R+YAP&J?Z-"P1^,D/&($Y(?B5)B'RE2(Q[KT <]-F7R
M>VS'YOG$C=/MB2^/\Y-0?H<G,8)V3U.$K9_FB%H^+14W>[I"PN19EY31L]72
MAL_G9 R>[Y;5?W%.5N_% UF]I^^)3[]8(#N8F@<8V$'R#P)4G0;(OT*!Y#L,
M$/>6&R+>BE&"WRE0_=YIT7F^-V)P?6_%Y/C!D<7N@P>;]4=_#LN/89QF'V.Y
M33ZE\!I^RN73_U0NH/NY45#[<Z^0YI<Q88TO&T74E_:)J"V=$U5=>D@\_<4Z
MLH/!K21_/\D_"9!W"2#Q)D#$&R8(_LX-OBA"\4!9JC.JTNQ)[[=&$WH+M&8P
M14=&(_1@TD<_9ET,8=;&:!9-3&95PQPV%2QG5\)&#@5<R2F/8UQRN(%;%G?Q
MR. IXOPOAK< M),S4'T<(/<"R;\!$'P7P/<; [@C!SBA -BB!,42%:@FJ$XU
M1%V:+AK3M-"23@/MZ%31A5X9O>@5,8!!#L,99#">40HS&,6QF$D4ZYE$L)M9
M&%<S"^$Z9D%<(';\HI.<@9JCY/[/D_SK $$DW_T5@"-2P0;9P RYP0B%*'HH
M2=%">8H:JE*548LJC_I4632A2J$E30+M:&+H3!-&3YH@!M#Q8P0=#R;1<6,.
M/2=6T'-@,]%+SXZKB?%?H+$F%<VT:&BM34,[/3JT,V% .WLFM/=F0]MP;K1.
M%D"+ F$TJQ9#DU8)-.Z30J/5TFBX5A8-9V718(L<&NR41X,#Y+).*:#^'\1]
MXB7Q20$-4.$[\?4?BE\,4&FY_UV#A2;))QQ^?!]CQ(!.MDSHY,F.CJ$\:)<H
M@#:Y(FA9*8[FS9)HUB.-ID-D!.-R:#PCC\:;%-!H.[%/$8V.$Y>4T.@N\5SI
MN]%'I26C[XJ?C5'QDQ$J$RH?_@.:D&NP5B/YA(LF';H9TJ.[-1.ZN;&C:Q /
M.L4)HD.6*-J62:!U QE]IRQ:K))#\S7R:#ZE@&;SBFBV50E-=RNCZ1'BG/)W
MT]LJ2Z9/53Z9OE?^8/9=^9T9JKPU1=4WIJCVTA35ET,S=2K:*5/119F&'FIT
MZ*U'CSX63.CCPHY>_CSH'BV(+NFBZ%0DB?:U,FC;)H<V*Q70>D01K2:4T&J]
M\G?+S2K?+!=5OUH>5/UB>5KUH^5UM?>6C]5>6[Y3?6GY3>VY):H_LT#-IQ:H
M]=#R5VBE0D4G!2IZD,[M0ZXC0(<> \T8,="1#?V]>= G7!"]DL70/4\*72IE
MOSDU*2PY=BE]<1A0_F2_1N6CW;3J>[MYM7>VV]3?VNY5?V-[0N.5[1\:SVP?
M:CRV>ZO^P/:KUCT;U+YK@SIW;%#WNBWJ+8>VBE1T)=W;A_3=($4:AI%]A!LS
M8H0M&X9Z<&-0D.!W_SBQ+SZ94A^]2N3>N=<IOG%K4W[ELE+UI?.P^G/G"8UG
M3NLUGSANUGSLN$OKH>-1K0>.%[7^=KJO=<OQC<Y?CDMZ5QU0_XH#&EQT0,/?
MG'Z%#G)4]"1=-T"2^K__.R.:["-6GP'CK%@QQH7K2X2?P/O02+'70:E2+_SS
MY9_Z5BH]\FY4?>#9I7[/8Y7FW^YKM.ZX36O?<MN@<\-UA^Y?KH?TKKF<T[_B
M>D__O.LK@]]<EHQ.N:#)">*8*YH>=/L5NDA3T5><BJ&D^\:06222?223?:28
M,7].<N!\$^_%_SPZ5.111(+4O=!L^3M!I<HW ^K4_O)KU;SJTZMSV7M([Z+7
MA/YYS_6&9SVV&)WQV&-\RN.DR0F/&R9'/)^;'O3X;+[/ \WW>*#%+D^TV.[U
M*W0GW3] A(*11"*91QHY&YD:=)^SC!C?9-JP/4USY;F?'"A\*SY&\L_H-/G+
MX04JYT,K-'\+;M Y%=BA?R*@S_"8WXCQ$=^UI@=]Y\WV^^RPV.MSV'*/SR7+
MG3Z/++?Y?+!>\$'KS;YHO9&8\_L5>HE1,(1TSCC2?=-(]\^6I7[+5Z&]+="E
M?UI@SG(WUY'S>J:OX.74",FS"8D*IV*S58]%%6L=BJC6VQ_69+@WI,MD5_ J
ML\6@-1;; ]=9;0W88K,E8*_M)O\SMO,!=^UF ][:K0O\;C<=B'9K@]!N_#^@
MKS %PTG?2R*].XO,HD"*\K%$@?J\3(-VK\R(\7J)'?O%?$^!TUDA$L?28A4.
M)J6I[4W(U]X96ZZ_/;K.>"&RU6Q3>*_EAK AZ]G02=N9D'G[Z9!%A[7!QQTG
M0FXZCH6\=!P-_>HX$HJ.0V'H,/@?T)_,((KTO1]_WYLG"%@B1GE3*4-Y6*U,
MO5FC2W>ITHKM=(D;_Y&" (E]V5'R.S.2U+:F9NML3BHVF$^H,ED?UV@^'=-A
MM3:JWW8\<HW]:,2,XTC$5N>A\$,N ^&_N_1'/'/IB_SBO#(2G7NBT*D["AV7
MPR#2NV-)W\O@ 2SDAZ4*(7A>*PY_-\A2?F_0H)VI-6<]6NG,M[?45WQ'0;C\
MEMQXM?G,=)V9]'S#J90RT_&D.HO1A%;KX?A>NX'88<?^F"GGWIA-KMW1^]PZ
MH\^[=<0\<FN/_>3:%HLNK7'HW/(?,(27@@FD[V:3WEW" Q]K^.!1@R#<:!&#
M\RUJM..-IBS[ZQQY%RN]Q3:7ALC-%<:H3N>E:$]DYQB,9A:;#J576:Y*;;19
MF=QIWYTTX-21,.[2FC#OUAR_R[TQ_HQ'0\(#CQ6)']Q6)*)K?1*ZUB6ARW(8
M1O:01#IO'KF.<BYX6\\%]UJXX?<.03C=KD(]U&K$O*O1CF>ASE-TKC)(=KHL
M2G6L*$E[)#_38""WP'1E=KEE=V:]37MZFWU+6I]38^H:U_J4]>ZUR3L\JI-/
M>%:EW/6L2GWG49F*;H3K?\$(TGE32><LX("E*G9XTDBZ=P<;G._FA^/=BM1]
M'09,VUMMN#<TNHNLJPN0&:^*4!DNC]?J+TG3[RG,->G(+[5HS:VQ:<QI<:C/
MZG&NR1QQJ\Q8YU&>L<VS-/V85TG&;:_BS#<>Q9G?W8LST8UP70ZCR S2V0&+
MV>!%+2O\U<(,E[M8X,Q*7CBT4IZZLT>/<7.'-=?Z5E?AB48_Z9&Z,.7^ZEC-
M[HH4_?:R;./FDB+S%455-K4%C?:5^5W.9;E#;L4Y4QX%.0M>^3F'O7)S;GCE
MY;[RS,O]YIZ7BV[_!6/(#$CO_5K* C=7,,"5=B8XUTNZ_RINV+=*EK*M3X=A
MOL>2<ZK366BTU4=J55.(4L^*:(WVVB2]INI,X_K* O/J\@KK\M(5]B7%'<X%
M10-NN863'MF%F[TR"PYZ911>(UYZ9A1^]<@H1/?,0G1;#N/(#')8X%4% _S9
M2 _G.QGA5#\3'!KB@IU#TI3-@UH,,_WF'&.]CH*#75Z2O6U!BNTMD>I-C0FZ
M=2O2C:KJ\LQ+:TJMBZKJ[/,JVYRRR_M=T\O&/5++-GHFE^[S2BJ[0CSW3"Y;
M\D@N0_>44G1;#A-8 /.9X$XU%2ZWT,/I'@8X,L@ >U=SP+912<K<:@WZR2%3
MMI%5]OQ]*STD.GH"Y)LZP]7JVN-T*EM2#4N:<\P*&HNM<E94VV76-SNFUJYT
M2:I9XQY?/><16[W',Z;Z O&4O/_L'EN-;G%5Z+H<)C/!4A$=7*^CP+D..CC6
M3P_[1^AAQQ@;;)P0@^EQ-;K1-<:LJU;;\G4-N8DUK_*3K>L+4ZGLC=$JZ4[6
MS^_,,LEN+[1(;ZNT26YI=(AO[G:.:5KM&MFXWCVB<9='6.-9C_#&Q^[A#9_<
MPAO0-6+%KS"='IZ4 5QI!#C538.#@S38N88&FZ>8869:&,:GE6F#:PV8NR>L
M>5K&7$3J1GVD*T9"E(J'HC3R!A)U,_LSC%+[\LT2>\NM8GM6V$9U=3J$=0T[
MAW3.N 9U+KH%=IXA'KH&=GQT"6Q'EZ!V=%X.LREPNPK@7"O D3XJ[%Y-A2V3
M #/KZ6%\CA^&YA2HO;-ZC*WK+3GKUSD)5DQY211-!LGGCD>H9HS%:Z6,ING%
MK\XUCAXI-8L8JK,*&6RW#1P8M/<;F';T&=CNY#UPRLE[U0,G[_[W!#IZ]_WJ
M0R' U7J DUT ^X<HL)7TW]EUI/^3_CFXA1MZ%V0H;5NTZ.LWF[%5;'3@*]K@
M(9HS%R"=/ANFF#03JQ:W+D4K:CI;+VRJV"AH;8VI_V2KA??$*BO/B;4V[A-;
M;=TF3A#W;%W'WMFZKD&[_W*WG,R@!> 0Z=\[2/^=GR+]^T?_W ;0N9,#6G9)
M4.IVJ=/*=QHS%R[:<F5O=Q-,W>8KGK U1"9F(5HA8DN2:LCF3(V 384ZOINJ
M]3TWMABY;>PW<=DP:>:T8<'<<<-QXJZ9P_Q;<X?9[Q;VLVBYW)^U ,?)#'8/
MD_Y/=K!V]L?]D_Q=%%AQD!FJ#PE!Z2$E:OXA?8;,@U9LR0><>>+V>PM&[@L2
M"]T7*16X-T'.;T^&HO>> A7WW97J+KN;M9QV]^G8[Y[0L]V]1<]F]U%]V]U_
MZ]GL?*MOO?C-T&H'_N(LF<'^50!;Q@"F9P"&R0ZZ%@%6'*!"Z0E&R#O- UEG
M9"BII[5H":?-&*-/V[.%G?+@#CH5P.]W*ES8^V2<F,?)-$G7DWDR3B<JY.Q/
M-"K:GEBI9'UB7,7RQ&95BY-'B#LJ%L??J)H?^ZIN=A0UECO2 ["=[&"&[&!D
M T#W#I)/.GCI<1IDG6.$Q-_9(>X/$8BZJD()NVI "[IJS>!WU87%ZZH/N_O5
M$"Z7/V)X'?](%K#_(T?(YH\R$:NK#6+F5WLDS*Z.29I<VR1E?.TP<4O*^(^7
M4D97/LL87D;9Y7:2'<R2'8S. ?20,]"PC^0? \@Z2X/XWQDA_"X'A-P5A8"[
MBA2?>SI4CWMF="[W[!@<[[LSV=_W9[&Y'\9F=3^.P^)!&I?I@P(>XP=5?(8/
M6_GU'PX(Z#U<)ZCS:%%(Y]$9(>U']X6T'[P3TK[_]1<;R',PMA[(^0=HW/M/
M?N99@-C?*1!TDQ[\7G"!]TM1<'^I0'%^I4FU?V5$LWYM26?QVI'>[(T'@\D;
M?T;#-V%,^F_CF'7?IK-HORMDTWQ7PZ[^KH-#]?T(I\J'62[E#WNXE#Z<Y5;\
M^(!;\?WK7TR0Y["/G,'&W23_Z#_Y,7\ !-P$\'C%""Y?N,!A21ALEF0HEE]5
M**;?=*A&WXRI^M\M:3K?'6A:Z$:G@;[TJAA"KXPQ#(J8RB"'!8RR6,,DC9U,
M4CC"+(FSS!*XBUD<3S*+X8U?K")GL'D70-D1DO\;R;\*X$_RG>\!V"W1@R5R
M@"GR@Q&*@1[*4;11E:*.VA05-*"2LDN51QNJ+#I1I="#)H'^-#$,IPEC(IT@
MYM#Q8R4='[;2\^(@/0].T7/C%F+/+UK),U!^B.2?^2??[Q: XWT B]< QD@A
MN:R@A5R@A@*@3*Y# 65 !A4IDJA&$2/7(H(&%"$TH_"C-8677 LW>E*Y,)#*
MCM%4-DRCLF QE1E7T)BPF\:((S0&7/L+U-:FHH$&]7_? 9CJT-#4F Y-;>G1
MV),1C<)8T"")'?7RN%"GB@>U6_A0JU< M88$47.<6">$&AN%46,;L8<X*H(:
MYXC;Q%/B'?%5Y*LF"B]IHL@7#10EQ)9#79)MK$9%<W4J6FC1T-* #BVMZ='<
MG1'-@EG0))X#C7*XT:"<%_4;^5&O2Q!U!X10=XTPZDP1<R*HO4#L$D7M0\09
MX@;Q6/2;]EO1+SI+HI]T4/2C#HI]T$;Q]]HHL1SJDWPSTO]_? ?PX]_&V/[X
M/LB2'FU<&-$Z@ 4M8SC0/(,;34OXT+A. (W:A="P3Q@-1L@:)D51?[T8ZF\B
M=HBC_G[BI/A7_:OB7_0?BG_4?RW^3O^+^!M]E'BMCY*O]%'JI1Y*+X=&)-N2
M]'];TC,=E*GH3/;A;$:/3HZ,Z.#+BG:1G&B3PH-6!?QH4456WRR,9MVB:#HH
M]LUDC?A7DVGQ)>-YB2_&6R4_&^^1_&1\3/*#\27)-\;W)%\:OY)\9O)%\HDQ
M2C\V1ME'QBCW\!_R/T.S'_FR5'0BG=N-7(>G)@V]C.G1PY81W3Q9T264$YT2
M>-$^6^"K;9GP%YL5HI^LV\4^6/5)O+<<D7QK.2'UQF*]U&N+S=*O+'9*O[ X
M+/W<XIST$XN_I1]8OI2^:_%9]HXYRM\R1\6;YJAT_3^@I2P%':4HZ"9!06\Y
M*OJKT3! GP[]+1G0UX7ENU< YQ>/&-X/KNF";YT+15XY5HN]<&B6>&;?+?74
M;D#ZL>T:F4>VT[(/;#?(WK?9+G?/YH#<W[9GY&[9WI;[R_:Y_.\VGY0NV:#*
M!1M4/6>-JF>M46TYM"7Y+J1[>XE2,%":@J%*5 PC^P@U9?@:[,#\(<";X[5?
M..]S[R3!QYXY(@_<R\3ON=9+_>W2+GW;>:7L3:=AN>N.$PI_.LXJ7G584+KB
ML$?IDL,)Y0L.UU5^<WRF<M+AH]IQ!_*YY(":AXE#Q,%ET('T?0_2^P.(,#*+
M*'DJQJC3OL88TK^+LF9Z$>[&_B@DB.=N4*S@+?\,T;]\"B6O>E7)7/9LDKO@
MWJEXSJU?Z3>WU2JG7:=43[K,JQUWV:%^S.60QA&7"YH'71]J[G5YI[W;!746
MB1VNJ+O]/Z +Z?L^I/>&D.X?36:1($WYGJ1,?9>D0WN6:,9P/\Z)]5:T']>U
MB C!BZ')8F>#<J1.!Y3*G?"K53SJTZ)RV+M;[:#7@,9^SS'-O9[KM'=[;-;9
MZ;%'=X?'*;UM'G?TMGB\UM_H^<U@WA,-YHC9_X#NI/O[D\X9R0>8( 28*D[Y
ME"Y'>9ZA1KV?;D!W(]66Z7*B)]=O<2&")Z+BQ(^$I\L<#"U0V!M<H;P[L%YM
M,:!-<[M_K_96OV'=+;Z3>IM\Y@WF?788SOD<-5KO\Z?1M,]SX[6^7XPG?-%X
MG!CS0Z/ET)./@L&D[\:2[I]"KB-3&-[D2,*#/ 7*C3QMZJ5L2Z;3Z:Z<1Y,#
M! \D1(GOCDV6V1&5K;@UHEAU<UB5QH;01NVYX [=]4']^M.!HX9K ]<93P0L
MF(P%'# =#;AH-A+PV&PH\)/98"":#02AZ:I_F/P,?<@,PDC?^]'_T[GA2RX?
M/"T4@MO%DG"Y6)UZNL",\4B.$\>^3%^!Q=0P\86D>)F-\>F*<['YJC/199I3
MD74Z$Q$M^F/A/8:KPX:,AT,G30="-IKWA^RVZ LY8]D;<M^R._2]15<H6G2&
MH3EAUK$,^G,#1I*^ETRN(YL#WA=RP8-2;KA6+@1GRU6H1TN-&?85VG/LR//B
MWYP5+#:?'B.S+B59<6U2MMI80I'FZK@JW:&8!H-5T1U&?5&K3'LBQ\R[(F8M
M.R(6K=HB3EBW1-RQ;HY\:]44B99-46C1^ _SGV$@Z=TQ;(!I;/ ICPT>E[#!
MS0HVN%C-#R>J%2D'*@T8%LMLV+<4N?//Y0>(3N=$RHQG)BBN3LM0&TK)U^I/
M*M/M3:PSZ(IO-6Z/6VG6&KO:HBEFG55#S#:;^IBC-G4Q-VUK8U_;U,1^LZZ)
M0RO"<CD,)O<?QPJ8P0)/"IG@KW(FN%Q#NG\=#QRNEZ/LKM6C7ZBR8ILO<^6;
M*O83'2L(DQ[.C5-8E9VJVIN9H]F57JS;GEIMT)+29-R8U&U6GSAD69,P95V5
ML,6V(N&@77G"-;NRQ)>V98E?K<N2T.K_6/X,0\D,$IGA8S8CW"RAA\M5C'"V
MGG3_!M+]&V4HVQNTZ3;66;"NJW;F'2_W$1DN"9'J+XQ6Z,E/4NW(S=1LR2[4
M;<RL,*C/6&%2D]YA7IDZ8%F6.F%3G++)MBAEOUU!RF7[@M3GM@6I2S8%J6A=
MD$8^>9;!<-*[DQGA61X-_BRC@_.U#'"RD1$.-W/"KA8IRI9F3;K91C.6R7I'
MGI%J+^%5%4&2/661\NW%"2K-A>D:*_+S=&KRR@PJ<^J,R[+;S(NS^JP*,L=L
M\C(VV.5D[+7/RKA@GY7YU"XK\XMM=B9:$U;96?^&D4SD9P(=W"D N%Q)@],K
MZ.%H"P/L:V.';1T2L*%=G3;5:L(\VF3//;#"0ZBG-D"BO2I<KJDB3KF^+%6]
MNB1'I[RH6+^DL,:XL*#%+#=_I65VWJA-1NZ<75KN;OO4W+/$8[O4W$^VJ;EH
MDY:+UH35SS":'KYD4.!&,<#Y&BH<;Z*# ^UTL+.+#39WB\),MRIMO-.(::C-
MEK.WV4VPO=%/O*D^5+:N-D:IJCI9O:PR2[NHHE _OZS2*+NTT2RCI-LRM7C$
M.JEHO6U"T:)=?-$9^_BBA^3U(_DSVA#6A-7/,(X&+[))[R7]_W0]%0ZWTF!W
M%PT6>IEAKD\(UO8I44=Z#1C[NJTY.CM<^)O;?,3J6D)D*INB%$L;$M4*ZS.T
M<FOS]3)KR@W3JE>8)E=V6B14#%G'5JRSC2[?;A=5?M(NLOR^;53Y!YNH<K2.
M+D>KY3 1X&X>P,5*TCL;*;"O@PK;5U)@PRH&F!KDA]%!!>JJ 5V&KGY+MI:5
M3GSU/5XBE5U!4B4=D?(%;?$J.2UI&AG-N3HIC:4&"0UUQK$KVLVBZ@<LP^NF
MK$/KMMJ$U!VW#:F[:Q-2^\XZM!:M_H_ESS %X&81P&^D^QYJ!=A)NM\FTC^G
M1ZBP9I0'!D9E*3VKM>E;1\Q8ZX<<>"H'/(1*^@,D\OO"9;-Z8Y72NE/4DKJR
MM>([B_6BVVL,(]I:34):^\V#6B<M UJV6/FU'"7N6/DUO[7T;_YNZ=^$%LN]
MS 3XG>SA1 / 7M*_MY+\]:3_K2']:V"2"WK62E%:)S5H]1/&S)7CMIS%:]P$
M\D9]13-'0J12AJ/E$P:3E&,',M4C5Q5JA?97Z07U-1OZKUQI[+-RW-2K=Y.Y
M9^]AXI:99\\;,\_N;P2:>7;]VSVRAW/5_\Q@L0]@GN1/D Z^BO2OSO7LT#(K
M"O6S*M2*]08,13/6;#GKG'G2I[V%DJ>"Q.(F(Z6C)A+DP\?3E8/'\M4"QBHT
M?=<TZGB.]NB[CZXQ=%V]T<AE]4$CY]4WC)Q'7ADY#W\U<AY"X^7^*OEG!GNZ
M 38/ DRM(?V?=/ NTH$;-C-!]18!*%M0H!1LT:7+WF+.G+K9D2-ADR=OS,8
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M^=QF%ZIX32ZT\AE=&!0PN# CJ']AMZ#>Q8N"^N>?">B=^RBD>Q9%EEL8(&>
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MPHL/&8<5WS .+WYM%%[TW3"B" T(_9^]CP.XG@5PBG3? [4 VTG^AC;2NSH
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M6%T#T+\)H'870.$U@-QW%I!&+I!$ 1!#,1!&&1!$)>!'#>!%?>!!,^!"6^!
M-V#' &#%&&#&3&#"2@HC=E+H<0V%#C<0>R@T//XOM20_G^0GDOR0<R2?W+LE
MN7?=.P#*]P&DGP%(? ,007J2R48RN4@>'\D3)GD2)$^6Y"F1+ T@)1UH: Z
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MO4J\U(Q+_:H>EXKJ\:FH]K-WY"S<2"![R"3=OX#,@/S:M9%TKZD*"HQ6<L%
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M\W_*T/A*!QI?&T/]Z]%0^V8"X0S5;WVA<B,"*C=3H'RS",JW&B#_;C[DM]=
M=GL_%&]_#NEWCZ!XZR44;[[YAV[2G[D.J-X*Y%/N291W*&E[G@8FG@<L+P,C
M/P/TKP.:WS!0N26$\ET9Y'=5(;NG \5[1I#^8@Z%^S:0W'>$Z($7! _"P'^0
M#-Z#8C /FH#["PD2>4 /?_ Y\0OP\,D_M-$_U0Z=0>T#DH\"8:3M0=KVI#V6
MM$V^!/2^!=2^ ^0_ HJ/62B\4(#HA1R"%ZK@O= &GNL3(PE+PAYXX4X$$]04
MO* 7T0O:?%[0@GM)8B])Z(^SQ*?_4+?M_1D4C7DXU=R3M.U)>_3_ *,;@/9M
M0.4GTKX+B"AL_FN X7C4"(L)&?"W,J%.][J$$6%.C"<F$P$$O10Y:HHXJ@='
MDX^C1<?1H'.[_H$;-HH808\@KZMA"D[%$IRR SBY#\/)(AA.FL)P"@5$)=%(
MM!%SB1YB"<-)5A"#X"2;B!W$?N($_I9<PI^26W@E>8#GDA?X3<+AF0*'IPH<
M\U3Z?^$,3, 9&('3)W0H%JTQ%(L].#5/BB>4X903&4Z>0Y03=40+T4%T$WW$
M,F(U\[=\/?.G?"OS1KX'K^5'\8?\/)[+O\4S^7T\EC_'0SG'/%#BF/M#*'/,
M+Q_!&1N ,R;/;T08D.<V,*>Z3*"ZN%(\@0RG$<MPZAD,IU9,5#-_JS4Q?ZK-
M8EZKSF5>J?8P?ZCV,R]45S#/5=<ROZMN9GY3W<4\53W,_*IZEGFD^A7SB]H]
MYH[:<^8G=8[Y09UCO]=XQ^V/X$;J@1M%_G^$)KB1%,<H&I,1UA23(\7C"VYX
M)/.77@KS2C>/>:E;P?RN,XUYIM/"/-7I8)[HS&<>ZRQB'NHL8Q[HK&9^T=G(
MW-/9P=S5.<C\K'.:^5'G.O.=[CWFAMYS]BL]CKT^C.-=([X8QO$__PC.G/0M
MR/^;JX(;HTW0F(P935_;XR]3#[P<&<+\9A+//#'.9!X:%3._&%4S=XT:F9^-
M6IF?C#J9'PP7,M\;]C/?&:Y@;AFN8VX8;6.^,=K/?F5TDKUN] 7[F?%=]K+Q
M[[P+)AS_G DG.&O""<_\!VX,:5LJ@;,FWS]>G:"ZC!N)U];6>&;IA(=C_'#7
M(HKYT2*%N6V>Q]PT+V>^,9O*_,^LF;UN-IO]PJR+_<RLEW?5;"GOBMEJWB6S
M3;P+9KMXY\V.\L^:7>*?-O^!?\+BJ?"HQ=^BPQ:<^.![#EAPD@]PUJ0_3@K.
M3@9N(L4Q20.O[/7QQ-8,=\?;XO8X=WP[+@37;>*93VTRV<O61>Q%ZTK>>>MI
MO+-6,_BGK=KYIZSF"SZQ6B0X834@/&:U5GC$:IOPL-4!T4&KLZ+]UC=%>ZP?
M2W9:OU'8;LU)M[YGRT=PXQ5)7PC.24)+6A%_.2OCB9,&?IID@&\GC<7G#DZX
M[.#'G)L4R9R:E,R>F)C#.V9?PC]B7R4X9%<O/&#7(MIGUR'::]LMWFW;+]EE
MNU*RPW:CPC;;W=*MMB>DFVVO23?8W5=<:_>';-".5I ])U_U'SA[$3A'%IPK
M#\_<!?C%78*?7>3X:K(FKKB:XJR;'3YQ\V2.N(6P!USC>'M=TOB[)^<)=SB7
MB;8YUXBW.C5*-CNU*FQT[)1N<.Q17.>X3#;HN%:VVF&[?)7C8:45CI>5!ASO
M*"]Q>J[2[\2I+";Z_@/GP) ^\,2+/)\O^7]? ;[PEN"2ERI.^1CCB*\-]ONZ
M,+M\_-GMWI'\S5Y)@HV>F:)U'H7B0?<*A=7N4Z4KW:8KKG";)1MP[5):ZMJG
MW.^Z4J7/=;/J(M?]JCVNY]06N'ZO-M_M-_4N-TY]'C'7G5/[F*&CY5>>P$_D
MO[^B+?Y*"(OS04*<#%#"H:#AV!,\%MN"'9A-0=[LNL 0_IJ 6.%*_U3Q@%^.
M9*EOL;3?IU+6YSU-WNL]0VFA5X=*M]="U2ZO96ISO=:KS_':K='A=4JSW>N&
MYBSO7S5;O?\B.,V9/IS&QW N].JB_&^2][T: 9PA[W<\@H=#88K8%:Z#+1'F
M6!]AQZP.=V>7AP7PEX9&"A>')(I[@S,4%@;E*\X/+)//"ZA1Z@QH5.GP;U.=
M[=^EWN;7KS'3;U!KAM\.[6:_X]K3_;_4:?1_I-T0\"?!:=6_0_,#G =P)Q#X
MDO3/D^\['D=]=BR#W=$2;([1Q-K8D5@9.XY9%C.9[8OVY?=$A0F[(V/%\\)3
M%.:$9RNVAQ7)9X5.49X94J<Z(Z1%;7IPIT9C\"*M^N"5VG5!6W6F!A_1K0G^
M3+<Z^(%N=<AKG:H0;@AM0NL#?W@#/X0"G\:0YTPD[Y],7H->N5OCA5B;H(85
MB<98DFB%10F.;'>\%V]>7)"P(S9*/"LF4:$U.D-Q1E2^?'IDF7)#9(WJM(@F
M]:GALS5KPA=J5X4OUYD2ODFW//R@7EGXY6&EX??T2B->Z99&<$/H$-H?>.)'
MXT UN!A/-2#?MR^=^NPTZG.36:Q,4<:25'WTIH[!_-2)3&>R.V]V4H!@9F*X
MJ#DA3J$I/E6Q/BY'7A=;K%P36ZE:%5.O/B6F3;,\>KYV2?12W>+H#7J%T?N'
M%41?')X??6=8?LQ+O?P83I?0*?B(!S0.7T63]Z?\#Y/^KBSR_L1JNE^:+D=O
MQC#,SS3'G Q;9E:Z"Z\ES5?0E!HJJD^)D4Q-3I)6)V7**A,+E"L2RU5+$^K4
MBQ-:M KCYVGGQ_?KYL:O&Y8=OW=X5OPYXB?BQ;"L>$Z/T"5T/G"/YN(7- =.
M4>X'R']OSR7O3QYX@.)8E"W#_!P=S,DU15O..&9&MC/;F.7-K\L,$M9D1$HJ
MTQ.DY6EILM*T/*6BU%+5@I1:];R49LV<Y$Z=K.0^W8SDP6%IR;N'IR:?)7XD
MG@]+3>;T"-VTC_@IG-8#S8/CF>3]27LSM3RKB<5TWYTOQ9Q\3;05C$!S@373
MD._ 3LWSX%?E!@@K<L+%I3EQ"D79J;*"K&REW,QBE>S,*O7,C";-](P.[=3T
M1;K)Z6N&):;O')Z0?IKXGOA]6$(ZIY>8SNE^S&U:BQ=I'APA[[N3M#>4DN<K
M(<]']W.*Q&@M5D-SB1'J2\8RM243V<IB-UYYD9^@N#!45% 0HY!7D*R8G9\E
MS\PK5$G+FZ*6DMN@F90S6SLAIT<W+GN57DSV]F'1V2>'1V=_1_PV+":;H^]Q
MNA_S+8W#61K[@_DT%TE_+?G/?F(>W;>5"3"]7 73*O114V&!*16V3&F%"Z^H
MW$>07Q8LRBF+DF26)DK32S+D*27YRDG%Y:KQ1=,T8HM:M:(+%^A$%J[0"R_8
M-BRLX 1Q@WA*7_^M&Y[/#:'S@6LT#B=I'NRE]G?S%&!5]= 9$'FN2O*=50RF
M5BNAJD8/Y;6F**D=QQ34.+&Y-9[\K.I 87IUA#BE*EXAJ3)-,;XR5REV2JE*
M5$6M6D1%BV98>9=V2/F 3E#9%MW LF-Z 65?ZP66_:H;6/J7;E IIQ-4\B]7
M4H&C5(.=Y;0>:\AWU@V= 0$MQ%2ZGS)-$24-6BAL&(&\1BLFNW$2F][HSDMI
M\!,DU8>*XNMC)#'3DJ51T[)DX77%2J%3JU6#IS:K!]3.U?2K7:KE6[-)V[OF
MB(YWS74=[^HGVCY5?Q*<MD\EI_6!\S3_#]+X;Z7\U]23[VL$.H@&HH)L0>$,
M"7);U) UTQ#IK6.0TFK')+:ZL'$SO7DQ,X,%D3.C1.$MB9*0&1G2H!D%LH#F
M*4J^S8TJWM/GJ'E.[]=P;]J@Z=9T4-.UZ7--M\9'FFX-;S3=ZKG_PR=4@SU4
M]XU#YU#DP;MGD.]J(=\SDWS7;/*^[3RDSE%&4J<>$N::(G;N.$3-=60BYGJP
MH7/]><&=X8+ SCBAWYQ4L<^<7 6OCG)%]XYZN6O[;*7)[7TJ3NWK5!W;]ZLZ
MM%]5=9SU0-6Q[;6:8ROW?SA<1G.1:CY(VHO;:"W, AI)NV(.D-5%WG,!$-.C
MB,A>383W&B-TT5@$+;)#P"(7QF^1#^NS*)CGU1O%]^A-$KCU9@DG]Y2(G7JF
M2AQZVJ03>WH4[18.RFP7[I5/6'A)-F'!+[()W7_()W1Q2A^SI^;=.=0 :2_H
M!%KG4@U(NXBTTQ8!44O(_P\(X;=<&3[+]>"]8A0\5UC#8Z4#W%:Z,RXK_1CG
ME6&LX\HX=M+*-)[]B@*^[8HJP?@5,X0V*[I%UBM6B2U7["+.BRV7WQ6/7?92
M,G8IIS!VR;]L(PNVFO)>1-J=I-M(MK"\#\A>2OY_!?G_-8 7V<3)&Q3AM%$=
M#AL-,&FC.29N&@?[38ZPW>2!"9L#,&YS!&.S.9&QVIS-CMU<QH[>W,BSV#R7
M9[9Y@&^Z>3M_U.;3_%&;?N*-W/"</W(])QBY[E_6D?Z2><!\LL8MBX&: ?*_
MJX"4M4#$1L"7K*'S=F#"+AZL]L@Q=H\FQNPQQ.B]YK#8.P[F^QQ@ML\#IOL"
M,6I_%$;L3X')_@(8[Z]A#/?/8@SV+V:&']C$##MPG!FV_SMFV-YGC-Z>/UF]
MW=P_+"?]A93[+*IY'=G18M).WP1$DZX_65*7O8#M 6 ,V?81QX0P^$2&X9^H
M8]@G^M [.0JZ)ZV@<VHBM$^Y0>N4/S1/1T'C=!K4SY1 [4PC5,_,A\K9-5 ^
M>P!*9Z]!^<QC*)]Z#>63W#\LZJ6U2'5OH-S+-M Z(!\>NQL(("_N>HCTCY('
M/P&8G ;TSC-0OR2$\J=2R#]3@>PS'<((BI]9$!,@_7PR%#[W@^2+*"(=XB_*
M(;S6 L&U/O"O;0+O^G$PUV\0CX@7_S!W&="TYMT94/8.((ZT X]0_L>I_B<!
MB[. T05 YPJ@^CD@^Y*!Y%L!A#=DX-]0 >^F-LA@ ;?,@.]L@-O4H'[O0XU1
M)/!CQKL_RO033?B?J- _;R4HH9^O4_-V]Q]FD'[EYG=G0/&4=Q#]B.LI8/S;
M\Q_ X%- ZQJ@_#4@O0D(O@<]C_A91+\O ^ZJ /<T@5^& _=' @\L@4>3WC7J
MOU)S])1>R$]I\W_6#OQ&!?^-)MCO)/3[N7^HWO+N#"B1<@\A;=?SI'\9,/T,
M&/XEH'X#D-\&Q#\"S!W2OD\\?L\3/NDHD(:<GJU*S],&7E!-_K  7ML"?U&S
M^G?X^\^"5+W_3$H_09..V_X/G*8). WRN2J$; 0X"?E=H3TXGB<XA!%)1"Y1
M3M01,XAV8C[12RPE5N(OK,4;;,8K[,)+',)SG,9O^ S/J&A/Z7]/\)K"YM[R
MZ#]P.H;@M(=3'(2R 3BY.3C%"> 4W,")@L )XL#Q,XEBBJN::"+:B$[\Q2[
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M4'[ES=V9RZ#4V4\#:EHP>A?VQY]:D=1*I$XF-0IP@G$<8QQ'.2Z'&<<AQG&
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MIP>EOB,H\5V&8K]-*/3;CP+_\^06\OT_(C\3^=]<#V-)0K:2E62"I=@\QC+
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M0FUI)1!&>Q10#W@VTO^VT'^U:\"R4Q\6G<8PZ[*":9<C3+H\20",NR0PZDZ
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M&@QC46^8C%JC#-08Y:'*J!251C4H-VY%F7$_2DP6H-AD)0I-MZ+ ]"CRS9Y
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M&,>3=)9/,(Y+,U=F+*=_GL8Y.N:SG+2G^>PD(SJ!_S"BGSC$\O_#?^]*X=!
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MX^3Q59;;;\;3'^.K^0PD=AR9\Q.O@X_Y[G?2'WU5H"-M+JJR[ Q*@")'T.;
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M=+9-D$ZV:=+1-ELZV!5*A5V9E-MUEC+['E)J/U!*'$9)L<-$*7*<)H6.<Z3
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M\JG-X AX!_Q@_MWP:>@;KVX/9NGOJR6] 1U5>J:QI&HE#C92;..$?%?DZZ6
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MJ\DH&I.GN+C[@S!Q=H\3)X]T<? H$GO/SF+GV5]L/4>+C><4R^'YGB1C'@<
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MQZB< \=H3QRPOOLBL'[Z(:B:-A=4_KCK%]7:HG[17D$C+]M2QT,Z:P5X=UA
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MP-4C67$_Y^3LNUR0M_<2/'_/153![HOHPET_88MV_H2'[;Q @NVX0(5O/\]
M/$E /_Y9H/_L'5 Q:RI0+5MS5[HEX8H@#G62D\$YRB[4U+-+'%$VV57+8KC#
MC%)OB,+VUQ"Y@2".7Q,L$88":'$X@)*%_4AEQ ]71_PP7:V_R%3K+C)'1MI_
M#?\U_.\S?/#0,',J*!\R;$[X61"+.L%-YQYE%VCKV!A'E$-RU;+I[C"3Z0U1
M6?X:$B<8Q/-K B5E83]:'/&C9!'(4.N#JZ,^6&746V2*.HNJ:D<:,$ &PY1W
M@&[&5*!>NN:.;%/"SV7[B@=XR;PV;JZNCHMR1'D$5X1'\X19#%\-O300)+-K
M @1NV(\5U/HPHJ@7):WS(I7U7KBFW@/3USMAQGHKS!0=:<#P/F28_ ZH'#(L
M67-'OO'P9>%>] #_,+^5EU59QT,XHGQL=41 ]88X-'^0R:@)4$O#?B*GUHOC
MUWDPPGI/L;3!C50VNA':)B=,WV2!&QJ,<%/=2 /&]YX%QDEO@\KI4X%F\4/#
M'DQ_V2%^*_^(OHY?Y*@58*K#961O#8\:"++H(3^=&?&2V'4>/*_!75+65%TL
M;78A52TNA*[% J]L-B+TC3JDL6ZD_=N@_W[(L/:.8D/B)=$N3+_P@*!%D&ZH
M$Q0X:H7%U6$1T5<CH 0#G.%]4-1#*6UP$SA-KI*R%F>QM,V!*F^W(K3M1J2N
M18?4-VE0QOJ1-FPP??K H%VT]B_%^L1+DAV8?E&LH*4LQ5@GS'74BI#583'>
M%Q22:_P\2L1;2JMSTYB-+B*[Q8$5M-O1T@Y;L;K3B-(<U:$J6M7%E4U*M+%^
MI '3NP\,AFF08>$#@S0&TR_9*V@6)AGK1-F.6@G,'9)@?4$)N<8G(-=Z.-2&
M:@:]9>@FQH;C=UHQTBXC6M55@=9TJ-$5;0I,9;,,8Z@?:0\,$Q\8*B"#<EWB
M)=E63+]TEZ!9G&"LDQQQU$H+W2$9QA^0D4(^$2DZ=!?C+*6VV:C,3@N!UU.%
MDQVO*%%VEY>H.^4E%6T2;&6S"&MH&&G ],ZSH&K(\!UD^!$RK$VZ)-^,Z9=O
M%S1+#AKKI&F.6GF>.Z1 ^0,*8M@K'7ZCU&+GD(]:&/1N$YG;KR-(!_ZU@Q'C
MM>U"?&6S &]H&&F@ZIUGA@W&AP;5VJ3+RHV8?L560;,LSE@O3W;4*K/=(17"
M'U#APAX%L6'X;8Z =*R*0^W3,SB#*JKDI(2LZ!62RH\)2-IV'JFRF4LR-(RT
M!X9/(,/4J4"W #*L2;JL6H_N5VT2M"CV0I\T"?9:=49U2%/H]VM*(FXUL=&A
M(+9;I*0>@Y!R:F@'(F:)3_&9BN-<>GD7FZ8]RJ+J6DHIAL:1!JK>?@:8(8-I
MR#!_[6W5ZJ3+ZC7H?O5Z?HMJIZ%>?< >K4BI#E7F^OV5J(A;1VRT:XE'C2KB
M<34T]XM$]+,\D?@TBR?O8W)478Q230>#J6NE,_1-(PV8_V7X=BJHA SEJY,O
M:U<5#U2LXK5JMNH;='MM46.\*UR5X0N8"T,N(ZZIJH+8H2TG]$@5A'[.\/Z!
M"R7OHPJ5W52^NH/"J6BCL"J;1AHPCWL&6#Y^&U0-&>:MO:U>F?RS;AGJA&$I
MMZUR766C:9NEWK[7'JD^[*FV%$0LT*Q964$XJH1F?X$*U\M0$/M)<N8 42GJ
M(RJ4W42QNI-8IFTG\BJ;1QJP#!O&@:IOI@+]W+5_:9<E73$L0IXTSV<?-2_1
M-CM7F^K]6ZP>9Z+/8BFL-4 ?!S4T_TN@V9\#.:C0QP.OHO66J+B]6+6T&ZM2
M=V)EVG:<2-<RTH#EK6> ]:-QP/SUM\ P9^U?E8L2KYKGP4^[IC./>6<H6R-S
M]#YOC-/B2 GH+46U%29<@UR/:RG38=M**W =9 WA&$Y-Z4*K2[N*-8)CQ5I%
M1[%&VXY6Z%I&&K"^^0RP?3@.6+[Z%AAGK[MKG)?PBW-&X;F:+\A]K1^7!6L6
M5%G<N]R5]K2@Q@*+J*"Y6SPT_T.S_]#]P=#M ;:"/'Q#@*K@'$7H1.V(2E4;
MHD+7,M* [8UG@'W".&#]XEM@FK7NGG7FP=\"7V9?;/L(W=CZB=CJ7V[35<=Z
MRNU'@@HK/"R#YG]!%:Z>9<0U#-T?$/7$X;L#M)[6BJPL;47H>2TPO:2YR* >
M<<#^^C/ \<%;P#[E6V">ONX?SU?[KC9_E'QL\/5B3^MGDHK .JNB^J!'ZL@*
MB&V(&A$T_W,MN%IH_A^^/R"8B U8(WGHAJ 1960T(HSL1KA1T%ADDC6,-.!\
M[6G@>N\MX)ST#7!\O?IFW4?;>D^]<3 \^";&V/:M2![::!"Y$ZH%SFP?WX$(
M\&S8FJ$;!&C^'[H_J"682;58,WGXAJ"XBEZ'K"JM@U=QZV!F872D@>JQ3P/W
MVV^"ZH^_N5/ST>*3_:\OBUY]X[!U\%V,HF,Z3U"_J9P3.F1B^;+L+#?<7>HJ
M\3$<^ #53J@AV8@A@HT<^M?M =I*#Z.LS C"RH[ K;SP2/O#.^;I?WQOO''?
M]\'7/W6\^GWCSZ^N<=P<EZ@Z-Q')[YU-9[9O+*,U'E!0HAE:2KA03ZQ!FG!!
MM 7C+[$6^W!VI _O@'N)3IB'["SR4%T%'KHKW\VLSG5S1MS)X'-/_14:^_KU
MQK$36TZ,^=;UU^OK-'].."2X_'4>?7 !AMBWB8KMVL\N.9HF*&[+$2-:"J1%
M33!%02-2F==07)Y37Z+.KL-I,NL(FB-1DC8C2JE(KZ57I-:6ZD;:\=!SHT_4
MOS"VI>NE<>[++W^O!>/6E-V=LI=^8W8R_N<5N<47ML(1@_LQA2>3\+D#Z>3,
MOBQJ1F\>/:VGD)G2#2]-[D*Q$KO0[,/'L)R$8WAN?">1>ZB#PCO8P>"/M,[(
M<Z/;6EY\UCOP_'NZ^V.G"<&$I0PP=3/^[L*]J#_6QQ?=V)F2<RWN2/J50SG)
MEY+S$W_**$JXD T_=#X?>?!<$6K_641QW!D4.G80@]DWB"W9>YJ W7.*C-M]
MBHX?:2W1YT;Y.I][OO+2<^^+P)M?,<"D.7@P:QD*+%M?!#;'9/V]8T_J[7W[
M$_XX&'_P9E)BW(WTE'V_9J7M^24O??<OA4=V78-G[KR*RMIQ!9.]_0HN.^9G
M8LZVGRFY6R\S\D::O^G94883HU\0@3%O,\%[G^+!5]^@P)S9A6#%HDRP864R
MV+;^(-B])?;^@>V[[QW>M?/OU#TQ=S+W;?LK-W;+[<*XS;?A^S?=0AW8^"?F
MX,8_<8<V_$&,7_\'-6'=[Z6'1QI0O/LT4'W]&E#,FPPDJ^<#P8ZM?['C$Z^5
MIA6=8^:1^QDH02>=J&JET?4-%)8U2N*Z:O%\=P0K]$0P8D^X6.8-(Y6^,%SM
M"\$J?*$BO3]46.4/%3A\_L*1]5_#?PW_PZ"$#.5?08:YD&$59-B^]2_.H:1K
M[&38658.I8^)*.M@X-3-#)JIGE[JB%(XU;4$GCN"*_.$,6)ON%CJ"R$5_A!<
M[8<,@5"1,1 JM 0"A7:_>X0],'SY&E#.F0RDJQ: LIAMM[D'DJ]R#\//L(_0
M>EF%HO;2$FTCDVR),IFN6BJK.D+B>L(X@3=4(O*'BJ6!&J0B6 -7!X,P74VP
MT%03*+0&W86VH*/('AA)0 49U%] AA\@P\H%0 @9^+')5WF'X&>X:?0>=IZD
MC56L:V 1;5$6PU5++W6'R1QOB,#WUY0( S7%DF 0J:@)P#6A0)$^%"BTA-Q%
MEI"CR%ICAMD"(PF4/S2H((-L!638%G-;L#?YJF _8I"?3._A9$M;V0A]'1OO
MB+)IK@B3Z0E3V;X0D1<(8LMJ FA)*(!4A/UP3<1?9(AXBLP11Y$Y;(%90D:X
M+3B2(,-30/,Y9)@]&<@A@VAKS&WA[N2KPEC$H""!T<T[(FWA%AGJ."6.*)=2
M'6$Q/"%:Z?!.*H 3A(;V43ZDHM8'UT:],%.= U85-</,$2/<$M(AK#4C":@?
M&LIG08;E#PRB'<E7Q7L0@\*#C&Y!JJR%EV^LXZ(=M3Q2=9A#]X88S*&=5,B/
MYT6&]E$>I*+> ]<U.&"&!C/<5&> 5]56(,QA-=):,Y*&#=K/'A@4RQ8 \9;M
MMR4QR5<E.Q&#XEA&MS!1UBS(,=;Q$8Y: ;XZS*?Z:ECTX-!.RD?@1H?N@JI1
MBB87HK*Y"JYOU".,]5JD*5J.,H<5*&O-2 *:(<.45X%ZY@.#9//VV[*MR5=E
M,?!!V6YZMSA>UBP\8JPK*W+4"DN&;X2"7%J-G\&H]9#8#=5#NR"4LLV,J&BK
M1%8V:U"&!E6Q*2HO-D>D:&O-2 ):R%#Q+\/2'X%T4\QM^>:DJXJM\#.*'?1N
M69RL69QJK!/G.6K%*'=(3/0'!)20ET6KJZ:4-CMP@J,V=/DQ7;'F:#E:UZ)
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M.&7ZP,DILYLO?;TQ<//[0^;+<_*4IY;@^-U;2YEM!T64ADP5H1:F0]>@3?
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MBKRRKPUY:5\_\FS<:>3 _C.(SH-GD4<?$2B #+F0(0\RY"QY'Q2L_PS M\\
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M(JK&3,3*L<.!]TPFW*6%X*PB"@<]<;B;2\++81J\.?/@Y;\$'@(5N*=JP;6
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M/<)DUW$1TGEI%%E_>0ZS^9+RB-H+!I/+SEK/SSWMHI!ZPE,K]IB?4?C1,,N
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M<Z#1-A?JF^9!?>=\J!U< +73"Z%VD^J6AMHG:E :=.9O=4@/:$#FLQ9DW^I
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M&9_V.6QRTN>RZ3'?/TP/^KXUW^>#%GM\T6+*#RTV^Z/%A@ T7_\5Z$8U\),
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MMGB!6V71,H^RPDFODH*#WD6%/Q&O/(N*<$YQ(;H6%Z!+<3XZ$8XSP0B:A62
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MM@PN8TOA%$<2O^-(?GK%D?B ;(GWQ+LO&:-SL&\S0"/E%Q^C_/, $;1W[^L
MCC<!+"G?^-7T<P!^T$51T$(94"?G5T%M4$0C(-$"&70 29S#B&, (XI1C#!F
M,()8P0A@)XL?QUE\N)/%BS^P>/ 5@?_%P": >91?,IU_@?)_ /"BO=O?!C"]
M#Z#S!$ # 5210YF"E"D&TB@-$J@ 8J@&PJ@#0F@,_&@-/.@('/0"NDDGDAG
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MW_O DKN+;+D[R)']';EFLI+RARF_@_*K=U+^0:K_"8#0<^3@WP X? =@?AU
MGWQ<ZPD?:#P3 [7G<J#R7!V47AB PDM+D'OE"#*OO$#J=0A(O$D \3?YC-A?
MC8SHVX6,R+L-C/"[4\1C1N@-,D*OB)=?LICFOXOR:RD_[Q#ET]Y#+@*X7P&P
MO09@\BN ]FT E8< BG]S@QQYOPQ*@"0YOSBJ@2CJ@C":@A#:@@"Z 1\& #==
MB#F8"RQL!.8_SK^)H$WA,P+_BQZ:OSK*SZ?>)YZA?*J[VX\ -C> :@Z@?@]
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M,*1^EU%P_3=&P75/#4/JT""D%O5":U WK!IU9O)'/,!E.A>/E)-WTFWXQE:
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M=FDU2_7R09;JI3LLE8OOV<KGD:-\#KF4SB+W3-91_E+*[Z?\>53[4MI[QBZ
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M_8..'S6B<E M.@=58G)0.2;[?WD4^OF9Y#&JP:XBF@/RWY555 .BIP*@O4H
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M_]5/(/ ]@L"5_\#\RRCE]U+?&]=\?@:42ON.W ?@?9CJ3ZIN3CZN>Q9 Y2*
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MQ%#;C[HS=&=@AMUEV]\#])[5:?Z3O$[>E,^BZ,Z%R/LA'RB C]@V'S,GG]D
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MXPINX1E&\CX>9^:N0;YKZ?]%LE!I'W,C/^Y&7V ?-62;FE-W!'/H2$T->U8
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MJU1ID5O5*9%'])(CK^DE1;ZNEQCY@SHQ4E(E1DA*HD@,EQ1)Y"76]08USR0
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M3T,8> [BP%<0MTA0;I:@VJ1E@'7LH0U<0,TJDL//\<O8!BOH_U?3?_8#CIN
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MZ$[FQ"X% I:S#Z[2GLH9OXGZ6P'+0<!D-Z"FD>:RG8.*@AARLF,<1QG'L>'
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M 0N<]0>S.\3<5+I9CE,R^\$AF5M3?X#-?:_+X(W7ZE^PP:_IO*]@Q%_"_K^
M<YO3,+.W<9@=(69'QJMRWDIAKWUX.VL0WDX[S(TEYI80LT/%/+6FTUZ+<9Q.
M6:9OX+E?P7._P([/L>-3[/A$9^MC7:B/8($?PC/-Z93W8,COX,2W>/<F?_G&
M2;474_LP)T*>M=M@ZAYF)X2+\]789';*)-&N//ZR$GW-V-^+CE'D+T+^<F2O
MHPNV('L7<O?3KL/(/@:SO8B67T5XW$R8W(.N)_4;.N]%K#4Z?^W$T\Y:A/U4
MB%S_K?[ 3([.0+P70YLRT%>,OEKTM.LO],D?X?V_A_>_@ATOX8\7Z9?GL>,Y
M['@6.WX)DWX*QOT$??*X?L80>@0]+^&1C_00GGP0+0;F^3[WR/&LGY/U?V,/
MJ;GXSH\VA=%?B>C*H1WEV-Z@9^B3IS3 <!RG#=/(7HZ&M<C>C,Q=ND\'B((C
MNAN6?R=]<H=N@K??RY3R2_N>F9N(DO_<E7']23:8"W#>EV,3UDO$QK/P_B>(
MB\>4AIY"]%2CHQGY7<@?I(7CR)_6K=AQ,W;<A!TW8,?U.E77$:/7Z&)=C2^N
M)"XN1\IEM.@2O&OV-1E<<A)F];_CXACFO[)/!W/PEQ^^"J$M\;0C"STEV%^C
M$XR3:]6#_$'DCR-_6L>QXU+BXQ)M)1KV$IF'\,1Y.M=>#;D%BQ[446+S"(/W
M#'K;/'?H9'QC'HSEX[B<^DE>'V"*N=/53,F>Z+30I@@B+!E=>>@IIPUUZ&A#
M1R\ZAM QP8A8C(Z5.E,;D+F#J#B@T]%\&G]Q*M[93W^<@F?WNKRC/:[?:+<;
MZ]2<G_!/=/^59>]I<"_+SBU,M=?RV54L 9>[^="V0$9^C,YU2=?9KH4ZTZU*
M9\QIT*&Y'3K=O4\'W8=UJL="[?>8T;YY:[1WWA;MF7>*=GD>T0[/B[7=ZX2V
M>MVCS=[/:)//V]K@^RU@C3@)[S*5O13#TA&-?I:]*R-83OGL7):?<_S<=,S+
M3T>\0W7()U$'?;.UW[=$I_A9M<>O6;O]NK1S?K]V6,:TS3*MK985VFS9J(W^
MN[7!_[#6^5^H-?[7:77 W5H9\(Q6!+ZC98'?:VF0S8% !UZ+<=1@[@37D(9<
M&$^Z$0OG8OD[R)1_:L \[?,/T)Z :.T,2M.VH'QM":[0II Z;0QIU?K0'JT+
M'=*:T$FM#IO1RK"U6A&^7<O"#VHF_%PMB;A:TQ%W:%'$4UH8^:8FH[[51)1-
M$Y$_P9Q.^GD&RW(Z*08X*PW=?+8W =Z'+3LBW;0M?+XV181I?52BUD9G:W5T
ML5;&5&M%3*.6Q79H:>P"+8D;U>*X:4W'K=14_&9-QN_31/S9&DNX0J,)MVDX
MX7$-)?Y-@XG?:"#1IH&$G_!")DL^J<]UX'QPNK/VL0U;-J60W^";M?$^6I40
MK.6)L5J:E*XE2?E:G%RN12EUFDIIU61*CR92AS2>.JG1U&4:2=N@H;0]&D@[
M4_WIEZDO_5;UIC^FGO2_JCO]*W6EVQQ(LZD;/)OGN)GE"G 6V$_JL8W/-F#+
M:FQ9@6^6I7EJ29J_%J5':6%&LB8R<S2>6:+1K&J-9#5J.+M3@]G]&L@>5W_V
M$O7EK%-OSBYUYYRASMQ+U)%[L]IR'U%K[O^ +]62RTJ8 [)M:@5/%3$.BTGS
MP&&P&VSBL]78LXR4# JCJ>RYFLBQ:"PW3"-Y"1K*R]1@?J'Z\RNTH*!>?05M
MZBWH57?AB+H*I]51N%KMA=O56G2Z6HHN4E/1C6HH>DCU17\ GP.;Z@M!@0/F
MGYUN A> @V [6$MJO(S48YHT:!);1@M<-5SHJX&B8"THCE5?<9IZ2O+475*F
MSM(:=90VJ[VT6VUE0VHIFU)SV4HUEFU50]E!U95?H-KRZV4M?U#5Y;]55?EG
MJBJSJ;K4B1*;'JDD%L Y8!_8;.HO%:;V@GYL&<&6 5[[RKS54QZHKO(H=50D
MJ[TB6ZV5Q6JIK%)S5:.:JCK46-6O^JH)U54O5TWU9EFK#ZBJ^CQ55)]0>?7]
M*JM^6:75GZJTRJ:R2B<J;+J?]/<JLSL([#'[7\ R/EL(1K"G'WMZ>.VLFJ>V
M:G^U6,/57).@QIH,-=04J+ZV0G6U=:JM;9.UKD_5=6.JJIM11=T&E=7M4VG=
M.2JNOU9%]?>JH/Y%%=1]HH):FPH-:FPJLMIT%ZGO<7 8[*B3UH#%O!\' S7P
M#=#.^^:ZN6JL]U-]0XAJ&V)5TY@J:V.NJAI+5=ED5453L\J;NE76/**2YL4J
M;EZGPN8]RF\^6WG-5RNG^1YE-S\//E9VDTTYC:#!@=N@1!>#@V +6 &FP##H
M!:V@L0G^W^PB:XN/JEH#5=$:I?*V))6U9:FDK4C%[94J:F]087NG"MH'E=<Q
MI=R.U<KNV*6LCJ/*Z+A2:1UW*;7C.?"14MMM2FL#K3:EM]AT4[-T'M@'-H"E
MI@8$!D G5*FQ%=[73L[= ?_N]%1QET6%W6$JZ(Y3?D^:\GKRE-M3IIR>6F7U
MMBJS=X$R>B>4UKM"J;W;E=Q[AI)Z+U="+RMP[[.*Z_U \3UDK-V@RZ9$<"UI
M]UE@%UB#KFDPTNZH ;6AMQ:J5-D-]X0^YB^8H^Q^7V4-!"EC($KI@TE*&\Q2
MZF"A4@:KE#S4I*2A;B4,C2I^:*EBA[8H9NAT10U=JLBAVQ0^]#1X3Q&#-D4.
M@'Z;HA;8='D7:T.78R_0"C )!D 7>IM(QZOZX#W]Z!^$?T-54L8\E3AN4<)X
MJ.(G8A4WD:K8B1Q%3Y0J:K)6D9/MBI@<5-CDM$(G-RAX\H"")B]2X.2M\I]\
M KRC@/$?%#AFLR-HU*8+T;$?;  S8!3T@38H6AVZ&?(J&$7_./P7ZA@[[::(
M)3X*F_%7Z$RX0F;B%3R3KJ"E^0I<6J& I8WR7]HKR]))S5^Z6GY+]\IWZ7GR
M67J#O&8>!:_+>\DW\EELD^^T V?3OEU@-9@"0Z ;- [C W073<#_H4@IB]$/
M;0R'1@>NGBO+6E_YK0N0[[H(^:Q+ )GR7E<DKW56S5O7+H]UPW)?MU1SUFV3
MZ[HSF?BN!O?3X1"R-9_)9379]"J;W,#I8XP'L Q,H+,?M/*^9I(^6 3W6X)^
MZ%'L*O2O1?]&.-@6-WEM]]+<[1:Y;"?YV4[BL9W%?P>+S XFM!T,IAT$T X<
MMV,]@,3O,-<^0%RW0=JV?@+((K<X< IM7 <6\_51T,7[>MI<3IOS:'/J&O1O
MD,*V2 ';X<!P=-(DN>Z?)QV SQT@\3J51.,@B<A!%MK36/!.8U([K=5Q%=)I
M"#EM#[B W]_*=R&0!R"%!WX@"&QV;$?72G-##^U=P&L+;:Y:30QB?MIF*0Z]
M88CPWR?YP-'=#Y/TXEJ=Y09(/L\F\3N&'>=@Q[G8<5XJ28#9FLKD=KZY'HM&
MG8^@\R'VYT'FSX-$G_L6W_^.O[/9L1%]R\P-/>9T%KZNP==%V^#_M#=NOQ1Z
MNF0Y(GF?#0<^#]T7@4L!KM5Q[+@<?UR!/Z["CJM) J_!CNM(/JYC 3X![S]!
M<)TPCPI#V'60^VLA]-= GJ_YDN_;[%B'SJE-C(6MQ.%.YB'\G$7WQ=/6T'/0
M#U7W,O67*YWUE]F]**8><@O O;J-Y/QGWM(=%I(1XN-N[+B7Q.->%KY[VYTG
M=?#%?<< ?WCO+Z5[/N)[-CN6[6)>WLM8A))7X>=<OI:(WC!,MA#*GM<[=?W,
M67>9K84\"!YRUD1,C>(Q",'C^.0)^N8I<VL)=CR;!6%A\7N.^'QN&:!#G[L<
M\,?/_07 ;)ZS:>$AUD5S0S%^+L3'J>B-O('^_R_T&YWW.77]W%ES,7609YUD
MR-1#GC^I'F+V:OQNKO1'B,I? J2_88?91OQ&O?0F\?D60?;V60!?O$5LOO4.
M[[_4$&UNO=P\H8D^H+VQZ UD&'L_ZM3YM%/?"_II/\B?G+60'T_G.&LALZ=F
M[$_6A:!\3HQ\36+\#3'Z+\;)M\3G=SC^^TO '> 9\*9^.A'BXWP_>RIDMOY@
M;NCHDN,))5-R/"EEG1Q/SS5UD .PM\/Z#K;U+QC8-_"[K^!67\ 2/Z>3/H,Q
M_U,?VN]*G;V=P]0A_I\<>R">L_--4_MP=]8>S%X(LP=C=C^*.2%3;:_%_* ^
M?:M1=$SK2ZU _CKD;T'^+N0>@*\?1M,Q>//%>A<V:DZGO$%'_IW.>YUWK\&Y
M9Y^(8DZDF/T73\BQ#^*G_1=RUD&,3X)H6QSMRJ1-)>BJ0T\'.@:0/X[\Q4A=
MH;]AQVO8\6?L^!-VO K;_!TL]!4&[V]@JB_ N7^-+WZEW^H9/&'V?#SEA-E[
M<;^S!O&?>S"^PA>?X(L/X+KOX(LWX;I_4R5ZFO1[^N1E^/:+V/%K[/@5_?(,
MO/]I>/^3V/$+['#<D'$^.JX@E&]B"-W'?\^BZVW=C2?O<M8]S-X+\[SCFTZR
MP9Q*,8>NWI(K^GRQ/(AVQ-)?&>@IPG:K'J=/'E6W'L:.![#C/OKEGA_W86Q&
M[B[=!M.^%19^,Y/934PH-S"H3^!Q<W?)-?2@><Z0V7=A7LWSAB]WVO"=LZ3W
MNG.(/8TO'L,7#Q$7]RD1/3GH*$5:+?);D=^#[$%DC^/Q1<A>ALPUR-R,S-TZ
M;F?]QXB,XW9++L#B\QC$Y]*;9L_%L9-@?C;Z/W8.M5\YIX'[\,7MC)-;&",W
M*!H]J>C)1T<%4NN1WX;\'D;!(/+'D;\(^<N1N9;1L14OG$*/'"$Z+M(A_OIT
M>N @GCQ S^XGJLW.JOTGX7.FM]=9>IYABGO @VF7)>!&^[3L09OFHR\42?'T
M< 8V%Z*C"AT-:&AC)/2B8Y!6CZ-C&ATKD+D!"W9J#Y_NQK*=6+Z#'MJ&9[<R
M*C;3'Z:Z>3+,P\E_PS3_$+@%7,54>PE3_P4L >?*6V?)'WT1Z$I"3PYZ2FB'
M57O5B)X.(J //</:KDGTS#!*UFBSRU9M=-FO]:YG:YWK<:UQNU6KW1[1RCE_
MT KW?VJ%![/,27B-J?U)EMW;P54L>Q>PY!QEFCV$/:?YN.J@NZ_VNP5IS]P8
M[?1(T_9Y>=HZKTR;/6NUR;-9&[PZM=ZK7VN]1[7&>UJKO%=JI<\F+?<Y1<M\
MCFK&]S(M]KU%T[Z/:)'OJUKH]YDF_6S_AM]%.6HPUS.U7\3K$7X^$ 'WQ:8=
M@<#BKNV^\[79+TP;_!*T;GZFUE@*M<I2J966>BWW;],R_Q[-^ ]I2<"DI@.6
M:5' >BT,V*V)P#,T'GB)1@-OTG#0PQH*^KT&@S_30+#M)P0Q5R8X;D6Y,I%T
M!!PPM8]X>"<VK8\DQ\*6M8$^6A44I.7!,5H:DJHE(;F:#BW5HE"K%H8U:3*L
M0Q/A"S06/J;1\,4:CEBCH8CM&H@X70LB+U1?Y/7JB7Q W9$OJ2OJG^J,LMG1
M91!ITY/F9!*IS\6ICOTGNU,=M8\UI(<KL&49MLQ$SM/B2']-145H,CI1XS&9
M&HLIU$ALA89CZS04UZJ!N![UQPVK+WY*O?$KU1V_15WQIZHCX3RU)5RGUH1[
MU9+P@IH3/U93HDU-"38U&\3;]&@&_9!)B@5.9;G?QNM:/EM&"K(86Z:P93)A
MCL;C_322$**AQ%@-)*6I/RE/"Y)+U9ML54]*D[I3.M69,J".U FUI2Y3:^I&
M-:?N4U/:.6I(NT9U:7>K-NW7JDG["-CLJ$UUX %2X:M9XL_*E?:"C6 %/T_S
M^23VC.&;87PSD.JC!6F!ZDV/4G=ZLKHRLM214:3VS$JU9=:K-:M-S5E]:LH:
M4V/6C.JSUZLV>Z]JLL]6=?95JLJ^4Q79SX(/@,V!+ ?N)@V^/%\Z@R5^)U@+
M9L DGXU@#U1.?: GVU.=V?YJSPE76VZ"6G(SU)R7KZ:\,C7DU:@^OT5U^3VJ
MS1^6-7]:U05K55FP6^4%1U56<(5*"NY0<0&S?L%[P*;B?"?R;/I9(;%0Q#@D
M!=T*5H)%8)3/!OA=+S9V8D];OKM:"N:KJ3!$#86QJB]*56U1CFJ*2V0MKE9U
M<:.J2CI543*H\I(IE9:L5DG)#A65'E%!Z7'EE_Y,N:5/@W>56_*#\HIM#A39
M=$L):3?8#S79Y-S_8NHO0Z"7SSNPI06;&DO<5%?JJYJR(%G+HE15GJ3*\BQ5
ME!>JO*)"917U*JEH5W%%OXHJ)U50N4)YE=N46WE8V967*:OR-F54/JGTRK>5
M4?$]L"FSW*:L,INN1^<QTM\]%8Q#L 2,53CJ+UV@F=_7\UH#;:FJ\E9%E;_*
MJL-56AVO$FNZBJQY*K26JJ"F1ODU+<JKZ55.S9BR:Y<ILW:+TFM/4UKM)4JI
MO57)M;]04NU;2JKY3LE6FU*J';@:V6=6,1>1_JX"4V (]( V4 ^JK/ N*$M)
MW3P5U<U707V(\NMCE-N0K)R&;&4W%"FKL4J9C8W*:.Q26N.(4IN6*+EIHQ*;
M3E5"TT6*:[I9L4W_K9C&-Q3;^*UB&VR*J[<IOLZFX\@_'?E;:J7E8 +T@TY3
M_P'6.K@W]+&H">[7[*;L%E]EM@8HHS5"Z:T)2FM+5VI;OI+;RI745J?$]G8E
MM \JKGU:L>WK%=V^3Y'MYRNB_4:%M?]<H>VO*ZSM7PIOM2FBQ8&+2+OW@PWH
M60)&G#6@-E /3:I$=W$+^MO@_QWPWRY/)75;E- =HOB>:,7U)"NV)TLQ/<6*
MQGE1O2V*Z.U3>.^D0GM7*Z1WCX)ZSU%@[_7R[WT8_%7^/5\KH)OLN8NL$9R#
MCMW-<'\PA:Y!T 6: =VK4FA2?B?ZH8XI4)6X?C=%#?HH8LA?X4-A"AV*4\A0
MJH*'\A0T5*[ X7H%#'?)?WA4EN$5FC^\4W[#9\EW^!IY#]\O[Z'?@<_E,TCF
M.D FWV_3&;1O&WJ6@W'0!W"G&DP-"MV%Z&;J$5.@XH?@/Z-2\(2'_!?ZRK(P
M$$3(;V$"R)#OPD+Y+*R6]\)6>2T<T+R%B^6Q<+/F0J3<%EXNUX5WR77R>? /
MN4V0R8_;-!<<0,<&L!@,@V[0 JP]Q""Z<]"="D6*'T,_M#%X$1QPB9M\EGEK
MWG*+W)<':^[R*,U9GB37Y=ER65[JV."U'"'+)P!$>CE\=QED>=EMTE)XS5*X
M_PP9W R9Y!)8R@+&0S]SP@+'6; .4,_/Y=#EO!'X_SCZH4<1BZ6@I>A?(?FL
M=I'[.I*O]20\ZTDVUH?1$/C4!B;UC4QJ&QEL&^%5&W'<1GCF1LCT1@CT!LCR
M>LC;>@C9.FQ8:[-C,WJ6TLXQT,>?-)L:$&TNH,T9TU+"#/K1&[1&\H,N>L'1
MYVPCV=L!K]Q!PK43.W:1:.P.9Y*)8]%AL=O+!+N70;477^Q="/BCO6?P^VO!
MPWP7<KCK7_PM-NRP:2VZ%N&R8;,/A_>UM+EX"3&X'/Z]&OWH#82V^VV7YNV6
M7$]!/QQ=!UV8X$GX3L>.0_-9<+#C"':<:?XA*-.Q)^4L<QB3AAU=">B/HY<Y
M]Z.\RO>_^G$_R@KT$3KJ XWF'!A?SUDG):$W8@?Z]TJ^!R3WT]%[!)PMDV@R
MP3MQ(?ZX"'Y["?ZXE'XY3K]<CAU7L/!>R>1W)8%]A;D>".==#KF_'$)_G S^
M^"?29=APJ4U+S5DHT(:OJS<2 WPU>0_QA]Z P_3]62?57TSM9;868M^+XJR)
MW(!/;B(IOP7.?RM<^V?8<0<)V1W$QAUUSG,YYG'9-.1V_O#VQ_C.VR3QW]EO
MC5V(WIXMQ"%A4[R/&.1KT>@-I(T^ETIN5SIUW>BLN=SNK(7<!>YQUD3N=]9$
M'IXC/8I/'C.WEI $/IGDV*QKKI%_BKAXF@Y]^@( [W_Z97[WJ?V).4.TN87^
MK2!DL@C=N(N)/_3ZGD#_+4Z==^NG?2AF#\H33LR>R3$UD=F]&O:S,N;V5OKF
M?_#'7Q@K?V71>XT)[G6"^_73I+_AB[_!IOY&;+[^N;J/$H>TN0 _)_.KL)N)
M/\R<:^HO#SMU/N74,WMCJ_E':;,Q_U5G/<1^%N<_:B$?F"?Y8L?GQ.D7Q.B7
M],E7#,*O&2/?$%#?$!=?(_AK<Q;&6S^=_YB]F=/Q9)"?GIIKGEAK]H*8FT+,
M4V/,C:GK96X+^0$V]1W,YUN8W3<PL:]TB;X@8#ZCXS[%>1_#(#^"<W_(-\RM
M'!\X:Q"F_O%+9PW"4?N8Y?YSG?4'<V-)O!Q/23$W=#3H>W6B8P =$["U)<A?
MJ4^PXQ_8\2%VO,^ ?9>!\P[L\TU8Z=\)UM<)G+_ UO\$DW^5OS)G7\S>$[,'
MXQ?.&L0#_T?]P=1EOH???:-(?0G7_1Q?? +'_%#-Z.A&_I#SEM E2%ZA/VH=
MLK?H%>QX"3M>T)GHN("NNY)VWDPW/H"^Y^W/C9D]>V)PK[,&\5__88-Y"/*G
M^.)]^>DMA=".>-J1"2<OP?X:_-=*Z/7H&>QX"CN>@.<^#M]^#+[]*.SU8=CG
M@]AQ/ZSX7ICYW0S@.W4'NGZAGR'-W"-KZAZWR+$/XUIG'>*G^HOC#,J?Y=B#
M\1R^>!I?/*%DPC(7'67(K]-]V'$W=IA]&+?_N ]C&2U>X]R'L5LGX-S7ZACR
MC^.-F^#O#_+N)::7C^TGJ,R^"[,/PSQWZ'RG#5\ZP_D5YW![!%_<AR_N)"YN
M4RPZTM%1@/P*IHIZ(JY-5V''%=AQG#B]5(N0N8QI; V]L 6Y>YE*#V/%!?#V
M:_'*G?30TT3MVWSZK7TWTV$GS/NOY;B0YP5G_>,>YU1T E]<C2\N5SCV)V)[
M%CJ*D%^%_ ;DMR&_!]D#1.(8\A8A;QD>6*>#VLY(.:!]3.RG(&$/$G?CR5WT
MJKEOUYPP.QFFG/FR*VT'M[DXIL3+P<7XXCS&R-D*HAW1M"$%'3GH**''J[4?
M.T[!CKW8L0=_[*)?=M(OVQDO6[41;^S1)OYJ(Y+6X\%U1(G91;2&D;0:O2?C
M-9:])YCF;P=7@0OX^2RF_C.PZ73FC .RT)Y0),:A)PV[\[2-V-C"O+%9C>AH
MUP;UHF,('9/HF-$JWJW FN58O!3/S= ?2XBB:>:*17H/?&<_>3>+EYC:[V>9
MN8XE[P)P!N_WLQ3O\65Y]W31#C=OVN6/O@AT)6J=2Z;6N!1JE6NY5KK5:KE;
MLY;-Z=32.0NT9.ZH%L^=UJ*YJS3EOD63[@<TX7&.QCRNUJC'G1KV^*6&/-_1
MD->W&O2RV3$$?AG,$F;.WC"UGPGV\7Y;"&D/Z< Z[%OK.U=K/7VURC-(R[VB
MM=0K14N\<[38IUB+?*HTY5.OA;ZMFO#MT;COD$9]%VK$;X6&_#9KT&^_^OW.
M49_?U>KUNTO=?L^JR_(^^![8?L2CD8[MG^='._XY:#NOZ_EY903I'_;,! '+
M/"V>;]&4)4R3EGB-^Z=KS#]?(P%E&@ZP:BB@20,!G>H/[%=?X+AZ Y>J.VB#
M.H/VJB/H++4%7:&6X-O5'/RTFH+?55/(#\#&>P?N(PV\RJ0^+/=[P,8$1^UC
M,9]/8<\$MHR'NFHLV%?#(4$:#(G60&BR%H1EJR^L2#UAE>H.KU=7>*LZ(GK5
M'C&B5I+/EHBU:HK<I8;((ZJ//*[:R-M4$_F$K%%OJ3KJ.UY9B2(=N"/1L17W
M4#(^,/47L(3WDWPVBCU#V#* +?U1WNJ+"E!W=(2ZHA/4$9.N]IA\M<66JB76
MJN:X)C7%=:DA;E#U<5.JC5^EFOCMJHX_K,KX2U4>?ZO*$AY7:<(;X%O 2A3O
MP*WHO) E_@"IZ&:P'$R!D31T\[L^;.S!ELX$#[4G6-2:$*J6Q%@U):6H,2E'
M]4E%JDNN5&UR@VJ2VU6=TJ^JE E5I"Q7><I6E::>IN+4BU64RBR7^ICR4_\&
MOE%!BLV.PF2;;D#?.1FDO5G$ 9@A#1SG=9 EOY?/.[&E'5M:4N>H,=57]6E!
MJDN+4DUZHJSIF:I.+U!51KDJ,VI5GM&JLLQ>E62.J3ASJ0HS-RD_\U3E95VH
MG*R;E)7UJ#*S_LKKU\K*M"D[PX%KS;9L].[,@>_EDF/G.NHO??S<"5KY?1/V
MU(&:+&]59_FK,CM<%3GQ*L])4VE.KDIR2U2<:U51;I,*<[N5#S')RUNBG+P-
MRLK;KXR\\Y6>=X-2\QY62MZ?P5=*S;4IS2#'IBO0<YC4<UL^L5C@V/\R"+KY
MN14T\KM:;*KBM2+?4Z7Y%I44A*BX($:%A<DJ*,Q2?F&A\HHJE5O4H.RB3F45
M#2FC>%KIQ>N46GR*DHO/56+Q"244/Z3XXC\JONA+)139E%@("FRZ%#T'"QU[
M@9:",5+0OF)'_:4)U((*?E_*:U&QNPI*_)17&JC<TDCEE"8HNRQ=F67YRB@K
M4WIYK=+*VY12WJ_D\BDEEJ]1? 4S;,4QQ51<IZB*!Q19_GM%E7^AZ#*;'3&E
M-EU0Y+@A9QV49!H,@V[0"NI!%2@N(]\LEW(K7)55Z:V,*G^E5X4IK3I6*=4I
M2J[.45)UL1*MU4JP-BO.VJM8ZX2B:U8JLF:G(FK.4EC--0JIN4_!UE<48OU,
MH=4VA54Y< P=N]"Q"AT+G36@#M!DZC^@'!1 57*L4CKT+:5NGI+J_910'Z3X
M^DC%-20JMB%#,0T%BFJH4&1C@R(:NQ36.*K0QN4*;MRNP,8S%=!XE?P;[Y&E
M\259&CZ5?SV9*PBLL^D(]'1;E6,OT!CH!:VS-2!0@NY<=&= I9,;X;_-;HIN
M]5%DF[_"VT(5UA:CT+84A;3E*+B]1$'MM0IL;Y=_^Y L[3.:W[Y%?NV'Y=M^
MN7S:[Y17^W/R;OM0/JUDKBT.'$3'QAK'7J AT 6:0 TH)QTO0'=F$^UO03]4
M):I#"NGV4&"OGP)Z ^7?&RY+;[SF]Z;+KS=?OKV5\NUKEG=?G[SZIN39MUX>
MO0<TM_=BN?7^EUQ[GY9;S[O@6\WMMLF]RZ:]Z%C=P'B@C0M .VC@YRI>B]&=
M@^[4=O1#&Z-ZI- ^.." F_R&O>0]8I'72+#FC43)8R1)[B-9FCM2(K>16KF,
M\ <C$/B1E>:1OP#". SW'WZ<QI(U#7W# +398<Z$+0.CK<R'O+: 6E#&SWGH
M3N^"_T.1HOII_Z#D#TWQ'7>5YT)/S9F"PTRQX$^QX"YB4E_$A+N(0;R(#EZ$
MD$7PS$60ZD60V$60J2DRI"G(VA1D:"$V3-KL6(]OIS%YL--Q%JRQPU$#*NBF
M#VAS(F*BAM$_CGXHH^\B:1YB79>1Z"PGZ5E.LK&"A7XE?&H5B]TJ)MY5#+95
M=.8J&K#*/(9I/8#(KH)$KH2<KH"8K2"+7HX-RV!,Z)F@G0M .[ZNX;68-F</
MP?]'X;^("#'UGQDX\'+)?16)WCJPWDW: *_<2+*SB41C"XO\5A*!;2PPV[,<
MF_^V-9O'80%XYC;S..)+^ YD><MO69R^ -BPR:8E?&4$'_?2WD9>R_%U+FU.
MF4(_[0U&KV6-Y+5!FK,9W:8&LPOL,<".4[!C'_XX@!VG8L=IV'&Z68B97 ]5
M.S8^G3[E>"30Z9#JTR#2!W_%=__)WSCVHDRA;XC0:>.U&E\73!.#RZ28U>A'
MKQ]_ZKE3<C'UEP,R228)GQS[48Z:F@B)\#'S#W DHN?1+Q=@QT78<0D+W27T
MR24$]R4T]&(:<M$A0$Q<^ N^]SZ)D\V.27,6"M3CZQ)". ,_QVY!/WK]]DD>
MISGK+\><=9>+Y=B+<MR9@)OZQ-6F)H)/3N"3&^B;FP(=FY1O9=&]E<GO5H+L
M5I3<@@-OAN#?#*F_B9BXZ6O[F9PANJH5$RMH<XZY!V<OXP^]?K33XURGSN-.
M/2?DV(=B"(@YEV/VAMQQ4CW$U L>A/,_3-_\G/'RN#FXSJ+\./'YWW3T?]/
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M8446SBBB:(O"B@XII.BX@@IO5V#AL^!#WML47&!32+Y-AY&]!=E+S3X@T%V
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M^$XX7@?$M0/2V'$AW[T-0$[:X-UM-CL6T[8!=+2!VDK'/J!"]&;QFEQ%#-3
M/VE28"/Z6^#@B)T';7/M@;_TLLCWPK?[6/@6,*$/,)$-)#J*G.:2H8%&Q^&6
M 0CT $1NX!P&']G: K+6!1_Q=S8[)M#1 YJ U4H_.&M J;0Y#JK*U*O -E/_
M@0/V2.Z()%F0ADEV1D@R1KW-/RXPL%C8)EE\%IK"OSETF>^X=,@\]&DAA-H<
M<)B$P$Z>8$*&&(Y_P-_9[!C"U YT->#C*N<^H/0F*;Y5BH":!9KZ#WJ]!N&
M<'02&.2!16 Q=BQQ9Y+%'\NP8P5VK&+!7<WDOSK=4?!;C;#50WR^"L#Q5D*<
M5SPB+7_'O@]%2\FGT-7::NX#P@?X.JN=&.AB#/2A'[U^Z)U',UP(;U(C_A:8
M_2AKY-B3 E_6)OIE,\G85OIE.W;L8H';S6*SFT&W"U_LHB$[%P/([0XRYNV0
MV*VODS!^9]^/THV^%G,?#Z]Y^#JEGSD(>AQ(./NBUWV94^=L_<740G;*L1?%
MU";V.1/@@_CDD-F03)P>Q8YCV'&,<7*,P75VH^,RX*,(.?,L$M=;^1YD^=!7
MTNDV=?4Y[L,IHLWI8XR!*<<9*%_TSMW@U+G;J<O4)&;O13$)^'_60^S[0_#)
ME=AQ#7:<8-$_8>XG(<"OQ1?7(/@:#+X*8G\E,7$YS.ZX3<WXNIPV9]/F>/P<
MLLZQ!V;N;F?[#COUS>Y#,7M"?MQ_(D<]Y$;]^YVM=Y$,WTNL/H@=#YD+])A\
M'R3H'J"1]]&H>V$1]][']_X.J?I.-?1Q_DK&(6X*8_C,W^>\ \:T\4*GSFN<
M!&3V/([9>V*OM^A_UT)F]X28RP->]'(\Q?<5QNO+C-67Z.P7<? +./(Y#/XU
M[.K7'ZN4(9,.H8C>+_DS=.:=Y]1[K9/TF1J/J8.<O!_DZ9/TS-Y),EL',?M!
MS#TAYA^0S4;^]_''!XR5]UF8WL<7[S.HWM_%9Y<!&O'![T_B_>8.# \YSJ&8
M/1CFF2CF/@YS-ZIY-HMY<JYY1DR_S)F8[QF<YF[2?\& OB98OX09F;M)_PG[
M_)B.^Y .>P_'O8V#WH#)OP;/-+M.S!X,<Q;$/!7U3F<-XO_:@S%['X<-KFMJ
M,=_"9;Z"3WT&C_D8YO(A=KP+RWD+YO,&K.MU!LY?8(!_PHX_8,<K!.UO"-+G
M=1T,\V[<]BO<]Y$>=]8_C.Z;Y;B#\]J3;##/(C'G4,Q9B$_DB1Y_](3K'?C,
M6W"JO\+[_R"K7H8AO0![>@ZF\RQ,ZVG8UY.PL<=A@X\Q63R*'0\1S \0R/?2
MJ7?I%D+H4=U&Y]RJ[^RZ3>WC,OUT#L3H-_>0FF>AF!J$N8OB97CF<_CB&7SQ
ME*)I0XK]+,HC\-P'X'7WXH^[Z)?;85NWP?9NA0'>#".\$8YY CNN90*Y&I9^
M)0/W.!HOY=L7XY6+Z"FCT^S#,$_V,;4(<P;$G('YT!E&OW*&M]F2=(>\&&H6
M6A&*_#C",PW/YB&[3%?@C^-J1';[2?=AC"%[6N=@Q]GTRU$F%7,3QF'8_.E(
M.(B7'/=@..Z^V -V@YVRV:^U,0^)_H5SR-WH'/Z7:"ZR?8FN )T+USU'"0S7
M#&3G([L,V5;[/HR#,-D#L,Y]+&2G8,<>[-A%O^R <V_CTZW\U68LW\C@VJ"7
MF&Z_M)_L,C#/@S:W_O[).:S-5K"KG%,>LZE]:]ZIQ,4^N.XI<-V]<-T]2D)^
MIK9CQU;Z90MQNDGUR&]%9A?+1S\RQQ@IB[%B#4O+#D;.(9:92_CD5JQ[@M'T
M :^V'['(7JMS3 &7.Z?#@\ZE8+M]>9B+[3[(]D=B*(A!?C+RLY"?C_Q2Y%<3
MD?7H:$5>-R-ED"B=)$*68<TF1L]^.+NY/?4$OWD(;_T5? L<.[X,[G=.NV<[
MEP3SSP%F.63J1(H+\CVQUP_Y@<@/9]F.0T,*2W@6.@H8&:7HJ$9' _+:\$0O
M(V:$:)TF4M9@U2Y&T9E$\!5$SUU\XT7P&;#989Z3;6HPYACHJ2QY6^:Q1,YS
MI 3FGVE,JC"*+X;QQ1#Q.6"O/T2B(P$=:6C+1D<AO5"&'BMZFI#9B4<&U(*E
MS<1G(ZUJH&?KB.!:HKP6S]?H?7OEM]:):]!YICF6R]*_QORS$!@#@WRV@)2@
M%WMZ7.>ARQ?I >@)14\,;4A$3SIZ<M%<A*X*>J2._UJ1VXM%8WAG1E7T1P61
M54Z$ES&Z2AD?)<QL)<P(YE:F4G I^@[Z.;;$+O5WI&3]O.\&[7S>RN];O-S4
MXN&EICE^:G0-5+UKA.I<XU3KEBRK6Z:JY^2K:DZI*N=853&W2>5SNU4Z=U@E
M<Q>KR'V#"MSW*]_]?.6YWZ#<N8\H9^Y?E./^A;(];,H!YYE__D'O&I:WJ2#:
M#[I!*S\W!I!;\/M:;*GU=5>MEX^LGA95>8:HTBM*Y5X)*O-*4ZEWCDJ\BU7L
M7:E"[P85^'0JSV=(N3[3RO99KTR??<KP.5]I/C<HU><1)?O\1<F^7RC%UZ94
M8.Z"V8[.Y2'FW UI+NE/&Z\-H(94N8K?5?"=<G\7E<^?IS(_7Y7Z!:C8+TQ%
M?K$J\$M6_OPLY<TO4*ZE0MDD_UF6#F58!I5FF5:*9;V2+/N5:+E \9:;%&OY
MN6(LKRO&_RO>VQ0'#J%C,_J60 ^&(QQ[3YIXK065?%:&3<785\3W"@/FJ"#
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M(=I2# <J=9%7A8?<*[WE6L4D6LTD9F606QE$UA2'(+.9Q J)M4+2K9 8*]F
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M *JX-A;R1C/Y)T 6[Z51O 1"6;$IW$1X*C\1F"Y,>-4QP*BC@\^ <<^  <U
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MEW&Z01QG&&"OP>!#>:*P,@E #J_'H%15#!E34:X&RF6?QVD+&[&&C5C!1BS
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MY 7W$UE!,R(CZ$%&",00:8$B(L7?023Y[@.? 4ILF./Z((_9,K]:DOV3[1Q
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M!K,LS16Z<"9"K+,XG1%C.B$JL@</6[2+-6(J2T1_S'F<9ISS.(T1B1MB C'
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M3)5%4&=QIM(C4&MYIMI*3+W'HN(3F)JK,56?@;K/9BJ_@*G]4E1_)5/_M5"
M%J.!K8P*=D$'VHP2=!@M&$ -QHP>+!A%V$(3CHPJW* ++T89_HPV0J"."$8?
ML8Q"DJ"1-$8EV8Q."J"4$D8KE5!++:.71D8QK=!,)Z.:'D8W_5#.&48[%QCU
M7(%^KC,*N@,-_<&HZ FCHS^AI#>,ECXR:OKVG5H8VL]@VIV'Y8#]MS'\'][_
M7ZXOPL7%S<W#PPL=\ L(" H*00_"(B*B4,5P<7$):$-*&OJ0D85&Y$=")U *
MM *U0"]0#*,9EFK8NODOY;!T ]5H;62Z$GJ2]OZ#A_0,#(U-+:QL[!U=W#U]
M_ )#PB*C8Q.24M(RLG+R"M!=F-Y2>P259-7QOZK(KB.KDDPM44W4$Q5%35%5
MU/6/!ZCMH\>H[]-GJ/&+/_]\B4J_?O/F+>K]_L.'CQ\_H>Y?OG[]]NW[K_K3
M@O'\-%]=C!8ND*,U*\?2E@TS:==.S>_'#FJ_/G[8^GZW>>!O1ZU33M7:EQXK
M<VQL*W3I;LSQ&*C)\+U0EAIRO2 IX<&_Q2\.OSC\XO"+PR\.OSC\XO"+PY Y
M%'(X%(%#[4H5V@H.QW9H?NT]H/WJI('-O5[3H,N=5FD#3;;EW37V1ULJG([7
ME;B=+LOSNIB;&7 M)37RSK\%BT,!.!0OD*5'P*%]PPS:LT/S4]_^?7^>UK>Y
M=\HD^%*O17I?AW5E6X/MT;IJAV-EI<[]N07NYU)R?*Y$9X3<^+?XBT,I.-2#
M0^>&&=].;M=\?WK?ON?G=&WOG#4*.3=@EM'=:5G1T&C35%YCUY57[G@RM=CE
M3&R^Y\60[( K_Q:TB,.A#!P:5BK3K@TS/@]L6_7FG+;VD]\/V=Z\?#ADX)1I
M>DN715E5LW5#09UM>WJ5_?'X,J?^L"*W0?]\GXO_%BP.A>!0L4"&-JU0_GY\
MO?J',]M6O;R\1_OA[8.VEZ\:!!\_;9):=\R\N+C%JC:SP?IH8JUM9V2E8V]@
MJ6N_5Y'7F7\+6@P.1>!0.5^&'ETQYDOO^NEO+VQ=^?3&;NU[#_;;G+EF$-0V
M:))<V6-6D-MN697<;-4076_3&EQCW^53Z=SC5N[1]V]!B\<Q'$1I]?P1M&W%
MZ ]]ZZ?_>67+B@?W=NZ]_FB?=>\-_8"&<\8)12?-<M*[+$KC6JUJ0IMM&OSK
M[5L\:ITZG*K=N_\M:,DX/EH,#D?F2W_O7*'TYO3ZJ8]O;%YVY_'VO1>>[+/J
MN*7O6W7!*"9GP#0CL<>B(*+3JBRPS:;:ZZA=O6NC4Y-]O5O+OP4M!8>2Z:*T
M89[4I^/+%9^?7S?E[KV-RZ[]N6U/_W-MB\8[>E[%EXTBT@9-DV+Z++*">ZP*
M?+MM2MPZ["L<VYRJ;5K<COQ;T#)P* .'H_,DW_0M'W7_ZKJ)5QYI+3OS9NON
MSC_WFE7>UW7-OFX4&'_1+#ILT#+)_Y1UND>?7;9SKT.>W7'G0LMN]Y)_"UH!
M#M73A;]TSAO^Y.QRV:MW5T\\]4)K^;%/6W;6O]EC6/!8US[ICI%GQ#6SP(#?
MK,*]+MK&N)YSB'<8=$ZR.>V6:G[*,_W?@E:-Y:4-4X5>G9PC<N/Z8JG33U9/
M[GJ_85D#W;RU],.>0VE_ZII%/3*V#[AOX>9UV\;;Y::]G\-UYT#;JVXAEE<\
MP\PN^T;\6]":L;R?.]3X[UV<+G#FP4*9KC>:4^KHNL7%=)-6YK?=>V+>Z^H&
MOC(Q\7IN9>GRQ-[6X9&3@\U#5R?+/SQ<S.Y[NYG<\W?_MZ#U*CQ/!U2XS]Z;
M(-#]:H%\W?<5DPOIZOEI=*-F+-VU.?"[WB[/SZ;[G3Y8'[)[YZ!O]<;YL,5K
M=R/35U[&QB]]30W_###[MWC?/8KKXBT)KNX_587KORX864273$BAJS0BZ(;%
M 72GICO5W>! 33=;4^MMYM1AA^EWEUW&W]QW&W[UVF/PU5=;_TO@OG^+BX/#
MR/'GDMSU7U1%B^D<^12Z<&PX7:[F3=?/<J;;%]A0G:7FU&2E,;72/$SMU^A3
MI[5ZU&V=+O5<KT-]UA^D_AO^+6B6"A_-F"I",^>-H,7+E6C-NBFT8?LBVG1@
M\Y<&0_T7=59.=\L=0J[DNZ6<2?,J/!GG7],=$=S<'AS><=0OIJ?1*VF@SB-[
ML-(E_]P_Q2\.OSC\XO"+PR\.OS@,B4,6.)0N4Z)'P*%YVR+:LG_SYZ.'#9XW
M63C?J;8+NU3LDGXJRZ.T)\FGOB,FH/UH>$A/0U#4J5J_Q/-5/MF7BSQS+_Q3
ML#AD@D/V7&E:!@YUX- "#FW[MGQN-S!XUFKN<KO>-N)"A5-F?[YK17>Z9W-K
MHN^QQNB@_MJP\/.500E7"OTRKN;XYESZIZ#9' XYX%"^3)$VK)U"V[8NHIW:
M6SYWZ1]^UF7J>K/9.NI\C4/.R6+GZLX<M];F-*\3=8G^@]7Q$9?*8I*N9H>D
M7T\-SO[MG^(O#KG@4 $.C6LGTPYPZ-;>\NFXWN&G/29N-]LMH\\UV.7U5CH>
M:2]RZ6S*\^JKRPD<+$^/N)27&'\U-2;]>D)DUI5_"A:'+'#( X=*<&@"AZXM
MB[[W[-WRX>0APZ?]1NXWCEG$#+;:%/34V=>W5;MT-I1[G:PL"A@LR F]E)X>
M<S4A)?UZ5'S6E7\*FL/AD \.U4L5Z%%P.+9EX9>3>[:\&] Q?#QHZ'Z]SRSV
MS#&KPJZCMO4-M8Z=Y>5N)_.+O<ZDYP=<C,^.N!*1E7(M-#WKRC\%BT,V.!3.
MD:(UX-"R=M+WWLT+/P[LWO+Z[$'#AQ<-/*X.FL2=[+$H/-IB75=QQ*XCK\+Q
M1&JQZ^G8 J_SH;F!O_EGQ_SNGYO^VS_%7QR*P.$(.+2MF?3UY*:%[\[LVOSB
MT@'#^U?U/"Z<-X[MZC7//X*8N[#>MI7)@<1Q<B!^^3X7/7+#+KOE)5SZIZ"Y
MRFP.Q7,D:=W24;1CS<1/ YL6O+ZP<_.3Z_L,;]_6]3B%N+OEI%EN>;ME57:C
M=5-"K5UG1*5C3T"I:[\GVL2Y,.B<0T'4^7\*%H<<-6%:"@X-2T9]ZUXS\=WI
M3?-?_+YCTX-[>P]?N7O(K>>2851=OVE609=%6<I1J[KH>MN6X!J'3B8'XEKN
MT6=?ZC]@4Q)VZI^"YH%#+CB4SY:@S4M&?NI9,^'EN8WS'M_>IG7W\6Z#,_=U
M7-M^,PRO.&6:EG7<O"BNW:HJM-FFWJ_!_JC[$:=VQQKW;ILJW^.6E4&]_Q0T
M'QSRP*%JMCAM72+WMF_U^"=7-LZY^W"SUO4_=^KW/M!QKKMZ.*3@K$EB\DGS
MG(AC5L4!'3:5GBWVM<[-3@UVC6[-EO7>K69U >W_%+1 F9?F@\.1V<._="V1
M?3ZX6N7.K0VSKCS=K#7X9H=>ZZ.#]F4W#?PS+II$QYRQ2 GJL\KV[K$M<.VV
M+['O="ZW;G>K,FOUKC5N\3_R3T$+P:%XRC#:-$OTS8G%TO>O:"I=?K!N]L"K
M35K'/VS7J7EVP#KGKH%'PC63H-!+EE&^9VT2W$[;ISH..&78]+ED6YSPR#7I
M\2DP/!Y0^$]!B\?PTLK)@E\[-(0?#RX2_^W."J7^Y^MF=WS<N+[QR[9]A:\.
MF"0_/FP??M?4P^^&E;_[5;L0I]^<PNTNN4997?"(,3_G'6]\UC_Q\&!0TC\%
M+1W#0^LG\;\\.4/@Z@T-D8$G*Y3;WZ^=74NU5I?0K3O3/APX%/GRL&G 4W,;
MCX<VCD[W'5WM[KIX6-UQ]S*_Y>UC<M//S^A&4,#AZR&!_Q2T8C3/IX[Q/+<N
MJW //)HYO/WM<I5JJJF13]<O3Z=;-T9]/[ KX)/A08^WE@:.K^V,;?]T-K-\
MX6YA_MS+RO29K[71DP#;PT]"[/0?A]O_4] &!>Y'IZ6Y3CU0Y&U_,T.RABY1
MR:,KIB?2M0LBZ)95_G3_!C=JM-7^N^4NJZ]V>\V_..\S^>1^P.BCUT'#CWXZ
M!A\"#^F]#]'5?1^N]T_QYOAP<N:J,&E[HRA00V=*Y]$%HQ/HTLDA=+6&-]V\
MP)GN6V9##37-J<5:8VJWWI Z:1E0MXUZU&N3+O7=?(@&;#E(0[8>I&'_&*<&
MA$C[ Q&N*JHDE$_5I1+H;(4@NFB<.UTUQ8YNG&%.]\PVHOKS]:G90EUJLUB'
M.BPY0%V6[J?NR_91K^7:U'?Y7AJX8@\-_L>@*:/Y:.(489J L3I[R4A:O$:5
M5FZ=1:OV:=**P[L_EE@9/\]S=KF7YA5T+38@_F)8>.9@0$SA@'="^0GWE)H>
ME\SZ;L>\YD[[TM8VF]KV9JN:CJ'B%X=?''YQ^,7A?SV')'!( H<<<"A=/9Y6
M;YE%:[0U:;7![@_E%B;/BIS<[F1ZA/Z>Z)=T+C(D=R XLNR$;US-<<^DQB[7
M])9VI]R.5H?2[GJ;RF-';*NZA@HVA\G#:/)L29JW>"0M!X<CFV?1NKVK:9W^
MGO<UYF9/*AP\;N6Y15Q*\TD_'1M8?"(LM*8[(*JYPSN^O<4]]5BS2\Z)>L>2
M_@J'\MXRQXKC0P5-'<U+D\$A=98D+5@L3RO!H7[3+-JX9S5MU-W[KM[4_'&M
MG=>-8N?H"UF>V?V)ON7'(X,:_\Z!) _4N><,ECD7#!:XE)[,=RGO'2K^XI V
M2X(6@D.5YGC:" Y'=Z^F+8?VOFTVL7C88.-SO=PQ[FR^6][)5*^:SCC_UI;P
MD)[&X.B!NL"4,[6!^>?RW?//97F4]&=ZE)X<*F@:.*2 0SHX%"V2IS6:XVCS
MQEFT=??J[^TZ>]^V&5D^/&KE>[7&/F&PV*6P)\NCKCW)I[,Y/K2W/B9VH"HB
M>; T-.=\IF_>A12?XE/)OB7]0\5?'#+ H621'*T%AY:-&K1CU^IO70>UWW09
M6CWHL/#[O<$NZ72%4_'Q K?&]AR_SH:TD-[*A*A3Q3$)@[F1F>=3@G(OQ <6
MG8X++!X8*O[BD*DA04O!X0@XM&IIT*Z=J[\</Z#]IN>PU1_'S/VOM-@DGZIU
M*#M6X=[07.#349T9V%N<$CZ0DQ![-BTV[4)\9.[%J-#",U&AQ0-#!8M#*CAD
M:8C3,G"H7S66MFMI?#^V4_/3B?W:K_H,K/XX:1IPN<LJM;_9OK2]VK7A2(E7
M1VFN?V]N1NA 6FKT8$)2ROFH^-R+H=&%9T*CBD\-%32=PR$;',K!H0$<.K1F
M?NW=H?F^?[_VGZ?UK.^?-@Z\T&.1VM-J5]I<YUQ?6>'17E#DVY.1&SR0D!4Y
M&)6>>#XL/?="8$+AF<#XHE-#!9O#I&$T%QPJ%LK21G#HTIKYJ6^[YIO3VMK/
MSA^ROGW6,/#,2?/4S@Z;DKHFI_J2&O?VK'*?GJ3BP/[H_/ SH;D)YP)R<\[[
MI!>>\4DM.C54T'0E7IH&#GG@4 4.S:M4OAW;,./]J6VK7I[?N_?151WK:Y<,
M OM.F:8<1;Q;T6)?EUOGTI9<Y7$LNMSO9$A)R"F_HIA!S\+TLQ[YA:?=<XL'
MA@J:P>%0,',XK5DH0UM7*7_NW3#CS;FM*Y]>W;WWWJT#5A>NZ0=T#YHDU1RW
M*,IOM:Y-KK=OB:QQ[@ZL\.CU+O/M=RT)/>U8''_&L23OE%-9<?]0P>*0#@Y%
MX' $'-I7CGG7OV'ZB\M;5CRXLVOW]?O[+ =NZOL=/6<<7W+"/"^MW;(RNLFF
M,;#.OLVSVKG;J=*]U[;<K\^B++S?HBRES[(\Z\1003/!(6.2$"V9*48;%DA_
M[EXY^N69]=,>WMB\[.[C;;O//]*VZ+JMYUUST2@FI]\L,_Z897%(FTVU=[-]
M@TN#TU'[.K<VRUJ?3M/JX&ZCZMACAM6)0P;- H=,<*B8(4J/+I!Z>V*%XJ-+
MZZ?<NJ^U]+=G6W?UO=AKUGA/U[WXBE%8ZJ!94D2?9;;?<9LBMT[[<H<VYVKK
M%K<CYLW>#<9-@4T&C5'-^@TQ1X<*F@T..1,%:8VZ\)?.^1+/SJR0OW5KS<0+
MC[66];_:NK/]]1[CB@>Z3IDWC/QC+YE'!0U:)7H.V*4[GW3,L>UUR;<\[EYD
MTNU38M@96*[7$5&AVQ%5.5307$4>6CA!@#9.%WI]8I[HG2O+I<\_6#WYQ$NM
M9>T?MVRO?;=;/_>IKG7"/2.WT!L6_CY7;,)<+SI$VY]WB;,^ZYYH?L8KQ?B4
M7YK!0'"&;G]$UJ&^J"&#YH-#A2K?E_:I_ _.SA*\<'>1S(D7JZ>T?%J_I/K[
MYLV%GW?O3WZE:QS^U-C&[X&EL]M=.P^'6\X^-C?<_"VN>0697O4+,?H],-3@
MM[!PW<O1D8<NQ0P9M$B!A]:/Y7G1I\ISZ=8D@1//%LD?_;AJ2@5=NS"/;ER7
M2G?OB/BD>\#_K>EA]Y?6IH[/'2UMGKK:6#SVM#=[Y.MH_"# R?"/8!?]^^&N
MNO=BW _=BQTR:-DH[@^=BER_7Y?D.O%TXK"C'Q:.+*?+)V73U7,2J-;R"+IK
M@Q_5W>;VS6RW_6>;_58?'77,W[OIFKSSTC=ZZV=P^$V@H?[K4"/=5Y'&.B]C
M371>QID.%;1Q!-?E06%RXHD4=_.'2:+E=/[(3+I$-9:N4@^B&^9[TQW+G*GN
M:EMJNMZ<6F\TH8Y;#*G;5@/JM5V?^NW0I8$[#WT/V77P>\3N ]]B]^S_%C=D
M7#XN2'HO"I&F#]*\97226":=)1=-%RC[0Q>N=)VZ+=TVQYP>7&!,C1<;4*ME
MNM1^N0YU67F0>JPZ0+TU]U-_S7TT:+4V#5VSAT8!T6N'BN,G!$CC-0&N$BK#
MGT4GBT93]1%^=(Z"$UVB8DG73#2D6]1TJ?;T ]1@QCYJKK&7VLS>0QWF[*(N
M@/O<G=1K[@[J.V\[#9B_C88 H4,&C57DI=$8HR)FB]-DS%G9JY1IX::IM&CO
M(EI@H$5S+/=]2',V?9'@X_0P,L3W3F!4V'7OA+@K[FDI%YVS,\\YY.<.VI44
MG+:I+#YE55_:;]%><<RDK7(H^,7A%X=?'/Z7<HCC<(B:)4Y3P2%WU1A:LG$J
M+=VSB!;K:=%\\_WOLAS-GZ5XN=Z/"0J\&1(1?<4O+OF"9TK66=>,_-..N24#
M]D7E?38552>LZFJ[S)OK6LU;:H8"&@\.,1.%: S\ZO0%,C1_Y1A:KC655NQ:
M3"L.;?Q>8GKP;8&]Y9,L#X\[B7YAOT>&)EX(BLX^XY-0U.^>6G'".:OVN$-!
M0[=M67.G=5U+HV5]\Q&KIOJA@,4A%ASBX--F@D,1.%1NF$IK=BZFU3J;OE4:
MZ[PNM;5^F._J<S/5.^I2;%#ZF;#PPC[_F*KCGDGU72[I+>V.>1VM]F7==5:5
MQRIMC[26V34T#04T08'-(0$<LL&A9,5H6KU^*JW;L9C6'=ST[8C1H5=5UK8/
M2IS]KF5YQIU/\LL9B PI/QX86=_I'=_6ZI9Z[*AK7D^C2]F)<KORWB*'FHX"
MI_JC0P&+0QPX),X83G/FCZ"EX%"[7HVU%J3QP*8O#8=U7]99VM^O< C\/=\M
M<3#-N^!$;$!-5VA82UM0?&=+0,;Q!M_\$]6>I2<+G$I/YKA4=V6Y'FD="O[B
MD 0.>>!0#@YUX- ,#D?W;_IXU$#OSR9SAWNU=L%72EQ23F=YEO0D^]=UQ(6W
M-D7$=1T)2>FI#,PY6>I?TI?E7M*?YE'9G>)9VS84T$0.AV1U,9H/#A7+E6C]
M.C5F+<BWMGV;WK?IZ[UH,W.\VV 3<JG2*6V@P+VT.\.OKCDQI+4V)KJK/#RQ
MMR@DXV1>4&%_BG?Q0*)/Y?$$GYKVH8#%(7Z"$$T!AX+YTK02'!K7L=:"?.W0
MWO2V2T_O69>)TYT6Z[#S-?89)XK=2ENS?>KJ4H-:R^,CN@NCXWNS(]+ZTL/R
M!Q("BP=B BIZH@-J.H8"#@=!FLKLAYDG3:N7*](F<.C8NNAS]]Y-KX_KZC_N
M,7:ZT6X1?KK.+J.[S*6T,=^SKC+#O[4P.;0K.SZF-S4FN2\Q*F<@.JSX5'A(
M>4]X2'7G4$"3P"$!'-*8_3#@4 ,.1\&A>\O"C[U[-KT\J:/_X*2A\Y4NLXB^
M1IN,MBJGDMHB]R,E.;XM.>G!7:G)4;WQB8E]T?%9 V$QQ:>"(LM[@R*JNX8"
MFC2*A\4A8[HH+9DG18\L4Z2M:R=_[=F\\'W?[DW/3Q_4OSM@X'S^N&GX\1:K
M]*9:AY**,K<C>87>+6DY@5WQ&1$]D6GQ)T-3,OH#4XH'?./*>WUCJ[J&@K\X
M9()#*3C4+U.@[6LG?3JY:<&;T[LV/KFP7^_FH)[SZ1/&81WMEFFUC7;%1=4N
MM9EEGD<3BOP[(_/"C@?GQ)[PRTKM\\XNZO=(+>_U2*[J&@IH,C@D@D,V.)3/
ME:2-RT9]ZUH[\?W IOE_7MBA]>!W;;TK%W6=3@P8A38?,T^M:+4MRFEPJDFN
M\6B*JO!M#RX-.>9;'-WK491RTK6HH,\IM[S'.:NZ:RA@<4A2%:2YTT5H)3@T
M+QWYZ?B:":_.;)SWY-KV#;=O[3UT]JJ.8]?9PR%'^LQ2"KNM"]+:'*IBFMP:
M@NN]6WUJ SO=JB...58F]MA5YO3:5E0<MRVI[AP*: HX)(-#_C1A6C-'XGO;
M4OFW)]>,?WIQXYP_[FU9]_N]W3I]MP[:'_W-(+!\T"0QXX1%7DRG37E@B\,1
MST;79J<ZKS;;VH .BYJ(+M/JI&Z3FH(N\[K:MJ& IH)#"C@431U&Z^<,_]2U
M5/;%F=5C[U_7FGGCX>9U@X]V'>R\?\"V]J:!;]Y%DYB$ 8OTD![K J].NW*G
M5J<:ZV;W>K-&GR:CAJ"C^O71+;KU::WZC87-0P%- X>T\0*T;*H0;9XM^OK$
MDA%_7%H]^NJ]=1J#3S>MZWV^XT#CD_V6Q7?U/5)_-PF-/&\1[W_*)LWMI$/.
MCST@)IT^Y8?;@RKUVB*K==J2:@ZV9@X)-'TD#\T>QT^KU00_=<X2?CRX6/SJ
MK16*9QZOTSC^:M/:EM?;M"M>[C/)?*CO&'O;Q"?HJE6(YT6[:*=S3@DV9]Q2
MS$]YI1OW^V4:] 5GZYZ(S#W8FY"_OS=M2*"9X% PEH\V3N9[>7*FP/5KLT7.
M/%PQNOO5VEE-G[165WW8NC/WW3Z]A.<&%J$/S1R][UI[N-QT\+6[YAID^;MG
MJ-EOON%&EP(C#2Z&1>M>B(X]>"XQ?O^YM(2A@.;(<],*99Z/':H\=R^.YSGS
MA\;P[I<KE!L^K]$H^[YA1>[W+9N3ONS3#GMW6-_WI;FIZS-;:_O'SO96#]V=
MS/_P<36^Y^]N>#?80_].N->AVS$^!V\E^NZ_F>HW%- \<&A0Y'I\2I9K\)X2
M3_=+#<GZS\M42A#[9]!UBQ/HEK5A=-\6WV^'=[M^LCA@_]Y.U^JMBX'9:T\C
MXU>^)H8O TT-_@PUUWL1:7'H>:SE@6=)UON?IMD,!;1\!->;8^+DW%5ATO7G
M:/ZZ+QI2Q731F#2Z0BV:KIT31#<O]:+:JYWIX0TVU&*S.;7;9D)==AI^]]QM
M\,UWC][7P+VZ7T*U=3Y'[COX.7;__D])!_9]3#LX%'QN%B.G!X1(YP-1KMJO
M8P2+J(94*IVO&$&7JOK2U=-<Z:;9=G3/ @NJO]2$FJ\X3&U7Z5&GU8>H^QH=
MZK/V  U8MY\&K]]'PS=HTVBM/31AXVZ:,B2<[N(G[6<%2,U[,>X"JBR40J=)
MAM-9\MYTX1A'NG*"!=52,Z0[U/7H(8V#U&3V?FHU5YO:S]M+7>;OH1X+=E/O
MA;NH_\*=-&C1#AJV>#N-7KR-QBT9"MIZ^$CU;WPDCXKSI% 5H3 Z:;@G51]A
M1^>--*'+1NO1=6/WT:VJNZGVQ)U4;_(V:C)E*[52VT+MIFZF3M,V45? 8_I&
MZCU=B_JK;Z#!0-B00,/@/P1/%*3^L\1HU )IFK1"@69NF$ S=\^B&7HK:(K%
M9AKGO/]CA*_1Z^ PFV>^<2Z/W%.\[SMG!MZQSPN]95,<><.J,N::Q9'XJ^;-
MB5?,NI,OF9Q*/75X(.UG\?\;#O0NI>M6KM39LFWSZG5:FD1 Z'\#JU\<_K_C
M$ (. 1IB-!H11S*'0]:N6313=P5-M=A"$YP.?(CR,7X5$F;[U"_6[:%'LN\]
MYXS@V_9YX3=LBZ.O657$7;4\DGC%_&CR9;/NM',F_>G]AC\/&J[ 0T/@80;/
M%*-Q\/;3EBO0W/43:/Z.63179R7-,MWZ+=5>YUV\I_GSR&#GAT%1/G>]$T)O
MN*5&7W7*3KQL7YAZT:8\\[Q5;<Y9B^:\0?-CA3U&QPH[34[D_"QH!#B$@D/H
M#%&:.%>*9BX;10O63:!%VV?1H@,K:;[Q]J_9MGJO4]VMG\0'>-P+"PN^X1\;
M<\4S.?F":V;668?\_-.VI<4#5M5E?19-E=TFK=6M9IVEC1;'"WX6- *>51@X
MA*N+TF1PR :'HK6JM&S;+%JV?Q4M,=SQN<#:X&66B]W#9%^?6U'!$;\'1R6=
M]TG(/N.65M3OF%-QPJZXIL>ZJK[+HK&QV:RI_HAE6V6U=5?QSX)&,AS@84:"
M0^H<29J[="0M6<M>H5*Y;Q4M-]CYJ=3R\)\%3HY_9'@%7(\/B+T8'IYQQC^V
MJ _APG'GS/INAZ+F+ON:EB;K(RTU5@U-Y38M-25V'64_"Q:'<'"(1L21!@[Y
MX%"V1I76,"M4]J[Z6JV_\WVEN='S4@?G>SGNP;\G^R6>BP[)ZP^*JNCQ3:KK
M]LIN:G<O;FEQK6ZKL:]M*[&M:RFT;SZ2Y]A>\;.@42P. C1FF@C- (?")2-I
MQ1K."I4]JS[7Z>YZ4VMJ_*S*SO5.H6O8Y0SOU-/Q@46]$1%5'4'Q]4=]TYOK
MO?);:SW*V\M<:CKR'&O;LIV;ZC-=VJI^%BP.$> 0!PZ9LR5H\1)Y6K5Z/&W8
MI/&]<?>J#XV'=KUL,#9Y=,3:[6:I4\39+/>,$TE^11W1H55-83$-M8')1RO\
MLMM*?$HZ"CRK.]/!(]6ML3'9HZ7Z9T&C1[(YQ#,[9,"A!!QJ5H^C31LUOK;L
M6O6N16?7\Q8CDWOUEAZ7R^VB^O-<,[K2O(N:XH.J:Z(B&\I"$UH*@S+:<P,*
M.K/\J[H2/:N[XKT:FN*\6VI_%BP.D>"0P.R0 8>RQ7+T"#@<W:CQN7WGJC<=
M!W8]Z3AL>JO)S/-LE4U43Z%S>DN69U%M<D!565Q80T%D7$M66&I[6DAN5W)P
M>7>T;U5WE%]]<Y3_T2,_"S8'1#V):L(T=[8X+0>'>LVQM%5KYL>N'2M?'MN_
MZ^$Q?=.K+2:>IVJMHSI+'=,;<MV+*M)]JPJ20AHRXZ);4J*2V^,CLKMBPDNZ
MPX(KNT.#ZXZ&!C?7_2QH##A$@4,R..3/$J>5X-"HR5J9\;YG^\H7)_?MNM>K
M:WJQP]CS1(-E9$N%?7I-H6MA4;9W559:8'UR4F1+7$)">V1L1E=H;%%W8&1E
MMW]$74M >'/=S^(O#BG@4#AK.*U>Q%H5\;5KPXRW?=M6/#V]=^>MOD.F@]V&
M'MW-YA$--;9I967.A;D%GI4IV?[UL1EA1\-3X]J#DM,Z_9,*NKT3J[J]8H^T
M>L<TU?\L:"PX1(-#FMHP6@0.M8MD:,LJY4\]&]1?G=FZ_.'Y/3NNGCEHTM][
MV+VMS2R\NL$ZM:#:L2"]U+TBKM"W+CPOI#DP.[K-)S.EPR,SM\LMLZK+)>5(
MJVM24_W/@L;*LSED3!E&2S%WUB\:\;5CU9BW)]=/>WYAR])[5W9MOW#^@'%/
MO[Y;8[=)6&F+57)6@WU>0HUK>42%=VU :5"C5U%DBVMA4KM387:'?6%%AUU.
M78M]9E/]SX+&@4/,. &:-46(EFN(TJ:%TA^/K53Z\_1ZM8=7-R^^<7/GUM-7
M]AFU#^JY5I\T"LGOMDA*:;7-B6IR+@FL]ZSVJ@VH=ZD.;[*O2FBQKLIJM:PJ
M;[4HJV^V+&JN^UG0>'"(!8?<R8*T>J;(]]8%DJ]/K%!X=&'=I#MWM!9>O+=]
M:^\-[<.-EPXYEPP:!F7TF<7']%AG!G4Y%GJUNY<[M_K7V!X-J[-HCFLP;4IO
M,FHL AH;C&M;:GX6-$&.AR:,Y:<%DP1HW8QA'[L6B#\]LT+N]HTUXR_]L6'A
MP,.M6]KN[=6ONJECGWOEL%_B!=.HT#-6*5XG[7(<CCL7679YE)FT^U<>;@NK
MT6V-J]5IS0#*:_0ZVBM^%C01'%*4^6CI1'[:K"[X\B2S*F*9U,5[FJK]3S<L
M['JV>?.11[L/%?ZA8Y5ZU] ]\KIYH/\EFRC7LPX)=J==T\S[O;*,3OCGZO>&
MYNL<CRG<?SRE2/M8?I'V\>J?!DV6Y::98WAIE2K?Q\YI_ _.:@A>NK-(NN^)
MYL2.U^L7UK_:I%7RYZY]&<]UC&.?&-D%W;-P][QIZ^MXU3G8^C>/<+.+OM&&
MYX-B]<^%)^@,QB;N/Y.2O/=,;LJ>TV6I/PN:"@X%2CRT<2S/\SY5GLLW)_'W
M/5XHV_YFU:0C']<M*/ZP<6W6^YT[X]_I' IY96SL_<S*VOF1@X/M'ZXN%G>]
M/$QN^WL?OA7BJW<CTE_G>ES@@6LI0=I7<T+V_%[\TZ#I,MRT8A3W^RY%KFM7
MI;CZ'DT2:GNS4+[VV\J)A=_7S$G_IK4R[MO.C:'?=';Y?#(YX/+.6L_NM:.1
MY4MW4],7/A9&SP*M#)Z&V>@^B;+5>1QO?^!1BH/VPVRG/0\*G7\6-'<$%VT<
M0:X,"I/^AU+<K6\F"==\6RB?3Y>IIE#-F5%TPZ(@NF.5%]79X$Q-MMA0ZQWF
MWQSWF'QQUS;\[+-?_V/@0=T/83HZ[Z-U#[Y/T-O_+E5?^VVVP9XW!8=_%K1"
MG%P^)DA.7AA&6MZ.X*FBDT7SZ%RY)+I8)8RN5/.AZV>YTFT+[.C!I9;4>*4)
MM5IC2!W6Z5.W#;K41TN'!FPZ0$,W[Z=16[1IW-:]-'G;;IJY?1?-V_&S^/TH
M'^DY(4":?Q<DY526+Y=.$4V@&C(A=+Z2)UTVWH&NG6)!MZ@;4>U9^O3PW$/4
M8OY!:K=P/W5>K$T]ENRAODMWT\!ENVC8LITT:OD.&K]B.TU=N95F_31ZV_E(
MXVD^4GI?D"N+RO/'TXDB072:E!N=+6]#%RN94,VQ>G2CZCZZ:](>JJ.VBQI/
MW4$MIV^G=NK;J/.,K=1]QA;J/7,S]=?81(,U-M+P65HT=M8&FCC[9]%XG(>4
M7.0FZ9^$N>/H*+X .G:8"YTTW)+.D#Y,Y\L=H,M'[:;KE;;3;6.VT+TJ&^FA
ML1NHX;CUU&S\.FHU?BVU4UU#G5174[<)FM03\)VXB@9-7$G#)OTLJ!]B'.\)
M M0-<T7@/ D:N4R>QJU3H0D[I](XW?DTVD*3ACEOIH'^>[_Z1NI^\$@T?NN<
M8?G*/L_NA4V)TS/+2M<GYD<\'ILV>STT[O1Y8'3"[][AP8 ;^E<"+QRZ&O0S
M^,7A%X?_(P>/F2(T>*X$C5XJ1Q/ (6G'5)JH,Y_&F6G22*>M--AWWV?_<(-W
M7O%FKUS3;%\XYCH]M2UR>VQ5X?70O-;W#],F__LF'4%WC4^$W#8<#+VL?SE\
M4.]*Z,^ ^B/.\@$'[QDB-&R.!(U;(D=3UJC0]&U3:>J!!3399 V-L]_^/=)3
MYT-PB,DKWQC;YQ[)+H^=L[S^L,_WOV==&GS;HCK\IEECU W3CIAK)B?C+AD.
M)@P8G(OK/7PQ\F=  \#!%S&.K[H(C41\D0C?/GVU,LW>,I5F[5M(TPW7TF2;
M75_BW/7>1@1:O B*='KDG>!]WS4]Z+9#+I.'B;EJ595PQ:(QY9)99_IYD[[,
MOL-]F=U&IY/;3<[%_0QH(#CX@4/ =&$:C?@B9;$LS0*'O,U3:9[V0IIML(YF
M6.WYG.QR^%6LG\V3L'#W^WZQ@;<\4B*O.F<G7+8O2KU@79EUSJ(A;]"LL^"$
M87=1IW%O;HOI0%JC^9G$G\%?'(*F"=,X<$A#?)&C.886;9Q*"_<LI/EZZ[_F
MF._]D.YH_&>BM\/#J!"?VT'1X5>]$Q,NN69FG',HR#MM75X\8%%??L*LO:+-
MN*.\R>Q8X1&+DUG55J=2?@8T"/&%/WS[D*G"-$%C.,U ?)&_:@PMU9I*2W<O
M_%Y\:,/' E/M-SGVIL_3/5WNQP4&7@^+B+WD%Y\^Z)Y6,."45WK"OJSBN%U]
M58=U:W6]66MUM6572;EU;VZ);7_ZS^ O#F&(<9+ (6NA#"U<-9J6;U"CE3L7
M?BG7V?"NU'C_BT(;\X?9KO\/>^<5UD37-NJA*O;>>^\%1%%ZD=X[(22$D! @
MA(00""$0$CJAAMY[[[V(%$%1 0N6SXH%L:)BP:[/'M_OO_:U#U[0P_]@']R7
MA^MVUIJ9=8\SD?L@51!U(S8B;3@T+G\@*+7TC'].U6EV:6V'3UU]*ZNCH9K>
MT5#.Z*XJ]NXO*F1=R/D;( )U"$4=HM'&29-= /F*RZ%<<R/4H@[UEHI?ZAT,
MWM62L2\K/6F/"GUX-](#XH820M+/1D47=(4DEK7S,JJ;N(5U=9S*QFJ_EJ82
M[_:F M;IVES?OI)LOX&\O^'_.L3^_DH'=2@\L1PJ-39 O?[>G\T6BI^:L09O
M&IT=QFNHGG>+F?Q+V9RXL\G\]*[8B(+6B/CR^I#4FJJ@W/JRP+*FXH"&YEQ.
M6TNFWZGZ=/_>LC3NN8*_ 2)1A[#MTA#_^PN9P_.A^,0RJ$8=FO3W?F\S/_&A
M'6/PLLT)]ZC>C7ZMG,X_G^<;UYT>F-XJ"BVHBXXNKXA(JBD.R6K($Q0U9_-K
M6M)YK:U) 1V-B;R>"A'O;.'? )%H9X5MDX:$W3*0C3J4'E\&M1KKH45OSY=.
MTQ.3I^T,GG42</>:71B7JCSY?46LV/8L;GI]BJ"@(B&JO# ZH28G,KTA/2R_
M.26TLC4QM*4UEM_>%!O<71D3W%_\-_SC$(XZ)*(.N:A#^?&E4*^^#MKU=G_J
M,3G^^HR-_I-NO,/-=C+]0IU'4%<9,[8ICY->F1%44)0<7IZ=$%N3&IO2(!+F
M-L=%E;=&1S6U182U-4>$=U5%A/>5_ T0]3\.2:A#/GJMK#R^!)K4U_TXI;OK
M8Y^QPJL!:_V'?3B'JYTDS_Y&]Z#V2D9,;9%O6DE.8'Y.1DA9:DIT34)B4D-T
M0E9S1%Q):VA<?9L@NK5%$-U5'1S=5_(W_.,0@3JD[)H-A:A#M<(2:%%;^ZU+
M=^>[ >-CSX:L=.\-8+%#W43/[E977E,=/;J\G)6:5^B?EY8K*$O(C*R.2A<U
MA*9D-/.3BUH#DVM;_46M+0$)IVL"XL^4_@T@1!TB48<TU*$8O5[7H??O=K75
M7\[H['@S:"3_Y(JE]HU!>_N!/B=:QRE*8$T335A8PTS)*.?DBHJ#2J+RPZM"
M<N/J [/3FCA9^2WLS*H65D9KBV_:Z1IVRIG2OP&BT>:-0KL[ [UWEAZ< XW'
M%OXXK;KJPSGMK2^O&,H^O&%^\O)E.TSO>4=J4P^96]9!C<IN\DI.JF/G"*L"
MBX/+0BL"2J)KV47)#=Z%N4V,PHIFSZ+V)GI>5[57]IG2O^$?A^@MTI"-.E0<
MD(&6HPL^]ZJL>#VDO>G)+8,#M^^9:EVX;FM[:ACG7G..Q"GH<8M(/447Q;2R
M,D,:N04!]<%E/K5158SJQ%J/ZNQZM^KR!M?JUGJW\NXJ]Y*^DK\!8E:)0]PF
M*<C;(0TU^V?_/"4_[]V \M+Q:UKK[C_4W7_ED8G&F;O6UDW7'"BEPT1VQGE*
M:%P?+2ZTQSLMX#0GQZ>#7T1OCRQS;Q-5N+1F59':RJJ);2W5SLV]Y:2ZLT5_
M \2BW9VX41**MDM!XS[IS[UR,L\O*2V\-ZJV^LJX[H&!<2.-]H=6EE5W[4FY
M-PC>HBMD?O@P51AXT2O1Y[Q?NN<Y?H[;V<@"TEE1D5-_=@F^O[34H;^I%-?7
M7X0_?3[O;X!XU"%MO224;Y6$]MV2;\X?EKY_Y\B<*T_4UYY[I7.@\Z6A>MU3
M"_/",0PA]2&!%GV?XB>X2Q-P;K,BO6YPX]Q'!(FDRQ&ICL-Q&=BAU"S,8%ZV
M[6!EMLU@1[;=T%#ZWP BM/VST3UE[2;Q3SW;Q1]?VR9Q94QVWMD)M?4=[W0.
MUKTU4"U^;6:<\0J#B7OI1 I][D8+>.;%8HVQ_3T?!@:YW@\)<;X;%>YX.R'2
MX5::$',S+\;V9EFL]8VF6,L;O7\%)"T7AZ+5XM"Z3NS%X JQJX_6BY^=.+R@
M8TIM0\WGDP<*I_25,CZ:ZL9_P%B$?2#:![ZG.OF^8U(8;S@>U%=!=)<784SB
MLV@?QZ<BML.3- YF+,??=JPXP/IQ;:#EH[:_ M*6BD'U,K$/?0N1D5MSD?Z)
M#9)MGPXOKOZILJ'@I^;>U!^ZQV)_F*B'_K#3"_A!-/7]X6%-_^Z-<?_*P5$^
M\PG.4^%$PH<8$OY]HHO#NW0*9C+'U?9ML;OUVVJJY9LFC[\!"A<A[]KG(9<N
MR"#]#^8B+9\W2E>![)(\4%R?!.H[HT#G,!^,CW/ 5I4)3B=I0-5S!:8A&3@F
M1 @R<X0P"QQ$6V)!9(7YE69C]S/;UN9'D9W5]TJ,Y?=Z^[]ALG8V,MP]"^D9
MGHTTO5D@7@Z;9^?"X<4B.+8F'%2V!,#)W2PP.D0#*WE7<#Q. C<E C!4\."K
MAH5 #0R$:-I!I)8-Q)VTAB1M*\C0L8 \77,HU3.#:OV_X7*;)-+5)X4T7)=&
M2GXMDLB"K;/C8?_"$)!;X0>*Z^B@N<45]'<Z@?D>!\#NQP#ID"UX'+8&IIPE
M^!VQ@$!Y<P@Y:@J1QTP@5L$8$A6,(/VX(>2=,("2OZ*[4P*INRB!%-Z3$$N'
M)1)QL&6V ';-]X&#2SS@V$H2J*[%@<X&6S#>; DV6\T O]T82#N,@+K3 !B[
M],%GMQ[X[]&%H#TZ$+I7&R+WHF&V3PN2]FE"QOZ_H?Z,&%(X@B#)KR3$HF&I
M1!"LD_:&K7-<8<\"1W1=V,&)Y1:@L=(8]%8;@-D:7;!=IPT.Z[6 N%X37#:H
M W6C&M WJH+W)A5@;U(&[B8EX&]6A'"4Z"U_ W#62X#/+FGPDIL+W&,+(41U
M.43HK@>AQ4Z(=#P,81Z*(/#3@L P0_!/L #?#%OP+G#XP2@C?*/5.']Q;W+Y
M[-KA.D7I=?] /N_QECCL.4&X1G^&O\]X[##.O&__](_\?X?_30[HO<)WIS1X
MR\X%WM&%$*:\'(0ZZR'6;"=$XPY#I+L2A/IJ S_8& +BK,$O#?N#E4?XZE5"
M^NQ9[3I%;:1^<&OW?$_I84R2SS,GG(=9SPG7?<;PH[YW'<;\;CB,^_P)\/\?
M!]]#<T @OP"BE)9#G/9Z$)GLA 2L+,12E"'*6Q?"@LR!+\3\"$@F?&%GNTQY
M%WF\9U0P)FEUWF_<6WPG7+LX+UT& IZ1+O$>.]T,NHV_S[^"?Q@XY#CF_R>
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M"UO$;]_?+CDT?FSQF9>:6UJ?Z<I5/3'1RGMH;9%TW\$QX@[1/?"F&XMUG1Y
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M^NYLI!!62F; WKFQ<'A),"BL\0.U3730V>$*)GN)8'L0#TZR6' _@@&OH[;
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MCRU ]-\%A(A]@$\Z"+A<67 HEP?[^F. :5< 3.\)L!M4!-L;2F#S0!FLGZJ
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M[3Y;/\1\M[AK#R;_L0>CZ0!'U,'A][.@W=+ ^/T<Y/?W24J+($![)02:;H0
MAUW@YW8(6#X*P!"H_O"(.?G-+=7@BTNNR2=2J<5'IUKK#XYM=N_PO=A)AV'<
M:^Q#Q^>8"<(CS'O'._:?[*]AO]E<=OAI,80#L^D PD8)<-PIB5YVI8"%=C?W
M\!S@GU@$P5HK(<1H(P3;[0(>6?8'QTOQ"RM0<XH18?#>0V3VUC7#^C6YP/XE
ML0+_W+&!^!3727Z"/>_ZR/Z.^WW,2_=KV$GR,&Z*<![_%=OO^,.VE_#+:CK
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M]GQ (*&/'4;I\H[U:*>G>+70<E@-U%)VK5N]?[7K:6Z%ZW! F=L8IYCZPJN
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M@IAJ^-(QU_2Y0ZGEN'VMS9A=&^:139_# YL1W!WKI[B;=A\P(]@?5L,X,+V
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MN[*+7*8R*CTG4AM\QY([ H<3^T(&XS>']<?MB.R-/1S5$WLYJCO^>?B&Y/F
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MR)]#P669DS58J-+0CG#08$ G/29T-&=!!T=VI/MSH6TL#UIG\Z%5^2JT;!9
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M0YUM]+IV^_"Z <>0NJW.P76'78+J;CJ'K'M/#ZM?L(JH1[/(!C1>"A, GA8
M_$[Z?[85R!V@P/X!"NS8##"^A1,V;9&@;!C78&K?;,I5/TP7J!QT%R_I]Y?+
MZPM3R=P0JYG:G:*7T)5M'--9;!;146,5VM9J&]BVT=Z_==+!M_6@HT_K=4??
MMG=V 6V_+(/:T32X'8V6PA2 !R5D#TC[GNH$F-D(L'.8]#]IGZ$I=NC=+DKI
MF%)E:-AJQ%$U8<M?,NXBDC?J(Y4Q$JR8O"E*+7XH43MJ(%,_K+_0.&ACE9E_
M7[.E=V^?C6?OA)U[[XR=6^\U\OC6VK/WI[EW+QK[]*+A4A^RR%TD_7^N!> (
MZ>]=I'\GQA;GD_[<PP1M>P6@88\BK6JW'FO)M"5/[@XG@?0I+[&D;8$RL9,1
MBA$3\6HA6]*U L8+]'S&*@P]1YM,W$9[S9TW;[%PW#QCZ3AZS=)Q\QLSY\T_
MC5U&T,!U!/66>DS.X4H=P FR!WL' +:2,]BTE?0GZ;^F@U2H/;P2*@[+4(H.
M:3'E'#1;D3ICSY>PWUTH>I^_6-C>,.F@/;$*?KM3E;UVY:F[[RK7<IYNU'68
MWJ!/WSEN:#M]P-!F^IJA[<XW!G8[?NK:[4!M^G;46NH.N8MGR1X<[ .8(F<P
M,D'ZD_1?\P& RF,T*#RS O+.K(',,ZJTY-.&++&G;#@C3KKP!I_T$? _$2+J
M?3Q&POUXBK3+L5QYQV-E2O2C#2HV1S>H61T=U[ X.J-A<>PW#8LC;]4M#O]2
MLSB$JH3*4I?7 1SM)G=@$&!T'*!W!T#+?H"JHP %9QD@]0HK)%[CA]AKLI3(
M:]H,(5?-6?RO.G!X7_'D=K\2R.=R)5+ \7*B,/UR]AJ;RVO%+2\W2)I?[I$V
MO3PN:WQY1M;XR@U9XTOO9(PN_I QNH R1N?_[60[P)Y^\AH8!=A([D#KWK_G
MYY,&3KW, %$W62'D'@\$WA,'WWLJ5,_[A@QN]ZV9G.Z[L-K?]^6PO1_*974_
MCL?B?CJOZ?TB?N/[=:L-'W0)ZC_8+*3W8)^0[L-+0KKW7POIW)L7TKZ+PMI_
M_ML!<@83(P#]DP!M>\C\(W_/3[Y"&O@F#?P>LH#W2UYP?R4.SJ^4*/:O=*@V
MKTT9+%_;,9J]=F4V>>/':O@FC$W_30*'[MNL%5IO2SDUWS9QJ;_;R*WZ;AN/
MROMCQ#T>Y;<?>)1?+_ HOT+NI;9M A@DK\-V<@>K#Y/Y9P"2R/RP/P"\28>[
M?&(#AZ^\8/M-%*R^R5',OJE3C>;UJ?KSYC2=[W8,6M]=&=5_^#*J_@AE4OH9
MSZSP,XM%[F<YJ\RO%E;I7X-L4@L[V"073K%+X -VB5\?V<1__OR73>1UV$GN
M8,W!_SL_]!: QWT ^G, *V0!,^0&(Q0$/90 ;52@J*,Z107UJ(IH2I5#:ZH,
M.M(DT9,FCD$T48QA$,8,!D$L95R-S8RK<(")'[<S\>$QXB83+[[XE_7; 6IG
MR/T[_??\D-L ;@\ K)\"&'\!,I<!M' %J"$O**$0R)-UR* <10)5*&M0DR*,
M^A1!-*.L0ELJ'SI3>="'RHUA5$Y,HG)@(8T=ZVELN($8I['B'AH+GOB7=>0U
M4'B2S+],YM\!<'T$8/D,0/<U@ 8"*!-RR Q2R GBN!)$4  $4!3XR5I6HBQP
MHS*%$S4H*U"/PH:F%!:TI3"B*X6"_A3 &"*+**<"MA!]Q.B_H*H:%;5(_^NI
M4%%?G3SJTE#;C $U')E0S8\9E6-84#&+%17*V%"^D1WEUQ,#Q"@'RFTC=A,'
MB5/$90Z4OT=^[P7QB?A!(!LJ_(/\,M3);%U%*AH01JI4--2FH;XQ ^K:,Z&6
M#S-J1+*B6CH;JI2PH\HZ#E3N(/I6H/((,4GL) ZL0*7CY/$"<9MX1GP@OA/(
ML:""'+_^#V5D7PHUE2AH0/I_\3V Q<_&F*K3T,20 8UMF=# DP7UPEA1)YD=
MM0HX4+-Z!6JTD*WO(8:X4&.<"]6GB#W$86Y4/TO<(!YSH\8[[@6->:X?&L@U
M3WS30,ZO_]O<$J@C3T%C&0J:2U/12N[OSZ58ZS&@I143FKNRH$D0&QK%<Z!!
MS@K4+^<BWXUSHUXG#^IN)$96HNXD,<V+.C/$2>(*[T^=A[SSNF]XYW2_\G[2
M1=X/NKCR_2(]Y'GW-^Y_0H/%^1(4M!&GH)TD%>T5J.B@S8#V9HQHZ\B"UGYL
M:!F] LW3N="TF =-:E:B22O?@G$/_R_C0?Z?1F.KOAM-K9XWVKOZF]'1U7-&
MYP4^&_TI\-[HI< ;HSF!ET:X^KDQKGYFC*N>FB#_$Q/D6PI-)"EHO8:"]J2_
MG<FCFRP5W<EYN!DQHHLM"SIZLB,]C!-MDWA^V.3Q?K,NYY^S:EC]V;)#X)-%
MG^ 'BV'A=^83PF_-IT7>F!T4?65V9LT+L]_7/#%[+O;(_/.:^^8+HG<M4/B.
M)0K=LD2!/RQQ]5)H+D9!.NE<%P'*?S\#X"-%13]R'K[D/+PMF='#F7W>+8#S
MBW/LR@].&:O>.A0+O*)7"[^P:Q9]9KM>[(E-O_A?UJ.2#ZVGI!Y8[9.^9W5"
MYD^KJ[+_L7HB>]WZD_15FP7)2[8H?M$.UYRW0Y%9.@HOA=9DKM,J,I_TOQ]9
M1S!94RBYGR&:M%_!)DQS ?9L[WV]N5YZ1_ ^]4@6>.26*W+?I4SL3Z=UDK<<
MVZ1_=]@@>]U^2/Z:_1:%*_1IQ4OT0TH7Z+/*Y^CWE4_3WRF=</@I?\P198XZ
MH>019Q0_[(QBQ)I_0CLRUY5TKP\/8 @_8 0YDVAIRD*T"O5SE#[CFW KUJ>A
M[IP/@H+Y;OO%"=WPR5ASU:M0\J)'I>QYMP;YLZX=BJ==>I5/N@RK'G?>JG;4
M::_Z8:<3&@>=KFON=WJAL=?EF\IN-U3<Y8YRNSQ0>MH#)9="!]+^GF3^8O-%
MD/:/6TVZ2XPRERA/>9VH27L<;\K\9XS3BNL1?GR70B.%SP4EBY\*R)$^[E<B
M?\2G6NF@=Y/J <\N];T>_9J[/4:UIMUWZ.QP/Z0[Y79!;ZO;7WH3'I^UMGBA
MZK@/*HW[HCPALQ0Z\P+ZD-X+)>T=2_HWB1=^I G"NW1)RN-T9>J=-$/&:TET
MCMDX+[Z3T:'"1R+B)&9"TV7W!N<K[@HL4]D14*<^Y=>J->G;H[/%9TAOS&=2
M?[/W7L-A[]-&0]YWC09\WNL-^"UH#@2@:G\@*O4'H?Q2Z$;VP)_T7B212-:1
MQ@U?LGCA>8X0W,V5H5S+T64XEV'-<3S%C>]@8J#PWM@HB9W1R7+;(K*5)L**
MU,9"*S5'@ANT-P5UZ T$;C38&#!JM,%_ITFW_U'3]?[733L#7AMU!O_0Z0I!
MC:Y05.D*0\6ET(.<01#IO1A6P!0VF,OB@'=YG/"P<"7<*!*'\X5:#,=S+=AG
MLIQY=Z?Y"4\EA4ML28B7&XU-5]H4G:<V$%6JU1=1J]L3WJ+?%=ICU!&RR:0U
M9)M9<_!!\\;@2Q8-(<_-&L/G]1LC4*LI"M4)Y:;H_PF]%\^!='<\$WS.8()'
M>4QPIX@5;JWE@$MEHG!JK3KM8)$9V^X\QY7;LKV%QM-#)(938F0'DE*4>A.R
MU;KCBK4Z8RMUVZ(;#)JC.HT;(@=,ZR(FS&O"]UE6A<]:5D8\MJB*^FI4'8,Z
M-;&H41.'JC7QJ/)/Z$O.()P!%I)H\#B; G<*&>%Z*0M<K6"#LU5"<*12A;:W
MS)AU>S%]Y7B^A^"FG$#QC9F1LCUIB4J=*1EJK<GY6DV)9;KU\76&M7%MQE6Q
M?6;E,6,6I3&[K4IB3EL7Q3RT*HG[8KPV ?5*$U&K+ G5ED)_=G(7*/ Y%>!^
M'L"-M0QPN8()SM>PP(E: 3A0HT3=667(,E%FRS-<XB:PL<!?K#LW7*8].TZQ
M.3-5K3X]5ZLVM42W*J7:L#RIV61M8H]Y4<)FR_R$G=:Y"2>L<Q+N6N<E?3+-
M3T']@E34+DQ#]:(E,)!T=PS ,]+>MPM)[Y338+:&$4ZM8X)##?RPNUZ>NK5.
MGWESE35W?[F+0/=:WS7M1:'23?DQBNMRDU6KL[,TR[.*=-=F5!H4I3>:Y*>M
M-\])W629F;+=.CWEF$U:RBV;C+0/9ID9:)"=B3HY6:BQ% 8OW@6 1Z3Y;A0#
M7*BBDOD,<+21$?8U\\*.9EG*>*,.\^ Z2\X-U4ZKVBN\19O*@J7K2J(4JHH2
M5<H*,C2+\_)U"G++#7)RZHTSLSO-T[(&+9,SMUDG9AZV2<C\W28IZYUY2LZ"
M86HNZJ;GH2:A\4\82H6O20#W<@&NEI'FJJ7 L48:'&BEP70[#TRV2U&&6[68
M^IK,5W36._ WUWJ*U%4'2E961,B7EL6K%*U-T\@KR=7)*BK53R^L,TXI:#=+
MS.^WC,N;M([).V@3E7?-)B;_K7E<X2_#A$+432Q"S:4P'. EN0NW2'=>K 0X
M2?K[8"L%=G=28.MZ3MB\7H+2WZ7!N+[=E*.EA<ZWKLE=N++>7V)M79A<84VL
M4FY5BGIF9;9V:GFQ7F)9C5%<::MI]-H^BXB2+59A)0>L0TNN6(>M?6T>4?K3
M,*H4=:/+4"NF##7_":, GI"[<)WT_]D:TM[-I'U)_T[UD/;KY8#!OC70TZO*
MT-9CQ%;?9;NRJL-5<&VKKUA!<XA,=E.T8GI#DFKRNDS-^+I"W9C:2H.(ZF:3
MT*H-9D%5XQ8!5?LL_:LN6@94O30+JOYA&%*-NJ$UJ+G4KSB !SD ETC[GF@
M.$#:;P>9/[X18&"0%7J&A*!]4(G6,*#/4K71BGOM!J?5^=U>HEGK@R33.B/E
M$ML3E&/;TM6C6O.UPIK+]8*:&@W]&WM,?!M'S;P:]YI[-EXP]VI\8>+3^-W
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M&/ANTL)@HK<PA&@M#"4:B-I$B"?./9"&_D^#1TD47$MGP*]9PG I2PQ.Y2C
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M1DKF6O.DS%&+Q,Q3%HE9#V<D9W\T2<TAD])RB3ZB.Q$2AFL!W?M2+CH?UN
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M9D]>?YP]>=U]MO&:CQSC0<(Q7OU/=N :6(_U[\/\13CWAC[T7_3@S+4 L<,
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MR!?4AB) =2@%E(>*06FH&12&>D%^: 3DADZ"W/K'E-S:+Y1@#:$)!O]F=1-
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MRH0U:N4)V]5+$XYJE"1>U2A.?)WX3KTX250C5(L3IZ BX5W6]6GJ_\OD/5G
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MO$Z>FK)')27EC$IRRE,J22F?$K\3HCSY(=QF/[B<Q;F O/NH?[>6LAV()47
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M"UM+?;?V$0[^EX#5%(:K_V#%Q2EL6L0'N4?(.X\\]>NH?]=S/M@(1&X&?+<
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MSC8@1^H$Q^(VP'L[X$AY:D8W&E*?Z^P!5/:2?S\Q*1 ,RB=IA[0GY0#M.,
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MNK_+*>453F]/&7#ZX["^R"GO+,?)<1B0TXQ\CMC--MF.8/+$T/9D>CN++5_
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MDQKCVM00-TKU\1-5ES!3M0E+59VX154D8Y5)-ZHBZ0&5)_\>^4SE*79>[:I
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M90_&LL/U,'H\@![WXY?[U$?9LRE[ 64O@]FN W4;3>8*N/M)FM)YFM2]NH[
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MQ@0PIH(Q"XR%6L6_Y8Y=*0>U&%LLI%8+\.A\6LH\HGTNV$;F(>:8H5_Z.,\
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M>Q,=6A/^:#*;VW!@$S]H J")4;AQJ_,!IX/(UAI>)-#0H<ZN'6!MF.9<A[*
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M">9Z(X%[/;:XEE^?@7.;N8_3<NY!.>A:@S$P_V*PS1S$\PYWNN'B +!LX,2
MD4+YN91=1MFU.H\>-^"7ZV%ZU\+ SL+$KH'IGD:/4XZ5!DNPP#JX^RX8WE&:
MZSGMA]GOQ3N[X=QF[F.'G.=@F#48C%R.^1>SG.A)5ZA=<(2\#UA!X(2!$4?Y
MZ92=C_YEE%U#V8V.9Y(<@/WMAU/MA>?N@5?M@H'OP![;M P,<QK&?ICW:2QS
M.]'RA%803<O!77[9&@QZ*L?\RV.NYF2:FYF6/"UW\ + LM+U1%)^@G;"TK:C
MA_,LC&K*'T3Y0[06QKN&&%E%C*P@5I=CCR6.TSA7PIO-4U*.8)T;-!L/SG2L
M)OK&<0:&D6FR._ ?<36_\ZXNX9BKR]N%+;;21C8H!(QH2DRD_ R&BGR\7J*%
M\,M^>.Y\F.]<8F0.>LQ"CQG8HP^T7K0PIY3VX/6)1,)XQRJ>9QQK,+I=:S",
MF"UP/W%U0:8;/.SJFLT4^5ILL5S^X 6#%09&#!A)8&2 D0=&":VBDDBH V<P
M.*W@=((SEK*GJ@O-1F&93FS1[IB]N@6+743;OSI._QF0>TD);PJ@VZ5;/4Q*
MM,O+.1R9/P^8(7&NO, ,!,\*3CBM( :,9# R:!5Y1&0Q.!7@U-%2!KOV@8SB
M_PF.'3)#L,5@O&:B9Q"Q68\_ZNE%ZNAUS$E$1NXP6RT9XHXA>\T>&/.X.O19
MA"XF79A&&YDH7VIF <\&5@0XL> D@Y,!3BZ16:QF]!A,B8V\:^".>C0TJU2J
MB<]*/%E!U);1>DJ)^!):7PD]03'X1FYB2#E-^G60+GT'LB[">5S\7+-$%KM,
M8.@9+4]LZ0]F$/4*H65&4*=8<))!S:"5Y(%5#%:E8R:D#,U*2?:*T;[0<8+)
M<N[8B;8GE</@DDWKS]+?D.\<*_*N-V>A)#&$,L1N1E;2K2] EQGH,@F[=#'D
MC/ AKZ#?:J2=U!$;5>A105LIH\V6HD>Q,NE)\\ J)5IKP!H,U@C*'^N(G'1:
M21H19DZZ2::'3M+CR-M$^%>.IX6=(?V\DJ%U%_QZ RG@,GC<O($U(*3JG:0
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M/(]$$<@B#LIY@!PL0"<T0"?[0=/(0=7;P?L! R<(SL'$*P0&=$$PV0F ]R$
MWH< L D!M"$#D "(_05 I0(@MA$ @2$_"";X0$#""^)N7B #SP;L OI<7!".
M>H#0PQY])BRXC,&E >+[DT 6(2 ?.] )/= )%9!E-ZAR!] +F!* DL"$)@UT
M(05T(0ET(4GQ,Z$K =Z'!+ )"?#R) !8 C"10/X\V%,,!&]BP%L3;0)M /8@
MO $[A_Y]9F R;A9@G@"QO*4UZ)>@*RFC/R<"<G$#^9B!3@Z!:O8"O9 ">0B
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MSH=@?8\#P_Q6)P3TE]"]/Q?)0L$@'P)T$0*,.P0H\0JHX#((["\] W7/P6Q
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MJ8'FVF=;%[],..=DI! RN55YXQDI5O2GN?>W*']S0>)'[^:Z,H,;D*>S]P>
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M^J(,C_]^6[>QRD,QYR2L!(0-Q%SX( F(&$@YC CB]&9! 5 AL-P#V!F(#%@
MZ"#% @7(0@!*4  G!& /!1R$ *Y" =L@"]*%6%)"5HMZL #0%\H,!=1# +I0
M0,'?29D* ;1 QZ H"&!#'P*X# 7DD&("_*" #2=, '::9!F! 9#' H 7PL0A
M**V".&WO%70E,@D' $__@,9?EB=?0*ECI<0!31=?,!&C_6./9 !6\1.GXYM?
M%732V[AP!/-EDT BUBBH1<)N80+N8@$@$<@0%D &(@-6=$ + 8AB53&."3B-
M!8"L8%S" E1@ NYA 2")EA8L &3#VAP5%! (:884%. ( :"@ ",( "N84X8
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M%T>Q %<Q *M8'Y) O^(XBP6 1"#96"X(9+&X'6N<8\($+-I! ;L@JHHX $5
M )58F\D@@/=.T,$8 MA(W>RN[>76Q/K<9<C]AQ3;J=EEC+RBRW&<*E9K(*=K
M[74YH;!IJ^^S.UO?SF]1A"<\_9=I;75E%3LK-EMU+SDV(NSR^>  7V]/=P\O
MWV#,Q: I#3&>8PQ'*/>2D?QR\B%]$SLZ@'2<1.CZ)130A.V"8 (^03_:P>J;
M85A;8B& ^UCI'@B@!RL3"]75I<.8Y430^;](>5/I05'3<] :W@?\'&UW,8AH
MNT24X#A]N<;@N*BRD>/9N/NM6^S@+$DI?=*W]>'S>,+3OY=6YCZ^?3W0V]W9
MWM[>T37P9@IR=GIE6)"/FZ.=M869L:&!OKZA&1+RV6\#+QW57E*,?"TF8 :R
M?QJ&M9W]/#$4 -ECF8NU!E*"">B$?@8"2\0$+)^!+&! ]\QMI&%F<[9Q0$_L
M:K'XG2?9Q:GIG0+](:O%ZSP_"LF9Q/6]XW$=P?[8ZB"[^"ESS^M93[?8HWDO
M./9>S5]NX,2OC>#I/XJ&VIXTU%:5EY84%1>753UXW@/UG>,<K<T,$5H:IU24
M%!645#4-;2#;$[)8=Y-@YBCU, %MT%W[T!!EP0^:2&& ")'*!P'LA@ :,;:K
M[^ U@IZN.A%,]ZMT.YNJ6\(CZ)$>&UD_/ Q":FX5N[""'AQ9R"ZOHZPB*F9>
M$;DM6V0@"MPOW<I[]&KKW[?9&,'G+O#T?XP:BG,RT^_<3DV]DYZ95_J@=0CJ
MVX<9Z6BH*BG(R9Z4.2FKJ&Z(@GZKEL(%W8<! 3R&>#&4T$W:'P,V!1@[!4Y?
MQ3I=,57ZCU)B%A6W^$?84<!3&_0JZGYV.<L+6:VX-E!-A0MR2&G9G4NNW>K
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MT;> *\Y6M>^?7LXK6/)MO5-64%ZM;T?>8&&I\J$ZTW#*/T+>G.T-EW=H94C
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M9ZK[O3*C#RJIA.)-]_,JZXS9Q2L4$Q^K8Y\W:S7UN]RE*H\;]<A\1OCT=&S
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M5+91S6H2KBP5"".^3' 8>F6X7 A3) +2-F/%L.2K STF-<QNO\HF1B#D+Z/
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M0]V:E[\.(?]XN.?X_X7!O-L>LXQ&O5BCA.)&P:0[0:R+84VVU CP.>5@3:X
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M3A]>&V0+,Z[D?P/$>QMQ_CXN4?A) !S\60!@AYJ6$0#P,Z7YW@\3E;1G/9Y
M.NJ.@_O><B _*,0 ER#Y&C5-7#,!AD"9TI186)R,V@D'!QOI)9!BL7?HE]EO
MP/-O ,?4+S%=JEGI -JYU^! 2VI!ID#\O!NT9TZ<&<6'XM^ ?*/EJ*2:MUQ.
MQRD;#0C( Z29^QQR<F8"#F[PD)R$O?Z@ *?=71Q,6)BA>#&5WP#5PR?9T\73
M7[VZU"B%QG $/&'P D'!R)248MA!04[8%+/$T??_P*)H"LJ!XA#J895D!=BS
M+\C8%5EJB DD78RH?N)],@@ )>7'&&?L':H^H]\ H]U?1:^]":<L7WDPAE*C
ML1BO<X+EA$NQ/B$%>44^(@U%Y?G\ Q.^*.#41N/!P@N6<,JIP_<=7&'A4,D&
M98H+!U"24^11_ 8$;O_:<9>EC?U@#Z)MU[G T&_"@XF>I%S'I494"W]W3=RG
M8L+X2U(8CF+QYM7Y1<QHGV;_/^UY>F]>I!R=O)[-.D6O1MI@:$>ZQG1.Q)=6
M5->?V:M%O6,.RW+/H5W,:B7G=4GZ3@"VVV=-&]H*._NHV7.TK5VWM)B7MM/.
MHGS2EKM%7E(/);_+9[(L,?Q5(V-!Y&^M(^+H[MFL9601RU5X;[+GI,ULM:S'
MI,^J%Y=6:*UOBV'&IE/$UJ,:<B"SH(ZA]%0QE?OT.NX;*&\G72T][5/I^J%9
M#P8B1&1^ULW=X%;$=,S\"[=>O=8@Q7J168,_MO*Z-%LC6<TI 9]P!/4.I?C3
M!EME90Y&"]1_WV8L_CR[Y7 \04VJTCUMV6LH";3ZP0-NW1?#;9\/D>G"IF/C
MA$6OPL?V8O5V,85/B,V\/M-RD%5/I1H=@6YNI+*FV=?=#5K;TFY[S[0IT$L_
MY(]0=N=VC9_!<^AB_1PWY2PM+]D3_*'6@0Y#4;/U(H]."#6^LDO:($J.4([3
MH#BX3 C"^<V*8]>/M! BAGG'1-#>8>*<)]E<$,=SC3:FK19R=ZPB>@;<K\,N
M8&2'?KQ#K&M6]'!6N_<?& PQS*V\NJ_:]6:G"@V!9+6+X[XPGRZ#(247>C;,
ME9=O'?B"=:M;)<Q3# C4M/+-TY6.&=6W^T;*U:E&A;TB89C"A(VILF$EX ,D
MX .](F""-:^)L0/;XA,.=Z]X0]6"N&/F8]LN6'HC54W 2+-H$*W<1#WYV&;B
M9M7JX7S(=?YP92$*F?G7=B7#:-1Z9:S<FHX7^<%SO1--?R%GMO@]O:;S,O9+
MAYIA3+;.A)),KT9 4 40:W]Q)L$]-VI?8,S-"&PR$VL0;6!2X4]J.;&FK^L-
MI"\MS%68-US62F<>!95%S.RU3W+B:?._QK3;O\_^?&OZN&6VR% 1/P)'1T1\
M0M<)TC=[_]BNC0F-]WEA*IO0XW- <6:QHDNPGC]IEM&QTGFO.G=1I!ATU$%P
M=N9NJI956[M4'M^IZ-"D:TNH=H:SUFDYB><KUTC^Z73=X9%/1Q^KW>A#S !P
MV;;5V!?XN! /,6SJ%%>'WL$U%</AAS%-3)JFYIM%P4@?  !X*(H_%,>%98.\
M0A, 5\:)\I1N*+18*=,O2%9[MP^/CY^'C &JYC#+IW])R%Z$7C7332W_\(YL
M_Y4B^3.1#I^8)F[@G"$&D]O ^%Y_*N[591Y9=%:W$SKE86+KPBA&JDI *&LL
M<>=;)&K%$1XN"[7V?I4 '=$%4=[YI=41V1R8#R=N*V^3P?J@1=WW]O>5C83-
ME4"V"\I3<'>ETWK6S.?ER[M<P\WLU?A?)[BOGP\=A<3;GG7H'E=&[:L3;SS.
MVX$T;LCMPX5[,M15A=+'I>X*DB&1RJ+TQXE#<,1A!^0:4411/W:S7$K6\JG0
M.,6'6E#EK^!?BS&#Q2H^5V*R5(& 5<C!R[(Q&:AP!(93,>EGP<M'?IY"C;I=
MIC0XO,U0'?L!!_N\NDKHBO GK8NZB@5F"1;WC#B?DP%06IV<RT2]O5R2 A?3
MC%TE-CE/4JI+YF!*+![<!>N5KNV/\W(W'J,QG9J"Q]KC2=:E*O871'WP&YD*
M4/7L=ZL6._%<QY7!FM6V:[]PW0:;PMWIGQP>H25^1#TQ$; -BDS'<4$>PGIW
ML[>5;);5U&G?4!$1QWBM<AJ42@P;NIH;$Y.SU8E4+?#3?/4AS,"/[T^H8W'[
M0^Q ?)9!@FZFF=LKW]5JV;0R[H[RYW&@.GW/]TL!^Y;W>G,F,^ZYO-[6'=,L
MJ 797#EOUPE7\$46: C101V+N9]N/7IH5@DTE;TKQ1<"3L(\ZAH;:CY.:OZE
M8;'-W9K71S,YTV'?3@L-KQBQP0BNSFCTW4I4F"$0<N&27'YFON;]V>0R*=:>
MS_#1;GRMG%T+?T9)'U]G"^J;Z@(%P9 P[R:GGF5?$#=_T9XKJR6L^<)\F3V%
MY1QND2#=&S-6)CEC16 :,I&0TFBQ&<:D;^YW-,^_N>\C]%Q.IDY0:3@&ZY-V
MM@BIT:M!M>4:+6)L*T,,<=0MEM8_T_$2S!&PUIYQ^(7#:Y40E^PP:S(+^RLQ
MNIF&V"6*S]9=<4"B>;'"K=P2?;&GNL-P".T@S:;>\'/$S+WUF[Z VGKUG+4K
M9$AH1]7C!#DR:FH9O=T&>.5%N0F)T,[6EREWK"N5UWH2Q8B^?NF>SXAR1/U/
M$+M@WRR]3,(^0P;;;9M=VIP@LQJA66E0HK=,#*(MH,M/R]&H2J,;>P\39<:Z
M1_V6<*FO\,KAU[[FFPYDHNQ\Y_+EY\X<OJYE.W$VY&Q&U('4["X*>22VVGWC
M2KK6,%E?Y"_A/3-3Y[4=O>KI+\#VNZZ># ,]%AECMFN]*DBUK3 8S*.ND5$-
M0Y?/J[P2]>KC<E?B_@:)@,RWUI3FY!IKSVP*KB9GLG36^:0!)TF!BHVOZSG\
MXSMYA)EX"7@2@N>9 Y#5:KZ^802S]OE:::Z^I-_;HX9?I)8XN1D/?-3Q0NM\
M7 OZZWJ_ ,7< XPRJ<$S9?12R1DTE0Y8G0Z+#?N/J%HV-27B=UBT+9=4E]ES
MEBZTQ\11_<J!*\")',<6( T-B]9AQQV]I*#__'CX[ ?VP<G!$7>AG#T6\Z+Q
M(06>,*KG9^V8)9I!2?%R G<2?ND!([WY'':K^L:&.7>O&XU*^]3NQZJ*&U\/
M+\9FY0A(9 HUDR\(- !67D^S 4K?QZ4S0#7-WE8VQ%Q 9N3J10:9#^KN*!#,
MMIJ+."Q''(\Q*)R@GNMQ0MR>= VH4 J@),_IX(>Z;%<J?'D9.O-#1)%0K?C;
MN7:X*BN4-B?/DYK.2!EYR41$&0_J';N-E:* Z4X9R88-J/<J$45VLYH\5>?P
MZ*A?D):B\,:8';?B<Z,,/Y+EU3!4_P I16_ELC-?=JBEPC3LB"'H)$T& NE?
M0=_]B^;TK88@F:\:Z8"G@8(&(4&XZII\H5/K)2P-L:)AF19LN,O$@ZDY>-[(
M+;6Z5)17]24TA$GJ#:PRW[5/V ONQB5/(:<! Y.G#F!L-+W.T0XR#$5?DTV!
M0%<NW]&>!\6/>0B@SJ+DDU/R_6SF3A%H^]W,3[U@UN*/".$?4JU*#^] U>S;
M2"F(Q$-2-A@)-7R3_2U+6I "G2:^5&:,@OV]DC6Q%$^P.]>@3)C^@\"\-:L\
M\;&6)7A&HS'I)S<SKEE6]C'3AJ"E6^6G)QWX-1*D2",GB=POT66=(UCVA-TW
M+:RU1@FDB"605<12.&6)FDW#M-.OFK;MCDUUTTYO <7>D(T\9:?%:CNLY@\R
M+3W7"]]M_R[JG.3V%HE*1/$K#SQ"SK.>,*7_?-=8NFR7_G8N/8T$891[ ^,
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M\US\;TBP!*:KD'3F:^5Y&)@3_,D-/JTPP.Z"#,T5!\<[U:%5S6$M@*BW\&\
M6=*9 ; D\OJ("?Y56)YBU/O5ZEMW3^[\'3[^]6"0<(<^20"9UVP+Q2GL'0OC
MZ<.,W&G-/E3&"_;96#(F?IX'X_@1E?T/$6>/"Z%_NV:XY?9%X+)JSM!_S,0'
M8I<NM'"ISJU.C=+EN>_EV]F9,P+=7&J/326Q54C*</CX.2_=)7WY4J/%OJ$(
M7,U'<M*.(4V][CC=?J):?WS>PU.^)T"Z]ZPC,G4X!%[]GE>N ^DUO:N-A\PH
M- \S-D3J^WJ45H5FN$X._D]RX@;^EO:(^Q_2'G])EWF$.&2WV]5[)SFMFQ-P
MX&":+RB-?.Z2"HK$S92*PL+>[1?V3E1(E-W#EKT/7<KNB/R@(81>51SXKB]$
M;,NRYH[VLN).?TYI[VN^@NP<U:I"*"\ND#--B,=0@4P&!X_>4U%.R*7S.SUU
MUA?&^F0<:4V<6 UU[1Z'JA%E[[GYW"+;Y/B79F72A77C/(XVT&^ ^J&38Q)8
MX @S;)$(FJ?JPS5Q7G OEO^"VVFD$]W<;'4S]"9%=C3@'*+OVJ!Q>Y>@4<1$
M.0$9X2[^I_*_F?9MIXHIG@EE_Q CO E5MWV,788*FW=ZHC1-7?U-X3-6KL@>
MP/I96Z$WU-+BPR)_G(]8@/4U>NK"G2IB>]WW-*[./&J,G?Y!T\:]*2//^8#9
M83#AL[OI'ON'9TS>-?;=DW%/K:T7H"QOYT+7NA=OV,?? ![:+ZH-[XXYSC(:
M+4GO6![C,,)/-@,*8OJ-70T7#_H3*DN9OER6H/:$FT3[C]GV7)2JW7_FVX=X
ME%0)!QP@3AJ]0@E],#J&F*RR@I-5#E[3F&JS>.+BBYFH!]J+6#ADK)QLO[C-
M<KYA7^9Z(M'GW.6>DVUJWMMK)UTZ$;5O%YC+BY^3V'-TR+",F"NRBB]6WPO2
M6,\.8 KT\U8\<S9C6_,@86][^'1G__91\(OK@JCUCR%#@I:"6<*K-O^[]MS.
M06\^L2,VL7)5EN(1@K]7P>GE_^OA+&*J#X&+-[\!0T:[O&+]O9>!J6U7?)DZ
M_HDXA4TYQZB#E0;6+3RC&C\S(ZQL/CE8Q%"\CCKBJPUN"1<SQ7T?2'FXF(RH
MK1,Y>[*ES8W\D.&0</]PNWBBE'_+$>,\4@+A>R&B&CP! J^-1QI2,8OV[D*^
M]0<OJ:D>LP_/Q=I'FSMND$-2NQUZ&4-=FZG,<LA%YHN0P/P^:)FG[WUDE20\
M#AVRU)6SF>DA(?6C>9GYO!\/;OG6QLHP29+3*V0(^'QYYEQ+>@Q5+;Z-2A6(
M8VN4@-*->^YEXS8^[[+I'2$QT U;^FHO"+(I:^W-*>A*5#$#Y6LE:@;J8YO'
MJRJW2FK/VE(Y_]\][N9OI?I%21[H7TU^ [[C\'HV4$>P5S@3&YM++EX0,C\Q
M<BOA<;M1I=J3:I']4!8M2@7:-1B8$,AHX8F_F%UM87-E//T&J%5F8WV\R)"2
M#*?O?N-\K.F$'+K)YDI$,YRTHTA(BV*'=\=0G-TT'>0#9O=X2U9%?D#6%8&(
MS\V-\^6#!4'9"E$A@>2-RLS>(^X_M=>0>MUL-8OU$DL3E;(4'2:D:(>&6'YV
MWW%GH09"R ZO8D]?@DF-R*P;@N_"1SLF)+M&['W]F.6XH5\V_RD&M\?'Z,KC
MD#H&9@PN><;#+L$>D*.\S"S>))HAIE[S:4]'DHNWE: I1JN#JJFL[=0H!8V=
MADZ_75B7_?JNR;"Y-RY:_4KD_GE,M)^"@O;.Y[*?\(@,\9Y'2.4N\IQ->NVZ
M.Q^GJ36QA@EYHRV\LF'CVUG;WEMYR9'W/D4"&-$F]<-ZNE^^R:>FU%\DFF;-
M":E$@B+5[A<.2P2>:N%)5I,WOT2W^W]5\?OE.\\ZBB_J\;/GX-IEXS!#0;RV
MXO"D9Y5_69U,0^!,D&BPU;;[^<91W[_;_]D3RR%;L(JQ(1\A7N%(I5O_T^[6
MTJL8A;/-T.,3RAZ*H/2P7W&-/Z[O8V\PV<MOP&;6BUA_X()M8'3@QF\ D_,!
M_=R;"P_,XF;Z4=NO7)4TE]3#!VS<@&A5YD&FN:.&3  Z-1SE<BLYPKL?#S&.
M6Y^ZT"M;J5QD M4UEF0/5ZV C36O0C_8%A]'<WTZ[;;?6Q0 FS"%] ^U+_N/
M:B(;@M9A??@@GM,,M7T,.Y*#"HQ/KIJJK2HRWWUY>7_JL/##9K\'$ \?IY_T
M,H6542V"RI0;PI7@,M&E,@$#C(\;TJ*!ZLY?P=,C_GZYBF3" ;E)<K4REE?+
M5%463.J&3Y0A/F*BO>'U?#Y2B:R/:<<.)/X2(V_9^:NSJO_\#Y)Q4;?Y$D2)
MBG"%2)QR6W25_I>W&*4TW"!-GYC<#H-ZAGB7=[I<%RH]N04R*2K%F\BH2-A(
MF!TQ;*>K>%L#I/U4/[SK/C^LD4>QX*>\OAQXUX</8B)^3&)B8W_BBK(#R:YF
M:-$P).&L#EU3HJ[KXR4]30X.89"#NEM%NHMDZ1(ZI?K''117+$R']X0;L@D%
MNK7K\6D*+XM@=W6]$H/;"TY/&/#E[OA-]VN#N[ J4T$:]U57^-F=+V/3[AQ8
M9-WSG%%AJ?F+W[,QX>EA!<PK_NU(5,'JQ]-KRAP>6GBJ/9SL]\OOX3^MSS+U
MQT*)9$RKHF<%$=0P9>1,KYB"/N ^Q8;4*\Z-;L\6%G=V>99^LW$J855/73,@
MY4HS1R=^=]K37_<;(",B5Z*]@9<TKG<XB3D^%2USFT&H=5ZEUMSQ=DVP7:.$
MF#R*Z_.J2A6S@$PG.!:JSV/^T#=GN(D94BY'&9J>#WU*ZR\R$,#_7+3QEO)*
M5BF>F?:6\(1RJ\+U-T#N8=<^==&(Q3X-JCST/>2@NU012EYOF-[7;M\X.'#/
M5'/0DGZMG]PBBS;MHY.&IKGLB":I[W[#U#GO!Z@W$DG7L6D5O%8MA?PZ"70X
M9=*KA=&+K-/5]0EW!+LM"C&+'(B/X"0-9ZL[CX]OD2=&_DH<'1L*\GRG!G.E
M=5P>'>."P_M)G=TMP.!;>V74_@W!G3"0^["JK8OI7.6+%H )8WV[2]?'.-;$
ML(QG"\RFMS[YX_WWYI/QIYLU%AYNC@TNLVG5[AUE!.&TKQKCP<&?/R]7^Q-%
M)BS.LNM(6)K;Q2ZW6>]TR7_%YPZ/J6/^@7WQ@0JYT#8E2UT+@8I3P61\M3>9
M8&7Y0;^Z_FV!@<?IV&>]VOV##?\5O)4C1'0ATTU'8T].G3?]C_,=(E+9Q>YM
M*S?;J\6ST(8PR5S\')$MW;34FP(?AVA89VU-4Y:-F(5JQ.F1'GF^&+&Z-VYK
M[]Y5+[@4O&E$P-%]QRQ<CO6. N(80<:Y8T^ZZEO8(T1G80^LJ%DQL"M^] ;)
M !%E#3.*1>[W F2-Z,:.Y^^4NVI.0]7.76:&PFPOR<D)F#I^ X@^T#TW[N;G
MW_B>N,-X0" UB"(H.8$H%!U?*/.\MDSZOC'=A\VS:,72F@9+B,L=V*GCH2@)
MY\--!,Y^\)7*)82\EG0GY^G;Y\DN7]U+^5KS).WN;RE+-<X\D%UNEN!@AQ]>
M-![KK&D+^Q.\.$J-K5KPOQ_%LO!+U?,!!"^?UIGR,0_)J;H%6T=3L$-&FLL@
M#95U_'+Z/#21A-@L[C.<P%/!B['0$&8$:HSQ3-)5TJ[3;JN[%L%*_2_5TCO+
M&Z.J":T:2\]!%=,1/^N@UG7\$BPLR_-V-SLLP=\NVR>0HQ9^,D=E(V4V'-34
M"(WV.ZF54*],6&!Y@$@*;FP]+,++VY;YI'T[%S%363\:*!<8\FN1N)FMA3Z\
M<86S')11IXZ+7UX).M8HW_HFK92K'[=IU:2?N\=R=PD&64X-+K!7=_>2WCT_
M-.-H// K:^K8$/)[>."7NZR9HLD$9.]2K!=VI)XLCJU8UXM,B1#XBU$EDMAA
M]BA:MR3:2C8#/O*;Z7$F(W9?[_ND<<NLLR.Y"^?@&'65)AO'%O;51RI_P^BP
M%-*:5&$J;RA]G_HKDZ'93U[=J'/D^DG9T2S4\JM\("_P1YUI)7,'@TRE1B_Z
MN+QC$WO+SX*XC2FTOGTB':"%;=]BS$NI!Y^&YV;]:<,F)9N%8[LZ .W>VPE<
M;5L=-1R)1ILI>Y][9O,\L3-<]K!$3'A:85POSWCV7L6%$G.\C9=J,D=-.I)3
M5D$ 4TAP-O]:$ 'QN^[FA*MPRKWCU>/RL./L79 0,IL5 :R,! SEP::F2TO.
M\$M.SHE_@?7N SO:)\.*T^^KAF+QXTV_@NSN_C_2WC(LSFY+URTL$ C!(4!P
M+RP$=W>7PBT$U^#N$-Q=@TM1N#L)[EJXN[OK^;ZU5O?9N[NOT[W/_OW6C_=Z
M:\XQGS'F>.XA[G,%K%^UAL';D%'!+J#]02>#0.L3D,@%<'L#""%^: 8  /<
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MA@>6/ =(/YR+!V1C!8P1)0:DEE=/_U86DNB4;X=;U_*'9^7-]B-E5F8W485
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M,/6^_ZR2D% 0,5S<M>5H'.XH)U2DM=S<QEG1H>^LKZ4;7;]O_SX/=G1RG[@
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ME9)0 %%U]=)BOP'B+;2#I0[MOX2!Y'(,M^E$3.MD[Y=SQW_Y:B7W\/O14S&
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MM/,["AZOV_W]YA@@'T?("Z$0(>I\;LFY??[;X9[3DM+@SW2N3/)*DUK[0ZA
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M,9+CT0<=-"B&Y2M!,(./,O6X<>G0?R>":63&T&U5B9PGA8(!+)$U07*%M#$
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MYO@UL+IT4AZBC&C] #;4_1@7B,$4/G+ER>]#W 5%E%=.B39_QA<4EJB<+]G
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M[UKC[3<HO2H*,[8<\5:]O#JZT]V51N+& %;G=N%_6MYB\(Q3IN61WSPLL'/
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M*GHKKJ754PFP?,H$G5MHDP)G<W#8 /_X.0  IP  <OB? QS,1O<_9+;^]Z@
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M,]'#6;O9)FUXO,;MB7ZOO_1N]<[]U_Q2$NF$]>,S0#3XI1VR9<ELZLQ] DY
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MC212[N1]4L84V&[E3%F;[:SI=%>UN7K1XON"-&DRHNOW&<?"O+C,+8')B<L
M4C-1RXXA-.D4M7*&S)5Z0QB$JN2DI),F.)05RNP4R;@DG2?8M; !C1GH(-FH
M<FZK,TQSR5142+3C"J&E)'TORE=Y5;/L:7Z0$NM4:*+OFQ'/,2A2K_OH>!8<
M8DW'"UV*D@W9-8)\48IG!O?IXC"J,!YK$!,7AK.0I.7"' AW@)0!F@QHF&XE
M$A$F7/=C%KXV<F/^PU;JT]JPCQH@F>[T8J]9NPJ>EMY1KNGB8UAK>AY.!+EA
M8993^HDJ,H#U%@J-+*K'*R,/)!DC#JH=5NU.(\Z88:S RC)#,:X84Q,V;@[[
M+HB/M+BN)M<I+.<)+L2X#.R893:D:,01B8)1J7?28,12=7FZU>/'_YAN&J8)
M6$5$&!%J4(LC)%7EP7$]$_OY0JR<)[CY>G--3,W#'#B5'B>C6/J$&<\I;CS(
M]#K2STIB.!SCP[&!8VF9UMQ"Y)4HG\+XFF1KH1;H*FQU2K@8V_RHRR0Z/3H'
M<72S(_:X?@!.:% 0D7Z[&-NJ&(KM69+*\P:D-]LH4T<-U]0ZY227;H[0G)H,
MQ/*THF$QO14!#0(#+"B;[#>540T(<:%28,9 7P(\)G;W7(-NR=EY@F@D6N&Z
M*TPF';'O)W@P1+!J3X>JI6%<![*12,?M#R$$2*AD=,H(_ Y1 K)=K49DXX 9
M^JEY@I;2ASHAA>1<AN RMA<'7N45=R8O]A[3%JXX:\ 7&A!@[;*^,<@/1XPQ
M24 9/J6DXD6)4"X_:<(\BR$D(92]B+0+6#F7J.)6%N)R)9>H1B([:\!+0Y#,
MS%L6N:F6Q4T/ $YB^0H4NY@#M!A[F"C%IC\_S][ P@B^TP^5_*SQJ?.4T%+X
M=(1V6PA;9WI$A@_B"%7!7]::UF]FUC3@:W4T"2QPP*C3!>>+!T-..:P #C1;
M=]*)B*9:T4A@X*%2PGIR!>QU,XV2V4_$EE#1<])DYLL.9AF=K.L$F*7@$0@-
M5=:6_3*715IM;>@.<G W-#P2U&F8J^7: :#Q8Z<!X:((-/JJ88&ZX6@DX/3S
M^*R]!;UAKFMF_*%C#=WQ,-=*4Q$BM0G\I7YFC6 E.NXMM"%BQA<]*;80,&W-
MVU*\W$6W[,RJKW+>[Z4SJ!;J6A@EQ90=NU=156A*E":AG7)1H456\T@K2SA2
M?L*@838.Z,'&M;EN)[6VAD?9J7$!4^62Z?7L:I2=-K;M2J@W622+I\H9J*/H
MD0[W9]VHKJ E3S(;ON%FDJY/]I2X=NL&Y("%(EY68,]W"3JVL5=B7K/J*PT-
M$_UAL3MU-)4$H&JN 9:&5-V&LQ)8LG&(=8 >DBMC#C$DBRP@"-6HY/<&;-L,
MJNTR+T.)?J"-*V%CH?JB._Y &V&8.C3Q4K,=D2@*THE4KP&:810D6=<O 18'
ML0W!"&40CW(MG4XA>1XO#:P0,?J%;MQCIH#&9*$D'L@-V-(+D#50^49)#J)6
MHB&.\H[487JI%$:VXS#(]XMJ5\Z%F7#0Z(3CJF6I/583D8R@43VBC2(2T$[$
M7?-L5V3,CPM^3TDG$$K4A$PFBZ;SS*OSD#7.,>M&-^(A6G+H4$X64)%.#8&T
M05HJ#5F*$(.AEW-ZG:&D2Q4%&H1D3J-R@SQ/>85 [D&S35VQ!PY0, \F.0@$
M,W0.16& 3B9I@NX0]<0P.6#A$&4[C4[<B9EN9XQ/NO@P-2%8FX9+([0](+1$
M3ZV*%E&:U3:$)":ZA4)8&4/TT/38M0U!G:1%EFZ28C&V&R63Z/A$6L!#B:@4
M"U+H(%RS+(E=H)++3&KY>F<F<F[0RPT@!A^R-2*E(G!6[Z&A.U'@3F\ A@F$
M!JEZE:\10+/BPDXW3KIL%-&NA1K= :XH1-$AU4:N)@FM,%R(-EF:392<- ^E
MT]G"R,V41U5U0BIHMLY+47-"8_5\&\T!-B#9(V_BMUBTUE (N%(>I_.1EZQY
M==Q M"0=S1IP;(Q+T"";M_*%OL1Y$SKV91? R@5V(("E?'_,=WO-,>J@Y9!H
M8DTG5VA&8Q:.&W*P7_*L7&=<TJLUJA-6HED:+7.\Z.<)':G6*:>DC3B P;A$
MF4B,V>:PT=!*Z4QM;,)]C[=;X"B-)#@HE=,3<00>$B5IDI)<H='"F_5B YP]
MG6VB>0[LQ$5&<@0/)64HLF-80@* \JJEKF UJD'5I1G="T44&)>*V9R0+I+)
MPA@8:JT@Q>BJ!/N<P _<%CJK;<BZZ%:;<370*U5[?6MHH9($5R)):MIL&\S5
MNU[$E,.N5P]$B5;S_2+%YJL%7^W!H^+ZQKYV;1/7&G&EB@5H7  U6_%W,S85
MI&_$C@"!B5$$XGR>&19RL*N#()F=^/G>L%P*#;=G14V3(1$!K<L+S_A1H=P%
M>L64/<SK7+G>S@3CHB:V*-LE[(6XQ51D#YRD41HL.KY8H]=.S5G/FM!*4E3#
MR2Q\=>1RK\OF2 JI=^)T4P-:*9.R-0[2:2)%:U2KU:N#2F!GG Q, V KFQ^,
MBZ/:&*#(21+O8#V\#0_H1"^1 &9VJ((P/ZDEHZ"F( EQ,NFK%H:"?2U N'$J
MBXP'M428*=,ZCW)#D$8JM?Y8K7LTZZ1Z%:@$MZ->()8L.S;MV2-V6N2H.&][
M!%+OY_QB2(:TQ&E8!(IX'ZKE:[($37<Y&\ 0L\=H6&#-@C"*76\"M6J-9&GL
MZU(I4FM-55=GQ5(.XGF!F_".;GM4T07:3-J#F(XHV9E&KEG!Z^Z@Y6:<AEW5
M$Y-"-*:9!A32KJJZ"=R 00.+PPCJI8PZ6';G"5;Y/ Y)C%!WG1[E:$R4K5-&
MIR\5LD8PX285,NI"'%+L<FS#-5F\"X0]&TY-THKA9&MB:+" /=3'-7T@NZ-9
M6Y%)1W@5X^AB,<^+&@'Z<$7HFN&DV6R5I68OV[;4H08$%0,RL.Z0(*I#$0)0
M#J2=IC+.Z5FTU/;B",OB>'=6??%TH9%")NVQ -AX(=4!AD0U,U#TJE$DAFRY
M#)B)(M8:YRT]2<.6R:->.=E)<_7!$!T-N!(AY;1L)UU,5)59;4. 0]'AB@,K
M(Y1["L_FF 33\Y2(D7-UI"6FTT34QF5#E_C8CH 6C:6+6#E/6WVFK"B#.)<(
MM=AW*BIA2K/V5FH26#-?%A)E81A6>J;.#8@&ZA>J.%GG4G$NIKED1* A1L.!
MI_D%F$JQ%)EB\MT^UH5:%L<G!D6[:F0#:Y9&LU8;Z>MI=E.U/UF8^N/:M?]Z
M#QW\;+Q&E&O%9?.LHP<Q \JC0ZL+S>\Z#&LR(JA(KQN.?5MJ@&0N0+ H,[3!
M3,6K@[+8*F(P/)RD':HC"TG:Z< 5;!#V.OWNK $OC+HF4TE5^'R^DBKDTF6J
M'M3[;5NLTT"/T(=QL!BFQJFAQQ>\I)#'!;D,60&',GDQU\O5VU:O'N1=/]<D
M@%DWNDX34 N5?@;IR+(VZLF$8!AV.G92UU*!/N<QZ:":'2$CCLE =4@!&[T*
M&!D8IU!U'_>1<7*V9>H&J)?'_$2&96LRD?!T5P6=9EC5"4-A6MWNF#1&(Q#E
MP7IYJ MA#LZ-DQ,$G/" CQA:C<'#>"Z.1MM^>99&QT8-E1&K94X4*X&X,M3*
MZ(.QK8Z:R7R%,W(Z"99HM$N(E;I6;Z5J1!5 ,0^&2]4!1%3KDD>DF9I$#7N8
M4YLEJ7*MF!75"E)7TRDP4<,-B#)5FAIF8;W1P R7'Q4*;GFD3F@Z7OBQ+.?S
MI7&MXLM9=Y)O@W2A-N;;;$_.,K,]V&P!2K>J5*STL%6L!UY%K_(ELE&0RK6Z
MF ;*%I=H=1)Q>= I=#*\AV938[HX<'22'%NY!FZ$8B,D:HE2W6=F28KL,9";
M"3AK/!YA?J!40:3:S-+=H6X@E-*4!\DQ'S5ZK4")HF$&&"E@O1A'RF2WD#1$
MO$KV*QE#C?W<Q9Q9Q)9UKU2+^+B"2BL45QY:$Y&M,)5:U:LEB5:9G5B09XUR
MQ68[)$(M9(*AJ(VR81K.*T*ZRR:[C7ZR6Z:+732:Q4.3QM&0&.MRR^OT^$FZ
M !/9C%["^49'1S#0LLPF(SEXVQA8=3NGHDR$->/:TE.2C@./DDY6C88%6"BT
M1]@L.&A&FXL4@RT$\WENW;XT*P]BPYY6@(E1W%/S%29<LZ%#IN/B;Y29=H8]
MP$\.[3(V:QXGO2RF2_# 9Y%$IVWYV$"0,P+6[IO=$)%9TQ4$1D33:4T6N4+.
M8IAA4UU_ZV$LQ\8=1;,M@@4/<89\X#C!$!5* %A+\ V#JKN0J" @#8-BH4:7
MNO4X\V5RO%[@2HP,YN2!FG#;7 7L9\" +1(E:/8L((?J(2KD^%$$8SQ?RF1+
MLI(9I,HU&)?IXHCT5=ZNL*[:BW+=?(71#'8"DI26U&6NQ2,52[(<.E>@VAV>
MFX6O-)86*(H?QT  4?)()ZZY2:PPR5CS<^?#E("&*2VE)VJ#'(A82:T<A24W
MSA!8LU_J-%F.[EF9!D7W[=DJ"[;=YMR>;WDUVRV/:V";QEAB-([;S9)A%SNI
M;H!WFXHQ27,P*0 @UN$'/1A@!(8I%EIP3S'AJ.J-J(I7G+WG@ )M3.Q9;K/'
MDUT&3(0IU(QMDJWDU&*ZZ(M0"C3-@E8VI6IMXBM]C!:DFNV 8XH>>40>:(P@
MOZHSC;BFG;V[1Y!8VK,&18HG2@9+<+J)CZ4.PGC%1*&5F- E<QS7:E[&'N=K
M=+[I5OV272O5FF6*;<&P$/4ZTKB.6F%*;9@+FQ@).T(*O0K!$7+8K%1;?C'.
MQ5U3[R0-FM!"D4S@;8Y.MN)8D3!<)YL<*')+K_@!F.::C5[!R;HY4>P)PUE;
MT;*!:@+$V!0=EL;-9"K.,%D:-2,\:@)8Y/<[.2+1RP&\VT@ S>:DJ,E>4Y<+
MCA=GJ%3=KN2'V403:75&(KOP3(JU+</'.Q$E9%.M?M7JCODPG>8T+:08J4%Q
MG7$6,B:A!*J2)HD@K3%CJT:I/)2#LG6,J>&A._!'24S"9ENFQ0TW^8"-/N:>
MIKD1.4US#![QC9K19^-:L>/U+(M+EEH@[\W><Z! %1E&?:SEY"UST/'K>IV!
MLTRWDJ_FE'Q'K*4FD=?H<T(Y+V#X,"D@?F."EG+LB.&%2EZH9@31PIA46D1F
M]6$^R,B#1%45JXUD#4Z"( O@82H)"0P0=W6Y?E<K*C5BW+'X8IHJ%%L4R[M>
M.L\9;NG%70FWD>Q*6%A8:"OHN%LR&@TP7\SZ0V BMP$Q)I^W@6:M@EN6[<<5
M.B[CWA@L9D>2:4Q*O(\/<+\)M.R*[X@9CN+D@JR79@'6&L6UB*$!Z%@T6,GD
MI5S=@D8MSTUQ%4FJPU:3)MPJ."G#7%-ARNVXNN2H$E!DFX,>A_EZ"AWT#:0B
M-/EH5GVUNT-T &CL$*SFDI-"<V.;M2]]."U#II6:$*@CVT2S3%UKU,L4TZ'R
M E^;E<39;&S.4HWO=O$&G53; $^ 24#IC6!JA%<,MRU5>D)2T*LE,VDHBEAN
M%0G. T:C/ [;.JH9%C$HC;"HCP SURM4FB"-XF:BTJ#86CQ7DRL0:(H+NJF0
M'V(&/C&<3('3W![MEJ/ H;RDZN0GZ08JV86D..:I<J]%FJ,!DF;7>P+^BO99
MK6'0@FHB.,$AOEEF0T>9U!*M0E$A/'EFA^6FU.V&H[%0+N>&*=^"Y'("*30'
M;AD0/(2;O<4PRLZW/F1I[8"/,$$E:7<K6,:UBZTN1-*S-],2;H0 (=8DRKV!
M6>5</8A[APP5^50S5QS3N*\:# \Z8[6 &(5R1==XVZAK'8!C^P$>ZHV@!"6A
MFJ!5BK-G]#5/!,6P)7&%22-MRSF"8:NYMC["U9$?-O!)#[1Y#&@ELPEU@D%8
MI0]!&FO&-(TP!<8!@NW71YO?^UIK%Z5O)W4+S@M.HN9Z3*R9?#Y9JB0#--\$
MC&RDNQ4H&G/)+%8.N:(4S1[ZFWJ\RJ*9[P.-EE: ,)O@VA9$-%K=<FOBPEA+
M2!%2W)LW$9NL"*EZ')1ZJB&7L R.9^/0A@*IN-U(! V\7YT5G"E9;WHAES(@
M.B[< 56"^@CG6DJK775'M;"54E,0J**%1,](]H(\X8]]U6YQ*=]LA!B8*Y?B
MT&>@=H(S9CD%2+=$!_!'C5P]@]) %U5-)C)[Z6I)2#>@,3+)8C05KNEHI_O,
ML5E-E"$XW6>.P]E:Q<1L4W?-(R(A#X.L-\84H!EA71KN*Q+/%ADVU!-6OY"S
M6Y)9%:AVKYJ%,L6JDAU%8AW'9=A#>K$'U>2B#,[>MV''4J+;!3Q#]$PLZTIT
M68#2M&VDI3BUBFD[4R:L.@M8964X'(-#=EAG.2@U7[Y++(0&,E]HU84&Y)C0
MPK-1&Q9#-A\"C!_,N[_FUGO:I$PYII^!(JQ12*,2Q5#M6-2&2P&QC [;F@R]
MO#M&<2HSH#RE)A5<7QS.=.B4U>F/X#2YF'!MKCI@-+''$9-L<D(TB)S1C4M]
MM #YZ<*@S";Y@)[$GB^B?M<O<X&20:FAPD;=-)MW7&%68Z/%D6S4JJ,HT<RV
MPDG+:175>B@7QH3[2O?%!5"*N]RN/ NP"B@20E /"X 0#/T1T[?MD8TF,+I#
M6E%6;A@P7RD,Z$Z/[:(4$[>9U#"=KT,F;OF%"1QDJ)"M Z@MP'5CUCS*=)[+
M50(0#L   TN6J:I&PJBEP@9@848A76#'! XGLQXRB%OS-,0CF5I#\W$G;FEM
M$E([:@2#EEO5H]0LT<N%=A020(H8IO)MK!7U"[U&#HQT(TP:Y62^ZR8[4*$E
MD8Q?'E7U3KZJ.L/U'WNL>>(Q>Y2YUF./>FU>)9MX,E:-9]PO1HJ4U ,]9#Q:
M,MUA;5 P$!%L()%HSM[$&$HRZ)"R)C?86A)T78J-VB)I!K6J,%:KC)U)CVIZ
M2&C)YKC?C!)MEJNAH(]9[J".J11L<.,N#!B%6*+63&2GWX^767;2N;1/YF6+
M@:AT@)"DG4;R]83*D16 1XNI,581#,HOV]UF-LPP8\S;R'J_['M?KJ5+6J!+
M?MS+\UY9F3#UN,L0LXQ:SY&F&0VK6&I0#?A&;&.YKC!+ 7[4"O+#5C9,=M51
MQ2" (@+V:92TW'8MAQ>!-$@W4H"ACP<D6EA3^(RR^7P-7+/?1DY[?*!4FD5L
M,#=[OR\;]T-J++Q60WP.-I.FV=,S<<M6[XF"* R!NN:+34)I(,-D@-$#/041
M(.1H$1H[KE:8R/T!,ZN^&*8:-6HNU&R17KUE:K@H :UA">WKXTX0.7J[D?.A
M%-"/+*(\LG@?39F"/ #&2)QDVOBDQ@_&DW8Z=C13F-6';&6"HU:&#900R?7Q
M),(@U;B#9QLY(F(B$&'86E KI$IAGL<&F!$,B4P!\@2%KA'-/IRAJV6^!Y<3
MEB0!LUWBHJ>W^ME<MX6&-5S,D>5*V^EU2[UZS8\Z3H+OM=JZ3=0)4 B(N)B7
M9!Q,5"9@BBFU4:\0M(9.892 )$ :IF:)O@^)0;>FYA.1"(4^"LF=KAW@L"3*
M#&S7\%I:3C7HJN@:"B7&O9VEI$!WTH@+ %*+^\"TE6>\K%?&BV(7G.64 !?&
M/EHHRRH?%:B,X=%U/!@ZD1BOGB,!8-*'L=A;Z%;L9JUX_<:LI"1Y832=5+<4
MY&4H#5!FH*6Z]FS+5*0#TW/BJ=OVH%<QT4F'8M6Z#+6Z5=&VJ2A4Q08XI3S*
M>&7=P&/*Q'1:>;@/2'P.K :XKAEF.LC8LVT6)C5(1H'IQK8UU1+<\N)>KA!K
M:909=RG1E"=&!3)!6P)H)XC<B=1. [FR:! %E([J@,YX(.09!C%5[CS!J8;)
MRA2W5XE5Z M"EE<P,MD)V4!F1BX#-?,)),YMO7A*M2Y(LAT%"VMIHU.V93$U
M (5R)YX.P:#HC"!)3>?43G&@;T=BL]P:=AG(2%+#MBA*&.753)TOV%FBF>QV
MAT1^84(X*?:'')#U06!^+E(\%].:/9.*US3(M^02;&=QEI)3*%V%7$ZA&D)R
M8O!N?JI7L27:GM3AHA+E!:J6EAS"CU5+,N)P",RKEDPCQL(,\_6FZ\?2CBR)
M(S)HQ#(3M0T[$9UKUXN K]7&<6U*U8M>9BP'3:Z%5KH-.UW0&;'AQR65F7(*
M74,J]^N)67 H)<RJ;;/C"=;%H9JG28B;+*JQXVE-*VQ&5-Y'(J#2\WLR7&9
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M F;2_&F07J_#+^_!^P0S_\'EWJ=MX_MW%(9-&G)>S$(SV$0:)%0]2Z)'7DS
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M%5H1A<1Z:H /M0V9&-\#UDND(K%EZ9#J,F7O*O?>J('2MN7%TX#YFLZ1KF7
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M(/:WNQF%O&]0 5B9JQ'7U<8,_LH,>&G+-?[B"U8GKIJ=S=+SD')L!FK-9P6
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M32@[T)<$%O!-Q)43 B&<ILN4WVX7&MH1;7PA/FZY*D?,5F4E6^UG2/4OU?!
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MAPI/Z?[.<[R>EUI4H\K8N/1LGVD1@T]>,&=J/(2<F/ 7[^N/Q?W?08I_NF'
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MG5A4>:1?WE^AW6I7CD@,]#*=&;41<>RQULT,"1B8V8"!NP2,4J7)G[3Y] =
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M6UO:6LX3')]PUK@KS$$KT*0A2=NKRT6RF1^V-<O!<+JLWZ><C90\-(.8A/A
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M3/8GJ)< L($#>3;0K4W6!>),\IR%7$2EL= $%!)KQ,1.JQB3R$O\E??Q($O
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M=N1>HN-NG:3,7/7/X:;V'>W+; F+N8:J6%%GQI$JX'CMB<<^NK6R/U= QAN
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MOH,(D=8W[*7:&[EU?W%L,^,I?V]F5[AV$F'*'&\,\BA+-)Z2-.]E^"D=5U:
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M?5D?%6Z,ZSEW%3#[T:H]L);'T)\KGF9Q2)+^Y :L&>?TAP!/-@-"8536OK/
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MIBMV*6@/(V4:3R'5'%S?IJ7UAV7*$%:Y)&T8GUJ$D]< [% A6DKXP6(\;-"
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MY1SCQVK'L./M=F_@ZI-?#RH*EXZJ-P\/.VD,>\#Z(#Z-*BGBO*']CF=QRHU
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M%O17^4T'NB;>@2'6UN5&13D#:OV][W([AU45*4 Y13K9PH!*36^*IZJ(KKC
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M;'^P&M*D*'PC#9BH,OC3.//**$K#5$(HEKL[6_W]8G[]I^-XS/^-+0'DR!K
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M9I</Y;@K:I1>AVQD&XIV[?3(7R#?M.&3"%.(7/A>>%S@#JSDS,-85'I61W>
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M2&;$-$6+R^'PVG*AXV'=JF7\N1$O2]]P#WC?+7;C.-EOE8=P5IEOE6]@=0
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MORRARMZC?BCF%#BEA4O'Q6U[OTC&A23?(M%&_L-UW8)-?.H\@B"<\TQ-Z6$
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M#EV:9\3ZYFR6U\WX-9.=ET5UNYF:(:DQ.78MLZ6BJU&5-:I$%US/?J* X?-
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M[<_:$<@H[LY.VNRA<,[)6W&J\#-HF8E=44?.B#H;:#5E6[<QUP.EJX+ELC*
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M/1E98=6U3S,QWOFJ0UG,]1H5_&R(97?YN>P!G9X*MYRT/]3ZSD7@H*QC+2?
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M13J5<VWT[ZKW5O$5_G* XJ[<F?997BI] K.7?I3L+0B0;!-OCI\CWB.ZL;1
M[")*=]DD/B+*'U5UF<IF0X8L6F%7:Z*%R9C:0]!ETNGJU_FEXDNJ^#B$Z*+B
M3=!)T6)%JDNBJ$\^;E29VQ6OFKA2D;RP(8A*D9ZJVP:A2DI-*_/ZQ?,,$V,O
MB>;4%@65"O-T[V?^$FY6*:QJC@+</2+Y(+O:\81R0QK;>@I\0WR\:7O>5)&X
MP2EVM5!6G[CDH>"ONL4S]PCNJ"I&E>DOA?WF7 E?1MOXAI(KN;$A IPFSNQ2
MYVI$=NVU:R\);5L_+A$*PIO<9\($ZU36-;;Z:N,=\ CWBB4%JL#=KAL+#ZTZ
M9'R%.)PI,DQ")48_KQ6B!_V2=(\Q6YSAAEN8)?]1C+/JU0T*3!5W7;TS-@.W
MPG00%UGE;6C#S\]X73M$<(@&ZGP)3WPO: E$JG-X[0?"V]%[J4R6>91K'()Y
M)W4JEF%$4%,KR_595'W&2AV4^F352<T=VFK? LT<&L;93K>$MG!4*<_4C7!7
MLK4F).<ZAF\(X% JU+73.-[I-&T8^^DJ7_46]H'%MU1WV3U.YS5:=J]5 <Q;
MI=VL(\8"R0[T5KV[^&CY5MUXT:WUES5S1 XKZU7-0NIBDG*_<)53OWJFP)H=
M%#FF([H$EHN!K#F)'E.[0KVZ?*+60[ES?8@Z1%&^<J&R20Y=/%\Q)"]QDBGW
M232C2G[$Y%K_B5FG/V/^C.+J),:+951-N7Y'6J.*H'NSHD-Q5WMJT1GY5>UA
M)XBB00JSJARCN7TO<[X^LW4M"J"S:=*5?E2?LKQ)<U?>J+NXPENQWGQC$4P>
M;IKEE"SODUI' /D8X\K^0XR#M>][;R UVKJN[E*N.K==D[I56=2:$75&?J3Y
MPR(/V4#]/*<YLB_2L%'%D_1, X<15W1\A/P#GM$V%T;.O]M,AO]<)VMT1&*7
M;[8L0VV?7UI_#UUHG]\P@/:TJJE=;]$@PJWVRY@$4'_+(ZQ_/J?)!S=S79!E
M ^[G<E#=0?S)^7YU"82Y]NQZ/&'IJ.(:.@UD,"&Z34QN!<UOUI$?Y+UJ.$]9
MF;"I/IO2O!Q@!E%^SGMF&J'.L&\P@ZA=5@7HB&&GX]6MD6Q 35E3&FLH+\TB
M9W$3YM2YLB#+9*;%K+)Y+48"*]]^HU'&THTJ3G7[0G$"[G7+ A$9N*UQA; _
MMZF>(G@3;S!]%10OFVUT$HR=5VB($4RWWZV_S3LWJMA7VY+593AP<YK*#1C8
M4*$XF3NCSB17Q4\S396)0X\9QDO?S//3+Y!5VH_4E@O>616B56T283\UF0VG
MJX<MW?JQ.0WFOW6I<9W&#,W;4))^A:9HWHS:N>K']G=UCL*Q5C6]=7KS!>S!
MIMF-.ZJ9%A<+(B?#[%\7'I=NT)LZ0UUJE:8*SR,ZE)YE_U@+$-I9*Q7G6G;W
M%&,9C=L[GU<'UG>V!V=_-?6W=,2--4QN#@BYIOO>2/<T:Z\:)MK?TT3]>R_B
MUBW[02S(ATWA$/MB=M\#J#S-M6<W?.PJ4>==1'' RO9G2)CKC@XC$CY&TMJ+
M_E<5;CZ+RH2<&%B$=B_.V]")_I+ZI3L;<W,5NJ,4NSL@LBT1!W6]U]:%BQ_S
MLSF,8!UMB Z#=.)C2'G_5=+LXK&]":3RU.;.9Z2#JQ:U/2<'!#BW'"7S75^V
M/"%GCRUM^$*UCJ*$ODWNS!+PDSX&<V81J?L=XV9J:$<MX^#*HZUFQA'_L\U0
MQCG71\V%C-UC^^J_,@>L*G;C>\$=,&M#OB"P:%S7&;XH97L[@O=N);:EFJ?R
M5S<%\V"NUQH_\?:.?5$7Q?DVJO#W-TY32,&+>@ER;.% YSU9?DI9&T6:OW)N
M,UA2YU_6Z"H!NYYO&)+P;+Q,0UP/JZKM!^I7@A[V[->=*$1V>FG7IKBV]JMO
MK;C85*=ZZ1_4$*4>[_JW1:\LL,DU0KDQ5E72=Z5A+&BP)Z ^JC"X0VC.3;[:
M:F=L6U';^-RPS>^916<@NNZJ/Z+>82,Q9'&KK2JPC]GA MK:O:?-K3"P_7OS
MV>3AEI+&XRMHC8L;WOD]J]]3KW,]5_=6?<RF3R_GTD<5-'BO3<W6DM.[5H,=
MT^]M-T#0:[VVCH,>"?7=]!CVWLMC8!6\U7'>X#K8/0"@R1:W:51!7NQ9B0PN
M.;,S GDU_<-0#,JR-FXS"8T,+1H(Q"SUPO4G82R.VS8^1C\$ !KVD1=;U:G=
MCPC5)0W#?Q/8Z9>VGB$,K_7>](+H%IK1KR;2O30;Q,2-3G/ZCA&] 0"+A#[?
MJKIW8>FPDHKM-?2YZ:(M);0G,6\'2+1;H0%]TVFOO70];VF?G4"]=VE7 8!Z
M,*O%JJ@[E_)8)<N&O+A_I^=NGL%-CMFZT8]S)71Z[W9.G5=MMX#3Z-33$\39
M" #4P=D JTK;L4*ZJV3NMCF2X^FQ@P#QC9C&_LEBYY#O/1J1UJNA*U*TS^EA
MUP;A[S6>6?U?M7B8I?E9,GUK@OI8>O0F5Q4WIK9OMA(>\J:[7G''JZLS6!GG
M/+^S0/H$ ##=_J^:O/V=N:#$94NC\6%Z[$"!(2=&NR%5;Q]RO^MH[9"7I:-4
M-^(<W5$@_?Y;K?M7@;]N5S4_*_':,JTI,3UCX[8&>HRAM]ZR,.1)UZ1ZI-=@
M>ZUIOG-N.T_F   8-_^K3J7#$36Q.QXA@\"$C@NHJU"U^A],%;R6YHB]C514
MY^#7HQDI<$([-GUI/[$'=WGR4?)2W-#)8LA+3/9P/NP1%M2.0 SA2*HF% @O
MI-S#V!&,5:NP!F)'<@7N*ZD^:!!_@YSC\)"()STX+@8=IY</:2 WZ,6M=V G
MZ65*;X29SB!K4+GTWLJIZ%_T6TD%6!3#=LD1G!_#UF$>_B6==W07\*XH?>L!
M\$1A>LMLZ"1!N;P.]I8O(ODB3O$NE%]'R7E+$K,QX[B*P"<8,^?9)"*NGCU\
MQ+4Z7ANZ97$-79W=Q ,KE$R9$Y0GWT6X D?*7,HV(]=*6M>5HPZ(UP3.1?N)
M/";>QY+YF8<.5P$:Y@W>!$;7H1O#03G&;9(3D"S]1'PG+$$K*.U S%.')'"1
MG<K% 1#D0_GAB6 ,7S3AX%#%C^YIFRY6KVXW-OC6Y#1_%>\"9S? <#W0S+II
M)<?@(89?\4<1@[79_N<1)[7O)HY%[Q >.O"B8L66"9LF5[$V'K)D 16]*:+K
M($''=>P)"+]EN/@7#-$X+GX!_&G=#__U\&NFX@D#Z.E"^0%H^:Z_?@X(*K\.
M/ZK?7/UYBTZTL.;NQC2L"_CO'EQQ"?1 QZHX&3RL=97?$3C TCT!@9XJ+-LS
M@%<"R_MM"5S0GCHX$0-Y)=Q#*H3]P#J18Q#?B@LI_JB7<5E4)\PN/QOJ;9S;
M>#9C)H[Q5SQV)>KUAB>X&DR4N1!/P*(%0P0BSH1Q).+P?Q5!21C"[5@BN81X
MWS><,HZDMOM *R)/W[4/'4B%]:["8*E#Q@O8.NH7?C1NB!:#VH\_0],7QA+N
MTYZOQ1$OTX,7YY/2Z-%V5,IE.GSG8F0)_T1W'6HS/\2P%/V<9^!>P<[F_D22
M<>NY[ (?/)GK&",@(#E-BS2$[9Q .R>R@+UT>"/\G&IQEP\R6'&P=B^*+D_G
MP-'#TMN(>,PG"3]_%BY4G+FF&Q\@BO*YA8\54L9M)57SX-O),(.YKN,]_)<1
MH5,A4_5>[+4HC?9O>!#ZFGH@;S%VIG+[ZKNX:8JI/JNPW^2YXT#$6[RN(2ZT
MOGUZ^W>X?<L"K1:1W3B.E8BLJWL(2T ],W[)+<<$ZG-7K\)ZZ,*]=V-N:;W&
M^9"2>/1M)R&W-QK;5\%2>A]I#L,UG9^91,29-CLH"36_J2*G#8VTA$5W8DK,
M[[P3T4\-=VW?DUIX!=MR(94[%K0-0X]OW:[Q@OT<^,PX@EBR817D#)+:^3;'
M"76X#13MBM[8,GGA4?0,L\SV!.D1;^4F-/U7=5]S*L,=Y*Z:PLB&Y-$-# L,
M!/[)>(, 9L<R<U%9JZ8P+V&<%@!8&[#>8SYQ0/@Q UG4<\CFIA":#WJ:XC:-
MB@'3"+1+V![0.WHD[EY6%GV ,'UE.,.?Z.ZUEG&<V#1FB+61C-GH3KY$UC3\
M0TFEN,GW4(8H&FHRU9L*J+E/M5")F34T#^J+%6A: RUEOH4^EI8]AL'TH^?U
M#9.<N2 +CF3B+I2%D6=RSI"_D@T<+' CQ8?CG5%(V<U^$*6B1K+;YCVD5K-S
MQR0SSK%V;J@A&.6KZSV)OK+5D@?$K=*%I$%2M 10;2%=$3U+KR$SA-\BCY*_
M"OWF)9(?"T;&>#)=V0=[U^,AAN"Z"02;6K+X'$&C-1#;B5[JGJH6XG[EY?5:
M4I4B+-*-=%OVQ7,OR20; OQ@YK W]*!QY.8EYH5XEX8]HJ?XMOJ9A/V$929@
MY0CA;_W=M.M$MFXP0DI\IEWDF4'$J4< MYDBMK'[!'9_;X0)AZOLFBGRPSUN
MZ\/_PF.;(RH=":X-T]+\"$?KR.$_B/YF9X]7!&KM>\!1YB:VL+L8&[LUW_@:
M>W>35*C"%?55X@MQ5[K#*W!X8CLGM8,POV53.)W :Q)ZD/#=^GC 5N8Y-J65
M)3A<[:9K%LRLD?",? OX #::GP ]5S;,GP0_D?R&]Q;9MYS#]T2OFP,45/QG
MGF6G$'>VF'C#")ZVBQ>'FL!E<Q^C$9AEW";,GM*#7!C.-MF%6XB/6K:/RR"$
MSS[&0Q%J_C,[4'<TRSC7B)<T-1PQ2<8IX421_=!3.3;D?27[V+<H.4GA["N4
M^\O&L=]1U\\.X]11_?^CF)%--6PW]D)U".LF>S[;A=7%MD%-8U%8MXJOLZI9
M!Q+9K!I6?RB9Q635SCK!NL.R)H[&*.8F"4.U@,D0GV&-9Z:+?B'N,_U$[D67
MF7.%2>LTS&"!.60S,T8P>58$LT#@,*H:8AEJ[4OE @90HV=.9$2JG>!O&6Y*
M4N$'AJ/\<\(5AIML,&0.8X'TIMM1^C=IS:BR,.B]%I"B@"ZL@S!6TO-,@7!O
M>JC^?F$H/5!W/"&4'JZ=&-Q!]]-XNV%H1Y7_)OH'M&\=[^1#M!MM.70EK:L9
M!B/1* W8 @D-4W<\7D7CF0X&>] 0QB]NGM1#ZA]6Q:"Q!IKD$;3*/B3M.VU>
M]S7H+>K]CA7Y/ZGG6]WCW:C_-,]:.D ]TM#D.DQYJ]X^JFK/J1RJM,*WB@;@
M&])K.07L"6J22: ^N;.EN^ SUJZ4^B+N!!*EBU$)TX[)ZU'3__37ZEIG10"<
M*O23?4+\)#E*'Z# -2<E[]'[<@HD"[&38C1B'2XZX+:8@9\[K5+*P/7]2=E#
MNJ6R,D*"8(XTE>A(=)6L(QX"7A17D]#9#%$3>=::*Z)IY!T!B<*7%(]I-F(6
MN6[T";7^DF'&-_XD\6;F OQ;T7[FLNJGPKO,J*P>82 S84V@H(>9XW]20&1F
M3]TA;&9:$X<F2)PB'.$YB;*$>;CO0IC@8-4'@5;@GOF!?XW/66WA%_,=_(OX
MGKR]4TG\QSRAM7J0)XI2[>%F"Y.4FW%K!>4*4M5\OD#ND[F -R)]'?V6%RL%
M^)WG_I T3O7@@<21UCI M[#2M(U3)R ;7; "OD0?40GB]>CB,Q#<MQII= X7
MJ([Q0W&^J=VG/.#.E;M9E:=@=\L>S@3^M28#Y@GO3L/LBA'N^SI9^B5NF*EP
MU0[.9L-[W]><2$/\E,V<*3+K3K%RCR"N]Q/;R =VYV&J>)4=<171W,K6>>GY
M'&.3:54N9V(CT+>>K:Q?-@7#CI.='%4BNJFA:@858C !"^"QM?= Y.([NFH(
M-B51ZP1+C5RN\81_6'A-$XX<,VF%3H_ _^FO>.$EPP^8E')&[X$8"S/K($A0
M<9SF.FIO\FXU#6,7L4?%P?HL)*N(V&.3 C6NV+C1>PD]]>MPU\DO=6)\!_2\
MYAJANHBFSB#.3790?B!>C A4?"7A%SHJ+I)V39JC/$9BC"K!.MTF^DS23\UW
M>@ID1%U"QQ5V*O^F&Y.2%7+ZOG"-O);^8(%%GD]_.&F,?#?#^E;R4=H2?@')
M5SW('P_^K'+EM10<4=3QEB9VR]=PCX>/DV5P10O"I3^YH(DOI&\X+ZUU@)V:
M!/DQ(E;5+7L%CE8Z2=\7N,HEDF>)=K) \8\PBW2AN,CKF62?&#;QF@0DG&Y5
MWFJ\/I;P1GE3]QJT6Q&EK<P7RKK5A]?!I*DJ<-AT28S2Y-4HWJP\,O&(V%V4
M:*T##*HN-YPF$)4QEG&@2+G1_"K?5OK1.)+P5*(SS%JN$LOU,*]0T9/:&1.'
M1,ZB5595J*KNY!-F*DZW%]6<E+NT',W32$%-2Q+XXD\-F<M7B!Y8T/-?BB*,
MC1/UPGB1M?9%5;=V5**1TYJ]J_7E&QI>UC1G>M8_ DMC\NOF0M."[II^P@[.
MX9CWPZ-M;IM:X'O^HUAG*=];UD!IB.;&$=C=\E +"[$F8T=="5(?,\;$1IT/
M:C,FH2_.J3&>P8RW]30X8ZR[[1184RLV'_ZR(08WKZRA[CWN8<8\TSE\WQJN
MX2T!'!2K'R3\G+/<,([PS393=YB4.JK(AQJ=J>[PX/I=U(K24V8RU9).-^93
M;ZQ^KN?0W)=<J%U!6S_[4RV(MM06K]E'3[&JV9:]G%<P<1V6LZ-TKFD9A[C^
MF&$:)V UN#:4_7E)M?85^\;L;=H/[*NV2M4/=L.H(@GK=TIN0[^:<9+P$ITQ
M2$Q8'ZF?(.J/OJN;+QJ_Q$VS0S@X6Z5I$,VT[582>=Y6-:7NIN8*E&UJ5!\J
MF6'(5PG3=M;Z*==%([2K%6F!A]0GY.]G"]5 >;OM4<5B7I2U>K"E+L[\#)IL
MLC/QBF_J-QI.IN%T%7J'Z+D:H.YR8)7JF^[\[""57+/2]I)\#L_ZIA!AYLNM
M?M"Q1D4SK5BF]VDL3INC';'$KCJO/E3O%NBC2C:_GCU>>4H;;WM5ELF+'U5(
MN_Z("EVE36])E38GLFL[D)< Z8@"Y86GMKF#/_DL;W6!SI[JV\Z"=/U.;1>0
ME:,*P>MSAD17[.R9#55E_^B,A]U)6-W6C/ -#VLI1V;Y1#<O1<V>BFD-0$I_
MI[8 ',2J7'HYZ"T5$5TZ#"[;U+X5&Q9_J]4&-R;L1=,.W$Z?V8U8?.!4;?,T
MG D T#>3@T85O*7[*=F^?*#3AIR5]:/-GVR)AS93R:_")(TAE#7>-RTW*/"I
MQL9@\@< H#:(7F55B[K4+'AY>/L *SV+TW*-Y1=WK\F;91NVU'*6^=Z[H1[-
M?#M5:Q$R[P$ VL?_YDK87YTBX=NR:VT=0E+6PN:C@OMQ@L9)@O3E5^LW\!]X
MH^H6\2]-U=;;\'_G9<V1_ZKJCNU*1IFF];QB(/-VTR/YYKC(AKFR7<N%=;ME
ML[VCS ME25,[S-V2WUE>??V_:D&'D\&Y++O5N_9#IJ4I1-<4^\Y2IBU8OMK\
M7K-EX1-3A6;W5*ZI7\[[K7S^5=#7[2T-]\IR6]HMW9GF1E/=I]BK]:WFW.4A
M9A?3F87?C5##HZF]QAYY(V"22LJV'U456X;IY9*<]]OHE9F)+9O5U:XK*@8.
M @\&[.J7@Q;.T?;'@H;MBS>V@V  @"X?:SU[4!&T70.ZGG-TZWK(V$3MX QH
M^ K4QDFPFH '&YK@U7->;Y@(WVG_IF\"_'?_:EU(R%%5_G1H$O)Y#FGS7I0V
ML60 BXY;L;8O S,^X'+/:4R7^_2><9CC$XI[.C"_WRSU'1K;JGJW5A.NYBP<
MG$5T6_>C_RRQ8H5M[P;BSH#>;D_2)'>7KF"2W83N+BHI' !0[67-M"KPY@_T
M\]E/!OKH>]?MZ2NA]T?MZ FE6P*4G7IZJ[M;AY)NGO"T0\SX/4LJ]__;AN6!
M@W_SWF0?W<CA&=>U;5C \XVJ[WK#W1^ ZEC'Y;DO;'?F-D_T:1OA1@  BGO_
MJK(?F[[+IF=OZU=(&>M,O1Z2W5&RSCL2^X"2]J7B(7>_UEL2SXG UB2A^+<*
M^:^ZMBE/&Y^]N>^DAKG.U+-.38P2='Q120*2V]:H@.ZN+<^5NR?26SQ$+@"
MW/)?M7_@IKDY>U>?O^FO=6W=&B,G2M01:N '9+8B# 'N(2UC=&D3M<WS1;_'
M&3G@7[5_&FA&V8N-%R 1E5OK7\!6 <O%\Q$+0"]Q$.1G**1D.WH'_%S\46P<
MRMG_#,X;?7.B+=$7,WVO9_5"Z+G^Y!HI7%"G!.]%^@L?0\^C3F+CX6<PY<7=
MR$'LL[CCZ$1\EM]C]!M"R00$'DR _958H2=T;1!6>Q+3S.-K&,1W AQX"ZD#
M_1EZGEQ<Q(&?I4R)/8%$4P;\G)#7J!/MGV!O4 -VD<J2V24]PQ4?V$[&M=5P
MUC'>RYK]+ 7*"!G#@A1FPEQ9J6O/P/>P%OO&P.\S7]@3,5N8PATC)3DRVV[/
M<A?)#?WFRD[Q-BX$Z" R(C-!E4)EP3*(6M 5\P@6P3^U6 )SX\^RGXXMX$8/
M8XKVZ;=T7BS5ZG;5HBL"--LX2ZM:54.(@!H;Q<7\%> PN7O,+,@]:?.B!Q"F
M9'#\?NP#P:KMQ864YJJ.D9+<AD8=M.Q#W4[VTDJT\19\9?4M_=(\*&B6=M\:
M#'B7>F!1.=A%=6(\'5<@<!Y2%K V.':,*Z[LHFLMI3_;]K#**HC-]C!DU2.+
M.;>_QM^L6GT9=-SHX_.\YJY^_OA8W##_Z=#$_(O;^MJ91=L&H[4VI;%]'<R=
MY8/=\Z!GJMS;;7(]@.7-S-6I-:\;/7R0P&/FLO&N>!O^R)8PY/.RA%8S>GWE
M4HTCIJOZ"1.,_0@B0;?BHR$O<IX0./#4Z-W$=B3)>RRI$/7=-I@V 3-U\ #<
M'[*AA88X Y.K :AT1#H#AOX+^0MR$.N);LIQQ)&QP:L^XYMQ=0OS"$YXLLT=
M"I9P?--2R#;<^Z93,";^MI*&\"0,TSXB^XER,!4=1"K/>H%I(0>N_(D]3KZQ
M0(1]2/&V,5.>4>,W:D%<ID>C-Z2&&2#_&S:/&4C5PX\R%X/"D1!F4.8UU$MF
MU,HY&!?F"J_SZ#M,9YLB:A;3K]\9V"1.L&P!F40R&1P"$>ZD!,(\!7=JIL'/
M"69D7$'"^: 5R2@M[ZA7$,J.EV7C3>WG<#=<KG;5,NK9-1[J[](UH*^J K(C
M9*]B #@.1I7/2O^(F"D=B*I%1DK$\YL1)1*/L5^I7[@VO3<J;UBVU4FJG]=A
M)<DU)XT_21Y@O5[P^TTHUBU+7P[[J?&._(68JE+-7P)[JKPQ]A(MC/.TUZOB
M>><+\TC5S[8G8C[P6G,W,1?4U%!950Z!UE6L9\.F&\]%(N'S##/G'8?VZM1C
MM].@G,L]_15Q@Q[F^*KL_B+18^#\GE3"8,V-CKC*P^#6EO:TK]"DQJ&(9[ D
MR]=YZR%2@V!L$TW'.=S13II1>M! )0U4[!2&DHNK\?@NRO2:;Q6O*1<@H#0[
M:CUL>[B,5H/8._<D/0IYX3\C +:\G8RG@!7Z0D(V5"D80UP(A^!DQ(](G_*7
MI).H2ZGSR6T8>-A!2@WVZ-Q%E*NXC/\HTKBVY5@7;'KM6)P'#LF[CW?$X[%@
M_&="3=ESPC_$K)1XXE'2\K I) 'IA7L#24O^LP-.<VTYA/I ^Z158%SHZ[GY
M6 ^Z'..&FTO?43J,7TA_DKR",)?ANGP9X1)C^9QW!!+#YD_*;FV&([T%%DTX
MJE 0Q;%'$_C;41<Q/+Y'R59L+4^=E(-KXKDLH^-3N?USH#@!%S4ZLC6EPP=4
MN6I/Q"OE*M9GU#3Y)^0IM+^LH?@O3)PT)U&!39$L#[V.?2NNFOT*<U*<;,WF
M"!C;/$VU G[,F,":CGBICT:\1DW2^12]1 =J0M?=P(2IQ*$%F,-*S&PUND1A
MW85I. 0UM%Y02F'WFO.8^8AQ#1K$,J1[W>ZBY:@8D]^Z('2FP2WD'/JBWF-V
M)&J9AFI5V9 W?4:E/6QE#Y:Q'Y[=\19N1)2UP@H[D(RFU(1M*&F#34@NZE<]
M>=8A9(+6FMI,Z2QC::$TD86NB*>YLLA5GZ$&5F,-,?\JZPKX4MP1=B!L<M #
M]A[XK9G;N"L1H?]1Q&)C%F,VR"2)9T1 VJEC&-4P$43#L"!2\UXP[B%_QGYC
MKD&K@B*8?V&.SUS.VH+9]2=E@PP1U"OH/>(Q-$_L&/(#6B7.!TRF;<*'Y7ZE
MVQ,B8Y?0T<3%2XSTZ\2K,PXSUA$%?U+;._TX\B'*(^%NBB\52S)2!-3K( KE
M#BTBUYF:1E.NQ5#WT6XLF4";39\XHX;F3NL<_;MT%TCC>8Z"C206]QV13WK*
MW5232L[D9N9XD(]ROL48*.LX6P/S*%H.<?H32BHGRYK-+Q+:Y<G\'J*W3$3@
M$XU2#3"?9"?A94>2F&+>FG]('T4; XZ0@T0!TSFD(T+KO;3C\5R]A'>=X%#K
MA=].8&CIU1K"2_7^+ 81KEJ\9@WQKN).0"'QNR)K>@21*;.N'#10W.^,P@O#
M!UE.X"?A&^O(58\(]J9IF5<(0OV[U2U$0&V-_]_$\;J?TSX02 JF-='_P/[H
MGL/=B5-U2'$,W/M6754./J-)E9F%/V+YL3J$$%$/]8<30LSR:3+\5H5U?UGF
M+V:6O&9.$?67'T5=$+E70<L3A,/ Z^OQ0@S89Z6?L 8:M6BW\ 5LAZ.=^"<L
MX3^*<D&:(0RMZ6=$"MK!VY#/!0'0NC(<_S2\,FTG7XIT6J'BTU&J1:OYM]&J
MR5>$B:@/?_HK7U+*'X_*HKOSVM%MB!>\&,SU4A+W'?9KZFWN+ORDJ*O<0?Q7
MGRW<3P31Y$;>(_RKT2<4K^=.)SVF?N4<)AOAPQPRQ;>$SPFF=*<".).I<Z.\
M...I'!]_3C!UP^0:SCEJB;4.D,3.9<LH/]BSV6VP ZS;;$.QC-7)1J: 6#1V
M8F0WB\$.\+[!4K*=)V>R?K(>6Q,]F#5>LIZRG'E5? $VEEDO]BHZP"P5Y28K
MF&%"8\0/IK]P@G<&<X'@VN3)3"K?>F)<,,AXIYU"IC!&-';0!(9"M;UH,B--
MF9YT@[%8X111PY@I]U_X@7Y/'NGPE!$L-EC5?(9[W272(_HW<RQD$WV[L:R0
M0D?I*Y,2Z?&ZS>$7Z*':P85<VD-MDL-)NH_8^HOB#]-9;8,D/+V\I0^RA#ZM
M*;S@(VVW93#Q,DU4UQ=.I,',_RSTICD8O1RDM#*Q=01@KM5\*:G!_*W6E,^J
MAJ@PE9TY.Y4\X/BX/8J#H(A0#P46,MOCO#(7ZF*7IC1#_]0!Z"<9--5C8#?&
M5[D)U%RU66&&L'+<Y.VPM7'+93?@#T*VR1C(. ^EW ?YCQU4]A'Y^D_*OD7?
MJ+B".(>.E!]&>57>E^U&5V:G2<]BE+$RZ61L6TB@I <G]%@N]<*-V)$D37B_
MT2>D'9>](#Q!Q4I?$GLK;DF^D+*S!))II#=KKXA+R+3@-M%'\J.Y-\7QY!=V
M=)&6LM=:!W@B36*.0Y(E^<S8"C<QC%F=N4FD9$+79@A/,A'!RX4@)FEN@U#.
MK+*3"X[\NRM-G2_^*HQ%[!#/%'PK+Q7Y"D29DX0Q_,\Q.P5T/F;I6_XGON=<
M)/\+/\I.PU_!O6ZM _!$[Y5R1*1HEN)TV3VAC_Q$!DD0).N*<>-#I)N7EO-N
M28/G+N:U225V,NX[/MRJ;$6^AIOP'<)L_6!9B:"@UB?] S]'2U]3Q^-IE@9=
MY'Y6'W,?YM:K+MM). _XUA,FY%:AMBD5GBG8TW"R]"E_N/Y(.I?786Y=LYQ[
MP+0P2,CU-@ZY<S@#NG=V#,YTOC578@;JKQ9O!KXQ?RJ+*8@RE5=L34XS?*_Z
MMF*B_N^:\;YW]0Q0X\Q HP!T]'>2F@SYTX:L)/2G.L=J.1!D2JA!Y6\UM()7
M)]W1>T$^1PWIGL)XO@,Z)'S#S""]"[P6L$2]!SDT>B_T>M,T>$QUJP&*4.8[
MUIY$CB1%ZU)1WZ)"M5,P$WQS-5S,B9DSM#<P @!.B<:'C"J4SK 4=Z_J7*T!
MWY_GIQM/ "8J-"KBU$BSNHC8O?B!:C]IPHQ;ZFO$?D"K'$:)M=8!KM36T]15
M+CH'VMU<C(9+=U]W5CV!OC9RJO(,';28H%Q*I\^PJ!SID8"#TEZ&]4U!!NN*
M>(65=,UEWJJ<&^IUW&_KHI0GN"T1?(60F[LX2+Z'&S:#J*CF@@'_2'S81FL=
MH$^[7N93\4%]2=J2DZV*D]Q/V*+8*YD182<GBHF+SL@:Q!DS"+)[8MLQ-J+;
M;.LO"A&CD>DF5@RJ7;3+<J8J*9HQ"1#Y!=5@^&X97GEA$5K:J+*=X28]*F\>
M,TMXCKW'6@=XI?Y<[UA1IF*8/V?O4%PTE24XRST-@^%8Z:#^W*((R6&]S_3O
MDN/*H#$^0AOVL5$%K.S,*]I4.+7=HW1&ZNM6KW+@Z@W-196*I6^;QE6#/1\U
M30-*)WUKV06<]3OKU2*L5:SJ+>TC53X%G:W*ZC>INF9$S:;5\$8:.'?I><LO
MR%[/=Y9+4*G#^L:OD!\ @.P;=L2J_%H?0PD%#LW#L.%4M\9:^)OHSY8ZY-RE
MK/HIJ%F>9^OVH_0.# L<90< 2&FDUE%5U= R'K,A']9X%TM- 5N.XU9$$^K.
MX3XLG6)>AU=XJDVW\ <=E'5N^!P 0#*=]L"J')N0Y-=Y=QJR*/G)M^JC*/VK
M[IFC*<^#MAI[J#Z>J<8 ZE('I6D,U1< $)UC6495I;K1GYV;A[',9%<D$\R?
MV>M6T8WOV+."<@QIK*^>"_6MK,\.>L-<]A0 0+CUWS1:Z=T0(-J;YU;O*J(D
M+S"]%GY>M<AP0UBSY*L^6.CH\; 6(8QUZ*O%"R8# (+3_ZJ*2Y92E5_N2%V2
MLC[I@FF.8L_*J_H?\NM+-M;&RHD>,AU3/N @T2W\SZ@KF/=?I:\_:3B5N]>\
MT; @Z; 17OMJY5_Z1;J^)1MT23J0QZ"V2//*8:_FN;@) .#_-V47> WV%U:G
MS1K(+%;$5/>[E?8NLVQP+6_T\>^Y5^DU0[>AHA)L$]<S5%4( (@?8:P[(_GH
M3: *1NK._KM5LV.\-D"K=RQC]0361/I$=OT%*I_QM/L,"&USOG,O^/?J6M1,
MW&Q5]ANU8'!J4M\DB'K-V1X)=.NR\*YPV&D?UXX^>-W,B9TX.-TVHNT=@OR[
M#4'4FZ,J;V-?%RHRY7:O-^K'FKRN;O2.T$<=.1B$]^VVW9CG,R>VIV$VV/);
MBK'??[?&&J;U^Y2\S-X?Q#DITFXN4;K&MN,7\6FHM*V3%.*]L^4#"3%S0FL)
M:;'M@28[\IW?K;'JW];(_=73S_!*2>_R922MOM3>P$@++6T-8T1[:YOQC)"9
MLYN-C)FVORROF+]74+S2_ZJ=W<W\@)3%G5/Y,U?O:"/PCH:N:1G+@WOCFT)Y
M"3/=FP)XHG&KZN=Q?_<7M_^_2M!U7K8V95I'L/3'ZMY6GA04&MST4W+&NZ1Q
MGN3$C%^-4R3+QZ6:-_!^S^/<F?]5E5VA6F:*0SM5.W]U5\M.34YH8).7NMT;
MU+!$;9[I;?FHN#\.:D+S>@  #OM?M<V[(JM@<]O/JG,E-MKE-4O*PUA",*8J
M!78+VE03G[<(OA&R<(TOLA)VQN<9\F_$3;L=^#;DX2V^):>K*UHQY74U?>J+
M5<O!#YG)P(TP9^A.\&3$HMRYT-6HP-7+8-\Q=CZN\*G84KLJPC+<FL&TPD'4
MF.;>DBWH)%5J.0\CIU^N\L:>AB"!??C)V=] /PEKHU=!=A%SO3,@0-)$.Q?"
M-O+\ 7S> PJG\6;13,H-A;QT C6"5E!^GFH$3Z]BT<9D700^I<%6I8&Z:8<6
M&FMNTIZ-NT1<0*_KWY-#YKUMB,\_S2/(;8ON<3]2;I4>YE)J[E;(N?:9QZJG
M< 96$H$G./D+WE;S.5/&-1!Y;$1?9A9165/_*?>)PE4Z4CA=MH\\7#)9"@6>
M+KLO693QJ!(MGKAB3_5"D=N"RDJ"L&$<DGB!U[DA(..,Z5+=TYQ\PY#D;+ZF
MED<Z4632%E2_*F6KLS,65$Q7"E8LKAQ6.'B]+C\F;QT73YK)T_2FI_/;EM?-
MS9[=O%8R,:^P(8SD4%A=%U4=5I)M9*>3R][HYT99*J2Z7"]E&5SS?)PW*85'
MZ]F_WM1/,&NS0GN:Q>1<>,<.(J4 W?*Y:E-Q::,YW;;T:_WAJ$7EK+IQ7O-+
MXPQSQTTFD7C0;A?P]8)$4Q6TIWA = 8.*WM(7(CTJ'Q=!42= -Y8S\*4@;LB
MYV,'8+Z>C[%OX"-C4AAGD.\Z.4!Q%<D8"NH WA?^!:D#+R4$P(C0JDHV(@;.
M2-N"?(-D1>#1J]!QGD7HL9B4,8',,;BC[;<JQ0BEGE5]#>4H"*OYAB;CAL&_
M,!<KPJ&O<-ZI!O@P'A+.0?P@T#T:$(&$+V.F,P/(P+;0LBLDL>Y293HYB&>H
MKB4?Q9;5#%,RRGZ"3U%NI,BAO=2JL VPA]0S<[]"&ZAW #^8V?2:ENX2%H>A
M+2]WXY1P RKI'&_TS^IA]MW2QS5WV.W)1O!%-FGY8Z@-.WDN#(QGNP.>,@FL
MB\U516H93>-7&B,U<":4#TNTJ"=5$\2\DH? U2)NTG'0,F';\K7@?,%G]Y<U
M&P1_ ZXQ-6Q=4UG!%SU>'5R\6S?"GE6V2O,-95=1KUY0,J7JKA*5- UX0_YN
MV=Z:![([[BI@B$P.&&%VLZ6-#?F[FBI4N"*QY1.KH'1R71$RJ1QNW%M<6#FL
MKT@$5^_009:% 3=KP]PCJVW5RP'[F3O9W$;WO*L]RY5/"SLZ'9@'2[Q:NQ";
MRVA-:45G*PY9\M=]J#I0-S[T8'6KZ<&<DU63=63 ,/,XFUZ_'+TY_Y/\$F:D
MN)P!PKXI4\-WXV=7R@OO$&*!U0G[B2#PM."W)#"TW*V4= I6^*<JXFZ^@Q!5
M*F1MR)= )_I2]!H0!-:&D4-:"AY@S\'VQ#_$CT?L# ['?T"5NY[''T?=^).R
MCYD$T!:XIS0:OAIQE#8%\1<J!RI >:./Y+]$\["+XETQQW'XI69L!Y[N6H7U
MQO\Y<TN]:[0%CR.8Q?LA)XE,"@\&(L5#(N'/25_R]B#AY+:XF:@#E#5!1]$2
MRG:7$ZCG%/F?J@A&WPP\PG(4@4"=K!7D$$@I*Q[T&?J%%9%[!"YF^<=&(%ZP
M%@7-0C:RYKID(NV8KT='MEI:U5.Q5I@"O"V>2/(&=8IR:SY!LH3RG,O0%X*1
MM2QXFL!OB1C^B+]WYA,XEK_/FLU5E97:J0)@=8WZ*C&^9KFJIF8>Z(7B;LYD
MB%;.B+D,?2_+73(#!I7VS6R >4F.6E/VK8K >@E_<U64N86@!#H:"4!DS4%]
M9'8I&*%;&;,$<EZS.5 '#=0LG)D+G:&PKC>T->6I[>_X@94EK2#\M^K%3?SJ
M:\#+%DO651"USF7-?O U4U;@?(BKL7S& TB*\O2H4M+)C_('.3Z4S.()V.V4
M.V6+*G]2^973,L?0EE9?C&Z@O0*5^JV@'X84.=]BID/*__37!$4FX4[%3K8S
MT5R]&F,A9=;45_P@.X$O9'B0ST"?K;I)T<,O^#91$Y"KG<4T >+CG_[RD+OC
M9D.W,?_"3X!3T#3\/:1[^0/"+E1K>C!1A9FZ:A:I!%OB.XGT A?GO)+BC/VS
M \[8)KV$UN$V,V"8;OP^U&)L"Z&_[#%.012M7X^GDI)7@@CK2=\6*PE_D2'.
M-L3G)&M_271(&'TC/1UE9LQ$3D+W,/)*AS$=#&I:";:14;="BF,P=BZZB3O"
M..C40EC(:+1F<PF\73!$2T#<$U 1CLA? H>2H^@)?&XJ"S.>]ROJ'N8ZS[RH
M"/.+!W0JQ+5POUJS^6:8OW(GE0"G*&[!UR L\H,E8Y$;9)J4(ZA-4EK4.C13
MTNGS%8V60)P"L04BM%4Y0,<:=U!.P?(-L3 ]G%[+*2Y!2+0]*5Y(I<8ILA=5
MI/KHPT;YJ)X[ 3#I4NLW"$(C9$'S%LIZ**MQ*VPBK-&24706WF*^E=R%:#">
MCXQ#EADV^LQ 3M #';O0&HFU#L"YPI'EEQ#R.?E%1M 13F%I2_YS#J."M&X_
M9[AZ=I@-UZ<&,_\<SQWTV?X1OQUT^T]5!,<^R1PJOXL',T]4E=5<9+X ;LMW
M8<T%/5HWB54.>;L<S3H!VS$?Q.;#C]O?YCR!_SGUP;!C[:1/AI3@(NBYL,7
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M;BSI%^"[,1^DTT&N?ZHB9?A\\>RR1^ M(G-E5M%C46!U8^IGX;6:PZMZA!O
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M .V,SF14YX3$6Z(^YKY+.@?2ATO3'&-6%^S,P'IV(DJ!5/.BPB;PLC67D"?
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M+^0DX6(<&G.QN"L[\W*=\&NU-!$5^'F;C5R;N9F26.@(=**4 V]EZU.ZX@K
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M7J@A.@L&SUEKC^:I!6(OD$> ANA4]GNWW:)@",W:4O@<>G]GC$@-=E$G2*R
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M-WAID6I5;L^"!9P3*,O_SH;/A$J1?]@E2*59T&+U2)F,2#<,41Q&7-$[J%R
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M<>"2J,VY^[)WQ>FE5D"<$E^%QL$L4F4NC3DS@+=&'W)+L]I6*@I> B%S>G:
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M)VNOX&>AENI(TBW87,0!.]\/-F8CR@GJ'V1<% 6;=(]%6^8ZV&:B+^;E&C[
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M8LA=&&)8^YB]?R^Y/)V%LCZH8#*C=S&% 8PPI==A17$ Z\1!N0*'L>WC2U]
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MA030\!HERP.O$H*EMK:AQ&-<R-.GJ,J3B$N]149C;T96%QT[2&AT1-/WF8H
M&$3;++H"RZCO3O^ :R__&9B&_R(?L?E)1/&$3XU0L9<]+WY!W3A=,1Q2!#OR
MIP&.-CA(%=9CUO2N+?J$-6WAIL-PR=7B@&_X?<KO-J-$!S[M01E3&ZM_7L1@
M8;$'-S%68N_7[Z%WX(#"9?04_/*B4?I6_(UT*NT=X7A@+.T!\94MD:Y.+KIW
MGRZFMYU+H>O1G@SJT/II[G6[:2#J4?YSFBDU!U5+6T9U2D-2?U,W!!31UE*W
MVMRC)5$#[T;2/$6>9XY2;PC@^XNI=-[!F@EJ*'<OKX]JP7Z'5%*-68=3)51[
M)M]_F ID)-C$4<?H2VZ/47>73)PVI)Q4?AI0HQ#E7M4IE C)$!=%"1;!"SF4
M%(%URB"%PGWHOX8RP499WZ;:,3IO^5"\ZCU/]I,?5!/ZRLFUY9>KEI"I)4$<
M3S)=<1O!([=+%<EOR?=$V_P(%"=>GC6*,LRRFOE.EG8>/H$B6[>J[\LBO6E(
MJ'A(NE(]P78CW2T/**@F+U==3'8BQ\D<?#^1CPE=K/4ID6SQC6?DA8,V$[FD
MQGWDWA126L?)\D<D[^;MK#124JTL_PE)7OXAJ9IT7Z7G2R.GB"]9721_XQR_
ML8)4<K1TO)CD//R@AT)\/;"N7(-XOBN4*2,^;:[(=R*9UTPE;21Q2H_[;B<O
ME9E:*<@]W,GI;%+0V3?'WQ#?C!MU3Q!+1^W+?(CY RZ,>T1N9P*\F7BM$9#8
M27*IU/6Y0CJE<+/*(J-X79??"E^B;XS)!41,?,<AOCGF=DDZ]S>62&_C/,%Y
MYUUBW\';):YGW2'X^1"8[XEU5DG,C>2<2T4")?7H82#?GNK:WL#]1+E4G,2Y
M1F'3>MB7*:#<9ZR'%'""!_,7A>!]CFE&&;9\PX!332[NXL?PAPZMXRWFV;<Q
M.*<Y9U1V[#&V@EK!NLABY+QG?F/*XO.89HQZ;U,&ACYF*:)?I5V>G.1Y*9M&
M!CBS<L?6U>Q)R0/%<]9943\%S?PL&(!]9]KRCL6U,XB<XUY5])NL'DLG>C C
M]3R-"ZUF#D,X.RKLFD^S%Y1\E_>Q-)0WR$"FM6P2MH[!$L_$?J??$8Q[;:5'
M<'$6[VE7F"?.)7,.MT*'0MCX1H>F 59\[3)9)S.SXC4)QU"5W(7ZTY\K)F-3
MZ3&22L\^VK1 SZ*?ELO6.IO-L>WS.9C&^M!EU'B2.=GR1WJ:,5-_E]C'T*LZ
M VFD(TMK8V[0;BO</.-IA2*R!96VCF-TII9]<G358"6+?T"M<0$SJ^>:5)T!
M:ZLC_*2W-V @6G3=*IL8*(U3W.2I1=LB:;&(HTYR-Y[19!=-G!]<Q'(]?*0A
MD;EZD"1)9.CT&A(RZ9&M5\$BVI$Z2(P&S;VLUV.">E_&M;"CJKB/CH^H9HON
M[#NCZ$,7UN3+I)C50J5$ACF-2Q&U8=M!OP5G<0>CSO)>XE^XCW-7$'/,H6P#
M,N 847F48M=[4<X@3U<SI7EDA>" &$\NQ+*$]60<R)Y_@]P4I<M;17[J[L+Q
MIR2;F[)0U.5'$Q7U7$I/O2R?XU%%D"2Q=?@](@Q+'U,LZ&7Z $&\GPQ^)(3K
M1Y_:>Y2MI#N8?6).T:J.^,H5LNENHC17,EP9+ :)VGDM0I+@)+J:?XZ_(DO&
M,^9F1ASC<-@]>R-8;YD?S":8P8S58T:RPQ6[NE"2TE+K"E=1B2J2*Q <D?.*
M6ODK)5.9$URJR#["F/V:CW9[S0)RI&:5C,O,S,-&,OU&9"=:/%O;4>XEG*U\
MQJD3&);9HZ9X6)4@4X?S5'8KO)F=*5[I5L9\R?MMAF/DL,2'PJ2E7=T=36)L
MVXHRI!#="&#/\!MK#J!V<W]7Z&2P.,CBA' GUG-9KELLDRZT-TMAK&7+1VND
MU@=NM'\7K]D77WI<N+IC/]N<[]2\!,GE%M<F ?YP],J583=9RG\$OS[33&QA
MYDN?Y!2,;I#<'?O:7B@Z,<0NM1 <Z;O)*N8][M1#JG$]FZ(!"O:):E08FQ5>
M$NMZG_%1<M?,AJ[B&NU?6>-69-.85;F[:%*16>:(QM/>%X,PO@5FB@:L<YJ?
M]#XN+:1*K(UO=7$0F!%]3+JX6\@Q TNJC4D_&QHJ=$F#\NY2(Y*8YJ-*)O'S
MR?)&4E]J@^0#62U$4V1#ACE?Y0,H6B95'!#E3?_F*CWV:'U7^0I6K>Q2R39F
M+16HS&1<@O?)AAC&*1\E&^@UP60AE+[5F<1KHXV82-A':3E]QI7&DLRZ]C)#
M$45ZK-A3,$HA*,A\W;S;TD?<RA1?<23'/.B78!]KU-F:I\X,,F&PK>FG]H54
M!)=NK9THC52A)%,JM/P!62(?D6;FZ4EU13^2:T5*05,02["(M\?I%3>7W6>"
M8PTP%_6BRCMJ9VHU2GJK0)+-RLMEWTF3\@W%=;F9$JHB*EE3^%/R)TB?CQ'*
MG'HY;[D?3 I80:SU/2/E%FVXFL@2^R9G,5096_N19"BKJNS+F90L*RU*4@AY
MREV!$[Q?DDXG.H?)_V8"97Y@+^W97C:Y[W?UH>*KG2]%5Q4?6@X3%3*'>FY.
M@+BQ*B9II]"B=$D@GM<DYS@E<TR%XR99S';VY>[V,MHPNMJOF#M $\4H&KH3
MB3K2AZV;8%/BB+K[B6<%MRO$@0Z\#)6FDQ7[@SC0)(U9P,&VJ+4.HXZ6D!MO
M%25S#M9M02_'5%05H1^ G<HF,4_BQHLWX#;YU<E]\5B'>V(?HLEN2]YO<D"S
M3<LX2;/X8\,]X@6.0^UFXB!F8R62>#I[?^DEDE9<H,J(A/5SE*61U1Q:17GD
M4[N#>7LHEYHHS6,LMV+;^D=,9[:H9@LC 0VK(-([LW5+'M)-8H\J_6EG?"])
MA32\ U;800O9#>3R:2Z-)YHNB))5V74_!=6L?=5[^0N*VLO+N&(0N&0EQR_6
M44%BK_9%2"XR;SJ$"/XP>G;C.1_HK$;U)FT53-E<YRZ?9;ZI8DF;4$_+'HH1
MP%/%0<*@F"'Y*;Z+[V:)(7>]PVX!D/5BMXA3P.AHR&K,JI(HE]26E@.8X95W
M2KQ1866N2B>@JZI9YA@3)-\@WN-S5<P0&#DLY=_@?-Y=R5%C=M9?:'C<5*S@
MU^K5-3*N5L95#2 OE/:436:=4.U0??C_&"RK\"82+@SC#HN[UZA1H:6E[NZE
ME%*HN\5]DIG)S,3=TS1-W=UP=^='%BGNMMCB^N_EN7@OSO.=YSMOZC]*BVIJ
MF%XV3C;&\ZVH6'AQ73NO!1,V)#0*NIGJ.9:=;8>0':8/C9](.PP1%L?\;,V>
MZN)4@S)8JPC+D;8J=)ZCHNGBJG5#O$Q>2/WSQL#A*%6/I:QW%_>SJ;[]#_&K
M_D-30/Y436$M/S5=\<9P,&R#-%MUW?.8\*+DS+I]O%6\F\:N@0IRJ=BO^R3Y
M.V!N]Z%T5QYH&J1*LOKJEM+,B0VF'/K#H-\Z*C/1_;8R#)AO\UF\D^-G7-HO
M!OQ$3[IN V.!F+80UL?*TL9^8''6%LLB@)B87)T/_ @ZJ(78C>[_4V1R)+9^
MHD?@B*&^3XB\%.WH?,C]S+K<&L)UJ'C>, 2;=SRH70T')/QKI,&3@K@:"_30
M_:1<!#VS98KLX=F&M;TZ,4MXNN.C<)2UOF6;(*\BH_XD?]F./',@;WR"RE"/
MC0V*5%]%)[D?E%U&5MGV"@7<2+VAYX)ZO-"OPT6QAUG3K)?IRT_63Y+HMO]3
M0Q'U)_CH'PL>!,U3K^%/=M\E6X^YV-X6_$8R];-[/*MY@@/M:KV":=7T13-4
MGE97J/RXG6^Z*@^)?Z?WE"@#7ZK8PAON@]):_FR[<0(1&JOK[&ZN?R?8UCZI
M-IQQI*FLNJWLF^6&?L5V;U.,VAB_2]>CF!YX7OE44N;>)UTNV&.W1N" +=)%
M=D>T>PF6MM4UG6/P&C_5990-6Y)-[S,_51_1&^,Y.A^U=V"G$I$==N^5[!6Y
MV_GR;V-'M!^[?O;E\B^UQ7?:,_P;:YJOEA%J/]7Q,@]6%YJ2X[=I[^KF!QJ4
M'HJ3_U$,<85=(M_,BY/.V9="7@XVC#PBUQ$7]J.4Y(*"KD54KRTU+2!M<]2K
MNAYZI^^^:@/3P<558P6,LQXKC>:X2@[NI;.X('MD+"N$\*Y/RO(MV-0YDX7;
M4ME<P;H7=<)B!C#?3J.8'>>2HK;BI%M720K 6@FZIXH[ *X?^@.?)+3WHO",
M_!<=XZ#J+;9-^=".*$UM#13O:S!HH<TN>%4@)+$^+S9#+R3!NRN$!SC7AL8*
M/ F!/2+>K7Q9^SAL3]KUQBKT4E2V>0 =ZXOI=R*!+B(EA5MCLTKTGCM'_':7
M5G& PQUTD!GPS[H')'7Y[FV.HLMIF@:%<%V46\TCOL&7JOO(F^32H#B!(C8%
MHFQD@5B_\[U^%\=C -2\P]=WCU7%YOW;2I>?3LNLORO-BII58R_ZXUNFBQ34
MN(PHG'E^-A;A8^2S.'PGOE;"_K?_BVD9OK0+IS^0=[#EO@9,<ZV/4VZ)_&BJ
MD3GZ%FI[15]<3LG;^$=M+@A!=$@\>^1SLSO[>#]0_Q<^L/-]S><\4TNVX=^T
MV77GM>,C;YGLE3-]MVO]I+-=;LH]A?-L/@F=L131U9&6SOWL_OZ5+5?P;IUP
M_:T\K'FTYGO:N+I 0VCDS>IZM<*W3'-%=M?EG>R5R,5VON 5]C]XYHD"TF>R
MZ) 'N:#X]YZ)E.F9I8-=E'\3;G=/IBT-X;9,IX,;C]8.,6<YGM$]87U:&RX;
MX=C DX^#S&]DX\%$9FO)A-V3F+69Q0-*YFC"C<[;K*P0<=-M8,7&1V8^>XS3
M4NUICL/:Z])#(!^>?2P'[B/S#_A"AXO?[7P-S<R,Z:\$^Q..=HR BA!AXP&P
M>>/O&C+XMU..YCSD:Y4F>0D=A_\Z&B;P(N/WK^;M*3XQ<ADC9]KW):'DA*[V
M!F0H!&O8B2SP6FAB<T5.M>IW7!NK0Y(-\#WHQY%462\Y<Y^#I+&X;_BZZ&+F
MC-XM0N>$NK86_NX08?UY7J&72W43MMCI;[4K\M1ZN=C _1NZ?5BC746.W9NC
MXA1W#$]03,V<V0-+CR34M?XM-H1HZGX*$:\8XU,^Q7FR2H*QK$O$"Y$.:/^A
M;Z8\<M">/0:KXHZA5.W$S'G=%U2S$]I;'>6>(4UUVR0%7H7&4*'>>8-J+.^.
M=:NH"]T.60YQZHGD37LVF"7%O8-'C'LSEW=[ZF8E#+;H57#(@.6Z[+L78#@C
M9CAO52H$LZQOB=+0MQ#_T)+6)++W[D,-@\5[!L-J5V8Z=PT8AQ).MRS0$D,N
M6G8H_;VJ#?G2><YTI;]PBLTXT1RL\.E.:C^IY']I-/5_N_'H>(I'LP\CBNH@
MJV=:TS;1WK+^HA?F)@)_,3IB+K+]6>L\>CE[@3^/A\G7.:2+@Y0'',<]?U'O
ML[\W_D,;93^3XNFC[(_46XR7G*4YJ:Q9G)CH+T V1^<QB?V#\_/A$U*\4'3^
M/;E4L'071@%YQQK85"W6)G&D#:*]E(/TA\C9[ *F+?=AM =+"W_:@&?'08\?
MK"/\U$C/;2!9J::,7"5'R)OK?E$(TG+1#6J7N(Q<1_LB)&6Q&>G\TBB(^0#S
M<W\-]'('[FGPSRW,,RW$>:9_AV-)P0:!14*F:T.$<LHQU2*2F.8@G[:C@=X@
MOA8YR@P59+LS 6LTZVXP?EY'VND,0F#S]:%QQ*KZW-H$4I=YD@!/F6 X1.13
M:1I@^W7Z),7BR C&/O$6]R6L;NS1'4=<Y?"24S%X0V_SP%O"D8[5YF#2N*9V
M/D@NM$02]E*>&J]MMZ/!&IN(4XP8V0*WTZQ(ON_ME*I_#^XY2<4OVQT_,(<0
M,#!2LYW(Z%K":R(]:)81QE/PM1\RJVF+#6,BMM-?*31N/.:_@J+1P:KF,U8G
M;N%.'!GHS\7?V3O.5$.<->B+O211.CGX',JTQM;,>=3])EKX%WJ-ZH1;,K-7
MF'M]-;B N/1H-;B$M*D7 M>1$ZI/@T&4$JP#+*#J\7F@CO8D<P-X@Y$0L1(*
M8'YRXT!W@5_7&ME%@/$(D2T&JGM*V(- HW$7^R%P&*WEK 1^X$HYE>S$;<F<
M_[$'PHO '1POMS'0&L[CJU:L?_GS#UT'UO$F=/T#Y&#C#"E .[H.*62/1<JK
MMK/QW",9!/9[[N*P71P#C'=5@A1HZ'(M<T!)/AC&?"LO[<QA>4JK=)]8$K&$
MNQX8*[Q:F08(!39;+6P;7E'8"O8S5.SJPKG-+?[?>D:;Z<3^.XR7AO/MOYF;
MM'>T#4RSZB<\D;5"X5R1R3HD):?? 4@B?:B"'<>'76YQTI O%[_1;[;,W=?%
M6-'@VG:945D;HD$8-ZJW0>.8!3IV.8TU6U63[LRZ*:L-G0><$D6[J-@/L=P+
MO^B>?7%[!^G,3G;K=?K)%HE:QO"HUX!VC+,U+66'F:B^>8N!M455&=()I$MN
MNJ2S89[EPB;:OCTE>][2QPQUM$ZA1_;TJ/;1>]M,G%Q&;(.L; ES7DWEEL7,
M][H)(2FL[W)[%UNV*[__?"^M[%C6GNVTKOTM+=FTYR,:U11Z>.\V]F[Z_3;K
M4B&CM^[OM"9FM=$O^ ^K3[E^_1_@K4![:BK_,F'BB _O.3&B<2=O%8FJH&(X
M<NM_B5V@O"NYA_K2MJ?9(/WTE\%\))2Y;SV+^PWX=N(V+Y+Y9-@#X[!6-;2B
MIUG;Y&34GM7,.H^8@&DE8Y$U@'AS-G>(O3KH#;>(?7N]'=>'<_;X(/H /3,T
M!G5&Q]4W(# 2(MO&_<2M91[G,KA+BY=Q%\%=J1;X#!P6E N;H:?.=V$9A!S;
MAC3+9 -&[D?)X[JUW RQGW0&?%O8RK# H&!CD1WLS;N0\A >CV4%WH7>(#><
MS=!G[LJCL[A-AJ#^!/BS]D#M?;A0O5$\"GU0]-&U4*UL8V$L1!!?2?&%DH4I
M@950*J_.N0@B(-K#G^#1^D]]OK![K<E\&6HP68M&(0]]$ZT/?*&Q+Q" AQ0]
MR>W@3NFRP*G@!:&/LQ?X!WU\>"[LWVGJS8 ,K7DU_T 3&CX+OX'Z6@+U&9AN
M_)#_!/31%B:O!S<HN@-V@EEBL_-LL(XW]5 !=&+8H:<%LNF;6>,,BCOJA1O!
MA<U3J>Z<FQ9Z?B3GG/%ZTB[.9<V8 #PX3GK$Z1V8S)]P\!^(?*"^9R5X;9?!
M) +=!I8*A)S>SFR*CH-KZLT[PRDU?TC*Y+!U/P/<.7OE9J?KX%S^M=TT10\^
MHGVN["E!I?\JC2->XJT47R7/(?U/5$JIRMTFG$S]D+B$WTPW^8_G)3'ECBW8
M9.#?71QY&$/;YB2M8;S43Y3,9X9B7J)69@_QBS"&M3%'R__)NI-0P>L#JOV$
M&(4M<.2@H9R!G4SI-^[9U@F2?&Z@]H?H 3R".@DQ.)8X7> +?<L^SY\ '8@_
MAUV")'XKT!ZHS'$;HH8VCY1(CDO&-(^*-XG,FJ/"4\*-B*T SW]!6,KWYXUD
M3^(MQ>3Q'N@?-,]W+_(-<7+TX7Z#KP\GB,]I;9NNBT)5G]5[!3<5A[ES^7*9
M'._$*Y"49 5@F:+$N#HT1;#"-Q?)PDXYKN:2D(U#V\0S:Z,;[PN%IGC5*<%J
MPR;8F3>J78[+P4948W=HT&[9@SAK9*>XW7<!]Z; PW$J=PQ:.:@245O3&A<+
MOC3RE7_X$HL$*N-%F("J <Q>7[9C*FJOCH@]B+C+OOO<X!:)2AP^P_48,/!9
M-*XOJH$F$'0V*3?SE[3L!@]AY^I;JN:C_37*[1!R2%\<NX-[637=IX$[19+E
M\ Q.X>4-"(0]N]?4?Q=X#UH41WA'N@=!>ZRB55XI0Q/JR[8O1')-KK%3N;#F
MF$\Y?$PVW>$6/(^_JG.;\1!N;XV5WI$P39*@.4E,9EU6P:2&LE>*4,J<C'NR
M<=3VZ*7B$7J1=[6P@$FRG\0?#[SN4!M .FPBZ,;2GXGEZE;&5M9292'C;IF/
MW(6)9@1+?K-BHS2B(X"3=Y0 98?83^9Y<HSM1_6AL%,UJ+D!'1 -J+A0%M-'
MD0@M+27*[,%_MQHET\$G47.%C\"'7K_Y>\!O]E,P$+)KNZ9S% X9(?5Q 5_8
MK&3R"QF9\BA>8DFK=".6D?Y%[("61]8*%R)LKX/\\5R9_53T'JQN_:QU5,4:
M3*I+BAV"_0JYC$ GRXHD:/%;2:*H)3U'E"&X%NDIV,K[X"7@[4"_V4]#T[BW
M6QTTQ.I[^B>JI08WP73Y=2V>ME/:IVHO]A,WRA]ON23LEJZ(N,C?)PKV2L:N
M\KWMIR'WD=\MH/I!8ZI^HU)N><3?)H^NB:;-DJXVF(M:Q4LT;[9L%=HKW2(X
M?$]IBM<Z+$L88#\= =$OS5_4Y,YF78?2IK6"=U(VVO"!RI9TUFXN6BUJ,0ZD
M/1$<UOR,<.%=5JSVFHC^$D_YCW+!SC1KU5:#=W5^BNL]?_.B9?SV,LI/24+C
MF<)>45BM79I4D&<@A;_BP2KCQE%TMT1L/YW[ED<SGV^<CLN4-UN&\8W0MQHQ
MX0WAB)%$BLGST*623Z8HU594?&B,_ 8]P*-$0F!FVS8('@"/S1OK/](:Y7:U
M'?19$-[$IDL)?H8<AEWNH#:$\31EE6HY\VS(6]D=UCF/8#&//<GVK& *!ZHQ
MUIT&C\G*S#*P%#Q9G0.NQ<OT<>"8W"4:'\Z?Y :E-;@T1"O]#$9XK! -@"K;
M=_PH\(?IH66 ?T)JKN'P=G)>&C.Q7;AKNFCT:@Y)'87.2EZM"$6VA@1(;;E-
M&WX(/\$_[/[BU<.;36MK+\J') ],M=)O'"<#)(G"S=>21(W9]U3EP@E)G7(Z
MGQ[\45**W=UP7QB';K)SX,WA"JNQVBGZ?DE(]4-M&%NJ/Z&Z4,71[%1LSDY7
M#DCO)$7)=HE+@H?%>P3/-IP6#/.B[((P Z(W_C0S+'+QN>HM-57LA7IWHWWE
M'\UR[=6L.\J5*B3QA6R]W#X8$#N)=VT8$FP26-FE8AM0CE%BGM,:)MYF?-M8
M"EATQRU)E6)UBVE)%DG1IGN<*),>434$!XN.RR(W-/"O"H_9Y:$/L""C=\VQ
MGENB/T9+AQ^P25?5'%1IK8ZJ6Y*U5!%1_2DQ1IJK/1$\6T10<#>(^3+Q&KLJ
MM Z[IWC3)<--1':V<? AU)5-4H*L9%E=-?%CQJT:$1F,-1C2J9O\SZB_T9>Z
M(O)"9H(U+#("HPJLTT2]A52T"FFAE#.-?-K9XM,6C$[/$)D(C*38='T8,\7?
MK'K+(KH*9&7 )>M+PGY.B6)9!X/#X#YM(7+L*6D-Y>S/Q?&U%>Q_,U95YW 6
MQ$[4!7.V^5<JOW,&7,52 ;C!9H'@*7A%7MV>@[WC)C5GH3_(O?79Z(JB8^9<
MI&!KB[&0>S&F2[N9&^_OJUP!7W,520["!)MDP49XF?RO-JIT*WRDB2$^2EY6
M!XH"B]QJ$,'YK5X&A$^(R= @/!O_68H,].I_U*S_!I1OX?K+9*U'-;OAR,;3
M*H349#FKB"W<;SHO6Y9^27]>_"%FH?J(\)S?:WD+O]%5(B9B%38]_#6(C\RY
MU=KT WK8Z&I<20JPN.D<"S--[FKW=$#OJ?")OJ-VEOKY79=/$&UPE8N>\9?;
M7.;M0N=(K[?L;UP"=3><M"A)DVIWF2X7+JINT/](]]+5:=9'FU5=BFR_7IE6
MPG-5B "!P>8-+Q\]+E6W$#OF0F4-Q.9KQ .U&?6!!1>J_6OX6[[KO/3WH@FJ
M,+67GT[F(Q.Y2D1NPJNV$WFKL'1T[TA$50<]MQ_!W2H_T76*8)OUHO4M49?\
MJN$>V2U\@EE-^>/=:IA!^^3T4>7-]%_;(+$#+J/P<!5U(3VFSTBEEW=V'J!-
MR3K?<IYV,OE2_2!]5]BGFG+&3>\NW2O6,F<;I1U@MEH@=N6DHG%#\6Q?VO=>
M-O"^O*2C&KB0A34W \^3-74*MDO8)5,:N]:[1?N08^N<H-C &;6BB[:"O>CX
MP77H>IJI9SL27_:MG<.59CDWB>&?R3$6!#:$-51O@>.]39J/\!QGG#P3^F!U
M7E@+/4.Z_SN5.;30[A)A;5E-FU00L>-<8S5_4O*46@7V+(QJ)*-WO16:U?_9
MFD16R[UOO5#P!_Z!9/13E*^I7[HZY4_+4EO/2)_LX#5<%?^;=-9\5C0O+-70
M+@CR%J@+>#CG)NE7M-XZ1<#D/D?^ZGMBJ*7NZ5JH&U.VM-51G;0CH<%%T9"D
M-SO(QH=M-,P4EWCS50<%YYSW2$MY+M:H8"8RP+W;5VI9295T&DP/2E^UM!J
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MP:F$//8P[Z[?""<1/>?X 9S#I>[DL=0FN.4UJ]KP4MO":M?9(9=9E]2)A,/
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M)5Z]$X3UI.(94AGPL,Q;ME;PI,I3_H#*H40H)Q0OKR54&6E;.5/5G5%5@KO
M3[^ETE>@R86B^@F'Z#P*"C4_U5=*5H$R_L_R]^!52G=-!A10])5V'6I.RV"M
M@_^)FLD_ !O]6J23D-DN&E49LDL;DOM%FZWZ552G'<2/*AM#M)#?5_42DXKH
M5!D^-_46TX@'1+[BG<7.^YDD%9C$I4EY#AM/J'.&UA6IB@I.65)X"TH1\R R
MMS+9N*3P!27=4)HJ8[3KQT>NXHW7GO5#Q <)PF6QDHK[X1^S\):/RBOYDF8_
MGFM)2N.4FI\5OM9;A6WD4LOZU(C:$Z;&2( K,8C\:L3YN@27=<J1A"T^DUN?
M=T"QF<\O^LUY+125)5:O$#=4M1:,E9ZF_$ZN5<0P.L*C5'>X'.]5FO.B-8X:
M^*M"@U*9E+(!<C%[:V4S^PYO)MFYZK2@A;8GOTKLRQ0D/90-XJ:&O5$.$Q9Z
M+P;*I'L=]T(G5>WP&YJ%DB:;S,BA.[+.L$<R?E?>YEYAW\Q;+#C).YU$%O\2
M/@CKEY.ECM[=ZA&*=8X_P0. !3*2Q[!-DOTT;^Y29C<CDG^D<BR[1/@\]P>O
M5S(E\;W(4T8.DTH?*DYZ]RCOJ!5._II;8 D84?E3O$Z\C,R43F>TT?;*@(K1
M3!?YY=QTSEYE;")=,%>U-\Q6T@N0O(V*A^!TIRK-%.B3QK6\4+U#M*KJ%R"J
MW43IU(PM3ZE-TBS(Z67;@U&)?\\0?!7Z7&R"UG@CBN&PS@D'A @-2".-Q>J%
MCRK>8HVU@VOV8ZRR9;2EF'?.+.9>]$?"(MX4]&KH$5$;>M ;E6>A&YT6JA^B
M"]0])3ZFZ<+T\CBC@"ZNCC7 9>[4?+TH>QFC1R=(B.&Z:M6A#<*+1*,W)%N/
M+W#:KI9BJ]0V11L;,P272:_J?]%^5XVU)I-V4^(LY.SBVA4F4\(P3I5A7RA9
M&*H?Y$V3Q6ECG$ZKI^%F)4\Z-/\?WCM9:;$G=9;\9!F]Y)*RN&I=9H+J+75V
M['I@'6-7T!JPD]OI40H?%-VUIV,3%5WRJ\)II%W<,Z)+E5D4'\F\FOLE,V52
MFBYCLX+*3(PM4<%<OR ]L$^8Z\&#DJ0G['<AUU5S90:NF(QS6OG-- XY2+B*
M45(<+S['SLP8*YO((\4\4.B%=4&Y:GO)2P^YYKVBW6$D?!302+-8-JQP-I/3
MS)'73.5]XVTJ H5TP8]TGOBGN#!&(]LO/1%DKURMJ/5 @&/J,(=LZ!KH*[&M
M=1<^8!4P'XFEU7:<1NF PD7\!)DE[;/(1N$>XR$-4-X+&J)@J-=Z-*H/:I8Y
MZ*#1T!:Q/76.4L'$:SM4E"H1"U&'%GSGBH A:=4"$W [^ISXJN9\X"5Y)GC5
MHU'U&'KOL DD(^-$A60N?)YQB#8'F5YYA+$-"2ZH9=]%XE+O\/V1TFBU:!."
M!VZ7E2*[/+I4;L@OAYN:<VB8<&UUE^X1(XCR16>MC*^-U[[)?\MJT0:FJG@3
M"&VTO? 8_B30*FW#RSP6*,W8$8>?FBHL0!A>Y52WO/8(>;EE3\5E^A1S;7X]
MTVB\D>K#=3:0HSX(!^B^!3(E7[7S/>J54XD4Q\F: =@?WGG@5/YD6H;&4.Q3
MQ@>I9>1<=RBY:DU2+^Q-=8[P0[P9E_R*T0SN;M<PK%L\UA8EABC6<UE*6U(Q
M-4D55?&(U*:NKB%RM !."T[RU6Q@C@A_#0WACO/+@"7"5%<6^J_TLNU+;(]J
M$2=.NJ1F <5;;DOM*-VAL-1V9A]6?F0M3>Q3B[B7P[LU_PI]_?S LY+UKF9X
MFT)CEXXN!+AL-Q' N$.>+8EFAY7LD+[B=F2/D<\3#$F<H&2)3.'1ZE*IO]\8
M#47^W74A9%5]M>M"EH,C64[\7L&HFD#A,N'AXH?B+C&>E2*MDR8F],K;Y-/"
M/BA/*\?Z?@9FJJ>[;@?UFC2[V_ 5"&1&<CWD+M4U?+XBJ=A;V*4LRMPB/JBB
M) 3+AJFAL%,*";#-][WJ.SC4]:)F <2PGPH[P_L8('L8.*'J -< =A:MX#\!
MOV:FB.*AS/C3DDW0VC"MO CV\7VH^@?>[?H$N(WDVJ= S<B5VH?,:'Q;53C[
M-;ZRR)<'XI49MP6_L??Q"O$<;$Y8A(R#5?KN529@/JZ?@%CTAST/FH'NJY7\
M_2;/JCS+ZC42A2>X) .:8>#_T!?&AXFVZ"+#IDK[M)&^RQ1]1);K._51O,;>
M F['4*H6OYEWK^PC_J[H2_XDPJ[,(_4"D5E%Q%00 NJ8X,%$#^.R5S9Q@WO5
MB:I-% ?/OJ0]J#A"240XI5O*!B.W*G+S4M&,ZA^I(>ARZL'HC]APQN:@2YB&
M<\>K A\D#'-:CJ^3WK8I(,2J/G(B.+NZD30:O$>9EZN%&NG;4AI@'^;+:!0^
MRTT,ZD3J!,>\RM%*B<+I/I:KH-CLQM.!BIHB]=C:ZE('8"KS6DZ?9C"G)OFM
MYB'O>_0P\+1P?5 1=%[2Y)4#/Y,W.(]!9ZEVV,["TC5/JD6*7)YM28ZR4S T
M^X%JG_!#<HKZIOAY5)]FJ&Q T%0P1Q'BE0 M5F'.?L@$X+DM%Q5 J55]TH>2
M$\4=<I[,/CM5<5HN2-JOLE?LBXI7PRJWP._ 1_5JKV00TZ0X%\)NX#/;5<@6
M&*C\*#ZF3BIZ+VT AF=MD;L!ZY-R%"LT99'/5<'@I,"SZJO@8Z\JC0XZ[JR&
M:N UM@\06P2M9(@&(75%1LDPY$@64WH..9PT72Y%UD<>4<Y"=@3VJUXBM[P2
M@'WH).<&<"<:9S<.[D4K*WX*&G7=14ZB/;JLK%&2C=IYB6=D*N)<9(<BBG ,
M;%*YXPU>T8 #/LZY!TS ZNP"X 1L',ELB<BCY'TUMQ9AZ3/, TB[XVZ9JJL\
MP\3&)90+?@&&UXQ];G,-"=R']E?UF\7%L\CZ?,6U4K'A5\F5O,F&K>586I:A
MO#HY+D9_G^H3-EY/8J3Y_:N[PIGGMD?'$-HY!.MF2N_/>J5]IUI2TJF]5)6>
M&ZF]2I:GSM%NI6V(7:I5,">&KM&Z<>;X/B>>"DANEXAMDA 'C%BC2)G-)'8#
M6<7GL5NT-3D*?#:C,.4F'LH>%NN(!W&OAN;A;H(SOGMP+_%+M[MXK-S983<N
M46&SS^*;-4>*)R#NG#'9^Y 5/)>4<.2W("NF _47X:$C48KDGF\/VBNO<7N*
M?E2^=GB'D8$F&W?L(C2UJ 8\**K(G@V9Q<^3U\%3I4",-PS*)X?LAF\J3OD:
MD6S5$K</R'G XC@+E8$R&RDV%8XL/ 1L4*BS6C5;E6AR JA1R:*O0:/5@A -
MU $0OEPX0+/>?3A\&7SMF(0LA^UMUJ(:)+ P7O4$+,N: OB"EY,N:5P@[VB]
MYBZ$A\2!==![WPBH %:Y#X;'(6,=A? ?I-WF'O(+'5QP5RG&;3)/JC[C4Y,6
M +;8GF@Q\ HCA11K%F,S?%D@B'YU=X5HZ%-',PRCIVV'(YWHRIRK+;]R%Z=E
M-&L+S\>+FR:09D=$-^@J>P/N6:]1%)X[ZAP9+<[Q9H#[T+;5^%DLG#G=L%'Q
M)/MDX_?B;:D%#:_*H#BT?DU533ADC:6( WB65;7[/-O-LSFYSCSC?.%@NP&&
M NFCF9OTJ:HEV9.L7RM.I-19O6IFQ5ZJ<Z=JPYZ;GS)F!4PPF=@//-5&?_Y=
MYT;]*_$7NPK=+87OK$C="" F2V690#F;_-P,TGMC_4UKF UA&N-*SGS_8P83
M_ZYGK5XH3G%>H^/(]MHMU7:HLF>M(;YJEF=>-U8S3R<7&L=S[&-6&S0\X]\;
MN%0XW'^1;H]XFV>E]K[,['Q&.U5)M7M)0$#\[/'$>/!E9KSN#?](TF'=.V%;
M3)RN2RP(/:C]+*WVEVK#Y2)/&F%2]CJ_Q=^IK]N[X'7@B-D4/ <>G+&3."MM
M2<K2VLEN1C_4#E(XA.H)BU+CGX5_4KWW+,?Y .[R+_8%G&I?@>V%YLSNQ5;#
M;S*R\ %JW\0G>(?Z?70;O@:8'UJ"5VM(_M[8<S# ,QFS0'8N,[  >(J]%IL.
M?YM]'?-"-J;_0$&X+[$#*X!O1!=C<^''H?X8#_[F[X2-0_P\B]#C".CBAK8C
MY^R[T7GH3)M_T(-HT8 !?_[\K\UGR/P'_%V#A]@/&#!PP/^^_F_/ P<-'O+/
MT&'#1XP<-7K,V''C)_P[<=+D*5.G39\Q<]9L&UL[>P=')V<75S=W#T\O;Q]?
M/_^ P*#@D-"P\(C(J.B8V+CXA,2DY)34M/2,S*SLG-R\_(+"HN*24E)9>45E
M574-F4*ET6L93!:;P^7Q!4*16"*5R15*E1K0@!",H!A.:'5Z@]%DMM19ZQL:
MFYI;6MO:.SJ[NGOFS)TW?\'"18M[^_J7+%VV?,7*5:O7K%VW?L/&39NW;-VV
M?<?.7;OW[-VW_\#!0X>/'#UV_,3)4Z?/G#UW_L+%2Y>O7+UV_<;-6[?OW+UW
M_\'#1X^?/'WV_,7+5Z_?O'WW_L/'3Y^_?/WV_<?/7[__#!@X<-"@P8.'_&TP
M=-BPX<-'_.TP:O3H,7]3C!L_?L+?&A,G_>TQ9>K?(M-G_&WR-\K?*G^S_.WR
M-\Q_E?GO-/^SS?\1Y[_;_$V3E9V;5U!87$HJKZPF4^D,%H<O%,L4:A#&"+W)
M4M_8W-;1U3-W_L+%?4N6+E^Y:LW:]1O^2OZWX_^A^#\=_UORORS_:O[U_"OZ
MU_2OZE_71X__VCY]]M?WQ<N_QJ_?O'G[5_K]AP\?_WI__O+EZ]=O?]U__/SY
MZ]?O__C_Z0\/^+,H)>/7@FSRN]XLR>,E6=KK2_/:S_27]1_IHZ\[N$2X>=\2
MU8Y=2["]V_L,AS<O-IS8L,!P=LU<X^45W99;?1UMC_]_]W\8_L/P'X;_,/R'
MX3\,_V'X#\/_&T-RQJ^%6>3W?9GBQ\LRB.O+L]O.+"OI.[J4LO;0<NZF_2OE
MVW>O@/9L7TX<VKS4<'Q]O^'LBD6&R[WS3#>[NQON_?_N/_UA 7\6_V58E$E^
MWY\N?KP\#;^Q*J/E[,J"Q<=65JTYO(:YX< Z\=8]&_X'^W85W>:=KWV_LV=V
MI]TST^E,.].9ME-,TS9-TC"3$S/&##$S6T99S&!)%DN6Q9+%8,NR99F9.7;L
M,#,S-?!_E+1/G_6N=ZW&3D_V00^^YY]EZ4#7??\,ZVBNP_7;390QBXX\K:TA
MS\D4Y",\&?W$KPWH_Z_!-^&.WAMRT>*).U;GQ9VQ!:I&ZR.MPTW)MH'67$=K
M0WFGO18W8'49]'K2E%)#G!6I2 =9"NJ17]N/!G>_YS4^"7>-G@67:MVQQQOV
ML&>;O!7CSF#3:'>LI:,YU]E@+^^VUN(&C2;RJ-I G)1HB?OY-<0##!7EX*\-
MZ#?^:-!ZQ=\UN>=?KG?#G&S>P9SOV"V9ZO/5]';&UC4Y<UMJZ\M[C"Z#UDP:
MD1N)XR(]88JC)<[0:L@'?FW X#)H7 :=9_P]Z^Z\*XT[4*<[MM*/#&X3C@YZ
M:UK:8^UU37EMQGI8C[86/Z"R$(<E)L*8P$B88.F)4Q4Z\OY?VX^&/7[ L"?N
M?MW.W&O-6^#G^C92CL^N9_?T^^CK6^,=1D=^NZ8>WJVNP_?+K,0AD84XPC41
MQRJ-I FJ@3SY:P/&#6N =K<?,+G%/K!OS;[1L0%Z:6PM=GIF+:^YS\]@:DEL
MTC@@[2H[HEMN(_2):XD# I>#[7+0S:11BHD\_FL#QO4_&BS;8QXY-V;<[E]=
M>/+@<L3 ]'J!K3?0J&E.<2H<1>VR!F27I)[04U5'[..Z'$PK:9!F(0]3+)21
M7QLPK5L#=+O\@&USU...U<D7)U=D39]:@FF9VEBE[PTQREO3'6)'<9NH =59
M92=T\^M)/6P;J:^RCM1?44L>(-=2!G]MP+QV#3!M]0%-:T)O#2V+.73B\_3>
MDTOPULEM(D5?A+ZZ/=,N=)8V\QM1';P&0B?'3NIBVLG=]'IR#]5&Z27;J'V_
M-F!=O0;8UGH\ZO[6_^3\EP%#ES[+;CBQE*B:<A-6#49K>-W9%G9[J9W5@FIB
M.0G-C"9B*\U!:J<VDCO(#91.8@.UZ]<&ZKY? UJ^W7EI\I.=XQ<^"G'>^#Q/
M>V(YH6K&@\L>VR=C#.1HZ;VE)EH7TDKIQ-B([=AZ0CO>CFLC-&!:B8WH5K+C
MUP;LR];<'OQX[?XS[V]IO_M1A.'&TCS1Z?48YB%?!G4Z3D >SY$01TJ4N*'R
M&O0 0HOL1^D0_6@]K ]K*._%&Z&]!-.O[8?.C[^9/_[.E]VWWM]I>?9)I/36
MBFS6^1TP\HE  NY0 AUS((<-WP_A0Z=*JDHGH:+B"9BX: (A*1Q'22!C&&G!
M&%;V:SL\\Z=_]5]_YUO;LW^Z*<"2<,Z]]6F4JYX0S/DP&.)T$J;L>":QZ&@^
MI>!P847>H1)ZSB$H(WL>5IDU#V=FSB&9&7-HUJ\-U&Q>!A2>NX!L;_@/RKUI
M-VN"2\]I0LE'U/N$T\HTS; ,8AN0(AR]4D)+E[BBLUU [VUE,P::&:R1)BIW
MO(%8-67'*6:L&/7LZ_:;X3?#;X;?#+\9?C,LRB /"OM!%9AZ4Q-4>EX73#JB
MC1+L5R?7C"CRZ@844$>O'-O2):-VME=7]+7PZ4--K,JQ!AI[JIXL/%!+4![4
MXU1SK]M+@_*%(3#L!W5 ZBUM8,EY0Q#QJ#Z</Z--4(W69%D'U"6-O2I42Y>2
MU-DFH_8UBRJ&'3SZ1#V3.5M;(3RD)\F.J$C*^=?M9X,B(.Q)C7_J+;U_R05C
M(.&8*90[8]RG'-.EFP>UD(8^+;RY2X/O:%-3^IIEE)$&4<64C<^<,W.KCBAI
MTF.2"L6AUPW4;'(9/'8!I7_8$XU?RFV#7_$%LS_AN'4OYX E2CYN2C8.F7+K
M^TUE3=TF='N[@=C;K"&/-*BH4Q9IY5R-D']$S)$>$S+EAUXWH/F_!K_0)UK?
ME-M&GZ*+5E_<"5L >\X6+IVTQ>M';)EU@_;BACX[LKG#ANUILN!':EW[7ZNB
MS4FEG".":NDQ#E]^^'7[V:#R#7VB\TZ^8_8NO%3GC3W9X,N<=P2+IYMB-./-
M:>;1CL+:GA9$D]..[:YU[5Z=@30ITU .\)7,0TQ%]5&&1'[X=7MI4+D,:I_0
MIWJOI#M63\AENR?FE-.+<;@ML&JV*U(Q/9"B&>B&6%N;84Z;RV"TDH:4!N)$
ME98TPU15'*0HN8<I*NFAUPUH-KH,[KM C7?(4Z-'TMU:]X(KCCVH,^WN%<=Z
M?7F'1L.J1P>3->T=^39[4WF+J1[;HW$9)$;B.$]'G*;54 X0U,QYO%KXV@'M
M2X,;T'B&/#.Y)]ZKWYU_M=D-<:YG-_GDN&?E[%1(54]_DKZA+:_!["AOT[H,
MBEKBH,A,'&4;B)-4'7D_7L.8Q6JXK]W/!JU'\'/+[H3[C3MSK[?O*+\XM MW
M:MZ3,C(1+&[N33196O,<6D=YN])ED+S8_Z[O!--$'*,8R)-X/7T*HV--OVY
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M67VW;\W:LP<VK9H]O6WGX*7=(2WGO5,L9P**%"?#,+S#<;2*F0P>80(B1HU
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M)BJ_5D.2VI5XC4.&JVT28YW.*IRS28!O:>3C6QH6$N"],&S_!(C=EP'EGO5
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MRUL#*[XX>6CMQ]-GMZSLO[1[5_-YG[WFTX$)\A/AN=RCL5#*H10<>BZ[HNQ
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MR%QE#5ZLE6/5!@G:8A*AF\U"=+>9C^DV\; ]!BZV]Y6]--!<!M'.SX!BY[=
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M^1\8V/15/MBQ(AUXK$D _ANC0<C6<!"U(QC$[0H"R;O]0?H>7Y#M[@/R/;Q
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M7LA1$<]E&BEGTNLK3J>VT4^E##&.I1Q@3*7/,X8RYRJ[LPXP6[,/,)MS?CD
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M6TOU5:;B^FI]<8=$6SPF49:.B65EXV(Q=**Z&CHA^J4 ^HLW 7;-NX"]Z5]
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M.:FP<UD,:&P(!OT=/F"ZAPM6ZC3 :+D 7A</) ,LT(WL@6-B"QYFUB PMX0
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MT?UUW4;GU]@?76A'D-Y>2:3EC"12,2R-Y(W-0=)G5DO&_U:4"T<[MS]HK_0
MX_4LL-Q*!8P"$?!*."#M=0"ZJBUPU:W 2\,<A)HF$+K?"&*T]2%55Q?R]+2A
M7%\+&@TTH=M0 TX8[H,AHS_I.X@@+0,(4CZ$(#GW))'DGPLDHF"-9!!LEQ7
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ME<&B5!7,:]3!K'D?F'9I@&FO)I@,:H'))2TP_F<_&#_?/V/\8?\/XV_[OYJ
MUA=T#CI?^ZT9Z+PV_W^!Q6XIL$%S..Z1!F<5&2#MEP>JZ4*@8%: J\LZ(+(W
M \YW!V##E, ^82_89JF"=;$Z6%5J@&6#)EBT:X'%(?18^K5_FY_7_F5^4^>[
MV3.=+^;O=*;-O^I\1&>\-P?=-Q:@-VX)^F.S $LTP[_[081=TD#:(P-NFG+
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ME=!JO?(WR\TJ7RV75;]8'E3]9'E:];WE-;6WEH_47EJ^47UN^57MF26J/[5
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MEI0N.^Q1NNAP0OF"PS657QR?JIQT>*]VW(%\+CF@YF'B$'%P!70@?=^#]/X
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MJ3WL\Y?VH.\K[0%?U.[W0^T^/]1:"3U)=A#IW5&L\#F!#5ZDLL/== [X+4,
MSF0J48ZD&]+M3;5CWI'DR;DE/HA_0TRTR/JH9(FYB"SIF? B^<G02L6)D$:5
ML> .M9&@08VAP-5:_0'K=7H#MNEV!QS5ZPJXKM<1^$*O/?"K;EL0?J=#:/\(
MO4GO#F4F,V"")RF,<#V#":YDL\"Y'%XXEBM/V9>C1]N19<VT.=V-8R'%GV\N
M,4)X.CY>8G5LNLQ8=)[\2%2ITF!$K6I?>*MZ3UBO5F?HF$Y[R*Q>:\@6_>:0
M@P:-(;\9-(0^,Z@/_:Q?'X9Z=6&HNQ+ZDMX=S@!O$^C@9CH-+N<PP/E\9CA9
MP T'"F5@N4";MCG/@G$^VYEC-L.';S(M5'@\.49\.#%%9B A6[XWKDBI*[92
MM3VZ4:,EJDNK*7)8MSYR6K\V8J-!=<0^HZJ("T:5D8\-*R(_&51$H3ZAMQ+Z
MD]X=10</DP'^R**1?'HX542Z?PDG["Z5A*423>I"D1GC;+X#^V2N%^]85I#0
M8$:4>&]JHG172H9\>U*^4DMBF6IC0IU&75R[=G7L@%YE[*1!6<RB84G,;N/B
MF+/&1;$/C8IB/Q@6Q:$!H;\2!M(#QE#@=AKI_KE4.%U$!T=+Z6%?.3MLKQ"'
MC15JU+5EQ@R3Q79L8X4>/(-Y 4(].>%B'5EQ4BT9J7*-:3E*=:DEJM4I-1H5
MR2W:I4E]>D6)$P8%">N-\A)V&N<FG#;)2;AOG)/XWB@G$0USDM" T/\1!E/A
M73R0<T#Z5@$%CI?2X$ EZ?Y5I/O7B,#Z&A7J=)4A_7BY#>M@J2MW3Y&?8'M!
MJ&AS7HQ4?4ZR7'5VEF)%9J%J:4:E1E%ZDW9!6H]>;NJ805;*6J.,E!TFZ2DG
M3=)2[IJDI[XU2D]%0\)@)0P%>$*Z]U72_\\4 QRNH,+N&AILK6.&Q7HAF*U7
MHDS4Z=,/UUBQ]%8Z<[67^P@TEP:+UA5'2585)LJ6Y6<H%N?EJQ3DEFODYC1H
M9V5WZ:5GC1JD9LX9)6=N,TG*/&Z2F/D7\<8H*1,-"8.5, +@+NG>%TGO/$&Z
M[W[R:]>.>@IL;&2$M<W\,-DL3QEMTJ7K:[!@[JASY&RN]N*OJPP4J:R(D"@M
MBY<I*DE3R"O.5<DN*E7/**S32BWHT$W*'S9(R%MC%)>[9!R3>\0D)O<6\=HH
M-A<-"8.5,!K@5CK90R' D4J W?4 2Z1[K6^EP70;+XRURU(&VK1H7:UF3"W-
M]AQUC1Z\E?7^0J6U8>*%-;'2N54I\IF5V<IIY<5JR64UF@FEK3JQ)8/Z4<73
MAA'%FXW"BP\9AQ5?-PXO?FD47O3-,*((#0C]'[V- [B6!7"*=-\#M0#;2?Z&
M=M*[.@'&N[E@L$<*NKLU:"U=QHQU';9LE>UN/"6MOH+YS2&BV4W14AD-2;(I
M]9F*B76%JK&UE1I1-<W:X=5]NJ%5DP;!E1L- RL/& 56_D%>7Q@&57PU"*I
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MK;+NK4/RKJUK%)U;MRDYM9Y2<FIYH.C<_%[)N0D5G1O_Z0(YBP?).=Q61V9
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MF+7&]3$[3&IC3IC6Q'QC6AW[F'AM4AW'&1-&'_-V'&+)^Z>2]R?]8[GD>_.
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M;O%NNS[)+KM5DAUV&Q6VV>V6;K4[(=UL=TVZP?Z>XCK[OV0#]K2"'#CYZO_
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M?=I>N!$L_C85X;F1(AY0'#_HZN$K74M\.FP"+@[WQMGA83BIGX#C^ADXJE^
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M&<061T2RA1'QO/R(-'YN>*XP.[Q4E!E>)\X(GZ:0%CY/FA*V5)8<MD&>&'Z
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MIN^3H3]UFWCTEG:J=_W0YW HY^0-- :4K]<NTM]+^@< 8_H5G6. RB> XFE
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M'DAO*E%-]X5$6B%YCA+2+R?O2S;)HUH*UQI5N-3JP;EV!!SKQF!BG1TFU+O
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M?(,SPN\X+9+CE/B_R'E(R?647WGSD[88WZMKX9Y@@+=%-K@C]L*+XC#<5DG
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MV%_F@7Z9@WR9G;O,7%QF+BY=(W?(Q^1SS%FNO ZG?)K'XF8>!SL5]T$!WD<
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ME=!WT;:&5-#[5=/[U(KA7*\#QP8#.#28PZ[1'K:-;K!I](4U%Q.KIFA8-J7
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M[TGKZ$2K8INE!JL<79CG&L LUPRFN;8PR76!<:XWC#B1#?-D,,A+(?F0Y-5
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MU8YGZA]K_(F",4)&BGPK\L.0'XO\9$9D)CKR:'$).BK148>.)G0T([,GT3&
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MT=<%NEH/*D 1R 49V)/">XD@#GNB03C70N+<%13G)UN\6=;X0%D3PF5)B%5
M0HK,B;F@5*;$=O)/ZBJ_I('R31HCGZ2'Y9TT2UY)J\!>>2:=DV?B)_)*_)-&
M(;\/^CI!S^I &2@ 62 MP:C]D.^"&! !0K@>F.0F:[*W E),,J=:94H-D7]J
MM/Q2$^6;FBF?M")YI]7(*ZV3/-/ZRB-]M-S3[Y=;>HM<TY?+)6TWPL_P^)%<
M4K_2,/3TA"JW)^6L!L4@%V2TU7_0&0LB>1[&]2 HG#7-30'IWO+/\I=OED7>
M64'RRHJ09U:\/++2Y):=)]?L"KD8-T]DPS5S1C@V<&>3J&<O!23?661,61^"
MKS0(V5U3''N1*D AR 9I7$L"\2 :A',M&)I@S23_SW*3*<=+/GG^\LPWRRW?
M)I<"8R#360486@#W+X#C%=8[CC<MA&L6PFT*R0P*R*4+( 'Y\.Y\LL?\K]0/
MV9V170LU+&W; \3K5.A[HK,&%<&U$&BT#=H6 $TPY;O*M\A+'L5^<BUA0B]E
M,BUCHBF+<&RF*N,+Y7"K<OBNO18S$$ @RN'^90L &4/I"? ^ ^ K]:1=[9%?
M9;\'#)>!#*XE@[@L1PTJ-)<8@$);$&LJAH.4NLJCPE,NE2QX52PHU0&.B=TH
M+-?ABSI\4<>7ZN!6=<:F LAK'9RB%@)3"W&I(6NK@8Q4OPN^4E?:5L_'R]MJ
M0+Q. PD\CZ;-807H1Z^E5/)'I$^5Y$'SU(Z%O1YNV<#BVH@=[?%%!WS1D8FD
M(\';$5]T+';<8-/1.'J5F.A AM2!;*T]66O38? VW_U*'=%1 TI^5 -*YGEL
M$3% EP:6H[_*J/_ P>E>-Z@KBS@RX=J=/5ADL:,+=G2C3[H;"R\3>R\FDU[X
MHA>-Z,67>](?/0<!8J('<=E])9^'[W:]!KY4 WHJ2QS[@'+1F\IC/)0LHI(Q
M0'LMSOJ/%_S<%5$D,<@ 1CVD-W;TP8Z^V-'?N2]E,'8,#744P(=F.(ZE'H*
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M..8U9>LB+.$L#.(T=IS CF/PF",PK4,PL!<9- =@@?L)WKW8L1NVNH/@V4;
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MAKR""N415"/WX,YR"QX@U^ Q<@E^U'%X?C#)6-!! ,\*_+UZ&?NAT%EI;!T
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MSO= 6SVD!COJ6.#KO1Q_]&B/'9V8^#J%.O>D& = 5SA^"KF]<4X+9+D1TMA
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MPL*^2GR]NX+49M>2NJLUI)-52O(I+33SJZ34<Q()_;Q0RCLOD$K/<$6* 8Y
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M7*>@ M?%TN%/C+P]():3>W'E]%YL.:<7HQ7W8"K4W0\3\#SW)/"^-@743%L
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M)E4Q0[G5C #<3O=A711/:0W)@_<0:@A>G)OH*W63H(^2_1@7Q8]R40-()SV
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M[\0$.79"F&8C1D;>'8S,_:AJUKV97Q(KMJAB!9;*6+ZYNFXL =-+CP#S6Y.
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M$^IT=:N\P-@@P3BB951?@,F*NG'B5A.RHD.#-C3+,>:8!&L-EY7:0R*<(R#
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M-K$36P2EN[N[>[/I[N[N;D$!"04%Q<3"3JRQ'5LQ0%%$410!O<]R?O]S7LS
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M@IXQ3X<\9MX-O>,R$'K!]7WX<?=W$0<]WT7L\7H?L<O[?7BKST#8=I^!T,G
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M;-H$A781R!\4A=Q).N>R.&3O2T"V3Q(R7ZAQBJ:0I10A,:8"J:^JD!Y4A_2
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M2Q:!<;XX#"NEH-\@"[U6>>CN58#.427H7%"&]AWE">VW*J/:PRHC.K^5O^A
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M3SKZ=J>C][=@,/4AGK*SR76F_+]&%-XVB\/#=AGXM4N5N=)ERCG3[B)\9':
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MYYYQ"QU\[!HZ@"ZA_>@<T8U.D9UT5]3Q->^SOO3A3 O  ?+O2?+?=92_;!G
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M!H=19CJ[>ZD'"P&64OX@Y;=. %1MH_P] ,F'*)^4T/<T"UPN\(#]%6&PNZ(
MMM_K@LWW5F#]@PM87O5C+*Y&,&8_)K-,?LQC&_U4PS&XULVE?VV42_?GK=PZ
MUR]PZ_STC%O[!^33NH("FM^AH,9E%)K.)CK_EM'\S:?ZMU-^-=4^;Q_EDX>'
MGR0'/P?@=!G ZBH'C&[R@^%M"3"XHP)ZO^N#[ETKT+GK#-KW?$'S?@1HW$]A
MU!X4,*H/&EC*?PRPE!ZN9"D\W,^2?W2')7__(TON'K+E[B)']G?DFLX*RE]
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M18W.:: '>;<?P/,(@%MQ -^3;YQ/8</I%&XXEB(&^](U84>Z)6MSFAO7^I1
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M>>E/LT!].$LU.$#>-UE /2#W6DXLHM?SBD2AOT0%NDJ,F?82!_;L8@^>^J)
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MU09RIQ:![.E-('/Z',B<?,'('$=&^ABRI(\@>SHK!K]\%ZJ;>EY/>R_:0#-
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M&92$?F%0'";I%8=*ND2'J(M#M'SBS79@O:]1^TP"U]AD2RS]5A37F(RC.]P
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M2:!&!C.<SR&J#%=02XTYU&BEQF*6MYRJ:W$:6W"2N3B.$SC*2 [SHC[(]CC
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M7'1-F%3TOC"I\#=A4KXD3,X;(E<23E%G()O7)&FE7ATI(=G\G)!+)YA/_4+
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M\3W$P,-2!.WT?Y+8,_67YYTZ7SZEYO*_[M#1CSM%_FUVB9BGV."3KR$KWZ9
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M'$*V^E.YK"*;7FF3&SASG/$ EH))= Z -M[73M$'"^%^B]$//8I;B?XUZ-\
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M[99<A,47,(C/IS?-GHNCI\!\-OH_= ZU7SFG@?OQQ1V,DUL9(S<J!CUIZ"E
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M_ 40QA&X_\@3-):L:?AK!J#-#G-/V%(PUL9\R&LKJ /E?,Y'=T8W_!^*%#U
M^X>D &B*WX2KO!9X:<XT'&::!7^:!7<AD_I")MR%#.*%=/!"A"R$9RZ$5"^$
MQ"Z$3$V3(4U#UJ8A0PNP8<IFQSI\.X/)0UV.>\&:.ATUH,(>^H V)R$F>@3]
M$^B',OHME.8BUG4IB<XRDIYE)!O+6>A7P*=6LMBM9.)=R6!;26>NI $KS6.8
MU@&([$I(Y K(Z7*(V7*RZ&78L!3&A)Y)VCD?=.#K6EY+:'/.,/Q_#/Z+B%!3
M_YF% R^3/%:2Z*T%Z]RD]?#*#20[&TDT-K/(;R$1V,H"LRW;L?EO:XMY'!:
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MXH,*+3ZNX*([%%3T''B?]S:%%-H46F#3(61O1O82LP\(]!3B U#'^RI0"@I
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MIGAP$!V;T+<8>C 2Z=A[TLQK':CB6CDVE6!?,;\K"IRCPD ?%01:E!<8HIS
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MR?I6KEFLG^:>-&3W(KL9>E8-2D >G[- &M\E@3C>1V5*8=#9H%Q76?+GRK_
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M('<D_LKBFA0^%U?E)F(3!8CP9&$B.$6,\$^1(KQ3Y CWE-&$2VT"#%F=O7!
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MIL3(;N"87P[+'+E0YC"2C+@J&6V2A-@N'K81 QY1X!$.^PA%M!>,^#((@W@
M;.0P;,27%>T;HWZVD.4))A'02C:&,29+=)LEDWG*$+/W8S /<9ICXF6<;A#'
M&0;8:S#X4)XHK$P"D,/K,2A5%4/&5)2K@7+9YW':P49L8"/6L!%+\+  #S/8
MJ0GN8)_%F8A8OHSU1!WF*4/,N@MF[P?S!&CFY-\V3MV3.,.=%V?8989@:^@"
M'C'*%,/P+ 7(H^PQ*%L5-55#V3,QE,Y%V8M0[G)8Q!H,ZYM0_DZ4K0\KL<0K
M=];3:[>37%A."R+AQZQ]'\QNLTT<,.G69,Z0Z\(9'@]QAFF,:"B3#V4*@[,X
M, (8A?*5,8VHHFPUL@T1[E9$OEO 8S-X;((^-N+5!MRY'DS7L4X,"0"[%+(:
M%KL*MKD*(X 69 \BBU-_1CZS)!)#%NMG"6:*9*;*S80;Y0H"HBA; I!!^0JP
M1&64KXKRU5#^#)0_%^4M)BOQC\F$+$?--5&+I:C5$FAW,>M4V1)8\PG@#>NI
MW P6$<IJ?R]._9FI<1=A_U2"Z0OEP^4!M* +=OY!#) $9"%#$3)4(&,"9*A!
MQDR4.0^6NI3,Q[?F0=M,EF@V6FX6:J@!*YZ)]IB!'CT#(P#S1"KF5&@-5HX2
MTR&F6V-,_;OA#ND(L',?*_!>$]>78 I<1'A0OB#*%P7$(4,:D(<,);3"6,B9
M"#G34-XL%A-UL)R.6DR#-4R%-:JQ=C,%8:1+)Y,P5DPB-U@KX)@=B<Q3NGSA
MBED)PB7!U+)5F/T3V7)@,=[/Q[0W!Y_-!I]9W/R0,0PRQ% '"6 $9(V$K-&0
M-0YR)D...OX_%V4O!:NUT- V5O9L'*Q[+'J9"BQ?&:.,,GJC,MJ#R88S)T2Y
M0XZ)"'L-S$8F_\+\7 G,PWL-0!V?30.GJ4(\9"J_(%'C%2%3N(>3R5R29!*7
M+)G(I0!9RI U :/85,B;1<9R+28J7*N(,M=F,IIK'U'BLB *7-ZPYGBP+@5Z
M@*>LG9',:=V.D&$$F=N9I=KB[/S+?$ #F(YK:OAL$C!!E(M,$.$C$X8-(ZJ"
MHF2\@#@9QR]-5/CEB3+_:#)&8!P9+3"%* G,)(H""XB"X$HR4G 3D1?<2V0%
MS8F,H"<9(1!#I 6*B!1_!Y'DNP]\!BBQ98[K@SQFR_PJ2?9/MG, =6 *KDT$
MQN/SL8"*&"]1%A4@RB+"9(RP&!DM+$D4A66)@H@"&26B0D:*3"+R(C.(G,A\
M(B.Z@HP0W42D1/<225%S(B[J18:+QA(QT2(B*M(._ :\ RBQ1-E[F9]'X0JO
M8-:^ #.9W LP$=?& RK@,P;W*$GP$ 5Q/J(P7)",&BY"1HJ)$_GATD1V^$@B
M,UR9C!"?2*3%U8FD^'PB(;Z2B(OK$#'Q?414W)R(B'L08?%H(B1>0 3%6XF
M^&W@+1$8CG$;9>^"O/5P@S41GLP%U(') ,)IH@*,QN>*X#)2BIO(2_(264E^
M(B,YC(R0%"/2DI)$4E*.2$@I >.)N-0T(B8UEXA*:Q(1Z?5$6'H7$9(^1 2D
M70B_= 3AE<XC/%(MA%OJ)N&2?$NX)9EG5\,6(&^-+'OO$9,#F@I,!,8R>1=
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M?/3XZ;/G+UZ^>OWVW?L/GSY_^?J=_NA_/^O__WG]N;B9&@LP519!G<692H]
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M7.(FZ9^$N>/H*+X .G:8*YTTW(K.D#Y(Y\OMH\M&[:3KE+;2+6-TZ&Z5#?3
MV/74>-PZ:CY^+;4>OX;:JZZFSJJKJ/L$+>H%^$U<28,FKJ!ADWX4]#!B')\)
M M0=<T7@/ D:J2E/X]:JT(3M4VF<_GP:;:E%PUPVT4#_W5_](O4_>"::O'7)
ML'KED&?_PK;$^9E5I=L3BR.>C\V:O1^:=/H^.'3B\+V# P$W#:\&7CQP+>A'
M\)/#3P[_1PZ>,T5H\%P)&KU4CB: 0]*VJ311;SZ-,]>BD<Z;:;#?GL_^X4;O
MO./-7[FEV;UPRG5^:E?D_MBZPONA1:W?[V9-_O=-.X+NFIP(^<UX(/2*X97P
M 8.KH3\"ZH\XRQ<<?&:(T+ Y$C1NB1Q-6:U"T[=,I:G[%M!DT]4TSF'K]T@O
MO0_!(::O_&+LGGLFNSYVR?+^W2'?_YY-:?!OEM7AM\P;HVZ:=<1<-ST9=]EX
M(*'?Z'Q<[\%+D3\"&@ .?HAQ_-1%:"3BBT3X]NFKE&FVSE2:M6<A33=>0Y-M
M=WR)\S!X&Q%H^2(HTOF13X+/_?_%WGF%-=&UC7JHBKWWWGL!490B37KOA$ (
M(2&0D 1"((1 "!U"#37TWGL'D2(H*&#!\EJQ@145"W9]]OA^__5?^^ #/=P'
M^^"^/%RWLV;6K'N<B9S,\(>L_-_/81+NT&N2;[FWB&Y0NC-'7"]D7R!>R#[K
M,IS6Z7HU\6^ ,-0A&'4(/3@7XM&^$"FOA!S4H<!X/Q1@%"'761>RZ#;?TGR)
M[X3!'B\%T=RQ8&'8 W]1[!UV;O)-KY+T:XSJG*ONS067*=U%_:2S)=WD\_FG
MW08S6JB74OZ&_W4(/S 7$E&'#+0O\DYM@A+#_5!LHPB%3GH_\JBVGS.]R6]3
M EG/XB+Y#\/CH^\$IB3?X&1G7645%0PS*DL'W9LJ^RF=56?(796ME-[B!O>!
MG%KZD.AO@'"T+T+0O7WD_KF0++<0LM"^*-3<!.4&^Z'<6O%7J:/^ER(WS(<\
M+[?7F0&^8XEA8?<$,<(;P4F9E[D918,^!>7]7A55?<RFFBY&1VT3I:.VEM93
M5LDXGU_F>3'S;_A?!P':.*FH0X[B"BC6W B5^ON@VE+Q>R5.?ZJ<C'U3[$%]
MELOA/D@-BKH1&Y$V'!J7UQ^86G+6+[OR#+NDIMV[MJZ%U5Y?Q6BO+_/HJBSR
MZBLL8%W(_AL@ G4(11VBT<9)DUT >8K+H4QC(]2@#G46BE_J[/7?U9"P+ROH
MM$<%WKP;(O^XH800T;FHZ/S.D,32-EYZ52.WH+:64]%0Y=O<6.S5UIC/.E.3
MX]-;G.7;G_LW_*]#[.^O=%"'@A/+H4)] ]3I[?W99*[XJ0FK_Z;!V7Z\FDJ_
M6\3D7\KBQ)U+YHLZ8R/R6R+BR^I"4JLK W/J2@-*&XO\ZYMR.*W-&;ZGZT1^
M/:5IW//Y?P-$H@YAVZ4A_O<7,H?G0]&)95"%.C3J[?W>:G;B0QM&_V6KD\.C
M.C?&M3(&?R#7)ZY+%"!J$8;FUT9'EY5')%47A636YP85-F7QJYM%O):6)/_V
MAD1>=[F0=Z[@;X!(M+/"MDE#PFX9R$(=2HXO@QKU]="LN^=+A\F)R3.V^L\Z
M\ [WFEP\+E72^;V%K-BV3*ZH+B4HOSPAJJP@.J$Z.U)4+PK+:TH)K6A)#&UN
MB>6W-<8&=U7$!/<5_0W_.H2C#HFH0P[J4'9\*=2IK8,VW=V?NHV/OSYKK3?6
MA;._V49B7*AU#^PL9<8VYG)$%>F!^87)X659";'5J;$I]4)!3E-<5%E+=%1C
M:T18:U-$>&=E1'AO\=\ 4?_CD(0ZY*%K9<7Q)="HMN[':9U='WN-%%[U6^D]
M['6PO]I!I/<U4 +;*CQB:@I]THJS _*RTT-*4U.BJQ,2D^JC$S*;(N**6T+C
MZEJ#HEN:@Z([JX*C>XO_AG\=(E"'E%VSH0!UJ%)8 LVJ:[]UZNQ\UV]T[-F0
MI<Z]?BQVJ(M [VIQY376,J++REBIN05^N6DY0:4)&9%542)A?6A*>A,_N; E
M(+FFQ4_8TNR?<*;:/_YLR=\  M0A$G5(0QV*T/6Z%KU_MZFN_G)6>\>;04/Y
ML2L66C<&[>SZ>YUH[:?) =6--$%!-3,EO8R3(RP*+([*"Z\,R8FK"\A*:^1D
MYC6S,RJ;6>DMS3YI9ZK9*6=+_@:(1ILW"NWN=/3>67)P#C0<6_CCS,E5'\YK
M;7UYQ4#VX0VS4Y<OVV)Z!ARIC=TD;FD[-2JKT3,YJ9:=+:@,* HN#2WW+XZN
M81<FUWL5Y#1Z%)0WT0O;&AFYG56>66=+_H9_':*W2$,6ZE!^0 ::CR[XW*.R
MXO60UJ:Q6_H';M\ST;QPW<;F]+ #I?H\D9/?[1:1>IHAC&EA980T<//]ZX)+
MO6NB*CVJ$FO<J[+JW*K*ZEVK6NK<RKHJ*<6]Q7\#Q*P2A[A-4I"[0QJJ]\_^
M>5I^WKM^Y:7CUS37W7^HL__*(V/ULW>MK!JOV9-+A@GL] %R:%PO+2ZTVRO-
M_PPGV[N=7\AHBRREM K+75HR*XFMI56$UN8JYZ:>,F+MN<*_ 6+1[D[<* F%
MVZ6@89_TYQXYF>>7E!;>&U5=?65<YT#_N*%ZVT-+B\J[=L2<&W@OX142/WR8
M*@BXZ)GH/> KHI_G9[N=B\PGGA,6.O5E%>/Z2DKL^QI+''K["G%G!G+_!HA'
M'=+62T+95DEHVRWY9N"P]/T[1^9<&5-;>_Z5]H&.EP9JM4_-S0J>8/"I#_&T
MZ/MDWZ"[M"#.;5:DYPUN'&4D*)%X.2+5<3@N'3N4FHD9S,VR&:S(LAYLS[(=
M&A+]#2!$VS\+W5/6;!+_U+U=_/&U;1)7GLC..S>ANK[]G?;!VK?Z)XM>FQJE
MO\)@XEXZ$4.?N]'\GWFR6$_8?O2' 8&N]T-"G.]&A3O>3HBTOY4FP-S,C;&Y
M61IK=:,QUN)&SU\!2<O%H7"U.+2L$WLQN$+LZJ/UXN<F#B]HGU+=4/WYU(&"
M*3VE](\F.O$?,.9A'PAV >^I3C[OF&2/-QQWZJM ALN+,";A6;2WXU,AVWXL
MC8-YDNUG\Z3(W^IQ38#%H]:_ M*6BD'5,K$/O0N1D5MSD;Z)#9*MGPXOKOJI
MLB'_I\;>U!\ZQV)_&*N%_K#5]?]!,/'YX6[%^.Z%H7SE.) _\_'.4^$$_(<8
M(NY]HHO].Q$9,YGM:O.VB&+UMHIJ\:;1_6^ @D7(N[9YR*4+,DC?@[E(\^>-
MTI4@NR07%-<G@=K.*- ^S >CXQRP.<D$IU,TH.JZ M. !!QC @2:.D*8N0-$
M6V!!:(GYE69M^S/+QOI'H:WE]PJ,Q?<ZN[]ALF8V,MPU"^D>GHTTOED@7@:;
M9^? X<5".+8F'%2V^,.IW2PP/$0#2WE7<#Q.!#<E/'BHX,!'%0L!ZA@(T;"%
M2$UKB#ME!4E:EI"N;0ZY.F90HFL*57I_P^562:2S5PJIORZ-%/]:))$)6V?'
MP_Z%(2"WPA<4US% 8XLKZ.UT K,]]H#=CP'B(1MP/VP%3#D+\#UB#@'R9A!R
MU 0BCQE#K((1)"H8@NBX >2>T(?BOZ*K0P*IO2B!%-R3$!/!$HDXV#(["';-
M]X:#2]SAV$HBG%SK -H;;,!HLP58;S4%W'8C(.XP!.I.??#8I0?>NW7!;X\.
M!.[1AM"]6A"Y%PVS?9J0M$\#TO?_#75GQ9""$01)?B4A%@U+)0)AG;07;)WC
M"GL6.*+GA2V<6&X.ZBN-0'>U/IBNT0&;=5I@OUX3".LUP&6#&E WJ@)CXTGP
MVJ0"[$W*P-VD!/S-BA".$KWE;P#.>@GPWB4-GG)S@7ML(82<7 X1.NM!8+X3
M(AT/0YB[(@3Y:D) F 'X)9B#3[H->.7;__ HQ7^C53M_H32Z?'9M=YTB]U ^
MD ;<WQ*&Z1/X:XQGN/L>C^W'F??MGOZ1_^_P_Y(#>J_PV2D-7K)S@7=T(80I
M+P>!]GJ(-=T)T0Z'(9*B!*$^6L /-@+_."OP3</^8.7BOWH6$S_3JURGJ W4
M#VYM]/?D;H])T@!SPGF8]1Q_W?L);M3GKOT3WQOVX]Y_ OS^Q\'GT!P(DE\
M44K+(4YK/0B-=T("5A9BR<H0Y:4#88%FP!=@?O@GX[^PLURFO K=WWN4>TS2
M:KW>4)I])EP[.2]=^OV?$2_Q'CO=#+R-N\^_@GL8,.3XQ.]/ !=U8*/[%PZZ
MC_O]+DB,XC(0:JZ#%*.=D(R1!2%1!6(]]"#*W_)7:(3#UT"ART>_=-JD=Q[S
MM6<)^R6]VO\YM3'PJ6M'\)C+^;!'Z(W\MM,_49?QMR,&G.X']1$>\OX$^*/M
M[XLZ< _,^?==D'BTLY(UUD&ZP4X0V<A!"N$D"&D&$,NQ_A$9ZC05$D>9#$AE
M3OAF<YY[%06.,RI"'U,;(A^ZG8X>)9^/NT.Z*KSD=%78[WPCNH=X-^P,Z7[0
MG_C7@8,Z\-#N%J"-DWABZ;_OQ&3I[X L*SG(P*M"*M7PN] ;\SF&3WH?$<V8
M"$KR?>:7P7_"RH]XX%$6>\^]3GB;<CKE']<!T9#S8,8YXJ74;I>1A';RK:AF
MU[MA?P("4 <_U(&_5P9B4(=DM+,RU-="KMX.R+.0@QR<VO=,5^-/J4S[=\(
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M[]132_9H+J,'5.:S(@NSN,+,M*#TY*2HW+@$85%4+#HM,445P=&UE?R8SLI
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MO.C4)UPOE\<A;*?',7X.CY,#[!YF!]H\* FR'*T+-A_M##8;'0DVO7TOZ$]
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MR<T%KQ,+P4=C.?@:K0,.9AOXD/>"E[<<>(0<!UK\2:!F:(!;D3:0J_3 I=D
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MW#YBCA _$A0</U*4[*>\3MI.<=6MIT(T+:9BM$P_I>H8?\K3,_Q4J:__N<U
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M@5G@<F0.N*DL (K.4G S7PUD_$8@,;8#P7\/.$8<!(=$.<!F'06[(@7 5)T
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ME4ZNEUI<G2[UN3M<FO2PNW3 DW[YLB?]T@ORZR^N]N?1V?X<.JWD20O U4&
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MWM,0J=]>FV#:5)5N75N1;U]96N9<6E+O7EC4X95;N,DWJV R(#U_?V!:_KG
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MZIBZ2@4+.96PCDL1N[GE<91;#G?SR.(9XCZ/#+XG%OYEG)Q![RXRG]R!XGF
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ML^R4S189R=NMTI*/6:<FW[1.3WUGFI&.^ED9J)V=B>K+8=#270!X0)KO>A'
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M!-!X!B#["LA< %%""!EA+7*0F=S @WS A0*PBJR%'26 !>6 $56 2M8"9"V
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MA/KA+*B;_+\8.P^HJ*XNWN\[#09FAAGJT#M($110*0HHO??>>^^]@W011%#
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MS9#@!Z#H+P,BN.C(6@07&L$BDZO_8/XNT1D@0*(H'^?N\A. ]4T DWL VH\
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MQ^3@14F3 []QIN[[S#7>2[C&>PAO,CMP[0]C_@K,7X3Y]3CWXFW8 _30Z'T
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M?2@'RH_40/&1/@@?3P/YQU8@]ZL#R#[Q!NDGX2!XF@+\WTJ0!<![-@"\WW<
M]_?SP'GV!#A//P+G5_(/>C&_=>3+&536 <P_COF8[8395IAM^@. [B\ JK<
MA$]H(/]&$F3?"$#P5@'X;]6 ]TX7N.^F@N3[&<#^8 =B']R!\3$$Z)^2@?:Y
M!.!3&X(7V4=L[L=+R%/D(_+IO[1A?I7H#&P"(!;G[G\>P/$RP"S,-L9L+<Q6
MO <@\QB _QZ 1UC )1R0('P0([+ ($I $0T HH],0ZP1)_AS@TCPABSZ"XG^
M/'O <1 L-#F%W/L'-9B?B_EQ^*V BP .5P%F8K;A;0#U^X!UQFP<.@?SV02
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M2TQXH9642-22$XER2B)13$DBPJ_\+KH>17W &AS"_-T% %MP^S6,]!<PH:=
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M!#\, ?_'_<AUX%]Y"?SO"/ O$XI_Z6]68OYBS*_'VA?AW%-QWA&8[7T$\T\
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M1[S/<C6[QW)$8HGE'HENJS.2BZWN22ZR?B/1;DW8"VV(."(V&5'^<\R_@S?
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M<4$[Y6*#OI&/"7H@%QO\7CHVF$C%A1 >PD4X(AY@'RYAW8_@W'?C)FAS,M8
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M=M5ZKG75/IYU]56N=>5SKG4%X2"2UN5_<QAKL+T08#WF]V-N5P/:<!- 13-
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ME?VLC&V=07]'W0"\Z6=[UG<*ZVM$7IU'^9=/U?F71SM$OE'O$OEW+D3!\G2
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M%ISPCBPX_@="E 7'B4*(&E?)<3*=\Q%Y-S,4'Z;.'Y3.X5"/-]$?Y;0C)U%
M6KP^DN,G(#%A&N(3'!"7, LQ";Z(3@Q!5&(T(A.3$9&4C?"D$H0FU2,D:8X0
ME+Q8"$S>( 0D[Q?\4B[)_%+>)+X7_))%%9)$P9]X,IE](5N5!QHM 5:5 8N(
M;NKQ.MI5PK]ETL;$%%W$I1@C)M4<4:FVB$AU1GBJ%\+2 A&:%HF0M$0$IV<B
M,+T( >DU\$_O@&_&@."3L4[PRM@G>&9<$#PR7Q,\,K[C:U'P3/\;YUG^88:;
M.Z2].-3@0PS#%U >S:Y@.]".0OHDC;;$9&DB/,L0H5F3$))MB:#LF0C,=D=
MMA_\<\+@EQ,'WYPT^.3FPRNW"IZY;7#/72"XY0X+KGE[!)>\<X)SWBO$ \$E
M5Q1<<M3(%H4S[ /[6?^MY%U;QS%9#_01;;74//PLMYS:FW^/*)(AL$ ?_H7C
MX5MH 9]".W@5N<"SR!L>1<%P+XJ&6W$R9A7GP+6X',[%S7 JF8>9):LQHV07
M'$K."O8E+\*^Y!O!OE@4[(M$P4%"H2@<9SWWL/Z;R+NZF>W0PC%)-#>K]J%D
MTJZX&B"$]GA5:,.]P@BS*LS@6FD)E\H9<*YT@U.E'QRKPC&S*AX.59FPKRJ!
M774#;*KGPKIZ"%;5VS&]^C2F5=\AOL+TJK\PO5+$] I1L"0.EZOWXK12>W>P
M'3HY)CO5^U#:@11*@DC:Y$^;9C7),:-1'_:-XV'7: [;)AO8-#G!NLD35DU!
ML&R.QO3F5$QM+H!%<PW,F^=@<O-2F+5LP:26$S!MN073YB\QL>DA)C6*F-2@
MPKXZ]7FH.1P//6R'7K8#44GDS 7B^5E(-WU .%)"6\W1A,6<<3#O,L64KJF8
MW&4'LRX73.KRP<3N4$SHCL?X[FR8=%? N+L=1MV+8-@]BG'=1V'0?0,&7?=@
M,.=WC.MD]"QAMHB=Y-_(\H>DFWK[J?\ID>L'J/^)5"*2\"5<"!O"G!@_H VC
M188P7&1*3(7!(GMB%O07^1&1T%N4"MU%1=!>U BM1?.AL6@ME /[(1^X#,7"
M]XCOH5P@0J-?A2VLY_!\^F 1UX<E0,M2S@GJLT!QE,I!*P$WPHZP6$4-NAH8
MMT8.G6$]: P;0;%F$N1KID-8PT!H#?7E,!?_82X^:SBHU[ 3K:&#U["PU=1W
MJY_@X'\%6$EAN/(/5EP<PX8%?)![@+RSR5.]AOIW+>>#]4#H1L!S!' @IE*?
M3]A$_BV SE;JT&T,?K<Q$-YF0DPF& 1N9^"SG4'0=BXRVSGQ;"]478"TC<[=
MQ@*V45AOI=;=0J&Z^3>"-FP2QW(P@^3N'F8;4)H7\I^FD"=\.^"] YA!\Z?M
M)O\>P& ?H$6-SB":DXJ"T"%HQV':<81V'*$=1VG',09%Q[@0'>-$>TRZJIP=
MZ2@=>)0%'*6P/D+Q?/A'XD]"5.5@UJMR,"64Y6F[V ?X3[W)-9-<4P^S_8\"
M^B< C5/DIFRG8%&#HN0\_7&!=EPT)A@@/\D ]3+MN,+ Y"H7HZNYJJNJK](7
M5S<3+.0J!?V5^P05S>6_,)_^;J5OR\F=L1^(/L(^>)S\)\E/>6[")M2[ ,@O
M27D7XKJT#T6-&\2SQ"V*I.<H4FY3%#QO2H' @/@5VO$J@['7N"B_Q@GW=0[\
MU]G!7F<%W[A,O$-\0_P\EH.IW MDL[XQY/4[2_[S['_D-":GSG4UURUUWN4E
M]9Z05]7YD#<?Y4-DP'M:P(?TR2=LF[L6P!<S"09)7W+A^Y(3X7T.OJ]8Z:_8
M+[YB);Y^B_@,U?1Y+C^*(W< >1W):_$48,3Z:4OYGO_>AR+E7#Y6[T%Y_'Z2
M?^\+83_Y3A?XB6WS*X7*'_3'G\' 7^P;?W$R%#D Q:WJFU*O$<^K]QH\RCV8
MC&END9I;M0=#NBE5.@,BW5):#M4-H=)>$.E>$.E78Z0S,:N(]<1FJ,[$',1?
M5((/J3-_I^-^H['231Q2WD/:^_$35'L_I!S$7:C.@JCV7NBK8:#.QTC[41Z=
MR9'N!)%N*2T:R\7\A2:6WTD%W<OR!UC^,I:_FN5OH%[>2K8]Y#B"!U2FW^!I
M?(6WZ**O\06_)>4]I+LW[JES'^\^RC^,Y3ZD?0\:C^4?I+M)9D!U)T@X^9+)
MDT..TK&S* _0PO+GL.0^EC_ \I>Q_-4L?R.;9QOKMF_L+,H'5/[_H&+_/];X
M35HIG4-Y50WI/,H+4-TKJ\HY/,H_*,;\\3M,^0UKUFD6_D5??(,8^BZ-'/GX
ME&WR$>I8?@O+GX-W:,>;M.-UVO$JUK#+CK#L'6R%0RS_+&[2%\_P7SU%RZ_3
MB]>@.K5TY3&(LO_\0:(?H4E.(];-G'6:03XOO,=^\39U_VO4_2^AD#6KP&W:
M<8MVW&"[/,UVN4X[KM&.*QAF3]B$BVR3<SA&*R[A-*TZ24^=8,M)IZ>DK-DQ
M-:378S^"!-5EP-^JN_A'T"/G!/K+BGPNK(\_N2)9ER1R9+'40ER@'>=HQUG:
M<9IVG*0=QVG'4:S 8:QCS]R&_3B O?P7N_GMG?B0WOE^+'NW38VM:DC[8'Z6
MCKIQ.'W$J?<MA90*5;*.AN2<C,NP)Y\[2PK"*423)X4]+IN>+B1#!5N^EC5N
M(4\G>?K(L9CEKN(H&>7_]K"'G."HN8JU'-S#]/ :]DWI=-DJX6_\QBGE/H?R
M^Q,X_4A;[Z34,Z>\)V4Z[-G&+&$J.6>2SXLEAG#TQ6*[D(JMLFQLEA5B5%Z!
MC?(ZK)>W8*UB#H85_5BM7(:5RG58H;$#RS2.8%#S22S1>@6+=;["@.Y#+-03
ML> Q2#F8CSFEO31=M?_C(E^?GLAEAM/N(6U][-$TQ79M:VS6<<%&75^LUPO#
ML%X<5NNG8J5^#E;H%V&9?@66ZM=CB4$;%AG,Q8#!8BPP6(/YX[:B;]PA]!I>
MQ%S#E]%M]#7F&(OH)&:;_(TOIJI2W#<XK5XD3CA0_UL#NSC%;3618V2<(88-
MIV"ED3V6&[MCT"0 BTTB,# ^ 0O&IV'^^!STC2]&[X0J]$QH1->$V9AC.A^S
M35>@?>((VB;N0\ND)] \Z0Z:S+Y P^2'J)\B_@<^ME/E8*0]**<\R,_G3B=J
M#7X^/(TQYD0]+)EDBH5F5I@_V0F]4[S1,R487>91Z#1/1(=Y!MHL\M!J48IF
MBQHT36U%P]2YJ)^Z!+73UJ%FVBY433^%2LN;J+"\BW*KWU%F)?X'_H]\-SRY
M!'.I/>)'K</G)H8APZ[4?/3) DLM]$XW1I>E!69;V:/-R@TMUGYHL@Y#@W4L
MZJR346N3A6J; E395*#"M@'EMITHLUV($KO5*+;;CB+[XRAP>)KX&/DS?D'>
M#/%O.'"^8OAUS4^5@SD0PE"'6,^E;@7#D(6S&.?/E*/=;AR:[<W0X&"-.@<G
M5,_P0M6,0%3,B$#9S'B4SDQ#\<P<%,TL0:%C+?(=VY'G- ^Y3D/(=MZ"+.<C
MR'2YB@R7]Y'N^A,A(MWE;SQ/KB?)?SR<.D/:@T*L"0.6T(Y>'Z"=;=/@I(<:
MYPFH=)Z&,A<'E+BXH<C%#X6NH<AWC4:N:Q)R7#.1/:L06;,JD>'6C'2WN4AS
M6X94]U$DNQ]"DL=E)'F^@T3/'PA1!0\5;C',.$_^P]3X.QB*;B2&&/XLY&==
MM*V)=E2Z:Z/4W1A%[N;(=[=%KH<SLCV\D.41B S/"*1[QB/-,PVIGGE(\2I#
MDE<C$KV[D."]!/$^&Q'K<P QOA>%&-\WA&C?[PA1 L;@(^)IZ?_^BF([4']O
M2Z+V)Y8Q])E/.SIH1QWM*/'10+ZW(7)\)B'3QPKI/C.1ZN..%%\_)/F&(M$W
M!@F^R8CWRT:<7PEB_>L0X]^)J(!%B Q8CXC ?4)XX'DA+.A5XE^$*(0%_ANX
M%J[* ^UE&+PYE>V0QG;@LS>1<3Y]0PF'_" 9,@,,D!8P 2D!TY 48(^$ %?$
M!7HC)C"(B$1T4 *B@C(1&5R(B. :A(=T(#1D(4)"UB(X= ^"0L\)@6$O$]\2
MHA 8JD)0"+4_?7",?+O)/9K)\#^+FI//;KYOI#_*Z(]LVI$2JH?$$!/$A9HC
M)M0&T:%.B SU0$2H/\+#PA$6%H?0\#2$A.<C.*(*01%M"(CHAW_D&OA%[H)O
MU%G!)^H%XFM"%'PB1<%70H2("W'J/!"Y-S $'LKC>.1S#B5*+3\OHGT9L=1\
M4=J(CC1"9*09PB.M$!8U R%1;@B.\D505 @"HV,0$)T"_YA<^,64PS>V&=ZQ
M??"*707/N!WPB#L-][@[<(O[BL^_X!XKCL&#>((<!Z4\$+G749(L*V)?(#KR
MV0ZTJR"=FH_M%!VO1&B< 8+C3!$4-Q4!\7;PCW>!7[P7?!."X),0">^$)'@F
M9L,CL13NB8UP2YJ+64E#<$G:!N?DDW!*?H[X$DY)?\(Y281SH@K2W<C2O3B;
MR;NF3'46J)?/UA+&^P6,=_FW9-H2D28@($4/OBDF\$Z9 J\4:WBF.L(CU1WN
MJ?YP2PW'K+1XN*1EP#F]"$[I=7!,[\:,]&5PR-@"^XSCL,NX27Q./(1]N@C[
M-!6.9:G.9(V0>U6UZBQ0-Y]-E(JEM"6+TB">MH30%J]L+;AE&6)6]D2X9$^#
M<[8]G+)=X9CCC9DYP9B1$P.'G%38Y>;#-K<&-KF=L,X;A&7>)DS/.XII><\0
MGV%:[N^8GBMB>@XC5^(0?;Z=_.O)O:)!=1:HDZCGZZ):ZB[:$DVY%E!*[5LL
MQ\PB?3@4F<"N: ILBZUA4SP3UL7NL"KVAV5Q!*:7)&):20ZFEE3 O+0-4TH'
M8%:Z$9-*#V-BZ5,P+?T4$TM^PZ1B1O 2BD3L8]F;R35,:3K8"O2UJ_:A5+>I
M]J&P61%&>[SK &?::5VMA6G5XV!1/0'FU1:84FV+R=7.,*OQPJ2:8$RLB85I
M308FU); I+89QK7],*I=!\/: QA7>Q4&M1_#L.87&%93352IL%/:B]-"*4XI
M-D"9WMW]G_M0HF?3!_R;&^VRIUU3"=-6'9BT&A(38=PZ#49M]C!L<R5\8= 6
M3B1#OZT >FUUT&V;"YVV5=!JVPV-MO/0:'T=FJT/H-7"*+Y9A;'S4)W TAZ.
M!TJQV?/I R)OOFH?2N@\]@-B)O]F24PBC/H4T.O3@TZ?$;3[S*#59PG-OAG0
MZ'.'HB\(\KY8"'WL:'ULQ#Y6HF\I.[ITT28%[-P7N!!^1?Q.,)+M%L?N!5[)
M<A<MX$?JLT#%2]@/!H$H?M6/<":LB<F$,:&_3(#&<AT(R\<!R\=S0$\A&/@L
M9R"PG(O@<DYJRY)5 WU9$T'-O90Z<RD%_"!%Y))[P.)?"7$,4@YF*;GGL^RV
MY4 %I7'V*NK/-4#@6F 684-,7D?^]>3? &BP.(Q0:X\P\-S(H&^$ >$(@\ 1
M&\*%8# PPHE^A+X88:<>Z59=_+J1FGL#!>WZCXB?."&)8QAB?1>MX%@@;\TP
MVX <B:,<BYL!]RV '>7I%+K1F/I<;R>@V$7^/<1>@6!0OI=V2'M2]M&.?0P
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M7']AY#/GM*)I:D_(,15ZK[T[\L->P>#%@I5./0K J* .(RBYF1;0#D8W&)/
MF ;&+% 7@K&<<M?34G9J!Y]N1;LM:+\)*V[0'^PS>>ODF%D<EO>\P&?8^17=
M[/U<;_=V3$F?DP>_#J!.8> EX.%,<(K J *C 8QF,-JI<3<X?=J,'AO18P/Q
ML4XKM88[J^P:G< ZUVH)'>HBO#M$"UI(U)M9SF'Y,]WJDZ'@A\,[S?+#8,?6
MT$O1[0A]QWY9B?9(;5<2]<D&IYA:5J%_@U:CQTKT6*'QX/2!,UV+B8\A7BW@
M&_.PQ1RL-0N/S=0=1/'C1-#;&G#Y6M-=;3_(\W2GOXAS'(-U'6G(9;'2,5*2
M PP]N[#+%G<_,(/!BP$K1; 6+78IT9!+M1:X-FB>6[/FNK5KMGNW9KE/UJ#[
M# UX+-!TCY6:ZKE54SP/:K+7Y>KSODT3O1_3!)\WU>OW)6+[09X$]]XTAJ],
M>"]RG-<'2$5VQI!Z8)]5 6Y:XF/1 N]0S?6)TVS?-,WTS=,,OU)-]ZO6-+\&
M]?NW:(I_AR;Y]ZK/,E43++/5:UFJ;LM&C0O8KZZ ,^H,N%7M@;]4N_4MM5F_
M06QJ"[+9KX^2?OW,S,$4,,07.,X V4,JM)DA;U4\:1<VF1/DI8$ JZ8&1FB*
M-4&3K!F::,U7K[5,/=8:=0>-U+B@5G4%C5-G4)_:@V>H+7A(8X+7J35DKYI#
M3FITZ$T:%?J(FL)>5U/XUXCM!WDPQS',7T7Z=8)A]@#7[;Q?E^-(#^?BH^E1
M+NH+M:@W-$3C0V/4%9:BSK!LM8<5J2V\0F/"Z]4:/DHM$>T:'=&K41'3U!0Y
M3XV1J]00M5,CHH^K+OIZU<8\I)J85U03^Z5J8VT_R#VDH#?"JR]G>+V$5'1O
M-3$ OUU9#-_#)H,,O9/QS?@8'[5'634V.D*MT0EJCD[7Z)@\-<64:&1,M1IC
M&]40VZKZV'&JBYNLVOC9JHE?KJJ$;:HD&:M(O%;EB?>K+.F/R.<J2[9QM:D<
M^3GUOA;<T_7X@>%U-[(1GKV,=' >>DQ#CU[BI#W90\T) 6I*"%5C0HQ&)"2K
M/C%+=8F%JDDL5W52G:J21JLRN4,5R7TJ3YFITI0E*DG=HN+4PRI*.Z>"M'M5
MD/X[Y%/$ID*GW '6.? OA5M?W"3M0-:1?BTA%9S%9U-*L &I86NFBQI2_567
M$J2:U$A5I2:H,C5=Y:FY*DLK46E:M4K21ZHX?:R*,GI5F#&@@LQ%RL_<J-RL
M@\K)ODK9V7<K*_L%9>5\HNP<&^]MW+?I5NI\)?C'28'WDW)M0]:,)A:Y-X@>
M?>C1B1ZCT*,VRT<5F5:598:I)#-6Q9DI*LS,4D%6H0JR*Y2?/4)Y.:W*S>E6
M3NXT9><N5&;>>F7D'5!Z_EFEY=^EU(+GD'\HK<!FE_1\FV["]E> >72,<R\0
M]&B5.8L$7::C1R]ZM!$KC?BLLL!3Q7D6%>:%*#\O2GEYB<K)RU!V?KZR\LN4
M55"GS()F911V*:VP7ZE%\Y52M%;)Q?N45'R%$DKN5'S),\A'O+8I$4DJMNEZ
M;']FC.//H7NZH"=F'0K7^>WF+!+X%I^/0<\1Q&MYN:ORB_V54QRDK.((91;'
M*[TX56DE.4HM*59*:;622YN45-:A1$AR0OD<Q9>O5FS%7L547*;HBCL45?EK
MY -%5]JXYY!KJ.\I\ _![7>1@F^$GBWG.A==IJ#'./1KP4YUQ$@)-LFN\E%:
M18!2*D*57!FCI,ID)59F*J&R4/%5E8JK:E1L=9NBJR<JJF:6(FM6*+QFM\)J
M3RNT]C:%U#V)O,_K?W'/QF?D$-C_!/@'2#=WP._73R8>N<Z&'DWB?B<V&<UW
MJM&U$)MD-'@HL=ZBN/H@Q=9'**8^7M'U:8JJSU/DB#*%CZA7V(A6A3;T**1A
MAH(;ERFH<8>LC2<5V'BK D8^CKS'Z^^Y9Y.UP:8KJ.\Q0\>@R-O@]6N@1(NF
M.?;B3.RC3:);([J40QUST26E58H9[:.(48$*&Q6JT-$Q"AF=K.#160H:7834
MR-H\6H'-XQ30,EV6EL7R;]DJOY9C\FFY0=XMCR!O\/I+^3:3.2)GP#@"WMX9
MCC-I5\XB'F<Z]N+TH$\+NM6B2S'?R^R&>Z%S1*>[@MK]%=@>I(#V""1>EHXT
M^7?DRZ^C0KX=(^73T2&OSBGR[%P@]\Z-<NT\+)=.N'_'@\@K<NGX%+')M9U\
M"OR#8.Z:"RV>[UB',M^<"0LUZX*2C$27B@&XUU1L@#[1^"FXST66B3[RF1 @
MKPDA\IP0+?<)R7*;D"W7"32@"70X$\8Z##EQ#J_7(G#-"7#_"61(O1"37K*W
M'K*X'O(Y\/>#O6T1='P)8P0T?1;7B;P?LY!8Y+-B],N@J#AL%,;W ]#+9X:W
MW&:0^ PPR \PL TPP TPP PP\ W0\0X0R ,$]P!?G@['FPYQGP:AFP:)FOH"
M M?L1X=^FXZ LP?<S7QM]2K\L)JO<>V")H_D7ODR^#>?)Z)7!!3)BFZ^B.L0
M/&H(;KD03K>007XA?'LA \L".-4";+&@ 2&(%F# !?QP/@1_/J1V'J1U[F\8
MC#]"OB?X;3JPW+$7:,-ZQSJ4F<@$I'6#5(,4("E\%K5."L*DOH@;HK5P[;4D
M?FNPQ1JK<TT*2<<:^/8:.M75V&)UBV.R<S7&7&4V^QPEX""5*R"IR]\'\#O$
M9C^/9>MF?K85-;?3)Z!N.S)B)S[8):5QC4:"$-^=9@T*^-PGP>/J1K*#'CO1
M8R=Z[$2/721BN_#)+@:\771N.VG<.PGX':L=#R#>3EQN(W/>2B:]!4:SQ:8=
MVQS3-(OVX#*HZ+C]^(#P*8.B9R Q2- A\!&9-2B7($<O%!>$Y/,HB=]1]#B&
M'L=(#H^;I(RDX#AQ<8S8/#;D>!#046+B$N+RR,N41U9_V&;?"[0,W$&P>H[0
M'QVC'9R0LBZ58D^"CPM]AM>@\',("PG/3\3,C5SMS@#L(UU#0GPM\7$=>EQ/
M;%R/3ZZGP[T.6UR'0Z]#\6MO1>#]U\"JSGVKE=1O-G6;"&X+6%7@9(,31]E!
ME.T]/.]R@\P?/06A<LR%#,OPWISAN9&[B-5[\,U](=(#M)4'B(T'B<\'&00>
MH@$\B!,?H. ''N+U7[A^JGE@3P)[++@UY^@+KP??>1:MUZU.C#N=\RW#<Q(/
M.^41Y_S$>3G.*!F>#_FUF^.LUA<@"K\E&?PML?$[!L#?TP&_1 -X"5O\X1:$
M'[ST5_5?00R"74<]"\!, #,(3*][+L!\Q(DQO![D65VP]D0_GM7ZLG,NQ*P+
ML3]#!CT^P!X?DB!_1"+R#]KJQW1^GQ 7GV#P3S#</\UJ!#?G'(2[<S[$[(TQ
MSZ<U9Y*:_3#F/ [S?!AS-JI9"S(#CCH/IK18>!+VN%Y?P[2^I*%\H8OACL?M
M)RQ\@O/^ 5O]$.-\ )/^.]\:/H?4S$.8O2"_=,Y!_/?\@YF+,6>"F.?"YNC?
M<,QO-1*,-LHV>U'Z*7N0LN=1[F+]S?YLE/5PYJW.9Z,<P@R7ZC6"]16"YV4,
M^1)L]O?\TIS!8?:__-J);>8@?OX_=/B7O/45_.XS1>MCN.Y'<,R_J8;R1^L-
M^/:KFD ]^O5']/@]>OP6%OD"#.PY6.8SZ/$TO/\I6.(3,.1?$<SG07F$=P^C
MY8/ZSK[VXS[G_(=9?W'=!3K\VSD'\2&^>4<6ZA*F/V.+E^"8+ZJ,\NO1OX72
M.K'A!,KNI^Q!RIY+V8LH>P7U6J=[8,%WP77OI/.XG89\JVX&RZP(^8.NIV;#
M9X&:)_J8,S!..76@Q[0_;N@=9U@]3UP\I2"PHL%)I81\=*^D:310=BME=U)V
M+Z5/H?P!/#^'^@Q1_G+X^CJ\L!WT W0GE^HTB">QQ:64> R+'J6VYE1=\X0A
ML_["G++[C7/^Q6SY>L'9M!XF/N]QKL&X5?'4(1.,(LJO@D$W$G&MU*&3\GLH
M?S+E3R<29U/^0LI>3D1L(#IWPMD/8Q&S*N1FNO>'M0-/;B>RMNG']1=;['-U
MCJ563SN;X+W.KN<&;'$U<7$Y;>24DG4"GQR%]Q]1-?HWHG^+]A$?>]4-QB0P
MIH$Q&XPAREZIS?S;B ;K^.4:;+$:*ZZD02\GPI:!>Z&\[D&3]Z7N-.4[Z6IO
M='=TO9<1%\=I(X<50GUBP$H%)Q>,$C"J06@$HX46T:ZUZ+%&?5J%'BO08QGM
M92EW%J'50DI8@.7F4;,Y1.ELO:U9M#3S)&RSXLM<7Z1[?Y3N[.=T)3=PO8)A
MYP3Z'*:KVR<O2@G 7F%8-YY2T\#)HRZE8%1K"?&Q2,W@M(/3#<XD(G0 G'F4
MOYR>9!->VJ>I6+*?R)F,/R;A#S/+:4X@ZG/*D^'8WQR!Q1!S)</NB2AR.X:<
MW:0F6[#+6A=?ZF8%+P*L!,U7!O7)!Z<4G!IP&D!MQ@+M8/40I5,H?R9E+Z+U
MK.7.;K0[KG$NUZG+Y7YUNOY.'>Z?J,/#]H,\:N9@DAG"TN"]R&%>[^;>YDA2
M#^RRQ.*J>9[^FN46I '7*$US2U*_>Z8FNQ>HSZ-,$SUJU.O9J![/%HWW[-0X
MKPGJ])JN#N]Y:O->J3$^V]7J<U0MOM=HM.^]&N7WHD;Y?ZPFB\TNHY 'Z,IO
MSF)(SF6H-W]^8;C=1@JREK1L"6G17&PR$.BAR7X63? -48]?C,;[):O+/TL=
M_@5J]R]7FZ568RPCU6H9HV;+>(T.F*)1 ;,U,F"9&@*V:D3@$=5;SZG6>J]J
MK+]53= _$9M=:I&[LQS;;\\4.Y;![BF"[YD],*0@"TC+!K')9/PU/LA;[8%6
MC;6&J]4:IV9KJD9;<]045*21015J#*I70]!HU0=WJ"YXHFJ#!U4=LEA5(9M4
M$7I0Y:%7JBSL+I6&/:>2\'^H--SV@]S!\'Z.%/1D!=R?H6T'J<\ZWB_A_AQL
M,A4[]9(&M$>ZJSG4HI&AP6H(C=*(T$35A66H-BQ/-6&EJ@JO5F7X2%6$CU5Y
M1(_*(J:K)'*ABJ/6JS!JOPJBKU!^])W*B_D-\J'R8FW*CW'(K68M#MC'X;3[
M:_$#L@:>/80>,PL<:T#&$2<M"5)#M*]JHZRJC@I7952<RJ-35!:=I=+H0I5$
M5Z@XIEY%,2TJB!VG_+A^Y<7-4V[\&F7'7Z2LA,N4F7"[,A*?4GKBW[G^6YF)
M-KO<1+VO /<HZ>?>1L=9K*N@* L,12@CORJ$%N5(H]"C)M%+Y?$!*HD/47%\
ME KC$U40GZ[\A#SE)90J-[%&.8FCE)W4J:RD2<I(GJ/TY%5*2]FME)332DZ]
M34FI3R@I[6]*3OL7[VU*04RZ=P;\P_#9W:2?&T<1"[R>Q[UI?-:#CF.)D4;B
MM3+=344I_LI/#E)N<KBRD^.4E9RBS)1L9:04*3VU2FEIC4I-:U-*^D0EI\]2
M4L8*)63L5'SF2<5EWJ*8K%\A[RHVZSO%9=FXSQA&G4^!>1 JL!.>O\&L0^'U
M7'29@A[C\5$+L5*/S\J(U=Q,'V5F!"HC(U1I&=%*S4A22F:&DC/SE915KL2L
M$4K('J/X[%[%Y<Q0# 0I.G>[HG)/*"+O)H7G/8:\S>MO%9EG4Q1R-?8_ >8!
M./6.#N+1K$,Q?ZI&ETFCS%DD4G,=N1XQ4T*,9!=X*C77HJ3<8"7F1BHA+U[Q
M>6F*R\M5;'ZI8O)K%5W0K,B"\8HHG*[PPL4**]JJD*)C"BZZ44'%CR)_57#Q
M-]RSV>6L2?_!WP<5V0;'7P.W7@RWGDGJ-Q$].DA%1V&G&FQ2A&\RRMV44.RG
MV&*K8HK#%%4<H\CB9$649"F\I$AAI=4*+1VED-(N!9=-55#9D*SEFQ58?HD"
MRJ^7I>)AY#59RK_D/9DC<ADXEX"_%WJZ9:)S'0H\?P;O)W"_'9N,Y#N5Z)J/
MS5*Q26RUM\(K Q16&:S0RDB%5"4HN"I=057YLE95*+"Z40'5[;+43$;FRP_2
MZ%MS4#ZUY^15>S_R!WG7?B*?&AOWR6.H[R%2_]UP^DW]CG4H\^'XTWG?@RYC
ML$L]WRG%5MGX+ G_1(YT4W"#GZPCK H8$8;$RM*0(O^&'/DUE,JWH5X^C6/E
MU3A1GHUSY-ZX1FZ-^^72>"7!#4EH?)'7_T"^EVN#S7XV\,5F/])T:?T,QSJ4
MN<@TWH]'G]'0M&J^@WN5AEUBL4OH6/A_J[?\6@+DW1(LKY8H>;8DRJ,U4VZM
M17)M)9!;4;BUQSS4!H'$MT(F6R%KK1"'%HA!"[R[A0RNQ::CU'D?F-MF,4;,
M(1[GTC_.=>S%:>=^ [2D#%VRT3,1?2*PC96B_;J]Y#'>(I=Q071B=.;CXAR=
MV3@ZV'$$\#B":!R!-8[*C%N*0):[((Y=9$B=9$R=9&\=Z-!A<YP) ^;F!8YU
M*.;9Q(/0TQ[>-T-'JM&E /U2^5[T@!1,D?Y3)<^I<+I^$HTI#/)32#ZF1#DF
MMB<S $TN00CBR>V.A3V3AQR+*B8=E_K@5WU/$/!P_PGH,,&FB^<[]@)M&%Z'
M@DQ9C@UX/V()[9'/,BDB#JH8RG<MZ.6%:"Y)SEP2C#D6\\<%&G.86>2(,,#,
MQA:S:42S\,<L##?++/+90&.#5 ]"Z&8\1B?\+O(M@6?37LRT=95C'<H2LPX%
MZ>;U:*02:IB#)/)Y."X-0+S04<.RG$1P.8G@<I*Q94&.-2G+&."692#88BF=
MRU+\L12G+J&0)0=H^!#+19#5(<C@PJ\9%&S:N=9Q)NWP.I2^K;0%I!8IV"8E
M<XW@?B#BA9!,_BCF_1;TV((>6[#'%O38@AY;X+E;&&0V,_AM;D4(IDT8=-,N
MQ_DH&\B<UY-)KX/1K+5IFSF3%@JZ@)#IAY9W$+XCS#-Y]A$#2"02B'B9M2=4
M@Z2=CMTI%P\+?KG8FWOH<1 ]#J+'(1*R0PR\AXB+@]CB((%U,96]&*)_@+C<
M_QR-X6/$IHW@+@9S.ACC*'?D8?J"2Z1TZ'G4,>S_PSDH<JP_.>.<#_FIF/F1
M*[#)%<3I61+C*]'CJE3''XBNHK.]"EM<29!="=#9ZQ"(_!5_L^_)648]!L'M
M 7,4..6GZ8\I,XHR Z^0/'ZZ!N5&YUS(L-CWY#CG1LQY);>[D*#Z.,\H(2F]
MF]BX&Y_<PT!T-[:X&P?>147NHJ^ZZP_()YI-72><I*L MQ*\+$(F^EKJ?[WD
M?J.S_-N<<RUW.TG0_?K)7APY_D \/!]BUFP\X05Q0H_?D+0_P\#_+/'Y' /!
M\S2"YW#JLQ3^++9X]J^:!/:8J^@'J&,N]8H%,Q!WN0_/O0SOQWE$/ZX'^;53
MS'S(\-DD+UPP%S)\=NJ;^.9=]'B/MO(W!O_WB<^_TT8^("X^H.(? O3A+W_"
M_<UZ$+,'Q#PKQIQ):O;#F/,XFF36@CCVHO3#DF;J:YC&E[".+V ]G\. /H5%
M_A,V]C&\ZB-8Z <X\'T,^!X&>@<F_3:<>_@<CA>=:S >=LY!_/<<B)F+<:Q'
M^1=\YALXYA>JH_QFRNZB[(FPYZEZ%SW>1H^WT.--F.3KL+[7T.//<,R78=8O
MV?>B7(]Y[H9E/LV_]^US'V;URV/..0CS)-];_H<.7\N#.@7H'_"JO\-UW\46
M;ZJ"\ALH>XQ^KW'48Z*>1X]GT>,W\+I?PR^?1(_'T>.7,-+S,-1'X%8/P](?
M(%COY=W=E'"7?:>08_[#K,$PSR$Y>X$.9@Z UFK?VO2Z_/1'!8,5"TXZ&(64
M7TW9(['L6#V$'O>CQ[WXY1X-4O9<REY$V2M@MAM W4&3N1CN?HJF=!U-ZFY=
M1>!<2<V&SP(U:S',>1B7.'4PYX#\_8(YB*>(B_,*!"L"FR6"D4WY)7BWAJ;8
M1-EC*+F+LB=0ERF4/T!]YE#^$!Y80?D;B8C=8!S14>X>0:M#-)J+B8@#1),Y
M4<:(67]AGKK\N1S+F5YRAKII7O?(Q;X&XR9L<9W]'(P4,'(IOY2:U=)=-5'^
M&,KOI/P>RI],MSF=\F=3]A"1N1(--E/^17CF!-WZM;R[!\U>P%O__(\U&*ME
ML\___-;9[$R3O\/9#5V%+<X0%R=H(Y? ^P_ADP/P_HM4AOZUVH5?=JB%*.P
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M'EV6DRH-T5_,(3X'%016)#CQX*2"DPU.(8CEX-00G8U$1@M8G>!,I.P!WBU
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MDQ-$T(UX[U%ZFK>QWO>(S2X_)_VYCB'_-,/M(;JS7;S?B#XKT851#FPW</W
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M Z"=I#'0#M*K$#[I=6@[Z0"X%L#O:U \X!<.0L.3DC_WH8"?5B">- :R: N
M, 2XI#*@OQ @C.0%?<,.^F8?%1Y$38X/D9$2 EXD$,EN<HB8E!9<C! 1*2=$
M2"8$[2*3AG;N485V[#& \,F1T#9R/V@K>12$1X%RE( _2]X+KGEPK4 70=O#
M .]@V?5]*$[@.H8ZCQ7UG;R@3!'TC33H&Q'0-SQ )VS 7O>!\)IJ[Q:(E)(
M(B(G@7:1[X$(**BAG13[H1V4[! ^)3^TC4H2VDJE#.%1@Z"5&@0A-#[K+ZS3
M &>3!O4E?B#6HP;Q!?4*%"NY?BQ@D/SZ>2@.X+($OQN"SS2!; I 1U(@7!(&
M.N$!.F$%X2P=L%?R_5L@8CH"B("6&,*G)8.VT5)!6V@9(+R]H' O,&XZH$PZ
M11 D@L"0_AAPU+W6G75Z\$2B!S$O/? 2Z( ,=*M0M.SZ$FB \OH^% =P'46]
MBP-NUS@$9  ZD0)R"@-9N(#-,H+JJ8$<I&Q;($)F F@[(S&$MQ\,FOU@\.P'
MQLL(%,4(#(D)*)%)#ES EV8",18S"."849O7@;/,!)Q3)N!L,@(9]J]"D8#_
M*<#WN,;Z/A0[X'):@-_UU4#,!V21!^620!9^H!,V( <]L!]R8*_$/%N@'0=V
M0G@<8&)G!Q,(&Q@T[&#"90<&S Z$9 = #J!,#E A!PBL.4",Q7$&7.#)R Z>
MDFS@B<T&[('U&Q0.^(< WGZ'P;@$:D."\-0<_-0#XJN#S^6 + B@$VX@!Q,(
MEZB!G9"")NX2PH.V"H )E!],7GQ !EXPJ?*" <P+C(47&#$O,"1>H$1>$/OS
M@@"9%P33O""@X@&!"@_P%+@[@&*!#%S?H7- S!. KZ\!&)=&8%R"R\QP_3P2
M%2"+%"@7 '*P 9W0 YV0@Z81@ZKQ0?^ B1,$Y^#!*PHF= 1XV(F _A !_2$"
M;$($9<@ ) )B?Q%0J0B(;41 8"@,@@DA$) (@KA;$,@@L :=19V+"\)1;Q!Z
M.*'.A 67&;AT0'PO#V01!?)Q 9TP IU0 5E(0)4[@5[ (P$H"3S0#@)=R )=
MR !=R)"M)W2E07]( YN0!ITG#<#2@(DT<OU@3TD0O$D";TWB(6@#L >Q->@T
MZON9@<EX6H'G!(CEK6W!N 1#20WU.A&0BQ_(QPIT0@NJ(05ZV07DP0.Z 0]2
MT%G@4@.QI2J(MU6 72@#72@#72B!!Z$2Z \E8=2738,+=+0B8* (O!(%$$S*
M@X!-#@1"A]Z"-JQ!)T&1'Q#1':C*P0G8(PB!=(#C( ]D$0%EG);KWXFS!\A#
M"+IU"RKO8?CS^K$G!5RZ0(XCH$\.@SXY#,:(#M"%#A@?.J _=( 1Z6C\W(\"
MQJ<6"&PU@=>H 8(RM1D@_]J/[T9&[4-!?3>Q+;@,@/FJ@+\E@#P\H(S1'H(H
M@(S$0*:M/_(=X++ZX=R B03ZN2<%7.9 #G,@AQF0PPR,$3.@"U/P\#,%!FP*
MC,D$"&\"*C<&X],(S)6&($@T !&%WO?U?2A@"G/T!;>!GYK>H'O!)0!$9O$$
M-@#D(D:]AP-NAS9>J(4F8.IH>U,<@7TX$*P[0 Z4$&0/[,*>?_T@*#M@6':H
MPV="0&-!4&T#@E?KYZ ]JY#_<5 E,!5+<!T&ESRXA(/ .  7#?B=) #P__'>
MS<]KX_LXQW]>_ALOO/4S8_V!'/Z@3_S9UQ^&?L"@?8'B?/W7O[/8&XQ/KWY@
MB)\A3^# V@#1],'050)3B.A98 .A8+H%%PGX?1OJ'-A?9\&&07_R(1COXT#H
M[^J$@_$20;J^2!8!)OEPH(MP8-SA0(GG005A(+ _]P#4O0#9@?J-4$?Y@/LD
M(L$XC%X_#W8WN+;%_G3V4?M,-N9"4&>3H+V#\_.SE)\!PJ]S2S*!')E@O&:"
M/LD$8R03Z"(#&%0&:'1&!K@: .X%9 K,5 /PD@9\> &??8 /*:A_VZ\S4'Z=
M!_OK79Q?[][\^HGV'@[T)R?R*Q]2 ^RCAO+GV21@<JL%NJ@%1G@-,+T&P-<Z
M(2TP91P$//D!/T;P2",#C];M&_>@_#H/%E7GK^^I0>5"?NTY02W0HX+4W^_A
M0'_>ET&=H?KCO! P=W0#QZ,'V&</>#@\ KIX!#K_$6#X"%4!.N%MW;8=?R?!
M+D)BDMUD>\@IJ*AI]M+1,^QG9&)F96/G/,#%S<O'+R D+"(J)BXA)2TC>TA.
M7E%)645-74-+6^>PKIZ^@9&QB9FYQ=%C5M8V2#M[1R=G%S=W#T]O'U__XP&!
MP2=.GCI]YNRYL//AD5'1L1<NQEU*2$Q*24W+R,S*OG(U)S>_H+"XI+2LHK*J
MYEIMW?6&&XTW;]V^>^]^<^N#AVT=G5T]CWK[!@:'AD?'QB>>/'WVXN7DZZDW
MT[-OY^;?+;Y?^OCI\]?EE=7O:_]5PK7__WC[\;:@6KP#U60BT&925*,I0:MI
M4<W>AVHW"V@X!ZKE/*BF"X*V(U"-ET2U_B!HO@*J_:I  9HH#1Q!J< 0Z, 4
MI01+E!9L@1H<4'IP12G""VC"#Z6*(*"+$)0R0E':B #JB$'I(QZED&2@D724
M2BZC=)('E%*$TDHY4$LU2B_U*,4T <W<0:FF!:6;=J"<;I1V^E'J&0'Z>8Q2
MT'.@H5<H%<V@=+0 E/0!I:4O*#5]^[[F:H<Z20$\=_' ?(D'-P8L?__2%Q:%
M;::Q_UV5_6.-_55A,'U!>'A;MFS=N@WH '\'2@M #81$1,1 $[M)2<F ,L@I
M@#JHJ(%"?F@$J 3H!"@%: 6H!:67'XI9MR689GXH!NA%4PLUE,!(,C4_>LS:
MUL[!R=7=T\<O(/CDZ;-A$5&Q%^,3DU/3,[.OY.2!X8(:+=4UH(D_6@AKX+I-
M_# *5"-!*T$S03M!0T%+05-?O0:-?3,-FCO[%C1X?F'A'3"2]Q\^+(%V?_K\
M^<N7KZ#M*ZNKW[Y]Q[4?1SC"$8YPA",<X0A'.,(1COZGZ<5I$C4%!<O#NCK*
M:II*$ '!_[9 ./K_+2W]@_+9WG\ ^#R-"XQQA*/_?]+SKN&_ED]4)-7_=0II
MB78HF/H;H#,C(O>O@.7NQM:/?Q4"1SC"T?\*/6ZY^=>Q>?M2X+F6OY2/7S23
M019^VK3\>Y.O"*2?/KLIH#_AI!J/=MK;S<I'!MIK3B)=\[[^18BEEO**MK^4
MXPA'./J7Z-U0ZZ9#$]#KQC@?FY+/FQ5_:D[S5F(7.=&Y&:#VE(' +HCV6/4F
MY3T^"$((@G;I%FP"2!)97]W6V03PR9$!@@B(\ ETJ[ #.J1(R!&:9EJ:1^]C
M!Q0=$ST6EEU76G1]%#O@67+,K5>;B+=.<W^;O'"$H_]8FAUM;WJP>7%/VFE7
M4^7PF<W*FX-EV5&OYE9N4O[LK/2/T<UW?@X[H%2/] > VG4(:_G**<'U^8'
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MRB%,7TL9'1 "+W^*7@[YP '), #&+-8- ]A@R'" &>UU!2L,0$/.*2,QZM\
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MAV!6G0,K+X>58TQ267" %PP ?_I#EC# &!R@!0,LPP%2\%:0P !<\%RN, Q
M!W=BCL( N^%.S 48 /\1#/ (+F4[7$IN&  C+WX*!NB  SY3X6W?OG7=)<3#
M)Z;! *RMSCX?Z4&]:-\W,/SXQ:8+;SCZM]+B6.MF):TYH0Y:0C00)=;\8T.P
M,LTO:_#$+!X.WI@^D,+P8I[:$FRT)R(,K]AG*[K%Q<#*6RC1RS$"C%2XU6O
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M6EJ2BNXVOBCK4%.479],;-UM'&W_F(2DK01"V,X*:<>+$+-%\(H*BUCS6DN
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M *-W^->[Y__%;A,6L$4@Q1'BO +" B*\2$$P)"0$Q"1XA:R%Q(400D@[883
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M4X^FSF+<=G=TG A-RX!WZ%M^VZ/7#:BZ]L9+-QQ!1O0(.3Y7(AA:ROA\UNM
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M+R[Y^)V:![)C 0M^IBG?DJ:<#?>4RV:K0GMJ+1?\9<OT&=/,;=-R)_(0"GZ
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ML#-DM#-ANQ!9P+;N] "0>*,N#D/1Y>/.OSM4XY.25>0XH:;!Y-[<E@\1%"+
MBO'516"C$]'@-? L*=UF=,1*,T(BU=_YZ;$1;6XV6'+W/7XI2_=&+W&$-(XQ
M\M7F6W39X<B<5/O_T_?X7TS"%\?CTI*&%[4O ^(X4F6G/DMCS370UR8[*BY\
M-0."M#14^BG"77L\9?B']&!<^L7&UJ7PTF,S/).4.0>'?1WMCB3K,+92U%P2
MN66]Q1DH[H%J7/Y>BSAMEOGG]6ZJZI\[I$4YV> LB.BXPFX[%U1C?QQDUK[7
M8;Z"V -$]>7O>G1:6[2;B7RB]%-&"9C,UL,@ E[8S3\&3_SS3U.(QSKG! ;J
M6Q+)A1@.$W\5D8+>N?>H\W]5+1<XRS=3"=,%\>[C<E=KR%YV*_>\MY-3M[::
M2#/A0A6LHAE-&(;LBH?5'-NR*)I:]'Y %',04803Z'=H;4H4>;I:<MO&V:1:
M(:,S[)5[DTA%@NIDV4IL711,9VH^1?H+NE3@L@#LS(CC#JEF"V+FO#C1KC*)
M&L#,T@EP4]GH$[DX5[VY;=$% UZG.+X\7/O6!/W.9V8QO ##A!=#"'B"3?RQ
M/4/M^<>/G0=IPIBG5P0 9A='NXX&K\Z*J_'H^PQ!"6[KG!&F.%3>/,ZGCU#K
M@7Z$NX_ _E.2"QI#<L&2N=--.>N4UIEDZ_=NK?T'@;:>^0IC\B&OIE?4@N(O
M1!Q&: _C&T@6:T*JE\F$ZIPW-U\ESD_QP.=^:@T>AVB/3,E>OW_TF7.'2@;E
M&Z;*(NU4?+#%E#!"=IOC$$6I=2$4L;3."N*B5Y"%M7YWBU0A97MI/1!FX/"2
M#3G17 3K(YE)- >HN#WY]F/)5^_[2^2='P!K6-F:HG0SF)(*$:#F94;#0 CI
M;("9K&R"T9)3?$>G&)@9N$>QL1I&-I-%V>)M;\6'"*@:59.$=[*WFJ9E-)PV
MA'> SA1)5/W/.T3+N:;KM37=C9S*;]V>MI'_*3&L?%9+MUOE;YHL;@IOQ,LK
M@[I>CQ*/PEZL#LUQM9?')]G8+&@27E"HM)5I0B@Q)DT]"7O.L_H^^.G\BYZZ
M_R_?_:L$^^_JF0J:+G(#T?(&N].ET;[FPJ8Y'N8TUPSK A[C[$%9,8_#^R_H
MB4$QCL*MB\\,>BIQ&>,VGVD%RU_N>+?8,A'UL:OJZC$QKUG9Y:P7"\TIOE&0
M*2NN>IPH>/@I2;<:X,:U;%K PJ6/O68PU)W(*9\<6>F@/S/2HFY2K]%EW#>%
M]2F^S?KM76@0ANPLN7+,+M 9VNBTB(*-7>5V04[RWJ]S3.+9:RK,L-9-&_&2
MBTT<JY@FQCD*=J7H>(3U.'(C\35$5OI*'Q)7UJ*C-;A+MSG9"P4C0W/5VO@"
MYH$#0Q0VS@66BOV#: LN,U@'"7&L9ML*4E,6_(GSA ;S:: 2\3)>0JZX-%;J
MC,X!*GDHA_5!8IR8G[&:AM<S:DA[_"H7B6!R_2'C<QVC#^RCIZI+RK.P.7ID
M2:P"HI:!C<;*/RLT.L0YL,E(</@%W6EA:ED^99.RP&!4,H*/NC8XFAROP!>O
MXH>%Q8DL"PTQ,1&CI1.UN+QW+.9;S5RYZD\FL\\P&7ORJ4N(_?S5/PP?96;4
M/M.,EP:C-V7&T5Z\+Q6@?<*U4KB1=ZVX6DWH)'B3$5)E0QB_2#\=X!T^4G+@
MY.QX5;"5%P8<4L8V;$Q[2"CIM3S,='Y*.O$XVU\)509,18WIJ50T%^DT4PAL
MK2F;#Y2_P",E+-5>-TF(4'A]Z-":S,CI'"[37JUCIV^JX.LVW-V6((A+Z:SY
MC2K%I*.Y+4? Y6?2=(%NG]&8A</[<5E.P="5KB\,XIJQ5AQ8N\^!"VZA"5"
MBR12/\[/N2;/(GR:%]9BW8[3XAJ,F.'%#P]+))ZN"YSXNBW?\@7@N"P-)&%
M%^^2%I=$9V$EE)(FLD&IJ!%;''QZ\SKEUR?E5S.OY?2O7U3;Z;O&6"<W<$=
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M&W*?PU(P$H_R2-31-_.1_X*F-I:P=!.56>!J;*94))"JB(M$#K,5]NCJ*U&
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MXL>//>/G69,QM;_X%DBV12FW5<A/U+%C#M_#D593GQ)-<H?>C*_\FC?_SXW
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MU-,2TE$D4"Q!R/:X;1O)H=)T>7<UJA%F';8O$%NMA*\?IWC+1]'&2QHM&$,
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M50.+@;RH/:BG5)ZG9UI34]K++2-!%E^53]\:]R;.^GO#26F+^2B9<?C]J7^
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M_='/JDX_6M;XD>HFK >!17VJIN41@,1'C%$F@)2N854W@M&EH56PUO$0>_1
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MO,/ZHUA:)FL?#/&^>SE3GAN[-V!%YX!)+9.E'3D-$0,ZZ/QH\R:NE@UDLN'
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M3HEOYQOV%^&8)UX*,R!U*ER;"3 ]*5==ST.-$>(/!E;"C4SAM<VM>"'-%M)
MZWBQ,X[ZVGI DE7_I#]P"='MBV?W-VST#YCY_P9>_*^I_P7+O^#QO^',K3\8
M_^+5W[#H/\.#_29U=@^X_[O<1/\/8,? ?^9J8'F\>)_P-\F_K-A_7]__]N_]
M,T_'_Z**_T[R^]>_EL*_^-)_(9S_]K\X_5/.?T'NA)PO5<*?=>Z'^8)T]_S9
MQG4TVWU^[0E]/'<NT673"O@H$;V;2;.5-3#)F9"W\Q\>JOXMQGN+'4&7KUR
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MC)N=L42U1P[.(N#/Q1LX0_=![ Z0N_/Y!H7>+)>'[!W(CN?D+I'TR37^V!9
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M#VVD@R%O;5%LKKB]THQ*9.25BM0[W39OW:$O)HWW*K@LY%9Z,5/:$$W)DM<
M@\"I2_.-+C'[B18:R$?"X0#.-ZHQ2O:%N1<-4CW+9M!:#/ROA5/C=QO0>J+Y
M5\ $,1U:)Z-;CQVS/(!T!C-.S..95(5]/*"<Z,094+#NK10#LSY?H4RE9&UF
MVP4I<":BS$&?#=WK2^]TTZS:)1'F;(T72J<E3R\^GP(T%8L)J=(DLV&S6/)B
M""M:=X.$)J4QX8*D:DT;'0K?1SZ.B59H&,CF!!(@L6 _7]\C5IXFY35E-777
MD6_3-*!08V>J7JP=/0N@P10KFAZ8YS%8_F8!_]/M6^,S8Z$P#?=:F*Q#>]V
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M/$@U&KC/LR,K>T+@A218.R(NF4AO&MYE1.BI2[1M)QPH>F<02F"1JT9^2#_
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M&LWJZJ3G%=!*N["[RIUE#5X_%<)2N8U,1BJR4U.FDQ1S" ,4W&@E];RDG6X
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MZE3VEH%D948BJ+]=,2]R30]<7N37WCE7+G#Q[<B1\4:];7S&2;&IX'TII@O
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MI6W#U:=QWDU?16#<J_H0;"'^K+6[@$'H-Q/CH$2(X5S (J)(G^UPF.PJ6'T
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M"$6OJIP8=.%/]@D&1S@#KF;4"39FES*&^:;5PXQ?O$\^[<Q8'M]N'&L=Y^(
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MNULSJW28^\$B2[G$#3?EK=K!V6+XX/^&$VF(G[*%,T5FVRE6[A7$=7YF&_G
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M3R6_#I?4AE#6^-RRWJ3 IQIKEY(_ @!5P?1RFUK8IF;!2R*:^U@IZ9R&:ZR
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M12K>P"[L&"K]R'8VKJV LX[S7E4>8"E01L@H%B0O#>;&2EI[%KZ7Y><? W_
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MB^"$$+-\F@R_36';7Y8M$C,+WS"GB'I*CJ$NB#S*H24)PB'@C4UX(0;LNS)
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MLW8<\\S_4?-KQ_!SUZZWXOB8"(YE@+]TD=GLR+OC.=XTE??@_['U%E!-<'_
MOPBB@@6BJ-B"2#<(@M+=W8RQL8 -QL:ZNWMT=X. 02@&V&(K8G=W]_]YD/>\
MS^^\?\[@G.W<SV&[]^X;]QMW24<9CD6:LT=>3B?]EPI_5VTADOEMJU2+N-M!
MY>=%"ZRY9<N$T@W+2SX(>Y=<+UW/]Y]S2P:AE_R7:I],?1[77MZ=<3R)S/\
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MP*]UOT4SQDNMM]",\/?7FM&VX=\M3*4-$LK_.X=IGN2W5*_H:Y0HJC*@G%)
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M6U:G/IJ^8>Y%^;G,F5P4V$QN#P'SE_(JD%+2?CE'2VLS/ENNDE[):E\/D8$
M3Y?^D5_+MIS;(='-F;&0D3,2@#+KW7A6B(R %4X8$0RTU<)?U W&K"L7;\X-
M6]HJ698+F5LNF(#.K!=&Y[^SL>,T[STLP[&%SX,SMLGYC_+RUND*?//>+=TE
M:,J[.K>%IXV<Z6E#V/$_U J.1:&%PT?.[\(WYE^Y.!1AK80[AAI<\H3;@^+.
M+6%/8&;JH_^]4_[_4AYDY@A.SR&#=0Y'-L>RP;B>M;;L4ES;DD9V"$XY%\F:
M2[3Z?]?+8S&]@VIN_X3QF1IEKL_LHCJ8/&">H6HM43#3J;9S!0P^]<__2\V9
M\^?/__U%Y&(<_WEICH[V/TZ"UIS__?G_>?[/8^X_#U.==?.FY\,67-=SU><L
M.K[XSU*'99D&(L-]R^^OT%_I:)RTBK"Z;,T>DXMKWZPWVY"RD;>I?_/TEC]F
M6[;ZF^=NXUJT6AZW>FJSP':;7; ]S$'@V.)TQ/FVRP^W5=M=W&,\$#L$GLU>
M1W;>WO75Q\#7PL_7/SV@.% 6U!Y\-.16Z)=PPPCK2+^HE.B"&&YL55Q__,F$
M.XF?DQ>G;$GU2(M)S\W 9PJS*@'=V0>!YW+N@M[ESH480K? G."^>;'YF0@(
M$E5 +&2AQ$5J=!6FL;@#NQNW#W^ <)1X@G26/$DY2SU#.TT_R3C.G& =88]Q
M1KC[> /\'D&[L$E4(RZ3**1<&4E>J  IDU7A:F^-4\G6TM5EB\K^E+^O>%AY
MM>I$]4A-=VUMG;2>W !O3&H*:'9JV=BZI/5GV_/V:QT3G0-=]=VR'DIO7E_*
M[J!^UP'30<,]<_:\VCN][\3^/4.-P_(1ZFC>@92#06,NAS8?7G;X]Y&71Z?'
MCT_L.=9X7'&">C+_5,II_S.V9U=-:DV^.'?E_,$+K1?EEPB7LZ^$7'6XMFIJ
MSM3CZV>G^V^4W:3< MX.NF-]=]G=C_>F[H\\J'E(>I3TV.G)DB=/GQY^5O$<
M]2+XY;J7;U\=?5WR!OLVX9W3^Z7OGW\X^K'J$_ISR)?U7SY\/?9-\SW[A\6/
M%S];?Z7_UO\]^"?UWUVC]52[=9ZU+GO^V((G>CKZ*Q>M7;Q^R=JEJY<9&Q@9
M+ENN;Z1C]'/%AY6/C:=6G5E]=<UMDWMK[ZV[L_[&AJL;+VPZO7E\RT'3_68#
M6WO,.[:U6#18UEG56%?;5-AJ[!3VDG]V ]>)Y<QPH;G2W&C;Z>Y,#]H.JB?9
MB[R3O(OB3?-A^G+\!/Z2 &5@65!%<&5(=6AM6&-X2T1'9&_48/1PS*'8XW&3
M\5<2KB5>3[J1?#OE;NJ#M"?ISS->9;[+^@3XFOTS9PY(&ZP%_I/[$_(=^A7V
M"?XA[VW^:\0+Y-."1X7W4+>+IM%7,6>+CV*'<+WX9D(E44[BD(F4 BJ(EDR/
M8/@P75@6[+6<99S?W%>\&_Q3@OW"%I%&S)*@I !9I-Q+8:TT4>FIOJN?::Z7
MG"P=+FLM5U70*Q%5J=7!-:ZU9G5&]3KUGQH>-TXUG6H^T+*[M:6MLEW1P>ND
M=>&Z"WH@O8"^U-WQ_5$#X8,A>P+W!NSSWQ\P%#@</!(Z&GD@]F#26,:AG,/P
M(T5'2>/L">$Q^?&2$]4GFT]UG]Y[9NSLB<F+YVZ>?WSAW<4?EW6O&%Y=?\UR
MRNVZ_W3,C<R;>;<(M[EWU'>K[C7<;WO0_;#_T=['PT\./#WT[.CSRR\>O?ST
M6N>-X=N-[ZS?;__@]S'R4\KGG"_PK\AO!=_S?X!^)O[R_VWWQ_C?]9\[3WMJ
M'E3WV +=A8YZL?K@146+\4N(2XG+B 8$P^+EA4;0%9DK8XT#5KFMMECC;.*U
MUGO=KO4>&YPW6F_:LGGUEJ6F.J;?S%YO?6 ^M>V,Q6'+O5:=UK4V*EN>'=F^
MT 'DF.(4X>SCXNIJY;9I^TIW?8\Y'I]WO/)\X'5CYZ5=I[W'?0[X[O/K]^\*
M: FL#ZH*+@U1A\K#I.&B"&&D((H?S8\1Q/+C^/'\!'ZB($F8+$J1I,K2%.FJ
MC)+,LG_D0G5V+; NIQ[4"&[*;8&T0MM@[?".O([\3D0GLK.@L[ =U5;4C&[$
MU!578\MQ&KR"(";R2$PRF8*E%M!@]&Q&*C.&%<S>R7'A6O$V\8T%BX1SA5]$
MK\3W)5/2L[*C\B%%K[)95:56:@0E]%)\66$YO"*G,K,JI3JA)K8VNBZJ/JHA
MNC&V*:$YI26K-;<-V8[O8'9*NZJZ.WM&>L_TW=G]86#AX,8]V_?&[,O?SQMJ
M&CXR<N^ UL%-8WZ'P(=Y1SJ.3HZ_.[;BN/N)S)/,4RVG3YUY-;GLG./Y^ N8
MB^I+_9?/77EQ37=J_777Z? ;V3<QMWBWR^ZTWAVX=_#^\0=G'UYX=/'Q^2=G
MGHX_&W[>]:+R)>]5P>OD-^EOT]XEO@__X/71\I/AI\^?KWX9^"KY!OQN]_WC
MC]T_<W\9_!KX'?'[WA_4S/?_NK9DWD+=^/FT!24+Z_6:]&L7J18SEQ0NS5H6
M;N!FN&GYPN5OC:ZN&%E9:\Q:Q5A-68,QR5V;L,YGO?4&XXUS-C[?=&GS@2TM
MIG(SXE:0>>0V=PLSRV66OZR>6U^S&;?=;5=C+W8@.$*<$IS]71Q=-[L9;-?:
M_L[]OL>E'>.>>[Q:=I;M$GI3? I\@7X)_B$!GH'V05N"C4/T0_Z$?@A[&GXS
MXGSD1-10='=,?:SFGWU 3$ D9B7%)/NEN*1N35N5OC#]>\:+S)M99P 'LKN
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M_OC)4]=GW.=3+ZU>T5]?>^OP3O[^S<>(3QU?=+ZF?NO\_OFGQR_2[Y$__VR
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M\:XD)V9.G8/PCS]&&\VO<QV1NW #;.H%C^'/HLA=6+.8^>_ %^,*;'EWC>Y
MP4'+?34[PZTQ0;$E^J.Q3NKD7ZSI$WYQ/25KYQVUN2!@(T.BN2.?6SV8QP>
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M5$$P,1\@??EN+!OX:M(?%H/S,7 YZSMGDO,R=A/X8;<28"M^MGT&V/)-VBY
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M6;M#GL(*UDN/7YQ';!O;K9Q8=HG&BW>6F\F?RSV%7J9'HY=1I\H)R!.D>@>
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MJOJ+ZE)'1)Y5,ZS%*V&5MMHV/+@<^&K:ZUX![=(IF[J,[^I6D6KC)/H&E<G
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M'6X(>ZY5S6=RV\ J88]@"&^/^+D(J/@A8TK'9S8H)\B/1>HUHU7'O1:"E4#
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M0ZSC.4.-+-B-YV;H$RT75.JWUCT2[=&=*IPDK2"?)JU7^)+#0BZJ,XAI'@E
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M3ZKG?A+TJ+;4^1&V%_Q"_@OXR4YKS,!*Q51!$VBGS*7Z@=TJI#@;"E'O2E-
MK[6CH^SA_8#(CXT<!#^[3$$?PUW$1TT*L%?=K+D/5O"7:Y7@C;I28 *46G0"
M. [M2IL"KH>C(]] Z^ 3?@SX#L)RB4&]T/'$--4>8H'JAEI*M/ ':681Q;6K
M-"?QST5NVGZ\.W45,!]/BUP-'L:^^Q7 <[#5+G6(#:/@-"5@R5.YJ1+-';QR
MU1=3>^T$]0XCK[!?L]00DYJDW:>?' D!W\F7?AF0DMCB B)C< 5V5:%M.:!<
MH,QOKN)>5(UK[*AI5UUOZ"[T45^Q=*;<TXXVM4<F -6&5K]$\(T.<FF%%Q-,
M3"#?WOU.&:+HZGS,I2LKVDMJO%6N+5#!=;5GXZ*4 8W(>C1RHO:6Z9F?&VC0
M_W(9@'-(3U!K/EC)E3PV/:TY6_^W*83F6?'&V,@TY9XRW.<,3EQF".6O"OM+
MWRXFO$?H)\MW.C)UVS7Y0)^QFFXG\3,<9)ZK'VWP9P,5=/U"GG\N73]1\#N1
MH6L0_QOZ5C==/MG;F3RD@ASWDBV I_:(?@QWNSA-MXR_AYFC"Q/NIVPECXN/
MY]PE:Z1/$\>2PQ6NH2>)O2J]=RC1J9WK-)IH N]H'A#OI"&B*F*MK)M!)>KD
M'RG#B$G*O)P<_))J9\)J?)DF)K07-VNO>L?B36"'4RZ^'N9I1N!.FOG"1NR'
MEDGOPXX#T\M3L39@;_9-3  *$THQ >0?*L,TT!_O-&P%_,#)@+U%SJC3T#[T
MD^ .VH39T7ZB$LRQ;!^:BXW.%J)QZ*>$8+0 ?1?*177H9^]2] [ZRVD;EHL-
M5:U .$8G 0V1&[;2;$B585!9 1*C=\H>A"3JTN-O(V)2&YJ#;".V>%>BP?@#
MI]OH<7R<RA.6-<[@/X>MM@FTF3!@75+Z J:;?V0M@Q6F\G@SO,NP-W0>,DWO
MXUV'K""M3K_02ORU\@3T=_MIO@FZWN9/W0&=:AE6V@QM;;1E4:'3#7/BJ^!Y
MYJVA@^!&8ZEW.1*M>^L\#1U*+)4H6VLK[5AKFV_52*J%37+JJ<(MC<.886D[
M&P#VD>CSED=\0R!@SA5KW&\:3\N/VO<8I)I*\:KF$!J5-;7Q/G-<U6.;F76L
M,*?!A=N:IK"L%\#1F\R1XJY @_&$[*;'5(-$5>\P2A\'.(N^V/YPL/K2ANN\
MUJH<:[]@;<$12Z'H1MI4TV^I?31DW"!O",0-;-4<CR1]M.:A T\7"!X315O?
MBPEFF^6I=%"EV7Q2AA:$F^8K1J<N,XJ5JZ*C#%EJ9J!8[ZN-]*#KO,%0AWUD
M!IP@U%M\5!+&<W.LNK;BJ2E,DYB_T&BO=4C--(P#)D?]UD\ 9P56ZV9" 1XP
M&0O7.?Y%X$B+X+%I%YS+J# ^A#=4< POX'?YOOH'B%W*:]T#I#3J*?D!61)8
M3=HCOSRZ"!%:Z9B WT+_%E0:]>1'^A7#(?( Y;7^.EF1MU=WB[B6TDJ^)BA1
M6\B)^-- $9&&DQZ;\;WX7$<I7HAMY+\U=%N4]%[]:_,1RC[]8-/JO';RD[$T
M14D.-TR)LA"9NF>!V?@"\I+'8=R+6./8@]W'"7ZW_D'S?GJF/K+)0A'JBFV[
M\G+)#&M_2B)19>Z.$N++C>L"T_ )^NL>%[$=Y!?''9B1\*V_VQ=8L;CZ6<_(
MZB?%/9W/J(F9;]H7,O8GS&IU8G/"6$UF?HYO><,S<9WK4$NY_+C=".,O#;W>
MJ2>="E?SN^(9GL5^';/K/V0N:SW#N17_N9G"?Q'&L]T4>_OJK.6R+M<JTUM5
MEEV#83<PC]G>Y<[VJ;K2$<_-*=K>%LS',F.;OPNOQ6]M7"S)"BMK2)&]]%UH
M?J%<ZSI@7*M9;C](OQ3<R!S6,5NXO2JB+5M<4#2]I4+R->-L4ZQL6SS3-EK1
M&!9DN:HR^JXV#6AZ76\;6H ;]@S=9G@.0]Y6K@BNW-BR1)E9V-MT0$7-H-C^
M5@/Q+M9%FHUA$\PMP!#?M48CR'0;H>^''MIO)Q\C5?3W+2^!996QS=E@5&%X
MHQ+<D?%7@QKRCGMHD4 ;0_\SR> 2WXT&*_*7FX?N!++?_C<9@<KH1/-![$7%
MPZ90?%#!"QL;NY>^SRK$EL<M-JLP)/2&T8:)?'?KMV BMPS=5(SK$$ZLPNKH
M7DWG#>\K&AN+#;J"OH9&_<%TV-*MNQXG,JW4#0I=;KA*QOJNTH\B6MTX)(S?
M<6 18;@+[4G3S(;+%6+;"NNW M3ZR*)+9YGOF$['R8R/C1&AQPPS]<=]S^@$
M.JF;GAQ.3G*PXK?PHU5M ]64[\4%B]NK [.>+%A>UY*4T<=EN$7V=]UG?0MT
M;_?AC_&L:^:+<YQJ&_;*+\]=9J[5<"IO+5E;)RFZLO 3W2X+[O_"_)$TK&<-
M9WBDOM.!GQX8VPJ)#G@.-%Z649W.6]-54?/B3!. Z97\14OJMQ75SO_-?IKE
MV#>5%Y&XH^N:8%]D;3M3+ Q,;+XOR_6\;JM49CO[FK]IU/,.&5Z#_96C%W3R
MKQ;^VS],:,W<T!,HKDJ4=$Z1%D4&MAZ22P-CFAC*K9Z_&D9HQCL#IHN U2Y$
M_Q'Z5K&L_[3T>6%';['<+;.VJU$A2W1N1Y5G(Z>WY*A+ J,:)VM^>,VQW '6
M.>\V7H)4=NUZ.\2G(JVO1/VI,+O[@V9?IFMGA!9*^-$6#,1$_&B> ,X,3&UX
M#LWPBC+?@)V=/QB^(F%VCW4"-)3RI=<)OE XJ>L\XI[QJV,>4IAPL]41D4;<
M:QJ+K I,LOY ?GI5F[ZA5!<G0QQZR-Z-O(E-IVSK\2>!@F>=S\BJC+OM$<3;
MA*,ML41]Q(7&0/QS8( U E_@56?*QNM<LO3+\-GV520#NTBQ=HM-GPO.=GJ:
M:!DGVQ!C<<+.9KUA5L0U&Z#[%9AJL9&_O13&O\EI+@R]#Q%BKR>'X=RU:/6C
M4N_Y076_*]QL>L:DFFEP#BN ^E.PD*M@/JLZ(GC)>9<=+>D0>D1/5/1(=_N,
MT/Q0/5EMI;RIH_5MK!;3J0W!=??JRR%W1CDGA]_/^L3/K'S..R:B936(+DB7
M1"V3ARA#O+^J/VKC5NXM97.QGM\5<7S,<J3Z/R$"7*0>%I,\#7/#_Q#A%^>J
M_&#F76&X:FQ4@O2SIM/[I7H$J%K^L2A6+N_.+F,H"+-;)5/9KL5J!:HUW&+Z
M<O6EBJGL.=IQF5'\<T!-Y!/)7?"F]UU5.&Q:EI2OAI,Z3Q??AT7&HQ0GN$<3
M4LV$CW"JJ+?A;Y3,^CXD+F,-KQ-IC.P4OT8^>5]6DJAHZ95<!\.'#FOA(4.L
M84-9A!Y5QU9NTNUFPW4UY,_RE<Q",C4C@FLC6B-+Q [X'>]3BA>XTY)5V9[-
M\G9S_L_&Z_KS)7TV+Q50D6!5LL[6VIF/E,]F))LFI=_EK#.413J)%#JC]V$%
MEUB\^$AF5\_&MD-YC5TN>L?BW'9"^9 RL>46*Z5F2E-XV4)Z?8,M7<?^:3X?
M\5WXU/#*>Z]B$/EBL7>&9 G>%IX++OBJ6U24W5>ME)0[=AVM?U8=W1Y11J&M
M;IZ?GL*F-SR.."64F7YX[Y2OT?U<=)7Q;VEHZQ46MR)*E\EY5N.NG,77T(;7
M2T4^S+>E2Z03.=_3_!4>PO!P;W6'])IG%4A1CU[H30VH?=*RE#&!]I-,K;]?
M/T01P]G#&<+<RM_+'UTZ6O19%)AZ6%8O)<+^5?DKO3P90+8V<[ZE^AQ'VSR8
M.HBW#/^',4=P7/:6E2AZQNCC-DFGE'@)9\DK4QTE=Y2'PA8HOFGXGCQM%5C?
M][+BB/1)H[@F5AZ"U5"[%(#T ..W<C>]D]VM'E%<QQ=J."E=8D3[((PB?P(:
M/,4:,US5RRF? X;:)E1> #>@,VK9T"R)C?X7I*7MJ/\'NE>TFOL-IJ3,$^7!
MM\/FR;X@*D^%^C+JVN-1<D_'L[ZA'-%-0*946\E>\5)J+3F-^IS)(EJ*9G'^
M)F8F[Q)FXLM#7\F\\1!/K3H"V]?M5CS8)K$.*9_0$ /'5_ZT/!0]J?UJ5E#C
M& &FD84=[/6&^<DB@4 ?$'I<BI%;/"'5=L*YBUZH[PRTY)9N;'>".BJVM]P5
MY=9<:"+KMM!];#Z%LUG7+)>3Y_#WFB2A*R3_ZM]ZHJI<LK3S3@%O09/Y5,F*
MOJ709,K>;KGP<O6S#J^Z?%IER\N""RS'QN5)-_F>UOQ00$(:KWCBRN^ZHHXJ
M?FAIF:E=.*RB#'07O:R)%0Z3/*--KV7+AS)_YJ]2YG!')!:KCP@S@U6 3?K!
M[2:\1.W=]I2]M)9GI'.OTYJ!D8)1S*6"\:(<]L::'LDFWLG\D?),T;"$1ZHI
M4GYPFM9?Z>[V#;)I"UMQ)HVM,8QBO>0>T_SAT@0C^#/XCT5)U9=%-HDE3RF5
MR-XFF!0FI2+86?U1$^,^!>P&BUM&T!02FFXA,T'Z2-W.^B0OYW[G;E4<JKHM
M6*D*S=TNOJS>GS!*'J*E![U2/0(#W;V @[!?T[K:%UH_LHKV4OM*Q6)>!9HY
MC]AG0->JF;ROX('<62(V)(@?D(V"W8(.*S_#W]SC@)'(W<:FZF/X8Z*H[B/^
MCU+-&(6OY8QB!>+LR@IN ^Z4TR/TQE[$%TF'8SN#%BD],:M[OI:/U=A65?ZQ
M<'&P-M?<K=A$,YA:V.7,*T9AQ2Y.C2$SQU'@H?>,GRKQTHT-LBA@XJ%[C>8Y
MOJ;A>T5SZUKL2O6/ELF*B=2<)G_6$<8VFWM%,)MJ=<Q>PR\USXT[*8:-4X,4
M\G>ZS^Y<#4P<:T I4&\'5E'UO3M<WEQ7T:%B9=$OM1HH%UBM37W93-Z2ALUQ
M%M%K\X&@;#EA^-M=IG$G-UE&R/XNQ9 <^=T*J?29TK,FGWE!U4AS+D_3C*D?
MF;E<NY8[*P8 E4*:_W58+YOD@J-7U.FFG>+\VK_@4,E-FK_DB4S S&)\5HQG
MT\LZE6=YEDQG]7;A]1AW[6EID?\AR$WIY+(=V:8M,\*"$!8(OA>-YSP2WQ7?
MY<<S1DCW";M*;\GWB7]G]"G?RHCH&YHLI9?_!N"U9HK+4W@'F& (X])%CX"-
M?%AB$ZT7FF3N]!#Q OF^4A_I/65EAJNB4#T^NE?U07/'?T![%;CE.@&Z#0_1
M_69]5@=J![A)&E?A.CZJ^8_F+SRF/5DBD<0 />E6V7L0BHY4GH%$_CK-<QAP
M#8+F(3WD#^9+E*U9SZY%!P1GN(?0[52F(!S=7'Q8=!-=GSY7NAW='O5%<0H]
M[2_1S$&?N.:#,#:(]&2$&;GJ5_6G#.\$LSBYAHBZ0[S'^KKB8.$&G3%MLV0[
MN37JA/P-\=R?K1804UTYP%<\G##0KC9YJPN9.MM//LFV:U#517'/6HX4;1?L
M,$])2Q,_,[*B#/($_5[_*M5MW6!7$+ 0\<0DZO'./M4=AJ5]#W\,*ZB577N"
M\Z[I>E$5_XTM*VVX.,QR*"I/MM$4X1^I$NL7N5J!8'(F<@F 2A<JAH&#*V!.
M'[BQIK"Z"9+37 L<X.3ZB<DK$1^N5_@F-$0(^I1C2EF($P5_IJZ#EZNS:N;+
MIVB\J<?9^[73&<^K[@#CV./RN\#IO/3D;"A!N"I<!UNE43YT=)+2WFD VZNE
M0 V*HOHFZ4<EQAG.NJ1:SE-7C51?%CS/>Z^=*18F70-TLBGAZ= DQ5T?!GQ5
M_<+I&;H=] $ET@$A6W)#/EH<7+]742_Y5)FF/"S;G)>KSE! 23S-!U5=^&1@
MGZ;6APGM RS.CLAEZ#I0+<Y1AHHO21ZJ2ICG9#PUM4(@_Z*IS;V@7*EE)TU2
MVP R[)6V%=SD(P!/0C^=BY$)2+E6*JR WHDGBF? '*:SY""\BW) )H?_S0U6
MY"*!B>M4E0@>MDG3C-SQH0$_T"1G".:A*S6;^-MU"E&EL$V7RH#$E>1-BI?4
MA\S.V2#W) XDYBNKB80PFWHS?L*'#F3@.<X+H ?8:<UL'M.Z37A64&EY0/\L
M"C-O*]\LF6>JRDF6A1N')KQ7-.HWAU'4PW0\'[IV&SG=>1<DPP^J5W&K6]<+
MJ7Q62S3=*"QLRBW/$:?:'++_E4HLGQ/VR.^:KH3YJ)2&[3[9VG1=A_-Y:!9A
MD9\A&DI[N?<(:06[3D" -2$E J*)-BYS#K&X?ECL16(_-R!X.O%!V.(YALR7
ME3@PR"MJN6P?VEHSESL6/45-J]V #6>(BV]BR:QE&9LQ'?=+;#OVCU 1/!K/
ME-I[AN"/E',<CA'SM1724] ^9C-G,AS#GE[S#%[+G5_LCLP2^&3X(<VB2[&)
MJ)-T0= ;](RBV;, 6Z3>[S@'MX$S)9<!7_Y;]BS@KO!J]2<0%F\O4D)SI O2
M%T"GY9TQC^ NY9J@HPBHONU)10U E&,]MAA:+WZN_BB/8"5JSBK(:B]MN_)
MX1:@2O4E/0 ,UD3&=$+AVO:@%7 !.-A3AC1"9L<!]!HR2SQ5-0:0U\/J\:!C
M%:C^"FXL=-/<A7S2]FK_@3;&<,%!<'90+Y0!_^NI@W<@RQQOHCYHN8BET. (
M\[UR$=Y1-42U!)<5;%?/Q_W32C2[L,\Q<X&AV)D@ \C!-G@VPT,PF],P9"'&
M$=Z6!YFRF&*%W'BRTJRT&#X4Y*FZ]*]3?ZC/Z#Y$G]>&Z88&50-_DTZ>/9"
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M;7(4V/PJ&WK$/]VW6^SE>L=#QMOJZ+D?]>^ !\4C.XI82[-/MFW@O$[):[G
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MZ =ZC(<HA;QSD'_U5,%YR92Z Z+S#( !2\Z64=EJV=7,#/YFQ8^8+1(/=7S
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M/3&'WUAP6/6W4%CRA_=6+*E(KETC;:II+QHO/T?[DUJOBF-U1<9H[O%YONO
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M2S A+98/"Y&ZOAI\0R>3TM94P>PRE=?TU>'%@QJL>DB,5 _S4;I^'DK?NY)
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MXVX"V.V& &[^)8\#PW,>A$>GWHE.2+B5F!Q[(RTUZGI6>L2UO,R#5XNRPJ]
MLD.OP')"+I?E!%]&Y09=PN8%7B+F!UPD%RRWT?XW7FL__,8?]'??_JL0?/@I
M$WRSA@@V;2\#^P\4 R_W+!#@FPS"@N(>1X5&/4HX>/!A2F38@XRHD/LY,<'W
M\W_Y_*$D+N!N:;S_'?BSSQX2?&]C$GUNXY.66_O(ZZ_5'7_]CT+PSCM,\.]_
M$\'WWY:!;1N*@...3.#AD C\G*-!B-M!$.D9"N*\@T"2;P!(\_,'F?Z^("?
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M 2_8_RGW8-1]3FSJ#59*P25Z;MDB%89?*,=2CV/(54<0#.[A4D[M5'&M>+)
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M ^>=:<#3(1X$.$>!,+=P$.49#.*] T&*KS_(L/_QG>WO _("O$%1H"> !'D
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M+*0KJ2?2=)4G4DST^>0FYO&D3GL#5<>2)JLF4B:9(ZF352\*8)X;/@!XYZ\
MU6L=8 ;N E6A+H 1%0 J$R,?4#*3;^$+<ZZB$"47X82R)0@->Z:013R5QZ.<
MS!;33F0HZ?/I.N;Q5'/57$H+^UAR#_M8TECU9.HX>S!MO+HW?>R% :S=@+4;
MB$Y? ;KG.L#RVPG8P2Z %>$/F'$1#VEI2;=)>3E7<:4E%Y%8Q%(I!7>FF$E:
MR.=23^2(Z,<S%55SZ7KVL=2&ZJ,I[9RCR8,UAU)':X;21VNZ,T:Y[9DC+PS@
M[ :<W4!R_ HP/7Y\_CD()] 95(?Y G;,P8>,Y,3;U.SL:^4EQ1<Q*,1B&0EW
M&D(GGRSDT.9SA<RY+ 7[:$8=YTA:(W<VI8LWG3K"&TX?X75G#O-;LX8%3=DO
M[KD!;S=0'+\$+/<?08W7#L#U<P3<8!]0$QG^$SLAX0XC/>M:14'114)9V2**
M@#L%HY%/%%=7'L^O91W-5G!F,^JY,VG-_,.I_8*1C"%!3^90;5OVH-"2,R@T
MY;XX@/_F9P/UP)>@VFTMX'IL!WR? T 0Z WXX:&/N#%Q=]DI&=?IV867R)"R
M)1P&=PI!H9R L.C'"@3LPSER[F16G6 LPRH<2>\1]60-B%JS!\26W'YQ?5Z_
M6)?_X@#!;B#8#97[O[3O_S6 [[8-"#WW Y&?)Q"%!#^JC8JYPTM,N\K.R#]?
M600[34)BCV/+R=-E=,9X20UGJ$#,[\]5"[MS3!);=KNT):=/:L[KD]7E]\G4
M!7U21>&+>VX@;OL T!V^ %RGU:#690L0N^\#4E_WI]*@P'N2B,CKHKCD"_S4
MG-/L LA<)1Q]J!Q/'D97,/O@K!H;1%#;5B07-^7K99:\)KDIKT>A*^A1*(MZ
M%-+B7KFXY,4!XB\&IMW <UP-1$Z;@=1M+Y![NSY2!OK=5H0?O"R/23@K2<F<
M%^07'6)!T4,5:'(W@<1L0].Y5GB-T 052^N+U0IMD5FI+K*I9,7=*C&D6RF
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M>AN%J0:\VK,&BMZ]"A>;X4(/\H4L7U9?2HCWB;CHP,ZHI+"6L*SH^N"B^.K
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M=]@HX@([)4AP8 D.%%98@]IJ,]!99PA&&W3!8I,68#:K V[+$7#<J@*4;4I
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M<_5?$W]TN0U!>GJ$D>8+PDCYB"B2,[$(29W?*!S[6UHB%.W<OJ"VW@WTMKJ
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M'#Y3KQ&_T"Z1OM#.DK_0SU 6!F0T VV_&'CL%X? ?]^+H;$&H@PW0[3E+HC
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M6^EQU*?,XRROU..V;['G:UZ!UQN?7*^W/MG<=]XH[D* CO8KGVUHYT37(N6
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M$6=8AA!@M1 &70MSD!(Q!&E179 5TP!E\2.@(:$$NA+R8"0I"^:+#H'-H@.
M6RP-CHOW@O.2W<!8LA,\E^X _K)M$+9\"R0LWP09*S9"$:IDY4+ 2D8$S)3$
M *,L#O@CDD#27PX4B_5 PF\#!]H>P'O(@&V0'%C'*H%%ABJ8%JF#294F&#=I
M@5&G#ACVZ(+!6=15/="_IP_ZDZCW!J#_!35O .CG[T:@_\D$#&9,%P;6!T3
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M;'6/5_#JU;Z!X_-^_N-[_?W&+Q*/_?S&WOOYCZ"?__"/L(@);C<#7!B@DN>
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M&8#\7RF0?)L)XE[Q0L0K<4K(:T6J_VMM!J\WQDQN;ZQ9G-XZL=F_]>2P>1?
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M>TVOM?68WF[G/GV2N&OG-OG:SFT-VO^7.^5D#5H!#I/^7B+]NSA+^OM;?^X
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ME[L ]I\8P0JYP P%P!C%01_E*3JH1M% '8HJ&E))[%(5T)8JA\Y4:?2D26(
M31S#:2*8R""$.0P"6,G CVV,JW"$D0]G&7EQ*['W!VWD&2@_3.:?_6>^_TT
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MQ3^<YI4N.VY3_M5QK_(OCB=5+CI>4_W)Z8GJ*<=WZB<<R?<E1]0Z0APF#JV
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M,U-<.F>V<FN?/<&M?>8>E]:I-]R:)[_P:IY ON]M' 287$W. %G_YD6 LNT
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M8J-B8G=W=XZ.SIU01V>L,<<>=73_%L9<[_S_SWT^S]X@['>M]8V]WN^<"Z=
M2+^RBO07DOYTTF]9#=11[D7;@332CCX(!!PE#WR*#X?S$@R^H()!%_4Q\*(%
M[+X;"-OOG&!SR0L#+@6CW^486%].8RR_+V LOJ]A^GS?PII?F<F:7EG!FES=
M35QFC;]_R!I??LTSNL3QOV41Z<\D_;;57\Z@=@'I!TB?M -. L// O;?,1AP
M58@^OTAA?D,59C?T8?IK'YC<M('Q34<8W7*'X:U &/P6!?W?4Z'W>R%T;]=!
M^_8$1NM.%Z-Y=QVC<?<0HW[O.J-VYRFC]ON[_V$VZ4\D_7K2+]T-9!PB_1.
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M'(H\>.<X\ETMY'O&D^^:2-YW$@_I4Y21TJZ'I*D6B)\Z"#%3G9FHJ5YL^-1
M7FA[I""X/4$8,"5=[#<E7\%G<J6BY^0&N?NDB4K#)\U5<9FT4M5YTBY5ITD7
M59TG/%1U;GNGYMS*_0_[*F@N4LU[2'M>&ZV%"4 3:5=- 7(ZR'O. .)F*2)Z
MMB8B9YLB?,X A,QQ0- <-R9@CA_K-R>4YS,[AN\U.T7@,3M'.'Q6F=AEUBB)
MTZPVZ=!9LQ0=9O;([&?ND ^9>4XV9,8?LB&=?\F'='!*W[*][O,Y5#=ISV@'
M6J=2#4B[A+0SY@ Q\\G_=PL1L$@9?HOTX+NX+[P7V\%KB1,\EG@R;DL"&-<E
M$:SSD@1VV)(,GN/B(K[]XAK!X,7CA ,7=XKL%B\5VRS>2IP6VRRZ)QZP\(UD
MP ).8<#\_[*1+-@RRGL.:;>3;A/9PLJY0.X"\O^+R?\O!WS()@Y?K0B7->IP
M6F.$86NL,'3M(#BN=8;]6B\,61>$0>NBF('KDAG;=;GL@'45;+]U33SK=5-Y
MENNZ^1;K-O'[KCO.[[OV-J_/ZE?\/JLX09^5_V4EZ<^?!DPG:]PR#ZCK)O^[
M%$A; 42M ?S)&KIN H9LY<%VNQP#MFNB_W9C]-MA!>L=@V"UTPF6.[U@L3,8
M?7?%P'Q7&LQV%<%T5QUCO&L"8[1K'F.P>RVCO_L0H[_K5T9_QW-&;_O?K-XV
M[A\6D?Y,RGT"U;R>[&@I:6>N!6))-Y LJ=L.P'XWT)]LN_E!(8R.R&!P1!WZ
M1PRA=[0O=(_:0N?84&@?\X#6L4!H'H^!QO$,J)\H@]J))JB>F Z5D\NA?'(W
ME$Y>@?*))U ^]@[*1[E_F#.;UB+5O9%RKUA-ZX!\>/PV((B\N/M>TC] 'OPP
M8'8<T#O-0/V<$,K?22&_I +9)1W"!(J7K(DAD%X>#H7+ 9!\'T-D0OQ])817
M6B"X,A?\*VO!NWH(S-5KQ&/B]3],70@T+_]\!I2[&4@@[>#]E/\AJO]1P/HD
M8'(&T+D J%X&9#\PD/PB@/":#/QK*N!=UP89+."&)?#K0. F-:BW_*@QB@9^
MS_K\1YENTX2_386^LX&@A.Y<I>;MWC^,(_WJ=9_/@!(I[Q#Z$?=CP.!/YS^
MT7> UA5 ^2= >AT0W (]C[@CHM^7 ?=4@/N:P!\&P(,^P$,;X/&PSXWZG]0<
M/:,7\C/:_)]/ EY0P5_0!'M)0B]/_4/M^L]G0,F4>QAINY\F_?. Q27 X =
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M#4SC5P?D"JH"2H05 =6BLH!&<8G_!$F1_PQIH?\BQ7S_];*\@/VRW( K\IR
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M_V>?"_DCJ>ROE'T-. .X4=.&FL:/ CI7 '5V072#?O]I\HP2\"SC>)9QW#0
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MVQCC]%Q,G6GJK*;.!NILPTWFXAD<PU,XQPBNX E^YRJCOL(L/L[Q>)PJCSV
M3$<9,G7Z?W6^JFA")N@QU^8<.V?J!K!_T<Q=*GN23ZURME;/V-N8X1[J+*#.
M&'4F<1W+<8USXPK'Y''FXE'.BTLXS4P\RIGQ'*-Y'V>%;W!&^!VG13(\)/XO
M,AY2,AW%(V]^TA3C>U4-W!7T\;;(&K?%GGA1'(KGE.+QM%(FGE0JPC7E2EQ1
M;L!CRNVXK-R+2\H+<%%Y(2ZH+,%YE1F<55F/,ZK;\9#J?IQ4/8GC:I=P3/U9
M'-%X%X<UO\5!K3]Q0%N&_?/LTY;O1P%_<(GYDLO=7?*VKAAOJFOB934C+D$.
MN*[EARO:D;BLG82+VMDXKU.,LSK5.*W3B(=TVG%2IQ<G=(9Q3&<<1W67X;#N
M&AS2W8(#>GNQ3^\X]NI=Q&[]9[!3_SUL-_@.6PUEV&+$\]0\FXSDUR8!7UER
M2>$2=YO<XONGC93QI)X.'C.PQ,.&[CAK%(Q3QC$X;IR*(\9Y.&12B@,F-=AO
MTH2])AW88]*'728CV&FZ&-M-5V";Z7IL,=N)369'L-'\/-:;/XE9BW]AC>77
M6&7U)U9:R>:8F>>>-9<89RY!/.7<].!R[\):WPYXV%P3IRV,<<S*$8>L?;'?
M)AQ[;!*PTR8#VVT*L-6V')MM:[')MAD;;#NQWG8 Z^P68JW=4JRV6X.5=ELQ
M8W\ R^U/8]KA*I8YO"9,.7XA3#K]+BQVD@D3#_ E]=_V9O_]%:>;<US:3C*>
MHT[*..BHCSU.UMCA[($M+L'8Z!*-]2[)6.>2C34N15CE6H$9USJL<&W%M&LW
MEKD.88GK!"9=9X3%;AN%<;<]PB+WD\*8^Z/"J/M+PK#'I\*0YZ_" D_9'(-R
M/&3"1UY<_H. )\. "^18,'" L>QF7-L]=+#)TPRS7DY8X^V'E=[A6.X=CV7>
M:5CBG8M)GQ(L]JG"N$\#%OFT8\RG7QCQ&1.&?98)"WS6"0.^.X5^WV.B7M]'
M1#U^MT3=?A^)NOQ_%G7ZR_X/[_.4?TO"4V\4O;^4]6TXZ\M0UMF!]!O^&ECM
M;X3E 798&NB)R<!@3 1&85%@$L8",S$26("AP#(L"*S%0&"ST!?4+?0&#0G=
M09-"5]!J44?0-E%;\&%1:_ %<4OPL^+FD+OBII ?B4ST(/^BWM/4OQ@''(FE
M]X]F?<G3S!KF9$6(*I:&ZF-QJ!46AKEB-,P?0Y)P#$KBT"])1:\D!SV28G1)
M*M$A:1#:)>U"JV1 :)&,BYHD,Z(&R69Q??@!<5WX.7%M^%/BFH@[2M41/XBK
M(V3W$<EY+0*X3OVSB<Q! OL?3_T8>C[F9"I"A$41.AB)-,.@U!']4F_T2$/0
M)8U&AS0)[=),M$KST2PM0Y.T5FB0M@CUTEZA-FI,5!TU+:J*VBBNB-HG+H\^
MHU06_21Y5ZDT^GLB$S_(B^SWE23.0Y8]N^3[+WR_@K&P7,="?F\H1@O],<;H
MCK5#1ZP'VF(#T1(;@::X>#3$I:$^-@>UL<6HB:L2JN(:A<JX+E%YW+"H+&ZI
MN"1N5EP<MT>I*/XAI<+X)Y0*XM\BWY&_Q 7QLK]Y3KX7EJJX#F=;&G/ ]TL8
MRR+F8P'I3=! 9X(!VA*MT9SHBH9$/]0EAJ$F,1K5B<FH3,Q$>6(!RI+*A=*D
M>J$XJ4,H2EH@*DB:%.<GK17G)>]2RDD^2:XJ92>_J9R=_ U?_R0RL9P<\C3'
MX")+C(-D<P:]#F.98"S#S$<O8^E(5D5+BAX:4BQ0F^J$ZE1O5*8&HSQ5BM+4
M!!2GIJ$H-1>%::5"05JMD)?6*N2F#8BRTR;$66FKQ9EI.Y4RTD\HI:=?44I+
M?UTY+?UKOO]3*3U-)K[/DQR#\SG OFR. UF6!8PQGG[FHX.Q-*<KH2Y#!]49
MIJC(M$=9I@=*,@-0E!F.@LQ8Y&>E("\K&SE9Q4)V5K60E=4L9&3UB=*S%HE2
MLU:)4[*V*R5G'U-*RGZ,O$:^4DK*^H/(Q,GS7&7?3^=Q+N1R'.1[0&2(,77Q
M\V;&4\>X*G.T499CA.)<&Q3FNB(_UP^Y>6'(R8M&5EX2,O,RD9%?B+3\2B$U
MOU%(R>\6)>6/B1+S9\3Q^5O%<?E'E6+S+Y-7R)=*L7F_B^/R9 IR9>+'J'&B
M@'.!S)!%M 7]I)6QU#&V"KXO*=! 0:$!\@HMD5WDA*PB;V04!R.].!)IQ0E(
M*4Y'<DD>DDK*A(22>B&^I%.(+1D1Q91,BZ)*-HNE)8?%D267E")+7E**+/Y<
M'%G\FUA:)/N;1ZAQN!C81);1#HR0;M)82'V^%I?0_Y>J(JM,#QEE9D@KMT=*
MA0>2*P*06!&.A,I8Q%>F(*XR!S&5)8BNK!6DE>U"9.4"47CE4I&D<J,HK/*@
M.+3RHCBD\@5Q2,6GXM"*7\6AY3)QF)PRF?@\M?>5T?O3!DR2P5+%'E -/RLJ
M9[U=2>];)4)*C382:XR04&N#N#H7Q-3Y(+HN!%'U49#6)R*R/A,1]860U%<A
MK+Y%"*D?$(+K)X7 ^O6B@/K](O_Z"^0YD7_=)R+_VE^(3!10H^ T2_^=U%E)
M%I(>TD0JJMC_&NK7T7?1*L4V:2"J61^1+1:(:'& I-438:T!"&T+1TA;+(+;
M4A'4EH? MG+XMS7"KZU'\&D;%[S;U@I>;7L%S[:S@D?;LX)'ZT>"1\M/(L]F
MV=\<E]^31JVE9(AT\.LZ4E)/S],$)+?0^[8#X5W*".G605"/,0)[;!#0ZP*_
M7A_X]@;#IT\*[[Y$>/5EPK.O&!Y]M7#OZX1KWQA<^E;!J6^7X-AWFCPE./;>
M%1Q[[@F.W3+!L4O!?O9Q;0/7!-)'6OAU%;4+6NG[.NA]:8\B^NB]!@&?80UX
MCNC#8\0,[J/V<!UU@\NH'YS'PN T%@/'L10XC.7!?JP"=F,ML%VX -8+IV$U
MM@V68R=@,?8$>0\6(]_#<O@O6 [)!#GRYP*M(".DD]33&I92.YO:B;1%4MK5
MX%'J+Z+_G13#88DV[)8:P':I!:R7.L!JF0<LE_G#8ID$YLOB8#:= =/I(IA,
MU\-XNA=&TY,PF-X(_>DCT%_V./26O0G])=] ?^IW&$S134S*L+Z+<[$3&.!K
M*ZGL ?*IG4KMF(5 Z&+Z?]I$5UHT>_ISBS4J,%ZG#<-90QC,6A 'Z,]Z0&]]
M (F [OH$Z'"QTUY? :WU;=!</PJ-]6N@-KL7JK,7H+KN%OD8JFOO06W-'X3U
M'/7&2#>I9[Z+AX%,]CE^$I!,T_]3UVTM]==3G_[<<"L]^ XU:.[2@?HN0ZCM
MLH#J+@>H[/* TJY B'=)(=K-Q7<W%YO=\H=0<2!W+27\Q9TG",W[#OKM'5^2
M'UDH_8*I$9Z;2 OS74%[GCL%)+'/D:OI_ZGK3EU[6E3SW?3 ^ZA_$% _H@SQ
M47KMHS0&1UD4'Z/7/N9(/('C+,J.\X1[G">>XSS(CW-2'V?CQ]F1XS3XQRX2
M&NFC'Y)OR ]8Q%QWL\^U#+5PAF/ 'XW:Q#DHOP9G#_4/4/\(]6G7M>G/5<_0
M9].CXX(J81P7&,?#C.-A%N07Z;4?81R76!!>XLG_,A?[RSS0+W.0+[-SEYF+
MR\S%I6OD-OF8?(X%*Q37X93-\EC<PN-@E_P^*,#K*.!PDOK4U+^@V']1>I3:
M5\BU>9Y080&DR6)4%[A!<_*4.8LR%N7/R(MTYD->&-SBHG^+8W*+ WV+ WMK
M+_#\.?(DW[]&_HVNC5P3MW$>LL])A[@.4-?W+.#$E)E?!O2HJ<$A%)Z<WW]Y
M;GXO1,Z+Y"4Q:(A8&-.HO<:<O&X"O&D#O.4&O,LXWF,1\C[GQOO--#&<Y'<X
MP'<H=(?)O,..W'D*30RKE+G.> B(?IAS@+I.U#6CKMY3@-K]_9>7YO=>WIC?
M"_GW_+TY[][?#U$"/M  /J)Q_(0Y^9QSY"M7X%N.RW<L1K[GB><'+G8_</#O
M<;#O<6+=.TW.T_7^O_8?O(B$))*<N?MA_J+7_1WM^!5]^!G#=/'CN(>E=-(S
M].AKZ9,WXFMLQU?82[]^!)_3[WZ*R_3.S]"WOTW7_17NLH7_YWTHT",/[C]8
MSM^3$T3=6/Y6!C6+J%=-K29\@TYJ#%!C%)_-7X?Q,5929QUU-K/-G;B# W@/
M)ZC\,--UG;[]5;S.B&ZSI=?8LIQ7'T"AK4[N[S^84->!/^U+W0CV+YD]R*5>
M&77JV(]6:G138Q#O,(ZWL)A#LXQ#M(HZZ]G^5KR"/1RZ(W@!9W +C^$F_WZ&
MO_DTL_84>S9W'0:Y,8],K,*_!2)_U6*N]=E?:WP!=_8QA'V+Y7"GLT\%U*E@
M7^JIT4:-'FH,LO4Q3M/%>!;3U%E-C8UL?P>>8"ZNXB0>QR-XE.J7&.TC[,W#
M^(W(_@\R3B49[J/"/&NSOR;LIP/^R5R\QER\Q'GQ/+*H4\S6JJC10(TV:O3P
M4!UD3\>H,TF=Y;C(N7&!8W*>N3B+HYP5YW&*/WV"+1WC>!QCAH]22<Z1>60\
MQ&7*G+IBQ:U?_X$J^ZM'74OFT)7]"F0+4=1*H4XN^U+"V*O9<B,UVICM'CR$
M!=192)TI'.<</<HQ.<Q<',0A[&<4^YB-/<)+V"WZ&+N4[F&GD@P[E!5L5Y;O
MB2D>M?.A?(N32\W+7'*>$VMRG QQ162+2V(O7% *Q5GE.#RDDH83*GDXIEJ*
M(ZK5.*S:B(.J[3B@UHM]:D/8JS:.W6K+L%-]+7:H;\4VC?W8HG$*FS4?PT;-
M%[%!ZR/,:O^$=3HRK)UG#?E)'_C8E,L*E]J;7.:N<=E]E/%<TM#&.4U3G-)V
MPC$=/QS6B< !G03LU<W ;MU\[-0MPP[=&FS3:\)6O0YLUNO#1KT1;-";Q*S>
M2JS3WX0U^GNQ2O\$5AI<Q@J#%S!M^#&6&?V,)<:R.:;F^<H">,>>RY SO3>7
M^W.V]'W\[+B1"@X;Z&.?D0UV&7M@NW$PMIA$89-),C:89&'6I!!K3<NQVK06
MJTR;,6/:B16F Y@V6XAE9M-88CZ+2?.=6&QQ%.,6%['(\B866MW%J/6/&+&6
M8?@!/J+NJUS>G_"B[_7@:8Q+VSZ> G<SEAT6.MAL98;UUDY8:^.+U382S-C$
M8KEM*I;9YF");1&F;"NPV+8.$[:M6&37@X5VPQBUF\2(_6H,V6_%H,,A##B<
M1[_C4^AS?!\]3C^@VTDV1]<\[U+_.3_F/H"G5+[N\0&V,I:-C&7640.K'0VQ
MPLD62YT],.4<A,4N4BQR2<!"EW2,NN1AV*4$0RY5&'1IQ(!K!_I<!]#KN@C=
M;BO0Y;8)'6[[T>Y^1FASORZT>KPM-'M\)S1[RH0F.1X*_N'+4UX(<(;LY]*^
MA:>96<:RTIO^WT,%2]SU,.%A@86>SACQ],605Q@&O6+0[Y6,7J],]'@5H,NK
M#)U>M6CW;D&;=P]:O$?1[+,,C3[KA0:?/4*=[RFAUO>J4.OWAE#C]XU0[?<G
MD?W-2]2\$L'Q#V>)0V;#Z+<8RQ+F9<)/P)BO#H;\3##@9X]>?T]T^P>ATS\2
M[?[Q:/-/0TM #IH#BM$84(F&@$;4!72B-G (U8%30E7@6J$R:)=0'G1"* M^
MG-P62H._(G\()<&R.4K)<]2\%*6X!F:+%%@527W&LBB4WIOQ#01IHB?8$)W!
MUF@+=D5+B!^:0L+0$!*-^I DU(9DHB8D'U6A9:@,K4-%:!O*P@:$TK )H3AL
MM5 DV2X42HZ)"B2/BO+#7R%?D-^%_'"9D"]1\#0US\=R'K+LV4"F68:-,Y9A
MQM'/^+HD:FB3Z*-98H&&<"?4A7NA)CP(5>&1J(R(1WE$&LHB<E 248SBB&H4
M13:C(+)7R(]<*.1)9X1<Z58A6WI$E!5UB;Q$/A-E1OW&5YF0)55PG9JG66;L
M(FO)%$N?4<;2SS@Z&5^+5!D-4AW41IFB*LH>%5'N*(OR1TF4!,51,2B,3D)!
M=";RHPN1%U.!G)A&9,=T"UFQHT)F['(A/7:+D!9[6)0:=Y&\0#XEOXI28V5R
M!#GR>\).)-)WDY5D(E&Q_]+-.%I(?:R ZEAM5,0:H33.&L5Q+BB,\T%^7 AR
MXZ3(CHM'=GPZLN+SD)E0AHR$>J0E= JIB<-"2N(R(3EQDY"8>%"4F/2P*"'I
M%OE$E)#X"Y&)$A4(C['$.<)2?!.9)F/)]%O\K(WYJ&<L50FL-1,U491H@((D
M2^0F.2([R1-928'(2 Y'>G(LTI)3D9J2@Y24$B2GU"(IM1T)J0N$^-0E0ESJ
M!B$V]8 H)O6"*#KM)OE(%)WZ,[^6B6)2YA#D]Z4=2 /6DR5DB'3QLT;FHXKQ
ME#*NPE0UY*;I(3O-#!EI]DA+=T=JNC^2T\.0E!&-Q(PD)&1D(3ZS"'&9U8C-
M;$%,YH 0E3DI2#-GA<C,?4)$UCE1>-:SY$-11.9/1"9$9,B$2'(AD^M2!K"&
M3) !TD9J&$LI+4(!W^=D*B,C2P>IV<9(SK9!8K8+$G)\$)<3C-@<*6)R$Q"=
MFXZHW'Q(\RH0F=>$\+P^2/(FA+"\M4)HWAXA).^,$)SW-+G+]S\*(;DR(21'
M)H22T]FT.F2&C)$>TD0J: T*^)K-TCPM3T!2OA;B"PP06V")F$)'1!5Z0EH4
M@,BB<$04Q2*\*!62XER$%9<AI+@>P<7=""I>* 06KQ;\BW<)?L4/D1ODCN!7
M=$_P+Y()_H4*CLGO22-+R1#IR%/L 97D4Y\E>6H1D%!,[UFJ!FF9'B+*3"$I
MMT-8N2M"*WP14A&"X(HH!%4D(; R"_Z5Q?"KK(5O90=\*D?A53D#S\H=@D?E
M2?*$X%[YGN!1\;W@4?Z7X%DN$SS+9,+!0L7U2!.DCS13LXH44#>#5BVQG#4_
MK5)XM1)":K015&N(@#HK^-<YPJ_.$[[U ?"I#X=W?1R\ZM/@T9 /]X9*N#6T
MPK5A 5P:IN'<L!5.#<?AV' 5#@UOP;'^.SC6_2DXU<KFV,6R?X:,4J^+U).R
M,LZ!"B"E"HBMH7X]O5\3O4^+!KQ:]>#1:@KW-ENXM;G M<T'+NW!<&Z7PJD]
M"8[MV7#H*(5=1R-L._I@TS$%ZXY-L.HX LOVQV#1_@]8MGT-J]8_8-4BFV,S
MM9:00=(JOPZ(%%$[HY;>NX'>E_8HN(WZG?3?/4IP[-.&?9\![/HM8-MO#YM^
M-U@/^,%J( R6 S&P&$B#^4 !3 =K8#+8!>/!<1@-SL)PX  ,!AZ!_L K,.C_
M$@9]O\&P5S;'6O9S$>FF9B,IIS7,I78*M:-HBT)I5_UZZ;]I%QV& :LQ59@N
MTH')(D,8+[*$T;@##,<]8##N#_WQ<)( O8DLZ$Z406>B!=H3P]":6 G-\=W0
M&#\+]47/0F/1A]!8> ^:8W]"<U2&Z4;.1=)&:IGO(EKUC';%'I"D'_ ?HO^F
M=7<<IS[]N3']N=YR-6C/Z$!KQHA80G/&$1HSGE"?"83:C!0J,RE0GBF TDPM
M1#.]$&:6<,!IJ%?0O"^GQUS^%A?$+\F/Y#>,,\^]I)FZY1V<!SWTO@,< _8Y
M<!'UJ>NXC/KTY\:KJ;\.T-J@ I6-6A!M9#&ZB1YWDS5QX@'&8FPS3_R;8Q2;
MWUM*%3>>;68G-J_ES^PG--,;:98WT/=O^)[0.5*SD]3T\5A@OE-'>!RPS\$,
MW8NZCFL 2UIE(]I4W:WTX#L I=TT GO4@;TLR/<:\*3+HG@?X]C/HO0 BY\#
M//$?Y$)_,(?(;T;D8!YD @]L)S37^V^0=\@7_+WOT;^ :Q+S73H&9-(2Q['/
M8:L GUGZ[\W4IZ;1'D"'75"G91<=I0DY04[2')VD,3A%S_\0\_$0\W&:7OL,
M\W&6<9R3$)YXSO. /\]!/L_.R?]#XG/TV^<O\95F_MP=\ADZY-?A3 %YRSD&
M['/$1LY!ANM"72O^N"$UM4\"JJ?G]U^82AHJT%+3!(B(&O"8%HMR&H(K1L!5
MFH0G6!0_R3ANL BYP9//4SS8GY+_A_$4>IK)?)H-/BV_+^<%\A8:9[@F,KQT
M]CEZ)^?  1Z#QP!KILSH'/4? 53N[[\\09ZZ?RT*>9;(]R=N,2?/<VQ>F+\_
MYQ4SX#8-PQN,XTT6(?_B2>G?').W.,G?6@F\S0Z^S4Z]_1B-Q5.HXG3-W<7U
MF'T.8XZ]J&O'?AH_3GU.8:4;\WJWYO=!Y->AW)Y'OA_RY@/[(>_1--[A^-RE
M8?N(8_.I'? EX_B*A>)7//%\S8/O&\[/;SBQO]U+F(]O+SRP_Z SO_]@/7\/
MR/UG@F32K1?A=WK,7^:>A=&)>QB@BQ^A/Y_ MUB*K^DQO\(Z>O7-^!P[Z5L/
MX&-.FH_H?C_ =7K8V[C#[[Q/5W__'A0Y[\VCV'_0F-^#T)V_'L6)NO[4E5(W
MA9IYU"JC3AUU6O$9NO$)_?9'&*7&!.YB&356LKU9O(,M=/F[\2^ZWC?HB&_3
ME;]*U_XR?_(EMO0"6_]?9% C8J(\M__P!XSHSFW93T]\@U!JQE$O Q^BD#J5
MC+^!&FW4Z*&&_#J,T;GK,%YA'"]AU?QU&-LY3?9S"$]P^ES$D_S["?[6-6;L
M*A6N4.E!_KOW &9*E?G58]8LJ.G,W/ESF"/Q3R13*X=]*:9&%34:.1W;J-'#
MU@>I,<J,+Z;&--M<PYYOPJ/8Q</G,",XRQ&YBG.,\@Q'Z30S>YIJ#SW ??T_
M(7_TKL",:3%B([S&7+S(7#R'$&K%X ;2V)<\:I12HYJ'9B,>81P/<UPN,(YS
MC.,L)MG^"K:[#B>Q#<>9BZ-\=Y@_?9 M'>"H[<</V,>1WD?5^\CU?X+BD3=W
MYBZ#4F$_=:EIQNB=V!]?:H53*YXZ&=3(QRG&<8)Q'.>X'&4<1QC'(<9Q$&/4
MF&*[*[$'&YF)W=C!G]C&W]["C&WF;-G$$=[(F;:1RG(VD%]Y.'TNO]V-A_8+
M/*QN*,N7 @WJZE/3BIINU MD2U+J)+(OF=3(IT8I-:IY%#10IXTZ/=B*!=09
M9]O3V""LPZRP'6M%A[!:= ZKQ-<QH_PF5JA\A16JOV&Y&L^7\\@?\_,>E[?G
MC:EMH-A^/LUE[Z2*-HZ*C7% V0Y[5;VP2RT$V]6BL54]&9O5L[!1O0#K-<HP
MJU&-M1J-6*/1CE4:?5BI.8(5FE-8KKD:R[2V8HG6 4QJG\5B[>N8T/X7%NE\
M@X6Z?V),5X8Q/07R/9C7;+C$\I1SALO]$7.>2AC/'CTE[-;6Q38=<VS2<<9Z
M75^LTY-@M5XL5NJE8(5>-I;K%6*97CF6ZM=B2K\9B_6[,*$_B$7ZXUAHL *C
M!ILP;+ /0X:G,6AX#0-&;Z#?^&OTFOQ)9'/TD'=LN>3R='>!'.8ROXM+[!;&
MM(&QK#?2Q!HC(\P8VV+:Q!U+3 (Q:1J)Q:;Q&#=-PT+3'(R:%F'$K )#9G58
M8-:* ;->])N/HM=\*;HM9M%EL1L=EB?1;O4XVJQ>1:OUEVBQ^9W(T#S/:R[,
M@0=S3W;+]S[<Z#48SPH'EA?6*EABJ8<)*PLLM';"J+4/AFQ"L, F"@,VB>BS
M34>O;2ZZ;4O095N%#MM&M-MUHM5N 5KL)]%DOP:-#CM0[W ,=8Z74>OX$FJ<
M/B._H=I)]C?/L^QXQ)?>GVPAJ[F\+V,LBQG+(IZ&1QVTL<#1&/V.=NAU<D>W
M4P ZG<+1[AR+-N=DM#AGHLFY (W.96APJ46=2RMJ7?I0[;H(5:XK4>FV%>7N
MAU'F?A%E'L^CU.,3E'C\0F1_\XP_YT$@QU]^[0F9EN]],)81QC+(6/K<--#M
M9H!V=TNTNCNCV<,;C1[!J/>0HLXC'C4>::CVS$&59S$J/*M0[M6$4J]NE'B/
MHMA[.8I\-J/ YR#R?2^0F\CS_8C\3&1_\V0(2Q*RG:PBDRS%1AA+/V/K9BSM
M/BIH\=9#@X\9ZGSL4>/K@2I??U3X2E#N&X-2WR24^&:BV"\?17[E*/"O1[Y_
M!_("AI ;L!39@1N0%;@?F8'GD!GTC) 1] 'Y"1E!,@6!,CS.<N<(V4R6DX5D
M@*585Q!K?<;2&"!";8 VJ@*,4!%H@[) %Y0$^J H,!B%09'(#XI'7E :<H-R
MD!-<@JS@&F2&M"$C9!#IH5-("YU%:MA>I(2=%9+#GB+_(3\2V=]<BF")QS)C
MO7P/B R3'I8_;8RC@7FI(14AFB@--4!1J 4*0AV1%^J)G-  9(=)D!D6@XRP
M9*2'92%-4HA42152PEN0'-Z/I(C%2(Q8BX3(/8B//"W$1=X0XJ3O\_4'(E,0
M0=\MY5Q@B;&&3)!!TL'/FAA'#7-2SM?B<#7D1^@A-\(,61%VR(AP0WJ$+U(C
M0Y <*24)2)*F(U&:CX2H"L1'-2$NNA>Q+(YCHM<@.F87HF(>$J0QU\F[Y'LB
M$Z*B%9QF&;Z#S,1R'$AOK&+_I9;Y*&<L18PI+TH96=$ZR(@V1FJT-9)CG)$4
MXX6$F$#$QX0C+C8.L;&IB(G-171<&:+BZB&-[T9D_$)$Q*]">,).2!)."I*$
M:T)8PMM\_4Z0Q/]%9'.<B.,QR3)\F@R3+M)(*AE'$<GE]S/C1$B-UT)2O $2
M$BP0E^" V 0/1"?Z(RHQ#-+$:$0F)2,B*1OA2<60)-<B++D#H<FC"$F907#*
M=@2EG"!7$9CR;[Y^BZ#D/PFKM209CB1P34P$IEB&#\KW@$@MOR[EY[DD@U^G
M)+/>3-9 ;(H>HE/-($VU0V2J*\+3?"!)"T%8FA2AZ0D(2<] <'HA@C*J$9C1
MAH",(?AG3,,O8RM\,X_!)_-Q\@9\,KZ!;\:?\$V7P8_L9_MK4X!QTDN:6(I7
MRO=_2 ;?)Z?1<Z2SYLY0042F#B19Q@C-LD9(MA."LST1F!V(@)QP^.?$P2\G
M#;ZY>?#)K8!W;C.\<@?AF;L4'GF;X9YWA#P*M[S;<,_]&NXY?\ C1P:/;!EV
M46.&C%*GD]33HI617)+"DCP^&Y#2+DGR1 C.UT)@@0'\"\SA5V@/GT(W>!?Z
MPJLH%)Z<.!Y%27 ORH9;<2E<BQO@4MP'Y^)).!5O@&/Q(3@47R*OD"_A6/0;
M' M9N9(MU%DJOQ>,M))J:K(99%(W,8_]SZ=^$7U'"?U_F1H\RW7A46X,MPIK
MN%8XP:7"$\X5@7"J#(=C93P<*C-@7UD$NZI:V%9UP:9J'-95ZV!5M1^650_#
MHO)%6%9^!LN*7V%5+IM#_ER@<?F]8*2!FN4DC[II!4!L,7T7;6MP.;U?%;U/
MC1A.=5IPJ->'?;T9;!OL8-/@"NL&'UAQ,;%LC()%8S+,&W-AUE@)T\8VF#2.
MPKAQ%8P:]\"P\1P,&I^#0<,G,*S_&49ULCGDUR,-TQ*VDQKY=4 DF]I)U)96
M "&T1WYU@'L#_6\S_5>;*LP[=&#680B33@L8=]K#J-.=^,&P4P*#KCCH=V5
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M?2&=]9#.DTLZ3U3MO$_&^!6;R]CQ.HG8Z_3)50;]53K\RG0>Z<BK-.S*?]=
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M</]".%Y1@_-XTR*X9A'<IHC,H)!<NA 24 #O+B![+/A*@Y#=$]EU4,.RSCU
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M#&\Z.N[2% ;O]8Y34_<RW"\PK7W'N\[[/\;\Z!Z0):[A?H]K2-[L&)Z^R+(
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MC#^>)K(:)AH_J-D!R)+BL2'N$OC"<1Y0C5&'<MU_E0SB>1UMU']X+S3"34'
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M\[K37_\;A_T?>>S_79?]7WOL_]1A_^4ON;FYNWMX>.(#;Q_#"[@AP&0RXXE
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M;0^\KTYX,&R8MN:.]8ND,[I%S#HI9)"F.,**;$] "7^X!U$,[T':32)\CT%
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M0!&/]J-)1_JQI"-]>'),'XD2TTNE/DW1QA>?-0\\-TD*7OJ(":;,)X+/5Y:
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MYGG'?O)_DGFEY3UD??._A&;?:HO&&>,NMYX,R,Q%80DT__.J,+4,/:9NZ/X
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M/](/[?P].V;[W?S#V^X6'=EZ!WYTRV^H8UM^PQS?_"L^=M.OY+B-OY2>&&E
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MD(&^:AHH6S\'"#<M ^)MFX%XSX'?10<3;@N.9U_C)2$NLG)(9^A(5B^)*.S
ME):WP,LJ&PH4574Y!G,TVV-UYKJMQGRW55O@L:H+/9;R(J]95N0S28O]58\+
M4" #'3*40@;FRFE L/9+(%Z_%$@W;P*R'?O_D.T]\9/T<.9U41SL4ME)PAE6
M(;.7CA&V$ZCE32BNKJY(;J[)-=D]>4Z'L<#IT!2Z'.7%+INLV&V5P#P6$=QK
M%L)]IL<%J(\,#,C 7CD5FO]G ]G:;X!BPP:@W+KWGG)7["_*_>DW%$>++DL3
ML><$6:6G.'!^.XU0WHAEZ:,P&;@(P+J5*P]OW;YES;J-JT<]/];FSS>YC05V
MM[K(X9+#G XQW&47(MPV/L)C+4-Z+#RDU_RXAE6ECU2\%5.!>.470+%Z"5"M
M70<T&W?=K]QV]#?MGI1;E8?RKFJ.HRXH4\F]D@)N$P>M")%I!@=:X*B":[W*
M8JM/ K=[!$BGLPSELG-1;ANGQ&-EEW@LK!*O^7$!&F1@0 8F9. O_Q!(EP^]
M8%L$-*N_!?IU.QY4;8[YS;0CX:9E?^9EZ]&BT\8T3+,ZEQT2P14V)J&JDL1V
MRK!*/[_$'."@;5X6QN%B8EP.!L9M*\6XK:48C^5) ?K+HP$3,K @@V#I!T"^
M]'-0L6PAT*]8#4QKMOYAW;#_MG/[\6O>?<F#_MC,#D=*252?Q7*4%\JU?'25
MA%GJ9%.E 1K9'*00K3X*T>ZF$)P."L%EI^#=-@K>8X6R/*Z'AO=> &S((%KR
M+U"^>";0+OD:&)>M +95&W_SK-MU,[CMX.7:_4?[:HZ=;/ EHKR6=*9!FR>3
MR9$&EI#L)'*%?C3'&,0PK#X<S>[&4QU./,7I()!==B+);2.2/);'!4HA PLR
M<.9. I)%[T/3^*= OW >L"Y9^J=GQ;<_A==NOM:P;?M@QX%];8U'4L.1>*3%
MG5JJ-&=+>5J8CJ0DV!$RGC=?J@\4"ZP^!,?F03$=+G2ITXFAN^P8JMN*I7HL
MCPLP)HP&;,C G3,)R+Y^#VB^^AB8OOX2N!8NNA-:NOQFX[>K+_7N7-W;OV=O
M77M,LJL^%JX-)]-$GDP1S09-PE582ZZ.[3JIJ_1DJJ"_M&*[NY#O<,*X3@><
MY;8A&!X+LM1K?ER "1DXD($'&13SW@6Z.3. ;>ZL/P)?S?NA8<G7%WO7?MU_
M?M/JEL'=NX-]!Q--[<>*Y T)9%;U23XVD*?,]Z -:2Z6-<&E<21:7(Z3%4Y'
MEMQESQ6Y;?E\C[60ZS47<7RFQP58D('[WO. /^=UH/IB,C!^\>%?GED?WZ[]
M<N:E[D6?]9Y?MK#IN[4;0Q<V'[2>W9VBZCM46-891R"UIK)A#;G2K"BZ(B7$
MT,<'Y,:X@,-XPN8U)^N\YC25UYPA\YFRQ'YCML!?];@ &S*4O?L\$,^>""IG
MO@5LG[S[6^3C#RYWS/Q7S_DYGS5<6[PT<&WE-O-WZXXJ+VY)YPWNAI$&CA"0
M7<G,_)8\07I]B3RIAJ8Z42W4Q%7K*XY&_-KCKJ#NA"FH3]0&]2FJH"Y5$=(^
M+L"!)E !9!BZ]#5\-.E/[X?_O-;R_IL]@].FU%_[8K;OQP6K3#>7[2J_OB:6
M=VU3!OG2+ACJS%%<04\*+;,CCY/2@A+$-Y(EL?5<V='Z<OF1>JO\4%UU^>%
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M;CG12ZZ-[Z6$$GHIWL1>BN<Q@:+71H."*<^"0LA0O/1M@%T['9"VS@&4O<L
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MI$HLA%+<_^M41*!%713:M:6F.PV4QX^8:;T_3C8</$6WN'O4A77Q@*=_;W-
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M>EJ09* !V89J4&*D"C7X(:C55!D.F2K!:3,E.#>G,UT(=9Q&J.XZ0H7/$<J
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M>RLO,*7XP4E;&%S-UH*[[7;P8$@!QUT%V($ZX!)C#*PT2V#DD\"QW YH-0Y
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M3U"'R-^I+VQ_./Q#F72X.P=@XN<71YR!(LT/='E!<--8 EY&:\';9AMXTB2
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MX]F!S48BF._D 2-Y/K!0Y <;-4&@& J#G?5JH- W LE#%*R#Q<$B7@9,LQ7
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M+&&+8RM'#!=P1'$=1P0/<0GC[\1; O^'$9K!SOU4_U, N90?_S- X"T U_L
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M6&*_.FZ5XV3<%N>)V$,NX['?N([%_>DR&O?997$\.B],0,?A!'083$#[K\%
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M'VK8'_ZL;7L0=6T.H)[M7M2WW8T&LSG707,XTX-E- ,K 192?O=,_EZ TL,
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MW91?MXOR#U']3P)$G"<'OPS@^"V ^0T ??)QK:=\H/%<#-1>R('*"W50>FD
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MY)S33LYYI)6<\UDC)0?54K)1)34;E6?S+(1F(1'@--5@?R$Y7QG5@&X!QRL
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M7K%6Q&K% 5'+%;^*6([_)6JQ#,4MQH@E*#&;0S//(ZGOJRA_=)C.A1& UB4
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MO67M/\^ ,FG?,?L!_(Y0_4G5S<G'=<\!J%SZ?PA[#["JCK;[>^U]"OW0F]C
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M'W'>KBGBGEUCY)=V#9%_V<Z-E*R)%;$D%H^0_ZKA<^;@U5CFGU/^9?K?TVG
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M8J>D&K%=4@_?1K9*>H^0]Z%V47\#M5>L 190MX9>O$#> Z(?CMP)^-.3>QX
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MVP'O9?1?].?C5M.#K3'&\+66&+9V()S6C83C.C<,7>>)(>O],7A]) :M3\7
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MS^]#:=IF5 )3:)K&UP&C:5J<&O4QI,D,@YML,;!I"!R:G#&@:3SLYT^%W?P
MV,Z/ALW\=%C/+X%5<P,LFKM@WKP-9LUG8-K\*LR:?H1Y([U% [W%7"U;6;]E
MY73"U*LB^22%GR.KV 8TT5-G Q-H8D<W4;\%<%A$5[C$ .;M9L069AU#B#,T
M'1.(%TPZ@F'<D0"CCCP8=M3"H*,->AT;H6X_"E7[,U O^0IZ;1+T%W-=OTC+
MNEK.EJSG[)GLBR23[V-G <%SV <:@8G-=.0TL$Y+J+^4^LOIRKL5,.PQ@KK'
M',H>.X@]0R'T<.KOX92XA@/\&E[P:]C1UK!":QA\SRI"F[N:SG,U[>.JWX!N
MZ6_D)R4W4Z^&]<WG:Q+K'#:?;= *3&X#QE+7:04P@,;1<BU=.9V[P29 V*+/
M:8].<PN7AUNY/-O*Y=@V+H^V<4FRW5^[';Z=G6L[*[F]@]]O(73A6VF?M_Q$
MJ+]92SOKV4#-,MW)G.C%@%\G^^!R[:F<8>NIWP=8; 5,=@!J&FDNVSFH*(@A
M)SO&<8AQ'+8'CLA_+<8XCG%Z/L8)YUBB]CB6_$]T'64%CAXBM/5'O]6>4-&Q
MD'6M)7D,-:&+;<"T3:6N*^LZ;#OUJ6E!MV[\:$?F)#E+SLF(P'GFXP*7YA<M
M@$MVG(2Y7'QBK':I=HT3X+5TX#H;^7H[88'7+Y*/^/VO1.JGD7DNI6X:PXQ@
M?:?SUR;LT9Z*&4!-\U. T7E O*3;C;DNGTPA3Y%;NEV2IU5<GAEQJ6Y*NT#+
M\,(0X&7&\2J7(Z]RPGF-%_KK;/37>P@K\P9S\<97Y'=^IJ_NY9C(/,>QO@$'
MM7<F.;.> QFN.34-KNOTGB;/DN=UNQ0OZTZ*R*<VWM*=W'B/]NE#YN03MLWG
MM U?<;G\M?S$$DXZWY0 W[)S?[L9>, D/F !#QC'@X<H87=-/<)^*#\=AKIC
MJ#OP!F#&.NK).T"/=D8>G4R1=T8^>G0JY;^<%/F>[?,C^\DOM"Q_T#+TWUH_
M0_?45K:)M S:?S'FT5-"/M#M2%CH^/==(3.@?2K%_]Z1T-XELX1TD=5D(]E*
M%[L7?](7_D%?^AN3IWU"QT/\S)_^I.-;W6[(AX]V)/IW0S0Z3'5QR'>%/'I*
MB'Q"1;Y#)@/:NU,J6'X=RV]D^:TLNYWE+L>/Z,$/Z,7W=)X/Z$>_H1_^FIWG
M2R;P/C]]P3_YF4Y;WA&1GX@AWR7R8G\,\HZ$(;2G(>0="7F71#ZA(C^Q57YJ
MK"_U(JB31(UL?(=BEEB%K^C O\0\EMW*<MO9+"O8/&M8MTULKEVLWQ$VW04Z
MZCOX'_[T%6;C)=TNB,QSY!G=[H166Z';D5#TQ_0';%@_)VJZ,F_3J!?$9H^A
M1BH^8)N\BQ)VPRJ\P3A>91PO,XX7T<'NNA+WL(Y==RO+W\=+YA2[\PT\R6BN
M,_JK+%WF"1WR*8U+_3'\YT-X?V),W[!]/F,N/L HYFP2M7RH$T:->):?QE;.
M8_PEO$2KJ%"':XSC*N.X@DZ6N8JUWXCSV(DSS,4I?G."M3[.%CG&VLGW4\D<
M?0Q)U&K_*7=I73=_%\;4M,9=.%)O'+4\60]_:D3@(A)8?CJ'J3R<9APG&<=Q
MYN,8XSB"13B,93C(-MF/+>R=^[&;D>QDQ#MX,6UC#;?V]]S_1'[X,$>*_@<!
MR3LBK_8/ VKFSY2:]M0;0:T)K(L78PZB1A1[7!(SG8$]R*=&*35F4F,.->:S
MS"78S#;I8RXV]N^/'&?K7&=4;[/7?M]_!:W2T:WC3U[*#SCD?R#?D&@&W. 0
M<TE/'HH-J6M!S<&LS6CJ3::6#W5"6,,8]KQD] J9V" 48+U8AK5B#=8H&K!:
MT8I5RF58J5R'Y:H=6*8ZBJ7J)]"A_SK:#1Z@S5#"8J/_Y"?J?FK+88C#R35.
M?Z=L./UPZ-_/6/;JF6"GR@9;])S0:^"*]8:>6&ODAQ[C<*PRCL-*DU0L-\E&
METD1EII4HE,S&^V:9BS1=&"Q9@T6FFY#J]D1+#![ LUF;V&>^4,T6$B8^R^^
MI?Y;G&9N#:<3'D;MH9QJ&<\F?M]KKL1&C1G6F#F@VWP4EEM,Q%)+;W18!F*)
M52066R5@H74Z6JUSL<"F%,TVU6BR:4"C[6(TV':CWFXS9ML=1)W])<RR?P75
M [[#3 <)53(#_N$S:K[ Y<=E3C&'.+QO=0;6,YY5_'X%8UEN:XQ..QNT#7#"
M0@<7+!@X!?,'^6+>H% T#H[!W,%)J!^2B=E#"E WI *U0V>C9F@+9CIVH=)Q
M(RH<]Z',Z3Q*G9Y'L=,W*!HFH5#&28>CA/='<CIR8PXF +O&4]^5VHR'RS.T
M,99%0_6Q8*@%FIP&HV'8:,P9/@EU([Q1.R( -2,C,'-D/*I&I:%B5"[*1Y6B
MS+D6)<Y-*'+N1.'H=<@?O1NYH\\@9_2SR![S%3+'2,@<_1C.$E[GE/(DESY'
MR);)K+^\&\)X6EWHN1A+H[,"]:/,,&OT -2,&8&JL6ZH&.>)\G&^*'4)08E+
M-(I<D_#_V#H/\#B+:_V_*]FRK>95[[WWWJ55[]WJS;)LR;WWBFV,;<!@.@;3
M,3V$WB&$4 (AA  I?U(A-[100F^7LO_?[*[!-_<^/"^[^^WJG#-GSLR<]WB^
M^::S)[0D>T93.6LUF;-="W/.T'C.A1K-N<XRDG./93CW.<M@[K\L [G?6P9R
M['(@VXF7T/<SEOE;RJ1CI!UGDP+M*R;'S8=WXI>-^&5MMH]6Y01K16Z<EN9E
M:#J_4$ORJS15T*!%!>V:+%R@B<)1C1<NUFCA*HT4;=%0T>D:*#K?TE]TC65!
MT5V6WJ)?6GJ*WK9T%WT'[);N0A<*[)9?H^^A*OJ!9?Y"<+ "KH--F[%E';Y9
MC5^6%WIJIBA BXNCM:@D50M+\C116JZQTEJ-EK5HI*Q'0V5#&BR?5'_Y<O65
M;U)O^5Y+=_FYEJ[RJRP=Y7=8VLN?LK25OVEI+?_6TEIF=Z+4;FD#SZ+OWAIB
MD27^*-A/6KP-F]9CRTK\LA0L+INCR7(_C5=$:+0B22.5V1JJ*M%@E4W]MB;U
MV3JUP#:@7MN$NJN7JK-ZO3JJ]UC:JH]86JJOL#17WVYIK/Z%I:'ZGY8&VS?
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M?+DIPA/4E^/,R_<X'XE\&63^&.3YTG\#]%_BQ*[-S,WHG )]^+II)^-P+V,
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MEV^G=LSOTW;KJ+9:I[3%NER;K!NTP6^7UOL=UEJ_B[7:[WJM\K]'*_R?U?*
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M 85.3"ED8KV")O8K<.(2!4S<)K^))\';\A_[7@&C=@<"1^RZ&!W[P'HP#49
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MDFSJ3FY45W*'.I+[U9XRKM:4I6I)V:"FE+UJ3#U/]:G7JC;U'M6D_EK5J1\
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M%&XN.TPMQMP/8\[C*'#48KY5,]RT6Y]I2!]CQ[]A3N_#Z]Z%R;T#"WH+.][
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M(MGF5ZIJ?KTJK.TJM_:KU+I0Q=95*K3N4+[U;.59KU2.]2YE67^E++_W :L
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M?+N7A6\!$WH_$UE_@K/(:0X9ZF]PWMS2#X'NA\CUG\?@(UM;0-:ZX /^SN[
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MF=9VI5L'E&J=4K)UG1*M^Y1@O4AQUIL58_V9HJVO*]KO2][;%0L.H6,3^I9
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MT+,L]"MAPY?;GP?I7X?"Y,23O]>?I)/_SH7T[Y-AP4(-;*0>/(YAPF]$FS3
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M\?F$""V$[,6$3>8H"V#Y$ /P6 L>ZR1YBRTWR_$V?F[1XB6Z-B/FWHSVV(1
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MPL%U&7PN-4*0B(\2(2*C,<"-P0 V3H;7D778 BI\00=^O,Y$?BZ&;21@AQG
M>=?QQWT($L8A$!@+#F/AR8ZA9 -;C\3V@K%U0"-Y.: 1N#8,LM0@4QF0QVL.
MKLO@<TEMQ."HIO X#/(ZF%PF2O &T\D8T/2@"SWH0@]?T!L'H#WT$+CJ(;[2
M@S\_!<'#%'@JDQ%7Z-[EY6$F4F( R@O87K#1O'5 H]D:(,C2@$Q50 &O97%=
M!G(E4:R8#N(PA ED,F)M/?"8!AXSV.2"@7TVVF0..M <Z&*.-N^ F3GS>0\9
MG@.[G.V&^Q#;S*S&=VYA,.3E89:S_6#L'!Y@_-B_<T!#\5<1<F5Q709R!T&N
M*(H40/B*R1+E ',PJ<X#CP5BO'4IBV5X"?>EK*-!%TOQQ26S> ]<7@*O9#$"
MJ44(H!;"<]2_C._!JY^/J 6A^4PTW23\'3N>[4.#'?#7(,E.Y.5_)"!7> 9D
MHGDQD>.[ ,N'L+P$-Q^"27X5>!A(\B:^]?*\I.MZMN@)7UZ']EC''OQK2<@:
M] V#?/Z^H _<LUGFPWRGL74XDWA[P88#JG@OI\?6_T ^Y IR<S]\F<OYS@US
M<M;Q'1YN/@0ZV0['PQ \=K-)"&VR!\:T!Y79#>*[T!X[X2$:PF/:GL$[IW;+
M&^Y:E-G3^>?Q@,M(_CXP>:A/!G+%%W*=J+]E]N=?^G,AW+4H?,>3.8'<_ 2<
M#2OPL./PGIMC"P.S@0 ;]D D?,'2!?<@B#9#)&'Z%-^C9";D34%]Q_#W8;$U
M.#*HKQB3R_(^&_DRV5J4/?\IB_!R(2PW8<]WQ/OWR?C 1@+ (QBV$:3.>UB<
M/VS3%S&W+[[DA>C!LY00M^N$N'PA,U%?'7RLA3HK@^K@U9#/],OR3+OX,LW(
MW^M0^M>$>/$=473YOW(A_7MDV!Z.1-A(&OHLVS#,GE63"B4GH6+Q*/"('R$Q
M&+,/(V@_])9,1IU'L7U0J#,'>A8WY#NWYN3O/ BK&UM\W7]&:[^<O]:>D+_S
M(/^Y3J,6/!K19QLQV=2CD]6BLM50:CF45HKV**DCI. 7,@YVI0$5R:&I!K$Z
M6_+URNH92/X^E^1_\R!L8?Y_/K>W_YP0MA8$YL;-2W!S(,*\9\1<09M<A-&=
M6\U[5F]/*"%=**"SCVA!MM(^]APF]'U69[:^AZU#83_\LN KDR^3!8-L4P +
M2OOWWS!9[!R2_K4@;-% ?P[D)\([%_4Y\!K]Y17:Y%?TU1<PN&<0^M@3 7X:
M[FO^O^4??D<L\8Y(D4_<-1BJ?,]7A[\69!XW,OJ,3O()QOH>T<@?,-2W\-]?
M0X&_(O)\@6CT*>*J7]!8]]$X=T@M(JOSY#)*[22\O2^9_-Q'_SF8O&>@\/9@
M/.7C!7B\ 8\/B&?>PQO^ Q[S*WCPS^&W/T)$\P \[B"2NX'.>@6=YB*,]QR,
MMQ<\3H-'-R+N+D3D;9!T',;12-I)'7G"?09+!E\VV_]QD)^#>$5XVX?NDK\?
M/\R>B7*#B)%+B"4N(8ZXC%BF#[Y[-Z*)#O!HA3Z.8\!JQ,!1CX&J%G%=-0:+
M2AAS.:+Z$AA4$8PX'\:;@UIGXHXT<@VF^YE;;W;VA1<_!\&>-,R.LV6Y#[8&
MX12_F1NX9B9 JA#?E:--*A#W5R#>+D;DD@\>V9@P,C!HIR'B8Y%L$@:2! Q>
M1S!P\?:B6$*6"[KJ0=0W'MVV"*^Z(/L5-__!<A]L_P<[X=8<8&;$4GE-?!-G
MW2N9WPUBB2CT)@W(H5Q5= ]-$@D>8> 1 OL(XJ[FUX<^EV*H6(WR-\(:=F#X
MV(<Z6J..'FB9<.( QG9H#1MRC[OOA.4]6 YB#S\/T<8W=R8[COR]!H,M2_.$
M+MR)!/<L3G?$F&Z(BIS!PQ'M8H^8RA;1'SN/TXI_'J<Y(G$S3""F&%1-\']C
MW&6$-MD##>U&"^V"M>R$A;$G/[,]("P/P<ZAJ";_O0?$F3\T6?*'Q_U$&.5)
M AQ $1B*LC51]FB4JX-RIT#B#-1^'LI># M=#>O8A'^[(,,<5NL&BPDG:R%E
M#:S( %:_FO#V?_2?09'+E^_-E\VF C8ML"F)#==;H(O-L,]-:)--L(W-1 EE
M#P5_392MC;+'H]S)*'<&M# /92]!N0:8TK?BE3$W2[2(!&"J3T*K56':_X&[
M_V,^OZ>SO_'\^K.IP(0OFTT7;+IB/U>PGRV60Q?+$7,O0YLL X_EX+&4J$&&
M)LK71OGC4?YDE#<#Y<Z'M2Z'I:PGLZ#YF6BE&6C5Z;"H:;#-:=S3;O[@GD(T
ME3_JA/'US^K/\A_K^'+9SS7,56&NPUPB"(B1.1@SYI#!@!QD*$.&&LK71/G:
M*$N'FWW0P]7)8*4+S4R"+B9R3U!UPJ=A0#;8-@//N"O@QO-'/Z8#E@/:#1=D
M@R#/)6*YCSEXS5PGYKIAQD/I(H $( T9'$ ><E0@1QTRM%#6&)0YD8P#&[8R
M9 PT-AH:U4;+CD(KCX2EC^ ^<>@H[K[+'7W9B4@C">4N!=V/:64KAO35<,<6
MB<-E$^>YJKJX-@$NB0XXC2="*%\,Y4L",H LY"A"CBKD:$#.2/P;AW(GH_Q9
MT,YBC"AKR3!8K ;:0QT6IX;^,10CSE",JNS)6&QGI!I@#QE&XKPU,,M8_@68
M!N@"XW%M#%SW4?A\I)@@&2$L2D8(2A M 2G(&0PY<I"C!#E#(6<XY&BCS(EX
M-QV]> '8K8*FMJ'5S'"7.QA' X7HY2> 7[E9>792E17*WPEY:Z1XR[69BSX9
MT)%F>0_$&KBN"0R3%" :@T2(NK@X41>5)&HBTD1-F$.&"BL056$50(.H"(\@
MRL+CB9*P'E$4GDL4A)<3>:'-1$[(A,@*N1".8 3A".1R3X0>C!EB,/G*725Y
M /*W2;-S3^!F(TR9!DP$Q@ C<6TXH X,E18@JM+"1$5*C*A(2A!E"2E ABA)
MR!%%"26B(#&4R$M ,Q)C %TB"V>8([&4#);82&0DC(FTA!.1$@\CDN)99)!8
M(QDD>HL,$GE'!@E38@+YFR!C&0M/V-H765[8QG(OFH Z, 1\5 8+$"498:(H
M(T84I"6(O+0DD9>2)G)2'"(KI4 X4JK ,#)8:C21D9Y$I*5G$2GII412>@.1
MD-Y+Q*4=B*AT"!&1SB#"4G5$2.HR$91Z300E*??GR/60LQAR9\HAS@#& "/D
M6-X%]0=4 $4.XGZ.")'CB!'9P1*$,W@0X<A($1D9&2(S6(Y(#U8F4AQU8"09
MQ-$A$ISI1)RSD(ARUA(1SFXBQ+$C APX@QS$O(/AP\G V9&!QR*#.0/RUT">
M/MR<Z?P<D#:@B?=J@"H^4P(49(6(G*PHD945)QS.("+#D232LI)$2E::2,K)
MDD%RBD1";@@1E],DHO)CB8B\'A&2GT\$Y=F&?3BI\A@!Y#$3R<%WD@,'V1^
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MMFFUC4[%1=4>M9EEOL<3BH(Z#N=%G@S+B3MU,"OUC']V4:]/:GF/3W)5YT!
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MV>3%=CB4AS2['/5M]&QRJ_-K=:P-;K>IB>JTK$[JLJ@IZ+2NJVT="&@J.*2
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MI><+1WOGI^[.=H^]W:Q_"? T?QCD;?8@S,?D_B&_O3_%!NRYEQBXZV[JP8&
MYH%#@[K T[/* A<>:@AUO=*3J_^DKU6"V#^#KIR70->OB*0[UP=^V;_-\Z/-
M;N=W3L9VOWN86KWQ/6#^.M#"[%6(I>EO$=;[?CULL_=EG.WN%TGVNYZG.0P$
MM%Q1X.T)#KET4Y)T_C9,M.Y//?EB.G=X&EVD$T-73 ^EZQ;X4<-E[G3_:@=J
ML\Z:.FVTH!Y;S+[Z;C/]$KA]W^>0'<9_1A@:?3J\<\^GN%V[/B;MWODA;<]
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MC]JV5E;;=Q9_*^AAQ@$>YF%P2)TN1W,7#*$E*W@K5"IW+J'EIEL^EMKN_ZW
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M<FD>TOMH =+\>8MD)4@OSP7Y38F@NB<*M*0X8'B2"=;*-'#4H )%QQ5H^L[
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M,?&S1Y7K-*6!\L&MS>,]J<MKTKF?-N$T1'^!O^D[BAOQNV\WZG_+;MSW3T#
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M YQ:M8#0I0/X/EW #>J#W0V#']@1PZ^8,:-IFU?&4];O3-Y8?31Y:?75>#;
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MP5B.L=YXI8G.^%E3[6=745Z8:H]],=%^\L-H)IZD(<A0&8)T-(@B#1UB2.F
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MQ\&V2 XP5:? NDD!K,XI@56?,EC>4/UA,:;VU>+MZ6GS3^J39C]^[P&IOK0
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M8TK>Z,<!!8.?Y[&'"OH_/F%?-G1X'*%9O >#AQ!J.XM0U77<X,_H409L)B2
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MU@V$8OY"*& %(7= B HLR 8X"6:PA6@(PD0=D"2I@SQ)!53I%$";7@8,Z*7
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M>.D,:L^=064C0)$B@K,,";RE21 H2P]A*HP0J<<"D18<$$'EA3!O 0B.%(6
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M+?Y+_2)"!:?P_*L(!>/Y;H_Q[)<(F:PAI <(:>*]4,'K4,#KD $!@@2($41
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M[1G70[U%?@X*YWT7D"1YP2]']HQ/J?PIKSJE$YXM*D<].M4.>_2J'W1?J7G
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MBED[O2%F^\QY,4=GUL7\:E47^]RB/IX8STL@^O,2B<Z\)*(]%0F<7 ?,_JD
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M<AQ5W.FX6VF[XW'E;8X_J6QV?*P\ZOQ188,S$:YW(;)(9ITKD9J*./&!>(@
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M[II6H?V:7H79:]8ISEJS5\EVS65%V]5/%6U7?5:P74GD9ZTDPJF.X[6X&_?
M1JR_$NLOQ;FW#F'^Q1R>OQ'S%V;AB#$1"!V3AN#MFA"X?1KEM]V6YKW=B>XY
MYLUT&PMF.X]%<QS'DL4<MN7R[+95B-MN:Y:PWMHC-7/KB/2,K7NDIV^[)#U]
MRU-IR\V?I2TW$6G+T7_:CVNP%>/@&JS?-X!K@'.OPSA6A#DX;3M %&91OWT4
MN!_@@=L!>7"9T 7G"0MPG)A-S9EPI>PG_&BS)\+H-A/Q3*N)3-:,B5(1RXGY
M'/.);M%I$\-BIA/C7).#%\5,#CSA&N_[S#/:2WA&>PA_JAVX]T>P_G*LOPCK
M-^#<2[;A&F .C=D'$' 0,^A1"F:?8H'5:0',/*T(,\[HPO0S%F!Y=C98G'4%
ML[/^U+2SD93)N62:T;E\FL&Y6KK^N4Z&[KDAAL[YG0SM\Q<8VF>?,+1.?V1I
M?D/8FJ?^:0/NOT&LWX7U&T<!RG#NF7L 8K%VP%&LCS%Y]AD RV\98/@]!W1^
M$@?MG^1!^V=MT/IY&FC^8HN<0>-7/U#_+1+4?DL#E:LEH'RUF5*ZUD\I7-M$
MR5\[3@FOWJ.$O[ZEA+\0FMS/_[0*UW\)UF\>_7(&E85SCSV"];&V"]:VO0!@
MAGE<_R< ]:M,4+G/!^7[,J#X0 7D'^B"\.$TD'UH#3*_.X+T(Q^0?!0!$H]3
M0?"D%"T _M-!X/^Q WA_G ?NTT? ??P1N+^3?^C%^JVC7\Z@L@]@_>-8'VL[
M8VUKK&WZ(X#V;P#*-P"$CV@@^T8,I-](@,1;.1"\50'^.VW@O3,&L??3@?/!
M'M@?/(#Q,13HGU* ]KD4X%,;PHOL(R[NQTOH,?J(/OU7&]:OGCP#FP"(P[D'
MG =PN@PP$VL;86T-K"U_!T#J(8#@/0"?L(!'N"!*!, FTL @"D 1-0"BBZ8A
M&^0,?SX@$KPA3_X/B?X\>\!Q$&PT.87N_$,MUL_#^O'X1X$7 1Q_ )B!M0UN
M JC>!>PSUL:A<[$^AP"P$(TP\+_E(!X2(&FD@-21/K)$#LCGK\^"X V1-*-E
M"#<]V?L/1 VSI8;N%ZH&%)&?1A%):XH(G"G""Z0(-XXBHMDTPBE'\U$'13@]
M: "M01O0-HJ(C*.#Z!OT [J+GJ$/@*GV"PZA_B=-S/K:F"\G:>(XE(TH(IQ.
M$9FY.!8_'$LTC? S4 FJ0PM0%UJ&5J$1'.MFM /M1R?0)70+/:4^\]Y3[WF$
M>L?_V]M_(3J:0/34OM#1 **AA\MK3A$E>^R)%T7DPFE$)IE&I/)1%6I"'30B
MV8,&T!JT 6U#X^@(.D=]DKQ&O9-Z3+V2>DN]D"+4<_1,BM#^D/[_(P:8]8V4
M$.9M0V5<3NS'Y'F0MBVNCQNN3Q"-*,?3B"*NAT(IJD?8"P7LA4(_[9/"2MI'
MA1':!X5-M'<*.VEO%29HKQ6^H;U0^(7V5.$A[9'B&]H#14*[KTCH]Y0(_2ZZ
M,TGQ;\08:T^3 V(F@Z^8N<VP'],,@)C,H(BA(T7T?&GX]$,C6JFTCYH%]'>:
M5?0W&HWT5QKM]!<:2^G/-9;3_]!837^JL8'^6&.,_DAC+_VAQ@GZ?8TK]-N:
M#^C7-5\SKFH2QB]:A/$3^A']!_TP!3'#NI:20&9@WIXI!<1Z\DQ&&W]M1A&+
MV=0G,P_JK4D([:5Q OT/HVSZ8\-2^D/#.L9]@Q;&78-.QAV#7L8M@T'F#8.U
MS.L&FYE7#78S?S4XROS9X#+KBN$]UD7#5^SS1H1]%IU&WZ!31H0U%9F.]:TQ
M>]M@[K<3X"6%8[+'7LPV@'>V,ZGG5D[4HQG^M'O3H^BW+%/IURT*&+]95#)_
M-F]@_6#>QOK>O)M]V6R9R$6S(9$+9ALXY\RV<\Z:'1 ];79&]*3Y#;&CYL_$
M#EE\%INP(*+[T3X+PODW8HUU9V/V=N  <<)QN& _G.7AC9,F/)EC"G?M9U'7
M[3RHGV>'TKZ;E<#XUC:+=<ZFF'W:IIISRKI1](3U0K%C5DNX1ZR6\PY;K>$=
MM-K$/V"U6WR?U3'QO5;_$>RR>B38;OU!?)L-X6^U(;PM-H2[V8:(345F85T'
M%M;%[.N.X_#DP3L/"7CLK@"W7'3@9Y<9<,G%F3KK[$\_Z13%/#HW1>30W%S1
M W-*Q?8YU/+VV#?Q=]MW"';:+978;C<@N<UN1&JKW3;IS783TJ-VYV4VV-V5
M&;%_(S7L@%>0 Q&L=B#BB+]ZSM^(_>3\\>W* ^"-#PT>^;'@H:\8W/(2P ]>
M*G#>>QJ<]+:G#GMY,?9[AK+&W>,Y.]W2N6.N^?PM+N6"32YU$AN=6Z36.W5*
MCSCUR0X[#LFM=AP5KG(<EU_I>$I^P/&ZPG*G%W+]SD2FSX5((0DDZ)V"S&7^
M^1&[-[Z8O?$M_K=@"OX3S((K 6)P-E >C@49PH$@6VIW@!MCS#^ O=DO2G2#
M3Q)OQ#M+?-BK2&+(LU)JI<<\F0&/!7++W;N%_>XK%'K=1A27NFU76N)V1+G+
M[4?E3O>GBHL\/@L7>1+9#D\BW>%%)*?Z\_;B"?  ZU\- _@N$N!\) /.A+'A
M:)@,[(O0A1T1,ZDM84Z,#:&^[.'@,-&AH#C>8&":8+E_KE2?7XE,CU^-W!+?
M)ODNGPZ%13Y]2NW>JY7;O+>H+O ^H-;B?5&MV?MWU2;?CXI-?D2(9)%TD__?
M)GOP%GMP&W/GE6B <YAY3L31X$@,$_9%2\".6$W8%&M!C<0XT(>B/-D#$4&B
M_>%1_)ZP)(GND$RISN "V8Z@"F%;T#R%UL %2LT!2U0: P95&_PWJM?[[]&H
M]3^K41-P3[TF\)UR31!1J DF<D@6R7PUN0^>8/Z_BO/_-AYS+V:>0Y@_]R72
M8$>".&Q*5(.1Q&G4JH39].7Q;JR>6'_1KIAPWJ*H>(F%D6E2K1&YLDWA)<+Y
M834*\T*;E6I#.U6K0Y:K5X:LTR@/V:59&G)*JR3DME9)Z!O5TC"B6!I.Y)$<
MDOV*>.$ZA #\A/G_+-8^DH;U,??LQ-?-J3P825."56G&U+)4&_K29&=69Z*/
MZ,*$4%YK?(R@*399JB$F2[8NNE!8$U6I4!G5H%P>V:Y:$M&G7A0QK%D0L5TK
M/^*X=F[$#>V\R-=J^5%$*3^:*" ADOOJT^1>Q.S]'3YNG,*Z$Y@]=V?CLS:^
MKLL4@U59\K \RX!:FCF3UIGNR&Q+\^(TIP1Q&Y(C!76)"5+5">DR%?%YPK+X
M,H7BN'KEPM@VU;R8'HV<F-5:63';M#-CCNBDQUS5R8A]J9X91Y0SXXEB5CR1
M1\*O7OD#W,3L_2WVX%@F9O]<S#OYF#?0ZEP16)XK!SUYNM"9.YW6EN/ ;,IR
M%YF7$<"M20\7KTR+DRQ-29$N3LF1*T@N4<A+JE'.3FQ1S4SLUDA/6*65DK!%
M.SGAD$Y2PL\Z28G/-9*3B$I*$E%,32+RJ<E$^-4?D]?CY#I@#PYA_=V% %OP
M\6L$#10RH:=0&A87:4%;H3FMJ<".49_G*E*=ZRM6GAW*+\F*D2C,3)+.R\B2
MR\XH5,A,KU)*2VM234E=K)&8.J@5G[)).RYE0B<V]0?T3",NC:C$IQ&EA#2B
M@.2_>H37PT^3ZX ].("/7#OP,71C.< 0ZBVEH+-, MK*U*&IS)2J+[5E5!4[
ML\N*O$6+"H+Y^?E1$CEYB=*9N1FR:3GY\BDY%4J)V?-5XK(6J<=DK=",RMRH
M'9&Y7R<\ZSN=B*RGFI%91#4JFRA%9Q,%)/_5_0B RRFX#MB#/26X#S#_CM1@
M#]!BS($+JL2AL5H%ZJN-J:HJ:WIIA2.KL-R3DU<6R,TJC1"DE\1+I12GR286
MY0KC"\L48PKFJ406M*N%YR_3",U?KQ6<OU<[*/\B>J(1DO]9)32?*"&%L'PB
M_]4M?.0\C]?!(5R#G14 H[6X#^9A[FL :,,L/+^>![7S%*!RGCY54C^#5E#O
MP,RI=1?)J/$32ZT.Y2=5Q4C$5Z9(QU1DRT56E,B'E]<IA92UJ0:6]:G[EXYH
M^)6.:_J67D"/U/U*/ZGXEQ+%@%(B/]557(=O,/_OQS78AO77S<<>X"-P%YJ/
MJILY4-8B"T4M.I#78D[+:I[-2&MR824W^G#B&X.Y,?.CQ",;$B7#YV7*A-07
MR076U2CXU;4J^=3VJ'C5KE7SJ-VM[EY[3MV]YG=5CYJ/2IXU1 ')>]40X5=7
M4G$=L >[L>^;L/YJS.!]&$O:VP&J4'$' W(724)VISJD=YI0R8NL:0D=<QDQ
M'9[LR/8 T;"%X=R0MGCQP+8T2;\%^=+>K95R'JW-\FXM2Q5=6M8H.[7L5'9L
M.:/LV/Q0R:GI@X)3$Q$Z-Q$YY\:_G<_^<AXXAOU?AU%D10?V '-X4S=FOZ68
M_3 /I_3R(;%/$>+[]"&F;SH5T6M'#^UU90;W^+(#>D(XODMCN%Y+4O@>2W(%
MKMWE4D[=C3)SN[KE'+I6"^VZ=LC/[CHM/WOQ ^'LSO=R=HN(+)*9Z@3V8!S7
M8!/.?P@S> _6;L,<7-L/4(A9- GC4=0J#H2ODH;0(0T('C*%@"%KRF_(D>:]
MRI/AL2J0Z;8J@NV\,I'CN#)+S&&PA&\WV""P'5PL83VP2M)J8+O4S,%OI&8.
MW)><L?R]Y(QE1')&/Y&8.<5!O [&<-W78OWE2P Z^W ?8.W259B_AS%_KL/\
MA]'(>Y0/GJ,*X#&J"VZC%N R.IMR&G6AYH[ZT!Q&0^AVH[%,V]$TEO7&0I&9
M&^LXEAL7B9EO7,DUV[B-.VWC*>ZT#?>XINO>\TQ'",]T[3_MQCVP$?L_B/67
MX-R;!S'_8@[.70^0N D@="N YW: .;M88+=; F;O5@';W?I@,VX)UN-V,'/<
M%6:,^U&6XQ&4^7@2;=IX+MUDO(IA--[&-!A?P=0?W\+2VW."J3=^EZF[ZQU;
M9P=AZVPG(E-MG3P'P_J]& 7;5DU^#@@@'W-P\C: <,RBWN, <_<#6!VDP/0H
M!XR/28+1,14P/*8/!L<M0/_X;- [X0JZ)_Q!YT04:)], \V3)93&R29*[60?
MI7IRE%(Y=812.7F;4C[^EJ9TE-"5COR)\=7:)7]]%FH(H![[7K@%(!5K1V <
M]<$L//<PUC\&8(J96.<L U0NBH+B)0E0N*P \I>U0?B=*;(!N>^=0/9[/Y#!
MAQ#I*YD@]4,52/YG$4C\. R"G_:CJR"X\@($WQ$07":4X-+?5F#]Q5B_ 7M?
MC'-/PWE'8FV?(UC_!,#,;P",SP%H8297N@(@\S,3!#?%0'!+ OBW%9 F\.X8
M _?.3!"[.Q=$[_H"YUXTB-S+!M;=.F#>70J,NZ- NWL<J+L8Y.^]0QC>[_ZM
M&^LW;OCR.:1TG'LDSMOG)*[_&8#I%P ,+@.H_P @_PN Y#4 WBT L6<BP'G!
M!_8+*6 \5P#:<PV YP8(,_]S>X0/)<_Q9OP<+_SG>-$_QXW^8C/";_SR#GJ-
M/OQ7,]8OQSV7L0^OP:-8_S2  ]:V^ Y [T< E=]P[C< Q&\#B-X'8+X H'^B
M #Z* 'S@(0DDB[]603IH&L"G60"?W1'>C#Y/_AP*CH/@. AN<H*3)/B-R>W_
MJL3Z6;CGHH\#^)['^CAO\Y]P[:\"*-[$N6/[N ^Q]F/ ,2,RU=>S$#Z21,*_
MSD$F/P\R$[F@L+\^DU*'\$V/C/QU'K/_OXBB#A ES-H*2$87B, 8B.@,($Q'
M()0?12 &9:(25(^E%Z NM RM0B-H$]J.]J*CZ#RZAAZAMXC I_\+HJJ)U(&H
M('G\6DH?IV4.A.N 4_2F"#N"(HQ4BM +435J1HN T'K0"K0:K4=;<<R[T4%T
M&OV"W_TA?(37?X[B#0W1";QF_(7Y-Z*ABI2PA4@%OQ9.]L,46SL+>^*.XPFA
M"#>!(F(YJ!S-0VVHBR*B_6@E]FTM&D78"]']\$GT)'P0_1[>B-Z#%Z(OX0]1
M D_%"#SA$GC,)=2_$6W,^CI"(-IR. Y\59OLB2&NS4S NQH0:7^*2.)Z2*2C
M(H2]$#11GP0=U$?!4NJ]8#GU3C!$O1&LIUX+ME(O!>/P0G 4G@DNPF/!';@O
M\1SN2GRF;DL2ZA:Z^9<;4Q!]S/H&4D#T)8'HXJL>]D,7]X6F!8[''HBR%^Z9
M,.JC?!+U5CZ'>BTLHUX(ZZEGPE;JJ;"3>B+LI1X)!ZF'PF'J@7 3=4^XD[HK
M/$3=%IZGKLO?HGY5>$;]J/"9]KTBH5U&E]#%?R'&6-M$'&'^-A4@[(<)]L((
M]Z:^-;S3<8&76H'44XT8ZG>-=.J^>B%U5[V*NJ4^G[JAOI"ZKMY-755?1OVJ
M/D3]K+Z!^E%]C'9%_0#M.XW3M(L:UVCG-/^@?Z/YB7Y2B]"/HV/H*#HR!9F&
M]<W%@%B( )F!XYB!8YJN )_,M>'E-'-X;&P/]XR\X*9A&/6;82+UDT$V=<6@
MA';9H)9VT:")=L&@@W[.8"G]C,$*^FF#-8Q3!IL8)PQV,XX9'&,>-;C"/&CX
M.W.?X3O6'B/"VFU$F+O0SG\AEERLB]G;F@YD%HYC%@\^V4K!,RMEN#]='ZY;
MSH2?+%S@DF4 ==XBFCIMD4H[:9%'/VY>QCAB7L<X9-[,/&B^B'7 O(>USVR0
MO<=LA#UNMDUDE_D!D1WFYSACYG<XFRU><48M"&>C!1%9;T'8D]9-06:ROQSO
MV@&\GT/!LSDL>&;/@[NS).$7&U6X:&L&9V8YP/%9WM3A66&T [;Q]+VV&<S=
M-@6LG385[.W6]2+;K%LX6ZT[13=;]8F.6@V);;#:R%UOM9LW8G6"-VQUE3]D
M_8RWTH9P!VV(V( -$5UA0SA3$5O:G_7?..'M S/X-3<*?G9AP4\.8G!^KCR<
M<#*$@TZVL-?)C=KE&$@?FQO%V#(WF34Z)XN]P:&(,^)0*3ILWR"VQGX!;\BN
MF[_2;H7X@-U:P7*[,8EE=H<D^NR^E^RQ?RRQQ/ZC>+<#X7<Y$&[7'+RRI_CS
MXW6.F'OQ[?VJ#^9.S)_G?>APQET$CKI+PWX/'=CE.0.V>CK21CU\Z.O<0YG#
M;G'L(==4SJ!+KN@*EQ+N,N=J?I]SHWB/4X=@B5.O9)?CD%2GXR;I18[[9-H=
MS\NT.=V76>#\7K+5A0@0O\6%\*::/-I^CO._A;6_Q]QW-AC@>!# 83\&[/65
M@.U^&K#)WQS6^=O35OMYT =] YG+?:)$^KP319=Z97"[/?-YBSW*Q3L\ZB06
MNK=*+G#ODFYQ6R'3Y+9>MM%MEUR#VREAO=MM8;W'&YDZ#R)9YTD$2!SQOYKL
MP2-/S)Q8_P+>7H[CK6X"[0FE8"R(#QM#5&!MB FL#+&EE@>[T'N#_)C=@6$B
MG0&QHNW^*=PVOVQ^BV^1H,FW2G*^3Z/4/)\.F3KO?KD:[V%AE?=V^0KO8PKE
MWM<4RGQ>RI7Y$FDD6>9'!$C\JT]X:[N'/?@!<^<W>,L_A/EW'(WAUQO#N3 <
MH0"#D0;0'VE%+8EPI'>&>S$7A@6+M(9&B3:%)'(;@C/X]4'Y@MK <LGJP'KI
MBH VV;* I<(2_R'Y(O^MBH7^AQ7S_7]1R@]X+I\?2&3R@XA401"10(*O7KCA
M.F /+D9B#^(FSU\P]Z)-\0##,1P8B)6#OEA=Z(Z=3G7$.- 71'LPFZ("V V1
MX:)U$7'<ZO!4?F58CJ LK%BR)+1&NBBD1:X@I%N8&[)2(2=XDV)6\(129L@5
MY<R0/Q0R0XE<9AB1S@HCDDCBJV>X#M=" ,YA[CR<A#W W+4E#?,.YN"5"2SH
M2Y2&KB0M:$\TIUH39M/FQ[LRZN-\V=6Q(9R*F&BQTN@D7G%4IJ PJE R+[)2
M.B>R42XKHE,^(V*%8EKX1J64B'W*R1&7T!/%Y,C/<BF11"8EBDBE1A')KQ[C
MM?!S.*X#SOL UM^1@;DW"Y^U\;4_E09=J1+0GJH.+:FFU/P46UIMLA.C,LF;
M5988Q"E.B!0KB(_GY<6GBV?'Y4EFQI9+I\<VR*7$=,@GQ2Q33(A9KQ0?LT<Y
M-N8">J08%_M)&!]+9)!40BR1_.JA/UX/N/;'L0=[L>XVS+_K\C!OX.L2?/QI
MSQ! <Z8*-&0:04VF%:TB8RZ])-V#59@6()*7&BZ:G1+'RTQ.%4]+RI%(22J5
M3DJLEXU/7"B,3>A3B$X848I,V*T<D7 ./52*3/PHC$HDLD@Z.I%(?747K\5O
M8[^<A>W&NIL*<!\4X?,^9L".7,P\N3R8EZL(U7GZ4)X[G2K.L:<79+LQ<[+\
MV)E9H:+IF3'<E(QD?E)ZED1\>K%4;%JM;%3: F%$:H]"6.JP4DCJ3N7@U#/H
MOF)(Z@=A:"J1#4TCTF&I1.JK&W@]GL4].(%SWH[U-Y0 K,(,W%,*T(+CJ"\4
M@ZHB.2@KTH&B(G,JKW V+;O0A9%1X,-.S0_F).5%B<7G)?)C<S,$43F%DA$Y
M53*AV2URP5E+Y .SUBCZ9^U0\LOZ1LDWZQY^_5[HGT5D K*(-)+ZZE=<AU.I
M7\["MF+]M9@_5U1].8.9AV.I*&=#<;DT%%1H0DZ%*959;D-+*W>D)Y5Y,N-+
M T1B2\-%HTKBN.'%:>*A17D204454@&%3;*^A=U"[X(A>:^",06/@I/HCH)G
MP3LYKP(B@Z2\"XCD5]_C]7@4>[ +^S^*]5=C!N^M!UB(*FHP=]72(*=6 C+K
M5""MS@B2ZV92"74.]-A:-T94C1\KO"94)+0Z1BRH*H7G7Y4C[EM9)N%5V2#M
M4;%8UJUBI9Q+Q5:A<\5QH5/%;:%S^5M9EW(B[5)&)%W+B,17YY-Q'7 /CI7C
M7L3'[Q68@;N: )I0*<I$*<T\2&R6A[@678AIL: B6V;1PIJ=Z2'-WHS IB"6
M7U.DB$]CHJCG_"RN^_P2<9>&>@FGAD52<QL&I!WF;9&Q;S@J8S?OIHQ]_1LI
M^WHBZ5!'))#@JY/8@W%<@TV3YU"-V(-6[$$;[@/,PH68QY,78?98Q(&(3FD(
MZU2'D,7&$-AI1?EWSJ'Y=+K3O3K]&!Z+PIBNB^+8SAWIG+D=A6(.[;4\N_9V
M\5GM*P0V[9LDK-N/2%BUWQ!8M;T66"T@XM:M?^)_=0CWX?9J[ '.=\4"W =8
MMVDQKD,W0#9&DMA>@*!^"GS[Q<%GF0)X+=,%CV7FX+9L%N6RS(ER6N9%F[LL
MB.[0'\6PZT]AVO;GL:W[JD1F]BT0G=ZW3,RB;U3,O.\0U[SOFIA9SRLQLZ5$
MS&P)ZO[;G@KL <Y_".?>TXGY'W-X+=8M6(YK,(#Y>Q7FO]4 SL,<F#LL!0[#
MJF _; !V:RUAUEH[L%WK2EFO]:5FK@VC35\;3[-8FT4W6UO.,!UN9AH/][*,
MAC>P#(<G6 ;#5UD&JU^Q]8<(6W\5$=%?^;?)<ZBU6'\9SKVS!_,WYO"2E9@_
ML6X,QK( S*,NHP"S,+).W\H%BVTR8+Y-'<RV&8+IMNE@,F8'QF-N8#3F#X9C
MD: _EDKICA51.F,-E-;8$IKFV A-8_M^FOKV7VCJ6U_0U;80NMIFPE#=]+>-
M;7]]%@GGWKP"UP!K9Z\#B,.ZP5L!W#&/V^W$##R.&7P?';0.\$!C0@;4)]20
M :A-6(#JP=F@<M 5E \&@-*A&% XE 7RAZI >*@#Y X/@>SAW2!]^#N0.?@,
M9 X02F8_H:3W$=I70UV3/X\&L& 0H'H8('<C0 +6#L&Z'EC7#O.XQ036Q[BL
MCKE8_A03I,Z*@<0Y2:0(@G/:('[>%/CG;9 +\,X' .]"'' OY('8A080O= +
MG N;0.3"270?1,Y_ ,Y9\@]]6+\=Z]>N!<C':)Z$D3AT+];'NG98U_P8@-Y)
M -4S '*8RR4N80[_@0DB/W&!]9,D,']6!,;/6D#_Q02H7ZP!?G7&!Z+)OY29
M_$% ?*.]VH(W9MQ8U_ ;7[L </T)OKY'Y+\6X=K7CWPY TK>!1"&M3V. LP^
M 6!V&D#G'(#R10#I[P'X/P%P?@.@W\#<?XN-> "W,?/?D<<'8@U\&,+,_V &
MP.^3#V>3'P[%<3S&"__)0C0$\!0;^Q0G\?1W@#]>_]=\7/MB['TJ_G'X(0!/
MG/,LG+,I#EGK,H#"CP"2O^+<KP,P;V'M>^CWOSQFXO<6P^\C '@F _!"!>"E
M+CZD6P"\PP?5]WA3_H WHX^3GTG!-YQ/:P ^[T8X.7+MOTHGSZ"P]Q%' +RP
M]JQO 4QPSAH_8^^O @ANXMSO8KT'Z!'Z [W^RQOT%KUG?SF3^22!WQ-[0C21
MZ9?0\N?/YDQ^)@7'0=K_^DP*-IWL^R\BJXE9'_.E).)C[F<9  ',NS '^: H
ME(:*4 UJ1HM0#UJ!5J/U: O:A2;0*?0#N@>?X07Z_.=9QT?TX7\@"FHX=!4<
M"Q+@UZ+:0!C3\$]F(T\4AI)0'JI #:CMK[.8/C2(AM%&-(:U]N+W/0;OX2*V
MZ!:VZAFV[".\Q#^=].)_(,J8]97D<1Q(6A%[@?W@&@'A6 -AN@"A!>*_%8LR
M4?%?O6A"'6@)SG Y5AC"FNNPYA9XA;UX 8>P\EE<MFOP!/]Y!.]P^TR>RB"*
MP(-_(6J8]56E<1Q20.1DL!_*0*3TL">60'BX'EQ<#TX$$)$4E >?V>7PD5V/
M6Z 5WK([X36K!UZP!N 9:PT\96V$QZSM0&X2XN[H&.L7X.OB[N4,(IR'K/UP
MG_4-W&7]"K=9C^"FR'NX+DK@JAB!WR9Q"?PZ!='$]*\I *+.!Z*"KRI"'"'N
M&J$I=LH6=XX[?!0$PUOQ.'@IG@'/Q(O@*;\*'O/GP^_\-GC [X)[_'ZXRU\%
MM_GKX"9_*USG[X&K_!/P*_]G^$'P""Y+O(=O)0F<ER34.716BE!G)DE^073%
M@>AR@6AS@.CP\!4[I(DKIJ8''Y2FPRN%N?!4Z L/Y2+@KFPRW)+-@>NRI7!5
MMA9^E6V&GV0[X ?9I?"][ JX++<&+LJ-P@7A+C@G/ )GA9?AE,)]ZICB6^JP
M(J$.*A%J0HG0#DQ2_!LQQ/J&3$0'8HSC,,)^Z,O &QTU>*)I#/?4;>"&JAO\
MHAH$5]1BX9):&EQ0RX=SZN5P1KV>^D:]A3JIOH@ZKMY#'5,?I(YHC%"'-+92
M$QK[:0<TS]#V:MZB[=)Z2=NA1>AC:.M?MDQ!3%E?+F[SR1]\H\$[<Q%X8\J'
MWPUEX8:N!ORH:PX7]>? 60,?.&D0#L<,$JC#!IG4A$$AM=^@@K;78!YMCT$K
M;;=!)VVG01]]A\$0?<Q@(WVKX2[&%L/CC$V&OS#6&SUEC!A]9@X;$<8:8\)8
M/<GH;U]JXQN=%;XQX0W@)KHZG0U737APR5013IL9P3$+6YBP<(.]EH'4;HLH
M:H=%,FV;139MBT41?9-Y)7W4O(&QP7P!8YUY-W.M^7+6L/E:UFKS;>Q5Y@?9
M*\TOL5=8/&0OL_C [K,D[%Y+PNKY@OG5G__S(ZS_$-_DKLT%N(*^M:?#>2L1
M.&$E Q,V.C!N.P.VSW*$+;-\J(VVH;1UMG'TM3:I]#4VN8PAFQ+F2NMJUH!U
M(WNY=3N[WZI'I,]J%:?':E1TB=4>T6[K,V*+K>^(+;)Y(]IN0S@+;8D(8D\U
M6?\9UK^%-\#OW3%]> "<<,44-(<!^^PE8,<<==@\UPS6.]K!L*,[M6IN(&U@
M3B1]^9P$1I]#!K/'(9^UQ+Z,W65?*])IWR*ZR&ZQ6+O=<FZ;W0BOU6X'K\7N
M.+_)_CI_OOU+7H,#$4.B\QP(9]X<(O(5F?7EQO<KUCZ';_;'_#")8BH==Z=@
MS(4/&]V48-C="%:YV\!R=V>JS\V'ML0UE-[E&L-<Y)+,:G?)8K<Y%W):G2M%
MFYT:Q!J=VKD-3KW\>L?5XK6.6P4UCH<%54X_2U0Z/1.O<":\"A<BAD01YZM7
MV(.[;E].A4X%X9,_IL'=^+H-Q[+!2PQ6>PMAP$</^GQFP!*?.52GMR>MW3N0
ML< K@MGL&<]J]$P3:?#(Y=1YE(K5N-=RJ]Q;^15NW>)E;BL%I6Z;)(O=#D@6
MN5^6*G1_(E'@0<01#XG]1732<US_ZUX %P*Q_Y@$]T1@?4SF&T+PZ3^ #<L#
M9* G4 L6!YI#>Z =U1K@2FOR]V,T^(<RZ_QB6#6^R2*5OEF<<I]"L5*?2EZQ
M=R._T+M3D.^]0C+7>X-4CO=>Z2SO"^AWJ2R?3X(L7\)'7"3VU1/<![_BG$^'
M8@\P">Z,P2=O-!R)3_\A#%@:(@F=H>K0%F8*S:&V5$.($ZTVQ)M>%1S$K B*
M9)4&)8@4!Z9Q"@/SQ/(#RGBY ?/$L_W;)3+]^R73_4>D4_UWRZ3XGY5)#G@@
MG1SP02(ED(@C'N)^]1#WX17LP0F<_SY,Y-OPYK\>K<2O>_#W%D4(8$&D"C1&
M&D%]I!55'3F'5A'A02\-]V<4A86Q\L-BV;FA*9SLT&RQS) 27GI(K7AJ\ *)
MY.!>J<3@8>GXX)TR<<'?R,8&WY.)"WDO&1="Q.-#"1_Q$'?2/5R'2]CW(SCW
MW?@0M#D%>X"6)^'3/_Y>:PP?YL<J0EVL/E3%3J?*8NUI13&N]/QH7T9N5 @S
M*RJ*G1&9R$F+S!1+B2CD)454BR=$M$C$AB^1B@E?+1T5OETF,ORD;$3X'9G(
MB'>2D1%$$!5!^(CWU>0IX7E<_X/Q #NP]H9T@%49F +3, %A/QH2N%"3*(2*
M1!TH232'PL195&Z",RTKWHN1$1_$3(V+8"?'Q8LDQJ:+QL?F<V-C*OG1,4T2
M$3'=DF'1JZ1#H[?)A,0<EPV.N86O;R1#8H@@-(;P$>^KJ[@.WT0#[,=Y;\/:
M(]F80'(P@>!K8RI 32H'RE)EH"A5$_+33"$GU9K*3)U+2TOQH">G!# 3D\-8
M<<FQ(C%)J:)12;G<B,1R?ECB?$%PPF+)P(254@$)6V3\$X[*^"7<P-?7DOX)
M1!"00/B(]]5/(5].Z,9QWINP]IK\+Z<RB_"U%A-R6283"C(E(2=+%3*SC" M
M:R:5DN5 2\QTH\=E^C)B,D)841G1[/#T9$YH>K98<'HI+S!MGKA?VB()G]0!
M*>_43=*>:8?156G/U%>27JE$'/&]4PGOJ\L17T[H=F3A.F B7E7RY51F ;Z6
MXSCR46:^.*3E*T%*@1XD%EA"7,%L*J; F1:9[TT/SP]BAN9%LH+R$D4"<C-%
M_7*+N-XY=7S/G':!>\YR"=?L44F7G(-2SCF_2KIDOY1PR2;BKMF$[YI%>%^=
MP_U_ /? -JRU%FNOJ/QR*M.$K\5E6!]_+[F4"_%E<A!;I@71Y=,@HMR&"BN?
M2PLI\Z %EODS_$O#F+ZE<6RODC01CY("4;?B:JYS\0*^8W&_^-SB#0*'X@/H
M)X%#T0MQAR+"GU.(SVR%A/O5Y*?5QG$-1G'>J[%V;^V74YEZ5%"']?'7T;4B
M$%XK!:%U:A!<9PB!]3/ O\Z.\JUSH7G7^= \:X/I[K713)?:%)9339[(W)I*
MCGU-B]CLZE[NK.IU/)OJ?7R;FA]X-E7/>#:5A(O$;"K^=AA[L+T(8!W6'\"Z
M7?,Q#3<!5#8#Y* X%-Q,@5\+'WQ:%,"[50<\6Z>!>ZL-N+7.I5Q:/2BGU@#:
MW-8(ND-+(F-V2S;3MJ6,9=W<)#*S>2EG>O.(J&7S7E&+YN]$+9K^X%@T$H[%
M?-3PM[UY^)Y0\>730;W-DS\=A3U8./G)&$Q#BS -=0+X8E)W[1(%IRXI<.Q6
MA3G=!N#0;0GVW;-A=K<SV'9[4S;=(915=RQM1G<ZW;*[F&[>U<"8UM7--.D:
M9AEWC;.,NBZQC!8_91DN(BS##M1.V%_MP#5?A_578%A=C+6;._\^E8GOQ1[T
M [@O![!?08'U !]F#LC!C$$-L!PT HO!Z6 ^: =F@ZXP;:4?F*R, ..5293A
MRGQ*?["6ICO82=,9'*)I#>ZB:0Y>H&D./*%K+O],UUA&&!K]?]N$_5^%]9?B
MO-NZ\'KLP7VP#/<!AN?PR5,9#(USAP%F8E(V6<\$_0WBH+=!"+H;-4!GHQ%H
M;YP.6AOM07.C&VB,!H+Z: RHC6: RF@Y*(^V@>+H "B,CH'\Z!F0W_B(DE__
MB1*N(S3AR-_6M@+T8\\7+<'WQ/[)GX["-5@-$(4U_38 .&T"L,; :(I)50<#
MO<HN%LB/BX-P7 [DQM5!=MP 9,8M07J/'4CM<0?)/4$@N3<!)/;F@V!O XCO
M_?\8>^OX*H_M>W@]1^()$0@$$B >B$"4N+N[N[L2DI! ($"0! @:W-VE6+&V
M% JEI52_=;O4A;I0RO-;3\[AEGO?^\?[N9_5<W+"F;7WGGEF]MIW9C(,@PM'
MH'_A>>B?_P(&9_^"P1D1!D_]@RV,_6K&O9_Q[I)VYI"[\#"02G4>>0KP/4-^
MJG1;"E:+R\"89ZB,KVE ]X8!=*Z/@?;UB="Z[@#-ZV[0N!$ Y8T8(@OR&Y60
MW>B <&, N,&&KU.!WZ"TOWZ?>$B(_\8ZQG[I%M7.G ;Z74SNM*?(?Y[\%QG_
M*X -5?J$YP&3%P #JG6M.P*$NSK 74/"E(O>1. U>R9"KDP(F9B]R<7X+28C
M;_&A>ZM'^E/AQ'[B*O$Q\3/QB!!',,A^GRM5A>A["?U.OT!^^NM#7F?R6I'7
M[#9@= ?0HQO*-ZG^WR/>EP,?T(X/1S$9'@U\8LZDW :XY\+$S!?X@G9\R<7P
M2T[X7W'0?;6!.$I<)SXE?B)^'<$\J2K$7Y4QYAF7I)-1Y+\!.-'?R>0U)>^H
MM^B[Q/N15)$A/E-71[X4F)!K,B'5![XS @49$V1+X&='X#<FR[\S2?R#B\&?
M7  ?<.)YP Y_P$ _(,F#=XF/1C!3J@JQJS(9\VAR^]!GQ[O I#> T?QG^A^I
M*S*/*R/2#A%V*:4VN8A?I0J)C%S:;,\ ^-N$8H$Q$1T(+ZAN3*4=TI_N$A>I
M3\@<5I^,N30"T6@R5?=$*FY"84F];D](%8E (I[((2K^?U8D3A#GU;M#[A"?
MXA%^P-_XZS^J( _^"^)HZEOC\1 -""V^AV2',^%+1!,91 E13\PB>M75&55%
M0MJE\@@[R+,/#W&$'$_A3US&'[B%W_$^P_0MP_7'2/7C)^)'XH?_@CB66G^,
M*>,QAK$8"U%IP4\=""\BC$A65XBJB):16#Q$'^U?RI:'R+.>/%OP"W:1YP Y
M3K#=\_@>U\C^.K[FP/F*_^(+?O-SXK/_ 7$\M?XX(\;#$.(HONJ;0=2QH2WL
M#R%072'*HJ^EY*UG:^WT9PYY%I)G@#RK\ V&R;.-/'O(<P3W&(M/<14?XV5\
MR$'\/K_Q+B/UMKIN]::@ADR%D;J'N3[CH<MX4/>/9CR,)K%OID+4]<;?6A'X
M0R,%ORCR\;VB$E\KFO"YO /W%+WX5-&/CQ6#^%"Q!A\H-^$]Y0Z\K3R -Y4G
M\9KR(NYJW,(=S8_QDM:/N*4CX@5=$3?T1%S_+XB6>A G4_^;RR%:Z$"<0)O&
ML7]&6^,WH^FX;Q"(KPUB\9E^)C[1+\8'^C5X1[\%;^IWX77]^7A5?PE>T5^)
MEPW6X[;!5KQHL!<W#8[AQJ@+>-[P)IXS_ A7C'["16,1%TQ$G#,1A;/_!=%6
M0U5@E&!#.RQU\+>%$7X</P%?FMKCD]&>>-<D#*^/3L*=,3FX/:8,-TWK<-VT
M#=?&=N/9L7UX9MQ27!DWA$OC-N"BV0Y<,#N(<V9/X<SXY_#4^+=P8L)WPE'S
MA\)A"U$XJ,:!)S#R&'.:?325CSWQA;V +ZRT<<_"$.],L, K%LZX-=$?ST^.
MP=7):;AD68 +EA4X9]6 ,U8S<=JJ!R>M%@@GK)8)QZQ6"T>L-PN'K?<(!ZV/
M"_NM+PG[;.X(NVV^E.VP_5.VS5:4;26V$)N?@.A$&YPY];AQJO4 WG7GM.\B
MQVNV.KAE.Q;/VMOCXA0OG)T:AE..B3CNF(4CCL4XY%@E''!L$O8YSA+V.,X1
M=CLNE.UT7"[;[KA.MLUQNVR+XR'Y)L>S\HU.+\B'G3Z5KW7^5;':692O(H9<
M".=_(!T^_(F\]SC%OQ5 _<\EYP4?X)JK$I==C'!FNB5.N$W'8?< ['>/P1[W
M5.QTSQ6VNY<*6]QK9)O<FV4;W3MDPVZ]\G5NB^5KW(84J]TV*8;<]BI7N)U4
M+G=_3F/ _7V-I1X_:2SV$)7]*B@6/8&'Y/^&_.^'4&^%DYNXS/?G_02<FF&
MP][FV.OCB)V^WMCJ%XY-?@G"L&^FL-:W0+;:MUPVY%LG7^'3*A_TF:U8YM.G
M7.HSH%SLLTYCD<\.S04^1S7[?"YIS?=Y7:O7]WNM.;Z/-'O\1 U"^21^F<$E
M*)A++Z?UZ[',\^. ,USRCH=1;P3J8E?06&P-ML.&$ ^L#0G"JI 8845(BC 0
MG"-;&EPL7QQ<)5\4U*!8$-2NG!\T1Z,W<+'FG,!56MV!6[1G!Q[4[@P\K],1
M]+).>]#7.C.#'VK-#!8U"8VV)_"C'Y=#ZO^7J'VO4GN>30:.\74_[=D1KHE-
M$:.Q+M(*0Y'3,1CECZ61$4)_9**P(#)#-C\B7SXWHDS1$UZKF!W>HNP*[]+H
M"._3:@];KMT6ME&G)6R?;G/8&;W&\%MZ#>%?Z#5$/-"ICQ"U",TG\6T0\#;]
M?H'<%].!DQGTGZ\[^?/&6!E6QQAA>>PD+(USPJ)X;_3%A0J]<;%"3VRJK"LV
M6]X16Z1HCZE4ML4T:+3$S-)LBN[5:HA>IET?O5ZW-GJW7G7T*?VJZ.OZE3'W
MB#]T*V-$[<I848NOFH_Q)6/^6@+P'+7O.:8^1YEV[.'K%MJR)I%Z)]$ BY,F
MH"]I"GJ3/=&='"1T)D4)LY*29&V)&?*6Q'Q%4T*9LB&A5J,NH56S)J%'JRI^
ML4Y%_!K=LO@=^J7QQPU*$IXS*$[XA/A-KSA1U"&T":W'^!?'P<OT^4H6-6<>
M<(@:?">Q@4O^<MK5GZJ'>6GCT)-FBZYT5[2G^Z,M+5QH3HN7-:2FR>I2<^0U
MJ<6*JI1JC8J49LVRE"ZMDI2%.L7)J_0*D[?IYR<?-<A+><8@-^7#4;DIO^KE
MIHHZ>:FB=EZ*J/48'['?;Y'KHE2'HO;<5T*]1:PM!);0KGF9.IB=-0:SLJS0
MENV"YBP?-&2%"+59,;+JS&1996:6O#RS4%&:4:$LSFC0+,SHT,K/Z-/)S5BA
MEY.Q13\KX[!!9L:541D9[Q$_ZV=DB+J9&:*V&EH2WF,_7"?7>7(>+:7VKZ#V
M)X;*F.OG,]?-TT![GC%:\B:A,=\1=?E>J,X+$BKRHH2RO$1926Z&O"@W7U&0
M6Z;,RZW3R,EIU\K*F:>3D3.HFYZS23\UYY!!2LXE@^2<MXF?]%-R1%U"A] F
MM"2\D<*QP!@\1=\/5?)9J*;F8SH\6 7,*:;>*)*CJ<@0=47FJ"YV0&6Q.\J*
M_862XG"AJ"A>EE^4)L\KRE7D%)4HLPIK-#(*V[32"N=JIQ0LTTTJV*B74'!
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MEC_D+LVBW*7I'TA[HO;3_ZVS@#6S@264(G/G<"P0Y7R?U4WMR\]#N^3P[S*
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M]_H8N-6GPK4^']/J*^%2WP:G^CYA:OT:84K]7L&A_H)@W_"68%_WDV!?*X[
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M4SRY,LE31(XJW$,CA\5,^M!-+^?C?=KQ+NUX"VO9YF:\BMUX!4?Q$LYS*+_
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M%[T$^Z+O!/M"4; O$ 4'"?FB<)1^[J+_&\B[HI']T,1GDFAL5.U#2:==,55
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M!).!]9SHUS,6ZSFHUW>J+GY=1\V]EH)VS4?$KYR0Q!$,T-\%R_@LD+=JB'U
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M_^%AY_V7[@$QS@0QSB0=*]MYH,9:$&,OBO%<E)$],=MAD'OU+YC=#]8S.<[
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M*C*J3!%1#0J/[E1HS!2%Q PI.':= F,/*B#V6OG'/22_N+]P_5(!<18%(F?
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M8(L>;-%C=+!TN#TTN!X4[Z&@[E6VC15=D+AQD+*Q</^QZ-!IT6ZP-PW;UZ%
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M09B#FQ80!LLI?QUAL9W:'\"-)PF?&]'B?ES[HF[%<L8>E)LO68-Q_!(=C#D
MX['';\B8UG+5\_"JI['%DW"[QY6F1^!3#ZI"]\'.[D:/\^AQ)ZSK#AC?;3#
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MIBO,<ZE"/7<HV/.D@CQO5Z#G1068WD6^5: )[@_^(3CDSGS;T71+&>;G\GZ
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M8TRO'(Q#(V,@+3&, C$DO3$DFS&O()]AU'_K$/7?V6!;DFZL0QDVSH0U]N)
MF3O@^@W8I (]"] EC9B-I>V$8!/?9">9XMWE%N<EYSA?C8X+D5-\M$;%)\LA
M@2!+X$<)%)H(84Z$8R5"EA+)(1.-ATD^B/P?GZ-#PK]U /SM8*YKMZU#&4*F
MP?5[X=;M%%'/Y^7HDH--DM CDO@)P";>F8YR3W?7Z#0O.:32P:<&&A-FQJ(=
ME$71-$-I?IQ.#IM.+IW.Z),.B4B##*213Z?]B>]^9IV',9Z/M!7,M5VV=2AS
M>VQ'1TR LK=QOPY=BIIHDU"E.&P22O5\B1//0D<YY\%E<AE<<NG$<AAT<NC4
M<@B8'!IV+D&=RX]RQR+3$(AL+J-QSAF$3"'[)>0SZSR,=3^2\7SF7MLZE-E(
M/S*>]V/0I9+/<Z%(R=@DDFH1[O+"?ZX5H^10SL!6QJ!2"J<JH1,KH1,IH8,M
M24%P7 E?+*$B)7#_$KA-,62N& )3!%DH@G<7?F:=A]F%NS9-MJ]#@9;.,I8J
M(%U3\ .4O9C/,[!1++H$HXN9>'%''\=&!X*% :V>P:0.6]1BBQHZ]AHZM!K\
M46-L;L.!-?R@!H :1N'J+;8'G%:1K56^2*"A0[E%V\%:/\VV#F4^H3/3OA>G
M=9"O]6.#/L('NX1#TWRQER?Z..$G!F^"%M[?CBW:L$4K@ULKMFAAX&UA$&S!
M'RW$1(NQP(D?CYF+;+0=<-D$26N$^S? _>LMV@+V&IK.TB';F;#3AK'!/#Y"
MER)T226<HM Q 'U,V,H9G4B24!3!3NIU(GC08X*G;4V*L="Q!UOTT)GTX(\>
MG->-XMT4UD7[[")+'$?6.!9"UOD)];!HXY!M'<KB)?9G$R]&;5Q7OH!P0:=8
M/@]")R_T=)YM36I^$O27=5T*>@RBQR ^F88>TQCDIM&I#M"A#!#$ S2Z?BK1
MOQQ'0ZZGD#7WD45._IBZ6+3.6(>R$AO0?*=R[41J:$9Y2"(_"5E&#/ =%_33
MSV617:QK4T@ %Z+' NRQ@+:Z@,%E 7$QG\8\G\YF&*,-+[ MMI@'F9[[* /3
M^U3\WUIC/)>'Y'$0Z=Z #Y!"W):,A/':C+A8SX*UR\B>G(V7W%M_J1"GZ]%C
M/;&Q'I^L)R[68XOU!- ZC+=NH_V,6$CTZM=QPG=:MAFS$JX3MA$NVVE"J)EF
M/P_6!W$967<R<B;L_]R/<XE8/\,W!SQM">I!?'* 3NT MCA@',J#<?<?XKN0
M^GW/4^;GF@OF9#!:]Q$#_#[C(/T 7_&Y'/Q+UY]<.A=RE?YS'XYU+XYLYY48
M8IV[H,V<0X]S])_7XI-K&8ROQ1;7TC[. 7J./OO<!;[WOJ: VPYF%5C9-)L8
M<'PQE<O(O M=JW6.Q9A?&7DVSJWZ'_MP]-/9(2-K1>ZG#WG06$1.;#Q$,O(0
M_>9#V.(A@N_AHPA??O#W&DL=:T[0#U"7./#\P'.]3O^Y!N5.>[G&_,K(>I/_
MM0_GTOD0XP_8QKJ0WZ/'2\89K0SX?R8^7Z:-O$Q#^S.V^#.L[D^__!_S#\;Y
M("/[8:)A(FGP8N.OD57ZE'S98$@?DK=_0"?Q'KG[._"IM^!U;\(J7R=_?HU@
M?0669NQ%^0.&? %C/8>BS^@-U/K>N@_%0#UOGX.X]G_,@1CS %_!:8QGHGQ,
M_OX!6?C;9.JOD\7_A<S^CW"8WZ''"^CQ'!W5,_"II^DHGH*-/4E#_35L]P(-
MYU$"^&$"Z0%0[L,Q]_#MN_39C\]!,;"O^MD:C)^>AV*LPW"&"7GI]_"(Y^%4
MOX'W/P%_N "C^"5Z/(0>MC-!NRE[(F5/I>SIA,0\RE^$"U<3.EMU \SU.@+W
M&FQQEE^?AG,;<Q^G9-N#<L"^!F-D_L7 -N8@GK>ZTP$7>X#E TXH&+&4GT;9
M^91=INO1XUK\<@U,[RP,[ Q,["J8[BGT.&E=:; 8"ZR%N^^$X1VAN9[3/IC]
M'KRS"\YMS'ULE^T<#&,-!B.7=?[%6$[TI#W4SEM#W@4L+W#\P0BG_ 3*SD#_
M?,HNI>QJZS-)]L/^]L&I]L!S=\.K=L+ MV./K5H*AG$:QCZ8]RDL<RO1\H26
M$TW+P%UVR1H,>BKK_,MC]N9D-#=C6O*41H'G 9:9KB>(\B.U Y:V#3UL9V&4
M4'X5Y==K#8QW-3&RDAA93JPNPQZ+K:=QKH W&T]).8QUKM5L/#C3NIKH>^L9
M&(9,D\6*_XB]^5UO[Q*.VKN\G=AB"VUDO7S!"*'$*,I/9*C(P.NY6@"_'(;G
M#L%\YQ(C<]!C%GK,P!Z#H V@A7%*:1]>GT0D]%I7\3QC78/18U^#88BQ!>X7
M]B[(Z 8/V;MF8XI\#;98)G?PO,'R!R,4C&@P$L%(!R.75E%$))2#4PM.$S@=
MX(RG['YUH=E8+-.!+=JLLU<W8;$+:/N^]?2?$;F'E/ &#[I=NM5#I$0[1]N&
M(^// \:0.%>CP?0$[__9>P^PJ)*E?_B0@X#D($%R3D/..4K.29$T!,DY"*)@
M $22J( @"@(J&! $% 0#29)*%@041 5$1!1%!;X>T5WFS+#[WO>]S[W_^]VI
M9\\R3O].5W5U=7=5IZ$&?!A *]@!>' !'OR@58@"BT0 /G* CPIH*5J_SH&8
M@__;_SPAHP-TH05J#64]ZL V54%]J()>1 7T.JB;B%!/!>JH)1CBLL&3C#H#
M@_JY.B!/ ) %Y2ZX@#;B )&"DE$"?C2 %R/@PPKX< $^_("/"+!,!*0-Y- "
M.6J 3VH H0HD1.U2403V*0]J4@Y8K0QH/=+ XJ5 ZY,"/0$"\$<]I6!(R0/N
M5QKHT@^#)X9QX[IX;]066: 7>S#T6$"$0)?D@"<5*!<M:)F,H$RL@ \7X,H/
M6HDHX(4 O.1_SH3( ,FD@;.' -)+_+S!)!0@C@!I<R!A,+@(@=8O",V"9^WG
MCKP+J+M0.,$0"H;8>/"$@V[=#\CB#F1Q!'JQ!$..$0GP*T"_I0':B0JP#04@
MAQQH*S*@S4H#.1"0 .A)10$O:6"M2H"7%N!E!/*W^6DY?*"5\ (+0]UTPP5Z
M:$[H/GA> 0M?^?EK807 _<P$0^M1$%_' A<P!,1Q/K_W@ !7W12X 'I )^K
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M<E#SX4/;N,D@(DY*"&\G:#0[0>/9"8R7$RB*$Q@2%U BER9X@"_-!6(L;A#
M<:,VKP-GF0LXIUS V>0$,NS\ :4 _@<!WRBCC7THGL#EW ,^6QN"F _(H@72
ME8 L$D G?$ .-F _=,!>*47Q(1(A4@A/ '3L_* #X0.-AA]TN/S @/F!D/P
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MSJ_O<GX%"+_O+2D <A2 ]EH ZJ0 M)$"H(M\8%#YH-#Y^>"Y#7"3D",P4R/
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M 156U#\!3/Z#6-._'T1L] ]DKMC[H%Y'_%_[8_9@!UR2_;V!9G<?5D <Y6^
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M80 ).. Z#& )!\#CP6@X( T&*($##L( PW  AA,C!P/XPP&Q,( /'#!$B0[
MG":!A4&83LRZN8J>J;7#'E</;[^@B -8?%(<_6MI8:"^^'BH(];EAZ]-:1Z:
M7#_72"%+S(#T2X$M\Y^5S01O%NO3?HQHY@!O_NON,(MSAJ7#9A<@2!8FQ 4X
M@ :VO- !!T#UZ(#W&( +,"$HX( 4&$ ,#HB  4S@  \8(! .L(0!LN$ #1@
MPPV2A %FX;T8-PRPK@,#,, !AV" ;?"MO>W;T 'X&'O[X'X0QL:V1^@>)82Y
M&%RP:<J*A(H)RX+TP.V&^VT] Z,O7\]_VG+M#T?_"'V=V&*+Q+O6DB1_:V4N
M$D@*RZK;4):#T)^U=1XC/1E]3,*8@/"$F8L4; +B%"P=(H YO65P %P(#/<
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M5^TAFF%8<K,YS!P*T=.+,'Q[6$B+X7=#<N@ C-E%B 3F],*G." (-E6+X1Y
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M12QX\-A>[]B7^;G%$?+C)>EGWRPSFHXM+U/=3?4**NFL<6)?FB25KTMZG;Q
MQWI3?BF]C6,5>;7B5MM!8A]UTK>E>-32/K8B!P_NUR'BZ\+'6YAY]^5UEI5^
MI5"BVB1^^G32P,#S2\/)-E?>)2_0UEZ:=)^@Y4.H)]J%#1A:?LFRD#5:A\)R
M.T)^K/4F':MZ+#N/>,/J&VMLEMV\:D7W(V]URJI4IF^'SPF9UCQW$U0S,/;Y
M-W[ANZW)N>C6F,]\EDU^UV4GB+^']C9S0_=1_X\%F@T>,DX'4N[&OKH_9B*)
M(#4G$+R27&K%)G/K9ATS Z)+<9C^PFNIG&3N<TLT^#R$.KH(&AKE0&6=^5UW
MJI3S^O'8NGR-3OFROW#;Y<:_/Y,T5<?XD;&.?IS>O'^GUQ"K%,-<$WMM:YX/
M-Y^HR5D7F[-\>_8@C2UKO/B7$7,/-1O#QW_<K_]TKU22C,CM['G*ZO)R0E5=
M@E;YMYGQ'CG)683R 7HW]'B3N/6B][>N.5;TG7JG58.0<C*"(D^E9R-2)O*9
M^&[<UV&*7J!A_QQ='[0..?HIM_;?'7G'2FPX.%)JY9/UY$!CJE[];NV])C_X
M2Q[W.99 #J3'56,ZD )3T^R[#'D-98TOC @FTV@*S]+IV@X:.1:IS!_@MCDO
M>#Q<ZM3<4*E818^SII5/?[GM@QTUES\_$7;)D&M6>B2?U[U?"F^935S_V/.D
M-_3.+=/D7:.Z[71'::C'ZFZX.29"-[O+\JU]6[B^TA2[>EZ1HV>?>-YI]XI,
MVB=L^4G*L=&E]CU\<M)DW54O=2Y\.*HEO"*/\$[E-1\:EMG/.Y/)0H%(9C82
MC#QZ0[RBA&_75=N[CAI\,I>E"ISH3\;<I$C3YWDY;W]LMVOEZ1WM-]=*3G%U
M'*>*NXA@9/,_?:K.O3.++?QZ&:OM&%DFJ5UBN(J:>/9AX1T,ER[[!CU2.)L5
M>B[1I'%1/H/TN>_3I9G!L+6NNGLQ(5X,W'X#5W3>5;,]Y+-4VE4T<SA1[SW=
MVW@R"[,'07GM.3-GXRA./$<FW=)Z**+BIL?<N&?%J(>?G'27P!B/VM<A$O6'
M.6I";=)TS0HC*\:A!A1S]HE);\A>TQ$X7"U'%'([I'[GC\@]X6?"HW6QV4?5
MCH3=^GIM4N#U67(>#AKC;#\;ID-N+Y$JLA;F%$7E5XK*S,>FF-\@#L>D^89W
MVG)TBM\85"WA;WUT1I&^9TD:@7BCUCZB^K1<YL;7"J3PUPYZX<$+%FYY [89
M,T*^[_ ES:V4][_V]-S?U36[(ETL4Y)$*'"+JC*'AN@.AUZR7<1EHGO9G;FR
MIX\K769WISYJ/I-?IIABQ?R #X\RY9&'Q>K1U9;HP&W5+Y)'.Z/HD@KNGEW9
M+VLY01$TMMH0N?VE6/O2Q^[\/4S4G_EY5PR3N%D4:4YFYF2-R$]X#_(?$ U>
MJ'_N?Z6<1F?IK0'A^)"!AF2DL?4CPH\*E[/OKV:2$@D=FS],.!Y=.\2B6- Q
MEZL6*I83UK6R(#6L6/CPS?R ZXLU9NA(V;9=5Z8.F)<2&>C'*S!?,CR4/-%
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M\X6" \HKY,QW6D+Y0JZ2G]?B<QL=VL.MKW)>JC4C'6'FROY%Z&/RP+B4I5R
M:GZU2J*0_6U"TIG4U-"+SI51SS1F\^;WR"LEB6<^_,Y IYBB%D?2'NIPJ.*1
M'SX!628G(I-+<"F!)2DG9[FY]=OXL=(..[=ZVT\*1"DAQO:E%<7!LC=X#S87
M-U!W-;=ESXWES 7\L_S22V\>K1:SE(577@^LZ!T8"I9ZIVIZF*/NEG^N$7U"
MJY3K7JT3ND?.U744K1*(S90/Y20.MWHX&_2PUNZ[V5SQYL%>2V[%[FZWHTTB
MBGMHCS[JY+@A=.G.%)VG'UN*EK7D6]GLBGF[ZQ(VEPL.[3)@]3.BOWU]&9ER
MD:M9))1MAGQ.K[F-U86!NI<E2?6!L+#EV6M+]7S7=[&L=1T-E]YID%5AS_WJ
M'8V$,^\EH\8;9@:)^XV4E@ZWJJ;Z[/OLRVYAR:'6237VE,XBH&#7>'F;8^M2
M>)ZXMC/^OE5?4>F0BAS!?"K_# _>$)L*=F5#Z!!](R6/UMSK-;V"C[375)E*
MN(U<'KKZ.E*2SY+G.OB>,LDJ1H:ZV/<%R7Y.VK''O^/.:*E,?\QTVUN+5V_F
M8\9V/KU[9H>OZSZ)GF+[M;;LZZ^?!\@,/MQ"KXW[>+-:W@OG[3MYW7GVL%!G
MO]+![6'WN/HA':5/<Z_5U>1S/A;<HJ-1+>5V?^R3=&YM[=N-AK+^B^2\&>5#
M>ZE;$!1V&9EIN]Q8NUIH*_I?\$FNY!2QDXP3G-5=('O.]J10M>6H=%-35,Z
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M4[R;O\2G]E<20SUMZQ"E1\QRVSR;_@<;LR6)QQ-*A4G,ZU#]<Z_Y=2CN]O7
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M&3W%2>F]"MV9UH>- 2JG^ACT#TWD'F1XV7*'-'EP<TNSZD(5/=TH(^BG+F^
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MO*H;:X_UCJS2I1%VJB2M8I-"!"_7+XC7P4V]J4NFHYF9-^H(3KYA3 $=9)2
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M0@7U;>0(T>7&,F E4LT N&LO=7?6@2BU$;2JH9&(=:92DN*5),NI0@8."6@
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M<""Y&<[?#46+=W;E 4$7D4@X1,R1V98A2ZI_4TP.>=>3/RZ&6I(.[+R[]2)
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M>;F<&0&,9P;ZY,V*/?9V+0N^@UOKY(0F1#L_/#_96,H1NR6++ S7\*9_E\1
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M/?NO\=A@CGXP\D47=D+XZS]8:\=KC?U):7)R89HMM8LY"PZ(R"SEW.;5:5#
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MXARTS_-\8VV_$ENQB8S8NB5G#E-/A\%=ECF-?-V:0&H<17.@HGNF#'WL]ZS
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MI>45DHU7=$MEQ%935(=P39;NUPMK[+RKPA$RRE#O<LCE<X"5J)29YT90!=$
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MY%G=VJ>-KS"%E)YE<A\!SF6OR -SRDWMH][:VNW1+>3>*ZS\Y1KQHQ+Q#]*
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M1UTBEU.7I:%[#-1\B)Q]$2M/X.44Q.EE,U^B6[E6B;ID[4D[*S5[?&';5J5
M$! #R;^QMU&;^?HY>Y_^P35I"7QN=6UI0/BQC$U O=G].,W6:;_VE-^51R#H
M&3TE!8I\3\EUKW!3LJ9C[;/^S%]]A?7Q.3:I 7++$ ?&-S+E2HN)!8EM_"!U
M<<?R=U%XBP_4]OD>;!E2IC;U ;]UP3'*3Y5WT[6L#:=L/%$.I88H%ZZT#X>7
MDJ)I$N]EFS6><OSPE(SP^25LDG7WH+IR*QPNH*[Z@_ J3Y8/W!07NU^1Y+O+
MLQ*83VZK4X9JZ!2.>5_6G/'Y1#[W;S9F#?/)%RSI:!.QJ)VXN;V=;=B]UDXL
M0:4^6." KW>[J,,VV[+1KG<DC$&QW.5G76L\9^3@H^PM;)S3H&RA*A;79,ZT
M6&O0;8CN<A*EM[/,#9(=(5'6/[R\@LN+9H@J(D/Z/6;=/3%-A-MXMP3&/A+^
MHX2-H1BB(G4U,PY0+4,N+RN8%TV!%$M[4)#GBY!17[6)IB5HZ6,01#E5QQ_&
M,?I5F+*5(+>L\/YVT*$R:F4=G^17TM50/NW%4A5EU5+0[D>^,M5UFUE^QJ\Z
M;%&FOZ1I@>0)3S[!L+:3WJKT=?X7[@1!E5H6%XQ6H0Z"0T.@50O&2N=6E0AX
MIEB?][',/RP<].CRR<Q)N[M+=4";L7?H %MKIODNM1&E1O7A?:9>;B0A@5JE
M-S>%F21VTU:N&T[:5(P+CI@]YR%OTI?\C 9:>=-W>PW<,P<(IMBTJ3+G3C42
MXYT APEB#G6'H&RE_YIBGK&@!AELB&Z;<C*#2D@49RDCUS73\F,\*.)5K.:X
MKNKO<7QD""I'2/?'H$<946N*JY[&?$* 2ES-HTS@H>!,[X]-=!#]/NOBCU:C
M^L2$_;XP]D-6R'-/Y?W"7(O$MB?ZVAY:NO[#B?&ZM=K.4O'^/WLTHFZ2(FE[
M:;"X8WMNXY)6._.<[5@5#QQSEO8\'^=*8W1.G:.RFS:RD6 4M)3]36([Y@3H
M9@7>2H&.6$@SZ3+%Y6GB<J1$1944FR&<WV#59X1S^7N;/S%]O_6G\Y7?F_^B
M4$"/&"39DV+Z:]S"06"]?$MSA2/2E%&W\/+R^;RX:,4C;10-P,0>\@7^U 'I
MMR]K+.C\E8B'VO69^-I^;-Y>SREE7]7?B>_ESK\ZOX5[I//:(T_,;;H%).DJ
M['\]$L974K"03-VQ6%6J84^WJ!NA@),, 2)ZM'A:1M?OGH;H(<JK9[@Z@X?5
M<I\1=JRU;[B[]YL3U#SA-=:T$*'1U"?-V955YCH(70J.)F))/OK*6)UR%[ Y
M:L+PMR,S[ 7'):+[':\EU['0("&'-<V)Z/--OS:';DEY01>;%<X*J7F+_!N>
MM%TA78=.(N/,, N[SP,:7V!"1?1.6X4H65US;\=$#,T^7RXX0^>K6+I6B8;D
MQ*XTJZ0R$-]=@#2!(C"CEN#K9HZ.IC8UA172[F-(0:GJ(TTO[7#N//^CR@[C
MEWFHA4.RT.'G25GRK8JZ<3RQR"J%9I7I5EV?0!7D-Y3HD).[6]] <(_B; B)
MV]S83\NCEKQ1(0JC$*_C%_/L13,(#$ZNQ8"1>Y<15;:1&J$QV0 C>.X%M<I
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M"6/SC[#"6H9 (PT&=XDTE80\ZIR0\?F0 &_E=&4/PA)*-,1T'IX/(5+8?:G
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MBPKDM.\D>J,R\Z2,1"&<RW%OL2QP<-0!CB%2.0BLV>#U-J]>+W;^!DU[PI+
M;KV'U*',39#BT0!N2D4.YJ,\!\-(KNXT0T4>44%:?JO2QTS.8]9U]45ZKV..
M.)BHDL"\S45AX6]L?NVN,IKI"Y=Q2F9A&"X3WTE[@*&#HX-:^E>31!\OJ1M#
M\J>M<5S'<&_58J9=,CZ')7DFZEPE]]^<L>Y"!MUU@@E]Q\P[*H]BOK/@L)[,
MAY'5(3RXL[F?JY8 ^7T96*Y0[D;>>TK_I[4&]SS!L_"-_/,6T-%M_@?&Y79-
M-8.$)@4&,AZ@F!#5*I"RTJN1KOVSS5@]?1'\&2<%6>:HU9!3][K6F7:8)G:3
MUU=97K81M>D6^-6OTL;I F;KR&B[B^2 XQ]Q-1G#)@.H(CHYE;0?LA!&=J;V
M2PB2NB1ZR?3-]OGA&61'U@=&OI$A4=?Q$P,15F.GWFC\/POVHDZ\?G1+*4N:
M- B'*=-(LUB4VZ1UY+<AKF966D5;"$G155I+ P,Z+K#G#4-MX,\8P2FG1;LZ
M#?=,#88YTQM9;FT7"=L=4<6W )>&N1R&ZWR_3;9T?(B?)6,3!4-Y2-PHQI"M
MNF^;' E;L18)+K$@25(7:]-M;O8B!U>7&C-B.'M6_3>FU"8MUM3&:B)#NZS_
MD^G\4I5D/TK"I9G9&-/M6TS8,H&$# ,2 SVP!@2*&RM@MZ*_8B]X;P4GR!16
ME9,@MI/.BXFNPWY[0K/R2)S-CMYE><)Z X[3T!H[??[#@M[N)CZ4(\M<QD1'
M;M4"L92_6J2-!2Q7D=Q17!\A29]@&J7;#\T^+T4E7[!9/B7TSI+&;8S :C_0
M("E0NWX@,I/)J6Q0WNJ1$NZ]2SZ_VU A^75[@/&3+&6A^=)-',]6B%XG3RDP
MP@37+-'$H#(,ZE0M3M&!GMA8@.-7+7BWH79H"VBWYA!:D[:K.*_QB(QZ#4W/
ML>O4Z)S\W 6IB/RRLA-2SO?TE#VAC%H66_5-RO.R#2]7N+QZU$81JWF<IJN.
M31@15QT<_X;G-.5]-#^7=X%/)JBF/G66%YPBB)?UJB1X%.Z_RI$-U2,\S*A;
M^4$0R_8U@;I6P58])&HT2>+071T>KV$5'G1U6F]\YM(<&+/A:$5??NV-UJ7]
M+(WBX(6Q[IN<FM"Y"RF4_R,MN<2^09R.?YS>K)O'E>)J#Z*-&[*-CWVN.YR[
M:&D:K\,K,"!/$&5J9S8ESW0],2<^(U$]9FW2C #5J"R#&%@)*E0M *R-@,L@
MNAN"GPQ_?0_"INNZZJX^)>@+-@501Q1Z&4\!.$9<#)#R==F;&0SYVD1R4\'Z
M*P\"-OWH"V5NIB<S);>4X+8]KQT0E:=XNC6)F =/&2C;>_ET5 ==[FZ4A@4;
M- "8GP/%6H3"?>I"W%?EB5EZT,?D4"L:  P@N^KGR]2,K2$W0GA  ,DXQ55C
M260"0,]Z^+5ZU\>?#^%#. WNY;<'Z @NQH^9U6K_"N8XR,FJY:#,*2D=-TP^
M!;-0*)<5._7J_/-@:QM-;TJL9NU.JYNE]IT]V[".5NUX%YGYLM:ZZ\=';Z*C
MN)/IN*3\GIL$*8P1#^HOV#$I&12L^Z<D&"=3UQF'/%QZV<G&.7$"462DO;;>
M"5,C'>&R4;G#8Y+*)&QS2<MU_S,1YRS*>I2NMOSB\W5>:%WQ2.Y51O5$;,K*
MN[FI?#7TLR?84H9X*"TY*RT%'E<#24ZNSH.,%E4ZW3*7OI.:Q"8.=6*L<&<:
M+'O&+I:5T_*.R(5K#1 \9^91: F1/1L4E3.%M1C]**SH]O I9LN90LY8%U3T
M%=^W_,B99<GZIZ4:EM^%+P-I\V ,<'Q?8HYA#VFS_CM?.4#H:#(X::@T6/C&
MGG4M<G1<IT I@L5QS/<_.(/2.C#1?CH@2SDW]9L5M^=/H0U<B8E<Y59PJZ!%
M5+.IMLB):E=>J._4W#$CXS.?24Z_?,Y0SH?G#[T[<5F,FB%HI>HI.N==".4Y
M/B\D7"UA"UL9:C7<U7EWK6I1$X9-"(H 0;&LT%A:<W)RGKZ6*)F N86.S8?(
M(;Z*"%&O$48V!KS'IV+,\QR;99K?2JNX+:0A<(D1<&9R %KU%\OXO4R")E9N
M;J/8>E8:;1<[5>:[P&D =C*-6YH]IXBY?ZO "N5U[EA$8$"$[3I>FJ/=;XFP
M8Q8DN)3ALXTIA^9N:UR-B:-TEHE=(]VZ^#;^6N1@[4DI_],[-Y2Q)XB=X1RG
M%?'DRY?O(HC4[R+??X<:0ER'GK+1 9L&U9[YF&2];81\R945A/*,J3*X=-]2
M'TR[#J'Y;15LJP+.)I_S4KNUS@F5A"\]9K2+NNLOR?&]M[48R]4L"6N+J.:^
M$,1VX]ZNIZ6DN]=&B?P!!.J%+E0/;4;.PK.*2<=F Y.Z*45/V0%Y)*-7G_D@
MX_+TU\VCK+HVN^=&$RK_J,ZEML?Q* E+>';"QG5/"*;,,)D @[>XY]UY^7,5
M.Z5GM=[,.,@G81P\JS\6F+E!P1?J_]ZD<-+8:FAXS=Y"TOWG[N^GS 1^V:0=
MZ]J7;GGYGA?^^/13]09&HH1XL(U_7J%.5(0Y13I02-US9=Q(#[=B*[B2@/FP
MRZNS":9-6B<U-;T7X#@,64K]C*5[$D]&\V4ARM@#PP\Y\6P5O():-JO3*F'D
M,H(*9E7M8)A5B[UI;1ZK,69P;YI8%,N5&BDEZ_*4F-Z=9(W,ED/,W 4QP:'2
M\\)+P,$A'B4;P\'!><+AW$W^Q&RXH/BU:]1YX[5X[IDL;P2/AT?A-GR+URX3
M:#/RIO%IIZ<):CK>M,[\+;CK\>"-=K*:9]#-_6"X\W/)VFO)#>K!(NI_<"N.
MG&\^:JV#\::U6A)O;I>#+U^2U6V#82>#X8U?I:MF2.""7EV_OC&,_ >WZ87J
M=]+?'C5:8B_\B.A^D3\>XF<\V3F,JK;E1<XVG,O?G4'1BS8%BFZ2;?M*])G,
M54)37E5"??Q7M*G&2%=?H0A(P'#BH+98W7JTSJ(B@C.G[HIVS6&,.GY@>>"^
M_;HIP]\8]I-H#B:HF_4IMBN U3V(YL92E$& )W'0MIQ,\((;3W?6<(I\C.S.
M/9G7!=@'KB?[[O7RZ?\U2:GLC*'CNDGQ @I.%-';\RX8EM&G)U/PDK+YB;J2
MWZ@).BEP# AB:2^@$ZY0\4,4RJ7I$P]!9]+@0A6_W^[2U$'I;MO (1>CBF0V
M]N[2?V])<%XQTFL$8*:WKB-%##OQ7]3(LH%CY#68F.MP?P1U66?2K<6H$XZ%
M<!6L O3#B$?/8DDW!7R)>GPBC[QDI:__3K(P&,U?VBLQR5Q#@_$&UB_ZD"T3
MVFJ5@MEY57=C !PRM.D#\@K4!>932*Y]T3$G)C#B:LR>4J&D4N )%6>]7C:J
M?0W/F3PC);<--TZJE"$/XJK!^CUJKE,%\7G62H5!6QIRXR"=;JKF>*VA^>F.
M!XL"9D2XLM7S25107  ZN$/7#@(-\)KQ9VG2"[$ICUA[/5JC+2W=*EL=]WR\
M3*\,]U18@U,M&1*.@?/"@UOP,"K'),_Y0 9$H\TA3><.A4]\G8JS (CU]&1T
MC-+(@R"1R( /9( <O#3FF*2W* ;;\]B-SN1C[_!,4Z..A%W_PY>_?J6+$'=V
M]J6ZFF";: G0O'9-+]=<>6[TJ!#TZ1O&H](;+E*)@_IYQX48[6WF)?+F1FBN
M>RT7?7SK^)@"!FE7%B*#$)8; P\M@?#RG/BG<1>("_Z,L=]5$W&EIZ%A\;7Y
MC/.LQ9]3Q!S\F-Q$D-#_F2#UU^3/E]7WC?]]TCY:$.]Z^?_? VR;+K]/'+F5
M/R]N?I;KZH?^A4)'&P[&V$7:O:.*R?DN5C:.RQ\.)K"7HU GX[:\SQD0+V;>
MMEDHF\K&95O RP4![C7??2\1DG1 UN(UX[OF8_H+-%/+9:GGZTU\)8IYGH:S
M:Q6@JOL]4#V'#1GQL77'7^Q11+QG\J5?)2YR!7KG!U%MSS_)\Z&!87<>[KLV
M'A#_55.^U.KBYI49W7J*S,N* &8:Y.FYP D96>Y@!9/%P16DKQX.SM_>59*+
M//X)0.*WC5=M8.IKQG]PJN_/FRO_P6E5E4S_!^?W']S[ 2SHO?_-:^#?TK<*
MT[ "!LO9).TE9V%GT'OS1J;XYX&:45D# ;;42S67E/L%MI6F8@E#HN8ZXIZK
M_)[4(.'G-6UR*^4:+*K-"0*?.PK[,:*N@.C&"54"6UH7CGS^7-V0JJS*B:*6
MULZH6EQ<,$&.-M]$^32Y?@EGWG<Q]!>^_A^L*YPX6X=IP9_@8[__]9WY,'N+
MU,TQRS!G0I?FGNH/[2ZMQ$],/J]Q=!AW0)E3?J*:W9^O4W;@(9H7(1,A[*$S
M)KD-B'83=_#4H6;*'9;AUXQ$*"C$5OTCB?^ BYT[XD+EYB]4 54PI5/.%O],
M1BXQ1OB+1\EY&<@SF*&ZV@[^(7WC_< ?X'Z3S#LW)[<K.?9W;FQJ,0OL][P,
M%'].E"QS&)CN\-@X72T #4IHFFU?C:YWQ+\EMJU7.4Y3BD)M18@_YN5CC?P<
MP?DF1JFMI>F-3Y;1\X-#WE;MC7*HJN:?JASN>NZ^I"4F,O"I61+6KX;X?$J=
MPN;(' N&G(<=>&[@UF'I1%;$MZ\C:Q'/%Z^MGB>Y(R9380%P.P@Y#1__$,D:
M>4M<8!W6.<9SL\7F5:R1L#LV.A(T=F2&TD]8E_D>0,,'F.H;= 88#@",>U>6
ME]+@FL3"ULP.OBQG.4U.:V+=3VXS>HF(GPP#(W,?TG@<*K=%%9?5T2/QDC1W
M;P=))%?PYN&?AJ: E;S UPPU(IMYMAC#M!)<'D-:_9:;<2\"FU5<(OWOKGB:
MQ>&+)27YL$ :VN^5R0RODF-G K3,NOV[1FNX\[FI1A76WM](6:T5#\TW47HN
M]>FGQ6*AT]"O-=_PVJZ,=8@TPSUXL$P=WTU=G&UJA/*;IVB(L$@/^EM%9OM2
M@G\P7"_)8WM0O$G ?6/ &&02U>-GT4GH4XG?T-&LA24)Y#8ZWL6,^;)_MQ!*
MC!9!V&"8D(])E?NU=G(>K.$\.;::J5G]=R..YU7=F&5=A]WM][P+-S4/ BV^
M(X<Z/"T-V=325=?5CA>=K_>V/^58CQW##_ER ?$] P7^F0S,]/ 6-9O<95SU
M,!05#7D"(1FD2ES<N:-DWP&_4^XV,4"*S=:KR]8,8U?1VH"YS-\/]K$O7@FO
ME$%88TB+:'/2EH4>M]%Q %*>8\F_ BV8DQE)MQT-OY/F%N8Q##5%VAU(M[2S
M-'C)&?ZX.%OM]KNVS*1[S^4%6GV(3C)BLZ#>0_G!5#I;$,N@Q>0*/WJ"&$_7
MC<JD;/4+4&'9,F<_AYG-Q,:LD"J?,(<V-NTD(K/0FAQ>7#)?7A5!C63I;GZ+
M0P '-S:F0/Y! (%:=">5< S3A1Y(O@#9V/N>;*.;LTI@.+ Y61/!FHI[;;4:
M%]#:R6[CMU-#6[K/0::[L9>/M(^A<#^)QB,P(J"!9;FNKL9TDH;.5NM__2(#
MNZB,]%^@^NM]L=)8L3XRQC_>@;$F9J.',8N7?@HV6#((T5=F"F5WKKEQ>A"Q
MVZ8=T824Z-;K6YT^=:>T:Q)SC\HRS?+]!L!;*6)<@-EDDB5 *"+G 3B4(B)@
M0G9;JY3O ]-? [?_@T,KTN%]- WH[S8LV&1Q0E$=M?M I)7:^K(WINPICQ3M
MEKB\%IY.FO"1QT3]V$;DVNT/\;H?<ZYEYEK)I5%_L<X*X6'UJ+#[WY0Y7[Y4
M>MI5#'"K\^E?M&+FZ\KBX=FEZ['9\ A)U]VPEIQ;<7J8$%OAYIBGEG9V(=!(
M07)4%:IG;(<N0O>-!C#A8/ ?7"O*=>>Y06WWI!+X-  ^ T3JJ [-5V!QU&FT
M*'KY^TD^5\6X3XG6OH+%S=V]\1,C L0K-I=I_&K6CPC/H2+ER 28?;(R-U2V
MSM>X=]&1Q*OEW<C; DQMT8=EQ$1^-K&D>U63R,<1;,*Z^2VL+_#]\MS/\W:3
M-MQ@4;^?Z 2^&);;HMX FEFNXY?S<.7!Z8X>U$>F.T) ;@E#]U<^'4=M$VB;
M--]4L$\X\NSS%-F\LY,2S(;FY]:F+[.9U"X79@G!01W8<+7*Y:VH-SWE+C_'
MZ]3'V2%^<<K44W [(*TGV)A1S#M&A.J?6PH_^K?*M6^35G'5&9-I&1O8-JCO
M\+&'<92.>PYJ#99T.T5&HZ6&43)%X^"Z*3.??C U6N7)"[/(M##4-Z;]T"S/
M2A2[3FXRVIZT!M.SCBK=-]"3VA9\-!.K\Q5)LX3G&+7\*<NJS@$5X&ZYOL9W
MN$:2$QH/=:=,P&<N/;1MC'']B<>-$9J(+0:[2KS<>K"NI%3ZN)N:>W3;W#'B
MS5.=?J-%[\XZO!/I_>9<2:%ZU#Z_&-Y9TJ.MX=='2]=YS+I$A(KK)BGD^DQ-
M7H]C/$E/U)O6^VF0J;_69$7V8[>[=%1A=I]E6)6*L> /BWS-7ZU,'Q=8J*I:
M.MG*R_S8HVW-M1/RLV2-BZ!,,W.!">E?07.B.@P_R&3(.A]B21RW.8E\_\8[
M6[MM15I7.EKEFA%[2%.R:*]7V#Q[)3$KQP+Y\M&,)(%C]%/<K%9)/YX$_2DQ
M@[4 @4RL3;&3@X!S<0 LJ2R4HF6YGJHG%YPPAVBWA5B$-0'YJ?%\] <[@/V9
M>,>,5?=H[<W^=]\.R9LL([S_UM^\-ML@@49BL_UAMI&>>]N7XV:$PV?Y^9U3
M)T+7-*DK7%;9[<:>P4^W3@6JY%Q]8RJ!$^(+"N \P>D@/IT%ZV9,G9LX#Z*K
MQ%VQ(L]<A;(<_">=;^Y$H&+48NFXZ9/;+\-S)!:<:]\FB+_&"9.0^2!&P^B$
M4Q=< O@6/^55@SV_T%J@3V7ITG7G#V//J<ZCJNCZ[VAO%G!+3D,%O:-^[F!
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M_@AL^W(5?ZI0/QLT_EOOM]L"'\E2CPF_>:JJI^RQR=$N/I:D=E^&LA$O-!Z
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MPAJG#Z1D>$)7CCGZ"A1#"XS_H%>0J-"Q2RJ0ST=7.O]_//3!JQ,!%[G#I86
M5.3W<RCWR E:6F+ % ?%;_W;C;![<Y GYGPC-_^.9N7,Y!*_W%G;K)2"4179
MYA&E/GD;=)\"28KS0(#U62@2Q..(42Y=!ZN/<S"C2NF"=-QZ(;+2@0R'D^M_
M(<;'#<$0K68=503U)<+F.DZS/K'%#2WXV<R\8YG$&-3'6T;P%SAS[(.FBVA@
M1;UU6J;J(ZU!7FL!\CXIN&0Q>/P4<1LV(A4F<\$+>+4*.T?M&O5 C51-[MJT
M3HB \M])2>)U/57]+Y X*'9&$/-S[ X]U1JA>UL+JP6#M3(R!>>++&R&R,G
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M>[U9R1?]+?-',7<)%V\6^/(0P\*$&W4P9%*-A_CW@R&))%$C++5/;JKK!%@
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M&6+7\C1R^)JGR_]K0F?#0WM7';)>84^O..[_RP@U-N;;--%]NIDIVQ:R!X$
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M^XWMW(L4P(B729\I,MM;+=*>WP(<M@WS=R*;&C')XZ*2J7K<2L[>9'L'?._
MQ.V@@A#>^%&>MZF,YP?5UNXZ;AVL*N@4@%5;,S@@X14Q14H#+B40R&#F#[F!
MR0K=WA2*U0]STH%'(</>KW171$L&%7RLYS:UDU(_NKVYIGG0_8HKP?W6@?1%
MW/#>-6H4E<%.AVME[ WTL"(\MJMAY_HMTR?*STD_=R#2HBMGZ-!:<:_.#' .
MXX3@=2CX0O:!;7U2=;V.SI_EBL]E=,SIC+R2@\?T2-F!=(;0/^D4:1M!3A;+
M:4V85&=Z*- FXH[[I7GUJBF+SQDL0W7\@_B*YG5J4<B:-AD'7;1(98=L>CLU
MB>/L^$:1FL)E]>P,SY;RJAAU+7$VKC* )0A0+CQNHELO\VGNG9!=LO<>]\39
M1NWUE[V^2[:85&L&&IUS*3(]J>DA5\HN8D%6!C%'*H9"PW<-C:_L[P1XL/KC
MFC6SC.?;4"7WMQ)]F*UAX#@2_"U%T2O=UY)!?];C=KI3=W5#1&F2)2]DAYEZ
M?L#K._W$#/Q(R&-;.&+@Z_OD'L39:L<'IC/MD$=U<AG_)+8DQH./E8Q(-4&X
M>O'X^Q)EV#M4B,"W=;:PV-D\4[Z4$HD.54JT+^H+WW'5FCFE)B:M&NH_O6&Y
M^#JCW51FO50]5H2?B:6-DDKYFT!T3XA+).^+"+R>9N'6#*UA:!&]2=U.ASI.
MK-4TY]9O$VOD[J:4B49HBH_RJYZN52>9>JY1/+X0*C-%-RP/@(SUI<9[<\D5
M$>/%/AYV55I!6 #-\..G+1_QY^P7:;3!K^,VX' (?-Q02E.^M^ZJB_8R[B%E
M:TO134<?<_%[9.O77S</!NFB10.^1#"5L-3:'5+J.# -;YB13PN9T.N1(4+5
MPA&#Y,I&=@&W)ERK<WEPV>%^!-_KM2G2[RH&7M\RR,(_R<K=_3+G-/MH<95E
M%NE1+S)F/]D@":\&;QD6TD4U4J=&)ON6<;L>@(UQ:0/ORPRO9; 0MHK;,.+\
MPNQXLY';:QOKG7[=//H\=; =,7-*%_HG<H*@>CP]\$)_<AUA<V+)8L,AKX$1
MR:D@EU'<1/^!>S6(.4#6<]5QDU/N&DLJ".?3P-3[PCG/*IN25SK$I<,W.@CM
MQU1T61X7G!>+^T%*_:Q&V2TR7%J_1 T'L(O91BN7(AE KJ=9VA/1-HKN!C^!
M5.+0;2KS[Y1EF03PR.?88I,V5'@9!G":*R#/*<294CEA2=XJ.)F4'?6D(:N]
MWR1 6--("4M\%(<K=[%Z4RR/##2X',0_?65,8S24YVRQ0O0G2#N)?F@RZZ^T
MRI\R$-+9\ZO&#3)O+!>'F[1X/16V7O1HI83.+QMN!*66RNM*>NU==:Z<^NU@
MUMJ6SA#>8#6U8?W<%(1%Z2SN]3DGB& LNJOENI-X''4EODK@[G9'V@>AU%/1
MB'W:IRZ?W+5N@GXYEU6_#A$<\:%.8.1P0E::AAM8:>.:( VJ2]SP'+\CY!C:
MKAD3J5E+4*T16&],I(PW(D3G]346%.S%I83U9*?0V..V*N"FW.G7QKW;T>D9
MEZWZPU?#C7'1SVZ?Z#K<5S23V)-L?'I*,_CAHPDV*HN3\+(_>VC9=,9NL)F:
M6Q!>K.EJAIA3U9P4:&0S2\/G8WXACW5WF9U5W&QAF;Y HHU#40#;[.J( .?G
MJ0UGA>KDR5,>MFEY5X'"T]%J;R,BVNN**K8*Y-D<=('8R0825+)'!HR.U6BE
M:_%) F9G-DU1Y:5%?^B>*/Y27#M.B9L+/]J?.W\;)B;B=OFBXO,BZ1CO66MF
M<&]@SF&2!IT=6>:=,"YIH9FT'4EX.^W)[YKHM8]%%I*[*D8IK.'N[BV)\[BV
MR#,:RE"P(2-7PJ9Y&>[@''$AYLAC$\LBC&GZF(8<H\KN&40HF+2%A.=+-O+N
M[.*MK.^<K/Y=E(]'Z? SNI'6I0F%M-?>K12.@X7QC(DZ&T955=6&?H".]BM\
M\CZC:),6$Z[E8VOR3=*]4"KG-F^[X'GI+T=X+%Y6ISWQGNQ$",JE2=(,,XKC
M7(/O?"D==DN3K2H5).P8\::X: HXKA?]3OJ>:498?D;F^12C*N!W(],?R(42
M@/Z-!B7R,0F=Q%34.PMTHC4IM3K<S<S2C8V/H=]$WLBZD%5R]7AONP?,5+B9
MEI!X&]@Y9,?O&6%+^;$F;@%=G3"O#M$/\<V!A%*&KZ8/Y<NMO^>FP)'4@FN$
M6;I)!S"&#NKUJ#:-?"C#&1OS785_:4I8:I #ISN&;:-N[DD#/44NZS+Z\ [M
M3G+[>Z8.3^WT>!.Q+42*:,VXT7$!T<2X,CRMW#S1==A(IW=(F'32^_$4!D=Q
MT$T!(W!EOCF[A^!7N+8_?K5F&X+-?_5>:>:3T:X+N!]C4#,U6XG5@@<?+ 9%
M[UTBYE?Z&N39.>;O(H5LW_2>U\!P6L;%MHE!P__=EH'F)UT4P[(MXIZFVBDZ
M!".J=,^1C8&=A.0CDM7-T**:A!Q;;X>+D)TL-R4-Y?*.XORZP4UQ;,5N=W7&
M[]='Y"M[M :Q@TX:-G4FN+(2WE(ZH9Q^+5E%1CDD%"_OQIBXMUEG31];[^;\
M?G'?5\LC>H(<W"H8R&*<YZSI5<DT^N(*A(N^1[)SQGPWZ[2.%3GLYL=UP,Z8
M]$)Y2K[%S$B!\!VY&(7Y(Z+:CH\1TZHLO4:%:A)7<+#[CI=9T$3 Y;'$-JMF
M;RZBZP)*)"YJ?BOV]>0N*.25_%#2G8&;_M9,["*@[2^2_=Y];?^:AX.?9JM&
M5>_)^-BVWT>8DSII)!?UL^WYFE_.B]P6RL \,9-SV*W96R94-$0SF9#HI\UB
M%9OSZBU7 E=;WM-7\)$BRU&';"S;K3?\7@1ZW#$]>(!X@:3*',88.QV=BDDD
M,)(1[20DE-P $X3G8;9?7[0,-3,,2U&X>VCE%("QIK23&<OHG=V]+3%4*R2P
M?W ](/]MF6+*;O3&ZZUY7??9F9.7J$8=53<$\JKO4F0.SA !_F3-'44T:G+"
M#.6F;TVF,GK/-6\JZ@ @@N-D!<?N>QSXHWM5JC#DCWR>@BB0.ID"H6NZK6X"
M1-CB'5,8Q%%HGUDV._%@B=S"U 94A>:%]7V:8W>LKO8:'RS8M$31"E;IA'HC
M?=?NH8F VF8XD1G2MI!0=LQ3MH=3CQ9;78<&C>6JCG]8>\!&<%*V^:#A&<0,
ML75YM^\8]01#*Z^M;;1)#[Q>H&)TY-;@N,5>:4!;=9_1BOFH;3:74DG=IZ'M
M0GN/5O88 H2.<?#D[7,U:O&D:#=.H:;M0 B=$D[U352(;1ND*WT%V4?Y"_5D
ME%&;?TO%#=E6+)/PV.!O^$S-V ?5SUTGV>TO01DJ?L9.7_A(HII^HN!J37QS
MA^KUY;+"Y>5$I\G(E3S$[=PE3+Y I%N8=KB:.@IRT!;S0:6B=EJUDZ+*L\A;
M+J\7"V7(WLN*<=WTP$.E*SAF<4\Z MOZ#:[?[PET#KUN"N\^O#$558@RG?3R
M#MQ3X0&7Y=$HYDGY2),;8#P+I)QGG]J;JA%4.^$FIZ X;$6KL@ZGNZ^)W806
MLK*WOG<Q8H38@[T80 :N,YXC1Z55![5Y3[SVUE630:P"K5(@OR4X"66W0;-H
MEKV1]Q<)]U_DS9="F280CBQ[NV5^A!<=3AS(WI1NY$ZC-\M:]"Y)@6_=\ROM
M%PJ (#Y5EM(N@@5#-W@YN2W7[."9?!F5<I[C4#IU*@.3YBX(*T^'+,=5>TBG
MD[YTC^"]KD66\="L2U )QOV]\K"0GQCQ19I;7-TM$\Y8?36@3C>-J^.&]VJ%
MCP8EO*_\+Y(:KY>IB Z)?GDZ4C:R=V$B@Q9GX=NIZ(';8\.^+DLS:B/9S'M:
MW=.4F[](VG9=[@/,3*E96Z"#M9'G8D-U%Z"8;A=^#:/!3%6F(9UX,M$KL R=
M%P4N5D!296&?+:7+8<F"D'QFZB2BAK(%?W1,?L9R-FB=DB/7])6C[^-I?L4_
MQ)JX29U>*V7%AZR2T\'4"UHY+S@#.L<_U*4.] =+[.BU73K-(L;&5G5\"1CW
M&DE;6$T+1P%D0#:NC#C+45L#\)-<#\'X:XD0Z4;B,7?F['Z0GB4\<-UG=!A"
M6YYY=<B9;)2A$;V5^IOF2L>%<=:;8\CF]E1$J8EHO_F1?EQ$6+[=W,LGGSS9
MV(>.^QKP^Z*M^KKSJ/';9'C&8TC8GT_VP0UX?SY/_8H(^94NT_%G/3W"+31D
M.>)'_\CNX%WJL.7O3Y^^_T52_,XO'3<P]S^]H#!TH2$[OOSF-:?KW)M_)XBW
M7?9].K.@3L*QEI/MZ@NV(;=-T0G7J:J\' C$0B@&@GLI/S6J(VQ=S1*2@WKT
MA*X<6(95GP_9V&PZ[@:>MJ)CNT&<P'=6I%F_@J-1=(28YHBE%SN.YDAHKOM
MSKB>ZXF/\U+3QB?U1LZH!JYWKJ!G;6=G'C>+2/,,?M_J0@]FKE/G9R#';4W4
M*UN[,Z7RH^HCMN'N^"Z+"G$*U9I$P<GDL;73H0HN%9XI@QIS(EP#;U@VH9?$
M8L>+VIY?V4Y@4>9> JG\7$+FG\GG*+<L7 J+" ];YF8-3_4 0?J21>HOY/IK
M8!L-E0&S\%@^S?!U^.(+S69XJ+/-O.S@\B=37)T_?M03C]*5?Y%$C\)=G61]
M'OZ4@./Z<U["A_AD?_DR*&Q8!KYN6/TA$T'_%RD,%I2P?:9W+?L7R6CE\\^_
M2#?KX[*O"G^GW[K_">/Y]!<IU"3,K>>THJ_O^.W<E%U"W2H*GZ!]_>Z+[A0W
MQ\!HO23I2A1O"8XR9YTCQ<+;J#2DV0K;Z7,#S![>2;KA4ZX'YY]B1VL3(OG3
MO9]-:LS8<B]N9%T,7$=9-LF=[RO6U+&Q]X)F'->;>.B5SZB87T/ZU=41#;M<
MZ\YF/JZG7H8N?&1ZS*H+V/7Z#:/T'7RC3YG,30U!U6 C_1F$G,]SB5!V2^9"
M4S-U:RJQ8,O])U/E<665UMJM=?\G9?G#CVVV4[4L.@X$1;596"QZ'&6Q3""F
M$,'C]?T!&K\X.+9YWP&-&:2RWN[A"+KA#0 *M7FP$@WNKV<?D(GL%;QP<7+;
M@&?%D!)XK4!"_*B9OSX@HRF]5E3^L]M>XC$?<3?SUG%2YIRLW?=Q!&[!1_CT
M SPY[NY,ZL9V[@,K4$>K)]Q0C.#'V!/%7DJ6[E1K5K8#[[S!EJ#PNB!*FCK+
M"C76Z!%F(A3SYK(KJ.WXA(:IH\9>/% N5_U!'J5-6"[OF0]N!M(XD'PV5ZP:
M:2$WL3+0(\T7_?;.>JR*$]V*2V%_A.UH!*!G!FT%\D6T)18[I_'YIU1/RY2R
M-CAOC10EZ?ON 7>(VV_4G,-BF1MX>#,DKU=XO>O]C-JT3Z3>Q83MR<K7GOB6
MFJH9VN0R1Y4Z<9LZFTYF-HM_S]9-YI-'T^@IJ^G68I3>Z7IL,)YL@,SX72%,
M60FT&X,J(>!DD?.1X4^>^LTMA3V[*HP=HKFS(2P =V0.PQDN8.W3$:0;Y0I5
M\<'WM;,8%;UKL(9ZMVL]2+O:;3LMW7_70Y0.!]?\XID<FJBK&Y1:N?QK65J.
M9>K+1$+@'657)W!^*8LE*D92E1?<'5U(N&P._G30="CMUM'$*B$@/2^$O\]]
MGS-D:NJ=8&-XB)%(?)FD434?6Y\:<'2"&YM;IP1K3.@U(-3=\349/FEUZ;12
MM4HT@X;D)E>P(*WT04^BUM<*=&D&WXZI+S)6^C\VIA1MN64'U5M7\#\HZ_92
ME7WL],ZN9?&!V19O;W/L;ALL6PRD1*DHS?BI6P.FH-L]O'?I$[ZP2YP/XYOE
MDQ:"+:MLO#:7;NNJ''G#UDUH"H:>>L2L[8Z0TX)[ 6OQQP+]NH4WPELSJ&BQ
M#?,OJ&(IPRQHQU A8D(=R;YM4?NNTL%&A/G7[P6A\/:MS ?57HT&C'YFQPS5
M2LD4[OI3%BKQ@F %:)R4\:&X\3MOZ#&G(J8(W@REJNK,51*5S2BW36BEJ7P'
M!<D<+C$3L9-K,X 20/?0(5?J?4A%FHRL>)@8BTN%SFTBY&XL%,F)]!GZ05V9
MW6G%:JGO9.59CIWYIH4LE<;#K4O4OJ1FX=%BLER@P[+R(:6@^=LKY\6Q'/8&
MJ2DB"?2-87HWXS67BH"WZ19=^-NI$WL@>'I_0KB]TQOV.MTR@@4:7E*\K*7F
MCT=A,"-Y0*<6,"FAVN[[_&LF_^QJ7_UPOIZOUS/@;>]5SJU:K"SH,[/ZA78,
M#'?/OBL6N<T(WI+/TO:=#EPHT2:ZEK;N;43)<3[YJ/E#1F2'-MI);+9L2[+.
MI-( 3KQ.<*.I+BH1,\-1-?=9-L-VD;2?:0F[9K!"R8JK KR-*;QZ<*#TZL[(
M96;56%?05<B5;VQUB_&Z$N.A7AGK#09/%)]4SF]64QC.'XX1.29?!FM;_X =
MK@U29KA_J?!I,M.D: NA!L^?\_9V_TZ<GU<:V?*EZ,T_$09QYUX-JU$S;%BX
MI:F-*<?)#&:#&$-\Z$4!%5UH2(:WOP5([(($R-55Q\QQ?"IU=?!BUJFD"')G
MORED$+&=NDV6)C)G)L 6#$?5-I"$&EKD@(<L:JAMDP;6HF.JV"9..!DL.GS6
M<GQ85<S@17<#KT?-02;6-WN_([JG4^T_VS1,,/=Q:$#.B"J34AV,P$$Q,5_K
M]JU9ARE[-6*QII17_0P$)D4%IZ(-V*Q;B-4L#:V%ZZ_[$GZ:?HW1:V5'"6';
MELC7*/2]EF3BE."\;L<F-VF(G\DAZ-_'RDL,.9QLH+\X;YRO"4,8PIJ%#]YM
M&HZ;14K?T?[0<K)(7KE^I%5DGM2H:6G'A:M^=KZ\,'@JXJO![YB-(IICLV50
M'71_V"'S4O&:T5)5&>J2\JW:3_Q2Z<-8[@];.]_N3$.G(A#]01V/)L5S\GTQ
M?9*ZKHG.S5,%T"$XK N2OZ=7S],ME0BO[UGY=BU^OC!I#/GP57?_QUT!L%;6
MWQ8XF<PR7 V1,_3FJIUQD.Y7_7!!?H!&)1VXF=OPBWDB\$G25/)-F)._Y*93
M+G?"%46A>MI6&CR17052C^./J%9#J5C2TM,IR+0+YT\X%^H41&K&DQL/=](E
MOC(AQ+ 9#R&[=7\1JB396Q!R.F;Q8WPL,2ENMX5HC7LKYM<]96:<I/[&JP68
M4HA^_D>O<2:OCH]/T]PZ4T-/NGDG.#!;,EM[__5V(Y/#Y6 ?$0;>=L?F3Q":
MG5E=O?4<Y_L@LJ/%#MH35B<CIS*U9<K*9*%2 :1C1OL%.60:6 :M^A(SRYH=
M'FB"&C<AFR<29^,-".(Z63]-(< *C,8RL. 3CC5@2V[Q<LI&MO!J3T 95Z8W
MY1Y:%^6A\R@<_9B"GD+%E-AY,:_U!;[LM"N\Z]3"M59S\]HTN^*:+3,[DR"N
M6]R1<O,AU+LSM 61YJR&#C&;:LC"RVX:-2Y5K]F3GR2BQ;!J=IR3QZR]HCMI
M.!-7#VI^-#><%=BOT!-P%/UHSNC^4;6OE,O?1::#ARG7K2H: C@Z7^\3*0_R
M95OYI,PBFLBF?D+ 9"G-ZW^)G=$>\R$)7-CV6?GJF?=>+<0P^Z,C=6SD VO)
M<\%Q1[DF[\N][)L%7(."VM[,5#\S+VG=AC\?SB5@;5<\U%UF-2V$H"2.KRX,
MFI<QM:W<@L;!E71ZDQ7T%U=D&?<9>_H?>01S.#/)>%8#-SA]^8!]>4N#[OD@
M&.7F^0E80:V ]W:R>=Y*6\YW_[WP]&P7?L BI(X;4Q%6ZT&P&"?I_KF/F\/Q
MV6WKM8;+BU(S8=L;,T[X(=^"E/U\I75?A5C0=CM8WJ@HIW8PPW(B.QS@C1CJ
M<M??X^TI2)I:-+6Z$/Q<@6>$W$=+,B>_J3U!+6B((0HPT51B[$F*]B+B;Y@N
MT\AQ&7A;G=*:J8=RIA+3%9],7#$KMZWR:KW9[OO2+QB64T-EM!AETAJV! @L
MH5L(7-OUA:KA.HR&I#56&5VZUP(39V:NGIX#$ 7M*KC'I?5WQ*H(5MTL_0E7
M\+.88 M?/=R( E[8QHF3U,.XCG0ORF-G0ALKD $4H?9:<31K6G(_PFU+;+5W
MUSF1J-0@\Q"YI^@Q>,=K(^^BEJ/)UZ"6.:U]@E]H@N:CSJANGZY9EBJ!S62>
MC.E=S\(6*8JHC<C9@=3J7FX#EB=W7X'7_8\^YFH^O^YL_R[#-U^FK)U4;=$V
MN6$J/T<G5-:LS^)RQL:4I5V%1$R)ROZG/="@]6EO1I_?/. E]DH-"=I%/&](
MG8"'9\S,Q C1$4(GD>#!K_/19UDU<BV],IZ"OR+.8.D:9]'?$,_,+4H<5DP9
MOP/"XX[L7/)R]-PHC)[TW.Q5K9H9(%WM\LQ*K*%CZ&\E7;S39RQY@-F$VBSC
M<E38: 2X/Q0QR0>-,]&_KMGSH!."7]P5UB:3UA1NU.($$JQ0(%C'<1AL]F(C
M]8@#U$J@IS&;"U<K.=HP1'$414N:L%YN<M+>"@U''8+A'Q^:<8V]%*P,K[)S
M6J=[W<XCG=#T.G(IY=6 R N@,(!'6KAHIVTF+.7:Y&>4_ >BFJ'V7&L&+@1B
MP+W3S'R4]33#LT@57)1PN*X__V7IH? B$\<-'T4$!:???R@WV:BR57QK28UF
MV&*;_"<.G*FI"7YQN6DJIF,8RXQS8GL&4W&]!I16@>S1E#.E76WG6>93Y6SF
MV 6X9; ;0@S+1456AP'?>S$E#6L</!H#Z+?@7W>-_/*7I/!''5<2*4+75MN+
M^PUKVY- N?X!X-4LKW(8FS<WM0@&'*^T0;^>@L:T[*<=3]= H ]';O9'NX+>
M/)>J[#0)\]1^_WY#6V?>*3>;BNDY;FMR@WX7=)'QZ40WGCS1@!D;)EM1;A;#
M*MD33;=J)LU&8S*K-9RFZ@=B@P]+7RS-DB!%E1)X&$S3&$Q)C*Q $!(K4%$Z
M!NV?2<=@-AA H;#$?[8%"0&!@L8F6FST2- )WP"!0!(2ND.(32#TO2LH(#6\
M143RO]%M'>;O1L>Q:<1K*FZ0M9<UI[2@9D<M?KNBLD1#IP"=Y-VOK;7@4E"2
M%B%E#^GQ02IO^Z8"B62*2EM&\6I.^Q-:242H<ZQ#H_FDY959<B0HQ/S:11 =
M@P1X(OC/L]"..F.Y4T)QL-?_'R?^[P67XQXL27G[>1VU&0=LCNBXRRJE#',R
M=18#LG_'7$,_ARE%B40"]"9'L0H9F7 6A!PE!V%#)V;!$%!X(^OYG]AD-Z#0
M8EL6.04K138A-!8A@(*.U#"V\C()R1X;&QM[G_,JLFG#RI%>7)V<PEH9L8Y=
M5M*[)!M\ZJQY4L$&,HT4;_R"3*558*[QB2I>;1QPGDT@X70*P($% +RC1$J$
M09%23Y$ #M:4,%AD:IE8<?E 4R1E-D="E."I8$)"-I\QO<U[03X=HKV $IV$
MSXZI%JUTFO\=K$CR^.*YYS=O<L>D6 NN"?[UM0ZLK=]OJ;IE?VC^J&<%MZD]
M[_WP[0]C'>D/QK2TLF(S[-8]RU024&SZ50=(A$5ET,79LR1![,7V[$-/?<7C
M*)LSYX?2M*U_'Q%!(S.)>2<A$(!H8L(60+I,!%-*=5 2SOGL]O/\]SW#W8_P
M'V8/.S0O_=E_D2[^V/Q%BD\-=?C'](,C>Q%7_\7TE_<OHNL*WR8OK[;^#RC_
M_X;1\+@;1UY3_U44ET9*. ;/SMX\R-YWZZJ]8[[WU1O]!C5\\V@;5DZ>[[K
M/K94$W'@1&-H"27MF_>YPK&X] ":10Y""?63:MI39G1F(B R.I 'L($F49$
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MW9[\(!YG^P ^I)&XV)3DOIC=\9QKK;'/+I0#D>*9?\G.((@NPN^E4* QKK5
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M@?*?_4$W'?\KX"[VT@]%X6_6VM\8_>SNGMM_J7SF OD-"("8F"Y[K 4UIG.
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MA>\!Z:'1&0F&:NYB44WQF5<K$KI;VIQIM,5D^IS4'S9C>^0>J2>MMOS8Z3T
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MP.=HF33]?$__+EQ;1Z53\OVR2!++N-K//W0'IT)X^[[X#1K)^%^]JZ0(4P?
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M!\B,!:#\[@N5LC-LD<0:^X3I\5$Z,48;*3WMKO]!8M,Z3?B][/A2I(=[T>=
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MX[V8^P,_^"&W*3=BE%%2QF)2@G!&G%39R=>[2K[-E#K#5,YP*>"GC,+U=Q4
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M;4J+(!P#VMRN4J\4^$!5S=ACHXLO1S\3WZB6,-^V*7;I9;K9MMV[\<$4\G6
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M6TWN8U2\5 2.X$)2(7-H@]<'J*JJD'>)(K4,T8PO-?/5\A>1^7RTN.UWFQ&
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M/MO3,]Q7@'T=,%:][V;*D7V?#"2',*S2:.-,V.Y\9&ME=C)I^(8UK, VB;;
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MD)I[9*OBP7MOOF$1&^/??;7:;72RNHT$\W5:@98Y"F2L2I,1X^A!"^4MI9:
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MY7J9.X8:RR$>0=P==*#@\1'^:]U1BNBSTYF&*[X\Q/UC1H*7&Q7EHO&/>57
M5C,#:9X+TZL&U^8((G%:)#0'HW_3JX<^CY76Z^FVAG;L,GT*#6*P6N]%+EHU
M1Q[L^_KIYAJF8$IST<<7!)@D0JC_83R5J1@0<0I05[3[H,IJ\%31'=WGL.$
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MVPM+8N441<P/U>%FN6,Q@HTQS.]/8 J&>):2RA7@.?($8SK9(+2+BK@[IVE
MF^=^5\]]SRD!,G ;6SZ?I[)R8KCE$5F6\E; 4O5 #2D,7CEF/1<7]C''9&G,
M' 1P6\$B%;6B3M,Z3A"$K]O>!C'2W"XYX[A68?3DQ[O!(U_T)3[2.34,>+F0
M]&5:PEL?% Z2,-CU?#46/BVZ!>'NB;,8KM<@+_;P#C2:1=. <(%&=5(21M]K
MA;REW<KO*Q]',<"6DXN<NVN9[4)2EUP)O2A,.RF@RX+F?;T<)@8RA\1-.](%
M,'@;OAOB1 _3HLGC&VD(1ZI64M5R=+ [23 '&0NS#E-.XCA2.PU#<*"Y*Z71
M[:-4U"UGB_(,-3;UU*)I*@;DP=0<GR6-O3-4#DN@D*45K8WU\EUOQ<P]<?![
M)A=>48,6ZC_FT1ZC&=S9BZX*!<>8\J);.TT?=7ZO".R"<P7XT0*[X-QS#D\$
M\]I]VBXVG8X(3:<S! YV?1GB+!AL^U6C^GE+GE:^PLIP$KIV%TW)>JQ&0]&?
ML;5JQ5+6-P>2&51"/H%6:.N#Q636X9PMN*6,P*H>FB>>*:,CB20[$AL:TFM1
M(\FLE_O*J5]U^;@J @UA,0I]QVD.G#_QDWXEXO*$:[>VD:2+=3HGIB<K1:8"
M3' A3/KA(5N?>K5IY@&<3Z:VJ^Q@GK?R)4>-MGR>!!/UXE$IV";:"=C6$C!9
M<$>6"R6/O']%FLZQ,]H Y<DG214\R.'IZ*UH@M@@-;O,HE!;CK:\D;%PIZ,D
M-UT>@WU?[M=JWL:[$.,-GB4/Q<20.G3K#S;NYTB%+3<BAOC%)D7 M0K*WI&I
M)%T+CO0:/([5J*K9L<>#>T 8<J!-PQZ"GO)%=/ _8)C$*>RQH&\-'IP)!6"V
MT;NT=6GS *+(,/DA=YQ2>Q+U=4RBZ1P<<^QEAVW;A4>C]WBG*V\FOB3CTWBN
M -/6#B.K3Y2A%@)*=.5!3F3!HA-(Z'[KVVQRP&@ H=F0WF"(P+,AQXJ>A*%4
M,<3F-<O7"G4"DXF51?&8$@]^6ME']2P"RM(UZ+IK/!7(PK[O=0:;;-;+L%'U
MND(VJZB;++-VA6==N KX1O)B'<<[<#-=R[SMQU0TIL1F&M(L+2('*UA(T#[
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MWC_O_64#JIL0I&KXLBTKU,#!:US!^ ^A@ S_",H# ..CS &%D2[-H9A+<S!
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MSA"-AJP.IZDALM]EO;KV(4@<8]0=FK@%4PC\HLG=N_[R"/U5]'J\RW>OOSR
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M_MW\S_V+'_[J]W_1S_S.__"%?^KYQ7/_\U>_CGS?S__RE_W[7_WFM__M7_G
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M-CUO_R]>;YP4,7(]D\E0SDW,YZW<5\*O$3GXA,;1&,753JA(>N085 L%(V'
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M!)A5P&L %^.[:@T?XF <?J5E%_J:IX\6<[P(GKL>-\+2YE6>']E'VC=$A43
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M&9-P^5!:6;:R;3$;H<-?36)744%\'H<1)J0R,B;KC0A(! SRAPJ\U/$F("O
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M#<\H'9C]?OW&3LNNLV@)%C][VSRP7R,S2;5L:(7!JL%DA)+!$?0"Q!$=F7A
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M0W5N=)%2(\ZY'M5TWR2,-^NN_KQ>&?YM^/7+36=U@08>E>HKB\)>X- ;1L"
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M,0.44>]CMMA1.9-ENIF.,#9,#%BSSLU'SZ3M^$[1&KG#^A8%0P<<<1FC* 6
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M]-SP7XQ6K:9A,UA&&C?EE9F%72^%AVH'KU_!F!7]U7Y]_&?WCU;/@;)U_ZA
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MTT[YY^Z,N=*;,N/L."'PKBVZG J7$G"G"B-NME0XG?B'?"Q"\<&/9A0"KH8
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M]LQ@XSZV$'718D<SY=84Y\GY9*:LZX-!Z;7N4G%_7>6D:!0,G%0MC72+R:)
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MD:K^.?H O&NNEPU6:R**2I.4XJK_-)W>Q.$X:R:DJ"'8SVTFG!^#&LF@[QW
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M?SPM_S\_!6-20Q+L3[Y@-QV+_C;RULG09-5<&SZI-&PWDK'STDZ;P%_G36T
MT:3MV(Y+;&Q;!]-XR<$[*7:>)&D4;Z.[_(RJFI&8\0S5O^S71#*7&MK2OXOB
M9=9IW8! \L*N6+7%L@'[9,YI?9:$9R%.QP%K9L<7,JK Y=&/UO@1R2%$PWHM
MY[95#-DD.%K$$OM.PDC$5#4XO.V@*]A;8#K3/$^%UU<&KGKMW?WU5,506!DA
MCP?GTQK%@9 ;2+&!K!Y"<BW8)XT$](#7[&5FLG:%NV]2/XYLAO\L8G]J92QI
MWM>"NS& C%T*4K='),,<F0GM^Y4E\D22/XZ,IE/H.^JI.GU6T=-47!&:>\Z9
MW)U9+(F/_+A76)S3';^0SKO,N\+KU2AXB'>!8"?C=7QK?GP$$52PG,\,ZPM9
M<7MJE]70=6T41' L@12H*Y%1JA[LG2EE9U5.0P'!W9BL[*P$6*^A?B0I+X99
M#7<X=Q\'56#T?W =+R4T->U %\_S;=*?A*POV3J!MS.V;'?'K]>OS*P,Y?%K
MN9?20IRB>T1I*-G.C,24Q=CFQ54Q&>_84TX="ZQ*K0>U++;+]_DXI2TD0>L/
M75^OLC$"[FY_FD7Z1VTPKGWZ6*U'V.9<'X,W'<>O3ZWZP.;*!1H29>"O%:3,
M?YZ7@;0#7;L.@VAAIRY^1(["A1;T8+EI$2[H+KORDX\@<;FNR!G5Q$'*:':$
MSR0-_]6A:B/6$K>HD*A@:+9DTV9RG\ )O4O23!"^_HX/OO&69.QR$'S 3K6V
M;N>G1M=@DH7'X9<I7W*ZZ\-9%EZ?2A'>+*-W,UD@([W1:6_A8D57$63[UR4.
MG6%5]'U^N<30H<:(3B*NL0X,9@I&E*& 20@$HLH.3N&@V4WA4).UY#OWJYGV
M5:G+RY210+.,CP-+*<5.G,++2!UFY:<T.?0]@]_- W)].7H_^!>_L/N.'ZAX
MPQ6G3H[GK[Z?=D4?XH!,I=;WX.SG$]A3WJMI:3&S]):K$*?7Z00EDA[@^S0>
M(F!P#!@B:;]G&2/6P)1_!<2ED^NK:FC#IZ_-G+=/T96F\UI[9+EXAD*4PE$U
MZRI&$[PIDT!>A:M(KKM:".#>6BX'@SY)!1_:/23Q96U$WP0>\G8UAM2$)-O;
M4BY^*OAV[]5S6;;(63E3^W/ECM<S6!FN0TLXQ)[8R_@10AX<'JC'3H% ''87
MH(Y*?XE,<T[KFILD4G R]/5_<?GL.>2@]7%YZKDG**UBJ2P#3REKRXVG6/!%
M#4F%3T4HD:7:"[*[YET:3.]6W.+W1P50O3W&M4K)_*89ESO#K(3E(;G8LCY;
MJ6E/4)QM#O$"JS[9(BH:?I@\ ZYYJPF_L.IBYPXSH)1#:0;"H8<X-919BF\&
M7#9C8#$#CAW)RD4-#DFZY7&U!L"L,H;8PBEF+Y;'WQ4*:YV1)R)Z;J9_,;8E
M(M&'$4X!&\+>ZW^D_ZC8_9:F;PQKJY6!@O_KR&G9Q7]-_[CNC+4>O\"OC[DT
MM78Z2P<+L^KQ,^=C-OLP[&2^P4U@#L=R@J<*QX#B\L/AWEWI6B9A@^T 8U>+
M\*YT;!$KVTQ_&X\]Y(561Y$T'IK[6,PKL9!!#T4'=+,Q6UH<W%T1Y]YR?%G_
M?:YOI.N3'N'JO<=.>I;43,TBO)W1_&S0RUZXQ(ZW59#!:?J595DC-T69H./;
M;FK2+W?*-!/3Z0Z:A3<?G%C?NS;$\N/AC\?N?^!ELW[MT%67(+Q/AXW6U2F
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M2Y.R3@(V.,/UA#CE9-QLG$JH!_D)G_Q$E!KKT0R].T7&=S+<J$'1ISAF\:1
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ME*5T2\6^'&>S.[9(L%W!6W;2> LFV*GDT:5LK(>I_$>T IU4\CU",29M^TY
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M*.Z%3X^\JR J1S%LG].26V"@/<5_M/\7:>;MC99;F[Z0V^L1.[NUROD?SS"
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MXXFP'>\JVZ7@?.N$RD3$YY-.5#GF!F"JCY%SRZ;-QJZ=61#+VLW[#MIG$%/
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MV69Y8JK@K 7/E(,-7RR DH4;])3,JIH1JVYKU B+&%L]&,AT 1G3[3"R!00
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M:WS4T[D4X9.DT*(N\V'J=05)U0^.<Y3K9V^HM=.N>H3I.!EV-O0_<$DU;7?
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M2)*>2NVI@WSE@R:#.:,9Q[:1?WE?R3[GE?<2Q#+LU'MXP/BS+=C+M<MT<'/
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M\X:''H49;M3G]^Z\HGMN*N6&?&G0Y4207X!@FWBES_]Q_RXDO*'P^X#%35Z
M4[]1ZIU#HWZ+6:"EE6FJPZVSWA9X]('AA^GWZS)N X-U-I1(,E]:LW^47S,@
M==7%O7.J#L28?X%V;1?!0!F8QH#SNXZ_>/D':D<4M"3_/4&T%K?>+)+9]KXF
MVAR#_,C(T,F[9B;85-:1\7CI\SE^H'C^@T#G+A$2"4+1H61S4NTB9^!@,175
MUTNS$OXA&\W&BM7EG\^A?ZSX*V1J+WPR/6*?S,@5B2NEY'7!(MJ<$Q@,-*]
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MUVX _'P4O_JP.+LUZBWQ^7YM/B+Y)5$/:4Y)_$L]LN4']=GV]OW& A*<LY>
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M7^R/F--<]_@]!:_D:4)YA@F\/3JW]K%S]/SY1 86.KJ*\C"+?-!BJ.:$LM?
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M"5."&5H$+)0,3\O4VIS7PHT^VS)*0;K=T@)_8KHV _GN;4[M\>8V**^!F\D
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M,!C=)<XZ2L>IRYBF) @71.0_ZBF 3H9BDA'<KFGF1IXH\B:$"3*,L%.OX:V
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M_[2)_7\[[9T_+-QFV$NQ^OLU^GN#4R_!<O9IIPM@ZV'VX1[G4VG-7ZU3DYD
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MNWIC*71X_/_#N;&_&_\#4$L#!!0    ( *.%+%:WJ[P+]RL! %B? 0 1
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MY!)H"?R&1;Y^BUQ.0'.%Y0@^5U^.HG/YY? F -/KZ/0Z,;T.;7(=A:<$L!@
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M8JN##D,%R;_:+[\!.Y%05R=X/RC6X6P/'C7*Z5)^MB@<HI5+DY9#*(SFZ*,
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MF0Q!AGF((\O#')P&Z>Q$B!0C62DJ M]SQ=BHR?9$55)->5K!SI*4IT)=4IU
M$S##4R$:)\<!2A7&<071X'19MT(4B"25-OJR$REX"9Y$(Y[5U 9>[/J!J,O)
M=%9K-$-74=S99EK PGE$*JFDG5(8/@KC/)G4V6I7T6)EC.F1$O]%T9GISF<<
M#:1U:LDV&#MD)R088CI!ZD"Q, M?#F* 4>P=CIZ$T5H=)&IC4.H#Y9B8%B5
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MS:?EC&EWF['OH@,H"=I<$QRP5C1N&? L8N-F;+CYM!EG@KK,X$EB(N 06/:
MBN<6Z:JJ9N4:4''+?#93+97+0)>0(BD:=+"13TT<+,/7!YUB#BS6:MZL:(>K
M,!O)<31DZ7J@^;U*AH"\8=94FEJQVHE#N]B9""%9SN13E981]0<34RQ62H.$
MTDQTFJ68>2(:%:KM9):;N5XW5>EH;C;;-*14M5O4LUTD5(9QL5E,!"40-[)@
MHHNW>B6Q+DV%Z><+$5\T!"<)FN/8AK41F+5;DZ2HXVLC]HA,)#U?!WA,=RLZ
M-]TO;+1UHAZ"(9\?-9( 827M2: G.("T[78UP:S?WO<%40=*0ETGQK-H4P,S
MJ9[;BL8A* FMJ2KC_C$K%$>X!<A"7L%3JE;GB:J,9C)69#+57K\GYX.T7V\
M,C,)J9INH%W#H_3);!.#2(!6P^N1-HQ[9%P.)9M9PB<+<#:;QA0N.;+HH9*I
MVW0NEPWB=%+))ZPAKV<&5C..;22K(HA3<YS11"ZRL[:B4'6D*CQI14$A&$,P
MG"LVH]# .I::"OEF6\H(C.)6W<&@CS 30-;LL=N>:!I88&"UZEMAGDOB#9R#
MG2$V"U]8PV5--:J1"30Y:0= #1AJTH UH-C'\R.IP:-1.H4;?M]#*WPUC<%,
MJ 9,"RT0@ZC:EUH#G,K(!70\".JS.X]U03'ZXT'$$B,A=N9:@B.M?LUJUD@)
M'J.32:Z9J,(>35<5CBXUI$DU,*0)GQGP1 ,OC <EC\H[0U-W0ER9W6R5*\6X
MSH62E6155SRCA/CPD//:56%   5/Y$O$(&0ADVC(0)&IN:79VHX$?E1K5X-F
M@NAT8JLU)-S!9O?HJ2'<J.829EAJ.8B+=.TP853JT2 NJUI==-0 >J$\[D2,
M$YL3*E9&A)Q(QDDM:.JM$5D8"_'$!(( Z_@(GVT1T&"Q#1IZ30>JP6A8 ^RI
M[H8NZ#A)!N3J.AX+YR?"0:':-QA&Q<QA+6>9;-T98$D:G7#)/#RLEFI==I Q
M5P=8*"B-((@V_7@R(%,8P5(UGZV.+:M=QWK#=*W7ZBJ5;+J2=DMCE,NV/79
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M\+93/G#6^]]NOOWF+^;9[^[VP/-*[FMW'U_YT]*G_[KC@U]!.WMO]8]+7UK
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MV5J<$_>_5L=I\,S1&+/Z=Y]<5]<I=0/E=#D_6QEKUS0T/'KXV7[Q]WWE19X
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M;L+7Y6)GGMV?C_.T:@#"E=1W>7(S ,Y>_D(7%V-X>UQEFW&#$DKO7B(#9B<
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ME:=O7%NU3^Q#D.(%D 7?#.KA2D!$.CXC5/R=>YZ/KQC4MD 1)!']Y 'EP>:
MRUF ?Q,VXU;(I0Q.8I"G,MR_)5W$Z_?1&WN]^ =.M-8MK P\T5]@$A>2X(2I
ME/Q<)9]R)GD\B"9 &YN5LL*YT4TB?L7!7*].L(C9K'NPLVH;!'A]FXC9HP:L
M^@];CC2J,[1:R=X7Z\4:GAF7D3YCIONEV3?0D!/$3$(ZY"/A;S%%\TK. 0@/
M:7DI*(&J+!>OJYA8*5D]4L'7ZU%NIQ_!WDFMV:WP<)ZNFF[\7=;,GQQHII!B
MD6[AZMV#1%"EH:'O-C.;3L\^8^0>.A(C0F>04>I(Z@9&Z.Y//81&R<<$WH'
MBJ%@#?>48Z]9C1X(,L4GO0C4Y<Y>:FD?IVOZ28IG./V<K6*:!X.84O;-Z>:T
M?,ARLB#G>8RF=@ @7J^[WAB%*1F6,8#$MVU:3:H^CZD<W+>3H$]@KENN&"OA
M7XX&T/?=V0O2LOO\K244L!?UHXJ8JV +=36!A_([WJ\\@?[^AK)?ZO]PN[39
MMF4TOX"?.IM$H7\",H-6WEKDR(TZ:!1K"/UE2]+M$3V(63&OZ[O^[H6-19I5
M-<<1A3U1\JO(=+)I*W;B$&W#"@HW+NU0X8]A?7+B)<5UE<5SX['RCA<K$?6S
M*AT(YPVQZ= LI[YSH^D5#3TKK)3\DQ5!S,KOKIDL--5P'XE+/.A'?NKV[C(K
M: L9:O2#VN?EAOZ&8>[K-3OI^Z;UL$)72D_(Z0:MB JNEPRX4!FC^?15]>VS
MM_+-V:&MX7$#R.<]SSPG9:-;/M9>$IO[OL3O<6KOFF =:;I<\TF9Y5.%!5DY
MF1O^W:*QDMB#]T'*G=XE!,G9L-*BNL9)AG)$\(P3T4IOGA&A.E,\)QQU#5E1
MV6Z=)54D9>JX4P@M[:ZXIJE<3&^0A4:KBN!\!3T;;<]/9FBH%>L(/A=\1N'I
M#OM6_VX"Y8EKBOFC;@Z"NL@_"A5*,DF&NUOWBD^+")WV/2'XLYYY\M'WGFCL
M>>9C?A%I_\ SK'C[RC6L$($+N-N']0]MRD;(^.S*VJ<K-NAN6L-C-CV:P(M8
M)CUO'V#?\ LAG5L"YDITLO,XV4J3)'5%<Q3.3CQ)"T3Z.6"#G!)%.L<\:< &
M)^$X7!:HF^:#EA=/Z9.(^?!E:5[ZDUJ1Z9EK%I=Y+=VZGCB=DJR:F^F0/'?S
M3P2W(L ;[IL!GW&>HC6'V/H(5>A1LVU'>?,9YP<JWCBD-SZM#KFF2IL&_0CZ
M*"#WC&P1X #G85%H'C:+8^5WY!ID\VX7R.!QHQ?LC0>\=,^I(+7STEV-FLRK
MP-8N9.0#,_ER2KH/?@:PD#0P--=)JHL]*Z54!"@Q#RQ>D*G<>=[5MY::'%K2
M5AG<U!,V]C-S[OQ)X.TLAR$36/3C3?ZZJP<6S@5D[Y5KY3G&0'$^&XYZF8Y
MW<91R?#0NV5[3"V'(%_+$&6K+E-_";2P>68=H@"'0/OLS@;I]1>\Z1L#2QO!
M58XXH:_*=8)W*LOVQ.U$[%;Z*MJ1XY9Z;UEEM<F\)AG0.W[,=/425 (A@ 5
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M$-254/>&[*B_$=*A=NDNN!<-T>D]#/*'P?.EICWK*<EQ<W-+,1= &]+^@8S
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MO+H885XPL;&.T(_^SR?5$WV0NU>5^_;N]7R$9VJR7BD$1@XW;%HD-ZA6HW8
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M2#\WFJ01JO^8=T.J[2J<;S#D/LOM\$;CHT%5JQ[Y=04YT54+798QRN99E.M
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M6BTB1T,Q?#-@/'(9*FV9QA=\[0!F%PU] CS*M80F,_[!N\I'GN>BF''U"32
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M1??P31CK$I#R'125"'+)LI!D].'PX]0C8+5 D@[_!,RISD'+3C.A -9J8\_
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M@%E>+9SA,E)U2:*6$F.'!,9(XC/\-1OND,C,_]4B2%,BKJKS+'5-5JA52>K
MU[KN!U4BB<4[-AE1WS@%*L[8-^\L'"):'97 /!^(>V\^I7.&:GQS4E&-W=)$
MGE7XE YY5^$>K%W6&<]-FH5LU..[%DK<&H35C*%>28I+>);\!( U@!ZX]\TN
MF4>&/J_<474^_(3?+CTK.P5?COPI8;L&2 Y*KAO\_KCY7S'HUZMWO5 Q@?WP
MM6:MI;UNZ^/QU2ZA>';5)7)PM>M]#&5@(76NS1+@/L(Z6 3X!*AJM@V\P_S8
MWQZ,.M:N6XRM>BE_E^OPL*7](,I367;H/OS/Z]U(_5&.#<3!Z;NI]VA>%I&*
MU$:JW%\IGZ<@JE\9Q_V N(0;?'T>AH'[F9O^6=K,=S$GD>7J @H[?V-=8P9^
M$:;(&1D;H)U1L6)T' (,)]OGLN+R[E>3S)G^U:O!+"-L(J6%KJE@KS2^+KJO
MR%\$8J<WQ+=)8F"@_S[X@CRV^!KG_8* M;T-UQ9!J>$@?GOD"*R.I8BNA*">
M+46.PFSTG51H$Y2O'^@8,@EU&V %AE3&R7ZRF/,N<LCJ2; \=\@$\LP)L*B*
MWCA11/DOR0MB%6._<>0G^*4@\&O;!@QGH40=BM9>)#.^!,Z4E_I7EU7)Q)4@
ML).TM*VL%L;=\48"44]!X0T%$X7XX\VYBE,R^1 %H(R-%:>.:T=L6Z'FSC>"
M(4'FC65Y9;@O5$-@/Q[$1A>9]DZ*Z)L<4GFX+5EK="N*Q<Q%MJO_3 O9QYBD
M#)C5LBQ0I=A:(?)"(_5 63NV ,&?O&3=L"$#[=<*G\]7+1L:DW'HBK[ 0\<H
M*$UN[B]RFCUM6RI8;=BOBBG+6CA1P?!CE8ZTI5P4 .?7@O&KZ#OQ.PGP1^&F
M!D'^>^(C,-?E,ZOSD97U?H^AHY^DKIKSP-\%%?AVE,=^L*V4[6^Y![NZ#T=4
M?/77U<8U(E?2Q4ZY'[3T8OBQ?44'3@?/9C4NO4J#KN+AB_<&KPPR[[*GZC2:
MBTN[TE!$J:W]K&_VB^Z$==H#>I4/'SE3.$<>QO:,6'].3:^KO,C"X6VIOK^8
M^IC)OM*Z4>#S!"!62K8-VO'F@KKL.9PPAXZB_(.,)Y,BP;%,@WSM7L+) X+>
M KY)[[8_#55PMHMYT]@JUA_Y[F:V=T.VX"M-5$K6%$UI+0I?/7_\TDLVRVI*
MJ,DWNFKQ^G<5L?.K03]53!G'WJ[U&JB?9K;2Y^_?=.:QXA:(64R7"EUI,\N#
MZ"W"/6"*T(Q:I$+EC$3,R5'^]ZPY(0R8N.^HCE3_B:H\^H$.)Y5]^B7/)IB(
M,@I<%G ;6*,FO:"IX?2>4EKI=KJ4 \>UM<UNSNK28534M,Z&!)]UY?0E0[C_
ME\D^HPCSO?[_,@QV^6G59I<Y?$&.<=M?Z-POHM&Q<^-L"TV#OX:/_TTACU%L
M;DW.%=*.47HB(^.TDAZGZ!]?@9KWIAF\QZW])X;*+?"/6<%K<*^CC,WCY>\$
MT%51C)^EE)A"':/PAS8VGP LS13,QK^EV9QC6\I9P!7D8_DZ6PJWG^1F23:$
M;5U/K!IM/OR.^C?/8:7<Z8=IW1=+P12G6U87^.WZWFHB'!HNM L58>P>7>Y[
MVD5O[=!IP] !PT(;0/P!3GK2+MRH@,E_IB@FXTQZ='2>OT^P_#UKJFBCL*R&
M AC!1&JLJ0H+T"R<8K><H&O=S=X5[N%7,M6D7*A2<""'L+LS2LMG3(;\)T5M
M]AQZ/Q7]L2[/KY28SO-02H6$?.)B/YC0GCCS]:#*Q]Y"LN>K@V0XD.XZ$)PR
M<9M(&-)+P!J<<!#>.3E([_G3J"4?#4A-\A]NK,<Z9]F4=KRV1Q\:M0L,K'O1
M%SG[JZ\T0<)@3)%Z[*TP'W!FO'9!;]NGQYF@_@-QC^?2H)MI:*DBZB*DMGA8
M-4HN"0$DRI7\7^WW)_)^$ JKX;_IRM+QRM:)@6]/6!T7<51_/DNPJAMF5GP"
M$,7(I) QHAM0_JW3-FMN*V!9O/($()>T_*\F7'NT4G_C]@!5"OI_/117SS@&
M7X^:R,U/E-\M_S.3_/\.1NB[M#M[U59'\:>"\4:BK-Z![OI[ZWY>961"V(8-
M)\6:[U&9EEX2XJ6]C\@9!+S#<NU&]?[#A7,Y_%#ZK'_H%<^R^V!N.PCX33CP
M9;J<-9!)0_);ZE<,R9TGG&N+NXMEPO&8&'T9HZ.CG=&=3PY"\[36-%>WTD34
M=T_THX@05@L3[O(6(O;V><6]:$H&$'P9!TV0HIB-;WPRSCNUZZK^>'X[O;!2
MLN3EI'DW!0+>V]\"Y/,J!^<MMT$@*5OBZ5@=P&J;S$(==TJ.#Z^4O12?-;FY
M9=]!2XP59,RCWF.!.&^!R^4E6YUA\L6@?DF=DVK)9&Z?T_JPM[)%'G4A%G,>
M/,#X39SASD"0P:9>F8C+[P%*QX*51D>$_)G]EHW1E"!NDW6Q:6FW7V/MS"TC
MB->"7]$)"BTGZRJ3/Z:P'ZJURO[WTH#4,#F=2WZ:)@B,^]7IVT0>#V)OTM&&
M=$KS<M8[VPO_?0B0@^EM>7ZH M(USJDG2"@DRYU6,>@95#1;L]I5-5>7PUFT
M1$=Q/48*SA0F\"UCJ4^ 3:&( DTQA:F *BQ<?%!?5%EXHRQ_VU#F0_6BU-@7
MOZ%BK>+X-_#CG5-V,/P#4H'%AF)X1PY!08[2*^$812W5U\3G1=(N%':&F2XR
M[UHQ2@CC54HF*UQ-,V!VR7E"Z/@EBE^?<</01CBE."= G)*DR,^<Z+$O6EWY
M[#SIM>F!F<^5".B4K1MYK('>.')@JDW\!;\4(P&ZGB6I&'E#Y7X9*RM+4C#5
M=4(KL=:KWB2JZ>H['#J5EL'AHK$-ES?53'1V&N3:,#RR/Q]L4^T$W/\N>?FO
M- O=;S!X8 GXF.I=<4=@:R/K^A"_]OA[Z,$%,.,G?V?+_ 18M\:XU DT%NT%
M#OW]%UL;I??.>KLH06,&Q\MFBQYMUP'GGVG4Y^Y>2,P+/LK$BVLE:-2X (*D
MJMLS<X/G?M:T?8P4WUQI#[<S*]6.8@E@_#B."#HM"<HBG=/U:?@5\D]I7_PK
MB1-9A^#<F-X[[ET8],B+]N&&Y'R'6.3+#<+M\45I4#:M>> ?2LGT6S#XJV+
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M+MVON[!Y>[!0\LI0E%=PC? $&N8";4?SU1*<T4Z<VW,,3DK45(3 -$OPINK
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M!B%?XGGL;5FTQ+_.B<R0L 3Z%]6D\F?O05ABDZ@2-$+J96?X"!NO$1B(]ZK
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M6Y&3PU$U=?_^40M8E<[U9Z5IBD.3^,UG)4VBY)6-D_:["(=;VG<.AG4O,)R
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MS#=.QE.N&^*=+!3I8?2TAW)U"VKQ<9/#,,6ZZ(4[T'Z((Q9D*,L^X>%0_O6
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M;+"#8W%J!*%#7>K0;5J07MW[7]@6AC,ZUR,(N,!1BE7-Y,>D&(/V:5;M9 .
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MZ3,?0::+Q:'(D1E"H!?"W<5+PFZ0$/";/NH_/35NVAJM#XE7&C-!!YOYY),
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M6%S_@TZ&;(0:]JN.5L TR]8@/Z3E8Y.*5,14)VL@5L2"UD>HG@U-58:;26#
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M0^N$"1N"A/^$'%U,9\L4TYFF=O^"O+Q5?RZ@86A75?0TWS\7_AM02P,$%
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MT-4'P7T.I'?#,[Y_-^O[9)4M]:7\V 9QUE]3QF^PJ]EL3FHZ)]75LAU$470
MQN&8:%%,U-J23K<F2MJ$+LA&'#^G%55>UOFZU#OP-\W4#7W*^/&[]6[V= 6Q
MQ7_+D0U5Z$AABW9.X$1.TC5K#$'[O\$'\-EB7ZFNBK3>3\NRP!?I 2EVN:[I
M79F3[9LHMF33>5W@^K?0H:.M1]"W;-W8(? #2O8)M%2>,KXUD>5*M"'HX_N+
M%5[B-*ZW6*%5NJASZF1[EWPK</NVZ!WMME9D0#EVTY#]!RJJG$SSZOA^C!>X
M7H(6N;ZMF+91?1+-'SJAY3DZHW&JM"V#GQ-TND,0K1=IH3?-;TT"N">&:6FB
M W X>T%G'X3V.5P=A@"9'H1\"WK U>?X-SW9L;\WRZF:-0B;N!R3X$Y_2! ,
M35=IO:YN003"DX!)0(<$5VFYPA=[];:\N5B/JC?K:JU#TOEVY)%'IBM<KZQR
M)8$O5W1K.+ABK9?7>JVE*PN<SDWJ30@<;0T4)VF&M:9$6C(L\SMT6B]MM6RD
M9'ME3K6@ZD5.TR99R)O$#,@HU06AWN2ELL4@U-4NKR58L[R[EY=Z=8N&K1>-
M 6_OZW!MTMLK6(%C$]S$_\VG(^$G^O$@/MNE]0_2\1/C@A7:_AT8!@VLVV'"
M0V)YQXQE.R^6MXPI%E]?S JJ+*W3?EKG^@>\<R( 3@3<Z0T^C=H J,\)3+9O
M0[LU3IWE2^T?A;*)<BL,G\I9K3\&8S/*P3#J:KI>%_J["6+S!>0CX=[#*5YB
MZTWMB,V@-C!LA96N&"(CT;R@_<38-/!#IE6-2ULK<LKX%*?5#;7(C=^&88.D
M@=GK:_*L7NEW0'!'K\V:=L14X086<K_#M8EI0]..N#;DB7 B@&_BVR9Y;,O'
MBW29Z[>C5;O+XTF2M4(X5?9X/>6 A_1X0QZ/WXXD/5H&KS18'#5I'&V&_#$C
MYO&XDC6!\-@ 3^?Q>BSZ@2?@Z:P_3W* V7J2'J_=YO+X:UB-<80%#Y[N,I3L
MC"=D=9:3 :\G$_"6,YBW7,.]R7S8URSCWG(YZO?4([YF/=(!]'L],;^G.?!)
M^CVN1,#CCON]L33F3:8#K2:#M[1BL.4N_?O3# 2]S2+A]P!Y2T(>KV126*K>
MZ>L ;D'\$S]VMV5HLNS!+7,]S4"J:[(GE/(D8RG+M("'[E@?] Q8EPQX-CU)
MS-,,X=:P!'V>FF6>U5<.^;>FVS"&'I]EK34NQ9 O68]:W3Y+@-]33OJL-FM$
M+" I9DU6+&6-/Q9*A5K);  /. )\,1_(Q&2\XFU1K22?\'8SHQZLQ%H%WNU+
MM<N-@) T4^F:$FGGG0D?D4E*-3AN$A4V4PBF_8 1"H7KL;"O4BY4PM;0*220
MU8ELQ*NV7?9$H ,(QM- (4=A DV!+38GH%3!49%I4=<8"FKDG2F0E5@7EY.1
M4A"TE9SQ0"5/!_F0&.%=;:):M_EJ$)D59"XO%CJ "B.%'9P$1:IRA!)EF)<5
MQ=!4&F[44];X6N:'_-ZDY2[)?,!G.00S,&:5@-_K"Y"Q3 #+I(A*J%QHE0N!
M=@>PS@2;6"R8<I&$#\N&^6(C8(;]*7^Y0I.9-L7GD:C/ZTR0!!<.E%MLIM8L
M=TP.5PL8SK,U%LLXW4K<;+;+<@<0L"7,2IBLZ;%T!DJD!#9/964FAX%<#DP)
M!9&MTY2L,CAH,(X?,K\#:/,+88H2(+X@RD91*L"EFA*OR30M*1%14>"VKBJV
MAIVV',T_X!&! 1?SNSV(I'(JQ[!$@S&K*"-J^7:W=%!R@:Q $X%:*IBHPE5G
M,1H$6AK9]LMH'*-P&QFUFY5$5"F),I/.B#5WRXPF_"%=8G0<E#!<R]:;*:2=
M*%-\I@,82[5@22EF"SKD:Y1B.LC1HJUAYF(!I-'6V9 !Z(%""*OS9LOGK FE
M2MCIKP&T[B]GHZ6$VZ.(]1REYQI"&B4Z@$DZ*H-VV6>@9I31B0A>DVI\+9 .
M1[VM:(H7TI15OUESF:==C*]=T53&).2DCK#>8""HJ4:JK" ^U5*E9>L6%2Y%
M"D)%NJ$X-([48V B*[L0WF;46"A<S]M3R2J(^X!T#4U4/(@+RY<@(Z["$,2[
M6QPEVP&)A7&%"E0=0@7K !8,/9@QW,5J6L?MOF235\H(8HMCF3#4!A&S(@=K
M-HA)VSU$%&90BL(C3K&F$P2)8^E(+6\WG,6R-YW,Y+"<T@%$039%X9*9RYIA
M*@)4:(K.*AYW'HS&6G*2]9:SD QE&@QN<[ML!<2/AIP.@198N!Y&?&180.,T
MCC?U0C@4H+H:%EQ<ALEY:T6OIP5YP)":5&0N8X^C>LG!(D6X ;E$G61L2%4+
M^0PIY-)#A33F,\N.BBW<E!)P,9NF0'LJX^R.H=,D(!&(FN$2#/I+CJPC11 Q
M?S!(,*VX%,&)D*N4RF,)1S*"!)MQ+X7#)0*J@TRN3@0-IF1&PP429F7!&9.Z
M56Y:RX=##E&4(&>2B[L*8M+&-_!84')'LQX'9,VO&H3*<)6V,2@)YK(H!O)Q
MTZU0T;8C6]/<A%%-ZE'8[Q3,5@=0\HITUL5K-$8V D4[#S$1S0V4,HE$,2<@
MF0: HB1@LS9U&3&89<2J0P-%18T4Y"S/!<MPB,JV?1CDKWE;CF8',")P#:==
MHG,9Q-\&2VTX&\[;\BZ&CS@;>96#91C(E!0QYF9X1:@GS;HK@81A)AM1N*JS
M =4I0W/8A7@< 9!L!] KZ]6 3:&A8C+G80NXHI%Q+Y&""IX*JP0R. 3S]2P#
M\6##9.4$E+45B(+@;CJLO4Z%B4:CLJ,.ESP:F<(*W1202(>B9LCN;52<2(FV
MUB )Z5FWZ R*$LFFJX9.NH$4GZ<0VET#3932"K*,D5@Y6@A% W+(WDRTG+@S
M5*1=V=R&I:<Y86NT,ZJE@J(%:VV BCLT-.-J)H($&V[3D!!H4VH8CE1JU6Q5
M,[U* &AEX_:VM7WVT&U;BH@WZ@A@!?MNM(EI*(S0+;C",C27$G4@#93EC"_*
MTP$657SE5K;:$.,VT)Y+)+*5NJV>B_.R'\I'8+G(4Q0=]ZH&3;A4.ESN +;\
M,3AE (:CZ:4:.8Q*6\8Z<_5 IDVW(+H:J\H83DD"40CCOI#N<:!4J)7UPB##
M,:%Z(JS+JDU6PTK&9A#=K%=TBH)-I:-A#UAAVUXJ$RLYZJ#J<.!>*N[TT6:!
M,@0:#%K!@\ &0D),;_@9$^<R=%$06-4+9XI-EC:CGIK9 <QZ$0['LDX)MH,\
MZ):= *@J05%Q2$$Y4D-;0::5BIIBBJ2X>)C*Y=$JKSI\)(6;FD,PPD:,:. Y
MT0B3WE0WP%)J''($DUEK5<6XC E50"?)(!D]TRBH7!OD4C(;U ,IAG/I3**6
M\I&N3,(4DKYD10?5M*4)5,I)=4? +BCN#J A(U6*]=9H'T(CK!R6\SE6TM6J
MZ$#D<""51'E?(UO,IDJBO5;#]%A4RC)L$@FEY$!2*KHKE*;@D:([U72$@AW
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M;:*PT&(XL2$;:J[8UG!2\&?R6)ZI.Q5GD3*L[8.?R[&JK3N&!*6W F&"H_U
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M*'"@%G*2;3TO8"TBIFHJX2\5<2I<#Q;H=K*[7S;=U8:)8%FBF3 ]H+_-0A7
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M_D>&;Z6$UK&W8QU5X75N@_J;-?\PAEAGN7Y?+!_9P-SY^X?9!J[*]B=2<5^
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M=!-O__"/__C?_./^C_L__,-__+_^EV<V3=V/(-B,/P1Q&R8_1&T-;D$'PC]
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M19[@3H*?!3>*/6+@4V!U5LX',%M(-<5CL$U)A<Z_:<<P*%WKWPA]MZT60%X
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MMR9\1VQRZ09GNPNA"ZH;U05S)G!M</KUM<;V)P0=![*03F3X=JWM'XN(QA^
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M98#+YZZ8 0-:87Q.^U>+DMC5$W/:93K"ZP;^</<[=>U1N</#1I&"V<1?:0'
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MPGJU_#EH7CA!KQ'LCJ12U-7&4&J-\$[A&Z"II&^^3 EHBN O<.?2CWV'0M]
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MG:&.3YZX*UO(M5)ZG-@:.%P9G[B9S#4'(8\=M<3UZ8UQS3>82XBODHZL[>8
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MPMDVRH#W/5CXCJ['N?@Q;+( AY8KZ$2X.Z&'>W#FW-2I)PQYX8_!@_;E.L5
M+4)S-P-\#-X23<YU$:U@EU7:6\V_D<.+62>Q?YD/6J<;NB@3/<M A1CFANXI
M1Y<2M#R,!J=H=N)IZ^'C,C*:N-5O)_>@-#*K)38.,+":'NA[0Q* $UDO.W:_
MX0&754)%;%QQ1M8&Z VJD#N)RW26?.("-L\"=49](D6&S:!*=ZD:&[9H,U:R
M:Y"[H?,^AN.NC'=Y1NXY;^ B#V/R.$?#@36TJZ8=)Y5M,X;$ !7[EJ,5L4N1
M$TS=-7AE%P.\8*9T1INKSOCZ1U_OL]&O'=H^\)C4T905Q7HJCMV+>,8R97J_
MN.<L.-%+;IXX[U:PA&\?HQ$Y.LB(-VHN#8:X^,Z4;6^PE-%.#L;#SD(VEF:"
M>IEF /C6MBI J"XPSW1 =\$Y689;G5P4G[ AN8OX[7'A^SGO;\\+\S;YEB (
M0WA.B3S/R1ZVC:HD4/(JJL]28U!SCC'/X%ELUX5H,9"=+","FP7>--9Y<:7]
MGH)1+_5]?T.1BXTGH]6T.7*MH:PCF+MYLS.Z "7B:;Y@3^O 8+FQN\W2EY6"
M4N+5:*HXADDY/3A/@=:N&SE\VBBY$;\2<-H$[^4B"(O!4'GB,9V3>*0H&T1Y
MA;+6%%VE( 4S)Q]4T$A@19_^\:&74 Y[XDQ2-0TN7$$)4K['<+B]X(J!%_Z)
MN5[[K&3(.+7;/]SW<D))$J 332^K>4FKI9U'5W$+A!E7<ELD/5@-1=XW5$;3
M;CRVM\GLBR(H]*;G^K$?0@:K=LJ*H#X/9,D[-FQ&2VGOJ+P&W@[ZEGI[,(=;
M*IQ<)3+906[7JOE=_YS![KV6V\2"05&H8L#3=_(Y'>R%0"()OZS]Y&%WP#"-
MM-198;W_;&H^''O7/4BYG/#NMD3[)O?F;KM?H4@A]YI@/A398H:7>D$TP"RZ
MV-(<_YP-X8;4P.,N0[.)W^]0CHZ^Q+EW=!H2[59;JF-:SB/HVQNC(>I[#)7>
MC[!#/QP[YP:HH*;X"A%K-79WW7,>]>PKN^O2KU=9!J[E=\3XR WA1161G/>X
MK[/]F0)Y R'<E_4U2;4%R$@/%+=P%07X2<>UIM-06+YVQ35++@ ;)_++H2YE
MRL!IK),/[!RE! 'JH\E?!2W? ^9Q8QB=>7Z]MNHGH23G&A?CKNN*]GR_F3<S
MR?,74&C;]MRN8JX9D5H?86(;?W2Z_,OC?4#SS;M'B=*'=%)EVG6( B K\*&C
M:DNMLTU>0='7!5JD=_8X8^4?'EV_MPC^A0[=.KX!T.KA=6TT92'4!O?B3OSU
M E%L 2^LF-912A'Z<4TX^E@^W[]WVL]"@3J*CSL(3R_3(Q+&=!I0SK#$J>FA
MZ4 LX-DOC?Y6_:]'2'^NT=^J_U[+_ZF:G:09ZA&RU@LQX&Z)<6G?^) =/%7Q
MB-7<+%7C_:':F%1ITMG',#>F:](]_>01V 47A,IQN>MI5TZWP=1Y5L]>"9E?
M@%1>HMFZ">'[-[]=.F'!- <I3MT_[EB_57A&$MDDRP5<MI1B7ED!^!MXM*"J
MK,T<$Y0 @#<0$Y_@Q\PP6D&MRS5Y']"@PYJ2E'>&\Z_%'Q-'_2(.N/(ZW@@G
M]OZ-N/7ZM>0G<>A[E_@M[JL.*_,;<7^_=A^*O1W[#[2K]KE(_>>=*CQIW<UJ
M%^53G=\?%/NZ1$3*'B=B?ZFT]AT/ :&H])F5Q1$JU;+852^"G[058;92566U
M6??J6!G-0L^(\R%GN8,*BE<!>H_;ND?T :$//4+B0?'?EY.IZD06V!E2KMK%
M5VIGW6N+OW371W2Y+AQ9^@T>2QP+-;.&$X_4'+B]$,#[8DKF.CW#$PA44XOS
M59Z+[WWL'HT>@YCW/E8_.TGE_!*7NWN:$[R RP8.PP !X#I_JRH@?!22U*LP
MVM%PZ#Y>NR+B[N552@N9;P$9O/&A=P%CF1Z3 *AY*].WP<#\0"0=TP<=UE,.
M<#2W;L-=4&6M1:UP*73C)C62NI@(^KB<8WCG5LN5?.9X\V6B#%5F!V-/'I&Z
M*FYE5O&/,9G3(\KSQ1]>JSJ_@*H;Z2'F)5:D8C"VD"UZH5?&;"#3+,QJF+.N
MPJ WG,L7; +'&XUB)*+S=>3A0R#(XBT?[\:)UN=ZS(+K37?<Q^,5?ER2B#3)
M)8OGS=57.&P'[M&8N^!$ P!^_9,4B:I-R^%!/+Y<GIL;DW125L')M?*1":).
MBDWMB=#ABQF(5-4+WPK"1Z_:+<YXSP$X]M,-^5MWDDCS;7+N0L78DD416T0D
MXDUFYY3;+EROY??[3=H$.+OY:X<U(RP_TSUZL7'HT<U*G3:N4WI<( N#M-"]
M%<T[VF3YW)("L8CCLU$I<MLV^8%#=@WM$&T,8U"_/FZXU:44Z560* $DM4W3
M$S!Z!$CMWOIGK$W*\[2P6M\I .@E,_)N/71R?,C+[D'YP$8>19G6K4H(RZY[
MO*<00Z/URQK'Z&-OB)"&9*Y?/+5XV:38$*3HX4I,M_<U_O+%H7"K$+ ?%!7?
MPR3D#KZ :W?AS.\TN<6H5&R53NH43)]\O%)<UAZH8[_?N%Z=YH8D?!QR^<%^
M16_ ^6A4&?0!89BG0 HTXU869*J<0[UCD)@>/34!E:[.#?&B[H.DLY'&3>NY
M.L(G&NV.BCTKD8O[EZ.?*>>]=9^S"I7IBX#0MA>C+65(59367DO=R,0-D0=.
MT+5Q77@N:0L@/RG.[+2XHL)[O\&MM3Z=BX,S@64R]^+K=M]209U^+L:TQCO"
M0N_G8C@\OM2#((R#8)JN=JR&M-*;9?EH,)B9]*RS.IV+:G'P 4M;P7Q$T? !
MO*&(P!>^?NA0?\ :=CKS:WYVT"*&AIE4')_?-B&\\25V[+<*1W-F[/-&*3:D
M?[*6)8Y<M," 5S:%/]3B^_3VDWUYYJ[S6,R:&:2YS_&<S5F6VE:\X!U]D8A2
MMF+-N(@T12XVGG+;5J'9*ET+"U3J;^Z,?0H<'^Z^Y=:]U,W,EJF3#HJ\1&2J
M;4XB/KB)E ^BC:D71]"D@Q"4O#+S-(4BXIP_GX@:J@,PW,34CUM$[S$L]U&C
M-1MP/BY<7!KPKN_N2D*XCMOT">'Y<_U^OJKVQ(U9:TM/QZL1=RU+]4!>$[:=
MP#DL/345WIL8+GZ=@C@:AWL,]&!>^'9)-8#;!4#75B5MO'09SC4H%:!M7DCA
M<E(WXVEB**V0#UHFE+W!DZQ>)"SFWY,BXK3)*CW7NY"U1(H8S%)]A4N6(ZD>
M7CF_,&@75>IY%Z>)@Q!XD4@$@0#^2LU]ZH:U=G.JJH-H$V:^_I9Z@J\\[^2Y
M]* >HWBU=P4W*]>7= 5IYFI%>^\Z^6MI::Q78G+*!?5DE^0!KA>==))*N5N@
M/.Q%ZMW>M_ODN=[<P&WD:@E=>!SM[-6BK'DB8I-O74ML"9J!U895&D8[ 2ZX
M473)F7:4V*G"<"\^0PP.I0F]'[VOAPL\U&PINU#AB(!1B7L  '9IT$ #OLAI
MA03&;@?WP++47?,2)']6;9_4097T#B"L*[MEH ; VCZP^#LO0S6_E:,8WR>,
MY)_EX>:&.-KEBZG:]<QZLM:NO.;41)5NG@\W> K5V\Q&KELC]!#Q]R=[/SEF
M")1=_]X52:7'!7O1-^*Y%Y78YB80D*('7O3*>Z8MO[7,*@"Y05Y0KDC'=-*8
MC::I*DF!DY/J5G_'+6J>B$8Q!_5K/"RC: H#!2NS^[,*L1@V0%\(IQ=X^N\R
MV6/W<;>D6W:<N#SO^[ /@5%/3]"Z!QVX+)A.,0^$>(8'^/Y3->!D$IX)V"=Z
M=JD$GQX+MW#9*[AB61Y(2H(J'R8%6[]TVTBJB]SUR6+EZ0UIN0<)GO[D$3#@
M"I7]>+Z9E*/5J^OGY6.'EP#IV(S9<\V46K]%K;)P^F5M8HM=JEJ7F@(J4UI]
MY9()I:6WUZ^/*X87-YQ?3C)(X?ML=+>XMC748^S\&NLO3CT;TJG^::SCD#^M
MR>ZG)>B[0G)R4OGC#M3K .L&5Y[QUR7]!NT JP-!6DY9R@;V/IF.*,2YS/CI
M"](\1<XX@"X4D6G*Z%D4CPOD,#Z"")P:7;CH)5RD$9GWC7W_VL/[-@MLVZ*(
M2SZY7V59 JTJQKG'HVS9]5E"K',/GH'"[0S1Q\V0%-YX&.X###V5&(Y YGV)
MOY8,+/=6D'YE 3:7F9J$WVZ*SD#'.HB#;5[LL]YUSPC*6HE\8FVFA@'Y43J0
MND>8?RNM0=F-+'M8C^=#B-0KF[<R\O5&D&)!F4JCNA"NKQ?O/BK3L$<]?[Z>
MAF)8E\/Q8P_J>;B8\1"Y:G!]41UR;\?P)?HGZ*NS-J^F>94V['T"_CKRBR\K
MC\HW]O)FR:\BX@1F=X:>G$(+3;#YA/UD\G']O'J*>3[=D>>+O5Z"JW'?,X':
MS@Q0E7GZ4,QWM'F:>U6HE.$SE[U?E0>#U3,@G#QDHRP]X=9=N2-RKU:DOYF\
MZR9W\87E:J&UCJ6NAN34C3@G]],^UGIOZHH7=Y4,FNZU!N&,>AEZ'LHD++<2
M\PE+G5NYXBU@KXR]F[(AW/O]G$0%VZ_[C(7M6EX=8Y>D51J,^_;^A9<.(K&2
MBZ"KH8MMP^Q!8G*"A%Q?I7S=6GDT^B+=I%9]A)](76(NTIVY[_;'96?T/D7K
M< _/I'I%$?^]S8*P?5J>^,SB&"234I5_F?;N4G/GCA'U,!4.HH)YX9AI=R;'
M8:_+L7LGBRBP,NQ7 H9!(YQQH$?.!N\4L$7@#<#RNDAL[%X#-U<"A"5_EO&-
MMTY=,MZVC=74[W=Q=)RG8EF:T?<76)(09E?4NAKO:' LBL"JY5?B<R<B0ER?
M+<V@MY6EI-8(!-9BC(?'5/8<]LCT%&:E]T7EYZDN-K]N+_E[IOMGYYK':HG'
MU[]%(!/B(9+R*K+BR2=$LC<-#,IAS0+'YZ 3I!29DG]^T;X/<]YE+J(]N;/>
MX+$F+OO7@9"!BW)30FI^0^+[-/06.='&TI*]E1*(/T=*Z5T>4.#(E'WR),E]
M9%:E(>L.X1:&0=AEY- #D 'HI$ 6Z3T$6%)V(@G,KXZ][?7554)HSG4.Y1IB
MKERW".,X,P0YZ$0(XV:%BG58=ONTZMJZ"[+8@X_8\^O%-8<LB6P1[;1A^SJ&
MR7TSF85+<>D>P&LA&[*IVV9IV0G!>E2K*Z_7]'07Y<19L-/WNV5J_*6FHPQ6
M/0X.GV18#,@*:*GT>ILL\"]%0PG20P7<(B[Z+3*GQ.MSK EP'[XO1#YO3\@R
MU@KV,+H:[ 66^D)U&LN\DTU*Q;L"'=0<B]#[KHB]^4B,QENEY#+YFN6UMK1
M5B!C+Z#%UB5]BLJ[%=#192^KBK6O8LN!+Z<E,N QOSSZD*(#?9#$V(]ODTO+
M)"DR0@XA4<&1;P73ILLS@[<')S;=<[^7#74M^R7=R[R$4>)@8ZO>:O:ND@=C
MFXOL<>C%O!JH?'^;W OUP@Z4T:JUBAR>8GDRB8!"!3Z;![BRYRP\"+B$IBU^
M(>I]N=PL\WJ=>E332][,%@^K;C<]<YB<V=^W6>[C=.?@ QE((5@ %RF(KK^1
M)U+!S[3S\3OT\!,J"_J>/&;E27'!_<423V%+ YIX\&K4,1U'WWE3DC3P'6#[
M,TP -E@A\>U!DLYES8J7 PQ<H-RXIVE7G"&WVT!C;20>S?YLS.VD6]2UKD$)
MW1$4'L S^*0>*_K)FYJM3 '[7"DZ0.&^ C$R$72C3BIH%\L<0Z8$//0*L$Z/
M3HB%E:N##H<C1RO:.?B%'%KO"5/Q@C]:0'7?C@V55K)HX#1)DP'*S)6\0(!A
MNZ_)S0ROG'CK 2?J+G-9&!N[=KW*E;T/AZ*(/D#W57>GYT=:4.G@<R#^]:H;
M-S>;RTVH.BT? %U\65?I=1$$?G*Y4'69'%SDC.#.X#^>DX>&*<;TPV-@=Z%[
M5!V]/;<#93=/==Y0A)W!MH(MS'2>9FD6$!$ECUM[0@=1DW:NAK:5N9:E3;4Q
M7]_VZ9"4"P^UP*"$"[]Q422T,LE;_"O.CW>2XF19WA""E0#-':B..R'EY)$N
MK8-R:+?#3MUA7:07D)'ENIF'UC>%4+J Z2._ED 7LIO -:T5V;4LOEF P=2@
MO&0>4:,@<_6ID]&"[@#=5^ZI:QS$/*J;YIAM6N /@338-#CG++$:TR /0-^
M2B ZP'6SH.FC]S9+BU9'O%O'LM?%"4=Y+W>NW%7K'#E@DU9((SA73V<;FZ[=
M[S5\PIN>FJ5D]0+;>P8G&<@XKPC4B<L,[:TA%::<M460CBSY34WYNPC*VTQ#
M0IC^O^R]!U14V;(WC@'%+ AF% 5,#71.J"AT-YV[Z1P0M#.= YU1QXAB!@45
MQ8@$R2"@($90%#," L(HIA'%,<<)_W:8N6^"<^?>^]WO>V_]WVW6<ME[[ZHZ
M>U?MJE^=??J4)LJ UD2)[1".G8>!Q.DP?)J-:%(*#6*%"VZ1]!JED,-7,WA&
MD1D6+B3V:EDI$^/I:IPH'"$WL % E%KDFA:<8.(@6'+^YY?1Z$T@E5"O(:O4
M.@8JSHZ5147*#28\0\&!LFQVJBLZ*)"?GW.7,WJ= PLI0BHU.IH-P:=*5 Z9
MBHCG(>5@ M;EKLD,DUS(T]#-#)&.1""S;"J#7@$%0P%0*<3@<K9P$1C+$2,Y
MP@@:00I%L'[&AU8\+)P/QO%H6B;+%$YCLJVP> E30XRD4-BN/8K0A%M=>S.<
M)%&KJ&*H!N700-512 <19R8J72FODLB-PE/E."FB]X=7)->V)M@=-B#)CG3$
MF2E ,I8%,AM@9H;.E=1(' XF/@*D%RB%S'"^"6=%VKDZDI&N"N?0PB/BZ!(T
MC@$2F.0NLXK\^56B""(0SD'#90 3FV>WFE!V/@$+9O 5Q"B#'B5"RE1L)-4D
M-9N-'#V5H-(YV*Y=SN5Q66@@A0<&\[EFL07-TJEY41QY[Y19$4@AF,=@&@CA
M!#0KGDMGJLT(E3&"+XJC$QV@"!;;$$=TD!# >"!':>*CS-)(LYG+YT9:3&9D
MO"R>Y31C9'P3P.PT]B8^+*P<):=( 0X /AS.YE+C#'HE/U)H!4#1<B@QTNKX
M[!-5##9#B[9:(FWQ&%:X@Z'5FV$\!5M@QW')=)9<+N&XHA2O]W8?G$S#\:0(
M@(VCTD<Y(" M%"P0F2-E4(%5H]'J>%Q5!)&!@NFA$!B/9 #SK! 95*:G<\!L
MJDB"<8DV:[1<.N._S@+L47PS!05TBNP4J8@IY\73E"BB&606\M4<!9<+T;K
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M@$,RL:!F&%1M,6DELG@-4\(G.UFN8,5FD:$VHU%-9O(Q0KM5;5>I'!@:W\I
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M1!7+1' >U!*ILG!9/#*53] C>QFJH7:J0("VV3DH.\ADIMA@:"36CM("#4C
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MCW:D[CF>+"!F/NL!'VQQL.LGI#X-0/H]'S%P8RHM^\:"K;*AML7CRCW?M\\
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M0[-N;OSVJS%QE;MW&6Z%II23FZOA'4<VG1CPQBH66+_O.^GDR,@2T?JYI8R
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M#UW^JAY,02^O$;R%OTLI1PWYU[4-\1ND?H"H]&P7:FDA_V(H02[[A: %_P-
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M(_1O-I.YP9H%<10U5-1!#,O)(VK#3$" ;DH3=>3Q%3K_\=?8#B).='!0+5X
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M7<H9,ZD[<?5PJ))Q="PQ%#?ES/^>J\M@B!',!.&'YU^] <@M-L;A(4A;FXB
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MAV.=6=EUDU7XU,I82^#DP+S8;J=Q >DMS?;.V?0ZA4@[\0NY]\G'X%++3KB
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M>NH\#<[\-=(Y)B$\D$*:9YDXQ#"-V#_]8\B(\DNEFO(8L+5!!&^^]-,"(]S
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M-F*A^A-YH@(*,P2#]+!V)YZ&++HXVHL<G 9W?/7CS4=]P N H47N?CKVZPM
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M+GJY>A]_W>._ .K=Y%X_N"=>&G\!P)UX'^RWK=/VK_!&L?W3T[G^20C&/[T
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M'RUQ\_[FR?V,_TH[%'8><5/3+N98_]/LYK]"HF42GJ297C<^HN=&UO1O>R^
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MJ4C+OTM$F.CD]DVF25>XD424N:!M^KX6\CQ^2 08I#DQE)TN7#7+!GUX3\\
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M_ZA]V[&R^SO]Y'#[KF*[]>!<"!*AJ5*%46D3BG6X GXRP^DHN7)$7*:98:@
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MNI\I,*BM*Y!S![Q1%#YH0&+$1C^T3&TM:J&"R3@B;Q _-<I3Y$_:XP57[HR
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MO:.2?/)ZA>"<)UURUW.=Y(3?<(AF9O)KVQ\XD%N:8YH*T'B:U_/4(J/-S]8
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M&NVZ1 ?4-T'%C^[;^:V#KG,39'I/(CZZ^$=_/NTU/T1IS3C>ACPG/ILO^/R
M+PH<'#L3-'?OS'S<6$O 4Q:PH[ZOGA:1:VK2[Z:6B=5%O!'_[M19FZAM5=F_
M'X:FF?_823,XPYP=0H/7Y.O[";-J1##&[9=%B1P54H1\-'YY\P#+U4]%]X=#
MD>E/VG"HP?BZ^W]Y% T7,]E%9K96303;JN#:7IT!37-+I\6&B^SR,T[N#4 8
M'\&U$CM,B7^.#\P_?3TZQ0"C$2CT=YH"WG2D&>AW=?Q*"_GB!D#^7 O * 8
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MHFQ$O.3IUP^?-E+-<8D<A_OV-)8Y72"7.9@L4S%E,$VQC;::(:%79,;JOT=
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M1,)]@;I&'2+B#XTF9.1Q6TKM$7Q8=#CZ%R"\7I0;NF$!O\J=,81;TM)C\?9
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M&*JF+SLEAI)5&Z'":(#BF-:^$*=!E;@YZ8>OH\EC%!.CR0>>KW[^A!,1%8L
M^1QQ9.,NM$#Y??'#"$0.VWXZM2I?V5PZ0G.#]%1^2'?.J$[F1)5:YANG!<\
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M$#X4W6P$+&F"KY8T7W:'Y&%.O&C27#T694D\!ORK$5KLJ@@E[,,>=9Q_ZLC
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MDM:2/\-2,SC#U%Z3 %I>Q.*5'B38;CPNN_]IFGTD[+_/L,=WX@X+:?#<X0(
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MNM7"[7O?BZZ^U?0) >.T%?CA"S;/R&I'WQI0NX\';;T""5&Q3GN%4C[EC&P
M88J4Q,JASMO;7P8H0#/ 6$&HI.;D4?:*Y^MI;ST7U]5<K8^X0+F@ \$8M9_@
MU]@NY1A[X)(IBJ,%4Q'0U]JIT;%L%\KI36P_HI(944A*)\A'>,)C%4L7/%:5
M)-)NZK&LPM0>7/KZ&,^6>KRI<E46G]3]7'"GA#TA$-)9J&KNN_GLO@O"SMHC
MBL;"H]0+[[-GI-E>)<NJ*5'Y]60W7"PVZ]931Z=L\YQ:Y>#MO&MW>?[L?- B
MY@%L:K>_C626M#.*D:FV0<=G&]5_\S[ET[ZNGH:WZ/'&2/>BAPL:]V0=,*,B
M2I8@=*K\:FPR6*@S"(!?C0K9#A]@N&]..PS=%%QRD$XAA:GTD:I.$9 05DCY
MA5<LOPFYK8T V>K:3";J'MU64]P?0:,U[X@?%D,$*$=BS.PZ<U6VCO:.[!..
MG[BXC+NK3C;C#DVM18QY# L;XT'PUES:K 3Z5<VE*<'K^.#X_C15^,FM>D.#
M=D/Q,AZK$1B]LU)MZ<G8AT&X1(*O7Q[' ']A'=U,JK_W]%QP[=M87/)V5I>X
M!8;9ZMEUV^(22)8KK,^C:I0&)2]GMN>XOI$'PJA]Y6((+,>'1PJ)O$N'4O[#
M6"GWV4/CS@ZE>,[=[JM!R\EH2P/$OF+YU'1AH[M4=BFIWXW2F/>N_LPTXQ>G
M1=P7''+IVF@"O$\BQBG'8]I^QM=D%4;VSXVR3>2*(-FLD33+7422=CFZ/+46
M%I'S7(=SU";S^_J:S>;%HT ;C;R:<P6]1C<KJ!A8:O/E;)4 U>[N>MED->#C
MLC8DJ9G<-1"'ME!B363_$:\1)AV6R?SG\5;AHM2< '!VW81*I!-2L6Y]/SLX
M/Z1I46&#</)"8WPPH=RNL3%;<Y?D5;GRA;IJ189D8,*\:WA?+N'J'4H!JR$)
MJ\OEL\ LZX-XQ%%)=:JFOI1S L_R9N=\=[4/^C[3JJCP8#28#U(H;,GH48?U
M@\%5(Q3(&=N?1K?=A%ID'&BXRKX,NIP*U4FW$L8O<+P>26"33L0-[F#\KGW"
M>?/,N#C%U]-4R!LUHF+;8MQU9B?G8"=YNP!Q&_]"# ,\D@2/6=$1?*7.+8V"
M+XJ2,9Z2]-*TH5&FZM6C'_KJ_!)-J!AX8._CDYGS%ZU-'?&3L;2!N"L:/;*:
M](EL; -?0$WSFX-,)1%AY8 ,QZKUHJ6A*DI_'IUN6^-(+Q/F],^$4E:JE2JK
M,>7"GM)AAZF.J"&;[/.I-1>$D\TU@W9]$4(P)G*UZ@RNY[ZX:Z*J! 8S4F$?
MXD4!Z^J2ANQ5<:5F',UL.-V/6:@DQ"1X2B\2BI%!Z/VL]AHWIN6*AX$6@JMN
MO#L;O=ZJ6R!;.A=V5,53:_1QV_JG@?_&SEO&Q %_;[ZXNQ6W00<I7KPX#&XS
M#(.[T^+>XJZ#>W$;W*VX2W%W:\L 18H4*OO;W3>[V7NS+V]N\L_S_B2?Y#DY
MY_M-GH//0;GLL2)+&85TA:Y6M?)]I>A"OK]#R3.'K!NW[SA=/<M^^UL88UGF
M5+%]CXE<G()M#3;]H(,RDVHSOZ-2GP'M+3UP'88VK%&C++)&VV[LM"P6XSFZ
M3- 01"4H'E&=!L6@)H1^=OB',K8E2^MC_IW))N\[@Y261MW:P46_SU[:G_)!
M8R,6%TJG"L6+7UHG32S$@^[>_AV9:U-LZE I:K5$1CNWDX'6#+CTI>O]OF91
M7W^?AF_YJNL?IJDE<\G%#"WMEY\9,M*\T'H 0$;>&2#A_$-DKV$P5O/36"JY
MA<M5L,\T5Q9#:.>6F3]<T*GJ$H(1^B=I@G"K?R3Y2N9B2ZMPW>1J?_?L11"8
M"ZS6KEO9K5F?\V@XRZ]I^.[2XE:J6T4IZ@VD/I2T=&ZW:Q:P,8H9:R_.%3V&
M (2.XU-%H,NF174U[<]N& S ;/@.Y'G$8"5?"R[_7K?&1(<B;003IZJ1\OOE
MEK#:0WF@#UPT'(&SS-NJ@;%9.R,3W6'#I9^Q6AK;XI]\1Z*A!DYTCD6Y9 20
M&>=$ =$-B;S+_#9^%YJ!%O7V&I>""%<,=M]OK$XZ)#%']W19/'^5]GXZU*!O
M$(-YB6P[T^3,6FL0M817/4?^LF1PYX!]])1$*IHL61C[H//E[XJN^3R7&3LA
M!VTVE]9]I#W'ET?,%Z/%^C7;7&]P1X55CU2RY#^<#IU3,1FK#_0RY&E!P 0[
MH[=@YBA[N5% LK],><U!YNW=1IULUF=W[:7[XE:Q0-M+[S>U/\W.PC*QOX"U
MS,0PD;X09*:$-74P;K>/HV'@AESKZ0BS]1A!+E(0-2$5JQ=#.#WV#ORFYP\G
MR,=(?:67<=Z\8</[5];Y>B<F@^^ HO/J:&[6G'<G^PN$5R6%GK((>&^3PY>@
MKPV(-QAB>S@W\=]BT9:B5S&F!;$UU48%&'$!E/7E[0GFC79U^PK9&KU[6\*"
MBQE,D$$K\OIB'PHN,Q6]MHVMD= 7\7O)^LU>QMOTT/'=@N56]?F&O%A:"F[T
M$DXJ+/M.OJ?2[7AMAP"7AD#SB?+D^G.?#<V\PGU5LT5]^S*7->7M$&Z3JO6)
M,-W8H^198NGDEJD_LXL91CE]H$88571'H0'US:>>] $R3H?HCB*OK9UDD"H*
M&G8?CNP/ C\1\Z[>E=['SB"M]Q1"->5:]QJFSI%;R5OG32M<]T2/_GUY7!]8
M$^T //%,;LFR@J*@@%G2"&&A(V7Z2ARID9FV$J_%O?SR&BW1_I\,5JT[@044
MEY,<]4WK+O?7BF:CTC,N8^5+;2P4_OI5-FW]B[@S%'$M12>A[+Y5%#(7WZ1@
M$@P;35>WYM0H ;*6MR@'>57E6X3QOM=[ORI-A[<#2VH?HIKVH2Y#MW'#CB_8
M :&H3GN6PQDI+ MW+GG?$,-#U41AJB6H2:WMWR/M^N0T;K OGW]4PQYBJOH#
MD^)#K#I75AI7?1VP)#IH=S'S*24_C-X(Q2W-SU,?YMOR%KG^&5_>CZ.26 .]
M1R)Q+C:O3XRJ,)9H8S]1)IO@I5B!PX 05O6)[2=9D4D=YC#U2^V.QWPGH[7=
M8XO%^G49KWTWKPU8W"1=6"BE!G_VIRL]([P_SE&-!B:V[.KKM(4TD[[IV:_*
M-@FRE#;AKAU]Z>Z\,F=E-3WH!K8,'\;_ *5T5(.T\WHQ\B"MGI6/=F5Y2?E!
MA&EM:_P&08A&_7Z25<O(\03]XG"S:RT#*Z%B,JX3.%^DKXV5N*$_($>RW,,W
M2A5'W/<#32Q;[]W@1F.SKYG.%M'EPX#/.LI:S\M[)'\SJO1W%[G-:Y:Q)>L'
M8Y.+.C94K3G9,<L"'H=/A$ 4(?NSL1AV+YZ(TW[JH(+UQM4=[V+YGQ_BYQ+,
M5#5J.]8 C80@F[3]$+%:!D\P')+<:Q*O'K)<GL7:2->#T<[*,\GN_XZP]Y&7
MM<().%J1NQ+*;*P9-7P[A/.!(HKW8RHQNJ@!8E4F#@$LE,KOD!SXP%+O_5V<
MZ+L0JQ1GZ0/E6ZCVCF+YTNATU?HNL<K6X^ ];?]&A7TMXYC#!M6&3P#Q9 +>
MJC,MY5G@56TW8ML$:;A\;]\C4WG%C?4LT6/QL;ZW(P4D9)[+OVG\0!L2_,BW
M$+T[A02O+07%5M\:5/&>6ZV K-4YG#VI/P$&>9S[:G +*#!?=4B4XR3K@8N,
M<*=0=XU>UP02=S+_8 031M4H&)QWNB_*KRSWG#A?J+=:X=)WM"^5^%CY-@RF
MEGE83O/P!@^+VE<E-:WOVCTEM+?2=)SBI'WAU/WI%L\8)]J;>[53LN3I3EYS
M4$)9NT;+4/D<TL<1%7$@'4>FEK;M>%IG9VQJ8,_.:<S1OIK^CA<8Q]X>NNK
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MV;N;*E(5W\=LEG#8>?I5W,<J50@LUVHZ-"R"\#2GJ'-9,B1[U*FX0X$7K Y
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MOD,<7MCX6E%S^M.6QA@*]:=F)9<;',J"7]\=L3GZ9$422.[4O.51/>+8!<&
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M]UE]E1][:@(*-AH HFR7%X6V3F@M9.>X^D&@Q]"9_OHE?P%-^]8_BVW%&O0
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MF\BBS%I8/]JE3=IA3GW^:XC)=U.UK R@*%NT_2/^>+:+N!.V9YY*]U[0KVZ
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M@)!R9Q=W6V\&.J7I=^0H=%-,LZW@-P'RERJ>T2TR=LS6#=+3#%4/KJNC=",
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M9;FINZS,[%YG72<QZ6GJ?T 4"ZU57-.90'5=VAG"#6*8G*' E@QW-UGR[YN
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M)IW<^:JOE1[W+Y/Q\'B  9CLK[/I3?E*%&Z%C1D#6\V>'^TX*AUJ6F@E10C
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M;()GHL5MM)]/8D?/N;\"9DQE KT9%X687.FT]+3.N$CS9G%I*$&?(A3PWFV
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MCF5>H;D_Q$U^)UU5JW'?!4RPW!&2=:YVH^R%YZ>O8:&/>UTRI'-2F'Z[_TH
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M$ZM5I?YEE5KYBD/\1^6(@'A1&77"$6BS96QNO5OHJ:O"0QT>:00;,@5>2#X
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M=DXG%H*<?1LK7%_9)0P=K]-I(RRNU*T6W118)UQ;M3O;G\;">XN;G_[>BIA
MCA<Y6;?N8]%H#%TJXJ?*5RZ.U8_@^<RIAZ,6A?4I!#%2#[PTS7)F;J]9'.7V
MW%?@4*V[6U &\=WO0:5CC+O5V&W#BS^) _+F54)Q UH-G)=;*T\LRQN> /=Z
M2U4MZV)6BP(U&O5HD,,Z>Q,*Z\0:-F7J?3OU&?GC;+LR W_MB:ZM#@9:O,\*
M77==4[0:J(F7TS-)H,AP-OEH9O*W@(K(X)J'VR21TLVE%WQ_>V4^?Y6C[ZA/
MFC_,FY;L&UG M"-?69V.!&E"B4W(L]@3[,X-X&)P*IQM9NP!%D'?K)=3-Y9
MBMW77<P6)#59SKA7YS'I0,($&DX1*\'QVS.3O(/%U(Y)(75942/'W[9N%N%W
MSN.F7RNJLT9/_T/1=WY7<TSJ.T5:=^8.VFBK0\S9D^YKU75FJ-%%C&%V[#=I
M8.K2#5'9>0/7_]$!M<CFDAWQ<E]SX1R7QCIKD!U5>G,+COA.% N$,S3XP4/0
MK>NMHW>?]IUKU:> WR%"6F8@N#ZI3)@^E7F&*G5AY\XWX'?2.6QED!>#_X[_
M4'U0NI>SY-!BE)M0@/IY2!@C)IF&J8Q+@U\B:Z+;I>Y.QLBP%=62LQ;Z,$Z'
M673-4>ZHPW@@K1YPC&KO78'%8R:?ZP&8E,@@7T5BO'!R0MBE#O=>_? -0V?8
M*V%):< W8T!U98N9>UU)D"GMC=D30N4SHK*9L(WF=SF$T2][:2_&32":)=)R
M>.B'3=59(ZRZ.Q7Q2?9)J%WTS6-3<Y+'<L3\PSOP\[5PF>:2UO&$[($;9%5X
MX^C(D%U57EV $)S _\[=*RV7KVF&VK1-1/2VV$+_HXL6;K6[0L?@C*[R>2S%
M<G-[FP+=-;(?XVB< 70DNLG2V/6B8\/K'F:Z6J[:5A4 S\GK62M+:"/:_9-=
M=T;6"F!CL^D1P!L0E$ L;'[WD%@QR43FBS.)GM,V-;Q!MU999C<G *_X.7*9
MWHW5?-S[D0#!05DSPS!]4.IA[+5$P/C[E#]Q@4^>@_=J6RK)?2E5E .;3]>_
MHEJ_WXG4X;E:C8B(0/HP#PC3-R'I<!9>^<!%+03:6B5OJQ<5XYRU*LCZ>Q;8
MWFSTF2^6V%H$BIHUE/;+\:X%8+16W<O/^?M&^.@'L,K _L@%0F_4DEP_2@0=
M%_C8+<PW^UGU%D>9VN\9.J(ZP=[S?E]A(OWVVVL7V2[CO4KZ75 =IM$!V&33
M]WI23:>,X1GB3'KJ]F*%Q+CRFB,:8 %;+B\;5!&.6G3R-B@"1,28G06UVMEL
MBQME;4H;?.GUH>V;]&Y!#+2Z#HW;QU]6<I[EFP;%2LDU,IO.OJ,3E%D#II6/
M1Z<->F[W'1KJ!QJ4KY-/-<>79[[X"=+#7T758U;@-1H: Q>>->DEU:SP&N\D
M*I7)!")AZZ&Z;YY_RR\3U'[$87+E^PXM:JX'/SD(M![3.$ UYWIK/G<QD$.W
M]=) V84)CWI6[AK>$KXXXJ?3H7]QAA;4<$KK"8R/ZIJP?J6LR'#<:@^RFY +
M$1ZC_5'T/77$K7%_URWL<#*O\N>]\T<7T8$E!Y$(](2JU?6^\5*.$;2_7!*B
M>Y;8(]44S32/6_I![F^<BDV?X_70"."RJ6TU<X;9HU=H)]RZ>;W1396[(R>[
M'A/;MCR"XDG#:B0L %N#- I_/-\0SH9_:M-0Q@TJ,&O:F.^MSS:_"6PMLG1Q
M,#6R-<W:CG%+O/[>"K3"L<MZI10KFIZWOC#]!#[E>RIGJ-;>=G^O9>G;9^%7
M&_I%DQ')^&VA4>#L[HNMA+=>1UT\4W";,<9[S)'W M\SI E'$SM4:9+G>!%4
M_L+V*HXNWS]TA@XA:^:%ID8Y,CL8@OTB@5;2N#2.&'\"\KN6U2\N?.].:FXK
MRY S23K%RP.&\M!\+_T$MU6XY)TDAI;_PA4Y:_Z(*EK2BBWUDM028&:RY.Q=
M-P6R\A0])'XIJ+4V5KI6\A_6Q/;4TX2#"XO7H?'A;F+=% J\P_4+JD^BH5\Y
M^*I(XJH75U)J<Q=3[6O)C#(FN-@WGLA?+'2=;9:-?>W4#()RZ4LRKJ\K[!MJ
MN=.N ;CK4IJW9/-]YD:UPGM!]>M)UVJZK5\_%V-4@O)ZBV/%OR0&?CVC8+W<
M2H8M18L$_L0.Y1[[,$8HLG3YN&3AJG=GV-O(-V;MVOR:BI;FFY3,QYI5V0N3
MC@BJ8%2OJ"6'<>Z@.H+7).].FAU)\SI,(# KZ'#7$+C)#="?M=2E>EE<P.1R
M)?)H2;M@N3NU><VA;.<O"8(UPA:B@;J'*2R?9"A[JUW?1>+]83<E,U.[TU/K
M$AIJ2V^T55[BNI@SCQ2;7^!>25K<]7#$75?J\Q,^\8=O$::LZL4Z:]-[K(BD
MF=**$'B.$ .]WO6'%W]4;*QK^(3,!I@KC@L -')7.O(NJ-7$H;$FBDTIB+R#
M-XM1YNG6&*D!(PT.WDL&.53#A4286L[,DD%*4@!-7[->VX7Y"_4@K%0=+*VM
M>L*,Q>5:#D->-YBB89CA:U"N?(3I@.5-/_UGCF\IUDON$=[?]-VK2_W*NJA>
MVC_GI6O1EU%Q ; )3EW83"/M#@;'[I2C/$NGJ_1>F3(OCV\@B$"JL[:>%'#@
MNWTT;,Z>YL9Z@N-3\V;KZ*!)PSD[)7Y5$94YL9(K_;2FJ>_4E,3CC8KT.&GU
M'RG^0>;=;]\VTY 0[)2Z^,63LDH>&)"VFE1-U<3=F*(4>]HPW]\0A[=)B_73
M*YQ%[M%=D^'"XCM<]:0M<\1H&JC<KVMRY>23D+OI+])M Y'MO+ >\RH")WO%
M&L"FR,E^CC<S*@&*E_.UB5;+^*!ZU*PUK2GZP-,5?E<*]*LN<^- 5D#VXJR@
M<%./M#(VW]GXY^NJ#38-C^PM(8O#+TTJB[T27ZL T\03ILD&$L%W1M!6)W?Q
MNO%)#)TQ[J:7JV_44#"6AJ@R;8K'_EOC)7EC18@*OT0*S('^W2?\&XO EN@V
M?(^6R$8V1GBI%-L0SO'"L!1,W(.N]>!/@;J=RAC;6O<0#Z^+8DI7( $XOF8J
M]K>N[ BRZ2X<PWW]+?U&YC7 SB&J]([8K-Y#PL^I/+7^XM?:\$<==AKN-VO)
M1J0L..^3-&-5"[9>XV[= +ZMH[?ZAMF63"_Z*R^/O=>FR6W&6^$+3+=+70H\
MH4_\$IID6_ZF/T$DT2EPPEO_FIVVB2 B(/G9N5ZPM4WW_P0+"O3U#/BP'>0:
MMS7E;,9A^YCRUDCAM5VL3F.5)XY27$DKR*DJH8V,)#*#^"RE@=YL]/OU?6V%
MNGJ2&IL)9[>KV":^@L]6>E8J*L35JD5>62K),+$:7%*N02)(Y%0Y25^Z:;+F
M#MLA:?1JQ!#;$ZU4/3FD0C=SQ/@=6;/6+#:)\F=#-&F8AI O*S59N/MVCPRA
M_-FJ21+<!4$;7S#LR#;5@U5YIY&>OL+%NXYA(;9QR1QJH*)W)W>Y)#X<[+&(
MY>XMRTB#47>D]@\>SAJTJR0W^GZ6JT\(M]\?3=BO/8=I%EE59A'S-7M^-322
M<V*OA!"B02F*W?I)M8B=W[9A]'KIVZ6KL1U0V3KS8+\JFC;.H+J ;KJ/M(ZD
MBJ8DC62UL(4VP$&H$64EPP]8H:B;D=4@JJ!EAW%54HQM,Z0Q4-G7L5P)FC[[
M;6#6C[>WMD6)9D7N(X0(W;SPO=&N=(;*2;=V$I036[.]Z:V%&\S5(['A:N.@
MNRG$G?XE>6U)4G<(K RFPAD*EI?#S\_JOOJ3>:C++4*M64O5?*%O=G).Y%6>
MOMD3^F9\"V1AE5<8FI3:(!ZGC"E<JS=80R[6$#ZT+]CEGX[*/5L:[.B()56>
M2-9=#]SEJ>'(5CMJ\3-+R#X;),R22>)Y2=TK=Z@_',_36Z:Y4:6E7L2UNN3U
M$^V-F#Q)]2\=I8JQ#@64GJ1R5ZPK &MX=>/PI2J@+B 733;(L[K>P2=54HS#
MIO?/L9O!=6+G*LS&:U%N4/:HM4PAQ$8S!CYKLTD!?.5^+'E/17!;+@2,65#B
MN)N?;562R@LS(9])0I^(B2D^M5&B,O/)0GQ CA)"0#WD.5Y.8H.D]I'-KYVU
MM.9:?6>_W!K2S5@OW,VT5A:W!"S(I@>2$S0*K%3$#")>U2)-2>INX*W>HEN+
M5,>2H 3NWV0WR1T^R6JST>YT7;E <J^NC+$&629JBK5KH]_^*_9\_-'PHL>?
M*GB"[I:#"8>QS;.I)"8EF99WT^OI+;*2\PSU9Q)80L%\7PK$?N^)&K,2H5D[
M&)R33Z8VM>ZMJ6M&]&'J_?[I]4):Y6W2VE$UJ$JHSBKZS0F^^>!.Z(JNSQ3&
M6-%:OZ]T-VG$EU!%^I=.V'"$]8NSVN68\Z5634*HV3:NR'+MJ2EBE63U:5*#
MZWKJ<U6,;;C-1@;[[,6OM>PTK>B9Y-W6(F\":6NS['76.5$B-+'6K^#:F;P@
M0&L2??2A)+CDO[_D8-?HO9*]47JE2\D73O4- *[5YDK6-EL#<UE.+UCM9HM?
M!_<RS=JI"S!(!X')27U/JYV"KB^N5@1643K;K&A=9*5L8/;#6OKC0KC!TB(9
M>*F 14@^SL/7.R!!^185T8_4R4RLV[$\:UL *,B.FW5XI=E0D^Z">+VQ6)]C
M-7>))X9XC<8A4=%'@6*[H(_'255DB[6\!V(0"55Z;WE<Z"<0=]G74NGJE^&U
M+1MTK2:>,-++!*[+>U^PBF:<TYZTCU[7?&+T,:-.<G<'J==(-PZ$V0U1*];2
M&GR&X+SV#-N.U9YV7?MTU2S$33P=LO+1*.QQ>W[B7LS.5*2B! :;(BW)99+4
M3.$[2%HMW&D[PK:%2&@@\4<05)8U0,47A"U6)8S^-F]U@$][)J=,6TM=$V)J
M<%J35/M;F\F)K$M=V]:Q),T(E8-,L>UMRV!Y@)&!)&7E 0TY4ND.PHD7KRUL
M33-3OM,UEM;NN=N6L)I.D$HY2K]@72!'6ZQ\(O-;K#K(A^3"BG&G"$<A7Y<7
MUP%$+)C17W)4NX@+7C7N2P36*NH2*RJSJ5DHA5L!F5?$Y8*2A[2L@8!RO+ :
MFKT=>5=$+^IJW:FOV75TUO7/)3D62MO.^37^&DK"L5B9D68%UD@=>^%)0JL9
M=H#H7:J+L[54S; "J7T?K?J32M:B]@D$!+-(K.[ZCM.Q7\!8JS#L&$G51Z"$
M+"*M4+8]"A&%, &8BH(X8[]^.]NXIJUI:LDL#6-K/9>!>^+Q:<M:.!XY6C]S
MF=T>26(,R<R<]S,,E:3HJS2V.M?9P5;L=#I>GKX[SB*RU;<U=E8O0V*R6/OQ
M6E#+%7J6F1)@L 3LCC;(C(Z1;UD:IJE(2'!Q++2NK':33>Q; @\'DL]C=B;B
MBP8NOK!.E/OI)2!(.S19FS3!^_-#[$$L)!3 (87DR)T]64;FD+4LW>QCFV>L
MMP1^&P.OKU&8V$4!>T-)&176.N3&Z+S(R@*N16Z.W+:VM3\*!+%3IKJ/57YQ
M-$PWU_:HBT9W8GQ&BAL*^PEGNB.>&>0K#'*S/)F!NO038!FL;5#@=.T6#+M?
M1W4&H:WG#M$ALQNP].G&EG;NM<=]2H,I$,U$:9O#*,GI38J8SA'FI'IFWP[R
M!)*K/<F81;FU:D\ISS0F5.R'S'O#N0GP3[@+ _EXPW.B;TU;910ZFDC6>C]5
MJZ_G24)O:CRF:Y[I]Q@DRA;BCQF$3#C^]]]\UW3 "Y=OI1VJ'*6<K!O6U%3W
M$HK:A=C*"=WZ*,U\MIYL]+@/$(HFSFG34J49BR'U9,!-<JRXF2R3Q)7"DMO%
MJ1'*DR2I9F.IG]Z-'I78W2WV!NTM$@10A51V/8_$5X&Z@U,%OJIIJLU.:M-K
MZ?M52'A6)(MQIIH)=4)W0NL=F8S%I58\RPZ_D]PD#9":QUP[,QMWZXVF9UU6
M0B*]<.WTF^0*9;*?&$'A>Y1Y1=+G@LR8;%S.LE"+  E8V=A6Z3F!9VDN Z_6
M0$*&W%S2;#7&I8K)/(_B1:GP&FBE+H]1E\97XYB0JID6,P1#NB/#R2R,W,.O
MH.H5W.OV4M&O$*]OJE[J5+558IHMM'*:C0]R"W,))!!)8%ZT_99',,->!$":
MBWW51[6U;T=U_P!B@ZPY:(W1<AI;8HH]MK6%5;B"CNR%X]NZ8G[06-IZKSXU
MZ=EX^&+&RP^+)JRK34A7JM9E$=I7LI8EN7J[R>$=TMRNZ5;,G+) "4N"MW3>
M"!(O$;JB,PE\*5N9 O+W=9/KX-/H[\-<V1T;)J+\4VSUU<+%-L#]^U+[$QU#
M=^\/W30RS31HU8V:L?;6:3:2/UOW K&[+/K#1X470]VC^ATJN42[$*D*M 2G
M:8%8?O4*57T3U5>)LJOYE"L@!UK3/II F)(IL<*;$:8#%M:=A4XIQ6;KM/3;
M=B2:%97C>6VP$!#E?$->3M;O:+B559?#*DETZ-=!M?\ VO9UVGACI;=.BVKT
MKCUHK,-341 W4:#O]6380=T?@1V@]222.06(W0"&7<GI9J79>G*WNL#L<>S
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M?I"#;$CG1#B8N_3A@//25]B1/^#@<?F'01 Z#B$%\O%@TNG\ 6.,&Y_1UU5
M0A(SOKF#O[O#*;;R>=M(3W0E_7K4[V,.V>OXG\[&4!PD<0;OU,]VCZRBF?X
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MKS!#G_3A>.L"1D-OVUO?FZYU&,\>&&Y"^1*#T\60=1"]#D$Y1"C/R6HE'Y%
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M.QBK_&,QT;=C "D:NQ)X86^'?\2R%^YG"HIF\G7[<;\3B\'LU4)>#"PREJN
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M@9N#,7#3AX'SR%W0)?G+_P-02P,$%     @ HX4L5J.'B/G]$P  RRL! !4
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M"R4&K:\Y1Q2%4?4;[W #%GQ/;Q[IL"O@"QF&@0Z[ZDMXZ3SM4T0*&+/*>>H
M02LO,R%M?^5YTPIUEK2G,]M_J9_5G*.0\9P2 P02@IS9[+6CFM^F-E@.1%\'
M0HI0=PD=SFSV\P).\"TL]]XW@)@-&)50(.2H($@X:FO12]:(C<H7/&Q>NS*7
M\Z].RO/F-\(@:7]/(AY6EY_UXT0GZ#E9IC D?#DSU>M#N65B-8/Y3"(0"#\R
M]27AO,ZL\3.</4 VU;*Q7J^-U7VA:OPKW2@:25^8DGM--  D7#DSVLMK11O
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M[)H=IOFZ&]7"BHP,C-(SMZ8$@8Y!*QP3!L"(7:L!"0.:I5)T;!>=G3H.VS.
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M+!HCU@UZ+L'DT8)J5/I].+8J(_+",[D&MV6R7V_[^8F_^!7Q)M77($<",[D
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M38KLI*Y.@JU-<WS^*!%G.59M I]DG)[9K YP9;WH>'P.T-P>,^_2^ZQ$[=7
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M4AW2;AK0R]0"U\S#ZAG]@G^+TJ(7W)/#'(.$#=9$0 #M#S?PB+7?2')3SRV
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M5O$\?\AY@&_7$ZPW:1*WHRR)HW;!G.:HP(O59F:6(.E.M;V+AR>\R%TE_&"
MNC^%9W(GWN"Z-QIF]0/X-]C?QS]6RV60KR;SG@?<^J(7GT"F&&U(0K6,G636
MG\GXG[E!91 GXNW[L-:HU<YR=DN>D#)#5*Z!V9&;5_VZ& %NX12P:]BHZ^B^
MW .;>DM4219O3LV0JD,#&H]P)H\*(Z]>S1P8Y(]P8TF2OYO=IZ/%P;FA+>ZX
MJ]F=C2Y7?@TG"6O:]O@@IZ9VT4%.AUE1V\6L&Z=6;J=5O9B%/50=[+&GU3.>
M+]MWAJ/WTIO-R>Z9^;76BCNYT.)/S_P6=UL$UZ"2V=[^*&B,T3TE$?T-+-(G
M%RX]R93(D-RV-(CVQ?Z,I?7/HZQ1H=3ZV<B_+YM$(JV_VQ9%M>^1_1F+ZR1G
M";?3JFU;&@CF-H@DLR!91C9G0YX%2J;:[.C$R?LU'6NT##)_MI'UDSDT38*P
MWB6,WTAN-2B]E134ZW;A%WIZ[>;7)/HK4&%V=.K$Y51=:<R^RD5ESO8)",[?
MSG/J4*"VW5!T4P"B^EO8* V%&%78U$O3(6V-A .(^K?1Q-(:>@TWRAIYP3Q'
M@?+OCS7RXMS?;;VBVO?*&GGA9'?)[;2JUL@+G[:1_1#9O2 WX^_XH89EMY6R
M]>FNWNX]/BB?DK^-0BNSHS,GEOCA;&P.C,&0S6UF!:BXFUJ9NE0;9HP1\.96
M U_#4/X--KL8J)F+7_G-KCHMTK9L.':9?YO>DXMS0U/B*%OV[KM!KOS[LNDE
MTOJ[Z554^QYM>K&X3EY*<CNMLBT;?-CH8-/;!2'[A@*RX:B]<^5WO/JBIO!V
MP>('RH=JT21'B]VIC6[5I#Q6N?5F1Y^=!KP3J)>]AY5 I/M6WD%TGL,S,S?%
M Z/S</C@R._%AG04>==)4)#L@B39$;!9%=:A*C%C9M<0QJ=ABT\O%Y;N7>N@
M" H] <']%5R8XC%T>RW<UZJIG$V7 )?N_:Y;GESOB(T3IG6G;/7I\YG#I\_*
M<YT("'_S[,\I$4OKX_OF7?L65WX@'(^7VG8] VE3NVBFT>&,K.U]LYL4"-Q.
MJW@1=0B;^B[LG\G_"/(\4#J& PRW#0EOF'8*=L:*"QV1\=KFN;<(&X7PP=&,
M.1.^)^#K@-&A& +_+9S6#;DGR9O\68J7-NI?@,<C'QW4+UP=?D0JE+0N7X"'
M'!^O4"Z<'V&TJ7VO'-3=).7F=EI5HSXGP[;.!53DXKM3$$^/[H(?#%]2-\7W
MYK;D<1'D:)$E^/O%#?Y&&"LXFVNUU,A<ES#+=UO>S[;#XV,IUJHC01W+.K>1
MFHN0=!NS(T,OZV1#9@HU#UEWE0!Z<;$2+E!4)6B-]FI58Q?>LL"UJ)K,7/5R
MKUP&$R>)QXLK&-/&QL\^7*S($B)M>?QLX%[%G"WLLW\'AT:%DB:PSP9N1TQJ
MV]^#@Z+:]\@;"(OKT\&AZ;2JEL?//@6]N\Z6R[C.1%B0^-M9'=0(I5HBW?7:
M#K;:EG6$5VBBT^^!CL1[X@]S39N2U>FS"#,&==CV.52QC,X^!.O?P&R*]65F
M.RMO-AW$C/3VZ #T:O3/KHJE-70\'+4].F#N1T'Y]V<S>G#D\_9(2>U[9%?%
MXGJ52.H02/(HA.!#X&G.SDC-AJ76T.S(4'0O&?.MGEW!&.#>;(Q);IJU]])D
M/LW16YQ51;)J4K,SXEN/M0H7>=GKE?A?M$?B?V!=8B1IP?ST=5#KB[^;5FVC
MY?=(+8^UAF&W+>1=.L_RY3JR^#3(B9M?MGP-TM4D35:J8W%TZYUBSIP\3!E'
M)#10]6K%F)5:,$BH"9"G(?#@IM8"16SS[*:1_3%X_PY6[2-#+\_DSF]CR)$]
MPAW!#],\/%08N^$;<X2K52AWEN!<X'EHX<;2>GR$4U/[/EFXCTQ%*!UVA#O:
M#9(I!\&;C?QC]5R@ORH\57YYV].GKJ=V,RAO:TS*40.J,SLRY#TZ_HGKZ8[;
MN"0:+[PP1CYO/;48E64<%[#\7NQ"_7G>>NHP#*$,6WQZN; ^TO/64U>Q"M54
M#I@*^+@^TO/64^=1#HT3MK_/6T\=1J%2GNM$0/;H>:M_(:<:%4I>Y\$A];Q\
MWNIQR"E%M>_7\U:?0DXUG5;U%A4VPSMXWKJ;+N]J5?^T^IA954\M/[0@;U0*
M?&;]-PK+I^Q;D$;D*ZL'%*%E3?_U(DA?4'&7TE_5$9P:$J3.][J^,3L^<A?)
M50.OP"E&KWI\,##<H#JH?/R&"OEN E?"P-S<EQKE7837!V/#78HG8O04O,O3
M"%7!H-R]+31&(A^M#Z:'+T&>8HS%%.7U3"//I* FANCDNL$LH5*@O3!59&F(
MSX]Y[6CQ$!=_7N<HBDOR$]^)!:J%H;G+ZV.,3R%@'_P%N["8DWG/C:8H\ZJ^
MIF_Z((=5J?H8KI/4;F;Y58"NVU0RA.E[]*,'.\]2_&.3=Z?HG6JDIF?5IK 2
MW'F'&N-_F!9TVW&&;9+G*,>3$=[=YR]J&V5>Q=GQH9,(6Z8WRV+,&JQ#XW=;
M]3O\;ZA<9-%=BK?VI=P,SJV'X;G+#6ENIR6&S+="6=IG!<6"N*#C_Q")WX*$
M2BGE-BQ3'\,U=+/G=.\E#QVP6MCU'[\*BKB8S+>P*RS)<@VTFCLQ],C/*><#
M5 !P;]DGIG'\>$"O63Z$>JGZ+>RSTP_(O+H& .+MFKB>\B!">)::E N4KQ51
M/* 0X?GJ.4'"E5NJ?@?;5(Q?E\2K:P @WJYAC.PY4F)H5[%MLJM0<!]PZRT%
M&F#4KDF,)")'>;F:)@1[&I%-QRN9D^09EFVB V\JD99+Q@<I >@!=@UIWPLT
MF7\IRG@9E(CG$;E9$.]!/Z!IA(418,FN$6R2OP1I_)_:)'N=I06&&-7_6&\>
MISDJ<&]K?E45&'*!\1=A'M>"XQZYJQ^9P6WTNUB_']"\:D%E0)>T:XS;P*9P
MN.=4P^@^YGV* #' IUT['*-[XK[(58;" 7]0LU@['_"^=+Q&@/YBU\KW6Y9%
M/^(DP;+?81CI2XQ/+I=%@51,??*-T)W3!^P2 ]4 ^+O8-0'>H&>%TP*C-(7T
M 8^"(KP A3I2CBMAXL;74V^):L:,!Q,<:D\[DSHTH//IG+<1' Y<OA+1PM(&
M[R*D #T>AG(X\/$=R8'\@X8#^!W)D8>Q' Z\?DBBIG?10Y(CGX(Y'!C*.#OP
M)<G!@)<D!W!VV2.[%J<'?#K!"B"WT3?H#259;<[\\OY*(N,(KW@D:G?;($.9
MR)QN^U3Q Y3;M>C<I=,\"U%1L*47DBY5G\+^@!>ZZAH B+=K^OF*)4;H*PH*
M%:<Z3JT.HIO,4V9)EL4-4&O72O. >U]:H5NL&Q(2- _"\H^X7%Q719DM42[/
MMEI#5!$?\$P_0A7 \Q8=,?0?T#.YM!(SRBG=RGIN*GZW"]ID\0+<:#'%H/PM
M#M$MDN8'KD%E_D"&4!7, $]*=A&(IR!!>.TNJSR5)@JN0J7^0-><2J !JI1L
M)&#*D&FP(INJRZ*(BS)(0XEW>I(U*88/M'T9@AW@SZZ/4OVH\ KOMB(2%!D?
MH)I R>UM^5W]6BU^0\3W1OQL8$!KG4H^HL?Y6'T 7<2N$U/K1X$A/,=IC4#<
M$^!*+<#/ABS:;J^?Y6 #O#H)*5IK8L+71&W._V"1372X JH'<;\*$K(N/"X0
M:F)M<5=4U39FQ\=[NV\]W,T_-PR^#Q%'J-C;#_B)@TI(+%=Q4I4H$O:!D2UB
ME>RMU]=NC]"B# V!3'QV"CBTF'G8T+C7H &-3@$F+YW'^008\A*WXA-PJ)*_
M^ #V%??QCMK446:42\#A3EQ5KOSVHZ@.U[;/'@%*:A=Y!"C=4IMV"' 3!(#;
M:54= N!'_>?VCV)=Z)AO*" )J6A*G'U,]'!NUTC1.R>TT0E[H7B(?:7Q^!VP
MWU9IL(7OZ!PFR8MH4ST8L0]'KT[F1EI\%O@:!\]Q@CE Q7IH19/T 855GN-=
M"BYPGZ5Y^\_Z 8%T+]'_L2X4P8F36\)1/<BP-GR(0+D%D0&J0:'>=X1-S8Y/
M]F]2&0;2AT"5G>0;(?LF<Q*J3XE>7GT,U]>40A*<BI'Y$)F2KFLTQ&UO7KHL
M.SP#-@=J36*E.+FMUK0O& +6AWB6% &]D&NO:G\$>51G%&ENY0H"I'DV6!15
M$]QZR*91QX>P IU<D6OJ+?I4X$.DS+%)R@QE_!R:I(Q#("R_1J.JR1PEX]+Q
MG/N;>FPW@:4(B.X8E.82Q)Q[:#.M52AGO*OEUQT?TJ2V/;:9JJE=9#-5"]IH
M.A_/N5=&T[K7*AI-:PA^Q$@TDGK24 @$,_._&BPO ASJRFEX;NC@K#'WY#D<
MMH:/RXN A/J(<KW6&&=,N ;9M7AT!W*^^;6VO'U/L^<"Y75HS+OTM2KQG[,T
MQ+7JDYF2I4OCYSK#KZ'MN!7[F"E]"&(;6KRS?$!%JZ$ZZ-);G%5%LKK#YWD4
M=0DP.BUJNLX4N%UVGH(, :Z#QLS N]U4;J,EY^A<P_M#=9]22,\#7$N%3750
M/[MYO3&*FJV=K@X5&+OQU-<-QK-/E6CF],+V+71']09>G>&%?#5Z'1F*%R#G
M23B&'%EKV!$<#\##H$)'GPU=_H^QAM4JE#/+U/+OC;\FEM;U"46;VD4G$9]"
M"AU]=N+/P.VTBL:P&@+_>LKB;KP7Z7@R[X=*ODRC]F7:!,_(S;NTM5OVZ%==
MO:]F&U\-.%_E[K_'MSH[M9RKI\F:W)Q[>.;'7C$LH[LGKSK4"Y@B=R#ZX!5(
M'M6OK3?3/ Y1^UZ(QQ50!8-RES7%(&]<N.8>30U"Q'T\-;S%V>F!F2$)OY[2
M3Z@6'7CQ?FK,:_7+\*\J+AH"^5="0 VL!S/#7/YYU6@2F0.=B]<'ASV6@.3'
M'"'A/82P+AXQAF+C25\<<0F0YXP!RP=G.^/LN3ZKF:91ZR,P#8D(\Q@5D_E=
M&L5O<53AE6QUMR0I?/(X2!B "O! .+9)K!RG;R(D!R&PO1H%6H,3'?1F/8P3
M]#[%.[UEP#_*[Y;L+J7<A'(:Q8L,) W><Y )I34FY"]XFUT]WZ6AP(X"56@%
MOCC>O[&A@,R'U,M8N"*.XB!?]<Y*(G\CJ Y>)EQ']#>SO10@]B*S<D^R^V")
M?WS*@[0(0B*5<),BKHS[NB'+IKQS$I\%H0F B\P/[S_S'/JRTS1(IM!S28>)
M9UH_&R)1[L+:CO!'D&-92OZ*QZV$17?K%R0Y4ACKG00N+]S_[J83X4Z^*X/E
M=ON.<1 ?  PO?/@F;RB_3)*LK'VK:F&$=(!U,"ZW[PY'T2. I3W3KUEGBY,+
M0Z_Z7&W\1%"UY_@UY0B Q35TL3/"[:+1X:[&0?FUYZ\UJ6[7.RQM>A?NH[18
M#72%;CIWLAIPNRW+,B""X$6JU@>4X.U<- WR<M5;UHJK5?\O C.!?"/40&7F
MIM*U^6"@)KS(UMJ74'@$W2U, ;E:AD:2(&:4 51'DE:/F'.]HMFG4)C&4$MH
MW2S/\>X_$UQ1;)2B,CJ)-"_9_UG7$C ,[8E1-2YYP]:X?A<\/OE;+6H[T+7G
M8=7(KM*TN'N^[V!ZNK;M<*'$) .DCIRNWG/I^6JGF53A2J<C/N_C*YY8LERP
MT/4+=1*>.LGZJ3XT6$L>"$A']E9 U9<O.:IM\,#*M5N(KL4.HT086*@$2'4D
M4A5Q ,Y)K&)4.E=1( 0:XZF7 4%'.E-3"G8]Q^O4M&@&UY(LM,Y;&C]7M8[2
MZ&L6I)U$_&E=7)-B<9?VD->1&6PH@C*8*?0&/9=?WL,ZNK4D(YPJU#_)72)#
M12IDT1C, OKE3;#>=@4Z,(=F<M@[76O9* VF]*P_R%\">D6H5*Z<Y3E:@M3)
M$%U'CDW="O5B/1VI6>$ZJN.=\0/*>F.-/T^SRE)YG;C&<CLF0]-""(*LD78L
M"C=H6955D*S%O%K=I465DX1\S=7>(PEO5(<\:IZ _I9G17$=%(MIGH4(13P+
MX>BV9Z>'[I**FGN:J4DO0/\9[ADPR*^I7*#\+BWQ%B3&"V23%N >E9QN 569
MG1Z;V1FX99L/%R!1QU%\BK=#J+YKG\RGU7,2A\U;;FC.A<IC09T8HDR^I^5C
M!4BQZXC R#W\6*+7WHN,+_BG$D\>)<*2EW?="PT*CC,*=32/M>5N*38W8O6I
M!GA^:]>-81WJ<NV8/,D?XI=%>5\1U4[F=*VY#I($15>K=;EB79"WP(]L>79Z
M]!$G?"U: 7J.73<*QBNPZZPH)_-U?X^:_4KO=H#\6?%QODR+6"<?:0G2H@V@
MA]B-_EQO;KZG^-,_2*].7[Z\OY)P;Z+M'Z,*1O41%Q,^7(!$'1:B&S1'.>Y#
M_6_?(GC[!Y7'@KI+0F\LG H/*T"*Y0<CI-],?J0H+Q;Q:[O5P.L*EAQ+*YIH
M9:ICM.Z2R1L><5+0 :(M9[.BCVFN,=(X6F-^0"&*WTB(Z=[\SV%<J1V,W]V%
MDY6@5[(Z /J 72O<?9;&ZWYZA0+22V_0:X9W!+V0XQSJ9:ICM.[NM<PQ+@\=
M(-JNN:RQ_OP+)=$=[HI5P;.3[93%.#YBA$$ )\"7#LM8;YK8B+'9=ZP&7;4D
MZF( 'RFDH")N@#@=SB]M),.>R0ZT9NX6Q>)]I.L$/DP@=I@.AQB&?>P!10@M
MN89'V:JS4S?)UDVR) T;8$V'MTQC@<KF!?<28+,4C8O\D7:+(J  "7I"9S0W
M>"1P&-9BD#3CMCV;P),9MUHG_<5'LJ<J(P=XTV%,(:M?-O^Q-M7R]@:T5.?V
M;,CAR?%F   *D*##1:>^!W]==P@Q&T!Q*NV'VPS(( ;XT>'@T]L*AL3($BRS
M*F6=<#BE.UD_U,VB+&" '!WO4&JK6+:>-D/ >@B4I#)^)'NA#%B $ <^-NMK
M Z'-MRV']Y,?B2P.1H C'8:"M2WI+BVSIP6JC1.784B&+2?A@&1-+/R'VU3+
MH@8HTV$B^(HE;X_#(I)89;& '\E.*L )A*2VZZ#".!VW%^"-X;[.,MG3C9I;
M$[\MK(>/:%0=J >@/]B.WE&4>1R6*").K]=5'3V!PSFS/,;SD6RP$E@![G28
M+?[(\C_)U6GP&I=! DVGFZ6P4!_N@,5""*C=<G3/SA4QS)9HO0S_$9>++NWB
M75J4<5F_VL.%<A04N%CS7\[0&M7N[/3D(UD^-.H$Z#,ZC"2M7?-YC3$*5D)C
M;[\L?=G_X:SP0K@ +3IL(_>H?-IX 0!RLEV02OCA]J5\K  ;.HPAZT&+59&5
MY) 2-(<4P6%NNSB-:_&13MK2B %^=$3R:*=8!!L]F.4Z^<X^W-&:"Q6@0LD$
M,OZ= =Z0<K82Y,]4Z(^X-]]!"-!B]QW1MR#_$X/ <VSO[8'P3,6IU4$\_T@[
M!%7@0 JGX983V;C,9-N9OV;Y^EU24*)K,C7GJ^LL8FWE)6O26!,?Z>)E"'B
M6>=/;_IO%G_/B,MZY]O<FG8D#&-J#=('ZQ]I0=6H$Z"SV'V%0^+ D#-G7I$
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MOY0KWHV_0C-4"?OIY#T:,T"\#I^ RY>7'+T$)>H%2  ?)0EJ4)GW^/&+)#R
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MPHMX]R)J0TT_?OSX]2T._\12O@7U'B#,\M=?PVSYJ=86"283U^'4B2&>Y#/
MTPM*PQBUROAY=!1@^HF _8E.W]#4K]#$[/Q(AT5%_,4GX*I.I?KL_-#,^2](
M$J#K*ZN2L2HIH2,R1N4_0EP*]]0O27VY@/6.7I:-Q\WZ[TE6H.B?/^/!@\ 1
MXH-Q6I FE5,+Z\-U>C,UYE0LSQ0@FSL_+A9$B3:Y]?!X,+0AD<Z/*E2^VFU!
M#Q:;-2\>@8YGS75:-M/TB1*VZ5@1'\,X0>\RJ31YQ;&T3MX.*HP$QH+'!0-D
M%':2T:L7<4ZP3@$U,"0S%W!6UR@N." !E'.^FKLJ))SMA'4Q3$-'*^EUBDN
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MS#-KS<Z/G;P]% T)GK&= P0@R:ZEQ01)3C<7O6CZ]\$2;3RR;4D[!@>6$!A
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MD]>?S0T3LZT]C#MV;#DD-GGR\RQ^%?2L\BKH">7+0QY\8Q^=G;@]HPB(9<\
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M>'000998H.B/+/]SGN6AP*L#*D_%=GJW/&88,AQ I-#Z8'S^&H>D=Z<OE_A
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M<58>5EGJQN#TP:'\0&'==(EP ?JW>]-/+H$F\\L\)X'U.88[;GD*:W]M>/(
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M&4&]2>:[@.SJR)[=JZ &X=RNVI^IT([K'9[1#1'='ZW!V=OM'$/QT',E26A
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M]Z2]6UW9*@1AGTM=E&.(8YB_5!>WT]4=SO/JU/T99Z]!%HG"3N!.#)\?D\T
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M?;"1%R:5]&10?86FZ;&AP20 TD10QR3X]'TVZ)98Z0&B6Z]5DU ;/&3D-V2
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M (!R3=3F&JA<W]._.2U+YWDMNQ_0]N\X^[&-DT1R7'C4C$GIQ?20C4Z.ED4
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M(_-FY-0+X,[D)MUPHAAU>W>Y+ ?$--%N"?3BHLCRZLCPS__TQ^\_?/\7_VO
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M&VV+=RLG_"IXN813C9[B.65US\VRM;:?1.TWZR<"57OVV17J?^8$[V[<BS5
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MEZF@+M@VJZT+L#TI\R9]H?DS<E>=[=%Y5<V^!)8:V"%:SN9FDH3_^K8LC9$
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MRJPV7KLOH+SMNR,0VMMV?<'3:M>%GD7G75:Q;-3>KTUZDY6XCA39IC(?K8D
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M=X(I@=]=F6<.1\Q\N,!AMM^3HQ@1FRPJ5\<TTFRE1DK ?=,LA9@IEE-P2V=
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M0_^_E7=\AA<L<[SG6\1+EE,,T!VF"T6<Q$WD=,C&0WSQ1@8H;P>(_4XCMZL
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M!J/*3E22P<#U8#Q6@[$,U]YH5="DZQBK!] IRW8['/*#=\7D'5FE!J'"[LO
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MYUE*#.DR?DPP7[NJI<M00L- !58YP\2]X'5L"5!#P3<@;YOG#$*T4GC?-NT
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M0^.4*]?F!4%]NN(?4MZV*MN#7;2J.5:?'9NV%?9]7*Z.X7L)9UXKG/3O4B%
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M;D?66BVB=GER>SAFL!,8"2!R*K(>SFH3R;B>%*?IUO%@V!S["1_5BHR9)RM
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MBZY2I15H5OB0*\"OH2/-C6^F-,H'T%E+L6,7M=WW\._Q@8WNDVWVP'<5G=5
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M=B7A9?(5/R+UM(=7Q>%8G/*$?O>^3&-<@;-(D,*T,ZOF%-TG3V=(+<N/4G*
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MW-A0C.#F>Y'(YD5QN58T9?X#1N43^K+LK,%LBF$L&A52&RT>F0?JAH=,,45
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M.<>6..W?H\MGWE^B3#["5M"D&<;4&K4%LFL8$S^X)<XQROJZ1_)TL[J?NW*
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M;>WMQF/+[;2BRAXFIXR\EW-7Y"\?GF!Y *,[CQ7XE?0/Z&[C0/OR>XP#U7L
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M<"(;/N%_.&;%.X27,(>[M+Y'G%;2#6O]_NYJ:FI+-*VVV'<%&WPII^D,FMZ
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M #+_B71/*#9[0'UM- \<SZS@8_F. \Z#/*$/*!(.HW8N]P]&'$[T3';Y<(,
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M?04PGR$VU'W(0\9L93WUXA\[\:.1^+%(?&<YMC7,:)"$"]:&M+)TSFR)J3.
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MM;*I?]FG\;Y;,&Q*R,YX[8*"=]%Y_4_ZV">UKS?Y%BJ-7W5CWTT-R'>9)3U
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MHKU;'' YU@*#QW!#2^,<3(C5O>3(59-3P3TW\CP&MZFS(TY</B=#W=X?0:W
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M(E^(XCZ<,,@J:MNUJ $+X+<K=J.U-O=(WDE<:.RZX@YKDGSZA&Q3:L5I#4P
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M'DKQ5LF+W@"45F/17_3/ $U4G9.Z8K_%;OFL:83QSO*EOCUY6]E;F_A_+\+
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M&0VQB[NIB0EM@B"<4:0OZ/LM'G8)&0G]-QFF C&*? 3]/<D[1WSW)2/[+I/
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ME @58D NW'ENW]P%]<V1DE[<$+=7'BU=Q(! N!.XJ4\V*Q$S='O=*^^X*7)
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MEJ3)#-WK=H5HKZ_;%.+HKML5V;6NV]7T]_.Z3;&-Z[I=$=OLNEV!&$4X4=?
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MW=X$1H02X'#W\+N!SBXOF[-WR/0_+(_9NQ<Q?X?!(:;3GU(*,QUW?Z>9/GA
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M-R.4#<SJ=$/>290T5H_T<-+H7Q,,JP95WR>5*0T H7'%M%LG7C"YQ(B[4$T
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MS<\$]YCB^FEUZ"60<!6>'R %T\G%":;K3,6!3::I8.QUXB4*$<FVJ2+[+I/
MZ8\L\9*U<I98%@4IL04[GA*$L^F7V-- >MUAN>(]EG#^*4_\OS3>0 O[T,T'
MTT1DMBMJHG$VZU(##7NJ-)D]IUZ<T7.=(E&_>U9VIM1!TMLU&0=P6Q,85B:F
MSFR_>Y@H7SK7;2A6)'W:E!]B;FX!02U/V3TL^)VDEU&4E*]4)B4*)2?!/I0@
MV(D).G%6 0RUD*6)8GBO>JPC[T718IK1S4Y4;3Q8>9RZGZE,FJN"FC<%P_=
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MB<:NSF9&>OVK-5RL[03->'/Y2E$M%(;-C49UQ8U#9XT#,!Z /6B6FWJF<O/
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M*U]FJZ4*]:V32*%FB;&Z8K6@BIG]"=?:][5@#T8--F.P R]XX/1&K(</X.5
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M2$JE?C*[BX/P/0P*+XJ6=XL%W??2T(L$Z#-P,^\Z)*4DLD5"D]EB2>D&&[(
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M%[\5^3/]EN+: G594X7'0(U]=S1"9,GY,ORE181.>7F!.W&B(!^"6ES39[@
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M-'+6B]UW.<>UOP<K?;TF_P"FF^%SUB]MJ[CCR0EVLDLSAHFY+@.'ZGV&JDQ
M9ZO<^Z'H1O%B+]DNS-2'^..XDX\QZR>/X3!7$6?/O<TGXTL 7I)=T]M\ IJ2
MW?<VGXPL 7A);%-O\PEH]W/!VVQEZ['DC+8[%[H5CM_OV._.CTQ[9SW==EY
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MQ*%8.T5?I!=O#!+PH_"*]E[$:"Q9,W;IO\DP%8A1^"/[RT1XC!05J2+[+I/
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M1RD!S.%^]19J?Z7A2)Q\R)[MMBPW%B E%9SU9SY0M53'G;'1CD/'SB[=@67
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MU8T4?]W_8LSNQN4\;3A5WGHZ;0WG3;_0>E2'$Q&]?ZSUA"^/MLG#E&X'<6K
MHCW>^$/Y.H8U?Q1C?*T2C/,CYA?K[%61S4\<VA=6K-(H7:?+K4&RLA%^'<8F
MJ\QG_8EM+W1W/Q#7U5UQ]AM $GG)T'$- G$U#L+KM&X YUFQ9\;\3V#"_ ]_
M/@J 2"#<P;^W$*GSD@\CVM&2'D4^K8O )N+B$:V'+0 FU8DK2CHBCN2]J2[Y
M=I)GEZ-#*=!!&X!*M>144'\J$O[NTRKNHI,I^*F7:;\-0*5RW-G)A+Z[M^59
M.B\O;A5!>.X>#B135^X>82X=B#9'EWZ);+-[-$;>.L?_8"(2B$6S5Y;Q#6[E
M%Q0N0I/LYN.]!(@V]7AE._M3&/GXO)+F<9N6;T(<XX>%J#7T&D<LB42QW+$\
M$[+?!IV(KX6-9_^CT>GHQC=938I!V/J6KOEC1/UY"M,__/56+:K,S/X;OX)0
MWZLLC<#7;@M*^Q7L7@*T^V<F&(Q75QD%?J6ET!%K]7:?^).H7Z*5[M,_\\-@
MO+I*O/ K?!*/<?[].F/L)N%H^$9KS"62[+=;H3Y3>X*\^P"T=+I*4_%KK(]D
M=(V\.E*\ @CWST0P$*NNTGK\JM/ R.LBQ2N ;,25@7^1CT'"JJMD(I0?@ZMH
MXV8E*:I.J&X_#/>C( UQTIMIGQ'8\>@J!4K7Y<\_%QXD\?J_4:?Q'-3"R9EU
ME>_EUUCR7_UD61CG["&+E?EAAOM1$.<?EZ<S'EVEHI$8N0]1^/,5.[WI3Q))
MOQ\=,T_OG_E[)K^G:20"DG?W&U55H?H]L#6)MV_]&*&FE##C-ZJL0@XU=SP&
M&5'F*+3]I;JK^U0$6>'1%+MCJ%IUY#=)?>'X]RS-!PD6Q'\-%)G,6G)B1JPC
MS5$0/]7FOYHUJ^MFEV7&/]0:9L5(OI<6LUU"J-)UV#\,F)S,9MVU^?7CI.\=
MA,^U=25L*9+5^#= 7J?9@L4BDZ+@_^KG2YQ53V@_R &'2^UOMTI-)R)I8H.G
M'85];W+X;NS36,Y2E;J?O#&K*7-TOZ5>SEXE'IKO;@835S@&-]^3WP(M)G,;
M>6+FJZ;,[[IW#C_MH\L2@_L][=Z@U6PZ06X3,_,N1#JZ\C)M5P1ZZ4ZZT1WJ
M,W#W%J#@W]9U,1"9CJ["3'4NT+'6$$/^+5B]""A(5*EU^I]#=SX=W8Z9ZA?1
M=Q=/M&;J]5ZMOM.)$IW82LH=O7_7BS3>[BZF$SLWL6^B"Y&N[LS\&JXAHB_
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M4;EF]XO3]P9)L%)AED\ 8%3IRMSK<S3D]R!D$D7'<A;^:YF^_E?$XMIL^/^
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M*C^/3J<XT>NTWZ:)P7E'Y:NSU E]=T0G#WPV5;93<;9_L0[R_'Y171K4W3+
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M@PR6C3M)])RIATQ)4X!&-7 :$R\90G6 $*V&=Z\8:'5NKM7Y,33"8#HG6LD
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M-&1E>#(S,2YH=&U02P$"% ,4    " "CA2Q6;?N9S!("  #K!   $0
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M2P$"% ,4    " "CA2Q6%3S,Q^!&"0!Z!5X #@              @ %O'@
M9#0R.#4S-&1S,2YH=&U02P$"% ,4    " "CA2Q6VBQ7-37S   N8 $ $0
M            @ %[90D 9S0R.#4S-&<P,&$P,2YJ<&=02P$"% ,4    " "C
MA2Q6\8KRLQ28  #6  $ $0              @ '?6 H 9S0R.#4S-&<P,&$P
M,BYJ<&=02P$"% ,4    " "CA2Q6O42YSS9L"@"K:0T $0
M@ $B\0H 9S0R.#4S-&<P,&$P,RYJ<&=02P$"% ,4    " "CA2Q6^_I,^W![
M 0!$Q@$ $0              @ &'714 9S0R.#4S-&<P,W8S,"YJ<&=02P$"
M% ,4    " "CA2Q6?+;&RUK    [%P$ $0              @ $FV18 9S0R
M.#4S-&<P-&$P-"YJ<&=02P$"% ,4    " "CA2Q6BY/FU!S6  "7-@$ $0
M            @ &OF1< 9S0R.#4S-&<P-6$P-2YJ<&=02P$"% ,4    " "C
MA2Q6WX&^LH\R 0 =DP$ $0              @ 'Z;Q@ 9S0R.#4S-&<P-W$T
M-RYJ<&=02P$"% ,4    " "CA2Q6.LH"JOSL  "*/0$ $0
M@ &XHAD 9S0R.#4S-&<S,&TW-2YJ<&=02P$"% ,4    " "CA2Q6Q%V$Y,'+
M!@#AR0D $0              @ 'CCQH 9S0R.#4S-&<T,G@V,BYJ<&=02P$"
M% ,4    " "CA2Q6J\8-4CX] 0"XGP$ $0              @ '36R$ 9S0R
M.#4S-&<T,W8U.2YJ<&=02P$"% ,4    " "CA2Q6<R/I)#GO!@ B^@D $0
M            @ % F2( 9S0R.#4S-&<T-VHU-2YJ<&=02P$"% ,4    " "C
MA2Q6G0U$A1GL!P"0\PH $0              @ &HB"D 9S0R.#4S-&<T-VPU
M-BYJ<&=02P$"% ,4    " "CA2Q6Z/[9J3-@ 0!1T0$ $0
M@ 'P=#$ 9S0R.#4S-&<U-FHT.2YJ<&=02P$"% ,4    " "CA2Q6MZN\"_<K
M 0!8GP$ $0              @ %2U3( 9S0R.#4S-&<V-' V,2YJ<&=02P$"
M% ,4    " "CA2Q6TBU&EO@E  #.1@  $0              @ %X 30 9S0R
M.#4S-&<W,V4Q,2YJ<&=02P$"% ,4    " "CA2Q6I==<N5U) @#*Q0( $0
M            @ &?)S0 9S0R.#4S-&<X.7$Q,2YJ<&=02P$"% ,4    " "C
MA2Q6MD'[.IPG  #;R0$ $0              @ $K<38 <V-L>"TR,#(R,#DS
M,"YX<V102P$"% ,4    " "CA2Q6HX>(^?T3  #+*P$ %0
M@ 'VF#8 <V-L>"TR,#(R,#DS,%]C86PN>&UL4$L! A0#%     @ HX4L5HU^
M,'4]H0  ",T) !4              ( !)JTV '-C;'@M,C R,C Y,S!?9&5F
M+GAM;%!+ 0(4 Q0    ( *.%+%;KLI$NI-H  !$C#  5              "
M 99.-P!S8VQX+3(P,C(P.3,P7VQA8BYX;6Q02P$"% ,4    " "CA2Q6^>^.
ME/NO  "!< L %0              @ %M*3@ <V-L>"TR,#(R,#DS,%]P<F4N
9>&UL4$L%!@     ; !L N 8  )O9.     $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
